{"meta":{"query_hash":"74551677015f","filters":{"topic":"Prostate Cancer Treatment and Research"},"cohort_total":3880,"direct_labels_cover":13,"predictions_cover":3880,"exported":3880,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/74551677015f","api":"https://metacan.xera.ac/api/v1/cohort?topic=Prostate+Cancer+Treatment+and+Research"},"results":[{"id":"W1005040161","doi":"10.1055/s-0035-1555899","title":"The GnRH Antagonist Degarelix Directly Inhibits Benign Prostate Hyperplasia Cell Growth","year":2015,"lang":"en","type":"article","venue":"Hormone and Metabolic Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Stromal cell; Prostate cancer; Hyperplasia; Prostate; Cell growth; Chemistry; Cancer research; GNRHR; Apoptosis; Endocrinology; Internal medicine; Andrology; Medicine; Hormone; Cancer; Gonadotropin-releasing hormone; Luteinizing hormone; Biochemistry","score_opus":0.06464793432746092,"score_gpt":0.35533970222491773,"score_spread":0.2906917678974568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1005040161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81993055,0.12566383,0.0000027013862,0.0042907926,0.00008138933,0.0012225035,0.000024076126,0.000058834208,0.048725333],"genre_scores_gemma":[0.9017079,0.07172921,0.00013534403,0.000083059946,0.00029572425,0.00024336186,0.000045157005,0.00004765573,0.025712613],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99632585,0.00035155824,0.00030840602,0.0004978954,0.0014140393,0.0011022539],"domain_scores_gemma":[0.9973666,0.00025559496,0.000046083584,0.00048058564,0.0009916686,0.00085943245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027399545,0.00023267519,0.0003987651,0.00026858185,0.0007844169,0.00026928534,0.00021832681,0.00011783743,0.000008226],"category_scores_gemma":[0.00037446956,0.0001319082,0.00008244703,0.00086731836,0.00068920944,0.00017389498,0.00027773797,0.00075439364,0.00015620235],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016017599,0.0017503786,0.051346276,0.00041416916,0.0007481602,0.0011495949,0.008979705,0.0000011374902,0.24898197,0.008272594,0.536862,0.12547639],"study_design_scores_gemma":[0.010714322,0.0023436118,0.029899923,0.000062959865,0.00013656166,0.0002211272,0.0033129556,0.000094840616,0.3049658,0.0018864261,0.64597774,0.00038374783],"about_ca_topic_score_codex":0.0006713295,"about_ca_topic_score_gemma":0.000022877495,"teacher_disagreement_score":0.12509264,"about_ca_system_score_codex":0.00009678644,"about_ca_system_score_gemma":0.00088783965,"threshold_uncertainty_score":0.603318},"labels":[],"label_agreement":null},{"id":"W1024263097","doi":"10.1096/fasebj.20.5.lb103-a","title":"Characteristics of in vitro prostate cancer models grown in human serum","year":2006,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"LNCaP; Prostate cancer; Angiogenesis; Integrin; Cell culture; Vitronectin; Flow cytometry; Cell growth; Biology; Cancer research; Cancer; Andrology; Immunology; Medicine; Internal medicine; Receptor","score_opus":0.029064496157587365,"score_gpt":0.3098583783292443,"score_spread":0.2807938821716569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1024263097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99665546,0.0008140111,0.000007737189,0.0014078559,0.00005865191,0.00023917234,0.000043963515,0.000004609183,0.0007685231],"genre_scores_gemma":[0.9974528,0.00070163317,0.000028857543,0.00005254903,0.0001596632,0.00001528031,0.000015450923,0.000012799264,0.0015609666],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990188,0.000057100937,0.00031488054,0.00008508873,0.00024621707,0.00027793084],"domain_scores_gemma":[0.9996367,0.000019464162,0.00010546644,0.000112868314,0.0000715347,0.000053980024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035376125,0.00008813087,0.00022544689,0.00015735983,0.000061880906,0.000016791426,0.00009007953,0.000035378296,0.00006868774],"category_scores_gemma":[0.000005682773,0.00005178444,0.00004940891,0.00018424449,0.00008396672,0.00008568401,0.000024927098,0.0003920172,0.0000016118321],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001445383,0.00035156406,0.28482148,0.00009200442,0.000043573673,0.00046307416,0.001148317,0.0003177437,0.7046309,0.00011269789,0.00021782132,0.0063554],"study_design_scores_gemma":[0.00628757,0.0002371464,0.5557936,0.00046621327,0.000052316955,0.00012755985,0.00024040716,0.0018156832,0.43083414,0.003935899,0.00007837616,0.00013106928],"about_ca_topic_score_codex":0.0006520052,"about_ca_topic_score_gemma":0.00010770939,"teacher_disagreement_score":0.2737968,"about_ca_system_score_codex":0.00020557457,"about_ca_system_score_gemma":0.00017794892,"threshold_uncertainty_score":0.21117081},"labels":[],"label_agreement":null},{"id":"W103407665","doi":"10.1200/jco.2014.32.4_suppl.79","title":"The molecular and pathway characterization of patients with metastatic castration resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Prostate cancer; Abiraterone acetate; Medicine; Comparative genomic hybridization; Prostate; Biopsy; Cancer research; Cancer; Liquid biopsy; Oncology; PTEN; Pathology; Androgen receptor; Internal medicine; Androgen deprivation therapy; Biology; Gene; PI3K/AKT/mTOR pathway; Genetics","score_opus":0.054671961056361164,"score_gpt":0.3879471556691834,"score_spread":0.33327519461282223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W103407665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98611313,0.000922833,0.000037482056,0.010582619,0.00024474016,0.0016644442,0.0003884558,0.000008900388,0.000037367805],"genre_scores_gemma":[0.98986006,0.007905047,0.00042905041,0.00090521015,0.0002381238,0.00012643378,0.00009831577,0.000044618326,0.0003931703],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9958792,0.00094059797,0.0016925689,0.0003636492,0.0007548742,0.00036911023],"domain_scores_gemma":[0.99438477,0.0016280904,0.0020933384,0.000353369,0.001226564,0.0003138616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022735011,0.00027055005,0.001013363,0.00006602272,0.00018164475,0.00005088302,0.0002001297,0.00012747766,0.000016348347],"category_scores_gemma":[0.0006690047,0.000106707834,0.00009336036,0.00025406055,0.0005089422,0.00022181039,0.000055616736,0.000658316,0.000001336004],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5627944,0.0018378653,0.11454758,0.00010242855,0.0017103404,0.0003036452,0.0038750826,0.00018366148,0.03231373,0.000011331789,0.0005588797,0.28176108],"study_design_scores_gemma":[0.029682266,0.06384249,0.87779075,0.0007213276,0.00047769875,0.00002113067,0.000489905,0.00007085493,0.005640879,0.000035030796,0.021038732,0.00018893272],"about_ca_topic_score_codex":0.00032923228,"about_ca_topic_score_gemma":0.0014575736,"teacher_disagreement_score":0.7632432,"about_ca_system_score_codex":0.0001994187,"about_ca_system_score_gemma":0.0022008002,"threshold_uncertainty_score":0.4351419},"labels":[],"label_agreement":null},{"id":"W103820817","doi":"10.1016/j.ucl.2012.07.008","title":"Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer","year":2012,"lang":"en","type":"review","venue":"Urologic Clinics of North America","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Cancer; Androgen receptor; Oncology; Cancer research; Prostate; DNA repair; Internal medicine; Biology","score_opus":0.12655659254906218,"score_gpt":0.4220701466796564,"score_spread":0.2955135541305942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W103820817","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023544796,0.9945608,0.0000018856293,0.00022066236,0.00016774448,0.0020017717,0.000519384,0.000031882446,0.00014139614],"genre_scores_gemma":[0.0021105257,0.9950785,0.00054209254,0.00014433131,0.00009266575,0.00059924216,0.000869573,0.000050166338,0.0005129199],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99705034,0.0002943572,0.0012107899,0.00046536708,0.00039562272,0.00058351585],"domain_scores_gemma":[0.99781007,0.0005241263,0.00084559555,0.00047531674,0.00015832746,0.0001865852],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003517875,0.0004453407,0.0024303847,0.00032916432,0.000046694466,0.000011708356,0.00021818207,0.00014702963,0.00031173663],"category_scores_gemma":[0.00014903473,0.00027851365,0.00046795793,0.00079643936,0.00037257955,0.00006230302,0.00007145712,0.00069233036,0.00004323367],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036902467,0.0004509074,0.011787231,0.0058731665,0.0006723764,0.00011771661,0.0002088799,0.000006217983,4.859157e-7,0.0000022513573,0.00010193277,0.9804098],"study_design_scores_gemma":[0.0009953667,0.0011938898,0.0046397364,0.0012526027,0.0017402169,0.000009707868,0.000042116706,0.0000085982465,3.8264554e-7,0.00002238722,0.9898344,0.00026058836],"about_ca_topic_score_codex":0.00026440062,"about_ca_topic_score_gemma":0.00022719041,"teacher_disagreement_score":0.98973244,"about_ca_system_score_codex":0.00013923507,"about_ca_system_score_gemma":0.0012331416,"threshold_uncertainty_score":0.9999667},"labels":[],"label_agreement":null},{"id":"W114188019","doi":"","title":"Controversies in prostate cancer radiotherapy: consensus development.","year":2001,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Medicine; Brachytherapy; Prostate cancer; Randomized controlled trial; Radiation therapy; Prostatectomy; Hormonal therapy; Oncology; Clinical trial; Hormone therapy; Cancer; Internal medicine; Breast cancer","score_opus":0.0340971891343823,"score_gpt":0.2950780289722715,"score_spread":0.26098083983788917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W114188019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97310406,0.008266046,0.0000021746657,0.011286258,0.00012743137,0.0015980559,0.000006125419,0.00003894508,0.0055708988],"genre_scores_gemma":[0.96487784,0.0033061341,0.00017640539,0.0009720188,0.00008548928,0.0027197509,0.00001089093,0.000019819778,0.027831644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989594,0.00002309621,0.0001564833,0.00018820948,0.00019082167,0.00048195387],"domain_scores_gemma":[0.9995808,0.000088551365,0.000030112082,0.00010602603,0.000051207935,0.00014332967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017293324,0.00010443026,0.00020531203,0.00013654596,0.000042593234,0.00001632153,0.000042882304,0.000035191104,0.000102707716],"category_scores_gemma":[0.00006566309,0.00007928326,0.000029765111,0.00023491716,0.00008120936,0.000025207726,0.000014159282,0.000111602276,0.0000058728033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019771603,0.000125949,0.6412768,0.00004083581,0.00015646871,0.0004939288,0.0006259982,0.0000057143807,0.00021856681,0.000012790626,0.0042012087,0.3508646],"study_design_scores_gemma":[0.0078038126,0.000028969658,0.7242041,0.000030123047,0.000014448165,0.000033883938,0.0001292031,0.000028854234,0.0018980947,0.000013614386,0.26570696,0.00010793748],"about_ca_topic_score_codex":0.0001783926,"about_ca_topic_score_gemma":0.00016442534,"teacher_disagreement_score":0.35075665,"about_ca_system_score_codex":0.00047350617,"about_ca_system_score_gemma":0.00021331345,"threshold_uncertainty_score":0.32330775},"labels":[],"label_agreement":null},{"id":"W1157462478","doi":"10.1038/onc.2015.309","title":"Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival","year":2015,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; U.S. Department of Veterans Affairs","keywords":"Demethylase; Gene knockdown; Biology; Ubiquitin ligase; Cancer research; Cell growth; Histone; Epigenetics; Molecular biology; Ubiquitin; Cell culture; Gene; Biochemistry; Genetics","score_opus":0.033241684849210036,"score_gpt":0.3501035583772647,"score_spread":0.31686187352805467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1157462478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773101,0.018560767,0.00022372478,0.0019860913,0.00017957487,0.0008360642,0.0001582619,0.0000135829805,0.0007318103],"genre_scores_gemma":[0.99106044,0.0016536389,0.00041972197,0.000063670195,0.00015159686,0.00013117521,0.000102283215,0.000020794028,0.006396707],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991514,0.000043481716,0.00015723999,0.00018906404,0.000287153,0.00017167178],"domain_scores_gemma":[0.9993917,0.000041431867,0.00008653128,0.00015052994,0.0002035722,0.00012627883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023286739,0.0000985254,0.00018100967,0.000025778678,0.00006822537,0.000008480452,0.000048756345,0.00005530422,0.000044612112],"category_scores_gemma":[0.000025423235,0.00005919759,0.000043028955,0.00008128965,0.000104056635,0.000064661835,0.000037122958,0.000052981828,0.0000012040512],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013629418,0.00011983826,0.002337974,0.00016635872,0.000037628546,0.0000016633121,0.0009659522,0.0000012205008,0.9720517,0.00000665751,0.017746154,0.005201954],"study_design_scores_gemma":[0.0042382656,0.0003256493,0.0004505596,0.000053602304,0.000098465396,0.0000021235933,0.00023077877,0.00014999887,0.98745066,0.00009015567,0.0068415427,0.000068227266],"about_ca_topic_score_codex":0.00064381916,"about_ca_topic_score_gemma":0.000032115375,"teacher_disagreement_score":0.016907128,"about_ca_system_score_codex":0.00010470628,"about_ca_system_score_gemma":0.0001989617,"threshold_uncertainty_score":0.24140078},"labels":[],"label_agreement":null},{"id":"W1179093790","doi":"10.71781/26110","title":"Caractérisation du Prostate-derived Ets transcription factor (PDEF) comme antigène tumoral candidat des cancers invasifs du sein","year":2007,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Institute of Cancer Research; Canadian Institutes of Health Research; Fondation du CHUM","keywords":"Cancer research; Medicine","score_opus":0.112165977187244,"score_gpt":0.3851648962676349,"score_spread":0.27299891908039087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1179093790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797092,0.004585859,0.0001325609,0.00092767616,0.0021338335,0.0052661574,0.0011315043,0.0000109947205,0.0061022206],"genre_scores_gemma":[0.95853347,0.005302125,0.0007363908,0.00011026041,0.0007283185,0.00028227543,0.017156444,0.00014467172,0.017006066],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99532306,0.00034307415,0.0009865633,0.0010930297,0.00094488065,0.0013093887],"domain_scores_gemma":[0.99739116,0.00018665007,0.00051891146,0.0004909515,0.0007292632,0.0006830388],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008177308,0.0008607811,0.001140214,0.0004536474,0.0008042007,0.00051433954,0.0005667367,0.00063209387,0.0056132595],"category_scores_gemma":[0.00016067125,0.0007813185,0.00025693662,0.00057897443,0.0004946191,0.0010626399,0.00008403997,0.0009333601,0.0004582455],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012537819,0.001088203,0.22663635,0.0017531458,0.0012735248,0.0019735706,0.12540236,0.00011020775,0.30622444,0.000018591285,0.0013700224,0.32161176],"study_design_scores_gemma":[0.014308158,0.0022165421,0.37528932,0.004610086,0.0010964999,0.00013089764,0.025290634,0.0010123587,0.5576495,0.00004771082,0.016960884,0.0013874162],"about_ca_topic_score_codex":0.03843492,"about_ca_topic_score_gemma":0.04234899,"teacher_disagreement_score":0.32022434,"about_ca_system_score_codex":0.003895198,"about_ca_system_score_gemma":0.00340863,"threshold_uncertainty_score":0.99992865},"labels":[],"label_agreement":null},{"id":"W120435776","doi":"","title":"An oncology perspective on the benefits and cost of combined androgen blockade in advanced prostate cancer.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal General Hospital","funders":"","keywords":"Medicine; Oncology; Prostate cancer; Internal medicine; Trastuzumab; Vinorelbine; Anastrozole; Breast cancer; Irinotecan; Cancer; Metastatic breast cancer; Colorectal cancer; Tamoxifen; Chemotherapy; Cisplatin","score_opus":0.036550062844791016,"score_gpt":0.3297556217806309,"score_spread":0.2932055589358399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W120435776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834571,0.0034304038,1.369362e-7,0.0050477153,0.000048027545,0.0026776753,0.00003006462,0.000011742926,0.0052971374],"genre_scores_gemma":[0.99445057,0.0021354558,0.000015397361,0.00017166584,0.000014891877,0.00277827,0.0000062127456,0.000012431631,0.0004150855],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990848,0.00009900651,0.00013202935,0.00021863749,0.00015225199,0.0003133211],"domain_scores_gemma":[0.99944067,0.00010409258,0.00005091667,0.00016712995,0.000106211555,0.00013096297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028647465,0.00009917402,0.00022921352,0.000086514185,0.00004665259,0.0000066032453,0.000051893185,0.000050099297,0.000019510468],"category_scores_gemma":[0.00011363958,0.000060533268,0.000022701453,0.000224121,0.00014350441,0.00004326637,0.000012733213,0.00015782169,7.1629273e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0097897975,0.0020945556,0.42485562,0.00010161465,0.00032928592,0.00013157989,0.0066286144,0.00018431056,0.002156833,0.013307395,0.00024198391,0.5401784],"study_design_scores_gemma":[0.017345613,0.0021184683,0.88868576,0.00009681103,0.000080322825,0.000021720545,0.004728354,0.000060109753,0.08157884,0.00090721285,0.004184468,0.00019234123],"about_ca_topic_score_codex":0.00017702374,"about_ca_topic_score_gemma":0.00027134974,"teacher_disagreement_score":0.5399861,"about_ca_system_score_codex":0.0003930895,"about_ca_system_score_gemma":0.00015073744,"threshold_uncertainty_score":0.2468475},"labels":[],"label_agreement":null},{"id":"W1210100457","doi":"10.1158/1538-7445.am2015-966","title":"Abstract 966: LSD1 functions as a global androgen receptor coactivator and is a therapeutic target in prostate cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Coactivator; FOXA1; Androgen receptor; Prostate cancer; Enzalutamide; Transactivation; Cancer research; Enhancer; Histone; Transcription factor; Demethylase; Biology; Chemistry; Medicine; Cancer; Gene; Genetics","score_opus":0.1201457261693139,"score_gpt":0.4461896029677064,"score_spread":0.3260438767983925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1210100457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95029825,0.032888312,0.000001359375,0.011015997,0.00020004631,0.001515081,0.00038576452,0.000044423694,0.0036507682],"genre_scores_gemma":[0.9832576,0.005762705,0.000036875717,0.00039856718,0.00027089255,0.0014297335,0.000049486476,0.000041676714,0.008752461],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99715745,0.00013018235,0.00024336614,0.00057693425,0.0010038648,0.0008881899],"domain_scores_gemma":[0.9983061,0.000076014614,0.000043268086,0.0003239816,0.0005696734,0.00068094063],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007889308,0.00021103387,0.0003414146,0.00023825876,0.0001707588,0.00009123224,0.00014180031,0.00012554695,0.0016774706],"category_scores_gemma":[0.000091087655,0.00016204674,0.000057133453,0.0010672889,0.00038790458,0.00020608278,0.00011950227,0.00066168734,0.00018479874],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011595255,0.00073437823,0.8027272,0.00050760503,0.00065495603,0.00037200612,0.004751343,0.000016370052,0.02619972,0.00013284734,0.09310594,0.059202358],"study_design_scores_gemma":[0.031237368,0.0035338856,0.1972829,0.0017078654,0.00015054777,0.00012650013,0.009954482,0.00020484833,0.07523584,0.005396232,0.67407584,0.0010937126],"about_ca_topic_score_codex":0.0077473545,"about_ca_topic_score_gemma":0.00056804734,"teacher_disagreement_score":0.6054443,"about_ca_system_score_codex":0.0018710645,"about_ca_system_score_gemma":0.0033539736,"threshold_uncertainty_score":0.99923515},"labels":[],"label_agreement":null},{"id":"W129180016","doi":"10.1007/978-0-85729-999-4_6","title":"Androgen Deprivation in Elderly Prostate Cancer Patients: Side Effects and Their Prevention","year":2012,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Androgen deprivation therapy; Medicine; Androgen; Internal medicine; Cancer; Oncology; Hormone","score_opus":0.019553336554453397,"score_gpt":0.28988806798550276,"score_spread":0.27033473143104936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W129180016","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6564496,0.049591534,0.0000293976,0.0008184989,0.0003454402,0.008856766,0.0000967658,0.00013183929,0.2836801],"genre_scores_gemma":[0.47803047,0.017523153,0.00007744692,0.00013449448,0.00019362466,0.00036450542,0.0007797019,0.00009406597,0.50280255],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990113,0.000018494138,0.00022242042,0.00029229734,0.00019763963,0.00025789006],"domain_scores_gemma":[0.99947613,0.00004672349,0.000093170274,0.0001579324,0.000103882136,0.00012217952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104380146,0.00024977195,0.00033935052,0.00019314335,0.000036681555,0.000016042608,0.000033755474,0.00020647983,0.00014419545],"category_scores_gemma":[0.00001274758,0.00016439578,0.00006272509,0.00003491057,0.000053673135,0.00012416941,0.000048155674,0.0002365654,0.000019646792],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006199615,0.00023207517,0.10678853,0.0012751389,0.0003348907,0.000020459953,0.0007455143,2.6414605e-7,0.0004411178,0.00096773193,0.00038163597,0.88819265],"study_design_scores_gemma":[0.059552353,0.012853812,0.5811273,0.019020924,0.0016063775,0.000049878214,0.00018876855,0.00010930862,0.042260364,0.045749035,0.23441067,0.0030712113],"about_ca_topic_score_codex":0.00008833272,"about_ca_topic_score_gemma":0.00017540713,"teacher_disagreement_score":0.88512146,"about_ca_system_score_codex":0.00025049454,"about_ca_system_score_gemma":0.00011931669,"threshold_uncertainty_score":0.67038655},"labels":[],"label_agreement":null},{"id":"W1458426854","doi":"10.1016/j.urology.2015.07.034","title":"Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer","year":2015,"lang":"en","type":"review","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Enzalutamide; Androgen deprivation therapy; Prostate cancer; Hormonal therapy; Internal medicine; Oncology; Hormone therapy; Hormone; Androgen; Castration; Androgen receptor; Cancer","score_opus":0.0725861009409397,"score_gpt":0.36521729229363686,"score_spread":0.29263119135269716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1458426854","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.037833188,0.95877135,0.0000010926155,0.000547828,0.00002294709,0.002369532,0.000078883975,0.0000070034034,0.00036815187],"genre_scores_gemma":[0.008832661,0.9902861,0.00003468483,0.00012413567,0.00003884057,0.00037851554,0.00017407164,0.000022113967,0.00010888563],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987737,0.00019485426,0.00031385786,0.00031030574,0.00019335687,0.00021391148],"domain_scores_gemma":[0.9994246,0.000071969545,0.00015482724,0.00020887672,0.00008532638,0.00005440029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041090103,0.00022321408,0.00071312924,0.00015709201,0.000042239622,0.000013869123,0.00006669082,0.0001525179,0.000006188178],"category_scores_gemma":[0.0000030415963,0.00012377925,0.000054159955,0.00020410525,0.00019273347,0.00004077476,0.000036667287,0.0002670826,0.0000010783826],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013340444,0.000083650746,0.00006639542,0.00086356193,0.00060944166,0.00021176881,0.0011387366,2.456042e-7,0.000058940615,0.000105085324,0.00026259036,0.99526554],"study_design_scores_gemma":[0.00899067,0.004308012,0.011610396,0.00059207267,0.0006357369,0.0002231385,0.0005074601,0.000013571061,0.000031379568,0.00034396633,0.9724571,0.0002865125],"about_ca_topic_score_codex":0.00009977836,"about_ca_topic_score_gemma":0.000028701394,"teacher_disagreement_score":0.994979,"about_ca_system_score_codex":0.00006339642,"about_ca_system_score_gemma":0.0002598755,"threshold_uncertainty_score":0.5047571},"labels":[],"label_agreement":null},{"id":"W1479898930","doi":"10.1046/j.1464-410x.2001.02184.x","title":"Combined androgen blockade in prostate cancer: meta‐analyses and associated issues","year":2001,"lang":"en","type":"review","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"","keywords":"Prostate cancer; Citation; Blockade; Biomedical sciences; Medicine; Library science; Psychology; Family medicine; Cancer; Internal medicine; Computer science; Pathology","score_opus":0.11993346353606693,"score_gpt":0.4339209135808293,"score_spread":0.31398745004476236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1479898930","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016663392,0.9964691,3.2416628e-7,0.0009482664,0.00011754745,0.00059087214,0.00009698964,0.000010180979,0.00010039678],"genre_scores_gemma":[0.0003759642,0.9976067,0.00003064704,0.00008451837,0.00016114091,0.0000584675,0.00007067746,0.000045599903,0.0015662613],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974185,0.00053390884,0.000990466,0.00028016884,0.00032560347,0.00045131595],"domain_scores_gemma":[0.9985054,0.00019180926,0.00070136867,0.00011533991,0.0002633445,0.00022271746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069584965,0.00030135465,0.0036541487,0.00049697235,0.000057054258,0.000049640905,0.0001543656,0.000300892,0.00023901448],"category_scores_gemma":[0.00020897135,0.0002334802,0.0005744688,0.00052277476,0.00017720611,0.000075303054,0.000064401655,0.0010220103,0.0000029151527],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036079832,0.00044562962,0.0015705691,0.002872326,0.020007832,0.028912533,0.000059777234,0.0000025153943,0.0000031385216,0.0000013528526,0.0024198922,0.94334364],"study_design_scores_gemma":[0.005249663,0.0016281694,0.00060325034,0.0063710674,0.033563916,0.019911222,0.000019116196,0.0000045896677,0.0000055959936,0.00010993725,0.93226945,0.0002640287],"about_ca_topic_score_codex":0.00068021275,"about_ca_topic_score_gemma":0.00031853217,"teacher_disagreement_score":0.9430796,"about_ca_system_score_codex":0.00018395885,"about_ca_system_score_gemma":0.0006861486,"threshold_uncertainty_score":0.9521046},"labels":[],"label_agreement":null},{"id":"W1482976758","doi":"10.1023/a:1025948823955","title":"Function of PEA3 Ets Transcription Factors in Mammary Gland Development and Oncogenesis","year":2003,"lang":"en","type":"review","venue":"Journal of Mammary Gland Biology and Neoplasia","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Biology; ETS transcription factor family; Carcinogenesis; Subfamily; Gene; Transcription factor; Progenitor cell; Mammary gland; Genetics; Embryonic stem cell; Cancer research; Cell biology; Cancer; Stem cell; Breast cancer","score_opus":0.04755337132886493,"score_gpt":0.32793077810754795,"score_spread":0.280377406778683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1482976758","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10882595,0.89036083,0.000052980908,0.00006551801,0.00024004473,0.00028873695,0.000012636986,0.0000034010793,0.00014987164],"genre_scores_gemma":[0.005253166,0.9939695,0.00026039119,0.00001966923,0.0000723468,0.000007074721,0.000109172,0.000012115067,0.00029656774],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848765,0.00022593942,0.0007264458,0.00021549923,0.00013437174,0.00021007976],"domain_scores_gemma":[0.99917036,0.00013263276,0.00038389722,0.000095225,0.00007543205,0.00014244221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047737898,0.00027132934,0.001338824,0.00050499063,0.00004937199,0.000010813775,0.00007120091,0.00044379817,0.000012548429],"category_scores_gemma":[0.000015738175,0.00015556117,0.0001633851,0.00017810581,0.000081189486,0.00009606799,0.000024594088,0.00040897718,5.0185156e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000793874,0.00015713462,0.047902953,0.005923375,0.0007137183,0.00024301866,0.00020635109,2.6821454e-8,0.0001222324,0.000028778048,0.00012598312,0.94378257],"study_design_scores_gemma":[0.0040716156,0.0019179599,0.04316433,0.0048993407,0.0009046056,0.0021284053,0.00006494279,5.1980305e-7,0.00014273502,0.000075284304,0.9423896,0.00024065813],"about_ca_topic_score_codex":0.0000075670805,"about_ca_topic_score_gemma":0.000023964738,"teacher_disagreement_score":0.9435419,"about_ca_system_score_codex":0.00008924349,"about_ca_system_score_gemma":0.0006083153,"threshold_uncertainty_score":0.63436},"labels":[],"label_agreement":null},{"id":"W1489117452","doi":"10.5489/cuaj.2994","title":"What’s New in Prostate Cancer Research? Highlights of GU-ASCO 2015","year":2015,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Canadian Urological Association","funders":"Association Française d'Urologie","keywords":"Prostate cancer; Medicine; Oncology; Cancer; Gynecology; Internal medicine","score_opus":0.13900407770504478,"score_gpt":0.43115125634870827,"score_spread":0.29214717864366346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1489117452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020498689,0.97207105,1.4168708e-7,0.02489545,0.00086950115,0.0010956412,0.000105103274,0.0000099696645,0.0007481299],"genre_scores_gemma":[0.0001165387,0.9784923,0.000024423114,0.00019177415,0.0010375855,0.00007603445,0.00012662233,0.000038003018,0.019896697],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951736,0.00096816785,0.00093916204,0.00039129928,0.0013619402,0.0011658543],"domain_scores_gemma":[0.99558866,0.00029682156,0.00057922857,0.00023061251,0.0012485184,0.0020561859],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0035427324,0.00031740568,0.0017251743,0.0013188603,0.0001424008,0.00018391814,0.0003302747,0.00069358206,0.0007097515],"category_scores_gemma":[0.0008235216,0.0002070519,0.0003464624,0.0012041113,0.000104076506,0.00025122915,0.000054843178,0.0025051937,0.00012516664],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00014556864,0.0001195583,0.005631384,0.0010666912,0.0005597492,0.0010358401,0.00041171184,0.000003083647,6.790224e-7,0.000093815346,0.32679385,0.6641381],"study_design_scores_gemma":[0.0013768591,0.00044213588,0.000973844,0.004252366,0.00023344094,0.000101895566,0.00006872987,0.0000014290013,8.440419e-7,0.00062962546,0.9917429,0.00017594143],"about_ca_topic_score_codex":0.008971134,"about_ca_topic_score_gemma":0.0070785303,"teacher_disagreement_score":0.66494906,"about_ca_system_score_codex":0.010034434,"about_ca_system_score_gemma":0.022860767,"threshold_uncertainty_score":0.9997961},"labels":[],"label_agreement":null},{"id":"W1489890125","doi":"10.1111/bju.12589","title":"Radiographic progression by Prostate Cancer Working Group ( <scp>PCWG</scp> )‐2 criteria as an intermediate endpoint for drug development in metastatic castration‐resistant prostate cancer","year":2013,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Pfizer","keywords":"Docetaxel; Medicine; Prostate cancer; Hazard ratio; Prednisone; Internal medicine; Oncology; Sunitinib; Enzalutamide; Cancer; Placebo; Proportional hazards model; Surgery; Urology; Pathology; Confidence interval","score_opus":0.0201216627369534,"score_gpt":0.32508315439255786,"score_spread":0.3049614916556045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1489890125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96240205,0.03327561,0.00004157995,0.0015549081,0.00045401746,0.0021357837,0.00007759666,0.000022661792,0.000035784058],"genre_scores_gemma":[0.9824663,0.012739405,0.0019454745,0.00041307948,0.00019316509,0.0014785115,0.0001490812,0.00006387706,0.00055111916],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99697495,0.0002764064,0.0010262446,0.00042202964,0.00047620453,0.0008241754],"domain_scores_gemma":[0.9982419,0.00016015006,0.00054311904,0.00013464259,0.0004954364,0.0004247546],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009128514,0.0002827187,0.00067524594,0.00045541103,0.00017891385,0.00018710144,0.00020884478,0.00009867414,0.00014362049],"category_scores_gemma":[0.00013909292,0.00024690348,0.00013735742,0.00035656642,0.00022451933,0.00045931147,0.000054506047,0.00056411757,0.0000035835042],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062726825,0.0026333379,0.13322896,0.0012592786,0.0015169085,0.0056697316,0.012467649,0.00006549219,0.068237826,0.000027793494,0.026506139,0.7421142],"study_design_scores_gemma":[0.056757607,0.013023177,0.7648986,0.0078097438,0.0011175505,0.0067962687,0.00455844,0.0013962341,0.026275832,0.0037195217,0.1126375,0.0010095609],"about_ca_topic_score_codex":0.0008892562,"about_ca_topic_score_gemma":0.0016563602,"teacher_disagreement_score":0.74110466,"about_ca_system_score_codex":0.00031235113,"about_ca_system_score_gemma":0.0007640658,"threshold_uncertainty_score":0.99999833},"labels":[],"label_agreement":null},{"id":"W1496135731","doi":"10.1111/bju.12309","title":"Clinical trial risk in castration‐resistant prostate cancer: immunotherapies show promise","year":2013,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Clinical trial; Disease; Internal medicine; Oncology; Drug; Prostate; Cancer; Pharmacology","score_opus":0.036126367725369604,"score_gpt":0.3578999256971966,"score_spread":0.321773557971827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1496135731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738217,0.021143414,0.0000038501394,0.0035138258,0.0004171616,0.00091245136,0.000018520645,0.0000073733213,0.00016171159],"genre_scores_gemma":[0.96311486,0.035085965,0.00026679182,0.00019684328,0.00047504777,0.00007973198,0.000005037459,0.000017413682,0.0007583191],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99812776,0.0003359133,0.0008360041,0.00016160397,0.00023642146,0.0003022999],"domain_scores_gemma":[0.9989402,0.0001399159,0.00035586144,0.00010474534,0.00031057338,0.00014866759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089829916,0.00009820284,0.00047279467,0.00012740669,0.000060696228,0.0000546113,0.000107272324,0.0001254918,0.00054699136],"category_scores_gemma":[0.00026173177,0.000083617,0.00015568832,0.0001219528,0.0002056612,0.0001573858,0.000020226486,0.00071699306,0.000012167173],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14549911,0.0017297919,0.20615171,0.000061887666,0.0007058808,0.0046816296,0.00058246474,0.00003092246,0.0033334766,0.000009809819,0.00760263,0.6296107],"study_design_scores_gemma":[0.18629079,0.0113333585,0.788667,0.00023620002,0.00017505493,0.0025436755,0.00019520673,0.00007376765,0.00015759902,0.00087787834,0.009281876,0.00016757395],"about_ca_topic_score_codex":0.001308746,"about_ca_topic_score_gemma":0.00049667293,"teacher_disagreement_score":0.6294431,"about_ca_system_score_codex":0.000087250235,"about_ca_system_score_gemma":0.00059762516,"threshold_uncertainty_score":0.5989172},"labels":[],"label_agreement":null},{"id":"W1505602238","doi":"10.1111/j.1464-410x.2011.10871.x","title":"Advances in the management of high‐risk localised and metastatic prostate cancer","year":2012,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Docetaxel; Prostate cancer; Cabazitaxel; Androgen deprivation therapy; Prostatectomy; Radiation therapy; Oncology; Internal medicine; Cancer; Disease; Localized disease","score_opus":0.015615920459970421,"score_gpt":0.31644164334281555,"score_spread":0.30082572288284515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1505602238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.838059,0.16005382,0.000049768576,0.0012288607,0.00010114809,0.00023077526,0.000014255072,0.0000014071719,0.00026094264],"genre_scores_gemma":[0.8372472,0.16219617,0.0003055478,0.0001359411,0.000046829427,0.000013213135,0.0000016996424,0.000005086673,0.000048331574],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99915147,0.0001370561,0.0002512246,0.000061254206,0.0001911708,0.00020781097],"domain_scores_gemma":[0.99958575,0.000063997846,0.00016093387,0.000055685698,0.00006901539,0.000064646374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060077955,0.000055111806,0.00022932075,0.000072996554,0.000027311355,0.0000070269853,0.0000640252,0.000019872985,0.000042960673],"category_scores_gemma":[0.000016411594,0.00003710527,0.0000346593,0.000116733325,0.00013653004,0.00013187938,0.000020236963,0.00020526776,6.203813e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017218794,0.0005298849,0.19007479,0.0004354945,0.0004313128,0.0022500374,0.0010613165,0.00007684981,0.000052285854,0.0002373336,0.0005470581,0.8025818],"study_design_scores_gemma":[0.011761433,0.0016223113,0.9594195,0.00043415604,0.00082037854,0.00548524,0.0014110539,0.00003322031,0.00022911947,0.001888945,0.016792241,0.00010244072],"about_ca_topic_score_codex":0.00017138771,"about_ca_topic_score_gemma":0.00005323982,"teacher_disagreement_score":0.8024793,"about_ca_system_score_codex":0.000022510245,"about_ca_system_score_gemma":0.000033795433,"threshold_uncertainty_score":0.15131089},"labels":[],"label_agreement":null},{"id":"W1506162348","doi":"10.3747/co.v13i3.85","title":"Maximal Androgen Blockade for the Treatment of Metastatic Prostate Cancer—A Systematic Review","year":2006,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; London Health Sciences Centre; Cancer Care Ontario; McMaster University; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Flutamide; Meta-analysis; Oncology; Systematic review; Cyproterone acetate; Internal medicine; Randomized controlled trial; Subgroup analysis; Cochrane Library; Castration; MEDLINE; Cancer; Androgen; Androgen receptor; Hormone","score_opus":0.13501467743068563,"score_gpt":0.45587346878262597,"score_spread":0.32085879135194034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1506162348","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03501262,0.9491793,0.00006694956,0.0044036773,0.0004024138,0.010539783,0.00019919293,0.00002694578,0.00016912344],"genre_scores_gemma":[0.176636,0.7907909,0.0005024067,0.00024053888,0.00060361717,0.024326105,0.000514899,0.000080814585,0.0063047],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987041,0.00010020998,0.00048334486,0.0002080243,0.00019638697,0.00030793864],"domain_scores_gemma":[0.99891406,0.0003276274,0.00021880493,0.00027393468,0.00019811219,0.00006748607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024102502,0.00016822031,0.00091096363,0.00005918631,0.0000767713,0.00000563836,0.00008878889,0.000030766332,0.00005717279],"category_scores_gemma":[0.00004194953,0.00008170312,0.00022798586,0.00017001422,0.00013422804,0.000020889232,0.000013699672,0.00006207006,0.000008473506],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021890395,0.008590094,0.011368837,0.8685859,0.0029443502,0.00011338672,0.0011770161,0.000020218491,0.0007694468,0.00062515633,0.01583539,0.0877812],"study_design_scores_gemma":[0.04863218,0.027968833,0.003021039,0.13401173,0.046407476,0.00047090286,0.000868126,0.0023618191,0.022560427,0.0014867386,0.7113002,0.0009105491],"about_ca_topic_score_codex":0.000077257006,"about_ca_topic_score_gemma":0.000049388404,"teacher_disagreement_score":0.73457414,"about_ca_system_score_codex":0.00045903245,"about_ca_system_score_gemma":0.00039233832,"threshold_uncertainty_score":0.33317566},"labels":[],"label_agreement":null},{"id":"W1506877195","doi":"10.1111/j.1464-410x.2011.10127.x","title":"Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?","year":2011,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Rehabilitation Institute; Baycrest Hospital; Cancer Care Ontario; York University; University Health Network; Toronto General Hospital; University of Toronto; Institute for Clinical Evaluative Sciences; Toronto Public Health","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Antiandrogen; Population; Internal medicine; Bicalutamide; Oncology; Prostatectomy; Flutamide; Cancer; Androgen receptor","score_opus":0.0866915360597118,"score_gpt":0.3404078411806021,"score_spread":0.2537163051208903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1506877195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988137,0.010338599,0.00009142159,0.00090309145,0.00013934672,0.0002723199,0.000007586928,0.000008276301,0.000102379025],"genre_scores_gemma":[0.9856662,0.012945166,0.0004460144,0.0006390296,0.00014552934,0.000011013719,0.0000025612317,0.000017886587,0.00012658942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990267,0.000072415496,0.00032246357,0.00013828202,0.00016393003,0.00027620027],"domain_scores_gemma":[0.999369,0.00004155594,0.00017028832,0.0000627871,0.00022629325,0.00013002827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027965227,0.000079067955,0.00029000294,0.00019331911,0.000052481486,0.00002876831,0.000078052806,0.000059105492,0.00007494027],"category_scores_gemma":[0.000090665104,0.00007653771,0.000054676453,0.00018045392,0.000049488506,0.00017819006,0.00002026779,0.00030512677,0.0000036209856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016587579,0.000113347836,0.8539616,0.000015145082,0.00010137026,0.0035850701,0.0014882871,0.00008139374,0.0033239594,0.0000038577614,0.00037929293,0.13528791],"study_design_scores_gemma":[0.0077944016,0.0021272006,0.9684553,0.0006880609,0.00005640175,0.0043000453,0.0003516993,0.00006431064,0.009670621,0.00027668968,0.0060378993,0.00017733888],"about_ca_topic_score_codex":0.00071671244,"about_ca_topic_score_gemma":0.00042739997,"teacher_disagreement_score":0.13511057,"about_ca_system_score_codex":0.00012882607,"about_ca_system_score_gemma":0.0001454298,"threshold_uncertainty_score":0.31211174},"labels":[],"label_agreement":null},{"id":"W1507097934","doi":"10.1210/en.2012-1011","title":"Selective Cleavage of Human Sex Hormone-Binding Globulin by Kallikrein-Related Peptidases and Effects on Androgen Action in LNCaP Prostate Cancer Cells","year":2012,"lang":"en","type":"article","venue":"Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Dihydrotestosterone; Sex hormone-binding globulin; Androgen; LNCaP; Biology; Androgen receptor; Proteolysis; Endocrinology; Internal medicine; Prostate cancer; Chemistry; Biochemistry; Hormone; Cancer; Medicine; Genetics; Enzyme","score_opus":0.02185593404293199,"score_gpt":0.3357615613602231,"score_spread":0.3139056273172911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1507097934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991637,0.0058127097,4.0784644e-7,0.00021169665,0.00009204871,0.0007804116,0.000026161693,0.00003596757,0.0014036067],"genre_scores_gemma":[0.9947167,0.0036790003,0.000010266256,0.000044228418,0.000053951968,0.00012010423,0.00004922073,0.000022978136,0.001303543],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99871165,0.00011674052,0.00020283202,0.0002552906,0.0001413986,0.0005720664],"domain_scores_gemma":[0.9995419,0.00010431711,0.00008408957,0.00012146836,0.000030453219,0.00011781805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008209818,0.00016724282,0.00034145723,0.0002044861,0.000069628666,0.000005348628,0.000042958025,0.00009831097,0.000023046674],"category_scores_gemma":[0.000016166741,0.00013761985,0.000036598813,0.00019681599,0.000121249686,0.00008897646,0.000041179115,0.000311539,0.000016015489],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079774094,0.00033436593,0.17163809,0.00018431692,0.00020696176,0.00007602203,0.0014203773,0.0000024214796,0.80897915,0.000045451026,0.0028317084,0.013483391],"study_design_scores_gemma":[0.0046004783,0.00136313,0.074269116,0.000096386735,0.000054231274,0.000024958576,0.00021537246,0.000008170673,0.91868216,0.000030285742,0.0005422704,0.00011344528],"about_ca_topic_score_codex":0.0004160364,"about_ca_topic_score_gemma":0.000026964086,"teacher_disagreement_score":0.109703,"about_ca_system_score_codex":0.00024507102,"about_ca_system_score_gemma":0.00004381802,"threshold_uncertainty_score":0.56119746},"labels":[],"label_agreement":null},{"id":"W1507398635","doi":"10.1158/1538-7445.am2014-610","title":"Abstract 610: Preclinical evaluation of novel androgen receptor N-terminal domain inhibitor EPI-002 for the treatment of castration-resistant prostate cancer","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Androgen receptor; Prostate cancer; LNCaP; Cancer research; Reporter gene; Transfection; Tramp; Transcription factor; Chemistry; Luciferase; Androgen; Biology; Cancer; Medicine; Gene expression; Internal medicine; Endocrinology; Gene; Biochemistry; Hormone","score_opus":0.24168133760158508,"score_gpt":0.5061190440993341,"score_spread":0.264437706497749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1507398635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836967,0.00765305,0.00002877377,0.0027355044,0.00022695298,0.0047745467,0.00060599885,0.0000114262475,0.00026702942],"genre_scores_gemma":[0.9896592,0.0036210285,0.00036797475,0.000014137581,0.00065561535,0.0043794434,0.00009560939,0.000037815575,0.0011692101],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99660647,0.00021579514,0.0005902864,0.00044109422,0.001609724,0.000536656],"domain_scores_gemma":[0.99616116,0.0009834875,0.00019501364,0.0004822152,0.0019867113,0.0001913994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033526164,0.00018949836,0.00044507126,0.00017276384,0.00021952704,0.00002915954,0.0001739752,0.000107526066,0.0005695868],"category_scores_gemma":[0.00029176185,0.00011321124,0.00019245116,0.0003678632,0.0005574698,0.00008274321,0.0000313118,0.00021446496,0.0000051976326],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016860945,0.0028068025,0.008333867,0.0011100592,0.00092947035,0.000006441832,0.003016111,0.00033718473,0.7107041,0.00018633626,0.0037549143,0.25195378],"study_design_scores_gemma":[0.039273746,0.011042729,0.04309273,0.0014553983,0.00077245466,0.0000094441575,0.0013621068,0.004304725,0.8477157,0.00047317697,0.05012779,0.00037003023],"about_ca_topic_score_codex":0.0012693863,"about_ca_topic_score_gemma":0.00071994844,"teacher_disagreement_score":0.25158376,"about_ca_system_score_codex":0.0009181382,"about_ca_system_score_gemma":0.0022256477,"threshold_uncertainty_score":0.62365764},"labels":[],"label_agreement":null},{"id":"W1511220590","doi":"10.1002/j.1939-4640.2004.tb02791.x","title":"Medical Castration With LHRH Agonists: 25 Years Later With Major Benefits Achieved on Survival in Prostate Cancer","year":2004,"lang":"en","type":"review","venue":"Journal of Andrology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Prostate; Endocrine system; Population; Internal medicine; Oncology; Disease; Estrogen; Gynecology; Blockade; Hormone","score_opus":0.03564886583901987,"score_gpt":0.3601942859551712,"score_spread":0.32454542011615134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1511220590","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.037011195,0.95970005,0.0000016973011,0.0019869523,0.00023714744,0.00073736685,0.000033939414,0.000007460048,0.0002841981],"genre_scores_gemma":[0.004655284,0.9941725,0.00006932072,0.00010386253,0.00030382638,0.00004128427,0.000056168305,0.000046420177,0.0005513201],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979106,0.00014659418,0.0005962801,0.00025305361,0.00070960575,0.0003838276],"domain_scores_gemma":[0.99891293,0.00008053888,0.00044154434,0.00015158141,0.00015890508,0.00025449687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044465662,0.00029014217,0.0015340861,0.0003863864,0.000033858818,0.000020595257,0.00013667742,0.0003073569,0.00020024249],"category_scores_gemma":[0.000024166331,0.00014844444,0.00014538532,0.0002714809,0.00017100426,0.000066832225,0.000020424739,0.0012335387,0.000009400036],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013814722,0.0010065052,0.009642322,0.009127119,0.0023809916,0.03297618,0.00048540323,0.000082730934,0.000002638407,0.000087619104,0.00020633155,0.93018746],"study_design_scores_gemma":[0.055524047,0.04825247,0.023083236,0.15454869,0.004634253,0.031111455,0.000107046515,0.000008065843,0.000033410633,0.000070397655,0.6815164,0.001110539],"about_ca_topic_score_codex":0.00008758892,"about_ca_topic_score_gemma":0.0006161253,"teacher_disagreement_score":0.9290769,"about_ca_system_score_codex":0.0004635396,"about_ca_system_score_gemma":0.0035750626,"threshold_uncertainty_score":0.63420075},"labels":[],"label_agreement":null},{"id":"W1516406055","doi":"10.1111/j.1365-2559.2011.04030.x","title":"Targeted therapy in prostate cancer","year":2011,"lang":"en","type":"review","venue":"Histopathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Prostate; Cancer; Oncology; Targeted therapy; Gynecology; Internal medicine","score_opus":0.11267244047604905,"score_gpt":0.4058579241463719,"score_spread":0.2931854836703228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1516406055","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011752044,0.99473494,3.221841e-7,0.0000762696,0.000449337,0.0016595747,0.000052073738,0.000050526927,0.002859409],"genre_scores_gemma":[0.000016432512,0.981454,0.000056806824,0.00009700083,0.0001257634,0.0014114823,0.00021904275,0.0000740606,0.01654539],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99828166,0.00019542075,0.00042421167,0.0005072676,0.00011266582,0.0004787547],"domain_scores_gemma":[0.99924296,0.000029650324,0.00015320379,0.00039737904,0.0000629627,0.00011385822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019893193,0.00034460783,0.0016625185,0.0004760419,0.000036705318,0.0000042510405,0.00014279335,0.00030428922,0.00080988015],"category_scores_gemma":[0.000019247022,0.00022883165,0.0002601783,0.00035017336,0.00019304047,0.00002654669,0.000047241723,0.0006173323,0.00019964023],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017279474,0.00016823396,0.0011073423,0.0041363123,0.000023222494,0.0019497713,0.00042175545,1.0492406e-8,0.0000061134406,0.00003775394,0.0013088533,0.9906678],"study_design_scores_gemma":[0.0011844429,0.0003903156,0.0013778236,0.002998456,0.0001534965,0.00026783205,0.000005411015,1.4467768e-7,0.0000031764935,0.00003253782,0.9933909,0.00019542596],"about_ca_topic_score_codex":0.00019909673,"about_ca_topic_score_gemma":0.00004431655,"teacher_disagreement_score":0.99208206,"about_ca_system_score_codex":0.00061658246,"about_ca_system_score_gemma":0.0010591979,"threshold_uncertainty_score":0.9331483},"labels":[],"label_agreement":null},{"id":"W1525421321","doi":"10.1016/j.urolonc.2014.07.015","title":"Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial","year":2014,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Howard Hughes Medical Institute","keywords":"Dutasteride; Medicine; Placebo; Prostate cancer; Urology; Internal medicine; Prostate; Prostate-specific antigen; Oncology; Gynecology; Pathology; Cancer","score_opus":0.06643154723480511,"score_gpt":0.39528646442052867,"score_spread":0.32885491718572357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1525421321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951201,0.00041715507,0.0000081483995,0.0023826319,0.00009494075,0.0013498142,0.000012931849,0.000011387959,0.0006028628],"genre_scores_gemma":[0.9849752,0.0005430272,0.013269055,0.00056367693,0.000050252107,0.00028005787,0.00010378042,0.000013316061,0.00020162416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984706,0.00024947964,0.00047664158,0.00034787512,0.00018842478,0.00026699385],"domain_scores_gemma":[0.9992671,0.00011954715,0.000192477,0.00018260522,0.00009766175,0.00014058275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006923904,0.00013059423,0.00042619495,0.00018088415,0.00004182086,0.0000069798048,0.000066865134,0.00016728207,0.000011267608],"category_scores_gemma":[0.00024005368,0.000092699534,0.000032609845,0.0002892369,0.0005124017,0.00005899072,0.00003694878,0.00031766918,0.000001173379],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019853469,0.0005954363,0.9751395,0.000045763958,0.000041800842,0.00005784494,0.00020276206,0.00004120948,0.00023967953,0.00020449887,0.00008235339,0.0034956862],"study_design_scores_gemma":[0.1945832,0.036956824,0.7110987,0.0005864851,0.00033087755,0.000014822405,0.00015295701,0.0009772663,0.0038495434,0.0030269423,0.04802765,0.00039474925],"about_ca_topic_score_codex":0.00010782839,"about_ca_topic_score_gemma":0.000080567566,"teacher_disagreement_score":0.26404083,"about_ca_system_score_codex":0.00011821341,"about_ca_system_score_gemma":0.0003671141,"threshold_uncertainty_score":0.37801772},"labels":[],"label_agreement":null},{"id":"W1527439723","doi":"10.18632/oncotarget.4105","title":"Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression","year":2015,"lang":"en","type":"article","venue":"Oncotarget","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada","keywords":"Androgen receptor; Prostate cancer; Enzalutamide; LNCaP; Cancer research; Medicine; Cell growth; Cancer; Biology; Chemistry; Internal medicine; Biochemistry","score_opus":0.02812540724146859,"score_gpt":0.3326202619359871,"score_spread":0.3044948546945185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1527439723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835446,0.010597876,5.1928924e-7,0.0044203955,0.00017314022,0.0007703868,0.000058930244,0.000024305333,0.00040983682],"genre_scores_gemma":[0.9964742,0.0005960419,0.00016592469,0.0000760201,0.00018790722,0.00012020231,0.00008918185,0.000021399896,0.0022690988],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989005,0.0000465328,0.00020413812,0.00021478301,0.00037527108,0.00025879254],"domain_scores_gemma":[0.9992852,0.000035500594,0.00008446415,0.00019361671,0.00017537206,0.00022580281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028818322,0.00013231582,0.00023751696,0.00005876729,0.00012143062,0.00001665506,0.00007129084,0.00005678058,0.000049832805],"category_scores_gemma":[0.000050699367,0.00007183967,0.000043957032,0.00018264755,0.00019430005,0.00009797695,0.000105908744,0.00014563493,0.000005555753],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041234507,0.0008508943,0.6742018,0.0008002545,0.0004658309,0.00012132828,0.022115672,0.000030226107,0.20862761,0.000041724896,0.058808763,0.02981249],"study_design_scores_gemma":[0.0063250605,0.0016867302,0.003396948,0.000857453,0.00016854111,0.000025890686,0.0017282299,0.00018702155,0.9225158,0.00014287881,0.062726304,0.0002391495],"about_ca_topic_score_codex":0.00017996453,"about_ca_topic_score_gemma":0.00001187084,"teacher_disagreement_score":0.71388817,"about_ca_system_score_codex":0.00010902072,"about_ca_system_score_gemma":0.00032116062,"threshold_uncertainty_score":0.29295367},"labels":[],"label_agreement":null},{"id":"W1527731547","doi":"","title":"Inhibition of angiogenesis and MMP-9 expression by PCK3145 is mediated through targeting of the Akt signaling pathway","year":2006,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université du Québec à Montréal","funders":"","keywords":"Prostate cancer; Medicine; Angiogenesis; Cancer; Protein kinase B; Prostate; Cancer research; Internal medicine; Endocrinology; In vivo; Metastasis; Biology; Signal transduction","score_opus":0.05163472821041296,"score_gpt":0.3615203585525663,"score_spread":0.30988563034215333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1527731547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978741,0.018393723,0.00001910169,0.0013735737,0.000036725472,0.00055245124,0.00016913228,0.000012195648,0.0007020994],"genre_scores_gemma":[0.9976449,0.0010233315,0.00010200953,0.00004352584,0.00011223071,0.00009393192,0.0000626399,0.000023260036,0.0008941857],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980102,0.00018364665,0.0002871197,0.00026814695,0.0008819008,0.0003689796],"domain_scores_gemma":[0.99892545,0.00020509564,0.000093716066,0.00022331148,0.00048214637,0.00007027569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006163229,0.00010881428,0.00024359068,0.00010672114,0.00017378242,0.000012475523,0.000096488,0.00009995447,0.00022660357],"category_scores_gemma":[0.00009834864,0.00006711788,0.00007943653,0.00063199585,0.00041069312,0.000088615736,0.00013117654,0.0002286478,0.0000021518563],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028036284,0.00009410134,0.021096874,0.0003321094,0.000030940195,0.0000054095585,0.000696595,0.00000432631,0.9638762,0.00001667836,0.012991928,0.0005744833],"study_design_scores_gemma":[0.0013113461,0.00013867924,0.001276408,0.00064212544,0.000016661359,0.0000012040566,0.00042531526,0.000017249056,0.9938932,0.0002602687,0.0019557981,0.000061744184],"about_ca_topic_score_codex":0.0019598566,"about_ca_topic_score_gemma":0.000015586555,"teacher_disagreement_score":0.030017009,"about_ca_system_score_codex":0.00013782646,"about_ca_system_score_gemma":0.0003008423,"threshold_uncertainty_score":0.296273},"labels":[],"label_agreement":null},{"id":"W1528881540","doi":"10.18632/oncotarget.3602","title":"Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer","year":2015,"lang":"en","type":"article","venue":"Oncotarget","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"National Institutes of Health; Prostate Cancer Foundation","keywords":"Enzalutamide; Prostate cancer; Medicine; Lapatinib; Cancer; Cancer research; Oncology; Pharmacology; Internal medicine; Androgen receptor; Trastuzumab; Breast cancer","score_opus":0.027407113972026963,"score_gpt":0.31807678849248483,"score_spread":0.2906696745204579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1528881540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994215,0.00067576615,0.000007777569,0.0022383432,0.00009040617,0.0008369492,0.00007187526,0.000021895543,0.0018419698],"genre_scores_gemma":[0.99821436,0.00017090712,0.00038720877,0.00009880278,0.00007863083,0.00011087502,0.00004915382,0.000020925994,0.0008691021],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99853724,0.00010124992,0.00031722654,0.00026370594,0.0004917518,0.00028880208],"domain_scores_gemma":[0.99916035,0.000058380392,0.00013813401,0.00024081007,0.0002707827,0.00013155316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031124742,0.00015251704,0.00029867774,0.00007765339,0.0000534127,0.000017866107,0.000070572285,0.00004949241,0.000041496933],"category_scores_gemma":[0.00014541004,0.00008604488,0.00004513943,0.0004099606,0.00022384585,0.000098235,0.000031365606,0.00020012578,0.0000063965276],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008449889,0.0016624201,0.3811136,0.0005778089,0.00015000725,0.00040844808,0.0042499476,0.0005972757,0.5987198,0.0004104685,0.0019203848,0.0017399992],"study_design_scores_gemma":[0.009233638,0.002108587,0.62693167,0.0019473967,0.0001008422,0.000021010046,0.0007841889,0.00015862424,0.35564092,0.00024711588,0.0025759346,0.00025006314],"about_ca_topic_score_codex":0.0010406795,"about_ca_topic_score_gemma":0.0012850562,"teacher_disagreement_score":0.24581808,"about_ca_system_score_codex":0.0002726349,"about_ca_system_score_gemma":0.00091608806,"threshold_uncertainty_score":0.35088083},"labels":[],"label_agreement":null},{"id":"W1529733618","doi":"10.1016/s0079-6123(10)82014-x","title":"Hormonal Therapy of Prostate Cancer","year":2010,"lang":"en","type":"article","venue":"Progress in brain research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Prostate cancer; Testosterone (patch); Medicine; Androgen; Dihydrotestosterone; Castration; Prostate; Internal medicine; Endocrinology; Hormone; Cancer; Blockade; Metastasis; Urology; Receptor","score_opus":0.09183477743785337,"score_gpt":0.4797506931542794,"score_spread":0.38791591571642603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1529733618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.966965,0.013593818,2.0997123e-7,0.015652057,0.000090270245,0.0013685243,0.000018750223,0.000024075782,0.0022872481],"genre_scores_gemma":[0.99225396,0.003466996,0.00035585873,0.000056545967,0.00015098261,0.00089055113,0.000019467918,0.000030517405,0.002775121],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746966,0.00014584864,0.0002494845,0.00033541798,0.0010982689,0.0007012991],"domain_scores_gemma":[0.9986058,0.00027818303,0.00003821184,0.00036815667,0.0005234069,0.00018624215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019371862,0.00012163515,0.000257849,0.00049501704,0.00008299968,0.00003005608,0.00023323963,0.0001235765,0.00052531826],"category_scores_gemma":[0.00017077551,0.00008488447,0.000060967966,0.000903568,0.0010535999,0.00008010564,0.00011888278,0.0011708523,0.000016951359],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016921699,0.0005091605,0.67493665,0.00011564644,0.00004926666,0.000104135266,0.00075749354,1.9171381e-7,0.019445216,0.00038700728,0.0017006494,0.30030242],"study_design_scores_gemma":[0.007897231,0.0013657783,0.8393362,0.00028540005,0.0000039821907,0.000020264273,0.0002578715,0.00021551897,0.106707335,0.0014069816,0.042318154,0.00018529888],"about_ca_topic_score_codex":0.00018077453,"about_ca_topic_score_gemma":0.000102334576,"teacher_disagreement_score":0.30011714,"about_ca_system_score_codex":0.00008472838,"about_ca_system_score_gemma":0.00071968307,"threshold_uncertainty_score":0.57518667},"labels":[],"label_agreement":null},{"id":"W1532826293","doi":"10.1186/1471-2407-6-112","title":"Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group","year":2006,"lang":"en","type":"review","venue":"BMC Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Sunnybrook Health Science Centre; Cancer Care Ontario; McMaster University; London Health Sciences Centre","funders":"Ontario Ministry of Health and Long-Term Care; Cancer Care Ontario","keywords":"Medicine; Docetaxel; Mitoxantrone; Oncology; Internal medicine; Hormonal therapy; Prostate cancer; Cancer; Randomized controlled trial; Clinical trial; Chemotherapy","score_opus":0.05645599594862284,"score_gpt":0.36891650566873985,"score_spread":0.312460509720117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1532826293","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009865554,0.951758,9.238163e-7,0.00026465964,0.00017187012,0.03442642,0.0034135194,0.0000758847,0.000023112227],"genre_scores_gemma":[0.0027822584,0.86947393,0.000044170294,0.00025494694,0.00042070152,0.12486208,0.0013290265,0.00022058966,0.0006123145],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9929862,0.0008083315,0.0017371177,0.0018062956,0.0014727965,0.0011892541],"domain_scores_gemma":[0.9960716,0.00047869096,0.0010908982,0.0013383448,0.000511408,0.00050910766],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005562618,0.0015155773,0.004893737,0.00041839504,0.00020274225,0.0001833748,0.00062419893,0.00033040676,0.00014217451],"category_scores_gemma":[0.000035476904,0.0008131824,0.00066666154,0.001267555,0.00032644285,0.00035145952,0.0001623242,0.001416255,0.000005981673],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0028084747,0.00032077028,0.07539813,0.7870014,0.0012070464,0.00073148555,0.0022553082,0.000057931877,0.000003725436,2.9195107e-7,0.0015933565,0.1286221],"study_design_scores_gemma":[0.0061806436,0.00072471704,0.015529688,0.9090523,0.009967986,0.000016133152,0.00050027604,0.000032197368,0.0000014371889,6.894035e-7,0.05694753,0.0010464129],"about_ca_topic_score_codex":0.49476516,"about_ca_topic_score_gemma":0.53272235,"teacher_disagreement_score":0.1275757,"about_ca_system_score_codex":0.011431955,"about_ca_system_score_gemma":0.018402133,"threshold_uncertainty_score":0.9997593},"labels":[],"label_agreement":null},{"id":"W1533921436","doi":"10.1038/nrurol.2011.70","title":"Searching for bone metastases—how, when and why?","year":2011,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Referral; Bone metastasis; Radiology; Prostate; Oncology; Cancer; Internal medicine; Family medicine","score_opus":0.1258269472875962,"score_gpt":0.43365792864587666,"score_spread":0.30783098135828046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1533921436","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.6477645e-7,0.9909096,0.00006616201,0.0016338999,0.00027011926,0.006062877,0.0001272109,0.00003803651,0.0008918819],"genre_scores_gemma":[6.249001e-7,0.9915447,0.002525697,0.0009241307,0.0005140217,0.0011859009,0.00075406977,0.00009418226,0.0024566662],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971405,0.0006369225,0.00057892804,0.00080085784,0.00018320323,0.0006595688],"domain_scores_gemma":[0.99814254,0.00044999574,0.000349953,0.0006257527,0.00012753514,0.0003041974],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014349156,0.0005798049,0.003993277,0.00039671536,0.000112765956,0.000031278298,0.0002168349,0.001154802,0.00015043632],"category_scores_gemma":[0.00068608637,0.0003344041,0.00085042015,0.00023156118,0.00018322776,0.00006613719,0.00016532555,0.0022475964,0.000047500613],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000087070315,0.000052387866,0.0000017434236,0.040740684,0.00049300096,0.00008000653,0.00003304392,6.66562e-10,7.230552e-7,0.000911392,0.023716135,0.9338838],"study_design_scores_gemma":[0.00080796255,0.00060903234,7.055796e-7,0.0038906431,0.004634323,0.0008760259,0.0000016997911,6.431544e-7,8.462461e-7,0.00038703677,0.988551,0.00024003173],"about_ca_topic_score_codex":0.0000075029834,"about_ca_topic_score_gemma":0.000008046481,"teacher_disagreement_score":0.9648349,"about_ca_system_score_codex":0.000097148,"about_ca_system_score_gemma":0.00036041075,"threshold_uncertainty_score":0.9999108},"labels":[],"label_agreement":null},{"id":"W1541194979","doi":"","title":"The Synthesis of Abiraterone O-β-D Glucuronide For Use In Clinical Trials As A Reference Standard","year":2013,"lang":"en","type":"article","venue":"Journal of undergraduate research in Alberta","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Chemistry; Glucuronide; Metabolite; Glucuronate; Epitestosterone; Abiraterone; Chromatography; Urine; Combinatorial chemistry; Steroid; Prostate cancer; Biochemistry; Hormone; Cancer; Medicine; Internal medicine","score_opus":0.33327806631928825,"score_gpt":0.5214241290618334,"score_spread":0.1881460627425452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1541194979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81892765,0.0012690302,0.000027990427,0.17684858,0.00014596463,0.0021571151,0.00001137586,0.0000026549103,0.00060963124],"genre_scores_gemma":[0.9825755,0.0142019065,0.0005318952,0.00003460299,0.00011800252,0.00014394513,0.000002444703,0.00002573977,0.0023659829],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9928321,0.0028107725,0.0021753388,0.00024088018,0.0012416766,0.0006992317],"domain_scores_gemma":[0.9584168,0.038786173,0.0005826473,0.00043259468,0.0014212705,0.00036051322],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.023112576,0.00015241222,0.0010722575,0.0005696332,0.000100293735,0.00013228763,0.0003781273,0.00015049193,0.000023904298],"category_scores_gemma":[0.030806327,0.00008044611,0.00029561378,0.0005791529,0.0004833873,0.00030739894,0.00009834041,0.0010942342,0.000022766697],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10946801,0.004390223,0.38236648,0.0015384444,0.002693343,0.0007954841,0.00049795967,0.000057784808,0.0143799605,0.033454258,0.04194206,0.408416],"study_design_scores_gemma":[0.08318243,0.037810054,0.10121132,0.013863877,0.00054080045,0.00045673913,0.0027455902,0.0023488784,0.07648465,0.60393745,0.07640499,0.0010132282],"about_ca_topic_score_codex":0.005321795,"about_ca_topic_score_gemma":0.0029943024,"teacher_disagreement_score":0.5704832,"about_ca_system_score_codex":0.00044006898,"about_ca_system_score_gemma":0.0017339435,"threshold_uncertainty_score":0.9773576},"labels":[],"label_agreement":null},{"id":"W1541275643","doi":"10.1158/1557-3265.pms14-a12","title":"Abstract A12: Identification of pathways associated with abiraterone resistance in metastatic castration resistant prostate cancer: Preliminary results from the SU2C/AACR West Coast Prostate Cancer Dream Team","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Enzalutamide; Prostate cancer; Medicine; Biopsy; Oncology; PTEN; Cancer; Metastasis; Liquid biopsy; Prostate biopsy; Abiraterone; Circulating tumor cell; Cancer research; Internal medicine; Pathology; Androgen receptor; Biology; PI3K/AKT/mTOR pathway; Genetics","score_opus":0.2170817800880807,"score_gpt":0.4558618881354091,"score_spread":0.2387801080473284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1541275643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96868026,0.0120096635,0.0000019091956,0.009654469,0.00028570075,0.0039971825,0.0048071383,0.00006278528,0.0005008983],"genre_scores_gemma":[0.9829466,0.009940042,0.0000854401,0.00009254168,0.00028505016,0.002169727,0.0009287164,0.00009364178,0.003458266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9913058,0.0013339384,0.0022951206,0.0012798966,0.0026147594,0.0011704544],"domain_scores_gemma":[0.99241,0.0022586528,0.00092132937,0.0010996106,0.0027409275,0.0005694958],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009133241,0.0004262393,0.0010036756,0.0002738288,0.00031435292,0.00016336593,0.0005645579,0.00024855172,0.000083835555],"category_scores_gemma":[0.002684961,0.00027517552,0.00014909709,0.0017592547,0.0014648768,0.00040315773,0.0001892385,0.001791398,0.000022201246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3550245,0.0061805435,0.48770767,0.001340537,0.002130283,0.0013573685,0.02582132,0.0012622238,0.039937124,0.000099724384,0.05271281,0.026425911],"study_design_scores_gemma":[0.020911742,0.0031580655,0.9544659,0.0041396697,0.00026414063,0.0000026677894,0.0041031917,0.0002759137,0.010037574,0.00058522035,0.0016380564,0.000417807],"about_ca_topic_score_codex":0.03022969,"about_ca_topic_score_gemma":0.10626475,"teacher_disagreement_score":0.46675828,"about_ca_system_score_codex":0.0018077275,"about_ca_system_score_gemma":0.006536921,"threshold_uncertainty_score":0.99997},"labels":[],"label_agreement":null},{"id":"W1544248116","doi":"10.5772/52905","title":"Trithorax Genes in Prostate Cancer","year":2013,"lang":"en","type":"book-chapter","venue":"InTech eBooks","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Prostate Cancer Canada","keywords":"Prostate cancer; Biology; Gene; Computational biology; Cancer; Genetics","score_opus":0.047925809360503106,"score_gpt":0.3354997646771337,"score_spread":0.2875739553166306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1544248116","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039219004,0.014160267,0.000004478788,0.00088687974,0.00027897386,0.0025812655,0.00009320687,0.00012066103,0.97795236],"genre_scores_gemma":[0.021702643,0.0033608319,0.0001080685,0.00019445998,0.00025743767,0.0005942907,0.00005584542,0.0001095183,0.9736169],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983637,0.00001203258,0.00037062043,0.0004619277,0.00038204752,0.00040971936],"domain_scores_gemma":[0.9990861,0.000031845062,0.00010480557,0.00039187638,0.00021048324,0.00017493448],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000113105765,0.00037119992,0.0005952473,0.0004062456,0.000038710423,0.00003304042,0.00013972928,0.00031911075,0.0018094402],"category_scores_gemma":[0.000009314444,0.00027571773,0.0001584918,0.00002203705,0.00021038698,0.00002880427,0.0001056823,0.00076785055,0.00046572258],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013897424,0.00008724498,0.0012025146,0.0010129415,0.00066426524,0.0022826854,0.00071642996,1.5735536e-7,0.041324385,0.0020643617,0.006567219,0.94268805],"study_design_scores_gemma":[0.0031875232,0.00053729845,0.00011519987,0.003262873,0.00015673341,0.000068406414,0.000043520027,0.000006767565,0.10386566,0.00878347,0.87944996,0.00052255683],"about_ca_topic_score_codex":0.0004762355,"about_ca_topic_score_gemma":0.00019871202,"teacher_disagreement_score":0.9421655,"about_ca_system_score_codex":0.00049012364,"about_ca_system_score_gemma":0.00055578916,"threshold_uncertainty_score":0.9999695},"labels":[],"label_agreement":null},{"id":"W1544742800","doi":"10.1002/cncr.21695","title":"First‐ and second‐line chemotherapy with docetaxel or mitoxantrone in patients with hormone‐refractory prostate cancer","year":2006,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Abbott Laboratories","keywords":"Mitoxantrone; Medicine; Docetaxel; Oncology; Chemotherapy; Prostate cancer; Internal medicine; Cancer; Refractory (planetary science); Prostate","score_opus":0.009183391678185947,"score_gpt":0.2689616571266287,"score_spread":0.25977826544844274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1544742800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827334,0.013979055,0.0000045742277,0.0016531509,0.00004362169,0.0011299024,0.00011928061,0.000033244425,0.0003037406],"genre_scores_gemma":[0.9799446,0.006502534,0.00017718604,0.00036654677,0.00019351002,0.0004860004,0.0000631767,0.00005864937,0.012207808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865925,0.000013785103,0.00018647083,0.00038399873,0.00031800626,0.00043850706],"domain_scores_gemma":[0.99941397,0.000024418474,0.00008183735,0.00020048859,0.00014984331,0.00012943895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005131042,0.00023888322,0.00035523385,0.0001136465,0.00007240182,0.000025437123,0.000054413413,0.000070138456,0.000566303],"category_scores_gemma":[0.0000029075836,0.00012974725,0.000021200261,0.000293188,0.00017987042,0.00014950971,0.000017182392,0.00021781864,0.0000031416148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019684872,0.0005557625,0.95994675,0.0002568503,0.00018752375,0.00009670122,0.00044844052,0.000058204547,0.00059054414,0.0000034834802,0.0037295865,0.014441302],"study_design_scores_gemma":[0.028046453,0.0018972869,0.93736297,0.00037571788,0.0000633237,0.0000042437855,0.000047745827,0.000054754863,0.0013393972,0.000010804578,0.030553548,0.00024378372],"about_ca_topic_score_codex":0.0011510011,"about_ca_topic_score_gemma":0.005312498,"teacher_disagreement_score":0.026823962,"about_ca_system_score_codex":0.00038427638,"about_ca_system_score_gemma":0.000402307,"threshold_uncertainty_score":0.62006205},"labels":[],"label_agreement":null},{"id":"W1547584179","doi":"10.1111/j.1742-1241.2012.02944.x","title":"Targeting the Androgen receptor: 70 years on and still relevant","year":2012,"lang":"en","type":"editorial","venue":"International Journal of Clinical Practice","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Androgen receptor; Androgen; Endocrinology; Internal medicine; Prostate cancer; Hormone; Cancer","score_opus":0.067930952205883,"score_gpt":0.4884388193514877,"score_spread":0.42050786714560473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1547584179","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005434637,0.008392347,0.000019093637,0.027266134,0.9555912,0.00027194247,0.00008559405,0.000010235355,0.0029288218],"genre_scores_gemma":[0.008888545,0.041310947,0.0010610557,0.0008534214,0.94597507,0.0000038918924,0.000078778554,0.000039842933,0.0017884369],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958296,0.0004319026,0.0011401599,0.00019440257,0.0022102874,0.00019363781],"domain_scores_gemma":[0.9806393,0.015505565,0.0015274722,0.00016179399,0.0019219047,0.00024399764],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0052806595,0.00015826931,0.00048485523,0.00010972967,0.000039260467,0.0000908064,0.00034433862,0.00039366164,0.00015394154],"category_scores_gemma":[0.051274966,0.00009026994,0.00024685732,0.00005124318,0.00016483918,0.00030435115,0.000120678975,0.002981819,0.00008496929],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007587118,0.00042252257,0.00050064764,0.000016702408,0.0014500617,0.00057673024,0.00013323959,0.0000014639788,0.000016313597,0.000026471738,0.95840293,0.030865809],"study_design_scores_gemma":[0.00265006,0.0009591964,0.00039146486,0.0003710287,0.00039956803,0.00016149192,0.00010981184,0.000006994528,0.000017253205,0.00005593284,0.9947938,0.00008344153],"about_ca_topic_score_codex":0.000017091033,"about_ca_topic_score_gemma":5.5192334e-7,"teacher_disagreement_score":0.045994308,"about_ca_system_score_codex":0.00016431457,"about_ca_system_score_gemma":0.0008118524,"threshold_uncertainty_score":0.99931836},"labels":[],"label_agreement":null},{"id":"W1547768274","doi":"10.5489/cuaj.867","title":"IRM et cancer de la prostate: vers de nouveaux horizons","year":2013,"lang":"fr","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Internal medicine","score_opus":0.012569680591383057,"score_gpt":0.29556828909316707,"score_spread":0.282998608501784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1547768274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5912497,0.022446694,0.00006798926,0.36671242,0.0020065093,0.0007012459,0.000357255,0.000039335275,0.016418852],"genre_scores_gemma":[0.9450641,0.015713356,0.00026468444,0.008901899,0.0018315808,0.00012331082,0.000040237737,0.000035538753,0.028025247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99623096,0.0010312786,0.00033163774,0.00024010667,0.00044705978,0.001718975],"domain_scores_gemma":[0.9962465,0.0005368965,0.00020831531,0.00010976962,0.0004292011,0.002469321],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018873429,0.00022582836,0.00031770716,0.00020490821,0.0004496498,0.00038616167,0.00018556655,0.0006536342,0.008060407],"category_scores_gemma":[0.0012113199,0.00018748961,0.00017599978,0.00032270624,0.0001936334,0.00025863745,0.000024356666,0.0018584937,0.00042673058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000065313696,0.000119204,0.74764764,0.00002420415,0.00040037686,0.00061317807,0.0011639702,0.0001969463,0.00034233325,0.00083986134,0.22406025,0.02452675],"study_design_scores_gemma":[0.0020386905,0.0006675405,0.57554126,0.00010019988,0.00017136209,0.0002604679,0.00048188976,0.0004715155,0.00005639564,0.0025915483,0.41742143,0.00019772696],"about_ca_topic_score_codex":0.060869787,"about_ca_topic_score_gemma":0.00439709,"teacher_disagreement_score":0.35781053,"about_ca_system_score_codex":0.013987804,"about_ca_system_score_gemma":0.009446413,"threshold_uncertainty_score":0.9961691},"labels":[],"label_agreement":null},{"id":"W1549522748","doi":"10.1016/j.eururo.2015.04.032","title":"Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302","year":2015,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Alberta Cancer Foundation; Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Abiraterone acetate; Concomitant; Prednisone; Prostate cancer; Interim analysis; Post-hoc analysis; Hazard ratio; Internal medicine; Oncology; Placebo; Cancer; Urology; Surgery; Androgen deprivation therapy; Clinical trial; Confidence interval; Pathology","score_opus":0.02907524792620767,"score_gpt":0.3280388085479521,"score_spread":0.2989635606217444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1549522748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99691504,0.0011510318,0.0000015257673,0.00018797172,0.000018649174,0.0012798555,0.0002448586,0.000021969507,0.00017911804],"genre_scores_gemma":[0.9991216,0.00014936409,0.00003883131,0.00005237565,0.00001016674,0.000042655047,0.00030857473,0.000049606984,0.00022682792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774337,0.00058897934,0.00057091913,0.00036217485,0.0003776924,0.00035685985],"domain_scores_gemma":[0.9984579,0.000053058284,0.00032838064,0.00033290792,0.0006766782,0.00015103786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043411186,0.00026312648,0.00085457636,0.000642557,0.000028658422,0.000012030017,0.00010143213,0.000029723158,0.00013342994],"category_scores_gemma":[0.00003580929,0.00016084511,0.00012029402,0.0011440173,0.0002196964,0.00008436336,0.00002880247,0.00015276737,0.000005252388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027716992,0.0025339192,0.934388,0.00003614661,0.006352819,0.00030067813,0.012005946,0.00063419633,0.014727742,8.209795e-7,0.000054630807,0.0012481291],"study_design_scores_gemma":[0.01754834,0.02320549,0.9561471,0.000018731778,0.0012877573,0.0000029507698,0.0007661652,0.00016015448,0.00071625685,0.0000016114276,0.000016010878,0.0001294578],"about_ca_topic_score_codex":0.0014527305,"about_ca_topic_score_gemma":0.00093781075,"teacher_disagreement_score":0.021759093,"about_ca_system_score_codex":0.0001631675,"about_ca_system_score_gemma":0.0002988907,"threshold_uncertainty_score":0.65590733},"labels":[],"label_agreement":null},{"id":"W1549596568","doi":"10.1002/pros.22965","title":"Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America","year":2015,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Western University; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; BC Cancer Agency; Université de Montréal; University Health Network","funders":"National Cancer Institute; Astellas Pharma; Exelixis; Sanofi; Pfizer; Amgen","keywords":"Enzalutamide; Prostate cancer; Docetaxel; Cabazitaxel; Medicine; Adverse effect; Internal medicine; Oncology; Population; Discontinuation; Expanded access; Cancer; Urology; Androgen deprivation therapy","score_opus":0.03335284117947412,"score_gpt":0.3166108667720986,"score_spread":0.2832580255926245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1549596568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941894,0.00063733885,0.000006233629,0.0006328119,0.000015591831,0.003996219,0.00020545354,0.000031357165,0.00028561114],"genre_scores_gemma":[0.9976868,0.00048136924,0.00017722746,0.00007624473,0.00000950147,0.00058383297,0.00026854224,0.000045098415,0.00067140517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977,0.00018587164,0.00051093445,0.00037394906,0.0006685727,0.0005606693],"domain_scores_gemma":[0.9986651,0.00006356933,0.00026988372,0.00039665366,0.0004094714,0.0001953073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003043982,0.0002894882,0.0005762826,0.00022594842,0.000058248774,0.00004380075,0.00019623856,0.000027024644,0.00002288109],"category_scores_gemma":[0.000039555183,0.00014474428,0.00003532546,0.0013019174,0.00031274476,0.00031234178,0.00006501941,0.00026616856,0.0000039849724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03709252,0.0006147065,0.94731146,0.00022273303,0.000214777,0.00012742472,0.0074053113,0.0018662767,0.00009542697,0.0000029049997,0.000038906004,0.0050075306],"study_design_scores_gemma":[0.027846752,0.0032522439,0.9643496,0.0006385463,0.00022442457,0.000006442516,0.000971439,0.00018206553,0.0020194137,0.000040227147,0.0002061113,0.00026270398],"about_ca_topic_score_codex":0.0038309284,"about_ca_topic_score_gemma":0.009563745,"teacher_disagreement_score":0.017038148,"about_ca_system_score_codex":0.00042444724,"about_ca_system_score_gemma":0.00091341726,"threshold_uncertainty_score":0.59025},"labels":[],"label_agreement":null},{"id":"W1549619413","doi":"10.1038/ng.3315","title":"Spatial genomic heterogeneity within localized, multifocal prostate cancer","year":2015,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":489,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Genome British Columbia; Université Laval; University of Toronto; University Health Network; Toronto General Hospital; BC Cancer Agency; Simon Fraser University; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Cancer Research UK","keywords":"Biology; Prostate cancer; Genomics; Cancer; Genetic heterogeneity; Prostate; Computational biology; Tumor heterogeneity; Genome; Single-nucleotide polymorphism; Genetics; Gene; Genotype; Phenotype","score_opus":0.03187420802986779,"score_gpt":0.3501329320635392,"score_spread":0.3182587240336714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1549619413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711295,0.02558132,0.00009173864,0.0010197954,0.0008671087,0.0007709899,0.0000806827,0.0000641311,0.00039472917],"genre_scores_gemma":[0.9937958,0.0010492263,0.0022115088,0.0006628393,0.00061497296,0.00006583421,0.000096599564,0.00004584589,0.0014573528],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984219,0.000048615617,0.00022599965,0.00037436347,0.000526754,0.00040234614],"domain_scores_gemma":[0.9988163,0.000013004346,0.000065147775,0.00034232793,0.00031306085,0.0004501255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018929993,0.00020953745,0.00027464255,0.0000795242,0.00006215395,0.000029564035,0.00012708738,0.00035150634,0.000041837262],"category_scores_gemma":[0.00004656595,0.00015413362,0.00008050451,0.00016617129,0.00013728974,0.00002683036,0.00009896728,0.00067005923,0.000060134855],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052336007,0.00047094777,0.896707,0.0002282453,0.0005178509,0.00047210217,0.0021489426,0.0011145251,0.017146846,0.000015111441,0.010853743,0.06509109],"study_design_scores_gemma":[0.035457365,0.0027811895,0.21599045,0.00028561516,0.00066497637,0.0002499857,0.00044289874,0.021296317,0.51007015,0.00047853813,0.21111624,0.0011662825],"about_ca_topic_score_codex":0.00021057771,"about_ca_topic_score_gemma":0.00041966734,"teacher_disagreement_score":0.6807165,"about_ca_system_score_codex":0.000360128,"about_ca_system_score_gemma":0.0007478193,"threshold_uncertainty_score":0.62853867},"labels":[],"label_agreement":null},{"id":"W155649943","doi":"10.1007/978-3-540-78281-0_10","title":"Metronomic Chemotherapy: Principles and Lessons Learned from Applications in the Treatment of Metastatic Prostate Cancer","year":2009,"lang":"en","type":"article","venue":"Recent results in cancer research/Recent Results in Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Prostate cancer; Cancer; Chemotherapy; Prostate; Oncology; Internal medicine","score_opus":0.29082674168846484,"score_gpt":0.5052753002687065,"score_spread":0.21444855858024164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W155649943","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76834756,0.07007458,0.0000020753537,0.14597003,0.00013657457,0.010067758,0.0026594691,0.000044343433,0.0026976278],"genre_scores_gemma":[0.42043352,0.57211727,0.00015006731,0.00010026012,0.0002224593,0.00526165,0.00036935767,0.000061466824,0.0012839347],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9875618,0.002340379,0.0019565283,0.0022010682,0.0032589296,0.0026812819],"domain_scores_gemma":[0.9935625,0.0027254263,0.00034949748,0.0016936309,0.0011479742,0.0005209376],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.007939607,0.0006800936,0.0013838777,0.002543866,0.0004115111,0.00021760465,0.0010723743,0.00030556228,0.00023807301],"category_scores_gemma":[0.00070816546,0.00046209796,0.00017056255,0.0064463285,0.0013023228,0.00028493724,0.00022271022,0.0023857986,0.000012475889],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037077833,0.0067264796,0.023673419,0.00033389035,0.00037901814,0.00018051088,0.016942043,0.0013030942,0.00474148,0.00030891175,0.0017963923,0.90653694],"study_design_scores_gemma":[0.055424612,0.004780237,0.21484123,0.0030172835,0.0001132199,0.0000064616165,0.00900242,0.0011696186,0.04030119,0.0034379049,0.6670323,0.0008735291],"about_ca_topic_score_codex":0.059815306,"about_ca_topic_score_gemma":0.050361022,"teacher_disagreement_score":0.9056634,"about_ca_system_score_codex":0.008644216,"about_ca_system_score_gemma":0.0041886047,"threshold_uncertainty_score":0.9999157},"labels":[],"label_agreement":null},{"id":"W1556592686","doi":"10.1111/ijcp.12025","title":"Systemic bias in the medical literature on androgen deprivation therapy and its implication to clinical practice","year":2012,"lang":"en","type":"review","venue":"International Journal of Clinical Practice","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Capital District Health Authority; University of British Columbia; Dalhousie University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Psychosocial; Side effect (computer science); Internal medicine; Cancer; Psychiatry","score_opus":0.4365754954751532,"score_gpt":0.6272090881338267,"score_spread":0.19063359265867352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1556592686","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001623543,0.9568273,0.000030656305,0.03742903,0.0018705417,0.0011668738,0.000017730887,0.0000074844766,0.0010268339],"genre_scores_gemma":[0.0047890027,0.9822524,0.0005865457,0.0064514927,0.005705029,0.000045900444,0.000060148443,0.000032016218,0.0000774249],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99014634,0.003377767,0.0033796804,0.00037124875,0.002491273,0.00023372115],"domain_scores_gemma":[0.96594566,0.02822894,0.0028577943,0.00034031385,0.002164708,0.00046257142],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.021771833,0.00028182022,0.0013958464,0.0003738393,0.000044481138,0.00016700753,0.0007150563,0.00068708067,0.000041650845],"category_scores_gemma":[0.07428325,0.00014660365,0.00055291713,0.00040548688,0.00006685669,0.00072945066,0.00010915398,0.003376209,0.000092661896],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003401654,0.0015985653,0.00052764936,0.00039492312,0.0011821986,0.0015026387,0.00019637439,1.8543794e-7,2.2296996e-7,0.000475316,0.0012237508,0.9894965],"study_design_scores_gemma":[0.0024419026,0.0012237554,0.0012896735,0.011007701,0.00076541543,0.016459484,0.00008519778,0.0000056097733,6.186053e-7,0.000028996192,0.9665693,0.00012233388],"about_ca_topic_score_codex":0.000005367294,"about_ca_topic_score_gemma":9.309309e-7,"teacher_disagreement_score":0.98937416,"about_ca_system_score_codex":0.00019916023,"about_ca_system_score_gemma":0.001382853,"threshold_uncertainty_score":0.99892306},"labels":[],"label_agreement":null},{"id":"W1557260195","doi":"10.2741/1063","title":"Androgens and androgen receptor in prostate and ovarian malignancies","year":2003,"lang":"en","type":"review","venue":"Frontiers in bioscience","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Health Canada","keywords":"Androgen receptor; Prostate cancer; Androgen; Carcinogenesis; Cancer research; Endocrine system; Prostate; Signal transduction; Medicine; Biology; Internal medicine; Endocrinology; Cancer; Hormone; Cell biology","score_opus":0.03698583581743815,"score_gpt":0.3252284744304228,"score_spread":0.28824263861298466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1557260195","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012434367,0.9964401,0.000010699205,0.000115734656,0.000322236,0.0014229934,0.00006347607,0.000012982278,0.0003683559],"genre_scores_gemma":[0.000049053026,0.9945293,0.0035889675,0.00004471874,0.000017799013,0.00012449273,0.000028623273,0.00002209255,0.0015949537],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981084,0.000107192165,0.0003556941,0.00066638563,0.0002514613,0.00051086483],"domain_scores_gemma":[0.9994265,0.000027601003,0.00009220401,0.00022819651,0.000028464285,0.00019707797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005163899,0.0002931301,0.0010522509,0.00059118867,0.00007372318,0.000056936653,0.00011838735,0.00016927396,0.000010280747],"category_scores_gemma":[0.00006873245,0.00020815234,0.00006118768,0.0010161418,0.0005912993,0.00011689955,0.00008594504,0.00029650267,0.0000031142213],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006508412,0.0001098369,0.046991836,0.008140072,0.0000499463,0.0003624548,0.00043002522,3.743406e-8,0.000017068483,0.000055135122,0.0023671468,0.9414114],"study_design_scores_gemma":[0.0011812383,0.00020413753,0.0005634733,0.0075404313,0.000094042436,0.00018712733,0.00017314903,0.000012102824,0.000031537424,0.00009340129,0.98961544,0.00030391506],"about_ca_topic_score_codex":0.00002448484,"about_ca_topic_score_gemma":0.000008921658,"teacher_disagreement_score":0.9872483,"about_ca_system_score_codex":0.0002551427,"about_ca_system_score_gemma":0.0005083346,"threshold_uncertainty_score":0.8488206},"labels":[],"label_agreement":null},{"id":"W1559024130","doi":"10.5772/26201","title":"Prostate Cancer Progression to Androgen Independent Disease: The Role of the Wnt/β-Catenin Pathway","year":2011,"lang":"en","type":"book-chapter","venue":"InTech eBooks","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Androgen; Prostate cancer; Androgen receptor; Cancer research; Medicine; Testosterone (patch); Internal medicine; Endocrinology; Wnt signaling pathway; Tumor progression; Cancer; Biology; Signal transduction; Cell biology; Hormone","score_opus":0.027493560328204422,"score_gpt":0.29859245574301935,"score_spread":0.2710988954148149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1559024130","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025747987,0.03713724,0.000011274424,0.0034976297,0.00087157614,0.015003076,0.0010399879,0.00021687105,0.91647434],"genre_scores_gemma":[0.56381875,0.00029670473,0.000011464436,0.00013530317,0.00013313483,0.0006525727,0.000020297197,0.000077059885,0.43485472],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980298,0.000032911048,0.0003557474,0.00043041765,0.0007880152,0.00036309098],"domain_scores_gemma":[0.998517,0.000026122128,0.00022423672,0.0006548729,0.00030915454,0.00026863278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019414701,0.00035822898,0.0003979812,0.00012302096,0.00013848837,0.000022872935,0.00044219237,0.00021035076,0.00030172186],"category_scores_gemma":[0.000019885974,0.00016183745,0.00027335138,0.00003330694,0.000356958,0.00001842076,0.00044743478,0.0006500539,0.00005127783],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060500763,0.00021688279,0.00554575,0.00065749604,0.0013769614,0.00030963807,0.0053427606,3.5964376e-7,0.10298567,0.008367014,0.0010448626,0.86810255],"study_design_scores_gemma":[0.00084156386,0.000396316,0.00045948953,0.0031075098,0.0003019085,0.000017485256,0.00007191414,0.0000012146969,0.7258188,0.016860172,0.25186232,0.0002613228],"about_ca_topic_score_codex":0.00016048788,"about_ca_topic_score_gemma":0.00009470253,"teacher_disagreement_score":0.8678412,"about_ca_system_score_codex":0.00022786131,"about_ca_system_score_gemma":0.0009149995,"threshold_uncertainty_score":0.65995395},"labels":[],"label_agreement":null},{"id":"W1567742721","doi":"10.1016/b978-0-12-387688-1.00007-7","title":"Prostate Cancer as a Model System for Genetic Diversity in Tumors","year":2011,"lang":"en","type":"review","venue":"Advances in cancer research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research; University Health Network; Queen's University","funders":"American Cancer Society","keywords":"PTEN; Prostate cancer; Field cancerization; Biology; Carcinogenesis; Cancer; Prostate; Genome instability; Cancer research; Telomere; Disease; Bioinformatics; Gene; Genetics; Medicine; PI3K/AKT/mTOR pathway; Pathology; DNA; DNA damage; Signal transduction","score_opus":0.26375470188431793,"score_gpt":0.523370565050757,"score_spread":0.25961586316643903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1567742721","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006986941,0.98788327,0.000009893028,0.000089044464,0.00025298644,0.008591836,0.00047895932,0.000046888465,0.0019484548],"genre_scores_gemma":[0.0010567834,0.97708964,0.00031668696,0.000016680646,0.0002190036,0.015951358,0.00007609264,0.00012875936,0.005145003],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948489,0.0003361953,0.0008114472,0.0012668642,0.0010701361,0.0016664756],"domain_scores_gemma":[0.99794316,0.0003383655,0.00020603838,0.00067853404,0.00047972624,0.0003541779],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012605201,0.0005492375,0.0021225354,0.0014417841,0.00029310954,0.00003782664,0.00072222465,0.00034872015,0.00009501859],"category_scores_gemma":[0.00010210443,0.0004193615,0.00034523342,0.0017363008,0.00042856066,0.00027185158,0.0007580953,0.0015636496,0.0000428018],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012571211,0.0002231785,0.0033357244,0.09138337,0.00014368894,0.0004109318,0.00082315033,0.00020583243,0.0000013305743,0.00022782489,0.00020142227,0.90178645],"study_design_scores_gemma":[0.0048145456,0.00076140923,0.000117016105,0.10411535,0.0003376078,0.00004283212,0.00041703726,0.0008170076,0.000039714505,0.0010427285,0.8867614,0.0007333052],"about_ca_topic_score_codex":0.0064487043,"about_ca_topic_score_gemma":0.0035394274,"teacher_disagreement_score":0.90105313,"about_ca_system_score_codex":0.005940431,"about_ca_system_score_gemma":0.005195175,"threshold_uncertainty_score":0.99982584},"labels":[],"label_agreement":null},{"id":"W1576854193","doi":"10.1002/tre.379","title":"Advanced prostate cancer: advancing patient care","year":2014,"lang":"en","type":"article","venue":"Trends in Urology & Men s Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Multidisciplinary team; Medicine; Context (archaeology); Multidisciplinary approach; Prostate cancer; Palliative care; Cancer; Patient care; Disease; Population; General surgery; Family medicine; Intensive care medicine; Oncology; Nursing; Internal medicine; History","score_opus":0.014818642396682284,"score_gpt":0.3696511550315698,"score_spread":0.3548325126348875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1576854193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93492025,0.021195678,0.000014317677,0.026076324,0.0003932185,0.00082079874,0.00004473822,0.00013304211,0.016401622],"genre_scores_gemma":[0.9928866,0.0025859352,0.00048118146,0.002400484,0.00008725214,0.00027910728,0.00015214592,0.00003309312,0.0010942038],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978973,0.00018644247,0.00036552237,0.00045260793,0.00023469023,0.00086339196],"domain_scores_gemma":[0.9991232,0.000057457622,0.00011816086,0.00032476176,0.00007564279,0.00030074595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002566734,0.00019091337,0.00048093914,0.00035355426,0.00012308298,0.0000051216985,0.00007972637,0.00008818452,0.0001494614],"category_scores_gemma":[0.000024533147,0.0001526045,0.00005465955,0.00039592982,0.00009467152,0.00005895234,0.00005077643,0.0003785119,0.000015465588],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011079151,0.00011660344,0.07784972,0.00015310559,0.000026890071,0.000039668426,0.005728678,0.00019767562,0.000160115,0.00006042424,0.0014772374,0.91308194],"study_design_scores_gemma":[0.03898173,0.037302177,0.3668728,0.00060842687,0.00015393393,0.00011942213,0.0058593005,0.00250388,0.0030727917,0.0005380839,0.5429985,0.0009889633],"about_ca_topic_score_codex":0.00062490534,"about_ca_topic_score_gemma":0.001083291,"teacher_disagreement_score":0.912093,"about_ca_system_score_codex":0.0006728114,"about_ca_system_score_gemma":0.00039288003,"threshold_uncertainty_score":0.62230307},"labels":[],"label_agreement":null},{"id":"W1577006641","doi":"10.1096/fasebj.28.1_supplement.85.2","title":"Treatment resistance in prostate cancer: Rationale of combination therapy (85.2)","year":2014,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; LNCaP; Medicine; Cancer research; Epithelial–mesenchymal transition; Cancer; Androgen deprivation therapy; Oncology; Internal medicine; Metastasis","score_opus":0.03263576277125648,"score_gpt":0.32255934906003664,"score_spread":0.2899235862887802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1577006641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833824,0.0038375403,0.000020605496,0.010195235,0.000079143676,0.00043205183,0.000007795977,0.000005651821,0.0020396016],"genre_scores_gemma":[0.98468244,0.008244973,0.00011883279,0.0000751431,0.00009113718,0.000047412217,0.000010659777,0.000008314458,0.0067210887],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99922544,0.0000991992,0.0001901464,0.000079129626,0.00025679672,0.00014929072],"domain_scores_gemma":[0.9995406,0.000059703827,0.00010259694,0.00012056853,0.00012296918,0.000053518208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003036522,0.00007581482,0.00015574518,0.00008186012,0.000095287476,0.000015126792,0.000060997758,0.000018500177,0.00008839134],"category_scores_gemma":[0.000018096049,0.000039056766,0.000052919095,0.0001449383,0.0000909957,0.00005713971,0.0000059419685,0.00012122205,0.000003835295],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013577385,0.0025215254,0.48627582,0.00014696107,0.0006435101,0.00015744774,0.014362021,0.00016394461,0.25372684,0.007828581,0.0024684344,0.21812752],"study_design_scores_gemma":[0.040648606,0.0035921948,0.33298025,0.00056258484,0.00009648303,0.00013630347,0.0006772233,0.0008464766,0.5790647,0.011535523,0.029625326,0.00023431428],"about_ca_topic_score_codex":0.000054912634,"about_ca_topic_score_gemma":0.00009798947,"teacher_disagreement_score":0.3253379,"about_ca_system_score_codex":0.00024618095,"about_ca_system_score_gemma":0.00022581173,"threshold_uncertainty_score":0.15926887},"labels":[],"label_agreement":null},{"id":"W1581316612","doi":"10.1002/iub.260","title":"Androgen receptor and caveolin‐1 in prostate cancer","year":2009,"lang":"en","type":"article","venue":"IUBMB Life","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Tellabs (Canada)","funders":"","keywords":"Androgen receptor; Prostate cancer; Androgen; Caveolin 1; Prostate; Receptor; Cancer research; Internal medicine; Chemistry; Endocrinology; Medicine; Cancer; Hormone","score_opus":0.025964563965388068,"score_gpt":0.34089793847088545,"score_spread":0.3149333745054974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1581316612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97563857,0.009209135,5.0484584e-7,0.012510596,0.000060720387,0.00046050726,0.000020269039,0.000030567368,0.0020691191],"genre_scores_gemma":[0.988711,0.004780437,0.000105983985,0.0012480875,0.00014760796,0.000050344595,0.000021356343,0.000010318328,0.00492488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99924374,0.00001817808,0.00012985713,0.00019263588,0.00015384365,0.0002617553],"domain_scores_gemma":[0.9996027,0.00001414701,0.000021139702,0.00011176707,0.00004125831,0.00020900388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009785265,0.00009244531,0.00018132689,0.00008623722,0.000032564913,0.000014518973,0.000031164745,0.00004203263,0.00014388151],"category_scores_gemma":[0.000033922646,0.000067999594,0.000022406535,0.00017026758,0.000046659938,0.000056493038,0.000014514385,0.00012865858,0.000024792784],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020240021,0.00034757823,0.8430831,0.00014646938,0.00009727011,0.00030986257,0.002354486,0.0000060314414,0.009446758,0.0001631322,0.019478412,0.12254292],"study_design_scores_gemma":[0.016290208,0.0015168242,0.8276546,0.00057465443,0.00008416646,0.000053176827,0.00046151862,0.00025259465,0.027219938,0.00067004777,0.12475689,0.00046539487],"about_ca_topic_score_codex":0.00017431403,"about_ca_topic_score_gemma":0.000038846934,"teacher_disagreement_score":0.12207752,"about_ca_system_score_codex":0.00009165688,"about_ca_system_score_gemma":0.00020337894,"threshold_uncertainty_score":0.2772943},"labels":[],"label_agreement":null},{"id":"W1582958597","doi":"10.1002/pros.20940","title":"A novel communication role for CYP17A1 in the progression of castration‐resistant prostate cancer","year":2009,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"CYP17A1; Prostate cancer; Androgen; Cancer research; Internal medicine; Orchiectomy; Endocrinology; Biology; Androgen deprivation therapy; Cancer; Medicine; Hormone; Enzyme; Biochemistry","score_opus":0.03887365212605288,"score_gpt":0.38281098693697374,"score_spread":0.34393733481092087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1582958597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93384814,0.0076219128,0.000040128416,0.04956157,0.000035472807,0.0069117863,0.00017573239,0.000048519938,0.0017567547],"genre_scores_gemma":[0.9963529,0.0010075279,0.00071759627,0.00026711443,0.000029075884,0.00074629363,0.00008981936,0.000011825931,0.00077785214],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989529,0.00007395092,0.00027182492,0.00014953424,0.00028745137,0.00026428374],"domain_scores_gemma":[0.99913585,0.00010259636,0.00013095305,0.00042214774,0.00017211109,0.000036352132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006865096,0.00011463095,0.00017460527,0.00005932815,0.00016465453,0.000030010637,0.00020450365,0.00003604884,0.0000075936346],"category_scores_gemma":[0.000037380356,0.00005425776,0.000057299232,0.00027871373,0.00013527562,0.00008432656,0.000025289686,0.00017727005,0.0000015680366],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01831528,0.0026300452,0.011183127,0.00055636384,0.00017989789,0.000018657996,0.06320632,0.0002414422,0.6388536,0.0040996107,0.0023211762,0.25839448],"study_design_scores_gemma":[0.04179117,0.011376739,0.5799775,0.0041298,0.0006813536,0.00012395595,0.014138414,0.009959056,0.2755315,0.028139144,0.033243626,0.0009077029],"about_ca_topic_score_codex":0.00020706555,"about_ca_topic_score_gemma":0.00016049777,"teacher_disagreement_score":0.5687944,"about_ca_system_score_codex":0.00006162416,"about_ca_system_score_gemma":0.00020478555,"threshold_uncertainty_score":0.22125672},"labels":[],"label_agreement":null},{"id":"W1588056981","doi":"10.1002/pros.23054","title":"Prolactin‐ and testosterone‐induced carboxypeptidase‐D correlates with increased nitrotyrosines and Ki67 in prostate cancer","year":2015,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research; Dalhousie University","keywords":"Prolactin; Prostate; Prostate cancer; Internal medicine; Testosterone (patch); Endocrinology; Medicine; Cancer; Hormone","score_opus":0.0317664806013831,"score_gpt":0.2961184020686694,"score_spread":0.2643519214672863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1588056981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988667,0.004125724,4.2446663e-7,0.004449875,0.000040448485,0.0022402713,0.000030194653,0.00008026986,0.00036581067],"genre_scores_gemma":[0.99706566,0.0006903515,0.000080116995,0.00021403171,0.000047952424,0.000507749,0.00002631228,0.000044747467,0.0013230534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985631,0.00009390298,0.00021242011,0.00036431637,0.0003043183,0.00046190585],"domain_scores_gemma":[0.9991029,0.00008568027,0.000087637054,0.000248365,0.00017879013,0.00029660732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040729722,0.00025413025,0.0003321192,0.00012635549,0.000110915054,0.00007749125,0.000066990324,0.000053542353,0.0000068003196],"category_scores_gemma":[0.00006849843,0.00013496807,0.000016693526,0.00032479814,0.0003036868,0.0001806859,0.000096873126,0.00034516217,0.0000057783686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011572961,0.00015350113,0.9608347,0.0002110795,0.00010829002,0.00020415217,0.0074088746,0.0000075262537,0.012226373,0.000015389613,0.0002506026,0.0070065744],"study_design_scores_gemma":[0.031446308,0.004714917,0.92779404,0.0014475212,0.00037523743,0.0005694073,0.0036018605,0.0017936853,0.02555684,0.0009776267,0.0010137196,0.000708815],"about_ca_topic_score_codex":0.0017527724,"about_ca_topic_score_gemma":0.0004987231,"teacher_disagreement_score":0.033040617,"about_ca_system_score_codex":0.00012676379,"about_ca_system_score_gemma":0.00039621475,"threshold_uncertainty_score":0.5503838},"labels":[],"label_agreement":null},{"id":"W1588197864","doi":"10.1002/pros.22742","title":"Distribution of metastatic sites in patients with prostate cancer: A population‐based analysis","year":2013,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":564,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Lymph; Thorax (insect anatomy); Metastasis; Population; Cohort; Bone metastasis; Cancer; Prostate; Pathology; Internal medicine; Oncology; Anatomy","score_opus":0.015332742192458036,"score_gpt":0.2925605081949433,"score_spread":0.2772277660024852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1588197864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960366,0.00022574507,0.000031721356,0.0014860714,0.000010022632,0.0019033133,0.00025963347,0.000019259474,0.000027664648],"genre_scores_gemma":[0.99704987,0.00004780256,0.00013369601,0.000051198025,0.0000054621914,0.0003794119,0.0018963243,0.0000134896445,0.0004227228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988198,0.00007560825,0.00026685005,0.00019033797,0.00037120725,0.00027617073],"domain_scores_gemma":[0.9991936,0.00005360121,0.00013663463,0.00026083871,0.00028346406,0.00007185933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016342303,0.00013216819,0.00031730006,0.00017607499,0.0000617214,0.000022402255,0.00006907535,0.000018596027,0.00013358881],"category_scores_gemma":[0.000027012285,0.00006782928,0.00006984031,0.0012658705,0.00009014207,0.00012298442,0.00002282231,0.00011275161,0.000009826295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001096575,0.00024341869,0.9942141,0.000099760575,0.00039334915,0.0000021991355,0.0003699617,0.00093399576,0.00009583505,0.00000847157,0.00005974999,0.0024825477],"study_design_scores_gemma":[0.0034853918,0.00035599797,0.99186486,0.00007363429,0.00054537883,1.5909887e-7,0.00006265349,0.0024972246,0.0008849623,0.00012732191,0.000021625043,0.000080762795],"about_ca_topic_score_codex":0.0032645164,"about_ca_topic_score_gemma":0.0002953629,"teacher_disagreement_score":0.0029691535,"about_ca_system_score_codex":0.00016231027,"about_ca_system_score_gemma":0.000108189095,"threshold_uncertainty_score":0.4934994},"labels":[],"label_agreement":null},{"id":"W1590340975","doi":"10.1002/cncr.28809","title":"Under‐representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993‐2013","year":2014,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Oak Ridge Institute for Science and Education; U.S. Department of Energy","keywords":"Medicine; Clinical trial; Population; Food and drug administration; Census; Family medicine; Demographics; Demography; Environmental health; Pathology","score_opus":0.038591868582698224,"score_gpt":0.3656713039866044,"score_spread":0.32707943540390616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1590340975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830249,0.002736143,0.000022200926,0.012506784,0.00028263967,0.0012365453,0.00005225321,0.0000145520635,0.00012400956],"genre_scores_gemma":[0.99487,0.001720705,0.00008582262,0.00035284847,0.0003281648,0.00072281,0.000025961112,0.000016108548,0.0018775701],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877775,0.00011495187,0.00025813503,0.00028223655,0.00030370135,0.000263225],"domain_scores_gemma":[0.9993802,0.00008713384,0.00007339793,0.00015226338,0.00020645311,0.00010059743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040635228,0.00013144886,0.0002692038,0.0001243456,0.00009265112,0.000026956872,0.00006272314,0.00003090906,0.000047094054],"category_scores_gemma":[0.00009782883,0.000091346206,0.000036741538,0.0002971797,0.00010894279,0.00008431222,0.00006362798,0.00010444921,0.0000024946487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014896087,0.0003468676,0.6494581,0.0021494967,0.0009490857,0.000049906746,0.03716731,0.001993116,0.025234617,0.00013691645,0.03451543,0.23310307],"study_design_scores_gemma":[0.008057579,0.0024227619,0.8794605,0.0009929918,0.00036384602,0.000018405442,0.01583154,0.00065697666,0.08100152,0.00022786397,0.01045936,0.0005066663],"about_ca_topic_score_codex":0.001104865,"about_ca_topic_score_gemma":0.007191516,"teacher_disagreement_score":0.2325964,"about_ca_system_score_codex":0.00017192872,"about_ca_system_score_gemma":0.00024254875,"threshold_uncertainty_score":0.40130347},"labels":[],"label_agreement":null},{"id":"W1592504557","doi":"10.1016/j.eururo.2015.04.036","title":"Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives","year":2015,"lang":"en","type":"review","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Primary tumor; Radiation therapy; Cancer; Regimen; Randomized controlled trial; Internal medicine; Clinical trial; Multimodal therapy; Retrospective cohort study; Metastasis","score_opus":0.06470803242639699,"score_gpt":0.40190043351056,"score_spread":0.337192401084163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1592504557","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009122343,0.9937751,7.657726e-8,0.00067976984,0.00030289864,0.0020350616,0.00015578997,0.000014203531,0.0021248478],"genre_scores_gemma":[0.00027597262,0.9982161,0.000014164998,0.00003098715,0.00033759497,0.00014930718,0.00007051159,0.000054896234,0.000850444],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997661,0.0010050213,0.00039785466,0.0004396768,0.00019243192,0.00030400947],"domain_scores_gemma":[0.99910754,0.000077171295,0.0002525679,0.00035122727,0.00009245026,0.00011903194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021574921,0.00033953812,0.0014295114,0.00015874095,0.000035591343,0.000007861843,0.00013452514,0.000037558733,0.000032404358],"category_scores_gemma":[0.000020625932,0.00016649143,0.00020346824,0.00025668778,0.00039982353,0.000023119586,0.00011214505,0.0003292466,0.000013440822],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001528192,0.00032645333,0.00054014893,0.00407103,0.0002823413,0.00033769294,0.002643018,1.9142794e-7,8.7212754e-7,0.000039708662,0.00026682354,0.9913389],"study_design_scores_gemma":[0.002313962,0.0009790848,0.0014927123,0.0008292531,0.0010376852,0.0001840533,0.0002016671,8.522358e-7,7.170011e-7,0.000007710602,0.9928316,0.000120719036],"about_ca_topic_score_codex":0.000021394575,"about_ca_topic_score_gemma":0.000008180382,"teacher_disagreement_score":0.99256474,"about_ca_system_score_codex":0.00044853793,"about_ca_system_score_gemma":0.0009924355,"threshold_uncertainty_score":0.67893237},"labels":[],"label_agreement":null},{"id":"W1593747583","doi":"10.1038/pcan.2015.22","title":"High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer","year":2015,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Institute of General Medical Sciences; National Cancer Institute; Prostate Cancer Foundation","keywords":"Prostate cancer; Medicine; Transcriptome; Oncology; Prostatectomy; Biomarker; Internal medicine; Gene; Cancer; Bioinformatics; Gene expression; Biology; Genetics","score_opus":0.03065867305798077,"score_gpt":0.32150383907430213,"score_spread":0.2908451660163214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1593747583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76663136,0.22522959,0.000009893626,0.0035099592,0.0001763976,0.0033401,0.0009333505,0.000089730056,0.000079625024],"genre_scores_gemma":[0.938869,0.054955814,0.00030882188,0.0004664146,0.00009548738,0.0031391575,0.00043754058,0.000085427455,0.0016423435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965958,0.00016509868,0.0006065441,0.0010755117,0.0006145049,0.00094252446],"domain_scores_gemma":[0.9982234,0.00009969664,0.00017061862,0.00035827962,0.000280761,0.0008672415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031539364,0.00059281656,0.0010052309,0.00059584883,0.00019513183,0.00023154911,0.00013439155,0.00010009335,0.00017791032],"category_scores_gemma":[0.00003721149,0.00045285939,0.00015887068,0.0011981092,0.0007191387,0.0003403906,0.00008496985,0.00025874414,0.000008232075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013843085,0.0007475877,0.784907,0.0017220458,0.003303819,0.0009844606,0.013477179,0.00018950645,0.0032683525,0.00015137198,0.0010192066,0.17638639],"study_design_scores_gemma":[0.04768033,0.003772619,0.8667524,0.0017278983,0.008064478,0.00009759723,0.010958393,0.0027496712,0.017608197,0.011544979,0.02617071,0.0028727378],"about_ca_topic_score_codex":0.0028017096,"about_ca_topic_score_gemma":0.00052943354,"teacher_disagreement_score":0.17351365,"about_ca_system_score_codex":0.0004141803,"about_ca_system_score_gemma":0.00091437215,"threshold_uncertainty_score":0.99979234},"labels":[],"label_agreement":null},{"id":"W1595251153","doi":"10.1111/j.1743-7563.2010.01328.x","title":"A phase II trial of weekly i.v. KW‐2170 in advanced castrate‐resistant prostate cancer","year":2010,"lang":"en","type":"article","venue":"Asia-Pacific Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Medicine; Neutropenia; Prostate cancer; Internal medicine; Phases of clinical research; Nausea; Oncology; Chemotherapy; Cancer; Gastroenterology; Urology","score_opus":0.09392100312257858,"score_gpt":0.5098557369329367,"score_spread":0.41593473381035817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1595251153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97789735,0.00075457414,0.0000044857898,0.011250768,0.0025556928,0.00092241255,0.00003651103,0.000008641036,0.00656958],"genre_scores_gemma":[0.9925124,0.0025890756,0.0012165138,0.00007958675,0.0009255174,0.00004033639,0.000008101779,0.000026966187,0.0026014969],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99545234,0.00035581095,0.002804687,0.00031489573,0.0005625497,0.00050969515],"domain_scores_gemma":[0.9961854,0.00084846624,0.0014710942,0.0003141893,0.0006663813,0.0005144309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032360624,0.00021951245,0.0017621699,0.00032084688,0.00006178414,0.000009820842,0.00023760271,0.0004245823,0.00036359823],"category_scores_gemma":[0.0013871486,0.00014881302,0.00046597602,0.0003875987,0.00059758895,0.00016458853,0.00006294738,0.002104893,0.0000074163045],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54060435,0.018344834,0.009668593,0.00009061849,0.00047137387,0.00266016,0.00068234315,0.0000053573053,0.046625853,0.00011095525,0.002649487,0.3780861],"study_design_scores_gemma":[0.6232749,0.18176898,0.013184304,0.00043358625,0.0004327531,0.00036695215,0.0021297522,0.000051098956,0.0079032965,0.000769789,0.16940816,0.00027641462],"about_ca_topic_score_codex":0.000056267196,"about_ca_topic_score_gemma":0.00034932772,"teacher_disagreement_score":0.37780967,"about_ca_system_score_codex":0.0001850162,"about_ca_system_score_gemma":0.0050445725,"threshold_uncertainty_score":0.9144831},"labels":[],"label_agreement":null},{"id":"W1597708363","doi":"10.1111/j.1464-410x.2011.10922.x","title":"Phase II study of cytarabine in men with docetaxel‐refractory, castration‐resistant prostate cancer with evaluation of TMPRSS2‐ERG and SPINK1 as serum biomarkers","year":2012,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Toronto Western Hospital; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; TMPRSS2; Oncology; Cytarabine; Internal medicine; Population; PCA3; Prostate-specific antigen; Cancer; Chemotherapy","score_opus":0.030207793021977354,"score_gpt":0.35590701767951616,"score_spread":0.3256992246575388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1597708363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98728675,0.011068164,0.0000023644309,0.0005225713,0.000035647903,0.0008384849,0.000026147329,0.0000023936118,0.00021746593],"genre_scores_gemma":[0.9984887,0.0012565395,0.00006584584,0.000018240264,0.000053308308,0.000028879957,0.0000068203863,0.000014362428,0.00006726262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832624,0.00021854331,0.00045693942,0.00013468257,0.0006148536,0.00024873897],"domain_scores_gemma":[0.99864423,0.00003436056,0.00042074028,0.00009336446,0.00066574017,0.0001415436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011178374,0.000111437985,0.00041959042,0.00022269401,0.00004918825,0.000008211574,0.000053880285,0.000054480483,0.00010094618],"category_scores_gemma":[0.000054303986,0.00008306203,0.000024725525,0.00022549735,0.000174675,0.00021854992,0.000020339881,0.0002189702,1.756296e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07151162,0.018470315,0.7041308,0.00032819877,0.002806861,0.0020309514,0.007682898,0.0003976972,0.041749798,0.000007402605,0.00036270308,0.1505207],"study_design_scores_gemma":[0.08666022,0.074245706,0.8280229,0.00044684985,0.0012067478,0.003316455,0.0027564522,0.00022342036,0.0027834754,0.000026801104,0.00016381753,0.00014717181],"about_ca_topic_score_codex":0.0010881574,"about_ca_topic_score_gemma":0.0012380539,"teacher_disagreement_score":0.15037353,"about_ca_system_score_codex":0.00011050691,"about_ca_system_score_gemma":0.00059570227,"threshold_uncertainty_score":0.3387171},"labels":[],"label_agreement":null},{"id":"W1599124340","doi":"10.1016/j.eururo.2015.06.054","title":"The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression","year":2015,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; Université Laval; Centre hospitalier universitaire de Québec","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Androgen; Dihydrotestosterone; Internal medicine; Endocrinology; Medicine; Glucuronidation; Testosterone (patch); Prostate; Steroid hormone; Sex steroid; Cancer research; Prostate-specific antigen; Hormone; Cancer; Steroid; Biology; Enzyme","score_opus":0.033078212054541735,"score_gpt":0.30294599947776335,"score_spread":0.2698677874232216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1599124340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888298,0.0058668563,0.0000068971885,0.0036719262,0.00007216605,0.00054301636,0.000024960746,0.00001322931,0.0009711388],"genre_scores_gemma":[0.99649996,0.0017106181,0.000026751042,0.00011125131,0.00006251709,0.000032618827,0.000005847524,0.000020571899,0.0015298593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873555,0.00047717354,0.00021938757,0.00017526156,0.00021538445,0.00017726916],"domain_scores_gemma":[0.99913514,0.000113637725,0.00020465278,0.00029395966,0.00018495998,0.00006765866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068525266,0.00010111574,0.00017631987,0.00004556094,0.00010281764,0.000009876761,0.00009814177,0.000031122705,0.0000065017584],"category_scores_gemma":[0.00009432574,0.000045847046,0.000034849854,0.00011095821,0.00040621246,0.000039586874,0.00011273446,0.00012575781,0.0000036723725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007797795,0.00024988287,0.5266451,0.00019809758,0.00058738526,0.0000412741,0.021792404,0.000041303578,0.059308186,0.000121652025,0.002814902,0.380402],"study_design_scores_gemma":[0.009321623,0.0063159917,0.6203739,0.00015941376,0.00041285146,0.00007043741,0.0028913901,0.0010649143,0.29356,0.00058868324,0.06498161,0.00025916068],"about_ca_topic_score_codex":0.000057987305,"about_ca_topic_score_gemma":0.000009742821,"teacher_disagreement_score":0.38014284,"about_ca_system_score_codex":0.000027217573,"about_ca_system_score_gemma":0.000103489314,"threshold_uncertainty_score":0.18695882},"labels":[],"label_agreement":null},{"id":"W1599268725","doi":"10.1111/j.1747-0285.2011.01290.x","title":"Learning From Estrogen Receptor Antagonism: Structure‐Based Identification of Novel Antiandrogens Effective Against Multiple Clinically Relevant Androgen Receptor Mutants","year":2011,"lang":"en","type":"article","venue":"Chemical Biology & Drug Design","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Bicalutamide; Androgen receptor; Antiandrogens; Antiandrogen; Chemistry; Estrogen receptor; Androgen; Endocrinology; Internal medicine; Biology; Prostate cancer; Biochemistry; Medicine; Hormone; Cancer; Breast cancer","score_opus":0.04629151220809766,"score_gpt":0.30830043120133815,"score_spread":0.2620089189932405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1599268725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942324,0.0005544326,0.0030997845,0.00012550243,0.00022127634,0.0012044184,0.00043232602,0.00009110706,0.000038755563],"genre_scores_gemma":[0.98434013,0.00024037155,0.013343221,0.0000855575,0.00013529435,0.00007841082,0.0016908722,0.000044146404,0.000041999087],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975795,0.00029444115,0.0007419061,0.0007195717,0.00020510574,0.00045948476],"domain_scores_gemma":[0.99786663,0.00084128976,0.00036977275,0.00039701673,0.00027364638,0.00025167278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005026706,0.0002959565,0.0006588287,0.00011319391,0.00009759731,0.0000100380985,0.00023910214,0.00039869203,0.00018971993],"category_scores_gemma":[0.0009164774,0.00022877114,0.00020921491,0.0002488953,0.0005505543,0.0000567142,0.000072097995,0.0005016204,0.00005764388],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034699056,0.0004693992,0.052980613,0.000038564707,0.0003969071,0.000010247282,0.0004867423,0.0000058739497,0.93424237,0.000005171656,0.00010752023,0.0077866632],"study_design_scores_gemma":[0.0049763937,0.0005348564,0.0013401436,0.00008985157,0.00016250949,0.000004222968,0.00011156635,0.0012524641,0.9910845,0.00008005436,0.00015034876,0.00021308956],"about_ca_topic_score_codex":0.00004568522,"about_ca_topic_score_gemma":5.627096e-7,"teacher_disagreement_score":0.056842107,"about_ca_system_score_codex":0.00013998982,"about_ca_system_score_gemma":0.00023892346,"threshold_uncertainty_score":0.9329016},"labels":[],"label_agreement":null},{"id":"W1606098363","doi":"10.1111/bju.12262","title":"Interrogation of <i> <scp>ERG</scp> </i> gene rearrangements in prostate cancer identifies a prognostic 10‐gene signature with relevant implication to patients' clinical outcome","year":2013,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Alberta Cancer Foundation; University of Calgary","funders":"Movember Foundation; Prostate Cancer Canada; University of Calgary; Prostate Cancer Foundation","keywords":"Erg; Prostate cancer; Gene signature; Hazard ratio; Proportional hazards model; Internal medicine; Oncology; Gene; Medicine; Gene expression; Cancer; Biology; Confidence interval; Genetics; Ophthalmology","score_opus":0.021872638160318945,"score_gpt":0.33234762588298583,"score_spread":0.3104749877226669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1606098363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947399,0.0023335721,0.000045130342,0.0014911805,0.00017990448,0.0011186907,0.00003282388,0.000007384246,0.000051413674],"genre_scores_gemma":[0.9965967,0.0016903398,0.00046561199,0.00041194705,0.00009422251,0.00012520922,0.000051680196,0.000022634718,0.00054166676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806106,0.00014666085,0.0009059423,0.00022772745,0.00036321869,0.0002953767],"domain_scores_gemma":[0.9980312,0.00014368068,0.00046743872,0.00013144767,0.0010492291,0.00017703124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004553642,0.000119352466,0.00045938324,0.00021654241,0.000032296994,0.000028429875,0.00013248045,0.000108751025,0.000059910377],"category_scores_gemma":[0.0004600809,0.000097475124,0.000083108025,0.00026305238,0.00010979772,0.00017804942,0.000052997337,0.0004016545,0.0000138220685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078962976,0.0006794078,0.9615481,0.00009384258,0.0002063298,0.0002662456,0.00039886497,0.000039274364,0.00844912,9.838556e-7,0.0043169586,0.02321123],"study_design_scores_gemma":[0.0054866816,0.0031856564,0.9870172,0.0002419268,0.00012899317,0.00030750086,0.000110291585,0.000020258234,0.0027432067,0.0000683098,0.00064263586,0.000047329973],"about_ca_topic_score_codex":0.00032945763,"about_ca_topic_score_gemma":0.0002539561,"teacher_disagreement_score":0.025469096,"about_ca_system_score_codex":0.000121741505,"about_ca_system_score_gemma":0.00021623769,"threshold_uncertainty_score":0.39749202},"labels":[],"label_agreement":null},{"id":"W164349540","doi":"","title":"Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.","year":2006,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Prednisone; Asymptomatic; Prostate cancer; Population; Internal medicine; Cancer; Oncology; Urology; Watchful waiting; Hormonal therapy; Surgery","score_opus":0.019594989195160003,"score_gpt":0.27831242302160397,"score_spread":0.25871743382644397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W164349540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96968514,0.019277371,0.0000036992933,0.0026560964,0.00007848363,0.0022911974,0.000017486478,0.00009249831,0.00589802],"genre_scores_gemma":[0.97323143,0.004451188,0.00006525187,0.00013209731,0.00016509341,0.0062046987,0.000039523802,0.000032551765,0.015678138],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986342,0.000035720914,0.0002478134,0.0002531791,0.00029054674,0.0005385455],"domain_scores_gemma":[0.99952483,0.000031653013,0.000057548048,0.00021860091,0.00004611937,0.000121246914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002022465,0.0001424833,0.0002571729,0.00017449138,0.0000390668,0.000023605584,0.000068163914,0.00006888049,0.000034027613],"category_scores_gemma":[0.000015105669,0.00010871265,0.000051246414,0.00032045005,0.00007013024,0.000107641434,0.000018332823,0.00016453885,0.000014064658],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030707824,0.0012452968,0.33580434,0.00020473081,0.00016534778,0.0002568014,0.00052838825,0.000034664718,0.004284064,0.000054061846,0.010012352,0.64433914],"study_design_scores_gemma":[0.0068482324,0.00010948905,0.97989565,0.00003637199,0.000023166185,0.0000061036358,0.000030724474,0.00008019166,0.0022226118,0.00025675035,0.010367614,0.00012311387],"about_ca_topic_score_codex":0.0010289167,"about_ca_topic_score_gemma":0.00013999525,"teacher_disagreement_score":0.64421606,"about_ca_system_score_codex":0.0004631713,"about_ca_system_score_gemma":0.00010780675,"threshold_uncertainty_score":0.44331732},"labels":[],"label_agreement":null},{"id":"W1650161272","doi":"","title":"Number of sexual partners linked to PCa risk","year":2014,"lang":"en","type":"article","venue":"Urology Times eNews","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business","score_opus":0.02404632056894875,"score_gpt":0.3543635560735457,"score_spread":0.33031723550459696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1650161272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9431659,0.00015903325,0.00018936,0.0023415512,0.00010682596,0.00026564507,0.0000096238355,0.000043852906,0.053718183],"genre_scores_gemma":[0.9742227,0.00005158398,0.0008796191,0.00094976585,0.00016763603,0.00003024185,0.000028984568,0.000016833983,0.023652637],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991116,0.000100164994,0.00016002009,0.00022211942,0.00013575799,0.00027031818],"domain_scores_gemma":[0.9993226,0.000116981806,0.000047144862,0.00028850534,0.00006129468,0.00016345309],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022004957,0.000099110126,0.00025627823,0.000069890506,0.00003521666,0.0000029592395,0.00007661366,0.00011261539,0.0010148691],"category_scores_gemma":[0.000094232484,0.00007246143,0.000038320406,0.00011354462,0.000113904105,0.000017720697,0.000050038238,0.00015016744,0.0006804431],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029584747,0.00046555515,0.8165748,0.00009403821,0.00054777594,0.000060348404,0.0015469958,0.00015637699,0.014438738,0.0011375109,0.07018042,0.09183895],"study_design_scores_gemma":[0.008509247,0.006452611,0.17011318,0.000018332585,0.0005797137,0.00009468704,0.00015276692,0.0013975338,0.0058592684,0.0015167523,0.8049503,0.00035562614],"about_ca_topic_score_codex":0.0001262027,"about_ca_topic_score_gemma":0.000020521113,"teacher_disagreement_score":0.7347699,"about_ca_system_score_codex":0.000020809128,"about_ca_system_score_gemma":0.00006924679,"threshold_uncertainty_score":0.9998983},"labels":[],"label_agreement":null},{"id":"W1659724067","doi":"10.1063/1.2759724","title":"A Hybrid Systems Approach to Hormonal Therapy of Prostate Cancer and its Nonlinear Dynamics","year":2007,"lang":"en","type":"article","venue":"AIP conference proceedings","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of British Columbia; Princeton University","keywords":"Prostate cancer; Androgen suppression; Hormonal therapy; Computer science; Nonlinear system; Androgen; Hormone; Prostate; Cancer; Medicine; Internal medicine; Physics","score_opus":0.03996934118834823,"score_gpt":0.3137290691387632,"score_spread":0.273759727950415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1659724067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886056,0.0032715201,0.00028805123,0.00075577124,0.000053525797,0.0014044527,0.0000545583,0.000043645992,0.0055228733],"genre_scores_gemma":[0.99429435,0.0029868258,0.0004927475,0.000098256765,0.00010216096,0.00014354203,0.00003052285,0.000025258732,0.001826336],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99856305,0.0000034076418,0.00027240528,0.00034872963,0.00039880804,0.0004136211],"domain_scores_gemma":[0.9987137,0.000019634477,0.00009311854,0.00007547421,0.00081975077,0.00027836958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036064303,0.0001864273,0.00034323148,0.00017660095,0.00006269128,0.000049622537,0.00010844879,0.000064462125,0.000008626101],"category_scores_gemma":[0.000031008592,0.00013666258,0.000037536032,0.00024448035,0.00009002454,0.00012561564,0.00005795987,0.000191543,0.0000038901517],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009989337,0.0016247174,0.63780344,0.0034400278,0.0008683387,0.00006737046,0.015301052,0.000003972583,0.207768,0.014311125,0.0015468296,0.10727578],"study_design_scores_gemma":[0.029310856,0.012024834,0.25932696,0.0041329763,0.0004339996,0.00088503107,0.019321349,0.40994102,0.24025187,0.0008087023,0.020949323,0.0026131102],"about_ca_topic_score_codex":0.00014694098,"about_ca_topic_score_gemma":0.0000034894583,"teacher_disagreement_score":0.40993702,"about_ca_system_score_codex":0.00014227691,"about_ca_system_score_gemma":0.00025152878,"threshold_uncertainty_score":0.55729383},"labels":[],"label_agreement":null},{"id":"W1672944621","doi":"10.5489/cuaj.1146","title":"PSA-based treatment response criteria in castration-resistant prostate cancer: promises and limitations","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Prostate cancer; Castration; Medicine; Oncology; Cancer; Gynecology; Internal medicine; Hormone","score_opus":0.045031074641537494,"score_gpt":0.30996734645917723,"score_spread":0.26493627181763973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1672944621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9003559,0.0006530186,0.0000010672582,0.09782189,0.00006497238,0.0006811473,0.000054592925,0.000012460138,0.0003549497],"genre_scores_gemma":[0.9963596,0.00049887795,0.00022319375,0.0009655001,0.00008558651,0.00026829125,0.00003013151,0.000009833102,0.0015589871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865276,0.00025576257,0.0002707784,0.00017954853,0.00020989422,0.00043127197],"domain_scores_gemma":[0.9986197,0.00032220015,0.00010656525,0.00006944469,0.00027016303,0.0006119362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003794222,0.00012709053,0.00020890715,0.00026246614,0.00022754396,0.0001681479,0.00003941329,0.00011781331,0.0004605369],"category_scores_gemma":[0.00058703223,0.00008952459,0.00005244137,0.00020187258,0.00004718046,0.00013413942,0.0000043308464,0.00022469343,0.00002023181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019699738,0.0002245593,0.96309096,0.00001487272,0.00013833265,0.00034580214,0.00092191325,0.00007156672,0.0109559875,0.000027532526,0.005124639,0.017113866],"study_design_scores_gemma":[0.0033311187,0.001199064,0.98226625,0.000030260291,0.00004105507,0.000026200181,0.00019035667,0.0003915446,0.00022176023,0.0002467131,0.011957996,0.000097668686],"about_ca_topic_score_codex":0.005870798,"about_ca_topic_score_gemma":0.009630359,"teacher_disagreement_score":0.096856385,"about_ca_system_score_codex":0.0025140934,"about_ca_system_score_gemma":0.0018785896,"threshold_uncertainty_score":0.887493},"labels":[],"label_agreement":null},{"id":"W1692684203","doi":"10.1155/2015/820403","title":"The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada","year":2015,"lang":"en","type":"article","venue":"Journal of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Royal Jubilee Hospital; University of British Columbia","funders":"Vancouver Coastal Health Research Institute; Astellas Pharma; European Association of Urology","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Oncology; Internal medicine; Androgen; Cancer; Hormone","score_opus":0.02508443038808714,"score_gpt":0.3153097149362931,"score_spread":0.29022528454820595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1692684203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99122256,0.0075268173,0.0000013555406,0.00055995345,0.000094211704,0.00041359226,0.000017217935,0.0000013340402,0.00016296722],"genre_scores_gemma":[0.9676092,0.03180065,0.00004743231,0.00002309368,0.000032066255,0.000017362596,0.0000016061724,0.0000081736725,0.00046037897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988458,0.00021284686,0.00033435502,0.00008529176,0.0003320727,0.0001896071],"domain_scores_gemma":[0.9990031,0.00022905078,0.00031218817,0.00007590323,0.00028064137,0.00009910467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065704493,0.000053198357,0.00031744223,0.00004583932,0.00003542111,0.00001615333,0.000080322345,0.0000478281,0.000012331483],"category_scores_gemma":[0.00013131554,0.000040569863,0.000029438486,0.00020260375,0.00009123055,0.00006816718,0.000014243584,0.0002438742,5.0608058e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010991954,0.00007738865,0.9741316,0.000039925424,0.00012739278,0.00013734149,0.0006687122,0.00012032055,0.00007985288,2.5669456e-7,0.0010052249,0.022512816],"study_design_scores_gemma":[0.008218471,0.0024404314,0.979859,0.0002553586,0.000048076974,0.000049096772,0.0018173446,0.00004548663,0.0007132822,0.00007294391,0.0064259577,0.000054557077],"about_ca_topic_score_codex":0.7470015,"about_ca_topic_score_gemma":0.96378267,"teacher_disagreement_score":0.21678112,"about_ca_system_score_codex":0.0014314792,"about_ca_system_score_gemma":0.0069947666,"threshold_uncertainty_score":0.99863464},"labels":[],"label_agreement":null},{"id":"W1720362365","doi":"10.1111/j.1442-2042.2012.02997.x","title":"Gonadotropin‐releasing hormone: An update review of the antagonists versus agonists","year":2012,"lang":"en","type":"review","venue":"International Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Gonadotropin-releasing hormone agonist; Testosterone (patch); Internal medicine; Endocrinology; Androgen; Gonadotropin-releasing hormone; Gonadotropin; Agonist; Hormone; Receptor; Luteinizing hormone; Cancer","score_opus":0.08228680414706313,"score_gpt":0.43036619727674263,"score_spread":0.3480793931296795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1720362365","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011499363,0.9931349,0.000009459585,0.0031934083,0.0027913405,0.000331627,0.00005461299,0.0000045404513,0.00036510377],"genre_scores_gemma":[0.0006677228,0.9973656,0.00011269435,0.00044646763,0.0011788864,0.0000075920448,0.000085098094,0.000032117554,0.00010384825],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99754286,0.00033068637,0.0009686491,0.00015943582,0.0007462983,0.00025205538],"domain_scores_gemma":[0.99730146,0.00014121535,0.0013271747,0.00029861546,0.0007691679,0.00016238326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003872579,0.00023838453,0.0012484443,0.00023304166,0.000039439336,0.000015482958,0.00074744486,0.00018463541,0.00018562976],"category_scores_gemma":[0.00018340966,0.00013093045,0.00073283224,0.00015533765,0.00021411905,0.00011759903,0.00014757882,0.0007622808,0.000024790263],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009797502,0.0002773887,0.000053646014,0.008231449,0.0020626285,0.00030330275,0.000025083951,2.0135167e-7,0.00001519996,0.00024922917,0.0018012392,0.9860009],"study_design_scores_gemma":[0.0013852017,0.000604014,0.00027228604,0.013346093,0.0020843167,0.0030728152,0.0000024912677,6.434841e-7,0.000005215719,0.000018955629,0.97911566,0.00009228759],"about_ca_topic_score_codex":0.000009434186,"about_ca_topic_score_gemma":0.0000013663147,"teacher_disagreement_score":0.98590857,"about_ca_system_score_codex":0.00033435694,"about_ca_system_score_gemma":0.0011063608,"threshold_uncertainty_score":0.53391886},"labels":[],"label_agreement":null},{"id":"W1736083604","doi":"10.5539/gjhs.v8n4p1","title":"Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature","year":2015,"lang":"en","type":"review","venue":"Global Journal of Health Science","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Reimbursement; Cost effectiveness; MEDLINE; Systematic review; Cost–benefit analysis; Randomized controlled trial; Health care; Family medicine; Medical physics; Cancer; Internal medicine","score_opus":0.09056704752912703,"score_gpt":0.43337999872846905,"score_spread":0.342812951199342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1736083604","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014255557,0.9919247,2.1523152e-7,0.0022979158,0.00015929129,0.0039378502,0.0002396221,0.0000010293883,0.000013844868],"genre_scores_gemma":[0.00067765336,0.9988323,0.000103613216,0.00025588073,0.000022508255,0.00006785122,0.000004539944,0.0000066269513,0.000029039513],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99650174,0.000599947,0.0017706826,0.00023388342,0.0005661448,0.00032758346],"domain_scores_gemma":[0.9962561,0.00009641283,0.002650989,0.00033623,0.0003768863,0.0002833903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004231361,0.00024492235,0.0026463862,0.00018163967,0.00011327725,0.000028471411,0.00024020993,0.000037185982,0.0000014468759],"category_scores_gemma":[0.00009395448,0.0001007673,0.00019041228,0.0007679816,0.0005039666,0.00012464965,0.000028784865,0.00021291559,1.2040285e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000055933255,0.00021082371,0.000050052382,0.9026797,0.000116058225,0.00027649023,0.0017769609,6.3543735e-7,1.1751247e-7,0.000059928025,0.00028351005,0.0944898],"study_design_scores_gemma":[0.001783394,0.002696065,0.00012468608,0.9209293,0.001181616,0.02538774,0.0005730244,0.0000084189005,3.1182566e-7,0.000032994798,0.047163453,0.000118967975],"about_ca_topic_score_codex":0.0006894246,"about_ca_topic_score_gemma":0.00024153136,"teacher_disagreement_score":0.094370835,"about_ca_system_score_codex":0.004506245,"about_ca_system_score_gemma":0.019876968,"threshold_uncertainty_score":0.99931526},"labels":[],"label_agreement":null},{"id":"W1756131458","doi":"10.1002/9780470755006","title":"Challenges in Prostate Cancer","year":2006,"lang":"en","type":"book","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Cancer; Prostate; Medicine; Oncology; Internal medicine","score_opus":0.08278476200696,"score_gpt":0.3613460843294017,"score_spread":0.2785613223224417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1756131458","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001123129,0.07703827,1.0227821e-7,0.004398596,0.00008774186,0.00084088976,0.000029036722,0.000051869563,0.9174412],"genre_scores_gemma":[0.00029265115,0.06527882,0.000031266096,0.00008569485,0.00028828226,0.00021307929,0.00023808096,0.000048825903,0.9335233],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987888,0.000011697432,0.00019458728,0.0003690698,0.00030846134,0.00032742324],"domain_scores_gemma":[0.9995314,0.000024786992,0.000041887324,0.00024399754,0.00007225216,0.00008568352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008758122,0.00021803552,0.0004159403,0.000244372,0.00001616761,0.000008719734,0.000059273883,0.00018069382,0.0005713263],"category_scores_gemma":[0.0000036734234,0.0001496494,0.000079952064,0.000052647076,0.000065933295,0.00002768999,0.000038040194,0.0003909633,0.00011523449],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005600426,0.00026097315,0.0036654456,0.0019889392,0.00024260019,0.0021668533,0.0002951559,0.0000027660437,0.000031671836,0.0019092687,0.7915902,0.1972861],"study_design_scores_gemma":[0.0023051954,0.0001950083,0.0044656205,0.0011171807,0.000057066638,0.000016207765,0.000019329644,0.0000053631466,0.00013540515,0.001395231,0.99009097,0.00019740997],"about_ca_topic_score_codex":0.00026384808,"about_ca_topic_score_gemma":0.0016596684,"teacher_disagreement_score":0.1985008,"about_ca_system_score_codex":0.00075368833,"about_ca_system_score_gemma":0.0010769515,"threshold_uncertainty_score":0.62556225},"labels":[],"label_agreement":null},{"id":"W1779133220","doi":"10.1200/jco.2000.18.5.1036","title":"Serum Human Glandular Kallikrein-2 Protease Levels Predict the Presence of Prostate Cancer Among Men With Elevated Prostate-Specific Antigen","year":2000,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Prostate cancer; Odds ratio; Confidence interval; Prostate-specific antigen; Urology; Prostate biopsy; Cancer; Prostate; Internal medicine; Rectal examination; Quartile; Gynecology; Biopsy; Oncology; Gastroenterology","score_opus":0.10882255173298519,"score_gpt":0.4401482671797492,"score_spread":0.33132571544676404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1779133220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887267,0.0015492544,0.0000045625784,0.0052860696,0.00012756862,0.0019854943,0.00005561265,0.000017087365,0.002247665],"genre_scores_gemma":[0.98777324,0.0051818956,0.0002215692,0.0001739357,0.00055260636,0.00007726321,0.000009894577,0.000035241523,0.0059743486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956356,0.00065490825,0.0019846924,0.00032132657,0.0009015104,0.0005019469],"domain_scores_gemma":[0.99637926,0.000551644,0.00131996,0.00039073714,0.00089935114,0.00045905396],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029797293,0.00023678584,0.001307546,0.00011122433,0.00014609142,0.000023575025,0.00036219455,0.00026748024,0.0009848245],"category_scores_gemma":[0.00027194578,0.000113301656,0.00028203728,0.00035887703,0.0010886134,0.00022231802,0.000053870506,0.0012952054,0.00000849241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025603043,0.001721516,0.9044787,0.00012771615,0.0012429836,0.001545978,0.001199203,0.0001762728,0.0032568278,0.000020662974,0.0035149609,0.0571121],"study_design_scores_gemma":[0.015617699,0.018543113,0.9204205,0.00061028457,0.00027451193,0.00010339761,0.00019710122,0.00012012984,0.0049184165,0.0001580446,0.03889205,0.00014471468],"about_ca_topic_score_codex":0.00021813375,"about_ca_topic_score_gemma":0.00006984153,"teacher_disagreement_score":0.05696739,"about_ca_system_score_codex":0.00017146199,"about_ca_system_score_gemma":0.0023489434,"threshold_uncertainty_score":0.9999284},"labels":[],"label_agreement":null},{"id":"W1782284105","doi":"10.1200/jco.2015.33.7_suppl.228","title":"Treatment patterns of new metastatic castration-resistant prostate cancer (mCRPC) therapies: Real-world evidence from three datasets.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Enzalutamide; Medicine; Cabazitaxel; Docetaxel; Abiraterone acetate; Prostate cancer; Abiraterone; Internal medicine; Oncology; Medical prescription; Cancer; Pharmacology; Androgen receptor; Androgen deprivation therapy","score_opus":0.4458819072764866,"score_gpt":0.5576866826355011,"score_spread":0.11180477535901456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1782284105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759795,0.0077089146,0.00008021289,0.014310142,0.00068522,0.0005644846,0.00043625006,0.0000072768958,0.00022801755],"genre_scores_gemma":[0.96734405,0.024666939,0.004400295,0.00033044085,0.0010535339,0.000026135676,0.000102532955,0.000026173477,0.0020498896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99642575,0.00036094926,0.0020371713,0.0002489302,0.00065420975,0.0002730166],"domain_scores_gemma":[0.99504954,0.0018048374,0.0015486969,0.00034285104,0.0005208715,0.00073322374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014608436,0.00019194778,0.0014973136,0.00014063322,0.000029829986,0.000016221205,0.00019887133,0.00010815931,0.00039308312],"category_scores_gemma":[0.0008377629,0.00010899572,0.00031988183,0.00017506907,0.00017166536,0.00023149031,0.00004360575,0.0004153074,0.000012445941],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02893374,0.0020674684,0.7211069,0.000069408816,0.0029252244,0.002060871,0.0017391217,0.000047145866,0.00089657906,0.000033644716,0.010775683,0.22934422],"study_design_scores_gemma":[0.03408932,0.04296263,0.8519541,0.0011156275,0.002453331,0.00006909057,0.001060704,0.0001240627,0.0018466924,0.0017501521,0.062355567,0.00021872052],"about_ca_topic_score_codex":0.015494291,"about_ca_topic_score_gemma":0.020838765,"teacher_disagreement_score":0.22912548,"about_ca_system_score_codex":0.0006662252,"about_ca_system_score_gemma":0.009240433,"threshold_uncertainty_score":0.99702835},"labels":[],"label_agreement":null},{"id":"W1788564901","doi":"10.1200/jco.2015.33.7_suppl.151","title":"Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: Exploratory analysis of a randomized controlled trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Hazard ratio; Urology; Proportional hazards model; Confidence interval; Internal medicine; Cancer","score_opus":0.08898261223170705,"score_gpt":0.43744846036789686,"score_spread":0.3484658481361898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1788564901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97537386,0.021559514,0.00005565926,0.00041644266,0.00055375084,0.0018326294,0.00002722111,0.0000034095106,0.00017749725],"genre_scores_gemma":[0.9831432,0.015583591,0.00067943777,0.000029101733,0.00024866735,0.00019044554,0.0000055878636,0.000017025057,0.00010296028],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99205196,0.0023754088,0.0039586257,0.00022259165,0.001159483,0.00023194651],"domain_scores_gemma":[0.9887692,0.0038710262,0.00406086,0.0003654244,0.0024946555,0.00043886303],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013643902,0.00018609007,0.009297477,0.00047379246,0.000012304451,0.0000021990277,0.0001589224,0.00031372524,0.000039701732],"category_scores_gemma":[0.010425055,0.000096652286,0.004146575,0.00057722314,0.00068396155,0.000078357596,0.000051536175,0.0006522669,7.7160547e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87775904,0.0017630233,0.0264418,0.000055493598,0.09079067,0.00018203797,0.00031670407,0.0004360531,0.000033561064,0.0000018727249,0.00020382491,0.0020159145],"study_design_scores_gemma":[0.916296,0.01756075,0.0019117156,0.00018727033,0.06233177,0.0000059183785,0.00022635238,0.00015842877,0.0007405699,0.000045032448,0.00045899674,0.000077220335],"about_ca_topic_score_codex":0.00015779622,"about_ca_topic_score_gemma":0.000028639732,"teacher_disagreement_score":0.038536932,"about_ca_system_score_codex":0.00021444436,"about_ca_system_score_gemma":0.0042819628,"threshold_uncertainty_score":0.99791056},"labels":[],"label_agreement":null},{"id":"W1795921002","doi":"10.1186/1471-2164-8-32","title":"Novel expressed sequences identified in a model of androgen independent prostate cancer","year":2007,"lang":"en","type":"article","venue":"BMC Genomics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research; Health Canada; Michael Smith Health Research BC","keywords":"Prostate cancer; Biology; Gene; Cancer; Untranslated region; Computational biology; Prostate; DNA microarray; Human genome; Genetics; Cancer research; Genome; Gene expression; Messenger RNA","score_opus":0.07726733380986435,"score_gpt":0.34134946924519755,"score_spread":0.2640821354353332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1795921002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960793,0.0011059978,0.0013093448,0.000098147626,0.00006299784,0.0006853906,0.000081507154,0.0000137548495,0.0005635148],"genre_scores_gemma":[0.99417734,0.0006481244,0.003060105,0.000039927214,0.00003864484,0.00005339082,0.000024561983,0.000019364572,0.001938518],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988524,0.000009666458,0.00032107875,0.00023769951,0.00025742975,0.00032174497],"domain_scores_gemma":[0.999478,0.000030563402,0.00008782123,0.00019911007,0.00009672389,0.00010780533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038962057,0.00011367404,0.00023755663,0.00017423526,0.000026986001,0.000011957171,0.00010279964,0.00007677166,0.000018743856],"category_scores_gemma":[0.000017932469,0.00009345479,0.000058068505,0.00016954991,0.00007864609,0.00006195601,0.000056581714,0.00012632388,0.0000037893085],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015265956,0.0002536582,0.113586456,0.00023290163,0.00005813519,0.000028411616,0.00258001,0.004295611,0.8746503,0.00005380081,0.000044288092,0.0026898393],"study_design_scores_gemma":[0.00865354,0.00016298926,0.030716255,0.00020040447,0.0000732582,0.000013928655,0.0013524683,0.02002612,0.93764454,0.00069897703,0.00021453644,0.000242977],"about_ca_topic_score_codex":0.0006918041,"about_ca_topic_score_gemma":0.0014890285,"teacher_disagreement_score":0.0828702,"about_ca_system_score_codex":0.00031244205,"about_ca_system_score_gemma":0.00082895596,"threshold_uncertainty_score":0.38109758},"labels":[],"label_agreement":null},{"id":"W181353580","doi":"10.1096/fasebj.21.5.a259-a","title":"Transcriptional Regulation Of The Threshold Response Of Prostate Cancer Cells To The Anti‐Androgen Casodex","year":2007,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Coleman Foundation","keywords":"LNCaP; Cancer research; Biology; Androgen receptor; Apoptosis; Prostate cancer; Dihydrotestosterone; Cell cycle; Survivin; Downregulation and upregulation; Internal medicine; Androgen; Endocrinology; Medicine; Cancer; Gene","score_opus":0.03177376700224264,"score_gpt":0.315820743718626,"score_spread":0.28404697671638335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W181353580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865214,0.0016885247,0.000063381834,0.010659061,0.00023169347,0.00055462646,0.000052938587,0.000003825841,0.0002245022],"genre_scores_gemma":[0.9963438,0.00033405618,0.000035987356,0.00021281213,0.00017330656,0.0000069457747,0.00000192866,0.000011481268,0.002879714],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986519,0.00013115282,0.0002945824,0.000086351305,0.0006047317,0.0002312684],"domain_scores_gemma":[0.9991725,0.00011481134,0.00013878867,0.00025244054,0.00023240988,0.00008906072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019860542,0.00008831931,0.00015136754,0.000074850206,0.00022380926,0.000013515412,0.00020223056,0.00003580658,0.00015866889],"category_scores_gemma":[0.000027930266,0.00003416221,0.00013917878,0.00030775258,0.00018795131,0.000043958113,0.000027075228,0.0002702666,0.00000381949],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065177744,0.00006507474,0.01835126,0.00002008741,0.00012573371,0.000012627686,0.0031383696,0.00068879797,0.9682622,0.000049129812,0.0012777112,0.0014912081],"study_design_scores_gemma":[0.0011890167,0.00019494389,0.20583591,0.0001445456,0.000092427064,0.00011721606,0.00042991168,0.00007452538,0.7902742,0.00011292259,0.001496485,0.000037903017],"about_ca_topic_score_codex":0.000043549706,"about_ca_topic_score_gemma":0.00003930241,"teacher_disagreement_score":0.18748465,"about_ca_system_score_codex":0.000112041125,"about_ca_system_score_gemma":0.00035065302,"threshold_uncertainty_score":0.17373131},"labels":[],"label_agreement":null},{"id":"W1820440715","doi":"10.1517/17425255.2015.1085506","title":"Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Drug Metabolism & Toxicology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Prostate cancer; Pharmacodynamics; Medicine; Pharmacokinetics; Cancer; Oncology; Pharmacology; Internal medicine","score_opus":0.08517929021166616,"score_gpt":0.4622642591928121,"score_spread":0.37708496898114596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1820440715","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000121516794,0.9886335,0.000004107467,0.0008795437,0.0022476555,0.006564516,0.00081048487,0.00006232786,0.00067631825],"genre_scores_gemma":[0.000040008377,0.98668736,0.00031218163,0.00029875635,0.000927082,0.006595958,0.0007269858,0.00014072827,0.0042709545],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997001,0.0003159162,0.0008066906,0.00080705096,0.000410235,0.0006591374],"domain_scores_gemma":[0.99818534,0.0002468056,0.00044974498,0.0003729951,0.00034078184,0.00040434673],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045480594,0.000638884,0.0028418303,0.0005324819,0.00008757113,0.000015719903,0.0002355504,0.00032913504,0.00029085582],"category_scores_gemma":[0.000064436965,0.00044120612,0.00041114766,0.0003528389,0.00028746406,0.00006759328,0.00013957033,0.0005026936,0.000020302381],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084047765,0.00039302878,0.0000027542756,0.008484013,0.0006625536,0.000011699632,0.00043023808,9.869761e-7,0.00024403434,0.00011672194,0.026573127,0.96224034],"study_design_scores_gemma":[0.005723878,0.0005232127,0.0000076002816,0.0032900204,0.0005005221,0.00003969625,0.00004406934,0.00008666939,0.00070893945,0.000024383144,0.9886924,0.00035858652],"about_ca_topic_score_codex":0.000050053815,"about_ca_topic_score_gemma":0.0000023641426,"teacher_disagreement_score":0.9621193,"about_ca_system_score_codex":0.00027301014,"about_ca_system_score_gemma":0.0014336287,"threshold_uncertainty_score":0.99980396},"labels":[],"label_agreement":null},{"id":"W1824496400","doi":"10.1016/j.eururo.2015.09.031","title":"Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location","year":2015,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Cancer Institute","keywords":"Androgen receptor; Prostate cancer; Medicine; Prostatectomy; Prostate; Cohort; Cancer; Androgen; Internal medicine; Endocrinology; Oncology; Cancer research; Hormone","score_opus":0.02677328838147414,"score_gpt":0.3189734396350947,"score_spread":0.2922001512536206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1824496400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99073523,0.0042472184,0.000067188295,0.0023479527,0.000100609606,0.00036987205,0.000008497095,0.000035558012,0.0020878569],"genre_scores_gemma":[0.99862087,0.00021960576,0.00019222322,0.0004945379,0.00009872655,0.000026869084,0.000050586375,0.000026396005,0.000270217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899393,0.00026964323,0.00016112876,0.0002444654,0.00010938708,0.00022143852],"domain_scores_gemma":[0.9995665,0.000025695379,0.000047019083,0.000115359384,0.00011993189,0.00012550369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040070942,0.000094076655,0.00014922621,0.00014936393,0.000038330723,0.000013744888,0.000046624442,0.000023442255,0.00003931225],"category_scores_gemma":[0.00012184047,0.000080414466,0.000015886959,0.00024240061,0.00007406903,0.000050070146,0.00004008156,0.00015176734,0.00005587311],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01154329,0.00075381744,0.6133318,0.00028033397,0.00055194454,0.0045203073,0.019024523,0.0014267465,0.29212868,0.0017863422,0.004034264,0.050617933],"study_design_scores_gemma":[0.08761773,0.017543063,0.4652473,0.00060521334,0.0013357537,0.001147391,0.0017312424,0.013245949,0.17226002,0.004849606,0.23165229,0.0027644238],"about_ca_topic_score_codex":0.00006158854,"about_ca_topic_score_gemma":0.00003603752,"teacher_disagreement_score":0.22761804,"about_ca_system_score_codex":0.0001011624,"about_ca_system_score_gemma":0.0002481645,"threshold_uncertainty_score":0.32792068},"labels":[],"label_agreement":null},{"id":"W1824567653","doi":"10.7759/cureus.365","title":"Complete PSA Response Following Stereotactic Ablative Radiotherapy for a Bony Metastasis in the Setting of Castrate-Resistant Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"Cureus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Ablative case; Prostate cancer; Radiation therapy; Radiosurgery; Cancer; Prostate; Metastasis; Radiology; Lesion; Oncology; Internal medicine; Surgery","score_opus":0.10072694169183499,"score_gpt":0.39967967488608497,"score_spread":0.29895273319425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1824567653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834211,0.009869572,0.000052597024,0.004197863,0.00011101079,0.0019009772,0.00022893054,0.000015415024,0.00020256995],"genre_scores_gemma":[0.9975057,0.00016561656,0.0011728428,0.00016500716,0.00004725725,0.00040421906,0.000029132296,0.000026838487,0.00048337586],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984833,0.0002919392,0.0002893188,0.00022536896,0.0003551305,0.00035493326],"domain_scores_gemma":[0.9989096,0.0004550852,0.000116412215,0.00026149856,0.00015573173,0.00010167123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014751116,0.0001541129,0.00037095178,0.000095114534,0.00006911568,0.00002786173,0.000121571094,0.00004159475,0.000016763779],"category_scores_gemma":[0.00019361643,0.0000933553,0.0001298433,0.00031930886,0.00006797283,0.00011202312,0.000017906681,0.00014630909,0.000001024901],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18481505,0.001763977,0.16340984,0.001164089,0.007207457,0.0015378972,0.20781836,0.0003045691,0.40734747,0.00037354138,0.008938642,0.01531909],"study_design_scores_gemma":[0.16760519,0.033423193,0.41000113,0.0046490566,0.004188804,0.00033016902,0.12574539,0.011490807,0.08187678,0.0030979586,0.15498519,0.0026063235],"about_ca_topic_score_codex":0.00074013806,"about_ca_topic_score_gemma":0.0003911981,"teacher_disagreement_score":0.3254707,"about_ca_system_score_codex":0.00040412048,"about_ca_system_score_gemma":0.0005496308,"threshold_uncertainty_score":0.38069186},"labels":[],"label_agreement":null},{"id":"W184856732","doi":"","title":"Secondary hormonal manipulation in castration resistant prostate cancer.","year":2014,"lang":"en","type":"review","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Castration; Prostate cancer; Hormone; Prostate; Medicine; Hormonal therapy; Cancer; Oncology; Gynecology; Internal medicine","score_opus":0.09719563394009521,"score_gpt":0.3623366651044223,"score_spread":0.2651410311643271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W184856732","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019514364,0.9909122,6.646941e-7,0.00022201457,0.00017448625,0.004591532,0.000087949265,0.000035247285,0.003780772],"genre_scores_gemma":[0.0010293227,0.9809785,0.000017562845,0.000025539375,0.00031034942,0.010731087,0.001023811,0.000049350216,0.005834477],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980908,0.00011875334,0.0005412158,0.0004126818,0.00034977504,0.00048677594],"domain_scores_gemma":[0.9992649,0.00005278793,0.00020148666,0.00024591113,0.00006533742,0.00016957083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045905242,0.00027888894,0.0010207709,0.00033671252,0.000047397338,0.000040675044,0.000082356324,0.00021874162,0.00005589599],"category_scores_gemma":[0.000036630754,0.00020190436,0.0001880917,0.0003580827,0.000049455022,0.0000857081,0.000032784003,0.00049456785,0.00001888938],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016242429,0.000044243323,0.0001471347,0.012987367,0.000097124444,0.0000916346,0.00002546857,4.0516883e-7,6.4883056e-7,0.000023409506,0.0005939697,0.9858262],"study_design_scores_gemma":[0.001243083,0.00006787618,0.03045765,0.0034852682,0.00037278372,0.000029180945,0.0000063802936,0.000005084999,0.0000037540249,0.000039124265,0.9640818,0.0002079636],"about_ca_topic_score_codex":0.00016338662,"about_ca_topic_score_gemma":0.00023226993,"teacher_disagreement_score":0.98561823,"about_ca_system_score_codex":0.0009768481,"about_ca_system_score_gemma":0.0006906899,"threshold_uncertainty_score":0.8233421},"labels":[],"label_agreement":null},{"id":"W1850931324","doi":"10.1593/neo.10866","title":"ERG Cooperates with Androgen Receptor in Regulating Trefoil Factor 3 in Prostate Cancer Disease Progression","year":2010,"lang":"en","type":"article","venue":"Neoplasia","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Prostate Cancer Canada; National Cancer Institute; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Prostate cancer; Erg; Cancer research; Androgen receptor; Biology; Chromatin immunoprecipitation; Cancer; Internal medicine; Gene expression; Medicine; Gene; Promoter; Genetics","score_opus":0.014111551858934956,"score_gpt":0.3187222272072908,"score_spread":0.30461067534835584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1850931324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960762,0.00079074944,1.7158946e-7,0.0016168462,0.00009886088,0.00093846367,0.00004418981,0.000042007494,0.0003925132],"genre_scores_gemma":[0.99658823,0.00023737588,0.00030843986,0.000045351815,0.0000876949,0.0003761475,0.00008905457,0.000032833075,0.002234892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877656,0.000034216046,0.00019058755,0.00033219796,0.00027892005,0.00038751925],"domain_scores_gemma":[0.99939746,0.000029032384,0.000047434467,0.00019700185,0.000082513325,0.00024654862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008966795,0.00016993229,0.00023366962,0.00015009491,0.00005552168,0.00003037055,0.00005962776,0.00006471291,0.0003399204],"category_scores_gemma":[0.00004527113,0.00010377214,0.00002538203,0.00040210233,0.00009010857,0.00012791234,0.000028753233,0.00037987813,0.00001574269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028689438,0.00020821167,0.93275326,0.00012288528,0.000018051624,0.00022045946,0.0007922764,0.000010927167,0.024377711,0.000007697743,0.00013181509,0.038487755],"study_design_scores_gemma":[0.011312082,0.00059558224,0.9208322,0.0014756342,0.000029553317,0.000021504151,0.00023425862,0.0006886013,0.058659445,0.00001997598,0.005819154,0.00031201544],"about_ca_topic_score_codex":0.00020340031,"about_ca_topic_score_gemma":0.002046709,"teacher_disagreement_score":0.03817574,"about_ca_system_score_codex":0.00013776588,"about_ca_system_score_gemma":0.000549126,"threshold_uncertainty_score":0.42317048},"labels":[],"label_agreement":null},{"id":"W1860525478","doi":"10.1111/his.12803","title":"Gleason and Fuhrman no longer make the grade","year":2015,"lang":"en","type":"review","venue":"Histopathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Grading (engineering); Medicine; Renal cell carcinoma; Pathology; Clear cell; Prostate cancer; Chromophobe cell; Radiology; Internal medicine; Cancer; Biology","score_opus":0.12153852363554096,"score_gpt":0.4089485282730502,"score_spread":0.28741000463750926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1860525478","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022777383,0.9887253,0.0000012007475,0.0004326323,0.0005304444,0.0008926936,0.000026894879,0.000036876052,0.0093311835],"genre_scores_gemma":[0.0000065257723,0.95949435,0.00005366714,0.0001458828,0.0004445114,0.00016938009,0.00016803706,0.000044379332,0.039473243],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986237,0.00022786658,0.0002461256,0.0003758841,0.00020083082,0.00032557605],"domain_scores_gemma":[0.9990845,0.000069419286,0.00010985443,0.00048310607,0.000091325106,0.00016182473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037046213,0.0002722438,0.0011245081,0.00012474424,0.00008957428,0.000011713599,0.00013878374,0.00029219172,0.000101417616],"category_scores_gemma":[0.00005764692,0.00013993488,0.00017142745,0.00012854965,0.0004098389,0.0000141442915,0.00011428979,0.0005467776,0.0005126678],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045825585,0.00007192766,0.00008515307,0.0060062944,0.000029988058,0.0014224756,0.00022676268,2.7673925e-9,0.0000019552667,0.00013094035,0.03480933,0.95716935],"study_design_scores_gemma":[0.00048954476,0.00028556582,0.000164869,0.0011021582,0.000733226,0.002144458,0.000010798534,5.100143e-7,1.6178413e-7,0.000033478093,0.9949087,0.00012653318],"about_ca_topic_score_codex":0.0000124120525,"about_ca_topic_score_gemma":0.0000060160946,"teacher_disagreement_score":0.9600994,"about_ca_system_score_codex":0.00028137103,"about_ca_system_score_gemma":0.0004117193,"threshold_uncertainty_score":0.6589478},"labels":[],"label_agreement":null},{"id":"W1868820390","doi":"10.1200/jco.2015.33.7_suppl.5","title":"Place of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy: A phase III trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Centre hospitalier universitaire de Québec; Centre de Santé et de Services Sociaux de Chicoutimi; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Radiation therapy; Bicalutamide; Urology; Randomized controlled trial; Prostate; Log-rank test; Proportional hazards model; Surgery; Internal medicine; Cancer; Androgen receptor","score_opus":0.15267072776502538,"score_gpt":0.5027679033095561,"score_spread":0.35009717554453074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1868820390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99385965,0.0034202111,0.00003225365,0.0012433737,0.00028884894,0.0009977425,0.000010456622,0.000006908739,0.00014055739],"genre_scores_gemma":[0.97532046,0.023388203,0.0003494285,0.00016714713,0.0004932528,0.000041361334,0.000009725544,0.00002100864,0.00020942985],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968305,0.00051935826,0.0018294532,0.00018241712,0.00040754533,0.00023069311],"domain_scores_gemma":[0.99698126,0.0007237337,0.0012337829,0.00016011175,0.00054930034,0.0003517981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030669142,0.00014543635,0.0014033783,0.00022893913,0.00001611247,0.0000070733604,0.00012459549,0.00023080086,0.000056436595],"category_scores_gemma":[0.0006171734,0.00008004884,0.0001916413,0.00026872777,0.0002607075,0.00012670382,0.000016093118,0.0006615392,7.5369735e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42618623,0.0028494478,0.36506042,0.000010026297,0.000540899,0.0003861207,0.0006143797,0.000019689765,0.00031725856,8.678417e-7,0.00037764004,0.20363702],"study_design_scores_gemma":[0.7618601,0.14760862,0.07890836,0.00028882164,0.00029395366,0.00010024372,0.00029708404,0.00031844174,0.0026833203,0.000051527684,0.0074512525,0.00013828841],"about_ca_topic_score_codex":0.00013368853,"about_ca_topic_score_gemma":0.00015672603,"teacher_disagreement_score":0.33567384,"about_ca_system_score_codex":0.00040328488,"about_ca_system_score_gemma":0.0033565087,"threshold_uncertainty_score":0.59543025},"labels":[],"label_agreement":null},{"id":"W1880033105","doi":"10.6004/jnccn.2014.0007","title":"The Prostate Cancer Risk Stratification Project: Database Construction and Risk Stratification Outcome Analysis","year":2014,"lang":"en","type":"article","venue":"Journal of the National Comprehensive Cancer Network","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec; Montreal General Hospital; Juravinski Cancer Centre; Kingston Health Sciences Centre; Cancer Care South East; BC Cancer Agency; Kelowna General Hospital; Princess Margaret Cancer Centre; London Health Sciences Centre","funders":"Ontario Institute for Cancer Research; Association of Canadian Universities for Research in Astronomy; Canadian Association of Radiation Oncology; National Comprehensive Cancer Network; American Society for Radiation Oncology","keywords":"Medicine; Prostate cancer; Brachytherapy; Radiation therapy; Oncology; Proportional hazards model; Risk stratification; Database; Internal medicine; Prostate; Survival analysis; Gynecology; Cancer","score_opus":0.05022082447700471,"score_gpt":0.3718909252158641,"score_spread":0.3216701007388594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1880033105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9671404,0.017683614,0.0014444838,0.009801945,0.0014810562,0.0016267492,0.00043786757,0.000024596478,0.00035933824],"genre_scores_gemma":[0.97295415,0.023810191,0.0011106519,0.0002236298,0.0013183958,0.000087687105,0.000044224285,0.000016946155,0.00043410674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763584,0.0004184182,0.000619889,0.00022500817,0.00087544747,0.00022537755],"domain_scores_gemma":[0.99563223,0.00053280627,0.001253024,0.00022185601,0.002264457,0.00009562888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007219675,0.00016489017,0.00032132136,0.00014621466,0.00075538445,0.00010969763,0.00017830246,0.00006212396,0.000021708975],"category_scores_gemma":[0.00027788614,0.000087193825,0.00019247332,0.0009156253,0.00029721737,0.00018381941,0.000043900938,0.000573181,0.0000010788439],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015033055,0.0000748779,0.911609,0.00006902615,0.003469337,0.0000013346997,0.00034717616,0.034125954,0.0010582177,0.0013871376,0.00750285,0.038851812],"study_design_scores_gemma":[0.0025697993,0.00021778567,0.94442284,0.00018442872,0.0033408115,0.000039386603,0.00043608795,0.02152839,0.00053469243,0.0036004155,0.022931704,0.00019367812],"about_ca_topic_score_codex":0.0002588343,"about_ca_topic_score_gemma":0.00029853077,"teacher_disagreement_score":0.03865813,"about_ca_system_score_codex":0.0003464057,"about_ca_system_score_gemma":0.00052709493,"threshold_uncertainty_score":0.5809883},"labels":[],"label_agreement":null},{"id":"W1880813018","doi":"10.1016/j.eururo.2015.10.008","title":"Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel","year":2015,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Hazard ratio; Internal medicine; Response Evaluation Criteria in Solid Tumors; Confidence interval; Proportional hazards model; Oncology; Urology; Prostate-specific antigen; Cancer; Progressive disease; Chemotherapy","score_opus":0.04632432652286356,"score_gpt":0.30313933970059315,"score_spread":0.2568150131777296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1880813018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99170214,0.00046753985,0.0000031934658,0.0041875322,0.00008478366,0.00044698382,0.00005241003,0.000023140914,0.0030322925],"genre_scores_gemma":[0.99710536,0.00013074238,0.000106122156,0.0001237905,0.00009210681,0.000020404397,0.00012128219,0.000027180713,0.0022729987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986458,0.0003758546,0.00016726872,0.0002513086,0.00027477424,0.0002850112],"domain_scores_gemma":[0.9993569,0.000101228026,0.00011043207,0.00011238005,0.00018093058,0.00013807463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071414275,0.000117665346,0.00024140494,0.000114621944,0.000043465156,0.000024598572,0.000046466008,0.000025678739,0.000017941176],"category_scores_gemma":[0.00018035217,0.00008508975,0.000011199629,0.00017067815,0.000054334494,0.000066587665,0.00004098474,0.00017711593,0.000013918381],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010354565,0.00006367336,0.989468,0.00002681754,0.00014347426,0.00007214726,0.0008424188,0.000005571526,0.00006736524,0.0000041196995,0.00033349052,0.00793747],"study_design_scores_gemma":[0.006057793,0.001354008,0.98826677,0.000029943527,0.00012814037,0.0000013400143,0.000078082274,0.000009065227,0.000036966852,0.000015524514,0.0039343317,0.00008801771],"about_ca_topic_score_codex":0.00021248637,"about_ca_topic_score_gemma":0.00091305724,"teacher_disagreement_score":0.007849452,"about_ca_system_score_codex":0.00020998422,"about_ca_system_score_gemma":0.000108479675,"threshold_uncertainty_score":0.34698594},"labels":[],"label_agreement":null},{"id":"W1882091585","doi":"10.1593/neo.121368","title":"Role of Proprotein Convertases in Prostate Cancer Progression","year":2012,"lang":"en","type":"article","venue":"Neoplasia","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada; Fonds de Recherche du Québec - Santé; Ministère du Développement Économique, de l’Innovation et de l’Exportation; Movember Foundation","keywords":"DU145; LNCaP; Gene knockdown; Cell growth; Cancer research; Proprotein Convertases; Prostate cancer; Furin; Biology; Gene silencing; Cell culture; Cell biology; Cancer; Endocrinology; LDL receptor","score_opus":0.015265733535222125,"score_gpt":0.33666367701520356,"score_spread":0.3213979434799814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1882091585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880116,0.008270248,2.4970237e-7,0.00048009254,0.000044869194,0.0011145072,0.000017473494,0.00002136192,0.0020396223],"genre_scores_gemma":[0.9976237,0.0003103045,0.00019830893,0.000029911675,0.00005854989,0.00034890595,0.000023014543,0.000014451673,0.0013928514],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991359,0.000025713258,0.00015424729,0.00012009947,0.00024057602,0.00032342624],"domain_scores_gemma":[0.99963105,0.000014302452,0.00004927549,0.0001288441,0.00005697531,0.00011957785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000106477484,0.000092889604,0.00019784989,0.000091661626,0.000021039878,0.0000040067907,0.000037928927,0.000046497014,0.00025001072],"category_scores_gemma":[0.000020216721,0.000060953007,0.000031175718,0.00019114645,0.000069840265,0.00010003715,0.000027151924,0.0001242799,0.000023292725],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089121476,0.0004180389,0.88898295,0.00024013095,0.000031531104,0.00001675916,0.0012190188,6.071772e-7,0.057951115,0.000058038913,0.0002447215,0.04994588],"study_design_scores_gemma":[0.0032864516,0.00044821802,0.35986784,0.0003636125,0.000060686823,0.000022525724,0.0004387649,0.000053134147,0.62680393,0.00005662097,0.008486039,0.00011214562],"about_ca_topic_score_codex":0.00026705422,"about_ca_topic_score_gemma":0.00004253488,"teacher_disagreement_score":0.56885284,"about_ca_system_score_codex":0.00008730434,"about_ca_system_score_gemma":0.00017851198,"threshold_uncertainty_score":0.2737442},"labels":[],"label_agreement":null},{"id":"W1887565043","doi":"10.1593/neo.131870","title":"Tumor-Suppressive Activity of Lunatic Fringe in Prostate through Differential Modulation of Notch Receptor Activation","year":2014,"lang":"en","type":"article","venue":"Neoplasia","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation","funders":"National Cancer Institute","keywords":"Notch signaling pathway; HES1; Prostate cancer; Biology; Cancer research; Prostate; Carcinogenesis; Cell biology; Endocrinology; Signal transduction; Cancer; Genetics","score_opus":0.0175157365816881,"score_gpt":0.29465209485636196,"score_spread":0.27713635827467387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1887565043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974398,0.000013281835,0.0005002793,0.00030135168,0.00008060075,0.0005805714,0.0000123646805,0.000014370331,0.0010573564],"genre_scores_gemma":[0.9992405,0.000022662838,0.00034012913,0.000009177158,0.00004456305,0.000040532763,0.000049792423,0.000014342109,0.0002383078],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99905133,0.00007194014,0.00021408616,0.00018478543,0.0003082847,0.00016955833],"domain_scores_gemma":[0.9994202,0.00008038911,0.00016686392,0.00018129766,0.0001131091,0.000038103244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008692697,0.00010673544,0.0002909753,0.0001059067,0.000020854473,0.0000049463742,0.000048643804,0.000052529576,0.00007827644],"category_scores_gemma":[0.00009596151,0.00008485873,0.000050136245,0.00019974947,0.000066482135,0.00016436876,0.000029817342,0.00014724892,0.000004242169],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020324735,0.00050060265,0.07080423,0.00052927557,0.000047380538,0.0000023368077,0.0020454135,0.00006586759,0.905236,0.00017548517,0.00012336281,0.018437557],"study_design_scores_gemma":[0.0029583133,0.00036507708,0.3611179,0.00028482053,0.000020398364,0.0000017878838,0.000053420426,0.0040785386,0.6307268,0.000255462,0.00007314263,0.00006431381],"about_ca_topic_score_codex":0.00020891432,"about_ca_topic_score_gemma":0.00001645531,"teacher_disagreement_score":0.29031366,"about_ca_system_score_codex":0.00010342655,"about_ca_system_score_gemma":0.000077141405,"threshold_uncertainty_score":0.34604385},"labels":[],"label_agreement":null},{"id":"W1897407769","doi":"10.6004/jnccn.2014.0074","title":"Intermittent Versus Continuous Androgen Deprivation Therapy","year":2014,"lang":"en","type":"review","venue":"Journal of the National Comprehensive Cancer Network","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Prostatectomy; Clinical endpoint; Oncology; Internal medicine; Randomized controlled trial; Quality of life (healthcare); Prostate-specific antigen; Cancer","score_opus":0.15959646740038702,"score_gpt":0.43107974396040766,"score_spread":0.27148327656002064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1897407769","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001714225,0.9949968,0.000013467556,0.00073540444,0.0028738882,0.0007722889,0.000021471946,0.000008273745,0.00040699638],"genre_scores_gemma":[0.00029155324,0.9932159,0.000081031045,0.0006447727,0.005135485,0.00004887611,0.000027830556,0.00004307363,0.00051143783],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974715,0.00027233185,0.00076657714,0.00019750975,0.0010294075,0.00026267185],"domain_scores_gemma":[0.9958047,0.00056182826,0.0012432976,0.00018006522,0.0020840126,0.00012607056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000262655,0.00030358482,0.0014039393,0.00015707123,0.00013780996,0.000039638082,0.0003790429,0.00018451411,0.000089291],"category_scores_gemma":[0.00011265045,0.00015986321,0.0010111035,0.00042426007,0.00010828006,0.00005906526,0.00009898348,0.00078302005,0.000010744719],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013417827,0.0000801136,0.00015139136,0.0013243181,0.0031062828,0.000019770989,0.000030430685,0.00024106566,0.000002839593,0.00007744274,0.072981276,0.92064327],"study_design_scores_gemma":[0.0029959248,0.00035452028,0.000309286,0.009770046,0.0006923723,0.00018751115,0.000006179833,0.000018110952,0.000005199809,0.00013662333,0.9853852,0.00013903854],"about_ca_topic_score_codex":0.0000033531885,"about_ca_topic_score_gemma":0.000001371956,"teacher_disagreement_score":0.9205043,"about_ca_system_score_codex":0.00099659,"about_ca_system_score_gemma":0.0012806045,"threshold_uncertainty_score":0.6519032},"labels":[],"label_agreement":null},{"id":"W1898026383","doi":"10.1200/jco.2014.32.4_suppl.86","title":"Degarelix monotherapy versus luteinizing hormone-releasing hormone (LHRH) agonists plus antiandrogen flare protection in the treatment of men with advanced prostate cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Goserelin; Testosterone (patch); Antiandrogen; Urology; Hazard ratio; Agonist; Internal medicine; Proportional hazards model; Prostate-specific antigen; Androgen deprivation therapy; Luteinizing hormone; Gynecology; Cancer; Oncology; Hormone; Confidence interval; Receptor","score_opus":0.10982308765571903,"score_gpt":0.4488715295684615,"score_spread":0.33904844191274247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1898026383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812527,0.010961996,0.00010493751,0.005637587,0.00021978206,0.0010732508,0.0000044090916,0.000008749093,0.0007365965],"genre_scores_gemma":[0.95785403,0.040406518,0.0009506157,0.00011054589,0.00045314847,0.00007426131,0.0000046584864,0.000024501802,0.00012170343],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9972809,0.00049886224,0.0012214483,0.00022203183,0.00045815937,0.00031858002],"domain_scores_gemma":[0.9975083,0.0006746401,0.0010781274,0.00021602094,0.0003484392,0.00017446205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011453836,0.00018702203,0.0011635727,0.00014306675,0.00008232403,0.000014593845,0.0001414037,0.00020530343,0.000007277085],"category_scores_gemma":[0.00023588931,0.00009463187,0.00024860053,0.00027350354,0.0002251744,0.00012413082,0.00001225519,0.0005165287,0.0000016606464],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18204486,0.0023502724,0.007358373,0.00004881209,0.0010244923,0.00049586524,0.0030031248,0.0004380643,0.00525976,0.000018443174,0.00022619855,0.79773176],"study_design_scores_gemma":[0.23953712,0.38794884,0.2807492,0.00066623115,0.0011145069,0.0003746437,0.0031275104,0.0025260488,0.0061398605,0.00020599987,0.07720492,0.00040512992],"about_ca_topic_score_codex":0.00024398924,"about_ca_topic_score_gemma":0.0001705951,"teacher_disagreement_score":0.7973266,"about_ca_system_score_codex":0.0006657564,"about_ca_system_score_gemma":0.0014763344,"threshold_uncertainty_score":0.38589755},"labels":[],"label_agreement":null},{"id":"W1905250185","doi":"10.1111/j.1464-410x.2010.09470.x","title":"<i>PTEN</i> genomic deletion is an early event associated with <i>ERG</i> gene rearrangements in prostate cancer","year":2010,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Queen's University; Calgary Laboratory Services; Kingston General Hospital; Alberta Cancer Foundation; McGill University; University of Calgary","funders":"","keywords":"PTEN; Prostate cancer; Erg; Prostate; Biology; Cancer research; Cancer; Gene rearrangement; Gene; Genetics; PI3K/AKT/mTOR pathway; Apoptosis","score_opus":0.014041368076877952,"score_gpt":0.2837379030337754,"score_spread":0.26969653495689744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1905250185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99477595,0.0024848576,0.000010438948,0.0020023426,0.00023093067,0.00033115596,0.00003622545,0.0000096193335,0.00011846783],"genre_scores_gemma":[0.9949147,0.0032594742,0.00012010427,0.0009258936,0.00017590424,0.000024495876,0.000027706334,0.000029088174,0.0005226328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986415,0.00010236785,0.00036733685,0.00019579436,0.00031613457,0.0003768825],"domain_scores_gemma":[0.9990741,0.000021349057,0.00024225251,0.000112764414,0.00034936293,0.00020015825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047354872,0.000114968956,0.00032933548,0.00015373598,0.00006218821,0.00003302418,0.00011454992,0.000109635475,0.00018304364],"category_scores_gemma":[0.000039897677,0.00010288451,0.00006238133,0.00017569544,0.00011456,0.00016018433,0.000022787111,0.00071263796,0.0000049716245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045577185,0.0011325028,0.7919653,0.00002937119,0.00051807484,0.008921226,0.0008080997,0.00006108837,0.12394868,0.0000028442996,0.0024274082,0.06562771],"study_design_scores_gemma":[0.011390899,0.0030164805,0.9763789,0.00015557924,0.00016614061,0.0033038938,0.00003758516,0.000081667604,0.0023568664,0.000089990375,0.0028709378,0.00015102887],"about_ca_topic_score_codex":0.00080138224,"about_ca_topic_score_gemma":0.0021861151,"teacher_disagreement_score":0.18441366,"about_ca_system_score_codex":0.00013545653,"about_ca_system_score_gemma":0.000337861,"threshold_uncertainty_score":0.41955084},"labels":[],"label_agreement":null},{"id":"W1908203980","doi":"10.1093/annonc/mdu336.54","title":"A Prospective, Multinational Observational Study of Men with Later-Stage Prostate Cancer, a New Global Study to Examine Patterns of Care and Outcomes","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Observational study; Prostate cancer; Stage (stratigraphy); Multinational corporation; Oncology; Prospective cohort study; Cancer; Gerontology; Family medicine; Internal medicine","score_opus":0.12135896974923743,"score_gpt":0.45308857348550974,"score_spread":0.3317296037362723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1908203980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953578,0.0001422187,0.0000058453693,0.0015341786,0.000019834504,0.0022724492,0.00016645622,0.0000074094287,0.00049379334],"genre_scores_gemma":[0.99832106,0.000036847337,0.00023167174,0.00008991456,0.000024661958,0.00014244848,0.000024501769,0.000008928772,0.0011199506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881405,0.00008573882,0.0003108548,0.000242901,0.00037842576,0.0001680112],"domain_scores_gemma":[0.99871194,0.00010325154,0.00017852518,0.00015137225,0.0007455824,0.00010935417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019575098,0.00012332262,0.0005327942,0.00008960102,0.000026967984,0.0000032473724,0.00007383632,0.00003205933,0.000030601754],"category_scores_gemma":[0.000070000155,0.000082747654,0.000027851107,0.00017927124,0.000057795216,0.00005096149,0.00008327337,0.0000625924,3.260774e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002836345,0.0031457462,0.971139,0.00016989006,0.00046230527,0.000014959287,0.01193057,0.000041666106,0.00014045174,0.00005266637,0.00011396904,0.009952409],"study_design_scores_gemma":[0.011516026,0.036737505,0.94283533,0.00006177445,0.0000755453,0.0000016348561,0.0077331015,0.00001884046,0.00070945284,0.000021795178,0.00022481344,0.000064203006],"about_ca_topic_score_codex":0.0029290754,"about_ca_topic_score_gemma":0.004701163,"teacher_disagreement_score":0.03359176,"about_ca_system_score_codex":0.00008025605,"about_ca_system_score_gemma":0.00037543217,"threshold_uncertainty_score":0.44279054},"labels":[],"label_agreement":null},{"id":"W1911252495","doi":"","title":"A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.","year":2001,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Mitoxantrone; Prostate cancer; Medicine; Chemotherapy; Internal medicine; Cancer; Urology; Phases of clinical research; Neutropenia; Gastroenterology; Oncology","score_opus":0.03681151704988009,"score_gpt":0.30888877347669086,"score_spread":0.2720772564268108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1911252495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921134,0.0010495844,7.1359136e-7,0.00013354972,0.000024669744,0.0065243123,0.00006361606,0.000034696746,0.000055420616],"genre_scores_gemma":[0.99628735,0.001274778,0.00006677428,0.000017749597,0.00001986981,0.0018928066,0.00008037902,0.00004910431,0.00031120208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979924,0.0001223446,0.00034393984,0.00046237747,0.00046967308,0.00060929335],"domain_scores_gemma":[0.99897206,0.000051813695,0.00016872304,0.00032405014,0.00013077678,0.00035256724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016975221,0.00030119665,0.0006309877,0.00030486062,0.00008571406,0.000028864551,0.000053349835,0.000030770716,0.000006518474],"category_scores_gemma":[0.000011513924,0.00018091234,0.000027607368,0.0004671463,0.00014440226,0.00021460396,0.00002279757,0.00013060721,5.918799e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052590232,0.023824172,0.7757743,0.00008251299,0.0008639221,0.0011052936,0.0029553398,0.000010020465,0.00043539843,0.0000010058717,0.0000118387925,0.14234595],"study_design_scores_gemma":[0.1236971,0.030148262,0.84357107,0.000065307606,0.0004332439,0.000013492912,0.0012123302,0.000051725914,0.0005527816,0.0000020101163,0.000063713014,0.00018895276],"about_ca_topic_score_codex":0.0012655607,"about_ca_topic_score_gemma":0.00097244856,"teacher_disagreement_score":0.142157,"about_ca_system_score_codex":0.00035420255,"about_ca_system_score_gemma":0.00013132546,"threshold_uncertainty_score":0.7377391},"labels":[],"label_agreement":null},{"id":"W1920614447","doi":"10.1593/neo.121550","title":"Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"Neoplasia","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Prostate cancer; Concordance; Gene duplication; Prostate; Cancer research; Adenocarcinoma; Medicine; Pathology; Immunohistochemistry; Fluorescence in situ hybridization; Gene rearrangement; Cancer; Biology; Oncology; Internal medicine; Gene; Genetics","score_opus":0.022296990866230576,"score_gpt":0.3005276816320121,"score_spread":0.27823069076578155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1920614447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98927265,0.00408109,0.0000056808835,0.004775558,0.00012502095,0.0011117224,0.000101764694,0.000051025112,0.00047549],"genre_scores_gemma":[0.9925365,0.0025736012,0.00009387105,0.00006966975,0.00004385283,0.0003448979,0.000099801175,0.000024371753,0.0042134444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989252,0.0000315242,0.00023068754,0.00029149652,0.00020897713,0.00031211987],"domain_scores_gemma":[0.9992416,0.000049906328,0.000109640845,0.00021416128,0.00017033202,0.00021435313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000024921434,0.00016899167,0.0002868222,0.00010634696,0.00009697038,0.000030900686,0.000050023118,0.00003318226,0.00042847733],"category_scores_gemma":[0.000023955257,0.00012432667,0.000056045683,0.00019869053,0.0002030817,0.00008650549,0.000033866138,0.00015621293,0.000046634723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031443173,0.0007961914,0.7993567,0.00040709868,0.00071617804,0.00030452508,0.0017154125,0.000019798812,0.09783195,0.00015184966,0.007615592,0.09077025],"study_design_scores_gemma":[0.011129429,0.00097520166,0.86144245,0.00034429054,0.00047610834,0.00027320086,0.0005229931,0.0008512858,0.11452101,0.00008792774,0.009066804,0.00030931193],"about_ca_topic_score_codex":0.0006522997,"about_ca_topic_score_gemma":0.00002665132,"teacher_disagreement_score":0.090460934,"about_ca_system_score_codex":0.00009935592,"about_ca_system_score_gemma":0.00017066783,"threshold_uncertainty_score":0.5069894},"labels":[],"label_agreement":null},{"id":"W1923726874","doi":"10.1158/1078-0432.ccr-15-0744","title":"Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Cancer Institute","keywords":"Cyclin D1; Adenocarcinoma; Cancer research; Metastasis; Prostate; Medicine; Pathology; Carcinoma; Small-cell carcinoma; Cancer; Oncology; Biology; Cell cycle; Internal medicine","score_opus":0.35106830331324973,"score_gpt":0.49947318720320816,"score_spread":0.14840488388995843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1923726874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708099,0.012721964,0.000024301216,0.006820987,0.0008595489,0.003064231,0.00028347835,0.0001264254,0.0052891993],"genre_scores_gemma":[0.9770139,0.0009468584,0.000910695,0.00046343205,0.0017884985,0.0009938574,0.00037719464,0.00013715342,0.01736844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99234605,0.0010997793,0.0012694931,0.0014251531,0.0021701658,0.0016893798],"domain_scores_gemma":[0.9922286,0.0022930012,0.0001999966,0.0012339312,0.0020225088,0.0020219362],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003937747,0.00044448194,0.0010482392,0.000307399,0.0003395778,0.00020172307,0.0006534601,0.00036797006,0.0004936347],"category_scores_gemma":[0.0040812837,0.0003374814,0.00026663768,0.0012575904,0.0015976523,0.00014779955,0.00059403694,0.002342383,0.0006667762],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048850626,0.0013752608,0.94470674,0.0005533362,0.00016848091,0.0018545793,0.0015565908,0.000004683831,0.00049187196,0.00003625348,0.032483425,0.011883707],"study_design_scores_gemma":[0.043753993,0.010407316,0.8723328,0.0013671283,0.0006161089,0.000058226753,0.005265773,0.001933457,0.015866844,0.006533296,0.04047418,0.0013908431],"about_ca_topic_score_codex":0.0060417852,"about_ca_topic_score_gemma":0.0004581709,"teacher_disagreement_score":0.07237391,"about_ca_system_score_codex":0.00096911076,"about_ca_system_score_gemma":0.005317388,"threshold_uncertainty_score":0.99995923},"labels":[],"label_agreement":null},{"id":"W1925809211","doi":"10.4081/aiua.2015.2.121","title":"Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis","year":2015,"lang":"en","type":"review","venue":"Archivio Italiano di Urologia e Andrologia","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cabazitaxel; Abiraterone acetate; Enzalutamide; Docetaxel; Prostate cancer; Internal medicine; Oncology; Hazard ratio; Adverse effect; Mitoxantrone; Placebo; Cancer; Pharmacology; Androgen deprivation therapy; Chemotherapy; Confidence interval; Androgen receptor; Pathology","score_opus":0.15219520548552481,"score_gpt":0.41998844399190693,"score_spread":0.26779323850638215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1925809211","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015654832,0.97983074,0.000009293751,0.0002498424,0.000019654084,0.014155599,0.0041163815,0.000021715738,0.00003131713],"genre_scores_gemma":[0.0072236303,0.98305446,0.0005247704,0.000076593875,0.000014182793,0.0068015903,0.00085500814,0.000053452906,0.0013963355],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9957402,0.0006192012,0.0018650074,0.00084094965,0.00040756227,0.00052708125],"domain_scores_gemma":[0.9968129,0.0005714455,0.00134677,0.00069328875,0.00030428285,0.00027134144],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008881426,0.0007841692,0.010332529,0.00045343992,0.00007956346,0.00003577364,0.00015723096,0.0001641158,0.000107730535],"category_scores_gemma":[0.00015348828,0.0004107522,0.0015832057,0.0005925886,0.0004894723,0.0000880773,0.0000957519,0.00015376494,0.0000015296048],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016009161,0.00062320614,0.00018258631,0.7847843,0.20238574,0.00014259492,0.00026486395,0.0000023703299,0.0000037766779,0.000011588131,0.0000559678,0.009942092],"study_design_scores_gemma":[0.0029146657,0.004802855,0.0002786221,0.013149761,0.97244763,0.00008467788,0.000015394813,0.000018841038,0.000009644544,0.00003204366,0.0058866986,0.0003591529],"about_ca_topic_score_codex":0.000045841734,"about_ca_topic_score_gemma":0.00007453746,"teacher_disagreement_score":0.7716345,"about_ca_system_score_codex":0.000114229675,"about_ca_system_score_gemma":0.0005263625,"threshold_uncertainty_score":0.9998344},"labels":[],"label_agreement":null},{"id":"W1926009117","doi":"10.1158/1538-7445.am2014-1632","title":"Abstract 1632: Discovery of a novel series of androgen receptor antagonists with potential therapeutic applications in castration-resistant prostate cancer","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Bicalutamide; Enzalutamide; Antiandrogens; Androgen receptor; LNCaP; Androgen; Medicine; Cancer research; Androgen Receptor Antagonists; Cancer; Pharmacology; Chemistry; Internal medicine; Hormone","score_opus":0.052938950992479736,"score_gpt":0.38397622675363685,"score_spread":0.3310372757611571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1926009117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99303794,0.0031030965,0.00006490226,0.0013510325,0.000033095497,0.0016091423,0.00039753882,0.000011721476,0.00039155135],"genre_scores_gemma":[0.99496263,0.0020737858,0.00016173377,0.000011199396,0.00009216255,0.0010928911,0.000086806656,0.000031565898,0.0014872282],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99805945,0.00006218892,0.00033750074,0.00034193508,0.0007552542,0.0004436541],"domain_scores_gemma":[0.9987976,0.00008542483,0.00011121461,0.0003426646,0.0005505267,0.00011258558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004757652,0.00014900249,0.0003485512,0.00026378763,0.00010629052,0.000036252157,0.0001552612,0.00007149633,0.00011380827],"category_scores_gemma":[0.000018016486,0.00010206891,0.000056197416,0.00071255787,0.0006060397,0.0002144154,0.000044239187,0.00031295422,0.0000018087609],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005888163,0.0005771062,0.038556848,0.001006313,0.00018780393,0.000008287101,0.0007381366,0.00014224974,0.94713277,0.0004832065,0.000118650256,0.0051604677],"study_design_scores_gemma":[0.007541734,0.0015566462,0.14609082,0.0011268604,0.00007774166,0.000008749592,0.0015983641,0.0000722445,0.8373369,0.00017963508,0.0041537257,0.00025656962],"about_ca_topic_score_codex":0.003067035,"about_ca_topic_score_gemma":0.0014457101,"teacher_disagreement_score":0.10979587,"about_ca_system_score_codex":0.00028379625,"about_ca_system_score_gemma":0.001632329,"threshold_uncertainty_score":0.463646},"labels":[],"label_agreement":null},{"id":"W1926992252","doi":"10.1200/jco.2012.30.15_suppl.4519","title":"Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Université de Montréal","funders":"","keywords":"Medicine; Placebo; Clinical endpoint; Internal medicine; Interim analysis; Docetaxel; Adverse effect; Randomized controlled trial; Oncology; Chemotherapy","score_opus":0.28065086882574053,"score_gpt":0.5250663325708724,"score_spread":0.2444154637451319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1926992252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927232,0.0031677468,0.000011238548,0.0022888456,0.0007030644,0.00047583913,0.00008131104,0.000004724293,0.00054401305],"genre_scores_gemma":[0.99591666,0.000829624,0.0007925029,0.00043530104,0.0019111157,0.0000037748393,0.00002902187,0.00001422241,0.00006775038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994279,0.0014735898,0.0032299247,0.00019298974,0.0005682621,0.00025623615],"domain_scores_gemma":[0.99110603,0.0053599137,0.0022426748,0.0002818551,0.0004258668,0.000583653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009903721,0.00014006594,0.0016428402,0.00008070381,0.00006283229,0.0000075085877,0.00017766001,0.00023373804,0.00014566955],"category_scores_gemma":[0.0029175386,0.00007662743,0.00024090918,0.00011882594,0.00035705365,0.00018834045,0.00010852772,0.000923461,0.0000020371099],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24147734,0.044767912,0.36611882,0.0001456522,0.0035204063,0.00013458697,0.016915021,0.0000045033644,0.025361976,0.000047134246,0.006418107,0.29508853],"study_design_scores_gemma":[0.2904408,0.11555362,0.51240474,0.00035342964,0.0014261024,0.000051564857,0.017991966,0.000018734749,0.012871128,0.0001773322,0.048391953,0.00031866785],"about_ca_topic_score_codex":0.00021795814,"about_ca_topic_score_gemma":0.00006277941,"teacher_disagreement_score":0.29476985,"about_ca_system_score_codex":0.0000956922,"about_ca_system_score_gemma":0.001493353,"threshold_uncertainty_score":0.40120298},"labels":[],"label_agreement":null},{"id":"W1932317695","doi":"10.1023/a:1012258723075","title":"Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer","year":2001,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; National Center for Research Resources; McGill University","keywords":"Medicine; Docetaxel; Prostate cancer; Toxicity; Internal medicine; Clinical endpoint; Analgesic; Cancer; Oncology; Surgery; Anesthesia; Clinical trial","score_opus":0.10827415176359521,"score_gpt":0.465925237781815,"score_spread":0.35765108601821977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1932317695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990425,0.002112599,4.833978e-7,0.0036995811,0.0000750645,0.0012575495,0.000018833978,0.000012249075,0.0023986744],"genre_scores_gemma":[0.9945366,0.003242435,0.000017216806,0.0001669123,0.000036468464,0.00017895835,0.000010854218,0.00001352241,0.0017970713],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99852633,0.00010535075,0.0004848568,0.0002260597,0.0003127796,0.0003445978],"domain_scores_gemma":[0.9991662,0.00006152554,0.00018327672,0.00022835378,0.00024337479,0.000117281095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039422448,0.00012730462,0.00060455356,0.00027500163,0.000037127895,0.0000024587684,0.00010308615,0.000086451415,0.00023119568],"category_scores_gemma":[0.000039294577,0.00009614128,0.000066222914,0.00036754145,0.000105740866,0.00006326698,0.00007558505,0.00015986162,0.000005183554],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011724408,0.0695538,0.4594156,0.000436931,0.0010496875,0.0019816624,0.015462132,0.000044288932,0.010478361,0.000045704484,0.0032876402,0.42651978],"study_design_scores_gemma":[0.24027283,0.40695375,0.22538981,0.0010783552,0.0006821867,0.00033411678,0.01720055,0.0008780689,0.07339635,0.0009879745,0.032129075,0.0006969409],"about_ca_topic_score_codex":0.0007826402,"about_ca_topic_score_gemma":0.00067244994,"teacher_disagreement_score":0.42582282,"about_ca_system_score_codex":0.00008976061,"about_ca_system_score_gemma":0.0004590668,"threshold_uncertainty_score":0.39205277},"labels":[],"label_agreement":null},{"id":"W1932364922","doi":"10.6004/jnccn.2012.0115","title":"Androgen Deprivation Therapy: Minimizing Exposure and Mitigating Side Effects","year":2012,"lang":"en","type":"review","venue":"Journal of the National Comprehensive Cancer Network","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Radiation therapy; Brachytherapy; Intensive care medicine; Quality of life (healthcare); Disease; Side effect (computer science); Management of prostate cancer; Oncology; Cancer; Internal medicine","score_opus":0.11714701237884668,"score_gpt":0.39061392929566496,"score_spread":0.2734669169168183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1932364922","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013413656,0.9964131,0.0000050857757,0.00038888963,0.0008671691,0.0008078175,0.000012393893,0.0000067965016,0.00015738854],"genre_scores_gemma":[0.0018997263,0.99275565,0.00039940336,0.0005344118,0.0041714557,0.000049981478,0.000014958803,0.000042830536,0.00013159795],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99784577,0.00030158553,0.0005920825,0.00017138761,0.00079948193,0.0002896887],"domain_scores_gemma":[0.99681854,0.0009143735,0.0009793084,0.000114054004,0.0010211284,0.00015260023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029243456,0.0002879678,0.0010603761,0.00013273577,0.00020785026,0.000039077247,0.00017666807,0.00018354195,0.000014444384],"category_scores_gemma":[0.000102355014,0.00015862667,0.0004678926,0.0003873437,0.000097896205,0.00011348496,0.00009579961,0.0007174745,0.0000017732576],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001813674,0.000053650216,0.0015041211,0.0050300877,0.0019924443,0.000019424262,0.00013289004,0.000102296544,0.000041526575,0.000034927976,0.0029274651,0.98797977],"study_design_scores_gemma":[0.0018728515,0.00019845722,0.0030382122,0.02479856,0.0013626363,0.0005646744,0.000017183256,0.000015177438,0.00005018407,0.0002674191,0.96761185,0.00020281816],"about_ca_topic_score_codex":0.0000027017052,"about_ca_topic_score_gemma":8.1401305e-7,"teacher_disagreement_score":0.987777,"about_ca_system_score_codex":0.00049154385,"about_ca_system_score_gemma":0.00076479244,"threshold_uncertainty_score":0.6468608},"labels":[],"label_agreement":null},{"id":"W1934264093","doi":"10.1093/annonc/mdv245","title":"Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra","year":2015,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health","keywords":"Docetaxel; Medicine; Prostate cancer; Internal medicine; Oncology; Hazard ratio; Androgen deprivation therapy; Tolerability; Clinical endpoint; Cancer; Chemotherapy; Confidence interval; Clinical trial; Adverse effect","score_opus":0.21872978042644023,"score_gpt":0.4953311044673172,"score_spread":0.276601324040877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1934264093","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018731647,0.9841457,0.0000033339688,0.0006275512,0.00005700277,0.0066783424,0.0061766664,0.000009799628,0.0004284403],"genre_scores_gemma":[0.0015775764,0.9958536,0.00040161537,0.00009008971,0.000046541394,0.0007864675,0.00095089443,0.000052114676,0.00024111957],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980968,0.00014547435,0.00056935276,0.00037537175,0.00041935346,0.00039362774],"domain_scores_gemma":[0.99591494,0.0002702475,0.0006300512,0.00021912248,0.0027558063,0.00020982217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003505794,0.0003372286,0.0033891143,0.0002046938,0.000040300987,0.0000060685443,0.00008048824,0.00020038767,0.000005549191],"category_scores_gemma":[0.0001163791,0.00019858334,0.00020823396,0.00018892532,0.00041856442,0.00005597573,0.00005352818,0.00023902098,3.7467663e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009781149,0.0003128694,0.0001392141,0.031867888,0.0020698956,0.00005143553,0.0012917082,2.7511163e-7,8.204145e-7,0.00003547834,0.0036294856,0.9508198],"study_design_scores_gemma":[0.008757359,0.039739486,0.0000659003,0.0052517354,0.0030748895,0.0000109669645,0.00047311813,8.632655e-7,0.0000727828,0.000037555983,0.9423167,0.00019864173],"about_ca_topic_score_codex":0.00007283168,"about_ca_topic_score_gemma":0.0000792307,"teacher_disagreement_score":0.9506211,"about_ca_system_score_codex":0.00021547775,"about_ca_system_score_gemma":0.0033219121,"threshold_uncertainty_score":0.8097993},"labels":[],"label_agreement":null},{"id":"W1934417358","doi":"10.1200/jco.2013.31.15_suppl.lba4510","title":"Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Jewish General Hospital; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; McGill University; Centre Hospitalier de l’Université de Montréal; Centre Hospitalier Universitaire de Sherbrooke; McGill University Health Centre; Centre de Santé et de Services Sociaux de Chicoutimi; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Randomized controlled trial; Oncology; Clinical Oncology; Clinical trial; Internal medicine; Gynecology; Family medicine; Cancer","score_opus":0.09654002515118829,"score_gpt":0.4726979184230209,"score_spread":0.3761578932718326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1934417358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98727816,0.0017991879,0.000032017342,0.008372516,0.0004933221,0.0018244642,0.0000024254123,0.0000034853288,0.00019442113],"genre_scores_gemma":[0.9518407,0.046308674,0.00082219025,0.00024512922,0.00043182497,0.000105172134,0.000004609582,0.000008653508,0.00023301953],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995767,0.0010175736,0.0026594838,0.00011311242,0.0002945098,0.00014833345],"domain_scores_gemma":[0.9943393,0.0025492967,0.0022474884,0.00010601373,0.0006198347,0.00013806684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005327292,0.00008466813,0.0015953392,0.0001681845,0.000017965669,0.0000066236507,0.00007476556,0.00020688606,0.00019558845],"category_scores_gemma":[0.0042950986,0.00004702208,0.0003237522,0.0001715695,0.00018846556,0.00014463,0.0000145443255,0.00050307147,0.0000055383443],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66689736,0.0009833762,0.07490205,0.000012021188,0.00033487173,0.00002827133,0.00016116054,0.000010686,0.00024484977,0.000020705273,0.00048204508,0.25592262],"study_design_scores_gemma":[0.9113613,0.011507853,0.07173991,0.00007710363,0.00013654017,0.000010058809,0.000045319684,0.00017984545,0.0011305242,0.0023650203,0.0014026756,0.000043859567],"about_ca_topic_score_codex":0.0006907461,"about_ca_topic_score_gemma":0.00004796891,"teacher_disagreement_score":0.25587875,"about_ca_system_score_codex":0.00013628785,"about_ca_system_score_gemma":0.0016989468,"threshold_uncertainty_score":0.5141944},"labels":[],"label_agreement":null},{"id":"W1938050263","doi":"10.1200/jco.2014.32.4_suppl.lba1","title":"Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre","funders":"","keywords":"Enzalutamide; Medicine; Interim analysis; Placebo; Clinical endpoint; Hazard ratio; Internal medicine; Prostate cancer; Population; Docetaxel; Asymptomatic; Oncology; Cancer; Randomized controlled trial; Gastroenterology; Urology; Confidence interval; Androgen receptor; Pathology","score_opus":0.11634759506263968,"score_gpt":0.5176789045011821,"score_spread":0.40133130943854245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1938050263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98878753,0.000730821,0.000023765186,0.0063064587,0.00015128346,0.0010257188,0.000012647586,0.000005434481,0.0029563608],"genre_scores_gemma":[0.9943349,0.0021328188,0.0009278979,0.00046095406,0.00028979612,0.000032957912,0.000003514532,0.000021960992,0.0017952253],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99561906,0.0007861598,0.0024595924,0.0002500508,0.000579494,0.00030566097],"domain_scores_gemma":[0.995404,0.0016847447,0.0017854266,0.00023605886,0.0005813568,0.0003084357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005729652,0.0001673666,0.0018783065,0.00021330039,0.000024554272,0.0000064711858,0.00016937684,0.00011929521,0.00008555015],"category_scores_gemma":[0.0012530101,0.00009291288,0.00019855269,0.00028389663,0.00030819772,0.00011086831,0.000035995134,0.0008135616,0.0000030250192],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31977826,0.023286803,0.18569653,0.00018367087,0.0028683492,0.0015911153,0.004939748,0.000108661414,0.0009906774,0.000019126343,0.004423451,0.4561136],"study_design_scores_gemma":[0.5226707,0.19079949,0.24737768,0.0008586909,0.0014437864,0.00015227808,0.0027524068,0.0006940779,0.0027615172,0.0003929652,0.029837517,0.00025891923],"about_ca_topic_score_codex":0.00024633875,"about_ca_topic_score_gemma":0.00028361243,"teacher_disagreement_score":0.45585468,"about_ca_system_score_codex":0.00023015405,"about_ca_system_score_gemma":0.002150732,"threshold_uncertainty_score":0.38153064},"labels":[],"label_agreement":null},{"id":"W1955008898","doi":"10.1002/pros.22988","title":"Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation","year":2015,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada; Movember Foundation","keywords":"Stromal cell; Prostate cancer; Vimentin; Prostate; Androgen receptor; Stroma; Cancer research; Biology; Tissue microarray; Immunohistochemistry; Internal medicine; Medicine; Endocrinology; Pathology; Cancer","score_opus":0.0190069844285051,"score_gpt":0.3054239071132663,"score_spread":0.28641692268476115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1955008898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99166465,0.0037076874,9.042482e-7,0.0013102262,0.00014140326,0.0026882938,0.00009079731,0.00006762246,0.00032843722],"genre_scores_gemma":[0.99224544,0.0010256518,0.00028015248,0.0000126581335,0.00008281409,0.00082051806,0.00017612487,0.000050357034,0.005306285],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978344,0.00018596981,0.00042665534,0.00037639527,0.0006518561,0.00052471756],"domain_scores_gemma":[0.99889374,0.000031108713,0.00025539467,0.00035938926,0.00024335105,0.00021704574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040314865,0.00024521953,0.00035825418,0.00016006456,0.00009901964,0.00003461728,0.00015782927,0.00009881976,0.00045597996],"category_scores_gemma":[0.000040020805,0.00014321004,0.00006404791,0.00034697758,0.00013983529,0.00022006885,0.00016459028,0.0003425736,0.000027309683],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005847013,0.000578755,0.2164861,0.00041538235,0.000031696683,0.00000952049,0.011859152,0.000016817386,0.75621253,0.000003068003,0.0005538132,0.00798617],"study_design_scores_gemma":[0.0068901605,0.00087681675,0.04021572,0.0011008157,0.000041914358,0.0000045408096,0.0010925708,0.00013251197,0.9483905,0.00006890296,0.0010038238,0.00018172029],"about_ca_topic_score_codex":0.00018104022,"about_ca_topic_score_gemma":0.000027925686,"teacher_disagreement_score":0.192178,"about_ca_system_score_codex":0.00032967931,"about_ca_system_score_gemma":0.0003144166,"threshold_uncertainty_score":0.5839936},"labels":[],"label_agreement":null},{"id":"W1956657204","doi":"10.1200/jco.2013.31.6_suppl.6","title":"Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Clinical endpoint; Placebo; Internal medicine; Docetaxel; Adverse effect; Concomitant; Abiraterone acetate; Oncology; Urology; Cancer; Randomized controlled trial; Androgen receptor; Androgen deprivation therapy","score_opus":0.1868019128820495,"score_gpt":0.5268007643341991,"score_spread":0.3399988514521496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1956657204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711144,0.000113157475,5.370606e-7,0.00068108155,0.00017023776,0.0018298024,0.0000085201145,0.0000028892075,0.00008234234],"genre_scores_gemma":[0.9991295,0.00032549404,0.00003678562,0.00018653808,0.0002667449,0.000012933059,0.0000029654489,0.000013464323,0.00002559002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99547315,0.0013408265,0.0021825864,0.0002152952,0.00055571523,0.00023241773],"domain_scores_gemma":[0.99400836,0.0038700039,0.0011217969,0.00032781827,0.00035861015,0.00031341266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00300991,0.00016280172,0.0014279893,0.00016566053,0.000038431812,0.00001358211,0.00018200112,0.00016495507,0.000101145444],"category_scores_gemma":[0.0017511266,0.00007908779,0.00021420768,0.00020418073,0.0002168959,0.00015564053,0.000050124738,0.0009633648,0.0000043885098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08369541,0.104732335,0.70382124,0.0000135207165,0.00084473763,0.0003870742,0.004042289,0.000028440218,0.0011465065,0.0000023522537,0.0006214564,0.100664616],"study_design_scores_gemma":[0.07181422,0.2730022,0.6519741,0.00008082708,0.00017856526,0.0000308928,0.0025792818,0.000018436283,0.000116613584,0.0000063621615,0.00014968544,0.000048795613],"about_ca_topic_score_codex":0.00029218555,"about_ca_topic_score_gemma":0.00010186625,"teacher_disagreement_score":0.16826987,"about_ca_system_score_codex":0.00016839335,"about_ca_system_score_gemma":0.00058308383,"threshold_uncertainty_score":0.4185394},"labels":[],"label_agreement":null},{"id":"W1958187625","doi":"10.1093/annonc/mdv267","title":"Treatment of mCRPC in the AR-axis-targeted therapy-resistant state","year":2015,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Princess Margaret Cancer Centre; Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Abiraterone; Prostate cancer; Clinical trial; Oncology; Intensive care medicine; Internal medicine; Androgen receptor; Cancer","score_opus":0.3831027820635907,"score_gpt":0.5307939155282516,"score_spread":0.1476911334646609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1958187625","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001302103,0.9887557,1.8582003e-7,0.0012085404,0.00008841025,0.0019911607,0.00018530017,0.0000081956205,0.0064604087],"genre_scores_gemma":[0.0006332289,0.99735916,0.000027419346,0.00009364822,0.000079943486,0.00030201187,0.00024119503,0.00003041899,0.0012329791],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975667,0.0006056534,0.0007771844,0.00028596018,0.00036642322,0.00039810422],"domain_scores_gemma":[0.9982265,0.0003967781,0.00046152686,0.00051325664,0.0002930414,0.000108877015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006756812,0.0003176682,0.0025348484,0.000323429,0.000021560189,0.000004242838,0.00023335029,0.00026330273,0.00007538163],"category_scores_gemma":[0.00004554534,0.00014953985,0.00047739496,0.0004452847,0.0002526886,0.000023677565,0.000027003476,0.00021558617,0.000016317503],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010718642,0.0018335901,0.000073451556,0.0020553095,0.0007403827,0.00040272062,0.0010100286,1.4849888e-7,0.0000068780614,0.00003185909,0.0028181246,0.98995566],"study_design_scores_gemma":[0.002838942,0.01656318,0.00009747494,0.0011518064,0.00024184221,0.00005312964,0.00010485537,5.952404e-7,0.00008259893,0.00019085697,0.9785705,0.000104174454],"about_ca_topic_score_codex":0.0002715591,"about_ca_topic_score_gemma":0.00006568585,"teacher_disagreement_score":0.9898515,"about_ca_system_score_codex":0.00026192798,"about_ca_system_score_gemma":0.0024145746,"threshold_uncertainty_score":0.6098058},"labels":[],"label_agreement":null},{"id":"W1959412140","doi":"10.1016/j.tranon.2015.03.004","title":"[18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments","year":2015,"lang":"en","type":"article","venue":"Translational Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Hospital","funders":"National Cancer Institute; National Institutes of Health; Dana-Farber/Harvard Cancer Center","keywords":"Prostate cancer; In vivo; Positron emission tomography; Medicine; Fluorodeoxyglucose; Nuclear medicine; Ex vivo; Preclinical imaging; Tumor microenvironment; Cancer; Prostate; Pathology; Internal medicine; Biology","score_opus":0.055140955541485584,"score_gpt":0.37677136568230396,"score_spread":0.3216304101408184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1959412140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839658,0.0075495816,0.00092681096,0.0040900283,0.00014691101,0.0015440814,0.00022024811,0.00006186122,0.0014946555],"genre_scores_gemma":[0.9931559,0.00011978133,0.005482643,0.00010537894,0.000058924383,0.00011028589,0.00060374447,0.00002429347,0.0003390745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980733,0.00010785039,0.0005121334,0.00036089448,0.00055545394,0.00039037288],"domain_scores_gemma":[0.99896365,0.000077641314,0.00013379149,0.00017820498,0.00034893773,0.0002977502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029220415,0.00021800259,0.0005079944,0.00038228574,0.00006968414,0.000010766657,0.00011050238,0.00014772135,0.00008791062],"category_scores_gemma":[0.000007079106,0.00018856693,0.00011740606,0.00055301783,0.00020106613,0.00013928891,0.000018905652,0.00024630097,0.00000655005],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030162858,0.006899615,0.5924822,0.00069477776,0.0010255114,0.0004756179,0.014179492,0.047032733,0.23039787,0.0007302471,0.005590416,0.07032869],"study_design_scores_gemma":[0.06118624,0.00826518,0.7280032,0.0010066074,0.00070815673,0.00008461966,0.0006210539,0.11932072,0.055120908,0.010272799,0.014321941,0.0010885677],"about_ca_topic_score_codex":0.00041655547,"about_ca_topic_score_gemma":0.00075286883,"teacher_disagreement_score":0.17527695,"about_ca_system_score_codex":0.00018959316,"about_ca_system_score_gemma":0.001215562,"threshold_uncertainty_score":0.7689536},"labels":[],"label_agreement":null},{"id":"W1962964452","doi":"10.1002/ijc.29147","title":"The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors","year":2014,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada","keywords":"Androgen receptor; Gene knockdown; Prostate cancer; Glucocorticoid receptor; Cancer research; Androgen deprivation therapy; Androgen; Signal transduction; Biology; Endocrinology; Medicine; Internal medicine; Glucocorticoid; Cancer; Gene; Cell biology; Hormone","score_opus":0.013486505471342912,"score_gpt":0.3281512701945314,"score_spread":0.3146647647231885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1962964452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922536,0.0021617399,0.000031987547,0.004635727,0.00038669154,0.0002559805,0.000056832556,0.0000036473307,0.00021376292],"genre_scores_gemma":[0.9965814,0.0017756005,0.00015087782,0.0001433036,0.00018435954,0.000017944565,0.000012309975,0.000015315025,0.0011189317],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99844897,0.00008087689,0.00047898866,0.00012042373,0.0007092167,0.00016150436],"domain_scores_gemma":[0.9982949,0.00016520679,0.0005025802,0.00008194656,0.00087602134,0.000079384234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031687494,0.00010168298,0.00023932352,0.00013034428,0.000033983204,0.000023101557,0.00019552589,0.00003890193,0.0002881698],"category_scores_gemma":[0.00011387549,0.000060225197,0.00009576601,0.0001395258,0.000099143785,0.0001576929,0.00003513737,0.00023656653,0.0000040033497],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007473552,0.00013138226,0.022580564,0.000025476542,0.00036513305,0.000013569581,0.0014083625,0.00008212837,0.9261583,0.000023182196,0.005583114,0.036155198],"study_design_scores_gemma":[0.0037876978,0.00036496535,0.003936333,0.0010486472,0.00002311683,0.000012148691,0.0003380319,0.000104127495,0.97297984,0.0001823298,0.017157815,0.00006492378],"about_ca_topic_score_codex":0.000065750864,"about_ca_topic_score_gemma":0.0000050678996,"teacher_disagreement_score":0.046821527,"about_ca_system_score_codex":0.00035813954,"about_ca_system_score_gemma":0.00031481104,"threshold_uncertainty_score":0.31552574},"labels":[],"label_agreement":null},{"id":"W1963523058","doi":"10.1038/sj.bjc.6604558","title":"Fusion in the ETS gene family and prostate cancer","year":2008,"lang":"en","type":"review","venue":"British Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"TMPRSS2; Prostate cancer; Fusion gene; Chromoplexy; Biology; Prostate; Carcinogenesis; Cancer research; Cancer; Genetics; PCA3; Gene; Pathology; Medicine; Disease","score_opus":0.06031547168416199,"score_gpt":0.39752636842868,"score_spread":0.337210896744518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963523058","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0052007777,0.9927963,4.1876538e-7,0.000405976,0.0002959544,0.00089774135,0.00012097765,0.000004274092,0.0002775547],"genre_scores_gemma":[0.00012475713,0.9976436,0.000039959872,0.00025582578,0.00071994064,0.00016090798,0.000018162167,0.000042967327,0.0009939076],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99795127,0.00017519238,0.0006706093,0.00022166863,0.00064358494,0.00033765187],"domain_scores_gemma":[0.9989797,0.00008041229,0.00042073987,0.00013244548,0.00023559638,0.0001511423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034709452,0.00024058645,0.0012667188,0.00021184197,0.00010318839,0.00006910666,0.0001903026,0.00016946798,0.000069471665],"category_scores_gemma":[0.00003119286,0.00015183403,0.0002956451,0.0003675219,0.00014770869,0.00010020948,0.000046851783,0.0010153517,0.0000021714593],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009493533,0.00007126439,0.00034887134,0.002669987,0.00020638996,0.006245753,0.00019737444,5.6339206e-7,0.000006535979,3.89521e-7,0.0073450864,0.9828128],"study_design_scores_gemma":[0.001801345,0.00017402995,0.0036530644,0.04316381,0.000452657,0.012698221,0.00004300699,6.429391e-7,0.000005174447,0.00000793849,0.9378533,0.0001468023],"about_ca_topic_score_codex":0.0011496007,"about_ca_topic_score_gemma":0.00042406915,"teacher_disagreement_score":0.9826661,"about_ca_system_score_codex":0.00039436037,"about_ca_system_score_gemma":0.0018856004,"threshold_uncertainty_score":0.6191612},"labels":[],"label_agreement":null},{"id":"W1963765725","doi":"10.1016/j.eururo.2013.09.024","title":"The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":198,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Internal medicine; Oncology; Metastasis; Lymph node; Proportional hazards model; Bone metastasis; Urology; Cancer","score_opus":0.02300769354330687,"score_gpt":0.2933294950658087,"score_spread":0.2703218015225018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963765725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837152,0.0032701315,0.000009753924,0.0046271477,0.000027016424,0.001654249,0.000021473857,0.000021896007,0.0066531324],"genre_scores_gemma":[0.9962658,0.00038581944,0.00028366616,0.00020516283,0.000021585864,0.00025401782,0.000031354066,0.000036173216,0.0025163905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835783,0.00034585045,0.0003839601,0.00026698053,0.00024081685,0.0004045616],"domain_scores_gemma":[0.99902344,0.0002491576,0.00016209255,0.00028984962,0.00017360887,0.000101828635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004330957,0.00015939528,0.0002823502,0.00009358189,0.000075687065,0.000024479905,0.00011255885,0.000011731284,0.00015199036],"category_scores_gemma":[0.000106298074,0.00008401748,0.000036684465,0.00029075608,0.00030250128,0.000083697254,0.000038958675,0.00020111639,0.00007325981],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003604611,0.0004980117,0.9507907,0.0003694316,0.0007974588,0.0021915906,0.003100564,0.0002809881,0.02663082,0.00044931917,0.0032261931,0.008060335],"study_design_scores_gemma":[0.0047491156,0.0021667476,0.9881824,0.00007353002,0.00026495603,0.00008189166,0.00046942296,0.0006510723,0.0005952418,0.00020609412,0.002403056,0.00015643593],"about_ca_topic_score_codex":0.0003073785,"about_ca_topic_score_gemma":0.0006721924,"teacher_disagreement_score":0.03739176,"about_ca_system_score_codex":0.000051121206,"about_ca_system_score_gemma":0.00021921839,"threshold_uncertainty_score":0.34261334},"labels":[],"label_agreement":null},{"id":"W1964444824","doi":"10.1016/j.eururo.2008.01.074","title":"Perspectives on Prostate Cancer Biomarkers","year":2008,"lang":"en","type":"editorial","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Prostate disease; Prostate; Cancer; Oncology; Gynecology; Internal medicine","score_opus":0.016973879192088984,"score_gpt":0.3171113776083485,"score_spread":0.30013749841625953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964444824","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005062456,0.02684022,0.0000013102205,0.005571478,0.8048944,0.0012384448,0.0005229058,0.0002922883,0.15557653],"genre_scores_gemma":[0.0063084792,0.058098085,0.000035872814,0.00039056604,0.8787944,0.000091902366,0.0008532416,0.0002714846,0.055155993],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972588,0.0004091306,0.00026450996,0.0008602238,0.00060396304,0.0006033643],"domain_scores_gemma":[0.9985111,0.00030354082,0.0001381024,0.00051669346,0.0003050192,0.00022559705],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026439113,0.00040418957,0.00053286104,0.00033147127,0.00014579519,0.000019701538,0.00022281804,0.00031254342,0.00037035794],"category_scores_gemma":[0.00044054422,0.00030317868,0.00018685038,0.00019292644,0.0004833719,0.00002879255,0.00011664945,0.0012872566,0.0008730668],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037620568,0.00020632155,0.00030788456,0.00007228016,0.0006861036,0.0034407235,0.0014916545,0.0000019808542,0.00008774253,0.0000067702144,0.9866971,0.0032394251],"study_design_scores_gemma":[0.0032401918,0.0023353125,0.0014496034,0.00007794664,0.00016362425,0.000027961578,0.00011925481,0.0000027835647,0.000034148856,0.0000041399626,0.9923008,0.0002442171],"about_ca_topic_score_codex":0.00007036004,"about_ca_topic_score_gemma":0.000006229767,"teacher_disagreement_score":0.100420535,"about_ca_system_score_codex":0.00034105458,"about_ca_system_score_gemma":0.00072406844,"threshold_uncertainty_score":0.999942},"labels":[],"label_agreement":null},{"id":"W1964593378","doi":"10.1038/ncponc0425","title":"Are prostate cancer clinical trial enrollment criteria and endpoints appropriate?","year":2006,"lang":"en","type":"article","venue":"Nature Clinical Practice Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Prostate; Clinical trial; Oncology; Medical physics; Internal medicine","score_opus":0.11155385858593407,"score_gpt":0.5612569716889142,"score_spread":0.4497031131029801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964593378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84685814,0.01929647,0.0000093811705,0.10191779,0.006848838,0.0036901513,0.00006535993,0.00013709476,0.021176776],"genre_scores_gemma":[0.95008785,0.012176609,0.005192721,0.015811818,0.008851311,0.0004212102,0.00010546038,0.00007433814,0.007278709],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99482036,0.0014820942,0.0015878209,0.000971047,0.00054348836,0.00059521507],"domain_scores_gemma":[0.99238986,0.005087135,0.0010393835,0.00046203096,0.00057874905,0.00044282642],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0047789803,0.0002995339,0.0011934718,0.000103571634,0.00016455943,0.000059362595,0.0001566907,0.0016576089,0.00031696405],"category_scores_gemma":[0.010461841,0.00021140653,0.00028724642,0.00022640347,0.00067490933,0.00025453468,0.00019890458,0.0037207375,0.000077695244],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4885797,0.012059605,0.09153347,0.00019125678,0.0009713724,0.0037352422,0.000100909005,7.358096e-7,0.00017737299,0.000575172,0.13362354,0.26845166],"study_design_scores_gemma":[0.12894526,0.007324455,0.13662887,0.000092293034,0.0007297335,0.00015685057,0.00022965462,0.000040518138,0.00007238174,0.0009923215,0.72453845,0.00024923115],"about_ca_topic_score_codex":0.00010214105,"about_ca_topic_score_gemma":0.00010496388,"teacher_disagreement_score":0.5909149,"about_ca_system_score_codex":0.00030596938,"about_ca_system_score_gemma":0.0010872912,"threshold_uncertainty_score":0.99963844},"labels":[],"label_agreement":null},{"id":"W1964631256","doi":"10.1038/pcan.2008.36","title":"The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer","year":2008,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Testosterone (patch); Body mass index; Internal medicine; Docetaxel; Prednisone; Prostate-specific antigen; Androgen deprivation therapy; Obesity; Oncology; Endocrinology; Cancer; Urology","score_opus":0.030696377723422916,"score_gpt":0.31454059866551276,"score_spread":0.28384422094208983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964631256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720526,0.01891399,0.0000070717233,0.0043338905,0.000024975736,0.003244447,0.0012844341,0.000037364807,0.000101262944],"genre_scores_gemma":[0.98623675,0.008050672,0.00015038514,0.0000985266,0.000016712802,0.0020134593,0.00009464303,0.0000549161,0.0032839223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976669,0.00010619001,0.00049145514,0.0005251411,0.000647724,0.00056260114],"domain_scores_gemma":[0.99819887,0.00047955263,0.00023425024,0.00032497558,0.00026915572,0.0004931957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016339523,0.00038567733,0.00056638103,0.00017557769,0.00041913864,0.00008405842,0.00008541378,0.00003167495,0.000022322709],"category_scores_gemma":[0.00010625909,0.0002071851,0.000043825028,0.00046859306,0.0009956649,0.0003438268,0.000044134198,0.00022401767,7.4517044e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012221945,0.00023851477,0.9810561,0.0011791616,0.0003183232,0.00033683403,0.0017108595,0.00009101253,0.00014078854,0.00010845202,0.00007826766,0.0025197582],"study_design_scores_gemma":[0.0086620245,0.00095269614,0.9862041,0.000818647,0.00047005346,0.00002203389,0.0013123666,0.00036712992,0.00016941104,0.00063172344,0.000103888175,0.0002859645],"about_ca_topic_score_codex":0.00065216277,"about_ca_topic_score_gemma":0.0005496372,"teacher_disagreement_score":0.014184199,"about_ca_system_score_codex":0.0001465275,"about_ca_system_score_gemma":0.0014216817,"threshold_uncertainty_score":0.84487635},"labels":[],"label_agreement":null},{"id":"W1964842484","doi":"10.5489/cuaj.1665","title":"Survival analysis of patients with biochemical relapse after radical prostatectomy treated with androgen deprivation: Castration-resistance influential factors","year":2014,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Castration; Prostatectomy; Androgen deprivation therapy; Androgen; Urology; Medicine; Resistance (ecology); Internal medicine; Prostate cancer; Oncology; Biology; Hormone; Cancer","score_opus":0.007661316667285366,"score_gpt":0.22328815765434268,"score_spread":0.2156268409870573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964842484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982522,0.000049431997,0.00010877626,0.0008723076,0.0000267271,0.0002882101,0.00012345833,0.0000144125615,0.00026445926],"genre_scores_gemma":[0.99901724,0.000008695856,0.00015463226,0.00014592195,0.000064706575,0.00001740518,0.0004196172,0.000012626443,0.00015916879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981527,0.00015840934,0.00034590665,0.00024371574,0.0006953318,0.00040398256],"domain_scores_gemma":[0.9982078,0.00012008739,0.00026369473,0.00013244816,0.0006623289,0.0006136521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000277745,0.0001708843,0.00042093167,0.00036387428,0.00015006676,0.000056347188,0.00007990227,0.00019011174,0.00032850163],"category_scores_gemma":[0.00020039642,0.00010326273,0.000121628254,0.0008999408,0.00011904176,0.000110835754,0.000008110257,0.00036029442,0.0000028137395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015712673,0.000108163586,0.9966538,0.0000072401135,0.001219247,0.00003143662,0.00008196891,0.000034779547,0.000043771375,0.000028609275,0.00013107913,0.000088618035],"study_design_scores_gemma":[0.003490674,0.00058986654,0.993142,0.000017472245,0.0008799734,0.0000030752308,0.000022084252,0.000056481185,0.00031902152,0.000019262021,0.0013378346,0.00012227256],"about_ca_topic_score_codex":0.00031118508,"about_ca_topic_score_gemma":0.0014064544,"teacher_disagreement_score":0.003511837,"about_ca_system_score_codex":0.0006812004,"about_ca_system_score_gemma":0.0004299392,"threshold_uncertainty_score":0.4210932},"labels":[],"label_agreement":null},{"id":"W1965760309","doi":"10.1074/mcp.m600169-mcp200","title":"Identification of Putative Androgen Receptor Interaction Protein Modules","year":2006,"lang":"en","type":"article","venue":"Molecular & Cellular Proteomics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Androgen receptor; Identification (biology); Computational biology; Chemistry; Biology; Cell biology; Genetics; Prostate cancer; Ecology","score_opus":0.011271021928440721,"score_gpt":0.2724376157581181,"score_spread":0.2611665938296774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965760309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97494435,0.0005841076,0.021546928,0.00041348374,0.000048856582,0.002014702,0.000029029268,0.00003625858,0.00038230408],"genre_scores_gemma":[0.9931756,0.00001870202,0.004503461,0.000011553251,0.00005449582,0.0002579644,0.00040556813,0.000032625427,0.001540003],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879944,0.00007788578,0.00035053748,0.00027217882,0.00030351806,0.00019640976],"domain_scores_gemma":[0.99926466,0.000007131955,0.0001815356,0.00026498488,0.00022454144,0.00005714157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020674133,0.00013859286,0.00021031368,0.00013782937,0.00005069198,0.000024725914,0.000075272605,0.000090797315,0.000029356766],"category_scores_gemma":[0.000034796296,0.00012318089,0.000115095674,0.00021009173,0.0000924233,0.00008746909,0.000033568882,0.00015226923,0.000039593902],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030285612,0.00022936537,0.00034363128,0.00014222527,0.000073782205,0.00003851959,0.000095931566,0.00009281855,0.9969589,0.0004897363,0.000035723435,0.0011964742],"study_design_scores_gemma":[0.0010502649,0.00020140264,0.00022553568,0.00006340611,0.000049478374,0.0000075492453,0.0000701774,0.0012112348,0.9955334,0.0011579728,0.00032541787,0.00010415016],"about_ca_topic_score_codex":0.000088542845,"about_ca_topic_score_gemma":0.0000012120624,"teacher_disagreement_score":0.018231297,"about_ca_system_score_codex":0.0001611365,"about_ca_system_score_gemma":0.00008522252,"threshold_uncertainty_score":0.5023171},"labels":[],"label_agreement":null},{"id":"W1965822866","doi":"10.1056/nejm200212123472424","title":"Book Review Prostate Cancer (American Cancer Society Atlas of Clinical Oncology.) Edited by Peter R. Carroll and Gary D. Grossfeld. 402 pp., illustrated, with CD-ROM. Hamilton, Ont., Canada, BC Decker, 2002. $159. 1-55009-130-1","year":2002,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Clinical Oncology; Oncology; Cancer; Gerontology; Internal medicine; Gynecology","score_opus":0.035291587490434095,"score_gpt":0.35556337717413605,"score_spread":0.32027178968370196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965822866","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17499658,0.7648312,0.0000038951443,0.057770927,0.0006565179,0.0008085869,0.00011525277,0.00001406756,0.0008029858],"genre_scores_gemma":[0.035902467,0.92470115,0.00018305633,0.016094655,0.0035429543,0.00003251219,0.00005538345,0.00005731486,0.019430526],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959075,0.00026069809,0.0015447496,0.00041400676,0.0012527758,0.000620285],"domain_scores_gemma":[0.99608207,0.00040163498,0.0012062029,0.00028990657,0.0008868042,0.0011333933],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011541529,0.00041608175,0.0020952034,0.00008428055,0.00010781294,0.000010192456,0.00019455791,0.00015352856,0.0020499197],"category_scores_gemma":[0.0001798698,0.00023242901,0.00018738436,0.00045599276,0.0010265104,0.00015514305,0.00003427045,0.0012366563,0.0000013377653],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019891695,0.00019125374,0.03298777,0.00065456104,0.0009971269,0.00075743336,0.00078175636,0.0000046015502,0.0004968474,2.3425689e-7,0.89463335,0.066505924],"study_design_scores_gemma":[0.050674442,0.006966578,0.02034794,0.006127071,0.0013678599,0.00066514034,0.0002349879,0.00004916905,0.00015790132,0.0000014091256,0.9131655,0.00024201651],"about_ca_topic_score_codex":0.13402049,"about_ca_topic_score_gemma":0.0900775,"teacher_disagreement_score":0.15986995,"about_ca_system_score_codex":0.00048397493,"about_ca_system_score_gemma":0.0029884407,"threshold_uncertainty_score":0.9988623},"labels":[],"label_agreement":null},{"id":"W1966005110","doi":"10.1002/pros.21283","title":"Use of irinotecan for treatment of small cell carcinoma of the prostate","year":2010,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Irinotecan; Medicine; Prostate; Cisplatin; Prostate cancer; Topoisomerase; Carcinoma; Pathology; Chemotherapy; Cancer; Urology; Internal medicine; Cancer research; Oncology; Biology; Colorectal cancer","score_opus":0.05926440628933335,"score_gpt":0.29890022642509095,"score_spread":0.2396358201357576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966005110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942062,0.00033948303,0.0000073609417,0.0013955898,0.00013335029,0.0032222085,0.00036532708,0.0000102327995,0.00032023882],"genre_scores_gemma":[0.9904471,0.00020293004,0.00055552943,0.000023952576,0.00003661115,0.00018540073,0.00002600035,0.000029329982,0.008493128],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988858,0.000047762747,0.00034904853,0.00018988184,0.00022542276,0.000302075],"domain_scores_gemma":[0.99852353,0.0001772428,0.00025020711,0.0006821341,0.00029335666,0.000073511364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019138755,0.00016612558,0.00036428377,0.000062809864,0.00007682527,0.000007982589,0.0001644193,0.000055087614,0.000018447536],"category_scores_gemma":[0.000041723353,0.00007465666,0.00021311756,0.00018872412,0.00043336346,0.000037954662,0.00006487656,0.00010241915,0.0000016529514],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048273588,0.0017323274,0.18034157,0.0010564118,0.00023453031,0.000008472782,0.01021792,0.000031304444,0.7767162,0.00025986246,0.0003002271,0.02427386],"study_design_scores_gemma":[0.0039002653,0.0027289093,0.059337962,0.00005309146,0.00021167607,0.0000065014133,0.00017209524,0.00018352688,0.9290878,0.00023754073,0.0040055644,0.00007502766],"about_ca_topic_score_codex":0.00065636914,"about_ca_topic_score_gemma":0.00013797027,"teacher_disagreement_score":0.15237167,"about_ca_system_score_codex":0.000046985442,"about_ca_system_score_gemma":0.00032277143,"threshold_uncertainty_score":0.304441},"labels":[],"label_agreement":null},{"id":"W1966124461","doi":"10.5489/cuaj.2873","title":"CUA-CUOG CRPC Guidelines: A useful compendium","year":2015,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"","keywords":"Compendium; Computer science; Data science; Library science; World Wide Web; Geography","score_opus":0.09885346336666,"score_gpt":0.34220646958946194,"score_spread":0.24335300622280193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966124461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6706905,0.0024563589,0.00011501513,0.29745364,0.0012161004,0.00047492163,0.000070853326,0.00008359174,0.027439047],"genre_scores_gemma":[0.9795395,0.00018599712,0.00049935427,0.010282166,0.0013157818,0.000010605194,0.00005802093,0.000016449503,0.008092092],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99816656,0.0001317035,0.00034629152,0.00017097665,0.000590539,0.0005939502],"domain_scores_gemma":[0.996693,0.00006982867,0.00014698521,0.000111153786,0.0010994005,0.0018795918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010416503,0.0001265948,0.00026344002,0.00019781574,0.00019550567,0.00010453557,0.0001276204,0.00021012969,0.0008219339],"category_scores_gemma":[0.0016610281,0.0000889723,0.00011777318,0.000236866,0.000037074355,0.000100535784,0.000018155786,0.00058022013,0.00037557856],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010838048,0.000042372045,0.68052167,0.000002371019,0.00011023962,0.00042649722,0.000110166184,0.000021764428,0.00002520673,0.00008130438,0.31710505,0.0014450018],"study_design_scores_gemma":[0.0034154612,0.0006167776,0.26259816,0.000019010138,0.00007371588,0.0004908905,0.00021877338,0.00026495208,0.00003098117,0.0012578325,0.73086846,0.00014496609],"about_ca_topic_score_codex":0.001225528,"about_ca_topic_score_gemma":0.00064685557,"teacher_disagreement_score":0.41792348,"about_ca_system_score_codex":0.0024914397,"about_ca_system_score_gemma":0.0020835232,"threshold_uncertainty_score":0.89996},"labels":[],"label_agreement":null},{"id":"W1966134512","doi":"10.14740/wjon903w","title":"Liver Metastases in Prostate Carcinoma Represent a Relatively Aggressive Subtype Refractory to Hormonal Therapy and Short-Duration Response to Docetaxel Monotherapy","year":2015,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Docetaxel; Hormonal therapy; Oncology; Prostate cancer; Chemotherapy; Internal medicine; Metastasis; Radiation therapy; Hormone therapy; Prostate-specific antigen; Prostate; Carcinoma; Cancer; Breast cancer","score_opus":0.09782510262680942,"score_gpt":0.3856070039682947,"score_spread":0.2877819013414853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966134512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97463864,0.011444627,0.00003023171,0.012636907,0.00011800388,0.00076466944,0.000009442647,0.0000061721807,0.00035133385],"genre_scores_gemma":[0.99268,0.0023522298,0.0021173093,0.00072045263,0.00014266928,0.00004061101,0.0000041647736,0.000019941264,0.0019225978],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9980491,0.00056789914,0.0004970186,0.00022714736,0.00038329998,0.00027554415],"domain_scores_gemma":[0.99820304,0.00040228537,0.00027368087,0.00015272413,0.00049572147,0.0004725209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015360425,0.00015509115,0.00048012746,0.00083904614,0.00004244353,0.000020368243,0.00008971212,0.000056543206,0.000038677703],"category_scores_gemma":[0.00046227497,0.00010665018,0.00006453167,0.0004697436,0.000092349,0.00017036445,0.000036017933,0.00037992097,0.000008364539],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43653306,0.001551454,0.23474832,0.000024422687,0.00052160356,0.01646284,0.024369754,0.00016664359,0.055525888,0.00006677463,0.019421289,0.21060793],"study_design_scores_gemma":[0.015114235,0.027102947,0.76889706,0.0002108683,0.00007229509,0.0009450649,0.0010619665,0.00006701912,0.0076820087,0.00022092652,0.17840324,0.0002223468],"about_ca_topic_score_codex":0.00008632146,"about_ca_topic_score_gemma":0.00020364759,"teacher_disagreement_score":0.53414875,"about_ca_system_score_codex":0.00075810374,"about_ca_system_score_gemma":0.0012429102,"threshold_uncertainty_score":0.43490678},"labels":[],"label_agreement":null},{"id":"W1966146854","doi":"10.1097/01.ju.0000180649.70924.05","title":"RE: A PROSPECTIVE ANALYSIS OF THE TIME TO NORMALIZATION OF SERUM ANDROGENS FOLLOWING 6 MONTHS OF ANDROGEN DEPRIVATION THERAPY IN PATIENTS ON A RANDOMIZED PHASE III CLINICAL TRIAL USING LIMITED HORMONAL THERAPY","year":2005,"lang":"en","type":"letter","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Androgen deprivation therapy; Hormonal therapy; Randomized controlled trial; Clinical trial; Androgen; Prostate cancer; Internal medicine; Testosterone (patch); Oncology; Urology; Gynecology; Hormone; Cancer","score_opus":0.04781405721123684,"score_gpt":0.37070043793175483,"score_spread":0.322886380720518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966146854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976684,0.00073421054,0.00005603623,0.019742267,0.00012117909,0.0025952016,0.000039861337,0.0000022308673,0.000025054755],"genre_scores_gemma":[0.9894457,0.0010215809,0.000040782325,0.009006714,0.00036835953,0.000014037532,0.000045244633,0.00002457271,0.000033032422],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954945,0.0017373442,0.0016590687,0.00017051582,0.0007205428,0.00021802263],"domain_scores_gemma":[0.9962431,0.0009762473,0.0018898227,0.00032043087,0.0005268718,0.000043492604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002736347,0.0002066837,0.0019037393,0.00083220005,0.00004408827,0.000004389598,0.000255333,0.00035572465,0.000067301975],"category_scores_gemma":[0.00041408924,0.00010166415,0.0010041227,0.0010103087,0.0001908951,0.000053509448,0.00003817276,0.0007462291,3.285377e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9534338,0.0013553216,0.027787628,0.000009418161,0.009981699,0.000018955463,0.0011735758,0.000909219,0.00064166734,4.5785936e-7,0.00080256374,0.0038856852],"study_design_scores_gemma":[0.9523699,0.015393029,0.020801503,0.00012442884,0.005395454,0.0000065451586,0.000026011548,0.002879689,0.002485155,0.00004147244,0.0003492477,0.00012751504],"about_ca_topic_score_codex":0.00003100506,"about_ca_topic_score_gemma":0.000006049162,"teacher_disagreement_score":0.014037707,"about_ca_system_score_codex":0.00012331705,"about_ca_system_score_gemma":0.00034160342,"threshold_uncertainty_score":0.41457435},"labels":[],"label_agreement":null},{"id":"W1966328145","doi":"10.1016/j.clon.2013.04.004","title":"Locally Advanced Prostate Cancer: Current Controversies and Optimisation Opportunities","year":2013,"lang":"en","type":"review","venue":"Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Malignancy; Radiation therapy; Intensive care medicine; Systemic therapy; Oncology; Prostate-specific antigen; Cancer; Androgen deprivation therapy; Population; Internal medicine; Breast cancer","score_opus":0.38522478611873356,"score_gpt":0.5542898600844367,"score_spread":0.16906507396570314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966328145","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000114660616,0.9918854,0.000003967466,0.00226799,0.0011800161,0.0030265665,0.000084902116,0.000053479922,0.001382995],"genre_scores_gemma":[0.0000071368136,0.98950016,0.0002498415,0.0003207377,0.00058330374,0.0011276188,0.0003484026,0.000044135933,0.007818683],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99725956,0.00038977587,0.0011529202,0.0005567485,0.00021735394,0.00042366987],"domain_scores_gemma":[0.99643,0.0019704744,0.0005677398,0.0002830537,0.0002780911,0.00047068464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054897316,0.00036558582,0.0029192148,0.00013778967,0.00008012362,0.000026196603,0.00012111431,0.0005422979,0.00025360676],"category_scores_gemma":[0.00052351283,0.00023655036,0.00039431508,0.00009888113,0.0007855836,0.00009605622,0.00015436538,0.0009652284,0.00007244337],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025635058,0.00026171823,0.00012301658,0.007225912,0.00039989207,0.000092584065,0.000035749268,1.6830636e-7,7.6246536e-8,0.0000786106,0.009526797,0.9819991],"study_design_scores_gemma":[0.0036789028,0.0020170594,0.00006125893,0.006461583,0.001453563,0.000031755768,0.00008104622,0.000011952423,2.4089536e-7,0.00005432683,0.9859368,0.00021148479],"about_ca_topic_score_codex":0.000024014525,"about_ca_topic_score_gemma":0.000009418959,"teacher_disagreement_score":0.9817876,"about_ca_system_score_codex":0.00052216277,"about_ca_system_score_gemma":0.0041465242,"threshold_uncertainty_score":0.9646244},"labels":[],"label_agreement":null},{"id":"W1966478315","doi":"10.1118/1.3611956","title":"SU‐E‐T‐06: Investigating in Vitro Gamma‐H2AX Response and Chromosome Damage in Human Lymphocytes and Lymphocyte Subsets for Biomarkers of Radiation Sensitivity","year":2011,"lang":"en","type":"article","venue":"Medical Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Radiosensitivity; Lymphocyte; Population; CD8; Medicine; Nuclear medicine; Oncology; Cancer research; Radiation therapy; Pathology; Biology; Immunology; Internal medicine; Immune system","score_opus":0.04148655295152759,"score_gpt":0.31585718278544644,"score_spread":0.27437062983391886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966478315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983898,0.00069834705,0.000052132084,0.00026393385,0.000021823234,0.00046083535,0.000025021292,0.000013702235,0.00007442596],"genre_scores_gemma":[0.99929374,0.00021236559,0.00019341287,0.00009166018,0.0000558793,0.000034142427,0.00007705893,0.000016863023,0.000024884079],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987505,0.00017863567,0.00025857502,0.00024784656,0.00030130814,0.0002631229],"domain_scores_gemma":[0.9990726,0.00045940056,0.00007424742,0.00013371253,0.000040464878,0.00021955083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011091015,0.00012873202,0.00033456643,0.00012334656,0.00004693706,0.0000083886325,0.0000376589,0.0001080588,0.000008650223],"category_scores_gemma":[0.00059421425,0.00010971753,0.000032490254,0.00024452107,0.0004739336,0.00010945895,0.0000535353,0.00011385,5.8120725e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007288488,0.0005408112,0.2502387,0.00085980946,0.00011803565,0.000396541,0.0064845425,6.6627575e-7,0.6373477,0.00008174412,0.000086670414,0.09655629],"study_design_scores_gemma":[0.011494928,0.0003119406,0.29374155,0.00039104564,0.000029399596,0.000015096375,0.0001478195,0.0025980957,0.69025075,0.00085547206,0.000031600794,0.0001323215],"about_ca_topic_score_codex":0.00046964223,"about_ca_topic_score_gemma":0.000045775432,"teacher_disagreement_score":0.09642397,"about_ca_system_score_codex":0.00022859187,"about_ca_system_score_gemma":0.00039666984,"threshold_uncertainty_score":0.4474151},"labels":[],"label_agreement":null},{"id":"W1966947676","doi":"10.1016/j.ijrobp.2010.03.018","title":"Population-Based Study of Cardiovascular Mortality Among Patients With Prostate Cancer Treated With Radical External Beam Radiation Therapy With and Without Adjuvant Androgen Deprivation Therapy at the British Columbia Cancer Agency","year":2010,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Hazard ratio; Internal medicine; Radiation therapy; Cumulative incidence; Cohort; Population; Proportional hazards model; Cancer; Surgery; Oncology; Confidence interval","score_opus":0.016688704982046446,"score_gpt":0.31655113869616286,"score_spread":0.2998624337141164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966947676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958376,0.0019213229,0.00014494112,0.00015583285,0.00022949063,0.0015829667,0.000101964804,0.000017984956,0.000007864729],"genre_scores_gemma":[0.9966851,0.002259669,0.00012746401,0.00010233689,0.00034639201,0.00018235948,0.00022120627,0.00003817552,0.00003728633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979808,0.000223357,0.0005064167,0.0003232172,0.0007500263,0.00021622353],"domain_scores_gemma":[0.9975018,0.00009847408,0.00088074943,0.00021808912,0.001171722,0.00012918617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040211162,0.00020189145,0.0005669144,0.00007621587,0.00025792856,0.00010095237,0.00018341112,0.0001315374,0.00006704026],"category_scores_gemma":[0.000028864433,0.00013686293,0.00011087397,0.0002255314,0.0003313519,0.00026466767,0.000021240796,0.0004029841,2.517179e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034403384,0.0009723955,0.88117534,0.0000075784533,0.0028222003,0.000020361242,0.00038741753,0.0013753962,0.00043807528,0.0000014407839,0.0000220723,0.10933739],"study_design_scores_gemma":[0.027116336,0.003691754,0.96659213,0.00009495525,0.00038024172,0.00002658939,0.000033710563,0.00040997335,0.0011577125,0.00003710361,0.00030718982,0.00015229048],"about_ca_topic_score_codex":0.0146843605,"about_ca_topic_score_gemma":0.007972837,"teacher_disagreement_score":0.1091851,"about_ca_system_score_codex":0.0004699116,"about_ca_system_score_gemma":0.00064245926,"threshold_uncertainty_score":0.99187696},"labels":[],"label_agreement":null},{"id":"W1967456673","doi":"10.1371/journal.pone.0005722","title":"Molecular Signatures of Prostate Stem Cells Reveal Novel Signaling Pathways and Provide Insights into Prostate Cancer","year":2009,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Institutes of Health; School of Medicine, New York University; York University; Memorial Sloan-Kettering Cancer Center; Amgen","keywords":"Stem cell; Biology; Prostate; Prostate cancer; Cancer stem cell; Wnt signaling pathway; Cancer research; Carcinogenesis; Progenitor cell; Population; Cell biology; Cancer; Signal transduction; Genetics; Medicine","score_opus":0.036179161926913804,"score_gpt":0.26598395347124554,"score_spread":0.22980479154433173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967456673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825654,0.014188396,0.000010446031,0.001076889,0.000019266123,0.0018266756,0.00003691756,0.00005716137,0.00021885298],"genre_scores_gemma":[0.9954678,0.001594181,0.001494477,0.00028400702,0.0000621558,0.00011573648,0.000025441723,0.000032711956,0.0009234819],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982477,0.000039239574,0.0003316255,0.00040573836,0.0006119491,0.00036375888],"domain_scores_gemma":[0.99904877,0.00004048607,0.00013504297,0.0002461187,0.00031262764,0.00021695194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012993967,0.00022818225,0.0004794178,0.00015896886,0.000082845974,0.000028425642,0.00008694099,0.00010694455,0.000009540849],"category_scores_gemma":[0.00001698768,0.00017023254,0.000057454723,0.00026051942,0.00011753205,0.0001235379,0.00004792701,0.0002941833,0.0000027903216],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090464886,0.0013406852,0.001760685,0.0010851059,0.00031899844,0.00011515205,0.003492264,0.000033830293,0.98564637,0.00007882129,0.00004261256,0.005180805],"study_design_scores_gemma":[0.002804963,0.001359101,0.0010769975,0.0015023788,0.00024687633,0.0000015934703,0.00015821209,0.0002758239,0.9919348,0.00038216883,0.00007295134,0.00018418214],"about_ca_topic_score_codex":0.000074440446,"about_ca_topic_score_gemma":0.000007106109,"teacher_disagreement_score":0.012902412,"about_ca_system_score_codex":0.0001212722,"about_ca_system_score_gemma":0.00029073659,"threshold_uncertainty_score":0.6941882},"labels":[],"label_agreement":null},{"id":"W1967884488","doi":"10.5489/cuaj.2380","title":"Role for &lt;sup&gt;11&lt;/sup&gt;C-choline PET in active surveillance of prostate cancer","year":2015,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Alberta Cancer Foundation","keywords":"Prostate cancer; Medicine; Choline; Positron emission tomography; Prostate; Biopsy; Nuclear medicine; Prostate-specific antigen; Urology; Cancer; Internal medicine; Radiology; Oncology","score_opus":0.025363704047505813,"score_gpt":0.2991988230797701,"score_spread":0.27383511903226426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967884488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9712839,0.0014074965,0.000007721083,0.024768695,0.0001638784,0.00069994765,0.00057551573,0.000014767408,0.0010780665],"genre_scores_gemma":[0.995635,0.0005018618,0.00013338866,0.00076318864,0.0004201075,0.00009546648,0.00011747582,0.000020638041,0.0023128751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783397,0.00020167771,0.00044347905,0.00025672672,0.00051546056,0.00074870297],"domain_scores_gemma":[0.9974796,0.00020089821,0.00030176548,0.00011655073,0.0009696889,0.00093145034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012305725,0.00017584699,0.000477158,0.00028187755,0.00012040108,0.000042080228,0.0001415212,0.00018432477,0.0002041008],"category_scores_gemma":[0.0012573856,0.00013416301,0.00013251431,0.00037711006,0.00006428293,0.00013425115,0.000020205673,0.0004666542,0.000010605275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012125192,0.00013980253,0.9761415,0.000019751062,0.00017648702,0.00013244488,0.000916875,0.00059858285,0.00050243543,0.00006489832,0.0142363785,0.0058582863],"study_design_scores_gemma":[0.010036222,0.0011847012,0.8545721,0.00006117497,0.000066120774,0.00009273745,0.00040746224,0.0024110475,0.00029536744,0.0013752051,0.12923793,0.0002599349],"about_ca_topic_score_codex":0.0023621216,"about_ca_topic_score_gemma":0.016706156,"teacher_disagreement_score":0.12156945,"about_ca_system_score_codex":0.002905015,"about_ca_system_score_gemma":0.0022124492,"threshold_uncertainty_score":0.9322427},"labels":[],"label_agreement":null},{"id":"W1968149100","doi":"10.1097/01.pas.0000157936.93999.18","title":"Immunohistochemical Stains for p63 and α-Methylacyl-CoA Racemase, Versus a Cocktail Comprising Both, in the Diagnosis of Prostatic Carcinoma","year":2005,"lang":"en","type":"article","venue":"The American Journal of Surgical Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ECW Press (Canada)","funders":"","keywords":"Pathology; Medicine; Carcinoma; Immunohistochemistry; H&E stain; Immunostaining; Prostate; Intraepithelial neoplasia; Staining; Biopsy; Frozen section procedure; Cancer; Internal medicine","score_opus":0.036334490906403935,"score_gpt":0.35814350166345443,"score_spread":0.3218090107570505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968149100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771965,0.003851452,0.00008004553,0.018316707,0.00003949935,0.00041022128,0.00001474516,0.0000028262177,0.000087991946],"genre_scores_gemma":[0.99777824,0.0012577819,0.0005781308,0.00017218402,0.00013291677,0.00003576247,0.0000026728846,0.000012263754,0.000030051982],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985268,0.0003502008,0.00045248988,0.00012792497,0.00025187945,0.00029071004],"domain_scores_gemma":[0.99674904,0.0024934097,0.00035417278,0.00018293348,0.00013647105,0.00008394953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010439397,0.00012024797,0.000573178,0.00011995564,0.00006650272,0.000008200403,0.00016649629,0.00003415329,0.0000142798035],"category_scores_gemma":[0.0001833546,0.000055756365,0.00013935153,0.00023025964,0.0012290777,0.00004526782,0.000044483244,0.0003194945,7.5481483e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14167401,0.0025198753,0.29518038,0.00042838816,0.0007550869,0.0064058285,0.02274777,0.00005909572,0.08454231,0.0010343596,0.0017757877,0.4428771],"study_design_scores_gemma":[0.19014122,0.09004884,0.5221039,0.00144239,0.002657767,0.02498919,0.050270833,0.0009820113,0.066717036,0.0032380037,0.045983583,0.0014252397],"about_ca_topic_score_codex":0.000018980085,"about_ca_topic_score_gemma":0.0000022670467,"teacher_disagreement_score":0.44145188,"about_ca_system_score_codex":0.000121281744,"about_ca_system_score_gemma":0.00014281564,"threshold_uncertainty_score":0.4528588},"labels":[],"label_agreement":null},{"id":"W1968280941","doi":"10.1002/(sici)1097-0142(20000215)88:4<955::aid-cncr27>3.0.co;2-4","title":"Report on Prostate Cancer Tumor Marker Workshop 1999","year":2000,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"World Health Organization","keywords":"Medicine; Prostate cancer; Cancer; Tumor marker; Oncology; Gynecology; Internal medicine","score_opus":0.028650509830800933,"score_gpt":0.3572453819387357,"score_spread":0.32859487210793475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968280941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9359155,0.01197784,8.0707287e-7,0.010400103,0.00045390872,0.00095839414,0.00006989668,0.000121495505,0.04010204],"genre_scores_gemma":[0.5680734,0.009643692,0.000062001454,0.002660759,0.00081340433,0.0011901481,0.00007176695,0.00006989869,0.41741496],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982908,0.000026223799,0.00024918644,0.00048416894,0.00043042778,0.00051923655],"domain_scores_gemma":[0.9990894,0.000034354038,0.000058545327,0.00044639537,0.00010981234,0.00026150185],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014279004,0.000211745,0.0002983151,0.00008159219,0.00010927873,0.000029627081,0.00008550085,0.00006717682,0.01787745],"category_scores_gemma":[0.00002427769,0.00014963065,0.00010691004,0.00031880554,0.00012205081,0.000077482466,0.000019973195,0.0003047166,0.00027746675],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006969144,0.00040623368,0.25798833,0.00025883655,0.0004997394,0.0075610015,0.0005585977,0.00016286504,0.0014023538,0.000028769113,0.25489202,0.4692721],"study_design_scores_gemma":[0.0033179924,0.00021087784,0.13205107,0.0007945817,0.00012302127,0.00017183025,0.000053073476,0.0000936962,0.0067161466,0.000051918938,0.8561229,0.00029288442],"about_ca_topic_score_codex":0.00055786356,"about_ca_topic_score_gemma":0.0000925624,"teacher_disagreement_score":0.6012309,"about_ca_system_score_codex":0.0005010048,"about_ca_system_score_gemma":0.00061283796,"threshold_uncertainty_score":0.98302037},"labels":[],"label_agreement":null},{"id":"W1968735621","doi":"10.1016/s1470-2045(15)70027-6","title":"Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Pharmaceuticals; Takeda Oncology; GlaxoSmithKline; Public Health Agency; Astellas Pharma Canada; Novartis; Exelixis; Ministry of Education, Culture, Sports, Science and Technology; Bayer; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Medicine; Prednisone; Prostate cancer; Abiraterone acetate; Internal medicine; Placebo; Clinical endpoint; Enzalutamide; Androgen deprivation therapy; Clinical trial; Population; Oncology; Cancer; Surgery; Urology; Pathology; Androgen receptor","score_opus":0.09142640043602607,"score_gpt":0.3987588878018678,"score_spread":0.30733248736584173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968735621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729393,0.0006388988,0.000018169469,0.004810386,0.00029654836,0.020076925,0.0000696506,0.00004603255,0.0011040827],"genre_scores_gemma":[0.9904562,0.00027187367,0.00030078198,0.000491718,0.00039880033,0.005800022,0.00017784955,0.000046565303,0.002056164],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972979,0.0004661203,0.0005849799,0.0004063847,0.00055120996,0.00069342915],"domain_scores_gemma":[0.9983804,0.0003164034,0.00033611254,0.00039619833,0.00032022878,0.0002506373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011027253,0.00031330448,0.0014464076,0.00014282374,0.00009859286,0.00003991783,0.00019065733,0.00010309517,0.00010619435],"category_scores_gemma":[0.00008775408,0.00016416673,0.000097770164,0.00029782456,0.0002326985,0.00012357066,0.000036337242,0.00039786717,0.000018885004],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98556006,0.0024537516,0.0017387568,0.00006348491,0.00094016286,0.00013712014,0.0053326376,0.00017905717,0.00011325897,0.000013633435,0.0010736192,0.0023944627],"study_design_scores_gemma":[0.98812604,0.007750344,0.0006194017,0.00008567672,0.0005466497,0.000006347105,0.0006112666,0.000575257,0.00027368715,0.000041742966,0.0011826796,0.0001808898],"about_ca_topic_score_codex":0.00046669872,"about_ca_topic_score_gemma":0.001124265,"teacher_disagreement_score":0.017516918,"about_ca_system_score_codex":0.0010849455,"about_ca_system_score_gemma":0.0020052572,"threshold_uncertainty_score":0.6694525},"labels":[],"label_agreement":null},{"id":"W1968802517","doi":"10.1158/0008-5472.can-08-0645","title":"Targeted Overexpression of Vav3 Oncogene in Prostatic Epithelium Induces Nonbacterial Prostatitis and Prostate Cancer","year":2008,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"University of Cincinnati; Ohio Cancer Research Associates; College of Medicine, University of Cincinnati; National Cancer Institute; National Institutes of Health; Ohio Cancer Research","keywords":"Prostate cancer; Prostatitis; Prostate; Cancer research; Cancer; Oncogene; Intraepithelial neoplasia; Tramp; PCA3; Medicine; Biology; Internal medicine; Cell cycle","score_opus":0.07736956106048473,"score_gpt":0.4065717295991332,"score_spread":0.3292021685386485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968802517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871985,0.008112387,7.2333955e-7,0.0014111731,0.00012773722,0.0024666763,0.00032426536,0.00002639882,0.00033216606],"genre_scores_gemma":[0.97519577,0.019626746,0.00017407039,0.00004166343,0.00019133273,0.0014937617,0.00007239232,0.00005425506,0.0031499849],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99678653,0.00025855392,0.00046078712,0.00057912304,0.0010664846,0.00084851333],"domain_scores_gemma":[0.99846715,0.00016098302,0.000108308064,0.00032222443,0.00062726834,0.00031407023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006190681,0.00023264851,0.00053603656,0.00055576186,0.00020914571,0.000027860728,0.00015133792,0.00014607783,0.0005197882],"category_scores_gemma":[0.00015759486,0.00017585179,0.000054865115,0.0009579743,0.0008012261,0.0002273745,0.00018669767,0.000631753,0.000008787713],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036199975,0.00030358325,0.12541617,0.0008701765,0.000081949474,0.00020668675,0.005179564,0.0000065258378,0.8525254,0.000012945642,0.001433939,0.010343038],"study_design_scores_gemma":[0.0074198553,0.0010818895,0.20666002,0.0019167914,0.000020931759,0.000031946085,0.00040941223,0.000044087898,0.7804717,0.00014932807,0.0015685116,0.00022555553],"about_ca_topic_score_codex":0.00485803,"about_ca_topic_score_gemma":0.00031389465,"teacher_disagreement_score":0.08124385,"about_ca_system_score_codex":0.0005044311,"about_ca_system_score_gemma":0.0020849449,"threshold_uncertainty_score":0.73439205},"labels":[],"label_agreement":null},{"id":"W1969135551","doi":"10.1158/1538-7445.am10-5376","title":"Abstract 5376: Antisense oligonucleotide targeting insulin-like growth factor-1 receptor (IGF-1R) enhances paclitaxel sensitivity in a castrate-resistant and paclitaxel-resistant prostate cancer model","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Docetaxel; Paclitaxel; Prostate cancer; Cancer research; In vivo; Androgen deprivation therapy; Pharmacology; Flow cytometry; Growth factor; Apoptosis; Medicine; Cancer; Biology; Receptor; Internal medicine; Immunology; Biochemistry","score_opus":0.05089294191755297,"score_gpt":0.3744116511016078,"score_spread":0.32351870918405484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969135551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846124,0.0077295583,0.000004893345,0.003352092,0.00037488027,0.0021672514,0.0009999176,0.00010730256,0.0006517245],"genre_scores_gemma":[0.9801587,0.01645815,0.00054348237,0.00011579438,0.00039466104,0.00065484404,0.00008074159,0.00013600566,0.0014576528],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99354315,0.00037104567,0.0008355385,0.0014453154,0.0016607532,0.0021442],"domain_scores_gemma":[0.99637103,0.0005826058,0.00020406785,0.0006455675,0.0012316379,0.0009651199],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00275366,0.0006100093,0.0009378222,0.00070026703,0.0005891553,0.00028044762,0.00025455162,0.00036538587,0.00040506112],"category_scores_gemma":[0.00063050183,0.0004953492,0.0001657175,0.0011247983,0.0011902994,0.00051588716,0.000293468,0.0028161926,0.00004280597],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005582336,0.00037249253,0.024053382,0.0009597641,0.00016416147,0.00087516103,0.0022231294,0.000032073942,0.95952034,0.000107794796,0.0017751793,0.004334211],"study_design_scores_gemma":[0.010355452,0.0010815943,0.26661438,0.002379293,0.000095005424,0.000037365666,0.0029999015,0.0020931503,0.70886314,0.0008743305,0.0031596287,0.0014467676],"about_ca_topic_score_codex":0.015596299,"about_ca_topic_score_gemma":0.017144315,"teacher_disagreement_score":0.25065717,"about_ca_system_score_codex":0.001006787,"about_ca_system_score_gemma":0.0027093373,"threshold_uncertainty_score":0.99974984},"labels":[],"label_agreement":null},{"id":"W1969394658","doi":"10.4161/cbt.29689","title":"The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy","year":2014,"lang":"en","type":"article","venue":"Cancer Biology & Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Alberta Bible College; Prostate Cancer Canada; University of Calgary","funders":"Prostate Cancer Canada; Movember Foundation; Prostate Cancer Foundation","keywords":"Prostate cancer; Androgen receptor; Androgen deprivation therapy; Erg; Androgen; Medicine; Prostate; Internal medicine; Oncology; Cancer research; Cancer; Endocrinology; Hormone; Ophthalmology","score_opus":0.014222650293685399,"score_gpt":0.2823701542150323,"score_spread":0.2681475039213469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969394658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97843856,0.01808575,0.000016825603,0.0011323505,0.000083133826,0.0021266867,0.000063774845,0.000022267937,0.000030630083],"genre_scores_gemma":[0.959966,0.038319916,0.00006188592,0.00022613602,0.000037625774,0.0010445241,0.00014223724,0.000028222148,0.00017345947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987091,0.00019373183,0.00024255615,0.00036324284,0.00016227725,0.00032909002],"domain_scores_gemma":[0.9992105,0.00013955742,0.00016108203,0.000243738,0.0001648211,0.00008031793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023946071,0.00019666618,0.00032236046,0.00006583865,0.00013300666,0.000013818657,0.000121002886,0.00010213132,0.000042113206],"category_scores_gemma":[0.00001722486,0.00010276276,0.000029944611,0.0002303899,0.00036532676,0.00006001301,0.000022620208,0.00015505105,7.6895367e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009432403,0.00016612805,0.8334914,0.000024795454,0.00013623967,3.857642e-7,0.00036171748,0.0000020997597,0.05427168,0.000009266797,0.0003329768,0.10177092],"study_design_scores_gemma":[0.023997491,0.003926873,0.75405127,0.00027668956,0.00002610662,4.0286943e-7,0.00008420107,0.00003455455,0.19824168,0.00024970854,0.01885842,0.00025262538],"about_ca_topic_score_codex":0.00012902173,"about_ca_topic_score_gemma":0.000041144944,"teacher_disagreement_score":0.14397,"about_ca_system_score_codex":0.00009502706,"about_ca_system_score_gemma":0.00012332958,"threshold_uncertainty_score":0.4190544},"labels":[],"label_agreement":null},{"id":"W1969735359","doi":"10.3747/co.v17i0.709","title":"Androgen Deprivation Therapy for Prostate Cancer—Review of Indications in 2010","year":2010,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Radiation therapy; Disease; Oncology; Androgen; Prostate; Cancer; Internal medicine; Hormone","score_opus":0.13408609337094848,"score_gpt":0.4897625416395646,"score_spread":0.3556764482686161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969735359","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82725817,0.15791574,0.000039299,0.010317561,0.0008590218,0.003209569,0.00007774868,0.000016841725,0.00030605806],"genre_scores_gemma":[0.4563981,0.5382737,0.00055269693,0.0003796496,0.00023173289,0.0032756894,0.0005374601,0.000021997024,0.00032901144],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993534,0.00002616715,0.00022418814,0.00014400727,0.00009433396,0.0001578691],"domain_scores_gemma":[0.99944305,0.000069965885,0.000104527346,0.00014498367,0.00017990278,0.000057540452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002509064,0.00006691519,0.00023547276,0.00011310948,0.000024997153,0.0000017251107,0.0000643688,0.00006195022,0.00015481185],"category_scores_gemma":[0.00009100611,0.000048968603,0.000048671536,0.00019780043,0.000087450935,0.000031460684,0.00001484101,0.00019585478,0.0000040507307],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027805986,0.0007070662,0.2561907,0.0015453608,0.00003901858,0.0000012699178,0.00027196258,1.0586785e-7,0.0059323567,0.00022371372,0.0040978407,0.73071253],"study_design_scores_gemma":[0.008514356,0.0010644638,0.18148622,0.0016183998,0.00008598812,0.000008939694,0.000028890743,0.000069563466,0.015278158,0.0007815321,0.7909443,0.00011922842],"about_ca_topic_score_codex":0.00002724966,"about_ca_topic_score_gemma":0.00009554177,"teacher_disagreement_score":0.7868464,"about_ca_system_score_codex":0.00008955927,"about_ca_system_score_gemma":0.00062358956,"threshold_uncertainty_score":0.19968817},"labels":[],"label_agreement":null},{"id":"W1969870246","doi":"10.1002/dc.20582","title":"Secondary prostatic adenocarcinoma: A cytopathological study of 50 cases","year":2007,"lang":"en","type":"article","venue":"Diagnostic Cytopathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Cytokeratin; Medicine; Pathology; Carcinoembryonic antigen; Immunostaining; Cytopathology; Adenocarcinoma; Prostate-specific antigen; Prostate; Cytology; Fine-needle aspiration; Biopsy; Immunohistochemistry; Cancer; Internal medicine","score_opus":0.0376473743677126,"score_gpt":0.34428229598566107,"score_spread":0.3066349216179485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969870246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992994,0.0031300122,0.00017878308,0.0002367071,0.00019288242,0.0017391732,0.000036797937,0.00007418675,0.0014174205],"genre_scores_gemma":[0.9985109,0.00013509505,0.000483801,0.00020226695,0.00012674101,0.00014445353,0.000055971712,0.00002905227,0.00031170176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978254,0.00015962089,0.00056190963,0.0005059608,0.00034753684,0.00059958315],"domain_scores_gemma":[0.9966977,0.0022938028,0.0001305846,0.00046827274,0.00018110401,0.00022851258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075228186,0.0002380504,0.00065818056,0.00030835127,0.000095799296,0.000008666351,0.00013693809,0.00015280374,0.00023254784],"category_scores_gemma":[0.002106107,0.00017810344,0.00010227329,0.00032942148,0.0003555971,0.00005142223,0.00013791586,0.0004060564,0.000057338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011659296,0.0033617138,0.933925,0.00016674577,0.000050814855,0.04966383,0.0022193608,8.697707e-7,0.0026408983,0.00012947408,0.00021816452,0.006457226],"study_design_scores_gemma":[0.0055872905,0.010396353,0.97166187,0.000068548245,0.00021574568,0.0048708725,0.0033954964,0.0000026083355,0.003328443,0.00014414315,0.00017105632,0.00015760536],"about_ca_topic_score_codex":0.00007194568,"about_ca_topic_score_gemma":0.000081690625,"teacher_disagreement_score":0.044792958,"about_ca_system_score_codex":0.00010266418,"about_ca_system_score_gemma":0.0002011574,"threshold_uncertainty_score":0.72628474},"labels":[],"label_agreement":null},{"id":"W1970097733","doi":"10.1016/j.jsbmb.2008.11.004","title":"Comparable amounts of sex steroids are made outside the gonads in men and women: Strong lesson for hormone therapy of prostate and breast cancer","year":2008,"lang":"en","type":"article","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Castration; Prostate cancer; Dihydrotestosterone; Medicine; Antiandrogen; Internal medicine; Endocrinology; Androgen; Testosterone (patch); Prostate; Sex hormone-binding globulin; Breast cancer; Hormone; Cancer","score_opus":0.02031287962132376,"score_gpt":0.30852880847038466,"score_spread":0.2882159288490609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970097733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9621563,0.036322817,0.00001930548,0.0011595032,0.000009334641,0.0002537011,0.000059077556,9.439045e-7,0.000019025092],"genre_scores_gemma":[0.97284275,0.026924908,0.000025102916,0.000068652036,0.000023807486,0.000012968547,0.000004447896,0.0000067772476,0.000090563495],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993308,0.000060705683,0.0002464222,0.00009734694,0.00008610639,0.00017861408],"domain_scores_gemma":[0.9994728,0.00004794331,0.00021945003,0.00010259636,0.0000955911,0.00006164343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003127262,0.00010642072,0.0003233139,0.00003447318,0.00005199073,0.0000038763046,0.0000763069,0.00006237111,0.000002107691],"category_scores_gemma":[0.0000061442643,0.000053515138,0.000028672715,0.000050532097,0.000502852,0.000020401063,0.000040503346,0.00014075568,1.1950017e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038016979,0.00007320649,0.03952856,0.00010528449,0.00019904951,0.0000111296595,0.0020342304,0.0000027663193,0.9521659,0.0000012638297,0.000059512025,0.002017379],"study_design_scores_gemma":[0.007683413,0.0013915179,0.06277587,0.00016042091,0.00004838463,0.0006988072,0.0040711416,0.000035333756,0.9228544,0.00009618058,0.00009693317,0.000087597335],"about_ca_topic_score_codex":0.000035614612,"about_ca_topic_score_gemma":0.0000015160714,"teacher_disagreement_score":0.029311523,"about_ca_system_score_codex":0.00003290387,"about_ca_system_score_gemma":0.00007408823,"threshold_uncertainty_score":0.2182284},"labels":[],"label_agreement":null},{"id":"W1970266782","doi":"10.1097/pas.0b013e318124a865","title":"hCAP-D3 Expression Marks a Prostate Cancer Subtype With Favorable Clinical Behavior and Androgen Signaling Signature","year":2008,"lang":"en","type":"article","venue":"The American Journal of Surgical Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Research Institute for Sustainable Humanosphere, Kyoto University","keywords":"Prostate cancer; Tissue microarray; Androgen receptor; Prostate; Immunohistochemistry; Prostatectomy; Microarray analysis techniques; Microarray; Biomarker; PCA3; Androgen; Cancer research; Cancer; Biology; Oncology; Pathology; Medicine; Internal medicine; Gene expression; Gene; Hormone; Genetics","score_opus":0.0334499066060478,"score_gpt":0.35055727531294195,"score_spread":0.31710736870689415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970266782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99139315,0.005797115,0.000011462836,0.0023269558,0.00006909427,0.00028679337,0.000009283341,0.000010900478,0.000095222545],"genre_scores_gemma":[0.98653513,0.012069189,0.0004896803,0.000224316,0.00023502592,0.000020721924,0.000003033032,0.000022670325,0.00040025706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982841,0.00039103723,0.00042401018,0.00021858666,0.00034284368,0.00033944682],"domain_scores_gemma":[0.99856675,0.00028738088,0.00043372758,0.00017403904,0.00025452953,0.0002835934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006981732,0.00016318947,0.00069027074,0.00009101393,0.00016086567,0.000010498789,0.0001221829,0.0000753985,0.000086535256],"category_scores_gemma":[0.000028838085,0.000075576754,0.00012212453,0.00025052452,0.0014776388,0.00007127464,0.000054925385,0.0008491636,0.0000023928956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025928581,0.00056652183,0.87317103,0.000029029407,0.0002267786,0.037723053,0.0011953495,0.000027175704,0.022892097,0.000006001503,0.0007769267,0.037457462],"study_design_scores_gemma":[0.04120494,0.047932506,0.68791604,0.0015205299,0.0018723331,0.16075158,0.0043252627,0.000083423765,0.03451585,0.00023190919,0.018582497,0.0010631055],"about_ca_topic_score_codex":0.000022299908,"about_ca_topic_score_gemma":0.0000015584667,"teacher_disagreement_score":0.18525498,"about_ca_system_score_codex":0.00004359462,"about_ca_system_score_gemma":0.0003468054,"threshold_uncertainty_score":0.5444422},"labels":[],"label_agreement":null},{"id":"W1970919014","doi":"10.1074/jbc.m200135200","title":"The Androgen Receptor Can Promote β-Catenin Nuclear Translocation Independently of Adenomatous Polyposis Coli","year":2002,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Androgen receptor; Chromosomal translocation; Adenomatous polyposis coli; Catenin; Cancer research; Nuclear receptor; Chemistry; Internal medicine; Biology; Wnt signaling pathway; Cell biology; Medicine; Signal transduction; Colorectal cancer; Genetics; Cancer; Prostate cancer; Gene; Transcription factor","score_opus":0.036820092969146484,"score_gpt":0.2724552000322013,"score_spread":0.23563510706305482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970919014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99113894,0.0046217563,0.0000016885774,0.0034276312,0.000034893852,0.0001240478,0.000012353723,0.000007583233,0.00063111895],"genre_scores_gemma":[0.99459267,0.004509813,0.00008944071,0.00003530196,0.00011768477,0.0000030228055,0.000005087124,0.0000074012937,0.00063955877],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991034,0.000029747562,0.0003465795,0.00009456448,0.0002519574,0.000173733],"domain_scores_gemma":[0.99932617,0.0000485113,0.0002134536,0.00010073108,0.00016840047,0.00014275097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020619459,0.000089326524,0.00023573388,0.0000177352,0.00007582527,0.000013581563,0.00015113474,0.00013936039,0.00036154847],"category_scores_gemma":[0.00007288372,0.000044446777,0.00013502182,0.000109198314,0.00016987172,0.000022245544,0.000016877748,0.00026909186,0.000005080381],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066924054,0.00028526504,0.0036414857,0.000054304386,0.00018450752,0.00004767356,0.00021304603,4.8189963e-7,0.9816348,0.0000041827657,0.0009353591,0.01232967],"study_design_scores_gemma":[0.0019080231,0.00081903866,0.001970517,0.00012641173,0.0000537179,0.0003593599,0.00032894767,0.00003868249,0.9903961,0.000040017858,0.003882515,0.00007667395],"about_ca_topic_score_codex":0.00000514107,"about_ca_topic_score_gemma":3.3946478e-7,"teacher_disagreement_score":0.012252996,"about_ca_system_score_codex":0.00009223941,"about_ca_system_score_gemma":0.000054348377,"threshold_uncertainty_score":0.39587024},"labels":[],"label_agreement":null},{"id":"W1970984074","doi":"10.1016/j.eururo.2014.11.002","title":"Steroids in Prostate Cancer: The Jury Is Still Out... and Even More Confused","year":2014,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Jury; Prostate cancer; Prostate; Cancer; Gynecology; Prostate disease; General surgery; Oncology; Internal medicine; Law","score_opus":0.03192176005783713,"score_gpt":0.3097317675125048,"score_spread":0.27781000745466766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970984074","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030059334,0.005004298,0.0000023625607,0.95420825,0.00037385066,0.001044888,0.000120843535,0.000052023126,0.009134168],"genre_scores_gemma":[0.056220517,0.0027737028,0.000009557418,0.9006866,0.0020712325,0.00008831923,0.00027737,0.0001473556,0.03772531],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99752706,0.0006564837,0.00032151197,0.00060437486,0.00027259573,0.0006179562],"domain_scores_gemma":[0.9989684,0.00016860898,0.00012915634,0.0005619802,0.00008080317,0.00009104831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040777703,0.0003418654,0.0005496779,0.00018267875,0.000061398074,0.000033488035,0.0002563963,0.0002085075,0.00015888781],"category_scores_gemma":[0.000039032293,0.00020705035,0.00007554318,0.00009544573,0.00051163696,0.00002692267,0.00019085819,0.001959783,0.00018110045],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039370515,0.000024204768,0.0074856114,0.00018274099,0.0001708275,0.0027386213,0.0028841975,0.0000011068934,0.00007409143,0.0000018446996,0.97978586,0.0062571648],"study_design_scores_gemma":[0.0028911037,0.0006107397,0.014774554,0.000060686176,0.00013953818,0.00010597951,0.000021826692,0.000023680392,0.000026377633,0.000019151803,0.9811428,0.00018354548],"about_ca_topic_score_codex":0.00009016632,"about_ca_topic_score_gemma":0.000025507532,"teacher_disagreement_score":0.053521596,"about_ca_system_score_codex":0.00007708673,"about_ca_system_score_gemma":0.00015243416,"threshold_uncertainty_score":0.8514391},"labels":[],"label_agreement":null},{"id":"W1971081363","doi":"10.1038/sj.bjc.6603924","title":"FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome","year":2007,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":293,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Canadian Prostate Cancer Research Initiative; Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"PTEN; Prostate cancer; Biology; Prostate; Fluorescence in situ hybridization; Cancer research; Tissue microarray; Oncology; Pathology; Internal medicine; Medicine; Cancer; Gene; Genetics; Chromosome; PI3K/AKT/mTOR pathway","score_opus":0.057729583069028256,"score_gpt":0.39167460119885167,"score_spread":0.3339450181298234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971081363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99208343,0.0056350026,0.000101290316,0.0010202118,0.00020178569,0.00030705731,0.00027548464,0.000010701348,0.00036504163],"genre_scores_gemma":[0.98826855,0.008156177,0.00015587178,0.0010747443,0.00020678274,0.000008025587,0.0000406202,0.000029653644,0.0020595714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749374,0.000076845085,0.00097438274,0.00022564482,0.0008168223,0.000412539],"domain_scores_gemma":[0.99771005,0.00013300162,0.0008497431,0.00013332957,0.00087050465,0.00030338162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015120046,0.00015142803,0.0009518309,0.0003596366,0.000071599265,0.000038775608,0.0001402531,0.0001320984,0.00058086234],"category_scores_gemma":[0.00011653051,0.00012515965,0.00046215646,0.00073119695,0.00020699223,0.00014941407,0.000025113704,0.00048838335,0.0000010449143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024481954,0.00017494686,0.9143792,0.000041937652,0.0064660497,0.0012459172,0.0001973832,0.00009809943,0.0004390947,4.976055e-7,0.002790783,0.07171792],"study_design_scores_gemma":[0.006076936,0.00068822765,0.9830193,0.00060001935,0.003659898,0.00018399995,0.00019458187,0.00015306061,0.0016541724,0.0000057463494,0.0036154024,0.00014866609],"about_ca_topic_score_codex":0.001817428,"about_ca_topic_score_gemma":0.012681916,"teacher_disagreement_score":0.07156925,"about_ca_system_score_codex":0.0009795842,"about_ca_system_score_gemma":0.0007094051,"threshold_uncertainty_score":0.7076807},"labels":[],"label_agreement":null},{"id":"W1971122592","doi":"10.5489/cuaj.12058","title":"Canadian Consensus Conference: The FDA decision on the use of 5ARIs","year":2012,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Queen's University; University of British Columbia; University of Toronto; University Health Network; Université Laval; University of Alberta; Western University; Sunnybrook Health Science Centre","funders":"","keywords":"Dutasteride; Medicine; Prostate cancer; Finasteride; Prostate; Cancer; Urology; Oncology; Internal medicine; Gynecology","score_opus":0.09326528830489315,"score_gpt":0.3037858315857027,"score_spread":0.21052054328080955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971122592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83252555,0.00027873387,0.0000059265417,0.16395287,0.00031059264,0.00026745448,0.00007501146,0.000004912765,0.0025789402],"genre_scores_gemma":[0.99138224,0.00012858347,0.000045852536,0.0068127695,0.00025365863,0.0000068144145,0.000009091619,0.000006617601,0.0013543664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843484,0.0002494179,0.0002228773,0.00008523063,0.00041298958,0.00059465057],"domain_scores_gemma":[0.9972947,0.0010441697,0.00013814666,0.00014670631,0.0003654589,0.0010108068],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001013882,0.00009566144,0.00016414159,0.00013703886,0.0004650396,0.00008064424,0.00012576998,0.00016780714,0.0014015714],"category_scores_gemma":[0.0020563887,0.000043215634,0.00009690136,0.00020164587,0.00008207466,0.000045441873,0.000009698413,0.0006616942,0.00007467721],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011310005,0.000035784473,0.826488,0.0000013198147,0.00014219081,0.00004586505,0.00032819057,0.000017412402,0.00003461683,0.0016033363,0.16433585,0.00685432],"study_design_scores_gemma":[0.00054430316,0.00021823257,0.6775481,0.000018418066,0.000053820833,0.00008561528,0.00017568421,0.000106685184,0.000048033737,0.0004785483,0.32066023,0.00006230308],"about_ca_topic_score_codex":0.08925222,"about_ca_topic_score_gemma":0.09403449,"teacher_disagreement_score":0.15885669,"about_ca_system_score_codex":0.0016373787,"about_ca_system_score_gemma":0.001723217,"threshold_uncertainty_score":0.9995113},"labels":[],"label_agreement":null},{"id":"W1971305282","doi":"10.1016/j.ijrobp.2012.07.019","title":"Radium-223 Chloride Safety and Use of External Beam Radiation Therapy (EBRT) in the Phase III Randomized Trial (ALSYMPCA) in Patients With Castration-resistant Prostate Cancer (CRPC) and Bone Metastases","year":2012,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Canadian Cancer Society Research Institute; National Cancer Institute; Brain Tumor Funders' Collaborative; Bayer HealthCare; Research Councils UK; Cedars-Sinai Medical Center; Royal Marsden NHS Foundation Trust","keywords":"Prostate cancer; Medicine; External beam radiation; Oncology; Randomized controlled trial; Radiation therapy; External beam radiotherapy; Urology; Internal medicine; Nuclear medicine; Radiology; Cancer","score_opus":0.030092383488882355,"score_gpt":0.35842010747781666,"score_spread":0.3283277239889343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971305282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928808,0.0038691747,0.00027425835,0.00095771294,0.00041082516,0.001453004,0.00013706429,0.000004604134,0.000012536069],"genre_scores_gemma":[0.9878758,0.010812988,0.0003185458,0.00020336184,0.00054306374,0.00007245178,0.0001440809,0.000014635476,0.000015071152],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99782836,0.0004850811,0.0009008834,0.00016487892,0.00038969275,0.00023108853],"domain_scores_gemma":[0.9975819,0.0008584474,0.0009796316,0.00009424911,0.00038662378,0.00009912692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014489078,0.00018333038,0.0007430654,0.00025085566,0.000053133994,0.000031921354,0.000105878826,0.00009833497,0.000018567544],"category_scores_gemma":[0.00022860202,0.000109026856,0.00009842805,0.00019471439,0.00030215768,0.0005727967,0.000020446616,0.00030837857,3.315623e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63369733,0.0016913175,0.3019298,0.000010488333,0.00043750374,0.000015731977,0.0019370831,0.00008434149,0.0012983799,0.0004948749,0.00003140588,0.05837174],"study_design_scores_gemma":[0.83245003,0.002690064,0.16004325,0.00009709444,0.0001875875,0.000028393977,0.000104115,0.00026086494,0.0024449935,0.00028182485,0.0012874245,0.00012432842],"about_ca_topic_score_codex":0.00022552136,"about_ca_topic_score_gemma":0.000023578516,"teacher_disagreement_score":0.19875273,"about_ca_system_score_codex":0.000403213,"about_ca_system_score_gemma":0.00040121662,"threshold_uncertainty_score":0.44459862},"labels":[],"label_agreement":null},{"id":"W1971715644","doi":"10.1158/0008-5472.can-06-2616","title":"Androgen-Independent Growth and Tumorigenesis of Prostate Cancer Cells Are Enhanced by the Presence of PKA-Differentiated Neuroendocrine Cells","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"U.S. Public Health Service; McKnight Foundation; National Cancer Institute; Sanofi; U.S. Department of Health and Human Services","keywords":"LNCaP; Prostate cancer; Neuroendocrine differentiation; Paracrine signalling; Cancer research; Androgen; Prostate; Biology; Internal medicine; Endocrinology; Tumor progression; Carcinogenesis; Cancer; Medicine; Receptor; Hormone","score_opus":0.03592840544183467,"score_gpt":0.35957330584924974,"score_spread":0.32364490040741506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971715644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841622,0.012152881,0.000021059153,0.0011172632,0.00019248897,0.001775065,0.00031414928,0.000021911628,0.0002429998],"genre_scores_gemma":[0.9696839,0.026543379,0.000015908663,0.000037438276,0.00009161856,0.00028602406,0.000017236913,0.000048092792,0.00327642],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962446,0.00022129546,0.0005018414,0.00057378097,0.0014793732,0.0009791265],"domain_scores_gemma":[0.99764985,0.0003966946,0.00020277147,0.0004964385,0.00090983475,0.00034442535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073540414,0.00024979803,0.0005268224,0.00029089465,0.00019599909,0.00003088453,0.00035406052,0.000063131694,0.00025487752],"category_scores_gemma":[0.00008062225,0.00016047055,0.000098196884,0.00097142434,0.00084826007,0.000093775336,0.0002669867,0.0005729895,0.0000039667057],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002334846,0.00028110974,0.030365402,0.000992994,0.00019789583,0.00008424285,0.0006085762,0.0000064490378,0.95881784,0.00001235376,0.0024569144,0.0038413878],"study_design_scores_gemma":[0.002594705,0.00047584093,0.017392041,0.00036193285,0.00006716338,0.0000074611694,0.0006013246,0.000020771466,0.97789884,0.000035486442,0.00041328478,0.00013117652],"about_ca_topic_score_codex":0.002836023,"about_ca_topic_score_gemma":0.00032145853,"teacher_disagreement_score":0.019080983,"about_ca_system_score_codex":0.0001926124,"about_ca_system_score_gemma":0.0004887727,"threshold_uncertainty_score":0.6543799},"labels":[],"label_agreement":null},{"id":"W1971773966","doi":"10.1038/sj.onc.1209663","title":"Enhanced metastatic dissemination to multiple organs by melanoma and lymphoma cells in timp-3−/− mice","year":2006,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Tech University; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research","keywords":"Biology; Cancer research; Lymphoma; Melanoma; Metastatic melanoma; Immunology","score_opus":0.008842573541314893,"score_gpt":0.2910057231465889,"score_spread":0.282163149605274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971773966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595493,0.0011054649,0.00038670262,0.0007184978,0.000038198123,0.00047813312,0.000061092076,0.00001955253,0.0012374069],"genre_scores_gemma":[0.9899737,0.0001422805,0.0012053857,0.00009594712,0.000038015973,0.000059192324,0.00016725098,0.000018941892,0.008299258],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991933,0.000026375863,0.00015487843,0.0002255715,0.00017268992,0.00022717011],"domain_scores_gemma":[0.9996249,0.000083956256,0.000026703852,0.000111252404,0.000046673027,0.00010648203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098285505,0.00010809216,0.00018712375,0.00010586093,0.000035348738,0.000015029728,0.00003981844,0.000035583274,0.00006220854],"category_scores_gemma":[0.00002730763,0.000087849454,0.000021466141,0.00025278257,0.000027374612,0.000045271056,0.00002434976,0.000036038717,0.00005041912],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017949031,0.0002514693,0.0025249238,0.000039148654,0.000018651355,0.00004804056,0.00026245794,0.000002685113,0.96814567,0.0000033513086,0.0031668365,0.025357304],"study_design_scores_gemma":[0.0027592045,0.00025604424,0.010678582,0.00006103355,0.00003406333,0.000009663009,0.0001230066,0.00019947848,0.98267365,0.000015960672,0.00308922,0.000100080026],"about_ca_topic_score_codex":0.0003831595,"about_ca_topic_score_gemma":0.00025385537,"teacher_disagreement_score":0.025257224,"about_ca_system_score_codex":0.00018104239,"about_ca_system_score_gemma":0.000055022698,"threshold_uncertainty_score":0.35823968},"labels":[],"label_agreement":null},{"id":"W1971893249","doi":"10.3747/co.22.2219","title":"Adherence to Abiraterone among the First 86 Recipients after Release in Saskatchewan","year":2015,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Saskatchewan; Ontario Drug Policy Research Network","funders":"College of Pharmacy and Nutrition, University of Saskatchewan; Pfizer Canada; AstraZeneca Canada; Merck Canada; Saskatchewan Cancer Agency; University of Saskatchewan","keywords":"Abiraterone; Medicine; Abiraterone acetate; Docetaxel; Prostate cancer; Pharmacy; Internal medicine; Cancer; Oncology; Family medicine; Androgen deprivation therapy","score_opus":0.13614631485153011,"score_gpt":0.42215032035404426,"score_spread":0.28600400550251415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971893249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99176013,0.0017628942,0.000011519877,0.003503115,0.0009905702,0.00081881875,0.000007764166,0.000023508695,0.0011216899],"genre_scores_gemma":[0.99695784,0.00010099238,0.0000451795,0.00034297208,0.00020188674,0.0005512747,0.000018991825,0.000013886514,0.0017669883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998758,0.00008917353,0.00022440951,0.00028489454,0.00025196618,0.00039153648],"domain_scores_gemma":[0.99914634,0.000055804747,0.00004199248,0.00029632778,0.00012768968,0.00033186408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033664177,0.00013057188,0.00024974789,0.000110315275,0.00003912232,0.000013659971,0.00014439071,0.00008326033,0.00012861814],"category_scores_gemma":[0.0001096135,0.00007927633,0.000042016574,0.0002996946,0.00015832386,0.000057198104,0.00013021936,0.0003216136,0.0003469089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021202,0.00069028814,0.8950835,0.000040768267,0.000020645966,0.00021618916,0.00687894,0.000003837047,0.000041034386,0.0000041569365,0.01878523,0.07611519],"study_design_scores_gemma":[0.0064632413,0.0032053608,0.75028354,0.0003381501,0.000045944515,0.0000168506,0.0021122445,0.000054901247,0.00048776262,0.00012014215,0.23670073,0.00017113074],"about_ca_topic_score_codex":0.000286301,"about_ca_topic_score_gemma":0.0046601095,"teacher_disagreement_score":0.21791549,"about_ca_system_score_codex":0.00069527974,"about_ca_system_score_gemma":0.0005605285,"threshold_uncertainty_score":0.44589275},"labels":[],"label_agreement":null},{"id":"W1972246509","doi":"10.1016/j.jsbmb.2008.04.009","title":"An investigation into CAG repeat length variation and N/C terminal interactions in the T877A mutant androgen receptor found in prostate cancer","year":2008,"lang":"en","type":"article","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; John Abbott College; Biotechnology Research Institute; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Jewish General Hospital","keywords":"Coactivator; Androgen receptor; Transactivation; Prostate cancer; Mutation; Mutant; Biology; Cancer research; Cancer; Chemistry; Genetics; Endocrinology; Gene; Gene expression","score_opus":0.019408626968223645,"score_gpt":0.3291211271541078,"score_spread":0.30971250018588414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972246509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943901,0.002677839,0.000019755993,0.0026939753,0.00003285671,0.00016868178,0.000004478848,0.0000017332302,0.000010628742],"genre_scores_gemma":[0.997131,0.0024249696,0.000105802115,0.0002168331,0.000060439117,0.000011035104,0.000016097312,0.000004495858,0.000029344828],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99932563,0.00016078017,0.00021617419,0.00010517834,0.00007985418,0.0001123828],"domain_scores_gemma":[0.999616,0.00003950417,0.00011320909,0.000102727085,0.00007298091,0.000055527573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039109215,0.00008154237,0.00013253259,0.000059529102,0.000076803095,0.00001008713,0.00006585308,0.00004262398,0.000004334172],"category_scores_gemma":[0.000033037508,0.00004343578,0.000017113061,0.00011300452,0.0002264925,0.000061446386,0.000019427081,0.0002366657,1.3980481e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068023574,0.00005513795,0.033097405,0.00003676465,0.00003596586,0.00010981562,0.0078088823,0.0000034429333,0.95663875,0.0000026587702,0.000012973304,0.0015179752],"study_design_scores_gemma":[0.004670313,0.0015971692,0.07309615,0.0003702191,0.00013325243,0.006543773,0.0041586435,0.00021367626,0.9081108,0.00067356334,0.00025668985,0.00017577264],"about_ca_topic_score_codex":0.00023841475,"about_ca_topic_score_gemma":0.000048809405,"teacher_disagreement_score":0.04852797,"about_ca_system_score_codex":0.000067921814,"about_ca_system_score_gemma":0.00013081392,"threshold_uncertainty_score":0.17712598},"labels":[],"label_agreement":null},{"id":"W1972416917","doi":"10.1016/j.beem.2008.01.004","title":"Maximal androgen blockade for advanced prostate cancer","year":2008,"lang":"en","type":"review","venue":"Best Practice & Research Clinical Endocrinology & Metabolism","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"Sanofi","keywords":"Bicalutamide; Prostate cancer; Androgen; Androgen receptor; Flutamide; Endocrinology; Androgen suppression; Medicine; Antiandrogen; Internal medicine; Blockade; Enzalutamide; Androgen Receptor Antagonists; Cancer research; Oncology; Cancer; Receptor; Hormone","score_opus":0.289666491860588,"score_gpt":0.583559241591117,"score_spread":0.29389274973052903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972416917","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019119962,0.97681165,0.000006106312,0.006780427,0.0014066042,0.011067174,0.0006509848,0.00015830966,0.0029275443],"genre_scores_gemma":[0.000009991604,0.9627356,0.0028732163,0.00030028058,0.003353399,0.010745529,0.0005355218,0.00031612974,0.019130317],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98541147,0.0037337083,0.0027069657,0.0025524688,0.001973911,0.0036215],"domain_scores_gemma":[0.9809257,0.01192806,0.000974513,0.0018557996,0.0029834867,0.0013324445],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033592712,0.0010982469,0.005749507,0.0011151866,0.00082610955,0.00012457641,0.0011107473,0.0012607028,0.00030494595],"category_scores_gemma":[0.017910298,0.00079753215,0.0021094286,0.0014906729,0.0025267235,0.00056887325,0.0009757468,0.0073353006,0.0008421276],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00417442,0.002874048,0.000053442305,0.0048827427,0.003154031,0.0028528299,0.0000697471,2.789608e-7,0.000005228276,0.00040068463,0.009205398,0.9723272],"study_design_scores_gemma":[0.008686437,0.0026088492,0.000018516439,0.0032794164,0.004048095,0.00265435,0.00015190091,0.0000041307007,0.000036945134,0.00012862933,0.9777702,0.0006125114],"about_ca_topic_score_codex":0.00035699538,"about_ca_topic_score_gemma":0.00003054142,"teacher_disagreement_score":0.9717146,"about_ca_system_score_codex":0.00055734173,"about_ca_system_score_gemma":0.009712294,"threshold_uncertainty_score":0.9999358},"labels":[],"label_agreement":null},{"id":"W1972453208","doi":"10.1016/j.ejca.2007.06.006","title":"PSA and other tissue kallikreins for prostate cancer detection","year":2007,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Berliner Sparkassenstiftung Medizin; Deutsche Krebshilfe; Deutsche Forschungsgemeinschaft","keywords":"Prostate cancer; Medicine; Cancer; Kallikrein; Oncology; Internal medicine; Biology; Biochemistry","score_opus":0.10554676152379036,"score_gpt":0.4453220908145876,"score_spread":0.33977532929079723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972453208","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007880909,0.9962655,0.00022571278,0.00020760213,0.0005694632,0.0011164125,0.000115439914,0.000013567562,0.0014075399],"genre_scores_gemma":[0.000069905036,0.98662555,0.0002220268,0.00015319292,0.002214985,0.00005128117,0.0000058947685,0.00014866499,0.010508479],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981773,0.00016380892,0.00070297875,0.00024690432,0.00035828864,0.00035074263],"domain_scores_gemma":[0.99845576,0.00007616251,0.000664699,0.00015720386,0.00037300415,0.00027316966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009096974,0.0003160504,0.0010877068,0.0003299829,0.000084355604,0.00004589386,0.00012691689,0.000077186414,0.000156477],"category_scores_gemma":[0.000040274936,0.00019753014,0.00030898093,0.00021465242,0.00009968407,0.00006959946,0.00003367358,0.0005292337,0.00001157674],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039305372,0.000033863158,0.000040706374,0.0068206335,0.00066059845,0.00026561093,0.0001497087,9.20328e-7,0.00004140488,0.0000018739142,0.0016350314,0.9899566],"study_design_scores_gemma":[0.0018894037,0.00094781315,0.000056722256,0.014406815,0.0015978429,0.00029197632,0.000016138556,0.0000013437942,0.00020841238,0.0000036647534,0.9803955,0.00018439683],"about_ca_topic_score_codex":0.000032561304,"about_ca_topic_score_gemma":0.00004614197,"teacher_disagreement_score":0.9897722,"about_ca_system_score_codex":0.00039305977,"about_ca_system_score_gemma":0.0005893235,"threshold_uncertainty_score":0.80550456},"labels":[],"label_agreement":null},{"id":"W1972662858","doi":"10.1016/j.niox.2007.09.031","title":"A26. A phase I/II pilot trial of low-dose, sustained-release GTN for prostate cancer patients with recurrence after primary therapy","year":2007,"lang":"en","type":"article","venue":"Nitric Oxide","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Prostate cancer; Medicine; Oncology; Internal medicine; Cancer; Urology","score_opus":0.02074942606553895,"score_gpt":0.3302584797711352,"score_spread":0.3095090537055962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972662858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913618,0.0023936012,0.000082916646,0.00019417726,0.00010536116,0.005344212,0.00020418785,0.0000368858,0.0002768317],"genre_scores_gemma":[0.99449253,0.00085286854,0.00037917643,0.00024953013,0.00018181694,0.00089843565,0.00019222338,0.000046207162,0.0027071845],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980412,0.000033050932,0.00040452328,0.00036409916,0.0005751538,0.0005819623],"domain_scores_gemma":[0.9984898,0.00014763288,0.00017753096,0.0002871596,0.000652905,0.00024496717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003545718,0.00024064575,0.0004181906,0.00027510413,0.0000957677,0.000012368964,0.00010337803,0.0000656738,0.000059563336],"category_scores_gemma":[0.00008671864,0.00015496131,0.000101132486,0.00060492504,0.00014211556,0.00012465923,0.000036751535,0.00019344279,0.0000024248636],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83293474,0.008396351,0.03195564,0.00050990825,0.00024162675,0.000080814905,0.0003268117,6.641922e-7,0.0031332264,0.0000043926293,0.0016301279,0.12078567],"study_design_scores_gemma":[0.78810465,0.05260538,0.12164898,0.0006574337,0.00026750585,0.0000035723897,0.00014908689,0.00002266828,0.029989798,0.00011360526,0.005920986,0.00051634107],"about_ca_topic_score_codex":0.00013613465,"about_ca_topic_score_gemma":0.000013434776,"teacher_disagreement_score":0.12026933,"about_ca_system_score_codex":0.00034686684,"about_ca_system_score_gemma":0.0007450812,"threshold_uncertainty_score":0.6319139},"labels":[],"label_agreement":null},{"id":"W1972785878","doi":"10.2217/fon.10.145","title":"Novel Targeted Agents on the Horizon for Castration-Resistant Prostate Cancer","year":2010,"lang":"en","type":"review","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Prostate cancer; Medicine; Androgen receptor; Androgen deprivation therapy; Cancer research; Testosterone (patch); Orchiectomy; Androgen; Prostate; Cancer; Oncology; Internal medicine; Bioinformatics; Hormone; Biology","score_opus":0.09929114834197945,"score_gpt":0.43647364871926125,"score_spread":0.3371825003772818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972785878","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004260023,0.9809052,0.0000040428604,0.0067508807,0.002514531,0.006299425,0.001038665,0.00003994384,0.002404714],"genre_scores_gemma":[0.000011025813,0.98047173,0.0003014391,0.00034737884,0.0035573223,0.0045341016,0.0012528597,0.00008280664,0.009441308],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815935,0.00010221828,0.00042883563,0.0005071103,0.00028767926,0.0005148206],"domain_scores_gemma":[0.9984998,0.0003548759,0.0003103962,0.00044952965,0.00021660786,0.00016878001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039100705,0.00041754925,0.0012811357,0.0001430728,0.00022811875,0.000027494041,0.00022285347,0.0007683067,0.00037994568],"category_scores_gemma":[0.00008238874,0.00020413654,0.00041422714,0.00025741983,0.00013350224,0.000024523582,0.00004058696,0.0011279882,0.00005219829],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007287523,0.0003023234,0.000002085497,0.0043367445,0.0004823449,0.00006505571,0.000114969516,9.621629e-8,0.00017806128,0.00075685553,0.04206216,0.95097053],"study_design_scores_gemma":[0.0017504161,0.0022284375,0.000024519848,0.001942849,0.00096600625,0.000040589075,0.000054523145,0.0000020602133,0.000034156183,0.000021817323,0.9927471,0.00018748388],"about_ca_topic_score_codex":0.000043527605,"about_ca_topic_score_gemma":0.00030737635,"teacher_disagreement_score":0.9507831,"about_ca_system_score_codex":0.0007556236,"about_ca_system_score_gemma":0.0030415715,"threshold_uncertainty_score":0.8324446},"labels":[],"label_agreement":null},{"id":"W1972912578","doi":"10.1016/s1470-2045(13)70184-0","title":"Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":287,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Aflibercept; Docetaxel; Medicine; Prednisone; Prostate cancer; Placebo; Clinical endpoint; Internal medicine; Oncology; Chemotherapy; Surgery; Cancer; Bevacizumab; Urology; Randomized controlled trial; Pathology","score_opus":0.12222259731709838,"score_gpt":0.4218269267105545,"score_spread":0.2996043293934561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972912578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97867167,0.0006958747,0.000023544546,0.0055069095,0.00004525828,0.014039671,0.00005144671,0.000014666862,0.00095096877],"genre_scores_gemma":[0.98710364,0.0007758833,0.00080375455,0.00002775521,0.00009548404,0.009780367,0.00010774759,0.000021131438,0.0012842283],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99885935,0.0001405895,0.00028156012,0.00023006026,0.00018355211,0.000304914],"domain_scores_gemma":[0.9989219,0.00046958323,0.00018975213,0.00018913075,0.00015199464,0.00007769747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033376465,0.0001676648,0.0007250297,0.000088447596,0.00007044489,0.00002054704,0.000056924848,0.000048502385,0.00005683813],"category_scores_gemma":[0.000015636986,0.00008154004,0.000037602553,0.00016152942,0.00023000565,0.00009155652,0.00000952307,0.000070775364,0.0000012763094],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9840288,0.0016513892,0.00015531937,0.00012621701,0.00063236157,0.000022133461,0.0032602213,0.00003301264,0.0022867604,0.00009742087,0.00019348347,0.007512861],"study_design_scores_gemma":[0.95448893,0.03908378,0.00045390287,0.000062135194,0.00059352536,0.000010995775,0.00087828166,0.0006176771,0.002879546,0.00008146839,0.00075937307,0.000090353824],"about_ca_topic_score_codex":0.0008561152,"about_ca_topic_score_gemma":0.0014878552,"teacher_disagreement_score":0.03743239,"about_ca_system_score_codex":0.00035504275,"about_ca_system_score_gemma":0.0006097909,"threshold_uncertainty_score":0.33251065},"labels":[],"label_agreement":null},{"id":"W1973121454","doi":"10.1021/pr401106h","title":"Metabolomic Profiling Identifies Biochemical Pathways Associated with Castration-Resistant Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Proteome Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Cancer Institute","keywords":"Prostate cancer; Metabolomics; In silico; Computational biology; Biological pathway; Metabolic pathway; Biology; Cancer research; Cancer; Bioinformatics; Gene; Medicine; Gene expression; Genetics","score_opus":0.08383057731042572,"score_gpt":0.3788156664233696,"score_spread":0.2949850891129439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973121454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99017787,0.004197116,0.000009548323,0.003077592,0.000060155086,0.0021784515,0.00002077015,0.000017585488,0.000260936],"genre_scores_gemma":[0.99468535,0.00069741684,0.0008153657,0.000016610453,0.00023232175,0.00044013115,0.00001741784,0.000036945286,0.0030584307],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99638134,0.0002574539,0.00055053015,0.00025085395,0.0018573914,0.00070241926],"domain_scores_gemma":[0.9956578,0.00017207199,0.00025833288,0.00021330541,0.0033207573,0.00037773163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020198263,0.00017403271,0.00045612396,0.0005235286,0.0002171698,0.00019496096,0.00020482985,0.000118643795,0.0003314871],"category_scores_gemma":[0.00060411624,0.000101916674,0.00012027022,0.0008034959,0.00034752683,0.00039407593,0.0000687947,0.0011449466,0.000037034664],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017972358,0.00030873835,0.008195953,0.00020958594,0.0004773129,0.0003092155,0.00038968824,0.000004511053,0.9855812,0.000025336578,0.0019570168,0.0007442064],"study_design_scores_gemma":[0.0050852336,0.0024590455,0.050930094,0.0011376598,0.00011591527,0.00012836528,0.0014213615,0.00012618968,0.93739635,0.000839601,0.00017089647,0.00018927359],"about_ca_topic_score_codex":0.00018336053,"about_ca_topic_score_gemma":0.000014742331,"teacher_disagreement_score":0.048184834,"about_ca_system_score_codex":0.00058774865,"about_ca_system_score_gemma":0.0019730679,"threshold_uncertainty_score":0.49742866},"labels":[],"label_agreement":null},{"id":"W1973206059","doi":"10.1136/jcp.2006.043810","title":"Frequency of the <i>TMPRSS2:ERG</i> gene fusion is increased in moderate to poorly differentiated prostate cancers","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health; Vancouver General Hospital; University of British Columbia; Provincial Health Services Authority; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Sanofi","keywords":"TMPRSS2; Erg; Fusion gene; Oncogene Proteins; Prostate cancer; Prostate; Cancer research; Medicine; Oncology; Gene; Bioinformatics; Internal medicine; Biology; Genetics; Regulation of gene expression; Cancer; Coronavirus disease 2019 (COVID-19); Ophthalmology; Disease","score_opus":0.05842878232319803,"score_gpt":0.41397534680101544,"score_spread":0.3555465644778174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973206059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939319,0.0006140066,0.00013168056,0.0039583026,0.0006218376,0.00040399894,0.00002000757,0.0000047211915,0.00031353912],"genre_scores_gemma":[0.9965127,0.0006783701,0.0006875291,0.0016142986,0.00019319388,0.0000037052807,0.0000037015343,0.000016238497,0.0002902375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971436,0.00031062594,0.0015633211,0.00020631419,0.00042000326,0.00035608208],"domain_scores_gemma":[0.9980865,0.00031765964,0.0005947209,0.00026503496,0.00044211568,0.000293933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023282971,0.00013849973,0.00076375686,0.00021468331,0.000041218053,0.000006093329,0.0001998981,0.00019804353,0.000063957625],"category_scores_gemma":[0.0006802389,0.0000768493,0.000279463,0.0003870035,0.00020278408,0.00005410602,0.000078429,0.0007362328,0.0000048153593],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008156292,0.0007033965,0.80192566,0.000053960353,0.00012752456,0.0015854405,0.00067316234,0.000026977961,0.1758053,0.0000150620845,0.00075176364,0.010175441],"study_design_scores_gemma":[0.008209567,0.0019249459,0.9510242,0.00026286583,0.00010022918,0.00018567068,0.00007508204,0.0000641337,0.037259314,0.00063589675,0.00016921849,0.00008887564],"about_ca_topic_score_codex":0.00020428319,"about_ca_topic_score_gemma":0.00018293381,"teacher_disagreement_score":0.14909852,"about_ca_system_score_codex":0.00016229459,"about_ca_system_score_gemma":0.0007413047,"threshold_uncertainty_score":0.3198606},"labels":[],"label_agreement":null},{"id":"W1973474832","doi":"10.1038/sj.onc.1209715","title":"Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells","year":2006,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Michael Smith Health Research BC","keywords":"Biology; Androgen receptor; Prostate cancer; Signal transduction; Androgen; Cancer research; Protein kinase A; Cancer; Kinase; Cell biology; Endocrinology; Genetics; Hormone","score_opus":0.01792900272298074,"score_gpt":0.2846694554537093,"score_spread":0.26674045273072855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973474832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.966282,0.03264285,0.000011715312,0.00034820405,0.000045830428,0.00045338247,0.00010889996,0.000009421601,0.00009768968],"genre_scores_gemma":[0.9959062,0.0026003444,0.000046059035,0.000025652911,0.0000629264,0.00008156488,0.00007334436,0.000012196472,0.0011917206],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99926615,0.000032489224,0.00021518118,0.0001577134,0.00016975228,0.00015871467],"domain_scores_gemma":[0.999682,0.000024658226,0.00007238505,0.000118215845,0.00006842418,0.000034300418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019453476,0.00007709203,0.00013942466,0.000051222214,0.000046408757,0.000012075294,0.00004236414,0.0000317715,0.000027334525],"category_scores_gemma":[0.000004149085,0.00004896137,0.000025265528,0.00017938261,0.00007570061,0.00003501934,0.000018342675,0.000056862802,0.0000024770493],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010835279,0.000077414246,0.02617155,0.00005770277,0.000023799232,0.000008675357,0.00022211051,0.000043529744,0.96144533,0.0000055958226,0.0005907177,0.01124519],"study_design_scores_gemma":[0.0011532529,0.00006344426,0.0028076079,0.000038517424,0.000032805296,0.0000036213844,0.000114522896,0.00027729428,0.9937468,0.00007112683,0.0016383941,0.000052587184],"about_ca_topic_score_codex":0.0007070361,"about_ca_topic_score_gemma":0.00008074879,"teacher_disagreement_score":0.032301463,"about_ca_system_score_codex":0.0000631105,"about_ca_system_score_gemma":0.00009256071,"threshold_uncertainty_score":0.19965868},"labels":[],"label_agreement":null},{"id":"W1973572075","doi":"10.5489/cuaj.2332","title":"Effect of dutasteride in men receiving intermittent androgen ablation therapy: The AVIAS trial","year":2014,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Centre Hospitalier Universitaire de Sherbrooke; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Dutasteride; Medicine; Urology; Prostate cancer; Placebo; Dihydrotestosterone; Androgen deprivation therapy; Testosterone (patch); Regimen; Prostate; Prostate-specific antigen; Antiandrogen; Randomized controlled trial; Internal medicine; Androgen; Cancer; Hormone","score_opus":0.018082524013127974,"score_gpt":0.28617794026681953,"score_spread":0.26809541625369154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973572075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98639643,0.00020222462,0.000009332779,0.010938537,0.0001529518,0.00044871302,0.0000035179753,0.000004919504,0.0018433994],"genre_scores_gemma":[0.99885345,0.0001379869,0.0000059217464,0.00041454827,0.0002847793,0.000017958002,0.00000865945,0.0000059440977,0.0002707794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984257,0.00067902025,0.00026501965,0.00009838936,0.00026225028,0.0002695751],"domain_scores_gemma":[0.999042,0.00043382516,0.00017047682,0.00007622073,0.0000855656,0.00019192649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025679553,0.00008040708,0.0002266538,0.00012870328,0.00010167804,0.000035635123,0.00008321561,0.00010794448,0.0001742629],"category_scores_gemma":[0.0008388422,0.000042397278,0.00009460045,0.00014935253,0.000027288455,0.000048927126,0.00000927835,0.00035822272,0.0000081198505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009583482,0.000044578806,0.8951079,0.0000072635494,0.00012471041,0.000027407024,0.00034671574,0.000023349814,0.00040813605,0.000017442513,0.0013957646,0.09291323],"study_design_scores_gemma":[0.046574313,0.0062048673,0.9323318,0.000051919258,0.00005923873,0.000060944345,0.000055559027,0.0008330135,0.0010031592,0.00035222882,0.01237039,0.00010259466],"about_ca_topic_score_codex":0.0005451151,"about_ca_topic_score_gemma":0.00028046715,"teacher_disagreement_score":0.09281064,"about_ca_system_score_codex":0.0006523504,"about_ca_system_score_gemma":0.00017151792,"threshold_uncertainty_score":0.19080566},"labels":[],"label_agreement":null},{"id":"W1973631130","doi":"10.1593/tlo.10295","title":"Molecular Validation of PACE4 as a Target in Prostate Cancer","year":2011,"lang":"en","type":"article","venue":"Translational Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Centre National de la Recherche Scientifique; Agence Nationale de la Recherche","keywords":"DU145; Prostate cancer; Prostate; Cancer research; Cancer; Medicine; CD44; PCA3; MUC1; LNCaP; Internal medicine; Biology; Cell; Genetics","score_opus":0.054687397295609855,"score_gpt":0.3812521450745108,"score_spread":0.32656474777890093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973631130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767211,0.0009741562,0.000079113815,0.0026093347,0.000046749756,0.00047501936,0.00002000347,0.000010482,0.019064024],"genre_scores_gemma":[0.9975861,0.00013198536,0.0016360163,0.00010922555,0.00001620232,0.0000967782,0.000074321244,0.000008823958,0.0003405802],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99934506,0.000047806763,0.00018393538,0.00012362604,0.00016196359,0.00013761008],"domain_scores_gemma":[0.999721,0.000030216492,0.000042612315,0.000062921456,0.00009284169,0.000050431216],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012609315,0.00006240703,0.00017486513,0.00012256904,0.000011596518,9.4063216e-7,0.000030481906,0.00005895587,0.0009214122],"category_scores_gemma":[0.000009297565,0.000051508272,0.000040512186,0.00016481902,0.000075410804,0.000046884492,0.000004422571,0.00009480446,0.000013813244],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010365061,0.001954373,0.8322652,0.00028592214,0.00035948883,0.00071458856,0.014698804,0.0006118785,0.104593,0.011079206,0.000196199,0.022876278],"study_design_scores_gemma":[0.014803718,0.0025297655,0.4295411,0.00014723247,0.00013553182,0.00004319248,0.00022826892,0.00044749625,0.5206993,0.023395348,0.007814865,0.00021414137],"about_ca_topic_score_codex":0.00025662116,"about_ca_topic_score_gemma":0.000037892125,"teacher_disagreement_score":0.41610634,"about_ca_system_score_codex":0.00007920722,"about_ca_system_score_gemma":0.0005867776,"threshold_uncertainty_score":0.9999919},"labels":[],"label_agreement":null},{"id":"W1973672078","doi":"10.3747/co.21.1865","title":"Health Care Costs for Prostate Cancer Patients Receiving Androgen Deprivation Therapy: Treatment and Adverse Events","year":2014,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Toronto General Hospital","funders":"","keywords":"Medicine; Adverse effect; Androgen deprivation therapy; Prostate cancer; Myocardial infarction; Heart failure; Deep vein; Stroke (engine); Pulmonary embolism; Adverse Event Reporting System; Diabetes mellitus; Internal medicine; Osteoporosis; Cancer; Thrombosis; Endocrinology","score_opus":0.07655683291482773,"score_gpt":0.43852148738393143,"score_spread":0.3619646544691037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973672078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841341,0.010531397,0.00003545985,0.0018279558,0.0005303139,0.0027059454,0.000081603896,0.00003125524,0.00012201626],"genre_scores_gemma":[0.9851199,0.012680677,0.0001479805,0.00016120031,0.00016420255,0.0009390435,0.00062305795,0.00002273945,0.00014122938],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989641,0.00010294562,0.00019889722,0.00030417825,0.0001156755,0.000314225],"domain_scores_gemma":[0.9993074,0.00007374983,0.00011488502,0.00012544378,0.00019965728,0.00017887352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001275335,0.00014878844,0.00032098516,0.00008364417,0.00014730585,0.0000039289507,0.000035967023,0.000059489714,0.000009524914],"category_scores_gemma":[0.00003529864,0.000105857696,0.00005429939,0.00007850382,0.000044201697,0.000054321605,0.000024061384,0.000074579446,0.0000033418305],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063850626,0.00032411038,0.43389207,0.00009617585,0.0000463506,2.9092482e-7,0.001275172,5.9669543e-7,0.000021248505,0.0000076037986,0.00031278929,0.56338507],"study_design_scores_gemma":[0.03900296,0.014301831,0.5533846,0.00036655267,0.00010460362,0.000004132224,0.0004260545,0.00021961406,0.0012314657,0.00009357503,0.3906233,0.00024127573],"about_ca_topic_score_codex":0.00009595872,"about_ca_topic_score_gemma":0.00019912893,"teacher_disagreement_score":0.5631438,"about_ca_system_score_codex":0.0017021775,"about_ca_system_score_gemma":0.00039995255,"threshold_uncertainty_score":0.44511348},"labels":[],"label_agreement":null},{"id":"W1973760749","doi":"10.1158/1535-7163.targ-13-b129","title":"Abstract B129: Clinical implications of inter- and intra- prostatic heterogeneity.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; BC Cancer Agency; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Prostate cancer; Prostate; Genetic heterogeneity; Genome instability; Biology; SNP; Single-nucleotide polymorphism; Biochemical recurrence; Oncology; Medicine; Internal medicine; Cancer; Gene; Genetics; Prostatectomy; Genotype; DNA; Phenotype","score_opus":0.0746681729146952,"score_gpt":0.4133804645949236,"score_spread":0.33871229168022843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973760749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843853,0.0055565783,0.00062136125,0.008046162,0.000064297616,0.00083405233,0.000022301298,0.000023303872,0.00044666036],"genre_scores_gemma":[0.9949734,0.0026636396,0.000560555,0.0014185318,0.000035090983,0.00018724958,0.0000169008,0.000025405428,0.00011922127],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99906635,0.00003589896,0.0003211333,0.0002231425,0.00013797428,0.0002154937],"domain_scores_gemma":[0.99924403,0.00004594334,0.000085385036,0.00030263443,0.00018655512,0.00013547335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010600701,0.00012339614,0.0002515295,0.00005732684,0.00003508697,0.000021401627,0.00007914894,0.0000805591,0.00010847324],"category_scores_gemma":[0.000009753643,0.00009333188,0.00009039451,0.00011989222,0.00022910537,0.00004538189,0.000039453098,0.00017843381,0.000012689576],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019001232,0.00047376382,0.26847753,0.0003138559,0.0010000234,0.00001724429,0.00029865702,0.0000028402544,0.34874007,0.00026312866,0.0002892136,0.37993369],"study_design_scores_gemma":[0.003895365,0.0009102526,0.78476846,0.00025286785,0.00042720998,0.00002795113,0.00011171093,0.0002538075,0.20102873,0.0025557193,0.005485399,0.00028249092],"about_ca_topic_score_codex":0.00010329408,"about_ca_topic_score_gemma":0.0000138396545,"teacher_disagreement_score":0.51629096,"about_ca_system_score_codex":0.00005379549,"about_ca_system_score_gemma":0.00015046235,"threshold_uncertainty_score":0.38059637},"labels":[],"label_agreement":null},{"id":"W1973987878","doi":"10.1371/journal.pone.0042564","title":"Identification of CD166 as a Surface Marker for Enriching Prostate Stem/Progenitor and Cancer Initiating Cells","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation; Jean Perkins Foundation; Howard Hughes Medical Institute; U.S. Department of Defense","keywords":"Prostate cancer; PTEN; Cancer research; Progenitor cell; Stem cell; Prostate; Cancer stem cell; Biology; Cancer; Cell biology; PI3K/AKT/mTOR pathway; Signal transduction; Genetics","score_opus":0.07496573747237331,"score_gpt":0.3298234732000767,"score_spread":0.2548577357277034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973987878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925324,0.005456583,0.000017262737,0.00038539732,0.000052416213,0.00134314,0.0000689114,0.000020634303,0.00012329943],"genre_scores_gemma":[0.99481696,0.0007657475,0.0009088923,0.000039297767,0.000130576,0.00020027903,0.000020870822,0.000023354067,0.0030940145],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991146,0.00002956225,0.00021596673,0.00014179804,0.00024746137,0.00025062176],"domain_scores_gemma":[0.9993685,0.00010124736,0.000113569564,0.00012176218,0.0001841757,0.000110727575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003313769,0.0000855804,0.00019832522,0.0000455222,0.0000707157,0.000015802898,0.000032342658,0.00004237191,0.000028209184],"category_scores_gemma":[0.000042283507,0.000069617425,0.000029309387,0.00009951841,0.000037579906,0.00014869923,0.000027129645,0.000079606034,0.000007532259],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003754823,0.0005821756,0.14714053,0.0012962953,0.00037053926,0.0000010109497,0.0015480281,6.053136e-7,0.8461972,0.000012553035,0.000043197124,0.0024323724],"study_design_scores_gemma":[0.0014003295,0.00016026876,0.011667895,0.00032498088,0.00035069295,0.0000012967732,0.00033160762,0.0004304665,0.9851302,0.000023311728,0.00009627911,0.00008270148],"about_ca_topic_score_codex":0.000048159993,"about_ca_topic_score_gemma":0.000002020875,"teacher_disagreement_score":0.13893296,"about_ca_system_score_codex":0.00006597618,"about_ca_system_score_gemma":0.00007738446,"threshold_uncertainty_score":0.28389162},"labels":[],"label_agreement":null},{"id":"W1974443097","doi":"10.12968/hmed.2013.74.1.8","title":"Abiraterone has benefits for metastatic castration-resistant prostate cancer","year":2013,"lang":"en","type":"article","venue":"British Journal of Hospital Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Abiraterone; Prostate cancer; Abiraterone acetate; Oncology; Cancer; Internal medicine; Gynecology; Androgen deprivation therapy","score_opus":0.03873655891835039,"score_gpt":0.3137525860994252,"score_spread":0.2750160271810748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974443097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92587996,0.045323703,0.000058640348,0.026263388,0.0006920275,0.0015499118,0.00007620391,0.000015597358,0.00014059109],"genre_scores_gemma":[0.9902682,0.0052536344,0.0013215907,0.0002948315,0.00077016867,0.0002026955,0.000042897405,0.000040439973,0.0018055835],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980962,0.00003064705,0.00069127104,0.00019247686,0.0005945695,0.0003948336],"domain_scores_gemma":[0.997748,0.00009173216,0.0003240458,0.00011512461,0.0013410739,0.00038002827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035094208,0.00017425168,0.0005835927,0.00014199113,0.00014950303,0.00009007486,0.00011454084,0.000045195153,0.0006166473],"category_scores_gemma":[0.00026954405,0.00012996695,0.00012710252,0.00018823525,0.00027712167,0.00033019512,0.000017268947,0.0002572551,0.000010242595],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032364242,0.002246645,0.014967148,0.0018130802,0.002609437,0.0045441138,0.0036893126,0.00006903157,0.05119889,0.00016796349,0.23690915,0.6785488],"study_design_scores_gemma":[0.10543907,0.087735884,0.7052031,0.02482568,0.0034570687,0.008774623,0.007748758,0.0003800767,0.02387072,0.0044432036,0.026709137,0.0014126959],"about_ca_topic_score_codex":0.00097553857,"about_ca_topic_score_gemma":0.00008893005,"teacher_disagreement_score":0.6902359,"about_ca_system_score_codex":0.00015797574,"about_ca_system_score_gemma":0.00037575825,"threshold_uncertainty_score":0.67518556},"labels":[],"label_agreement":null},{"id":"W1975163069","doi":"10.1016/j.juro.2010.02.1592","title":"1743 RELATIONSHIP BETWEEN INITIAL PSA DENSITY WITH FUTURE PSA KINETICS AND REPEAT BIOPSIES IN MEN WITH PROSTATE CANCER ON ACTIVE SURVEILLANCE","year":2010,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Cancer; Urology; Biopsy; Gynecology; Oncology; Testosterone (patch); Internal medicine","score_opus":0.023949217153715854,"score_gpt":0.31952465926744794,"score_spread":0.2955754421137321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975163069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821475,0.0003632197,0.000006982897,0.016827563,0.00006513721,0.0002496207,0.000010651298,0.0000046499163,0.00032464456],"genre_scores_gemma":[0.99878114,0.00045616695,0.000068220594,0.00013171247,0.00044004273,0.000004485578,0.000004617121,0.000012135778,0.00010150145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915576,0.00016383405,0.00016928127,0.00010098851,0.00020516144,0.00020499002],"domain_scores_gemma":[0.999055,0.00036656403,0.00017289337,0.00013399553,0.00018905941,0.00008246181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041732375,0.000107300904,0.00026210753,0.00011833935,0.000076564975,0.000008073494,0.00006724128,0.000088632696,0.000011696549],"category_scores_gemma":[0.000065456574,0.000050073668,0.000016047978,0.00015367381,0.00031274147,0.00005371379,0.000022208866,0.00087850686,7.778543e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01861955,0.00005313892,0.97541016,0.000015375621,0.00012056035,0.0001676449,0.001765238,0.0000281471,0.0012726432,0.000020489244,0.000078565805,0.002448512],"study_design_scores_gemma":[0.0035217628,0.0034194754,0.9899512,0.00002661782,0.00010657352,0.00045266756,0.0002850183,0.000009896526,0.0017024066,0.00016170614,0.00030415878,0.000058529655],"about_ca_topic_score_codex":0.00006988041,"about_ca_topic_score_gemma":0.0011965372,"teacher_disagreement_score":0.016695851,"about_ca_system_score_codex":0.0000451772,"about_ca_system_score_gemma":0.00015649192,"threshold_uncertainty_score":0.3816724},"labels":[],"label_agreement":null},{"id":"W1975742490","doi":"10.1038/aja.2011.155","title":"Mathematically modelling and controlling prostate cancer under intermittent hormone therapy","year":2012,"lang":"en","type":"review","venue":"Asian Journal of Andrology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"Japan Society for the Promotion of Science; Council for Science and Technology Policy","keywords":"Androgen suppression; Prostate cancer; Androgen; Medicine; Schedule; Hormone therapy; Hormone; Prostate; Cancer; Oncology; Bioinformatics; Internal medicine; Computer science; Biology","score_opus":0.10646504793488165,"score_gpt":0.38647634100177475,"score_spread":0.2800112930668931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975742490","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006246124,0.99596953,0.00095303694,0.0014152199,0.00016553415,0.00062780915,0.000008737435,0.0000064276137,0.00022910301],"genre_scores_gemma":[0.0039479323,0.9946121,0.00044260826,0.000103717684,0.00041905607,0.0000324196,0.000007311966,0.000047808793,0.00038704573],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99831283,0.00013265513,0.0007537646,0.0001720824,0.00022269307,0.00040599724],"domain_scores_gemma":[0.9987545,0.000091668226,0.0005414416,0.00014360703,0.0001735494,0.0002952034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047896098,0.00029242394,0.0019306438,0.000269322,0.000053930962,0.000025733621,0.00010956956,0.0002412497,0.000060931878],"category_scores_gemma":[0.000008387813,0.00016221478,0.00035457313,0.00009516754,0.00015660594,0.00008273376,0.000031617386,0.0007225335,0.000005040511],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007094619,0.00015859239,0.000033129447,0.0021747197,0.0016675767,0.0002533424,0.00044073028,0.00000557798,0.000006141708,0.000053565152,0.000063874686,0.9944333],"study_design_scores_gemma":[0.010093913,0.00408395,0.00004813141,0.013185158,0.0050679576,0.009645905,0.00020511688,0.0001585686,0.0000054972625,0.0012750312,0.9557976,0.00043313781],"about_ca_topic_score_codex":0.0000023475168,"about_ca_topic_score_gemma":4.9244017e-7,"teacher_disagreement_score":0.99400014,"about_ca_system_score_codex":0.000109826826,"about_ca_system_score_gemma":0.0004264502,"threshold_uncertainty_score":0.66149265},"labels":[],"label_agreement":null},{"id":"W1976158108","doi":"10.3109/0284186x.2010.524936","title":"Broadening horizons in medical management of prostate cancer","year":2011,"lang":"en","type":"review","venue":"Acta Oncologica","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Medicine; Cabazitaxel; Abiraterone acetate; Prostate cancer; Mitoxantrone; Oncology; Internal medicine; Enzalutamide; Hormonal therapy; Chemotherapy; Androgen deprivation therapy; Clinical trial; Taxane; Cancer; Androgen receptor; Breast cancer","score_opus":0.12620369923566147,"score_gpt":0.4464296531495198,"score_spread":0.32022595391385833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976158108","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017931518,0.97177297,3.3671478e-7,0.00032462343,0.00016589384,0.0020181926,0.000032107215,0.000033598244,0.025472987],"genre_scores_gemma":[0.00037125027,0.99266124,0.00025038738,0.00003536525,0.00009210154,0.00110626,0.00009685115,0.0000353493,0.0053512165],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997789,0.00013715621,0.0006490073,0.00045070905,0.00049833115,0.00047579553],"domain_scores_gemma":[0.9989945,0.00012034588,0.0002648124,0.00034057908,0.00005583367,0.00022391211],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042805873,0.00031697773,0.0017612817,0.00025780802,0.000035023662,0.000006662,0.0003271148,0.00046051096,0.0017394368],"category_scores_gemma":[0.000042220705,0.00018725339,0.0002884918,0.0005374872,0.00018431945,0.000035387613,0.00028539228,0.0007042483,0.000034944544],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000121757075,0.00037103688,0.0002866225,0.017004108,0.00049130194,0.0015730838,0.00009079052,1.1248491e-8,3.4845112e-7,0.0000920613,0.0014714386,0.97849745],"study_design_scores_gemma":[0.001265174,0.0006718941,0.0003870072,0.032283064,0.0008076116,0.000050469356,0.000045629506,6.3157245e-7,0.0000025497643,0.000030740433,0.96428674,0.00016849379],"about_ca_topic_score_codex":0.00011773668,"about_ca_topic_score_gemma":0.000024967723,"teacher_disagreement_score":0.97832894,"about_ca_system_score_codex":0.00057565444,"about_ca_system_score_gemma":0.0010649024,"threshold_uncertainty_score":0.9991731},"labels":[],"label_agreement":null},{"id":"W1976572708","doi":"10.1016/j.urology.2013.03.029","title":"ERG Protein Expression and Gene Rearrangements Are Present at Lower Rates in Metastatic and Locally Advanced Castration-resistant Prostate Cancer Compared to Localized Disease","year":2013,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Calgary Laboratory Services; Hôpital du Sacré-Cœur de Montréal; University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Castration; Erg; Prostate; Gene; Disease; Oncology; Cancer; Internal medicine; Cancer research; Hormone; Genetics","score_opus":0.024064788381519,"score_gpt":0.3223245187508944,"score_spread":0.2982597303693754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976572708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98551434,0.004841722,0.00003302641,0.0057651377,0.00003940046,0.003703256,0.000051398947,0.000019799585,0.00003191811],"genre_scores_gemma":[0.99485713,0.00035979258,0.0004513244,0.00035411376,0.000021884023,0.0021247186,0.0000572835,0.00002090143,0.0017528298],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99865377,0.00011136618,0.00024496214,0.00041554068,0.0002075948,0.00036678027],"domain_scores_gemma":[0.99921316,0.00003898894,0.00006681209,0.00019439311,0.00011587862,0.0003707648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008503182,0.00017458359,0.00031398254,0.00011921137,0.00007665733,0.00002461067,0.00004702643,0.00003777983,0.00025062374],"category_scores_gemma":[0.0000468939,0.00012576254,0.000020499188,0.00012293638,0.00013283112,0.00009541366,0.00010970294,0.00010180938,0.000016079986],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039369337,0.0005789439,0.10817111,0.00058174465,0.00016319453,0.00087618054,0.0009534025,0.00091811037,0.8416671,0.0000076052333,0.0019695477,0.0047436818],"study_design_scores_gemma":[0.043625254,0.003496565,0.8450788,0.0009873982,0.00028467667,0.000029332683,0.0006040836,0.0090458095,0.084132865,0.0007095329,0.011216545,0.0007891245],"about_ca_topic_score_codex":0.00035473716,"about_ca_topic_score_gemma":0.00042596195,"teacher_disagreement_score":0.75753427,"about_ca_system_score_codex":0.00010330457,"about_ca_system_score_gemma":0.00010063205,"threshold_uncertainty_score":0.5128448},"labels":[],"label_agreement":null},{"id":"W1976718636","doi":"10.1038/sj.pcan.4500956","title":"Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer","year":2007,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Prostate cancer; LNCaP; Androstenediol; Intracrine; Flutamide; Endocrinology; Dihydrotestosterone; Internal medicine; Androgen receptor; Testosterone (patch); Dehydroepiandrosterone; Androgen; Medicine; Finasteride; Prostate; Cancer research; Cancer; Hormone; Receptor; Paracrine signalling","score_opus":0.014736589792067562,"score_gpt":0.31646917910765776,"score_spread":0.3017325893155902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976718636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9380439,0.056777697,0.0000034198217,0.0010422928,0.00017455415,0.0021930032,0.0015819874,0.00002228632,0.0001608624],"genre_scores_gemma":[0.98275346,0.015517348,0.00009012873,0.00019977133,0.000066651424,0.0004005934,0.000057554185,0.000043134656,0.0008713547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732125,0.000059872,0.00081469317,0.00048546004,0.00066610647,0.0006526241],"domain_scores_gemma":[0.99849236,0.00011037455,0.00035337204,0.00037911042,0.00034610654,0.00031869294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004043675,0.0003217151,0.00069832057,0.00021277054,0.00009184495,0.000021891074,0.0001565513,0.00006025116,0.00013419478],"category_scores_gemma":[0.000091679256,0.00020510523,0.00014312935,0.0007052584,0.00056480366,0.00017395262,0.00013482264,0.0002427781,7.422184e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037671847,0.00044773656,0.9457615,0.0016314648,0.00025755446,0.000101928716,0.0023091193,0.00003121741,0.0050094095,0.00011675888,0.00013087603,0.040435247],"study_design_scores_gemma":[0.00716569,0.00029898563,0.9046702,0.0009437033,0.00050901837,0.000030699743,0.0008762105,0.00007348214,0.08348987,0.00088329933,0.0007630539,0.00029582478],"about_ca_topic_score_codex":0.0007063172,"about_ca_topic_score_gemma":0.00084052497,"teacher_disagreement_score":0.07848046,"about_ca_system_score_codex":0.0001483742,"about_ca_system_score_gemma":0.0008262325,"threshold_uncertainty_score":0.83639485},"labels":[],"label_agreement":null},{"id":"W1977428762","doi":"10.1016/j.ejca.2014.06.004","title":"Abiraterone acetate in metastatic castration-resistant prostate cancer: A retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole","year":2014,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Prostate Cancer Canada; Princess Margaret Hospital Foundation","keywords":"Medicine; Ketoconazole; Abiraterone acetate; Prostate cancer; Urology; Docetaxel; Internal medicine; Log-rank test; Cancer; Retrospective cohort study; Androgen deprivation therapy; Proportional hazards model","score_opus":0.04270691158083056,"score_gpt":0.3753689660803812,"score_spread":0.3326620544995506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977428762","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017881852,0.9788395,0.0000025836334,0.00044045877,0.0002359151,0.0022590978,0.0001517356,0.00000455708,0.00018426677],"genre_scores_gemma":[0.013170631,0.9855391,0.00011029251,0.00007393627,0.00012035239,0.00014564724,0.0000074482505,0.00007332983,0.00075926795],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9954054,0.0009872532,0.0020228133,0.00037346355,0.00084961584,0.00036150022],"domain_scores_gemma":[0.99577314,0.00008416652,0.0027723762,0.0004426432,0.0007436308,0.00018403225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016557747,0.0004458138,0.0026599246,0.00022892912,0.00008046124,0.0000271592,0.00042686233,0.00004426272,0.00014279172],"category_scores_gemma":[0.00017107617,0.00024277909,0.00036875246,0.00060279394,0.0004551559,0.00016626772,0.0001756386,0.00067538157,0.0000013849717],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012761138,0.00033474257,0.0017111728,0.25149974,0.0012399446,0.000551912,0.0039159264,0.000009607335,0.0010229461,0.000017702296,0.00049396657,0.7379262],"study_design_scores_gemma":[0.007112449,0.0018815353,0.019680835,0.7088994,0.0026307288,0.00025735993,0.00018793026,0.0000059282943,0.0013516762,0.0000131774805,0.25745395,0.0005250344],"about_ca_topic_score_codex":0.000059163856,"about_ca_topic_score_gemma":0.000092002985,"teacher_disagreement_score":0.7374012,"about_ca_system_score_codex":0.00049258606,"about_ca_system_score_gemma":0.0015386346,"threshold_uncertainty_score":0.9900244},"labels":[],"label_agreement":null},{"id":"W1977446859","doi":"10.5489/cuaj.2293","title":"Complete response to ethnylestradiol prolonged for almost two years in patients with castration-resistant prostate cancer","year":2014,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Bicalutamide; Medicine; Prostate cancer; Urology; Castration; Antiandrogen; Prostate; Biopsy; Prostate-specific antigen; Prostate biopsy; Cancer; Internal medicine; Androgen receptor; Hormone","score_opus":0.022316540572685416,"score_gpt":0.28861838003096857,"score_spread":0.2663018394582832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977446859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97509795,0.00003774962,0.000015482254,0.023352657,0.00008278808,0.0010903346,0.00023354797,0.000010130073,0.0000793513],"genre_scores_gemma":[0.9970796,0.0000066500074,0.0003677434,0.0017711784,0.00013982264,0.00013941262,0.00007267425,0.000015634248,0.00040727883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983965,0.00023042815,0.00025512336,0.00020973128,0.0003568165,0.0005513829],"domain_scores_gemma":[0.9985522,0.00019299533,0.00012544531,0.00008696005,0.0003766752,0.00066572754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009663618,0.00011980197,0.00024140427,0.0002256637,0.00016435485,0.000068247005,0.00007978977,0.000094763665,0.000069259586],"category_scores_gemma":[0.0005715573,0.000087665285,0.000048850932,0.00025325382,0.000029266552,0.00006586944,0.000006223693,0.0003442669,0.00000995242],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008334985,0.000066714434,0.9857118,0.0000057011207,0.00006757526,0.000040229064,0.0003594721,0.00018855797,0.0005378483,0.000017450344,0.0014983274,0.0031713177],"study_design_scores_gemma":[0.007051836,0.0022276847,0.9692502,0.000035406978,0.000029580686,0.000005466615,0.000028716544,0.000086246895,0.000014129573,0.000070675575,0.021093626,0.0001064188],"about_ca_topic_score_codex":0.0011667297,"about_ca_topic_score_gemma":0.0070421165,"teacher_disagreement_score":0.021981645,"about_ca_system_score_codex":0.0017298604,"about_ca_system_score_gemma":0.00091669254,"threshold_uncertainty_score":0.4523525},"labels":[],"label_agreement":null},{"id":"W1977465091","doi":"10.5489/cuaj.1891","title":"A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration resistant prostate cancer","year":2014,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Juravinski Cancer Centre; Baker Hughes (Canada)","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Docetaxel; Internal medicine; Abiraterone; Oncology; Adverse effect; Cancer; Androgen deprivation therapy","score_opus":0.012881595367269785,"score_gpt":0.2624258442607687,"score_spread":0.2495442488934989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977465091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921428,0.00013115884,0.000004327594,0.006780874,0.00004968151,0.00038736142,0.00019431887,0.000004953985,0.00030455264],"genre_scores_gemma":[0.9987273,0.0000693702,0.000119224314,0.0005549095,0.000028533239,0.000022583585,0.00015795534,0.000010375758,0.0003097341],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998101,0.00022416111,0.000382586,0.00019650985,0.00042559157,0.0006701293],"domain_scores_gemma":[0.99805367,0.000073734496,0.0002620158,0.00009988543,0.000540415,0.0009703011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006426613,0.00013549847,0.0004190214,0.00089592126,0.00013311155,0.000050624374,0.000072138435,0.000090240224,0.00032260196],"category_scores_gemma":[0.00027196234,0.00009311266,0.00008423678,0.0009783104,0.00003934581,0.0001065628,0.000004737166,0.0003307122,0.0000050277345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041086847,0.00006250674,0.9955737,0.000011020527,0.0007625288,0.000058063324,0.00039398824,0.00092554564,0.00006829327,0.000015846379,0.00014411117,0.0015735071],"study_design_scores_gemma":[0.003646333,0.0004331489,0.9914419,0.000029123603,0.00070684875,0.000002048371,0.000077554345,0.001596164,0.00002507266,0.000026860225,0.0019184372,0.00009651698],"about_ca_topic_score_codex":0.3847779,"about_ca_topic_score_gemma":0.9157548,"teacher_disagreement_score":0.5309769,"about_ca_system_score_codex":0.0028782529,"about_ca_system_score_gemma":0.0016214085,"threshold_uncertainty_score":0.7526531},"labels":[],"label_agreement":null},{"id":"W1977806117","doi":"10.1098/rsta.2010.0220","title":"Piecewise affine systems modelling for optimizing hormone therapy of prostate cancer","year":2010,"lang":"en","type":"article","venue":"Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Prostate cancer; Androgen suppression; Medicine; Androgen; Computer science; Hormone therapy; Disease; Androgen deprivation therapy; Cancer; Hormone; Oncology; Internal medicine","score_opus":0.039096530417364425,"score_gpt":0.29236854089680314,"score_spread":0.2532720104794387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977806117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.928023,0.0008795485,0.06531923,0.004750171,0.00009750595,0.00075695483,0.000040942876,0.000036065576,0.00009662352],"genre_scores_gemma":[0.99170166,0.00022534508,0.0077715665,0.000008639957,0.00011362037,0.0001091626,5.5903365e-7,0.000010768939,0.000058669644],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99913687,0.0000065379954,0.00019179008,0.0001709896,0.00029229218,0.00020151204],"domain_scores_gemma":[0.9994589,0.00020905882,0.000043856304,0.00011968692,0.00007518225,0.00009329683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019447056,0.000118526434,0.00030669224,0.00001996665,0.00014771479,0.000017042717,0.00012038647,0.000057094974,0.0000055262085],"category_scores_gemma":[0.00001649773,0.00006469159,0.0002586639,0.00021203347,0.0005010407,0.00005615782,0.000011664329,0.0002481576,1.8039795e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003415843,0.0016177808,0.000059776834,0.0021552183,0.0005112909,4.5597145e-7,0.0026143636,0.7869096,0.16789952,0.035169512,0.000019646306,0.0027012702],"study_design_scores_gemma":[0.00075375376,0.00027713587,0.00005208916,0.00015623707,0.00006584787,0.0000017957193,0.00004968768,0.97857016,0.008056528,0.011914848,0.000020561114,0.00008133583],"about_ca_topic_score_codex":0.000017914866,"about_ca_topic_score_gemma":7.1410604e-8,"teacher_disagreement_score":0.1916606,"about_ca_system_score_codex":0.000012350025,"about_ca_system_score_gemma":0.000044656153,"threshold_uncertainty_score":0.26380464},"labels":[],"label_agreement":null},{"id":"W1978003256","doi":"10.1007/s00345-011-0745-5","title":"Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer","year":2011,"lang":"en","type":"review","venue":"World Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Antiandrogens; Prostate cancer; Medicine; Androgen receptor; Small molecule; Cancer research; Cancer; Androgen; Pharmacology; Enzalutamide; Oncology; Internal medicine; Bioinformatics; Hormone; Chemistry; Biology; Biochemistry","score_opus":0.05088291756404871,"score_gpt":0.3727862997181051,"score_spread":0.3219033821540564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978003256","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004475624,0.9966296,0.0000034883467,0.00033328452,0.0005122041,0.0018150217,0.00007641788,0.0000025107422,0.00017993698],"genre_scores_gemma":[0.00024333369,0.9975626,0.00018335339,0.000016299098,0.0001895055,0.00029740384,0.000016678494,0.000038156315,0.0014526729],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819654,0.0001327709,0.0010342107,0.00019446574,0.00013195201,0.00031003443],"domain_scores_gemma":[0.99784994,0.00033788534,0.0012291096,0.00021712673,0.00027220527,0.00009373301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026850085,0.00027357647,0.0018987138,0.0005218891,0.000021991913,0.0000024245742,0.00018174453,0.000115441246,0.000068899884],"category_scores_gemma":[0.000029062065,0.00013751324,0.00059249776,0.00038302373,0.00022205635,0.00004716322,0.000021434944,0.00025761136,9.666105e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020594061,0.00039656257,0.00042656812,0.0029596118,0.00057523476,0.000033052736,0.0003933534,0.0000073782553,0.000020968258,0.000019658033,0.0001759652,0.99293226],"study_design_scores_gemma":[0.0036201978,0.0049079643,0.000014241649,0.0024800391,0.0012854805,0.00004640397,0.000046560745,8.525099e-7,0.00037632696,0.000044617733,0.98708445,0.000092848684],"about_ca_topic_score_codex":0.000036051206,"about_ca_topic_score_gemma":0.00029330212,"teacher_disagreement_score":0.9928394,"about_ca_system_score_codex":0.00028816581,"about_ca_system_score_gemma":0.0012568672,"threshold_uncertainty_score":0.56076276},"labels":[],"label_agreement":null},{"id":"W1978342904","doi":"10.1016/j.jgo.2014.09.183","title":"Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Abiraterone; Internal medicine; Oncology; Cohort; Toxicity; Urology; Cancer","score_opus":0.02262232409326158,"score_gpt":0.3392136129774925,"score_spread":0.3165912888842309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978342904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99462646,0.0029195421,0.000039152856,0.0018646686,0.000052904717,0.00032015773,0.000007098891,0.0000021923202,0.00016782263],"genre_scores_gemma":[0.996179,0.0019920394,0.0015453578,0.00005169551,0.00007575175,0.000008453318,0.0000014052131,0.000008947347,0.00013739163],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99898714,0.00012431761,0.00041522188,0.000117660216,0.00018030951,0.00017538061],"domain_scores_gemma":[0.9991521,0.00016047714,0.0003177461,0.00006927493,0.0001713996,0.00012896025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051109825,0.00009903475,0.0005095361,0.00023095566,0.00002885915,0.00001024002,0.000036373003,0.00004671182,0.00002659738],"category_scores_gemma":[0.00006231282,0.00005991142,0.000023919485,0.00020854562,0.00013842335,0.00007950905,0.000016356098,0.00017675478,2.8998275e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060106087,0.0028190224,0.1980315,0.0016723793,0.0013463965,0.0019153946,0.0067615495,0.00030813614,0.6289968,0.00023902548,0.0005952337,0.097208485],"study_design_scores_gemma":[0.06411734,0.033257112,0.8729287,0.00046464262,0.0011097672,0.0017622228,0.0008058699,0.00023928675,0.021863077,0.00037378064,0.0028185444,0.00025969965],"about_ca_topic_score_codex":0.000106549116,"about_ca_topic_score_gemma":0.00021748268,"teacher_disagreement_score":0.67489713,"about_ca_system_score_codex":0.00013349432,"about_ca_system_score_gemma":0.00053909677,"threshold_uncertainty_score":0.24431169},"labels":[],"label_agreement":null},{"id":"W1978372198","doi":"10.1016/j.urology.2014.12.029","title":"Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer","year":2015,"lang":"en","type":"review","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Bristol-Myers Squibb","keywords":"Ipilimumab; Medicine; Prostate cancer; Immune checkpoint; Immunotherapy; Oncology; Immune system; Melanoma; Clinical trial; CTLA-4; Internal medicine; Cancer; Immunology; Cancer research; T cell","score_opus":0.10184268838080153,"score_gpt":0.44934737081664133,"score_spread":0.3475046824358398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978372198","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000042624448,0.996723,0.0000085590445,0.0006060698,0.00034119815,0.001974446,0.00020372412,0.000024397339,0.000075955344],"genre_scores_gemma":[0.000023609211,0.9968553,0.000037396785,0.00003261596,0.00024731387,0.0013630232,0.00030700988,0.000043286396,0.0010904389],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99889356,0.000058004778,0.0002874637,0.00031911195,0.00012261179,0.00031927568],"domain_scores_gemma":[0.99937874,0.00007492226,0.00012666387,0.00017360465,0.00014308315,0.00010299045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018644359,0.00023661669,0.0009231276,0.00015196204,0.00007210941,0.000017558328,0.000058405298,0.00013584403,0.00004693411],"category_scores_gemma":[0.000022300872,0.0001547592,0.00012996864,0.00009856051,0.000119072465,0.000026801821,0.00003271241,0.0002354272,0.000007242158],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030629276,0.000035833295,0.000016011343,0.008701905,0.00031287258,0.000014218472,0.00021925247,2.3219995e-7,0.0000045127804,0.00006205952,0.0014975584,0.98882926],"study_design_scores_gemma":[0.0012298231,0.0005534723,0.000007955616,0.0010986358,0.0007918261,0.000032782078,0.000015172491,0.000008698507,0.0000011188696,0.00010146904,0.9960339,0.00012516043],"about_ca_topic_score_codex":0.00003216729,"about_ca_topic_score_gemma":0.000025298474,"teacher_disagreement_score":0.99453634,"about_ca_system_score_codex":0.00013513166,"about_ca_system_score_gemma":0.0009481014,"threshold_uncertainty_score":0.6310897},"labels":[],"label_agreement":null},{"id":"W1978426649","doi":"10.1002/pros.21021","title":"Androgen receptor as a potential sign of prostate cancer metastasis","year":2009,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Prostate cancer; Metastasis; Medicine; Prostate; Androgen receptor; Prostate disease; Androgen; Sign (mathematics); Oncology; Cancer; Internal medicine; Cancer research; Endocrinology; Hormone","score_opus":0.022427427289106416,"score_gpt":0.32576964504005096,"score_spread":0.30334221775094455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978426649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9684209,0.007495186,0.000009779273,0.01929724,0.00012768572,0.0019261811,0.00020264684,0.0000750964,0.002445281],"genre_scores_gemma":[0.9804894,0.004547408,0.00021878377,0.00052494934,0.000105340994,0.00012993373,0.00006505534,0.0000276361,0.013891499],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983571,0.000090255555,0.00030916976,0.0002815105,0.0004960881,0.0004658339],"domain_scores_gemma":[0.9990779,0.000029744577,0.00013222318,0.00036799605,0.0002280695,0.00016406826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003876161,0.00019892873,0.00035307877,0.0000991396,0.00013796898,0.000028614299,0.00015655819,0.00005039064,0.0004925308],"category_scores_gemma":[0.000035333516,0.00011208799,0.00014772863,0.00037675133,0.00019541766,0.000101690835,0.00004836878,0.00021400758,0.00009155434],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018018905,0.001204218,0.006769829,0.00040872343,0.0016202682,0.0003228733,0.010632149,0.0001552739,0.32294732,0.0006007545,0.019570485,0.6177492],"study_design_scores_gemma":[0.011797422,0.0053551905,0.010624577,0.00046027915,0.0010379539,0.00014642526,0.0012505566,0.00025741805,0.91752374,0.005657188,0.045338776,0.0005504642],"about_ca_topic_score_codex":0.0002476103,"about_ca_topic_score_gemma":0.0000058915384,"teacher_disagreement_score":0.61719877,"about_ca_system_score_codex":0.00009220537,"about_ca_system_score_gemma":0.0003519421,"threshold_uncertainty_score":0.53928673},"labels":[],"label_agreement":null},{"id":"W1979393936","doi":"10.5489/cuaj.2076","title":"Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer","year":2014,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"Astellas Pharma; Michael Smith Health Research BC; Sanofi; Amgen","keywords":"Docetaxel; Medicine; Prostate cancer; Oncology; Internal medicine; Hazard ratio; Population; Radiation therapy; Cabazitaxel; Cancer; Surgery; Androgen deprivation therapy; Confidence interval","score_opus":0.019499550253797113,"score_gpt":0.3158566770265921,"score_spread":0.29635712677279497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979393936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94719136,0.00026505752,0.00006420807,0.05124407,0.00022180479,0.00068404735,0.0002405757,0.0000085094935,0.00008038059],"genre_scores_gemma":[0.99757445,0.00011635405,0.00008352379,0.0010798939,0.000596401,0.000091723574,0.00012443263,0.000013652732,0.0003195859],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835825,0.00029266198,0.0003151817,0.00017148118,0.0005046351,0.0003578055],"domain_scores_gemma":[0.99852353,0.00026969935,0.00028475377,0.00011669919,0.00053886895,0.00026645153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012415021,0.00013744182,0.00028395452,0.00014100439,0.00023343146,0.0000754608,0.00006215108,0.00008214515,0.0004529608],"category_scores_gemma":[0.0005389777,0.0000732676,0.00017889637,0.00014823736,0.000031861528,0.000074092386,0.0000025356944,0.00028756363,0.0000031127024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025378602,0.00016072967,0.94996274,0.00003356468,0.00064117485,0.00001621722,0.00025311622,0.0038752214,0.0010902853,0.00051297527,0.005994405,0.012080945],"study_design_scores_gemma":[0.004293159,0.0033227322,0.97903323,0.000019148461,0.000101038015,0.000008369919,0.00002629865,0.00047991375,0.00032047438,0.0019876736,0.01031001,0.00009792628],"about_ca_topic_score_codex":0.0032084247,"about_ca_topic_score_gemma":0.0015090025,"teacher_disagreement_score":0.050383084,"about_ca_system_score_codex":0.0016079881,"about_ca_system_score_gemma":0.0009619904,"threshold_uncertainty_score":0.49596033},"labels":[],"label_agreement":null},{"id":"W1979558617","doi":"10.1016/s0140-6736(05)73625-4","title":"Androgen blockade in prostate cancer","year":2000,"lang":"en","type":"letter","venue":"The Lancet","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Cyproterone acetate; Flutamide; Antiandrogen; Prostate cancer; Medroxyprogesterone acetate; Cyproterone; Medicine; Chlormadinone acetate; Internal medicine; Androgen; Endocrinology; Antiandrogens; Androgen receptor; Toremifene; Cancer; Breast cancer; Estrogen; Population; Hormone; Tamoxifen","score_opus":0.04690307071414924,"score_gpt":0.3384467993536622,"score_spread":0.29154372863951294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979558617","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025284844,0.013786009,3.7831647e-8,0.9485135,0.00013679375,0.00097356376,0.0002626761,0.00005553271,0.010987065],"genre_scores_gemma":[0.0044912514,0.035589706,0.000030081937,0.81770426,0.01701757,0.0007743755,0.000773758,0.00011040503,0.12350861],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998398,0.000080345206,0.00018822144,0.0003062522,0.0003694817,0.0006576966],"domain_scores_gemma":[0.99920726,0.00005128825,0.000050742623,0.0006150624,0.000030548606,0.000045080596],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015652261,0.00022844652,0.0006543683,0.000105679814,0.000053279025,0.000032320702,0.0002688828,0.00022425177,0.0010071672],"category_scores_gemma":[0.000008197157,0.00012378847,0.00008514982,0.00022958843,0.00012998439,0.000025390471,0.000043488868,0.0017685224,0.00016387254],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000543414,0.000022242328,0.007475235,0.0002639302,0.00013495555,0.001744886,0.00031632153,0.0000028532802,0.00003700484,7.479436e-7,0.9823848,0.007073636],"study_design_scores_gemma":[0.00297521,0.00007636241,0.0021609035,0.00043558318,0.00008688934,0.000052741303,0.000009251411,0.000012089257,0.00040578895,0.00016101704,0.99347806,0.00014608112],"about_ca_topic_score_codex":0.0004469938,"about_ca_topic_score_gemma":0.000060667284,"teacher_disagreement_score":0.13080925,"about_ca_system_score_codex":0.00020270795,"about_ca_system_score_gemma":0.00029166465,"threshold_uncertainty_score":0.99990606},"labels":[],"label_agreement":null},{"id":"W1979832268","doi":"10.1016/j.urology.2009.12.057","title":"Salvage Therapy With Bicalutamide 150 mg in Nonmetastatic Castration-resistant Prostate Cancer","year":2010,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Bicalutamide; Prostate cancer; Urology; Prostate-specific antigen; Antiandrogen; Metastasis; Internal medicine; Prostate; Oncology; Cancer","score_opus":0.01944744158477578,"score_gpt":0.3199685433335415,"score_spread":0.30052110174876573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979832268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98997396,0.00078863726,0.000013804159,0.0074679605,0.00010180907,0.00068244094,0.000021964144,0.000028984223,0.00092044973],"genre_scores_gemma":[0.9970138,0.0004535014,0.00029649085,0.00072764093,0.000070735645,0.00023303878,0.000033875414,0.000023761786,0.001147129],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989447,0.000049316823,0.00017270501,0.00027118737,0.00018292725,0.00037914194],"domain_scores_gemma":[0.99948317,0.00007368217,0.000043733522,0.0002215714,0.00006300279,0.00011482506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014837035,0.00013464641,0.00023626206,0.00014472984,0.000046323756,0.000013236794,0.000064542,0.00007853455,0.0005146409],"category_scores_gemma":[0.000022349073,0.0000836225,0.000028313785,0.00022564856,0.00022054046,0.000051334926,0.000013904099,0.0004137297,0.000030370722],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013509302,0.00080686266,0.2942427,0.00009161905,0.00028033406,0.002060232,0.001987966,0.000112676185,0.65752447,0.000517185,0.00056560803,0.028301038],"study_design_scores_gemma":[0.026849372,0.007973961,0.8924955,0.00005757394,0.00014611709,0.0002607373,0.00025340045,0.0011879469,0.026842643,0.00092292635,0.042523105,0.00048667475],"about_ca_topic_score_codex":0.00046830968,"about_ca_topic_score_gemma":0.0035089564,"teacher_disagreement_score":0.6306818,"about_ca_system_score_codex":0.000043168562,"about_ca_system_score_gemma":0.00034481977,"threshold_uncertainty_score":0.5634957},"labels":[],"label_agreement":null},{"id":"W1980208663","doi":"10.1054/bjoc.2000.1315","title":"Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer","year":2000,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Testosterone (patch); Prostate cancer; Cancer; Internal medicine; Antibody; Hormone; Prostate; Endocrinology; Prostate-specific antigen; Urology; Immunology","score_opus":0.01890449417211312,"score_gpt":0.31046679837093255,"score_spread":0.29156230419881946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980208663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824261,0.015818257,4.2045153e-7,0.00050173735,0.0001003076,0.00046233626,0.00035670798,0.0000060045645,0.00032815125],"genre_scores_gemma":[0.9833004,0.014991789,0.00017903208,0.000097524775,0.00008159966,0.000021572512,0.000009037368,0.000032072465,0.0012869696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982549,0.00004546933,0.00052827207,0.00019450144,0.00058652874,0.00039033906],"domain_scores_gemma":[0.99878985,0.000020461774,0.00029236218,0.000112547496,0.0006154402,0.00016934285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014359545,0.0001676827,0.000599194,0.0001557839,0.00005161343,0.000029171104,0.00010874221,0.000060056136,0.00059963035],"category_scores_gemma":[0.000016835857,0.00013826399,0.00006549945,0.00035083244,0.00017638243,0.0002688985,0.000015309299,0.00037756475,0.0000010340711],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016889366,0.0002862689,0.62475646,0.0001380516,0.0001688297,0.0005646934,0.00037344632,0.00023717844,0.0018435288,3.0694417e-7,0.0001313796,0.36981094],"study_design_scores_gemma":[0.011463867,0.0011100376,0.9725518,0.0040630605,0.00008657162,0.00015716952,0.00009259095,0.000002978885,0.009447327,0.000008368844,0.0008669425,0.00014926879],"about_ca_topic_score_codex":0.0018479533,"about_ca_topic_score_gemma":0.0024618169,"teacher_disagreement_score":0.36966166,"about_ca_system_score_codex":0.00026498327,"about_ca_system_score_gemma":0.0008181048,"threshold_uncertainty_score":0.65655315},"labels":[],"label_agreement":null},{"id":"W1980242979","doi":"10.1158/1538-7445.prca2012-c25","title":"Abstract C25: The 16p13.3 genomic gain in prostate cancer: A role for PDK1 in disease progression","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Prostate cancer; Prostate; Cancer; Cancer research; Fluorescence in situ hybridization; Metastasis; Lymph node; Primary tumor; Tumor progression; Medicine; Oncology; Biology; Internal medicine; Chromosome; Gene; Genetics","score_opus":0.0866243045279558,"score_gpt":0.4705110445223528,"score_spread":0.38388673999439704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980242979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9311689,0.053069085,8.249869e-7,0.010433462,0.0001446098,0.004577846,0.00012458839,0.00002461791,0.00045603554],"genre_scores_gemma":[0.97812885,0.00849486,0.00003058343,0.00011335531,0.0005535129,0.010519909,0.00005383317,0.000058488196,0.0020466063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99677116,0.00018062186,0.00031766013,0.00042843842,0.00076900475,0.0015331269],"domain_scores_gemma":[0.99852836,0.00027892904,0.00005288275,0.00042883906,0.00021389278,0.00049711374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022696417,0.00019656756,0.00029331452,0.00039860333,0.00021376417,0.00005759829,0.00026966725,0.00007929815,0.0002600929],"category_scores_gemma":[0.00017059728,0.00012146741,0.000090568035,0.0007519569,0.00031733594,0.0001995059,0.00015277886,0.0007975353,0.00003792264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007904763,0.0007623035,0.861132,0.0008315146,0.000062198655,0.00009871799,0.004929942,0.00007054713,0.032747302,0.00009407294,0.0024702847,0.08889636],"study_design_scores_gemma":[0.007374311,0.0002889558,0.92815715,0.0014071475,0.000030425877,0.0000034705274,0.0015288985,0.00043626345,0.013483152,0.0005287535,0.04649088,0.00027057214],"about_ca_topic_score_codex":0.0018764316,"about_ca_topic_score_gemma":0.0008525127,"teacher_disagreement_score":0.08862578,"about_ca_system_score_codex":0.0016908617,"about_ca_system_score_gemma":0.0015693499,"threshold_uncertainty_score":0.49532974},"labels":[],"label_agreement":null},{"id":"W1980426314","doi":"10.1002/pros.22636","title":"Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause‐specific mortality","year":2013,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"Canary Foundation; National Cancer Institute; Prostate Cancer Foundation","keywords":"Erg; Medicine; Prostatectomy; Prostate cancer; Prostate; Proportional hazards model; Oncology; Internal medicine; Cancer; Ophthalmology","score_opus":0.04454507106102549,"score_gpt":0.3435001850675586,"score_spread":0.2989551140065331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980426314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98395675,0.0077844313,0.0000027344524,0.003438461,0.00008107428,0.004205117,0.00005682491,0.000030800176,0.000443826],"genre_scores_gemma":[0.98932654,0.007502034,0.00010698084,0.000068249334,0.000040584942,0.0012620369,0.000021348878,0.000025110112,0.0016471379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834734,0.00011575676,0.0003670285,0.0003443576,0.00036640101,0.0004590937],"domain_scores_gemma":[0.9990871,0.000089279536,0.000121843324,0.0003753787,0.00018915774,0.00013725448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043559965,0.00019462476,0.00033296406,0.000100983656,0.00007835033,0.000037177997,0.00012236166,0.000045496163,0.0001198422],"category_scores_gemma":[0.00006201814,0.00011437959,0.00004221088,0.00041362748,0.00042577213,0.0001548088,0.00010693851,0.00031699086,0.000030401408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005685966,0.0002873077,0.94421154,0.00065684173,0.00014973039,0.00008135396,0.0048096767,0.000025681515,0.011144065,0.00029182778,0.00081057963,0.036962815],"study_design_scores_gemma":[0.0027977673,0.0005307803,0.9758156,0.0008441689,0.00007719379,0.00002549446,0.00042891494,0.00053067197,0.014916157,0.003079897,0.0007499837,0.00020336984],"about_ca_topic_score_codex":0.0029275157,"about_ca_topic_score_gemma":0.00018381722,"teacher_disagreement_score":0.036759444,"about_ca_system_score_codex":0.000120391975,"about_ca_system_score_gemma":0.00024469552,"threshold_uncertainty_score":0.46642643},"labels":[],"label_agreement":null},{"id":"W1980524353","doi":"10.1371/journal.pone.0113190","title":"Proteomic-Coupled-Network Analysis of T877A-Androgen Receptor Interactomes Can Predict Clinical Prostate Cancer Outcomes between White (Non-Hispanic) and African-American Groups","year":2014,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Institute for Research in Immunology and Cancer; Jewish General Hospital; Université de Montréal; Biotechnology Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Androgen receptor; Biology; Prostate cancer; Population; Interactome; Cancer research; Androgen; Testosterone (patch); Dihydrotestosterone; Cancer; Internal medicine; Endocrinology; Hormone; Medicine; Genetics; Gene","score_opus":0.04813437470198347,"score_gpt":0.3377659520673173,"score_spread":0.28963157736533385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980524353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936711,0.00028977272,0.00002624645,0.0037961118,0.00005031133,0.0015810766,0.0003162959,0.00006446479,0.00020459446],"genre_scores_gemma":[0.9942333,0.0014245859,0.0013701062,0.00017669854,0.00040738547,0.00037768707,0.00028921373,0.00005445195,0.0016665711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970087,0.00019686116,0.00084530213,0.00063280674,0.000702238,0.00061413675],"domain_scores_gemma":[0.99786085,0.00038070275,0.00045775436,0.0005499969,0.00029351286,0.00045720098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007862175,0.00032067904,0.001972212,0.00035071734,0.00009818849,0.000037460923,0.00019971255,0.00011518458,0.00020019173],"category_scores_gemma":[0.0002257687,0.0002317807,0.00030677574,0.0011519373,0.00048972375,0.000089557674,0.00013184486,0.00043291372,0.000008251305],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007279987,0.00070332875,0.9775864,0.00019868494,0.014905776,0.0000043635414,0.0010136471,0.00001047291,0.00097564294,0.0000029744317,0.0002547781,0.0036159712],"study_design_scores_gemma":[0.002683255,0.0019039467,0.9833095,0.00038077284,0.0076632984,4.108966e-7,0.00015923138,0.0020708675,0.0013792007,0.000021309494,0.00017141513,0.00025677495],"about_ca_topic_score_codex":0.00092309085,"about_ca_topic_score_gemma":0.00022608925,"teacher_disagreement_score":0.007242477,"about_ca_system_score_codex":0.00017521442,"about_ca_system_score_gemma":0.000218176,"threshold_uncertainty_score":0.9451743},"labels":[],"label_agreement":null},{"id":"W1980950441","doi":"10.1158/1538-7445.am2012-1686","title":"Abstract 1686: Identification of potential prostate cancer biomarkers associated with TMPRSS2-ERG fusion and PTEN deletions","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"TMPRSS2; PTEN; DU145; Fusion gene; Biology; Prostate cancer; Erg; Cancer research; Gene knockdown; Molecular biology; Gene; LNCaP; Cancer; Genetics; Medicine; Pathology; PI3K/AKT/mTOR pathway; Signal transduction","score_opus":0.05890981685796283,"score_gpt":0.4041013279733595,"score_spread":0.3451915111153967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980950441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865362,0.009115632,0.000012059157,0.002416358,0.0001240144,0.0010994293,0.00018683035,0.000033319673,0.0004761584],"genre_scores_gemma":[0.9891265,0.0070906715,0.000021894875,0.000017032286,0.00015666166,0.0004995821,0.00013809103,0.00003726994,0.002912302],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975196,0.00011968431,0.00030227916,0.00032443047,0.0010045846,0.0007293883],"domain_scores_gemma":[0.99828833,0.00009573489,0.0001228677,0.00027319725,0.00088063104,0.0003392411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012174328,0.00015121172,0.00025659363,0.00036090193,0.00028439352,0.00004326638,0.00010829665,0.000117700445,0.00038610504],"category_scores_gemma":[0.00011235568,0.000108474866,0.000052481693,0.0007751917,0.0005307703,0.0002468704,0.0000851663,0.00038826477,0.000012090303],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028980214,0.0006342559,0.23673199,0.0005073224,0.00080609834,0.00003562014,0.0013939578,0.000024305753,0.7188305,0.00005040515,0.0040995027,0.03398799],"study_design_scores_gemma":[0.003686764,0.00030113617,0.8994919,0.0006911061,0.00015318964,0.0000096502745,0.00071317435,0.00018224907,0.09323352,0.000042885476,0.0013037636,0.0001906728],"about_ca_topic_score_codex":0.0016092976,"about_ca_topic_score_gemma":0.00020148471,"teacher_disagreement_score":0.6627599,"about_ca_system_score_codex":0.0005239821,"about_ca_system_score_gemma":0.0006732877,"threshold_uncertainty_score":0.44234765},"labels":[],"label_agreement":null},{"id":"W1981090615","doi":"10.1016/j.ijrobp.2011.06.084","title":"Cardiovascular Mortality following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08","year":2011,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Term (time); Androgen; Internal medicine; Cancer; Hormone","score_opus":0.06279113646027992,"score_gpt":0.4024672297887658,"score_spread":0.3396760933284859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981090615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99403596,0.00145014,0.003034244,0.00018097516,0.0006989577,0.00034531121,0.000058996444,0.000016395781,0.00017902018],"genre_scores_gemma":[0.9951747,0.0028319322,0.0011764034,0.00012528744,0.0003713977,0.000029031135,0.0002596665,0.000019322644,0.0000122310275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974214,0.00036035897,0.0011921878,0.00029687054,0.00049037277,0.00023885445],"domain_scores_gemma":[0.998007,0.00014230987,0.00065357337,0.00026095426,0.0007819632,0.0001541896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001477785,0.00017645657,0.0009587259,0.00045456953,0.000038534698,0.00001246998,0.0003159355,0.00021946989,0.000059351565],"category_scores_gemma":[0.00018207966,0.0001463666,0.0008304675,0.00053343107,0.00016889414,0.0003239476,0.00005492855,0.0003601987,0.0000021270728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010991163,0.0006416525,0.90328664,0.000010708007,0.011080627,0.0001351036,0.0010382117,0.0011246705,0.0013036722,0.00020440899,0.0000089801,0.080066234],"study_design_scores_gemma":[0.008218254,0.0013565419,0.9752711,0.00008129347,0.0032213468,0.000020317326,0.00015270068,0.0053656558,0.00423635,0.0014009865,0.00049825385,0.00017716773],"about_ca_topic_score_codex":0.0003241602,"about_ca_topic_score_gemma":0.00008238115,"teacher_disagreement_score":0.07988907,"about_ca_system_score_codex":0.00075506204,"about_ca_system_score_gemma":0.00075151987,"threshold_uncertainty_score":0.5968657},"labels":[],"label_agreement":null},{"id":"W1981161413","doi":"10.1016/j.urolonc.2011.12.015","title":"Patients and partners lack knowledge of androgen deprivation therapy side effects","year":2012,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Medicine; Androgen deprivation therapy; Gynecomastia; Side effect (computer science); Psychosocial; Adverse effect; Prostate cancer; Sexual dysfunction; Oxandrolone; Libido; Osteoporosis; Internal medicine; Psychiatry; Hormone; Cancer","score_opus":0.06110046724457345,"score_gpt":0.3857950996238764,"score_spread":0.32469463237930296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981161413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98742265,0.007995137,0.000008192998,0.0011255412,0.000083617604,0.00043312588,0.000005460605,0.000019631956,0.002906674],"genre_scores_gemma":[0.9921072,0.0028238066,0.0039943564,0.0005046399,0.0000695682,0.00006925898,0.00006397959,0.0000082111055,0.00035898728],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992936,0.000095217445,0.00015404688,0.00015398482,0.00007375057,0.0002294042],"domain_scores_gemma":[0.99929464,0.000249761,0.000074997275,0.000087885805,0.00006840773,0.0002242982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020379397,0.000109352884,0.0002251676,0.0000949622,0.00010799201,0.0000052604623,0.00003121508,0.0001298484,0.000010691092],"category_scores_gemma":[0.00010990077,0.000077613,0.000025552865,0.00015154827,0.0005078234,0.00009901137,0.000031191805,0.00012866886,0.0000063574917],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001486857,0.00036855726,0.9763387,0.000053966563,0.000058236677,0.0000037729,0.0009607069,4.88427e-7,0.0010765211,0.0011683995,0.00096777844,0.018854177],"study_design_scores_gemma":[0.004855938,0.005002436,0.37339774,0.00006522115,0.00020587876,0.000053999513,0.00015641026,0.000105040155,0.015298156,0.0025428524,0.5981447,0.00017160825],"about_ca_topic_score_codex":0.000014294918,"about_ca_topic_score_gemma":0.0000026172122,"teacher_disagreement_score":0.602941,"about_ca_system_score_codex":0.000052429128,"about_ca_system_score_gemma":0.00014161058,"threshold_uncertainty_score":0.3164966},"labels":[],"label_agreement":null},{"id":"W1981375592","doi":"10.1016/j.juro.2015.02.2679","title":"MP73-03 REGIONAL DIFFERENCES IN CARDIOVASCULAR STATUS AND EVENTS IN PROSTATE CANCER PATIENTS TREATED WITH A LUTEINISING HORMONE-RELEASING HORMONE AGONIST VS ANTAGONIST: RESULTS OF A POOLED ANALYSIS","year":2015,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Agonist; Incidence (geometry); Internal medicine; Proportional hazards model; Hormone therapy; Hormone antagonist; Cancer; Hormone; Oncology; Gynecology; Antagonist; Endocrinology; Receptor; Breast cancer","score_opus":0.02574518256982657,"score_gpt":0.28266508110131544,"score_spread":0.2569198985314889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981375592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97616935,0.02228782,0.000005789759,0.0011213769,0.00002015212,0.00033098334,0.000025861984,0.0000032795442,0.000035374895],"genre_scores_gemma":[0.9904634,0.009354757,0.000035572568,0.00003934364,0.000027054048,0.0000073178403,0.000021556323,0.0000128952715,0.00003812885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785006,0.00045121685,0.00058478216,0.00018312057,0.00056520704,0.00036562828],"domain_scores_gemma":[0.9987756,0.00011411495,0.00039259813,0.00018906943,0.00035570966,0.00017291954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007745161,0.00016745419,0.00085193384,0.0005621117,0.000050430328,0.000008922309,0.000103285565,0.00006739694,0.0000010766965],"category_scores_gemma":[0.000089702575,0.00009108937,0.00012116629,0.00080340303,0.00026986454,0.00009721605,0.00004121255,0.00034642481,2.5531648e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058836408,0.0003734172,0.9316247,0.000019133298,0.0031178286,0.00021109568,0.0032056617,0.00039823254,0.0006003618,9.750255e-7,0.000031005336,0.0015811644],"study_design_scores_gemma":[0.02056229,0.0045571183,0.9715246,0.00008175914,0.0021465183,0.00008143098,0.00042133871,0.00031051136,0.00012130982,0.000041257947,0.00006314153,0.00008874472],"about_ca_topic_score_codex":0.0031709343,"about_ca_topic_score_gemma":0.00032232306,"teacher_disagreement_score":0.039899863,"about_ca_system_score_codex":0.00021577282,"about_ca_system_score_gemma":0.00040520387,"threshold_uncertainty_score":0.4793525},"labels":[],"label_agreement":null},{"id":"W1981652396","doi":"10.1021/jm200532b","title":"Inhibitors of Androgen Receptor Activation Function-2 (AF2) Site Identified through Virtual Screening","year":2011,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Chemistry; Androgen receptor; Virtual screening; Androgen; Function (biology); Receptor; Pharmacology; Endocrinology; Internal medicine; Biochemistry; Cell biology; Drug discovery; Hormone; Prostate cancer","score_opus":0.04752172691126391,"score_gpt":0.30095249521721906,"score_spread":0.2534307683059551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981652396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99396724,0.00095235056,0.00090571103,0.00032520734,0.00027136534,0.00009573506,0.000004633137,0.000009077468,0.0034686653],"genre_scores_gemma":[0.99643105,0.00020107956,0.0005833651,0.00006041447,0.0008688304,0.0000028482,0.000021963679,0.0000152552375,0.0018152097],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984742,0.000021456657,0.0005060367,0.00012447627,0.00069759577,0.00017627877],"domain_scores_gemma":[0.99875414,0.000053294858,0.00044916786,0.00013811182,0.00043238857,0.00017286348],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037708765,0.00012191025,0.0003262778,0.00006795346,0.00004894472,0.0000057185307,0.000085646905,0.00011493318,0.0011960024],"category_scores_gemma":[0.00015090895,0.00008718924,0.00014759018,0.00019695704,0.00013769769,0.0002090527,0.00002691638,0.00039274254,0.000005614966],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007160126,0.00037665654,0.028207144,0.00030805907,0.00069452805,0.00011387932,0.0031064919,0.0000016967389,0.93840665,0.000009281013,0.009990863,0.011624657],"study_design_scores_gemma":[0.0036274544,0.0010287628,0.0063471836,0.0009391273,0.00025870692,0.00016727662,0.0030642867,0.000003976819,0.98250175,0.00005250146,0.001928117,0.000080874335],"about_ca_topic_score_codex":0.000035363217,"about_ca_topic_score_gemma":2.1062512e-7,"teacher_disagreement_score":0.044095114,"about_ca_system_score_codex":0.00009637144,"about_ca_system_score_gemma":0.0002494907,"threshold_uncertainty_score":0.99971706},"labels":[],"label_agreement":null},{"id":"W1981713494","doi":"10.1038/aja.2013.38","title":"Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer","year":2013,"lang":"en","type":"review","venue":"Asian Journal of Andrology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Clinical trial; Disease; Androgen receptor; Immunotherapy; Targeted therapy; Cancer; Oncology; Bioinformatics; Intensive care medicine; Internal medicine; Biology","score_opus":0.0671645486621057,"score_gpt":0.387475698076151,"score_spread":0.3203111494140453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981713494","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026122944,0.9953034,0.0000037417349,0.0005523756,0.00014695855,0.0008358543,0.00005388073,0.0000039980255,0.00048748977],"genre_scores_gemma":[0.0027070523,0.9955899,0.0003411343,0.000023952241,0.00010480649,0.00007698761,0.0000281723,0.000040004277,0.0010879559],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981259,0.00014146957,0.00082791864,0.00025204197,0.00022177053,0.00043088422],"domain_scores_gemma":[0.9987952,0.0000812448,0.0005627016,0.0001464844,0.00015077266,0.00026358856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029736335,0.0003378883,0.0020195881,0.0005820584,0.000042324944,0.000036507274,0.000104481966,0.00016088223,0.00022622068],"category_scores_gemma":[0.000037714955,0.00019770046,0.00023261136,0.00025111265,0.00011743668,0.00012541514,0.000035183864,0.00058890966,0.000008555959],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056176056,0.0003776418,0.0028908723,0.0073580556,0.0023985705,0.004090952,0.00047426095,6.1082307e-7,0.00003790085,0.000013303436,0.0005847601,0.9812113],"study_design_scores_gemma":[0.03428406,0.014185353,0.008005236,0.05464625,0.015184475,0.027265705,0.0011958611,0.00004532911,0.000024646644,0.0002998806,0.8437524,0.0011107948],"about_ca_topic_score_codex":0.00005033112,"about_ca_topic_score_gemma":0.000041120227,"teacher_disagreement_score":0.9801005,"about_ca_system_score_codex":0.00020824079,"about_ca_system_score_gemma":0.0011032723,"threshold_uncertainty_score":0.806199},"labels":[],"label_agreement":null},{"id":"W1981805527","doi":"10.1016/j.juro.2011.02.1697","title":"728 AZD5363, A NOVEL AKT INHIBITOR, DELAYS PROSTATE CANCER PROGRESSION","year":2011,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Deutsche Forschungsgemeinschaft; Canadian Institutes of Health Research; Association pour la Recherche sur le Cancer","keywords":"Medicine; LNCaP; Prostate cancer; Protein kinase B; PI3K/AKT/mTOR pathway; Cancer research; Cancer; Population; Oncology; Internal medicine; Signal transduction; Biology; Cell biology","score_opus":0.052398954486886244,"score_gpt":0.34644784247518473,"score_spread":0.2940488879882985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981805527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97969073,0.009769093,0.000093084105,0.008080649,0.0004292119,0.00037878996,0.0000059481235,0.000012939908,0.0015395582],"genre_scores_gemma":[0.9956541,0.0023464302,0.00034610165,0.0005349719,0.0003459959,0.00001324707,0.000001413302,0.000018751683,0.00073895627],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99895185,0.00008784556,0.00029885423,0.00008834392,0.00027170315,0.00030138664],"domain_scores_gemma":[0.9991296,0.000055582466,0.00023958043,0.00015999758,0.0002734771,0.00014177038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005642973,0.00011092594,0.0002489091,0.00011863147,0.00008315785,0.000004987799,0.00014958825,0.000080981554,0.0002312324],"category_scores_gemma":[0.00004112366,0.000052610252,0.00007882855,0.0001410228,0.00021249295,0.00007643913,0.000059727256,0.00045677664,0.000016239488],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09805289,0.004443743,0.253641,0.00033531236,0.0025507554,0.0024732675,0.037082456,0.000059539303,0.39906612,0.00048132648,0.028987559,0.172826],"study_design_scores_gemma":[0.068499856,0.065016545,0.3290093,0.0013268882,0.0046379017,0.022585813,0.0026546344,0.00081142236,0.33669353,0.005239903,0.16242796,0.001096251],"about_ca_topic_score_codex":0.0000545581,"about_ca_topic_score_gemma":0.000012946572,"teacher_disagreement_score":0.17172976,"about_ca_system_score_codex":0.00006770509,"about_ca_system_score_gemma":0.00032074723,"threshold_uncertainty_score":0.25318328},"labels":[],"label_agreement":null},{"id":"W1982073179","doi":"10.1016/j.ijrobp.2005.07.506","title":"Iodine 125 Brachytherapy for Favorable Risk Prostate Cancer: Results for 509 Patients. When Can We Start to Trust PSA After Brachytherapy?","year":2005,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Brachytherapy; Prostate cancer; Iodine; Oncology; Radiology; Cancer; Internal medicine; Radiation therapy","score_opus":0.0237558915599986,"score_gpt":0.3545309693576499,"score_spread":0.3307750777976513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982073179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9087557,0.003325968,0.0076765465,0.06917384,0.0023886631,0.0028956097,0.0055772783,0.00005333946,0.00015302596],"genre_scores_gemma":[0.96022975,0.009753435,0.015661333,0.0047143064,0.005933555,0.00071921496,0.0009569537,0.00008485876,0.0019466131],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976734,0.00013301353,0.0009777736,0.00038546752,0.00035834676,0.00047199745],"domain_scores_gemma":[0.996174,0.0004800244,0.0009947751,0.00019320169,0.0018882207,0.00026978806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070745137,0.0002827397,0.0005902843,0.0002581629,0.00014532922,0.000049341157,0.0002973955,0.00020653698,0.00006660107],"category_scores_gemma":[0.0003268994,0.00022367734,0.0003158003,0.00015387284,0.0001208569,0.00030079272,0.000035631565,0.0003804859,0.000011841652],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02949469,0.001007544,0.2492695,0.000028119548,0.0012839916,0.000009276162,0.0029059618,0.0010175394,0.0009717829,0.0002618909,0.018276306,0.69547343],"study_design_scores_gemma":[0.054595053,0.010320376,0.020546913,0.00017502168,0.0002748516,0.000022105336,0.0001217836,0.0027562096,0.00700504,0.010559886,0.8932326,0.0003901697],"about_ca_topic_score_codex":0.000078136974,"about_ca_topic_score_gemma":0.0001235564,"teacher_disagreement_score":0.8749563,"about_ca_system_score_codex":0.0017178982,"about_ca_system_score_gemma":0.001006449,"threshold_uncertainty_score":0.91212976},"labels":[],"label_agreement":null},{"id":"W1983201610","doi":"10.1038/modpathol.2008.22","title":"Reply to Perner and Rubin","year":2008,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; BC Cancer Agency","funders":"","keywords":"Erg; Fish <Actinopterygii>; Fluorescence in situ hybridization; Chromatin; Confusion; Figure–ground; Biology; Chromosome; Genetics; DNA; Neuroscience; Retina; Psychology; Psychoanalysis; Gene; Fishery","score_opus":0.04586448223097087,"score_gpt":0.3221450143782009,"score_spread":0.27628053214723003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983201610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98674625,0.0010073908,0.00040109595,0.0074472986,0.000042409472,0.00020269373,0.0000042229212,0.000035514942,0.0041131084],"genre_scores_gemma":[0.97949725,0.00027694012,0.0007786484,0.0034285558,0.00006158364,0.000032996668,0.000008938285,0.000012167264,0.015902944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993925,0.000022182468,0.000073959774,0.00022597765,0.00008863775,0.00019676011],"domain_scores_gemma":[0.99962866,0.000013957627,0.000009010922,0.00018449733,0.000035881167,0.00012801937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006623637,0.00006578963,0.00014531915,0.000067168236,0.00006350566,0.0000025989466,0.000027853512,0.00004458899,0.000055470035],"category_scores_gemma":[0.000030119643,0.000047941932,0.000021493423,0.000051472933,0.00009884703,0.000018064817,0.000046905687,0.00008770425,0.00008774747],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022886798,0.0005614801,0.6060585,0.0001223511,0.00012928013,0.024542255,0.021340564,0.000014526539,0.20370513,0.0003405,0.041163705,0.09973303],"study_design_scores_gemma":[0.008270752,0.0033754157,0.8514448,0.000063310916,0.00008435446,0.013432926,0.00019329839,0.0010372878,0.023143973,0.002052922,0.09647457,0.000426391],"about_ca_topic_score_codex":0.000023485962,"about_ca_topic_score_gemma":0.0000024467868,"teacher_disagreement_score":0.2453863,"about_ca_system_score_codex":0.000029826717,"about_ca_system_score_gemma":0.00004623727,"threshold_uncertainty_score":0.19550152},"labels":[],"label_agreement":null},{"id":"W1983730319","doi":"10.1016/j.clon.2011.10.016","title":"Clinical Outcomes of a Phase II Open-labelled, Randomised Study Investigating the Tolerability and Efficacy of Anti-androgen Manipulation versus Taxotere and Anti-androgen Manipulation in Patients with Hormone Naive High Risk/Metastatic Prostate Cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Androgen; Internal medicine; Oncology; Hormone; Adverse effect","score_opus":0.1598036510852493,"score_gpt":0.46795415633656806,"score_spread":0.30815050525131876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983730319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928411,0.0006024806,0.0000043910777,0.00034138947,0.00018163446,0.0059581758,0.00004539574,0.000009097549,0.000016317523],"genre_scores_gemma":[0.9986217,0.0005696713,0.00045981485,0.000051621857,0.000050776183,0.00014422215,0.00006594945,0.000020219924,0.000016040376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958897,0.0013666835,0.0016757624,0.00044101488,0.00031003414,0.00031680727],"domain_scores_gemma":[0.99485576,0.003170935,0.0011607006,0.0003357364,0.00023861743,0.0002382388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035275829,0.00021767917,0.0015923012,0.0000816024,0.00014376747,0.0000125632,0.00013097876,0.00015141616,0.000019166306],"category_scores_gemma":[0.002121661,0.0001240755,0.00009294834,0.00024128307,0.00075148116,0.00018275913,0.0002777849,0.00044656632,7.4999457e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039064128,0.009994022,0.92255485,0.00005253423,0.00086578605,0.0000072467774,0.001204911,0.000015900074,0.000017124059,0.0000068616514,0.000010868821,0.026205799],"study_design_scores_gemma":[0.2484523,0.012384874,0.7376503,0.000049467675,0.0008112162,9.3324195e-7,0.00027197486,0.00022425517,0.000025467521,0.000023933559,0.000013257364,0.00009202569],"about_ca_topic_score_codex":0.0007946579,"about_ca_topic_score_gemma":0.00016007996,"teacher_disagreement_score":0.20938817,"about_ca_system_score_codex":0.00009162374,"about_ca_system_score_gemma":0.0002777451,"threshold_uncertainty_score":0.5059652},"labels":[],"label_agreement":null},{"id":"W1984150537","doi":"10.1038/sj.pcan.4500431","title":"Studies on phenotypic expression patterns of proteases and protease inhibitors in benign compared to malignant prostate tissues","year":2000,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Proteases; Protease; Prostate cancer; Phenotype; Prostate; Medicine; Pathology; Cancer research; Enzyme; Biology; Cancer; Internal medicine; Biochemistry; Gene","score_opus":0.030563533287147986,"score_gpt":0.34424379768507213,"score_spread":0.3136802643979241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984150537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9717981,0.019013088,8.570716e-7,0.0013150881,0.00005999278,0.0066913893,0.0009986956,0.00005564686,0.00006712482],"genre_scores_gemma":[0.98622423,0.008023153,0.00016540205,0.0002499183,0.000058714737,0.0034116204,0.000103483464,0.000049132872,0.0017143701],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755615,0.00011667925,0.0006004404,0.00070611824,0.0004859778,0.00053466193],"domain_scores_gemma":[0.99878114,0.00011934098,0.00013122073,0.00028303463,0.00018210994,0.00050312147],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017557554,0.00039841357,0.00073569576,0.0002731767,0.00014042207,0.000057188307,0.00007556712,0.000050164854,0.00012370909],"category_scores_gemma":[0.00011107273,0.00027967006,0.000057826914,0.00031649863,0.000252955,0.00019422128,0.00008365303,0.00016008706,0.0000061564756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01873928,0.001341027,0.773564,0.007412142,0.00023958021,0.00031850746,0.02263573,0.00020259981,0.0059780674,0.000034958553,0.0006569364,0.16887717],"study_design_scores_gemma":[0.030578846,0.010300602,0.57059395,0.038310606,0.00082879944,0.000041742736,0.016013678,0.00044373574,0.3230122,0.0031186992,0.0046737185,0.0020834247],"about_ca_topic_score_codex":0.00026579518,"about_ca_topic_score_gemma":0.000045728757,"teacher_disagreement_score":0.31703413,"about_ca_system_score_codex":0.00012435546,"about_ca_system_score_gemma":0.00024688873,"threshold_uncertainty_score":0.99996555},"labels":[],"label_agreement":null},{"id":"W1984156818","doi":"10.1007/s00345-003-0373-9","title":"Androgens and prostate cancer","year":2003,"lang":"en","type":"review","venue":"World Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Hormone; Nephrology; Prostate; Cancer; Hormone therapy; Phenotype; Hormonal therapy; Internal medicine; Androgen; Oncology; Cancer research; Bioinformatics; Biology; Gene; Genetics; Breast cancer","score_opus":0.05576463638866219,"score_gpt":0.3964574530233306,"score_spread":0.3406928166346684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984156818","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002128028,0.9966641,8.133792e-7,0.0009471128,0.00044040362,0.00037261163,0.000016552414,0.000004037053,0.0015331054],"genre_scores_gemma":[0.000019009176,0.97873366,0.00006203669,0.00021874635,0.00025246432,0.000020256351,0.000006563762,0.000033076307,0.02065421],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99868536,0.00015181482,0.000518425,0.00016831765,0.00018283629,0.00029321946],"domain_scores_gemma":[0.99897915,0.00009555074,0.00042375177,0.00012938245,0.0001471127,0.00022505443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002884334,0.00021913908,0.0015158394,0.0005342592,0.000033148975,0.000012288998,0.00007466817,0.00012855661,0.00022161465],"category_scores_gemma":[0.000024254394,0.00013012488,0.00027012822,0.00028817283,0.00015606407,0.000032797863,0.000030057927,0.0007266006,0.00000926948],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016525392,0.000056014294,0.00042103726,0.0031613884,0.00076489017,0.0011336715,0.000043874523,1.4414135e-7,8.7527076e-7,0.000024246036,0.0069585633,0.98727006],"study_design_scores_gemma":[0.001150634,0.0005141328,0.000020596744,0.0018516587,0.0020300443,0.0039639203,0.0000030988544,2.8266732e-7,4.5793448e-7,0.000047944828,0.99032575,0.000091451264],"about_ca_topic_score_codex":0.0000034813488,"about_ca_topic_score_gemma":0.000012336107,"teacher_disagreement_score":0.98717856,"about_ca_system_score_codex":0.00016785176,"about_ca_system_score_gemma":0.0012702362,"threshold_uncertainty_score":0.53063387},"labels":[],"label_agreement":null},{"id":"W1984249810","doi":"10.1002/pros.20278","title":"Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic","year":2005,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Prostate cancer; Medicine; Prostate; Pathological; Oncology; Internal medicine; Cancer; Mutation; Family history; Population; Gynecology; Genetics; Gene; Biology","score_opus":0.06577490289870494,"score_gpt":0.3881657273613151,"score_spread":0.32239082446261014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984249810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99588716,0.00031798636,0.000002120106,0.001374802,0.00005512836,0.0022303737,0.000042164822,0.000020680443,0.0000695708],"genre_scores_gemma":[0.9977969,0.00027818413,0.000093236384,0.00011853464,0.00006204837,0.0009158199,0.000052345073,0.00002318574,0.00065972534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800354,0.00023268517,0.0006299422,0.00026752133,0.0005333598,0.00033295408],"domain_scores_gemma":[0.9991189,0.000120121425,0.00025962637,0.00017645236,0.00016431141,0.0001605725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010899074,0.00014843218,0.00031435137,0.00008987844,0.00010334788,0.000024269213,0.00007554723,0.000030775867,0.0001611107],"category_scores_gemma":[0.0004891886,0.000099709956,0.000026411362,0.0002580828,0.0002067602,0.0001407525,0.00009001492,0.00028934097,0.0000063378066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084805564,0.00092859025,0.9297401,0.00019570043,0.00008493208,0.000021155967,0.018444097,0.0000059741137,0.00026356857,0.0000020877242,0.000029953746,0.049435828],"study_design_scores_gemma":[0.008481202,0.004251448,0.9810766,0.0006740124,0.00013852482,0.000010248815,0.0020191993,0.002206597,0.00085080613,0.00010445831,0.000054846583,0.00013205317],"about_ca_topic_score_codex":0.00038196004,"about_ca_topic_score_gemma":0.0005527133,"teacher_disagreement_score":0.05133655,"about_ca_system_score_codex":0.00015338053,"about_ca_system_score_gemma":0.00036265785,"threshold_uncertainty_score":0.4066054},"labels":[],"label_agreement":null},{"id":"W1984251852","doi":"10.1016/s1470-2045(14)70018-x","title":"Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology","year":2014,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Geriatric oncology; Prostate cancer; Task force; Multidisciplinary approach; Geriatrics; Cancer; Family medicine; Internal medicine; Gerontology; Physical therapy; Psychiatry","score_opus":0.092242447733692,"score_gpt":0.4246081119954325,"score_spread":0.3323656642617405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984251852","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066301613,0.9651243,0.000014469878,0.008786062,0.0015201633,0.005960071,0.0005465179,0.0000151426175,0.011403103],"genre_scores_gemma":[0.0037072499,0.99435395,0.00043688208,0.00009032859,0.000115858784,0.00036249132,0.0002444749,0.000019342595,0.0006694404],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99800575,0.00037681576,0.0009200937,0.00020840851,0.00025618414,0.00023273053],"domain_scores_gemma":[0.9978271,0.0002805045,0.001282122,0.00039149585,0.00019500495,0.000023737906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092402217,0.00016860518,0.0017028864,0.0001365183,0.000025054276,0.0000017535094,0.0004989556,0.00019590391,0.00011637733],"category_scores_gemma":[0.000019289968,0.00008795784,0.00031737454,0.00059782085,0.00028299616,0.000018392631,0.00033514295,0.00038295676,0.0000011973254],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043052575,0.0009354102,0.006137387,0.011922893,0.0016250071,0.0000024257558,0.0008093816,0.000004549032,0.000006895383,0.00044422256,0.011127099,0.9665542],"study_design_scores_gemma":[0.00467341,0.0004194005,0.004016603,0.007840645,0.00083262514,0.0000027432957,0.0001562692,0.000016167442,0.000018533605,0.000075663025,0.98187375,0.000074173804],"about_ca_topic_score_codex":0.00011417846,"about_ca_topic_score_gemma":0.00007016633,"teacher_disagreement_score":0.9707467,"about_ca_system_score_codex":0.0007191339,"about_ca_system_score_gemma":0.0005602014,"threshold_uncertainty_score":0.35868165},"labels":[],"label_agreement":null},{"id":"W1984653140","doi":"10.1007/s00439-012-1229-4","title":"HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG)","year":2012,"lang":"en","type":"article","venue":"Human Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":198,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"National Cancer Institute; National Center for Advancing Translational Sciences; National Human Genome Research Institute; Medical Research Council; National Institutes of Health; Universität Ulm; Technische Universität München; Cancer Council Victoria; Cancerfonden; University of Utah; National Institute for Health and Care Research; National Health and Medical Research Council; Pirkanmaan Sairaanhoitopiiri; Cancer Research UK; European Commission; Huntsman Cancer Institute; Royal Marsden NHS Foundation Trust; Centers for Disease Control and Prevention; Tampereen Yliopisto; Université Laval; Northwestern University; Fred Hutchinson Cancer Research Center","keywords":"Prostate cancer; Cancer; Odds ratio; Biology; Oncology; Genetics; Mutation; Prostate; Internal medicine; Medicine; Gene","score_opus":0.08720681193894855,"score_gpt":0.3839081071012775,"score_spread":0.2967012951623289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984653140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95871276,0.017250514,0.00012149119,0.0070196516,0.0009410534,0.0045584743,0.011181765,0.000054058193,0.00016022447],"genre_scores_gemma":[0.9676655,0.011238314,0.0024082267,0.0013739505,0.002427708,0.0022294475,0.0017449614,0.00009777742,0.010814114],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974345,0.000048785198,0.0005891814,0.0005933338,0.00051192445,0.0008222891],"domain_scores_gemma":[0.99788296,0.00022600191,0.00023856976,0.0006665558,0.0007006583,0.00028527065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005054601,0.0003177253,0.0003582268,0.00006309243,0.00038766096,0.00009239654,0.0003438532,0.00013829138,0.00023343504],"category_scores_gemma":[0.000085240215,0.0002232576,0.000200431,0.00012168809,0.00031870886,0.000065171596,0.00015135041,0.00021026519,0.000011654884],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068141785,0.00077903026,0.74595547,0.0003193696,0.0014101189,0.0000063583216,0.015583023,0.00012855988,0.087384276,0.000073429284,0.09756396,0.04398225],"study_design_scores_gemma":[0.02083289,0.0012450916,0.2880095,0.00022932145,0.0008986315,0.000006290824,0.00083860155,0.002295086,0.30739567,0.0014646021,0.37608156,0.0007027787],"about_ca_topic_score_codex":0.00081998407,"about_ca_topic_score_gemma":0.0010436637,"teacher_disagreement_score":0.45794594,"about_ca_system_score_codex":0.00044119792,"about_ca_system_score_gemma":0.0004972124,"threshold_uncertainty_score":0.9104181},"labels":[],"label_agreement":null},{"id":"W1985360090","doi":"10.1158/1078-0432.ccr-08-1726","title":"<i>In vivo</i> Knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors","year":2008,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Prostate cancer; In vivo; Androgen receptor; Gene knockdown; Prostate; Castration; Androgen; Internal medicine; Endocrinology; Medicine; Cancer research; Oncology; Biology; Cancer; Hormone; Cell culture","score_opus":0.10638888335839422,"score_gpt":0.432199639747603,"score_spread":0.32581075638920876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985360090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889094,0.001598162,1.379374e-7,0.006023128,0.00008723957,0.0012582355,0.0001453829,0.0000060791576,0.0019722013],"genre_scores_gemma":[0.98777145,0.009595863,0.000050845396,0.00005298134,0.000096258256,0.00012022339,0.000017799934,0.00001827427,0.0022763077],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99647135,0.0006214059,0.0010411957,0.00046773453,0.00095959497,0.00043873972],"domain_scores_gemma":[0.9979991,0.0006744283,0.0001881038,0.00037287144,0.0005867714,0.00017875024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002806758,0.00013956628,0.0004945096,0.00029140656,0.00011151138,0.000010829463,0.00014059982,0.00015354149,0.000118530974],"category_scores_gemma":[0.001029135,0.00008246472,0.000096179145,0.001236677,0.0012331511,0.00016192757,0.00016764688,0.00081034115,0.0000031174052],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03678985,0.0015209247,0.79459465,0.001047079,0.000061098835,0.00041650294,0.0022242253,0.000009467202,0.12748258,0.00014503388,0.03390376,0.0018048099],"study_design_scores_gemma":[0.022128515,0.0028116107,0.4384248,0.0046482137,0.000024457553,0.000033736782,0.0008161749,0.000075177,0.5261223,0.0006767458,0.0040085986,0.00022973218],"about_ca_topic_score_codex":0.0026222817,"about_ca_topic_score_gemma":0.00087022374,"teacher_disagreement_score":0.39863965,"about_ca_system_score_codex":0.00021345654,"about_ca_system_score_gemma":0.0012199424,"threshold_uncertainty_score":0.45435965},"labels":[],"label_agreement":null},{"id":"W1985483829","doi":"10.1007/s11934-015-0492-z","title":"Active Surveillance for Low-Risk Prostate Cancer","year":2015,"lang":"en","type":"review","venue":"Current Urology Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Disease; Conservative management; Watchful waiting; Internal medicine; Nephrology; Risk assessment; Cancer; Intensive care medicine; Prostatectomy; Oncology; Prostate; Surgery","score_opus":0.09591777721511714,"score_gpt":0.45373619876581556,"score_spread":0.35781842155069843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985483829","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015520811,0.98976773,0.000009836487,0.00013784783,0.0032331434,0.0055627134,0.0007552598,0.000093501105,0.00028476832],"genre_scores_gemma":[0.00006293071,0.9904377,0.000016686412,0.000018734092,0.0008187218,0.004222269,0.0023168698,0.00010517105,0.0020009389],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966669,0.00020918893,0.0009605387,0.0010396951,0.0003688029,0.00075485976],"domain_scores_gemma":[0.9968326,0.00023547752,0.0012149399,0.00073214533,0.0006085971,0.00037623403],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082472037,0.0005681637,0.0025085476,0.00024223766,0.000113565045,0.000018363013,0.0001203598,0.0004162665,0.00007256241],"category_scores_gemma":[0.00048495142,0.0003821955,0.0006104155,0.00030088655,0.00023545245,0.000052594558,0.00011376945,0.0009104067,0.000030585732],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003067656,0.00019478402,0.0024211856,0.0125815375,0.0006595663,0.00050782843,0.000074070165,6.907401e-7,1.2236107e-7,0.0000018933663,0.015365673,0.9678859],"study_design_scores_gemma":[0.0009355134,0.00039821985,0.00009976416,0.0021888614,0.0017221832,0.00063494185,0.000003880577,0.000004758224,0.0000019373597,0.0001194856,0.9935741,0.00031636446],"about_ca_topic_score_codex":0.000023507882,"about_ca_topic_score_gemma":0.000015272994,"teacher_disagreement_score":0.9782084,"about_ca_system_score_codex":0.00051607424,"about_ca_system_score_gemma":0.0035520047,"threshold_uncertainty_score":0.99986297},"labels":[],"label_agreement":null},{"id":"W1985491628","doi":"10.1038/pcan.2014.28","title":"Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer","year":2014,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Hospital; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"GlaxoSmithKline; National Cancer Institute; Stand Up To Cancer; Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Biopsy; Radiology; Soft tissue; Lesion; Cancer; Metastasis; Bone metastasis; Urology; Pathology; Internal medicine","score_opus":0.027456323346360906,"score_gpt":0.3402750758007429,"score_spread":0.312818752454382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985491628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817864,0.009533001,0.000006458566,0.0042197094,0.00011969759,0.0028684733,0.0010975095,0.00010084938,0.0002679213],"genre_scores_gemma":[0.99202865,0.003306767,0.0002114657,0.0012082676,0.00008245252,0.0015123003,0.00024243674,0.000079130004,0.0013284971],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968342,0.00017589318,0.0007192682,0.000902675,0.00057245826,0.0007954713],"domain_scores_gemma":[0.9979976,0.0005454153,0.0002914033,0.00027254637,0.00029754854,0.0005955065],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051770615,0.00049494364,0.0008413407,0.00024508234,0.00022896177,0.00020335363,0.00008050423,0.000050827945,0.00008813248],"category_scores_gemma":[0.0005643062,0.00033856058,0.000076485645,0.0004892276,0.00061691593,0.00030770668,0.000058528913,0.00036852696,0.000003020507],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009195076,0.0010178252,0.95689464,0.0015517263,0.00043516565,0.0005473404,0.0012186401,0.000037457445,0.00065176544,0.0001843899,0.0008801221,0.027385844],"study_design_scores_gemma":[0.018014086,0.0032257766,0.9637588,0.0053391447,0.0012701123,0.00008366156,0.0011812302,0.0031917498,0.0006303407,0.0014798348,0.0009259127,0.0008993039],"about_ca_topic_score_codex":0.00090706063,"about_ca_topic_score_gemma":0.0006234639,"teacher_disagreement_score":0.02648654,"about_ca_system_score_codex":0.00021666822,"about_ca_system_score_gemma":0.0010405404,"threshold_uncertainty_score":0.99990666},"labels":[],"label_agreement":null},{"id":"W1985553475","doi":"10.1002/ijc.25908","title":"Association of tissue promoter methylation levels of <i>APC</i>, <i>TGFβ2</i>, <i>HOXD3</i> and <i>RASSF1A</i> with prostate cancer progression","year":2011,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Lunenfeld-Tanenbaum Research Institute; Public Health Ontario; University of Toronto; Mount Sinai Hospital","funders":"National Cancer Institute; University of Toronto; Canadian Prostate Cancer Research Initiative","keywords":"Methylation; Univariate analysis; Prostate cancer; Cancer; Biology; Biomarker; Cancer research; DNA methylation; Oncology; Molecular biology; Internal medicine; Gene; Medicine; Multivariate analysis; Genetics; Gene expression","score_opus":0.03087872624554417,"score_gpt":0.3727027740100836,"score_spread":0.34182404776453945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985553475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868453,0.007050064,0.0001842592,0.0036843007,0.00048764568,0.0005685116,0.00017409195,0.000009345891,0.0009964416],"genre_scores_gemma":[0.99369663,0.0033284558,0.0015181822,0.00012206041,0.00022517795,0.00003418965,0.000006931962,0.000022377466,0.0010459938],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980122,0.000056271692,0.0005450143,0.00014775529,0.0010682796,0.00017050952],"domain_scores_gemma":[0.9965569,0.000052775886,0.0010703702,0.000088811044,0.002128317,0.00010282423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004138128,0.00013947723,0.00036648108,0.00020842168,0.000023504426,0.000014666506,0.00013167776,0.000082285864,0.00025493928],"category_scores_gemma":[0.000045615758,0.00009051501,0.00006696326,0.00016325185,0.00010219312,0.00031270302,0.00003855844,0.00021117626,6.3454206e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008580434,0.0005133807,0.59635293,0.00029916156,0.0023738765,0.00009729328,0.0036508685,0.000023270304,0.24626006,0.000047623515,0.0010298273,0.1407713],"study_design_scores_gemma":[0.0061426624,0.0014164022,0.15347241,0.0016385308,0.00043112767,0.0000617258,0.00009804055,0.000024173774,0.83154774,0.00031182446,0.0047259647,0.00012943351],"about_ca_topic_score_codex":0.00018975095,"about_ca_topic_score_gemma":0.00007377955,"teacher_disagreement_score":0.58528763,"about_ca_system_score_codex":0.0002892712,"about_ca_system_score_gemma":0.00047007017,"threshold_uncertainty_score":0.36910948},"labels":[],"label_agreement":null},{"id":"W1985630081","doi":"10.1002/cncr.20726","title":"Society of Urologic Oncology position statement: Redefining the management of hormone‐refractory prostate carcinoma","year":2004,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Position statement; Prostate cancer; Refractory (planetary science); Oncology; Cabozantinib; Prostate; Intensive care medicine; Psychological intervention; Internal medicine; Radiation therapy; Cancer; Gynecology; Family medicine","score_opus":0.040625617143652426,"score_gpt":0.345768325659155,"score_spread":0.30514270851550257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985630081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97342056,0.016391143,0.000065513545,0.005663877,0.0000883528,0.0007561769,0.00004574741,0.000017430108,0.0035511977],"genre_scores_gemma":[0.9830684,0.014916267,0.00091179594,0.0002867805,0.000037544552,0.00016580056,0.000035568086,0.000012422457,0.00056542375],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990534,0.000027821736,0.00025991476,0.00017574368,0.0002503747,0.000232724],"domain_scores_gemma":[0.9994575,0.000020529269,0.000157609,0.00020228361,0.00011143986,0.00005065473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021481108,0.00010043083,0.00021403839,0.000034067514,0.00006633855,0.0000036504111,0.000080030375,0.00005743283,0.000049287122],"category_scores_gemma":[0.0000016961103,0.00006127159,0.000101468606,0.00017151884,0.00021322655,0.000043471395,0.000058530102,0.00014573154,0.0000036215724],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020157205,0.005279874,0.14476529,0.0075254245,0.009499331,0.001026102,0.054270837,0.00401433,0.39140144,0.010129289,0.04800791,0.30392298],"study_design_scores_gemma":[0.047556378,0.016294088,0.61958563,0.0011997588,0.0022278768,0.00007013643,0.014812954,0.00036642514,0.16383892,0.004827893,0.12852407,0.0006958965],"about_ca_topic_score_codex":0.00017720078,"about_ca_topic_score_gemma":0.0000045214856,"teacher_disagreement_score":0.47482032,"about_ca_system_score_codex":0.0005634499,"about_ca_system_score_gemma":0.00030477205,"threshold_uncertainty_score":0.24985828},"labels":[],"label_agreement":null},{"id":"W1985734141","doi":"10.1016/j.eururo.2014.02.056","title":"Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)","year":2014,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":273,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Université de Montréal; Alberta Cancer Foundation","funders":"National Cancer Institute","keywords":"Abiraterone acetate; Medicine; Prednisone; Prostate cancer; Interim analysis; Hazard ratio; Internal medicine; Urology; Adverse effect; Oncology; Proportional hazards model; Androgen deprivation therapy; Surgery; Cancer; Randomized controlled trial; Confidence interval","score_opus":0.020455949766307106,"score_gpt":0.3179439517988702,"score_spread":0.2974880020325631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985734141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977942,0.0002995423,0.00010414201,0.0005857434,0.000049033242,0.0007688771,0.000046439454,0.000026326214,0.0003256736],"genre_scores_gemma":[0.9984316,0.00037306768,0.00014638758,0.00031600133,0.000024364368,0.000019043093,0.00022202969,0.00004286262,0.00042459808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980349,0.00047811176,0.0005238301,0.00042296754,0.00019335128,0.00034686792],"domain_scores_gemma":[0.9991688,0.000056897818,0.00020965522,0.00028496573,0.00014771518,0.00013193405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042672124,0.00021795333,0.000587848,0.000342728,0.000049654544,0.00001889748,0.00010633556,0.000033904158,0.0001863718],"category_scores_gemma":[0.00004413274,0.00016267394,0.00007306854,0.0004380346,0.00023898737,0.000068476504,0.00006063459,0.00018662744,0.000013646292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008504653,0.0005612432,0.9469569,0.00012664017,0.0012039971,0.00008879599,0.0016212726,0.00007503418,0.018740723,0.000005747417,0.000027436701,0.022087568],"study_design_scores_gemma":[0.011744071,0.0013166259,0.98347914,0.00004073681,0.0005431121,0.0000041340736,0.000013283001,0.00033552703,0.0020992458,0.0000034938726,0.0002904635,0.00013017973],"about_ca_topic_score_codex":0.000097889206,"about_ca_topic_score_gemma":0.00033748616,"teacher_disagreement_score":0.03652224,"about_ca_system_score_codex":0.00006609171,"about_ca_system_score_gemma":0.000064812775,"threshold_uncertainty_score":0.66336507},"labels":[],"label_agreement":null},{"id":"W1985737794","doi":"10.5489/cuaj.267","title":"Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto","funders":"National Cancer Institute","keywords":"Docetaxel; Medicine; Prostate cancer; Verapamil; Oncology; Internal medicine; Chemotherapy; Cancer; Pharmacology","score_opus":0.020192666766743063,"score_gpt":0.3167427570096246,"score_spread":0.29655009024288154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985737794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9587209,0.000111930705,4.1023748e-7,0.039754815,0.000018575192,0.00083616184,0.000032307318,0.00000261554,0.0005222605],"genre_scores_gemma":[0.99865437,0.00010960516,0.000005797839,0.0007885094,0.000025121946,0.00013878659,0.000006056445,0.000004075473,0.0002676761],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985812,0.00020255195,0.00031409442,0.00010142912,0.0005531557,0.00024759423],"domain_scores_gemma":[0.99880624,0.0002150368,0.00026794625,0.000098236036,0.0004028835,0.00020967348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062287116,0.00008270638,0.00024911473,0.0001581649,0.00008930362,0.000016634975,0.00013914681,0.00005725511,0.00017084125],"category_scores_gemma":[0.00030931877,0.000039423318,0.00003564216,0.00028758676,0.00007214359,0.00006184803,0.000009929737,0.00038551277,0.0000055070855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050550232,0.00023028652,0.995319,0.0000044536637,0.00015315926,0.000014977768,0.0017312157,0.00016734781,0.000039386614,0.000030858588,0.0014525721,0.0008062088],"study_design_scores_gemma":[0.0020136174,0.0010588975,0.99526775,0.000026167612,0.00005307066,0.000004479574,0.000971986,0.000029629393,0.000028485389,0.00009729037,0.00040874118,0.000039887895],"about_ca_topic_score_codex":0.010705638,"about_ca_topic_score_gemma":0.004166569,"teacher_disagreement_score":0.039933447,"about_ca_system_score_codex":0.0005408851,"about_ca_system_score_gemma":0.00074107165,"threshold_uncertainty_score":0.99588215},"labels":[],"label_agreement":null},{"id":"W1985783625","doi":"10.1186/1471-2164-10-476","title":"Identification of novel androgen-responsive genes by sequencing of LongSAGE libraries","year":2009,"lang":"en","type":"article","venue":"BMC Genomics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Michael Smith Health Research BC","keywords":"Prostate cancer; Androgen receptor; Biology; Androgen; LNCaP; Gene; Transcriptome; Gene expression; Serial analysis of gene expression; Prostate; Cancer research; Genetics; Cancer; Endocrinology; Hormone","score_opus":0.05125701377147848,"score_gpt":0.3076668522239885,"score_spread":0.25640983845251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985783625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99194604,0.0053354125,0.0019583004,0.00016879624,0.0000321082,0.00029989224,0.00008817954,0.000012508311,0.00015874034],"genre_scores_gemma":[0.99566346,0.00049694814,0.0026402404,0.000033390028,0.00003227746,0.0000050542762,0.00006883193,0.000009902047,0.0010498902],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99931437,0.000015356853,0.00026742514,0.000135992,0.00013952197,0.00012735942],"domain_scores_gemma":[0.9994541,0.000042821313,0.00013000245,0.00020684647,0.00011279527,0.000053458436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012626378,0.00007549648,0.00018689588,0.00008188502,0.00003000143,0.000010778961,0.00007371304,0.000051643932,0.000012463796],"category_scores_gemma":[0.00004554901,0.00006442044,0.00005812487,0.00012638645,0.00008340698,0.000073762705,0.000019437619,0.000046235054,0.0000028501668],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004391599,0.00010706275,0.0050105383,0.0000858028,0.000036334604,0.0000028210634,0.0005552657,0.000038641152,0.99105537,0.0002394399,0.000161797,0.0022677837],"study_design_scores_gemma":[0.0012193032,0.00021510384,0.006811557,0.0000290312,0.00004710388,0.00000912113,0.0004431961,0.00046349602,0.99027675,0.0001358024,0.00029284242,0.000056699253],"about_ca_topic_score_codex":0.000016678861,"about_ca_topic_score_gemma":0.0000030350157,"teacher_disagreement_score":0.0048384643,"about_ca_system_score_codex":0.000092156304,"about_ca_system_score_gemma":0.00039833042,"threshold_uncertainty_score":0.26269892},"labels":[],"label_agreement":null},{"id":"W1986471949","doi":"10.1158/1538-7445.am2012-3184","title":"Abstract 3184: Whole genome sequencing of low-input fresh frozen prostate cancer biopsies","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Prostate cancer; Prostate; Genotyping; DNA sequencing; Cancer; Whole genome sequencing; Prostate biopsy; Population; Biopsy; Malignancy; Medicine; Oncology; Genome; Computational biology; Biology; Internal medicine; Gene; Genetics; Genotype","score_opus":0.10786961761115928,"score_gpt":0.42035672455036627,"score_spread":0.312487106939207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986471949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9521159,0.039444406,0.000002087175,0.0023596415,0.00027525675,0.0013023237,0.0004914585,0.000058972848,0.003949986],"genre_scores_gemma":[0.9798289,0.008154377,0.00008776371,0.00009056232,0.00092305144,0.000760957,0.00010663459,0.00007916769,0.009968565],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959538,0.00012039204,0.00043309803,0.00046427106,0.0014212218,0.0016072372],"domain_scores_gemma":[0.9976193,0.00016132325,0.00010846332,0.00059605675,0.00088693696,0.0006279578],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013780927,0.0002609905,0.00051561784,0.00050990307,0.00026229833,0.000053624994,0.00031294292,0.00016884074,0.0023954895],"category_scores_gemma":[0.00012322876,0.00019909992,0.00014365223,0.00093281234,0.00066753675,0.00035698115,0.00022721816,0.00088252546,0.00021093957],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009782957,0.00023729287,0.10215848,0.0015251824,0.00031655005,0.00007392624,0.003938323,0.00004385967,0.8789531,0.000035693585,0.005378963,0.0063603353],"study_design_scores_gemma":[0.0048370445,0.00050024834,0.23838256,0.0019081542,0.0001000496,0.000020079058,0.0033943846,0.000041073086,0.7016606,0.00015428968,0.048481323,0.0005202279],"about_ca_topic_score_codex":0.0040945183,"about_ca_topic_score_gemma":0.00019882624,"teacher_disagreement_score":0.17729253,"about_ca_system_score_codex":0.0016814508,"about_ca_system_score_gemma":0.0019896976,"threshold_uncertainty_score":0.99851644},"labels":[],"label_agreement":null},{"id":"W1987087766","doi":"10.1038/nrurol.2014.64","title":"A consensus on trial design for focal therapy","year":2014,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Intensive care medicine; Consensus conference; Medical physics; Cancer; Internal medicine","score_opus":0.21601116722747213,"score_gpt":0.4914998879433195,"score_spread":0.2754887207158474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987087766","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.876418e-7,0.97654444,0.00016397162,0.0013048798,0.0010987545,0.020062272,0.0000372022,0.00005315799,0.0007350134],"genre_scores_gemma":[7.3786003e-7,0.9891491,0.00082783966,0.0020127406,0.002072994,0.003966515,0.00031868354,0.00009928166,0.0015521175],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99608237,0.001426821,0.00088297226,0.000772736,0.0002479309,0.00058715214],"domain_scores_gemma":[0.99624294,0.002232001,0.00046234005,0.0007382832,0.00012327386,0.00020113558],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0018213901,0.0006363544,0.004929054,0.0002865535,0.0000842457,0.000014430553,0.0002571356,0.0021332125,0.00010216098],"category_scores_gemma":[0.0011174863,0.00033334413,0.0015877786,0.00026946637,0.00014679828,0.0000072392786,0.000028719265,0.0020890967,0.00024781868],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023663262,0.00016720407,8.059205e-8,0.008717393,0.00035660676,0.00003872689,0.000003696503,3.2408504e-8,2.1002208e-7,0.00022270602,0.0660327,0.90079737],"study_design_scores_gemma":[0.026417574,0.011628685,7.584789e-8,0.0032760655,0.0013804581,0.00017936775,1.810954e-7,0.0000029517216,0.0000011031582,0.0001048945,0.9567737,0.00023491766],"about_ca_topic_score_codex":7.01943e-7,"about_ca_topic_score_gemma":5.242296e-7,"teacher_disagreement_score":0.90056247,"about_ca_system_score_codex":0.00016108833,"about_ca_system_score_gemma":0.0007846085,"threshold_uncertainty_score":0.99991184},"labels":[],"label_agreement":null},{"id":"W1987574013","doi":"10.1158/1538-7445.am2013-4082","title":"Abstract 4082: Mechanisms of androgen receptor splicing in prostate cancer cells.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"RNA splicing; Androgen receptor; Minigene; Biology; Splicing factor; Cancer research; Intron; Molecular biology; Alternative splicing; LNCaP; Trichostatin A; RNA polymerase II; Prostate cancer; Messenger RNA; Gene; RNA; Gene expression; Cancer; Promoter; Genetics; Histone; Histone deacetylase","score_opus":0.06564885891987825,"score_gpt":0.4002745788000257,"score_spread":0.33462571988014744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987574013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878327,0.0044958224,0.0000035894045,0.0030312997,0.00015992536,0.002250526,0.00007392238,0.00002920275,0.00212298],"genre_scores_gemma":[0.983705,0.007855349,0.00017517652,0.00007043079,0.00013413806,0.001734471,0.00002422426,0.000055071072,0.006246173],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971204,0.00009257924,0.0003867769,0.0004771725,0.0009721636,0.00095094275],"domain_scores_gemma":[0.998426,0.00012022522,0.000071408016,0.0003950296,0.0006675357,0.0003198036],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007834468,0.0001870303,0.0004161782,0.0005091293,0.000103704166,0.000044036846,0.00022823396,0.000114540984,0.004842218],"category_scores_gemma":[0.000045992867,0.00014336807,0.00008475889,0.00095913745,0.00025159962,0.00018989167,0.00013516514,0.0007139189,0.0002134733],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061252556,0.00021572661,0.012613191,0.0007005482,0.00009788107,0.000051942283,0.00081973354,0.000028687906,0.95143926,0.00009976759,0.007095478,0.026225278],"study_design_scores_gemma":[0.0027884312,0.00032198834,0.014958254,0.0009338138,0.000013361593,0.000002335835,0.0007472861,0.0000692719,0.9767812,0.00088608527,0.002332614,0.0001653686],"about_ca_topic_score_codex":0.017385902,"about_ca_topic_score_gemma":0.00036778845,"teacher_disagreement_score":0.02605991,"about_ca_system_score_codex":0.0007883933,"about_ca_system_score_gemma":0.0012010512,"threshold_uncertainty_score":0.99606746},"labels":[],"label_agreement":null},{"id":"W1987838312","doi":"10.1016/j.ijrobp.2015.07.1038","title":"Low-Dose-Rate Prostate Brachytherapy Is Superior to Dose-Escalated EBRT for Unfavorable Risk Prostate Cancer: The Results of the ASCENDE-RT Randomized Control Trial","year":2015,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Urology; Brachytherapy; Clinical endpoint; Prostate; Androgen deprivation therapy; Randomized controlled trial; External beam radiotherapy; Nuclear medicine; Cancer; Surgery; Internal medicine; Radiation therapy","score_opus":0.0287805121390641,"score_gpt":0.3681613727632261,"score_spread":0.33938086062416195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987838312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9374171,0.0011663052,0.00085567444,0.05007641,0.0038398118,0.005406818,0.001082873,0.000035587553,0.00011945639],"genre_scores_gemma":[0.99188644,0.0027781404,0.00030205448,0.0019829764,0.0018691652,0.00037536654,0.00008130248,0.000051109495,0.0006734374],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99616987,0.001255132,0.0013744507,0.0003034007,0.00051995233,0.00037720497],"domain_scores_gemma":[0.99343425,0.0018223344,0.0017875745,0.00027775168,0.0024627813,0.00021533454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047109495,0.0002662206,0.0010055411,0.0001434006,0.00013706184,0.000049452283,0.0005120531,0.00019894753,0.000016696637],"category_scores_gemma":[0.0023639074,0.00014014597,0.0005389613,0.0003188246,0.0004473373,0.00019861454,0.000056285542,0.00056613784,0.00000688041],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91338426,0.0006681736,0.0153350085,0.000016495553,0.0026039262,0.00001075576,0.0040798564,0.0018669029,0.0036908572,0.00029044118,0.0076677054,0.050385598],"study_design_scores_gemma":[0.92425877,0.0047514206,0.0036037283,0.00014733033,0.0005244055,0.000029095405,0.00019554516,0.0048913835,0.013898021,0.005092861,0.042420205,0.00018726074],"about_ca_topic_score_codex":0.00021662234,"about_ca_topic_score_gemma":0.000023851702,"teacher_disagreement_score":0.054469384,"about_ca_system_score_codex":0.00086318003,"about_ca_system_score_gemma":0.0025987036,"threshold_uncertainty_score":0.5714987},"labels":[],"label_agreement":null},{"id":"W1988049837","doi":"10.1158/0008-5472.can-04-2837","title":"p300 Regulates Androgen Receptor–Independent Expression of Prostate-Specific Antigen in Prostate Cancer Cells Treated Chronically with Interleukin-6","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Prostate Cancer Foundation; National Cancer Institute; National Institutes of Health; Terry Fox Foundation; Oesterreichische Nationalbank","keywords":"Androgen receptor; Prostate cancer; Coactivator; Androgen; Internal medicine; Endocrinology; Prostate; Cancer research; CREB; Cancer; Medicine; Biology; Transcription factor; Hormone","score_opus":0.04580033513448021,"score_gpt":0.36727588928392657,"score_spread":0.32147555414944634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988049837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763079,0.017481606,0.0000013120913,0.0023998215,0.000072087656,0.0028251489,0.0001442691,0.000054447664,0.0007133824],"genre_scores_gemma":[0.9600164,0.030961957,0.00023323357,0.000029674096,0.00022662523,0.0011629794,0.000081742335,0.00009565874,0.0071916925],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9954057,0.0002766463,0.00062445004,0.0009030897,0.0015374686,0.0012526694],"domain_scores_gemma":[0.99778026,0.00011662769,0.00014575468,0.0006736491,0.0008702892,0.00041340216],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00092866184,0.00035111108,0.0006726003,0.00068807864,0.00015933014,0.00006847515,0.00036049966,0.00017783273,0.0016923641],"category_scores_gemma":[0.000021390117,0.00023752713,0.00010406612,0.0013405863,0.00066144654,0.00026886418,0.00020526291,0.00092120585,0.00006010764],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01354884,0.0006399375,0.079700164,0.00043961103,0.00013884352,0.00018204341,0.0023749862,0.00029707485,0.8710902,0.00000916373,0.0051271524,0.026452001],"study_design_scores_gemma":[0.00747654,0.0014713455,0.014847322,0.0024354695,0.000018198198,0.000008896906,0.0004591551,0.000060907016,0.94768584,0.0000150723345,0.025261285,0.0002599731],"about_ca_topic_score_codex":0.0015476187,"about_ca_topic_score_gemma":0.00098243,"teacher_disagreement_score":0.07659566,"about_ca_system_score_codex":0.0020256122,"about_ca_system_score_gemma":0.0015863337,"threshold_uncertainty_score":0.99922025},"labels":[],"label_agreement":null},{"id":"W1988298681","doi":"10.1001/jama.2013.8638","title":"Androgen Deprivation Therapy and Risk of Acute Kidney Injury in Patients With Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"JAMA","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Internal medicine; Acute kidney injury; Odds ratio; Oncology; Orchiectomy; Cancer; Urology; Gynecology","score_opus":0.010129617053035101,"score_gpt":0.27700034305596644,"score_spread":0.2668707260029313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988298681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99787414,0.00020222338,7.672581e-7,0.0008092314,0.000013577373,0.0008646259,0.00010246649,0.0000074103596,0.00012553106],"genre_scores_gemma":[0.9946409,0.0046186806,0.00012334966,0.00012467387,0.000016408832,0.0001278081,0.00006998478,0.0000100895,0.0002681243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99949795,0.000020427959,0.00009558852,0.00011629243,0.0001485808,0.000121145524],"domain_scores_gemma":[0.9996271,0.000006884702,0.000050957824,0.00009901825,0.00013544268,0.000080594014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005061089,0.00006513596,0.00012170941,0.00006915267,0.000019021738,0.0000110461115,0.000023142748,0.00003523942,0.00007315937],"category_scores_gemma":[0.000012447211,0.00003800892,0.000011248737,0.00013248855,0.00004722803,0.00012706085,0.000014158353,0.00008337484,0.0000030183564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018312214,0.00009275409,0.8790793,0.00002177535,0.00015120288,0.0000013857521,0.00034859605,1.2085546e-7,0.0005554555,0.0000017445136,0.00072620116,0.11719026],"study_design_scores_gemma":[0.00823466,0.0006281186,0.9808986,0.00008205249,0.000029734732,2.629549e-7,0.000012740024,0.00002632572,0.009488167,0.000047617,0.0005077831,0.000043915694],"about_ca_topic_score_codex":0.0007975627,"about_ca_topic_score_gemma":0.000005349403,"teacher_disagreement_score":0.11714634,"about_ca_system_score_codex":0.000040967247,"about_ca_system_score_gemma":0.00008445193,"threshold_uncertainty_score":0.15499587},"labels":[],"label_agreement":null},{"id":"W1988535187","doi":"10.1358/dot.2009.45.10.1417873","title":"Degarelix for the treatment of prostate cancer","year":2009,"lang":"en","type":"review","venue":"Drugs of today","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Testosterone (patch); Castration; Androgen deprivation therapy; Gonadotropin-releasing hormone; Hormone antagonist; Prostate; Management of prostate cancer; Orchiectomy; Hormone; Internal medicine; Urology; Oncology; Cancer; Endocrine system; Luteinizing hormone","score_opus":0.06837846130566895,"score_gpt":0.4177318112487104,"score_spread":0.34935334994304146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988535187","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003868321,0.99360377,0.0000014117801,0.000581275,0.00014768988,0.0043794736,0.00052559905,0.00001275048,0.00070932915],"genre_scores_gemma":[0.000035866266,0.98339236,0.00009053131,0.000017194365,0.00019006066,0.001242689,0.00020631817,0.000038901195,0.014786106],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986842,0.00003421979,0.00047328224,0.0002556801,0.0002702891,0.00028232893],"domain_scores_gemma":[0.99863994,0.0003274191,0.0003215222,0.0004490557,0.00018379015,0.00007827404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013613445,0.0002911343,0.001538382,0.00012205708,0.000051097257,0.0000066290404,0.0001512187,0.0001329666,0.00006526964],"category_scores_gemma":[0.000018372612,0.00013090808,0.0007811742,0.000193671,0.00011983401,0.00001893867,0.000015074001,0.00009434287,0.000004931881],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001941054,0.00033765438,0.0000159782,0.010170914,0.0008719741,0.000004360088,0.00045482937,5.5390456e-7,0.0000013069413,0.0000243462,0.0024520764,0.9854719],"study_design_scores_gemma":[0.001621443,0.0015567612,0.000014564173,0.007578826,0.0027527297,0.0000032550045,0.00004227091,0.000003053025,0.00026870734,0.000022659215,0.98603076,0.000104985855],"about_ca_topic_score_codex":0.00021256412,"about_ca_topic_score_gemma":0.000010193188,"teacher_disagreement_score":0.98536694,"about_ca_system_score_codex":0.00030673464,"about_ca_system_score_gemma":0.00083373167,"threshold_uncertainty_score":0.53382766},"labels":[],"label_agreement":null},{"id":"W1988812429","doi":"10.1002/pros.10228","title":"Expression study of three secretory proteins (prostatic secretory protein of 94 amino acids, probasin, and seminal vesicle secretion II) in dysplastic and neoplastic rat prostates","year":2003,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute","keywords":"Prostate; In situ hybridization; Prostatic acid phosphatase; Biology; Immunohistochemistry; Prostate cancer; Secretory protein; Pathology; Seminal vesicle; Androgen; Secretion; Molecular biology; Endocrinology; Gene expression; Medicine; Cancer; Gene; Hormone; Biochemistry","score_opus":0.016369480876339413,"score_gpt":0.26036496669270215,"score_spread":0.24399548581636274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988812429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888976,0.0016124984,0.00006396913,0.0001318797,0.000047600537,0.009090594,0.000034523506,0.000034736604,0.00008656843],"genre_scores_gemma":[0.99780947,0.0001409495,0.00043447345,0.000011322341,0.00001848246,0.0009301451,0.000027008162,0.000047787085,0.0005803849],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99739873,0.00034620918,0.0006448427,0.0005237168,0.00058619736,0.0005002846],"domain_scores_gemma":[0.998699,0.00019794349,0.00031343166,0.00040420992,0.00021034358,0.00017505857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008885388,0.0003462793,0.0005883178,0.00024984565,0.00022425191,0.000029154773,0.00010945926,0.00009684531,0.000028441715],"category_scores_gemma":[0.00030527712,0.00022374108,0.000040814644,0.00044179722,0.00058013777,0.00021649868,0.00016059555,0.00040888516,0.0000016190933],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004837355,0.0014702666,0.22525372,0.0025750888,0.00011316879,0.00007960955,0.022901183,0.000030659707,0.7410448,0.00010551581,0.000024335151,0.0015642826],"study_design_scores_gemma":[0.026829304,0.024468794,0.26896462,0.0053528063,0.0004916255,0.00018446833,0.014844351,0.0025430343,0.65147644,0.00391499,0.0001211081,0.0008084658],"about_ca_topic_score_codex":0.000096679454,"about_ca_topic_score_gemma":0.00012676277,"teacher_disagreement_score":0.08956841,"about_ca_system_score_codex":0.0001051099,"about_ca_system_score_gemma":0.00033304447,"threshold_uncertainty_score":0.91238964},"labels":[],"label_agreement":null},{"id":"W1988867141","doi":"10.1371/journal.pone.0024197","title":"FUS/TLS Is a Co-Activator of Androgen Receptor in Prostate Cancer Cells","year":2011,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"LNCaP; Androgen receptor; Prostate cancer; Chromatin immunoprecipitation; Transactivation; FOXA1; Cancer research; Biology; Ectopic expression; Promoter; Activator (genetics); Cancer cell; Transcription factor; Cell biology; Gene expression; Cancer; Receptor; Cell culture; Gene; Genetics","score_opus":0.11018543922217193,"score_gpt":0.31414832720349606,"score_spread":0.20396288798132411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988867141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934664,0.001336526,2.2871684e-7,0.0004535473,0.000023121336,0.0008524005,0.00015502727,0.000020813437,0.0036919662],"genre_scores_gemma":[0.98938113,0.002965395,0.00064656744,0.00013991687,0.00005455562,0.00022957759,0.000025477959,0.000029060671,0.0065283063],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99899787,0.0000255298,0.00020354465,0.00020370755,0.00030092546,0.00026840862],"domain_scores_gemma":[0.99948055,0.000018419169,0.00006595737,0.00020273156,0.00010709732,0.0001252686],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009560466,0.00010806427,0.00033304468,0.000116979194,0.00001979323,0.0000037940774,0.00006477434,0.000052374482,0.0023274785],"category_scores_gemma":[0.000013446687,0.00008346783,0.000042568186,0.00020767325,0.00008443568,0.00006664572,0.000024984323,0.0001386401,0.00008581457],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020423555,0.0032369054,0.24486266,0.00066668465,0.000595354,0.00004489964,0.00557846,3.7098005e-8,0.73933804,0.0000049304704,0.002063839,0.0015658482],"study_design_scores_gemma":[0.0023009095,0.00047394555,0.006650584,0.00050974253,0.000085287254,5.559855e-7,0.0001302672,0.0000085224865,0.9891135,0.00002526803,0.0006161914,0.000085218686],"about_ca_topic_score_codex":0.00051703956,"about_ca_topic_score_gemma":0.000013626899,"teacher_disagreement_score":0.24977548,"about_ca_system_score_codex":0.00012311617,"about_ca_system_score_gemma":0.00023950454,"threshold_uncertainty_score":0.9985845},"labels":[],"label_agreement":null},{"id":"W1989035397","doi":"10.1038/modpathol.3800531","title":"Routine immunohistochemical staining for high-molecular weight cytokeratin 34-β and α-methylacyl CoA racemase (P504S) in postirradiation prostate biopsies","year":2005,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Cytokeratin; Prostate; Pathology; Adenocarcinoma; Immunohistochemistry; Medicine; Prostate cancer; Prostate carcinoma; Biopsy; Internal medicine; Cancer","score_opus":0.011374261153865235,"score_gpt":0.30025372810716994,"score_spread":0.2888794669533047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989035397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843135,0.0048543955,0.0025083441,0.006979385,0.000053201093,0.0010703547,0.000059594327,0.0000463223,0.00011493715],"genre_scores_gemma":[0.99142504,0.00020473724,0.006384354,0.00039252816,0.00008638117,0.00030138434,0.0004674084,0.00003457801,0.0007035933],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985678,0.0000895404,0.00032181822,0.00042086522,0.00015235084,0.0004476048],"domain_scores_gemma":[0.9993853,0.00010112948,0.000076710596,0.0002200305,0.00010980736,0.000107030304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038306494,0.00019192863,0.00037113123,0.000201083,0.000088127235,0.0000208219,0.000057058933,0.00016306799,0.0000204389],"category_scores_gemma":[0.00015991546,0.00016373799,0.00004590951,0.00011685478,0.0001675908,0.00009590398,0.00006272776,0.0002481555,0.000010119276],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027618676,0.00027446807,0.012408673,0.00015650637,0.000049018738,0.00056285714,0.0032490068,0.000088615656,0.95891523,0.00045857648,0.00012151731,0.020953659],"study_design_scores_gemma":[0.05452352,0.0044750064,0.047809545,0.00029474142,0.00035969663,0.00081526116,0.0006826598,0.06183486,0.8191508,0.00630447,0.0025981057,0.001151326],"about_ca_topic_score_codex":0.00003107066,"about_ca_topic_score_gemma":0.000013940796,"teacher_disagreement_score":0.13976443,"about_ca_system_score_codex":0.0002658074,"about_ca_system_score_gemma":0.00013651719,"threshold_uncertainty_score":0.66770416},"labels":[],"label_agreement":null},{"id":"W1989406895","doi":"10.3747/co.20.1217","title":"Analysis of Intraprostatic Therapeutic Effects in Prostate Cancer Patients Using [11C]-Choline pet/ct after External-Beam Radiation Therapy","year":2013,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Association of Radiation Oncology","keywords":"Medicine; Prostate cancer; External beam radiation; External beam radiotherapy; Radiation therapy; Nuclear medicine; Pet imaging; Prostate; Cancer; Radiology; Cancer research; Medical physics; Oncology; Positron emission tomography; Internal medicine","score_opus":0.05325592405964045,"score_gpt":0.419868031925732,"score_spread":0.36661210786609155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989406895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807859,0.016608879,0.000027505532,0.00016385817,0.0004130265,0.001944777,0.000024909634,0.000014477658,0.00001667046],"genre_scores_gemma":[0.9930938,0.005715172,0.0000592421,0.0001373527,0.000056995665,0.0007531853,0.000105020226,0.000022403337,0.000056826782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838054,0.00018080161,0.0004308718,0.0003201004,0.00029120635,0.0003964834],"domain_scores_gemma":[0.9990832,0.0001456235,0.00019547113,0.00020692736,0.00024413118,0.0001245964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017222321,0.00019814397,0.0006122588,0.0006627268,0.000031367534,0.0000151204085,0.00007988031,0.00002172014,0.000336954],"category_scores_gemma":[0.00003057668,0.00014286848,0.00013933415,0.00089305954,0.0001208193,0.00013345368,0.000029823503,0.00024319666,0.000010184472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064527174,0.0011932874,0.78456664,0.00014483204,0.0005339435,0.000051402683,0.00061416946,0.00007313603,0.0021752736,0.0000016116458,0.000019106727,0.20998135],"study_design_scores_gemma":[0.0076041794,0.0010290997,0.97812337,0.00019853639,0.0007188895,0.000005981436,0.000033878645,0.008475239,0.0031210354,0.00009634098,0.0004470494,0.00014640822],"about_ca_topic_score_codex":0.00046225268,"about_ca_topic_score_gemma":0.00005549085,"teacher_disagreement_score":0.20983495,"about_ca_system_score_codex":0.000650781,"about_ca_system_score_gemma":0.00026653754,"threshold_uncertainty_score":0.5826007},"labels":[],"label_agreement":null},{"id":"W1989654330","doi":"10.5489/cuaj.273","title":"Chemotherapy for prostate cancer: Clinical practice in Canada","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Prostate cancer; Chemotherapy; Medicine; Oncology; Prostate; Cancer; Clinical Practice; Internal medicine; Family medicine","score_opus":0.0267402702211714,"score_gpt":0.3429226220611152,"score_spread":0.31618235183994375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989654330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6763838,0.0012289316,0.000005788146,0.31940117,0.00045274882,0.0009791779,0.00004652978,0.000008004709,0.0014938908],"genre_scores_gemma":[0.96892375,0.0025865885,0.00045735535,0.025249358,0.0005564484,0.00017888322,0.000021668222,0.00001546421,0.0020105045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983639,0.00013446584,0.000412154,0.00017422161,0.00031374657,0.0006014982],"domain_scores_gemma":[0.9978397,0.00053531706,0.00019942156,0.0000708323,0.000571147,0.00078359345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079625583,0.0001006781,0.00026678285,0.00008702365,0.00012569466,0.00006199735,0.00008418263,0.00013544118,0.00074948685],"category_scores_gemma":[0.0015786744,0.00007359386,0.00008093352,0.00017151136,0.000020236286,0.00013800795,0.0000057857774,0.0005827571,0.000017011993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00015969804,0.00004113874,0.8500913,0.0000041074613,0.00010200636,0.00006941642,0.00005875445,0.000009885371,0.000009887884,0.000010587569,0.09126455,0.058178682],"study_design_scores_gemma":[0.002879212,0.00025023796,0.6794931,0.000011340969,0.00002360478,0.000034515713,0.00016374198,0.00021466175,0.000009643895,0.0002530582,0.31659123,0.00007564277],"about_ca_topic_score_codex":0.9122009,"about_ca_topic_score_gemma":0.87446296,"teacher_disagreement_score":0.2941518,"about_ca_system_score_codex":0.0055183177,"about_ca_system_score_gemma":0.010128764,"threshold_uncertainty_score":0.9982993},"labels":[],"label_agreement":null},{"id":"W1989660369","doi":"10.5489/cuaj.2545","title":"Serum follicle-stimulating hormone levels predict time to development of castration resistant prostate cancer","year":2015,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Prostate cancer; Medicine; Androgen deprivation therapy; Follicle-stimulating hormone; Internal medicine; Testosterone (patch); Endocrinology; Castration; Androgen; Hormone; Oncology; Cancer; Luteinizing hormone","score_opus":0.0495508422187048,"score_gpt":0.30033059964192155,"score_spread":0.25077975742321673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989660369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98178977,0.00039634836,0.000035877292,0.015824528,0.0000820155,0.00044646888,0.00014098517,0.000018638348,0.0012653575],"genre_scores_gemma":[0.99421644,0.000012692612,0.0012672937,0.00048919505,0.00018330528,0.000024658024,0.00002626985,0.000012348346,0.0037678163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982156,0.000096150325,0.00043522273,0.0001680106,0.00060228456,0.00048271703],"domain_scores_gemma":[0.99782085,0.000049369886,0.0002036662,0.000074446696,0.0006920491,0.0011595901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009957883,0.00012021838,0.00025709232,0.00018816216,0.00019507417,0.000048356564,0.000078658435,0.00013158651,0.00029586017],"category_scores_gemma":[0.0005075762,0.00009176646,0.000054739583,0.0003003953,0.000019460464,0.00009634794,0.000018693165,0.00028330644,0.0000707231],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023685535,0.00022196712,0.841119,0.000038603557,0.00081417337,0.0003556431,0.0059900614,0.0027254098,0.050420616,0.000021463953,0.0409566,0.0549679],"study_design_scores_gemma":[0.0035485837,0.0015488236,0.9656527,0.00006943975,0.000073480725,0.00003389457,0.00019296525,0.0007621442,0.0015049606,0.00011907811,0.02631861,0.00017533787],"about_ca_topic_score_codex":0.00046737437,"about_ca_topic_score_gemma":0.000615171,"teacher_disagreement_score":0.124533676,"about_ca_system_score_codex":0.002788113,"about_ca_system_score_gemma":0.0032863903,"threshold_uncertainty_score":0.72908187},"labels":[],"label_agreement":null},{"id":"W1989665858","doi":"10.1016/j.critrevonc.2013.01.006","title":"The effect of estrogen on the sexual interest of castrated males: Implications to prostate cancer patients on androgen-deprivation therapy","year":2013,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Dalhousie University","funders":"Medical Research Council; Beatrice Hunter Cancer Research Institute","keywords":"Prostate cancer; Estrogen therapy; Androgen deprivation therapy; Estrogen; Medicine; Internal medicine; Androgen; Castration; Oncology; Endocrinology; Gynecology; Cancer; Hormone","score_opus":0.16639744115831975,"score_gpt":0.4974359483198989,"score_spread":0.3310385071615791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989665858","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025997672,0.9596218,0.0000023187022,0.0036119572,0.00022529106,0.010132152,0.00010543454,0.000011654884,0.00029171884],"genre_scores_gemma":[0.0047294796,0.9864522,0.000028057562,0.00022401956,0.0000511319,0.00826873,0.00011130392,0.000043404765,0.00009165968],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99557096,0.0017269751,0.0014527056,0.00051871024,0.0002142948,0.0005163852],"domain_scores_gemma":[0.9922515,0.0059932424,0.0005222425,0.0007745699,0.00029695468,0.00016147814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010677144,0.00044421217,0.0027496614,0.00020952808,0.00010565784,0.000012354973,0.0004486655,0.0004036888,0.000094160234],"category_scores_gemma":[0.0036803614,0.00018965517,0.00030608088,0.00058351946,0.00071721047,0.000025872405,0.00010912591,0.00076076086,0.000120393204],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004199821,0.0005179503,0.0033789321,0.006373188,0.00020078955,0.000012246718,0.000075293865,1.0244372e-7,0.000012437047,0.006555249,0.0021795847,0.98027426],"study_design_scores_gemma":[0.0016767122,0.012823968,0.00035338453,0.022365237,0.0004685126,0.00006835423,0.00003634311,0.00000199479,0.00056708447,0.00016791957,0.9612325,0.00023801708],"about_ca_topic_score_codex":0.000026455553,"about_ca_topic_score_gemma":0.00002967034,"teacher_disagreement_score":0.9800362,"about_ca_system_score_codex":0.00043334544,"about_ca_system_score_gemma":0.0005350088,"threshold_uncertainty_score":0.7733913},"labels":[],"label_agreement":null},{"id":"W1990002146","doi":"10.1016/j.jsbmb.2009.03.011","title":"Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts","year":2009,"lang":"en","type":"article","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"LNCaP; Prostate cancer; Androgen; CYP17A1; Endocrinology; Androgen receptor; Internal medicine; Cancer research; Castration; Steroid; Androgen deprivation therapy; Medicine; Biology; Cancer; Hormone; Gene; Biochemistry","score_opus":0.009730506879473747,"score_gpt":0.2929083875530822,"score_spread":0.28317788067360844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990002146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919739,0.003567075,0.00010735469,0.0039143893,0.000042607127,0.00033609293,0.000013544592,0.0000061270903,0.000038944163],"genre_scores_gemma":[0.9980752,0.0005973656,0.000890704,0.00024436263,0.00007236031,0.000013739415,0.0000051515135,0.0000110752035,0.00009003654],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988371,0.00009880855,0.00037207233,0.00020161962,0.00019068159,0.00029967894],"domain_scores_gemma":[0.99932337,0.00003153238,0.00017127997,0.00018231678,0.000121656485,0.0001698526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038275358,0.00017908217,0.00029065541,0.000114779315,0.0000890226,0.000024346818,0.00012600709,0.00011242286,0.0000056954805],"category_scores_gemma":[0.000048124333,0.000109060325,0.000069354326,0.00014580315,0.0000951068,0.000041074167,0.00004938763,0.00018888048,9.845555e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003105718,0.00009173236,0.00040612658,0.00008784666,0.00006059999,0.00026876165,0.00032844523,0.0000022165416,0.9903247,0.000004762039,0.00001534141,0.0053038],"study_design_scores_gemma":[0.00127883,0.00070575456,0.001921202,0.0004389188,0.00007454288,0.00036710815,0.00023622384,0.000001614939,0.99470735,0.00013063935,0.000027752214,0.0001100404],"about_ca_topic_score_codex":0.0000023927826,"about_ca_topic_score_gemma":0.0000018282789,"teacher_disagreement_score":0.0061013396,"about_ca_system_score_codex":0.00006928525,"about_ca_system_score_gemma":0.00007413748,"threshold_uncertainty_score":0.4447351},"labels":[],"label_agreement":null},{"id":"W1990086381","doi":"10.1007/s00280-010-1389-7","title":"A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation; University of Toronto","funders":"National Cancer Institute; National Institutes of Health","keywords":"Docetaxel; Prostate cancer; Prednisone; Medicine; Internal medicine; Oncology; Cancer research; Castration; Cancer; Pharmacology; Hormone","score_opus":0.030365239443130243,"score_gpt":0.3928297857683229,"score_spread":0.36246454632519265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990086381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863021,0.004466484,2.1038514e-7,0.006117945,0.00030969537,0.00258437,0.00010762405,0.00001640597,0.00009518484],"genre_scores_gemma":[0.9796113,0.01743707,0.000016427697,0.00046722,0.00017356519,0.00065760664,0.000006904546,0.000026074937,0.0016038251],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879146,0.000059122787,0.00029708626,0.00037713174,0.00015663571,0.00031858403],"domain_scores_gemma":[0.999404,0.000057551566,0.00012355142,0.00018130009,0.00008598363,0.00014760866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011493021,0.00023305987,0.00043937025,0.000091600465,0.0002068153,0.000013359686,0.000072753,0.00008460546,0.0004528956],"category_scores_gemma":[0.0000054672237,0.00014686017,0.000046994104,0.0002285841,0.00029942582,0.000063724845,0.000041499123,0.00025274267,4.6190252e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015789844,0.005829423,0.03828064,0.00022683958,0.0007152381,0.00013843806,0.01784338,0.000049137823,0.8735339,0.000010456218,0.00036005964,0.047222633],"study_design_scores_gemma":[0.1859258,0.018278163,0.04386543,0.00017360317,0.00068609783,0.0000753716,0.0011368915,0.0010160983,0.7318024,0.00008580155,0.016570518,0.00038381296],"about_ca_topic_score_codex":0.0033570048,"about_ca_topic_score_gemma":0.0056912075,"teacher_disagreement_score":0.17013596,"about_ca_system_score_codex":0.00016935296,"about_ca_system_score_gemma":0.0004899649,"threshold_uncertainty_score":0.59887844},"labels":[],"label_agreement":null},{"id":"W1990110259","doi":"10.1016/j.ijrobp.2013.10.009","title":"In Regard to Freedland et al","year":2013,"lang":"en","type":"letter","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Biochemical recurrence; Oncology; Radiation therapy; Scopus; Internal medicine; Cohort; Cancer; Gynecology; MEDLINE","score_opus":0.032220464292648146,"score_gpt":0.3784557440689855,"score_spread":0.3462352797763374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990110259","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028404662,0.0006110721,0.0005898148,0.9642573,0.003509063,0.00054516084,0.00012265815,0.000019286064,0.001940968],"genre_scores_gemma":[0.015660388,0.002160814,0.002003327,0.9640294,0.012255215,0.000069101916,0.0007760554,0.000078273944,0.0029674696],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99767107,0.00029250173,0.0007981523,0.00032512375,0.000539909,0.00037322607],"domain_scores_gemma":[0.99755126,0.0004226383,0.0007300835,0.00020311546,0.00093794864,0.0001549489],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00054235966,0.00029025174,0.0007558852,0.0005444524,0.00003060717,0.0000463455,0.00048862735,0.0006326957,0.00030256363],"category_scores_gemma":[0.0002632194,0.00022812902,0.00027100203,0.00019365783,0.00013794501,0.00025916743,0.00010286581,0.0023722337,0.0002198229],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041940802,0.00019374733,0.026373882,0.000012175609,0.0006449021,0.00096935354,0.0002425633,0.00006636467,0.00070659776,0.00025974883,0.9524522,0.01765907],"study_design_scores_gemma":[0.0056980187,0.0014334412,0.0032275026,0.000167401,0.0000711436,0.00029316082,0.000013896503,0.00011535386,0.00041534682,0.0032062759,0.9851692,0.00018931173],"about_ca_topic_score_codex":0.00009522607,"about_ca_topic_score_gemma":0.000009953191,"teacher_disagreement_score":0.03271696,"about_ca_system_score_codex":0.0016942285,"about_ca_system_score_gemma":0.0012327544,"threshold_uncertainty_score":0.9999293},"labels":[],"label_agreement":null},{"id":"W1990341382","doi":"10.1016/j.ijrobp.2007.07.055","title":"RTOG 0215 Treatment of Erectile Dysfunction (ED) in Patients Treated With Neoadjuvant and Concurrent Androgen Deprivation (AD) and Radiotherapy (RT) for Prostate Cancer (PC)","year":2007,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Placebo; Erectile dysfunction; Prostate cancer; Urology; Sildenafil; Crossover study; Randomized controlled trial; Radiation therapy; Clinical endpoint; Internal medicine; Cancer","score_opus":0.01980596996856029,"score_gpt":0.3467595778992176,"score_spread":0.3269536079306573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990341382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930114,0.0031673252,0.0017380186,0.0008340074,0.00034232138,0.0007919849,0.00008483486,0.000008733935,0.00002134918],"genre_scores_gemma":[0.9897699,0.009019539,0.00057050417,0.00008368293,0.00027645446,0.000044054705,0.00017325142,0.000018260747,0.000044377975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989327,0.00005708538,0.00046178306,0.00019538836,0.00017358988,0.00017941913],"domain_scores_gemma":[0.9984858,0.00019157231,0.0005268829,0.00006109388,0.0006251714,0.000109484135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002464754,0.00015289256,0.00038984165,0.00020339238,0.000040152827,0.000010952357,0.000050578812,0.000110991066,0.000010917313],"category_scores_gemma":[0.000047244364,0.000106712505,0.00006086918,0.00011817738,0.00013981924,0.00014778251,0.0000094736015,0.00010785168,2.5723932e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038816722,0.00047909908,0.5959882,0.000011245926,0.00037068842,0.000006484838,0.000477956,0.00003401791,0.0018073755,0.00005388967,0.000050128874,0.39683923],"study_design_scores_gemma":[0.06926169,0.022231495,0.8669687,0.00019633696,0.00026221003,0.00006854532,0.00016188406,0.0016839108,0.027643958,0.00037278733,0.010932467,0.0002160325],"about_ca_topic_score_codex":0.00008023114,"about_ca_topic_score_gemma":0.000044291814,"teacher_disagreement_score":0.3966232,"about_ca_system_score_codex":0.0010519985,"about_ca_system_score_gemma":0.00032811222,"threshold_uncertainty_score":0.43516096},"labels":[],"label_agreement":null},{"id":"W1990643914","doi":"10.1159/000200800","title":"Health-Related Quality of Life in Patients with Hormone Refractory Prostate Cancer Receiving Gefitinib","year":2009,"lang":"en","type":"article","venue":"Urologia Internationalis","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gefitinib; Prostate cancer; Quality of life (healthcare); Antiandrogen; Internal medicine; Oncology; Prostate-specific antigen; Cancer","score_opus":0.03388270765459418,"score_gpt":0.34262796171888343,"score_spread":0.30874525406428927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990643914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870083,0.0022292465,0.0000033819158,0.009085669,0.000053889846,0.00051872124,0.000090926165,0.000030315143,0.0009795958],"genre_scores_gemma":[0.99746656,0.00064649014,0.00010141223,0.00089022616,0.000023416687,0.00003346196,0.0002493702,0.0000098762985,0.00057915563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984761,0.000094562616,0.0005111775,0.00023067267,0.00045747054,0.00023003227],"domain_scores_gemma":[0.99909693,0.000076514654,0.00028098474,0.00014938119,0.00029242266,0.00010379381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003682812,0.00011360558,0.00034144378,0.00017128738,0.000027669825,0.0000074172167,0.000088086614,0.00006534855,0.00014752918],"category_scores_gemma":[0.00022277952,0.00008029085,0.000040554973,0.00021968884,0.00007272096,0.000100927915,0.000020396365,0.00023849877,0.000004419439],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043852297,0.00057845225,0.9821379,0.000031166765,0.00009783434,0.0000064549013,0.00045961927,0.00003573293,0.00015986839,0.00012875785,0.00089471706,0.011084227],"study_design_scores_gemma":[0.0058277855,0.0016043026,0.9917968,0.00009905529,0.000007305268,6.157843e-7,0.00001928738,0.000028259361,0.000044467764,0.00013001305,0.00036757605,0.00007455057],"about_ca_topic_score_codex":0.002027206,"about_ca_topic_score_gemma":0.00014346265,"teacher_disagreement_score":0.011009676,"about_ca_system_score_codex":0.0002759608,"about_ca_system_score_gemma":0.00026735605,"threshold_uncertainty_score":0.32741657},"labels":[],"label_agreement":null},{"id":"W1990701421","doi":"10.1038/modpathol.2010.89","title":"TMPRSS2-ERG gene fusion in transition zone prostate cancer","year":2010,"lang":"en","type":"letter","venue":"Modern Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"","keywords":"TMPRSS2; Prostate cancer; Fusion gene; Prostate; Medicine; Erg; Cancer; Oncology; Pathology; Internal medicine; Biology; Gene; Ophthalmology; Genetics","score_opus":0.023921825058036368,"score_gpt":0.30705059185555394,"score_spread":0.2831287667975176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990701421","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41537482,0.0039412654,0.0003500307,0.57749057,0.00067926175,0.0013603233,0.00031519218,0.00008395083,0.00040457895],"genre_scores_gemma":[0.2091509,0.015771557,0.0014240055,0.70199233,0.0063782074,0.0028682565,0.011154961,0.00046255378,0.050797228],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975338,0.0001475515,0.00036931105,0.00078656775,0.0003942721,0.00076849223],"domain_scores_gemma":[0.9991204,0.00003549941,0.000104096616,0.000510092,0.00013468313,0.000095190706],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00021121789,0.000380129,0.0007162172,0.0004484877,0.00007252714,0.000016266824,0.00013621361,0.0021955401,0.00035538213],"category_scores_gemma":[0.000011456491,0.000304787,0.00014376726,0.00017773514,0.0002129758,0.00005803782,0.000058022582,0.00446265,0.000070542024],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025763465,0.0006017778,0.004137423,0.0016880818,0.00023137899,0.08697078,0.00813466,0.000086840955,0.5182098,0.000003007878,0.28770044,0.08965946],"study_design_scores_gemma":[0.031048119,0.0030929467,0.021736491,0.0017774688,0.0010546886,0.0041153696,0.00009087411,0.005372915,0.040974565,0.0023898839,0.8858554,0.002491301],"about_ca_topic_score_codex":0.00036083997,"about_ca_topic_score_gemma":0.00036673906,"teacher_disagreement_score":0.5981549,"about_ca_system_score_codex":0.00029837905,"about_ca_system_score_gemma":0.0003883647,"threshold_uncertainty_score":0.9999404},"labels":[],"label_agreement":null},{"id":"W1991482686","doi":"10.1158/1538-7445.am2014-1121","title":"Abstract 1121: Extracellular matrix-integrin B1 signaling is a major mediator of epithelial-to-mesenchymal transition and contributes to prostate cancer invasion and metastasis","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Prostate cancer; Epithelial–mesenchymal transition; Metastasis; Cancer research; Bone metastasis; Extracellular matrix; Biology; Plasminogen activator inhibitor-1; Cancer; Integrin; microRNA; Cell; Cell biology; Plasminogen activator; Endocrinology; Genetics","score_opus":0.04669212744388089,"score_gpt":0.38298029672965606,"score_spread":0.33628816928577515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991482686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96129304,0.018110031,0.00019735581,0.017630557,0.00008404093,0.0021094882,0.0004917582,0.0000259261,0.000057787012],"genre_scores_gemma":[0.9924604,0.0045518307,0.00041297026,0.00018240041,0.00020515527,0.0007030514,0.000030498459,0.00004956949,0.001404106],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99701416,0.00019084397,0.0004229659,0.0006438447,0.000961753,0.000766417],"domain_scores_gemma":[0.99784803,0.00036799937,0.00006672436,0.00030363735,0.00075749145,0.0006561169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020107182,0.0002455713,0.0005864646,0.00063758885,0.00020919529,0.000081170205,0.00014205094,0.00013269017,0.00041825662],"category_scores_gemma":[0.0002568759,0.00018571196,0.00007988258,0.00074119633,0.00029685814,0.0001332188,0.000120018456,0.0005100225,0.000021075817],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032252988,0.00011548086,0.006245835,0.0011584461,0.00025537732,0.00004529724,0.0035591167,0.000029440887,0.9520601,0.0001531367,0.0014178785,0.03173456],"study_design_scores_gemma":[0.0049927244,0.0010562856,0.011633109,0.0015904413,0.00016840255,0.000008628374,0.0011301549,0.00023512999,0.96805835,0.00035369635,0.010509002,0.00026407017],"about_ca_topic_score_codex":0.0030265746,"about_ca_topic_score_gemma":0.00025525448,"teacher_disagreement_score":0.031470492,"about_ca_system_score_codex":0.00029423466,"about_ca_system_score_gemma":0.00050776073,"threshold_uncertainty_score":0.75731146},"labels":[],"label_agreement":null},{"id":"W1991500129","doi":"10.1158/1535-7163.targ-13-b133","title":"Abstract B133: Regulation of the androgen receptor function by a metabolic kinase in prostate cancer.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Androgen receptor; Kinase; Cancer research; Androgen; Cancer; LNCaP; Kinome; Biology; Medicine; Internal medicine; Endocrinology; Cell biology; Hormone","score_opus":0.022211170552774218,"score_gpt":0.29957309379486463,"score_spread":0.2773619232420904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991500129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9569024,0.037148826,0.000026302008,0.004122276,0.00018234567,0.0013261391,0.000057276626,0.000019746532,0.00021472546],"genre_scores_gemma":[0.9926498,0.004918727,0.000037592552,0.0007225282,0.00004076879,0.00051411387,0.00003901195,0.000035049008,0.0010424118],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879795,0.000059436017,0.0002577291,0.00023149104,0.00037061208,0.00028280047],"domain_scores_gemma":[0.99930656,0.000012770137,0.00012258446,0.00030987101,0.00017973337,0.00006847678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010617449,0.00016029259,0.0002381827,0.00007622989,0.000051460018,0.000019683175,0.00010070116,0.00007925958,0.00045858792],"category_scores_gemma":[0.0000050150384,0.00010531769,0.00009991677,0.00043862747,0.000106829306,0.00008574663,0.000028289913,0.00019567253,0.000009973735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003640952,0.00014822483,0.035205886,0.00009006733,0.00026380256,0.0000021560159,0.00031864824,0.00009435899,0.88705266,0.000037117643,0.000639048,0.07578392],"study_design_scores_gemma":[0.002757498,0.00013036361,0.17204094,0.00020055812,0.00019558042,0.0000014823472,0.00009290833,0.00030468294,0.79484886,0.00032587108,0.02894542,0.00015583262],"about_ca_topic_score_codex":0.0017322137,"about_ca_topic_score_gemma":0.00007089346,"teacher_disagreement_score":0.13683505,"about_ca_system_score_codex":0.00019529526,"about_ca_system_score_gemma":0.0002567097,"threshold_uncertainty_score":0.5021216},"labels":[],"label_agreement":null},{"id":"W1992621490","doi":"10.1158/0008-5472.can-06-4556","title":"DJ-1 Binds Androgen Receptor Directly and Mediates Its Activity in Hormonally Treated Prostate Cancer Cells","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; Javna Agencija za Raziskovalno Dejavnost RS; Vanderbilt University","keywords":"Antiandrogens; Prostate cancer; Androgen receptor; Androgen; Prostate; Oncogene; Cancer research; Cancer; Internal medicine; Biology; Endocrinology; Immunohistochemistry; Medicine; Hormone; Cell cycle","score_opus":0.06302910905365398,"score_gpt":0.4051370833794658,"score_spread":0.3421079743258118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992621490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688572,0.024447946,6.050769e-7,0.0030737983,0.0001247613,0.0016755536,0.00018684211,0.00005999271,0.0015732452],"genre_scores_gemma":[0.945572,0.04253545,0.000027185013,0.000057371097,0.00027202693,0.0006446296,0.000040099603,0.00006275583,0.010788473],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963369,0.00019559478,0.00030082327,0.0007100409,0.0010918232,0.0013648315],"domain_scores_gemma":[0.998131,0.0003425323,0.00005861185,0.00029285398,0.0005582293,0.00061677734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019457375,0.00027323086,0.00047215787,0.00074606785,0.00020831279,0.00006931628,0.00017740495,0.00020832753,0.0005428963],"category_scores_gemma":[0.0001037465,0.00020901884,0.0000791572,0.0015528802,0.00040009385,0.00021486005,0.00016199294,0.0009048477,0.00005351213],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005178675,0.00028312363,0.13559315,0.00030685178,0.00018188897,0.00031334435,0.0011022722,0.000002383273,0.7864722,0.000007761599,0.0026756192,0.06788274],"study_design_scores_gemma":[0.004273999,0.0005655478,0.095216766,0.00036323647,0.00003150113,0.000005607713,0.00019665033,0.000042959142,0.8898194,0.000022341836,0.009231078,0.00023094137],"about_ca_topic_score_codex":0.0033777645,"about_ca_topic_score_gemma":0.0021244443,"teacher_disagreement_score":0.10334718,"about_ca_system_score_codex":0.0012073261,"about_ca_system_score_gemma":0.0010401302,"threshold_uncertainty_score":0.8523541},"labels":[],"label_agreement":null},{"id":"W1993025432","doi":"10.1158/1538-7445.am2012-lb-435","title":"Abstract LB-435: Double-blind randomized clinical trial of vitamin D3 showing effects on tissue calcitriol levels, gene expression and proliferation immunohistochemistry in prostate cancer","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"","keywords":"Prostate cancer; Medicine; Calcitriol; Prostate; Vitamin D and neurology; Calcitriol receptor; Internal medicine; Prostatectomy; Immunohistochemistry; Cancer; Randomized controlled trial; Urology; Cholecalciferol; Endocrinology; Oncology","score_opus":0.17003112970941617,"score_gpt":0.5049360436617828,"score_spread":0.33490491395236666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993025432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811325,0.010053877,0.000005726719,0.0007385484,0.0003880499,0.0072516548,0.000033620527,0.000020250209,0.00037578834],"genre_scores_gemma":[0.9892376,0.004884557,0.00009654061,0.000030509465,0.0010466675,0.00300779,0.000060913393,0.000047090754,0.0015883122],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961042,0.000625943,0.00081731594,0.0005370447,0.0010829716,0.00083255954],"domain_scores_gemma":[0.99736995,0.0013147226,0.00016993338,0.0004086293,0.00035503964,0.00038171696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005896911,0.00025811867,0.0009735325,0.00035188618,0.00015482864,0.000043860695,0.00015018848,0.00027090465,0.00016238591],"category_scores_gemma":[0.0007075249,0.00018516826,0.00013582414,0.00041694276,0.00045264832,0.00021557036,0.0001237211,0.0011209357,0.000008205537],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.526122,0.00042867428,0.0031826408,0.0006133766,0.000088937646,0.000027814876,0.00052240194,0.000003716751,0.45494157,0.000004558285,0.00025867726,0.01380567],"study_design_scores_gemma":[0.43907103,0.00041850444,0.0018099365,0.0009373486,0.00003671691,0.0000022730949,0.000042498832,0.000013396343,0.55738956,0.000009740796,0.00015876011,0.000110263565],"about_ca_topic_score_codex":0.00068470475,"about_ca_topic_score_gemma":0.000016306567,"teacher_disagreement_score":0.10244797,"about_ca_system_score_codex":0.0006589271,"about_ca_system_score_gemma":0.0009998173,"threshold_uncertainty_score":0.75509423},"labels":[],"label_agreement":null},{"id":"W1993614765","doi":"10.5489/cuaj.471","title":"Defining a new testosterone threshold for medical castration: Results from a prospective cohort series","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Testosterone (patch); Medicine; Prostate cancer; Prospective cohort study; Internal medicine; Castration; Urology; Androgen; Endocrinology; Cohort; Luteinizing hormone; Hormone; Cancer","score_opus":0.020291646436135055,"score_gpt":0.2709317056516741,"score_spread":0.25064005921553906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993614765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7537796,0.00090427994,0.00012929422,0.23484878,0.0004261211,0.001593359,0.00027389743,0.000056667206,0.007987989],"genre_scores_gemma":[0.98961014,0.000101966754,0.0011457666,0.0026299588,0.0010391343,0.0001012519,0.0002607972,0.000014665931,0.005096342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982499,0.00005143384,0.00037854593,0.00024720177,0.0005656414,0.0005072885],"domain_scores_gemma":[0.99768084,0.00027787196,0.00016595276,0.00009662734,0.0004314999,0.0013471802],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005361037,0.00013094643,0.00027076903,0.00009574465,0.0002967659,0.00016723055,0.00009901103,0.00029089418,0.0014794884],"category_scores_gemma":[0.002253109,0.0000944553,0.000095094474,0.00014609989,0.000046012534,0.0002071295,0.000013680771,0.00054352824,0.00011248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004155412,0.00003961092,0.91371226,0.000002490608,0.00026226768,0.000113192546,0.0002650565,0.000003889566,0.00005635053,0.00032091915,0.08141168,0.0033967649],"study_design_scores_gemma":[0.0052775806,0.0010092454,0.9735303,0.00003756626,0.0000860608,0.00020092208,0.00013366148,0.00020740136,0.00008078364,0.0053887567,0.013919081,0.00012863816],"about_ca_topic_score_codex":0.005956168,"about_ca_topic_score_gemma":0.00390284,"teacher_disagreement_score":0.23583052,"about_ca_system_score_codex":0.0013432502,"about_ca_system_score_gemma":0.0024174706,"threshold_uncertainty_score":0.9994333},"labels":[],"label_agreement":null},{"id":"W1993666315","doi":"10.1016/j.ijrobp.2007.04.070","title":"Prognostic Value of Abnormal p53 Expression in Locally Advanced Prostate Cancer Treated With Androgen Deprivation and Radiotherapy: A Study Based on RTOG 9202","year":2007,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Hazard ratio; Radiation therapy; Internal medicine; Oncology; Proportional hazards model; Univariate analysis; Androgen; Confidence interval; Multivariate analysis; Biochemical recurrence; Metastasis; Cancer; Subgroup analysis; Urology; Hormone; Prostatectomy","score_opus":0.014934093510081214,"score_gpt":0.3475411797488933,"score_spread":0.3326070862388121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993666315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99388796,0.0007107893,0.0036080915,0.00063370407,0.00016000723,0.00089360663,0.000022181768,0.00001377364,0.000069867216],"genre_scores_gemma":[0.99658597,0.000597636,0.0022744809,0.00018174016,0.00023015024,0.000040515322,0.000048149,0.000022430977,0.000018906178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985195,0.00013977202,0.00055739173,0.00021666993,0.00035739643,0.00020928818],"domain_scores_gemma":[0.99830925,0.00031997068,0.0005952156,0.00009963139,0.000573076,0.00010287534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059252576,0.00016849936,0.0003975102,0.0003227841,0.000039149436,0.000011182045,0.00012647017,0.00011264686,0.000015697182],"category_scores_gemma":[0.00009973186,0.000117738826,0.00005785193,0.0002640906,0.00013680513,0.00017644562,0.000018938008,0.00030194334,5.5399346e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009922885,0.0014628615,0.8529288,0.00001610686,0.00026231896,0.00013392266,0.0007205995,0.0032967692,0.013877496,0.00006480862,0.000009552256,0.11730385],"study_design_scores_gemma":[0.040929332,0.01297909,0.8996419,0.0005009534,0.0001267005,0.000063117775,0.00032160207,0.00869634,0.03586262,0.00018442767,0.0005125795,0.000181368],"about_ca_topic_score_codex":0.00004143052,"about_ca_topic_score_gemma":0.000023771958,"teacher_disagreement_score":0.11712248,"about_ca_system_score_codex":0.000670437,"about_ca_system_score_gemma":0.00057089556,"threshold_uncertainty_score":0.480125},"labels":[],"label_agreement":null},{"id":"W1993759141","doi":"10.1038/sj.pcan.4500792","title":"The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer","year":2005,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Prostate cancer; Medicine; Androgen suppression; Androgen receptor; Oncology; Androgen; Internal medicine; Endocrinology; Urology; Cancer; Hormone","score_opus":0.03136007122502136,"score_gpt":0.3477048475817159,"score_spread":0.3163447763566945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993759141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8008241,0.09451966,0.000009024173,0.094834104,0.00015102708,0.007967342,0.0016068392,0.00006215364,0.000025733318],"genre_scores_gemma":[0.9493974,0.0322113,0.000118651005,0.0015283845,0.0003104171,0.009352826,0.00014104,0.000080758655,0.006859228],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971484,0.00039648556,0.000548261,0.0006639589,0.00050328573,0.00073959195],"domain_scores_gemma":[0.99568856,0.002864313,0.00020939005,0.0004979619,0.0002814479,0.00045833082],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0009999158,0.00042020687,0.0004921193,0.0000980693,0.0015077211,0.00028462164,0.00023738074,0.0000719773,0.00003319542],"category_scores_gemma":[0.0006172226,0.00018597778,0.00015202652,0.0003260958,0.0008548245,0.00025706599,0.00015621248,0.00029061013,0.0000049291452],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09244601,0.00012106931,0.39171475,0.00029218898,0.0004879391,0.0000081758135,0.01206554,0.000024477033,0.0008734213,0.00015187812,0.007776091,0.49403846],"study_design_scores_gemma":[0.046878137,0.0026140842,0.618713,0.0015907356,0.0011582058,0.000036111105,0.004223266,0.00035860218,0.010868043,0.0032496853,0.309306,0.0010040981],"about_ca_topic_score_codex":0.00013661578,"about_ca_topic_score_gemma":0.0000526331,"teacher_disagreement_score":0.49303436,"about_ca_system_score_codex":0.00022490935,"about_ca_system_score_gemma":0.0005626431,"threshold_uncertainty_score":0.99979216},"labels":[],"label_agreement":null},{"id":"W1993832391","doi":"10.1007/s00280-012-1916-9","title":"Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Abiraterone acetate; QT interval; Medicine; Prednisone; Prostate cancer; Pharmacokinetics; Adverse effect; Internal medicine; Pharmacology; Abiraterone; Urology; Cancer; Cardiology; Androgen deprivation therapy","score_opus":0.022724383275859676,"score_gpt":0.355739936494965,"score_spread":0.3330155532191053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993832391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924278,0.0035481285,0.000001540535,0.002060743,0.00017673797,0.0016315219,0.000066184744,0.00001040201,0.000076931676],"genre_scores_gemma":[0.9962884,0.0017816932,0.000014621012,0.00073083775,0.00008075798,0.0006636942,0.000017396242,0.000025268491,0.00039733798],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888694,0.0001825477,0.0001991466,0.00019294414,0.00018001578,0.0003584068],"domain_scores_gemma":[0.9994798,0.00014171514,0.000103120954,0.000103706334,0.00006550315,0.00010617177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028996222,0.00019062495,0.00037671672,0.000072901574,0.000054459186,0.00000768032,0.00006038862,0.00003864183,0.0005742797],"category_scores_gemma":[0.000004010256,0.00009795981,0.00003468672,0.00016905145,0.00021880449,0.000084854575,0.000014761316,0.0001994276,0.000001839887],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16012926,0.001250244,0.5920661,0.0018121367,0.0022299555,0.00003273758,0.010435802,0.00015527006,0.16305833,0.00003220851,0.0020576243,0.06674032],"study_design_scores_gemma":[0.050319027,0.007269897,0.2027492,0.00037183735,0.00043909944,0.000003766164,0.00010631169,0.00016596189,0.7367201,0.000009031542,0.0016152923,0.00023051574],"about_ca_topic_score_codex":0.00015536946,"about_ca_topic_score_gemma":0.000034210945,"teacher_disagreement_score":0.57366174,"about_ca_system_score_codex":0.00021188421,"about_ca_system_score_gemma":0.00013781228,"threshold_uncertainty_score":0.62879604},"labels":[],"label_agreement":null},{"id":"W1993971008","doi":"10.1097/mou.0b013e32835e9f07","title":"Lessons from in-vivo models of castration-resistant prostate cancer","year":2013,"lang":"en","type":"article","venue":"Current Opinion in Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Vancouver General Hospital","funders":"Canadian Institutes of Health Research; BC Cancer Foundation; Prostate Cancer Canada","keywords":"Prostate cancer; Medicine; Androgen receptor; Antiandrogens; In vivo; Cancer research; Castration; Androgen; Androgen deprivation therapy; Bioinformatics; Cancer; Internal medicine; Hormone; Biology","score_opus":0.11152760560620713,"score_gpt":0.410158332037455,"score_spread":0.2986307264312479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993971008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729006,0.016628353,0.000031181367,0.007454044,0.0013217451,0.0010138792,0.00015794803,0.000015394184,0.0004767971],"genre_scores_gemma":[0.99339706,0.0058139185,0.000045103872,0.000025608382,0.00010451946,0.00041433037,0.000093113864,0.000010943582,0.00009542999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989326,0.00006243527,0.00031777576,0.0002548346,0.00015669165,0.00027568426],"domain_scores_gemma":[0.99952245,0.00006462797,0.00007104061,0.0001724461,0.00009413771,0.0000753179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007948358,0.00010857712,0.00026158034,0.00019298632,0.00001705588,0.000006441484,0.00007163392,0.000076218006,0.00047552475],"category_scores_gemma":[0.000016907328,0.00008727181,0.00003667219,0.00019717989,0.00010719377,0.000101465295,0.00003681412,0.00022130182,0.000012579361],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040513347,0.002859796,0.81531644,0.0013944765,0.00022072424,0.00003058991,0.007915045,0.0043478827,0.059616502,0.0062483083,0.018878352,0.079120554],"study_design_scores_gemma":[0.021434607,0.0016860033,0.884953,0.001384396,0.00007302255,0.000009527594,0.00071173836,0.032037526,0.00683591,0.02908655,0.021195037,0.00059266126],"about_ca_topic_score_codex":0.0024480985,"about_ca_topic_score_gemma":0.00021896545,"teacher_disagreement_score":0.0785279,"about_ca_system_score_codex":0.00009834515,"about_ca_system_score_gemma":0.00026616087,"threshold_uncertainty_score":0.52066624},"labels":[],"label_agreement":null},{"id":"W1994387563","doi":"10.1016/j.ijrobp.2012.07.246","title":"Diabetes and Cardiovascular Mortality in Men With Locally Advanced Prostate Cancer: Updated Analysis From RTOG 92-02","year":2012,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Hazard ratio; Internal medicine; Oncology; Radiation therapy; Cancer; Goserelin; Confidence interval; Urology","score_opus":0.016750360017552167,"score_gpt":0.3343243492304904,"score_spread":0.3175739892129383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994387563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889515,0.008272231,0.00066697056,0.0011022178,0.0003186289,0.0003081583,0.00011091398,0.00001627721,0.0002531131],"genre_scores_gemma":[0.99356824,0.004383927,0.0007640721,0.00021615931,0.00065266347,0.000037359147,0.00031787955,0.00001820732,0.00004147759],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984078,0.00020734876,0.00047610886,0.00023053237,0.00036997063,0.00030825243],"domain_scores_gemma":[0.99859196,0.00013763086,0.0003931756,0.00016058507,0.0005286655,0.00018798404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005784716,0.00017912863,0.000686033,0.00024920446,0.000042374504,0.000019838322,0.00015834795,0.00013437115,0.00006046883],"category_scores_gemma":[0.000055689663,0.0001299485,0.00021561289,0.00039597487,0.00019110463,0.00036948614,0.00004769782,0.00035801012,0.0000034651027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007101035,0.0002679196,0.924727,0.0000065002396,0.0096630715,0.000036144516,0.00054033165,0.001551351,0.0012306964,0.00009053328,0.000108485285,0.061067812],"study_design_scores_gemma":[0.011550105,0.00066205533,0.9739583,0.00006979968,0.0018425343,0.000013372477,0.00020931494,0.0026766406,0.004046051,0.0007095386,0.0040749274,0.00018733204],"about_ca_topic_score_codex":0.00024448463,"about_ca_topic_score_gemma":0.00004605947,"teacher_disagreement_score":0.06088048,"about_ca_system_score_codex":0.00064486323,"about_ca_system_score_gemma":0.00041286575,"threshold_uncertainty_score":0.5299146},"labels":[],"label_agreement":null},{"id":"W1995104782","doi":"10.1016/j.nucmedbio.2014.05.102","title":"Evaluation of [68Ga]-DOTA ghrelin (1–19) in LNCaP prostate carcinoma","year":2014,"lang":"en","type":"article","venue":"Nuclear Medicine and Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Scintigraphy; Urology; Medical physics; Radiology","score_opus":0.1164688328945796,"score_gpt":0.3982153369823704,"score_spread":0.2817465040877908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995104782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98424596,0.0024127227,0.0000019752454,0.0064745676,0.00008178637,0.0004226676,0.0000030594072,0.000013038283,0.006344243],"genre_scores_gemma":[0.998388,0.0005855779,0.00006000529,0.00061218743,0.00014035322,0.000012400829,0.0000396775,0.00001117659,0.0001506039],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989318,0.00020016005,0.0002328136,0.00021880287,0.00021653241,0.00019984138],"domain_scores_gemma":[0.99940246,0.0000746791,0.000057572037,0.00015989362,0.00020156123,0.000103835555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015231716,0.000095900694,0.00031460682,0.00018954565,0.000027372853,0.0000016002899,0.000040811537,0.000077350356,0.00029977557],"category_scores_gemma":[0.0004335179,0.0000591134,0.000022785583,0.00015549856,0.00031986643,0.000020806288,0.000032482632,0.00014096455,0.000011637525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00199602,0.00037535344,0.5442525,0.00046063965,0.00015634188,0.000036867197,0.006370287,0.0000036229712,0.122161634,0.0022371826,0.008546978,0.3134026],"study_design_scores_gemma":[0.04013326,0.012945823,0.84935915,0.00061694585,0.00070020446,0.00017934418,0.0031001463,0.016765459,0.0017838014,0.0086590685,0.06541145,0.00034534442],"about_ca_topic_score_codex":0.0005559542,"about_ca_topic_score_gemma":0.000037593458,"teacher_disagreement_score":0.31305724,"about_ca_system_score_codex":0.00006434323,"about_ca_system_score_gemma":0.0001063758,"threshold_uncertainty_score":0.3282332},"labels":[],"label_agreement":null},{"id":"W1995156882","doi":"10.1097/01.pas.0000213424.38503.aa","title":"TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion","year":2007,"lang":"en","type":"article","venue":"The American Journal of Surgical Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":431,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; National Institute on Aging; Johns Hopkins University","keywords":"TMPRSS2; Prostate cancer; Fusion gene; Malignancy; Medicine; Prostate; Cancer; Erg; Intraepithelial neoplasia; Fluorescence in situ hybridization; PCA3; Pathology; Oncology; Cancer research; Internal medicine; Biology; Disease; Gene","score_opus":0.0175685097098907,"score_gpt":0.32636967270682504,"score_spread":0.30880116299693433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995156882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946677,0.00097648724,0.00011415252,0.0036944493,0.000074005075,0.00024323336,0.0000055967985,0.000015838503,0.00020853181],"genre_scores_gemma":[0.99771667,0.0014661041,0.00012807662,0.00027958237,0.0001153958,0.000005804857,0.000007821745,0.000024620316,0.00025589977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980938,0.0003435922,0.00039729857,0.00018020891,0.0005390079,0.00044613265],"domain_scores_gemma":[0.9984172,0.00018217425,0.0005124991,0.00020853635,0.0003654914,0.00031407893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014159471,0.00015724757,0.000528414,0.0001584147,0.000102354716,0.000012428665,0.00016495318,0.000050421237,0.000045931687],"category_scores_gemma":[0.000043662254,0.000076528006,0.00012443127,0.00048177716,0.0006668579,0.00007534465,0.00004608315,0.00054083846,0.0000042593297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05069223,0.0019229712,0.37236357,0.000030153476,0.0008198459,0.087993436,0.0035063168,0.0002721035,0.14017534,0.000134738,0.00018240597,0.34190688],"study_design_scores_gemma":[0.014332952,0.04279969,0.90908235,0.00061114115,0.0005486622,0.0079630995,0.0017913535,0.00007648543,0.020064639,0.0003593804,0.0019594,0.00041087388],"about_ca_topic_score_codex":0.000087495195,"about_ca_topic_score_gemma":0.00001813116,"teacher_disagreement_score":0.5367187,"about_ca_system_score_codex":0.00019280697,"about_ca_system_score_gemma":0.000261602,"threshold_uncertainty_score":0.31207216},"labels":[],"label_agreement":null},{"id":"W1995627894","doi":"10.1111/j.1464-410x.2007.07283.x","title":"New blood‐based biomarkers for the diagnosis, staging and prognosis of prostate cancer","year":2007,"lang":"en","type":"review","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Biomarker; Kallikrein; Oncology; Prostate-specific antigen; Prostate; Metastasis; Internal medicine; Cancer biomarkers; Disease; PCA3; Management of prostate cancer; Biology","score_opus":0.06962605013797137,"score_gpt":0.39350234501161463,"score_spread":0.3238762948736433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995627894","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002659623,0.99611133,0.00007795526,0.0013692587,0.00023321819,0.0017365521,0.00018160992,0.0000053545864,0.00001878398],"genre_scores_gemma":[0.00018133706,0.99830353,0.0006133832,0.00013191487,0.00033976982,0.00019409975,0.000022399572,0.000045435874,0.00016812363],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982458,0.000110318295,0.00077561295,0.00021265926,0.00027766984,0.00037797305],"domain_scores_gemma":[0.99765724,0.0009567322,0.0007365167,0.00011450737,0.00032684742,0.00020816136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008237628,0.00021072563,0.0013176468,0.00027581843,0.000083344625,0.00003246866,0.00017410981,0.00020065458,0.00006928623],"category_scores_gemma":[0.00018580873,0.0001409206,0.00043842968,0.00025171167,0.0002323169,0.00004337052,0.000039099636,0.00048450293,2.713969e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038328773,0.00012380535,0.0042320243,0.0069726473,0.0020004255,0.00060221605,0.000024198815,6.283588e-7,0.0000012127842,0.0000018690223,0.0051725153,0.98048514],"study_design_scores_gemma":[0.004143801,0.0014844906,0.00096465845,0.012115685,0.0069461665,0.002753192,0.000016225968,0.0000044468557,0.000027555905,0.000016938466,0.971396,0.00013079043],"about_ca_topic_score_codex":0.00029217688,"about_ca_topic_score_gemma":0.00005596313,"teacher_disagreement_score":0.98035437,"about_ca_system_score_codex":0.00006606777,"about_ca_system_score_gemma":0.0016004569,"threshold_uncertainty_score":0.5746575},"labels":[],"label_agreement":null},{"id":"W1995922001","doi":"10.1158/1538-7445.am2013-86","title":"Abstract 86: Prolactin and testosterone induction of carboxypeptidase-D to promote cell survival is greater in prostate cancer cells than benign prostate cells, and their synergistic action in prostate cancer cells is effectively blocked by receptor antagonists Δ1-9-G129R and flutamide.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"LNCaP; Prostate cancer; Prostate; Endocrinology; Androgen receptor; Prolactin; Downregulation and upregulation; Cancer research; Internal medicine; PCA3; Testosterone (patch); Receptor; Cell culture; Chemistry; Biology; Medicine; Cancer; Hormone; Biochemistry","score_opus":0.03749523915747602,"score_gpt":0.3347341387463266,"score_spread":0.29723889958885064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995922001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98257524,0.0043500606,6.206509e-7,0.0026456795,0.0002575147,0.008823392,0.0012496363,0.00004053146,0.00005735587],"genre_scores_gemma":[0.97595567,0.016398177,0.000057636527,0.000075028336,0.00012683992,0.0039183074,0.000050625662,0.00014167825,0.0032760452],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99494416,0.0003998882,0.0007425811,0.0015099655,0.00092969293,0.0014737217],"domain_scores_gemma":[0.9977354,0.00021152494,0.00025160456,0.00046250646,0.00068318855,0.0006558091],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012177187,0.0006592567,0.0009776925,0.0008294953,0.00024215154,0.0002186586,0.00018898233,0.00026130467,0.00022594078],"category_scores_gemma":[0.00003699096,0.0005106628,0.000064595384,0.0011005423,0.0006477566,0.00050470734,0.00026158828,0.0012430006,0.000017175074],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041805324,0.0003541631,0.06163293,0.0026302403,0.00012117607,0.000035962094,0.012014431,0.000015452688,0.89671504,2.2395852e-7,0.0019919379,0.020307908],"study_design_scores_gemma":[0.005407889,0.0013195808,0.07380425,0.0015017602,0.000043824202,0.0000045825445,0.0014780265,0.00017665123,0.9149494,0.000030367573,0.00081010733,0.0004735479],"about_ca_topic_score_codex":0.034240324,"about_ca_topic_score_gemma":0.0021565924,"teacher_disagreement_score":0.032083735,"about_ca_system_score_codex":0.0012549468,"about_ca_system_score_gemma":0.0007973226,"threshold_uncertainty_score":0.9997345},"labels":[],"label_agreement":null},{"id":"W1996079511","doi":"10.1016/j.ijrobp.2011.06.608","title":"Low Dose Rate Prostate Brachytherapy (LDR-PB) for Intermediate Risk Disease: A Population Based Cohort Analysis","year":2011,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Brachytherapy; Cohort; Prostate brachytherapy; Prostate cancer; Population; Oncology; Internal medicine; Radiation therapy; Cancer; Environmental health","score_opus":0.025609424996418783,"score_gpt":0.35569156039349936,"score_spread":0.3300821353970806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996079511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95740193,0.00049554097,0.037858408,0.001309792,0.0013385279,0.0009800796,0.00046244057,0.00004781237,0.00010545812],"genre_scores_gemma":[0.9925591,0.001394995,0.002780385,0.00060389383,0.0011305317,0.000107892156,0.0012622606,0.000036799993,0.00012415426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979259,0.00032943476,0.00079276745,0.00032344504,0.00031748752,0.0003110091],"domain_scores_gemma":[0.996725,0.00037809685,0.0012498365,0.0002106533,0.001161704,0.00027469383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000986537,0.00023723805,0.0006080862,0.000476932,0.00010772756,0.00003253192,0.00027855116,0.00016538166,0.00016743974],"category_scores_gemma":[0.0003668315,0.00018645225,0.00056464935,0.00037339234,0.00015092161,0.0003066526,0.000031030715,0.00037046015,0.00001386656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067589846,0.00075216603,0.9233729,0.000019408328,0.0037233036,0.00006695333,0.00033393345,0.00062197226,0.0006931462,0.00040881202,0.00026038496,0.06298802],"study_design_scores_gemma":[0.011132748,0.0018226419,0.95815885,0.00005798726,0.0016212149,0.0000122008,0.000031089457,0.016377764,0.0023342315,0.0067435345,0.0015100574,0.00019770561],"about_ca_topic_score_codex":0.00006404488,"about_ca_topic_score_gemma":0.000014524439,"teacher_disagreement_score":0.06279031,"about_ca_system_score_codex":0.00085221604,"about_ca_system_score_gemma":0.0007789989,"threshold_uncertainty_score":0.7603302},"labels":[],"label_agreement":null},{"id":"W1996135170","doi":"10.5489/cuaj.10160","title":"Emerging novel therapies in the treatment of castrate-resistant prostate cancer","year":2011,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Denosumab; Prostate cancer; Docetaxel; Hormonal therapy; Ipilimumab; Oncology; Internal medicine; Combination therapy; Nivolumab; Dasatinib; Clinical trial; Abiraterone; Cancer; Pharmacology; Immunotherapy; Tyrosine kinase; Receptor; Osteoporosis","score_opus":0.05182196921740727,"score_gpt":0.2997207232699185,"score_spread":0.24789875405251122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996135170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98326075,0.0022212304,0.000002078611,0.012432744,0.00009204327,0.00029449316,0.00004830973,0.0000045292068,0.001643792],"genre_scores_gemma":[0.9968754,0.0019950478,0.00006601901,0.000417107,0.00009931692,0.000039434326,0.0000063181233,0.0000061641535,0.00049518957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989537,0.000090417845,0.00023650723,0.000104653736,0.0002472691,0.00036745137],"domain_scores_gemma":[0.9994003,0.00005502801,0.00013438705,0.000073677234,0.00014428733,0.00019230925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036082923,0.000095819494,0.00019157046,0.00013913591,0.00012103358,0.000022147211,0.00007738204,0.000079059726,0.00040861397],"category_scores_gemma":[0.000038444563,0.000049811035,0.00008658076,0.0002148036,0.000042315412,0.000045984274,0.0000023743316,0.00019318366,0.000003584987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004295826,0.00037885722,0.9778587,0.0000057060047,0.00021617334,0.00022624437,0.011120386,0.000007505971,0.0011433131,0.00013991316,0.00035658092,0.0081170155],"study_design_scores_gemma":[0.0021641755,0.0013495936,0.9751709,0.00001748832,0.000055663088,0.0000343154,0.0013650492,0.000021628073,0.0003024133,0.00027165096,0.019184148,0.00006295369],"about_ca_topic_score_codex":0.012103131,"about_ca_topic_score_gemma":0.008415941,"teacher_disagreement_score":0.018827567,"about_ca_system_score_codex":0.0010399984,"about_ca_system_score_gemma":0.0005718913,"threshold_uncertainty_score":0.99447536},"labels":[],"label_agreement":null},{"id":"W1996331760","doi":"10.1200/jco.2009.27.15_suppl.5123","title":"Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group (RTOG) prostate clinical trials","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Western University","funders":"","keywords":"Medicine; Prostate cancer; Cohort; Proportional hazards model; Internal medicine; Population; Prostate-specific antigen; Oncology; Urology; Radiation therapy; Hazard ratio; Cancer; Gynecology; Confidence interval","score_opus":0.34318990405283833,"score_gpt":0.6349536797485381,"score_spread":0.2917637756956998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996331760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98434764,0.001316225,0.00004156029,0.011784376,0.0010552619,0.0010861973,0.00003508639,0.000012302477,0.00032134753],"genre_scores_gemma":[0.97202975,0.02207505,0.0013347258,0.002466323,0.0019272421,0.000007741624,0.000021967891,0.000022981074,0.00011419907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9813111,0.007387561,0.009681604,0.0005057174,0.00061202666,0.00050202233],"domain_scores_gemma":[0.9612951,0.032916784,0.004008522,0.00033593006,0.0005375054,0.000906108],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.039524987,0.00032777584,0.0056768367,0.00038939348,0.0000351813,0.0000133994245,0.00024218306,0.0009912543,0.00015793035],"category_scores_gemma":[0.036471374,0.00018313146,0.002139948,0.00028988233,0.0007126533,0.00014559895,0.00003185122,0.0027534645,0.000008397356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041080404,0.009586732,0.51590127,0.000007662711,0.0008150057,0.00033634572,0.00003729632,0.0000035839107,0.0006806538,0.000023475961,0.0024290716,0.4290985],"study_design_scores_gemma":[0.068074286,0.107660964,0.8201554,0.00010576397,0.00030080168,0.0000988299,0.000030504865,0.00008413077,0.0001973096,0.00068358716,0.002473976,0.00013447131],"about_ca_topic_score_codex":0.00005077128,"about_ca_topic_score_gemma":0.00002341303,"teacher_disagreement_score":0.42896402,"about_ca_system_score_codex":0.00034962862,"about_ca_system_score_gemma":0.0033167042,"threshold_uncertainty_score":0.99954724},"labels":[],"label_agreement":null},{"id":"W1996460180","doi":"10.1016/j.juro.2014.02.1121","title":"MP49-20 FINE-MAPPING OF THE KALLIKREIN REGION AND ITS ROLE IN PROSTATE CANCER AGGRESSIVENESS: RESULTS FROM A CANADIAN COHORT AND THE EUROPEAN RANDOMIZED STUDY FOR PROSTATE CANCER SCREENING","year":2014,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Cohort; Randomized controlled trial; Gynecology; Oncology; Internal medicine","score_opus":0.020904145369820333,"score_gpt":0.2877544216792284,"score_spread":0.26685027630940805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996460180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9547029,0.016277794,0.000018640209,0.025958445,0.00010374671,0.00273752,0.000048369624,0.0000029311798,0.00014961859],"genre_scores_gemma":[0.99392176,0.0051655495,0.000014125459,0.00031300265,0.0001617127,0.000095009054,0.000004097609,0.000020423558,0.0003043131],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967918,0.0019638578,0.0005664458,0.00016921274,0.0002125884,0.0002961304],"domain_scores_gemma":[0.9976814,0.00113408,0.00061012374,0.00019895252,0.00026440568,0.000111062494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004741664,0.00014847949,0.0006509681,0.000137499,0.0001842273,0.000017338181,0.0001996862,0.000038208735,0.0000037658388],"category_scores_gemma":[0.00066976243,0.000061661725,0.00007845351,0.00015870726,0.00037777805,0.000056180146,0.0000779639,0.00037793763,1.4556267e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5668173,0.00015574056,0.33278993,0.00011702414,0.0023161008,0.00018162184,0.04846835,0.0021777332,0.002370866,0.00004255943,0.0005038713,0.044058904],"study_design_scores_gemma":[0.59477866,0.0014338358,0.38092494,0.0012833012,0.0019341415,0.00019962373,0.0026849944,0.010475016,0.00071677455,0.0011267497,0.004201609,0.0002403822],"about_ca_topic_score_codex":0.035185695,"about_ca_topic_score_gemma":0.053690962,"teacher_disagreement_score":0.048135005,"about_ca_system_score_codex":0.000060841023,"about_ca_system_score_gemma":0.00032492034,"threshold_uncertainty_score":0.9712391},"labels":[],"label_agreement":null},{"id":"W1997195909","doi":"10.1016/j.humpath.2006.07.003","title":"Comprehensive expression analysis of l-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors","year":2006,"lang":"en","type":"article","venue":"Human Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"","keywords":"Prostate cancer; Chromogranin A; Neuroendocrine differentiation; Tissue microarray; Androgen receptor; Prostate; Population; Internal medicine; Medicine; Hormone therapy; Hormonal therapy; Androgen; Immunohistochemistry; Endocrinology; Cancer research; Biology; Cancer; Hormone; Breast cancer","score_opus":0.02750831622787099,"score_gpt":0.31303445295401994,"score_spread":0.28552613672614896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997195909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960603,0.0026149908,0.00000283773,0.00012725462,0.000039211227,0.000577001,0.00003897499,0.00004320946,0.0004962377],"genre_scores_gemma":[0.99867463,0.0003811121,0.00013292317,0.000025215697,0.000025055562,0.000055483924,0.0005056414,0.000026036048,0.00017391681],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99820614,0.00019672215,0.00042252298,0.0004918524,0.00022920583,0.00045358375],"domain_scores_gemma":[0.99917465,0.00013878789,0.00014866098,0.00030888533,0.000110967856,0.000118061806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000087950575,0.00023200618,0.0006990975,0.0008690714,0.00008767267,0.000016030788,0.00007612885,0.000044043456,0.00003086668],"category_scores_gemma":[0.00003081551,0.00018900116,0.000106896325,0.00081710116,0.00027492095,0.00008940638,0.00009886398,0.0002419062,0.0000014214127],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007502108,0.0005346569,0.34067154,0.0001361856,0.0002579561,0.013881996,0.00035681707,0.0003585558,0.635025,0.0000335216,0.00035745554,0.0008841721],"study_design_scores_gemma":[0.016711414,0.0016579089,0.9407516,0.00010842912,0.0006921016,0.0001292109,0.00026609935,0.0011595822,0.038178377,0.0000646471,0.00007296426,0.00020765202],"about_ca_topic_score_codex":0.0007359991,"about_ca_topic_score_gemma":0.00011236545,"teacher_disagreement_score":0.6000801,"about_ca_system_score_codex":0.00009368911,"about_ca_system_score_gemma":0.000038897244,"threshold_uncertainty_score":0.77072436},"labels":[],"label_agreement":null},{"id":"W1997353298","doi":"10.1158/0008-5472.can-06-1593","title":"Impaired Dihydrotestosterone Catabolism in Human Prostate Cancer: Critical Role of AKR1C2 as a Pre-Receptor Regulator of Androgen Receptor Signaling","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Dihydrotestosterone; Androgen receptor; Androgen; Catabolism; Endocrinology; Internal medicine; Prostate cancer; Biology; Receptor; Prostate; Downregulation and upregulation; Cancer; Cancer research; Metabolism; Medicine; Biochemistry; Hormone","score_opus":0.04372021552373926,"score_gpt":0.4234314886908429,"score_spread":0.3797112731671036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997353298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97721666,0.01846442,0.0000024224873,0.0015040154,0.000116670526,0.0019863665,0.00024633977,0.000035979137,0.00042709694],"genre_scores_gemma":[0.9950895,0.0015658825,0.00014092692,0.000029272296,0.00032265304,0.0005815065,0.00008277195,0.00007925435,0.0021082596],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9954814,0.00023700442,0.0008123488,0.0006356281,0.0015306053,0.0013030259],"domain_scores_gemma":[0.99721605,0.0003512672,0.00012708292,0.00056534255,0.0011907486,0.00054949964],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022084867,0.00026496607,0.0007549416,0.0007715233,0.00016830555,0.00002603959,0.00033842563,0.00022699364,0.000997604],"category_scores_gemma":[0.0003995732,0.00023122803,0.00012588034,0.0014296897,0.0010204635,0.00018201304,0.00021466531,0.0007842579,0.000016487931],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047147926,0.00055043,0.059551917,0.00091097725,0.00013088257,0.00004274087,0.0038370169,0.00001718876,0.9199922,0.00022991165,0.0008301751,0.009191755],"study_design_scores_gemma":[0.004062789,0.0012683203,0.010096889,0.0016503592,0.00003946736,0.0000065464665,0.0010677148,0.000029205265,0.97787255,0.0004089019,0.0032872579,0.00021002139],"about_ca_topic_score_codex":0.009430806,"about_ca_topic_score_gemma":0.0004056443,"teacher_disagreement_score":0.057880312,"about_ca_system_score_codex":0.00091332436,"about_ca_system_score_gemma":0.0019554272,"threshold_uncertainty_score":0.9999156},"labels":[],"label_agreement":null},{"id":"W1997423100","doi":"10.1186/s13148-015-0074-4","title":"Polycomb-mediated silencing in neuroendocrine prostate cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Epigenetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; BC Cancer Agency; Vancouver General Hospital; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; BC Cancer Foundation; Michael Smith Health Research BC; Prostate Cancer Canada","keywords":"Epigenetics; Gene silencing; Prostate cancer; Biology; Cancer research; Downregulation and upregulation; EZH2; Repressor; Cancer; Genetics; Gene; Gene expression","score_opus":0.1459865484202626,"score_gpt":0.45257233560370635,"score_spread":0.30658578718344376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997423100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876631,0.005108044,0.0000125727265,0.0049200873,0.0005948732,0.0006022993,0.000022067146,0.000055770593,0.0010212073],"genre_scores_gemma":[0.9863162,0.009115429,0.00031655113,0.0010402219,0.00031335314,0.000061861625,0.000038306218,0.00003634071,0.0027617214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980029,0.00012905229,0.00063937204,0.0003690755,0.00036332262,0.00049629126],"domain_scores_gemma":[0.9985608,0.00026138287,0.000081597,0.0003205828,0.00017625719,0.0005993655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004225775,0.00015798792,0.0004269294,0.00011191995,0.000027534748,0.000016289501,0.00011559641,0.00006885506,0.00007393726],"category_scores_gemma":[0.0010155798,0.000121864105,0.000094063325,0.0003831002,0.00020656954,0.000037178284,0.00010474246,0.00047432844,0.000116892625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080624205,0.00046155334,0.96504694,0.00004659585,0.00004308303,0.00075072795,0.00016292626,0.00007997675,0.00042869232,0.000010986429,0.0017166268,0.03044563],"study_design_scores_gemma":[0.02446838,0.0038978315,0.92346776,0.00043333648,0.00015192467,0.00004685996,0.00040426882,0.006377422,0.008237845,0.0010081185,0.031014051,0.0004922276],"about_ca_topic_score_codex":0.00025996007,"about_ca_topic_score_gemma":0.000106932464,"teacher_disagreement_score":0.041579224,"about_ca_system_score_codex":0.00014666452,"about_ca_system_score_gemma":0.0008132616,"threshold_uncertainty_score":0.4969474},"labels":[],"label_agreement":null},{"id":"W1997434316","doi":"10.1016/j.urology.2006.11.001","title":"Evaluation of AIbZIP and Cdc47 as Markers for Human Prostatic Diseases","year":2007,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Intraepithelial neoplasia; Hyperplasia; Prostate; Prostate cancer; Androgen receptor; Pathology; Prostatic Diseases; High-grade prostatic intraepithelial neoplasia; PCA3; Cancer; Estrogen receptor; Internal medicine; Breast cancer","score_opus":0.05093706452477733,"score_gpt":0.42382763619218716,"score_spread":0.37289057166740985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997434316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940731,0.0017511463,0.0001393997,0.0008648005,0.000038471364,0.001002385,0.000011092255,0.000009937841,0.0021096794],"genre_scores_gemma":[0.99917763,0.000026705091,0.000052333035,0.00013573912,0.000038056565,0.000062049214,0.000055492183,0.000007040512,0.00044495708],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99938774,0.000038861566,0.000105574894,0.00011592081,0.00020040397,0.00015150737],"domain_scores_gemma":[0.99950707,0.00011762714,0.00003254468,0.00008282894,0.00019270426,0.00006722388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006602096,0.000047545185,0.00011297935,0.00008086586,0.000037006303,0.0000019870342,0.000018412318,0.00003758687,0.00010041682],"category_scores_gemma":[0.00022262377,0.000036084493,0.00002383917,0.000046225654,0.00011860728,0.000016997801,0.00001103769,0.000034935205,0.000002474055],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023025636,0.0016211339,0.4401239,0.0014551148,0.0014414375,0.00013128982,0.0023703766,0.00003075047,0.075778246,0.007397704,0.006026482,0.44059795],"study_design_scores_gemma":[0.023502948,0.011699978,0.9132321,0.000046809546,0.0025443935,0.000058141926,0.00045397607,0.0028445804,0.010128965,0.030658225,0.0046466943,0.00018319258],"about_ca_topic_score_codex":0.000018965782,"about_ca_topic_score_gemma":0.000018259809,"teacher_disagreement_score":0.4731082,"about_ca_system_score_codex":0.000036251884,"about_ca_system_score_gemma":0.00011652291,"threshold_uncertainty_score":0.14714828},"labels":[],"label_agreement":null},{"id":"W1998867125","doi":"10.1210/me.2009-0229","title":"TAF1 Differentially Enhances Androgen Receptor Transcriptional Activity via Its N-Terminal Kinase and Ubiquitin-Activating and -Conjugating Domains","year":2010,"lang":"en","type":"article","venue":"Molecular Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Biology; Androgen receptor; Ubiquitin; Androgen; Cell biology; Kinase; RNF4; Molecular biology; Genetics; Gene; Biochemistry; Hormone","score_opus":0.015974247876990273,"score_gpt":0.2960774292580847,"score_spread":0.28010318138109447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998867125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996179,0.0009203375,0.00060306385,0.0012087262,0.0001514868,0.00037368943,0.0000191665,0.00004604064,0.00049853075],"genre_scores_gemma":[0.99829525,0.00017099237,0.0010449591,0.000114684095,0.000108058186,0.00006889741,0.0000312298,0.000022488537,0.00014345752],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987201,0.00007890797,0.0001604933,0.00039934902,0.00018618838,0.00045495722],"domain_scores_gemma":[0.99948186,0.00006512473,0.0000630536,0.00014449593,0.000071435956,0.0001740121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006888653,0.00019397154,0.0002869302,0.00010818889,0.00017646291,0.00003245582,0.00006050402,0.00009943252,0.0001663353],"category_scores_gemma":[0.000060681064,0.00016604153,0.000055397966,0.00007327333,0.000267475,0.0000967722,0.00005968602,0.00043892598,0.000005687308],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003139182,0.00009973482,0.0030751692,0.00009601517,0.00011526021,0.0004634392,0.00018149515,1.000444e-7,0.9422525,0.00059490296,0.000004141105,0.05280329],"study_design_scores_gemma":[0.0025420585,0.00046084126,0.017753217,0.000042054453,0.00006510328,0.0008967117,0.000051837782,0.00013483758,0.976853,0.00017008133,0.0008670637,0.00016316843],"about_ca_topic_score_codex":0.000031222742,"about_ca_topic_score_gemma":0.000027479111,"teacher_disagreement_score":0.05264012,"about_ca_system_score_codex":0.000027174487,"about_ca_system_score_gemma":0.0000735213,"threshold_uncertainty_score":0.6770977},"labels":[],"label_agreement":null},{"id":"W2000062688","doi":"10.1136/bcr-2012-006540","title":"Clinical benefits of alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature review","year":2012,"lang":"en","type":"article","venue":"BMJ Case Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Radium-223; Bone pain; Cancer; Bone metastasis; Oncology; Chemotherapy; Prostate; Metastasis; Clinical trial; Internal medicine; Surgery","score_opus":0.05786721098175988,"score_gpt":0.4276658232753058,"score_spread":0.3697986122935459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000062688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7425158,0.25441778,2.2181082e-7,0.0009290632,0.00015854361,0.001670236,0.00003114584,0.000016682035,0.00026050437],"genre_scores_gemma":[0.8848321,0.11310317,0.0002327171,0.00021089368,0.00021723034,0.0002159677,0.0000614327,0.000031509702,0.0010949634],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9973038,0.00011061248,0.0013861035,0.00044062888,0.00032118274,0.0004376682],"domain_scores_gemma":[0.99813664,0.00007605864,0.00055756007,0.00057813735,0.00024338266,0.00040824874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022039635,0.0002293242,0.0007662579,0.00012494471,0.000050243925,0.000016274735,0.000018090785,0.00014403935,0.000074836455],"category_scores_gemma":[0.00024377326,0.00016467887,0.00013845382,0.00041062335,0.00012561097,0.00016233031,0.00003982948,0.00032969925,0.0000010459498],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032285912,0.00025844798,0.176766,0.0025784094,0.000093137016,0.7986046,0.0003508465,2.7936667e-7,0.000107549655,0.0000033846009,0.0010951763,0.019819297],"study_design_scores_gemma":[0.0012247842,0.00021536113,0.02420113,0.007594396,0.00016617354,0.9627053,0.000086971784,0.000003645461,0.00079516234,0.0000068703393,0.002842249,0.00015793259],"about_ca_topic_score_codex":0.00050333026,"about_ca_topic_score_gemma":0.00019187375,"teacher_disagreement_score":0.1641007,"about_ca_system_score_codex":0.000112317095,"about_ca_system_score_gemma":0.00040619183,"threshold_uncertainty_score":0.671541},"labels":[],"label_agreement":null},{"id":"W2000349726","doi":"10.1159/000179775","title":"New Hormonal Therapy in Prostate Cancer: Combined Use of a Pure Antiandrogen and an LHRH Agonist","year":2008,"lang":"en","type":"article","venue":"Hormone Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"","keywords":"Antiandrogen; Agonist; Endocrinology; Prostate cancer; Internal medicine; Testosterone (patch); Dihydrotestosterone; Androgen; Prostate; Medicine; Hormone; Flutamide; Seminal vesicle; Androgen receptor; Cancer; Receptor","score_opus":0.14033047214554142,"score_gpt":0.40362842563955514,"score_spread":0.26329795349401375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000349726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677704,0.028711773,0.000001868212,0.001954949,0.000014322,0.0012406651,0.00004255071,0.000023252705,0.00024020734],"genre_scores_gemma":[0.8966151,0.099416025,0.00025122587,0.00002846777,0.00007613754,0.00009898994,0.000068198686,0.00003292366,0.0034129177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754107,0.00018028158,0.00027727266,0.0003967831,0.00093912665,0.0006654869],"domain_scores_gemma":[0.9987129,0.00010713762,0.000040622625,0.0003551001,0.00033604083,0.0004481871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005219825,0.00016663183,0.000391447,0.00045414298,0.00018389853,0.000042900396,0.00013155559,0.00009804793,0.00006052814],"category_scores_gemma":[0.000047830064,0.00012461707,0.000052810232,0.0008479457,0.00046743685,0.00024895588,0.00009712343,0.00052478263,0.0000068044897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025104936,0.0014138408,0.6817428,0.00012763393,0.00030437746,0.0020577535,0.0053764083,0.000005695298,0.1834491,0.00018642076,0.025925582,0.07430548],"study_design_scores_gemma":[0.019230494,0.009416198,0.9155861,0.00013943562,0.000018695533,0.000167251,0.000390691,0.00043647917,0.04624527,0.00038198143,0.0077059255,0.00028144495],"about_ca_topic_score_codex":0.00484907,"about_ca_topic_score_gemma":0.00022649358,"teacher_disagreement_score":0.23384337,"about_ca_system_score_codex":0.00014694844,"about_ca_system_score_gemma":0.0012727572,"threshold_uncertainty_score":0.7330376},"labels":[],"label_agreement":null},{"id":"W2000524802","doi":"10.1073/pnas.0905524107","title":"Estrogen receptor–β activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFα mediated","year":2010,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":195,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Prostate Cancer Foundation of Australia; Medical Research Council; Prostate Cancer Foundation; National Health and Medical Research Council; U.S. Department of Defense","keywords":"Androgen receptor; Prostate cancer; Cancer research; Estrogen receptor; Estrogen; Apoptosis; Medicine; Hyperplasia; Internal medicine; Estrogen receptor beta; Tumor necrosis factor alpha; Androgen; Endocrinology; Cancer; Chemistry; Breast cancer; Hormone","score_opus":0.03115910350386801,"score_gpt":0.3270834252049321,"score_spread":0.2959243217010641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000524802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904766,0.00043843157,4.6173545e-9,0.008217102,0.000016191541,0.00041197755,0.00004651532,0.0000034067305,0.00038977747],"genre_scores_gemma":[0.99901605,0.00060216774,0.00011650531,0.00010133541,0.000019566402,0.000026149843,3.1171376e-7,0.0000039514393,0.00011399397],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998587,0.000006131271,0.00021954079,0.00020016776,0.00084590056,0.00014125538],"domain_scores_gemma":[0.99942636,0.00007004304,0.00021818411,0.000010684376,0.00022498253,0.000049742666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006245212,0.00008266454,0.00016873358,0.00013583993,0.000098345474,0.000011373205,0.00023148434,0.000090038106,0.000021231286],"category_scores_gemma":[0.00024474898,0.000042181615,0.000032473694,0.0006464225,0.0009864595,0.00018606953,0.00013042304,0.00025994136,1.3942199e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007339596,0.000032201257,0.36945617,0.00005751797,0.000023437713,3.6599312e-9,0.00048045508,5.834229e-7,0.62872916,0.00039457553,0.00007495601,0.00067754445],"study_design_scores_gemma":[0.0006327654,0.000052375697,0.19691904,0.00012303678,0.000016754122,0.000005670817,0.00022181173,0.00008268148,0.800615,0.0011701363,0.00012381299,0.00003690822],"about_ca_topic_score_codex":0.000065263164,"about_ca_topic_score_gemma":8.89741e-7,"teacher_disagreement_score":0.17253715,"about_ca_system_score_codex":0.000031922515,"about_ca_system_score_gemma":0.00011656944,"threshold_uncertainty_score":0.36346513},"labels":[],"label_agreement":null},{"id":"W2000707490","doi":"10.1016/j.urology.2006.08.319","title":"MP-08.12","year":2006,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Greenfield Research (Canada); Hôtel-Dieu de Québec","funders":"","keywords":"Bicalutamide; Medicine; Antiandrogens; Antiandrogen; Tamoxifen; Oncology; Prostate cancer; Breast cancer; Internal medicine; Urology; Cancer; Androgen receptor","score_opus":0.018840555191823836,"score_gpt":0.30816282353641883,"score_spread":0.289322268344595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000707490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72408605,0.0025707392,0.00016510057,0.023026444,0.00023869061,0.00029453926,0.0000057483185,0.00010224912,0.24951047],"genre_scores_gemma":[0.9789402,0.000044400393,0.000057993788,0.00069263537,0.00023160696,0.000013624677,0.00003833109,0.0000071819413,0.01997405],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99955165,0.000014623626,0.00006185347,0.00011003862,0.00006924683,0.00019257492],"domain_scores_gemma":[0.9997951,0.000021983085,0.000010343207,0.00011156405,0.000021263959,0.00003977957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000040331273,0.000045531375,0.000091700516,0.00004865802,0.000026341631,0.000002613678,0.000027591299,0.000054691314,0.00059152796],"category_scores_gemma":[0.000009097518,0.00003260227,0.000027430096,0.00004650937,0.00006527652,0.000011895172,0.00001597863,0.00008429136,0.00039608698],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003092976,0.0011097272,0.5396487,0.00010441547,0.00025627503,0.0026084639,0.00024724202,0.000067013396,0.043828707,0.014139996,0.3628926,0.03200389],"study_design_scores_gemma":[0.0046993457,0.0013629333,0.13702983,0.0000038895637,0.00007736675,0.00021402254,0.000013936134,0.00023202822,0.005629955,0.003630807,0.84700143,0.00010445454],"about_ca_topic_score_codex":0.00006785484,"about_ca_topic_score_gemma":0.000025556132,"teacher_disagreement_score":0.48410884,"about_ca_system_score_codex":0.000022340782,"about_ca_system_score_gemma":0.000043667245,"threshold_uncertainty_score":0.64768165},"labels":[],"label_agreement":null},{"id":"W2000853346","doi":"10.1002/cncr.23864","title":"Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancer","year":2008,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Victoria Hospital; London Health Sciences Centre","funders":"National Cancer Institute","keywords":"Medicine; Clinical endpoint; Placebo; Urology; Peripheral edema; Prostate cancer; Internal medicine; Doubling time; Prostate; Randomized controlled trial; Prostate-specific antigen; Adverse effect; Cancer; Pathology","score_opus":0.018030861533078778,"score_gpt":0.32557284645278883,"score_spread":0.3075419849197101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000853346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98255754,0.0075534345,0.000007665865,0.0002444485,0.00018374513,0.0087802345,0.00013653199,0.000017671962,0.00051873643],"genre_scores_gemma":[0.9830676,0.011465476,0.00006741119,0.00008937063,0.00011875476,0.003079041,0.00007175814,0.00003471631,0.0020058753],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979785,0.00014673996,0.00059266144,0.00029430637,0.0006138957,0.00037385957],"domain_scores_gemma":[0.99889606,0.00017949517,0.00027073734,0.00022593343,0.00025888087,0.00016889078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028931117,0.00023414241,0.0015959851,0.00020539558,0.00005440707,0.000006134495,0.0000700939,0.00006099711,0.00032844482],"category_scores_gemma":[0.00007442997,0.0001343769,0.00021535477,0.00027555504,0.00040697213,0.00011479183,0.000017220736,0.00021414373,0.0000044533717],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96886617,0.0029110347,0.02139479,0.00006353233,0.00071671506,0.00008248414,0.00068854674,0.000014475107,0.00032636037,0.0000032503153,0.0005906559,0.0043420033],"study_design_scores_gemma":[0.99029595,0.0028901137,0.0048809214,0.00015527761,0.00039870807,0.0000013400307,0.000045953842,0.00006809043,0.00071344856,0.000007172665,0.00039529763,0.00014774107],"about_ca_topic_score_codex":0.00047087745,"about_ca_topic_score_gemma":0.000048905757,"teacher_disagreement_score":0.02142978,"about_ca_system_score_codex":0.0003282764,"about_ca_system_score_gemma":0.0008364973,"threshold_uncertainty_score":0.5479731},"labels":[],"label_agreement":null},{"id":"W2001036136","doi":"10.1007/s00018-012-1000-y","title":"Expression and function of nuclear receptor co-activator 4: evidence of a potential role independent of co-activator activity","year":2012,"lang":"en","type":"review","venue":"Cellular and Molecular Life Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Nuclear receptor coactivator 3; Coactivator; Nuclear receptor; Biology; Nuclear receptor coactivator 1; Receptor; Thyroid hormone receptor; Androgen receptor; Nuclear receptor coactivator 2; Activator (genetics); Steroid hormone receptor; Cell biology; Carcinogenesis; Cancer research; Endocrinology; Prostate cancer; Transcription factor; Biochemistry; Genetics; Cancer; Gene; Estrogen receptor","score_opus":0.061872701248654564,"score_gpt":0.3527909379105438,"score_spread":0.2909182366618892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001036136","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16042474,0.8384484,0.00012509867,0.000019085313,0.00010028065,0.00068510626,0.000031273958,0.000008031602,0.00015799196],"genre_scores_gemma":[0.37689933,0.62284434,0.00012303943,0.000006193583,0.00004603889,0.000016010361,0.000014249288,0.000018093016,0.000032726202],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978726,0.00024008093,0.0003972491,0.00044675957,0.0007740956,0.00026925057],"domain_scores_gemma":[0.99874747,0.00008472882,0.00052569626,0.00026903773,0.00010266085,0.00027039764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063912093,0.00026297625,0.0010906701,0.0002521979,0.00011141045,0.000017020091,0.00015875597,0.00023784983,0.00010944523],"category_scores_gemma":[0.000098005934,0.00017917505,0.0002280998,0.00028345676,0.0008356758,0.00023615766,0.0001285257,0.00024268616,0.0000022685751],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046701354,0.0002446566,0.00021873896,0.01195968,0.00018987893,0.0000070733718,0.0001588577,2.2632021e-7,0.8403171,0.000021710579,0.0000480276,0.14636707],"study_design_scores_gemma":[0.0014273092,0.002729208,0.0003676381,0.019315498,0.0016416077,0.000029348255,0.00054252765,0.000023300812,0.85348845,0.000021563465,0.11994199,0.00047154378],"about_ca_topic_score_codex":0.000043595144,"about_ca_topic_score_gemma":1.4030866e-7,"teacher_disagreement_score":0.2164746,"about_ca_system_score_codex":0.0000407427,"about_ca_system_score_gemma":0.0005527073,"threshold_uncertainty_score":0.73065466},"labels":[],"label_agreement":null},{"id":"W2001196048","doi":"10.1016/j.eururo.2015.03.042","title":"Reply to Kevin Lu's Letter to the Editor re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status. Eur Urol 2015;67:441–7","year":2015,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Gynecology; Oncology; Internal medicine; Urology; Cancer; Androgen deprivation therapy","score_opus":0.025518869083985617,"score_gpt":0.300155917069719,"score_spread":0.2746370479857334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001196048","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14493515,0.0008541467,0.000014149029,0.84488076,0.0020162482,0.004947708,0.0011092678,0.00009482771,0.001147752],"genre_scores_gemma":[0.023478488,0.0006982513,0.00031992336,0.94091785,0.0038880997,0.0009907522,0.0016787685,0.0004612368,0.027566629],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918521,0.001748586,0.0011992414,0.0016715031,0.001614724,0.0019138696],"domain_scores_gemma":[0.996483,0.0002552157,0.000527833,0.0013801237,0.0008001897,0.0005536265],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001577205,0.0011036433,0.0014182321,0.0006553327,0.00021241064,0.00020482614,0.00070606015,0.00019360546,0.00015874898],"category_scores_gemma":[0.00028792402,0.0006711071,0.00016225078,0.0005208329,0.00032231543,0.00029949815,0.0004118178,0.0029618475,0.0007470086],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046356414,0.00017883154,0.039330292,0.00019961184,0.00053372467,0.0022994038,0.0026311965,0.00027287213,0.00011178363,3.0526752e-7,0.9484613,0.0013450487],"study_design_scores_gemma":[0.0056566135,0.004364943,0.088615924,0.00023554671,0.00032752057,0.000025075193,0.000072657436,0.000034575532,0.00008199288,0.0000015987465,0.89993894,0.0006445862],"about_ca_topic_score_codex":0.00061915943,"about_ca_topic_score_gemma":0.0008800212,"teacher_disagreement_score":0.12145667,"about_ca_system_score_codex":0.0006183441,"about_ca_system_score_gemma":0.0007615113,"threshold_uncertainty_score":0.999574},"labels":[],"label_agreement":null},{"id":"W2001203107","doi":"10.1158/1078-0432.ccr-05-0953","title":"Establishment of a Serum Tumor Marker for Preclinical Trials of Mouse Prostate Cancer Models","year":2005,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute","keywords":"Prostate cancer; Prostate; Cancer; Genetically modified mouse; Immunohistochemistry; PCA3; Intraepithelial neoplasia; Prostate-specific antigen; Biology; Tumor progression; Polyclonal antibodies; Medicine; Antibody; Cancer research; Pathology; Internal medicine; Transgene; Endocrinology; Immunology","score_opus":0.49579910674830113,"score_gpt":0.6044482097660626,"score_spread":0.10864910301776148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001203107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96239,0.012207826,0.00004306683,0.015138236,0.00030704963,0.0064395457,0.0023439806,0.000039393693,0.0010908851],"genre_scores_gemma":[0.9458952,0.022721507,0.0018508508,0.0003259566,0.0012118145,0.0032596332,0.00005413573,0.000092787945,0.024588123],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9925046,0.0011543329,0.0028908136,0.00082185026,0.0016050572,0.0010233363],"domain_scores_gemma":[0.99060947,0.0051339995,0.0005471933,0.00078585604,0.0023198903,0.00060358766],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.018936276,0.00025915157,0.001915896,0.00033690693,0.0001125112,0.0000315089,0.0004199012,0.0002596574,0.0013358704],"category_scores_gemma":[0.004620672,0.00017975403,0.0007915733,0.0006355731,0.0010784375,0.00022264909,0.0002793876,0.00096531067,0.000010964134],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10640382,0.007813611,0.2277163,0.0051248753,0.0030178244,0.000043287422,0.0010334756,0.00099949,0.009340505,0.00079573866,0.07938043,0.55833066],"study_design_scores_gemma":[0.13439739,0.02470852,0.0902662,0.006866227,0.0020016602,0.000015270403,0.001476376,0.03256645,0.43320316,0.0067393063,0.26609054,0.0016688786],"about_ca_topic_score_codex":0.0005406565,"about_ca_topic_score_gemma":0.00022795181,"teacher_disagreement_score":0.5566618,"about_ca_system_score_codex":0.000423806,"about_ca_system_score_gemma":0.0035110873,"threshold_uncertainty_score":0.99957705},"labels":[],"label_agreement":null},{"id":"W2001446904","doi":"10.1259/bjr.20140701","title":"Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer: author reply","year":2014,"lang":"en","type":"letter","venue":"British Journal of Radiology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Radioresistance; Prostate cancer; Radiation therapy; Medicine; Cancer; Oncology; Identification (biology); Internal medicine; Biology","score_opus":0.009170836937291786,"score_gpt":0.26520036551728116,"score_spread":0.2560295285799894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001446904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9441286,0.010377866,0.00027568336,0.04057125,0.00028591495,0.0035768216,0.000764195,0.000010592946,0.000009089127],"genre_scores_gemma":[0.7614624,0.030266449,0.03061497,0.15448378,0.0038155238,0.0020962365,0.003886776,0.0008574203,0.012516455],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99497306,0.0010686048,0.0018636953,0.00052254566,0.0009918787,0.0005802099],"domain_scores_gemma":[0.9962826,0.000332917,0.0019269894,0.00044755486,0.0008109909,0.00019896703],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024050465,0.00035433617,0.0017204107,0.0005384384,0.00010693826,0.00004033961,0.000549629,0.00034794054,0.00004083884],"category_scores_gemma":[0.00034120452,0.00026287255,0.00018459896,0.00041232715,0.00035106842,0.000066333414,0.000050118313,0.0014200571,0.0000021129342],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0179903,0.00020099695,0.093576625,0.00043856603,0.0017436699,0.00037688977,0.0020921351,0.00012439585,0.00175545,4.1816168e-7,0.8664502,0.015250362],"study_design_scores_gemma":[0.03770856,0.0042613694,0.6548702,0.0040303613,0.0008073009,0.0022381176,0.00012004545,0.00001908179,0.0060772956,0.00001546193,0.2891332,0.0007189934],"about_ca_topic_score_codex":0.0003755546,"about_ca_topic_score_gemma":0.000063438594,"teacher_disagreement_score":0.577317,"about_ca_system_score_codex":0.0008968637,"about_ca_system_score_gemma":0.001208645,"threshold_uncertainty_score":0.99998236},"labels":[],"label_agreement":null},{"id":"W2001823700","doi":"10.1517/14728210903142147","title":"Emerging drugs for prostate cancer","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Angiogenesis; Androgen receptor; Pharmacology; Matrix metalloproteinase inhibitor; Tyrosine kinase; Cancer; Cancer research; Matrix metalloproteinase; Internal medicine; Receptor","score_opus":0.0657725239338676,"score_gpt":0.44593343913200534,"score_spread":0.38016091519813777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001823700","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004216014,0.9855648,0.000017759026,0.0046525784,0.002438707,0.004327643,0.00015746006,0.00026882245,0.0025679895],"genre_scores_gemma":[0.000007135148,0.97951037,0.00030175433,0.0007155634,0.0027122966,0.0033041371,0.0013984658,0.00024775203,0.011802552],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956538,0.00013415894,0.0009507207,0.0012166213,0.0008904764,0.0011542217],"domain_scores_gemma":[0.99790484,0.0002161307,0.00041698813,0.0008063744,0.00023174885,0.00042389202],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044583468,0.0009618743,0.002315166,0.0007156483,0.00040271223,0.000078454694,0.00035382117,0.0003925847,0.00028009343],"category_scores_gemma":[0.000064466134,0.0007014549,0.0011308029,0.0006689191,0.000101053796,0.00013054923,0.00009417763,0.00073386723,0.0001142413],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024836403,0.00020335021,0.0000018489172,0.0059245666,0.00041651056,0.0000124751095,0.0024673794,0.000001765197,0.0000029839496,0.00010650675,0.05837652,0.93223774],"study_design_scores_gemma":[0.0023046813,0.0004805795,0.0000012374536,0.034614533,0.00013840885,0.000010826415,0.00036944906,0.000056073473,0.000051122996,0.00003288501,0.9612657,0.0006745157],"about_ca_topic_score_codex":0.00011936673,"about_ca_topic_score_gemma":0.0000012386176,"teacher_disagreement_score":0.9315632,"about_ca_system_score_codex":0.0009959801,"about_ca_system_score_gemma":0.0010772186,"threshold_uncertainty_score":0.99954367},"labels":[],"label_agreement":null},{"id":"W2001825810","doi":"10.1210/me.2011-1360","title":"Slug, a Unique Androgen-Regulated Transcription Factor, Coordinates Androgen Receptor to Facilitate Castration Resistance in Prostate Cancer","year":2012,"lang":"en","type":"article","venue":"Molecular Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Key Research and Development Program of China; U.S. Army; China Scholarship Council; National Natural Science Foundation of China","keywords":"Slug; Androgen receptor; Prostate cancer; Biology; Transcription factor; Cancer research; Androgen; Coactivator; Enzalutamide; Cell biology; Gene; Endocrinology; Cancer; Genetics; Hormone","score_opus":0.0415399088008224,"score_gpt":0.3117520025731147,"score_spread":0.27021209377229227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001825810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983263,0.010156225,0.00018513549,0.0040908777,0.00017477173,0.00146105,0.00012296184,0.000083748404,0.0004622104],"genre_scores_gemma":[0.9952477,0.0007613703,0.0004939362,0.00022988315,0.000032319695,0.00051803014,0.00016977392,0.000035705067,0.0025112454],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99796486,0.00017477415,0.00031848112,0.0004029593,0.0002279858,0.0009109298],"domain_scores_gemma":[0.9992438,0.00002009795,0.000050486167,0.00026987633,0.00014253335,0.00027323246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010408425,0.0002482664,0.00036478305,0.0003068641,0.000065466396,0.000016824495,0.00008933596,0.00010373084,0.00018775987],"category_scores_gemma":[0.000033660242,0.00022087884,0.00008205704,0.00047146142,0.00009899749,0.00015118504,0.00003125101,0.00025165523,0.000054421223],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022326615,0.00032076234,0.07796954,0.00019244303,0.00021259047,0.00044590258,0.0037522947,0.00003548846,0.90158975,0.0007709641,0.0005609173,0.011916664],"study_design_scores_gemma":[0.0048770844,0.0005597145,0.044935852,0.0001652386,0.000065959284,0.00009099237,0.00023860119,0.000023234901,0.88764906,0.00018142298,0.060845394,0.0003674631],"about_ca_topic_score_codex":0.00042662004,"about_ca_topic_score_gemma":0.0005068202,"teacher_disagreement_score":0.060284477,"about_ca_system_score_codex":0.00040037517,"about_ca_system_score_gemma":0.00014950648,"threshold_uncertainty_score":0.90071774},"labels":[],"label_agreement":null},{"id":"W2001994418","doi":"10.1002/path.4047","title":"From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer","year":2012,"lang":"en","type":"article","venue":"The Journal of Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":195,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Simon Fraser University; Ontario Institute for Cancer Research; BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Prostate cancer; Fusion gene; Chromothripsis; Massive parallel sequencing; Prostate; Molecular pathology; Biology; Cancer; Disease; Pathology; Bioinformatics; Gene; Medicine; DNA sequencing; Genetics; Genome instability; DNA damage","score_opus":0.030100180437076865,"score_gpt":0.3441477293200317,"score_spread":0.31404754888295483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001994418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735687,0.005463083,0.00011861851,0.020258257,0.00024214172,0.0002958018,0.000007779946,0.000004516144,0.0000411459],"genre_scores_gemma":[0.9960394,0.0020327428,0.00031845862,0.0012983712,0.0001814112,0.000015926204,0.0000010748422,0.000014027709,0.000098572695],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988546,0.00032796068,0.00022534831,0.00009276085,0.00015846574,0.00034086354],"domain_scores_gemma":[0.99937344,0.00013592123,0.000110431865,0.00017983095,0.00007474331,0.00012566624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006419421,0.0001022293,0.000236219,0.00009161877,0.000055517074,0.0000072068424,0.00013740496,0.00002274321,0.000034553956],"category_scores_gemma":[0.00012427899,0.00004855261,0.000033060925,0.00014555032,0.00013510529,0.00006442361,0.00011228504,0.00040459624,0.0000058381274],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008104977,0.00012616722,0.062094774,0.0000184727,0.00007185542,0.010275279,0.009024267,0.00002885683,0.9067602,0.000318972,0.00020089006,0.010269743],"study_design_scores_gemma":[0.011751288,0.0042367997,0.7030894,0.0006614926,0.0009876805,0.049424734,0.005680516,0.00020983744,0.20036772,0.019543042,0.0035369815,0.0005104922],"about_ca_topic_score_codex":0.00010257267,"about_ca_topic_score_gemma":0.00003268985,"teacher_disagreement_score":0.7063925,"about_ca_system_score_codex":0.00006420966,"about_ca_system_score_gemma":0.00008273055,"threshold_uncertainty_score":0.1979918},"labels":[],"label_agreement":null},{"id":"W2002175782","doi":"10.1007/s00280-012-2001-0","title":"Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; European Commission","keywords":"Abiraterone acetate; Pharmacokinetics; Prednisone; Theophylline; Pharmacology; Medicine; Dextromethorphan; Prostate cancer; Bioequivalence; Internal medicine; Cancer; Androgen deprivation therapy","score_opus":0.020446399794246364,"score_gpt":0.35373694292767893,"score_spread":0.3332905431334326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002175782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989307,0.00787573,0.0000042330416,0.001025096,0.00009425608,0.0015496227,0.000107006585,0.0000059400236,0.00003114098],"genre_scores_gemma":[0.9923405,0.006720202,0.0000646901,0.00032085337,0.000057068533,0.00032155827,0.000013249053,0.000024184565,0.0001376957],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99887425,0.00022014535,0.00024041375,0.00018548273,0.00018358382,0.00029612108],"domain_scores_gemma":[0.9993161,0.00024547122,0.00015067881,0.00009451381,0.00008786053,0.00010537332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038743607,0.00019218026,0.00043916976,0.00009501199,0.000041339976,0.0000047182707,0.00005216627,0.00003761063,0.00027620597],"category_scores_gemma":[0.0000052915193,0.00010209157,0.000027475688,0.00020997711,0.00032257772,0.000061277744,0.000016125137,0.00016856976,2.6331202e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.075762376,0.0007347281,0.30625474,0.0017549649,0.0013153821,0.000008294079,0.0043410077,0.00011942245,0.5571453,0.000026695398,0.0002050628,0.05233203],"study_design_scores_gemma":[0.031245314,0.004344021,0.117303945,0.00018081514,0.00044626652,0.0000020726836,0.000048792346,0.00019715876,0.84576786,0.000011574688,0.00032218485,0.00013000103],"about_ca_topic_score_codex":0.000090144255,"about_ca_topic_score_gemma":0.00000987574,"teacher_disagreement_score":0.28862256,"about_ca_system_score_codex":0.00008121643,"about_ca_system_score_gemma":0.000097780605,"threshold_uncertainty_score":0.41631734},"labels":[],"label_agreement":null},{"id":"W2002259918","doi":"10.3892/ijo.2014.2601","title":"Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review)","year":2014,"lang":"en","type":"review","venue":"International Journal of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"PI3K/AKT/mTOR pathway; Prostate cancer; Protein kinase B; Cancer; Cancer research; Disease; Medicine; PTEN; Prostate; Oncology; Oncogene; Signal transduction; Bioinformatics; Biology; Internal medicine; Cell cycle","score_opus":0.1809866893192689,"score_gpt":0.4550676315996492,"score_spread":0.27408094228038027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002259918","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026766602,0.97658,9.065724e-7,0.020400047,0.000770716,0.0005081428,0.000022938208,0.0000039079914,0.0016865445],"genre_scores_gemma":[0.000055610304,0.99760014,0.00003611087,0.0006244085,0.0008422348,0.00009648907,0.000029508878,0.000023332746,0.0006921435],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979489,0.0003707697,0.00088328484,0.00015834601,0.00043734472,0.00020138119],"domain_scores_gemma":[0.997961,0.0004553096,0.00088049215,0.00009656135,0.00050181255,0.00010482506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014146457,0.00020690226,0.001407018,0.00030310065,0.000026244974,0.000012923324,0.00031276396,0.00012040893,0.00008733661],"category_scores_gemma":[0.00019416177,0.000106712134,0.00022540809,0.00004890398,0.00015822268,0.0000668349,0.00011056422,0.00073587726,0.00000448317],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008820866,0.00007829721,0.000013627004,0.0066727954,0.00050027866,0.0012333507,0.0002112912,2.8822868e-7,4.950442e-7,0.00017290819,0.0023916757,0.9886368],"study_design_scores_gemma":[0.0009321879,0.0005391487,0.00001666537,0.038586404,0.00024658276,0.0017656395,0.00011982811,0.0000020606099,9.206927e-7,0.0000777704,0.95762944,0.00008334261],"about_ca_topic_score_codex":0.000014032832,"about_ca_topic_score_gemma":0.00001636335,"teacher_disagreement_score":0.98855346,"about_ca_system_score_codex":0.0005794198,"about_ca_system_score_gemma":0.0018434266,"threshold_uncertainty_score":0.43515944},"labels":[],"label_agreement":null},{"id":"W2002288165","doi":"10.1016/j.eururo.2014.08.033","title":"Androgen Deprivation Therapy in Prostate Cancer: Looking Beyond Prostate-specific Antigen and Testosterone Levels","year":2014,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Androgen deprivation therapy; Testosterone (patch); Prostate; Oncology; Urology; Androgen; Internal medicine; Gynecology; Cancer; Hormone","score_opus":0.04367162678622694,"score_gpt":0.29078069573304177,"score_spread":0.24710906894681484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002288165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6475495,0.01882308,0.000010584423,0.32772177,0.0002977735,0.0021526536,0.0000950465,0.00011050308,0.0032390505],"genre_scores_gemma":[0.5262204,0.033868432,0.0001945136,0.42847908,0.003479364,0.00023990798,0.0016779065,0.00046924176,0.005371166],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968419,0.0005987362,0.0005021908,0.00092212355,0.00033883442,0.0007962141],"domain_scores_gemma":[0.9988865,0.00013453393,0.00022906347,0.0005076667,0.00012794309,0.00011423748],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005595753,0.00046500895,0.0006772584,0.00046752093,0.000113494316,0.00006693216,0.00020202486,0.00027271433,0.0001231416],"category_scores_gemma":[0.000029410974,0.0003746141,0.00006916037,0.00024624835,0.00031481357,0.00008794205,0.00014522788,0.0015004792,0.0000886328],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003018796,0.00020982666,0.38432595,0.0005894724,0.0005433351,0.013882577,0.00353806,0.000020326426,0.01600235,0.000013217481,0.38910332,0.18875274],"study_design_scores_gemma":[0.005357411,0.0016709047,0.106001,0.00012947047,0.000037449066,0.00020789409,0.0000113394135,0.000022017362,0.0007346587,0.00006745614,0.885399,0.0003614337],"about_ca_topic_score_codex":0.000055729946,"about_ca_topic_score_gemma":0.0000117529835,"teacher_disagreement_score":0.49629563,"about_ca_system_score_codex":0.00013849366,"about_ca_system_score_gemma":0.00014870979,"threshold_uncertainty_score":0.9998706},"labels":[],"label_agreement":null},{"id":"W2002957679","doi":"10.1016/s0360-3016(00)80431-9","title":"Cryotherapy as salvage for locally recurrent prostate cancer after external beam radiation","year":2000,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba; National Research Council Institute for Biodiagnostics; Ottawa Hospital; Manitoba Health","funders":"","keywords":"Medicine; Cryotherapy; External beam radiation; Prostate cancer; External beam radiotherapy; Prostate; Cancer; Radiation therapy; Radiology; Internal medicine","score_opus":0.019622789366858767,"score_gpt":0.3763757233521545,"score_spread":0.35675293398529573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002957679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749479,0.009217017,0.003695878,0.007940117,0.0024030635,0.0009950033,0.0002358612,0.00004319511,0.0005219267],"genre_scores_gemma":[0.96743023,0.021076854,0.0017862106,0.002629423,0.0050571808,0.00025725525,0.00019659365,0.00005761946,0.0015086032],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99818116,0.00011759089,0.0006901651,0.0002797871,0.0003943683,0.00033689904],"domain_scores_gemma":[0.99806815,0.0002036331,0.00054204004,0.00013547254,0.0008535015,0.0001971909],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043179517,0.00022809456,0.00043695563,0.00017511731,0.00008086043,0.000046326728,0.00025894825,0.00020464783,0.0009192327],"category_scores_gemma":[0.00008021652,0.00018230466,0.0003001098,0.00014367356,0.00016616954,0.00031429916,0.00001978062,0.00040207308,0.00005675711],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009097473,0.0005923293,0.11657357,0.00001842255,0.0007145627,0.000063119885,0.0007803226,0.00033149324,0.0041853865,0.00041971236,0.0019839962,0.8652396],"study_design_scores_gemma":[0.058823504,0.015177751,0.16506074,0.0007334364,0.00064365426,0.0005414514,0.00015061455,0.0052772434,0.03762203,0.025889585,0.68920994,0.0008700424],"about_ca_topic_score_codex":0.000033613065,"about_ca_topic_score_gemma":0.0000051461966,"teacher_disagreement_score":0.8643696,"about_ca_system_score_codex":0.0012223637,"about_ca_system_score_gemma":0.0011270961,"threshold_uncertainty_score":0.99999404},"labels":[],"label_agreement":null},{"id":"W2003771456","doi":"10.1158/1538-7445.am2014-2001","title":"Abstract 2001: GATA2: Potential role as a prostate cancer metastasis-driving gene","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Community College","funders":"","keywords":"Prostate cancer; Metastasis; Cancer research; Gene silencing; LNCaP; Cancer; Prostate; Biology; Medicine; Oncology; Internal medicine; Gene; Genetics","score_opus":0.0649036143851218,"score_gpt":0.4278472268013677,"score_spread":0.36294361241624595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003771456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9678467,0.013042936,0.000023241506,0.008955691,0.00032021644,0.0015601959,0.0001244677,0.00011872535,0.008007833],"genre_scores_gemma":[0.9670276,0.012181211,0.00026054357,0.000247233,0.001183914,0.0013550672,0.00009861758,0.00010666156,0.017539123],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9949104,0.00024961328,0.00038058255,0.0008376217,0.0018582678,0.001763518],"domain_scores_gemma":[0.9973457,0.00015022137,0.00008248666,0.0007094621,0.0008802076,0.0008319563],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018417974,0.00031180267,0.0005117005,0.00048753576,0.0004977112,0.000174501,0.000383706,0.00015935871,0.0049364767],"category_scores_gemma":[0.00023608148,0.00024235407,0.00018331598,0.0008478952,0.0004364804,0.00024378474,0.00026556547,0.0011123087,0.0005594366],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027801634,0.00049526175,0.02012919,0.00056580664,0.0007797954,0.00051170145,0.0008822062,0.00022297184,0.7658715,0.0001928196,0.029328726,0.17823987],"study_design_scores_gemma":[0.011164402,0.0015916794,0.08085421,0.0013003997,0.00031720244,0.00011747671,0.0009773779,0.0011176665,0.685881,0.0024179865,0.21333219,0.0009283678],"about_ca_topic_score_codex":0.0059153177,"about_ca_topic_score_gemma":0.0004934777,"teacher_disagreement_score":0.18400346,"about_ca_system_score_codex":0.0008996191,"about_ca_system_score_gemma":0.0022255196,"threshold_uncertainty_score":0.99597317},"labels":[],"label_agreement":null},{"id":"W2003960290","doi":"10.1002/pros.20143","title":"Constitutive activation of gp130 leads to neuroendocrine differentiation in vitro and in vivo","year":2004,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Neuroendocrine differentiation; LNCaP; Cellular differentiation; Biology; Cell biology; Downregulation and upregulation; Cell culture; In vivo; Androgen receptor; Endocrinology; Internal medicine; Cancer research; Prostate; Medicine; Prostate cancer; Biochemistry","score_opus":0.02015780467120092,"score_gpt":0.30291599508785494,"score_spread":0.282758190416654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003960290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99363613,0.00006346272,0.000033231678,0.0050981957,0.000022157674,0.00077898614,0.000011578796,0.0000076036285,0.00034862937],"genre_scores_gemma":[0.9993988,0.00014246767,0.000049648585,0.00010622106,0.0000098957535,0.00004727685,0.000010379754,0.0000054553057,0.00022980894],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99948144,0.000024905998,0.0001255476,0.00011205616,0.00011267352,0.00014337286],"domain_scores_gemma":[0.9997862,0.00003135687,0.00002836747,0.00008714298,0.000032089858,0.00003484729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000068035806,0.000062517356,0.00012493553,0.00012684544,0.000021093912,0.000006047187,0.000027444336,0.000009347768,0.000005755812],"category_scores_gemma":[0.000044377986,0.000039647206,0.000011759454,0.00022926735,0.0000775512,0.00005866548,0.000030741612,0.00009809651,0.0000019165832],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037742185,0.00017407622,0.041604023,0.00007682085,0.000013324371,0.00003892,0.002424472,0.00019217505,0.9482245,0.00024197866,0.000012660666,0.0032228162],"study_design_scores_gemma":[0.0035923473,0.0001875725,0.11652846,0.00011345361,0.000008477533,0.0000074412183,0.00012532556,0.00004955146,0.8786779,0.0006171451,0.00005403859,0.000038299295],"about_ca_topic_score_codex":0.0002165838,"about_ca_topic_score_gemma":0.00005440487,"teacher_disagreement_score":0.07492443,"about_ca_system_score_codex":0.00009989431,"about_ca_system_score_gemma":0.00006764114,"threshold_uncertainty_score":0.16167662},"labels":[],"label_agreement":null},{"id":"W2004023311","doi":"10.1016/j.eururo.2014.08.006","title":"Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models","year":2014,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Enzalutamide; LNCaP; Medicine; Prostate cancer; Protein kinase B; Cancer research; PI3K/AKT/mTOR pathway; Androgen receptor; Apoptosis; Cell growth; Internal medicine; Pharmacology; Cancer; Biology; Biochemistry","score_opus":0.03715134515925831,"score_gpt":0.31742567586234643,"score_spread":0.2802743307030881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004023311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9650002,0.0010490156,0.0005680789,0.004486362,0.00013903555,0.0010038665,0.000030408159,0.000121843776,0.027601182],"genre_scores_gemma":[0.99630874,0.00046119775,0.00021031583,0.0009180039,0.00012840683,0.00008557858,0.00005674823,0.00007919256,0.0017518045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719495,0.0007798861,0.00047219047,0.0006142903,0.0003373781,0.0006012994],"domain_scores_gemma":[0.9988087,0.00026315876,0.00013285216,0.00040971403,0.00016391792,0.00022165354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010312154,0.00024967256,0.000432755,0.00022508354,0.00008445459,0.000025621812,0.00017749707,0.000087351174,0.000097880016],"category_scores_gemma":[0.00013749751,0.00018064145,0.00006496863,0.00028844964,0.00028633402,0.00011732731,0.00008600404,0.0005163972,0.00009527807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.104288094,0.0074035693,0.47411874,0.0012348541,0.001715445,0.008374775,0.013131739,0.040440843,0.12168569,0.021583319,0.005992488,0.20003043],"study_design_scores_gemma":[0.06041945,0.022403428,0.7895057,0.0006356693,0.00078493956,0.00025560366,0.00040134854,0.07455176,0.007173741,0.0072257677,0.034937605,0.0017049392],"about_ca_topic_score_codex":0.0001228683,"about_ca_topic_score_gemma":0.00021558751,"teacher_disagreement_score":0.31538698,"about_ca_system_score_codex":0.00014364792,"about_ca_system_score_gemma":0.00020634834,"threshold_uncertainty_score":0.7366345},"labels":[],"label_agreement":null},{"id":"W2004052104","doi":"10.1063/1.3526968","title":"Hybrid optimal scheduling for intermittent androgen suppression of prostate cancer","year":2010,"lang":"en","type":"article","venue":"Chaos An Interdisciplinary Journal of Nonlinear Science","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"Japan Society for the Promotion of Science","keywords":"Prostate cancer; Schedule; Population; Medicine; Androgen suppression; Piecewise linear function; Prostate; Prostate-specific antigen; Computer science; Oncology; Internal medicine; Cancer; Urology; Mathematics","score_opus":0.030217643059859897,"score_gpt":0.399495556037774,"score_spread":0.36927791297791407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004052104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963265,0.00034765928,0.00042756007,0.00146149,0.00090685557,0.00040678348,0.00006362896,0.000008153256,0.000051364692],"genre_scores_gemma":[0.97856325,0.00011388381,0.020569285,0.000024967721,0.00049641717,0.000014994114,0.00000898647,0.000018900088,0.00018930736],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982798,0.000016184098,0.0005238651,0.00026830542,0.00055014214,0.0003616828],"domain_scores_gemma":[0.9978481,0.00004178974,0.00036069358,0.0002646854,0.0011134982,0.0003712565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093550765,0.00014884301,0.0003599529,0.00036666027,0.0002675198,0.00004985071,0.00045877617,0.00004320943,0.00007965745],"category_scores_gemma":[0.00008790112,0.00009560954,0.00018345927,0.00022826204,0.00074076175,0.00058215763,0.00036337806,0.0004208958,0.0000016008698],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043382756,0.00088180805,0.012318613,0.0002481666,0.00009301499,0.00018670624,0.0035811558,0.00026208806,0.92210007,0.000021437367,0.00017630562,0.055792358],"study_design_scores_gemma":[0.0043645315,0.005881793,0.007364827,0.00125084,0.00012384128,0.0013280695,0.0018896904,0.05291598,0.9238983,0.00023955855,0.000520597,0.0002220187],"about_ca_topic_score_codex":0.000003432906,"about_ca_topic_score_gemma":0.0000031806512,"teacher_disagreement_score":0.055570338,"about_ca_system_score_codex":0.00009034006,"about_ca_system_score_gemma":0.0009003626,"threshold_uncertainty_score":0.38988438},"labels":[],"label_agreement":null},{"id":"W2004361934","doi":"10.1016/j.eururo.2014.04.015","title":"Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies","year":2014,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cabazitaxel; Medicine; Docetaxel; Androgen receptor; Oncology; Prostate cancer; Pharmacology; Androgen; Enzalutamide; Internal medicine; Antiandrogen; Chemotherapy; Androgen deprivation therapy; Cancer","score_opus":0.01093037077359175,"score_gpt":0.25004330030359995,"score_spread":0.2391129295300082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004361934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913486,0.0011099817,0.00006608064,0.0012928068,0.0001767396,0.0006116587,0.000072082024,0.00006605413,0.0052559813],"genre_scores_gemma":[0.997384,0.00005134204,0.00043655882,0.00079333736,0.00012307642,0.000049624534,0.00024485082,0.000066550965,0.0008506328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816763,0.0004098546,0.00025752166,0.00043407062,0.00022448029,0.0005064601],"domain_scores_gemma":[0.99932367,0.00006417827,0.000092956536,0.00027909817,0.000091627575,0.00014846015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033684153,0.00021760556,0.00031579053,0.00014839238,0.00007367456,0.000021199847,0.00012086517,0.00007961466,0.00013857734],"category_scores_gemma":[0.00013976093,0.00016231154,0.00007609301,0.00018539361,0.00017429933,0.000089803376,0.00008744669,0.00030292274,0.00013730503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010100877,0.0024313093,0.84249485,0.000077919554,0.00042151465,0.00021483359,0.005291683,0.0000018019757,0.07868465,0.000036376437,0.0059595443,0.054284636],"study_design_scores_gemma":[0.021672055,0.0043969913,0.8214207,0.000091479385,0.00007479472,0.0000134985985,0.00013521375,0.00007662589,0.011966132,0.000027203463,0.13966577,0.00045951392],"about_ca_topic_score_codex":0.000007761812,"about_ca_topic_score_gemma":0.000009350098,"teacher_disagreement_score":0.13370623,"about_ca_system_score_codex":0.00009170431,"about_ca_system_score_gemma":0.000048162656,"threshold_uncertainty_score":0.6618872},"labels":[],"label_agreement":null},{"id":"W2004509655","doi":"10.1016/j.eururo.2011.08.041","title":"Androgen-Deprivation Therapy and the Risk of Stroke in Patients With Prostate Cancer","year":2011,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Jewish General Hospital; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Cohort; Stroke (engine); Internal medicine; Population; Relative risk; Cohort study; Confidence interval; Gynecology; Surgery; Cancer","score_opus":0.021627332309026148,"score_gpt":0.24790607305865345,"score_spread":0.2262787407496273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004509655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99498034,0.0011425446,0.000002917873,0.00024635685,0.000019338677,0.00047967734,0.00001295246,0.0000070638857,0.0031088095],"genre_scores_gemma":[0.9973757,0.002213684,0.000038311115,0.00014529003,0.000012728737,0.000014178757,0.000007220572,0.000012800853,0.00018003931],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99935424,0.00022528874,0.000104283004,0.0001192308,0.00008039255,0.00011658278],"domain_scores_gemma":[0.9997011,0.000029134277,0.00006435,0.00012495827,0.000053825617,0.00002663737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002313414,0.000060791193,0.000121111065,0.00005137909,0.00002439638,0.0000020007074,0.000040537303,0.000013657226,0.000040473824],"category_scores_gemma":[0.000017566561,0.000028727642,0.000013868882,0.00006871978,0.00023376865,0.00002306963,0.000023851884,0.00010828561,0.0000031232964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0121975215,0.00009587876,0.9699095,0.0000055089567,0.00008158417,0.000009779927,0.0020205972,0.0000011951303,0.000036473615,0.000040545834,0.00001724165,0.015584205],"study_design_scores_gemma":[0.013641543,0.0010337847,0.98432446,0.0000061526334,0.000026790967,0.0000011082367,0.000022501736,0.000012208386,0.0003593891,0.000034624383,0.00050884363,0.000028585071],"about_ca_topic_score_codex":0.0001287782,"about_ca_topic_score_gemma":0.00001902041,"teacher_disagreement_score":0.015555621,"about_ca_system_score_codex":0.0000085410275,"about_ca_system_score_gemma":0.000022934608,"threshold_uncertainty_score":0.11714792},"labels":[],"label_agreement":null},{"id":"W2004608397","doi":"10.1002/gcc.20281","title":"Chromosome 18 suppresses tumorigenic properties of human prostate cancer cells","year":2005,"lang":"en","type":"article","venue":"Genes Chromosomes and Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"McGill University","keywords":"Prostate cancer; Chromoplexy; Biology; Cancer research; Cancer; Chromosome; Tumor progression; Prostate; Phenotype; Cancer cell; Pathology; Gene; Genetics; PCA3; Medicine","score_opus":0.03640160415290488,"score_gpt":0.3167091678931726,"score_spread":0.2803075637402677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004608397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82205987,0.17548385,2.0797856e-7,0.0011919079,0.00015530363,0.0006071463,0.00012441642,0.000043209122,0.0003341034],"genre_scores_gemma":[0.91290885,0.0761061,0.000045638015,0.000139933,0.000635276,0.00044709022,0.000021288595,0.0000442479,0.009651574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983783,0.000027819518,0.00033159385,0.00041169956,0.0003630991,0.0004875395],"domain_scores_gemma":[0.99920744,0.000010227048,0.000111527464,0.00028068747,0.00019028551,0.00019981632],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007502134,0.00026661498,0.0004946979,0.0001107773,0.0001682563,0.000034508546,0.00011680837,0.000083651634,0.0017430695],"category_scores_gemma":[0.0000029054404,0.0001830997,0.000107083964,0.00020936914,0.00032989177,0.00016923418,0.00009264108,0.00014078904,0.000011309608],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024526592,0.0001713593,0.015773224,0.001041368,0.00025884857,0.000021144311,0.0010357448,0.000033569817,0.94421166,0.000014529204,0.0017830174,0.03541024],"study_design_scores_gemma":[0.002204495,0.00035436673,0.004184376,0.000539503,0.00016519285,0.000017408662,0.00021482553,0.00003990599,0.9609197,0.000015003067,0.03111573,0.00022954254],"about_ca_topic_score_codex":0.00065611873,"about_ca_topic_score_gemma":0.00019275192,"teacher_disagreement_score":0.09937775,"about_ca_system_score_codex":0.00017830868,"about_ca_system_score_gemma":0.00038980495,"threshold_uncertainty_score":0.99916947},"labels":[],"label_agreement":null},{"id":"W2004636807","doi":"10.1073/pnas.0606718104","title":"Androgen receptor decoy molecules block the growth of prostate cancer","year":2007,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Prostate cancer; Decoy; Androgen receptor; Cancer research; Prostate; Cancer; Receptor; In vivo; Medicine; Chemistry; Internal medicine; Biology","score_opus":0.041832846487626245,"score_gpt":0.35618634344698963,"score_spread":0.3143534969593634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004636807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98329026,0.0012816126,1.4977161e-7,0.010735844,0.000015703868,0.00037441234,0.000023699255,0.000005619399,0.0042726747],"genre_scores_gemma":[0.99826235,0.0004896444,0.00041571548,0.00018978884,0.00006373408,0.000015377873,1.99924e-7,0.0000040051627,0.0005591657],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982119,0.000003923649,0.00026568613,0.00015674334,0.0011829644,0.00017874867],"domain_scores_gemma":[0.99900615,0.00009856862,0.00026937432,0.000008111825,0.0005744101,0.000043364227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013966736,0.000073862124,0.00014362884,0.00012603449,0.00013561292,0.000007926648,0.00038480313,0.000049074086,0.00001991985],"category_scores_gemma":[0.0002728681,0.000034420427,0.00007139699,0.0008009096,0.0011174612,0.00012895434,0.000085241794,0.0001339637,7.163486e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037539523,0.00014191754,0.23920463,0.00029825725,0.00011785186,3.6771635e-8,0.0010288145,0.000009792884,0.7426327,0.011268262,0.0030618592,0.001860492],"study_design_scores_gemma":[0.00041442795,0.00010527437,0.08972923,0.00016323876,0.000025784924,0.000006170492,0.0002919852,0.000048722708,0.904105,0.004731108,0.00033893267,0.000040132072],"about_ca_topic_score_codex":0.000025994586,"about_ca_topic_score_gemma":2.4733208e-7,"teacher_disagreement_score":0.1614723,"about_ca_system_score_codex":0.000051332547,"about_ca_system_score_gemma":0.00010759303,"threshold_uncertainty_score":0.41173324},"labels":[],"label_agreement":null},{"id":"W2004973733","doi":"10.1016/j.ejca.2009.11.007","title":"The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival","year":2009,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Oncology; Internal medicine; Cohort; Prednisone; Mitoxantrone; Enzalutamide; Chemotherapy; Cancer; Androgen receptor","score_opus":0.03458361840161109,"score_gpt":0.3294753051642432,"score_spread":0.2948916867626321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004973733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949806,0.0025854844,0.0002983746,0.00121801,0.00006035771,0.0004696739,0.0000794964,0.0000035543655,0.00030448992],"genre_scores_gemma":[0.9958601,0.0020874674,0.0017651971,0.0000340313,0.0000647095,0.000010863624,0.0000057408097,0.000020173986,0.00015170833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984571,0.00023675099,0.0005065515,0.000132639,0.00045149832,0.00021549303],"domain_scores_gemma":[0.9987061,0.00029278445,0.00047870394,0.000103525184,0.0002963541,0.00012252083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013793326,0.0001444615,0.00029201506,0.00011661811,0.0001360329,0.000027921918,0.000085506035,0.000009634389,0.000013200099],"category_scores_gemma":[0.00011786145,0.00007061288,0.000052725998,0.00015514312,0.00007596551,0.000058939728,0.000009096752,0.00022212381,2.1857741e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053040434,0.0007070221,0.5642995,0.00023643747,0.0011903946,0.00031965345,0.011955692,0.006259535,0.00533453,0.000040040297,0.00058958295,0.35602716],"study_design_scores_gemma":[0.010414774,0.0024092323,0.97641134,0.00050919823,0.0002465037,0.0000028954498,0.0010465475,0.00045250423,0.0062919254,0.000042064483,0.0020570557,0.00011596995],"about_ca_topic_score_codex":0.00006648948,"about_ca_topic_score_gemma":0.00086308474,"teacher_disagreement_score":0.41211182,"about_ca_system_score_codex":0.00016819032,"about_ca_system_score_gemma":0.00059760234,"threshold_uncertainty_score":0.28795096},"labels":[],"label_agreement":null},{"id":"W2005019641","doi":"10.1016/j.eururo.2013.10.035","title":"Evaluation of Prostate-specific Antigen Response Following Cessation of Abiraterone Acetate: Is There Evidence for a Withdrawal Syndrome?","year":2013,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate-specific antigen; Abiraterone; Prostate; Withdrawal syndrome; Internal medicine; Oncology; Prostate cancer; Androgen deprivation therapy; Androgen receptor; Cancer","score_opus":0.11147554840757741,"score_gpt":0.3597510663210894,"score_spread":0.248275517913512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005019641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8833301,0.009937301,0.0000578387,0.10274805,0.0003060474,0.0031075536,0.00007799137,0.000030918178,0.00040418174],"genre_scores_gemma":[0.984284,0.000689734,0.00022455389,0.010953224,0.00033880144,0.00019688254,0.00039185287,0.00013709613,0.0027838773],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99511635,0.002206673,0.00063750474,0.0005840463,0.0010239922,0.0004314545],"domain_scores_gemma":[0.9972681,0.00052760757,0.0005015543,0.00062582147,0.0010183317,0.000058600166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040470436,0.00030345394,0.00067938823,0.0003537606,0.000067064735,0.000021000309,0.00025066576,0.0002711704,0.000334314],"category_scores_gemma":[0.00045915335,0.0002349231,0.00023125016,0.00021906022,0.00023531857,0.00014223659,0.0000804424,0.00054693973,0.00008859901],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027578093,0.00037211986,0.013226866,0.002618806,0.003257355,0.0022745188,0.0067278678,0.000064963206,0.11344035,0.000004277166,0.8111824,0.019252406],"study_design_scores_gemma":[0.034646157,0.03136084,0.46720818,0.0037599567,0.0056055645,0.00043388578,0.00031394127,0.0012823909,0.02597059,0.00046346567,0.4275701,0.0013849495],"about_ca_topic_score_codex":0.000023370652,"about_ca_topic_score_gemma":9.2927866e-7,"teacher_disagreement_score":0.4539813,"about_ca_system_score_codex":0.00016303018,"about_ca_system_score_gemma":0.0005033126,"threshold_uncertainty_score":0.9579887},"labels":[],"label_agreement":null},{"id":"W2005124425","doi":"10.1038/sj.onc.1208229","title":"Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model","year":2005,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Institute for Prostate Cancer Research; Prostate Cancer Foundation","keywords":"Prostate cancer; Biology; Tramp; Genetically modified mouse; Prostate; Cancer research; Transgene; Adenocarcinoma; Cancer; Intraepithelial neoplasia; Metastasis; Genetic model; Gene; Genetics","score_opus":0.020733159809091004,"score_gpt":0.30462607619224863,"score_spread":0.2838929163831576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005124425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98543626,0.010243862,0.000088822206,0.0015963891,0.000025519197,0.0011779201,0.00024226427,0.000018941058,0.0011700377],"genre_scores_gemma":[0.98774064,0.0017692129,0.0010449238,0.00018592972,0.000054688735,0.00008826833,0.000025406547,0.00004361729,0.009047289],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981437,0.00008172054,0.0004681242,0.00032150725,0.00054066605,0.0004443085],"domain_scores_gemma":[0.99895906,0.00006217957,0.0001494785,0.0005961418,0.00012551516,0.00010763839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027381448,0.0002505279,0.0004384953,0.00012743543,0.00008379266,0.000009983921,0.00032280094,0.00013296219,0.000044737655],"category_scores_gemma":[0.000023647988,0.00013348916,0.00024674903,0.0003771885,0.00031190465,0.000087312306,0.00008099468,0.00030806608,0.0000032040768],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026075782,0.0009500216,0.022128202,0.00022932269,0.0003127996,0.00002864382,0.0033433454,0.079251796,0.871312,0.00014881785,0.00077754335,0.018909901],"study_design_scores_gemma":[0.0058178445,0.0004486895,0.0066224104,0.00016971923,0.00023552554,0.00004678987,0.00027984518,0.12619244,0.8594674,0.00030542264,0.00019450914,0.0002194468],"about_ca_topic_score_codex":0.00014756134,"about_ca_topic_score_gemma":0.0005990816,"teacher_disagreement_score":0.04694064,"about_ca_system_score_codex":0.00018905735,"about_ca_system_score_gemma":0.0007288504,"threshold_uncertainty_score":0.544353},"labels":[],"label_agreement":null},{"id":"W2005251971","doi":"10.4161/cbt.11.6.14376","title":"Detection of<i>ERG</i>gene rearrangements and<i>PTEN</i>deletions in unsuspected prostate cancer of the transition zone","year":2011,"lang":"en","type":"article","venue":"Cancer Biology & Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"PTEN; Erg; Biology; Cancer research; Prostate cancer; Cancer; Fluorescence in situ hybridization; Gene; Pathology; Medicine; Genetics; PI3K/AKT/mTOR pathway; Chromosome; Apoptosis","score_opus":0.041860667258228436,"score_gpt":0.315915244206479,"score_spread":0.27405457694825053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005251971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859875,0.011942026,0.000056263987,0.0008011496,0.00018778855,0.00078258367,0.00008854475,0.000014574826,0.00013959258],"genre_scores_gemma":[0.9646118,0.03468782,0.000043019085,0.00015101646,0.00004419586,0.00029168423,0.000016797598,0.0000128837955,0.00014074761],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992103,0.000090819754,0.00021968858,0.00020233785,0.000085245985,0.0001915842],"domain_scores_gemma":[0.99953985,0.000013811786,0.00009669813,0.00017536558,0.00013517847,0.000039119204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116742616,0.0001102426,0.00024131162,0.000106828375,0.00004939614,0.0000014290525,0.000064962114,0.00009184842,0.0001348759],"category_scores_gemma":[0.000003747985,0.000068388734,0.000058888272,0.00035233903,0.0003105616,0.000032083986,0.000012579377,0.00013380763,4.88979e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023143652,0.00016808193,0.096633576,0.000042148822,0.00019314956,0.000001977228,0.0032691315,0.0000029905461,0.8461633,0.000019811896,0.000016426278,0.051175047],"study_design_scores_gemma":[0.0047922786,0.00057642395,0.31391108,0.00013998934,0.000054119042,0.000004171696,0.00020327578,0.000027763954,0.67913747,0.00022651034,0.00084346073,0.00008347245],"about_ca_topic_score_codex":0.0024398847,"about_ca_topic_score_gemma":0.0007478849,"teacher_disagreement_score":0.21727751,"about_ca_system_score_codex":0.0000972425,"about_ca_system_score_gemma":0.0001362214,"threshold_uncertainty_score":0.3688392},"labels":[],"label_agreement":null},{"id":"W2005612083","doi":"10.1016/j.juro.2014.02.2514","title":"MP79-11 IMPACT OF KI67 LABELING INDEX ON PROGRESSION AND DEATH OF PROSTATE CANCER POST-PROSTATECTOMY: COMPARISON OF VISUAL AND AUTOMATED SCORING","year":2014,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Gynecology; Cancer; Prostate; Digital image analysis; Tissue microarray; Urology; Oncology; Internal medicine","score_opus":0.026784456732735253,"score_gpt":0.4165802542454316,"score_spread":0.38979579751269633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005612083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955486,0.0035437588,0.0000104790315,0.0005223037,0.00004883113,0.00028613966,0.0000100073585,0.000008794677,0.000021082435],"genre_scores_gemma":[0.99898446,0.00086388836,0.00006425794,0.000023073408,0.000035531775,0.0000023911002,0.000002339052,0.000014011153,0.00001002343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987819,0.00018730834,0.00046898244,0.00009167678,0.0002606434,0.00020945938],"domain_scores_gemma":[0.9985759,0.00021966673,0.00060765643,0.000103985374,0.0003951131,0.00009764169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006997754,0.00012198126,0.000558086,0.00021460996,0.000045156976,0.0000041910444,0.00007134768,0.00007223919,0.000010362476],"category_scores_gemma":[0.00010826695,0.00006232407,0.000054871976,0.00012121213,0.00021654482,0.00005265882,0.000055409095,0.0002654866,1.4167142e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009786206,0.00024823495,0.8536824,0.00021620339,0.00025165512,0.000008420826,0.0016648413,0.0004731011,0.12366296,0.00001003674,0.00001696147,0.009978999],"study_design_scores_gemma":[0.0074192504,0.02307824,0.87627435,0.00070948707,0.00033037135,0.00011566493,0.0002368506,0.0172358,0.07440298,0.000089401095,0.000023126377,0.00008450514],"about_ca_topic_score_codex":0.00027323113,"about_ca_topic_score_gemma":0.000015537189,"teacher_disagreement_score":0.04925998,"about_ca_system_score_codex":0.000043310767,"about_ca_system_score_gemma":0.00020535347,"threshold_uncertainty_score":0.2541502},"labels":[],"label_agreement":null},{"id":"W2005965803","doi":"10.1210/jc.2011-2064","title":"Differential Expression of the Androgen-Conjugating UGT2B15 and UGT2B17 Enzymes in Prostate Tumor Cells during Cancer Progression","year":2011,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Université Laval; Centre hospitalier universitaire de Québec","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Androgen; Lymph node; Cancer research; Prostate; Internal medicine; Medicine; Oncology; Cancer; Endocrinology; Biology; Hormone","score_opus":0.06211341834927865,"score_gpt":0.3898097624917796,"score_spread":0.327696344142501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005965803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984321,0.013771755,0.0000019255424,0.0007494612,0.0005810453,0.00046936912,0.0000068332906,0.0000065512468,0.00009205928],"genre_scores_gemma":[0.99020195,0.009011312,0.00019370783,0.000082278275,0.0003182052,0.000014924938,4.226509e-7,0.000017366501,0.0001598057],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997247,0.0006430003,0.0011819242,0.00017503278,0.00036469434,0.00038837327],"domain_scores_gemma":[0.9982155,0.00030555826,0.0008886428,0.00027057776,0.00018163092,0.00013810243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006952926,0.00017053912,0.0008032115,0.00011582682,0.00011120305,0.0000067743536,0.00027617055,0.00007175526,0.00010728442],"category_scores_gemma":[0.0002620629,0.000072968855,0.0002075673,0.00014603653,0.0006411673,0.00010113698,0.00024440288,0.0009389089,0.0000010001004],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014056711,0.001043128,0.6676301,0.0002530358,0.0003982171,0.00037703366,0.0036770313,0.000005578952,0.2862986,0.00015744439,0.00012761627,0.025975544],"study_design_scores_gemma":[0.0057934355,0.00025100805,0.4124681,0.00043845584,0.00022105203,0.00020539222,0.00023379181,0.000011015057,0.5799131,0.00018118751,0.0002270057,0.00005647434],"about_ca_topic_score_codex":0.000060367733,"about_ca_topic_score_gemma":0.000011232517,"teacher_disagreement_score":0.29361448,"about_ca_system_score_codex":0.000018767027,"about_ca_system_score_gemma":0.00021688559,"threshold_uncertainty_score":0.40791443},"labels":[],"label_agreement":null},{"id":"W2006069482","doi":"10.1586/14737140.4.1.37","title":"Bicalutamide (Casodex®) in the treatment of prostate cancer","year":2004,"lang":"en","type":"review","venue":"Expert Review of Anticancer Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Université Laval","funders":"","keywords":"Bicalutamide; Medicine; Prostate cancer; Antiandrogens; Oncology; Quality of life (healthcare); Disease; Libido; Internal medicine; Antiandrogen; Gynecology; Cancer; Androgen receptor","score_opus":0.0934430209650041,"score_gpt":0.4752597091126077,"score_spread":0.38181668814760356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006069482","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000048541835,0.9916956,9.021308e-7,0.001444171,0.00015666473,0.0061969003,0.000101411875,0.000013897741,0.00034192426],"genre_scores_gemma":[0.00001601392,0.99609846,0.00012650691,0.0004955725,0.00022814077,0.0025746678,0.000110985486,0.000070472066,0.0002791613],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996763,0.00033251752,0.0012385768,0.00049942726,0.00071408186,0.00045241325],"domain_scores_gemma":[0.99808854,0.00022386372,0.0005274619,0.0009018986,0.00016065611,0.00009759105],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041259086,0.00058743893,0.0038171164,0.0002125783,0.000036746245,0.000009714713,0.00035767994,0.00016375957,0.00045069234],"category_scores_gemma":[0.000022600369,0.000260633,0.0011403776,0.0009767488,0.00034944614,0.000046101744,0.00001847319,0.00024922495,0.000010106088],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015086224,0.0011393687,0.000056978846,0.08873315,0.0005474804,0.000060405804,0.00087199576,9.070265e-8,0.0000060909715,0.000028878238,0.00033073887,0.90807396],"study_design_scores_gemma":[0.0016831132,0.0012575926,0.000024327519,0.23482747,0.00034971634,0.000022747923,0.000027517412,2.3745527e-7,0.00011773431,0.0000134367765,0.76150423,0.00017187689],"about_ca_topic_score_codex":0.00054686883,"about_ca_topic_score_gemma":0.00001675387,"teacher_disagreement_score":0.90790206,"about_ca_system_score_codex":0.0008053186,"about_ca_system_score_gemma":0.0020173665,"threshold_uncertainty_score":0.99998456},"labels":[],"label_agreement":null},{"id":"W2006246160","doi":"10.1016/j.juro.2010.02.1473","title":"797 DUTASTERIDE REDUCES PROSTATITIS SYMPTOMS COMPARED TO PLACEBO IN MEN ENROLLED IN THE REDUCE (REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS) STUDY","year":2010,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dutasteride; Medicine; Prostatitis; Placebo; Prostate cancer; Urology; Prostate; Gynecology; Testosterone (patch); Prostate biopsy; Internal medicine; Cancer; Alternative medicine; Pathology","score_opus":0.017713107055300926,"score_gpt":0.33901699096876914,"score_spread":0.3213038839134682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006246160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818108,0.00060220103,0.0000016635681,0.015022444,0.00035054365,0.002051266,0.000023144112,0.0000041190146,0.00013380036],"genre_scores_gemma":[0.9987969,0.00035201918,0.000027311944,0.00014565607,0.00013644334,0.00012738368,0.000005239562,0.000018262415,0.00039077937],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99765396,0.0006771653,0.0007135479,0.0001675111,0.00044035644,0.00034746967],"domain_scores_gemma":[0.9988953,0.00019739161,0.00037597984,0.00025503975,0.00018088067,0.00009541963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020464852,0.00016635108,0.0005145202,0.00029579207,0.000058075006,0.000011491725,0.0003299295,0.000060076945,0.00008578622],"category_scores_gemma":[0.00011141601,0.00008754543,0.00005529051,0.00040697627,0.00015494473,0.00010495104,0.000065220855,0.00071080495,0.0000038345906],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055845257,0.0023126106,0.13615735,0.00006522965,0.00048064932,0.00022083412,0.06025833,0.0005998184,0.73177356,0.000004124638,0.0056947493,0.006587505],"study_design_scores_gemma":[0.05715652,0.019336682,0.7947104,0.0003848484,0.0007569472,0.0029903727,0.038247064,0.00029758614,0.08264797,0.0004178169,0.0025931387,0.00046062912],"about_ca_topic_score_codex":0.00052903977,"about_ca_topic_score_gemma":0.000380454,"teacher_disagreement_score":0.65855306,"about_ca_system_score_codex":0.0000946788,"about_ca_system_score_gemma":0.00028295832,"threshold_uncertainty_score":0.3569999},"labels":[],"label_agreement":null},{"id":"W2006884048","doi":"10.1158/1535-7163.targ-11-a194","title":"Abstract A194: A QT/QTc and multi-dose pharmacokinetic (PK) study of abiraterone acetate (AA) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; QT interval; Docetaxel; Pharmacokinetics; Internal medicine; Prednisone; Pharmacology; Cancer; Androgen deprivation therapy; Urology","score_opus":0.07343865574434846,"score_gpt":0.3474244786887221,"score_spread":0.2739858229443737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006884048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99025345,0.0061293026,0.00002753729,0.00013199849,0.000072844145,0.0031727222,0.00011679161,0.000028288287,0.00006709271],"genre_scores_gemma":[0.9967192,0.0014914842,0.00061376207,0.0001625501,0.000012657639,0.0006741753,0.00003042078,0.00008159084,0.00021417675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773526,0.000113244336,0.0005173914,0.0005201264,0.0006034521,0.00051054475],"domain_scores_gemma":[0.9989037,0.000019195539,0.00023605948,0.0003530726,0.00030924365,0.00017871494],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015031788,0.00038184048,0.0005790023,0.00021546967,0.00007091816,0.000029338547,0.00013445412,0.000058854526,0.000107926535],"category_scores_gemma":[0.0000038588682,0.00028118392,0.00005240619,0.0004002581,0.00019705962,0.00012673122,0.00005212803,0.00028872714,0.0000023062817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042930536,0.013531492,0.49904212,0.0020493567,0.0061782636,0.0018730075,0.0558523,0.0014778088,0.30459172,0.000008828624,0.000017924853,0.07244662],"study_design_scores_gemma":[0.06933326,0.005684502,0.8431763,0.0005677264,0.0015451745,0.000008231325,0.0024661548,0.0013356435,0.07522531,0.000020849593,0.000085419,0.0005514185],"about_ca_topic_score_codex":0.0024686852,"about_ca_topic_score_gemma":0.0021459572,"teacher_disagreement_score":0.34413418,"about_ca_system_score_codex":0.0003201618,"about_ca_system_score_gemma":0.00041884268,"threshold_uncertainty_score":0.99996406},"labels":[],"label_agreement":null},{"id":"W2007268427","doi":"10.1016/j.eururo.2014.04.001","title":"Reply from Authors re: Andrea Gallina, Alessandro Nini, Francesco Montorsi, Alberto Briganti. Metabolic Syndrome as a Marker for Prostate Cancer: Still a Work in Progress. Eur Urol 2015;67:71–2","year":2014,"lang":"en","type":"editorial","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Lower urinary tract symptoms; Urology; International Prostate Symptom Score; Tadalafil; Prostate cancer; Gynecology; Prostate; Internal medicine; Cancer; Erectile dysfunction","score_opus":0.013366993330854029,"score_gpt":0.30569772286199254,"score_spread":0.29233072953113853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007268427","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17253442,0.18646133,0.000050183604,0.018959088,0.6012082,0.012471484,0.0030128772,0.0006639389,0.004638491],"genre_scores_gemma":[0.21291709,0.038274206,0.0011591468,0.003236696,0.6262782,0.004954289,0.011827458,0.0021434561,0.09920946],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99132043,0.0015590746,0.0014423071,0.0025335765,0.0012324192,0.0019122034],"domain_scores_gemma":[0.99505377,0.0012524206,0.00085194217,0.001516353,0.00059767155,0.00072782097],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0019871162,0.0012330358,0.0025884137,0.0006635147,0.00019210001,0.00014789398,0.00090886035,0.0009772677,0.00041314622],"category_scores_gemma":[0.0014557783,0.001029454,0.00049604423,0.000720514,0.00070839125,0.0001674582,0.0003892213,0.0025450485,0.00038811663],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01874363,0.00046299247,0.029085482,0.00040054217,0.0012188209,0.0047324207,0.0013410063,0.00001447025,0.000018754245,0.0000046599544,0.9359236,0.008053663],"study_design_scores_gemma":[0.0122270305,0.0027700763,0.03647225,0.00074932503,0.0010192754,0.00006164035,0.000021512891,0.0000688715,0.000026907197,0.00008205967,0.94565225,0.0008488277],"about_ca_topic_score_codex":0.0021323115,"about_ca_topic_score_gemma":0.0004787695,"teacher_disagreement_score":0.14818712,"about_ca_system_score_codex":0.0002441786,"about_ca_system_score_gemma":0.001089848,"threshold_uncertainty_score":0.9997561},"labels":[],"label_agreement":null},{"id":"W2007554762","doi":"10.1016/j.jval.2014.03.415","title":"Have New Therapies Changed the Face of Metastatic Castrate-Resistant Prostate Cancer Treatment in Canada?","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Cabazitaxel; Docetaxel; Medicine; Prostate cancer; Abiraterone acetate; Denosumab; Oncology; Internal medicine; Abiraterone; Ketoconazole; Zoledronic acid; Prednisone; Taxane; Regimen; Chemotherapy; Cancer; Androgen deprivation therapy; Androgen receptor; Breast cancer; Dermatology","score_opus":0.09755681097515691,"score_gpt":0.3626020282345248,"score_spread":0.2650452172593679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007554762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.950034,0.015236761,0.0000050301387,0.032676753,0.0000841457,0.0017743283,0.00006001149,0.0000068782956,0.00012208137],"genre_scores_gemma":[0.9935604,0.00464333,0.00009100663,0.0003046317,0.000036398586,0.00016978278,0.000013725947,0.000017127955,0.0011636388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836946,0.00029033347,0.00037351862,0.00020628466,0.00031192068,0.0004484653],"domain_scores_gemma":[0.999273,0.00017132802,0.00011868934,0.0002391161,0.000034856796,0.00016300152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044147845,0.0001486348,0.00042104148,0.0001039041,0.000047932266,0.0000071749632,0.00007376341,0.00001851806,0.000038847804],"category_scores_gemma":[0.000024520925,0.00008212627,0.00003470537,0.00024556532,0.000050966846,0.00002552019,0.000012497719,0.00013591076,0.0000011546186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053553684,0.0010392191,0.67760104,0.0029018177,0.00068104,0.0003166565,0.09313271,0.0134748705,0.002471044,0.000580339,0.0021515223,0.20029439],"study_design_scores_gemma":[0.028575076,0.007346264,0.8735283,0.0031940385,0.00014615056,0.000028678533,0.028031198,0.01972032,0.01431675,0.0010840679,0.023450302,0.00057882466],"about_ca_topic_score_codex":0.99248827,"about_ca_topic_score_gemma":0.9685837,"teacher_disagreement_score":0.19971557,"about_ca_system_score_codex":0.002164824,"about_ca_system_score_gemma":0.0077153356,"threshold_uncertainty_score":0.99791},"labels":[],"label_agreement":null},{"id":"W2007843050","doi":"10.4161/cbt.8.2.7134","title":"TMPRSS2-ERG fusion is frequently observed in gleason pattern 3 prostate cancer in a Canadian cohort","year":2009,"lang":"en","type":"article","venue":"Cancer Biology & Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"TMPRSS2; Erg; Prostate cancer; Fusion gene; Medicine; Oncology; Biomarker; Cohort; Prostate; Internal medicine; Cancer; Prostatectomy; Cancer research; Biology; Gene; Ophthalmology; Genetics; Disease","score_opus":0.042853292932884444,"score_gpt":0.3535177329741073,"score_spread":0.3106644400412229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007843050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9409472,0.037048314,0.0000012280786,0.019564403,0.00027382284,0.0014772221,0.00019437083,0.000031084553,0.00046235896],"genre_scores_gemma":[0.92499423,0.06660786,0.000013250235,0.0066277273,0.00016312947,0.0005371579,0.00013621197,0.000026052956,0.00089436234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978942,0.00010505563,0.00032000174,0.0005712342,0.00014727667,0.00096222246],"domain_scores_gemma":[0.99915963,0.000021178388,0.00006899789,0.000311013,0.000103770195,0.00033538253],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024590688,0.0002745489,0.00048746026,0.00034640095,0.00007149203,0.000016011689,0.00017015965,0.00026271015,0.0012887839],"category_scores_gemma":[0.000008197295,0.00020745973,0.00008244782,0.0005067449,0.000119519675,0.00007205878,0.000014433548,0.0003980962,0.000017400569],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006164705,0.000091142356,0.77337354,0.000013146804,0.0000678635,0.00011370263,0.0010244066,0.0000058208298,0.01682255,0.0000063302728,0.00064622576,0.20721881],"study_design_scores_gemma":[0.0060017942,0.0006738596,0.9564612,0.00028192677,0.000015402182,0.000004459565,0.000066653585,0.00011553305,0.00567848,0.0001895925,0.030271778,0.00023934986],"about_ca_topic_score_codex":0.5549574,"about_ca_topic_score_gemma":0.54170847,"teacher_disagreement_score":0.20697945,"about_ca_system_score_codex":0.0017700358,"about_ca_system_score_gemma":0.0017744588,"threshold_uncertainty_score":0.9996242},"labels":[],"label_agreement":null},{"id":"W2007938794","doi":"10.5489/cuaj.1608","title":"Complications de l’hormonothérapie anti-androgénique du cancer de la prostate","year":2014,"lang":"fr","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Gynecology; Prostate cancer; Cancer; Internal medicine","score_opus":0.027051609830253003,"score_gpt":0.3322504478253767,"score_spread":0.3051988379951237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007938794","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026362336,0.92125916,0.00042091802,0.061770137,0.00091837323,0.0013249177,0.0006847665,0.000052660907,0.01093285],"genre_scores_gemma":[0.030333795,0.95860106,0.00024735526,0.0036830476,0.0029399367,0.00033487356,0.00021574201,0.00007041465,0.0035737532],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99361616,0.0025401849,0.00090215786,0.0004658128,0.00052363274,0.001952036],"domain_scores_gemma":[0.9940843,0.0013760726,0.000861992,0.00025331523,0.000630513,0.002793784],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0042285193,0.00050913775,0.0013837912,0.0004146668,0.00097064744,0.00039948686,0.00045384036,0.0013693155,0.0015653847],"category_scores_gemma":[0.0017483146,0.00040085966,0.00063458475,0.0005244898,0.0002859047,0.00011253993,0.000044472472,0.0030249162,0.0003734419],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000054339904,0.00031140563,0.52676505,0.0013136149,0.0021554574,0.0009665016,0.00051871,0.000151565,0.000027500548,0.0020177213,0.087200716,0.37851745],"study_design_scores_gemma":[0.0012090959,0.0002368221,0.14938359,0.0015223023,0.00093509763,0.0010095949,0.000020542953,0.00031113977,0.0000027381343,0.00081982394,0.84422535,0.00032389336],"about_ca_topic_score_codex":0.0051592663,"about_ca_topic_score_gemma":0.0007502127,"teacher_disagreement_score":0.75702465,"about_ca_system_score_codex":0.017097946,"about_ca_system_score_gemma":0.013113463,"threshold_uncertainty_score":0.9999271},"labels":[],"label_agreement":null},{"id":"W2008027307","doi":"10.1016/j.ijrobp.2007.07.1392","title":"Improving the Therapeutic Ratio in the Treatment of Intermediate Risk Prostate Cancer With Single Fraction High Dose Rate Brachytherapy and Hypofractionated External Beam Radiation Therapy","year":2007,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Brachytherapy; Prostate cancer; External beam radiation; Radiation therapy; External beam radiotherapy; Nuclear medicine; Dose rate; Prostate; Dose fractionation; Oncology; Cancer; Medical physics; Radiology; Internal medicine","score_opus":0.023639072413942672,"score_gpt":0.3455782140817056,"score_spread":0.3219391416677629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008027307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868022,0.0058968114,0.0036462736,0.0021547917,0.00069140585,0.0007445366,0.00003348096,0.000012375054,0.000018103696],"genre_scores_gemma":[0.9636812,0.03435994,0.0001838223,0.0005397183,0.0010769385,0.00005398949,0.00005160184,0.00002263889,0.000030158877],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99823254,0.00036002422,0.0006461424,0.00020596481,0.0003243238,0.00023098411],"domain_scores_gemma":[0.99690783,0.0010129077,0.0013374351,0.00014185606,0.00053790346,0.00006205749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011095088,0.00020426998,0.0003518084,0.00020392757,0.0001203634,0.00004436618,0.00017560726,0.00012758473,0.000023132552],"category_scores_gemma":[0.00006789081,0.00010555109,0.00010861059,0.0002476536,0.0002661223,0.00038921152,0.000009937326,0.00040219686,0.0000013992261],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005490692,0.0008425474,0.34914547,0.0000040165214,0.0005322557,0.000026561693,0.0017586907,0.00028891486,0.035060205,0.00014473943,0.000008826233,0.6066971],"study_design_scores_gemma":[0.021568777,0.009255385,0.9122282,0.000066311026,0.00019653165,0.00013226639,0.0005215373,0.001686534,0.04660016,0.0019836233,0.005596679,0.000163974],"about_ca_topic_score_codex":0.0004834839,"about_ca_topic_score_gemma":0.00007301564,"teacher_disagreement_score":0.6065331,"about_ca_system_score_codex":0.001038499,"about_ca_system_score_gemma":0.00043585047,"threshold_uncertainty_score":0.43042484},"labels":[],"label_agreement":null},{"id":"W2008086070","doi":"10.3747/co.v17i0.702","title":"Research in Castration-Resistant Rostate Cancer: What Does the Future Hold?","year":2010,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Prostate cancer; Medicine; Castration; Docetaxel; Androgen deprivation therapy; Tensin; Cancer research; Internal medicine; Oncology; PTEN; Cancer; PI3K/AKT/mTOR pathway; Hormone; Signal transduction; Biology","score_opus":0.1559605328925172,"score_gpt":0.5106868143009607,"score_spread":0.35472628140844353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008086070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92156017,0.021327944,4.471525e-7,0.0506445,0.0046394235,0.0009014381,0.00002332986,0.000022609047,0.00088014686],"genre_scores_gemma":[0.96533257,0.0312137,0.00002443766,0.000114473594,0.0017791344,0.00050331716,0.000059574515,0.000019054758,0.0009537371],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819124,0.00023038477,0.00023704288,0.00033076375,0.00043572037,0.0005748749],"domain_scores_gemma":[0.99887973,0.00024959195,0.000048544673,0.00036266545,0.0002955523,0.00016390732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00098568,0.00013061841,0.00024317698,0.00021254837,0.00020911678,0.0000824806,0.00019763199,0.00014840665,0.00036330766],"category_scores_gemma":[0.000034433193,0.000064377775,0.00005672923,0.000502621,0.00045169925,0.00017111348,0.00008811897,0.0016749451,0.00004480602],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017883803,0.00095639395,0.057681065,0.00021523109,0.000065317625,0.00034307485,0.003444311,0.000003545734,0.025786936,0.0020152254,0.00992035,0.8977802],"study_design_scores_gemma":[0.003793299,0.0006470752,0.08417444,0.00021320445,0.000033483815,0.000033763816,0.008060214,0.000107199674,0.002741817,0.0011384779,0.89892155,0.00013547592],"about_ca_topic_score_codex":0.00021921827,"about_ca_topic_score_gemma":0.01325851,"teacher_disagreement_score":0.8976447,"about_ca_system_score_codex":0.00039531756,"about_ca_system_score_gemma":0.0011743822,"threshold_uncertainty_score":0.739856},"labels":[],"label_agreement":null},{"id":"W2009004874","doi":"10.1007/s40262-014-0178-6","title":"Population Pharmacokinetic Analysis of Abiraterone in Chemotherapy-Naïve and Docetaxel-Treated Patients with Metastatic Castration-Resistant Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Clinical Pharmacokinetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Abiraterone acetate; Pharmacokinetics; Docetaxel; Medicine; Prostate cancer; Chemotherapy; Pharmacology; Abiraterone; Oncology; Population; Internal medicine; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.036582942117500156,"score_gpt":0.40118511546433133,"score_spread":0.3646021733468312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009004874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978052,0.00044028196,0.00002648042,0.00047360282,0.000060302704,0.0009752547,0.00009725772,0.000022273522,0.00009938651],"genre_scores_gemma":[0.9972945,0.001343201,0.00040135765,0.000268211,0.000048091384,0.00006148487,0.0003446324,0.00003123194,0.00020730867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978725,0.00018968404,0.0008216856,0.00041858334,0.00039761234,0.00029993962],"domain_scores_gemma":[0.99879867,0.00020929628,0.0002716687,0.00021274331,0.00029265988,0.0002149793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039770544,0.0002298097,0.00078484777,0.0003505441,0.00003618646,0.00001933393,0.00007197901,0.000058459937,0.00019246196],"category_scores_gemma":[0.000055064196,0.00016093804,0.00010340886,0.0010102794,0.00020837896,0.0000779675,0.000026128613,0.0002392428,0.0000017671731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038050318,0.00090363785,0.96385396,0.00018547714,0.0015363588,0.00001178379,0.00012563234,0.00071236835,0.0032972784,0.00000531092,0.00006540548,0.025497777],"study_design_scores_gemma":[0.017255764,0.00095011713,0.96423787,0.00009970482,0.0031647305,4.943319e-7,0.000012803332,0.011503987,0.0023685861,0.000020239364,0.00022293818,0.00016274108],"about_ca_topic_score_codex":0.0002715215,"about_ca_topic_score_gemma":0.00010470055,"teacher_disagreement_score":0.025335036,"about_ca_system_score_codex":0.00006960269,"about_ca_system_score_gemma":0.000055613564,"threshold_uncertainty_score":0.6562863},"labels":[],"label_agreement":null},{"id":"W2009034973","doi":"10.1016/j.urolonc.2008.07.025","title":"The continued debate: Intermittent vs. continuous hormonal ablation for metastatic prostate cancer","year":2008,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Context (archaeology); Hormonal therapy; Prostate; Oncology; Androgen; Internal medicine; Androgen suppression; Cancer; Urology; Hormone","score_opus":0.04781095889643217,"score_gpt":0.3494929811726663,"score_spread":0.30168202227623414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009034973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9611113,0.0063658194,0.000072957475,0.029598517,0.0002232188,0.0014756861,0.000067279856,0.00005318708,0.00103205],"genre_scores_gemma":[0.921799,0.018757086,0.020689866,0.0039674863,0.00034805416,0.0031974905,0.0003584048,0.000044103428,0.030838482],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878925,0.00008977693,0.00029244897,0.00028705996,0.00015792876,0.00038355764],"domain_scores_gemma":[0.9988346,0.0005000894,0.00014550085,0.00013773094,0.00017981097,0.00020228398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003325764,0.00016727703,0.00032098746,0.000077317825,0.00076511153,0.000026292495,0.000081549195,0.00009336934,0.000030995507],"category_scores_gemma":[0.00019203014,0.00010026469,0.00007341545,0.00015567048,0.0011510148,0.0000741308,0.000033494554,0.0002378057,0.000006736332],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049564037,0.00055765547,0.82820046,0.00013479684,0.00079510844,0.0006643455,0.0030294526,0.00005281841,0.0038666988,0.007941818,0.080130644,0.06966981],"study_design_scores_gemma":[0.0030074304,0.003249127,0.021742148,0.000040217616,0.00031251134,0.00053953595,0.00024118235,0.001171928,0.00087793905,0.0028019685,0.96588,0.00013606396],"about_ca_topic_score_codex":0.000059629816,"about_ca_topic_score_gemma":0.000054515815,"teacher_disagreement_score":0.8857493,"about_ca_system_score_codex":0.00014970389,"about_ca_system_score_gemma":0.00056964497,"threshold_uncertainty_score":0.5884697},"labels":[],"label_agreement":null},{"id":"W2009087111","doi":"10.1038/modpathol.2014.85","title":"PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy","year":2014,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; Prostate Cancer Foundation; Ontario Institute for Cancer Research; National Institutes of Health; Prostate Cancer Canada; Patrick C. Walsh Prostate Cancer Research Fund","keywords":"PTEN; Prostatectomy; Prostate cancer; Medicine; Biopsy; Immunohistochemistry; Prostate; Cancer; Pathology; Urology; Oncology; Internal medicine; Biology; PI3K/AKT/mTOR pathway","score_opus":0.020121912593701975,"score_gpt":0.3041953524961638,"score_spread":0.2840734399024618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009087111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993872,0.0004291743,0.00093960704,0.003122357,0.000072072646,0.0007625332,0.0002460754,0.00006733806,0.00048883917],"genre_scores_gemma":[0.9967082,0.00007954747,0.0007474284,0.0005463209,0.0000709963,0.00019912563,0.0001228442,0.000045199013,0.0014803227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832284,0.00010663678,0.00025461445,0.00048743284,0.0003282579,0.00050018437],"domain_scores_gemma":[0.9990707,0.00008290604,0.000103634164,0.00032622204,0.0001869418,0.00022958235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002211328,0.00020007088,0.0005373872,0.00015629042,0.000066832414,0.000011421365,0.000113078946,0.0001449122,0.00011903167],"category_scores_gemma":[0.000088942594,0.00013702492,0.000062536965,0.00027044505,0.0002730117,0.00004595959,0.000066349654,0.00023332308,0.000021604568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055214,0.0008366562,0.7632825,0.00017133047,0.0007537271,0.0018336971,0.012485695,0.00007475352,0.17100567,0.000101710466,0.001061359,0.042871553],"study_design_scores_gemma":[0.045059927,0.00902781,0.615397,0.0023310976,0.0011027041,0.0005356772,0.0003766281,0.014209872,0.2976049,0.0077524395,0.00510205,0.001499968],"about_ca_topic_score_codex":0.00024176214,"about_ca_topic_score_gemma":0.000042724616,"teacher_disagreement_score":0.1478855,"about_ca_system_score_codex":0.00015894395,"about_ca_system_score_gemma":0.0001784906,"threshold_uncertainty_score":0.5587714},"labels":[],"label_agreement":null},{"id":"W2009262452","doi":"10.1016/j.jsbmb.2004.10.011","title":"Major impact of hormonal therapy in localized prostate cancer—death can already be an exception","year":2004,"lang":"en","type":"review","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"National Cancer Institute; Shionogi; Blue Cross and Blue Shield Association","keywords":"Prostate cancer; Medicine; Bicalutamide; Flutamide; Castration; Prostate; Antiandrogen; Internal medicine; Androgen; Oncology; Cancer; Androgen deprivation therapy; Hormonal therapy; Urology; Hormone; Androgen receptor","score_opus":0.04269367804057838,"score_gpt":0.4087455731475844,"score_spread":0.36605189510700603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009262452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32530648,0.6740276,0.000008723695,0.0001475737,0.000020867268,0.00035734623,0.00011991227,0.000001979221,0.00000949123],"genre_scores_gemma":[0.10829243,0.8912816,0.000025094203,0.00003694621,0.000078248806,0.000017414452,0.0001976728,0.000021642392,0.00004896459],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998561,0.00022356484,0.000584681,0.00019078444,0.00016252634,0.00027741233],"domain_scores_gemma":[0.99887943,0.000033207834,0.0005501995,0.00022918216,0.00014832588,0.00015963885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042727377,0.0003078229,0.0011486404,0.00013259207,0.00003513302,0.000008864736,0.00019195939,0.0002944806,0.000023940447],"category_scores_gemma":[0.000014899229,0.00015058897,0.00031846797,0.00015435934,0.00029111365,0.000022071681,0.000043436983,0.0004942511,1.4372581e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005610183,0.0006375743,0.00093973934,0.007197084,0.0027647829,0.00038700033,0.0006509521,0.0000060668744,0.36896878,0.000005459793,0.000043821536,0.61278856],"study_design_scores_gemma":[0.09542436,0.09497532,0.0033244328,0.118226655,0.014017058,0.025290038,0.0011775413,0.00001941997,0.54952806,0.0027135867,0.09131046,0.0039930805],"about_ca_topic_score_codex":0.00029732788,"about_ca_topic_score_gemma":0.000006850884,"teacher_disagreement_score":0.60879546,"about_ca_system_score_codex":0.00032376443,"about_ca_system_score_gemma":0.0013484884,"threshold_uncertainty_score":0.614084},"labels":[],"label_agreement":null},{"id":"W2009546025","doi":"10.1158/1538-7445.am10-320","title":"Abstract 320: Fine structure genomic mapping of chromosome 10q23 interstitial deletions in prostate cancer reveals the <i>PTEN</i> gene locus as the minimum region deleted","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Princess Margaret Cancer Centre; Calgary Laboratory Services; University of Calgary; Toronto General Hospital; University Health Network; Queen's University","funders":"","keywords":"PTEN; Biology; Comparative genomic hybridization; Locus (genetics); Fluorescence in situ hybridization; Breakpoint; Genetics; Bacterial artificial chromosome; SNP array; Cancer research; Molecular biology; Gene; Chromosome; Genome; Single-nucleotide polymorphism; Genotype; PI3K/AKT/mTOR pathway","score_opus":0.05186825954907479,"score_gpt":0.36976373662065454,"score_spread":0.3178954770715797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009546025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679215,0.006973523,0.0000027996907,0.021831859,0.0003588388,0.0022376736,0.00021325095,0.000023968985,0.00043660525],"genre_scores_gemma":[0.9910929,0.0050824117,0.00002573456,0.0002488462,0.0007150919,0.0007578658,0.00006439369,0.000055554236,0.0019571884],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99692404,0.00020282355,0.00051041367,0.00051995856,0.0009066382,0.0009361494],"domain_scores_gemma":[0.9978046,0.00032658543,0.00015096832,0.0008103309,0.0006965036,0.0002110017],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00096569594,0.0002522444,0.00040692883,0.00036775268,0.0003831053,0.00007117755,0.00059168035,0.00016953661,0.0009357026],"category_scores_gemma":[0.00020338761,0.00014101317,0.0001269184,0.0011358798,0.0010949973,0.000110529334,0.00024024751,0.0020624818,0.000026432754],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013242785,0.000092140945,0.009504511,0.00027341137,0.00016754135,0.00021864945,0.0020698714,0.00006224809,0.9665042,0.000064598615,0.0051125283,0.014606],"study_design_scores_gemma":[0.01532043,0.0013339854,0.19923335,0.0030706027,0.00022192966,0.00055421557,0.003288247,0.00055090955,0.7086272,0.003075674,0.06371578,0.0010076395],"about_ca_topic_score_codex":0.005135077,"about_ca_topic_score_gemma":0.005108867,"teacher_disagreement_score":0.257877,"about_ca_system_score_codex":0.000592319,"about_ca_system_score_gemma":0.0016936974,"threshold_uncertainty_score":0.9999776},"labels":[],"label_agreement":null},{"id":"W2009623312","doi":"10.1016/j.juro.2015.02.2182","title":"MP61-01 FUNCTIONAL ROLE OF THE KALLIKREIN 6 REGION OF THE KALLIKREIN LOCUS IN GENETIC PREDISPOSITION FOR AGGRESSIVE (GLEASON ≥8) PROSTATE CANCER: FINE-MAPPING AND METHYLATION STUDY IN A CANADIAN COHORT AND THE SWISS ARM OF THE EUROPEAN RANDOMIZED STUDY FOR PROSTATE CANCER SCREENING","year":2015,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Cohort; Cancer; Internal medicine","score_opus":0.02669861936884077,"score_gpt":0.29381250205173565,"score_spread":0.2671138826828949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009623312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749804,0.0102113485,0.00006747635,0.006788941,0.00012075761,0.0077788653,0.00002707533,0.0000014794347,0.000023638326],"genre_scores_gemma":[0.9987541,0.00072402775,0.00001717254,0.00006250126,0.00007955441,0.0002788796,0.0000021053631,0.000017900464,0.00006379216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965668,0.002016754,0.00066056254,0.00015202453,0.00035443046,0.00024946217],"domain_scores_gemma":[0.9976262,0.000600868,0.0010382876,0.0002180718,0.0004463691,0.00007020168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044870507,0.00014631015,0.0005583337,0.00014888318,0.00014309693,0.000009840423,0.00021307822,0.000044344106,0.0000016649803],"category_scores_gemma":[0.00047954556,0.000057560093,0.00010718414,0.00028989677,0.00046121769,0.00005392592,0.000084862215,0.00031347346,1.779159e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1384248,0.000327373,0.80890703,0.00009303197,0.0009228413,0.000010869625,0.030365642,0.011272484,0.0018243699,0.00002587348,0.000080054015,0.0077456306],"study_design_scores_gemma":[0.13978253,0.001869091,0.8431901,0.0004213364,0.0012061354,0.0000674971,0.0053237923,0.0058371946,0.0008318346,0.0013162672,0.000067651454,0.00008659082],"about_ca_topic_score_codex":0.029408645,"about_ca_topic_score_gemma":0.07857399,"teacher_disagreement_score":0.04916534,"about_ca_system_score_codex":0.00014717947,"about_ca_system_score_gemma":0.00064970803,"threshold_uncertainty_score":0.9770546},"labels":[],"label_agreement":null},{"id":"W2009712841","doi":"10.1097/mnm.0000000000000023","title":"Safety and antitumor efficacy of 153Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer","year":2013,"lang":"en","type":"article","venue":"Nuclear Medicine Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Misericordia Community Hospital","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Confidence interval; Internal medicine; Chemotherapy; Oncology; Urology; Prostate-specific antigen; Cancer; Surgery","score_opus":0.0430588302410738,"score_gpt":0.3410164836932971,"score_spread":0.2979576534522233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009712841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96674657,0.0016355667,0.000009594419,0.027536549,0.000023554772,0.0020092537,0.00008183077,0.000030782572,0.0019263022],"genre_scores_gemma":[0.9929534,0.0027199897,0.0032947413,0.00039457157,0.000015893647,0.00007719181,0.00012380972,0.000030258965,0.0003901113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882954,0.00007982388,0.0003646924,0.00021906469,0.00030303313,0.00020385384],"domain_scores_gemma":[0.99828833,0.00013953917,0.00013031864,0.00073675154,0.0004247362,0.0002803114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001417201,0.00015474785,0.00037099427,0.00014375354,0.00020400339,0.000024270199,0.00017066642,0.000027228376,0.00025925902],"category_scores_gemma":[0.000111536865,0.00010176678,0.000021347678,0.00026523758,0.0005824567,0.00012184949,0.00015071704,0.00016450092,0.000010427773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02142981,0.006442566,0.50715816,0.003931674,0.004410703,0.00008646876,0.06593522,0.000033895125,0.16548966,0.008206607,0.011885098,0.20499016],"study_design_scores_gemma":[0.0109302895,0.0021869414,0.97372407,0.00094166346,0.00041501486,0.000013455364,0.00091837364,0.000182603,0.00015938697,0.00004167458,0.010317296,0.00016921057],"about_ca_topic_score_codex":0.0012439035,"about_ca_topic_score_gemma":0.00025301363,"teacher_disagreement_score":0.46656597,"about_ca_system_score_codex":0.00006208122,"about_ca_system_score_gemma":0.00015016968,"threshold_uncertainty_score":0.4149929},"labels":[],"label_agreement":null},{"id":"W2009962900","doi":"10.1186/1755-8794-3-43","title":"LNCaP Atlas: Gene expression associated with in vivoprogression to castration-recurrent prostate cancer","year":2010,"lang":"en","type":"article","venue":"BMC Medical Genomics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health","keywords":"LNCaP; Prostate cancer; Biology; Androgen receptor; Cancer research; Transcriptome; Gene expression profiling; Gene; Gene expression; Cancer; Genetics","score_opus":0.02681902409121974,"score_gpt":0.34131634290452495,"score_spread":0.3144973188133052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009962900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964925,0.0006252969,0.00006116228,0.0011745193,0.00032388006,0.0010137663,0.000032181983,0.00004195101,0.00023471133],"genre_scores_gemma":[0.9937605,0.00048714562,0.0032109704,0.00022424808,0.0003865603,0.00042571893,0.00020272398,0.00004069211,0.0012614395],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980163,0.000058110527,0.00030703284,0.00039099346,0.0007704264,0.0004571582],"domain_scores_gemma":[0.99876386,0.00011068467,0.00007659026,0.00023902199,0.00013181972,0.00067799824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041973434,0.00018365232,0.00028925968,0.00012358213,0.00009093512,0.00002654696,0.00013503555,0.00020162335,0.00054135604],"category_scores_gemma":[0.00035108943,0.000116980984,0.000043720614,0.000266152,0.00011087436,0.00004319948,0.00008137544,0.00056597975,0.000033470522],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005367796,0.0016182312,0.5663286,0.00027731614,0.00010446123,0.0005871886,0.0033539992,0.00006578508,0.33273217,0.000026975682,0.004107263,0.08543022],"study_design_scores_gemma":[0.037288092,0.0043104105,0.45281008,0.0070944475,0.00022668336,0.00014538018,0.0010956471,0.0068243747,0.46601322,0.00014523709,0.022596266,0.0014501715],"about_ca_topic_score_codex":0.00011044887,"about_ca_topic_score_gemma":0.0063204668,"teacher_disagreement_score":0.13328105,"about_ca_system_score_codex":0.00028606562,"about_ca_system_score_gemma":0.0017433907,"threshold_uncertainty_score":0.5927469},"labels":[],"label_agreement":null},{"id":"W2010627375","doi":"10.1002/cncr.10219","title":"Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma","year":2002,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Testosterone (patch); Androgen; Prostate cancer; Internal medicine; Urology; Cyproterone; Antiandrogen; Cyproterone acetate; Endocrinology; Androgen deprivation therapy; Hormone; Cancer","score_opus":0.051136901220105856,"score_gpt":0.3152076136074137,"score_spread":0.26407071238730784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010627375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781368,0.015872087,0.000053978343,0.0022890654,0.00032041135,0.001961959,0.00006623152,0.00006126026,0.0012382059],"genre_scores_gemma":[0.98289365,0.0005633539,0.00030149356,0.00024801574,0.00025034748,0.0010197985,0.000075845666,0.000036140646,0.014611336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899364,0.00001620391,0.0001670722,0.00027984483,0.00019193663,0.00035127878],"domain_scores_gemma":[0.9995081,0.000039283776,0.000050352206,0.00018530268,0.00009477533,0.00012219218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000102438535,0.00013205556,0.00023599541,0.00007941483,0.000111324,0.000022074053,0.000046258945,0.00006614164,0.00020805994],"category_scores_gemma":[0.00003727075,0.00010218713,0.00011786037,0.00015007448,0.000032289663,0.00013195473,0.000018044982,0.000095344134,0.000026237858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026419589,0.00035022787,0.5618715,0.00074382813,0.00059011823,0.0002412002,0.0024820995,0.00005443297,0.0403652,0.000011754063,0.027070444,0.36357722],"study_design_scores_gemma":[0.07410391,0.011804096,0.42467502,0.0021460203,0.0023286769,0.000165864,0.0006890417,0.025124112,0.28279543,0.000918314,0.17320892,0.002040573],"about_ca_topic_score_codex":0.000039071347,"about_ca_topic_score_gemma":0.000020485264,"teacher_disagreement_score":0.36153665,"about_ca_system_score_codex":0.00028701054,"about_ca_system_score_gemma":0.00009561343,"threshold_uncertainty_score":0.416707},"labels":[],"label_agreement":null},{"id":"W2010741280","doi":"10.1038/sj.bjc.6601850","title":"Is there a role for chemotherapy in prostate cancer?","year":2004,"lang":"en","type":"review","venue":"British Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Mitoxantrone; Docetaxel; Medicine; Estramustine; Oncology; Chemotherapy; Internal medicine; Context (archaeology); Prostate cancer; Cancer; Clinical trial; Prednisone; Prostate; Cardiotoxicity; Paclitaxel; Prostate disease","score_opus":0.04388279243030324,"score_gpt":0.414976426730879,"score_spread":0.37109363430057574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010741280","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003909048,0.99597466,0.000002456207,0.0008814435,0.00027351957,0.0018498994,0.000446992,0.000007958952,0.00017214622],"genre_scores_gemma":[0.000064680076,0.9949806,0.00014955392,0.00020670141,0.00075560843,0.00061988947,0.00002162448,0.000089769856,0.0031115739],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798226,0.000044543718,0.0008033654,0.0002742408,0.00043776282,0.0004578323],"domain_scores_gemma":[0.99865043,0.000047660884,0.0005922382,0.00013794632,0.00037413504,0.00019759727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029527798,0.0002947176,0.0018310618,0.00023785165,0.000053489573,0.00007335863,0.00020830805,0.00019964002,0.0004958391],"category_scores_gemma":[0.000021641004,0.00023845825,0.00075317465,0.0003459079,0.00007611801,0.000106412685,0.000019375162,0.00072184054,0.0000029224245],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003716798,0.00014580383,0.00023743881,0.016821092,0.000704997,0.0008280007,0.00015931178,0.0000017944242,0.000001674471,0.0000017776775,0.002015054,0.97871137],"study_design_scores_gemma":[0.005586293,0.00029803062,0.00018784139,0.14400189,0.0005641635,0.0011189384,0.000031284297,9.73856e-7,0.00003721826,0.00013460916,0.84784883,0.00018993873],"about_ca_topic_score_codex":0.0011441959,"about_ca_topic_score_gemma":0.00052252074,"teacher_disagreement_score":0.9785214,"about_ca_system_score_codex":0.0015529747,"about_ca_system_score_gemma":0.004997205,"threshold_uncertainty_score":0.9724045},"labels":[],"label_agreement":null},{"id":"W2011246519","doi":"10.3816/cgc.2005.n.002","title":"Combined Androgen Blockade: The Case for Bicalutamide","year":2005,"lang":"en","type":"review","venue":"Clinical Prostate Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"","keywords":"Bicalutamide; Antiandrogen; Flutamide; Medicine; Prostate cancer; Castration; Urology; Antiandrogens; Internal medicine; Enzalutamide; Androgen; Oncology; Androgen receptor; Hazard ratio; Androgen deprivation therapy; Randomized controlled trial; Testosterone (patch); Combination therapy; Endocrinology; Cancer; Hormone; Confidence interval","score_opus":0.23588876844973317,"score_gpt":0.5315328612553668,"score_spread":0.29564409280563364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011246519","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017537046,0.98495823,0.000004904529,0.0038747664,0.0008373885,0.008707707,0.0010771021,0.00010261388,0.00026191882],"genre_scores_gemma":[0.00004122584,0.9750699,0.0001285909,0.00070097373,0.0024586655,0.0044044936,0.00044633562,0.00016991027,0.016579911],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958071,0.00032555338,0.0016935644,0.0009863625,0.00032802648,0.00085936463],"domain_scores_gemma":[0.99564934,0.0019971104,0.00050543534,0.0009652798,0.00032671768,0.0005561389],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013056246,0.0006393914,0.0027713594,0.00012008257,0.00031883718,0.000080287304,0.00035063858,0.00064272754,0.00035179165],"category_scores_gemma":[0.00048635484,0.0003235046,0.0016859064,0.00046035295,0.0007295265,0.00006076534,0.0001903803,0.0013763559,0.00013473656],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005929527,0.00028784125,0.000088348985,0.008715816,0.0010850868,0.0014094115,0.000034336932,4.2281778e-7,9.2158395e-8,0.000023604305,0.021010198,0.9667519],"study_design_scores_gemma":[0.00430902,0.00090445805,0.000008440867,0.0056089223,0.00400704,0.00069442316,0.000025200356,0.000039203107,0.0000026551543,0.000080972524,0.9839464,0.0003732758],"about_ca_topic_score_codex":0.00003486376,"about_ca_topic_score_gemma":0.000037675913,"teacher_disagreement_score":0.9663786,"about_ca_system_score_codex":0.000473576,"about_ca_system_score_gemma":0.0022493275,"threshold_uncertainty_score":0.9999217},"labels":[],"label_agreement":null},{"id":"W2011553422","doi":"10.1007/s00345-008-0261-4","title":"The management of high-risk prostate cancer in 2008","year":2008,"lang":"en","type":"editorial","venue":"World Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Université Laval","funders":"","keywords":"Medicine; Nephrology; Prostate cancer; Internal medicine; Prostate; Cancer; Oncology; Urology; Gynecology; General surgery","score_opus":0.009893848640586657,"score_gpt":0.3065521632431364,"score_spread":0.2966583146025497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011553422","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01123622,0.18066235,0.0000046448204,0.009022199,0.7960774,0.0010162907,0.0001901751,0.000009665104,0.0017811088],"genre_scores_gemma":[0.01867396,0.73710847,0.00012311434,0.000040867733,0.22225077,0.00004543467,0.000025443003,0.000047889425,0.021684036],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99756074,0.0001739846,0.0008515942,0.00018943698,0.000806921,0.00041733618],"domain_scores_gemma":[0.9977073,0.00053889677,0.00093213865,0.000262282,0.00044905924,0.00011031111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072427717,0.00020693056,0.00073190074,0.0004907683,0.00008270905,0.00000815256,0.00028934475,0.00020847871,0.00008437413],"category_scores_gemma":[0.00009058637,0.00011816785,0.00017552394,0.0003776986,0.0003153792,0.00003523271,0.00008658123,0.0017131625,0.000005429034],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006436646,0.00016371853,0.0036211463,0.00017953866,0.0013025701,0.0024360158,0.00015491893,0.00009128614,0.000006485107,0.000019970565,0.9437925,0.0417952],"study_design_scores_gemma":[0.00585018,0.001028364,0.005918217,0.00031229894,0.00045447974,0.000045437457,0.000026712323,0.0000036958043,0.000024387191,0.00023862776,0.98601115,0.00008645839],"about_ca_topic_score_codex":0.00031531652,"about_ca_topic_score_gemma":0.0006686638,"teacher_disagreement_score":0.57382655,"about_ca_system_score_codex":0.00028381718,"about_ca_system_score_gemma":0.000816385,"threshold_uncertainty_score":0.7442934},"labels":[],"label_agreement":null},{"id":"W2012920679","doi":"10.1016/j.ccr.2013.02.016","title":"The E3 Ubiquitin Ligase Siah2 Contributes to Castration-Resistant Prostate Cancer by Regulation of Androgen Receptor Transcriptional Activity","year":2013,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Wellcome Trust; Canadian Institutes of Health Research; Cedars-Sinai Medical Center; U.S. Department of Veterans Affairs","keywords":"Ubiquitin ligase; Androgen receptor; Prostate cancer; Biology; Cancer research; Ubiquitin; Cell growth; Cell biology; Cancer; Gene; Genetics","score_opus":0.016489797246240674,"score_gpt":0.2908976135692427,"score_spread":0.27440781632300204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012920679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711326,0.013996645,0.000030551313,0.01146246,0.00017931852,0.0018434431,0.00059326267,0.000024364961,0.0007373873],"genre_scores_gemma":[0.98163044,0.002958116,0.000045500077,0.00017176247,0.0001102428,0.0011949048,0.000105399246,0.000021510717,0.013762118],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987948,0.000051412808,0.00024563077,0.00025710333,0.00032070486,0.00033033435],"domain_scores_gemma":[0.99903655,0.00007550115,0.0000996855,0.00019993803,0.00041442437,0.00017392059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014987387,0.00015062999,0.00022565026,0.000035282508,0.00017757129,0.000046552483,0.00008586969,0.000067472356,0.00083553855],"category_scores_gemma":[0.00001577875,0.00009995418,0.00007571779,0.00019799042,0.00012921104,0.00015363471,0.000016024218,0.00011421697,0.000021626956],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012909251,0.00011442246,0.0023252422,0.00011665802,0.00009535469,9.328438e-7,0.00034308044,0.000023736755,0.94151884,0.00004519512,0.039602518,0.01452309],"study_design_scores_gemma":[0.0021594348,0.0002665563,0.022078484,0.00013251086,0.00006732417,5.280587e-7,0.00020298127,0.00011045269,0.9248532,0.00007776678,0.0499385,0.00011222891],"about_ca_topic_score_codex":0.003087831,"about_ca_topic_score_gemma":0.0005392836,"teacher_disagreement_score":0.019753242,"about_ca_system_score_codex":0.00048528894,"about_ca_system_score_gemma":0.0005911151,"threshold_uncertainty_score":0.9148561},"labels":[],"label_agreement":null},{"id":"W2013426357","doi":"10.1038/bjc.2012.486","title":"An inherited NBN mutation is associated with poor prognosis prostate cancer","year":2012,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Coalition for Research in Women's Health","funders":"Ministerstwo Edukacji i Nauki","keywords":"Prostate cancer; Medicine; CHEK2; Cancer; Prostate; Mutation; Nijmegen breakage syndrome; Allele; Internal medicine; Oncology; Genetics; Germline mutation; Biology; DNA damage; Gene; DNA","score_opus":0.02492486793701148,"score_gpt":0.34331637563185075,"score_spread":0.31839150769483926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013426357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624579,0.034730382,0.000009652889,0.0018213458,0.00021132323,0.00045997632,0.00011906325,0.000023639544,0.00016669281],"genre_scores_gemma":[0.9893321,0.00791653,0.00020823305,0.0006330367,0.00053446944,0.00011756966,0.000032578988,0.000044557524,0.0011809227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983427,0.0000782046,0.00033640032,0.00014150237,0.00065120705,0.00045000418],"domain_scores_gemma":[0.998247,0.000024553125,0.00032665062,0.000068656445,0.0009456527,0.0003874719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003387138,0.00013896849,0.0003510352,0.00011708058,0.000111263405,0.00008292379,0.00008217543,0.00008399388,0.0006321066],"category_scores_gemma":[0.000046425626,0.000113018046,0.000085235384,0.00038318968,0.00009978536,0.0006264247,0.000010502162,0.00034085935,0.0000027703759],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019716516,0.0010136494,0.6962123,0.000117944284,0.0012047073,0.0012059757,0.0020344104,0.000023007808,0.0053368397,0.0000015787625,0.008213514,0.28266442],"study_design_scores_gemma":[0.010552772,0.0016494424,0.9449674,0.003337108,0.0007075748,0.0017858542,0.00050056895,0.000090856236,0.026953459,0.000018850627,0.0091462545,0.00028987098],"about_ca_topic_score_codex":0.0010044463,"about_ca_topic_score_gemma":0.0006072064,"teacher_disagreement_score":0.28237453,"about_ca_system_score_codex":0.00047340122,"about_ca_system_score_gemma":0.0005947102,"threshold_uncertainty_score":0.69211245},"labels":[],"label_agreement":null},{"id":"W2013612743","doi":"10.1158/1078-0432.ccr-08-1899","title":"Global Gene Expression Analysis of Reactive Stroma in Prostate Cancer","year":2009,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Prostate cancer; Stroma; Cancer; Gene expression; Biology; Prostate; Cancer research; Pathology; Gene; Medicine; Genetics; Immunohistochemistry","score_opus":0.21587473288739326,"score_gpt":0.5894723836277024,"score_spread":0.37359765074030915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013612743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877783,0.0051913937,0.0000058329088,0.003793406,0.00009152054,0.00091919303,0.00023400167,0.000021592823,0.001964774],"genre_scores_gemma":[0.9890796,0.008889062,0.00017328335,0.0001378091,0.00022000384,0.00020983444,0.00006510167,0.00001284643,0.0012124804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960785,0.00046810726,0.0007567474,0.0006891679,0.0012511666,0.0007563138],"domain_scores_gemma":[0.9978155,0.00036017413,0.00012718858,0.0005462838,0.00075399,0.0003968729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002013566,0.0001687981,0.00085697515,0.000579087,0.000078676814,0.00002180975,0.00024931884,0.00017354294,0.00048396972],"category_scores_gemma":[0.000378173,0.00012306224,0.00030715668,0.003933854,0.00044585872,0.00011043633,0.000121474106,0.0007635018,0.000008301377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007601845,0.0009838708,0.94005,0.000050706913,0.0006303525,0.00020307991,0.00020159796,0.000109245884,0.0117255,0.000037706228,0.0018080284,0.036598064],"study_design_scores_gemma":[0.003922007,0.001334597,0.9792458,0.00030215888,0.00027871956,0.0000010904877,0.00017267998,0.00033673138,0.0132462,0.00034042448,0.00070089474,0.000118709846],"about_ca_topic_score_codex":0.0027927465,"about_ca_topic_score_gemma":0.0009932952,"teacher_disagreement_score":0.039195787,"about_ca_system_score_codex":0.0010299495,"about_ca_system_score_gemma":0.001322146,"threshold_uncertainty_score":0.5299129},"labels":[],"label_agreement":null},{"id":"W2013939406","doi":"10.1080/00926230903554552","title":"The Unique Needs of Couples Experiencing Androgen Deprivation Therapy for Prostate Cancer","year":2010,"lang":"en","type":"review","venue":"Journal of Sex & Marital Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Prostate cancer; Androgen deprivation therapy; Psychotherapist; Psychology; Androgen; Prostate; Cancer; Medicine; Oncology; Internal medicine; Hormone","score_opus":0.06817308382838914,"score_gpt":0.4019736531684994,"score_spread":0.33380056934011026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013939406","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019001374,0.978029,0.000022087039,0.00033158963,0.00034396487,0.0021414014,0.00004293823,0.000008504114,0.0000790991],"genre_scores_gemma":[0.0009498613,0.99703324,0.00017804274,0.000052001575,0.0005944187,0.00028343458,0.000032439668,0.00007163478,0.00080492755],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981045,0.00008791542,0.00089679734,0.00013853979,0.00045802802,0.0003142093],"domain_scores_gemma":[0.9975601,0.00039562522,0.0010195296,0.00027843582,0.0006185289,0.00012776934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008813457,0.0003164319,0.0012665637,0.00026440914,0.00016837376,0.00006356689,0.00030181734,0.0002571544,0.000037867336],"category_scores_gemma":[0.000043037497,0.00015233672,0.0006391566,0.0003358627,0.0001878056,0.0001261651,0.000025876849,0.000635672,3.833692e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001160672,0.00013661654,0.0003858864,0.0009340146,0.00081652106,0.000010335966,0.0015553006,3.2883304e-7,0.0007847538,0.000021889116,0.00021073241,0.993983],"study_design_scores_gemma":[0.0028723537,0.0016169148,0.000035724654,0.0029836902,0.00014908322,0.0001266242,0.0006580228,0.000004391515,0.0025377003,0.00016342083,0.98869926,0.00015283155],"about_ca_topic_score_codex":0.00002813376,"about_ca_topic_score_gemma":0.000006053041,"teacher_disagreement_score":0.99383014,"about_ca_system_score_codex":0.00020918236,"about_ca_system_score_gemma":0.0015791445,"threshold_uncertainty_score":0.6212111},"labels":[],"label_agreement":null},{"id":"W2013966013","doi":"10.3389/fphar.2015.00057","title":"Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance","year":2015,"lang":"en","type":"review","venue":"Frontiers in Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"McGill University","keywords":"Antiandrogens; Bicalutamide; Enzalutamide; Flutamide; Antiandrogen; Prostate cancer; Androgen receptor; Medicine; Pharmacology; Agonist; Cancer research; Internal medicine; Endocrinology; Cancer; Receptor","score_opus":0.07719989532208256,"score_gpt":0.41724383358704303,"score_spread":0.3400439382649605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013966013","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021105255,0.9923964,0.0011605712,0.00037687767,0.0011338914,0.0045295763,0.000050104092,0.000043021097,0.000098487304],"genre_scores_gemma":[0.00019684396,0.9807526,0.015924787,0.00013984181,0.00021472675,0.0016628543,0.0005265374,0.00008690665,0.00049493194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966934,0.00073586206,0.0007787227,0.0006561339,0.0003722757,0.0007636539],"domain_scores_gemma":[0.99906105,0.0000973608,0.0002515944,0.00018279366,0.000113103786,0.00029407837],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015123254,0.00039431563,0.0016958166,0.0014611217,0.000055059772,0.000019988644,0.00024294585,0.00033626778,0.000049754413],"category_scores_gemma":[0.0000629477,0.0003412774,0.00015465643,0.0013305906,0.000112365655,0.000068971094,0.0000654651,0.0006454277,0.00003000885],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017940815,0.00047982778,0.001335175,0.008686373,0.00042193747,0.0047343737,0.0003679533,0.00003369514,0.000041635183,0.0000010058386,0.22710474,0.7549992],"study_design_scores_gemma":[0.00562191,0.00042427922,0.000039060575,0.0045648487,0.0006776881,0.000022801298,0.000095123985,0.00031608416,0.00020313522,0.000024619667,0.9875959,0.00041453412],"about_ca_topic_score_codex":0.000004653516,"about_ca_topic_score_gemma":0.0000017468293,"teacher_disagreement_score":0.7604912,"about_ca_system_score_codex":0.002224694,"about_ca_system_score_gemma":0.0015355585,"threshold_uncertainty_score":0.9999039},"labels":[],"label_agreement":null},{"id":"W2014298811","doi":"10.1158/1538-7445.am2013-lb-47","title":"Abstract LB-47: SPEN is a novel candidate tumor suppressor gene that regulates response to tamoxifen in estrogen receptor positive breast cancers.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta; Jewish General Hospital; McGill University","funders":"","keywords":"Tamoxifen; Breast cancer; Estrogen receptor; Cancer research; Estrogen; Biology; Estrogen receptor alpha; Cancer; Internal medicine; Endocrinology; Medicine","score_opus":0.05524917409467897,"score_gpt":0.3835509574379317,"score_spread":0.3283017833432528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014298811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651735,0.0022425212,0.0000020646708,0.026609391,0.00014651805,0.0037435314,0.0014241809,0.000052767442,0.00060556596],"genre_scores_gemma":[0.98744756,0.0006914079,0.0003148394,0.00065185176,0.00037422014,0.0024311086,0.0001372088,0.000114616196,0.007837162],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948615,0.00025785668,0.00043636642,0.0010567739,0.001565311,0.0018222108],"domain_scores_gemma":[0.9967481,0.00037632626,0.00008547556,0.0008434621,0.000889355,0.0010572695],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014140086,0.0003981485,0.0006302787,0.0008555792,0.00026178508,0.00021732734,0.00055474887,0.00017818101,0.0064058653],"category_scores_gemma":[0.0001851395,0.00032157818,0.00014245124,0.0013131778,0.00042206622,0.00038271496,0.0003733396,0.0009750445,0.0008939175],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018731745,0.00027895643,0.019502733,0.00015292356,0.00026827367,0.00027868335,0.0028146536,0.000023463903,0.91588104,0.000008673113,0.03857971,0.0034791762],"study_design_scores_gemma":[0.005060287,0.00057764805,0.3373654,0.00084483763,0.000025834206,0.00007592975,0.00080375845,0.000052762356,0.64897174,0.00005525588,0.0057969275,0.000369589],"about_ca_topic_score_codex":0.0488358,"about_ca_topic_score_gemma":0.0008080055,"teacher_disagreement_score":0.31786266,"about_ca_system_score_codex":0.0038699314,"about_ca_system_score_gemma":0.0028559607,"threshold_uncertainty_score":0.99995404},"labels":[],"label_agreement":null},{"id":"W2014560120","doi":"10.1097/coc.0b013e31825d5664","title":"Intermittent LHRH Therapy in the Management of Castrate-resistant Prostate Cancer (CRPCa)","year":2012,"lang":"en","type":"article","venue":"American Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary; Capital District Health Authority","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Quality of life (healthcare); Randomized controlled trial; Testosterone (patch); Castration; Hormone therapy; Androgen suppression; Internal medicine; Cancer; Urology; Surgery; Gynecology; Hormone; Breast cancer","score_opus":0.14756225226109435,"score_gpt":0.5198408230466267,"score_spread":0.3722785707855324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014560120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849919,0.0026656552,0.0000070240094,0.009124583,0.00038278432,0.00036773068,0.00000443898,0.0000024801868,0.0024534138],"genre_scores_gemma":[0.9810069,0.016673904,0.00072064064,0.0010049103,0.00031095612,0.000025988196,0.0000012840019,0.000011386834,0.00024403939],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974291,0.0005076172,0.0012140432,0.00011520233,0.00038391296,0.00035013253],"domain_scores_gemma":[0.99803853,0.00048363858,0.00090346806,0.00018771821,0.0001821615,0.00020449501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002545705,0.00011563777,0.00085006503,0.000104882085,0.000021601152,0.000005010138,0.00021582228,0.000052765627,0.000090178866],"category_scores_gemma":[0.00004443495,0.00005772021,0.00025467025,0.00029367497,0.0006451494,0.00006812556,0.000036911133,0.0005656411,0.000004305427],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010597441,0.0019512431,0.24491076,0.00003679123,0.0006826014,0.00053680356,0.0011043373,0.0000030034216,0.00018689106,0.00008961485,0.00060122256,0.7392993],"study_design_scores_gemma":[0.0077340463,0.019381907,0.92704064,0.0002539578,0.00019498932,0.00013748596,0.0058003007,0.000004742421,0.00023587329,0.00006977598,0.039066795,0.00007951527],"about_ca_topic_score_codex":0.00012711137,"about_ca_topic_score_gemma":0.000021106705,"teacher_disagreement_score":0.7392198,"about_ca_system_score_codex":0.00014894418,"about_ca_system_score_gemma":0.00045949177,"threshold_uncertainty_score":0.24574606},"labels":[],"label_agreement":null},{"id":"W2014862652","doi":"10.1158/1538-7445.prca2012-b14","title":"Abstract B14: Developing small-molecule inhibitors to the androgen receptor N-terminus domain for the treatment of advanced prostate cancer","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Androgen receptor; Prostate cancer; Antiandrogens; Intracrine; Transactivation; Cancer research; Medicine; Androgen; Cancer; Internal medicine; Pharmacology; Endocrinology; Receptor; Chemistry; Transcription factor; Hormone; Biochemistry; Paracrine signalling","score_opus":0.09851968613890107,"score_gpt":0.427689093179413,"score_spread":0.32916940704051195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014862652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93765146,0.03977223,0.000016401638,0.015888527,0.00044756007,0.0058071036,0.00020824144,0.00002403147,0.0001844437],"genre_scores_gemma":[0.96158034,0.018651504,0.0004826902,0.00020274082,0.0012549273,0.013062705,0.000048060425,0.00008590929,0.004631121],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99733204,0.000102495265,0.00033171187,0.00037408568,0.0006903668,0.001169318],"domain_scores_gemma":[0.99808687,0.0004120674,0.000081352286,0.00052134733,0.0005667722,0.000331599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009653012,0.00023652152,0.00033628033,0.00017466814,0.0004940747,0.000044518732,0.00028704148,0.00008330348,0.00023302664],"category_scores_gemma":[0.000059315287,0.00011725782,0.00015741336,0.00066723983,0.0002844928,0.000091206835,0.00008926954,0.00023118578,0.0000342098],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072727706,0.00074209424,0.02904349,0.0006623452,0.0009820048,0.000035396566,0.023007583,0.00006166824,0.18252698,0.00017664248,0.01777223,0.7377168],"study_design_scores_gemma":[0.0034769522,0.0010116943,0.009401097,0.00033855607,0.00006211385,0.0000057958478,0.0029105027,0.000003329761,0.59957564,0.000025505095,0.38300648,0.0001823324],"about_ca_topic_score_codex":0.0010325388,"about_ca_topic_score_gemma":0.000716578,"teacher_disagreement_score":0.73753446,"about_ca_system_score_codex":0.0014263906,"about_ca_system_score_gemma":0.0012761215,"threshold_uncertainty_score":0.4781635},"labels":[],"label_agreement":null},{"id":"W2015025295","doi":"10.1016/j.eururo.2009.11.007","title":"Reply to A. Edward Friedman’s Letter to the Editor re: Kim N. Chi, Anders Bjartell, David Dearnaley, et al. Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets. Eur Urol 2009;56:594–605","year":2009,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Pathophysiology; Psychoanalysis; Gynecology; Gerontology; Internal medicine; Cancer","score_opus":0.021125117700257556,"score_gpt":0.2981560969134668,"score_spread":0.27703097921320924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015025295","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13313046,0.003443057,0.0004360859,0.85424685,0.0027359298,0.0032421243,0.000297125,0.00019714296,0.002271214],"genre_scores_gemma":[0.16261886,0.0018120309,0.002532797,0.7844466,0.019577883,0.00020022005,0.0005362503,0.00021197266,0.02806341],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961521,0.000661797,0.0005641304,0.0011835041,0.00043633665,0.0010021003],"domain_scores_gemma":[0.9975198,0.00013631773,0.00013794085,0.0009922783,0.00013643298,0.0010772486],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036603963,0.0005218857,0.0006110756,0.00021470578,0.00022826492,0.000084216015,0.00039496805,0.00008840157,0.00043886207],"category_scores_gemma":[0.00015551454,0.00034919957,0.00019263232,0.00039046173,0.000076646764,0.00009636063,0.0001411407,0.000491529,0.0012232234],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005379617,0.00019008484,0.00051090843,0.000004263307,0.00022574519,0.0008362345,0.0041166274,0.0005195155,0.030751213,0.000010110097,0.93386346,0.023592196],"study_design_scores_gemma":[0.0032656551,0.0087381555,0.030411813,0.000032274056,0.00016670825,0.000013553493,0.00007133604,0.000012078154,0.0012604351,0.000087287495,0.9556217,0.0003190114],"about_ca_topic_score_codex":0.0033280891,"about_ca_topic_score_gemma":0.0008629467,"teacher_disagreement_score":0.06980027,"about_ca_system_score_codex":0.00027902276,"about_ca_system_score_gemma":0.000648283,"threshold_uncertainty_score":0.999896},"labels":[],"label_agreement":null},{"id":"W2015713954","doi":"10.1016/j.urology.2008.07.072","title":"Focal Therapy for Prostate Cancer: Analysis by an International Panel","year":2008,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Prostate cancer; Task force; Modalities; Prostate; Ablation Therapy; Cancer; Medical physics; Internal medicine","score_opus":0.057113332721413675,"score_gpt":0.3700184621544203,"score_spread":0.31290512943300663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015713954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876444,0.0017337449,0.0006475761,0.0086868545,0.00014100038,0.0004505668,0.00015192779,0.00004237953,0.0005015955],"genre_scores_gemma":[0.9882555,0.0047514536,0.000088270346,0.0011759183,0.0001516082,0.0002596398,0.000588972,0.000011940166,0.00471672],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.999313,0.000022833447,0.000105019746,0.00022130576,0.00012199727,0.00021584774],"domain_scores_gemma":[0.9996105,0.00003313892,0.000028936083,0.0001336381,0.00010316515,0.000090645444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000062045525,0.000076322234,0.00018195272,0.00012574629,0.00006752628,0.0000046618666,0.00007927413,0.000061002855,0.00032102395],"category_scores_gemma":[0.000010373677,0.000055140223,0.00008509865,0.00015047804,0.00010765031,0.00004855326,0.0000115782195,0.000078584395,0.000006369847],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009042774,0.00080277736,0.8923346,0.000011576726,0.0035550913,0.00012632243,0.0013739777,0.00018201774,0.00936499,0.000082554245,0.017632386,0.06549093],"study_design_scores_gemma":[0.021008922,0.008768905,0.28424224,0.000003977104,0.00079846516,0.000118342956,0.00009465006,0.023653297,0.012030355,0.00038852764,0.64854294,0.00034936075],"about_ca_topic_score_codex":0.00017928435,"about_ca_topic_score_gemma":0.000038065384,"teacher_disagreement_score":0.6309106,"about_ca_system_score_codex":0.000048667127,"about_ca_system_score_gemma":0.00010359528,"threshold_uncertainty_score":0.35149872},"labels":[],"label_agreement":null},{"id":"W2016001535","doi":"10.5489/cuaj.275","title":"Optimal management of patients receiving cabazitaxel-based chemotherapy","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Charles-Le Moyne","funders":"","keywords":"Cabazitaxel; Chemotherapy; Medicine; Oncology; Intensive care medicine; Computer science; Internal medicine; Prostate cancer; Cancer","score_opus":0.013291606002984036,"score_gpt":0.25262784327614546,"score_spread":0.23933623727316142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016001535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98127484,0.00011718146,0.000048608003,0.014152784,0.00011188592,0.0003556507,0.000012076421,0.000010442394,0.0039165015],"genre_scores_gemma":[0.9960911,0.00010393615,0.0010351095,0.0013372508,0.00007713342,0.000018273568,0.000028483912,0.000009142559,0.0012995364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887747,0.000057937024,0.00022618883,0.00011466014,0.00034943235,0.00037430172],"domain_scores_gemma":[0.99889505,0.00004264009,0.00014784852,0.00007600731,0.0003736052,0.00046487193],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025111806,0.00008735678,0.00017506212,0.00013272827,0.00011440015,0.00003821463,0.00008067516,0.00010929516,0.0018504845],"category_scores_gemma":[0.00006618727,0.00006380869,0.00009498086,0.0001618703,0.000026816684,0.00006634021,0.0000074395484,0.0002503026,0.00005822675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006884223,0.000111321264,0.97288835,0.000014827371,0.00017952664,0.000026116142,0.000045552377,0.000044121924,0.00003616544,0.0000151029135,0.010501613,0.016068464],"study_design_scores_gemma":[0.0026547464,0.000359168,0.9885533,0.000024530818,0.000032192514,0.0000028317943,0.000042761443,0.00019249624,0.000101235935,0.00007838012,0.007894883,0.000063496125],"about_ca_topic_score_codex":0.00037399222,"about_ca_topic_score_gemma":0.000027323258,"teacher_disagreement_score":0.016004968,"about_ca_system_score_codex":0.0010060092,"about_ca_system_score_gemma":0.00022286666,"threshold_uncertainty_score":0.99906194},"labels":[],"label_agreement":null},{"id":"W2016024198","doi":"10.1371/journal.pone.0107586","title":"Nuclear Ep-ICD Expression Is a Predictor of Poor Prognosis in “Low Risk” Prostate Adenocarcinomas","year":2015,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Prostate adenocarcinoma; Oncology; Medicine; Internal medicine; Cancer","score_opus":0.06643627141122534,"score_gpt":0.28020786901238875,"score_spread":0.21377159760116343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016024198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99461037,0.0014263757,6.3950586e-7,0.0014473603,0.000021407972,0.0014158976,0.00008608519,0.00005768531,0.00093419134],"genre_scores_gemma":[0.99577963,0.0005811888,0.0013663251,0.0000652583,0.00008375029,0.00016161977,0.000036490936,0.000041223157,0.0018845154],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982342,0.00007459966,0.00032130018,0.0003008482,0.000726754,0.0003422787],"domain_scores_gemma":[0.99908155,0.000040230483,0.00012091685,0.00023820768,0.00022843748,0.00029066595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025472607,0.00014900912,0.0003925258,0.00018412067,0.000034715576,0.000012979165,0.0001074719,0.00010051796,0.0001620004],"category_scores_gemma":[0.00023638165,0.00011097477,0.00005836391,0.00028482528,0.000106473344,0.00011625341,0.00009505387,0.00026665808,0.00007648827],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025432038,0.0046422016,0.91557634,0.0007994838,0.00023420609,0.00009980769,0.0055930833,6.861967e-7,0.067631274,0.000003833002,0.0022627083,0.0006131592],"study_design_scores_gemma":[0.011549599,0.0033112888,0.15868576,0.0036884814,0.00033339445,0.0000057956504,0.0008604212,0.0013275313,0.81957847,0.00016350645,0.00027132267,0.0002244043],"about_ca_topic_score_codex":0.00013625702,"about_ca_topic_score_gemma":0.000005713972,"teacher_disagreement_score":0.7568906,"about_ca_system_score_codex":0.00015420851,"about_ca_system_score_gemma":0.00020785247,"threshold_uncertainty_score":0.45254198},"labels":[],"label_agreement":null},{"id":"W2016222691","doi":"","title":"Prostate Adenocarcinoma Metastasis and Papillary Thyroid Carcinoma: A Case Report of Coexisting Thyroid Tumors","year":2012,"lang":"en","type":"article","venue":"Journal of Current Surgery","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Thyroid carcinoma; Metastasis; Pathology; Thyroid; Thyroglobulin; Thyroidectomy; Adenocarcinoma; Papillary adenocarcinoma; Carcinoma; Thyroid cancer; Papillary carcinoma; Immunohistochemistry; Cancer; Oncology; Internal medicine","score_opus":0.07970267661223941,"score_gpt":0.34657116571979985,"score_spread":0.26686848910756045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016222691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8694693,0.1292768,0.00001682361,0.00029825984,0.000545733,0.00024373045,0.000023223345,0.00000914445,0.00011701786],"genre_scores_gemma":[0.9970998,0.002029176,0.00019119172,0.000017882074,0.00050477695,0.0000078384155,0.00001918852,0.000029180794,0.00010095639],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9973728,0.0001498714,0.0011384739,0.00017583779,0.0006615793,0.0005014292],"domain_scores_gemma":[0.9973125,0.00042203447,0.001013425,0.00024008735,0.00048756273,0.0005244298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021155938,0.00022368123,0.0008800891,0.00047687147,0.00010065771,0.00002021302,0.000052727333,0.000052866224,0.000032536675],"category_scores_gemma":[0.0005286809,0.00015423358,0.00034260793,0.00031619988,0.00017064814,0.0003432806,0.00007290821,0.0004309844,0.000001956074],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006646492,0.00041221737,0.9252213,0.00072919525,0.0002563106,0.057712156,0.0008052778,4.3249153e-7,0.0017171892,0.000011398243,0.0047840793,0.007685763],"study_design_scores_gemma":[0.0033723474,0.000960836,0.3739694,0.0014909738,0.0011631085,0.590977,0.0015353753,0.000025461897,0.022472242,0.00007114744,0.0035530434,0.00040903385],"about_ca_topic_score_codex":0.00002734167,"about_ca_topic_score_gemma":7.9331727e-7,"teacher_disagreement_score":0.55125195,"about_ca_system_score_codex":0.00012467371,"about_ca_system_score_gemma":0.0005613958,"threshold_uncertainty_score":0.6289463},"labels":[],"label_agreement":null},{"id":"W2016636564","doi":"10.1038/sj.bjc.6605519","title":"Prostate cancer genes associated with TMPRSS2–ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts","year":2010,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Center for Advancing Translational Sciences; Emory University","keywords":"TMPRSS2; Erg; Prostate cancer; Biochemical recurrence; Fusion gene; Prostatectomy; Oncology; Proportional hazards model; Nomogram; Internal medicine; Medicine; Prostate; PCA3; Cohort; Biology; Cancer; Gene; Genetics","score_opus":0.0157146526414504,"score_gpt":0.2990337131224295,"score_spread":0.2833190604809791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016636564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95570076,0.04321859,0.0000021416922,0.0003610202,0.00017368946,0.00042886508,0.000086890774,0.000005629825,0.00002239945],"genre_scores_gemma":[0.96795714,0.031436715,0.00025289188,0.000025675308,0.000105581945,0.000051523843,0.000013802581,0.000018627898,0.00013801249],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987263,0.000035176494,0.00037076353,0.00017829187,0.0004255275,0.0002639322],"domain_scores_gemma":[0.9988094,0.00007952839,0.0002757693,0.00007371746,0.00058408064,0.00017751308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027655557,0.000117186595,0.0003979412,0.000112046015,0.000045667693,0.000024232668,0.00007202065,0.00009524732,0.00007602095],"category_scores_gemma":[0.0002397857,0.000094335825,0.000046588873,0.00026396906,0.00023373718,0.00010706908,0.000031707023,0.00047339793,1.7073468e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084011385,0.00021765384,0.77162683,0.00010267405,0.000117893935,0.00059523707,0.00013752488,0.000008670891,0.14961675,3.2971516e-7,0.00022908034,0.07650722],"study_design_scores_gemma":[0.006056184,0.0004543251,0.8932446,0.0035262608,0.00013441528,0.00066553825,0.000040533436,0.000119844306,0.09517644,0.000015928457,0.0004349864,0.00013091601],"about_ca_topic_score_codex":0.0010955965,"about_ca_topic_score_gemma":0.0039543784,"teacher_disagreement_score":0.121617764,"about_ca_system_score_codex":0.000110979265,"about_ca_system_score_gemma":0.0006121192,"threshold_uncertainty_score":0.38469034},"labels":[],"label_agreement":null},{"id":"W2016771357","doi":"10.1007/s00018-011-0766-7","title":"Androgen receptor and its splice variants in prostate cancer","year":2011,"lang":"en","type":"review","venue":"Cellular and Molecular Life Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Androgen receptor; Prostate cancer; Druggability; Cancer research; Alternative splicing; Androgen; Cancer; Transcription factor; Biology; Prostate; splice; Receptor; Computational biology; Hormone; Bioinformatics; Gene; Endocrinology; Genetics; Gene isoform","score_opus":0.06944372481219316,"score_gpt":0.3596400032147122,"score_spread":0.29019627840251905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016771357","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050221006,0.9923249,0.0000022576403,0.00011443629,0.00012289049,0.0012667772,0.000038423575,0.000015437654,0.001092769],"genre_scores_gemma":[0.0006875387,0.99796736,0.000084940875,0.00008946601,0.000053069725,0.00017824181,0.000033562435,0.000026919617,0.00087887363],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981521,0.000118436226,0.00030940457,0.0006990511,0.00027629375,0.00044475467],"domain_scores_gemma":[0.9993014,0.000028485068,0.000103433646,0.00016848175,0.000050773884,0.0003474744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004824806,0.0003096187,0.00088506314,0.0002940969,0.00012676857,0.000036695877,0.00015536249,0.00015177637,0.0000888733],"category_scores_gemma":[0.000054064938,0.0002048129,0.000103779144,0.0005556926,0.00032311885,0.00009222218,0.00014102408,0.0002593581,0.000018357796],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011684345,0.00024050343,0.0010187031,0.025982399,0.0004604423,0.0009925143,0.0010854069,2.9268355e-7,0.0015283186,0.00066894747,0.00048941653,0.9674162],"study_design_scores_gemma":[0.0011115209,0.0003804523,0.000029663946,0.00924105,0.000563893,0.00008138282,0.0000986971,0.000027520378,0.0013237492,0.000060938615,0.9866177,0.00046344844],"about_ca_topic_score_codex":0.00010584544,"about_ca_topic_score_gemma":0.000006370222,"teacher_disagreement_score":0.9861283,"about_ca_system_score_codex":0.000047878097,"about_ca_system_score_gemma":0.00094004726,"threshold_uncertainty_score":0.83520275},"labels":[],"label_agreement":null},{"id":"W2016993746","doi":"10.1371/journal.pone.0108780","title":"Complex Impacts of PI3K/AKT Inhibitors to Androgen Receptor Gene Expression in Prostate Cancer Cells","year":2014,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada","keywords":"Protein kinase B; PI3K/AKT/mTOR pathway; Prostate cancer; LNCaP; Androgen receptor; Cancer research; Alternative splicing; Biology; Androgen deprivation therapy; Cancer; Medicine; Signal transduction; Internal medicine; Gene; Messenger RNA; Cell biology; Genetics","score_opus":0.05700181713641366,"score_gpt":0.3084010456614723,"score_spread":0.25139922852505864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016993746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965258,0.0006607492,0.0000028647676,0.0012366463,0.000039817598,0.00103822,0.000071165836,0.000025704552,0.00039900673],"genre_scores_gemma":[0.99541736,0.0005468362,0.0024357724,0.00015485403,0.0001583723,0.00013303499,0.0000644939,0.00002988684,0.0010593756],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986587,0.000056042212,0.0002567797,0.00024861237,0.000436944,0.00034291056],"domain_scores_gemma":[0.9992535,0.000033590935,0.00006726257,0.00024104335,0.00013902146,0.00026555383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001800123,0.0001337744,0.0003794892,0.00017675942,0.000032155687,0.000008979356,0.00007436781,0.000052819854,0.0003095552],"category_scores_gemma":[0.000053849784,0.000100142955,0.00003897529,0.0002851024,0.00004984462,0.000056426183,0.0000689472,0.00012722462,0.000055460303],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078763894,0.00094158616,0.07069814,0.00034089875,0.00007881666,0.000006928119,0.00079624046,0.000005097022,0.92341554,8.280997e-7,0.0016791946,0.0012490762],"study_design_scores_gemma":[0.0024630039,0.0007147045,0.008159912,0.0011608156,0.00004684902,4.754762e-7,0.000045205434,0.000052532832,0.98654467,0.000010474437,0.00069728476,0.00010410052],"about_ca_topic_score_codex":0.00020761263,"about_ca_topic_score_gemma":0.000044314223,"teacher_disagreement_score":0.06312909,"about_ca_system_score_codex":0.00017018455,"about_ca_system_score_gemma":0.00011556351,"threshold_uncertainty_score":0.40837112},"labels":[],"label_agreement":null},{"id":"W2017040238","doi":"10.1080/20014091084236","title":"The Role of Molecular Forms of Prostate-Specific Antigen (PSA or hK3) and of Human Glandular Kallikrein 2 (hK2) in the Diagnosis and Monitoring of Prostate Cancer and in Extra-Prostatic Disease","year":2001,"lang":"en","type":"review","venue":"Critical Reviews in Clinical Laboratory Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Prostate cancer; Prostate; Medicine; PCA3; Prostate-specific antigen; Kallikrein; Cancer; Prostatic Diseases; Prostate Diseases; Urology; Oncology; Internal medicine; Pathology; Biology","score_opus":0.2013098631195926,"score_gpt":0.5148938345907917,"score_spread":0.31358397147119915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017040238","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33540314,0.66231716,1.1395105e-7,0.00016063631,0.000031253465,0.0019604014,0.00011014297,0.0000014102142,0.000015772941],"genre_scores_gemma":[0.106000096,0.8933452,0.00009017432,0.000013375026,0.000022295175,0.0005038364,0.0000056884396,0.00001368835,0.0000056992667],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.9952501,0.0008818972,0.0023179215,0.0005614029,0.0005774677,0.00041122804],"domain_scores_gemma":[0.9955669,0.0031890485,0.00046518006,0.00038654252,0.00019131106,0.00020102922],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.005882266,0.00029635645,0.0021196404,0.00020957891,0.00008345084,0.000036779056,0.00034003548,0.00014597515,0.000009443042],"category_scores_gemma":[0.0034470297,0.00013405197,0.00014733976,0.0014737118,0.0039142137,0.0001384025,0.00013173101,0.00049867155,1.8518915e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021414625,0.0004068887,0.5525148,0.020762313,0.000027925038,0.0000738414,0.0003091343,2.0933582e-7,0.00003689955,0.0007218563,0.000006383052,0.4249256],"study_design_scores_gemma":[0.006256072,0.00701003,0.3084732,0.33596644,0.0014969326,0.000014704442,0.0040445672,0.0000435841,0.0008914417,0.010437974,0.32412404,0.0012410076],"about_ca_topic_score_codex":0.00005859001,"about_ca_topic_score_gemma":0.00007810781,"teacher_disagreement_score":0.4236846,"about_ca_system_score_codex":0.000041206345,"about_ca_system_score_gemma":0.0007022653,"threshold_uncertainty_score":0.9987966},"labels":[],"label_agreement":null},{"id":"W2017047836","doi":"10.1097/00001813-200511000-00002","title":"Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer","year":2005,"lang":"en","type":"review","venue":"Anti-Cancer Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Prostate cancer; Medicine; Prostate; In vivo; Cancer; Malignancy; Cancer research; Internal medicine; Endocrinology; Pathology; Biology","score_opus":0.04893492827377968,"score_gpt":0.3765215155615032,"score_spread":0.3275865872877235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017047836","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012969878,0.9715702,0.0000049148425,0.00081129564,0.00032681212,0.011580391,0.0021223968,0.000103356295,0.0005107613],"genre_scores_gemma":[0.0062205726,0.913175,0.00007825874,0.00016321629,0.0008720589,0.0077936356,0.000517908,0.00025240678,0.07092695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953743,0.00019387767,0.0011480304,0.0011792867,0.0008914337,0.0012130461],"domain_scores_gemma":[0.99752975,0.00010467674,0.000764686,0.00060145615,0.0006314853,0.00036794218],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004734424,0.0010410356,0.0029516355,0.00045259154,0.00025871623,0.000094904746,0.00035187308,0.00048355895,0.00035543242],"category_scores_gemma":[0.000028867906,0.00076180545,0.0007340525,0.00045069895,0.00048313502,0.0003124439,0.00018931832,0.0007401257,0.000028318853],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010266289,0.00027717938,0.00015296708,0.073513515,0.0024301503,0.000043774864,0.001855743,0.0000042143056,0.0010008658,0.0001511166,0.0007163727,0.9188275],"study_design_scores_gemma":[0.0054456564,0.00095971645,0.000090770496,0.027285356,0.0034186142,0.000042755913,0.00040718168,0.00009451016,0.0047629494,0.00013788458,0.95632654,0.0010280428],"about_ca_topic_score_codex":0.00071580656,"about_ca_topic_score_gemma":0.000049594073,"teacher_disagreement_score":0.9556102,"about_ca_system_score_codex":0.0006598404,"about_ca_system_score_gemma":0.0034987722,"threshold_uncertainty_score":0.9994833},"labels":[],"label_agreement":null},{"id":"W2017801391","doi":"10.1016/s0093-7754(03)00348-8","title":"Conservative versus radical therapy of prostate cancer: how have recent advances in molecular markers and imaging enhanced our ability to prognosticate risk?","year":2003,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Prostate; Cancer; Internal medicine; Gynecology","score_opus":0.044790958423923326,"score_gpt":0.4334559548225279,"score_spread":0.3886649963986046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017801391","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008528153,0.9832969,0.000007341511,0.00218284,0.0002717728,0.0050383066,0.00009769354,0.000012298595,0.00056471187],"genre_scores_gemma":[0.00077588286,0.9958526,0.0012574248,0.00008349324,0.000023106082,0.0017891196,0.000057122437,0.00004405915,0.00011720312],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99675053,0.0009667206,0.0006169516,0.00078118587,0.00028013688,0.0006044793],"domain_scores_gemma":[0.99816936,0.0007384235,0.00038229444,0.00031465097,0.0001803465,0.00021494672],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00096985867,0.00042202376,0.0020305961,0.00037491438,0.000035416408,0.000010364959,0.00015545002,0.00027387563,0.000023322145],"category_scores_gemma":[0.00084291806,0.0003215281,0.0001293839,0.0006426443,0.00044636225,0.00006580884,0.00008921325,0.000810566,0.0000013098413],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038224522,0.00032868626,0.00864565,0.0029728904,0.00013747794,0.00037836016,0.00059801876,0.0000016242523,0.000041244042,0.0000039991355,0.0001828014,0.9828868],"study_design_scores_gemma":[0.007931957,0.0026241236,0.0003824983,0.011734367,0.00024321374,0.000028191758,0.0011384002,0.000008521126,0.00064419606,0.00007314967,0.9748415,0.0003498788],"about_ca_topic_score_codex":0.000083369276,"about_ca_topic_score_gemma":0.00018187349,"teacher_disagreement_score":0.9825369,"about_ca_system_score_codex":0.0016334904,"about_ca_system_score_gemma":0.0019521177,"threshold_uncertainty_score":0.9999237},"labels":[],"label_agreement":null},{"id":"W2017839954","doi":"10.1172/jci66398","title":"An androgen receptor N-terminal domain antagonist for treating prostate cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":311,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; Medical Research and Materiel Command; Canadian Institutes of Health Research; DOD Prostate Cancer Research Program; Prostate Cancer UK","keywords":"Androgen receptor; Prostate cancer; Small molecule; Cancer research; Chemistry; Antagonist; splice; Androgen; Alternative splicing; Cell biology; Cancer; Receptor; Biology; Pharmacology; Computational biology; Hormone; Medicine; Internal medicine; Biochemistry; Gene; Gene isoform","score_opus":0.09595565761914551,"score_gpt":0.45022585827511646,"score_spread":0.3542702006559709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017839954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99082124,0.00035577736,0.00008364096,0.007629705,0.00030888466,0.0006859859,0.000017431452,0.00001153244,0.000085800784],"genre_scores_gemma":[0.97253114,0.0006815033,0.022623511,0.000776501,0.0021269852,0.00010597669,0.00007212419,0.000029831233,0.0010524243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981989,0.00013422311,0.0009991596,0.00015992716,0.0002999313,0.0002078172],"domain_scores_gemma":[0.99790496,0.00023612344,0.00060559466,0.000122561,0.00065386266,0.00047689673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011285685,0.00010905354,0.00041485336,0.00008194974,0.000100166355,0.000065789216,0.00008278188,0.00010941104,0.00014317753],"category_scores_gemma":[0.00037459965,0.00007127201,0.00018555844,0.00011289872,0.00021294845,0.0004094405,0.000009529308,0.00027525454,0.000011568916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025475244,0.00047860487,0.7563895,0.00023213385,0.00031023065,0.000049748454,0.0009185483,0.000013070963,0.068594985,0.00008003522,0.012248083,0.15813753],"study_design_scores_gemma":[0.053864717,0.03411788,0.6313657,0.0033173265,0.0012028203,0.0006001166,0.0026604198,0.006926373,0.19720577,0.028755527,0.03904821,0.00093511754],"about_ca_topic_score_codex":0.000050900588,"about_ca_topic_score_gemma":0.0000057872044,"teacher_disagreement_score":0.15720241,"about_ca_system_score_codex":0.00009274871,"about_ca_system_score_gemma":0.00063001807,"threshold_uncertainty_score":0.2906388},"labels":[],"label_agreement":null},{"id":"W2018556051","doi":"10.1021/jm3015712","title":"Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1<i>H</i>-benzimidazole Derivatives","year":2013,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Chemistry; Androgen receptor; Antiandrogens; Bicalutamide; Enzalutamide; Antiandrogen; LNCaP; Flutamide; Thio-; Prostate cancer; Benzimidazole; Androgen Receptor Antagonists; Androgen; Stereochemistry; Pharmacology; Cancer; Biochemistry; Internal medicine; Medicine","score_opus":0.024768438029991197,"score_gpt":0.27946138196793807,"score_spread":0.2546929439379469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018556051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993735,0.0027460188,0.0005687893,0.0017445836,0.0001667184,0.00023771376,0.0000049347345,0.0000058462238,0.00079040404],"genre_scores_gemma":[0.9966776,0.00026390015,0.0019016801,0.00010662054,0.0004021168,0.000008715706,0.000012491217,0.000017721759,0.00060918153],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99782085,0.000060831877,0.0007515834,0.00013212324,0.0009858934,0.0002487423],"domain_scores_gemma":[0.998173,0.0001826024,0.0007915495,0.00018704288,0.0005512142,0.00011456513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074115,0.00016710204,0.00039444666,0.000039791412,0.00017846611,0.000012009936,0.00022928888,0.00009827564,0.0005861242],"category_scores_gemma":[0.0003077944,0.000079921345,0.00015456673,0.0002871808,0.0003022953,0.00015091232,0.000098052675,0.00055931805,0.0000037991108],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054563506,0.00011067879,0.016987696,0.0002578495,0.00040171703,0.0000050893914,0.0042607593,0.000019786323,0.9676318,0.0000027009312,0.0023924534,0.0073838327],"study_design_scores_gemma":[0.0022695265,0.00030397347,0.0076488047,0.0012223363,0.00016913206,0.000077176046,0.010213711,0.000047726437,0.9739492,0.000032568765,0.0039726137,0.00009322534],"about_ca_topic_score_codex":0.0000152252305,"about_ca_topic_score_gemma":3.6596472e-7,"teacher_disagreement_score":0.009338892,"about_ca_system_score_codex":0.00011823956,"about_ca_system_score_gemma":0.00048141752,"threshold_uncertainty_score":0.6417649},"labels":[],"label_agreement":null},{"id":"W2018769494","doi":"10.1158/0008-5472.can-12-4576","title":"The 19th Annual Prostate Cancer Foundation Scientific Retreat","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of British Columbia","keywords":"Prostate cancer; Cancer; Multidisciplinary approach; Medicine; Disease; Tumor microenvironment; Resistance (ecology); Prostate; Cancer research; Oncology; Internal medicine; Biology; Political science","score_opus":0.08146201446562601,"score_gpt":0.44546998162997364,"score_spread":0.36400796716434763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018769494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95138705,0.01129825,0.0000020692853,0.029079188,0.00065598055,0.0027785753,0.000064274594,0.000071442104,0.0046631983],"genre_scores_gemma":[0.7663032,0.007399265,0.000022577133,0.00008172041,0.00049023,0.0036372128,0.00006668217,0.000043541768,0.22195557],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99634236,0.0001935669,0.00024235134,0.0005637539,0.0015276112,0.001130377],"domain_scores_gemma":[0.9965949,0.00021957935,0.00004736744,0.0006372524,0.0021364624,0.0003644521],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013542239,0.00016639571,0.00019912564,0.00027007307,0.0016881643,0.0006326068,0.00031709205,0.0000822357,0.0023482342],"category_scores_gemma":[0.00017367979,0.00009470397,0.000077684184,0.0013255265,0.0013680161,0.0003694429,0.00018451529,0.00067295856,0.0010671704],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012928827,0.00021852786,0.057351593,0.00028422402,0.00029051313,0.000053585616,0.0030921565,0.00000976783,0.056427088,0.00052557833,0.3799274,0.5005267],"study_design_scores_gemma":[0.0044347877,0.0007736649,0.08415738,0.00055095763,0.00006080258,0.000016625176,0.0030958308,0.00039028877,0.057766207,0.002189662,0.84619343,0.00037037188],"about_ca_topic_score_codex":0.004208753,"about_ca_topic_score_gemma":0.00067171146,"teacher_disagreement_score":0.50015634,"about_ca_system_score_codex":0.0010822953,"about_ca_system_score_gemma":0.0018532189,"threshold_uncertainty_score":0.9997106},"labels":[],"label_agreement":null},{"id":"W2018805075","doi":"10.1038/ncpuro0726","title":"Introduction: A multidisciplinary approach to genitourinary malignancy: does this topic warrant further debate?","year":2007,"lang":"en","type":"article","venue":"Nature Clinical Practice Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Warrant; Multidisciplinary approach; Malignancy; Genitourinary system; General surgery; Intensive care medicine; Internal medicine; Social science","score_opus":0.03217753699569791,"score_gpt":0.41761100057098155,"score_spread":0.38543346357528363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018805075","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30936813,0.012421657,0.0019841264,0.57251513,0.00837898,0.0030027472,0.000017482127,0.00035057784,0.091961175],"genre_scores_gemma":[0.92382795,0.0008877771,0.02778696,0.013115701,0.013659198,0.00008599003,0.00008491477,0.000071754024,0.020479731],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99682665,0.00040969264,0.00071167125,0.0009213681,0.00045757645,0.00067305606],"domain_scores_gemma":[0.9963647,0.0018698281,0.00018078824,0.00070477,0.0004149623,0.0004649585],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002799986,0.00026119297,0.00053610856,0.00016765029,0.00019267378,0.000023837794,0.0002240115,0.0010607608,0.0005308564],"category_scores_gemma":[0.004042301,0.00016124084,0.00021449686,0.00040912497,0.00025354294,0.00020534136,0.0002243839,0.0029192641,0.00030764486],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15098566,0.02972982,0.11329881,0.0007725953,0.004381303,0.01999801,0.0065875524,0.000044104305,0.006471867,0.0038395398,0.42330936,0.2405814],"study_design_scores_gemma":[0.0053182323,0.0049137715,0.06881723,0.000020350173,0.00062464154,0.002188789,0.00093121815,0.00009509725,0.00071749685,0.0005677968,0.91542375,0.00038165145],"about_ca_topic_score_codex":0.000024645233,"about_ca_topic_score_gemma":0.000010429113,"teacher_disagreement_score":0.6144599,"about_ca_system_score_codex":0.00010929383,"about_ca_system_score_gemma":0.0002134959,"threshold_uncertainty_score":0.99938107},"labels":[],"label_agreement":null},{"id":"W2018809096","doi":"10.1210/jc.2011-1049","title":"Deletions of the Androgen-Metabolizing<i>UGT2B</i>Genes Have an Effect on Circulating Steroid Levels and Biochemical Recurrence after Radical Prostatectomy in Localized Prostate Cancer","year":2011,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; Hôtel-Dieu de Québec","funders":"Canadian Institutes of Health Research; Centre Hospitalier Universitaire de Québec","keywords":"Prostate cancer; Hazard ratio; Androgen; Prostatectomy; Internal medicine; Proportional hazards model; Endocrinology; Biochemical recurrence; Biology; Confidence interval; Oncology; Hormone; Medicine; Cancer","score_opus":0.08712731927178657,"score_gpt":0.4037390054554278,"score_spread":0.3166116861836412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018809096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97444886,0.023051765,0.00001430952,0.0011782623,0.00037670485,0.00084030814,0.00002712405,0.000008892575,0.000053803455],"genre_scores_gemma":[0.99329066,0.0056957393,0.00027178507,0.00036499382,0.00025194118,0.000059394093,0.0000015911394,0.000025027279,0.000038837064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99585146,0.0015155583,0.0013605845,0.00029661937,0.00045979163,0.0005159861],"domain_scores_gemma":[0.9977705,0.0006936926,0.00060392363,0.00042160143,0.00026335297,0.00024694164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018539114,0.0002588098,0.0011222058,0.0001741769,0.000092936934,0.000010708559,0.00032920053,0.00015859076,0.00006022236],"category_scores_gemma":[0.0006589079,0.00012298522,0.00027860343,0.0002681951,0.0014048648,0.00011587818,0.0001464537,0.0012900401,0.0000016954443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026392927,0.0014057781,0.8111826,0.00021491961,0.0008686472,0.0003884156,0.0027728395,0.000014855974,0.027561223,0.00021245153,0.000060084003,0.12892522],"study_design_scores_gemma":[0.016183522,0.0022071726,0.83657944,0.00066585024,0.0009310951,0.00075431314,0.00020424034,0.00008435779,0.13940787,0.00079437206,0.0019777615,0.00021003057],"about_ca_topic_score_codex":0.000097410804,"about_ca_topic_score_gemma":0.000020435076,"teacher_disagreement_score":0.12871519,"about_ca_system_score_codex":0.000032696436,"about_ca_system_score_gemma":0.0003492977,"threshold_uncertainty_score":0.5604654},"labels":[],"label_agreement":null},{"id":"W2018842713","doi":"10.1007/s00332-008-9031-0","title":"A Mathematical Model of Intermittent Androgen Suppression for Prostate Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Nonlinear Science","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of British Columbia; University of Tokyo; Princeton University","keywords":"Prostate cancer; Androgen suppression; Androgen; Medicine; Androgen deprivation therapy; Androgen receptor; Prostate; Internal medicine; Endocrinology; Oncology; Cancer research; Cancer; Hormone","score_opus":0.07743063603248347,"score_gpt":0.38955191741505296,"score_spread":0.3121212813825695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018842713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99663436,0.00044198413,0.0013394242,0.0010783272,0.00006654078,0.0002708005,0.000022082715,0.0000030604126,0.00014344492],"genre_scores_gemma":[0.9677516,0.00072009146,0.03023309,0.000054307682,0.00009774567,0.0000088878205,9.259372e-7,0.00000823272,0.0011250741],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988339,0.000006769064,0.00031016828,0.00010026182,0.0005577288,0.00019114895],"domain_scores_gemma":[0.9988608,0.00003261352,0.00017270104,0.00010833216,0.0006590098,0.00016658304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004123805,0.0000635219,0.00023337579,0.0001561995,0.00007882453,0.0000074855016,0.00015681377,0.000023250475,0.000017586677],"category_scores_gemma":[0.00013477405,0.000036016445,0.00010071976,0.00019864882,0.0004041557,0.0001627844,0.000043934408,0.000106731604,9.790015e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045939325,0.0018100751,0.026083203,0.00073812256,0.00015271909,0.00023621351,0.00562447,0.0012997581,0.9255533,0.00009671811,0.0027026597,0.03110883],"study_design_scores_gemma":[0.0056378064,0.0022010836,0.0028663317,0.0010482973,0.000109577,0.0009195841,0.00022533427,0.4241621,0.5614127,0.00070843956,0.0005810542,0.0001277027],"about_ca_topic_score_codex":0.0000018716453,"about_ca_topic_score_gemma":2.712669e-7,"teacher_disagreement_score":0.42286232,"about_ca_system_score_codex":0.00008626648,"about_ca_system_score_gemma":0.0011700591,"threshold_uncertainty_score":0.20756346},"labels":[],"label_agreement":null},{"id":"W2018899393","doi":"10.1007/s12672-011-0096-0","title":"Beyond Castration—Defining Future Directions in the Hormonal Treatment of Prostate Cancer","year":2011,"lang":"en","type":"review","venue":"Hormones and Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Prostate cancer; Cancer; Testosterone (patch); Abiraterone acetate; Androgen; Castration; Enzalutamide; Medicine; Intracrine; Abiraterone; Internal medicine; Prostate; Oncology; Androgen deprivation therapy; Cancer research; Hormone; Androgen receptor","score_opus":0.06339424091530371,"score_gpt":0.3743805644422678,"score_spread":0.3109863235269641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018899393","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001184051,0.99488544,9.425956e-8,0.00035437656,0.00019516786,0.0013173935,0.00043297783,0.000011499727,0.0016189729],"genre_scores_gemma":[0.00031479783,0.99502397,0.000019957244,0.000024311812,0.000412004,0.0024076863,0.00016830068,0.000031335632,0.0015976535],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998744,0.00006810511,0.00037082424,0.00032334693,0.00020357891,0.00029015925],"domain_scores_gemma":[0.9994042,0.000047410973,0.00017244395,0.00022218116,0.00007233807,0.00008143971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009501457,0.00032337336,0.00095087895,0.00016578444,0.00011085359,0.000023229812,0.00007325144,0.00016656976,0.00012858775],"category_scores_gemma":[0.000002249156,0.00016180753,0.00022235332,0.0003881253,0.0001197842,0.0000554518,0.000018310993,0.00021375243,0.000003309748],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001069716,0.00016799134,0.0006963749,0.0019980723,0.00031430382,0.000035627756,0.0022236714,1.2727537e-7,0.0000015345611,0.000188678,0.00044583407,0.9938208],"study_design_scores_gemma":[0.00089435483,0.0005681572,0.0023066066,0.0020176857,0.0011421393,0.00005736529,0.00039385638,0.0000013101086,0.000005709535,0.000030753516,0.9924233,0.00015877733],"about_ca_topic_score_codex":0.0020610096,"about_ca_topic_score_gemma":0.0008134327,"teacher_disagreement_score":0.99366206,"about_ca_system_score_codex":0.00026434296,"about_ca_system_score_gemma":0.0007365608,"threshold_uncertainty_score":0.65983194},"labels":[],"label_agreement":null},{"id":"W2018948966","doi":"10.1158/1538-7445.am2014-2114","title":"Abstract 2114: UGT2B17 is a unique co-regulator of the androgen receptor and androgen receptor splice variants in prostate cancer","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"LNCaP; Enzalutamide; Androgen receptor; Dihydrotestosterone; Prostate cancer; Androgen; Cancer research; Endocrinology; Internal medicine; Biology; splice; Cancer; Medicine; Genetics; Hormone; Gene","score_opus":0.05141161238189077,"score_gpt":0.39401230057858455,"score_spread":0.34260068819669376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018948966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98319876,0.007035859,7.133488e-7,0.0052266046,0.0001436387,0.002076311,0.00040881417,0.00002390962,0.0018853755],"genre_scores_gemma":[0.9818398,0.011016071,0.00006000092,0.00023074602,0.00024025432,0.00080825784,0.000031817424,0.000067678644,0.005705379],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966525,0.00031753228,0.00042769697,0.0006538795,0.0010576575,0.0008907593],"domain_scores_gemma":[0.99809706,0.0002149409,0.00012081855,0.0006749613,0.0005247147,0.00036748662],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016604938,0.00025600387,0.0005155166,0.00031059847,0.00022658437,0.000043960405,0.00035217986,0.0001804513,0.0015383369],"category_scores_gemma":[0.00016157977,0.00016965436,0.00009728395,0.0009708114,0.0007094642,0.0001525424,0.00020988294,0.0007912856,0.000039950024],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042774356,0.00044938707,0.47394314,0.0016855093,0.00041978798,0.000029885046,0.004756453,0.00000904428,0.43249193,0.00022899985,0.038756605,0.04295182],"study_design_scores_gemma":[0.008148857,0.0006186258,0.18289922,0.0021023608,0.00005602672,0.000016327573,0.0006149853,0.00011823387,0.70098716,0.00036196318,0.10367704,0.0003991771],"about_ca_topic_score_codex":0.004003859,"about_ca_topic_score_gemma":0.00054335885,"teacher_disagreement_score":0.2910439,"about_ca_system_score_codex":0.0006108729,"about_ca_system_score_gemma":0.0014049675,"threshold_uncertainty_score":0.9993744},"labels":[],"label_agreement":null},{"id":"W2019449237","doi":"10.1373/clinchem.2009.140046","title":"Prostate Cancer Screening with Prostate-Specific Antigen Testing: More Answers or More Confusion?","year":2010,"lang":"en","type":"article","venue":"Clinical Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Confusion; Prostate-specific antigen; Prostate; Prostate cancer; Medicine; Antigen; Cancer; Prostate cancer screening; Oncology; Internal medicine; Immunology; Psychology","score_opus":0.09653026578055933,"score_gpt":0.4168338305914459,"score_spread":0.32030356481088657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019449237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99085045,0.00049931096,0.0000047302656,0.0052087344,0.00014672341,0.0008309267,0.00008342194,0.0001695434,0.0022061346],"genre_scores_gemma":[0.96776843,0.0010691782,0.003973085,0.0005287869,0.0009412064,0.0002086298,0.0002473378,0.000099324054,0.025164023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749863,0.000019862391,0.0005633692,0.0007586599,0.00053338136,0.00062609214],"domain_scores_gemma":[0.99775696,0.0003139503,0.00018518545,0.0006185701,0.0004912481,0.00063409674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037957198,0.00032059549,0.00053751486,0.000032095937,0.00019292696,0.00006179394,0.00021325123,0.00028856026,0.00080097775],"category_scores_gemma":[0.0004238217,0.00019412482,0.00012184138,0.00040648432,0.0010123666,0.00008657343,0.000112801215,0.0013580783,0.00001778566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008368634,0.0004885436,0.8636212,0.0003554422,0.00020159248,0.0009998769,0.00028495482,0.0000052665346,0.092286564,0.0000010550827,0.0049577523,0.028429152],"study_design_scores_gemma":[0.026862126,0.0023628674,0.47781762,0.0022090285,0.00034686035,0.00039308073,0.0023982702,0.0009333388,0.2638263,0.000025068155,0.22143875,0.0013866724],"about_ca_topic_score_codex":0.000045764897,"about_ca_topic_score_gemma":0.000009312091,"teacher_disagreement_score":0.38580355,"about_ca_system_score_codex":0.0000512471,"about_ca_system_score_gemma":0.00089276204,"threshold_uncertainty_score":0.87701446},"labels":[],"label_agreement":null},{"id":"W2020278137","doi":"10.1016/j.juro.2011.02.1706","title":"737 UTILIZING METFORMIN AS A RADIOSENSITIZING AGENT IN THE TREATMENT OF PROSTATE CANCER","year":2011,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Hyperinsulinemia; Prostate cancer; Metformin; Radioresistance; Cancer; Internal medicine; Diabetes mellitus; Type 2 diabetes; Cancer research; Oncology; Radiation therapy; Insulin; Endocrinology; Insulin resistance","score_opus":0.08700295935507504,"score_gpt":0.3549156354889875,"score_spread":0.26791267613391245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020278137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97898746,0.016182821,0.000002933023,0.002629185,0.00011277684,0.00035251558,0.000002124843,0.000002368778,0.001727838],"genre_scores_gemma":[0.97938883,0.019922145,0.00007314666,0.00029775035,0.00008632773,0.000010327784,6.393255e-7,0.000008964375,0.00021183868],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9989406,0.00023457398,0.0003222865,0.00006401615,0.00020524251,0.00023332193],"domain_scores_gemma":[0.99931294,0.00016659587,0.00020676224,0.00016582252,0.00009531309,0.000052585365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007322182,0.00009643406,0.000301351,0.00013766864,0.000045117173,0.00000277768,0.000118075215,0.00004029409,0.00007675097],"category_scores_gemma":[0.000026855298,0.000039337618,0.00009991458,0.00015180778,0.00015082887,0.00003965752,0.000012995845,0.00018374342,0.000003867792],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048023794,0.0044848435,0.14741705,0.00015319308,0.0030049654,0.009536743,0.39783248,0.00011071394,0.04556452,0.0011534842,0.0010770034,0.3416412],"study_design_scores_gemma":[0.05735212,0.10839211,0.40346795,0.0006259561,0.006299759,0.034554638,0.045802094,0.000824755,0.250643,0.008943915,0.08241541,0.0006783223],"about_ca_topic_score_codex":0.00047718195,"about_ca_topic_score_gemma":0.00006210744,"teacher_disagreement_score":0.3520304,"about_ca_system_score_codex":0.00011883777,"about_ca_system_score_gemma":0.00020239745,"threshold_uncertainty_score":0.16041416},"labels":[],"label_agreement":null},{"id":"W2020402215","doi":"10.1002/1097-0215(20010520)95:3<135::aid-ijc1023>3.0.co;2-3","title":"Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy","year":2001,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Oncology; Radical retropubic prostatectomy; Internal medicine; Prostate; Population; Urology; Lymph node; Cancer","score_opus":0.011693186057993304,"score_gpt":0.34464998924460233,"score_spread":0.33295680318660903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020402215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807413,0.011473818,0.00005242649,0.0063049663,0.00037744807,0.0004938263,0.00014544839,0.000012692841,0.00039805815],"genre_scores_gemma":[0.9823229,0.014616588,0.00018797794,0.00013908002,0.00027447398,0.00009304524,0.000033446933,0.000027064534,0.0023054301],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978841,0.00004302468,0.0006355336,0.00019313206,0.0009731331,0.00027107957],"domain_scores_gemma":[0.9980328,0.00004281124,0.00044151404,0.00011094374,0.0012091377,0.00016277467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016972423,0.00017408682,0.00038165174,0.00034372156,0.000021732394,0.000021659527,0.00023023339,0.000084278116,0.0004977985],"category_scores_gemma":[0.000049159335,0.00012191461,0.000115885545,0.00029110216,0.00010122766,0.00032352496,0.00004303099,0.0003316335,0.0000021054125],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013307791,0.00046256118,0.57524043,0.000095421354,0.00048981415,0.0008350142,0.0007970148,0.0007076543,0.33230007,0.000005145789,0.0067345225,0.06902459],"study_design_scores_gemma":[0.039973095,0.001600194,0.10753942,0.0075251726,0.00017622935,0.0002844569,0.00042635997,0.00026214693,0.7511837,0.0002038083,0.090478234,0.00034718972],"about_ca_topic_score_codex":0.0003182401,"about_ca_topic_score_gemma":0.00023834992,"teacher_disagreement_score":0.467701,"about_ca_system_score_codex":0.00060960377,"about_ca_system_score_gemma":0.00064398756,"threshold_uncertainty_score":0.54505444},"labels":[],"label_agreement":null},{"id":"W2020509695","doi":"10.1517/13543784.16.3.397","title":"3<sup>rd</sup>PacRim Breast and Prostate Cancer Meeting","year":2007,"lang":"en","type":"article","venue":"Expert Opinion on Investigational Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Androgen receptor; Breast cancer; Context (archaeology); Estrogen; Medicine; Estrogen receptor; Cancer; Prostate; Oncology; Internal medicine; Gynecology; Cancer research; Biology","score_opus":0.03216663827553005,"score_gpt":0.34997464406226947,"score_spread":0.3178080057867394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020509695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8941841,0.012471223,0.000029397605,0.074412584,0.00053042494,0.0012890365,0.00014938031,0.00021176333,0.016722063],"genre_scores_gemma":[0.98029536,0.004841684,0.0018182604,0.005847954,0.0017301695,0.00023343806,0.00051514816,0.00006895667,0.0046490463],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822927,0.00004280922,0.0002837259,0.00039284065,0.00064746616,0.00040388803],"domain_scores_gemma":[0.9989748,0.00016071762,0.00006906489,0.00016756103,0.00018635947,0.00044150028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004057131,0.00020417313,0.00020575729,0.00018407353,0.00023455221,0.000039555292,0.000066350665,0.000091140995,0.00015407712],"category_scores_gemma":[0.000076166405,0.00016004188,0.000054594973,0.00024338135,0.0003428538,0.0001428504,0.0000499661,0.00023442882,0.00003997033],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071612983,0.00137688,0.31033778,0.0007788292,0.0009664636,0.00018806945,0.07373097,0.00070199254,0.04578388,0.032771606,0.25237685,0.27382538],"study_design_scores_gemma":[0.016884465,0.0012943529,0.28287768,0.0045768977,0.00003438853,0.00039502323,0.008319644,0.006416813,0.07689859,0.004905835,0.5959671,0.0014292008],"about_ca_topic_score_codex":0.0003601155,"about_ca_topic_score_gemma":0.0000036627684,"teacher_disagreement_score":0.34359026,"about_ca_system_score_codex":0.0002727177,"about_ca_system_score_gemma":0.0003672478,"threshold_uncertainty_score":0.6526318},"labels":[],"label_agreement":null},{"id":"W2021180228","doi":"10.1039/c1ib00038a","title":"Dynamic rewiring of the androgen receptor protein interaction network correlates with prostate cancer clinical outcomes","year":2011,"lang":"en","type":"article","venue":"Integrative Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; McGill University Health Centre; Biotechnology Research Institute; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Prostate Cancer Foundation","keywords":"Prostate cancer; Androgen receptor; Receptor; Androgen; Medicine; Cancer; Oncology; Biology; Bioinformatics; Internal medicine; Cancer research; Endocrinology; Hormone","score_opus":0.0549000236057121,"score_gpt":0.390274357004888,"score_spread":0.3353743333991759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021180228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964054,0.00058778306,0.000050886334,0.00064424216,0.00039409692,0.0010220311,0.000025192767,0.000021292779,0.00084907166],"genre_scores_gemma":[0.9963264,0.00030587922,0.0006091222,0.00007119844,0.000037679652,0.00020936756,0.000020804478,0.000013453205,0.0024061017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990107,0.00018984606,0.00028470915,0.00022765584,0.00007178218,0.00021532003],"domain_scores_gemma":[0.9992752,0.00009890156,0.00018636645,0.00018592353,0.0002025847,0.000051028885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019311576,0.00013896289,0.0003413885,0.000036597598,0.00005571074,0.0000031501213,0.000096010175,0.00010475831,0.00018655621],"category_scores_gemma":[0.00009431828,0.00005590444,0.000105943414,0.0001576842,0.00046454088,0.000043298016,0.0000510752,0.00037051266,0.000010181492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030341863,0.00011251708,0.98442197,0.000016271035,0.0003957757,0.0000032333091,0.0012056591,0.0000010682946,0.002478681,0.00016913183,0.00016395531,0.007997559],"study_design_scores_gemma":[0.0045386967,0.0058546667,0.93440604,0.0016259279,0.0002347594,0.000024500716,0.0021955392,0.00024486316,0.04522279,0.0013424422,0.004021292,0.00028850944],"about_ca_topic_score_codex":0.00041138986,"about_ca_topic_score_gemma":0.0006122556,"teacher_disagreement_score":0.05001595,"about_ca_system_score_codex":0.00010729165,"about_ca_system_score_gemma":0.00018205229,"threshold_uncertainty_score":0.22797169},"labels":[],"label_agreement":null},{"id":"W2021423217","doi":"10.1002/ijc.11335","title":"Role of the stromal microenvironment in carcinogenesis of the prostate","year":2003,"lang":"en","type":"review","venue":"International Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":372,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Stromal cell; Carcinogenesis; Prostate; Biology; Androgen; Androgen receptor; Cancer research; Endocrinology; Internal medicine; Epithelium; Hormone; Prostate cancer; Medicine; Cancer; Genetics","score_opus":0.028589973802731868,"score_gpt":0.36968305508908045,"score_spread":0.3410930812863486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021423217","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01723778,0.9810512,3.5173576e-7,0.00039196273,0.0005098496,0.0004349778,0.000121040684,4.4031546e-7,0.0002523826],"genre_scores_gemma":[0.01566189,0.9834352,0.000018770133,0.000033191427,0.00013679577,0.000023433142,0.0000027435478,0.000017309541,0.0006706772],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981394,0.00011610691,0.000693731,0.00009870558,0.00082771893,0.00012437048],"domain_scores_gemma":[0.99861574,0.00004137396,0.00090537476,0.00017407365,0.00022442556,0.0000389814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019728472,0.00014180379,0.0006328541,0.00014786562,0.000013390296,0.000005916778,0.00045697961,0.00006865811,0.00015500002],"category_scores_gemma":[0.000022559638,0.000063740015,0.00055284495,0.00015078923,0.00013303508,0.000031325,0.00009173868,0.00032535274,7.4635096e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004368752,0.0004086943,0.05171252,0.0025439842,0.0027196147,0.0000549281,0.00035255193,0.00005688186,0.0018477268,0.000037407797,0.00040428253,0.9394245],"study_design_scores_gemma":[0.002071674,0.0001481487,0.024254626,0.022708854,0.0010379341,0.0002210477,0.00007450674,0.0000017349661,0.0057416046,0.00006779134,0.943572,0.000100083125],"about_ca_topic_score_codex":0.00007026238,"about_ca_topic_score_gemma":0.000029645382,"teacher_disagreement_score":0.9431677,"about_ca_system_score_codex":0.0007097217,"about_ca_system_score_gemma":0.0011851252,"threshold_uncertainty_score":0.25992423},"labels":[],"label_agreement":null},{"id":"W2021426678","doi":"10.1038/nrurol.2012.257","title":"Familial prostate cancer: the damage done and lessons learnt","year":2013,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Alberta Cancer Foundation; University of Calgary; Hôpital du Sacré-Cœur de Montréal; McGill University Health Centre","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Prostatectomy; Oncology; Androgen deprivation therapy; Genetic testing; Bicalutamide; Internal medicine; Cancer","score_opus":0.07260176527563644,"score_gpt":0.4359557841087305,"score_spread":0.36335401883309404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021426678","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015257529,0.98223305,5.387554e-7,0.009570066,0.0004925851,0.0065137353,0.00009367798,0.000040067698,0.0010409969],"genre_scores_gemma":[0.000008100143,0.98660076,0.000048214595,0.0011247838,0.00070988043,0.0024001775,0.0002523394,0.00007896085,0.008776771],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968155,0.0008026662,0.0006834644,0.0007603879,0.0002864178,0.00065154233],"domain_scores_gemma":[0.9981648,0.0002799045,0.0004010082,0.0007986292,0.00012518917,0.00023051584],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007507676,0.00062852266,0.003099594,0.0001835164,0.00019156755,0.000042979253,0.00033704969,0.0011926431,0.00025831087],"category_scores_gemma":[0.00021795559,0.00027801326,0.0005240351,0.0004611146,0.00043500907,0.000052998137,0.00024704257,0.0039222613,0.00026011642],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003678314,0.000040839583,0.000029435043,0.01553764,0.00027774388,0.00007050397,0.00005100689,1.557185e-8,0.0000016633151,0.00013276417,0.021648899,0.9621727],"study_design_scores_gemma":[0.00059002347,0.00025674354,0.00004624592,0.004032589,0.002357582,0.00028900476,0.000004990493,0.000001953817,5.365868e-7,0.000034014014,0.99215704,0.00022927424],"about_ca_topic_score_codex":0.00007515591,"about_ca_topic_score_gemma":0.00004454573,"teacher_disagreement_score":0.97050816,"about_ca_system_score_codex":0.00016580643,"about_ca_system_score_gemma":0.00063830725,"threshold_uncertainty_score":0.9999672},"labels":[],"label_agreement":null},{"id":"W2022023878","doi":"10.1038/modpathol.3800759","title":"A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis","year":2007,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McGill University; McGill University Health Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"TMPRSS2; Prostate cancer; Fusion gene; Prostate; Biology; Erg; Fusion transcript; Gene isoform; Cancer research; Chromoplexy; PCA3; Cancer; Genetics; Gene; Pathology; Medicine","score_opus":0.02335603275979903,"score_gpt":0.33857595824291675,"score_spread":0.3152199254831177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022023878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785639,0.0035186824,0.0052763238,0.010607417,0.000027981958,0.0017380512,0.00005345961,0.000025311665,0.0001888711],"genre_scores_gemma":[0.9944111,0.0012108155,0.0019112191,0.00029374164,0.000035021283,0.0016082007,0.000057254583,0.00002333416,0.00044929923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990248,0.000015375503,0.00014976715,0.00036430932,0.000076981836,0.00036878113],"domain_scores_gemma":[0.99951446,0.000042485368,0.000038317987,0.00021127099,0.000104090155,0.000089390975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002525373,0.00011206822,0.00019746505,0.0001401278,0.000064949665,0.0000073893157,0.000038892045,0.000050818544,0.0000068335917],"category_scores_gemma":[0.000028576109,0.0000773226,0.000022556382,0.00015430285,0.0000973768,0.000039596267,0.00003462709,0.00010908228,9.1380167e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026061882,0.00054338673,0.63005984,0.0002611165,0.00007683174,0.0010738486,0.0028877712,0.00003677281,0.13015862,0.00067366473,0.00015030545,0.23147167],"study_design_scores_gemma":[0.0073483954,0.001522382,0.9483456,0.00015214735,0.00012932581,0.00056727434,0.00009179304,0.0004956585,0.03469552,0.0046258075,0.0017852078,0.00024091099],"about_ca_topic_score_codex":0.00010781633,"about_ca_topic_score_gemma":0.00039262627,"teacher_disagreement_score":0.31828576,"about_ca_system_score_codex":0.00010536531,"about_ca_system_score_gemma":0.00014213429,"threshold_uncertainty_score":0.3153124},"labels":[],"label_agreement":null},{"id":"W2023011880","doi":"10.1038/modpathol.2008.96","title":"Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome","year":2008,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Astellas Pharma; American Urological Association Foundation; U.S. Department of Defense","keywords":"TMPRSS2; Erg; PTEN; Prostate cancer; Fusion gene; Prostate; Cancer research; Medicine; Cancer; Biology; Internal medicine; Oncology; Gene; Genetics; Ophthalmology","score_opus":0.05093665690103059,"score_gpt":0.3308141187015916,"score_spread":0.279877461800561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023011880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99545795,0.0022440325,0.000030022235,0.0012661408,0.000023083,0.0003863691,0.000075247954,0.000021695156,0.0004954347],"genre_scores_gemma":[0.9924613,0.0021750182,0.00012247743,0.00020654839,0.0000088323395,0.0000829489,0.000019323603,0.000016546246,0.0049069766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898726,0.000044968707,0.00020492928,0.00027487674,0.0001747277,0.00031326854],"domain_scores_gemma":[0.9995041,0.00004976598,0.000073634714,0.0001741942,0.00011797871,0.00008033864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011743326,0.00012104602,0.00038156874,0.0001313857,0.00006675339,0.0000030821557,0.000049257902,0.00007793808,0.000044667606],"category_scores_gemma":[0.00005061803,0.00008243686,0.000026280348,0.00021104969,0.00032579372,0.00005158227,0.000049456306,0.00017873695,0.0000030295885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036127272,0.00019471615,0.9849,0.000054944387,0.000043932207,0.0018103375,0.003862413,0.000029037457,0.007693906,0.000006621753,0.000083126535,0.0009597123],"study_design_scores_gemma":[0.0048709745,0.0006064431,0.98908925,0.0001933413,0.000042109707,0.00030649637,0.00014986673,0.0015307119,0.0027316967,0.00026627973,0.000072286464,0.00014053361],"about_ca_topic_score_codex":0.0004697141,"about_ca_topic_score_gemma":0.0004444831,"teacher_disagreement_score":0.0049622087,"about_ca_system_score_codex":0.00008529917,"about_ca_system_score_gemma":0.00022110408,"threshold_uncertainty_score":0.33616775},"labels":[],"label_agreement":null},{"id":"W2023072606","doi":"10.1016/j.clgc.2014.06.001","title":"A Phase II Study of GW786034 (Pazopanib) With or Without Bicalutamide in Patients With Castration-Resistant Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Queen's University","funders":"National Cancer Institute","keywords":"Bicalutamide; Medicine; Pazopanib; Prostate cancer; Castration; Oncology; Internal medicine; Cancer; Urology; Androgen receptor; Hormone","score_opus":0.06198738149956967,"score_gpt":0.42551997177265527,"score_spread":0.3635325902730856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023072606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959179,0.0003214248,0.0000042853953,0.00038371392,0.00013620265,0.0029233843,0.000081633385,0.00003839581,0.00019304745],"genre_scores_gemma":[0.995867,0.00026919137,0.000253132,0.00014926445,0.00027251986,0.0007325342,0.000036832873,0.00006137684,0.0023581486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969422,0.00022620705,0.00087157305,0.0006910508,0.00075530325,0.0005136563],"domain_scores_gemma":[0.9982117,0.0001707451,0.00029907012,0.0005222373,0.0004482597,0.00034801097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039232045,0.0003300668,0.0009160474,0.00016896524,0.00013403501,0.000018103467,0.00016420886,0.00011121685,0.00022579118],"category_scores_gemma":[0.000073968426,0.00018160668,0.00007508462,0.0005832936,0.00033353263,0.00013846827,0.00009117014,0.00049117254,0.000003801319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09307196,0.017837575,0.86398995,0.00017111399,0.00037144206,0.00019486794,0.00079823454,0.000075869626,0.00021493924,9.35102e-7,0.00024395304,0.023029154],"study_design_scores_gemma":[0.09618953,0.12949301,0.77035254,0.00074212806,0.0004183785,0.000004279672,0.0005793668,0.00025161853,0.00038217095,0.0000054183192,0.0012409032,0.00034064206],"about_ca_topic_score_codex":0.0009801262,"about_ca_topic_score_gemma":0.0034815639,"teacher_disagreement_score":0.111655444,"about_ca_system_score_codex":0.00022137426,"about_ca_system_score_gemma":0.0011419232,"threshold_uncertainty_score":0.74057055},"labels":[],"label_agreement":null},{"id":"W2023559232","doi":"10.1016/j.yexmp.2009.11.005","title":"EGFR ligands exert diverging effects on male reproductive organs","year":2009,"lang":"en","type":"article","venue":"Experimental and Molecular Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Biology; Transgene; Genetically modified mouse; Sperm; Epididymis; Hyperplasia; Reproductive system; Endocrinology; Internal medicine; Andrology; Genetics; Medicine; Gene","score_opus":0.00833047482308805,"score_gpt":0.3005216898950487,"score_spread":0.2921912150719606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023559232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98672765,0.005106963,0.000032782627,0.0022641222,0.0001088941,0.00035497808,0.0000018114522,0.00003737223,0.005365416],"genre_scores_gemma":[0.99642116,0.000119409626,0.00019529281,0.0015376554,0.00009834847,0.000030462672,0.000022833272,0.00001223396,0.0015626021],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991243,0.000031864427,0.000082120605,0.0003940875,0.00012620735,0.00024143889],"domain_scores_gemma":[0.9996359,0.0000109395105,0.000019589463,0.00020413157,0.000020031177,0.00010944284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005788582,0.00013557318,0.0001973285,0.000072541516,0.000086228254,0.000009293263,0.0000367894,0.000063622865,0.000039642833],"category_scores_gemma":[0.000017687258,0.000092920454,0.000047507332,0.00007851948,0.00008325834,0.000028779026,0.000042330998,0.00011898645,0.000024710205],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040633322,0.00026513994,0.0010590645,0.000011341799,0.000026494998,0.004381718,0.0009697334,1.8830879e-7,0.98625064,0.00032276296,0.00031944335,0.005987117],"study_design_scores_gemma":[0.0020397508,0.0031704193,0.006089059,0.00004241417,0.000021159265,0.00079425576,0.00022780319,0.0000029964772,0.9870309,0.000132867,0.00034625572,0.000102071645],"about_ca_topic_score_codex":0.0000037682355,"about_ca_topic_score_gemma":6.239141e-8,"teacher_disagreement_score":0.0096935015,"about_ca_system_score_codex":0.000062170024,"about_ca_system_score_gemma":0.00001969066,"threshold_uncertainty_score":0.37891862},"labels":[],"label_agreement":null},{"id":"W2023595415","doi":"10.1038/pcan.2009.64","title":"Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay","year":2010,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Ontario Genomics","funders":"Industry Canada","keywords":"Medicine; Biopsy; Prostate cancer; Cutoff; Receiver operating characteristic; Prostate biopsy; Polymerase chain reaction; Prostate; Predictive value of tests; Pathology; Cancer; Radiology; Internal medicine; Oncology; Gene; Biology","score_opus":0.014374844803174643,"score_gpt":0.3074316387798778,"score_spread":0.29305679397670314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023595415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820371,0.004166902,0.00005703021,0.0030361179,0.0007524253,0.002964829,0.006547751,0.0001530801,0.00028471916],"genre_scores_gemma":[0.98732525,0.0036928335,0.0005032712,0.00024868854,0.00016390292,0.0013741683,0.0015885124,0.00007885256,0.0050244983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974376,0.000079878635,0.00062187726,0.00066110486,0.00062108086,0.00057847326],"domain_scores_gemma":[0.9982429,0.00014926615,0.0002720129,0.0004116386,0.00041539216,0.0005087568],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021414693,0.00039554748,0.0006151625,0.00018995263,0.00020298162,0.000102663034,0.00010701467,0.0001267601,0.00021051559],"category_scores_gemma":[0.000270835,0.00028632133,0.00015397707,0.00035099703,0.00048806897,0.00038196926,0.000076763026,0.0003366605,0.000007856789],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055184215,0.0008665138,0.7842297,0.0016889481,0.00053677004,0.00007340032,0.0018241358,0.0000049329556,0.15676425,0.00008964401,0.010161838,0.038241424],"study_design_scores_gemma":[0.035870686,0.0035184056,0.79118735,0.0014174362,0.0025295154,0.00017315704,0.0014343029,0.0017344673,0.12282513,0.0032182175,0.034561645,0.0015297022],"about_ca_topic_score_codex":0.00021337577,"about_ca_topic_score_gemma":0.000017798215,"teacher_disagreement_score":0.036711723,"about_ca_system_score_codex":0.000071654,"about_ca_system_score_gemma":0.00050939526,"threshold_uncertainty_score":0.9999589},"labels":[],"label_agreement":null},{"id":"W2024399113","doi":"10.1593/neo.06283","title":"Three-Color FISH Analysis of TMPRSS2/ERG Fusions in Prostate Cancer Indicates That Genomic Microdeletion of Chromosome 21 Is Associated with Rearrangement","year":2006,"lang":"en","type":"article","venue":"Neoplasia","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"TMPRSS2; Fusion gene; Biology; Fluorescence in situ hybridization; Erg; Chromosomal translocation; Fusion transcript; Molecular biology; Gene rearrangement; Chimeric gene; Chromosomal rearrangement; Cancer research; Genetics; Breakpoint; Gene; Karyotype; Chromosome; Pathology; Gene expression; Medicine","score_opus":0.016980114052502323,"score_gpt":0.27331547974762554,"score_spread":0.2563353656951232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024399113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99638635,0.00077771896,0.000004506216,0.0012629754,0.000024684665,0.0007621671,0.00043040502,0.000018544022,0.00033265993],"genre_scores_gemma":[0.99771166,0.000611331,0.00008611411,0.00006014977,0.000019724523,0.00013512104,0.0005803199,0.00002080492,0.0007747958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986207,0.00003281789,0.00033565843,0.00029532026,0.00040259396,0.00031293192],"domain_scores_gemma":[0.9992596,0.00005075686,0.00025564744,0.00021649616,0.00015452175,0.00006301063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016604197,0.00016187177,0.0005549398,0.00055625936,0.000046709316,0.000008969246,0.0000862759,0.000090287795,0.00039386813],"category_scores_gemma":[0.000010949852,0.00011860496,0.00011799436,0.0012872217,0.00013581765,0.00005316487,0.000038378934,0.00014656184,0.0000029903993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006967924,0.00048398197,0.88856864,0.00008869958,0.0011310792,0.00004295792,0.0007639156,0.00022188196,0.10624176,0.0000052664795,0.0010439713,0.00071104843],"study_design_scores_gemma":[0.0033634838,0.00038480049,0.94293845,0.00022275287,0.00107006,0.00000220427,0.000111881265,0.00068575365,0.05088312,0.000021085008,0.00020645862,0.00010994821],"about_ca_topic_score_codex":0.00540907,"about_ca_topic_score_gemma":0.022969676,"teacher_disagreement_score":0.05535864,"about_ca_system_score_codex":0.00038401553,"about_ca_system_score_gemma":0.00025837647,"threshold_uncertainty_score":0.99485856},"labels":[],"label_agreement":null},{"id":"W2024548912","doi":"10.1002/cncr.27674","title":"Phase 3, randomized, placebo‐controlled study of zibotentan (ZD4054) in patients with castration‐resistant prostate cancer metastatic to bone","year":2012,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Placebo; Clinical endpoint; Hazard ratio; Peripheral edema; Internal medicine; Adverse effect; Bone pain; Randomized controlled trial; Common Terminology Criteria for Adverse Events; Population; Cancer; Surgery; Confidence interval; Pathology","score_opus":0.025181598308587877,"score_gpt":0.3572338929697615,"score_spread":0.3320522946611736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024548912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98574203,0.0031441378,0.000009923192,0.00037515705,0.00015163248,0.010274261,0.0001121252,0.000016932434,0.00017378868],"genre_scores_gemma":[0.9933764,0.00017417899,0.00013412761,0.0001064905,0.00006874138,0.004562741,0.000034183933,0.000035647565,0.0015075116],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99782187,0.00019900527,0.000567402,0.0002867212,0.00061187113,0.0005131394],"domain_scores_gemma":[0.99885374,0.00011238017,0.00019472928,0.00025813273,0.00028077606,0.0003002458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054354087,0.00024604643,0.0011826138,0.0002646423,0.00005773471,0.000016246313,0.00006705323,0.000030216996,0.0002911258],"category_scores_gemma":[0.000073990035,0.0001473602,0.000087613975,0.00044575147,0.000094976196,0.00016902432,0.000029211125,0.00015557178,0.0000056629274],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83510435,0.0070342016,0.14500141,0.00015506131,0.0010780027,0.00004032412,0.0063744197,0.00013472402,0.0011523702,0.000008444056,0.00023123813,0.0036854823],"study_design_scores_gemma":[0.9519105,0.0029749647,0.040742286,0.00030328464,0.0009119217,0.0000011466807,0.0014039933,0.000056848447,0.0013951145,0.0000045308298,0.00010273374,0.00019267785],"about_ca_topic_score_codex":0.0012145139,"about_ca_topic_score_gemma":0.0009783962,"teacher_disagreement_score":0.11680618,"about_ca_system_score_codex":0.00044317503,"about_ca_system_score_gemma":0.0003387938,"threshold_uncertainty_score":0.6009175},"labels":[],"label_agreement":null},{"id":"W2025897548","doi":"10.1016/j.eururo.2014.08.012","title":"Toward Predictive Signatures of Enzalutamide Response and Resistance","year":2014,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Internal medicine; Prostate cancer; Androgen receptor","score_opus":0.026024943631652444,"score_gpt":0.2793693159428512,"score_spread":0.2533443723111988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025897548","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023354886,0.013396364,0.000085214844,0.9067846,0.00028018665,0.0007508348,0.00014845004,0.00010332858,0.055096146],"genre_scores_gemma":[0.3494153,0.0010428247,0.00032552375,0.6091199,0.0028041292,0.000026089216,0.00034193054,0.00019189218,0.036732405],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99704194,0.0015036955,0.0002869146,0.00050147466,0.00028906832,0.00037687883],"domain_scores_gemma":[0.99848026,0.00068842154,0.00016612868,0.00044061072,0.00013811151,0.00008649495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006742896,0.00025585858,0.00053762767,0.00024735177,0.000042339416,0.000008968897,0.00017370383,0.00034268678,0.0000709395],"category_scores_gemma":[0.00043248705,0.00019547786,0.00009414671,0.00009321489,0.00055788935,0.000019803409,0.00012486741,0.001491713,0.00004280659],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012316971,0.000026527912,0.00032773684,0.00040389874,0.00026894466,0.005717501,0.0004234578,8.4047997e-7,0.0017805515,0.000020715652,0.97846586,0.00024697062],"study_design_scores_gemma":[0.0017311483,0.001880776,0.013663358,0.00010789135,0.00021012417,0.000100341575,0.000009517737,0.000004608868,0.00031351324,0.00013617022,0.9816964,0.0001461025],"about_ca_topic_score_codex":0.0000036619422,"about_ca_topic_score_gemma":8.155256e-7,"teacher_disagreement_score":0.3260604,"about_ca_system_score_codex":0.00004762449,"about_ca_system_score_gemma":0.00012922256,"threshold_uncertainty_score":0.7971356},"labels":[],"label_agreement":null},{"id":"W2026083620","doi":"10.1359/jbmr.090522","title":"Correlates of Trabecular and Cortical Volumetric BMD in Men of African Ancestry","year":2009,"lang":"en","type":"article","venue":"Journal of Bone and Mineral Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute; National Institutes of Health","keywords":"Anthropometry; Tibia; Medicine; Cortical bone; Osteoporosis; Internal medicine; Bone density; Cohort; Bone mineral; Quantitative computed tomography; Prostate cancer; Endocrinology; Cancer; Anatomy","score_opus":0.07205728027254198,"score_gpt":0.39857613592832797,"score_spread":0.326518855655786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026083620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98109376,0.016118092,0.0000042205343,0.0012723285,0.000010831684,0.00014187109,0.000002323129,9.057142e-7,0.0013556706],"genre_scores_gemma":[0.9923229,0.006574134,0.00024767016,0.000008959727,0.00004210255,0.0000010823555,0.0000010744211,0.000004405042,0.00079763326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850786,0.00009647833,0.00042828184,0.000097065364,0.0006235444,0.0002467936],"domain_scores_gemma":[0.9990549,0.0001995522,0.00009882841,0.00007918688,0.00037203656,0.000195459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013026436,0.000065471555,0.0004248388,0.0007254258,0.000025917272,0.000009183207,0.00004289766,0.00006516403,0.000018279577],"category_scores_gemma":[0.00045153807,0.00004360458,0.000054327204,0.0006544712,0.00025945425,0.00007948247,0.00002586218,0.0005073444,2.6355585e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006637766,0.0013126077,0.5498675,0.00040297315,0.0001730618,0.0014973923,0.001327046,0.0000049777973,0.34850147,0.00023096544,0.0024756414,0.08756859],"study_design_scores_gemma":[0.005755259,0.0073189996,0.97404605,0.0004832508,0.00005366576,0.0003082073,0.0011787222,0.00049228047,0.0094522815,0.0005703753,0.00027488696,0.000066003115],"about_ca_topic_score_codex":0.0000808265,"about_ca_topic_score_gemma":0.00000569588,"teacher_disagreement_score":0.42417854,"about_ca_system_score_codex":0.000046281704,"about_ca_system_score_gemma":0.00022425086,"threshold_uncertainty_score":0.22041872},"labels":[],"label_agreement":null},{"id":"W2026830074","doi":"10.1111/j.1464-410x.2004.04803.x","title":"A re‐assessment of the role of combined androgen blockade for advanced prostate cancer","year":2004,"lang":"en","type":"review","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"AstraZeneca","keywords":"Blockade; Prostate cancer; Medicine; Androgen; Urethroplasty; Buccal mucosa; Infertility; Cancer; Gynecology; Urology; Oncology; Internal medicine; Hormone; Urethra; Biology; Pregnancy; Oral cavity; Receptor","score_opus":0.025710286190278302,"score_gpt":0.3772392219599257,"score_spread":0.3515289357696474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026830074","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001579203,0.9955363,0.0000060606317,0.00044588427,0.00023931527,0.0017386035,0.00031631466,0.000003369433,0.00013494992],"genre_scores_gemma":[0.006862172,0.99222046,0.0003024648,0.000031703305,0.0001124258,0.00013997268,0.000027435937,0.000041233478,0.00026210997],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979957,0.0001501783,0.0010103675,0.0001863271,0.00034938278,0.00030806707],"domain_scores_gemma":[0.9976424,0.00014142744,0.0013583336,0.00020213495,0.00054378895,0.00011191914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037598686,0.0001973309,0.0018773894,0.00014688984,0.000053061565,0.000007711453,0.00028105782,0.00020598757,0.000051501025],"category_scores_gemma":[0.00009248618,0.00013531842,0.000739451,0.00022330774,0.00022858218,0.000037575453,0.0000690268,0.0005577094,2.132504e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006656339,0.00042686803,0.0005168596,0.011607115,0.0013616831,0.00020870689,0.000061118735,0.000024074729,0.000072174764,0.000028184622,0.00019181993,0.98483574],"study_design_scores_gemma":[0.012901312,0.0051821857,0.000462973,0.03572608,0.004550513,0.0038420628,0.00007866974,0.000009349762,0.00042070568,0.00092395674,0.9356825,0.00021972599],"about_ca_topic_score_codex":0.000059570662,"about_ca_topic_score_gemma":0.000041784922,"teacher_disagreement_score":0.98461604,"about_ca_system_score_codex":0.00022912554,"about_ca_system_score_gemma":0.003067987,"threshold_uncertainty_score":0.5518125},"labels":[],"label_agreement":null},{"id":"W2026901798","doi":"10.1371/journal.pone.0020293","title":"A Tri-Marker Proliferation Index Predicts Biochemical Recurrence after Surgery for Prostate Cancer","year":2011,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Center for Advancing Translational Sciences; National Institutes of Health; National Cancer Institute; Georgia Clinical and Translational Science Alliance; National Center for Research Resources; Burroughs Wellcome Fund","keywords":"Prostate cancer; Proliferation Marker; Prostatectomy; Biochemical recurrence; Medicine; Proliferative index; Proliferation index; Oncology; Hazard ratio; Biomarker; Tissue microarray; Prostate; Prostate-specific antigen; Immunohistochemistry; Internal medicine; Ki-67; Receiver operating characteristic; PCA3; Proportional hazards model; Cancer; Biology; Confidence interval","score_opus":0.09695836617822405,"score_gpt":0.29999431323990927,"score_spread":0.2030359470616852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026901798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941316,0.0021552546,0.000027525855,0.000970774,0.00006360885,0.0021458934,0.00011250979,0.000060826773,0.00033197072],"genre_scores_gemma":[0.9913754,0.0010729105,0.0004772928,0.00016281409,0.00022908788,0.0040085097,0.00012432584,0.00002720229,0.0025224835],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99877197,0.000025968464,0.00021855553,0.0002951342,0.00034369327,0.00034468246],"domain_scores_gemma":[0.9992265,0.000070213515,0.00005428856,0.00018866133,0.0002881175,0.00017222285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019491953,0.00013387656,0.00028172616,0.00010779961,0.000044696946,0.00001454044,0.000044417622,0.00009569428,0.0002717775],"category_scores_gemma":[0.00017294598,0.000100782,0.00007167404,0.00016926935,0.00008155624,0.000106523556,0.000025836753,0.00014637488,0.00001588269],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013374509,0.002697802,0.95853275,0.0012255823,0.00053746224,0.00003241594,0.001025008,3.6086504e-8,0.013373289,0.0000036890747,0.0043902188,0.004807239],"study_design_scores_gemma":[0.0055863988,0.00097071176,0.31206924,0.0029540302,0.0006427625,0.000006346452,0.000048269474,0.0010454287,0.67525923,0.00030546376,0.00071270514,0.0003994132],"about_ca_topic_score_codex":0.000031169468,"about_ca_topic_score_gemma":0.000008505424,"teacher_disagreement_score":0.661886,"about_ca_system_score_codex":0.00011261053,"about_ca_system_score_gemma":0.00036392632,"threshold_uncertainty_score":0.4109771},"labels":[],"label_agreement":null},{"id":"W2027102691","doi":"10.1038/oncsis.2014.30","title":"Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer","year":2014,"lang":"en","type":"article","venue":"Oncogenesis","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Michael Smith Health Research BC","keywords":"LYN; Androgen receptor; Prostate cancer; Cancer research; Tyrosine kinase; LNCaP; Proto-oncogene tyrosine-protein kinase Src; Downregulation and upregulation; Receptor tyrosine kinase; Kinase; Chemistry; Carcinogenesis; Cell biology; Signal transduction; Biology; Internal medicine; Medicine; Cancer; Biochemistry; Gene","score_opus":0.021631851966270405,"score_gpt":0.3062238376102353,"score_spread":0.28459198564396493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027102691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935216,0.004078811,0.0000045364814,0.0013418357,0.000070337126,0.0005198105,0.000055881366,0.00003841645,0.00036882155],"genre_scores_gemma":[0.99445,0.0022631832,0.0002862743,0.00004981649,0.00010344627,0.00016071838,0.000030304727,0.000032371325,0.002623913],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987163,0.000096751486,0.00017505963,0.00039892367,0.00024980953,0.00036318848],"domain_scores_gemma":[0.99933904,0.00005592887,0.000064438944,0.00024461187,0.00007816827,0.0002178027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024081784,0.0001908931,0.00033165741,0.00012963919,0.000098457254,0.000030327468,0.00005326999,0.00009897192,0.000118786156],"category_scores_gemma":[0.0000372191,0.0001391494,0.000047011265,0.0002489918,0.00010876775,0.000108673834,0.000057212677,0.00010965911,0.000010238168],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002304547,0.00017893838,0.08013887,0.00019226786,0.000030397157,0.000048715403,0.00019563636,0.000005909294,0.8664677,0.000004742841,0.0004638677,0.04996841],"study_design_scores_gemma":[0.0034712325,0.00041461864,0.10237107,0.00041014174,0.000047227757,0.000007901401,0.00006161398,0.0001687803,0.8873091,0.000026286494,0.00553952,0.00017251022],"about_ca_topic_score_codex":0.0007616784,"about_ca_topic_score_gemma":0.0002654305,"teacher_disagreement_score":0.0497959,"about_ca_system_score_codex":0.00019732276,"about_ca_system_score_gemma":0.0001561265,"threshold_uncertainty_score":0.5674348},"labels":[],"label_agreement":null},{"id":"W2027494146","doi":"10.1111/j.1464-410x.2008.07733.x","title":"The Canadian Uro‐Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone‐refractory prostate cancer progressing after mitoxantrone/prednisone","year":2008,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Université de Montréal","funders":"McGill University; Canadian Urological Oncology Group; Sanofi","keywords":"Mitoxantrone; Medicine; Docetaxel; Prednisone; Internal medicine; Neutropenia; Febrile neutropenia; Prostate cancer; Chemotherapy; Oncology; Gastroenterology; Cancer; Surgery","score_opus":0.022634100609112428,"score_gpt":0.31664309657831036,"score_spread":0.29400899596919794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027494146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9608392,0.03522835,0.0000041455864,0.0018789682,0.00008140047,0.0017681202,0.00005849068,0.000008260496,0.00013304377],"genre_scores_gemma":[0.99340427,0.0053952085,0.0003492179,0.00012571715,0.000096825905,0.00022680605,0.000012325754,0.000048411657,0.00034122702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699146,0.00045795966,0.0008112988,0.00033527575,0.0006018279,0.0008022007],"domain_scores_gemma":[0.9980303,0.0001651717,0.00062620145,0.00023135926,0.00049054454,0.0004564121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005231797,0.00026269077,0.00087247044,0.00032546857,0.00041319642,0.00004087532,0.00021908928,0.00011310105,0.000032959557],"category_scores_gemma":[0.00006723218,0.00017530736,0.00007686502,0.0003271492,0.00071494345,0.000244364,0.000057657708,0.0007564684,7.217646e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22496344,0.024876982,0.31363407,0.0002476908,0.0050497684,0.18196122,0.027135681,0.00016919733,0.002239851,0.0000016700303,0.002759529,0.21696089],"study_design_scores_gemma":[0.18532968,0.1643967,0.5924124,0.0007779128,0.0019849944,0.034310706,0.008751222,0.00037824467,0.0001539448,0.000017514525,0.0109215295,0.000565146],"about_ca_topic_score_codex":0.019789794,"about_ca_topic_score_gemma":0.3055151,"teacher_disagreement_score":0.28572533,"about_ca_system_score_codex":0.0005664991,"about_ca_system_score_gemma":0.002889818,"threshold_uncertainty_score":0.9867375},"labels":[],"label_agreement":null},{"id":"W2027791854","doi":"10.1016/j.clgc.2014.12.003","title":"Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Hormonal therapy; Population; Androgen; Cancer; Hormone","score_opus":0.0790272422180056,"score_gpt":0.3952314846535048,"score_spread":0.3162042424354992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027791854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99413,0.0009959644,0.00003766916,0.0003739452,0.00021733629,0.004134408,0.000034975423,0.000048060294,0.000027611666],"genre_scores_gemma":[0.9970732,0.00015737022,0.00025144388,0.00052958366,0.00022910057,0.0014689751,0.00012119302,0.000050277362,0.00011886009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706924,0.00044556466,0.0006218083,0.0006779331,0.0007819003,0.0004035326],"domain_scores_gemma":[0.99849856,0.0001360969,0.00011737111,0.0006557015,0.0002944154,0.00029785614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008364745,0.00026000498,0.0007302879,0.00016799514,0.000091179216,0.000025979245,0.00012913645,0.00006784769,0.00008276176],"category_scores_gemma":[0.00009257941,0.00017966024,0.00021320871,0.0005543695,0.000047739617,0.00009912392,0.00004541059,0.00027203973,0.000008818384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004300094,0.002109808,0.951999,0.00005850916,0.0009162946,0.00004922246,0.00017659354,0.0020918695,0.000010364262,3.1670984e-7,0.000052534484,0.038235378],"study_design_scores_gemma":[0.01929229,0.0034687808,0.9755042,0.000118648546,0.0002931555,2.3374801e-7,0.00005164575,0.00021797167,0.00014017955,0.000010745942,0.0006798153,0.0002223391],"about_ca_topic_score_codex":0.0010576559,"about_ca_topic_score_gemma":0.0004961451,"teacher_disagreement_score":0.038013037,"about_ca_system_score_codex":0.0003278998,"about_ca_system_score_gemma":0.0003777874,"threshold_uncertainty_score":0.73263323},"labels":[],"label_agreement":null},{"id":"W2028039306","doi":"10.1016/j.eururo.2010.11.026","title":"A Panel of TMPRSS2:ERG Fusion Transcript Markers for Urine-Based Prostate Cancer Detection with High Specificity and Sensitivity","year":2010,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Prostate cancer; TMPRSS2; Internal medicine; Prostate; Urine; PCA3; Fusion gene; Erg; Biopsy; Urology; Cancer; Oncology; Disease; Ophthalmology; Biology","score_opus":0.019534251122526505,"score_gpt":0.2542456640168484,"score_spread":0.2347114128943219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028039306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99592113,0.000107313754,0.0006513792,0.0017674835,0.00016899858,0.00077676785,0.00006694844,0.00003931318,0.0005006509],"genre_scores_gemma":[0.9987092,0.000090144225,0.00035318252,0.00016085364,0.00012144338,0.000028191434,0.000029715407,0.00003386124,0.0004734086],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990518,0.00014981828,0.00014362653,0.0002921982,0.0001173969,0.0002451733],"domain_scores_gemma":[0.99942726,0.00009145924,0.000066668756,0.00017356563,0.00013565869,0.00010541606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036954964,0.00013167788,0.00021998117,0.0000951521,0.000076473785,0.000006712268,0.00002541645,0.00004810342,0.00004127613],"category_scores_gemma":[0.00003317587,0.00009233755,0.000041598374,0.00009596633,0.0002584365,0.000030964835,0.000015777905,0.00023841609,0.0000022754639],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01866239,0.00018307957,0.018491546,0.00020618168,0.000090909125,0.0002523936,0.00023427444,0.00002898713,0.9372023,0.000018059429,0.000115288276,0.024514593],"study_design_scores_gemma":[0.014610807,0.0056451214,0.7081212,0.00005081345,0.00030370918,0.00018048499,0.000058195692,0.002081268,0.25289813,0.000028538045,0.015770048,0.00025168768],"about_ca_topic_score_codex":0.00018562957,"about_ca_topic_score_gemma":0.0005881487,"teacher_disagreement_score":0.6896297,"about_ca_system_score_codex":0.000020083238,"about_ca_system_score_gemma":0.000083397565,"threshold_uncertainty_score":0.37654158},"labels":[],"label_agreement":null},{"id":"W2028051779","doi":"10.1038/nrurol.2013.137","title":"Overview of the latest treatments for castration-resistant prostate cancer","year":2013,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Castration; Prostate cancer; Medicine; Prostate; Gynecology; Oncology; Cancer; Internal medicine; Hormone","score_opus":0.1454082604368124,"score_gpt":0.471499263090729,"score_spread":0.32609100265391655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028051779","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006839656,0.98393697,2.9265348e-7,0.0012054292,0.0004697995,0.013491294,0.00048669378,0.000014399214,0.00038826244],"genre_scores_gemma":[0.0000071607224,0.9871313,0.00012757626,0.00028790784,0.00023067005,0.0057753944,0.0003966369,0.00006658153,0.0059767636],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974374,0.00035266037,0.0009629286,0.00053547835,0.0002561999,0.00045532972],"domain_scores_gemma":[0.99780136,0.00022692431,0.0008394135,0.0007581829,0.00025285623,0.00012123248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033557694,0.0005327929,0.0030259828,0.00012749122,0.00009680742,0.000013698063,0.00030707015,0.00086790335,0.0002257911],"category_scores_gemma":[0.00018115845,0.00023558078,0.0012181269,0.0004896949,0.00015674488,0.000042095748,0.000079352576,0.00094668515,0.000045487363],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007765981,0.00013941723,0.000048529513,0.053963106,0.00088094606,0.000008569262,0.00002337064,8.18686e-8,0.000010767147,0.00013029117,0.010685136,0.93403214],"study_design_scores_gemma":[0.00090956513,0.00041312387,0.000054522294,0.011664834,0.005960588,0.000053119733,0.000001012063,8.3697626e-7,0.000007847077,0.00005297276,0.9807215,0.0001601105],"about_ca_topic_score_codex":0.000043176842,"about_ca_topic_score_gemma":0.00004288838,"teacher_disagreement_score":0.9700363,"about_ca_system_score_codex":0.00028072562,"about_ca_system_score_gemma":0.0010784819,"threshold_uncertainty_score":0.96067053},"labels":[],"label_agreement":null},{"id":"W2028101771","doi":"10.5489/cuaj.175","title":"Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy.","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Transsexual; Transgender; Incidence (geometry); Cancer; Prostate; Estrogen therapy; Hormonal therapy; Disease; Hormone therapy; Estrogen; Oncology; Gynecology; Breast cancer; Internal medicine; Psychology","score_opus":0.0247656976725592,"score_gpt":0.2920200290660006,"score_spread":0.2672543313934414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028101771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777287,0.0050291144,0.000004219043,0.016373843,0.000091050584,0.0005674129,0.00006077789,0.0000068747963,0.00013799424],"genre_scores_gemma":[0.9967869,0.0016998994,0.00009960104,0.000825761,0.000102316946,0.00020372572,0.000009649106,0.0000116026995,0.0002605604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858636,0.00011769926,0.00032597547,0.0001451899,0.0003278947,0.0004968817],"domain_scores_gemma":[0.9989459,0.00014879376,0.0001253987,0.00007013099,0.00023917214,0.00047059095],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034937833,0.0001198724,0.00028909146,0.00022532484,0.000059619528,0.0000436359,0.000082549544,0.00010752427,0.0025133297],"category_scores_gemma":[0.00015626133,0.00007993495,0.00009526583,0.00026288774,0.000051450308,0.0001255709,0.000005279717,0.00040210792,0.000022749828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018969022,0.00008356331,0.9793234,0.0000094112265,0.00016824524,0.00023118155,0.00040684667,0.000021885178,0.00030387403,0.000010676499,0.00054472906,0.018706502],"study_design_scores_gemma":[0.0028866697,0.0004183858,0.9932615,0.000027763144,0.00003446617,0.000019169209,0.00009891483,0.00006307725,0.00016159084,0.00085049,0.0020965145,0.00008147234],"about_ca_topic_score_codex":0.00782288,"about_ca_topic_score_gemma":0.009908852,"teacher_disagreement_score":0.019058172,"about_ca_system_score_codex":0.00070483313,"about_ca_system_score_gemma":0.00092732377,"threshold_uncertainty_score":0.9987841},"labels":[],"label_agreement":null},{"id":"W2028853380","doi":"10.1158/0008-5472.can-04-0788","title":"A Synthetic 15-mer Peptide (PCK3145) Derived from Prostate Secretory Protein Can Reduce Tumor Growth, Experimental Skeletal Metastases, and Malignancy-Associated Hypercalcemia","year":2004,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Prostate cancer; Medicine; Prostate; In vivo; Malignancy; Syngenic; Endocrinology; Cancer; Internal medicine; Pathology; Biology; Transplantation","score_opus":0.044433615377309395,"score_gpt":0.35654409205703275,"score_spread":0.31211047667972336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028853380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764061,0.015744958,0.0000030742003,0.0033285862,0.00009986907,0.0030734604,0.0006023563,0.00011637305,0.0006252355],"genre_scores_gemma":[0.9928399,0.000826183,0.00027367656,0.00017248919,0.00022910621,0.0025805435,0.00029100795,0.0001246724,0.002662436],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9952154,0.00041350874,0.00042781633,0.0010916166,0.0014322818,0.00141937],"domain_scores_gemma":[0.99786663,0.00012629553,0.00009720108,0.0005268828,0.0005891135,0.0007938866],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007105475,0.00042777025,0.0006551727,0.00035399487,0.0005339293,0.00013225203,0.00027651887,0.00016041285,0.00074569305],"category_scores_gemma":[0.00032299227,0.0003503889,0.00015368989,0.0006938295,0.0011402083,0.00020043437,0.00029277446,0.0010142626,0.000069200105],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017791437,0.0006140724,0.0023246922,0.00024041923,0.00048338083,0.0013579566,0.0022928887,0.0000031865386,0.9888726,0.000088556524,0.0008566317,0.0010865116],"study_design_scores_gemma":[0.009452819,0.001415466,0.005599084,0.0016961308,0.00011668165,0.00006232601,0.0022226516,0.000015576737,0.9776214,0.00063628523,0.0007080083,0.0004535746],"about_ca_topic_score_codex":0.01156002,"about_ca_topic_score_gemma":0.0005077497,"teacher_disagreement_score":0.016433798,"about_ca_system_score_codex":0.0023667885,"about_ca_system_score_gemma":0.002392431,"threshold_uncertainty_score":0.9998948},"labels":[],"label_agreement":null},{"id":"W2028958736","doi":"10.1074/jbc.m702099200","title":"Androgen Receptor Regulation of the Versican Gene through an Androgen Response Element in the Proximal Promoter","year":2007,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Versican; LNCaP; Androgen receptor; Dihydrotestosterone; Chemistry; Molecular biology; Biology; Cancer research; Prostate cancer; Cell biology; Androgen; Endocrinology; Proteoglycan; Cancer; Extracellular matrix; Genetics","score_opus":0.048395228257678176,"score_gpt":0.33361369336421326,"score_spread":0.2852184651065351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028958736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997019,0.00033549013,0.0000091949205,0.0020781076,0.000022382676,0.00024053962,0.0000071400473,0.0000025531674,0.00028560657],"genre_scores_gemma":[0.9991246,0.00009732481,0.00043072595,0.000086780565,0.00016085447,0.0000029441373,0.000009655272,0.0000036702418,0.00008346893],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989812,0.00011539224,0.0003275805,0.000101479294,0.00030338528,0.00017098416],"domain_scores_gemma":[0.9993868,0.00008341707,0.00019202106,0.0001685789,0.00011152437,0.00005764832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014893619,0.000078836165,0.00017275049,0.00001632744,0.000039661576,0.0000063680814,0.00017508565,0.00010076156,0.000111908405],"category_scores_gemma":[0.00014028286,0.00003193064,0.0001013626,0.00016211695,0.00015038638,0.00004920849,0.000032050244,0.00024212236,4.998251e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007152226,0.00034350052,0.04894269,0.000021595495,0.000042849217,0.000036516616,0.00037965906,0.0000010020932,0.94203126,0.000004285482,0.00011354038,0.00093087053],"study_design_scores_gemma":[0.0014930238,0.0009103925,0.08620659,0.000052039013,0.000021911757,0.0001395458,0.00043889772,0.0000040124214,0.9083792,0.00012877767,0.0021864732,0.000039137743],"about_ca_topic_score_codex":0.0000022345116,"about_ca_topic_score_gemma":5.249953e-7,"teacher_disagreement_score":0.0372639,"about_ca_system_score_codex":0.00012916123,"about_ca_system_score_gemma":0.00011990069,"threshold_uncertainty_score":0.13020936},"labels":[],"label_agreement":null},{"id":"W2029659708","doi":"10.1038/aja.2011.108","title":"Quality of life issues in men undergoing androgen deprivation therapy: a review","year":2012,"lang":"en","type":"review","venue":"Asian Journal of Andrology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Androgen deprivation therapy; Medicine; Quality of life (healthcare); Adverse effect; Prostate cancer; Radiation therapy; Hormonal therapy; Depression (economics); Sexual dysfunction; Disease; Hormone therapy; Oncology; Androgen; Internal medicine; Hormone; Cancer; Breast cancer","score_opus":0.15230930846010884,"score_gpt":0.4519817460750563,"score_spread":0.29967243761494744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029659708","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023982112,0.9957565,0.000008050048,0.0021756997,0.00007674845,0.0005894927,0.000004598768,0.0000030437893,0.001146037],"genre_scores_gemma":[0.0011983739,0.99820536,0.0001132789,0.00013184016,0.0001894017,0.000011637246,0.00002678301,0.000022038364,0.00010126337],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99736416,0.00065357366,0.0013137651,0.00013622236,0.00027754024,0.00025471108],"domain_scores_gemma":[0.9981609,0.00015478673,0.0011401982,0.00021765447,0.00015999805,0.00016643794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017278139,0.00020161299,0.0026003716,0.00033261278,0.000018736579,0.00000422155,0.00015694095,0.00022136062,0.00016783977],"category_scores_gemma":[0.00024116297,0.00012432227,0.000427188,0.00029127838,0.00008170891,0.00008719127,0.000030297548,0.00047112102,0.000007346291],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021868736,0.00017547006,0.004939461,0.030108307,0.0007026518,0.00006148786,0.00015739542,2.3505827e-8,0.0000027108752,0.000038815837,0.00040945696,0.96318555],"study_design_scores_gemma":[0.0030955558,0.0012079815,0.0015288601,0.038896613,0.00074926944,0.00052068394,0.000055397923,1.1115516e-7,0.0000075156736,0.00015794842,0.9536312,0.00014881839],"about_ca_topic_score_codex":0.000009886849,"about_ca_topic_score_gemma":0.000006769398,"teacher_disagreement_score":0.9630367,"about_ca_system_score_codex":0.00011202444,"about_ca_system_score_gemma":0.001030362,"threshold_uncertainty_score":0.5069715},"labels":[],"label_agreement":null},{"id":"W2029964158","doi":"10.1016/j.urology.2009.07.382","title":"UP-2.163: Outcomes of Brachytherapy as Monotherapy for Clinically Localized Intermediate-Risk Prostate Cancer: An Analysis of 95 Consecutive Patients","year":2009,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Brachytherapy; Prostate cancer; Prostate; Urology; Cancer; Oncology; Prostate brachytherapy; Internal medicine; Radiation therapy","score_opus":0.020797369978131423,"score_gpt":0.39146729997960056,"score_spread":0.37066993000146914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029964158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959833,0.0008891297,0.00027148164,0.0011065542,0.00013955835,0.0011414156,0.00039372453,0.000023062095,0.000051799514],"genre_scores_gemma":[0.9928204,0.004742288,0.00016586728,0.001593487,0.000027835542,0.00010158612,0.00028206024,0.000018389026,0.00024813204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821717,0.00017118042,0.00071677245,0.000355823,0.00021299762,0.00032603886],"domain_scores_gemma":[0.99817085,0.00043590026,0.0004578424,0.0003352294,0.00046015182,0.0001400211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031061756,0.00018106173,0.0010311131,0.00029083062,0.000038079175,0.0000042865777,0.00013412854,0.00015913688,0.00015390026],"category_scores_gemma":[0.00021499798,0.00012736417,0.00033583166,0.00033753648,0.00032394455,0.00004935986,0.000014115416,0.00015616944,0.0000019251836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025710285,0.00093890756,0.9083099,0.000018126795,0.0033339278,0.0000054999164,0.0019957845,0.000094289855,0.0004176486,0.00005391039,0.00013069222,0.058991063],"study_design_scores_gemma":[0.026141437,0.029459339,0.9325257,0.000014821513,0.002324327,8.630422e-7,0.00018247863,0.003891558,0.0026237273,0.0011013206,0.0015511503,0.0001832624],"about_ca_topic_score_codex":0.00039284182,"about_ca_topic_score_gemma":0.00012245434,"teacher_disagreement_score":0.0588078,"about_ca_system_score_codex":0.000052535423,"about_ca_system_score_gemma":0.00024461024,"threshold_uncertainty_score":0.519376},"labels":[],"label_agreement":null},{"id":"W2030196700","doi":"10.1200/jco.2005.03.2557","title":"Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice?","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Context (archaeology); Prostate cancer; Disease; Androgen deprivation therapy; Intensive care medicine; Quality of life (healthcare); Androgen suppression; Prostate-specific antigen; Oncology; Cancer; Internal medicine","score_opus":0.6002203921010725,"score_gpt":0.658352061162411,"score_spread":0.05813166906133849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030196700","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012684521,0.977103,0.00002349227,0.016525887,0.0018096612,0.0010031435,0.000008272596,0.0000110377,0.002247081],"genre_scores_gemma":[0.0003615396,0.9890169,0.0026593693,0.00229013,0.004849601,0.000021789483,0.000044861587,0.00005096183,0.000704845],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98674047,0.002743799,0.008795745,0.00044451747,0.0008467344,0.00042871357],"domain_scores_gemma":[0.981343,0.011399328,0.0055385893,0.000405545,0.0006630978,0.00065049715],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.01654809,0.0003581142,0.007105548,0.00045974285,0.000029007862,0.00002063026,0.00038643152,0.0018783868,0.00019933615],"category_scores_gemma":[0.021924606,0.00021477147,0.0023433845,0.0003738455,0.00029556276,0.00021920682,0.00017939559,0.005455555,0.00006070516],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023295928,0.0038155108,0.0077186655,0.0007195412,0.0012689586,0.00361585,0.000028126642,3.3582657e-7,4.6513094e-8,0.000023504557,0.004897642,0.97558224],"study_design_scores_gemma":[0.010366219,0.008980678,0.003409205,0.0048610615,0.003114885,0.0016009514,0.000042414693,0.000009331905,2.3358358e-7,0.000024365385,0.967429,0.000161692],"about_ca_topic_score_codex":0.000010357264,"about_ca_topic_score_gemma":0.000034982204,"teacher_disagreement_score":0.97542053,"about_ca_system_score_codex":0.000959449,"about_ca_system_score_gemma":0.008325896,"threshold_uncertainty_score":0.99941736},"labels":[],"label_agreement":null},{"id":"W2030390619","doi":"10.1016/j.ijrobp.2013.06.323","title":"Validation of a Genomic Classifier That Predicts Metastatic Disease Progression in Men With Biochemical Recurrence Post-Radical Prostatectomy","year":2013,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Biochemical recurrence; breakpoint cluster region; Internal medicine; Proportional hazards model; Metastasis; Cohort; Oncology; Context (archaeology); Cancer","score_opus":0.029245140970823476,"score_gpt":0.35528122216067565,"score_spread":0.32603608118985217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030390619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927188,0.00067870476,0.0007010489,0.004518428,0.00022684726,0.0008643801,0.000057744393,0.000014460899,0.00021958501],"genre_scores_gemma":[0.9965876,0.0005286905,0.0020706085,0.00012790285,0.00027508909,0.00008687299,0.0002675108,0.000019297688,0.000036453715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982958,0.00021200745,0.00057774415,0.0002268116,0.00045519863,0.00023248348],"domain_scores_gemma":[0.9978844,0.00021976331,0.00070197234,0.00012706628,0.00084551494,0.0002213115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003706548,0.00016832407,0.00040214328,0.00024485457,0.000030154119,0.000022542017,0.00023043752,0.0000957838,0.00008881371],"category_scores_gemma":[0.0002095566,0.00011292718,0.000109234395,0.00017282879,0.000341572,0.00033707303,0.000051972434,0.0004053624,0.00001479065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059649125,0.0018219162,0.8399783,0.00009753313,0.0007281636,0.00018092204,0.00066916976,0.00013241496,0.06845582,0.0006255782,0.0011536202,0.08019169],"study_design_scores_gemma":[0.038556416,0.0080352295,0.7939851,0.0013530735,0.0005302114,0.0004146138,0.0004631642,0.008916123,0.13401423,0.010793364,0.0024442368,0.0004942166],"about_ca_topic_score_codex":0.000017858307,"about_ca_topic_score_gemma":5.4582625e-7,"teacher_disagreement_score":0.079697475,"about_ca_system_score_codex":0.00064895954,"about_ca_system_score_gemma":0.0011733869,"threshold_uncertainty_score":0.46050367},"labels":[],"label_agreement":null},{"id":"W2030714208","doi":"10.1038/pcan.2014.24","title":"An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study","year":2014,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Bicalutamide; Medicine; Discontinuation; Antiandrogen; Urology; Prostate cancer; Clinical endpoint; Androgen; Internal medicine; Androgen deprivation therapy; Goserelin; Randomized controlled trial; Cancer; Androgen receptor; Hormone","score_opus":0.06466855488777716,"score_gpt":0.4243131971048261,"score_spread":0.35964464221704895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030714208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987459,0.0013439554,0.000008915958,0.0022079858,0.000039998205,0.0077127367,0.00081507926,0.000016969518,0.00039537103],"genre_scores_gemma":[0.99666345,0.0004257363,0.00023415782,0.00015632626,0.000069275666,0.0017635731,0.0002920926,0.000034564993,0.00036083855],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9972876,0.00047968433,0.00045420436,0.00070268015,0.00050479674,0.0005710371],"domain_scores_gemma":[0.9980275,0.0002919048,0.00009903621,0.00036157292,0.00033489632,0.0008850792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007626451,0.0002303506,0.00053708715,0.00041423822,0.00021200706,0.00016641087,0.00013858627,0.000064905944,0.00004976556],"category_scores_gemma":[0.00020339651,0.00017479854,0.0000117760455,0.00051853847,0.00035813937,0.00031154286,0.00006874261,0.0002204109,0.000001478391],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5083429,0.0064403145,0.40201285,0.00056535896,0.00031985962,0.00030140983,0.014946331,0.000028718247,0.0067690983,0.00021958236,0.0008383781,0.05921514],"study_design_scores_gemma":[0.37014472,0.045979775,0.5692475,0.00058705435,0.00057243294,0.0000060551724,0.0060709873,0.0018044583,0.00066219456,0.0024890194,0.0018418954,0.00059395324],"about_ca_topic_score_codex":0.07609087,"about_ca_topic_score_gemma":0.14570935,"teacher_disagreement_score":0.1672346,"about_ca_system_score_codex":0.00022643476,"about_ca_system_score_gemma":0.0015141724,"threshold_uncertainty_score":0.9300615},"labels":[],"label_agreement":null},{"id":"W2030924837","doi":"10.1016/j.bbagrm.2014.05.020","title":"Androgens and mammalian male reproductive tract development","year":2014,"lang":"en","type":"review","venue":"Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Japan Society for the Promotion of Science","keywords":"Androgen receptor; Paracrine signalling; Biology; Androgen; Epididymis; Context (archaeology); Morphogenesis; Cell biology; Endocrinology; Sexual differentiation; Internal medicine; Receptor; Prostate cancer; Genetics; Medicine; Hormone; Gene; Sperm","score_opus":0.04420181436308417,"score_gpt":0.32574926164117046,"score_spread":0.2815474472780863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030924837","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.111781254,0.8827097,0.00007666902,0.00047516485,0.00046229878,0.0035671957,0.00019925735,0.00021410348,0.00051438645],"genre_scores_gemma":[0.011998661,0.9749244,0.004220963,0.00012651578,0.00075559196,0.0005026471,0.0011883648,0.00030907043,0.005973779],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948998,0.00034675538,0.00097311253,0.0020152135,0.000847454,0.0009176514],"domain_scores_gemma":[0.99691975,0.00008833295,0.0006106389,0.0015734449,0.00017821706,0.0006296437],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00074185664,0.0011789018,0.002802108,0.0004952385,0.00031331353,0.00010471658,0.00038902453,0.0006868268,0.00010814386],"category_scores_gemma":[0.000040523628,0.00089819107,0.0007088527,0.0005125316,0.00029470306,0.00012430288,0.0003484773,0.00069365825,0.00015758583],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004879115,0.0016676453,4.4391018e-7,0.026219033,0.004003901,0.00048576016,0.00090221775,1.3127195e-7,0.22108139,0.0012514082,0.002847987,0.74105215],"study_design_scores_gemma":[0.0013683753,0.0007743288,0.00013993008,0.005314959,0.0023993147,0.001062661,0.00004685944,0.000003795707,0.7771756,0.00023137973,0.21021958,0.0012632363],"about_ca_topic_score_codex":0.000006462558,"about_ca_topic_score_gemma":0.0000012260957,"teacher_disagreement_score":0.73978895,"about_ca_system_score_codex":0.0005082164,"about_ca_system_score_gemma":0.0013213959,"threshold_uncertainty_score":0.99934685},"labels":[],"label_agreement":null},{"id":"W2031119737","doi":"10.1016/j.ijpharm.2014.05.021","title":"Docetaxel–carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer","year":2014,"lang":"en","type":"article","venue":"International Journal of Pharmaceutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto Metropolitan University; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; National Institutes of Health; National Cancer Institute; Ontario Ministry of Economic Development and Innovation","keywords":"Docetaxel; Prostate cancer; Medicine; Cancer; Pharmacology; Drug; Drug delivery; Drug resistance; Oncology; Androgen deprivation therapy; Internal medicine; Cancer research; Biology; Nanotechnology; Materials science","score_opus":0.0493984479314545,"score_gpt":0.398848460667952,"score_spread":0.3494500127364975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031119737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962917,0.0009352121,0.00029645677,0.0015500664,0.0004005977,0.00021873935,0.00004570251,0.0000057336542,0.00025579194],"genre_scores_gemma":[0.99770427,0.0014876344,0.00033119155,0.00009388035,0.00020564815,0.000010443264,0.000004834792,0.000015640231,0.00014647843],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99830914,0.000089489484,0.00051889796,0.00013630957,0.00073502003,0.00021111841],"domain_scores_gemma":[0.998537,0.00010714358,0.00039952062,0.0000964282,0.00071726006,0.00014266076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004847594,0.00013381495,0.00032460075,0.00025842685,0.000022329352,0.000023807632,0.00018270552,0.000033323733,0.00006226446],"category_scores_gemma":[0.00007078833,0.00010185636,0.00013043123,0.00016703829,0.00009991002,0.00027422304,0.000044542332,0.00029046743,0.0000016875078],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029020307,0.0006057492,0.008504645,0.00009298856,0.00033263874,0.00016907262,0.00045144648,0.0047986954,0.9732468,0.0001336563,0.000015683478,0.008746559],"study_design_scores_gemma":[0.0057565207,0.00024789426,0.010984378,0.00032270368,0.00010397064,0.000040164727,0.00005795285,0.017844332,0.96389365,0.00032640612,0.00033290542,0.00008913673],"about_ca_topic_score_codex":0.00008541535,"about_ca_topic_score_gemma":0.000037675323,"teacher_disagreement_score":0.013045637,"about_ca_system_score_codex":0.00023438537,"about_ca_system_score_gemma":0.0003305683,"threshold_uncertainty_score":0.4153582},"labels":[],"label_agreement":null},{"id":"W2031338147","doi":"10.1038/nrurol.2014.362","title":"The year chemotherapy finally gets some respect!","year":2015,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Chemotherapy; Medicine; Landmark; Prostate cancer; General surgery; Intensive care medicine; Oncology; Cancer; Internal medicine; Geography; Cartography","score_opus":0.073607739079441,"score_gpt":0.44068925738522846,"score_spread":0.36708151830578745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031338147","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.7734284e-7,0.9865363,5.5692726e-7,0.0043560243,0.00064325257,0.0032851142,0.000020700127,0.00004762872,0.0051099975],"genre_scores_gemma":[2.0909056e-7,0.98377293,0.00008511848,0.0014890721,0.0014713304,0.00042489826,0.00017638487,0.00008884822,0.012491177],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969255,0.0006853816,0.00071716815,0.0006079026,0.00042526505,0.00063880073],"domain_scores_gemma":[0.99778867,0.00030797313,0.00039257287,0.0010892171,0.00018254298,0.0002390092],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0017395214,0.0005367412,0.002925616,0.00017384658,0.00013588267,0.000033185224,0.000531577,0.0014187056,0.000116894946],"category_scores_gemma":[0.00044594135,0.00024248836,0.00087990396,0.0003316321,0.00023025944,0.000037618724,0.00011512894,0.0031452177,0.0010627396],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001233347,0.000042753276,0.0000022004524,0.0044377567,0.00026481398,0.00013129266,0.000013928315,2.4302205e-9,1.449738e-7,0.00040120463,0.08899443,0.90558815],"study_design_scores_gemma":[0.0007763947,0.0004496514,0.0000040863415,0.0021449667,0.00092972536,0.00027900565,0.0000012131109,2.0608609e-7,3.0811972e-7,0.0003755909,0.99484444,0.00019444025],"about_ca_topic_score_codex":0.0000018769981,"about_ca_topic_score_gemma":0.000004960399,"teacher_disagreement_score":0.90585,"about_ca_system_score_codex":0.0003173033,"about_ca_system_score_gemma":0.0012149469,"threshold_uncertainty_score":0.9998777},"labels":[],"label_agreement":null},{"id":"W2031568203","doi":"10.1038/nrurol.2010.141","title":"Intermittent androgen suppression for prostate cancer","year":2010,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Shionogi","keywords":"Medicine; Prostate cancer; Androgen suppression; Oncology; Androgen; Prostate; Cancer; Gynecology; Internal medicine; Urology; Hormone","score_opus":0.05738004604705119,"score_gpt":0.448244273816484,"score_spread":0.3908642277694328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031568203","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000025048464,0.9866136,0.000004487475,0.0011986223,0.0015764056,0.0098914,0.00029023414,0.000046409124,0.00037638735],"genre_scores_gemma":[0.0000016233814,0.98605496,0.00023038991,0.0006695202,0.0009908369,0.0058936607,0.001239255,0.00010952271,0.0048102066],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972443,0.00024935824,0.00081500626,0.0008195957,0.00021767107,0.0006540634],"domain_scores_gemma":[0.9981582,0.00019270554,0.00048019472,0.00071700366,0.00019037847,0.00026147644],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00055925746,0.0006191298,0.0035193944,0.0002747135,0.00009550752,0.000020445797,0.00031692095,0.0021411958,0.00027779263],"category_scores_gemma":[0.0002789683,0.00033261624,0.0012108597,0.00028354788,0.00013398765,0.000041125397,0.00013966994,0.0032290788,0.000099416124],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014944548,0.00007951566,0.000023460843,0.03566806,0.00021575906,0.000049933915,0.000017963166,5.074079e-9,0.000005983887,0.000021825452,0.024819933,0.9389481],"study_design_scores_gemma":[0.0009631423,0.00044231635,0.0000032212354,0.010082959,0.0028852425,0.0003296066,6.5946733e-7,0.0000016560285,0.000010186392,0.000029660287,0.9849871,0.0002642938],"about_ca_topic_score_codex":0.0000039398155,"about_ca_topic_score_gemma":0.000012517509,"teacher_disagreement_score":0.9601671,"about_ca_system_score_codex":0.00017640932,"about_ca_system_score_gemma":0.0007194592,"threshold_uncertainty_score":0.99991256},"labels":[],"label_agreement":null},{"id":"W2031924887","doi":"10.1016/j.eururo.2010.05.017","title":"Re: Effect of Dutasteride on the Risk of Prostate Cancer","year":2010,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Dutasteride; Medicine; Prostate cancer; Placebo; Urology; Prostate; Biopsy; Internal medicine; Prostate biopsy; Prostate-specific antigen; Cancer; Gynecology; Pathology","score_opus":0.016672015792672863,"score_gpt":0.2910840502042073,"score_spread":0.27441203441153444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031924887","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40120906,0.0013297044,6.513601e-7,0.5713972,0.00068024884,0.0013760932,0.00038356122,0.000031940457,0.023591569],"genre_scores_gemma":[0.58635765,0.003799083,0.000021257643,0.3797952,0.004574402,0.00017212844,0.0004727704,0.00033678245,0.02447076],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971809,0.0014689058,0.00032705613,0.00035027118,0.00031071622,0.0003621675],"domain_scores_gemma":[0.99791044,0.0008407792,0.0003688844,0.0007342816,0.00009891632,0.000046675545],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00081414054,0.0002724055,0.0006026777,0.00014571028,0.000047349084,0.000005358894,0.0002677305,0.0003136798,0.00055522297],"category_scores_gemma":[0.00028178756,0.00013432925,0.00019595421,0.0001154104,0.00050551246,0.000010776691,0.000120659504,0.003623515,0.00012682372],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033265508,0.000047456964,0.01787744,0.0006183036,0.0007296001,0.0015165723,0.0003308496,0.0000037290877,0.0026039341,0.0000029582416,0.9666396,0.0063030217],"study_design_scores_gemma":[0.002362272,0.0061305356,0.009365074,0.0001554909,0.00067696866,0.000024692863,0.0000049761097,0.0000064048854,0.011416758,0.000013831327,0.9697038,0.00013920119],"about_ca_topic_score_codex":0.00008587345,"about_ca_topic_score_gemma":0.000010226271,"teacher_disagreement_score":0.19160199,"about_ca_system_score_codex":0.000026714319,"about_ca_system_score_gemma":0.00009376224,"threshold_uncertainty_score":0.99867517},"labels":[],"label_agreement":null},{"id":"W2032001273","doi":"10.1016/j.jsbmb.2014.05.012","title":"Combined blockade of testicular and locally made androgens in prostate cancer: A highly significant medical progress based upon intracrinology","year":2014,"lang":"en","type":"review","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Prostate cancer; Blockade; Medicine; Testicular cancer; Urology; Oncology; Cancer; Internal medicine; Receptor","score_opus":0.014786561152010923,"score_gpt":0.33495480462742266,"score_spread":0.32016824347541173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032001273","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2093019,0.7888076,0.000030660336,0.0012963935,0.00003891218,0.00048355557,0.000031377564,0.0000037443574,0.000005857122],"genre_scores_gemma":[0.1429602,0.85668904,0.000099382545,0.00007447702,0.000063182255,0.00003163659,0.00004370996,0.000021043003,0.000017341372],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99797904,0.00036374413,0.0008153797,0.0002580639,0.0002410512,0.00034269903],"domain_scores_gemma":[0.99857897,0.00019798963,0.0005862293,0.00023387728,0.00016264543,0.0002403066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072258356,0.000316503,0.0015465047,0.00015320569,0.000034974684,0.000007971621,0.00023372164,0.00042501566,0.000012516356],"category_scores_gemma":[0.00015014435,0.00017030539,0.00015352039,0.00016380745,0.0010168134,0.000009144616,0.00012016728,0.0007214437,2.743431e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005054219,0.0009873578,0.0034856868,0.05044291,0.0026535029,0.003861423,0.0001972731,0.0000020294117,0.1519533,0.00003212461,0.00008175513,0.78124845],"study_design_scores_gemma":[0.048087355,0.028434996,0.0005011149,0.124656975,0.015692571,0.02283768,0.00032486627,0.0005508155,0.62900406,0.00039607644,0.1271236,0.0023898864],"about_ca_topic_score_codex":0.000013428276,"about_ca_topic_score_gemma":0.0000012673786,"teacher_disagreement_score":0.77885854,"about_ca_system_score_codex":0.00006596809,"about_ca_system_score_gemma":0.00093172357,"threshold_uncertainty_score":0.69448525},"labels":[],"label_agreement":null},{"id":"W2032266538","doi":"10.1097/mou.0b013e3280dd8a4f","title":"Novel targets and approaches in advanced prostate cancer","year":2007,"lang":"en","type":"review","venue":"Current Opinion in Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Cancer; Oncology; Gynecology; Medical physics; Internal medicine","score_opus":0.2940844525592117,"score_gpt":0.4804178245050336,"score_spread":0.18633337194582195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032266538","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000629215,0.99517417,0.000015575095,0.0002729387,0.002019543,0.0022106988,0.000073362724,0.00002016393,0.00015060931],"genre_scores_gemma":[0.000051244522,0.99782735,0.000081868144,0.000014600699,0.000280943,0.0010361423,0.00054662867,0.000043492102,0.0001177531],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978734,0.000094015995,0.00058965746,0.0006609518,0.00018256862,0.00059940235],"domain_scores_gemma":[0.9992982,0.00013338108,0.00016163554,0.00022933824,0.000034754376,0.00014270369],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035092563,0.00037048192,0.0013538257,0.000723554,0.00002678272,0.0000089377645,0.00010995334,0.00032251742,0.000029507564],"category_scores_gemma":[0.00004873912,0.0002744496,0.000111267,0.0004900033,0.00018593301,0.000051959,0.00012269657,0.0009874481,0.000009951574],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020103426,0.00030009387,0.0023759818,0.022150503,0.000043490512,0.000010716431,0.00014976342,0.000002587055,4.2006403e-7,0.0000739836,0.00015732837,0.9745341],"study_design_scores_gemma":[0.0027233413,0.00021905807,0.0013788901,0.0072547593,0.000067276036,0.000050880466,0.000014274237,0.000033591044,4.5293237e-7,0.000025523339,0.98801297,0.00021899409],"about_ca_topic_score_codex":0.000029141613,"about_ca_topic_score_gemma":0.000022339163,"teacher_disagreement_score":0.9878556,"about_ca_system_score_codex":0.00029729406,"about_ca_system_score_gemma":0.0005143517,"threshold_uncertainty_score":0.9999708},"labels":[],"label_agreement":null},{"id":"W2032565720","doi":"10.1016/j.jval.2014.08.2365","title":"Skeletal-Related Events (SRES) Impact Significantly the Health-Related Quality of Life (HRQOL) of Chemo-Naive Men With Metastatic Castration Resistant Prostate Cancer (MCRPC)","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Asymptomatic; Quality of life (healthcare); Internal medicine; Placebo; Spinal cord compression; Oncology; Surgery; Cancer; Pathology; Spinal cord","score_opus":0.06869137059026577,"score_gpt":0.386963759052084,"score_spread":0.31827238846181827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032565720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98321885,0.0049234773,0.00001703264,0.008359893,0.000053533604,0.00294702,0.00017740001,0.00002673574,0.00027605955],"genre_scores_gemma":[0.99755985,0.0014824508,0.00017217937,0.00012411384,0.00001932053,0.00010775223,0.0001173242,0.000038085494,0.0003789094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99494714,0.0015344805,0.0016342347,0.00039688495,0.00084748474,0.00063979044],"domain_scores_gemma":[0.997264,0.00041547418,0.0011912549,0.0004855738,0.0002706087,0.0003730835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004130503,0.00026091776,0.001050348,0.00021478743,0.00013206663,0.000008657635,0.0001458824,0.00007532648,0.000066099106],"category_scores_gemma":[0.00028157953,0.00014901736,0.00012772005,0.00088816375,0.0002418579,0.00008939863,0.000028594512,0.0004387144,0.000003637857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.070341356,0.0067628473,0.66357017,0.034678277,0.0066282917,0.00008919996,0.09209396,0.045558672,0.03213538,0.0048434306,0.0035955438,0.039702892],"study_design_scores_gemma":[0.022459587,0.011764333,0.94129175,0.0037344794,0.00017115408,0.000019708661,0.0033447866,0.011675039,0.0033124574,0.0017025642,0.00010549395,0.00041865345],"about_ca_topic_score_codex":0.09506013,"about_ca_topic_score_gemma":0.0008305608,"teacher_disagreement_score":0.27772158,"about_ca_system_score_codex":0.00086252793,"about_ca_system_score_gemma":0.0040275874,"threshold_uncertainty_score":0.9109659},"labels":[],"label_agreement":null},{"id":"W2032597933","doi":"10.1038/sj.pcan.4500440","title":"Castration-induced upregulation of insulin-like growth factor binding protein-5 potentiates IGF-1 and accelerates androgen-independent progression in prostate cancer","year":2000,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"","keywords":"Prostate cancer; Medicine; Downregulation and upregulation; Insulin-like growth factor; Internal medicine; Androgen; Endocrinology; Insulin-like growth factor-binding protein; Castration; Prostate; Growth factor; Cancer; Oncology; Cancer research; Hormone; Receptor; Biology","score_opus":0.024295949977459725,"score_gpt":0.3224459150868357,"score_spread":0.29814996510937597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032597933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751389,0.018504346,7.484613e-7,0.0008776968,0.00007519765,0.004343114,0.00093780283,0.000063137595,0.00005903471],"genre_scores_gemma":[0.9828276,0.013664996,0.00013621265,0.000049700575,0.00004964959,0.0017543236,0.00030568347,0.00005739138,0.0011544444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99736094,0.00010261399,0.0006359905,0.00070898974,0.00058493915,0.000606547],"domain_scores_gemma":[0.9988084,0.00006732641,0.00022481021,0.00020395465,0.00030107857,0.00039447582],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015484417,0.00041899565,0.0005862933,0.00028575832,0.00021360253,0.00015269358,0.00008360856,0.00009825641,0.0003470669],"category_scores_gemma":[0.000041674215,0.00032110416,0.0000723651,0.0005065995,0.0002370278,0.0005808802,0.00006124869,0.00023133044,0.0000032655128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049650357,0.00055699924,0.722345,0.0027917286,0.00021816653,0.000110267916,0.0035723825,0.000021469568,0.044537775,0.00002644887,0.00003774568,0.22081698],"study_design_scores_gemma":[0.01599798,0.0019648457,0.79598033,0.004669718,0.00044299522,0.000043913806,0.001142811,0.0011571728,0.17635657,0.001127821,0.0001868531,0.0009290067],"about_ca_topic_score_codex":0.00071764854,"about_ca_topic_score_gemma":0.00013561487,"teacher_disagreement_score":0.21988797,"about_ca_system_score_codex":0.00019707215,"about_ca_system_score_gemma":0.00068535673,"threshold_uncertainty_score":0.9999241},"labels":[],"label_agreement":null},{"id":"W2032762751","doi":"10.1016/j.ijrobp.2011.11.017","title":"Hypoxia, Androgen Deprivation and Systemic Metastases in Prostate Cancer (In Response to “Antivascular Effects of Neoadjuvant Androgen Deprivation for Prostate Cancer: An In Vivo Human Study Using Susceptibility and Relaxitivity Dynamic MRI”: In Regard to Alonzi R et al. (Int J Radiat Oncol Biol Phys 2011;80(3):721–727)","year":2012,"lang":"en","type":"letter","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Androgen; Hypoxia (environmental); Oncology; Internal medicine; Prostate; Cancer; Hormone","score_opus":0.026070081330642536,"score_gpt":0.3731554959382613,"score_spread":0.34708541460761877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032762751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96679676,0.0030470004,0.00018447054,0.022708826,0.0004527706,0.006234416,0.00056217925,0.000012556733,0.0000010028554],"genre_scores_gemma":[0.9904039,0.003521103,0.00055662997,0.0041514174,0.0003266822,0.0007146503,0.00024455698,0.0000671871,0.00001389122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99493957,0.0019121417,0.0014152798,0.0007439136,0.00045721664,0.0005319091],"domain_scores_gemma":[0.99694395,0.00086462375,0.0011200041,0.00028888477,0.00060842774,0.0001741261],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003462603,0.0004502912,0.0013723742,0.0013331245,0.000061214465,0.000039270013,0.00026195296,0.00037209602,0.000006022576],"category_scores_gemma":[0.0004049134,0.00040337112,0.0001418194,0.0004481815,0.00015136084,0.0004980323,0.00014067833,0.0010027834,5.973292e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006488981,0.0010641179,0.8891306,0.00031599324,0.000506339,0.00022451692,0.004063471,0.0015639644,0.07864257,0.0000084980165,0.0005729127,0.017418014],"study_design_scores_gemma":[0.038400974,0.008111672,0.9286089,0.0032951555,0.0004790629,0.00015919872,0.000611895,0.003331811,0.010835191,0.00063265563,0.0046992246,0.0008342594],"about_ca_topic_score_codex":0.00253072,"about_ca_topic_score_gemma":0.0035385862,"teacher_disagreement_score":0.06780738,"about_ca_system_score_codex":0.004344105,"about_ca_system_score_gemma":0.0011377407,"threshold_uncertainty_score":0.9998418},"labels":[],"label_agreement":null},{"id":"W2032949489","doi":"10.1118/1.4815021","title":"SU‐E‐T‐593: Comparison of Three IMRT Adaptive Methods: The Case of Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"Medical Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Prostate; Prostate cancer; Nuclear medicine; Image registration; Gold standard (test); Radiology; Cancer; Computer science; Internal medicine; Artificial intelligence","score_opus":0.09592014586182679,"score_gpt":0.4451405970007423,"score_spread":0.34922045113891553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032949489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771864,0.0056539355,0.00636721,0.0063696466,0.00023692838,0.0017788304,0.000052167034,0.000032854634,0.0023220459],"genre_scores_gemma":[0.9981549,0.00021526255,0.0008135026,0.00012780036,0.00018654575,0.00016696063,0.000011649621,0.000017992546,0.0003053889],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985914,0.00010547988,0.0003319071,0.00017896279,0.0005252695,0.00026698463],"domain_scores_gemma":[0.99865687,0.0003705028,0.00013928596,0.0003072682,0.00032190687,0.0002041622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036966294,0.00013141683,0.00046801235,0.000026321068,0.00005991871,0.0000063951484,0.00014138375,0.00007726744,0.0005285644],"category_scores_gemma":[0.00013448358,0.00006820092,0.00011218412,0.00027782778,0.0006600063,0.000058885398,0.0000951719,0.0003681462,0.000015707881],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004204287,0.00092116004,0.049919263,0.0003929215,0.00058548845,0.00018544336,0.003683739,0.000010832345,0.00218013,0.00088348147,0.0076105036,0.9332066],"study_design_scores_gemma":[0.019261843,0.0060035028,0.051898785,0.002672809,0.0017264936,0.00030662297,0.00986917,0.050882436,0.80435604,0.047116272,0.004964254,0.0009417611],"about_ca_topic_score_codex":0.0037036636,"about_ca_topic_score_gemma":0.00013310001,"teacher_disagreement_score":0.93226486,"about_ca_system_score_codex":0.000061405546,"about_ca_system_score_gemma":0.00039202857,"threshold_uncertainty_score":0.57874095},"labels":[],"label_agreement":null},{"id":"W2032995675","doi":"10.1038/sj.pcan.4500716","title":"Whole-mount prostate sections reveal differential endoglin expression in stromal, epithelial, and endothelial cells with the development of prostate cancer","year":2004,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"McGill University","keywords":"Endoglin; Prostate cancer; Stromal cell; Prostate; Stroma; Intraepithelial neoplasia; Medicine; Pathology; Cancer; Epithelium; Cancer research; Biology; Internal medicine; Immunohistochemistry","score_opus":0.015062955589734191,"score_gpt":0.29029172600732,"score_spread":0.2752287704175858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032995675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824662,0.008295831,0.00003739046,0.0021095437,0.00014309774,0.0039418926,0.0029151856,0.00005498086,0.000035845864],"genre_scores_gemma":[0.98898256,0.0057108803,0.00067330967,0.00011617313,0.00009265998,0.0029389418,0.00018935426,0.00007613369,0.0012199772],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971209,0.00009820678,0.000640382,0.0007306128,0.00065225636,0.00075763307],"domain_scores_gemma":[0.9986655,0.00011570478,0.00027058276,0.00030116088,0.00024703564,0.00039999472],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019103997,0.00052066887,0.0006737197,0.00022898754,0.00040756835,0.00012660683,0.00012575692,0.00007709167,0.00012227555],"category_scores_gemma":[0.000024436782,0.00029255677,0.00007538821,0.00039917242,0.0006748727,0.0002819946,0.00014206658,0.00035140058,0.0000020149025],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028582301,0.0024808422,0.24011745,0.007243186,0.0009351806,0.0003179378,0.071169645,0.0011162673,0.5783078,0.00010342729,0.0005029159,0.06912306],"study_design_scores_gemma":[0.042002555,0.0029560835,0.32371077,0.005997918,0.0009710514,0.00005423347,0.00797412,0.00012846525,0.6081072,0.000909571,0.0058658193,0.0013221903],"about_ca_topic_score_codex":0.00054531154,"about_ca_topic_score_gemma":0.000583992,"teacher_disagreement_score":0.08359332,"about_ca_system_score_codex":0.00037486755,"about_ca_system_score_gemma":0.0016620817,"threshold_uncertainty_score":0.9999527},"labels":[],"label_agreement":null},{"id":"W2033528425","doi":"10.1016/j.ijrobp.2008.06.934","title":"Biochemical Response is More Critical than Total Duration of Neo-adjuvant Hormone Therapy (NAHT) Prior to Radiotherapy for Localized Prostate Cancer: Analysis of the 3 vs 8 Month Data","year":2008,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Adjuvant radiotherapy; Oncology; Adjuvant; Hormone therapy; Prostate; Cancer; Internal medicine; Urology; Gynecology; Breast cancer","score_opus":0.042984528572866124,"score_gpt":0.4067370736128949,"score_spread":0.3637525450400288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033528425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9660009,0.0033275394,0.004660283,0.02382241,0.0004160714,0.0006890616,0.0010667553,0.000010168172,0.000006779089],"genre_scores_gemma":[0.9900842,0.0052623004,0.0028859382,0.0008303857,0.00053418125,0.00004169857,0.00023794275,0.00002272706,0.00010064776],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99795693,0.00024019928,0.0008404693,0.0002761654,0.00046707306,0.00021917751],"domain_scores_gemma":[0.9968232,0.0006710315,0.0006993803,0.00035472683,0.0013209261,0.00013075957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006833167,0.00017421156,0.00070309045,0.0002758049,0.00008380165,0.0000101777605,0.00050339627,0.00016231171,0.00003947474],"category_scores_gemma":[0.0005954137,0.00011462662,0.00034785215,0.0005090117,0.00045363532,0.00017085312,0.00007850483,0.0002390665,7.075097e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11109746,0.0020924218,0.32944667,0.000034927532,0.010619473,0.00004261765,0.007159749,0.0012383101,0.44700235,0.0003655288,0.010382845,0.08051765],"study_design_scores_gemma":[0.0404428,0.012140076,0.6112495,0.00021333531,0.0020204755,0.0002275702,0.00042792878,0.052541964,0.25344753,0.00069006503,0.02611869,0.00048009417],"about_ca_topic_score_codex":0.00006909103,"about_ca_topic_score_gemma":0.0000034363754,"teacher_disagreement_score":0.2818028,"about_ca_system_score_codex":0.00057586335,"about_ca_system_score_gemma":0.0012409401,"threshold_uncertainty_score":0.46743378},"labels":[],"label_agreement":null},{"id":"W2033586061","doi":"10.1158/1538-7445.am2014-ct313","title":"Abstract CT313: An exploratory analysis of efficacy and safety of abiraterone acetate (AA) in black patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (ctx)","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Tolerability; Internal medicine; Placebo; Urology; Docetaxel; Prednisone; Hazard ratio; Gastroenterology; Oncology; Cancer; Androgen deprivation therapy; Adverse effect; Confidence interval; Pathology","score_opus":0.06204232408946977,"score_gpt":0.3943474755229883,"score_spread":0.3323051514335186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033586061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99650335,0.0008905209,0.000008616319,0.00042357133,0.0000202662,0.0018080735,0.00019489933,0.000015035782,0.00013564782],"genre_scores_gemma":[0.99659586,0.0023924266,0.0001765654,0.000036754394,0.0000303658,0.00032008358,0.00009847748,0.000054114407,0.0002953774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99666804,0.00031369936,0.0006179486,0.00060191663,0.0011721723,0.0006262161],"domain_scores_gemma":[0.997797,0.00015623348,0.00023224666,0.0005276014,0.000977061,0.000309872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013267758,0.00026323638,0.00088684843,0.0008688987,0.00010280481,0.000038656075,0.0001814407,0.00007337733,0.000239037],"category_scores_gemma":[0.00006368112,0.0001851672,0.00006966636,0.001724424,0.00082148093,0.0002661995,0.00005184996,0.00040598423,0.0000025050947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042456474,0.002142529,0.7001895,0.0021562884,0.003493853,0.000041457715,0.015634557,0.0018123242,0.17700909,0.00003809655,0.00008897886,0.054936852],"study_design_scores_gemma":[0.017553383,0.0021381534,0.9357511,0.0007048067,0.00044170694,4.439932e-7,0.00097575295,0.0006726142,0.04129255,0.000019396664,0.00022767589,0.00022241368],"about_ca_topic_score_codex":0.002418835,"about_ca_topic_score_gemma":0.005480508,"teacher_disagreement_score":0.23556161,"about_ca_system_score_codex":0.0004254284,"about_ca_system_score_gemma":0.0008683325,"threshold_uncertainty_score":0.75508994},"labels":[],"label_agreement":null},{"id":"W2034017362","doi":"10.1016/j.ucl.2009.11.011","title":"Novel Targeted Therapies for Prostate Cancer","year":2010,"lang":"en","type":"review","venue":"Urologic Clinics of North America","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Signal transduction; Tyrosine kinase; Cancer research; Cabozantinib; Receptor tyrosine kinase; Prostate; Receptor; Bioinformatics; Oncology; Cancer; Internal medicine; Biology; Cell biology","score_opus":0.0958860115552395,"score_gpt":0.4227895161005104,"score_spread":0.3269035045452709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034017362","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024069534,0.9932704,0.000056368346,0.00046207957,0.00042454194,0.003476448,0.0018961745,0.00006091144,0.00011240764],"genre_scores_gemma":[0.000027948478,0.99211,0.0027151112,0.0003725745,0.0003034213,0.0013692373,0.0014805192,0.000077144425,0.001544001],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976218,0.000052661915,0.00090666476,0.0005946558,0.00029562897,0.00052862987],"domain_scores_gemma":[0.99722236,0.0007462079,0.0008993542,0.0005912698,0.00035473966,0.00018609194],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023677586,0.00045973202,0.0024888378,0.00019850006,0.00008302899,0.000012221062,0.00031710454,0.00037043195,0.00013030262],"category_scores_gemma":[0.0003633136,0.00027874287,0.00090304477,0.0004159379,0.00051585876,0.000030197878,0.00009380197,0.0008877224,0.000019387522],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035796507,0.00035924776,0.0017805875,0.005507663,0.0006852016,0.000009936126,0.00005999887,0.0000011005926,0.0000014771364,0.000002168075,0.0007272522,0.9905074],"study_design_scores_gemma":[0.0012724778,0.0019364815,0.0003212268,0.0008104556,0.0014087463,0.000009011989,0.000007515571,0.000016542872,8.161581e-7,0.000022243103,0.9939482,0.0002462334],"about_ca_topic_score_codex":0.000060339913,"about_ca_topic_score_gemma":0.000038847105,"teacher_disagreement_score":0.993221,"about_ca_system_score_codex":0.00005509645,"about_ca_system_score_gemma":0.0012774051,"threshold_uncertainty_score":0.9999665},"labels":[],"label_agreement":null},{"id":"W2034254687","doi":"10.1016/j.juro.2011.07.035","title":"Gonadotropin-Releasing Hormone Blockers and Cardiovascular Disease Risk: Analysis of Prospective Clinical Trials of Degarelix","year":2011,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Clinical trial; Prostate cancer; Disease; Gynecology; Family medicine; Prospective cohort study; Internal medicine; Cancer","score_opus":0.1153575137765118,"score_gpt":0.38919551849426115,"score_spread":0.27383800471774933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034254687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9546118,0.04432112,0.00034728827,0.0003272514,0.00005766345,0.00024562777,0.000019620804,0.0000021773362,0.00006748179],"genre_scores_gemma":[0.97094935,0.028694674,0.00022062541,0.000022336479,0.0000872104,0.000001596888,0.0000011499469,0.0000075781127,0.00001546405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970881,0.0014307522,0.00092827145,0.00010983956,0.00029603633,0.00014703484],"domain_scores_gemma":[0.99780506,0.0006786264,0.0007066136,0.00028430464,0.00035419545,0.00017118629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047157663,0.00008965908,0.001246314,0.0002794206,0.000038934657,0.0000017118962,0.00010397559,0.000068412286,0.0000378474],"category_scores_gemma":[0.0016471165,0.000046402845,0.00086404115,0.00029823303,0.00048353948,0.000030000003,0.000041307132,0.00032370715,4.4415532e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04201799,0.0005515942,0.8764903,0.000038618364,0.0625136,0.00017715621,0.0014413177,0.00015991268,0.001133526,0.000043965367,0.00019758014,0.015234444],"study_design_scores_gemma":[0.0043371767,0.00270712,0.95332897,0.000015606243,0.038331874,0.00004301244,0.0001722902,0.00024433745,0.00035572247,0.00032437127,0.000099971294,0.000039530336],"about_ca_topic_score_codex":0.0001659113,"about_ca_topic_score_gemma":0.000003007685,"teacher_disagreement_score":0.076838695,"about_ca_system_score_codex":0.000021953874,"about_ca_system_score_gemma":0.00019269358,"threshold_uncertainty_score":0.19718713},"labels":[],"label_agreement":null},{"id":"W2035211602","doi":"10.1002/pon.1794","title":"A description of heterosexual couples' sexual adjustment to androgen deprivation therapy for prostate cancer","year":2010,"lang":"en","type":"article","venue":"Psycho-Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Androgen deprivation therapy; Testosterone (patch); Prostate cancer; Sex therapy; Psychology; Sexual function; Androgen; Clinical psychology; Developmental psychology; Medicine; Sexual dysfunction; Cancer; Internal medicine; Hormone; Psychiatry; Psychoanalysis","score_opus":0.07069864708614683,"score_gpt":0.40884507505139334,"score_spread":0.3381464279652465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035211602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910162,0.0011292008,0.0003706301,0.0033587443,0.0009805971,0.0028052686,0.00009449899,0.000034588633,0.0002102708],"genre_scores_gemma":[0.99184996,0.0009736931,0.0026167028,0.0007530861,0.00046771413,0.0019663076,0.00015359631,0.000032775442,0.0011861933],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881417,0.000032099597,0.00028171524,0.0003317499,0.00020502575,0.00033523518],"domain_scores_gemma":[0.99912935,0.00006427081,0.00010609459,0.00024286797,0.00027566895,0.00018171893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026672008,0.00014285342,0.00031750472,0.00014300946,0.000060492515,0.000008654475,0.00008770073,0.0001584491,0.0001602601],"category_scores_gemma":[0.000032476237,0.000108870365,0.00005286217,0.00017675753,0.00009186909,0.00006261221,0.000021585549,0.00017433196,0.000011543193],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066851107,0.0007582395,0.047448456,0.00007136719,0.00015831011,0.0000038701496,0.004197727,0.0000054071315,0.66862774,0.000038304748,0.0036589322,0.26834655],"study_design_scores_gemma":[0.04466336,0.033934508,0.20562972,0.00008782757,0.00019727476,0.000084274056,0.0037872754,0.0006914014,0.29113457,0.00075878575,0.4184642,0.0005668001],"about_ca_topic_score_codex":0.00016223376,"about_ca_topic_score_gemma":0.0003738003,"teacher_disagreement_score":0.41480526,"about_ca_system_score_codex":0.00024075122,"about_ca_system_score_gemma":0.00037650418,"threshold_uncertainty_score":0.4439605},"labels":[],"label_agreement":null},{"id":"W2036449946","doi":"10.1016/j.eururo.2013.08.007","title":"Initial Biopsy Gleason Score as a Predictive Marker for Survival Benefit in Patients with Castration-resistant Prostate Cancer Treated with Docetaxel: Data from the TAX327 Study","year":2013,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Mitoxantrone; Oncology; Internal medicine; Cabazitaxel; Prednisone; Cancer; Androgen deprivation therapy; Urology; Chemotherapy","score_opus":0.042908328178824236,"score_gpt":0.30756362990908587,"score_spread":0.26465530173026164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036449946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917955,0.00025831434,0.000006690773,0.0009681831,0.000065432585,0.004685041,0.0012328349,0.000038127142,0.00094990496],"genre_scores_gemma":[0.9969375,0.000027300628,0.0000501678,0.00016862324,0.00013765354,0.00037828548,0.0017877085,0.00006526992,0.00044749898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981384,0.00025713723,0.00025181362,0.0006191933,0.0003261501,0.00040729754],"domain_scores_gemma":[0.9986623,0.00017692056,0.00012006401,0.0006260623,0.00029773422,0.0001169512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024513763,0.0002408661,0.00030086059,0.000071683404,0.0001247307,0.00005371568,0.00027386248,0.000037250025,0.00022053512],"category_scores_gemma":[0.00006488798,0.00012325327,0.00002109918,0.00023129518,0.00020123489,0.0001733504,0.00013137417,0.00024171753,0.00003905099],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03219991,0.00077935535,0.9635478,0.000014334342,0.0004983615,0.00021794619,0.0008250923,0.000019243047,0.000115155075,0.0000036286503,0.00043550407,0.0013436342],"study_design_scores_gemma":[0.01581347,0.00933032,0.9733714,0.0000675134,0.00025324392,0.0000042132956,0.00047154547,0.0001485616,0.000028188455,0.000008902635,0.00036846634,0.00013418104],"about_ca_topic_score_codex":0.0038540475,"about_ca_topic_score_gemma":0.0025842797,"teacher_disagreement_score":0.016386444,"about_ca_system_score_codex":0.000073891184,"about_ca_system_score_gemma":0.00019118443,"threshold_uncertainty_score":0.58261925},"labels":[],"label_agreement":null},{"id":"W2036993107","doi":"10.1016/j.clon.2013.04.002","title":"The Future of Systemic Therapies for Localised Prostate Cancer","year":2013,"lang":"en","type":"review","venue":"Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Clinical trial; Systemic therapy; Disease; Radiation therapy; Cancer; Intensive care medicine; Prostate; Oncology; Internal medicine; Breast cancer","score_opus":0.20340969228134104,"score_gpt":0.5488737614692857,"score_spread":0.34546406918794464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036993107","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006936816,0.988693,0.0000029694343,0.0025091218,0.0020990418,0.0062589506,0.000115287396,0.0000232654,0.00022900343],"genre_scores_gemma":[0.000022049027,0.98457533,0.00009005753,0.00013716768,0.002282722,0.004173266,0.00010660451,0.00005473341,0.008558063],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969941,0.0005259448,0.001481956,0.0003946874,0.00019158718,0.00041172502],"domain_scores_gemma":[0.9943209,0.0037684506,0.00082039495,0.00048725787,0.0004215387,0.00018140327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012205337,0.00028826683,0.0030699528,0.000059232214,0.00010284302,0.000012767963,0.00029319897,0.0008453204,0.000073493866],"category_scores_gemma":[0.00021606655,0.00012172526,0.001016722,0.00016483615,0.00068884,0.000025099454,0.00007556117,0.00070700166,0.000042295665],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045812165,0.00017364931,0.00009138584,0.014698135,0.001255487,0.000011996569,0.0000674843,2.8853398e-8,4.007321e-7,0.00017353482,0.017079344,0.9659904],"study_design_scores_gemma":[0.0024340656,0.0021528734,0.000022262417,0.006631311,0.0014863301,0.000025609123,0.00020031775,0.0000024895432,5.661281e-7,0.000086767424,0.9868441,0.00011327809],"about_ca_topic_score_codex":0.000018306493,"about_ca_topic_score_gemma":0.000021356072,"teacher_disagreement_score":0.96976477,"about_ca_system_score_codex":0.0003372682,"about_ca_system_score_gemma":0.0039224876,"threshold_uncertainty_score":0.69583243},"labels":[],"label_agreement":null},{"id":"W2037353977","doi":"10.1016/j.eururo.2013.05.052","title":"Prime Time for Intermittent Androgen Suppression","year":2013,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Androgen deprivation therapy; Enzalutamide; Prostate cancer; Oncology; Androgen; Internal medicine; Androgen suppression; Radiation therapy; Androgen receptor; Cancer; Hormone","score_opus":0.026163918867318173,"score_gpt":0.28912788412625606,"score_spread":0.2629639652589379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037353977","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004274426,0.0018786427,0.000077956305,0.9458087,0.00078422844,0.0025231964,0.00013585734,0.00018521085,0.044331804],"genre_scores_gemma":[0.0027544056,0.00018684824,0.0002749852,0.6850959,0.007507146,0.000178458,0.0044965185,0.00028736002,0.2992184],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981568,0.00029229955,0.0002668288,0.00052468217,0.00019121508,0.0005682127],"domain_scores_gemma":[0.9990091,0.00013645933,0.000109586304,0.000509969,0.00012388342,0.00011104645],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00018276241,0.00028616918,0.00046086486,0.00017401346,0.00006522505,0.000025034096,0.0002390236,0.00031491768,0.0014528243],"category_scores_gemma":[0.00006432863,0.00019827999,0.00020568361,0.000046602534,0.000142928,0.000030893392,0.0001902437,0.00096608576,0.0044743097],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026241178,0.000042535183,0.00009519854,0.00011805176,0.00020172713,0.0015569929,0.00005033492,7.880736e-8,0.001716007,8.735283e-7,0.9874813,0.008474483],"study_design_scores_gemma":[0.0019851464,0.0014126606,0.00056815706,0.000050745046,0.0001964035,0.00021561793,0.0000012492858,0.000055233002,0.0006827488,0.000024723793,0.99463683,0.00017050744],"about_ca_topic_score_codex":0.0000035165629,"about_ca_topic_score_gemma":6.592143e-8,"teacher_disagreement_score":0.2607128,"about_ca_system_score_codex":0.00006604309,"about_ca_system_score_gemma":0.00008443906,"threshold_uncertainty_score":0.99946},"labels":[],"label_agreement":null},{"id":"W2037416732","doi":"10.3747/co.19.1298","title":"Androgen Deprivation Therapy in Advanced Prostate Cancer: Is Intermittent Therapy the New Standard of Care?","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Hormonal therapy; Quality of life (healthcare); Oncology; Internal medicine; Sexual function; Clinical trial; Cancer","score_opus":0.09249469185958584,"score_gpt":0.44947695139019717,"score_spread":0.35698225953061136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037416732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86968935,0.123973556,0.000013330283,0.004261452,0.00056440453,0.0012230441,0.000024469562,0.000013789021,0.00023659962],"genre_scores_gemma":[0.91873115,0.08041579,0.000053419502,0.00019045178,0.00019050053,0.00021677007,0.000035478846,0.000015509413,0.00015093222],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99891794,0.0000884064,0.0002540781,0.00017199117,0.00022393468,0.0003436618],"domain_scores_gemma":[0.9993457,0.000058080754,0.000112411086,0.00021887156,0.00015404343,0.00011089664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019250807,0.0001316897,0.00032723308,0.00009821963,0.000040605282,0.00000510402,0.000107055945,0.00006350131,0.00016035954],"category_scores_gemma":[0.000016769996,0.00007496227,0.00007594272,0.00022228656,0.00010722483,0.00008482689,0.000037484493,0.00021926913,0.0000047881863],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030990446,0.0002021947,0.34430623,0.000033643522,0.00004666313,0.0000016171489,0.009824789,0.000001270337,0.0010547602,0.000023528284,0.0012891175,0.64011717],"study_design_scores_gemma":[0.01631263,0.0038229357,0.18495189,0.00021471787,0.000032098666,0.000008451531,0.001706426,0.0000134042,0.07987913,0.0001699611,0.7127421,0.00014627108],"about_ca_topic_score_codex":0.0000630202,"about_ca_topic_score_gemma":0.00005305301,"teacher_disagreement_score":0.71145296,"about_ca_system_score_codex":0.0005119757,"about_ca_system_score_gemma":0.00059092784,"threshold_uncertainty_score":0.30568728},"labels":[],"label_agreement":null},{"id":"W2037700362","doi":"10.1038/onc.2013.284","title":"Mechanisms of the androgen receptor splicing in prostate cancer cells","year":2013,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":310,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"RNA splicing; Biology; Splicing factor; Androgen receptor; Alternative splicing; Prostate cancer; Cancer research; Messenger RNA; Enhancer; Minigene; Transcription factor; Gene; RNA; Genetics; Cancer","score_opus":0.018224105287353583,"score_gpt":0.29370062621958,"score_spread":0.2754765209322264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037700362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950666,0.0009556556,0.000008161065,0.0017023946,0.00014923242,0.0009772673,0.000020319776,0.0000103151,0.0011100579],"genre_scores_gemma":[0.99110883,0.00073355326,0.00048348415,0.00018167893,0.000037282192,0.00019297564,0.000006565204,0.00001804244,0.007237568],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992283,0.000028840832,0.00016012201,0.00014924731,0.00020987597,0.0002236134],"domain_scores_gemma":[0.99957925,0.000015831918,0.00005149625,0.00020588943,0.00007936937,0.000068179674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010256116,0.000084901534,0.00017610562,0.000051844887,0.00003173199,0.0000068069617,0.000081984224,0.000037818267,0.00071424217],"category_scores_gemma":[0.0000078437015,0.00004811691,0.000054131982,0.00024624902,0.000046982757,0.00004027278,0.000053177027,0.00009947778,0.000056505236],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067838206,0.00007502303,0.010117267,0.00006248462,0.00003404064,0.000004933788,0.0003030966,0.000008842656,0.9753026,0.000025956726,0.0009909766,0.013006944],"study_design_scores_gemma":[0.0013712106,0.00011720704,0.0041505457,0.00016992787,0.000020147036,0.0000028375168,0.00014299167,0.0000856692,0.9923549,0.00022697376,0.0013012694,0.000056311495],"about_ca_topic_score_codex":0.001282685,"about_ca_topic_score_gemma":0.00008685739,"teacher_disagreement_score":0.017052313,"about_ca_system_score_codex":0.00014238019,"about_ca_system_score_gemma":0.00017819626,"threshold_uncertainty_score":0.78204507},"labels":[],"label_agreement":null},{"id":"W2037909142","doi":"10.1210/en.2006-0986","title":"Time-Dependent Rescue of Gene Expression by Androgens in the Mouse Proximal Caput Epididymidis-1 Cell Line after Androgen Withdrawal","year":2006,"lang":"en","type":"article","venue":"Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Androgen; Biology; Androgen receptor; Endocrinology; Internal medicine; Gene expression; Gene; Genetics; Medicine; Hormone; Prostate cancer","score_opus":0.010137324035424038,"score_gpt":0.2632403127746837,"score_spread":0.2531029887392596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037909142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99190474,0.0049161636,0.000017766926,0.0010979302,0.00003012261,0.00070919853,0.000093005365,0.000027699909,0.001203376],"genre_scores_gemma":[0.99360037,0.00018275778,0.00021391684,0.000090795984,0.00013650552,0.00017018865,0.00022246671,0.000024760435,0.005358269],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983863,0.00015700032,0.00031288542,0.00032342252,0.0002943583,0.00052600744],"domain_scores_gemma":[0.9994078,0.00004432603,0.00005803988,0.00036997208,0.000057682526,0.00006216607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012698404,0.0001744226,0.0003257017,0.00012863465,0.00004654301,0.000007984806,0.00015292708,0.000096059724,0.00023779932],"category_scores_gemma":[0.000009237502,0.00010674945,0.000069084,0.00013576014,0.00021275294,0.000047944304,0.000069486734,0.0002632123,0.000046378846],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002622736,0.0016313582,0.07941636,0.00010566062,0.000057517904,0.0017875753,0.0006591409,0.00006485082,0.902154,0.000014234013,0.01083707,0.0006494649],"study_design_scores_gemma":[0.0040473593,0.00061113475,0.0029595308,0.000017375172,0.000039572307,0.00019698072,0.00012392539,0.000052129817,0.9892318,0.00003307024,0.002579727,0.00010736818],"about_ca_topic_score_codex":0.00035181004,"about_ca_topic_score_gemma":0.00005267637,"teacher_disagreement_score":0.08707779,"about_ca_system_score_codex":0.00007295654,"about_ca_system_score_gemma":0.000090385496,"threshold_uncertainty_score":0.43531162},"labels":[],"label_agreement":null},{"id":"W2038264173","doi":"10.1038/modpathol.2014.116","title":"Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer","year":2014,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":297,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Cribriform; Prostatectomy; Medicine; Prostate cancer; Metastasis; Cancer; Prostate; Proportional hazards model; Oncology; Pathology; Urology; Internal medicine; Carcinoma","score_opus":0.044839724992891516,"score_gpt":0.31234161669476035,"score_spread":0.26750189170186883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038264173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9765828,0.00881621,0.0030444646,0.008575029,0.00009757917,0.00180068,0.0007292846,0.000043957556,0.00030996068],"genre_scores_gemma":[0.9935729,0.0026369663,0.00081158796,0.00092161604,0.00008621204,0.0009429719,0.00015623638,0.000040392533,0.0008311362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848276,0.00008388476,0.00020727521,0.0005808765,0.00017919608,0.00046601315],"domain_scores_gemma":[0.9991588,0.00007875033,0.00005246238,0.00021803161,0.00021525126,0.00027672728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020391117,0.00021970274,0.000415594,0.00017209064,0.00011000115,0.000023128687,0.000068185676,0.000092610084,0.000026823514],"category_scores_gemma":[0.00008045456,0.00016197648,0.00007026431,0.00011853229,0.00017857715,0.00012752559,0.000060938677,0.00017942867,0.000004923796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013548005,0.000573988,0.89140046,0.0005680867,0.00027440666,0.0005464718,0.012465194,0.0000408064,0.010620733,0.0031643745,0.0032672698,0.06353021],"study_design_scores_gemma":[0.024382683,0.0056848223,0.87299454,0.0006628672,0.00058395526,0.00014502746,0.00046523046,0.025643831,0.025646731,0.032806326,0.010122416,0.00086158665],"about_ca_topic_score_codex":0.00007240945,"about_ca_topic_score_gemma":0.000033221615,"teacher_disagreement_score":0.06266862,"about_ca_system_score_codex":0.00018833726,"about_ca_system_score_gemma":0.0001816797,"threshold_uncertainty_score":0.6605209},"labels":[],"label_agreement":null},{"id":"W2038344188","doi":"10.1016/j.eeus.2006.05.001","title":"Novel Therapies in Advanced Prostate Cancer","year":2006,"lang":"en","type":"article","venue":"EAU-EBU Update Series","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Docetaxel; Prostate cancer; Medicine; Oncology; Internal medicine; Cancer; Angiogenesis; Prostate; Bevacizumab; Refractory (planetary science); Clinical trial; Pharmacology; Chemotherapy; Biology","score_opus":0.013012467642178841,"score_gpt":0.2983800072524225,"score_spread":0.28536753961024364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038344188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974406,0.009571045,0.000010629512,0.011854679,0.00021472368,0.00068585906,0.000086373046,0.00010822418,0.003062479],"genre_scores_gemma":[0.9683514,0.0048192013,0.0014873495,0.00036948916,0.00019665543,0.0002902139,0.00021356264,0.000047114325,0.024225015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987205,0.000019463776,0.00023678932,0.0003070083,0.00025492295,0.00046128719],"domain_scores_gemma":[0.9995268,0.000012250557,0.0000536444,0.0002387026,0.00009450774,0.000074111624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000097072356,0.00020004055,0.00029092425,0.00013938996,0.00008689992,0.000039017395,0.0000840938,0.000063239924,0.00030981953],"category_scores_gemma":[0.000010144345,0.00014748919,0.00005643701,0.00034021804,0.00017748828,0.0003215872,0.00004487974,0.00018304339,0.000049188926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010681442,0.0015673675,0.4775167,0.0006499911,0.0003796943,0.00062418036,0.0051376014,0.0004167657,0.38342965,0.003726516,0.010628019,0.105242066],"study_design_scores_gemma":[0.012041548,0.0006358725,0.58141685,0.00042946517,0.00006098301,0.000061944425,0.0018972681,0.000048936618,0.122637734,0.002271895,0.27791312,0.0005843801],"about_ca_topic_score_codex":0.0018811844,"about_ca_topic_score_gemma":0.0024328856,"teacher_disagreement_score":0.2672851,"about_ca_system_score_codex":0.00015427105,"about_ca_system_score_gemma":0.00020304114,"threshold_uncertainty_score":0.60144347},"labels":[],"label_agreement":null},{"id":"W2038394041","doi":"10.1002/ijc.26287","title":"Carbidopa abrogates <scp>L</scp>‐dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression","year":2011,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Wakayama Medical University","keywords":"LNCaP; Prostate cancer; Carbidopa; Endocrinology; Androgen receptor; Cancer research; Internal medicine; Enzalutamide; Medicine; Tumor progression; Cancer; Levodopa","score_opus":0.0247672383333643,"score_gpt":0.3329155122984597,"score_spread":0.3081482739650954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038394041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99352425,0.004163931,0.000011597494,0.00060915266,0.00053079973,0.00026553054,0.000033647026,0.000005258085,0.0008558392],"genre_scores_gemma":[0.99741465,0.0015133669,0.00034705384,0.00009896082,0.00022036902,0.00001997784,0.00000460576,0.000014166141,0.00036685602],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99880487,0.00003914242,0.00031784907,0.00010508944,0.0006027367,0.00013028811],"domain_scores_gemma":[0.9984425,0.00006920982,0.00041806325,0.00008347226,0.00088883436,0.000097959295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019025938,0.00009871693,0.00017763922,0.00012707362,0.000037360962,0.000016839402,0.00015753375,0.000028749184,0.00007133361],"category_scores_gemma":[0.00014035168,0.000055879886,0.00008173519,0.000110217,0.00013494957,0.0001658389,0.000057988782,0.0001816795,0.0000013389063],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00239029,0.00033614,0.86174643,0.000105255014,0.0012685172,0.00020206033,0.0034849138,0.000011269252,0.10247767,0.00013707475,0.0024117732,0.025428584],"study_design_scores_gemma":[0.004424285,0.00062112464,0.10373364,0.0010671263,0.00017510462,0.00031556873,0.0005454981,0.00008684642,0.8820637,0.00044535683,0.006469663,0.000052123876],"about_ca_topic_score_codex":0.00008437888,"about_ca_topic_score_gemma":0.000013658531,"teacher_disagreement_score":0.779586,"about_ca_system_score_codex":0.00016393981,"about_ca_system_score_gemma":0.00036073528,"threshold_uncertainty_score":0.22787155},"labels":[],"label_agreement":null},{"id":"W2038418985","doi":"10.1007/s11934-015-0481-2","title":"The Role of Intermittent Androgen Deprivation Therapy in the Management of Biochemically Recurrent or Metastatic Prostate Cancer","year":2015,"lang":"en","type":"review","venue":"Current Urology Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Quality of life (healthcare); Libido; Internal medicine; Oncology; Radiation therapy; Nephrology; Cancer; Urology","score_opus":0.10366009347837725,"score_gpt":0.42941515132055413,"score_spread":0.3257550578421769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038418985","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005175915,0.9901681,0.0000012891815,0.0001833254,0.00040287542,0.0039078835,0.00002770315,0.000009010313,0.00012390102],"genre_scores_gemma":[0.0030609623,0.9948532,0.000018273951,0.000010534016,0.000043988908,0.0016548804,0.0002447795,0.00002656613,0.000086815606],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99720716,0.0002912311,0.0012226269,0.00042198985,0.0005214036,0.0003356112],"domain_scores_gemma":[0.9978238,0.00012873345,0.0010250029,0.00071394444,0.00023788726,0.00007062953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012426713,0.00031090548,0.001130368,0.00016719937,0.000040787098,0.000010732161,0.00026792736,0.00009690754,0.000018655785],"category_scores_gemma":[0.00004422875,0.0001281116,0.0002766114,0.00046601592,0.00026785687,0.000025695486,0.00013604084,0.00042671556,0.0000016163051],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046369806,0.00043561263,0.0011829531,0.004871085,0.0008278684,0.0002377754,0.00029052288,2.9802817e-7,0.0000028591114,0.000020953576,0.00033085368,0.9913355],"study_design_scores_gemma":[0.0008487081,0.00065448834,0.00018583892,0.004081178,0.0013338828,0.00034340576,0.00011732618,0.0000052737932,0.00006205139,0.00036268542,0.99187624,0.00012892131],"about_ca_topic_score_codex":0.000012392587,"about_ca_topic_score_gemma":0.0000067996475,"teacher_disagreement_score":0.9915454,"about_ca_system_score_codex":0.00015121231,"about_ca_system_score_gemma":0.0007179996,"threshold_uncertainty_score":0.5224239},"labels":[],"label_agreement":null},{"id":"W2038432711","doi":"10.1002/pros.20949","title":"Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization","year":2009,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital; University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"TMPRSS2; Prostate cancer; Biology; Microdissection; Field cancerization; Comparative genomic hybridization; Prostate; Prostatectomy; Laser capture microdissection; Fusion gene; Copy-number variation; Pathology; Cancer research; Genetics; Cancer; Medicine; Gene; Genome; Gene expression; Disease","score_opus":0.03693855269396947,"score_gpt":0.344867039373548,"score_spread":0.30792848667957856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038432711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821814,0.0038768884,0.00016527243,0.00980664,0.00015255228,0.0031111215,0.00022103488,0.00009989612,0.00038523145],"genre_scores_gemma":[0.9907635,0.00138514,0.00018477968,0.00018426224,0.00012459808,0.00035290795,0.0008664264,0.000029265591,0.006109142],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99778146,0.00019862677,0.00044549906,0.00048196767,0.00047939958,0.0006130585],"domain_scores_gemma":[0.9989973,0.00004182691,0.00021097659,0.00037793882,0.00021679523,0.00015519022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044082597,0.00025972226,0.00037146232,0.00015918449,0.0003061409,0.000101256985,0.00015475655,0.00007211379,0.000016164522],"category_scores_gemma":[0.000023379034,0.00016976635,0.00006608891,0.00058346393,0.00017649007,0.00028448994,0.00003984179,0.00038411314,0.00004296575],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072301915,0.0009423313,0.010823877,0.00017810019,0.00016457461,0.00010017455,0.031618588,0.00047717706,0.93243,0.00011149158,0.0065834145,0.009340066],"study_design_scores_gemma":[0.033039957,0.0063999174,0.54628253,0.004459567,0.0005354232,0.000069162874,0.004197176,0.0072067813,0.36428413,0.008353832,0.02334244,0.0018291079],"about_ca_topic_score_codex":0.0002721711,"about_ca_topic_score_gemma":0.000049623028,"teacher_disagreement_score":0.5681459,"about_ca_system_score_codex":0.00035491906,"about_ca_system_score_gemma":0.00021265128,"threshold_uncertainty_score":0.6922871},"labels":[],"label_agreement":null},{"id":"W2039303934","doi":"10.12968/hmed.2013.74.5.250","title":"Prostate cancer patients with BRCA2 mutations require urgent treatment","year":2013,"lang":"en","type":"article","venue":"British Journal of Hospital Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Prostate cancer; Download; Cancer; Germline; Oncology; Internal medicine; Family medicine; Gene; World Wide Web; Genetics","score_opus":0.010849820668804988,"score_gpt":0.28098867677430467,"score_spread":0.2701388561054997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039303934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97631115,0.010811504,0.000007696184,0.010698037,0.00043809792,0.0011682011,0.000035709603,0.000016984399,0.00051264866],"genre_scores_gemma":[0.9900554,0.005610488,0.00021119064,0.00020358908,0.0004689556,0.000118692646,0.00006855514,0.000034614866,0.0032285068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823827,0.000031574396,0.00048473576,0.00018759731,0.0007104814,0.00034733885],"domain_scores_gemma":[0.99778813,0.000040967345,0.00027669125,0.00012184255,0.0011916646,0.00058071344],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010069664,0.00018172729,0.00048283575,0.00014424007,0.000115130235,0.00003725694,0.00008308368,0.000047546473,0.0015077088],"category_scores_gemma":[0.00012462026,0.00011349286,0.00009205417,0.00024057097,0.0002731091,0.0003854925,0.000015910666,0.00021279587,0.000018305518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084418175,0.0033925928,0.5575477,0.000175019,0.001386272,0.0030251082,0.0026794842,0.000011448449,0.00031628806,0.00001219538,0.025963925,0.4046458],"study_design_scores_gemma":[0.026824761,0.033792045,0.92486924,0.003600946,0.0005417021,0.0006932069,0.0011035821,0.00001249803,0.0005226377,0.00017849762,0.0076063,0.0002545668],"about_ca_topic_score_codex":0.0010763784,"about_ca_topic_score_gemma":0.000034748988,"teacher_disagreement_score":0.40439123,"about_ca_system_score_codex":0.00041600905,"about_ca_system_score_gemma":0.0003968526,"threshold_uncertainty_score":0.999405},"labels":[],"label_agreement":null},{"id":"W2039377776","doi":"10.3389/fonc.2014.00370","title":"Androgen-Targeted Therapy-Induced Epithelial Mesenchymal Plasticity and Neuroendocrine Transdifferentiation in Prostate Cancer: An Opportunity for Intervention","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Queensland Government; Prostate Cancer Foundation of Australia; Movember Foundation; Prostate Cancer Foundation","keywords":"Prostate cancer; Transdifferentiation; Androgen receptor; Cancer research; Medicine; Metastasis; Androgen; Epithelial–mesenchymal transition; Cancer; Hormonal therapy; Tumor progression; Neuroendocrine differentiation; Oncology; Internal medicine; Biology; Stem cell; Hormone","score_opus":0.08092183267431105,"score_gpt":0.4113621826616734,"score_spread":0.3304403499873624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039377776","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08597361,0.9068091,0.0002462144,0.00027329792,0.0012322073,0.00511181,0.00028699092,0.00003580744,0.000030972584],"genre_scores_gemma":[0.008629999,0.9879555,0.00028903122,0.000044505337,0.00018990083,0.0016338466,0.0010111984,0.00005777261,0.00018826108],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972589,0.00069774274,0.0007498118,0.00060544745,0.00016811558,0.00051999715],"domain_scores_gemma":[0.9990788,0.00013629456,0.0002911652,0.0001748664,0.00007751958,0.00024137247],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040081746,0.00038304232,0.0020198964,0.00066060177,0.00006025798,0.000018529623,0.00013099104,0.00024175258,0.000037265145],"category_scores_gemma":[0.00010740452,0.00029600432,0.00023807814,0.00026175252,0.00011096622,0.0001004644,0.000033417386,0.00060263195,5.9182844e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020991948,0.0006212995,0.0024857388,0.0053424984,0.00021019622,0.00013517546,0.00025396174,6.586904e-7,0.000027739112,0.0000059417307,0.00023251039,0.9885851],"study_design_scores_gemma":[0.029362023,0.010727833,0.0038762314,0.0056276815,0.000894714,0.000162396,0.00024712557,0.0017636602,0.00031566736,0.0004435766,0.9458819,0.0006972062],"about_ca_topic_score_codex":0.0002224487,"about_ca_topic_score_gemma":0.00055914256,"teacher_disagreement_score":0.98788786,"about_ca_system_score_codex":0.00075594615,"about_ca_system_score_gemma":0.00087652047,"threshold_uncertainty_score":0.9999492},"labels":[],"label_agreement":null},{"id":"W2039457659","doi":"10.1158/1535-7163.targ-11-a221","title":"Abstract A221: A phase II study of SB939 in patients with recurrent or metastatic castration resistant prostate cancer (CRPC).","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Ontario Institute for Cancer Research; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Oncology; Cancer; Adverse effect; Androgen deprivation therapy; Lymph node; Prostate; Clinical trial","score_opus":0.08893729981605718,"score_gpt":0.3766998605302653,"score_spread":0.2877625607142081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039457659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994489,0.0022946852,0.000011869431,0.00012140764,0.00008301422,0.0027265497,0.00011334562,0.00002008185,0.00014000501],"genre_scores_gemma":[0.9983226,0.0005713903,0.00020940637,0.00010526672,0.000012968088,0.0005342406,0.00004289259,0.000049866685,0.00015138552],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980899,0.00008112015,0.0004454519,0.00037376254,0.00062787876,0.00038188728],"domain_scores_gemma":[0.99898916,0.00001410534,0.00020735156,0.00035631936,0.00031814384,0.00011493127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015072631,0.00026215578,0.00042180848,0.00019606702,0.00007241324,0.000012650237,0.00011092238,0.00004687198,0.00022569367],"category_scores_gemma":[0.000005467427,0.0001681427,0.000053670636,0.0004827848,0.000092156464,0.00008969966,0.000033846005,0.00023846753,0.0000012333271],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18861938,0.05796636,0.2949269,0.0013664485,0.0053646546,0.0016511453,0.058283124,0.00015425711,0.069628425,0.000034354398,0.00006309482,0.32194185],"study_design_scores_gemma":[0.12920475,0.081293084,0.68999064,0.0017301765,0.0024712903,0.000005212153,0.004566714,0.00019239214,0.08847806,0.000101588405,0.0010187924,0.0009473238],"about_ca_topic_score_codex":0.0013620267,"about_ca_topic_score_gemma":0.0019785766,"teacher_disagreement_score":0.3950637,"about_ca_system_score_codex":0.0003166862,"about_ca_system_score_gemma":0.00058162963,"threshold_uncertainty_score":0.685666},"labels":[],"label_agreement":null},{"id":"W2039543196","doi":"10.1002/gcc.20939","title":"<i>PTEN</i> genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications","year":2011,"lang":"en","type":"article","venue":"Genes Chromosomes and Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"PTEN; Biology; Cancer research; Prostate cancer; Cowden syndrome; Comparative genomic hybridization; Cancer; Genetics; PI3K/AKT/mTOR pathway; Gene; Genome; Apoptosis","score_opus":0.04043175026836321,"score_gpt":0.31112079600735015,"score_spread":0.27068904573898694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039543196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9652239,0.028677858,0.000008154922,0.003201571,0.00031227837,0.0011693668,0.00075156585,0.000063854866,0.00059144245],"genre_scores_gemma":[0.8966284,0.092255525,0.000303496,0.0012438663,0.00034878068,0.002150686,0.00015996098,0.000055474102,0.0068538385],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99863297,0.000020568574,0.00018735278,0.00047584504,0.00020808967,0.00047519305],"domain_scores_gemma":[0.9990881,0.0000112164835,0.00011559411,0.0002928435,0.00012754241,0.00036470464],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005263332,0.00023973414,0.00029929986,0.00011187216,0.0002313737,0.000039211634,0.00010892859,0.0000706075,0.0016107885],"category_scores_gemma":[0.0000029770988,0.00018271903,0.00008079292,0.00022213311,0.00014258348,0.00012833273,0.00010610414,0.00012924112,0.00006800611],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011595591,0.00042438213,0.2999868,0.00036826776,0.00075915304,0.00023334181,0.0065286234,0.000004533794,0.3231296,0.00015824453,0.0045765215,0.362671],"study_design_scores_gemma":[0.0050234357,0.0006398117,0.57888883,0.000681473,0.00050277956,0.00017914372,0.0008042775,0.00005649627,0.22233818,0.00012999156,0.18999027,0.0007653236],"about_ca_topic_score_codex":0.001103461,"about_ca_topic_score_gemma":0.00020966757,"teacher_disagreement_score":0.36190566,"about_ca_system_score_codex":0.0002823404,"about_ca_system_score_gemma":0.0003171487,"threshold_uncertainty_score":0.99930185},"labels":[],"label_agreement":null},{"id":"W2040556993","doi":"10.1002/pros.20188","title":"Differential alterations in 5α‐reductase type 1 and type 2 levels during development and progression of prostate cancer","year":2004,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"University of Texas Health Science Center at San Antonio; GlaxoSmithKline","keywords":"Immunostaining; Prostate cancer; Medicine; Prostate; Intraepithelial neoplasia; Dihydrotestosterone; Finasteride; Cancer; Hyperplasia; Urology; Staining; Pathology; Internal medicine; Androgen; Immunohistochemistry","score_opus":0.03775263379248115,"score_gpt":0.35159218713156676,"score_spread":0.3138395533390856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040556993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99510473,0.0023216805,0.0000013175581,0.0015293526,0.000063821,0.0008965784,0.000018876748,0.000018980914,0.00004463441],"genre_scores_gemma":[0.99743134,0.0011984009,0.00030539974,0.00001719714,0.000025917408,0.00007993764,0.000027399938,0.000014179228,0.0009002143],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99922687,0.00002366642,0.00018806293,0.00017842595,0.00016297941,0.00021999444],"domain_scores_gemma":[0.9996394,0.000011802927,0.000050842642,0.00011000435,0.00011181033,0.00007611937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008813763,0.000111137364,0.00016092771,0.00007965723,0.00012156977,0.000021721486,0.000034654528,0.000028648712,0.000025390951],"category_scores_gemma":[0.000019612573,0.00006497118,0.000009358244,0.00022909435,0.00014216988,0.00006783627,0.0000730538,0.00012877055,0.0000022797744],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011696809,0.0009994197,0.33827338,0.002055404,0.00041542583,0.00024798437,0.08235626,0.00015305019,0.4593774,0.00030310836,0.00008976115,0.10403199],"study_design_scores_gemma":[0.0073044803,0.00054819457,0.4687135,0.0010644298,0.00006196465,0.00004522518,0.0004141899,0.000058323993,0.5207899,0.00052165665,0.0002901434,0.00018798039],"about_ca_topic_score_codex":0.00008752355,"about_ca_topic_score_gemma":0.000063820626,"teacher_disagreement_score":0.1304401,"about_ca_system_score_codex":0.0000869612,"about_ca_system_score_gemma":0.00033380708,"threshold_uncertainty_score":0.2649448},"labels":[],"label_agreement":null},{"id":"W2040620678","doi":"10.3390/cancers3021498","title":"To Die or to Survive, a Fatal Question for the Destiny of Prostate Cancer Cells after Androgen Deprivation Therapy","year":2011,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Necroptosis; Prostate cancer; Androgen receptor; Androgen deprivation therapy; Cancer research; Medicine; Androgen; Programmed cell death; Cancer; Wnt signaling pathway; Internal medicine; Oncology; Signal transduction; Biology; Apoptosis; Cell biology; Hormone","score_opus":0.06842546604473172,"score_gpt":0.3505302981296928,"score_spread":0.28210483208496107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040620678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282134,0.0021096782,0.00067328836,0.00074720813,0.00024238552,0.0030180588,0.00019124095,0.000024113158,0.00017268486],"genre_scores_gemma":[0.9904185,0.0021180385,0.001124918,0.0006015573,0.000114982846,0.002737726,0.000015843969,0.000028859635,0.002839593],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991905,0.000020737156,0.00015095224,0.0002143115,0.00017402935,0.00024948647],"domain_scores_gemma":[0.99932015,0.00006097002,0.00004572344,0.00020641257,0.00022990146,0.00013681478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015958819,0.000114459595,0.00016411365,0.00007151652,0.000056724646,0.000008623183,0.00008661942,0.00003654363,0.00020171325],"category_scores_gemma":[0.00003584689,0.00006330284,0.0000504911,0.0002150709,0.000059355003,0.00005461259,0.000024242156,0.000055134988,0.000006765114],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10350258,0.00020861393,0.18413438,0.00065122475,0.00091575895,0.00006945903,0.03586576,0.0006065396,0.10719717,0.000065018074,0.01009839,0.5566851],"study_design_scores_gemma":[0.004051188,0.002461016,0.12603776,0.00036666414,0.00010453271,0.0000033235922,0.00061962125,0.00012696168,0.84480476,0.000056104836,0.021142196,0.00022586415],"about_ca_topic_score_codex":0.0031689608,"about_ca_topic_score_gemma":0.0013724493,"teacher_disagreement_score":0.7376076,"about_ca_system_score_codex":0.00051749934,"about_ca_system_score_gemma":0.0006162223,"threshold_uncertainty_score":0.47905418},"labels":[],"label_agreement":null},{"id":"W2040890164","doi":"10.1136/pgmj.2005.038042","title":"Application of Gleason analogous grading system and flow cytometry DNA analysis in a novel knock-in mouse prostate cancer model","year":2006,"lang":"en","type":"article","venue":"Postgraduate Medical Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Prostate cancer; Flow cytometry; Grading (engineering); Prostate; Medicine; Pathology; Adenocarcinoma; Prostatectomy; Cancer; Oncology; Internal medicine; Biology; Immunology","score_opus":0.017969500524578783,"score_gpt":0.31277426525183427,"score_spread":0.2948047647272555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040890164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818513,0.003170096,0.011901134,0.002435408,0.000034156652,0.0004264136,0.000048868395,0.000020189924,0.000112452275],"genre_scores_gemma":[0.9971883,0.0012972151,0.0010707031,0.000043358446,0.000103971404,0.000053061623,0.000051476618,0.00002152069,0.00017039201],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99746835,0.000073310155,0.0006962063,0.00030606487,0.0010026062,0.00045346684],"domain_scores_gemma":[0.9990435,0.000069663416,0.0001993571,0.00016171545,0.0001726809,0.0003530661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009035873,0.00018600852,0.00064149196,0.0012228808,0.00006615047,0.000028934486,0.00012264909,0.00013243507,0.000010895581],"category_scores_gemma":[0.00008314727,0.00013645829,0.00013347153,0.0016081143,0.00013627629,0.00009957704,0.000044459477,0.00056671543,0.0000012284248],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001099391,0.0008083898,0.91555005,0.0005697193,0.00055046944,0.00047922053,0.00072161,0.0064013978,0.04035429,0.00012049624,0.00007016493,0.03327478],"study_design_scores_gemma":[0.006280467,0.00015610526,0.1305022,0.00061072584,0.00039886613,0.00031511884,0.00023638368,0.8574757,0.0037140127,0.000115861214,0.000022985874,0.00017159506],"about_ca_topic_score_codex":0.0022703174,"about_ca_topic_score_gemma":0.00082425337,"teacher_disagreement_score":0.8510743,"about_ca_system_score_codex":0.0007164183,"about_ca_system_score_gemma":0.00052772905,"threshold_uncertainty_score":0.55646074},"labels":[],"label_agreement":null},{"id":"W2040932345","doi":"10.1016/s0147-0272(00)90007-2","title":"Early prostate cancer","year":2000,"lang":"en","type":"review","venue":"Current Problems in Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"DU145; Prostate cancer; Cancer research; Rottlerin; Medicine; Cell migration; Protein kinase C; Prostate; Motility; Cancer; Cell culture; Internal medicine; Cell biology; Signal transduction; Biology; LNCaP","score_opus":0.15218955696368794,"score_gpt":0.46256325349801675,"score_spread":0.3103736965343288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040932345","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000084321495,0.99142134,5.103521e-7,0.00016383504,0.0012632179,0.0049999338,0.00048298397,0.00009081393,0.0014930204],"genre_scores_gemma":[0.000012624952,0.9792558,0.000011932308,0.000025436653,0.00071739865,0.010366981,0.00032401423,0.00015232361,0.009133501],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99634105,0.0001200278,0.00092665886,0.00099069,0.0006134608,0.0010081204],"domain_scores_gemma":[0.9986624,0.00005551215,0.000277396,0.00057270046,0.000118184005,0.0003137692],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022911374,0.00073477544,0.002205041,0.00058436405,0.000078656485,0.000071028735,0.00031499992,0.00034489614,0.0019740392],"category_scores_gemma":[0.000010842596,0.0005091346,0.00050725846,0.0011097647,0.00018221531,0.00014669496,0.000107796,0.0015700469,0.00023049724],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051675343,0.00027386565,0.0013531189,0.04502088,0.00022789495,0.00004300066,0.00026256547,0.0000065713966,2.352446e-7,0.00000616064,0.003526203,0.9492278],"study_design_scores_gemma":[0.0014733972,0.0001241848,0.000115872645,0.10949326,0.0006910657,0.00001207628,0.0000025635654,0.0000032711964,0.0000015645211,0.00004844033,0.8875829,0.00045138193],"about_ca_topic_score_codex":0.0006182038,"about_ca_topic_score_gemma":0.00012732824,"teacher_disagreement_score":0.9487764,"about_ca_system_score_codex":0.0018667909,"about_ca_system_score_gemma":0.0031031875,"threshold_uncertainty_score":0.999736},"labels":[],"label_agreement":null},{"id":"W2041002214","doi":"10.4161/cbt.6.1.3489","title":"Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression","year":2007,"lang":"en","type":"article","venue":"Cancer Biology & Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"TMPRSS2; Prostate cancer; Fusion gene; Medicine; Prostate; Erg; Oncology; PCA3; Hazard ratio; Internal medicine; Cancer; Fusion protein; Clinical significance; Cancer research; Disease; Gene; Biology; Confidence interval; Genetics; Ophthalmology","score_opus":0.054312206697036555,"score_gpt":0.4132996575416807,"score_spread":0.3589874508446441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041002214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94712925,0.04730523,0.0000430699,0.00078163715,0.00054186885,0.0034090248,0.0007268866,0.000046410034,0.000016636279],"genre_scores_gemma":[0.9294107,0.06682148,0.00059149455,0.0003982666,0.00030652955,0.0019066588,0.00015200123,0.00006222203,0.0003506649],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99761266,0.00006992234,0.00061397604,0.00067481905,0.00024521173,0.00078344234],"domain_scores_gemma":[0.99868447,0.00008732226,0.00031968465,0.00034573235,0.00032009813,0.00024268038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037381047,0.00033654302,0.00060333975,0.0002502043,0.000108518674,0.00000987011,0.00017993321,0.00027356445,0.00059263076],"category_scores_gemma":[0.000011450687,0.00021504356,0.00013105819,0.00032163746,0.00024053863,0.0001022843,0.00004433304,0.0002511335,0.0000011400824],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004541596,0.0002734769,0.32020637,0.00010098523,0.00006146316,0.000013318043,0.0014347648,0.0000030787683,0.56538785,0.000001882155,0.00012430795,0.10785091],"study_design_scores_gemma":[0.00595574,0.0018548323,0.09787066,0.00055148586,0.00003482168,0.000002262508,0.00013871708,0.00007283252,0.88526624,0.000069894064,0.007950322,0.00023217237],"about_ca_topic_score_codex":0.0007809493,"about_ca_topic_score_gemma":0.0004664563,"teacher_disagreement_score":0.3198784,"about_ca_system_score_codex":0.00038940492,"about_ca_system_score_gemma":0.00075987686,"threshold_uncertainty_score":0.8769222},"labels":[],"label_agreement":null},{"id":"W2042287139","doi":"10.1016/j.ijrobp.2011.06.210","title":"Surrogate End-points for Prostate Cancer Specific Survival: Superiority of the Interval to Biochemical Failure: An Analysis of RTOG 9202 and 9413","year":2011,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Randomized controlled trial; Prostate; Surrogate endpoint; Survival analysis; Urology; Cancer","score_opus":0.05098310975905773,"score_gpt":0.37277250047794913,"score_spread":0.3217893907188914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042287139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947648,0.00042567524,0.0008450846,0.0023735613,0.0007663125,0.0003714832,0.00039812774,0.0000066319535,0.0000483006],"genre_scores_gemma":[0.99708074,0.0007354693,0.0015377674,0.00012914157,0.00037375896,0.000020766713,0.00007414269,0.000014820948,0.000033390672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985832,0.00016182337,0.0006056963,0.00020625057,0.00026235014,0.00018070497],"domain_scores_gemma":[0.9978186,0.00020435297,0.0005561281,0.00015890025,0.0011276134,0.00013440376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057729066,0.00013874663,0.00056778867,0.00023146943,0.000037982096,0.0000093020235,0.00029850163,0.00012287896,0.0001058187],"category_scores_gemma":[0.00014844735,0.000094439434,0.00028096818,0.00033526713,0.00031394113,0.00013391032,0.00008366047,0.00022083601,8.7621436e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024461525,0.00051991,0.9252669,0.000024460103,0.0025370684,0.000006014656,0.0024509456,0.00003393577,0.040330008,0.0019956676,0.00021434786,0.024174562],"study_design_scores_gemma":[0.010516693,0.0038321957,0.78563106,0.00016254892,0.0015735236,0.000035496592,0.00076296926,0.0016243274,0.18187349,0.0038926213,0.009835878,0.00025919586],"about_ca_topic_score_codex":0.000112644055,"about_ca_topic_score_gemma":0.000080520134,"teacher_disagreement_score":0.14154348,"about_ca_system_score_codex":0.00033702987,"about_ca_system_score_gemma":0.00037555207,"threshold_uncertainty_score":0.38511285},"labels":[],"label_agreement":null},{"id":"W2042692879","doi":"10.1002/cncr.22996","title":"A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer","year":2007,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":292,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Prostate cancer; Placebo; Urology; Peripheral edema; Hazard ratio; Oncology; Adverse effect; Gastroenterology; Randomized controlled trial; Surgery; Cancer; Confidence interval; Pathology","score_opus":0.018917828034522237,"score_gpt":0.3564106759370143,"score_spread":0.33749284790249207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042692879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730443,0.016415052,0.000015437316,0.00054987054,0.000072800525,0.008877139,0.00005292186,0.0000069028624,0.00096558436],"genre_scores_gemma":[0.98877084,0.009265165,0.000038076363,0.000042617354,0.000060528546,0.0006890856,0.000006541711,0.000018049841,0.0011090775],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983899,0.0001685898,0.000590848,0.00019570689,0.00039157667,0.0002633802],"domain_scores_gemma":[0.99867517,0.0005889965,0.00030349536,0.0001953633,0.00013620529,0.0001007909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010926176,0.00016135367,0.0012767719,0.00012154157,0.000035033314,0.0000047571752,0.000064638596,0.00003842257,0.0000723114],"category_scores_gemma":[0.00013175233,0.00007424372,0.00014545908,0.0002887609,0.0004654368,0.00004752603,0.000022138585,0.00017282052,1.9149628e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97790647,0.0008632513,0.0010307761,0.000114270464,0.00087300467,0.000024905676,0.0011358369,0.000010375432,0.00944222,0.00001751927,0.00008457607,0.008496815],"study_design_scores_gemma":[0.988068,0.001185887,0.0021876744,0.00032460102,0.0007712598,0.0000025215775,0.0002599649,0.00009209351,0.006793891,0.000016777403,0.00021767503,0.00007964339],"about_ca_topic_score_codex":0.0006148194,"about_ca_topic_score_gemma":0.00019858936,"teacher_disagreement_score":0.015726566,"about_ca_system_score_codex":0.00019080775,"about_ca_system_score_gemma":0.00059818896,"threshold_uncertainty_score":0.30275708},"labels":[],"label_agreement":null},{"id":"W2042984497","doi":"10.1111/bju.13013","title":"Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence","year":2014,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Genome British Columbia","funders":"National Cancer Institute; National Research Council Canada; Mayo Clinic","keywords":"Medicine; Prostate cancer; Metastasis; Biochemical recurrence; breakpoint cluster region; Prostatectomy; Oncology; Cancer; Gene expression profiling; Cancer research; Internal medicine; Prostate; Gene; Gene expression; Biology; Genetics","score_opus":0.03431463986601797,"score_gpt":0.38473673456290197,"score_spread":0.350422094696884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042984497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985878,0.013015381,0.000098844386,0.0007306124,0.00003445876,0.00017802234,0.000029922843,0.0000015787106,0.000033212626],"genre_scores_gemma":[0.99221665,0.0061696605,0.0014495474,0.00008534842,0.00002766795,0.000005946596,0.000009840797,0.000007372639,0.000027966518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987266,0.00022017719,0.0005411327,0.00015465406,0.00020624058,0.00015119142],"domain_scores_gemma":[0.9987585,0.0001602004,0.00039353926,0.00008027128,0.0004773073,0.00013019689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062282686,0.0000786098,0.00069986633,0.00017834251,0.000024092162,0.000008128144,0.000065949025,0.000052426454,0.000045463807],"category_scores_gemma":[0.00009355829,0.00005581296,0.00010685012,0.00028078145,0.0006205459,0.000050803912,0.00003147619,0.00026549833,2.0318834e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008977374,0.00096538046,0.7955904,0.00020429987,0.00534314,0.0005550858,0.00043551397,0.000048335198,0.013680457,0.000037781232,0.00040963397,0.17375258],"study_design_scores_gemma":[0.010162516,0.012656893,0.96327597,0.0006620184,0.0050763744,0.0025743162,0.00022775153,0.0010400777,0.0033884316,0.00010100885,0.00069046486,0.00014418288],"about_ca_topic_score_codex":0.00006440545,"about_ca_topic_score_gemma":0.000043706783,"teacher_disagreement_score":0.17360839,"about_ca_system_score_codex":0.000019023051,"about_ca_system_score_gemma":0.00023960836,"threshold_uncertainty_score":0.22864272},"labels":[],"label_agreement":null},{"id":"W2043144737","doi":"10.1158/0008-5472.can-08-1718","title":"Crosstalk between the Androgen Receptor and β-Catenin in Castrate-Resistant Prostate Cancer","year":2008,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Michael Smith Health Research BC","keywords":"Prostate cancer; Androgen receptor; Wnt signaling pathway; Colocalization; Cancer research; Androgen; LNCaP; Biology; Prostate; Dihydrotestosterone; Endocrinology; Internal medicine; Cancer; Signal transduction; Hormone; Medicine; Cell biology; Genetics","score_opus":0.13127130669302153,"score_gpt":0.4273878702266003,"score_spread":0.29611656353357874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043144737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9685658,0.020848041,4.875579e-7,0.008020031,0.00006514455,0.0015285402,0.00021285971,0.000029586368,0.0007294756],"genre_scores_gemma":[0.9678915,0.02031775,0.000028615814,0.00006592058,0.00029653026,0.0011244855,0.000037177204,0.000046104724,0.010191891],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969862,0.00022751545,0.00031311437,0.0005406929,0.00091413833,0.0010183196],"domain_scores_gemma":[0.9986861,0.00020057331,0.000045463745,0.00034523688,0.00037931142,0.0003433315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009826586,0.0002055734,0.0003733324,0.00029949815,0.00055967073,0.000071799754,0.00021556889,0.00011703148,0.0004797681],"category_scores_gemma":[0.00007114216,0.00012631153,0.000058668014,0.0011181552,0.0012572998,0.00013082642,0.00017089261,0.0009008151,0.000039952432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026374073,0.00013516856,0.8813294,0.00031366362,0.00022166957,0.00064994575,0.0053282287,0.000006153723,0.07809996,0.00002895689,0.012319794,0.01892964],"study_design_scores_gemma":[0.00813064,0.0008885521,0.79586124,0.0006818199,0.00004255854,0.00006549844,0.0016906398,0.000029194385,0.12921286,0.00021356245,0.06278667,0.00039675154],"about_ca_topic_score_codex":0.0070545534,"about_ca_topic_score_gemma":0.00096834026,"teacher_disagreement_score":0.08546816,"about_ca_system_score_codex":0.00067833,"about_ca_system_score_gemma":0.0015740291,"threshold_uncertainty_score":0.99955755},"labels":[],"label_agreement":null},{"id":"W2043155628","doi":"10.1369/0022155413490946","title":"4FISH-IF, a Four-Color Dual-Gene FISH Combined with p63 Immunofluorescence to Evaluate <i>NKX3.1</i> and <i>MYC</i> Status in Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Histochemistry & Cytochemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec; Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Immunofluorescence; Prostate cancer; Fluorescence in situ hybridization; Prostate; Pathology; Biology; Cancer; In situ hybridization; Biopsy; Cancer research; Medicine; Antibody; Chromosome; Gene; Gene expression; Genetics","score_opus":0.013066094024588606,"score_gpt":0.279098178397365,"score_spread":0.2660320843727764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043155628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894738,0.003035952,0.0000057162433,0.0051631858,0.000072962415,0.0010880396,0.00007253786,0.00002795215,0.0010598184],"genre_scores_gemma":[0.9908271,0.001544663,0.0014021386,0.00068297813,0.00027183632,0.00043520558,0.000046826157,0.000070413684,0.0047188736],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99666935,0.000039260376,0.00087053055,0.0005398674,0.000997923,0.000883093],"domain_scores_gemma":[0.99697345,0.00008874861,0.00048528807,0.0004809104,0.0010588507,0.0009127683],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003697451,0.00047515973,0.0008566275,0.00013652445,0.00012336888,0.00009878471,0.00024946328,0.00018224535,0.00029768623],"category_scores_gemma":[0.00013311332,0.00036363213,0.00014774378,0.00047587627,0.00031854815,0.00024812075,0.00013751954,0.00089361455,0.000009337892],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059572603,0.0003604171,0.021587156,0.00061229797,0.00024825445,0.0009985823,0.000560615,0.000039729155,0.95169985,2.3357799e-7,0.015819194,0.0021164124],"study_design_scores_gemma":[0.01427465,0.0016774583,0.015017801,0.0017987227,0.00028115136,0.001948647,0.0005682312,0.00009079327,0.9595842,0.000036408393,0.004149771,0.0005721781],"about_ca_topic_score_codex":0.00020987932,"about_ca_topic_score_gemma":0.000009737781,"teacher_disagreement_score":0.011669422,"about_ca_system_score_codex":0.0012768309,"about_ca_system_score_gemma":0.0016107683,"threshold_uncertainty_score":0.99988157},"labels":[],"label_agreement":null},{"id":"W2043188252","doi":"10.1016/j.jval.2014.03.453","title":"Cost Comparison of Different Forms of Androgen Ablative Therapies in Metastatic Castration-Resistant Prostate Cancer in Canada","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Cabazitaxel; Prostate cancer; Docetaxel; Castration; Goserelin; Androgen deprivation therapy; Enzalutamide; Abiraterone; Oncology; Abiraterone acetate; Urology; Androgen; Internal medicine; Cancer; Gynecology; Hormone; Androgen receptor","score_opus":0.09347933362338731,"score_gpt":0.38975220975759584,"score_spread":0.2962728761342085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043188252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938603,0.0035166254,0.0000050850126,0.0011856857,0.000035541125,0.0012444108,0.00009004832,0.0000021244616,0.0000601529],"genre_scores_gemma":[0.9988142,0.0009022119,0.00006913354,0.00003478962,0.000005392924,0.0001114865,0.000026046644,0.0000092353,0.000027475053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984688,0.00018391003,0.00061286014,0.00014873048,0.00029565924,0.0002900448],"domain_scores_gemma":[0.99937594,0.00017865795,0.00018749223,0.00012078232,0.00005407856,0.000083067665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036217022,0.00010481423,0.0005535652,0.00017515173,0.000017312967,0.0000025882061,0.0000481745,0.00001824241,0.000018891058],"category_scores_gemma":[0.000030068788,0.00007126244,0.000020979365,0.0002898231,0.000050015442,0.00003566331,0.000011598735,0.00015057759,1.4179906e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008030972,0.00027462724,0.9746604,0.0010553455,0.000043558735,0.000008697494,0.008591434,0.0036955993,0.00063516543,0.00021723019,0.000020731393,0.009994121],"study_design_scores_gemma":[0.005971336,0.0009977008,0.95654905,0.0015445977,0.000012611293,0.0000010533417,0.0055084927,0.018500725,0.01010317,0.00061846594,0.00008616488,0.000106655774],"about_ca_topic_score_codex":0.9140489,"about_ca_topic_score_gemma":0.9437062,"teacher_disagreement_score":0.029657317,"about_ca_system_score_codex":0.0012745179,"about_ca_system_score_gemma":0.002851406,"threshold_uncertainty_score":0.5058272},"labels":[],"label_agreement":null},{"id":"W2043475610","doi":"10.1016/j.urology.2008.08.103","title":"POD-5.02: Clinical Application of Chromosome 8q24 SNP 's in Prostate Cancer Detection","year":2008,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; SNP; Prostate cancer; Single-nucleotide polymorphism; Cancer; Prostate; SNP array; Chromosome; Oncology; Genetics; Computational biology; Gene; Internal medicine; Genotype; Biology","score_opus":0.049132341521256166,"score_gpt":0.3932520494280753,"score_spread":0.3441197079068191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043475610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563986,0.0011176598,0.00012392932,0.0017759058,0.00012425894,0.00053014216,0.000007731665,0.000023253913,0.00065724476],"genre_scores_gemma":[0.9970847,0.0018971531,0.000030046647,0.0002030606,0.00013020395,0.00017807295,0.000020842244,0.000011031757,0.00044488607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991284,0.00006224118,0.00027595842,0.00021980407,0.00011399733,0.00019957863],"domain_scores_gemma":[0.9995677,0.000056652996,0.000070613496,0.0001690484,0.00007287499,0.00006314182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015642645,0.00007106221,0.00023785963,0.00011472977,0.000028513474,9.934927e-7,0.00004448013,0.000104025145,0.000057958565],"category_scores_gemma":[0.000038725197,0.000056824767,0.000047970938,0.00020967018,0.0002102934,0.000033925196,0.000022987006,0.00021490463,0.000030122077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026066122,0.0005554013,0.83634835,0.000076507684,0.00008066604,0.00015106642,0.00041518727,0.000041744683,0.033044074,0.000051092637,0.00022313239,0.12640613],"study_design_scores_gemma":[0.007007823,0.002690596,0.94204795,0.000017466356,0.00006343934,0.00018565364,0.000027107531,0.0020490452,0.027458068,0.000294557,0.018034426,0.00012386485],"about_ca_topic_score_codex":0.00034024895,"about_ca_topic_score_gemma":0.00021974192,"teacher_disagreement_score":0.12628227,"about_ca_system_score_codex":0.00006907665,"about_ca_system_score_gemma":0.00015089639,"threshold_uncertainty_score":0.23172466},"labels":[],"label_agreement":null},{"id":"W2043646280","doi":"10.1016/j.jsbmb.2014.09.004","title":"Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro","year":2014,"lang":"en","type":"article","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"GlaxoSmithKline foundation","keywords":"Abiraterone; Dutasteride; Biosynthesis; In vitro; Androgen; Chemistry; Pharmacology; Androgen receptor; Endocrinology; Internal medicine; Medicine; Biochemistry; Prostate cancer; Enzyme; Cancer; Hormone","score_opus":0.01945055924328086,"score_gpt":0.26489857254019394,"score_spread":0.24544801329691307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043646280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944201,0.003816426,0.00006795164,0.00144477,0.00005690964,0.00015798815,0.000018680044,0.0000028864088,0.000014286158],"genre_scores_gemma":[0.9973736,0.0019964147,0.00017367888,0.00028316662,0.000107822874,0.000004827719,0.000013667001,0.000013359817,0.00003345541],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99883133,0.00020858203,0.000398102,0.00019955913,0.00011262847,0.0002497686],"domain_scores_gemma":[0.99943495,0.00006116139,0.00017208525,0.00015186929,0.000067372384,0.00011253449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006380351,0.0001748688,0.00035205524,0.00012683538,0.000038414128,0.000028061737,0.00009365019,0.00013946887,0.0000035750827],"category_scores_gemma":[0.00003781251,0.00011090234,0.000047275833,0.000091072594,0.00020424915,0.000048134945,0.00007862421,0.0001909908,8.3099326e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015165028,0.00005582573,0.0015393344,0.000077947065,0.00005191933,0.000068204055,0.00018225343,0.0000026779885,0.985858,5.9166234e-7,0.00000869153,0.010638005],"study_design_scores_gemma":[0.0020753941,0.00044869178,0.00061195326,0.00010947541,0.000069686226,0.00025561263,0.00016677579,0.00012286486,0.99593645,0.00001998369,0.00007801436,0.00010509596],"about_ca_topic_score_codex":0.00002558699,"about_ca_topic_score_gemma":0.0000029949988,"teacher_disagreement_score":0.010532909,"about_ca_system_score_codex":0.00004774519,"about_ca_system_score_gemma":0.00004356231,"threshold_uncertainty_score":0.4522466},"labels":[],"label_agreement":null},{"id":"W2044170670","doi":"10.2353/ajpath.2010.090293","title":"Tumor Suppressor Function of Androgen Receptor Coactivator ARA70α in Prostate Cancer","year":2010,"lang":"en","type":"article","venue":"American Journal Of Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; School of Medicine, New York University; York University; U.S. Department of Defense","keywords":"Prostate cancer; Coactivator; Androgen receptor; Nuclear receptor coactivator 3; Function (biology); Suppressor; Cancer research; Androgen; Oncology; Medicine; Internal medicine; Cancer; Biology; Cell biology; Breast cancer; Hormone; Estrogen receptor; Genetics; Gene; Transcription factor","score_opus":0.012399084517068417,"score_gpt":0.31133821506251586,"score_spread":0.29893913054544746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044170670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99778944,0.0003568472,0.000012774018,0.001131276,0.00035166787,0.00018970601,0.000025717032,0.000004734518,0.00013781445],"genre_scores_gemma":[0.99867016,0.00028572336,0.0005386255,0.00014730566,0.00015647175,0.000018255061,0.000004943393,0.00001593271,0.00016259182],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989769,0.000093764924,0.00036977048,0.00013071988,0.0001934088,0.00023547056],"domain_scores_gemma":[0.99900043,0.00006450196,0.0004207384,0.00013513012,0.00024548275,0.00013373802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030648196,0.000100478304,0.0004725118,0.00024758346,0.000019482368,0.0000037770092,0.00007896742,0.000032848777,0.00023969272],"category_scores_gemma":[0.000090393776,0.000070370144,0.000083983265,0.00026938034,0.00043207037,0.000077194294,0.00002025934,0.000479367,0.0000044582143],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00500532,0.000292792,0.2716527,0.000035659992,0.00010692378,0.00078039337,0.000621208,0.0000044118237,0.68512094,0.000018482133,0.00051498105,0.035846196],"study_design_scores_gemma":[0.01118802,0.013780949,0.49026033,0.0002848219,0.0002585399,0.0030865776,0.0020609193,0.000028440765,0.4675478,0.00024982175,0.010975902,0.00027788372],"about_ca_topic_score_codex":0.00008234399,"about_ca_topic_score_gemma":0.000024532512,"teacher_disagreement_score":0.21860762,"about_ca_system_score_codex":0.00006174929,"about_ca_system_score_gemma":0.00042953753,"threshold_uncertainty_score":0.28696114},"labels":[],"label_agreement":null},{"id":"W2044275998","doi":"10.1016/j.ijrobp.2014.05.1429","title":"Radiation Therapy-Induced Castration in Men With Advanced Prostate Cancer: Results of a Prospective Phase 1 Study","year":2014,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Endocrine system; Urology; Prospective cohort study; Castration; Prostate; Dose fractionation; Testosterone (patch); Cancer; Surgery; Gynecology; Hormone; Internal medicine","score_opus":0.026871899010299658,"score_gpt":0.39262673039152024,"score_spread":0.36575483138122056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044275998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952626,0.00034303946,0.0003122742,0.0019011663,0.00033508163,0.0011891219,0.00005287608,0.000015665139,0.00058813556],"genre_scores_gemma":[0.9976597,0.0010996977,0.00031935205,0.00007897101,0.00058327,0.00009192774,0.00009318074,0.000020907974,0.000053013613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981343,0.00028332364,0.0007454336,0.00025212398,0.00038633027,0.00019846548],"domain_scores_gemma":[0.9974174,0.00021120628,0.0010925331,0.00013443269,0.0010561037,0.000088356486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007434913,0.0001750749,0.00048081635,0.0002626262,0.000043288735,0.000015293233,0.00016964845,0.000107036605,0.0000116628635],"category_scores_gemma":[0.00017977384,0.00012712933,0.00008097981,0.00029769065,0.0000989061,0.00031966963,0.000018931392,0.0003574853,0.0000020088276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02049128,0.0027322322,0.4788513,0.000008443744,0.0006478279,0.000036545738,0.0041122865,0.00070534163,0.023460038,0.00038053104,0.00006674464,0.46850744],"study_design_scores_gemma":[0.25638157,0.059865177,0.5755899,0.00028162685,0.00023714213,0.000098615645,0.0016815783,0.005793224,0.093642555,0.0032604362,0.0027653466,0.00040283776],"about_ca_topic_score_codex":0.00013710465,"about_ca_topic_score_gemma":0.000043798,"teacher_disagreement_score":0.4681046,"about_ca_system_score_codex":0.0009602781,"about_ca_system_score_gemma":0.00087195437,"threshold_uncertainty_score":0.5184183},"labels":[],"label_agreement":null},{"id":"W2044287047","doi":"10.3747/co.19.1281","title":"Targeting the Androgen Receptor in the Management of Castration-Resistant Prostate Cancer: Rationale, Progress, and Future Directions","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Enzalutamide; Prostate cancer; Medicine; Abiraterone acetate; Androgen receptor; Disease; Clinical trial; Abiraterone; Hormonal therapy; Cancer; Bioinformatics; Oncology; Cancer research; Pharmacology; Androgen deprivation therapy; Internal medicine; Biology","score_opus":0.06395084433925094,"score_gpt":0.4030367403447434,"score_spread":0.33908589600549244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044287047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7944429,0.18140303,0.0000016004711,0.020287402,0.000779725,0.0021772888,0.000046072895,0.000013299631,0.0008486826],"genre_scores_gemma":[0.9323429,0.064500295,0.00031868904,0.000061057624,0.00085912814,0.0015033326,0.00014840286,0.0000112293465,0.000254955],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992274,0.00011056842,0.00017495544,0.00011046121,0.00016986975,0.00020676326],"domain_scores_gemma":[0.9996686,0.000051688272,0.00007171416,0.000097135875,0.00006796565,0.000042914908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039700864,0.00007630111,0.00012427768,0.000042128428,0.000125886,0.000009060452,0.000055032302,0.000032451368,0.00005625407],"category_scores_gemma":[0.0000050810604,0.00003807719,0.00002481101,0.00021488754,0.00015732096,0.00005742382,0.000027868833,0.00015631497,0.0000020926718],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094713224,0.0014718628,0.44027895,0.00077320315,0.00030747137,0.00001530874,0.0145182805,0.0000026298321,0.00062647095,0.0040467875,0.009634318,0.52737755],"study_design_scores_gemma":[0.0015401437,0.00020852119,0.1310043,0.000093837545,0.00010883514,0.000011237356,0.00484991,0.000024095314,0.00023071782,0.000048100963,0.8618226,0.000057685964],"about_ca_topic_score_codex":0.000013382996,"about_ca_topic_score_gemma":0.000028059794,"teacher_disagreement_score":0.8521883,"about_ca_system_score_codex":0.00012067922,"about_ca_system_score_gemma":0.00010788993,"threshold_uncertainty_score":0.15527427},"labels":[],"label_agreement":null},{"id":"W2044948447","doi":"10.1158/1538-7445.fbcr13-c41","title":"Abstract C41: Chc1L is a tumor suppressor involved in development of histiocyte-rich neoplasms","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Centre for Phenogenomics; St. Michael's Hospital; University of Toronto","funders":"","keywords":"Pathology; Biology; Cancer research; Carcinogenesis; Knockout mouse; Prostate cancer; Histiocyte; Histiocytic sarcoma; Mesenteric lymph nodes; Cancer; Bone marrow; Tumor suppressor gene; Multiple myeloma; Spleen; Medicine; Immunology; Gene; Genetics","score_opus":0.10367429989856271,"score_gpt":0.4029268421346082,"score_spread":0.2992525422360455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044948447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894005,0.0028684048,0.0000019978897,0.0023142677,0.000085750864,0.0015447953,0.000023859839,0.000025039217,0.0037353819],"genre_scores_gemma":[0.9928602,0.00038037283,0.0003992664,0.00010790529,0.0000957817,0.0014811,0.000033761826,0.000039514896,0.0046021147],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99684966,0.00007547543,0.00048587273,0.00046613507,0.0012097511,0.00091313454],"domain_scores_gemma":[0.9982654,0.00017990102,0.00006721136,0.0004252296,0.00072838744,0.00033389436],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007495725,0.00018848071,0.00042059738,0.0006033676,0.00012468448,0.000042574233,0.0002850481,0.00010657593,0.00505697],"category_scores_gemma":[0.0001360645,0.00014584365,0.00006343516,0.000881165,0.000302751,0.00016152221,0.00017662226,0.00069115765,0.00037392083],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022065134,0.0013118975,0.14543971,0.0024447937,0.00035165,0.00030403084,0.009042726,0.0000091912725,0.75490427,0.00006826901,0.053503036,0.030413896],"study_design_scores_gemma":[0.0043100724,0.00024308315,0.27653018,0.0007156459,0.000011302984,0.000004513775,0.00096203573,0.00006283163,0.705637,0.0001685794,0.011151721,0.00020307006],"about_ca_topic_score_codex":0.00306107,"about_ca_topic_score_gemma":0.00051936315,"teacher_disagreement_score":0.13109046,"about_ca_system_score_codex":0.001167212,"about_ca_system_score_gemma":0.0024450512,"threshold_uncertainty_score":0.99585253},"labels":[],"label_agreement":null},{"id":"W2045088884","doi":"10.1158/1078-0432.ccr-14-1961","title":"Improvements in Radiographic Progression-Free Survival Stratified by <i>ERG</i> Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Abiraterone acetate; Prostate cancer; Medicine; Abiraterone; Oncology; Cancer; Internal medicine; Castration; Urology; Androgen deprivation therapy; Hormone","score_opus":0.15304353272124482,"score_gpt":0.47019087363733947,"score_spread":0.31714734091609464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045088884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868815,0.0056169643,0.0000013644485,0.0016960672,0.00019255346,0.004545482,0.0007173044,0.000047308906,0.00030147127],"genre_scores_gemma":[0.98807526,0.0062797735,0.00020129282,0.00010314579,0.00010155556,0.0030291043,0.0006136469,0.00009666785,0.0014995625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99184096,0.0011771059,0.0013467756,0.0011893311,0.0026464625,0.0017993931],"domain_scores_gemma":[0.9961549,0.00038172078,0.0002392343,0.00077685126,0.0012996128,0.0011476647],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035111564,0.00044646702,0.0010037184,0.0006591676,0.00014647035,0.00014507561,0.00041316717,0.00018894626,0.00011119716],"category_scores_gemma":[0.0004253775,0.00030461673,0.00011245842,0.0025236057,0.00087394856,0.00034525807,0.00020227971,0.0014306346,0.000012824652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026299037,0.0030072245,0.9464226,0.00025753767,0.0003428644,0.00046204627,0.0004966975,0.000033551834,0.00492665,0.0000071484737,0.0032471118,0.014497525],"study_design_scores_gemma":[0.111473285,0.0150087485,0.8536598,0.0014823177,0.00019000519,0.0000031058498,0.0010333307,0.00037692537,0.013198081,0.0002985846,0.0024427574,0.00083303824],"about_ca_topic_score_codex":0.0144333765,"about_ca_topic_score_gemma":0.01695212,"teacher_disagreement_score":0.09276279,"about_ca_system_score_codex":0.0012345094,"about_ca_system_score_gemma":0.003441041,"threshold_uncertainty_score":0.9999406},"labels":[],"label_agreement":null},{"id":"W2045294456","doi":"10.1016/j.eururo.2014.01.030","title":"Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status","year":2014,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Docetaxel; Internal medicine; Proportional hazards model; Prostate-specific antigen; Oncology; Urology; Log-rank test; Exact test; Progression-free survival; Cancer; Androgen deprivation therapy; Overall survival","score_opus":0.019178178618573894,"score_gpt":0.28189704072956195,"score_spread":0.26271886211098805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045294456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921833,0.00021704023,0.000009663552,0.0015119269,0.00007428836,0.00070681993,0.00003840044,0.000035484176,0.0052230353],"genre_scores_gemma":[0.994109,0.00026142967,0.00015169213,0.0008433168,0.0000334961,0.00006837115,0.000101737074,0.000057964186,0.004372991],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998028,0.00032514537,0.00033604418,0.00039364013,0.00027818175,0.0006390302],"domain_scores_gemma":[0.99924964,0.00005868473,0.00011780022,0.00024692563,0.00014418302,0.00018275122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002986789,0.00023788046,0.00039958404,0.00018064979,0.00008348489,0.00002696411,0.000095360374,0.000024491601,0.000090123634],"category_scores_gemma":[0.00004681548,0.00015306314,0.00003479239,0.00015748042,0.00018044727,0.00012533907,0.000051018636,0.00026164248,0.00009541812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002828324,0.00023854134,0.98646575,0.00011089831,0.00013081315,0.00017713262,0.001104354,0.00021232282,0.000601472,0.000015039308,0.00023312966,0.007882209],"study_design_scores_gemma":[0.009172108,0.0030330645,0.98094445,0.0000469733,0.00008065559,0.0000071783134,0.000051448373,0.00062700367,0.00051447476,0.0000061192814,0.005354006,0.00016250476],"about_ca_topic_score_codex":0.00016707978,"about_ca_topic_score_gemma":0.00040520748,"teacher_disagreement_score":0.007719704,"about_ca_system_score_codex":0.000110375004,"about_ca_system_score_gemma":0.00012738086,"threshold_uncertainty_score":0.6241734},"labels":[],"label_agreement":null},{"id":"W2045299216","doi":"10.1016/j.juro.2011.02.1466","title":"613 IMMEDIATE, COMPARED TO DEFERRED, COMBINED ANDROGEN BLOCKADE PROLONGS TIME TO CASTRATE-RESISTANT LNCAP PROSTATE CANCER PROGRESSION <i>IN VIVO</i>","year":2011,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"LNCaP; Medicine; Prostate cancer; Bicalutamide; Castration; Androgen; Blockade; Androgen deprivation therapy; Cancer; Internal medicine; Oncology; Androgen receptor; Hormone","score_opus":0.0291317016951,"score_gpt":0.3095694496839002,"score_spread":0.2804377479888002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045299216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98574466,0.0017797307,0.0000035480207,0.010157742,0.00013734878,0.0013550951,0.000025996935,0.00001525533,0.00078062725],"genre_scores_gemma":[0.9972576,0.00023635756,0.00019331061,0.0007534298,0.00011106296,0.000066055756,0.0000036892993,0.000030340529,0.0013481484],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981356,0.00021664998,0.000529742,0.00018655085,0.0003668806,0.00056452927],"domain_scores_gemma":[0.9988,0.00007303941,0.000220051,0.00023617262,0.0002736627,0.00039711423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007243143,0.00020049783,0.00052123115,0.00026597807,0.00007685802,0.000011709469,0.00027896246,0.0000923607,0.0005786547],"category_scores_gemma":[0.00004625249,0.00011243026,0.00007716416,0.0003753317,0.0001309507,0.00006513602,0.00009589088,0.00040276913,0.00008886853],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25614527,0.0023654439,0.10112407,0.00019034592,0.00092757854,0.003820566,0.022667501,0.00036823563,0.57390964,0.00001331343,0.032019738,0.0064483345],"study_design_scores_gemma":[0.064472415,0.08144799,0.28584352,0.0015545986,0.002189325,0.004638266,0.0020990858,0.0008119988,0.50044686,0.0010494367,0.053962406,0.0014841079],"about_ca_topic_score_codex":0.00017129898,"about_ca_topic_score_gemma":0.000110151,"teacher_disagreement_score":0.19167285,"about_ca_system_score_codex":0.00013677205,"about_ca_system_score_gemma":0.00038225524,"threshold_uncertainty_score":0.6335863},"labels":[],"label_agreement":null},{"id":"W2045589622","doi":"10.1016/j.eururo.2014.06.045","title":"Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Patients","year":2014,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone acetate; Prostate cancer; Abiraterone; Oncology; Chemotherapy; Urology; Internal medicine; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.02039178408978887,"score_gpt":0.3027230015513336,"score_spread":0.2823312174615447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045589622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954703,0.000459828,0.00001695437,0.0008892536,0.0001331896,0.00066830183,0.000015519641,0.000026896301,0.0023197967],"genre_scores_gemma":[0.99843794,0.00012607766,0.0001756821,0.0004385525,0.000044805973,0.000026394475,0.000059272,0.000048613132,0.0006426483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825233,0.00041613827,0.0004084006,0.00032308165,0.00022171736,0.0003783285],"domain_scores_gemma":[0.9993337,0.00011700445,0.00013548028,0.00022774268,0.000084205894,0.00010190152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043863806,0.00017633817,0.0003839877,0.0001708244,0.000042520987,0.000010561821,0.000104374936,0.000026874855,0.000070596565],"category_scores_gemma":[0.00011590677,0.000136867,0.000087846776,0.00020962789,0.000114183145,0.00006172981,0.000040737756,0.00018305022,0.000042269556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017314129,0.0027039195,0.6373843,0.0005029529,0.0013272237,0.0009174214,0.011619772,0.00080113625,0.25148416,0.00017758644,0.00071300426,0.075054415],"study_design_scores_gemma":[0.021657094,0.0023379794,0.96380216,0.00009327165,0.00015649188,0.0000043901177,0.000051156665,0.00019137532,0.008752958,0.000058155198,0.0027155185,0.00017947357],"about_ca_topic_score_codex":0.00010284395,"about_ca_topic_score_gemma":0.00004386784,"teacher_disagreement_score":0.32641783,"about_ca_system_score_codex":0.00007373722,"about_ca_system_score_gemma":0.00008379202,"threshold_uncertainty_score":0.55812746},"labels":[],"label_agreement":null},{"id":"W2046003313","doi":"10.1002/path.2154","title":"Morphological features of <i>TMPRSS2–ERG</i> gene fusion prostate cancer","year":2007,"lang":"en","type":"article","venue":"The Journal of Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"NIH Clinical Center; National Cancer Institute; Prostate Cancer Foundation; National Institutes of Health; University of California, San Francisco; National Institute on Aging; Deutsche Forschungsgemeinschaft; Dana-Farber/Harvard Cancer Center","keywords":"TMPRSS2; Erg; Prostate cancer; Fusion gene; Prostate; Cancer; Biology; Cancer research; Oncology; Medicine; Internal medicine; Gene; Genetics; Disease","score_opus":0.02710436547551293,"score_gpt":0.3493619663808476,"score_spread":0.3222576009053347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046003313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839927,0.01125466,0.00011378929,0.0033922486,0.00030508696,0.00019298146,0.000009519532,0.000005812946,0.00073321466],"genre_scores_gemma":[0.9905113,0.0071012485,0.0005071982,0.00035116175,0.00026500833,0.0000020021255,0.0000029062817,0.00001078489,0.0012483821],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988612,0.000121781566,0.00035983024,0.00008210022,0.0003021083,0.00027296162],"domain_scores_gemma":[0.9990253,0.00013627738,0.00028069818,0.00016060352,0.00029181837,0.0001053386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013787131,0.000099334524,0.0003280358,0.00012057109,0.000057213452,0.0000027173821,0.0001438092,0.00010000778,0.000106869105],"category_scores_gemma":[0.00007070288,0.000046013334,0.000103546816,0.00016320308,0.00029084532,0.000032125325,0.000056827463,0.00041842996,0.0000036635172],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057970732,0.00021825581,0.016861644,0.000035155354,0.00008927494,0.004838986,0.001176563,0.00001924687,0.9524193,0.000028042932,0.0028598101,0.015656667],"study_design_scores_gemma":[0.005730473,0.004367983,0.47669774,0.00016206138,0.0003695097,0.021490827,0.0007021708,0.0000047867607,0.48662144,0.00053913606,0.0031910613,0.00012280555],"about_ca_topic_score_codex":0.000025918605,"about_ca_topic_score_gemma":0.000011726076,"teacher_disagreement_score":0.46579784,"about_ca_system_score_codex":0.0000666523,"about_ca_system_score_gemma":0.00014397911,"threshold_uncertainty_score":0.18763693},"labels":[],"label_agreement":null},{"id":"W2046199531","doi":"10.1016/j.jtbi.2010.02.027","title":"Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Theoretical Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"Health Canada","keywords":"Prostate cancer; Androgen suppression; Cancer; Testosterone (patch); Hormone; Medicine; Prostate-specific antigen; Prostate; Internal medicine; Endocrinology; Oncology; Urology","score_opus":0.054017032873421016,"score_gpt":0.3838090427708154,"score_spread":0.3297920098973944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046199531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897655,0.001001546,0.0037380315,0.004544423,0.000094051946,0.00055482634,0.00003072717,0.000003420327,0.00026742116],"genre_scores_gemma":[0.9855481,0.00052809005,0.013611243,0.000101083,0.00007042343,0.000037409205,0.0000031702439,0.0000113340575,0.00008917655],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988873,0.000037295842,0.0005618689,0.0000890995,0.00020777578,0.00021663784],"domain_scores_gemma":[0.9988504,0.0003135116,0.00026999027,0.0001501703,0.00031000806,0.00010590516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092881836,0.000103822786,0.0004602163,0.00007140184,0.000036123034,0.0000034914692,0.00017782036,0.00011501739,0.00008654776],"category_scores_gemma":[0.00021537389,0.000043551074,0.00016157472,0.00005897202,0.000910435,0.00002108506,0.00004016465,0.0002978706,7.403086e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015111913,0.0011395835,0.02006347,0.0002530072,0.0010775652,0.000008695237,0.0041815466,0.0000111670415,0.6191234,0.3089158,0.0005180167,0.02959586],"study_design_scores_gemma":[0.018337475,0.006290755,0.009946526,0.0002598225,0.00043908393,0.00019553314,0.0006199965,0.008271398,0.54099786,0.41181186,0.0025579326,0.00027173705],"about_ca_topic_score_codex":7.845711e-7,"about_ca_topic_score_gemma":8.5806454e-7,"teacher_disagreement_score":0.10289609,"about_ca_system_score_codex":0.000027219452,"about_ca_system_score_gemma":0.00032420576,"threshold_uncertainty_score":0.33545357},"labels":[],"label_agreement":null},{"id":"W2046335421","doi":"10.1016/j.clinbiochem.2012.08.011","title":"CUB and zona pellucida-like domain-containing protein 1 (CUZD1): A novel serological biomarker for ovarian cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Biochemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Mount Sinai Hospital","funders":"National Cancer Institute","keywords":"Medicine; Biomarker; Ovarian cancer; Prostate cancer; Breast cancer; Colorectal cancer; Cancer; Oncology; Prostate; Internal medicine; Lung cancer; Lung; Gastroenterology; Biology","score_opus":0.11752484204431338,"score_gpt":0.4262228577718232,"score_spread":0.3086980157275099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046335421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902179,0.0031720842,0.00031548605,0.003851272,0.0001910557,0.000949632,0.00008699086,0.00005725053,0.0011582897],"genre_scores_gemma":[0.99031496,0.00016738045,0.0038456558,0.0007547156,0.0009269952,0.00042141404,0.00010572591,0.000029507726,0.003433647],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981835,0.000032608135,0.0004451536,0.0005064412,0.0002044597,0.000627819],"domain_scores_gemma":[0.99859345,0.0002762539,0.00010590402,0.0003170562,0.000112340436,0.000594982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087271474,0.00022075271,0.00043514764,0.00002728999,0.000116093026,0.000024485933,0.00010628212,0.00041700425,0.00017054736],"category_scores_gemma":[0.0003633988,0.00015660863,0.00019505677,0.000109735214,0.00039426514,0.000054468386,0.00012524695,0.00035826012,0.000010374638],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008090102,0.0016309333,0.4350668,0.00076326623,0.000640642,0.000037844362,0.00015330156,5.730657e-8,0.52665454,0.0001374188,0.0038755373,0.022949534],"study_design_scores_gemma":[0.058145277,0.003796535,0.44414172,0.0014679498,0.00092860253,0.0002912415,0.0010687666,0.00039494314,0.32863793,0.00079990196,0.15865126,0.0016758654],"about_ca_topic_score_codex":0.00001805638,"about_ca_topic_score_gemma":0.0000015009404,"teacher_disagreement_score":0.19801664,"about_ca_system_score_codex":0.00009439379,"about_ca_system_score_gemma":0.0002476566,"threshold_uncertainty_score":0.63863146},"labels":[],"label_agreement":null},{"id":"W2046631216","doi":"10.1038/nrurol.2010.231","title":"Blockade of testicular and adrenal androgens in prostate cancer treatment","year":2011,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Wilfrid Laurier University; Université Laval","funders":"","keywords":"Antiandrogens; Antiandrogen; Medicine; Prostate cancer; Androgen; Testosterone (patch); Blockade; Bicalutamide; Internal medicine; Endocrinology; Flutamide; Androgen receptor; Prostate; Abiraterone acetate; Dihydrotestosterone; Dehydroepiandrosterone; Cancer; Hormone; Androgen deprivation therapy; Receptor","score_opus":0.06673028031812712,"score_gpt":0.4099033334963851,"score_spread":0.34317305317825797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046631216","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011103635,0.995304,1.3963478e-7,0.00014687866,0.00011303973,0.0038151434,0.00011186103,0.000012600047,0.00038528923],"genre_scores_gemma":[0.000047428293,0.9976657,0.00011827976,0.000066914006,0.00012521687,0.0010289109,0.00015957709,0.00004732625,0.00074063754],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977227,0.00032576793,0.00078550656,0.00059047726,0.00013335295,0.00044220386],"domain_scores_gemma":[0.9988257,0.00012057459,0.0003793564,0.0004223864,0.00007723187,0.00017470622],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030117042,0.0005123252,0.0035891233,0.00038143355,0.000025071813,0.0000043021323,0.00011251206,0.0007685476,0.0001806956],"category_scores_gemma":[0.00011144851,0.00028129705,0.00042223564,0.00045142169,0.00019674764,0.000022178529,0.00006533905,0.0009873931,0.000021702279],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010588999,0.00021449747,0.0012150825,0.019414341,0.00037865972,0.0003256277,0.000073099785,2.1620647e-8,0.0000024156452,0.000029937197,0.00020209987,0.9780383],"study_design_scores_gemma":[0.0012724428,0.0009582454,0.000095502946,0.008100828,0.0029125228,0.0006108844,0.0000010452967,8.98446e-7,0.000009527458,0.000016079377,0.98583883,0.00018319732],"about_ca_topic_score_codex":0.00007338225,"about_ca_topic_score_gemma":0.00006526442,"teacher_disagreement_score":0.9856367,"about_ca_system_score_codex":0.00022660963,"about_ca_system_score_gemma":0.00064655,"threshold_uncertainty_score":0.99996394},"labels":[],"label_agreement":null},{"id":"W2046632683","doi":"10.1158/1538-7445.am2014-2508","title":"Abstract 2508: The development of anti-androgens with a novel mechanism of action for treatment of castration-resistant prostate cancer","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Androgen receptor; Prostate cancer; Enzalutamide; LNCaP; Coactivator; Cancer research; Docking (animal); Androgen Receptor Antagonists; In silico; Mechanism of action; Binding site; Chemistry; Cancer; Computational biology; Pharmacology; Medicine; Biology; Transcription factor; Biochemistry; Internal medicine; In vitro; Gene","score_opus":0.16582030833316927,"score_gpt":0.43818341111575015,"score_spread":0.2723631027825809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046632683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555546,0.0008139576,0.00027862182,0.0006794343,0.000048966525,0.0021858495,0.00023624525,0.000007784093,0.00019368881],"genre_scores_gemma":[0.9961897,0.00082664215,0.00079341215,0.000004639943,0.00006841568,0.0013007283,0.000035541565,0.000027286902,0.0007536208],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981327,0.000041116004,0.00039373443,0.000269633,0.00077057135,0.00039225703],"domain_scores_gemma":[0.99816525,0.00019530617,0.00018068639,0.00030186036,0.0010520393,0.000104856415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064193376,0.00014746228,0.00040094717,0.00018619964,0.00016610138,0.000010780452,0.000111600224,0.00006126569,0.000087716195],"category_scores_gemma":[0.00003095452,0.00007996532,0.000082154016,0.0003605924,0.0002788586,0.00005246143,0.000022259881,0.00009403069,7.206133e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004099572,0.0005745145,0.0026151016,0.0010078604,0.0005391052,0.0000018911917,0.002910494,0.000066407134,0.9670993,0.0004534873,0.000057840105,0.020574436],"study_design_scores_gemma":[0.0047826366,0.0018206189,0.017861672,0.0004184786,0.000086150496,0.0000020458363,0.0009160874,0.000095806645,0.9718839,0.000064885964,0.0019876517,0.00008006903],"about_ca_topic_score_codex":0.0011972165,"about_ca_topic_score_gemma":0.0017704895,"teacher_disagreement_score":0.020494366,"about_ca_system_score_codex":0.00046786116,"about_ca_system_score_gemma":0.002132504,"threshold_uncertainty_score":0.37829706},"labels":[],"label_agreement":null},{"id":"W2046793647","doi":"10.1016/j.ymeth.2014.03.018","title":"Model predictive control for optimally scheduling intermittent androgen suppression of prostate cancer","year":2014,"lang":"en","type":"article","venue":"Methods","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Canada","keywords":"Androgen suppression; Model predictive control; Prostate cancer; Computer science; Schedule; Androgen; Internal medicine; Medicine; Oncology; Hormone; Control theory (sociology); Control (management); Cancer; Artificial intelligence","score_opus":0.06005106731247348,"score_gpt":0.4355313209340246,"score_spread":0.37548025362155113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046793647","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16162664,0.0014948003,0.833541,0.0009078382,0.00014139595,0.0015220691,0.000111358284,0.000036596623,0.0006183566],"genre_scores_gemma":[0.64073086,0.00016531887,0.35730594,0.00010464985,0.000084112486,0.00048812904,0.000022094011,0.000025025969,0.0010738394],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9989416,0.00014740677,0.00023199248,0.0002442234,0.00017318994,0.00026158703],"domain_scores_gemma":[0.99910074,0.00021391927,0.00009171455,0.00019471627,0.00027732813,0.00012159913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090403843,0.00012409282,0.0003694895,0.00008145276,0.000053619628,0.00000848266,0.00007720023,0.00007109839,0.00002054639],"category_scores_gemma":[0.00021342571,0.000083513056,0.00012107901,0.00007378111,0.0000828414,0.00005886775,0.000039677823,0.00011951429,6.023735e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015613514,0.0004532163,0.03178674,0.0012203509,0.00091806584,0.0000060381694,0.0022243524,0.037297066,0.45620552,0.00034184643,0.00057034794,0.45336294],"study_design_scores_gemma":[0.0060306024,0.00081188115,0.0011090039,0.00027190516,0.00020827644,0.0000026318191,0.00006659851,0.7898717,0.20025393,0.00070667354,0.000584286,0.00008249389],"about_ca_topic_score_codex":0.000013531194,"about_ca_topic_score_gemma":9.026614e-7,"teacher_disagreement_score":0.7525746,"about_ca_system_score_codex":0.00007955292,"about_ca_system_score_gemma":0.00016972215,"threshold_uncertainty_score":0.34055638},"labels":[],"label_agreement":null},{"id":"W2046845276","doi":"10.1016/j.jgo.2013.12.001","title":"Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial","year":2014,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McMaster University; University of Toronto","funders":"National Cancer Institute","keywords":"Tolerability; Medicine; Mitoxantrone; Prostate cancer; Internal medicine; Docetaxel; Regimen; Adverse effect; Oncology; Population; Chemotherapy; Cancer","score_opus":0.02576693296431182,"score_gpt":0.3581483699954005,"score_spread":0.3323814370310887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046845276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99264,0.0016185164,0.000008203641,0.0038421764,0.00009315666,0.0011180943,0.000007679077,0.0000017970109,0.00067033916],"genre_scores_gemma":[0.99844885,0.00074438367,0.00037616777,0.000060484148,0.00015704865,0.000043694876,0.0000016441738,0.000009716432,0.00015802473],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979011,0.0005599581,0.0007494945,0.00016382254,0.0003515513,0.00027406865],"domain_scores_gemma":[0.9984933,0.00060302165,0.00047683498,0.00015113245,0.00017587976,0.00009981716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022189151,0.00013356096,0.00078306085,0.0002774829,0.00002915936,0.000013631885,0.00011280882,0.00006514241,0.000053905398],"category_scores_gemma":[0.0001963983,0.000066256995,0.000068841546,0.00045576802,0.00017451262,0.00008050499,0.000021499205,0.00040923947,5.0360063e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7097779,0.010168172,0.16241871,0.0012401317,0.0009407756,0.0026841299,0.01696516,0.00042815568,0.007746435,0.0001617716,0.0024860436,0.08498262],"study_design_scores_gemma":[0.2985742,0.025949027,0.6677031,0.0002554257,0.0006307678,0.00044993893,0.0021938703,0.00016195506,0.00067890796,0.00037328704,0.002853259,0.00017629065],"about_ca_topic_score_codex":0.00048468425,"about_ca_topic_score_gemma":0.00054450997,"teacher_disagreement_score":0.50528437,"about_ca_system_score_codex":0.0002974483,"about_ca_system_score_gemma":0.0010903183,"threshold_uncertainty_score":0.27018818},"labels":[],"label_agreement":null},{"id":"W2047091296","doi":"10.1259/bjr.20130753","title":"An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy","year":2014,"lang":"en","type":"review","venue":"British Journal of Radiology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Prostate Cancer Canada; Ontario Institute for Cancer Research; Movember Foundation","keywords":"Medicine; Radiation therapy; Prostate cancer; Malignancy; Cancer; Oncology; Internal medicine; Precision medicine; Pathology","score_opus":0.03852976415061698,"score_gpt":0.39005355555943855,"score_spread":0.35152379140882156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047091296","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027576145,0.9937392,0.00038552005,0.00033865636,0.00053083623,0.0021058696,0.00009577947,0.000009921038,0.000036630146],"genre_scores_gemma":[0.00016578946,0.9963942,0.0011636948,0.00012834564,0.0014456359,0.00019160277,0.00011814354,0.0000893239,0.00030325018],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99686444,0.0007621233,0.0012202924,0.00042408178,0.00024740145,0.00048167084],"domain_scores_gemma":[0.9979311,0.000559681,0.00074183143,0.0002145812,0.00021250019,0.0003402874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019546808,0.00034687945,0.0035558587,0.00050787925,0.000074339245,0.00003390782,0.00025177427,0.00044553753,0.00012692522],"category_scores_gemma":[0.0002558837,0.00025982066,0.00031813918,0.00018878964,0.00034318722,0.000089249195,0.00001989183,0.0007963029,6.6293603e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011910674,0.00008117463,0.00026188084,0.005059785,0.00048467438,0.0008761733,0.00012847235,0.0000032698822,0.000130151,0.0000042420065,0.0078989975,0.9838801],"study_design_scores_gemma":[0.015916962,0.0039639473,0.0008124837,0.028971964,0.00094024674,0.044534273,0.000028863493,0.000078640274,0.0000026429043,0.00015934475,0.90429175,0.00029890414],"about_ca_topic_score_codex":0.0001379432,"about_ca_topic_score_gemma":0.00008000593,"teacher_disagreement_score":0.9835812,"about_ca_system_score_codex":0.00054495066,"about_ca_system_score_gemma":0.00064903335,"threshold_uncertainty_score":0.9999854},"labels":[],"label_agreement":null},{"id":"W2047500117","doi":"10.1002/pros.10340","title":"Dutasteride, the dual 5α–reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line","year":2003,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"LNCaP; Finasteride; Dutasteride; Dihydrotestosterone; Endocrinology; Internal medicine; Prostate cancer; Programmed cell death; Antiandrogen; Apoptosis; Cell growth; Androgen; Chemistry; Medicine; Prostate; Cancer; Biochemistry; Hormone","score_opus":0.03907408125529749,"score_gpt":0.31711324462240464,"score_spread":0.27803916336710716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047500117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761932,0.010614109,0.0000015509489,0.008213373,0.00015659287,0.003344671,0.00011126736,0.000038366055,0.0013268519],"genre_scores_gemma":[0.9874148,0.0069078594,0.000050353818,0.00050472916,0.00016148678,0.0005948425,0.000057911693,0.000047657482,0.0042603603],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99774367,0.00038227983,0.00035485573,0.0004196237,0.00046697631,0.0006325892],"domain_scores_gemma":[0.9990033,0.00013920669,0.00014042527,0.00046702378,0.00012194923,0.00012809172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010578913,0.00031656405,0.0002772908,0.000069121335,0.00039828778,0.0001375207,0.0001453078,0.000076391865,0.000063901396],"category_scores_gemma":[0.000044200224,0.00013802353,0.00006817896,0.0004038994,0.00028513116,0.00021367567,0.000092437105,0.00053222995,0.000021810802],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0115491785,0.0044811144,0.09460846,0.0029983395,0.0005691269,0.0011902497,0.14107491,0.0002211284,0.6929146,0.00043863346,0.0113288155,0.03862542],"study_design_scores_gemma":[0.008876028,0.0015594803,0.006250206,0.0002975888,0.00029276998,0.0003618788,0.0077277008,0.00030609267,0.9553802,0.00117589,0.017333338,0.00043884572],"about_ca_topic_score_codex":0.0005215219,"about_ca_topic_score_gemma":0.00027247652,"teacher_disagreement_score":0.26246557,"about_ca_system_score_codex":0.00014703788,"about_ca_system_score_gemma":0.00033589118,"threshold_uncertainty_score":0.5628436},"labels":[],"label_agreement":null},{"id":"W2048068525","doi":"10.1038/stemcells.2008.143","title":"Grow your own prostate","year":2008,"lang":"en","type":"article","venue":"Nature reports. Stem cells","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Community Based Research Centre","funders":"","keywords":"Prostate; Medicine; Internal medicine","score_opus":0.02573766296148421,"score_gpt":0.3048667100992722,"score_spread":0.27912904713778797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048068525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94124365,0.015695281,0.000006589956,0.0015959118,0.0011022555,0.001485395,0.000017717062,0.00022238636,0.0386308],"genre_scores_gemma":[0.8872789,0.0014642102,0.00021718026,0.00028417943,0.0002810501,0.00004552387,0.000052757645,0.00004287507,0.11033333],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99785596,0.00003151471,0.0003807313,0.000501396,0.00074814697,0.00048226697],"domain_scores_gemma":[0.9986734,0.000030172265,0.00017025352,0.0005700323,0.0002641618,0.00029202978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002503794,0.0002288381,0.0003927787,0.00014116401,0.00016629483,0.0000189357,0.00006969667,0.0003620377,0.00016935711],"category_scores_gemma":[0.0000169396,0.00015520658,0.00017380225,0.00033407126,0.00011797397,0.00009990948,0.000054134056,0.00086269516,0.00008352329],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017034216,0.0014305939,0.3133099,0.0012654074,0.00096651976,0.20396188,0.0029807994,0.000014189649,0.19185527,0.00009847429,0.24979736,0.032616187],"study_design_scores_gemma":[0.0024404302,0.000567533,0.020752924,0.00020614882,0.00014218886,0.010780359,0.000184731,0.000016645532,0.4940482,0.00009153896,0.47036394,0.00040533365],"about_ca_topic_score_codex":0.000025506122,"about_ca_topic_score_gemma":0.0000020116443,"teacher_disagreement_score":0.30219296,"about_ca_system_score_codex":0.00018897979,"about_ca_system_score_gemma":0.000451938,"threshold_uncertainty_score":0.63291407},"labels":[],"label_agreement":null},{"id":"W2048229987","doi":"10.1038/aja.2010.174","title":"Androgen deprivation therapy for prostate cancer: not so simple","year":2011,"lang":"en","type":"article","venue":"Asian Journal of Andrology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"U.S. Department of Veterans Affairs","keywords":"Androgen deprivation therapy; Prostate cancer; Medicine; Cancer; Oncology; Prostate; Gynecology; Internal medicine","score_opus":0.052887520756258175,"score_gpt":0.3405318370308154,"score_spread":0.2876443162745572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048229987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892981,0.0024101886,0.0002812667,0.006602342,0.00016988727,0.00047875586,0.000016022492,0.000008563339,0.00073485234],"genre_scores_gemma":[0.99608195,0.0022558146,0.00058862375,0.0006010081,0.00020362914,0.00002653855,0.000010696291,0.000015138445,0.0002166035],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99926996,0.000030927586,0.0002493915,0.000101840094,0.000116179406,0.00023170414],"domain_scores_gemma":[0.99935377,0.000020696472,0.00016633968,0.000093085255,0.0002446603,0.000121456884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022207185,0.00008470643,0.0002535781,0.00012346299,0.00007324056,0.000008034267,0.00007455809,0.00006821103,0.00018118539],"category_scores_gemma":[0.000022839373,0.00005638979,0.000105326886,0.00007829592,0.00009193825,0.00008136199,0.000009297452,0.0001295551,0.0000029922023],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026088778,0.00045819586,0.40009326,0.00007364665,0.0009221154,0.00034988765,0.006945807,0.0000020236564,0.015685678,0.00024432904,0.0040168716,0.5451194],"study_design_scores_gemma":[0.04991145,0.03392361,0.33651137,0.00015048684,0.00044535956,0.0022782923,0.0010514593,0.00008812391,0.34399965,0.01097189,0.22025755,0.00041076343],"about_ca_topic_score_codex":0.000020279515,"about_ca_topic_score_gemma":0.000011799828,"teacher_disagreement_score":0.54470867,"about_ca_system_score_codex":0.000042020507,"about_ca_system_score_gemma":0.00030895765,"threshold_uncertainty_score":0.22995088},"labels":[],"label_agreement":null},{"id":"W2048274452","doi":"10.1016/j.eururo.2009.04.036","title":"ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice","year":2009,"lang":"en","type":"review","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":386,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"TMPRSS2; Prostate cancer; Medicine; Fusion gene; Cancer; Population; Prostate; Prostatectomy; Oncology; Cancer research; Internal medicine; Bioinformatics; Gene; Disease; Genetics; Biology","score_opus":0.10478676234238236,"score_gpt":0.46481463941728624,"score_spread":0.36002787707490386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048274452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006749687,0.9793391,0.0000071905615,0.0054635415,0.00065544585,0.0019158131,0.0003131653,0.000059524373,0.011571227],"genre_scores_gemma":[0.00008112177,0.98839766,0.00051477365,0.0035687687,0.0012082737,0.00010437484,0.00077017874,0.00011954941,0.00523528],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946867,0.00220661,0.0011132722,0.0010366086,0.0003045021,0.00065228017],"domain_scores_gemma":[0.99748147,0.0009171289,0.0003217775,0.0007832715,0.00010076197,0.00039558744],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001097892,0.00045211392,0.0018706862,0.000328694,0.00006662219,0.000046961464,0.0003566107,0.00020267622,0.00012509066],"category_scores_gemma":[0.0009869077,0.00031954097,0.0003555371,0.00048651712,0.00012904688,0.00011799534,0.0003586104,0.001488373,0.00118457],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007516732,0.00044927147,0.0003016594,0.0004000935,0.00030362108,0.008432874,0.0001510151,0.0000016514991,0.000003868464,0.0000090096655,0.0096422285,0.97955304],"study_design_scores_gemma":[0.0015664164,0.0012423042,0.0028798531,0.0017087423,0.0011140199,0.00014394274,0.000011204512,0.0000010680665,6.1287267e-7,0.000008179699,0.9910625,0.00026114032],"about_ca_topic_score_codex":0.0002019428,"about_ca_topic_score_gemma":0.00006505607,"teacher_disagreement_score":0.9814203,"about_ca_system_score_codex":0.00023022525,"about_ca_system_score_gemma":0.0010311602,"threshold_uncertainty_score":0.9999257},"labels":[],"label_agreement":null},{"id":"W2048278293","doi":"10.1086/319502","title":"HPC2 Variants and Screen-Detected Prostate Cancer","year":2001,"lang":"en","type":"article","venue":"The American Journal of Human Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"National Cancer Institute; Canadian Prostate Cancer Research Initiative; Institute for Prostate Cancer Research","keywords":"Prostate cancer; Medicine; Prostate; Asymptomatic; Biopsy; Gynecology; Prostate biopsy; Internal medicine; Population; Cancer; Genotyping; Oncology; Genotype; Biology; Gene; Genetics","score_opus":0.029848834066996847,"score_gpt":0.3458609643912328,"score_spread":0.316012130324236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048278293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99196404,0.005401856,0.000019517594,0.0021203302,0.00004129702,0.00017367693,0.0000046124096,0.0000076030337,0.00026708818],"genre_scores_gemma":[0.98629767,0.011884104,0.0003086701,0.0002497488,0.00025965003,0.0000036331012,0.0000011165331,0.000020703317,0.00097471767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990534,0.000072783645,0.00024165136,0.000096872944,0.00029628098,0.00023901359],"domain_scores_gemma":[0.99914044,0.00003383864,0.00026472614,0.00017454602,0.00021814485,0.00016829692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021582241,0.000107434425,0.00027594704,0.00010091448,0.00013224075,0.000027247253,0.00012487016,0.000014619945,0.00006793495],"category_scores_gemma":[0.0000135818555,0.000060055107,0.00005409848,0.00023112302,0.00046906082,0.00002937154,0.000042044194,0.00023794161,0.000002423049],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042378996,0.00027921816,0.48405525,0.000040755916,0.0010087442,0.00089711143,0.0034278037,0.000051615178,0.13316199,0.000025846584,0.0019890133,0.37082475],"study_design_scores_gemma":[0.0032147293,0.005769053,0.9805627,0.00016250211,0.00032790337,0.001116279,0.000998901,0.00008008824,0.0047746445,0.00037132972,0.0024774724,0.00014440004],"about_ca_topic_score_codex":0.00008289814,"about_ca_topic_score_gemma":0.0000138613495,"teacher_disagreement_score":0.49650744,"about_ca_system_score_codex":0.0000580609,"about_ca_system_score_gemma":0.00014609404,"threshold_uncertainty_score":0.24489762},"labels":[],"label_agreement":null},{"id":"W2048524209","doi":"10.1016/j.eursup.2009.06.001","title":"Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment","year":2009,"lang":"en","type":"article","venue":"European Urology Supplements","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Sanofi","keywords":"Medicine; Docetaxel; Prostate cancer; Oncology; Genitourinary system; Internal medicine; Chemotherapy; Cancer; Renal cell carcinoma; Clinical trial; Adverse effect","score_opus":0.03192870313935767,"score_gpt":0.37659558665161086,"score_spread":0.34466688351225316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048524209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97728133,0.0007249797,0.002580594,0.0077109416,0.00042361178,0.0028838587,0.0016935263,0.00011998666,0.0065811556],"genre_scores_gemma":[0.9807806,0.0007478718,0.012535906,0.0017685782,0.0004186705,0.0002215679,0.0014517207,0.0000512454,0.0020238287],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979281,0.00020093753,0.00034838702,0.0006303037,0.00026137836,0.0006309221],"domain_scores_gemma":[0.99866325,0.00019669723,0.00008993624,0.0005424991,0.00010878579,0.0003988053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017320534,0.00028072437,0.0003686145,0.00017405234,0.00025180264,0.000025566842,0.0001906605,0.000045348468,0.0005126508],"category_scores_gemma":[0.00006955985,0.00021413087,0.00015552227,0.00014872178,0.00004253472,0.0000709403,0.00007793701,0.00015245817,0.00019641194],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009041845,0.0019878172,0.14958163,0.000008171271,0.0015341643,0.0013557437,0.0011053949,0.00031553107,0.011371571,0.00008385991,0.026757635,0.79685664],"study_design_scores_gemma":[0.025027527,0.030853653,0.42146948,0.000036755875,0.00065065117,0.000026599972,0.0001642423,0.00028128497,0.0017958819,0.0003927173,0.51892954,0.00037168805],"about_ca_topic_score_codex":0.00009316962,"about_ca_topic_score_gemma":0.000033725126,"teacher_disagreement_score":0.79648495,"about_ca_system_score_codex":0.00062067196,"about_ca_system_score_gemma":0.00020397716,"threshold_uncertainty_score":0.87320036},"labels":[],"label_agreement":null},{"id":"W2048775704","doi":"10.1111/j.1464-410x.2004.05091.x","title":"Prostasomes: a role in prostatic disease?","year":2004,"lang":"en","type":"review","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Mary's Hospital","funders":"","keywords":"George (robot); Medicine; General hospital; University hospital; Management; Library science; General surgery; Family medicine; Art history; Art","score_opus":0.031009242278900995,"score_gpt":0.354838747707137,"score_spread":0.323829505428236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048775704","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001411234,0.9979279,0.0000028210989,0.00036902857,0.00015721425,0.0011437886,0.00005962553,0.000008748154,0.00018973679],"genre_scores_gemma":[0.00031222965,0.99867034,0.000077897705,0.00013016278,0.00021855545,0.000079732505,0.00006916742,0.00005464354,0.00038725624],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978259,0.00017617337,0.0009280187,0.000254726,0.00036060094,0.0004545428],"domain_scores_gemma":[0.99878645,0.000088279834,0.00046541527,0.00016089015,0.00016788341,0.0003310926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003883045,0.00024474922,0.0018352048,0.0005035179,0.000036782723,0.00003923422,0.0001944158,0.00022622406,0.00010086438],"category_scores_gemma":[0.00023080655,0.00020458143,0.00048970134,0.00035805136,0.0001585719,0.00008432818,0.000055336954,0.001187246,0.000028897855],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002964977,0.00047653742,0.00028720044,0.015225828,0.00026626972,0.03862803,0.00004531237,0.00000152752,1.5445278e-7,0.000012537117,0.00038742996,0.94437265],"study_design_scores_gemma":[0.0035069103,0.0011217152,0.0009783189,0.04123312,0.0012114049,0.03079168,0.000016136068,0.0000010422342,1.6379941e-7,0.0006692257,0.92029226,0.00017801914],"about_ca_topic_score_codex":0.00002631303,"about_ca_topic_score_gemma":0.000014615929,"teacher_disagreement_score":0.9441947,"about_ca_system_score_codex":0.0004377768,"about_ca_system_score_gemma":0.0037433845,"threshold_uncertainty_score":0.8342589},"labels":[],"label_agreement":null},{"id":"W2048856583","doi":"10.4161/onci.29243","title":"Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy","year":2014,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Victoria","funders":"BC Cancer Agency; Canadian Institutes of Health Research","keywords":"Medicine; Prostate cancer; Autoantibody; Androgen deprivation therapy; Cancer; Oncology; Radiation therapy; Prostate-specific antigen; Internal medicine; Androgen; Immune system; Androgen suppression; Immunology; Antibody; Hormone","score_opus":0.012896353262131238,"score_gpt":0.2829936209693502,"score_spread":0.270097267707219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048856583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969594,0.00170139,0.0000055555824,0.00034048923,0.00004174438,0.0007556799,0.000013717517,0.000050795526,0.00013125938],"genre_scores_gemma":[0.9972938,0.0015468566,0.00003728849,0.00015031935,0.000013486488,0.00013322299,0.00015463209,0.000027330416,0.0006431191],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989367,0.00008401497,0.0002226345,0.00027101487,0.0001732955,0.0003123421],"domain_scores_gemma":[0.99948853,0.000050109415,0.0001519437,0.00012423424,0.00013604717,0.00004911037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001332635,0.00017623471,0.00034743853,0.00017626717,0.00008304443,0.000018691311,0.000046926325,0.000073719224,0.000021694348],"category_scores_gemma":[0.000030494672,0.00010924207,0.00001921759,0.00022603368,0.00015284799,0.00011329048,0.000019211788,0.00019991623,0.000004654243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031455231,0.00027311782,0.97065693,0.000016187425,0.00017207892,0.000031686068,0.00046640207,0.000009817745,0.0021830413,0.000008248437,0.000008666427,0.023028312],"study_design_scores_gemma":[0.016651247,0.0031054243,0.9760092,0.00015401751,0.000046622044,0.000018839411,0.00003617771,0.0002494923,0.003349625,0.000017323284,0.00023152254,0.00013051134],"about_ca_topic_score_codex":0.000972837,"about_ca_topic_score_gemma":0.0001801141,"teacher_disagreement_score":0.022897802,"about_ca_system_score_codex":0.00026498444,"about_ca_system_score_gemma":0.00010266987,"threshold_uncertainty_score":0.44547623},"labels":[],"label_agreement":null},{"id":"W2049136550","doi":"10.1016/j.eururo.2014.08.056","title":"Identifying Optimal Candidates for Local Treatment of the Primary Tumor Among Patients Diagnosed with Metastatic Prostate Cancer: A SEER-based Study","year":2014,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Androgen deprivation therapy; Primary tumor; Proportional hazards model; Oncology; Internal medicine; Cancer; Prostate; Radiation therapy; Lymph node; Epidemiology; Dissection (medical); Metastasis; Surgery","score_opus":0.026586483389811177,"score_gpt":0.29047562621983997,"score_spread":0.2638891428300288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049136550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9500138,0.00067868095,0.00021874702,0.038480774,0.00034151945,0.009441632,0.00053924153,0.0000653114,0.00022028944],"genre_scores_gemma":[0.94467413,0.000044615586,0.00019159334,0.04888732,0.00048410983,0.0016256585,0.0015497655,0.0002561504,0.0022866519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967279,0.0008473372,0.00051187986,0.0007179008,0.00052214164,0.00067283475],"domain_scores_gemma":[0.9980882,0.00039216655,0.00047331522,0.0006671032,0.00027164014,0.00010758632],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025223507,0.0005152845,0.0009775871,0.00021195726,0.00016031477,0.000031610183,0.00028878285,0.00007577015,0.000037165006],"category_scores_gemma":[0.000039719413,0.00027472482,0.00023259399,0.0001905635,0.00048231723,0.000039135433,0.00008444217,0.00050549844,0.000009640089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075687566,0.002935836,0.8851946,0.0016452197,0.0032256488,0.004885508,0.0024409557,0.00062034343,0.00003634982,4.7026987e-7,0.08713813,0.00430819],"study_design_scores_gemma":[0.07561965,0.05971338,0.62917364,0.00055994344,0.008186244,0.000046032244,0.00025833832,0.00080290774,0.0006660398,0.0000046168734,0.22399758,0.0009716064],"about_ca_topic_score_codex":0.0003498828,"about_ca_topic_score_gemma":0.0001393789,"teacher_disagreement_score":0.25602093,"about_ca_system_score_codex":0.00038998906,"about_ca_system_score_gemma":0.00048724597,"threshold_uncertainty_score":0.9999705},"labels":[],"label_agreement":null},{"id":"W2049161486","doi":"10.1111/j.1464-410x.2008.08183.x","title":"The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer","year":2008,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":614,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Memorial Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Urology; Testosterone (patch); Androgen deprivation therapy; Hormone antagonist; Clinical endpoint; Randomized controlled trial; Population; Prostate; Dosing; Prostate-specific antigen; Cancer; Internal medicine; Hormone; Endocrine system","score_opus":0.035359166531701465,"score_gpt":0.3437018922021902,"score_spread":0.30834272567048876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049161486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837391,0.012583667,0.0000136370445,0.00045927844,0.0000635539,0.0029417996,0.000017688084,0.0000027766057,0.0001784915],"genre_scores_gemma":[0.98734844,0.012176409,0.00010305684,0.00007304133,0.000028960832,0.000083431136,0.000008723601,0.000012399338,0.00016551114],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980657,0.0004617117,0.0006872739,0.00017536739,0.00033081428,0.00027910835],"domain_scores_gemma":[0.99863005,0.0003882652,0.00039338105,0.00011241353,0.00034242566,0.00013345436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075678393,0.00013233622,0.0009944133,0.00009332511,0.00018739472,0.000026856394,0.00017820564,0.00004535419,0.000023497902],"category_scores_gemma":[0.000086853186,0.00008115692,0.000040502215,0.00014762173,0.00063127093,0.00013477825,0.000082100116,0.00038875177,3.4985175e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8011584,0.004823462,0.17594601,0.000013982312,0.00070294115,0.0012834789,0.0018106974,0.000037053484,0.000012169431,0.0000048812035,0.0005466504,0.013660229],"study_design_scores_gemma":[0.65938723,0.0102630975,0.32883725,0.00012140105,0.00016173752,0.0004745362,0.00017424313,0.000032189804,0.0000053270414,0.000013123915,0.00046294692,0.00006694581],"about_ca_topic_score_codex":0.0006447578,"about_ca_topic_score_gemma":0.0010639654,"teacher_disagreement_score":0.15289123,"about_ca_system_score_codex":0.000055914912,"about_ca_system_score_gemma":0.00025579132,"threshold_uncertainty_score":0.3309483},"labels":[],"label_agreement":null},{"id":"W2049848204","doi":"10.1136/jmg.40.3.e22","title":"The <i>RNASEL</i> 471delAAAG allele and prostate cancer in Ashkenazi Jewish men","year":2003,"lang":"en","type":"letter","venue":"Journal of Medical Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"McGill University","keywords":"Prostate cancer; Loss of heterozygosity; Allele; Locus (genetics); Cancer; Prostate; Biology; Genetics; Oncology; Medicine; Gene","score_opus":0.020774952112640157,"score_gpt":0.3314335390345009,"score_spread":0.31065858692186077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049848204","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008610591,0.14995286,0.0000057069346,0.8394953,0.00052027754,0.00045000826,0.000025923086,0.000004664088,0.00093469536],"genre_scores_gemma":[0.0015914652,0.677497,0.00022894652,0.30049425,0.0055165743,0.00005171667,0.000037234713,0.00010647247,0.014476303],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955649,0.00022593215,0.00081142253,0.000231486,0.002562356,0.0006039278],"domain_scores_gemma":[0.9983747,0.0002883872,0.00036399256,0.0002472248,0.00030604028,0.0004196536],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0014358631,0.00027288127,0.0006508743,0.00016447676,0.000091442686,0.00007092425,0.0003518565,0.0007233423,0.0002358004],"category_scores_gemma":[0.00027683683,0.00014670992,0.00014729326,0.00020155881,0.0003897339,0.000031669144,0.00009633019,0.003841462,0.000004495936],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017730337,0.00006210261,0.0040138797,0.00019381984,0.00030906455,0.005086812,0.00016380832,0.0000025064844,0.000029653305,0.0000013080132,0.93267375,0.057285972],"study_design_scores_gemma":[0.0041794376,0.0005770341,0.0008886156,0.0006836123,0.00020308798,0.00081669126,0.00009512489,0.00009175138,0.00017373617,0.00021266847,0.9919264,0.00015187413],"about_ca_topic_score_codex":0.000027778886,"about_ca_topic_score_gemma":0.000045769422,"teacher_disagreement_score":0.539001,"about_ca_system_score_codex":0.00025354253,"about_ca_system_score_gemma":0.001935174,"threshold_uncertainty_score":0.9984567},"labels":[],"label_agreement":null},{"id":"W2050216721","doi":"10.1097/spc.0b013e328363602e","title":"The role of intermittent androgen suppression in biochemically recurrent or newly diagnosed metastatic prostate cancer","year":2013,"lang":"en","type":"review","venue":"Current Opinion in Supportive and Palliative Care","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Androgen suppression; Oncology; Internal medicine; Randomized controlled trial; Quality of life (healthcare); Cancer; Clinical trial; Radiation therapy; Hazard ratio; Prostate; Urology","score_opus":0.13641883420941217,"score_gpt":0.4618950484774085,"score_spread":0.32547621426799633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050216721","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026500742,0.99133354,8.4960334e-7,0.00006621506,0.00079424586,0.004357024,0.0007609568,0.0000089564755,0.000028131197],"genre_scores_gemma":[0.0010306613,0.99418,0.000019273035,0.0000039058964,0.00009840093,0.0030431747,0.0014964625,0.000038921447,0.00008920017],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971546,0.00031341225,0.0010442674,0.0006017289,0.00039767427,0.0004883066],"domain_scores_gemma":[0.9981447,0.00042867413,0.00055587996,0.00028314508,0.00039006895,0.00019756409],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019312715,0.00049465074,0.0014959385,0.0002853271,0.00006333822,0.000035884066,0.00019663414,0.000141404,0.00010550082],"category_scores_gemma":[0.00018465286,0.0002493483,0.00026810373,0.00049122906,0.0002678467,0.000078332734,0.00020582858,0.0006788718,0.0000066944267],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039687532,0.00020957198,0.02134007,0.025015177,0.0001830659,0.000011818242,0.0028232795,1.0020935e-7,0.000004264009,0.00001321949,0.0006550821,0.9493475],"study_design_scores_gemma":[0.0029863722,0.0006690055,0.0023799688,0.096504144,0.00030863035,0.000003639975,0.0034492488,0.00001355625,0.0001902241,0.000059402442,0.8930681,0.00036771345],"about_ca_topic_score_codex":0.00006217077,"about_ca_topic_score_gemma":0.000035932517,"teacher_disagreement_score":0.94897974,"about_ca_system_score_codex":0.00044757064,"about_ca_system_score_gemma":0.0010486664,"threshold_uncertainty_score":0.9999959},"labels":[],"label_agreement":null},{"id":"W2050606109","doi":"10.1159/000066118","title":"Phase II Study of Repeated Single 24-Hour Infusion of Low-Dose 5-Fluorouracil for Palliation in Symptomatic Hormone-Refractory Prostate Cancer","year":2002,"lang":"en","type":"article","venue":"Urologia Internationalis","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Regimen; Fluorouracil; Chemotherapy; Toxicity; Prostate; Refractory (planetary science); Surgery; Hormonal therapy; Urology; Prostate-specific antigen; Prospective cohort study; Progressive disease; Cancer; Internal medicine","score_opus":0.05607173498319795,"score_gpt":0.3488255260198171,"score_spread":0.29275379103661914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050606109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99618816,0.0010518268,0.000015459467,0.0006802568,0.000112167305,0.0016336307,0.00011511237,0.000028910152,0.00017447244],"genre_scores_gemma":[0.9977234,0.00050106685,0.00008003717,0.00005762051,0.00004017859,0.00035949817,0.00014425938,0.000017746781,0.0010761782],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99853116,0.000058795817,0.0005480299,0.00024272154,0.00043282614,0.00018643847],"domain_scores_gemma":[0.99886286,0.00012734793,0.0003089595,0.00019172564,0.0004577958,0.000051303647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023540674,0.00013633318,0.00030239893,0.0003015906,0.000041119005,0.000007696133,0.00011390998,0.00007670004,0.00020371276],"category_scores_gemma":[0.00026981503,0.00010706794,0.00006918875,0.0002489271,0.000054255328,0.00013126359,0.000058058224,0.00012547922,0.0000024638312],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015765514,0.0708071,0.31110284,0.00085966365,0.001258597,0.00015814435,0.027763613,0.0008545138,0.45408267,0.00008056419,0.004920315,0.11234649],"study_design_scores_gemma":[0.22550926,0.16593054,0.3888887,0.0017628275,0.0008061662,0.000029641491,0.0033030545,0.09917032,0.10971204,0.00067628024,0.003163987,0.0010471833],"about_ca_topic_score_codex":0.00041039198,"about_ca_topic_score_gemma":0.00011762214,"teacher_disagreement_score":0.3443706,"about_ca_system_score_codex":0.00024084724,"about_ca_system_score_gemma":0.000051337018,"threshold_uncertainty_score":0.4366104},"labels":[],"label_agreement":null},{"id":"W2051131004","doi":"10.1093/carcin/bgs153","title":"Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis","year":2012,"lang":"en","type":"article","venue":"Carcinogenesis","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; University of California, San Francisco","keywords":"Prostate cancer; Stromal cell; Metastasis; Prostate; Carcinogenesis; Androgen; Medicine; Androgen receptor; Cancer research; Internal medicine; Cancer; Hormone; Malignant transformation; Endocrinology; Oncology","score_opus":0.04517602224427981,"score_gpt":0.33747696209480926,"score_spread":0.29230093985052946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051131004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92102224,0.07524914,0.00001204959,0.0008794332,0.00021688742,0.0023099412,0.00014750788,0.00008043423,0.000082382816],"genre_scores_gemma":[0.9793771,0.018239643,0.0002767423,0.0000690916,0.00017772194,0.0013652479,0.00025963617,0.000074566444,0.00016027491],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703944,0.0002012348,0.0005830019,0.00050038664,0.00066500984,0.001010946],"domain_scores_gemma":[0.99870354,0.000047313915,0.0001602831,0.0003010841,0.00019847277,0.000589281],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00065158284,0.00041661452,0.000622083,0.00047841607,0.00020842323,0.000046962516,0.000095630625,0.00018087911,0.000082227176],"category_scores_gemma":[0.000033650387,0.0003142715,0.00013321894,0.00073660957,0.0001647623,0.0006164244,0.000055628734,0.0002003649,0.000015477932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016950883,0.00034107358,0.80756205,0.0007010644,0.00029230525,0.000051554936,0.005992768,0.0000072828548,0.06279356,0.000019283427,0.00017358686,0.120370395],"study_design_scores_gemma":[0.0063343053,0.00071758556,0.575075,0.00030605015,0.00082047115,0.0001529404,0.0027564222,0.00017040281,0.41109598,0.00002896186,0.002017639,0.00052428886],"about_ca_topic_score_codex":0.00030829143,"about_ca_topic_score_gemma":0.00009291802,"teacher_disagreement_score":0.34830242,"about_ca_system_score_codex":0.00045487186,"about_ca_system_score_gemma":0.00031677302,"threshold_uncertainty_score":0.9999309},"labels":[],"label_agreement":null},{"id":"W2051133253","doi":"10.1038/pcan.2011.35","title":"18F-fluorocholine for prostate cancer imaging: a systematic review of the literature","year":2011,"lang":"en","type":"review","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Medicine; Positron emission tomography; Radiosynthesis; Docetaxel; Nuclear medicine; Biodistribution; Prostate; Cancer; Radiation therapy; Radiology; Oncology; Internal medicine; In vivo","score_opus":0.03672072542709307,"score_gpt":0.38188996847583273,"score_spread":0.34516924304873964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051133253","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010317664,0.95697045,0.0000019202578,0.0007784484,0.00037018937,0.027681576,0.014039507,0.00006713923,0.000080476435],"genre_scores_gemma":[0.000024445973,0.9624292,0.000059519614,0.0007875044,0.00016175942,0.028089566,0.0012107034,0.00018986312,0.0070474176],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9956078,0.00028683708,0.0016590186,0.0009916545,0.0006207483,0.0008339545],"domain_scores_gemma":[0.99585843,0.00031768827,0.0012918117,0.0010162324,0.0010257857,0.000490033],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043179604,0.0010222333,0.0042929435,0.00024739729,0.00024796693,0.00012541065,0.00042517454,0.00013157367,0.000103527556],"category_scores_gemma":[0.0004629734,0.0005268806,0.0011430263,0.0009915088,0.00048947224,0.00021442537,0.00022672606,0.00050623657,0.000004305023],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002967843,0.00018656008,0.00031709744,0.84451467,0.0009452801,0.000027590015,0.00072313653,4.1905793e-8,8.375532e-7,0.000039251245,0.0031739622,0.14977477],"study_design_scores_gemma":[0.0015199047,0.00018484899,0.000028791595,0.80511093,0.017190026,0.000076600416,0.000057795543,0.0000065252502,0.000012132451,0.00021180182,0.17511843,0.00048223406],"about_ca_topic_score_codex":0.00007616684,"about_ca_topic_score_gemma":0.000006810605,"teacher_disagreement_score":0.17194447,"about_ca_system_score_codex":0.00032356931,"about_ca_system_score_gemma":0.0027717543,"threshold_uncertainty_score":0.99971825},"labels":[],"label_agreement":null},{"id":"W2051321553","doi":"10.2478/v10019-012-0034-y","title":"Imaging primary prostate cancer with 11C-Choline PET/CT: relation to tumour stage, Gleason score and biomarkers of biologic aggressiveness","year":2012,"lang":"en","type":"article","venue":"Radiology and Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Standardized uptake value; Prostate; Stage (stratigraphy); Biochemical recurrence; Positron emission tomography; Nuclear medicine; Cancer; Urology; Oncology; Internal medicine; Prostatectomy","score_opus":0.024021341898828017,"score_gpt":0.33796814031318745,"score_spread":0.3139467984143594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051321553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97430545,0.022282818,0.000022326674,0.002131346,0.00013464075,0.00065579434,0.00003377097,0.00002138013,0.00041245559],"genre_scores_gemma":[0.99310744,0.0050458736,0.0007685775,0.00038188076,0.00009448142,0.00010432778,0.000080256126,0.000014213289,0.00040294896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891764,0.00015658601,0.00019097263,0.0002716325,0.00007273071,0.00039041022],"domain_scores_gemma":[0.9993152,0.00015213444,0.00013470005,0.00011089203,0.00008549108,0.00020160912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034802113,0.00015162563,0.00043646066,0.00016166252,0.00009277551,0.0000034976135,0.000041426916,0.000040392322,0.00003715636],"category_scores_gemma":[0.00005045314,0.000097026736,0.000022735501,0.00015932166,0.00049412926,0.000093358234,0.00005776488,0.00018154155,0.00000198349],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003819835,0.00010973709,0.9515606,0.00015786401,0.00016668804,0.00041783586,0.00031192123,0.0000066062576,0.021704892,0.00008680347,0.00019851846,0.021458685],"study_design_scores_gemma":[0.0037165766,0.0014365035,0.98535633,0.00017989658,0.00014537049,0.0024022195,0.00020285019,0.00003711589,0.0029221487,0.00003389925,0.0034394753,0.00012763053],"about_ca_topic_score_codex":0.0001327689,"about_ca_topic_score_gemma":0.000033863562,"teacher_disagreement_score":0.0337957,"about_ca_system_score_codex":0.00018928261,"about_ca_system_score_gemma":0.00023513273,"threshold_uncertainty_score":0.39566356},"labels":[],"label_agreement":null},{"id":"W2051410494","doi":"10.1038/nrclinonc.2010.136","title":"Drug resistance in metastatic castration-resistant prostate cancer","year":2010,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":340,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Vedecká Grantová Agentúra MŠVVaŠ SR a SAV","keywords":"Prostate cancer; Medicine; Docetaxel; Androgen receptor; Drug resistance; Cancer; Cabazitaxel; Oncology; Cancer research; Internal medicine; Enzalutamide; Tumor microenvironment; Metastasis; Androgen deprivation therapy; Biology","score_opus":0.1910857334701918,"score_gpt":0.5670317297040429,"score_spread":0.3759459962338511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051410494","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000016158643,0.9833615,4.0100076e-7,0.0031322045,0.0016044802,0.007782455,0.00014570051,0.000040976676,0.003916133],"genre_scores_gemma":[0.000003281584,0.9727679,0.003030131,0.0008038546,0.00084107625,0.0026371677,0.000457091,0.00010248659,0.019357026],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.990773,0.0023765953,0.0041287676,0.0013311293,0.00055136485,0.0008391252],"domain_scores_gemma":[0.99397534,0.0024253735,0.0017199576,0.0010473208,0.0002919603,0.00054007536],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.005367069,0.0008126416,0.008795571,0.00038477912,0.000090345675,0.000034019005,0.00047986032,0.0022407155,0.0003774124],"category_scores_gemma":[0.0028260853,0.0004829644,0.0016984267,0.001168379,0.0004678117,0.000092811744,0.0001286598,0.010670192,0.00027373226],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004437179,0.0006556089,0.00007187291,0.029252829,0.000272431,0.0010159918,0.000040322597,1.0828252e-8,8.4584315e-7,0.00019624531,0.018865936,0.9491842],"study_design_scores_gemma":[0.0023877653,0.00032135652,0.00009594218,0.031649545,0.0024347177,0.00004226901,0.0000053847384,3.3702398e-7,4.6334068e-7,0.00014406373,0.9625342,0.00038397784],"about_ca_topic_score_codex":0.00003950959,"about_ca_topic_score_gemma":0.0062356754,"teacher_disagreement_score":0.9488002,"about_ca_system_score_codex":0.0011203709,"about_ca_system_score_gemma":0.007597372,"threshold_uncertainty_score":0.9997622},"labels":[],"label_agreement":null},{"id":"W2051674705","doi":"10.1053/sonc.2002.32904","title":"Doctor's dilemma: Incorporating tumor markers into clinical decision-making","year":2002,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Dilemma; Clinical decision making; Intensive care medicine; Oncology; Medical physics; Epistemology","score_opus":0.04443460594989301,"score_gpt":0.42330899374947184,"score_spread":0.3788743877995788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051674705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723898,0.0021856632,0.0000417735,0.002146504,0.00072973873,0.00051215483,0.000002639943,0.000052067866,0.021939656],"genre_scores_gemma":[0.98051584,0.0009281724,0.016375711,0.00073537516,0.0003392193,0.00006908916,0.000008271869,0.000026920094,0.0010013729],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99801,0.00020868472,0.0006432979,0.0004313511,0.00028133774,0.00042534465],"domain_scores_gemma":[0.99746364,0.0018144891,0.00014604231,0.00030809813,0.000088697336,0.00017903483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011024997,0.0001649851,0.0005306694,0.00024508237,0.00009524408,0.000014692449,0.00016349542,0.00021487076,0.00086497597],"category_scores_gemma":[0.0015180034,0.00013244482,0.00011458031,0.000423198,0.00033493692,0.00008306143,0.00017527421,0.0006325989,0.00018561818],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012227633,0.00060129224,0.34676275,0.000039843035,0.000048833834,0.0045071086,0.00042063458,0.0000058752253,0.00011994713,0.00011225387,0.022311464,0.62384725],"study_design_scores_gemma":[0.03495219,0.021909472,0.2414316,0.0070563448,0.00034300008,0.0023018653,0.00390784,0.016460422,0.0005349596,0.021113394,0.64851964,0.0014692917],"about_ca_topic_score_codex":0.0000364139,"about_ca_topic_score_gemma":0.00011063293,"teacher_disagreement_score":0.6262082,"about_ca_system_score_codex":0.0007879951,"about_ca_system_score_gemma":0.00022567253,"threshold_uncertainty_score":0.94708806},"labels":[],"label_agreement":null},{"id":"W2052229320","doi":"10.1007/s10637-013-0040-y","title":"Synthesis and in vitro characterization of ionone-based compounds as dual inhibitors of the androgen receptor and NF-κB","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Androgen receptor; Antiandrogens; Prostate cancer; NF-κB; Androgen Receptor Antagonists; Chemistry; Androgen; Mutant; Cancer research; In vitro; Hedgehog signaling pathway; Signal transduction; Pharmacology; Biology; Medicine; Cancer; Internal medicine; Biochemistry; Gene; Hormone","score_opus":0.015647080231729855,"score_gpt":0.24870473195222512,"score_spread":0.23305765172049525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052229320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894134,0.00010515418,0.0000011467589,0.009926107,0.000032431202,0.00036963163,0.000030876734,0.0000052672794,0.00011599561],"genre_scores_gemma":[0.99898875,0.000032576492,0.00032029487,0.00022362894,0.000047225905,0.000031593216,0.000082955965,0.000007597959,0.00026538016],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99931043,0.000047018213,0.00019848424,0.00011898733,0.00023925581,0.000085841995],"domain_scores_gemma":[0.9995254,0.00013097479,0.000088121786,0.00008203204,0.000086633525,0.00008683231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010090188,0.00007337816,0.00015194168,0.00009098588,0.000032623127,0.000010162845,0.000030243273,0.000046871042,0.000060430364],"category_scores_gemma":[0.0001021049,0.00005030058,0.000023162806,0.00017390575,0.00029516578,0.000090485955,0.000025897423,0.00006415278,0.0000035949236],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013427246,0.000043252257,0.05344689,0.00007612236,0.000021659811,4.145307e-7,0.0003754393,0.0000010743619,0.94413304,0.00008917144,0.00023485124,0.0014438342],"study_design_scores_gemma":[0.00096770417,0.000038586695,0.12585706,0.00018471963,0.000016004145,0.0000033057756,0.000051563402,0.0001786187,0.87192667,0.000576205,0.0001571022,0.000042490396],"about_ca_topic_score_codex":0.00027044702,"about_ca_topic_score_gemma":0.0000023780071,"teacher_disagreement_score":0.072410166,"about_ca_system_score_codex":0.000036487985,"about_ca_system_score_gemma":0.00036029084,"threshold_uncertainty_score":0.2051198},"labels":[],"label_agreement":null},{"id":"W2052410863","doi":"10.1097/spc.0000000000000076","title":"New developments in the imaging of metastatic prostate cancer","year":2014,"lang":"en","type":"review","venue":"Current Opinion in Supportive and Palliative Care","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Lymph node; Cancer; Androgen deprivation therapy; Metastasis; Magnetic resonance imaging; Prostate; Biomarker; Oncology; Radiology; Whole body imaging; Internal medicine","score_opus":0.19680446685342032,"score_gpt":0.5025930203207523,"score_spread":0.3057885534673319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052410863","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008586552,0.99670976,0.000016692935,0.000083758176,0.0005580918,0.002184869,0.00022085044,0.000004914068,0.00013520494],"genre_scores_gemma":[0.0005560168,0.9974553,0.00006547224,0.000015330943,0.0001045465,0.000562309,0.0011291197,0.000024362134,0.000087553606],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979335,0.0002690856,0.0006952047,0.00041190628,0.00035871888,0.00033159627],"domain_scores_gemma":[0.99898577,0.00018338671,0.00036272968,0.00017521517,0.00018992991,0.000102942366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027366192,0.0003458693,0.0012687478,0.00033271342,0.00003507788,0.000019092116,0.0001397636,0.000055529992,0.000048436465],"category_scores_gemma":[0.00006400895,0.0001981452,0.00016364262,0.00052535406,0.00010343304,0.00005738717,0.00007299781,0.00048518722,0.0000053352824],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043966083,0.00005121585,0.09953331,0.04614272,0.000095936375,0.000007648778,0.007297703,1.1076043e-7,5.6278164e-8,0.000055408418,0.0008119131,0.84596],"study_design_scores_gemma":[0.0017317953,0.00010376281,0.017060524,0.06436878,0.00022646524,0.0000029473053,0.0016616454,0.0000016041404,0.0000026733287,0.000041115683,0.91457623,0.00022243815],"about_ca_topic_score_codex":0.000071851275,"about_ca_topic_score_gemma":0.000017981605,"teacher_disagreement_score":0.91376436,"about_ca_system_score_codex":0.0002846806,"about_ca_system_score_gemma":0.0014840313,"threshold_uncertainty_score":0.80801266},"labels":[],"label_agreement":null},{"id":"W2052876452","doi":"10.1016/s0022-5347(05)64108-0","title":"RE: DOES PC-SPES INTERACT WITH WARFARIN?","year":2003,"lang":"en","type":"letter","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Cancer; Internal medicine","score_opus":0.024991245989031942,"score_gpt":0.31022569505735975,"score_spread":0.2852344490683278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052876452","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017492529,0.0036361099,0.000029347599,0.9748938,0.00057855406,0.00022265775,0.0000055713317,0.000007254123,0.0031341836],"genre_scores_gemma":[0.0673049,0.0055743344,0.00014324134,0.9001816,0.0048939874,0.0000068719582,0.00002661345,0.00008568716,0.02178277],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984667,0.0003337626,0.00033126707,0.0001198489,0.00039631283,0.00035212922],"domain_scores_gemma":[0.9986273,0.00037112515,0.00037931144,0.00031102682,0.00024275127,0.00006845635],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00046434003,0.00020667122,0.00055008737,0.00020461052,0.000058675898,0.000013586149,0.00026506127,0.0003011851,0.00066656905],"category_scores_gemma":[0.000058558326,0.00007312313,0.00012927673,0.00009798388,0.00026658585,0.000046178477,0.00003701266,0.00312036,0.00003052028],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031773823,0.000058458114,0.0012799604,0.000070671376,0.00097029185,0.0056835134,0.0003556602,0.0000029748524,0.000119268414,0.0000017886282,0.9871801,0.0010998916],"study_design_scores_gemma":[0.002060787,0.003971418,0.00038944665,0.00008692447,0.0008483858,0.0051157796,0.00011220238,0.0000018743934,0.0004520972,0.00025944362,0.9866044,0.00009723631],"about_ca_topic_score_codex":0.000021108855,"about_ca_topic_score_gemma":0.000016504035,"teacher_disagreement_score":0.0747122,"about_ca_system_score_codex":0.000096518284,"about_ca_system_score_gemma":0.00031112356,"threshold_uncertainty_score":0.9991795},"labels":[],"label_agreement":null},{"id":"W2053273553","doi":"10.1074/jbc.m114.553818","title":"Selectively Targeting the DNA-binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Androgen receptor; Prostate cancer; Cancer research; DNA; Receptor; Medicine; Cancer; Oncology; Chemistry; Internal medicine; Biochemistry","score_opus":0.024110466836624548,"score_gpt":0.31744225812932136,"score_spread":0.2933317912926968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053273553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944574,0.0015236117,0.00001207781,0.0029315022,0.00005968729,0.00053195475,0.000020623458,0.000005444711,0.0004576565],"genre_scores_gemma":[0.99782217,0.00085769396,0.00022232134,0.00010342073,0.00038588914,0.000061072235,0.0000037837867,0.000009159156,0.0005344664],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990966,0.000063084735,0.00027627597,0.00013309203,0.00021411892,0.00021686885],"domain_scores_gemma":[0.99895084,0.00019748502,0.0003435033,0.00009246704,0.00034495987,0.00007076781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006836687,0.00011234481,0.00027461184,0.000012248151,0.00013879314,0.0000124017915,0.00017171181,0.000095138246,0.00008889659],"category_scores_gemma":[0.0003845188,0.00004146369,0.00020835912,0.00015180148,0.0002056133,0.000025052832,0.000034115514,0.000301059,6.0427834e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00243117,0.000114273644,0.07132108,0.000047994887,0.00021509005,0.0000018083497,0.0003846817,0.000001201525,0.9224533,0.00001153106,0.0006723138,0.0023455925],"study_design_scores_gemma":[0.002554841,0.00084706384,0.006249615,0.0001276743,0.000025863475,0.000038075865,0.00043642384,0.000005917542,0.98202455,0.0010082535,0.006621576,0.000060157243],"about_ca_topic_score_codex":0.0000040246064,"about_ca_topic_score_gemma":2.2170575e-7,"teacher_disagreement_score":0.06507146,"about_ca_system_score_codex":0.00015268128,"about_ca_system_score_gemma":0.00021939819,"threshold_uncertainty_score":0.16908403},"labels":[],"label_agreement":null},{"id":"W2053701960","doi":"10.1111/j.1464-410x.2003.04726.x","title":"Effect of time of castration and tumour volume on time to androgen‐independent recurrence in Shionogi tumours","year":2004,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"National Cancer Institute; Shionogi","keywords":"Castration; Androgen; Medicine; Prostate cancer; Internal medicine; Endocrinology; Cancer; Urology; Hormone","score_opus":0.008888084534203027,"score_gpt":0.2797088185912968,"score_spread":0.2708207340570938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053701960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970948,0.0015927567,0.00001339528,0.0008055217,0.000035657828,0.00024241616,0.00001304205,0.0000020693524,0.00020031109],"genre_scores_gemma":[0.99940145,0.0003151369,0.000056187688,0.000041321517,0.000040536397,0.0000026918046,0.000004674345,0.00000692713,0.00013107],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99905765,0.00012357529,0.00032528193,0.00011279655,0.00022198725,0.0001587013],"domain_scores_gemma":[0.99950135,0.000068198344,0.00014885554,0.00005306112,0.000113926624,0.00011462868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005943892,0.00007268944,0.00036335512,0.00019494609,0.000015841653,0.000006271328,0.000060009803,0.00006529722,0.00010432956],"category_scores_gemma":[0.00015573185,0.000066866945,0.00005279836,0.00012113298,0.000074763964,0.000053352185,0.000018148752,0.00022814194,0.000018749437],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036534347,0.00299575,0.29443812,0.0007801593,0.00050253054,0.024265308,0.0015535421,0.0038021551,0.29346734,0.000040254145,0.0033627138,0.3382578],"study_design_scores_gemma":[0.023441026,0.06956987,0.773834,0.0017276274,0.00024428387,0.02820524,0.000042743042,0.0001700394,0.10213729,0.00024317214,0.00016218092,0.0002225253],"about_ca_topic_score_codex":0.00006350394,"about_ca_topic_score_gemma":0.000019013634,"teacher_disagreement_score":0.4793959,"about_ca_system_score_codex":0.0000687579,"about_ca_system_score_gemma":0.00014628234,"threshold_uncertainty_score":0.27267548},"labels":[],"label_agreement":null},{"id":"W2053857173","doi":"10.1097/mou.0b013e32835f89b8","title":"Predicting high risk disease using serum and DNA biomarkers","year":2013,"lang":"en","type":"review","venue":"Current Opinion in Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"","keywords":"Prostate cancer; Medicine; Disease; Plasminogen activator; Oncology; Cancer; Internal medicine; Cancer research; Bioinformatics; Biology","score_opus":0.13941142132870188,"score_gpt":0.43550589068781675,"score_spread":0.2960944693591149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053857173","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028844906,0.99149024,0.000009303083,0.00014044333,0.0035476296,0.0016625635,0.00020849172,0.000037748792,0.000019094037],"genre_scores_gemma":[0.00033459227,0.9982146,0.00003405787,0.0000062718777,0.00062866823,0.00021997579,0.00049585645,0.00004571392,0.00002025367],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978891,0.00035521408,0.00049791014,0.00058648986,0.00019071803,0.00048054082],"domain_scores_gemma":[0.998851,0.00019716746,0.00025587349,0.00031467195,0.000047818354,0.00033344034],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025058526,0.00035216552,0.0010386929,0.00047289472,0.00008638324,0.000022573544,0.000108071166,0.00024657627,0.00011627903],"category_scores_gemma":[0.00014916655,0.00025452164,0.00016684092,0.00029329126,0.0002083827,0.00006242872,0.00018618128,0.00068643637,0.000029790688],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009665178,0.00012986793,0.038799584,0.024935301,0.00023703626,0.000019357067,0.00002912266,7.8200213e-7,1.5101453e-7,0.00002268326,0.0005661918,0.93516326],"study_design_scores_gemma":[0.0021364044,0.00027581723,0.00683982,0.012241271,0.0010752501,0.00008331046,0.000012958592,0.0007540058,1.4242195e-7,0.00012677137,0.9761336,0.0003206698],"about_ca_topic_score_codex":0.00006894209,"about_ca_topic_score_gemma":9.0710296e-7,"teacher_disagreement_score":0.9755674,"about_ca_system_score_codex":0.00019312219,"about_ca_system_score_gemma":0.0004870821,"threshold_uncertainty_score":0.9999907},"labels":[],"label_agreement":null},{"id":"W2053870324","doi":"10.7326/0003-4819-133-8-200010170-00014","title":"Update in Oncology","year":2000,"lang":"en","type":"review","venue":"Annals of Internal Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Cancer; Oncology; Internal medicine; Colorectal cancer; Tamoxifen; Mastectomy; Metastatic breast cancer; Chemotherapy","score_opus":0.21141421569648897,"score_gpt":0.5290562002426916,"score_spread":0.3176419845462026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053870324","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000046655652,0.9582393,0.0000010232985,0.0034133226,0.00021177254,0.00060029107,0.000021369917,0.000012942889,0.037453298],"genre_scores_gemma":[0.00004908584,0.9933903,0.000020384086,0.0010358501,0.00049741106,0.000058045545,0.00012671055,0.000037052072,0.0047851163],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997774,0.00014035834,0.0010029078,0.00032265656,0.00038326494,0.00037680598],"domain_scores_gemma":[0.99881506,0.00021786468,0.0002880469,0.00033547066,0.00012809831,0.00021546408],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000512834,0.00031224053,0.0028263708,0.00077620376,0.0000106454,0.0000023723708,0.00025133375,0.00027693532,0.0025018621],"category_scores_gemma":[0.00015170286,0.00017845962,0.00032735307,0.00039805213,0.00030169115,0.000032990727,0.00005763549,0.00071686413,0.0001663085],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004072524,0.0001824383,0.000037668495,0.0075251223,0.00034777902,0.0012223336,0.00008272782,2.7625665e-8,7.414122e-7,0.00003461821,0.02193325,0.968226],"study_design_scores_gemma":[0.0013042429,0.0018988883,0.000018339562,0.07222208,0.00029204052,0.0002835958,0.00001848589,9.366597e-7,0.000016548038,0.000080570106,0.9237609,0.00010335855],"about_ca_topic_score_codex":0.00030101382,"about_ca_topic_score_gemma":0.00001807449,"teacher_disagreement_score":0.96812266,"about_ca_system_score_codex":0.00012349458,"about_ca_system_score_gemma":0.0005286052,"threshold_uncertainty_score":0.99841},"labels":[],"label_agreement":null},{"id":"W2054565675","doi":"10.1200/jco.2005.03.1435","title":"Management of Advanced Prostate Cancer After First-Line Chemotherapy","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Docetaxel; Mitoxantrone; Vinorelbine; Chemotherapy; Capecitabine; Prostate cancer; Oncology; Internal medicine; Prostate; Cancer; Ketoconazole; Radiation therapy; Hormonal therapy; Palliative care; Colorectal cancer","score_opus":0.18161181108515118,"score_gpt":0.5740732991290675,"score_spread":0.3924614880439163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054565675","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006581736,0.9922622,0.0000051074367,0.0035637266,0.0009400636,0.0012005902,0.000030359559,0.000006691893,0.0013331252],"genre_scores_gemma":[0.00013261255,0.98813426,0.0022747354,0.00036278073,0.0015946972,0.00012748317,0.000011694427,0.00005629597,0.0073054372],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946706,0.00024573214,0.0038749604,0.00029799613,0.00055364874,0.0003570399],"domain_scores_gemma":[0.9948614,0.0006838632,0.0032864227,0.00031851575,0.0004731278,0.00037662982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017608455,0.00033092208,0.00541554,0.00022952716,0.000022144492,0.0000055667415,0.00026267464,0.00059466966,0.00073755794],"category_scores_gemma":[0.00012582075,0.00018771319,0.0017250018,0.00027061146,0.00026035277,0.000073709656,0.00008568622,0.0013785219,0.000023490073],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058952896,0.0015000504,0.0003274778,0.009611825,0.0025319112,0.0016465841,0.00003238691,0.0000034574216,5.7928386e-8,0.0000053765716,0.001348912,0.9770967],"study_design_scores_gemma":[0.009599979,0.006105852,0.0012487398,0.020456638,0.002999981,0.00011855285,0.000014327557,0.000001328264,0.000001396143,0.000030558887,0.9592828,0.00013983126],"about_ca_topic_score_codex":0.0000034921234,"about_ca_topic_score_gemma":0.000014297475,"teacher_disagreement_score":0.97695684,"about_ca_system_score_codex":0.00055918645,"about_ca_system_score_gemma":0.0025560213,"threshold_uncertainty_score":0.8075742},"labels":[],"label_agreement":null},{"id":"W2055346449","doi":"10.1016/s1470-2045(14)71205-7","title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1354,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Janssen Research and Development","keywords":"Abiraterone acetate; Prednisone; Medicine; Prostate cancer; Placebo; Internal medicine; Oncology; Castration; Urology; Abiraterone; Enzalutamide; Cancer; Androgen deprivation therapy; Hormone; Androgen receptor; Pathology","score_opus":0.15890906001276825,"score_gpt":0.4258998720708133,"score_spread":0.2669908120580451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055346449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97999656,0.0012359832,0.00007198528,0.003110346,0.00016069006,0.013286943,0.00019430928,0.000055568646,0.0018875914],"genre_scores_gemma":[0.99102753,0.0005633815,0.00027294434,0.00008901483,0.00018337353,0.0047456753,0.00019599556,0.000057940702,0.0028641436],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995339,0.0011372853,0.0009978913,0.00068211573,0.000950179,0.0008935454],"domain_scores_gemma":[0.9970813,0.0007721098,0.00066802575,0.0007054448,0.0004818679,0.0002912504],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029988727,0.00051346363,0.0032825975,0.0004817025,0.00012812486,0.000057915062,0.00036290666,0.00012711262,0.00019067863],"category_scores_gemma":[0.00009622835,0.0003006473,0.00021976221,0.0010922953,0.00040412525,0.00017520985,0.00008584069,0.00051378645,0.000007720719],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9464379,0.002250246,0.0020993405,0.00011443043,0.014893086,0.00046957773,0.017457305,0.013764849,0.0015997664,0.000026489806,0.0003336929,0.00055333256],"study_design_scores_gemma":[0.9573971,0.011831927,0.001784175,0.000074258365,0.007183235,0.000012477719,0.0056852424,0.014815172,0.00073730893,0.000026562908,0.00015600615,0.00029652027],"about_ca_topic_score_codex":0.0035522305,"about_ca_topic_score_gemma":0.010290279,"teacher_disagreement_score":0.011772063,"about_ca_system_score_codex":0.0017690195,"about_ca_system_score_gemma":0.0030783482,"threshold_uncertainty_score":0.99994457},"labels":[],"label_agreement":null},{"id":"W2055689281","doi":"10.1016/s0009-8981(00)00319-3","title":"Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland","year":2000,"lang":"en","type":"article","venue":"Clinica Chimica Acta","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Kallikrein; Thyroid; Proteases; Prostate; Immunohistochemistry; Pathology; Prostate cancer; Antigen; Prostate-specific antigen; Biology; Hyperplasia; Cancer; Medicine; Endocrinology; Internal medicine; Enzyme; Immunology; Biochemistry","score_opus":0.04083136375798164,"score_gpt":0.34368835830575,"score_spread":0.3028569945477684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055689281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924915,0.0008333109,8.890518e-8,0.0021362524,0.000021274222,0.0006531465,0.000018760144,0.000016018368,0.0038296885],"genre_scores_gemma":[0.9921914,0.0067157047,0.000076905984,0.0001470483,0.00010043654,0.000025975667,0.00009189744,0.000016192938,0.0006344423],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99869937,0.00012462387,0.00038293572,0.00029249594,0.00025376838,0.00024683858],"domain_scores_gemma":[0.99922013,0.00016326222,0.00006949747,0.00042930173,0.000031474883,0.00008630934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004706756,0.00013239832,0.00031367433,0.00007102686,0.00008999562,0.000022347096,0.00016700313,0.000099475496,0.0003769063],"category_scores_gemma":[0.000027369011,0.00007404751,0.00006895859,0.0001593595,0.00022666075,0.000060577542,0.0000394571,0.0002972627,0.000009008473],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032992992,0.0011275194,0.36976483,0.00013743609,0.000058350855,0.0001123635,0.0036917897,3.9896412e-7,0.60944957,0.000051216266,0.007812711,0.0044945492],"study_design_scores_gemma":[0.007815296,0.0015864,0.90011436,0.0003927553,0.000032639127,0.00002331097,0.00026892254,0.000010378869,0.03164459,0.00038031518,0.057566307,0.00016472916],"about_ca_topic_score_codex":0.000031518146,"about_ca_topic_score_gemma":0.000011122266,"teacher_disagreement_score":0.5778049,"about_ca_system_score_codex":0.00001771779,"about_ca_system_score_gemma":0.000048562615,"threshold_uncertainty_score":0.41268596},"labels":[],"label_agreement":null},{"id":"W2056052378","doi":"10.1002/cncr.25982","title":"The association between radiographic response and overall survival in men with metastatic castration‐resistant prostate cancer receiving chemotherapy","year":2011,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Oncology; Chemotherapy; Castration; Internal medicine; Prostate; Cancer; Hormone","score_opus":0.03901570953446192,"score_gpt":0.31713427720046766,"score_spread":0.27811856766600573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056052378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902338,0.004633325,0.0000039242145,0.0034774824,0.000050355527,0.000806565,0.00004514111,0.000022278073,0.0007271785],"genre_scores_gemma":[0.9844036,0.01029534,0.00011135631,0.00007984481,0.00006823771,0.00038586988,0.000009424492,0.000028315257,0.004618008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866813,0.00019105473,0.00020330476,0.0002462677,0.00033647084,0.00035476623],"domain_scores_gemma":[0.999242,0.00024763306,0.00011916906,0.00016050259,0.00012717598,0.000103521765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008792038,0.00014592649,0.0002545247,0.00011118711,0.00014867632,0.00004317945,0.000060687144,0.000044902776,0.000060266502],"category_scores_gemma":[0.000042569198,0.00008613737,0.00003470702,0.00033804338,0.000101865735,0.000115740506,0.000012962377,0.0001964608,9.958416e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010275346,0.000038753158,0.97545385,0.000052566666,0.000529585,0.000034481374,0.0034678786,0.0000028433305,0.0030697994,0.000024378,0.000328943,0.006721574],"study_design_scores_gemma":[0.0047630393,0.00032251846,0.9896875,0.00018223631,0.00012569054,0.0000018265482,0.00033209345,0.000027420216,0.0026524833,0.000119642034,0.0016696762,0.00011587422],"about_ca_topic_score_codex":0.0020660884,"about_ca_topic_score_gemma":0.002075141,"teacher_disagreement_score":0.014233648,"about_ca_system_score_codex":0.0005932893,"about_ca_system_score_gemma":0.00042132306,"threshold_uncertainty_score":0.351258},"labels":[],"label_agreement":null},{"id":"W2056379162","doi":"10.5489/cuaj.1532","title":"Synchronous primary malignancies of the male urogenital tract","year":2014,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Cystoprostatectomy; Medicine; Bladder cancer; Prostate cancer; Genitourinary system; Incidence (geometry); Prostate; Cancer; Population; Oncology; Urinary bladder; Urology; Internal medicine; Prostatectomy","score_opus":0.02700141778462955,"score_gpt":0.2872743204188114,"score_spread":0.26027290263418185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056379162","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009571513,0.9917119,0.0000023524312,0.0018822398,0.00036657805,0.00054758065,0.00014127334,0.00000843848,0.004382482],"genre_scores_gemma":[0.003948685,0.99026173,0.000025224314,0.0005639334,0.0005800372,0.000024329682,0.00006775887,0.000025729383,0.004502545],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99776983,0.0003914989,0.0005771785,0.00019429998,0.0005301462,0.00053705205],"domain_scores_gemma":[0.9981168,0.00024947678,0.0006718538,0.00019616148,0.00024351905,0.00052219984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007246664,0.0002360856,0.0011625425,0.00018795609,0.00023400098,0.00005058332,0.00027981336,0.00051398505,0.00061764586],"category_scores_gemma":[0.0005115766,0.00012386849,0.0008526891,0.00028508005,0.000089665366,0.000039830258,0.00003295764,0.0011214812,0.00006656226],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036766483,0.00023067824,0.06024149,0.003928409,0.0014494376,0.0005962533,0.00008348665,0.00000180189,0.000004168619,0.00009889321,0.03239907,0.9009296],"study_design_scores_gemma":[0.00038553297,0.0002316218,0.012367797,0.00089673523,0.0008020208,0.0016608315,0.0000056285508,9.301487e-7,8.020203e-7,0.00003430698,0.9834956,0.00011817817],"about_ca_topic_score_codex":0.00017070185,"about_ca_topic_score_gemma":0.00006594206,"teacher_disagreement_score":0.95109653,"about_ca_system_score_codex":0.0028754973,"about_ca_system_score_gemma":0.0041938187,"threshold_uncertainty_score":0.75193256},"labels":[],"label_agreement":null},{"id":"W2056491603","doi":"10.1007/s12094-014-1259-6","title":"Immunotherapy in prostate cancer: review of the current evidence","year":2014,"lang":"en","type":"review","venue":"Clinical & Translational Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Current (fluid); Immunotherapy; Oncology; Cancer; Gynecology; Intensive care medicine; Medical physics; Internal medicine","score_opus":0.2961254309978133,"score_gpt":0.601470170958419,"score_spread":0.30534473996060574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056491603","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008304852,0.98808086,0.000004146474,0.0075115017,0.00076134154,0.0032127334,0.00006597701,0.000008782269,0.00034633698],"genre_scores_gemma":[0.000015991602,0.9979502,0.00006628267,0.00063179655,0.00031453083,0.00059737515,0.000093302784,0.000029148117,0.00030140436],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99550325,0.0012364147,0.002122436,0.00043206208,0.00043812074,0.0002677118],"domain_scores_gemma":[0.9957383,0.002836129,0.00067605736,0.00043209715,0.00021622633,0.0001011647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022138366,0.0002665412,0.0029372876,0.0000961203,0.000034172208,0.0000032288153,0.00033414256,0.00024547335,0.0002754623],"category_scores_gemma":[0.00039922947,0.00014080519,0.001184698,0.0005030784,0.00046893716,0.000037083522,0.000037583603,0.0013510833,0.000027984821],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001764262,0.00030402793,0.0017639672,0.08843607,0.0001534546,0.0000061058595,0.000014850675,2.4779638e-7,1.0325888e-7,0.0000612062,0.00082542305,0.90825814],"study_design_scores_gemma":[0.0010467434,0.00032533315,0.001561913,0.25558794,0.00053582946,0.000009514888,2.4377928e-7,0.0000025402828,1.3400872e-7,0.00009437752,0.74074733,0.00008808087],"about_ca_topic_score_codex":0.000015440022,"about_ca_topic_score_gemma":0.000025830494,"teacher_disagreement_score":0.90817004,"about_ca_system_score_codex":0.0002738491,"about_ca_system_score_gemma":0.00633832,"threshold_uncertainty_score":0.9992948},"labels":[],"label_agreement":null},{"id":"W2056673480","doi":"10.1007/s11626-006-0009-7","title":"Molecular analysis and characterization of PrEc, commercially available prostate epithelial cells","year":2006,"lang":"en","type":"article","venue":"In Vitro Cellular & Developmental Biology - Animal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"Health Canada","keywords":"Cytokeratin; Western blot; Immunohistochemistry; Prostate; Androgen receptor; Chromogranin A; Prostate cancer; Biology; Prostate-specific antigen; Blot; Antigen; Molecular biology; Pathology; Cancer research; Cancer; Medicine; Immunology; Gene","score_opus":0.010434569915994446,"score_gpt":0.2461459252415445,"score_spread":0.23571135532555004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056673480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979996,0.0003904851,0.00009068324,0.00014618968,0.00003699828,0.0004915507,0.0001212318,0.000018090936,0.00070517766],"genre_scores_gemma":[0.9959741,0.00015241624,0.0014551315,0.00005515414,0.000025544623,0.00003538737,0.0017274847,0.000015546837,0.0005592267],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872726,0.00008446366,0.00037938493,0.0003447368,0.00013505395,0.0003290812],"domain_scores_gemma":[0.9996434,0.000021761945,0.00010127532,0.000101787606,0.00006536228,0.000066424465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019973252,0.00017397164,0.00042776766,0.00035260414,0.000051970324,0.000011927721,0.00006980469,0.00013370004,0.00011324926],"category_scores_gemma":[0.0000056975623,0.00014934698,0.00009092387,0.0005008627,0.00020655687,0.000057489626,0.00008114841,0.00013225907,0.000022516497],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012009591,0.00019079258,0.15819865,0.000040346775,0.00023998105,0.00007698327,0.000110618064,3.9211253e-7,0.83908284,0.000019335988,0.000008543053,0.000830545],"study_design_scores_gemma":[0.0015067114,0.0002283811,0.110450186,0.000014098685,0.0001537159,0.0000061396704,0.000020547404,0.00008574586,0.8868625,0.000023014569,0.00052286795,0.00012609616],"about_ca_topic_score_codex":0.00033510308,"about_ca_topic_score_gemma":0.00002467077,"teacher_disagreement_score":0.04777965,"about_ca_system_score_codex":0.00011226681,"about_ca_system_score_gemma":0.00016498494,"threshold_uncertainty_score":0.60901934},"labels":[],"label_agreement":null},{"id":"W2057068658","doi":"10.5489/cuaj.2029","title":"ECF chemotherapy for liver metastases due to castration-resistant prostate cancer","year":2014,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"Eisai; Celgene; Eli Lilly and Company","keywords":"Prostate cancer; Castration; Medicine; Chemotherapy; Oncology; Internal medicine; Metastasis; Cancer; Cancer research; Urology; Hormone","score_opus":0.025326071875360665,"score_gpt":0.2979412556575699,"score_spread":0.2726151837822092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057068658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8171823,0.0010367344,0.0005260124,0.17765851,0.00041840048,0.0014906934,0.0004589945,0.000040956034,0.0011874238],"genre_scores_gemma":[0.98491025,0.00022171348,0.000957403,0.009607009,0.000717207,0.00013916365,0.000055666893,0.000019201603,0.00337236],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863565,0.00009911092,0.00023443482,0.0001940531,0.00029992842,0.00053681555],"domain_scores_gemma":[0.99831086,0.00015086772,0.000119020304,0.000082680315,0.0004626189,0.00087395473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006834062,0.00012667962,0.0002603089,0.0001563448,0.00030836638,0.0001061811,0.000079808335,0.00011267225,0.0006342571],"category_scores_gemma":[0.00046377807,0.00009066251,0.00011899744,0.0001769676,0.000022219372,0.00007155099,0.000005892222,0.00023628313,0.000031126532],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004956395,0.0004335243,0.40900892,0.000117407275,0.001732046,0.0005867409,0.0019130667,0.0004598621,0.011605874,0.0018439329,0.36359432,0.2037479],"study_design_scores_gemma":[0.0042583225,0.0017181434,0.40314358,0.000033799202,0.00014185628,0.00008345874,0.00007449719,0.00037996136,0.0011423691,0.00082416664,0.58798283,0.00021700325],"about_ca_topic_score_codex":0.001673055,"about_ca_topic_score_gemma":0.0036309364,"teacher_disagreement_score":0.22438848,"about_ca_system_score_codex":0.0012506803,"about_ca_system_score_gemma":0.0007775438,"threshold_uncertainty_score":0.69446707},"labels":[],"label_agreement":null},{"id":"W2057332580","doi":"10.1158/0008-5472.can-14-3602","title":"PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Boehringer Ingelheim Stiftung","keywords":"Prostate cancer; Mediator; Androgen deprivation therapy; Suppressor; Castration; Androgen; Cancer; Medicine; Oncology; Prostate; Internal medicine; Cancer research; Hormone","score_opus":0.1323011254307638,"score_gpt":0.43091777429584993,"score_spread":0.2986166488650861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057332580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97099847,0.01562616,0.000008736541,0.009401181,0.000085413965,0.0029616312,0.00040989835,0.000018961673,0.00048956065],"genre_scores_gemma":[0.9910842,0.0032205319,0.0007377692,0.00030601455,0.00014028928,0.001988757,0.0000424055,0.000060182552,0.0024198582],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958325,0.00029032858,0.0005754553,0.0006253943,0.0018156439,0.0008606666],"domain_scores_gemma":[0.99697167,0.00018582564,0.000098582976,0.000541802,0.0015396919,0.00066245144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013540805,0.0002339679,0.00052437617,0.00059504283,0.0000851816,0.00005718636,0.0002993104,0.0000687863,0.00041727224],"category_scores_gemma":[0.00037510067,0.00018491036,0.00007403011,0.0016797127,0.00031230508,0.0001433572,0.00010643716,0.00041403854,0.00004279567],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034098197,0.0010111643,0.07780124,0.0010989633,0.000469278,0.0006436472,0.014540239,0.00011143006,0.8365058,0.00021130125,0.026156249,0.007352516],"study_design_scores_gemma":[0.01105189,0.0015167918,0.023057299,0.0008577284,0.00004455525,0.0000070295378,0.001539561,0.00011422686,0.94467354,0.0006878366,0.016140418,0.00030915617],"about_ca_topic_score_codex":0.0017948974,"about_ca_topic_score_gemma":0.002714994,"teacher_disagreement_score":0.10816773,"about_ca_system_score_codex":0.0009982808,"about_ca_system_score_gemma":0.004014497,"threshold_uncertainty_score":0.75404257},"labels":[],"label_agreement":null},{"id":"W2057400303","doi":"10.1016/j.urolonc.2012.02.008","title":"Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials","year":2012,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Ketoconazole; Oncology; Enzalutamide; Abiraterone acetate; Internal medicine; Cabazitaxel; Prednisone; Chemotherapy; Hazard ratio; Androgen deprivation therapy; Urology; Cancer; Androgen receptor; Confidence interval; Dermatology","score_opus":0.1952417861184199,"score_gpt":0.49993038371269305,"score_spread":0.30468859759427314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057400303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755242,0.0055139773,0.00004996054,0.015297463,0.000109625114,0.0033292682,0.00007480605,0.00001714489,0.00008357338],"genre_scores_gemma":[0.9722363,0.0024012995,0.02201418,0.000956452,0.00009537697,0.0020409094,0.00012000848,0.000017136887,0.00011835835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978082,0.00044853377,0.0009634615,0.00028589586,0.00010746653,0.00038643842],"domain_scores_gemma":[0.9968603,0.0023577109,0.0003208609,0.0001748642,0.00007497059,0.00021123882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032979613,0.00016933877,0.0007860723,0.000236199,0.00010400349,0.000011439026,0.00007760933,0.00014830392,0.000028044304],"category_scores_gemma":[0.0007535513,0.00012356455,0.00017265361,0.00038606487,0.0003786136,0.000107445085,0.000010571972,0.00024826918,9.2738316e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026167692,0.0013292792,0.9540364,0.000057034318,0.00014393624,0.000008298069,0.00059738307,0.000057982532,0.0063990764,0.0010332039,0.0002448283,0.03347578],"study_design_scores_gemma":[0.037650935,0.0052509764,0.8399122,0.00021225828,0.00039280756,0.0000149585985,0.00030628644,0.0006405604,0.0048035104,0.0032803318,0.10726522,0.0002699997],"about_ca_topic_score_codex":0.000111358924,"about_ca_topic_score_gemma":0.00009901048,"teacher_disagreement_score":0.114124276,"about_ca_system_score_codex":0.00016824782,"about_ca_system_score_gemma":0.0012059879,"threshold_uncertainty_score":0.50388163},"labels":[],"label_agreement":null},{"id":"W2057424941","doi":"10.1158/1538-7445.am2011-4491","title":"Abstract 4491: AZD5363, a novel Akt inhibitor, delays prostate cancer progression by inhibiting androgen-receptor activity","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"LNCaP; Prostate cancer; Cancer research; Medicine; Protein kinase B; Population; Transactivation; PI3K/AKT/mTOR pathway; Cancer; Biology; Signal transduction; Internal medicine; Cell biology; Biochemistry; Transcription factor","score_opus":0.12379443124574548,"score_gpt":0.4253914490580969,"score_spread":0.30159701781235143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057424941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810722,0.010344739,0.000012348393,0.0019227004,0.00031644592,0.0026349714,0.00047840446,0.0001543695,0.003063844],"genre_scores_gemma":[0.98772943,0.0043762275,0.00026125473,0.00008374234,0.00061932317,0.0025923073,0.00010638207,0.00013057914,0.004100735],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948353,0.00014159003,0.0004293671,0.0010292612,0.0018211051,0.001743331],"domain_scores_gemma":[0.9974255,0.00012417846,0.00015594564,0.0004986576,0.00097577536,0.0008199197],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012830355,0.0004145784,0.0005360301,0.0004112574,0.0006108549,0.00011767072,0.00031458435,0.00030512395,0.002083124],"category_scores_gemma":[0.00013462991,0.0003171487,0.00016947767,0.0011020369,0.0006531323,0.00046772548,0.00033844478,0.0016164237,0.00015335438],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046193595,0.0011596711,0.022650266,0.0005991397,0.00023127378,0.00011546546,0.0018294834,9.234863e-7,0.8654639,0.000018507795,0.019424217,0.083887756],"study_design_scores_gemma":[0.0054412037,0.0008154554,0.0055713877,0.0014692995,0.000043745964,0.000014658729,0.00037657013,0.00003777383,0.96916,0.00003333891,0.01665471,0.00038182168],"about_ca_topic_score_codex":0.003963193,"about_ca_topic_score_gemma":0.00020259808,"teacher_disagreement_score":0.1036961,"about_ca_system_score_codex":0.001353074,"about_ca_system_score_gemma":0.0018790963,"threshold_uncertainty_score":0.99992806},"labels":[],"label_agreement":null},{"id":"W2057672608","doi":"10.1002/cncr.23908","title":"An updated catalog of prostate cancer predictive tools","year":2008,"lang":"en","type":"review","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":260,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Nomogram; Generalizability theory; Predictive modelling; Prostate cancer; Clinical trial; MEDLINE; Disease; Medical physics; Intensive care medicine; Machine learning; Cancer; Computer science; Oncology; Internal medicine; Statistics","score_opus":0.08558351400700404,"score_gpt":0.4252806458500926,"score_spread":0.3396971318430886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057672608","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028970736,0.9906236,0.0000019516217,0.00007222269,0.00037893147,0.0028451416,0.004791394,0.00007852667,0.00091853],"genre_scores_gemma":[0.00011084205,0.9868409,0.000030169831,0.000052546657,0.000498235,0.0021319038,0.0048092,0.00011623279,0.0054099937],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976131,0.000104377184,0.0006025447,0.0006580072,0.00048539866,0.00053660356],"domain_scores_gemma":[0.99818057,0.00004417083,0.00036794518,0.00066763535,0.00040963513,0.00033003633],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008244759,0.0005015146,0.002077027,0.00026301807,0.000084152976,0.00001941686,0.0002622747,0.0003560911,0.0008557679],"category_scores_gemma":[0.00001751651,0.0003355715,0.0003940929,0.0006377912,0.00035276072,0.00018828841,0.000065962005,0.00056757004,0.00003216478],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031574583,0.00019572959,0.00058897113,0.0094480645,0.0012397809,0.00019144351,0.0004008446,0.0000036434972,0.000012498994,0.0000055335495,0.017919365,0.9696784],"study_design_scores_gemma":[0.0012565779,0.00047782258,0.00021868924,0.012127038,0.0013500613,0.00006232211,0.000026732805,0.0000074815807,0.00020629317,0.0000043107107,0.9839557,0.0003070082],"about_ca_topic_score_codex":0.00070647,"about_ca_topic_score_gemma":0.000059637703,"teacher_disagreement_score":0.9693714,"about_ca_system_score_codex":0.0009802795,"about_ca_system_score_gemma":0.004558448,"threshold_uncertainty_score":0.99990964},"labels":[],"label_agreement":null},{"id":"W2057734107","doi":"10.1016/j.eururo.2009.06.027","title":"Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets","year":2009,"lang":"en","type":"review","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":255,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Cancer Research UK","keywords":"Medicine; Prostate cancer; Clinical trial; Oncology; Androgen receptor; Immunotherapy; Internal medicine; Bevacizumab; Bioinformatics; Cancer; Chemotherapy","score_opus":0.06359432475833031,"score_gpt":0.3659656362270145,"score_spread":0.3023713114686842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057734107","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001367063,0.99121547,0.000015432926,0.002550098,0.00045718113,0.0023716732,0.00035112677,0.00012076862,0.002781522],"genre_scores_gemma":[0.000019080999,0.9596655,0.00062006107,0.0011601622,0.0022203855,0.000089334426,0.0016421808,0.00014222357,0.0344411],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965424,0.0006148561,0.0007164662,0.0011047736,0.00022438138,0.0007971553],"domain_scores_gemma":[0.99788105,0.00013518379,0.00025905194,0.00075330527,0.00006948267,0.00090192124],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011136601,0.0007364047,0.002107923,0.0002858573,0.00009780464,0.00003574409,0.00027860573,0.00021944042,0.0006792674],"category_scores_gemma":[0.000051464136,0.00049767195,0.00045600143,0.0003221809,0.00007217913,0.0000366516,0.00010419634,0.00044522213,0.0017982833],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006834059,0.00014544623,0.000008414123,0.00030035523,0.00054604356,0.0022542996,0.0004035507,0.0000044036838,0.00013691971,0.000009760258,0.029307434,0.9662],"study_design_scores_gemma":[0.0020536769,0.0047678975,0.00033325056,0.00087227963,0.0014770526,0.000038369923,0.000005243756,6.3646456e-7,0.000011244446,0.00013004988,0.9899594,0.00035087718],"about_ca_topic_score_codex":0.0021076924,"about_ca_topic_score_gemma":0.00022694007,"teacher_disagreement_score":0.9658491,"about_ca_system_score_codex":0.0005461594,"about_ca_system_score_gemma":0.0026262987,"threshold_uncertainty_score":0.9997475},"labels":[],"label_agreement":null},{"id":"W2058238465","doi":"10.1002/cam4.49","title":"Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of <i><scp>TMPRSS</scp>2:<scp>ETS</scp></i> fusion gene markers","year":2012,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Medicine; PCA3; Biopsy; Prostate biopsy; Internal medicine; Cancer; TMPRSS2; Oncology; Prostate; Odds ratio; Prostate-specific antigen; Prospective cohort study; Urine; Receiver operating characteristic; Disease; Coronavirus disease 2019 (COVID-19)","score_opus":0.0704397069507736,"score_gpt":0.3600992697251262,"score_spread":0.28965956277435256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058238465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762679,0.016866762,0.00012628558,0.00019962218,0.0010269637,0.004734899,0.00021860216,0.00007397748,0.00048500556],"genre_scores_gemma":[0.9864596,0.008587284,0.00020191255,0.00017693194,0.001063577,0.0017844946,0.00003294248,0.00011401885,0.0015792155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99506783,0.0001811904,0.0014419594,0.00080724765,0.0014324103,0.0010693383],"domain_scores_gemma":[0.9958255,0.00084848795,0.0009932751,0.00065608433,0.000989627,0.00068702333],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014636209,0.0005478768,0.0014025279,0.00042211637,0.00020714852,0.000010762055,0.00024106512,0.00024576948,0.000100817],"category_scores_gemma":[0.0010973251,0.0003923223,0.00022337276,0.0011954389,0.0007720593,0.0002339964,0.00022237128,0.0005786105,0.0000059007357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001010518,0.0014198229,0.6438612,0.0005347705,0.0007462093,0.000025609033,0.012109421,0.000022048975,0.33596373,0.0000016705917,0.00050479133,0.0038002399],"study_design_scores_gemma":[0.01820098,0.0071005384,0.7516118,0.0024438635,0.0019221171,0.000027521322,0.008389655,0.00017593849,0.20831724,0.0000162644,0.0016483036,0.00014573184],"about_ca_topic_score_codex":0.0044768066,"about_ca_topic_score_gemma":0.00015094831,"teacher_disagreement_score":0.1276465,"about_ca_system_score_codex":0.0012532114,"about_ca_system_score_gemma":0.0006759159,"threshold_uncertainty_score":0.9998529},"labels":[],"label_agreement":null},{"id":"W2058403800","doi":"10.1111/j.1464-410x.2008.08200.x","title":"Integration of <i>ERG</i> gene mapping and gene‐expression profiling identifies distinct categories of human prostate cancer","year":2008,"lang":"en","type":"letter","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Cancerfonden; National Institute for Health and Care Research; Cancer Research UK; European Commission; Royal Marsden NHS Foundation Trust","keywords":"Erg; Prostate cancer; Biology; Prostate; Gene expression profiling; Gene; Gene expression; Computational biology; Cancer research; Cancer; Microarray; Genetics","score_opus":0.030689688874643278,"score_gpt":0.3032587059967026,"score_spread":0.27256901712205933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058403800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9286133,0.050810654,0.00009412099,0.019298175,0.00043035048,0.00048162593,0.00017577193,0.000009094138,0.000086910455],"genre_scores_gemma":[0.9160865,0.06950463,0.0012434061,0.0068416735,0.0029489093,0.00006183541,0.00075032416,0.00010311557,0.002459613],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99798363,0.00015747423,0.00087524526,0.00024195915,0.0004486057,0.0002930578],"domain_scores_gemma":[0.99792844,0.000076428216,0.0010113062,0.00013563044,0.00077798264,0.0000701937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027688558,0.00020123085,0.00086049084,0.00031743088,0.00012089191,0.000024661947,0.00013400769,0.00035802484,0.00003553758],"category_scores_gemma":[0.00009313992,0.0001757507,0.00015551521,0.0001274383,0.0005225137,0.00012476524,0.00007361652,0.0011802037,3.0997606e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008118006,0.0001450723,0.020239968,0.001788879,0.0006269324,0.008924014,0.0012498323,0.000008120573,0.8125215,0.0000018832444,0.1448042,0.0088777775],"study_design_scores_gemma":[0.009200028,0.0037932014,0.048283678,0.0055181724,0.0011483158,0.02974045,0.00041693257,0.000023941135,0.8723347,0.0008956489,0.027997846,0.0006470571],"about_ca_topic_score_codex":0.00042502742,"about_ca_topic_score_gemma":0.000046981128,"teacher_disagreement_score":0.11680635,"about_ca_system_score_codex":0.000075968805,"about_ca_system_score_gemma":0.0003528386,"threshold_uncertainty_score":0.71669054},"labels":[],"label_agreement":null},{"id":"W2058795397","doi":"10.1016/j.ejca.2012.01.001","title":"ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Prostate Cancer Canada; Alberta Cancer Foundation; University of Calgary; University of Alberta","funders":"","keywords":"Erg; Prostate cancer; Medicine; Hazard ratio; Internal medicine; Proportional hazards model; Oncology; Cancer; Cohort; Prostate; Confidence interval; Ophthalmology","score_opus":0.06908365167858256,"score_gpt":0.350750875269375,"score_spread":0.28166722359079244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058795397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93746364,0.059952993,0.0000033553251,0.0015300356,0.00007443995,0.00048825174,0.00004381651,0.000011925961,0.00043155096],"genre_scores_gemma":[0.98551995,0.010336239,0.00015827116,0.000100054705,0.000343375,0.000025819667,0.0000043189907,0.00004457319,0.00346743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826634,0.000399735,0.00028291065,0.00019482046,0.0004926833,0.00036351194],"domain_scores_gemma":[0.99884856,0.00003975225,0.0002933667,0.00014059366,0.00025415389,0.00042357176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079903327,0.00021025586,0.0003392254,0.000107692715,0.00011901139,0.00004362373,0.000050902923,0.00003054986,0.000120894394],"category_scores_gemma":[0.00003811221,0.00011948499,0.00005404476,0.00015135805,0.00015425899,0.0002269468,0.00003294177,0.00023835612,0.0000020877246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034825187,0.0005135031,0.5531936,0.000096456206,0.00093206705,0.0014586332,0.006181765,0.0000036613135,0.34350437,0.000003271657,0.0038204377,0.05546703],"study_design_scores_gemma":[0.007427616,0.0031778794,0.8670084,0.0018479052,0.00020892362,0.00011464036,0.00015904706,0.000003369783,0.10139633,0.0000047422113,0.01848459,0.00016659164],"about_ca_topic_score_codex":0.000028306606,"about_ca_topic_score_gemma":0.000011334741,"teacher_disagreement_score":0.31381476,"about_ca_system_score_codex":0.0004447434,"about_ca_system_score_gemma":0.0002894586,"threshold_uncertainty_score":0.48724565},"labels":[],"label_agreement":null},{"id":"W2059068580","doi":"10.1016/j.humpath.2013.10.012","title":"The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature","year":2013,"lang":"en","type":"review","venue":"Human Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Erg; TMPRSS2; Prostate cancer; Prostate; Medicine; Immunostaining; Tissue microarray; Adenocarcinoma; Clinical significance; Cancer; Pathology; Prostate-specific antigen; Transurethral resection of the prostate; Immunohistochemistry; Oncology; Internal medicine; Ophthalmology","score_opus":0.07048881949045828,"score_gpt":0.4015588700141579,"score_spread":0.33107005052369964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059068580","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.110984206,0.88223016,1.860753e-8,0.00006579459,0.000035556608,0.0065772077,0.000036931553,0.000005924423,0.00006418483],"genre_scores_gemma":[0.08068282,0.91798264,0.000006772585,0.000015550497,0.000027225586,0.00095665164,0.00004696124,0.000026998605,0.00025439193],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99723834,0.0011771872,0.0007105579,0.00034418696,0.00023925908,0.00029047322],"domain_scores_gemma":[0.9980155,0.0006785755,0.00046122732,0.0006281407,0.00017337965,0.00004315097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083651074,0.00029846505,0.0016609726,0.00014664557,0.0001718324,0.000016767963,0.00023264695,0.00015204526,0.0000112583775],"category_scores_gemma":[0.0005297512,0.00013258202,0.00019936336,0.00044695326,0.00040915067,0.000038920054,0.00036924073,0.00065594417,0.0000020389714],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001162914,0.0017254036,0.104520984,0.478833,0.00065561035,0.0025223808,0.007254224,1.1410834e-8,0.00022591809,0.00017995617,0.00020344066,0.4037628],"study_design_scores_gemma":[0.0035758344,0.006920815,0.17590606,0.7728225,0.005885577,0.00491328,0.0016608078,7.131684e-7,0.00005342786,0.00038091704,0.027301386,0.0005786913],"about_ca_topic_score_codex":0.000036326674,"about_ca_topic_score_gemma":0.00003183034,"teacher_disagreement_score":0.4031841,"about_ca_system_score_codex":0.00010729565,"about_ca_system_score_gemma":0.00028600378,"threshold_uncertainty_score":0.5406538},"labels":[],"label_agreement":null},{"id":"W2059081518","doi":"10.1016/j.ijrobp.2014.05.195","title":"Identification of Single Nucleotide Polymorphisms (SNPs) Associated With Late Toxicity Following Radiation Therapy for Prostate Cancer Through a Meta-Analysis of Genome-Wide Association Studies (GWAS)","year":2014,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Prostate cancer; Single-nucleotide polymorphism; Genome-wide association study; Oncology; Internal medicine; Meta-analysis; Radiation therapy; Cancer; Genetics; Genotype; Biology","score_opus":0.0625530680824732,"score_gpt":0.38024948051918306,"score_spread":0.3176964124367099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059081518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824325,0.004385291,0.0061832564,0.0053591523,0.0006002692,0.00068167376,0.00029491363,0.000020733281,0.000042251515],"genre_scores_gemma":[0.9952874,0.00271865,0.0004945221,0.0005453641,0.00032165836,0.000080912476,0.00031213192,0.00002867392,0.00021064331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99736714,0.0003831187,0.0011678359,0.00026321277,0.00057602796,0.00024266228],"domain_scores_gemma":[0.9918087,0.0019152517,0.003626388,0.00015705638,0.0024297035,0.00006290557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017282075,0.00021340634,0.0013465113,0.00034231646,0.00008912,0.000021839824,0.00021737606,0.00017746964,0.000022272294],"category_scores_gemma":[0.0014292728,0.0001558787,0.000935194,0.0005856388,0.00012912482,0.00036837952,0.000025370058,0.00019704945,9.591179e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018929793,0.0012605068,0.6142933,0.000029125691,0.27731594,0.0000047233125,0.0035661666,0.008239832,0.07889984,0.00038739384,0.00025686427,0.013853366],"study_design_scores_gemma":[0.037769966,0.01102048,0.48815656,0.00018012214,0.15888913,0.0000060418556,0.0006274784,0.012594702,0.2693875,0.014519117,0.0059924508,0.000856466],"about_ca_topic_score_codex":0.000042248168,"about_ca_topic_score_gemma":0.000030319397,"teacher_disagreement_score":0.19048767,"about_ca_system_score_codex":0.0015940252,"about_ca_system_score_gemma":0.00038806756,"threshold_uncertainty_score":0.6356549},"labels":[],"label_agreement":null},{"id":"W2059097089","doi":"10.1021/jm201098n","title":"Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening.","year":2011,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research","keywords":"Androgen receptor; In silico; Mechanism of action; Virtual screening; Prostate cancer; Chemistry; Antiandrogen; Mechanism (biology); Computational biology; Cytotoxicity; Function (biology); Androgen; Drug; Binding site; Drug discovery; Pharmacology; Cancer research; Cancer; Biochemistry; Biology; In vitro; Cell biology; Genetics; Gene","score_opus":0.04831820523702504,"score_gpt":0.30406744972603417,"score_spread":0.25574924448900915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059097089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935273,0.0018762649,0.00012563342,0.00084881135,0.00020968355,0.00011494273,0.0000054085936,0.0000060694892,0.0032858695],"genre_scores_gemma":[0.9969289,0.00021727606,0.00019624612,0.00010329604,0.000865454,0.0000022721938,0.000008111167,0.000014314119,0.0016641538],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99853504,0.000043974225,0.0004271615,0.0001024277,0.0006935036,0.00019791092],"domain_scores_gemma":[0.99895644,0.000061591716,0.0004580742,0.00017850909,0.00024623968,0.00009915306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000699773,0.00011662528,0.00025898815,0.000026578928,0.00017898556,0.0000066234734,0.00018338562,0.00008393163,0.0008558408],"category_scores_gemma":[0.00017431263,0.000053398002,0.0001715701,0.00018679605,0.0002587473,0.00008406613,0.000057003897,0.0006009086,0.0000029340044],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001102443,0.00013144838,0.05568499,0.00015024967,0.0003612317,0.000048524544,0.0024153898,0.0000025346212,0.9317394,0.00000977727,0.0061672674,0.0021867536],"study_design_scores_gemma":[0.003922931,0.0010276324,0.009782953,0.0012205006,0.00054200046,0.00043849283,0.0064369366,0.00001658707,0.96835214,0.000079929814,0.008069918,0.00010997854],"about_ca_topic_score_codex":0.000020637737,"about_ca_topic_score_gemma":3.1993068e-7,"teacher_disagreement_score":0.04590204,"about_ca_system_score_codex":0.000083139705,"about_ca_system_score_gemma":0.00015664697,"threshold_uncertainty_score":0.9370856},"labels":[],"label_agreement":null},{"id":"W2059255702","doi":"10.1007/s10637-014-0106-5","title":"A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Docetaxel; Dasatinib; Medicine; Prostate cancer; Oncology; Cancer; Internal medicine; Prostate; Pharmacology; Tyrosine kinase; Receptor","score_opus":0.03335540329604145,"score_gpt":0.3297910892392198,"score_spread":0.2964356859431784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059255702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99368966,0.00014274767,0.000005052048,0.001807286,0.000104138184,0.0034485764,0.000047246696,0.000024698225,0.0007306088],"genre_scores_gemma":[0.9980111,0.00004058591,0.00039531634,0.000071278875,0.000063585234,0.0003926691,0.0004480804,0.000028185083,0.0005492102],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971137,0.00033492397,0.00078998524,0.00042189952,0.0010389149,0.00030056955],"domain_scores_gemma":[0.9985064,0.00036200453,0.00032905626,0.00021404879,0.00038899813,0.00019949219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008217006,0.00023987069,0.0006676186,0.0004175951,0.00010094979,0.000023400287,0.00009749405,0.00007570307,0.000037454636],"category_scores_gemma":[0.0004295042,0.00018413879,0.000052486103,0.0007657736,0.0002539108,0.0002435173,0.000032872795,0.00024791167,0.0000021855492],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8873422,0.009633924,0.051926292,0.00035524936,0.000367173,0.00005063537,0.03155755,0.0004001931,0.013010154,0.0015908221,0.000498884,0.0032669085],"study_design_scores_gemma":[0.9236452,0.008383076,0.059605904,0.00064616743,0.00016222877,8.2262636e-7,0.00095963734,0.0010942623,0.0038325002,0.0013385,0.00009897174,0.00023271525],"about_ca_topic_score_codex":0.003718333,"about_ca_topic_score_gemma":0.0029945588,"teacher_disagreement_score":0.036302995,"about_ca_system_score_codex":0.0003381139,"about_ca_system_score_gemma":0.00083548645,"threshold_uncertainty_score":0.75089616},"labels":[],"label_agreement":null},{"id":"W2059411419","doi":"10.1016/j.urology.2011.05.052","title":"Targeting the Androgen Receptor—Theory and Practice","year":2011,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Testosterone (patch); Androgen; Androgen receptor; Androgen deprivation therapy; Hormone; Prostate; Internal medicine; Endocrinology; Oncology; Cancer; Bioinformatics; Biology","score_opus":0.03967328395582221,"score_gpt":0.32792747686475865,"score_spread":0.28825419290893645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059411419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7273356,0.038410176,0.0007315355,0.04105402,0.0005564575,0.0012289761,0.000008879673,0.00014000713,0.19053437],"genre_scores_gemma":[0.99408484,0.0010463997,0.00042643305,0.0025249645,0.00011565606,0.000023547069,0.000007929229,0.000010518493,0.0017597022],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994101,0.00021507964,0.00006020387,0.00010930416,0.00005485797,0.00015048818],"domain_scores_gemma":[0.999396,0.00038975597,0.000023412054,0.00010193359,0.0000411696,0.000047691377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064319413,0.0000460071,0.000072384675,0.000022375612,0.00006937319,0.0000032745177,0.000035681198,0.000044737793,0.00045534517],"category_scores_gemma":[0.0005124995,0.000025114196,0.000013264955,0.000043768716,0.00016345098,0.00003501486,0.000037727405,0.00012472775,0.0000701401],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.101878814,0.002131565,0.18773556,0.00030318744,0.0036219505,0.0024424978,0.08520578,0.000004439137,0.1020597,0.1600956,0.11609383,0.23842707],"study_design_scores_gemma":[0.0043563037,0.003209312,0.0063604764,0.000010365013,0.00045818882,0.0012394055,0.0035801483,0.00007802123,0.009211505,0.008919629,0.96237844,0.00019818083],"about_ca_topic_score_codex":0.000016037677,"about_ca_topic_score_gemma":6.980249e-7,"teacher_disagreement_score":0.8462846,"about_ca_system_score_codex":0.00000901185,"about_ca_system_score_gemma":0.000033132364,"threshold_uncertainty_score":0.49857104},"labels":[],"label_agreement":null},{"id":"W2059557295","doi":"10.1200/jco.2009.25.2221","title":"Reply to K. Lin et al","year":2009,"lang":"eo","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine","score_opus":0.23384896435461994,"score_gpt":0.5941704826705838,"score_spread":0.3603215183159639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059557295","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20002055,0.004613534,0.00009248859,0.77192086,0.0037380701,0.00035395805,0.000007320913,0.000010108905,0.01924308],"genre_scores_gemma":[0.4856478,0.0150323445,0.0035889465,0.48129985,0.004211915,0.0000023045138,0.0000042199035,0.000024966206,0.010187677],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942354,0.0009825195,0.0031869204,0.00031032256,0.0007617678,0.0005230517],"domain_scores_gemma":[0.9934142,0.0026729272,0.0013623792,0.00032964337,0.00083081436,0.0013900361],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009494215,0.00020130552,0.0020061892,0.00024132969,0.00005171245,0.000024558169,0.00032334612,0.0004094405,0.0005291831],"category_scores_gemma":[0.0086526135,0.00013094036,0.00075056875,0.00028965378,0.00017450929,0.00013012295,0.00007441508,0.0025004488,0.00039330497],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014613151,0.0030908724,0.0065718843,0.000011041082,0.00039879308,0.004299141,0.00022743973,0.000008800269,0.00018265266,0.00016630533,0.60974437,0.36068556],"study_design_scores_gemma":[0.010923078,0.07130316,0.10861789,0.00029112914,0.0002590747,0.00026784668,0.00011027664,0.000020152549,0.00012108145,0.00060282554,0.80737996,0.00010355007],"about_ca_topic_score_codex":0.000025619373,"about_ca_topic_score_gemma":0.000010366744,"teacher_disagreement_score":0.36058202,"about_ca_system_score_codex":0.00040128487,"about_ca_system_score_gemma":0.0056411666,"threshold_uncertainty_score":0.99999595},"labels":[],"label_agreement":null},{"id":"W2059953383","doi":"10.1038/sj.pcan.4501010","title":"A genome-wide association screen identifies regions on chromosomes 1q25 and 7p21 as risk loci for sporadic prostate cancer","year":2007,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Prostate cancer; Single-nucleotide polymorphism; International HapMap Project; SNP array; Cancer; Haplotype; Oncology; Prostate; Biology; Medicine; Genetics; Genotype; Gene","score_opus":0.018147923178076123,"score_gpt":0.3254779086371734,"score_spread":0.3073299854590973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059953383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9314347,0.051990643,0.0000335573,0.006439958,0.00020613485,0.0050574453,0.004352722,0.00014369232,0.0003411605],"genre_scores_gemma":[0.9026567,0.07543167,0.00014800494,0.0013138639,0.00032610906,0.0021674382,0.0010243009,0.00011364127,0.01681828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968483,0.000072140836,0.00055163953,0.0008534117,0.0006721102,0.0010023861],"domain_scores_gemma":[0.99732107,0.0007807305,0.00039903357,0.00031167068,0.00046950666,0.00071798865],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005836766,0.0004754791,0.00066244515,0.00030841635,0.00061550905,0.00023199621,0.00010194854,0.00012781382,0.00011116116],"category_scores_gemma":[0.0005716147,0.0003778009,0.00015318033,0.00041812073,0.00035433532,0.00033983187,0.000076601784,0.00029545702,0.000011831185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067206845,0.00032708584,0.9442217,0.0015651131,0.00078644545,0.000112343914,0.004001495,0.000014872964,0.00035087444,0.0001311924,0.004845475,0.036922727],"study_design_scores_gemma":[0.010993683,0.001867,0.9479392,0.0009730275,0.00157491,0.000012251243,0.0020836059,0.00009153919,0.0030753384,0.00830455,0.022348309,0.00073658576],"about_ca_topic_score_codex":0.0010423757,"about_ca_topic_score_gemma":0.0003373257,"teacher_disagreement_score":0.03618614,"about_ca_system_score_codex":0.0006558471,"about_ca_system_score_gemma":0.0007009878,"threshold_uncertainty_score":0.9998674},"labels":[],"label_agreement":null},{"id":"W2060374612","doi":"10.1074/jbc.m111.252080","title":"Regulation of Androgen Receptor and Prostate Cancer Growth by Cyclin-dependent Kinase 5","year":2011,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Beef Cattle Research Council","keywords":"Prostate cancer; Cancer research; Androgen receptor; Prostate; Cancer; Cyclin-dependent kinase 5; Cell growth; Kinase; Cancer cell; Biology; Chemistry; Endocrinology; Internal medicine; Medicine; Cell biology; Cyclin-dependent kinase 2; Protein kinase A; Biochemistry","score_opus":0.040188566159768166,"score_gpt":0.29930274677726965,"score_spread":0.25911418061750147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060374612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939107,0.004855056,0.0000036250622,0.00036892618,0.000027708997,0.00009131128,0.00003267766,0.000004520262,0.00070548936],"genre_scores_gemma":[0.9931684,0.005706159,0.00023024972,0.000025266441,0.000084973515,0.000004438294,0.000014475216,0.000004844484,0.0007611941],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99932367,0.000018127108,0.00027508903,0.00010506058,0.0001551712,0.00012286639],"domain_scores_gemma":[0.99936634,0.000022615039,0.0002116299,0.00005997616,0.00019445363,0.00014498216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017701834,0.00008099774,0.00023227184,0.00001743087,0.000020761892,0.0000037644918,0.000051735045,0.00010594485,0.00044134344],"category_scores_gemma":[0.00006721357,0.000045756038,0.000060898506,0.00005499622,0.0001338369,0.00003635427,0.000026425309,0.00016104213,7.6636326e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015023992,0.00018130729,0.12105541,0.000103894155,0.00008394475,0.000024929052,0.0000992923,5.7361994e-8,0.8733094,0.0000015848045,0.000979002,0.0026587984],"study_design_scores_gemma":[0.0015590698,0.00048179989,0.022452481,0.00010681255,0.000038751463,0.00006211523,0.0000829134,0.0000018125434,0.9744842,0.00019115068,0.00048627355,0.000052596584],"about_ca_topic_score_codex":0.000014200579,"about_ca_topic_score_gemma":1.17233e-7,"teacher_disagreement_score":0.10117484,"about_ca_system_score_codex":0.000054972395,"about_ca_system_score_gemma":0.00007700664,"threshold_uncertainty_score":0.48324013},"labels":[],"label_agreement":null},{"id":"W2060540117","doi":"10.1016/j.cbi.2015.02.002","title":"p,p′-Dichlorodiphenyltrichloroethane (p,p′-DDT) and p,p′-dichlorodiphenyldichloroethylene (p,p′-DDE) repress prostate specific antigen levels in human prostate cancer cell lines","year":2015,"lang":"en","type":"article","venue":"Chemico-Biological Interactions","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Environment and Climate Change Canada; Vancouver Coastal Health Research Institute; Vancouver Coastal Health; Simon Fraser University","funders":"Canadian Institutes of Health Research","keywords":"Internal medicine; Prostate cancer; Endocrinology; Prostate-specific antigen; Prostate; Medicine; Cancer research; Cancer","score_opus":0.1296505758097094,"score_gpt":0.3825595607000039,"score_spread":0.2529089848902945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060540117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9709086,0.017403774,0.000013020953,0.0020751485,0.0005378406,0.0018225784,0.00022786936,0.00028533343,0.0067258226],"genre_scores_gemma":[0.97940993,0.010508234,0.00050447125,0.0003546947,0.0006174027,0.0007457487,0.00048662923,0.00008752416,0.0072853337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99553764,0.00016002274,0.0010748705,0.0014700874,0.000551094,0.0012062881],"domain_scores_gemma":[0.9970989,0.00026777448,0.00032727007,0.0007659204,0.0006102568,0.000929883],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00066676346,0.00071469304,0.0010704573,0.00033075316,0.00027533327,0.00014393053,0.00034403263,0.000379601,0.0008148653],"category_scores_gemma":[0.00026249766,0.00054130726,0.00021587961,0.00076445803,0.0006658975,0.0005738659,0.0003967109,0.0011912938,0.00007188978],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026310259,0.0014719646,0.115819804,0.00019278182,0.00019156795,0.0004160026,0.0031804368,0.000032524473,0.86382437,0.000058997568,0.0056511005,0.006529422],"study_design_scores_gemma":[0.014758479,0.0019636606,0.074507274,0.0007897049,0.00016719155,0.00030592325,0.004845491,0.00019689555,0.83884573,0.0013588115,0.060855057,0.001405763],"about_ca_topic_score_codex":0.0014915606,"about_ca_topic_score_gemma":0.00028022513,"teacher_disagreement_score":0.055203956,"about_ca_system_score_codex":0.00090050703,"about_ca_system_score_gemma":0.0002979645,"threshold_uncertainty_score":0.9997038},"labels":[],"label_agreement":null},{"id":"W2060717021","doi":"10.1186/1472-6963-14-252","title":"Drug costs in the management of metastatic castration-resistant prostate cancer in Canada","year":2014,"lang":"en","type":"article","venue":"BMC Health Services Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Université de Montréal; Université du Québec à Montréal; McGill University","funders":"McGill University","keywords":"Medicine; Prostate cancer; Nursing research; Health informatics; Castration; Drug; Health administration; Oncology; Internal medicine; Cancer; Public health; Gynecology; General surgery; Pharmacology; Pathology; Hormone","score_opus":0.05111256891878256,"score_gpt":0.42373937249983307,"score_spread":0.3726268035810505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060717021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875453,0.003743919,0.000001616355,0.0042799674,0.00004571327,0.0027082115,0.000053493324,0.0000048260626,0.0016169585],"genre_scores_gemma":[0.99598014,0.0023299388,0.00018322117,0.0003874056,0.000023324767,0.0005647597,0.000041229025,0.0000147554965,0.0004752228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961895,0.0008196786,0.00049465295,0.0002978796,0.0014170172,0.00078131084],"domain_scores_gemma":[0.998811,0.0003338081,0.00008135962,0.000392753,0.00019661195,0.00018448354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033395218,0.00011961395,0.00031430187,0.0002772757,0.00011243752,0.000023977185,0.00028334477,0.00001763941,0.00006109599],"category_scores_gemma":[0.000006423863,0.00007659352,0.000024522966,0.0011897219,0.000061584215,0.0000643685,0.00007284101,0.00037869197,0.0000056705167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004189919,0.0008770379,0.8446394,0.049657516,0.00018559638,0.00049921015,0.019509537,0.0005846398,0.00035031652,0.0015783645,0.0006233916,0.07730508],"study_design_scores_gemma":[0.0038603928,0.00028786392,0.9634912,0.0024229467,0.000011721443,0.000003241783,0.024699887,0.0024182382,0.00026978616,0.00014752588,0.002295108,0.00009208674],"about_ca_topic_score_codex":0.9410097,"about_ca_topic_score_gemma":0.99121845,"teacher_disagreement_score":0.11885181,"about_ca_system_score_codex":0.0020062842,"about_ca_system_score_gemma":0.0048027583,"threshold_uncertainty_score":0.85198873},"labels":[],"label_agreement":null},{"id":"W2060924022","doi":"10.1002/cncr.25762","title":"Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration‐resistant nonmetastatic prostate cancer","year":2010,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Internal medicine; Bone metastasis; Androgen deprivation therapy; Metastasis; Oncology; Proportional hazards model; Hazard ratio; Urology; Prostatectomy; Prostate; Cancer; Confidence interval","score_opus":0.011168703169638685,"score_gpt":0.29292478933922395,"score_spread":0.28175608616958525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060924022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99256927,0.0028577836,0.00000117414,0.0020710812,0.000031577532,0.0015135854,0.0008046366,0.000013693918,0.00013717402],"genre_scores_gemma":[0.9953806,0.0013348658,0.00026587528,0.0000767004,0.000067101624,0.00083050376,0.000049395567,0.000030193767,0.001964802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988541,0.000020861444,0.00022943766,0.00032391402,0.00028793435,0.00028377518],"domain_scores_gemma":[0.9991005,0.000041746218,0.00010484747,0.0001816666,0.00016096464,0.00041028936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010628801,0.0001859423,0.00036477388,0.00013844055,0.000065815744,0.00003198407,0.000042463533,0.000035643283,0.00034403568],"category_scores_gemma":[0.00005254756,0.00012659519,0.000021261014,0.00021468426,0.00017773203,0.00010441898,0.00004222002,0.00016279412,0.000004305835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070695104,0.00025377897,0.9610641,0.00093917944,0.0004251245,0.000621397,0.0020447974,0.0000059953322,0.023133889,0.000024460614,0.00039937336,0.004018377],"study_design_scores_gemma":[0.0037021975,0.0008617004,0.98577297,0.00086804846,0.00054929114,0.00002239666,0.00013047739,0.00021217923,0.0062942877,0.000013626051,0.0013557523,0.00021707878],"about_ca_topic_score_codex":0.00043318185,"about_ca_topic_score_gemma":0.0004035431,"teacher_disagreement_score":0.024708847,"about_ca_system_score_codex":0.00009789245,"about_ca_system_score_gemma":0.00052321516,"threshold_uncertainty_score":0.5162402},"labels":[],"label_agreement":null},{"id":"W2061278069","doi":"10.1158/1538-7445.am2011-290","title":"Abstract 290: Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre; University Health Network","funders":"","keywords":"TMPRSS2; Prostate cancer; Docetaxel; Medicine; PCA3; Oncology; Internal medicine; Cytarabine; Prostate; Cancer; Mitoxantrone; Cancer research; Urology; Chemotherapy","score_opus":0.3606366684749604,"score_gpt":0.5433848099392202,"score_spread":0.18274814146425983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061278069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99069816,0.0031616588,0.0000010554677,0.0013321843,0.00015668992,0.0037250994,0.00082137017,0.000014267508,0.00008954423],"genre_scores_gemma":[0.98440486,0.012646153,0.00016484426,0.000063167536,0.00009382509,0.0015418611,0.000067162495,0.000039623286,0.0009784958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99578285,0.00050786324,0.0013550043,0.0008366345,0.00062921585,0.0008884166],"domain_scores_gemma":[0.99759823,0.00031767844,0.00027565638,0.0005288548,0.0007605416,0.000519044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023323486,0.00028657753,0.0011612178,0.001783139,0.00008248408,0.0000220404,0.00020933348,0.00025436183,0.0008537368],"category_scores_gemma":[0.00044753196,0.0002256433,0.00013181721,0.0029945297,0.0010112089,0.00026312078,0.0002091305,0.00078051956,0.0000032322746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10962593,0.0026158511,0.6108987,0.0005276842,0.001086715,0.00018626687,0.006825696,0.00006464774,0.15861882,0.000016747908,0.00034734927,0.10918565],"study_design_scores_gemma":[0.10315679,0.009165644,0.8007829,0.0010048194,0.00035346337,0.0000020930952,0.00050054135,0.00030193987,0.08233566,0.00013707692,0.0018456028,0.00041343283],"about_ca_topic_score_codex":0.04814374,"about_ca_topic_score_gemma":0.023099959,"teacher_disagreement_score":0.18988429,"about_ca_system_score_codex":0.00045521694,"about_ca_system_score_gemma":0.0024868345,"threshold_uncertainty_score":0.99472594},"labels":[],"label_agreement":null},{"id":"W2061880783","doi":"10.1016/j.urolonc.2013.10.020","title":"Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer","year":2014,"lang":"en","type":"review","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Prostate cancer; Medicine; Disease; Malignancy; Oncology; TMPRSS2; Precision medicine; Personalized medicine; Internal medicine; Cancer; Copy-number variation; Genomics; Bioinformatics; Pathology; Gene; Biology; Genetics; Genome","score_opus":0.11562089813087034,"score_gpt":0.46778681922508075,"score_spread":0.3521659210942104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061880783","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15106076,0.8448635,0.0000012171237,0.002244746,0.0001303099,0.0011493918,0.00004758457,0.000020719848,0.00048180108],"genre_scores_gemma":[0.00023807163,0.99545425,0.002402666,0.00061361166,0.00014037109,0.0002586641,0.00016343792,0.00002187096,0.00070708466],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971443,0.0006617898,0.0009319972,0.0006985667,0.00018647531,0.00037690607],"domain_scores_gemma":[0.9979733,0.0008206016,0.00049305,0.00023491282,0.000083093255,0.0003950216],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0010945044,0.00038030127,0.00254192,0.0003006333,0.000115188705,0.000008528405,0.00012913231,0.0006148551,0.00012874774],"category_scores_gemma":[0.0003795648,0.00023675659,0.00019075208,0.00029151657,0.0042128917,0.000037410344,0.0001257756,0.0008615118,0.000008909185],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004177533,0.00042789543,0.47127256,0.0058415,0.00055349414,0.0009731039,0.0005636844,8.8001485e-7,0.00001688168,0.0014112431,0.0018703756,0.5166506],"study_design_scores_gemma":[0.002175762,0.004339518,0.0015203984,0.002649725,0.0015902171,0.0004509075,0.00007257639,0.000022267424,0.0000015126203,0.00066329486,0.9863245,0.00018935536],"about_ca_topic_score_codex":0.00016758835,"about_ca_topic_score_gemma":0.000051483024,"teacher_disagreement_score":0.9844541,"about_ca_system_score_codex":0.00022476896,"about_ca_system_score_gemma":0.0010917239,"threshold_uncertainty_score":0.99849707},"labels":[],"label_agreement":null},{"id":"W2062027909","doi":"10.6000/1929-2279.2014.03.01.9","title":"Vascular Disease and Prostate Cancer: A Conflicting Association","year":2014,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Disease; Prostate; Internal medicine; Hormone therapy; Coronary artery disease; Urology; Oncology; Cancer; Breast cancer","score_opus":0.03488040284080648,"score_gpt":0.42324938334928947,"score_spread":0.388368980508483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062027909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9439832,0.032862082,0.000008403557,0.022162843,0.00014462702,0.00042988083,0.00002299907,0.000012878515,0.00037310092],"genre_scores_gemma":[0.9443183,0.051690135,0.00009481492,0.00021208635,0.0008360518,0.00007593305,0.0000069616867,0.000027955999,0.0027377955],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972572,0.00026207865,0.00033372932,0.00019196572,0.001438763,0.0005163129],"domain_scores_gemma":[0.9972568,0.0002862873,0.00022215911,0.00015286282,0.001517017,0.0005648604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028448787,0.00011856999,0.00034200083,0.00032449097,0.00020382894,0.00011809689,0.00011663392,0.000059140566,0.0001721351],"category_scores_gemma":[0.0008679942,0.000081878075,0.00010713491,0.00034196652,0.00012918201,0.00023969334,0.00007401514,0.0006646942,0.0000062767276],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024199034,0.00016503906,0.91332954,0.00048986473,0.0010250808,0.00011008535,0.0008155536,0.000042213225,0.012032864,0.00014174804,0.011348726,0.05807935],"study_design_scores_gemma":[0.013905176,0.0019183574,0.45532364,0.002612591,0.0007210437,0.00003063271,0.00065035466,0.0014975258,0.023079004,0.0019665232,0.49792752,0.00036766336],"about_ca_topic_score_codex":0.00035247317,"about_ca_topic_score_gemma":0.000044669665,"teacher_disagreement_score":0.48657876,"about_ca_system_score_codex":0.0007298049,"about_ca_system_score_gemma":0.00086137827,"threshold_uncertainty_score":0.3338891},"labels":[],"label_agreement":null},{"id":"W2062128863","doi":"10.1158/1538-7445.am2011-2815","title":"Abstract 2815: Urine TMPRSS2:ERG for prostate cancer risk stratification in men with elevated serum PSA","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"TMPRSS2; Medicine; Prostate cancer; Biopsy; PCA3; Urology; Erg; Internal medicine; Prostate biopsy; Prostatectomy; Cancer; Oncology; Gynecology; Ophthalmology","score_opus":0.11246886914826054,"score_gpt":0.4201569551074045,"score_spread":0.30768808595914393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062128863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858861,0.0026433233,0.000013358916,0.0018953109,0.00006270382,0.004120122,0.0003682445,0.00006529009,0.004945537],"genre_scores_gemma":[0.97696567,0.007793408,0.0002308441,0.000026267287,0.00018527641,0.0050163753,0.00011864883,0.00007371734,0.009589804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99695134,0.00011522556,0.00036468788,0.00067269703,0.000827244,0.0010688282],"domain_scores_gemma":[0.9980035,0.00012020802,0.0001082002,0.00050709397,0.00093686837,0.0003241625],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012008022,0.0002400535,0.00035829828,0.00044407928,0.0002335533,0.00005124674,0.00023514373,0.00013501744,0.001077192],"category_scores_gemma":[0.000081473496,0.00016894985,0.00006160805,0.0009846977,0.0003120902,0.00021688938,0.000055185985,0.0008016819,0.000034882334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030791307,0.0014894269,0.7410337,0.0018551277,0.0008330847,0.0002954014,0.007392219,0.00009878193,0.109631225,0.00033554048,0.010416577,0.09582763],"study_design_scores_gemma":[0.011313741,0.0017844462,0.7401024,0.00076565566,0.00008555463,0.0000061048163,0.0013028645,0.000497332,0.23842679,0.00074191927,0.004605612,0.00036756106],"about_ca_topic_score_codex":0.011461105,"about_ca_topic_score_gemma":0.004368376,"teacher_disagreement_score":0.12879556,"about_ca_system_score_codex":0.0009013785,"about_ca_system_score_gemma":0.0017046442,"threshold_uncertainty_score":0.99983597},"labels":[],"label_agreement":null},{"id":"W2063066449","doi":"10.1016/j.juro.2011.02.2533","title":"2288 PROGNOSTIC IMPACT OF INHERITED GENETIC VARIATIONS IN SRD5A AND ANDROGEN INACTIVATING UGT2B GENES IN PROSTATE CANCER AFTER PROSTATECTOMY","year":2011,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada","keywords":"Prostatectomy; Medicine; Prostate cancer; Single-nucleotide polymorphism; Cancer; Gene; Cohort; Androgen; Demography; Oncology; Gynecology; Gerontology; Internal medicine; Genetics; Genotype; Biology; Sociology","score_opus":0.028865739177803145,"score_gpt":0.32062531587324716,"score_spread":0.291759576695444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063066449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914846,0.0074954433,0.000010832099,0.00038140456,0.00002674223,0.00054936524,0.00000832291,0.0000027774956,0.000040543182],"genre_scores_gemma":[0.9976459,0.002026512,0.00018552734,0.00004137522,0.000025329055,0.000042804822,0.0000011898113,0.000013560337,0.00001776695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989498,0.00019928698,0.00039507187,0.000088061664,0.00012516917,0.00024259534],"domain_scores_gemma":[0.9993409,0.0001194469,0.00022039459,0.00009718672,0.00015496385,0.00006708978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004146455,0.000104611325,0.00029274254,0.00029774697,0.000021776425,0.000004030511,0.00006790725,0.00005212622,0.000067912086],"category_scores_gemma":[0.00009715229,0.000058713827,0.00004115117,0.0003226206,0.00014620397,0.000076604694,0.00003904176,0.0002819134,4.3658557e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004240324,0.00022569789,0.97519463,0.00004622174,0.00014520544,0.00021604853,0.0058686524,0.000067696725,0.009358531,0.0000015413648,0.000005173047,0.004630263],"study_design_scores_gemma":[0.003000469,0.002140559,0.9922813,0.00010581309,0.000100109944,0.00032538458,0.00013317996,0.0003205231,0.0012058784,0.0003267074,0.000008903143,0.000051146042],"about_ca_topic_score_codex":0.00078183797,"about_ca_topic_score_gemma":0.00023165351,"teacher_disagreement_score":0.017086681,"about_ca_system_score_codex":0.000100445846,"about_ca_system_score_gemma":0.00033956126,"threshold_uncertainty_score":0.23942804},"labels":[],"label_agreement":null},{"id":"W2063137562","doi":"10.1016/s0360-3016(03)00827-7","title":"A randomized trial comparing two fractionation schedules for patients with localized prostate cancer","year":2003,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Ontario Clinical Oncology Group; Ontario Institute for Cancer Research; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Randomized controlled trial; Prostate; Dose fractionation; Hormonal therapy; Urology; Cancer; Internal medicine; Oncology; Surgery","score_opus":0.032800840525100586,"score_gpt":0.3865773739941879,"score_spread":0.35377653346908733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063137562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691002,0.0006806807,0.02299899,0.0020926653,0.0023216754,0.002238362,0.00006028317,0.000028605262,0.0004785883],"genre_scores_gemma":[0.9905336,0.00069033547,0.006696608,0.00028948046,0.0011220105,0.00026806598,0.00025825063,0.000028235409,0.00011340566],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99824184,0.00030444033,0.0006557113,0.00020101645,0.00037788108,0.00021908573],"domain_scores_gemma":[0.9963308,0.0006448581,0.0009692502,0.000086295615,0.0018542932,0.000114525166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008000963,0.00017479331,0.0006881718,0.00018325503,0.00009662061,0.000033467128,0.00013130948,0.00011496716,0.000057944806],"category_scores_gemma":[0.0006414994,0.000120221004,0.00023917029,0.0001382839,0.00020773763,0.00027611552,0.000014608174,0.00032250996,0.000004880408],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70332515,0.00112702,0.24861242,0.000015517779,0.0017603077,0.000006138849,0.00021462317,0.0008460628,0.00011946556,0.014427649,0.00020931456,0.029336307],"study_design_scores_gemma":[0.9657943,0.0019176338,0.001777001,0.00008222805,0.00032054272,0.000012697026,0.000038268758,0.0024054952,0.0010899627,0.008873799,0.017550765,0.00013727453],"about_ca_topic_score_codex":0.000022950871,"about_ca_topic_score_gemma":0.0000055415903,"teacher_disagreement_score":0.26246914,"about_ca_system_score_codex":0.00089846033,"about_ca_system_score_gemma":0.0010843131,"threshold_uncertainty_score":0.49024704},"labels":[],"label_agreement":null},{"id":"W2063299023","doi":"10.2353/ajpath.2009.080868","title":"Novel Biomarkers for Prostate Cancer Including Noncoding Transcripts","year":2009,"lang":"en","type":"article","venue":"American Journal Of Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Intron; Prostate cancer; Biology; Prostate; Cancer research; Gene; Cancer; Genetics","score_opus":0.05533906905993802,"score_gpt":0.38597026209799906,"score_spread":0.33063119303806104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063299023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796117,0.0018816132,0.0049607814,0.012542839,0.0002490865,0.0003550166,0.000028005206,0.000013463205,0.00035749556],"genre_scores_gemma":[0.9888861,0.0009964514,0.008738167,0.00096133474,0.00023121502,0.0000136520275,0.0000042940314,0.000015554055,0.00015318967],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99896175,0.000035388974,0.00033441267,0.00014808815,0.00017599753,0.00034435687],"domain_scores_gemma":[0.9991378,0.000068593305,0.00027919965,0.00009196945,0.00025298825,0.00016941811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036891087,0.00012012859,0.00045126147,0.000244321,0.00007734577,0.000009816028,0.00009061811,0.00003498941,0.000014222676],"category_scores_gemma":[0.00005963402,0.00008587463,0.00016846468,0.00026016939,0.0002278199,0.00007897117,0.000008076565,0.00018749991,8.407994e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033551287,0.00020569947,0.008869037,0.000029305556,0.00021464074,0.0006323953,0.0015967119,0.000009877457,0.59272635,0.00004216953,0.0005072181,0.3918115],"study_design_scores_gemma":[0.09061604,0.12285383,0.4324119,0.003050665,0.0031548264,0.0337527,0.01608995,0.0011861522,0.2430522,0.0024686954,0.0494198,0.0019432205],"about_ca_topic_score_codex":0.000018683244,"about_ca_topic_score_gemma":0.0000032521475,"teacher_disagreement_score":0.4235429,"about_ca_system_score_codex":0.00016898043,"about_ca_system_score_gemma":0.00028658484,"threshold_uncertainty_score":0.35018656},"labels":[],"label_agreement":null},{"id":"W2063330244","doi":"10.3747/co.19.1304","title":"The Changing Landscape in Prostate Cancer","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Pride; Cancer; Data science; Internal medicine; Computer science","score_opus":0.12835592573880508,"score_gpt":0.4683972279053007,"score_spread":0.34004130216649564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063330244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9088995,0.08047104,0.000002103845,0.004924331,0.0015409634,0.00050951034,0.000005005517,0.00002248477,0.0036250588],"genre_scores_gemma":[0.9856777,0.0114390245,0.000009737578,0.000069141184,0.0005251771,0.00034817678,0.000017091825,0.00000999093,0.0019039279],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907374,0.00005061773,0.00011396082,0.000098203,0.000111070636,0.00055239734],"domain_scores_gemma":[0.999636,0.00008119943,0.000030834046,0.000105551895,0.00003899929,0.000107393935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003501257,0.00007161664,0.00013899234,0.000099123805,0.00009020332,0.0000067185406,0.000050569823,0.000032613316,0.0000951543],"category_scores_gemma":[0.000029610537,0.0000393595,0.000030947216,0.00022812303,0.000068004476,0.000046105873,0.000050278144,0.00021965991,0.00004698927],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002545757,0.00023179995,0.7187677,0.000039512797,0.000019506588,0.000011234806,0.0022052804,5.105035e-7,0.000062441526,0.00015434461,0.003658794,0.27459428],"study_design_scores_gemma":[0.0029237894,0.0001905258,0.15461406,0.00009088706,0.000029579936,0.000020284282,0.0010691208,0.00013324642,0.00041652605,0.000056390243,0.84037954,0.00007604685],"about_ca_topic_score_codex":0.0000111444115,"about_ca_topic_score_gemma":0.000044247947,"teacher_disagreement_score":0.83672076,"about_ca_system_score_codex":0.00025798957,"about_ca_system_score_gemma":0.00017679566,"threshold_uncertainty_score":0.16050337},"labels":[],"label_agreement":null},{"id":"W2063514355","doi":"10.1038/nrurol.2014.334","title":"Bicalutamide dose increase in castration-resistant disease","year":2014,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Bicalutamide; Medicine; Antiandrogen; Prostate cancer; Castration; Blockade; Oncology; Androgen; Urology; Internal medicine; Orchiectomy; Androgen receptor; Cancer; Hormone; Receptor","score_opus":0.04891083148099889,"score_gpt":0.41911507609732596,"score_spread":0.37020424461632706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063514355","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011012131,0.99376243,0.0000016254872,0.000864704,0.00023731303,0.0037852623,0.0000720802,0.00003670119,0.0012288514],"genre_scores_gemma":[0.00008009284,0.99541265,0.000092994305,0.0009267544,0.0005277056,0.0008471177,0.0010760975,0.0000690475,0.00096754654],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99588954,0.001187751,0.0011481805,0.0008331766,0.00033340158,0.0006079178],"domain_scores_gemma":[0.99765295,0.00038913515,0.00037677583,0.0009224068,0.000082159626,0.0005766011],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0010409207,0.0006150125,0.0037691027,0.0005455013,0.000055442248,0.000020849535,0.0002844378,0.0011720596,0.0002736728],"category_scores_gemma":[0.001307776,0.0003703945,0.0008360709,0.0007363692,0.00016261921,0.000043134798,0.00010002357,0.0027254552,0.0004697323],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037462215,0.00021266597,0.00007918032,0.04013748,0.00010819328,0.0013331857,0.0000059716076,7.616985e-8,0.0000011593263,0.00037847823,0.0035483772,0.9538206],"study_design_scores_gemma":[0.00095474976,0.00024235534,0.00023598546,0.008955151,0.0017271248,0.00013179226,4.102582e-7,0.0000032151122,7.252153e-8,0.000072753726,0.987413,0.0002634109],"about_ca_topic_score_codex":0.000023479251,"about_ca_topic_score_gemma":0.000055531265,"teacher_disagreement_score":0.9838646,"about_ca_system_score_codex":0.0003448526,"about_ca_system_score_gemma":0.0012361332,"threshold_uncertainty_score":0.9998748},"labels":[],"label_agreement":null},{"id":"W2064662414","doi":"10.1002/path.3987","title":"Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer","year":2012,"lang":"en","type":"article","venue":"The Journal of Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Simon Fraser University; Ontario Institute for Cancer Research; BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; Vancouver Coastal Health Research Institute","keywords":"Transcriptome; Biology; Prostate cancer; Chromoplexy; Gene; Genome; Exome; Computational biology; Cancer; Exome sequencing; Cancer research; Genetics; Mutation; Gene expression; PCA3","score_opus":0.040995023883108765,"score_gpt":0.32429042947912545,"score_spread":0.2832954055960167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064662414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9674055,0.03135355,0.00010775217,0.0007570746,0.000118727134,0.00018128108,0.000035448607,0.0000028684954,0.000037772705],"genre_scores_gemma":[0.98973376,0.009669027,0.00018239542,0.00007047801,0.00007846996,0.0000045057195,0.0000024165686,0.0000093449435,0.0002496267],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992893,0.0000568726,0.00025227043,0.000055043478,0.0001338512,0.00021271707],"domain_scores_gemma":[0.9993029,0.000056962712,0.0002723918,0.00007324948,0.00019673244,0.00009772095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006032333,0.000086270804,0.00028300157,0.00012113743,0.000051178384,0.000005853079,0.000052696298,0.00002753695,0.000021692174],"category_scores_gemma":[0.000048734113,0.000043830973,0.000036305977,0.00007688543,0.0003131982,0.00013604577,0.000024700523,0.00022755217,3.9804115e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010220876,0.00005626818,0.013046414,0.00013849796,0.00016962767,0.00033388057,0.01627529,0.0000013370835,0.9657571,0.000015195174,0.00003294074,0.0031513628],"study_design_scores_gemma":[0.01961391,0.004963556,0.3518323,0.0019892245,0.0023048478,0.10570619,0.02181723,0.00016829808,0.4878425,0.0019449444,0.0013720833,0.00044489087],"about_ca_topic_score_codex":0.000042102452,"about_ca_topic_score_gemma":0.000008268589,"teacher_disagreement_score":0.4779146,"about_ca_system_score_codex":0.0000730257,"about_ca_system_score_gemma":0.00013475087,"threshold_uncertainty_score":0.17873752},"labels":[],"label_agreement":null},{"id":"W2064927794","doi":"10.1097/coc.0b013e3181beac33","title":"A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer","year":2010,"lang":"en","type":"article","venue":"American Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Lapatinib; Medicine; Internal medicine; Prostate cancer; Rash; Oncology; Clinical endpoint; Cancer; Prostate-specific antigen; Breast cancer; Population; Phases of clinical research; Adverse effect; Clinical trial; Trastuzumab","score_opus":0.09440197135542061,"score_gpt":0.5517576730823424,"score_spread":0.45735570172692175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064927794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98878926,0.00022638895,0.0000064113424,0.0075908857,0.0016355598,0.00092218164,0.000026277154,0.000009870896,0.00079318683],"genre_scores_gemma":[0.9892575,0.0040977034,0.004309431,0.00076752185,0.0010084508,0.000041346197,0.0000100522775,0.000029412397,0.0004785531],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99408424,0.0007513135,0.0038528796,0.00035271415,0.0004984225,0.0004604249],"domain_scores_gemma":[0.99309117,0.002387189,0.0027388267,0.00031894428,0.0008469002,0.00061698933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038744276,0.00021675052,0.002449996,0.0002486719,0.000041183517,0.0000058924957,0.0002697436,0.00025969406,0.00027124808],"category_scores_gemma":[0.003630958,0.0001416124,0.0006352985,0.00042412875,0.0016757891,0.00012211688,0.000096239906,0.002151007,0.000007726986],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3591224,0.008830518,0.082099974,0.000011166232,0.000329092,0.00038819967,0.00016854766,0.0000018279814,0.0012485819,0.000007852894,0.00031770038,0.54747415],"study_design_scores_gemma":[0.57006687,0.25720736,0.12190379,0.0002310429,0.00043479286,0.00007260865,0.0003575606,0.00012754716,0.00056882907,0.00006785093,0.048760988,0.0002007788],"about_ca_topic_score_codex":0.00014463536,"about_ca_topic_score_gemma":0.0002591468,"teacher_disagreement_score":0.54727334,"about_ca_system_score_codex":0.000110589746,"about_ca_system_score_gemma":0.0033083574,"threshold_uncertainty_score":0.9345175},"labels":[],"label_agreement":null},{"id":"W2065827460","doi":"10.1111/jcmm.12537","title":"HES6 promotes prostate cancer aggressiveness independently of Notch signalling","year":2015,"lang":"en","type":"article","venue":"Journal of Cellular and Molecular Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Fundação para a Ciência e a Tecnologia","keywords":"Prostate cancer; Cancer; Notch signaling pathway; Prostate; Signalling; Medicine; Cancer research; Biology; Oncology; Internal medicine; Cell biology; Receptor","score_opus":0.03117837144004758,"score_gpt":0.32483652519527395,"score_spread":0.29365815375522636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065827460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9206121,0.07378297,0.0013962159,0.003323047,0.0002030696,0.0003222239,0.0000033981992,0.0000053860317,0.00035155806],"genre_scores_gemma":[0.99626094,0.002707627,0.00026574818,0.0001360171,0.00022868738,0.0000058080727,0.0000085204565,0.000022377291,0.0003642984],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99820685,0.00007410342,0.0004926889,0.0001442609,0.00086152134,0.00022058019],"domain_scores_gemma":[0.9981742,0.000032890937,0.00039846354,0.00012444626,0.0008605004,0.0004094888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007282482,0.00015528986,0.000570435,0.00023802451,0.000028519733,0.000008280129,0.00009352411,0.00007816943,0.000040968785],"category_scores_gemma":[0.0001556997,0.000094837225,0.000089778434,0.00020076393,0.00020917635,0.00007720935,0.000036786972,0.0002891041,6.7329125e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014222991,0.00016696568,0.008676941,0.00041211824,0.0003895102,0.0027083473,0.001963186,0.000029293491,0.976217,0.0000332935,0.00023502216,0.00774608],"study_design_scores_gemma":[0.010979287,0.0032282285,0.0009798087,0.002757536,0.0005901209,0.00047040134,0.00096567394,0.00013680977,0.9771961,0.00055336603,0.0020086747,0.00013399075],"about_ca_topic_score_codex":0.00006727298,"about_ca_topic_score_gemma":0.0000018534128,"teacher_disagreement_score":0.07564879,"about_ca_system_score_codex":0.00006961535,"about_ca_system_score_gemma":0.00051992625,"threshold_uncertainty_score":0.386735},"labels":[],"label_agreement":null},{"id":"W2065918528","doi":"10.1016/j.ijrobp.2005.07.035","title":"MDM2 Expression Is Independent of P53 and Ki-67 in Predicting Prostate Cancer Outcome: An Analysis of RTOG 92-02","year":2005,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Prostate cancer; Proportional hazards model; Multivariate analysis; Oncology; Internal medicine; Mdm2; Cancer; Metastasis; Randomization; Radiation therapy; Immunohistochemistry; Survival analysis; Stage (stratigraphy); Pathology; Clinical trial; Apoptosis","score_opus":0.03268447832061183,"score_gpt":0.40324363468328966,"score_spread":0.37055915636267783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065918528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99522007,0.001277002,0.0003051709,0.002416172,0.00029780698,0.00021697745,0.00014245814,0.000007572011,0.00011677912],"genre_scores_gemma":[0.99604285,0.0022226996,0.000871175,0.00023850221,0.00044579594,0.000013295619,0.00007544149,0.000013377837,0.00007683558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813837,0.00015330173,0.00092402304,0.00020704878,0.0003929087,0.00018432848],"domain_scores_gemma":[0.9978258,0.00018448626,0.0010571575,0.00012257094,0.00069170527,0.00011825856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006077923,0.00014104432,0.00060450414,0.0005452199,0.000030980023,0.00001001118,0.00019234563,0.00016817931,0.00010861054],"category_scores_gemma":[0.00011996656,0.00010939814,0.00016636157,0.00031301795,0.0001605078,0.00030478547,0.00006391628,0.0003610809,9.919627e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086074794,0.00048495448,0.9106933,0.000018948396,0.0010181341,0.0000141964565,0.002169135,0.001739319,0.015333697,0.00012667378,0.00006465388,0.06747628],"study_design_scores_gemma":[0.009754438,0.0013730953,0.9314499,0.00017774933,0.00067569414,0.000026746498,0.0004890186,0.01619592,0.037976395,0.0005511285,0.0011882213,0.00014169312],"about_ca_topic_score_codex":0.00015055225,"about_ca_topic_score_gemma":0.00007532608,"teacher_disagreement_score":0.067334585,"about_ca_system_score_codex":0.00062728894,"about_ca_system_score_gemma":0.00040687667,"threshold_uncertainty_score":0.44611266},"labels":[],"label_agreement":null},{"id":"W2065967196","doi":"10.1016/j.ucl.2005.12.001","title":"Combined Androgen Blockade: An Update","year":2006,"lang":"en","type":"review","venue":"Urologic Clinics of North America","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Bicalutamide; Flutamide; Medicine; Blockade; Prostate cancer; Androgen receptor; Androgen; Adverse effect; Antiandrogen; Oncology; Urology; Internal medicine; Endocrinology; Receptor; Cancer; Hormone","score_opus":0.07828782877592227,"score_gpt":0.4035043707804299,"score_spread":0.3252165420045076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065967196","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014848937,0.99553597,0.0000071188615,0.0001610182,0.00015158036,0.0013316437,0.00039260674,0.00009230753,0.0008428418],"genre_scores_gemma":[0.00016353685,0.99301624,0.00048411454,0.00028063252,0.00021109934,0.0001014448,0.005020927,0.00006187957,0.0006601265],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99706465,0.00021981454,0.0011153546,0.0006661114,0.00041506812,0.00051902165],"domain_scores_gemma":[0.9975088,0.00029582722,0.0007971652,0.00093527744,0.00017233758,0.00029057078],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023479086,0.00048169625,0.0028520937,0.00025062409,0.00007100516,0.000013655245,0.00041450933,0.00033767725,0.0001736416],"category_scores_gemma":[0.00012648864,0.00031934364,0.0007432072,0.00061451807,0.00046879897,0.000040216823,0.00015546767,0.0007414496,0.00015659542],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021658526,0.00073387154,0.008083974,0.0027359766,0.00040462587,0.00023853984,0.0000063247317,0.0000024006156,1.8719748e-8,0.000002617724,0.0017690738,0.985806],"study_design_scores_gemma":[0.0011209481,0.0033257212,0.00046794064,0.0004540096,0.0018112011,0.000028218363,0.0000023779046,0.000022449038,2.2522352e-7,0.000037152287,0.9924692,0.00026058886],"about_ca_topic_score_codex":0.000042656262,"about_ca_topic_score_gemma":0.0000107279175,"teacher_disagreement_score":0.99070007,"about_ca_system_score_codex":0.00006233817,"about_ca_system_score_gemma":0.0006989985,"threshold_uncertainty_score":0.99992585},"labels":[],"label_agreement":null},{"id":"W2066875072","doi":"10.1093/annonc/mdu336.49","title":"Prosper: a Phase 3 Study of Enzalutamide in Non-Metastatic (M0) Castration-Resistant Prostate Cancer (Crpc) Patients","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Internal medicine; Placebo; Oncology; Androgen receptor; Cancer; Pathology; Alternative medicine","score_opus":0.08478641429722598,"score_gpt":0.45563239507221664,"score_spread":0.37084598077499065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066875072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958962,0.00023908366,0.0000017794447,0.0007535061,0.00007529141,0.0019652494,0.00005993683,0.000007364664,0.0010015487],"genre_scores_gemma":[0.99881333,0.0002460393,0.000092960974,0.00014885238,0.000028444863,0.00029950772,0.000038208087,0.000016655451,0.0003159961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832284,0.00015900006,0.00058878266,0.00026158747,0.00033683368,0.00033098],"domain_scores_gemma":[0.9987935,0.00012528681,0.0002578327,0.00023214538,0.00047727258,0.00011397371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045258825,0.0001449981,0.0006127378,0.00023917435,0.000031899133,0.0000044661015,0.00009026824,0.00005563086,0.00006878314],"category_scores_gemma":[0.00014162349,0.00010945421,0.000059217244,0.00031434023,0.00013130717,0.00007540556,0.000038902785,0.0001523754,0.00000468698],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014801529,0.03349618,0.7335884,0.00079494563,0.00054067705,0.00018644135,0.012253328,0.00008859684,0.02680438,0.00005220923,0.0012922647,0.17610101],"study_design_scores_gemma":[0.07237364,0.10474326,0.77958727,0.00043877718,0.00024066262,0.000005200865,0.0021955192,0.00044849396,0.036250982,0.00026886206,0.0031703757,0.00027693235],"about_ca_topic_score_codex":0.0013109115,"about_ca_topic_score_gemma":0.0012652082,"teacher_disagreement_score":0.17582409,"about_ca_system_score_codex":0.00009268367,"about_ca_system_score_gemma":0.00041866128,"threshold_uncertainty_score":0.4463413},"labels":[],"label_agreement":null},{"id":"W2067158051","doi":"10.1097/00000478-200606000-00003","title":"Large Cell Neuroendocrine Carcinoma of Prostate","year":2006,"lang":"en","type":"article","venue":"The American Journal of Surgical Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital; University Health Network","funders":"","keywords":"Chromogranin A; Adenocarcinoma; Pathology; Synaptophysin; Immunohistochemistry; Medicine; Prostate; Neuroendocrine differentiation; Prostate cancer; Prostatic acid phosphatase; Carcinoma; Small-cell carcinoma; Cancer; Oncology; Internal medicine","score_opus":0.012647657879869795,"score_gpt":0.28934615115671397,"score_spread":0.27669849327684415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067158051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920577,0.0013643927,0.000014527298,0.0044054533,0.00006832558,0.00012768932,0.000012835601,0.0000052977402,0.0019437973],"genre_scores_gemma":[0.99797577,0.0006398984,0.00009738025,0.00012687712,0.00017844093,0.0000024750407,0.0000040855375,0.000013786363,0.0009612941],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867606,0.00021947292,0.00041174094,0.00010520383,0.00026569233,0.00032184712],"domain_scores_gemma":[0.9989511,0.00016097454,0.0004228821,0.00018319079,0.00018431325,0.00009757193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031652348,0.00010437686,0.00052144047,0.00011822857,0.00004147353,0.0000039720994,0.00013379671,0.000011446805,0.00005942297],"category_scores_gemma":[0.000014049191,0.000053761378,0.00017799676,0.00027587323,0.00059968134,0.00002931521,0.00005086713,0.00032109072,0.000007878087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020670908,0.003729152,0.797144,0.00016339005,0.00017035783,0.09974284,0.0008545806,0.00006148685,0.05384085,0.00075893773,0.0063228123,0.01654067],"study_design_scores_gemma":[0.02973824,0.025099473,0.7557679,0.00010888001,0.00048617047,0.059378494,0.0017085148,0.00007598239,0.06949594,0.0014180351,0.056385487,0.00033687847],"about_ca_topic_score_codex":0.000031370506,"about_ca_topic_score_gemma":7.247722e-7,"teacher_disagreement_score":0.050062675,"about_ca_system_score_codex":0.000030633626,"about_ca_system_score_gemma":0.000111357236,"threshold_uncertainty_score":0.22095509},"labels":[],"label_agreement":null},{"id":"W2067220192","doi":"10.2174/1875693x00801010013","title":"Molecular Genetic Etiology of Prostate Cancer","year":2008,"lang":"en","type":"article","venue":"The Open Genomics Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"National Cancer Institute; Canadian Prostate Cancer Research Initiative","keywords":"Prostate cancer; TMPRSS2; Biology; Locus (genetics); Genetics; Genetic predisposition; Genotyping; Single-nucleotide polymorphism; Allele; Disease; Gene; Cancer; Genotype; Internal medicine; Medicine; Infectious disease (medical specialty); Coronavirus disease 2019 (COVID-19)","score_opus":0.04780787955118584,"score_gpt":0.3512740997076337,"score_spread":0.30346622015644786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067220192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98873454,0.005363214,0.000032357984,0.0033057015,0.00009603257,0.00047382625,0.000007458037,0.0000024029378,0.0019844817],"genre_scores_gemma":[0.9791004,0.017492395,0.00078679307,0.00031905592,0.00011088241,0.000022985514,0.0000029277705,0.000017627668,0.0021469404],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992744,0.00007043436,0.0002080531,0.00009572906,0.00013814066,0.00021329409],"domain_scores_gemma":[0.9994443,0.000017836483,0.00011117121,0.0001889715,0.00013635436,0.000101376136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019907246,0.00007640358,0.00020216896,0.000045551726,0.00017622048,0.000019372215,0.00031153846,0.000032263102,0.00023582335],"category_scores_gemma":[0.000011431622,0.000042809683,0.00006193226,0.00008592299,0.0001977663,0.00003343102,0.00013805821,0.00024114069,0.0000134544125],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006574176,0.0005090663,0.21778256,0.00009738552,0.0018519188,0.0030849609,0.010441381,0.0030976816,0.692405,0.0003465754,0.010153984,0.05365531],"study_design_scores_gemma":[0.024101239,0.0034976993,0.51478094,0.00033588722,0.00069806806,0.024005892,0.0011143759,0.00087192224,0.36409628,0.005698545,0.06018874,0.0006104227],"about_ca_topic_score_codex":0.000121547746,"about_ca_topic_score_gemma":0.000005920295,"teacher_disagreement_score":0.3283087,"about_ca_system_score_codex":0.000121419616,"about_ca_system_score_gemma":0.0007194696,"threshold_uncertainty_score":0.25821003},"labels":[],"label_agreement":null},{"id":"W2067356799","doi":"10.1038/onc.2013.15","title":"ELF3 is a repressor of androgen receptor action in prostate cancer cells","year":2013,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research; Terry Fox Foundation; University of Nebraska Medical Center; U.S. Department of Defense","keywords":"Repressor; Androgen receptor; Biology; LNCaP; Transcription factor; Cancer research; Prostate cancer; Regulation of gene expression; Cell biology; Transcriptional regulation; YY1; Gene expression; Promoter; Gene; Cancer; Genetics","score_opus":0.03951850254530476,"score_gpt":0.3525393617832278,"score_spread":0.31302085923792305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067356799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99325556,0.00277173,0.0000011466759,0.0015920504,0.000108717766,0.0008529606,0.00004340289,0.000016051503,0.0013583563],"genre_scores_gemma":[0.9684342,0.0105579505,0.00047253724,0.00018704012,0.00011515507,0.00044665096,0.00003590819,0.000026672606,0.019723881],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991471,0.000025572936,0.00019189398,0.00021268261,0.00019967074,0.00022308556],"domain_scores_gemma":[0.9994904,0.000015688533,0.000064762535,0.00020689586,0.00012603813,0.00009625266],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008666052,0.00009194383,0.00021422021,0.00009761206,0.000020679961,0.000007898599,0.000046944086,0.00005365507,0.0023780358],"category_scores_gemma":[0.0000075841817,0.00006851336,0.000051618084,0.00022191709,0.000046739995,0.00008258178,0.000020541738,0.00009623946,0.00013079046],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004026197,0.00019819292,0.027322376,0.00015148876,0.00007907797,0.000013486332,0.0009616047,0.000003821908,0.89174175,9.0790104e-7,0.012537339,0.066587344],"study_design_scores_gemma":[0.0021220092,0.00022607566,0.0036266423,0.00013260874,0.000026067915,0.0000034250697,0.00014266248,0.000077610806,0.97631145,0.000026518039,0.01723293,0.000072020186],"about_ca_topic_score_codex":0.0016279754,"about_ca_topic_score_gemma":0.00004331353,"teacher_disagreement_score":0.084569685,"about_ca_system_score_codex":0.00016564749,"about_ca_system_score_gemma":0.00017555109,"threshold_uncertainty_score":0.9985339},"labels":[],"label_agreement":null},{"id":"W2067439152","doi":"10.1038/sj.pcan.4500967","title":"Androgen receptor CAG repeat length contraction in diseased and non-diseased prostatic tissues","year":2007,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Hôpital du Sacré-Cœur de Montréal; McGill University Health Centre","funders":"","keywords":"Androgen receptor; Prostate cancer; Prostate; Medicine; Pathology; Pathological; Carcinogenesis; Contraction (grammar); Prostatic Diseases; Internal medicine; Cancer","score_opus":0.013856387851474907,"score_gpt":0.3233200927002464,"score_spread":0.3094637048487715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067439152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95770353,0.03492677,0.000023165334,0.0018062626,0.00017466368,0.003967467,0.00097468967,0.00011370564,0.00030973172],"genre_scores_gemma":[0.98376006,0.012204534,0.00023780725,0.00042628642,0.00014041294,0.00084687525,0.0005893221,0.000076282515,0.0017184254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970574,0.00007780797,0.00060571637,0.000830159,0.00054426707,0.0008846659],"domain_scores_gemma":[0.99799496,0.0002650864,0.00016823219,0.00031883398,0.0002213788,0.0010314952],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000375948,0.00045330927,0.00065574545,0.0003355539,0.00023674595,0.00014861547,0.00007638654,0.00009850003,0.00014458802],"category_scores_gemma":[0.00019063702,0.0003634967,0.00008942011,0.00045819112,0.0004298983,0.00043429722,0.00006670339,0.00026222586,0.000010903271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011508274,0.00074562494,0.8651397,0.0027741739,0.00024103536,0.00054977153,0.0030134653,0.0000040607733,0.0029984897,0.00003676157,0.0010029355,0.11198568],"study_design_scores_gemma":[0.018849632,0.0015388329,0.95630246,0.0018384627,0.0008862242,0.00004258923,0.002935172,0.00065580034,0.008842971,0.0011268589,0.0060215103,0.00095948327],"about_ca_topic_score_codex":0.0004888972,"about_ca_topic_score_gemma":0.00014215783,"teacher_disagreement_score":0.111026205,"about_ca_system_score_codex":0.00030684806,"about_ca_system_score_gemma":0.0005900005,"threshold_uncertainty_score":0.9998817},"labels":[],"label_agreement":null},{"id":"W2068808066","doi":"10.1016/j.urology.2009.02.022","title":"Risk of Developing Prostate Cancer in the Future: Overview of Prognostic Biomarkers","year":2009,"lang":"en","type":"review","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Oncology; Disease; Internal medicine; Cancer; Prostate; Randomized controlled trial; Gynecology","score_opus":0.06651783806392556,"score_gpt":0.4039490298350155,"score_spread":0.33743119177108993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068808066","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022138057,0.9961565,0.0000021171684,0.0010411568,0.00013272508,0.0021402927,0.00009619608,0.0000075428775,0.00020208146],"genre_scores_gemma":[0.00028031392,0.9990161,0.000059393442,0.00010361097,0.000105343526,0.00027244887,0.00008700144,0.000020874459,0.00005488054],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981213,0.00046886216,0.00058378367,0.00027561295,0.0002278776,0.00032254],"domain_scores_gemma":[0.9988306,0.00030858355,0.00041792906,0.00031618917,0.00008895788,0.0000377368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054144516,0.00024193569,0.0013947656,0.0002869118,0.000023976958,0.0000030985664,0.00021532601,0.00024539087,0.00004467913],"category_scores_gemma":[0.0000906233,0.00012441342,0.00024065265,0.0007303104,0.00016722223,0.000017228742,0.00004298703,0.00042469846,0.000004650784],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012999566,0.00008389785,0.002532786,0.016911158,0.0004996851,0.000076063065,0.00019336147,4.424242e-7,3.5480116e-7,0.00010641386,0.00025154013,0.9792143],"study_design_scores_gemma":[0.0009858272,0.00066627696,0.004796404,0.0067643593,0.0019888582,0.000072155664,0.000033341366,0.000003076608,0.000003083046,0.00019264917,0.98435754,0.00013644602],"about_ca_topic_score_codex":0.00008818957,"about_ca_topic_score_gemma":0.000095506606,"teacher_disagreement_score":0.984106,"about_ca_system_score_codex":0.00010239713,"about_ca_system_score_gemma":0.0011697072,"threshold_uncertainty_score":0.50734323},"labels":[],"label_agreement":null},{"id":"W2069381249","doi":"10.1007/s10038-003-0091-6","title":"HPC2/ELAC2 gene variants associated with incident prostate cancer","year":2003,"lang":"en","type":"article","venue":"Journal of Human Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heritage Medical Research Clinic; University of Calgary","funders":"","keywords":"Prostate cancer; Linkage disequilibrium; Medicine; Prostate; Odds ratio; Internal medicine; Case-control study; Cancer; Allele; Gynecology; Oncology; Endocrinology; Genetics; Biology; Haplotype; Gene","score_opus":0.034397369884827604,"score_gpt":0.3389002335428813,"score_spread":0.3045028636580537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069381249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921572,0.0060874172,0.000023588284,0.00029430876,0.00014237754,0.00027192594,0.000009819443,0.0000082402075,0.0010050887],"genre_scores_gemma":[0.99247897,0.0022067952,0.0005342755,0.00013122484,0.0001518852,0.0000080943655,0.000007257224,0.0000342207,0.004447277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984477,0.000083706844,0.00038161315,0.00013072256,0.0006349036,0.00032135853],"domain_scores_gemma":[0.9986198,0.000025292533,0.00033356142,0.00015936523,0.00062098086,0.00024103135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038985803,0.0001467355,0.00032861863,0.00015350673,0.000115710405,0.00003613472,0.000093470335,0.00006876743,0.00025906088],"category_scores_gemma":[0.00006125155,0.00009483245,0.00008148355,0.00019929756,0.00008700981,0.000054733024,0.000018320861,0.0003138155,0.000004958404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011167126,0.0013464965,0.86223525,0.000112599424,0.0022447377,0.0031768994,0.003049434,0.00036759648,0.11649084,0.00008370151,0.006332509,0.0034431985],"study_design_scores_gemma":[0.0188871,0.008204106,0.8171158,0.0008651581,0.0010447083,0.00085282995,0.00039181052,0.000052231393,0.14619456,0.0009555509,0.005018811,0.00041733548],"about_ca_topic_score_codex":0.000009895668,"about_ca_topic_score_gemma":0.00003910216,"teacher_disagreement_score":0.04511948,"about_ca_system_score_codex":0.0003686909,"about_ca_system_score_gemma":0.0006730293,"threshold_uncertainty_score":0.3867155},"labels":[],"label_agreement":null},{"id":"W2069405463","doi":"10.1016/j.mce.2013.07.017","title":"The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer","year":2013,"lang":"en","type":"article","venue":"Molecular and Cellular Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Androgen receptor; Prostate cancer; Cancer research; Tyrosine phosphorylation; Phosphorylation; Tyrosine kinase; Receptor tyrosine kinase; Signal transduction; Effector; Tyrosine; Chemistry; Androgen; Endocrinology; Internal medicine; Biology; Cell biology; Cancer; Medicine; Biochemistry; Hormone","score_opus":0.008957424377922093,"score_gpt":0.27038526196153,"score_spread":0.26142783758360794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069405463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990614,0.00471971,0.000013846237,0.0030142763,0.000069150614,0.0009821983,0.0000051325155,0.000015330546,0.0005663673],"genre_scores_gemma":[0.9974551,0.0009906407,0.000027496817,0.00011132775,0.000021509279,0.00035561214,0.000044642955,0.000018462712,0.0009751713],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893945,0.000096861804,0.00019587037,0.00024210491,0.00014440311,0.00038130578],"domain_scores_gemma":[0.9994848,0.00005200063,0.00005852216,0.00021532517,0.00009791025,0.000091454036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006160496,0.00014575545,0.00024021995,0.000111097645,0.000055132925,0.000020196787,0.00007147406,0.000055025295,0.0001474204],"category_scores_gemma":[0.000046623885,0.00009215902,0.000055530425,0.00016260977,0.00018864307,0.000053277756,0.00006929498,0.0001847807,0.000029178213],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056994177,0.00012721246,0.0154309785,0.00010197482,0.0001241543,0.000100215955,0.00021780151,0.0000020879334,0.9542573,0.00026741298,0.00024867113,0.028552238],"study_design_scores_gemma":[0.0026320473,0.0005482819,0.003947314,0.000098163066,0.000032185977,0.00001845832,0.00014723396,0.000028359533,0.9879179,0.00016578332,0.0043762275,0.000088045635],"about_ca_topic_score_codex":0.000915774,"about_ca_topic_score_gemma":0.00001964647,"teacher_disagreement_score":0.033660587,"about_ca_system_score_codex":0.00008180508,"about_ca_system_score_gemma":0.00010751967,"threshold_uncertainty_score":0.37581357},"labels":[],"label_agreement":null},{"id":"W2070496808","doi":"10.1016/j.urology.2014.01.013","title":"Long-term Tolerability and Efficacy of Degarelix: 5-Year Results From a Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix","year":2014,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Tolerability; Prostate-specific antigen; Adverse effect; Urology; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Internal medicine; Clinical trial; Cancer","score_opus":0.029241939521043904,"score_gpt":0.33878677957944103,"score_spread":0.3095448400583971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070496808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995965,0.00033532578,0.00032956447,0.0013531212,0.00013942776,0.0012300512,0.00019935152,0.00004024943,0.00040791725],"genre_scores_gemma":[0.9982891,0.000042022195,0.00033977165,0.0004516201,0.00032542585,0.000042083626,0.000313784,0.00002453134,0.00017163392],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99811924,0.00014112983,0.00042685802,0.0006764351,0.00027763154,0.00035869193],"domain_scores_gemma":[0.9981754,0.0006224467,0.000121508,0.00061921496,0.00017435041,0.00028708522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028459364,0.00020117103,0.0006310037,0.00010011578,0.00007131981,0.000018504346,0.00010304403,0.00017787382,0.00015938384],"category_scores_gemma":[0.0005485992,0.00013742618,0.000068135625,0.00012726052,0.00027150763,0.000047373396,0.000108757704,0.00024658997,0.00002175271],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95738745,0.0018017783,0.016712168,0.00002263595,0.0002380161,0.00014776125,0.0011734082,0.000020232583,0.009477588,0.000016466018,0.00054446,0.0124580655],"study_design_scores_gemma":[0.70813566,0.032447238,0.24387792,0.00011646515,0.00055145647,0.000022309318,0.000036522906,0.00040656162,0.011771857,0.00032355264,0.0020189963,0.00029144608],"about_ca_topic_score_codex":0.001181582,"about_ca_topic_score_gemma":0.00021887303,"teacher_disagreement_score":0.24925174,"about_ca_system_score_codex":0.000047173417,"about_ca_system_score_gemma":0.00013998494,"threshold_uncertainty_score":0.5604077},"labels":[],"label_agreement":null},{"id":"W2070517005","doi":"10.1016/j.chembiol.2014.09.012","title":"Identification of a Potent Antiandrogen that Targets the BF3 Site of the Androgen Receptor and Inhibits Enzalutamide-Resistant Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Chemistry & Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Enzalutamide; LNCaP; Androgen receptor; Prostate cancer; Antiandrogen; Cancer research; Androgen Receptor Antagonists; Androgen; Biology; In vivo; Bicalutamide; Pharmacology; Cancer; Internal medicine; Endocrinology; Medicine; Genetics; Hormone","score_opus":0.013286815195763708,"score_gpt":0.27740327868029196,"score_spread":0.2641164634845283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070517005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896222,0.007550081,0.0000042291185,0.0020281796,0.000056556084,0.00037988808,0.00015849588,0.000008042804,0.0001923806],"genre_scores_gemma":[0.9971656,0.0015867626,0.000009805428,0.00005252113,0.000052847583,0.00005020907,0.000060558614,0.000009698562,0.001011991],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991674,0.00005623247,0.00024133176,0.0002220393,0.00012569432,0.00018729061],"domain_scores_gemma":[0.99925876,0.00004662515,0.00020290002,0.00030940384,0.00012843321,0.00005385397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026843426,0.00010998065,0.00022521892,0.000015600148,0.00007590213,0.000005914528,0.00010362289,0.00009376183,0.000047573943],"category_scores_gemma":[0.00007189988,0.000054854656,0.00006882058,0.00011350151,0.0004717478,0.000017760512,0.0000890493,0.000111550195,0.0000016667041],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026655005,0.000040916715,0.066265136,0.0002463028,0.000088748595,4.858251e-7,0.00040995347,8.254823e-7,0.9293716,0.000009471135,0.00016664912,0.0031333724],"study_design_scores_gemma":[0.000859062,0.00006359128,0.013316301,0.000093079005,0.00006950012,0.000008488558,0.00010168304,0.000037361075,0.98157763,0.000095307696,0.003722778,0.000055222506],"about_ca_topic_score_codex":0.00006578515,"about_ca_topic_score_gemma":0.0000071721197,"teacher_disagreement_score":0.052948833,"about_ca_system_score_codex":0.0000398143,"about_ca_system_score_gemma":0.000100710175,"threshold_uncertainty_score":0.2236908},"labels":[],"label_agreement":null},{"id":"W2070615987","doi":"10.1016/j.ijrobp.2010.07.103","title":"Initial Report of RTOG 9601: A Phase III Trial in Prostate Cancer: Anti-androgen Therapy (AAT) with Bicalutamide during and after Radiation Therapy (RT) Improves Freedom from Progression and Reduces the Incidence of Metastatic Disease in Patients following Radical Prostatectomy (RP) with pT2-3, N0 Disease, and Elevated PSA Levels","year":2010,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Bicalutamide; Prostate cancer; Urology; Clinical endpoint; Androgen deprivation therapy; Radiation therapy; Randomized controlled trial; Incidence (geometry); Prostate-specific antigen; Internal medicine; Placebo; Prostate; Cancer; Oncology; Androgen receptor","score_opus":0.01710896266047948,"score_gpt":0.36180607718119934,"score_spread":0.3446971145207199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070615987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953388,0.0020225423,0.000027044598,0.0007273659,0.00020015759,0.0015375478,0.00013847165,0.0000067461783,0.0000013397072],"genre_scores_gemma":[0.99701333,0.0021468261,0.00033627127,0.000040126833,0.0001978946,0.00014609762,0.00009724822,0.00001969579,0.0000024833898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814063,0.00021690504,0.0007523962,0.00028545834,0.00041473485,0.0001898439],"domain_scores_gemma":[0.9982209,0.00025123652,0.00092120195,0.000115931405,0.0003299988,0.00016073974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048931304,0.00019548126,0.00051591755,0.00020685988,0.000053173957,0.000027505623,0.00011244314,0.00006517785,0.0000069837297],"category_scores_gemma":[0.00017068148,0.000111979774,0.00006203014,0.00019950827,0.0005200106,0.00035469377,0.00003810826,0.0003330583,4.5602444e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12049954,0.0009360773,0.80897105,0.000021458744,0.0005479126,0.00029913048,0.0010649294,0.000034200846,0.022101348,0.000009234878,0.0000010686035,0.045514062],"study_design_scores_gemma":[0.16618486,0.003262148,0.8081891,0.00035956842,0.00016238187,0.000035718407,0.000058561945,0.00090330484,0.02011599,0.00055365235,0.000032226864,0.0001424999],"about_ca_topic_score_codex":0.00012826387,"about_ca_topic_score_gemma":0.000024373472,"teacher_disagreement_score":0.045685314,"about_ca_system_score_codex":0.000153971,"about_ca_system_score_gemma":0.0010974349,"threshold_uncertainty_score":0.45664027},"labels":[],"label_agreement":null},{"id":"W2070767684","doi":"10.1002/cncr.29285","title":"Quality of life in patients with high‐risk prostate cancer improves with shorter course of androgen deprivation therapy","year":2015,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Quality of life (healthcare); Randomized controlled trial; Testosterone (patch); Radiation therapy; Androgen; Guideline; Internal medicine; Cancer; Urology; Hormone","score_opus":0.03716660222956028,"score_gpt":0.3441052020457788,"score_spread":0.3069385998162185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070767684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99516106,0.0033230388,0.000008311085,0.00026455766,0.0000444578,0.00096502283,0.00016897064,0.000010064699,0.00005451041],"genre_scores_gemma":[0.99790347,0.0014539578,0.000100056495,0.00007300022,0.000036929112,0.00021617951,0.000057405494,0.000021479691,0.00013751346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988773,0.00005003158,0.00028190186,0.00020739678,0.00038864082,0.00019474111],"domain_scores_gemma":[0.9988513,0.000023349592,0.00022911448,0.00022177055,0.00054214505,0.00013231416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019376406,0.00012927674,0.0003644771,0.00006623555,0.00001556383,0.000004621108,0.000056163277,0.00004808356,0.00003306936],"category_scores_gemma":[0.000019778368,0.00007164439,0.00002490513,0.00025120034,0.00015218166,0.000102396756,0.0000143137595,0.000109158376,4.0180385e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010747827,0.0003424243,0.9612319,0.000093278024,0.00025174124,0.0000013058342,0.001303488,0.00005398341,0.00053933286,0.0000034860234,0.00015198688,0.025279243],"study_design_scores_gemma":[0.014869628,0.0012532755,0.96798575,0.00016140233,0.000037476853,9.9351894e-8,0.00021486792,0.000017104005,0.015174733,0.000023922581,0.00016480927,0.00009693548],"about_ca_topic_score_codex":0.004363306,"about_ca_topic_score_gemma":0.00080369995,"teacher_disagreement_score":0.025182307,"about_ca_system_score_codex":0.0001695138,"about_ca_system_score_gemma":0.001095124,"threshold_uncertainty_score":0.65960425},"labels":[],"label_agreement":null},{"id":"W2070823430","doi":"10.1016/j.ymthe.2004.12.005","title":"A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies","year":2005,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute","keywords":"Prostate cancer; Cancer research; Biology; Genetically modified mouse; Prostate; Cancer; Transgene; Gene knockin; Adenocarcinoma; Gene; Pathology; Medicine; Genetics","score_opus":0.14275642821468637,"score_gpt":0.4667619311088646,"score_spread":0.32400550289417823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070823430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9414203,0.0489281,0.00013724231,0.006871773,0.000032037868,0.0023655812,0.00016952193,0.000021136288,0.000054296674],"genre_scores_gemma":[0.97296727,0.01989766,0.0029407432,0.0008354275,0.000044890738,0.0017566377,0.000028099414,0.0000439884,0.0014853055],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986151,0.0000330209,0.0003116567,0.00042585476,0.00015102497,0.00046337192],"domain_scores_gemma":[0.99933124,0.00006924489,0.00007728802,0.00019680013,0.00019996228,0.00012549153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029669167,0.00021465064,0.0005238291,0.00013784003,0.000072936,0.000012373283,0.000085334876,0.000087441076,0.000014160113],"category_scores_gemma":[0.000027793127,0.00015431632,0.000084121035,0.0001645763,0.00019057853,0.000059691392,0.000048571477,0.00012809335,6.0605123e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002793872,0.00048407805,0.06956477,0.00022836369,0.0006357267,0.000011085785,0.0031513928,0.0017564464,0.8818882,0.00018006646,0.00024916776,0.039056834],"study_design_scores_gemma":[0.020422949,0.0029835308,0.004356609,0.00063766213,0.00013865124,0.0000065138365,0.0006037402,0.0050863465,0.95841324,0.0018800014,0.0050047063,0.00046604226],"about_ca_topic_score_codex":0.00018216716,"about_ca_topic_score_gemma":0.00038509388,"teacher_disagreement_score":0.07652505,"about_ca_system_score_codex":0.00013502502,"about_ca_system_score_gemma":0.00024916686,"threshold_uncertainty_score":0.62928367},"labels":[],"label_agreement":null},{"id":"W2070837962","doi":"10.1258/ebm.2012.012131","title":"Human periprostatic white adipose tissue is rich in stromal progenitor cells and a potential source of prostate tumor stroma","year":2012,"lang":"en","type":"article","venue":"Experimental Biology and Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"","keywords":"Adipose tissue; Prostate cancer; Stromal cell; CD34; Progenitor cell; Prostate; Pathology; Medicine; Population; Cancer; Stem cell; Cancer research; Biology; Internal medicine","score_opus":0.015888977274178543,"score_gpt":0.34368424983146667,"score_spread":0.32779527255728813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070837962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820437,0.016303264,0.0000025843242,0.0004708779,0.00013021106,0.0008348956,0.000025791036,0.000015652786,0.00017304206],"genre_scores_gemma":[0.99803984,0.00012070829,0.00018291114,0.00016462569,0.00018593961,0.00008131868,0.00006842101,0.00001718479,0.0011390415],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988146,0.00007100674,0.00029177984,0.00026825868,0.00013522882,0.00041913538],"domain_scores_gemma":[0.9994885,0.00001721924,0.000080190664,0.00012671026,0.000032257147,0.00025512767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018913214,0.00019186104,0.00042518802,0.00014802077,0.00008608263,0.000003851634,0.00004305615,0.00008294271,0.0007655914],"category_scores_gemma":[0.000010261042,0.0001312817,0.000022151995,0.00010704393,0.0007055395,0.00007232641,0.00007323198,0.00016259812,0.0000027251342],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005400985,0.00033451192,0.19426864,0.000107779524,0.00006398796,0.00003920313,0.008356669,4.254265e-8,0.79535735,0.000024601166,0.00022288633,0.0006842459],"study_design_scores_gemma":[0.009934408,0.007926553,0.08835297,0.0002062956,0.000114383176,0.0002610986,0.008374455,0.000014817885,0.88352376,0.000019207573,0.0010805519,0.000191475],"about_ca_topic_score_codex":0.00010259432,"about_ca_topic_score_gemma":0.0000017863193,"teacher_disagreement_score":0.10591567,"about_ca_system_score_codex":0.000045648234,"about_ca_system_score_gemma":0.000034121138,"threshold_uncertainty_score":0.8382689},"labels":[],"label_agreement":null},{"id":"W2071026034","doi":"10.1016/j.ijrobp.2008.06.936","title":"Final Report of a Canadian Phase III Trial of 3 vs 8 months Neoadjuvant Androgen Deprivation Prior to 66 Gray External Beam Radiotherapy for Clinically Localized Prostate Cancer","year":2008,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Northeast Cancer Centre; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; External beam radiotherapy; Androgen deprivation therapy; External beam radiation; Gray (unit); Radiation therapy; Oncology; Prostate; Internal medicine; Androgen; Urology; Radiology; Cancer; Hormone","score_opus":0.052925176796578106,"score_gpt":0.41362283437446945,"score_spread":0.36069765757789135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071026034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808921,0.0007816138,0.011159947,0.0038355,0.0013650237,0.001630133,0.00026860923,0.000010857862,0.000056172983],"genre_scores_gemma":[0.9829743,0.004368249,0.009602655,0.00061230455,0.0018655633,0.00013690293,0.0001958898,0.000033483597,0.0002106567],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972796,0.0001202476,0.0015991868,0.00026778696,0.00043575457,0.00029741816],"domain_scores_gemma":[0.9956924,0.00031943957,0.0016688193,0.0001818317,0.0018196924,0.0003178227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009170604,0.00019329773,0.0008321209,0.0005435705,0.00008388426,0.000009461551,0.00028979403,0.00021019495,0.000055235],"category_scores_gemma":[0.00050683203,0.00015632053,0.00035457042,0.00030866227,0.00024196345,0.00015771882,0.000025098238,0.00027949,0.0000012497951],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3236674,0.003021416,0.30410057,0.00004874689,0.0027393927,0.0006775469,0.0026955577,0.001349257,0.041700277,0.00045442133,0.0036216623,0.31592375],"study_design_scores_gemma":[0.7101904,0.046850063,0.027825708,0.0005729444,0.0006907708,0.0017439175,0.00014644113,0.0045911097,0.08443441,0.0026906056,0.11965287,0.0006107379],"about_ca_topic_score_codex":0.00267524,"about_ca_topic_score_gemma":0.00035124598,"teacher_disagreement_score":0.38652304,"about_ca_system_score_codex":0.0009945149,"about_ca_system_score_gemma":0.0043486524,"threshold_uncertainty_score":0.7714323},"labels":[],"label_agreement":null},{"id":"W2071120462","doi":"10.1002/pros.20959","title":"High‐resolution array CGH identifies novel regions of genomic alteration in intermediate‐risk prostate cancer","year":2009,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Prostate cancer; PTEN; Prostate; TMPRSS2; Concordance; Comparative genomic hybridization; Chromoplexy; Cancer; Oncology; Cancer research; Biology; Medicine; Internal medicine; Disease; Genetics; PCA3; Gene; Chromosome","score_opus":0.02297467338543312,"score_gpt":0.30908515395465436,"score_spread":0.2861104805692212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071120462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98969615,0.0017913802,0.0002443842,0.006268642,0.00021532107,0.0014534055,0.00014134169,0.000055022752,0.00013434683],"genre_scores_gemma":[0.99038494,0.0062123467,0.0001792992,0.00014520303,0.000117624986,0.00015571497,0.0001203468,0.00001960322,0.0026648985],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985388,0.000079702186,0.00044391677,0.00027572128,0.00027779263,0.00038410176],"domain_scores_gemma":[0.9991632,0.00005690978,0.0002217575,0.00033340874,0.00014753932,0.00007716053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045139916,0.00017286497,0.00028663743,0.00019015129,0.00012784514,0.000036151283,0.00012851406,0.000055315835,0.00003309586],"category_scores_gemma":[0.000059392125,0.000110628425,0.00007590555,0.00028716202,0.0001985167,0.00017061457,0.000033867007,0.00030164534,0.00002084869],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004717353,0.0007317502,0.02739846,0.000224785,0.00021295088,0.00003795173,0.020515956,0.0018544337,0.9170643,0.0005713633,0.0020482382,0.024622472],"study_design_scores_gemma":[0.010560688,0.0014926526,0.7419294,0.0008405257,0.0002716728,0.000028186096,0.00092311035,0.0021188615,0.22980642,0.010288994,0.0013453179,0.00039414194],"about_ca_topic_score_codex":0.0009939073,"about_ca_topic_score_gemma":0.00028182875,"teacher_disagreement_score":0.71453094,"about_ca_system_score_codex":0.0002515824,"about_ca_system_score_gemma":0.00022149584,"threshold_uncertainty_score":0.45112962},"labels":[],"label_agreement":null},{"id":"W2071923947","doi":"10.1158/1055-9965.epi-06-0477","title":"Obesity, Diabetes, and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial","year":2006,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":351,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute","keywords":"Prostate cancer; Medicine; Body mass index; Cancer; Internal medicine; Obesity; Oncology; Odds ratio; Prostate; Prostate biopsy; Confidence interval; Gynecology","score_opus":0.042161447824823825,"score_gpt":0.366606532982372,"score_spread":0.32444508515754816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071923947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89345974,0.09227298,0.000033616987,0.008336748,0.0008341998,0.0036146056,0.0012695,0.00006342919,0.000115198156],"genre_scores_gemma":[0.87362957,0.11475659,0.00052359205,0.00018525406,0.0009994588,0.0024319545,0.0014902375,0.000058812126,0.005924511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952418,0.0015439205,0.0012737578,0.00090190215,0.00030598277,0.0007325883],"domain_scores_gemma":[0.99681175,0.0010500553,0.0011797491,0.0005296151,0.0002620214,0.00016683068],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030757107,0.00037931907,0.00093095633,0.00013848928,0.00028861157,0.00001929172,0.00018911314,0.00030836326,0.00013294234],"category_scores_gemma":[0.00048955524,0.00025340027,0.00032873361,0.0003848049,0.00070873677,0.00019051875,0.00013782973,0.00041247092,0.000004631603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03581151,0.00030805526,0.87887293,0.00014895608,0.0016355345,0.0000041338185,0.00023206157,0.00005432298,0.0011555803,0.000035503454,0.0143690165,0.0673724],"study_design_scores_gemma":[0.059778992,0.0011860457,0.91025937,0.001565051,0.0019226169,0.0000016999822,0.00011666618,0.0005275296,0.0037015562,0.014983083,0.0056163836,0.000341012],"about_ca_topic_score_codex":0.02615633,"about_ca_topic_score_gemma":0.006354106,"teacher_disagreement_score":0.06703138,"about_ca_system_score_codex":0.00043912375,"about_ca_system_score_gemma":0.0006401745,"threshold_uncertainty_score":0.99999183},"labels":[],"label_agreement":null},{"id":"W2072050498","doi":"10.1177/1078155207085387","title":"Efficacy vs. effectiveness — docetaxel and prednisone in hormone refractory prostate cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Docetaxel; Medicine; Prednisone; Internal medicine; Prostate cancer; Oncology; Cancer; Chemotherapy; Clinical trial; Retrospective cohort study","score_opus":0.06481101481439419,"score_gpt":0.45124613304170885,"score_spread":0.3864351182273147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072050498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95334977,0.032985482,0.0000063986454,0.011110555,0.00027590687,0.00067382865,0.000005053716,0.000011365843,0.0015816448],"genre_scores_gemma":[0.8605004,0.13768478,0.0005294174,0.00057721545,0.00026999007,0.00003744928,0.0000023139148,0.00002197509,0.00037647694],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979195,0.0006259772,0.00050309947,0.00021395685,0.00039858592,0.00033889536],"domain_scores_gemma":[0.99701947,0.0015484457,0.0005445133,0.000116736126,0.00048933586,0.00028150273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015004055,0.0001740024,0.0006072861,0.00029386746,0.00010720524,0.000012900611,0.00009643232,0.00008636439,0.000051950792],"category_scores_gemma":[0.00080265576,0.00012816938,0.000079750236,0.00030513594,0.00024402332,0.0008224435,0.000056713372,0.0011175164,0.000008705225],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3292098,0.011655257,0.23352711,0.00048520658,0.00218979,0.038553976,0.0070755365,0.00009856734,0.15908004,0.000013321935,0.010368711,0.20774269],"study_design_scores_gemma":[0.08409297,0.0065340814,0.43264517,0.00026158072,0.0006960079,0.013390233,0.00027968586,0.000070116585,0.007456618,0.000016385526,0.45435828,0.00019889594],"about_ca_topic_score_codex":0.00014905194,"about_ca_topic_score_gemma":0.00000415636,"teacher_disagreement_score":0.44398955,"about_ca_system_score_codex":0.00076672854,"about_ca_system_score_gemma":0.0016375367,"threshold_uncertainty_score":0.5226596},"labels":[],"label_agreement":null},{"id":"W2073705494","doi":"10.1016/j.jsbmb.2009.02.002","title":"Androgens down-regulate myosin light chain kinase in human prostate cancer cells","year":2009,"lang":"en","type":"article","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"LNCaP; Androgen; Prostate cancer; Biology; Myosin light-chain kinase; Gene isoform; Microarray analysis techniques; Prostate; Myosin; Cancer research; Endocrinology; Cell biology; Gene; Gene expression; Cancer; Genetics; Hormone","score_opus":0.008160883880933268,"score_gpt":0.29983856101374795,"score_spread":0.29167767713281467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073705494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810732,0.0125933,0.000009829535,0.005970863,0.000033386106,0.00016938816,0.000009899504,0.0000029795644,0.00013716363],"genre_scores_gemma":[0.9968622,0.0022779794,0.00004415299,0.00038145634,0.00007768521,0.0000026162638,0.000008909568,0.0000067080846,0.0003383243],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99918824,0.000071780734,0.00026499561,0.0001299573,0.00009842645,0.00024656884],"domain_scores_gemma":[0.99951,0.00001144391,0.00013426942,0.00014686336,0.00007870797,0.000118732976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029994381,0.0001337335,0.00025274736,0.000067271656,0.00005999304,0.000009929148,0.00010031158,0.00010366832,0.000017964807],"category_scores_gemma":[0.000008363796,0.00007634807,0.00006218792,0.00010570646,0.00015057968,0.000018703176,0.000030385529,0.0002490081,5.514052e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007117562,0.00009874709,0.0007442537,0.000033340366,0.00006850488,0.0002417448,0.00030484414,0.0000033389908,0.9940347,0.0000053869676,0.00009404176,0.0036593114],"study_design_scores_gemma":[0.002255624,0.00081677974,0.0008615474,0.00014801756,0.0000712746,0.0002511091,0.000106735955,0.0000046015098,0.9946938,0.00021680312,0.00049262657,0.00008106867],"about_ca_topic_score_codex":0.000010464694,"about_ca_topic_score_gemma":0.0000018314391,"teacher_disagreement_score":0.015788978,"about_ca_system_score_codex":0.000056652734,"about_ca_system_score_gemma":0.00008475372,"threshold_uncertainty_score":0.3113384},"labels":[],"label_agreement":null},{"id":"W2074353902","doi":"10.1159/000271639","title":"Onkogene Transformation durch humane Papillomaviren-Typ-16-DNS in Anwesenheit von Progesteron oder Progestin aus oralen Kontrazeptiva","year":2009,"lang":"de","type":"article","venue":"Gynäkologische Rundschau","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Transformation (genetics); Chemistry","score_opus":0.04377731387912188,"score_gpt":0.32949300115296054,"score_spread":0.28571568727383867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074353902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8948472,0.06347891,0.00024116243,0.026605159,0.0007571341,0.0062161563,0.00013740914,0.00037651652,0.0073403507],"genre_scores_gemma":[0.9807139,0.0082546985,0.0003139126,0.0005469105,0.0009348059,0.00031376648,0.0012249631,0.00010865651,0.007588395],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9918124,0.00070438616,0.0018683869,0.0015403236,0.0016105206,0.0024639824],"domain_scores_gemma":[0.9968572,0.00024440818,0.0004768193,0.0012844416,0.00040511446,0.00073196343],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021372207,0.0011081969,0.0015806457,0.00092763995,0.000447968,0.00026012817,0.0007262713,0.0011449738,0.00075886503],"category_scores_gemma":[0.00039020134,0.00089115935,0.00041090316,0.0014624425,0.00057884643,0.00083457417,0.00013334339,0.0018867494,0.0010441965],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010539502,0.0091880895,0.27041745,0.0018453723,0.0017908509,0.004214292,0.014149337,0.00023356799,0.045609284,0.0025021152,0.010017297,0.6294928],"study_design_scores_gemma":[0.054638978,0.027382124,0.65349454,0.004504453,0.002872841,0.00039708443,0.0037613318,0.0030005567,0.12516631,0.0057722423,0.11417303,0.004836489],"about_ca_topic_score_codex":0.00045979975,"about_ca_topic_score_gemma":0.00047048068,"teacher_disagreement_score":0.6246564,"about_ca_system_score_codex":0.0013874344,"about_ca_system_score_gemma":0.0010106828,"threshold_uncertainty_score":0.9997336},"labels":[],"label_agreement":null},{"id":"W2074528665","doi":"10.1111/j.1464-410x.2005.05676.x","title":"Long‐term side‐effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study","year":2005,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Élisabeth Bruyère Hospital; Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Tolerability; Androgen deprivation therapy; Prostate; Sexual function; Osteoporosis; Urology; Testosterone (patch); Prostate-specific antigen; Cancer; Internal medicine; Adverse effect","score_opus":0.019871994973046626,"score_gpt":0.3492029511324243,"score_spread":0.32933095615937763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074528665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727713,0.0252093,0.0000026407683,0.0010176487,0.00013501117,0.00078061066,0.00003152625,0.0000036982292,0.00004828881],"genre_scores_gemma":[0.98296005,0.016625537,0.000025098818,0.00007801654,0.0001121531,0.00002118407,0.0000073120264,0.000014397885,0.00015627251],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983572,0.00019797454,0.00073231093,0.00016297848,0.00029887896,0.0002506978],"domain_scores_gemma":[0.9989847,0.00009234684,0.0004110742,0.00012979197,0.00026638058,0.00011572915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043065357,0.00010953408,0.0005653106,0.0002422822,0.000031844942,0.0000062867716,0.00013042249,0.000062377294,0.000028792556],"category_scores_gemma":[0.000101899655,0.000089306865,0.00010815366,0.00015421037,0.00012324129,0.00010012243,0.000059262995,0.0003240322,3.789902e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026460718,0.008546816,0.099722944,0.00012605268,0.00039068155,0.0074292133,0.0027636278,0.000025523253,0.03098507,2.881016e-7,0.0005065662,0.8230425],"study_design_scores_gemma":[0.16389023,0.08033993,0.65707207,0.0015919277,0.00023433159,0.0044314484,0.00021596049,0.00005983221,0.09119772,0.000034586832,0.00076545647,0.00016652282],"about_ca_topic_score_codex":0.00020929702,"about_ca_topic_score_gemma":0.00023691078,"teacher_disagreement_score":0.822876,"about_ca_system_score_codex":0.0000735649,"about_ca_system_score_gemma":0.00021985834,"threshold_uncertainty_score":0.3641828},"labels":[],"label_agreement":null},{"id":"W2074831305","doi":"10.3390/ijms140612496","title":"Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer","year":2013,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Genome British Columbia; Prostate Cancer Canada","keywords":"Androgen receptor; Prostate cancer; Androgen; Transcription factor; Cancer research; Cancer; Biology; Nuclear receptor; Computational biology; Chemistry; Medicine; Bioinformatics; Gene; Endocrinology; Genetics; Hormone","score_opus":0.08695535871402274,"score_gpt":0.4203868430213193,"score_spread":0.3334314843072965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074831305","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013445201,0.97939414,0.000015411353,0.0050152023,0.00055389665,0.0009062731,0.0000892313,0.0000058984806,0.00057476887],"genre_scores_gemma":[0.0020390323,0.99578154,0.0004597965,0.0003120131,0.00046697527,0.00010471365,0.000022698856,0.000020336054,0.00079288124],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973106,0.00015431516,0.0005574985,0.00026887,0.0014701876,0.00023854867],"domain_scores_gemma":[0.9981696,0.0002050176,0.00054935954,0.00011178825,0.00079939666,0.00016486352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061242346,0.00024053271,0.0005408621,0.00040768477,0.00012419667,0.00024159715,0.00069102924,0.000058300313,0.00038461207],"category_scores_gemma":[0.00022878568,0.00011376083,0.00031244676,0.00033964528,0.00018627419,0.00013483159,0.000078899255,0.00031861878,0.00006115471],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040097957,0.0002762104,0.00012274293,0.0007264805,0.001858181,0.0011460669,0.0010105481,0.00028708065,0.010878989,0.0006374065,0.011436214,0.9712191],"study_design_scores_gemma":[0.0012891415,0.0026116355,0.000016766378,0.021764763,0.0006655098,0.0003555587,0.00058254617,0.00006935343,0.013108588,0.0002811717,0.9587693,0.00048562133],"about_ca_topic_score_codex":0.00007560577,"about_ca_topic_score_gemma":0.000002690569,"teacher_disagreement_score":0.97073346,"about_ca_system_score_codex":0.00041236417,"about_ca_system_score_gemma":0.0010494024,"threshold_uncertainty_score":0.4639032},"labels":[],"label_agreement":null},{"id":"W2075872996","doi":"10.1158/1538-7445.am2011-1096","title":"Abstract 1096: Prostate tumor growth in pbARR2-Cre PTEN knockout mice is delayed in GH/IGF-I deficient mice","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"PTEN; Prostate cancer; Biology; Endocrinology; Prostate; Internal medicine; Cancer research; Cancer; Medicine; PI3K/AKT/mTOR pathway; Signal transduction; Cell biology","score_opus":0.10565667778009134,"score_gpt":0.3981641655475185,"score_spread":0.29250748776742713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075872996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716167,0.0066671656,9.873014e-7,0.0023042182,0.0001312757,0.0020550787,0.00011754567,0.000049048213,0.01705802],"genre_scores_gemma":[0.99095523,0.0028575691,0.00012616854,0.00030978542,0.00012871627,0.0010096069,0.000045810288,0.000081767765,0.0044853524],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9952612,0.00021486764,0.0005831097,0.0009247314,0.0012934392,0.0017226809],"domain_scores_gemma":[0.99806666,0.00018103315,0.00008088824,0.00050071,0.000676989,0.0004937279],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016900285,0.00032662164,0.0005263838,0.0010786584,0.0001657832,0.000053507072,0.000478049,0.0001688504,0.0015563718],"category_scores_gemma":[0.00016980668,0.00026547204,0.000118421114,0.0017654586,0.00051536906,0.0002032721,0.00025918742,0.0015389598,0.00043311363],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036962166,0.0053726453,0.48048297,0.0040759672,0.00061961147,0.011965278,0.063399814,0.00002360093,0.3516303,0.0006761619,0.02378931,0.021002183],"study_design_scores_gemma":[0.022687258,0.0023940543,0.4336793,0.0033132704,0.0000896046,0.000117248506,0.010992231,0.00040455765,0.5144866,0.002346451,0.008220262,0.001269158],"about_ca_topic_score_codex":0.022316702,"about_ca_topic_score_gemma":0.0022946515,"teacher_disagreement_score":0.16285631,"about_ca_system_score_codex":0.0016804258,"about_ca_system_score_gemma":0.0018091348,"threshold_uncertainty_score":0.99997973},"labels":[],"label_agreement":null},{"id":"W2075917655","doi":"10.1007/s00520-010-1023-6","title":"Predictors of hemoglobin decline in non-metastatic prostate cancer patients on androgen deprivation therapy: a matched cohort study","year":2010,"lang":"en","type":"article","venue":"Supportive Care in Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Hemoglobin; Internal medicine; Comorbidity; Cohort; Cancer; Univariate analysis; Prospective cohort study; Cohort study; Oncology; Multivariate analysis","score_opus":0.017226646591533133,"score_gpt":0.3483191014414256,"score_spread":0.33109245484989247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075917655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993368,0.00048383654,4.2228967e-7,0.0002861434,0.00037841738,0.00495742,0.00032371486,0.000017148064,0.00018485842],"genre_scores_gemma":[0.99623513,0.000992999,0.000026336456,0.00015933397,0.000058189653,0.0021131842,0.00024866342,0.000040273986,0.00012587477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789166,0.000070832684,0.0005574502,0.00047172784,0.000621849,0.00038645882],"domain_scores_gemma":[0.9987835,0.00006211831,0.00020211296,0.0002914468,0.0005405254,0.00012024901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029792442,0.00023952396,0.0005369686,0.00032846516,0.000030255176,0.000010705903,0.00011693149,0.000080900674,0.00031296653],"category_scores_gemma":[0.00008145746,0.00018046385,0.000069298985,0.0006059579,0.000108801476,0.00011668219,0.00005699561,0.00039598974,0.0000038855383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002748817,0.0015295411,0.97489697,0.0001360303,0.00019930743,0.000071593684,0.0075698225,0.00002751963,0.0019392181,6.2953103e-7,0.00011850294,0.010762069],"study_design_scores_gemma":[0.011383902,0.0019110889,0.95997894,0.00023089281,0.000058397647,5.517896e-7,0.0017396032,0.000024533814,0.024342647,0.000014302956,0.00016494046,0.00015019323],"about_ca_topic_score_codex":0.0038409722,"about_ca_topic_score_gemma":0.010828214,"teacher_disagreement_score":0.02240343,"about_ca_system_score_codex":0.00061754975,"about_ca_system_score_gemma":0.0006937029,"threshold_uncertainty_score":0.7359102},"labels":[],"label_agreement":null},{"id":"W2076335256","doi":"10.3747/co.v17i0.677","title":"Multimodal Approaches to High-Risk Prostate Cancer","year":2010,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Occult; Disease; Stage (stratigraphy); Prostate-specific antigen; Metastasis; Watchful waiting; Biopsy; Modalities; Oncology; Cancer; Internal medicine; Pathology; Alternative medicine","score_opus":0.2143912734669896,"score_gpt":0.4362790424896146,"score_spread":0.22188776902262497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076335256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98723525,0.0012403391,0.000038132253,0.0065296004,0.0023686844,0.0011536549,0.00008474955,0.0000732553,0.0012763558],"genre_scores_gemma":[0.9939927,0.00092991407,0.0015345543,0.00010509957,0.00083191623,0.0007621261,0.00008536328,0.000027405637,0.0017309193],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99869925,0.000055181405,0.00020666345,0.0003768111,0.00020541126,0.00045669422],"domain_scores_gemma":[0.9991146,0.00008041486,0.00006754203,0.00027117194,0.000099619756,0.00036669426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023071146,0.0001604077,0.00031338385,0.00013512534,0.00010229119,0.000013654882,0.00011259231,0.0001238056,0.00040220006],"category_scores_gemma":[0.00012369044,0.00011383204,0.000068013534,0.00020129187,0.00015102651,0.000044089644,0.00009620698,0.00072084216,0.0002144133],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086283224,0.00085609936,0.29339424,0.00008541733,0.00008579996,0.00003315679,0.0011437926,0.000009226396,0.002480696,0.00033129152,0.0062320842,0.69448537],"study_design_scores_gemma":[0.007765218,0.0015652679,0.22471657,0.00006394237,0.00019466334,0.000027057325,0.00017457304,0.0006223086,0.007998776,0.00042575962,0.75616837,0.00027751474],"about_ca_topic_score_codex":0.00026955424,"about_ca_topic_score_gemma":0.00041438275,"teacher_disagreement_score":0.7499363,"about_ca_system_score_codex":0.00022337907,"about_ca_system_score_gemma":0.0004905396,"threshold_uncertainty_score":0.46419358},"labels":[],"label_agreement":null},{"id":"W2077038168","doi":"10.1038/modpathol.2011.176","title":"ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer","year":2011,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Center for Translational Molecular Medicine","keywords":"TMPRSS2; Prostate cancer; Medicine; Prostatectomy; Biochemical recurrence; Erg; Tissue microarray; Immunohistochemistry; Prostate; Androgen deprivation therapy; Cancer; Oncology; Prostate-specific antigen; PCA3; Pathology; Internal medicine; Disease","score_opus":0.05097620291100834,"score_gpt":0.34466553532668437,"score_spread":0.293689332415676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077038168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9207998,0.0060869707,0.05509863,0.0015703653,0.0013034951,0.008633873,0.005183683,0.00020458047,0.0011186064],"genre_scores_gemma":[0.9758561,0.001046269,0.0032439285,0.000554221,0.0002441885,0.011068439,0.00032115245,0.00008481001,0.007580837],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972861,0.00006797266,0.00045408384,0.0009454522,0.0003199343,0.0009264733],"domain_scores_gemma":[0.998508,0.00013479101,0.00014653064,0.00047414997,0.00046842944,0.00026810792],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003387797,0.0003828091,0.0006326523,0.00011202925,0.00015478961,0.000017200691,0.0002137435,0.0003274969,0.0003020384],"category_scores_gemma":[0.00012413693,0.00028128063,0.00021397667,0.0001351759,0.0007355751,0.00012283862,0.000106450585,0.00041624147,0.000011670825],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5067836,0.0039087976,0.05317097,0.00593503,0.0016901864,0.0023848042,0.037623446,0.000018254817,0.056660645,0.00029682228,0.013618515,0.3179089],"study_design_scores_gemma":[0.124540426,0.03676632,0.10452188,0.003929633,0.0028541926,0.0014183515,0.001342496,0.032641307,0.60059094,0.03036751,0.05624528,0.0047816318],"about_ca_topic_score_codex":0.0000596583,"about_ca_topic_score_gemma":0.000016226615,"teacher_disagreement_score":0.54393035,"about_ca_system_score_codex":0.0003824765,"about_ca_system_score_gemma":0.0008967895,"threshold_uncertainty_score":0.99996394},"labels":[],"label_agreement":null},{"id":"W2077187099","doi":"10.1016/j.ijrobp.2004.07.233","title":"Prospective assessment of the relationship between traditional prognostic factors and novel biomarkers in prostate cancer patients treated with curative intent in a phase three randomized trial","year":2004,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Biomarker; Context (archaeology); Randomized controlled trial; Prospective cohort study; Prostate; Cancer; Stage (stratigraphy); Androgen deprivation therapy","score_opus":0.06346847012592743,"score_gpt":0.3928104854258067,"score_spread":0.3293420152998793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077187099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945708,0.00009844627,0.00068521843,0.0018000262,0.00025161504,0.002327364,0.00021060611,0.000005560849,0.00005035409],"genre_scores_gemma":[0.99906874,0.0000727183,0.00032597242,0.000032124677,0.00014638837,0.00017511752,0.00016186562,0.000012905853,0.0000041723324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833256,0.00021924813,0.00073987193,0.00019058786,0.00035863012,0.00015910358],"domain_scores_gemma":[0.9972771,0.0011163049,0.0008793019,0.00006238495,0.00059516355,0.00006976718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000498095,0.00016921984,0.00060300634,0.0002597318,0.000045530247,0.000013128484,0.00012509908,0.00009897935,0.000006163126],"category_scores_gemma":[0.00062997045,0.00009526885,0.00012941874,0.00033126015,0.00045410058,0.00021907326,0.000025770232,0.00044105633,1.6604709e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10312172,0.0017904622,0.8892572,0.000008920045,0.00079800637,0.0000075928037,0.0007932125,0.0001352203,0.000116470146,0.0025874716,0.0000026970893,0.0013810291],"study_design_scores_gemma":[0.4006493,0.0019320133,0.592152,0.00018884787,0.00010732445,0.0000046391892,0.00005785057,0.00013869177,0.0002888795,0.004424022,0.0000027695355,0.000053625503],"about_ca_topic_score_codex":0.00015212181,"about_ca_topic_score_gemma":0.000079426056,"teacher_disagreement_score":0.29752758,"about_ca_system_score_codex":0.0017318762,"about_ca_system_score_gemma":0.0013061898,"threshold_uncertainty_score":0.45287958},"labels":[],"label_agreement":null},{"id":"W2077244514","doi":"10.1038/pcan.2014.53","title":"Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel","year":2015,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health","keywords":"Docetaxel; Enzalutamide; Medicine; Prostate cancer; Abiraterone; Oncology; Internal medicine; Urology; Cabazitaxel; Context (archaeology); Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.034063736327393984,"score_gpt":0.33233267774957,"score_spread":0.29826894142217597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077244514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9695665,0.02115575,0.000006729328,0.0017617614,0.000022194556,0.004313129,0.003016326,0.00004857214,0.000109038076],"genre_scores_gemma":[0.9820288,0.010683744,0.00033990334,0.00011688927,0.000021093805,0.0028713848,0.00017386944,0.00007044722,0.0036938705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975017,0.00012178762,0.0004122212,0.00072227156,0.00061297655,0.0006290461],"domain_scores_gemma":[0.99836254,0.00011423866,0.00025628577,0.00028624674,0.00033295027,0.000647758],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015472672,0.00052008574,0.00088818773,0.00019226845,0.00011555111,0.00010143402,0.000065531465,0.000048849815,0.000064552805],"category_scores_gemma":[0.0000281309,0.0002903417,0.000042223142,0.00052365626,0.0005229609,0.00040401708,0.00004018572,0.00014770738,0.0000010842132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16829652,0.004730805,0.59255195,0.007319182,0.0027085706,0.0011321562,0.029998759,0.00010054019,0.032003827,0.000021596346,0.0017565275,0.1593796],"study_design_scores_gemma":[0.17347613,0.05922792,0.54169536,0.007571811,0.006461065,0.00022026777,0.012777492,0.002741275,0.18933588,0.0005236865,0.0031433771,0.0028257386],"about_ca_topic_score_codex":0.004716117,"about_ca_topic_score_gemma":0.0015398815,"teacher_disagreement_score":0.15733206,"about_ca_system_score_codex":0.00046645338,"about_ca_system_score_gemma":0.0020938555,"threshold_uncertainty_score":0.9999549},"labels":[],"label_agreement":null},{"id":"W2077669730","doi":"10.1158/0008-5472.can-09-0387","title":"Evaluation of the 8q24 Prostate Cancer Risk Locus and <i>MYC</i> Expression","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Prostate cancer; Locus (genetics); Oncology; Medicine; Internal medicine; Cancer; Biology; Gynecology; Cancer research; Genetics; Gene","score_opus":0.11016710765636818,"score_gpt":0.47507448636224997,"score_spread":0.3649073787058818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077669730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9575297,0.031915005,0.0000014327702,0.0066066943,0.000106430416,0.0017673885,0.00006272559,0.00001601826,0.0019946091],"genre_scores_gemma":[0.98189116,0.0150067285,0.000018370998,0.000073120485,0.00020254352,0.00041379966,0.0000054270345,0.000016419706,0.0023724416],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960778,0.0005471475,0.00020090245,0.000345876,0.0023716637,0.0004566202],"domain_scores_gemma":[0.9977635,0.000084344225,0.00007694626,0.0004302862,0.0014779766,0.00016690315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002910892,0.000121989506,0.00020937099,0.00014499387,0.00028322244,0.000029560884,0.00015732703,0.00008127093,0.00029261407],"category_scores_gemma":[0.0002239815,0.00006863233,0.00006013629,0.00061325904,0.00035027182,0.00009618959,0.000103607395,0.00054641266,0.0000053462204],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014818137,0.0002443363,0.07209503,0.00018969718,0.0001216402,0.000008201292,0.0020426677,0.00011003762,0.42135206,0.0000341233,0.015172575,0.4871478],"study_design_scores_gemma":[0.0075020934,0.00076059235,0.17667857,0.0013761454,0.00031816203,0.000007695072,0.00046997954,0.0006861909,0.800535,0.0030583804,0.008427091,0.00018005524],"about_ca_topic_score_codex":0.0008817218,"about_ca_topic_score_gemma":0.00009345339,"teacher_disagreement_score":0.48696774,"about_ca_system_score_codex":0.0005287715,"about_ca_system_score_gemma":0.0014327093,"threshold_uncertainty_score":0.3203919},"labels":[],"label_agreement":null},{"id":"W2077716704","doi":"10.1016/j.ijrobp.2013.06.404","title":"Intermittent Versus Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis","year":2013,"lang":"en","type":"review","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Meta-analysis; Randomized controlled trial; Oncology; Internal medicine; Regimen; Hazard ratio; Systematic review; Cochrane Library; Cancer; MEDLINE; Confidence interval","score_opus":0.1132197420287712,"score_gpt":0.4416635032237243,"score_spread":0.32844376119495305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077716704","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000073429575,0.9915904,0.00051255,0.0020096903,0.0005477459,0.0048055933,0.00041488497,0.00001931357,0.000026388516],"genre_scores_gemma":[0.00022068385,0.9955104,0.00045507553,0.00057874847,0.0004977169,0.0017461654,0.0006355465,0.000048136695,0.00030750985],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99685353,0.00048957224,0.0016751202,0.00037883362,0.00033969866,0.00026324976],"domain_scores_gemma":[0.99392253,0.00083994993,0.003180739,0.0002582353,0.001633731,0.00016483251],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00090995047,0.00043854362,0.005680729,0.00039961675,0.00006624667,0.000059663533,0.00038973324,0.0003035881,0.00010757735],"category_scores_gemma":[0.0003466363,0.00026110522,0.0023574678,0.00035577884,0.00013638394,0.00018886312,0.00006515823,0.0004468118,0.000010567751],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003835457,0.0003020598,0.0003348387,0.05983056,0.41989675,0.000023314942,0.00012915564,0.0000036710387,0.0000031329316,0.00026872166,0.00093910296,0.51788515],"study_design_scores_gemma":[0.0063268943,0.0020404353,0.000016083104,0.008605057,0.73607796,0.00015428792,0.000025582756,0.00007448567,0.000017609904,0.00033464865,0.24597538,0.00035157969],"about_ca_topic_score_codex":0.000021368549,"about_ca_topic_score_gemma":0.0000032752882,"teacher_disagreement_score":0.5175336,"about_ca_system_score_codex":0.0009919062,"about_ca_system_score_gemma":0.0009460061,"threshold_uncertainty_score":0.99998415},"labels":[],"label_agreement":null},{"id":"W2077730686","doi":"10.1158/1538-7445.am2013-2482","title":"Abstract 2482: Development of novel small-molecule inhibitors of androgen receptor variants lacking the ligand-binding domain.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Androgen receptor; Bicalutamide; Antiandrogens; Prostate cancer; Cancer research; Enzalutamide; Chemistry; Androgen; Mutant; Small molecule; Cancer; Internal medicine; Biology; Medicine; Biochemistry; Gene; Hormone","score_opus":0.11123254847496239,"score_gpt":0.3868492150700276,"score_spread":0.27561666659506523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077730686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935884,0.0015669754,0.000015554346,0.0013304672,0.00011241878,0.0012671428,0.000022477238,0.000014598923,0.0020819893],"genre_scores_gemma":[0.9968556,0.00043606324,0.0007493387,0.000020758527,0.00015430282,0.00036998483,0.000022463208,0.000036478832,0.0013549746],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976071,0.00006387882,0.00044204685,0.00031375018,0.0009347686,0.00063845085],"domain_scores_gemma":[0.9984426,0.0001800459,0.000117802614,0.0003584064,0.00069809693,0.00020303375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00126478,0.00015302979,0.00031703382,0.00027542972,0.0002448878,0.000039339055,0.0002966602,0.00010719324,0.00052004604],"category_scores_gemma":[0.00008280225,0.00009608087,0.00008427615,0.000693063,0.00038558448,0.00009074294,0.00020781813,0.00047366045,0.000056452427],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023639611,0.0002476275,0.007275632,0.0003806324,0.0002569043,0.000008143942,0.0028492054,0.0000017308806,0.9714012,0.00004113851,0.002762098,0.014539246],"study_design_scores_gemma":[0.0022354731,0.00014852875,0.012012333,0.0007171851,0.000013468037,0.0000035123278,0.002067306,0.000006192383,0.98002213,0.000025569336,0.0026432544,0.00010504461],"about_ca_topic_score_codex":0.00077676104,"about_ca_topic_score_gemma":0.00003910211,"teacher_disagreement_score":0.014434203,"about_ca_system_score_codex":0.00038471544,"about_ca_system_score_gemma":0.00199219,"threshold_uncertainty_score":0.56941396},"labels":[],"label_agreement":null},{"id":"W2077895617","doi":"10.1016/j.eururo.2011.06.034","title":"Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer","year":2011,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; Ontario Clinical Oncology Group","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Prostate cancer; Prednisone; Internal medicine; Confidence interval; Urology; Oncology; Cancer","score_opus":0.0831548646736861,"score_gpt":0.3774955184049625,"score_spread":0.2943406537312764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077895617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887422,0.001039119,0.0000054289285,0.00025142598,0.00000910195,0.00045261794,0.000021298718,0.0000038128337,0.009475011],"genre_scores_gemma":[0.99844646,0.00021286937,0.0009917696,0.000023149674,0.000007952227,0.000018023851,0.0000044206304,0.000015030613,0.00028033712],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989147,0.0003416554,0.00028897423,0.00014292185,0.00016880286,0.00014290828],"domain_scores_gemma":[0.999429,0.00009041455,0.00017566573,0.00016182208,0.00011103287,0.000032104093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059293734,0.00008159271,0.00024182374,0.00005223859,0.00001930583,0.000001651156,0.000061979204,0.000011791474,0.00007616546],"category_scores_gemma":[0.00004999142,0.000044892207,0.000020036052,0.00012479983,0.00034099302,0.000030130133,0.000037775662,0.0000897862,0.0000012612488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017872872,0.0008208182,0.751903,0.0009748345,0.0009435356,0.00024464977,0.03298608,0.00031719447,0.18021475,0.0017205279,0.0000736178,0.011928127],"study_design_scores_gemma":[0.006064899,0.0032365732,0.9707841,0.00013114553,0.000333291,0.000047824928,0.0008361252,0.00072100747,0.017483672,0.00026208945,0.00002566601,0.000073588766],"about_ca_topic_score_codex":0.00058982766,"about_ca_topic_score_gemma":0.00007087882,"teacher_disagreement_score":0.21888112,"about_ca_system_score_codex":0.000011936934,"about_ca_system_score_gemma":0.0001248705,"threshold_uncertainty_score":0.1830651},"labels":[],"label_agreement":null},{"id":"W2078039688","doi":"10.1002/pros.21199","title":"Development of metastatic and non‐metastatic tumor lines from a patient's prostate cancer specimen—identification of a small subpopulation with metastatic potential in the primary tumor","year":2010,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University; University of British Columbia; University of Toronto; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Metastatic tumor; Medicine; Prostate cancer; Primary tumor; Metastasis; Pathology; Prostate; Oncology; Cancer; Internal medicine","score_opus":0.024234298688451332,"score_gpt":0.28373588370699004,"score_spread":0.2595015850185387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078039688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947022,0.00066027354,0.00018851289,0.0008204993,0.00008507885,0.0033019534,0.00019851114,0.000014030315,0.00002892042],"genre_scores_gemma":[0.98756975,0.0001166967,0.01114972,0.00010512965,0.000023673465,0.00063258637,0.00023860978,0.000036397214,0.00012745101],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99756557,0.0001747904,0.0008897731,0.00036699773,0.0006499082,0.00035297047],"domain_scores_gemma":[0.99842215,0.00017155835,0.0006142373,0.0004321121,0.0002770659,0.00008287073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088664336,0.00026974548,0.0005200153,0.000205035,0.00013389844,0.000051559877,0.00018637716,0.000016457634,0.000029158562],"category_scores_gemma":[0.00006055855,0.000136744,0.00005950864,0.00049239234,0.0003488247,0.00015753819,0.00007583537,0.00032340607,0.000004026868],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009595896,0.0019922922,0.076479524,0.0025166695,0.0012747103,0.00034789403,0.07589532,0.00036804134,0.76870245,0.00007020593,0.000057930127,0.06269904],"study_design_scores_gemma":[0.010423654,0.0010635268,0.76057273,0.0007754763,0.0014322326,0.00011365761,0.0068865228,0.0038705908,0.21276852,0.0013578648,0.00027690068,0.00045829173],"about_ca_topic_score_codex":0.0010428951,"about_ca_topic_score_gemma":0.0017311911,"teacher_disagreement_score":0.68409324,"about_ca_system_score_codex":0.000069737776,"about_ca_system_score_gemma":0.00054882903,"threshold_uncertainty_score":0.55762583},"labels":[],"label_agreement":null},{"id":"W2078057935","doi":"10.1007/s10637-011-9722-5","title":"A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; London Health Sciences Centre; BC Cancer Agency","funders":"Bayer Canada","keywords":"Bicalutamide; Medicine; Sorafenib; Prostate cancer; Internal medicine; Oncology; Adverse effect; Clinical endpoint; Rash; Clinical trial; Cancer; Androgen receptor; Hepatocellular carcinoma","score_opus":0.031659175896759706,"score_gpt":0.30201894918646277,"score_spread":0.27035977328970306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078057935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970444,0.000039303464,0.0000026322534,0.0008689182,0.000013277699,0.0018094847,0.000019631003,0.000012356686,0.00019000728],"genre_scores_gemma":[0.99871373,0.000009412815,0.00055006467,0.00008563096,0.0000130476565,0.00015624495,0.00011799667,0.000017982527,0.00033588693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986956,0.000049405204,0.00029278148,0.0002466382,0.00054030644,0.00017528342],"domain_scores_gemma":[0.99937034,0.000022353335,0.000133828,0.00012372794,0.00023290615,0.00011685576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012423671,0.000134246,0.00021614217,0.00024386468,0.000042936863,0.000006944033,0.000051069102,0.000037574733,0.000049321625],"category_scores_gemma":[0.000016055623,0.00009309586,0.000013147533,0.00054743723,0.00014136334,0.00017658393,0.000013148179,0.00013964693,9.728882e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016196856,0.009656559,0.935629,0.00006228638,0.0001030024,0.000031826803,0.032685798,0.00004723925,0.0015687828,0.00019079755,0.000065533306,0.0037623048],"study_design_scores_gemma":[0.06624364,0.012815354,0.9122341,0.00036301918,0.00003458728,7.377312e-7,0.0010394283,0.00009638777,0.0062777447,0.0007607496,0.000015257613,0.00011893709],"about_ca_topic_score_codex":0.0028828003,"about_ca_topic_score_gemma":0.0012779937,"teacher_disagreement_score":0.050046787,"about_ca_system_score_codex":0.00022455331,"about_ca_system_score_gemma":0.00078592484,"threshold_uncertainty_score":0.4357951},"labels":[],"label_agreement":null},{"id":"W2078102851","doi":"10.1200/jco.2005.03.3068","title":"High-Risk Localized Prostate Cancer: A Case for Early Chemotherapy","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Radiation therapy; Prostate cancer; Docetaxel; Prostatectomy; Oncology; Natural history; Hormonal therapy; Chemotherapy; Hormone therapy; Internal medicine; Cancer; Systemic therapy; Disease; Neoadjuvant therapy; Localized disease; Surgery; Breast cancer","score_opus":0.21958434602035504,"score_gpt":0.573140924655637,"score_spread":0.353556578635282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078102851","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021904514,0.9906816,0.000040910287,0.0028343077,0.0016069579,0.0023466263,0.00017386375,0.000015329935,0.00010993805],"genre_scores_gemma":[0.00007178183,0.9854846,0.0041781147,0.00054251414,0.006030047,0.00020884714,0.00002314712,0.00009588355,0.0033650552],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99354696,0.00076758256,0.0043301284,0.000396023,0.00043158274,0.00052773673],"domain_scores_gemma":[0.98957384,0.0036383143,0.004901915,0.00032164186,0.00081936363,0.0007449192],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004151201,0.00042217155,0.00768722,0.0002860556,0.00009240295,0.000023389612,0.00025466506,0.0012024374,0.00025842208],"category_scores_gemma":[0.0014140919,0.00023677539,0.0028127688,0.00025587578,0.00032362164,0.00008730509,0.000047555164,0.002494085,0.000024967536],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006858099,0.0010995014,0.00023124462,0.002839765,0.0032069024,0.0069240825,0.000060478662,7.5096295e-7,4.1084846e-8,0.000009411301,0.007768684,0.971001],"study_design_scores_gemma":[0.022526048,0.017102625,0.00007872867,0.00452564,0.00614214,0.0043660314,0.000015478223,0.000005820554,7.0945964e-7,0.000091889626,0.9449494,0.00019548247],"about_ca_topic_score_codex":0.00018712277,"about_ca_topic_score_gemma":0.00007672208,"teacher_disagreement_score":0.9708056,"about_ca_system_score_codex":0.0008645132,"about_ca_system_score_gemma":0.011009449,"threshold_uncertainty_score":0.9998072},"labels":[],"label_agreement":null},{"id":"W2079320970","doi":"10.1097/spc.0b013e32830c48a3","title":"Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer","year":2008,"lang":"en","type":"review","venue":"Current Opinion in Supportive and Palliative Care","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Oncology; Internal medicine; Castration; Cancer; Hormone","score_opus":0.21821623481780758,"score_gpt":0.47607192942940235,"score_spread":0.25785569461159474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079320970","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026626985,0.9902275,0.0000029254707,0.00006906992,0.00080738484,0.0045765513,0.0016071865,0.00001751816,0.000029171619],"genre_scores_gemma":[0.005441054,0.9871286,0.000013167528,0.0000113613605,0.00022050369,0.0045763855,0.002413603,0.000057957634,0.00013733015],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99694616,0.00025463285,0.0010424079,0.0007853452,0.00043985873,0.0005316254],"domain_scores_gemma":[0.9986008,0.00015480626,0.0004078727,0.00026204772,0.00037462977,0.00019984547],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012761429,0.00064463343,0.0018811971,0.0005233374,0.00007793596,0.000035692356,0.00010394933,0.00016541731,0.00012959982],"category_scores_gemma":[0.000041422492,0.00043832013,0.00030627006,0.0006565298,0.00018401338,0.000117587195,0.000056035995,0.00071998534,0.000015014459],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012774512,0.0004607281,0.10800669,0.12326911,0.0004439312,0.00031964006,0.011705118,0.000003911128,7.9806125e-7,0.000020624082,0.0005149594,0.75397706],"study_design_scores_gemma":[0.0059872274,0.0007376582,0.0192009,0.13702951,0.00023179804,0.000035959696,0.0011175185,0.000006882582,0.00000486365,0.000018879651,0.83493376,0.00069501804],"about_ca_topic_score_codex":0.000083424806,"about_ca_topic_score_gemma":0.00014196227,"teacher_disagreement_score":0.83441883,"about_ca_system_score_codex":0.0008738822,"about_ca_system_score_gemma":0.001484527,"threshold_uncertainty_score":0.9998069},"labels":[],"label_agreement":null},{"id":"W2079398023","doi":"10.1002/pros.20779","title":"Expression and sub‐cellular localization of the CCAAT/enhancer binding protein α in relation to postnatal development and malignancy of the prostate","year":2008,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; McMaster University","keywords":"Prostate cancer; Prostate; Biology; Cancer research; Androgen receptor; Messenger RNA; Cytosol; Immunohistochemistry; Endocrinology; Pathology; Internal medicine; Cancer; Medicine; Immunology; Gene","score_opus":0.018827721525113413,"score_gpt":0.25600665463241734,"score_spread":0.23717893310730392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079398023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956827,0.0007392018,0.0000452858,0.0008654585,0.00003215893,0.0025462825,0.000011428085,0.000007750173,0.00006974072],"genre_scores_gemma":[0.9979884,0.00021899081,0.00016077334,0.000014590183,0.000008166792,0.000119292585,0.000010429084,0.000014863482,0.0014645077],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989353,0.00009682972,0.00028119105,0.00018187102,0.00031771726,0.00018713373],"domain_scores_gemma":[0.9994986,0.00002387613,0.0001320907,0.00021519614,0.000086826294,0.000043384953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003141828,0.0001120451,0.00015493191,0.000071374045,0.0001984227,0.0000075292382,0.00008221039,0.000041781812,0.000003900889],"category_scores_gemma":[0.00004960911,0.00005112465,0.000023247147,0.00036641464,0.00020148892,0.00007700019,0.00016488835,0.00012890722,0.0000013285079],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006306417,0.00006464211,0.05468647,0.00023416437,0.000017490105,0.000008882429,0.015131635,0.000036759866,0.92724174,0.000028864313,0.0000256727,0.0018930412],"study_design_scores_gemma":[0.0011973046,0.000100159996,0.060381696,0.0010223375,0.0000116154115,0.000012667063,0.0002502108,0.00012050851,0.9366426,0.000071638686,0.00012848478,0.00006078701],"about_ca_topic_score_codex":0.000039506656,"about_ca_topic_score_gemma":0.000014461147,"teacher_disagreement_score":0.014881424,"about_ca_system_score_codex":0.00007035015,"about_ca_system_score_gemma":0.00016140867,"threshold_uncertainty_score":0.20848028},"labels":[],"label_agreement":null},{"id":"W2080126527","doi":"10.1158/1538-7445.prca2012-b19","title":"Abstract B19: Induction of apoptosis and antitumor activity of the AKT inhibitor AZD5363 is enhanced by combination with hormonal therapies in preclinical models of prostate cancer","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); University of British Columbia","funders":"","keywords":"LNCaP; PTEN; Prostate cancer; Cancer research; Protein kinase B; Bicalutamide; Growth inhibition; Androgen receptor; In vivo; Enzalutamide; Medicine; Cancer; Cell growth; PI3K/AKT/mTOR pathway; Apoptosis; Internal medicine; Biology; Biochemistry","score_opus":0.10309099558510108,"score_gpt":0.42445592780645836,"score_spread":0.32136493222135726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080126527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99210083,0.005008797,0.000004408257,0.0014177533,0.000060731534,0.0011129068,0.00012188047,0.000004627003,0.00016804128],"genre_scores_gemma":[0.99430937,0.0050004236,0.000020199068,0.000010342125,0.000049871578,0.0002909977,0.000006478137,0.000018036542,0.00029427392],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981293,0.00013888172,0.000288206,0.0002297874,0.00085376494,0.0003600764],"domain_scores_gemma":[0.9988519,0.0001420552,0.00016780592,0.00022848173,0.0005110955,0.00009864489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008484374,0.00011828713,0.00034323698,0.00017329573,0.00006270172,0.000008064793,0.000103027174,0.00009768641,0.0000705825],"category_scores_gemma":[0.00004474097,0.00007101816,0.000047843685,0.00057017815,0.0007347743,0.00031449462,0.00007462091,0.00045697237,2.8110395e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039569326,0.0008595561,0.10901787,0.00067900354,0.00015340626,2.1986082e-7,0.0037040582,0.000012232307,0.86095196,0.000032818025,0.00042354682,0.020208368],"study_design_scores_gemma":[0.0024098312,0.00046514402,0.16727452,0.00054863916,0.000021243164,4.1798864e-7,0.00032947687,0.000034125645,0.82872653,0.00010204288,0.000029526786,0.0000585226],"about_ca_topic_score_codex":0.0023417166,"about_ca_topic_score_gemma":0.00009463449,"teacher_disagreement_score":0.05825664,"about_ca_system_score_codex":0.00021724138,"about_ca_system_score_gemma":0.00056102837,"threshold_uncertainty_score":0.35399905},"labels":[],"label_agreement":null},{"id":"W2080277140","doi":"10.1007/s11934-013-0325-x","title":"Intermittent Versus Continuous Androgen Deprivation Therapy in Advanced Prostate Cancer","year":2013,"lang":"en","type":"review","venue":"Current Urology Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Nephrology; Internal medicine; Oncology; Urology; Prostate; Androgen; Cancer; Hormone","score_opus":0.09671298049591492,"score_gpt":0.4258641023681983,"score_spread":0.3291511218722834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080277140","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016866254,0.9754072,0.0000012298347,0.00015977558,0.0027108695,0.004584418,0.00001591192,0.000063781976,0.00019058584],"genre_scores_gemma":[0.001073458,0.99361646,0.000011982986,0.000026973634,0.00020550126,0.0037009218,0.0007235454,0.000068942805,0.0005721866],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99716944,0.00014774571,0.0009843756,0.0008310221,0.00028278882,0.00058463664],"domain_scores_gemma":[0.998293,0.000087330416,0.0006611124,0.0005977909,0.0001820059,0.00017878372],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024546913,0.00048536903,0.0017411566,0.00037895265,0.000046947906,0.00002212365,0.000114523995,0.00031597566,0.00020159084],"category_scores_gemma":[0.0000956495,0.00033070354,0.00033130433,0.00033460537,0.00014193679,0.00009030884,0.000101796235,0.00079070264,0.000040706498],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003927953,0.00023814177,0.008744051,0.0021725944,0.0002965351,0.0010370096,0.00007957276,5.8462183e-7,0.0000027556164,0.0000019317438,0.00066071027,0.9863733],"study_design_scores_gemma":[0.0027407336,0.00067675486,0.00065825845,0.0028299682,0.0003847742,0.00041197956,0.000007425559,0.0000029215526,0.000011082047,0.000023456865,0.9919811,0.00027157922],"about_ca_topic_score_codex":0.000034894965,"about_ca_topic_score_gemma":0.000013156058,"teacher_disagreement_score":0.9913204,"about_ca_system_score_codex":0.0004265004,"about_ca_system_score_gemma":0.0008738751,"threshold_uncertainty_score":0.9999145},"labels":[],"label_agreement":null},{"id":"W2080520172","doi":"","title":"An Audit to Evaluate the Clinical Safety and PSA Response of Firmagon® (Degarelix) in Patients with Advanced Metastatic Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Radiation therapy; Incidence (geometry); Surgery; Internal medicine","score_opus":0.059559399343977776,"score_gpt":0.47796522229844285,"score_spread":0.41840582295446505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080520172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97770035,0.004334812,0.0000034735572,0.015778478,0.00008587587,0.0019925497,0.000069812624,0.0000046861696,0.000029944096],"genre_scores_gemma":[0.9897605,0.008820635,0.00045100428,0.00023163711,0.000086265805,0.00020043312,0.000007876265,0.000034103985,0.0004075233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99529904,0.0012434,0.00089522125,0.00029872073,0.0016674602,0.0005961615],"domain_scores_gemma":[0.9952572,0.0008007315,0.0002469236,0.00038087383,0.0028018532,0.00051244727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054415558,0.00018609768,0.0006407754,0.00047587266,0.00012744105,0.000066422814,0.00031509023,0.000050989678,0.0004156106],"category_scores_gemma":[0.00072332355,0.00009224086,0.00007668472,0.0007983163,0.0005131356,0.0004724802,0.00011126771,0.0008663816,0.000007953435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13227312,0.0008091967,0.7466636,0.00019307829,0.0005712587,0.00007061171,0.0015121094,0.0004962388,0.003971564,0.0000067373176,0.0041681416,0.10926435],"study_design_scores_gemma":[0.012471911,0.009978118,0.9690924,0.00094673736,0.000103763,0.000006745267,0.00060827896,0.00015227345,0.0032264374,0.0001425755,0.0031472873,0.0001234542],"about_ca_topic_score_codex":0.0006610868,"about_ca_topic_score_gemma":0.00028658533,"teacher_disagreement_score":0.22242883,"about_ca_system_score_codex":0.00041906393,"about_ca_system_score_gemma":0.0018214049,"threshold_uncertainty_score":0.45506448},"labels":[],"label_agreement":null},{"id":"W2080761866","doi":"10.1158/0008-5472.can-06-1637","title":"Emergence of Androgen Independence at Early Stages of Prostate Cancer Progression in <i>Nkx3.1; Pten</i> Mice","year":2006,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"PTEN; Prostate cancer; Intraepithelial neoplasia; Androgen; Prostate; Cancer research; Cancer; Carcinogenesis; Biology; Medicine; Internal medicine; Oncology; Hormone; PI3K/AKT/mTOR pathway; Signal transduction; Cell biology","score_opus":0.05460971642570126,"score_gpt":0.4281768162950432,"score_spread":0.37356709986934195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080761866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9678087,0.027938524,0.0000010531024,0.000875542,0.00008476241,0.0015606974,0.00016985674,0.000018752076,0.0015420901],"genre_scores_gemma":[0.98068,0.010558909,0.00007026785,0.0000118861235,0.00009734689,0.00073117303,0.00002834616,0.000037778253,0.007784289],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99620456,0.00018669225,0.0005259961,0.0005229363,0.0017327421,0.00082708494],"domain_scores_gemma":[0.99818176,0.00010495233,0.00015119245,0.00039811325,0.0009855884,0.00017837947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009799057,0.00019149829,0.00046378502,0.00046939752,0.000108844,0.000014027249,0.00029293573,0.00015333075,0.00069437065],"category_scores_gemma":[0.00005509827,0.00014627504,0.0000856539,0.0013937748,0.0006333742,0.00016340245,0.00027117878,0.0005652555,0.000011938817],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021500564,0.00028339436,0.69158286,0.00076356926,0.000046476158,0.000097414224,0.00066455937,0.00003203697,0.29196462,0.000030036688,0.0028518469,0.009533119],"study_design_scores_gemma":[0.0031711054,0.00061678234,0.1317898,0.0014823315,0.000024761472,0.0000054337797,0.00029420067,0.000039993058,0.8607357,0.00016361561,0.0015131449,0.00016313486],"about_ca_topic_score_codex":0.016275218,"about_ca_topic_score_gemma":0.0021464755,"teacher_disagreement_score":0.56877106,"about_ca_system_score_codex":0.00038273458,"about_ca_system_score_gemma":0.0013087223,"threshold_uncertainty_score":0.9902755},"labels":[],"label_agreement":null},{"id":"W2080844574","doi":"10.1007/s12094-014-1182-x","title":"ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer","year":2014,"lang":"en","type":"article","venue":"Clinical & Translational Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Rockyview General Hospital; Alberta Cancer Foundation; Prostate Cancer Canada; University of Calgary; Calgary Laboratory Services","funders":"Movember Foundation; Calgary Laboratory Services","keywords":"Erg; Medicine; Prostatectomy; Prostate cancer; Biochemical recurrence; Prostate; Pathological; Nomogram; Cohort; Internal medicine; Clinical significance; Cancer; Oncology; Urology; Ophthalmology","score_opus":0.03500636326416987,"score_gpt":0.39571183210009725,"score_spread":0.36070546883592736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080844574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959366,0.00049116294,0.000054003776,0.0018910404,0.00012441624,0.0009032972,0.00014900969,0.000035353303,0.00041512103],"genre_scores_gemma":[0.9975944,0.00028515104,0.0011004022,0.00032948024,0.00011012225,0.00015971542,0.0002548721,0.000029802408,0.0001360502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997046,0.0006675806,0.0008877761,0.00048754195,0.0005199652,0.00039113202],"domain_scores_gemma":[0.996854,0.00216427,0.0002587151,0.00020204023,0.00023082737,0.0002901197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014417392,0.0001981759,0.00081380666,0.0001448727,0.00006502589,0.0000066541284,0.00010827221,0.000430791,0.0001133365],"category_scores_gemma":[0.001118112,0.000137946,0.0002478462,0.00038243964,0.0005089219,0.00008220513,0.000023746534,0.0008362658,0.000008013266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009523918,0.0013934241,0.982407,0.00004201325,0.0003238451,0.000086860906,0.0005132942,0.000012213778,0.0018893563,0.000015994474,0.00046706438,0.0033250414],"study_design_scores_gemma":[0.029402977,0.0031933342,0.95744216,0.0006676951,0.00031581437,0.000005311753,0.00002090481,0.0006060286,0.005289252,0.0007915728,0.0020768403,0.00018809743],"about_ca_topic_score_codex":0.00019740962,"about_ca_topic_score_gemma":0.00008371286,"teacher_disagreement_score":0.024964802,"about_ca_system_score_codex":0.00016867858,"about_ca_system_score_gemma":0.0010837947,"threshold_uncertainty_score":0.5625275},"labels":[],"label_agreement":null},{"id":"W2081110856","doi":"10.3747/co.v17i0.718","title":"Current Management of Castrate-Resistant Prostate Cancer","year":2010,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Androgen deprivation therapy; Radiation therapy; Hormonal therapy; Disease; Cancer; Oncology; Castration; Internal medicine; Systemic therapy; Androgen; Gynecology; Hormone; Breast cancer","score_opus":0.12011094117271343,"score_gpt":0.47223039985600407,"score_spread":0.35211945868329064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081110856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769642,0.013710065,0.000009857796,0.0010392581,0.0030046192,0.0010424352,0.000076155295,0.000039895254,0.0041135508],"genre_scores_gemma":[0.98622406,0.011910963,0.00027140818,0.00001441775,0.0002511837,0.00037250196,0.00007922798,0.000022660402,0.00085357303],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99862957,0.000036527337,0.00032069188,0.00031100138,0.00029323742,0.00040897366],"domain_scores_gemma":[0.99914694,0.000027972521,0.00012137361,0.0002880418,0.00020923637,0.00020642606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019396788,0.0001652447,0.00035385386,0.00012762278,0.00005601179,0.000007773024,0.00012159315,0.000071384806,0.00047756385],"category_scores_gemma":[0.000008768508,0.00012123377,0.00009872229,0.000225965,0.00024558103,0.00004148964,0.00009229357,0.0005040308,0.00003961761],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020099897,0.0024041175,0.070419,0.0020840708,0.0002882503,0.00020191453,0.0005210213,0.0000018091595,0.020918647,0.0022446234,0.0063203964,0.8925862],"study_design_scores_gemma":[0.007900182,0.001195467,0.1495577,0.0006140743,0.0003873072,0.000026242422,0.00028677486,0.00007851925,0.01085296,0.00043386995,0.82843006,0.00023688094],"about_ca_topic_score_codex":0.00003015718,"about_ca_topic_score_gemma":0.00007472322,"teacher_disagreement_score":0.8923493,"about_ca_system_score_codex":0.00020117553,"about_ca_system_score_gemma":0.0004398658,"threshold_uncertainty_score":0.5228989},"labels":[],"label_agreement":null},{"id":"W2081576253","doi":"10.1007/s00345-004-0473-1","title":"Mechanisms of the development of androgen independence in prostate cancer","year":2005,"lang":"en","type":"review","venue":"World Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Prostate cancer; Androgen; Prostate; Medicine; Cancer; Oncology; Androgen receptor; Cancer research; Nephrology; Internal medicine; Biology; Hormone","score_opus":0.054521507802630494,"score_gpt":0.3800047631212064,"score_spread":0.3254832553185759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081576253","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026057256,0.9981453,0.000009256872,0.00045470413,0.00025329602,0.0005449295,0.000010727783,0.0000013258185,0.00031987682],"genre_scores_gemma":[0.0037722606,0.9933239,0.0004711217,0.000043126212,0.000055152646,0.000027094708,0.000002698347,0.00001994072,0.0022846602],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978469,0.00017222592,0.0011536235,0.00013822512,0.00044295896,0.00024607647],"domain_scores_gemma":[0.9983331,0.00008788526,0.0011086995,0.00018098592,0.00021336791,0.000075940945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007227443,0.0001846287,0.0014183387,0.00055871624,0.000019070245,0.0000023570758,0.00029289513,0.00012450162,0.00011818496],"category_scores_gemma":[0.00003529993,0.00009640347,0.00026721304,0.0005166712,0.000120894016,0.000031231117,0.00010223086,0.0007783392,0.0000019246577],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002703161,0.00014957448,0.00065433746,0.0026266917,0.00043320644,0.00009287343,0.00036576015,0.0000055583937,0.00003212033,0.000043707743,0.00012048194,0.99520534],"study_design_scores_gemma":[0.0015939744,0.00029613054,0.00042911043,0.007280848,0.0006417578,0.0003658241,0.000019747424,0.0000012810749,0.00021938942,0.00018709026,0.9888655,0.00009933569],"about_ca_topic_score_codex":0.000010411443,"about_ca_topic_score_gemma":0.00027952305,"teacher_disagreement_score":0.99510604,"about_ca_system_score_codex":0.0003300892,"about_ca_system_score_gemma":0.005156054,"threshold_uncertainty_score":0.9146619},"labels":[],"label_agreement":null},{"id":"W2081949544","doi":"10.1002/pros.10353","title":"Inhibition of cell signaling by the combi‐nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line","year":2003,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Health Canada; Royal Victoria Hospital; Royal Victoria Regional Health Centre","funders":"","keywords":"DU145; Cancer research; DNA damage; Epidermal growth factor receptor; Comet assay; Androgen receptor; Biology; Prostate; Signal transduction; Lomustine; Nitrosourea; Cell culture; Prostate cancer; Molecular biology; Chemistry; Cancer; Cell biology; Internal medicine; DNA; Medicine; Receptor; Biochemistry; LNCaP","score_opus":0.021081840919339845,"score_gpt":0.28684849383394134,"score_spread":0.2657666529146015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081949544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827485,0.008051935,0.000006149855,0.0033887168,0.00006247928,0.0024682204,0.00011063993,0.00001487291,0.0031484896],"genre_scores_gemma":[0.99360734,0.0031401739,0.000019641884,0.0004281489,0.000030415096,0.00038424451,0.00006786714,0.00003094328,0.002291211],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978966,0.00038569,0.00041878823,0.00026454494,0.0005373065,0.00049705023],"domain_scores_gemma":[0.9991048,0.00017439926,0.00016610119,0.00038195797,0.00010892217,0.000063836065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014334683,0.00021289768,0.00028025976,0.00006730842,0.0001442998,0.00004094761,0.00018799283,0.00007029617,0.00009074066],"category_scores_gemma":[0.000024843943,0.000096741904,0.00008068105,0.00047668602,0.00020450205,0.000092450275,0.000050750084,0.0005268152,0.0000117593445],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042875577,0.003205323,0.11056908,0.0010211738,0.00018896346,0.00031229953,0.082820825,0.0011624213,0.78796005,0.00022885295,0.0039443043,0.004299152],"study_design_scores_gemma":[0.008306624,0.000633427,0.002037483,0.00025810173,0.00011020506,0.000026446965,0.006969291,0.00020471057,0.97734344,0.0012844766,0.002619099,0.00020671867],"about_ca_topic_score_codex":0.0011778926,"about_ca_topic_score_gemma":0.00038956158,"teacher_disagreement_score":0.18938337,"about_ca_system_score_codex":0.00017768938,"about_ca_system_score_gemma":0.00023937336,"threshold_uncertainty_score":0.39450204},"labels":[],"label_agreement":null},{"id":"W2081968604","doi":"10.1038/ncponc1180","title":"Intermittent androgen blockade should be regarded as standard therapy in prostate cancer","year":2008,"lang":"en","type":"article","venue":"Nature Clinical Practice Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Prostate cancer; Medicine; Androgen deprivation therapy; Androgen; Blockade; Oncology; Internal medicine; Prostate; Urology; Cancer; Hormone","score_opus":0.14144241773103078,"score_gpt":0.5351353390789122,"score_spread":0.3936929213478814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081968604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7600767,0.023958405,0.0000012102737,0.19415109,0.0010479033,0.0015515886,0.00003048938,0.000071799135,0.019110823],"genre_scores_gemma":[0.85767853,0.100191526,0.001122768,0.03293255,0.00082949456,0.0002576176,0.000053864696,0.000055410215,0.006878228],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966274,0.0006811027,0.00081034045,0.00067062926,0.00064261735,0.0005679485],"domain_scores_gemma":[0.9959889,0.0023511145,0.00030865707,0.00042998052,0.00056372676,0.0003575873],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0017019972,0.00025523937,0.00086099555,0.0001617493,0.00012889315,0.00001543104,0.0001950282,0.0009936704,0.00046533428],"category_scores_gemma":[0.0049449964,0.0001774442,0.00021570778,0.00037832165,0.0005247714,0.00020826221,0.00010978948,0.004101249,0.000049082133],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12959155,0.0061677154,0.25513664,0.00008418527,0.0014213403,0.028893797,0.0020527525,0.000005563238,0.0008455442,0.00021310496,0.12164733,0.45394048],"study_design_scores_gemma":[0.017991843,0.008989672,0.030895637,0.000085650834,0.00013400581,0.0010814244,0.0003620965,0.000014914636,0.0015880533,0.00016546794,0.9384875,0.00020373306],"about_ca_topic_score_codex":0.00019049604,"about_ca_topic_score_gemma":0.0001889485,"teacher_disagreement_score":0.8168402,"about_ca_system_score_codex":0.0007243598,"about_ca_system_score_gemma":0.0028814988,"threshold_uncertainty_score":0.9981963},"labels":[],"label_agreement":null},{"id":"W2082136574","doi":"10.5489/cuaj.1015","title":"National survey addressing the information needs of primary care physicians: Side effect management of patients on androgen deprivation therapy","year":2014,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University of Toronto","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Family medicine; Side effect (computer science); Incidence (geometry); Internal medicine; Cancer","score_opus":0.030659040305308995,"score_gpt":0.27489515501422396,"score_spread":0.24423611470891496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082136574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938159,0.00012449143,0.000040522697,0.0009189502,0.000089612004,0.0003536934,0.00006996443,0.0000047693934,0.0045820777],"genre_scores_gemma":[0.99834496,0.00010688037,0.000017180117,0.00096394465,0.00006161476,0.000010174908,0.0004664502,0.0000043653795,0.000024436757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860686,0.00030424347,0.00025948414,0.000046268386,0.00060698576,0.00017614407],"domain_scores_gemma":[0.9985714,0.00025386328,0.00032022462,0.00006772466,0.0006987194,0.00008808716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095840404,0.00007883813,0.00017287032,0.00017828621,0.00014936352,0.000026944774,0.00008408109,0.00008087064,0.000018411716],"category_scores_gemma":[0.00023797482,0.000048012284,0.00007365801,0.00025722428,0.00003004241,0.00011781235,0.000009345931,0.00018908757,0.0000044761987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003550558,0.000041401472,0.89180946,0.00003786024,0.00015996817,4.522354e-7,0.0004202765,0.00012368143,0.00001874552,0.000081403414,0.0006450587,0.10630666],"study_design_scores_gemma":[0.0021499435,0.00065262243,0.9945712,0.000054600012,0.000023927194,7.0406134e-7,0.000092508504,0.00005773129,0.00026899524,0.00009357596,0.0019920778,0.000042097556],"about_ca_topic_score_codex":0.00020268922,"about_ca_topic_score_gemma":0.000045470817,"teacher_disagreement_score":0.10626456,"about_ca_system_score_codex":0.0008755503,"about_ca_system_score_gemma":0.00018493074,"threshold_uncertainty_score":0.22895336},"labels":[],"label_agreement":null},{"id":"W2082447227","doi":"10.1002/pros.21422","title":"Pathological significance and predictive value for biochemical recurrence of c‐Fes expression in prostate cancer","year":2011,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Queen's University","funders":"","keywords":"Prostate cancer; Biochemical recurrence; Medicine; Immunohistochemistry; Cancer; Pathological; Prostate; Oncogene; Metastasis; Hazard ratio; Stage (stratigraphy); Internal medicine; Intraepithelial neoplasia; Adenocarcinoma; Oncology; Pathology; Confidence interval; Prostatectomy; Biology; Cell cycle","score_opus":0.058347078924094166,"score_gpt":0.33760346907293254,"score_spread":0.27925639014883835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082447227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922034,0.0041140127,0.0000576762,0.00064185204,0.000056016237,0.0023399484,0.00027814016,0.000027378937,0.00028153937],"genre_scores_gemma":[0.99459237,0.0030925677,0.0008705583,0.000045664503,0.000027263268,0.0009860832,0.000027313814,0.0000139164,0.00034428478],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893564,0.00006780811,0.00023001645,0.00029719126,0.0001686068,0.0003007443],"domain_scores_gemma":[0.99941975,0.00011008192,0.000089262314,0.00018273485,0.00011490827,0.000083236475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034759796,0.00013295723,0.00024611794,0.000054005297,0.00005631953,0.0000060661946,0.00009383116,0.000054167507,0.000013472116],"category_scores_gemma":[0.00009283438,0.00007151019,0.00004084717,0.00015682951,0.00045354545,0.000062360945,0.00007839243,0.0001850138,9.3879504e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031175286,0.0010834148,0.28505883,0.0013229278,0.00012361747,0.000103704326,0.038333867,0.000014050683,0.60676014,0.00034042532,0.0012273566,0.034456395],"study_design_scores_gemma":[0.0037938827,0.0016580336,0.14552808,0.0007402966,0.000068764275,0.00001419553,0.000710968,0.00045346937,0.84116,0.005471861,0.00023710297,0.00016333876],"about_ca_topic_score_codex":0.000062793326,"about_ca_topic_score_gemma":0.0000024843841,"teacher_disagreement_score":0.23439988,"about_ca_system_score_codex":0.00004914184,"about_ca_system_score_gemma":0.00011746691,"threshold_uncertainty_score":0.2916101},"labels":[],"label_agreement":null},{"id":"W2082543156","doi":"10.5489/cuaj.10136","title":"The role of resection of pulmonary metastases from prostate cancer: a case report and literature review","year":2011,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Metastasectomy; Medicine; Prostatectomy; Lung; Prostate cancer; Nodule (geology); Prostate; Radiology; Resection; Lymphatic system; Metastasis; Cancer; Surgery; Pathology; Internal medicine","score_opus":0.021750320971885152,"score_gpt":0.28194615203052253,"score_spread":0.26019583105863736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082543156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66268665,0.32872868,7.063718e-7,0.006668901,0.000099533965,0.00037607976,0.00027857936,0.000005164717,0.0011557401],"genre_scores_gemma":[0.9021376,0.09712645,0.000045678895,0.00020000369,0.00008356878,0.000019534304,0.000033129276,0.0000050559015,0.00034902449],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998979,0.00016849242,0.000323955,0.00011203289,0.00021646578,0.00020008578],"domain_scores_gemma":[0.99872637,0.000101268626,0.00034781534,0.000095874464,0.00045820157,0.00027049272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007384346,0.00007245947,0.00022290062,0.0000673316,0.00016788515,0.000016704009,0.00004376631,0.00008213817,0.00012325688],"category_scores_gemma":[0.0004882421,0.000040197065,0.000073975934,0.00019803586,0.000058474,0.00006555514,0.0000118886055,0.0003178764,5.2143946e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006621178,0.000083721694,0.8953009,0.00014415968,0.0005769377,0.046641927,0.0007453117,4.4808678e-7,0.0005173314,0.000057942532,0.002889816,0.05237939],"study_design_scores_gemma":[0.0028735867,0.002630923,0.7355974,0.003457994,0.0015835703,0.13826944,0.001417626,0.00014539894,0.0042021796,0.008552207,0.1008994,0.000370286],"about_ca_topic_score_codex":0.006258057,"about_ca_topic_score_gemma":0.0015722826,"teacher_disagreement_score":0.23945093,"about_ca_system_score_codex":0.000219499,"about_ca_system_score_gemma":0.00038575818,"threshold_uncertainty_score":0.94603515},"labels":[],"label_agreement":null},{"id":"W2082769359","doi":"10.1158/1538-7445.am10-3995","title":"Abstract 3995: Differential expression of CD10 immunohistochemistry in stroma and epithelium of prostatic adenocarcinoma","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Prostate cancer; Prostate; Stromal cell; Immunohistochemistry; Tissue microarray; Stroma; Adenocarcinoma; PCA3; Pathology; Cancer; Epithelium; Cancer research; Lymph node; Medicine; Internal medicine","score_opus":0.03924448107238381,"score_gpt":0.3981601632851226,"score_spread":0.3589156822127388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082769359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954979,0.0028462752,0.0000013011486,0.00028645527,0.00007044581,0.0006542405,0.00005958701,0.000007572718,0.0005762265],"genre_scores_gemma":[0.9983306,0.00058476056,0.00009507801,0.0000027232343,0.00007825754,0.00016468257,0.000023284223,0.000022477634,0.0006981569],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998245,0.000047158257,0.00032348832,0.0002992989,0.00067143975,0.00041361534],"domain_scores_gemma":[0.99892944,0.00014485071,0.000076839315,0.00037786862,0.00030879615,0.00016219397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040721797,0.00012428728,0.00033870692,0.00026502463,0.000055077726,0.000011751222,0.00015932182,0.00013269736,0.00062329054],"category_scores_gemma":[0.00012474015,0.000094331444,0.000052314146,0.00027179325,0.00063727435,0.00006344098,0.00013543673,0.0008562922,0.0000024604292],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012870723,0.00021991857,0.112409145,0.0011117209,0.000023153858,0.000033889366,0.0005334877,2.431849e-7,0.882131,0.000016762291,0.00013438282,0.0020992153],"study_design_scores_gemma":[0.0019445149,0.00019994589,0.35284758,0.00043091402,0.0000086635655,0.0000052819723,0.00022301197,0.000010490015,0.6441765,0.00007854064,0.000021905014,0.000052681204],"about_ca_topic_score_codex":0.00076678983,"about_ca_topic_score_gemma":0.000031991047,"teacher_disagreement_score":0.24043845,"about_ca_system_score_codex":0.0001118759,"about_ca_system_score_gemma":0.00055031566,"threshold_uncertainty_score":0.6824595},"labels":[],"label_agreement":null},{"id":"W2083664020","doi":"10.1136/jcp.56.12.892","title":"α-Methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies","year":2003,"lang":"en","type":"review","venue":"Journal of Clinical Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Prostate; Prostate cancer; Malignancy; Medicine; Pathology; Haematoxylin; Surgical pathology; Biopsy; Anatomical pathology; H&E stain; Immunohistochemistry; Cancer; Internal medicine","score_opus":0.14909732877584203,"score_gpt":0.5002313629972562,"score_spread":0.3511340342214142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083664020","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022601753,0.97299993,0.000025150524,0.00096293964,0.0010841339,0.0019445668,0.000048259128,0.00001288562,0.00032038707],"genre_scores_gemma":[0.0012906801,0.9951454,0.0010133974,0.001069725,0.0005519137,0.00011478673,0.000039129045,0.000078267854,0.00069673563],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99266,0.0016961847,0.0037918498,0.00068510027,0.00046695027,0.0006999096],"domain_scores_gemma":[0.9925965,0.0043174285,0.0015964328,0.00046721083,0.00030216825,0.0007202246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045175287,0.000573365,0.005747704,0.0008365952,0.00007742769,0.000050050196,0.0002729173,0.0009703601,0.00014198117],"category_scores_gemma":[0.00804516,0.00037423673,0.0008259877,0.0005676579,0.00069795275,0.00007974841,0.0002486984,0.0022560747,0.00014203497],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018998233,0.0012885953,0.0018771937,0.008884089,0.00039320855,0.051172376,0.000228443,0.0000037861957,0.000021114518,0.00009759098,0.0012246135,0.9329092],"study_design_scores_gemma":[0.009506423,0.007154169,0.0021927978,0.008879336,0.0027304522,0.017416976,0.00013805945,8.033853e-7,0.000007750461,0.00077584834,0.9506624,0.00053501775],"about_ca_topic_score_codex":0.0000066426355,"about_ca_topic_score_gemma":0.000006194036,"teacher_disagreement_score":0.94943774,"about_ca_system_score_codex":0.00013557327,"about_ca_system_score_gemma":0.0018360222,"threshold_uncertainty_score":0.99987096},"labels":[],"label_agreement":null},{"id":"W2083774585","doi":"10.1016/j.jsbmb.2012.02.006","title":"Steroid derivatives as pure antagonists of the androgen receptor","year":2012,"lang":"en","type":"article","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Natural Sciences and Engineering Research Council of Canada","funders":"","keywords":"Bicalutamide; Flutamide; LNCaP; Androgen receptor; Dihydrotestosterone; In vivo; Endocrinology; Internal medicine; Androgen; Chemistry; Antiandrogen; Antiandrogens; Prostate cancer; Pharmacology; Biology; Hormone; Medicine; Cancer","score_opus":0.012714257731326126,"score_gpt":0.3070186421048416,"score_spread":0.29430438437351547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083774585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98175967,0.015437742,0.000033766642,0.0023405398,0.00008307177,0.00011505596,0.000010113665,0.0000018088269,0.00021824772],"genre_scores_gemma":[0.9981917,0.0011785746,0.00007615432,0.00021905759,0.00011217267,0.0000014966715,0.0000058302576,0.000006700925,0.00020828807],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993151,0.00011172755,0.00021093221,0.00006407392,0.00011708118,0.0001811],"domain_scores_gemma":[0.9993969,0.000032986918,0.00020163064,0.00017164566,0.000100006815,0.00009683527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003126084,0.00009838857,0.00020182838,0.000020259316,0.0000650593,0.0000044733665,0.00014568878,0.00008791933,0.000026416748],"category_scores_gemma":[0.000058026344,0.000043980297,0.0000842771,0.00007131946,0.00040886615,0.000024545841,0.000089876215,0.00019199535,0.0000010007792],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006262968,0.0000704927,0.016170789,0.000057729023,0.00019730596,0.0000035581015,0.00035980443,6.6817066e-8,0.98160416,0.000016383117,0.00015161767,0.000741794],"study_design_scores_gemma":[0.0010015551,0.00040393678,0.0014821328,0.000071548384,0.00008382675,0.00057655864,0.00040465567,3.402536e-7,0.9945751,0.000086093016,0.0012691313,0.000045164707],"about_ca_topic_score_codex":0.0000023046953,"about_ca_topic_score_gemma":9.8500884e-8,"teacher_disagreement_score":0.016432071,"about_ca_system_score_codex":0.000021985525,"about_ca_system_score_gemma":0.00008360582,"threshold_uncertainty_score":0.17934644},"labels":[],"label_agreement":null},{"id":"W2083865378","doi":"10.1371/journal.pone.0092714","title":"Prostate Stromal Cells Express the Progesterone Receptor to Control Cancer Cell Mobility","year":2014,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research; Prostate Cancer Canada","keywords":"Stromal cell; Prostate cancer; Prostate; Stroma; Cancer research; Biology; Cancer cell; Tumor microenvironment; Immunohistochemistry; Cell growth; Cancer; Internal medicine; Pathology; Medicine","score_opus":0.03519026691280616,"score_gpt":0.2742058055997368,"score_spread":0.23901553868693062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083865378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98880255,0.0007160429,0.00003970759,0.005461408,0.00006804013,0.003264928,0.00014481798,0.000061640254,0.0014408845],"genre_scores_gemma":[0.98500615,0.00021018728,0.0005852777,0.00060423213,0.000295817,0.0014984041,0.000020475165,0.00003377809,0.011745655],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983311,0.00011729752,0.00020609751,0.0003559927,0.0005285838,0.00046089396],"domain_scores_gemma":[0.9988679,0.00010146634,0.0000551508,0.00049719017,0.00020448364,0.00027379647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030753337,0.00017068835,0.00033847176,0.000027404356,0.00011250266,0.000037511087,0.00015680035,0.000059170106,0.00058677397],"category_scores_gemma":[0.00003680208,0.000101342324,0.000055002805,0.00011077542,0.000099016324,0.00007381502,0.00006145931,0.00020770397,0.00023202511],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018065709,0.003200038,0.01897998,0.00048369286,0.00029009863,0.0000044203903,0.00088903576,0.000009257482,0.9698914,0.00000837534,0.0025376952,0.0018994126],"study_design_scores_gemma":[0.004908057,0.0017682011,0.0066330945,0.0003100179,0.0002753096,4.97641e-7,0.00013795707,0.00033945154,0.98095524,0.000016886337,0.0044799997,0.00017526295],"about_ca_topic_score_codex":0.00022007122,"about_ca_topic_score_gemma":0.00004216505,"teacher_disagreement_score":0.012346885,"about_ca_system_score_codex":0.00020380842,"about_ca_system_score_gemma":0.0001172497,"threshold_uncertainty_score":0.6424764},"labels":[],"label_agreement":null},{"id":"W2083871892","doi":"10.1016/j.urolonc.2006.10.008","title":"Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: Clinical parameters","year":2007,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cyproterone acetate; Prostate cancer; Medicine; Urology; Androgen suppression; Radiation therapy; Cyproterone; Prospective cohort study; Prostate; Cancer; Prostate-specific antigen; Internal medicine; Androgen; Antiandrogen; Hormone","score_opus":0.05812133756169986,"score_gpt":0.4223162492147819,"score_spread":0.36419491165308204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083871892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98783153,0.0012354052,0.00003993836,0.0065771984,0.00020193367,0.0036880905,0.00035328447,0.000005174344,0.000067448935],"genre_scores_gemma":[0.9791161,0.0010055696,0.018080141,0.00032222355,0.00007533783,0.0010496374,0.00007419907,0.000009905683,0.00026690672],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986019,0.00007672249,0.0005685381,0.00031936506,0.000118400894,0.00031508142],"domain_scores_gemma":[0.9987819,0.000469109,0.00022598586,0.00015184129,0.00016260191,0.00020856877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091459666,0.00012770414,0.00038792923,0.00012383322,0.000121557605,0.0000043258815,0.0000997684,0.0002027157,0.0000039491506],"category_scores_gemma":[0.0004617571,0.0000809997,0.00010210876,0.00019984032,0.0010244631,0.00004159781,0.00002751423,0.00023966926,5.404303e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48528856,0.002393982,0.40968382,0.00017064725,0.00023662375,0.000046372257,0.0024185202,0.000035362547,0.0045731463,0.00025262136,0.0052343225,0.08966601],"study_design_scores_gemma":[0.4436786,0.1362563,0.027723039,0.0013125883,0.0006233161,0.00006752497,0.0005853864,0.0030240607,0.10118936,0.0061806836,0.27884558,0.00051356293],"about_ca_topic_score_codex":0.001083597,"about_ca_topic_score_gemma":0.004303113,"teacher_disagreement_score":0.38196078,"about_ca_system_score_codex":0.0003085322,"about_ca_system_score_gemma":0.0014490774,"threshold_uncertainty_score":0.3774677},"labels":[],"label_agreement":null},{"id":"W2084252795","doi":"10.1155/2014/420429","title":"Exposure of Prostate to Lipopolysaccharide and Hypoxia Potentiates Neoplastic Behavior and Risk for Prostate Carcinogenesis In Vivo","year":2014,"lang":"en","type":"article","venue":"International Scholarly Research Notices","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Prostate cancer; Prostate; Medicine; Saline; Lipopolysaccharide; In vivo; LNCaP; Carcinogenesis; Hypoxia (environmental); Inflammation; Andrology; Urology; Internal medicine; Immunology; Physiology; Cancer; Biology; Chemistry; Biotechnology","score_opus":0.03865679132299752,"score_gpt":0.3568626337968925,"score_spread":0.31820584247389494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084252795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954959,0.00089483464,0.000030183293,0.0015419951,0.00009122583,0.0016049267,0.00018663981,0.000014303967,0.00013999571],"genre_scores_gemma":[0.9964103,0.00072661473,0.0010450919,0.000027154127,0.00009075775,0.0004903979,0.000019728794,0.00002486124,0.0011650565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782634,0.00016177393,0.0003151586,0.00043368162,0.00084045564,0.00042261422],"domain_scores_gemma":[0.9978683,0.00062771013,0.0000791346,0.00017245862,0.0009752423,0.00027712912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017328418,0.00014257841,0.00025472546,0.0006521804,0.00014334527,0.00028771267,0.00018445829,0.00007577682,0.000035126264],"category_scores_gemma":[0.0017920908,0.000112607355,0.00004360035,0.00023247817,0.00018651692,0.00056034647,0.00019935034,0.0003566935,0.0000049644914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017712354,0.00019085758,0.9024324,0.00017089698,0.000100239886,0.000023124954,0.00076646626,0.000013782781,0.07016277,0.00015252187,0.000053170766,0.024162555],"study_design_scores_gemma":[0.003738653,0.0018714269,0.93296,0.00027864275,0.00008210989,0.0000128316515,0.00047011318,0.0008641982,0.05814233,0.00045847739,0.000980066,0.00014117382],"about_ca_topic_score_codex":0.0016341854,"about_ca_topic_score_gemma":0.0004834482,"teacher_disagreement_score":0.0305276,"about_ca_system_score_codex":0.00010067684,"about_ca_system_score_gemma":0.00012992791,"threshold_uncertainty_score":0.45919946},"labels":[],"label_agreement":null},{"id":"W2084378495","doi":"10.1016/j.bbcan.2007.12.001","title":"Prostatic preneoplasia and beyond","year":2007,"lang":"en","type":"review","venue":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; University Health Network; Toronto General Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine","score_opus":0.11506917400827471,"score_gpt":0.4442914818491642,"score_spread":0.3292223078408895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084378495","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009266963,0.9874948,0.0000010478554,0.0011009506,0.0003567353,0.0069103166,0.0004603265,0.0000929462,0.0026561378],"genre_scores_gemma":[0.000049422983,0.9903783,0.0002717563,0.0011093202,0.00070317136,0.0019784053,0.00072807237,0.00020660734,0.0045748986],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99536926,0.00035550326,0.0012628814,0.0013945109,0.0007140439,0.00090382417],"domain_scores_gemma":[0.9970877,0.00029458012,0.0008064303,0.0011138723,0.00012994997,0.00056743197],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006132564,0.001231155,0.0041344673,0.00047119954,0.00016628834,0.00011745854,0.00036023997,0.00049206143,0.00018566317],"category_scores_gemma":[0.00009100928,0.00076723844,0.0009965436,0.00096010143,0.00036623311,0.00012092242,0.00018945886,0.0011509423,0.00031396502],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019192121,0.00039153988,0.0000011154633,0.058433942,0.00070502196,0.000058918184,0.00014720755,1.00588275e-8,0.00036995843,0.000059422564,0.015126072,0.9245149],"study_design_scores_gemma":[0.0009604022,0.00075216603,0.000033946802,0.051549245,0.0025532849,0.000058478916,0.0000077152645,0.0000013642309,0.0015569506,0.000020967498,0.94181156,0.00069392106],"about_ca_topic_score_codex":0.00002790289,"about_ca_topic_score_gemma":0.000011423583,"teacher_disagreement_score":0.9266855,"about_ca_system_score_codex":0.0006008917,"about_ca_system_score_gemma":0.0012346514,"threshold_uncertainty_score":0.99947786},"labels":[],"label_agreement":null},{"id":"W2084403680","doi":"10.1016/j.ijrobp.2011.06.622","title":"A Nomogram Predicting 5-year Probability of Cause Specific Survival from Biochemical Failure following Radiotherapy","year":2011,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Nomogram; Radiation therapy; Oncology; Internal medicine","score_opus":0.05060681073814663,"score_gpt":0.3493691957937348,"score_spread":0.29876238505558816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084403680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929241,0.0010553978,0.002859743,0.00087679666,0.0015245061,0.00029495903,0.00008592972,0.000028072265,0.0003504726],"genre_scores_gemma":[0.98501647,0.0010423536,0.011938575,0.00007248967,0.0017622898,0.00000976778,0.00011656203,0.000024521052,0.000016995187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998297,0.00018760306,0.00068950234,0.00024064015,0.00036253696,0.0002227591],"domain_scores_gemma":[0.9981499,0.00030115191,0.0006403072,0.00017704956,0.0005869683,0.00014465908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005368281,0.00016977346,0.00051898084,0.00018540863,0.00004203942,0.000012917584,0.00030604968,0.00023236258,0.0001587517],"category_scores_gemma":[0.00018966185,0.00013560563,0.00034714458,0.00022203494,0.00023232194,0.000179209,0.00004823055,0.0004584885,0.000006141651],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001612373,0.00086682086,0.93437034,0.0000098208175,0.0018369302,0.00007121376,0.0012112814,0.000010314277,0.042701725,0.0007697545,0.0006641827,0.015875226],"study_design_scores_gemma":[0.068767175,0.011270287,0.61742634,0.00075287005,0.0012202015,0.00032225493,0.0017065884,0.0015159958,0.21685866,0.045580618,0.03354467,0.0010343681],"about_ca_topic_score_codex":0.00005093052,"about_ca_topic_score_gemma":0.0000044474455,"teacher_disagreement_score":0.31694403,"about_ca_system_score_codex":0.0005510529,"about_ca_system_score_gemma":0.00043936726,"threshold_uncertainty_score":0.5529837},"labels":[],"label_agreement":null},{"id":"W2084701311","doi":"10.1016/j.clon.2013.03.002","title":"Systemic Therapy in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Review","year":2013,"lang":"en","type":"review","venue":"Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; McMaster University; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Castration; Internal medicine; Prostate; Hormone","score_opus":0.2518473287199683,"score_gpt":0.5355218631562756,"score_spread":0.2836745344363073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084701311","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045018405,0.9735985,7.3159333e-7,0.0007329533,0.0001546146,0.024457501,0.0000518877,0.000042650558,0.000916164],"genre_scores_gemma":[0.00002451885,0.9774901,0.0001302769,0.000406188,0.00014119053,0.01667259,0.00019595557,0.000088212786,0.004850946],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9921084,0.0024875398,0.003523835,0.0008007296,0.0004832846,0.000596193],"domain_scores_gemma":[0.9948811,0.0020312413,0.001573995,0.0007953069,0.00034549864,0.00037285444],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026258521,0.00060615735,0.010251468,0.00023169999,0.000051183797,0.000028976505,0.00031060696,0.00041449853,0.00021249571],"category_scores_gemma":[0.000523966,0.00029493435,0.000664523,0.0006624755,0.00029732005,0.00007323298,0.00005705002,0.0011822284,0.00026805536],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026196532,0.0004537332,0.00003823027,0.7664296,0.0015345888,0.00090685877,0.00003818953,8.66317e-8,2.9020094e-7,0.000013278337,0.0015188772,0.22880432],"study_design_scores_gemma":[0.0042680437,0.0045342427,0.000014925139,0.82127374,0.00697846,0.0004888081,0.00006589529,0.000004622482,1.5397619e-7,0.000008742606,0.16206199,0.00030037525],"about_ca_topic_score_codex":0.0001914796,"about_ca_topic_score_gemma":0.00010809735,"teacher_disagreement_score":0.22850394,"about_ca_system_score_codex":0.0013397146,"about_ca_system_score_gemma":0.0069580586,"threshold_uncertainty_score":0.9999503},"labels":[],"label_agreement":null},{"id":"W2085019446","doi":"10.1038/onc.2011.590","title":"Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness","year":2011,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Biology; Prostate cancer; Comparative genomic hybridization; Cancer research; Chromodomain; Carcinogenesis; Chromoplexy; Prostate; Chromatin; Cancer; Chromatin remodeling; Genetics; Gene; PCA3; RNA; Helicase; Genome","score_opus":0.04764637116023085,"score_gpt":0.3163574141172791,"score_spread":0.26871104295704823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085019446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99414706,0.0023113554,0.000027941118,0.00028565846,0.000060116516,0.00072195346,0.0000191408,0.000010898836,0.0024158517],"genre_scores_gemma":[0.9943914,0.0023959354,0.001216659,0.00006655549,0.000030225905,0.00022902923,0.000016830158,0.00001783049,0.0016355736],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99920714,0.000022777673,0.00015248748,0.00020479976,0.00019952099,0.00021329513],"domain_scores_gemma":[0.9995135,0.0000130777835,0.00005202636,0.0001688826,0.00014507787,0.00010742941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009982408,0.00009450087,0.00019710389,0.00010932228,0.000016605041,0.0000022400218,0.000054907377,0.00002791402,0.00010319361],"category_scores_gemma":[0.000011605887,0.0000656428,0.000023096467,0.00032669038,0.00004169267,0.000040317344,0.000025201183,0.00008438674,0.00001599101],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015239943,0.0015553501,0.4461302,0.0011113106,0.00010308323,0.0004683265,0.0073062223,0.000065667635,0.3605998,0.0000316774,0.0006824342,0.166706],"study_design_scores_gemma":[0.0036822706,0.002041027,0.055387743,0.00078308233,0.000040888135,0.000008717975,0.00018323917,0.000016415128,0.9338024,0.000027305692,0.0038933223,0.00013358444],"about_ca_topic_score_codex":0.00055498804,"about_ca_topic_score_gemma":0.00057403673,"teacher_disagreement_score":0.5732026,"about_ca_system_score_codex":0.00017829706,"about_ca_system_score_gemma":0.00028703237,"threshold_uncertainty_score":0.2676836},"labels":[],"label_agreement":null},{"id":"W2085115464","doi":"10.1038/sj.bjc.6604054","title":"Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer","year":2007,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":260,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"TMPRSS2; Prostate cancer; Fusion gene; Medicine; Prostate; Erg; PCA3; Oncology; Hazard ratio; Internal medicine; Cancer; Cancer research; Disease; Gene; Biology; Genetics; Ophthalmology","score_opus":0.023943174988314376,"score_gpt":0.3299856356982167,"score_spread":0.3060424607099023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085115464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8696983,0.12615779,0.00018816063,0.0011560844,0.0014956156,0.0008263376,0.00041892438,0.000009163767,0.000049663577],"genre_scores_gemma":[0.92294353,0.07389889,0.00020779074,0.0002899705,0.0010166013,0.0002453637,0.000009203591,0.000041126954,0.0013474938],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99753326,0.000064234344,0.0007694254,0.00024572134,0.0008741608,0.0005131849],"domain_scores_gemma":[0.99758047,0.00016682505,0.00059982046,0.0001927022,0.0011929383,0.0002672712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082934456,0.00018488655,0.00053439994,0.00014319732,0.00014557222,0.000032526394,0.00018421492,0.00012726567,0.00036586824],"category_scores_gemma":[0.00014137282,0.00012930867,0.00034922402,0.0003650846,0.00021716839,0.00020118956,0.000066695306,0.00037881683,4.2330183e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012940323,0.00037307054,0.33535892,0.0010551044,0.00031579423,0.0005582287,0.00066279754,0.00016108455,0.073923714,9.745793e-7,0.03724712,0.53740287],"study_design_scores_gemma":[0.0060195974,0.0003028077,0.45024875,0.01538631,0.00035697996,0.00037613636,0.00011210439,0.00006553347,0.49705678,0.000055437584,0.02975971,0.00025985972],"about_ca_topic_score_codex":0.0012948146,"about_ca_topic_score_gemma":0.0014331716,"teacher_disagreement_score":0.53714305,"about_ca_system_score_codex":0.00043020354,"about_ca_system_score_gemma":0.0016600288,"threshold_uncertainty_score":0.5273055},"labels":[],"label_agreement":null},{"id":"W2085304975","doi":"10.1016/j.juro.2010.02.292","title":"234 TARGETING STAT5 DEGRADES ANDROGEN RECEPTOR VIA THE PROTEASOME AND PROLONGS TIME TO TUMOR PROGRESSION POST CASTRATION IN VIVO","year":2010,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"LNCaP; Androgen receptor; Medicine; Cancer research; DU145; Transactivation; Prostate cancer; Internal medicine; Biology; Cancer; Transcription factor","score_opus":0.009807196134235089,"score_gpt":0.29268872434456134,"score_spread":0.28288152821032625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085304975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96550345,0.00071128266,0.000006717879,0.032851927,0.00006165103,0.0008081416,0.0000032975518,0.0000051532825,0.000048362537],"genre_scores_gemma":[0.9988196,0.000049663427,0.00039639918,0.00031746872,0.00018972173,0.000020709373,0.0000021592532,0.00001104027,0.0001932398],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99908507,0.00018343238,0.00023487315,0.0000840817,0.00019329181,0.00021927361],"domain_scores_gemma":[0.9993902,0.00011163995,0.00015018883,0.000098210294,0.00014950875,0.00010027291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011513997,0.00008610558,0.00017132143,0.00009406787,0.000099112774,0.000015126319,0.0001073159,0.000051639985,0.0001828267],"category_scores_gemma":[0.00017685915,0.000037507933,0.000026139007,0.000116922005,0.00014168664,0.00007477954,0.00003873933,0.0005230885,0.000015840906],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004413222,0.00012319669,0.017945956,0.000022197895,0.000047187732,0.00009879793,0.0018185471,0.0000044773346,0.9658042,0.0000051319225,0.0011105582,0.008606498],"study_design_scores_gemma":[0.021393163,0.052859396,0.23848669,0.0004987363,0.00079229823,0.022426201,0.0024157884,0.0023442346,0.5786983,0.0015607908,0.077749506,0.0007749462],"about_ca_topic_score_codex":0.000014530844,"about_ca_topic_score_gemma":0.000022490443,"teacher_disagreement_score":0.38710597,"about_ca_system_score_codex":0.000024868608,"about_ca_system_score_gemma":0.00013535917,"threshold_uncertainty_score":0.22725882},"labels":[],"label_agreement":null},{"id":"W2085397350","doi":"10.1007/s00439-013-1384-2","title":"Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease","year":2013,"lang":"en","type":"article","venue":"Human Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Center for Advancing Translational Sciences; Universität Ulm; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Huntsman Cancer Institute; Johns Hopkins University; National Cancer Institute; National Institutes of Health; Cancer Research UK; Utah State University","keywords":"Prostate cancer; Single-nucleotide polymorphism; Genome-wide association study; Cancer; Prostate; Oncology; Pedigree chart; Disease; Internal medicine; Biology; Medicine; Genetics; Genotype; Gene","score_opus":0.038196429246541964,"score_gpt":0.343926303813082,"score_spread":0.30572987456654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085397350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735019,0.0114373155,0.0000024703124,0.0018484138,0.00024018982,0.0029553098,0.009931517,0.00001979678,0.00006307526],"genre_scores_gemma":[0.98268944,0.010850152,0.000041844276,0.00015414908,0.00015881541,0.0014081446,0.0014230446,0.000046149824,0.0032282395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970322,0.00013172992,0.0010105453,0.00041561687,0.0009746361,0.0004352402],"domain_scores_gemma":[0.9951728,0.00035461914,0.0014384061,0.0005097821,0.0023752518,0.00014912707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003906076,0.00027237413,0.00065574,0.0001579331,0.00018125567,0.000048030415,0.00030509607,0.00011869981,0.0004920897],"category_scores_gemma":[0.0002683565,0.00017177477,0.00031800204,0.00053533947,0.00038008345,0.00005834186,0.00011254465,0.00019726435,9.839518e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006807897,0.00029469136,0.9421454,0.000085685184,0.008034283,0.0000053315257,0.002878655,0.0016003494,0.0383069,0.000011623716,0.0019441457,0.0040121535],"study_design_scores_gemma":[0.0029617923,0.00026660558,0.9203697,0.00019586725,0.006223677,3.3743527e-7,0.0009515743,0.008003349,0.05811744,0.00037715316,0.002326422,0.00020607318],"about_ca_topic_score_codex":0.019337837,"about_ca_topic_score_gemma":0.007721231,"teacher_disagreement_score":0.021775687,"about_ca_system_score_codex":0.00048813215,"about_ca_system_score_gemma":0.00092118746,"threshold_uncertainty_score":0.98719245},"labels":[],"label_agreement":null},{"id":"W2086158679","doi":"10.1210/er.2004-0017","title":"Gonadotropin-Releasing Hormone Agonists in the Treatment of Prostate Cancer","year":2005,"lang":"en","type":"review","venue":"Endocrine Reviews","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"Université Laval","keywords":"Prostate cancer; Medicine; Cancer; Prostate; Castration; Oncology; Internal medicine; Endocrine system; Agonist; Hormone; Gynecology; Urology; Receptor","score_opus":0.12844757328065698,"score_gpt":0.45580320923222006,"score_spread":0.3273556359515631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086158679","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000048708713,0.99044627,3.1713046e-7,0.0006400336,0.00010232797,0.00761595,0.00008894727,0.00001851361,0.0010389118],"genre_scores_gemma":[0.0000071247255,0.990193,0.00014991156,0.000049545077,0.0005955094,0.0034552864,0.0002585523,0.000068927206,0.0052221506],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99671465,0.00045624631,0.0013057358,0.00051400374,0.00039510784,0.0006142302],"domain_scores_gemma":[0.99834603,0.00013586605,0.00050911214,0.0008213066,0.00006117513,0.00012652275],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020470301,0.00064252655,0.0036630763,0.00028081128,0.000063205465,0.000025462616,0.00025939013,0.00008958517,0.00013478026],"category_scores_gemma":[0.00004312995,0.00029658206,0.0010316022,0.0007619888,0.00012614005,0.000051647457,0.00003533978,0.00038101422,0.00011404],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060208327,0.0006113698,0.00003869177,0.013671064,0.00019714817,0.00022049923,0.00026011645,1.2525213e-7,0.0000011356999,0.000014605753,0.0014008607,0.9835242],"study_design_scores_gemma":[0.0015613972,0.000743047,0.00011871129,0.018152632,0.0013698003,0.0001867466,0.000015019136,8.402271e-7,0.0000038229227,0.000002737768,0.97762406,0.00022116628],"about_ca_topic_score_codex":0.00038796998,"about_ca_topic_score_gemma":0.000061200146,"teacher_disagreement_score":0.983303,"about_ca_system_score_codex":0.000996667,"about_ca_system_score_gemma":0.00064327253,"threshold_uncertainty_score":0.9999486},"labels":[],"label_agreement":null},{"id":"W2086269831","doi":"10.1002/pros.20636","title":"Therapeutic integration of c‐myc and bcl‐2 antisense molecules with docetaxel in a preclinical model of hormone‐refractory prostate cancer","year":2007,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Inimex Pharmaceuticals (Canada)","funders":"Ministero della Salute","keywords":"Docetaxel; Prostate cancer; Chemotherapy; Apoptosis; Cancer; Concomitant; Cancer research; Medicine; Downregulation and upregulation; Internal medicine; Prostate; Oncology; Biology; Gene","score_opus":0.05816092200794136,"score_gpt":0.3754706535648511,"score_spread":0.3173097315569097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086269831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870298,0.010092721,0.000332152,0.0009834846,0.000014852801,0.0011966283,0.000047122387,0.000019010977,0.00028420863],"genre_scores_gemma":[0.98765135,0.010979521,0.0005195343,0.000074543226,0.000012888947,0.00005503431,0.000013548651,0.000023288623,0.00067029725],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99874955,0.000057063786,0.0003857636,0.00021989676,0.0003029126,0.00028481352],"domain_scores_gemma":[0.99921787,0.00012175294,0.00016721363,0.00023572646,0.00018185908,0.000075605225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065735274,0.00015200843,0.0003287016,0.00012867275,0.000036012458,0.000008676181,0.000067852015,0.00005844371,0.0000037615205],"category_scores_gemma":[0.000028734372,0.00007908704,0.000041319832,0.00024800998,0.00043331741,0.00008738108,0.000037667618,0.000262185,6.718614e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03347325,0.0011061186,0.08599393,0.000477562,0.000429875,0.000084468666,0.021429904,0.00056113285,0.6904735,0.00040100608,0.00008418991,0.16548505],"study_design_scores_gemma":[0.026653994,0.0074786474,0.5653835,0.001637104,0.0006650088,0.00007104974,0.0031347645,0.05812408,0.3298543,0.0061232047,0.00023956718,0.0006347656],"about_ca_topic_score_codex":0.00025803168,"about_ca_topic_score_gemma":0.00019056538,"teacher_disagreement_score":0.47938958,"about_ca_system_score_codex":0.00005730426,"about_ca_system_score_gemma":0.000241939,"threshold_uncertainty_score":0.3225076},"labels":[],"label_agreement":null},{"id":"W2086410271","doi":"10.1016/s0959-8049(09)70077-2","title":"IMRT and molecular biological approaches in radiotherapy for prostate cancer","year":2009,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Radiation therapy; Brachytherapy; Oncology; Prostate; Cancer; Androgen deprivation therapy; Internal medicine; Prostate-specific antigen; Gynecology; Urology","score_opus":0.07443463574387811,"score_gpt":0.35634603123100633,"score_spread":0.28191139548712824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086410271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88932073,0.09644392,0.0002071221,0.012748682,0.000081780774,0.00041307916,0.0000093918,0.0000067107962,0.0007685619],"genre_scores_gemma":[0.9741626,0.022888359,0.0014260822,0.00072565203,0.0002889552,0.000012232782,0.000002030201,0.000018452329,0.00047564993],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99916804,0.000093391456,0.00024835445,0.00013313597,0.00014785602,0.00020921612],"domain_scores_gemma":[0.9995875,0.000019399351,0.000106138476,0.0000679408,0.00009484396,0.00012419822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045353317,0.00010494552,0.0002532373,0.00010827667,0.000025749205,0.000018444456,0.00006694277,0.000020225389,0.000031761272],"category_scores_gemma":[0.000021855349,0.00006435975,0.000074471405,0.00010784475,0.00006749117,0.000053681382,0.000007873619,0.00017416368,3.8639604e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005736996,0.0002493228,0.05637774,0.00007454012,0.0002788981,0.0010464402,0.0014996333,0.00013280216,0.10017606,0.00009567868,0.002080007,0.8322519],"study_design_scores_gemma":[0.03547296,0.010593739,0.7471668,0.0012261128,0.00019376878,0.00033757184,0.0004155021,0.00044553477,0.040222354,0.000513782,0.16290343,0.0005084108],"about_ca_topic_score_codex":0.0000058902046,"about_ca_topic_score_gemma":0.0000018430275,"teacher_disagreement_score":0.8317435,"about_ca_system_score_codex":0.0001181232,"about_ca_system_score_gemma":0.00012556215,"threshold_uncertainty_score":0.26245144},"labels":[],"label_agreement":null},{"id":"W2087332423","doi":"10.1007/s00428-014-1540-7","title":"Prognostic prostate tissue biomarkers of potential clinical use","year":2014,"lang":"en","type":"review","venue":"Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital","funders":"University Health Network","keywords":"Prostate cancer; Prostate; Prostatectomy; PTEN; Medicine; Fluorescence in situ hybridization; Biopsy; Pathology; Oncology; Biochemical recurrence; Prostate biopsy; PCA3; Internal medicine; Cancer; Biology; PI3K/AKT/mTOR pathway","score_opus":0.10870730346775972,"score_gpt":0.4781619505779521,"score_spread":0.3694546471101924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087332423","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005427294,0.9839929,0.0003837614,0.0003923521,0.0011650613,0.0060177585,0.0005397466,0.0003205098,0.0017606668],"genre_scores_gemma":[0.008861144,0.9803486,0.0039995788,0.00029676827,0.0010584272,0.00041274307,0.0034516023,0.00024239809,0.0013287681],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9882993,0.0029484495,0.0035454717,0.0022862752,0.0011554308,0.0017650458],"domain_scores_gemma":[0.98961836,0.004805944,0.0018918198,0.0023121554,0.00041206263,0.0009596353],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0033372883,0.001612877,0.007105187,0.0009331614,0.00026302366,0.00007439204,0.0012217041,0.0015041244,0.00012784307],"category_scores_gemma":[0.0050407783,0.0010027378,0.0020153914,0.0011060836,0.004131578,0.00019225593,0.0009742716,0.0031499378,0.00030590466],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00142367,0.0014773614,0.0018496301,0.01940766,0.005249908,0.0020958728,0.00013725788,0.000003891577,0.00028717113,0.00024793207,0.005368017,0.96245164],"study_design_scores_gemma":[0.006177333,0.00794488,0.0037401302,0.01877,0.014118615,0.00022918367,0.00011856723,0.00013834535,0.0002185467,0.0008851025,0.94618523,0.0014740783],"about_ca_topic_score_codex":0.00011663093,"about_ca_topic_score_gemma":0.0000067409455,"teacher_disagreement_score":0.96097755,"about_ca_system_score_codex":0.00014780238,"about_ca_system_score_gemma":0.0024754528,"threshold_uncertainty_score":0.99979216},"labels":[],"label_agreement":null},{"id":"W2087621604","doi":"10.1016/j.jmir.2015.01.003","title":"223Ra α-Therapy in Patients with Bone Metastases from Castration-resistant Prostate Cancer","year":2015,"lang":"en","type":"review","venue":"Journal of medical imaging and radiation sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Prostate cancer; Radium-223; Radionuclide therapy; Radiation therapy; Oncology; Radium; Bone metastasis; Internal medicine; Cancer; Nuclear medicine","score_opus":0.06420733552293886,"score_gpt":0.42316568879388367,"score_spread":0.35895835327094483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087621604","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014405726,0.98258936,0.0000034229226,0.0023611803,0.00022278963,0.0003392855,0.000053088555,0.000003999332,0.00002111887],"genre_scores_gemma":[0.0020467872,0.9973528,0.00015271791,0.00008742384,0.0002626335,0.000013428476,0.00003945829,0.000010111983,0.000034631736],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967863,0.00016183178,0.00061260315,0.00021615603,0.0020148559,0.00020823398],"domain_scores_gemma":[0.9986138,0.00018041444,0.00051289634,0.00007202863,0.0002650152,0.00035584587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001567109,0.00017506338,0.00089604786,0.0004217741,0.00007945515,0.00010393262,0.00013566815,0.00006868993,0.00007403988],"category_scores_gemma":[0.00015840596,0.00008337037,0.000080822596,0.0004916173,0.000382632,0.0002651663,0.000018171064,0.00039118895,0.000001037546],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014992182,0.00010519692,0.015638685,0.0002688653,0.00009367952,0.00012843646,0.00019407689,8.813728e-7,3.1298362e-7,0.0000014284777,0.0011483699,0.9822701],"study_design_scores_gemma":[0.01103552,0.001353182,0.015855923,0.02090241,0.00062864955,0.00011712796,0.00063392933,0.000121427925,0.0000036640797,0.0000562864,0.9489943,0.00029763018],"about_ca_topic_score_codex":0.00021067193,"about_ca_topic_score_gemma":0.000017336013,"teacher_disagreement_score":0.9819725,"about_ca_system_score_codex":0.00017453927,"about_ca_system_score_gemma":0.0034305034,"threshold_uncertainty_score":0.60855657},"labels":[],"label_agreement":null},{"id":"W2087779901","doi":"10.1007/s10637-014-0091-8","title":"A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Bicalutamide; Medicine; Vandetanib; Prostate cancer; Tolerability; Internal medicine; Urology; Oncology; Adverse effect; Pharmacology; Cancer; Tyrosine kinase; Androgen receptor","score_opus":0.017686455145267975,"score_gpt":0.3041144943748178,"score_spread":0.28642803922954985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087779901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99395674,0.000102694234,0.000016401777,0.002347194,0.000028354596,0.0034249183,0.000020749756,0.000017795865,0.000085119194],"genre_scores_gemma":[0.9987682,0.00005069157,0.0005030014,0.000103838,0.000026373425,0.00018853853,0.00016853122,0.000025028035,0.00016577427],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979584,0.00019473491,0.00051636365,0.00036535642,0.000729152,0.00023595919],"domain_scores_gemma":[0.99878865,0.00042393958,0.00019459768,0.00016271463,0.00022819471,0.00020192255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004546302,0.0002168143,0.00061189395,0.00025727556,0.0000820765,0.000019574407,0.00005971346,0.00005640123,0.000026387072],"category_scores_gemma":[0.00016063977,0.00014362944,0.000026200958,0.0005518118,0.00036727058,0.00015592553,0.000021429345,0.0001933356,6.7823225e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8316548,0.005960167,0.14125153,0.00010619985,0.000415116,0.00001992864,0.009518619,0.0005324469,0.0011582832,0.00047186672,0.00003470247,0.008876382],"study_design_scores_gemma":[0.66710615,0.004854322,0.32549897,0.00030890387,0.00008931223,6.417138e-7,0.00020695773,0.0008108549,0.000670328,0.00029106686,0.000027780608,0.00013470821],"about_ca_topic_score_codex":0.0012742298,"about_ca_topic_score_gemma":0.000863933,"teacher_disagreement_score":0.18424743,"about_ca_system_score_codex":0.00021909486,"about_ca_system_score_gemma":0.00055585714,"threshold_uncertainty_score":0.58570385},"labels":[],"label_agreement":null},{"id":"W2087797579","doi":"10.1158/0008-5472.can-03-3830","title":"Effect of Isocaloric Low-Fat Diet on Prostate Cancer Xenograft Progression to Androgen Independence","year":2004,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Center for Complementary and Integrative Health; National Cancer Institute","keywords":"Castration; Prostate cancer; Medicine; Androgen; Internal medicine; Prostate; Endocrinology; Cancer; Hormone","score_opus":0.04231164477874217,"score_gpt":0.4556033153417651,"score_spread":0.41329167056302296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087797579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855365,0.0058891377,0.0000057227207,0.0036703162,0.00020315831,0.0037868833,0.000085072104,0.00005940805,0.000763813],"genre_scores_gemma":[0.9910249,0.0039821677,0.000047742476,0.000107516746,0.0003067218,0.002908898,0.000026628595,0.00006368215,0.0015317199],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99543524,0.00025218117,0.0003094691,0.0006953552,0.002213644,0.0010941416],"domain_scores_gemma":[0.9978877,0.00018837147,0.00006466153,0.00056406,0.0006840209,0.0006112415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012805943,0.00027943336,0.00051829213,0.0005676907,0.00024432832,0.000045057946,0.00032263703,0.00017592094,0.00024763608],"category_scores_gemma":[0.00019110346,0.00018282952,0.00012913597,0.0016762496,0.0003717499,0.00011688508,0.0002298409,0.00090877514,0.00013563644],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10058451,0.0016704281,0.1572498,0.0061139367,0.0006829558,0.0011060579,0.004752262,0.0009174641,0.34210646,0.00018116266,0.007099108,0.37753585],"study_design_scores_gemma":[0.0074113584,0.017333155,0.00537756,0.003820698,0.000049156773,0.000006084673,0.00009066606,0.000012013095,0.96285945,0.0001142456,0.0027025945,0.00022303613],"about_ca_topic_score_codex":0.0012140638,"about_ca_topic_score_gemma":0.0001275007,"teacher_disagreement_score":0.620753,"about_ca_system_score_codex":0.0013565439,"about_ca_system_score_gemma":0.0010990951,"threshold_uncertainty_score":0.7455571},"labels":[],"label_agreement":null},{"id":"W2087943780","doi":"10.1016/j.ijrobp.2009.09.073","title":"Baseline Serum Testosterone in Men Treated With Androgen Deprivation Therapy and Radiotherapy for Localized Prostate Cancer","year":2010,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; McGill University; University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; Androgen deprivation therapy; Percentile; Prostate cancer; Testosterone (patch); Radiation therapy; Urology; Prostate-specific antigen; Internal medicine; Androgen; Oncology; Cancer; Hormone therapy; Hormone; Breast cancer","score_opus":0.02472191326485966,"score_gpt":0.35502567280727754,"score_spread":0.33030375954241786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087943780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876912,0.0018390466,0.0019589243,0.0073131304,0.00026548468,0.0007767073,0.000087151464,0.000017855675,0.000050492014],"genre_scores_gemma":[0.9861602,0.0074670548,0.0044783074,0.0006335778,0.00086270703,0.00010469877,0.00014723898,0.000032745447,0.000113451526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989242,0.000095222356,0.00040603464,0.00019887797,0.00017746598,0.00019822762],"domain_scores_gemma":[0.99854606,0.00024564614,0.00040102177,0.000091711205,0.0006137251,0.000101857026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049087044,0.00015799787,0.00037241817,0.00018122773,0.000046302564,0.000022483055,0.000121801,0.00015094943,0.000044524942],"category_scores_gemma":[0.000072626775,0.000108016226,0.0000628071,0.00015174615,0.0001600471,0.00019449517,0.000013095281,0.00031610034,7.5747147e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049219117,0.0002840016,0.6493004,0.00000738861,0.00043146737,0.000018839186,0.0003240637,0.00007348491,0.033217706,0.00020020183,0.00015954346,0.311061],"study_design_scores_gemma":[0.18164067,0.015137104,0.5351187,0.00031798653,0.0003037738,0.00063451496,0.00024990106,0.032280814,0.12192189,0.00494949,0.10673447,0.00071065885],"about_ca_topic_score_codex":0.000057452795,"about_ca_topic_score_gemma":0.000041087256,"teacher_disagreement_score":0.31035036,"about_ca_system_score_codex":0.00036722384,"about_ca_system_score_gemma":0.00051090005,"threshold_uncertainty_score":0.4404774},"labels":[],"label_agreement":null},{"id":"W2088819616","doi":"10.1038/onc.2009.479","title":"Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E","year":2010,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Biology; Prostate cancer; Heat shock protein; Androgen; Cancer research; Prostate; EIF4E; Chemotherapy; Cancer; Ablation; Internal medicine; Endocrinology; Oncology; Gene; Biochemistry; Hormone; Genetics; Messenger RNA; Medicine; Translation (biology)","score_opus":0.01850167401492246,"score_gpt":0.3207297933702062,"score_spread":0.3022281193552837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088819616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98721033,0.0012908769,0.000015077904,0.0074250097,0.00012257721,0.0018577185,0.000036844107,0.000027769267,0.0020137941],"genre_scores_gemma":[0.9811835,0.0015302164,0.0018836631,0.00068841793,0.00014271741,0.00034427404,0.000029025368,0.000038940198,0.01415921],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99892384,0.000022282446,0.00017567609,0.00033684177,0.00022610262,0.000315251],"domain_scores_gemma":[0.99950653,0.000014683758,0.000020401594,0.00021689886,0.00008926623,0.00015219394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014998457,0.00014884003,0.00023568331,0.00007410815,0.00005582087,0.000026646341,0.00005407672,0.00007718625,0.00019541546],"category_scores_gemma":[0.000011217371,0.000118440126,0.000028777818,0.00024488175,0.00007627727,0.000090614216,0.000022968636,0.00018855954,0.000017407805],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014881724,0.00010007244,0.017161183,0.00010353523,0.000038864222,0.000051988744,0.0013102437,0.0000037771829,0.97193366,0.00003527119,0.0014306838,0.0063425577],"study_design_scores_gemma":[0.0041370806,0.00023876672,0.004427917,0.00018149057,0.00001599465,0.000005316038,0.00008925703,0.000038128266,0.9126246,0.00013194169,0.07794954,0.00015995045],"about_ca_topic_score_codex":0.0003570343,"about_ca_topic_score_gemma":0.0015129029,"teacher_disagreement_score":0.076518856,"about_ca_system_score_codex":0.0001413776,"about_ca_system_score_gemma":0.0002394799,"threshold_uncertainty_score":0.48298484},"labels":[],"label_agreement":null},{"id":"W2089646911","doi":"10.1016/j.hoc.2013.08.003","title":"Imaging in Prostate Carcinoma","year":2013,"lang":"en","type":"review","venue":"Hematology/Oncology Clinics of North America","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre","funders":"","keywords":"Prostate cancer; Medicine; Prostate; Prostate carcinoma; Radiology; Medical imaging; Biopsy; Prostate biopsy; Disease; Cancer; Pathology; Internal medicine","score_opus":0.07037927222300128,"score_gpt":0.43070397543739086,"score_spread":0.3603247032143896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089646911","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00312821,0.991071,0.0000042619467,0.00045562748,0.00034915927,0.0031048858,0.00007898014,0.000052899682,0.0017550186],"genre_scores_gemma":[0.00076762604,0.9954905,0.00110921,0.00024864968,0.000080723046,0.000916613,0.00063704664,0.000095297066,0.0006543186],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954003,0.0004713717,0.002074305,0.00086175377,0.0002786816,0.00091359037],"domain_scores_gemma":[0.99610484,0.0011883975,0.0013054775,0.000816253,0.00027679506,0.00030826233],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003461402,0.000611457,0.0055679563,0.00080938713,0.00005615237,0.000007641827,0.00039368364,0.00043289765,0.00018196563],"category_scores_gemma":[0.000351184,0.00045347132,0.0007142443,0.0008685388,0.0011517238,0.000075974494,0.00029447992,0.0014089872,0.0004312647],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012693732,0.00052400853,0.14133613,0.010338943,0.00019423696,0.001847954,0.000084297695,2.165137e-7,5.450832e-8,0.000011354808,0.0020831074,0.84345275],"study_design_scores_gemma":[0.002152689,0.0010252744,0.0023183348,0.003296864,0.0008810713,0.0010783463,0.00008088588,0.000027672138,7.78519e-7,0.00003293052,0.988749,0.00035610478],"about_ca_topic_score_codex":0.00012058482,"about_ca_topic_score_gemma":0.000051715324,"teacher_disagreement_score":0.98666596,"about_ca_system_score_codex":0.0004151553,"about_ca_system_score_gemma":0.0034171918,"threshold_uncertainty_score":0.9997917},"labels":[],"label_agreement":null},{"id":"W2089783245","doi":"10.1016/j.urology.2013.01.033","title":"Commentary on: Abiraterone in Metastatic Prostate Cancer Without Previous Chemotherapy","year":2013,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Abiraterone; Prostate cancer; Chemotherapy; Oncology; Internal medicine; Cancer; Urology","score_opus":0.022483795739697884,"score_gpt":0.3329203990592867,"score_spread":0.31043660331958883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089783245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.898563,0.0017588993,0.0000057208067,0.097416826,0.00009047401,0.0014044142,0.00000825396,0.00003296082,0.00071941153],"genre_scores_gemma":[0.96380097,0.0013017844,0.00009564048,0.031630598,0.00007655827,0.0007487243,0.00003667368,0.000027268572,0.0022817606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900216,0.00007827055,0.00017550612,0.00024290543,0.00012972206,0.0003714631],"domain_scores_gemma":[0.9995809,0.000038683083,0.000037459115,0.0002030366,0.000039892373,0.000099984114],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000905469,0.00013834151,0.00029336498,0.00011758745,0.000029071305,0.000010101545,0.00006531141,0.00004496958,0.0013965701],"category_scores_gemma":[0.0000065291906,0.00009500265,0.00003232908,0.000120290046,0.00011611033,0.000052264557,0.000021972595,0.00021621409,0.00018522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062853694,0.0019580948,0.70854986,0.0002954874,0.0007607634,0.00050083495,0.0037393605,0.00016224122,0.012483025,0.00005160699,0.12105649,0.14415689],"study_design_scores_gemma":[0.08427,0.019736499,0.6447652,0.00034599288,0.00044222106,0.00021457598,0.0004958914,0.0053772135,0.027649445,0.00331663,0.21225142,0.001134903],"about_ca_topic_score_codex":0.0008246975,"about_ca_topic_score_gemma":0.00010748663,"teacher_disagreement_score":0.14302199,"about_ca_system_score_codex":0.00011391985,"about_ca_system_score_gemma":0.000065811204,"threshold_uncertainty_score":0.9995163},"labels":[],"label_agreement":null},{"id":"W2089853344","doi":"10.3747/co.19.1299","title":"Management of Castration-Resistant Prostate Cancer: A Global Approach","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Oncology; Disease; Cabazitaxel; Refractory (planetary science); Internal medicine; Overall survival; Chemotherapy; Castration; Intensive care medicine; Cancer; Androgen deprivation therapy; Hormone","score_opus":0.13891277662476714,"score_gpt":0.4604001954054598,"score_spread":0.32148741878069265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089853344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.912786,0.041564755,0.00010764153,0.0008368991,0.0010818456,0.0015765534,0.00012584825,0.000046677174,0.041873787],"genre_scores_gemma":[0.99451935,0.003207196,0.001010931,0.0000151549075,0.00017485145,0.00030494583,0.00009720158,0.000008459556,0.00066190545],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989505,0.00004467902,0.00022023969,0.00016776631,0.00023185929,0.00038499795],"domain_scores_gemma":[0.9994692,0.000011689945,0.00008291169,0.00016234456,0.00009581078,0.00017804622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017165049,0.00011119352,0.0002548751,0.000043885248,0.000041442803,0.000004092299,0.000064270906,0.00005176673,0.00008907663],"category_scores_gemma":[0.0000041850863,0.000082382285,0.00006424446,0.00022283054,0.00012063609,0.000058125952,0.000055523782,0.00010897462,0.000015587782],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002695687,0.004965921,0.45963505,0.002447861,0.0006365588,0.000064831846,0.0012419013,0.000007951141,0.00083693984,0.00846444,0.006071384,0.51293147],"study_design_scores_gemma":[0.01360436,0.0018460683,0.6151527,0.0005229719,0.00091281015,0.0000890112,0.0024068567,0.00018043198,0.0021797558,0.00034303474,0.36240277,0.00035922515],"about_ca_topic_score_codex":0.000034750454,"about_ca_topic_score_gemma":0.0000055336072,"teacher_disagreement_score":0.5125722,"about_ca_system_score_codex":0.0005818152,"about_ca_system_score_gemma":0.00022076142,"threshold_uncertainty_score":0.3359452},"labels":[],"label_agreement":null},{"id":"W2089890756","doi":"10.1074/jbc.m306576200","title":"ART-27, an Androgen Receptor Coactivator Regulated in Prostate Development and Cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; York University; New York Academy of Medicine; Chemotherapy Foundation; American Cancer Society; National Institute of Diabetes and Digestive and Kidney Diseases; U.S. Department of Defense","keywords":"LNCaP; Coactivator; Prostate cancer; Androgen receptor; Prostate; Cancer research; Androgen; Biology; Endocrinology; Internal medicine; Transcription factor; Medicine; Cancer; Hormone; Gene","score_opus":0.04029748278720218,"score_gpt":0.31961238498286887,"score_spread":0.2793149021956667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089890756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964194,0.002196109,0.0000019419547,0.0010589677,0.000029573986,0.00011460579,0.0000057226002,0.000007857698,0.00016576363],"genre_scores_gemma":[0.9966084,0.0017412663,0.0009080602,0.000072273746,0.00009781325,0.000007970098,0.000024730301,0.000006773599,0.00053273485],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999214,0.00001503065,0.0002825347,0.00014280988,0.0001542014,0.00019143446],"domain_scores_gemma":[0.9994952,0.000014976159,0.000111990994,0.000063131185,0.000089548594,0.00022512654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019104818,0.00010352506,0.00025408991,0.00003027506,0.000028723012,0.000011857302,0.000053712978,0.00010534933,0.00013919924],"category_scores_gemma":[0.000045382887,0.000060077225,0.000033377786,0.000110986766,0.000094034614,0.000057939502,0.000023539229,0.0002591675,0.0000022935822],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024817584,0.0004998136,0.11765984,0.00010091025,0.00012571088,0.00046432676,0.0003222604,0.000008520531,0.86739653,0.000002237407,0.0002344627,0.010703646],"study_design_scores_gemma":[0.003956459,0.00040642548,0.026147604,0.0002712525,0.000012114333,0.00023198931,0.00016715603,0.0000016062972,0.9577966,0.000082907085,0.010828332,0.00009756545],"about_ca_topic_score_codex":0.0000042173074,"about_ca_topic_score_gemma":0.0000011053626,"teacher_disagreement_score":0.09151223,"about_ca_system_score_codex":0.0002856001,"about_ca_system_score_gemma":0.00032194256,"threshold_uncertainty_score":0.24498782},"labels":[],"label_agreement":null},{"id":"W2089952228","doi":"10.1159/000081629","title":"Pharmacodynamic Equivalence of a Decapeptyl 3-Month SR Formulation with the 28-Day SR Formulation in Patients with Advanced Prostate Cancer","year":2004,"lang":"en","type":"article","venue":"Hormone Research in Paediatrics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Prostate cancer; Pharmacodynamics; Equivalence (formal languages); Urology; Oncology; Cancer; Gynecology; Internal medicine; Pharmacokinetics; Mathematics","score_opus":0.02815394195898186,"score_gpt":0.35393607324425436,"score_spread":0.3257821312852725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089952228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989515,0.0052821347,0.000110390356,0.0012399044,0.000027262873,0.0034645642,0.000047172423,0.000022181961,0.00029139692],"genre_scores_gemma":[0.9896033,0.009188708,0.00033089874,0.000018201252,0.00005717807,0.00052526046,0.00013088401,0.000043092536,0.00010252287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99633086,0.00015434183,0.00040732222,0.00041920238,0.001808736,0.00087953033],"domain_scores_gemma":[0.9982916,0.00026583616,0.00015362045,0.00034952763,0.00076020084,0.0001791924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012901044,0.00022283118,0.00032648313,0.0007855594,0.00015812201,0.000028287379,0.00020631027,0.00009642646,0.000008923111],"category_scores_gemma":[0.00009479242,0.00012958373,0.00004633654,0.0029505584,0.00017734249,0.0004782148,0.00009884712,0.0007134952,0.000004661668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015584605,0.0012274863,0.9123924,0.00039760268,0.00008369058,0.00008998406,0.0026576482,0.010438576,0.0019612042,0.0001614825,0.00010561141,0.05489973],"study_design_scores_gemma":[0.029994717,0.004165412,0.9596288,0.0003649034,0.000055566867,0.0000021532135,0.00033797265,0.0025230465,0.002150081,0.00033251112,0.0001918736,0.00025293816],"about_ca_topic_score_codex":0.00039099972,"about_ca_topic_score_gemma":0.00063574174,"teacher_disagreement_score":0.054646794,"about_ca_system_score_codex":0.0013127534,"about_ca_system_score_gemma":0.00085329346,"threshold_uncertainty_score":0.5284271},"labels":[],"label_agreement":null},{"id":"W2090006418","doi":"10.1515/bc.2008.072","title":"An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines","year":2008,"lang":"en","type":"article","venue":"Biological Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Androgen receptor; Prostate cancer; Transactivation; Protein kinase B; Cancer research; Androgen; PI3K/AKT/mTOR pathway; Dihydrotestosterone; Endocrinology; Internal medicine; LNCaP; Cell growth; Cancer; Biology; Chemistry; Signal transduction; Transcription factor; Cell biology; Medicine; Hormone; Gene; Biochemistry","score_opus":0.04296117889697542,"score_gpt":0.3121011328747572,"score_spread":0.2691399539777818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090006418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899083,0.008684862,9.337781e-7,0.00018734008,0.000029028064,0.00040922602,0.000049084516,0.000063276304,0.00066795136],"genre_scores_gemma":[0.98834735,0.009974985,0.00006256388,0.0000395551,0.00013303314,0.00012889934,0.00007706426,0.000015605807,0.0012209244],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99851596,0.000033605098,0.00020190974,0.0005838895,0.00025673257,0.0004078815],"domain_scores_gemma":[0.99927855,0.000030147297,0.00006513984,0.00027115515,0.000061134684,0.00029384968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013447998,0.00023789107,0.00034327677,0.000021943235,0.00011756734,0.000017829729,0.000106718086,0.00025538163,0.0002667568],"category_scores_gemma":[0.000016879332,0.00014950405,0.000058273727,0.000094795854,0.000212416,0.00010012988,0.00010911268,0.0002867127,0.0000028216537],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088287133,0.0004491879,0.28691784,0.00009256905,0.000013622738,0.00034748032,0.00009279491,0.0000036294844,0.71028924,2.467687e-7,0.00005344014,0.00085706805],"study_design_scores_gemma":[0.0024643985,0.00025540948,0.05836292,0.00007792647,0.000011941468,0.00012600863,0.00010552166,0.000074686584,0.93811065,0.000030881536,0.00019558365,0.00018407995],"about_ca_topic_score_codex":0.000096402924,"about_ca_topic_score_gemma":0.00001551557,"teacher_disagreement_score":0.2285549,"about_ca_system_score_codex":0.00015940194,"about_ca_system_score_gemma":0.000120475706,"threshold_uncertainty_score":0.6096598},"labels":[],"label_agreement":null},{"id":"W2090617408","doi":"10.1016/j.juro.2011.02.2049","title":"1911 LARGE-SCALE MITOCHONDRIAL GENOME DELETION AS AN AID FOR NEGATIVE PROSTATE BIOPSY UNCERTAINTY","year":2011,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Thunder; Bay; Creed; Medicine; History; Philosophy; Archaeology; Theology; Geography; Meteorology","score_opus":0.03274258130519984,"score_gpt":0.3149844365688836,"score_spread":0.2822418552636837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090617408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940866,0.00051343517,0.00093623006,0.0028493307,0.00035735298,0.0006544341,0.00002903967,0.000010040591,0.0005635195],"genre_scores_gemma":[0.9945833,0.00043760688,0.0027528661,0.0006083001,0.0007425874,0.000023567247,0.000023154866,0.000023385846,0.0008052262],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99890596,0.00020103261,0.00028102734,0.0001103427,0.00017619604,0.00032546933],"domain_scores_gemma":[0.9990133,0.00010473678,0.00021546653,0.00016716601,0.00034777442,0.00015153406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066329737,0.000108728695,0.0002599773,0.000109542605,0.000142076,0.0000062673203,0.00015129267,0.00008483823,0.00020147185],"category_scores_gemma":[0.00009827598,0.000058733855,0.00010213744,0.00009864726,0.00016591822,0.00009710855,0.000027826844,0.00033195925,0.000017811835],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.410804,0.0044052806,0.013115558,0.00023214426,0.002847815,0.00090451934,0.12323529,0.000326188,0.4232218,0.0015263655,0.004447965,0.014933076],"study_design_scores_gemma":[0.15612689,0.21777919,0.12610361,0.00020428779,0.005997734,0.018976241,0.02028562,0.0049356977,0.08109882,0.12226206,0.24477614,0.0014537048],"about_ca_topic_score_codex":0.00005729359,"about_ca_topic_score_gemma":0.000027984488,"teacher_disagreement_score":0.34212297,"about_ca_system_score_codex":0.000068624126,"about_ca_system_score_gemma":0.00022129477,"threshold_uncertainty_score":0.2395097},"labels":[],"label_agreement":null},{"id":"W2090773286","doi":"10.1002/pros.21126","title":"Inhibition of DHCR24/Seladin‐1 impairs cellular homeostasis in prostate cancer","year":2010,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Université de Sherbrooke","funders":"Canada Research Chairs; Canadian Institutes of Health Research; Canadian Urological Oncology Group; Canadian Urological Association","keywords":"Prostate cancer; Prostate; Homeostasis; Medicine; Endocrinology; Internal medicine; Cancer","score_opus":0.016540693082713293,"score_gpt":0.3005275021093279,"score_spread":0.2839868090266146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090773286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901956,0.0016630262,0.0000028202805,0.0049822475,0.00019118628,0.0015874176,0.00012674277,0.000064732914,0.0011862773],"genre_scores_gemma":[0.99494636,0.0018988341,0.000101323916,0.00011484643,0.00008086585,0.00029588747,0.000075222124,0.00003858017,0.002448103],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99841225,0.000064784384,0.00036443252,0.00028733234,0.00037584477,0.0004953402],"domain_scores_gemma":[0.99908715,0.00006030844,0.0001280691,0.0004125579,0.00017541043,0.00013647987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005654802,0.00019637884,0.00032535318,0.00020538307,0.00009443831,0.00002306666,0.00010991098,0.000074302334,0.00026357677],"category_scores_gemma":[0.000045824727,0.00011960303,0.00009867199,0.0005541828,0.00034106759,0.00012453808,0.00008020737,0.00056855957,0.000038751725],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029190574,0.0005874903,0.13705401,0.0006039426,0.00017538505,0.0002875862,0.0111210635,0.000035861944,0.80253565,0.00024062175,0.0015818407,0.042857513],"study_design_scores_gemma":[0.007649087,0.0007659562,0.059619263,0.00044306123,0.00014699208,0.000040979485,0.0009708533,0.0004184218,0.9221148,0.0028244483,0.0046743047,0.0003318295],"about_ca_topic_score_codex":0.00083224993,"about_ca_topic_score_gemma":0.00039724112,"teacher_disagreement_score":0.11957918,"about_ca_system_score_codex":0.0001043261,"about_ca_system_score_gemma":0.0003032839,"threshold_uncertainty_score":0.48772702},"labels":[],"label_agreement":null},{"id":"W2091288012","doi":"10.1038/modpathol.3800963","title":"Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization","year":2007,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"DiagnoCure (Canada); Occupational Cancer Research Centre; Université Laval; Hôtel-Dieu de Québec; Centre hospitalier universitaire de Québec","funders":"Radboud Universiteit; Johns Hopkins University","keywords":"PCA3; Chromogenic in situ hybridization; Pathology; Prostate cancer; In situ hybridization; Intraepithelial neoplasia; Prostate; Cancer; Chromogenic; Prostatectomy; Medicine; Biology; Chemistry; Internal medicine; Gene expression; Gene","score_opus":0.018901820855485318,"score_gpt":0.3164625971727146,"score_spread":0.29756077631722927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091288012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930235,0.0008200729,0.0048653358,0.00033798252,0.00004878938,0.00047782145,0.0000074970994,0.000010219862,0.00040875818],"genre_scores_gemma":[0.9989479,0.00006453288,0.00008571297,0.00004605523,0.000011129022,0.000029810952,0.0001262658,0.000011094079,0.000677503],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990565,0.000050196915,0.00033406037,0.0002052169,0.00013388868,0.00022012508],"domain_scores_gemma":[0.9996386,0.00003519888,0.00006841424,0.00016154554,0.00005894465,0.000037262635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048232323,0.00006925925,0.00018281203,0.000259542,0.0000121496705,0.0000028878717,0.000042473486,0.00007065001,0.0000071746263],"category_scores_gemma":[0.00006054964,0.00006231302,0.000019320812,0.00022863846,0.00007103712,0.000048163532,0.000017546708,0.00010969025,0.0000073396186],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025102752,0.00023213483,0.34556964,0.00008258901,0.0000034356422,0.00028668667,0.001537531,0.000012546934,0.64519674,0.000033254764,0.000059724916,0.0067346953],"study_design_scores_gemma":[0.0026787338,0.00021428426,0.69440776,0.000034571876,0.000011893806,0.00004188792,0.00014795741,0.0015141717,0.30001223,0.00084567204,0.00002401641,0.000066822664],"about_ca_topic_score_codex":0.00004749403,"about_ca_topic_score_gemma":0.00015453764,"teacher_disagreement_score":0.34883812,"about_ca_system_score_codex":0.00014137366,"about_ca_system_score_gemma":0.00006465049,"threshold_uncertainty_score":0.25410512},"labels":[],"label_agreement":null},{"id":"W2092222339","doi":"10.1016/j.eururo.2013.09.007","title":"Surgical Management of Node-positive Prostate Cancer: Perspectives from Breast Oncology","year":2013,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Oncology; Prostate cancer; Prostate; Internal medicine; General surgery; Cancer; Management of prostate cancer; Gynecology","score_opus":0.016949416555269506,"score_gpt":0.2998620626426468,"score_spread":0.2829126460873773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092222339","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028688243,0.011721493,0.000004685326,0.80813205,0.0005543779,0.001655604,0.001559165,0.000102207574,0.14758217],"genre_scores_gemma":[0.23927628,0.06075938,0.0014012322,0.47290817,0.021080242,0.0009498283,0.013601311,0.0010788208,0.18894474],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99684197,0.00082450313,0.0004341295,0.000854274,0.0003742832,0.0006708339],"domain_scores_gemma":[0.9985843,0.00020157515,0.00026371898,0.00052328274,0.00028897895,0.00013819999],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018657155,0.0004119047,0.00088708365,0.0002237076,0.00006553362,0.000015768148,0.00029670063,0.00036039838,0.0021797337],"category_scores_gemma":[0.000006123689,0.0003134193,0.00022267345,0.00015595845,0.00066373165,0.000042401127,0.0003203895,0.0016593834,0.0006204744],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026306673,0.00044970246,0.0025668298,0.00037116662,0.0036920689,0.062262543,0.0024827635,0.000003654067,0.00015716415,0.00006611608,0.8993698,0.025947541],"study_design_scores_gemma":[0.005297111,0.0014720238,0.025138972,0.0002178076,0.0008573495,0.00051552756,0.0003409117,0.000010820028,0.000051887768,0.000045721066,0.9657378,0.00031401956],"about_ca_topic_score_codex":0.00048422124,"about_ca_topic_score_gemma":0.000003597879,"teacher_disagreement_score":0.33522388,"about_ca_system_score_codex":0.00036166832,"about_ca_system_score_gemma":0.00019403653,"threshold_uncertainty_score":0.9999318},"labels":[],"label_agreement":null},{"id":"W2092515164","doi":"10.1177/1756287213490054","title":"Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer","year":2013,"lang":"en","type":"article","venue":"Therapeutic Advances in Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Docetaxel; Cabazitaxel; Prostate cancer; Clinical endpoint; Oncology; Internal medicine; Androgen receptor; Adverse effect; Placebo; Randomized controlled trial; Cancer; Androgen deprivation therapy; Pathology","score_opus":0.08138430740976331,"score_gpt":0.4173034587040115,"score_spread":0.33591915129424815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092515164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.782486,0.20417443,0.0003038057,0.0094357915,0.00013925631,0.0033426469,0.000015131758,0.000017017386,0.00008590874],"genre_scores_gemma":[0.9655282,0.031771574,0.0003805863,0.0008621962,0.000036260157,0.001131927,0.0000043962445,0.000026734953,0.00025812848],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99846727,0.00013155672,0.00041624997,0.00030494077,0.00019151322,0.00048846204],"domain_scores_gemma":[0.99753195,0.0018592124,0.00012984345,0.00030403578,0.00012223308,0.00005272546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003887067,0.00018274096,0.00042758082,0.00014435765,0.000041579042,0.0000090933845,0.00019503215,0.000054349257,0.00019909393],"category_scores_gemma":[0.00008959553,0.00010779144,0.00007365323,0.0003517839,0.00038982296,0.00017971273,0.000023160968,0.00022198302,0.0000060343527],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032149367,0.0009831773,0.08620941,0.0007212837,0.00054042274,0.00006909008,0.0050311983,0.0034132446,0.11163067,0.0009132981,0.00004797087,0.7582909],"study_design_scores_gemma":[0.060859192,0.013849373,0.77042156,0.0015683369,0.0009058846,0.00010933901,0.0036681402,0.013796352,0.067045115,0.040020853,0.026612356,0.0011435081],"about_ca_topic_score_codex":0.0005261973,"about_ca_topic_score_gemma":0.0004980037,"teacher_disagreement_score":0.7571474,"about_ca_system_score_codex":0.00012221867,"about_ca_system_score_gemma":0.00025383604,"threshold_uncertainty_score":0.43956074},"labels":[],"label_agreement":null},{"id":"W2092860006","doi":"10.1158/1078-0432.ccr-14-1549","title":"Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Abiraterone acetate; Prostate cancer; Medicine; Prostate; Prostate-specific antigen; Urology; Castration; Oncology; Antigen; Internal medicine; Abiraterone; Cancer; Immunology; Hormone; Androgen receptor; Androgen deprivation therapy","score_opus":0.2623718972814189,"score_gpt":0.4778958899465421,"score_spread":0.21552399266512318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092860006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896762,0.0040796627,0.000002876523,0.0024238417,0.00033571987,0.0025923941,0.0002897181,0.00004714158,0.00055245135],"genre_scores_gemma":[0.9860883,0.009875101,0.000063538675,0.000044556695,0.00040443172,0.0003960792,0.00048399172,0.00006751254,0.0025765318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948478,0.0007120283,0.0010390274,0.00088346325,0.0015156348,0.0010020963],"domain_scores_gemma":[0.9966158,0.00046521027,0.00016127595,0.0004029903,0.0015449955,0.0008096874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023564666,0.00030414062,0.0007205274,0.0003510924,0.00015668228,0.00014314627,0.00015823083,0.00028538177,0.00012107797],"category_scores_gemma":[0.0003555367,0.00023873246,0.00007945928,0.00083759526,0.0007133047,0.0002545108,0.00019780558,0.0011726135,0.000051054303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007942492,0.000616429,0.97342527,0.00012664226,0.000111790054,0.0001170581,0.00077164685,0.00005080899,0.0014902363,0.000016631677,0.0023001377,0.013030842],"study_design_scores_gemma":[0.014866114,0.0033419663,0.972669,0.00036319744,0.000037285434,9.3568116e-7,0.00020395801,0.00020209303,0.0011583884,0.0002068122,0.0066959253,0.00025433503],"about_ca_topic_score_codex":0.0032226103,"about_ca_topic_score_gemma":0.0012116906,"teacher_disagreement_score":0.012776506,"about_ca_system_score_codex":0.00094673893,"about_ca_system_score_gemma":0.0010427411,"threshold_uncertainty_score":0.9735227},"labels":[],"label_agreement":null},{"id":"W2093031239","doi":"10.1016/j.juro.2011.02.1696","title":"727 ANTISENSE OLIGONUCLEOTIDE TARGETING INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR ENHANCES PACLITAXEL SENSITIVITY IN A PACLITAXEL- RESISTANT PROSTATE CANCER MODEL","year":2011,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Paclitaxel; Prostate cancer; Medicine; Androgen receptor; Cancer research; Cancer; Internal medicine; Chemotherapy; Oncology","score_opus":0.03768286415080809,"score_gpt":0.29940420004873725,"score_spread":0.2617213358979292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093031239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884423,0.00568612,0.00009711626,0.0046475306,0.00029683526,0.0003959081,0.000052397438,0.000017690365,0.000364093],"genre_scores_gemma":[0.984049,0.01416976,0.00076621195,0.00055994274,0.00016613389,0.000009104767,0.000003899254,0.0000342072,0.00024170606],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975152,0.0006027393,0.00066928804,0.0002214328,0.00038504764,0.0006062944],"domain_scores_gemma":[0.99838257,0.00029288264,0.0004526003,0.00022424838,0.00043923242,0.00020846528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018023164,0.00023691279,0.00059751153,0.00025260632,0.0001221707,0.000011647753,0.00015559506,0.00013005207,0.00008929865],"category_scores_gemma":[0.00029698046,0.00013942059,0.00013702289,0.00028055182,0.00034521002,0.00018784268,0.00008498986,0.00082479557,0.000015867934],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04193766,0.00092961447,0.10180312,0.00023821188,0.00068420824,0.001929278,0.025724104,0.00021820486,0.82025635,0.00010812257,0.002976643,0.0031944597],"study_design_scores_gemma":[0.030535351,0.015368478,0.6070899,0.0012143344,0.0014098018,0.0018471571,0.0068243057,0.007694844,0.31147867,0.010139184,0.004798291,0.0015997034],"about_ca_topic_score_codex":0.0006058698,"about_ca_topic_score_gemma":0.00027803844,"teacher_disagreement_score":0.50877774,"about_ca_system_score_codex":0.00020346834,"about_ca_system_score_gemma":0.00046529935,"threshold_uncertainty_score":0.5685407},"labels":[],"label_agreement":null},{"id":"W2093199757","doi":"10.1038/onc.2013.143","title":"The role of DAB2IP in androgen receptor activation during prostate cancer progression","year":2013,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"U.S. Army; National Natural Science Foundation of China; University of Washington","keywords":"Prostate cancer; Androgen receptor; Cancer research; Suppressor; Biology; Androgen; Prostate; Cell growth; Signal transduction; Cancer; Cell biology; Endocrinology; Biochemistry; Genetics","score_opus":0.013329194776014162,"score_gpt":0.32177345562975945,"score_spread":0.30844426085374527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093199757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936738,0.003271528,2.59205e-7,0.0013632773,0.000034516506,0.00090464903,0.0000067951473,0.000013074422,0.0007321199],"genre_scores_gemma":[0.99493396,0.0021506997,0.00010717084,0.000010746985,0.000068160174,0.00042730029,0.00002304059,0.000013428933,0.002265509],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99928063,0.000027074184,0.00015103802,0.00012860382,0.00020831877,0.00020431611],"domain_scores_gemma":[0.99961424,0.000022826742,0.00006202879,0.00014047729,0.00010175303,0.000058664726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000095601645,0.000071286384,0.00011530859,0.000051957515,0.00007179337,0.000012460117,0.000051363255,0.000040101233,0.00013514137],"category_scores_gemma":[0.000019629213,0.00003939212,0.000027713273,0.00018475638,0.00005231451,0.000083972605,0.00003287337,0.000087032095,0.000017934297],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036427402,0.000076965094,0.1109035,0.0000361873,0.000027652344,0.0000011983635,0.00037525097,0.0000021237356,0.6886071,0.000004214723,0.00009754808,0.19950402],"study_design_scores_gemma":[0.0013961891,0.00012772565,0.043820757,0.00022541112,0.00000785542,0.0000012507422,0.00023087124,0.0000741337,0.9487668,0.00006483089,0.00523726,0.00004687532],"about_ca_topic_score_codex":0.0003823979,"about_ca_topic_score_gemma":0.000029808554,"teacher_disagreement_score":0.26015976,"about_ca_system_score_codex":0.00015359599,"about_ca_system_score_gemma":0.00012699445,"threshold_uncertainty_score":0.1606364},"labels":[],"label_agreement":null},{"id":"W2093229695","doi":"10.1038/modpathol.2012.162","title":"PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade","year":2012,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; Robarts Clinical Trials; University Health Network; Queen's University","funders":"Ontario Institute for Cancer Research","keywords":"PTEN; TMPRSS2; Prostate cancer; Erg; Fusion gene; Tensin; Prostate; Biology; Tissue microarray; Cancer research; Prostatectomy; Pathology; Fluorescence in situ hybridization; Malignancy; Cancer; Medicine; Chromosome; Gene; Genetics; PI3K/AKT/mTOR pathway; Disease","score_opus":0.0531280467573636,"score_gpt":0.31105702246436423,"score_spread":0.25792897570700063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093229695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99082047,0.007504709,0.000060240607,0.00085846864,0.000052205298,0.0005337342,0.000024622928,0.000043947304,0.00010162504],"genre_scores_gemma":[0.9987506,0.00008103612,0.00016703612,0.00019964087,0.00005273611,0.00010340239,0.0000618066,0.00003080134,0.0005529398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998651,0.00014041923,0.00015652724,0.00031027236,0.00018823425,0.0005535467],"domain_scores_gemma":[0.9994418,0.000066201865,0.00006527414,0.00019237539,0.000050052604,0.00018429082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018322447,0.00017531482,0.00035615297,0.000106645915,0.00005468902,0.000011109406,0.00004489821,0.00015208693,0.000018897885],"category_scores_gemma":[0.00005036753,0.00012125154,0.000030569885,0.00012370491,0.00020791769,0.00009617242,0.000053472137,0.00024155506,0.000011106554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039041118,0.000502884,0.99286866,0.000068739326,0.000054161137,0.0008542759,0.0010091892,0.00000268704,0.0030245408,0.00000970755,0.00004019972,0.0011745443],"study_design_scores_gemma":[0.0041120695,0.00042776403,0.99167436,0.00011371834,0.000066092296,0.00018901732,0.000079258585,0.00045391798,0.0026259904,0.00009347778,0.00003221892,0.00013210549],"about_ca_topic_score_codex":0.000042463125,"about_ca_topic_score_gemma":0.00016246125,"teacher_disagreement_score":0.007930154,"about_ca_system_score_codex":0.00015256627,"about_ca_system_score_gemma":0.000044752196,"threshold_uncertainty_score":0.49444944},"labels":[],"label_agreement":null},{"id":"W2093425856","doi":"10.1016/j.eururo.2014.01.026","title":"Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Androgen deprivation therapy; Hazard ratio; Prostate cancer; Acute kidney injury; Internal medicine; Urology; Orchiectomy; Retrospective cohort study; Cohort; Proportional hazards model; Confidence interval; Oncology; Cancer","score_opus":0.006215485402694604,"score_gpt":0.2543343339433628,"score_spread":0.2481188485406682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093425856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928713,0.00030302737,0.0000089621235,0.0029507498,0.000068246234,0.00039538438,0.000036028716,0.000036470265,0.0033298426],"genre_scores_gemma":[0.99627924,0.00071245024,0.000104222265,0.0018624016,0.000080596146,0.000015266407,0.00007723294,0.000044122753,0.0008244676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988441,0.00018587195,0.00015266599,0.00031465408,0.00014044918,0.00036226102],"domain_scores_gemma":[0.9994681,0.0000144974865,0.000051229297,0.00018411112,0.00006515908,0.00021689947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104468636,0.00014720108,0.00022418717,0.00012130999,0.000062927735,0.000016542226,0.000060266066,0.00003319622,0.00002285704],"category_scores_gemma":[0.000040125808,0.00010259344,0.000017345636,0.00013197176,0.00018452035,0.0000534478,0.00007464798,0.00023506915,0.00003449939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009329169,0.00021311431,0.9411814,0.000047610498,0.0001595724,0.00020532384,0.00047687296,0.0000017797329,0.0019210764,0.00004572251,0.0030821266,0.043336194],"study_design_scores_gemma":[0.0063086804,0.0025236188,0.9628909,0.00003199095,0.00005949183,0.0000086799455,0.0000023717262,0.000036403246,0.00007097057,0.000013455608,0.027944194,0.00010922708],"about_ca_topic_score_codex":0.00004560625,"about_ca_topic_score_gemma":0.0000026324753,"teacher_disagreement_score":0.04322697,"about_ca_system_score_codex":0.000056591496,"about_ca_system_score_gemma":0.000079481055,"threshold_uncertainty_score":0.4183639},"labels":[],"label_agreement":null},{"id":"W2093894651","doi":"10.1177/1078155209337661","title":"Use of combined androgen blockade for advanced prostate cancer in British Columbia","year":2009,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Antiandrogen; Androgen deprivation therapy; Agonist; Cancer; Population; Urology; Androgen; Blockade; Internal medicine; Goserelin; Gynecology; Oncology; Hormone; Receptor","score_opus":0.06731656353968259,"score_gpt":0.4495899731008029,"score_spread":0.3822734095611203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093894651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761378,0.0039032877,0.00000813402,0.018338202,0.00027119298,0.0010355543,0.000046107976,0.0000070209576,0.00025266348],"genre_scores_gemma":[0.9716802,0.01976244,0.0048417114,0.0015630604,0.00017274565,0.000045222347,0.000008134926,0.00001941106,0.0019070555],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848276,0.00015991993,0.00063981244,0.00014570332,0.00027684396,0.00029498406],"domain_scores_gemma":[0.99734896,0.0007106026,0.00075379235,0.00009139261,0.0009188093,0.00017644749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072335365,0.00008661098,0.0005344634,0.00011321369,0.000053036947,0.000042780077,0.00009494727,0.000062790205,0.00011918246],"category_scores_gemma":[0.00083688326,0.0001007322,0.00011724679,0.00025583667,0.00007890985,0.00076424505,0.00001731115,0.00046246458,7.5929137e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055845965,0.0061929733,0.13410805,0.0002245682,0.0009632765,0.004694078,0.00086528674,0.0002279437,0.11102655,0.0000037694494,0.024882765,0.6609648],"study_design_scores_gemma":[0.09768997,0.016071642,0.05003171,0.0006779153,0.001407763,0.0040859133,0.00064037327,0.00043364987,0.03024518,0.0001939737,0.7982628,0.0002591397],"about_ca_topic_score_codex":0.0009917765,"about_ca_topic_score_gemma":0.0009863065,"teacher_disagreement_score":0.77338,"about_ca_system_score_codex":0.000420343,"about_ca_system_score_gemma":0.0013508354,"threshold_uncertainty_score":0.41077396},"labels":[],"label_agreement":null},{"id":"W2093960755","doi":"10.1016/j.critrevonc.2008.07.019","title":"Optimizing treatment for men with advanced prostate cancer: Expert recommendations and the multidisciplinary approach","year":2008,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Cancer Research UK","keywords":"Multidisciplinary approach; Medicine; Prostate cancer; Docetaxel; Disease; Multidisciplinary team; Cancer; Palliative care; Intensive care medicine; Oncology; Family medicine; Medical physics; Gynecology; Internal medicine; Nursing","score_opus":0.15436456547267305,"score_gpt":0.5045686602154852,"score_spread":0.3502040947428121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093960755","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000025258096,0.9743324,0.00015975803,0.009701083,0.000131803,0.013208771,0.00006990142,0.000035301582,0.0023584685],"genre_scores_gemma":[0.000004340436,0.9283732,0.02449989,0.00017209457,0.00011082092,0.045715556,0.00035316066,0.000076519624,0.00069438777],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958849,0.00094130577,0.0012459408,0.0009642225,0.00014732625,0.000816282],"domain_scores_gemma":[0.99521583,0.0035218426,0.000293239,0.00056173524,0.00014354858,0.0002638203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005985487,0.0006822947,0.005384536,0.00023216907,0.00034105885,0.000018027464,0.00021635508,0.00048170047,0.000032193555],"category_scores_gemma":[0.00061579957,0.0003187525,0.0004824732,0.00036940828,0.0016400279,0.00008073484,0.00015480146,0.00065566343,0.000009583441],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011232182,0.00074758887,0.000014571985,0.009785922,0.00028963241,0.00016921108,0.0012780818,2.879116e-7,1.7432629e-7,0.0026561366,0.0022440725,0.9816911],"study_design_scores_gemma":[0.009137979,0.0016049766,7.2337286e-7,0.021328347,0.0009189958,0.0021601366,0.0004130847,0.00012842476,0.000002401703,0.00011454781,0.9638758,0.00031460606],"about_ca_topic_score_codex":0.00002299892,"about_ca_topic_score_gemma":0.000026460975,"teacher_disagreement_score":0.98137647,"about_ca_system_score_codex":0.0011619378,"about_ca_system_score_gemma":0.0013361976,"threshold_uncertainty_score":0.99992645},"labels":[],"label_agreement":null},{"id":"W2093984374","doi":"10.1016/j.clgc.2014.03.006","title":"Metastatic Large-Cell Neuroendocrine Prostate Carcinoma: Successful Treatment With Androgen Deprivation Therapy","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Prostate; Neuroendocrine differentiation; Context (archaeology); Adenocarcinoma; Neuroendocrine tumors; Oncology; Small-cell carcinoma; Internal medicine; Androgen; Carcinoma; Cancer research; Cancer; Pathology; Hormone; Biology","score_opus":0.06053790294127071,"score_gpt":0.37806420833724846,"score_spread":0.31752630539597776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093984374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898118,0.0047115926,0.00009590904,0.0023498475,0.0002404631,0.0014564856,0.000052857456,0.00009237532,0.0011886938],"genre_scores_gemma":[0.9802332,0.011453355,0.00050200976,0.0007523729,0.0006253214,0.00053247414,0.0001395672,0.00007156017,0.0056901425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975366,0.00025655367,0.0005211335,0.00066596654,0.00039383728,0.0006258961],"domain_scores_gemma":[0.99843633,0.00023591344,0.00016817133,0.0005602837,0.00019610398,0.00040320586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002410428,0.00034209562,0.0006252141,0.00010858369,0.00016683248,0.00003653565,0.00013617796,0.00004676312,0.00025031136],"category_scores_gemma":[0.00002617213,0.00020790203,0.00021326206,0.00029647877,0.00016664008,0.0001245697,0.00005799745,0.00028477615,0.000055743956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061684903,0.003067941,0.8995698,0.00012016492,0.00034016385,0.0011403767,0.00011428033,0.000022870157,0.000611667,0.000007833848,0.00087112986,0.087965265],"study_design_scores_gemma":[0.11932063,0.05422996,0.47363663,0.00019964919,0.0011731545,0.00041320312,0.0002732855,0.0031107212,0.054918792,0.00024089638,0.29137418,0.0011088892],"about_ca_topic_score_codex":0.00012531421,"about_ca_topic_score_gemma":0.000037538637,"teacher_disagreement_score":0.42593318,"about_ca_system_score_codex":0.00018820411,"about_ca_system_score_gemma":0.00045861478,"threshold_uncertainty_score":0.8477999},"labels":[],"label_agreement":null},{"id":"W2094355087","doi":"10.1016/j.eursup.2006.12.004","title":"Advanced Prostate Cancer: Hormones and Beyond","year":2007,"lang":"en","type":"article","venue":"European Urology Supplements","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre","funders":"AstraZeneca","keywords":"Medicine; Prostate; Hormone; Prostate cancer; Cancer; Oncology; Gynecology; Internal medicine","score_opus":0.014152635682304893,"score_gpt":0.3188268048638979,"score_spread":0.304674169181593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094355087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9650551,0.005018398,0.000029398394,0.0046420004,0.00019464278,0.0006705289,0.000076707365,0.00007250864,0.024240728],"genre_scores_gemma":[0.9905745,0.002253294,0.0004493811,0.0014764686,0.00012396483,0.000018860912,0.00016333077,0.00004050909,0.004899706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987001,0.00006862308,0.00022487146,0.00033069044,0.00015609448,0.0005196399],"domain_scores_gemma":[0.99944276,0.000036318437,0.000053571897,0.00019151859,0.000062556115,0.00021326607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043599374,0.00015413109,0.0001834002,0.00012826236,0.00011917757,0.000012046007,0.00007442508,0.000029673738,0.0003165598],"category_scores_gemma":[0.000019891346,0.00012152753,0.000032099302,0.0001225409,0.00016414949,0.00006935277,0.00012001556,0.00017799002,0.00007531186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033798602,0.00026693265,0.7043242,0.00007770386,0.0003434514,0.0015878394,0.0015738722,0.0000021494236,0.029424628,0.00014782618,0.0149010485,0.24397048],"study_design_scores_gemma":[0.009918696,0.0018385807,0.5145129,0.000015304473,0.00013023116,0.00009850746,0.00030657844,0.000012220133,0.006802166,0.00009109727,0.46607715,0.00019655043],"about_ca_topic_score_codex":0.000017670074,"about_ca_topic_score_gemma":0.00002673934,"teacher_disagreement_score":0.4511761,"about_ca_system_score_codex":0.00004477446,"about_ca_system_score_gemma":0.000040041683,"threshold_uncertainty_score":0.4955749},"labels":[],"label_agreement":null},{"id":"W2094429978","doi":"10.1038/aja.2013.109","title":"Chromoplexy: a new paradigm in genome remodeling and evolution","year":2013,"lang":"en","type":"letter","venue":"Asian Journal of Andrology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Prostate cancer; Biology; Genome; Computational biology; Chromoplexy; Massive parallel sequencing; Chromothripsis; Evolutionary biology; Gene; Cancer; Genomics; Genetics; Genome instability; DNA; DNA damage","score_opus":0.024344479531790503,"score_gpt":0.28442353980299073,"score_spread":0.2600790602712002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094429978","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05051422,0.015843662,0.00029939893,0.9318996,0.00023214889,0.00030144668,0.0000036835604,0.00000578767,0.0009000304],"genre_scores_gemma":[0.72287464,0.01012244,0.0023883951,0.2353409,0.017601103,0.0000178174,0.00018774414,0.00015968831,0.011307302],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99875647,0.00008552061,0.00041321976,0.00018006876,0.0002054793,0.00035924325],"domain_scores_gemma":[0.9993812,0.000028704755,0.00022484295,0.000136117,0.000074200594,0.00015497342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019262191,0.00016605952,0.00060241343,0.00051756494,0.000027739512,0.000017138336,0.00009319812,0.00049361325,0.0001362796],"category_scores_gemma":[0.000025807341,0.00012130117,0.00009703898,0.00010788261,0.00009624939,0.000092208706,0.000025532827,0.001624039,0.000014957332],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018459096,0.00013930131,0.019894296,0.00059172726,0.00085590314,0.023989435,0.002150842,0.000030679086,0.0014230339,0.00005933421,0.9156707,0.033348832],"study_design_scores_gemma":[0.014954674,0.0068865614,0.051968973,0.00095726165,0.0005436702,0.030311782,0.00014504314,0.00027379885,0.000030105646,0.012833796,0.88063437,0.00045997615],"about_ca_topic_score_codex":0.000061553576,"about_ca_topic_score_gemma":0.0000090756375,"teacher_disagreement_score":0.6965587,"about_ca_system_score_codex":0.00021986244,"about_ca_system_score_gemma":0.0006244943,"threshold_uncertainty_score":0.7055732},"labels":[],"label_agreement":null},{"id":"W2094642217","doi":"10.1097/01.ju.0000136430.37245.b9","title":"EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER","year":2004,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Dutasteride; Prostate cancer; Finasteride; Medicine; Internal medicine; Prostate; Gynecology; Oncology; Cancer","score_opus":0.010879538521839455,"score_gpt":0.31906529118751364,"score_spread":0.30818575266567416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094642217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988538,0.0018253806,3.396008e-7,0.008893376,0.00027843687,0.00037406792,0.000011503345,0.0000014869294,0.00007735447],"genre_scores_gemma":[0.99910647,0.00051412155,0.000007608389,0.00015985538,0.00010009738,0.0000056462795,7.6029227e-7,0.000010226748,0.00009523443],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987095,0.00040230798,0.00034808312,0.000068903726,0.00028786625,0.00018335805],"domain_scores_gemma":[0.9991293,0.00020902799,0.00035398887,0.0001694196,0.000084923384,0.00005332408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009812174,0.000100002195,0.00033302532,0.00012611039,0.00002979561,0.0000016092207,0.00011544693,0.00003498908,0.000032959753],"category_scores_gemma":[0.00014463864,0.000038583654,0.000091315866,0.00017475596,0.0002774955,0.00003096071,0.00004791679,0.0003869991,0.0000012104263],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20141466,0.0006661687,0.055806264,0.0005049026,0.000399697,0.0009738219,0.0025109183,0.0020392016,0.72264,0.00002101789,0.0017350815,0.011288293],"study_design_scores_gemma":[0.017761236,0.022445364,0.06664722,0.0012779564,0.00033794658,0.0012178665,0.0002252267,0.000020046673,0.8894358,0.00021379026,0.00033889202,0.000078658355],"about_ca_topic_score_codex":0.00009352645,"about_ca_topic_score_gemma":0.000017157898,"teacher_disagreement_score":0.18365341,"about_ca_system_score_codex":0.000108287946,"about_ca_system_score_gemma":0.00029953278,"threshold_uncertainty_score":0.168134},"labels":[],"label_agreement":null},{"id":"W2095303664","doi":"10.1158/1535-7163.targ-11-cn08-01","title":"Abstract CN08-01: Targeting the androgen receptor in castration-resistant prostate cancer.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Androgen receptor; Castration; Medicine; Androgen; Enzalutamide; Cancer; Internal medicine; Oncology; Biology; Hormone","score_opus":0.05933011130010995,"score_gpt":0.3317127302610393,"score_spread":0.27238261896092936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095303664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9618256,0.031418316,0.000016978833,0.003309989,0.0002345224,0.001161421,0.000073157935,0.000049376704,0.001910656],"genre_scores_gemma":[0.9912549,0.0063707484,0.0002726327,0.0009963149,0.00009651058,0.00042786932,0.000038594848,0.000055153952,0.00048722673],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983884,0.00006471144,0.000323234,0.0003310395,0.00038905954,0.0005035691],"domain_scores_gemma":[0.9993095,0.00002405446,0.000105691644,0.00031468316,0.00013490827,0.000111159505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025774902,0.00022800955,0.00024717487,0.00008244064,0.00013338117,0.000035329333,0.00016982754,0.00009714787,0.0005934683],"category_scores_gemma":[0.000007962445,0.00014980778,0.00010245212,0.0003563769,0.00014231281,0.000072185336,0.000034943605,0.00035417874,0.000018383615],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024591293,0.00035051804,0.049493566,0.00020194094,0.00069576025,0.00039545685,0.008086194,0.00010181569,0.9019586,0.00014307497,0.00038575663,0.035728198],"study_design_scores_gemma":[0.0052689207,0.00048763634,0.07056845,0.00047718213,0.00031649502,0.000011208471,0.0018257799,0.00023087717,0.8855568,0.00046568245,0.034240674,0.0005502677],"about_ca_topic_score_codex":0.0018861447,"about_ca_topic_score_gemma":0.00052374887,"teacher_disagreement_score":0.03517793,"about_ca_system_score_codex":0.00033927325,"about_ca_system_score_gemma":0.0005328075,"threshold_uncertainty_score":0.6498062},"labels":[],"label_agreement":null},{"id":"W2096151138","doi":"10.1158/0008-5472.can-04-1330","title":"HOXB13 Induces Growth Suppression of Prostate Cancer Cells as a Repressor of Hormone-Activated Androgen Receptor Signaling","year":2004,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Androgen receptor; Transactivation; Prostate cancer; Repressor; LNCaP; Cancer research; Biology; Internal medicine; Endocrinology; Transcription factor; Cell biology; Cancer; Medicine; Gene; Genetics","score_opus":0.07033288674640714,"score_gpt":0.4032703358494214,"score_spread":0.33293744910301426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096151138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824674,0.013065797,0.000002093985,0.001896595,0.00013108649,0.0016439072,0.0002233417,0.000038050952,0.00053173077],"genre_scores_gemma":[0.9776334,0.019735161,0.00015365942,0.000027308644,0.00015569362,0.0006148699,0.00005091453,0.000062656174,0.0015662952],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964202,0.00019877833,0.0005003011,0.00059601176,0.00148608,0.00079863716],"domain_scores_gemma":[0.997277,0.00015389275,0.00019237855,0.0004770346,0.0015451713,0.0003544881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007832912,0.00023594343,0.00058822974,0.0004833726,0.00016884468,0.000028311015,0.00030464656,0.00019658278,0.0005307486],"category_scores_gemma":[0.00015103308,0.00017514608,0.00013705036,0.0012737293,0.0005869375,0.00021369438,0.00016277118,0.0007010765,0.00002068533],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057444167,0.00037918863,0.0029898852,0.00059774297,0.00030029155,0.00005110189,0.0029486602,0.00008723941,0.98329973,0.00004107309,0.0019355465,0.0016251344],"study_design_scores_gemma":[0.005003848,0.0011854643,0.0009356489,0.0012680738,0.000050572075,0.0000041743237,0.00064425083,0.000003628465,0.98955876,0.0003495934,0.00083413895,0.00016187089],"about_ca_topic_score_codex":0.007383146,"about_ca_topic_score_gemma":0.000023127472,"teacher_disagreement_score":0.0073600183,"about_ca_system_score_codex":0.00062529417,"about_ca_system_score_gemma":0.0019967277,"threshold_uncertainty_score":0.99922675},"labels":[],"label_agreement":null},{"id":"W2096505838","doi":"10.1007/s12149-009-0273-1","title":"18F-choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer","year":2009,"lang":"en","type":"article","venue":"Annals of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"DOD Prostate Cancer Research Program; Medical Research and Materiel Command; National Cancer Institute","keywords":"Medicine; Prostate cancer; Lymph node; Positron emission tomography; Response Evaluation Criteria in Solid Tumors; Standardized uptake value; Nuclear medicine; Radiology; Prostate; Cancer; Internal medicine; Progressive disease; Disease","score_opus":0.09240970385580845,"score_gpt":0.3980750980247731,"score_spread":0.30566539416896465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096505838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8912045,0.029279042,5.442308e-7,0.067756616,0.0000847711,0.0005399122,0.000029175972,0.000038235255,0.011067249],"genre_scores_gemma":[0.95890015,0.037554443,0.00009225994,0.0016998715,0.00011205674,0.000008154955,0.000030134357,0.000030558305,0.0015723871],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980243,0.000062563384,0.00058985216,0.00028795045,0.0006211418,0.0004142251],"domain_scores_gemma":[0.99867445,0.000069847854,0.00020729756,0.00038313202,0.00044486512,0.00022040957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000686526,0.00018864208,0.00066724804,0.00038643854,0.000053077998,0.0000040287473,0.00013882354,0.000013893804,0.00035486545],"category_scores_gemma":[0.000297072,0.00013437371,0.00009107371,0.00054856716,0.00031895319,0.00013744099,0.000030954667,0.00033725923,0.000009950072],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008809151,0.0026933176,0.020794367,0.00066021323,0.00032580062,0.0045772693,0.0030954937,0.00003256599,0.36893687,0.00027349129,0.19733228,0.3924692],"study_design_scores_gemma":[0.025561364,0.009219703,0.70843095,0.009701966,0.00037167835,0.00069926825,0.0039675813,0.0008124262,0.022124255,0.0014776029,0.21689832,0.000734887],"about_ca_topic_score_codex":0.001283526,"about_ca_topic_score_gemma":0.000024385397,"teacher_disagreement_score":0.68763655,"about_ca_system_score_codex":0.00007349552,"about_ca_system_score_gemma":0.0001699182,"threshold_uncertainty_score":0.5479601},"labels":[],"label_agreement":null},{"id":"W2096582651","doi":"10.1016/j.critrevonc.2006.06.006","title":"Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review","year":2006,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University Health Network; University of Toronto; Toronto Rehabilitation Institute","funders":"","keywords":"Androgen deprivation therapy; Prostate cancer; Medicine; Sexual function; Adverse effect; Quality of life (healthcare); Disease; Bone mineral; Oncology; Sexual dysfunction; Randomized controlled trial; Internal medicine; Cancer; Physical therapy; Osteoporosis","score_opus":0.04513563591893599,"score_gpt":0.4416818956491786,"score_spread":0.3965462597302426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096582651","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000682176,0.97592664,0.000018752668,0.00057144917,0.00011571815,0.022754682,0.000026409423,0.0000225671,0.0004955811],"genre_scores_gemma":[0.000059277096,0.9827062,0.00039787818,0.00034507926,0.000049401944,0.015816968,0.00034487533,0.00009247545,0.00018783673],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9920253,0.0025804306,0.0031350737,0.00095519033,0.00041199848,0.00089197495],"domain_scores_gemma":[0.9945392,0.0031278734,0.0009115845,0.0008784723,0.00031556602,0.00022730627],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017385872,0.0008856147,0.012218687,0.0007327702,0.00004287168,0.000020679528,0.00038619014,0.0006273007,0.000025082389],"category_scores_gemma":[0.0021859533,0.0005037871,0.0005877904,0.0018605285,0.00049382064,0.000117022966,0.00010451506,0.0012862715,0.000033345586],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010882711,0.00065767195,0.000804613,0.7254144,0.00021520354,0.0042771064,0.000081427665,2.808722e-8,0.0000012414338,0.00015136503,0.0003737125,0.26791438],"study_design_scores_gemma":[0.003192248,0.0014856706,0.00008319392,0.956965,0.0025055392,0.002331355,0.000005306192,0.0000031958384,0.000021554533,0.0000697818,0.032946832,0.00039029063],"about_ca_topic_score_codex":0.000018818051,"about_ca_topic_score_gemma":0.000069603455,"teacher_disagreement_score":0.2675241,"about_ca_system_score_codex":0.0009489212,"about_ca_system_score_gemma":0.0017045867,"threshold_uncertainty_score":0.9997414},"labels":[],"label_agreement":null},{"id":"W2096601243","doi":"10.1002/ijc.21614","title":"Steroid hormones stimulate human prostate cancer progression and metastasis","year":2005,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Institute on Aging; National Institutes of Health; U.S. Department of Defense","keywords":"Renal capsule; Prostate; Stroma; Hormone; Endocrinology; Testosterone (patch); Internal medicine; Metastasis; Epithelium; Prostate cancer; Mesenchyme; In vivo; Carcinoma; Cancer; Biology; Kidney; Medicine; Pathology; Immunohistochemistry","score_opus":0.03130336677816084,"score_gpt":0.44086560667267044,"score_spread":0.40956223989450957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096601243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.948811,0.036328495,0.000013904014,0.013996694,0.00032520966,0.00019936373,0.000038978225,0.000010081399,0.00027625437],"genre_scores_gemma":[0.98527586,0.011433593,0.0004974818,0.00029661108,0.0009222131,0.000028853432,0.000006534756,0.000017330065,0.0015215124],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986396,0.00002446511,0.00034397992,0.0001267313,0.0006981942,0.00016707017],"domain_scores_gemma":[0.9988154,0.000021256297,0.00024767016,0.00006458295,0.00070126593,0.0001498158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017987707,0.00011680697,0.0002303428,0.00020553874,0.00005339009,0.000056584715,0.000119928445,0.000037094225,0.00036292427],"category_scores_gemma":[0.000013911682,0.00007592461,0.00008652392,0.00006939288,0.000083833846,0.0002765254,0.000049733113,0.00019836111,0.0000031350542],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035047992,0.00027912605,0.13258912,0.000058786714,0.001910504,0.0002740949,0.0008500955,0.00023438514,0.08538428,0.000055928802,0.0030282557,0.7718306],"study_design_scores_gemma":[0.03464087,0.0023526337,0.45616952,0.0030792211,0.0011055318,0.0007063154,0.0002997143,0.0008458895,0.22204645,0.0007342492,0.27741787,0.00060174667],"about_ca_topic_score_codex":0.000061497456,"about_ca_topic_score_gemma":0.00006146146,"teacher_disagreement_score":0.77122885,"about_ca_system_score_codex":0.00030353773,"about_ca_system_score_gemma":0.0001997776,"threshold_uncertainty_score":0.39737663},"labels":[],"label_agreement":null},{"id":"W2096809954","doi":"10.6000/1927-7229.2013.02.03.3","title":"A Review of the Expression of Genes Involved in Sex Steroid Hormone Metabolism in Prostate Tissue: A Need for Epigenetic Information","year":2013,"lang":"en","type":"article","venue":"Journal of Analytical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Epigenetics; Steroid Metabolism; Gene; Hormone; Prostate cancer; Biology; Prostate; Sex hormone receptor; Gene expression; Steroid hormone; Bioinformatics; Steroid; Endocrinology; Cancer; Genetics","score_opus":0.032076734190393454,"score_gpt":0.36095471057059164,"score_spread":0.32887797638019817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096809954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.946358,0.044635605,0.000084199586,0.00720958,0.000060918865,0.0014324401,0.0000056081853,0.000001303048,0.00021233977],"genre_scores_gemma":[0.9553827,0.04257096,0.0011677891,0.000587102,0.000051634084,0.000052717474,0.000006041313,0.0000073787483,0.00017369328],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99846476,0.00013146216,0.0009464913,0.00005600616,0.00023575664,0.00016551036],"domain_scores_gemma":[0.9987568,0.00015585178,0.00046110552,0.00011653947,0.00042906476,0.00008061737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006878452,0.000077419194,0.00066044,0.00024181884,0.000010100856,0.0000036601198,0.00010711737,0.00007145596,0.00003988088],"category_scores_gemma":[0.00033767553,0.000040427603,0.00011698543,0.0003174025,0.00009940033,0.00015606063,0.000042200878,0.00019375398,0.000001444785],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0117518185,0.004204481,0.08592756,0.023058487,0.00072783895,0.000107565895,0.006217016,0.00016488958,0.48598298,0.00026654504,0.029517706,0.35207313],"study_design_scores_gemma":[0.05628469,0.019195797,0.5068315,0.024715519,0.0014813232,0.0002216968,0.003437031,0.0043686274,0.2758376,0.0033531575,0.103820205,0.00045278601],"about_ca_topic_score_codex":0.00004384214,"about_ca_topic_score_gemma":0.00001020538,"teacher_disagreement_score":0.42090398,"about_ca_system_score_codex":0.00013183351,"about_ca_system_score_gemma":0.00041398837,"threshold_uncertainty_score":0.16485898},"labels":[],"label_agreement":null},{"id":"W2097027305","doi":"10.1042/bj20021816","title":"Identification and characterization of a prostate-specific androgen-independent protein-binding site in the probasin promoter","year":2003,"lang":"en","type":"article","venue":"Biochemical Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"LNCaP; DU145; Footprinting; Biology; Molecular biology; Transcription factor; Nuclear protein; Prostate; Prostate cancer; Binding site; Biochemistry; Gene; Genetics; Cancer","score_opus":0.022385441513368885,"score_gpt":0.27866580336243246,"score_spread":0.25628036184906355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097027305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99761665,0.0005156208,0.000073481635,0.000797524,0.000025157637,0.0009099136,0.000008381024,0.000004295064,0.00004899625],"genre_scores_gemma":[0.9991728,0.00031955948,0.000161198,0.000016493028,0.000045047927,0.000043680626,0.00003627189,0.000008577968,0.00019637153],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990078,0.00008519707,0.00027829956,0.00014434896,0.00031520138,0.00016912741],"domain_scores_gemma":[0.99960375,0.000010055107,0.00011671498,0.0001048935,0.00009533362,0.00006922594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005452674,0.00008191205,0.00012428507,0.00010124361,0.000057350735,0.000057341145,0.00004983026,0.000059766367,0.000022724063],"category_scores_gemma":[0.000036407688,0.000049148057,0.00003463539,0.00019175118,0.00006585555,0.0000806528,0.000011176329,0.00023262603,0.000004829543],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020486637,0.00018997637,0.016485421,0.00006767286,0.000014140679,0.00003565823,0.0005397258,1.744481e-8,0.9808902,0.000036560745,0.000053037,0.0014826924],"study_design_scores_gemma":[0.001802551,0.00016479379,0.024323246,0.00023080848,0.000016437589,0.00047835434,0.00012451872,0.000014206307,0.971602,0.000074508265,0.001103122,0.00006543709],"about_ca_topic_score_codex":7.868193e-7,"about_ca_topic_score_gemma":2.3538055e-7,"teacher_disagreement_score":0.009288213,"about_ca_system_score_codex":0.00007645983,"about_ca_system_score_gemma":0.00008056044,"threshold_uncertainty_score":0.20041996},"labels":[],"label_agreement":null},{"id":"W2097121410","doi":"10.1158/0008-5472.can-13-2921-t","title":"High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":365,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Medicine; Cancer; Prostate; Prostatectomy; Transdifferentiation; Adenocarcinoma; Oncology; Androgen receptor; Cancer research; PTEN; Internal medicine; Bioinformatics; Biology; PI3K/AKT/mTOR pathway; Stem cell","score_opus":0.08682408592693788,"score_gpt":0.3958406394443298,"score_spread":0.3090165535173919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097121410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98321605,0.006230925,0.000018134286,0.00598229,0.00020441665,0.00408571,0.0000918604,0.000046866964,0.00012377612],"genre_scores_gemma":[0.9788104,0.0029958442,0.0013233472,0.00023076782,0.00031303713,0.010191595,0.00010037403,0.00005462822,0.0059799557],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99712765,0.00010912744,0.0003638089,0.00060819933,0.00076987635,0.0010213471],"domain_scores_gemma":[0.9980678,0.00021192803,0.000066305896,0.00028658257,0.0009886964,0.0003787194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054315955,0.0002243689,0.00035169907,0.00020985078,0.00059570366,0.00029533877,0.00013978838,0.00007796694,0.0003813311],"category_scores_gemma":[0.00011483692,0.00016266396,0.000058459664,0.00036700183,0.00029697272,0.00046632165,0.00024560528,0.00043850823,0.000022152177],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022710478,0.0003866723,0.061791852,0.0019367367,0.00056746096,0.00003823512,0.009871605,0.000024917344,0.3898544,0.00010930337,0.04713046,0.4860173],"study_design_scores_gemma":[0.009029214,0.0008206474,0.10203096,0.001312351,0.000062573265,0.0000070661417,0.0033111328,0.00020104117,0.845935,0.0006930648,0.035946816,0.00065015786],"about_ca_topic_score_codex":0.005036749,"about_ca_topic_score_gemma":0.00044207243,"teacher_disagreement_score":0.48536715,"about_ca_system_score_codex":0.000739373,"about_ca_system_score_gemma":0.0013861639,"threshold_uncertainty_score":0.76140916},"labels":[],"label_agreement":null},{"id":"W2097382536","doi":"10.1158/1535-7163.mct-10-0850","title":"Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression <i>In vivo</i>","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Deutsche Forschungsgemeinschaft","keywords":"Gene knockdown; LNCaP; Transactivation; Cancer research; Androgen receptor; Prostate cancer; STAT5; Androgen deprivation therapy; DU145; STAT protein; Biology; Transcription factor; Medicine; Apoptosis; Internal medicine; Cancer; Signal transduction; STAT3; Cell biology","score_opus":0.052477183403012474,"score_gpt":0.33209017566095417,"score_spread":0.2796129922579417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097382536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975067,0.021864958,0.00021972557,0.0008205742,0.00016383342,0.0013218978,0.0002045295,0.00005104401,0.00028640535],"genre_scores_gemma":[0.98013747,0.017335014,0.0009266429,0.0003185533,0.000043888555,0.00056450034,0.00006192876,0.000048725033,0.000563273],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837255,0.00008569308,0.00031455734,0.00042177047,0.00039405472,0.00041136568],"domain_scores_gemma":[0.9993767,0.000012064197,0.00010611892,0.0001963426,0.00016067427,0.00014810877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011202988,0.00025705202,0.00027684684,0.00013607065,0.00010746829,0.000041411902,0.000075353,0.00012436941,0.00033584566],"category_scores_gemma":[0.0000029920466,0.0002004268,0.00006619685,0.00028607534,0.00012932687,0.00017923431,0.00001610957,0.00020472228,0.0000029212279],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00178858,0.00015735606,0.014703043,0.00016002671,0.0001909399,0.00004763159,0.003854341,0.00000315999,0.91090673,0.00003970504,0.000029739707,0.06811874],"study_design_scores_gemma":[0.0028724582,0.0006519917,0.007127334,0.0003598887,0.0001616163,0.000006140493,0.00034637295,0.00016059662,0.98269963,0.00011022817,0.0052435347,0.00026020058],"about_ca_topic_score_codex":0.00062595383,"about_ca_topic_score_gemma":0.0006582588,"teacher_disagreement_score":0.0717929,"about_ca_system_score_codex":0.00028069608,"about_ca_system_score_gemma":0.00034653314,"threshold_uncertainty_score":0.8173168},"labels":[],"label_agreement":null},{"id":"W2097444820","doi":"10.1677/joe.0.1650425","title":"Prostatic secretory protein (PSP94) expression in human female reproductive tissues, breast and in endometrial cancer cell lines","year":2000,"lang":"en","type":"article","venue":"Journal of Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Lawson Health Research Institute; Micropharma (Canada); TransCanada (Canada)","funders":"","keywords":"Biology; Endometrium; In situ hybridization; Prostate; Northern blot; Endocrinology; Internal medicine; Messenger RNA; Molecular biology; Gene; Cancer; Medicine; Genetics","score_opus":0.029309990321860612,"score_gpt":0.34695504271683886,"score_spread":0.31764505239497826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097444820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837722,0.013699615,6.1359543e-7,0.0009795692,0.00009511043,0.0006591329,0.00000850045,0.0000063474868,0.00077886943],"genre_scores_gemma":[0.9928214,0.0034902368,0.0002457812,0.000023120192,0.00046889624,0.000060976046,0.0000043978466,0.000016305607,0.0028688672],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998555,0.00015044345,0.00047517262,0.00024994026,0.00021499109,0.00035445057],"domain_scores_gemma":[0.9994194,0.000054745782,0.00016156016,0.00014867297,0.000113454385,0.000102197424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022044471,0.00013414,0.0004605702,0.00039633084,0.00003781446,0.0000099903045,0.000077405246,0.00006748333,0.00067874894],"category_scores_gemma":[0.00007039699,0.00009664064,0.000045777066,0.00023340684,0.00013211141,0.00015925524,0.000033318396,0.00044469512,0.0000028467355],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014500304,0.0014267742,0.24436222,0.000435752,0.00010903365,0.005204306,0.0028480384,0.000056996523,0.67682725,0.000015613743,0.00046392504,0.053749755],"study_design_scores_gemma":[0.04193055,0.0043624253,0.28033635,0.0018798232,0.000100016,0.0030543162,0.0014848738,0.000021870548,0.6590741,0.0004869468,0.0069082077,0.00036046194],"about_ca_topic_score_codex":0.00041815045,"about_ca_topic_score_gemma":0.00016355416,"teacher_disagreement_score":0.053389296,"about_ca_system_score_codex":0.0002575005,"about_ca_system_score_gemma":0.00019319786,"threshold_uncertainty_score":0.7431825},"labels":[],"label_agreement":null},{"id":"W2097477872","doi":"10.1373/clinchem.2011.165977","title":"Molecular Alterations during Progression of Prostate Cancer to Androgen Independence","year":2011,"lang":"en","type":"review","venue":"Clinical Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Prostate cancer; Androgen receptor; Androgen; Cancer research; Cancer; Prostate; Internal medicine; Medicine; Endocrinology; Biology; Hormone","score_opus":0.12087017116898899,"score_gpt":0.49963872893382105,"score_spread":0.3787685577648321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097477872","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018806916,0.9787668,9.919979e-7,0.00008425528,0.00007630423,0.0012673952,0.00010187284,0.000030409365,0.00086505496],"genre_scores_gemma":[0.0012621904,0.9948288,0.00012751603,0.000020688647,0.00020155267,0.0005798888,0.00015190351,0.000047210473,0.0027802442],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99791425,0.000052645853,0.0008781459,0.000540665,0.0003158645,0.0002984343],"domain_scores_gemma":[0.9985109,0.00006287189,0.00029051155,0.00052818103,0.00021114857,0.00039636123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002482954,0.00027382822,0.0012758344,0.00004414903,0.000044251887,0.0000120713685,0.00020841497,0.0004460957,0.00023515946],"category_scores_gemma":[0.00019910664,0.00018890327,0.00045369266,0.00024605068,0.00014711815,0.000027359201,0.00019291636,0.00070659845,0.00002710591],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029241806,0.0005690928,0.004947686,0.06366457,0.0006542635,0.0003647059,0.000060632512,2.7421194e-7,0.00038573617,0.0000028266668,0.00035675193,0.92870104],"study_design_scores_gemma":[0.0021274695,0.00041867132,0.00012334611,0.07591979,0.0018989772,0.0001126974,0.000012482311,0.0000018627236,0.05198083,0.000017740496,0.86682826,0.0005578407],"about_ca_topic_score_codex":0.0000057296515,"about_ca_topic_score_gemma":4.8235154e-7,"teacher_disagreement_score":0.9281432,"about_ca_system_score_codex":0.00011997117,"about_ca_system_score_gemma":0.0011204001,"threshold_uncertainty_score":0.7703252},"labels":[],"label_agreement":null},{"id":"W2097563063","doi":"10.5489/cuaj.540","title":"Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Queen's University; University of Calgary","funders":"Abbott Canada","keywords":"Medicine; Testosterone (patch); Luteinizing hormone; Goserelin; Prostate cancer; Buserelin; Hormone; Internal medicine; Endocrinology; Follicle-stimulating hormone; Population; Prostate-specific antigen; Urology; Cancer; Agonist; Receptor","score_opus":0.03349535001355164,"score_gpt":0.30676958016721545,"score_spread":0.2732742301536638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097563063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98312366,0.00033453063,0.0000061867213,0.013465858,0.000025966183,0.0007046318,0.000064994856,0.000012023724,0.0022621616],"genre_scores_gemma":[0.9963459,0.0002806014,0.0002723467,0.0004966733,0.0001365246,0.00010199073,0.000022412001,0.000016859902,0.0023266852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979319,0.0001967906,0.00047780946,0.00025829332,0.00049430766,0.00064092054],"domain_scores_gemma":[0.99805194,0.00014531157,0.00031508264,0.00010309861,0.0006184322,0.0007661269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060246687,0.00017057147,0.0004654524,0.00018778833,0.00011206752,0.000058296813,0.00010948634,0.00019821075,0.0007882768],"category_scores_gemma":[0.00012164778,0.0000995758,0.00007556837,0.00039802032,0.00016202596,0.00015182028,0.000009564693,0.0007346958,0.000017616769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090692285,0.00011701931,0.99158335,0.000008698032,0.00022350717,0.00024506412,0.000102771184,0.000071241004,0.0002139676,0.000010264342,0.0023717193,0.004145498],"study_design_scores_gemma":[0.0044741267,0.0018390124,0.99147373,0.000054774177,0.000062656465,0.000057816455,0.000093653885,0.0002373446,0.00013426217,0.00006176037,0.0013825853,0.00012826343],"about_ca_topic_score_codex":0.009621098,"about_ca_topic_score_gemma":0.0032347888,"teacher_disagreement_score":0.0132222595,"about_ca_system_score_codex":0.0012491846,"about_ca_system_score_gemma":0.0020352872,"threshold_uncertainty_score":0.99697393},"labels":[],"label_agreement":null},{"id":"W2097764048","doi":"10.1038/onc.2010.121","title":"Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails","year":2010,"lang":"en","type":"review","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; National Natural Science Foundation of China","keywords":"Prostate cancer; Stromal cell; Androgen deprivation therapy; Androgen receptor; Cancer research; Metastasis; Cancer; Prostate; Internal medicine; Cancer cell; Oncology; Biology; Medicine","score_opus":0.06215031498559043,"score_gpt":0.3645695030006148,"score_spread":0.3024191880150244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097764048","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.103522606,0.89160866,0.0000087695125,0.00012556196,0.00043773904,0.0036928277,0.00049886206,0.00003379258,0.00007117215],"genre_scores_gemma":[0.0016727614,0.9942623,0.00007460015,0.000037966292,0.000492823,0.0012844342,0.001188744,0.00012949259,0.0008569182],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99671334,0.0002609198,0.0010160216,0.0007268356,0.0006694234,0.0006134781],"domain_scores_gemma":[0.99829024,0.00013856702,0.00052909856,0.0006004256,0.00017701942,0.0002646217],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022811908,0.0006962005,0.0025527137,0.0005033932,0.00006450145,0.000046752477,0.0002811955,0.0005873117,0.0017280563],"category_scores_gemma":[0.000020972579,0.00043627326,0.00058383506,0.00050352124,0.00014315317,0.00009751059,0.00010215084,0.0007050648,0.0000319498],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044970497,0.00068212306,0.00059437595,0.004787404,0.00044844733,0.000038509643,0.00026725142,4.0108668e-7,0.04250909,0.00000196531,0.0005859299,0.9496348],"study_design_scores_gemma":[0.004073765,0.0005650123,0.00002808153,0.0072569097,0.00038103442,0.000011017778,0.000027398293,0.00000610174,0.15345521,0.000016956914,0.8337219,0.0004566483],"about_ca_topic_score_codex":0.0001366353,"about_ca_topic_score_gemma":0.000068071,"teacher_disagreement_score":0.94917816,"about_ca_system_score_codex":0.0004245228,"about_ca_system_score_gemma":0.0007506869,"threshold_uncertainty_score":0.9998089},"labels":[],"label_agreement":null},{"id":"W2097777568","doi":"10.5489/cuaj.1542","title":"CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC): 2013 Update","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; St. Boniface Hospital; Health Sciences Centre; University of Toronto; University of Manitoba; BC Cancer Agency; McMaster University; University of British Columbia Hospital; McGill University Health Centre; Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Abiraterone acetate; Enzalutamide; Prostate cancer; Docetaxel; Regimen; Androgen deprivation therapy; Oncology; Internal medicine; Lymph node; Hormonal therapy; Cancer; Urology; Androgen receptor","score_opus":0.05058529004435187,"score_gpt":0.3341715898734305,"score_spread":0.2835862998290786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097777568","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36616188,0.006204307,0.00015461781,0.62301695,0.00056575274,0.002648515,0.00022435766,0.000023280834,0.0010003273],"genre_scores_gemma":[0.9755234,0.009152469,0.0015723421,0.0040540816,0.0005337228,0.0004264532,0.00006451458,0.000019798377,0.008653212],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9986256,0.000052387244,0.00040058425,0.00014276904,0.0003551505,0.00042351172],"domain_scores_gemma":[0.99788886,0.00007725374,0.0002480447,0.00010853564,0.0013600196,0.00031727095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061010395,0.00010823035,0.00018603895,0.00008905313,0.00028753167,0.000081299564,0.00011404661,0.00009695334,0.0007680697],"category_scores_gemma":[0.00011331268,0.000060645205,0.00011077447,0.00016466151,0.000041203028,0.00010423164,0.000012774088,0.00021862966,0.000026763058],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009432612,0.00011560128,0.122959845,0.00013573423,0.0019287737,0.00008070183,0.00028623524,0.0005579361,0.001484393,0.0008316109,0.7887266,0.0819493],"study_design_scores_gemma":[0.0036065455,0.0005813515,0.66228175,0.00010899526,0.00040582265,0.000029694986,0.00054503634,0.0015745553,0.00027020948,0.0025094734,0.32790753,0.00017904896],"about_ca_topic_score_codex":0.0046837125,"about_ca_topic_score_gemma":0.0015940885,"teacher_disagreement_score":0.6189629,"about_ca_system_score_codex":0.00073459884,"about_ca_system_score_gemma":0.00040846923,"threshold_uncertainty_score":0.84098244},"labels":[],"label_agreement":null},{"id":"W2098128741","doi":"10.1186/1756-8722-7-21","title":"Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients’ prognosis","year":2014,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Prostate Cancer Canada; University of Calgary","funders":"Prostate Cancer Canada; Movember Foundation; Prostate Cancer Foundation","keywords":"PTEN; Prostate cancer; Erg; Immunohistochemistry; Internal medicine; Biochemical recurrence; Medicine; Cohort; Prostate; Cancer; Oncology; Cancer research; Pathology; Biology; Prostatectomy; Signal transduction; PI3K/AKT/mTOR pathway; Genetics","score_opus":0.011443042562657504,"score_gpt":0.3113333247399142,"score_spread":0.2998902821772567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098128741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896034,0.0019006575,0.00012843467,0.0069169435,0.000052377447,0.0010841902,0.0000071777963,0.000008724943,0.00029807934],"genre_scores_gemma":[0.99673635,0.00020722684,0.0024266143,0.00026010317,0.000041816944,0.0001922279,0.000008698327,0.000022746444,0.00010420622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985812,0.00015758652,0.00051022077,0.00020713104,0.00025355525,0.000290318],"domain_scores_gemma":[0.998113,0.000082810315,0.00052347424,0.00015863014,0.00090596563,0.00021615082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034276507,0.00015209579,0.00073707785,0.0002720599,0.000042231688,0.000004803653,0.00009445965,0.00014550709,0.00002167927],"category_scores_gemma":[0.00014896682,0.00009799818,0.000056621397,0.00023893503,0.00017747648,0.000059999806,0.00005051344,0.00025687148,0.000003206347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007146628,0.0008486258,0.9141566,0.00059090497,0.00055424497,0.00023191451,0.0008423113,0.000008157467,0.061783426,0.00069975614,0.0009160868,0.012221299],"study_design_scores_gemma":[0.03335029,0.06606108,0.4641423,0.0017106769,0.001434716,0.0038764223,0.00044578302,0.00009084153,0.4052482,0.00095807604,0.02211319,0.0005684435],"about_ca_topic_score_codex":0.000060275168,"about_ca_topic_score_gemma":0.000057280053,"teacher_disagreement_score":0.45001435,"about_ca_system_score_codex":0.00017054475,"about_ca_system_score_gemma":0.0005208181,"threshold_uncertainty_score":0.39962497},"labels":[],"label_agreement":null},{"id":"W2098467164","doi":"10.1016/j.urolonc.2013.02.015","title":"Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer","year":2013,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Prostate cancer; Medicine; Comorbidity; Internal medicine; Oncology; Charlson comorbidity index; Cancer; Castration; Gynecology; Urology; Hormone","score_opus":0.03491996582786097,"score_gpt":0.30608319226866965,"score_spread":0.2711632264408087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098467164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97775346,0.0005005807,0.0000024104384,0.020406397,0.000024561432,0.00080835115,0.000018546902,0.000009006498,0.00047668282],"genre_scores_gemma":[0.995802,0.00083562214,0.00159883,0.0002720134,0.000016414988,0.00021512697,0.00001886506,0.0000073399765,0.0012338222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991041,0.00013239915,0.00017111441,0.00019439742,0.00020539941,0.00019259714],"domain_scores_gemma":[0.99933296,0.00017111877,0.00015545955,0.00009769285,0.00014671075,0.00009605955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024262769,0.00011314032,0.00026486005,0.00006992562,0.00012559924,0.00001536761,0.000037048856,0.00007241562,0.00003089086],"category_scores_gemma":[0.00005139551,0.000057605288,0.0000132632995,0.00025006922,0.00042663186,0.00010363543,0.000022657832,0.00022712939,8.38983e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037299862,0.0001129348,0.994638,0.00004526699,0.000083413935,0.000029251009,0.00045403762,0.00004161934,0.0028397467,0.00016812902,0.00061711686,0.0005974874],"study_design_scores_gemma":[0.0041808104,0.0024911165,0.9779694,0.0001614049,0.0003094945,0.00008098353,0.0009344235,0.0015862415,0.0011937213,0.000903605,0.010067308,0.00012145308],"about_ca_topic_score_codex":0.0019255013,"about_ca_topic_score_gemma":0.0018391303,"teacher_disagreement_score":0.020134384,"about_ca_system_score_codex":0.00016880682,"about_ca_system_score_gemma":0.00042407846,"threshold_uncertainty_score":0.2910795},"labels":[],"label_agreement":null},{"id":"W2099037568","doi":"10.1016/j.eururo.2013.10.032","title":"Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist","year":2013,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":338,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Myocardial infarction; Prostate cancer; Vitamin K antagonist; Heart failure; Cardiology; Sudden cardiac death; Heart disease; Endocrinology; Confidence interval; Cancer; Atrial fibrillation","score_opus":0.023439555135874323,"score_gpt":0.26627709641805025,"score_spread":0.24283754128217594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099037568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98513746,0.0037439626,0.00005666894,0.0011470373,0.000044177166,0.0003945878,0.0000073654774,0.0001037405,0.00936498],"genre_scores_gemma":[0.9976406,0.00079605513,0.00014790252,0.00038318298,0.00016171066,0.000011659076,0.00010644384,0.00005007766,0.00070235034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998479,0.00042793454,0.0001392863,0.00037247874,0.00020299871,0.00037827904],"domain_scores_gemma":[0.99921066,0.000034864403,0.000042869484,0.00036114093,0.00011531345,0.00023516086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020793009,0.00015893579,0.000310251,0.00006824774,0.00016406081,0.00004783316,0.00007668969,0.00005225028,0.000045110097],"category_scores_gemma":[0.00007147101,0.00011393026,0.00006329558,0.00011823563,0.00030930413,0.000100100006,0.00006338661,0.00026242636,0.00010011237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070209783,0.0033975765,0.5207221,0.00032194098,0.012896793,0.025796343,0.003970265,0.00016483793,0.15566467,0.00069402356,0.02439983,0.24495062],"study_design_scores_gemma":[0.003367471,0.0021073432,0.9834037,0.000013020218,0.00019721033,0.00025157406,0.000035579942,0.00018422128,0.00016833287,0.000027160333,0.010094058,0.00015033378],"about_ca_topic_score_codex":0.00025532706,"about_ca_topic_score_gemma":0.000008941052,"teacher_disagreement_score":0.4626816,"about_ca_system_score_codex":0.000060230712,"about_ca_system_score_gemma":0.000056926336,"threshold_uncertainty_score":0.46459413},"labels":[],"label_agreement":null},{"id":"W2099242522","doi":"10.1002/pros.21490","title":"Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor‐axis in castration‐resistant prostate tumors","year":2011,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Deutsche Forschungsgemeinschaft; Prostate Cancer Canada","keywords":"Bicalutamide; LNCaP; Prostate cancer; Carbidopa; Medicine; Androgen receptor; Combination therapy; Cancer research; Androgen deprivation therapy; In vivo; Internal medicine; Antiandrogen; Endocrinology; Pharmacology; Urology; Cancer; Biology","score_opus":0.053326726879032005,"score_gpt":0.3006745781873894,"score_spread":0.2473478513083574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099242522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99177253,0.00031313673,0.000001692183,0.0024633408,0.00009138844,0.001608331,0.00007989628,0.000030234633,0.003639461],"genre_scores_gemma":[0.9971964,0.00038269378,0.000064538304,0.00007685558,0.000032757078,0.00016699429,0.000014011033,0.000023614359,0.0020421373],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99835414,0.00021114759,0.00030545783,0.00028842158,0.00041511154,0.0004257372],"domain_scores_gemma":[0.99910676,0.000098445795,0.00015151975,0.00044345928,0.00011026479,0.00008954843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071682426,0.00019947272,0.00031727835,0.00010341823,0.00014393062,0.000021426462,0.00019278617,0.00004039788,0.00014574228],"category_scores_gemma":[0.00007112319,0.00009647284,0.00008482854,0.00043545227,0.0004806335,0.000107896725,0.0000661936,0.00034122835,0.000042087027],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023652788,0.0017291337,0.08819577,0.0004716543,0.00036114856,0.0004091616,0.028373204,0.000017845785,0.84245473,0.0017298355,0.0011392288,0.011465499],"study_design_scores_gemma":[0.0016093709,0.0014540034,0.09193841,0.00030111242,0.000041194446,0.000014916249,0.00092472974,0.00008289059,0.90222454,0.0008868698,0.00037051173,0.00015147882],"about_ca_topic_score_codex":0.0009139946,"about_ca_topic_score_gemma":0.00020325508,"teacher_disagreement_score":0.059769783,"about_ca_system_score_codex":0.00011335481,"about_ca_system_score_gemma":0.00027786382,"threshold_uncertainty_score":0.3934048},"labels":[],"label_agreement":null},{"id":"W2100471642","doi":"10.1093/annonc/mdn288","title":"Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Mitoxantrone; Docetaxel; Medicine; Oncology; Prostate cancer; Internal medicine; Crossover study; Chemotherapy; Cancer; Pathology","score_opus":0.09394859648610601,"score_gpt":0.42496393803982735,"score_spread":0.33101534155372137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100471642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944528,0.00024979783,4.6848083e-7,0.0037426709,0.000067909605,0.001013077,0.00006142929,0.0000034444859,0.00040845724],"genre_scores_gemma":[0.9975382,0.00050522014,0.00003092049,0.0006893755,0.00003366108,0.00007642678,0.0000061402693,0.000009084742,0.0011109379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984436,0.00047833528,0.0002932898,0.00020797086,0.000317992,0.00025883445],"domain_scores_gemma":[0.99872524,0.00060528493,0.00008830739,0.00023254863,0.00026318213,0.00008543591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007608737,0.0001089103,0.0004410652,0.00015972776,0.00004183485,0.0000035452165,0.00010251968,0.00007937705,0.00009268863],"category_scores_gemma":[0.00038414606,0.00006350823,0.00004200766,0.0003031416,0.00022110766,0.000053524083,0.00006836081,0.00013917599,0.000005639908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1561634,0.0036318786,0.8109442,0.000047063284,0.0001824924,0.00062947196,0.017309127,0.0000013060322,0.0009331132,0.0000023580897,0.0075693037,0.002586294],"study_design_scores_gemma":[0.009081628,0.01702586,0.9615637,0.00003671037,0.000030476856,0.0000063675047,0.0015598234,0.0000018084065,0.0013354326,0.000006492411,0.009292591,0.000059075453],"about_ca_topic_score_codex":0.000474611,"about_ca_topic_score_gemma":0.0006475532,"teacher_disagreement_score":0.15061954,"about_ca_system_score_codex":0.0000485912,"about_ca_system_score_gemma":0.00030673755,"threshold_uncertainty_score":0.25897908},"labels":[],"label_agreement":null},{"id":"W2100960809","doi":"10.1126/scitranslmed.3005688","title":"A Preclinical Xenograft Model Identifies Castration-Tolerant Cancer-Repopulating Cells in Localized Prostate Tumors","year":2013,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Prostate cancer; Medicine; Cancer research; Castration; Stromal cell; Prostate; Cancer; Androgen deprivation therapy; Oncology; Internal medicine; Hormone","score_opus":0.0774734027286277,"score_gpt":0.40595458034267656,"score_spread":0.3284811776140489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100960809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978773,0.0006644647,0.00062348286,0.017019406,0.00020015136,0.0015396918,0.000015593758,0.00004794942,0.0011162387],"genre_scores_gemma":[0.9961688,0.00009226857,0.0019781962,0.00022087187,0.00012250876,0.00025260155,0.000039726885,0.00001453788,0.0011105196],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99690604,0.000040060317,0.00069795817,0.00052228535,0.0013112916,0.00052238],"domain_scores_gemma":[0.99884886,0.00012780947,0.00010265097,0.00021188211,0.00039970042,0.00030910876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009133916,0.00018463186,0.0003675361,0.00039280043,0.0002145191,0.000046391684,0.00016744167,0.000048142807,0.00046543963],"category_scores_gemma":[0.00010788304,0.00012680869,0.000057269765,0.0010426578,0.0012915867,0.00052408886,0.000019058969,0.00028978064,0.000024226803],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000919558,0.00056586706,0.27336124,0.00047830213,0.00007105848,0.00013250677,0.014093839,0.039326273,0.64219654,0.0007791482,0.00064149505,0.027434172],"study_design_scores_gemma":[0.009219176,0.00046423404,0.24945164,0.0016247993,0.00007582758,0.00003982005,0.0010340103,0.7144676,0.016374841,0.0068525644,0.000059291837,0.00033618964],"about_ca_topic_score_codex":0.0017707864,"about_ca_topic_score_gemma":0.00029382808,"teacher_disagreement_score":0.67514133,"about_ca_system_score_codex":0.00013453892,"about_ca_system_score_gemma":0.0011477164,"threshold_uncertainty_score":0.5171109},"labels":[],"label_agreement":null},{"id":"W2101009063","doi":"10.1158/0008-5472.can-07-0478","title":"Androgen-Induced Wnt Signaling in Preosteoblasts Promotes the Growth of MDA-PCa-2b Human Prostate Cancer Cells","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"T.J. Martell Foundation; U.S. Department of Defense","keywords":"Dihydrotestosterone; Wnt signaling pathway; Androgen receptor; Prostate cancer; Cell growth; Endocrinology; Paracrine signalling; Androgen; Chemistry; Internal medicine; Cancer research; Signal transduction; Biology; Cell biology; Receptor; Cancer; Medicine; Hormone; Biochemistry","score_opus":0.09344612595770783,"score_gpt":0.4287663579007316,"score_spread":0.33532023194302374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101009063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891276,0.0047324183,0.000001764425,0.0019966408,0.00012566827,0.0028792166,0.000038431008,0.000031848416,0.0010664107],"genre_scores_gemma":[0.99527407,0.0012236208,0.000024830693,0.000054026023,0.00030956746,0.0006782653,0.000015890566,0.00006299021,0.0023567337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99586576,0.00025352466,0.0005489991,0.0005714418,0.0014555287,0.0013047478],"domain_scores_gemma":[0.99783164,0.00035665443,0.00011264635,0.00045388014,0.0009388399,0.0003063614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031448635,0.00024755392,0.0004519455,0.0005678979,0.00030224284,0.000051276653,0.0003911089,0.00015232764,0.00033938795],"category_scores_gemma":[0.00011422366,0.0001588257,0.00011204005,0.001575368,0.000506876,0.00012776739,0.00021047768,0.0010681323,0.000017030112],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013344674,0.0002913853,0.04481537,0.0006484898,0.00013545837,0.00018267435,0.003607419,0.000008457576,0.9416553,0.000101990605,0.00041146608,0.006807546],"study_design_scores_gemma":[0.0030834568,0.00073754863,0.012104402,0.000920534,0.000030238018,0.000005949307,0.0008140474,0.000020753432,0.9814889,0.0002957648,0.0003359168,0.00016248545],"about_ca_topic_score_codex":0.00560072,"about_ca_topic_score_gemma":0.0019303866,"teacher_disagreement_score":0.039833628,"about_ca_system_score_codex":0.00091903895,"about_ca_system_score_gemma":0.0012347952,"threshold_uncertainty_score":0.8466651},"labels":[],"label_agreement":null},{"id":"W2101265600","doi":"10.1200/jco.2013.54.8404","title":"Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline","year":2014,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":224,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Université de Montréal; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Genentech; Astellas Pharma; Bayer HealthCare; Sanofi; Exelixis; AstraZeneca; American Society of Clinical Oncology; GlaxoSmithKline; Cancer Care Ontario; Amgen; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Cabazitaxel; Docetaxel; Enzalutamide; Prostate cancer; Internal medicine; Oncology; Abiraterone acetate; Prednisone; Mitoxantrone; Androgen deprivation therapy; Cancer; Chemotherapy; Androgen receptor","score_opus":0.30336439310637164,"score_gpt":0.6127817755872027,"score_spread":0.30941738248083106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101265600","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01110313,0.9786163,0.000017714676,0.00565887,0.0010014668,0.0026751189,0.0000868462,0.000010592857,0.0008299642],"genre_scores_gemma":[0.0012809014,0.98257625,0.011841981,0.0016049728,0.0017911078,0.00018981527,0.000055741704,0.000083118095,0.0005761013],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.976689,0.0058198883,0.014952592,0.0008613724,0.0010509508,0.00062622223],"domain_scores_gemma":[0.9642786,0.014104721,0.01716841,0.00052033534,0.0030380248,0.00088990876],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01917472,0.0006424025,0.015142472,0.00024948976,0.000071876646,0.000024427001,0.00041864885,0.0011020541,0.00008581605],"category_scores_gemma":[0.0032405674,0.00035820896,0.0021237624,0.0005051367,0.0017856124,0.00018470375,0.00012683222,0.0053314464,0.0000032099424],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01881503,0.0021526555,0.023281557,0.004008163,0.0063201915,0.0010803721,0.0006323889,0.000009378834,7.824501e-7,0.000006012369,0.007187504,0.936506],"study_design_scores_gemma":[0.021153504,0.049892984,0.0046783285,0.008966575,0.006515374,0.0006839507,0.0015785645,0.000023305569,3.8520844e-7,0.000007048652,0.90620816,0.0002918142],"about_ca_topic_score_codex":0.015409323,"about_ca_topic_score_gemma":0.027181758,"teacher_disagreement_score":0.93621415,"about_ca_system_score_codex":0.002299147,"about_ca_system_score_gemma":0.06945899,"threshold_uncertainty_score":0.999887},"labels":[],"label_agreement":null},{"id":"W2101506484","doi":"10.1016/j.eururo.2015.08.027","title":"Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08","year":2015,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Hôpital Notre-Dame; Alberta Cancer Foundation","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Androgen; Prostate; Oncology; Internal medicine; Term (time); Urology; Prostate disease; Cancer; Gynecology; Hormone","score_opus":0.07159375603985815,"score_gpt":0.372412872666056,"score_spread":0.30081911662619787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101506484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99477106,0.002821171,0.0002017481,0.00017022983,0.00012197456,0.00046063855,0.000016686534,0.000040636143,0.0013958242],"genre_scores_gemma":[0.9987562,0.00050116953,0.00011497678,0.00015813977,0.0000719027,0.000024328689,0.00026748527,0.000030249039,0.0000755807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973882,0.00082943897,0.00058805593,0.00047088208,0.00039528144,0.00032816397],"domain_scores_gemma":[0.9988524,0.000045650806,0.000083064835,0.0006275453,0.00015385813,0.00023750655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021391402,0.00015321889,0.00075946574,0.00033050354,0.000028813478,0.000010340278,0.00015650148,0.00007138794,0.00002560972],"category_scores_gemma":[0.00017264379,0.00012598638,0.00041786506,0.0007064623,0.00012685903,0.00008589404,0.00009532954,0.00020505565,0.000010045214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008579932,0.00019328819,0.9816895,0.000020596968,0.003944434,0.00086607394,0.0007388131,0.002012723,0.00042276015,0.0000056667222,0.000022101745,0.009226061],"study_design_scores_gemma":[0.00483963,0.0008799113,0.9857655,0.000016329977,0.0035766978,0.000007083512,0.00008840737,0.0029330663,0.0002671086,0.00002012838,0.0014639029,0.00014222269],"about_ca_topic_score_codex":0.000389656,"about_ca_topic_score_gemma":0.00022013756,"teacher_disagreement_score":0.009083839,"about_ca_system_score_codex":0.00010778844,"about_ca_system_score_gemma":0.00019780341,"threshold_uncertainty_score":0.5137576},"labels":[],"label_agreement":null},{"id":"W2103129429","doi":"10.1158/1055-9965.epi-08-1223","title":"Genetic Variants and Prostate Cancer Risk: Candidate Replication and Exploration of Viral Restriction Genes","year":2009,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; V Foundation for Cancer Research; U.S. Department of Veterans Affairs","keywords":"Prostate cancer; Candidate gene; Biology; Population stratification; Cancer; Population; Disease; Genetic association; Genome-wide association study; Family history; Genetics; Oncology; Single-nucleotide polymorphism; Gene; Medicine; Internal medicine; Genotype","score_opus":0.058803022280181895,"score_gpt":0.3948959696089704,"score_spread":0.33609294732878847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103129429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93935245,0.052644223,0.0013998044,0.0052570025,0.00015950552,0.0010594538,0.00004460465,0.00003653779,0.000046436766],"genre_scores_gemma":[0.82389295,0.17351809,0.0016360666,0.000110556866,0.00011072662,0.00026654958,0.00011892084,0.000012089716,0.00033407222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818623,0.00039726755,0.0004943557,0.0005453659,0.000103998194,0.00027277757],"domain_scores_gemma":[0.99893427,0.000093304574,0.0004182394,0.0002948347,0.00013201742,0.00012735666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089813187,0.00016323621,0.00037273535,0.00017418721,0.000131063,0.000007321899,0.000041470976,0.00015678261,0.000022321403],"category_scores_gemma":[0.0001858121,0.00013478944,0.00005752071,0.00019517481,0.00018568993,0.00025168207,0.000023620803,0.00012404223,9.775767e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013074841,0.00006145987,0.617116,0.00009242872,0.00022596761,0.0000027630647,0.00015317276,0.000024670366,0.016596572,0.00008271461,0.0006140283,0.36372277],"study_design_scores_gemma":[0.0019071648,0.0007007979,0.98199016,0.00024534896,0.00031914611,0.0000099880845,0.00005533947,0.0013210967,0.0028861794,0.010051014,0.00039305704,0.00012068449],"about_ca_topic_score_codex":0.001274342,"about_ca_topic_score_gemma":0.00014679546,"teacher_disagreement_score":0.3648742,"about_ca_system_score_codex":0.00016213843,"about_ca_system_score_gemma":0.00015709567,"threshold_uncertainty_score":0.5496554},"labels":[],"label_agreement":null},{"id":"W2103289610","doi":"10.1210/endo.141.12.7818","title":"A Comparative Study of Hormonal Regulation of Three Secretory Proteins (Prostatic Secretory Protein-PSP94, Probasin, and Seminal Vesicle Secretion II) in Rat Lateral Prostate**This work was supported by an RGC Earmarked Research Grant (CUHK 4131/00M) from the Hong Kong Research Grant Council (to F.L.C.) and a grant from the Medical Research Council of Canada (to J.W.X.).","year":2000,"lang":"en","type":"article","venue":"Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"Chinese University of Hong Kong; University of Hong Kong","keywords":"Endocrinology; Internal medicine; Androgen; Dihydrotestosterone; Biology; Testosterone (patch); Seminal vesicle; In situ hybridization; Secretory protein; Messenger RNA; Secretion; Hormone; Prostate; Medicine; Gene; Biochemistry","score_opus":0.12440488321069852,"score_gpt":0.34282528574434973,"score_spread":0.2184204025336512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103289610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97932845,0.0023596429,0.0000037506006,0.0057913586,0.00006126844,0.0119113745,0.00036405877,0.000019619329,0.00016049316],"genre_scores_gemma":[0.9969059,0.000259693,0.00010317295,0.00005072645,0.00011092647,0.0016289745,0.00017395313,0.000048440732,0.00071818253],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.98340327,0.004283376,0.0011599741,0.0011269012,0.008508554,0.0015179164],"domain_scores_gemma":[0.99192846,0.0020669715,0.00018696659,0.0009131047,0.0043421374,0.0005623538],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010914618,0.00038223818,0.0010265769,0.00031700762,0.00079661066,0.000054575165,0.000606435,0.0002025412,0.0004476856],"category_scores_gemma":[0.0016334498,0.0002477957,0.000054299755,0.0017688107,0.0024214108,0.00018385556,0.00049366255,0.0021092908,0.000003525952],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07873482,0.0054379315,0.26276234,0.00061000924,0.0011167842,0.0013017361,0.25698313,0.0000460499,0.3516617,0.00009969035,0.026936283,0.014309511],"study_design_scores_gemma":[0.01868614,0.020122895,0.878875,0.0025482345,0.0001312977,0.000055811513,0.031945083,0.0023206666,0.037817597,0.001671625,0.005243425,0.0005822147],"about_ca_topic_score_codex":0.44639692,"about_ca_topic_score_gemma":0.43495348,"teacher_disagreement_score":0.61611265,"about_ca_system_score_codex":0.002257662,"about_ca_system_score_gemma":0.0114698475,"threshold_uncertainty_score":0.99999744},"labels":[],"label_agreement":null},{"id":"W2103407911","doi":"10.1002/jcph.564","title":"Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer","year":2015,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Astellas Pharma; Pfizer","keywords":"Abiraterone acetate; Pharmacokinetics; Prostate cancer; Medicine; Meal; Prednisone; Endocrinology; Internal medicine; Adverse effect; Cancer; Androgen deprivation therapy","score_opus":0.09995530838740403,"score_gpt":0.4608467841323652,"score_spread":0.36089147574496117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103407911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887092,0.0019946299,0.0000038729454,0.0077146585,0.0006431681,0.0008699388,0.000010986731,0.000004796094,0.000048712503],"genre_scores_gemma":[0.994802,0.0021958994,0.000094687064,0.0024899067,0.0003263832,0.00001961522,0.000003113328,0.000017212384,0.000051171675],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9977567,0.00073836907,0.0006899574,0.00013316302,0.00039987915,0.00028192092],"domain_scores_gemma":[0.9979026,0.00088836486,0.00038725894,0.000080859085,0.00035800601,0.0003829211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015334446,0.00014103181,0.00052927836,0.00011712055,0.000040780797,0.0000087702365,0.00009070396,0.000042435157,0.0000213848],"category_scores_gemma":[0.00013229555,0.0000698016,0.00004250585,0.00017622049,0.00020061553,0.00007373383,0.000027549724,0.00065758004,0.0000029902808],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.527475,0.0046600807,0.41251495,0.00066689664,0.002037388,0.0010274432,0.0019572047,0.0007752044,0.0044807056,0.0000111182735,0.01064682,0.033747155],"study_design_scores_gemma":[0.16999131,0.14718673,0.6657205,0.0004443104,0.0017467388,0.00010290612,0.0002041651,0.00024973063,0.011263317,0.0002446766,0.0025963683,0.00024920964],"about_ca_topic_score_codex":0.000018429646,"about_ca_topic_score_gemma":0.000032770666,"teacher_disagreement_score":0.3574837,"about_ca_system_score_codex":0.00012060667,"about_ca_system_score_gemma":0.0006730133,"threshold_uncertainty_score":0.28568947},"labels":[],"label_agreement":null},{"id":"W2103449692","doi":"10.1038/sj.pcan.4500674","title":"Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues","year":2003,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada","keywords":"Medicine; Prostatectomy; Immunohistochemistry; Prostate cancer; Pathology; Immunostaining; Kallikrein; Intraepithelial neoplasia; Prostate; Cancer; High-grade prostatic intraepithelial neoplasia; PCA3; Internal medicine; Biology","score_opus":0.016526133277327156,"score_gpt":0.32448141718630363,"score_spread":0.3079552839089765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103449692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9410572,0.056284994,0.000016192924,0.00031012722,0.000028909342,0.0016994716,0.00021181443,0.00002806119,0.00036322293],"genre_scores_gemma":[0.9878087,0.00973037,0.00015551572,0.00009019093,0.000014099946,0.00041516972,0.00016107054,0.000035779132,0.0015891242],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983846,0.00007628327,0.00042277027,0.00046449114,0.0002778865,0.00037397817],"domain_scores_gemma":[0.99919957,0.00008485183,0.00011175885,0.00017959444,0.00014574514,0.00027849973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015995555,0.00025545346,0.0004837253,0.0001692926,0.00012516932,0.000051866755,0.000038873484,0.00006282082,0.0001203626],"category_scores_gemma":[0.00011029228,0.00020232308,0.000032951302,0.00024620577,0.0005327926,0.00016114856,0.00004625194,0.00011439415,0.00000103372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023917588,0.00080218015,0.93249977,0.007616428,0.00023939274,0.00017240524,0.009556738,0.000016298236,0.020174796,0.0015113306,0.00061155594,0.024407376],"study_design_scores_gemma":[0.06827838,0.013948949,0.5980912,0.014456098,0.0033940068,0.0003553533,0.01461664,0.0043844907,0.20969206,0.054489583,0.014247208,0.0040460797],"about_ca_topic_score_codex":0.0002792901,"about_ca_topic_score_gemma":0.00004080734,"teacher_disagreement_score":0.33440858,"about_ca_system_score_codex":0.000088969646,"about_ca_system_score_gemma":0.00024939413,"threshold_uncertainty_score":0.8250496},"labels":[],"label_agreement":null},{"id":"W2103934194","doi":"10.1158/0008-5472.can-10-2470","title":"Insulin Increases <i>De Novo</i> Steroidogenesis in Prostate Cancer Cells","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; University of British Columbia","funders":"Prostate Cancer Foundation of Australia; National Cancer Institute; Prostate Cancer Foundation; American Association for Cancer Research","keywords":"Prostate cancer; Endocrinology; Dihydrotestosterone; Internal medicine; Androgen deprivation therapy; Insulin; Downregulation and upregulation; Testosterone (patch); Medicine; Cancer; Androgen; Androgen receptor; Prostate; Cancer research; Biology; Hormone","score_opus":0.13231598041086023,"score_gpt":0.4080896529445855,"score_spread":0.27577367253372526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103934194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778696,0.015708644,0.0000016288411,0.0009789933,0.0001132756,0.001328471,0.00012984533,0.000053536147,0.0038160349],"genre_scores_gemma":[0.959837,0.030269107,0.00014430373,0.00025293662,0.000232229,0.0019569122,0.00001785495,0.000068337744,0.0072212885],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967294,0.00027992565,0.0003166171,0.00057213183,0.0008285255,0.0012734452],"domain_scores_gemma":[0.9984388,0.000118255215,0.000043035998,0.00046422408,0.00045062782,0.00048507145],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010644092,0.00021840874,0.00037590394,0.0005696743,0.00014895636,0.00004037845,0.00028998428,0.00011764277,0.0019413772],"category_scores_gemma":[0.0000711299,0.00017461053,0.00008350272,0.0012423334,0.00039162426,0.00014799445,0.00019539085,0.00070101913,0.00013424378],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009467127,0.0015964255,0.50702673,0.0009097586,0.00024637443,0.0021865754,0.006249544,0.000016604758,0.4188681,0.00007011762,0.0062155602,0.047147058],"study_design_scores_gemma":[0.007467611,0.0007818648,0.10777494,0.0008912424,0.00005216544,0.000033775108,0.0009872912,0.000043577063,0.869948,0.0002776023,0.011386092,0.00035583568],"about_ca_topic_score_codex":0.024712564,"about_ca_topic_score_gemma":0.002051751,"teacher_disagreement_score":0.4510799,"about_ca_system_score_codex":0.0012787638,"about_ca_system_score_gemma":0.002107412,"threshold_uncertainty_score":0.998971},"labels":[],"label_agreement":null},{"id":"W2104762821","doi":"10.1097/01.ju.0000141580.30910.57","title":"CELL LINES USED IN PROSTATE CANCER RESEARCH: A COMPENDIUM OF OLD AND NEW LINES—PART 1","year":2005,"lang":"en","type":"review","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":355,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Compendium; Medicine; Prostate cancer; Cancer cell lines; Prostate; Cancer; Cell culture; Cancer research; Oncology; Internal medicine; Genetics; Cancer cell; Archaeology","score_opus":0.2579289734385583,"score_gpt":0.47416160080959235,"score_spread":0.21623262737103405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104762821","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0068180226,0.98687416,5.999691e-7,0.0051314025,0.00018427863,0.00081775204,0.000022528136,0.0000030720007,0.00014816942],"genre_scores_gemma":[0.0009315826,0.9929396,0.000038086106,0.00008238934,0.0009652351,0.000014350834,0.000009147989,0.000036434754,0.0049831555],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972362,0.000774768,0.00091989985,0.00016512735,0.00046356526,0.00044043426],"domain_scores_gemma":[0.99782914,0.0007972852,0.0005885531,0.00026676097,0.00031084925,0.0002074279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002148265,0.00023085847,0.0016725365,0.00066982594,0.00004423566,0.000009446748,0.000297343,0.00019824882,0.00014836904],"category_scores_gemma":[0.00011354268,0.00011575426,0.00018201956,0.00045750255,0.00036665623,0.00004687713,0.00013124911,0.0016447037,0.000009166339],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054053185,0.0007368523,0.0018017859,0.013977207,0.0009723736,0.0009705524,0.0024205365,0.000031763084,0.000229237,0.000025074729,0.031929757,0.94149953],"study_design_scores_gemma":[0.0028171237,0.0015466843,0.00012145569,0.003446623,0.0007701002,0.0006657384,0.000052039766,0.000005895793,0.000045296358,0.000054573367,0.99038595,0.000088496075],"about_ca_topic_score_codex":0.00026472128,"about_ca_topic_score_gemma":0.00014182413,"teacher_disagreement_score":0.9584562,"about_ca_system_score_codex":0.00013929608,"about_ca_system_score_gemma":0.001978044,"threshold_uncertainty_score":0.71455103},"labels":[],"label_agreement":null},{"id":"W2104957891","doi":"10.1038/aja.2013.13","title":"The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing","year":2013,"lang":"en","type":"review","venue":"Asian Journal of Andrology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada; Prostate Cancer Foundation","keywords":"Chromothripsis; Prostate cancer; Biology; Context (archaeology); Chromoplexy; Transcriptome; Copy-number variation; Cancer; Computational biology; Genomics; Genetic heterogeneity; Genome; Genetics; Bioinformatics; Genome instability; Gene; Phenotype; PCA3; Gene expression","score_opus":0.1772156237958015,"score_gpt":0.40927600011300425,"score_spread":0.23206037631720275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104957891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020366253,0.9775758,0.000042398675,0.00069574476,0.00042021048,0.0007424949,0.000015316873,0.0000021786582,0.00013960405],"genre_scores_gemma":[0.012721157,0.9865583,0.00011047175,0.000037106183,0.00017618567,0.000069981295,0.00003241079,0.000018513485,0.00027584893],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982664,0.00031263457,0.0007832447,0.00015904903,0.0002254622,0.0002531842],"domain_scores_gemma":[0.99876547,0.000047555153,0.00063655514,0.00019961242,0.00027162337,0.00007918632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034714007,0.00017859752,0.0009015021,0.0001742947,0.00008907157,0.000037746016,0.00014911595,0.0001325235,0.00005397676],"category_scores_gemma":[0.000042491458,0.00010011893,0.00030041733,0.00020960311,0.00015472845,0.00016940889,0.000038023936,0.0004474512,0.0000053751655],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001922233,0.000103044855,0.00033168882,0.0020370055,0.001410706,0.0011297626,0.0015043532,0.000025874107,0.0014971243,0.0001570277,0.0007031842,0.990908],"study_design_scores_gemma":[0.014728693,0.0077435924,0.000496529,0.031453677,0.009991043,0.009496623,0.0034886678,0.00021345358,0.011477941,0.0014194694,0.90814906,0.0013412288],"about_ca_topic_score_codex":0.00009761569,"about_ca_topic_score_gemma":0.00012841338,"teacher_disagreement_score":0.9895668,"about_ca_system_score_codex":0.0002626227,"about_ca_system_score_gemma":0.0009757678,"threshold_uncertainty_score":0.40827316},"labels":[],"label_agreement":null},{"id":"W2105616386","doi":"10.1158/0008-5472.can-06-3591","title":"A Common 8q24 Variant in Prostate and Breast Cancer from a Large Nested Case-Control Study","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical","funders":"National Cancer Institute","keywords":"Prostate cancer; Breast cancer; Medicine; Oncology; Nested case-control study; Internal medicine; Case-control study; Minor allele frequency; Prostate; Confidence interval; Genotype; Gynecology; Cohort; Cancer; Single-nucleotide polymorphism; Allele; Biology; Genetics; Gene","score_opus":0.05620664064524062,"score_gpt":0.43526204054601153,"score_spread":0.3790553999007709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105616386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98473763,0.007067726,0.000010429222,0.003018938,0.00011149355,0.003703433,0.001022254,0.000044405184,0.0002837092],"genre_scores_gemma":[0.9962285,0.001052887,0.000015769638,0.00016515255,0.0003030438,0.0009853827,0.000021848566,0.00005419356,0.0011731933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963295,0.0003839744,0.00039489963,0.00068347395,0.0009091842,0.0012989846],"domain_scores_gemma":[0.998148,0.00044632354,0.00004936696,0.00045133356,0.0004079246,0.0004970248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028813842,0.00023591229,0.00052374584,0.00055113767,0.0002774599,0.00008956397,0.00014785871,0.00011030788,0.0006635474],"category_scores_gemma":[0.00005731402,0.00017790981,0.0000486819,0.0011069712,0.00022570582,0.00014756467,0.00017056342,0.0010438995,0.000017383234],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008290969,0.0012389751,0.8908111,0.00013064432,0.0003288804,0.057659853,0.005092768,0.00000331626,0.0036148203,0.000022301494,0.00045638287,0.03234999],"study_design_scores_gemma":[0.023324782,0.00079951994,0.9664295,0.00043172267,0.00010629811,0.0009924099,0.005742605,0.0003560056,0.0006322096,0.00010391298,0.00084449595,0.00023656711],"about_ca_topic_score_codex":0.052680217,"about_ca_topic_score_gemma":0.048236713,"teacher_disagreement_score":0.07561837,"about_ca_system_score_codex":0.0009279744,"about_ca_system_score_gemma":0.00074030925,"threshold_uncertainty_score":0.96913046},"labels":[],"label_agreement":null},{"id":"W2106446521","doi":"10.1210/me.2014-1078","title":"Crosstalk Between Nuclear MET and SOX9/β-Catenin Correlates with Castration-Resistant Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Molecular Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute on Minority Health and Health Disparities; National Center for Advancing Translational Sciences; National Center for Research Resources; National Cancer Institute; National Institutes of Health","keywords":"Prostate cancer; LNCaP; Cancer research; Androgen deprivation therapy; Androgen; Biology; Homeobox protein NANOG; Internal medicine; Medicine; Endocrinology; Cancer; Hormone; Gene","score_opus":0.013759787582480415,"score_gpt":0.29072629294387375,"score_spread":0.27696650536139333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106446521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937399,0.0017348402,0.00005458147,0.0026446027,0.000040795792,0.000468391,0.000028117322,0.000072148854,0.0012166104],"genre_scores_gemma":[0.9979619,0.0002902024,0.00050080445,0.00020642427,0.000046968595,0.00007791106,0.00006098246,0.00004325746,0.00081155385],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99866074,0.00006859275,0.00017746272,0.00038333476,0.00019581466,0.0005140403],"domain_scores_gemma":[0.99940354,0.00004109426,0.00005954365,0.0002202414,0.00010735179,0.00016821484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059331174,0.00019361412,0.00033257218,0.00011074562,0.0001324893,0.000039807117,0.00006909463,0.00007119868,0.00007777626],"category_scores_gemma":[0.000023830953,0.0001384076,0.000041932515,0.00013325685,0.000349367,0.000052771302,0.000062158855,0.00023881938,0.000024476109],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003332859,0.00022600408,0.39639947,0.0003631896,0.0015175366,0.002983798,0.0013395936,0.000077716,0.5290669,0.008090076,0.0005547377,0.056048125],"study_design_scores_gemma":[0.031115904,0.013121162,0.41451937,0.00047850583,0.001678325,0.0014020127,0.000924961,0.00051407254,0.47218183,0.0022947956,0.06037497,0.0013940757],"about_ca_topic_score_codex":0.00028989938,"about_ca_topic_score_gemma":0.000045272052,"teacher_disagreement_score":0.05982023,"about_ca_system_score_codex":0.000064666856,"about_ca_system_score_gemma":0.00010377125,"threshold_uncertainty_score":0.56440985},"labels":[],"label_agreement":null},{"id":"W2106556127","doi":"10.1016/j.ijrobp.2014.04.052","title":"Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy","year":2014,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":146,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Receiver operating characteristic; Prostatectomy; Nomogram; Cumulative incidence; Hazard ratio; Radiation therapy; Internal medicine; Proportional hazards model; Incidence (geometry); Urology; Area under the curve; Oncology; Nuclear medicine; Gastroenterology; Cancer; Confidence interval; Cohort","score_opus":0.01639347299094469,"score_gpt":0.3279302965722462,"score_spread":0.3115368235813015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106556127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99188423,0.0020224736,0.00013504749,0.0048106695,0.0005555247,0.00039753705,0.00011714572,0.000011107901,0.00006624622],"genre_scores_gemma":[0.9940033,0.003541999,0.00040866536,0.0009931749,0.000735978,0.000052640684,0.00019641247,0.000020307632,0.00004753176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864554,0.00022130676,0.0004606461,0.00022235278,0.00024222616,0.00020791966],"domain_scores_gemma":[0.9987026,0.00015945772,0.0003712752,0.00008494328,0.00055682287,0.00012493435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032153938,0.0001698313,0.00035985358,0.00019300687,0.0000384878,0.000027973854,0.00012524064,0.00016252502,0.0000567978],"category_scores_gemma":[0.00013173406,0.00012581112,0.00008978995,0.0001187505,0.00017815808,0.00023959322,0.0000392754,0.00035868623,0.0000060792518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021742582,0.00036051235,0.8431758,0.000006167259,0.00034686195,0.000012424777,0.0006170023,0.000037683018,0.004660775,0.0001901099,0.0007580477,0.14766033],"study_design_scores_gemma":[0.01981456,0.0024339536,0.94119257,0.00007783488,0.000075974844,0.000020255828,0.000053606447,0.00077078055,0.007962421,0.0011497112,0.026277695,0.00017061435],"about_ca_topic_score_codex":0.00002105986,"about_ca_topic_score_gemma":0.000006179968,"teacher_disagreement_score":0.14748971,"about_ca_system_score_codex":0.0006959782,"about_ca_system_score_gemma":0.0004023928,"threshold_uncertainty_score":0.51304287},"labels":[],"label_agreement":null},{"id":"W2106579630","doi":"10.1021/pr8003216","title":"Proteomic Analysis of Conditioned Media from the PC3, LNCaP, and 22Rv1 Prostate Cancer Cell Lines: Discovery and Validation of Candidate Prostate Cancer Biomarkers","year":2008,"lang":"en","type":"article","venue":"Journal of Proteome Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Prostate cancer; LNCaP; PCA3; Metastasis; Cancer biomarkers; Cancer; Prostate; Medicine; Cancer research; Prostate-specific antigen; Rectal examination; Oncology; Internal medicine","score_opus":0.05160757722274463,"score_gpt":0.36993922949568564,"score_spread":0.318331652272941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106579630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810783,0.012847664,0.000013942464,0.0030758157,0.000056846642,0.002096885,0.00079174346,0.000004628587,0.00003414388],"genre_scores_gemma":[0.95053643,0.048115917,0.00027008285,0.000015431575,0.00014564495,0.00024363252,0.00008751277,0.000025849673,0.00055949314],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996615,0.000415201,0.0008046079,0.00030604962,0.001433159,0.0004259843],"domain_scores_gemma":[0.9969502,0.0004250787,0.00062183925,0.000284863,0.001469359,0.000248651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017672924,0.0001980245,0.00075129303,0.00068502926,0.00022782621,0.00005480789,0.00018798972,0.000103566985,0.00016446442],"category_scores_gemma":[0.00026383233,0.000114368355,0.00016281859,0.0013454325,0.0010075478,0.00048544278,0.00012154752,0.000521992,6.5674107e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006119617,0.00026306757,0.47429687,0.0005401703,0.003071847,0.00010461622,0.00637756,0.000053046955,0.5071471,0.000002711286,0.0007515231,0.0012718834],"study_design_scores_gemma":[0.005965452,0.00095118623,0.39622414,0.0008365609,0.0010564622,0.00002807068,0.0014431378,0.0003499903,0.59272623,0.00017714658,0.00008714254,0.00015447426],"about_ca_topic_score_codex":0.008062133,"about_ca_topic_score_gemma":0.00031464378,"teacher_disagreement_score":0.085579164,"about_ca_system_score_codex":0.00029936506,"about_ca_system_score_gemma":0.001525985,"threshold_uncertainty_score":0.99854326},"labels":[],"label_agreement":null},{"id":"W2106982669","doi":"10.1373/clinchem.2014.221457","title":"Hypothetical Structure of Prostate-Specific Antigen","year":2014,"lang":"en","type":"article","venue":"Clinical Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Prostate-specific antigen; Antigen; Prostate; Computational biology; Medicine; Biology; Internal medicine; Immunology; Cancer","score_opus":0.048406086587149635,"score_gpt":0.37470494975744534,"score_spread":0.3262988631702957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106982669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99156445,0.00037781894,0.00001031848,0.000824968,0.00007273446,0.00014576227,0.000021424312,0.000028804445,0.006953742],"genre_scores_gemma":[0.9966989,0.000321553,0.00044386764,0.00008094146,0.00037354731,0.0000025949944,0.00005498298,0.000016574717,0.0020070486],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988641,0.000027696358,0.0003877512,0.0002729045,0.00023376055,0.00021377507],"domain_scores_gemma":[0.99904233,0.00018297287,0.000067711,0.00037498906,0.000109787296,0.00022220457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018299096,0.00010625244,0.00034404872,0.000011254703,0.000025601652,0.000006948434,0.00010048645,0.0001870434,0.000632914],"category_scores_gemma":[0.00026770585,0.00007430035,0.00014459473,0.00008734346,0.00040605644,0.000015328447,0.000048289985,0.00033412507,0.000023959738],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019409755,0.00068721175,0.51686406,0.0005862254,0.00015202287,0.00004341785,0.000055997563,7.987277e-7,0.43966547,0.00013929523,0.0076984535,0.032166086],"study_design_scores_gemma":[0.0046054344,0.000555931,0.06282285,0.00014521184,0.000046713583,0.000025293079,0.000037835835,0.0000635164,0.8488721,0.0010365733,0.081622206,0.00016630114],"about_ca_topic_score_codex":8.007407e-7,"about_ca_topic_score_gemma":8.448654e-8,"teacher_disagreement_score":0.4540412,"about_ca_system_score_codex":0.00002138382,"about_ca_system_score_gemma":0.000090341055,"threshold_uncertainty_score":0.6929965},"labels":[],"label_agreement":null},{"id":"W2107023460","doi":"10.1016/j.urology.2014.02.001","title":"Maximal Testosterone Suppression in Prostate Cancer—Free vs Total Testosterone","year":2014,"lang":"en","type":"review","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Ferring Pharmaceuticals; Sanofi; GlaxoSmithKline; Janssen Pharmaceuticals; Genentech; Bayer; Astellas Pharma; Astellas Pharma US; Amgen","keywords":"Medicine; Testosterone (patch); Prostate cancer; Prostate; Urology; Internal medicine; Free testosterone; Cancer; Oncology; Gynecology; Endocrinology; Androgen; Hormone; Sex hormone-binding globulin","score_opus":0.042422743991676455,"score_gpt":0.36063088074421445,"score_spread":0.318208136752538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107023460","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00090485794,0.99283314,0.000003176555,0.0018338002,0.00057484827,0.002451796,0.00019113817,0.000081942875,0.0011252933],"genre_scores_gemma":[0.0005990915,0.9901297,0.0000584635,0.00025558996,0.00043962352,0.001094451,0.0006194623,0.00012939575,0.006674211],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966108,0.00033635518,0.00077977625,0.00089930964,0.0003710191,0.0010027181],"domain_scores_gemma":[0.99812186,0.00027737024,0.00028097729,0.00095262245,0.000082533654,0.0002846166],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031680972,0.0006239685,0.0026545688,0.0005779047,0.00006947692,0.000024300063,0.00036656647,0.00059035915,0.00044259743],"category_scores_gemma":[0.00017288484,0.0004318937,0.0002689511,0.00039612185,0.0002744304,0.000070382885,0.00047150315,0.0011856977,0.00024242581],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012949461,0.00037587853,0.0013345322,0.017032446,0.00024762878,0.0012085004,0.00013294596,0.0000031881507,0.000029469977,0.000015007209,0.0072343936,0.9710911],"study_design_scores_gemma":[0.0043444196,0.0028297598,0.00041874227,0.005286366,0.00074678584,0.0008120959,0.0000046819882,0.00002971026,0.000011905831,0.00004401782,0.98508936,0.0003821541],"about_ca_topic_score_codex":0.00016877343,"about_ca_topic_score_gemma":0.00009203664,"teacher_disagreement_score":0.97785497,"about_ca_system_score_codex":0.0004035138,"about_ca_system_score_gemma":0.00078496616,"threshold_uncertainty_score":0.99981326},"labels":[],"label_agreement":null},{"id":"W2107491914","doi":"10.2967/jnumed.110.084582","title":"In Vivo Imaging of Intraprostatic-Specific Gene Transcription by PET","year":2011,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Congressionally Directed Medical Research Programs; National Cancer Institute; Canadian Institutes of Health Research; Université Laval","keywords":"In vivo; Reporter gene; Prostate cancer; Cancer research; Thymidine kinase; Promoter; Cancer; Molecular biology; LNCaP; Gene; Chemistry; Biology; Gene expression; Herpes simplex virus; Virology; Virus; Genetics; Biochemistry","score_opus":0.03676147486810809,"score_gpt":0.29564449986742686,"score_spread":0.25888302499931876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107491914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815426,0.005746481,0.00007341468,0.008228438,0.00032985085,0.0002115339,0.0000076223373,0.000007257726,0.003852802],"genre_scores_gemma":[0.9927724,0.005210574,0.0011085712,0.00045026184,0.00020086924,8.9924436e-7,0.0000024465892,0.000024068788,0.0002298834],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998693,0.000042254058,0.0005533406,0.000099576595,0.00042554125,0.0001862689],"domain_scores_gemma":[0.9992901,0.000025151845,0.00020946613,0.00011966366,0.00020023799,0.0001553904],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047030742,0.0001027053,0.00040598263,0.00032050474,0.000019729992,0.0000028223712,0.00009210925,0.000026288124,0.002191779],"category_scores_gemma":[0.000036154517,0.00006702337,0.00007140493,0.00022037093,0.00019567188,0.00015735794,0.000008369577,0.00027823084,0.000004903294],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023276957,0.0004011175,0.0038538873,0.00010816402,0.000079988786,0.001226231,0.007357715,2.0964663e-7,0.9218235,0.00008264207,0.05815435,0.0045845243],"study_design_scores_gemma":[0.08441348,0.020617535,0.114246376,0.0063926266,0.0010181203,0.009711454,0.022807818,0.0005144535,0.43674886,0.0027270967,0.30005404,0.00074814504],"about_ca_topic_score_codex":0.000058058213,"about_ca_topic_score_gemma":0.0000012908727,"teacher_disagreement_score":0.4850746,"about_ca_system_score_codex":0.000120647834,"about_ca_system_score_gemma":0.000054839405,"threshold_uncertainty_score":0.99872035},"labels":[],"label_agreement":null},{"id":"W2107529812","doi":"10.1158/1078-0432.ccr-13-1100","title":"Importance of 5α-Reductase Gene Polymorphisms on Circulating and Intraprostatic Androgens in Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Canadian Institutes of Health Research","keywords":"Dihydrotestosterone; Androsterone; Prostate cancer; Endocrinology; Internal medicine; Testosterone (patch); Androgen; Biology; Linkage disequilibrium; Prostate; Cancer; Allele; Hormone; Medicine; Genetics; Gene; Steroid; Haplotype","score_opus":0.18140556058099866,"score_gpt":0.5032266453304121,"score_spread":0.3218210847494134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107529812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98152786,0.00856367,5.8111345e-7,0.007227862,0.00011634691,0.0021131816,0.00008789334,0.000019910824,0.00034271195],"genre_scores_gemma":[0.9872395,0.01001216,0.00016369176,0.00031673032,0.00021328212,0.0010512584,0.000028766965,0.00004558581,0.0009290723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963639,0.00030959237,0.0008762934,0.0007107023,0.0008824462,0.0008570975],"domain_scores_gemma":[0.997729,0.00064131897,0.00014045805,0.00046932188,0.00052544504,0.00049447943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017376982,0.00020691127,0.00063544343,0.0003523977,0.00011602296,0.000041011637,0.00015906346,0.00012233133,0.0006835793],"category_scores_gemma":[0.0005595718,0.00015539395,0.000102097685,0.000855066,0.0009814947,0.00012900395,0.00014230204,0.0010291025,0.000027545875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001341401,0.00049434055,0.90797585,0.00030743438,0.00013204174,0.00024376865,0.00047464407,0.000014188185,0.02273081,0.000050784645,0.0013406251,0.064894095],"study_design_scores_gemma":[0.007839046,0.0019953712,0.9567661,0.0010877642,0.000049497463,0.00002569603,0.00038498762,0.0008899771,0.029211812,0.0011609434,0.00030200317,0.00028678938],"about_ca_topic_score_codex":0.0033888454,"about_ca_topic_score_gemma":0.00028341662,"teacher_disagreement_score":0.06460731,"about_ca_system_score_codex":0.00033514682,"about_ca_system_score_gemma":0.0010229815,"threshold_uncertainty_score":0.7484714},"labels":[],"label_agreement":null},{"id":"W2108743117","doi":"10.1111/j.1464-410x.2007.06596.x","title":"The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight","year":2006,"lang":"en","type":"review","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Quality of life (healthcare); Prostate-specific antigen; Clinical trial; Hormonal therapy; Internal medicine; Oncology; Randomized controlled trial; Urology; Cancer","score_opus":0.054748021978365286,"score_gpt":0.38582922988477797,"score_spread":0.3310812079064127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108743117","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015692948,0.9943104,0.00008550878,0.0014251552,0.00066736294,0.0017727219,0.00012815467,0.000006462885,0.000034975616],"genre_scores_gemma":[0.0010341445,0.9977509,0.00003953297,0.00007338457,0.00059986854,0.00018661983,0.00007712009,0.000049674367,0.00018876838],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975198,0.00028667192,0.0010726632,0.00021440371,0.0003611507,0.0005452915],"domain_scores_gemma":[0.9973767,0.0004943838,0.0012613107,0.0001977622,0.0005591694,0.00011070519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083837897,0.0002319411,0.0010722796,0.00013480255,0.00021723779,0.00006238505,0.00030126644,0.0001327445,0.000012169485],"category_scores_gemma":[0.00009490416,0.00012382392,0.000598298,0.00019622824,0.00025710478,0.00005375659,0.00005965394,0.00079737627,9.398758e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003285576,0.00012461425,0.00029050183,0.0013076793,0.00066246995,0.00007777038,0.000045593202,0.000005141064,0.0000017790088,0.00002057338,0.003627782,0.99350756],"study_design_scores_gemma":[0.002233219,0.0007944679,0.0009791552,0.0036840788,0.00073580386,0.0016614143,0.000017865308,0.000008487858,0.0000104485525,0.00045959174,0.98932165,0.00009379985],"about_ca_topic_score_codex":0.000106902524,"about_ca_topic_score_gemma":0.00007709453,"teacher_disagreement_score":0.99341375,"about_ca_system_score_codex":0.00026518496,"about_ca_system_score_gemma":0.0013890342,"threshold_uncertainty_score":0.5049393},"labels":[],"label_agreement":null},{"id":"W2108830038","doi":"10.1016/j.eururo.2013.06.038","title":"Intermittent Androgen Deprivation Therapy: Clarity from Confusion","year":2013,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre","funders":"","keywords":"Medicine; Androgen deprivation therapy; Gynecomastia; Libido; Prostate cancer; Adverse effect; Androgen; Internal medicine; Erectile dysfunction; Sexual dysfunction; Endocrinology; Testosterone (patch); Estrogen; Antiandrogens; Hormone; Antiandrogen; Cancer","score_opus":0.045858137463887436,"score_gpt":0.28477856026545945,"score_spread":0.238920422801572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108830038","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21343084,0.0034729596,0.000052403782,0.7583541,0.0007286754,0.0010915293,0.00007434244,0.00015842421,0.02263668],"genre_scores_gemma":[0.060946405,0.0021589773,0.00009784074,0.91415584,0.005551352,0.000042088093,0.0054827104,0.00015283132,0.011411963],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997948,0.00057244144,0.00028257127,0.00054687436,0.0002613624,0.00038873183],"domain_scores_gemma":[0.9989827,0.000107248576,0.00013034334,0.00056707923,0.00012471518,0.000087886365],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00016523944,0.00028036063,0.0004040292,0.00015062385,0.00007052824,0.000035181652,0.00022681787,0.0004097861,0.002048232],"category_scores_gemma":[0.000041199153,0.00020193057,0.00013869237,0.0000669356,0.00015667947,0.00003947764,0.00018057531,0.0017199883,0.0020807125],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026432282,0.00006410408,0.00534769,0.000023961273,0.00028599094,0.002661611,0.0001616002,9.467242e-8,0.001622781,0.0000023437947,0.9549418,0.034623712],"study_design_scores_gemma":[0.0021468513,0.00063530245,0.04793067,0.00002713776,0.000083202256,0.00005652142,0.000003838217,0.000020743923,0.00027085,0.00009942105,0.9485641,0.00016135057],"about_ca_topic_score_codex":0.00013807371,"about_ca_topic_score_gemma":0.0000018848905,"teacher_disagreement_score":0.15580168,"about_ca_system_score_codex":0.00007692574,"about_ca_system_score_gemma":0.00007704113,"threshold_uncertainty_score":0.99886405},"labels":[],"label_agreement":null},{"id":"W2108922654","doi":"10.1016/j.ejso.2015.06.011","title":"Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years","year":2015,"lang":"en","type":"article","venue":"European Journal of Surgical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Comorbidity; Hazard ratio; Prostatectomy; Internal medicine; Proportional hazards model; Epidemiology; Cancer; Prospective cohort study; Confidence interval; Oncology","score_opus":0.06082732432159396,"score_gpt":0.3713799595873057,"score_spread":0.31055263526571175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108922654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951423,0.0018380082,0.0000042629963,0.001348418,0.00019152401,0.00037240502,0.000010415785,0.0000055564733,0.0010871544],"genre_scores_gemma":[0.9863483,0.012906184,0.000109602624,0.0003049113,0.00020093848,0.00001279517,0.000014993795,0.000023346178,0.00007897927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976769,0.0006628268,0.0005802831,0.00018270077,0.0006277879,0.00026950415],"domain_scores_gemma":[0.99868155,0.00012389405,0.00026456677,0.00009517328,0.00026257307,0.0005722304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021110298,0.0001336556,0.0004981164,0.00017260388,0.000027629012,0.000014817368,0.00011372625,0.000050984214,0.00019081928],"category_scores_gemma":[0.00010344986,0.0000899191,0.000069135574,0.00023401596,0.00019244089,0.00011218077,0.000060289654,0.00046526495,0.000008718927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045056255,0.0008301262,0.8151124,0.000029257788,0.00021274299,0.0089610815,0.0011588435,0.000007796999,0.00015469434,0.0000014943824,0.00092698,0.16809897],"study_design_scores_gemma":[0.03280634,0.0026535378,0.94507617,0.0002146567,0.000059531376,0.0001475023,0.00009081818,0.000080095175,0.00016779474,0.000025446683,0.018577663,0.00010044305],"about_ca_topic_score_codex":0.00014990724,"about_ca_topic_score_gemma":0.00004149872,"teacher_disagreement_score":0.16799852,"about_ca_system_score_codex":0.00029431732,"about_ca_system_score_gemma":0.0008054623,"threshold_uncertainty_score":0.36667946},"labels":[],"label_agreement":null},{"id":"W2109103692","doi":"10.1186/s13059-014-0426-y","title":"Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer","year":2014,"lang":"en","type":"article","venue":"Genome biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada; National Cancer Institute; Prostate Cancer Foundation","keywords":"Biology; Chromothripsis; Prostate cancer; Transcriptome; Chromoplexy; Tumor progression; Genetics; Computational biology; Cancer; Genome instability; Cancer research; Gene; Gene expression; DNA damage; PCA3","score_opus":0.02435837050415369,"score_gpt":0.32156558619721787,"score_spread":0.2972072156930642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109103692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955099,0.0022336063,0.00005104657,0.0012625197,0.00012006528,0.00045788888,0.00011137731,0.000010586072,0.00024300204],"genre_scores_gemma":[0.99827814,0.0009562914,0.00005517824,0.00031526654,0.00009495413,0.00011929268,0.000050393865,0.0000088522065,0.000121639394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990372,0.00020630067,0.0002146875,0.00020009068,0.00007115426,0.00027056417],"domain_scores_gemma":[0.9995449,0.0000635407,0.00006667391,0.00023446619,0.000045018794,0.000045383244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004088098,0.0000980915,0.0002627376,0.00009087595,0.000031389398,0.000003491979,0.00013488058,0.000051236464,0.00008412021],"category_scores_gemma":[0.0000319802,0.000052975614,0.00006186563,0.00014685796,0.00019097055,0.000015576374,0.000023416196,0.00016969904,0.000013169529],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014728713,0.00031476474,0.8055064,0.00019082706,0.00022016659,0.000025270954,0.0036255524,0.000010374421,0.15424177,0.00034398463,0.000105284045,0.033942737],"study_design_scores_gemma":[0.0055284807,0.0025531421,0.9266702,0.000050818002,0.000099602024,0.0000264733,0.00024557425,0.000045064,0.01493735,0.0014286063,0.048248164,0.00016650678],"about_ca_topic_score_codex":0.0015273375,"about_ca_topic_score_gemma":0.00039654734,"teacher_disagreement_score":0.13930443,"about_ca_system_score_codex":0.000056957877,"about_ca_system_score_gemma":0.00005852516,"threshold_uncertainty_score":0.23088875},"labels":[],"label_agreement":null},{"id":"W2109783350","doi":"10.1016/j.eururo.2014.08.025","title":"Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial","year":2014,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate-specific antigen; Quartile; Baseline (sea); Prostate; Internal medicine; Prostatectomy; Oncology; Urology; Confidence interval; Cancer","score_opus":0.028676018643462732,"score_gpt":0.30663772382565424,"score_spread":0.2779617051821915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109783350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9620094,0.0008029576,0.00005943281,0.019196372,0.00025906373,0.0011213993,0.0000120264895,0.000063926134,0.01647543],"genre_scores_gemma":[0.9951292,0.00019846763,0.00003500812,0.0024624125,0.00029987705,0.000026031745,0.00013760236,0.00003514868,0.0016762336],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99755585,0.0011752043,0.00030078937,0.000328703,0.00022739655,0.00041202552],"domain_scores_gemma":[0.9989265,0.00045643456,0.00005654873,0.00043597785,0.00003466505,0.00008985877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015979173,0.00015805756,0.00028116239,0.00009816703,0.00007756768,0.000024120807,0.00021313364,0.00004253311,0.00019127519],"category_scores_gemma":[0.00024560583,0.00008935892,0.00008233524,0.00018345029,0.00015191559,0.000030378562,0.000049600574,0.00031939472,0.0006305654],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19441542,0.0061456016,0.10169838,0.00006712272,0.00028944464,0.0018966391,0.0078768395,0.00004436721,0.013048129,0.00084384414,0.5008081,0.1728661],"study_design_scores_gemma":[0.066288434,0.003770998,0.1023289,0.0000065331524,0.000022678334,0.000016283615,0.00007873915,0.000082003535,0.00020567792,0.000023851795,0.82705146,0.00012444644],"about_ca_topic_score_codex":0.000016241669,"about_ca_topic_score_gemma":0.0000066787834,"teacher_disagreement_score":0.32624337,"about_ca_system_score_codex":0.000022831327,"about_ca_system_score_gemma":0.00003095015,"threshold_uncertainty_score":0.8104853},"labels":[],"label_agreement":null},{"id":"W2109847618","doi":"10.1016/s1470-2045(04)01468-8","title":"Environmental, genetic, and molecular features of prostate cancer","year":2004,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Prostate cancer; Carcinogenesis; Cancer; Disease; Prostate; Oncology; Androgen; Medicine; Stage (stratigraphy); Internal medicine; Cancer research; Biology; Hormone","score_opus":0.052135824976632876,"score_gpt":0.40191947715364446,"score_spread":0.3497836521770116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109847618","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008863409,0.9952945,6.2055767e-7,0.0012293173,0.00008355699,0.0013614305,0.00014592557,0.000012581547,0.0009857445],"genre_scores_gemma":[0.00026634114,0.99772835,0.0002020772,0.00019224102,0.0002021136,0.00033450118,0.00006197307,0.00003566984,0.0009767385],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99884975,0.0001610761,0.00024701713,0.0002576962,0.00017113177,0.00031330742],"domain_scores_gemma":[0.9993019,0.00007790713,0.00017825325,0.000350788,0.000013037658,0.00007808568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016013287,0.00022596809,0.0015357654,0.000063881,0.000042301534,0.0000060438833,0.00015440093,0.00021015368,0.00009086785],"category_scores_gemma":[0.000009776133,0.000116215626,0.00014194184,0.000089197434,0.00043696826,0.0000098422415,0.00012121132,0.00042150504,0.000011181344],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016526498,0.000090467256,0.000113622205,0.011680596,0.0005163084,0.00024111853,0.00018579944,6.7379455e-7,0.000048426235,0.00006729732,0.000893929,0.9859965],"study_design_scores_gemma":[0.0017299934,0.0005158659,0.0006206229,0.0035551924,0.0012096833,0.0002693639,0.000020463938,1.6171099e-7,0.00008624142,0.00014828911,0.9917331,0.000111023815],"about_ca_topic_score_codex":0.00006519017,"about_ca_topic_score_gemma":0.000008270621,"teacher_disagreement_score":0.9908392,"about_ca_system_score_codex":0.00037179654,"about_ca_system_score_gemma":0.0006634532,"threshold_uncertainty_score":0.47391358},"labels":[],"label_agreement":null},{"id":"W2109848380","doi":"10.1002/ijc.21469","title":"Cyclin G‐associated kinase: A novel androgen receptor‐interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer","year":2005,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Transactivation; Androgen receptor; Prostate cancer; Coactivator; Cancer research; Biology; Androgen; Endocrinology; Prostate; Transcription factor; Internal medicine; Cancer; Medicine; Hormone; Gene; Genetics","score_opus":0.03886037253165231,"score_gpt":0.3686972717550236,"score_spread":0.3298368992233713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109848380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9595432,0.02129266,0.000026050351,0.017226268,0.0008661686,0.0002812277,0.0004715405,0.000014474969,0.00027836382],"genre_scores_gemma":[0.98099077,0.015188338,0.00024089885,0.00097193,0.00095997186,0.000056342717,0.000041754094,0.000034944882,0.0015150771],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976775,0.00004391892,0.0005773237,0.00022787791,0.0011637253,0.00030965664],"domain_scores_gemma":[0.9983003,0.00011643783,0.0005040858,0.00009370379,0.0008071336,0.00017831325],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003022932,0.00020041886,0.00036801657,0.00035165477,0.000045259814,0.000060522674,0.0002255004,0.000111600435,0.001486941],"category_scores_gemma":[0.00009062242,0.00016173648,0.00020512858,0.00017011116,0.000066364366,0.0006310926,0.000031528816,0.00060535246,0.000008185448],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012678672,0.002011818,0.16344368,0.00004235467,0.003234897,0.00016837422,0.0039217444,0.0006455892,0.74405277,0.000035399342,0.014908817,0.054855913],"study_design_scores_gemma":[0.04522895,0.00081944786,0.3019885,0.0048707053,0.0003823867,0.00018627972,0.00089475897,0.0012138849,0.26314098,0.0000712072,0.3805547,0.00064818165],"about_ca_topic_score_codex":0.00044026336,"about_ca_topic_score_gemma":0.00019893107,"teacher_disagreement_score":0.48091176,"about_ca_system_score_codex":0.0021501987,"about_ca_system_score_gemma":0.00077355985,"threshold_uncertainty_score":0.9994258},"labels":[],"label_agreement":null},{"id":"W2110253182","doi":"10.1016/s0165-4608(02)00540-x","title":"Resolution of genotypic heterogeneity in prostate tumors using polymerase chain reaction and comparative genomic hybridization on microdissected carcinoma and prostatic intraepithelial neoplasia foci","year":2002,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Canadian Prostate Cancer Research Initiative; Institute for Prostate Cancer Research","keywords":"Biology; Comparative genomic hybridization; Microdissection; Laser capture microdissection; Polymerase chain reaction; Prostate; Molecular biology; Pathology; Intraepithelial neoplasia; Carcinoma; Prostate cancer; Cancer; Chromosome; Genetics; Gene","score_opus":0.06840823650803213,"score_gpt":0.31305077647605195,"score_spread":0.24464253996801982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110253182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761265,0.022603331,0.000029644198,0.0001406063,0.00004726011,0.0009226512,0.000103895836,0.000008842536,0.000017277172],"genre_scores_gemma":[0.98701966,0.0122664375,0.00047528336,0.000043042106,0.00005490604,0.00003664836,0.00003494856,0.000023022547,0.00004604121],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987788,0.00007515469,0.00033048826,0.00037310846,0.00016341139,0.00027903524],"domain_scores_gemma":[0.9994371,0.000026256212,0.00013386203,0.00015032236,0.00010461705,0.00014782534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008450653,0.00020704002,0.00032913854,0.00018751081,0.00010465781,0.00002427781,0.000031504078,0.000069159236,0.00000556343],"category_scores_gemma":[0.0000080524205,0.00019180863,0.000023401622,0.00020150145,0.00022697663,0.000028687358,0.000041633848,0.00013485017,4.0529918e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008075385,0.00013453429,0.3675133,0.00027579008,0.000061324456,0.000025740295,0.0024952246,0.00035414263,0.618936,0.000012414597,0.000010296259,0.009373676],"study_design_scores_gemma":[0.0033673418,0.0010322176,0.57352734,0.00019845623,0.0001246423,0.000077180994,0.00028429236,0.032867867,0.38822132,0.000032007574,0.000052926214,0.00021441674],"about_ca_topic_score_codex":0.00020858465,"about_ca_topic_score_gemma":0.00017704374,"teacher_disagreement_score":0.2307147,"about_ca_system_score_codex":0.00016427107,"about_ca_system_score_gemma":0.000099569515,"threshold_uncertainty_score":0.7821729},"labels":[],"label_agreement":null},{"id":"W2110534364","doi":"10.1056/nejmoa1014618","title":"Abiraterone and Increased Survival in Metastatic Prostate Cancer","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4394,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Université de Montréal; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Abiraterone acetate; Medicine; Prednisone; Prostate cancer; Hazard ratio; Internal medicine; Urology; Clinical endpoint; Placebo; Antiandrogen; Interim analysis; Adverse effect; Androgen deprivation therapy; Oncology; Randomized controlled trial; Cancer; Confidence interval; Pathology","score_opus":0.06641357971523264,"score_gpt":0.3362644191071107,"score_spread":0.26985083939187804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110534364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839194,0.009985796,0.000017433393,0.004460842,0.00024805227,0.00022380162,0.0000031194784,0.000005723314,0.0011358638],"genre_scores_gemma":[0.9921478,0.0057599326,0.00041701965,0.00019280754,0.00066088844,0.000004350431,0.0000037636619,0.00001482083,0.0007985862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987901,0.000101238984,0.00040584925,0.00011403529,0.0003672209,0.00022155033],"domain_scores_gemma":[0.99915576,0.00009031581,0.00014863405,0.00009080187,0.00014544821,0.00036906145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090992404,0.00012690583,0.0005007003,0.00027421134,0.000021613245,0.0000046595583,0.00005717826,0.000028217035,0.00042965636],"category_scores_gemma":[0.00013948345,0.00007003058,0.000028149887,0.00019236935,0.0001419793,0.00009458989,0.000016316144,0.00029212903,0.0000016551243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014157538,0.0003013609,0.7102682,0.00026225726,0.0004343419,0.0038765506,0.01184532,0.0000015229435,0.013144247,0.00008430406,0.0017151567,0.2439092],"study_design_scores_gemma":[0.2470421,0.006753054,0.7253301,0.0019394457,0.0006034303,0.0015180885,0.0013429595,0.0000412402,0.0053820084,0.0016856147,0.008162842,0.00019906502],"about_ca_topic_score_codex":0.002258063,"about_ca_topic_score_gemma":0.00030603344,"teacher_disagreement_score":0.24371013,"about_ca_system_score_codex":0.00006776714,"about_ca_system_score_gemma":0.00032507678,"threshold_uncertainty_score":0.47044358},"labels":[],"label_agreement":null},{"id":"W2111580333","doi":"10.1093/carcin/bgt055","title":"The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial","year":2013,"lang":"en","type":"article","venue":"Carcinogenesis","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"National Cancer Institute; GlaxoSmithKline","keywords":"Prostate cancer; Medicine; Confidence interval; Mutation; Family history; Prostate; Internal medicine; Prostate biopsy; Dutasteride; Cancer; Biopsy; Oncology; Gynecology; Genetics; Biology; Gene","score_opus":0.03338152269047158,"score_gpt":0.30352789075262127,"score_spread":0.2701463680621497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111580333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868338,0.0027477127,0.0000070678657,0.0046906313,0.00012220067,0.0037796663,0.0016892456,0.000025568224,0.00010408834],"genre_scores_gemma":[0.9952441,0.001329962,0.000049640337,0.00012457739,0.00022768704,0.0013977792,0.0003964824,0.00003025981,0.0011995052],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9985123,0.00017384953,0.0003273116,0.00028675364,0.0003903596,0.00030937587],"domain_scores_gemma":[0.997182,0.0013506742,0.00030055447,0.00041225244,0.00065484794,0.000099677345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004886027,0.0001536378,0.0002785959,0.00003456057,0.00034232604,0.000042637646,0.00014758173,0.00007591882,0.000032487987],"category_scores_gemma":[0.00073534943,0.00006937417,0.0001200076,0.0002796829,0.0002009084,0.000058889877,0.000024988223,0.000111581954,0.000005573041],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4258114,0.00079629937,0.2568835,0.0001342345,0.005539119,0.00003665026,0.0154066,0.000057375284,0.04073933,0.000026992222,0.07531558,0.17925291],"study_design_scores_gemma":[0.15441856,0.0025688652,0.6223612,0.0002928546,0.0015085861,0.0000025427155,0.0020773304,0.0010153488,0.21334513,0.00047883263,0.0016709637,0.0002598247],"about_ca_topic_score_codex":0.016996043,"about_ca_topic_score_gemma":0.00049469195,"teacher_disagreement_score":0.36547768,"about_ca_system_score_codex":0.00017032982,"about_ca_system_score_gemma":0.00050216896,"threshold_uncertainty_score":0.9895499},"labels":[],"label_agreement":null},{"id":"W2111879252","doi":"10.1093/annonc/mdt397","title":"Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"Canadian Institutes of Health Research; Swiss Cancer Research Foundation","keywords":"Medicine; Docetaxel; Prostate cancer; Prednisone; Oncology; Clinical trial; Internal medicine; Castration; Cancer; Hormone","score_opus":0.5467539969191952,"score_gpt":0.6379546010847985,"score_spread":0.09120060416560327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111879252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97565055,0.0013902273,0.000021341446,0.018234314,0.000054157146,0.003797765,0.00010138882,0.000008282383,0.0007419555],"genre_scores_gemma":[0.98745936,0.005335207,0.0062841563,0.00028722436,0.00007378146,0.0002247644,0.000018842482,0.000022071394,0.00029461866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.988399,0.005516553,0.0048921034,0.00047592603,0.0004016604,0.00031471605],"domain_scores_gemma":[0.98276573,0.013509342,0.0022802956,0.00025936367,0.00086092466,0.00032432948],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029769542,0.00021789236,0.00406025,0.00018583525,0.000026702117,0.0000124395365,0.00007163746,0.00022375074,0.00004274716],"category_scores_gemma":[0.013769279,0.00011874311,0.00020165333,0.00022886514,0.00064838043,0.00019488936,0.000031912172,0.0003730693,8.9269764e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07143323,0.0023811774,0.6722616,0.00035100582,0.0026734031,0.00009206056,0.0017203775,0.0000075571593,0.0015911323,0.000029594206,0.00052289607,0.24693596],"study_design_scores_gemma":[0.059038844,0.058689177,0.87245256,0.00072750566,0.0017785295,0.000020787604,0.0031850883,0.00020067088,0.00248317,0.00014052606,0.0010682108,0.00021495846],"about_ca_topic_score_codex":0.001158997,"about_ca_topic_score_gemma":0.0008815051,"teacher_disagreement_score":0.246721,"about_ca_system_score_codex":0.000022330987,"about_ca_system_score_gemma":0.0012070963,"threshold_uncertainty_score":0.99905646},"labels":[],"label_agreement":null},{"id":"W2112044462","doi":"10.1126/scitranslmed.3001970","title":"Urine <i>TMPRSS2:ERG</i> Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA","year":2011,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":351,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Cancer Institute","keywords":"TMPRSS2; Urine; Prostate cancer; Medicine; Erg; Prostate; Cancer; Internal medicine; Oncology; Urology; Endocrinology; Ophthalmology; Coronavirus disease 2019 (COVID-19)","score_opus":0.03786330777587562,"score_gpt":0.3155952775987733,"score_spread":0.2777319698228977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112044462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698277,0.001866891,0.00012835918,0.012126489,0.0001562563,0.0013300262,0.000073944444,0.00007497875,0.014415352],"genre_scores_gemma":[0.99598086,0.0013760285,0.00059911975,0.00013686539,0.000112947346,0.000114058465,0.00004353571,0.000019688307,0.0016168854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99716663,0.00004754249,0.00037923554,0.0005397029,0.0012993402,0.0005675408],"domain_scores_gemma":[0.99900246,0.00004651432,0.00008522319,0.00024119929,0.0003235314,0.00030105974],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00081141794,0.00023432031,0.00034180016,0.00045002348,0.00023570067,0.000013638727,0.00019424006,0.000049702452,0.001070978],"category_scores_gemma":[0.000031024152,0.0001388979,0.000035582067,0.0016792951,0.001484898,0.000406319,0.000010412895,0.00034729304,0.00000850442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061751893,0.00058137364,0.7753743,0.00024011079,0.00011674702,0.00023663831,0.02518537,0.00013389224,0.1683074,0.0009318601,0.00036183532,0.022355283],"study_design_scores_gemma":[0.013024094,0.0015342719,0.9383918,0.0008383167,0.00015511058,0.00003752753,0.0014009558,0.0020132393,0.04024416,0.001410193,0.0006688658,0.00028148416],"about_ca_topic_score_codex":0.0017502387,"about_ca_topic_score_gemma":0.0012765268,"teacher_disagreement_score":0.16301747,"about_ca_system_score_codex":0.00011235932,"about_ca_system_score_gemma":0.0010650177,"threshold_uncertainty_score":0.99984217},"labels":[],"label_agreement":null},{"id":"W2112856704","doi":"10.1371/journal.pgen.1001204","title":"Analysis of the 10q11 Cancer Risk Locus Implicates MSMB and NCOA4 in Human Prostate Tumorigenesis","year":2010,"lang":"en","type":"article","venue":"PLoS Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Emerald Foundation; Howard Hughes Medical Institute; Dana-Farber/Harvard Cancer Center; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation; H. L. Snyder Medical Foundation","keywords":"Biology; Prostate cancer; Carcinogenesis; Allele; Genome-wide association study; Locus (genetics); Prostate; Cancer research; Genetics; Genotype; Gene; Internal medicine; Endocrinology; Cancer; Single-nucleotide polymorphism; Medicine","score_opus":0.019527861223699296,"score_gpt":0.32195848314044984,"score_spread":0.3024306219167505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112856704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965925,0.0021887766,4.998218e-7,0.00043865494,0.00003644202,0.00046785938,0.00009889339,0.000009683344,0.000166645],"genre_scores_gemma":[0.9970064,0.0023839066,0.00005271749,0.000028428098,0.000043776326,0.00007933433,0.000013253992,0.000016384603,0.0003757897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990663,0.000034601788,0.00021467911,0.00022467761,0.00023272201,0.00022701392],"domain_scores_gemma":[0.9992856,0.000039238206,0.00009216275,0.00037934366,0.00011455058,0.00008914922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011380444,0.00011228298,0.00028806162,0.0001845732,0.00007898571,0.000012296764,0.00011104556,0.000060237104,0.00006831809],"category_scores_gemma":[0.000027714861,0.00006842157,0.00007846384,0.0006914614,0.00019617534,0.000014265708,0.00008358164,0.00021692515,0.0000012240993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003637366,0.000112712325,0.7603596,0.000044350338,0.00040521953,0.000003193771,0.00037821717,0.000030115232,0.2365543,0.000005418063,0.000020327063,0.0020501784],"study_design_scores_gemma":[0.00065639947,0.00008639625,0.6207586,0.00002328556,0.0011099059,8.9615713e-7,0.000051867602,0.0009256262,0.37605643,0.000092352995,0.00017180486,0.00006646023],"about_ca_topic_score_codex":0.00051898,"about_ca_topic_score_gemma":0.0023365214,"teacher_disagreement_score":0.13960102,"about_ca_system_score_codex":0.00003799072,"about_ca_system_score_gemma":0.00010167174,"threshold_uncertainty_score":0.27901506},"labels":[],"label_agreement":null},{"id":"W2112958085","doi":"10.1002/ijc.21174","title":"Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma","year":2005,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; Royal Ottawa Mental Health Centre; University of Saskatchewan","funders":"Kreftforeningen","keywords":"Prostate; Prostate cancer; Estrogen receptor; LNCaP; Adenocarcinoma; Downregulation and upregulation; Stromal cell; Receptor; Medicine; Androgen receptor; Sex hormone receptor; Internal medicine; Stroma; Endocrinology; Cancer research; Pathology; Immunohistochemistry; Biology; Cancer; Breast cancer","score_opus":0.014279743291392604,"score_gpt":0.34901599905020464,"score_spread":0.33473625575881205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112958085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98757565,0.008903867,0.000068030575,0.0026986902,0.0002891312,0.00042117055,0.000031247786,0.000002302868,0.000009885814],"genre_scores_gemma":[0.9945531,0.0040767896,0.00041150657,0.00006873897,0.0004308322,0.0000722494,0.000013173389,0.0000117928275,0.00036183815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991148,0.000019932884,0.000324237,0.00008999818,0.000347136,0.00010386669],"domain_scores_gemma":[0.9993512,0.00003016839,0.00019754597,0.000042257736,0.0003240253,0.000054791624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000087233886,0.00007876611,0.00018114144,0.00020729119,0.000010834516,0.000017005188,0.00006380109,0.00003065073,0.00016352773],"category_scores_gemma":[0.00001804237,0.000052491876,0.000055649198,0.00004234273,0.000044500168,0.0001841312,0.000014492037,0.00009156255,3.4394378e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01061391,0.00019942936,0.67115813,0.000064941174,0.00017203296,0.00002293003,0.0029706496,0.000015943962,0.0166304,0.0000064371598,0.0002798398,0.2978654],"study_design_scores_gemma":[0.014576221,0.0014856139,0.731289,0.0009130482,0.000047334317,0.000036659887,0.00014690445,0.0002466135,0.24417111,0.00027553213,0.006721412,0.000090498266],"about_ca_topic_score_codex":0.000015415948,"about_ca_topic_score_gemma":0.000040378098,"teacher_disagreement_score":0.29777488,"about_ca_system_score_codex":0.0001745619,"about_ca_system_score_gemma":0.00012169153,"threshold_uncertainty_score":0.21405566},"labels":[],"label_agreement":null},{"id":"W2113026851","doi":"10.21236/ada405914","title":"Locating a Prostate Cancer Susceptibility Gene on the X Chromosome by Linkage Disequilibrium Mapping Using Three Founder Populations in Quebec and Switzerland","year":2002,"lang":"en","type":"report","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Linkage disequilibrium; Genetics; Linkage (software); Founder effect; Biology; Prostate cancer; Chromosome; Cancer; Gene; Evolutionary biology; Haplotype; Allele","score_opus":0.17980629970879347,"score_gpt":0.3822059857163818,"score_spread":0.20239968600758834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113026851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9736865,0.015053675,0.00006069975,0.003300102,0.0002882473,0.0031760219,0.00019676003,0.00007133993,0.0041666254],"genre_scores_gemma":[0.9485657,0.004171854,0.00021083422,0.00015160014,0.00052990497,0.00032869505,0.0006431186,0.000111343055,0.045286924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969517,0.00008979541,0.0006444328,0.0007926139,0.0008930738,0.000628383],"domain_scores_gemma":[0.9985527,0.00013325157,0.00023876234,0.00060978456,0.00028049495,0.00018505596],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006552338,0.0004438607,0.0006807171,0.0002304253,0.0002503015,0.00013668319,0.00011619917,0.00028935415,0.00038968434],"category_scores_gemma":[0.0001474672,0.00026646155,0.00012073598,0.0004482248,0.00025207555,0.0001320833,0.00014105703,0.00078887795,0.0000066551534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020220263,0.00045266276,0.96717477,0.0023842582,0.0004155522,0.00022272444,0.001357663,0.000074989126,0.011972921,0.000021897893,0.005191795,0.01052858],"study_design_scores_gemma":[0.014591916,0.0012909921,0.9021227,0.01660059,0.0015936672,0.00040969523,0.0020289824,0.033276528,0.0030382692,0.001306707,0.020089176,0.0036508278],"about_ca_topic_score_codex":0.10712316,"about_ca_topic_score_gemma":0.08627482,"teacher_disagreement_score":0.06505211,"about_ca_system_score_codex":0.0023978946,"about_ca_system_score_gemma":0.0014823218,"threshold_uncertainty_score":0.9999788},"labels":[],"label_agreement":null},{"id":"W2113194416","doi":"10.1016/j.eururo.2011.04.038","title":"New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety","year":2011,"lang":"en","type":"review","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; Université de Montréal; Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Castration; Oncology; Prostate; Cancer; Gynecology; Internal medicine; Urology; Hormone","score_opus":0.08461366801589301,"score_gpt":0.3722958268717825,"score_spread":0.28768215885588944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113194416","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019089315,0.9914083,0.000024714696,0.00054934237,0.00019342598,0.0024054216,0.00013020642,0.00005562484,0.005213867],"genre_scores_gemma":[0.00003961632,0.9867718,0.00030715193,0.00012159067,0.00047328442,0.00010219055,0.0002651374,0.00010766876,0.011811522],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983688,0.00026429837,0.00040763456,0.00048534496,0.00008790352,0.00038599322],"domain_scores_gemma":[0.99905705,0.00018660676,0.00017608782,0.0003007513,0.00006893537,0.00021058664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027097607,0.0003355813,0.00097567233,0.00013482681,0.000114087205,0.000023651857,0.00012809821,0.00010741282,0.0001952043],"category_scores_gemma":[0.000044385626,0.00021877889,0.00017167845,0.000108428685,0.00013727274,0.000028616772,0.0000671611,0.0002965237,0.00006175727],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011718312,0.00003979853,0.000018949086,0.0031894743,0.0005204303,0.00010323193,0.00038738482,5.559079e-8,0.0000056053136,0.00024286952,0.0032453784,0.991075],"study_design_scores_gemma":[0.0025219114,0.0013005079,0.00048048256,0.0009279345,0.0010556537,0.00007608141,0.0000060229704,3.1495432e-7,0.0000010797146,0.000024408448,0.9934302,0.00017538754],"about_ca_topic_score_codex":0.000047978592,"about_ca_topic_score_gemma":0.000019401528,"teacher_disagreement_score":0.9908996,"about_ca_system_score_codex":0.000064690714,"about_ca_system_score_gemma":0.00063672394,"threshold_uncertainty_score":0.8921544},"labels":[],"label_agreement":null},{"id":"W2113195986","doi":"10.1016/j.urology.2012.11.023","title":"Commentary on: Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy","year":2013,"lang":"en","type":"letter","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Clinical endpoint; Radiation therapy; Urology; Prostate-specific antigen; Androgen; Randomized controlled trial; Quality of life (healthcare); Androgen suppression; Internal medicine; Oncology; Cancer; Hormone","score_opus":0.044958749453208983,"score_gpt":0.3346023540952501,"score_spread":0.2896436046420411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113195986","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008082417,0.003330135,0.00033475555,0.98516214,0.000890496,0.0017039434,0.00025683927,0.000040971725,0.00019828383],"genre_scores_gemma":[0.0048606643,0.00045425433,0.00032253892,0.97944343,0.0048360634,0.00080064917,0.0016859233,0.00009415698,0.0075023104],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839854,0.0001064433,0.00023862942,0.00047539017,0.00021746673,0.00056355103],"domain_scores_gemma":[0.9991253,0.00020163777,0.00007937074,0.00043405738,0.0000690046,0.00009062742],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000084178115,0.00030865343,0.00052864064,0.00021853118,0.000069809146,0.000021860153,0.00014983813,0.00067009166,0.0011744101],"category_scores_gemma":[0.000009912151,0.00021084216,0.0002142315,0.000040263578,0.00014804026,0.00003419113,0.000059463822,0.0010200742,0.00006825504],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020351717,0.00009122009,0.0008487494,0.00016929791,0.0004233504,0.00076306966,0.0001524778,5.731587e-7,0.00022218161,4.1939384e-7,0.98347664,0.011816831],"study_design_scores_gemma":[0.0041519837,0.0024902786,0.0005078596,0.000099102224,0.00016223083,0.00010342648,0.0000049591386,0.00013333377,0.0006856022,0.00007931881,0.9913985,0.00018339694],"about_ca_topic_score_codex":0.0000398259,"about_ca_topic_score_gemma":0.000002232372,"teacher_disagreement_score":0.011633434,"about_ca_system_score_codex":0.00020445042,"about_ca_system_score_gemma":0.00006215266,"threshold_uncertainty_score":0.99973863},"labels":[],"label_agreement":null},{"id":"W2114830715","doi":"10.1016/j.molonc.2013.12.004","title":"Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient‐derived, advanced prostate cancer tissue xenograft model","year":2013,"lang":"en","type":"article","venue":"Molecular Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Prevention of Organ Failure; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Docetaxel; Prostate cancer; Medicine; Cancer; Oncology; Cancer research; Prostate; Internal medicine; Pharmacology","score_opus":0.012330266426310547,"score_gpt":0.33639952916276067,"score_spread":0.32406926273645015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114830715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463445,0.001524451,0.0005631138,0.0010721452,0.000036078884,0.0015988094,0.00002122281,0.000011595483,0.0005381521],"genre_scores_gemma":[0.9970237,0.0011065934,0.0011137591,0.000099102384,0.0000037899083,0.0004751918,0.000015552621,0.000019102445,0.00014321625],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988291,0.0000853595,0.0002797847,0.00028244173,0.00022545285,0.0002978152],"domain_scores_gemma":[0.9992179,0.000042285574,0.00017139813,0.00018309703,0.0002899894,0.000095318115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008004736,0.00014617837,0.00049302296,0.0001907238,0.000021536833,0.0000044607477,0.000054331857,0.00011123851,0.000050883144],"category_scores_gemma":[0.00003765786,0.00012400176,0.000038842154,0.0002731664,0.00025846733,0.000118389245,0.00006724455,0.00016492086,0.0000016040769],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010495087,0.0006062527,0.0022406916,0.00025702553,0.000058766273,0.000049097067,0.0014055474,0.00025997878,0.89102495,0.00004694048,0.000017930217,0.1029833],"study_design_scores_gemma":[0.0067018247,0.0024445015,0.010340262,0.0001379828,0.000050766757,0.000007718151,0.0001963945,0.00468051,0.97481835,0.00043565824,0.00006809916,0.00011792056],"about_ca_topic_score_codex":0.0005549252,"about_ca_topic_score_gemma":0.00009992617,"teacher_disagreement_score":0.10286538,"about_ca_system_score_codex":0.00020335888,"about_ca_system_score_gemma":0.00034982368,"threshold_uncertainty_score":0.50566447},"labels":[],"label_agreement":null},{"id":"W2114875729","doi":"10.1186/s12955-014-0104-5","title":"Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union","year":2014,"lang":"en","type":"article","venue":"Health and Quality of Life Outcomes","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Cabazitaxel; European union; Enzalutamide; Patient-reported outcome; Quality of life (healthcare); Brief Pain Inventory; Family medicine; Cancer; Physical therapy; Internal medicine; Androgen deprivation therapy; Chronic pain; Business","score_opus":0.2694615134421238,"score_gpt":0.4301721743707721,"score_spread":0.16071066092864827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114875729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872946,0.0026775016,0.00015318999,0.0080256015,0.000022044194,0.0017158998,0.0000700128,0.000012732598,0.000028379343],"genre_scores_gemma":[0.9946352,0.001761067,0.0014425432,0.0017091491,0.000010924497,0.00011881923,0.00024997513,0.000014533011,0.000057771576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974803,0.000847856,0.00073740975,0.00025687236,0.00039875112,0.000278853],"domain_scores_gemma":[0.9989053,0.00025468835,0.00028832591,0.00016088093,0.0001482301,0.00024260028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036150701,0.00016191852,0.0005011015,0.00012747904,0.0001689641,0.000027700558,0.00002955327,0.00002166476,0.0000010390187],"category_scores_gemma":[0.00027090716,0.000092238,0.000034947334,0.000140036,0.00010633772,0.000049751012,0.00001931089,0.00009748443,7.9415294e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006899559,0.00030600093,0.97650933,0.0025840125,0.0002101945,0.0000019608374,0.0071617304,0.000016674177,0.00015040797,0.00013933494,0.000038801703,0.012191614],"study_design_scores_gemma":[0.010458684,0.0014209589,0.9791797,0.00017320344,0.00011905323,0.0000032981272,0.0071009267,0.00068089605,0.000046290454,0.00011667894,0.0005580818,0.0001422516],"about_ca_topic_score_codex":0.0045839855,"about_ca_topic_score_gemma":0.00046493267,"teacher_disagreement_score":0.012049363,"about_ca_system_score_codex":0.00007565215,"about_ca_system_score_gemma":0.0001706268,"threshold_uncertainty_score":0.69296455},"labels":[],"label_agreement":null},{"id":"W2115163916","doi":"10.1530/erc-15-0137","title":"Regulation of tumor cell plasticity by the androgen receptor in prostate cancer","year":2015,"lang":"en","type":"review","venue":"Endocrine Related Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Prostate Cancer Canada; Movember Foundation; Prostate Cancer Foundation","keywords":"Prostate cancer; Androgen receptor; Transdifferentiation; Androgen deprivation therapy; Cancer research; Cancer; Biology; Androgen; Tumor progression; Medicine; Bioinformatics; Internal medicine; Stem cell; Hormone; Cell biology","score_opus":0.03718822712498839,"score_gpt":0.3640658753312958,"score_spread":0.32687764820630744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115163916","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016340436,0.9927932,2.850351e-7,0.00036907077,0.0003178295,0.0027474998,0.0007539554,0.00003929566,0.001344813],"genre_scores_gemma":[0.00053987384,0.975443,0.00001425704,0.000018991059,0.00013387995,0.0012957463,0.00050449965,0.00009323857,0.021956531],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972669,0.00021261447,0.0008645506,0.0005134652,0.00059080095,0.00055167574],"domain_scores_gemma":[0.9985614,0.00012919432,0.00051766564,0.00035836684,0.00024516994,0.00018821328],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024691204,0.00045293136,0.00159161,0.00023518076,0.00005476647,0.000015102315,0.00021022685,0.00014430481,0.000998212],"category_scores_gemma":[0.000047966983,0.00026057128,0.00026506226,0.0009833609,0.00018204623,0.00007506735,0.00009379884,0.00091261487,0.000046649373],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073968724,0.00043099083,0.001254392,0.0228819,0.001075728,0.0001647723,0.00043559854,0.000069531314,0.00033252596,0.000017914273,0.096297175,0.8762998],"study_design_scores_gemma":[0.002789947,0.00021369293,0.000028292048,0.010244755,0.0009620022,0.000052682077,0.000025919675,0.000032210024,0.0012837567,0.000017855804,0.984096,0.00025289503],"about_ca_topic_score_codex":0.0014417799,"about_ca_topic_score_gemma":0.00007786979,"teacher_disagreement_score":0.88779885,"about_ca_system_score_codex":0.0013579216,"about_ca_system_score_gemma":0.0020754235,"threshold_uncertainty_score":0.9999846},"labels":[],"label_agreement":null},{"id":"W2115517212","doi":"10.1186/1756-9966-32-77","title":"Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Experimental & Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Tianjin Medical University; National Natural Science Foundation of China","keywords":"Prostate cancer; Biochemical recurrence; Proportional hazards model; Immunohistochemistry; Oncology; Medicine; Hyperplasia; Cancer; Survival analysis; Prostate; Internal medicine; Biomarker; Tissue microarray; DU145; Cancer research; Biology; Prostatectomy","score_opus":0.15966607593069193,"score_gpt":0.5641492340042136,"score_spread":0.40448315807352164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115517212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737127,0.0081434,0.0000024191709,0.011545516,0.00032737813,0.004867092,0.00006685606,0.000014240804,0.0013203863],"genre_scores_gemma":[0.98895055,0.004452837,0.0005660837,0.0002779697,0.0004935673,0.0033155405,0.000015992528,0.00007351593,0.0018539149],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932655,0.0007890148,0.0018609171,0.0005939242,0.0025396098,0.00095100375],"domain_scores_gemma":[0.9957054,0.00056898076,0.00068969367,0.0004582935,0.0019350862,0.0006425383],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00306224,0.0003287082,0.000988473,0.000720421,0.00014014154,0.000094472874,0.00042440658,0.00019622972,0.0026922254],"category_scores_gemma":[0.00041901946,0.00023098507,0.00032467622,0.0010552125,0.0007698586,0.00042152006,0.00014628809,0.0020258925,0.000028431668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01398022,0.0076513574,0.72490484,0.0006510345,0.00040374647,0.00026688355,0.0010057995,0.00018863362,0.20193966,0.00009212692,0.005252635,0.04366307],"study_design_scores_gemma":[0.031933904,0.018648393,0.47167102,0.009331825,0.00012761807,0.000017346232,0.0023424414,0.003691487,0.45659485,0.00035732344,0.0046677315,0.00061606144],"about_ca_topic_score_codex":0.003087258,"about_ca_topic_score_gemma":0.00010069794,"teacher_disagreement_score":0.2546552,"about_ca_system_score_codex":0.0018777807,"about_ca_system_score_gemma":0.0043300684,"threshold_uncertainty_score":0.99821943},"labels":[],"label_agreement":null},{"id":"W2115996689","doi":"10.1111/j.1464-410x.2007.06955.x","title":"Multiple intracrine hormonal targets in the prostate: opportunities and challenges","year":2007,"lang":"en","type":"review","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Intracrine; Library science; Prostate cancer; Citation; Medicine; Oncology; Internal medicine; Cancer; Computer science","score_opus":0.16891532328722128,"score_gpt":0.37103071870769194,"score_spread":0.20211539542047066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115996689","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001688674,0.9959468,0.0000028384277,0.0026861406,0.00012538525,0.00052623916,0.000032032647,0.0000044047274,0.00050728983],"genre_scores_gemma":[0.00061776215,0.99850464,0.00006133308,0.00017996671,0.0003998612,0.000024195815,0.000044190998,0.000026865282,0.00014119825],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815303,0.0003059478,0.00068476045,0.00017476613,0.00031331717,0.0003681548],"domain_scores_gemma":[0.99882895,0.0004491528,0.00031584452,0.00010701455,0.00015713883,0.00014191435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013899951,0.00019994528,0.0011922356,0.0003417668,0.00005400871,0.00003143346,0.00017642158,0.00023277247,0.000034905537],"category_scores_gemma":[0.00018910757,0.00013297223,0.00018728143,0.000103483224,0.00027598257,0.0000707757,0.000054921467,0.0011570608,0.0000020296254],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018254321,0.00016728339,0.00003383012,0.0033444038,0.00018311443,0.028171128,0.0001596261,4.9088303e-8,1.2465163e-7,0.00003279102,0.0008296357,0.96689546],"study_design_scores_gemma":[0.0014324746,0.0010864171,0.0009463332,0.0024963,0.00031529347,0.08907055,0.00021139323,8.835927e-7,1.4784712e-7,0.00006786653,0.9042788,0.000093527306],"about_ca_topic_score_codex":0.00002540783,"about_ca_topic_score_gemma":0.00007156434,"teacher_disagreement_score":0.96680194,"about_ca_system_score_codex":0.00006120907,"about_ca_system_score_gemma":0.00043679972,"threshold_uncertainty_score":0.54224503},"labels":[],"label_agreement":null},{"id":"W2116534677","doi":"10.1530/erc-10-0204","title":"Androgen receptor levels are upregulated by Akt in prostate cancer","year":2011,"lang":"en","type":"article","venue":"Endocrine Related Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; University of California, Los Angeles; School of Medicine, New York University; York University; American Cancer Society","keywords":"LNCaP; Protein kinase B; Androgen receptor; Prostate cancer; AKT1; PI3K/AKT/mTOR pathway; Biology; AKT2; Endocrinology; Cancer research; Internal medicine; Transgene; Phosphorylation; Signal transduction; Chemistry; Cell biology; Cancer; Medicine; Biochemistry","score_opus":0.03953331237177583,"score_gpt":0.32293153682708375,"score_spread":0.28339822445530793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116534677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94958645,0.039946537,9.98891e-7,0.0029199799,0.00042189268,0.0013113905,0.0003730716,0.00018393373,0.0052557695],"genre_scores_gemma":[0.93909425,0.01172548,0.00008052791,0.00019841194,0.00008386657,0.00077577925,0.00013137981,0.00009192223,0.04781841],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99769384,0.000074011994,0.0004600781,0.0005734095,0.00037859968,0.0008200707],"domain_scores_gemma":[0.99899805,0.000022270715,0.00015353876,0.00035341812,0.00017422599,0.0002985106],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011501448,0.00032720403,0.00051140424,0.00021947865,0.000079924896,0.000016013393,0.00014618103,0.00011969083,0.008229192],"category_scores_gemma":[0.000026713593,0.0002575359,0.000110068955,0.0007989278,0.00014377665,0.00017595563,0.00007084225,0.0005577475,0.00012631444],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00358568,0.0009536388,0.81402,0.00040770852,0.0014512901,0.0016369729,0.003483825,0.000043182692,0.054091223,0.000059478727,0.07014354,0.0501235],"study_design_scores_gemma":[0.025019981,0.00075366226,0.12592132,0.0022025865,0.00037695895,0.00016315126,0.0004492372,0.00023388193,0.7282863,0.00033400266,0.11519547,0.001063432],"about_ca_topic_score_codex":0.0037627236,"about_ca_topic_score_gemma":0.0002360092,"teacher_disagreement_score":0.6880986,"about_ca_system_score_codex":0.00068911834,"about_ca_system_score_gemma":0.00037000896,"threshold_uncertainty_score":0.99998766},"labels":[],"label_agreement":null},{"id":"W2117460748","doi":"10.1093/annonc/mdv257","title":"Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":321,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia","funders":"National Cancer Institute; Swiss Cancer Foundation; Astellas Pharma; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Prostate Cancer Foundation; Movember Foundation; AstraZeneca; Amgen; European School of Oncology; Swiss Cancer Research Foundation; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Sanofi; Prostate Cancer UK; Cancer Research UK","keywords":"Medicine; Prostate cancer; Expert opinion; Consensus conference; Cancer; Management of prostate cancer; Gynecology; Hormonal therapy; Intensive care medicine; Oncology; Disease; Family medicine; Internal medicine; Medical physics","score_opus":0.10097020056016866,"score_gpt":0.4302916006142122,"score_spread":0.32932140005404353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117460748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9560233,0.003097723,0.0000029821276,0.03230858,0.00027827887,0.0026520567,0.0010120097,0.000017060025,0.0046080244],"genre_scores_gemma":[0.98379934,0.010652225,0.0008772731,0.0002052947,0.000015703174,0.000448331,0.00010721761,0.0000251947,0.0038694236],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99825156,0.00012941305,0.00051835075,0.00028858255,0.00044219333,0.00036992787],"domain_scores_gemma":[0.99675643,0.00007250122,0.0006056003,0.0003888183,0.0020124842,0.00016418216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027434665,0.00018667638,0.0005773662,0.00009960037,0.000051060302,0.0000035136943,0.0001886556,0.00007136271,0.00007815696],"category_scores_gemma":[0.000040710005,0.000115633964,0.000070555296,0.00033531012,0.0004990776,0.0000779427,0.0001330984,0.0001671461,0.0000018617235],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031829484,0.0036408915,0.26225123,0.0017406072,0.0023746109,0.000057597597,0.0061742594,0.00094974635,0.0012618949,0.0007950775,0.048953526,0.6399711],"study_design_scores_gemma":[0.074698865,0.028480656,0.36831027,0.005199089,0.001028925,0.000009721993,0.010672552,0.00015079035,0.07197707,0.001570219,0.43705034,0.00085149874],"about_ca_topic_score_codex":0.0003148544,"about_ca_topic_score_gemma":0.00030380525,"teacher_disagreement_score":0.63911957,"about_ca_system_score_codex":0.00015982914,"about_ca_system_score_gemma":0.0012914104,"threshold_uncertainty_score":0.4715416},"labels":[],"label_agreement":null},{"id":"W2117473333","doi":"10.1155/2013/786545","title":"ERG Protein Expression Is of Limited Prognostic Value in Men with Localized Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"ISRN Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Prostate Cancer Canada; University of Calgary","funders":"Prostate Cancer Canada; Movember Foundation; Prostate Cancer Foundation","keywords":"Prostate cancer; Erg; Protein expression; Value (mathematics); Expression (computer science); Oncology; Medicine; Prostate; Internal medicine; Cancer; Gynecology; Biology; Statistics; Ophthalmology; Mathematics; Genetics; Gene; Computer science","score_opus":0.016212898970680935,"score_gpt":0.2923139931866411,"score_spread":0.27610109421596013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117473333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882996,0.0010378526,0.000019505644,0.0062825778,0.000019268287,0.0029782015,0.000010347313,0.000031575102,0.0013210363],"genre_scores_gemma":[0.99483246,0.00018971988,0.00035400884,0.00031691176,0.000028367738,0.0015657768,0.000022032775,0.000026553113,0.0026641954],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987251,0.00010341926,0.00023596651,0.00029642097,0.00023245173,0.00040661785],"domain_scores_gemma":[0.9993624,0.000052525043,0.00008400686,0.00023045996,0.00016107937,0.00010949155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010563288,0.0001468391,0.00033685737,0.00016780381,0.000025588366,0.000006498653,0.00008007034,0.000117007316,0.00046495377],"category_scores_gemma":[0.0000450595,0.00009005456,0.000031204672,0.00028165747,0.00019238176,0.00007083066,0.00004942831,0.00022106846,0.000034084558],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006838439,0.000712152,0.7689497,0.00042693963,0.00018000779,0.00019553577,0.002130841,0.00009672575,0.21095036,0.00005781463,0.0024682675,0.0069932365],"study_design_scores_gemma":[0.038588826,0.011427194,0.39068675,0.0013680834,0.00026806624,0.000073975796,0.00058843556,0.008753953,0.5381535,0.0018224149,0.0076678004,0.00060096604],"about_ca_topic_score_codex":0.0013184387,"about_ca_topic_score_gemma":0.000062620995,"teacher_disagreement_score":0.37826294,"about_ca_system_score_codex":0.00006800066,"about_ca_system_score_gemma":0.00025400845,"threshold_uncertainty_score":0.5090918},"labels":[],"label_agreement":null},{"id":"W2117583432","doi":"10.1002/pros.20911","title":"Overexpression of 5α‐reductase type 1 increases sensitivity of prostate cancer cells to low concentrations of testosterone","year":2009,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Testosterone (patch); Endocrinology; Internal medicine; Dihydrotestosterone; Prostate; Prostate cancer; Androgen; Transfection; Downregulation and upregulation; Biology; Medicine; Cell culture; Cancer; Hormone; Gene","score_opus":0.021551194248783555,"score_gpt":0.32091121784830606,"score_spread":0.2993600235995225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117583432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955332,0.0007465973,0.0000064436704,0.0015248324,0.000045539357,0.0013313047,0.0005976457,0.00001562449,0.00019880994],"genre_scores_gemma":[0.99808604,0.00065851276,0.00019989723,0.000125946,0.00003186089,0.000020366582,0.000052829753,0.000012716444,0.0008118171],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988,0.00011927151,0.00032164107,0.0001816652,0.00032517302,0.00025225984],"domain_scores_gemma":[0.9987974,0.00012275175,0.0001876563,0.00033899376,0.0004262299,0.00012694966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029004048,0.00013649656,0.00034330512,0.00007498919,0.00005285956,0.0000058048595,0.00006964375,0.000036689125,0.000054908316],"category_scores_gemma":[0.00009619867,0.00008368663,0.000056411445,0.00035354757,0.00021048557,0.00007276595,0.000049509094,0.00011125848,0.0000048490274],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027968627,0.00054706045,0.0053953514,0.0002167322,0.000059153946,0.000010579559,0.0020458782,0.00016544631,0.98283714,0.000026116346,0.0010230684,0.0048766225],"study_design_scores_gemma":[0.0014281115,0.0012178654,0.027663438,0.0008214199,0.00008161966,0.000005860928,0.0002058535,0.00013034785,0.96816003,0.00009468156,0.00011202971,0.000078731275],"about_ca_topic_score_codex":0.0007365091,"about_ca_topic_score_gemma":0.000020360514,"teacher_disagreement_score":0.022268087,"about_ca_system_score_codex":0.000054884793,"about_ca_system_score_gemma":0.00035031047,"threshold_uncertainty_score":0.34126416},"labels":[],"label_agreement":null},{"id":"W2117638862","doi":"10.1158/0008-5472.can-04-1121","title":"Changes in Androgen Receptor Nongenotropic Signaling Correlate with Transition of LNCaP Cells to Androgen Independence","year":2004,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":227,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Tufts University School of Medicine; Adobe Systems","keywords":"LNCaP; Androgen receptor; MAPK/ERK pathway; CREB; Androgen; Cancer research; Signal transduction; Biology; Endocrinology; Internal medicine; Cell biology; Chemistry; Prostate cancer; Transcription factor; Medicine; Cancer; Hormone; Biochemistry","score_opus":0.053671819372918705,"score_gpt":0.362093116561756,"score_spread":0.3084212971888373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117638862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993514,0.0018851027,0.00012765294,0.002758507,0.000054454347,0.0013713001,0.00005043678,0.000018766159,0.00021977072],"genre_scores_gemma":[0.99695647,0.0016577926,0.0003555311,0.000083738756,0.00010301987,0.00035028683,0.000022111642,0.000033343607,0.0004377231],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99768543,0.000092005386,0.00019428975,0.00040170882,0.0010071388,0.0006194377],"domain_scores_gemma":[0.99895376,0.000050343402,0.000033032054,0.00025295498,0.00043361363,0.00027629084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005543194,0.00014270957,0.00030927794,0.0004948481,0.00008776557,0.000019600642,0.00015576037,0.00012031561,0.0003380956],"category_scores_gemma":[0.000017876935,0.00010827236,0.00003692545,0.001155866,0.00018811648,0.00008015871,0.00004559913,0.0005157878,0.000045995483],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040487866,0.0002607133,0.0062810313,0.00042805512,0.000118620235,0.00027882194,0.005533933,0.0017111732,0.97459877,0.000036120655,0.000105555235,0.006598428],"study_design_scores_gemma":[0.0046481453,0.0019802696,0.0017276141,0.0012066491,0.00002424999,0.000012246755,0.0007231464,0.00001762555,0.9888935,0.00008394307,0.00054401695,0.00013859222],"about_ca_topic_score_codex":0.001530428,"about_ca_topic_score_gemma":0.0015115138,"teacher_disagreement_score":0.014294739,"about_ca_system_score_codex":0.00069936126,"about_ca_system_score_gemma":0.00089949113,"threshold_uncertainty_score":0.44152188},"labels":[],"label_agreement":null},{"id":"W2117783793","doi":"10.1158/1078-0432.ccr-07-1036","title":"A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":362,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Celgene; Sanofi; Bristol-Myers Squibb","keywords":"Medicine; Nomogram; Internal medicine; Hazard ratio; Prostate cancer; Proportional hazards model; Oncology; Docetaxel; Prostate-specific antigen; Multivariate analysis; Urology; Performance status; Mitoxantrone; Cancer; Gastroenterology; Chemotherapy; Confidence interval","score_opus":0.28410465965835746,"score_gpt":0.5593244166085639,"score_spread":0.27521975695020645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117783793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96198565,0.019051963,0.00023431769,0.0027345866,0.000100168516,0.013505388,0.000278416,0.00011914864,0.0019903712],"genre_scores_gemma":[0.9813671,0.003157349,0.00040076996,0.00014261923,0.0004382119,0.0066077067,0.00015216965,0.00009592705,0.007638125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933768,0.0006202278,0.0012011306,0.0012623715,0.0020108717,0.0015286183],"domain_scores_gemma":[0.9927779,0.0030844985,0.00025156612,0.00084646087,0.0019876133,0.0010520058],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009598349,0.00038394477,0.00135294,0.00097231375,0.00041067105,0.00012341265,0.0003987309,0.0001523515,0.00017942543],"category_scores_gemma":[0.0008574719,0.0002483829,0.0004541868,0.0034488805,0.0009791956,0.00019483383,0.00018403394,0.0014066944,0.000022110697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037420366,0.00524957,0.8946458,0.00031728676,0.008968579,0.0008726385,0.0010919853,0.000012674978,0.0002046936,0.000007751049,0.013009553,0.038199067],"study_design_scores_gemma":[0.03619597,0.034786556,0.884329,0.00033715408,0.0042898413,0.0000065729964,0.0068845325,0.0007386583,0.00031963238,0.00008844836,0.03139326,0.00063034106],"about_ca_topic_score_codex":0.0039485255,"about_ca_topic_score_gemma":0.0023812347,"teacher_disagreement_score":0.03756873,"about_ca_system_score_codex":0.0006580883,"about_ca_system_score_gemma":0.0034809855,"threshold_uncertainty_score":0.99999684},"labels":[],"label_agreement":null},{"id":"W2117857186","doi":"10.1158/1078-0432.ccr-14-1108","title":"Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Prostate Cancer Canada; Prostate Cancer Foundation","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; splice; Cancer research; Cancer; Oligonucleotide; Biology; Medicine; Cell growth; Prostate; Internal medicine; Genetics; Gene","score_opus":0.2523537678405155,"score_gpt":0.4732531516307663,"score_spread":0.22089938379025081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117857186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9380072,0.05012968,0.000001730998,0.00801902,0.0005048834,0.0018580661,0.00021375378,0.00005309321,0.0012125797],"genre_scores_gemma":[0.92687476,0.06638169,0.00013509364,0.00034867052,0.0016246843,0.00052656303,0.00006462847,0.00007148213,0.003972398],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9950029,0.0010722203,0.00071261224,0.00087007385,0.0013346054,0.0010075532],"domain_scores_gemma":[0.99606943,0.0007219581,0.00013202458,0.0004418844,0.0017801664,0.00085453095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004853507,0.00026999734,0.00053485995,0.000109651715,0.00052650046,0.00015204161,0.0003054162,0.0002108938,0.00036201914],"category_scores_gemma":[0.0012520916,0.00016969531,0.000120891076,0.0006112855,0.0005870413,0.00028476314,0.00037584745,0.0010223967,0.00007410153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018530015,0.0015481946,0.1457366,0.0014921118,0.0009507277,0.00060339906,0.005782611,0.00006101754,0.52352667,0.00039990086,0.2805408,0.020827942],"study_design_scores_gemma":[0.031828083,0.0059763114,0.045500472,0.0013518689,0.0006350247,0.000050889295,0.005891071,0.01040332,0.7903569,0.00066853466,0.10580291,0.0015346546],"about_ca_topic_score_codex":0.003085859,"about_ca_topic_score_gemma":0.00044356767,"teacher_disagreement_score":0.26683018,"about_ca_system_score_codex":0.00048603382,"about_ca_system_score_gemma":0.0015243539,"threshold_uncertainty_score":0.6919974},"labels":[],"label_agreement":null},{"id":"W2117965089","doi":"10.2174/0929867003375371","title":"Androgen Receptor Antagonists (Antiandrogens) Structure-Activity Relationships","year":2000,"lang":"en","type":"review","venue":"Current Medicinal Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":234,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Wilfrid Laurier University; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Antiandrogens; Flutamide; Prostate cancer; Antiandrogen; Androgen receptor; Internal medicine; Endocrinology; Androgen; Testosterone (patch); Dihydrotestosterone; Medicine; Enzalutamide; Chemistry; Hormone; Cancer","score_opus":0.1085032400324328,"score_gpt":0.3998477820769277,"score_spread":0.29134454204449495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117965089","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011856089,0.99444616,0.0000029534567,0.00011264823,0.0004938764,0.0009983075,0.0006272848,0.00010850249,0.0020246806],"genre_scores_gemma":[0.00049463223,0.9916832,0.000035043162,0.0000069881794,0.0015373302,0.000104333456,0.0040632337,0.00009315623,0.0019821045],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99689543,0.00013585895,0.00062580314,0.00085833954,0.0008359873,0.0006485781],"domain_scores_gemma":[0.9980217,0.00014709054,0.0003082565,0.0007395976,0.000109094326,0.0006742647],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023922985,0.00072808506,0.0020065801,0.0001333567,0.00025026384,0.000038622144,0.00027655726,0.00061575137,0.0035435809],"category_scores_gemma":[0.00012884586,0.0005208174,0.0006064205,0.0005309394,0.0003304925,0.00006729539,0.00007670829,0.0024169232,0.00020346025],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001616951,0.00019107288,0.0001463689,0.04222635,0.00040198924,0.00013903933,0.00003886482,3.5926917e-8,0.000088966925,0.0000013103439,0.0066158082,0.9499885],"study_design_scores_gemma":[0.0010919878,0.000069222966,0.00001077376,0.019737918,0.0019816,0.0007416474,0.000011266945,0.0000024394926,0.0011634878,0.000011334886,0.97475815,0.0004201594],"about_ca_topic_score_codex":0.0000048577867,"about_ca_topic_score_gemma":5.3255116e-7,"teacher_disagreement_score":0.96814233,"about_ca_system_score_codex":0.00064094,"about_ca_system_score_gemma":0.0017429165,"threshold_uncertainty_score":0.99988455},"labels":[],"label_agreement":null},{"id":"W2118238803","doi":"10.1016/j.ccr.2010.04.027","title":"Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor","year":2010,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":508,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Transactivation; Androgen receptor; Prostate cancer; Androgen; Cancer research; Receptor; Small molecule; Androgen Receptor Antagonists; Endocrinology; Biology; Internal medicine; Chemistry; Gene; Medicine; Cancer; Transcription factor; Biochemistry; Hormone","score_opus":0.015185918052990861,"score_gpt":0.29117719181743623,"score_spread":0.2759912737644454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118238803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875697,0.008566121,5.3023393e-7,0.00067705486,0.0008144517,0.001019922,0.00051549764,0.00000684458,0.00082988106],"genre_scores_gemma":[0.99388534,0.0014342443,0.000045418008,0.00003788922,0.00010664989,0.00016761887,0.000016817747,0.00002657887,0.0042794156],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986558,0.00007092784,0.00035099115,0.00024898784,0.00039513063,0.00027818186],"domain_scores_gemma":[0.9987918,0.00002946475,0.0003444954,0.00049168384,0.00023771233,0.00010484534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014132736,0.00018406767,0.00033181987,0.000029784509,0.000066400644,0.0000057399016,0.0002538008,0.000105369894,0.0002987857],"category_scores_gemma":[0.000015559679,0.00008683564,0.00017185793,0.00025192156,0.0004231814,0.000034981644,0.00012093631,0.00029321993,0.0000012651975],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005750002,0.00024229973,0.030979376,0.00051088183,0.000052442283,0.0000033531355,0.0011663523,0.0000012193852,0.95368344,0.000004887377,0.0063142576,0.0064664846],"study_design_scores_gemma":[0.0021549908,0.00023867475,0.0030294606,0.00072161906,0.000086481756,0.0000033852846,0.00022919566,0.000010394939,0.98754793,0.000010480762,0.005878406,0.000089000474],"about_ca_topic_score_codex":0.0010896162,"about_ca_topic_score_gemma":0.00064741616,"teacher_disagreement_score":0.033864465,"about_ca_system_score_codex":0.00013782013,"about_ca_system_score_gemma":0.00072612445,"threshold_uncertainty_score":0.35410544},"labels":[],"label_agreement":null},{"id":"W2118373933","doi":"10.4103/1008-682x.122875","title":"Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification","year":2014,"lang":"en","type":"article","venue":"Asian Journal of Andrology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Vancouver General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Metastasis; Gene silencing; Prostate; Gene; Cancer; Medicine; Cancer research; Oncology; Biology; Internal medicine; Genetics","score_opus":0.035556712427286294,"score_gpt":0.2993582182426982,"score_spread":0.2638015058154119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118373933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98664236,0.004774464,0.0005812844,0.007530771,0.000121731566,0.00015538624,0.0000030318245,0.0000040400237,0.00018695589],"genre_scores_gemma":[0.9974502,0.0018983447,0.00029462768,0.000049590322,0.00015013387,0.000009133699,0.0000049774744,0.000009998775,0.00013300893],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991383,0.00012279775,0.00029637932,0.00012952049,0.00012014682,0.00019283104],"domain_scores_gemma":[0.9995567,0.000022015805,0.00016249028,0.00008676992,0.00007335113,0.000098639954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005166653,0.000088452914,0.00028083715,0.00022127092,0.000045162327,0.000020127649,0.000060270202,0.00005673593,0.000022441158],"category_scores_gemma":[0.000028071976,0.000058270012,0.000054386237,0.000099986275,0.00012148626,0.00010895937,0.000020952028,0.00018655897,0.000001272415],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011150229,0.00020438018,0.33559814,0.00012906484,0.00037306937,0.0001790526,0.00308624,0.00008111596,0.026752234,0.00015513062,0.000122033474,0.63220453],"study_design_scores_gemma":[0.011455582,0.0027077862,0.9428709,0.00031368362,0.00044083584,0.00275732,0.0041528735,0.0017588177,0.023286033,0.0031309528,0.006844057,0.00028112333],"about_ca_topic_score_codex":0.000008393626,"about_ca_topic_score_gemma":0.000025039806,"teacher_disagreement_score":0.6319234,"about_ca_system_score_codex":0.000035452296,"about_ca_system_score_gemma":0.00009182545,"threshold_uncertainty_score":0.23761821},"labels":[],"label_agreement":null},{"id":"W2118478807","doi":"10.1128/mcb.05429-11","title":"Regulation of Androgen Receptor-Mediated Transcription by RPB5 Binding Protein URI/RMP","year":2011,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; U.S. Public Health Service; National Institutes of Health; School of Medicine, New York University; York University","keywords":"Corepressor; Androgen receptor; Biology; Transcription factor; Transcriptional regulation; Transcription (linguistics); Chromatin immunoprecipitation; Bicalutamide; Gene; Cell biology; Gene expression; Promoter; Repressor; Prostate cancer; Cancer research; Genetics; Cancer","score_opus":0.020177939546196705,"score_gpt":0.24839871552715093,"score_spread":0.22822077598095422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118478807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943796,0.003089591,0.0010560038,0.0001228816,0.000034337245,0.00047605002,0.000028904236,0.000020675978,0.0007919485],"genre_scores_gemma":[0.9979917,0.00014103416,0.00031399904,0.000020643653,0.000012123483,0.000031836003,0.00078487064,0.0000132535415,0.0006905775],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992883,0.00008164606,0.0001630146,0.00020572318,0.00007882458,0.00018244602],"domain_scores_gemma":[0.9996917,0.0000051832676,0.000049055994,0.00012293263,0.00004918766,0.000081903745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013037476,0.000100108446,0.00018665647,0.00008983877,0.000035642006,0.000002880166,0.000037018694,0.00014584116,0.00017159479],"category_scores_gemma":[0.000012186818,0.00007865897,0.00005440921,0.00011777712,0.00013294982,0.000023726243,0.000013474242,0.00008213651,0.000010489679],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029992693,0.00008800351,0.0025865901,0.000057464877,0.00007923806,0.000010819269,0.00023497226,2.1573124e-8,0.9942452,0.0002033802,0.00006463961,0.0021297764],"study_design_scores_gemma":[0.0013773246,0.00067758485,0.000249491,0.000033670432,0.000037677408,0.0000055311175,0.000049316597,0.00001745603,0.99505615,0.00020685555,0.002212383,0.00007657919],"about_ca_topic_score_codex":0.00005089608,"about_ca_topic_score_gemma":6.695037e-7,"teacher_disagreement_score":0.0036120543,"about_ca_system_score_codex":0.000021482008,"about_ca_system_score_gemma":0.000036477442,"threshold_uncertainty_score":0.32076198},"labels":[],"label_agreement":null},{"id":"W2118521074","doi":"10.1016/j.eururo.2013.09.005","title":"Efficacy and Safety of Abiraterone Acetate in an Elderly Patient Subgroup (Aged 75 and Older) with Metastatic Castration-resistant Prostate Cancer After Docetaxel-based Chemotherapy","year":2013,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Université de Montréal","funders":"","keywords":"Medicine; Abiraterone acetate; Docetaxel; Prostate cancer; Hazard ratio; Internal medicine; Clinical endpoint; Proportional hazards model; Urology; Prednisone; Placebo; Post-hoc analysis; Confidence interval; Androgen deprivation therapy; Chemotherapy; Oncology; Cancer; Randomized controlled trial; Pathology","score_opus":0.012385192065177481,"score_gpt":0.2647034834322848,"score_spread":0.2523182913671073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118521074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99448067,0.002062715,0.000017866034,0.0019181127,0.000018136325,0.0013551059,0.000023000892,0.000019436315,0.000104933904],"genre_scores_gemma":[0.99843425,0.00040247463,0.00034720852,0.00047214664,0.000015739124,0.00011351924,0.000035577017,0.000042531683,0.00013656379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852604,0.0003323035,0.00031283085,0.0003626216,0.00015259607,0.00031362651],"domain_scores_gemma":[0.99937785,0.00005403407,0.00010205854,0.00021758223,0.00009620076,0.00015228668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001914276,0.00019607352,0.0003357079,0.00013097718,0.000043567168,0.000028334562,0.00004725933,0.000026584843,0.00015501786],"category_scores_gemma":[0.000009228487,0.00013095832,0.00001817814,0.00013345035,0.00030250562,0.00011596723,0.000017565571,0.00016974048,0.0000052268347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07809543,0.002181243,0.48742634,0.0010209227,0.0006807555,0.0020730863,0.019512586,0.0002890798,0.2463989,0.00002377796,0.00017964734,0.16211824],"study_design_scores_gemma":[0.016975787,0.006190412,0.9732723,0.000082888466,0.0000750399,0.000020493664,0.000099851255,0.00012208585,0.002815109,0.0000109894845,0.00019375783,0.00014127417],"about_ca_topic_score_codex":0.0002129288,"about_ca_topic_score_gemma":0.00023003753,"teacher_disagreement_score":0.48584598,"about_ca_system_score_codex":0.00003080071,"about_ca_system_score_gemma":0.00007184084,"threshold_uncertainty_score":0.5340325},"labels":[],"label_agreement":null},{"id":"W2118564089","doi":"10.1093/annonc/mdt138","title":"Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":341,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Abiraterone acetate; Prostate cancer; Prednisone; Docetaxel; Urology; Internal medicine; Oncology; Chemotherapy; Cancer; Androgen deprivation therapy","score_opus":0.09984311915605092,"score_gpt":0.4478292512835438,"score_spread":0.34798613212749285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118564089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957325,0.0005396601,0.00000194929,0.0021857647,0.000045193527,0.0012644443,0.00003669785,0.000007109961,0.00018668937],"genre_scores_gemma":[0.9983258,0.00027020343,0.0007013715,0.00014422745,0.00001764701,0.00031505426,0.00001623436,0.000015923371,0.00019353227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847233,0.00020138365,0.00049559516,0.00023818605,0.00026708495,0.0003254054],"domain_scores_gemma":[0.99877304,0.00011098571,0.00029704047,0.0001801771,0.00052307534,0.00011566703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035750106,0.00013391598,0.0005954623,0.00012922044,0.000019309451,0.000007757739,0.000055946268,0.00007054543,0.00013039577],"category_scores_gemma":[0.000046740715,0.000086055166,0.00006201602,0.00019508261,0.0003695438,0.00018965431,0.000033438457,0.0001928748,0.0000056337935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01119285,0.002035387,0.8248733,0.00029382118,0.00027862084,0.00006160241,0.00047967152,0.000009319245,0.002877956,0.000002527776,0.0001520429,0.15774286],"study_design_scores_gemma":[0.0067254133,0.0068265246,0.97555166,0.00027745025,0.00006712302,0.0000012224641,0.000054114793,0.000030639865,0.010120017,0.000056330766,0.00020953221,0.000079940066],"about_ca_topic_score_codex":0.0006020105,"about_ca_topic_score_gemma":0.0004057357,"teacher_disagreement_score":0.15766291,"about_ca_system_score_codex":0.00006611695,"about_ca_system_score_gemma":0.0005670248,"threshold_uncertainty_score":0.3509228},"labels":[],"label_agreement":null},{"id":"W2118721274","doi":"10.5489/cuaj.2526","title":"The 2014 CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC)","year":2015,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta; University of British Columbia; Queen Elizabeth II Health Sciences Centre; Dalhousie University; University Health Network; Health Sciences Centre; University of Toronto; Western University; McMaster University; Sunnybrook Health Science Centre; McGill University Health Centre; Juravinski Cancer Centre; Hôtel-Dieu de Québec; BC Cancer Agency; Princess Margaret Cancer Centre; Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Cabazitaxel; Enzalutamide; Abiraterone; Prostate cancer; Docetaxel; Medicine; Abiraterone acetate; Radium-223; Oncology; Cancer; Internal medicine; Androgen deprivation therapy; Androgen receptor","score_opus":0.0919398916217547,"score_gpt":0.3643775347136136,"score_spread":0.2724376430918589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118721274","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16095386,0.021471655,0.00020656221,0.81009954,0.0013853969,0.0025384885,0.00024624844,0.000026183308,0.0030720788],"genre_scores_gemma":[0.9706535,0.009467502,0.0006918286,0.0026055025,0.0009291463,0.00025517543,0.000036560083,0.00001985813,0.015340964],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998672,0.0000762809,0.00033937203,0.000109586435,0.0004342783,0.00036848857],"domain_scores_gemma":[0.9977191,0.00015654239,0.00023084389,0.000110473986,0.0014466017,0.00033641103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016616035,0.00008587663,0.00013785888,0.00004692999,0.00042741603,0.00007848214,0.00012835799,0.000074154224,0.000044513716],"category_scores_gemma":[0.00036201454,0.00003969381,0.000089651105,0.00013073017,0.00005483274,0.000048631373,0.000012516254,0.00020509631,0.0000062780714],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020385105,0.0000632333,0.1204157,0.0000456502,0.0013768976,0.00008502047,0.000490902,0.00060993433,0.000221982,0.001684859,0.8134245,0.059542798],"study_design_scores_gemma":[0.0036014714,0.0007345601,0.18920611,0.00005759155,0.0003333701,0.000029396504,0.001321734,0.00085227896,0.0001240612,0.0026864929,0.80094075,0.00011218234],"about_ca_topic_score_codex":0.0014656306,"about_ca_topic_score_gemma":0.0027132493,"teacher_disagreement_score":0.8096996,"about_ca_system_score_codex":0.0010018994,"about_ca_system_score_gemma":0.00086865394,"threshold_uncertainty_score":0.32873818},"labels":[],"label_agreement":null},{"id":"W2118835332","doi":"10.1007/s00345-007-0146-y","title":"Role of nomograms for prostate cancer in 2007","year":2007,"lang":"en","type":"review","venue":"World Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Nomogram; Prostate cancer; Medicine; Oncology; Internal medicine; Cancer","score_opus":0.05465554780946365,"score_gpt":0.4192353885530706,"score_spread":0.36457984074360694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118835332","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004284855,0.9973654,0.000007114346,0.00034503906,0.00034856348,0.0010255297,0.00004903984,0.000003004997,0.0008134385],"genre_scores_gemma":[0.00017987945,0.99638695,0.00018929731,0.000070950904,0.00048608455,0.000060529066,0.000020199275,0.000039911003,0.002566218],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980345,0.00008258583,0.001049788,0.0001700187,0.0002308287,0.00043232896],"domain_scores_gemma":[0.9983266,0.0002805326,0.0007967006,0.00015509181,0.00029087576,0.00015018614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008124233,0.00022223966,0.001932927,0.0012282935,0.000017140184,0.0000044144854,0.00016772747,0.00019004932,0.00019521639],"category_scores_gemma":[0.000053118954,0.00014372595,0.0005181203,0.0005140561,0.00013357511,0.000032318752,0.000031731088,0.0007336797,0.0000036679373],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011282286,0.00019454141,0.0009777144,0.00454014,0.00043523242,0.00019352416,0.00006210607,0.000002464399,0.0000066379107,0.000026681591,0.0009903677,0.9914424],"study_design_scores_gemma":[0.00218408,0.0011247247,0.00014948919,0.0037789787,0.00086353434,0.00025024882,0.000012436203,0.0000028568695,0.0000065036284,0.00011310649,0.9914209,0.00009313103],"about_ca_topic_score_codex":0.000033863365,"about_ca_topic_score_gemma":0.00020042482,"teacher_disagreement_score":0.9913492,"about_ca_system_score_codex":0.00023082372,"about_ca_system_score_gemma":0.001049325,"threshold_uncertainty_score":0.5860974},"labels":[],"label_agreement":null},{"id":"W2119034557","doi":"10.1093/annonc/mdt581","title":"Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Oncology; Internal medicine; Univariate analysis; Cohort; Cancer; Androgen deprivation therapy; Urology; Multivariate analysis","score_opus":0.09108394557001714,"score_gpt":0.4321348236176081,"score_spread":0.34105087804759093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119034557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99272424,0.000080697006,0.000014147148,0.005655272,0.000047877038,0.000994544,0.00007444991,0.000015722228,0.000393068],"genre_scores_gemma":[0.9971423,0.000082067614,0.00073883915,0.00084070396,0.000019161671,0.00015249605,0.00006920311,0.000024202092,0.0009310298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775857,0.0006650096,0.0004995178,0.00031958162,0.00033727603,0.0004200763],"domain_scores_gemma":[0.99818164,0.0005333541,0.00022640788,0.00021892537,0.0006297568,0.00020993437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016633442,0.00016291058,0.00065812515,0.00018858377,0.000042055945,0.000010268968,0.00008172709,0.000081601436,0.000054307187],"category_scores_gemma":[0.0004670056,0.00010131319,0.000038468323,0.00040571162,0.00019557509,0.00008056662,0.000029112318,0.00019951424,0.000007582505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1606238,0.0030602338,0.80824417,0.00010464597,0.00089507736,0.00017617433,0.0011324562,0.00028786308,0.0018111769,0.00004797579,0.001479255,0.022137182],"study_design_scores_gemma":[0.016137669,0.031956077,0.94664574,0.00033207983,0.00011555653,0.000001502978,0.00007591649,0.00003397336,0.0010542689,0.000052320804,0.0034644336,0.00013044736],"about_ca_topic_score_codex":0.00025903183,"about_ca_topic_score_gemma":0.0013133775,"teacher_disagreement_score":0.14448613,"about_ca_system_score_codex":0.00013324535,"about_ca_system_score_gemma":0.0010666451,"threshold_uncertainty_score":0.4131432},"labels":[],"label_agreement":null},{"id":"W2119426396","doi":"10.1177/002215540405201011","title":"Cellular Localization of mRNA Expression of Enzymes Involved in the Formation and Inactivation of Hormonal Steroids in the Mouse Prostate","year":2004,"lang":"en","type":"article","venue":"Journal of Histochemistry & Cytochemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Genome Canada; F. Hoffmann-La Roche","keywords":"Stromal cell; Hydroxysteroid; Sulfotransferase; In situ hybridization; Prostate; Messenger RNA; Estrogen; Internal medicine; Endocrinology; Biology; Enzyme; Hormone; Androgen; Cell type; Hydroxysteroid dehydrogenase; Isozyme; Reductase; Dehydrogenase; Cell; Biochemistry; Gene; Cancer research; Medicine; Cancer","score_opus":0.01615037471402459,"score_gpt":0.2669048081259167,"score_spread":0.25075443341189213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119426396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996685,0.0021502224,0.00041076797,0.00030146542,0.0000064787855,0.00026680352,0.000009269966,0.0000016128403,0.00016837234],"genre_scores_gemma":[0.9993672,0.0002947764,0.00018463082,0.000018510884,0.000035837387,0.000012918408,0.000051081966,0.0000071851337,0.000027857524],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99849546,0.000041565563,0.00069251173,0.00009652595,0.0005542275,0.00011973714],"domain_scores_gemma":[0.99876744,0.00006147863,0.00067617634,0.00018949399,0.00026832032,0.00003709012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053335016,0.000115574185,0.00028301275,0.000087259454,0.00002779652,0.000006970475,0.0001598002,0.00010435996,0.0000052717814],"category_scores_gemma":[0.00010840834,0.000069704736,0.00007264553,0.0002354713,0.00017498866,0.00015588613,0.000023413275,0.0002940309,4.2433815e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009422087,0.0003651795,0.003320395,0.0009864916,0.00001474733,0.000020130443,0.0033790225,0.0001636512,0.99048644,0.0000045045226,0.00011252882,0.00020468791],"study_design_scores_gemma":[0.0031311968,0.00025517287,0.0010994987,0.0007159876,0.000035519686,0.00005938467,0.004177029,0.00007030467,0.9902193,0.00015366216,0.000029893788,0.000053045875],"about_ca_topic_score_codex":0.00001989177,"about_ca_topic_score_gemma":0.0000013353344,"teacher_disagreement_score":0.0026821948,"about_ca_system_score_codex":0.00022888232,"about_ca_system_score_gemma":0.00022843794,"threshold_uncertainty_score":0.28424767},"labels":[],"label_agreement":null},{"id":"W2119581973","doi":"10.3747/co.v17i0.698","title":"Cardiac and Cognitive Effects of Androgen Deprivation Therapy: Are They Real?","year":2010,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; University of Toronto; University Health Network","funders":"","keywords":"Androgen deprivation therapy; Medicine; Cognition; Androgen; Bioinformatics; Internal medicine; Prostate cancer; Psychiatry; Hormone; Biology","score_opus":0.06201588564433522,"score_gpt":0.41503429272286274,"score_spread":0.3530184070785275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119581973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912965,0.0061749485,0.000005513699,0.00024334081,0.0005462705,0.0006560854,0.000012789675,0.00001580218,0.0010487319],"genre_scores_gemma":[0.9913521,0.00827588,0.000022377437,0.000017998344,0.00015005263,0.00007684235,0.00004608711,0.000008295701,0.000050405815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994638,0.000062810825,0.00009493557,0.00014751233,0.00009689734,0.00013404732],"domain_scores_gemma":[0.9993815,0.00024166015,0.00006476897,0.000093949624,0.00013983437,0.0000782799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011820863,0.000075179814,0.00024457718,0.000063479936,0.000033709755,0.000003092071,0.000027021588,0.00008414439,0.000013634496],"category_scores_gemma":[0.00010309756,0.00005160287,0.00004131529,0.000057626978,0.00012663305,0.00002557593,0.000027761225,0.00019734919,0.0000045112915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045335823,0.0003180407,0.58678156,0.00016450205,0.00012571443,0.000014352471,0.00073090254,7.566929e-9,0.02251223,0.000082248785,0.00022635674,0.38859075],"study_design_scores_gemma":[0.007064674,0.0015943428,0.8843274,0.00017948795,0.0001853212,0.000012376338,0.00022037605,0.000011638782,0.088214666,0.0004738354,0.017616903,0.00009894374],"about_ca_topic_score_codex":0.000020850433,"about_ca_topic_score_gemma":0.000014463432,"teacher_disagreement_score":0.3884918,"about_ca_system_score_codex":0.000029133074,"about_ca_system_score_gemma":0.00013749415,"threshold_uncertainty_score":0.2104304},"labels":[],"label_agreement":null},{"id":"W2119941182","doi":"10.5489/cuaj.10167","title":"Guidelines for the management of castrate-resistant prostate cancer","year":2010,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":179,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McMaster University; Université de Montréal","funders":"","keywords":"Prostate; Cancer; Medicine; Prostate cancer; Gynecology; Urology; Oncology; Internal medicine","score_opus":0.05470869977293354,"score_gpt":0.3500303856171281,"score_spread":0.2953216858441946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119941182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7371537,0.002077177,0.00004978061,0.25660512,0.00092935184,0.0011559455,0.00024850067,0.0000148083345,0.0017655782],"genre_scores_gemma":[0.9897756,0.0011673502,0.0009668116,0.001597169,0.00045559247,0.00009971093,0.000013554202,0.00001042107,0.005913784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989853,0.000021928488,0.00027072267,0.00010447615,0.00027142404,0.000346145],"domain_scores_gemma":[0.99849194,0.00008551039,0.00015760072,0.00008898297,0.0008804571,0.00029548295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070276315,0.000079325946,0.00014672513,0.000062652456,0.00023830458,0.00003987023,0.00010384247,0.00009090819,0.00035529103],"category_scores_gemma":[0.00016255051,0.00004237643,0.000104133855,0.00012751184,0.000044523036,0.000032610104,0.000009307914,0.00033213545,0.000003996849],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022174327,0.00021063797,0.6474907,0.00020544247,0.003497316,0.00038404774,0.0004698849,0.00023280561,0.012331211,0.0041350154,0.19653645,0.13228907],"study_design_scores_gemma":[0.0030793091,0.00045192536,0.5649718,0.000047468635,0.00035992294,0.000048400274,0.00032662458,0.0003871709,0.0006085435,0.0011846386,0.42841598,0.000118238524],"about_ca_topic_score_codex":0.0012695392,"about_ca_topic_score_gemma":0.002503108,"teacher_disagreement_score":0.25500795,"about_ca_system_score_codex":0.00030319378,"about_ca_system_score_gemma":0.0005271437,"threshold_uncertainty_score":0.38901877},"labels":[],"label_agreement":null},{"id":"W2120286226","doi":"10.1158/1078-0432.ccr-11-2901","title":"Correlation of ERG Expression and DNA Methylation Biomarkers with Adverse Clinicopathologic Features of Prostate Cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Erg; Methylation; DNA methylation; TMPRSS2; Prostate cancer; Immunohistochemistry; Cancer; Biology; Cancer research; Internal medicine; Oncology; Gene expression; Medicine; Gene; Immunology; Genetics","score_opus":0.15345956948294687,"score_gpt":0.5082174998636494,"score_spread":0.3547579303807025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120286226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819245,0.014833334,0.000017241045,0.0009122603,0.00019335905,0.0011393174,0.000054216325,0.000017943961,0.0009078788],"genre_scores_gemma":[0.98669505,0.0112968115,0.00041329738,0.000030781677,0.00021319918,0.00020425259,0.000034570177,0.000024494939,0.0010875157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971363,0.000557194,0.00060981646,0.00036437972,0.0008470256,0.00048526167],"domain_scores_gemma":[0.99747026,0.0009188331,0.0002550153,0.00032181395,0.0007138823,0.00032018355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034605234,0.00014575623,0.0004936348,0.00024709813,0.0001003984,0.000006635575,0.00009937038,0.00021544454,0.00020100751],"category_scores_gemma":[0.0005720652,0.000089909874,0.0000987153,0.00057311426,0.0010836147,0.0001976663,0.0001249814,0.000625362,0.0000037112204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011010113,0.0004306352,0.91682714,0.00042339793,0.0001459336,0.0000097991515,0.0005414255,0.00001161771,0.021840045,0.00003973114,0.0010418023,0.047678374],"study_design_scores_gemma":[0.005072035,0.0018210905,0.94041914,0.0008367468,0.00011811006,0.00000526752,0.0005096526,0.000060594324,0.05002379,0.00007851133,0.00094070536,0.00011433983],"about_ca_topic_score_codex":0.00031289048,"about_ca_topic_score_gemma":0.000046939404,"teacher_disagreement_score":0.047564033,"about_ca_system_score_codex":0.00012381244,"about_ca_system_score_gemma":0.00052274275,"threshold_uncertainty_score":0.3992623},"labels":[],"label_agreement":null},{"id":"W2120292596","doi":"10.1056/nejmoa040720","title":"Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer","year":2004,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5725,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"","keywords":"Prednisone; Mitoxantrone; Medicine; Docetaxel; Prostate cancer; Oncology; Internal medicine; Cancer; Chemotherapy","score_opus":0.03697808835937899,"score_gpt":0.3596593328284429,"score_spread":0.32268124446906393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120292596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8209414,0.059166376,0.0049006264,0.108189106,0.0024157679,0.0034514877,0.00009732864,0.00008320876,0.00075470767],"genre_scores_gemma":[0.93268704,0.023137726,0.007569683,0.00097555993,0.01069531,0.00012483084,0.00006754069,0.00010789182,0.024634397],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971821,0.000047791167,0.0008609004,0.00031467684,0.00094246893,0.000652112],"domain_scores_gemma":[0.9975838,0.00022144258,0.00048189992,0.000276668,0.0006491006,0.00078708166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006853042,0.00034074314,0.001137954,0.00030581132,0.00013801595,0.000020638987,0.0002088275,0.000119824195,0.00030141734],"category_scores_gemma":[0.0005020251,0.00018524528,0.00016559502,0.0003629898,0.00023666596,0.00023138119,0.000035754376,0.00050789653,0.0000051404395],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2583257,0.000967663,0.0032339706,0.0019519769,0.0027368455,0.003366605,0.016724618,0.0057308003,0.07955432,0.00026271064,0.041387968,0.58575684],"study_design_scores_gemma":[0.78010505,0.022082243,0.0023650648,0.00521046,0.0014423879,0.0026756772,0.0013040158,0.00023386936,0.018841222,0.0015152011,0.16380191,0.00042287237],"about_ca_topic_score_codex":0.0002504863,"about_ca_topic_score_gemma":0.00016483114,"teacher_disagreement_score":0.58533394,"about_ca_system_score_codex":0.00089301687,"about_ca_system_score_gemma":0.0032536876,"threshold_uncertainty_score":0.75540835},"labels":[],"label_agreement":null},{"id":"W2120893462","doi":"10.1002/jcb.10425","title":"Mouse PSP94 expression is prostate tissue‐specific as demonstrated by a comparison of multiple antibodies against recombinant proteins","year":2003,"lang":"en","type":"article","venue":"Journal of Cellular Biochemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Immunohistochemistry; Prostate; Polyclonal antibodies; Blot; Antibody; Biology; Western blot; Recombinant DNA; Molecular biology; Epitope; Gene; Immunology; Biochemistry; Cancer","score_opus":0.020515015204702922,"score_gpt":0.30726853712917324,"score_spread":0.2867535219244703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120893462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833358,0.014885966,0.00013675378,0.0002239944,0.000085646076,0.0004201374,0.000029740404,0.00001215642,0.00086982397],"genre_scores_gemma":[0.99191296,0.0018439998,0.0013908999,0.000017644137,0.000044253124,0.0000076051588,0.0000667775,0.000029360164,0.0046865176],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811196,0.00006358018,0.0007176588,0.00022448694,0.000570296,0.00031203576],"domain_scores_gemma":[0.9984157,0.000034668785,0.00057542813,0.0002764367,0.00043808715,0.00025966173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028675926,0.00022251943,0.0005598615,0.000092345945,0.0000889056,0.000028124485,0.00013739405,0.00017420537,0.000108734035],"category_scores_gemma":[0.000121388126,0.00016139317,0.0001603791,0.0001911718,0.00017378049,0.000074021125,0.000028120814,0.0004238703,0.000007671531],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073967513,0.0010567646,0.011130934,0.00036632284,0.00011821378,0.00015896594,0.00037058356,0.0000018238372,0.9740556,7.9617666e-7,0.010959977,0.0010403764],"study_design_scores_gemma":[0.0036994023,0.00064729544,0.000042700092,0.0006807887,0.000046755515,0.00007412362,0.0008420731,0.0000220671,0.9879515,0.000017714812,0.0058245063,0.00015107267],"about_ca_topic_score_codex":0.0000053680296,"about_ca_topic_score_gemma":1.3053372e-7,"teacher_disagreement_score":0.0138959335,"about_ca_system_score_codex":0.000121094134,"about_ca_system_score_gemma":0.0003390035,"threshold_uncertainty_score":0.6581422},"labels":[],"label_agreement":null},{"id":"W2121098984","doi":"10.1126/scitranslmed.aac9511","title":"Plasma <i>AR</i> and abiraterone-resistant prostate cancer","year":2015,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":441,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Prostate Cancer UK; National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Abiraterone; Prostate cancer; Medicine; Cancer; Abiraterone acetate; Prostate; Oncology; Internal medicine; Urology; Androgen deprivation therapy; Androgen receptor","score_opus":0.06533960079360934,"score_gpt":0.36954620893228995,"score_spread":0.3042066081386806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121098984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9278277,0.005059764,0.00003759702,0.05569247,0.0003126299,0.0006099943,0.000028947452,0.000044478504,0.010386428],"genre_scores_gemma":[0.99586403,0.00034590764,0.00047119087,0.00040365278,0.00019078364,0.00004739656,0.000018489065,0.000010204981,0.0026483447],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980055,0.000016342065,0.00020743518,0.0003392215,0.0010960606,0.00033545526],"domain_scores_gemma":[0.9989273,0.000040078037,0.000036968766,0.00013307012,0.00033852833,0.0005240528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070549647,0.0001248287,0.00021010202,0.00020846004,0.00015582693,0.000020052068,0.000090748734,0.000025519777,0.00013579793],"category_scores_gemma":[0.00006748393,0.00007740911,0.000017174894,0.00061648776,0.001677143,0.0002392847,0.000016351802,0.00012480769,0.000016178863],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008595761,0.00039689412,0.26854277,0.00049810886,0.00017490808,0.00033108075,0.022971928,0.00016515728,0.58459735,0.006660731,0.009189886,0.09787543],"study_design_scores_gemma":[0.06601593,0.006407367,0.7428599,0.0022639676,0.000507954,0.00040483335,0.00420133,0.010194414,0.06507748,0.012219564,0.08875783,0.0010894096],"about_ca_topic_score_codex":0.0001748596,"about_ca_topic_score_gemma":0.000044608514,"teacher_disagreement_score":0.51951987,"about_ca_system_score_codex":0.00010160971,"about_ca_system_score_gemma":0.0010334678,"threshold_uncertainty_score":0.6179504},"labels":[],"label_agreement":null},{"id":"W2121380279","doi":"10.1200/jco.2014.56.5119","title":"Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Takeda Oncology","keywords":"Prednisone; Medicine; Placebo; Clinical endpoint; Adverse effect; Nausea; Internal medicine; Prostate cancer; Gastroenterology; Urology; Clinical trial; Cancer; Pathology","score_opus":0.2686344685691638,"score_gpt":0.4731839606446225,"score_spread":0.2045494920754587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121380279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98675954,0.0011183625,0.00013688237,0.0017558411,0.00052477134,0.009596733,0.000026585127,0.000024053466,0.00005720594],"genre_scores_gemma":[0.99546885,0.000247313,0.001900725,0.00020413016,0.00038292905,0.0012649277,0.000048006004,0.00006721184,0.0004159025],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99346143,0.0010151871,0.0028977639,0.000529767,0.00137975,0.00071611325],"domain_scores_gemma":[0.9942464,0.0010565068,0.002460378,0.0003394825,0.0010854881,0.0008116996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034484232,0.0004791725,0.003697604,0.00036403947,0.00010886477,0.00012092435,0.00023480556,0.00024305898,0.00011831353],"category_scores_gemma":[0.0003595906,0.00024028259,0.0003378041,0.00033990238,0.00081311923,0.00045526502,0.000052945463,0.0011670963,0.0000033397166],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93394345,0.012310278,0.044589665,0.00016947587,0.0022495403,0.0020615614,0.0015050368,0.0010185882,0.000019424806,5.1815346e-7,0.00007272186,0.0020597642],"study_design_scores_gemma":[0.94224346,0.044748202,0.007705941,0.0009159527,0.0012124212,0.000034266755,0.00035657024,0.0018865678,0.00035378776,0.0000037569052,0.00026689892,0.00027218217],"about_ca_topic_score_codex":0.0001944869,"about_ca_topic_score_gemma":0.0011444988,"teacher_disagreement_score":0.036883723,"about_ca_system_score_codex":0.0011572653,"about_ca_system_score_gemma":0.009056306,"threshold_uncertainty_score":0.9965614},"labels":[],"label_agreement":null},{"id":"W2121518362","doi":"10.1002/cncr.20408","title":"Human prostate cancer risk factors","year":2004,"lang":"en","type":"review","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":650,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Centre for Disease Control","funders":"U.S. Environmental Protection Agency","keywords":"Prostate cancer; Medicine; Cancer; Carcinogenesis; Disease; Epidemiology; Prostate; Risk factor; Oncology; Bioinformatics; Internal medicine; Biology","score_opus":0.10324352436261952,"score_gpt":0.4560787160261041,"score_spread":0.3528351916634846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121518362","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000461382,0.99401,3.7049335e-7,0.00008305081,0.0005976444,0.0024553942,0.0011833207,0.00012034413,0.0010885345],"genre_scores_gemma":[0.000070576876,0.9665221,0.000012977208,0.000030212945,0.00065752334,0.0019379145,0.0004437706,0.00016329509,0.030161636],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975245,0.00007975348,0.0005029359,0.0007177884,0.00046852938,0.00070650823],"domain_scores_gemma":[0.9985332,0.000035383557,0.00035665548,0.00055094744,0.00014772914,0.00037610662],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011308589,0.0006442804,0.0019368735,0.00026483097,0.00023600984,0.000047931633,0.00021584345,0.00037778012,0.0019971267],"category_scores_gemma":[0.000020328645,0.00039695846,0.0006823755,0.000501702,0.00019977141,0.00007101849,0.0000870741,0.0010142152,0.000116618656],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031296953,0.00012096245,0.0023033493,0.04210641,0.0015333763,0.0001500492,0.00032295127,0.0000042567244,0.0000026000066,0.000021441116,0.0045299684,0.94887334],"study_design_scores_gemma":[0.0012082431,0.00014932062,0.00030048855,0.037938055,0.0028577524,0.000008203238,0.000020647138,2.0957266e-7,0.000028843902,0.00003494424,0.9570499,0.0004033909],"about_ca_topic_score_codex":0.0029940489,"about_ca_topic_score_gemma":0.00013435775,"teacher_disagreement_score":0.95251995,"about_ca_system_score_codex":0.0027569183,"about_ca_system_score_gemma":0.0033057632,"threshold_uncertainty_score":0.99984825},"labels":[],"label_agreement":null},{"id":"W2121671287","doi":"10.1186/1476-4598-6-38","title":"Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"National Cancer Institute; Associazione Italiana per la Ricerca sul Cancro","keywords":"Androgen receptor; Coactivator; Biology; LNCaP; Prostate cancer; Cancer research; Androgen; Microarray analysis techniques; Endocrinology; Gene expression; Transcription factor; Gene; Cancer; Hormone; Genetics","score_opus":0.013622494892887757,"score_gpt":0.30087976130742755,"score_spread":0.2872572664145398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121671287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752385,0.02126652,0.000054580116,0.001089562,0.0002405601,0.001684832,0.00019003224,0.000076341,0.00015906796],"genre_scores_gemma":[0.99421877,0.0019627067,0.00004190537,0.00040388328,0.000107393396,0.00038103102,0.00023668267,0.000098059456,0.0025495791],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99734575,0.00011075316,0.00045010113,0.00061206747,0.00062077283,0.00086053705],"domain_scores_gemma":[0.99883425,0.00003113993,0.00013472255,0.00047494122,0.00020829869,0.00031665654],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028922327,0.00038534633,0.00045670068,0.00017983855,0.00019091579,0.00005749483,0.00022008173,0.00015819918,0.00053898],"category_scores_gemma":[0.000010001349,0.0002625711,0.00015451624,0.00068289484,0.00021577442,0.00008643662,0.00008842109,0.00036472653,0.00001139483],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010503253,0.00026948264,0.018192826,0.00007380251,0.0004246519,0.00037253226,0.000329744,0.000099789155,0.9674948,0.000008607561,0.0018615673,0.009821905],"study_design_scores_gemma":[0.005099219,0.00018391396,0.00473107,0.00017691623,0.00014360769,0.000011860707,0.00007733867,0.00019253964,0.981352,0.000022686003,0.0076973587,0.0003115337],"about_ca_topic_score_codex":0.0025243473,"about_ca_topic_score_gemma":0.00062830513,"teacher_disagreement_score":0.019303812,"about_ca_system_score_codex":0.0007057166,"about_ca_system_score_gemma":0.00036213946,"threshold_uncertainty_score":0.99998266},"labels":[],"label_agreement":null},{"id":"W2121879128","doi":"10.1016/j.ijrobp.2011.06.023","title":"Ki-67 Staining is a Strong Predictor of Patient Outcomes for Prostate Cancer Patients Treated on RTOG 94-08","year":2011,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Proportional hazards model; Oncology; Univariate analysis; Androgen deprivation therapy; Quartile; Biopsy; Multivariate analysis; Cancer; Randomization; Radiation therapy; Urology; Randomized controlled trial; Confidence interval","score_opus":0.039747022849246076,"score_gpt":0.36323376884966535,"score_spread":0.32348674600041927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121879128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99535584,0.0002397975,0.00025019477,0.0011567815,0.0011506992,0.0007342709,0.00066057994,0.000019430754,0.00043238193],"genre_scores_gemma":[0.99752617,0.00044569036,0.0006587043,0.00053067354,0.0003562268,0.00008562363,0.00019194953,0.000030307527,0.00017467505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827784,0.00009733607,0.0007472652,0.00022089128,0.00037917602,0.0002774631],"domain_scores_gemma":[0.9968805,0.0002315748,0.0010750652,0.000121044235,0.0015500368,0.00014180868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021423597,0.00020306092,0.00050728914,0.00022165627,0.00005868971,0.000009841849,0.0002085788,0.00015423285,0.000118295175],"category_scores_gemma":[0.00018595382,0.00014645196,0.00025608475,0.00011358024,0.00015042012,0.0001759773,0.00004272036,0.00027116784,0.0000059181116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003705082,0.0012143678,0.90882415,0.00002021218,0.001295012,0.000011955422,0.0028450373,0.000039442024,0.00036397853,0.00068631856,0.0009828833,0.08001155],"study_design_scores_gemma":[0.053531367,0.032081228,0.8408211,0.0005531465,0.00071726256,0.000020075746,0.0006997326,0.001595936,0.04698269,0.005288543,0.017210316,0.0004985939],"about_ca_topic_score_codex":0.000065421526,"about_ca_topic_score_gemma":0.000004079098,"teacher_disagreement_score":0.079512954,"about_ca_system_score_codex":0.0008799397,"about_ca_system_score_gemma":0.0006067472,"threshold_uncertainty_score":0.59721375},"labels":[],"label_agreement":null},{"id":"W2122468352","doi":"10.1016/j.ijrobp.2009.07.252","title":"Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer","year":2009,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Internal medicine; Androgen deprivation therapy; Concordance; Oncology; Proportional hazards model; Cancer; Prostate-specific antigen; Radiation therapy; Androgen suppression; Hazard ratio; Stage (stratigraphy); Urology; Confidence interval","score_opus":0.029676745485801456,"score_gpt":0.388541773499275,"score_spread":0.35886502801347353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122468352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85444146,0.0012589004,0.032376766,0.10899807,0.0016486122,0.0010350695,0.00015315844,0.000017786482,0.000070174305],"genre_scores_gemma":[0.99538416,0.00038401762,0.0014099214,0.0009037326,0.0016773434,0.00004284111,0.000061273095,0.000012170815,0.00012455908],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986109,0.00009790107,0.0006709846,0.0001527418,0.0002901279,0.00017735836],"domain_scores_gemma":[0.99747366,0.00037836464,0.00074873073,0.00013642739,0.0011948642,0.00006794776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008069926,0.00011657768,0.0002576784,0.000086025626,0.00009336225,0.000032372085,0.0004022488,0.000099852754,0.000020448639],"category_scores_gemma":[0.00040535184,0.00006594859,0.00021312182,0.00015743311,0.00014783967,0.00011808988,0.00004093234,0.00029175903,0.0000038688477],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025857594,0.0004781895,0.025310878,0.000021042017,0.0011731624,0.00001104854,0.0020850394,0.0012629634,0.45783168,0.004057145,0.008036697,0.4971464],"study_design_scores_gemma":[0.02061014,0.007374944,0.09306175,0.00047196978,0.0012417197,0.00039376202,0.0016106667,0.010286527,0.75404924,0.024548467,0.08584327,0.0005075214],"about_ca_topic_score_codex":0.000015148491,"about_ca_topic_score_gemma":0.0000027940164,"teacher_disagreement_score":0.4966389,"about_ca_system_score_codex":0.0003999098,"about_ca_system_score_gemma":0.00047121223,"threshold_uncertainty_score":0.26893055},"labels":[],"label_agreement":null},{"id":"W2122558264","doi":"10.2217/fon.12.3","title":"The Current Role of Circulating Tumor Cells in the Diagnosis and Management of Bone Metastases in Advanced Prostate Cancer","year":2012,"lang":"en","type":"review","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Circulating tumor cell; Management of prostate cancer; Oncology; Cancer; Prostate-specific antigen; Prostate; Internal medicine; Disease; Disease monitoring; Metastasis","score_opus":0.05575054018666093,"score_gpt":0.4170604696478369,"score_spread":0.36130992946117596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122558264","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020107497,0.99387693,8.3258755e-8,0.00035658682,0.00027146083,0.00301263,0.0001283184,0.0000032803703,0.00033994293],"genre_scores_gemma":[0.0018125629,0.99525356,0.00007385667,0.000015321404,0.0001450558,0.0025858488,0.000057160705,0.000019561234,0.00003706117],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998151,0.0004377527,0.00059520884,0.00023591513,0.00023064042,0.00034948386],"domain_scores_gemma":[0.9987797,0.000448967,0.00041157368,0.00026609722,0.00004530281,0.000048343165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008706891,0.00022031128,0.0012060516,0.0001544811,0.000040686853,0.0000051588877,0.0001348883,0.000077125864,0.000016739532],"category_scores_gemma":[0.000013908819,0.000102124395,0.00013695854,0.000404025,0.00014629922,0.000029939321,0.00010855071,0.00045677525,0.0000011814399],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010165046,0.00030121175,0.0008911734,0.01742276,0.00016497269,0.00007724339,0.00056954875,8.371467e-7,0.0000036556107,0.0001293456,0.000096277494,0.9802413],"study_design_scores_gemma":[0.0011368798,0.00021672428,0.0012138569,0.007729141,0.0008734205,0.00001568298,0.00091858703,0.0000011483957,0.000023816938,0.00003159659,0.9877528,0.000086341875],"about_ca_topic_score_codex":0.00006388861,"about_ca_topic_score_gemma":0.000268491,"teacher_disagreement_score":0.98765653,"about_ca_system_score_codex":0.00027006172,"about_ca_system_score_gemma":0.00027522547,"threshold_uncertainty_score":0.4164512},"labels":[],"label_agreement":null},{"id":"W2122572242","doi":"10.1002/pros.22861","title":"Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone","year":2014,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Abiraterone; Medicine; Prostate cancer; Prostate; Oncology; Internal medicine; Prostate disease; Abiraterone acetate; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.0214486952429575,"score_gpt":0.29529711722839896,"score_spread":0.27384842198544146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122572242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98706126,0.00119139,0.00005318946,0.004413417,0.000023876244,0.0024874513,0.00012446858,0.00006295595,0.0045820186],"genre_scores_gemma":[0.9856128,0.0005433983,0.00072915474,0.000097017,0.000032499134,0.00054081227,0.000054145694,0.00006178742,0.01232835],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99805444,0.00012654159,0.0003090188,0.00037069368,0.0005955813,0.00054374686],"domain_scores_gemma":[0.99871653,0.000069173315,0.00019973313,0.000546921,0.00028352762,0.00018409415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038839728,0.00030777988,0.000500445,0.00008824853,0.00015450284,0.000039244525,0.00013071409,0.000027616992,0.00008843155],"category_scores_gemma":[0.000010031566,0.0001305271,0.000053028427,0.00037915102,0.00047015614,0.00010115102,0.000042534557,0.00020058358,0.00001820043],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24184489,0.0051259524,0.24175262,0.0073351446,0.015300891,0.0026080336,0.049389675,0.0028662104,0.32917532,0.0027801765,0.006009003,0.09581208],"study_design_scores_gemma":[0.06477591,0.04590371,0.1373373,0.0037607017,0.0047110557,0.00049532583,0.0060293586,0.0025415882,0.72057873,0.0015262383,0.01081285,0.0015272237],"about_ca_topic_score_codex":0.0009935354,"about_ca_topic_score_gemma":0.00028494265,"teacher_disagreement_score":0.39140344,"about_ca_system_score_codex":0.00016957536,"about_ca_system_score_gemma":0.00039196786,"threshold_uncertainty_score":0.53227407},"labels":[],"label_agreement":null},{"id":"W2122925840","doi":"10.5430/jbgc.v2n1p57","title":"Examining the value PSA=10ng/ml as a cutoff for predicting metastatic bone disease in NaF18 PET/CT bone scans: a pilot study","year":2012,"lang":"en","type":"article","venue":"Journal of Biomedical Graphics and Computing","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Bone metastasis; Metastasis; Confidence interval; Odds ratio; Cutoff; Prostate; Nuclear medicine; Biopsy; Radiology; Cancer; Urology; Internal medicine","score_opus":0.06691965896299512,"score_gpt":0.3549181489475081,"score_spread":0.287998489984513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122925840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98676115,0.009134444,0.0007762933,0.0022972769,0.0002692956,0.00071947963,0.0000073954443,0.000013136425,0.000021526701],"genre_scores_gemma":[0.9980458,0.00041955113,0.0006605154,0.00028950445,0.00051411317,0.0000157192,0.000005904404,0.000023096398,0.000025798448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974444,0.00020525098,0.00076759275,0.00019638495,0.000847392,0.0005390144],"domain_scores_gemma":[0.9979154,0.0007920552,0.00034120743,0.00015170722,0.00014441166,0.00065523636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003903005,0.00018811302,0.0005134454,0.00045597742,0.00027815226,0.000062153704,0.0001261567,0.000010874038,0.000006470483],"category_scores_gemma":[0.0005949711,0.00010887992,0.000116839954,0.0005640617,0.00025588888,0.00012480935,0.00011606311,0.000567191,3.6249133e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050085383,0.010907131,0.91709036,0.0011778126,0.0018151373,0.00893374,0.0056661307,0.000045678447,0.0011442937,0.0010180501,0.0005473973,0.04664575],"study_design_scores_gemma":[0.058108427,0.051896796,0.67318666,0.0076383813,0.0042707087,0.014508069,0.03419773,0.1482266,0.000121732024,0.0035763266,0.0032157754,0.0010527937],"about_ca_topic_score_codex":0.00007008006,"about_ca_topic_score_gemma":0.0000040936843,"teacher_disagreement_score":0.24390368,"about_ca_system_score_codex":0.00006661993,"about_ca_system_score_gemma":0.00028583748,"threshold_uncertainty_score":0.4439994},"labels":[],"label_agreement":null},{"id":"W2123098020","doi":"10.1158/1078-0432.ccr-07-0944","title":"Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study","year":2008,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":208,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Mitoxantrone; Docetaxel; Prostate cancer; Quality of life (healthcare); Internal medicine; Oncology; Prostate-specific antigen; Cancer; Chemotherapy","score_opus":0.4838946235681214,"score_gpt":0.5233336333598677,"score_spread":0.039439009791746305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123098020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9647816,0.027337467,0.0000016296827,0.003595945,0.000033439574,0.0039500427,0.00025103235,0.000013199701,0.000035665387],"genre_scores_gemma":[0.9236792,0.07447403,0.000045173267,0.000017752496,0.00015892925,0.0007264551,0.00002040889,0.000033776392,0.0008442825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9891401,0.0068703014,0.0012030213,0.00071159546,0.0014495568,0.00062543293],"domain_scores_gemma":[0.98964465,0.008352424,0.00026235456,0.00064707134,0.0007119,0.00038161202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012221822,0.00026455696,0.0010807755,0.0002972217,0.0003420563,0.000027868351,0.00019104149,0.00016611241,0.000032004777],"category_scores_gemma":[0.0017635139,0.000135958,0.00008800577,0.0009774604,0.002150425,0.0001272063,0.00009560067,0.0009623769,0.000001575416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09327546,0.0021306819,0.8872709,0.00013621768,0.0003229396,0.0001358627,0.008484083,0.0000020723996,0.00060453464,0.0000058858755,0.00035708176,0.0072742873],"study_design_scores_gemma":[0.016175725,0.019894486,0.9531374,0.00011791123,0.000050739327,0.0000031358738,0.007784576,0.00000859265,0.00012789904,0.000012461874,0.0025422159,0.0001448686],"about_ca_topic_score_codex":0.0048276633,"about_ca_topic_score_gemma":0.0022524884,"teacher_disagreement_score":0.07709973,"about_ca_system_score_codex":0.000281526,"about_ca_system_score_gemma":0.0023311428,"threshold_uncertainty_score":0.79233307},"labels":[],"label_agreement":null},{"id":"W2123526148","doi":"10.1016/s0140-6736(10)61389-x","title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","year":2010,"lang":"en","type":"article","venue":"The Lancet","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3284,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Cabazitaxel; Mitoxantrone; Docetaxel; Medicine; Prostate cancer; Prednisone; Internal medicine; Oncology; Taxane; Enzalutamide; Clinical endpoint; Abiraterone acetate; Hazard ratio; Randomized controlled trial; Cancer; Surgery; Chemotherapy; Androgen deprivation therapy; Confidence interval; Breast cancer","score_opus":0.13283047456194982,"score_gpt":0.4254878231418871,"score_spread":0.2926573485799373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123526148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9603578,0.0037444537,0.000037660953,0.01485089,0.0005627847,0.018923443,0.0009870243,0.00008432426,0.00045165126],"genre_scores_gemma":[0.94388676,0.0008769187,0.007240989,0.00037554314,0.0021907724,0.024680475,0.00023041703,0.00009136805,0.020426761],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978687,0.00011873198,0.00044736697,0.0004590649,0.00036199906,0.00074412586],"domain_scores_gemma":[0.99842876,0.00031671388,0.00020584629,0.00066288566,0.00018919336,0.00019662714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006037885,0.0003373041,0.0010299429,0.00006933357,0.00035916417,0.0003395327,0.00032007368,0.00007508929,0.00025725484],"category_scores_gemma":[0.00014491157,0.00016048958,0.000119058364,0.0002202032,0.00025081597,0.00021836541,0.00007051815,0.0002695791,0.000013247243],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94694936,0.0010877899,0.00019993423,0.00029009153,0.000977677,0.0001524836,0.0016552251,0.0000028107881,0.02685197,0.00004141629,0.003386181,0.01840503],"study_design_scores_gemma":[0.9632098,0.0043082996,0.00053725817,0.00028253088,0.0012548221,0.000046093253,0.00020782326,0.0012435332,0.0087406365,0.00021842888,0.019651346,0.0002994141],"about_ca_topic_score_codex":0.00037614896,"about_ca_topic_score_gemma":0.0017406375,"teacher_disagreement_score":0.019975109,"about_ca_system_score_codex":0.0002467706,"about_ca_system_score_gemma":0.0013965138,"threshold_uncertainty_score":0.6544575},"labels":[],"label_agreement":null},{"id":"W2123864864","doi":"10.1016/j.ijrobp.2010.07.915","title":"Effect of Androgen Deprivation Therapy on Hemoglobin, Testosterone and Erythropoietin Levels in Prostate Cancer Patients Receiving Radiotherapy","year":2010,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Erythropoietin; Hemoglobin; Radiation therapy; Internal medicine; Urology; Testosterone (patch); Prospective cohort study; Androgen; Gastroenterology; Cancer; Incidence (geometry); Anemia; Hormone","score_opus":0.018007924615671977,"score_gpt":0.3593365843958038,"score_spread":0.3413286597801318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123864864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99569756,0.0008556328,0.0000680547,0.0018991311,0.0008643141,0.000494708,0.00004060208,0.000009538236,0.00007048263],"genre_scores_gemma":[0.9949981,0.003665798,0.00047270244,0.0002627948,0.00048205667,0.000024959018,0.00004509767,0.00002158132,0.00002692818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870026,0.00020302166,0.00048458605,0.00018483216,0.00025457723,0.00017270244],"domain_scores_gemma":[0.9983669,0.00041913468,0.0005840338,0.00009648501,0.00045480492,0.00007865909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006294596,0.00015851436,0.0004081045,0.00020608917,0.00003629341,0.000014090705,0.00014188903,0.00014352864,0.000038935737],"category_scores_gemma":[0.00020673948,0.000115048795,0.000081916616,0.0001486417,0.00017859747,0.00016678756,0.000023677183,0.00044310183,0.0000016144056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001788903,0.00029516694,0.6157173,0.000011018124,0.00017602253,0.0000074172067,0.00041089344,0.000028734934,0.03962609,0.000052194704,0.000066416964,0.34181982],"study_design_scores_gemma":[0.03503631,0.01106233,0.8045599,0.00021805176,0.00004886758,0.0000611672,0.000018948129,0.000474656,0.14394927,0.0007444185,0.0036459928,0.00018009743],"about_ca_topic_score_codex":0.00003652373,"about_ca_topic_score_gemma":0.000009122769,"teacher_disagreement_score":0.34163973,"about_ca_system_score_codex":0.000419077,"about_ca_system_score_gemma":0.00031298609,"threshold_uncertainty_score":0.46915537},"labels":[],"label_agreement":null},{"id":"W2124972309","doi":"","title":"Whole-transcriptome analysis reveals established and novel associations with TMPRSS2:ERG fusion in prostate cancer.","year":2012,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"TMPRSS2; Prostate cancer; Fusion gene; Biology; Cancer research; Prostate; Wnt signaling pathway; Transcriptome; Cancer; Erg; PCA3; Chromoplexy; Gene; Genetics; Gene expression; Internal medicine; Medicine","score_opus":0.03191397245546166,"score_gpt":0.29427548360320893,"score_spread":0.26236151114774725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124972309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99077296,0.0025845866,0.000032888973,0.0038809453,0.00006533467,0.0014257064,0.0001681979,0.000037843965,0.0010315198],"genre_scores_gemma":[0.990978,0.00056157185,0.000121878846,0.00013501306,0.000085854546,0.0020800757,0.00017307197,0.000018501409,0.005846021],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850047,0.00003875669,0.00021049017,0.00024286895,0.0003547051,0.0006527065],"domain_scores_gemma":[0.99927443,0.000049594124,0.00007410212,0.00017656213,0.000112062124,0.00031324875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005304759,0.0001404527,0.00036379832,0.0004052681,0.0000828553,0.000042963395,0.00004874671,0.000061179795,0.000023805713],"category_scores_gemma":[0.000058831778,0.000097434066,0.000055814297,0.0014289648,0.00006637875,0.0003106829,0.000025126941,0.00018370105,0.0000018632633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029270214,0.00027885192,0.9878568,0.000055213855,0.00049968873,0.000009312733,0.0008637655,0.0000106736625,0.002422863,0.000024827677,0.00024663532,0.007438672],"study_design_scores_gemma":[0.0032175907,0.000038884144,0.9939787,0.00002874356,0.00060478156,0.00000319563,0.00014921298,0.000043411244,0.00037131543,0.000011966263,0.0014353042,0.000116901014],"about_ca_topic_score_codex":0.0007391532,"about_ca_topic_score_gemma":0.00057885674,"teacher_disagreement_score":0.007321771,"about_ca_system_score_codex":0.00034345646,"about_ca_system_score_gemma":0.00008092951,"threshold_uncertainty_score":0.3973246},"labels":[],"label_agreement":null},{"id":"W2125013165","doi":"10.1186/1471-2164-7-246","title":"Analysis of the prostate cancer cell line LNCaP transcriptome using a sequencing-by-synthesis approach","year":2006,"lang":"en","type":"article","venue":"BMC Genomics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":213,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Michael Smith Health Research BC","keywords":"Biology; Computational biology; Transcriptome; Alternative splicing; Genetics; Cancer genome sequencing; LNCaP; DNA sequencing; Human genome; Exon; Gene; Genome; Prostate cancer; Cancer; Gene expression","score_opus":0.050481926977694616,"score_gpt":0.2914185630568272,"score_spread":0.24093663607913257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125013165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99193084,0.0050673406,0.0006324864,0.00010994683,0.000047302477,0.00060027797,0.0003306876,0.000017739141,0.0012633569],"genre_scores_gemma":[0.9943949,0.00046878107,0.002025382,0.000044390225,0.00007446033,0.00006879505,0.000066614004,0.000031219624,0.0028254834],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987672,0.00005604821,0.00031328786,0.0002792395,0.0002725146,0.00031173803],"domain_scores_gemma":[0.9992939,0.00003819242,0.00012805907,0.00036424832,0.0001058544,0.00006972677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018075452,0.00016265313,0.00041174275,0.00012464871,0.00009315619,0.000017353566,0.00014315028,0.00007783586,0.00007018088],"category_scores_gemma":[0.0000083912,0.00010501286,0.00030053625,0.0007091349,0.000120091565,0.00004288067,0.000031332365,0.00011485885,0.0000011129359],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039494628,0.0003447565,0.11590002,0.00042112963,0.00081365847,0.0000032682258,0.0010782657,0.023286942,0.8570208,0.000009522558,0.00027420514,0.00045247172],"study_design_scores_gemma":[0.0029532956,0.00012043849,0.022398554,0.00009087912,0.008507723,0.0000072697294,0.0013943922,0.12332556,0.8389852,0.00003885325,0.0017823373,0.00039548668],"about_ca_topic_score_codex":0.005111652,"about_ca_topic_score_gemma":0.0006508146,"teacher_disagreement_score":0.10003861,"about_ca_system_score_codex":0.0007684435,"about_ca_system_score_gemma":0.0005848044,"threshold_uncertainty_score":0.7727323},"labels":[],"label_agreement":null},{"id":"W2125346129","doi":"10.1530/erc-13-0293","title":"TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth","year":2013,"lang":"en","type":"article","venue":"Endocrine Related Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"York University; National Cancer Institute; National Institutes of Health; DOD Prostate Cancer Research Program; National Center for Research Resources; Office of Research and Development; U.S. Department of Veterans Affairs; U.S. Department of Defense","keywords":"Coactivator; Androgen receptor; Prostate cancer; Cancer research; Corepressor; Nuclear receptor coactivator 3; Nuclear receptor; Endocrinology; Androgen; Biology; Ectopic expression; LNCaP; Internal medicine; Cell growth; Prostate; Cancer; Chemistry; Cell biology; Medicine; Cell culture; Hormone; Gene; Transcription factor; Genetics","score_opus":0.013000437079938474,"score_gpt":0.31160680758527864,"score_spread":0.29860637050534017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125346129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97514784,0.008160414,0.0000041235744,0.010777783,0.00040459234,0.0030504602,0.00018620557,0.00032461592,0.0019439904],"genre_scores_gemma":[0.9531387,0.010553514,0.00065379246,0.0009064719,0.0005884624,0.00409773,0.00025774477,0.00020989982,0.029593647],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965843,0.00013099797,0.00047807276,0.00095997023,0.00065422826,0.0011924239],"domain_scores_gemma":[0.9976504,0.00006987555,0.00016240528,0.00041665806,0.0007744928,0.00092617463],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011030604,0.00054298976,0.0006971547,0.00034161436,0.0002710337,0.00010092626,0.00022572206,0.00016545161,0.007697391],"category_scores_gemma":[0.00009411474,0.00041551678,0.0001541074,0.0012373728,0.00014255337,0.00069914,0.00012789684,0.000673678,0.0006785498],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039456184,0.00093182485,0.2163117,0.00031453956,0.0025697867,0.00028110915,0.0028018928,0.00012961756,0.67059326,0.00018000042,0.050148793,0.05179184],"study_design_scores_gemma":[0.004997079,0.0012451197,0.010708103,0.00034765693,0.00015996065,0.000077085,0.00033203023,0.00009647363,0.91887844,0.000508897,0.062049806,0.0005993352],"about_ca_topic_score_codex":0.010193389,"about_ca_topic_score_gemma":0.00008777539,"teacher_disagreement_score":0.24828516,"about_ca_system_score_codex":0.001152765,"about_ca_system_score_gemma":0.0009962262,"threshold_uncertainty_score":0.99982965},"labels":[],"label_agreement":null},{"id":"W2125446878","doi":"10.1158/0008-5472.can-05-0399","title":"Somatic Mosaicism and Cancer: A Micro-Genetic Examination into the Role of the Androgen Receptor Gene in Prostate Cancer","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"John Abbott College; McGill University; Immunovaccine (Canada); Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Androgen receptor; Prostate; Somatic cell; Cancer; Biology; Genetic heterogeneity; Cancer research; Gene; Genetics; Phenotype","score_opus":0.02907656777478963,"score_gpt":0.36201813686124296,"score_spread":0.33294156908645334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125446878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8808264,0.108489,3.7574537e-7,0.008648746,0.000065475564,0.0017374668,0.000050412273,0.0000104756355,0.0001716113],"genre_scores_gemma":[0.95053,0.04417909,0.00010384019,0.00009248915,0.00021794622,0.0019812132,0.000008481539,0.00003462229,0.0028523093],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99760807,0.00033445307,0.0003148951,0.00037308154,0.0008005052,0.00056901504],"domain_scores_gemma":[0.9988755,0.0001299228,0.00007968556,0.0004182029,0.00036208602,0.00013463148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008532016,0.00016267014,0.00027213877,0.00021128618,0.00024780873,0.000039722592,0.00028786287,0.0000791885,0.00028984962],"category_scores_gemma":[0.00006531875,0.00009058894,0.00005482893,0.00091474626,0.00056497904,0.00009101774,0.00020765894,0.000497351,0.000008301184],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032798186,0.00010896088,0.14931592,0.0002496807,0.000098280645,0.0000050476356,0.009998313,0.000079545935,0.46569878,0.000012994876,0.0004323414,0.37367213],"study_design_scores_gemma":[0.002907469,0.00019187434,0.14294735,0.0007615164,0.000055446144,0.000008918702,0.0015623801,0.0007616645,0.82905734,0.00035578437,0.021232266,0.0001580106],"about_ca_topic_score_codex":0.008125492,"about_ca_topic_score_gemma":0.0040742657,"teacher_disagreement_score":0.37351412,"about_ca_system_score_codex":0.00097425224,"about_ca_system_score_gemma":0.0010641909,"threshold_uncertainty_score":0.9984795},"labels":[],"label_agreement":null},{"id":"W2125942853","doi":"10.1200/jco.2007.11.4769","title":"Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":274,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Mitoxantrone; Prostate cancer; Docetaxel; Prostate-specific antigen; Oncology; Internal medicine; Hazard ratio; Proportional hazards model; Prostate; Chemotherapy; Urology; Cancer","score_opus":0.13679853117234395,"score_gpt":0.49702988955167593,"score_spread":0.36023135837933196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125942853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97141224,0.023056928,0.000111923386,0.0043092626,0.00026068123,0.00043688016,0.000009808654,0.000007705954,0.0003945699],"genre_scores_gemma":[0.9436057,0.053563416,0.0014354622,0.000557485,0.00031084838,0.000008458383,0.000009544606,0.000018514504,0.0004905745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956803,0.0007096432,0.0023311423,0.0002856449,0.0005094566,0.00048386914],"domain_scores_gemma":[0.9949564,0.0027667016,0.0010647606,0.0001785795,0.00047673378,0.000556857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015057503,0.0001775219,0.0017254611,0.0007281167,0.000046188452,0.000018862045,0.00011581342,0.00020188978,0.00010858951],"category_scores_gemma":[0.0013033228,0.00011536648,0.00040524526,0.00087931193,0.00035298406,0.00018361269,0.000047642206,0.0010917936,0.000005040362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014538449,0.0013705543,0.65341604,0.000036735655,0.001577413,0.0032924016,0.00054191967,0.00001686468,0.00075124606,0.000011922526,0.0012860072,0.32316047],"study_design_scores_gemma":[0.011006687,0.009311323,0.9031235,0.00006807909,0.00065922743,0.000042155014,0.000626923,0.00009878092,0.00008451175,0.00015494737,0.07470747,0.000116401556],"about_ca_topic_score_codex":0.00015671257,"about_ca_topic_score_gemma":0.0005126803,"teacher_disagreement_score":0.32304406,"about_ca_system_score_codex":0.00035048882,"about_ca_system_score_gemma":0.0014096578,"threshold_uncertainty_score":0.521866},"labels":[],"label_agreement":null},{"id":"W2126040395","doi":"10.1074/jbc.m703370200","title":"UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 Enzymes Are Major Determinants of the Androgen Response in Prostate Cancer LNCaP Cells","year":2007,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research","keywords":"LNCaP; Prostate cancer; Androgen; Enzyme; Cancer research; Glucuronosyltransferase; Internal medicine; Medicine; Endocrinology; Chemistry; Cancer; Biochemistry; Hormone","score_opus":0.027235143547481452,"score_gpt":0.32079428775638247,"score_spread":0.293559144208901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126040395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99188,0.0070554367,0.0000011546518,0.00068696914,0.00005291615,0.00021554844,0.000043136668,0.0000037676068,0.00006109085],"genre_scores_gemma":[0.9972236,0.0021741767,0.000047859357,0.00007314501,0.000085479485,0.000005016406,0.0000012460109,0.000008144288,0.00038132595],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987311,0.00007501125,0.00050446833,0.00016270197,0.00023549005,0.00029124322],"domain_scores_gemma":[0.9990753,0.00022182039,0.00025021448,0.00013890889,0.00013163114,0.00018210901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009185806,0.00014525325,0.00042203735,0.00004722328,0.000042082618,0.000009048249,0.00013869,0.00013974974,0.00008266179],"category_scores_gemma":[0.00019155472,0.00007208008,0.00013314126,0.00016860392,0.0002787268,0.000037976897,0.00004748925,0.00037741798,4.7647774e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01103034,0.00015065803,0.39136428,0.00013343555,0.000037646943,0.0005092207,0.00011876483,0.0000010208953,0.5949061,1.6435251e-7,0.000059150785,0.001689211],"study_design_scores_gemma":[0.002732989,0.0003814109,0.22632967,0.00035569357,0.000033175715,0.0001887047,0.00026988177,0.0000031866985,0.76925933,0.00002022123,0.00035889103,0.0000668384],"about_ca_topic_score_codex":0.000014863196,"about_ca_topic_score_gemma":0.000008744287,"teacher_disagreement_score":0.17435323,"about_ca_system_score_codex":0.00011368796,"about_ca_system_score_gemma":0.00020227798,"threshold_uncertainty_score":0.29393402},"labels":[],"label_agreement":null},{"id":"W2126565162","doi":"10.1093/annonc/mdm554","title":"A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Queen's University; University Health Network; Hamilton Health Sciences; Juravinski Cancer Centre; CancerCare Manitoba; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Sorafenib; Prostate cancer; Internal medicine; Prostate-specific antigen; Discontinuation; Oncology; Clinical endpoint; Adverse effect; Urology; Cancer; Clinical trial; Hepatocellular carcinoma","score_opus":0.08156833559138355,"score_gpt":0.4511618509292627,"score_spread":0.36959351533787915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126565162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99669355,0.0002564107,7.870996e-7,0.0006687187,0.000033626373,0.0012835212,0.0000353187,0.000005579991,0.0010225021],"genre_scores_gemma":[0.99934393,0.000084564155,0.000048809936,0.00008440673,0.000021251402,0.0000564605,0.000029650766,0.000010328944,0.00032060174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887586,0.000037280948,0.00035699166,0.00017980463,0.00027583307,0.00027423663],"domain_scores_gemma":[0.9990375,0.000050346345,0.00017957776,0.00014405284,0.00050175417,0.000086761844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031248605,0.0001009277,0.00038310172,0.00018674492,0.00003366198,0.0000015532917,0.000052972533,0.000058428694,0.000051863324],"category_scores_gemma":[0.000027689479,0.000069802205,0.000028534912,0.0002975793,0.00012186046,0.000052848867,0.000028599889,0.00012078694,7.9173685e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07694255,0.054984745,0.73482823,0.00019572188,0.00054376625,0.00039188375,0.015742743,0.000015870342,0.008296926,0.000025611218,0.000819547,0.10721238],"study_design_scores_gemma":[0.0750731,0.17478506,0.70737964,0.00016078251,0.00009592363,0.0000018571391,0.0032299778,0.0000059486542,0.037727863,0.000034395704,0.0013771089,0.00012832414],"about_ca_topic_score_codex":0.0007754576,"about_ca_topic_score_gemma":0.0016673614,"teacher_disagreement_score":0.119800314,"about_ca_system_score_codex":0.00009361681,"about_ca_system_score_gemma":0.0004671826,"threshold_uncertainty_score":0.28464514},"labels":[],"label_agreement":null},{"id":"W2127118734","doi":"10.1158/0008-5472.can-04-4292","title":"Inhibition of HER-2/neu Kinase Impairs Androgen Receptor Recruitment to the Androgen Responsive Enhancer","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Androgen receptor; LNCaP; Cancer research; Prostate cancer; Androgen; Endocrinology; Biology; Tyrosine kinase; Epidermal growth factor; Internal medicine; Signal transduction; Medicine; Cancer; Receptor; Cell biology","score_opus":0.12704880667327142,"score_gpt":0.4416002549281202,"score_spread":0.3145514482548488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127118734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9521521,0.009513049,0.000011361904,0.03230877,0.00012502765,0.0037915087,0.00016510597,0.000036969883,0.0018961468],"genre_scores_gemma":[0.9787369,0.0049552824,0.00024620813,0.00048337693,0.0008116048,0.0030540372,0.0000632769,0.000054757074,0.01159455],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99659455,0.00039427239,0.00036136224,0.0005200839,0.001301469,0.00082829],"domain_scores_gemma":[0.9976294,0.00022547302,0.0000641632,0.00066943653,0.00096657523,0.0004449695],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016800482,0.00019874016,0.00034515758,0.0003959892,0.0002899266,0.000040482995,0.00023339683,0.0001195604,0.0019211831],"category_scores_gemma":[0.0002289191,0.00012715247,0.00013731747,0.0011990393,0.0003343701,0.00012159825,0.0002208567,0.000534792,0.00039109355],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010672475,0.00060062844,0.0030440527,0.00027034178,0.00038588594,0.000101032645,0.0062032673,0.000078413104,0.68626994,0.00013241594,0.12522049,0.16702107],"study_design_scores_gemma":[0.0019334876,0.0011207337,0.0006639838,0.00035502552,0.000029873334,0.0000092928185,0.0008339649,0.000015226171,0.7305712,0.000044275836,0.264303,0.000119943375],"about_ca_topic_score_codex":0.0003484467,"about_ca_topic_score_gemma":0.0003079721,"teacher_disagreement_score":0.16690113,"about_ca_system_score_codex":0.0013278703,"about_ca_system_score_gemma":0.0011458246,"threshold_uncertainty_score":0.9989912},"labels":[],"label_agreement":null},{"id":"W2127458009","doi":"10.1093/carcin/bgs337","title":"Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage","year":2012,"lang":"en","type":"article","venue":"Carcinogenesis","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Transactivation; Androgen receptor; Prostate cancer; Androgen deprivation therapy; Androgen; Castration; Cancer research; Orchiectomy; Internal medicine; Biology; Medicine; Endocrinology; Cancer; Transcription factor; Gene; Hormone; Biochemistry","score_opus":0.0331418835317584,"score_gpt":0.2927838540249543,"score_spread":0.25964197049319593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127458009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99077535,0.0053788433,0.000009309638,0.001026905,0.00014496571,0.0015799518,0.00058798527,0.00011205916,0.0003846176],"genre_scores_gemma":[0.9936415,0.0008709128,0.00017064971,0.000117268166,0.00019823479,0.00059657014,0.0008515092,0.00006354224,0.0034897958],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99802464,0.00010999492,0.0003164804,0.00036319828,0.00052200875,0.0006636978],"domain_scores_gemma":[0.9987139,0.00008645508,0.00011144497,0.0002718399,0.00032812502,0.00048819746],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027522029,0.00027635795,0.00034785763,0.00017368932,0.0002370224,0.000026647607,0.00008027947,0.00013514009,0.0010785764],"category_scores_gemma":[0.0000767735,0.00021453707,0.00012260365,0.00046227092,0.00011095565,0.00027318764,0.000025082149,0.00012775109,0.00007891001],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015819872,0.00021923015,0.4523948,0.00029505548,0.000179338,0.000016865408,0.0010927885,8.6159923e-7,0.5426464,0.000015631516,0.00044459224,0.0011124427],"study_design_scores_gemma":[0.0027528664,0.00025964927,0.27318,0.000085138505,0.00018561876,0.000009606249,0.00019939645,0.000031163265,0.72068834,0.000004142461,0.0023729233,0.00023112571],"about_ca_topic_score_codex":0.00088930654,"about_ca_topic_score_gemma":0.000100334306,"teacher_disagreement_score":0.17921482,"about_ca_system_score_codex":0.0007433801,"about_ca_system_score_gemma":0.00042638992,"threshold_uncertainty_score":0.9998346},"labels":[],"label_agreement":null},{"id":"W2127650989","doi":"10.1200/jco.2010.34.3996","title":"Chemotherapy-Based Treatment for Castration-Resistant Prostate Cancer","year":2011,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Docetaxel; Cabazitaxel; Medicine; Mitoxantrone; Prostate cancer; Taxane; Oncology; Internal medicine; Abiraterone acetate; Chemotherapy; Bevacizumab; Cancer; Clinical trial; Androgen deprivation therapy; Breast cancer","score_opus":0.46970167107768035,"score_gpt":0.6066352992605301,"score_spread":0.1369336281828497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127650989","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012894123,0.9940793,0.00001761881,0.0017499265,0.0010670229,0.0021853517,0.00011779517,0.000009192982,0.00064484816],"genre_scores_gemma":[0.00003658711,0.991376,0.0021924085,0.00033875112,0.0018685712,0.00032865754,0.000054488624,0.00006212322,0.0037424332],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995671,0.0003411288,0.0030540356,0.0003051785,0.00026497233,0.00036371787],"domain_scores_gemma":[0.99384254,0.0017530711,0.00299894,0.0002543728,0.00067124714,0.00047983645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016138384,0.00035727935,0.005058742,0.00021733314,0.000055182547,0.000013303128,0.00017146744,0.0007251257,0.00029420198],"category_scores_gemma":[0.00040083585,0.00018559108,0.0024405736,0.00014733979,0.00020996739,0.00004651692,0.000012256659,0.0007057242,0.000012953941],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008627165,0.0019611055,0.00009923245,0.003247904,0.002275242,0.00032945973,0.000041084106,3.8540935e-7,0.0000011770003,0.000020762827,0.0029470194,0.98044944],"study_design_scores_gemma":[0.013772772,0.03228965,0.000113779606,0.004640927,0.004240916,0.000073897965,0.000010300168,0.0000034662423,0.000010066111,0.000053985856,0.94464815,0.00014209378],"about_ca_topic_score_codex":0.00004289188,"about_ca_topic_score_gemma":0.000058375565,"teacher_disagreement_score":0.98030734,"about_ca_system_score_codex":0.0011465405,"about_ca_system_score_gemma":0.022716356,"threshold_uncertainty_score":0.9828239},"labels":[],"label_agreement":null},{"id":"W2127778583","doi":"10.1093/jmcb/mjs020","title":"Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression","year":2012,"lang":"en","type":"article","venue":"Journal of Molecular Cell Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Japan Society for the Promotion of Science; Council for Science and Technology Policy; Liber Ero Foundation; University of Tokyo; University of Washington; National Cancer Institute; Prostate Cancer Foundation","keywords":"Androgen suppression; Prostate cancer; Androgen; Biomarker; Disease; Prostate-specific antigen; Medicine; Oncology; Cancer; Bioinformatics; Hormone; Internal medicine; Biology","score_opus":0.023063770383527787,"score_gpt":0.32254681626736964,"score_spread":0.29948304588384184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127778583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963173,0.0019428318,0.0009723119,0.00008645423,0.000032942233,0.00024134754,0.000028687342,0.000001961887,0.00037613002],"genre_scores_gemma":[0.99827945,0.00032889025,0.0012612069,0.000011214156,0.000010614975,0.0000050979365,0.000032067775,0.000013393514,0.000058069098],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990624,0.00008137098,0.00039676562,0.00007894442,0.0001824569,0.00019806827],"domain_scores_gemma":[0.99898,0.000030324198,0.0003338349,0.000091264614,0.00045231666,0.000112302914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001556516,0.000104989995,0.00039987997,0.0001338931,0.000013262109,0.0000017547311,0.00006435931,0.00007229476,0.000047872512],"category_scores_gemma":[0.000026649694,0.00005752294,0.0000974371,0.00009419672,0.00010402148,0.000045224268,0.00003203084,0.00014488328,0.0000011983458],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012088214,0.0029392473,0.6195235,0.0008460221,0.0011352482,0.00009586232,0.001959628,0.0006282729,0.3538785,0.00019989522,0.000034753546,0.006670821],"study_design_scores_gemma":[0.01392404,0.019973444,0.0034627016,0.0017553868,0.0010236927,0.00008378043,0.0009991083,0.031352047,0.92673844,0.00035232012,0.000065251545,0.00026979332],"about_ca_topic_score_codex":0.000013894822,"about_ca_topic_score_gemma":8.6641035e-7,"teacher_disagreement_score":0.61606085,"about_ca_system_score_codex":0.00008367747,"about_ca_system_score_gemma":0.000093865674,"threshold_uncertainty_score":0.23457174},"labels":[],"label_agreement":null},{"id":"W2127851117","doi":"10.1016/j.urolonc.2007.05.010","title":"Therapeutic options for hormone-refractory prostate cancer in 2007","year":2007,"lang":"en","type":"review","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Oncology; Cancer; Disease; Clinical trial; Chemotherapy; Internal medicine; Prostatectomy; Prostate; Cancer research","score_opus":0.12100402262422334,"score_gpt":0.4518026388460617,"score_spread":0.33079861622183837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127851117","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038993626,0.99342865,0.000018873043,0.0016765863,0.00028024436,0.0030133165,0.0002776515,0.000051480678,0.0008632554],"genre_scores_gemma":[0.000009764162,0.9857874,0.005216274,0.0005760191,0.0002950437,0.00239385,0.0004752826,0.000045354653,0.0052010054],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978499,0.00015102018,0.00060535845,0.0005868426,0.00016987609,0.0006369932],"domain_scores_gemma":[0.99838835,0.00067504705,0.00025975748,0.00024448338,0.00010614837,0.00032621817],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006400171,0.00041621868,0.0013310148,0.00057718036,0.0002218139,0.000024659883,0.00013237503,0.00072829047,0.00009184248],"category_scores_gemma":[0.00008201966,0.0002929932,0.00021922948,0.00052549574,0.00079023745,0.00008505823,0.000048573715,0.00090140966,0.000019378225],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023226543,0.00039402256,0.0028875554,0.0026294813,0.00030555748,0.00020399138,0.00021061956,0.000003916755,0.0000061089663,0.0016034766,0.006878707,0.9846443],"study_design_scores_gemma":[0.0012613782,0.0021290295,0.00009879815,0.0014998516,0.001275938,0.00016059594,0.00005945495,0.000033497992,0.0000010968996,0.0011838004,0.9920375,0.00025907764],"about_ca_topic_score_codex":0.00006769008,"about_ca_topic_score_gemma":0.00006674643,"teacher_disagreement_score":0.9851588,"about_ca_system_score_codex":0.0007312164,"about_ca_system_score_gemma":0.0022530267,"threshold_uncertainty_score":0.9999522},"labels":[],"label_agreement":null},{"id":"W2129099526","doi":"10.1158/0008-5472.can-07-5237","title":"<i>ASAP1</i>, a Gene at 8q24, Is Associated with Prostate Cancer Metastasis","year":2008,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; Princess Margaret Cancer Centre; BC Cancer Agency; Ontario Institute for Cancer Research","funders":"Canadian Prostate Cancer Research Initiative; Michael Smith Health Research BC; Canadian Institutes of Health Research; Cancer Research Society; National Cancer Institute; Prostate Cancer Foundation","keywords":"Prostate cancer; Metastasis; Prostate; Cancer research; Cancer; Biology; Pathology; PCA3; Medicine; Internal medicine","score_opus":0.1407281959343804,"score_gpt":0.4234833091770286,"score_spread":0.2827551132426482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129099526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9681618,0.018212743,0.0000022362915,0.008421653,0.0000974246,0.0017411362,0.0005779711,0.00011421535,0.0026707763],"genre_scores_gemma":[0.85231185,0.02876259,0.000086565604,0.00066247856,0.00025581146,0.0021951853,0.00017063065,0.00012213924,0.11543273],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99480414,0.00024419202,0.00031418688,0.00084164145,0.002240762,0.0015550677],"domain_scores_gemma":[0.996994,0.00017072096,0.000088074645,0.0006345931,0.0014479468,0.00066461635],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007538017,0.00033016477,0.00060991815,0.0004215783,0.00088076567,0.000046553458,0.00027616965,0.00015619372,0.0033651618],"category_scores_gemma":[0.00011143287,0.00022551735,0.00014551038,0.0018745888,0.00096333434,0.00017002547,0.00025086384,0.00086251495,0.00019689855],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019394683,0.0013745415,0.40736964,0.00057312136,0.004677975,0.00675521,0.0096651465,0.000057313595,0.17939639,0.000023034505,0.354896,0.015816947],"study_design_scores_gemma":[0.017790796,0.002502985,0.07997658,0.001094988,0.0003717369,0.00032173708,0.00037582224,0.00010947695,0.76281494,0.00007141747,0.13374619,0.0008233495],"about_ca_topic_score_codex":0.0024555158,"about_ca_topic_score_gemma":0.0007543238,"teacher_disagreement_score":0.58341855,"about_ca_system_score_codex":0.0026821592,"about_ca_system_score_gemma":0.0025586113,"threshold_uncertainty_score":0.9975459},"labels":[],"label_agreement":null},{"id":"W2129709531","doi":"10.1016/j.urology.2007.06.675","title":"POS-03.126: SIOG (International Society of Geriatric Oncology) prostate cancer guidelines proposals in senior adult men","year":2007,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Life expectancy; Guideline; Management of prostate cancer; Geriatric oncology; Oncology; Gerontology; Gynecology; Incidence (geometry); Cancer; Internal medicine; Population; Pathology; Environmental health","score_opus":0.028885451034019256,"score_gpt":0.39377220295891846,"score_spread":0.3648867519248992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129709531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93139404,0.0022284286,0.000050283124,0.053878576,0.00048026597,0.0011436789,0.00006253084,0.00004544598,0.010716759],"genre_scores_gemma":[0.972063,0.006911438,0.0037084364,0.0033129854,0.00077483774,0.00017678145,0.00012859056,0.000040287494,0.012883653],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99847895,0.000040032635,0.0005047502,0.0002913409,0.00026785937,0.0004170384],"domain_scores_gemma":[0.9988965,0.00009332403,0.00013012825,0.000153633,0.00062672095,0.000099716475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057892955,0.0001354106,0.00033840587,0.00019365417,0.000030386533,0.000004025748,0.00012226145,0.00019583732,0.00026803877],"category_scores_gemma":[0.00011894076,0.00009874556,0.000105357256,0.0002879821,0.00016539135,0.000050365492,0.00007840404,0.0002335699,0.00002535222],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011876193,0.0014296739,0.6220415,0.00034026045,0.0009040562,0.0006516559,0.0039838497,0.00016790105,0.1147818,0.00025534927,0.1581448,0.085422955],"study_design_scores_gemma":[0.05291954,0.0088365,0.32634473,0.00023669997,0.00058020704,0.000446725,0.0023969505,0.011548762,0.09989359,0.0017197607,0.49413404,0.0009425232],"about_ca_topic_score_codex":0.0006774909,"about_ca_topic_score_gemma":0.00030585285,"teacher_disagreement_score":0.33598924,"about_ca_system_score_codex":0.00031455825,"about_ca_system_score_gemma":0.00063670834,"threshold_uncertainty_score":0.40267268},"labels":[],"label_agreement":null},{"id":"W2129737017","doi":"10.5489/cuaj.830","title":"Metastatic ductal carcinoma of the prostate: a rare variant responding to a common treatment","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Prostate; Prostate carcinoma; Oncology; Pathology; Internal medicine; Cancer","score_opus":0.02481151755415631,"score_gpt":0.2767595788343335,"score_spread":0.2519480612801772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129737017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9434084,0.00023649327,0.0000034435036,0.05431187,0.0001438864,0.0008185831,0.000056131994,0.0000069645143,0.0010141741],"genre_scores_gemma":[0.9939238,0.000027811664,0.00014388077,0.0012289594,0.00010786141,0.000064384185,0.000011205295,0.000010149806,0.004481963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984619,0.0002547216,0.00029653052,0.00014742085,0.00036878846,0.00047064308],"domain_scores_gemma":[0.9985996,0.00012633167,0.00016284251,0.00014316136,0.00027709568,0.0006909557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035795328,0.0001234907,0.00028324075,0.0003126405,0.00026042853,0.000069081485,0.0001187127,0.00007638299,0.00065959635],"category_scores_gemma":[0.00036923593,0.00006530699,0.00014832644,0.0005696121,0.000034927394,0.00007292178,0.00002245449,0.0002779948,0.000053283926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020927517,0.000118359145,0.9850328,0.000009007866,0.00025950721,0.00041094888,0.0011021965,0.000019495325,0.0012977461,0.00017558821,0.0075839907,0.003781091],"study_design_scores_gemma":[0.0019568827,0.0013947808,0.9821314,0.000027472057,0.000120157245,0.0004809097,0.00032035905,0.000096260694,0.00051750836,0.0005289547,0.012336306,0.00008901444],"about_ca_topic_score_codex":0.003990403,"about_ca_topic_score_gemma":0.00065616844,"teacher_disagreement_score":0.053082913,"about_ca_system_score_codex":0.0022356873,"about_ca_system_score_gemma":0.0009976962,"threshold_uncertainty_score":0.7222117},"labels":[],"label_agreement":null},{"id":"W2130121980","doi":"10.1186/1479-5876-8-98","title":"Treatment combining RU486 and Ad5IL-12 vector attenuates the growth of experimentally formed prostate tumors and induces changes in the sentinel lymph nodes of mice","year":2010,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"U.S. Department of Defense","keywords":"FOXP3; Cancer research; Tumor microenvironment; Prostate cancer; Medicine; Adjuvant; Cytotoxic T cell; Immune system; CD8; Immunology; Internal medicine; Cancer; Biology","score_opus":0.035163641149325436,"score_gpt":0.32293500376137474,"score_spread":0.2877713626120493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130121980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96515787,0.0033060203,0.000002198884,0.031030433,0.000056719273,0.00029561803,0.0000097768925,0.0000016517287,0.00013972612],"genre_scores_gemma":[0.99879587,0.00077527954,0.00014665847,0.000088071094,0.00013571407,0.000013064211,0.0000113185415,0.0000080603,0.000025991561],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99891233,0.0000539926,0.00038112578,0.00008688694,0.00043892098,0.00012672826],"domain_scores_gemma":[0.99904335,0.00043515192,0.0002377235,0.00006688683,0.00015359218,0.00006331314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047870813,0.0001162569,0.00033697297,0.00015751085,0.00005303149,0.0000058934493,0.00007519686,0.000035615656,0.00002076527],"category_scores_gemma":[0.000053522304,0.00004978449,0.000040595125,0.00012592807,0.00040663462,0.00007746821,0.000007820141,0.00016220601,7.005152e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001520853,0.00033755327,0.41003478,0.00021646584,0.00024304693,0.000053434163,0.022727713,8.085287e-7,0.5613925,0.0002983059,0.000022241418,0.0031522873],"study_design_scores_gemma":[0.011042755,0.0013512898,0.92278194,0.00061328214,0.00020053989,0.0005195589,0.0047812895,0.00007635259,0.058088224,0.00045747144,0.000027274895,0.000060032933],"about_ca_topic_score_codex":0.00009036497,"about_ca_topic_score_gemma":0.000024970399,"teacher_disagreement_score":0.51274717,"about_ca_system_score_codex":0.000017654302,"about_ca_system_score_gemma":0.000117370364,"threshold_uncertainty_score":0.20301524},"labels":[],"label_agreement":null},{"id":"W2130164418","doi":"10.1634/theoncologist.2015-0220","title":"Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; London Health Sciences Centre; Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Temsirolimus; Oncology; Castration; Internal medicine; Cancer; Discovery and development of mTOR inhibitors; Apoptosis; PI3K/AKT/mTOR pathway; Hormone","score_opus":0.09766706703691744,"score_gpt":0.3809797610678705,"score_spread":0.28331269403095305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130164418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9748202,0.0044910978,0.0000016800724,0.015385893,0.000245182,0.0009905486,0.000018106643,0.00003550166,0.004011776],"genre_scores_gemma":[0.9886984,0.0019393985,0.000055968685,0.0004905182,0.0002110661,0.00068755867,0.000012883763,0.000014509058,0.007889658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989414,0.00008692219,0.0001927194,0.00020503782,0.0002598572,0.00031404317],"domain_scores_gemma":[0.9994244,0.000032303495,0.00006361465,0.00023093293,0.00014582601,0.000102950224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045686224,0.00012397402,0.00019145601,0.00006315844,0.00005785792,0.00002862357,0.000087095,0.00006927661,0.00006751722],"category_scores_gemma":[0.000045131274,0.00006378746,0.00003857663,0.0002637002,0.0002710706,0.00008511274,0.000025992342,0.0002512841,0.00003312915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09557745,0.0032008851,0.5491411,0.0002332939,0.00054868305,0.0030614662,0.02223073,0.0005802512,0.07776073,0.00069454586,0.049683534,0.1972873],"study_design_scores_gemma":[0.020012124,0.0032965078,0.86081606,0.0002731043,0.000067114546,0.000105860556,0.0038653347,0.00016707851,0.009130439,0.0014103366,0.1004891,0.00036696508],"about_ca_topic_score_codex":0.0019977333,"about_ca_topic_score_gemma":0.0016871684,"teacher_disagreement_score":0.3116749,"about_ca_system_score_codex":0.0006954014,"about_ca_system_score_gemma":0.000621568,"threshold_uncertainty_score":0.30199885},"labels":[],"label_agreement":null},{"id":"W2130277194","doi":"10.1074/jbc.m605002200","title":"Ligand-independent Androgen Receptor Activity Is Activation Function-2-independent and Resistant to Antiandrogens in Androgen Refractory Prostate Cancer Cells","year":2006,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; U.S. Public Health Service; National Institutes of Health; Terry Fox Foundation","keywords":"Androgen receptor; LNCaP; Androgen; Prostate cancer; Bicalutamide; Cancer research; Antiandrogen; Endocrinology; Chemistry; Internal medicine; Dihydrotestosterone; Transcription factor; Biology; Medicine; Cancer; Biochemistry; Hormone; Gene","score_opus":0.023456180853336246,"score_gpt":0.2894430770827048,"score_spread":0.26598689622936855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130277194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577504,0.0019346579,0.00001040167,0.001560646,0.00007519028,0.00031960048,0.00005675702,0.000012681635,0.00025501876],"genre_scores_gemma":[0.99633753,0.0023467515,0.000077974124,0.00013073524,0.0002779031,0.000020301793,0.000015205277,0.0000141381415,0.0007794546],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99841005,0.00004390163,0.0004585991,0.00032798733,0.00042459284,0.00033488803],"domain_scores_gemma":[0.9990541,0.000058073674,0.0002754415,0.00014230284,0.00020951848,0.00026059904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038151222,0.00020433878,0.00042846776,0.00009582224,0.000074486314,0.00003679878,0.0000866724,0.00024853906,0.00022270007],"category_scores_gemma":[0.000043900192,0.00013565559,0.00011751287,0.00022943549,0.0000727699,0.0001066885,0.000060061324,0.00045097183,0.00000447439],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005012642,0.00038797242,0.076174736,0.000076313576,0.000097046155,0.00011895778,0.000071869064,0.00000694936,0.91384447,5.1225817e-7,0.0009885624,0.003219966],"study_design_scores_gemma":[0.0024080821,0.0006827812,0.06898886,0.00019479054,0.000043304568,0.000054210093,0.000104184146,0.000004544533,0.92111766,0.000048543807,0.0062061762,0.00014684463],"about_ca_topic_score_codex":0.00009637437,"about_ca_topic_score_gemma":0.000011185905,"teacher_disagreement_score":0.007273203,"about_ca_system_score_codex":0.00043741046,"about_ca_system_score_gemma":0.00024198461,"threshold_uncertainty_score":0.55318743},"labels":[],"label_agreement":null},{"id":"W2130525612","doi":"10.1016/j.jsbmb.2004.10.017","title":"Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development","year":2004,"lang":"en","type":"review","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":311,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Mesenchyme; Stromal cell; Biology; Paracrine signalling; Epithelium; Cell biology; Carcinogenesis; Androgen receptor; Prostate; Morphogenesis; Endocrinology; Androgen; Mesenchymal stem cell; Internal medicine; Cancer research; Receptor; Hormone; Prostate cancer; Cancer; Medicine; Genetics","score_opus":0.017672580701702807,"score_gpt":0.3068670247187314,"score_spread":0.2891944440170286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130525612","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18585445,0.8133731,0.00036282584,0.000083027284,0.000019877669,0.00027825116,0.000008701793,0.0000018025811,0.000017988898],"genre_scores_gemma":[0.085013196,0.91418517,0.0006030944,0.000023518358,0.000029691515,0.0000066116186,0.00006486825,0.000017288023,0.0000565602],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988861,0.000094341965,0.0005210781,0.00016586913,0.00014975053,0.00018283789],"domain_scores_gemma":[0.99911445,0.00006378169,0.0004415801,0.00013574983,0.000113815855,0.00013063347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031515764,0.00024061026,0.00076883804,0.000092012924,0.000056229866,0.000010811341,0.00008482693,0.00021338242,0.0000040382843],"category_scores_gemma":[0.000039232884,0.00013607444,0.00008807595,0.00008488076,0.00038350272,0.00001730042,0.00010244898,0.00029557451,2.6799145e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006312678,0.00013400587,0.000056175984,0.03208619,0.0014230469,0.00027362898,0.00036481797,8.949735e-7,0.73552316,0.000030056357,0.000016266606,0.22946048],"study_design_scores_gemma":[0.006615372,0.0038116558,0.0001954639,0.030879492,0.006059851,0.011934677,0.00024490326,0.000007959713,0.9003419,0.00055553194,0.03860829,0.00074487244],"about_ca_topic_score_codex":0.0000018158438,"about_ca_topic_score_gemma":1.0500599e-7,"teacher_disagreement_score":0.22871561,"about_ca_system_score_codex":0.000055742006,"about_ca_system_score_gemma":0.0005018685,"threshold_uncertainty_score":0.55489546},"labels":[],"label_agreement":null},{"id":"W2130955565","doi":"10.1158/2159-8290.cd-11-0130","title":"Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets","year":2011,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1020,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Weill Cornell Medical College; U.S. Public Health Service","keywords":"Prostate cancer; Cancer research; Prostate; Biology; Aurora kinase; Cancer; Adenocarcinoma; Neuroendocrine tumors; In vivo; Medicine; Internal medicine; Cell cycle; Genetics","score_opus":0.02261109907375157,"score_gpt":0.2972642332103163,"score_spread":0.2746531341365647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130955565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993928,0.004433205,0.00012734107,0.0006054658,0.00015752966,0.00048338034,0.0001449407,0.00001106088,0.00010906806],"genre_scores_gemma":[0.9857869,0.009285321,0.000021738842,0.00005962101,0.00004491918,0.00007668859,0.00007924643,0.00001900366,0.004626545],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99918574,0.000015686193,0.00025843678,0.00020558643,0.00018286763,0.00015166248],"domain_scores_gemma":[0.9994573,0.000005258906,0.00017272973,0.0001776395,0.000106723935,0.00008036607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004080419,0.00010102416,0.00021486152,0.00008736309,0.00001917352,0.000009202835,0.000051131618,0.000014910062,0.00006280431],"category_scores_gemma":[0.000010136153,0.000081376216,0.000044134864,0.00016505763,0.000097050026,0.00025830205,0.000035090656,0.000061667495,8.2300613e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074694376,0.000101932,0.09995928,0.0004775677,0.00011480667,0.000021174294,0.0012328305,0.0000031605878,0.88214666,0.00013558495,0.00012372549,0.014936337],"study_design_scores_gemma":[0.00096799206,0.000069757516,0.26693073,0.00013708173,0.00008843127,0.000002528262,0.000041530577,0.000034823737,0.7313556,0.00009924382,0.00021650604,0.000055784898],"about_ca_topic_score_codex":0.0007780542,"about_ca_topic_score_gemma":0.000016597474,"teacher_disagreement_score":0.16697145,"about_ca_system_score_codex":0.000049254544,"about_ca_system_score_gemma":0.00027348544,"threshold_uncertainty_score":0.33184257},"labels":[],"label_agreement":null},{"id":"W2131125612","doi":"10.1016/j.eururo.2007.10.052","title":"Type 1 and Type 2 5α-Reductase Expression in the Development and Progression of Prostate Cancer","year":2007,"lang":"en","type":"review","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"GlaxoSmithKline","keywords":"Dutasteride; Finasteride; Medicine; Prostate cancer; Prostate; Dihydrotestosterone; Testosterone (patch); Management of prostate cancer; 5 Alpha-Reductase Inhibitor; Androgen; Hyperplasia; Internal medicine; Oncology; Antiandrogen; Intraepithelial neoplasia; PCA3; Cancer; Urology; Cancer research; Hormone","score_opus":0.10370436565663399,"score_gpt":0.42925141271675027,"score_spread":0.3255470470601163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131125612","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011481389,0.9857366,2.3280951e-7,0.00012690572,0.000104029976,0.0009453924,0.000006017448,0.000009331715,0.001590115],"genre_scores_gemma":[0.0013560428,0.9976292,0.00019285892,0.000065828484,0.00007865144,0.000026783535,0.00010041781,0.00003463457,0.000515549],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985818,0.00038550887,0.00034108516,0.00029587818,0.00015579502,0.00023989682],"domain_scores_gemma":[0.99943167,0.00009590241,0.00013791346,0.00018743514,0.00007497028,0.00007211767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006677513,0.00019465071,0.00053864636,0.00017666759,0.00004534637,0.000008018199,0.00009341629,0.000087035565,0.00002525108],"category_scores_gemma":[0.00006519477,0.000097452976,0.000024291987,0.0002981785,0.00017321014,0.000017575321,0.00013197625,0.00035444688,0.000011903229],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034121005,0.00007776118,0.0009323009,0.003625655,0.000044884793,0.00034670046,0.001111623,3.7678745e-8,0.00003301232,0.000004164438,0.0005916411,0.992891],"study_design_scores_gemma":[0.00060830713,0.00053570705,0.001473268,0.0029266782,0.00013299547,0.00010745433,0.0000347233,3.5230357e-7,0.00005025961,0.0000019563333,0.99403596,0.00009231738],"about_ca_topic_score_codex":0.0000032703726,"about_ca_topic_score_gemma":0.0000037946388,"teacher_disagreement_score":0.9934443,"about_ca_system_score_codex":0.000033619926,"about_ca_system_score_gemma":0.0003229393,"threshold_uncertainty_score":0.3974017},"labels":[],"label_agreement":null},{"id":"W2131286608","doi":"10.1111/bju.12732","title":"The impact of androgen‐deprivation therapy ( <scp>ADT</scp> ) on the risk of cardiovascular ( <scp>CV</scp> ) events in patients with non‐metastatic prostate cancer: a population‐based study","year":2014,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Androgen deprivation therapy; Medicine; Oncology; Internal medicine; Population; Endocrinology; Cancer","score_opus":0.013504095079290738,"score_gpt":0.2793428027551193,"score_spread":0.26583870767582857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131286608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945872,0.0036628745,0.000049287086,0.00007885293,0.000068289475,0.0014806783,0.000046460453,0.0000038307953,0.000022520882],"genre_scores_gemma":[0.99748015,0.0022852533,0.000025366904,0.000039200782,0.000045081673,0.00005190087,0.000019491024,0.000027979628,0.0000255581],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718773,0.0009049776,0.0006116856,0.00019254856,0.0007705823,0.0003324426],"domain_scores_gemma":[0.99751496,0.0007820784,0.00071412063,0.00031683207,0.00057647866,0.00009552769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017482357,0.0001730454,0.00063259364,0.00021135855,0.00013417852,0.00001655481,0.000210608,0.0000560761,0.0000047610615],"category_scores_gemma":[0.0007357985,0.00009403622,0.00031089224,0.00040360738,0.00010590069,0.000084272375,0.000024294035,0.0004281163,7.4161807e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007057496,0.0011026828,0.9669243,0.000020289051,0.002175666,0.000036919773,0.0004932648,0.008362914,0.000024096049,9.4564905e-7,0.000116793424,0.020036375],"study_design_scores_gemma":[0.015445727,0.008765161,0.9743311,0.0001392507,0.0003242038,0.0000358475,0.00017403551,0.0003643858,0.00017280105,0.00012160718,0.00010220517,0.000023682673],"about_ca_topic_score_codex":0.0018038409,"about_ca_topic_score_gemma":0.0001136379,"teacher_disagreement_score":0.020012692,"about_ca_system_score_codex":0.00013339687,"about_ca_system_score_gemma":0.00030254514,"threshold_uncertainty_score":0.3834686},"labels":[],"label_agreement":null},{"id":"W2131456094","doi":"10.1158/0008-5472.can-08-3667","title":"Characterization of <i>ERG</i> , <i>AR</i> and <i>PTEN</i> Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":532,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"TMPRSS2; Prostate cancer; Erg; Abiraterone acetate; Cancer research; PTEN; LNCaP; Androgen receptor; Docetaxel; Prostate; Androgen deprivation therapy; Medicine; Cancer; Biology; Oncology; Internal medicine; PI3K/AKT/mTOR pathway; Apoptosis","score_opus":0.02910325348655226,"score_gpt":0.3281111560618453,"score_spread":0.2990079025752931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131456094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950446,0.0016597703,0.0000037480931,0.00060162763,0.000052937998,0.001555829,0.00087119004,0.000018653394,0.00019162605],"genre_scores_gemma":[0.9965342,0.0021425593,0.0001089723,0.00015809816,0.00009680259,0.00023797221,0.0004506567,0.000032664193,0.00023806193],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973675,0.00011922169,0.0003744507,0.00049638416,0.00094105455,0.00070140464],"domain_scores_gemma":[0.99861383,0.00007047787,0.00012463308,0.00027317356,0.0006556634,0.00026219274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028288708,0.00019412197,0.00037504584,0.00026092888,0.00012737198,0.000055683475,0.00009062673,0.000064325424,0.00009888022],"category_scores_gemma":[0.00002532772,0.0001488188,0.000030670504,0.0007597456,0.00020846467,0.0002206582,0.00004234458,0.0003817241,0.0000024016108],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025266793,0.00022942816,0.17804554,0.00013076008,0.000044304354,0.000068229325,0.0009558019,0.000021898684,0.80949146,0.00000791452,0.000058511443,0.008419459],"study_design_scores_gemma":[0.005841815,0.000688378,0.5497575,0.0006790209,0.00003170984,0.000001056944,0.00014135549,0.000082413666,0.44195658,0.00004330831,0.0006087952,0.0001680793],"about_ca_topic_score_codex":0.003666734,"about_ca_topic_score_gemma":0.00069893274,"teacher_disagreement_score":0.37171194,"about_ca_system_score_codex":0.00046604415,"about_ca_system_score_gemma":0.0009216341,"threshold_uncertainty_score":0.60686547},"labels":[],"label_agreement":null},{"id":"W2131928438","doi":"10.1023/a:1006459613498","title":"Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter","year":2000,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"","keywords":"Genotype; Breast cancer; Single-nucleotide polymorphism; Internal medicine; Oncology; Prostate cancer; Biology; Medicine; Breast carcinoma; Cancer research; Cancer; Gene; Genetics","score_opus":0.04569737626745415,"score_gpt":0.3270604888343454,"score_spread":0.2813631125668913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131928438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753138,0.006809482,2.876988e-7,0.011127248,0.00003386935,0.0051783146,0.0013040444,0.000013196948,0.00021977568],"genre_scores_gemma":[0.98982304,0.0066311187,0.000041631934,0.00003553482,0.00013446658,0.0019237833,0.000022603399,0.00003952938,0.0013483036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996432,0.0005557079,0.0004715792,0.0005729567,0.0011100168,0.0008577256],"domain_scores_gemma":[0.99855983,0.00017047653,0.00011450056,0.0006268577,0.00032313893,0.0002051816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084305636,0.00030874068,0.00047377642,0.00021602624,0.00022068027,0.000050234838,0.00028053793,0.00007274852,0.0005370085],"category_scores_gemma":[0.000009032676,0.00015197888,0.00013235779,0.0009314678,0.0008585334,0.00010141809,0.00008125297,0.00026405338,0.000006554601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058185574,0.006027696,0.51223487,0.00030977535,0.00056796474,0.00038859434,0.0044492413,0.000015076447,0.22534001,0.000028540167,0.00032503498,0.19212762],"study_design_scores_gemma":[0.0073031858,0.0029837838,0.8694104,0.00077171257,0.000087870765,0.0003644067,0.00043779294,0.000025341882,0.11620274,0.00010226754,0.002125219,0.0001853127],"about_ca_topic_score_codex":0.004653643,"about_ca_topic_score_gemma":0.00045155463,"teacher_disagreement_score":0.3571755,"about_ca_system_score_codex":0.00075266545,"about_ca_system_score_gemma":0.0011095764,"threshold_uncertainty_score":0.7034947},"labels":[],"label_agreement":null},{"id":"W2132355996","doi":"10.1111/j.1525-1497.2006.00506.x","title":"Disseminated Intravascular Coagulation as the Presenting Sign of Metastatic Prostate Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of General Internal Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Disseminated intravascular coagulation; Prostate cancer; Sepsis; Differential diagnosis; Etiology; Cancer; Internal medicine; Pathology","score_opus":0.024032722574148617,"score_gpt":0.3608099635791065,"score_spread":0.3367772410049579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132355996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797804,0.009856474,0.00022809095,0.007962074,0.00037378503,0.00034297223,0.0000042177485,0.000005999888,0.001446038],"genre_scores_gemma":[0.98540854,0.0011222531,0.00021829717,0.00013389769,0.001055813,0.000009376682,0.000011728416,0.000018736522,0.012021347],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99798745,0.00010906005,0.0007649284,0.000114853996,0.000802634,0.00022109732],"domain_scores_gemma":[0.998383,0.000119474396,0.00056908466,0.0001434973,0.0006742232,0.00011076431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007070643,0.00014460237,0.00046967075,0.00020177504,0.00005067488,0.000012776781,0.00015278484,0.000032762655,0.00030825948],"category_scores_gemma":[0.00017909423,0.00006864211,0.00014647475,0.00025412784,0.00024366254,0.00010436634,0.000030236035,0.00031520886,0.0000019820907],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004349895,0.0005645579,0.12628773,0.0005494294,0.0023479497,0.0014767498,0.0029833731,0.0013128585,0.7873186,0.00040294245,0.039558124,0.032847784],"study_design_scores_gemma":[0.019394197,0.00674905,0.3334349,0.006100277,0.0031236382,0.0030083507,0.0018238315,0.007411893,0.5994599,0.0039496613,0.015182278,0.00036200942],"about_ca_topic_score_codex":0.002377936,"about_ca_topic_score_gemma":0.00002852704,"teacher_disagreement_score":0.20714718,"about_ca_system_score_codex":0.00011662248,"about_ca_system_score_gemma":0.00015382245,"threshold_uncertainty_score":0.35947436},"labels":[],"label_agreement":null},{"id":"W2132365023","doi":"10.1007/s13167-011-0138-2","title":"Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?","year":2012,"lang":"en","type":"article","venue":"The EPMA Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Prostate cancer; Medicine; Cabazitaxel; Taxane; Oncology; Androgen deprivation therapy; Cancer; Malignancy; Androgen receptor; Enzalutamide; Internal medicine; Disease; Abiraterone acetate; Breast cancer","score_opus":0.0768418533837116,"score_gpt":0.41243847778124265,"score_spread":0.335596624397531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132365023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95995957,0.031216871,0.00004141007,0.007994125,0.00012955071,0.00044143695,0.000004227399,0.000003429318,0.00020935686],"genre_scores_gemma":[0.97024703,0.02891845,0.000027899321,0.0001289437,0.00023946402,0.00002399636,0.0000031443424,0.000007794973,0.0004032666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990013,0.0002505724,0.00023331633,0.00006074963,0.00027845916,0.00017558664],"domain_scores_gemma":[0.9994462,0.00014976582,0.00017059955,0.00009670638,0.00007950887,0.00005723238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001847751,0.00006628976,0.00012715177,0.00005307893,0.00010511383,0.00002114911,0.000072574585,0.000034492754,0.000099921126],"category_scores_gemma":[0.000056510362,0.00002838897,0.000054978213,0.00015581162,0.0001053538,0.00009279245,0.0000123919035,0.00020338008,0.000001316081],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030610114,0.00035650164,0.838378,0.00006582761,0.0004316569,0.00000927487,0.011541129,0.0000024876563,0.0023630683,0.000057603924,0.0017020934,0.14203131],"study_design_scores_gemma":[0.0065550087,0.0012091603,0.9754763,0.0004810289,0.0001671617,0.00017145094,0.01040567,0.00012440077,0.0011072857,0.00051649933,0.0036855452,0.000100479825],"about_ca_topic_score_codex":0.000037236758,"about_ca_topic_score_gemma":0.000009628183,"teacher_disagreement_score":0.14193083,"about_ca_system_score_codex":0.00003809584,"about_ca_system_score_gemma":0.00010625178,"threshold_uncertainty_score":0.11576686},"labels":[],"label_agreement":null},{"id":"W2132610466","doi":"10.1200/jco.2013.52.4546","title":"Reply to J. Zhu et al","year":2013,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Manitoba; University of Toronto; CancerCare Manitoba","funders":"","keywords":"Medicine","score_opus":0.22589682097931352,"score_gpt":0.5549399594787293,"score_spread":0.3290431384994158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132610466","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013706975,0.0069013676,0.00009240758,0.93983936,0.019611118,0.0007655571,0.000024816956,0.000010315029,0.019048106],"genre_scores_gemma":[0.00096117205,0.01468553,0.0037696278,0.8861927,0.02590011,0.000023970277,0.00002837939,0.00007359566,0.068364955],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9891908,0.0025142017,0.005327972,0.00056819513,0.0013215133,0.0010772826],"domain_scores_gemma":[0.98324376,0.009672153,0.0030511955,0.00058810663,0.0017297373,0.0017150322],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.009961567,0.00045673095,0.0042142835,0.00042654903,0.00007203737,0.0000493511,0.0006740362,0.0018532341,0.0054631643],"category_scores_gemma":[0.010902871,0.0002951207,0.001605535,0.00028159807,0.0006599638,0.00020572364,0.0002828971,0.010808169,0.0038605132],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038233215,0.0012758633,0.005043394,0.0001013777,0.0015327788,0.014844732,0.000110079505,0.0000052105866,0.000039720977,0.00005312512,0.8148394,0.15833099],"study_design_scores_gemma":[0.009702012,0.03938178,0.020981327,0.0010738255,0.0007345852,0.0011111927,0.000066254535,0.000016136133,0.00002643452,0.000313027,0.92635214,0.00024129626],"about_ca_topic_score_codex":0.0001655837,"about_ca_topic_score_gemma":0.000013979125,"teacher_disagreement_score":0.1580897,"about_ca_system_score_codex":0.001130787,"about_ca_system_score_gemma":0.010171634,"threshold_uncertainty_score":0.9999501},"labels":[],"label_agreement":null},{"id":"W2132768674","doi":"10.1016/j.urolonc.2015.05.030","title":"Cardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms","year":2015,"lang":"en","type":"review","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Prostate cancer; Androgen deprivation therapy; Medicine; Testosterone (patch); Oncology; Internal medicine; Disease; Hormone therapy; Endocrinology; Diabetes mellitus; Cancer; Gynecology; Bioinformatics; Breast cancer; Biology","score_opus":0.06289872378817953,"score_gpt":0.3693781705458584,"score_spread":0.3064794467576789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132768674","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016960439,0.992103,0.0004934739,0.0006858533,0.00016782423,0.004272149,0.0003902034,0.00007198046,0.00011950531],"genre_scores_gemma":[0.000018484614,0.97118175,0.02352462,0.00015210873,0.00024348209,0.0031834617,0.0009878522,0.000053685464,0.00065455394],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99791247,0.0002633521,0.00038181347,0.0006777773,0.0003188138,0.00044575296],"domain_scores_gemma":[0.99856347,0.00013361243,0.00032557984,0.0003469215,0.00026893048,0.0003614945],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007545808,0.00043383383,0.0016150543,0.00023426992,0.00034495327,0.000038077545,0.00012776937,0.00051580503,0.000021648542],"category_scores_gemma":[0.000057479916,0.0002635989,0.0003525618,0.00035960722,0.00049902603,0.00008176963,0.000045175875,0.00052262016,0.0000069782486],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049730367,0.00015970963,0.0017673637,0.0015605034,0.002545034,0.0001876339,0.00015307931,0.000042292682,0.0000018074722,0.00041837496,0.0019392804,0.9907276],"study_design_scores_gemma":[0.0026963556,0.004756729,0.0000084837575,0.00080080377,0.0054886653,0.00043464996,0.000043459495,0.00007119032,0.00001460553,0.003113975,0.98229873,0.00027235635],"about_ca_topic_score_codex":0.000112445065,"about_ca_topic_score_gemma":0.000014798287,"teacher_disagreement_score":0.99045527,"about_ca_system_score_codex":0.0003929003,"about_ca_system_score_gemma":0.0028175975,"threshold_uncertainty_score":0.99998164},"labels":[],"label_agreement":null},{"id":"W2133286849","doi":"10.1128/mcb.20.24.9337-9345.2000","title":"Male Sexual Dysfunction in Mice Bearing Targeted Mutant Alleles of the <i>PEA3 ets</i> Gene","year":2000,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; McMaster University","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; Medical Research Council; National Institute of Child Health and Human Development; Medical Research Council Canada","keywords":"Biology; Carcinogenesis; Mutant; Genetics; Gene; Allele","score_opus":0.009595214453187206,"score_gpt":0.23984191316784884,"score_spread":0.23024669871466164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133286849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925221,0.005894996,0.00010517643,0.00036613405,0.00003740226,0.00023251987,0.000007942042,0.000007110111,0.0008266216],"genre_scores_gemma":[0.9983463,0.00031285928,0.00007229635,0.00014870973,0.000021067532,0.000011390449,0.00007062877,0.000008891566,0.0010078151],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99933183,0.00008258271,0.0001356616,0.00018975562,0.00007244247,0.00018770255],"domain_scores_gemma":[0.99976563,0.000009861137,0.000022839124,0.00013917014,0.000021220234,0.00004129186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001052007,0.00008516413,0.00015908694,0.000044484812,0.00003662363,0.0000033128692,0.000052104708,0.0000925302,0.00016524484],"category_scores_gemma":[0.000007866199,0.000054677683,0.00003931089,0.00012365753,0.00012146748,0.000010624666,0.000033910168,0.00012331882,0.0000048956394],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019610052,0.00006553551,0.02132611,0.000027208207,0.000045687073,0.000077912286,0.000121675315,0.000012446218,0.9709589,0.00002655391,0.000014064741,0.0071278373],"study_design_scores_gemma":[0.0017101652,0.0003359549,0.004961731,0.000018261791,0.000037579066,0.00008598307,0.00008000117,0.0001475367,0.9899244,0.00007798992,0.0025494806,0.000070955364],"about_ca_topic_score_codex":0.00022265491,"about_ca_topic_score_gemma":0.00001834491,"teacher_disagreement_score":0.018965492,"about_ca_system_score_codex":0.000021800868,"about_ca_system_score_gemma":0.000040316754,"threshold_uncertainty_score":0.22296911},"labels":[],"label_agreement":null},{"id":"W2133494659","doi":"10.1155/2012/541353","title":"Transcriptome-Wide Detection of Differentially Expressed Coding and Non-Coding Transcripts and Their Clinical Significance in Prostate Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Prostate cancer; Transcriptome; Computational biology; DNA microarray; Disease; Prostate; Medicine; Microarray; Cancer; Biomarker discovery; Biology; Gene; Bioinformatics; Gene expression; Genetics; Proteomics; Internal medicine","score_opus":0.06328109965459179,"score_gpt":0.37909303998033833,"score_spread":0.31581194032574655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133494659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931286,0.004182404,0.00072823855,0.0011110376,0.00043661371,0.00031405647,0.0000069587,0.0000033298759,0.00008877854],"genre_scores_gemma":[0.9870167,0.012512841,0.0001202224,0.00007522976,0.00018898604,0.000014764548,7.351973e-7,0.000012041118,0.00005852986],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99873656,0.00014951234,0.0005972,0.0001174371,0.00013548305,0.00026382742],"domain_scores_gemma":[0.99909765,0.0002774194,0.00025547188,0.000059956674,0.00011789215,0.00019163445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082471897,0.00011279231,0.00059302506,0.00019218982,0.00003586255,0.0000075506355,0.000046850208,0.00010820902,0.00001396558],"category_scores_gemma":[0.00006535373,0.000074438954,0.00008487776,0.00010862221,0.00018454948,0.00017144482,0.000011218314,0.00041254636,1.3096613e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031124526,0.00031852382,0.28012392,0.00016234221,0.0001198079,0.00003413675,0.0035559624,9.855283e-7,0.6698271,0.0000041269577,0.0000255372,0.04271509],"study_design_scores_gemma":[0.012115932,0.0031369647,0.76567733,0.00048369524,0.00016625118,0.000119629345,0.0011924274,0.00010125505,0.21484895,0.000062713974,0.0019877062,0.00010713695],"about_ca_topic_score_codex":0.000038627993,"about_ca_topic_score_gemma":0.00006357166,"teacher_disagreement_score":0.48555344,"about_ca_system_score_codex":0.00013548986,"about_ca_system_score_gemma":0.0002172023,"threshold_uncertainty_score":0.30355325},"labels":[],"label_agreement":null},{"id":"W2133621280","doi":"10.1016/j.eururo.2015.10.021","title":"Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies","year":2015,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Post-hoc analysis; Oncology; Abiraterone; Post hoc; Internal medicine; Urology; Clinical trial; Androgen deprivation therapy; Cancer","score_opus":0.1580192024020125,"score_gpt":0.4869502137233973,"score_spread":0.3289310113213848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133621280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876391,0.008379897,0.000002227377,0.0021033734,0.00011909505,0.0013305274,0.000117200754,0.000031251795,0.00027731012],"genre_scores_gemma":[0.9930139,0.0058347587,0.00007250276,0.00037565277,0.00006754124,0.000045999186,0.00015202654,0.000038304614,0.00039927234],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964405,0.0014655786,0.00090428704,0.00044875438,0.00030688397,0.00043401995],"domain_scores_gemma":[0.9981109,0.0005696424,0.00028732093,0.0003859042,0.00039306917,0.00025318944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016088581,0.0002708364,0.0012159203,0.0005505737,0.000041274347,0.00001362102,0.00013082183,0.00002631696,0.000097120974],"category_scores_gemma":[0.00043994442,0.00016316616,0.00030689838,0.000691148,0.00032025488,0.00005813087,0.00004713788,0.0002854891,0.000028362707],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81004995,0.006740496,0.03075674,0.00009672347,0.022678392,0.0048124865,0.008639703,0.0033830332,0.027252972,0.000015997546,0.0009062174,0.08466732],"study_design_scores_gemma":[0.5046405,0.061212786,0.4224978,0.00008017701,0.004183478,0.000032729542,0.00075285375,0.0010853395,0.0030777105,0.000019661788,0.0020020776,0.00041484452],"about_ca_topic_score_codex":0.000109849374,"about_ca_topic_score_gemma":0.00010014984,"teacher_disagreement_score":0.39174107,"about_ca_system_score_codex":0.00013449724,"about_ca_system_score_gemma":0.00037177512,"threshold_uncertainty_score":0.66537225},"labels":[],"label_agreement":null},{"id":"W2134193340","doi":"10.1016/j.ajpath.2011.11.030","title":"Integrative Molecular Profiling Reveals Asparagine Synthetase Is a Target in Castration-Resistant Prostate Cancer","year":2012,"lang":"en","type":"article","venue":"American Journal Of Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Université de Montréal","funders":"National Cancer Institute","keywords":"Prostate cancer; Asparagine; Biology; Profiling (computer programming); Prostate; Cancer research; Computational biology; Cancer; Bioinformatics; Oncology; Medicine; Enzyme; Genetics; Biochemistry; Computer science","score_opus":0.01912535622994244,"score_gpt":0.3541167269203728,"score_spread":0.3349913706904304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134193340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905146,0.005563283,0.0001588478,0.0030180304,0.00009971754,0.00030971007,0.000042947864,0.0000054713073,0.00028743877],"genre_scores_gemma":[0.99251616,0.00055974675,0.0060359323,0.00050877285,0.00010773338,0.00004257509,0.000009094639,0.000018778464,0.0002011796],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985332,0.0002239174,0.00044129655,0.00014406299,0.00023902352,0.0004185284],"domain_scores_gemma":[0.9989639,0.000063473235,0.00036163096,0.00013393504,0.00025916097,0.00021792065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005571987,0.00015300784,0.0005407339,0.0002700423,0.000029149816,0.000007945905,0.0000760935,0.00003723422,0.000098227574],"category_scores_gemma":[0.000120850884,0.000100555866,0.00009868339,0.00036612095,0.00024429994,0.00012797533,0.000020356636,0.00039258302,0.000006209386],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029118746,0.0005439857,0.28104502,0.00006715365,0.00027328424,0.006652151,0.007764995,0.0000317646,0.6874701,0.00023334949,0.00036660422,0.012639771],"study_design_scores_gemma":[0.011160543,0.013201102,0.18700805,0.0017127105,0.0006635112,0.008178337,0.018993791,0.00015670624,0.7544996,0.0013678827,0.0022346703,0.00082309794],"about_ca_topic_score_codex":0.000075294316,"about_ca_topic_score_gemma":0.000005987179,"teacher_disagreement_score":0.09403696,"about_ca_system_score_codex":0.00022023477,"about_ca_system_score_gemma":0.0003603876,"threshold_uncertainty_score":0.4100549},"labels":[],"label_agreement":null},{"id":"W2134297013","doi":"10.1016/j.cancergen.2014.09.003","title":"Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data","year":2014,"lang":"en","type":"review","venue":"Cancer Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"PTEN; Biology; Prostate cancer; Genome instability; Fusion gene; Copy number analysis; In silico; Copy-number variation; Cancer research; Comparative genomic hybridization; Genome; Somatic cell; Genetics; Cancer; Gene expression profiling; Microsatellite instability; Gene; Gene expression; Microsatellite; Allele; PI3K/AKT/mTOR pathway; DNA","score_opus":0.3428671216261207,"score_gpt":0.48922054584201574,"score_spread":0.14635342421589503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134297013","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013712477,0.99118185,0.000004006956,0.00018168807,0.00017654251,0.00216499,0.0046119625,0.000014373475,0.00029335072],"genre_scores_gemma":[0.0003295254,0.98862505,0.0002870986,0.00006775253,0.00014588995,0.0016628648,0.0062566716,0.00007962205,0.0025455526],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960849,0.00036635806,0.0013212604,0.0011627754,0.0004826397,0.000582065],"domain_scores_gemma":[0.99669874,0.000106659085,0.0005023614,0.0021719262,0.0002639278,0.00025636322],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00077005185,0.0005065176,0.0043556383,0.0008829608,0.000045302648,0.0000694566,0.00071659335,0.00021741819,0.00301937],"category_scores_gemma":[0.000036112204,0.00037498667,0.0006509628,0.002312924,0.00013623833,0.00012033521,0.0003099229,0.00054204656,0.000044275075],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022896091,0.0009840601,0.044122927,0.020731365,0.12014782,0.000063114196,0.00069153967,0.00082037435,0.000016422555,0.000023650051,0.009729361,0.8024404],"study_design_scores_gemma":[0.000791983,0.000117911724,0.0002419744,0.000882215,0.15521926,0.000003036637,0.000016306403,0.0012096261,0.0000247613,0.0000046660753,0.8411455,0.00034275185],"about_ca_topic_score_codex":0.004971516,"about_ca_topic_score_gemma":0.028702995,"teacher_disagreement_score":0.83141613,"about_ca_system_score_codex":0.0010307899,"about_ca_system_score_gemma":0.0032354912,"threshold_uncertainty_score":0.9998702},"labels":[],"label_agreement":null},{"id":"W2134726500","doi":"10.1093/annonc/mdn549","title":"Reply to the letter “About sorafenib in castration-resistant prostate cancer” by G. Colloca, F. Checcaglini and A. Venturino","year":2008,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of British Columbia","funders":"","keywords":"Medicine; Sorafenib; Prostate cancer; Discontinuation; Castration; Population; Oncology; Internal medicine; Antiandrogen; Androgen; Urology; Gynecology; Cancer; Hepatocellular carcinoma; Hormone","score_opus":0.07694193941573961,"score_gpt":0.39032747025996956,"score_spread":0.31338553084422993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134726500","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.083979666,0.011404817,3.057621e-7,0.9012224,0.00024802895,0.0015880329,0.00038592948,0.00001308331,0.0011577382],"genre_scores_gemma":[0.016759627,0.023476489,0.000046942852,0.9399723,0.0015503694,0.00076273404,0.00046810176,0.00005840323,0.016905043],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977074,0.00018527711,0.0005666321,0.0005152617,0.00041434736,0.0006110587],"domain_scores_gemma":[0.99875605,0.00019222981,0.0002446874,0.00041072402,0.00027631092,0.00011999912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034179696,0.0002900376,0.0007810439,0.00021943793,0.00009340417,0.000017367394,0.00018520524,0.000443096,0.00007713254],"category_scores_gemma":[0.00006775665,0.00019496141,0.00010940046,0.0002751328,0.00035060354,0.000046237958,0.00008557221,0.0011239199,0.000017863707],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013960684,0.00013145762,0.0013034556,0.00024540923,0.00019370497,0.0017985348,0.00092438323,0.0000033967824,0.0009336822,0.0000015323611,0.9871357,0.005932693],"study_design_scores_gemma":[0.0020207185,0.00228256,0.0032878558,0.00026163517,0.00005574107,0.000058774272,0.000045355162,0.0000026432801,0.0031647112,0.000019053718,0.98863,0.00017096628],"about_ca_topic_score_codex":0.0017928976,"about_ca_topic_score_gemma":0.00048777994,"teacher_disagreement_score":0.06722004,"about_ca_system_score_codex":0.00019458613,"about_ca_system_score_gemma":0.0010614408,"threshold_uncertainty_score":0.7950296},"labels":[],"label_agreement":null},{"id":"W2134788484","doi":"10.1200/jco.2007.13.4536","title":"American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Nonhormonal Therapy for Men With Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"American Society of Clinical Oncology","keywords":"Medicine; Guideline; Docetaxel; Prostate cancer; Oncology; Cancer; Internal medicine; Context (archaeology); Intensive care medicine; Gynecology; Pathology","score_opus":0.3416810237339488,"score_gpt":0.6018721482134523,"score_spread":0.26019112447950343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134788484","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035393306,0.9817139,0.00004842355,0.0069862395,0.00095924863,0.0045685107,0.00038824533,0.000006952224,0.0017891618],"genre_scores_gemma":[0.0009070346,0.9824075,0.011886538,0.0020435068,0.0014366664,0.00028880168,0.00007028664,0.00007615482,0.0008835085],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9868379,0.0017367827,0.00881607,0.0005977787,0.0014455881,0.00056585635],"domain_scores_gemma":[0.9675831,0.010631403,0.016807396,0.00054461195,0.003953473,0.000479968],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009811341,0.00055878743,0.007849891,0.00018077096,0.000105731604,0.000011315086,0.0005766128,0.0006622852,0.00012786579],"category_scores_gemma":[0.0016002813,0.00026596338,0.0031951172,0.00043541356,0.001422679,0.00012608552,0.0000983282,0.003267483,0.0000011170405],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049284875,0.0042092726,0.00084888114,0.0015126523,0.009757383,0.00012718952,0.00058869855,0.000016035303,0.0000151747845,0.000010197112,0.026603593,0.90702605],"study_design_scores_gemma":[0.016920066,0.07287797,0.0029113805,0.0027689198,0.007021358,0.000059555903,0.0010833845,0.000007632799,0.000015988111,0.000008596384,0.8961179,0.00020719608],"about_ca_topic_score_codex":0.0054756277,"about_ca_topic_score_gemma":0.00916622,"teacher_disagreement_score":0.90681887,"about_ca_system_score_codex":0.002886591,"about_ca_system_score_gemma":0.06493657,"threshold_uncertainty_score":0.99997926},"labels":[],"label_agreement":null},{"id":"W2134889564","doi":"10.1016/j.ijrobp.2014.05.640","title":"Identification of a Proteomic Signature to Predict Recurrence in Intermediate Risk Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Identification (biology); Signature (topology); Oncology; Biochemical recurrence; Internal medicine; Cancer; Prostatectomy","score_opus":0.015276119504942084,"score_gpt":0.3547022631052062,"score_spread":0.33942614360026413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134889564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99089897,0.00047647257,0.0033959027,0.0028165753,0.0014699254,0.00067285413,0.00015322419,0.000013160533,0.000102938444],"genre_scores_gemma":[0.99578494,0.0022543215,0.0005582155,0.00019610206,0.0009553477,0.000081150465,0.000057932535,0.000016649392,0.00009531892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807006,0.00027503291,0.0008964406,0.00022617081,0.0003227716,0.00020952076],"domain_scores_gemma":[0.9973675,0.00023596978,0.001193214,0.00014122041,0.00093649124,0.00012560548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010676034,0.00014623048,0.0004111035,0.00032509735,0.000031045318,0.000015676977,0.00031325594,0.00016587913,0.000030429841],"category_scores_gemma":[0.0009316032,0.00011662571,0.00012422992,0.00027928373,0.00014690669,0.00019565773,0.0000553304,0.0005626843,0.000014758642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017373376,0.00037490414,0.68258446,0.000030759882,0.00026944594,0.000011565787,0.0012754857,0.0009293508,0.037430752,0.0003870682,0.00053570763,0.27443314],"study_design_scores_gemma":[0.019539045,0.005822307,0.8168465,0.0009422024,0.00027180737,0.00006860033,0.00018029766,0.011793462,0.115685664,0.015034731,0.013428021,0.0003873536],"about_ca_topic_score_codex":0.000039523515,"about_ca_topic_score_gemma":0.000012463922,"teacher_disagreement_score":0.2740458,"about_ca_system_score_codex":0.0007543314,"about_ca_system_score_gemma":0.0006724572,"threshold_uncertainty_score":0.47558585},"labels":[],"label_agreement":null},{"id":"W2137336295","doi":"10.1016/j.clgc.2012.06.004","title":"Neutropenia as a Potential Pharmacodynamic Marker for Docetaxel-Based Chemotherapy in Men With Metastatic Castration-Resistant Prostate Cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group; McMaster University","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Neutropenia; Internal medicine; Oncology; Hazard ratio; Proportional hazards model; Placebo; Chemotherapy; Cancer; Confidence interval; Pathology","score_opus":0.05422431967467393,"score_gpt":0.4329186536417635,"score_spread":0.37869433396708957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137336295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98240983,0.0069985297,0.0000603729,0.0058094584,0.00038451032,0.0032839556,0.00019237296,0.000044326836,0.0008166369],"genre_scores_gemma":[0.9823891,0.0033156518,0.0014135123,0.0012622883,0.0009069364,0.0027005733,0.00010650876,0.00009470133,0.0078107156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733114,0.00017124553,0.0006710154,0.0005328463,0.00043135116,0.00086237455],"domain_scores_gemma":[0.99857605,0.00019447005,0.00020114261,0.00031177947,0.00023342695,0.0004831621],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006147377,0.00034523167,0.0006391817,0.00014921922,0.0001239964,0.00003732304,0.00014995816,0.00010316809,0.0010446653],"category_scores_gemma":[0.000027273236,0.00024041334,0.00023373101,0.0003439611,0.00024242444,0.00022719344,0.000032395037,0.00042537166,0.000027096574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23875478,0.00787095,0.56359935,0.0016829527,0.0036542022,0.0016501232,0.00077806873,0.0016179503,0.06496951,0.000027552436,0.013172157,0.102222435],"study_design_scores_gemma":[0.12773395,0.0077451896,0.78386366,0.00096719654,0.0022825282,0.00010702426,0.0005721413,0.013576565,0.0166576,0.00011175257,0.04494587,0.0014365342],"about_ca_topic_score_codex":0.00036130231,"about_ca_topic_score_gemma":0.00011145192,"teacher_disagreement_score":0.22026432,"about_ca_system_score_codex":0.0004224423,"about_ca_system_score_gemma":0.0014836555,"threshold_uncertainty_score":0.9998685},"labels":[],"label_agreement":null},{"id":"W2137372444","doi":"10.1200/jco.2008.20.0923","title":"Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":334,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Institute for Clinical Evaluative Sciences","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Diabetes mellitus; Hazard ratio; Internal medicine; Cohort; Myocardial infarction; Sudden cardiac death; Proportional hazards model; Cancer; Endocrinology; Confidence interval","score_opus":0.13411804558813858,"score_gpt":0.4945700752033169,"score_spread":0.3604520296151783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137372444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98966944,0.007815381,0.0000064531464,0.002028891,0.00007449886,0.00014535546,0.0000021930257,0.0000023753914,0.00025539903],"genre_scores_gemma":[0.9890381,0.010167071,0.00012155827,0.00030393465,0.00033682646,8.593197e-7,0.0000020383181,0.0000042442625,0.000025387964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876124,0.00017560102,0.00059956126,0.00008962378,0.00025973906,0.00011426681],"domain_scores_gemma":[0.9986446,0.00042481138,0.0002917682,0.00013374149,0.00020741824,0.00029768952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001257068,0.000065068874,0.0007330934,0.00008011666,0.00001559575,0.000003177193,0.000045759098,0.000097736134,0.000020517784],"category_scores_gemma":[0.0007635726,0.00003490416,0.0006559482,0.00006937384,0.0000933423,0.00004746023,0.0000072244775,0.00025758278,0.000001109414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062538395,0.0009997024,0.51857865,0.0000067580118,0.0015593512,0.00014760629,0.000020840556,0.000026412301,0.00025326893,0.000010175812,0.0003555216,0.4717879],"study_design_scores_gemma":[0.008182454,0.026416356,0.9617642,0.000048060305,0.00025005874,0.000011774417,0.0000034708378,0.0000377264,0.0002999318,0.00060850277,0.002347016,0.000030424904],"about_ca_topic_score_codex":0.0000035864125,"about_ca_topic_score_gemma":1.0575965e-7,"teacher_disagreement_score":0.47175747,"about_ca_system_score_codex":0.00006877271,"about_ca_system_score_gemma":0.0007753295,"threshold_uncertainty_score":0.14233501},"labels":[],"label_agreement":null},{"id":"W2137467802","doi":"10.1056/nejmoa1209096","title":"Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2795,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Juravinski Cancer Centre; Université de Montréal","funders":"National Cancer Institute","keywords":"Prednisone; Medicine; Abiraterone acetate; Hazard ratio; Prostate cancer; Internal medicine; Interim analysis; Urology; Chemotherapy; Oncology; Surgery; Cancer; Gastroenterology; Androgen deprivation therapy; Randomized controlled trial; Confidence interval","score_opus":0.040248268317293716,"score_gpt":0.3675862686758338,"score_spread":0.3273380003585401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137467802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94161785,0.03862555,0.00005288528,0.018248707,0.00044766473,0.00041687218,0.0000019493373,0.00000905887,0.0005794915],"genre_scores_gemma":[0.9807634,0.012075967,0.0005099134,0.00071088725,0.002686242,0.000009710972,0.0000047892395,0.00002656107,0.0032125772],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841315,0.00009022205,0.0004928823,0.000099911784,0.0005144312,0.00038938376],"domain_scores_gemma":[0.99897325,0.000071101545,0.00021624214,0.0001279253,0.00014528201,0.00046619662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010796982,0.00016188358,0.00060905935,0.00026230092,0.00002348301,0.0000063069324,0.00007882987,0.00003526897,0.0005458939],"category_scores_gemma":[0.00009642054,0.000086816726,0.000051933417,0.00024967338,0.00010204058,0.00016707493,0.000010732092,0.00037338663,0.0000058515607],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058914674,0.00035064254,0.5830376,0.00019554871,0.00036609752,0.00031469404,0.009097696,0.000010492605,0.011119941,0.000015829095,0.005926242,0.38367373],"study_design_scores_gemma":[0.40096438,0.0067473133,0.41490647,0.004063815,0.0008675337,0.0031805255,0.00096815807,0.000064338325,0.011462334,0.00049720146,0.15591756,0.00036034707],"about_ca_topic_score_codex":0.00024726317,"about_ca_topic_score_gemma":0.000038934882,"teacher_disagreement_score":0.3950729,"about_ca_system_score_codex":0.00016912563,"about_ca_system_score_gemma":0.00032310444,"threshold_uncertainty_score":0.59771556},"labels":[],"label_agreement":null},{"id":"W2137605045","doi":"10.7150/jca.4192","title":"Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC)","year":2013,"lang":"en","type":"article","venue":"Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; BC Cancer Agency","funders":"Cancer Care Ontario","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Proportional hazards model; Retrospective cohort study; Cancer; Stage (stratigraphy); Disease; Gynecology; Confidence interval","score_opus":0.030083897738494722,"score_gpt":0.38024635003197665,"score_spread":0.3501624522934819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137605045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924733,0.0033141228,2.0997902e-7,0.0024668865,0.000060078808,0.00057564245,0.0000558554,0.000003946337,0.001049981],"genre_scores_gemma":[0.9903334,0.0055161705,0.00004165787,0.00007284079,0.00008123698,0.00017613758,0.0000023135387,0.000025669333,0.0037505757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984857,0.00003892975,0.00043165957,0.00013825187,0.00056871644,0.00033674578],"domain_scores_gemma":[0.99888146,0.00007725502,0.00033683787,0.00015182543,0.00033211758,0.00022050459],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013417836,0.00018197675,0.0005937659,0.00024055855,0.00003047285,0.000020328185,0.00009182698,0.00005267765,0.0012467898],"category_scores_gemma":[0.000020943438,0.000090549285,0.00017365658,0.00023447759,0.00009874356,0.00015528992,0.000020881462,0.00026659487,0.000005884051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048683444,0.00033851503,0.9742949,0.000096630836,0.00069802784,0.00055161666,0.00062423915,0.00034062672,0.00925802,0.000001715142,0.0049548927,0.003972444],"study_design_scores_gemma":[0.0062862206,0.0031324115,0.9752728,0.0008807606,0.000115284805,0.00001713437,0.0001196017,0.000013928837,0.013689582,0.000020548036,0.0003499076,0.00010184432],"about_ca_topic_score_codex":0.006633666,"about_ca_topic_score_gemma":0.0018551733,"teacher_disagreement_score":0.0047784927,"about_ca_system_score_codex":0.0014114586,"about_ca_system_score_gemma":0.00073556544,"threshold_uncertainty_score":0.9999812},"labels":[],"label_agreement":null},{"id":"W2137996608","doi":"10.1158/0008-5472.can-06-3332","title":"Intraprostatic Androgens and Androgen-Regulated Gene Expression Persist after Testosterone Suppression: Therapeutic Implications for Castration-Resistant Prostate Cancer","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":524,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Immunovaccine (Canada)","funders":"National Center for Research Resources; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute on Aging; National Cancer Institute; Prostate Cancer Foundation; National Institutes of Health; Michael Smith Health Research BC; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Oregon National Primate Research Center; National Institute of Child Health and Human Development; U.S. Department of Veterans Affairs","keywords":"Prostate cancer; Androgen; Androgen deprivation therapy; Medicine; Androgen receptor; Internal medicine; Endocrinology; Testosterone (patch); Prostate; TMPRSS2; LNCaP; Cancer research; Cancer; Hormone","score_opus":0.0799958214474921,"score_gpt":0.4127913581025604,"score_spread":0.33279553665506834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137996608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95934457,0.030138696,0.00012380106,0.0060376166,0.00010405792,0.0035035405,0.0005928628,0.000059357644,0.00009551703],"genre_scores_gemma":[0.98973036,0.003133027,0.0006369299,0.00016410946,0.00023555532,0.0034251004,0.00018498169,0.00007516532,0.0024147672],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99707663,0.000097724784,0.0004084793,0.0007288626,0.0006162548,0.001072056],"domain_scores_gemma":[0.9976617,0.00028843785,0.000078727215,0.0004915328,0.00093813246,0.00054147985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008929936,0.00027558792,0.00036210116,0.00036219973,0.0006242426,0.000121848854,0.0001466719,0.00016627653,0.00027309856],"category_scores_gemma":[0.00005306472,0.00020573346,0.00009229756,0.00064910663,0.00054926483,0.00018005604,0.00010325682,0.00039305177,0.000005248777],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067349975,0.00020730648,0.041844636,0.00044391345,0.00018488054,0.00005018919,0.0013654247,0.0000044249095,0.9264232,0.00004356344,0.0012761023,0.021421375],"study_design_scores_gemma":[0.0065150848,0.0011809078,0.17943394,0.0006704216,0.0001810549,0.0000646585,0.00077032734,0.00006402531,0.80411,0.00051243725,0.00612768,0.00036946393],"about_ca_topic_score_codex":0.00018610718,"about_ca_topic_score_gemma":0.0003067793,"teacher_disagreement_score":0.1375893,"about_ca_system_score_codex":0.00054489385,"about_ca_system_score_gemma":0.00077946397,"threshold_uncertainty_score":0.8389567},"labels":[],"label_agreement":null},{"id":"W2138448729","doi":"10.5489/cuaj.229","title":"Metastatic castration-resistant prostate cancer: The emerging continuum of care","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Castration; Medicine; Oncology; Cancer; Internal medicine; Hormone","score_opus":0.018106239959708757,"score_gpt":0.28416249237474606,"score_spread":0.2660562524150373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138448729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93216205,0.0036238616,0.0000034398847,0.061721046,0.00020080815,0.0006137206,0.000072095376,0.00001020925,0.0015927618],"genre_scores_gemma":[0.99689335,0.00037943572,0.00007312093,0.0008101919,0.0001546871,0.00006259886,0.00002141152,0.000008422257,0.0015967903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986596,0.00013601953,0.00030819944,0.0001143858,0.0003718062,0.00041000498],"domain_scores_gemma":[0.998409,0.00010879665,0.0002327812,0.00008796194,0.0007809616,0.00038052563],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032316128,0.00009924559,0.00022577793,0.00010324925,0.0002883355,0.00007998471,0.00009520935,0.00006228945,0.0011214587],"category_scores_gemma":[0.00024435125,0.00005584909,0.000107756656,0.00020826508,0.00005675657,0.00009494806,0.00000921267,0.0003750525,0.000023944782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021211577,0.00005923412,0.9325125,0.000064747655,0.00067430927,0.0001331843,0.0033610084,0.00007212139,0.005276541,0.00016830426,0.03660396,0.02086198],"study_design_scores_gemma":[0.0021409742,0.00065315224,0.9585103,0.000054724358,0.00022425053,0.000055316334,0.0031679245,0.00010082238,0.00073835504,0.00070045446,0.033521786,0.00013197312],"about_ca_topic_score_codex":0.007314883,"about_ca_topic_score_gemma":0.0057428484,"teacher_disagreement_score":0.064731285,"about_ca_system_score_codex":0.00085811835,"about_ca_system_score_gemma":0.0009988839,"threshold_uncertainty_score":0.9997916},"labels":[],"label_agreement":null},{"id":"W2138809580","doi":"10.1016/s1470-2045(12)70473-4","title":"Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":280,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Abiraterone acetate; Prednisone; Prostate cancer; Medicine; Placebo; Oncology; Castration; Internal medicine; Pain control; Enzalutamide; Cancer; Hormone; Androgen deprivation therapy; Surgery; Pathology; Alternative medicine","score_opus":0.04245628526734094,"score_gpt":0.342165039565691,"score_spread":0.2997087542983501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138809580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915587,0.0023299041,0.000014612125,0.0005665398,0.000028509274,0.0047029033,0.00077816873,0.000009079309,0.000011608176],"genre_scores_gemma":[0.99852526,0.00045104473,0.000057152323,0.000060262828,0.000029755698,0.000416834,0.0004236538,0.000016955715,0.000019078077],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965437,0.0021074177,0.00041966696,0.00029615496,0.00031519003,0.00031787617],"domain_scores_gemma":[0.99677855,0.0022199834,0.00037707016,0.00044806293,0.00007913171,0.00009719889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029400643,0.00021531858,0.0013359524,0.000101793106,0.00007499267,0.00000919696,0.00013368376,0.00005514129,0.000014946632],"category_scores_gemma":[0.0001150732,0.00009553632,0.000027735881,0.00030164025,0.000463734,0.00013335966,0.000056405966,0.00020274588,2.8869593e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69900006,0.00044026252,0.2900956,0.0001576639,0.004181913,0.000006448909,0.0024299675,0.00008424066,0.000779446,0.0000025730058,0.000046428024,0.0027754116],"study_design_scores_gemma":[0.627124,0.0101595875,0.3550452,0.00021589856,0.004447541,0.000001175118,0.00029904646,0.0022997994,0.00026272432,0.0000073628617,0.000030231187,0.00010742792],"about_ca_topic_score_codex":0.00039672802,"about_ca_topic_score_gemma":0.00080541434,"teacher_disagreement_score":0.07187603,"about_ca_system_score_codex":0.00008116023,"about_ca_system_score_gemma":0.00014922483,"threshold_uncertainty_score":0.3895858},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2139995572","doi":"10.1158/1078-0432.ccr-09-2514","title":"Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer","year":2009,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":206,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Internal medicine; Oncology; Prednisone; Mitoxantrone; Chemotherapy; Cancer","score_opus":0.2418637237828623,"score_gpt":0.5093903416955697,"score_spread":0.26752661791270743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139995572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979437,0.003224146,0.000015978576,0.013121799,0.00013611821,0.00198067,0.00010679448,0.00003295206,0.0019445253],"genre_scores_gemma":[0.98746586,0.0089184875,0.00018888395,0.00010086708,0.0002433735,0.00037681608,0.000050058126,0.000032576747,0.0026230991],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99629986,0.00031501273,0.0007988058,0.0005532822,0.001364195,0.00066884374],"domain_scores_gemma":[0.99820656,0.00048181642,0.00011616863,0.00038594825,0.0005244524,0.0002850407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028115239,0.00019315323,0.00068706693,0.0002829388,0.0001277884,0.00003260246,0.00016931293,0.00010539023,0.00024062431],"category_scores_gemma":[0.00021259606,0.00013195169,0.0001557338,0.0011237412,0.000324158,0.00014853696,0.000031329266,0.00080196233,0.0000048812294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046867616,0.0031251027,0.8345305,0.0006995247,0.0010307073,0.0006930987,0.0017911057,0.00042504302,0.011957241,0.00015203991,0.0028604658,0.09586761],"study_design_scores_gemma":[0.0319323,0.010156757,0.9408838,0.0018914883,0.00018122917,0.0000040806303,0.0007425883,0.001481692,0.007841057,0.0006706858,0.0039408137,0.00027346858],"about_ca_topic_score_codex":0.002000482,"about_ca_topic_score_gemma":0.0020128414,"teacher_disagreement_score":0.106353395,"about_ca_system_score_codex":0.00047656152,"about_ca_system_score_gemma":0.0015609456,"threshold_uncertainty_score":0.5380834},"labels":[],"label_agreement":null},{"id":"W2140059261","doi":"10.1016/j.ijrobp.2011.06.630","title":"Population-based Validation of the Bolla Study in T3-4 Prostate Cancer in British Columbia","year":2011,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Comorbidity; Cancer registry; Androgen deprivation therapy; Population; Radiation therapy; Internal medicine; External beam radiotherapy; Cancer; Oncology","score_opus":0.03327637993750619,"score_gpt":0.357195058176952,"score_spread":0.3239186782394458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140059261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997367,0.00029389557,0.000033736655,0.0006372943,0.0008274704,0.0006264291,0.000056886205,0.0000067686224,0.00015047693],"genre_scores_gemma":[0.99902946,0.00024234236,0.00017001032,0.00012894986,0.00023759085,0.000042183477,0.00003898048,0.000014285307,0.00009620331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841243,0.00028274316,0.00068637385,0.00015756048,0.00030041824,0.00016045623],"domain_scores_gemma":[0.9985127,0.00012695095,0.00066437986,0.00010948759,0.0005368039,0.000049694274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056723296,0.00008572322,0.00034013463,0.0001369828,0.000037138623,0.000022143893,0.00023331061,0.000107390304,0.00012993686],"category_scores_gemma":[0.00017060008,0.00008479005,0.000106745094,0.00031741752,0.00009399554,0.00015909423,0.000035252717,0.00032375994,0.0000015639828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036626065,0.0011513542,0.96305543,0.000010135609,0.00014144863,0.00003991472,0.00090165983,0.00049749453,0.0004076958,0.000035189616,0.00007835058,0.033315085],"study_design_scores_gemma":[0.00811664,0.0007371973,0.98727053,0.00013686735,0.000047626683,0.000015729638,0.00020627727,0.0003945316,0.0011399755,0.0016805759,0.00018474378,0.000069304864],"about_ca_topic_score_codex":0.011801484,"about_ca_topic_score_gemma":0.009832253,"teacher_disagreement_score":0.03324578,"about_ca_system_score_codex":0.0009374492,"about_ca_system_score_gemma":0.0008608676,"threshold_uncertainty_score":0.994779},"labels":[],"label_agreement":null},{"id":"W2140357489","doi":"10.1016/j.urology.2011.07.053","title":"MP-03.04 The Combination Treatment of Bicalutamide Plus Carbidopa Significantly Enhances the in vivo Antitumor Activity on LNCaP Castration-resistant Prostate Cancer Xenograft Tumors Compared To Single Use of Each Drug","year":2011,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Bicalutamide; Medicine; In vivo; Prostate cancer; Carbidopa; LNCaP; Pharmacology; Oncology; Cancer research; Internal medicine; Cancer; Urology; Androgen receptor; Levodopa","score_opus":0.08130772656476404,"score_gpt":0.3203432956378528,"score_spread":0.23903556907308876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140357489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520457,0.00034102655,0.0000073856127,0.0022213997,0.00010062199,0.0016569287,0.000096180345,0.000014979626,0.00035690994],"genre_scores_gemma":[0.99894756,0.00017662416,0.000028366347,0.00008132652,0.000024306333,0.0002737397,0.000014443864,0.000015682715,0.0004379545],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985174,0.00025711852,0.0003297447,0.00029161962,0.000282879,0.00032123298],"domain_scores_gemma":[0.99897665,0.00027864598,0.00018151263,0.00034045143,0.00014644627,0.00007632476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019824592,0.000180653,0.00042759118,0.0001678556,0.00008701905,0.000011213652,0.00012437871,0.000045652952,0.00006250909],"category_scores_gemma":[0.000047063553,0.000096099786,0.00007308623,0.00034675674,0.00038405915,0.000064056236,0.000026927039,0.00012951769,0.000004147906],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018988397,0.00424842,0.036896616,0.00012239406,0.000357924,0.00016890063,0.02430123,0.0010766508,0.9100852,0.00037823498,0.0003270135,0.0030489904],"study_design_scores_gemma":[0.0036754634,0.005685454,0.18163224,0.00007334303,0.00015323146,0.0000058531627,0.00071927655,0.0008305692,0.80625856,0.0000794065,0.0007566147,0.0001300027],"about_ca_topic_score_codex":0.008161252,"about_ca_topic_score_gemma":0.006208273,"teacher_disagreement_score":0.14473562,"about_ca_system_score_codex":0.00026136782,"about_ca_system_score_gemma":0.00030601962,"threshold_uncertainty_score":0.9984435},"labels":[],"label_agreement":null},{"id":"W2140725200","doi":"10.1158/0008-5472.can-13-1462","title":"Androgen Glucuronidation: An Unexpected Target for Androgen Deprivation Therapy, with Prognosis and Diagnostic Implications","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Androgen deprivation therapy; Androgen; Medicine; Glucuronidation; Oncology; Internal medicine; Endocrinology; Prostate cancer; Physiology; Biology; Hormone; Cancer; Biochemistry","score_opus":0.09685667553276887,"score_gpt":0.41098529621588004,"score_spread":0.31412862068311115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140725200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98052895,0.0047653136,0.00016638535,0.009288993,0.000016597156,0.0048839166,0.000058433692,0.000081852835,0.00020955129],"genre_scores_gemma":[0.9811055,0.0032776182,0.0012867246,0.00008516531,0.00018445041,0.013113924,0.00039309257,0.00004414475,0.00050937943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984417,0.000086730484,0.00015988736,0.00043976668,0.00038252515,0.00048940437],"domain_scores_gemma":[0.9979311,0.00031971667,0.000037102487,0.00032046545,0.0010910472,0.00030055593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002748904,0.00013496264,0.00018526275,0.00020033446,0.00036924816,0.00012517508,0.00011923448,0.00007531108,0.0003238107],"category_scores_gemma":[0.00013484324,0.00009312002,0.000028498962,0.0005754107,0.0002427051,0.00029142408,0.000041111267,0.00018272425,0.000014059912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013080311,0.00073302374,0.78832287,0.00025176283,0.0004102975,0.00000903068,0.0011272709,0.000010122127,0.06963275,0.00054501503,0.007354271,0.13029553],"study_design_scores_gemma":[0.014822679,0.008404777,0.6745184,0.00032145056,0.000107614906,0.000054308286,0.0010103034,0.0009407187,0.26337352,0.004233339,0.031659883,0.00055300613],"about_ca_topic_score_codex":0.00045849624,"about_ca_topic_score_gemma":0.00006658516,"teacher_disagreement_score":0.19374076,"about_ca_system_score_codex":0.00019884558,"about_ca_system_score_gemma":0.00049512275,"threshold_uncertainty_score":0.37973243},"labels":[],"label_agreement":null},{"id":"W2140768127","doi":"10.1002/dvg.20386","title":"Temporally controlled prostate epithelium‐specific gene alterations","year":2008,"lang":"en","type":"article","venue":"genesis","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital; Alberta Bone and Joint Health Institute; University of Calgary","funders":"","keywords":"Cre recombinase; Biology; Prostate; Prostate cancer; Fusion gene; Carcinogenesis; Gene; Cancer research; Transgene; Epithelium; Gene targeting; Genetically modified mouse; Genetics; Cancer","score_opus":0.042696699272324334,"score_gpt":0.2956452117172289,"score_spread":0.25294851244490457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140768127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98475176,0.0070120264,0.00013300253,0.0030744446,0.00015816714,0.0013194378,0.000038049347,0.000106292035,0.0034068373],"genre_scores_gemma":[0.9635231,0.005035493,0.0018993194,0.00030943763,0.0003647018,0.0003446042,0.00014613732,0.000035310743,0.02834189],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99880105,0.000047326634,0.00025645338,0.00027127794,0.00030861795,0.00031530097],"domain_scores_gemma":[0.99921715,0.000041218926,0.000050630853,0.0003140303,0.00019523717,0.00018171775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013036978,0.00014862452,0.00035386038,0.00013565355,0.00026561433,0.000019589841,0.00006715599,0.00005346547,0.0003414026],"category_scores_gemma":[0.000020708128,0.000104354775,0.0001450829,0.00022136918,0.0000998187,0.000066239096,0.00002519082,0.000082794024,0.00034316088],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009997082,0.0013779891,0.13790736,0.00013192871,0.001112254,0.0027226156,0.003809116,0.000102532525,0.7619933,0.00020207942,0.0637295,0.016914267],"study_design_scores_gemma":[0.09721451,0.0025644903,0.3778593,0.00014688961,0.0004679192,0.0013183955,0.00034291402,0.0009997386,0.34767926,0.00038245495,0.169941,0.0010831389],"about_ca_topic_score_codex":0.000051719737,"about_ca_topic_score_gemma":0.0000039458423,"teacher_disagreement_score":0.41431403,"about_ca_system_score_codex":0.00010840745,"about_ca_system_score_gemma":0.00027560556,"threshold_uncertainty_score":0.44107533},"labels":[],"label_agreement":null},{"id":"W2140835621","doi":"10.1002/1097-0045(20000701)44:2<156::aid-pros8>3.0.co;2-8","title":"Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors","year":2000,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Paclitaxel; LNCaP; Apoptosis; Medicine; Prostate; Internal medicine; Cancer research; Chemotherapy; Endocrinology; Chemistry; Cancer; Biochemistry","score_opus":0.01423139587265814,"score_gpt":0.27657115704446533,"score_spread":0.2623397611718072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140835621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9661259,0.029062685,5.3079674e-7,0.0018691901,0.00005081345,0.0012951234,0.000048132875,0.00005527252,0.0014923502],"genre_scores_gemma":[0.97394663,0.0116457455,0.00007022288,0.0001114951,0.000041218595,0.00007411334,0.000041906118,0.000043396973,0.014025296],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980895,0.000107588756,0.00039902717,0.0003962857,0.0004794028,0.000528207],"domain_scores_gemma":[0.9990395,0.000082267354,0.00014987568,0.00041687296,0.000095059724,0.00021647802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003864894,0.000293254,0.00044511489,0.000105688065,0.00021823897,0.000043372194,0.00015001766,0.00006653941,0.00023342017],"category_scores_gemma":[0.000019444296,0.0001550759,0.00009468114,0.000345985,0.00043366852,0.000120074874,0.00008377615,0.00030650463,0.000053084474],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0148578845,0.0015194754,0.083991006,0.0015856435,0.0010963985,0.0006365588,0.028397715,0.000036092828,0.400487,0.0000850105,0.0023216398,0.46498558],"study_design_scores_gemma":[0.0074904035,0.0018673872,0.038815428,0.0010314006,0.00033263335,0.0003164144,0.0023963915,0.00027713695,0.942678,0.0010109637,0.003285104,0.00049878313],"about_ca_topic_score_codex":0.00027091577,"about_ca_topic_score_gemma":0.0000042875104,"teacher_disagreement_score":0.54219097,"about_ca_system_score_codex":0.00005990178,"about_ca_system_score_gemma":0.00019392619,"threshold_uncertainty_score":0.63238114},"labels":[],"label_agreement":null},{"id":"W2141253922","doi":"","title":"AIbZIP, a novel bZIP gene located on chromosome 1q21.3 that is highly expressed in prostate tumors and of which the expression is up-regulated by androgens in LNCaP human prostate cancer cells.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"","keywords":"LNCaP; Biology; Prostate cancer; Prostate; Cancer research; Messenger RNA; Gene expression; Molecular biology; Gene; Cancer; Genetics","score_opus":0.036778627617219666,"score_gpt":0.2631621288883463,"score_spread":0.2263835012711266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141253922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870177,0.0040393616,3.899368e-7,0.0041304687,0.000079740785,0.0039331126,0.0005278442,0.000044063334,0.00022733907],"genre_scores_gemma":[0.98859745,0.0026828712,0.000010010245,0.00036558343,0.00003267903,0.0030568906,0.00010138997,0.00006632973,0.0050867693],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971432,0.00009935896,0.00052185566,0.0006994551,0.00064022746,0.00089591934],"domain_scores_gemma":[0.9988064,0.00006139317,0.00020740938,0.00050904066,0.00016016427,0.00025556845],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003478835,0.00037537536,0.0005870955,0.00033705373,0.00012383991,0.000048807447,0.00019940642,0.00014659169,0.00012920116],"category_scores_gemma":[0.000021958485,0.00024610088,0.00006376877,0.00095486816,0.00024813128,0.00016929996,0.000113884016,0.00041470097,0.0000043442533],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016054525,0.0011707532,0.045325503,0.0004380361,0.00016008281,0.00009142907,0.009448751,0.00003903121,0.9224729,0.0000023499672,0.012497851,0.006747884],"study_design_scores_gemma":[0.00959758,0.00020851934,0.08566795,0.0004304099,0.000048709135,0.000008282972,0.00023236025,0.0003790653,0.9022465,0.000019814417,0.00090620184,0.00025465188],"about_ca_topic_score_codex":0.00095090683,"about_ca_topic_score_gemma":0.000120679324,"teacher_disagreement_score":0.040342454,"about_ca_system_score_codex":0.00029656664,"about_ca_system_score_gemma":0.00007305102,"threshold_uncertainty_score":0.9999991},"labels":[],"label_agreement":null},{"id":"W2141265794","doi":"10.1111/j.1365-2559.2011.04116.x","title":"Interactions and relationships of <i>PTEN</i>, <i>ERG</i>, <i>SPINK1</i> and <i>AR</i> in castration‐resistant prostate cancer","year":2012,"lang":"en","type":"article","venue":"Histopathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Calgary Laboratory Services; Kingston General Hospital; Alberta Cancer Foundation; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"PTEN; Erg; Tensin; Prostate cancer; TMPRSS2; Biology; Androgen receptor; Cancer research; Immunohistochemistry; Prostate; Cancer; Molecular biology; Pathology; Medicine; Genetics; PI3K/AKT/mTOR pathway; Immunology","score_opus":0.04378699696402396,"score_gpt":0.32682298153528166,"score_spread":0.2830359845712577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141265794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756813,0.018240217,0.000009699517,0.0019516002,0.00018372112,0.0003900494,0.00003940898,0.00001893574,0.003485076],"genre_scores_gemma":[0.9953345,0.0020238846,0.0003861466,0.00015274851,0.00006105921,0.000111877765,0.000025934913,0.000014229601,0.0018895996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990799,0.000097928874,0.00026359162,0.00018897971,0.0001036156,0.00026602892],"domain_scores_gemma":[0.9994882,0.000082254934,0.00008345073,0.00014413634,0.00006948888,0.00013250981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027765703,0.00011190552,0.00025028386,0.00017407707,0.000089618225,0.0000054035672,0.00002605784,0.000072960844,0.000035874764],"category_scores_gemma":[0.000057847003,0.0000955335,0.000024428022,0.00017294096,0.00026685113,0.00016113286,0.00003555293,0.00028683338,0.000004000087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005309225,0.00020287614,0.83089745,0.00016703768,0.000008498379,0.00007031775,0.003426042,0.000001706389,0.16152859,0.00067979324,0.0006205927,0.0018661899],"study_design_scores_gemma":[0.0022822712,0.00022475961,0.9743179,0.00014304944,0.00008804673,0.0005079743,0.0005453623,0.000021211205,0.004145413,0.00016802481,0.017423853,0.00013209642],"about_ca_topic_score_codex":0.00020686243,"about_ca_topic_score_gemma":0.00035721433,"teacher_disagreement_score":0.15738317,"about_ca_system_score_codex":0.00011704867,"about_ca_system_score_gemma":0.000102646176,"threshold_uncertainty_score":0.3895743},"labels":[],"label_agreement":null},{"id":"W2141323228","doi":"10.1158/1535-7163.mct-11-0826","title":"Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Prostate cancer; Cancer; Prostate; Cancer research; Medicine; Gene; Chromoplexy; DNA sequencing; Internal medicine; Oncology; Biology; PCA3; Genetics","score_opus":0.08997307342824663,"score_gpt":0.33383762010003104,"score_spread":0.24386454667178442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141323228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8661769,0.13197401,0.00046416506,0.00021147655,0.00027673342,0.0006414225,0.00018173554,0.000023514795,0.000050036724],"genre_scores_gemma":[0.99324006,0.00375176,0.0018990688,0.00045191904,0.00009840715,0.0002806662,0.00012349448,0.000053210253,0.00010143337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980808,0.00010758576,0.00044451328,0.00029529238,0.0006012526,0.00047054206],"domain_scores_gemma":[0.9987774,0.000022067163,0.00025319005,0.00038980198,0.00039466357,0.00016287445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019021695,0.00022714643,0.00041809358,0.00012720043,0.00007814067,0.000024539197,0.00011750681,0.000075051306,0.00022258393],"category_scores_gemma":[0.000012165024,0.00018493639,0.00011308762,0.00037668433,0.00014331934,0.0003007328,0.000048999034,0.00016733655,0.0000024271947],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031303026,0.00035601205,0.023734722,0.00016031493,0.00030890456,0.000016896885,0.007188913,0.00037696696,0.95966053,0.00003627055,0.000042586555,0.007804825],"study_design_scores_gemma":[0.0011630148,0.0004285079,0.0014205185,0.00017621221,0.00036503872,0.000003221291,0.0013661197,0.0012626494,0.9929251,0.00009746669,0.0006110305,0.00018109818],"about_ca_topic_score_codex":0.0029858984,"about_ca_topic_score_gemma":0.000067141955,"teacher_disagreement_score":0.12822226,"about_ca_system_score_codex":0.0003983259,"about_ca_system_score_gemma":0.000564516,"threshold_uncertainty_score":0.7541487},"labels":[],"label_agreement":null},{"id":"W2141458651","doi":"10.1677/jme.0.0260175","title":"Steroid-sensitive gene-1 is an androgen-regulated gene expressed in prostatic smooth muscle cells in vivo","year":2001,"lang":"en","type":"article","venue":"Journal of Molecular Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Dihydrotestosterone; Flutamide; Endocrinology; Internal medicine; Androgen; Castration; Testosterone (patch); In vivo; Gene expression; Biology; Messenger RNA; LNCaP; Prostate; Androgen receptor; Hormone; Prostate cancer; Gene; Medicine; Cancer","score_opus":0.022956930552940045,"score_gpt":0.29983847288319,"score_spread":0.2768815423302499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141458651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964793,0.0015576337,0.00011603807,0.0011212577,0.00010221072,0.0004403523,0.000015893798,0.000009608187,0.00015771136],"genre_scores_gemma":[0.99682343,0.0015100837,0.00090347667,0.0005039948,0.000051583553,0.00001217941,0.000008798963,0.00003237346,0.00015408837],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997984,0.00024533764,0.0005679442,0.00027454147,0.00034028338,0.00058791984],"domain_scores_gemma":[0.9990896,0.000039613733,0.00019439249,0.00026329394,0.00021163952,0.00020147245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017643243,0.0001961038,0.0005422766,0.00062170986,0.000026613356,0.00001615356,0.00013524444,0.00010404871,0.00009668649],"category_scores_gemma":[0.000031509673,0.00016163988,0.000114766524,0.00035809728,0.000108399196,0.00011886081,0.00004953112,0.0004068549,0.0000060650705],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013380994,0.00053769315,0.005606592,0.000025662823,0.00010340277,0.040309448,0.00083149946,0.00019503743,0.9473911,0.0000052160945,0.00008173607,0.0035745446],"study_design_scores_gemma":[0.009986337,0.0014701039,0.017684245,0.00009371223,0.000052508836,0.0014355934,0.0003154095,0.00038892514,0.96724707,0.00014807672,0.0010322053,0.00014581638],"about_ca_topic_score_codex":0.000089266876,"about_ca_topic_score_gemma":0.000038856262,"teacher_disagreement_score":0.038873855,"about_ca_system_score_codex":0.00023113728,"about_ca_system_score_gemma":0.0002359495,"threshold_uncertainty_score":0.65914834},"labels":[],"label_agreement":null},{"id":"W2141569270","doi":"10.1158/0008-5472.can-08-0249","title":"Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth","year":2008,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1412,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Center for Research Resources; Oregon National Primate Research Center; National Cancer Institute; Prostate Cancer Foundation; National Institutes of Health; University of Washington; National Institute of Diabetes and Digestive and Kidney Diseases; U.S. Department of Defense","keywords":"Prostate cancer; Castration; Androgen; Medicine; Prostate; Orchiectomy; Testosterone (patch); Internal medicine; Androgen deprivation therapy; Androgen receptor; CYP17A1; Cancer research; Cancer; Intracrine; Endocrinology; Oncology; Biology; Hormone; Gene; Receptor","score_opus":0.10793038384495086,"score_gpt":0.4065856309627567,"score_spread":0.29865524711780583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141569270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98972195,0.0031306539,0.00003170719,0.0032304986,0.00010181567,0.0029995318,0.00047381085,0.00002437014,0.0002856589],"genre_scores_gemma":[0.98797184,0.0049991207,0.00069632847,0.00009103821,0.000100457066,0.0034373156,0.000043675052,0.00004959819,0.0026106508],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99701065,0.00013700032,0.0004776806,0.00050484977,0.00088317815,0.0009866196],"domain_scores_gemma":[0.99762136,0.00017479372,0.00009840602,0.0002974856,0.0015396357,0.00026831194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007726069,0.00020595944,0.00054478366,0.00048459152,0.00020449112,0.000020944499,0.00019532676,0.000051054976,0.00013108984],"category_scores_gemma":[0.00025611272,0.00016044964,0.00011841631,0.0010917446,0.0005051822,0.00013855654,0.00006182165,0.0004509552,0.0000055853093],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02488648,0.0014533201,0.06115043,0.0051089623,0.00070388603,0.0037137961,0.0062308856,0.000054736687,0.85851556,0.023166476,0.011615035,0.0034004494],"study_design_scores_gemma":[0.022322217,0.0040782243,0.02060137,0.0020024534,0.00013801723,0.00023234647,0.0023885195,0.00093337795,0.9349138,0.010520954,0.0013023973,0.0005663025],"about_ca_topic_score_codex":0.0038658807,"about_ca_topic_score_gemma":0.0015611964,"teacher_disagreement_score":0.07639828,"about_ca_system_score_codex":0.0007972522,"about_ca_system_score_gemma":0.0030807313,"threshold_uncertainty_score":0.6542946},"labels":[],"label_agreement":null},{"id":"W2141873881","doi":"10.1158/0008-5472.can-08-3380","title":"LEF1 in Androgen-Independent Prostate Cancer: Regulation of Androgen Receptor Expression, Prostate Cancer Growth, and Invasion","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; National Center for Research Resources; U.S. Department of Defense","keywords":"LNCaP; Androgen receptor; Prostate cancer; Cancer research; Androgen; Gene knockdown; Biology; Cancer; Prostate; Internal medicine; Endocrinology; Medicine; Cell culture; Hormone","score_opus":0.05182841548603007,"score_gpt":0.3796057018448488,"score_spread":0.32777728635881875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141873881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9617363,0.028378874,0.0000011719845,0.006537806,0.00012586152,0.0026419265,0.00015879516,0.000040638377,0.0003785938],"genre_scores_gemma":[0.92293745,0.072589256,0.00007956129,0.000089918634,0.000186497,0.0009927319,0.000077058125,0.000046224937,0.0030013116],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959761,0.00027737254,0.00056382787,0.0008199428,0.0013984448,0.0009643426],"domain_scores_gemma":[0.99810404,0.00009697541,0.00014912199,0.00042522035,0.000796953,0.00042768085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009976056,0.00029363856,0.000577087,0.0006915286,0.0002315731,0.000060637452,0.00020945774,0.00021230386,0.00043011562],"category_scores_gemma":[0.00011170571,0.0002283693,0.00007843651,0.0012084004,0.00036753324,0.00034038688,0.00015724785,0.00071452913,0.0000073621886],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049361764,0.00030727612,0.28207022,0.0006966194,0.00007498911,0.000059707385,0.0029271843,0.00003434583,0.641896,0.000056851826,0.0037395833,0.06320101],"study_design_scores_gemma":[0.007194551,0.00093342486,0.10528703,0.0024069655,0.000036825062,0.000012308781,0.0005163563,0.00008241708,0.87962466,0.00069716614,0.0029182918,0.00029001868],"about_ca_topic_score_codex":0.0032377206,"about_ca_topic_score_gemma":0.0004974807,"teacher_disagreement_score":0.23772863,"about_ca_system_score_codex":0.00082563097,"about_ca_system_score_gemma":0.0016462087,"threshold_uncertainty_score":0.931263},"labels":[],"label_agreement":null},{"id":"W2141976382","doi":"10.1158/0008-5472.can-08-3506","title":"Osteoblast-Derived Factors Induce an Expression Signature that Identifies Prostate Cancer Metastasis and Hormonal Progression","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health; Michael Smith Health Research BC","keywords":"Prostate cancer; Gene signature; Osteoblast; Cancer research; Biology; Metastasis; Cancer; Gene expression; Phenotype; Prostate; Tumor progression; Gene; In vitro; Genetics","score_opus":0.11172701462873631,"score_gpt":0.4458255886357266,"score_spread":0.3340985740069903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141976382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9672079,0.026552761,0.0000027460915,0.003875761,0.00013719084,0.0017706375,0.0001423285,0.0000977384,0.00021295727],"genre_scores_gemma":[0.98627484,0.010174618,0.0001057234,0.00010435097,0.00025398386,0.0005302548,0.0001605285,0.00005132957,0.0023443555],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99577737,0.0003270367,0.000259642,0.0008538907,0.0017277726,0.0010542643],"domain_scores_gemma":[0.9980273,0.00011109219,0.00008777833,0.00046575148,0.0006016606,0.0007064222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070281053,0.00034324685,0.00046036096,0.0004774704,0.0006101604,0.0002455438,0.00025923573,0.0002496024,0.00038331054],"category_scores_gemma":[0.000081299324,0.0002230942,0.00008990361,0.00067016535,0.0004534538,0.000634761,0.00018903722,0.0011953377,0.00000720173],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022087968,0.00024793466,0.022954985,0.00019537057,0.000100736026,0.00012392829,0.0030097135,0.0000031409334,0.89104706,0.000010107486,0.0021818157,0.0779164],"study_design_scores_gemma":[0.0023142071,0.0014561289,0.102761775,0.0008042973,0.000060308157,0.00001031457,0.0020182815,0.000025812245,0.887758,0.00024556636,0.002283542,0.00026173147],"about_ca_topic_score_codex":0.00033024725,"about_ca_topic_score_gemma":0.00007443032,"teacher_disagreement_score":0.07980679,"about_ca_system_score_codex":0.00043619072,"about_ca_system_score_gemma":0.00072243856,"threshold_uncertainty_score":0.9097518},"labels":[],"label_agreement":null},{"id":"W2142190412","doi":"10.1093/annonc/mdr336","title":"A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; London Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Clinical endpoint; Internal medicine; Adverse effect; Phases of clinical research; Cancer; Urology; Surgery; Toxicity; Clinical trial","score_opus":0.12227081436402093,"score_gpt":0.4053715914620224,"score_spread":0.28310077709800147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142190412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923102,0.0003663056,4.249125e-7,0.00028843613,0.0000275788,0.00597288,0.00010272639,0.000015376965,0.0009160479],"genre_scores_gemma":[0.99855715,0.0001117393,0.0001485403,0.00013465468,0.000010082661,0.0008270513,0.000079406855,0.000030972446,0.00010038351],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99737066,0.0004816235,0.0006703577,0.00046412737,0.00037828757,0.0006349493],"domain_scores_gemma":[0.99814016,0.00009067752,0.00041671284,0.00034965875,0.0006732204,0.000329601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005191224,0.00027870425,0.0010792257,0.0005473529,0.00006583534,0.000005066384,0.00014842524,0.00009215943,0.00015391971],"category_scores_gemma":[0.00003992314,0.00017328499,0.00004340079,0.0007339644,0.00026210284,0.00011256033,0.000030588297,0.000271768,0.000002201889],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044567708,0.054895718,0.8703356,0.00009665007,0.0012642221,0.0019196821,0.014047659,0.000009652992,0.00008904817,0.0000070295187,0.00008060772,0.012686458],"study_design_scores_gemma":[0.053380646,0.34769142,0.5931748,0.00006685828,0.0005063276,0.000008097506,0.0045361603,0.0000057280636,0.0002398592,0.000012155987,0.00023487912,0.00014306637],"about_ca_topic_score_codex":0.19010043,"about_ca_topic_score_gemma":0.5451847,"teacher_disagreement_score":0.35508427,"about_ca_system_score_codex":0.0003214687,"about_ca_system_score_gemma":0.0018675149,"threshold_uncertainty_score":0.8152928},"labels":[],"label_agreement":null},{"id":"W2142466432","doi":"10.1016/s1470-2045(12)70560-0","title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":740,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; National Cancer Institute; Institut National Du Cancer; Sanofi; Roche; Bayer; AstraZeneca; Unicancer; Novartis; Pfizer; Amgen","keywords":"Medicine; Docetaxel; Androgen deprivation therapy; Prostate cancer; Internal medicine; Oncology; Estramustine; Clinical endpoint; Chemotherapy; Goserelin; Prostate-specific antigen; Urology; Cancer; Randomized controlled trial","score_opus":0.14905012062048997,"score_gpt":0.44504975400106633,"score_spread":0.29599963338057633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142466432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96770895,0.001382793,0.000027183407,0.017832682,0.00014818058,0.011559781,0.000038916638,0.000034928325,0.0012665897],"genre_scores_gemma":[0.97286826,0.008064532,0.0013034997,0.0026238172,0.00051047903,0.009630096,0.00010943185,0.000057726025,0.0048321383],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977265,0.00044350725,0.0004713348,0.0003990828,0.00030034024,0.00065921515],"domain_scores_gemma":[0.99863744,0.00035198074,0.00024196779,0.0004425977,0.00017765522,0.00014838659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011929037,0.00026563444,0.0011188668,0.00011912808,0.00012860137,0.000092088005,0.0003521029,0.00008572644,0.00087159174],"category_scores_gemma":[0.00006730586,0.00012246238,0.000039737137,0.0004975838,0.000262637,0.00025983344,0.00008246191,0.0004094558,0.00007312008],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9152576,0.002894945,0.0013802142,0.00008777365,0.0006759848,0.00040859246,0.0018694534,0.000011793266,0.010478036,0.000028302804,0.006630282,0.06027706],"study_design_scores_gemma":[0.97248507,0.012260279,0.0014043674,0.00012646521,0.00015506311,0.00009701401,0.0003003701,0.0005111106,0.0036003033,0.00035014102,0.00850944,0.00020037952],"about_ca_topic_score_codex":0.0012176653,"about_ca_topic_score_gemma":0.0007363964,"teacher_disagreement_score":0.06007668,"about_ca_system_score_codex":0.0002924768,"about_ca_system_score_gemma":0.001160226,"threshold_uncertainty_score":0.9543318},"labels":[],"label_agreement":null},{"id":"W2143351292","doi":"10.1093/annonc/mdn477","title":"The changing face of hormonal therapy for prostate cancer","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Hormonal therapy; Oncology; Hormone; Prostate; Cancer; Internal medicine","score_opus":0.16613090493638386,"score_gpt":0.45866731350037276,"score_spread":0.2925364085639889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143351292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9579772,0.020091077,0.000017315826,0.019794222,0.00008546401,0.0007698757,0.000039983064,0.0000074427376,0.001217448],"genre_scores_gemma":[0.93924767,0.055957593,0.000072771254,0.0004167347,0.00008512447,0.00020118407,0.000010669248,0.000009499757,0.003998744],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993266,0.00002554563,0.00016012594,0.000094165836,0.00012769185,0.00026589798],"domain_scores_gemma":[0.99928576,0.00017812566,0.00009505025,0.00010666298,0.00028929385,0.000045112527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002521895,0.00006155944,0.0002203145,0.00006185888,0.00010415081,0.0000011254332,0.0000669021,0.000048732865,0.000019160476],"category_scores_gemma":[0.00003067054,0.000034192173,0.000086045315,0.00012184338,0.00025345324,0.00002167181,0.00001884369,0.00006270252,0.0000010845202],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012484878,0.0006957009,0.021098075,0.00013295513,0.00077547785,0.00004186104,0.0095452545,0.000017017283,0.025251085,0.0004864533,0.035561424,0.8939098],"study_design_scores_gemma":[0.008631343,0.013977282,0.041762028,0.000077357494,0.000035160883,0.00003958836,0.0010612456,0.00016840562,0.32721013,0.0007183046,0.60619926,0.000119920674],"about_ca_topic_score_codex":0.00005102059,"about_ca_topic_score_gemma":0.0000107535525,"teacher_disagreement_score":0.8937899,"about_ca_system_score_codex":0.000023119386,"about_ca_system_score_gemma":0.00044251874,"threshold_uncertainty_score":0.13943163},"labels":[],"label_agreement":null},{"id":"W2143912139","doi":"10.1093/carcin/bgl236","title":"PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility","year":2006,"lang":"en","type":"article","venue":"Carcinogenesis","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovation Cluster (Canada)","funders":"National Health and Medical Research Council; Medical Research Council; Queensland University of Technology","keywords":"Prostate cancer; Genotype; Genotyping; Androgen receptor; Allele; Single-nucleotide polymorphism; Prostate-specific antigen; Internal medicine; Prostate; Endocrinology; Population; Androgen; Medicine; Biology; Cancer; Cancer research; Genetics; Gene; Hormone","score_opus":0.023219656161009947,"score_gpt":0.2758058724309923,"score_spread":0.25258621626998234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143912139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99155706,0.0041654464,0.0000028230515,0.0022844404,0.000079484795,0.0011124922,0.0003803544,0.00008650977,0.00033137097],"genre_scores_gemma":[0.9903759,0.00041750795,0.00009814622,0.00021408629,0.0001406694,0.00019478089,0.00028221685,0.00006276843,0.008213922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980137,0.000070051574,0.0002567344,0.00061918405,0.00043276878,0.00060760457],"domain_scores_gemma":[0.9990701,0.00004043131,0.000102967824,0.00031919824,0.0002259117,0.00024140031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021725576,0.00029379877,0.0004280677,0.00016556091,0.00020500859,0.000051643823,0.000074809526,0.00012960576,0.00039425024],"category_scores_gemma":[0.000020673086,0.00020542505,0.00009104932,0.0004053676,0.00025451984,0.0001177641,0.00005422528,0.00015134437,0.000022963754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007763985,0.00015855828,0.89170367,0.00012091397,0.00028288757,0.00010245673,0.00056815514,0.0000012404333,0.10069186,0.0000022170293,0.0026568696,0.0029348044],"study_design_scores_gemma":[0.006470409,0.0007356539,0.5960282,0.00042396697,0.0005196666,0.000046439065,0.00024539945,0.0000674339,0.3932424,0.000030906427,0.0016855563,0.00050397776],"about_ca_topic_score_codex":0.0010241175,"about_ca_topic_score_gemma":0.00021844626,"teacher_disagreement_score":0.29567546,"about_ca_system_score_codex":0.00047532673,"about_ca_system_score_gemma":0.00027430514,"threshold_uncertainty_score":0.83769906},"labels":[],"label_agreement":null},{"id":"W2143935078","doi":"10.1373/clinchem.2010.147918","title":"Can Chemoprevention Reduce the Risk of Prostate Cancer?","year":2010,"lang":"en","type":"article","venue":"Clinical Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Prostate cancer; Coca cola; Medicine; Cancer; Prostate cancer screening; Family medicine; Prostate-specific antigen; Advertising; Internal medicine","score_opus":0.042906914976604725,"score_gpt":0.4229802945868007,"score_spread":0.380073379610196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143935078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902697,0.00039601987,3.1494707e-7,0.0062089222,0.00018419929,0.00025140608,0.000047373578,0.000020661048,0.0026213648],"genre_scores_gemma":[0.9844876,0.0016529508,0.00006167655,0.00006659046,0.00047156925,0.000051612285,0.0000346826,0.00001227211,0.013161065],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990487,0.000026686173,0.00034021647,0.00021345781,0.00019412032,0.00017680335],"domain_scores_gemma":[0.99902546,0.00015510242,0.00015991264,0.00040474322,0.00013663986,0.000118131386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004450149,0.00008816024,0.0002179812,0.000006506313,0.00005840467,0.000006969668,0.00012507195,0.000136832,0.00035297972],"category_scores_gemma":[0.00051259197,0.000050633727,0.0001765373,0.000106313884,0.0004006837,0.000014801638,0.00004979864,0.0007726169,0.0000060359307],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000604399,0.0004140238,0.7637383,0.00029048644,0.00024549593,0.000012940703,0.00009907052,4.983583e-7,0.18694584,0.000006761566,0.005876737,0.041765444],"study_design_scores_gemma":[0.0027729364,0.00011194723,0.15184066,0.0001221593,0.0002563413,0.000013532345,0.00008981614,0.000054128453,0.83244085,0.00042442084,0.0117715,0.00010173745],"about_ca_topic_score_codex":0.00007486951,"about_ca_topic_score_gemma":0.000015943293,"teacher_disagreement_score":0.645495,"about_ca_system_score_codex":0.000025564601,"about_ca_system_score_gemma":0.00033463692,"threshold_uncertainty_score":0.38648805},"labels":[],"label_agreement":null},{"id":"W2144087378","doi":"10.1046/j.1525-1411.2000.23003.x","title":"Bicalutamide and Flutamide, Each in Combination with Luteinizing Hormone‐Releasing Hormone Analogs, in Advanced Prostate Cancer: Exploratory Analysis of Impact of Extent of Disease by Bone Scan on Outcome","year":2000,"lang":"en","type":"article","venue":"The Prostate Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"AstraZeneca","keywords":"Bicalutamide; Medicine; Flutamide; Antiandrogen; Prostate cancer; Internal medicine; Oncology; Hazard ratio; Urology; Cancer; Endocrinology; Confidence interval; Androgen receptor","score_opus":0.01753570239040011,"score_gpt":0.3190161873781584,"score_spread":0.3014804849877583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144087378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98512006,0.013266934,0.00000658871,0.00060940284,0.000010851952,0.0007744115,0.00017299205,0.0000075223693,0.000031266638],"genre_scores_gemma":[0.97728455,0.022371685,0.000072141505,0.000023035022,0.00000866632,0.000038903898,0.000037347272,0.000027124526,0.00013654177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975987,0.00021674077,0.00088128995,0.00025325577,0.00063935725,0.00041067737],"domain_scores_gemma":[0.99865925,0.00013050475,0.0004776105,0.0002595935,0.00022940544,0.0002436285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071954244,0.00023728191,0.000833007,0.0007496997,0.00007637691,0.000022455295,0.00010706497,0.000044905984,0.000026411328],"category_scores_gemma":[0.00007399379,0.0001383497,0.00016190117,0.0016158082,0.000300172,0.0002690344,0.000028689547,0.00045587713,2.6772514e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034679558,0.0013488496,0.82959604,0.00016458587,0.0011020603,0.00014133482,0.004889903,0.011305079,0.061943237,0.00000521748,0.000041803705,0.05478234],"study_design_scores_gemma":[0.009778799,0.0028130547,0.98072726,0.0005408245,0.0005886088,0.000010884688,0.00074102584,0.0027600692,0.0017815658,0.00010462416,0.0000063520915,0.00014695595],"about_ca_topic_score_codex":0.0006040525,"about_ca_topic_score_gemma":0.000071849085,"teacher_disagreement_score":0.1511312,"about_ca_system_score_codex":0.0005008768,"about_ca_system_score_gemma":0.00037015192,"threshold_uncertainty_score":0.5641737},"labels":[],"label_agreement":null},{"id":"W2144935753","doi":"10.1186/1477-5956-12-40","title":"Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality","year":2014,"lang":"en","type":"article","venue":"Proteome Science","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Center for Advancing Translational Sciences","keywords":"Prostate cancer; PTEN; Multiplex; Biomarker; Cancer; Biology; Immunofluorescence; Cancer research; Phenotype; Medicine; Pathology; Computational biology; Bioinformatics; Internal medicine; PI3K/AKT/mTOR pathway; Gene; Immunology; Signal transduction; Antibody; Genetics","score_opus":0.019864676863949413,"score_gpt":0.35254552093634184,"score_spread":0.3326808440723924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144935753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98663795,0.0024420333,0.00040598743,0.002356541,0.00016635044,0.0073517966,0.00006511797,0.00023003557,0.00034420073],"genre_scores_gemma":[0.99177027,0.00020573534,0.0040902477,0.000091695794,0.000022468521,0.0032225088,0.000016718397,0.000028925533,0.0005514579],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99682003,0.00010665674,0.00040919468,0.0009952788,0.00077799644,0.00089082145],"domain_scores_gemma":[0.9983975,0.00015159942,0.00019337636,0.00036671828,0.0006246709,0.00026612013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021804485,0.00029845195,0.00040289047,0.0003690977,0.00047042617,0.00020105047,0.0003208403,0.0000647507,0.000019811148],"category_scores_gemma":[0.0014272096,0.0002339349,0.00006326291,0.0012801167,0.0021824886,0.0010343721,0.00021232275,0.00026279342,0.000012433551],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029847291,0.00015402382,0.03526063,0.00041545733,0.000052624364,0.000021103102,0.002815273,0.000011056966,0.951109,0.00015271956,0.00006481177,0.006958571],"study_design_scores_gemma":[0.004072832,0.00078302977,0.1573772,0.00094584597,0.00003058958,0.000012296897,0.0011965794,0.037391625,0.79699004,0.0007690196,0.00013076994,0.00030018404],"about_ca_topic_score_codex":0.002644836,"about_ca_topic_score_gemma":0.000110003166,"teacher_disagreement_score":0.15411897,"about_ca_system_score_codex":0.0005190526,"about_ca_system_score_gemma":0.0008879496,"threshold_uncertainty_score":0.95395887},"labels":[],"label_agreement":null},{"id":"W2145300558","doi":"10.1093/annonc/mdm083","title":"Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Collège Montmorency","funders":"Sanofi","keywords":"Docetaxel; Estramustine; Medicine; Prostate cancer; Internal medicine; Oncology; Chemotherapy; Clinical endpoint; Prostate-specific antigen; Urology; Phases of clinical research; Cancer; Randomized controlled trial","score_opus":0.09273829699834261,"score_gpt":0.42329552431899564,"score_spread":0.330557227320653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145300558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99149287,0.0043292064,0.000008758917,0.0005314806,0.00005254739,0.0031084802,0.00003999326,0.000010790358,0.00042587434],"genre_scores_gemma":[0.99782735,0.0013839301,0.00018800561,0.00011445378,0.000021333828,0.00012934417,0.000037432652,0.00002103975,0.0002770872],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997924,0.0001904419,0.0007375372,0.00030239165,0.0004205046,0.00042513575],"domain_scores_gemma":[0.9984073,0.0003136758,0.00041613026,0.00020225471,0.00047914233,0.00018151694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011569055,0.00021169914,0.0012839867,0.00036553372,0.000047282505,0.0000044353756,0.00007495464,0.00006835604,0.000035626705],"category_scores_gemma":[0.00016039413,0.0001356426,0.00006855668,0.00032833946,0.00040426,0.00009938467,0.00006568682,0.00021951001,5.8867283e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7970939,0.03659889,0.031899557,0.00031457611,0.0015509635,0.00039199513,0.009596857,0.000042425403,0.0020726784,0.000011865297,0.00027553437,0.12015071],"study_design_scores_gemma":[0.85802543,0.07869925,0.05790488,0.0001533169,0.00055770413,0.0000066212406,0.001480296,0.000048754537,0.0022215405,0.00003804371,0.00069225626,0.00017193069],"about_ca_topic_score_codex":0.0006810251,"about_ca_topic_score_gemma":0.00032552794,"teacher_disagreement_score":0.11997878,"about_ca_system_score_codex":0.00012399394,"about_ca_system_score_gemma":0.0003810296,"threshold_uncertainty_score":0.55313444},"labels":[],"label_agreement":null},{"id":"W2145434047","doi":"10.1016/s1470-2045(14)70417-6","title":"Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McMaster University","funders":"Janssen Research and Development; National Cancer Institute","keywords":"Abiraterone acetate; Prostate cancer; Medicine; Oncology; Chemotherapy; Protocol (science); Internal medicine; Castration; Abiraterone; Cancer; Urology; Androgen deprivation therapy; Alternative medicine; Hormone; Pathology; Androgen receptor","score_opus":0.1270490815713082,"score_gpt":0.4639079775581205,"score_spread":0.3368588959868123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145434047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9111521,0.00003893242,0.000092776354,0.002207463,0.00004959637,0.08618813,0.00014199107,0.000018475808,0.0001105178],"genre_scores_gemma":[0.7926154,0.000018549099,0.00440272,0.0003845294,0.0001530284,0.20177172,0.00010516035,0.000037125497,0.00051175815],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982018,0.00026926975,0.00041626225,0.00034321006,0.00030277474,0.00046668036],"domain_scores_gemma":[0.99857605,0.00017580182,0.00040194913,0.0003638719,0.00039024273,0.00009208291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000626966,0.00020493104,0.0009600341,0.00012925887,0.00012221378,0.00010640509,0.0003094692,0.00005324063,0.000100063364],"category_scores_gemma":[0.00004381229,0.000106162595,0.00006377717,0.00049934327,0.00024836336,0.00018467585,0.00008353697,0.00014775906,0.0000013835697],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86799604,0.0030496216,0.079715885,0.0006192496,0.0037943562,0.000016383708,0.0017631762,0.000054107826,0.00072590465,0.000022002137,0.000253573,0.041989725],"study_design_scores_gemma":[0.69737697,0.023253705,0.256343,0.00036238795,0.004404973,0.0000017324369,0.000077944474,0.0027449853,0.0021459663,0.000118442236,0.012830456,0.00033941751],"about_ca_topic_score_codex":0.0002408679,"about_ca_topic_score_gemma":0.0006947275,"teacher_disagreement_score":0.17662713,"about_ca_system_score_codex":0.00018495579,"about_ca_system_score_gemma":0.00043724588,"threshold_uncertainty_score":0.4329185},"labels":[],"label_agreement":null},{"id":"W2145633869","doi":"10.1517/14728222.10.5.777","title":"Novel targets in prostate cancer","year":2006,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Targets","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Prostate cancer; Medicine; Context (archaeology); Sorafenib; Prostate; Cancer; Disease; Oncology; Internal medicine; Cancer research; Bioinformatics; Biology","score_opus":0.040874257755146005,"score_gpt":0.35918908279755435,"score_spread":0.3183148250424083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145633869","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060254276,0.84737635,0.0005150504,0.060720526,0.0048582694,0.0057776975,0.00018652408,0.00061630254,0.01969504],"genre_scores_gemma":[0.9737226,0.015765231,0.0005479048,0.002932011,0.00077625294,0.0006713897,0.00024878458,0.00008437856,0.0052514942],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982433,0.000039907103,0.0002926677,0.00043370944,0.00042498048,0.0005654676],"domain_scores_gemma":[0.9994143,0.00004520356,0.00006157821,0.0002831262,0.0000770744,0.00011871202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013888751,0.000256042,0.00031909262,0.00021962576,0.000091029695,0.000024208819,0.00010425748,0.00009274236,0.0004761202],"category_scores_gemma":[0.0000076292417,0.00018832734,0.00009558646,0.00027462756,0.00008853528,0.00008754478,0.00002767879,0.00025046,0.000070925336],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011857335,0.009842674,0.089843705,0.00027435698,0.0006830443,0.00040822895,0.00857684,0.000299027,0.46931192,0.007835261,0.05403544,0.34703216],"study_design_scores_gemma":[0.012463493,0.0009529851,0.09594835,0.00037286,0.000007224775,0.000029858073,0.00028057586,0.0004921285,0.089963116,0.0009821247,0.7979818,0.00052545744],"about_ca_topic_score_codex":0.00092889415,"about_ca_topic_score_gemma":0.000050846058,"teacher_disagreement_score":0.9134683,"about_ca_system_score_codex":0.00035118253,"about_ca_system_score_gemma":0.00018958858,"threshold_uncertainty_score":0.7679766},"labels":[],"label_agreement":null},{"id":"W2145985979","doi":"10.1002/jcb.20802","title":"Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer","year":2006,"lang":"en","type":"review","venue":"Journal of Cellular Biochemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Prostate cancer; Androgen receptor; Cancer research; Hormonal therapy; Androgen; Prostate; Cancer; Internal medicine; Hormone; Endocrinology; Biology; Medicine","score_opus":0.014790395373808902,"score_gpt":0.33968928465773873,"score_spread":0.32489888928392985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145985979","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06326592,0.93457097,0.0000059594518,0.0003995865,0.00012299277,0.0012735932,0.00016116252,0.0000027970525,0.00019699326],"genre_scores_gemma":[0.005504487,0.989299,0.0004773941,0.000025125995,0.0004076039,0.00012312406,0.0001123971,0.00006642736,0.003984461],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972135,0.00015716105,0.00103209,0.00023751747,0.0010614876,0.000298289],"domain_scores_gemma":[0.9974283,0.000042173124,0.001460863,0.0004897795,0.00039323632,0.00018564703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005581567,0.00034252618,0.0011892845,0.00009235869,0.00005642625,0.000015947053,0.00051046,0.00025075607,0.000077100056],"category_scores_gemma":[0.00006127563,0.00015400513,0.00095221226,0.00036717675,0.00022620807,0.0000206654,0.0001699906,0.0005727664,0.0000019620525],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010093554,0.0015473117,0.00023754752,0.042022143,0.002280484,0.00097330386,0.00035073128,0.0000061883943,0.5572306,0.0000044808476,0.009800912,0.38453695],"study_design_scores_gemma":[0.0006053744,0.00039213515,0.0000034882419,0.017743677,0.0008425858,0.0003242433,0.00003203943,3.4161724e-7,0.7233826,0.000022195962,0.2565189,0.00013244317],"about_ca_topic_score_codex":0.00001076897,"about_ca_topic_score_gemma":1.8173986e-7,"teacher_disagreement_score":0.3844045,"about_ca_system_score_codex":0.00030875448,"about_ca_system_score_gemma":0.0021894912,"threshold_uncertainty_score":0.6280147},"labels":[],"label_agreement":null},{"id":"W2146873467","doi":"10.1186/1471-2407-8-230","title":"Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer","year":2008,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver General Hospital","funders":"National Cancer Institute; National Human Genome Research Institute; National Institutes of Health","keywords":"TMPRSS2; Prostate cancer; Fusion gene; Erg; Oncology; Prostate; Population; Medicine; Internal medicine; Cancer research; Cancer; Biology; Genetics; Gene","score_opus":0.06964547080744926,"score_gpt":0.3871040679308264,"score_spread":0.31745859712337715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146873467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973258,0.00037847174,0.0000065116988,0.00036586815,0.00012956721,0.0009448223,0.00081645884,0.000015765827,0.000016779975],"genre_scores_gemma":[0.99672145,0.0011383077,0.0003028444,0.000050539824,0.00009693878,0.00011114037,0.00023459198,0.00001874785,0.0013254434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837524,0.0000897154,0.00057556294,0.00028812955,0.0005053556,0.00016598652],"domain_scores_gemma":[0.99858576,0.00027773436,0.00048134848,0.00022488562,0.00033815127,0.000092122005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023853328,0.00013100554,0.0005216799,0.000074790994,0.000061964325,0.0000047136887,0.000042527412,0.00008300245,0.000044371714],"category_scores_gemma":[0.00015968301,0.000087075496,0.00005228835,0.00017115286,0.000046885983,0.00004309064,0.000023744236,0.0001305594,6.681926e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005655814,0.0006448135,0.99024403,0.00006728535,0.0002633554,0.000013215574,0.00096134766,0.000047281705,0.0004013058,1.7043376e-7,0.00014063924,0.0015607417],"study_design_scores_gemma":[0.014275366,0.00081437576,0.9832552,0.00020225171,0.0002527223,3.6246178e-7,0.00012044781,0.0003465695,0.000571181,0.0000014925125,0.00007187765,0.000088164365],"about_ca_topic_score_codex":0.011472988,"about_ca_topic_score_gemma":0.004382244,"teacher_disagreement_score":0.0086195525,"about_ca_system_score_codex":0.0002518058,"about_ca_system_score_gemma":0.00054094347,"threshold_uncertainty_score":0.9951097},"labels":[],"label_agreement":null},{"id":"W2146948875","doi":"10.1158/1078-0432.ccr-08-2704","title":"The Importance of Protein Kinase A in Prostate Cancer: Relationship to Patient Outcome in Radiation Therapy Oncology Group Trial 92-02","year":2009,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Proportional hazards model; Radiation therapy; Oncology; Internal medicine; Immunohistochemistry; Multivariate analysis; Cohort; Metastasis; Prostate; Cancer; Pathology","score_opus":0.3069216573441769,"score_gpt":0.576214524932824,"score_spread":0.26929286758864707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146948875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9449628,0.008031137,7.43553e-7,0.038943682,0.00019679955,0.007371167,0.000021584432,0.000014479927,0.00045763265],"genre_scores_gemma":[0.98694026,0.008032767,0.000055562883,0.00046210233,0.00025631153,0.0034722774,0.000016603155,0.000020336878,0.00074376236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951599,0.0011992798,0.0014071864,0.0005341447,0.0009445801,0.00075487787],"domain_scores_gemma":[0.99716085,0.0015117482,0.00019956239,0.0004924158,0.00034601486,0.00028938573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005951072,0.00015890166,0.00057044486,0.0003704294,0.00014493272,0.00002822363,0.00025638108,0.00018868764,0.00008513489],"category_scores_gemma":[0.0022706585,0.000101558915,0.00013132568,0.0015047448,0.00032939823,0.000091956696,0.00007110725,0.0014049102,0.0000113943115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0943586,0.0009716723,0.6018308,0.00002880881,0.000020741047,0.000082334285,0.0005513341,0.000014507715,0.0002724712,0.0002213769,0.00058636616,0.30106103],"study_design_scores_gemma":[0.06308445,0.015838604,0.8989577,0.00029114645,0.00000854014,9.831141e-7,0.0003086666,0.00008071155,0.00077179103,0.001945365,0.01855569,0.00015633304],"about_ca_topic_score_codex":0.0013863633,"about_ca_topic_score_gemma":0.0036843983,"teacher_disagreement_score":0.3009047,"about_ca_system_score_codex":0.0012497694,"about_ca_system_score_gemma":0.0017529852,"threshold_uncertainty_score":0.6103714},"labels":[],"label_agreement":null},{"id":"W2147436556","doi":"10.1200/jco.2012.46.5492","title":"Treatment of Prostate Cancer With Intermittent Versus Continuous Androgen Deprivation: A Systematic Review of Randomized Trials","year":2013,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Randomized controlled trial; Cochrane Library; Oncology; Hazard ratio; Internal medicine; Cancer; Sexual function; Meta-analysis; Confidence interval","score_opus":0.3671423601141902,"score_gpt":0.5729585546394367,"score_spread":0.20581619452524647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147436556","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023586747,0.9859134,0.00000659377,0.00082188955,0.0007292463,0.012002469,0.000036492987,0.000004219823,0.0002498342],"genre_scores_gemma":[0.000051385952,0.9971489,0.00043218728,0.00006506617,0.00043129828,0.0010936934,0.000026966252,0.000035095145,0.0007154096],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.97996444,0.0060730223,0.012759952,0.00025570122,0.00070593506,0.00024094508],"domain_scores_gemma":[0.9566231,0.018217165,0.022405986,0.00043399128,0.0019745887,0.00034519492],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.011752444,0.0004081909,0.040416315,0.0002599637,0.000016817012,0.000007635687,0.00022670659,0.00044689284,0.00020628997],"category_scores_gemma":[0.01627757,0.00016019885,0.0050336393,0.0002571162,0.00045346725,0.00005800554,0.000039386192,0.0005180797,0.000007370453],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07111262,0.001038974,0.00003512344,0.48679757,0.016644023,0.0002495348,0.00003891275,5.6031826e-8,1.08182086e-7,0.0000072752177,0.00028669654,0.42378908],"study_design_scores_gemma":[0.21328624,0.021158079,0.000003110733,0.60511595,0.070816115,0.00033069527,0.000026897127,0.0000010753811,0.0000049153164,0.0000066886028,0.089141175,0.000109068016],"about_ca_topic_score_codex":0.00003202238,"about_ca_topic_score_gemma":0.000004136073,"teacher_disagreement_score":0.42368004,"about_ca_system_score_codex":0.0006171335,"about_ca_system_score_gemma":0.007149823,"threshold_uncertainty_score":0.9984787},"labels":[],"label_agreement":null},{"id":"W2147887481","doi":"","title":"Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer.","year":2015,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Enzalutamide; Abiraterone acetate; Prostate cancer; Medicine; Abiraterone; Pharmacy; Oncology; Docetaxel; Internal medicine; Cancer; Intensive care medicine; Androgen deprivation therapy; Family medicine; Androgen receptor","score_opus":0.17216793423209267,"score_gpt":0.39443692102316064,"score_spread":0.22226898679106796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147887481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9621484,0.025596313,0.000014027015,0.007368488,0.00010651954,0.004080621,0.0001618184,0.000026420063,0.00049737154],"genre_scores_gemma":[0.9878783,0.0028622544,0.00047959344,0.000041872096,0.000071915754,0.003494702,0.00003986099,0.000012764057,0.005118715],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99921113,0.000023956338,0.00016406077,0.00016537082,0.00018533679,0.00025012062],"domain_scores_gemma":[0.9993778,0.00005656592,0.00006644873,0.000089421585,0.0001338932,0.00027590833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013623462,0.00011264677,0.00023208112,0.00006009568,0.00003696031,0.000021956646,0.0000316927,0.000012321976,0.000008525041],"category_scores_gemma":[0.00003259509,0.000069989335,0.000040485218,0.00009925595,0.00009207763,0.00008915997,0.000007987379,0.000027823504,5.07448e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00572613,0.00028393537,0.0455793,0.00021825336,0.0010459775,0.00004620365,0.0043194555,0.000009771585,0.003153369,0.00020687826,0.0018069583,0.9376038],"study_design_scores_gemma":[0.14226143,0.00768233,0.32314518,0.0003391008,0.0033841152,0.00015517502,0.008862372,0.00076154113,0.36848098,0.005332405,0.13855106,0.0010443202],"about_ca_topic_score_codex":0.0021891145,"about_ca_topic_score_gemma":0.00025736127,"teacher_disagreement_score":0.93655944,"about_ca_system_score_codex":0.0002692857,"about_ca_system_score_gemma":0.0005587813,"threshold_uncertainty_score":0.33093008},"labels":[],"label_agreement":null},{"id":"W2148047944","doi":"10.1158/1535-7163.mct-14-0521","title":"Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Transactivation; Androgen receptor; CYP17A1; Enzalutamide; LNCaP; Prostate cancer; In vivo; Chemistry; Reporter gene; Luciferase; Androgen deprivation therapy; Cancer research; Internal medicine; Pharmacology; Biology; Cancer; Transfection; Medicine; Gene expression; Gene; Biochemistry","score_opus":0.07939099133391246,"score_gpt":0.38985684938807197,"score_spread":0.3104658580541595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148047944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911692,0.004325259,0.0015551525,0.0010328023,0.00011992887,0.0010426125,0.00016255828,0.000020783127,0.0005716621],"genre_scores_gemma":[0.99662775,0.0020731802,0.00053138455,0.00022975226,0.00006108553,0.00024513708,0.000007705064,0.0000544851,0.00016951717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978766,0.00012362054,0.00049423357,0.00045307423,0.00058083714,0.00047167615],"domain_scores_gemma":[0.99872416,0.00009178549,0.00024450218,0.00038496722,0.00042730907,0.00012729861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033132161,0.00026533214,0.00071205106,0.00017368994,0.000032923424,0.000010260065,0.0001404094,0.00017083794,0.00002527786],"category_scores_gemma":[0.000021393409,0.00021610089,0.00017132927,0.0005819955,0.0003217572,0.00009325331,0.00005676518,0.00038739134,5.241652e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061382023,0.0012667375,0.013182337,0.0005086454,0.0006427011,0.00001963991,0.0012168217,0.0028345683,0.95269144,0.0002643881,0.000013163462,0.021221347],"study_design_scores_gemma":[0.00888389,0.0013298885,0.01618453,0.0007895755,0.00035081038,0.0000035123958,0.00008071416,0.022339849,0.94894195,0.00045805363,0.0003540734,0.0002831616],"about_ca_topic_score_codex":0.0019454876,"about_ca_topic_score_gemma":0.0005454952,"teacher_disagreement_score":0.020938186,"about_ca_system_score_codex":0.00036021307,"about_ca_system_score_gemma":0.0011418626,"threshold_uncertainty_score":0.8812338},"labels":[],"label_agreement":null},{"id":"W2148643283","doi":"10.1056/nejmoa1207506","title":"Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4574,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Université de Montréal","funders":"Janssen Pharmaceuticals; Chugai Pharmaceutical; Genentech; Cilag; Astellas Pharma; Teva Pharmaceutical Industries; Eisai; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Amgen; Pfizer; Active Biotech; Celgene; Astellas Pharma Global Development; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Enzalutamide; Prostate cancer; Medicine; Androgen receptor; Oncology; Overall survival; Internal medicine; Chemotherapy; Cancer","score_opus":0.020389206161236496,"score_gpt":0.3202014771681385,"score_spread":0.299812271006902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148643283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97191244,0.014282029,0.000019928375,0.012488747,0.00027834845,0.000251592,0.0000026909488,0.0000070390247,0.0007571829],"genre_scores_gemma":[0.9908887,0.0037799978,0.00021463292,0.0006065289,0.0034563565,0.000010609909,0.000004564921,0.000024714185,0.0010138737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985241,0.00007985355,0.00034057847,0.00009725664,0.0005879715,0.00037021952],"domain_scores_gemma":[0.99897385,0.00010439262,0.0001428068,0.00011967185,0.00015828003,0.00050101476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009228829,0.00015527052,0.00048442627,0.00024408246,0.000018557206,0.0000053750027,0.0000624683,0.00004018232,0.0006339602],"category_scores_gemma":[0.00006758347,0.00007725282,0.000040203646,0.00026591384,0.000115115516,0.00014604596,0.000009030761,0.00037939637,0.0000029173473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020335954,0.0001805472,0.9052799,0.0000664166,0.00017471556,0.00063543004,0.003169748,0.0000031693244,0.0033100643,0.0000072039315,0.00095042255,0.06588645],"study_design_scores_gemma":[0.16962563,0.0022559164,0.78275466,0.0016058694,0.00020376004,0.00092906336,0.00042752986,0.0000075104,0.003364467,0.00006408307,0.038615607,0.00014591328],"about_ca_topic_score_codex":0.00069481216,"about_ca_topic_score_gemma":0.00018230402,"teacher_disagreement_score":0.14928967,"about_ca_system_score_codex":0.00016936175,"about_ca_system_score_gemma":0.0004108075,"threshold_uncertainty_score":0.6941419},"labels":[],"label_agreement":null},{"id":"W2148772838","doi":"10.1016/j.juro.2011.02.438","title":"353 TESTOSTERONE BREAKTHROUGH ON LUTEINIZING HORMONE-RELEASING HORMONE AGONISTS: THE SIZE OF THE PROBLEM AND PREDISPOSING FACTORS","year":2011,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Luteinizing hormone; Testosterone (patch); Hormone; Population; Incidence (geometry); Internal medicine; Hormone therapy; Endocrinology; Cancer; Breast cancer","score_opus":0.03804772305556575,"score_gpt":0.2732121725857291,"score_spread":0.23516444953016336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148772838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838199,0.007560614,0.000025345267,0.006936483,0.000098197146,0.00033751587,0.000003966579,0.000006427956,0.0012115678],"genre_scores_gemma":[0.99718,0.0021061974,0.00013814564,0.00032146258,0.00011501135,0.000001944258,4.0955402e-7,0.00001856911,0.00011827003],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987005,0.00026884177,0.00036830897,0.000096680604,0.00029826097,0.00026743102],"domain_scores_gemma":[0.99856925,0.0005766373,0.00039238742,0.0002652947,0.00012684353,0.00006957847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005500534,0.00014110553,0.00030178498,0.000049834984,0.00023577335,0.000011215504,0.00025590454,0.000078258745,0.000012080886],"category_scores_gemma":[0.00013506034,0.000052694344,0.00009065785,0.00014584925,0.00057648116,0.00007944114,0.00010464257,0.0005742768,0.0000010465907],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032015856,0.00146335,0.06441131,0.00019029452,0.0025679288,0.0002127131,0.07757853,0.0000665882,0.7890671,0.000897101,0.0029627618,0.028566469],"study_design_scores_gemma":[0.006174406,0.011854092,0.94105077,0.00023370991,0.0012053379,0.0022750706,0.0026780257,0.000056957382,0.030590758,0.0024131131,0.0012940482,0.0001736875],"about_ca_topic_score_codex":0.00009355169,"about_ca_topic_score_gemma":0.0000056056015,"teacher_disagreement_score":0.8766395,"about_ca_system_score_codex":0.000056258104,"about_ca_system_score_gemma":0.00011565093,"threshold_uncertainty_score":0.24949788},"labels":[],"label_agreement":null},{"id":"W2148849030","doi":"10.1016/j.ijrobp.2012.07.1100","title":"Does Phoenix Failure Definition Apply to EBRT + HDR Brachytherapy Boost in Prostate Cancer?","year":2012,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Brachytherapy; Prostate cancer; Hormonal therapy; Population; Urology; Cancer; Surgery; Internal medicine; Radiation therapy","score_opus":0.027848937648523506,"score_gpt":0.363310374827788,"score_spread":0.33546143717926447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148849030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97439516,0.001319003,0.0007078889,0.019791476,0.002512961,0.000585534,0.00012584358,0.000029807044,0.0005323199],"genre_scores_gemma":[0.9899178,0.0026900314,0.0019452506,0.0019809748,0.003035153,0.000095048345,0.00014327595,0.000030800078,0.00016164979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983235,0.00015919388,0.00058665656,0.00019857596,0.00033702835,0.0003950598],"domain_scores_gemma":[0.9984053,0.00018555541,0.00046665053,0.000118075244,0.00058099645,0.00024342672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005430543,0.00019401003,0.00042500193,0.00029985025,0.000058829253,0.0000263189,0.0002167723,0.00016031165,0.00014310893],"category_scores_gemma":[0.00011343679,0.00012691892,0.00014888127,0.00026482056,0.0001094057,0.00041050705,0.000045077504,0.0004919352,0.000052502775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018204275,0.0006827812,0.81070834,0.000015202449,0.00040300723,0.000052243806,0.0021171537,0.000103056256,0.014327575,0.0021315794,0.0018787397,0.16575986],"study_design_scores_gemma":[0.03463476,0.0045452313,0.45303607,0.000560113,0.00027698878,0.0005029317,0.0010960286,0.00034074756,0.05230173,0.017961476,0.4339598,0.0007841262],"about_ca_topic_score_codex":0.000069516405,"about_ca_topic_score_gemma":0.00004604609,"teacher_disagreement_score":0.43208107,"about_ca_system_score_codex":0.0014468136,"about_ca_system_score_gemma":0.0006210122,"threshold_uncertainty_score":0.51756036},"labels":[],"label_agreement":null},{"id":"W2149307190","doi":"10.1016/j.cancergencyto.2006.04.003","title":"Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias","year":2006,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"U.S. Army Medical Command; Medical Research and Materiel Command; U.S. Army Materiel Command; National Cancer Institute; University Health Network","keywords":"PTEN; Biology; Cancer research; Fluorescence in situ hybridization; Prostate; Prostate cancer; Cowden syndrome; Cancer; Pathology; Chromosome; PI3K/AKT/mTOR pathway; Gene; Genetics; Medicine; Apoptosis","score_opus":0.0211090869891369,"score_gpt":0.29189155706774383,"score_spread":0.27078247007860695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149307190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778875,0.019788118,0.000050004015,0.0003787945,0.00006225496,0.00070330204,0.0010759938,0.0000053023264,0.00004871311],"genre_scores_gemma":[0.96830696,0.030378975,0.00068988965,0.000051358256,0.000031153377,0.00014992531,0.00013561094,0.000020918917,0.00023521735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847806,0.000050232833,0.0006545997,0.0003267956,0.00020677247,0.00028354215],"domain_scores_gemma":[0.9992484,0.000057848123,0.00021955011,0.00021874713,0.00016714609,0.000088294975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011962571,0.00019218282,0.0007106968,0.0006275182,0.000032396903,0.000008507459,0.000078859,0.000109429435,0.000032752658],"category_scores_gemma":[0.000010946405,0.00017006781,0.00008206226,0.000825752,0.0004088004,0.000020384525,0.000068669535,0.00014989746,1.0730891e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005066038,0.00045009376,0.86747247,0.000554842,0.000443371,0.000019742076,0.0011448037,0.0084808925,0.11107026,0.000026308802,0.00007781494,0.00975279],"study_design_scores_gemma":[0.0038646644,0.000581552,0.91186625,0.00019948976,0.0011485979,0.000007079587,0.00021599307,0.002906786,0.07844765,0.00020969434,0.0003649732,0.00018728102],"about_ca_topic_score_codex":0.0037227315,"about_ca_topic_score_gemma":0.01788672,"teacher_disagreement_score":0.044393763,"about_ca_system_score_codex":0.0002504104,"about_ca_system_score_gemma":0.00041925503,"threshold_uncertainty_score":0.99812096},"labels":[],"label_agreement":null},{"id":"W2150701033","doi":"10.1073/pnas.1101263108","title":"HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer","year":2011,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Cancer Research UK","keywords":"PTEN; Prostate cancer; Cancer research; Senescence; Loss function; MAPK/ERK pathway; Cancer; Prostate; Biology; Medicine; PI3K/AKT/mTOR pathway; Internal medicine; Signal transduction; Phenotype; Cell biology; Genetics; Gene","score_opus":0.11403011780090261,"score_gpt":0.38422300960078026,"score_spread":0.27019289179987765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150701033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98775524,0.00032554087,8.4125155e-8,0.007065788,0.000027420161,0.0005079914,0.000022396413,0.000013323539,0.004282202],"genre_scores_gemma":[0.9977088,0.00028290038,0.00046033057,0.0004622698,0.000066002925,0.000059585695,1.3028324e-7,0.0000059662702,0.00095401594],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980389,0.0000049075866,0.00023327406,0.0002723963,0.0012123793,0.00023815637],"domain_scores_gemma":[0.9990016,0.00003866264,0.0003049351,0.000011737068,0.00053906796,0.00010395376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005054913,0.00010486178,0.00019058117,0.00018916234,0.00015280416,0.000012917614,0.00042720104,0.000061599196,0.000046750833],"category_scores_gemma":[0.0003216406,0.00006117969,0.00006549575,0.00087135873,0.0005758282,0.00029895917,0.00015067714,0.00015821894,0.0000038727194],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052037026,0.00022581992,0.43431512,0.00033206682,0.00014355103,6.392363e-7,0.004335256,0.0000050885583,0.54926145,0.005315817,0.001320431,0.004224413],"study_design_scores_gemma":[0.0004082821,0.00014609718,0.37873065,0.00048433073,0.000027257196,0.0000132598525,0.000258085,0.000038564445,0.6164951,0.003243932,0.00008304756,0.00007144145],"about_ca_topic_score_codex":0.0000910513,"about_ca_topic_score_gemma":4.59202e-7,"teacher_disagreement_score":0.06723363,"about_ca_system_score_codex":0.000094988776,"about_ca_system_score_gemma":0.00016183313,"threshold_uncertainty_score":0.24948356},"labels":[],"label_agreement":null},{"id":"W2150775704","doi":"10.1158/0008-5472.can-06-0028","title":"Short Hairpin RNA Knockdown of the Androgen Receptor Attenuates Ligand-Independent Activation and Delays Tumor Progression","year":2006,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Small hairpin RNA; Androgen receptor; LNCaP; Prostate cancer; Cancer research; Bicalutamide; Gene knockdown; Endocrinology; Internal medicine; Transactivation; MAPK/ERK pathway; Androgen; Tumor progression; Biology; Medicine; Chemistry; Signal transduction; Cancer; Transcription factor; Apoptosis; Cell biology; Hormone","score_opus":0.05021880836211736,"score_gpt":0.39125638510971195,"score_spread":0.3410375767475946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150775704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892804,0.0036543107,0.00000663925,0.004224025,0.000073754614,0.0012762023,0.000022447679,0.000022529164,0.0014396984],"genre_scores_gemma":[0.99595505,0.000777865,0.000041454994,0.000024694513,0.00024038852,0.0003345576,0.000029694898,0.00002649096,0.0025698324],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977898,0.00013076572,0.00023517356,0.00033940354,0.0010489366,0.0004558922],"domain_scores_gemma":[0.99895453,0.00008609792,0.000051336112,0.00031687575,0.000462448,0.00012868058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065345294,0.00013158662,0.00023335536,0.00016773665,0.00027175082,0.000040049472,0.0001629609,0.00008361351,0.00008308714],"category_scores_gemma":[0.00007288177,0.00007654366,0.00006521496,0.00051827927,0.00037104983,0.00010170621,0.00018640226,0.00043606324,0.0000081106255],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010841818,0.00016590385,0.22374284,0.00026598942,0.000076930395,0.000015497291,0.00019268916,0.0000065549348,0.73759717,0.00007588984,0.009506407,0.027269935],"study_design_scores_gemma":[0.0013018035,0.00026241154,0.06480746,0.0006043385,0.000021409647,0.000009907313,0.00013944434,0.00006480153,0.9281827,0.00014072293,0.0043823086,0.00008268834],"about_ca_topic_score_codex":0.00056147453,"about_ca_topic_score_gemma":0.000076747536,"teacher_disagreement_score":0.19058552,"about_ca_system_score_codex":0.0003559027,"about_ca_system_score_gemma":0.00045119217,"threshold_uncertainty_score":0.312136},"labels":[],"label_agreement":null},{"id":"W2150793436","doi":"10.1002/pros.22783","title":"ERG–SOX4 interaction promotes epithelial–mesenchymal transition in prostate cancer cells","year":2014,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"National Natural Science Foundation of China","keywords":"Chromatin immunoprecipitation; Erg; Cancer research; Epithelial–mesenchymal transition; Biology; Chromatin; Promoter; Gene expression; Downregulation and upregulation; Gene; Genetics","score_opus":0.017854316564983645,"score_gpt":0.3111104948163281,"score_spread":0.2932561782513444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150793436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815905,0.00046295286,0.000049432678,0.014146874,0.00031211087,0.001902819,0.0000560447,0.00008656856,0.0013926857],"genre_scores_gemma":[0.9937294,0.0011500177,0.00009189856,0.00039587452,0.00020087957,0.0004342671,0.00006191815,0.000040503186,0.0038952276],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99834824,0.00017763862,0.00030461227,0.0003425031,0.00032726608,0.00049972883],"domain_scores_gemma":[0.9993026,0.000081996004,0.00008788547,0.00029122693,0.000118496886,0.000117761156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057991844,0.00021245556,0.00027619372,0.00015082816,0.00013662645,0.00005221821,0.00010570145,0.000055666416,0.0001467595],"category_scores_gemma":[0.000028666936,0.00012805639,0.00008428052,0.00033307585,0.00015246162,0.00020217095,0.000035971476,0.00041196652,0.00011372455],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009706993,0.001061476,0.013114052,0.0010258508,0.00029454933,0.00018903337,0.039200075,0.0010098412,0.72638834,0.00019744487,0.0018482537,0.2059641],"study_design_scores_gemma":[0.011639341,0.0020625633,0.025990255,0.0012651073,0.00022817233,0.000089325564,0.0015064677,0.015995983,0.9161709,0.0030584366,0.021387007,0.0006064183],"about_ca_topic_score_codex":0.00069551845,"about_ca_topic_score_gemma":0.00020234837,"teacher_disagreement_score":0.20535769,"about_ca_system_score_codex":0.00021581548,"about_ca_system_score_gemma":0.00015062856,"threshold_uncertainty_score":0.5221988},"labels":[],"label_agreement":null},{"id":"W2150912285","doi":"10.1093/annonc/mdp311","title":"A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"Abbott Laboratories","keywords":"Docetaxel; Medicine; Prostate cancer; Adverse effect; Pharmacokinetics; Internal medicine; Urology; Toxicity; Population; Chemotherapy; Taxane; Cancer; Phases of clinical research; Oncology; Pharmacology; Gastroenterology; Breast cancer","score_opus":0.05257857176817571,"score_gpt":0.4300862478470566,"score_spread":0.3775076760788809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150912285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99628174,0.00023023592,6.686789e-7,0.0013267057,0.000013673855,0.0017042723,0.000018664912,0.0000051859042,0.00041883715],"genre_scores_gemma":[0.99944407,0.0001468419,0.000076771445,0.000090747046,0.000005012983,0.00010776221,0.000038970975,0.000007366746,0.00008243716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989423,0.000067535686,0.00031782972,0.0001877857,0.00027133952,0.00021319347],"domain_scores_gemma":[0.9992009,0.000033085184,0.00018175664,0.0001298511,0.0004008339,0.00005357828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015942457,0.00010399791,0.00039033132,0.0002380723,0.000016844733,0.0000025405907,0.00004692399,0.000043108517,0.000013897788],"category_scores_gemma":[0.000018917242,0.00006932179,0.000015205451,0.00040629331,0.00007115463,0.00010719606,0.0000075192656,0.00012058411,3.3143223e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07560972,0.05538479,0.7017864,0.00012860112,0.00015708357,0.00025064827,0.0071464265,0.00025077627,0.0030249204,0.00006576021,0.00008751638,0.15610734],"study_design_scores_gemma":[0.072264805,0.11623771,0.8072278,0.00019607248,0.000028182418,8.8815955e-7,0.00085117953,0.000020722768,0.0029566009,0.0000553776,0.00008977222,0.00007088522],"about_ca_topic_score_codex":0.00040708866,"about_ca_topic_score_gemma":0.0022370175,"teacher_disagreement_score":0.15603645,"about_ca_system_score_codex":0.00010593342,"about_ca_system_score_gemma":0.00039699394,"threshold_uncertainty_score":0.28268602},"labels":[],"label_agreement":null},{"id":"W2151063703","doi":"10.1200/jco.2010.32.8815","title":"Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":250,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Prednisone; Internal medicine; Adverse effect; Hazard ratio; Clinical endpoint; Urology; Interim analysis; Calcitriol; Oncology; Randomized controlled trial; Surgery; Chemotherapy; Cancer; Confidence interval; Vitamin D and neurology","score_opus":0.27565016283390886,"score_gpt":0.5186674086071955,"score_spread":0.24301724577328665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151063703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98763967,0.00077711034,0.00013154362,0.0012314391,0.0021433914,0.006944992,0.00018052112,0.000008773458,0.00094254693],"genre_scores_gemma":[0.98943526,0.0017805076,0.0058511184,0.0001697475,0.00080512476,0.000442904,0.00005219921,0.0000406991,0.001422425],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99449676,0.00057512894,0.0033663595,0.00036196798,0.0007307876,0.00046899557],"domain_scores_gemma":[0.99107164,0.0027971286,0.003344361,0.00029610444,0.0019245961,0.0005661864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038296203,0.00028469609,0.0036196534,0.00018031998,0.00010495312,0.000025489875,0.0003756361,0.00034231774,0.00018456992],"category_scores_gemma":[0.0025883834,0.00016196708,0.00044127717,0.00021570249,0.00070044136,0.00031274158,0.00009876664,0.00069425965,0.000002810875],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9605397,0.012742624,0.00029312895,0.00010463167,0.0026572451,0.00020995548,0.0005021489,0.000008624326,0.000066983,0.0001627152,0.0011813989,0.021530846],"study_design_scores_gemma":[0.8853643,0.10889498,0.0007845353,0.0002159731,0.0021044558,0.000009145885,0.00011325895,0.00015173272,0.0002355053,0.00020106556,0.0017732787,0.00015180136],"about_ca_topic_score_codex":0.0006016528,"about_ca_topic_score_gemma":0.0002204091,"teacher_disagreement_score":0.09615236,"about_ca_system_score_codex":0.00054577546,"about_ca_system_score_gemma":0.008719676,"threshold_uncertainty_score":0.99689996},"labels":[],"label_agreement":null},{"id":"W2151494200","doi":"10.1093/annonc/mdv356","title":"High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK; Royal Marsden NHS Foundation Trust","keywords":"Medicine; Germline; Prostate cancer; Germline mutation; BRCA2 Protein; Oncology; Mutation; Cancer; Cancer research; Prostate; Internal medicine; Genetics; Biology; Gene","score_opus":0.10567736926503578,"score_gpt":0.4453790284623112,"score_spread":0.3397016591972754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151494200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855023,0.001160658,0.00001832832,0.012070079,0.00007539772,0.00039935365,0.00014220427,0.0000069586067,0.00062471256],"genre_scores_gemma":[0.9970272,0.0014246865,0.00048244823,0.00014797442,0.00009773417,0.000080687954,0.00030450337,0.000008206884,0.0004265134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99922186,0.00006830376,0.0002766226,0.00015375765,0.00014418788,0.00013529054],"domain_scores_gemma":[0.99915653,0.0000776021,0.00013145166,0.00011295122,0.00041926847,0.0001021636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020618405,0.00006911787,0.00027292714,0.000088041525,0.000016495498,0.0000038690496,0.000033384884,0.00006868897,0.00007869485],"category_scores_gemma":[0.00006683797,0.000057899262,0.000021754675,0.00015095978,0.00014212003,0.00007603726,0.000016940254,0.000083169754,0.000004407911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009634302,0.0013329118,0.61626935,0.00039146622,0.00083867105,0.00024628,0.045610625,0.0016790999,0.055535115,0.0016532767,0.030280279,0.23652864],"study_design_scores_gemma":[0.044924583,0.00977599,0.5098395,0.00077427685,0.00047970682,0.0000739074,0.009273407,0.003677218,0.33778062,0.021784155,0.06097198,0.00064465514],"about_ca_topic_score_codex":0.008945334,"about_ca_topic_score_gemma":0.0003850169,"teacher_disagreement_score":0.28224552,"about_ca_system_score_codex":0.000081127706,"about_ca_system_score_gemma":0.0004983306,"threshold_uncertainty_score":0.9976542},"labels":[],"label_agreement":null},{"id":"W2151547940","doi":"10.1002/pros.20499","title":"The effects of the dual 5α-reductase inhibitor dutasteride on localized prostate cancer—results from a 4-month pre-radical prostatectomy study","year":2006,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Princess Margaret Cancer Centre; London Health Sciences Centre; Surrey Memorial Hospital; Vancouver General Hospital","funders":"","keywords":"Dutasteride; Urology; Medicine; Prostate cancer; Dihydrotestosterone; Prostatectomy; Prostate; Testosterone (patch); Antiandrogen; Androgen; 5 Alpha-Reductase Inhibitor; Finasteride; Internal medicine; Cancer; Hormone","score_opus":0.009357589768781911,"score_gpt":0.2881557248147882,"score_spread":0.27879813504600626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151547940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764145,0.0025522583,0.0000018735454,0.0076151895,0.0007141204,0.011420954,0.0008980357,0.00010311663,0.00027993272],"genre_scores_gemma":[0.9907186,0.00046656159,0.000020888849,0.00019523011,0.00040930617,0.0016862078,0.0001270413,0.00008504625,0.0062911403],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9954348,0.0007003884,0.0008996882,0.0007238716,0.0013109386,0.0009303017],"domain_scores_gemma":[0.9967479,0.0010580419,0.00044063656,0.0013180862,0.00023789023,0.00019741364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087585364,0.0005122977,0.0006170113,0.00008446987,0.0007628811,0.00014374596,0.00046273973,0.00009333755,0.00001351026],"category_scores_gemma":[0.0004064238,0.00021076234,0.00023274483,0.0006335911,0.0011201798,0.00010651545,0.00033768546,0.000745652,0.000023546674],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36825204,0.017913315,0.123109706,0.0022066643,0.0055366773,0.0028189835,0.06535862,0.0011800807,0.27817047,0.0006180844,0.04629922,0.08853615],"study_design_scores_gemma":[0.086176194,0.011681756,0.27855822,0.0028047448,0.0015222497,0.000062791936,0.0032006584,0.0007783252,0.5944258,0.0039345957,0.015872857,0.0009818458],"about_ca_topic_score_codex":0.0050321245,"about_ca_topic_score_gemma":0.0008195559,"teacher_disagreement_score":0.3162553,"about_ca_system_score_codex":0.0003016446,"about_ca_system_score_gemma":0.0006383179,"threshold_uncertainty_score":0.85946393},"labels":[],"label_agreement":null},{"id":"W2151698969","doi":"10.1158/1078-0432.ccr-04-2140","title":"Timing Is Everything: Preclinical Evidence Supporting Simultaneous Rather Than Sequential Chemohormonal Therapy for Prostate Cancer","year":2005,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Paclitaxel; LNCaP; Prostate cancer; Medicine; Internal medicine; Oncology; Chemotherapy; Androgen; Cancer; Castration; Endocrinology; Cancer research; Hormone","score_opus":0.46391349536295806,"score_gpt":0.6067462781873147,"score_spread":0.14283278282435669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151698969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9187248,0.023908483,0.000064418084,0.051497806,0.000483199,0.004605832,0.00015633156,0.00013076556,0.0004284024],"genre_scores_gemma":[0.92871666,0.036140177,0.0009367894,0.0021268614,0.0045143226,0.0019682741,0.000042287153,0.0001302622,0.025424376],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99306387,0.00048909633,0.0014307221,0.0013919111,0.001841261,0.0017831504],"domain_scores_gemma":[0.9910451,0.0054212087,0.00027036085,0.0007224277,0.001714568,0.00082632987],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007394899,0.00037953348,0.0008784138,0.00020571201,0.00053835113,0.00017306293,0.00054656266,0.0004378914,0.0024337214],"category_scores_gemma":[0.00355172,0.0002812431,0.0005978939,0.0005868196,0.00094748905,0.00034096482,0.00029116683,0.0019611283,0.000124088],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033937104,0.0014388013,0.15489826,0.00052043353,0.00092269335,0.00019364349,0.0023551947,0.0001445621,0.011059952,0.000021232478,0.03709826,0.7574099],"study_design_scores_gemma":[0.04850262,0.015549746,0.03579328,0.005658181,0.00062464987,0.0000878979,0.0010456035,0.056494527,0.15032226,0.0012586318,0.68242925,0.002233332],"about_ca_topic_score_codex":0.0006242441,"about_ca_topic_score_gemma":0.0001832198,"teacher_disagreement_score":0.75517654,"about_ca_system_score_codex":0.0008355611,"about_ca_system_score_gemma":0.0038624164,"threshold_uncertainty_score":0.999964},"labels":[],"label_agreement":null},{"id":"W2151702398","doi":"10.1002/pros.20532","title":"Rapid, non‐destructive, cell‐based screening assays for agents that modulate growth, death, and androgen receptor activation in prostate cancer cells","year":2007,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; London Health Sciences Centre; Western University; Vancouver General Hospital; University of British Columbia","funders":"University of British Columbia; Javna Agencija za Raziskovalno Dejavnost RS; University of Toronto","keywords":"LNCaP; Prostate cancer; Androgen receptor; Cell growth; Cancer research; Prostate; Cell; Cancer cell; Receptor; Cancer; Chemistry; Endocrinology; Medicine; Biology; Internal medicine; Biochemistry","score_opus":0.04706629479563396,"score_gpt":0.3175568465837521,"score_spread":0.27049055178811815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151702398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920807,0.000520779,0.0008965155,0.0018959161,0.0001193629,0.003878357,0.00011702736,0.00004834554,0.00044298032],"genre_scores_gemma":[0.9950183,0.0010960017,0.001325084,0.00027548277,0.00008136872,0.00029794298,0.00013984278,0.00006651752,0.0016994418],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811494,0.00006693913,0.00029802654,0.00045599812,0.0003628133,0.0007012625],"domain_scores_gemma":[0.9990357,0.00018607483,0.0001600388,0.00024469194,0.00018786879,0.00018560035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009029191,0.0002769484,0.0003202753,0.00022582265,0.00024703366,0.00005778465,0.00011397057,0.00008934861,0.000034188353],"category_scores_gemma":[0.000025958683,0.00018777077,0.00007926745,0.00033580442,0.00014096902,0.00022593485,0.000050213377,0.00028451515,0.0000050601575],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020442432,0.0005054553,0.37068027,0.0013578471,0.000374605,0.00006971217,0.00866351,0.00043712868,0.5139064,0.000042133237,0.0013957826,0.08212473],"study_design_scores_gemma":[0.009440112,0.00046351206,0.05860211,0.00032480268,0.00008635459,0.0000033389701,0.0005284235,0.0023751108,0.92642874,0.0004299611,0.0010522145,0.00026534247],"about_ca_topic_score_codex":0.0005112574,"about_ca_topic_score_gemma":0.00003120229,"teacher_disagreement_score":0.41252232,"about_ca_system_score_codex":0.00024006187,"about_ca_system_score_gemma":0.0001617127,"threshold_uncertainty_score":0.76570696},"labels":[],"label_agreement":null},{"id":"W2151732765","doi":"10.1016/j.celrep.2015.07.012","title":"The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"Cell Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":301,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada; Movember Foundation; Prostate Cancer Foundation","keywords":"Cancer research; Prostate cancer; Androgen receptor; Biology; Context (archaeology); E2F; Cancer; Downregulation and upregulation; Prostate; Gene; Cell cycle; Genetics","score_opus":0.028934228828421543,"score_gpt":0.3394615824990267,"score_spread":0.31052735367060513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151732765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98441136,0.0088616125,0.0000010441871,0.0014927099,0.00037627577,0.0011216848,0.0000050769604,0.000038153397,0.003692057],"genre_scores_gemma":[0.9824125,0.001081928,0.00010151297,0.000020108291,0.0000998328,0.00013656045,0.00003620103,0.000023080667,0.01608824],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99865496,0.00003119546,0.0002920679,0.00023629164,0.00048405115,0.0003014238],"domain_scores_gemma":[0.99902064,0.000022729258,0.00018873072,0.00033277538,0.00022071782,0.00021438605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019653709,0.00011752438,0.00018079818,0.000037101112,0.000082403276,0.000017709885,0.00004956415,0.000019645786,0.000023989873],"category_scores_gemma":[0.000073164745,0.00006161696,0.000057164605,0.00013874976,0.0001438563,0.000046557383,0.00007750213,0.00013442336,0.000004313023],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029018223,0.0011216993,0.7115942,0.00053110515,0.00014492491,0.01619978,0.0012359793,0.000016418398,0.17989378,0.00000768852,0.020143943,0.06620867],"study_design_scores_gemma":[0.0017884334,0.00090347644,0.006984057,0.00013107457,0.000065629836,0.0010877388,0.00020114287,0.00008341825,0.95551735,0.00010288843,0.03303645,0.00009834198],"about_ca_topic_score_codex":0.000064474305,"about_ca_topic_score_gemma":0.00000748921,"teacher_disagreement_score":0.77562356,"about_ca_system_score_codex":0.00009582272,"about_ca_system_score_gemma":0.00052767433,"threshold_uncertainty_score":0.25126666},"labels":[],"label_agreement":null},{"id":"W2152067759","doi":"10.15252/emmm.201303701","title":"Targeting the adaptive molecular landscape of castration‐resistant prostate cancer","year":2015,"lang":"en","type":"review","venue":"EMBO Molecular Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Castration; Cancer research; Biology; Medicine; Oncology; Internal medicine; Cancer; Hormone","score_opus":0.054114341201458686,"score_gpt":0.38003073290783457,"score_spread":0.3259163917063759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152067759","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014661248,0.9919637,0.00008940038,0.0010970985,0.00023049266,0.002876039,0.00011369246,0.000039242623,0.0034437662],"genre_scores_gemma":[0.0008409587,0.9958577,0.0002016997,0.00016418973,0.00032519922,0.00052349083,0.00066199945,0.00011801245,0.0013067195],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963203,0.00035294273,0.0010031775,0.00049789966,0.001285715,0.0005399597],"domain_scores_gemma":[0.9976042,0.000104958184,0.00059927796,0.0006988944,0.00067071494,0.0003219374],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009445061,0.0005849595,0.0022384485,0.00029225124,0.00008776825,0.000014453291,0.00031849797,0.00024744569,0.00023844765],"category_scores_gemma":[0.00019903327,0.00029674606,0.0003696722,0.0008660522,0.00044724517,0.00003801264,0.00011940031,0.0007322543,0.000018352892],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013188265,0.00041944504,0.000043690296,0.039813004,0.006333058,0.0056590107,0.003253218,0.00008022376,0.007610243,0.00095291995,0.027649375,0.90686697],"study_design_scores_gemma":[0.0031570168,0.0014862355,0.0000073480664,0.026482096,0.005247239,0.00012919781,0.000828332,0.00005772791,0.00045629017,0.000108182765,0.96162087,0.00041945273],"about_ca_topic_score_codex":0.00020312676,"about_ca_topic_score_gemma":0.000005677835,"teacher_disagreement_score":0.9339715,"about_ca_system_score_codex":0.00028332425,"about_ca_system_score_gemma":0.002015542,"threshold_uncertainty_score":0.99994844},"labels":[],"label_agreement":null},{"id":"W2152111808","doi":"10.1053/hupa.2002.124033","title":"Prostate carcinoma expression of estrogen receptor-β as detected by PPG5/10 antibody has positive association with primary Gleason grade and Gleason score","year":2002,"lang":"en","type":"article","venue":"Human Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital","funders":"","keywords":"Prostate; Prostate cancer; Medicine; Estrogen receptor; LNCaP; PCA3; Carcinoma; Immunohistochemistry; Adenocarcinoma; Estrogen; Pathology; Oncology; Internal medicine; Urology; Cancer research; Cancer; Breast cancer","score_opus":0.024644412928918988,"score_gpt":0.2830361450499062,"score_spread":0.2583917321209872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152111808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931917,0.0044094427,0.0000081027565,0.00053573464,0.000030519735,0.00083792966,0.00008378907,0.000049665894,0.00085309724],"genre_scores_gemma":[0.99525315,0.0003814504,0.00030533693,0.000057404242,0.00005962237,0.00005456093,0.0007244657,0.000034740715,0.003129281],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99847615,0.00017855629,0.00021970666,0.00040144767,0.00034824474,0.00037588493],"domain_scores_gemma":[0.99917936,0.0000587312,0.00021272223,0.00021173901,0.00020055297,0.00013692077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001395666,0.00019558512,0.00039806074,0.00011912826,0.00018477984,0.000021415493,0.00006396833,0.00019422217,0.00025084856],"category_scores_gemma":[0.000050010243,0.00015202047,0.000046778212,0.00015188253,0.00024851,0.00009770605,0.000053468608,0.00025450208,0.000021938395],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005956868,0.0002866028,0.32812455,0.0000998259,0.000047612597,0.00014002476,0.0010792343,1.08490354e-7,0.66672945,0.000010460227,0.0020888709,0.0007975378],"study_design_scores_gemma":[0.006048187,0.0053257262,0.420631,0.00035922465,0.00015982233,0.00013252124,0.00014642942,0.000013624991,0.56646276,0.000051720803,0.00046125462,0.00020774532],"about_ca_topic_score_codex":0.000059786755,"about_ca_topic_score_gemma":0.0000036154968,"teacher_disagreement_score":0.10026672,"about_ca_system_score_codex":0.00024552134,"about_ca_system_score_gemma":0.000059748898,"threshold_uncertainty_score":0.61992145},"labels":[],"label_agreement":null},{"id":"W2152580800","doi":"10.1016/s0303-7207(01)00560-3","title":"Androgens induce expression of SPAK, a STE20/SPS1-related kinase, in LNCaP human prostate cancer cells","year":2001,"lang":"en","type":"article","venue":"Molecular and Cellular Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"LNCaP; Androgen receptor; Androgen; Prostate cancer; Endocrinology; Cancer research; Internal medicine; Kinase; Biology; Prostate; Cancer; Cell biology; Medicine; Hormone","score_opus":0.016972308034331873,"score_gpt":0.2950947806582112,"score_spread":0.27812247262387935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152580800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849093,0.012452218,0.000014406163,0.00037465882,0.00006945974,0.000615249,0.000011463505,0.000027272165,0.0015259666],"genre_scores_gemma":[0.99622935,0.0021996123,0.000047416954,0.000065323926,0.000016520153,0.00008470262,0.000060299797,0.000030209298,0.0012665779],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99839866,0.00011090911,0.00033250081,0.00040548187,0.00020396858,0.00054848904],"domain_scores_gemma":[0.99940306,0.000015519192,0.0000827935,0.00028492874,0.00007166514,0.00014203001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000765053,0.00020346347,0.00041563043,0.00027429228,0.00006113859,0.000008552678,0.000085750085,0.00013451504,0.0002097063],"category_scores_gemma":[0.000008318644,0.00016927441,0.00008155126,0.00029359592,0.00020492513,0.000040543327,0.00010568038,0.000309697,0.000008708397],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002847884,0.00025741922,0.0369485,0.000114715396,0.000070564245,0.0038780405,0.00038064743,0.000015553887,0.9554792,0.0001771087,0.000043696426,0.0023497643],"study_design_scores_gemma":[0.0046818973,0.00045437564,0.004316214,0.00015498092,0.00006842645,0.00010225845,0.00019521292,0.000029385263,0.98817486,0.0002297419,0.0014394114,0.00015322604],"about_ca_topic_score_codex":0.0003416394,"about_ca_topic_score_gemma":0.000033611785,"teacher_disagreement_score":0.032695666,"about_ca_system_score_codex":0.00006715666,"about_ca_system_score_gemma":0.00008511055,"threshold_uncertainty_score":0.69028103},"labels":[],"label_agreement":null},{"id":"W2152716163","doi":"10.1016/j.celrep.2014.06.053","title":"Intratumor DNA Methylation Heterogeneity Reflects Clonal Evolution in Aggressive Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Cell Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":271,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"Helmholtz Association; Federalno Ministarstvo Obrazovanja i Nauke; Deutsches Krebsforschungszentrum","keywords":"Prostate cancer; DNA methylation; Biology; Computational biology; DNA; Cancer research; Somatic evolution in cancer; Methylation; Genetics; Cancer; Tumor heterogeneity; Gene; Gene expression","score_opus":0.019676289466916606,"score_gpt":0.32919422696832634,"score_spread":0.3095179375014097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152716163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920246,0.002527124,0.000059234895,0.0004667853,0.00030632387,0.0006342871,0.000003088026,0.000040307412,0.003938253],"genre_scores_gemma":[0.99708736,0.00022364553,0.000099613375,0.00008051884,0.00017053442,0.00015002882,0.00008281147,0.000019959165,0.0020855062],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99854976,0.00007990953,0.00032489828,0.00037879695,0.00034043,0.00032617763],"domain_scores_gemma":[0.999136,0.000029313533,0.00027334658,0.00026473275,0.0001505228,0.00014610466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039015678,0.00013843973,0.00023400402,0.00014168295,0.000063281674,0.000017427998,0.000029682473,0.00008478006,0.000051056966],"category_scores_gemma":[0.00012634236,0.00010851953,0.000060059556,0.00025252826,0.00006264948,0.00009288277,0.000029947332,0.00020290427,0.000009830059],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014604534,0.00068973406,0.43135262,0.0005607889,0.00011064576,0.004669985,0.0011058411,0.0005569712,0.5235835,0.000057287914,0.0026919437,0.033160273],"study_design_scores_gemma":[0.0024690856,0.00046819262,0.36630082,0.00042069834,0.00008316734,0.00032891432,0.0000479337,0.0007535281,0.623901,0.0016024498,0.0033483612,0.00027582375],"about_ca_topic_score_codex":0.00018985345,"about_ca_topic_score_gemma":0.00014984363,"teacher_disagreement_score":0.10031758,"about_ca_system_score_codex":0.0004910161,"about_ca_system_score_gemma":0.00035470366,"threshold_uncertainty_score":0.44252983},"labels":[],"label_agreement":null},{"id":"W2152774786","doi":"10.1373/clinchem.2012.198739","title":"The Long and Winding Road to FDA Approval of a Novel Prostate Cancer Test: Our Story","year":2012,"lang":"en","type":"article","venue":"Clinical Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Test (biology); Medicine; Drug approval; Cancer; Internal medicine; Pharmacology; Biology; Drug","score_opus":0.09264885022634976,"score_gpt":0.44340407204971105,"score_spread":0.3507552218233613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152774786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909388,0.0034777694,0.00000389343,0.004210641,0.00011380445,0.00031162324,0.00002289384,0.00001655893,0.0009040565],"genre_scores_gemma":[0.9879165,0.0005877116,0.000120564335,0.000107462496,0.0006130844,0.00006157708,0.0000070982637,0.000016107948,0.010569876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989599,0.000015337137,0.0002761278,0.00019892224,0.0002113801,0.00033833898],"domain_scores_gemma":[0.9989733,0.00026926692,0.0000816389,0.00023281488,0.00008631405,0.00035664975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072710396,0.0001058909,0.00023737093,0.000010281404,0.00009314699,0.000011548978,0.00008634181,0.0000988016,0.000011470191],"category_scores_gemma":[0.0007872199,0.00006446148,0.00007426378,0.0000963504,0.0001547712,0.000039663646,0.00010455318,0.00036717593,0.0000042845477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044514015,0.00045447057,0.9400611,0.0003048505,0.000106362364,0.000007146387,0.00020859747,4.2330979e-7,0.023797402,0.0000019364682,0.0023078402,0.03230472],"study_design_scores_gemma":[0.008822407,0.00050058105,0.80049556,0.0007893912,0.00027566755,0.0000581719,0.0021558602,0.00012336086,0.16468732,0.000008527769,0.021713665,0.00036945246],"about_ca_topic_score_codex":0.000011527924,"about_ca_topic_score_gemma":0.0000017190508,"teacher_disagreement_score":0.14088993,"about_ca_system_score_codex":0.00007159747,"about_ca_system_score_gemma":0.00019271643,"threshold_uncertainty_score":0.2628663},"labels":[],"label_agreement":null},{"id":"W2152976165","doi":"","title":"Real-World Corticosteroid Utilization Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in 2 Large US Administrative Claims Databases.","year":2013,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Prostate cancer; Population; Cancer; Concomitant; Pharmacy; Internal medicine; Oncology; Hormonal therapy; Database; Intensive care medicine; Family medicine","score_opus":0.07694346426682161,"score_gpt":0.3422435871159196,"score_spread":0.265300122849098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152976165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930731,0.00010285116,0.000011084221,0.00045876193,0.00005691981,0.005235162,0.00058218866,0.000022998465,0.0004569095],"genre_scores_gemma":[0.9903522,0.00021358146,0.000054513835,0.0000964707,0.000018742803,0.0070554344,0.0010930906,0.000028402517,0.0010875528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809265,0.00008928769,0.0004004246,0.00037409176,0.0004301136,0.0006134466],"domain_scores_gemma":[0.999197,0.0000457117,0.00012472995,0.00024471013,0.0001828179,0.00020501514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016711555,0.00019722406,0.00030683776,0.00028307838,0.00004567885,0.00004954203,0.000061833176,0.000024681767,0.00023327993],"category_scores_gemma":[0.000028940442,0.00013969072,0.00002493427,0.00055027526,0.000056330966,0.00039157434,0.000031337455,0.00019301726,0.000008111681],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012116464,0.0006916828,0.98448,0.00013875334,0.00006372886,0.00008130977,0.00032526554,0.0000091433785,0.000032293887,0.000020084723,0.00006817574,0.012877896],"study_design_scores_gemma":[0.008038341,0.00021025258,0.99035335,0.00015078539,0.000048053083,7.5247283e-7,0.000202526,0.00008768865,0.000657526,0.000015363696,0.00009133087,0.00014403531],"about_ca_topic_score_codex":0.0040851557,"about_ca_topic_score_gemma":0.040960878,"teacher_disagreement_score":0.03687572,"about_ca_system_score_codex":0.00052985887,"about_ca_system_score_gemma":0.00025397938,"threshold_uncertainty_score":0.9765391},"labels":[],"label_agreement":null},{"id":"W2153148011","doi":"10.1186/1477-7525-9-88","title":"Pain in castration-resistant prostate cancer with bone metastases: a qualitative study","year":2011,"lang":"en","type":"article","venue":"Health and Quality of Life Outcomes","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AstraZeneca","keywords":"Medicine; Quality of life (healthcare); Context (archaeology); McGill Pain Questionnaire; Debriefing; Prostate cancer; Pain assessment; Physical therapy; Brief Pain Inventory; Pain scale; Bone pain; Cancer; Chronic pain; Internal medicine; Visual analogue scale; Pain management; Nursing","score_opus":0.22192334907187897,"score_gpt":0.48243014129830125,"score_spread":0.26050679222642226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153148011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905204,0.0036577277,0.000009977237,0.0039936574,0.000016323846,0.0015830579,0.00010310397,0.000015688553,0.000100026235],"genre_scores_gemma":[0.99724436,0.00038897147,0.0007792491,0.0009958458,0.000009170229,0.00019426909,0.000026353115,0.000011565764,0.000350189],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973721,0.0010151431,0.0006601436,0.00025673048,0.00038170975,0.00031420196],"domain_scores_gemma":[0.99880683,0.00027757633,0.00023984456,0.00017971991,0.00011732229,0.00037869404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034330385,0.00015016257,0.00074606814,0.00014202906,0.00007259653,0.0000071834143,0.000033156386,0.000027077349,0.000044684788],"category_scores_gemma":[0.00021148426,0.00009254956,0.000040041607,0.00021517325,0.00014131983,0.0000766202,0.000016838796,0.00013660673,9.0812097e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005297167,0.0010015187,0.81330085,0.0011653538,0.00018099182,0.000017222423,0.17637713,1.5655431e-7,0.000023814933,0.00017760704,0.00006371158,0.0023944934],"study_design_scores_gemma":[0.0078252675,0.0047946195,0.76771265,0.00018587045,0.000026890937,8.018351e-7,0.21916728,0.000001952696,0.000035925426,0.0000693876,0.00006702143,0.00011234808],"about_ca_topic_score_codex":0.029660238,"about_ca_topic_score_gemma":0.012993806,"teacher_disagreement_score":0.045588195,"about_ca_system_score_codex":0.00008697385,"about_ca_system_score_gemma":0.0011344436,"threshold_uncertainty_score":0.97680134},"labels":[],"label_agreement":null},{"id":"W2153242439","doi":"10.1002/pros.21198","title":"Effects of castration on insulin levels and glucose tolerance in the mouse differ from those in man","year":2010,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Castration; Internal medicine; Endocrinology; Insulin; Medicine; Biology; Hormone","score_opus":0.021491131260928543,"score_gpt":0.30415371615331643,"score_spread":0.2826625848923879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153242439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959799,0.00056594936,0.0000015608309,0.0021708591,0.000035347526,0.0010965645,0.000028605255,0.0000068561762,0.00011435202],"genre_scores_gemma":[0.9990214,0.00032449485,0.000037139635,0.00021728709,0.000033328673,0.00009112793,0.000015850084,0.000009018136,0.0002503274],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99930745,0.000095546624,0.00013327984,0.00013788718,0.00016992226,0.00015589512],"domain_scores_gemma":[0.99948597,0.00022519362,0.00003544818,0.000204286,0.000019851337,0.00002923174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026427946,0.00008976136,0.00014202774,0.000048969596,0.000033778393,0.000015418378,0.00007785171,0.000039440434,0.000008465745],"category_scores_gemma":[0.000050479277,0.000042617026,0.000017345796,0.000112243666,0.0001067629,0.00004450787,0.000022602688,0.00033847216,0.000005773456],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026597118,0.00062542653,0.045282707,0.00018726112,0.000028070153,0.00015291249,0.022648584,0.000011059843,0.89339393,0.00018173787,0.000068712594,0.034759887],"study_design_scores_gemma":[0.0036850732,0.00029310546,0.6645543,0.000112137604,0.000012676545,0.000003150985,0.00014884236,0.00022765031,0.33009017,0.0007383631,0.00008602006,0.00004853558],"about_ca_topic_score_codex":0.00038749317,"about_ca_topic_score_gemma":0.00037471243,"teacher_disagreement_score":0.6192716,"about_ca_system_score_codex":0.000018810853,"about_ca_system_score_gemma":0.00003440813,"threshold_uncertainty_score":0.17378719},"labels":[],"label_agreement":null},{"id":"W2153460792","doi":"10.1038/sj.pcan.4500982","title":"Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer","year":2007,"lang":"en","type":"review","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Prostate cancer; Oncology; Androgen deprivation therapy; Goserelin; Internal medicine; Prostatectomy; Cancer; Population; Hormonal therapy; Adjuvant therapy; Adjuvant","score_opus":0.043354475830214054,"score_gpt":0.38166789010624,"score_spread":0.33831341427602596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153460792","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02522092,0.95209336,0.00000864964,0.00075722585,0.0001254595,0.01651737,0.005139461,0.00009488284,0.00004269377],"genre_scores_gemma":[0.0075047016,0.97260356,0.00005703013,0.0004255631,0.00016638587,0.0161477,0.0014494593,0.00025497092,0.0013906555],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945308,0.00024790084,0.0012177378,0.0016017567,0.0010022222,0.0013995613],"domain_scores_gemma":[0.9973501,0.00026158357,0.00071340293,0.00041735393,0.00037623462,0.00088130444],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0003965697,0.0013362257,0.0029411116,0.0006644632,0.00025862563,0.00027912346,0.00021310948,0.00025482493,0.0001902831],"category_scores_gemma":[0.00003157409,0.0008594678,0.00023347554,0.0009751996,0.00060757704,0.0004603966,0.00011761205,0.0006711733,0.000005546709],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029185049,0.0004421719,0.3224147,0.029338675,0.001449758,0.0003830799,0.000818419,0.0000032816847,0.0000061544893,0.000003102104,0.0002771627,0.641945],"study_design_scores_gemma":[0.105418,0.0071093403,0.26933286,0.23109703,0.026111694,0.00042410445,0.00095427,0.00050100294,0.00030519892,0.0003069527,0.351445,0.0069945664],"about_ca_topic_score_codex":0.0007283209,"about_ca_topic_score_gemma":0.00043471085,"teacher_disagreement_score":0.6349504,"about_ca_system_score_codex":0.0007932653,"about_ca_system_score_gemma":0.0027644308,"threshold_uncertainty_score":0.9999389},"labels":[],"label_agreement":null},{"id":"W2154086425","doi":"10.1007/s10637-009-9251-7","title":"Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Antiandrogens; LNCaP; Chalcone; Antiandrogen; Prostate cancer; Androgen receptor; Pharmacology; Antagonist; Cancer research; Chemistry; Biology; Internal medicine; Endocrinology; Medicine; Cancer; Receptor; Stereochemistry","score_opus":0.022414702491515264,"score_gpt":0.2939460139984815,"score_spread":0.27153131150696624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154086425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929054,0.000119802084,0.00005837798,0.00579059,0.000045006716,0.00079556793,0.00014187815,0.000026118209,0.000117259544],"genre_scores_gemma":[0.9962774,0.0001762122,0.0020714859,0.0008152801,0.000092215734,0.00004192026,0.00041841768,0.000015674352,0.00009141422],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986782,0.00006607093,0.0004124637,0.00031179408,0.00033090252,0.00020058491],"domain_scores_gemma":[0.9988985,0.0004544826,0.00015837951,0.00013757136,0.00014288606,0.00020816289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002772265,0.00015614206,0.00034325427,0.00020366009,0.000052080995,0.000014380206,0.000057043657,0.00011237269,0.000023176286],"category_scores_gemma":[0.0007110698,0.00013310502,0.000066709,0.0002897414,0.00017706119,0.00011219883,0.000015756963,0.0001313266,0.00001409999],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019042058,0.00026736775,0.020935059,0.000056292844,0.000055178,0.000012566027,0.00031182144,0.000009589534,0.9596331,0.00004151675,0.0000143376765,0.01675893],"study_design_scores_gemma":[0.004108301,0.00024508665,0.15040968,0.00040701855,0.00003697412,0.000007977246,0.000028702656,0.0017449094,0.8425027,0.00026071208,0.00012478084,0.00012313349],"about_ca_topic_score_codex":0.000034115583,"about_ca_topic_score_gemma":0.0000020854347,"teacher_disagreement_score":0.12947462,"about_ca_system_score_codex":0.00008757895,"about_ca_system_score_gemma":0.0005566679,"threshold_uncertainty_score":0.5427865},"labels":[],"label_agreement":null},{"id":"W2154125954","doi":"10.18553/jmcp.2014.20.5.477","title":"Adherence Patterns for Abiraterone Acetate and Concomitant Prednisone Use in Patients with Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Managed Care Pharmacy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Abiraterone acetate; Prednisone; Concomitant; Prostate cancer; Internal medicine; Medical prescription; Population; Cancer; Androgen deprivation therapy; Oncology; Pharmacology","score_opus":0.03293191264913797,"score_gpt":0.33480896597467863,"score_spread":0.30187705332554066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154125954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972142,0.00092281116,0.000084572544,0.0006515638,0.00012220522,0.0009139268,0.000057085443,0.0000069357484,0.000026728592],"genre_scores_gemma":[0.99804235,0.00101842,0.00028320486,0.00018381662,0.00008924377,0.00005009029,0.000016632954,0.000024189854,0.0002920303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895257,0.00006563885,0.00028527115,0.0001573403,0.00028602144,0.0002531733],"domain_scores_gemma":[0.9990543,0.00006963189,0.00020277935,0.000098092045,0.00041495886,0.00016023013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020423665,0.00013948497,0.0003261949,0.0001409111,0.000046815312,0.00004761273,0.00007282113,0.000019317276,0.000021072907],"category_scores_gemma":[0.000026540443,0.00008775423,0.000044630073,0.00008927887,0.000049186594,0.00029333294,0.000029686942,0.00022638962,6.8124376e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010588148,0.00012498767,0.93874764,0.0005250081,0.00017977023,0.000063305706,0.0012442541,0.000025892816,0.00046583798,0.0000015682439,0.00031490982,0.047718674],"study_design_scores_gemma":[0.05821356,0.0028711234,0.928286,0.000977227,0.00030609494,0.000012818904,0.0004339764,0.00020807423,0.0042281486,0.000015774976,0.0042705014,0.0001766814],"about_ca_topic_score_codex":0.00012124373,"about_ca_topic_score_gemma":0.000083742765,"teacher_disagreement_score":0.04762541,"about_ca_system_score_codex":0.00015925044,"about_ca_system_score_gemma":0.00009408437,"threshold_uncertainty_score":0.35785136},"labels":[],"label_agreement":null},{"id":"W2154226543","doi":"10.1210/me.2003-0020","title":"The Role of Hepatocyte Nuclear Factor-3α (Forkhead Box A1) and Androgen Receptor in Transcriptional Regulation of Prostatic Genes","year":2003,"lang":"en","type":"article","venue":"Molecular Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"FOXA1; Biology; Androgen receptor; LNCaP; Chromatin immunoprecipitation; Hepatocyte nuclear factor 4; Hepatocyte nuclear factors; Nuclear receptor; Transcription factor; Androgen; Enhancer; Endocrinology; Molecular biology; Internal medicine; Promoter; Prostate cancer; Gene expression; Gene; Cancer; Hormone; Genetics; Medicine","score_opus":0.013954052379083669,"score_gpt":0.267662823099115,"score_spread":0.25370877072003134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154226543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867277,0.011788885,0.000023793702,0.00040534599,0.000030102967,0.00046139825,0.000013640534,0.000007972392,0.0005411715],"genre_scores_gemma":[0.9981514,0.0012872864,0.00037971797,0.000019508085,0.0000052701816,0.00002949802,0.000016330196,0.000013588561,0.000097366494],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991276,0.0001061658,0.00021811001,0.00015514642,0.00015647645,0.00023648093],"domain_scores_gemma":[0.9996525,0.000034401957,0.00005266936,0.00014929369,0.00006778053,0.000043371707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006244808,0.00008791592,0.00020086206,0.00009308711,0.00003970512,0.0000040353093,0.000044533317,0.00004922142,0.000054609376],"category_scores_gemma":[0.000033399767,0.00006240506,0.000048044654,0.00011319014,0.0002073821,0.000026437832,0.000013915728,0.00009194325,0.0000024125843],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049187866,0.00010745957,0.060358636,0.000074272866,0.0001017402,0.000022971595,0.0004132812,0.000006556105,0.90513825,0.016466977,0.000006952029,0.016811037],"study_design_scores_gemma":[0.0030639833,0.00061432156,0.04169491,0.0000472072,0.000039085524,0.000083386636,0.00035073076,0.00016442266,0.93357456,0.0023209006,0.0179581,0.00008840693],"about_ca_topic_score_codex":0.00004254727,"about_ca_topic_score_gemma":0.000013194768,"teacher_disagreement_score":0.028436305,"about_ca_system_score_codex":0.000042585103,"about_ca_system_score_gemma":0.0000781503,"threshold_uncertainty_score":0.25448045},"labels":[],"label_agreement":null},{"id":"W2154986877","doi":"10.1016/j.urology.2007.06.305","title":"MP-08.01: Salvage therapy with bicalutamide 150 mg in patients with PSA failure under LHRH therapy or surgical castration for advanced prostate cancer","year":2007,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Bicalutamide; Castration; Prostate cancer; Urology; Oncology; Cancer; Prostate; Internal medicine; Hormone","score_opus":0.021005856602544008,"score_gpt":0.32840851360304174,"score_spread":0.30740265700049774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154986877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912639,0.0009010391,0.00030996153,0.0047883643,0.00006086323,0.0024766028,0.000032227228,0.000045038916,0.00012199423],"genre_scores_gemma":[0.9966961,0.0006626567,0.00043267634,0.00075616513,0.00011252164,0.00036875627,0.0001776071,0.000048817077,0.0007446613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983702,0.00005577425,0.00024174304,0.00042354313,0.0002845146,0.00062427524],"domain_scores_gemma":[0.99923193,0.00016109168,0.00008338402,0.00020934163,0.000173708,0.00014053164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019985838,0.00022881899,0.00034956602,0.00016180359,0.000076197095,0.000013543026,0.00007232234,0.00015278145,0.00017492104],"category_scores_gemma":[0.000009123535,0.00011982142,0.000039964743,0.00032261253,0.00019485569,0.00010428112,0.0000107,0.00026350925,0.0000041355615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23581305,0.0011168274,0.67362964,0.00005627129,0.0003690151,0.0004592428,0.0009713289,0.0004761016,0.0022960687,0.0001311816,0.00023794358,0.08444334],"study_design_scores_gemma":[0.1253789,0.034852654,0.7845753,0.000085140244,0.000067240224,0.00006406068,0.00031754162,0.00012491235,0.00559159,0.00019486774,0.048253674,0.000494149],"about_ca_topic_score_codex":0.00007241771,"about_ca_topic_score_gemma":0.0015911454,"teacher_disagreement_score":0.11094564,"about_ca_system_score_codex":0.00015043386,"about_ca_system_score_gemma":0.00031690884,"threshold_uncertainty_score":0.48861757},"labels":[],"label_agreement":null},{"id":"W2155273887","doi":"10.1158/0008-5472.can-09-1504","title":"Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":201,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Docetaxel; Prostate cancer; Paclitaxel; Androgen receptor; Cancer research; Gene knockdown; Chemistry; Maspin; FOXO1; PTEN; Small interfering RNA; LY294002; Cancer; Cell culture; PI3K/AKT/mTOR pathway; Biology; Apoptosis; Medicine; Internal medicine; Transfection; Protein kinase B; Metastasis; Biochemistry","score_opus":0.06360354436155137,"score_gpt":0.4047751119384639,"score_spread":0.3411715675769125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155273887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854807,0.00251964,0.000003846351,0.008771773,0.00006589093,0.0017949293,0.000092696246,0.000010406193,0.0012601112],"genre_scores_gemma":[0.990889,0.0051872814,0.00005581497,0.00020606114,0.00008395087,0.00036858037,0.000010444278,0.000021035308,0.0031778456],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997955,0.000095934854,0.00029044994,0.00028489344,0.000913941,0.00045974358],"domain_scores_gemma":[0.9989167,0.000044888155,0.00008590661,0.00033558058,0.00050454756,0.00011236314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068152027,0.00012214996,0.00030189232,0.00026644918,0.000068782465,0.000010035116,0.00015979385,0.00008811325,0.00060582056],"category_scores_gemma":[0.00006693671,0.00007847951,0.00008830122,0.0011395178,0.00025454143,0.00007278466,0.000054312408,0.0004405416,0.00000573061],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002293931,0.00042835166,0.005335215,0.00021534725,0.000059063528,0.000008921714,0.0016979418,0.00000719359,0.9730645,0.0007957804,0.0011193969,0.014974389],"study_design_scores_gemma":[0.0050549204,0.00068508653,0.0064460956,0.0009557071,0.000011150126,0.0000038572043,0.00031219167,0.000031060088,0.9834716,0.0014212091,0.001528669,0.00007850776],"about_ca_topic_score_codex":0.0018803996,"about_ca_topic_score_gemma":0.00018240343,"teacher_disagreement_score":0.0148958815,"about_ca_system_score_codex":0.00051374675,"about_ca_system_score_gemma":0.0012362938,"threshold_uncertainty_score":0.66333103},"labels":[],"label_agreement":null},{"id":"W2155466895","doi":"10.1002/pros.22872","title":"A retrospective, Canadian multi‐center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration‐resistant prostate cancer","year":2014,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Abiraterone acetate; Oncology; Internal medicine; Urology; Cancer; Androgen deprivation therapy","score_opus":0.052396001603954294,"score_gpt":0.3747850796432772,"score_spread":0.3223890780393229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155466895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99235165,0.00014083821,0.0000031365203,0.001934007,0.000052393523,0.0050872574,0.0002901965,0.000020089517,0.00012043347],"genre_scores_gemma":[0.9980677,0.000054408614,0.00009184834,0.00008305201,0.000020118176,0.00039526328,0.00001418194,0.000045733897,0.0012277388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714535,0.00074012514,0.00058051076,0.00040298753,0.00049648853,0.0006345109],"domain_scores_gemma":[0.99828255,0.0002758971,0.00022847117,0.00067370926,0.0002850484,0.00025433613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002149425,0.00029512114,0.0005758023,0.0003814696,0.00016911088,0.000042207852,0.00025232963,0.000031584626,0.000043625227],"category_scores_gemma":[0.00041456084,0.0001455573,0.00010282016,0.00075064134,0.0002156282,0.00008236546,0.00006868113,0.00034085978,0.000013434301],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0879517,0.003639404,0.6728012,0.00022018484,0.001356541,0.0002090484,0.106875025,0.0039763683,0.11361005,0.000021371034,0.00025814096,0.009080959],"study_design_scores_gemma":[0.013360801,0.0055265776,0.97460717,0.0003228908,0.000107193315,0.000006725565,0.0013146688,0.00041532904,0.004126062,0.000022502141,0.00004581031,0.00014424739],"about_ca_topic_score_codex":0.064121954,"about_ca_topic_score_gemma":0.05251977,"teacher_disagreement_score":0.30180597,"about_ca_system_score_codex":0.0007623262,"about_ca_system_score_gemma":0.0010605864,"threshold_uncertainty_score":0.9647693},"labels":[],"label_agreement":null},{"id":"W2155628202","doi":"10.3747/co.v15i4.257","title":"Defining the Optimal Treatment Strategy for Localized Prostate Cancer Patients: A Survey of Ongoing Studies at the National Cancer Institute of Canada Clinical Trials Group","year":2008,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Hôpital Notre-Dame; Kingston General Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Prostate cancer; Clinical trial; Cancer; Disease; Oncology; Internal medicine; Prostate","score_opus":0.5430443527942997,"score_gpt":0.5743673891365019,"score_spread":0.031323036342202126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155628202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9536275,0.03938998,0.000008755735,0.0014908694,0.0016854476,0.0022741726,0.0014363776,0.0000063816537,0.000080462974],"genre_scores_gemma":[0.9683002,0.028620124,0.000047625657,0.00010406711,0.00021688982,0.0016970817,0.0003894777,0.000016846538,0.00060768187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971909,0.0007486445,0.0010006161,0.0002733973,0.0004367009,0.00034973366],"domain_scores_gemma":[0.9947944,0.0031916676,0.0005860708,0.00013262875,0.0012070555,0.00008814753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025495943,0.0001778307,0.00096403225,0.000046752073,0.0002930281,0.0000032290102,0.000112923546,0.00006752573,0.000043824624],"category_scores_gemma":[0.00188265,0.00008221261,0.00017241831,0.00019351076,0.0007539336,0.000040714738,0.00007969965,0.00015654144,4.8719954e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011596701,0.0017569495,0.823832,0.00027778026,0.0028006444,0.0000088340075,0.0017375661,0.0011764463,0.000027494967,0.00019829927,0.04209084,0.114496455],"study_design_scores_gemma":[0.051443864,0.009738453,0.6677693,0.0005615588,0.0011083481,0.000012905719,0.0008323779,0.0013172115,0.001588435,0.00005668201,0.26523274,0.00033812888],"about_ca_topic_score_codex":0.0687452,"about_ca_topic_score_gemma":0.43414325,"teacher_disagreement_score":0.36539805,"about_ca_system_score_codex":0.0019776546,"about_ca_system_score_gemma":0.0075088944,"threshold_uncertainty_score":0.9981176},"labels":[],"label_agreement":null},{"id":"W2155672452","doi":"10.1002/pros.23003","title":"A multicenter study shows <i>PTEN</i> deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer","year":2015,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; Queen's University","funders":"National Cancer Institute; National Institutes of Health; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Canary Foundation; U.S. Department of Defense","keywords":"PTEN; Prostate cancer; Prostate; Seminal vesicle; Medicine; Prostate disease; Cancer; Multicenter study; Oncology; Pathology; Internal medicine; Cancer research; Urology; Biology; Cell biology; PI3K/AKT/mTOR pathway; Signal transduction","score_opus":0.04268805744554664,"score_gpt":0.32153102680867524,"score_spread":0.2788429693631286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155672452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913853,0.002198277,0.000011685923,0.002443172,0.000047703503,0.0037392955,0.000050806113,0.00006195918,0.000061835395],"genre_scores_gemma":[0.9964266,0.00041676938,0.000061524835,0.00035831248,0.000029950677,0.0005375503,0.000054600223,0.00003954744,0.0020751364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979005,0.00019541124,0.0003113503,0.00044148017,0.00063857867,0.00051270606],"domain_scores_gemma":[0.9989935,0.000041686235,0.000119301636,0.00029794456,0.0003213547,0.00022621357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009335515,0.00024709335,0.00034155417,0.00009793926,0.00011974946,0.0000621028,0.00008480706,0.000052281768,0.00002726086],"category_scores_gemma":[0.00004608022,0.00013896723,0.000032437274,0.00031479276,0.0001813076,0.00016482278,0.000102265454,0.00031324918,0.000007854461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01544842,0.0022311313,0.92425054,0.000101668345,0.00038694177,0.00049574126,0.03771439,0.00012939458,0.0072300015,0.000002528008,0.0015394322,0.010469784],"study_design_scores_gemma":[0.15752858,0.01891098,0.6804637,0.003248844,0.0015992074,0.00006933319,0.047937714,0.049455892,0.034874592,0.00043129578,0.004033436,0.001446443],"about_ca_topic_score_codex":0.0009706914,"about_ca_topic_score_gemma":0.0008290291,"teacher_disagreement_score":0.24378689,"about_ca_system_score_codex":0.00038224796,"about_ca_system_score_gemma":0.00024585277,"threshold_uncertainty_score":0.5666919},"labels":[],"label_agreement":null},{"id":"W2156194835","doi":"10.5489/cuaj.412","title":"Luteinizing hormone-releasing hormone antagonists for urinary obstruction in prostate cancer","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Urology; Prostate cancer; Bicalutamide; Luteinizing hormone; Creatinine; Hydronephrosis; Prostate; Testosterone (patch); Urinary system; Prostate-specific antigen; Hormone; Internal medicine; Gynecology; Endocrinology; Cancer; Androgen receptor","score_opus":0.02128010707542666,"score_gpt":0.28071901526162885,"score_spread":0.2594389081862022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156194835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9560609,0.0038903144,0.000013840713,0.038620226,0.00023901086,0.00076339016,0.00003628947,0.000021215204,0.00035482933],"genre_scores_gemma":[0.994714,0.0021718007,0.00038139534,0.0008989526,0.00045586936,0.00016697012,0.000042142783,0.000018227904,0.0011506347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983919,0.00007927504,0.000331926,0.00021000367,0.00027411786,0.00071275927],"domain_scores_gemma":[0.9987411,0.00008473046,0.00017353408,0.00007147063,0.00034250412,0.0005866998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030758505,0.00013756084,0.00025321974,0.00026254932,0.00031797471,0.00013259794,0.00007301497,0.00017431325,0.00014265634],"category_scores_gemma":[0.00026448717,0.00010852825,0.00010080278,0.00025619645,0.000035843124,0.00024196802,0.000011821605,0.0005345555,0.000024081493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007112584,0.00014907341,0.9179449,0.000025673064,0.00021191701,0.0002885492,0.000522646,0.00006756806,0.008527673,0.00006908731,0.027412433,0.044069223],"study_design_scores_gemma":[0.0032184706,0.00069866725,0.9782691,0.00002586711,0.00003686089,0.00017774786,0.00017036006,0.0005471253,0.00007002159,0.0011090868,0.0155394245,0.00013728178],"about_ca_topic_score_codex":0.0044315183,"about_ca_topic_score_gemma":0.00032500442,"teacher_disagreement_score":0.06032419,"about_ca_system_score_codex":0.0030753065,"about_ca_system_score_gemma":0.00071131706,"threshold_uncertainty_score":0.804182},"labels":[],"label_agreement":null},{"id":"W2156306108","doi":"10.1016/j.juro.2008.11.032","title":"Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial","year":2009,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1228,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute","keywords":"Medicine; Radiation therapy; Prostate cancer; Prostatectomy; Randomized controlled trial; Oncology; Internal medicine; Metastasis; Adjuvant; Clinical endpoint; Cancer; Urology; Surgery","score_opus":0.06022286967598006,"score_gpt":0.4160290638458764,"score_spread":0.35580619416989634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156306108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9607042,0.033674788,0.00036318062,0.0030544514,0.00032368125,0.0018003815,0.00006529447,0.0000048449683,0.000009181485],"genre_scores_gemma":[0.9356233,0.06338059,0.0004608051,0.00011191122,0.0003168088,0.000025295261,0.0000037911964,0.000011494571,0.0000659824],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99627197,0.0018325563,0.0012232851,0.00015321137,0.0002689894,0.00025000196],"domain_scores_gemma":[0.99497217,0.0031715254,0.0012464793,0.00016558552,0.00032647236,0.000117773416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075984127,0.00015646663,0.0017880613,0.00012373539,0.000049901853,0.0000062052136,0.00015486724,0.000116178235,0.00002285311],"category_scores_gemma":[0.0011027816,0.00007023874,0.00052661356,0.00009439781,0.0007978071,0.00004740556,0.000015276775,0.00033897482,8.45297e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88997704,0.0006197662,0.0044786837,0.000035615038,0.0015026934,0.00004701331,0.00052958203,0.0000062078366,0.031555034,0.000016562584,0.00009065753,0.07114114],"study_design_scores_gemma":[0.8902229,0.050458986,0.04393138,0.00007412115,0.0043664784,0.00016645316,0.0001734433,0.00011912541,0.008880833,0.0013886257,0.00009547151,0.00012216646],"about_ca_topic_score_codex":0.000016928798,"about_ca_topic_score_gemma":0.0000063460966,"teacher_disagreement_score":0.07101897,"about_ca_system_score_codex":0.000019117493,"about_ca_system_score_gemma":0.00029133083,"threshold_uncertainty_score":0.29395536},"labels":[],"label_agreement":null},{"id":"W2156422391","doi":"10.5489/cuaj.274","title":"Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Docetaxel; Prostate cancer; Medicine; Oncology; Castration; Internal medicine; Overall survival; Cancer; Hormone","score_opus":0.02976100057978632,"score_gpt":0.3090468671719275,"score_spread":0.27928586659214116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156422391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9307611,0.0011369889,0.000019856954,0.06592998,0.0001786021,0.0010577351,0.00055392826,0.000011459033,0.0003503645],"genre_scores_gemma":[0.9963304,0.00036148765,0.0005246742,0.0004954103,0.00014232326,0.0002671484,0.000088476925,0.000013966497,0.001776144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851495,0.00010338772,0.00042816068,0.000164851,0.0002991044,0.0004895738],"domain_scores_gemma":[0.9979212,0.0002746223,0.0002249235,0.00008602441,0.0010179741,0.00047523517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000489679,0.00012358098,0.00030166158,0.00027331742,0.0001692955,0.000066910194,0.000083943785,0.000103231825,0.00076194084],"category_scores_gemma":[0.00064516714,0.00009429678,0.00012139512,0.00027658968,0.000044572695,0.00016724443,0.0000071505274,0.00033010612,0.00001495237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002831163,0.00030503192,0.98026365,0.00005791343,0.00045326262,0.00003853154,0.0005712946,0.0007025124,0.0076408293,0.001372574,0.0019369518,0.0063743303],"study_design_scores_gemma":[0.0027480049,0.0005935495,0.98989004,0.00004385657,0.000113838396,0.000016883143,0.00033282672,0.00036413074,0.00009055145,0.0017539376,0.0039365017,0.00011588065],"about_ca_topic_score_codex":0.025935775,"about_ca_topic_score_gemma":0.03785758,"teacher_disagreement_score":0.06556928,"about_ca_system_score_codex":0.0011963937,"about_ca_system_score_gemma":0.0011977085,"threshold_uncertainty_score":0.9805506},"labels":[],"label_agreement":null},{"id":"W2156454983","doi":"10.1016/s0960-0760(03)00069-4","title":"Secretion of endogenous kallikreins 2 and 3 by androgen receptor-transfected PC-3 prostate cancer cells","year":2003,"lang":"en","type":"article","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Medical Research Council; Promotion and Mutual Aid Corporation for Private Schools of Japan","keywords":"LNCaP; Androgen receptor; Dihydrotestosterone; Endocrinology; Internal medicine; Androgen; Transfection; Secretion; Prostate cancer; Biology; Cell culture; Chemistry; Hormone; Medicine; Cancer","score_opus":0.010775040555132568,"score_gpt":0.2664904205017652,"score_spread":0.2557153799466326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156454983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.965208,0.033894446,0.00009737319,0.00043612634,0.000033465305,0.00016696501,0.00005226541,0.0000024399087,0.00010892498],"genre_scores_gemma":[0.9805571,0.019130189,0.00007312804,0.000092262846,0.000020101108,0.000003303504,0.000019812824,0.000007935433,0.00009618286],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999348,0.00009914191,0.00021145007,0.00009980131,0.000086563734,0.0001550321],"domain_scores_gemma":[0.9995345,0.00003285212,0.00012359205,0.00008935367,0.000121113095,0.00009861565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023578473,0.00010444794,0.00022364937,0.000026811334,0.00004543906,0.0000046541104,0.00004972015,0.0000929974,0.00002471407],"category_scores_gemma":[0.000020155516,0.000061600746,0.000042599877,0.00006442369,0.00025951018,0.0000140175525,0.0000142439985,0.00015380552,1.8335129e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006937622,0.000055144003,0.0011401577,0.00012087211,0.00020663015,0.000016081944,0.00026100996,4.939267e-7,0.99642867,0.0000041099374,0.0001028033,0.00097028085],"study_design_scores_gemma":[0.001832388,0.00081453763,0.000029346988,0.000070324175,0.00013730733,0.00040304757,0.00016029582,0.000001257951,0.9952664,0.00004753397,0.0011797921,0.000057795198],"about_ca_topic_score_codex":0.000014259726,"about_ca_topic_score_gemma":4.8767845e-7,"teacher_disagreement_score":0.01534909,"about_ca_system_score_codex":0.000023991932,"about_ca_system_score_gemma":0.00010337747,"threshold_uncertainty_score":0.25120056},"labels":[],"label_agreement":null},{"id":"W2156569777","doi":"10.1158/0008-5472.can-05-3928","title":"Androgen-Dependent Regulation of Her-2/neu in Prostate Cancer Cells","year":2006,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"LNCaP; Prostate cancer; Androgen receptor; Cancer research; Androgen; Endocrinology; Gene knockdown; Internal medicine; Prostate; Tramp; Dihydrotestosterone; Cancer cell; Biology; Cancer; Medicine; Chemistry; Hormone; Cell culture","score_opus":0.05746381969102102,"score_gpt":0.4072790718170662,"score_spread":0.34981525212604514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156569777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829696,0.010132797,0.0000023926282,0.0019253033,0.000118824944,0.0013554472,0.000079622376,0.00002318191,0.003392868],"genre_scores_gemma":[0.9745603,0.004035388,0.00003919085,0.000021943713,0.0002135091,0.000619902,0.000039227318,0.00003649539,0.020433998],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972889,0.00014582848,0.0003548556,0.00041432373,0.0011056755,0.0006904172],"domain_scores_gemma":[0.99885505,0.000075420874,0.000062648905,0.0003407448,0.00052715285,0.00013895819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077095133,0.00014330546,0.00031777844,0.00048446006,0.0000859696,0.000025471189,0.00014094744,0.00009186494,0.00079036714],"category_scores_gemma":[0.000018991348,0.00011518194,0.00006575943,0.0009520996,0.00027712955,0.000108156746,0.00008728928,0.00044187167,0.000028069751],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002012608,0.00044448095,0.1655192,0.00059689797,0.00006550089,0.00015053732,0.0004465574,0.000586893,0.81178415,0.00018711643,0.006022217,0.012183816],"study_design_scores_gemma":[0.0042746663,0.00029982557,0.088432446,0.0004917128,0.000019564732,0.0000054014135,0.0001756967,0.00015957531,0.90016586,0.0006509744,0.005185191,0.0001390931],"about_ca_topic_score_codex":0.012207561,"about_ca_topic_score_gemma":0.0020918474,"teacher_disagreement_score":0.08838168,"about_ca_system_score_codex":0.00092163135,"about_ca_system_score_gemma":0.0009772079,"threshold_uncertainty_score":0.9943702},"labels":[],"label_agreement":null},{"id":"W2157408303","doi":"10.1016/j.urology.2006.08.004","title":"PD-01.03","year":2006,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Goserelin; Prostate cancer; Adjuvant; Agonist; Antiandrogen; Prostatectomy; Oncology; Urology; Internal medicine; Radiation therapy; Cancer; Gynecology","score_opus":0.017650215352334468,"score_gpt":0.3105807579199042,"score_spread":0.29293054256756973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157408303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77766407,0.0026539976,0.000088345696,0.015858522,0.0001938129,0.00023699054,0.0000044440367,0.0000823731,0.20321743],"genre_scores_gemma":[0.98046005,0.000042130523,0.00005457943,0.0006802534,0.00022327263,0.000013389402,0.000035221354,0.000007251559,0.018483855],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995571,0.000014560587,0.00006202734,0.0001092285,0.00006795403,0.00018915917],"domain_scores_gemma":[0.99979657,0.000021863434,0.00000992857,0.00011134545,0.000020819049,0.00003947257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003891038,0.00004550603,0.00009202326,0.000047445472,0.000026291409,0.0000026438684,0.00002778869,0.000054240525,0.0006262414],"category_scores_gemma":[0.000008785082,0.000032455413,0.000027853242,0.00006123424,0.00006652616,0.000011556855,0.000015421383,0.00008419703,0.0005485062],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039245794,0.0012822102,0.50436074,0.000121458,0.00028528934,0.0031801905,0.0002466482,0.00007101812,0.05284084,0.016906684,0.39058834,0.026191996],"study_design_scores_gemma":[0.0050713555,0.0014848688,0.1726951,0.0000045488055,0.000085874584,0.00022773471,0.000015584747,0.00027164508,0.007602686,0.0050740778,0.8073479,0.00011862496],"about_ca_topic_score_codex":0.00007186879,"about_ca_topic_score_gemma":0.000017272803,"teacher_disagreement_score":0.41675955,"about_ca_system_score_codex":0.00002200988,"about_ca_system_score_gemma":0.00004297686,"threshold_uncertainty_score":0.7050121},"labels":[],"label_agreement":null},{"id":"W2157550245","doi":"10.5539/cco.v1n1p118","title":"Cabazitaxel for Metastatic Castrate-Resistant Prostate Cancer: A Case Presentation","year":2012,"lang":"en","type":"article","venue":"Cancer and Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Cabazitaxel; Prostate cancer; Docetaxel; Medicine; Taxane; Oncology; Internal medicine; Cancer; Prostate; Mitoxantrone; Urology; Chemotherapy; Androgen deprivation therapy; Breast cancer","score_opus":0.19507611749631126,"score_gpt":0.5385440241314717,"score_spread":0.34346790663516047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157550245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9717562,0.019342965,0.000049565337,0.0052032345,0.00080955983,0.001776625,0.0003090139,0.000032492317,0.0007203426],"genre_scores_gemma":[0.9832381,0.008750095,0.0007995647,0.00073642883,0.00076250127,0.0014780328,0.00005634715,0.00002866153,0.004150285],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983609,0.000119086624,0.0005181877,0.00031815327,0.00014074893,0.00054292637],"domain_scores_gemma":[0.9983471,0.00062250055,0.00015148263,0.000149754,0.00019915451,0.00052999833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063881214,0.00016359924,0.00056802237,0.000057524656,0.00013828377,0.000015922464,0.000041911746,0.00013009722,0.00016405234],"category_scores_gemma":[0.00015236197,0.0001160163,0.00014405836,0.00012548573,0.00029805186,0.0001315983,0.000035852096,0.00025154723,0.0000068010536],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015422834,0.0021438506,0.23116024,0.0010237974,0.0017516211,0.0018378552,0.0018783546,0.000006137356,0.0013014697,0.00053518073,0.014188381,0.7287503],"study_design_scores_gemma":[0.097408555,0.024848357,0.33800268,0.00058883976,0.008977702,0.003575163,0.007899566,0.0017404166,0.0044836784,0.0014050294,0.5097145,0.0013555492],"about_ca_topic_score_codex":0.0009796415,"about_ca_topic_score_gemma":0.0010132026,"teacher_disagreement_score":0.72739476,"about_ca_system_score_codex":0.00029855123,"about_ca_system_score_gemma":0.00089118903,"threshold_uncertainty_score":0.47310072},"labels":[],"label_agreement":null},{"id":"W2158381779","doi":"10.1016/j.juro.2007.03.092","title":"Prostatic Stem Cell Marker Identified by cDNA Microarray in Mouse","year":2007,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"York University","keywords":"Stem cell; Stem cell marker; Population; Biology; Telomerase reverse transcriptase; Pathology; Prostate; Immunostaining; Medicine; Cell biology; Telomerase; Immunohistochemistry; Gene; Cancer; Genetics","score_opus":0.015995034502243377,"score_gpt":0.2933549770016797,"score_spread":0.2773599424994363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158381779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99052095,0.0045836163,0.00014479242,0.0035275132,0.00012686603,0.00023091157,0.0000030814087,0.00000398291,0.0008582666],"genre_scores_gemma":[0.9879796,0.0006985497,0.000044953886,0.00053268083,0.000060603463,0.0000013064191,0.0000021425278,0.00001329054,0.010666893],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989147,0.00015095448,0.00036199702,0.00007119731,0.00020475869,0.00029637775],"domain_scores_gemma":[0.99929297,0.00021790675,0.00016190858,0.00013945757,0.00009090211,0.00009682976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017253183,0.00008258343,0.00022110571,0.00015949708,0.000033497738,0.000006566203,0.0001308787,0.000065248496,0.000081492486],"category_scores_gemma":[0.000018313896,0.00004534058,0.00005148634,0.00013037871,0.00011180162,0.00004492257,0.000024544555,0.00041838991,0.00002303681],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012024965,0.0005249589,0.05050007,0.0000836601,0.0001507515,0.00082615204,0.0023978136,0.000008568128,0.9086741,0.0000069163657,0.019959737,0.004842257],"study_design_scores_gemma":[0.03329337,0.0077130683,0.13901292,0.00011153187,0.0006237744,0.0036493626,0.0041103135,0.00010063384,0.77090275,0.00056546996,0.0395305,0.00038634133],"about_ca_topic_score_codex":0.000017142265,"about_ca_topic_score_gemma":0.000018026416,"teacher_disagreement_score":0.13777143,"about_ca_system_score_codex":0.00008453738,"about_ca_system_score_gemma":0.00010051251,"threshold_uncertainty_score":0.18489352},"labels":[],"label_agreement":null},{"id":"W2159274496","doi":"10.1016/j.brachy.2015.02.246","title":"Single 15 Gy High-Dose-Rate Brachytherapy Boost for Treatment of Prostate Cancer: Clinical Implications of Dosimetric Parameters","year":2015,"lang":"en","type":"article","venue":"Brachytherapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Common Terminology Criteria for Adverse Events; Brachytherapy; Interquartile range; External beam radiotherapy; Univariate analysis; Nuclear medicine; Confidence interval; Radiation therapy; Cancer; Urology; Internal medicine; Multivariate analysis","score_opus":0.15066448467636867,"score_gpt":0.4243469738119731,"score_spread":0.27368248913560445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159274496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788465,0.0119626075,0.00016013441,0.004923843,0.00034258215,0.0030942603,0.0004333774,0.000059686034,0.00017702069],"genre_scores_gemma":[0.9804136,0.012737825,0.0031686525,0.0003212815,0.00024585726,0.0009090856,0.0002541094,0.0000775562,0.0018720101],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99774903,0.00015056491,0.00084228005,0.0004914461,0.00029899715,0.0004676614],"domain_scores_gemma":[0.99745727,0.00052744977,0.00043806073,0.00062916847,0.00059723895,0.0003508131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046952022,0.0002913253,0.00093859236,0.00030686383,0.00007085532,0.000019340796,0.00014505134,0.00015620074,0.000043029646],"category_scores_gemma":[0.000091243994,0.00021087514,0.00035531033,0.0007420345,0.00033237928,0.00011644532,0.000015240838,0.00008411915,0.000007011554],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015018454,0.0058404133,0.34429777,0.0001705171,0.0015658068,0.00001324146,0.0010376392,0.0000656246,0.02720747,0.0004201024,0.0024953764,0.6018676],"study_design_scores_gemma":[0.10032923,0.070529036,0.42491078,0.00030400165,0.00087012094,0.00004444512,0.00033765074,0.00038547534,0.31960416,0.0051882253,0.07661242,0.00088446215],"about_ca_topic_score_codex":0.00067927665,"about_ca_topic_score_gemma":0.000076727316,"teacher_disagreement_score":0.60098314,"about_ca_system_score_codex":0.00037383588,"about_ca_system_score_gemma":0.0007551559,"threshold_uncertainty_score":0.8599239},"labels":[],"label_agreement":null},{"id":"W2159470156","doi":"10.1158/1078-0432.ccr-11-2147","title":"<i>NKX3.1</i> Haploinsufficiency Is Prognostic for Prostate Cancer Relapse following Surgery or Image-Guided Radiotherapy","year":2011,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"Memorial Sloan-Kettering Cancer Center","keywords":"Haploinsufficiency; Medicine; Prostate cancer; Prostatectomy; Oncology; Radiation therapy; Internal medicine; Proportional hazards model; Image-guided radiation therapy; Prostate; Comparative genomic hybridization; Cancer; Gene; Biology; Genetics; Phenotype","score_opus":0.4063422715897345,"score_gpt":0.541383628515185,"score_spread":0.13504135692545044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159470156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9541663,0.02313784,0.00013481834,0.010176578,0.0021432876,0.0075458474,0.00026959725,0.00024163537,0.0021840832],"genre_scores_gemma":[0.7877121,0.11809393,0.0048472416,0.0039847833,0.0039117807,0.015209264,0.00012935822,0.00051650073,0.065595046],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936046,0.00048595067,0.0012716838,0.0012953008,0.0014749567,0.0018675213],"domain_scores_gemma":[0.9925186,0.0037051241,0.00018476251,0.0008670564,0.001836688,0.000887787],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0056250617,0.0003923511,0.0011259665,0.00045073507,0.000528828,0.0001066937,0.00045645298,0.00033031704,0.0022041574],"category_scores_gemma":[0.004811542,0.0002632582,0.00083412084,0.0014302665,0.0009980804,0.00028472862,0.00016948997,0.0012047964,0.000083541556],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025301944,0.0029822888,0.5689645,0.0017252684,0.001335541,0.0011422267,0.0033827364,0.0000010708686,0.0021434252,0.000040034953,0.31711212,0.075868875],"study_design_scores_gemma":[0.066609494,0.023613062,0.26616547,0.009548885,0.0016804611,0.00009654901,0.0022289963,0.0020446859,0.049190562,0.0022852602,0.57312113,0.0034154549],"about_ca_topic_score_codex":0.001591329,"about_ca_topic_score_gemma":0.00021838269,"teacher_disagreement_score":0.30279902,"about_ca_system_score_codex":0.00067409215,"about_ca_system_score_gemma":0.0065429,"threshold_uncertainty_score":0.99998194},"labels":[],"label_agreement":null},{"id":"W2159660532","doi":"10.1016/j.jsbmb.2014.05.009","title":"Multiple roles for udp-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution","year":2014,"lang":"en","type":"review","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Prostate cancer; Dihydrotestosterone; Glucuronidation; Androgen; Androgen receptor; Androsterone; Endocrinology; Dehydroepiandrosterone; Testosterone (patch); Glucuronosyltransferase; Internal medicine; Intracrine; Chemistry; Cancer research; Enzyme; Biology; Cancer; Hormone; Medicine; Biochemistry; Receptor; Steroid; Microsome","score_opus":0.017687893870081402,"score_gpt":0.33980532588945006,"score_spread":0.32211743201936865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159660532","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.113258995,0.8855039,0.00012026001,0.00030239602,0.000042131076,0.00064169464,0.00012276233,0.0000028957645,0.0000049484033],"genre_scores_gemma":[0.065450415,0.9340999,0.00008343044,0.000047741414,0.00013069597,0.00005330836,0.000059132268,0.00002093733,0.000054443015],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99880666,0.00016828194,0.0004464653,0.00023523507,0.000084343104,0.00025904714],"domain_scores_gemma":[0.9992334,0.00014123505,0.00024605723,0.00014119841,0.00009596678,0.00014211157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051821023,0.00027778296,0.0010572373,0.0001073655,0.00007055187,0.000017070663,0.00009627531,0.00025139944,0.000002372126],"category_scores_gemma":[0.000065726534,0.00015323106,0.00013724073,0.00007224262,0.00031377326,0.000025648429,0.000055272183,0.0003285728,1.0674374e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003426767,0.0001794726,0.001427625,0.024259387,0.0019408241,0.000093303395,0.000532137,9.5186715e-7,0.1460395,0.00007060373,0.00013625942,0.82189316],"study_design_scores_gemma":[0.027432324,0.0036816671,0.000412223,0.022490766,0.010939849,0.0054980516,0.0005941779,0.00007396865,0.22925256,0.0009044327,0.6973328,0.0013871462],"about_ca_topic_score_codex":0.000019952919,"about_ca_topic_score_gemma":0.0000079857155,"teacher_disagreement_score":0.82050604,"about_ca_system_score_codex":0.000052565832,"about_ca_system_score_gemma":0.00023249393,"threshold_uncertainty_score":0.6248581},"labels":[],"label_agreement":null},{"id":"W2159753688","doi":"10.1158/1078-0432.ccr-07-0648","title":"An Antibody Targeting the Type I Insulin-like Growth Factor Receptor Enhances the Castration-Induced Response in Androgen-Dependent Prostate Cancer","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"DOD Prostate Cancer Research Program; National Cancer Institute; National Institutes of Health; U.S. Department of Veterans Affairs; U.S. Department of Defense","keywords":"Castration; Prostate cancer; Medicine; Androgen receptor; Androgen; Prostate; Internal medicine; Orchiectomy; Cancer; Endocrinology; Urology; Hormone","score_opus":0.16681916483910428,"score_gpt":0.5321808771038311,"score_spread":0.3653617122647268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159753688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787189,0.005803323,0.0000055075047,0.01214047,0.00085983926,0.002193342,0.00006312485,0.00004379436,0.00017171836],"genre_scores_gemma":[0.9837844,0.012843601,0.000044103253,0.00043299078,0.0010355336,0.0003196889,0.000049959774,0.00005356265,0.0014361547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99342775,0.0020139057,0.00093795196,0.0007986532,0.0015982627,0.0012234625],"domain_scores_gemma":[0.9945056,0.0029744944,0.0001530148,0.0006710713,0.0012432098,0.0004526551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014909662,0.00025927197,0.0004463028,0.00024486514,0.00060869945,0.00015121656,0.0006094997,0.0002492088,0.0006328717],"category_scores_gemma":[0.0019881185,0.00013631144,0.0001268623,0.0015131929,0.0007562109,0.0002242897,0.0001720961,0.002255452,0.000082742015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.066795275,0.0010906168,0.47674727,0.00014656938,0.00027493906,0.0003381272,0.0048206947,0.0000124211665,0.41257226,0.00005360357,0.0023197036,0.034828514],"study_design_scores_gemma":[0.008336375,0.006859183,0.7845416,0.0005244099,0.00006364265,0.000014769628,0.005797454,0.00023352104,0.17424601,0.00019053242,0.01866441,0.0005280778],"about_ca_topic_score_codex":0.0031723818,"about_ca_topic_score_gemma":0.002201751,"teacher_disagreement_score":0.30779433,"about_ca_system_score_codex":0.0006776267,"about_ca_system_score_gemma":0.002846454,"threshold_uncertainty_score":0.9798942},"labels":[],"label_agreement":null},{"id":"W2160248812","doi":"10.1371/journal.pone.0039236","title":"Performance of an Adipokine Pathway-Based Multilocus Genetic Risk Score for Prostate Cancer Risk Prediction","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Liga Portuguesa Contra o Cancro; Universidade de Coimbra; Cancer Research Society; McGill University","keywords":"Prostate cancer; Adipokine; Oncology; Single-nucleotide polymorphism; Medicine; Internal medicine; Framingham Risk Score; Cancer; Bioinformatics; Biology; Disease; Genotype; Genetics; Obesity; Gene","score_opus":0.05029765333177751,"score_gpt":0.2836790339184392,"score_spread":0.23338138058666166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160248812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99342453,0.0030935006,0.000045816454,0.00006414238,0.00006806424,0.001954104,0.0012415403,0.000063530955,0.000044751418],"genre_scores_gemma":[0.9903444,0.0027635412,0.004964039,0.000021731097,0.0003766109,0.0008289277,0.00021536002,0.00004244354,0.00044294223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862206,0.000049331917,0.00026839497,0.00022579925,0.00040454348,0.00042988273],"domain_scores_gemma":[0.99894065,0.00004832877,0.00017477608,0.00030839242,0.00028460688,0.00024324891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002609952,0.00015451456,0.0002970037,0.00011752839,0.00012048189,0.000006714681,0.000066201355,0.00007863783,0.00007607143],"category_scores_gemma":[0.00007206946,0.00011725034,0.00006381597,0.0001600173,0.0000942773,0.00014563443,0.00001665703,0.00018339173,0.000008698972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026392634,0.0026245732,0.9211936,0.0009272148,0.0003621549,0.0000014626736,0.00043380103,0.00011652268,0.0364956,2.9252178e-7,0.000027628259,0.035177883],"study_design_scores_gemma":[0.0051683527,0.002657803,0.5197723,0.00046606417,0.0007706621,8.6116256e-7,0.00002383622,0.040055364,0.43088356,0.00000390852,0.00008954969,0.00010774378],"about_ca_topic_score_codex":0.00027841196,"about_ca_topic_score_gemma":0.00003097558,"teacher_disagreement_score":0.4014213,"about_ca_system_score_codex":0.00013838772,"about_ca_system_score_gemma":0.00019952405,"threshold_uncertainty_score":0.478133},"labels":[],"label_agreement":null},{"id":"W2160442647","doi":"10.1016/s0090-4295(01)01234-1","title":"Overview consensus statement","year":2001,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Centre hospitalier universitaire de Québec; Université Laval","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Statement (logic); Consensus conference; Family medicine; Library science; Gynecology; Internal medicine; Cancer; Law","score_opus":0.07973751251475603,"score_gpt":0.38903064353366495,"score_spread":0.30929313101890893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160442647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89960814,0.012717919,0.000055080945,0.04312235,0.00020756703,0.0004472387,0.000007223919,0.00007364217,0.043760862],"genre_scores_gemma":[0.98399717,0.0032600323,0.000075047596,0.002495518,0.00008110876,0.000023912837,0.000024950567,0.00000933285,0.010032929],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99942046,0.000030725543,0.00010370911,0.0001268357,0.000093084345,0.00022516011],"domain_scores_gemma":[0.9996847,0.000034810877,0.000017517697,0.00013945065,0.000038605755,0.00008490863],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008542994,0.000057159374,0.00012496873,0.000047371883,0.000028740264,0.0000028337977,0.0000275222,0.00003933403,0.0013545064],"category_scores_gemma":[0.000018199353,0.000040928302,0.00003047817,0.000077963436,0.000070050526,0.0000067534916,0.000022503029,0.00008264653,0.0003329036],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011471327,0.002068166,0.44631588,0.00041399882,0.0013645312,0.018064445,0.0011325979,0.00005579276,0.015396973,0.010579054,0.2685972,0.22454002],"study_design_scores_gemma":[0.0033309567,0.0011279159,0.016274838,0.000006969622,0.000058873145,0.00039891867,0.000031337262,0.00016219978,0.00049135555,0.0006753247,0.97737855,0.00006273944],"about_ca_topic_score_codex":0.000027446384,"about_ca_topic_score_gemma":0.000011075862,"teacher_disagreement_score":0.70878136,"about_ca_system_score_codex":0.00004089495,"about_ca_system_score_gemma":0.00007498245,"threshold_uncertainty_score":0.9995584},"labels":[],"label_agreement":null},{"id":"W2160463964","doi":"10.1158/1078-0432.ccr-14-2666","title":"Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":479,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Prostate cancer; Androgen receptor; Medicine; Cancer research; Prostate; Androgen; Cancer; Castration; Oncology; Internal medicine; Hormone","score_opus":0.2777102049017103,"score_gpt":0.5002984513579463,"score_spread":0.22258824645623598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160463964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96632457,0.021848954,0.000002486555,0.006688684,0.00020609824,0.0017643966,0.00015964519,0.000020551286,0.0029846393],"genre_scores_gemma":[0.9910774,0.0047311005,0.0004935679,0.00007491542,0.00018854311,0.000828277,0.00005086812,0.00004429282,0.002511033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954748,0.0007270283,0.001124717,0.000655677,0.0012300978,0.00078764925],"domain_scores_gemma":[0.9973515,0.00050428696,0.0001681909,0.00067465164,0.00088802027,0.00041332789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042281835,0.00019741838,0.000585645,0.00046220634,0.00010340126,0.000039485356,0.0003325237,0.00021001534,0.00019164452],"category_scores_gemma":[0.0007756774,0.00016398629,0.000121421865,0.0017951607,0.00062814093,0.00015366037,0.00014353069,0.0008565205,0.0000131180705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014288948,0.001833126,0.8154408,0.0009077794,0.00036755772,0.00037592795,0.004047058,0.00015702138,0.13946465,0.00019519833,0.0119435955,0.010978379],"study_design_scores_gemma":[0.060730107,0.003344798,0.80072844,0.0037307744,0.00018329576,0.0000081647495,0.00628937,0.0010280384,0.10290546,0.0056296913,0.014319476,0.0011023654],"about_ca_topic_score_codex":0.0035938337,"about_ca_topic_score_gemma":0.016524069,"teacher_disagreement_score":0.04644116,"about_ca_system_score_codex":0.001139066,"about_ca_system_score_gemma":0.004186588,"threshold_uncertainty_score":0.9220818},"labels":[],"label_agreement":null},{"id":"W2160579552","doi":"10.1046/j.1432-0436.2002.700902.x","title":"Role of stroma in carcinogenesis of the prostate","year":2002,"lang":"en","type":"review","venue":"Differentiation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":307,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Stromal cell; Carcinogenesis; Biology; Stroma; Prostate; Mesenchyme; Cancer research; Endocrinology; Paracrine signalling; Internal medicine; Epithelium; Androgen receptor; Mesenchymal stem cell; Receptor; Cell biology; Prostate cancer; Cancer; Immunology; Medicine; Genetics","score_opus":0.047001206721106435,"score_gpt":0.32937916761819785,"score_spread":0.28237796089709144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160579552","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.039090455,0.95939356,4.2313667e-7,0.000013941242,0.000044413697,0.0010971733,0.00006852257,0.0000041913877,0.00028731243],"genre_scores_gemma":[0.06035227,0.9388374,0.0000047978356,9.982675e-7,0.000021734595,0.000075555814,0.00016184486,0.000017166962,0.0005282109],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99898684,0.00009462259,0.00038146556,0.00014530585,0.00026373236,0.00012805981],"domain_scores_gemma":[0.9993501,0.000031387728,0.00026682662,0.00026416214,0.00006220098,0.000025350266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058144087,0.00013576046,0.0007374586,0.00017394629,0.000013835047,0.000003177143,0.000090056994,0.00010663876,0.000064284264],"category_scores_gemma":[0.00001917692,0.00007332006,0.00025981406,0.0003158666,0.000037978112,0.000017898523,0.000041251955,0.00012831728,0.0000032262878],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030440598,0.00028490025,0.03496525,0.019319545,0.00019961472,0.0000016141892,0.00029018012,2.2604334e-7,0.0002714903,0.00004253611,0.000025778158,0.9445684],"study_design_scores_gemma":[0.005975596,0.00079509994,0.74284285,0.07142277,0.0056448653,0.000022169683,0.00021831147,0.00020963643,0.007352435,0.0002837593,0.16461843,0.00061406987],"about_ca_topic_score_codex":0.000048639216,"about_ca_topic_score_gemma":0.000012976213,"teacher_disagreement_score":0.94395435,"about_ca_system_score_codex":0.0001150835,"about_ca_system_score_gemma":0.000118393466,"threshold_uncertainty_score":0.29899052},"labels":[],"label_agreement":null},{"id":"W2160836548","doi":"10.1016/j.juro.2015.02.2678","title":"MP73-02 PATIENT UNDERSTANDING REGARDING END-OF-LIFE PROSTATE CANCER AND PERSPECTIVES REGARDING COST/BENEFIT OF CURRENT TREATMENT PARADIGMS","year":2015,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Cancer; Disease; Intensive care medicine; Gynecology; Internal medicine","score_opus":0.1703892608237261,"score_gpt":0.3726092766225729,"score_spread":0.20222001579884682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160836548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91905063,0.07532132,0.00009386155,0.004273565,0.00025890546,0.00044404293,0.000016284122,0.0000050774647,0.0005363154],"genre_scores_gemma":[0.97411704,0.025602197,0.00004038183,0.000027451166,0.00011440507,0.000009503301,0.0000015585699,0.000014923999,0.000072528994],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9986862,0.00013407608,0.00044102132,0.00012591516,0.00034539486,0.00026740317],"domain_scores_gemma":[0.9986096,0.00020994896,0.0005057301,0.00015546262,0.0002963878,0.00022286836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004581156,0.00014808887,0.0005287884,0.00020214077,0.00007069676,0.000007466408,0.0000817541,0.00004840849,0.000018910765],"category_scores_gemma":[0.00011163659,0.00007971474,0.000102282116,0.00013988077,0.00033520005,0.00008394168,0.000048781552,0.00023053249,4.8992655e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06681525,0.002141787,0.5595449,0.00058516214,0.006179318,0.0003430022,0.17600416,0.003909041,0.0101678325,0.010699325,0.002810548,0.16079967],"study_design_scores_gemma":[0.20827083,0.15690205,0.09608603,0.0055652326,0.014462371,0.0070482097,0.2949411,0.0046874443,0.08134659,0.037995186,0.09035283,0.0023421452],"about_ca_topic_score_codex":0.00009251658,"about_ca_topic_score_gemma":0.000023828048,"teacher_disagreement_score":0.4634589,"about_ca_system_score_codex":0.00067036034,"about_ca_system_score_gemma":0.00051594456,"threshold_uncertainty_score":0.32506725},"labels":[],"label_agreement":null},{"id":"W2161245944","doi":"10.1158/0008-5472.can-07-6055","title":"Activator Protein-1 Transcription Factors Are Associated with Progression and Recurrence of Prostate Cancer","year":2008,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":146,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Prostate cancer; MAPK/ERK pathway; Cancer research; PTEN; Cancer; Transcription factor; Prostate; Biology; Activator (genetics); Signal transduction; Kinase; Medicine; Internal medicine; PI3K/AKT/mTOR pathway; Gene; Cell biology; Genetics","score_opus":0.11784495281120548,"score_gpt":0.4152820933890138,"score_spread":0.2974371405778083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161245944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907342,0.005593304,0.000001657255,0.0010384526,0.000038311744,0.0022629024,0.00012708026,0.00003913078,0.00016494961],"genre_scores_gemma":[0.99155366,0.004230892,0.000027946544,0.00000887363,0.000051720875,0.0011232257,0.000037423746,0.000035002584,0.0029312314],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974955,0.00016774966,0.00020039822,0.00042275377,0.0011396442,0.00057400926],"domain_scores_gemma":[0.99847674,0.00007117808,0.00011037811,0.00021481192,0.00085661525,0.00027026737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035904435,0.00017786134,0.00035584005,0.00024061347,0.0002998246,0.000018257533,0.0001008894,0.000112746646,0.00014526625],"category_scores_gemma":[0.00012493749,0.00011096656,0.000043131815,0.0008020785,0.0008061183,0.00018645922,0.0000416788,0.00058863393,0.0000013910903],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042549814,0.0004351634,0.7068067,0.000702451,0.00023007201,0.00011288598,0.0034087636,0.0000019074907,0.27300897,0.000012039646,0.0007448264,0.010281189],"study_design_scores_gemma":[0.0039704507,0.0016094231,0.42876598,0.0040989323,0.000037079575,0.000008338183,0.0006233058,0.000017226192,0.5596915,0.000027753902,0.00096800714,0.00018201604],"about_ca_topic_score_codex":0.0004831829,"about_ca_topic_score_gemma":0.00015921655,"teacher_disagreement_score":0.28668252,"about_ca_system_score_codex":0.0004747341,"about_ca_system_score_gemma":0.0010953487,"threshold_uncertainty_score":0.45250848},"labels":[],"label_agreement":null},{"id":"W2161615846","doi":"10.1530/erc-13-0165","title":"GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer","year":2014,"lang":"en","type":"review","venue":"Endocrine Related Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Wilfrid Laurier University; Université du Québec","funders":"","keywords":"Enzalutamide; Prostate cancer; Antiandrogen; Blockade; Medicine; Androgen; Bicalutamide; Castration; Oncology; Prostate; Internal medicine; Metastasis; Androgen receptor; Cancer; Endocrinology; Hormone; Receptor","score_opus":0.039029580951642,"score_gpt":0.366636645280232,"score_spread":0.32760706432859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161615846","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008321924,0.9866593,2.1182177e-7,0.0010089995,0.00022451676,0.003300819,0.00014900345,0.000045013767,0.00029023932],"genre_scores_gemma":[0.0030102897,0.99091667,0.00003022678,0.000055777353,0.0001186041,0.0011602837,0.00018538606,0.00011308967,0.0044097],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966511,0.0006089157,0.0010494067,0.0005997635,0.0004404697,0.0006503023],"domain_scores_gemma":[0.99791497,0.0006527844,0.0005306886,0.00054386875,0.00015648022,0.00020123027],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052092003,0.0005658016,0.002772926,0.00037897477,0.00010172422,0.00004942158,0.0001819178,0.0001981379,0.0001774662],"category_scores_gemma":[0.00019042421,0.00031906296,0.00037882084,0.00082887703,0.00058191665,0.000095220115,0.00017608728,0.0010806829,0.0000073395368],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033585855,0.00019739622,0.006641437,0.025254246,0.0029404748,0.00053748867,0.00042146994,0.00001631117,0.000018936,0.00017496897,0.00090111495,0.95953757],"study_design_scores_gemma":[0.015025156,0.00020601843,0.00030672993,0.031810638,0.0027340073,0.00037803006,0.0000145952545,0.000093912,0.00010888406,0.000054505137,0.94886845,0.00039908252],"about_ca_topic_score_codex":0.0063709947,"about_ca_topic_score_gemma":0.00023695342,"teacher_disagreement_score":0.9591385,"about_ca_system_score_codex":0.00050775456,"about_ca_system_score_gemma":0.0010687024,"threshold_uncertainty_score":0.99992615},"labels":[],"label_agreement":null},{"id":"W2162609598","doi":"10.1016/j.urology.2015.05.001","title":"Associate Editor for Review Articles: Dr. Fred Saad","year":2015,"lang":"en","type":"editorial","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; University hospital; Family medicine; Medical education; Cancer; Internal medicine","score_opus":0.03741670231248764,"score_gpt":0.3850939817575772,"score_spread":0.3476772794450895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162609598","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014368313,0.089857645,0.0000152399725,0.011573221,0.8956187,0.0014517715,0.00050470803,0.0000711677,0.00089318404],"genre_scores_gemma":[0.000012978015,0.019032678,0.000041210158,0.00082765066,0.9554052,0.0004845116,0.0022939441,0.000060557693,0.021841267],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979469,0.00011251917,0.0003339131,0.000427628,0.0006200781,0.0005589304],"domain_scores_gemma":[0.9975871,0.00073712476,0.00017271309,0.00038504336,0.00087496615,0.00024306471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079605944,0.00024268338,0.0008934992,0.000090750196,0.000054430126,0.000011857449,0.00017085906,0.00091127644,0.00016917232],"category_scores_gemma":[0.0039665727,0.00018069947,0.00020800624,0.000117943935,0.00011175407,0.000028368499,0.00006967081,0.00067770074,0.0002585161],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006523796,0.00009677815,0.000018695999,0.0013585689,0.00029187923,0.000044551518,0.000034600893,8.859197e-8,0.000014098235,0.0000026793773,0.99562716,0.0018584944],"study_design_scores_gemma":[0.0036892402,0.0017443197,0.0000035179214,0.0003725485,0.00077886187,0.0000027342894,0.0000044767507,0.000011382337,0.000021409098,0.00033057676,0.9928998,0.00014117241],"about_ca_topic_score_codex":0.000029372295,"about_ca_topic_score_gemma":0.000016803044,"teacher_disagreement_score":0.070824966,"about_ca_system_score_codex":0.00033332178,"about_ca_system_score_gemma":0.0013858426,"threshold_uncertainty_score":0.73687106},"labels":[],"label_agreement":null},{"id":"W2162873294","doi":"10.1016/j.ijrobp.2007.03.008","title":"Racial Differences in CYP3A4 Genotype and Survival Among Men Treated on Radiation Therapy Oncology Group (RTOG) 9202: A Phase III Randomized Trial","year":2007,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute","keywords":"Medicine; Goserelin; Oncology; Internal medicine; Prostate cancer; Genotype; CYP3A4; Radiation therapy; Flutamide; Androgen deprivation therapy; Cancer","score_opus":0.03757494381200668,"score_gpt":0.3919237120000965,"score_spread":0.35434876818808986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162873294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914193,0.00089151284,0.0013689245,0.0014469053,0.0017610118,0.001364753,0.000024994428,0.00002620769,0.001696356],"genre_scores_gemma":[0.9910757,0.0053300415,0.00015454537,0.00028158506,0.0027745373,0.000057084497,0.00019418175,0.00002386143,0.000108471606],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970242,0.0007890682,0.0011176593,0.00030431015,0.00042182487,0.0003429478],"domain_scores_gemma":[0.9964472,0.0017934458,0.0010373384,0.00011038411,0.00041833703,0.00019329901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025701225,0.00026015833,0.0011710142,0.0004930777,0.00008803247,0.00003174587,0.00021832838,0.0003815216,0.00009479743],"category_scores_gemma":[0.00044833097,0.00018707693,0.00025164784,0.00025004355,0.00044032358,0.00022472856,0.000034015786,0.0006240636,0.0000061310247],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6051795,0.0017180317,0.073303446,0.0000032829093,0.0008755437,0.0001496317,0.0010721548,0.000007555313,0.0021210895,0.002033009,0.00009253322,0.31344423],"study_design_scores_gemma":[0.9424741,0.01120038,0.037338443,0.000043301865,0.00014825174,0.00003696938,0.00015141194,0.0011621629,0.0016431735,0.0024915193,0.0031230692,0.00018716752],"about_ca_topic_score_codex":0.00013135988,"about_ca_topic_score_gemma":0.00004411062,"teacher_disagreement_score":0.33729464,"about_ca_system_score_codex":0.0010400211,"about_ca_system_score_gemma":0.0005448082,"threshold_uncertainty_score":0.7628776},"labels":[],"label_agreement":null},{"id":"W2163019678","doi":"10.1016/j.ijrobp.2006.12.072","title":"Mature Results of the Ottawa Phase II Study of Intermittent Androgen-Suppression Therapy in Prostate Cancer: Clinical Predictors of Outcome","year":2007,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Élisabeth Bruyère Hospital; Public Health Agency of Canada; Ottawa Hospital; Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Androgen suppression; Androgen; Internal medicine; Prostate-specific antigen; Oncology; Hormone therapy; Hormonal therapy; Urology; Prostate; Cancer; Hormone; Breast cancer","score_opus":0.048834709129808196,"score_gpt":0.4435373269500958,"score_spread":0.3947026178202876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163019678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99492615,0.00073921715,0.000035552064,0.0014677196,0.0018842125,0.0006831874,0.00015903835,0.0000053451276,0.00009958697],"genre_scores_gemma":[0.997591,0.0015558585,0.000101591446,0.000106164174,0.00051931106,0.000009092665,0.00003144655,0.0000136766075,0.00007185611],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99697053,0.00032440817,0.0018913265,0.00018385507,0.00045316407,0.0001767338],"domain_scores_gemma":[0.99628663,0.00040822363,0.0021195288,0.00019509967,0.0009084765,0.00008206695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017369926,0.00014555015,0.000645174,0.00020972344,0.000033729128,0.000003293522,0.00037723835,0.00016992456,0.000015660687],"category_scores_gemma":[0.00033671502,0.000086086555,0.00024710275,0.00024877876,0.00028199278,0.000105807776,0.00009961046,0.00056579674,3.4909186e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010381077,0.0053110104,0.86140853,0.000014444961,0.0006974224,0.000031222342,0.0022592163,0.000094572286,0.006027661,0.00004682075,0.0004109307,0.1133171],"study_design_scores_gemma":[0.06896401,0.021490257,0.8661397,0.00030852918,0.00014869978,0.000039198123,0.0007766225,0.00021751097,0.037140053,0.00034338786,0.004321151,0.00011089112],"about_ca_topic_score_codex":0.000075213815,"about_ca_topic_score_gemma":0.000040028404,"teacher_disagreement_score":0.11320621,"about_ca_system_score_codex":0.0003255061,"about_ca_system_score_gemma":0.00046633737,"threshold_uncertainty_score":0.35105076},"labels":[],"label_agreement":null},{"id":"W2164293187","doi":"10.2174/1389450033491190","title":"Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer","year":2003,"lang":"en","type":"review","venue":"Current Drug Targets","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital; Vancouver Hospital and Health Sciences Centre","funders":"","keywords":"Prostate cancer; Cytotoxic T cell; Medicine; Cancer; Prostate; Cancer research; Hormone; Bioinformatics; Oncology; Internal medicine; Biology; Genetics","score_opus":0.036915335263146304,"score_gpt":0.40830706003666606,"score_spread":0.3713917247735198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164293187","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0057292082,0.9875639,0.0000029972264,0.00034934207,0.000724191,0.005164204,0.00028191126,0.00006629364,0.00011792895],"genre_scores_gemma":[0.0004748192,0.99364245,0.00022767359,0.00006401202,0.00016600177,0.0020676332,0.00028066227,0.00012690583,0.0029498318],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964292,0.00021837142,0.0007437582,0.0011111061,0.0004937008,0.0010038856],"domain_scores_gemma":[0.9985091,0.00009420621,0.00024385177,0.0005167345,0.00014783072,0.00048825145],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003427572,0.0008151476,0.002255529,0.0005609564,0.00012143892,0.00005153387,0.00018230875,0.00017386067,0.00008057062],"category_scores_gemma":[0.000065303146,0.0005881044,0.0002683255,0.000775157,0.00014929273,0.00014265165,0.0001364212,0.00085252436,0.000087460394],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020084735,0.0003065174,0.00022521718,0.012733885,0.00019533606,0.00017721456,0.0010649355,5.0199264e-7,0.00018011004,0.000007718951,0.003947823,0.9809599],"study_design_scores_gemma":[0.0013346332,0.00018300982,0.0001657114,0.016869923,0.00025247753,0.000022462504,0.000048617727,0.0000016659955,0.0004309898,0.000041608924,0.9800433,0.00060562376],"about_ca_topic_score_codex":0.000026908656,"about_ca_topic_score_gemma":0.000032929223,"teacher_disagreement_score":0.98035425,"about_ca_system_score_codex":0.0005761976,"about_ca_system_score_gemma":0.0007293446,"threshold_uncertainty_score":0.99965703},"labels":[],"label_agreement":null},{"id":"W2164426377","doi":"10.1016/j.urology.2007.06.400","title":"MP-11.17: Pathological review of radical prostatectomy specimens identifies patients who benefit most from immediate post-operative irradiation (EORTC 22911)","year":2007,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Prostatectomy; Pathological; Prostate cancer; Urology; Prostate; Radiation therapy; Surgery; Cancer; Internal medicine","score_opus":0.014740813218361067,"score_gpt":0.3123823542019757,"score_spread":0.2976415409836146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164426377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785852,0.014516568,0.000058111207,0.00343457,0.00027202917,0.0014130849,0.00030314887,0.000041486463,0.0013758163],"genre_scores_gemma":[0.9783012,0.013413913,0.00017803593,0.004125,0.00028111154,0.000083146144,0.0025379357,0.00003432133,0.001045307],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977915,0.00012438837,0.00062839955,0.00047883426,0.0004578267,0.0005190342],"domain_scores_gemma":[0.99852693,0.00025727783,0.00019570383,0.0003142696,0.00048157413,0.0002242555],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047517876,0.0002328735,0.0006524119,0.00016675808,0.00008504668,0.000010907535,0.00013266396,0.00022301124,0.0010718001],"category_scores_gemma":[0.00038334334,0.00016541059,0.000120450604,0.0002840496,0.00038074315,0.0001018829,0.00009694281,0.00033303586,0.000085945554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011812529,0.0042464132,0.86055714,0.0027887644,0.0011505246,0.002755362,0.0047569955,0.000018845254,0.037329998,0.0014736693,0.021295005,0.05181474],"study_design_scores_gemma":[0.005837501,0.003112459,0.97270703,0.00051366613,0.00026210738,0.000025982466,0.000079903555,0.000042087187,0.0059503494,0.0004212331,0.010815436,0.00023225724],"about_ca_topic_score_codex":0.000101376194,"about_ca_topic_score_gemma":0.000060305134,"teacher_disagreement_score":0.112149864,"about_ca_system_score_codex":0.00012617557,"about_ca_system_score_gemma":0.00012884376,"threshold_uncertainty_score":0.99984133},"labels":[],"label_agreement":null},{"id":"W2164566492","doi":"10.1158/0008-5472.can_10-3398","title":"Small Molecule Inhibitors Targeting the “Achilles' Heel” of Androgen Receptor Activity","year":2011,"lang":"en","type":"review","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"DOD Prostate Cancer Research Program; National Cancer Institute; Medical Research and Materiel Command; Canadian Institutes of Health Research","keywords":"Androgen receptor; Prostate cancer; Medicine; Transactivation; Cancer; Androgen; Androgen Receptor Antagonists; Cancer research; Androgen deprivation therapy; Pharmacology; Internal medicine; Hormone; Chemistry; Biochemistry","score_opus":0.2289123433616003,"score_gpt":0.4516203472506589,"score_spread":0.22270800388905862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164566492","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034349775,0.9896374,0.0000011578273,0.00031484108,0.00024070567,0.0032210052,0.00016345968,0.000034006316,0.002952468],"genre_scores_gemma":[0.00055003917,0.99254924,0.000027595574,0.000011888261,0.00070045475,0.0013330522,0.000111885725,0.00012680537,0.0045890445],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99584174,0.000965621,0.0005337715,0.00070973416,0.0009367885,0.0010123539],"domain_scores_gemma":[0.99754,0.00037845457,0.00024831155,0.0008763478,0.0006150255,0.00034187612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002095735,0.0004214686,0.0015277298,0.00046856227,0.00031499838,0.000039701175,0.0006364045,0.00039561462,0.00089838676],"category_scores_gemma":[0.00020229425,0.00023274777,0.00061752304,0.0012883631,0.0007580658,0.000055282177,0.00051055505,0.002163919,0.00012887348],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025001465,0.00019291352,0.000081765385,0.016560124,0.00074155,0.000041741077,0.0003551642,5.8019683e-8,0.00043963332,0.00004054566,0.015198392,0.96609807],"study_design_scores_gemma":[0.0006201563,0.0003474503,0.000005697195,0.008772374,0.00030493413,0.000011769437,0.00012975863,5.584612e-7,0.010932561,0.000011038567,0.9786497,0.00021400153],"about_ca_topic_score_codex":0.0014720933,"about_ca_topic_score_gemma":0.000048704616,"teacher_disagreement_score":0.9658841,"about_ca_system_score_codex":0.00081994507,"about_ca_system_score_gemma":0.0043214904,"threshold_uncertainty_score":0.98367053},"labels":[],"label_agreement":null},{"id":"W2165542862","doi":"10.1200/jco.2007.12.4008","title":"Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Docetaxel; Mitoxantrone; Prednisone; Prostate cancer; Internal medicine; Urology; Survival analysis; Surgery; Oncology; Cancer; Chemotherapy","score_opus":0.20676789271621865,"score_gpt":0.5167604900016837,"score_spread":0.309992597285465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165542862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974713,0.0027082488,0.00006985968,0.017001703,0.001462082,0.0035992416,0.000066397624,0.000018153296,0.000361289],"genre_scores_gemma":[0.98142266,0.008455556,0.001385774,0.00077120087,0.001422002,0.00030698892,0.000023227036,0.000042837302,0.0061697457],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9942851,0.00099088,0.0027223425,0.00041445647,0.00089960586,0.00068759645],"domain_scores_gemma":[0.99424523,0.002771704,0.0014208771,0.0003801434,0.0007916718,0.0003903717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045718937,0.0002888795,0.0023629623,0.00020041993,0.00018180477,0.000018434077,0.00046124574,0.00032010593,0.00012747008],"category_scores_gemma":[0.002215875,0.00014776443,0.0004292662,0.00048626825,0.0004479719,0.00021415002,0.000092367016,0.0014098625,0.000008555526],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49875766,0.023978107,0.29092452,0.00026995083,0.0034496777,0.013247127,0.009835739,0.0009790984,0.0006565691,0.00003900536,0.044140358,0.11372218],"study_design_scores_gemma":[0.29112107,0.122660264,0.4361692,0.00034545487,0.00137869,0.0011819766,0.008484102,0.0011277983,0.00030725304,0.00019777715,0.13655102,0.00047540772],"about_ca_topic_score_codex":0.00017276965,"about_ca_topic_score_gemma":0.0010640036,"teacher_disagreement_score":0.2076366,"about_ca_system_score_codex":0.0007896245,"about_ca_system_score_gemma":0.007858319,"threshold_uncertainty_score":0.9977662},"labels":[],"label_agreement":null},{"id":"W2165688222","doi":"10.1054/bjoc.2001.1883","title":"Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer","year":2001,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Prostate cancer; Androgen; Identification (biology); Prostate; Biology; Gene expression; Cancer; Cancer research; Differential (mechanical device); Differential display; Medicine; Endocrinology; Gene; Genetics; Hormone","score_opus":0.019773230577731435,"score_gpt":0.30706366908218485,"score_spread":0.2872904385044534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165688222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677405,0.031333815,0.0000517866,0.0002448284,0.00010043046,0.00045908804,0.000049726532,0.0000037847751,0.000016053586],"genre_scores_gemma":[0.95743626,0.041849677,0.00009438904,0.00000713484,0.00006183749,0.000029068824,0.000014002496,0.000014842878,0.0004927926],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985509,0.000072908755,0.0006778588,0.00015916069,0.00038285853,0.00015630115],"domain_scores_gemma":[0.9990181,0.0000224121,0.0004534286,0.00007883253,0.00032701655,0.00010025451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023030356,0.00009830725,0.000366299,0.0001780863,0.00004147876,0.000022591918,0.000043174387,0.00007222239,0.00010526254],"category_scores_gemma":[0.000028339035,0.000085205655,0.000048491533,0.0001928401,0.0001406616,0.00025062117,0.00001603469,0.0001476448,4.9712735e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022247669,0.00015252712,0.10312243,0.0004435524,0.00005137456,0.00005710859,0.0007052911,0.000030484909,0.8204638,0.0000013951591,0.00017952202,0.072567776],"study_design_scores_gemma":[0.0057948725,0.00022473444,0.458657,0.005082383,0.000103173166,0.0002318576,0.000123831,0.000217901,0.52904373,0.00012318337,0.00032044644,0.00007689573],"about_ca_topic_score_codex":0.0002254548,"about_ca_topic_score_gemma":0.0001564562,"teacher_disagreement_score":0.35553455,"about_ca_system_score_codex":0.00006657497,"about_ca_system_score_gemma":0.0001573622,"threshold_uncertainty_score":0.34745857},"labels":[],"label_agreement":null},{"id":"W2165886955","doi":"10.3747/co.v17i0.711","title":"Intermittent versus Continuous Androgen Suppression Therapy: Do We Have Consensus Yet?","year":2010,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Androgen suppression; Androgen; Oncology; Randomized controlled trial; Internal medicine; Cancer; Hormone","score_opus":0.13149632642867348,"score_gpt":0.44745394474907985,"score_spread":0.31595761832040636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165886955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9694242,0.0129815005,0.0000028833035,0.0051184404,0.006628016,0.00074900937,0.000027956628,0.00006909051,0.0049989047],"genre_scores_gemma":[0.9927201,0.005354095,0.00009298905,0.000055324377,0.0004673073,0.0001051819,0.00007091187,0.000025776908,0.001108262],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987167,0.00008849285,0.0002313284,0.0003351446,0.0002198554,0.00040845195],"domain_scores_gemma":[0.99892384,0.00022966841,0.00008427877,0.00032822965,0.00017623561,0.00025775266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001774125,0.00018088106,0.00038214985,0.00011726822,0.00008566796,0.000019076413,0.00012492317,0.00018550425,0.00075400324],"category_scores_gemma":[0.00010408875,0.00012237145,0.000120504075,0.000077138,0.00031501718,0.000023748935,0.00009531098,0.0006519664,0.00011987728],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065954523,0.0011164529,0.03577216,0.000052261454,0.00017255335,0.00032854406,0.0007723355,9.139422e-8,0.019384181,0.00013877718,0.038480673,0.8971865],"study_design_scores_gemma":[0.018718095,0.0025239103,0.0045096595,0.000113563205,0.00007893767,0.00014062547,0.00043919074,0.000058474794,0.016231881,0.00018510855,0.956841,0.0001595505],"about_ca_topic_score_codex":0.000010580876,"about_ca_topic_score_gemma":0.000023864339,"teacher_disagreement_score":0.91836035,"about_ca_system_score_codex":0.00014967787,"about_ca_system_score_gemma":0.00033448386,"threshold_uncertainty_score":0.8255807},"labels":[],"label_agreement":null},{"id":"W2166339241","doi":"10.1016/j.eururo.2014.07.020","title":"Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":336,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Oncology; Cancer; Proportional hazards model; Lymph node; Epidemiology; Prostate","score_opus":0.01796808666336216,"score_gpt":0.3020701490429054,"score_spread":0.2841020623795433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166339241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969934,0.00010370612,0.000002710273,0.00022745962,0.000045142686,0.00038186,0.000116821575,0.0000054703796,0.0021234083],"genre_scores_gemma":[0.99960786,0.000023091046,0.000020036445,0.000082883795,0.000013480073,0.0000058980463,0.000026487736,0.000020918538,0.00019934028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987027,0.0005549802,0.00018532154,0.00015422213,0.0002053342,0.00019741734],"domain_scores_gemma":[0.9993786,0.00010280244,0.000116208765,0.00025782478,0.000096868316,0.000047695463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030173495,0.00010531895,0.0002774545,0.00009745525,0.000016867154,0.0000020307211,0.000070448936,0.000009948977,0.000068430876],"category_scores_gemma":[0.00008627484,0.00004869792,0.000066967485,0.00020089853,0.00016913828,0.000020478636,0.000044326665,0.00012950914,0.00000917983],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032519593,0.00037244972,0.9923068,0.000037754384,0.00018440919,0.00001087001,0.00027835433,0.00034429345,0.00041454093,0.000026457144,0.000096910524,0.00267517],"study_design_scores_gemma":[0.00499262,0.0043155816,0.989747,0.00003419868,0.00009125277,8.932292e-7,0.00000584013,0.00002674793,0.00042047517,0.0000079029705,0.00031487236,0.00004263115],"about_ca_topic_score_codex":0.00015234928,"about_ca_topic_score_gemma":0.000058140384,"teacher_disagreement_score":0.003943132,"about_ca_system_score_codex":0.00003405974,"about_ca_system_score_gemma":0.00007788629,"threshold_uncertainty_score":0.19858435},"labels":[],"label_agreement":null},{"id":"W2166368669","doi":"10.1016/j.ccr.2006.03.031","title":"NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss","year":2006,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"National Cancer Institute","keywords":"PTEN; Cancer research; Protein kinase B; Prostate cancer; Androgen receptor; Biology; PI3K/AKT/mTOR pathway; Cell growth; Prostate; Transcription factor; Suppressor; Programmed cell death; Tumor suppressor gene; Signal transduction; Apoptosis; Cancer; Cell biology; Carcinogenesis","score_opus":0.015248493543788669,"score_gpt":0.29081336166915916,"score_spread":0.2755648681253705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166368669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775654,0.014061335,0.000019527173,0.0030566854,0.0001308757,0.0009449778,0.00022583743,0.000075096206,0.0039202627],"genre_scores_gemma":[0.97787285,0.0058263144,0.000023994802,0.00033913087,0.00029147117,0.00045127267,0.00030527555,0.000042688247,0.014846997],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99855644,0.000033443604,0.0002634534,0.00040872116,0.0003340057,0.00040396355],"domain_scores_gemma":[0.9992228,0.000046667352,0.00011566101,0.00019186028,0.00027013806,0.00015288308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009653765,0.00021707921,0.0002665757,0.00007002527,0.00014428729,0.000047593727,0.00005318204,0.00011015843,0.0005562002],"category_scores_gemma":[0.000010940792,0.000175346,0.000042210635,0.00024055554,0.00014638786,0.00023934018,0.00003705406,0.00017850293,0.0000070915116],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012668469,0.0005865919,0.39002165,0.00092838757,0.0001803216,0.000045362845,0.0023959514,0.00008722229,0.49864155,0.000036428926,0.08984761,0.015962053],"study_design_scores_gemma":[0.0073400857,0.0002226947,0.024993384,0.00025780592,0.00013148783,0.0000028288318,0.00026592478,0.000117622,0.9221778,0.00016488148,0.04400814,0.00031737902],"about_ca_topic_score_codex":0.0038882557,"about_ca_topic_score_gemma":0.0006417879,"teacher_disagreement_score":0.4235362,"about_ca_system_score_codex":0.0005837422,"about_ca_system_score_gemma":0.0004155526,"threshold_uncertainty_score":0.7150402},"labels":[],"label_agreement":null},{"id":"W2166435610","doi":"10.1158/1535-7163.mct-13-0032","title":"Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression <i>In Vivo</i>","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Bicalutamide; LNCaP; Prostate cancer; Androgen receptor; Protein kinase B; Antiandrogen; Cancer research; In vivo; PI3K/AKT/mTOR pathway; Medicine; Growth inhibition; Androgen; Internal medicine; Pharmacology; Endocrinology; Cell growth; Cancer; Apoptosis; Chemistry; Biology; Biochemistry","score_opus":0.02192626339959827,"score_gpt":0.3056647247005957,"score_spread":0.28373846130099745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166435610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9653983,0.03087084,0.00007826467,0.0014303819,0.000106348416,0.0016517851,0.00014913289,0.000033020722,0.00028193503],"genre_scores_gemma":[0.9929308,0.0046998924,0.0007717267,0.0002844917,0.000054090488,0.0007427852,0.000041036266,0.000057605448,0.00041755658],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981289,0.000096264645,0.0004336478,0.00041441267,0.00045063984,0.0004761158],"domain_scores_gemma":[0.99907845,0.000041660052,0.0001664013,0.00024204202,0.0003014837,0.00016994453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017355489,0.0002622982,0.0003915486,0.0001250779,0.00008846534,0.000042699365,0.00009604353,0.00012034269,0.00027609983],"category_scores_gemma":[0.000013465471,0.00020007549,0.00007422073,0.0003465416,0.00019477269,0.00009484659,0.000043042073,0.0002167969,0.000003800561],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055032753,0.00016258362,0.014216863,0.0003391755,0.00021033912,0.00006634318,0.00087241776,0.00006437539,0.9550372,0.000041921918,0.00014034401,0.02829814],"study_design_scores_gemma":[0.0027007118,0.0006244005,0.0014518556,0.0006452801,0.00013996144,0.0000034611821,0.00043061312,0.00082212774,0.98887134,0.00013949526,0.003890912,0.00027984814],"about_ca_topic_score_codex":0.0010385856,"about_ca_topic_score_gemma":0.000104171806,"teacher_disagreement_score":0.033834163,"about_ca_system_score_codex":0.00022519325,"about_ca_system_score_gemma":0.00047836974,"threshold_uncertainty_score":0.8158842},"labels":[],"label_agreement":null},{"id":"W2166437348","doi":"10.18632/oncotarget.2809","title":"Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer","year":2014,"lang":"en","type":"article","venue":"Oncotarget","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada; BC Cancer Foundation; Prostate Cancer Foundation","keywords":"Prostate cancer; Medicine; Cancer; Biomarker; Oncology; Cancer research; Internal medicine; Biology","score_opus":0.016653923210047637,"score_gpt":0.3400973932915227,"score_spread":0.32344347008147506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166437348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821994,0.0032088396,0.0030686134,0.008324015,0.0005057124,0.0018183027,0.0001265017,0.0000677407,0.00068090745],"genre_scores_gemma":[0.9874505,0.0005715199,0.00045645068,0.00029427808,0.00020157284,0.000334931,0.0001377152,0.00003403859,0.010519043],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99884546,0.000042687887,0.00028181472,0.00025814024,0.00026975176,0.0003021239],"domain_scores_gemma":[0.9992651,0.000041023868,0.000121395715,0.00023931856,0.00022590582,0.00010727218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016154221,0.00012684969,0.00025410188,0.000094103154,0.00007172016,0.00001640293,0.000084939355,0.000025940255,0.00017136498],"category_scores_gemma":[0.00005639999,0.00009675828,0.00011425398,0.00014409125,0.00007994826,0.0000709532,0.000022219456,0.000092167254,0.000026157119],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005840372,0.0009782583,0.08728633,0.0012183563,0.00054175535,0.000053665604,0.00058779516,0.00027034114,0.83980834,0.0018018739,0.007718995,0.05389391],"study_design_scores_gemma":[0.0151495505,0.00436049,0.06517578,0.00018696702,0.00051108416,0.00007533508,0.00015486058,0.016086644,0.7037287,0.013790668,0.18035328,0.00042666454],"about_ca_topic_score_codex":0.000074845,"about_ca_topic_score_gemma":0.0000049984324,"teacher_disagreement_score":0.17263429,"about_ca_system_score_codex":0.000064991465,"about_ca_system_score_gemma":0.0001810629,"threshold_uncertainty_score":0.39456883},"labels":[],"label_agreement":null},{"id":"W2166535645","doi":"10.2174/1573406411666150212120628","title":"New Testosterone Derivatives as Semi-Synthetic Anticancer Agents Against Prostate Cancer: Synthesis and Preliminary Biological Evaluation","year":2015,"lang":"en","type":"article","venue":"Medicinal Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières","funders":"","keywords":"Cyproterone acetate; Prostate cancer; Antiandrogen; Testosterone (patch); Medicine; Abiraterone acetate; LNCaP; Bicalutamide; Androgen; Hormone; Pharmacology; Cancer; Internal medicine; Oncology; Androgen deprivation therapy; Androgen receptor","score_opus":0.08506915519158377,"score_gpt":0.3664941828855822,"score_spread":0.28142502769399846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166535645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751023,0.013341753,0.000011838332,0.0051618107,0.00008039797,0.000643928,0.000016438833,0.00005585426,0.005585657],"genre_scores_gemma":[0.992988,0.003220427,0.00017965963,0.00026612228,0.00032533673,0.00027104942,0.000067061155,0.00002401404,0.002658354],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980928,0.00006378063,0.0002448398,0.00046087816,0.0007638912,0.00037386734],"domain_scores_gemma":[0.99868965,0.00013194274,0.00009150158,0.00024329631,0.00022566486,0.00061792845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045878944,0.0002369954,0.00036727975,0.000043392396,0.00007691127,0.000019904708,0.00009792271,0.00013529467,0.00058378174],"category_scores_gemma":[0.00088338676,0.00016333746,0.000041814237,0.0001769402,0.00031326065,0.000071164905,0.00008745226,0.00024089857,0.000017285724],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066896733,0.00048451952,0.20696141,0.0010110189,0.00053208263,0.0005602283,0.0041234987,0.000022530638,0.28828445,0.0000029014964,0.01451616,0.47681153],"study_design_scores_gemma":[0.012473909,0.002357712,0.083317704,0.003448843,0.0009933232,0.00046375475,0.004464695,0.00195082,0.8807242,0.00040826565,0.00869923,0.00069757196],"about_ca_topic_score_codex":0.00011711232,"about_ca_topic_score_gemma":0.0000013187978,"teacher_disagreement_score":0.5924397,"about_ca_system_score_codex":0.0003722813,"about_ca_system_score_gemma":0.0010067519,"threshold_uncertainty_score":0.6660708},"labels":[],"label_agreement":null},{"id":"W2166594813","doi":"10.1158/1078-0432.ccr-13-1869","title":"Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Marsden Fund; Pfizer; Prostate Cancer Foundation","keywords":"Medicine; Docetaxel; Prostate cancer; Clinical endpoint; Internal medicine; Adverse effect; Prednisone; Urology; Phases of clinical research; Oncology; Chemotherapy; Cancer; Randomized controlled trial; Surgery; Gastroenterology","score_opus":0.21302490922324202,"score_gpt":0.5482458703631305,"score_spread":0.33522096113988853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166594813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836788,0.0031454463,0.000058862977,0.0021199987,0.00010708445,0.008891455,0.0018143333,0.000027476297,0.00015654655],"genre_scores_gemma":[0.98934793,0.0019641495,0.00029254126,0.000098614495,0.00023120083,0.0048088823,0.00022794187,0.00005148213,0.0029772245],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99492025,0.00083992176,0.0011665577,0.00086037046,0.0013823245,0.0008305453],"domain_scores_gemma":[0.9943169,0.0026528186,0.00029552935,0.0005938513,0.001627518,0.00051343057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056007365,0.0003117931,0.0017485755,0.00026307744,0.00048719856,0.00010175961,0.00022007283,0.0001034929,0.0002198402],"category_scores_gemma":[0.0013886486,0.00019010625,0.00021475667,0.0005774335,0.0016631237,0.0001761309,0.0001660303,0.0007057824,0.0000030330043],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9515752,0.009695532,0.0031571116,0.0014455082,0.0024995813,0.00009357027,0.0023847169,0.000089927766,0.0017244968,0.00014161966,0.0072392984,0.019953432],"study_design_scores_gemma":[0.9513122,0.033263974,0.0020860406,0.00054016896,0.001048665,0.000008831468,0.000939734,0.0021519237,0.0020190359,0.00048172046,0.005824029,0.00032371996],"about_ca_topic_score_codex":0.0033744362,"about_ca_topic_score_gemma":0.002099833,"teacher_disagreement_score":0.02356844,"about_ca_system_score_codex":0.00024137762,"about_ca_system_score_gemma":0.001761835,"threshold_uncertainty_score":0.77523077},"labels":[],"label_agreement":null},{"id":"W2166600720","doi":"10.1016/s0090-4295(02)01639-4","title":"Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?","year":2002,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"AstraZeneca","keywords":"Medicine; Blockade; Prostate cancer; Term (time); Androgen; Oncology; Prostate; Antiandrogen; Urology; Cancer; Internal medicine; Hormone","score_opus":0.02518589648529442,"score_gpt":0.3071356991829931,"score_spread":0.2819498026976987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166600720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626147,0.009496637,0.000027622935,0.024839206,0.00016093875,0.001995478,0.00015657177,0.00008271303,0.0006261386],"genre_scores_gemma":[0.9880321,0.0020539367,0.000021498043,0.0007454808,0.00008859042,0.00024078685,0.000046998117,0.00003110946,0.008739505],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984872,0.000087394445,0.00030625565,0.00031785134,0.000226894,0.00057442044],"domain_scores_gemma":[0.9991433,0.00007687541,0.00011552723,0.00029862908,0.00015499305,0.00021064555],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010089992,0.000187629,0.00053526676,0.00013867352,0.00007246591,0.000009125233,0.000122031786,0.00014845628,0.0012223794],"category_scores_gemma":[0.000043427328,0.00012391442,0.00008457266,0.00023790318,0.0002883169,0.000035557747,0.000041782776,0.00022560959,0.000022703078],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021467028,0.0012154372,0.9303486,0.0006819735,0.0011512564,0.0018935266,0.0014762747,0.00007629137,0.011436474,0.000072131115,0.0047049965,0.025476018],"study_design_scores_gemma":[0.4083148,0.07479494,0.19743645,0.0008995014,0.0055467198,0.0017275186,0.00037227117,0.030547611,0.21020533,0.0011888758,0.066488326,0.0024776456],"about_ca_topic_score_codex":0.00022651457,"about_ca_topic_score_gemma":0.00034330718,"teacher_disagreement_score":0.7329121,"about_ca_system_score_codex":0.00009025899,"about_ca_system_score_gemma":0.0002678913,"threshold_uncertainty_score":0.99969065},"labels":[],"label_agreement":null},{"id":"W2166906233","doi":"10.1002/pros.1060","title":"Changes of phenotypic expression of prostatic antigen in secondary transitional cell carcinoma of the prostate: Evidence for induction phenomenon as a mechanism for acquisition of prostatic antigens in prostatic transitional cell carcinoma","year":2001,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Prostate; Urinary bladder; Transitional cell carcinoma; Immunostaining; Stroma; Medicine; Pathology; Prostate-specific antigen; Prostatic urethra; Carcinoma; Epithelium; Urothelium; Urology; Cancer; Internal medicine; Immunohistochemistry; Bladder cancer","score_opus":0.04313941037593193,"score_gpt":0.3035892205548141,"score_spread":0.26044981017888214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166906233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98246396,0.0014044973,0.00046098055,0.0019041722,0.000105355124,0.0123807425,0.0011862499,0.000012790609,0.000081226994],"genre_scores_gemma":[0.9957993,0.00040979328,0.0013552896,0.00008239804,0.000043228214,0.0015820302,0.00035260423,0.00006607616,0.00030930332],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99659526,0.00028701738,0.0011681404,0.0005419241,0.0007827707,0.00062486215],"domain_scores_gemma":[0.9974414,0.00044443327,0.0007657042,0.0004688999,0.00078183867,0.00009774225],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010749933,0.0003811609,0.00081915484,0.0004664957,0.00014592631,0.000013450718,0.0002646734,0.00014650311,0.000050148137],"category_scores_gemma":[0.00008093715,0.00025767984,0.00022747258,0.0008543286,0.00047337625,0.00029296556,0.000055099503,0.00031193637,8.825489e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014292246,0.0014759733,0.026666405,0.010953503,0.000044442953,0.0000127017,0.034242257,0.00015668284,0.9104426,0.00029500274,0.000031275587,0.0013869456],"study_design_scores_gemma":[0.010417458,0.0033497452,0.113576636,0.0019599244,0.00017485539,0.00002337555,0.004001028,0.0009219007,0.8566449,0.008685587,0.0000071816808,0.00023735603],"about_ca_topic_score_codex":0.0002568797,"about_ca_topic_score_gemma":0.00011513072,"teacher_disagreement_score":0.08691023,"about_ca_system_score_codex":0.00021389854,"about_ca_system_score_gemma":0.0011246629,"threshold_uncertainty_score":0.99998754},"labels":[],"label_agreement":null},{"id":"W2166918329","doi":"10.1056/nejmoa1405095","title":"Enzalutamide in Metastatic Prostate Cancer before Chemotherapy","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3031,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"Cliniques Universitaires Saint-Luc; National Cancer Institute; Knight Cancer Institute, Oregon Health and Science University; University of California, Davis; Duke Cancer Institute; Astellas Pharma Global Development; Weill Cornell Medical College; Rigshospitalet; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Institut Gustave-Roussy; Astellas Pharma; Université de Montréal; University of Washington; University of Alberta; Memorial Sloan-Kettering Cancer Center; Monash University; Oregon Health and Science University","keywords":"Enzalutamide; Prostate cancer; Medicine; Oncology; Chemotherapy; Internal medicine; Docetaxel; Cancer; Androgen receptor","score_opus":0.02304102603670297,"score_gpt":0.34232875898785187,"score_spread":0.3192877329511489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166918329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9324593,0.006158862,0.00013827402,0.0594875,0.0003575502,0.00030577034,0.0000020790512,0.000009888612,0.0010807659],"genre_scores_gemma":[0.98902404,0.0035292853,0.0005267477,0.0013219592,0.0024097727,0.0000059543763,0.0000060602288,0.000024638814,0.0031515548],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984846,0.000090827554,0.00048167017,0.0001255491,0.00053910905,0.00027823725],"domain_scores_gemma":[0.99904025,0.000121288824,0.00019876813,0.00013511658,0.00017426634,0.0003303405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011115747,0.00014843397,0.00057876454,0.00031343714,0.00002523274,0.0000067747346,0.000095061805,0.000035170742,0.0004062182],"category_scores_gemma":[0.00023246194,0.00008019953,0.000062829764,0.00027542646,0.00011059854,0.000081910955,0.000010141687,0.0003886346,0.0000038033302],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004407223,0.000151812,0.14969863,0.00016659457,0.00025848747,0.000509068,0.005582884,0.000041760817,0.0055229366,0.00010357387,0.005899157,0.8276579],"study_design_scores_gemma":[0.46466908,0.013913247,0.21781743,0.00446817,0.0006028954,0.0020139345,0.0007035211,0.00059382315,0.0068516694,0.009493302,0.27855697,0.00031593817],"about_ca_topic_score_codex":0.00032212964,"about_ca_topic_score_gemma":0.0001921544,"teacher_disagreement_score":0.8273419,"about_ca_system_score_codex":0.0001415183,"about_ca_system_score_gemma":0.00035743142,"threshold_uncertainty_score":0.44478044},"labels":[],"label_agreement":null},{"id":"W2167749314","doi":"10.1158/0008-5472.can-07-5997","title":"Androgen Levels Increase by Intratumoral <i>De novo</i> Steroidogenesis during Progression of Castration-Resistant Prostate Cancer","year":2008,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":739,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"National Cancer Institute","keywords":"Prostate cancer; Dihydrotestosterone; Androgen; Androgen receptor; LNCaP; Androgen deprivation therapy; Tumor progression; Internal medicine; Endocrinology; Cancer research; Cancer; Prostate; Medicine; Biology; Hormone","score_opus":0.08711475349095844,"score_gpt":0.4118222421841693,"score_spread":0.32470748869321087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167749314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807967,0.015427844,0.0000016382683,0.0013397593,0.000058755362,0.0013917179,0.0005796956,0.000043857355,0.00036006086],"genre_scores_gemma":[0.98666203,0.006402055,0.00010712439,0.000042636635,0.00019991308,0.001080367,0.00006646533,0.000058109053,0.0053813],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965648,0.00022796165,0.0004050769,0.0005176776,0.0012944875,0.0009899861],"domain_scores_gemma":[0.9981347,0.00007195588,0.00009889453,0.0003983988,0.00078414514,0.0005119398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006011658,0.00022979021,0.00041770606,0.00027564316,0.00046761462,0.000036279118,0.00021460654,0.00012144468,0.0004927691],"category_scores_gemma":[0.000071008115,0.00017948565,0.00009464131,0.0008509376,0.0006791263,0.00018056628,0.00012935311,0.0004983478,0.000010512868],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048760413,0.00032802433,0.10281358,0.00068630936,0.00014589666,0.00068357115,0.0010358549,0.000009480846,0.88183224,0.0000065278186,0.0039800736,0.0036023683],"study_design_scores_gemma":[0.0045829667,0.0006654491,0.04135608,0.00065899926,0.000041757543,0.00012586077,0.00022178177,0.000019552315,0.9504408,0.000017744042,0.001676506,0.00019245833],"about_ca_topic_score_codex":0.0021826404,"about_ca_topic_score_gemma":0.00020619556,"teacher_disagreement_score":0.068608575,"about_ca_system_score_codex":0.0009241637,"about_ca_system_score_gemma":0.002689094,"threshold_uncertainty_score":0.73192126},"labels":[],"label_agreement":null},{"id":"W2167968468","doi":"10.1158/1535-7163.mct-13-0267","title":"Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Basis Foundation","keywords":"Androgen receptor; Prostate cancer; Enzalutamide; Androgen; LNCaP; Antiandrogen; Androgen Receptor Antagonists; Cancer research; Endocrinology; Medicine; Internal medicine; Pharmacology; Cancer; Hormone","score_opus":0.014741834600917476,"score_gpt":0.29646458112044477,"score_spread":0.2817227465195273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167968468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98918897,0.004633201,0.0016716932,0.0024979915,0.00005218813,0.0018478064,0.000046187648,0.00001938661,0.00004257082],"genre_scores_gemma":[0.9934844,0.0046260175,0.0003537712,0.00035412723,0.000032906344,0.00052294665,0.0001202974,0.00004599878,0.00045953784],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987851,0.00004057594,0.0003047973,0.00026689714,0.00033562118,0.00026702936],"domain_scores_gemma":[0.9991612,0.000006432698,0.00020555321,0.00027258927,0.00026920755,0.000085014326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000054279426,0.00017747984,0.0003321726,0.00012420799,0.000023973174,0.000011923312,0.00009819131,0.000086066335,0.00008234925],"category_scores_gemma":[0.0000010483325,0.00013401436,0.00005900503,0.00043936653,0.00010891928,0.00009954996,0.000019197938,0.00013049625,0.0000031084342],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001126712,0.00014944628,0.03179789,0.00014920211,0.0002371115,0.0000036568633,0.00054867344,0.00010317301,0.829178,0.00002263445,0.0000039193897,0.1366796],"study_design_scores_gemma":[0.004635852,0.00052608503,0.039507493,0.0002472274,0.00016725187,0.000003811983,0.0000962528,0.00095510745,0.9507914,0.000100013465,0.0027974038,0.00017207892],"about_ca_topic_score_codex":0.0008219282,"about_ca_topic_score_gemma":0.000050696235,"teacher_disagreement_score":0.13650753,"about_ca_system_score_codex":0.00016984317,"about_ca_system_score_gemma":0.0005839004,"threshold_uncertainty_score":0.5464947},"labels":[],"label_agreement":null},{"id":"W2168063883","doi":"10.1093/annonc/mdt571","title":"Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Janssen Pharmaceuticals; Amgen; Astellas Pharma; Association for Federal Information Resources Management","keywords":"Enzalutamide; Medicine; Prostate cancer; Hazard ratio; Placebo; Internal medicine; Population; Docetaxel; Adverse effect; Progression-free survival; Urology; Confidence interval; Oncology; Androgen receptor; Chemotherapy; Cancer; Pathology","score_opus":0.058052921820775295,"score_gpt":0.3790785064417077,"score_spread":0.3210255846209324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168063883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805026,0.0002495416,0.0000023842103,0.015444619,0.00007815722,0.002909887,0.00066296436,0.000016098998,0.00013371586],"genre_scores_gemma":[0.9979202,0.0001425712,0.000094855684,0.0004538099,0.000099057346,0.0004555304,0.0003852526,0.000024000676,0.00042472148],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99805665,0.00034365,0.00051167386,0.00034389657,0.0003659364,0.00037816676],"domain_scores_gemma":[0.99797124,0.00079025124,0.00037151048,0.00035683773,0.0004015779,0.00010857004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005718435,0.00022412754,0.00062277936,0.000060669256,0.00011311211,0.00002234833,0.00014097596,0.00007648967,0.00004204429],"category_scores_gemma":[0.00017938047,0.0000908219,0.00007068413,0.00029004875,0.00031598296,0.0000931803,0.000026372454,0.00025891347,0.0000025513107],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8480211,0.003980683,0.028717762,0.00004139901,0.0015494408,0.00005474835,0.005229273,0.000021822983,0.0046904506,0.000015008503,0.0039389716,0.10373934],"study_design_scores_gemma":[0.79711103,0.105419666,0.041725196,0.00032011973,0.000700726,0.0000029017017,0.0018115062,0.00015417353,0.032088976,0.00004721239,0.02022964,0.00038882872],"about_ca_topic_score_codex":0.0035825688,"about_ca_topic_score_gemma":0.006076887,"teacher_disagreement_score":0.10335051,"about_ca_system_score_codex":0.000100054196,"about_ca_system_score_gemma":0.000592367,"threshold_uncertainty_score":0.54157966},"labels":[],"label_agreement":null},{"id":"W2168108459","doi":"10.1016/s1470-2045(12)70379-0","title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1387,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; BC Cancer Agency","funders":"Janssen Research and Development; UCLH Biomedical Research Centre","keywords":"Abiraterone acetate; Medicine; Placebo; Prednisone; Prostate cancer; Clinical endpoint; Interim analysis; Internal medicine; Enzalutamide; Docetaxel; Population; Oncology; Androgen deprivation therapy; Clinical trial; Cancer; Androgen receptor; Pathology","score_opus":0.18733768892073796,"score_gpt":0.45450891352613365,"score_spread":0.26717122460539566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168108459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98377466,0.0020158333,0.0000366939,0.0025252688,0.00025799108,0.010718818,0.0003864799,0.00001464593,0.0002695927],"genre_scores_gemma":[0.992819,0.0007175906,0.000120541124,0.000055391465,0.0002155359,0.00391535,0.000096358635,0.00002131474,0.0020388823],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974428,0.0006404388,0.0007126536,0.00024953968,0.0003933646,0.0005612333],"domain_scores_gemma":[0.99766606,0.0008552834,0.00055557623,0.0005318313,0.0002778269,0.00011340019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001641254,0.00025928149,0.0021501505,0.00016138237,0.00015786044,0.000013555997,0.00019760417,0.000056607896,0.00013749774],"category_scores_gemma":[0.000052384887,0.00011732227,0.00044380027,0.00044234368,0.00025065572,0.00006796759,0.00003532356,0.000103790604,0.0000018582055],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9420376,0.0056364276,0.0147894565,0.00013018167,0.016882641,0.0000145626955,0.006387701,0.0005752128,0.010894626,0.00011251055,0.00015852197,0.002380588],"study_design_scores_gemma":[0.9551365,0.0074936403,0.008343978,0.000025561247,0.018755082,0.000005030901,0.0012187206,0.00083658943,0.006760625,0.00003229629,0.0012620721,0.00012990896],"about_ca_topic_score_codex":0.0007652444,"about_ca_topic_score_gemma":0.0014673716,"teacher_disagreement_score":0.013098926,"about_ca_system_score_codex":0.00041981207,"about_ca_system_score_gemma":0.0006199691,"threshold_uncertainty_score":0.47842634},"labels":[],"label_agreement":null},{"id":"W2168500832","doi":"10.1016/j.eururo.2014.05.038","title":"Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial","year":2014,"lang":"en","type":"editorial","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Pfizer UK; Institute of Cancer Research; Prostate Cancer UK; Cancer Research UK; Novartis; National Institute for Health and Care Research; Medical Research Council; Sanofi; Janssen Biotech; Astellas European Foundation","keywords":"Enzalutamide; Medicine; Abiraterone; Prednisone; Prostate cancer; Androgen deprivation therapy; Internal medicine; Oncology; Androgen; Urology; Androgen receptor; Cancer; Hormone","score_opus":0.02257539387822483,"score_gpt":0.29324291389917534,"score_spread":0.2706675200209505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168500832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84527165,0.003278652,0.00006629992,0.0017883731,0.13505314,0.0032832294,0.00004682572,0.000101449856,0.011110398],"genre_scores_gemma":[0.5304876,0.0035261556,0.00009429724,0.0010223164,0.46167213,0.00018829892,0.0013172673,0.00021530467,0.0014766644],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972224,0.0011682223,0.00030587337,0.00048080456,0.00045247521,0.00037021388],"domain_scores_gemma":[0.9985625,0.0007038274,0.00015610688,0.00041315978,0.00009038528,0.000073982585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001295138,0.0002766346,0.0004531542,0.0001637136,0.00009764307,0.00006178783,0.00021909046,0.00022675178,0.000019100571],"category_scores_gemma":[0.000239992,0.00015397907,0.000042002583,0.00013184494,0.00022445763,0.00004217643,0.00006781046,0.00089196616,0.000021449994],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26852664,0.0006895026,0.009129638,0.00018748907,0.00061848626,0.0015330395,0.0046233516,0.000011377771,0.0004617858,0.000095145784,0.69655436,0.017569197],"study_design_scores_gemma":[0.104152106,0.013638068,0.0034604163,0.000060721133,0.00011019501,0.000038243757,0.00005926649,0.000017745779,0.00005045479,0.00004847534,0.87815493,0.00020936354],"about_ca_topic_score_codex":0.0000466661,"about_ca_topic_score_gemma":0.00003733361,"teacher_disagreement_score":0.32661897,"about_ca_system_score_codex":0.000045412336,"about_ca_system_score_gemma":0.00021081707,"threshold_uncertainty_score":0.6279084},"labels":[],"label_agreement":null},{"id":"W2168897858","doi":"10.1158/1541-7786.mcr-13-0477","title":"Prostate Cancer Genetic-susceptibility Locus on Chromosome 20q13 is Amplified and Coupled to Androgen Receptor-regulation in Metastatic Tumors","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Androgen receptor; Prostate cancer; Cancer research; Locus (genetics); Biology; Cancer; Oncology; Genetics; Medicine; Gene","score_opus":0.04994690318444973,"score_gpt":0.3820164177959469,"score_spread":0.3320695146114972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168897858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799297,0.0043984456,0.00003350428,0.01037835,0.00005632344,0.004873643,0.000080059464,0.00003374557,0.00021625351],"genre_scores_gemma":[0.9920084,0.0013950202,0.00033693545,0.0005840264,0.000068258545,0.0034590743,0.000046644338,0.00006961356,0.0020320618],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960039,0.00030503486,0.0004073372,0.000924625,0.0013373846,0.0010216733],"domain_scores_gemma":[0.99802566,0.00009097114,0.00005381213,0.00060450035,0.0006402999,0.0005847398],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007062891,0.00028924568,0.0004827343,0.0005696104,0.0001603924,0.00012763996,0.0001824525,0.00009588368,0.002596892],"category_scores_gemma":[0.00011719819,0.00023395482,0.00007403058,0.0012364859,0.00029547344,0.000114541006,0.00016817937,0.00053769344,0.00022211894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021203542,0.00041798915,0.05154155,0.0005757999,0.00025555192,0.00019553558,0.0020332013,0.00042375666,0.8849486,0.000035084104,0.0063261352,0.05112645],"study_design_scores_gemma":[0.011752952,0.0031847877,0.2228163,0.0015103335,0.00009677537,0.000017794655,0.000828767,0.00436359,0.74800986,0.001535634,0.0050049224,0.0008782822],"about_ca_topic_score_codex":0.017878782,"about_ca_topic_score_gemma":0.0010477591,"teacher_disagreement_score":0.17127477,"about_ca_system_score_codex":0.0011009107,"about_ca_system_score_gemma":0.00073999603,"threshold_uncertainty_score":0.99831486},"labels":[],"label_agreement":null},{"id":"W2168912140","doi":"10.1002/pros.20712","title":"Prostate‐Specific genes and their regulation by dihydrotestosterone","year":2007,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"LNCaP; Prostate; Prostate cancer; Dihydrotestosterone; Biology; Transcriptome; Androgen; PCA3; Cancer research; Endocrinology; Internal medicine; Cancer; Gene; Medicine; Gene expression; Genetics; Hormone","score_opus":0.02220972016118114,"score_gpt":0.2821185158024915,"score_spread":0.2599087956413103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168912140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776007,0.013816645,0.00025625914,0.005297442,0.00007256272,0.0014093925,0.000038494654,0.00008497097,0.0014235111],"genre_scores_gemma":[0.9854017,0.0028540958,0.00012970864,0.00017459676,0.00010048962,0.000048585545,0.000118465985,0.000034083263,0.011138291],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99885166,0.000038815015,0.00021487984,0.0002648378,0.00021349434,0.0004163185],"domain_scores_gemma":[0.99931955,0.00008711706,0.00006365377,0.00030406326,0.000082808154,0.00014282044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005985931,0.00017431277,0.00018388068,0.00006721543,0.00022084203,0.000049303773,0.00007074076,0.000051693405,0.000042188934],"category_scores_gemma":[0.000010801632,0.00009091761,0.000036336758,0.0001999217,0.00026795975,0.00010069948,0.00006633209,0.00017153639,0.000034323082],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00240554,0.00017051742,0.017230736,0.00011333692,0.00011501332,0.000035769484,0.005938841,0.0000026890655,0.65855336,0.00013850331,0.0060143583,0.30928135],"study_design_scores_gemma":[0.0054923897,0.0011691608,0.059278857,0.00016222271,0.00005606669,0.00018017086,0.0012894964,0.00024350357,0.75698835,0.0026220735,0.1721606,0.0003570962],"about_ca_topic_score_codex":0.000028597815,"about_ca_topic_score_gemma":0.000007317822,"teacher_disagreement_score":0.30892426,"about_ca_system_score_codex":0.00007582136,"about_ca_system_score_gemma":0.000037155278,"threshold_uncertainty_score":0.37075126},"labels":[],"label_agreement":null},{"id":"W2169700609","doi":"10.1200/jco.2012.46.4149","title":"Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Takeda Oncology; Sanofi; Teva Pharmaceutical Industries; Genentech; AstraZeneca; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Docetaxel; Placebo; Prostate cancer; Internal medicine; Clinical endpoint; Peripheral edema; Adverse effect; Nausea; Hazard ratio; Oncology; Urology; Cancer; Randomized controlled trial; Surgery; Confidence interval; Pathology","score_opus":0.060853889279274966,"score_gpt":0.45027940075978057,"score_spread":0.3894255114805056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169700609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924314,0.00020301674,0.000011502484,0.0013129194,0.00010729813,0.005773655,0.0000036610904,0.0000024157048,0.00015411121],"genre_scores_gemma":[0.9987964,0.00017206665,0.00038878043,0.00008594815,0.00003376148,0.00030926018,0.0000065748363,0.000012858089,0.00019432034],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99535364,0.0010019552,0.0026058003,0.0001770096,0.00063370017,0.00022787493],"domain_scores_gemma":[0.9952708,0.001606284,0.0018825709,0.00012040028,0.00093575974,0.00018419897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031521975,0.00015422625,0.0027530836,0.00032596913,0.000022533379,0.000011985587,0.000085826294,0.00007831486,0.00010412284],"category_scores_gemma":[0.0007071514,0.00007535779,0.0001435016,0.00027989972,0.00022363785,0.00021783909,0.000014772213,0.00057897205,0.0000011488384],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7737049,0.027316546,0.18752968,0.00003296595,0.0009662188,0.0002771661,0.00074493204,0.00010714904,0.00002854777,0.0000064134547,0.00003967753,0.009245807],"study_design_scores_gemma":[0.7675517,0.05361736,0.17663562,0.00019020338,0.00054391206,0.000005478219,0.00101928,0.00028572502,0.000016955246,0.0000659518,0.000008252604,0.000059551647],"about_ca_topic_score_codex":0.00075145246,"about_ca_topic_score_gemma":0.0015869406,"teacher_disagreement_score":0.02630081,"about_ca_system_score_codex":0.00027367906,"about_ca_system_score_gemma":0.0014732932,"threshold_uncertainty_score":0.30730015},"labels":[],"label_agreement":null},{"id":"W2170018282","doi":"10.6000/1929-2279.2014.03.04.3","title":"The Association of Obesity and Sistemic Arterial Hypertension with High-Grade Prostate Cancer: Our Experience","year":2014,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Obesity; Blood pressure; Internal medicine; Cancer; Prostatectomy; Oncology; Surgery; Urology","score_opus":0.03206941211138102,"score_gpt":0.3664921075247853,"score_spread":0.33442269541340425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170018282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777556,0.0050629806,0.000002537632,0.016577914,0.00019287053,0.000353542,0.000013586758,0.000005340311,0.00003560733],"genre_scores_gemma":[0.9760132,0.022547897,0.000071220886,0.000044657732,0.00042163316,0.00004873371,0.0000027527396,0.000015470912,0.0008344291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974568,0.00026787893,0.00034797817,0.00016549739,0.0013454723,0.00041638105],"domain_scores_gemma":[0.99754965,0.00026821988,0.0003402981,0.00017452343,0.0014713221,0.00019597026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001688459,0.00011361009,0.00036496192,0.00014643004,0.00027400954,0.00007903799,0.00016046515,0.00006316679,0.000013026187],"category_scores_gemma":[0.0002660417,0.00005679971,0.000052560386,0.00029574404,0.00020070394,0.00018593387,0.00006227039,0.00046422932,0.0000011152346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011981478,0.0003564091,0.6660319,0.0003527756,0.00068078475,0.00008100164,0.0019944573,0.00004182326,0.28198287,0.0001261032,0.009571655,0.026798712],"study_design_scores_gemma":[0.017512055,0.0053708106,0.5710478,0.0023902901,0.0003115379,0.0001589382,0.0046648732,0.00031673285,0.36045372,0.0007504091,0.03671746,0.00030542043],"about_ca_topic_score_codex":0.0006754195,"about_ca_topic_score_gemma":0.0003182245,"teacher_disagreement_score":0.09498416,"about_ca_system_score_codex":0.0004547408,"about_ca_system_score_gemma":0.0005945092,"threshold_uncertainty_score":0.23162249},"labels":[],"label_agreement":null},{"id":"W2170071316","doi":"10.1200/jco.2005.02.129","title":"Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre; Jewish General Hospital; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Gefitinib; Cancer; Rash; Chemotherapy; Prostate-specific antigen; Randomized controlled trial; Clinical trial; Oncology; Epidermal growth factor receptor","score_opus":0.3188633390056988,"score_gpt":0.5975672502723148,"score_spread":0.27870391126661603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170071316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98657084,0.003121604,0.0000017334987,0.0053992034,0.0018600745,0.0025795999,0.00012013648,0.0000016767549,0.00034512376],"genre_scores_gemma":[0.9886882,0.009074048,0.0001448683,0.0002488692,0.0014843335,0.00008613583,0.0000033887668,0.000012625761,0.0002575855],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98420644,0.0040978403,0.009764312,0.00022965475,0.0014355248,0.00026625174],"domain_scores_gemma":[0.9794281,0.010322381,0.008339437,0.00019936656,0.0014720542,0.00023862981],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.028839096,0.00018164748,0.005386187,0.00022797336,0.000041107585,0.0000022250504,0.0003180621,0.00024450125,0.0001291607],"category_scores_gemma":[0.023107901,0.000096027,0.0010044044,0.00033934452,0.00095946173,0.00013099599,0.00010489592,0.0010411034,1.03420454e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89534706,0.023013934,0.010138986,0.00006323003,0.0021854034,0.000041148523,0.0005334127,0.00019459709,0.0009083469,0.000038924183,0.0024028742,0.06513207],"study_design_scores_gemma":[0.943438,0.032658283,0.013442193,0.00030647538,0.0010497698,0.0000070391548,0.00020794004,0.00009592615,0.00051596673,0.000119673845,0.0080813365,0.00007739686],"about_ca_topic_score_codex":0.030582199,"about_ca_topic_score_gemma":0.11561924,"teacher_disagreement_score":0.085037045,"about_ca_system_score_codex":0.00046039326,"about_ca_system_score_gemma":0.02108077,"threshold_uncertainty_score":0.9995113},"labels":[],"label_agreement":null},{"id":"W2170295948","doi":"10.4103/1008-682x.125394","title":"Next generation patient-derived prostate cancer xenograft models","year":2014,"lang":"en","type":"letter","venue":"Asian Journal of Andrology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver General Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Medicine; Cancer; Prostate; Cancer research; Disease; Oncology; In vivo; Pathology; Internal medicine; Biology","score_opus":0.062557221434581,"score_gpt":0.3092718100783343,"score_spread":0.2467145886437533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170295948","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0699058,0.007164985,0.00023922103,0.91994715,0.0010662897,0.00054861093,0.000028502367,0.000015501559,0.0010839666],"genre_scores_gemma":[0.4053236,0.006468716,0.0008438928,0.5699447,0.013932649,0.0000824855,0.0005517035,0.00015518277,0.002697115],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998019,0.00019589138,0.0005855783,0.00025371884,0.00044021598,0.0005055975],"domain_scores_gemma":[0.99850476,0.00002601282,0.00056450116,0.00022923017,0.00050030334,0.00017521052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017229056,0.00027542736,0.00076255674,0.000373821,0.000084899315,0.000042535663,0.00014355134,0.00056895905,0.00023510536],"category_scores_gemma":[0.000017849434,0.00019107865,0.0002547604,0.00011072015,0.00016162886,0.00017713982,0.00003025623,0.0016434138,0.000015041959],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000866523,0.000071274786,0.0004148628,0.00018192909,0.00082902354,0.0041488023,0.0012925331,0.00006291213,0.007568588,0.0000040224327,0.9316511,0.052908435],"study_design_scores_gemma":[0.005760243,0.0066465368,0.000087285385,0.00035970384,0.00071043224,0.0034302878,0.0000923874,0.0007072055,0.0036063653,0.00052558316,0.97774065,0.0003333176],"about_ca_topic_score_codex":0.000018092971,"about_ca_topic_score_gemma":0.0000063643693,"teacher_disagreement_score":0.35000244,"about_ca_system_score_codex":0.00016338291,"about_ca_system_score_gemma":0.0006005501,"threshold_uncertainty_score":0.77919614},"labels":[],"label_agreement":null},{"id":"W2170417128","doi":"10.1016/j.urology.2011.07.916","title":"UP-02.098 The Novel AKT-Inhibitor AZD5363 Abrogates Androgen-Receptor Signaling and Delays Hormone-Sensitive and Castration-Resistant Prostate Cancer Progression in vivo","year":2011,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Deutsche Forschungsgemeinschaft","keywords":"Medicine; Prostate cancer; Protein kinase B; PI3K/AKT/mTOR pathway; In vivo; Androgen receptor; Cancer research; Signal transduction; Androgen; Prostate; Effector; Pharmacology; Cancer; Internal medicine; Hormone; Cell biology; Immunology; Biology","score_opus":0.03103689972750052,"score_gpt":0.30348457630930376,"score_spread":0.27244767658180324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170417128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904174,0.006588055,0.000014347126,0.0016543409,0.00010957585,0.00091245846,0.00006896081,0.0000253295,0.00020952754],"genre_scores_gemma":[0.9979391,0.0010770969,0.00020620949,0.0001844856,0.00009569798,0.00016709082,0.00001858882,0.000021667338,0.00029005532],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99882203,0.00006832527,0.00022024744,0.00035205443,0.00015866656,0.00037868074],"domain_scores_gemma":[0.99945277,0.000095799245,0.000076946184,0.00012844679,0.00011499085,0.00013107504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021998226,0.00017657675,0.00024437322,0.00010325798,0.00014969899,0.00002103703,0.000043716205,0.000121349134,0.00006311844],"category_scores_gemma":[0.000032722222,0.00010763008,0.000027830005,0.00013966789,0.00034866825,0.000082951294,0.00006231196,0.00023552569,0.000003992686],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007650724,0.00019462462,0.031857427,0.000080586964,0.00018156022,0.00021496974,0.011662714,0.0000056226586,0.94059646,0.00017731726,0.00041217887,0.0069657993],"study_design_scores_gemma":[0.016421344,0.007137817,0.049009755,0.00028635887,0.00037207088,0.00034631937,0.004018798,0.0019705817,0.91490805,0.0003258889,0.0046192748,0.0005837528],"about_ca_topic_score_codex":0.00045339105,"about_ca_topic_score_gemma":0.0003783973,"teacher_disagreement_score":0.025688438,"about_ca_system_score_codex":0.000055226374,"about_ca_system_score_gemma":0.00014981664,"threshold_uncertainty_score":0.43890277},"labels":[],"label_agreement":null},{"id":"W2170501509","doi":"10.1158/0008-5472.can-04-2938","title":"Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells","year":2004,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":175,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Prostate cancer; Prostate; Androgen receptor; Androgen; Cancer research; Biology; Internal medicine; Endocrinology; Cancer; Medicine; Hormone","score_opus":0.08228398841353438,"score_gpt":0.4110044743045733,"score_spread":0.32872048589103897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170501509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99686545,0.00092153705,0.0000050254584,0.0007200023,0.00007114011,0.00095610955,0.000054416934,0.00002176439,0.00038454463],"genre_scores_gemma":[0.99744576,0.0011607372,0.000027172817,0.000015225208,0.00014238672,0.00014640445,0.000025643323,0.000023483042,0.0010132114],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99823374,0.00008131564,0.00021207864,0.0003183124,0.00069281406,0.0004617561],"domain_scores_gemma":[0.99905825,0.00003530837,0.0000461921,0.00024395934,0.00039507612,0.00022122805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044494777,0.00011748443,0.00025903445,0.00023914501,0.0002071918,0.000027194672,0.000092985734,0.00007323423,0.00011950915],"category_scores_gemma":[0.00002684009,0.00008905922,0.000054200165,0.00036748862,0.00026932947,0.00007698697,0.00009450741,0.0003619378,0.000012301643],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005070795,0.00018703713,0.0077629113,0.0002704242,0.0000735178,0.00003511176,0.00084816647,0.000002142122,0.98706275,0.00031890193,0.000060077055,0.002871867],"study_design_scores_gemma":[0.004113409,0.00091251166,0.025373362,0.00015307068,0.000025878477,0.000005048174,0.00014513159,0.000004880017,0.96781,0.0012295789,0.00014588791,0.00008126523],"about_ca_topic_score_codex":0.0012995878,"about_ca_topic_score_gemma":0.000117862786,"teacher_disagreement_score":0.019252788,"about_ca_system_score_codex":0.00035359806,"about_ca_system_score_gemma":0.00051138556,"threshold_uncertainty_score":0.36317298},"labels":[],"label_agreement":null},{"id":"W2170776261","doi":"10.1186/2193-1801-3-295","title":"Human kallikrein-2 gene and protein expression predicts prostate cancer at repeat biopsy","year":2014,"lang":"en","type":"article","venue":"SpringerPlus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Princess Margaret Cancer Centre; Mount Sinai Hospital; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Prostate cancer; Single-nucleotide polymorphism; Prostate biopsy; Medicine; Biopsy; SNP; Oncology; Prostate; Internal medicine; Odds ratio; Cancer; Genotype; Biology; Gene; Genetics","score_opus":0.01895916474337915,"score_gpt":0.3024522797341029,"score_spread":0.2834931149907237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170776261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920737,0.0028644605,0.000012302831,0.0007504955,0.000092484595,0.0011108739,0.000014560615,0.00012846342,0.0029526507],"genre_scores_gemma":[0.9652431,0.00036184007,0.0006028751,0.00007242993,0.00029062878,0.000342079,0.000030832343,0.00004412763,0.03301211],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984854,0.000044916305,0.00020839545,0.00047312153,0.00035728776,0.00043087156],"domain_scores_gemma":[0.99914753,0.0000119014885,0.00007485829,0.00039306728,0.00008276308,0.00028988725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021122865,0.00020032047,0.00027088137,0.0001033777,0.00025279334,0.00003232338,0.000078868856,0.00009836916,0.00015716722],"category_scores_gemma":[0.000033558084,0.00014455829,0.000052333155,0.00011259071,0.00014711535,0.00007643314,0.00020629146,0.00018400962,0.00003175208],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046849574,0.000075918884,0.048414763,0.00033215006,0.00005603522,0.00010115972,0.00043381884,0.0000032564444,0.9399003,0.000045043846,0.0006713594,0.009497708],"study_design_scores_gemma":[0.005576986,0.0006000379,0.12224828,0.0009248872,0.00007704224,0.000059826332,0.000028771181,0.00016803508,0.8455656,0.00017086782,0.02427755,0.00030211994],"about_ca_topic_score_codex":0.00016985541,"about_ca_topic_score_gemma":0.000024220515,"teacher_disagreement_score":0.09433469,"about_ca_system_score_codex":0.00023490447,"about_ca_system_score_gemma":0.00007321847,"threshold_uncertainty_score":0.5894916},"labels":[],"label_agreement":null},{"id":"W2170823000","doi":"10.1016/s0090-4295(01)01449-2","title":"Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer","year":2002,"lang":"en","type":"review","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Meso Scale Diagnostics","keywords":"Prostate cancer; Medicine; Prostate-specific antigen; Prostate; PCA3; Cancer; Malignancy; Kallikrein; Antigen; Internal medicine; Oncology; Immunology; Biology","score_opus":0.056687179002307776,"score_gpt":0.3554708266094483,"score_spread":0.2987836476071405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170823000","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010222818,0.99317616,0.000051300216,0.00016451738,0.00015181124,0.004711717,0.00031062122,0.00003176628,0.0003798345],"genre_scores_gemma":[0.0010083345,0.9954724,0.00004675379,0.000086706474,0.00008076678,0.0013330538,0.00010362217,0.00010314568,0.0017652581],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981996,0.00009058371,0.0004842061,0.000535528,0.00018434135,0.0005057576],"domain_scores_gemma":[0.9990793,0.00008823212,0.00027487558,0.00027466234,0.00015162518,0.00013131692],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020140484,0.00036240238,0.0012641478,0.00031380082,0.000061992156,0.000012277199,0.000092604416,0.00038039108,0.00013799367],"category_scores_gemma":[0.000028706978,0.0002540956,0.00026192324,0.00024441344,0.00017882648,0.00003838986,0.000047419853,0.00030406396,0.000013770229],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011389954,0.00008866878,0.00007477948,0.015532222,0.0006501676,0.00006076587,0.00009905118,0.0000012951914,0.00067755807,0.000050028288,0.00038731188,0.98123914],"study_design_scores_gemma":[0.001779831,0.001704623,0.000015473785,0.0010852268,0.00058461324,0.000065760454,0.000008774045,0.000042232932,0.0006840971,0.000039356953,0.9937852,0.00020483433],"about_ca_topic_score_codex":0.000020376425,"about_ca_topic_score_gemma":0.000012311313,"teacher_disagreement_score":0.9933979,"about_ca_system_score_codex":0.00012725005,"about_ca_system_score_gemma":0.00019435276,"threshold_uncertainty_score":0.9999911},"labels":[],"label_agreement":null},{"id":"W2171309933","doi":"10.1016/j.molonc.2014.10.014","title":"N‐terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy","year":2014,"lang":"en","type":"article","venue":"Molecular Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Taxane; Docetaxel; Prostate cancer; Androgen receptor; Cancer research; Epithelial–mesenchymal transition; Chemotherapy; Medicine; Cancer; Pharmacology; Biology; Oncology; Internal medicine; Breast cancer; Metastasis","score_opus":0.013908551237446897,"score_gpt":0.3402511032598872,"score_spread":0.32634255202244034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171309933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942861,0.00068549666,0.0005031317,0.0034560855,0.00008036239,0.00062228745,0.000027102948,0.000011372437,0.0003280704],"genre_scores_gemma":[0.9942009,0.00018382908,0.0045422576,0.00024945775,0.00004570195,0.00010298379,0.000024833102,0.000018938972,0.0006310889],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986968,0.00027272492,0.00032447846,0.00023404625,0.00022887449,0.00024304923],"domain_scores_gemma":[0.9992235,0.000083721796,0.00017100133,0.00018230549,0.00022560482,0.000113925526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007141707,0.00011293379,0.0003713687,0.00012529035,0.00003304355,0.000004183871,0.00007466358,0.000090214286,0.00013686693],"category_scores_gemma":[0.00017171526,0.0000899378,0.00006269015,0.0002097777,0.000110494584,0.000024285053,0.000025710764,0.00009179616,0.000004675088],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019069077,0.00017334174,0.0005069242,0.000116148745,0.00009322721,0.00013081751,0.0010524893,0.00001720088,0.9606311,0.00003740631,0.00037200245,0.017800301],"study_design_scores_gemma":[0.0024901638,0.005039038,0.001622587,0.00012254414,0.000046743175,0.000020596952,0.00014443696,0.00005632603,0.97541153,0.000032530075,0.0149317775,0.00008172025],"about_ca_topic_score_codex":0.00017404207,"about_ca_topic_score_gemma":0.00001779676,"teacher_disagreement_score":0.017718581,"about_ca_system_score_codex":0.00017247454,"about_ca_system_score_gemma":0.0005987123,"threshold_uncertainty_score":0.3667557},"labels":[],"label_agreement":null},{"id":"W2171316518","doi":"10.1002/prot.22592","title":"Study of the impact of the T877A mutation on ligand‐induced helix‐12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens","year":2009,"lang":"en","type":"article","venue":"Proteins Structure Function and Bioinformatics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Flutamide; Androgen receptor; Antiandrogen; Chemistry; Agonist; LNCaP; Androgen; Receptor; Prostate cancer; Biology; Biochemistry; Genetics; Hormone; Cancer","score_opus":0.02837089358977605,"score_gpt":0.28791620322345957,"score_spread":0.2595453096336835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171316518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977031,0.000045223867,0.00009045909,0.00017762069,0.00003613902,0.0018343242,0.000054093165,0.0000036677711,0.000055414937],"genre_scores_gemma":[0.99950224,0.000020873895,0.00042636087,0.000016370614,0.000009240964,0.0000078882895,0.0000040598015,0.0000043846876,0.000008597416],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99909455,0.00006939769,0.00037267257,0.00007556511,0.0002901586,0.000097682816],"domain_scores_gemma":[0.999234,0.000055734137,0.00034123348,0.00021106726,0.00013107165,0.000026856293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019402277,0.000107693086,0.00022479524,0.00009570318,0.000090778,0.00000806204,0.00006769647,0.00007295563,0.0000041531266],"category_scores_gemma":[0.00013804888,0.000044691325,0.0000603177,0.00038008083,0.00008414048,0.0000643983,0.000028185746,0.0001318004,3.6677356e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056034,0.0012109032,0.05839204,0.00061592367,0.00053475867,6.231269e-7,0.01465821,0.0014048401,0.89213884,0.00006535149,0.00003801274,0.025337104],"study_design_scores_gemma":[0.0032219484,0.0025374512,0.3560723,0.00047716624,0.000116573065,0.000014002008,0.0016486817,0.0022381076,0.63356113,0.000060586004,5.8636425e-7,0.000051477164],"about_ca_topic_score_codex":0.00008557878,"about_ca_topic_score_gemma":0.0000132275745,"teacher_disagreement_score":0.29768026,"about_ca_system_score_codex":0.00004033629,"about_ca_system_score_gemma":0.00010424237,"threshold_uncertainty_score":0.18224594},"labels":[],"label_agreement":null},{"id":"W2171351296","doi":"10.1158/1078-0432.ccr-04-2145","title":"A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer","year":2005,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Docetaxel; Medicine; Pharmacokinetics; Prostate cancer; Refractory (planetary science); Oncology; Pharmacology; Internal medicine; Pharmacodynamics; Cancer; Peripheral blood mononuclear cell; Gastroenterology; Urology; Chemistry; Biology; In vitro","score_opus":0.167860845813344,"score_gpt":0.5188297234039012,"score_spread":0.35096887759055717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171351296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835213,0.011777408,2.3977924e-7,0.0015134364,0.00004614523,0.0028288497,0.000080614685,0.000014061271,0.00021794252],"genre_scores_gemma":[0.96534795,0.03315498,0.000030592655,0.00007988215,0.00014720942,0.0004622253,0.00001822954,0.000023594986,0.00073531363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969725,0.0004262568,0.0005794502,0.0006594522,0.0007727327,0.00058960356],"domain_scores_gemma":[0.9982207,0.00047367925,0.00011583105,0.00023475927,0.00055096985,0.00040406067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012234137,0.00020499346,0.00061365013,0.0002757478,0.00014930489,0.000019351322,0.00011709685,0.0001317125,0.00015242884],"category_scores_gemma":[0.00016918694,0.00012614032,0.000040279854,0.0005448287,0.0011522364,0.00014065116,0.00028083482,0.0011045601,0.0000031606132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03320156,0.011620793,0.7628098,0.000049178358,0.00025424585,0.000040778006,0.0020408344,0.0000036126826,0.00032571223,0.0000024680721,0.0005750633,0.18907595],"study_design_scores_gemma":[0.081885196,0.039783146,0.87147194,0.00015930898,0.000088881156,0.000001037702,0.0009085542,0.00020584548,0.00013758929,0.0000112309535,0.005175448,0.0001718308],"about_ca_topic_score_codex":0.00075454265,"about_ca_topic_score_gemma":0.0002736367,"teacher_disagreement_score":0.1889041,"about_ca_system_score_codex":0.00019474965,"about_ca_system_score_gemma":0.00044206463,"threshold_uncertainty_score":0.5143853},"labels":[],"label_agreement":null},{"id":"W2171882815","doi":"10.3109/0284186x.2010.499371","title":"Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer","year":2010,"lang":"en","type":"review","venue":"Acta Oncologica","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Prostate Cancer Canada; U.S. Department of Defense","keywords":"Medicine; Prostate cancer; Oncology; Radiation therapy; TMPRSS2; Cancer; Internal medicine; Prostate; PTEN; Biochemical recurrence; Prostatectomy; Disease; Cancer research; Biology; Genetics","score_opus":0.03957051829063512,"score_gpt":0.3955613624689577,"score_spread":0.35599084417832255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171882815","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024072237,0.9684986,6.607806e-7,0.0002891468,0.00071207003,0.0041565145,0.0006379411,0.0000561502,0.0015767011],"genre_scores_gemma":[0.01185496,0.9845003,0.0001305531,0.000028145774,0.00038974098,0.0013101036,0.00027934293,0.000049764916,0.0014570752],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99667096,0.0004227389,0.0010668841,0.00073549384,0.0004906329,0.00061327394],"domain_scores_gemma":[0.9976652,0.00042353495,0.0008061051,0.0006507587,0.00017320666,0.0002811519],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008189606,0.0005004919,0.0026174043,0.00029359598,0.00006351488,0.000020106609,0.00038983658,0.00080961053,0.00088823086],"category_scores_gemma":[0.0009146733,0.00029366082,0.00059770985,0.00047219687,0.00052562926,0.00008253361,0.000154568,0.0019886098,0.000037017006],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007399205,0.0007594685,0.0035983543,0.008337513,0.00036181015,0.00027135274,0.00024308704,1.5528808e-7,0.0001234352,0.0000021673673,0.00063146604,0.9849313],"study_design_scores_gemma":[0.002547252,0.0018713048,0.0037335095,0.0064283977,0.0013146561,0.000056801684,0.000029135128,0.000002318772,0.00006336719,0.0001443456,0.98352236,0.00028653984],"about_ca_topic_score_codex":0.00038890942,"about_ca_topic_score_gemma":0.00012871974,"teacher_disagreement_score":0.9846447,"about_ca_system_score_codex":0.0008235778,"about_ca_system_score_gemma":0.0028990062,"threshold_uncertainty_score":0.99995154},"labels":[],"label_agreement":null},{"id":"W2176907647","doi":"10.1007/978-1-4419-0449-2_3","title":"Prostate Cancer: A Pathological Perspective","year":2009,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Intraepithelial neoplasia; Prostate cancer; Grading (engineering); High-grade prostatic intraepithelial neoplasia; Adenocarcinoma; Lymph node; Oncology; Androgen deprivation therapy; Cancer; Pathology; Biopsy; Prostate; Internal medicine; Biology","score_opus":0.042146623130993634,"score_gpt":0.35045488578303235,"score_spread":0.3083082626520387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2176907647","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015203898,0.013358618,0.000001558166,0.00819998,0.00007099015,0.0010952243,0.00007427619,0.00014597828,0.97690135],"genre_scores_gemma":[0.0021682533,0.016924122,0.00016962597,0.0007747169,0.00032967035,0.00005896486,0.000080797305,0.000042541527,0.9794513],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985771,0.000008112818,0.00018275711,0.0005114624,0.000392706,0.00032783955],"domain_scores_gemma":[0.9991148,0.000019936693,0.0000625607,0.00027548973,0.00031524597,0.00021193044],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000691903,0.0003154571,0.0005171804,0.00014046452,0.0000628875,0.00001980031,0.00007368594,0.00031258698,0.0045546973],"category_scores_gemma":[0.000012551773,0.00019468497,0.00021410319,0.000030114878,0.00017770966,0.000028194172,0.0000468637,0.0005808006,0.0003061926],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049989056,0.0005128214,0.00097494485,0.00032237635,0.001482568,0.012875051,0.0018347198,0.0000011883908,0.00055443926,0.43291056,0.0863597,0.45717272],"study_design_scores_gemma":[0.0049799713,0.00383146,0.0020083676,0.000976172,0.00062202296,0.0002854153,0.00025485305,0.000009329989,0.00048489912,0.07662345,0.9091472,0.00077687873],"about_ca_topic_score_codex":0.00006604743,"about_ca_topic_score_gemma":0.000019706751,"teacher_disagreement_score":0.82278746,"about_ca_system_score_codex":0.00072786433,"about_ca_system_score_gemma":0.0004503912,"threshold_uncertainty_score":0.9963553},"labels":[],"label_agreement":null},{"id":"W2179310179","doi":"10.14740/wjnu223w","title":"Disseminated Intravascular Coagulation as a Result of Metastatic Prostate Cancer: A Case Report","year":2015,"lang":"en","type":"article","venue":"World Journal of Nephrology and Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Disseminated intravascular coagulation; Malignancy; Occult; Prostate cancer; Consumptive Coagulopathy; Sepsis; Coagulopathy; Cancer; Prostate; Coagulation; Radiology; Intensive care medicine; Surgery; Internal medicine; Pathology","score_opus":0.03135590733785663,"score_gpt":0.3522692180565762,"score_spread":0.32091331071871954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2179310179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97837704,0.011397826,0.000032101834,0.0095298365,0.00013438109,0.00025312536,0.0000058577125,0.0000064810465,0.00026336755],"genre_scores_gemma":[0.9972873,0.0008707841,0.00027180073,0.0005137477,0.000084838604,0.0000107178075,0.000012730887,0.000010909068,0.0009371916],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9986659,0.000201675,0.00056308,0.00015489818,0.00018746003,0.00022698435],"domain_scores_gemma":[0.998538,0.00012650937,0.00043246476,0.0001446534,0.000527874,0.00023050095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000868016,0.000116518284,0.00051291747,0.00036878753,0.000043967757,0.000004646023,0.000046510984,0.000074712494,0.000056885263],"category_scores_gemma":[0.00021208006,0.00008156792,0.00007268173,0.00026125016,0.00035477206,0.000076298806,0.000030866915,0.00032702577,0.0000015006931],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049641203,0.0009615162,0.120909475,0.00029035896,0.004073141,0.75228673,0.0058433567,0.00036616952,0.019008406,0.0007829555,0.013958898,0.031877812],"study_design_scores_gemma":[0.019499728,0.010164891,0.047526926,0.00010862589,0.0024045715,0.8563268,0.00069383485,0.0005980094,0.0035511085,0.0046438943,0.05425993,0.00022163184],"about_ca_topic_score_codex":0.00017904237,"about_ca_topic_score_gemma":0.00017253702,"teacher_disagreement_score":0.10404013,"about_ca_system_score_codex":0.000044704586,"about_ca_system_score_gemma":0.00043216572,"threshold_uncertainty_score":0.33262432},"labels":[],"label_agreement":null},{"id":"W2180958531","doi":"10.3390/cancers7040890","title":"Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer","year":2015,"lang":"en","type":"review","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital","funders":"McMaster University","keywords":"Enzalutamide; Prostate cancer; Androgen deprivation therapy; Androgen receptor; Medicine; Abiraterone; Testosterone (patch); Abiraterone acetate; Cancer; Androgen; Oncology; Cancer research; Bioinformatics; Internal medicine; Biology; Hormone","score_opus":0.09250565318581327,"score_gpt":0.3965018497129142,"score_spread":0.3039961965271009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2180958531","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046126335,0.9866176,0.0000046712,0.0006241561,0.0012882709,0.007862975,0.0027358236,0.000049937862,0.00035528044],"genre_scores_gemma":[0.00015818309,0.96708935,0.00016468117,0.00015293816,0.00033136958,0.006663975,0.00034972324,0.00012667666,0.024963127],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99568653,0.00016113925,0.0012525613,0.0008145093,0.0011294428,0.0009557959],"domain_scores_gemma":[0.9969093,0.00008428758,0.00066313863,0.0007211641,0.0009923857,0.000629676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007446453,0.00073235837,0.0022245643,0.00027208318,0.0002368147,0.000067773835,0.00043898393,0.0002447504,0.00016779735],"category_scores_gemma":[0.000018079983,0.0004250681,0.00034549684,0.0010068769,0.0002680762,0.00008730805,0.00015986971,0.00057548104,0.00007734475],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0008308163,0.000044184464,0.000041421074,0.019095028,0.0016475258,0.000063363615,0.0040002856,0.00016946456,0.00011975308,0.0000070971123,0.035756584,0.9382245],"study_design_scores_gemma":[0.0015553979,0.00024863708,0.000016414751,0.016935892,0.0012072588,0.000005744803,0.00039430588,0.0000062702948,0.00078641454,0.000002278632,0.9783947,0.00044671702],"about_ca_topic_score_codex":0.0012829038,"about_ca_topic_score_gemma":0.0026639788,"teacher_disagreement_score":0.9426381,"about_ca_system_score_codex":0.010396986,"about_ca_system_score_gemma":0.039344065,"threshold_uncertainty_score":0.9998201},"labels":[],"label_agreement":null},{"id":"W2185458335","doi":"10.1016/j.jsbmb.2015.09.021","title":"Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer","year":2015,"lang":"en","type":"article","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Ectopic expression; Androgen receptor; Dihydrotestosterone; Androgen; Cancer research; Endocrinology; Testosterone (patch); microRNA; Internal medicine; Prostate; Medicine; Chemistry; Biology; Cancer; Gene; Genetics; Hormone","score_opus":0.015514029294175431,"score_gpt":0.30874366519983537,"score_spread":0.2932296359056599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2185458335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790857,0.01917644,0.00017601409,0.0013076777,0.00003211573,0.0001545357,0.00001802966,0.0000018313291,0.000047683017],"genre_scores_gemma":[0.9978204,0.0018392255,0.000103764265,0.0000857337,0.0000331684,0.000003987919,0.000017338778,0.000008098959,0.00008833026],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992354,0.00009600742,0.00030744233,0.00009841804,0.00010605461,0.0001566728],"domain_scores_gemma":[0.9994481,0.000034848097,0.00017117475,0.00010447118,0.0001519505,0.00008943094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032290598,0.00010246227,0.00023626667,0.000049000126,0.00002229486,0.000004822501,0.000077449804,0.000065972345,0.000005942816],"category_scores_gemma":[0.00004045036,0.0000629276,0.000036692596,0.00009320083,0.00019821126,0.000025162048,0.00002760236,0.00017002565,1.4290318e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013330914,0.00006591586,0.010306017,0.00008655223,0.000076590586,0.000012774042,0.00045739318,0.000008077694,0.98457897,0.0000010490788,0.000074286334,0.0029992852],"study_design_scores_gemma":[0.0023932098,0.000750977,0.0016448273,0.00019117081,0.000055584496,0.00013211739,0.0004596812,0.000008854471,0.99404055,0.00010360664,0.00016160439,0.00005779388],"about_ca_topic_score_codex":0.000049406844,"about_ca_topic_score_gemma":0.0000022878514,"teacher_disagreement_score":0.018734679,"about_ca_system_score_codex":0.00006636826,"about_ca_system_score_gemma":0.00016580072,"threshold_uncertainty_score":0.2566113},"labels":[],"label_agreement":null},{"id":"W218569663","doi":"10.1016/j.ijrobp.2006.07.046","title":"22","year":2006,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; McGill University Health Centre","funders":"","keywords":"Medicine","score_opus":0.024188553287802016,"score_gpt":0.36576779487348243,"score_spread":0.3415792415856804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W218569663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95307547,0.0026332925,0.00762864,0.014327328,0.003774111,0.0003466535,0.00006874319,0.00006585438,0.018079901],"genre_scores_gemma":[0.99145144,0.0006692432,0.0017684215,0.0006293251,0.0044506816,0.000007584436,0.00013897846,0.00001965558,0.00086467445],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987928,0.00009139735,0.00048030994,0.00014354002,0.0002915492,0.00020036534],"domain_scores_gemma":[0.998433,0.00016927595,0.0004595572,0.000100017045,0.00074296916,0.00009519898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031468295,0.00012499091,0.00030806666,0.000155205,0.00005152874,0.000020492902,0.00021536306,0.00015126416,0.00018665043],"category_scores_gemma":[0.00009427402,0.0000968024,0.00019425624,0.00013211794,0.00015329858,0.00017113732,0.000036698257,0.00034615243,0.00006626422],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011931201,0.0010975304,0.69591033,0.000011649086,0.0008182106,0.00028973314,0.0001620021,0.00026795754,0.016614078,0.02519086,0.02150458,0.23693995],"study_design_scores_gemma":[0.028512096,0.004256991,0.21452506,0.00013637525,0.00035567826,0.0011398263,0.00012729455,0.0017898774,0.033361938,0.0783202,0.637056,0.00041864757],"about_ca_topic_score_codex":0.000032644977,"about_ca_topic_score_gemma":0.0000025041538,"teacher_disagreement_score":0.6155514,"about_ca_system_score_codex":0.0007532191,"about_ca_system_score_gemma":0.000595696,"threshold_uncertainty_score":0.39474875},"labels":[],"label_agreement":null},{"id":"W2187815530","doi":"10.1200/jco.2013.31.6_suppl.3","title":"High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Jewish General Hospital; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; McGill University; Centre Hospitalier de l’Université de Montréal; Centre Hospitalier Universitaire de Sherbrooke; McGill University Health Centre; Centre de Santé et de Services Sociaux de Chicoutimi; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Prostate cancer; Goserelin; Urology; Clinical endpoint; Hazard ratio; Randomized controlled trial; Bicalutamide; Prostate; Radiation therapy; Cancer; Proportional hazards model; Internal medicine; Surgery; Confidence interval","score_opus":0.0717215730904065,"score_gpt":0.46243297186220134,"score_spread":0.39071139877179484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2187815530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907708,0.0046980064,0.000006383952,0.0019371462,0.00021881153,0.0021177197,0.00003484939,0.0000062265894,0.00021005905],"genre_scores_gemma":[0.9777585,0.020446803,0.0007994381,0.000045605775,0.0002593229,0.000061779174,0.000004866019,0.00002019762,0.0006034312],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99550635,0.00091582775,0.0026457498,0.00023144236,0.00045224137,0.00024839258],"domain_scores_gemma":[0.99217904,0.003545427,0.002764237,0.00021064088,0.00094554,0.00035513213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031347165,0.0001861012,0.0031099152,0.00018453805,0.000037369162,0.000007831063,0.00011173251,0.00019533787,0.0001645433],"category_scores_gemma":[0.0013908554,0.00009547882,0.00029679577,0.00022010048,0.00072297663,0.000100278805,0.00002712245,0.0005734029,8.440876e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86247945,0.004808984,0.03404777,0.000036868336,0.0048155254,0.00029460515,0.00086722174,0.00001784355,0.00041866,0.0000012721989,0.0010046865,0.09120714],"study_design_scores_gemma":[0.8988499,0.078457594,0.017551327,0.00014913153,0.0019366512,0.00003890001,0.00048990804,0.00024399212,0.0012956088,0.000031597883,0.00086561096,0.00008977105],"about_ca_topic_score_codex":0.0022192588,"about_ca_topic_score_gemma":0.0001366553,"teacher_disagreement_score":0.09111737,"about_ca_system_score_codex":0.0001289397,"about_ca_system_score_gemma":0.0014435153,"threshold_uncertainty_score":0.38935134},"labels":[],"label_agreement":null},{"id":"W2190126170","doi":"10.1016/j.eururo.2015.11.025","title":"It Is Time to Harmonize the Design and Conduct of Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer","year":2015,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Clinical trial; Prostate cancer; Oncology; Internal medicine; Population; Androgen deprivation therapy; Medical physics; Family medicine; Cancer","score_opus":0.36813012458798644,"score_gpt":0.47041072013199176,"score_spread":0.10228059554400531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2190126170","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007612138,0.004900318,0.000030481744,0.9804936,0.00020321083,0.0032502061,0.00027461312,0.000019970948,0.0032154263],"genre_scores_gemma":[0.0050528822,0.0030919195,0.0005510067,0.9596221,0.0015145437,0.0001314554,0.0001844872,0.000152179,0.02969944],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98587966,0.011398487,0.0012785341,0.0006073205,0.00036156454,0.00047440824],"domain_scores_gemma":[0.9950296,0.0036043264,0.00046232116,0.00043123518,0.00030251316,0.0001699645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013049669,0.00031748775,0.0019008504,0.0002274326,0.000034358276,0.000019336396,0.00019055262,0.00018800578,0.00027112194],"category_scores_gemma":[0.00286734,0.0001779646,0.00017917638,0.0002102934,0.00049612735,0.00003054599,0.00017812333,0.0015468458,0.00044986533],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039152247,0.000049361883,0.00009156864,0.000053673633,0.0006395708,0.0031429597,0.001602522,0.000005292506,0.00053392776,2.5540646e-7,0.9854238,0.0045418227],"study_design_scores_gemma":[0.0060113496,0.0029798287,0.0014812908,0.00008151925,0.0008378385,0.00009125586,0.000049846283,0.000110940746,0.00023427026,0.000033080658,0.98788774,0.00020102767],"about_ca_topic_score_codex":0.00005050964,"about_ca_topic_score_gemma":0.000002373542,"teacher_disagreement_score":0.026484013,"about_ca_system_score_codex":0.000057915786,"about_ca_system_score_gemma":0.0006060622,"threshold_uncertainty_score":0.72571856},"labels":[],"label_agreement":null},{"id":"W2196689106","doi":"10.1093/annonc/mdv594","title":"A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; University of Toronto; BC Cancer Agency","funders":"Janssen Pharmaceuticals; Genomic Health; Foundation Medicine; Chugai Pharmaceutical; Genentech; Bavarian Nordic; MannKind Corporation; Astellas Pharma; Teva Pharmaceutical Industries; Janssen Biotech; Les Laboratories Pierre Fabre; Endocyte; Exelixis; Sanofi; National Cancer Institute; GlaxoSmithKline; Takeda Oncology; Amgen; Pfizer; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Abiraterone acetate; Medicine; Docetaxel; Prostate cancer; Proportional hazards model; Hazard ratio; Internal medicine; Prednisone; Oncology; Univariate analysis; Population; Androgen deprivation therapy; Cancer; Multivariate analysis; Confidence interval","score_opus":0.10167911792994017,"score_gpt":0.37997730679471775,"score_spread":0.2782981888647776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2196689106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995542,0.0003216629,0.000102293496,0.0010509854,0.00002640002,0.0025240863,0.00023927115,0.000020903291,0.00017242394],"genre_scores_gemma":[0.99697137,0.00005694307,0.0008008845,0.00013580499,0.00002101437,0.0011876676,0.00015489614,0.000037440714,0.0006339672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983168,0.000085186606,0.00038352743,0.00033086073,0.00038887918,0.0004946928],"domain_scores_gemma":[0.9983855,0.00008485295,0.00020641317,0.00016574931,0.0009502723,0.00020722172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032544733,0.00021864501,0.0005767152,0.00017891177,0.000032330285,0.000014843041,0.000062976396,0.00006959118,0.000009517077],"category_scores_gemma":[0.000061029354,0.00013568126,0.00004070655,0.00022358657,0.00016001854,0.00018588184,0.000024084782,0.00015208795,0.0000010163412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067495175,0.0012180597,0.92259103,0.00028742166,0.00047118877,0.00011659468,0.0018063713,0.0035927144,0.000116178424,0.000009463754,0.000117701275,0.0021780943],"study_design_scores_gemma":[0.05478973,0.027481152,0.891131,0.0005716516,0.0004122636,0.0000073444344,0.00033954685,0.023761665,0.0008414071,0.00021809712,0.00014037717,0.00030579153],"about_ca_topic_score_codex":0.00049642654,"about_ca_topic_score_gemma":0.0018512221,"teacher_disagreement_score":0.03146006,"about_ca_system_score_codex":0.00017453845,"about_ca_system_score_gemma":0.001256477,"threshold_uncertainty_score":0.5532921},"labels":[],"label_agreement":null},{"id":"W2197212505","doi":"10.1371/journal.pone.0132343","title":"Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients","year":2015,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"National Cancer Institute; Canary Foundation; U.S. Department of Defense","keywords":"Prostatectomy; Immunohistochemistry; Erg; Cohort; Medicine; Staining; Pathology; Cohort study; Internal medicine; Urology; Oncology; Gynecology; Prostate cancer; Ophthalmology; Cancer","score_opus":0.1670394307588242,"score_gpt":0.38412028364360906,"score_spread":0.21708085288478488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2197212505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970585,0.001629706,0.000008610118,0.00011539813,0.000010306427,0.001014118,0.000036788984,0.000007861682,0.000118717624],"genre_scores_gemma":[0.998175,0.00015186181,0.0014187605,0.000014237267,0.000006303068,0.00008686799,0.00010716842,0.0000056635245,0.000034104927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984023,0.00009989028,0.0003140519,0.00018880217,0.0008607224,0.00013420975],"domain_scores_gemma":[0.9992281,0.000059966005,0.000076784185,0.000092365895,0.00043296,0.0001097796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010620405,0.00008906957,0.00038352344,0.00007653084,0.000018462782,0.0000033382178,0.00003093557,0.000085598695,0.000011212789],"category_scores_gemma":[0.0012667691,0.00006172173,0.000021440583,0.00008160785,0.00038221423,0.000050633218,0.000053691783,0.00015439329,7.314799e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006408205,0.0032018924,0.97800815,0.000100224766,0.00009024085,0.000005326429,0.00024766123,4.7922435e-7,0.016103199,0.00000736592,0.000011721298,0.0015829453],"study_design_scores_gemma":[0.018316524,0.001205829,0.9612987,0.0002961559,0.00029718442,0.0000023475563,0.00007814275,0.0017016816,0.016635926,0.00008548557,0.0000047091607,0.000077337216],"about_ca_topic_score_codex":0.000026656606,"about_ca_topic_score_gemma":0.0000011659301,"teacher_disagreement_score":0.017675705,"about_ca_system_score_codex":0.00017474753,"about_ca_system_score_gemma":0.00027832642,"threshold_uncertainty_score":0.2516939},"labels":[],"label_agreement":null},{"id":"W2198033618","doi":"10.1016/j.clgc.2015.12.023","title":"Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Cancer Society Research Institute","keywords":"Prostate cancer; Medicine; Androgen receptor; Prostate; Cancer; Cancer research; Androgen deprivation therapy; Oncology; Androgen; Adenocarcinoma; Internal medicine; Hormone","score_opus":0.12458159150662867,"score_gpt":0.45912500398680195,"score_spread":0.3345434124801733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2198033618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851264,0.0071963714,0.0000055303344,0.0046209395,0.0007909575,0.0016234394,0.0003698856,0.00009949332,0.0001669974],"genre_scores_gemma":[0.99394673,0.0014167671,0.00049845944,0.0006131251,0.0008187268,0.0005507743,0.000052509233,0.000084269814,0.0020186075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99602735,0.00068473927,0.0010389221,0.00087436364,0.00060037454,0.00077427336],"domain_scores_gemma":[0.99694294,0.00034575997,0.00020036023,0.0005883366,0.00065345713,0.0012691317],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000821309,0.0003678103,0.0008788811,0.0003580384,0.00007275043,0.000025852556,0.0002393442,0.0001360747,0.0001266938],"category_scores_gemma":[0.00067192176,0.00030519592,0.00021003361,0.0007618983,0.0003599082,0.00019558304,0.00027760735,0.00065159786,0.000016674896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38152105,0.0023301798,0.41269648,0.0009479265,0.00038474944,0.112890124,0.016168172,0.000795414,0.020462181,0.000007662256,0.004961106,0.04683497],"study_design_scores_gemma":[0.18412295,0.15134145,0.45063522,0.0056530354,0.0020128707,0.012493389,0.038077507,0.0059702075,0.07019989,0.000106626816,0.075184084,0.004202752],"about_ca_topic_score_codex":0.0016877502,"about_ca_topic_score_gemma":0.00036499006,"teacher_disagreement_score":0.19739808,"about_ca_system_score_codex":0.0006718378,"about_ca_system_score_gemma":0.002551776,"threshold_uncertainty_score":0.99994004},"labels":[],"label_agreement":null},{"id":"W2198966903","doi":"10.1186/s13550-015-0155-6","title":"The dog prostate cancer (DPC-1) model: a reliable tool for molecular imaging of prostate tumors and metastases","year":2015,"lang":"en","type":"article","venue":"EJNMMI Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; BioPhage Pharma (Canada); Centre Hospitalier Universitaire de Sherbrooke; McGill University Health Centre","funders":"McGill University","keywords":"Prostate cancer; Medicine; LNCaP; Prostate; Pathology; Immunohistochemistry; Cancer; Lymph; PCA3; Nuclear medicine; Internal medicine","score_opus":0.07634442533192384,"score_gpt":0.42429030500693404,"score_spread":0.34794587967501023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2198966903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9484968,0.031638872,0.00011071346,0.013387896,0.000070889655,0.0046377853,0.0002335431,0.00005053887,0.0013729739],"genre_scores_gemma":[0.97768784,0.0033945984,0.0015969513,0.00009693881,0.000068588175,0.0017328933,0.00005190632,0.000071925664,0.015298349],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99710613,0.00014224315,0.00029601657,0.00042692327,0.0011185196,0.00091017614],"domain_scores_gemma":[0.99738514,0.00026953846,0.00006812826,0.00045343203,0.0015007548,0.00032299812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030610322,0.00017866195,0.00033137653,0.00018012694,0.0003183956,0.000113837756,0.00019302244,0.000040327515,0.000009174649],"category_scores_gemma":[0.00050067075,0.00010752407,0.00008133233,0.00049389165,0.00063961913,0.00016289757,0.00022544157,0.00036953387,0.0000056017434],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038168866,0.0016944546,0.34435484,0.005785672,0.0020418998,0.0012454448,0.014603958,0.0033341737,0.17152633,0.011979225,0.2695418,0.13572334],"study_design_scores_gemma":[0.038142707,0.0055401465,0.006565479,0.0022080399,0.0004959387,0.00014374215,0.008395409,0.17303592,0.62996036,0.032706626,0.10159479,0.0012108358],"about_ca_topic_score_codex":0.0003916615,"about_ca_topic_score_gemma":0.00001668337,"teacher_disagreement_score":0.45843405,"about_ca_system_score_codex":0.00022374708,"about_ca_system_score_gemma":0.0015042631,"threshold_uncertainty_score":0.43847045},"labels":[],"label_agreement":null},{"id":"W2199700205","doi":"10.1200/jco.2010.28.18_suppl.cra4504","title":"Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633).","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Clinical endpoint; Hazard ratio; Urology; Radiation therapy; Interim analysis; Randomized controlled trial; Internal medicine; Oncology; Goserelin; Surgery; Cancer; Confidence interval","score_opus":0.07664262798473125,"score_gpt":0.4912143294757997,"score_spread":0.4145717014910684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2199700205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98692214,0.005127053,0.00009355847,0.0030897409,0.0013705518,0.0031623752,0.0000064449637,0.000013865189,0.00021429065],"genre_scores_gemma":[0.9514823,0.046440337,0.00035489348,0.00063905405,0.0006197872,0.00018536506,0.000015771657,0.00003509863,0.00022740857],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939256,0.0010934924,0.003554085,0.0003660251,0.00067673216,0.00038408462],"domain_scores_gemma":[0.9939725,0.0019998562,0.0024691655,0.0003308172,0.0008856476,0.00034201462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061688465,0.00028089108,0.0028094922,0.00042437424,0.000058364287,0.000017355891,0.00028717233,0.00041626117,0.0003539658],"category_scores_gemma":[0.0013929681,0.00017484749,0.0004904362,0.0004119478,0.00039320695,0.00025976796,0.00005345947,0.0016940506,0.0000042673537],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49366903,0.0062936805,0.042316835,0.000017517714,0.0009240975,0.0001893237,0.0020819735,0.00006376689,0.003933594,0.000014012482,0.00026416025,0.450232],"study_design_scores_gemma":[0.9239531,0.029642181,0.03247879,0.00015976885,0.0002295813,0.00004580804,0.0005676269,0.0008364804,0.004414396,0.0004288483,0.0070462856,0.00019713333],"about_ca_topic_score_codex":0.00033758464,"about_ca_topic_score_gemma":0.0004905811,"teacher_disagreement_score":0.4500349,"about_ca_system_score_codex":0.00036117688,"about_ca_system_score_gemma":0.0029484627,"threshold_uncertainty_score":0.7359901},"labels":[],"label_agreement":null},{"id":"W2200420649","doi":"10.1016/j.ijrobp.2015.10.046","title":"Patient-Reported Outcomes in NRG Oncology/RTOG 0938, a Randomized Phase 2 Study Evaluating 2 Ultrahypofractionated Regimens (UHRs) for Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McMaster University; Grand River Hospital; Hôpital Notre-Dame; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Oncology; Genitourinary system; Internal medicine; Quality of life (healthcare); Prostate; Radiation therapy; Cancer","score_opus":0.08119936446946018,"score_gpt":0.4718278260251652,"score_spread":0.390628461555705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2200420649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984655,0.00080560317,0.00080484845,0.0073610004,0.0027505122,0.0031730786,0.00010489361,0.000041454176,0.00030355775],"genre_scores_gemma":[0.9950644,0.00052160927,0.0017304464,0.0006113736,0.00083997153,0.0006348645,0.0002475949,0.00004107767,0.00030867776],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99618053,0.00083329383,0.001589415,0.00037353375,0.00064572797,0.00037751553],"domain_scores_gemma":[0.9930242,0.0015148991,0.0020269654,0.00017857201,0.0030074401,0.00024797255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029750238,0.0002846047,0.0012905685,0.0004281352,0.00008411393,0.000031817963,0.00022752916,0.00023756201,0.00004714542],"category_scores_gemma":[0.0030734844,0.00021011618,0.0003406765,0.0002987958,0.00023011825,0.00034272054,0.000053181215,0.00061201275,0.000008201249],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19568063,0.0089223245,0.49333352,0.000018091047,0.005386185,0.00038152735,0.0080315275,0.0014568424,0.004223221,0.00027314943,0.0016322724,0.2806607],"study_design_scores_gemma":[0.9335164,0.020308519,0.00953658,0.0001454656,0.0011450341,0.00025199153,0.0030245995,0.010654304,0.00238214,0.006974155,0.011664595,0.00039621064],"about_ca_topic_score_codex":0.00020366393,"about_ca_topic_score_gemma":0.00003171761,"teacher_disagreement_score":0.73783576,"about_ca_system_score_codex":0.0030631004,"about_ca_system_score_gemma":0.003386141,"threshold_uncertainty_score":0.8568289},"labels":[],"label_agreement":null},{"id":"W2202400394","doi":"10.1200/jco.2012.30.15_suppl.4509","title":"Final analysis of intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Credit Valley Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Hazard ratio; Interim analysis; Internal medicine; Oncology; Urology; Radiation therapy; Randomized controlled trial; Cancer; Gynecology; Surgery; Confidence interval","score_opus":0.12790433469173054,"score_gpt":0.5098900642798907,"score_spread":0.38198572958816013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2202400394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98428965,0.012174877,0.0002274709,0.0009134143,0.0004619157,0.0018258205,0.000009567051,0.0000059014887,0.0000913575],"genre_scores_gemma":[0.9502,0.04872194,0.00026124177,0.00027638115,0.00029440038,0.00010041808,0.000024380606,0.000019185536,0.000102024096],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99371123,0.001371162,0.003659538,0.00024654964,0.0006567298,0.00035478026],"domain_scores_gemma":[0.99365336,0.0019702408,0.0030544156,0.0002625883,0.0007774511,0.00028196184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006664393,0.00022377734,0.0034715412,0.0007978365,0.000035129542,0.0000068711465,0.00020356846,0.00026670363,0.0002442265],"category_scores_gemma":[0.001055206,0.00014006117,0.0007427277,0.00092953397,0.00028488354,0.00026000515,0.0000421208,0.00071907055,0.0000011133263],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47537792,0.008140675,0.20918334,0.000019208841,0.005347213,0.000044904522,0.003296742,0.00041835738,0.0008919905,0.000008447753,0.00008722817,0.29718396],"study_design_scores_gemma":[0.79371524,0.022597613,0.1748784,0.0001367629,0.0018605189,0.0000112966145,0.0008787092,0.001861019,0.0025714065,0.00009092719,0.0012430542,0.0001550272],"about_ca_topic_score_codex":0.00036547324,"about_ca_topic_score_gemma":0.0002302639,"teacher_disagreement_score":0.31833735,"about_ca_system_score_codex":0.0004472785,"about_ca_system_score_gemma":0.0016343773,"threshold_uncertainty_score":0.57115287},"labels":[],"label_agreement":null},{"id":"W2203257133","doi":"10.1016/j.purol.2015.08.039","title":"PAX6 est un modulateur de l’activité transcriptionnelle du récepteur aux androgènes dans le cancer de prostate","year":2015,"lang":"fr","type":"article","venue":"Progrès en Urologie","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Molecular biology; Biology","score_opus":0.0638047909211099,"score_gpt":0.3257280247384387,"score_spread":0.2619232338173288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2203257133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8519306,0.1001071,0.001096077,0.040363196,0.0013429073,0.0016697475,0.00014672882,0.00030298476,0.003040605],"genre_scores_gemma":[0.9622172,0.018629242,0.0010015696,0.00046321587,0.0011724062,0.0009045008,0.0000851121,0.00011208391,0.015414672],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959339,0.00061468955,0.0004002987,0.0007297199,0.00049230404,0.0018290884],"domain_scores_gemma":[0.9981184,0.00014807215,0.000114814065,0.00044820318,0.00030667672,0.0008638275],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013118517,0.00048825596,0.0005545871,0.000140613,0.00031485324,0.0001228715,0.00036269464,0.0004288664,0.00024038441],"category_scores_gemma":[0.000294189,0.00041651013,0.0002001549,0.0004306391,0.0006906041,0.0003974719,0.00013568855,0.00074351445,0.00015879203],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028173383,0.0024684786,0.6660625,0.0005817679,0.000809264,0.0021006628,0.020911083,0.0023298147,0.013580028,0.00080997683,0.003789538,0.2837396],"study_design_scores_gemma":[0.044054434,0.013224057,0.2762549,0.00097264675,0.0027355342,0.001506065,0.017058011,0.056195337,0.20199607,0.020043552,0.36329728,0.0026621078],"about_ca_topic_score_codex":0.004268368,"about_ca_topic_score_gemma":0.00032403486,"teacher_disagreement_score":0.38980755,"about_ca_system_score_codex":0.0011103097,"about_ca_system_score_gemma":0.003626806,"threshold_uncertainty_score":0.9998287},"labels":[],"label_agreement":null},{"id":"W2204221336","doi":"10.1200/jco.2012.30.15_suppl.4510","title":"Effect of denosumab on prolonging bone-metastasis free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Denosumab; Placebo; Clinical endpoint; Surgery; Prostate cancer; Population; Urology; Internal medicine; Bone metastasis; Cancer; Randomized controlled trial; Osteoporosis; Pathology","score_opus":0.07110886579197705,"score_gpt":0.4521721102600956,"score_spread":0.38106324446811857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2204221336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993633,0.0020493292,0.000014348061,0.0015392893,0.00023887059,0.0010171554,0.00003069324,0.0000067185097,0.0014706007],"genre_scores_gemma":[0.9971235,0.0008441282,0.001262704,0.00005639018,0.00036441945,0.00005663378,0.0000063815583,0.000042880678,0.00024298752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951701,0.001178113,0.0017248841,0.00027146656,0.00096108945,0.00069435127],"domain_scores_gemma":[0.9932542,0.0029993076,0.0025235487,0.00030387353,0.0004449168,0.0004741891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004597979,0.00028776098,0.002055059,0.00032691885,0.00004641961,0.000015390746,0.00020363425,0.00017607766,0.000061254075],"category_scores_gemma":[0.0017418772,0.00014933909,0.00023220881,0.00038750362,0.00043114505,0.00019497477,0.00007862106,0.0011403572,0.0000029202263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13518758,0.0035889721,0.7937876,0.0008221029,0.0021370582,0.0059295343,0.0009379112,0.0003791594,0.0015586987,0.00002177213,0.00038964293,0.055259965],"study_design_scores_gemma":[0.08670447,0.15948501,0.7179799,0.0033673223,0.0032221642,0.0008718056,0.0008302125,0.0002379111,0.025359895,0.000056831104,0.0014349719,0.0004495057],"about_ca_topic_score_codex":0.00017963517,"about_ca_topic_score_gemma":0.00036665838,"teacher_disagreement_score":0.15589604,"about_ca_system_score_codex":0.00032442264,"about_ca_system_score_gemma":0.0012066604,"threshold_uncertainty_score":0.6089871},"labels":[],"label_agreement":null},{"id":"W2213227385","doi":"10.1007/978-1-4614-6182-1_9","title":"Androgen-Responsive Gene Expression in Prostate Cancer Progression","year":2013,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Prostate cancer; Androgen receptor; Androgen; Prostate; Cancer research; Transcription factor; Biology; Internal medicine; Endocrinology; Medicine; Cancer; Gene; Hormone; Genetics","score_opus":0.033828429510261555,"score_gpt":0.34496402771270746,"score_spread":0.3111355982024459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2213227385","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03081156,0.065462776,0.000006846437,0.003924888,0.00049041834,0.009772702,0.00020711774,0.00025793197,0.88906574],"genre_scores_gemma":[0.0035379136,0.0164917,0.0008863486,0.00018981213,0.00021088173,0.0006887286,0.00029878478,0.00011312197,0.9775827],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99788415,0.000025400044,0.0003810992,0.00062521984,0.0006132394,0.00047090763],"domain_scores_gemma":[0.99883467,0.000042242824,0.00014301267,0.00042536555,0.00026935243,0.0002853591],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012320711,0.00042831217,0.0006083141,0.00039197935,0.00006617803,0.000032724503,0.000107718646,0.00035745857,0.007453474],"category_scores_gemma":[0.000015081585,0.00026746152,0.00013726464,0.000060729086,0.0001393983,0.000102594306,0.0001522269,0.0005741731,0.00045774126],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02035609,0.0010232414,0.01890743,0.0028321615,0.001189964,0.010264265,0.0024193795,0.000010484104,0.18705569,0.0033136765,0.16842887,0.5841988],"study_design_scores_gemma":[0.0131089445,0.0018295026,0.0021953203,0.01177273,0.00026988468,0.00015746798,0.00009760998,0.000077552024,0.37057894,0.0031307505,0.59544826,0.0013330318],"about_ca_topic_score_codex":0.00007017434,"about_ca_topic_score_gemma":0.00003019605,"teacher_disagreement_score":0.5828657,"about_ca_system_score_codex":0.0004379654,"about_ca_system_score_gemma":0.0006320161,"threshold_uncertainty_score":0.99997777},"labels":[],"label_agreement":null},{"id":"W2218191974","doi":"10.1158/1538-7445.am2015-1652","title":"Abstract 1652: Therapeutic targeting of ETS factor ERG for the treatment of prostate cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"TMPRSS2; Prostate cancer; Erg; ETS transcription factor family; Cancer research; Prostate; Transcription factor; Cancer; Fusion gene; Chromoplexy; Medicine; Biology; Internal medicine; Disease; Gene; PCA3; Genetics; Neuroscience","score_opus":0.25598791353889366,"score_gpt":0.4918970224277504,"score_spread":0.23590910888885674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2218191974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9109202,0.08060437,0.00001019066,0.0043173595,0.00023667936,0.0030997668,0.00037627234,0.000018805504,0.0004163335],"genre_scores_gemma":[0.9748223,0.018564343,0.000052922755,0.000029872323,0.00032281555,0.0018839809,0.000027997115,0.0000435149,0.004252289],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99769336,0.00008007994,0.00033478218,0.0003092558,0.0009340758,0.0006484481],"domain_scores_gemma":[0.99735266,0.00056305877,0.00010894658,0.0003828824,0.0013553757,0.00023708642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006903124,0.00017174531,0.00039806112,0.00017369802,0.00014245656,0.00002042913,0.00020218294,0.00008267816,0.00035960102],"category_scores_gemma":[0.00010496586,0.00009165195,0.00015639773,0.00042969442,0.00042612807,0.00006869997,0.00003789706,0.00021489996,0.0000064492397],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018706854,0.0022723216,0.13940094,0.002079653,0.0027718493,0.000045405828,0.022902869,0.00027063445,0.34567684,0.00018494995,0.01896131,0.44672638],"study_design_scores_gemma":[0.012589502,0.0050609973,0.047076553,0.0004940265,0.00018386867,0.000002338483,0.0034347007,0.00028774975,0.7954086,0.00040966272,0.13481778,0.00023419227],"about_ca_topic_score_codex":0.003406842,"about_ca_topic_score_gemma":0.00021453614,"teacher_disagreement_score":0.4497318,"about_ca_system_score_codex":0.0008703167,"about_ca_system_score_gemma":0.0020118735,"threshold_uncertainty_score":0.5150148},"labels":[],"label_agreement":null},{"id":"W2218712189","doi":"10.6000/1927-7229.2015.04.04.5","title":"The Role of the IGF Axis in Epithelial-to-Mesenchymal Transition during the Progression of Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"Journal of Analytical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Epithelial–mesenchymal transition; Vimentin; Cancer; Cancer research; Prostate; Medicine; Tumor progression; Oncology; Internal medicine; Metastasis; Immunohistochemistry","score_opus":0.023767323199884144,"score_gpt":0.37893150803423187,"score_spread":0.35516418483434775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2218712189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96687883,0.0014592167,0.0000032492403,0.030317398,0.00012247081,0.00037067986,0.0000060897414,0.0000014032323,0.0008406487],"genre_scores_gemma":[0.99882156,0.0004929257,0.000043691452,0.000073878,0.00014545483,0.000011251353,3.2198813e-7,0.0000065957893,0.0004043185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985177,0.00021319733,0.00049378927,0.0000790299,0.00047988133,0.00021640901],"domain_scores_gemma":[0.9988727,0.00019234259,0.0002443126,0.00014281525,0.0004120097,0.00013585176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010238843,0.000075224176,0.0003295653,0.000092235576,0.00005772668,0.000005953719,0.00017126148,0.00006941244,0.000019548163],"category_scores_gemma":[0.00023797007,0.00002738806,0.00013927821,0.00035028553,0.00030968152,0.00004386011,0.00004598246,0.00037777526,0.0000012818026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062132303,0.0035658,0.537083,0.00039379988,0.0014890768,0.00062546885,0.029484112,0.0026023719,0.12519789,0.0016587339,0.0022241054,0.23354329],"study_design_scores_gemma":[0.023064556,0.018709216,0.6816006,0.002016141,0.00097497966,0.00074200187,0.013026196,0.0056420756,0.19292195,0.0043342747,0.05669596,0.00027209468],"about_ca_topic_score_codex":0.00007921301,"about_ca_topic_score_gemma":0.00011672196,"teacher_disagreement_score":0.2332712,"about_ca_system_score_codex":0.00028152097,"about_ca_system_score_gemma":0.001009857,"threshold_uncertainty_score":0.17914431},"labels":[],"label_agreement":null},{"id":"W2222289322","doi":"10.1016/j.jmoldx.2015.10.001","title":"Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence","year":2016,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"National Cancer Institute","keywords":"PTEN; Biochemical recurrence; Prostate cancer; TMPRSS2; Hazard ratio; Erg; Proportional hazards model; Oncology; breakpoint cluster region; Cancer; Internal medicine; Fluorescence in situ hybridization; Medicine; Cancer research; Biology; Pathology; Chromosome; Disease; Confidence interval; Genetics; Prostatectomy; Gene","score_opus":0.013063392687460908,"score_gpt":0.28609624336262135,"score_spread":0.2730328506751604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2222289322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99495274,0.0032554513,0.00029636634,0.00079418684,0.00033763042,0.00025159476,0.00006490651,0.000005328014,0.000041778447],"genre_scores_gemma":[0.9939325,0.0056900475,0.00005804117,0.000022626635,0.000079288744,0.000011838496,0.000004568146,0.000017124961,0.00018397707],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986994,0.00007108408,0.00043646686,0.00009486598,0.0005141215,0.00018401723],"domain_scores_gemma":[0.99797845,0.00024091489,0.0005451636,0.00013174508,0.0009913781,0.000112342655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034561715,0.00010054485,0.0002704689,0.00012326872,0.000030052415,0.000016683709,0.00010163549,0.0000561369,0.000017440098],"category_scores_gemma":[0.0007561562,0.000057374837,0.00007755936,0.0001537685,0.00014714285,0.00010494194,0.00002060201,0.00013582931,0.0000023974956],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036792872,0.00093589415,0.6079636,0.00020633583,0.0014238608,0.001090455,0.0013115491,0.000038158672,0.3700768,0.0008258723,0.0013297313,0.011118455],"study_design_scores_gemma":[0.010305915,0.0031418307,0.44670832,0.0026417607,0.00063660985,0.000062288535,0.00009457028,0.0000081230655,0.53433037,0.0015131276,0.00036823095,0.00018888831],"about_ca_topic_score_codex":0.000016285205,"about_ca_topic_score_gemma":0.0000021861163,"teacher_disagreement_score":0.16425355,"about_ca_system_score_codex":0.00021502099,"about_ca_system_score_gemma":0.0004851453,"threshold_uncertainty_score":0.2339678},"labels":[],"label_agreement":null},{"id":"W2222700722","doi":"10.1200/jco.2012.30.15_suppl.4","title":"Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prostate Cancer Canada","funders":"","keywords":"Medicine; Prostate cancer; INT; Androgen deprivation therapy; Oncology; Clinical trial; Internal medicine; Urology; Gynecology; Cancer","score_opus":0.1729421620923322,"score_gpt":0.5120540794502855,"score_spread":0.33911191735795326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2222700722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934441,0.0006219124,0.00001915737,0.0018422384,0.0024052695,0.0009373596,0.00009690278,0.000006126306,0.0006269585],"genre_scores_gemma":[0.99453074,0.0035924108,0.0005045685,0.0002226187,0.0007945776,0.000026524505,0.0001027949,0.00001852907,0.00020721905],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952964,0.00063657673,0.0028317615,0.00022820351,0.00064854755,0.00035846536],"domain_scores_gemma":[0.99487585,0.0011759815,0.0021985276,0.00018254592,0.0011285009,0.00043860672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037216102,0.00017376206,0.0013245204,0.00029559268,0.000027542967,0.000010232351,0.00016661161,0.00019182524,0.00004613736],"category_scores_gemma":[0.0034070897,0.000120640965,0.00029177617,0.00018968443,0.00022315986,0.00044417073,0.00007833581,0.00072656514,0.00000547742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68147695,0.011973097,0.03601251,0.000019378656,0.0010948738,0.0002743037,0.0013385097,0.0000066521484,0.00042971558,0.000013358064,0.0013057294,0.26605493],"study_design_scores_gemma":[0.7445533,0.057390727,0.18490441,0.00022063473,0.00064184755,0.00004205645,0.0008200637,0.00019787595,0.0015401971,0.000048629856,0.009474208,0.00016602082],"about_ca_topic_score_codex":0.00015738637,"about_ca_topic_score_gemma":0.00007980786,"teacher_disagreement_score":0.2658889,"about_ca_system_score_codex":0.0005476855,"about_ca_system_score_gemma":0.0009862907,"threshold_uncertainty_score":0.49195957},"labels":[],"label_agreement":null},{"id":"W2224496334","doi":"10.4103/1008-682x.152819","title":"New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones","year":2015,"lang":"en","type":"article","venue":"Asian Journal of Andrology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Urology Care Foundation; Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Public Health Agency of Canada; Office of Research and Development; Leonard M. Miller School of Medicine, University of Miami; U.S. Department of Veterans Affairs","keywords":"Prostate cancer; Castration; Medicine; Hormone; Presentation (obstetrics); Internal medicine; Prostate; Pleasure; Oncology; Endocrinology; Gynecology; Cancer; Biology; Neuroscience","score_opus":0.04028202357834098,"score_gpt":0.32772428289512684,"score_spread":0.28744225931678585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2224496334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9658976,0.0042397324,0.0004631274,0.027206458,0.00026251914,0.0005184978,0.00003364318,0.00000792421,0.0013704667],"genre_scores_gemma":[0.99665356,0.00018943982,0.0017615261,0.00016740516,0.00016731324,0.000010451997,0.000010755771,0.00001503376,0.0010245284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906087,0.000055837725,0.00033875444,0.00010719031,0.00023106387,0.00020625473],"domain_scores_gemma":[0.9989963,0.000065954184,0.00026161983,0.00011348102,0.00036790583,0.00019472136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029407753,0.000108239205,0.0003607273,0.00020993291,0.000032767504,0.000008018626,0.00007493447,0.00006908251,0.000039674273],"category_scores_gemma":[0.0000649108,0.00007078917,0.00011972781,0.00011541951,0.00009187161,0.000062277,0.000004973421,0.00015071016,0.000001261288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20296037,0.0017814066,0.30670065,0.00065575266,0.0035963124,0.0020761811,0.015764505,0.0015330069,0.1947684,0.0009412277,0.081282765,0.18793944],"study_design_scores_gemma":[0.16253202,0.16625297,0.4803902,0.0016591233,0.0020626183,0.0014218102,0.006758603,0.0016336223,0.11819579,0.014328765,0.043821532,0.00094295124],"about_ca_topic_score_codex":0.000048542344,"about_ca_topic_score_gemma":0.000059118956,"teacher_disagreement_score":0.18699649,"about_ca_system_score_codex":0.000081571096,"about_ca_system_score_gemma":0.0012017506,"threshold_uncertainty_score":0.28866982},"labels":[],"label_agreement":null},{"id":"W2226426266","doi":"10.1200/jco.2014.32.15_suppl.5008","title":"Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial)","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Prednisone; Placebo; Chemotherapy; Internal medicine; Oncology; Randomized controlled trial; Clinical trial; Cancer; Urology; Pathology; Alternative medicine","score_opus":0.07938703583573291,"score_gpt":0.4593268820083639,"score_spread":0.379939846172631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2226426266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98653835,0.0003992889,0.00016344993,0.0029187165,0.0009663336,0.008476098,0.000020218318,0.0000077357045,0.0005097824],"genre_scores_gemma":[0.995611,0.0011565288,0.00085924263,0.00035091836,0.0006671627,0.0004466448,0.000017000822,0.000037154387,0.00085433037],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9916262,0.0021525954,0.0045260936,0.00032561,0.000943494,0.00042602353],"domain_scores_gemma":[0.9902128,0.0044962307,0.0037585835,0.00026838793,0.0008632772,0.00040073466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008666844,0.00029716836,0.005264259,0.0003011743,0.0000482171,0.000019282426,0.00018660682,0.00025151562,0.00016399175],"category_scores_gemma":[0.0038173993,0.00016189771,0.00073281256,0.000246989,0.0005013623,0.00016504942,0.000024617386,0.0008361728,0.000003241793],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.945304,0.0145963915,0.00050484104,0.00008521212,0.0022792488,0.00013274745,0.0004758201,0.00009674783,0.000071979935,0.000018471208,0.00024662408,0.036187913],"study_design_scores_gemma":[0.88929164,0.10650922,0.0005955603,0.00024385354,0.0014236916,0.000009414063,0.000091723894,0.0007416988,0.000107134794,0.00012391372,0.0007332279,0.00012892504],"about_ca_topic_score_codex":0.00012556335,"about_ca_topic_score_gemma":0.00020151884,"teacher_disagreement_score":0.091912836,"about_ca_system_score_codex":0.0004672476,"about_ca_system_score_gemma":0.004321841,"threshold_uncertainty_score":0.76667607},"labels":[],"label_agreement":null},{"id":"W2226811747","doi":"10.2741/4391","title":"Next generation biomarkers in prostate cancer","year":2015,"lang":"en","type":"review","venue":"Frontiers in bioscience","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Medicine; Prostate cancer; Occult; Prostatectomy; Context (archaeology); Disease; Biopsy; Cancer; Oncology; Clinical trial; Prostate; PCA3; Liquid biopsy; Internal medicine; Pathology","score_opus":0.1532235269057951,"score_gpt":0.4131373363783385,"score_spread":0.2599138094725434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2226811747","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001633556,0.9957119,0.0000150055075,0.00023033452,0.0015658176,0.0017967076,0.000046005487,0.000019045981,0.0004517779],"genre_scores_gemma":[0.000027371903,0.99579674,0.001589247,0.00004623342,0.000120101875,0.0004652265,0.00012168997,0.000025867334,0.0018075381],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779606,0.00011734344,0.0004322549,0.0006401336,0.0004875605,0.00052663067],"domain_scores_gemma":[0.9992853,0.000012326657,0.00012912748,0.00030859813,0.00007336818,0.00019132503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006938464,0.00028290314,0.001009218,0.0008938719,0.000045075205,0.000059031936,0.0002514038,0.00017616598,0.00001786496],"category_scores_gemma":[0.00006863614,0.00019706938,0.000110676265,0.001966612,0.00030869484,0.00020661925,0.0000753518,0.00034431028,0.000013991004],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034424247,0.000068190515,0.0034722988,0.0022387234,0.000038765236,0.00013524425,0.00013415315,8.661745e-7,0.000014533367,0.0000020052946,0.019163186,0.9746976],"study_design_scores_gemma":[0.00087525236,0.000106586835,0.00009931113,0.006811654,0.00009459368,0.000015023373,0.00008836678,0.00053983205,0.000013770219,0.000018290137,0.991088,0.0002493669],"about_ca_topic_score_codex":0.00022428032,"about_ca_topic_score_gemma":0.00007059883,"teacher_disagreement_score":0.97444826,"about_ca_system_score_codex":0.0018460985,"about_ca_system_score_gemma":0.0024436857,"threshold_uncertainty_score":0.80362564},"labels":[],"label_agreement":null},{"id":"W2227961447","doi":"","title":"Investigating androgen receptor antagonism by structural analyses, molecular dynamics simulations and support vector machines","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Androgen receptor; Agonist; Chemistry; Antagonist; Prostate cancer; Antiandrogen; Receptor; Androgen; Pharmacology; Internal medicine; Biology; Hormone; Cancer; Medicine; Biochemistry","score_opus":0.07754643704947568,"score_gpt":0.4658515299322195,"score_spread":0.38830509288274384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2227961447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99093753,0.0050557675,0.000094033145,0.0022049427,0.00008398938,0.0006206439,0.00038640408,0.0000433856,0.0005732781],"genre_scores_gemma":[0.9956263,0.00034534943,0.00042957996,0.00012285564,0.00016460057,0.00003528879,0.000813343,0.000041615236,0.0024210776],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977267,0.0000976242,0.0002591095,0.0004160215,0.00078633503,0.0007142223],"domain_scores_gemma":[0.9986442,0.00017316185,0.000044292166,0.00026880353,0.0003730343,0.0004965171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062928506,0.00017102588,0.0002623217,0.00029168013,0.00035521033,0.00007663603,0.00012488123,0.00011320189,0.00040522497],"category_scores_gemma":[0.00017049508,0.0001347384,0.00005455033,0.00072236324,0.00046613472,0.00011462404,0.000119446675,0.0005455347,0.000009222593],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024876447,0.000042842872,0.12162702,0.00018780802,0.00025871384,0.00010312476,0.0005557626,0.000030991872,0.8517134,0.00022747401,0.0016481223,0.023355959],"study_design_scores_gemma":[0.0069416487,0.0012570906,0.037272427,0.0002692496,0.00020431622,0.00008606609,0.00082426297,0.020817801,0.9227038,0.0011181678,0.007794572,0.0007106096],"about_ca_topic_score_codex":0.000947265,"about_ca_topic_score_gemma":0.00018571208,"teacher_disagreement_score":0.08435459,"about_ca_system_score_codex":0.00074524607,"about_ca_system_score_gemma":0.0006395515,"threshold_uncertainty_score":0.54944724},"labels":[],"label_agreement":null},{"id":"W2229126747","doi":"10.1200/jco.2012.30.30_suppl.37","title":"Discovery of a biomarker signature that predicts upgrading or upstaging in patients with low-risk prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Stage (stratigraphy); Biomarker; Oncology; Receiver operating characteristic; Cancer; Biopsy; Prostate; Internal medicine; Urology","score_opus":0.08199600246753193,"score_gpt":0.44670757782869425,"score_spread":0.36471157536116233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2229126747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958445,0.0017257187,0.000025522255,0.001041463,0.00064200046,0.00043780284,0.00002769674,0.0000042686975,0.00025105165],"genre_scores_gemma":[0.9959839,0.00258252,0.0004217674,0.00020087075,0.00032580356,0.000009105031,0.000005967644,0.000020107616,0.00044997493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99736476,0.00033746552,0.0012373317,0.00014453645,0.0005206983,0.00039523572],"domain_scores_gemma":[0.99654543,0.0012766718,0.0014753363,0.00013629603,0.0002787849,0.00028749026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002291355,0.00014100612,0.0010662815,0.0002068795,0.000029314597,0.000008133022,0.00011303295,0.00023168455,0.000045145673],"category_scores_gemma":[0.0012051302,0.00006867428,0.00018515295,0.00026755998,0.00023392936,0.00042257996,0.00005053892,0.0009857325,0.0000010619165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036514755,0.0021322458,0.9159862,0.00010537086,0.000413617,0.00014752324,0.00043178844,0.000008914507,0.000045337238,0.0000026130176,0.00065598154,0.043555662],"study_design_scores_gemma":[0.019624542,0.0074944696,0.9693469,0.0008510874,0.0002745068,0.000016521815,0.00019726223,0.000030759376,0.00031833348,0.000025407218,0.0017418544,0.000078351746],"about_ca_topic_score_codex":0.000044401546,"about_ca_topic_score_gemma":0.000041608382,"teacher_disagreement_score":0.05336071,"about_ca_system_score_codex":0.00028300326,"about_ca_system_score_gemma":0.0015339728,"threshold_uncertainty_score":0.42825723},"labels":[],"label_agreement":null},{"id":"W2229303152","doi":"10.1093/annonc/mdu336.19","title":"Analysis of Overall Survival (Os) for Patients (Pts) with Different Prognostic Risk Factors Treated with Cabazitaxel and Prednisone (Cbz + P) After Docetaxel (D) in the Tropic Trial","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cabazitaxel; Docetaxel; Prednisone; Oncology; Internal medicine; Chemotherapy; Prostate cancer; Cancer; Androgen deprivation therapy","score_opus":0.05122056784148065,"score_gpt":0.35210127048466067,"score_spread":0.30088070264318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2229303152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975058,0.00013075801,0.000035045232,0.00032438806,0.000020955333,0.0016939654,0.00014132794,0.0000053990307,0.00014240597],"genre_scores_gemma":[0.99918246,0.0002331621,0.00003286374,0.000039221228,0.000028918827,0.00023962524,0.0001546017,0.000012231692,0.00007691201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986405,0.0002628043,0.00030201976,0.0002467021,0.0002756886,0.00027230696],"domain_scores_gemma":[0.99856514,0.00069172826,0.00022281095,0.00020936351,0.00023454045,0.00007643127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024530574,0.00016595006,0.00078539725,0.0002577572,0.000032378804,0.0000068880536,0.0000761859,0.00009002229,0.00001895212],"category_scores_gemma":[0.0001564454,0.00007504729,0.000109526256,0.00028418863,0.0002005657,0.000039903876,0.00001979784,0.00011654552,1.5778578e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07618425,0.0020281528,0.9157132,0.00007587422,0.0015120095,0.0000055453957,0.00079477596,0.000010053575,0.0000138859705,0.0000141645105,0.00003058151,0.0036175244],"study_design_scores_gemma":[0.056510873,0.03968239,0.90130883,0.000042821266,0.0016410131,5.114951e-7,0.00013135582,0.00022319995,0.00020221321,0.000029287914,0.000152031,0.00007545198],"about_ca_topic_score_codex":0.0004748749,"about_ca_topic_score_gemma":0.0009823459,"teacher_disagreement_score":0.037654232,"about_ca_system_score_codex":0.000034846304,"about_ca_system_score_gemma":0.00007633725,"threshold_uncertainty_score":0.30603397},"labels":[],"label_agreement":null},{"id":"W2230741172","doi":"10.1200/jco.2014.32.4_suppl.14","title":"Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Internal medicine; Oncology; Progression-free survival; Antiandrogen; Antiandrogens; Population; Chemotherapy; Cancer; Androgen deprivation therapy; Urology","score_opus":0.08509615953393661,"score_gpt":0.4753897718246746,"score_spread":0.390293612290738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2230741172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99429345,0.00062296295,0.000005935845,0.0031659915,0.00032316134,0.0011182285,0.00021970188,0.000008200054,0.00024236183],"genre_scores_gemma":[0.9942146,0.0038347787,0.0011880435,0.00021854362,0.0003357386,0.000033436663,0.000055355875,0.00003599078,0.00008354407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99505985,0.000824744,0.0022984713,0.0003593894,0.0010420043,0.00041553675],"domain_scores_gemma":[0.9936024,0.0024923214,0.0021705271,0.00041788036,0.00091910217,0.00039775373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023283958,0.00028249942,0.001802808,0.00034058734,0.000048266564,0.00001545165,0.00026714566,0.00015846819,0.00011167256],"category_scores_gemma":[0.0014135265,0.00014655336,0.00045845952,0.00041660413,0.00036903747,0.00013261217,0.000029715873,0.00090566283,0.0000022609574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2122491,0.006255208,0.58884513,0.00003240264,0.0016415638,0.0002804125,0.00054711924,0.00007518796,0.00041534487,0.000007629583,0.000755205,0.18889572],"study_design_scores_gemma":[0.10136415,0.06908202,0.8269855,0.0005262812,0.0001654795,0.000008734947,0.000054709933,0.00006874904,0.0003969178,0.00017565637,0.0010468957,0.00012494999],"about_ca_topic_score_codex":0.00067525933,"about_ca_topic_score_gemma":0.00045792633,"teacher_disagreement_score":0.23814033,"about_ca_system_score_codex":0.00035279285,"about_ca_system_score_gemma":0.0023700097,"threshold_uncertainty_score":0.5976272},"labels":[],"label_agreement":null},{"id":"W2231255144","doi":"10.1200/jco.2007.25.18_suppl.5057","title":"The Prostate Cancer Clinical Trials Working Group (PCCTWG) consensus criteria for phase II clinical trials for castration-resistant prostate cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Clinical trial; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Cancer; Disease; Prostate; Oncology; Internal medicine; Phases of clinical research","score_opus":0.6791850158428799,"score_gpt":0.6901554039621502,"score_spread":0.010970388119270313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2231255144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8689723,0.016548619,0.00082518026,0.080221534,0.021064524,0.011408152,0.0005491292,0.00004470549,0.0003658549],"genre_scores_gemma":[0.89381397,0.047908567,0.012048909,0.0048799543,0.034650426,0.0011266412,0.00008818996,0.00016109864,0.0053222654],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.96814936,0.008001404,0.020948427,0.00078091683,0.00087648584,0.0012433897],"domain_scores_gemma":[0.84713227,0.1371807,0.011121583,0.00047433173,0.0027101361,0.0013809763],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.25951427,0.00044674645,0.0064482214,0.00019871384,0.000671678,0.00011355165,0.00041272904,0.0010601113,0.0001320845],"category_scores_gemma":[0.12550075,0.00023843518,0.003677899,0.00029395713,0.0013379377,0.00012631997,0.000106563784,0.0020624457,0.0000032872317],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30635577,0.003782134,0.01180688,0.000107848864,0.0027935011,0.00033287925,0.00016892966,0.0000037849184,0.001302383,0.00016519261,0.04608409,0.6270966],"study_design_scores_gemma":[0.1633517,0.07909093,0.014646721,0.0007108624,0.0037164064,0.00008160368,0.0006156746,0.00037525344,0.0005299794,0.0019596473,0.7345742,0.0003470059],"about_ca_topic_score_codex":0.0000669713,"about_ca_topic_score_gemma":0.0008225264,"teacher_disagreement_score":0.68849015,"about_ca_system_score_codex":0.00049575267,"about_ca_system_score_gemma":0.009199196,"threshold_uncertainty_score":0.9964177},"labels":[],"label_agreement":null},{"id":"W2235405584","doi":"10.1056/nejmoa1506859","title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2187,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Stand Up To Cancer; Genentech; European Society for Medical Oncology; Cilag; Astellas Pharma; National Institute for Health and Care Research; Sanofi; Public Health Agency; Prostate Cancer UK; GlaxoSmithKline; Les Laboratories Pierre Fabre; Medical Research Council; Celgene; Bristol-Myers Squibb; Prostate Cancer Foundation; American Association for Cancer Research; AstraZeneca; Royal Marsden NHS Foundation Trust; Pfizer; Oncolytics Biotech; Cancer Research UK","keywords":"Olaparib; Poly ADP ribose polymerase; Prostate cancer; DNA repair; Polymerase; Cancer research; PARP inhibitor; Medicine; Internal medicine; Oncology; Prostate; DNA; Cancer; Biology; Genetics","score_opus":0.05424186371494471,"score_gpt":0.3566528702221747,"score_spread":0.30241100650722996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2235405584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9550505,0.03026172,0.00001158849,0.0132728955,0.00030944063,0.0002643034,0.0000020972332,0.000011643607,0.0008157841],"genre_scores_gemma":[0.99175763,0.0045511248,0.00039517166,0.00040848847,0.0011376047,0.0000055147266,0.000004416986,0.000015988144,0.0017240694],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99862194,0.00009172338,0.00038947308,0.00012379256,0.00052934315,0.00024374122],"domain_scores_gemma":[0.998771,0.00012490197,0.00014336442,0.00009828459,0.00023462289,0.00062779593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011566007,0.00013338764,0.00051513984,0.0002927995,0.000020045522,0.000007145711,0.000051958832,0.00003237008,0.00006859132],"category_scores_gemma":[0.00042114605,0.00007363456,0.000044229993,0.0002441592,0.00012515137,0.00010921178,0.000020393683,0.00032891563,0.0000022542933],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012025094,0.00031080702,0.7300214,0.0004194395,0.0005626999,0.0059728734,0.01389462,0.000060733964,0.006154537,0.00010334281,0.044440083,0.18603432],"study_design_scores_gemma":[0.6116978,0.017132156,0.16074726,0.005038647,0.0014920876,0.0059459745,0.003631531,0.0003849004,0.0041573313,0.0041584224,0.18519048,0.000423404],"about_ca_topic_score_codex":0.0003993051,"about_ca_topic_score_gemma":0.00021135794,"teacher_disagreement_score":0.59967273,"about_ca_system_score_codex":0.0001473948,"about_ca_system_score_gemma":0.00073207385,"threshold_uncertainty_score":0.30027303},"labels":[],"label_agreement":null},{"id":"W2236532689","doi":"10.1155/2016/4829602","title":"The Androgen Receptor Bridges Stem Cell‐Associated Signaling Nodes in Prostate Stem Cells","year":2016,"lang":"en","type":"review","venue":"Stem Cells International","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada; Movember Foundation","keywords":"Stem cell; Androgen receptor; Prostate; Cancer research; Cell biology; Biology; Medicine; Internal medicine; Prostate cancer","score_opus":0.04758970731342841,"score_gpt":0.33555942708501113,"score_spread":0.2879697197715827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2236532689","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019321844,0.98987365,0.0000075994194,0.00029440873,0.0020518939,0.002359411,0.0010962322,0.00008025341,0.0023043468],"genre_scores_gemma":[0.0010361313,0.8882716,0.000013586359,0.000025826617,0.00036231245,0.0003544226,0.00021927958,0.00011272532,0.10960416],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99592596,0.00039815743,0.0011013182,0.000757712,0.0010814554,0.0007353813],"domain_scores_gemma":[0.99752456,0.0008186705,0.00065180694,0.00043656936,0.00036077897,0.00020761968],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00096736866,0.00059728586,0.0012695435,0.00034450126,0.00018984794,0.0001986546,0.000679948,0.00030780488,0.00021987173],"category_scores_gemma":[0.0000060674397,0.00033394984,0.00055267545,0.00031545473,0.00016636946,0.00012397797,0.0002368997,0.00064467697,0.0007406031],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024372974,0.000287376,0.000321579,0.0043912055,0.0011076921,0.00023268403,0.00027396274,0.0000034215168,0.00065106887,0.00004103792,0.0049532703,0.987493],"study_design_scores_gemma":[0.0019457042,0.00014814666,0.0000041673075,0.018191546,0.00022059413,0.000017426535,0.00022859286,0.00002441025,0.015519519,0.000007655281,0.963291,0.0004012495],"about_ca_topic_score_codex":0.00002502692,"about_ca_topic_score_gemma":0.000012339213,"teacher_disagreement_score":0.9870917,"about_ca_system_score_codex":0.0018155422,"about_ca_system_score_gemma":0.00086672127,"threshold_uncertainty_score":0.99991125},"labels":[],"label_agreement":null},{"id":"W2239698670","doi":"10.1016/s1470-2045(15)00518-5","title":"Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Sanofi; Amgen","keywords":"Enzalutamide; Bicalutamide; Prostate cancer; Medicine; Oncology; Internal medicine; Androgen receptor; Cancer","score_opus":0.09227178365285235,"score_gpt":0.4254760336601119,"score_spread":0.3332042500072595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2239698670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859946,0.0004328025,0.000062256244,0.0047189174,0.00013019734,0.008243828,0.00017379351,0.000026413309,0.00021721612],"genre_scores_gemma":[0.996784,0.00061062834,0.00023648953,0.0001205038,0.00014052159,0.0015839171,0.000031721647,0.000028042943,0.00046422085],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984608,0.00020138109,0.00033843564,0.000306302,0.00025857025,0.0004344526],"domain_scores_gemma":[0.9978093,0.0013350528,0.00018673138,0.00033000004,0.00021232691,0.00012660747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070602505,0.00018668843,0.00080859987,0.00008199182,0.00010684311,0.000008198959,0.00013249797,0.00004555884,0.00005799303],"category_scores_gemma":[0.0001401829,0.00007633577,0.00005608948,0.00015833144,0.0003973737,0.00005865935,0.00006230402,0.00012634708,0.0000031110233],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92806435,0.0022376934,0.013496845,0.00011002139,0.0011685941,0.000019931304,0.0017606085,0.0000025377947,0.0005082309,0.000047962072,0.0002585196,0.05232469],"study_design_scores_gemma":[0.9598843,0.019421104,0.012574334,0.00012431016,0.0008997969,0.000004163893,0.00029172434,0.000013017782,0.00072158553,0.0000538328,0.005891768,0.00012006665],"about_ca_topic_score_codex":0.00006959252,"about_ca_topic_score_gemma":0.000119512646,"teacher_disagreement_score":0.052204624,"about_ca_system_score_codex":0.0002093755,"about_ca_system_score_gemma":0.00033104143,"threshold_uncertainty_score":0.31128824},"labels":[],"label_agreement":null},{"id":"W2240654612","doi":"10.1200/jco.2015.33.7_suppl.261","title":"Characterizing the risk of drug-drug interactions in patients receiving enzalutamide for castration-resistant prostate cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Oxycodone; Adverse effect; Internal medicine; Androgen deprivation therapy; Pharmacology; Drug; Cancer; Oncology; Androgen receptor; Opioid","score_opus":0.16516455246892495,"score_gpt":0.5001147418595853,"score_spread":0.33495018939066035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240654612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988011,0.00041248562,0.0000065540767,0.0094799725,0.0011312396,0.0005291534,0.000030982734,0.000002743203,0.00039585112],"genre_scores_gemma":[0.99694467,0.0011369534,0.00057165464,0.00023629582,0.00045803416,0.00003065891,0.000007016568,0.000011016713,0.000603675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973747,0.00042872282,0.001595741,0.00011748728,0.00029081994,0.00019250462],"domain_scores_gemma":[0.9950869,0.0020948458,0.0016016103,0.00011794556,0.0009027496,0.00019592477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003731524,0.00008686673,0.0006892386,0.00011016076,0.00004718246,0.000009036016,0.000111692105,0.00004987489,0.000015183433],"category_scores_gemma":[0.0037750164,0.000048106023,0.00022640316,0.00013587951,0.00013428819,0.00015244656,0.000031003503,0.00070394657,0.0000015373461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017722504,0.0012322,0.8988626,0.000051039184,0.0003132737,0.000032739663,0.0022199138,0.000040310813,0.0005272726,0.000010918038,0.003020581,0.07596666],"study_design_scores_gemma":[0.013993078,0.0034530777,0.95822597,0.0003472995,0.00025524944,0.000009004312,0.0012120485,0.00012401037,0.0007775861,0.0002591899,0.021284498,0.000058972844],"about_ca_topic_score_codex":0.00029993948,"about_ca_topic_score_gemma":0.0013355013,"teacher_disagreement_score":0.07590769,"about_ca_system_score_codex":0.00037380055,"about_ca_system_score_gemma":0.0021056551,"threshold_uncertainty_score":0.45193198},"labels":[],"label_agreement":null},{"id":"W2240846239","doi":"10.1200/jco.2014.32.4_suppl.16","title":"Independent validation of a genomic classifier in an at-risk population of men conservatively managed after radical prostatectomy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Nomogram; Population; Cohort; Internal medicine; Oncology; Cumulative incidence; Proportional hazards model; Metastasis; Radiation therapy; Bone metastasis; Surgery; Cancer","score_opus":0.11385262494906857,"score_gpt":0.46056466779482513,"score_spread":0.3467120428457566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240846239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977473,0.00011184001,0.00007269946,0.0010413565,0.00014012147,0.000361439,0.000006415927,0.0000026332316,0.00051618763],"genre_scores_gemma":[0.9981163,0.00028829143,0.0011296778,0.000111762565,0.00015646091,0.000008487654,0.000012764847,0.000010743343,0.00016552169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962496,0.0011647125,0.0018881825,0.00015242671,0.00038761992,0.00015742701],"domain_scores_gemma":[0.9969053,0.0008583107,0.0015882441,0.00014207681,0.00031704525,0.00018898501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043635103,0.00008995277,0.000977512,0.0002187574,0.000017227001,0.0000032188198,0.000093139395,0.00026955875,0.0001243753],"category_scores_gemma":[0.0010941634,0.00006102798,0.00018397628,0.00011307517,0.0002235669,0.00011471969,0.000048421083,0.000601661,0.0000037497562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020786388,0.0010669134,0.9562087,0.000064967186,0.00015627715,0.00008661657,0.00024386967,0.000022707138,0.0020855758,0.00003956319,0.000082760685,0.019155627],"study_design_scores_gemma":[0.01296331,0.008775919,0.9746068,0.00009086116,0.00015650557,0.000023696579,0.00006821365,0.00043547514,0.0012771564,0.0008376881,0.0007148076,0.0000495298],"about_ca_topic_score_codex":0.000081560785,"about_ca_topic_score_gemma":0.00009777533,"teacher_disagreement_score":0.019106098,"about_ca_system_score_codex":0.0003014354,"about_ca_system_score_gemma":0.0005262223,"threshold_uncertainty_score":0.26139513},"labels":[],"label_agreement":null},{"id":"W2241641236","doi":"10.1200/jco.2007.25.18_suppl.5062","title":"The impact of the duration of adjuvant hormonal therapy in patients with unfavorable prognosis prostate cancer treated with radiotherapy: Secondary analysis of RTOG 85–31","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Hormonal therapy; Radiation therapy; Hormone therapy; Internal medicine; Proportional hazards model; Adjuvant therapy; Adjuvant; Cancer; Prostate cancer; Hormone; Oncology; Surgery; Breast cancer","score_opus":0.04711708049919901,"score_gpt":0.44102455459167295,"score_spread":0.39390747409247395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2241641236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616957,0.0018790397,0.000008003737,0.0010126546,0.00004666167,0.00068776304,0.000029197945,0.0000016221834,0.00016550074],"genre_scores_gemma":[0.9957384,0.003874175,0.00014572544,0.000054269913,0.000050046325,0.000009414108,0.000008394569,0.000012350473,0.000107261505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708396,0.00030840028,0.0016982673,0.00013149709,0.00054200506,0.00023588045],"domain_scores_gemma":[0.9954633,0.0008589106,0.0023183462,0.0001892506,0.0010499539,0.00012019968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024048171,0.00013370698,0.001274825,0.0002550265,0.000040814506,0.0000045289075,0.00015652142,0.00013830753,0.000054401055],"category_scores_gemma":[0.0001472635,0.000047038448,0.00043599904,0.0010555234,0.0006005629,0.000090126145,0.000013853826,0.00050757895,5.8876044e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060478296,0.0019777047,0.84951866,0.000014991568,0.005466395,0.000017096105,0.0003038591,0.00025943798,0.0005127692,0.0000020383422,0.00012377964,0.081324965],"study_design_scores_gemma":[0.017609973,0.032461133,0.94670874,0.00012647283,0.00067486026,0.000003832519,0.00009899984,0.00012962052,0.0019769769,0.0000122706515,0.0001492928,0.00004785576],"about_ca_topic_score_codex":0.00059467787,"about_ca_topic_score_gemma":0.00063780486,"teacher_disagreement_score":0.097190045,"about_ca_system_score_codex":0.00032647778,"about_ca_system_score_gemma":0.0029700072,"threshold_uncertainty_score":0.52686656},"labels":[],"label_agreement":null},{"id":"W2242741199","doi":"10.1200/jco.2006.24.18_suppl.4615","title":"Is physical function affected by androgen deprivation therapy (ADT) in men with non-metastatic prostate cancer?","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Grip strength; Prostate cancer; Androgen deprivation therapy; Prospective cohort study; Timed Up and Go test; Muscle strength; Physical therapy; Cancer; Internal medicine","score_opus":0.06673752220993559,"score_gpt":0.4557290388157098,"score_spread":0.38899151660577425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242741199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919213,0.0008894617,0.00007431355,0.005587151,0.0001150413,0.00050100905,0.0000070905708,0.000007238671,0.0008973935],"genre_scores_gemma":[0.9961698,0.0017903156,0.00024985595,0.0005663542,0.00048285737,0.00003170339,0.000018620334,0.000017394443,0.0006731109],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812347,0.00022639328,0.00085039216,0.00018055266,0.0003843817,0.00023480956],"domain_scores_gemma":[0.99838823,0.0004165977,0.000640363,0.000103178325,0.00030320478,0.00014841968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088611897,0.00012547625,0.000843248,0.00012097906,0.000030825708,0.0000101366595,0.00006618948,0.00011437625,0.000056107783],"category_scores_gemma":[0.00008897884,0.000071586706,0.00015176924,0.00029465492,0.00013517529,0.00013341023,0.000012332409,0.0005821715,0.0000061792493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03730949,0.006509821,0.6106733,0.000054007614,0.00075501885,0.000527613,0.00032987702,0.000059068312,0.007978627,0.000012312978,0.026768865,0.30902198],"study_design_scores_gemma":[0.046630006,0.030060343,0.90162176,0.00016433258,0.00028699322,0.00007186436,0.00011716227,0.0011994613,0.004996228,0.0007233817,0.013992867,0.00013558731],"about_ca_topic_score_codex":0.00020108355,"about_ca_topic_score_gemma":0.00006737186,"teacher_disagreement_score":0.30888638,"about_ca_system_score_codex":0.00025324913,"about_ca_system_score_gemma":0.0011299364,"threshold_uncertainty_score":0.29192212},"labels":[],"label_agreement":null},{"id":"W2243598500","doi":"10.1200/jco.2010.28.15_suppl.4677","title":"Initial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA) ± strontium-89 (Sr89) in hormone-refractory prostate cancer patients: ISRCTN12808747.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Adverse effect; Prostate cancer; Docetaxel; Zoledronic acid; Surgery; Cancer; Oncology","score_opus":0.1711104149319097,"score_gpt":0.5361155780872329,"score_spread":0.36500516315532316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243598500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879111,0.00095743506,0.000008716817,0.0066503854,0.001560984,0.002595345,0.00012579409,0.000010108475,0.00018014818],"genre_scores_gemma":[0.99040484,0.007205786,0.00051206443,0.00066695525,0.0009757885,0.00005903741,0.00006999746,0.000025969217,0.000079571204],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99248224,0.0013719421,0.0042366376,0.0006028357,0.00081484544,0.000491515],"domain_scores_gemma":[0.9941763,0.0021608805,0.0017280374,0.0003501941,0.00090869016,0.00067588215],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.010167368,0.00027956965,0.0019800044,0.00028237907,0.00008109582,0.000024902332,0.00022517757,0.00059696723,0.00009788164],"category_scores_gemma":[0.004731436,0.00017764016,0.00026786848,0.00030696788,0.0005164966,0.00034697173,0.00011194328,0.0031628823,0.0000031282104],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6176216,0.017501783,0.103116214,0.0000056699537,0.00021347098,0.00018272905,0.0005628156,0.0000043877094,0.00020807647,0.0000026742764,0.00035745002,0.26022312],"study_design_scores_gemma":[0.46547905,0.117497414,0.41138607,0.00010119752,0.00010500084,0.0000053413924,0.00007446527,0.00010051955,0.0000565298,0.00014285573,0.0049307873,0.00012077029],"about_ca_topic_score_codex":0.00044693335,"about_ca_topic_score_gemma":0.0033323716,"teacher_disagreement_score":0.30826986,"about_ca_system_score_codex":0.00059978355,"about_ca_system_score_gemma":0.004633936,"threshold_uncertainty_score":0.99913687},"labels":[],"label_agreement":null},{"id":"W2244136156","doi":"10.1200/jco.2006.24.18_suppl.4518","title":"Intermittent chemotherapy in metastatic androgen-independent prostate cancer (AIPC): Initial results from ASCENT","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Chemotherapy; Regimen; Placebo; Internal medicine; Chemotherapy regimen; Prostate cancer; Clinical trial; Surgery; Phases of clinical research; Cancer; Oncology; Urology; Pathology","score_opus":0.13366036448960994,"score_gpt":0.5048630603889855,"score_spread":0.3712026958993756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244136156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97608256,0.0019714823,0.000015303245,0.018935163,0.001073586,0.00045522515,0.000060237307,0.000008042161,0.0013983943],"genre_scores_gemma":[0.9911654,0.004282461,0.0008681889,0.0013790104,0.001342346,0.000017612228,0.00003137952,0.000022412603,0.00089119334],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956302,0.00041378185,0.0027360115,0.00028081477,0.00057966425,0.00035951054],"domain_scores_gemma":[0.99703646,0.00095597375,0.0011812776,0.00018273061,0.00034769494,0.00029584585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023212747,0.00017321385,0.0013483102,0.00019226773,0.000026994274,0.00001649987,0.00015919267,0.00020770503,0.00023675087],"category_scores_gemma":[0.0005395872,0.000111135334,0.00038921335,0.00016828993,0.00019017988,0.000105073486,0.00004874453,0.0010684335,0.000016553733],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08584773,0.0076393825,0.2422197,0.000045808953,0.0011444894,0.010715069,0.00058748346,0.00007189187,0.00067729375,0.000028294211,0.011579482,0.6394434],"study_design_scores_gemma":[0.10377798,0.011064084,0.80128,0.00048903783,0.00040616718,0.00023381216,0.0002993231,0.00028886757,0.0032087187,0.0015592412,0.077179596,0.00021316933],"about_ca_topic_score_codex":0.0009865423,"about_ca_topic_score_gemma":0.0007976637,"teacher_disagreement_score":0.6392302,"about_ca_system_score_codex":0.0005639535,"about_ca_system_score_gemma":0.0022916535,"threshold_uncertainty_score":0.46418715},"labels":[],"label_agreement":null},{"id":"W2247343443","doi":"10.1200/jco.2004.22.90140.4651","title":"Screening with prostate specific antigen and metastatic prostate cancer risk: A population-based case-control study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Arthritis Research Centre of Canada; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Odds ratio; Population; Asymptomatic; Cancer; Prostate cancer screening; Internal medicine; Confidence interval; Prostate; Oncology; Gynecology; Environmental health","score_opus":0.11857304626281617,"score_gpt":0.4734006581948243,"score_spread":0.3548276119320081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247343443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99211866,0.0021646635,0.00045971482,0.003535483,0.00018261689,0.0014479248,0.000041048672,0.000012579206,0.000037316833],"genre_scores_gemma":[0.9911162,0.0010911332,0.0070227133,0.00031719817,0.0003047552,0.00003383818,0.0000036233644,0.000028065371,0.000082428574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690276,0.00054623536,0.0014556185,0.0002791029,0.00048474516,0.00033154213],"domain_scores_gemma":[0.9965441,0.001069805,0.0012950882,0.00016807248,0.00047152498,0.0004514147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030416788,0.0001884626,0.0012941543,0.00020181181,0.00014506423,0.000030433706,0.00007098507,0.00009566984,0.000057449488],"category_scores_gemma":[0.00047841744,0.00010728976,0.00017617829,0.00023685509,0.00019594708,0.00014994132,0.000019412262,0.00091924577,0.0000022316456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029010624,0.0016870387,0.8575422,0.000032624648,0.0010829659,0.019675063,0.00044076864,0.0014621991,0.00001806033,0.000003117306,0.000035914014,0.08900942],"study_design_scores_gemma":[0.059727967,0.03140615,0.9045315,0.00019196284,0.0009554426,0.0012747705,0.0007744278,0.0002051415,0.000022136883,0.00011723188,0.00067540957,0.00011787185],"about_ca_topic_score_codex":0.00080918643,"about_ca_topic_score_gemma":0.00073305017,"teacher_disagreement_score":0.08889154,"about_ca_system_score_codex":0.00021590765,"about_ca_system_score_gemma":0.0018820057,"threshold_uncertainty_score":0.43751493},"labels":[],"label_agreement":null},{"id":"W2248059207","doi":"10.1200/jco.2008.26.15_suppl.5012","title":"Impact of androgen deprivation therapy (ADT) on bone, cardiovascular, and endocrine outcomes: A propensity-matched analysis of 20,000 patients","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Androgen deprivation therapy; Hazard ratio; Proportional hazards model; Propensity score matching; Confidence interval; Internal medicine; Diabetes mellitus; Myocardial infarction; Prostate cancer; Logistic regression; Surgery; Cancer; Endocrinology","score_opus":0.1754602754664063,"score_gpt":0.4750601057769342,"score_spread":0.2995998303105279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248059207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783224,0.0011488696,0.0000139177455,0.0003773609,0.00007715895,0.00031419587,0.000015268686,0.0000026344087,0.00021836656],"genre_scores_gemma":[0.99213576,0.0073429644,0.0002360559,0.00012002942,0.00006505277,0.0000027125898,0.000015259404,0.0000089302985,0.00007323015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997325,0.00033833884,0.0014750398,0.00015314201,0.0005462182,0.00016227522],"domain_scores_gemma":[0.99707,0.0006990866,0.0009959855,0.00023890965,0.00078431016,0.00021167716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012556952,0.00011946511,0.0025559193,0.0003831491,0.000027818947,0.0000020714501,0.000076837525,0.00014011576,0.00004929951],"category_scores_gemma":[0.0009595884,0.00006392156,0.001506977,0.00038481224,0.00021611793,0.000067847104,0.00003166201,0.00034513898,8.963647e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007595106,0.0024809611,0.9357264,0.000015532589,0.016084008,0.00023380683,0.00012583195,0.00007426431,0.00013684694,0.0000012149906,0.00018384319,0.03734218],"study_design_scores_gemma":[0.016595677,0.016816624,0.9635671,0.000028521452,0.0016732524,0.00005088295,0.000013389522,0.000044542954,0.000341913,0.000016259708,0.000803169,0.00004869471],"about_ca_topic_score_codex":0.000100415775,"about_ca_topic_score_gemma":0.000007585168,"teacher_disagreement_score":0.037293486,"about_ca_system_score_codex":0.00012500868,"about_ca_system_score_gemma":0.00074598513,"threshold_uncertainty_score":0.26066455},"labels":[],"label_agreement":null},{"id":"W2248440650","doi":"10.1200/jco.2012.30.5_suppl.14","title":"Role of 5-alpha-reductase inhibitors in active surveillance of patients with low-risk prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Dutasteride; Finasteride; Urology; Doubling time; Nadir; Prostate; Internal medicine; Gynecology; Cancer","score_opus":0.037348898462060943,"score_gpt":0.4343492008136843,"score_spread":0.3970003023516233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248440650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99617326,0.0021708552,6.906165e-7,0.0004972792,0.00037688395,0.00035762295,0.00006824282,0.0000019397755,0.00035322102],"genre_scores_gemma":[0.99672174,0.002571145,0.00024375717,0.00004533267,0.0003386516,0.0000077521145,0.0000075752223,0.000013096676,0.00005093629],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971795,0.00039914867,0.0015894625,0.00011458599,0.0004293289,0.00028794067],"domain_scores_gemma":[0.99575204,0.0009856073,0.002101305,0.00013057883,0.00073074707,0.00029970947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018751818,0.00011195805,0.0011808258,0.0001528055,0.00001528901,0.000001381023,0.00009365987,0.0001699703,0.00005759567],"category_scores_gemma":[0.0013773331,0.00006546413,0.00017556417,0.00024207638,0.00034172725,0.00015286972,0.000037780188,0.0007093643,0.0000015371913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021848736,0.0035615065,0.866208,0.00005457505,0.00028230797,0.000020570758,0.0005483531,0.000011564092,0.0003244311,0.0000030152187,0.00021349531,0.10692342],"study_design_scores_gemma":[0.013932511,0.009617209,0.9684709,0.00022381997,0.000102914266,0.0000054516545,0.0003290934,0.0000055563833,0.005313231,0.000044742144,0.001894341,0.000060237082],"about_ca_topic_score_codex":0.00017229823,"about_ca_topic_score_gemma":0.00011218286,"teacher_disagreement_score":0.106863186,"about_ca_system_score_codex":0.00021630475,"about_ca_system_score_gemma":0.0015567419,"threshold_uncertainty_score":0.30818743},"labels":[],"label_agreement":null},{"id":"W2248519216","doi":"10.1200/jco.2014.32.4_suppl.58","title":"Population pharmacokinetic analysis of abiraterone acetate in healthy volunteers and chemotherapy-naive and chemotherapy-pretreated metastatic castration-resistant prostate cancer patients.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Abiraterone acetate; Medicine; Docetaxel; Prostate cancer; Chemotherapy; Pharmacokinetics; Population; Internal medicine; Oncology; Pharmacology; Cancer; Androgen deprivation therapy","score_opus":0.06588766860972486,"score_gpt":0.46431214464099524,"score_spread":0.3984244760312704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248519216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99378383,0.0008479372,0.000015339001,0.004761285,0.000112423804,0.00041476358,0.000017466604,0.0000036327979,0.00004333751],"genre_scores_gemma":[0.99220693,0.006237809,0.00052068505,0.0008506815,0.00005920634,0.000009834385,0.000023425357,0.000014596229,0.00007683921],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972975,0.000405846,0.0015745137,0.00021195746,0.00029768696,0.0002124953],"domain_scores_gemma":[0.9977751,0.00047822008,0.0010226725,0.0000949299,0.0003889815,0.0002401272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014595473,0.00014287754,0.0014196233,0.00041478017,0.000028414086,0.000009369465,0.000053414264,0.00010592526,0.00006916149],"category_scores_gemma":[0.00027438617,0.000097003875,0.00015007061,0.00045730406,0.00019857958,0.000105313185,0.000015073861,0.00034017826,3.243088e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020214316,0.00088646787,0.8685229,0.000118198965,0.001911303,0.000023420096,0.0006538944,0.00014901359,0.0008103233,0.000005193556,0.00006620043,0.10663881],"study_design_scores_gemma":[0.023597803,0.009492288,0.9607591,0.00008411311,0.0013358936,0.0000050333274,0.000078851415,0.0039730812,0.00018109313,0.000067627574,0.0003506322,0.00007446792],"about_ca_topic_score_codex":0.0006012664,"about_ca_topic_score_gemma":0.0004953433,"teacher_disagreement_score":0.10656434,"about_ca_system_score_codex":0.0001707815,"about_ca_system_score_gemma":0.00031027608,"threshold_uncertainty_score":0.39557034},"labels":[],"label_agreement":null},{"id":"W2248833360","doi":"10.1200/jco.2006.24.18_suppl.4517","title":"Absolute PSA value after androgen deprivation (AD) is a strong independent predictor of survival in new metastatic (D2) prostate cancer (PCa): Data from Southwest Oncology Group Trial 9346 (INT-0162)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Urology; Internal medicine; Proportional hazards model; Cancer; Oncology; Biomarker; Hazard ratio; Prostate-specific antigen; Multivariate analysis; Gynecology; Gastroenterology; Confidence interval","score_opus":0.18630700911989892,"score_gpt":0.47589138088765387,"score_spread":0.289584371767755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248833360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852775,0.00490414,0.00023168835,0.005551904,0.0017838309,0.0014185739,0.0005153994,0.000010077084,0.00030693974],"genre_scores_gemma":[0.988456,0.003994767,0.003603024,0.00043008526,0.0024690905,0.000060913382,0.00027063463,0.000045983597,0.0006694614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933361,0.00094360975,0.0037186737,0.00053113606,0.0009623425,0.0005081292],"domain_scores_gemma":[0.9946139,0.0018388046,0.0021898414,0.0005289433,0.00036681688,0.00046172965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040485887,0.00026872582,0.0022580386,0.00028489836,0.000034555793,0.000020774294,0.00047588817,0.00048419932,0.0006634948],"category_scores_gemma":[0.001054247,0.00019005213,0.00037431763,0.0002749277,0.000299278,0.00032175359,0.00023442032,0.001323881,0.000014430529],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33916935,0.0073344135,0.5468965,0.00012387546,0.002449057,0.0023491113,0.0009089572,0.000058230642,0.00046660108,0.000045897028,0.0077716843,0.09242628],"study_design_scores_gemma":[0.23939599,0.020389086,0.68451476,0.00038716904,0.0018524434,0.00006580979,0.0004267861,0.00067515054,0.00017824578,0.0018432973,0.050008874,0.00026238637],"about_ca_topic_score_codex":0.0048161163,"about_ca_topic_score_gemma":0.009000898,"teacher_disagreement_score":0.13761821,"about_ca_system_score_codex":0.00068647624,"about_ca_system_score_gemma":0.007486796,"threshold_uncertainty_score":0.99813986},"labels":[],"label_agreement":null},{"id":"W2249185594","doi":"10.1200/jco.2004.22.14_suppl.4635","title":"Multicentre phase II trial of combination neoadjuvant hormone therapy and weekly docetaxel prior to radical prostatectomy in high risk localized prostate cancer (CUOG-P01a)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Vancouver General Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Docetaxel; Prostatectomy; Prostate cancer; Oncology; Urology; Prostate; Hormone therapy; Internal medicine; Hormonal therapy; Cancer; Gynecology; Breast cancer","score_opus":0.083241931915468,"score_gpt":0.4775061391273902,"score_spread":0.39426420721192224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249185594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97289205,0.003303144,0.00003950463,0.02070672,0.00054263265,0.0024306765,0.00002880946,0.000009318484,0.00004713653],"genre_scores_gemma":[0.9688061,0.027983801,0.0021282078,0.0004620278,0.00036421412,0.000060291684,0.000007947111,0.000022812275,0.0001646211],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958762,0.00051103777,0.0023248605,0.00029403708,0.00060990395,0.0003839512],"domain_scores_gemma":[0.9966471,0.00072619505,0.001362844,0.00016749905,0.00052954245,0.0005667769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028710011,0.00020138052,0.0017316455,0.0002942784,0.000076874225,0.000011932034,0.00013466364,0.00032054953,0.000035953275],"category_scores_gemma":[0.0016857157,0.00012800364,0.0002491845,0.0003348505,0.00039304968,0.00014354062,0.00006803305,0.0010816716,0.0000026689677],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.532869,0.017069012,0.009815392,0.00004209702,0.0004066678,0.0005987835,0.0011558146,0.000048266476,0.00139102,0.000053446143,0.00027785488,0.43627265],"study_design_scores_gemma":[0.75662166,0.13950305,0.09192781,0.00028557112,0.00024937926,0.00004427786,0.00020697809,0.00010601371,0.0014800505,0.0010930116,0.008342819,0.00013937269],"about_ca_topic_score_codex":0.000504599,"about_ca_topic_score_gemma":0.00010617731,"teacher_disagreement_score":0.4361333,"about_ca_system_score_codex":0.0004280064,"about_ca_system_score_gemma":0.0027227201,"threshold_uncertainty_score":0.5219837},"labels":[],"label_agreement":null},{"id":"W2249444889","doi":"10.1200/jco.2007.25.18_suppl.5009","title":"Analysis of prostate-specific antigen decline as a surrogate for overall survival in metastatic hormone-refractory prostate cancer (HRPC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Mitoxantrone; Surrogate endpoint; Prostate cancer; Docetaxel; Proportional hazards model; Internal medicine; Prostate-specific antigen; Hazard ratio; Prednisone; Oncology; Chemotherapy; Gynecology; Urology; Cancer","score_opus":0.1697459293748511,"score_gpt":0.5162281980362494,"score_spread":0.3464822686613983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2249444889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851999,0.0097345915,0.00015763298,0.002963637,0.0006068078,0.000881911,0.00006818508,0.0000074095847,0.0003798921],"genre_scores_gemma":[0.9611514,0.03489091,0.0024597293,0.00041183777,0.0003707646,0.000022615326,0.00003036315,0.000030973322,0.0006313706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942148,0.00038620242,0.0037366007,0.00033091535,0.0007446986,0.0005867949],"domain_scores_gemma":[0.9919295,0.0039373375,0.002153579,0.00024768728,0.0012389506,0.00049295893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009168439,0.00022386397,0.0027854103,0.00091367227,0.000039878552,0.00001224291,0.00021522002,0.00025682154,0.00013609324],"category_scores_gemma":[0.0017567333,0.00015126298,0.0009987421,0.0009176775,0.00033220262,0.0001708103,0.00006894397,0.00086172554,0.0000043645805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09921313,0.0045874594,0.70562947,0.00012215959,0.0065935417,0.0022304214,0.00074971264,0.00025929578,0.0027708567,0.00006140313,0.00085628586,0.17692627],"study_design_scores_gemma":[0.025513068,0.016676825,0.9036697,0.00012211558,0.0018790453,0.00002389881,0.00034775244,0.00025394425,0.00036922147,0.00045477273,0.050535064,0.00015457968],"about_ca_topic_score_codex":0.00037379726,"about_ca_topic_score_gemma":0.0011502277,"teacher_disagreement_score":0.19804025,"about_ca_system_score_codex":0.00043507892,"about_ca_system_score_gemma":0.0026862693,"threshold_uncertainty_score":0.61683255},"labels":[],"label_agreement":null},{"id":"W2250153760","doi":"10.1200/jco.2009.27.15_suppl.5137","title":"Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Internal medicine; Oncology; Chemotherapy; Prednisone; Logistic regression; Mitoxantrone; Concordance; Cancer","score_opus":0.19076603759104613,"score_gpt":0.4922645871125438,"score_spread":0.3014985495214977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2250153760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903936,0.00044136887,0.00011480064,0.008201541,0.00014120074,0.0005371692,0.000022425693,0.0000019068525,0.0001460266],"genre_scores_gemma":[0.9940899,0.0015190069,0.0037894223,0.0002313837,0.00006142206,0.000015688778,0.0000034543589,0.000005962667,0.0002837726],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965188,0.00033439277,0.0024238366,0.00014097085,0.00040936106,0.00017262257],"domain_scores_gemma":[0.99658275,0.00080541224,0.0017623038,0.00014916473,0.0005649055,0.0001354433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036303797,0.00009695855,0.0008084114,0.00015507676,0.00003486418,0.000004400232,0.00012613226,0.00007518981,0.00003265539],"category_scores_gemma":[0.0009776714,0.00005448705,0.00016141814,0.00027971235,0.00014045657,0.00007623127,0.0000128209695,0.0004181124,0.0000023732464],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033600982,0.0026847634,0.010651188,0.00007547934,0.0008275767,0.000097693,0.02097341,0.00020711847,0.055563074,0.000090723785,0.00053299457,0.874695],"study_design_scores_gemma":[0.0087195225,0.004967877,0.9521678,0.00017952688,0.00019042364,0.00001210128,0.002392861,0.000043432847,0.025238419,0.0009140899,0.005102394,0.00007152835],"about_ca_topic_score_codex":0.00007330905,"about_ca_topic_score_gemma":0.00039479107,"teacher_disagreement_score":0.94151664,"about_ca_system_score_codex":0.00028601257,"about_ca_system_score_gemma":0.002158557,"threshold_uncertainty_score":0.38291875},"labels":[],"label_agreement":null},{"id":"W2253592130","doi":"10.1200/jco.2006.24.18_suppl.14516","title":"Degarelix: A gonadotropin-releasing hormone receptor (GnRH) blocker, tested in two one-year multicenter, randomized, dose-finding studies in prostate cancer patients","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Urology; Prostate-specific antigen; Testosterone (patch); Hormone antagonist; Cancer; Internal medicine; Gynecology; Hormone; Endocrine system","score_opus":0.14801550605174538,"score_gpt":0.5026991636283441,"score_spread":0.3546836575765987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2253592130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981836,0.012251399,0.000002036581,0.0032872271,0.0010527725,0.0012308828,0.000008762343,0.000010902051,0.0003200025],"genre_scores_gemma":[0.96999115,0.026371814,0.0020488354,0.00028865956,0.00073093927,0.000066863075,0.000011505052,0.000031186202,0.00045903664],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99432606,0.001008824,0.003238231,0.0003097435,0.0005713398,0.0005458197],"domain_scores_gemma":[0.99446213,0.002946423,0.0014384222,0.00013465417,0.00078148016,0.0002368864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026682406,0.00023262601,0.0026115198,0.0004646971,0.000054654018,0.00001582424,0.00014524147,0.0001876049,0.000038043032],"category_scores_gemma":[0.004431169,0.00015694287,0.00040001847,0.00041759678,0.000501395,0.00016573543,0.00009158405,0.0013424614,0.000012348957],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2682912,0.0051824176,0.70241886,0.00009478882,0.00056988146,0.0005483002,0.00047479518,0.00004823272,0.0006396934,0.000016164415,0.0015611293,0.020154549],"study_design_scores_gemma":[0.5419412,0.0038140286,0.45008346,0.0012359374,0.00028097277,0.000012686222,0.0003082618,0.00018222172,0.0001264514,0.000189782,0.0016648435,0.00016014816],"about_ca_topic_score_codex":0.0009165014,"about_ca_topic_score_gemma":0.00067088497,"teacher_disagreement_score":0.27365002,"about_ca_system_score_codex":0.0012619987,"about_ca_system_score_gemma":0.0011992601,"threshold_uncertainty_score":0.63999444},"labels":[],"label_agreement":null},{"id":"W2254803621","doi":"10.1200/jco.2006.24.18_suppl.10029","title":"Detection of novel variant TMPRSS2 /ERG fusion transcripts suggests independent genomic alterations may underlie origin of multi-centric prostate cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Princess Margaret Cancer Centre; Hospital for Sick Children; Ontario Institute for Cancer Research","funders":"","keywords":"TMPRSS2; Fusion gene; Cancer research; Chromoplexy; Erg; Biology; Exon; ETS transcription factor family; Prostate cancer; Gene; Prostate; Genetics; Cancer; Transcription factor; Medicine; Pathology; PCA3; Disease","score_opus":0.1431247354124861,"score_gpt":0.46111072018170046,"score_spread":0.31798598476921436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2254803621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091154,0.0018892774,0.0030188386,0.0022574677,0.0011811194,0.0005179935,0.00003610368,0.0000063192792,0.0001813109],"genre_scores_gemma":[0.993517,0.0034970916,0.0016159932,0.000090124384,0.00050557405,0.000011447738,0.000009660317,0.000017790368,0.00073536445],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99669904,0.00022556694,0.002160174,0.00019629908,0.0004585902,0.00026035786],"domain_scores_gemma":[0.99710697,0.00043842898,0.0013947674,0.0001486275,0.0007024531,0.00020875604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014403855,0.00014061997,0.0010059206,0.00028035365,0.000052374246,0.0000068345553,0.000118068645,0.00029511715,0.000079640595],"category_scores_gemma":[0.00021192325,0.00009636563,0.00036077568,0.0002501334,0.00019215894,0.000100697725,0.000027278289,0.0006761829,0.0000025580293],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02308209,0.02207862,0.17545961,0.00043931056,0.0013419164,0.000988197,0.00060816604,0.0035428891,0.6038909,0.00032940527,0.0006150169,0.16762388],"study_design_scores_gemma":[0.06649753,0.016302943,0.8690746,0.00037970342,0.0011069665,0.0005492097,0.00015105122,0.0046477946,0.027685897,0.00018778541,0.013192144,0.0002244158],"about_ca_topic_score_codex":0.00054271135,"about_ca_topic_score_gemma":0.00074655336,"teacher_disagreement_score":0.69361496,"about_ca_system_score_codex":0.00045533304,"about_ca_system_score_gemma":0.0027898834,"threshold_uncertainty_score":0.4949133},"labels":[],"label_agreement":null},{"id":"W2257053422","doi":"10.1200/jco.2015.33.7_suppl.154","title":"A genomic classifier to improve prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Cohort; Internal medicine; Oncology; Adjuvant therapy; Biochemical recurrence; Metastasis; Stage (stratigraphy); Cancer; Surgical margin","score_opus":0.07712546034363023,"score_gpt":0.4076424814212207,"score_spread":0.3305170210775905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257053422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994287,0.0012846226,0.000022933062,0.0016365665,0.00095555425,0.0014443677,0.0003388485,0.000008494661,0.000021587266],"genre_scores_gemma":[0.99548423,0.002238153,0.00095134345,0.0005830104,0.00020246362,0.00018427076,0.000024874973,0.00003697534,0.00029469148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952115,0.00096771994,0.002395271,0.0003352479,0.0007228237,0.00036747058],"domain_scores_gemma":[0.9956643,0.000976164,0.0015549874,0.00019976476,0.0006301585,0.00097465434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003536319,0.00020650194,0.0015726874,0.00031685887,0.000021152959,0.0000122095225,0.00012233813,0.00014271072,0.000043850934],"category_scores_gemma":[0.002925765,0.0001340364,0.00028454687,0.0002947479,0.0003080924,0.00017249335,0.000064177984,0.0009613423,0.000007842268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08012782,0.0026975065,0.86871785,0.00006602846,0.0005920283,0.000551746,0.00087701256,0.000049926686,0.00015046385,9.276817e-7,0.002852166,0.043316513],"study_design_scores_gemma":[0.028644433,0.009321575,0.9580585,0.0002876736,0.00037364993,0.000006163054,0.00016967436,0.00018862245,0.00029021248,0.00033046296,0.0022048429,0.000124213],"about_ca_topic_score_codex":0.00027594308,"about_ca_topic_score_gemma":0.00006154416,"teacher_disagreement_score":0.08934061,"about_ca_system_score_codex":0.00061773194,"about_ca_system_score_gemma":0.003615938,"threshold_uncertainty_score":0.64145184},"labels":[],"label_agreement":null},{"id":"W2258617645","doi":"10.14288/1.0100952","title":"Bone stromal production of insulin-like growth factor binding protein 5 promotes growth and survival of prostate cancer","year":2011,"lang":"en","type":"article","venue":"cIRcle (University of British Columbia)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Stromal cell; Prostate cancer; Insulin-like growth factor-binding protein; Prostate; Insulin-like growth factor; Internal medicine; Growth factor; Endocrinology; Cancer; Medicine; Cancer research; Oncology; Receptor","score_opus":0.022435400647028047,"score_gpt":0.2187984080109677,"score_spread":0.19636300736393966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2258617645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977718,0.0004542134,0.0000042739853,0.0000981001,0.000092572875,0.0010827016,0.0002660034,0.00002738846,0.0002029514],"genre_scores_gemma":[0.9977201,0.0007384868,0.00043411294,0.000001306073,0.000020464595,0.0000039990305,0.000023630528,0.000015728605,0.0010421228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998901,0.000051955994,0.00016703783,0.00032956852,0.00032238313,0.00022806559],"domain_scores_gemma":[0.9990939,0.000012407546,0.00019999067,0.00014672577,0.00042828918,0.00011870329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014508901,0.000059669823,0.00038601752,0.000102355865,0.00009230167,0.000010698469,0.00008977284,0.00008081621,0.00006277931],"category_scores_gemma":[0.00004997786,0.00013760771,0.000071440045,0.00031748228,0.00048155113,0.00025593862,0.000090950816,0.00013242253,7.828682e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077617186,0.00077954325,0.74167347,0.002758157,0.00030776882,0.00015888597,0.0026648392,5.1714782e-8,0.17365417,0.000004154675,0.00008657758,0.07713622],"study_design_scores_gemma":[0.0025666982,0.0008063363,0.9863816,0.00074704457,0.00008988494,0.000025404102,0.0012734643,0.0000045750808,0.007914651,0.00006938043,0.0000036161339,0.0001173674],"about_ca_topic_score_codex":0.07292688,"about_ca_topic_score_gemma":0.015897328,"teacher_disagreement_score":0.24470812,"about_ca_system_score_codex":0.00006434827,"about_ca_system_score_gemma":0.00020900622,"threshold_uncertainty_score":0.9332466},"labels":[],"label_agreement":null},{"id":"W2259528854","doi":"10.1093/annonc/mdv600","title":"Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy","year":2015,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Chemotherapy; Cancer; Prostate; Internal medicine; Gynecology","score_opus":0.19323197578410067,"score_gpt":0.44471214094112205,"score_spread":0.2514801651570214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259528854","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016434724,0.0017172104,0.00000492658,0.9511189,0.00015785439,0.0020556885,0.000545991,0.000043314052,0.027921388],"genre_scores_gemma":[0.012429522,0.01851923,0.00081405626,0.8720941,0.002052142,0.0007476723,0.0014677433,0.00025447793,0.091621056],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971185,0.0002520683,0.00045676404,0.0006000635,0.0007828794,0.00078974676],"domain_scores_gemma":[0.997205,0.00021321826,0.00044154626,0.0004185972,0.0015109717,0.00021066281],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004826102,0.00046698799,0.0014900307,0.00029224186,0.000049589173,0.000015464062,0.00016277915,0.00055962143,0.00029429508],"category_scores_gemma":[0.000037179165,0.00030636735,0.00016678417,0.00027697586,0.00056277186,0.000079606245,0.000046576628,0.0015090302,0.000042151714],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071063605,0.00024797692,0.00020339293,0.0004604963,0.00246499,0.006916653,0.0014652513,0.000005365769,0.00046353295,0.000005864057,0.9608148,0.019845335],"study_design_scores_gemma":[0.007409736,0.01179575,0.0005421396,0.00047799863,0.0005891749,0.00028777678,0.0004627024,0.000028726141,0.02435138,0.00015554333,0.9535179,0.00038117985],"about_ca_topic_score_codex":0.0010792171,"about_ca_topic_score_gemma":0.000119022174,"teacher_disagreement_score":0.0790248,"about_ca_system_score_codex":0.00036454652,"about_ca_system_score_gemma":0.0031713478,"threshold_uncertainty_score":0.99993885},"labels":[],"label_agreement":null},{"id":"W2260123348","doi":"10.1007/s00428-016-1904-2","title":"In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading","year":2016,"lang":"en","type":"article","venue":"Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; Conselho Nacional de Desenvolvimento Científico e Tecnológico","keywords":"PTEN; Immunohistochemistry; Tensin; Fluorescence in situ hybridization; Prostate cancer; Concordance; Biology; In situ hybridization; Cancer; Pathology; Biopsy; Cancer research; Medicine; Gene; Bioinformatics; Genetics; Gene expression; PI3K/AKT/mTOR pathway","score_opus":0.014304780997837569,"score_gpt":0.3220447179494752,"score_spread":0.30773993695163765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2260123348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98660487,0.006975484,0.00006213695,0.0049463105,0.00006662276,0.0007704305,0.00030156985,0.000040348332,0.00023223861],"genre_scores_gemma":[0.9820203,0.016599229,0.0002673994,0.0002599751,0.000038159604,0.00015722534,0.0001383342,0.00002819996,0.00049114105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976931,0.00021475168,0.00054422166,0.00064693124,0.00034066377,0.0005602949],"domain_scores_gemma":[0.99836177,0.0006249402,0.00039940618,0.00029715936,0.00014081888,0.00017592798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005899733,0.0003272942,0.00071132224,0.00020800647,0.0001122516,0.000018323582,0.00013744805,0.00016458669,0.000011520918],"category_scores_gemma":[0.0005823166,0.00020347002,0.000053165506,0.00041012868,0.0010661646,0.00017177277,0.00012748985,0.0004802867,0.000001086432],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092698634,0.0001926738,0.23755194,0.00017098512,0.00014008203,0.00011782694,0.00045498987,0.0000034847112,0.75550634,0.000017826362,0.001212458,0.0037044073],"study_design_scores_gemma":[0.01627755,0.0017704488,0.18174186,0.0025220478,0.00038781253,0.00006910485,0.0026481014,0.0002888838,0.79185766,0.00055425934,0.0011684872,0.00071380957],"about_ca_topic_score_codex":0.0005840642,"about_ca_topic_score_gemma":0.00011825494,"teacher_disagreement_score":0.055810086,"about_ca_system_score_codex":0.00034297688,"about_ca_system_score_gemma":0.00028746217,"threshold_uncertainty_score":0.82972664},"labels":[],"label_agreement":null},{"id":"W2264413708","doi":"10.1200/jco.2015.33.7_suppl.8","title":"A biomarker panel associated with distant metastasis in prostate cancer patients treated with radiotherapy as prognostic for DM in a large cohort of prostatectomy patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Proportional hazards model; Oncology; Prostatectomy; Cancer; Biomarker; Radiation therapy; Metastasis; Cohort; Biochemical recurrence; Clinical significance","score_opus":0.1191811030429419,"score_gpt":0.45489174974573615,"score_spread":0.33571064670279427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264413708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514437,0.0005674634,0.000011893551,0.0007331879,0.00011439745,0.0031769236,0.00014385402,0.0000073448464,0.00010059305],"genre_scores_gemma":[0.9983089,0.00052396185,0.000380796,0.00016648296,0.000033572134,0.00027475096,0.000108688524,0.00004016293,0.00016266937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99617726,0.0004946292,0.0018522847,0.00029599146,0.0006821761,0.00049764384],"domain_scores_gemma":[0.99506557,0.0009795622,0.00157777,0.00013771035,0.0018539929,0.00038538544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027658395,0.00022670816,0.0018025326,0.0003312819,0.000022920523,0.000009904582,0.00011470957,0.00019579516,0.000020841564],"category_scores_gemma":[0.0024412554,0.00012131611,0.00017114545,0.00065797043,0.00025907537,0.00014690793,0.000022996552,0.00050347863,5.3958576e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08435343,0.010893851,0.8914797,0.00007343366,0.0013517423,0.00038826864,0.0004894843,0.000010479405,0.000013139283,0.0000021310527,0.0002532404,0.010691157],"study_design_scores_gemma":[0.09773389,0.05183761,0.84743613,0.00063870917,0.00042220345,0.000009567435,0.00013021733,0.00013228091,0.00009503091,0.000031934935,0.0014075271,0.00012491488],"about_ca_topic_score_codex":0.00023986839,"about_ca_topic_score_gemma":0.0008679385,"teacher_disagreement_score":0.04404353,"about_ca_system_score_codex":0.0009573386,"about_ca_system_score_gemma":0.0034612648,"threshold_uncertainty_score":0.6140135},"labels":[],"label_agreement":null},{"id":"W2265622440","doi":"10.1200/jco.2012.30.15_suppl.4558","title":"Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Placebo; Clinical endpoint; Prostate cancer; Internal medicine; Discontinuation; Prednisone; Oncology; Tolerability; Docetaxel; Randomization; Hazard ratio; Urology; Gastroenterology; Randomized controlled trial; Androgen deprivation therapy; Cancer; Confidence interval; Adverse effect","score_opus":0.22405257462937547,"score_gpt":0.516633520639768,"score_spread":0.29258094601039253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265622440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99307275,0.0048100753,0.0000073816723,0.00052660477,0.00021622067,0.0012496231,0.000066856315,0.0000032169564,0.00004726892],"genre_scores_gemma":[0.99487185,0.0043753437,0.0002965056,0.000031496835,0.000093642455,0.00009870952,0.000011629739,0.000017677294,0.00020316569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948796,0.00070459495,0.0031706765,0.00026266035,0.0005792715,0.00040320796],"domain_scores_gemma":[0.9961268,0.0009876314,0.0018224295,0.00022920694,0.00044808743,0.00038584523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034462258,0.00023182924,0.0031464894,0.00072079897,0.000030784333,0.000008429482,0.00010617199,0.0001371335,0.0000834857],"category_scores_gemma":[0.00025429772,0.00015161867,0.00027258493,0.0007679134,0.00025477514,0.0002529111,0.00004828821,0.0004232025,6.6846127e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.085291855,0.040865317,0.75866926,0.00023011958,0.010435177,0.0011166816,0.019460013,0.00093750964,0.0046657394,0.000015795702,0.000025613883,0.07828692],"study_design_scores_gemma":[0.15135811,0.038762394,0.7914103,0.00019557805,0.006697717,0.00001809219,0.009305402,0.0009011396,0.00093603745,0.00002760643,0.0002190611,0.00016854616],"about_ca_topic_score_codex":0.001063458,"about_ca_topic_score_gemma":0.010013349,"teacher_disagreement_score":0.07811838,"about_ca_system_score_codex":0.0006488058,"about_ca_system_score_gemma":0.0019254058,"threshold_uncertainty_score":0.61828303},"labels":[],"label_agreement":null},{"id":"W2269292530","doi":"10.1016/j.ijrobp.2015.07.320","title":"Validation of a Genomic Classifier for Prediction of Metastasis Following Postoperative Salvage Radiation Therapy","year":2015,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Cancer Institute; National Institutes of Health; Jazz Pharmaceuticals","keywords":"Medicine; Prostate cancer; Metastasis; Prostatectomy; Oncology; Internal medicine; Radiation therapy; Proportional hazards model; Salvage therapy; Cancer; Chemotherapy","score_opus":0.07522353382725602,"score_gpt":0.3895627843490779,"score_spread":0.3143392505218219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269292530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98042184,0.0014793002,0.013426998,0.0019403476,0.0015814416,0.0005852542,0.00030022618,0.000013357184,0.00025125078],"genre_scores_gemma":[0.99465764,0.00091498677,0.0028820636,0.00015641749,0.0008043388,0.000028301256,0.0004783002,0.000021087166,0.000056887795],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984107,0.00020825301,0.0007397191,0.00015801014,0.0003373203,0.00014601149],"domain_scores_gemma":[0.99701476,0.00029172923,0.0010002995,0.00010660165,0.0014854936,0.00010109075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009074696,0.00013634014,0.000468299,0.00025126836,0.00003886193,0.000011680572,0.00016667791,0.00015994284,0.000019528128],"category_scores_gemma":[0.00031823813,0.00010860466,0.00030727,0.00014559619,0.000107626154,0.0003153828,0.000021929542,0.00018456754,0.0000028836],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061438237,0.0012119403,0.36397442,0.000028991675,0.0043209232,0.000014500078,0.0038227697,0.0012637033,0.32212612,0.0032402615,0.002172758,0.29167977],"study_design_scores_gemma":[0.071314305,0.019136447,0.12390907,0.00019804161,0.0010887798,0.00013105085,0.0012117808,0.0074450634,0.72215325,0.015267944,0.037757903,0.00038635998],"about_ca_topic_score_codex":0.000014188714,"about_ca_topic_score_gemma":6.0025695e-7,"teacher_disagreement_score":0.40002713,"about_ca_system_score_codex":0.0007981804,"about_ca_system_score_gemma":0.0010136216,"threshold_uncertainty_score":0.44287694},"labels":[],"label_agreement":null},{"id":"W2270275021","doi":"10.1200/jco.2016.34.2_suppl.4","title":"Validation of a genomic classifier for prediction of metastasis following postoperative salvage radiation therapy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Metastasis; Internal medicine; Oncology; Radiation therapy; Prostatectomy; Salvage therapy; Proportional hazards model; Cancer; Chemotherapy","score_opus":0.2183303458427812,"score_gpt":0.4968435459335903,"score_spread":0.27851320009080915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2270275021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99130756,0.00086380093,0.0016405482,0.0049295085,0.0005804403,0.00039656393,0.000044491717,0.0000027076376,0.00023436463],"genre_scores_gemma":[0.9953244,0.0022524702,0.0016913617,0.00012407094,0.00032704376,0.000009215812,0.000008990715,0.000009266198,0.00025318313],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99796146,0.00028471855,0.001323067,0.00009733889,0.00022705358,0.000106373365],"domain_scores_gemma":[0.99664515,0.0015980899,0.0010793551,0.000089245164,0.00049151457,0.00009662989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024799567,0.00006560964,0.0007518101,0.00013236697,0.000021327105,0.0000020686048,0.000058883346,0.00016229821,0.000060480266],"category_scores_gemma":[0.0013108043,0.000033733064,0.0004895131,0.00006821666,0.00008315081,0.00013324281,0.000010559262,0.00014171975,0.0000014094287],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014501924,0.0011364456,0.09596297,0.00003225014,0.0018728459,0.000020243837,0.0003080875,0.0000051145576,0.2799332,0.00009161009,0.0015736448,0.6045616],"study_design_scores_gemma":[0.055636946,0.056135513,0.63733906,0.00024752953,0.001073453,0.000038166876,0.00022350618,0.0000820217,0.21701656,0.00094449107,0.031169599,0.00009315941],"about_ca_topic_score_codex":0.000003216458,"about_ca_topic_score_gemma":8.280703e-7,"teacher_disagreement_score":0.60446846,"about_ca_system_score_codex":0.0001606453,"about_ca_system_score_gemma":0.0009909588,"threshold_uncertainty_score":0.17579183},"labels":[],"label_agreement":null},{"id":"W2271989793","doi":"10.1186/s13059-015-0864-1","title":"Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients","year":2016,"lang":"en","type":"article","venue":"Genome biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":212,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Terry Fox Foundation; Prostate Cancer Canada; Movember Foundation","keywords":"Biology; Androgen receptor; Prostate cancer; Human genetics; Androgen; DNA; Genetics; Prostate; Mutation; Receptor; Cancer research; Cancer; Gene; Endocrinology; Hormone","score_opus":0.03456002242335774,"score_gpt":0.2913238280498985,"score_spread":0.2567638056265407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2271989793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944427,0.0020021766,0.00006134577,0.00052264624,0.0001447709,0.0004603443,0.0021040905,0.000016046402,0.00024587644],"genre_scores_gemma":[0.99570453,0.00053851935,0.00009202784,0.000040771585,0.000049148948,0.00011209053,0.0018555174,0.000014907584,0.0015924971],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986592,0.0000951909,0.00035140422,0.0004044974,0.0001817005,0.0003080347],"domain_scores_gemma":[0.999092,0.00012420524,0.00017405413,0.0003025055,0.00021830674,0.00008892437],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014187417,0.0001389217,0.00044107495,0.00037226386,0.00006264607,0.0000075689604,0.000111133144,0.00011015527,0.0010780267],"category_scores_gemma":[0.000054302847,0.00009292393,0.00012491284,0.0005140985,0.00017287218,0.00006225292,0.000067406894,0.000072401606,0.00002213605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033366942,0.00012313417,0.7972382,0.000023767094,0.0008332127,0.000005679449,0.00041348906,0.000010320968,0.20019633,0.000014771185,0.00013113905,0.00067634566],"study_design_scores_gemma":[0.0054561356,0.0001063728,0.9518849,0.00005774129,0.00047984032,2.654368e-7,0.00011610878,0.000012904537,0.03984204,0.00031165557,0.0015845579,0.00014744476],"about_ca_topic_score_codex":0.00033784294,"about_ca_topic_score_gemma":0.00038388587,"teacher_disagreement_score":0.16035429,"about_ca_system_score_codex":0.00022061114,"about_ca_system_score_gemma":0.00020784659,"threshold_uncertainty_score":0.99983513},"labels":[],"label_agreement":null},{"id":"W2274103071","doi":"10.1200/jco.2005.23.16_suppl.4516","title":"Interim results from ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC)","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Urology; Placebo; Clinical endpoint; Interim analysis; Internal medicine; Prostate cancer; Calcitriol; Chemotherapy; Statistical significance; Cancer; Oncology; Clinical trial; Vitamin D and neurology; Pathology","score_opus":0.1600227770498614,"score_gpt":0.489695076619122,"score_spread":0.3296722995692606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274103071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818052,0.003120276,0.000015855216,0.008872096,0.0013927193,0.00396505,0.00007629422,0.000019835912,0.0007326858],"genre_scores_gemma":[0.98869294,0.007179034,0.0005830879,0.00055348163,0.0013937585,0.00016375406,0.000029655055,0.000049251354,0.0013550145],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9884947,0.0018834725,0.0067546894,0.00070209923,0.0014091166,0.0007559098],"domain_scores_gemma":[0.99001735,0.003932026,0.0037219815,0.0005391258,0.0009878478,0.00080164836],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009328561,0.00046051102,0.0056447512,0.0006081752,0.000073851916,0.00003812879,0.0005207893,0.00066101307,0.00030607442],"category_scores_gemma":[0.0026770812,0.00029556509,0.00090733496,0.0004831197,0.00052824564,0.0002836186,0.00026602898,0.0025175824,0.000024942623],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9343325,0.0090753,0.010983005,0.000060560928,0.0026348818,0.0023224582,0.0040755393,0.0007213563,0.0001370023,0.000013176613,0.0008949067,0.0347493],"study_design_scores_gemma":[0.9501021,0.0128495945,0.027539691,0.00057153794,0.0012894587,0.00010912059,0.001201698,0.0012973297,0.0007486401,0.00012435982,0.0038947407,0.00027174695],"about_ca_topic_score_codex":0.0039480254,"about_ca_topic_score_gemma":0.0049739014,"teacher_disagreement_score":0.03447755,"about_ca_system_score_codex":0.0016937802,"about_ca_system_score_gemma":0.006045497,"threshold_uncertainty_score":0.99994963},"labels":[],"label_agreement":null},{"id":"W2274396712","doi":"10.1200/jco.2007.25.18_suppl.21073","title":"Use of nuclear androgen receptor status to predict early biochemical recurrence of prostate cancer patients","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Prostate cancer; Androgen receptor; Medicine; Cancer; Prostate; Staining; Immunohistochemistry; Stage (stratigraphy); Pathology; Internal medicine; Oncology; Biology","score_opus":0.1279145844002026,"score_gpt":0.47322708987640905,"score_spread":0.34531250547620645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274396712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99707574,0.00050053134,0.0000051098746,0.0010785848,0.00065726344,0.00041450566,0.000083631334,0.0000043194186,0.00018031808],"genre_scores_gemma":[0.9937747,0.0028695283,0.0025910866,0.00028938398,0.00028549484,0.0000028465552,0.000007240652,0.000017423296,0.0001622935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967488,0.00014845266,0.0020065843,0.00017525638,0.00057117234,0.0003497311],"domain_scores_gemma":[0.9957114,0.0009310204,0.0011883898,0.00015296019,0.0013308625,0.00068537856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015769448,0.00011234493,0.0010240664,0.00017284283,0.000018167337,0.000004299885,0.00013285925,0.00025339198,0.00013988718],"category_scores_gemma":[0.0030088094,0.00007494065,0.00026572836,0.00026887766,0.0003164594,0.00011125618,0.000077172954,0.0005881313,0.000007112899],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027414886,0.0022971432,0.8375525,0.000073874624,0.00034611078,0.000058089816,0.0004552379,0.0000016865245,0.0037334675,0.000007081548,0.012521069,0.11553889],"study_design_scores_gemma":[0.009849284,0.038878288,0.8323358,0.0005506488,0.00023437246,0.000010101414,0.00008359702,0.000006944293,0.014776044,0.000028046523,0.10314327,0.0001035562],"about_ca_topic_score_codex":0.00009369205,"about_ca_topic_score_gemma":0.00000950174,"teacher_disagreement_score":0.115435325,"about_ca_system_score_codex":0.00021758916,"about_ca_system_score_gemma":0.0012522147,"threshold_uncertainty_score":0.3602043},"labels":[],"label_agreement":null},{"id":"W2274728014","doi":"10.1158/1538-7755.disp13-c68","title":"Abstract C68: Global transcriptome sequencing of ethnically diverse formalin-fixed patient samples identifies biomarkers of recurrence in prostate cancer","year":2014,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Prostate cancer; Transcriptome; Single-nucleotide polymorphism; Gene; Cancer; Medicine; CHEK2; Oncology; Biology; Internal medicine; Genetics; Gene expression; Genotype; Germline mutation; Mutation","score_opus":0.10085774778281553,"score_gpt":0.40617580184800567,"score_spread":0.30531805406519014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274728014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758337,0.019359598,0.0003921219,0.001962932,0.00068780506,0.0012762118,0.00026060286,0.00003539679,0.00019160975],"genre_scores_gemma":[0.9898847,0.007917355,0.0014604238,0.00012299852,0.000043497545,0.00030819402,0.00018271564,0.0000190854,0.000061031275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996322,0.00065037195,0.0014423605,0.0006096791,0.000314703,0.0006609345],"domain_scores_gemma":[0.9978744,0.00045308494,0.0007957681,0.00037253322,0.00030611196,0.00019810614],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024745972,0.0003054155,0.0009779355,0.00026480894,0.00007130069,0.000005437349,0.00020643469,0.00024808323,0.00015980571],"category_scores_gemma":[0.00061298284,0.0002538725,0.00035819938,0.00056613155,0.00070739654,0.00024694522,0.00007511299,0.0002407897,0.0000030483359],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004726946,0.00025753272,0.7907502,0.0014925486,0.0010686696,0.00001364418,0.00070115004,0.00011826197,0.06478128,0.00021499056,0.0009803664,0.13489442],"study_design_scores_gemma":[0.004726416,0.00088639284,0.96253973,0.0037087312,0.00036280727,0.000009113551,0.0007337107,0.00043142276,0.021467851,0.0042268746,0.00057034433,0.00033659692],"about_ca_topic_score_codex":0.006151708,"about_ca_topic_score_gemma":0.0023576359,"teacher_disagreement_score":0.17178954,"about_ca_system_score_codex":0.00081432133,"about_ca_system_score_gemma":0.0006038887,"threshold_uncertainty_score":0.99999136},"labels":[],"label_agreement":null},{"id":"W2275085056","doi":"10.1007/s00432-015-2096-x","title":"ERG expression in prostate cancer: biological relevance and clinical implication","year":2015,"lang":"en","type":"review","venue":"Journal of Cancer Research and Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Calgary Laboratory Services; University of Calgary","funders":"Prostate Cancer Canada; Prostate Cancer Foundation","keywords":"Prostate cancer; TMPRSS2; Erg; Prostate; Cancer; Medicine; Fusion gene; Disease; Oncology; Prostate-specific antigen; Internal medicine; Bioinformatics; Cancer research; Biology; Gene; Genetics","score_opus":0.488036976029058,"score_gpt":0.669522474613049,"score_spread":0.18148549858399105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275085056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017321045,0.97665554,8.709877e-7,0.0036715316,0.00050627306,0.0015332148,0.000048399364,0.00000843743,0.0002546717],"genre_scores_gemma":[0.00043276447,0.99649966,0.00022260132,0.00010179058,0.0016525122,0.00023879681,0.000020927531,0.000038748618,0.0007921924],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921669,0.0024341107,0.0030553518,0.00073207443,0.0008499777,0.0007615926],"domain_scores_gemma":[0.9913204,0.004534451,0.001226879,0.00033312384,0.0013526753,0.0012324778],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.011524492,0.00033482042,0.0038954688,0.00049755303,0.000099865865,0.000042671632,0.00033383822,0.0010847755,0.000069211026],"category_scores_gemma":[0.002521011,0.00018781985,0.00045133947,0.00059673394,0.0015964367,0.00013939416,0.00038606644,0.0050167073,0.000008690079],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00454428,0.0009166111,0.027708786,0.0017293986,0.00035696945,0.000611235,0.00003040459,6.719034e-8,0.000007034485,0.000013954525,0.0066152425,0.957466],"study_design_scores_gemma":[0.006267055,0.013098113,0.0066632773,0.010326107,0.00034468743,0.00024202275,0.000066266315,0.0000026296725,0.0000042884235,0.0006371151,0.9621746,0.00017381701],"about_ca_topic_score_codex":0.000119363656,"about_ca_topic_score_gemma":0.00018291883,"teacher_disagreement_score":0.9572922,"about_ca_system_score_codex":0.0012102859,"about_ca_system_score_gemma":0.009174711,"threshold_uncertainty_score":0.99727875},"labels":[],"label_agreement":null},{"id":"W2275410382","doi":"10.1200/jco.2005.23.16_suppl.4666","title":"A retrospective review of prostate specific antigen doubling time (PSA-DT) in men with hormone refractory prostate cancer (HRPC)","year":2005,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Asymptomatic; Internal medicine; Oncology; Urology; Population; Retrospective cohort study; Cancer; Survival analysis; Log-rank test","score_opus":0.17566258617002448,"score_gpt":0.5208299196594822,"score_spread":0.3451673334894577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275410382","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006263031,0.98854077,7.1423983e-7,0.0020333226,0.00024770375,0.0030277744,0.00007208265,0.000012267302,0.005439035],"genre_scores_gemma":[0.00009057753,0.9943575,0.0007046568,0.00025035845,0.0015104905,0.0001095476,0.000054115342,0.00009985083,0.0028228934],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99032277,0.0011316561,0.00612476,0.00062309374,0.0011397467,0.00065797043],"domain_scores_gemma":[0.9893837,0.0010079544,0.007077182,0.0005059246,0.0014705895,0.00055464206],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.007041523,0.00057894463,0.010311236,0.0006270512,0.00004379699,0.00001642094,0.0004164604,0.0007753569,0.0003908996],"category_scores_gemma":[0.0009722747,0.00032383399,0.0013092664,0.0010054795,0.0005504871,0.00023772148,0.00012654693,0.0038541278,0.000045975587],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007425568,0.0016906995,0.0011405965,0.018710366,0.0017347588,0.002149741,0.00011843583,6.839329e-7,0.0000051364864,0.000005575812,0.011526273,0.95549214],"study_design_scores_gemma":[0.008172385,0.013614916,0.0030841597,0.13172132,0.0016531011,0.0003163041,0.00002015374,0.0000018288266,0.0000011918893,0.000014593148,0.8411432,0.00025685088],"about_ca_topic_score_codex":0.00004448255,"about_ca_topic_score_gemma":0.00002206442,"teacher_disagreement_score":0.9552353,"about_ca_system_score_codex":0.0022465356,"about_ca_system_score_gemma":0.012995148,"threshold_uncertainty_score":0.9999214},"labels":[],"label_agreement":null},{"id":"W2275578091","doi":"","title":"Clinical application of validated proteomic biomarkers to the diagnosis of prostate cancer","year":2007,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Miraculins (Canada)","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Prostate; Intraepithelial neoplasia; Biopsy; Gold standard (test); Prostate biopsy; Internal medicine; Oncology; Disease; Biomarker; Urology; Biology","score_opus":0.05189117854543209,"score_gpt":0.42809937571308637,"score_spread":0.3762081971676543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275578091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894995,0.0002767046,0.00058654445,0.006041037,0.000048258615,0.002585823,0.000024388111,0.000017266759,0.0009204569],"genre_scores_gemma":[0.9969891,0.0005707112,0.0009498758,0.00019246517,0.00005146096,0.0004465022,0.000018646082,0.000010111656,0.000771153],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99903446,0.000031718613,0.00037511738,0.00016276943,0.00022482089,0.00017110119],"domain_scores_gemma":[0.9992356,0.00011550102,0.00009198447,0.00025765618,0.00019867603,0.00010060886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008642244,0.000067170906,0.00019070407,0.00007664858,0.000023970788,0.0000025861532,0.000085826105,0.000047587942,0.00008554247],"category_scores_gemma":[0.00006501154,0.000035022025,0.00006982753,0.00039754246,0.0001197784,0.000019690682,0.00003617601,0.00007372361,0.000012908422],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014937762,0.00024512582,0.8649879,0.000088715606,0.00018758517,0.0000022414397,0.00018371326,0.0000025520928,0.018983707,0.00003181983,0.0033907134,0.11040215],"study_design_scores_gemma":[0.001619726,0.0004985933,0.41978717,0.00008196268,0.00007517792,0.0000010859434,0.00013426965,0.00006037129,0.5698223,0.000020698848,0.007847196,0.000051405947],"about_ca_topic_score_codex":0.0011148294,"about_ca_topic_score_gemma":0.0001470387,"teacher_disagreement_score":0.55083865,"about_ca_system_score_codex":0.000053186548,"about_ca_system_score_gemma":0.00012470999,"threshold_uncertainty_score":0.1685296},"labels":[],"label_agreement":null},{"id":"W2280639226","doi":"10.1016/j.urology.2016.02.010","title":"Practical Guidance on the Role of Corticosteroids in the Treatment of Metastatic Castration-resistant Prostate Cancer","year":2016,"lang":"en","type":"review","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Adverse effect; Castration; Cabazitaxel; Quality of life (healthcare); Chemotherapy; Oncology; Cancer; Orchiectomy; Prostate; Internal medicine; Intensive care medicine; Hormone; Androgen deprivation therapy","score_opus":0.11258351292096629,"score_gpt":0.4402014927698567,"score_spread":0.3276179798488904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280639226","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001050527,0.99220264,0.0000017287333,0.0034271355,0.000059836,0.0023514158,0.00018503006,0.000004029676,0.00071766495],"genre_scores_gemma":[0.0069021527,0.99130076,0.000020086445,0.000076549026,0.000051488725,0.0011501118,0.000031933894,0.00002074629,0.0004461627],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980451,0.00055988494,0.0005783956,0.00025535715,0.00028400013,0.000277258],"domain_scores_gemma":[0.9977101,0.0013236257,0.00036312378,0.00047657322,0.00008548867,0.000041064017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002962453,0.00023293006,0.0010144787,0.000114924114,0.00003124696,0.0000056395306,0.0001277544,0.000093583,0.00013699985],"category_scores_gemma":[0.00011003768,0.00008188809,0.00020307805,0.00019706474,0.0002878071,0.000019261572,0.000014778749,0.00018672975,0.000017317478],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017769171,0.0016585725,0.00025862653,0.002600474,0.0011073542,0.00031328417,0.0010553144,0.0000012681288,0.00016691179,0.0027433003,0.00033833107,0.98797965],"study_design_scores_gemma":[0.0013610988,0.005788692,0.0001531907,0.0016979029,0.0012312303,0.00006875033,0.00010214661,0.0000074131904,0.00017354952,0.00020189783,0.989127,0.000087132255],"about_ca_topic_score_codex":0.00010748245,"about_ca_topic_score_gemma":0.00010150846,"teacher_disagreement_score":0.98878866,"about_ca_system_score_codex":0.00017898675,"about_ca_system_score_gemma":0.0008611925,"threshold_uncertainty_score":0.33392993},"labels":[],"label_agreement":null},{"id":"W2280878155","doi":"10.1200/jco.2009.27.15_suppl.e16161","title":"A review of the patterns of docetaxel use for hormone refractory prostate cancer (HRPC) at the Princess Margaret Hospital","year":2009,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Medicine; Mitoxantrone; Internal medicine; Discontinuation; Regimen; Prostate cancer; Oncology; Chemotherapy; Randomized controlled trial; Clinical trial; Surgery; Cancer","score_opus":0.2383777072622688,"score_gpt":0.5475200020060633,"score_spread":0.3091422947437945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280878155","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014350797,0.9864806,0.0000024299907,0.007516924,0.00089082064,0.0032829097,0.00028527805,0.0000029557598,0.00010303052],"genre_scores_gemma":[0.00012994587,0.995463,0.00009473124,0.0011481773,0.00079480273,0.000121712415,0.00002700056,0.00003884996,0.0021817528],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931966,0.0010407399,0.004425282,0.0002886035,0.00069454266,0.000354225],"domain_scores_gemma":[0.98594385,0.0037685346,0.0082239555,0.0006077434,0.0012176502,0.00023824128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004337138,0.00033274436,0.0056096376,0.000092220514,0.000061473824,0.000007681957,0.0006392197,0.0005358718,0.00009261159],"category_scores_gemma":[0.0036510138,0.00012818766,0.002863225,0.00024509843,0.00047499788,0.00009375801,0.00021362133,0.0016930412,0.000002078983],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012690381,0.0011334405,0.0017320295,0.04426322,0.0014321443,0.00006782236,0.00004023308,1.1315574e-7,7.468145e-7,0.0000071594714,0.025188852,0.9248652],"study_design_scores_gemma":[0.0032297752,0.008256934,0.0069516036,0.09825097,0.0045361915,0.0000949703,0.000009173151,2.761637e-7,0.0000022246286,0.000020682688,0.8785388,0.00010841411],"about_ca_topic_score_codex":0.000039638766,"about_ca_topic_score_gemma":0.000039091286,"teacher_disagreement_score":0.92475677,"about_ca_system_score_codex":0.0006038272,"about_ca_system_score_gemma":0.006333342,"threshold_uncertainty_score":0.9992998},"labels":[],"label_agreement":null},{"id":"W2283893450","doi":"10.1200/jco.2012.30.5_suppl.46","title":"Testosterone suppression: Impact of testosterone level on disease progression in advanced prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Testosterone (patch); Androgen deprivation therapy; Internal medicine; Cancer; Oncology; Prospective cohort study; Urology; Cohort; Androgen; Hormone","score_opus":0.21067304210148521,"score_gpt":0.5605945311655919,"score_spread":0.3499214890641067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283893450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988214,0.0054497593,0.000002650957,0.004529659,0.00073334854,0.0005909958,0.000036219586,0.0000063408906,0.00043698968],"genre_scores_gemma":[0.99543434,0.0023194728,0.0007960343,0.00021545611,0.00062440074,0.000029834977,0.000009333619,0.000023433271,0.0005477149],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966409,0.00038308953,0.0017435781,0.00018501325,0.00056597235,0.00048143064],"domain_scores_gemma":[0.9960417,0.0010791727,0.001310867,0.00023805545,0.0003633992,0.0009667943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001846357,0.00018766269,0.0013099324,0.00022542114,0.000030208674,0.000004560446,0.00014637638,0.00021824094,0.00017304912],"category_scores_gemma":[0.0019110448,0.00010266397,0.0003848878,0.00022526892,0.00024971468,0.00026261373,0.00007726817,0.00094738713,0.0000088172055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04359796,0.004832605,0.71407115,0.00008859179,0.00013770438,0.00032067776,0.0001649804,0.000039167917,0.0020542992,0.0000032205257,0.0012971255,0.23339249],"study_design_scores_gemma":[0.016769644,0.025603889,0.9524324,0.0014283488,0.00013719924,0.00004864549,0.00004885045,0.000027255524,0.0012219559,0.000048710863,0.0021390712,0.0000940118],"about_ca_topic_score_codex":0.000022854849,"about_ca_topic_score_gemma":0.000008223099,"teacher_disagreement_score":0.23836124,"about_ca_system_score_codex":0.0004987201,"about_ca_system_score_gemma":0.0025491728,"threshold_uncertainty_score":0.45221233},"labels":[],"label_agreement":null},{"id":"W2284085687","doi":"10.1161/atvb.34.suppl_1.596","title":"Abstract 596: Androgen Deprivation Therapy--Induced Weight Gain and Atherosclerosis in Prostate Cancer: Differences Between Orchiectomy, GnRH Agonist and Antagonist","year":2014,"lang":"en","type":"article","venue":"Arteriosclerosis Thrombosis and Vascular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Orchiectomy; Androgen deprivation therapy; Medicine; Prostate cancer; Castration; Internal medicine; Endocrinology; Testosterone (patch); Agonist; Prostate; Weight gain; Urology; Cancer; Hormone; Receptor; Body weight","score_opus":0.05737615756286264,"score_gpt":0.31874116786504275,"score_spread":0.2613650103021801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2284085687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996368,0.0009191398,0.000013575659,0.0017602267,0.000060656956,0.00073173724,0.00005229349,0.00004195763,0.00005243501],"genre_scores_gemma":[0.9380623,0.06125918,0.00008901672,0.00019518111,0.0001057359,0.00016406253,0.00008800033,0.000032398228,0.0000040992136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981006,0.00017887223,0.00037531345,0.000695307,0.000156349,0.00049356994],"domain_scores_gemma":[0.9992035,0.00012953192,0.00011751601,0.0002771131,0.00005328387,0.00021905126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004317293,0.0003392468,0.0007361364,0.00016599179,0.00029952577,0.00011327392,0.000090894,0.00019523951,0.000031383308],"category_scores_gemma":[0.000021160102,0.0002439903,0.000083306724,0.00019191182,0.00042998753,0.00012453555,0.000103123784,0.00022586423,0.0000025551549],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024148005,0.000090427224,0.78881305,0.00006608239,0.00020327323,1.097582e-7,0.0006248972,4.7148344e-8,0.19468251,0.000045486948,0.0000072836688,0.0154426545],"study_design_scores_gemma":[0.0043494035,0.00081782014,0.98901445,0.00021947054,0.000085281834,7.1443264e-7,0.00011565744,0.00006135206,0.004435955,0.00014233722,0.0004861225,0.00027145067],"about_ca_topic_score_codex":0.0011808638,"about_ca_topic_score_gemma":0.00027770424,"teacher_disagreement_score":0.20020136,"about_ca_system_score_codex":0.00005588222,"about_ca_system_score_gemma":0.000051500465,"threshold_uncertainty_score":0.9949636},"labels":[],"label_agreement":null},{"id":"W2286143684","doi":"10.1093/annonc/mdu336.36","title":"Efficacy of Enzalutamide (Enza) Following Abiraterone Acetate (Abi) in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients (Pts)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Abiraterone acetate; Prostate cancer; Abiraterone; Oncology; Chemotherapy; Internal medicine; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.07218588100082024,"score_gpt":0.409645634980664,"score_spread":0.33745975397984374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286143684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99404186,0.00090990734,0.000007971071,0.0026836772,0.0001430178,0.0010087953,0.000042289652,0.000015159121,0.0011472931],"genre_scores_gemma":[0.99759525,0.0007846507,0.00039136838,0.00049190945,0.00003756293,0.000114366754,0.00006453478,0.00003194109,0.00048843864],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99790484,0.00021835677,0.00069321354,0.0003246059,0.00037995298,0.00047902763],"domain_scores_gemma":[0.9986983,0.00025574575,0.00032266538,0.0002691114,0.0003153142,0.00013889151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063568243,0.0002091557,0.00081852044,0.00025618298,0.000040911043,0.000007609962,0.00012602803,0.000095579235,0.000089647656],"category_scores_gemma":[0.00018040842,0.00016426624,0.00016939043,0.0003411202,0.00017969694,0.00011481216,0.00003790535,0.00018758612,0.000008198696],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023298778,0.007224811,0.23181963,0.0013860812,0.0021936412,0.00022468848,0.010194976,0.00047260337,0.20812583,0.00024364224,0.002213452,0.51260185],"study_design_scores_gemma":[0.053016145,0.013976462,0.64360803,0.0008203269,0.00033193085,0.0000055657247,0.0004393206,0.00032947198,0.27619213,0.0006525789,0.010205356,0.00042266434],"about_ca_topic_score_codex":0.0006767334,"about_ca_topic_score_gemma":0.00038318476,"teacher_disagreement_score":0.5121792,"about_ca_system_score_codex":0.00014370977,"about_ca_system_score_gemma":0.00045783026,"threshold_uncertainty_score":0.6698583},"labels":[],"label_agreement":null},{"id":"W2290464829","doi":"10.1177/1756287215617872","title":"Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?","year":2015,"lang":"en","type":"review","venue":"Therapeutic Advances in Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; Population Health Research Institute; McMaster University; Hamilton Health Sciences","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Mechanism (biology); Disease; Adverse effect; Observational study; Hormonal therapy; Androgen; Intensive care medicine; Internal medicine; Bioinformatics; Oncology; Hormone; Cancer","score_opus":0.09196722086384265,"score_gpt":0.3869940597528789,"score_spread":0.29502683888903625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2290464829","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000049670387,0.9969629,0.00018101613,0.0006414653,0.00023965094,0.0018044446,0.000008421043,0.000029721401,0.000082686376],"genre_scores_gemma":[0.00034184539,0.99816155,0.00004130536,0.00065305433,0.00019087628,0.00040168216,0.00007793671,0.00005490725,0.0000768679],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979924,0.00040466106,0.0003205258,0.00053605466,0.00037289306,0.0003734594],"domain_scores_gemma":[0.99881,0.00019420417,0.00010801812,0.00070054387,0.000071314906,0.00011591362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007254451,0.00034151567,0.0012193832,0.00016204895,0.000086613945,0.000040803523,0.00021322015,0.00023001175,0.000031108244],"category_scores_gemma":[0.000010564157,0.00018632304,0.00031137522,0.0002944757,0.00023849838,0.00020699117,0.000086049346,0.0004694629,0.000012509464],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001770808,0.000034941142,0.000050212213,0.0010614741,0.0008386998,0.000058235135,0.00022581933,0.0000030054466,1.5682916e-7,0.00035475317,0.0000026164068,0.997193],"study_design_scores_gemma":[0.0011236303,0.0002183135,0.000008815186,0.000999975,0.0010864908,0.0000849725,0.00006254855,0.00003967678,0.0000019501906,0.011307839,0.98489976,0.00016600384],"about_ca_topic_score_codex":0.000003381999,"about_ca_topic_score_gemma":0.0000012812804,"teacher_disagreement_score":0.997027,"about_ca_system_score_codex":0.00010389314,"about_ca_system_score_gemma":0.0003133765,"threshold_uncertainty_score":0.7598033},"labels":[],"label_agreement":null},{"id":"W2290479331","doi":"10.1515/raon-2015-0038","title":"Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel","year":2015,"lang":"en","type":"article","venue":"Radiology and Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Javna Agencija za Raziskovalno Dejavnost RS; Sanofi","keywords":"Docetaxel; Comorbidity; Medicine; Internal medicine; Prostate cancer; Tolerability; Oncology; Cancer; Proportional hazards model; Adverse effect","score_opus":0.0610006871023436,"score_gpt":0.40291874270406275,"score_spread":0.3419180556017192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2290479331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914139,0.0009422813,0.000001239061,0.0028118924,0.00001674546,0.0006779573,0.000019176436,0.000011758962,0.004105048],"genre_scores_gemma":[0.9982061,0.0007253304,0.000048614784,0.00013931387,0.000023350942,0.00013766628,0.000017943872,0.000009898718,0.00069182814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999134,0.00016580026,0.0001533825,0.0001958285,0.00008540679,0.0002656009],"domain_scores_gemma":[0.999378,0.00018120042,0.00008135981,0.00015538835,0.00008901285,0.000115014394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002574712,0.00013104023,0.00046898948,0.00008472358,0.000033896187,0.0000018972221,0.000052387288,0.00010118656,0.000035280013],"category_scores_gemma":[0.000034541164,0.00005313351,0.00002579123,0.00016960932,0.00049526046,0.000030328601,0.000016188049,0.00025499298,0.000002124154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01831071,0.00022279403,0.97571516,0.000016128371,0.00021782535,0.000248516,0.00074345403,0.00011788806,0.0003295768,0.000101553174,0.00064487976,0.0033314973],"study_design_scores_gemma":[0.0150125045,0.020435305,0.9622618,0.000051540173,0.00007882537,0.0002698037,0.00037506106,0.000102916034,0.00049550016,0.000080517384,0.00074714434,0.00008910751],"about_ca_topic_score_codex":0.0006524286,"about_ca_topic_score_gemma":0.00033151932,"teacher_disagreement_score":0.02021251,"about_ca_system_score_codex":0.00038057036,"about_ca_system_score_gemma":0.0005230908,"threshold_uncertainty_score":0.21667217},"labels":[],"label_agreement":null},{"id":"W2291500182","doi":"10.1016/j.jgo.2016.01.003","title":"A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone","year":2016,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Chemotherapy; Internal medicine; Quality of life (healthcare); Cancer; Prospective cohort study; Activities of daily living; Oncology; Physical therapy","score_opus":0.023156410249182625,"score_gpt":0.3458039490036923,"score_spread":0.3226475387545097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2291500182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944181,0.00073368615,0.000036234833,0.0024185025,0.00011065932,0.002112806,0.000004453774,0.000015067647,0.00015050189],"genre_scores_gemma":[0.99195254,0.0032107471,0.0008322206,0.000062339706,0.00014487134,0.00025950727,5.494974e-7,0.000042884338,0.0034943388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982736,0.0001271486,0.00051835726,0.00030806067,0.00034290602,0.00042991128],"domain_scores_gemma":[0.998645,0.00027331224,0.00045944846,0.0001651981,0.00028847475,0.0001685629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027910713,0.00026831133,0.00089863833,0.00038563303,0.000054067325,0.000014215616,0.000084825755,0.00008151916,0.00019758705],"category_scores_gemma":[0.000025381809,0.000098965174,0.000052844574,0.0003912434,0.000094010975,0.00018008432,0.000018822315,0.0001876793,0.0000033617368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.070778355,0.004100079,0.84486043,0.000049439623,0.0010327304,0.003296191,0.010533697,0.0000024746041,0.00039129503,8.350677e-7,0.000031304276,0.06492315],"study_design_scores_gemma":[0.09718472,0.105477326,0.78933895,0.0006362327,0.000300893,0.000470194,0.0052486826,0.0000016529622,0.0010234735,0.000011423603,0.00014743129,0.00015902863],"about_ca_topic_score_codex":0.00019887682,"about_ca_topic_score_gemma":0.0021107025,"teacher_disagreement_score":0.10137725,"about_ca_system_score_codex":0.0020948318,"about_ca_system_score_gemma":0.0022861178,"threshold_uncertainty_score":0.5477912},"labels":[],"label_agreement":null},{"id":"W2292759384","doi":"10.1200/jco.2011.29.7_suppl.1","title":"Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Bicalutamide; Urology; Clinical endpoint; Androgen deprivation therapy; Radiation therapy; Internal medicine; Placebo; Incidence (geometry); Randomized controlled trial; Cancer; Gynecology; Androgen receptor; Pathology","score_opus":0.05894315479136175,"score_gpt":0.43886286633248833,"score_spread":0.3799197115411266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292759384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949812,0.0023659882,0.0000047727776,0.00013923863,0.000079778125,0.0023761957,0.00004680255,0.0000037392867,0.0000022580853],"genre_scores_gemma":[0.9969349,0.0025991043,0.00023809393,0.0000261922,0.00005656658,0.00010664436,0.000015060983,0.00002113091,0.0000022916074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963553,0.00071221055,0.0017850088,0.00032885224,0.00058699393,0.0002316408],"domain_scores_gemma":[0.996964,0.0007835086,0.0014915541,0.00015825739,0.00019119917,0.00041152447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016293105,0.00021718668,0.0015538888,0.0002870508,0.000025861455,0.00000689864,0.00006570671,0.00009140866,0.000014079754],"category_scores_gemma":[0.00071394164,0.00011655744,0.0001207507,0.0002371702,0.00055682455,0.00020389115,0.00003445823,0.00043238606,3.3442014e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4406889,0.0021669546,0.5373168,0.00010149621,0.00034742214,0.00246019,0.00039084585,0.0000045965053,0.00031870758,2.3532967e-7,4.6609395e-7,0.016203383],"study_design_scores_gemma":[0.27901623,0.037744395,0.6774547,0.0011530248,0.00029931177,0.000016109023,0.000015734448,0.00009365851,0.00408142,0.00003698568,0.0000037797092,0.00008463701],"about_ca_topic_score_codex":0.00018936282,"about_ca_topic_score_gemma":0.00003601491,"teacher_disagreement_score":0.1616727,"about_ca_system_score_codex":0.000099383564,"about_ca_system_score_gemma":0.0014464607,"threshold_uncertainty_score":0.47530743},"labels":[],"label_agreement":null},{"id":"W2292883957","doi":"10.1200/jco.2005.23.16_suppl.4644","title":"What happens to men with prostate cancer whose PSA starts to rise while on neo-adjuvant androgen ablation therapy prior to external radiation?","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Urology; Radiation therapy; Androgen suppression; External beam radiation; Cancer; Internal medicine; Gynecology","score_opus":0.09703080406941084,"score_gpt":0.4772025214035026,"score_spread":0.3801717173340918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292883957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8909093,0.0018328293,0.00007832012,0.104655385,0.0004895064,0.0014163201,0.000011360202,0.000011327117,0.0005956544],"genre_scores_gemma":[0.9593014,0.011407757,0.0045641814,0.016130136,0.002888325,0.00011581262,0.0000058820865,0.000047188496,0.0055393097],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99719137,0.00023742404,0.0011838811,0.00031044864,0.00067695644,0.00039992537],"domain_scores_gemma":[0.997129,0.0004340038,0.0005147542,0.0002230971,0.0005927985,0.0011063413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016569126,0.0001867333,0.0009184581,0.00025402426,0.000084110994,0.00006098137,0.00015651902,0.00015497477,0.0003550319],"category_scores_gemma":[0.000266132,0.00011174459,0.00016162694,0.00026271705,0.000057781654,0.00033687157,0.00004004374,0.000523222,0.0001004276],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056200743,0.0012374051,0.04583344,0.00000953035,0.0003112963,0.00034897384,0.0021997597,0.0017571963,0.0008015222,0.000008133639,0.018396638,0.87289536],"study_design_scores_gemma":[0.017278455,0.04525455,0.3195372,0.0005704509,0.0001327626,0.00007601989,0.00031532708,0.00016863042,0.003312332,0.000046514415,0.61311644,0.00019132819],"about_ca_topic_score_codex":0.000048237747,"about_ca_topic_score_gemma":0.00025249718,"teacher_disagreement_score":0.872704,"about_ca_system_score_codex":0.0006563006,"about_ca_system_score_gemma":0.001710999,"threshold_uncertainty_score":0.45568123},"labels":[],"label_agreement":null},{"id":"W2295669653","doi":"10.1016/j.eururo.2016.02.035","title":"Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Abiraterone acetate; Prednisone; Prostate cancer; Incidence (geometry); Corticosteroid; Urology; Adverse effect; Castration; Abiraterone; Prostate; Internal medicine; Oncology; Cancer; Androgen deprivation therapy; Hormone","score_opus":0.015879586920593606,"score_gpt":0.274688650856204,"score_spread":0.2588090639356104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2295669653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960549,0.000042009902,0.00007006746,0.0012845106,0.00007978123,0.0020814412,0.00025147968,0.000042346583,0.00009349212],"genre_scores_gemma":[0.9973061,0.00004336043,0.00012186479,0.00053108315,0.00002420431,0.00012866552,0.00007122262,0.00007680229,0.0016966593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975553,0.0003577264,0.00042715666,0.000559243,0.00053941883,0.0005611535],"domain_scores_gemma":[0.9984155,0.00008227554,0.00024350274,0.00043180652,0.00045807217,0.00036882615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022331227,0.00030331098,0.00046874263,0.00019485006,0.00007534954,0.000008697923,0.0001758069,0.000033139706,0.00011529384],"category_scores_gemma":[0.00010351224,0.0001692342,0.000043612356,0.00031609178,0.0001403526,0.00012531076,0.0000921507,0.00013934949,0.00014569942],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039387975,0.001340567,0.89140314,0.00016619009,0.00064821204,0.0011160655,0.0016580701,0.00036210183,0.057747506,0.0000015816948,0.00012185497,0.0060467203],"study_design_scores_gemma":[0.01327274,0.01894536,0.95955986,0.00077816093,0.00019104093,0.000007760912,0.00001870199,0.0000025048444,0.0069990647,0.0000015038476,0.000024989564,0.00019830617],"about_ca_topic_score_codex":0.0000441059,"about_ca_topic_score_gemma":0.00043856123,"teacher_disagreement_score":0.06815671,"about_ca_system_score_codex":0.00023256255,"about_ca_system_score_gemma":0.00021137114,"threshold_uncertainty_score":0.69011706},"labels":[],"label_agreement":null},{"id":"W2298098514","doi":"10.1096/fasebj.23.1_supplement.361.2","title":"Protein‐coding and MicroRNA Biomarker Gene Panels Predictive of Clinical Recurrence in Prostate Cancer","year":2009,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute; University of Toronto","funders":"","keywords":"Prostate cancer; microRNA; Prostatectomy; Biochemical recurrence; Biomarker; Medicine; Gene; Gene expression profiling; Oncology; Cancer research; Internal medicine; Gene expression; Cancer; Bioinformatics; Biology; Genetics","score_opus":0.08375477705530981,"score_gpt":0.3961283136997909,"score_spread":0.3123735366444811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2298098514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990797,0.004476321,0.000027997217,0.0037580628,0.00009187402,0.000596927,0.000023544988,0.0000058018036,0.00022248404],"genre_scores_gemma":[0.992829,0.006299869,0.000197622,0.00008952716,0.00014096631,0.000014426407,0.0000026728803,0.0000065986887,0.00041929618],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987716,0.00015330839,0.00042658564,0.00015000573,0.00024595938,0.00025256092],"domain_scores_gemma":[0.9993622,0.00006602384,0.00018066754,0.00011993957,0.00012660958,0.00014461497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010961915,0.00010014143,0.0002765515,0.000093020666,0.000082653445,0.00001960846,0.000088612505,0.000045624925,0.000034398898],"category_scores_gemma":[0.000107064785,0.000054356387,0.00006643623,0.00018596325,0.00019743034,0.00008273448,0.00002762837,0.0004826088,0.0000014131136],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052821105,0.0002982102,0.2114032,0.0000602223,0.00017929042,0.00035172197,0.0016186064,0.000004460029,0.59436667,0.000012563789,0.00024813286,0.18617478],"study_design_scores_gemma":[0.005617666,0.0013802594,0.7207395,0.001203034,0.000087151675,0.00037639507,0.000309738,0.00041289575,0.26906556,0.0005560642,0.00014698974,0.000104746025],"about_ca_topic_score_codex":0.00002857275,"about_ca_topic_score_gemma":0.0000030787983,"teacher_disagreement_score":0.5093363,"about_ca_system_score_codex":0.00006822006,"about_ca_system_score_gemma":0.00032012977,"threshold_uncertainty_score":0.22165892},"labels":[],"label_agreement":null},{"id":"W2298315650","doi":"10.1016/j.eururo.2016.03.017","title":"The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Hazard ratio; Internal medicine; Androgen deprivation therapy; Oncology; Clinical endpoint; Gastroenterology; Urology; Cancer; Surgery; Confidence interval; Randomized controlled trial; Pathology; Androgen receptor","score_opus":0.016546739678843146,"score_gpt":0.29596243410123,"score_spread":0.2794156944223869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2298315650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97979975,0.0040201955,0.00008756819,0.0125563005,0.00002157716,0.002689154,0.0005465776,0.000032272073,0.00024659192],"genre_scores_gemma":[0.9876058,0.0013823969,0.00007852274,0.000438984,0.000026736807,0.0002555525,0.00007880606,0.000052174677,0.010080991],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847305,0.000397786,0.00029299883,0.00033522327,0.00020811136,0.00029280843],"domain_scores_gemma":[0.99878305,0.00046079687,0.0001360746,0.0002951033,0.00016702151,0.00015792374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006230505,0.0001857484,0.0003054876,0.000047857036,0.0001336202,0.000015711881,0.00007920948,0.000011938839,0.000029993995],"category_scores_gemma":[0.00009162608,0.000078330246,0.000046031648,0.00007766482,0.00026641344,0.000049681756,0.000037469727,0.000072191135,0.0000039026154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047606397,0.0015469403,0.78494585,0.00034025378,0.0023160672,0.00038903437,0.001733309,0.000008126299,0.08018005,0.000029823743,0.009886056,0.0710181],"study_design_scores_gemma":[0.023982598,0.006107528,0.94598866,0.00007927236,0.00096253125,0.000010008952,0.00022683735,0.00008415475,0.002183969,0.000033309978,0.020114198,0.00022694604],"about_ca_topic_score_codex":0.000048372032,"about_ca_topic_score_gemma":0.00004969273,"teacher_disagreement_score":0.16104281,"about_ca_system_score_codex":0.00005523368,"about_ca_system_score_gemma":0.00014027547,"threshold_uncertainty_score":0.31942147},"labels":[],"label_agreement":null},{"id":"W2299315051","doi":"10.1016/j.urolonc.2016.02.016","title":"Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases","year":2016,"lang":"en","type":"review","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; McMaster University; University of Toronto","funders":"Joseph and Silvana Melara Cancer Research Fund","keywords":"SABR volatility model; Prostate cancer; Medicine; Radiation therapy; Ablative case; Oncology; Androgen deprivation therapy; Prostate; Prostatectomy; Cancer; Internal medicine","score_opus":0.0718110862801678,"score_gpt":0.40692022173480086,"score_spread":0.33510913545463306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299315051","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18230632,0.81055766,0.000013671185,0.0012338122,0.000046775767,0.0017891171,0.004020325,0.000009755944,0.000022541646],"genre_scores_gemma":[0.0016497753,0.9936987,0.0025048766,0.00008634856,0.000033049924,0.000676408,0.00089294126,0.000020726662,0.00043716238],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998131,0.0002855731,0.0005880816,0.0005063843,0.00019200877,0.00029700305],"domain_scores_gemma":[0.99787325,0.0009633089,0.00039063737,0.00023313782,0.00010097455,0.0004387218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001929533,0.00037060247,0.0015749655,0.0003320213,0.00008517043,0.0000113177275,0.000091463575,0.00014933728,0.00011941677],"category_scores_gemma":[0.00016786241,0.00022040374,0.00015957205,0.00044038543,0.0008364749,0.00008552487,0.00004117083,0.0001886033,0.0000039683837],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015993883,0.0007172416,0.061214536,0.000526364,0.0017083347,0.0002484747,0.000992153,0.000007189499,0.0000713607,0.00032652437,0.00047829788,0.93211013],"study_design_scores_gemma":[0.002678525,0.0055597597,0.0019887146,0.0030464246,0.0013926562,0.00003484051,0.00008520201,0.000026301464,0.000047644437,0.0011211195,0.983821,0.00019782734],"about_ca_topic_score_codex":0.0005842852,"about_ca_topic_score_gemma":0.000039445415,"teacher_disagreement_score":0.9833427,"about_ca_system_score_codex":0.0007819445,"about_ca_system_score_gemma":0.0022303762,"threshold_uncertainty_score":0.89878035},"labels":[],"label_agreement":null},{"id":"W2301146256","doi":"10.1016/s0140-6736(15)01235-0","title":"Defining new standards of care for men with prostate cancer","year":2016,"lang":"en","type":"letter","venue":"The Lancet","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Docetaxel; Androgen deprivation therapy; Oncology; Hormonal therapy; Randomized controlled trial; Internal medicine; Cancer; Hormone therapy; Testosterone (patch); Gynecology; Prostate-specific antigen; Breast cancer","score_opus":0.03216326400322241,"score_gpt":0.3539904900396782,"score_spread":0.3218272260364558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301146256","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040179456,0.021771887,0.00004191815,0.9564561,0.00011042874,0.0018844724,0.0056669456,0.000045272234,0.013621169],"genre_scores_gemma":[0.008517959,0.027722508,0.0027586645,0.53266454,0.056308705,0.0031846096,0.0039610304,0.000651981,0.36423],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985288,0.000029944473,0.00015425457,0.00024392185,0.00055407995,0.000489015],"domain_scores_gemma":[0.9988196,0.00011798755,0.00013268895,0.00050784106,0.00037055544,0.000051362822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001721611,0.00020449045,0.0007451646,0.000052866602,0.00007142484,0.000017557793,0.00020400982,0.00015534973,0.00012588389],"category_scores_gemma":[0.000024877258,0.00008381958,0.00008663981,0.00008232198,0.00013765458,0.000026610107,0.000038444767,0.00045199823,0.000004241728],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044629904,0.000002983217,0.0015487737,0.0016776132,0.00038411273,0.000042951306,0.001230792,7.5633807e-7,0.000041768526,0.000019021154,0.97608197,0.014506266],"study_design_scores_gemma":[0.0066528637,0.00070561573,0.00018304246,0.0021108128,0.00029087378,0.0000067027927,0.00011521358,0.0000015457891,0.0018114507,0.00014194618,0.9878527,0.00012723825],"about_ca_topic_score_codex":0.00022480874,"about_ca_topic_score_gemma":0.00005612456,"teacher_disagreement_score":0.42379156,"about_ca_system_score_codex":0.00030423974,"about_ca_system_score_gemma":0.0016979964,"threshold_uncertainty_score":0.34180632},"labels":[],"label_agreement":null},{"id":"W2301205426","doi":"10.1200/jco.2006.24.18_suppl.4614","title":"Skeletal related events (SREs) in metastatic androgen independent prostate cancer (AIPC) treated with docetaxel-based chemotherapy: Results from ASCENT","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Incidence (geometry); Chemotherapy; Zoledronic acid; Surgery; Oncology; Urology; Gastroenterology","score_opus":0.06414390364074851,"score_gpt":0.4350035956280465,"score_spread":0.370859691987298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301205426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98699,0.0016771189,0.00000955475,0.009521603,0.00024171597,0.0007381895,0.00007936002,0.000015814443,0.00072665897],"genre_scores_gemma":[0.9955405,0.0013886443,0.00086479285,0.00051277684,0.00027803492,0.000024550118,0.00010375915,0.00003760089,0.0012493305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99521244,0.00059355696,0.002602708,0.00038091722,0.00076106313,0.00044933058],"domain_scores_gemma":[0.99648726,0.000910052,0.0015683117,0.00023994356,0.00043586234,0.0003585578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021556925,0.00025174028,0.0015864689,0.00026346566,0.0000413743,0.00001312288,0.00016802369,0.00029594908,0.00020308107],"category_scores_gemma":[0.00036837286,0.00014864533,0.00034232947,0.00040134494,0.00022044698,0.00011637908,0.000025566651,0.0011860102,0.000013605714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.082417235,0.006726952,0.8341302,0.000045664634,0.001662194,0.006485734,0.00017534079,0.0005947275,0.00035878125,0.0000072992284,0.0015140714,0.06588178],"study_design_scores_gemma":[0.13276371,0.011730059,0.84287465,0.0005538108,0.0006784328,0.000109775414,0.000080048434,0.0006275251,0.001836098,0.00043846772,0.008099233,0.0002082269],"about_ca_topic_score_codex":0.0017768446,"about_ca_topic_score_gemma":0.0010271566,"teacher_disagreement_score":0.06567355,"about_ca_system_score_codex":0.0006696787,"about_ca_system_score_gemma":0.0030658692,"threshold_uncertainty_score":0.6061581},"labels":[],"label_agreement":null},{"id":"W2304746423","doi":"10.3389/fonc.2016.00024","title":"Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer","year":2016,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Prostate cancer; Medicine; Biomarker; Radiation therapy; Disease; Targeted therapy; Precision medicine; Clinical trial; Cancer research; Cancer; Bioinformatics; Oncology; Computational biology; Internal medicine; Biology; Pathology","score_opus":0.031158920044011267,"score_gpt":0.3943940181091474,"score_spread":0.36323509806513615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304746423","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020676952,0.9907233,0.0019266134,0.0006473923,0.0010125252,0.005252517,0.00006538284,0.000035174653,0.00013034079],"genre_scores_gemma":[0.000113986374,0.99067163,0.0040769633,0.00015298456,0.00012897853,0.003744168,0.00027501557,0.000083800434,0.0007524839],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99756235,0.00038379614,0.00060932414,0.00069733703,0.00020308177,0.00054412306],"domain_scores_gemma":[0.9986542,0.0002263857,0.00047683247,0.00027619844,0.00016353538,0.00020285868],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003525793,0.00044486288,0.0024568567,0.00037141348,0.00010481838,0.000016659647,0.00017107508,0.0005609501,0.000028137232],"category_scores_gemma":[0.00019456998,0.0002700022,0.00023766253,0.0002470234,0.00030772312,0.000044110857,0.00008839495,0.00038766803,0.0000026750176],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018931001,0.00018469416,0.0001015286,0.008204171,0.0005745562,0.0003945056,0.00032160332,2.8374797e-7,0.000026759957,0.00017277537,0.0044992203,0.9836268],"study_design_scores_gemma":[0.009453602,0.0014571403,0.0000034835853,0.00671518,0.0003797183,0.0000105474355,0.000041407533,0.00009606395,0.00007791339,0.009918369,0.9715399,0.00030666546],"about_ca_topic_score_codex":0.00006339873,"about_ca_topic_score_gemma":0.000010703814,"teacher_disagreement_score":0.9833201,"about_ca_system_score_codex":0.0014509669,"about_ca_system_score_gemma":0.0016955663,"threshold_uncertainty_score":0.9999752},"labels":[],"label_agreement":null},{"id":"W2307758074","doi":"10.6004/jnccn.2014.0187","title":"New Developments in the Treatment of Castration-Resistant Prostate Cancer","year":2014,"lang":"en","type":"review","venue":"Journal of the National Comprehensive Cancer Network","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Achieve Life Sciences (Canada)","funders":"","keywords":"Medicine; Prostate cancer; Clinical trial; Intensive care medicine; Hormonal therapy; Immunotherapy; Oncology; Cancer; Internal medicine","score_opus":0.13388232305812728,"score_gpt":0.4345753972711803,"score_spread":0.300693074213053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2307758074","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002767657,0.99601287,0.0000023457023,0.0011456804,0.00085069885,0.0013822761,0.00006702415,0.0000025019904,0.00025986438],"genre_scores_gemma":[0.0005047185,0.99539185,0.00023938544,0.00027488434,0.0019951977,0.0001393913,0.000024982324,0.000029811543,0.0013997654],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968481,0.0003286454,0.0010815976,0.00019988994,0.0012423092,0.00029943982],"domain_scores_gemma":[0.9966785,0.00050428236,0.0013338487,0.00017625514,0.0012012771,0.00010584964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026302325,0.0003389695,0.0014172607,0.00019114636,0.000115993185,0.00003027708,0.00037283325,0.00013197321,0.00006270195],"category_scores_gemma":[0.000034408542,0.00015064332,0.00062395365,0.0007689729,0.00008996111,0.000054368753,0.000032326338,0.0004334988,0.0000025645124],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001462205,0.00044138974,0.0014009787,0.0048966086,0.0037129396,0.00007264133,0.0012687623,0.0030624452,0.00001671222,0.00019250372,0.060894947,0.92257786],"study_design_scores_gemma":[0.002019208,0.00041847792,0.0033605883,0.013725866,0.00084376737,0.000079157006,0.00003150013,0.00000615581,0.000008682084,0.00015681704,0.9792212,0.00012858439],"about_ca_topic_score_codex":0.00012261671,"about_ca_topic_score_gemma":0.00012199474,"teacher_disagreement_score":0.9224493,"about_ca_system_score_codex":0.0018394208,"about_ca_system_score_gemma":0.005823686,"threshold_uncertainty_score":0.99981236},"labels":[],"label_agreement":null},{"id":"W2311347322","doi":"10.1200/jco.2015.33.15_suppl.5003","title":"Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Prostate cancer; Medicine; Metastasis; Histology; Prostate; Cancer; PTEN; Biopsy; Adenocarcinoma; Pathology; Oncology; Cancer research; Internal medicine; Androgen receptor; Biology; PI3K/AKT/mTOR pathway","score_opus":0.09730843137049108,"score_gpt":0.4203768187639266,"score_spread":0.32306838739343546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2311347322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97284275,0.00088852283,0.000005785499,0.019602796,0.00088905985,0.0033929609,0.0022950901,0.00002088283,0.0000621776],"genre_scores_gemma":[0.9898043,0.0056956173,0.00053826615,0.0010425125,0.00056116143,0.00041270407,0.000340015,0.00009071494,0.0015146995],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99185616,0.0011795843,0.004003243,0.00071684225,0.0014348526,0.0008093298],"domain_scores_gemma":[0.99200493,0.0010782909,0.003255028,0.0005301299,0.0023408623,0.0007907345],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002410527,0.0004941561,0.0020618755,0.00026637912,0.000120522265,0.000061267085,0.0003758946,0.00015592047,0.00006713665],"category_scores_gemma":[0.0018321101,0.00026790297,0.00019232748,0.0008491337,0.00046059652,0.00051404635,0.00016390848,0.0012182037,0.0000059384683],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6072332,0.0031668001,0.33680335,0.00024114284,0.0008555103,0.0016552979,0.004032588,0.0011164509,0.009654006,0.000004285999,0.00334403,0.03189335],"study_design_scores_gemma":[0.048030358,0.047268655,0.885244,0.0019504676,0.00083374704,0.00003628312,0.00093064934,0.00011698436,0.003222635,0.000037715407,0.011996501,0.00033201592],"about_ca_topic_score_codex":0.005516983,"about_ca_topic_score_gemma":0.01787622,"teacher_disagreement_score":0.55920285,"about_ca_system_score_codex":0.0012092981,"about_ca_system_score_gemma":0.008923767,"threshold_uncertainty_score":0.9999773},"labels":[],"label_agreement":null},{"id":"W2311612417","doi":"10.1200/jco.2015.33.7_suppl.169","title":"Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Internal medicine; Incidence (geometry); Adverse effect; Gastroenterology; Prednisone; MedDRA; Urology; Cancer; Androgen deprivation therapy","score_opus":0.10421399605321649,"score_gpt":0.45806930629196396,"score_spread":0.3538553102387475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2311612417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944863,0.00015559737,0.000093648596,0.0026850344,0.00041054434,0.0019261264,0.00010453138,0.000012052604,0.00012619491],"genre_scores_gemma":[0.9949469,0.00015392392,0.003310038,0.00044755772,0.00011668965,0.00010340976,0.00004705267,0.000047736776,0.0008267184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99484146,0.0005927663,0.0022330524,0.00039500653,0.0013986763,0.0005390368],"domain_scores_gemma":[0.9933681,0.00033926588,0.002026852,0.00031156515,0.0026514928,0.0013027346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016835766,0.0003143245,0.0018094315,0.00024093511,0.00005799936,0.000014875874,0.00022671501,0.000158814,0.000070488386],"category_scores_gemma":[0.0005939449,0.00018748308,0.00019125376,0.00042919003,0.00018081465,0.00025844004,0.00009238407,0.00062376994,0.000013086333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05368268,0.0070387363,0.9191589,0.00018139166,0.0023886717,0.0014632116,0.0010452123,0.00091608247,0.0016942675,0.0000015944024,0.00058455754,0.011844735],"study_design_scores_gemma":[0.041862436,0.09210963,0.86294967,0.0009640297,0.0009388549,0.000037974343,0.00030376037,0.00003047364,0.0004345604,0.0000079776855,0.00018154568,0.00017906833],"about_ca_topic_score_codex":0.000070228285,"about_ca_topic_score_gemma":0.0011563926,"teacher_disagreement_score":0.08507089,"about_ca_system_score_codex":0.0011214083,"about_ca_system_score_gemma":0.0050861295,"threshold_uncertainty_score":0.9022575},"labels":[],"label_agreement":null},{"id":"W2312250478","doi":"10.1158/1538-7445.am2013-5456","title":"Abstract 5456: The E3 ubiquitin ligase Siah2 regulates the androgen receptor activity and contributes to castration-resistant prostate cancer.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Ubiquitin ligase; Prostate cancer; Androgen receptor; Cancer research; Biology; Carcinogenesis; Cancer; Ubiquitin; Gene; Genetics","score_opus":0.0575119219321257,"score_gpt":0.3926918297648122,"score_spread":0.33517990783268653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312250478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8944379,0.010265967,7.077736e-7,0.09058651,0.00009431893,0.0038956269,0.00018026035,0.00003693877,0.00050177524],"genre_scores_gemma":[0.9836783,0.0045579476,0.000015203148,0.00036062705,0.00032593534,0.00403068,0.000022297201,0.000040355393,0.006968658],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99715215,0.00023024181,0.000266309,0.0005254915,0.00087139173,0.0009544337],"domain_scores_gemma":[0.99743354,0.0006163981,0.00006733967,0.0005678435,0.00092352054,0.00039138194],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013069016,0.00023296164,0.00031738015,0.00015174155,0.0009025069,0.0003789075,0.0003012859,0.0001041887,0.0010555225],"category_scores_gemma":[0.0002565382,0.0001182826,0.00007278252,0.0007453895,0.00076261774,0.00020491058,0.00020456711,0.0007455766,0.00010973102],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023010918,0.00012919932,0.00694096,0.00024480536,0.00031628623,0.000032857726,0.0014708505,0.000015453174,0.86474913,0.0001359475,0.065002024,0.058661386],"study_design_scores_gemma":[0.0024440296,0.0005229978,0.21435812,0.0005410817,0.000058229016,0.000008682339,0.001584215,0.00006851918,0.74564236,0.0004965221,0.03404993,0.0002252896],"about_ca_topic_score_codex":0.012588443,"about_ca_topic_score_gemma":0.0021338216,"teacher_disagreement_score":0.20741716,"about_ca_system_score_codex":0.00059025746,"about_ca_system_score_gemma":0.0011642838,"threshold_uncertainty_score":0.99985766},"labels":[],"label_agreement":null},{"id":"W2315623477","doi":"10.1016/j.urology.2015.12.002","title":"Moving Beyond the Androgen Receptor in Advanced Prostate Cancer Commentary on: DNA-repair Defects and Olaparib in Metastatic Prostate Cancer","year":2015,"lang":"en","type":"letter","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Olaparib; Medicine; Prostate cancer; PARP inhibitor; Oncology; Internal medicine; Cancer; Poly ADP ribose polymerase; Prostate; Androgen receptor; Cancer research; Polymerase; DNA","score_opus":0.02250894578160814,"score_gpt":0.31478200617017005,"score_spread":0.29227306038856193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315623477","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39202058,0.025308829,1.5829312e-7,0.5785457,0.00046586664,0.0029611425,0.00040852875,0.000053181044,0.00023599606],"genre_scores_gemma":[0.050012924,0.015186507,0.00009629021,0.9217371,0.0011386736,0.005433588,0.0014933738,0.0002151712,0.004686403],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99651057,0.0005158375,0.00052085513,0.00088064943,0.00049200834,0.0010800887],"domain_scores_gemma":[0.99861497,0.00038778345,0.0002071027,0.00049931445,0.00012776189,0.00016309139],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00056317006,0.0005481318,0.0009939902,0.00045292452,0.00010257339,0.000028792065,0.0002079888,0.0003716832,0.00017369821],"category_scores_gemma":[0.00007436819,0.000360516,0.000111531794,0.00041858765,0.00041467117,0.00011238674,0.00019043325,0.0023487478,0.000018452212],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039952276,0.00018525633,0.08886614,0.0007021477,0.0005047312,0.00257799,0.0030777191,0.00023126566,0.0002741226,0.0000036173346,0.8914846,0.00809719],"study_design_scores_gemma":[0.01279234,0.0021834096,0.0025009776,0.00044667002,0.00040745465,0.000061080464,0.0002523052,0.00028897554,0.0004851484,0.00043012094,0.97960794,0.0005435635],"about_ca_topic_score_codex":0.0017258703,"about_ca_topic_score_gemma":0.0031463366,"teacher_disagreement_score":0.34319136,"about_ca_system_score_codex":0.00082449935,"about_ca_system_score_gemma":0.00072549,"threshold_uncertainty_score":0.99995285},"labels":[],"label_agreement":null},{"id":"W2315877032","doi":"10.1097/01.cot.0000455785.33540.15","title":"Joint Clinical Practice Guideline from ASCO &amp; Cancer Care Ontario on Systemic Therapy for Metastatic Castration-Resistant Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Oncology Times","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Guideline; Medicine; Prostate cancer; Androgen deprivation therapy; Cancer; Systemic therapy; Family medicine; Oncology; Internal medicine; Intensive care medicine; Gynecology; Breast cancer; Pathology","score_opus":0.10939629814232488,"score_gpt":0.46940437975086824,"score_spread":0.36000808160854336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315877032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8771426,0.034825575,0.0005103121,0.054519173,0.0028410763,0.008614708,0.0010981504,0.00019587144,0.020252554],"genre_scores_gemma":[0.7769918,0.014785577,0.061798315,0.018606633,0.0036732182,0.00798173,0.0035387431,0.00025248877,0.11237154],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99744874,0.00036001444,0.00082826806,0.0005762235,0.00036045164,0.00042631643],"domain_scores_gemma":[0.99713075,0.0010034051,0.00037215347,0.00040557148,0.0008694993,0.00021864045],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008656465,0.00026656955,0.0007882334,0.000088166154,0.0001692493,0.00003320378,0.000110046334,0.00017584067,0.0010297952],"category_scores_gemma":[0.00040900064,0.00018141179,0.00019470991,0.00009633755,0.00014576106,0.00009881427,0.00002793219,0.00040428803,0.00007567975],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050999764,0.0028861018,0.03481689,0.00056056323,0.0057368493,0.0002846089,0.016133089,0.0005416871,0.017409422,0.00037489453,0.4649145,0.40534163],"study_design_scores_gemma":[0.012682675,0.0047042402,0.0061275964,0.00035654005,0.00071363634,0.000020340212,0.0009577068,0.00011981903,0.0014386246,0.00013141918,0.97251743,0.00022997714],"about_ca_topic_score_codex":0.035048798,"about_ca_topic_score_gemma":0.06783064,"teacher_disagreement_score":0.50760293,"about_ca_system_score_codex":0.0015627021,"about_ca_system_score_gemma":0.0036925417,"threshold_uncertainty_score":0.9998834},"labels":[],"label_agreement":null},{"id":"W2315933221","doi":"10.1158/1538-7445.am10-1714","title":"Abstract 1714: Transcriptional networks downstream of the AR identify clinically relevant prostate cancer targets","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"","keywords":"Prostate cancer; Cancer research; Kinase; Biology; Chromatin immunoprecipitation; Androgen receptor; Gene; Androgen; Cancer; Gene expression; Computational biology; Cell biology; Genetics; Endocrinology; Promoter; Hormone","score_opus":0.06759293460744974,"score_gpt":0.4438031511632234,"score_spread":0.37621021655577364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315933221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97754514,0.005628145,0.000005587265,0.01096016,0.0012093015,0.0016987356,0.0002205603,0.000037958667,0.0026944214],"genre_scores_gemma":[0.9806705,0.010668689,0.000060667866,0.00015071286,0.00083291804,0.0006762913,0.00004065141,0.000052090076,0.0068474836],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9960433,0.00015215037,0.00062462443,0.0005665451,0.0016581068,0.0009552506],"domain_scores_gemma":[0.99725467,0.00029814086,0.00013824468,0.00074641634,0.0011802193,0.00038233332],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018874597,0.00022201256,0.00041079745,0.00018395728,0.00034663704,0.000060623828,0.00051852386,0.00026400606,0.0026534568],"category_scores_gemma":[0.00024931997,0.0001343051,0.00028121262,0.0007398422,0.0012722417,0.00013512782,0.0001496306,0.002687865,0.00003750233],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041245134,0.0007176611,0.20396686,0.0006102866,0.00047636314,0.000095492185,0.0007719404,0.00016375541,0.7273595,0.00042534864,0.0150947645,0.046193562],"study_design_scores_gemma":[0.00485883,0.00042026612,0.9009545,0.0008370595,0.00010194816,0.00001689375,0.00015419193,0.00022676907,0.04935465,0.00088812,0.041915867,0.00027091923],"about_ca_topic_score_codex":0.0013806054,"about_ca_topic_score_gemma":0.0009845558,"teacher_disagreement_score":0.6969876,"about_ca_system_score_codex":0.0002635717,"about_ca_system_score_gemma":0.0021915573,"threshold_uncertainty_score":0.999613},"labels":[],"label_agreement":null},{"id":"W2316150040","doi":"10.1021/jm201059s","title":"Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists","year":2011,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Androgen receptor; Antagonism; Chemistry; Prostate cancer; In vivo; Androgen Receptor Antagonists; Androgen; Pharmacology; Oral administration; Prostate; Receptor; Cancer research; Cancer; Internal medicine; Biochemistry; Hormone; Medicine; Biology","score_opus":0.035570265791768856,"score_gpt":0.3098949848165518,"score_spread":0.27432471902478295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2316150040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98687524,0.0038036956,0.000054622276,0.0006604251,0.00019013784,0.00009764831,0.000018875624,0.0000067702395,0.008292604],"genre_scores_gemma":[0.99468786,0.0014034468,0.0011904053,0.000072174684,0.00052373717,0.0000020089878,0.000011134778,0.000018562385,0.0020906609],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983513,0.000013444049,0.0005356189,0.0001393801,0.00072561554,0.0002346367],"domain_scores_gemma":[0.9987805,0.000073028874,0.00038413343,0.00019436309,0.00031405178,0.00025394792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000382428,0.0001548828,0.0005004287,0.000073296505,0.000031830918,0.000007633553,0.00017631547,0.00012313396,0.00049249345],"category_scores_gemma":[0.00026593756,0.00010107227,0.00020113206,0.00016975799,0.00028495982,0.00013441972,0.000032840737,0.00043914074,0.0000047320323],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031334015,0.0006627716,0.018070903,0.000569733,0.00040189765,0.00064373243,0.0006399447,1.4333824e-7,0.97263384,0.000009582927,0.001248036,0.001986013],"study_design_scores_gemma":[0.0036151167,0.0010625186,0.0032486713,0.0007417313,0.00024121335,0.0030662937,0.0013076455,0.000002093424,0.9847959,0.00011156001,0.0017108369,0.00009637942],"about_ca_topic_score_codex":0.000033529643,"about_ca_topic_score_gemma":2.7071468e-7,"teacher_disagreement_score":0.014822231,"about_ca_system_score_codex":0.00012440444,"about_ca_system_score_gemma":0.0006035643,"threshold_uncertainty_score":0.5392458},"labels":[],"label_agreement":null},{"id":"W2316226082","doi":"10.1158/1538-7445.am2015-ct302","title":"Abstract CT302: Pharmacokinetics (PK) and safety of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; BC Cancer Agency","funders":"","keywords":"Prostate cancer; Abiraterone acetate; Medicine; Enzalutamide; Docetaxel; Internal medicine; Androgen receptor; Pharmacokinetics; Prednisone; Pharmacology; Gastroenterology; Urology; Cancer; Androgen deprivation therapy","score_opus":0.08136193661629539,"score_gpt":0.39515731123476694,"score_spread":0.31379537461847157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2316226082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902128,0.005546233,0.0000031947316,0.0012245191,0.000033075496,0.0022509813,0.00027648365,0.000016772177,0.0004359167],"genre_scores_gemma":[0.99249643,0.0055102576,0.0002903036,0.000031057236,0.00004100518,0.0004940143,0.00006349253,0.000054516357,0.0010189153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969541,0.00014236197,0.0004018462,0.0005413777,0.0012494987,0.0007108229],"domain_scores_gemma":[0.9979975,0.000096703254,0.00012644804,0.00027701614,0.0010098325,0.00049249065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007883616,0.0002674321,0.0005116901,0.0003367021,0.00010944536,0.000064339096,0.000111086534,0.00005785395,0.000080051934],"category_scores_gemma":[0.000039008184,0.0001742761,0.000019872437,0.00067725824,0.0007580011,0.00024410198,0.000088749606,0.00052103493,0.000002810049],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12083193,0.0017887517,0.74222726,0.0044541564,0.001358087,0.0006990492,0.01114642,0.0010169145,0.061317705,0.000055156594,0.0013706619,0.05373393],"study_design_scores_gemma":[0.06437061,0.007288677,0.8556485,0.0024852115,0.0002849104,0.00002175242,0.0021688684,0.00026545057,0.0649541,0.000084964464,0.0018975827,0.00052934955],"about_ca_topic_score_codex":0.0027655736,"about_ca_topic_score_gemma":0.0018670033,"teacher_disagreement_score":0.11342128,"about_ca_system_score_codex":0.00051644567,"about_ca_system_score_gemma":0.0013552312,"threshold_uncertainty_score":0.7106773},"labels":[],"label_agreement":null},{"id":"W2316513783","doi":"10.1097/01.cot.0000288345.76177.b2","title":"Prostate Cancer","year":2007,"lang":"en","type":"article","venue":"Oncology Times","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Androgen deprivation therapy; Medicine; Prostate cancer; Clinical trial; Oncology; Cancer; Internal medicine; Intensive care medicine","score_opus":0.02900008868479506,"score_gpt":0.40246684778044234,"score_spread":0.3734667590956473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2316513783","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4863284,0.005767625,0.000019826,0.01485561,0.00034070725,0.0005990015,0.000009538654,0.00010796548,0.49197134],"genre_scores_gemma":[0.6694054,0.0012772338,0.0008311229,0.0011287912,0.000325487,0.00006805954,0.000027337113,0.000019716004,0.32691687],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993046,0.000013779009,0.00010977052,0.00014519096,0.0001172863,0.0003093955],"domain_scores_gemma":[0.9996042,0.000058664686,0.000027144566,0.00010695723,0.0000724853,0.00013054356],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002356934,0.00007105604,0.00016353093,0.000076757824,0.000053990752,0.000003901169,0.000037389684,0.00008403135,0.0015544388],"category_scores_gemma":[0.000017332395,0.00004906178,0.000038634775,0.0001250252,0.0001210693,0.000029604424,0.000024236155,0.00013974274,0.00022995844],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003029725,0.0005827065,0.27218083,0.00008256627,0.00031929856,0.0016443281,0.0013109464,0.0000015706977,0.01815556,0.00058635004,0.16195527,0.5401509],"study_design_scores_gemma":[0.003398851,0.0010720424,0.08533457,0.000038782466,0.000074430376,0.00007334566,0.00022795786,0.0000142791305,0.026391702,0.00022288709,0.88305616,0.0000950165],"about_ca_topic_score_codex":0.00006941508,"about_ca_topic_score_gemma":0.00005285579,"teacher_disagreement_score":0.72110087,"about_ca_system_score_codex":0.00026784962,"about_ca_system_score_gemma":0.00036155427,"threshold_uncertainty_score":0.9993583},"labels":[],"label_agreement":null},{"id":"W2316794472","doi":"10.1016/j.juro.2013.02.574","title":"992 A PARACRINE HEDGEHOG SIGNALING MICROENVIRONMENT IN ADT-TREATED PROSTATE TUMORS INDUCES STEROIDOGENESIS FROM BENIGN PROSTATE STROMAL CELLS","year":2013,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Paracrine signalling; Stromal cell; Prostate cancer; Medicine; Hedgehog; Cancer research; Hedgehog signaling pathway; Androgen; Androgen receptor; Androgen deprivation therapy; Tumor microenvironment; Internal medicine; Endocrinology; Prostate; Sonic hedgehog; Cancer; Biology; Signal transduction; Cell biology; Hormone; Receptor","score_opus":0.01772885349299453,"score_gpt":0.2542773712023228,"score_spread":0.23654851770932828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2316794472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99156284,0.003316383,0.000009808453,0.0041096355,0.000090451926,0.0008342457,0.000022322884,0.000009745861,0.000044551227],"genre_scores_gemma":[0.9975706,0.0013137921,0.00020556865,0.00032601095,0.00013443244,0.00003069607,0.000017246071,0.000033246917,0.0003684338],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99783677,0.00039479623,0.0006814163,0.0002088186,0.00034321522,0.0005349588],"domain_scores_gemma":[0.9988595,0.00020915616,0.00036659927,0.0002484718,0.000113429014,0.00020283571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005065636,0.00023734405,0.00053882116,0.00022472812,0.00007795953,0.000026365724,0.00023327097,0.00008916271,0.0004311433],"category_scores_gemma":[0.000020284417,0.00013703962,0.00010231289,0.00017627284,0.00021834458,0.00014460953,0.000093408235,0.0005338053,0.00007202414],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037400639,0.00040091007,0.064429276,0.000027841854,0.00029827666,0.000675505,0.0023322934,0.0005001628,0.9239369,6.877473e-7,0.00024862692,0.0034094425],"study_design_scores_gemma":[0.011503278,0.0072639114,0.38743225,0.0002081929,0.0005358561,0.00067787664,0.0018925365,0.00030078486,0.58898985,0.00040728247,0.00047752526,0.00031066284],"about_ca_topic_score_codex":0.00048565635,"about_ca_topic_score_gemma":0.00001866745,"teacher_disagreement_score":0.33494708,"about_ca_system_score_codex":0.00015580603,"about_ca_system_score_gemma":0.00013602315,"threshold_uncertainty_score":0.5588314},"labels":[],"label_agreement":null},{"id":"W2317493171","doi":"10.1097/01.cot.0000428624.15680.02","title":"Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"Oncology Times","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Randomized controlled trial; Genitourinary system; Radiation therapy; Cancer; Clinical trial; Test (biology); Radiation oncology; Family medicine; Gynecology; Internal medicine","score_opus":0.025384303641068622,"score_gpt":0.370821238426083,"score_spread":0.34543693478501436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317493171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5972021,0.0044129454,0.0000019717595,0.049585138,0.00023816497,0.001109272,0.000008223024,0.00010594863,0.34733623],"genre_scores_gemma":[0.531442,0.0014813425,0.0005617288,0.0013153885,0.00019348679,0.0007195172,0.000025844365,0.000018313393,0.4642424],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99940145,0.000022600003,0.00008955927,0.00014322122,0.000096417585,0.00024677653],"domain_scores_gemma":[0.9996096,0.000033692515,0.000023811679,0.0001158529,0.0000976539,0.00011938553],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00005182782,0.0000721544,0.0001683412,0.00005105626,0.000048640195,0.000009064728,0.000040435614,0.00007178342,0.009863092],"category_scores_gemma":[0.000013217249,0.000047012676,0.000036144083,0.00008773952,0.000113780865,0.000059364833,0.000028644743,0.00012119912,0.0016270211],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027962064,0.00032695598,0.12001352,0.00005930912,0.00022060244,0.00014436893,0.000642635,0.0000014593336,0.012643616,0.00018362817,0.5849273,0.28055698],"study_design_scores_gemma":[0.004523059,0.0015184272,0.124410994,0.00006166558,0.00009650069,0.00006208474,0.00028445243,0.00015458697,0.012161047,0.0009479925,0.85562325,0.00015597594],"about_ca_topic_score_codex":0.0002984404,"about_ca_topic_score_gemma":0.000012070793,"teacher_disagreement_score":0.280401,"about_ca_system_score_codex":0.0001768382,"about_ca_system_score_gemma":0.00034446904,"threshold_uncertainty_score":0.99915034},"labels":[],"label_agreement":null},{"id":"W2318183721","doi":"10.1158/1538-7445.am10-lb-21","title":"Abstract LB-21: Emergence of castration resistant prostate cancer class defined by recurrent <i>ERG</i> fusion","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Prostate cancer; Erg; Cancer research; Fusion gene; Cancer; Transcriptome; Chromatin immunoprecipitation; Medicine; Gene; Gene expression; TMPRSS2; Biology; Internal medicine; Promoter; Genetics","score_opus":0.0689584488285101,"score_gpt":0.42352315334370466,"score_spread":0.35456470451519456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318183721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97924083,0.008133908,0.00000210898,0.0065290923,0.0006441222,0.0014494606,0.00045863524,0.000044028628,0.0034978276],"genre_scores_gemma":[0.9773152,0.015751954,0.00009203679,0.00004515129,0.00030597506,0.0008155709,0.00016770486,0.000051172163,0.0054552197],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962342,0.000106777814,0.0005120612,0.0006276522,0.0016132718,0.0009060853],"domain_scores_gemma":[0.99745584,0.00014026705,0.0001439353,0.0005832303,0.0012444403,0.0004322939],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011006183,0.00024086327,0.0003843191,0.00028639642,0.00028652928,0.00004790624,0.00027990885,0.00019048054,0.0026801152],"category_scores_gemma":[0.00018157283,0.00018601723,0.00011404049,0.00092645333,0.00051322905,0.00017274125,0.00012495165,0.0013280604,0.0000405483],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030877977,0.0003577287,0.0059250738,0.0005269444,0.00007357098,0.000040531493,0.00039508138,0.000004188297,0.8919179,0.00010395501,0.069218986,0.028348275],"study_design_scores_gemma":[0.004211003,0.0012994376,0.031083483,0.0009025857,0.00006654519,0.000007670436,0.00057801255,0.0000957633,0.87020355,0.00028943457,0.09089829,0.00036422553],"about_ca_topic_score_codex":0.0040787766,"about_ca_topic_score_gemma":0.0030979782,"teacher_disagreement_score":0.02798405,"about_ca_system_score_codex":0.00030965812,"about_ca_system_score_gemma":0.0020175595,"threshold_uncertainty_score":0.9982316},"labels":[],"label_agreement":null},{"id":"W2318371367","doi":"10.1016/j.juro.2013.02.2690","title":"1336 PCK3145 SUPPRESSES THE INVASIVE CAPABILITIES OF HUMAN PROSTATE CANCER CELLS INDUCED BY TRANSFORMING GROWTH FACTOR BETA","year":2013,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Zhàng; China; Beijing; Prostate cancer; Medicine; Library science; Environmental ethics; Classics; Art history; Cancer; History; Philosophy; Internal medicine; Computer science","score_opus":0.0286154971443579,"score_gpt":0.30025384100211105,"score_spread":0.27163834385775315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318371367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97919846,0.0035683992,0.000002805594,0.0162729,0.00012519179,0.0005832833,0.00003595599,0.0000045533798,0.00020847822],"genre_scores_gemma":[0.99653506,0.00262738,0.000004125906,0.00033940424,0.00011178088,0.000024554729,0.0000028568356,0.000016496888,0.00033836535],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872524,0.00022481661,0.00039548991,0.000083759114,0.00027762694,0.00029309758],"domain_scores_gemma":[0.99857026,0.0004959019,0.0002542244,0.00017022241,0.00042087337,0.00008853944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003219187,0.00013221244,0.00036011412,0.000081138736,0.00012284948,0.000011651006,0.0002642736,0.00007368022,0.00047856887],"category_scores_gemma":[0.00004616381,0.000057276506,0.000100902726,0.00009856741,0.0004068295,0.00016624587,0.000032392243,0.0004530295,0.000003773323],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046798523,0.00009574021,0.0048300936,0.000123262,0.00034322008,0.0000059426807,0.010928595,0.0000035968594,0.97985446,0.000025929476,0.0025423118,0.00077885477],"study_design_scores_gemma":[0.0022203587,0.0027340814,0.010785778,0.000059625814,0.00030267742,0.000044847504,0.002357125,0.0000030661847,0.9798448,0.0010304324,0.00053613,0.00008106268],"about_ca_topic_score_codex":0.0010464526,"about_ca_topic_score_gemma":0.000098047734,"teacher_disagreement_score":0.017336603,"about_ca_system_score_codex":0.0000549426,"about_ca_system_score_gemma":0.00027436673,"threshold_uncertainty_score":0.52399933},"labels":[],"label_agreement":null},{"id":"W2318725153","doi":"10.1097/cej.0000000000000079","title":"The variant allele of the rs188140481 polymorphism confers a moderate increase in the risk of prostate cancer in Polish men","year":2014,"lang":"en","type":"article","venue":"European Journal of Cancer Prevention","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Prostate cancer; Odds ratio; Single-nucleotide polymorphism; Allele; Medicine; SNP; Oncology; Internal medicine; Prostate; Confidence interval; Cancer; Gynecology; Genotype; Genetics; Biology; Gene","score_opus":0.015299863229466956,"score_gpt":0.29882283215983574,"score_spread":0.28352296893036877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318725153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836433,0.005636647,0.00006535329,0.005930355,0.00015336453,0.0006737434,0.000029508943,0.0000026430419,0.003865114],"genre_scores_gemma":[0.9911645,0.0075937095,0.000023752953,0.00009020935,0.00014884699,0.000018784338,0.0000019960391,0.000018853012,0.00093931553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964973,0.0020384684,0.00064084673,0.00011647361,0.0004819455,0.00022498668],"domain_scores_gemma":[0.9986149,0.0001111544,0.0007276478,0.0002609685,0.00022382401,0.000061481835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037982836,0.000117971926,0.00027844548,0.00010701357,0.00008624104,0.000024679706,0.00031449477,0.000021182088,0.000044301047],"category_scores_gemma":[0.00014924558,0.00005268713,0.00016199288,0.00027986127,0.00016615455,0.00010363447,0.000055525674,0.0004143674,7.3480425e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024703087,0.0018707017,0.545531,0.000680541,0.0022936282,0.00040645152,0.031816788,0.008051191,0.021019632,0.001677611,0.010585301,0.35136408],"study_design_scores_gemma":[0.01249477,0.0010663738,0.9683006,0.0018581311,0.00043220152,0.000057927085,0.0010935024,0.001939481,0.0055544064,0.0014400965,0.005616705,0.00014583691],"about_ca_topic_score_codex":0.0015518415,"about_ca_topic_score_gemma":0.00071610435,"teacher_disagreement_score":0.42276958,"about_ca_system_score_codex":0.00013957614,"about_ca_system_score_gemma":0.00046921638,"threshold_uncertainty_score":0.23459305},"labels":[],"label_agreement":null},{"id":"W2323213552","doi":"10.1158/1538-7445.am2012-4542","title":"Abstract 4542: Early detection of clinically significant prostate cancer at diagnosis: A prospective study using a novel panel of TMPRSS2:ETS fusion gene markers","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"TMPRSS2; Prostate cancer; Biopsy; Medicine; Prostate biopsy; Cancer; Fusion gene; PCA3; Prospective cohort study; Internal medicine; Oncology; Pathology; Biology; Gene; Disease; Genetics","score_opus":0.19294162332719006,"score_gpt":0.4576746504209172,"score_spread":0.26473302709372715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323213552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990089,0.0041118674,0.000011078278,0.00014650924,0.00023664701,0.004998222,0.00021789953,0.000030217423,0.00015854416],"genre_scores_gemma":[0.99291855,0.0036199696,0.00012518691,0.000011797336,0.00032146464,0.0023770952,0.000010233319,0.00007456623,0.00054113363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953593,0.00023464319,0.00089006894,0.0006339459,0.0017866924,0.0010953395],"domain_scores_gemma":[0.9967614,0.00038391136,0.00035060622,0.0005564916,0.0014693436,0.00047829002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026930296,0.0002827733,0.00068466517,0.00048707612,0.0002867061,0.000025297879,0.00023040388,0.00017937178,0.0004098547],"category_scores_gemma":[0.00031325495,0.00021743323,0.00018228289,0.0011041297,0.00059894274,0.0002381896,0.00031284493,0.0007581558,0.000011122323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007335588,0.0017281111,0.5026095,0.00032790747,0.00035048282,0.000016538554,0.0030830286,0.000014029582,0.4773597,8.369681e-7,0.00002895572,0.007145288],"study_design_scores_gemma":[0.0045227516,0.0020730305,0.6502944,0.00053395465,0.00014542189,0.000004092812,0.0013291073,0.000035633606,0.34081498,0.000008672799,0.00008095281,0.00015696851],"about_ca_topic_score_codex":0.010515728,"about_ca_topic_score_gemma":0.00029527076,"teacher_disagreement_score":0.14768492,"about_ca_system_score_codex":0.0018600493,"about_ca_system_score_gemma":0.0011111042,"threshold_uncertainty_score":0.9960733},"labels":[],"label_agreement":null},{"id":"W2324598527","doi":"10.1038/sj.gt.3301895","title":"Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model","year":2002,"lang":"en","type":"article","venue":"Gene Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Prostate cancer; Enhancer; Biology; Transgene; Prostate; Genetically modified mouse; Gene; Gene expression; Genetic enhancement; Cancer research; Cancer; Genetics","score_opus":0.055886283546264987,"score_gpt":0.31204674756866363,"score_spread":0.25616046402239867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324598527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95089555,0.04015789,0.0002059149,0.002650509,0.00016296777,0.0051756953,0.00010991554,0.00039195543,0.00024961075],"genre_scores_gemma":[0.7752106,0.19091508,0.0026798535,0.00021839213,0.00025691485,0.0024694945,0.0002750614,0.00022690481,0.027747657],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959489,0.000190166,0.0007297543,0.0011286697,0.0007464529,0.001256063],"domain_scores_gemma":[0.9983933,0.000024782948,0.00020799424,0.00069271313,0.0003108604,0.00037032977],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030679148,0.00062189787,0.00073417154,0.00038029283,0.00023100013,0.00009036228,0.00025817822,0.00022758184,0.0004609907],"category_scores_gemma":[0.000010474701,0.00046799908,0.00016868277,0.00081726257,0.00018483224,0.00033289866,0.00005256735,0.0005483789,0.00005891114],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004924572,0.0008796854,0.0015188642,0.00013713271,0.0001090788,0.00016515798,0.013204836,0.00077181373,0.9167139,9.6641e-7,0.0042328537,0.057341173],"study_design_scores_gemma":[0.011387103,0.000938061,0.00058369705,0.00029761397,0.000026680538,0.000018900597,0.000090953574,0.0063592168,0.9682788,0.0001102068,0.011347236,0.0005615288],"about_ca_topic_score_codex":0.000082485705,"about_ca_topic_score_gemma":0.000028052136,"teacher_disagreement_score":0.1756849,"about_ca_system_score_codex":0.0005405788,"about_ca_system_score_gemma":0.00022820992,"threshold_uncertainty_score":0.9997772},"labels":[],"label_agreement":null},{"id":"W2324756289","doi":"10.1158/1538-7445.am10-5287","title":"Abstract 5287: Role of Wnt-beta-catenin pathway in the control of tumor cell invasion in the triple negative subset of breast cancer","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Wnt signaling pathway; Downregulation and upregulation; Cancer research; Extracellular matrix; Biology; Metastasis; Cancer; Signal transduction; Integrin; Cell; Pathology; Medicine; Cell biology; Gene; Genetics","score_opus":0.05194170739611255,"score_gpt":0.3658599155739682,"score_spread":0.31391820817785565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324756289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903072,0.002843549,2.817299e-7,0.0028273158,0.000060324717,0.0018125321,0.00050188735,0.0000036151284,0.0016432744],"genre_scores_gemma":[0.9982453,0.0007144308,0.0000071395284,0.0000625879,0.00010522286,0.00066429947,0.000018526638,0.000020715614,0.00016175282],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99694926,0.0004369231,0.0005027005,0.00029855783,0.0012590095,0.0005535474],"domain_scores_gemma":[0.99780494,0.0008338488,0.00017536514,0.00048891676,0.00060623983,0.00009071383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030761336,0.00015925425,0.0004879349,0.00037151953,0.00006615326,0.000015392965,0.0005915431,0.00010456531,0.00058979815],"category_scores_gemma":[0.00013659321,0.00008226227,0.000116106654,0.0011306226,0.0006995062,0.00009568558,0.00006418678,0.0012646255,0.0000053109575],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034253183,0.0007785369,0.08991013,0.0004321712,0.00005571476,0.000055069304,0.0072500193,0.00001753605,0.8922738,0.00014811833,0.00061775243,0.005035841],"study_design_scores_gemma":[0.005883686,0.00033661016,0.3639453,0.00030529953,0.000019546094,0.000007070772,0.0056769084,0.000050943487,0.6231238,0.00028224173,0.0002907041,0.00007787093],"about_ca_topic_score_codex":0.019834775,"about_ca_topic_score_gemma":0.008513527,"teacher_disagreement_score":0.2740352,"about_ca_system_score_codex":0.00016997769,"about_ca_system_score_gemma":0.0016165392,"threshold_uncertainty_score":0.98669225},"labels":[],"label_agreement":null},{"id":"W2325391880","doi":"10.1021/jm500802j","title":"Discovery of Small-Molecule Inhibitors Selectively Targeting the DNA-Binding Domain of the Human Androgen Receptor","year":2014,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada; U.S. Department of Defense","keywords":"Enzalutamide; Androgen receptor; Chemistry; Virtual screening; Prostate cancer; Small molecule; Mutagenesis; Computational biology; Drug discovery; Cancer research; Biochemistry; Cancer; Mutation; Biology; Genetics; Gene","score_opus":0.013563947773341,"score_gpt":0.27814300896357763,"score_spread":0.2645790611902366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325391880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99578536,0.0008661032,0.00002283304,0.0016582403,0.00010710014,0.00012442077,0.0000046280684,0.000002725176,0.0014285787],"genre_scores_gemma":[0.998624,0.00007305967,0.00008286574,0.00003733069,0.0006619567,0.000002329359,0.0000040962627,0.000014181867,0.00050015235],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99843186,0.000083076106,0.0005127412,0.00010633375,0.00066439394,0.00020159908],"domain_scores_gemma":[0.9987272,0.0001290428,0.00062976923,0.00016682828,0.00025646525,0.00009068236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011385374,0.00012236554,0.00035970262,0.000039373084,0.00010991822,0.000008832074,0.0002423893,0.00007699219,0.00004619679],"category_scores_gemma":[0.00029029325,0.00005749006,0.0002091591,0.00021632244,0.00030582878,0.000049834296,0.000061642146,0.0005017806,3.7172452e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022544949,0.00008493344,0.023051921,0.00026574678,0.00018124512,0.000011586378,0.0005527877,8.370216e-7,0.9736922,0.000008356311,0.001595203,0.00032974657],"study_design_scores_gemma":[0.001963615,0.0003333821,0.0019116965,0.000816629,0.00013852543,0.00012160705,0.0020818321,0.0000030139095,0.991954,0.00006800693,0.00055483566,0.000052824977],"about_ca_topic_score_codex":0.000012536197,"about_ca_topic_score_gemma":9.5118793e-7,"teacher_disagreement_score":0.021140225,"about_ca_system_score_codex":0.00013806298,"about_ca_system_score_gemma":0.00031094698,"threshold_uncertainty_score":0.23443764},"labels":[],"label_agreement":null},{"id":"W2325404207","doi":"10.1158/1538-7445.am2013-1070","title":"Abstract 1070: New potent inhibitors of the androgen receptor that target its BF3 surface binding site.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Transactivation; Androgen receptor; Bicalutamide; Prostate cancer; LNCaP; Antiandrogens; Chemistry; Cancer research; Binding site; In silico; Dihydrotestosterone; Pharmacology; Cancer; Androgen; Biochemistry; Biology; Internal medicine; Medicine; Transcription factor; Hormone","score_opus":0.10403281234376517,"score_gpt":0.38424054420310266,"score_spread":0.2802077318593375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325404207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974904,0.010142254,8.6849855e-7,0.0105823185,0.0003269102,0.0018101457,0.00008702992,0.000029515808,0.0021169845],"genre_scores_gemma":[0.9639544,0.003260387,0.000086973574,0.00005545147,0.00035754195,0.00011844461,0.000037235863,0.000048146605,0.032081425],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968391,0.00013265655,0.00027352342,0.00040757185,0.0015033209,0.0008438103],"domain_scores_gemma":[0.9982286,0.00015541147,0.000084748,0.0005081747,0.0005657109,0.00045735814],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00071435195,0.00018708808,0.00031709694,0.00018369066,0.00025518608,0.00007130053,0.0003423866,0.00014467558,0.0053127157],"category_scores_gemma":[0.00013595005,0.00011194927,0.0001573636,0.00085487287,0.0002783101,0.00020405636,0.0002629426,0.0007531807,0.0008383333],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033032152,0.00014470887,0.10097462,0.0003439574,0.0001783005,0.000016495876,0.00088986056,0.000040221163,0.70677894,0.000011137662,0.18338744,0.006904],"study_design_scores_gemma":[0.0018678622,0.00020259555,0.03298532,0.00061450247,0.000019153904,0.000004676164,0.0004653482,0.000030045638,0.9312486,0.0000611096,0.032353826,0.00014698131],"about_ca_topic_score_codex":0.0029972438,"about_ca_topic_score_gemma":0.00004316275,"teacher_disagreement_score":0.22446965,"about_ca_system_score_codex":0.0006396404,"about_ca_system_score_gemma":0.0013714624,"threshold_uncertainty_score":0.9999396},"labels":[],"label_agreement":null},{"id":"W2326498587","doi":"10.1016/j.brachy.2014.02.421","title":"A Prospective Cohort Analysis of Two Brachytherapy Techniques for Low/Intermediate Risk Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Brachytherapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; Prospective cohort study; Oncology; Cohort; Cancer; Internal medicine; Gynecology; Radiation therapy","score_opus":0.010955389244236011,"score_gpt":0.35063137972034003,"score_spread":0.33967599047610403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326498587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881429,0.002116755,0.0038096702,0.0005393003,0.00013019922,0.004074611,0.00038394364,0.0001826426,0.00061994966],"genre_scores_gemma":[0.9844248,0.007820887,0.0020757723,0.0003910008,0.00032601948,0.0025967923,0.0001967029,0.000077311444,0.002090661],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784267,0.000118991535,0.0005277489,0.00059273455,0.0004172539,0.0005006254],"domain_scores_gemma":[0.9981628,0.00023888948,0.0003776403,0.00053790136,0.00051195966,0.00017082629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074199395,0.00030760976,0.0009638843,0.0005385312,0.00013001329,0.000030913867,0.00015094712,0.00011075849,0.00020027191],"category_scores_gemma":[0.00007935984,0.00022528453,0.00049511984,0.0010019034,0.00024397235,0.0001245319,0.000023016348,0.00023547113,0.000004404258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034090723,0.00039278256,0.8372804,0.00011038532,0.0052269455,0.0000050066574,0.00091455394,0.00003327412,0.008551128,0.00018006301,0.0003403155,0.14355609],"study_design_scores_gemma":[0.010376094,0.003258168,0.8522884,0.00021018,0.0026231115,0.000005240027,0.000060359107,0.005944097,0.11509246,0.001878355,0.007831745,0.00043176912],"about_ca_topic_score_codex":0.0005278252,"about_ca_topic_score_gemma":0.00029304155,"teacher_disagreement_score":0.14312431,"about_ca_system_score_codex":0.00021420188,"about_ca_system_score_gemma":0.00020720887,"threshold_uncertainty_score":0.91868365},"labels":[],"label_agreement":null},{"id":"W2327345464","doi":"10.1016/j.juro.2013.02.1621","title":"241 DETERMINATION OF THE ACCURACY OF FDG-PET/CT IN THE PRIMARY STAGING OF BIOLOGICAL HIGH RISK PROSTATE CANCERS BEFORE LOCAL THERAPIES: INCREASED UPTAKE ASSOCIATED WITH HIGHLY AGGRESSIVE TUMORS","year":2013,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Internal medicine","score_opus":0.013934431055094612,"score_gpt":0.27122688976330567,"score_spread":0.25729245870821105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327345464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995579,0.0009233249,0.00002724219,0.002661202,0.000044023473,0.00069123815,0.00003165556,0.0000031572497,0.000039153067],"genre_scores_gemma":[0.99875546,0.00090133416,0.000049333696,0.00021704714,0.000026116722,0.00001608125,0.000007940508,0.000011013165,0.000015707286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976872,0.00094125245,0.000609471,0.00009555527,0.00041908282,0.00024739915],"domain_scores_gemma":[0.9961585,0.001182834,0.0019446228,0.00022716474,0.0004443915,0.00004249365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014028066,0.00013806208,0.00048275382,0.00012692223,0.00006793937,0.000004734662,0.000358154,0.00003147247,0.000031020823],"category_scores_gemma":[0.0006527498,0.00004870351,0.00009688462,0.0003265061,0.00090260326,0.00008796731,0.00005236343,0.0005252257,3.4789966e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012620166,0.0009141958,0.90367126,0.00017317914,0.001281121,0.00063520594,0.014309337,0.0006693618,0.018803153,0.00006496166,0.00018857756,0.04666949],"study_design_scores_gemma":[0.0047369753,0.0048745447,0.98101103,0.00031368897,0.00026223442,0.0003929711,0.00225645,0.0003622895,0.0047660363,0.00094284996,0.000021207527,0.00005973629],"about_ca_topic_score_codex":0.0015138815,"about_ca_topic_score_gemma":0.00014538033,"teacher_disagreement_score":0.07733977,"about_ca_system_score_codex":0.00017876893,"about_ca_system_score_gemma":0.000543751,"threshold_uncertainty_score":0.33256793},"labels":[],"label_agreement":null},{"id":"W2328700677","doi":"10.1007/s11934-016-0592-4","title":"Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy","year":2016,"lang":"en","type":"review","venue":"Current Urology Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Prostate Cancer Canada","keywords":"Medicine; Prostate cancer; Docetaxel; Prostatectomy; Oncology; Internal medicine; Neoadjuvant therapy; Hormonal therapy; Cancer; Breast cancer","score_opus":0.06374962966807887,"score_gpt":0.4359384621349274,"score_spread":0.37218883246684853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328700677","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033043558,0.9837593,0.00004097605,0.00052563776,0.0023569353,0.009307918,0.0004945277,0.00012606017,0.00008431025],"genre_scores_gemma":[0.0005241779,0.99204457,0.00015415254,0.00003142482,0.00055367325,0.0040535307,0.000556626,0.00015315032,0.0019287167],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929302,0.0005791076,0.0029618493,0.0017046632,0.00070319325,0.0011210113],"domain_scores_gemma":[0.9948541,0.00043741227,0.001978013,0.0014342213,0.00039998675,0.0008962968],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077454303,0.0009859905,0.0050797015,0.0005429496,0.00012755029,0.000019863412,0.00020855582,0.0006453446,0.00043780994],"category_scores_gemma":[0.00042397776,0.00053276366,0.0011604857,0.0005118398,0.00065413327,0.000050870785,0.00019274642,0.00071830355,0.00013636683],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001662482,0.0013169065,0.006339925,0.0058197156,0.0013497504,0.0026989349,0.000121640376,5.5222887e-7,0.0000019239965,0.0000073307037,0.0010432324,0.9796376],"study_design_scores_gemma":[0.00450061,0.005474192,0.00036748848,0.009243017,0.0039244303,0.0008785463,0.000002238929,0.0000011170634,0.000024060859,0.00008613094,0.97503614,0.0004620506],"about_ca_topic_score_codex":0.0001345983,"about_ca_topic_score_gemma":0.000012008639,"teacher_disagreement_score":0.97917557,"about_ca_system_score_codex":0.0008238696,"about_ca_system_score_gemma":0.0043282616,"threshold_uncertainty_score":0.9997124},"labels":[],"label_agreement":null},{"id":"W2329021282","doi":"10.1021/jm2015292","title":"Antiandrogenic, Maspin Induction, and Antiprostate Cancer Activities of Tanshinone IIA and Its Novel Derivatives with Modification in Ring A","year":2011,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Maspin; Antiandrogens; LNCaP; Chemistry; Prostate cancer; Androgen receptor; Antagonist; Cancer research; Apoptosis; Antiandrogen; Pharmacology; Cancer; Internal medicine; Endocrinology; Receptor; Biochemistry; Medicine; Metastasis","score_opus":0.06686049253920473,"score_gpt":0.31967081286963867,"score_spread":0.25281032033043394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329021282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922085,0.0070304475,0.000059553542,0.00038649273,0.000018166134,0.00009585358,0.0000050649674,0.0000024456424,0.00019346831],"genre_scores_gemma":[0.99604714,0.0034377936,0.0003176153,0.000010335461,0.000066702996,0.0000045515344,0.0000015270958,0.000008372061,0.00010593642],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99926203,0.000009667894,0.0002498805,0.0001060866,0.00025071332,0.000121608915],"domain_scores_gemma":[0.99943024,0.00002017928,0.00023484309,0.000055480312,0.00015554717,0.00010371571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020822117,0.000092318405,0.00027208714,0.0000847528,0.000026120904,0.0000044444955,0.000036471698,0.00005127711,0.000027979528],"category_scores_gemma":[0.000034776367,0.000061160594,0.000017981834,0.0001308333,0.0001681792,0.00015109683,0.0000149282205,0.00024856286,2.9562715e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019154465,0.00014454668,0.11316399,0.0006722571,0.00013746257,0.00007883039,0.0034478928,0.0000013897984,0.878165,0.000004540634,0.000005195378,0.0022634428],"study_design_scores_gemma":[0.003794746,0.00034857568,0.19155917,0.001002652,0.00009687847,0.0007024157,0.002383955,0.000059232807,0.7999667,0.000017035789,0.000009867637,0.000058789647],"about_ca_topic_score_codex":0.000047412872,"about_ca_topic_score_gemma":0.0000043861946,"teacher_disagreement_score":0.07839517,"about_ca_system_score_codex":0.000053850614,"about_ca_system_score_gemma":0.00020048994,"threshold_uncertainty_score":0.24940567},"labels":[],"label_agreement":null},{"id":"W2329116253","doi":"10.6000/1927-7229.2016.05.01.6","title":"Abiraterone Acetate in Patients with Advanced Castrate Resistant Prostate Cancer: Initial Real Life Experience in 2 Cancer Units","year":2016,"lang":"en","type":"article","venue":"Journal of Analytical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Internal medicine; Chemotherapy; Cancer; Adverse effect; Prostate-specific antigen; Clinical trial; Surgery; Gastroenterology; Urology; Androgen deprivation therapy","score_opus":0.057617050101848526,"score_gpt":0.40663691521271467,"score_spread":0.34901986511086613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329116253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99327767,0.00035484266,0.0000046924374,0.005348294,0.00014226753,0.00035322274,0.000028587701,0.000005472581,0.00048493396],"genre_scores_gemma":[0.99590415,0.0031641168,0.000094580464,0.00019338152,0.00010614397,0.000040991155,0.0000029151297,0.000019846888,0.00047387538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785495,0.00014900937,0.00074492366,0.00024439459,0.00046872537,0.00053799525],"domain_scores_gemma":[0.99836826,0.00013471079,0.00031459282,0.00013230102,0.0006434621,0.0004066901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003020065,0.00018308562,0.0007213236,0.00035858527,0.00003132125,0.000011524431,0.00012529992,0.00011442758,0.00018158674],"category_scores_gemma":[0.00015511898,0.00009554578,0.000047648307,0.00063912995,0.00033094513,0.00026504585,0.00003815055,0.00040139823,0.000003451412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07023864,0.0010626131,0.8851666,0.00006960101,0.00022104295,0.003220376,0.0015791429,0.00011683754,0.0028427304,0.00005848958,0.00021456668,0.03520936],"study_design_scores_gemma":[0.035943504,0.011718591,0.94715494,0.001081554,0.00010989289,0.00002600851,0.00050900626,0.000059367907,0.001409702,0.000046158028,0.0017470705,0.00019421423],"about_ca_topic_score_codex":0.0003545621,"about_ca_topic_score_gemma":0.0014676629,"teacher_disagreement_score":0.061988335,"about_ca_system_score_codex":0.0014508428,"about_ca_system_score_gemma":0.0027133203,"threshold_uncertainty_score":0.48133138},"labels":[],"label_agreement":null},{"id":"W2329606975","doi":"10.1097/01.cot.0000451734.26163.10","title":"Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Oncology Times","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Internal medicine; Oncology; Radiation therapy; Disease; Cancer; Comparative genomic hybridization; Prostate; Gynecology; Gene; Genome; Biology; Genetics","score_opus":0.023705121994704963,"score_gpt":0.37570956913795744,"score_spread":0.35200444714325246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329606975","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32285583,0.0029378778,0.000018972074,0.038488407,0.0003755961,0.000609618,0.000010127563,0.00013860037,0.634565],"genre_scores_gemma":[0.70408547,0.000937128,0.00058919773,0.0014227816,0.00032626657,0.00018059867,0.00002752995,0.000018859124,0.2924122],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994057,0.000039392275,0.00008387337,0.00014940868,0.00009884053,0.0002228282],"domain_scores_gemma":[0.9996329,0.000053069238,0.000025085259,0.00012546983,0.000060005656,0.000103462895],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001295037,0.000069513015,0.0001811662,0.000049695973,0.000052756302,0.000005145637,0.000040137093,0.00006993684,0.0014915541],"category_scores_gemma":[0.00002887718,0.00004679563,0.000036702342,0.00007967302,0.000110294,0.000027083175,0.000025586236,0.00011667161,0.0003379906],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011939358,0.00043815593,0.1543604,0.000109759145,0.0002619365,0.00014318587,0.00083107577,0.000005969157,0.009152691,0.0014451734,0.26687902,0.5651787],"study_design_scores_gemma":[0.0027498289,0.0010926686,0.021758301,0.000033317985,0.00006211169,0.000025856816,0.000045287146,0.000175158,0.005987297,0.00044958873,0.9675481,0.000072491544],"about_ca_topic_score_codex":0.000053308653,"about_ca_topic_score_gemma":0.00001606244,"teacher_disagreement_score":0.70066905,"about_ca_system_score_codex":0.00014215615,"about_ca_system_score_gemma":0.0002573876,"threshold_uncertainty_score":0.99942124},"labels":[],"label_agreement":null},{"id":"W2329619353","doi":"10.1097/spc.0b013e328362ffef","title":"The changing landscape in metastatic castration-resistant prostate cancer","year":2013,"lang":"en","type":"review","venue":"Current Opinion in Supportive and Palliative Care","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Enzalutamide; Cabazitaxel; Medicine; Prostate cancer; Cabozantinib; Abiraterone acetate; Oncology; Docetaxel; Disease; Androgen receptor; Internal medicine; Cancer; Pharmacology; Androgen deprivation therapy","score_opus":0.19748145070135392,"score_gpt":0.480525015493028,"score_spread":0.2830435647916741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329619353","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042302534,0.99466383,0.0000014478653,0.00013019785,0.00083996897,0.0033985204,0.00044943707,0.000010745186,0.00008281698],"genre_scores_gemma":[0.0004769652,0.9944698,0.000010154996,0.000005654953,0.00017752606,0.0030162625,0.0014772197,0.000033777298,0.00033261566],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977895,0.00021714611,0.00064674276,0.00048366838,0.00031382794,0.00054908847],"domain_scores_gemma":[0.9988715,0.00024124185,0.0002994789,0.00019228646,0.00025707472,0.00013842438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023455932,0.00040192253,0.0010296823,0.00039159023,0.0001413744,0.00007569272,0.00010066452,0.00009175409,0.000090039546],"category_scores_gemma":[0.00006263919,0.0002251918,0.00017121926,0.0006497227,0.00013598135,0.000089246365,0.00007959091,0.0006009462,0.000015843181],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010219473,0.00006958482,0.015068674,0.036026675,0.00017991802,0.000020000401,0.006402931,5.13939e-7,3.3479736e-7,0.000107439264,0.0006899484,0.9413318],"study_design_scores_gemma":[0.0015909027,0.00021549064,0.0039717304,0.04452456,0.00020776902,0.0000027516478,0.00641433,0.000014590824,0.0000024269825,0.00003501113,0.94270176,0.00031869017],"about_ca_topic_score_codex":0.000046740268,"about_ca_topic_score_gemma":0.00008205854,"teacher_disagreement_score":0.9420118,"about_ca_system_score_codex":0.0003992766,"about_ca_system_score_gemma":0.00093742175,"threshold_uncertainty_score":0.9183055},"labels":[],"label_agreement":null},{"id":"W2330334958","doi":"10.1097/01.cot.0000410634.85197.4e","title":"Prostate Cancer: New MET, VEGFR Inhibitor Produces Impressive Response in Bone","year":2011,"lang":"en","type":"article","venue":"Oncology Times","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cabozantinib; Medicine; Prostate cancer; Cancer; Oncology; Internal medicine; Docetaxel; Discontinuation; Prostate","score_opus":0.040972618898946815,"score_gpt":0.35724485309715254,"score_spread":0.3162722341982057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330334958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9643727,0.011302639,6.852508e-7,0.0076817847,0.00028023604,0.0010702987,0.000016686028,0.00006786487,0.0152071025],"genre_scores_gemma":[0.86278206,0.0017926417,0.0013554674,0.0003449801,0.0003406044,0.00042718486,0.00002062035,0.000038168688,0.13289826],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985148,0.00019123747,0.0002634428,0.00039159475,0.00018223385,0.00045669064],"domain_scores_gemma":[0.99921083,0.00011621118,0.00009687721,0.0002541083,0.00010132701,0.00022062534],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043109173,0.00017066787,0.0004220378,0.00024402964,0.0000571444,0.000008079347,0.000093723174,0.00015597131,0.0010387745],"category_scores_gemma":[0.00017253327,0.00012359594,0.00005915388,0.00028590436,0.00020141933,0.000114602226,0.00008266639,0.00029992545,0.00012563218],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13824993,0.0024431243,0.17747672,0.00024647318,0.00060306763,0.0061054733,0.036338415,0.000004129277,0.19894886,0.00014370779,0.1570922,0.2823479],"study_design_scores_gemma":[0.021841692,0.0151603585,0.22006014,0.0005855982,0.00030035307,0.00022103843,0.0018054657,0.00002833146,0.4937587,0.001127635,0.24456368,0.00054697815],"about_ca_topic_score_codex":0.0008641697,"about_ca_topic_score_gemma":0.0001373961,"teacher_disagreement_score":0.29480985,"about_ca_system_score_codex":0.00042756318,"about_ca_system_score_gemma":0.0020832631,"threshold_uncertainty_score":0.9998744},"labels":[],"label_agreement":null},{"id":"W2330516268","doi":"10.1097/00005650-200104000-00009","title":"Trends in Hormonal Management of Prostate Cancer:","year":2001,"lang":"en","type":"article","venue":"Medical Care","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences","funders":"","keywords":"Antiandrogens; Medicine; Prostate cancer; Hormonal therapy; Population; Cancer; Specialty; Oncology; Gynecology; Antiandrogen; Internal medicine; Intensive care medicine; Family medicine","score_opus":0.025168777554011253,"score_gpt":0.3637364023517046,"score_spread":0.33856762479769337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330516268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9480417,0.013401368,0.000002186126,0.0055005983,0.00008654016,0.00023396101,0.000018506715,0.00002146001,0.03269368],"genre_scores_gemma":[0.98700625,0.0066415356,0.00004678243,0.000118482065,0.00006134348,0.000085559135,0.00009518131,0.000009372869,0.0059354682],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99872595,0.000016173035,0.00016699747,0.0001601122,0.00069034315,0.00024042546],"domain_scores_gemma":[0.99960744,0.000009515388,0.000020133575,0.0001242375,0.00005479004,0.00018389252],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009639615,0.00007755562,0.0001855808,0.00015402675,0.000016439415,0.0000026410357,0.00007307441,0.00005944867,0.0018080629],"category_scores_gemma":[0.00000621618,0.000053824773,0.000053522603,0.000420616,0.00008599092,0.000020093219,0.00004810323,0.0001568188,0.000007173799],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049749156,0.000118723794,0.31511974,0.00027790075,0.00006113015,0.001970032,0.0009297399,0.000001188874,0.000022601873,0.000051542236,0.001576548,0.6793734],"study_design_scores_gemma":[0.010297443,0.0006877212,0.9213331,0.0011644036,0.000095818286,0.000041212134,0.0029290912,0.000114070215,0.0009215825,0.00004982098,0.06220974,0.00015604921],"about_ca_topic_score_codex":0.00021778196,"about_ca_topic_score_gemma":0.0001477835,"teacher_disagreement_score":0.6792173,"about_ca_system_score_codex":0.0001646438,"about_ca_system_score_gemma":0.000107365915,"threshold_uncertainty_score":0.99910444},"labels":[],"label_agreement":null},{"id":"W2331013251","doi":"10.1016/j.juro.2016.02.317","title":"MP46-19 CASTRATION-RESISTANT PROSTATE CANCER PATIENTS IN QUEBEC: MEDICATION USE IN THE LAST YEAR OF LIFE","year":2016,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Prostate Cancer Canada","funders":"","keywords":"Medicine; Prostate cancer; Cohort; Androgen deprivation therapy; Castration; Cancer; Oncology; Internal medicine; Cohort study; Gynecology","score_opus":0.02841135604439674,"score_gpt":0.3145599480442104,"score_spread":0.28614859199981363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331013251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98103815,0.00052114634,0.0000053619583,0.01807688,0.00006831507,0.00023029583,0.000009592681,0.0000010511562,0.000049221948],"genre_scores_gemma":[0.9976755,0.0017138316,0.000008686935,0.00033212826,0.000055660716,0.000007622803,0.0000020883554,0.00000493898,0.00019954774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897426,0.0002522727,0.00032714292,0.0000510495,0.00026100426,0.0001342791],"domain_scores_gemma":[0.9991782,0.00031163217,0.00021461784,0.00011089229,0.00013661206,0.000048046393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006607067,0.00005265621,0.00015358848,0.00012041479,0.000018229024,0.0000037923364,0.00011336261,0.000039510658,0.000049430066],"category_scores_gemma":[0.0002830283,0.000020050617,0.000026045056,0.0001281422,0.00014302359,0.000088007335,0.000013559658,0.00016144825,0.0000027664269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058178287,0.00032482296,0.9752162,0.000025945797,0.00006862139,0.000033555265,0.004148521,0.00002428381,0.008585541,0.000074429365,0.002200617,0.0034795988],"study_design_scores_gemma":[0.004573944,0.0008281292,0.99230075,0.000063918254,0.000039433507,0.000009189727,0.00030503504,0.000005183811,0.00033460642,0.000107221895,0.0014078323,0.00002478128],"about_ca_topic_score_codex":0.0033545713,"about_ca_topic_score_gemma":0.016600229,"teacher_disagreement_score":0.017744752,"about_ca_system_score_codex":0.00009804748,"about_ca_system_score_gemma":0.00044979536,"threshold_uncertainty_score":0.9263317},"labels":[],"label_agreement":null},{"id":"W2331962380","doi":"10.1158/1538-7445.am2013-4952","title":"Abstract 4952: A novel smoothened antagonist, TAK-441, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health; Vancouver Coastal Health Research Institute; University of British Columbia","funders":"","keywords":"Smoothened; LNCaP; Cyclopamine; Paracrine signalling; GLI1; Prostate cancer; Cancer research; Hedgehog signaling pathway; Internal medicine; Biology; Endocrinology; Androgen receptor; Hedgehog; Sonic hedgehog; Medicine; Cancer; Signal transduction; Cell biology; Receptor","score_opus":0.07902332384076281,"score_gpt":0.4364564706676511,"score_spread":0.35743314682688826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331962380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772725,0.0100389365,0.000011228457,0.0072503895,0.00013109682,0.0039927084,0.00026658812,0.000080367776,0.0009561622],"genre_scores_gemma":[0.9880692,0.0029476087,0.00027040203,0.00011304089,0.00029325846,0.003945299,0.00022115748,0.000104289276,0.0040357425],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99499404,0.00013789006,0.0006971627,0.0009178204,0.0016034361,0.0016496716],"domain_scores_gemma":[0.99761,0.00022640023,0.00015665457,0.0005122367,0.0009093361,0.00058541045],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011276193,0.00038772213,0.00054282346,0.00044433583,0.00046193274,0.0002877983,0.0003196992,0.00017246821,0.0016348922],"category_scores_gemma":[0.00013902092,0.00029099453,0.00011269773,0.0011698769,0.0004873525,0.0004042376,0.00016365222,0.0012198304,0.00008893819],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020672036,0.00072536094,0.048841942,0.0007651686,0.00012207389,0.00026725803,0.0011451747,0.00007196972,0.90364707,0.000028048262,0.0045043733,0.03781436],"study_design_scores_gemma":[0.026281338,0.0025145488,0.16514917,0.008259165,0.00012625588,0.00006772632,0.004483498,0.0027479604,0.7660771,0.00042608817,0.022169314,0.0016978575],"about_ca_topic_score_codex":0.012636098,"about_ca_topic_score_gemma":0.00086439634,"teacher_disagreement_score":0.13756998,"about_ca_system_score_codex":0.0014321073,"about_ca_system_score_gemma":0.0016841191,"threshold_uncertainty_score":0.9999542},"labels":[],"label_agreement":null},{"id":"W2332173011","doi":"10.1021/jm500684r","title":"Discovery of 1<i>H</i>-Indole-2-carboxamides as Novel Inhibitors of the Androgen Receptor Binding Function 3 (BF3)","year":2014,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Prostate Cancer Canada; U.S. Department of Defense","keywords":"LNCaP; Enzalutamide; Androgen receptor; Chemistry; Allosteric regulation; Prostate cancer; Indole test; Function (biology); Receptor; Pharmacology; Structure–activity relationship; Androgen; Androgen Receptor Antagonists; Cancer research; Biochemistry; Cancer; In vitro; Internal medicine; Cell biology; Hormone; Biology; Medicine","score_opus":0.01532315313797408,"score_gpt":0.2724060991395719,"score_spread":0.25708294600159787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332173011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99535096,0.0010566401,0.00006261428,0.00085224793,0.00037679935,0.00010110242,0.000009566954,0.000003613012,0.0021864322],"genre_scores_gemma":[0.9976549,0.00022026007,0.00006638525,0.000050864466,0.00082275557,0.000001697182,0.0000065694767,0.000014131921,0.001162405],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982477,0.000029204972,0.0005570478,0.00011254015,0.00087989,0.00017362951],"domain_scores_gemma":[0.9986503,0.00012554835,0.0006249379,0.00018507817,0.0002908815,0.00012326878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006730831,0.00012821188,0.00042024982,0.0000692182,0.00004302047,0.000007178651,0.00015522417,0.00010544507,0.00006862535],"category_scores_gemma":[0.00046554068,0.000070529066,0.00022639261,0.00023179088,0.00024282832,0.00010302374,0.000046412,0.00040960705,0.0000015288385],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012336434,0.00017056782,0.03228476,0.00049837184,0.0002099814,0.000006615417,0.00012964034,0.000003290478,0.96305203,0.0000059033723,0.0007895827,0.0016156015],"study_design_scores_gemma":[0.003627669,0.00068140146,0.003667953,0.0017677852,0.0002775576,0.00023382835,0.00070509646,0.000010213697,0.98748094,0.000043350337,0.0014434691,0.000060766106],"about_ca_topic_score_codex":0.000013629374,"about_ca_topic_score_gemma":3.557782e-7,"teacher_disagreement_score":0.028616806,"about_ca_system_score_codex":0.00012715814,"about_ca_system_score_gemma":0.00039813758,"threshold_uncertainty_score":0.28760916},"labels":[],"label_agreement":null},{"id":"W2332332196","doi":"10.1097/01.ogx.0000426493.20419.c0","title":"Intermittent Androgen Suppression for Rising PSA Level After Radiotherapy","year":2013,"lang":"en","type":"article","venue":"Obstetrical & Gynecological Survey","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier Universitaire de Sherbrooke; London Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Androgen; Androgen suppression; Adverse effect; Radiation therapy; Testosterone (patch); Internal medicine; Castration; Oncology; Clinical endpoint; Quality of life (healthcare); Urology; Randomized controlled trial; Cancer; Hormone","score_opus":0.09802743279384211,"score_gpt":0.3520207154689467,"score_spread":0.25399328267510457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332332196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98984903,0.004554041,0.0012662889,0.0013206117,0.0004392923,0.0020143278,0.00010311631,0.00008323216,0.0003700622],"genre_scores_gemma":[0.991758,0.00030970832,0.0025228,0.00068122975,0.00010925719,0.00058041763,0.00016190103,0.000028468463,0.0038482293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979649,0.00024922026,0.0003402577,0.00047554262,0.0003426187,0.00062746776],"domain_scores_gemma":[0.9960576,0.0029331967,0.000058326284,0.0002633997,0.0002723321,0.00041513864],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033104682,0.00022693364,0.0004870075,0.00012106414,0.000117864765,0.00007709047,0.00015261106,0.00026085958,0.0029571042],"category_scores_gemma":[0.0023338152,0.0001310249,0.00021559779,0.00038572494,0.00013209987,0.00010458853,0.000092647715,0.00027297667,0.00014485235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015846331,0.0011042441,0.74599385,0.000067596025,0.00018817616,0.00011937222,0.000075602366,0.0000015130377,0.0033574423,0.0000100614325,0.014985422,0.23251212],"study_design_scores_gemma":[0.0035258885,0.0014349556,0.9823074,0.000029893617,0.000026450736,0.000009578536,0.00002158822,0.00044001543,0.0011924893,0.00011787394,0.010710087,0.0001838058],"about_ca_topic_score_codex":0.000114459894,"about_ca_topic_score_gemma":0.000009283684,"teacher_disagreement_score":0.23631355,"about_ca_system_score_codex":0.000353205,"about_ca_system_score_gemma":0.000067611916,"threshold_uncertainty_score":0.9979543},"labels":[],"label_agreement":null},{"id":"W2333474348","doi":"10.1097/01.cot.0000305585.43199.b6","title":"Prostate Cancer","year":2007,"lang":"en","type":"article","venue":"Oncology Times","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Clinical trial; Internal medicine; Clinical endpoint; Placebo; Oncology; Chemotherapy; Surgery; Alternative medicine; Pathology","score_opus":0.02900008868479506,"score_gpt":0.40246684778044234,"score_spread":0.3734667590956473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333474348","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4863284,0.005767625,0.000019826,0.01485561,0.00034070725,0.0005990015,0.000009538654,0.00010796548,0.49197134],"genre_scores_gemma":[0.6694054,0.0012772338,0.0008311229,0.0011287912,0.000325487,0.00006805954,0.000027337113,0.000019716004,0.32691687],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993046,0.000013779009,0.00010977052,0.00014519096,0.0001172863,0.0003093955],"domain_scores_gemma":[0.9996042,0.000058664686,0.000027144566,0.00010695723,0.0000724853,0.00013054356],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002356934,0.00007105604,0.00016353093,0.000076757824,0.000053990752,0.000003901169,0.000037389684,0.00008403135,0.0015544388],"category_scores_gemma":[0.000017332395,0.00004906178,0.000038634775,0.0001250252,0.0001210693,0.000029604424,0.000024236155,0.00013974274,0.00022995844],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003029725,0.0005827065,0.27218083,0.00008256627,0.00031929856,0.0016443281,0.0013109464,0.0000015706977,0.01815556,0.00058635004,0.16195527,0.5401509],"study_design_scores_gemma":[0.003398851,0.0010720424,0.08533457,0.000038782466,0.000074430376,0.00007334566,0.00022795786,0.0000142791305,0.026391702,0.00022288709,0.88305616,0.0000950165],"about_ca_topic_score_codex":0.00006941508,"about_ca_topic_score_gemma":0.00005285579,"teacher_disagreement_score":0.72110087,"about_ca_system_score_codex":0.00026784962,"about_ca_system_score_gemma":0.00036155427,"threshold_uncertainty_score":0.9993583},"labels":[],"label_agreement":null},{"id":"W2334461454","doi":"10.1136/esmoopen-2016-000040","title":"International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries","year":2016,"lang":"en","type":"article","venue":"ESMO Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"Amgen","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Radiation therapy; Cancer; Hormone therapy; Orchiectomy; Gynecology; Breast cancer","score_opus":0.07717180705185608,"score_gpt":0.41484243752290983,"score_spread":0.3376706304710537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334461454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99143004,0.00028509094,0.0001301164,0.004413772,0.00012402803,0.0023410628,0.000574619,0.000006168091,0.00069512834],"genre_scores_gemma":[0.9917525,0.003491826,0.0002269942,0.0001270222,0.00002309088,0.00052386837,0.00016886009,0.000013980888,0.0036718578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993037,0.000036419708,0.00018873093,0.00015956972,0.00016763266,0.00014395955],"domain_scores_gemma":[0.999369,0.00017035623,0.00007277716,0.00012284276,0.00022192857,0.0000430465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005405128,0.00007276728,0.00018900596,0.00008607044,0.000025540241,0.000022257609,0.0001604282,0.000019108893,0.00041378225],"category_scores_gemma":[0.00010410377,0.000041935826,0.000022344897,0.00011895382,0.00005973141,0.0001730156,0.00005323672,0.000030696665,0.000007469228],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040465477,0.000120142024,0.94397897,0.00003992681,0.00016701336,0.0000071981945,0.00038856023,0.0000021925111,0.0011320071,0.000042053132,0.0021049096,0.047970463],"study_design_scores_gemma":[0.012679254,0.00030789498,0.9279616,0.00022912126,0.000010882351,0.0000021535106,0.000035913934,0.0000693441,0.03829805,0.0002517597,0.020073602,0.00008040977],"about_ca_topic_score_codex":0.0062475023,"about_ca_topic_score_gemma":0.0016942485,"teacher_disagreement_score":0.047890052,"about_ca_system_score_codex":0.0001422522,"about_ca_system_score_gemma":0.00045386617,"threshold_uncertainty_score":0.94443965},"labels":[],"label_agreement":null},{"id":"W2334961640","doi":"10.1158/1538-7445.am10-1708","title":"Abstract 1708: Telomerase as an important target of androgen-signaling blockade for prostate cancer treatment","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prevention of Organ Failure","funders":"","keywords":"Prostate cancer; Telomerase; Bicalutamide; Telomerase reverse transcriptase; Androgen receptor; Androgen deprivation therapy; Androgen; Cancer research; Downregulation and upregulation; Medicine; Cancer; Internal medicine; Biology; Hormone","score_opus":0.07610324182538035,"score_gpt":0.44646624196154944,"score_spread":0.3703630001361691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334961640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98782176,0.0056939586,0.0000016253161,0.0019780847,0.00024721376,0.0030763913,0.00064461236,0.00004910968,0.00048724026],"genre_scores_gemma":[0.9854027,0.0053962367,0.0004881384,0.000048969414,0.00068391534,0.0032930695,0.00020199317,0.00009041098,0.004394541],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99671847,0.000060589657,0.0005092094,0.00068253215,0.00092762377,0.0011015608],"domain_scores_gemma":[0.99737716,0.00018760134,0.00013146404,0.0006065109,0.0010106454,0.000686609],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001034802,0.00028897365,0.0005399125,0.00039733807,0.00033467237,0.00005954555,0.00023568276,0.00018217658,0.0017658733],"category_scores_gemma":[0.00011449822,0.00020559892,0.00018748557,0.00052157935,0.000465557,0.00016314666,0.0000561881,0.00062835455,0.000016713664],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004808316,0.0009475901,0.05899696,0.0005211419,0.00046275023,0.00019781187,0.0014093786,0.000019102381,0.89983016,0.00008775287,0.0007642926,0.031954743],"study_design_scores_gemma":[0.005857523,0.0022583622,0.004085013,0.00020591449,0.00008268497,0.000016552596,0.00044263943,0.00010458105,0.95277554,0.00064498174,0.033300966,0.00022525426],"about_ca_topic_score_codex":0.00514636,"about_ca_topic_score_gemma":0.00074321765,"teacher_disagreement_score":0.05491195,"about_ca_system_score_codex":0.0005250676,"about_ca_system_score_gemma":0.00382243,"threshold_uncertainty_score":0.99914664},"labels":[],"label_agreement":null},{"id":"W2334966231","doi":"10.5114/wo.2015.56661","title":"Low cost abiraterone","year":2015,"lang":"pl","type":"article","venue":"Współczesna Onkologia","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Library science; Abiraterone; Medicine; Computer science; Internal medicine","score_opus":0.09992640475621964,"score_gpt":0.36113723616934845,"score_spread":0.26121083141312884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334966231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8690323,0.027346324,0.00034291568,0.013754946,0.0062638614,0.004127656,0.00030369524,0.0005397535,0.07828853],"genre_scores_gemma":[0.92590725,0.0014862921,0.00030081454,0.00100628,0.0012211449,0.00015324884,0.0003206218,0.00008807931,0.069516234],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959944,0.0002595611,0.00057316053,0.00083217246,0.00090566324,0.0014350332],"domain_scores_gemma":[0.99704605,0.0001308,0.00017201026,0.0009257663,0.00051333266,0.0012120513],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00089459325,0.0005488869,0.0008249616,0.00025816078,0.00017676405,0.00012362022,0.00042855757,0.0005204869,0.0016138526],"category_scores_gemma":[0.00039147714,0.00041662672,0.00018102021,0.0006046021,0.00065835105,0.00021101985,0.00028924132,0.0008287396,0.009313038],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009442338,0.0051268195,0.2137492,0.0012923055,0.0019075907,0.008137885,0.005702623,0.00010810023,0.0091843875,0.0018388175,0.5919058,0.15160418],"study_design_scores_gemma":[0.09845346,0.023095712,0.14936055,0.0036408836,0.0024274508,0.0008464844,0.010082749,0.0033325364,0.14001887,0.0030868875,0.56086135,0.004793092],"about_ca_topic_score_codex":0.00029178488,"about_ca_topic_score_gemma":0.00003993868,"teacher_disagreement_score":0.14681108,"about_ca_system_score_codex":0.0009898135,"about_ca_system_score_gemma":0.0013978569,"threshold_uncertainty_score":0.9998286},"labels":[],"label_agreement":null},{"id":"W2335111169","doi":"10.1158/1538-7445.am2011-320","title":"Abstract 320: Association of higher Gleason grade with presence of PTEN deletion in prostatic adenocarcinoma","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Robarts Clinical Trials; University Health Network; Queen's University","funders":"","keywords":"PTEN; TMPRSS2; Prostate cancer; Cancer research; Fluorescence in situ hybridization; Prostate; Tissue microarray; Adenocarcinoma; Fusion gene; Grading (engineering); Cancer; Pathology; Biology; Medicine; Immunohistochemistry; Oncology; Gene; Chromosome; Internal medicine; Genetics; Disease; PI3K/AKT/mTOR pathway","score_opus":0.11401701115516859,"score_gpt":0.39439451656392255,"score_spread":0.28037750540875395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335111169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903945,0.0041387435,0.0000032519522,0.00074993377,0.00004012593,0.0010676389,0.00002355661,0.000011777887,0.0035705196],"genre_scores_gemma":[0.99545527,0.0010252538,0.00020216871,0.000009201107,0.00003818091,0.00027986447,0.000016611066,0.000022746242,0.0029507244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99772125,0.00013085669,0.0002917705,0.0002729338,0.0011069102,0.00047625197],"domain_scores_gemma":[0.9986411,0.00016896747,0.0001384234,0.00027145323,0.0006609555,0.000119106444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008701392,0.000107043394,0.00029566558,0.00033943425,0.00003835386,0.0000076528995,0.00014543654,0.00010375735,0.0005144304],"category_scores_gemma":[0.00011557676,0.00007718959,0.000042259344,0.00077348517,0.00021782078,0.00012949595,0.000046306533,0.00043184162,0.000010029436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035373499,0.00050926063,0.9483446,0.00097150035,0.00012662627,0.000073622636,0.0023085466,0.0000048521183,0.03904847,0.00014206623,0.0012980924,0.0036350489],"study_design_scores_gemma":[0.0026875872,0.00092255214,0.8753325,0.00076032133,0.000026304415,0.000001803395,0.00030596057,0.000030403362,0.11939742,0.00022137792,0.00023824802,0.00007555962],"about_ca_topic_score_codex":0.0039621894,"about_ca_topic_score_gemma":0.00033546286,"teacher_disagreement_score":0.080348946,"about_ca_system_score_codex":0.00064713985,"about_ca_system_score_gemma":0.0006190761,"threshold_uncertainty_score":0.59896713},"labels":[],"label_agreement":null},{"id":"W2335134348","doi":"10.1097/01.cot.0000414906.89555.81","title":"Androgen-Deprivation Therapy Has Impact on Bone Density and Physical Functioning at Three Years","year":2012,"lang":"en","type":"article","venue":"Oncology Times","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Androgen deprivation therapy; Medicine; Grip strength; Prostate cancer; Quality of life (healthcare); Physical therapy; Cancer; Internal medicine","score_opus":0.05177754994581832,"score_gpt":0.3585804652885604,"score_spread":0.30680291534274207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335134348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943451,0.0013221763,0.000008149129,0.0011283448,0.00007553126,0.00021375217,0.0000019144566,0.000030979023,0.0028740151],"genre_scores_gemma":[0.9972647,0.00019248531,0.000068826426,0.00015742694,0.00029321152,0.000015686835,0.000027894297,0.000010909974,0.0019688706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994439,0.000033986275,0.00006103553,0.00012736484,0.0001150381,0.00021870762],"domain_scores_gemma":[0.9996213,0.00009304571,0.00003072394,0.00011041741,0.000027900252,0.0001166549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013536676,0.00008426508,0.00018773702,0.000051612726,0.00011718268,0.000008294602,0.000016740047,0.00007585644,0.00023466356],"category_scores_gemma":[0.000016496791,0.00005557002,0.000049182727,0.000065146734,0.00012756888,0.00006307793,0.000028799204,0.00011850511,0.00012492877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027639822,0.0006058902,0.87866235,0.0000073281562,0.00023124623,0.00004268281,0.0010616063,0.0000020696298,0.021457952,0.000093838265,0.0083945505,0.08667653],"study_design_scores_gemma":[0.0028489744,0.0019129936,0.97326237,0.000011750377,0.00004302467,0.00008465901,0.000032409283,0.00009557099,0.0112751825,0.0001664755,0.010197218,0.00006935758],"about_ca_topic_score_codex":0.000025685858,"about_ca_topic_score_gemma":0.0000057212137,"teacher_disagreement_score":0.09460007,"about_ca_system_score_codex":0.00026988157,"about_ca_system_score_gemma":0.00007934076,"threshold_uncertainty_score":0.25694013},"labels":[],"label_agreement":null},{"id":"W2335487751","doi":"10.1515/hmbci.2010.046","title":"Expression of 5α-reductase type 1 in breast cancer and adjacent non-malignant tissue: an immunohistochemical study","year":2010,"lang":"en","type":"article","venue":"Hormone Molecular Biology and Clinical Investigation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Immunohistochemistry; Breast cancer; Medicine; Reductase; Pathology; Cancer research; Oncology; Cancer; Internal medicine; Enzyme; Biology; Biochemistry","score_opus":0.029531350430436205,"score_gpt":0.41249155537116855,"score_spread":0.38296020494073235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335487751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969903,0.001509092,0.0000080031805,0.000922289,0.000077685865,0.00045948842,0.000012501404,0.0000075254925,0.000013107655],"genre_scores_gemma":[0.9985908,0.0007464429,0.00037116956,0.00010134781,0.000044170865,0.00003187007,0.00009032088,0.000008098332,0.000015752847],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99905676,0.0001086294,0.00032309268,0.00029783056,0.000077844896,0.00013583529],"domain_scores_gemma":[0.9994379,0.000042524705,0.00007489381,0.00018107389,0.00008661697,0.00017698735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003588818,0.000100063524,0.00025753572,0.00005665457,0.000033191864,0.0000045823244,0.00004418161,0.00020177386,0.000014635538],"category_scores_gemma":[0.00009040343,0.00007174316,0.000020643447,0.00010751236,0.0005315866,0.000036516743,0.00005548288,0.00032045756,9.4836736e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060490327,0.0003441965,0.24953045,0.000010832406,0.000021641325,0.000017939756,0.00013343662,9.18839e-8,0.7461055,0.00003013875,0.000028621651,0.0031722463],"study_design_scores_gemma":[0.0032559605,0.0020928478,0.73865575,0.000060021157,0.00008067845,0.000022048598,0.00014373376,0.000087120505,0.25496823,0.00050897076,0.000023227854,0.00010139651],"about_ca_topic_score_codex":0.0001962959,"about_ca_topic_score_gemma":0.000022853439,"teacher_disagreement_score":0.49113727,"about_ca_system_score_codex":0.000013763492,"about_ca_system_score_gemma":0.00011071715,"threshold_uncertainty_score":0.2925601},"labels":[],"label_agreement":null},{"id":"W2335544039","doi":"10.1371/journal.pone.0152861","title":"Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Prostate Cancer Canada; Astex Pharmaceuticals; Canadian Urological Association; Gilead Sciences; AstraZeneca","keywords":"LNCaP; Protein kinase B; Prostate cancer; Enzalutamide; PTEN; Cancer research; Androgen receptor; PI3K/AKT/mTOR pathway; Growth inhibition; Cancer; Medicine; Cell growth; Chemistry; Biology; Signal transduction; Internal medicine; Cell biology; Biochemistry","score_opus":0.09755513344111376,"score_gpt":0.3343937115182147,"score_spread":0.2368385780771009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335544039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99280626,0.0025314917,0.0000034340633,0.0031273577,0.000020397241,0.00094700936,0.00011206301,0.00002657429,0.00042539535],"genre_scores_gemma":[0.9876708,0.0056986883,0.000282193,0.000057103043,0.000048803224,0.00017021749,0.000008246647,0.000023851268,0.006040105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984658,0.00007740877,0.000436677,0.00030519557,0.0004044199,0.00031052702],"domain_scores_gemma":[0.9991412,0.00019581089,0.00009039395,0.0002504755,0.00014202634,0.0001800491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032057735,0.00013348817,0.0005015997,0.00010447491,0.000024359735,0.000006439554,0.000068674024,0.00008888196,0.000087079294],"category_scores_gemma":[0.000109633605,0.00007895426,0.000047722016,0.00013943677,0.00022523738,0.00008656706,0.0000672879,0.00014891295,0.000005188039],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011722412,0.006715525,0.3526124,0.0009713549,0.0008613314,0.00012881233,0.0014197156,0.0000029200594,0.61576444,0.0002097839,0.00014575414,0.009445556],"study_design_scores_gemma":[0.031637177,0.0052289013,0.20456563,0.0060112313,0.0004227097,0.0000022102834,0.00009208832,0.0011118269,0.74608177,0.0043494906,0.00012575957,0.00037118318],"about_ca_topic_score_codex":0.00025753307,"about_ca_topic_score_gemma":0.0001310829,"teacher_disagreement_score":0.14804678,"about_ca_system_score_codex":0.00009965726,"about_ca_system_score_gemma":0.00027941892,"threshold_uncertainty_score":0.32196614},"labels":[],"label_agreement":null},{"id":"W2335708793","doi":"10.1158/1538-7445.am2011-5074","title":"Abstract 5074: Evaluation of PTEN and TMPRSS2-ERG abnormalities in prostate cancer by FISH and immunohistochemistry to address intra- and inter- tissue heterogeneity and disease progression","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Toronto; Queen's University; University Health Network","funders":"","keywords":"PTEN; Prostate cancer; TMPRSS2; Prostate; Erg; Immunohistochemistry; Tissue microarray; Prostatectomy; Pathology; Cancer; Biology; Fusion gene; Cancer research; Carcinoma; Medicine; Internal medicine; Disease; Gene; Genetics","score_opus":0.09877131346931951,"score_gpt":0.4575403250542027,"score_spread":0.3587690115848832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335708793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624642,0.034256194,4.412443e-7,0.0012043684,0.000029718754,0.0015503317,0.00025664832,0.0000100684565,0.00022801508],"genre_scores_gemma":[0.9869981,0.011359662,0.000023786053,0.000042812775,0.000036337482,0.0011339984,0.00004076835,0.000021769965,0.0003428124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981189,0.00012494116,0.00024978525,0.00045569454,0.00063484773,0.00041582552],"domain_scores_gemma":[0.9987612,0.000057795147,0.00005406318,0.00021339611,0.00042120685,0.0004923444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010860284,0.0001647377,0.00027156202,0.00018054016,0.00010974749,0.00004495603,0.00007680911,0.00006749341,0.00010958689],"category_scores_gemma":[0.00014456619,0.00013163462,0.00001444261,0.00018276222,0.0005973156,0.0001663468,0.00021055609,0.00030822642,4.429433e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076057413,0.00031590243,0.37582397,0.0036789859,0.00016312058,0.000087866516,0.0077762865,0.0000013267767,0.30464303,0.0000063012594,0.002843785,0.29705366],"study_design_scores_gemma":[0.0055645765,0.00065081567,0.6351867,0.0027465934,0.00010634533,0.000015372025,0.0011417357,0.00014492364,0.35313183,0.0001641769,0.00085059187,0.00029638677],"about_ca_topic_score_codex":0.0026209168,"about_ca_topic_score_gemma":0.00038932066,"teacher_disagreement_score":0.29675728,"about_ca_system_score_codex":0.00026978162,"about_ca_system_score_gemma":0.00046286124,"threshold_uncertainty_score":0.53679043},"labels":[],"label_agreement":null},{"id":"W2336057475","doi":"10.1093/annonc/mdw179","title":"Diagnostic Gleason score and castration-resistant prostate cancer","year":2016,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Cancer Research UK","keywords":"Medicine; Enzalutamide; Prostate cancer; Abiraterone acetate; Docetaxel; Internal medicine; Oncology; Prednisone; Cabazitaxel; Taxane; Cancer; Androgen deprivation therapy; Androgen receptor; Breast cancer","score_opus":0.11695407753687155,"score_gpt":0.42132227972682934,"score_spread":0.3043682021899578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336057475","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060996942,0.017475404,5.983393e-7,0.91659194,0.00025771442,0.0009878048,0.0004469878,0.000020478896,0.0032221237],"genre_scores_gemma":[0.08786491,0.1439084,0.00015945177,0.7060119,0.00839128,0.0012600246,0.0010322941,0.00017913379,0.05119264],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839973,0.00009695427,0.00032377732,0.00037713873,0.0003061733,0.00049623486],"domain_scores_gemma":[0.9983678,0.00064052205,0.0002230447,0.00024955577,0.00039901672,0.00012010372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016917477,0.00023502427,0.00066038023,0.00017049572,0.000053395426,0.000011143374,0.0000863283,0.0005356899,0.0003082369],"category_scores_gemma":[0.00019165798,0.00015058141,0.000098012526,0.000094113995,0.00039151846,0.000053099986,0.000053132815,0.00057516515,0.00002127962],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071260676,0.000064473476,0.004912177,0.0007989715,0.00032206374,0.0023106392,0.00015292928,1.0433442e-7,0.0014972411,0.00001648784,0.9151156,0.07409668],"study_design_scores_gemma":[0.00206095,0.0034613307,0.007592377,0.0011349982,0.00016527285,0.00005668825,0.000017195276,7.1869476e-7,0.0031802237,0.00032632344,0.98184454,0.00015936683],"about_ca_topic_score_codex":0.00033163,"about_ca_topic_score_gemma":0.0000864772,"teacher_disagreement_score":0.21058008,"about_ca_system_score_codex":0.00011577835,"about_ca_system_score_gemma":0.0011795183,"threshold_uncertainty_score":0.61405313},"labels":[],"label_agreement":null},{"id":"W2336217331","doi":"10.1159/000413927","title":"Combination Therapy with Flutamide and Castration (by LHRH Agonist or Orchiectomy): The Minimal Endocrine Therapy in Prostate Cancer","year":2015,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Flutamide; Prostate cancer; Orchiectomy; Medicine; Castration; Urology; Agonist; Endocrine system; Prostate; Oncology; Internal medicine; Cancer; Hormone; Androgen receptor; Receptor","score_opus":0.05448498252561768,"score_gpt":0.3360691513592729,"score_spread":0.2815841688336552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336217331","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5249495,0.06973304,0.000013512155,0.034391694,0.00032806472,0.016693054,0.00056939747,0.0002543302,0.35306743],"genre_scores_gemma":[0.15966903,0.05656263,0.000060590206,0.00036548995,0.0001336549,0.00043078206,0.000521997,0.00009481755,0.782161],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99842495,0.000037491915,0.00027663898,0.00041934376,0.0005266767,0.00031487757],"domain_scores_gemma":[0.9991586,0.00007384603,0.00012511517,0.00025933198,0.0002537928,0.00012930844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019095179,0.00037632376,0.00042691958,0.00014800428,0.000105198036,0.000075775664,0.00008625304,0.000105307394,0.00054634875],"category_scores_gemma":[0.000005826415,0.00016915283,0.000041311538,0.00008425296,0.0003196664,0.00010554025,0.000024280438,0.00042607743,0.000006850098],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10673995,0.0014488957,0.02363658,0.00057111145,0.0026185885,0.0023455755,0.006049974,0.000011020195,0.00975342,0.013247477,0.053071164,0.78050625],"study_design_scores_gemma":[0.084509164,0.027420597,0.012099758,0.0015032229,0.00026336114,0.0006889639,0.000751064,0.00026265453,0.014717528,0.0032507447,0.85299706,0.0015359021],"about_ca_topic_score_codex":0.0009931774,"about_ca_topic_score_gemma":0.0017813648,"teacher_disagreement_score":0.79992586,"about_ca_system_score_codex":0.00029182868,"about_ca_system_score_gemma":0.0008278381,"threshold_uncertainty_score":0.68978524},"labels":[],"label_agreement":null},{"id":"W2336322280","doi":"","title":"Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice.","year":2014,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Randomized controlled trial; Clinical trial; Radiation therapy; Systematic review; Oncology; Cochrane Library; MEDLINE; Quality of life (healthcare); Cancer; Internal medicine","score_opus":0.10057227571444492,"score_gpt":0.42622420715212495,"score_spread":0.32565193143768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336322280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7482462,0.029831098,0.009804473,0.10098203,0.0019917907,0.10470348,0.00003278583,0.00028413237,0.0041240244],"genre_scores_gemma":[0.929605,0.007703104,0.0016805377,0.001128227,0.0008579233,0.058048874,0.000057141893,0.000037579965,0.0008815808],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957188,0.0016160235,0.0015441251,0.0003573578,0.0003562252,0.00040750724],"domain_scores_gemma":[0.99073744,0.0077752466,0.0006563189,0.00021982516,0.00039554603,0.00021565062],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022693796,0.00019821362,0.0027023968,0.00011856207,0.00010726277,0.000066536144,0.00008394611,0.000115670635,0.000019562867],"category_scores_gemma":[0.019924771,0.00010818259,0.0009795831,0.00011235577,0.00010161247,0.00014395297,0.000014215686,0.00018386701,0.0000021737872],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39198056,0.00016942671,0.0024402128,0.000042491716,0.0014124016,0.0000019858542,0.00032115323,0.0000014989644,0.00008621932,0.00005703768,0.00023973566,0.6032473],"study_design_scores_gemma":[0.9665215,0.00037880533,0.004514748,0.000067615765,0.0012240034,0.0000046368114,0.00009358795,0.0017756654,0.0021273163,0.001149536,0.021983242,0.00015933391],"about_ca_topic_score_codex":0.0000673679,"about_ca_topic_score_gemma":0.000011147596,"teacher_disagreement_score":0.60308796,"about_ca_system_score_codex":0.00010264925,"about_ca_system_score_gemma":0.00017050908,"threshold_uncertainty_score":0.98833084},"labels":[],"label_agreement":null},{"id":"W2336668525","doi":"10.5489/cuaj.3721","title":"Assessing the utility of cabazitaxel in mCRPC","year":2016,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cabazitaxel; Computer science; Medicine; Internal medicine; Prostate cancer","score_opus":0.045205951619360196,"score_gpt":0.33133099084222384,"score_spread":0.28612503922286364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336668525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92476636,0.00032222967,0.000028498633,0.069639094,0.00009800765,0.000112596696,0.0000121552575,0.0000040875375,0.005016965],"genre_scores_gemma":[0.99852866,0.00011381764,0.00002756271,0.00056972,0.00010793523,0.0000035766734,0.0000015614715,0.0000033392228,0.0006438139],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989676,0.00017145854,0.00021353166,0.00008592062,0.00025293484,0.00030857048],"domain_scores_gemma":[0.99912596,0.00026327927,0.000115706665,0.0000744252,0.00017143745,0.00024917725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010448016,0.000054759614,0.00014556805,0.00009979283,0.000103538,0.000029651974,0.00007698847,0.00010190368,0.00077004253],"category_scores_gemma":[0.0009929586,0.00002383335,0.00006673614,0.00016647414,0.000057768673,0.00009748855,0.000009044163,0.00027695706,0.000012410922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022772943,0.000023849869,0.98131704,0.0000018197778,0.000027076661,0.000048987462,0.000050837843,2.1624086e-7,0.00036131023,0.00003589869,0.002830746,0.015279459],"study_design_scores_gemma":[0.0009348155,0.00008012759,0.98922795,0.000022237427,0.000012905944,0.00003354323,0.00007996671,0.000033594464,0.00012050378,0.0009068189,0.008517618,0.000029903615],"about_ca_topic_score_codex":0.0009679343,"about_ca_topic_score_gemma":0.0010320133,"teacher_disagreement_score":0.07376231,"about_ca_system_score_codex":0.0008293905,"about_ca_system_score_gemma":0.00082834635,"threshold_uncertainty_score":0.84314257},"labels":[],"label_agreement":null},{"id":"W2337584090","doi":"10.1158/1538-7445.am2015-4346","title":"Abstract 4346: Prognostic gene signature for intermediate risk prostate cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital","funders":"","keywords":"Gene signature; Medicine; Prostate cancer; Oncology; Cohort; Internal medicine; Cancer; Watchful waiting; Gene expression; Framingham Risk Score; Disease; Gene; Pathology; Biology; Genetics","score_opus":0.11562471563761231,"score_gpt":0.4515401193544227,"score_spread":0.3359154037168104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337584090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9622401,0.028113538,0.000017076809,0.00295781,0.00055553555,0.0042451303,0.00088642474,0.000097072945,0.00088728644],"genre_scores_gemma":[0.9692792,0.008586479,0.00016616876,0.00010817921,0.0012747628,0.006200078,0.00020929385,0.000106101914,0.014069729],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961955,0.00013002685,0.00035954107,0.00071152585,0.0012797053,0.0013237011],"domain_scores_gemma":[0.99623513,0.00039594094,0.00010643583,0.000475139,0.0018949889,0.00089233747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016953535,0.000272755,0.00041960145,0.00036393446,0.00026192472,0.000108194174,0.00029076613,0.00021189109,0.00045978953],"category_scores_gemma":[0.00096685474,0.00019742742,0.00014604034,0.00069448317,0.00046661866,0.00017220328,0.00016305812,0.0012221335,0.00012449252],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0210846,0.000982184,0.37452212,0.0020911815,0.0013511493,0.00067239004,0.0059702923,0.00021411732,0.078800194,0.00005884653,0.2689451,0.24530782],"study_design_scores_gemma":[0.040948328,0.007320394,0.28590462,0.0028860266,0.00061272085,0.000034929806,0.0019866938,0.00055933354,0.40408793,0.004472149,0.24971879,0.0014680774],"about_ca_topic_score_codex":0.0016262205,"about_ca_topic_score_gemma":0.0004163302,"teacher_disagreement_score":0.32528773,"about_ca_system_score_codex":0.00115931,"about_ca_system_score_gemma":0.0032175037,"threshold_uncertainty_score":0.80508566},"labels":[],"label_agreement":null},{"id":"W2338302780","doi":"10.1038/srep15182","title":"Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis","year":2015,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"National Cancer Institute; Prostate Cancer Foundation","keywords":"Prostate cancer; PTEN; Cancer research; Enzalutamide; Medicine; LNCaP; Gene knockdown; Prostate; Androgen deprivation therapy; Cancer; Biochemical recurrence; PI3K/AKT/mTOR pathway; Biology; Internal medicine; Signal transduction; Androgen receptor; Cell culture; Prostatectomy; Cell biology","score_opus":0.04047699441204022,"score_gpt":0.31637565235398,"score_spread":0.2758986579419398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338302780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99531585,0.0020483534,0.000010990459,0.00040087025,0.00095277553,0.00063206034,0.00004306155,0.000013108936,0.000582955],"genre_scores_gemma":[0.9969121,0.000012611648,0.000109275854,0.0000083168625,0.000025176261,0.000032496715,0.00016753221,0.000009414358,0.0027230566],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980071,0.000053872955,0.00050577335,0.00032998773,0.0008884532,0.00021479286],"domain_scores_gemma":[0.9984728,0.00001405213,0.0004105701,0.00034512885,0.0006544951,0.00010294382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016073616,0.00008870088,0.00017618384,0.000086046064,0.00013447725,0.00003620641,0.000042106873,0.000039835268,0.000035196943],"category_scores_gemma":[0.00016662502,0.000054332664,0.00007206807,0.0005194097,0.000290855,0.00009009805,0.0000466062,0.00008968814,0.0000010829515],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015204854,0.0000932306,0.017261153,0.00013947119,0.000029017969,0.000055324093,0.0022908554,0.00021452688,0.96188444,0.0000053291346,0.017493483,0.00038114414],"study_design_scores_gemma":[0.0005050912,0.000113005546,0.0008714193,0.00032412508,0.000064186905,0.000023396131,0.0010244815,0.00011979592,0.9937159,0.00040749274,0.0027663538,0.00006474558],"about_ca_topic_score_codex":0.00033817074,"about_ca_topic_score_gemma":0.00003238481,"teacher_disagreement_score":0.031831488,"about_ca_system_score_codex":0.00017245354,"about_ca_system_score_gemma":0.0007198841,"threshold_uncertainty_score":0.22156218},"labels":[],"label_agreement":null},{"id":"W2339271150","doi":"10.5489/cuaj.3470","title":"Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone","year":2016,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; CancerCare Manitoba; Hôtel-Dieu de Québec; Sanofi (Canada); Horizon Health Network; Sunnybrook Health Science Centre; London Health Sciences Centre; Grand River Hospital; Université de Montréal","funders":"American Society of Clinical Oncology","keywords":"Cabazitaxel; Medicine; Docetaxel; Prostate cancer; Neutropenia; Internal medicine; Febrile neutropenia; Abiraterone; Oncology; Androgen deprivation therapy; Cancer; Urology; Chemotherapy; Androgen receptor","score_opus":0.0347105101378969,"score_gpt":0.3026776626851829,"score_spread":0.26796715254728604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339271150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98951197,0.00016312445,0.0000011020253,0.008876417,0.000031210788,0.0005696244,0.0007575907,0.0000038379562,0.00008514608],"genre_scores_gemma":[0.9988407,0.00025140608,0.00005362704,0.00025165526,0.000023161887,0.000021212707,0.0000281376,0.000010914682,0.0005191702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807143,0.00023639099,0.00060146104,0.00018848757,0.00038224633,0.0005199702],"domain_scores_gemma":[0.9977562,0.0002129125,0.00038343968,0.00008470871,0.0005353044,0.0010274476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006713872,0.00014101315,0.00045513964,0.00029079727,0.00011148455,0.000019517398,0.00006292603,0.000103105886,0.0002676877],"category_scores_gemma":[0.0008415288,0.00007277908,0.000044529403,0.0002901741,0.000105902676,0.000100926496,0.000006801127,0.00019517133,0.0000016717314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053897733,0.00010550541,0.9898672,0.00003095271,0.00019818678,0.000055120996,0.00025622876,0.00000619887,0.0010923158,0.000018203014,0.000111999165,0.0028683187],"study_design_scores_gemma":[0.009914472,0.0011378638,0.9879582,0.000097720775,0.000056351022,0.0000055312034,0.000056970708,0.000006441266,0.00024733262,0.000011453099,0.0004131314,0.00009454332],"about_ca_topic_score_codex":0.32048774,"about_ca_topic_score_gemma":0.78821313,"teacher_disagreement_score":0.4677254,"about_ca_system_score_codex":0.0019390527,"about_ca_system_score_gemma":0.0041298885,"threshold_uncertainty_score":0.7326245},"labels":[],"label_agreement":null},{"id":"W2340932116","doi":"10.14288/1.0100342","title":"Androgen regulated genes in prostate cancer cells","year":2011,"lang":"en","type":"article","venue":"cIRcle (University of British Columbia)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Androgen; Gene; Prostate; Biology; Cancer; Cancer research; Medicine; Oncology; Internal medicine; Genetics; Hormone","score_opus":0.02007113410744869,"score_gpt":0.21589098550187377,"score_spread":0.1958198513944251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340932116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955971,0.0017088988,0.0000022260074,0.00007738947,0.000058172795,0.000449436,0.00010490718,0.000035009485,0.0019668192],"genre_scores_gemma":[0.9913224,0.0029014417,0.00020073452,0.00001914172,0.000012007043,0.0000018755604,0.000021235017,0.000012633558,0.005508517],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99918604,0.000027500084,0.00009122683,0.0002651527,0.0001745315,0.00025553582],"domain_scores_gemma":[0.9995045,0.0000071950394,0.00005110759,0.00017280497,0.00013745937,0.00012690604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008855708,0.00003655287,0.00023125594,0.00006411728,0.0000686934,0.000013760957,0.000106005624,0.000066467284,0.0004987372],"category_scores_gemma":[0.0000029383807,0.00010705419,0.00006787861,0.00031341895,0.00020608239,0.00012876112,0.000061583385,0.00010049861,0.000016532076],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002916592,0.00037333116,0.43608442,0.00020677391,0.0001267734,0.0021960177,0.001182961,0.0000017211428,0.0078028836,2.8982808e-7,0.0019019163,0.5498313],"study_design_scores_gemma":[0.0031385117,0.00016664105,0.9944016,0.0002656688,0.00005036334,0.00003862502,0.0007928139,0.000044625718,0.0005659007,0.000057592344,0.00036999222,0.00010771763],"about_ca_topic_score_codex":0.21639073,"about_ca_topic_score_gemma":0.20162523,"teacher_disagreement_score":0.5583171,"about_ca_system_score_codex":0.00011967234,"about_ca_system_score_gemma":0.00017975246,"threshold_uncertainty_score":0.81294304},"labels":[],"label_agreement":null},{"id":"W2342997665","doi":"10.1042/bse0400121","title":"Nuclear receptors and disease: androgen receptor","year":2004,"lang":"en","type":"review","venue":"Essays in Biochemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; John Abbott College","funders":"","keywords":"Apoptosis; Programmed cell death; Receptor; Cell biology; Immune system; Biology; Homeostasis; Cell; Disease; Cancer research; Immunology; Medicine; Pathology; Biochemistry","score_opus":0.028162894756714723,"score_gpt":0.33886909440976737,"score_spread":0.31070619965305263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2342997665","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002621871,0.99632704,1.1914415e-7,0.00021984128,0.00012029423,0.0005861237,0.00009872563,0.000048977814,0.0023366704],"genre_scores_gemma":[0.00006169808,0.9942708,0.00012695702,0.000023783688,0.00021626697,0.00009658075,0.0007430563,0.000074960815,0.004385914],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984679,0.00003302573,0.00032772118,0.0005686741,0.00025722373,0.00034543878],"domain_scores_gemma":[0.99891925,0.00003718906,0.00009479261,0.00041396162,0.000031781685,0.0005030278],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013039412,0.00036239682,0.0009366136,0.000108099186,0.000053648284,0.0000304605,0.00014162927,0.00037765337,0.00050343695],"category_scores_gemma":[0.00013046828,0.0002765249,0.00020972113,0.0002838113,0.00020818981,0.000027503864,0.00012352437,0.0005308509,0.00008195819],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019239937,0.0003497765,0.0003422963,0.12778084,0.00032973237,0.0004726996,0.00007038443,4.2467477e-8,0.00005204916,0.00006290348,0.010465311,0.8598816],"study_design_scores_gemma":[0.0009227423,0.000040411822,0.000002704612,0.036341704,0.00031613183,0.000050331928,0.000023492454,2.6038416e-7,0.00015863818,0.000064216634,0.96179014,0.0002892107],"about_ca_topic_score_codex":0.0000062526938,"about_ca_topic_score_gemma":1.5607971e-7,"teacher_disagreement_score":0.9513248,"about_ca_system_score_codex":0.0006075043,"about_ca_system_score_gemma":0.0010430787,"threshold_uncertainty_score":0.9999687},"labels":[],"label_agreement":null},{"id":"W2343066893","doi":"","title":"Tracer kinetic analysis of [18F]DCFPyL, a promising PSMA imaging agent, in mouse xenografts of prostate cancer","year":2015,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McMaster University; University of Alberta","funders":"","keywords":"LNCaP; Radiosynthesis; Chemistry; Prostate cancer; Glutamate carboxypeptidase II; Pharmacokinetics; Biodistribution; Imaging agent; Positron emission tomography; Cancer research; In vivo; Nuclear medicine; Cancer; Biochemistry; Medicine; In vitro; Pharmacology; Internal medicine; Biology","score_opus":0.051784893337876656,"score_gpt":0.3678857742906305,"score_spread":0.31610088095275385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343066893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933032,0.0028969676,0.000026795542,0.0008739319,0.000039466406,0.0006655391,0.000032965603,0.000023226128,0.002137901],"genre_scores_gemma":[0.99371123,0.00041424975,0.000521592,0.00005776063,0.00002328782,0.00006567708,0.00003679901,0.000020071395,0.005149345],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99853367,0.000050693237,0.0004195033,0.00025560643,0.00042189544,0.0003186386],"domain_scores_gemma":[0.99911565,0.00002907182,0.00012068603,0.00026918238,0.00028965023,0.00017578596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003194799,0.00014062106,0.00053367333,0.0007686585,0.000014633778,0.00001085142,0.00007723024,0.000032133357,0.00022411818],"category_scores_gemma":[0.0000476423,0.00009964677,0.00013446946,0.0014409377,0.00012691211,0.00011598274,0.000043233274,0.00011943594,0.0000025305146],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011415548,0.00057701446,0.9113773,0.00028876777,0.0010606047,0.000101661724,0.0048550502,0.0005427263,0.07044014,0.00001599684,0.0007002231,0.008898937],"study_design_scores_gemma":[0.02290623,0.0009528472,0.3590968,0.000804043,0.003826926,0.00001778072,0.0051121074,0.029120611,0.57556236,0.000113180315,0.0019150435,0.0005720907],"about_ca_topic_score_codex":0.00410468,"about_ca_topic_score_gemma":0.0008565769,"teacher_disagreement_score":0.55228055,"about_ca_system_score_codex":0.0002014373,"about_ca_system_score_gemma":0.0003022611,"threshold_uncertainty_score":0.62050754},"labels":[],"label_agreement":null},{"id":"W2343558773","doi":"10.18632/oncotarget.9045","title":"Bone marrow mesenchymal stem cells participate in prostate carcinogenesis and promote growth of prostate cancer by cell fusion <i>in vivo</i>","year":2016,"lang":"en","type":"article","venue":"Oncotarget","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Cancer research; Carcinogenesis; Bone marrow; Cancer; Stromal cell; Cancer stem cell; Tramp; Tumor microenvironment; Oncology; Stem cell; Internal medicine; Biology","score_opus":0.015512437185546055,"score_gpt":0.2706022970848877,"score_spread":0.25508985989934163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343558773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98963696,0.005777962,0.0000014753454,0.0021931743,0.00008578163,0.0014747363,0.00035976185,0.0000229442,0.00044720352],"genre_scores_gemma":[0.9797778,0.007821922,0.00009164319,0.00006797557,0.000029921252,0.0003011634,0.000012482218,0.0000452,0.011851891],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99777025,0.00011588744,0.00049273786,0.00051408884,0.00041533096,0.000691725],"domain_scores_gemma":[0.9991796,0.000057530302,0.00014161502,0.00024351756,0.00012618725,0.00025154813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041597505,0.00026368935,0.0005545551,0.00025428185,0.000041009698,0.000012626104,0.00008109927,0.00009413009,0.00013440374],"category_scores_gemma":[0.000009233554,0.0001660494,0.000060682225,0.00047057826,0.00016803195,0.00015512579,0.000095784686,0.00014606654,0.000009494927],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009573374,0.00022209354,0.43850467,0.00040682656,0.000015418284,0.00015235848,0.00082477316,0.0000012093193,0.5563193,0.0000029503317,0.0012665754,0.0013265087],"study_design_scores_gemma":[0.007536861,0.00069554045,0.019197425,0.00069148245,0.000043621887,0.0000057087996,0.00011223708,0.00008593998,0.9689162,0.000057911195,0.0024340325,0.0002230736],"about_ca_topic_score_codex":0.0012022705,"about_ca_topic_score_gemma":0.00025823718,"teacher_disagreement_score":0.41930723,"about_ca_system_score_codex":0.00035187812,"about_ca_system_score_gemma":0.0003237152,"threshold_uncertainty_score":0.67712986},"labels":[],"label_agreement":null},{"id":"W2343855777","doi":"10.1016/j.jval.2015.03.1174","title":"Use of Abiraterone in The Management of Castration-Resistant Prostate Cancer: a Real-Life Cost-Effectiveness Study","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Internal medicine; Abiraterone acetate; Oncology; Cabazitaxel; Cohort; Proportional hazards model; Chemotherapy; Androgen deprivation therapy; Cancer","score_opus":0.28544486676665515,"score_gpt":0.4453572295609907,"score_spread":0.15991236279433557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343855777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920118,0.0010380801,0.0000032278826,0.0010124871,0.00005700909,0.0057513807,0.000035741592,0.0000064240353,0.00008384827],"genre_scores_gemma":[0.99735934,0.0017669138,0.00008616664,0.000038912487,0.00001241465,0.00064671825,0.000013471405,0.0000107343,0.00006533849],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980269,0.00061663555,0.00045756807,0.00019304248,0.00045504718,0.00025081215],"domain_scores_gemma":[0.9992556,0.00011968897,0.00013573108,0.00026962854,0.00011160245,0.00010775293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019246974,0.00009838331,0.0003390249,0.00015012846,0.000023761444,0.000008416818,0.00007795447,0.000023921963,0.0000031646691],"category_scores_gemma":[0.00002439299,0.000062561216,0.000022361919,0.0005036705,0.00005790567,0.00006340077,0.000027989818,0.00012404186,8.569472e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008459797,0.003548798,0.9447293,0.004573997,0.00021475313,0.00031204475,0.022603003,0.008337115,0.00050681893,0.0006319982,0.00012970707,0.005952638],"study_design_scores_gemma":[0.0075993603,0.0028992204,0.979564,0.0012298151,0.000031454507,0.000001850552,0.007561141,0.0005091137,0.00036891177,0.00006123927,0.000112039874,0.00006183372],"about_ca_topic_score_codex":0.070381366,"about_ca_topic_score_gemma":0.0014202789,"teacher_disagreement_score":0.06896109,"about_ca_system_score_codex":0.00051569013,"about_ca_system_score_gemma":0.0008230437,"threshold_uncertainty_score":0.935809},"labels":[],"label_agreement":null},{"id":"W2344412413","doi":"10.1016/j.jsbmb.2016.04.008","title":"Progesterone receptor in the prostate: A potential suppressor for benign prostatic hyperplasia and prostate cancer","year":2016,"lang":"en","type":"review","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada","keywords":"Prostate cancer; Androgen receptor; Stromal cell; Cancer research; Prostate; Carcinogenesis; Stroma; Biology; Internal medicine; Androgen; Endocrinology; Hyperplasia; Receptor; Cancer; Medicine; Hormone; Immunohistochemistry","score_opus":0.019826490032162986,"score_gpt":0.35666107748987746,"score_spread":0.3368345874577145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344412413","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06497455,0.92975277,0.000018704377,0.0024458107,0.000079055164,0.0023895465,0.00032550812,0.0000036250087,0.0000104460305],"genre_scores_gemma":[0.008556888,0.99017584,0.0001256131,0.00011343234,0.00017364224,0.00034577076,0.00010066348,0.000034247336,0.00037391225],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982713,0.00029180077,0.00059805857,0.00027671506,0.00017219044,0.0003899658],"domain_scores_gemma":[0.9988373,0.00017220304,0.00048107153,0.00024184,0.00015376684,0.00011383701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076759065,0.00034297086,0.00095411384,0.00008812687,0.00009767511,0.000036812926,0.00023727815,0.00025594528,0.000008118258],"category_scores_gemma":[0.00007336811,0.00013697427,0.00017073593,0.00010700175,0.00047935886,0.000034700286,0.000090070505,0.0004567389,6.170732e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050805174,0.00033603335,0.00016870521,0.029171469,0.0015741141,0.00026796226,0.0015318169,1.5867724e-7,0.22530323,0.000021384758,0.0011565445,0.73538804],"study_design_scores_gemma":[0.0147802485,0.006998315,0.000037860176,0.03694854,0.0048479936,0.012729981,0.0010095899,0.000003832249,0.06413495,0.00044242336,0.8571704,0.0008958384],"about_ca_topic_score_codex":0.000004438419,"about_ca_topic_score_gemma":8.994692e-7,"teacher_disagreement_score":0.8560139,"about_ca_system_score_codex":0.0000754438,"about_ca_system_score_gemma":0.00046170337,"threshold_uncertainty_score":0.55856484},"labels":[],"label_agreement":null},{"id":"W2345488406","doi":"10.1200/jco.2015.33.7_suppl.178","title":"Comparison of active surveillance with other treatment options for low-risk prostate cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; SABR volatility model; Salvage therapy; Brachytherapy; Radiation therapy; Surgery; Cohort; Internal medicine; Urology; Cancer; Chemotherapy","score_opus":0.29605898496414546,"score_gpt":0.5816284992766806,"score_spread":0.28556951431253513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345488406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903309,0.0022270645,0.00019642153,0.005230518,0.00040114045,0.0006889316,0.000100502926,0.00000569538,0.0008188401],"genre_scores_gemma":[0.9915826,0.0026938997,0.0037788686,0.00010145244,0.00054068625,0.000050822535,0.000006945864,0.0000180367,0.0012267246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979643,0.00025377123,0.0011657435,0.00013823257,0.0002754543,0.00020247104],"domain_scores_gemma":[0.99549353,0.001379329,0.0015565851,0.00012965062,0.001085256,0.00035564267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013163066,0.00011167533,0.0013299999,0.000074006064,0.00003203187,0.00000395489,0.000074609154,0.00014384408,0.000030217498],"category_scores_gemma":[0.0008330909,0.00005845345,0.0002464665,0.00011148026,0.00026039386,0.000058327067,0.00001296394,0.00031965374,0.0000026165144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05384937,0.003942161,0.7624999,0.00003825046,0.0013736202,0.00004188565,0.0008643243,0.00032818117,0.0000824437,0.000027928349,0.0023971526,0.17455477],"study_design_scores_gemma":[0.09200791,0.21444775,0.42494214,0.0003655239,0.0012301267,0.000083395025,0.002413734,0.0007520631,0.004701803,0.00044925188,0.2583837,0.00022261804],"about_ca_topic_score_codex":0.00017765554,"about_ca_topic_score_gemma":0.0005061778,"teacher_disagreement_score":0.3375578,"about_ca_system_score_codex":0.00043963292,"about_ca_system_score_gemma":0.0036328724,"threshold_uncertainty_score":0.64445597},"labels":[],"label_agreement":null},{"id":"W2345499901","doi":"10.1158/1078-0432.ccr-15-2901","title":"Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Medical Research and Materiel Command; Canadian Institutes of Health Research","keywords":"Enzalutamide; Androgen receptor; Prostate cancer; Transactivation; LNCaP; Cancer research; In vivo; Biology; Mediator; Coactivator; Chemistry; Cancer; Transcription factor; Cell biology; Gene; Biochemistry; Genetics","score_opus":0.12729191842097548,"score_gpt":0.4604209835904444,"score_spread":0.33312906516946894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345499901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95897335,0.0012949712,0.0003376751,0.035227668,0.00028623102,0.0029604167,0.00016367876,0.00007407936,0.0006819344],"genre_scores_gemma":[0.9731711,0.0029748906,0.0008592063,0.0004047717,0.0005175627,0.002210475,0.000038763363,0.0000730492,0.01975015],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99559027,0.0004288965,0.000713423,0.00092276913,0.0013690949,0.00097555947],"domain_scores_gemma":[0.9970755,0.0008018051,0.00011700128,0.00045709932,0.0010062648,0.0005423501],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026995563,0.00023534858,0.00048801495,0.0003627836,0.00025393584,0.00006547633,0.0002031586,0.00018081079,0.0011951298],"category_scores_gemma":[0.000739537,0.00013990075,0.00008465392,0.0013097282,0.00030518352,0.00028606784,0.00010814706,0.00069434545,0.00011108614],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09608787,0.00097420125,0.22735316,0.0005709389,0.0004758428,0.0001645138,0.00091039774,0.00006082092,0.5849362,0.001183264,0.03041289,0.05686991],"study_design_scores_gemma":[0.043960776,0.0127135785,0.49768555,0.012398228,0.00017723725,0.000004914384,0.0020636264,0.00006253338,0.22859251,0.0055727246,0.19505619,0.0017121268],"about_ca_topic_score_codex":0.0010165138,"about_ca_topic_score_gemma":0.0024029317,"teacher_disagreement_score":0.3563437,"about_ca_system_score_codex":0.0013975713,"about_ca_system_score_gemma":0.0018762812,"threshold_uncertainty_score":0.9997179},"labels":[],"label_agreement":null},{"id":"W2345590823","doi":"10.1186/s13550-016-0195-6","title":"Automated synthesis of [18F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models","year":2016,"lang":"en","type":"article","venue":"EJNMMI Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McMaster University; University of Alberta","funders":"Canadian Institutes of Health Research; Movember Foundation","keywords":"LNCaP; Biodistribution; Prostate cancer; Radiosynthesis; Glutamate carboxypeptidase II; Pharmacokinetics; Medicine; Internalization; Positron emission tomography; Cancer research; Nuclear medicine; Cancer; Chemistry; Biochemistry; Pharmacology; In vitro; Internal medicine","score_opus":0.1324166819436146,"score_gpt":0.4631517041961011,"score_spread":0.33073502225248647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345590823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880231,0.0018231203,0.000027595606,0.0059456034,0.000052072257,0.0012376053,0.000043557087,0.0000887595,0.0027585777],"genre_scores_gemma":[0.99005663,0.0061529935,0.00015106007,0.000006427666,0.000055527882,0.00043578286,0.0000105047275,0.00002444614,0.0031066167],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997621,0.00040775986,0.00031745594,0.00039313038,0.00080525316,0.00045541354],"domain_scores_gemma":[0.99800205,0.0010557726,0.000056239438,0.00026997295,0.00045291946,0.00016301849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021433798,0.00011611298,0.00032706742,0.0004959619,0.00006895344,0.000019328521,0.000097732795,0.000100914454,0.000116053314],"category_scores_gemma":[0.0007527877,0.000071834045,0.00004436117,0.00059561065,0.00031251984,0.00024810428,0.000088953144,0.00021696436,0.000015426293],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005151009,0.0009745284,0.28757933,0.00097596773,0.000285731,0.00013626595,0.0013069471,0.00006637334,0.19949228,0.00023461916,0.003085216,0.50071174],"study_design_scores_gemma":[0.008045985,0.0012622532,0.16465022,0.0023825981,0.00006816809,0.000017198474,0.00015415116,0.024522414,0.7953935,0.0019145111,0.0012892014,0.0002997468],"about_ca_topic_score_codex":0.0005006163,"about_ca_topic_score_gemma":0.000045621226,"teacher_disagreement_score":0.59590125,"about_ca_system_score_codex":0.00036456628,"about_ca_system_score_gemma":0.00035036344,"threshold_uncertainty_score":0.29293075},"labels":[],"label_agreement":null},{"id":"W2345934280","doi":"10.1097/00042871-200701010-00174","title":"INTERMITTENT ANDROGEN SUPPRESSION IN THE TREATMENT OF PROSTATE CANCER: AN UPDATE OF THE VANCOUVER EXPERIENCE.","year":2007,"lang":"en","type":"article","venue":"Journal of Investigative Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Prostate cancer; Androgen suppression; Medicine; Androgen; Urology; Oncology; Prostate; Gynecology; Internal medicine; Cancer; Hormone","score_opus":0.06175597628912276,"score_gpt":0.37472997637808575,"score_spread":0.312974000088963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345934280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98906773,0.0035855952,0.000005630574,0.0062731015,0.00033888975,0.00053839065,0.000007985733,0.0000018290929,0.00018086146],"genre_scores_gemma":[0.99690145,0.0022257452,0.000108235196,0.00030549467,0.00019497673,0.000014194292,0.0000031238583,0.000009332869,0.00023743267],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981137,0.00015719197,0.0007016575,0.000117070864,0.00070333586,0.00020707313],"domain_scores_gemma":[0.99855787,0.000110142515,0.0005687435,0.00024233838,0.00036208998,0.00015884872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076361524,0.00014543682,0.0004765288,0.00018135013,0.00004397729,0.000002656382,0.00021042346,0.00004143796,0.000070819595],"category_scores_gemma":[0.00012370582,0.000052331805,0.000100629826,0.00042080527,0.0013832692,0.00010874007,0.00001992711,0.00020387542,1.8530463e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003348006,0.0014814822,0.62072057,0.00016947399,0.00032528443,0.00040852602,0.16427392,0.000024849674,0.16971985,0.0000721085,0.004329198,0.03512675],"study_design_scores_gemma":[0.008657586,0.0071873814,0.25082856,0.0020935428,0.00020262577,0.000084684485,0.025807548,0.0000320832,0.69873893,0.0006514481,0.005636806,0.00007880847],"about_ca_topic_score_codex":0.00023021536,"about_ca_topic_score_gemma":0.0003390433,"teacher_disagreement_score":0.52901906,"about_ca_system_score_codex":0.00022148601,"about_ca_system_score_gemma":0.0002747291,"threshold_uncertainty_score":0.50967133},"labels":[],"label_agreement":null},{"id":"W2346316361","doi":"10.4137/bic.s31802","title":"The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements","year":2016,"lang":"en","type":"review","venue":"Biomarkers in Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Notre-Dame","funders":"Canadian Institutes of Health Research","keywords":"Proteomics; Prostate cancer; Genomics; Biomarker discovery; Cancer; Computational biology; Disease; Immunotherapy; Medicine; Biology; Internal medicine; Genome","score_opus":0.030681547296808886,"score_gpt":0.3717864615792927,"score_spread":0.3411049142824838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346316361","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015787637,0.9898268,3.5908002e-7,0.002382938,0.00061767444,0.0050115287,0.00040830986,0.00001065848,0.00016297492],"genre_scores_gemma":[0.00004533251,0.99632424,0.00011686157,0.000015543772,0.00027443,0.0025904437,0.000042314336,0.00006447087,0.0005263502],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974101,0.00021136327,0.00080519175,0.0006833495,0.00024632592,0.00064365496],"domain_scores_gemma":[0.9987471,0.00017595934,0.00042479084,0.00044272447,0.00008467268,0.00012472006],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005179396,0.00046161437,0.0013243163,0.00040735156,0.00008813138,0.000025337484,0.00022314583,0.0002947765,0.000038044014],"category_scores_gemma":[0.00001943872,0.0002569253,0.00013351427,0.00041830342,0.0008208438,0.00007749316,0.00025251677,0.0003360354,0.0000014164282],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014522219,0.00006178885,0.004608698,0.007510336,0.0019656864,0.00004699633,0.00013735415,4.04861e-8,0.00009386096,0.000011544994,0.0006401429,0.98347133],"study_design_scores_gemma":[0.0035800617,0.00017790784,0.0014075574,0.0139198275,0.000224059,0.000022074128,0.00014494879,0.0000035753471,0.00011067055,0.000047349622,0.9800908,0.00027117215],"about_ca_topic_score_codex":0.000975513,"about_ca_topic_score_gemma":0.00044248582,"teacher_disagreement_score":0.98320013,"about_ca_system_score_codex":0.0013624715,"about_ca_system_score_gemma":0.0013436894,"threshold_uncertainty_score":0.9999883},"labels":[],"label_agreement":null},{"id":"W2346791303","doi":"10.1200/jco.2015.33.18_suppl.lba5002","title":"A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McGill University Health Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Docetaxel; Hazard ratio; Prostate cancer; Prednisone; Urology; Clinical endpoint; Radiation therapy; Stage (stratigraphy); Chemotherapy; Internal medicine; Androgen deprivation therapy; Oncology; Cancer; Surgery; Randomized controlled trial; Confidence interval","score_opus":0.08920992381682366,"score_gpt":0.5058327657049976,"score_spread":0.4166228418881739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346791303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710548,0.0027451168,0.00007570154,0.0045967754,0.00022022185,0.02101848,0.00007589716,0.00001134768,0.00020164094],"genre_scores_gemma":[0.9703576,0.012015693,0.0046308334,0.0007226423,0.0007030254,0.008755605,0.00003167586,0.00009755234,0.0026853879],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969944,0.00027860122,0.0014332185,0.00039277272,0.00051669695,0.00038435264],"domain_scores_gemma":[0.99585444,0.0010226187,0.0014175926,0.00019452094,0.0006386836,0.0008721753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020335023,0.00026906905,0.0016758803,0.00011424295,0.000086790475,0.000024930518,0.0001138304,0.00026544536,0.000059646798],"category_scores_gemma":[0.00087853696,0.00015745482,0.00014738431,0.00013265149,0.00069174723,0.00019818089,0.00007337298,0.00057403604,8.1988844e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.700618,0.0044689607,0.040912498,0.00042536305,0.0020365762,0.00049950636,0.0008124583,0.0000045856127,0.0024053429,0.000024830226,0.027544878,0.22024696],"study_design_scores_gemma":[0.6227087,0.16485152,0.0011865462,0.0005582624,0.0012087441,0.00048604544,0.00049162534,0.00029829695,0.013473718,0.00079699495,0.19365528,0.00028428735],"about_ca_topic_score_codex":0.00031006965,"about_ca_topic_score_gemma":0.000054294047,"teacher_disagreement_score":0.21996267,"about_ca_system_score_codex":0.00014826252,"about_ca_system_score_gemma":0.0024224578,"threshold_uncertainty_score":0.6420821},"labels":[],"label_agreement":null},{"id":"W2356434884","doi":"10.1016/j.eururo.2016.04.028","title":"SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition","year":2016,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; BC Cancer Agency; Simon Fraser University; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Cancer research; Medicine; Androgen receptor; Adenocarcinoma; Prostate; RNA splicing; Biology; LNCaP; Bioinformatics; Cancer; RNA; Gene; Internal medicine; Genetics","score_opus":0.02049081329495721,"score_gpt":0.2548148578924346,"score_spread":0.23432404459747735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2356434884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893963,0.00061079045,0.00036035062,0.0072636483,0.00012743348,0.00040677717,0.000050052393,0.000063857646,0.0017208377],"genre_scores_gemma":[0.99715155,0.00047830667,0.0000381144,0.00025182782,0.000112704685,0.0000118796015,0.000092959715,0.00003987013,0.0018227804],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986789,0.00030665137,0.0002633582,0.00029658194,0.00016576485,0.0002887439],"domain_scores_gemma":[0.9994331,0.000060048158,0.00008701784,0.00022203957,0.00008771556,0.00011009403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010820872,0.0001376185,0.00021455988,0.00014211916,0.00004321398,0.0000054208485,0.000057988127,0.0000227979,0.0003747721],"category_scores_gemma":[0.00003435274,0.0000848479,0.00007895927,0.00011165232,0.00017857188,0.000073386575,0.000040496037,0.000103385464,0.00016423689],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024002374,0.0003668584,0.08536275,0.00010488082,0.0001647896,0.00044957534,0.0005714186,0.0000021839683,0.8802516,0.000734068,0.0009933435,0.028598314],"study_design_scores_gemma":[0.011793715,0.0046047643,0.5632751,0.000092940325,0.00013919611,0.00025539967,0.000062591775,0.000016275206,0.4058028,0.00046633085,0.013263934,0.00022695493],"about_ca_topic_score_codex":0.0000029130024,"about_ca_topic_score_gemma":0.0000021041237,"teacher_disagreement_score":0.47791237,"about_ca_system_score_codex":0.00003373429,"about_ca_system_score_gemma":0.000051445608,"threshold_uncertainty_score":0.41034916},"labels":[],"label_agreement":null},{"id":"W2374022147","doi":"","title":"Role of Macrophages in the Development of Castration-Resistant Prostate Cancer","year":2016,"lang":"en","type":"dissertation","venue":"The Atrium (University of Guelph)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Castration; Medicine; Oncology; Internal medicine; Cancer research; Cancer; Hormone","score_opus":0.01841813085871795,"score_gpt":0.28006687497015503,"score_spread":0.26164874411143707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2374022147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925294,0.0030101987,0.0000012719354,0.0006380437,0.000040834933,0.0006416707,0.0000977933,0.0000042092884,0.0030365563],"genre_scores_gemma":[0.9892438,0.0010702912,0.000117751675,0.0000035831833,0.000017851424,0.0000028814695,0.00015275447,0.000009120828,0.009381962],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99904627,0.00006114683,0.00020147335,0.00014001239,0.00039912443,0.00015195877],"domain_scores_gemma":[0.9991355,0.000069556656,0.00028780458,0.00023386015,0.00024508822,0.000028222723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027746637,0.00011651924,0.00029578857,0.00014746652,0.000098951,0.0000027398467,0.00026883755,0.00008360461,0.0001469628],"category_scores_gemma":[0.0000102011045,0.000067446825,0.00009397963,0.00023749084,0.0001392524,0.000045675228,0.000028888202,0.00014008435,0.000003992156],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004051105,0.00015473315,0.0030946967,0.00087381236,0.00030287186,0.000021006554,0.047219306,0.0000022614727,0.92906046,0.00007741455,0.00020008822,0.014942245],"study_design_scores_gemma":[0.0022164683,0.00022974372,0.8602154,0.0008498134,0.00027669006,0.0000014369213,0.05978693,0.0000049488835,0.07513422,0.00014812416,0.001022353,0.00011381473],"about_ca_topic_score_codex":0.0013234909,"about_ca_topic_score_gemma":0.003745598,"teacher_disagreement_score":0.85712075,"about_ca_system_score_codex":0.00010542367,"about_ca_system_score_gemma":0.00082029955,"threshold_uncertainty_score":0.27504018},"labels":[],"label_agreement":null},{"id":"W2382331405","doi":"10.1200/jco.2015.33.7_suppl.139","title":"Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Clinical endpoint; Prostate cancer; Docetaxel; Internal medicine; Hazard ratio; Cabazitaxel; Enzalutamide; Urology; Prednisone; Oncology; Cancer; Gastroenterology; Randomized controlled trial; Androgen deprivation therapy; Confidence interval; Androgen receptor","score_opus":0.23504232106123368,"score_gpt":0.48438863708896096,"score_spread":0.24934631602772728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2382331405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956667,0.00252889,0.000006646971,0.0008427754,0.000120455865,0.0006369296,0.00007164066,0.0000053596427,0.00012058943],"genre_scores_gemma":[0.9940377,0.0039731977,0.0014071588,0.00007949541,0.000058122543,0.000027553268,0.000029408435,0.000017189599,0.0003702162],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99633616,0.00049207464,0.0019753422,0.00029126278,0.00057376776,0.00033137354],"domain_scores_gemma":[0.99590117,0.0010657113,0.0014205745,0.00016722335,0.0009300781,0.00051522546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019514596,0.00020952709,0.0020927538,0.00043928242,0.00003368887,0.000019717489,0.00009413657,0.0001502387,0.000049185484],"category_scores_gemma":[0.0011237322,0.000118708456,0.00015504542,0.000772021,0.00043276558,0.00019659863,0.00004646607,0.00048474857,6.741995e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14920783,0.002558464,0.8105881,0.00015108341,0.0044040647,0.00078720384,0.0008435394,0.00016864302,0.00018986828,0.0000085575275,0.00017947747,0.030913172],"study_design_scores_gemma":[0.07792339,0.04553999,0.8684732,0.0002879293,0.0056358986,0.00003937923,0.00059349247,0.00049236853,0.00020710696,0.00001843678,0.0006455524,0.0001432778],"about_ca_topic_score_codex":0.00062200194,"about_ca_topic_score_gemma":0.0032231384,"teacher_disagreement_score":0.07128445,"about_ca_system_score_codex":0.00022865357,"about_ca_system_score_gemma":0.002284281,"threshold_uncertainty_score":0.48407903},"labels":[],"label_agreement":null},{"id":"W2385742736","doi":"10.1038/modpathol.2016.88","title":"Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH","year":2016,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"DOD Prostate Cancer Research Program; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Canary Foundation; Congressionally Directed Medical Research Programs; National Cancer Institute; Prostate Cancer Foundation","keywords":"PTEN; Immunohistochemistry; Prostate cancer; Biology; Cancer research; Immunostaining; Pathology; Cancer; Medicine; PI3K/AKT/mTOR pathway; Genetics; Apoptosis","score_opus":0.051964775600334585,"score_gpt":0.4067279610610453,"score_spread":0.35476318546071073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2385742736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993947,0.0010463988,0.00059221167,0.0032691439,0.000045966277,0.00040083885,0.00010030997,0.000022857756,0.0005752204],"genre_scores_gemma":[0.9949569,0.00056138664,0.000138167,0.000093121045,0.0000308441,0.00012997155,0.000104821855,0.000021065107,0.0039636935],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984681,0.00013799548,0.00050181965,0.00037398288,0.00021958983,0.00029850347],"domain_scores_gemma":[0.99913025,0.000121280675,0.00020504389,0.00033023933,0.00012430332,0.000088888824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049059495,0.0001382138,0.00056496786,0.00008296084,0.000023779603,0.000004433161,0.0000953823,0.00012975425,0.000073726194],"category_scores_gemma":[0.00008711152,0.00008100352,0.00006607316,0.00013933111,0.00028143887,0.000052676885,0.000038108534,0.00020552047,0.000005514464],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015600935,0.00047062908,0.7719038,0.000098724166,0.0001130565,0.00014980503,0.00045925882,0.000014849149,0.194583,0.0000018784001,0.0015192307,0.02912566],"study_design_scores_gemma":[0.041331094,0.0026534172,0.41718358,0.0014784433,0.00057110953,0.00016284575,0.00029593383,0.005695939,0.5268634,0.00067983277,0.0023532226,0.00073122303],"about_ca_topic_score_codex":0.00011905081,"about_ca_topic_score_gemma":0.00003544127,"teacher_disagreement_score":0.35472026,"about_ca_system_score_codex":0.0001608359,"about_ca_system_score_gemma":0.00023311247,"threshold_uncertainty_score":0.33032274},"labels":[],"label_agreement":null},{"id":"W2388122605","doi":"10.1158/1078-0432.ccr-16-0381","title":"Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or <i>Frenemy</i>?","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Androgen receptor; Testosterone (patch); Androgen; Receptor; Signal transduction; Endocrinology; DNA repair; Internal medicine; Biology; DNA; Medicine; Cell biology; Genetics; Hormone; Cancer; Prostate cancer","score_opus":0.2828770154323315,"score_gpt":0.5202913688394077,"score_spread":0.23741435340707623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2388122605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97838175,0.007401997,0.000004228324,0.012151601,0.00015027676,0.0009506581,0.00004242429,0.00008189647,0.0008351803],"genre_scores_gemma":[0.9540366,0.02641096,0.00046326197,0.00037612813,0.0008308024,0.00045043865,0.00001117544,0.00006201411,0.017358653],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99636114,0.0005195058,0.00064267113,0.00077833876,0.00082046504,0.0008778818],"domain_scores_gemma":[0.99636,0.002203698,0.000054255634,0.0004650745,0.00032794618,0.0005890182],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035432389,0.00017986493,0.0005358552,0.000283995,0.00013344253,0.00003325179,0.00018106718,0.00022808395,0.0015919473],"category_scores_gemma":[0.0015534712,0.00009588167,0.00013036543,0.0006355507,0.00088373723,0.00013083545,0.00027189904,0.0006642698,0.00012881726],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011779535,0.0006996749,0.67270344,0.00033469245,0.00023293192,0.00052949495,0.00019834275,2.6792995e-7,0.05831023,0.000054852382,0.021308646,0.23384789],"study_design_scores_gemma":[0.066016175,0.016013991,0.20943148,0.008425959,0.00019367902,0.0001215573,0.0007707316,0.000104540304,0.16557573,0.0012809373,0.5308096,0.0012556514],"about_ca_topic_score_codex":0.00025767527,"about_ca_topic_score_gemma":0.00029925897,"teacher_disagreement_score":0.5095009,"about_ca_system_score_codex":0.00038199138,"about_ca_system_score_gemma":0.0011064339,"threshold_uncertainty_score":0.99932075},"labels":[],"label_agreement":null},{"id":"W2394733107","doi":"10.1158/1535-7163.targ-15-b29","title":"Abstract B29: A multicenter, open-label phase 1/2 study of oral CFG920, in combination with prednisone in adult patients with metastatic castration-resistant prostate cancer","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Adverse effect; Prednisone; Abiraterone acetate; Internal medicine; Hyponatremia; Enzalutamide; Pharmacokinetics; Cancer; Androgen deprivation therapy; Urology; Pharmacology; Androgen receptor","score_opus":0.08138194030855352,"score_gpt":0.39718238655424015,"score_spread":0.31580044624568665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2394733107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937498,0.0008789511,0.000026626969,0.00041682672,0.000044309898,0.004707352,0.00010519269,0.000012703459,0.00005824395],"genre_scores_gemma":[0.9980566,0.0001525631,0.00049120537,0.00016882319,0.000004196249,0.0008989586,0.000109732275,0.000050680275,0.00006726169],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979577,0.00011703925,0.00043392164,0.00038334323,0.0007490314,0.000358944],"domain_scores_gemma":[0.9986539,0.000019165593,0.00017105002,0.00029678462,0.0007210556,0.00013808024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020787962,0.00025843692,0.00046626848,0.00021196798,0.00003538882,0.00005167239,0.00016622072,0.000043212192,0.0000147599785],"category_scores_gemma":[0.000010157652,0.00017943737,0.000017173117,0.00061865564,0.00009392861,0.00021182012,0.000043209107,0.00022836792,8.2105294e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08437713,0.064849466,0.76609135,0.00054480747,0.0018686713,0.00090518844,0.02007076,0.001655768,0.02479316,0.000028835946,0.000022689197,0.03479219],"study_design_scores_gemma":[0.61816716,0.030382395,0.30824265,0.0018415333,0.0010622705,0.0000035285989,0.007530757,0.004014673,0.027799929,0.000054619726,0.00017203156,0.00072847644],"about_ca_topic_score_codex":0.0071308874,"about_ca_topic_score_gemma":0.011401187,"teacher_disagreement_score":0.53379,"about_ca_system_score_codex":0.0005705686,"about_ca_system_score_gemma":0.00080480217,"threshold_uncertainty_score":0.9994807},"labels":[],"label_agreement":null},{"id":"W2396153198","doi":"10.1200/jco.2006.24.18_suppl.4631","title":"Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Docetaxel; Medicine; Tolerability; Neutropenia; Prostate cancer; Febrile neutropenia; Internal medicine; Clinical endpoint; Adverse effect; Nausea; Phases of clinical research; Oncology; Chemotherapy; Urology; Surgery; Gastroenterology; Cancer; Clinical trial","score_opus":0.08346536495370124,"score_gpt":0.4967239650883408,"score_spread":0.41325860013463955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396153198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873801,0.007993557,0.00004403839,0.0024985145,0.00050176703,0.001462573,0.000041372914,0.0000068188197,0.000071300485],"genre_scores_gemma":[0.9810031,0.017048337,0.0004186773,0.00017746621,0.00071355083,0.000055999884,0.000016947462,0.000019070885,0.00054685946],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99711514,0.00037076094,0.0016716167,0.00021848816,0.00038352516,0.00024046168],"domain_scores_gemma":[0.99669284,0.00087744725,0.0015372649,0.0001425089,0.00052147784,0.00022846018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018390539,0.00014725912,0.0013216216,0.00013763247,0.00011285159,0.000008707039,0.00009162603,0.00021539147,0.00006916198],"category_scores_gemma":[0.00044011656,0.0000860446,0.00020411251,0.00011935461,0.00017182216,0.000109745495,0.00003904789,0.00043710927,7.349734e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10796746,0.015004804,0.074822776,0.000060499246,0.00090958533,0.00023793831,0.00096124486,0.000091151545,0.0017436182,0.000025519304,0.005077429,0.793098],"study_design_scores_gemma":[0.4977951,0.3438029,0.08470918,0.00019559289,0.0012707505,0.00009430972,0.0007509209,0.00085962005,0.008154274,0.002460334,0.05969397,0.00021302908],"about_ca_topic_score_codex":0.00072698906,"about_ca_topic_score_gemma":0.00009254045,"teacher_disagreement_score":0.79288495,"about_ca_system_score_codex":0.00015968029,"about_ca_system_score_gemma":0.0013903116,"threshold_uncertainty_score":0.3508797},"labels":[],"label_agreement":null},{"id":"W2396922882","doi":"10.1016/j.jval.2016.03.1492","title":"Utilization of Radium-223 Dichloride (Ra-223) in Patients with Metastatic Castration-Resistant Prostate Cancer in Canada: A Real-World Retrospective Study","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada; Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Denosumab; Prostate cancer; Enzalutamide; Radium-223; Internal medicine; Oncology; Bone metastasis; Abiraterone acetate; Cancer; Retrospective cohort study; Osteoporosis; Androgen deprivation therapy; Androgen receptor","score_opus":0.05146567593889032,"score_gpt":0.34171162970323177,"score_spread":0.2902459537643414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396922882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99488294,0.00036578524,0.0000024757378,0.0011820585,0.000076283,0.0032376528,0.00016947745,0.000007783971,0.00007555131],"genre_scores_gemma":[0.9987485,0.0006418854,0.000045278928,0.000033270102,0.00001441525,0.0002443535,0.000021923794,0.00002321368,0.00022718743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976162,0.00025107147,0.00066210516,0.0003606938,0.00065494527,0.00045499968],"domain_scores_gemma":[0.9991411,0.00009588394,0.00022560316,0.00022265874,0.00016776423,0.00014700415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005530024,0.00016412047,0.00051182316,0.00040606744,0.00003702107,0.000005311712,0.000063461615,0.000018593366,0.00002891782],"category_scores_gemma":[0.00007389309,0.0001020032,0.000016536898,0.0011212843,0.00005173924,0.00010864492,0.00001801836,0.00016362382,5.672071e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0028238778,0.0009445238,0.99138594,0.00024109632,0.000043881773,0.00007307169,0.0018399608,0.00027016047,0.000033123077,0.000051919626,0.000026172884,0.0022663036],"study_design_scores_gemma":[0.01483399,0.0014537643,0.98137784,0.0011318786,0.0000161124,3.1478262e-7,0.0006777253,0.00016583983,0.00017361758,0.000059950482,0.000013931123,0.000095009076],"about_ca_topic_score_codex":0.97297376,"about_ca_topic_score_gemma":0.98786014,"teacher_disagreement_score":0.014886366,"about_ca_system_score_codex":0.007758726,"about_ca_system_score_gemma":0.0066035734,"threshold_uncertainty_score":0.9990281},"labels":[],"label_agreement":null},{"id":"W2397107233","doi":"10.1016/j.brachy.2016.04.018","title":"Low-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer: A Dose-Response Analysis for 3392 Consecutive 125-Iodine Monotherapy Patients","year":2016,"lang":"en","type":"article","venue":"Brachytherapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Interior Health","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; Urology; Concomitant; Internal medicine; Proportional hazards model; Androgen deprivation therapy; Cohort; Prostate; Cancer; Implant; Radiation therapy; Nuclear medicine; Gastroenterology; Surgery","score_opus":0.016761519697724953,"score_gpt":0.31917783037353875,"score_spread":0.3024163106758138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397107233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97985095,0.0035814836,0.002501217,0.0043095266,0.00031080274,0.006202801,0.0030859173,0.00014348059,0.000013799017],"genre_scores_gemma":[0.9520392,0.037632544,0.00059904426,0.001341548,0.0003118586,0.0040653804,0.00031200968,0.0001683506,0.0035300762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99633086,0.00033949086,0.0007835104,0.0011040664,0.000399137,0.0010429093],"domain_scores_gemma":[0.9959956,0.0016893703,0.0005022565,0.0006186286,0.00073696725,0.00045719158],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010572115,0.00063783635,0.0011464529,0.0009149609,0.00036732532,0.00010143117,0.00020951878,0.00024133516,0.00020040614],"category_scores_gemma":[0.00023510298,0.00040289332,0.00057904853,0.0009485449,0.00048101594,0.00031018766,0.000036788446,0.00021023127,0.000012359851],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24545826,0.0013726582,0.43454075,0.00028807536,0.0071499143,0.000029991103,0.0030623167,0.000017647571,0.041970048,0.000036294114,0.0021225878,0.26395148],"study_design_scores_gemma":[0.14267029,0.015103393,0.7460648,0.0007929729,0.0014412816,0.000009114429,0.00030433288,0.0016477687,0.06382905,0.0012302743,0.025541691,0.0013650741],"about_ca_topic_score_codex":0.00012958623,"about_ca_topic_score_gemma":0.00014831632,"teacher_disagreement_score":0.31152403,"about_ca_system_score_codex":0.00032982207,"about_ca_system_score_gemma":0.00044533,"threshold_uncertainty_score":0.9998423},"labels":[],"label_agreement":null},{"id":"W2397200467","doi":"","title":"Response of PC-3 prostate cancer cells to combination therapy using irradiation with glucocorticoids or doxorubicin.","year":2000,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Trypan blue; Cell cycle; Apoptosis; Doxorubicin; Flow cytometry; Cytotoxicity; Cell growth; Fragmentation (computing); Molecular biology; Cell; DNA fragmentation; Biology; Chemistry; Programmed cell death; Internal medicine; Medicine; Chemotherapy; In vitro; Biochemistry","score_opus":0.04373446384967597,"score_gpt":0.31212209518132317,"score_spread":0.2683876313316472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397200467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943331,0.00034821415,0.000006290097,0.002084323,0.00005162235,0.0028290397,0.000018993967,0.000030336834,0.00029806176],"genre_scores_gemma":[0.98811674,0.00080608483,0.00014742934,0.00029712933,0.00003795801,0.0013291311,0.000011433693,0.000025085794,0.009229026],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99885744,0.000081419574,0.00019258534,0.00020381587,0.00033822987,0.0003265322],"domain_scores_gemma":[0.9993818,0.0000545592,0.000059480542,0.00018522427,0.00014991865,0.00016901073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031754162,0.000114920746,0.00020657275,0.00015817049,0.000055513934,0.00001775927,0.000050042254,0.000042567357,0.0002245783],"category_scores_gemma":[0.000021573456,0.00007070346,0.000029923762,0.00049982086,0.000058358775,0.000099247256,0.0000072560993,0.0000727802,0.000007715229],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14516144,0.0007533125,0.041141402,0.000113265014,0.00026124503,0.00008275988,0.0027475834,0.00061259046,0.11420878,0.0000090382755,0.00048818174,0.6944204],"study_design_scores_gemma":[0.0075289374,0.0009763723,0.6708931,0.00007063057,0.000050808252,0.000008517967,0.000073275245,0.0002142802,0.31679142,0.000010711367,0.0032611804,0.000120778706],"about_ca_topic_score_codex":0.00029553645,"about_ca_topic_score_gemma":0.000022811362,"teacher_disagreement_score":0.69429964,"about_ca_system_score_codex":0.00029133935,"about_ca_system_score_gemma":0.00025465968,"threshold_uncertainty_score":0.28832036},"labels":[],"label_agreement":null},{"id":"W2398256166","doi":"10.1016/j.jval.2015.09.1266","title":"Cost-Utility Analysis Of Enzalutamide For Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (Mcrpc) After Failure Of Androgen Deprivation Therapy (Adt)","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of Alberta; University of Toronto","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Androgen deprivation therapy; Hazard ratio; Internal medicine; Oncology; Prednisone; Cancer; Confidence interval; Androgen receptor","score_opus":0.08888325761911012,"score_gpt":0.37325963935964823,"score_spread":0.28437638174053814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398256166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932378,0.0018509898,0.00016210155,0.00096276763,0.000021726482,0.0032398165,0.0005077941,0.000009048943,0.000007986678],"genre_scores_gemma":[0.9964017,0.00048053823,0.0021591985,0.0001170209,0.0000115771645,0.00048630824,0.00028765792,0.000019494933,0.000036490117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831635,0.00013463899,0.0005414418,0.00026819654,0.00045548493,0.00028390146],"domain_scores_gemma":[0.9986271,0.00010471003,0.00029691277,0.00026068705,0.0005532755,0.00015729023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062964385,0.00014612828,0.00056616607,0.00031571652,0.000028932602,0.0000073197166,0.000056163284,0.000040305644,0.000027663615],"category_scores_gemma":[0.000048065747,0.00009946047,0.00008754379,0.00087634777,0.00008594345,0.00008884166,0.000008272061,0.00008474813,2.4189936e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012608311,0.0007755242,0.9665713,0.00060748355,0.0010426901,0.0000026682928,0.0046862313,0.0015462352,0.00021295718,0.000014454409,0.00006019372,0.011871961],"study_design_scores_gemma":[0.017522132,0.0031153108,0.96426374,0.00034927228,0.00038228952,5.016851e-7,0.00067159376,0.005956972,0.0067802765,0.00019115637,0.0006072818,0.00015945984],"about_ca_topic_score_codex":0.00457863,"about_ca_topic_score_gemma":0.0009467212,"teacher_disagreement_score":0.011712501,"about_ca_system_score_codex":0.00036347422,"about_ca_system_score_gemma":0.0013193893,"threshold_uncertainty_score":0.69215494},"labels":[],"label_agreement":null},{"id":"W2398715868","doi":"10.1177/1756287215592288","title":"Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy","year":2015,"lang":"en","type":"review","venue":"Therapeutic Advances in Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Abiraterone acetate; Enzalutamide; Cabazitaxel; Prostate cancer; Docetaxel; Oncology; Internal medicine; Adverse effect; Chemotherapy; Androgen deprivation therapy; Cancer; Pharmacology; Androgen receptor","score_opus":0.07728953142386998,"score_gpt":0.4469508642662002,"score_spread":0.3696613328423302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398715868","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046756634,0.9936212,0.000011301995,0.0011328572,0.00013045034,0.0037202216,0.000029754472,0.000011344889,0.00087535067],"genre_scores_gemma":[0.0014934535,0.9956495,0.00020009403,0.00043442682,0.00005580544,0.001557487,0.00003749024,0.000041416806,0.00053028605],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979503,0.00024366837,0.0006170869,0.00041158934,0.00033478523,0.00044254735],"domain_scores_gemma":[0.9991445,0.00008681446,0.00019223528,0.0004473926,0.00006574598,0.00006330737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005906136,0.00031859963,0.0012096303,0.00027716547,0.000024321136,0.000008420354,0.00031311825,0.00014395511,0.000058485846],"category_scores_gemma":[0.0000027078756,0.00018093616,0.00009834542,0.0006779059,0.0001642917,0.000056008525,0.00004315521,0.000358728,0.000013430769],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011647363,0.00021170579,0.00006613819,0.0057588387,0.00021237046,0.00014172083,0.0009375363,0.000020408352,0.000005263847,0.0001959381,0.000016030246,0.9912693],"study_design_scores_gemma":[0.0022307269,0.00088687305,0.0002656824,0.0022224109,0.00033411436,0.000021085825,0.0001946156,0.0000030868941,0.000005498073,0.00048328374,0.993192,0.00016058647],"about_ca_topic_score_codex":0.000036433947,"about_ca_topic_score_gemma":0.00013883664,"teacher_disagreement_score":0.993176,"about_ca_system_score_codex":0.00030154653,"about_ca_system_score_gemma":0.00035235807,"threshold_uncertainty_score":0.73783624},"labels":[],"label_agreement":null},{"id":"W2402002440","doi":"10.1158/1535-7163.targ-15-b173","title":"Abstract B173: Galeterone shows anti-tumor activity in multiple pre-clinical models that express androgen receptor splice variants, supporting correlative patient data seen in ARMOR2","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Enzalutamide; Androgen receptor; Prostate cancer; splice; Cancer research; Androgen; Alternative splicing; Cancer; Biology; Medicine; Internal medicine; Endocrinology; Messenger RNA; Hormone; Gene; Genetics","score_opus":0.22797474971661802,"score_gpt":0.40608981782862924,"score_spread":0.17811506811201122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402002440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913059,0.0041165473,0.001572855,0.00048817872,0.00026778821,0.0015627587,0.00037982024,0.00004091455,0.00026523796],"genre_scores_gemma":[0.9970197,0.0010407263,0.0007875309,0.0005254063,0.000070377624,0.00015284764,0.00025444845,0.00006922721,0.00007971595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970289,0.00027709303,0.00057811965,0.0008033016,0.0006525876,0.0006600158],"domain_scores_gemma":[0.9982241,0.00014843667,0.00027442886,0.0009328373,0.00013024316,0.00028997354],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082236755,0.00032290412,0.0006311733,0.00013894876,0.000047884372,0.00003456406,0.0003649993,0.00018611105,0.00006780767],"category_scores_gemma":[0.00006509649,0.0002765121,0.000087624,0.0002694032,0.00014635132,0.00031205677,0.00031012477,0.0007264742,0.0000099353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007787335,0.002994804,0.7553848,0.0002789148,0.0010837808,0.0018617462,0.0072317305,0.0037356203,0.13642947,0.000008120608,0.0005717729,0.08263188],"study_design_scores_gemma":[0.04418296,0.0025416687,0.3518977,0.0020055757,0.00070303486,0.000071614886,0.0028798266,0.32460165,0.2607372,0.0004502643,0.007816024,0.002112484],"about_ca_topic_score_codex":0.0012983523,"about_ca_topic_score_gemma":0.00032937605,"teacher_disagreement_score":0.40348715,"about_ca_system_score_codex":0.00045643665,"about_ca_system_score_gemma":0.0006629689,"threshold_uncertainty_score":0.9999687},"labels":[],"label_agreement":null},{"id":"W2402044355","doi":"10.1016/j.jval.2016.03.1637","title":"Castration-Resistant Prostate Cancer Patients In Quebec: Medication Use In The Last Year Of Life","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Abiraterone; Androgen deprivation therapy; Medical prescription; Cohort; Castration; Internal medicine; Abiraterone acetate; Cancer; Cohort study; Oncology; Pharmacology; Androgen receptor; Hormone","score_opus":0.06220926947193235,"score_gpt":0.3539470846249528,"score_spread":0.29173781515302044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402044355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98931044,0.00042010687,0.0000010781652,0.009229941,0.000053544652,0.0008945644,0.000040775583,0.000004107235,0.00004546476],"genre_scores_gemma":[0.997513,0.0018568407,0.00003466423,0.00019575538,0.000026095093,0.000108638356,0.00002157058,0.000007389084,0.0002360654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987558,0.00019761952,0.0003695239,0.00014192684,0.00031778048,0.00021735406],"domain_scores_gemma":[0.99946976,0.00016275745,0.00009642558,0.00014637974,0.00005333317,0.00007132579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005419459,0.000062213614,0.00015955073,0.00016122713,0.000016998185,0.000005838781,0.000056750043,0.000035160796,0.000020729442],"category_scores_gemma":[0.00019419011,0.000032511518,0.000015088886,0.00028823863,0.00005748763,0.00009388638,0.000010104608,0.00010329165,0.0000042685047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004278387,0.00028252654,0.9911311,0.00019088438,0.0000050342555,0.0000055866076,0.0030426802,0.000026167781,0.00022134784,0.00014217304,0.00036827681,0.0041563613],"study_design_scores_gemma":[0.0035958323,0.0002554462,0.994237,0.00084678986,0.000001925304,1.5645064e-7,0.000316746,0.000044680248,0.00012762779,0.00004879511,0.00049163116,0.000033348024],"about_ca_topic_score_codex":0.21900846,"about_ca_topic_score_gemma":0.11636753,"teacher_disagreement_score":0.10264093,"about_ca_system_score_codex":0.00049214746,"about_ca_system_score_gemma":0.0012055112,"threshold_uncertainty_score":0.8997565},"labels":[],"label_agreement":null},{"id":"W2402927443","doi":"","title":"Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen suppression; Androgen; Cancer; Urology; Prospective cohort study; Radiation therapy; Cohort; Antiandrogen; Internal medicine; Stage (stratigraphy); Oncology; Hormone","score_opus":0.02741675510860764,"score_gpt":0.2977060942361133,"score_spread":0.27028933912750563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402927443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957436,0.00086288224,5.7723065e-7,0.00036880068,0.00035892226,0.0012287231,0.000011396589,0.000010579235,0.0014145512],"genre_scores_gemma":[0.99512804,0.0004321211,0.000015516072,0.0001137528,0.000018477722,0.0018572318,0.000004112664,0.000010972171,0.0024197532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999031,0.00006970098,0.00017168245,0.00018516986,0.00023196032,0.00031048147],"domain_scores_gemma":[0.99951833,0.000008991129,0.000050345097,0.00026172303,0.000048596212,0.00011200602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016427708,0.000086325774,0.00015694852,0.00005957645,0.000034665623,0.0000076037386,0.00009865062,0.000030518393,0.00007961459],"category_scores_gemma":[0.000036004352,0.000046895504,0.000044715103,0.00021999104,0.00010240004,0.00010151993,0.000040347088,0.000110842935,9.1040977e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005134751,0.00031453877,0.8747307,0.00006880926,0.000035128764,0.000040007315,0.0021741814,0.000008658342,0.0010647166,0.00003038695,0.0019649009,0.11905447],"study_design_scores_gemma":[0.0035049692,0.00006804335,0.74366355,0.00009571607,0.000025617706,0.00000887182,0.0008930081,0.000027979371,0.2296226,0.00013391781,0.021849168,0.000106586136],"about_ca_topic_score_codex":0.000116345574,"about_ca_topic_score_gemma":0.0002595079,"teacher_disagreement_score":0.22855788,"about_ca_system_score_codex":0.0001295959,"about_ca_system_score_gemma":0.000090172056,"threshold_uncertainty_score":0.1912343},"labels":[],"label_agreement":null},{"id":"W2403998898","doi":"10.1001/jamaoncol.2016.0494","title":"Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute","keywords":"Enzalutamide; Prostate cancer; Medicine; Interquartile range; Oncology; Internal medicine; Cell-free fetal DNA; Prostate-specific antigen; Cancer; Androgen deprivation therapy; Androgen receptor; Biology; Genetics","score_opus":0.02452938334777873,"score_gpt":0.3308476599576475,"score_spread":0.30631827660986877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2403998898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9604585,0.0033534465,0.0000034559052,0.028866606,0.000088207256,0.00067015487,0.00007924946,0.000014497164,0.006465864],"genre_scores_gemma":[0.986956,0.0025592167,0.0004726403,0.00035006108,0.00010653377,0.00036221877,0.000012959095,0.00001591288,0.009164471],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988305,0.00010402432,0.0002962807,0.0003035322,0.00012514855,0.0003405103],"domain_scores_gemma":[0.99934804,0.00019162262,0.00006382632,0.00022748577,0.00006505114,0.000103996324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002550051,0.00011591332,0.0002565492,0.00019641366,0.0000496671,0.000017999195,0.00007663265,0.000115742,0.00010202865],"category_scores_gemma":[0.000088406356,0.000078222525,0.000023186065,0.00017915937,0.00014267948,0.0001196049,0.000052013103,0.00016475239,0.000011940381],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061733183,0.00044613553,0.17738406,0.00019719337,0.000040657196,0.0011748499,0.00353038,0.0000062859654,0.78191745,0.0011946228,0.0057993177,0.022135701],"study_design_scores_gemma":[0.025833787,0.0008780787,0.88901657,0.0004739781,0.00003775886,0.000022570332,0.00042029304,0.00002667756,0.028409828,0.003397026,0.051241044,0.00024241502],"about_ca_topic_score_codex":0.0005483668,"about_ca_topic_score_gemma":0.03588338,"teacher_disagreement_score":0.7535076,"about_ca_system_score_codex":0.0010308244,"about_ca_system_score_gemma":0.0007970233,"threshold_uncertainty_score":0.98170924},"labels":[],"label_agreement":null},{"id":"W2404852579","doi":"10.1016/j.clgc.2016.05.009","title":"Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Bone metastasis; Docetaxel; Radiology; Metastasis; Lesion; Nuclear medicine; Proportional hazards model; Cancer; Confidence interval; Internal medicine; Surgery","score_opus":0.14115413462752094,"score_gpt":0.4419744133769954,"score_spread":0.3008202787494745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2404852579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98543704,0.0065868595,0.00020316926,0.0057657184,0.00026171675,0.0012402674,0.00037595202,0.000030269943,0.000099040946],"genre_scores_gemma":[0.9897851,0.0052416027,0.0031308495,0.00025171437,0.00017627484,0.0004694058,0.000028620243,0.00003213539,0.0008843404],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973972,0.00022656588,0.0010198208,0.0005427293,0.00041127956,0.00040241855],"domain_scores_gemma":[0.9983622,0.00038198355,0.00022129253,0.000308505,0.00035900698,0.00036703498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070487044,0.0002446873,0.0008168074,0.00041126268,0.000058571448,0.000020181358,0.00007687217,0.00008629858,0.00015822588],"category_scores_gemma":[0.00014566004,0.0001532283,0.00018202647,0.0007456885,0.00035085666,0.00016488247,0.00008358477,0.00023017073,0.0000048767242],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011305489,0.0016653867,0.29042247,0.000683118,0.0009298175,0.00085449044,0.0007908939,0.000067697125,0.3172906,0.000078854544,0.0029208204,0.37299034],"study_design_scores_gemma":[0.011941883,0.0035013608,0.9368254,0.002439271,0.00057378213,0.00003487568,0.0005402251,0.0002120858,0.040148098,0.0002558879,0.0030638939,0.00046325417],"about_ca_topic_score_codex":0.00063858996,"about_ca_topic_score_gemma":0.001202917,"teacher_disagreement_score":0.6464029,"about_ca_system_score_codex":0.00019206046,"about_ca_system_score_gemma":0.000560952,"threshold_uncertainty_score":0.6248469},"labels":[],"label_agreement":null},{"id":"W2405138885","doi":"10.1158/1535-7163.targ-15-a150","title":"Abstract A150: Anti-BIRC6 antisense oligonucleotide inhibits enzalutamide-resistant castration-resistant prostate cancer growth in patient-derived xenograft model by suppressing multiple signaling pathways","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Occupational Cancer Research Centre; Spinal Cord Injury BC","funders":"","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Cancer research; Bicalutamide; Survivin; Apoptosis; Medicine; In vivo; Androgen; LNCaP; Cancer; Biology; Internal medicine; Hormone","score_opus":0.0526247472187007,"score_gpt":0.30567236337101195,"score_spread":0.25304761615231125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2405138885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758565,0.020289822,0.00023948522,0.0010653934,0.00016490005,0.0014484825,0.00066416553,0.000118534976,0.00015271375],"genre_scores_gemma":[0.995038,0.0024450861,0.00087019947,0.00086398755,0.000060454855,0.00029158042,0.00021146829,0.0001636212,0.000055652137],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961965,0.00014091395,0.00078913016,0.0007866257,0.0010269388,0.0010598629],"domain_scores_gemma":[0.9981679,0.00006231444,0.00029025754,0.00043757918,0.000574768,0.00046718726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030087735,0.00057042716,0.00067406625,0.0002698801,0.00020082325,0.0001668171,0.00019461864,0.00022399644,0.000026249656],"category_scores_gemma":[0.00003983419,0.0005043585,0.00018470292,0.0005513157,0.00023675214,0.00026954574,0.00008687947,0.00055672525,0.0000061587184],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020743383,0.00043147744,0.006981432,0.00024553924,0.00031924417,0.00084290106,0.0036390333,0.00910304,0.9721549,0.000013367461,0.00012453906,0.0040701893],"study_design_scores_gemma":[0.0066317036,0.00034589192,0.001724465,0.0008010097,0.00020663475,0.000011941888,0.00076616707,0.0118552325,0.9764939,0.00020235167,0.00037776717,0.00058296224],"about_ca_topic_score_codex":0.0018251331,"about_ca_topic_score_gemma":0.0003721869,"teacher_disagreement_score":0.019181447,"about_ca_system_score_codex":0.0009030388,"about_ca_system_score_gemma":0.0013573697,"threshold_uncertainty_score":0.9997408},"labels":[],"label_agreement":null},{"id":"W2406217810","doi":"10.1200/jco.2016.34.2_suppl.179","title":"Dehydroepiandrosterone in metastatic castration-resistant prostate cancer: Preliminary results from the SU2C-PCF West Coast Dream Team (WCDT).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Docetaxel; Androgen receptor; Internal medicine; Oncology; Urology; Androgen deprivation therapy; Dehydroepiandrosterone; Cancer; Chemotherapy; Androgen; Hormone","score_opus":0.13692311142152444,"score_gpt":0.465408239570739,"score_spread":0.3284851281492146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406217810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9275219,0.0023830205,0.000017556033,0.06766509,0.00075789425,0.0006472439,0.00026200124,0.000009171224,0.000736158],"genre_scores_gemma":[0.98850095,0.0073742056,0.0006022915,0.000784788,0.00091891346,0.00003448304,0.000022547492,0.000024042198,0.0017377549],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99512434,0.0008128998,0.0027264652,0.00032212524,0.0005847442,0.00042943493],"domain_scores_gemma":[0.9909874,0.006466932,0.0013986382,0.00033337806,0.0004154951,0.00039816363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036102186,0.00020314471,0.0012830948,0.00011505961,0.00008000046,0.000021366352,0.00026889602,0.00020074868,0.00012807436],"category_scores_gemma":[0.0031772638,0.000089999114,0.00028464745,0.00020764116,0.000491252,0.00020927702,0.00008578278,0.000870803,0.00003435847],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2480444,0.0042417003,0.29138222,0.00007444298,0.0016429431,0.008492278,0.0018641239,0.00006492254,0.007974483,0.00004122206,0.044363,0.39181426],"study_design_scores_gemma":[0.06179132,0.034196522,0.84949374,0.0013834374,0.00069295074,0.00033028887,0.0008542073,0.000067791385,0.0011195489,0.0006640656,0.049197033,0.00020908772],"about_ca_topic_score_codex":0.00083663856,"about_ca_topic_score_gemma":0.0039800727,"teacher_disagreement_score":0.55811155,"about_ca_system_score_codex":0.00046778147,"about_ca_system_score_gemma":0.0035680227,"threshold_uncertainty_score":0.6329519},"labels":[],"label_agreement":null},{"id":"W2406231314","doi":"10.1016/j.jval.2016.03.1654","title":"Impact Of Initial Local Primary Treatment On Late Regional Complications In Castration-Resistant Prostate Cancer Patients In Quebec","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"Sanofi","keywords":"Medicine; Prostate cancer; Prostatectomy; External beam radiotherapy; Cohort; Proportional hazards model; Logistic regression; Quality of life (healthcare); Radiation therapy; Complication; Surgery; Cancer; Internal medicine","score_opus":0.08621693277562745,"score_gpt":0.4200232491814673,"score_spread":0.3338063164058398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406231314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937278,0.00032252946,0.00000230096,0.004284334,0.000028930921,0.0012557985,0.00019979573,0.000007439817,0.00017108142],"genre_scores_gemma":[0.99791116,0.0013095123,0.000033488213,0.00009487045,0.000019906467,0.0002192667,0.00012257989,0.000012555024,0.00027666587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986023,0.00013876474,0.00045659798,0.00023488059,0.00024435678,0.00032310217],"domain_scores_gemma":[0.9994278,0.000110343295,0.00010859677,0.00016318027,0.00006605212,0.00012401876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015458783,0.0001234962,0.0002913069,0.00029677525,0.00002658096,0.0000039578913,0.00004113135,0.000046611847,0.000021746284],"category_scores_gemma":[0.000014572119,0.00007352416,0.000049826627,0.00028057725,0.000097497985,0.00006422588,0.000010265412,0.00009620093,0.000005309781],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003431386,0.0026474877,0.9318613,0.00018527896,0.000037033496,0.000037179732,0.0018162898,0.0015878755,0.00092633616,0.0001425869,0.0001258052,0.057201453],"study_design_scores_gemma":[0.00805135,0.0024896003,0.98768336,0.0011538424,0.000003225978,7.7737957e-7,0.000028917239,0.00016192936,0.00019427593,0.00009412778,0.00007618907,0.00006243125],"about_ca_topic_score_codex":0.35318774,"about_ca_topic_score_gemma":0.051339477,"teacher_disagreement_score":0.30184826,"about_ca_system_score_codex":0.0057370304,"about_ca_system_score_gemma":0.0028131604,"threshold_uncertainty_score":0.9980798},"labels":[],"label_agreement":null},{"id":"W2412838002","doi":"10.18632/oncotarget.9816","title":"Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor","year":2016,"lang":"en","type":"article","venue":"Oncotarget","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Androgen receptor; Enzalutamide; Agonism; Androgen; Medicine; Receptor; Mutant; Endocrinology; Internal medicine; Prostate cancer; Cell biology; Biology; Hormone; Biochemistry","score_opus":0.04653315585654029,"score_gpt":0.3004836998941429,"score_spread":0.25395054403760264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2412838002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98991275,0.0044848705,0.000034200828,0.0022075768,0.0001767059,0.00048690164,0.00013205127,0.000045338606,0.0025195912],"genre_scores_gemma":[0.9925861,0.0015799335,0.00044066762,0.0001500727,0.00014777048,0.00004443588,0.000042185773,0.000025829997,0.004983003],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99847925,0.000055189124,0.00033640547,0.00029927958,0.00044002355,0.0003898289],"domain_scores_gemma":[0.9990479,0.00007871559,0.00011243884,0.00032420017,0.00019263657,0.00024412268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024054444,0.00017663608,0.00040218726,0.0001034011,0.00006134432,0.000009951712,0.00013375272,0.00010218305,0.0008940602],"category_scores_gemma":[0.00008236694,0.000096404234,0.00014321036,0.00015386971,0.00024119794,0.000104494145,0.000059772225,0.00009344187,0.00018478642],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048463218,0.00016593217,0.16308117,0.000067448374,0.0002009519,0.00009277209,0.00021682975,2.2637852e-7,0.8312657,0.00018000674,0.0011169006,0.0031274462],"study_design_scores_gemma":[0.0037412315,0.00077781256,0.0072754025,0.00029484023,0.00006838267,0.00001705432,0.00013426885,0.0000037654809,0.9181086,0.00020687266,0.069228545,0.00014323961],"about_ca_topic_score_codex":0.000102137485,"about_ca_topic_score_gemma":0.0000059992194,"teacher_disagreement_score":0.15580577,"about_ca_system_score_codex":0.00015808985,"about_ca_system_score_gemma":0.00032944282,"threshold_uncertainty_score":0.97893316},"labels":[],"label_agreement":null},{"id":"W2413116512","doi":"10.1200/jco.2016.34.2_suppl.92","title":"5α-reductase inhibitors and the risk of grade reclassification for men with long-term follow-up on active surveillance for prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Brampton Civic Hospital; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Proportional hazards model; Hazard ratio; Internal medicine; Cohort; Prostate; Retrospective cohort study; Oncology; Cancer; Cohort study; Urology; Gynecology; Confidence interval","score_opus":0.11273512559925895,"score_gpt":0.4717229701598357,"score_spread":0.35898784456057675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413116512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9582433,0.00067609537,0.0001736797,0.03867664,0.00051155325,0.0014824796,0.00012425373,0.000003501972,0.00010851147],"genre_scores_gemma":[0.98783845,0.00981426,0.00031844235,0.000118715034,0.0007317475,0.00014298657,0.0000058743594,0.000015727339,0.0010138003],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981896,0.000341597,0.0008730025,0.00017968185,0.00022742219,0.00018865053],"domain_scores_gemma":[0.991765,0.0057861367,0.0015143834,0.00014103143,0.0006299534,0.00016344378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027319917,0.00010639838,0.0008394573,0.00006364674,0.0000670617,0.0000050703784,0.000085121086,0.00013435766,0.0000064934097],"category_scores_gemma":[0.0023684013,0.000040035684,0.00023750428,0.000074602634,0.00061840843,0.00006806882,0.000014910159,0.00026610246,3.557354e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2557552,0.0007278252,0.30688974,0.00010507731,0.0014019624,0.000018236857,0.00034372477,0.0000016678158,0.0011358025,0.00013235514,0.0052728616,0.42821553],"study_design_scores_gemma":[0.1482949,0.045447595,0.78129214,0.000671526,0.0009997711,0.00005124242,0.00028778592,0.000057617315,0.012213407,0.0016296105,0.008908986,0.0001453971],"about_ca_topic_score_codex":0.000021059315,"about_ca_topic_score_gemma":0.000095162664,"teacher_disagreement_score":0.4744024,"about_ca_system_score_codex":0.0001722751,"about_ca_system_score_gemma":0.0010903936,"threshold_uncertainty_score":0.28353685},"labels":[],"label_agreement":null},{"id":"W2414185687","doi":"","title":"Updates on therapeutic targets and agents in castration-resistant prostate cancer.","year":2011,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Cabazitaxel; Prostate cancer; Medicine; Docetaxel; Denosumab; Enzalutamide; Oncology; Abiraterone acetate; Disease; Internal medicine; Cancer; Androgen deprivation therapy; Zoledronic acid; Androgen receptor; Osteoporosis","score_opus":0.10749851579761605,"score_gpt":0.3208544418055928,"score_spread":0.21335592600797676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2414185687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872517,0.0043761535,2.6964028e-7,0.0011863129,0.00008221174,0.0014478017,0.000020758926,0.000024208304,0.0056105615],"genre_scores_gemma":[0.99448067,0.0013202801,0.000020179108,0.0002418956,0.000027340004,0.0016623719,0.000018445182,0.000012327564,0.0022164893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992199,0.00002360847,0.00011565909,0.00018714929,0.00014667916,0.00030701308],"domain_scores_gemma":[0.99970543,0.000013599249,0.000026168182,0.00010543093,0.000029164014,0.00012020204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012472562,0.000091787166,0.0001263133,0.00009016768,0.000037420567,0.000013172502,0.000034100784,0.000032531534,0.00008838066],"category_scores_gemma":[0.000010783573,0.00006388335,0.000017862329,0.00011209024,0.00005718023,0.000056573193,0.000013689007,0.00009540283,0.0000060943676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004306615,0.0005735927,0.60407656,0.00016377583,0.00021405946,0.00037101362,0.0032257463,0.0000013195137,0.00106304,0.00030228886,0.0008723807,0.38482958],"study_design_scores_gemma":[0.0018567682,0.00012369831,0.988791,0.000025088464,0.000021597749,0.0000025814056,0.00009508228,0.000010709657,0.0072828666,0.00026968966,0.0014537546,0.000067187844],"about_ca_topic_score_codex":0.00030939968,"about_ca_topic_score_gemma":0.00018425281,"teacher_disagreement_score":0.3847624,"about_ca_system_score_codex":0.0001055534,"about_ca_system_score_gemma":0.00005014479,"threshold_uncertainty_score":0.26050875},"labels":[],"label_agreement":null},{"id":"W2415007882","doi":"","title":"Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.","year":2015,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Cancer; Population; Gynecology; Disease; Urology","score_opus":0.07284991804897704,"score_gpt":0.346578097786971,"score_spread":0.27372817973799396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415007882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98927027,0.004320267,0.0001196133,0.0033931239,0.0003568918,0.0020730393,0.00005858757,0.00009068461,0.00031751333],"genre_scores_gemma":[0.9943638,0.00064129604,0.0019390092,0.00013591569,0.00031717052,0.0011489228,0.00008413547,0.000027492679,0.0013422777],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980894,0.000102155864,0.00027917244,0.0002993709,0.00038336017,0.00084656954],"domain_scores_gemma":[0.99902475,0.00002234292,0.00017601936,0.00020145247,0.00016826674,0.00040714347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008394751,0.00014287041,0.0002608112,0.000108334505,0.00015477122,0.00004442753,0.00005313243,0.000048443333,0.000012030609],"category_scores_gemma":[0.00013145602,0.00011209373,0.000040243052,0.0002930279,0.000049279934,0.00013673221,0.000025500076,0.0002790527,0.0000062926665],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033141614,0.0002742322,0.11526721,0.0004142184,0.0003544334,0.00009330779,0.0018958992,0.0013929188,0.0004644885,0.000083701954,0.0050053285,0.8714401],"study_design_scores_gemma":[0.03018609,0.0033822493,0.9085499,0.0006853473,0.0006997286,0.00018093838,0.0013378975,0.025120627,0.009534021,0.0037767077,0.015333006,0.0012134754],"about_ca_topic_score_codex":0.0075469976,"about_ca_topic_score_gemma":0.0009657528,"teacher_disagreement_score":0.8702266,"about_ca_system_score_codex":0.0020323773,"about_ca_system_score_gemma":0.0015587148,"threshold_uncertainty_score":0.9990618},"labels":[],"label_agreement":null},{"id":"W2415483975","doi":"","title":"Prostate cancer nomograms are superior to neural networks.","year":2006,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Nomogram; Artificial neural network; Medicine; Prostate cancer; Artificial intelligence; Machine learning; Cancer; Computer science; Oncology; Internal medicine","score_opus":0.024125667034596218,"score_gpt":0.27527243780162575,"score_spread":0.2511467707670295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415483975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820594,0.0035234073,0.000011840419,0.009846834,0.00033976673,0.0024908653,0.00002966698,0.00011554798,0.0015826296],"genre_scores_gemma":[0.97543895,0.00014280375,0.000030125651,0.0006433699,0.00064484857,0.006085213,0.000048589543,0.000030927335,0.016935166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859655,0.00001867079,0.00015758545,0.00027807883,0.00024147514,0.0007076543],"domain_scores_gemma":[0.9993726,0.000015155324,0.000029682737,0.00019793984,0.00009051666,0.00029407447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010196318,0.00014159869,0.00021961618,0.00008391494,0.0000765737,0.000050857256,0.00007340207,0.00005028075,0.000055116405],"category_scores_gemma":[0.000014775348,0.000102599886,0.000072556526,0.00035641837,0.000056668945,0.00006470099,0.000046099332,0.00014208569,0.000014316622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007353794,0.00016625167,0.65054095,0.000055602086,0.00006067184,0.00021972304,0.00007329555,0.0005641136,0.00007005295,0.000009647172,0.0147587005,0.3327456],"study_design_scores_gemma":[0.001705317,0.00006259651,0.96753395,0.00002229591,0.000043043045,0.000011676357,0.00003670298,0.00048079263,0.00078207563,0.000012047281,0.02917583,0.00013365447],"about_ca_topic_score_codex":0.0007370407,"about_ca_topic_score_gemma":0.0003121581,"teacher_disagreement_score":0.33261198,"about_ca_system_score_codex":0.00019312496,"about_ca_system_score_gemma":0.000034287965,"threshold_uncertainty_score":0.41839018},"labels":[],"label_agreement":null},{"id":"W2415524742","doi":"10.1038/cddis.2015.289","title":"DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis","year":2015,"lang":"en","type":"article","venue":"Cell Death and Disease","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Fundamental Research Funds for the Central Universities; National Cancer Institute; National Institutes of Health; U.S. Army; National Key Research and Development Program of China; China Scholarship Council; Terry Fox Foundation; National Natural Science Foundation of China","keywords":"Survivin; Gene knockdown; Transactivation; Apoptosis; Cancer research; Androgen deprivation therapy; STAT3; Prostate cancer; Biology; STAT protein; Signal transduction; Cell biology; Transcription factor; Chemistry; Cancer; Gene","score_opus":0.05218983459364644,"score_gpt":0.3273599306588932,"score_spread":0.2751700960652467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415524742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98634565,0.00933099,0.000039450148,0.002586164,0.000021144278,0.0007295344,0.000057554225,0.000015227209,0.0008743048],"genre_scores_gemma":[0.99554235,0.003001374,0.0002171815,0.00048239427,0.0000442309,0.0000997874,0.000028028826,0.0000140637085,0.00057061034],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99918455,0.000035339293,0.00013968935,0.00021893287,0.00021631473,0.00020515943],"domain_scores_gemma":[0.9991882,0.000054427044,0.0000618131,0.00014094407,0.00014836217,0.00040624948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013786403,0.000111636604,0.00014820157,0.000032678432,0.00011286173,0.00003178289,0.000037029567,0.000023124741,0.000007318011],"category_scores_gemma":[0.00008949025,0.000068746784,0.000023770363,0.0001328112,0.00009744376,0.000107925756,0.000040672367,0.000068432026,6.725848e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008928278,0.00022482351,0.940037,0.00069777266,0.00011249616,0.00003697723,0.011260506,0.000025699695,0.017903771,0.00034664845,0.0015579629,0.018868025],"study_design_scores_gemma":[0.027101234,0.0011085011,0.20878707,0.0014639829,0.00035813806,0.0000054361335,0.01023934,0.00039237543,0.7219365,0.0066285543,0.02116828,0.0008105851],"about_ca_topic_score_codex":0.00014866414,"about_ca_topic_score_gemma":0.0000062305676,"teacher_disagreement_score":0.73125,"about_ca_system_score_codex":0.00004810514,"about_ca_system_score_gemma":0.00031757963,"threshold_uncertainty_score":0.28034124},"labels":[],"label_agreement":null},{"id":"W2416122474","doi":"","title":"[Prostate specific antigen and diagnosis of prostate cancer].","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Rectal examination; Prostate cancer; Prostate; Prostatitis; Cancer; Urology; Prostate-specific antigen; Stage (stratigraphy); Urinary retention; Hyperplasia; Pathology; Internal medicine","score_opus":0.0406528257581336,"score_gpt":0.2861249273613165,"score_spread":0.2454721016031829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416122474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97153556,0.020835312,7.270031e-7,0.0012049725,0.00011666602,0.0015696709,0.000051385396,0.00002596696,0.0046597226],"genre_scores_gemma":[0.9505918,0.04329009,0.000078017896,0.00006177126,0.000039090806,0.0025786443,0.000012454264,0.000020878275,0.0033272272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988917,0.000034881326,0.00018620421,0.0002474606,0.00022730979,0.00041245026],"domain_scores_gemma":[0.9994117,0.00004151249,0.000058191712,0.00017914214,0.000096345735,0.00021310178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023076501,0.000120097524,0.00025155078,0.00010671331,0.000051620606,0.000017520222,0.00003955487,0.00004194452,0.00008306003],"category_scores_gemma":[0.000048109156,0.00008942823,0.000045631627,0.00025143422,0.00015780814,0.00006974171,0.000022693343,0.000098934055,0.000004387964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003315836,0.00012592581,0.8340044,0.00014602194,0.00009706419,0.00004342612,0.00034159166,6.756063e-7,0.00030133623,0.00012575835,0.0018535714,0.16262862],"study_design_scores_gemma":[0.0026016126,0.0001110203,0.8598124,0.00004638793,0.000036309328,0.000009879932,0.00011108687,0.0000012916929,0.060896315,0.00018355864,0.07608617,0.000103991166],"about_ca_topic_score_codex":0.00008644094,"about_ca_topic_score_gemma":0.000009196835,"teacher_disagreement_score":0.16252464,"about_ca_system_score_codex":0.000074647236,"about_ca_system_score_gemma":0.000072487004,"threshold_uncertainty_score":0.36467773},"labels":[],"label_agreement":null},{"id":"W2416393073","doi":"","title":"Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.","year":2009,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bicalutamide; Dutasteride; Medicine; Antiandrogen; Dihydrotestosterone; Prostate cancer; Urology; Testosterone (patch); Internal medicine; Endocrinology; Androgen deprivation therapy; Oncology; Androgen receptor; Androgen; Cancer; Hormone","score_opus":0.029141063147905988,"score_gpt":0.2772291722623604,"score_spread":0.2480881091144544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416393073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98677516,0.006276233,0.000011593319,0.0020981927,0.000015922524,0.0047494113,0.000016910793,0.000017178125,0.00003938358],"genre_scores_gemma":[0.9958466,0.0022859962,0.000036120076,0.00029049604,0.000023319268,0.0012540962,0.000020893885,0.000013212715,0.00022926048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988909,0.00010665681,0.00015240772,0.00025012725,0.00030643106,0.00029347627],"domain_scores_gemma":[0.9995531,0.000085451604,0.00005332464,0.00013167041,0.000063850865,0.0001126465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029766106,0.00013500024,0.00018893485,0.000069770744,0.00010340539,0.00006599844,0.0000441845,0.000029042925,0.0000036133054],"category_scores_gemma":[0.000021734471,0.0000716109,0.000010582111,0.00017206847,0.00008587995,0.00015749928,0.000015354268,0.00015125233,2.7096368e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004494521,0.0009418798,0.69664705,0.000008389276,0.00009686719,0.000017129083,0.0009858683,0.0000048424977,0.0004113408,7.2591416e-7,0.00040613153,0.29598525],"study_design_scores_gemma":[0.0103710415,0.0010867543,0.98735964,0.000014181135,0.000027388765,0.0000010710601,0.00018458632,0.000027130745,0.00022102203,0.000026255944,0.00059225515,0.000088695044],"about_ca_topic_score_codex":0.00011875051,"about_ca_topic_score_gemma":0.000026547152,"teacher_disagreement_score":0.29589656,"about_ca_system_score_codex":0.00010427815,"about_ca_system_score_gemma":0.000062707404,"threshold_uncertainty_score":0.29202077},"labels":[],"label_agreement":null},{"id":"W2416792394","doi":"10.1007/978-1-61779-243-4_7","title":"In Vitro and In Vivo Silencing of the Androgen Receptor","year":2011,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"LNCaP; Androgen receptor; Prostate cancer; In vivo; Gene knockdown; Gene silencing; Cancer research; In vitro; Small hairpin RNA; Androgen; Chemistry; Medicine; Biology; Internal medicine; Cancer; Hormone; Apoptosis; Biochemistry; Gene; Genetics","score_opus":0.05114471733162819,"score_gpt":0.4154833706151136,"score_spread":0.3643386532834854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416792394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994016,0.0020120267,0.0025094794,0.00022540246,0.000067421555,0.00029422584,0.0000033535814,0.0000024559208,0.00086965977],"genre_scores_gemma":[0.65484,0.00035379795,0.34434587,0.0002507296,0.000011685496,0.000054221513,0.0000021759151,0.000012114847,0.00012941752],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988997,0.00057563203,0.00016343196,0.00015703311,0.000036997324,0.0001671866],"domain_scores_gemma":[0.9997117,0.00007209741,0.0000289859,0.00014882417,0.000014303486,0.000024077615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007387994,0.000062917585,0.00021109065,0.0001436746,0.0000069334646,7.316381e-7,0.000065905886,0.00009204492,0.000052623913],"category_scores_gemma":[0.00018288527,0.000039387454,0.000027876142,0.00024351764,0.00013691628,0.000009911091,0.000073601055,0.00015024173,3.6312414e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028616405,0.000046271052,0.05773364,0.000022411357,0.000010336,0.000027525302,0.00071221084,2.0495587e-7,0.9357909,0.00007199967,0.0000029318742,0.005295418],"study_design_scores_gemma":[0.001058308,0.00009861352,0.0048790807,0.00003731698,0.0000054201087,0.0000073028964,0.00011761939,0.000030153205,0.99186355,0.0016971697,0.00016852249,0.000036922782],"about_ca_topic_score_codex":0.000295563,"about_ca_topic_score_gemma":0.00002550444,"teacher_disagreement_score":0.3418364,"about_ca_system_score_codex":0.000045965637,"about_ca_system_score_gemma":0.000048454844,"threshold_uncertainty_score":0.16061738},"labels":[],"label_agreement":null},{"id":"W2417008724","doi":"","title":"Genetic tests for prostate cancer.","year":2013,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Genetic testing; Cancer; Oncology; Internal medicine","score_opus":0.04597248465563366,"score_gpt":0.31585598116643215,"score_spread":0.2698834965107985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417008724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770098,0.003980083,0.00001379976,0.0086612385,0.00018010737,0.0074109198,0.000027203021,0.00007290182,0.0026439864],"genre_scores_gemma":[0.9215599,0.0005401957,0.00034191256,0.0003179723,0.00021859426,0.047784664,0.000015149558,0.00002186338,0.029199807],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991508,0.0000072917446,0.00010248464,0.00017195015,0.00013238449,0.0004351032],"domain_scores_gemma":[0.99946934,0.00003270591,0.000023116423,0.000143,0.00012896008,0.00020285169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058241756,0.00008041072,0.00012660066,0.000049642957,0.000047714566,0.000026208516,0.000047409947,0.000033028675,0.00010378927],"category_scores_gemma":[0.000044852703,0.00005527455,0.000046832713,0.00010157244,0.000045110864,0.000050510098,0.000017906652,0.000055026496,0.000041472358],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014118358,0.000079997844,0.15585652,0.00014483702,0.00008066331,0.000008161926,0.00008165619,0.0000015198351,0.00046593655,0.000008696081,0.026043897,0.81708694],"study_design_scores_gemma":[0.0021250113,0.000080452504,0.9720013,0.000012745073,0.000037810423,0.0000053749686,0.00001747432,0.00006583436,0.0026802216,0.00031237205,0.022589741,0.00007163618],"about_ca_topic_score_codex":0.00021958507,"about_ca_topic_score_gemma":0.000016827578,"teacher_disagreement_score":0.8170153,"about_ca_system_score_codex":0.000108571956,"about_ca_system_score_gemma":0.00007418255,"threshold_uncertainty_score":0.22540309},"labels":[],"label_agreement":null},{"id":"W2418296065","doi":"10.1200/jco.2015.33.7_suppl.269","title":"Drug-drug interactions in patients with castration-resistant prostate cancer undergoing abiraterone therapy: Characterizing the scale of the problem.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Pharmacology; Abiraterone acetate; Internal medicine; CYP2D6; Adverse effect; Androgen deprivation therapy; CYP3A4; Drug; Cancer; Cytochrome P450","score_opus":0.12019595650274383,"score_gpt":0.4470968468812693,"score_spread":0.3269008903785255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418296065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97425216,0.00033210815,0.0000013704272,0.023981184,0.00042240924,0.00056160643,0.000006333463,0.000002616063,0.00044020213],"genre_scores_gemma":[0.99779814,0.0004906927,0.00023206415,0.00048792554,0.0002034139,0.000021171862,0.000002386748,0.000012102984,0.0007521006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778616,0.00041730076,0.0010973335,0.00011420804,0.0004038873,0.0001811085],"domain_scores_gemma":[0.9974619,0.0005447935,0.0010793075,0.00014851833,0.00062931835,0.00013613018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015786071,0.000096450094,0.0005291021,0.00006584176,0.000056763394,0.000013321644,0.00014280977,0.000039791084,0.000022853439],"category_scores_gemma":[0.0001685501,0.000038769016,0.0001202943,0.00019648376,0.00024683043,0.00016452894,0.000038363552,0.0007036425,0.0000014292289],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013993623,0.0014387912,0.95930976,0.00003108476,0.00023314469,0.000023785318,0.002078659,0.00004539875,0.00068936957,0.000008037526,0.00095515384,0.021193216],"study_design_scores_gemma":[0.014070271,0.0027277889,0.97391146,0.00048148303,0.00008169367,0.00001157685,0.00078368635,0.00001272497,0.0008668154,0.00010628057,0.0068944506,0.000051765473],"about_ca_topic_score_codex":0.00020815145,"about_ca_topic_score_gemma":0.0027630809,"teacher_disagreement_score":0.023545971,"about_ca_system_score_codex":0.0002907244,"about_ca_system_score_gemma":0.0029764948,"threshold_uncertainty_score":0.5280174},"labels":[],"label_agreement":null},{"id":"W2424161365","doi":"10.5489/cuaj.3914","title":"What’s new in prostate cancer research?","year":2016,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Canadian Urological Association","funders":"","keywords":"Prostate cancer; Prostate; Cancer; Medicine; Oncology; Gynecology; Internal medicine","score_opus":0.12145797476943362,"score_gpt":0.42322360851731583,"score_spread":0.30176563374788223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2424161365","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000053426465,0.95861703,1.7745597e-7,0.03843199,0.00091906736,0.0009588389,0.00007256461,0.0000138164705,0.00093310693],"genre_scores_gemma":[0.00003258254,0.9421544,0.000009086403,0.0004958828,0.0016896091,0.000119751996,0.00004802311,0.000039787352,0.05541085],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99576294,0.00081008516,0.0006740649,0.00041353525,0.0009077074,0.0014316848],"domain_scores_gemma":[0.99665344,0.0004747202,0.00032609564,0.00019028307,0.00046900476,0.0018864608],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023316082,0.00029627545,0.0012194724,0.0012034975,0.00024588985,0.00034310564,0.0002717474,0.00065339607,0.0028850783],"category_scores_gemma":[0.0009897569,0.00017063334,0.00036814046,0.0008722428,0.00007584112,0.0002570182,0.000044213786,0.002758962,0.0005254131],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000039579172,0.00002667853,0.0035912618,0.000301596,0.00020924455,0.0008541324,0.000061938925,1.3681053e-7,2.0635075e-7,0.000028783978,0.07166465,0.92322177],"study_design_scores_gemma":[0.001063121,0.0002119463,0.0011044475,0.008532352,0.00011460904,0.00016619325,0.000024939925,3.2963828e-7,2.1228472e-7,0.00063850655,0.9879683,0.00017504691],"about_ca_topic_score_codex":0.0032979876,"about_ca_topic_score_gemma":0.0038299388,"teacher_disagreement_score":0.92304677,"about_ca_system_score_codex":0.01267673,"about_ca_system_score_gemma":0.01617582,"threshold_uncertainty_score":0.9995417},"labels":[],"label_agreement":null},{"id":"W2426334275","doi":"","title":"[Diagnosis based on prostate needle biopsy: inadequate correlation between pathologic results and clinical course for individual prognosis].","year":2005,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Biopsy; Prostate cancer; Prostate; Malignancy; Prostatectomy; Cancer; Prostate-specific antigen; Prostate biopsy; Adenocarcinoma; Radiology; Urology; Pathology; Internal medicine","score_opus":0.10868802497072466,"score_gpt":0.364098978870673,"score_spread":0.25541095389994833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2426334275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97376,0.00023561028,0.000049481965,0.019688874,0.00013238368,0.0050973,0.00050337514,0.00008862395,0.00044432445],"genre_scores_gemma":[0.9908414,0.00012965786,0.0008214981,0.0003928799,0.0005030123,0.005987672,0.00073002785,0.000025951853,0.0005679051],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981028,0.00010838341,0.00045597783,0.00044914597,0.00032790398,0.0005558181],"domain_scores_gemma":[0.99848217,0.0007208422,0.00014999055,0.00020309386,0.000112407564,0.00033149868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016315484,0.00017668176,0.00032695063,0.00014277296,0.00016678219,0.000058221623,0.000063358144,0.00018191023,0.0000038837156],"category_scores_gemma":[0.0006194164,0.00012849063,0.00010101036,0.00020539029,0.00023326988,0.00009995519,0.000035384408,0.0002593421,0.000011428528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013788034,0.00040592818,0.58646816,0.000035779944,0.00006385243,0.000020941821,0.00011562799,0.000008825029,4.1394654e-7,0.000004291301,0.0013731061,0.4101243],"study_design_scores_gemma":[0.011351731,0.0009808997,0.9810898,0.000059020047,0.00032154494,0.0000055435426,0.000040712923,0.00072131486,0.0002849235,0.000044370965,0.0049595213,0.00014064026],"about_ca_topic_score_codex":0.000017579598,"about_ca_topic_score_gemma":0.000009856936,"teacher_disagreement_score":0.40998363,"about_ca_system_score_codex":0.00014644572,"about_ca_system_score_gemma":0.00019297728,"threshold_uncertainty_score":0.5239696},"labels":[],"label_agreement":null},{"id":"W2431521472","doi":"10.1111/iju.13137","title":"Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic","year":2016,"lang":"en","type":"review","venue":"International Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Medicine; Cabazitaxel; Androgen deprivation therapy; Androgen; Abiraterone acetate; Cancer research; Androgen Receptor Antagonists; Internal medicine; Cancer; Oncology; Hormone","score_opus":0.05431369724814229,"score_gpt":0.4238036131582497,"score_spread":0.36948991591010744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2431521472","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014418758,0.98780406,0.0000050526764,0.0083890455,0.0013437659,0.0005918514,0.00023109515,0.0000063911843,0.0001868806],"genre_scores_gemma":[0.0010535008,0.99584264,0.00014468926,0.00027494496,0.0007757354,0.0000807137,0.000063977524,0.000032039563,0.0017317818],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99775845,0.00019179346,0.0010383831,0.00023722973,0.0005019241,0.00027224442],"domain_scores_gemma":[0.9982367,0.00021712357,0.0005983549,0.00013161646,0.00064908667,0.00016711284],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047606084,0.00023231108,0.0010601192,0.0007992087,0.00002159157,0.000025261998,0.00035745176,0.00019810985,0.0014155926],"category_scores_gemma":[0.00014566559,0.00013672939,0.00032286483,0.00018742094,0.00007949774,0.00008615987,0.00006005606,0.00047087588,0.00011158928],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002411248,0.00019922486,0.0008765318,0.0004268755,0.0018367533,0.0010197546,0.00029115297,0.0000011539139,0.00020796257,0.000028283208,0.0043987045,0.98830235],"study_design_scores_gemma":[0.0018924006,0.0011235892,0.00024732432,0.0034748241,0.00017589712,0.00038679937,0.000017199423,3.1581138e-7,0.00002453416,0.00010276458,0.9924359,0.00011845835],"about_ca_topic_score_codex":0.000027667325,"about_ca_topic_score_gemma":0.00004225972,"teacher_disagreement_score":0.9881839,"about_ca_system_score_codex":0.0005856147,"about_ca_system_score_gemma":0.0016646344,"threshold_uncertainty_score":0.99949723},"labels":[],"label_agreement":null},{"id":"W2431963657","doi":"10.1158/0008-5472.can-16-0902","title":"Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":228,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Center for Research Resources; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; National Cancer Institute; Urology Foundation; Urology Care Foundation","keywords":"Prostate cancer; Cancer; Oncology; Prostate; Medicine; Internal medicine; Outcome (game theory); Biology","score_opus":0.17242886122125436,"score_gpt":0.4514678559211168,"score_spread":0.2790389946998625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2431963657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98279244,0.0017661847,0.000058704056,0.01248187,0.00010139326,0.0014593109,0.0002722347,0.000042016876,0.001025869],"genre_scores_gemma":[0.9630644,0.0019131459,0.00016146307,0.00005828575,0.00018613451,0.0010753362,0.00002840383,0.000049686707,0.033463184],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997183,0.000114884606,0.0003716803,0.00049287954,0.0011181191,0.0007194098],"domain_scores_gemma":[0.99714696,0.0001695264,0.00011576076,0.00044917729,0.0018274605,0.00029113438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008755831,0.00018635209,0.0004019297,0.00039221474,0.00011939734,0.000024258436,0.00021629003,0.00010706446,0.0006821106],"category_scores_gemma":[0.00018807958,0.00009339143,0.00006632118,0.0010858254,0.0007340562,0.00014620349,0.00007014097,0.00040606468,0.00004605528],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044008214,0.00020219173,0.36939746,0.0003099159,0.00015306276,0.000026420903,0.00023258428,5.141633e-7,0.60218674,0.00018309156,0.0027102744,0.02019694],"study_design_scores_gemma":[0.015042712,0.002656539,0.6152831,0.0039648637,0.0001491032,0.000033259916,0.0009102265,0.00004969204,0.33206165,0.00014995602,0.029284887,0.00041406712],"about_ca_topic_score_codex":0.001656079,"about_ca_topic_score_gemma":0.0003822515,"teacher_disagreement_score":0.2701251,"about_ca_system_score_codex":0.0010093687,"about_ca_system_score_gemma":0.0019570969,"threshold_uncertainty_score":0.74686325},"labels":[],"label_agreement":null},{"id":"W2437235705","doi":"10.1385/1-59259-356-9:17","title":"Rescue and Isolation of Rb-deficient Prostate Epithelium by Tissue Recombination","year":2003,"lang":"en","type":"article","venue":"Humana Press eBooks","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Prostate; Epithelium; Biology; Cancer research; Molecular biology; Genetics","score_opus":0.040252776542330324,"score_gpt":0.3163910391926347,"score_spread":0.2761382626503044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2437235705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88702315,0.015789576,0.00031631728,0.0002080515,0.0001554796,0.001992881,0.000039601444,0.000071415074,0.09440353],"genre_scores_gemma":[0.97026587,0.00064134225,0.00020688283,0.000025431924,0.000013451008,0.000058204118,0.000037133537,0.000017518658,0.028734198],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991841,0.00006240653,0.00018248786,0.00019676384,0.00020275918,0.00017150624],"domain_scores_gemma":[0.9995683,0.00002183612,0.000056614597,0.000173989,0.00011027876,0.00006896876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019845965,0.00009406975,0.0001578635,0.00007235874,0.000073824805,0.000017032422,0.000032243795,0.000051531468,0.00002543275],"category_scores_gemma":[0.000027573164,0.00007567915,0.000021897991,0.000021036973,0.00009171907,0.00004017584,0.000019508947,0.00009110155,0.0000023763453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023308576,0.0014856826,0.0056950203,0.0025502038,0.0005475807,0.000088278706,0.017584449,0.000029584264,0.45384473,0.069205575,0.018957492,0.42768055],"study_design_scores_gemma":[0.0069872844,0.0018030317,0.004221128,0.00030422714,0.00016423715,0.00002404181,0.0002232703,0.00042567035,0.8294949,0.0018817177,0.15417802,0.00029247339],"about_ca_topic_score_codex":0.00017253899,"about_ca_topic_score_gemma":0.000012361098,"teacher_disagreement_score":0.42738807,"about_ca_system_score_codex":0.000044635966,"about_ca_system_score_gemma":0.00003455477,"threshold_uncertainty_score":0.30861062},"labels":[],"label_agreement":null},{"id":"W2463483058","doi":"10.1111/iju.13148","title":"Chemotherapy for metastatic castration‐sensitive prostate cancer","year":2016,"lang":"en","type":"review","venue":"International Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Castration; Oncology; Chemotherapy; Internal medicine; Disease; Cancer; Prostate; Hormone","score_opus":0.07265611125186403,"score_gpt":0.4582757852015092,"score_spread":0.38561967394964514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2463483058","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000038109647,0.98985004,0.00044041604,0.007221953,0.0012101019,0.0007655939,0.00031995398,0.0000057369048,0.0001481029],"genre_scores_gemma":[0.00015332748,0.9955085,0.00043133594,0.00038003956,0.0011937736,0.00009651482,0.00006812492,0.00003876358,0.002129637],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985257,0.00008455949,0.00064396416,0.00017372976,0.00036372957,0.00020835652],"domain_scores_gemma":[0.99746835,0.00034612083,0.00073994684,0.00009012439,0.001250173,0.00010530369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002846468,0.00020760075,0.0010410527,0.00039626326,0.00002404426,0.000020622856,0.00019302,0.00010889597,0.00020280496],"category_scores_gemma":[0.00010569015,0.00011603387,0.00052703166,0.00006497543,0.00010288623,0.0000791101,0.000021564028,0.00026497807,0.000017489561],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012836612,0.000106026266,0.000012053242,0.000692182,0.0040978254,0.0005108025,0.00007920254,7.3302306e-7,0.000022805849,0.00011600547,0.002329457,0.99074924],"study_design_scores_gemma":[0.0033932296,0.0008145195,0.000013707638,0.0026341525,0.0009081056,0.0023227085,0.0000081582275,0.00000383565,0.000040079674,0.0002841592,0.9894821,0.00009524091],"about_ca_topic_score_codex":0.0000050148033,"about_ca_topic_score_gemma":0.0000031404218,"teacher_disagreement_score":0.990654,"about_ca_system_score_codex":0.00035912322,"about_ca_system_score_gemma":0.0014853007,"threshold_uncertainty_score":0.4731724},"labels":[],"label_agreement":null},{"id":"W2464012705","doi":"","title":"Prostate cancer among Canadian men","year":2007,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Gerontology; Family medicine; Internal medicine","score_opus":0.019613043371164245,"score_gpt":0.33637728992082355,"score_spread":0.3167642465496593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464012705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55909353,0.000602557,0.000005866458,0.0034396187,0.0000755111,0.00048924267,0.000009581914,0.00004270932,0.43624136],"genre_scores_gemma":[0.85641617,0.0002381832,0.0000798228,0.00037830006,0.000092480324,0.000027257893,0.000020074063,0.000012207261,0.14273554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991347,0.000004639733,0.00009441005,0.00014076241,0.00016622272,0.00045921703],"domain_scores_gemma":[0.99922955,0.000011542187,0.000011293049,0.00012308432,0.00007852451,0.00054602575],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017593951,0.00007361856,0.00009982287,0.0001438195,0.00007126811,0.000012270692,0.000037049238,0.000044283468,0.0015296993],"category_scores_gemma":[0.000008318348,0.000049119426,0.000029706462,0.00017932364,0.00006338165,0.000048877966,0.000010332331,0.000102644146,0.00007885383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015569903,0.000026977134,0.95141757,0.000025645899,0.00007655331,0.00038334413,0.0005331029,6.155566e-7,0.0008322925,0.00012502371,0.020292496,0.026130674],"study_design_scores_gemma":[0.0016648086,0.00012462462,0.89452577,0.00004687483,0.000030821964,0.000008828897,0.00037589425,0.00004713334,0.017813642,0.000038522143,0.08521384,0.000109231034],"about_ca_topic_score_codex":0.45016465,"about_ca_topic_score_gemma":0.5456189,"teacher_disagreement_score":0.29732257,"about_ca_system_score_codex":0.00041787635,"about_ca_system_score_gemma":0.0005130252,"threshold_uncertainty_score":0.99938303},"labels":[],"label_agreement":null},{"id":"W2464971010","doi":"10.1016/j.urology.2016.04.002","title":"Chemical vs Surgical ADT in Metastatic Prostate Cancer: A Comparison of Side Effects. Commentary on Comparison of Gonadotropin-releasing Hormone Agonists and Orchiectomy: Effects of Androgen Deprivation Therapy","year":2016,"lang":"en","type":"letter","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Orchiectomy; Adverse effect; Urology; Internal medicine; Testosterone (patch); Oncology; Cancer","score_opus":0.021967924314633416,"score_gpt":0.34038237262889737,"score_spread":0.31841444831426396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464971010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.899231,0.01972319,0.000011124331,0.07891889,0.00010277368,0.0018929867,0.000073205716,0.000015769308,0.000031060274],"genre_scores_gemma":[0.98416716,0.004256181,0.00007952759,0.010536756,0.00023024062,0.00019970657,0.00045584276,0.000055023716,0.000019583109],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972789,0.000521057,0.0007825173,0.00048100945,0.00043481443,0.0005016732],"domain_scores_gemma":[0.9971334,0.0018114916,0.0005299961,0.00033249255,0.00010444261,0.000088206114],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014084055,0.00038140098,0.002006501,0.0004022361,0.000031269563,0.0000049527102,0.00014789097,0.00039429148,0.000008190827],"category_scores_gemma":[0.0000648905,0.0002671138,0.00014317292,0.00021552105,0.00058646186,0.000033295695,0.00008509196,0.00097480323,0.0000011739671],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.066864386,0.0036234474,0.37926507,0.014490905,0.0041597253,0.001968926,0.0037611956,0.000038243586,0.22659148,0.000032129574,0.08743537,0.2117691],"study_design_scores_gemma":[0.08523027,0.031124925,0.061100125,0.003936743,0.0016024977,0.00010625457,0.000046040128,0.0014720242,0.73635167,0.0003761677,0.07762134,0.0010319388],"about_ca_topic_score_codex":0.00057170226,"about_ca_topic_score_gemma":0.000014845487,"teacher_disagreement_score":0.5097602,"about_ca_system_score_codex":0.00018745323,"about_ca_system_score_gemma":0.0002016706,"threshold_uncertainty_score":0.9999781},"labels":[],"label_agreement":null},{"id":"W2466790534","doi":"","title":"Chemotherapy for non-hormone refractory prostate cancer.","year":2006,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Prostate cancer; Chemotherapy; Docetaxel; Oncology; Internal medicine; Androgen deprivation therapy; Prostatectomy; Randomized controlled trial; Hormone therapy; Cancer; Breast cancer","score_opus":0.022830283051663347,"score_gpt":0.2981644069393756,"score_spread":0.2753341238877123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2466790534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9516447,0.012106001,0.000063358326,0.013915623,0.0002986844,0.007729516,0.0001163561,0.00015991877,0.0139658125],"genre_scores_gemma":[0.9252751,0.0025953264,0.00018178787,0.00038575561,0.00061747513,0.012672727,0.00010252317,0.00004220992,0.058127135],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99893695,0.0000069632033,0.00014858072,0.00022649302,0.00019060334,0.0004903844],"domain_scores_gemma":[0.99952716,0.000029202174,0.00004527727,0.00017313378,0.000101168174,0.00012404172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014953417,0.00011807586,0.00019544904,0.00007029504,0.0000690315,0.000019642792,0.000055003948,0.000058665162,0.000023239973],"category_scores_gemma":[0.000011829818,0.00008661989,0.0000797616,0.0001369953,0.00006113934,0.00006391768,0.00001118921,0.00009187253,0.0000065730123],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042926734,0.0005629989,0.028593654,0.00020394188,0.00020114066,0.000032774886,0.00015925859,0.0000027290182,0.0075167487,0.000044961263,0.12422451,0.8341646],"study_design_scores_gemma":[0.008616955,0.00018274877,0.70458525,0.000015434316,0.000047099515,0.0000037112222,0.00002013341,0.0000397457,0.014729198,0.0002524646,0.2713734,0.00013384168],"about_ca_topic_score_codex":0.00023850171,"about_ca_topic_score_gemma":0.000020514388,"teacher_disagreement_score":0.83403075,"about_ca_system_score_codex":0.0002417294,"about_ca_system_score_gemma":0.000099150166,"threshold_uncertainty_score":0.35322568},"labels":[],"label_agreement":null},{"id":"W2467669285","doi":"10.1118/1.4957780","title":"WE‐AB‐209‐11: Prostate Cancer Treatment Planning: Sensitivity and Representative Objective Function Weights","year":2016,"lang":"en","type":"article","venue":"Medical Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Radiation treatment planning; Centroid; Cluster analysis; Medical imaging; Medicine; Mathematics; Mathematical optimization; Computer science; Nuclear medicine; Algorithm; Statistics; Artificial intelligence; Radiology; Radiation therapy","score_opus":0.03619136844100977,"score_gpt":0.3532843084433435,"score_spread":0.31709294000233373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2467669285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833115,0.0016754076,0.0011150801,0.011653806,0.00026814512,0.0008473183,0.00007488344,0.00009833415,0.0009555592],"genre_scores_gemma":[0.99042994,0.0031694337,0.000019970008,0.00017416995,0.000682004,0.0001664199,0.00003064578,0.00002541747,0.005302027],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983078,0.00008521825,0.00016139112,0.0004571844,0.0006209028,0.00036748967],"domain_scores_gemma":[0.99890095,0.00030891324,0.00006390887,0.00020346057,0.00011748779,0.00040528094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015255073,0.00021476603,0.00034664586,0.00004534669,0.0001299746,0.000013767159,0.000029087014,0.00010034056,0.00012694372],"category_scores_gemma":[0.00007297085,0.000109408735,0.00007858339,0.00015910513,0.0003801623,0.00013617563,0.000054026295,0.00014741262,0.000028418115],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003793686,0.0010894786,0.46785682,0.00014954728,0.001071371,0.0012206984,0.0070197172,0.0000015860725,0.009138038,0.00035892034,0.006303561,0.5019966],"study_design_scores_gemma":[0.0413067,0.0068525784,0.44126713,0.0036475223,0.0011960688,0.00016514829,0.001980481,0.0005743485,0.46253788,0.012387077,0.0269761,0.0011089651],"about_ca_topic_score_codex":0.0003387621,"about_ca_topic_score_gemma":0.00006110538,"teacher_disagreement_score":0.50088763,"about_ca_system_score_codex":0.00038633484,"about_ca_system_score_gemma":0.00039362547,"threshold_uncertainty_score":0.44615588},"labels":[],"label_agreement":null},{"id":"W2471550522","doi":"","title":"Screening and hormonal therapy of localized prostate cancer shows major benefits on survival.","year":2000,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Hormonal therapy; Stage (stratigraphy); Disease; Cancer; Prostate; Oncology; Internal medicine; Localized disease; Quality of life (healthcare)","score_opus":0.054402969399709004,"score_gpt":0.2959246140200367,"score_spread":0.2415216446203277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471550522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97996086,0.01260772,0.0000014375963,0.0017085425,0.00004110131,0.0013841417,0.000078275436,0.000029803236,0.0041881446],"genre_scores_gemma":[0.9755495,0.014976177,0.00005503539,0.0002368325,0.00009320409,0.0012966304,0.000027794771,0.000023899727,0.0077409213],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99888504,0.00003284073,0.00015881214,0.00022678856,0.00033653958,0.00036000652],"domain_scores_gemma":[0.9995392,0.000047441066,0.0000346488,0.00014223876,0.000056722245,0.00017974408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002121947,0.0001271027,0.00025556836,0.000076222976,0.000057773115,0.000014707246,0.00005027335,0.000050826315,0.00035097043],"category_scores_gemma":[0.000010446662,0.000086135486,0.00005171704,0.00015357822,0.00010578108,0.000050512805,0.000013634928,0.000116515235,0.000002289627],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004852406,0.00011555197,0.044455625,0.000031266525,0.00017134764,0.000013662781,0.00012582174,0.000012624411,0.00019965529,0.000024599558,0.00033747606,0.94965994],"study_design_scores_gemma":[0.01068804,0.00035689658,0.9584737,0.00008383002,0.000040612325,0.0000057144616,0.000044624037,0.0000674455,0.016123937,0.000046119458,0.013924426,0.00014465177],"about_ca_topic_score_codex":0.00025607707,"about_ca_topic_score_gemma":0.000027563785,"teacher_disagreement_score":0.9495153,"about_ca_system_score_codex":0.00004298354,"about_ca_system_score_gemma":0.000038948176,"threshold_uncertainty_score":0.384288},"labels":[],"label_agreement":null},{"id":"W2472429093","doi":"10.1016/j.eururo.2016.06.033","title":"Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302","year":2016,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma; National Cancer Institute; Celgene","keywords":"Medicine; Abiraterone acetate; Docetaxel; Prostate cancer; Discontinuation; Prednisone; Post-hoc analysis; Internal medicine; Chemotherapy; Oncology; Enzalutamide; Placebo; Cancer; Prostate-specific antigen; Surgery; Urology; Androgen deprivation therapy; Pathology; Androgen receptor","score_opus":0.01391030899297009,"score_gpt":0.26569581402143905,"score_spread":0.25178550502846897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2472429093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99641484,0.00055403804,0.000011284689,0.0017797876,0.000021606964,0.0007237484,0.00041632177,0.000014141099,0.000064207044],"genre_scores_gemma":[0.99770635,0.0012991243,0.000051500694,0.00022972452,0.00001325842,0.00008054562,0.000114491006,0.000035713456,0.0004692726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856937,0.00021568152,0.0003184193,0.00037447512,0.00019576875,0.00032628587],"domain_scores_gemma":[0.99930334,0.000045863737,0.00012744154,0.00025835878,0.00014496839,0.000120001925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013846064,0.000211287,0.00046926818,0.00031569626,0.000026243039,0.000011276698,0.00005183157,0.000021925554,0.00023825925],"category_scores_gemma":[0.0000060119924,0.0001102975,0.00005900752,0.0002564505,0.00017524126,0.000066029854,0.000022002696,0.000058048103,0.0000077909635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017954871,0.00048204622,0.9525867,0.000039516424,0.0018968703,0.00038024574,0.0013306192,0.000015001865,0.004598533,0.0000032608161,0.0000064255396,0.020705903],"study_design_scores_gemma":[0.013970571,0.00639363,0.9774876,0.000045048768,0.0007982741,0.000002712408,0.000034850214,0.000015940395,0.00088247634,0.0000017308822,0.00025278993,0.00011436228],"about_ca_topic_score_codex":0.0002801519,"about_ca_topic_score_gemma":0.0013275314,"teacher_disagreement_score":0.024900906,"about_ca_system_score_codex":0.00016792171,"about_ca_system_score_gemma":0.000087284716,"threshold_uncertainty_score":0.44978017},"labels":[],"label_agreement":null},{"id":"W2474090921","doi":"10.1200/jco.2015.33.7_suppl.163","title":"Cautionary tale of active surveillance in intermediate-risk patients: Overall and cause-specific survival in the Sunnybrook experience.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Prostate cancer; Cohort; Median follow-up; Cancer; Progression-free survival; Surgery; Overall survival; Gastroenterology; Oncology","score_opus":0.15772649233795646,"score_gpt":0.466060687397871,"score_spread":0.30833419505991455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474090921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962861,0.000972409,0.000003200936,0.001213751,0.000606919,0.00020939927,0.000010890525,0.0000013591356,0.000695999],"genre_scores_gemma":[0.99526167,0.0042572613,0.00005015835,0.00014052057,0.00022157052,0.000006341991,0.000005441173,0.0000054998877,0.000051518186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973456,0.0008449782,0.0011151741,0.00013082648,0.0003891198,0.0001742765],"domain_scores_gemma":[0.9968612,0.001914847,0.0006132922,0.000116391835,0.00032987873,0.00016439226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002903102,0.00008252974,0.0007301318,0.00012296943,0.000013863774,0.00000413662,0.00012874411,0.0001521895,0.000024448025],"category_scores_gemma":[0.0020805574,0.00004604414,0.00009680306,0.00014263278,0.00042074436,0.00011498642,0.000053480242,0.00074969744,0.0000018141018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074629537,0.0013070141,0.96813995,0.000008308014,0.00004983651,0.00032944625,0.0028606951,0.0000046188384,0.000008468097,0.000023897039,0.00097271334,0.018832099],"study_design_scores_gemma":[0.012669139,0.006271469,0.9727579,0.000045975663,0.000013873056,0.000026118263,0.002234949,0.000019168156,0.000015028917,0.00034447358,0.0055603073,0.0000416136],"about_ca_topic_score_codex":0.00007639711,"about_ca_topic_score_gemma":0.0003217532,"teacher_disagreement_score":0.018790485,"about_ca_system_score_codex":0.00022834902,"about_ca_system_score_gemma":0.0007810918,"threshold_uncertainty_score":0.32571042},"labels":[],"label_agreement":null},{"id":"W2474545910","doi":"10.1007/s40262-016-0425-0","title":"Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Pharmacokinetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Janssen Research and Development","keywords":"Prostate cancer; Abiraterone; Medicine; Oncology; Abiraterone acetate; Prostate; Prostate-specific antigen; Castration; Internal medicine; Cancer; Urology; Hormone; Androgen deprivation therapy; Androgen receptor","score_opus":0.11871878469080704,"score_gpt":0.40642099729193215,"score_spread":0.2877022126011251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474545910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99084055,0.0005623449,0.00026953884,0.005981077,0.000097972115,0.0019428668,0.00024555522,0.000026255744,0.000033836357],"genre_scores_gemma":[0.9976428,0.0008554172,0.0005372218,0.00017394041,0.000113703165,0.00013358693,0.00008521857,0.000041797786,0.00041630675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979017,0.00016623447,0.00069318607,0.00043525614,0.00040948583,0.00039415894],"domain_scores_gemma":[0.9985182,0.0005613788,0.000098467564,0.0002765101,0.00026285838,0.00028254418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005479248,0.00021456495,0.0003602067,0.00010571908,0.000118053766,0.00004503286,0.0001110028,0.00006180075,0.000025859192],"category_scores_gemma":[0.00014244489,0.0001062101,0.000044310575,0.0003302885,0.0002150006,0.00011433673,0.00006465616,0.00033835086,0.000012214282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002915503,0.00019218102,0.9841533,0.000059140406,0.000093047536,0.000019107481,0.0002396365,0.00031861232,0.00023702084,0.000037761227,0.00012560832,0.01160913],"study_design_scores_gemma":[0.01042843,0.0015605553,0.98575914,0.00034154244,0.00013304722,6.481461e-7,0.00009565578,0.00092612696,0.00011283273,0.00014532602,0.00031515045,0.00018154898],"about_ca_topic_score_codex":0.00003930914,"about_ca_topic_score_gemma":0.000099141216,"teacher_disagreement_score":0.01142758,"about_ca_system_score_codex":0.0002247143,"about_ca_system_score_gemma":0.00019578739,"threshold_uncertainty_score":0.43311223},"labels":[],"label_agreement":null},{"id":"W2475497292","doi":"10.1172/jci.insight.87850","title":"An imaging agent to detect androgen receptor and its active splice variants in prostate cancer","year":2016,"lang":"en","type":"article","venue":"JCI Insight","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; BC Cancer Agency; Canada's Michael Smith Genome Sciences Centre","keywords":"Prostate cancer; Androgen receptor; splice; Cancer research; Androgen; Prostate; Internal medicine; Medicine; Oncology; Cancer; Biology; Hormone; Gene; Genetics","score_opus":0.027437687820504555,"score_gpt":0.3349729627620629,"score_spread":0.30753527494155836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2475497292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915235,0.0025535214,0.000010315043,0.0038638618,0.00011342715,0.0009214842,0.00006533334,0.0000336687,0.00091490656],"genre_scores_gemma":[0.9947652,0.0026372045,0.0001267139,0.00034955237,0.000111603214,0.00023055747,0.000007802544,0.000026274334,0.001745098],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989214,0.00004807736,0.00013788565,0.0003636059,0.00018966438,0.0003393612],"domain_scores_gemma":[0.9993905,0.000032925367,0.00003090951,0.00017315803,0.00009245015,0.00028007443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010363478,0.00013639842,0.00019560353,0.00016488053,0.00005516438,0.000016011652,0.000060319246,0.00003462734,0.00023155777],"category_scores_gemma":[0.000034070184,0.00008046866,0.000021197897,0.00022829312,0.000031194828,0.0002318214,0.000050450162,0.00009216547,0.00006188327],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021482653,0.00014958894,0.04243847,0.000069909875,0.00008222591,0.00031089177,0.0044645676,8.646684e-7,0.63710546,0.000016980444,0.0007995312,0.31241322],"study_design_scores_gemma":[0.0080500515,0.00089185947,0.16926153,0.0008239896,0.000056179495,0.00003624898,0.00030987768,0.000101287296,0.772755,0.000092419585,0.04725139,0.00037017177],"about_ca_topic_score_codex":0.00017472457,"about_ca_topic_score_gemma":0.00013598838,"teacher_disagreement_score":0.31204304,"about_ca_system_score_codex":0.00032101016,"about_ca_system_score_gemma":0.0001596373,"threshold_uncertainty_score":0.32814166},"labels":[],"label_agreement":null},{"id":"W2476304059","doi":"10.1158/1538-7445.am2016-1342","title":"Abstract 1342: A production-scalable cabazitaxel cellulose nanoparticle exhibits significant efficacy in a bone model of docetaxel-resistant prostate cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Precision Nanosystems (Canada); Ontario Institute for Cancer Research","funders":"","keywords":"LNCaP; Docetaxel; Prostate cancer; Chemistry; Cabazitaxel; Prostate; Pharmacology; Cancer; Medicine; Internal medicine; Androgen deprivation therapy","score_opus":0.08827190825515753,"score_gpt":0.3820867306795323,"score_spread":0.2938148224243748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2476304059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809054,0.007569013,0.0000039093625,0.008026729,0.00011441647,0.0025073593,0.00018614525,0.00005127956,0.00063571945],"genre_scores_gemma":[0.96886265,0.0057071564,0.00007923214,0.000026217222,0.00015823786,0.001565251,0.0000087575945,0.0000730491,0.02351945],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99534005,0.00015507071,0.00068631023,0.00090842816,0.0015106759,0.0013994555],"domain_scores_gemma":[0.99742323,0.00025439207,0.00013673467,0.0007109639,0.0010058399,0.00046881224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015631716,0.0002904369,0.00060907094,0.00058669015,0.00015451924,0.00003915422,0.0002547757,0.00013693607,0.00076626707],"category_scores_gemma":[0.00040785494,0.00018493645,0.00012848788,0.0013272722,0.0007242919,0.00027716794,0.00015860429,0.0005552801,0.00007520568],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058732657,0.0012974474,0.0081024105,0.00065824046,0.00010543021,0.0001418992,0.001213224,0.00034262956,0.9655794,0.00006962481,0.003177986,0.013438466],"study_design_scores_gemma":[0.00763352,0.0004447161,0.018628819,0.0018938065,0.000038312945,0.0000034787834,0.00023651804,0.0003242454,0.96951663,0.00022542146,0.00079492875,0.00025958652],"about_ca_topic_score_codex":0.003073884,"about_ca_topic_score_gemma":0.0008610958,"teacher_disagreement_score":0.022883732,"about_ca_system_score_codex":0.0013189875,"about_ca_system_score_gemma":0.0025428291,"threshold_uncertainty_score":0.8390087},"labels":[],"label_agreement":null},{"id":"W2479321545","doi":"10.1158/1538-7445.am2016-118","title":"Abstract 118: A comprehensive profile of the genomic architecture of curable prostate cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Prostate cancer; PTEN; Exome sequencing; Chromoplexy; Medicine; Exome; Genomics; Cancer; Prostatectomy; TMPRSS2; Copy-number variation; Disease; Oncology; Biology; Cancer research; Bioinformatics; Genome; Gene; Internal medicine; Genetics; Mutation; PCA3","score_opus":0.07171690543858308,"score_gpt":0.4020554831768738,"score_spread":0.3303385777382907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2479321545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790409,0.009262986,0.0000020576342,0.0065805097,0.00013677434,0.0019135331,0.00045077057,0.00001621895,0.0025962305],"genre_scores_gemma":[0.9829915,0.004702673,0.000041439267,0.00004272634,0.00014595604,0.00061015796,0.00000591327,0.000039258877,0.011420383],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975291,0.00013455917,0.00032645458,0.0003636656,0.0009787957,0.0006674221],"domain_scores_gemma":[0.99780387,0.00025252448,0.00013021205,0.00060832856,0.0010329603,0.00017209568],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037046187,0.00016318152,0.0003879948,0.00021250089,0.00013627813,0.0000107112755,0.00035449854,0.000089873975,0.00161854],"category_scores_gemma":[0.00008290229,0.000075497774,0.00014945105,0.00062973617,0.0010214872,0.00006200685,0.00021932217,0.00048114738,0.000025033132],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018269592,0.0001348498,0.035731427,0.000964662,0.00021721094,0.000014332049,0.0007646779,0.000019874022,0.9024694,0.00005652362,0.005519939,0.052280128],"study_design_scores_gemma":[0.0039325245,0.00036774573,0.16565743,0.0021308272,0.000041216448,0.000007305792,0.00026610168,0.0000053041927,0.8030348,0.00045807223,0.023963748,0.0001349595],"about_ca_topic_score_codex":0.001797361,"about_ca_topic_score_gemma":0.0001794608,"teacher_disagreement_score":0.129926,"about_ca_system_score_codex":0.00047016938,"about_ca_system_score_gemma":0.0019452063,"threshold_uncertainty_score":0.9992941},"labels":[],"label_agreement":null},{"id":"W2481325258","doi":"10.1158/1538-7445.am2016-1800","title":"Abstract 1800: Inhibition of scavenger receptor class B type I suppresses androgen pathway activity and induces cytotoxic stress in C4-2 castration resistant prostate cancer cells","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; University of British Columbia","funders":"","keywords":"Androgen receptor; LNCaP; Prostate cancer; Endocrinology; Androgen; Propidium iodide; Internal medicine; Cytotoxic T cell; Chemistry; Medicine; Cancer research; Apoptosis; In vitro; Cancer; Biochemistry; Hormone; Programmed cell death","score_opus":0.0692038344768584,"score_gpt":0.3741344729543396,"score_spread":0.3049306384774812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2481325258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926447,0.0030976115,4.001056e-7,0.001867546,0.00011425955,0.0012641735,0.0006941653,0.000019704543,0.00029738943],"genre_scores_gemma":[0.98546755,0.012783115,0.000015155546,0.000008639559,0.00014713025,0.0004099516,0.00003001677,0.00003538984,0.0011030529],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975606,0.00020465827,0.00030684084,0.0005124262,0.0008045493,0.00061088044],"domain_scores_gemma":[0.99854064,0.00022388868,0.00010513814,0.00028811675,0.00061960233,0.00022262809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007283124,0.00018961492,0.00034965624,0.00038888797,0.00011675045,0.00004406989,0.000093307586,0.00017083435,0.0005227798],"category_scores_gemma":[0.00009831754,0.00012561373,0.00004266395,0.000610563,0.0004485539,0.00032480218,0.000090320864,0.00042227973,0.000012466843],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004213166,0.0002487023,0.011367744,0.00069499144,0.00006229901,0.00006613635,0.000552372,0.000003427752,0.9623554,0.000015024006,0.000551496,0.019869262],"study_design_scores_gemma":[0.0024831563,0.0005266739,0.04353639,0.001673165,0.000011977961,0.0000015619382,0.00025227945,0.0000033446445,0.95066136,0.00005582851,0.00065957935,0.00013465651],"about_ca_topic_score_codex":0.0023801017,"about_ca_topic_score_gemma":0.0019705899,"teacher_disagreement_score":0.032168645,"about_ca_system_score_codex":0.0006836264,"about_ca_system_score_gemma":0.0013001553,"threshold_uncertainty_score":0.57240725},"labels":[],"label_agreement":null},{"id":"W2483834070","doi":"10.1016/s1470-2045(16)30173-5","title":"Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":291,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Cilag; Johnson and Johnson","keywords":"Medicine; Prostate cancer; Concomitant; Clinical trial; Lymph node; Asymptomatic; Radium-223; Cancer; Internal medicine; Oncology; Surgery; Bone metastasis","score_opus":0.16484752784240742,"score_gpt":0.44727528475559597,"score_spread":0.28242775691318855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2483834070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98307264,0.00041856267,0.0000048153684,0.013085292,0.00020991785,0.0023528102,0.00018592921,0.000021174435,0.00064885966],"genre_scores_gemma":[0.99702454,0.001143083,0.0002445962,0.00042778606,0.00019444544,0.00044361746,0.000054601114,0.000021555637,0.00044577822],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985675,0.00025858474,0.0002818819,0.00030267469,0.00025291726,0.000336446],"domain_scores_gemma":[0.99908775,0.0002212298,0.00016707859,0.00026536835,0.00015603566,0.00010253291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047330768,0.00016043198,0.0004876709,0.00008352287,0.00009523188,0.00012169175,0.0003593854,0.000045033197,0.0001298351],"category_scores_gemma":[0.000051424347,0.00007236603,0.000013728256,0.0001431057,0.0003228304,0.0004901302,0.000104062616,0.00014936808,0.0000034411505],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6867419,0.011493723,0.14454362,0.00006256473,0.0009421085,0.00025001814,0.0036521582,0.0000010756519,0.009180187,0.00081791094,0.0008969849,0.14141774],"study_design_scores_gemma":[0.8036093,0.04201247,0.13564974,0.00026026968,0.00018457406,0.000011967863,0.00027295257,0.000025012398,0.0012624726,0.00077410834,0.01568312,0.00025400828],"about_ca_topic_score_codex":0.0005488482,"about_ca_topic_score_gemma":0.0013382263,"teacher_disagreement_score":0.14116374,"about_ca_system_score_codex":0.00039825143,"about_ca_system_score_gemma":0.00047063973,"threshold_uncertainty_score":0.2951001},"labels":[],"label_agreement":null},{"id":"W2485137616","doi":"10.1016/j.jsbmb.2016.07.013","title":"Reply to Commentary Letter by Dr. Melvin Khee Shing Leow","year":2016,"lang":"en","type":"letter","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canada Research Chairs","funders":"","keywords":"Ketoconazole; Prostate cancer; Androgen; Androgen receptor; Blockade; Endocrinology; Lyase; Testosterone (patch); Internal medicine; Biology; Receptor; Cancer research; Medicine; Hormone; Cancer; Enzyme; Biochemistry","score_opus":0.012519504867646988,"score_gpt":0.2978380761808221,"score_spread":0.2853185713131751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2485137616","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07787228,0.00855184,0.000239529,0.91270447,0.00016238943,0.00020823545,0.00009254638,0.0000060434736,0.00016267698],"genre_scores_gemma":[0.012727086,0.0014295522,0.00010038179,0.980151,0.0027848687,0.0000072539,0.00017590074,0.000035211568,0.002588718],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985478,0.00017431566,0.00039191564,0.00024873723,0.00023063307,0.0004066349],"domain_scores_gemma":[0.99896944,0.00011527821,0.00026241536,0.00038224238,0.00012041183,0.00015019992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043472092,0.00028013124,0.00048343514,0.0000761634,0.00008483696,0.000022431297,0.00031963093,0.00038699261,0.000047964506],"category_scores_gemma":[0.00004078438,0.00014263863,0.00014915432,0.000055958477,0.00029021042,0.000023527975,0.00017697184,0.0011791573,0.0000048980223],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002974697,0.0000106576845,0.000042762866,0.00006744708,0.00025747367,0.00034020928,0.000038541108,1.0777646e-8,0.46384838,8.783492e-8,0.5342372,0.0008597363],"study_design_scores_gemma":[0.00093150523,0.0005066741,0.0000032451567,0.0002587496,0.00016229767,0.0006461761,0.000019777146,8.9599e-8,0.410757,0.000039612507,0.5865662,0.00010863489],"about_ca_topic_score_codex":0.000016962887,"about_ca_topic_score_gemma":1.4606147e-7,"teacher_disagreement_score":0.06744657,"about_ca_system_score_codex":0.000115004645,"about_ca_system_score_gemma":0.00008472227,"threshold_uncertainty_score":0.5816634},"labels":[],"label_agreement":null},{"id":"W2488212638","doi":"10.1200/jco.2013.31.6_suppl.111","title":"Study of the impact of Charlson comorbidity index and hypertension on survival in patients with metastatic castration-resistant prostate cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Prostate cancer; Docetaxel; Enzalutamide; Proportional hazards model; Oncology; Cancer; Sunitinib; Performance status; Charlson comorbidity index; Comorbidity; Placebo; Anemia; Urology; Pathology","score_opus":0.1683811252259598,"score_gpt":0.4779750371065477,"score_spread":0.30959391188058794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2488212638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981408,0.00007948327,2.1081675e-7,0.00074701203,0.00013007615,0.0008405987,0.000009129389,7.9329027e-7,0.000051904954],"genre_scores_gemma":[0.9996911,0.00017412253,0.00002292152,0.000034073375,0.000034579207,0.000007730572,0.0000011341822,0.0000065796803,0.000027712444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790096,0.0004351228,0.0010019855,0.00010340854,0.0004304156,0.0001281081],"domain_scores_gemma":[0.997545,0.000625823,0.0009560101,0.00012459367,0.00062489754,0.00012369451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009111343,0.000089611494,0.0008983934,0.0000847309,0.000021572938,0.0000037508023,0.000068484675,0.000059821727,0.00002990251],"category_scores_gemma":[0.0004208639,0.000037117105,0.00010309589,0.00014760766,0.00016993292,0.000070116716,0.000027866387,0.00044020626,3.442786e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013847156,0.0057033645,0.96944445,0.000025027392,0.00034871278,0.000051006453,0.00027943432,0.000069149006,0.00015856959,0.0000010709924,0.00010333274,0.00996872],"study_design_scores_gemma":[0.02151941,0.048598997,0.9290494,0.0001446894,0.00012315012,0.0000053195427,0.00039672904,0.000049342416,0.000050841678,0.000025236634,0.0000061232913,0.000030781168],"about_ca_topic_score_codex":0.0018214616,"about_ca_topic_score_gemma":0.0005595195,"teacher_disagreement_score":0.042895634,"about_ca_system_score_codex":0.00013486517,"about_ca_system_score_gemma":0.0010097455,"threshold_uncertainty_score":0.27535173},"labels":[],"label_agreement":null},{"id":"W2489425084","doi":"10.1016/j.eururo.2016.07.032","title":"Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study","year":2016,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":419,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Chemotherapy; Internal medicine; Docetaxel; Urology; Gynecology; Cancer; Androgen receptor","score_opus":0.025524197897897706,"score_gpt":0.33593789526287937,"score_spread":0.31041369736498164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2489425084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931764,0.00047145082,0.000017118438,0.0028918115,0.000019593685,0.001207122,0.00005998406,0.000017176832,0.0021393378],"genre_scores_gemma":[0.99655616,0.00020563269,0.000033102406,0.00015780797,0.000019496063,0.000071964765,0.000008721425,0.000027744556,0.0029193852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998184,0.00059373956,0.0003362625,0.0003344332,0.00027146837,0.00028004675],"domain_scores_gemma":[0.99912375,0.000106286345,0.0001569533,0.000433597,0.000107436965,0.000072002236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004982217,0.00015431941,0.0004039917,0.0002481921,0.000045790614,0.000007695868,0.00015073633,0.000014614692,0.00022430018],"category_scores_gemma":[0.000044461158,0.00006808287,0.00007979196,0.000757512,0.0002110637,0.000046387442,0.000042319673,0.00011440485,0.0000069569096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029369986,0.006239229,0.6577779,0.00011446989,0.011840619,0.0016348419,0.013899769,0.00024792395,0.2118217,0.000075497985,0.0005563786,0.06642164],"study_design_scores_gemma":[0.023239616,0.0044839326,0.96317035,0.000044198146,0.0022590314,0.000010286318,0.00058552285,0.00015877481,0.005024325,0.000017760025,0.00087639067,0.00012983516],"about_ca_topic_score_codex":0.00016384576,"about_ca_topic_score_gemma":0.000669256,"teacher_disagreement_score":0.30539238,"about_ca_system_score_codex":0.000091707785,"about_ca_system_score_gemma":0.00018567947,"threshold_uncertainty_score":0.27763388},"labels":[],"label_agreement":null},{"id":"W2490975642","doi":"10.1158/1538-7445.am2016-4339","title":"Abstract 4339: Prognostic significance of copy number alteration burden in unfavorable intermediate-risk prostate cancers harboring intraductal carcinoma and cribriform architecture","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; Université Laval; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Cohort; Biochemical recurrence; Oncology; Internal medicine; Cribriform; Prostate; Cancer; Hazard ratio; Pathological; Clinical endpoint; Carcinoma; Pathology; Confidence interval; Clinical trial","score_opus":0.03260565768850089,"score_gpt":0.35373409606618317,"score_spread":0.3211284383776823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2490975642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930077,0.0020138978,0.000029188535,0.0021234013,0.00013672652,0.0019305632,0.00018020794,0.000029641571,0.00054865447],"genre_scores_gemma":[0.99260587,0.0052989353,0.000113045564,0.0000132922,0.0003267251,0.00075719453,0.000023092136,0.000050390052,0.00081147935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970279,0.0001541641,0.0004735224,0.0006200675,0.00080922537,0.00091517554],"domain_scores_gemma":[0.99831426,0.00045597984,0.00012784451,0.00034807975,0.0004333836,0.0003204512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095953804,0.0002396167,0.00042767334,0.0003739205,0.00013349406,0.000055813696,0.00018500662,0.000119058146,0.00030751782],"category_scores_gemma":[0.00041653143,0.00015842251,0.00005880243,0.00060646544,0.0007239322,0.00025485203,0.00011448931,0.0007359119,0.000019262165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027110234,0.00008308121,0.7055578,0.0009211178,0.000096769276,0.00016752453,0.002585983,0.00005245272,0.19916491,0.000042829437,0.0003155974,0.0883009],"study_design_scores_gemma":[0.008620056,0.001241808,0.57165873,0.0034015134,0.00006325148,0.000033023112,0.00093758234,0.00016398303,0.41037935,0.0015569895,0.0014978203,0.00044588227],"about_ca_topic_score_codex":0.007414115,"about_ca_topic_score_gemma":0.0008165751,"teacher_disagreement_score":0.21121445,"about_ca_system_score_codex":0.0011909688,"about_ca_system_score_gemma":0.0016435235,"threshold_uncertainty_score":0.9991956},"labels":[],"label_agreement":null},{"id":"W2492293688","doi":"10.1200/jco.2016.34.2_suppl.24","title":"Incidence of testosterone escape with LHRH agonists in patients receiving radiotherapy for prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Cancer Care Ontario; Dalhousie University","funders":"","keywords":"Medicine; Radiation therapy; Goserelin; Androgen deprivation therapy; Prostate cancer; Testosterone (patch); Internal medicine; Incidence (geometry); Oncology; Androgen suppression; Cancer; Urology; Gynecology","score_opus":0.08446186286263296,"score_gpt":0.4741246693844115,"score_spread":0.38966280652177854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2492293688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989513,0.0009733457,0.00011918757,0.0083732065,0.00032017875,0.0005645126,0.000008946752,0.0000031032407,0.00012451201],"genre_scores_gemma":[0.9904201,0.0044885576,0.0038898694,0.00033000184,0.0002673193,0.000025464393,0.0000011870089,0.000017369597,0.0005601017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779046,0.0001686376,0.0013191891,0.00015745831,0.0003166534,0.00024762648],"domain_scores_gemma":[0.99614024,0.0017222709,0.0011387938,0.0001261928,0.0006760253,0.00019649636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016613617,0.00010158685,0.0010154922,0.00012644712,0.000019398854,0.0000034888767,0.000120208155,0.00015130024,0.00004147518],"category_scores_gemma":[0.0012890327,0.000048375798,0.00013852863,0.00013446517,0.00026269158,0.00012653721,0.00002055367,0.00028279278,8.6813105e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021881731,0.00078963384,0.6504122,0.000045550474,0.00014943354,0.0000485073,0.0001146845,0.0000022594973,0.0010086516,0.0000029649666,0.0004162122,0.32512814],"study_design_scores_gemma":[0.038438812,0.04347861,0.9100794,0.0010485372,0.00007821817,0.000025552303,0.00002524275,0.000013022739,0.00097550586,0.00009296929,0.0056744847,0.00006961899],"about_ca_topic_score_codex":0.000028549432,"about_ca_topic_score_gemma":0.00013849072,"teacher_disagreement_score":0.32505852,"about_ca_system_score_codex":0.00038550727,"about_ca_system_score_gemma":0.001959063,"threshold_uncertainty_score":0.34752938},"labels":[],"label_agreement":null},{"id":"W2494450199","doi":"10.1016/j.urology.2016.08.002","title":"Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation","year":2016,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Radiation therapy; Prostatectomy; Internal medicine; Retrospective cohort study; Cohort; Hazard ratio; Myocardial infarction; Oncology; Cohort study; Cancer; Proportional hazards model; Surgery; Confidence interval","score_opus":0.01504748497860395,"score_gpt":0.2790330028593465,"score_spread":0.26398551788074254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2494450199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92558557,0.072778344,0.00004664947,0.0009998475,0.00005325814,0.00045237903,0.000013051482,0.000020760015,0.000050145638],"genre_scores_gemma":[0.9768447,0.0226398,0.000026489808,0.000031826854,0.000023124649,0.00007838387,0.000015928546,0.000019649306,0.00032009566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991001,0.00009170579,0.00018409801,0.00025999418,0.00013339141,0.00023071225],"domain_scores_gemma":[0.9995525,0.00009913283,0.00004946578,0.00017258563,0.000035956647,0.00009035078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017215888,0.00012454588,0.0004455877,0.000119115946,0.000043403983,0.0000029690434,0.000021811687,0.000098089076,0.000040022253],"category_scores_gemma":[0.00002375709,0.00007358976,0.00015663145,0.00010165032,0.00011148588,0.00005377326,0.0000184294,0.000036996087,0.0000014824353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069342856,0.00007327871,0.69455016,0.000033966728,0.0026382706,0.000051376574,0.00036712093,0.0000046754417,0.020465048,0.000018493676,0.000013172086,0.281091],"study_design_scores_gemma":[0.10901922,0.006297078,0.62072545,0.00057161925,0.004987815,0.00068296865,0.00020265824,0.0015880011,0.109886035,0.004305749,0.14062269,0.0011106838],"about_ca_topic_score_codex":0.00022602949,"about_ca_topic_score_gemma":0.00000981458,"teacher_disagreement_score":0.27998033,"about_ca_system_score_codex":0.00008662013,"about_ca_system_score_gemma":0.00009076849,"threshold_uncertainty_score":0.30009034},"labels":[],"label_agreement":null},{"id":"W2495059596","doi":"10.1016/j.eururo.2016.07.027","title":"Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial","year":2016,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Queen's University; Health Sciences Centre","funders":"","keywords":"Medicine; Enzalutamide; Hazard ratio; Prostate cancer; Confidence interval; Bicalutamide; Internal medicine; Quality of life (healthcare); Oncology; Urology; Cancer; Androgen receptor","score_opus":0.16597122953671442,"score_gpt":0.44820777346541885,"score_spread":0.28223654392870445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2495059596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937417,0.00017042967,0.00003393916,0.0017807616,0.000020584072,0.0012158373,0.0021529535,0.000011973765,0.0008718219],"genre_scores_gemma":[0.9990139,0.000097714976,0.00013393108,0.00015404909,0.000108468776,0.00007660749,0.00027192655,0.000023008204,0.00012038929],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99558866,0.0025249189,0.0009121341,0.0003335536,0.00039008097,0.00025067784],"domain_scores_gemma":[0.99515516,0.0037295453,0.000475332,0.00034428766,0.00015323999,0.00014243361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012571111,0.00018208496,0.000808423,0.000101382204,0.00003680685,0.000006844133,0.00013993408,0.00002878556,0.00085967046],"category_scores_gemma":[0.00088698394,0.00007028948,0.00016676683,0.00020026142,0.00068707985,0.000041324998,0.00002680455,0.00019788204,0.0000073919846],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8856599,0.0007946288,0.099255644,0.000017658647,0.001621158,0.00010982045,0.00036542627,0.00017290028,0.009073781,0.000015210922,0.0018999759,0.001013941],"study_design_scores_gemma":[0.26956984,0.0075606117,0.7219595,0.000115323906,0.00021649024,0.0000023694936,0.00007931839,0.000045619126,0.00022582767,0.000029018824,0.000109069326,0.00008702961],"about_ca_topic_score_codex":0.0012630129,"about_ca_topic_score_gemma":0.0007596666,"teacher_disagreement_score":0.62270385,"about_ca_system_score_codex":0.00007797938,"about_ca_system_score_gemma":0.00080799725,"threshold_uncertainty_score":0.9412789},"labels":[],"label_agreement":null},{"id":"W2495899124","doi":"10.1007/s13139-016-0439-4","title":"Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges","year":2016,"lang":"en","type":"review","venue":"Nuclear Medicine and Molecular Imaging","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Windsor","funders":"","keywords":"Antiandrogens; Enzalutamide; Medicine; Prostate cancer; Androgen deprivation therapy; Glutamate carboxypeptidase II; Targeted therapy; Androgen receptor; Oncology; Bicalutamide; Cancer research; Antiandrogen; Internal medicine; Pharmacology; Cancer","score_opus":0.14448616692864868,"score_gpt":0.3673068086906885,"score_spread":0.2228206417620398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2495899124","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020505784,0.97148895,0.0000017143965,0.006388998,0.000020559648,0.00058094674,0.000008506028,0.000014200949,0.0009903657],"genre_scores_gemma":[0.0046116626,0.9945525,0.000031979693,0.0006638397,0.000037593454,0.00001784995,0.000017018609,0.000045136003,0.000022425767],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99874794,0.00009303024,0.0003992037,0.0002547276,0.00032453527,0.00018052962],"domain_scores_gemma":[0.9991362,0.00010154206,0.00024284163,0.00030198562,0.00012652909,0.00009087207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003753251,0.0002357227,0.0007948735,0.00023920879,0.0000598392,0.000005609692,0.00009776337,0.00006690405,0.000040842155],"category_scores_gemma":[0.00012457096,0.000114946095,0.00009062037,0.00010371712,0.00038923539,0.00004623006,0.000059206322,0.00016460812,0.0000010285033],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000466868,0.000025486675,0.000014670699,0.004145893,0.00028808363,0.00006902321,0.00079997064,5.1099104e-8,0.00057801494,0.0007948657,0.0002421135,0.99299514],"study_design_scores_gemma":[0.0011159619,0.0003042794,0.0001571227,0.024626622,0.0003156959,0.00005342332,0.0006625888,0.0000074935388,0.00013296648,0.000081868566,0.9724277,0.00011427845],"about_ca_topic_score_codex":0.00001682402,"about_ca_topic_score_gemma":1.3077192e-7,"teacher_disagreement_score":0.9928809,"about_ca_system_score_codex":0.00002323994,"about_ca_system_score_gemma":0.000103902996,"threshold_uncertainty_score":0.46873656},"labels":[],"label_agreement":null},{"id":"W2498190063","doi":"10.1158/1538-7445.am2016-1976","title":"Abstract 1976: Androgen receptor activity is reprogrammed by lysine-specific demethylase 1 in prostate cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"FOXA1; Enzalutamide; Androgen receptor; Prostate cancer; Enhancer; Demethylase; Cancer research; Transcription factor; Histone; Coactivator; Biology; Chemistry; Cancer; Biochemistry; Genetics; Gene","score_opus":0.10823051482741243,"score_gpt":0.4313663604379637,"score_spread":0.3231358456105513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2498190063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9517189,0.020790726,0.000003851383,0.02387445,0.00017612297,0.0020306073,0.0005429667,0.00007606271,0.0007863103],"genre_scores_gemma":[0.9207543,0.05617313,0.00004960134,0.000120177996,0.00034673154,0.002706387,0.00004278592,0.00008770625,0.019719137],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99527615,0.00023041075,0.00038694535,0.0011089089,0.0014278922,0.0015697025],"domain_scores_gemma":[0.99758285,0.00029365317,0.00008935197,0.0007929449,0.0006213134,0.00061990053],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015931766,0.0003098856,0.00052057486,0.0004881357,0.00021262815,0.00008443621,0.0003068389,0.00018739003,0.005773861],"category_scores_gemma":[0.00014984615,0.00019730107,0.00013974964,0.0014351305,0.00062130456,0.00029852206,0.00016917672,0.00083571207,0.00030302015],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036328768,0.00039064162,0.046613645,0.00016424891,0.00012952604,0.00013920928,0.00034940397,2.837742e-7,0.49130476,0.000004790985,0.10850176,0.34876886],"study_design_scores_gemma":[0.006334654,0.00035330906,0.016178833,0.0006998896,0.000015247345,0.0000043532236,0.00011778838,0.0000036709314,0.6482944,0.00008030267,0.32764465,0.00027291646],"about_ca_topic_score_codex":0.0035927373,"about_ca_topic_score_gemma":0.00045395675,"teacher_disagreement_score":0.34849593,"about_ca_system_score_codex":0.002145529,"about_ca_system_score_gemma":0.0012928067,"threshold_uncertainty_score":0.995135},"labels":[],"label_agreement":null},{"id":"W2500651515","doi":"10.1158/1538-7445.am2016-2192","title":"Abstract 2192: Fusogenic targeted liposomes as next-generation nanomedicine for prostate cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of Alberta","funders":"","keywords":"Liposome; Biodistribution; Doxorubicin; Bombesin; Drug delivery; Targeted drug delivery; Nanomedicine; Cancer research; Cancer; Prostate cancer; Nanocarriers; Medicine; Chemistry; Pharmacology; Drug; In vitro; Internal medicine; Chemotherapy; Biochemistry; Nanotechnology; Materials science; Receptor","score_opus":0.1553752418068312,"score_gpt":0.44108609140474436,"score_spread":0.28571084959791315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2500651515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9322851,0.028827272,0.00001634415,0.033397127,0.0005755867,0.00340355,0.00030006963,0.00009650538,0.0010984935],"genre_scores_gemma":[0.9195687,0.025748119,0.00007022494,0.00030035988,0.002162416,0.004666511,0.00014470755,0.00009037987,0.04724856],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963511,0.00008939972,0.00039373117,0.00074068987,0.0011816757,0.0012433828],"domain_scores_gemma":[0.9972968,0.00029397366,0.00008118866,0.0004950847,0.0012931391,0.00053982507],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010021054,0.00026818528,0.00042917908,0.0004667858,0.00039041883,0.00008018772,0.00024266083,0.00017236914,0.004080139],"category_scores_gemma":[0.000338231,0.00015688644,0.00015484243,0.0006717497,0.0004550884,0.00030705947,0.00008958796,0.00037407948,0.00020446346],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022408816,0.00013691181,0.0042426814,0.0003155013,0.0002598523,0.000050370814,0.0003367991,0.0000020503105,0.83729196,0.000104027335,0.040106446,0.11491251],"study_design_scores_gemma":[0.012034933,0.0017925458,0.0136820525,0.0011203655,0.00009990229,0.000015114682,0.0002630262,0.000059972364,0.8103406,0.00065723126,0.15955918,0.00037511144],"about_ca_topic_score_codex":0.0011822943,"about_ca_topic_score_gemma":0.00039400414,"teacher_disagreement_score":0.11945273,"about_ca_system_score_codex":0.0013259454,"about_ca_system_score_gemma":0.0024982356,"threshold_uncertainty_score":0.9968303},"labels":[],"label_agreement":null},{"id":"W2502092973","doi":"10.1158/1538-7445.am2016-lb-176","title":"Abstract LB-176: The human androgen receptor regulates DNA damage response (DDR) in prostate cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Androgen receptor; Androgen; Cancer; Androgen deprivation therapy; Cancer research; Medicine; DNA damage; Radiation therapy; Internal medicine; Oncology; Gerontology; Biology; DNA; Hormone; Genetics","score_opus":0.08555712398716706,"score_gpt":0.4340862496885026,"score_spread":0.34852912570133554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2502092973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9551336,0.005983253,1.883677e-7,0.035629682,0.00013910733,0.0018821193,0.00018457705,0.0000594898,0.000987979],"genre_scores_gemma":[0.95273376,0.0057300893,0.000009592004,0.0001258538,0.0003711098,0.0017143936,0.000019071758,0.00007726162,0.039218865],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957394,0.00056099,0.00041557537,0.0007033466,0.0012520421,0.0013286438],"domain_scores_gemma":[0.99747217,0.0006780581,0.0000765329,0.0008643364,0.0005396875,0.00036923372],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034322022,0.00026702782,0.00038585695,0.00048932416,0.00046153317,0.000096314325,0.00048034493,0.00014226767,0.0042164265],"category_scores_gemma":[0.00033633978,0.00013488521,0.000112878086,0.001048531,0.0010003382,0.00022932151,0.0002394034,0.00079035084,0.00022916243],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069621704,0.00019994342,0.06923786,0.00016406436,0.0001393227,0.0002753573,0.0012942011,0.000002443666,0.87267697,0.00006807647,0.02940463,0.019574955],"study_design_scores_gemma":[0.0075166877,0.0006008165,0.36980402,0.001817275,0.00002631444,0.000009934564,0.0008222538,0.000004547978,0.5134154,0.00048362536,0.1051743,0.00032482875],"about_ca_topic_score_codex":0.0024595764,"about_ca_topic_score_gemma":0.0012696565,"teacher_disagreement_score":0.35926157,"about_ca_system_score_codex":0.0016466412,"about_ca_system_score_gemma":0.0015829486,"threshold_uncertainty_score":0.99669385},"labels":[],"label_agreement":null},{"id":"W2502183409","doi":"10.1200/jco.2015.33.7_suppl.3","title":"ASCENDE-RT*: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; Clinical endpoint; Urology; Randomized controlled trial; Androgen deprivation therapy; External beam radiotherapy; Goserelin; Internal medicine; Radiation therapy; Cancer; Oncology","score_opus":0.11810769766377882,"score_gpt":0.4752221609193588,"score_spread":0.35711446325558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2502183409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824827,0.0056097303,0.0006574892,0.0033450595,0.0022960582,0.0052499156,0.000043890308,0.000025086883,0.00029011475],"genre_scores_gemma":[0.9437612,0.049143363,0.0030853609,0.00045451368,0.0020868818,0.0003455711,0.00004016939,0.00008493599,0.0009979876],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99299747,0.0020326367,0.0032098389,0.00038405208,0.00084226165,0.0005337211],"domain_scores_gemma":[0.98805666,0.0050618392,0.004067308,0.00029833568,0.001765075,0.0007507898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010930025,0.00034245517,0.0034417356,0.00024725232,0.000084194035,0.00003105791,0.00025586164,0.00045657644,0.00007586495],"category_scores_gemma":[0.0032771,0.00019480863,0.00091437047,0.00030651875,0.0006250394,0.0002510292,0.000029308898,0.0010252771,0.0000040596783],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8554539,0.0035182561,0.0045295525,0.00004895813,0.0030883509,0.00012219448,0.0005435856,0.0002633387,0.00045867366,0.000009385688,0.0008764916,0.13108733],"study_design_scores_gemma":[0.9176358,0.066282466,0.0027572303,0.00026417698,0.001028985,0.000020868143,0.00017997323,0.004154852,0.0015232437,0.00024279403,0.005728289,0.00018133041],"about_ca_topic_score_codex":0.00032025506,"about_ca_topic_score_gemma":0.000042572454,"teacher_disagreement_score":0.130906,"about_ca_system_score_codex":0.0005292007,"about_ca_system_score_gemma":0.0058609853,"threshold_uncertainty_score":0.9997749},"labels":[],"label_agreement":null},{"id":"W2504612473","doi":"10.1111/bju.13586","title":"Liquid biopsy: ready to guide therapy in advanced prostate cancer?","year":2016,"lang":"en","type":"review","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Prostate cancer; Liquid biopsy; Circulating tumor cell; Medicine; Androgen receptor; Abiraterone; Biopsy; Cancer; Oncology; Cancer research; Prostate; Abiraterone acetate; Disease; Internal medicine; Bioinformatics; Pathology; Biology; Androgen deprivation therapy; Metastasis","score_opus":0.04685111826743603,"score_gpt":0.405660897430891,"score_spread":0.35880977916345497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2504612473","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016029482,0.9940934,0.0000047243807,0.0019366094,0.00054796174,0.0011730223,0.00014236104,0.000012572586,0.00048640918],"genre_scores_gemma":[0.00006215591,0.99569774,0.0001468793,0.0003955838,0.0005484079,0.00017042337,0.000026494052,0.00007612716,0.0028761874],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972705,0.00027623776,0.0011529037,0.0003584689,0.00033766765,0.00060420454],"domain_scores_gemma":[0.99833256,0.00014306726,0.0005523739,0.00022617595,0.0004073316,0.00033847347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006268234,0.00030353933,0.0021176555,0.0005726323,0.00004259043,0.000024755718,0.00030413255,0.0003038485,0.0002441742],"category_scores_gemma":[0.00018004092,0.00021572379,0.0003449671,0.00038284267,0.00011288466,0.000090686204,0.000066725355,0.00079659536,0.000048031645],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017637232,0.00013451274,0.00006299492,0.00088968076,0.00030216252,0.009068234,0.00003968877,6.4770364e-7,0.000039396557,0.000003078699,0.0036641927,0.9840317],"study_design_scores_gemma":[0.0034915395,0.003976389,0.00015779809,0.018143618,0.00015206028,0.012988956,0.0000068610966,7.1168266e-8,0.000008075508,0.000018503591,0.9608703,0.0001858063],"about_ca_topic_score_codex":0.00014970497,"about_ca_topic_score_gemma":0.0000569295,"teacher_disagreement_score":0.9838459,"about_ca_system_score_codex":0.00052213663,"about_ca_system_score_gemma":0.0019489111,"threshold_uncertainty_score":0.8796961},"labels":[],"label_agreement":null},{"id":"W2507534879","doi":"10.1016/j.eururo.2016.08.022","title":"Reply to Mieke Van Hemelrijck, Hans Garmo, Jan Adolfsson, and Pär Stattin's Letter to the Editor re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thromboembolism. Eur Urol 2016;70:56–61","year":2016,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Androgen; Theology; Internal medicine; Philosophy","score_opus":0.01757143683601436,"score_gpt":0.28046108216353627,"score_spread":0.2628896453275219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507534879","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09851811,0.010432523,0.00041404238,0.8759615,0.0030004205,0.008576389,0.0025258258,0.00013758503,0.0004336418],"genre_scores_gemma":[0.024674542,0.026455568,0.0006384389,0.8596018,0.070653774,0.00181689,0.0014572812,0.00083951076,0.013862175],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99495846,0.00091492553,0.00084368343,0.0013762577,0.00063892954,0.0012677457],"domain_scores_gemma":[0.99686885,0.00041572246,0.0005841842,0.0012033286,0.0005521405,0.00037576977],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001284683,0.0007765132,0.0011738569,0.00038322317,0.00039710055,0.000105470164,0.0005016621,0.00036755303,0.00012796688],"category_scores_gemma":[0.00024112071,0.000489456,0.0002169478,0.00025353945,0.00045691596,0.00010924565,0.0003322981,0.0012626232,0.000079050405],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002747914,0.00013518595,0.007418543,0.00025715685,0.0010523765,0.00021506954,0.003740466,0.0000055372707,0.0019929945,0.0000019438673,0.9513934,0.031039396],"study_design_scores_gemma":[0.004966678,0.0041508414,0.013408949,0.00021130493,0.0005351638,0.00003765426,0.000046273217,0.000007603381,0.0010919014,0.000050491344,0.97499466,0.0004984722],"about_ca_topic_score_codex":0.0002858925,"about_ca_topic_score_gemma":0.00008074147,"teacher_disagreement_score":0.07384357,"about_ca_system_score_codex":0.00016477307,"about_ca_system_score_gemma":0.00033959319,"threshold_uncertainty_score":0.9997557},"labels":[],"label_agreement":null},{"id":"W2508189660","doi":"10.21037/tcr.2016.07.35","title":"Directing abiraterone metabolism: balancing the scales between clinical relevance and experimental observation","year":2016,"lang":"en","type":"letter","venue":"Translational Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"National Cancer Institute","keywords":"CYP17A1; Abiraterone; Prostate cancer; Androgen deprivation therapy; Context (archaeology); Androgen; Medicine; Abiraterone acetate; Pharmacology; Oncology; Cancer research; Endocrinology; Internal medicine; Cancer; Chemistry; Biology; Androgen receptor; Enzyme; Hormone; Biochemistry","score_opus":0.25940519876178203,"score_gpt":0.4930232687432193,"score_spread":0.23361806998143725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508189660","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17799716,0.03281089,0.000039253406,0.7863616,0.00030874004,0.0014469032,0.00028598268,0.000059063874,0.0006904036],"genre_scores_gemma":[0.79593116,0.017818615,0.0010914371,0.08970243,0.063326694,0.002402321,0.0017669644,0.00041936012,0.027541049],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950885,0.000713314,0.0006068219,0.00076737895,0.0020047072,0.0008192686],"domain_scores_gemma":[0.9962932,0.0025304842,0.00011480356,0.000389333,0.0005128277,0.0001593796],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002334964,0.000304743,0.0006092662,0.00021858301,0.00056373375,0.00010683083,0.00025658865,0.0005007023,0.00026927207],"category_scores_gemma":[0.00013066837,0.00017625594,0.00017072848,0.00036728883,0.0008770371,0.00020636998,0.00008148139,0.0028364807,0.000037785747],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026594526,0.00013669253,0.25632846,0.0012551241,0.001797879,0.00030701733,0.0015182421,0.000005167124,0.012654661,0.00015211549,0.59644,0.1267452],"study_design_scores_gemma":[0.004128419,0.0002685996,0.18520248,0.0010163563,0.00016923624,0.000016933216,0.00006837595,0.000041987063,0.0074704518,0.0006499316,0.80059856,0.00036866352],"about_ca_topic_score_codex":0.00032748858,"about_ca_topic_score_gemma":0.000042437656,"teacher_disagreement_score":0.6966592,"about_ca_system_score_codex":0.00030796046,"about_ca_system_score_gemma":0.0006887707,"threshold_uncertainty_score":0.99946404},"labels":[],"label_agreement":null},{"id":"W2511128880","doi":"10.1016/s0167-8140(16)33497-1","title":"98: Concomitant Hypofractionated Imrt Boost for Localized High-Risk Prostate Cancer: Five Year Results of a Prospective Trial","year":2016,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Concomitant; Medicine; Prostate cancer; Oncology; Prostate; Internal medicine; Cancer","score_opus":0.01989463919303695,"score_gpt":0.3487516995199768,"score_spread":0.32885706032693984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2511128880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793466,0.0047088033,0.00027683165,0.009094182,0.0005023481,0.0045458577,0.0010116806,0.00004912663,0.00046457018],"genre_scores_gemma":[0.9436353,0.041597664,0.002005323,0.0003019591,0.000650872,0.001089073,0.00005612562,0.00004719832,0.010616529],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987416,0.00011768284,0.0003717487,0.000340727,0.00014417882,0.0002840591],"domain_scores_gemma":[0.9984819,0.00075754867,0.00025086073,0.00015729526,0.00023242057,0.00011993876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037580926,0.00014846158,0.0005821097,0.00010006051,0.00008833105,0.000006134416,0.000051142924,0.00017079117,0.000107583386],"category_scores_gemma":[0.0001967843,0.00008527255,0.00009119362,0.00011922059,0.000334293,0.00007696112,0.000012020739,0.00012324881,0.000002186339],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83094877,0.0005962227,0.0072177863,0.0000664293,0.0011323895,0.000034385972,0.0014680224,0.0000022429447,0.017569404,0.0006455987,0.006978034,0.13334072],"study_design_scores_gemma":[0.6812442,0.028975755,0.010531926,0.00017243015,0.000256336,0.00002251185,0.0002366661,0.00012028172,0.02730883,0.0015758786,0.24932727,0.00022792135],"about_ca_topic_score_codex":0.0007233701,"about_ca_topic_score_gemma":0.000140861,"teacher_disagreement_score":0.24234924,"about_ca_system_score_codex":0.0008708372,"about_ca_system_score_gemma":0.0006422624,"threshold_uncertainty_score":0.34773138},"labels":[],"label_agreement":null},{"id":"W2512634266","doi":"10.1158/1538-7445.tme16-c06","title":"Abstract C06: Multi-lineage differentiation potential of carcinoma-associated fibroblasts isolated from primary tumors of metastatic prostate cancer patients","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prevention of Organ Failure; University of British Columbia","funders":"","keywords":"Metastasis; Pathology; Primary tumor; Cancer research; Mesenchymal stem cell; Prostate cancer; Cancer; CD90; Stroma; Carcinogenesis; Stromal cell; Prostate; Tumor microenvironment; Biology; Medicine; Tumor progression; Cell; Immunohistochemistry; CD44; Internal medicine","score_opus":0.04956639251163257,"score_gpt":0.35795732061138924,"score_spread":0.30839092809975666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2512634266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939888,0.0018107106,0.00003291774,0.00037002272,0.00015765254,0.0015722504,0.0019846074,0.000032091953,0.000050942093],"genre_scores_gemma":[0.9958713,0.0014363474,0.00006239215,0.000014769903,0.000073848896,0.00029650462,0.00049444,0.00006406889,0.0016863329],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99619174,0.00025557203,0.00073023577,0.0005459125,0.0015107956,0.0007657149],"domain_scores_gemma":[0.9969257,0.0002691412,0.00035426652,0.00041151285,0.0017598353,0.00027950728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048054702,0.00026187496,0.00069496385,0.00043505486,0.000116006944,0.00001951066,0.00024851706,0.00012703547,0.00088293874],"category_scores_gemma":[0.00022434202,0.00016840233,0.00017999226,0.00064278045,0.00042187536,0.000215769,0.0001708083,0.00039043595,0.000015152948],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042146766,0.0013906722,0.30764323,0.0006987678,0.0006877171,0.000044963894,0.00063952425,0.00001634289,0.6746157,0.0000021679737,0.0005633782,0.0094828755],"study_design_scores_gemma":[0.010670934,0.0006626697,0.7589689,0.0013786842,0.00011823718,3.4816398e-7,0.00006646979,0.0001994951,0.22773877,0.000029349105,0.000018290282,0.00014789496],"about_ca_topic_score_codex":0.006032624,"about_ca_topic_score_gemma":0.0003548037,"teacher_disagreement_score":0.45132563,"about_ca_system_score_codex":0.0010594814,"about_ca_system_score_gemma":0.0012124925,"threshold_uncertainty_score":0.966756},"labels":[],"label_agreement":null},{"id":"W2512647917","doi":"10.1007/s00228-016-2120-3","title":"High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate","year":2016,"lang":"en","type":"article","venue":"European Journal of Clinical Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canada Research Chairs; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Joseph and Silvana Melara Cancer Research Fund","keywords":"Abiraterone acetate; Prostate cancer; Drug; Abiraterone; Medicine; Pharmacology; Castration; Cancer; Oncology; Prostate; Drug-drug interaction; Internal medicine; Androgen deprivation therapy; Hormone; Androgen receptor","score_opus":0.03840507762027174,"score_gpt":0.3893474036379929,"score_spread":0.3509423260177212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2512647917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99564755,0.00015811747,0.000021269481,0.0031495595,0.0004119505,0.00043783552,0.000056725792,0.000007950356,0.00010905819],"genre_scores_gemma":[0.99611104,0.0009513601,0.00021878173,0.00011927012,0.0002675379,0.0000070512356,0.0000048598476,0.000029285975,0.0022908074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972982,0.00080644654,0.0010863123,0.0002222725,0.00032919497,0.00025758764],"domain_scores_gemma":[0.9980102,0.00018800554,0.00078477897,0.00011641065,0.0006742956,0.00022631958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007900234,0.00015744191,0.00050958234,0.00016221122,0.00003580594,0.000007728837,0.00013810708,0.000013248418,0.00047253512],"category_scores_gemma":[0.000042891596,0.00007544907,0.00008649195,0.00016494532,0.00035863658,0.00021283144,0.00003298111,0.00039914725,0.0000111253075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.085452005,0.0020249188,0.8659463,0.00018089179,0.0008634898,0.0017945152,0.0002554323,0.00017978234,0.025781816,0.000001501961,0.0028074281,0.014711951],"study_design_scores_gemma":[0.0364895,0.0037013942,0.950167,0.00071685563,0.00042979047,0.000025023732,0.000024320821,0.000006199836,0.007827141,0.000002981661,0.00051082793,0.00009895883],"about_ca_topic_score_codex":0.000027556174,"about_ca_topic_score_gemma":0.00002797288,"teacher_disagreement_score":0.08422074,"about_ca_system_score_codex":0.000093462986,"about_ca_system_score_gemma":0.00033655504,"threshold_uncertainty_score":0.5173928},"labels":[],"label_agreement":null},{"id":"W2512753852","doi":"10.1158/1538-7445.am2015-731","title":"Abstract 731: Integrative genomic analysis to identify emergent enzalutamide resistance mechanisms in castration-resistant prostate cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Medicine; LNCaP; Oncology; Cancer; Disease; Biology; Cancer research; Bioinformatics; Computational biology; Internal medicine","score_opus":0.12845619304502007,"score_gpt":0.47315546625779775,"score_spread":0.3446992732127777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2512753852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980043,0.00807309,0.00006367295,0.006586861,0.00024789586,0.0024131918,0.00033394943,0.000050980158,0.0021873924],"genre_scores_gemma":[0.9775381,0.0023256156,0.00042640572,0.00014722496,0.00018610475,0.0025626482,0.00010794007,0.000062267565,0.016643697],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9949106,0.0002793037,0.00066419726,0.0009905011,0.0019026496,0.0012527766],"domain_scores_gemma":[0.9965916,0.00012565292,0.000107750595,0.000672728,0.0015346847,0.000967561],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022404364,0.00034289394,0.000690339,0.0016546191,0.00021648905,0.0001530143,0.00039534824,0.00014619889,0.001094081],"category_scores_gemma":[0.0002793747,0.00026983226,0.00019367247,0.004309919,0.00021699542,0.00022550623,0.00018762186,0.0009120053,0.0001567264],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012486387,0.00054495176,0.025850171,0.00038230824,0.0022029546,0.0011020934,0.013066166,0.0018805079,0.9148884,0.00077990134,0.022375599,0.0044405665],"study_design_scores_gemma":[0.011089918,0.0014020132,0.6502618,0.001828506,0.0008284457,0.0000060163943,0.017493203,0.0002678746,0.28683195,0.005102952,0.02357879,0.0013084827],"about_ca_topic_score_codex":0.013264498,"about_ca_topic_score_gemma":0.075730115,"teacher_disagreement_score":0.6280564,"about_ca_system_score_codex":0.005134075,"about_ca_system_score_gemma":0.0031759893,"threshold_uncertainty_score":0.9999754},"labels":[],"label_agreement":null},{"id":"W2513654162","doi":"10.1200/jco.2015.33.7_suppl.184","title":"Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Taxane; Abiraterone acetate; Cabazitaxel; Docetaxel; Chemotherapy; Internal medicine; Post-hoc analysis; Oncology; Prostate cancer; Prednisone; Discontinuation; Regimen; Surgery; Cancer; Androgen deprivation therapy; Breast cancer","score_opus":0.10662071090769616,"score_gpt":0.46189632758958854,"score_spread":0.3552756166818924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513654162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977452,0.0010803607,0.000008761427,0.020166658,0.0001927977,0.00097058184,0.000075630676,0.000005739081,0.00004746081],"genre_scores_gemma":[0.9941759,0.0017086507,0.0010955869,0.0020941,0.000072120245,0.00008578194,0.000020851818,0.000032502172,0.0007145056],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9954303,0.00079781364,0.0020911144,0.00032088746,0.00095638615,0.00040350854],"domain_scores_gemma":[0.99513364,0.0006539646,0.0013168,0.0002975575,0.0019302974,0.00066772156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037906964,0.00024838996,0.0019102009,0.000645359,0.000030617895,0.000020798843,0.00017852185,0.00015920664,0.0003002059],"category_scores_gemma":[0.0006482671,0.00014713217,0.0003273409,0.00093251705,0.00026755265,0.00016832718,0.000030148827,0.00051489286,0.0000105473455],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69010794,0.0040464783,0.2636979,0.000040755036,0.0043582236,0.0013875815,0.0029180616,0.00070904585,0.0013643667,0.0000021326957,0.0004900526,0.030877447],"study_design_scores_gemma":[0.055766884,0.09599176,0.83534825,0.00022800623,0.0010912548,0.000021723801,0.00050914416,0.00007422354,0.000969528,0.000025701309,0.009783525,0.0001900075],"about_ca_topic_score_codex":0.00041367643,"about_ca_topic_score_gemma":0.0019758274,"teacher_disagreement_score":0.63434106,"about_ca_system_score_codex":0.0007950783,"about_ca_system_score_gemma":0.0038936639,"threshold_uncertainty_score":0.69071925},"labels":[],"label_agreement":null},{"id":"W2513757436","doi":"10.1016/s0167-8140(16)33467-3","title":"68: Intermediate-Risk Prostate Cancer, Androgen Deprivation Therapy and the Risk of Death","year":2016,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Androgen deprivation therapy; Prostate cancer; Medicine; Oncology; Internal medicine; Cancer","score_opus":0.022962732181065645,"score_gpt":0.3320454792208327,"score_spread":0.30908274703976707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513757436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94234335,0.053123303,0.00012384955,0.0034461264,0.00008345302,0.00071030104,0.000039674516,0.000015221812,0.00011474217],"genre_scores_gemma":[0.57300144,0.42615578,0.00015273555,0.00017606819,0.00008953574,0.00008162294,0.0000023477733,0.000010134602,0.0003303276],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99907583,0.00023181173,0.00020133506,0.00019806999,0.000104461375,0.00018849708],"domain_scores_gemma":[0.9990516,0.0004964658,0.00016237624,0.00015288338,0.000060258117,0.00007643758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049511454,0.000114419716,0.00033767917,0.00006439241,0.00009632134,0.0000072190555,0.000053161442,0.0000907025,0.00007619363],"category_scores_gemma":[0.000055870467,0.00004739841,0.000051249106,0.00007478832,0.0005538918,0.0000507267,0.000017012337,0.000114993294,8.771448e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067022336,0.00005830928,0.47098774,0.0000139429885,0.0003386745,0.0000056050353,0.0015471898,2.5686396e-7,0.0031865323,0.00016443995,0.00013849215,0.5168566],"study_design_scores_gemma":[0.07716392,0.0050924905,0.7941972,0.00015043477,0.00024138896,0.00008515542,0.00022194625,0.00031423435,0.015114538,0.0032354468,0.10397276,0.0002105053],"about_ca_topic_score_codex":0.00038238335,"about_ca_topic_score_gemma":0.00007856385,"teacher_disagreement_score":0.5166461,"about_ca_system_score_codex":0.00014628461,"about_ca_system_score_gemma":0.00015831884,"threshold_uncertainty_score":0.20408374},"labels":[],"label_agreement":null},{"id":"W2514715990","doi":"10.1074/jbc.m116.734475","title":"Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain","year":2016,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Enzalutamide; Androgen receptor; Prostate cancer; Transactivation; Druggability; Cancer research; Chemistry; In vivo; Biology; Cancer; Pharmacology; Gene; Gene expression; Biochemistry; Genetics","score_opus":0.05726821652356534,"score_gpt":0.314040069103481,"score_spread":0.25677185257991564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514715990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99693465,0.0002746577,0.00011566039,0.0020623493,0.000032965905,0.000094808835,0.00003078071,0.000005563043,0.00044854573],"genre_scores_gemma":[0.9982886,0.0005176898,0.00026245852,0.00008110571,0.00011387712,0.000004773806,0.00001098094,0.0000060811717,0.0007144566],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990723,0.000023994537,0.0003482383,0.00014205654,0.00023165497,0.000181766],"domain_scores_gemma":[0.9992271,0.000102494596,0.00027465733,0.000094720875,0.00017758508,0.00012345551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027738087,0.00011398012,0.0003081462,0.00005987936,0.000024698718,0.0000072555395,0.00009115161,0.00018341793,0.00040494898],"category_scores_gemma":[0.00012566063,0.000056000463,0.000122747,0.00014200345,0.00013671421,0.000077746176,0.000030262625,0.00020382687,0.0000030332483],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028160652,0.0003049844,0.068171985,0.00006767114,0.000065539265,0.000038667586,0.000039120714,6.5083476e-8,0.92517966,0.000003997166,0.00024871575,0.0030635584],"study_design_scores_gemma":[0.0033139174,0.0007614212,0.03424296,0.0004392079,0.000018016843,0.00016819194,0.00013265356,0.0000015107963,0.9588935,0.00012772331,0.001829373,0.00007154627],"about_ca_topic_score_codex":0.0000033932563,"about_ca_topic_score_gemma":1.7841191e-7,"teacher_disagreement_score":0.033929024,"about_ca_system_score_codex":0.0002164207,"about_ca_system_score_gemma":0.00019439425,"threshold_uncertainty_score":0.44339073},"labels":[],"label_agreement":null},{"id":"W2514909607","doi":"10.5489/cuaj.4055","title":"Chemotherapy research for metastatic prostate cancer","year":2016,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Canadian Urological Association","funders":"","keywords":"Oncology; Chemotherapy; Medicine; Prostate cancer; Prostate; Internal medicine; Cancer","score_opus":0.14993392354011428,"score_gpt":0.4487195777270549,"score_spread":0.2987856541869406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514909607","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022073598,0.96818453,0.000007570394,0.027800912,0.0003648847,0.0022881068,0.00067307573,0.000019119661,0.00063974503],"genre_scores_gemma":[0.000028193967,0.97617924,0.00010955063,0.0007117004,0.0013071563,0.0008393679,0.000115993425,0.00006546796,0.020643353],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99620515,0.0005993568,0.00061589904,0.0004089319,0.0007870244,0.0013836175],"domain_scores_gemma":[0.9960183,0.0009936192,0.00040835858,0.00018774947,0.0011417444,0.0012502566],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030003905,0.00031617426,0.0013577954,0.00072069274,0.00053896604,0.00016889272,0.00025427793,0.00047259702,0.001459986],"category_scores_gemma":[0.001070145,0.00017299938,0.00065117434,0.0005119589,0.000097437,0.00007707548,0.00002043455,0.0014286735,0.00017178315],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000090882764,0.000044315162,0.0007619813,0.0010435156,0.0009891692,0.000108793254,0.000043192893,7.289892e-8,5.4924806e-7,0.000060703776,0.08050031,0.9163565],"study_design_scores_gemma":[0.0017836749,0.00047983864,0.00017608675,0.0023615623,0.00041006203,0.000121910925,0.000011961204,0.0000016752296,8.0045663e-7,0.00082410267,0.99364245,0.00018586272],"about_ca_topic_score_codex":0.00037007546,"about_ca_topic_score_gemma":0.00023276561,"teacher_disagreement_score":0.91617066,"about_ca_system_score_codex":0.007557075,"about_ca_system_score_gemma":0.00844598,"threshold_uncertainty_score":0.9994528},"labels":[],"label_agreement":null},{"id":"W2514939920","doi":"10.1007/s10637-016-0386-z","title":"Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC)","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Medicine Hat College; BC Cancer Agency","funders":"Canadian Urological Oncology Group; Pfizer","keywords":"Docetaxel; Sunitinib; Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Oncology; Adverse effect; Cancer; Surgery; Urology; Clinical trial","score_opus":0.04279131410167663,"score_gpt":0.3346133206473061,"score_spread":0.29182200654562945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514939920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9171023,0.00069340866,0.00002157802,0.08067576,0.000072283,0.0009750188,0.00014198381,0.000033275777,0.0002844216],"genre_scores_gemma":[0.9674995,0.00043613018,0.0018814766,0.0026982415,0.00012083119,0.00061347155,0.000033143544,0.000031504896,0.026685704],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99815977,0.00016374663,0.00035178266,0.00037111287,0.0005494486,0.0004041546],"domain_scores_gemma":[0.9988161,0.00025157662,0.0000716968,0.00022484212,0.0002246906,0.00041113238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051322323,0.00019118503,0.00023120019,0.00026703932,0.000053405514,0.00003425567,0.0000871927,0.00004357808,0.00042418615],"category_scores_gemma":[0.0001822555,0.000117818665,0.00005625778,0.0004681561,0.00017887678,0.00021300258,0.000020163954,0.00012466963,0.00010558535],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07293225,0.00033470843,0.049200263,0.00011369138,0.00022531333,0.0007619585,0.009703634,0.000051176503,0.80893254,0.0014501237,0.0138567155,0.042437617],"study_design_scores_gemma":[0.019977417,0.0010815338,0.7995566,0.0020115436,0.000045841145,0.000043203177,0.00043025432,0.000033914774,0.08751698,0.011076383,0.07770959,0.0005167136],"about_ca_topic_score_codex":0.00058981293,"about_ca_topic_score_gemma":0.00032157428,"teacher_disagreement_score":0.7503564,"about_ca_system_score_codex":0.00045298092,"about_ca_system_score_gemma":0.00218835,"threshold_uncertainty_score":0.48045057},"labels":[],"label_agreement":null},{"id":"W2515865322","doi":"10.5489/cuaj.4057","title":"Androgen receptor axis-targeted agents","year":2016,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Canadian Urological Association","funders":"","keywords":"Androgen receptor; Receptor; Chemistry; Internal medicine; Medicine; Prostate cancer","score_opus":0.05550757616248328,"score_gpt":0.335494686620196,"score_spread":0.27998711045771274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515865322","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005934258,0.989812,0.0000021098335,0.0053997054,0.0006512494,0.0005829536,0.00036933285,0.000028948993,0.0030943647],"genre_scores_gemma":[0.0000565146,0.98489034,0.00003534257,0.00072026235,0.0013169089,0.000044041055,0.00030264907,0.000039724433,0.012594186],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99726546,0.0003946005,0.00057638256,0.0003217302,0.00055546156,0.00088638964],"domain_scores_gemma":[0.99720156,0.0001869158,0.00048878917,0.00017068564,0.00030576473,0.0016463074],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0007196539,0.00032190062,0.0011962124,0.00042224798,0.00029859398,0.000102141414,0.00022002528,0.00083731604,0.007171992],"category_scores_gemma":[0.0007223788,0.00018124307,0.00065378245,0.0003259643,0.000042321444,0.00007034413,0.000024728128,0.0011072045,0.0017040741],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024962965,0.00003895338,0.0065788575,0.00030424065,0.0009603153,0.00039757724,0.000016911723,2.5142716e-8,4.0210688e-7,0.00001709676,0.14592062,0.84574],"study_design_scores_gemma":[0.0007895311,0.0002298422,0.0005950973,0.001290515,0.00039270733,0.00039393036,0.0000036614038,4.0203727e-7,3.987709e-7,0.000062780695,0.99604726,0.00019384669],"about_ca_topic_score_codex":0.00012093175,"about_ca_topic_score_gemma":0.00004998485,"teacher_disagreement_score":0.8501267,"about_ca_system_score_codex":0.0055995085,"about_ca_system_score_gemma":0.0034344639,"threshold_uncertainty_score":0.9990732},"labels":[],"label_agreement":null},{"id":"W2518656184","doi":"10.1158/1538-7445.am2015-3661","title":"Abstract 3661: Development of novel small-molecule inhibitors of ETS oncoproteins as anti-prostate cancer agents","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Prostate cancer; TMPRSS2; Erg; Cancer research; Cancer; Prostate; Chromoplexy; Medicine; Biology; Internal medicine; PCA3","score_opus":0.2218284548490204,"score_gpt":0.4605774152983867,"score_spread":0.2387489604493663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518656184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887456,0.0043934607,0.0000058737555,0.0013368871,0.0002185716,0.0015867732,0.00009378287,0.00002672592,0.0035922893],"genre_scores_gemma":[0.9947411,0.0012568895,0.00037064435,0.000052435094,0.00016993604,0.00056227105,0.000043602664,0.000061764214,0.0027413794],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960539,0.00007226026,0.00060775457,0.00051268237,0.0018900953,0.0008633142],"domain_scores_gemma":[0.996971,0.0000540373,0.00017410942,0.00046917232,0.0017117662,0.0006198898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013166443,0.00024120513,0.00054507115,0.00050821045,0.0001295059,0.00002535046,0.00031825472,0.00015869169,0.00050401274],"category_scores_gemma":[0.00014455432,0.00019155031,0.000107479114,0.00097106287,0.00047278628,0.00010145992,0.00027606607,0.0005956979,0.00004553407],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034605977,0.0017855637,0.07288853,0.0022768744,0.0009066186,0.0002627119,0.012782208,0.00012439786,0.8305074,0.000052287694,0.009581314,0.06537149],"study_design_scores_gemma":[0.0063637453,0.0005059139,0.035250366,0.0011549081,0.000030392563,0.0000047343206,0.0015205455,0.00002019088,0.94700736,0.00001907732,0.007928269,0.00019449831],"about_ca_topic_score_codex":0.006018364,"about_ca_topic_score_gemma":0.00050174724,"teacher_disagreement_score":0.116499946,"about_ca_system_score_codex":0.0011217003,"about_ca_system_score_gemma":0.008275749,"threshold_uncertainty_score":0.9973464},"labels":[],"label_agreement":null},{"id":"W2518965337","doi":"10.1016/j.mce.2016.09.010","title":"Cell-lineage specificity and role of AP-1 in the prostate fibroblast androgen receptor cistrome","year":2016,"lang":"en","type":"article","venue":"Molecular and Cellular Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Ray and Shirl Norman Cancer Research Trust; Prostate Cancer Foundation of Australia; Prostate Cancer Foundation; Cancer Australia; Canadian Cancer Society; U.S. Department of Defense","keywords":"FOXA1; Prostate cancer; Biology; Androgen receptor; Cancer research; Fibroblast; Chromatin immunoprecipitation; Prostate; Cell biology; Cancer; Cell culture; Genetics; Gene expression; Gene","score_opus":0.009537926753997056,"score_gpt":0.24003799642066162,"score_spread":0.23050006966666456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518965337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99003524,0.0070862593,0.00009372462,0.0010834053,0.000016722732,0.00042021764,0.000025952239,0.000010291184,0.0012282187],"genre_scores_gemma":[0.9981641,0.0011324186,0.00011737558,0.000051570794,0.000021632486,0.000030282,0.000020113821,0.000013113117,0.00044939757],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998946,0.00012632513,0.00018631459,0.00026646178,0.00014279767,0.00033207293],"domain_scores_gemma":[0.9995625,0.00005983975,0.00004356217,0.00022868057,0.00003463536,0.00007078973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012213681,0.00012925522,0.00024019122,0.000093015144,0.000036426387,0.000008628215,0.000077391654,0.000055230405,0.000058180955],"category_scores_gemma":[0.000017955228,0.00007036478,0.000047188732,0.000101071164,0.0002686061,0.000027170332,0.00007319049,0.00012170496,0.000008119685],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042709563,0.00012629987,0.016873743,0.000079320926,0.000035540797,0.00039857498,0.0003393615,2.7611785e-7,0.97723264,0.00045852445,0.00007064052,0.0039580087],"study_design_scores_gemma":[0.002903328,0.00062908937,0.0037056478,0.000050557544,0.00002863418,0.00011278881,0.00034744182,0.000009598834,0.9856942,0.00026394954,0.0061655915,0.0000891717],"about_ca_topic_score_codex":0.000041187406,"about_ca_topic_score_gemma":0.0000036548095,"teacher_disagreement_score":0.013168095,"about_ca_system_score_codex":0.000020556341,"about_ca_system_score_gemma":0.000034600696,"threshold_uncertainty_score":0.28693923},"labels":[],"label_agreement":null},{"id":"W2519439632","doi":"10.1634/theoncologist.2016-0161","title":"Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institutes of Health; National Cancer Institute; Prostate Cancer Foundation","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Abiraterone; Cancer research; Abiraterone acetate; Population; Cancer; Medicine; Mechanism (biology); splice; Bioinformatics; Computational biology; Biology; Gene; Internal medicine; Genetics; Androgen deprivation therapy","score_opus":0.04893143347236359,"score_gpt":0.3605005743744425,"score_spread":0.3115691409020789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519439632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8889562,0.020250458,0.0006143167,0.0758244,0.00048752173,0.010920451,0.000366141,0.000039879513,0.0025406505],"genre_scores_gemma":[0.9476102,0.011976865,0.0017665831,0.00020915814,0.0005324057,0.0020459963,0.00001805164,0.000038149934,0.03580261],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989211,0.0001267978,0.0002408279,0.00018543756,0.00023689622,0.00028896471],"domain_scores_gemma":[0.99857473,0.0005911813,0.00021375211,0.00047940994,0.00009538768,0.000045560057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004729558,0.00014171834,0.00026628177,0.000015158861,0.00026772878,0.000007992312,0.00031586882,0.0000463746,0.000074354146],"category_scores_gemma":[0.00007332744,0.00003429445,0.00017364125,0.00015300233,0.00079082587,0.000026436459,0.000057527424,0.00007237468,0.0000026432404],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015480881,0.0015308253,0.022607261,0.00025703406,0.0014893176,0.000010287275,0.01563823,0.00031116,0.11856457,0.00068423175,0.030203314,0.7932229],"study_design_scores_gemma":[0.031506617,0.008593428,0.008299659,0.0005064583,0.0013731811,0.00006602275,0.011127847,0.00040004245,0.23560295,0.0017809126,0.70036316,0.00037970545],"about_ca_topic_score_codex":0.0002933813,"about_ca_topic_score_gemma":0.000057816527,"teacher_disagreement_score":0.79284316,"about_ca_system_score_codex":0.00032615993,"about_ca_system_score_gemma":0.0004813504,"threshold_uncertainty_score":0.2913831},"labels":[],"label_agreement":null},{"id":"W2521561070","doi":"10.1200/jco.2013.31.6_suppl.44","title":"The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Mitoxantrone; Prostate cancer; Oncology; Internal medicine; Prednisone; Cabazitaxel; Cancer; Chemotherapy; Androgen deprivation therapy","score_opus":0.17066052728771366,"score_gpt":0.48586772246307847,"score_spread":0.3152071951753648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521561070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809109,0.0010905544,0.0000063395037,0.0137250805,0.0009443236,0.0027813965,0.0003037283,0.000004672403,0.00023302589],"genre_scores_gemma":[0.9962103,0.0013424809,0.00017829544,0.0004706238,0.0010926215,0.00017772715,0.00007032659,0.00002451251,0.0004331404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969704,0.00039841825,0.0012762556,0.00031067716,0.00067196065,0.000372264],"domain_scores_gemma":[0.99244475,0.0048733116,0.0009696591,0.00048302082,0.0009780393,0.00025121056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028081243,0.00016830524,0.0008728823,0.00004854411,0.00014570566,0.000047547474,0.0005723082,0.0001645597,0.00012592177],"category_scores_gemma":[0.0023288117,0.00006679738,0.000132951,0.0001741532,0.00039813438,0.00024898222,0.00022135649,0.0009774115,0.000011073545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.065289594,0.0021611168,0.8592424,0.000008323916,0.0010709694,0.00007968678,0.00024480448,0.000003863076,0.00000208168,0.000004703316,0.004621952,0.06727054],"study_design_scores_gemma":[0.028868254,0.0235927,0.93843263,0.00017665098,0.0003851365,0.0000068851805,0.0009853847,0.00015478567,0.000003733123,0.00038859757,0.00693146,0.00007380513],"about_ca_topic_score_codex":0.001319597,"about_ca_topic_score_gemma":0.0020454298,"teacher_disagreement_score":0.07919024,"about_ca_system_score_codex":0.00021074401,"about_ca_system_score_gemma":0.0020617135,"threshold_uncertainty_score":0.4246421},"labels":[],"label_agreement":null},{"id":"W2522167924","doi":"10.1158/1078-0432.ccr-16-0718","title":"<i>BIRC6</i> Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Enzalutamide; Prostate cancer; Cancer research; Downregulation and upregulation; Apoptosis; Androgen receptor; Biology; Medicine; Cancer; Gene; Internal medicine; Genetics","score_opus":0.1496112798920293,"score_gpt":0.5339874969569492,"score_spread":0.38437621706492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522167924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9136805,0.03746237,0.000081530634,0.041424185,0.0010133524,0.004687036,0.00042912032,0.00014385907,0.0010780559],"genre_scores_gemma":[0.8480872,0.11246328,0.0003938738,0.000972421,0.0022294133,0.0044981604,0.000041855048,0.0001431747,0.031170638],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942354,0.00044570587,0.00092991185,0.0011846884,0.0015054889,0.0016988165],"domain_scores_gemma":[0.9951323,0.0015316174,0.00016388013,0.00064749666,0.0017370817,0.00078760175],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038004576,0.0003289216,0.0007285439,0.0002315628,0.0005101833,0.00008303038,0.00042675814,0.00027752985,0.001507866],"category_scores_gemma":[0.0013400222,0.0001885014,0.0004511903,0.0005727633,0.0010481369,0.000226488,0.00021189073,0.00083010946,0.00016339075],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05819153,0.000779605,0.026150279,0.00030468297,0.0005280964,0.00019901295,0.00017283215,0.000007945274,0.2556107,0.00020146336,0.04120417,0.6166497],"study_design_scores_gemma":[0.05235934,0.0093798535,0.016017767,0.001844427,0.00012708941,0.000011879534,0.00046704445,0.00007362391,0.17089881,0.00470682,0.7433087,0.000804595],"about_ca_topic_score_codex":0.00058787223,"about_ca_topic_score_gemma":0.00008671214,"teacher_disagreement_score":0.70210457,"about_ca_system_score_codex":0.0007097334,"about_ca_system_score_gemma":0.0028227044,"threshold_uncertainty_score":0.9994049},"labels":[],"label_agreement":null},{"id":"W2522434183","doi":"10.1097/spc.0000000000000216","title":"The evolving role of chemotherapy in prostate cancer","year":2016,"lang":"en","type":"editorial","venue":"Current Opinion in Supportive and Palliative Care","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; University hospital; Gynecology; Cancer; Library science; Family medicine; Internal medicine","score_opus":0.03662668972778751,"score_gpt":0.41913107479032696,"score_spread":0.3825043850625395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522434183","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011748111,0.4993646,0.0000019097265,0.0006862381,0.4830296,0.0025963767,0.002132731,0.000016964563,0.0004234617],"genre_scores_gemma":[0.038726564,0.7652179,0.000008539184,0.000008481292,0.19231139,0.001161927,0.0015770915,0.0000776072,0.000910484],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980924,0.00009777673,0.00046116742,0.0004273522,0.0005305725,0.0003907157],"domain_scores_gemma":[0.9982269,0.00044334022,0.00028126888,0.00019454822,0.0007620432,0.00009192721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020930792,0.00028025493,0.00053052313,0.0001757486,0.00006362841,0.000021265852,0.00011772887,0.0001992543,0.000067435474],"category_scores_gemma":[0.00021877272,0.00015797916,0.000096644355,0.00021898001,0.0002567177,0.000067250876,0.00007071562,0.0006292978,0.0000024092092],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017552332,0.00012519064,0.6161398,0.0026489706,0.00014618157,0.0000044681046,0.011631578,2.3867815e-7,0.00007243091,0.00003581985,0.28051355,0.08692651],"study_design_scores_gemma":[0.0048490167,0.0003598084,0.065246075,0.008831125,0.000022407472,1.0450662e-7,0.0026868552,0.000005862773,0.00046849644,0.00020666934,0.9171058,0.00021775406],"about_ca_topic_score_codex":0.00009216818,"about_ca_topic_score_gemma":0.00006520052,"teacher_disagreement_score":0.63659227,"about_ca_system_score_codex":0.0005065508,"about_ca_system_score_gemma":0.001073647,"threshold_uncertainty_score":0.6442203},"labels":[],"label_agreement":null},{"id":"W2523469334","doi":"10.1158/0008-5472.can-16-1518","title":"UGT2B17 Expedites Progression of Castration-Resistant Prostate Cancers by Promoting Ligand-Independent AR Signaling","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; University of British Columbia","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Prostate cancer; Androgen receptor; Cancer research; Androgen; Tumor progression; Biology; Cell growth; Cancer; Prostate; Internal medicine; Endocrinology; Medicine; Biochemistry; Hormone","score_opus":0.06782664749403781,"score_gpt":0.42718711304914425,"score_spread":0.3593604655551064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523469334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98595655,0.0074382517,0.000021460839,0.0036553715,0.00011324932,0.0019368909,0.00015508757,0.000056305526,0.00066685304],"genre_scores_gemma":[0.99188596,0.0022480157,0.000103992825,0.000019554112,0.0003161675,0.0009498543,0.000033184286,0.00005504851,0.0043882267],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958673,0.00023920632,0.00049817277,0.0006117898,0.001820795,0.000962752],"domain_scores_gemma":[0.997733,0.00030675385,0.00016000729,0.0003950932,0.0009823577,0.00042278922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017514311,0.00022224942,0.00038575774,0.0002969536,0.0002867872,0.000057859117,0.00022723385,0.00013400531,0.00032824412],"category_scores_gemma":[0.00024428347,0.00013102194,0.00010068106,0.00058009697,0.00047463004,0.00021825037,0.0001244135,0.0004329057,0.000021324298],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018013709,0.00015270872,0.013233047,0.0004978004,0.00011782508,0.00008644023,0.0010272382,0.0000022888812,0.9417056,0.000029050958,0.004048256,0.03729837],"study_design_scores_gemma":[0.003262992,0.0012665472,0.0008854198,0.002791016,0.000028188015,0.000007307556,0.00077061716,0.000029009834,0.98822147,0.00009839395,0.0024742666,0.00016476007],"about_ca_topic_score_codex":0.0005652216,"about_ca_topic_score_gemma":0.00007250757,"teacher_disagreement_score":0.04651588,"about_ca_system_score_codex":0.0012888013,"about_ca_system_score_gemma":0.0021202962,"threshold_uncertainty_score":0.534292},"labels":[],"label_agreement":null},{"id":"W2523547317","doi":"10.1200/jco.2016.34.2_suppl.1","title":"NRG Oncology RTOG 0415: A randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McMaster University; Cancer Care Ontario","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Interim analysis; Internal medicine; Randomized controlled trial; Clinical endpoint; Oncology; Clinical trial; Cancer; Urology; Confidence interval","score_opus":0.07586299186364398,"score_gpt":0.5099397561842397,"score_spread":0.4340767643205957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523547317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99324965,0.00019507116,0.0002782319,0.0029780667,0.00084271666,0.0020481711,0.0000098662895,0.000010705901,0.00038752917],"genre_scores_gemma":[0.9966603,0.0016508206,0.0007137603,0.00017156948,0.0005390341,0.00010581724,0.000006098769,0.000019532117,0.00013308696],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99460495,0.0014543826,0.0026446357,0.00030444292,0.0006316275,0.0003599833],"domain_scores_gemma":[0.99172467,0.004060558,0.0025083928,0.00018352458,0.0011484909,0.00037433684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006604412,0.00020115843,0.002751158,0.00029652513,0.00008428655,0.000012423678,0.00014217183,0.00022509361,0.00012825674],"category_scores_gemma":[0.0033629003,0.0000991074,0.00028514178,0.00023354181,0.000431284,0.00028893468,0.000065250344,0.0011589014,0.000011238635],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36915234,0.009082259,0.52281535,0.000011112358,0.00060263055,0.00019032318,0.00021100744,0.000017317847,0.000019352367,0.000005562944,0.000053537497,0.09783923],"study_design_scores_gemma":[0.5676119,0.018389745,0.41206217,0.00020900572,0.0004221443,0.00000743076,0.00015110716,0.00015858536,0.00003583394,0.00010371637,0.00076685246,0.000081539016],"about_ca_topic_score_codex":0.00038742763,"about_ca_topic_score_gemma":0.00089417293,"teacher_disagreement_score":0.19845955,"about_ca_system_score_codex":0.0011000608,"about_ca_system_score_gemma":0.0033559327,"threshold_uncertainty_score":0.59532803},"labels":[],"label_agreement":null},{"id":"W2523960744","doi":"10.1038/pcan.2016.44","title":"Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer","year":2016,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Bristol-Myers Squibb","keywords":"Medicine; Hazard ratio; Placebo; Internal medicine; Prostate cancer; Docetaxel; Oncology; Prednisone; Abiraterone acetate; Confidence interval; Enzalutamide; Randomized controlled trial; Cancer; Androgen deprivation therapy; Pathology","score_opus":0.03437655681682068,"score_gpt":0.34857019579536724,"score_spread":0.3141936389785466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523960744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837662,0.00619136,0.000007026256,0.0023469017,0.000050071205,0.003303544,0.0039646807,0.000053492968,0.00031672412],"genre_scores_gemma":[0.98921853,0.0046982905,0.00013662995,0.000091815746,0.000027923195,0.0018036681,0.00010464201,0.00007285821,0.0038456628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971329,0.00010403755,0.00062570116,0.0006834497,0.0007155429,0.0007383424],"domain_scores_gemma":[0.99827373,0.00026668474,0.00028013342,0.00038325842,0.00031139064,0.00048481472],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015941734,0.0005013181,0.0008722781,0.00031843173,0.000104037805,0.00006923334,0.00010544917,0.00004573819,0.00024348802],"category_scores_gemma":[0.000090017915,0.00025205757,0.00014856602,0.0004390295,0.00043899042,0.00032915748,0.00004964182,0.00013141983,0.0000051641264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02095896,0.0015993095,0.9108202,0.0011496877,0.0010198448,0.00024777395,0.0023406842,0.000102001686,0.019030413,0.000042645188,0.00047403947,0.04221443],"study_design_scores_gemma":[0.02112076,0.0070837303,0.9593715,0.0027416968,0.00066098804,0.000012101894,0.0006236693,0.000071550705,0.0071989708,0.00044660326,0.0001550462,0.0005133809],"about_ca_topic_score_codex":0.0013642946,"about_ca_topic_score_gemma":0.00030254596,"teacher_disagreement_score":0.04855129,"about_ca_system_score_codex":0.00067375874,"about_ca_system_score_gemma":0.0013169945,"threshold_uncertainty_score":0.99999315},"labels":[],"label_agreement":null},{"id":"W2525038995","doi":"10.1158/1078-0432.ccr-16-0987","title":"A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Discontinuation; Dutasteride; Abiraterone acetate; Urology; Prednisone; Internal medicine; Clinical endpoint; Oncology; Enzalutamide; Cancer; Androgen receptor; Androgen deprivation therapy; Clinical trial","score_opus":0.26474424529358437,"score_gpt":0.5426248698811699,"score_spread":0.2778806245875855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525038995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979015,0.0006573063,0.00008845425,0.012372307,0.000095973985,0.0067090443,0.00067552936,0.000031568572,0.00035484383],"genre_scores_gemma":[0.97844774,0.0015816392,0.0005507081,0.00006472428,0.00031510965,0.0052948305,0.000051480394,0.00007163641,0.013622123],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99604034,0.00034250205,0.0008499817,0.00068381464,0.0012436302,0.0008397266],"domain_scores_gemma":[0.9961961,0.0010397079,0.00023029667,0.0005455258,0.0015171999,0.00047119794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022882458,0.00025275798,0.0008672278,0.00020809952,0.000249226,0.00003728834,0.00021158789,0.00008671465,0.00040649346],"category_scores_gemma":[0.00029535862,0.00011850398,0.00013768121,0.00052950013,0.0012445727,0.00016762414,0.00009349587,0.00036815603,0.000006768045],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9151374,0.004520669,0.0019086421,0.0005485825,0.001031969,0.00012291707,0.0002917078,0.0000025378367,0.031511225,0.000088107416,0.00362099,0.04121522],"study_design_scores_gemma":[0.70835,0.23266482,0.0016265119,0.0018778477,0.00046303472,0.000007872798,0.00036222447,0.000094017414,0.046651095,0.00027264454,0.007308485,0.00032142113],"about_ca_topic_score_codex":0.00055609434,"about_ca_topic_score_gemma":0.0007959097,"teacher_disagreement_score":0.22814415,"about_ca_system_score_codex":0.00033902135,"about_ca_system_score_gemma":0.0032672402,"threshold_uncertainty_score":0.5795944},"labels":[],"label_agreement":null},{"id":"W2525688488","doi":"10.1158/1078-0432.ccr-16-1224","title":"The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Université de Montréal","funders":"National Cancer Institute","keywords":"Prostate cancer; Context (archaeology); Oncology; Medicine; Proportional hazards model; Internal medicine; Population; Biomarker; Enumeration; Circulating tumor cell; Cancer; Metastasis; Biology; Mathematics","score_opus":0.17360426255789002,"score_gpt":0.5257510472557954,"score_spread":0.35214678469790534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525688488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886079,0.0012301557,0.000021389082,0.007140577,0.000121153025,0.0025988203,0.00006895945,0.000012844974,0.00019824631],"genre_scores_gemma":[0.99668527,0.00096895546,0.00043190247,0.000045313696,0.00010109823,0.0013402577,0.000014611368,0.000031806,0.0003808062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953703,0.0010822305,0.0011091746,0.0005206501,0.0012292742,0.00068831304],"domain_scores_gemma":[0.9968045,0.0018675003,0.00018680029,0.00028818953,0.00062817294,0.00022486223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006127142,0.00015666118,0.0004581699,0.0003436701,0.00019375398,0.00009510419,0.00015895818,0.00006866242,0.000093033304],"category_scores_gemma":[0.0016832406,0.00008990394,0.00009782694,0.0011840232,0.00025452283,0.00022605424,0.00008536765,0.0005063172,0.0000047275144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073569664,0.00028171422,0.8292583,0.00036512877,0.000069993206,0.00011120364,0.00051320967,0.00018054545,0.03494986,0.00007828693,0.000254101,0.12658067],"study_design_scores_gemma":[0.0064944876,0.0011784625,0.9736178,0.0023918473,0.00004032898,0.0000018249776,0.00085301214,0.00085823296,0.01362792,0.00043837514,0.0003308265,0.00016688638],"about_ca_topic_score_codex":0.00458052,"about_ca_topic_score_gemma":0.0055139204,"teacher_disagreement_score":0.14435948,"about_ca_system_score_codex":0.0012601716,"about_ca_system_score_gemma":0.001971434,"threshold_uncertainty_score":0.6924407},"labels":[],"label_agreement":null},{"id":"W2526220138","doi":"10.1200/jco.2016.34.15_suppl.5003","title":"A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); Hôpital Notre-Dame; Cancer Care Ontario; McMaster University; Health Sciences Centre; CancerCare Manitoba; Ontario Clinical Oncology Group; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Urology; Prostate; Radiation therapy; Regimen; Hazard ratio; Randomized controlled trial; Hormonal therapy; Dose fractionation; Nuclear medicine; Cancer; Internal medicine; Confidence interval","score_opus":0.15974073505868924,"score_gpt":0.5331915029740711,"score_spread":0.3734507679153819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526220138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9527158,0.0037125947,0.0027196954,0.03569264,0.0015946405,0.0033589702,0.000027297552,0.000003784108,0.00017454509],"genre_scores_gemma":[0.9611235,0.03554931,0.00081600493,0.000113650705,0.0011271368,0.00024461938,0.0000038547546,0.000009672471,0.001012238],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973344,0.00040819636,0.0017447444,0.00009556276,0.0002994065,0.00011769392],"domain_scores_gemma":[0.98897517,0.008346565,0.0017489099,0.000108244785,0.0007261007,0.00009503996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030413088,0.00007885311,0.0013664503,0.00009112014,0.00002614712,0.000002377836,0.000057205303,0.0001528014,0.00010824056],"category_scores_gemma":[0.0025807682,0.00002932065,0.0007372188,0.00007653627,0.00031172438,0.0000703613,0.0000054212846,0.00010251845,9.0587463e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6419394,0.0015693298,0.001206277,0.000013580908,0.0009688048,0.000003761602,0.00008884966,0.0000063223247,0.00024322649,0.000048917787,0.0003085415,0.35360295],"study_design_scores_gemma":[0.9233827,0.028023738,0.0016971658,0.00007863566,0.0010022358,0.000006594475,0.000040538944,0.00027480288,0.00319376,0.0005424959,0.041727055,0.000030254098],"about_ca_topic_score_codex":0.00003058512,"about_ca_topic_score_gemma":0.000012858741,"teacher_disagreement_score":0.3535727,"about_ca_system_score_codex":0.0002650967,"about_ca_system_score_gemma":0.0017974541,"threshold_uncertainty_score":0.31886065},"labels":[],"label_agreement":null},{"id":"W2527751194","doi":"10.1016/j.cbi.2016.10.002","title":"Achieving resistance specificity in prostate cancer","year":2016,"lang":"en","type":"review","venue":"Chemico-Biological Interactions","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Department of Science and Technology, Ministry of Science and Technology, India; Clayoquot Biosphere Trust","keywords":"Prostate cancer; Cancer research; Androgen deprivation therapy; Androgen receptor; Epithelial–mesenchymal transition; Cancer; Androgen; Medicine; microRNA; Metastasis; Internal medicine; Oncology; Biology; Hormone","score_opus":0.1674697035752967,"score_gpt":0.4574062643798693,"score_spread":0.28993656080457264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527751194","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008138494,0.9837164,0.0000024202502,0.000707049,0.0003535345,0.0012080696,0.00028221277,0.00008650274,0.012829952],"genre_scores_gemma":[0.00038597535,0.96567017,0.0000639044,0.000051438208,0.0004527639,0.0010381881,0.00028851855,0.00003957451,0.032009456],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779654,0.000102824546,0.0006635703,0.000722684,0.00016385183,0.0005505073],"domain_scores_gemma":[0.998614,0.00044892132,0.00024035148,0.0004046277,0.00010279471,0.0001893018],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016016718,0.00043270434,0.0014675508,0.00022157625,0.00008917138,0.00003321363,0.00021384913,0.0002803044,0.0017183354],"category_scores_gemma":[0.00020917784,0.00023031456,0.0004775808,0.0004118605,0.00021831764,0.0000918955,0.00013775291,0.0011310511,0.0002810926],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049763464,0.00057820167,0.0011583869,0.007946568,0.00044766278,0.00039831814,0.000081406244,5.197609e-8,0.0016548431,0.000112656555,0.011554623,0.97556967],"study_design_scores_gemma":[0.00045004248,0.000045367404,0.00010800526,0.030550761,0.000114603296,0.000048742637,0.000021369697,1.7165398e-7,0.00018231822,0.00004169216,0.9681819,0.00025501725],"about_ca_topic_score_codex":0.000020424697,"about_ca_topic_score_gemma":0.000040869418,"teacher_disagreement_score":0.9753146,"about_ca_system_score_codex":0.0014463377,"about_ca_system_score_gemma":0.00031519574,"threshold_uncertainty_score":0.9991942},"labels":[],"label_agreement":null},{"id":"W2527805287","doi":"10.1016/j.ijrobp.2016.06.1199","title":"Assessment of Biochemical Outcomes with Increasing Dose Escalation in Localized Prostate Cancer (PCa) Treated with Precision Image Guided Radiation Therapy (IGRT)","year":2016,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Image-guided radiation therapy; Prostate cancer; Context (archaeology); Nuclear medicine; Prostate; Radiation therapy; Dose fractionation; Clinical endpoint; Urology; Cancer; Internal medicine; Randomized controlled trial","score_opus":0.026292029124644876,"score_gpt":0.3932917065858876,"score_spread":0.3669996774612427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527805287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99150836,0.00040104447,0.003364642,0.0037012885,0.00017280264,0.00061763223,0.00005754093,0.000020234664,0.0001564675],"genre_scores_gemma":[0.99246275,0.0030028375,0.0038922892,0.0001319696,0.00026648535,0.00004898433,0.000110292705,0.000029030965,0.000055337558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796546,0.00030406524,0.00074791117,0.00025632264,0.0004961528,0.00023006611],"domain_scores_gemma":[0.9971421,0.00049543066,0.0009951306,0.0001456675,0.0011089725,0.000112700574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006501527,0.00021600665,0.00057631894,0.00031180892,0.00003738096,0.000019029718,0.0001760453,0.0001664276,0.000058138492],"category_scores_gemma":[0.00015878178,0.00011485759,0.00011354298,0.00028586478,0.00025049085,0.00037329036,0.000027106953,0.00024928144,0.0000019269125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052729,0.000537218,0.78620386,0.000009179801,0.00052546145,0.000031892196,0.0001559356,0.00011359132,0.08443759,0.00014842457,0.00008104314,0.12248288],"study_design_scores_gemma":[0.037570197,0.002852458,0.9023457,0.00040610792,0.000105595245,0.0000784832,0.000038823047,0.001171721,0.054002695,0.00060663436,0.0006526537,0.00016892827],"about_ca_topic_score_codex":0.00015381604,"about_ca_topic_score_gemma":0.0000110551455,"teacher_disagreement_score":0.122313954,"about_ca_system_score_codex":0.0015803508,"about_ca_system_score_gemma":0.0010975857,"threshold_uncertainty_score":0.46837565},"labels":[],"label_agreement":null},{"id":"W2528063771","doi":"10.1016/j.ijrobp.2016.06.278","title":"Prognostic Significance of Tonsil Expression and the Homologous Recombination Pathway in Intermediate-Risk Prostate Cancer Recurrence","year":2016,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre hospitalier universitaire de Québec; Université Laval; Ontario Institute for Cancer Research; University Health Network; University of Toronto","funders":"","keywords":"Prostate cancer; Biochemical recurrence; Cohort; Homologous recombination; Oncology; Prostatectomy; Internal medicine; Prostate; Medicine; RAD51; Cancer; Perineural invasion; Cancer research; Biology; Gene; Genetics","score_opus":0.019463293013904415,"score_gpt":0.33487825868735954,"score_spread":0.3154149656734551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528063771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98908544,0.0026038273,0.0010257576,0.005399597,0.0010823087,0.0005950174,0.00009068343,0.000010659085,0.00010671198],"genre_scores_gemma":[0.98628986,0.01274344,0.00033195436,0.00009324065,0.00033602212,0.00008755176,0.000016625741,0.000012465051,0.00008883196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982706,0.00043895308,0.00066251773,0.00019699484,0.00024620994,0.00018474326],"domain_scores_gemma":[0.99672574,0.0013259932,0.0010598351,0.00011063985,0.0007056445,0.00007217507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009873799,0.0001348793,0.0003857716,0.00016199032,0.000044247558,0.000011347081,0.00022017304,0.00012586292,0.000028063132],"category_scores_gemma":[0.0012478674,0.00007097836,0.00009376859,0.00015229027,0.00058519444,0.00021045508,0.00006363805,0.00033810773,0.0000030248177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023452432,0.00025814376,0.5619168,0.000015449168,0.00013628969,0.000023725997,0.00095983763,0.00002146587,0.013721137,0.0008320753,0.00015783968,0.41961196],"study_design_scores_gemma":[0.083601706,0.006617322,0.6350716,0.0025859945,0.00028558774,0.0003044498,0.0005784402,0.0014554231,0.1751842,0.08700703,0.0067912615,0.00051702996],"about_ca_topic_score_codex":0.000055434037,"about_ca_topic_score_gemma":0.000016153945,"teacher_disagreement_score":0.41909492,"about_ca_system_score_codex":0.00048599383,"about_ca_system_score_gemma":0.0006756896,"threshold_uncertainty_score":0.28944138},"labels":[],"label_agreement":null},{"id":"W2528156286","doi":"10.1016/j.ijrobp.2016.06.1254","title":"The Frequency of Druggable Targets in Localized Prostate Cancer: Initial Analysis From a Commercially Available Genomic Expression Database in Urologic Cancer","year":2016,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; DECIPHER; Prostate; Cancer; Metastasis; Oncology; Biomarker; Biochemical recurrence; Internal medicine; Pathology; Bioinformatics","score_opus":0.03181917723461767,"score_gpt":0.36738132919819083,"score_spread":0.33556215196357314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528156286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98234504,0.007904787,0.0008529674,0.006868415,0.0007918538,0.00038065875,0.0006541034,0.00000967054,0.00019248892],"genre_scores_gemma":[0.97874475,0.019377489,0.0006814916,0.00031544344,0.0005265164,0.00007808774,0.00015209512,0.000015818532,0.000108307264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979083,0.0003908195,0.0008614287,0.00024861886,0.00029669274,0.00029416961],"domain_scores_gemma":[0.99764925,0.00068871694,0.00086765963,0.00018095084,0.0005193171,0.000094097304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007384389,0.00016278797,0.0005854183,0.00032491173,0.00005853,0.000014560051,0.0003857195,0.00015384433,0.00039163744],"category_scores_gemma":[0.00021865625,0.0000935066,0.00016765334,0.0003839556,0.00027829554,0.0002477311,0.00009132346,0.0003618954,0.000010376919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026436453,0.0003628645,0.8776638,0.0000062300646,0.00085500156,0.0000752434,0.00040976546,0.00041170212,0.072391205,0.00019147183,0.0006726389,0.04431646],"study_design_scores_gemma":[0.08792883,0.0033245203,0.65834886,0.0013353039,0.0016465158,0.00003671953,0.00049279525,0.0070966943,0.15702957,0.029312458,0.052565627,0.0008821383],"about_ca_topic_score_codex":0.0023531672,"about_ca_topic_score_gemma":0.0011331687,"teacher_disagreement_score":0.21931495,"about_ca_system_score_codex":0.0013160125,"about_ca_system_score_gemma":0.0015006883,"threshold_uncertainty_score":0.42881554},"labels":[],"label_agreement":null},{"id":"W2528347464","doi":"10.1158/1535-7163.mct-16-0354","title":"Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Prostate Cancer Canada; U.S. Department of Defense","keywords":"Enzalutamide; Androgen receptor; Antiandrogens; Prostate cancer; Tetratricopeptide; Cancer research; Small molecule; Chemistry; Pharmacology; Biology; Cell biology; Medicine; Cancer; Internal medicine; Biochemistry","score_opus":0.03141413035605064,"score_gpt":0.3114934926663247,"score_spread":0.2800793623102741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528347464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869387,0.0042400076,0.0010790863,0.006914796,0.0001797671,0.0004472653,0.000026391246,0.000026437216,0.00014754912],"genre_scores_gemma":[0.9957619,0.0029942447,0.00006918149,0.00041377015,0.00006972575,0.000033942793,0.000009622392,0.000026786052,0.000620868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99927086,0.00004569761,0.00016300024,0.00016370502,0.00021165283,0.00014506262],"domain_scores_gemma":[0.99955463,0.000031143372,0.00008214872,0.00014521147,0.00014171579,0.000045127887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000086996966,0.00010033557,0.00012580036,0.000058479374,0.0001166761,0.000009883855,0.00005461395,0.000051943174,0.00022560768],"category_scores_gemma":[0.000009342153,0.000057075307,0.000050640654,0.00015590488,0.00008321215,0.00007649665,0.0000146704515,0.00009921305,0.000005037142],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029394132,0.000042931613,0.0029493617,0.000032192333,0.00026074034,3.874678e-7,0.00035268546,0.0000037841303,0.95092636,0.00009662001,0.000104291,0.044936676],"study_design_scores_gemma":[0.0018000522,0.00013815548,0.0014091784,0.0003250605,0.00013554933,0.000003654684,0.00019201422,0.00011566586,0.96156526,0.00004010223,0.034177255,0.000098044264],"about_ca_topic_score_codex":0.000011931627,"about_ca_topic_score_gemma":0.0000015871574,"teacher_disagreement_score":0.04483863,"about_ca_system_score_codex":0.0001277043,"about_ca_system_score_gemma":0.0000891177,"threshold_uncertainty_score":0.24702458},"labels":[],"label_agreement":null},{"id":"W2528516628","doi":"10.1016/j.ijrobp.2016.06.279","title":"The Use of a Biopsy-Based Genomic Classifier to Predict the Risk of Distant Metastasis After Definitive Radiation and Short-Course Androgen Deprivation Therapy for Intermediate- and High-Risk Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Prostatectomy; Androgen deprivation therapy; Biochemical recurrence; Radiation therapy; Biopsy; Metastasis; Oncology; Internal medicine; Prostate; Cancer; Urology; Confidence interval","score_opus":0.036317952696411866,"score_gpt":0.34070155411039543,"score_spread":0.3043836014139836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528516628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98259073,0.0022462942,0.008327405,0.0041275076,0.00043067872,0.0008189674,0.0014509903,0.000005641841,0.0000017819667],"genre_scores_gemma":[0.9768161,0.021614527,0.0008659122,0.00016437833,0.00031005175,0.00015603403,0.00004269946,0.000018359322,0.000011938149],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985878,0.00027218193,0.00057371997,0.00018393282,0.00021446639,0.00016793607],"domain_scores_gemma":[0.9964876,0.001654867,0.000849738,0.00013043941,0.0007897704,0.00008756965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007227486,0.00014532954,0.00031789028,0.00011094926,0.00009192258,0.000024033325,0.00013560816,0.000098651326,0.000006767844],"category_scores_gemma":[0.00045867675,0.00006956969,0.00012496232,0.00010323144,0.00042641378,0.00016395959,0.000036526497,0.00016305511,4.291158e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005569254,0.000103009406,0.5887082,0.0000060899133,0.0010193308,0.000002200173,0.00042994844,0.00006940399,0.0040097903,0.00023686505,0.00010113563,0.39974472],"study_design_scores_gemma":[0.010554993,0.0029636577,0.9532202,0.00012396523,0.0005995331,0.000015508076,0.000120810975,0.0016500897,0.019159248,0.0034111333,0.008052885,0.00012799764],"about_ca_topic_score_codex":0.00006027273,"about_ca_topic_score_gemma":0.00003002395,"teacher_disagreement_score":0.39961672,"about_ca_system_score_codex":0.00029252536,"about_ca_system_score_gemma":0.0004763254,"threshold_uncertainty_score":0.28369695},"labels":[],"label_agreement":null},{"id":"W2528747356","doi":"10.1016/j.eucr.2016.08.010","title":"Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report","year":2016,"lang":"en","type":"article","venue":"Urology Case Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Genome British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Genomics; Profiling (computer programming); Clinical trial; Clinical decision making; Oncology; Bioinformatics; Internal medicine; Intensive care medicine; Genome; Cancer; Gene","score_opus":0.03861350675390608,"score_gpt":0.4119745764772986,"score_spread":0.37336106972339256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528747356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923532,0.00042402107,0.004417093,0.00058825477,0.000666344,0.00090687536,0.0000093451845,0.00011310416,0.00052174693],"genre_scores_gemma":[0.99751127,0.00005975937,0.0009462171,0.00024437692,0.00046093884,0.00006709093,0.000033151515,0.00004864941,0.00062857644],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9967091,0.00019083575,0.0011254597,0.0009395878,0.00042941968,0.00060559344],"domain_scores_gemma":[0.99719447,0.0005832201,0.0004987383,0.0010656004,0.00022727715,0.00043068375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015659668,0.00028625358,0.0005640951,0.00026071418,0.00020287297,0.000017393022,0.00003813831,0.00037512876,0.00044663268],"category_scores_gemma":[0.0014328106,0.00014815283,0.00038128,0.00014550431,0.00021533805,0.00009060728,0.00014240496,0.0003999715,0.000052147927],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033444874,0.00032493152,0.12897807,0.000012900413,0.00013467527,0.8435949,0.0000247929,0.000008381072,0.0059719663,5.239575e-7,0.00054887583,0.017055504],"study_design_scores_gemma":[0.0019374348,0.0024821248,0.013824515,0.00009194769,0.00017524936,0.97690505,0.000013093355,0.000043287022,0.003169534,0.00032434746,0.0008696575,0.00016375656],"about_ca_topic_score_codex":0.00003048632,"about_ca_topic_score_gemma":0.000006332261,"teacher_disagreement_score":0.13331017,"about_ca_system_score_codex":0.00022944734,"about_ca_system_score_gemma":0.00046433858,"threshold_uncertainty_score":0.6041497},"labels":[],"label_agreement":null},{"id":"W2528809584","doi":"","title":"Integrating endocrine regulatory mechanisms in prostate cancer progression","year":2014,"lang":"en","type":"article","venue":"Endocrinology and Metabolic Syndrome","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Biology; Androgen receptor; Cancer research; Prostate cancer; Tumor progression; LNCaP; Autocrine signalling; Paracrine signalling; Androgen; Paxillin; Receptor tyrosine kinase; Cancer; Signal transduction; Cell biology; Endocrinology; Receptor; Focal adhesion; Hormone; Genetics","score_opus":0.015127625898199992,"score_gpt":0.31827559868984795,"score_spread":0.30314797279164796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528809584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821476,0.013475033,0.00004065163,0.0020013328,0.00025104196,0.00063648494,0.0000058256396,0.00008388966,0.0013581384],"genre_scores_gemma":[0.99180377,0.0036968219,0.0012984722,0.00021391835,0.00005891383,0.00038820136,0.00001930703,0.000025338706,0.0024952586],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983776,0.00012745112,0.0002680552,0.00041199801,0.00019198914,0.000622901],"domain_scores_gemma":[0.99942803,0.00005362287,0.00006557086,0.00024329167,0.000050734918,0.00015875035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020530574,0.00020772469,0.000527171,0.00030277736,0.00009803255,0.000012923917,0.00007615995,0.000062978244,0.00013295446],"category_scores_gemma":[0.00007693375,0.00014674017,0.00005206235,0.000234374,0.00018436793,0.000094661365,0.000097286524,0.00036990765,0.000017167788],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009445712,0.0005055668,0.28741425,0.0004124519,0.0003818888,0.002622712,0.0011958067,0.0000044981775,0.0483673,0.08843397,0.00019902883,0.56951797],"study_design_scores_gemma":[0.011266699,0.0012659837,0.85830885,0.00059611496,0.00019939513,0.005875029,0.00039618285,0.0002745768,0.081300244,0.0074565206,0.032603677,0.0004567161],"about_ca_topic_score_codex":0.00014410258,"about_ca_topic_score_gemma":0.000043027936,"teacher_disagreement_score":0.5708946,"about_ca_system_score_codex":0.00004459923,"about_ca_system_score_gemma":0.00009706427,"threshold_uncertainty_score":0.598389},"labels":[],"label_agreement":null},{"id":"W2529673068","doi":"10.1200/jco.2015.33.7_suppl.6","title":"PATRIOT Trial: Randomized phase II study of prostate stereotactic body radiotherapy comparing 11 versus 29 days overall treatment time.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; BC Cancer Agency; CancerCare Manitoba","funders":"","keywords":"Medicine; Prostate cancer; Clinical endpoint; Randomized controlled trial; Prostate; Urology; Radiation therapy; Quality of life (healthcare); Surgery; Internal medicine; Cancer","score_opus":0.2773814154203507,"score_gpt":0.5392107581566548,"score_spread":0.26182934273630404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529673068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99086714,0.0015043479,0.000009616023,0.0017891137,0.0017947416,0.0029663462,0.0000044500953,0.000013857234,0.0010503832],"genre_scores_gemma":[0.9949184,0.0019039911,0.0003795168,0.000097899225,0.0011292371,0.0000431902,0.000008769183,0.000028983653,0.0014900237],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936581,0.0019127926,0.0031223719,0.00025885773,0.0007112046,0.00033662346],"domain_scores_gemma":[0.9923177,0.003792959,0.002278608,0.00031238704,0.0006245044,0.00067387806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061510545,0.0002443367,0.004263572,0.00022732015,0.00006157836,0.000015839569,0.00017419142,0.00021072834,0.00011983399],"category_scores_gemma":[0.002294142,0.00013888051,0.00077022874,0.00014988633,0.0002617417,0.00014069726,0.00005759574,0.00057412154,0.000007834994],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9278935,0.038326837,0.006338325,0.00001523031,0.004232876,0.0009916465,0.0017541699,0.00001723985,0.00008151882,0.000006756764,0.001447936,0.018893952],"study_design_scores_gemma":[0.70281947,0.2852665,0.0004837592,0.000042280317,0.0014265624,0.000043770546,0.0002776084,0.00044676106,0.000062016574,0.00003202207,0.009019431,0.0000798008],"about_ca_topic_score_codex":0.00014379183,"about_ca_topic_score_gemma":0.000032272237,"teacher_disagreement_score":0.24693966,"about_ca_system_score_codex":0.0007624319,"about_ca_system_score_gemma":0.0028264192,"threshold_uncertainty_score":0.5663383},"labels":[],"label_agreement":null},{"id":"W2529979227","doi":"10.1074/mcp.m116.060244","title":"Immunoseroproteomic Profiling in African American Men with Prostate Cancer: Evidence for an Autoantibody Response to Glycolysis and Plasminogen-Associated Proteins","year":2016,"lang":"en","type":"article","venue":"Molecular & Cellular Proteomics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"IONICS Mass Spectrometry (Canada)","funders":"National Institute on Minority Health and Health Disparities; National Center on Minority Health and Health Disparities","keywords":"Autoantibody; Prostate cancer; Glycolysis; Medicine; Cancer; Internal medicine; Immunology; Antibody; Metabolism","score_opus":0.024144816672178937,"score_gpt":0.3194609226134236,"score_spread":0.2953161059412447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529979227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97858703,0.0006955504,0.0029084678,0.0039398107,0.000017248312,0.013629411,0.00010764086,0.00009411895,0.000020748741],"genre_scores_gemma":[0.9756745,0.00026041173,0.016395515,0.000092847135,0.000029261639,0.006639307,0.000038534126,0.00012410356,0.00074548763],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968115,0.00035755557,0.00044651574,0.0009626426,0.00051510497,0.0009066631],"domain_scores_gemma":[0.99830145,0.00012440691,0.00023162419,0.0006177767,0.0003107328,0.00041404003],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011302194,0.0004180226,0.0006653402,0.00041089903,0.00016988376,0.00008552419,0.0002426416,0.000116464864,0.000007645109],"category_scores_gemma":[0.00045741856,0.00028200375,0.00009816113,0.0008262084,0.00029370812,0.0002214095,0.00012598313,0.00023434378,0.0000047204853],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04380771,0.0002401103,0.019639878,0.00012788338,0.00021166468,0.00022718753,0.0008598538,0.00003399616,0.92935634,0.0000100481675,0.000005747422,0.005479567],"study_design_scores_gemma":[0.0067514963,0.006380651,0.011484548,0.0011551944,0.00014804781,0.000014720735,0.0003355897,0.00078447815,0.97236925,0.000045501194,0.00008930767,0.0004412006],"about_ca_topic_score_codex":0.0010307108,"about_ca_topic_score_gemma":0.00017085364,"teacher_disagreement_score":0.043012913,"about_ca_system_score_codex":0.00096626446,"about_ca_system_score_gemma":0.0010713713,"threshold_uncertainty_score":0.9999632},"labels":[],"label_agreement":null},{"id":"W2530071461","doi":"10.5489/cuaj.1236","title":"Moderated Poster Session 4: Prostate and Testes Cancer","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Session (web analytics); Prostate cancer; Prostate; Cancer; Medicine; Psychology; Internal medicine; Computer science; World Wide Web","score_opus":0.019205569919549928,"score_gpt":0.2774709185120122,"score_spread":0.2582653485924623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530071461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91387993,0.00093291345,0.0000022105771,0.083517015,0.000094021394,0.0003032836,0.000017515042,0.000016530059,0.0012365798],"genre_scores_gemma":[0.99022657,0.0005699812,0.000051380895,0.0038373591,0.00017055092,0.000037791164,0.000016528209,0.000009220447,0.005080603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898845,0.000072925846,0.00016489605,0.00013877978,0.00022012518,0.00041481663],"domain_scores_gemma":[0.99867785,0.00005204015,0.00008393874,0.000047571644,0.00038811637,0.00075049006],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018431572,0.00009670568,0.00016179148,0.00011395531,0.00023951671,0.00016129708,0.00003738318,0.00014097414,0.0013920425],"category_scores_gemma":[0.00016182126,0.0000610633,0.000037403017,0.00012420939,0.00003058588,0.00015998585,0.000012177522,0.00038551085,0.00005612822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004140567,0.000021056527,0.97475433,0.000005638713,0.00006751877,0.000044429413,0.000170641,0.0000044493045,0.0009706285,0.0000068780405,0.013842847,0.010070148],"study_design_scores_gemma":[0.0013501799,0.0002714791,0.98840594,0.000029203726,0.000035006826,0.000120132936,0.000049826318,0.0005252076,0.00018964584,0.0006833193,0.008248665,0.00009138008],"about_ca_topic_score_codex":0.002332031,"about_ca_topic_score_gemma":0.0002977664,"teacher_disagreement_score":0.07967965,"about_ca_system_score_codex":0.0007090952,"about_ca_system_score_gemma":0.0004786805,"threshold_uncertainty_score":0.99952084},"labels":[],"label_agreement":null},{"id":"W2530263771","doi":"10.1016/j.ijrobp.2015.07.294","title":"Sexual and Hormonal Function Recuperation After Cytoreductive Drug Therapy Prior to Prostate Permanent Seeds Brachytherapy: A Randomized Trial (Dutasteride + Bicalutamide Versus LHRH Agonists)","year":2015,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Dutasteride; Urology; Bicalutamide; Prostate cancer; Prostate brachytherapy; Hormonal therapy; Sexual function; Prostate; Testosterone (patch); Leuprorelin; Randomized controlled trial; Brachytherapy; Luteinizing hormone; Internal medicine; Gynecology; Hormone; Cancer; Radiation therapy; Gonadotropin-releasing hormone; Androgen receptor","score_opus":0.03606796812265098,"score_gpt":0.3616043812666888,"score_spread":0.3255364131440378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530263771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98296505,0.0015870976,0.0016914458,0.008847561,0.0031928483,0.0014967853,0.000054132808,0.00002981463,0.00013527028],"genre_scores_gemma":[0.9921402,0.0012457948,0.0011109787,0.0008967675,0.0038767327,0.00020183108,0.00019101545,0.00003415194,0.00030255486],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99767435,0.0005310722,0.0007178059,0.00031179847,0.00050575705,0.0002592368],"domain_scores_gemma":[0.9975591,0.00038014952,0.0005106433,0.000123851,0.0011172788,0.000309033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012524434,0.00024780037,0.0006695051,0.00024801015,0.00008211302,0.00007980256,0.00014129808,0.0001625927,0.000035748453],"category_scores_gemma":[0.0003265217,0.0001800785,0.00017999121,0.00016348816,0.00028990707,0.00039031386,0.00005141631,0.00041147738,0.000019784839],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8547969,0.00050644146,0.004504969,0.0000052450487,0.0012608304,0.000049041715,0.0032981213,0.00010373302,0.0039010446,0.00035598016,0.00060017675,0.13061753],"study_design_scores_gemma":[0.95678777,0.014189717,0.0055114427,0.00004546078,0.00031144317,0.00018201927,0.00062722614,0.0010879415,0.0016165003,0.003109569,0.016243005,0.00028792725],"about_ca_topic_score_codex":0.000029434728,"about_ca_topic_score_gemma":0.000005724667,"teacher_disagreement_score":0.13032961,"about_ca_system_score_codex":0.0010777884,"about_ca_system_score_gemma":0.001039146,"threshold_uncertainty_score":0.7343388},"labels":[],"label_agreement":null},{"id":"W2531068159","doi":"10.1007/s12253-016-0119-9","title":"SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion","year":2016,"lang":"en","type":"article","venue":"Pathology & Oncology Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Calgary Laboratory Services; Prostate Cancer Canada; University of Calgary","funders":"Prostate Cancer Canada; University Health Network; Movember Foundation; Prostate Cancer Foundation","keywords":"PTEN; Prostatectomy; Prostate cancer; Erg; Intraepithelial neoplasia; Immunohistochemistry; Prostate; Population; Medicine; Biochemical recurrence; Cohort; Pathology; Fluorescence in situ hybridization; Cancer; Pathological; Internal medicine; Cancer research; Biology; Oncology; Gene; Genetics; Apoptosis; Chromosome","score_opus":0.05130531824265631,"score_gpt":0.4052702033111483,"score_spread":0.353964885068492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531068159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99133307,0.002002053,0.00004122193,0.004119669,0.000040879055,0.0015963365,0.000054124113,0.00003285698,0.0007797899],"genre_scores_gemma":[0.9923309,0.0049846433,0.00019535645,0.00010834529,0.000044125332,0.0007397687,0.000049821003,0.000033538538,0.0015134966],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9962285,0.0013165519,0.00040926546,0.00062701065,0.0005974938,0.0008211773],"domain_scores_gemma":[0.9980735,0.0006569868,0.00017970757,0.00032050698,0.00052438554,0.00024486758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001386392,0.00021000042,0.0006614665,0.00060292776,0.00016477008,0.0000071611157,0.00014925876,0.00046498945,0.00014106408],"category_scores_gemma":[0.00046554755,0.00011906243,0.00005288158,0.0005595367,0.0013015281,0.00012251236,0.00032031955,0.00067319436,0.00000914163],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018526796,0.0010426771,0.21807092,0.00019538899,0.00012703,0.004426652,0.0021004337,0.0000045774427,0.71239126,0.000050048864,0.00096888904,0.04209533],"study_design_scores_gemma":[0.114708655,0.036162436,0.4116482,0.020088807,0.00022460891,0.0011568241,0.0048648794,0.0005020238,0.40098992,0.0036666072,0.005032073,0.00095496775],"about_ca_topic_score_codex":0.00011337038,"about_ca_topic_score_gemma":0.00014564149,"teacher_disagreement_score":0.31140134,"about_ca_system_score_codex":0.00076689495,"about_ca_system_score_gemma":0.001000863,"threshold_uncertainty_score":0.48552248},"labels":[],"label_agreement":null},{"id":"W2531708639","doi":"10.1016/j.ijrobp.2015.07.1039","title":"Post–Biochemical Failure Risk Stratification to Predict Survival in Prostate Cancer: A Recursive Partitioning Analysis","year":2015,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McGill University Health Centre; Hôtel-Dieu de Québec; Princess Margaret Cancer Centre; BC Cancer Agency; Centre hospitalier universitaire de Québec; University of British Columbia, Okanagan Campus; University of British Columbia; McMaster University; London Health Sciences Centre","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Prostate-specific antigen; Internal medicine; Concordance; Oncology; Prostate; Radiation therapy; Risk stratification; Urology; Stage (stratigraphy); Surrogate endpoint; Cancer; Confidence interval","score_opus":0.027959322555739755,"score_gpt":0.3698404915469794,"score_spread":0.34188116899123966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531708639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98198754,0.0006761251,0.0029419176,0.012693791,0.0007406983,0.0004222328,0.000297703,0.000022661934,0.00021733575],"genre_scores_gemma":[0.995028,0.0008715281,0.0021963555,0.000234215,0.0010527874,0.000056187833,0.0004711333,0.000016341555,0.0000734201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981285,0.00027853687,0.000648878,0.00026652365,0.00042698003,0.00025059152],"domain_scores_gemma":[0.99693006,0.00019276398,0.0006468552,0.00013667613,0.001808978,0.00028465368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008069845,0.00015890527,0.00046043302,0.00042049933,0.000046305126,0.000034869816,0.0002263086,0.00015295189,0.000046995883],"category_scores_gemma":[0.00057928625,0.00013361576,0.0001868544,0.0005738937,0.000113875234,0.0002325959,0.00004325307,0.00049562095,0.000019707804],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022004002,0.00045753186,0.9532004,0.000006744281,0.0017864795,0.00006292989,0.0018957347,0.0063734385,0.003484497,0.0009637419,0.0014798406,0.028088275],"study_design_scores_gemma":[0.053006813,0.013199939,0.7833829,0.0005717828,0.0044501293,0.00027465372,0.005529801,0.021841997,0.04164707,0.036896314,0.037918717,0.0012799101],"about_ca_topic_score_codex":0.00020839149,"about_ca_topic_score_gemma":0.00010071761,"teacher_disagreement_score":0.1698175,"about_ca_system_score_codex":0.0015701995,"about_ca_system_score_gemma":0.0013129818,"threshold_uncertainty_score":0.54486924},"labels":[],"label_agreement":null},{"id":"W2531770271","doi":"10.1007/s00428-016-2033-7","title":"Small cell-like glandular proliferation of prostate: a rare lesion not related to small cell prostate cancer","year":2016,"lang":"en","type":"article","venue":"Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Calgary Laboratory Services","funders":"","keywords":"Prostate; Prostate cancer; Pathology; Medicine; Cell; Cell growth; Cancer; Cancer research; Oncology; Biology; Internal medicine","score_opus":0.047877123406481537,"score_gpt":0.3513127599885738,"score_spread":0.30343563658209227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531770271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98170966,0.0046866294,0.0003082293,0.005903155,0.00042298879,0.0040498087,0.00036294974,0.00026687127,0.0022897304],"genre_scores_gemma":[0.98053813,0.007931804,0.0028896867,0.0011195287,0.00022178357,0.00063160557,0.00049850997,0.00012056808,0.00604838],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99444616,0.00066071353,0.0012916592,0.0014807504,0.00074246957,0.00137825],"domain_scores_gemma":[0.99634033,0.0007079281,0.0005588909,0.0011969979,0.0004932598,0.0007026147],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001245736,0.0007978776,0.0013458368,0.0005351646,0.000286333,0.000035369023,0.00059785886,0.00048534764,0.00012889768],"category_scores_gemma":[0.000536385,0.00045636581,0.000356033,0.0007912048,0.00086446357,0.00016745403,0.00048472048,0.00093672593,0.0001391249],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074104797,0.001141402,0.06866257,0.00094071456,0.000378329,0.0006303248,0.003213877,0.00011101373,0.87965834,0.00020036635,0.0019340598,0.035718504],"study_design_scores_gemma":[0.0196923,0.008130336,0.068804525,0.0019389008,0.00090704823,0.000032093623,0.0010765675,0.0003553438,0.88832897,0.0020532205,0.007536257,0.001144428],"about_ca_topic_score_codex":0.00027208243,"about_ca_topic_score_gemma":0.000058638245,"teacher_disagreement_score":0.034574073,"about_ca_system_score_codex":0.00021006014,"about_ca_system_score_gemma":0.001187084,"threshold_uncertainty_score":0.9997888},"labels":[],"label_agreement":null},{"id":"W2533101571","doi":"10.1158/1078-0432.ccr-16-1790","title":"A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre","funders":"","keywords":"Bicalutamide; Prostate cancer; Urology; Medicine; Testosterone (patch); Agonist; Antiandrogen; Goserelin; Luteinizing hormone; Androgen deprivation therapy; Dihydrotestosterone; Prostatectomy; Internal medicine; Leuprorelin; Hormone; Endocrinology; Androgen; Gonadotropin-releasing hormone; Cancer; Androgen receptor; Receptor","score_opus":0.2569833737468409,"score_gpt":0.5723141692703112,"score_spread":0.3153307955234703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2533101571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718213,0.0012640433,0.0000026268735,0.0069905976,0.0005778321,0.018448412,0.00020818049,0.00003637699,0.0006506367],"genre_scores_gemma":[0.98064643,0.0038958127,0.00010903628,0.00015083795,0.00024047989,0.009313503,0.000027946739,0.000085172294,0.0055307928],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9915143,0.0016544804,0.0018744224,0.0013589464,0.002146227,0.001451613],"domain_scores_gemma":[0.9936177,0.002578612,0.0002512709,0.0008845752,0.0015865389,0.0010812997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006581646,0.0003869774,0.0019197579,0.00058679364,0.0003425579,0.00009270594,0.0009012342,0.00019713365,0.00066105643],"category_scores_gemma":[0.0035804808,0.00022270142,0.00017735008,0.0015450983,0.0014399278,0.00025064967,0.0015092255,0.0011605015,0.00007596894],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70149314,0.037887536,0.04353072,0.00014759238,0.00046276228,0.0002344658,0.0013738304,9.901346e-7,0.0005945261,0.000020502135,0.0035244187,0.2107295],"study_design_scores_gemma":[0.9345669,0.04728045,0.0070669707,0.0014330382,0.00014136684,9.2116323e-7,0.00036762867,0.000042739946,0.0018402705,0.00008330138,0.0068617146,0.00031470117],"about_ca_topic_score_codex":0.004824019,"about_ca_topic_score_gemma":0.0022269175,"teacher_disagreement_score":0.23307374,"about_ca_system_score_codex":0.0012090547,"about_ca_system_score_gemma":0.0031603016,"threshold_uncertainty_score":0.90815},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2534296705","doi":"10.1016/j.ijrobp.2015.07.1112","title":"Active Surveillance in Intermediate-Risk Patients: Overall and Cause-Specific Survival From a Large Single-Institution Experience","year":2015,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Interquartile range; Prostate cancer; Hazard ratio; Internal medicine; Prostate-specific antigen; Oncology; Watchful waiting; Confidence interval; Radiation therapy; Cancer; Gastroenterology","score_opus":0.045169752141545554,"score_gpt":0.3537628399716184,"score_spread":0.30859308783007283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534296705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99431217,0.0007515772,0.0014145705,0.0005632652,0.00228216,0.0002102494,0.0002210155,0.0000159623,0.0002290036],"genre_scores_gemma":[0.9961872,0.002078603,0.0002578724,0.00015625176,0.0010337062,0.000011724884,0.00024544031,0.000014044168,0.000015150501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984482,0.00026646303,0.0004896247,0.0002366166,0.0003341075,0.00022501686],"domain_scores_gemma":[0.9980987,0.00028381855,0.00055209355,0.00010433848,0.0007891463,0.00017195941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039911392,0.00015561088,0.00038129682,0.00016066026,0.0000415073,0.000027297221,0.00017714806,0.00015752835,0.000023943554],"category_scores_gemma":[0.00046549077,0.00012762233,0.000076065735,0.0001249128,0.00020981215,0.0003885285,0.00007557007,0.00042142937,0.000010917318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020691466,0.00070891186,0.95047235,0.000002216917,0.00020816986,0.000063817424,0.0026664373,0.000037776557,0.00061372854,0.0005559863,0.00022746407,0.04237397],"study_design_scores_gemma":[0.024025677,0.0020095939,0.95028937,0.00008428126,0.00003522341,0.000024299543,0.0006855222,0.00064748595,0.0014016347,0.003826732,0.016780196,0.00018999902],"about_ca_topic_score_codex":0.000074250245,"about_ca_topic_score_gemma":0.00005860365,"teacher_disagreement_score":0.04218397,"about_ca_system_score_codex":0.0014595945,"about_ca_system_score_gemma":0.00041098866,"threshold_uncertainty_score":0.5204288},"labels":[],"label_agreement":null},{"id":"W2535680910","doi":"10.1016/j.jgo.2016.09.005","title":"A comparison of the CARG tool, the VES-13, and oncologist judgment in predicting grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer","year":2016,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Prostate cancer; Internal medicine; Docetaxel; Toxicity; Confidence interval; Oncology; Chemotherapy; Odds ratio; Observational study; Cancer","score_opus":0.055667313157783,"score_gpt":0.4052563230151122,"score_spread":0.3495890098573292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2535680910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97145087,0.005603322,0.000032532134,0.021579003,0.00021370617,0.00097113627,0.000011423802,0.0000025976674,0.00013542948],"genre_scores_gemma":[0.9931682,0.0058072363,0.0003275625,0.00013444317,0.00013665104,0.00008187629,4.3868243e-7,0.000011585023,0.00033204062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853075,0.00021035934,0.00065130874,0.00011726901,0.00022630773,0.0002639814],"domain_scores_gemma":[0.9980489,0.0011672822,0.0005345927,0.00010239168,0.00010242791,0.000044431596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010954096,0.00010866161,0.0005621505,0.00016947709,0.00006124261,0.0000092519385,0.00012455061,0.00005958727,0.00001391062],"category_scores_gemma":[0.00021940566,0.000044972323,0.00008744603,0.00023995368,0.00019611843,0.00007514115,0.000044252527,0.00021844888,1.0869373e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054406547,0.000814301,0.905914,0.00036677514,0.00040488152,0.00004803934,0.009841357,0.00014724265,0.018399185,0.00006921156,0.0020762577,0.05647807],"study_design_scores_gemma":[0.06403425,0.012951639,0.86719584,0.0015042039,0.00063110853,0.00024062616,0.01776426,0.00083012495,0.024328347,0.0026457885,0.007616514,0.0002572994],"about_ca_topic_score_codex":0.00016292451,"about_ca_topic_score_gemma":0.0008584323,"teacher_disagreement_score":0.058593594,"about_ca_system_score_codex":0.0009009476,"about_ca_system_score_gemma":0.0011236595,"threshold_uncertainty_score":0.23559467},"labels":[],"label_agreement":null},{"id":"W2537692172","doi":"10.1200/jco.2013.31.6_suppl.lba8","title":"Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Bristol-Myers Squibb (Canada)","funders":"","keywords":"Medicine; Docetaxel; Dasatinib; Clinical endpoint; Internal medicine; Prostate cancer; Hazard ratio; Urology; Oncology; Progression-free survival; Phases of clinical research; Randomized controlled trial; Gastroenterology; Cancer; Tyrosine kinase; Clinical trial; Chemotherapy; Confidence interval","score_opus":0.13517631676059172,"score_gpt":0.46769107226991663,"score_spread":0.3325147555093249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2537692172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98861,0.0007230732,0.000006897977,0.006363852,0.0006859779,0.0027292417,0.00020972629,0.000003905188,0.0006672967],"genre_scores_gemma":[0.9954656,0.002743476,0.0008384622,0.00020820364,0.00029735206,0.00006793933,0.00008296457,0.00001763089,0.00027840096],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937593,0.0015310512,0.0034203082,0.0002733154,0.00072158675,0.0002944734],"domain_scores_gemma":[0.9842337,0.011712826,0.0026008287,0.00025741587,0.000903634,0.00029159384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052896263,0.00020587641,0.0024611126,0.000098042816,0.000058705224,0.00002409224,0.00015192867,0.00014714312,0.00015842897],"category_scores_gemma":[0.0051513137,0.00009649874,0.00025105948,0.00016221723,0.00061748753,0.00021685977,0.000044539735,0.0007897443,0.0000026613443],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9709086,0.002703419,0.0056945817,0.000021927926,0.001574189,0.00008484391,0.0005164479,0.000017081262,0.000044299344,0.000040889234,0.00072695164,0.017666787],"study_design_scores_gemma":[0.88884985,0.016431449,0.0920782,0.0001963882,0.00087977736,0.0000021407398,0.00024667196,0.000093850926,0.000024676325,0.00019118248,0.0009150727,0.0000907553],"about_ca_topic_score_codex":0.0022357826,"about_ca_topic_score_gemma":0.0007400162,"teacher_disagreement_score":0.08638362,"about_ca_system_score_codex":0.0001728964,"about_ca_system_score_gemma":0.0020626704,"threshold_uncertainty_score":0.61669755},"labels":[],"label_agreement":null},{"id":"W2537819449","doi":"10.1007/s40273-016-0457-1","title":"Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal","year":2016,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Technology Assessment Programme; Queen's University; Queen's University Belfast; National Institute for Health and Care Research","keywords":"Docetaxel; Cabazitaxel; Medicine; Oncology; Prostate cancer; Regimen; Quality of Life Research; Internal medicine; Health economics; Nice; Cost effectiveness; Chemotherapy; Cancer; Public health; Androgen deprivation therapy; Nursing","score_opus":0.09311260996567614,"score_gpt":0.45005130497973883,"score_spread":0.3569386950140627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2537819449","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000461231,0.9854049,0.000060486243,0.0012868987,0.000113356975,0.011683198,0.0006951797,0.00013240505,0.00016230813],"genre_scores_gemma":[0.0003089255,0.9891905,0.0011133766,0.00016310127,0.00017763172,0.007882334,0.0002332345,0.00022275391,0.00070810865],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960596,0.0002474535,0.001260321,0.0012831299,0.00024521688,0.0009042545],"domain_scores_gemma":[0.9958963,0.00077907194,0.0015088536,0.0007878977,0.0006629698,0.0003649491],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00086343894,0.0008922152,0.003937089,0.0005732886,0.00012440281,0.000039146056,0.00048703916,0.0002136398,0.000084434745],"category_scores_gemma":[0.00028076879,0.0005681569,0.00058919436,0.00059288234,0.00043602064,0.0004932617,0.000115159615,0.0005660298,0.00001913567],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051195794,0.0008414929,0.00006186509,0.10886237,0.007056395,0.0001379765,0.00050006947,0.0000013733918,0.00046667704,0.0003100526,0.0018504723,0.8747917],"study_design_scores_gemma":[0.013559192,0.010229016,0.000002063925,0.23623386,0.022937583,0.0004962636,0.00041162458,0.00006465381,0.0005216179,0.000082408806,0.714142,0.0013197217],"about_ca_topic_score_codex":0.00020042059,"about_ca_topic_score_gemma":0.000046931524,"teacher_disagreement_score":0.873472,"about_ca_system_score_codex":0.0019679791,"about_ca_system_score_gemma":0.002112589,"threshold_uncertainty_score":0.999677},"labels":[],"label_agreement":null},{"id":"W2537989070","doi":"10.1016/j.celrep.2016.09.064","title":"Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein","year":2016,"lang":"en","type":"article","venue":"Cell Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Defense","keywords":"Androgen receptor; Repressor; Retinoblastoma protein; Psychological repression; Biology; Cancer research; Prostate cancer; Hyperphosphorylation; Gene; Retinoblastoma; Activator (genetics); Transcription factor; Transcription (linguistics); Cyclin-dependent kinase; Cell growth; Androgen; Cell cycle; Cell biology; Kinase; Gene expression; Endocrinology; Cancer; Genetics","score_opus":0.02759952317313718,"score_gpt":0.27986785672927256,"score_spread":0.25226833355613537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2537989070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919408,0.00086429797,0.000023850173,0.001137071,0.00017599248,0.0019050429,0.000054405442,0.000059091053,0.003839456],"genre_scores_gemma":[0.9607757,0.00012241445,0.00009583752,0.00007499853,0.00006797084,0.00037344074,0.00010899784,0.00003073248,0.038349915],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984533,0.00004154349,0.0004118087,0.00036438782,0.0004478187,0.00028109335],"domain_scores_gemma":[0.9989097,0.000036780493,0.00025938492,0.00041163818,0.00018557209,0.00019692702],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002509111,0.0001455404,0.00027081964,0.00007450501,0.000039197716,0.0000062232166,0.00003950726,0.00008026358,0.0017414154],"category_scores_gemma":[0.00009764792,0.00008456535,0.00008892345,0.00013984989,0.00009725869,0.00006186402,0.0000374429,0.00007763314,0.00007450749],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080317684,0.0002479892,0.007734063,0.00013182987,0.00007108429,0.00027815864,0.000083463805,1.2577181e-8,0.9420026,0.0000010175752,0.04515402,0.0034925707],"study_design_scores_gemma":[0.0013915688,0.00087974645,0.0006528166,0.0002188043,0.000047573605,0.000051783987,0.000025700634,9.4625534e-7,0.88155806,0.000043173502,0.11504157,0.00008827519],"about_ca_topic_score_codex":0.000020558376,"about_ca_topic_score_gemma":8.4912176e-7,"teacher_disagreement_score":0.06988755,"about_ca_system_score_codex":0.00014273879,"about_ca_system_score_gemma":0.00018829941,"threshold_uncertainty_score":0.99917114},"labels":[],"label_agreement":null},{"id":"W2540786849","doi":"10.1158/2159-8290.cd-15-1263","title":"The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":444,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Androgen receptor; Cancer research; Neuroendocrine differentiation; Transcription factor; SOX2; Prostate; Enzalutamide; In vivo; Tramp; Biology; Cancer; Medicine; Internal medicine; Gene; Genetics","score_opus":0.03884735603184115,"score_gpt":0.3067152536351832,"score_spread":0.26786789760334206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2540786849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884036,0.0024492827,0.000018316368,0.007313601,0.0004254202,0.0007560201,0.00058224634,0.00001935449,0.000032144715],"genre_scores_gemma":[0.98262835,0.009840219,0.0000036459842,0.00015371527,0.00012959828,0.00028161262,0.00004243617,0.000030449472,0.006890007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986002,0.00007854724,0.00028412841,0.00033294142,0.0003298482,0.00037436042],"domain_scores_gemma":[0.9993795,0.000042495725,0.00009792935,0.00028826128,0.00009224627,0.00009957774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000041823685,0.00018010716,0.0002506873,0.00008787528,0.000067174966,0.000044927252,0.0001194731,0.00002964988,0.00039135132],"category_scores_gemma":[0.0000090835065,0.000090023925,0.00009461215,0.00016623024,0.00013108875,0.0006343285,0.00002894571,0.000121733356,0.0000038016017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024213402,0.00013454106,0.49368688,0.0001179279,0.00009570634,0.000012870347,0.0008145703,0.000006346564,0.46490297,0.0000100365905,0.0007320687,0.037064746],"study_design_scores_gemma":[0.006601629,0.00044481934,0.5012792,0.0003994041,0.00008558805,0.0000039565966,0.0001636377,0.0001630101,0.4865427,0.000063527485,0.0040603997,0.00019213572],"about_ca_topic_score_codex":0.00045520678,"about_ca_topic_score_gemma":0.00050779467,"teacher_disagreement_score":0.03687261,"about_ca_system_score_codex":0.00030364774,"about_ca_system_score_gemma":0.00018072894,"threshold_uncertainty_score":0.42850226},"labels":[],"label_agreement":null},{"id":"W2541899361","doi":"10.3747/co.23.2953","title":"Long-Term Health Care Costs for Prostate Cancer Patients on Androgen Deprivation Therapy","year":2016,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Public Health Ontario; University of Toronto; Toronto General Hospital; Toronto Public Health","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Term (time); Cancer; Androgen; Intensive care medicine; Oncology; Bioinformatics; Internal medicine; Hormone","score_opus":0.11184886378577082,"score_gpt":0.4725377607620563,"score_spread":0.3606888969762855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2541899361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796274,0.010885835,0.000044743298,0.0053999247,0.00088097993,0.002808326,0.0002100868,0.00003751553,0.000105240164],"genre_scores_gemma":[0.9813781,0.015932215,0.000024464287,0.00042002558,0.00027314422,0.0011151722,0.00050489214,0.000026850652,0.00032514345],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99890983,0.000061296014,0.00019271421,0.00029243968,0.00017850492,0.0003652026],"domain_scores_gemma":[0.9992018,0.00008109184,0.000106357955,0.00015488348,0.00029671853,0.00015915128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000911934,0.00013042797,0.00025218463,0.00009226993,0.0000979968,0.000006262954,0.000061987506,0.00006457439,0.00005581777],"category_scores_gemma":[0.000029479877,0.00007328646,0.00006336797,0.000079552265,0.00006482482,0.000047929618,0.000020956784,0.00008451075,0.000019249339],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015049465,0.000383272,0.44514218,0.000079404,0.00003207644,0.000001483521,0.00039086066,4.087975e-8,0.0000847715,0.000013329702,0.0027233316,0.5496443],"study_design_scores_gemma":[0.03319264,0.012331808,0.77129894,0.00068074936,0.00003370379,0.0000022462068,0.000055811626,0.000003058949,0.007880136,0.00004652191,0.17427993,0.00019442593],"about_ca_topic_score_codex":0.000014961546,"about_ca_topic_score_gemma":0.00006630912,"teacher_disagreement_score":0.54944986,"about_ca_system_score_codex":0.0018523978,"about_ca_system_score_gemma":0.00062126515,"threshold_uncertainty_score":0.4843956},"labels":[],"label_agreement":null},{"id":"W2544318409","doi":"10.1016/j.jval.2016.09.2250","title":"Development of a Global Model for the Economic Evaluation of Personalized Medicine for the Treatment of Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Christian ministry; Personalized medicine; Economic evaluation; Medical physics; Precision medicine; Prostate; Gynecology; Oncology; Cancer; Internal medicine; Bioinformatics; Political science; Pathology","score_opus":0.23587646054394062,"score_gpt":0.4658859456792348,"score_spread":0.23000948513529418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544318409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9398253,0.027150724,0.0020218827,0.022552963,0.0001437073,0.007877531,0.00039571046,0.0000046082578,0.000027579923],"genre_scores_gemma":[0.9860418,0.01009173,0.0014819768,0.000040884355,0.00005539328,0.001958936,0.000012757078,0.000009874159,0.0003066916],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99889773,0.000052759286,0.0004556383,0.00013839247,0.000265979,0.00018950774],"domain_scores_gemma":[0.99894863,0.00041610058,0.00022409977,0.0001638476,0.00020402452,0.00004330369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014613417,0.000084724365,0.00031057934,0.0000336949,0.00005377255,8.1499974e-7,0.00006124689,0.000024559933,0.00002352651],"category_scores_gemma":[0.000051386563,0.00003207317,0.000063531406,0.000066346205,0.00014683175,0.000016655895,0.0000067224696,0.000014642754,2.0618411e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009940576,0.0005787373,0.022752415,0.0016524968,0.0008887177,1.805735e-7,0.03287649,0.020010136,0.0015113838,0.0029376966,0.0006262436,0.9062249],"study_design_scores_gemma":[0.046830017,0.0035024583,0.01778415,0.001608785,0.00045957288,0.0000016083094,0.0017520427,0.9148169,0.0058039976,0.0024409739,0.0048943474,0.000105105835],"about_ca_topic_score_codex":0.002326615,"about_ca_topic_score_gemma":0.0005612554,"teacher_disagreement_score":0.9061198,"about_ca_system_score_codex":0.0022080278,"about_ca_system_score_gemma":0.0042862054,"threshold_uncertainty_score":0.7603544},"labels":[],"label_agreement":null},{"id":"W2545075008","doi":"10.1016/j.prp.2016.10.007","title":"Evaluation of ERG and PTEN protein expression in cribriform architecture prostate carcinomas","year":2016,"lang":"en","type":"article","venue":"Pathology - Research and Practice","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Sunnybrook Health Science Centre; Centre Hospitalier de l’Université de Montréal; University Health Network; Health Sciences Centre","funders":"","keywords":"Cribriform; PTEN; Pathology; Concordance; Erg; Carcinoma; Prostatectomy; Immunohistochemistry; Medicine; Immunostaining; Biopsy; Prostate; Biology; Cancer; Internal medicine; Apoptosis","score_opus":0.13433724314769882,"score_gpt":0.44800917897257875,"score_spread":0.31367193582487995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2545075008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757579,0.004428531,0.000029432334,0.013408797,0.000017646302,0.0016599913,0.000019128305,0.000009298232,0.004669275],"genre_scores_gemma":[0.99603987,0.0016639755,0.00082388875,0.000025064332,0.000040719413,0.000294553,0.000008975765,0.0000126338955,0.0010902935],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99667436,0.0015016869,0.00019452989,0.0003510054,0.00087405706,0.000404345],"domain_scores_gemma":[0.99771464,0.0009855593,0.00006570627,0.00023556827,0.0008420879,0.00015643427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008162475,0.000099839235,0.00020082785,0.00032544127,0.00009181678,0.000014844396,0.000054738724,0.000114487666,0.000062492545],"category_scores_gemma":[0.005645858,0.000050947136,0.000015772828,0.00022125634,0.0005016976,0.00024504252,0.00013612291,0.0003847986,0.000005777044],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006886166,0.00030467592,0.023418313,0.00022258416,0.00003610711,0.00039395853,0.0020150135,2.2928076e-7,0.7133563,0.000099676174,0.00009318491,0.2531738],"study_design_scores_gemma":[0.031527884,0.009893369,0.3183926,0.0021365394,0.00026109722,0.0022160893,0.004521156,0.00018668787,0.5804864,0.039315384,0.010615017,0.00044777285],"about_ca_topic_score_codex":0.00007971771,"about_ca_topic_score_gemma":0.00004382084,"teacher_disagreement_score":0.29497427,"about_ca_system_score_codex":0.00010012453,"about_ca_system_score_gemma":0.00039133627,"threshold_uncertainty_score":0.6759027},"labels":[],"label_agreement":null},{"id":"W2545460684","doi":"10.1016/j.jval.2016.09.2308","title":"Castration-Resistant Prostate Cancer (CRPC): Evaluation of The Quality of Care and Disease Management in Real-Life Setting","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Enzalutamide; Docetaxel; Medicine; Cabazitaxel; Abiraterone acetate; Prostate cancer; Abiraterone; Internal medicine; Oncology; Quality of life (healthcare); Cancer; Androgen deprivation therapy; Nursing","score_opus":0.13060201330648763,"score_gpt":0.456727396626098,"score_spread":0.3261253833196104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2545460684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862235,0.0049590594,9.951951e-7,0.0068150107,0.00003934578,0.0016718804,0.000090254325,0.0000035937637,0.00019635352],"genre_scores_gemma":[0.99588263,0.0038011658,0.000053383228,0.000046888155,0.000012981603,0.00012482802,0.0000074065347,0.000005957402,0.00006477683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983314,0.00041799774,0.00041098276,0.00016126508,0.0005152752,0.00016306361],"domain_scores_gemma":[0.9993204,0.000077286706,0.0001635492,0.00018822368,0.00014049988,0.000110053326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015141149,0.000061537175,0.00017111877,0.000081645114,0.00003186478,0.0000024450858,0.000036062935,0.000017625436,0.000010304094],"category_scores_gemma":[0.00017284432,0.00003369021,0.000023634842,0.00018130914,0.000065288485,0.000035434357,0.00002797073,0.000049874907,1.7333889e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015722081,0.00013740305,0.9270798,0.005590452,0.000037463862,0.0000044608787,0.0048802523,0.00078810996,0.0014261239,0.001020195,0.00004707441,0.05741648],"study_design_scores_gemma":[0.0035499467,0.000118650714,0.99196887,0.0019251478,0.00002489507,1.0369552e-7,0.0011371489,0.0005531914,0.00032290863,0.00034488566,0.000018028808,0.000036229078],"about_ca_topic_score_codex":0.008606326,"about_ca_topic_score_gemma":0.0012444158,"teacher_disagreement_score":0.06488909,"about_ca_system_score_codex":0.0005776197,"about_ca_system_score_gemma":0.00144446,"threshold_uncertainty_score":0.99799544},"labels":[],"label_agreement":null},{"id":"W2547141003","doi":"10.1097/01.cot.0000471130.82578.7f","title":"First Indication Chemotherapy Has Role in Adjuvant Therapy of Localized Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"Oncology Times","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Docetaxel; Radiation therapy; Prostate cancer; Oncology; Internal medicine; Prednisone; Cancer; Chemotherapy; Stage (stratigraphy); Urology","score_opus":0.04518263264492983,"score_gpt":0.36649508496549105,"score_spread":0.3213124523205612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547141003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94893754,0.01737247,0.0000070298056,0.022948131,0.00009342928,0.001035691,0.000012695531,0.000033627795,0.0095594],"genre_scores_gemma":[0.98385113,0.009426479,0.00032686783,0.00043263385,0.00006431763,0.00027846376,0.00004170621,0.000019885598,0.005558527],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991773,0.000056139266,0.00020328182,0.0001750107,0.00017735737,0.00021095916],"domain_scores_gemma":[0.9994902,0.00004312746,0.00009439806,0.00015310735,0.000115089955,0.000104085324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025494132,0.00009839785,0.00033396907,0.00013482472,0.000027765389,0.00000491726,0.000070375674,0.000117250056,0.00040583874],"category_scores_gemma":[0.000022002596,0.00006883719,0.000037372996,0.00021930702,0.00022581288,0.000047140333,0.000016728627,0.00012654817,0.000025870455],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011080032,0.0017420703,0.6744236,0.0000690992,0.0002799092,0.00007508559,0.014710365,0.00007345376,0.0062683388,0.0000758849,0.021036047,0.27016616],"study_design_scores_gemma":[0.04675065,0.005139395,0.14907272,0.00023076803,0.0000417507,0.000021548682,0.0013716117,0.0010572028,0.07614967,0.0016539327,0.7182734,0.0002373347],"about_ca_topic_score_codex":0.0005780015,"about_ca_topic_score_gemma":0.0002117565,"teacher_disagreement_score":0.6972374,"about_ca_system_score_codex":0.00035730685,"about_ca_system_score_gemma":0.001081737,"threshold_uncertainty_score":0.44436496},"labels":[],"label_agreement":null},{"id":"W2548076679","doi":"10.1016/j.ijrobp.2015.07.1033","title":"Regional Quadrant Dosimetry and Late Genitourinary Toxicity After Low-Dose-Rate Prostate Brachytherapy","year":2015,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Quadrant (abdomen); Prostate cancer; Nuclear medicine; Genitourinary system; Interquartile range; Dosimetry; Prostate; Univariate analysis; Brachytherapy; Radiation therapy; Urology; Radiology; Surgery; Multivariate analysis; Internal medicine; Cancer","score_opus":0.03444559368160646,"score_gpt":0.35958174874517534,"score_spread":0.32513615506356885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2548076679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871703,0.00303196,0.00054541475,0.00753005,0.0011151574,0.00029945676,0.00005055986,0.000027878792,0.00022925921],"genre_scores_gemma":[0.99178493,0.0029063586,0.00096745364,0.0017736267,0.0020809865,0.000022150067,0.00008389913,0.000029461595,0.0003511568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982997,0.0002620658,0.0005517761,0.00024974547,0.00036025626,0.0002764124],"domain_scores_gemma":[0.9979148,0.0002054877,0.0005167755,0.00013149493,0.0009251899,0.0003062818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073416316,0.00020845716,0.00042817023,0.00020154302,0.00005970669,0.00003804515,0.0001880277,0.00019668325,0.000046671066],"category_scores_gemma":[0.00012520028,0.0001592601,0.0001578475,0.00015777278,0.0002900931,0.00034732607,0.00006648767,0.00049938995,0.000028312406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01704479,0.001526472,0.7769342,0.000041302483,0.0017697401,0.0011782353,0.0024003442,0.00021835856,0.022938112,0.0008942908,0.003356811,0.17169736],"study_design_scores_gemma":[0.07059588,0.015757132,0.73414034,0.00048481545,0.00050991814,0.0030486705,0.00053059607,0.0059641576,0.030432422,0.04474306,0.09277028,0.0010227243],"about_ca_topic_score_codex":0.000018012348,"about_ca_topic_score_gemma":0.0000026271268,"teacher_disagreement_score":0.17067464,"about_ca_system_score_codex":0.00066704425,"about_ca_system_score_gemma":0.000893383,"threshold_uncertainty_score":0.6494438},"labels":[],"label_agreement":null},{"id":"W2550634544","doi":"10.1101/087809","title":"A community-based collaboration to build prediction models for short-term discontinuation of docetaxel in metastatic castration-resistant prostate cancer","year":2016,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Innovates; University of Alberta","funders":"U.S. National Library of Medicine; National Institutes of Health; National Cancer Institute; Boettcher Foundation; Turun Yliopisto; European Commission","keywords":"Docetaxel; Discontinuation; Medicine; Prostate cancer; Clinical trial; Adverse effect; Prednisone; Internal medicine; Oncology; Placebo; Cancer; Pathology","score_opus":0.04914711516172023,"score_gpt":0.321440757661702,"score_spread":0.2722936424999818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550634544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769601,0.0007069235,0.007920032,0.0018158511,0.00034255424,0.0066828947,0.0054604798,0.000104796454,0.000006363978],"genre_scores_gemma":[0.99052,0.00020428874,0.004089146,0.00007782022,0.00013364245,0.0048257615,0.000028533574,0.00009803481,0.000022798717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971946,0.00027346934,0.00087278336,0.0006159391,0.00056430546,0.00047890618],"domain_scores_gemma":[0.9968306,0.00012910094,0.00035783232,0.00086485484,0.0015692007,0.000248448],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010419104,0.00043761957,0.0007647762,0.00065135973,0.00016097008,0.00010614391,0.00022605922,0.0002376421,0.000009774638],"category_scores_gemma":[0.00016005647,0.00037041656,0.00013767135,0.0006851947,0.00011622536,0.0002845137,0.0001098592,0.0004833019,0.0000017556074],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028645592,0.00086967426,0.019102946,0.0027389266,0.00033954452,0.000018025297,0.00022914656,0.003119809,0.97024024,0.00025572078,0.00019553983,0.000025897902],"study_design_scores_gemma":[0.009857612,0.00170801,0.1473818,0.008303504,0.0009082938,2.2562473e-8,0.00007744364,0.012855201,0.8175241,0.00006396537,0.00042780765,0.00089228014],"about_ca_topic_score_codex":0.0002719414,"about_ca_topic_score_gemma":0.0002357515,"teacher_disagreement_score":0.15271616,"about_ca_system_score_codex":0.0010789692,"about_ca_system_score_gemma":0.0026263327,"threshold_uncertainty_score":0.9998748},"labels":[],"label_agreement":null},{"id":"W2553214654","doi":"10.1158/1078-0432.ccr-16-1357","title":"Neoadjuvant Enzalutamide Prior to Prostatectomy","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Princess Margaret Cancer Centre","funders":"National Cancer Institute; U.S. Department of Veterans Affairs","keywords":"Enzalutamide; Prostatectomy; Medicine; Prostate cancer; Urology; Oncology; Internal medicine; Cancer","score_opus":0.306227843421037,"score_gpt":0.5871699679220427,"score_spread":0.2809421245010057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553214654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92562115,0.0018077277,0.000070805094,0.06475573,0.0003861358,0.0024746307,0.000068198504,0.000119134405,0.0046964767],"genre_scores_gemma":[0.9334502,0.00424565,0.00042065003,0.0010529581,0.0012168115,0.0011245861,0.0000068990526,0.00007138065,0.058410842],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954885,0.00040411117,0.0006171364,0.0008522674,0.0013989902,0.0012389927],"domain_scores_gemma":[0.995729,0.0012801139,0.000046886846,0.0007729409,0.0009471005,0.0012239205],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.003388207,0.00019266066,0.0005143446,0.00034050105,0.00022002382,0.000050437175,0.00034541442,0.0001831217,0.0019329591],"category_scores_gemma":[0.0020317023,0.000101971535,0.00020120115,0.0008885065,0.00066379696,0.00010783912,0.00037937777,0.0007736254,0.0021595594],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008481487,0.0005906802,0.15076543,0.00013597621,0.00018165614,0.00042179096,0.00018358357,4.180193e-7,0.026220229,0.0001762188,0.06353972,0.7493028],"study_design_scores_gemma":[0.014823129,0.005561126,0.25048855,0.0015552038,0.000053553547,0.000022578835,0.00013238318,0.000011103158,0.05106805,0.0009846932,0.6749081,0.00039155863],"about_ca_topic_score_codex":0.00026814244,"about_ca_topic_score_gemma":0.000092256385,"teacher_disagreement_score":0.74891126,"about_ca_system_score_codex":0.00065786147,"about_ca_system_score_gemma":0.0017017674,"threshold_uncertainty_score":0.9989794},"labels":[],"label_agreement":null},{"id":"W2553944050","doi":"10.1021/acs.jcim.6b00400","title":"Cheminformatics Modeling of Adverse Drug Responses by Clinically Relevant Mutants of Human Androgen Receptor","year":2016,"lang":"en","type":"article","venue":"Journal of Chemical Information and Modeling","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Canadian Cancer Society Research Institute","keywords":"Androgen receptor; Enzalutamide; Cheminformatics; Antiandrogens; Computational biology; Prostate cancer; Mutant; In silico; Bicalutamide; DrugBank; Transcription factor; Drug repositioning; Drug; Biology; Bioinformatics; Chemistry; Medicine; Genetics; Pharmacology; Cancer; Gene","score_opus":0.044407726852495014,"score_gpt":0.3498515790777051,"score_spread":0.3054438522252101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553944050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955382,0.00021704404,0.003312057,0.00042289015,0.000027644292,0.000114958704,0.000028529925,0.000005826585,0.00033284532],"genre_scores_gemma":[0.99649596,0.001362136,0.0019733927,0.00006500478,0.000030305975,0.0000012866694,0.000013539972,0.0000057169345,0.000052673004],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979579,0.000011453271,0.0014452023,0.00004551748,0.00040251328,0.00013742699],"domain_scores_gemma":[0.99846005,0.00008714934,0.00055699603,0.000100797,0.000633456,0.00016157373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067487557,0.0000943993,0.00035659337,0.00013400316,0.000024959229,0.000005320361,0.00007895807,0.00008664182,0.000024268744],"category_scores_gemma":[0.0003647803,0.00005540453,0.00011447968,0.000070635244,0.000072013354,0.0006161306,0.00003903681,0.0001564517,0.0000015036707],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00793301,0.00021740345,0.0011566423,0.00081350695,0.0002774857,0.0000029043908,0.003986341,0.0005261733,0.9636429,0.000066656896,0.0012105709,0.020166416],"study_design_scores_gemma":[0.009175174,0.0006812918,0.0000050922554,0.0020830138,0.00014871193,0.00007550165,0.0017479182,0.21071614,0.7744898,0.0003745378,0.00032885742,0.00017397365],"about_ca_topic_score_codex":0.000003031607,"about_ca_topic_score_gemma":3.9265586e-8,"teacher_disagreement_score":0.21018997,"about_ca_system_score_codex":0.00006061552,"about_ca_system_score_gemma":0.00016489263,"threshold_uncertainty_score":0.22593312},"labels":[],"label_agreement":null},{"id":"W2554598643","doi":"10.1016/j.euf.2016.10.011","title":"Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation–Supported West Coast Prostate Cancer Dream Team","year":2016,"lang":"en","type":"article","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Cancer; Prostate; Oncology; Population; Accrual; Internal medicine","score_opus":0.035091666355802055,"score_gpt":0.29917530977398243,"score_spread":0.26408364341818036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554598643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92978495,0.022844119,0.000024099694,0.033115245,0.0010961634,0.0055988817,0.0048601897,0.0002835626,0.002392772],"genre_scores_gemma":[0.9258768,0.058615167,0.000046296176,0.0009382369,0.00037381012,0.002954106,0.00020242605,0.0002609254,0.010732242],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99357027,0.0012048315,0.0011149747,0.0015001908,0.00075614377,0.0018535783],"domain_scores_gemma":[0.997083,0.0004316107,0.0006864232,0.0007970407,0.00051319436,0.0004887002],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010783175,0.00095858006,0.0010716429,0.0004326221,0.0006222927,0.000116762094,0.000429052,0.000113747454,0.0017350807],"category_scores_gemma":[0.00014530827,0.0005249201,0.00022026512,0.00081348507,0.0008605771,0.00033749995,0.00021031492,0.0006783574,0.0002873034],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06764775,0.0025339762,0.21415713,0.00047297264,0.0060470696,0.005801777,0.028039593,0.0018201018,0.09345395,0.0008230947,0.032036226,0.54716635],"study_design_scores_gemma":[0.11210164,0.022505313,0.22477348,0.004732593,0.0044998685,0.00015332033,0.006982416,0.0019261085,0.06905471,0.0015323568,0.54678833,0.004949848],"about_ca_topic_score_codex":0.0071637444,"about_ca_topic_score_gemma":0.008677508,"teacher_disagreement_score":0.5422165,"about_ca_system_score_codex":0.00212029,"about_ca_system_score_gemma":0.0023232175,"threshold_uncertainty_score":0.9997202},"labels":[],"label_agreement":null},{"id":"W2554843886","doi":"","title":"Prostate Cancer Genetics: A Review.","year":2015,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Prostate cancer; Epigenetics; Single-nucleotide polymorphism; microRNA; Cancer; Precision medicine; Personalized medicine; Biology; SNP; Computational biology; Bioinformatics; Medicine; Genetics; Gene; Genotype","score_opus":0.09533640558302653,"score_gpt":0.3569532581874826,"score_spread":0.26161685260445605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554843886","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23750149,0.6676822,0.000003911641,0.04231838,0.0005353497,0.007043915,0.00004139011,0.00016119143,0.044712182],"genre_scores_gemma":[0.63236886,0.2517964,0.0001967914,0.0056257155,0.0006283634,0.019769767,0.00007296382,0.000056423647,0.08948473],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907786,0.000021989392,0.000118531534,0.00016362779,0.00028186283,0.00033615407],"domain_scores_gemma":[0.99923724,0.0000072053904,0.00002761239,0.0001894498,0.00016040445,0.00037809653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025437225,0.000080558464,0.00017246616,0.000040687908,0.000019222967,0.0000101103,0.000052254894,0.000025946301,0.00004730226],"category_scores_gemma":[0.000069161346,0.00005418951,0.000041257023,0.00016901783,0.000046370926,0.00003512591,0.000033109412,0.0000878916,0.00005419586],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031098828,0.00010357386,0.1125,0.0007268881,0.00011699433,0.00010251088,0.00017390748,0.000001010513,0.000020263522,0.000009961056,0.16454972,0.72138417],"study_design_scores_gemma":[0.0036906884,0.00010857317,0.24712732,0.00036058167,0.00017516606,0.000030415862,0.00003962115,0.000015903091,0.002406383,0.00014277062,0.74575317,0.00014939845],"about_ca_topic_score_codex":0.000054081967,"about_ca_topic_score_gemma":0.000008560876,"teacher_disagreement_score":0.7212348,"about_ca_system_score_codex":0.00017920554,"about_ca_system_score_gemma":0.00019184958,"threshold_uncertainty_score":0.22097841},"labels":[],"label_agreement":null},{"id":"W2554916046","doi":"10.1158/0008-5472.can-16-1204","title":"Androgen-Dependent Repression of ERRγ Reprograms Metabolism in Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute","keywords":"Prostate cancer; Cancer research; Prostate; Androgen receptor; Cancer; Biology; Androgen; Cancer cell; Endocrinology; Internal medicine; Medicine; Hormone","score_opus":0.09417733955383542,"score_gpt":0.4526365801995482,"score_spread":0.3584592406457128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554916046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.959777,0.03194292,0.000003326237,0.0049663065,0.00017180177,0.0016067947,0.000089024965,0.000038609476,0.0014042023],"genre_scores_gemma":[0.9480614,0.033246614,0.000051703,0.00003218579,0.00019177693,0.0016371611,0.000009310189,0.000046577014,0.016723257],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99632627,0.00025358013,0.00043258513,0.0007136358,0.0013529301,0.00092100946],"domain_scores_gemma":[0.9980436,0.00013991585,0.0000864569,0.0007348535,0.0006840816,0.00031107143],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015310986,0.00018158821,0.00047596192,0.0004969287,0.00009296858,0.000022598584,0.00024569832,0.00011490541,0.0012261629],"category_scores_gemma":[0.00019854709,0.000102349775,0.00010393291,0.00094953366,0.00047537478,0.00016397782,0.00023966428,0.00045619928,0.000033764834],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048887036,0.00044842658,0.20470132,0.00042089802,0.00018011032,0.00033369064,0.000948237,0.0000057951966,0.46339038,0.0001329393,0.0025857894,0.32196373],"study_design_scores_gemma":[0.011222361,0.0004941808,0.059046645,0.0029887555,0.000049969974,0.000020069801,0.0003587241,0.000015218038,0.8951276,0.0007663164,0.029660767,0.00024940656],"about_ca_topic_score_codex":0.0036598535,"about_ca_topic_score_gemma":0.0005337575,"teacher_disagreement_score":0.4317372,"about_ca_system_score_codex":0.00065113715,"about_ca_system_score_gemma":0.0010894777,"threshold_uncertainty_score":0.99968684},"labels":[],"label_agreement":null},{"id":"W2557050169","doi":"10.1016/j.euf.2016.11.002","title":"68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis","year":2016,"lang":"en","type":"review","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":255,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Positron emission tomography; Meta-analysis; Prostate; Magnetic resonance imaging; Positron Emission Tomography-Computed Tomography; Prostate-specific antigen; Radiology; Receiver operating characteristic; Nuclear medicine; Biopsy; Cancer; Pathology; Internal medicine","score_opus":0.050103882859024076,"score_gpt":0.33655366067756404,"score_spread":0.28644977781854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557050169","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026110196,0.98011756,0.00004127604,0.0016165394,0.00010427863,0.016532678,0.0010971804,0.00019230686,0.00027208906],"genre_scores_gemma":[0.00017248692,0.9919417,0.00014436236,0.00033047431,0.00012522949,0.00246864,0.00068014005,0.00024833053,0.0038886436],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9926727,0.0019984406,0.0019628613,0.0017560645,0.0005253571,0.001084568],"domain_scores_gemma":[0.9957802,0.00051674317,0.0012741409,0.001378039,0.00048130882,0.00056951167],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019301181,0.0012706002,0.011013401,0.0015365779,0.00031125365,0.00010393894,0.00051864627,0.00024015117,0.00013731213],"category_scores_gemma":[0.00009310801,0.000672399,0.0042238813,0.0022224688,0.00034629,0.000108237015,0.00024754257,0.0006195319,0.00005387234],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036339677,0.00023178548,0.000044675937,0.72255296,0.25158533,0.00054896774,0.00010879542,1.6417644e-7,0.000043496417,0.0000126379655,0.0023533914,0.02215438],"study_design_scores_gemma":[0.0017614487,0.0010070455,0.000014136952,0.03236031,0.6921651,0.000193062,0.0000033142073,0.0000021520834,0.000052173447,0.000011774464,0.27177182,0.00065768976],"about_ca_topic_score_codex":0.000012505227,"about_ca_topic_score_gemma":0.000004860675,"teacher_disagreement_score":0.69019264,"about_ca_system_score_codex":0.00011036418,"about_ca_system_score_gemma":0.00025064207,"threshold_uncertainty_score":0.9995727},"labels":[],"label_agreement":null},{"id":"W2559773245","doi":"10.18553/jmcp.2016.16233","title":"Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide","year":2016,"lang":"en","type":"article","venue":"Journal of Managed Care & Specialty Pharmacy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Genentech; Astellas Pharma; Janssen Scientific Affairs; Regeneron Pharmaceuticals; Novo Nordisk; Sanofi; GlaxoSmithKline; Pfizer; Allergan; Bristol-Myers Squibb","keywords":"Abiraterone acetate; Enzalutamide; Medicine; Prostate cancer; Hazard ratio; Internal medicine; Proportional hazards model; Oncology; Docetaxel; Cancer; Urology; Gynecology; Androgen deprivation therapy; Confidence interval","score_opus":0.030423283707478124,"score_gpt":0.34325781161561675,"score_spread":0.31283452790813865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559773245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964159,0.0009422848,0.0000031559769,0.0010143811,0.00013052924,0.0009448289,0.00006507203,0.000009052442,0.0004747803],"genre_scores_gemma":[0.9878292,0.009232875,0.000072599054,0.000046706875,0.00024596287,0.00004327221,0.000014902117,0.00003153852,0.0024829514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982659,0.00011608499,0.00063829566,0.00019626075,0.0004743518,0.0003090971],"domain_scores_gemma":[0.99853593,0.000052950883,0.00049010804,0.00014371703,0.0006024947,0.00017479435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015349197,0.0002208334,0.00052742125,0.0002993415,0.0000465538,0.000017547227,0.00009648762,0.000027659753,0.000299214],"category_scores_gemma":[0.000027261638,0.00009992637,0.000107626285,0.00034318,0.00009059803,0.00025763313,0.0000204185,0.00014159385,0.0000058409364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035510447,0.00074683054,0.7800178,0.00024996808,0.0005930245,0.0010685746,0.0025158352,0.000025581066,0.022388786,0.0000029168457,0.00041125732,0.15646899],"study_design_scores_gemma":[0.10078572,0.01000951,0.5502481,0.002001527,0.00088150235,0.00007179326,0.00092257047,0.000012245463,0.31900072,0.000016299713,0.015708588,0.00034144204],"about_ca_topic_score_codex":0.00029413815,"about_ca_topic_score_gemma":0.00075918675,"teacher_disagreement_score":0.29661193,"about_ca_system_score_codex":0.0016930929,"about_ca_system_score_gemma":0.0006012924,"threshold_uncertainty_score":0.4427379},"labels":[],"label_agreement":null},{"id":"W2559783268","doi":"10.1200/jco.2011.29.7_suppl.131","title":"Intermittent androgen-deprivation therapy in the management of castrate-resistant prostate cancer (CRPCa): Results of a multi-institutional randomized prospective clinical trial.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Androgen deprivation therapy; Randomized controlled trial; Prostate cancer; Quality of life (healthcare); Androgen suppression; Internal medicine; Testosterone (patch); Androgen; Cancer; Urology; Surgery; Hormone","score_opus":0.3080507567097401,"score_gpt":0.5188036444834452,"score_spread":0.2107528877737051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559783268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917327,0.001318192,0.00006626849,0.0016055705,0.0007122471,0.0028454415,0.000020343048,0.0000033322497,0.0016958931],"genre_scores_gemma":[0.98090905,0.016097873,0.002313155,0.0001610981,0.00021897313,0.000109475404,0.000004511628,0.000008823309,0.00017701487],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99316174,0.001393114,0.0044724066,0.00023276864,0.00053705345,0.00020290562],"domain_scores_gemma":[0.9948213,0.0015480872,0.002554975,0.00022650509,0.00072097714,0.00012814459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01294635,0.00015050583,0.0019136491,0.0001525812,0.000030745807,0.00000473656,0.00023558999,0.00021099213,0.000041701824],"category_scores_gemma":[0.00124595,0.00007023654,0.00075311644,0.0002304401,0.0009380814,0.000086074906,0.000047529807,0.0007271514,0.0000013845143],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89544016,0.00794892,0.019509949,0.00006259754,0.0017715859,0.00060357415,0.0010067722,0.0000053176195,0.000060499977,0.00037699507,0.00011218073,0.07310147],"study_design_scores_gemma":[0.71408707,0.017239744,0.26576132,0.00036282558,0.00034294513,0.000026795815,0.00047676836,0.000058043213,0.00044866034,0.0004937475,0.00064461835,0.000057493937],"about_ca_topic_score_codex":0.00015468728,"about_ca_topic_score_gemma":0.00007924035,"teacher_disagreement_score":0.24625137,"about_ca_system_score_codex":0.00016177208,"about_ca_system_score_gemma":0.0016110651,"threshold_uncertainty_score":0.44869724},"labels":[],"label_agreement":null},{"id":"W2559823317","doi":"10.1200/jco.2011.29.7_suppl.147","title":"Tolerability and efficacy of anti-androgen manipulation versus taxotere and anti-androgen manipulation in patients with hormone-naive, high-risk/metastatic prostate cancer: A phase II, open-labeled, randomized study.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Prostate cancer; Internal medicine; Androgen deprivation therapy; Randomization; Oncology; Cancer; Clinical trial; Urology; Adverse effect","score_opus":0.15198837334142098,"score_gpt":0.4516235399127012,"score_spread":0.2996351665712802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559823317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951809,0.0009071662,0.000015418567,0.00021330474,0.00017746114,0.0034369342,0.000020833737,0.000005064089,0.000042886593],"genre_scores_gemma":[0.99661547,0.0022339968,0.000971228,0.000027534374,0.00005421458,0.000038749193,0.000020289024,0.000018990007,0.00001950298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99568385,0.0011108342,0.0021827456,0.00034462195,0.00042425093,0.0002536826],"domain_scores_gemma":[0.9958363,0.0011508124,0.0019892065,0.00020407113,0.0005473941,0.00027218147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003703358,0.00021190944,0.002493783,0.00020535896,0.00008751241,0.000017967071,0.00013422866,0.00014575805,0.000042420805],"category_scores_gemma":[0.0011111264,0.00012992501,0.00012754776,0.00022680739,0.00037832203,0.00031591253,0.00014203422,0.00052684644,5.356305e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36514664,0.008215938,0.5982743,0.00003603576,0.0008715958,0.00011134716,0.0007351023,0.000013321566,0.000013971066,0.000005781269,0.000014086631,0.0265619],"study_design_scores_gemma":[0.42883518,0.02861675,0.54107535,0.00007566901,0.00091412466,0.000008056159,0.000113871734,0.00015091206,0.000045134988,0.000068532965,0.000020381627,0.00007604768],"about_ca_topic_score_codex":0.0008387874,"about_ca_topic_score_gemma":0.000178799,"teacher_disagreement_score":0.06368856,"about_ca_system_score_codex":0.00013818513,"about_ca_system_score_gemma":0.000576705,"threshold_uncertainty_score":0.52981883},"labels":[],"label_agreement":null},{"id":"W2559825321","doi":"10.1200/jco.2011.29.7_suppl.190","title":"Association of baseline risk factors with cardiovascular (CV) events during long-term degarelix therapy in men with prostate cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Prospective cohort study; Proportional hazards model; Cumulative incidence; Regimen; Incidence (geometry); Cancer; Confidence interval; Cohort","score_opus":0.0977173856996109,"score_gpt":0.4240858204945931,"score_spread":0.3263684347949822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559825321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99674916,0.0019493153,0.000021133428,0.0004030344,0.0001277592,0.00045785916,0.000010216496,0.0000051138422,0.00027638904],"genre_scores_gemma":[0.9752502,0.023701513,0.00030232494,0.000030223784,0.00019232705,0.000013727053,0.0000042538204,0.000020585305,0.00048486935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971317,0.0006080916,0.0011478525,0.00018166282,0.0006589505,0.00027172983],"domain_scores_gemma":[0.9970763,0.00045235528,0.0014475517,0.00017807333,0.00063003023,0.0002157126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031983315,0.00014134291,0.0012964413,0.00015440166,0.0000317368,0.000002865835,0.000108803586,0.0002087953,0.000089501154],"category_scores_gemma":[0.0004589912,0.000073633666,0.00033640277,0.00020487465,0.0000936106,0.00011847177,0.000021062415,0.0007950211,0.0000010708501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028749391,0.0011973314,0.94716585,0.000046063622,0.0037496914,0.00051405275,0.0006011516,0.000059157497,0.000040125546,2.2691374e-7,0.000043339565,0.017833622],"study_design_scores_gemma":[0.025456708,0.013352629,0.95858157,0.00028739986,0.00058156176,0.000030297988,0.000119672186,0.000010929115,0.0013301319,0.000011713383,0.0001604181,0.0000769963],"about_ca_topic_score_codex":0.0005820204,"about_ca_topic_score_gemma":0.00035582104,"teacher_disagreement_score":0.021752197,"about_ca_system_score_codex":0.00050229987,"about_ca_system_score_gemma":0.0013229226,"threshold_uncertainty_score":0.34540153},"labels":[],"label_agreement":null},{"id":"W2559888887","doi":"10.1200/jco.2011.29.7_suppl.108","title":"Long-term results of salvage cryotherapy for prostate cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Cryotherapy; Prostate cancer; Perioperative; Surgery; Salvage therapy; Cancer; Radiation therapy; Retrospective cohort study; Prostate; Internal medicine; Chemotherapy","score_opus":0.2856062605475759,"score_gpt":0.5464977228279001,"score_spread":0.2608914622803242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559888887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875185,0.002673864,0.00009723383,0.0050486103,0.0010138563,0.0006090357,0.000041196505,0.000006706509,0.0029910002],"genre_scores_gemma":[0.98043114,0.011398848,0.003368004,0.00069448515,0.0009780724,0.0000220671,0.000006090031,0.000022588327,0.003078701],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973251,0.00015386145,0.0018779312,0.0001495635,0.0002532544,0.00024025953],"domain_scores_gemma":[0.99640435,0.0009485645,0.00145939,0.00016408923,0.0007409266,0.0002826901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023832393,0.00010081381,0.0010957712,0.000107062915,0.00002504037,0.0000027416356,0.00014555316,0.00022839388,0.00014607029],"category_scores_gemma":[0.0009758657,0.000060606497,0.00044793595,0.00009730163,0.00028274365,0.00007134809,0.000022174045,0.00044281376,0.0000031975069],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13023704,0.003048111,0.41735026,0.0001757446,0.001092048,0.00058332516,0.00085207797,8.832305e-7,0.0011212593,0.000051527666,0.008890541,0.4365972],"study_design_scores_gemma":[0.047365192,0.04971048,0.8702793,0.00031501282,0.0003792967,0.000082591556,0.00006851975,0.00001125703,0.0067485613,0.00061598636,0.024329698,0.00009411094],"about_ca_topic_score_codex":0.000043007512,"about_ca_topic_score_gemma":0.000054201,"teacher_disagreement_score":0.45292905,"about_ca_system_score_codex":0.00011069061,"about_ca_system_score_gemma":0.0019700543,"threshold_uncertainty_score":0.34947917},"labels":[],"label_agreement":null},{"id":"W2559923310","doi":"10.1200/jco.2011.29.7_suppl.151","title":"A phase II study of sunitinib (SU) for maintenance therapy in metastatic castration-resistant prostate cancer (mCRPC) after response to docetaxel (D).","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Clinical endpoint; Internal medicine; Adverse effect; Sunitinib; Chemotherapy; Phases of clinical research; Clinical trial; Oncology; Urology; Cancer","score_opus":0.31119724182316544,"score_gpt":0.5511332515752233,"score_spread":0.23993600975205787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559923310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99322605,0.00066755863,0.000021245281,0.0036860562,0.00029436836,0.0019350718,0.000048816168,0.0000036342958,0.00011720229],"genre_scores_gemma":[0.99503636,0.000761792,0.0021965278,0.00064970745,0.0001358439,0.00028803834,0.0000015595485,0.000020158124,0.0009100283],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9962541,0.0007000393,0.0021429635,0.00021833151,0.00035297452,0.00033163073],"domain_scores_gemma":[0.9962912,0.0013524194,0.00091113395,0.00019783978,0.0009187173,0.0003286476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049761077,0.00015203809,0.0012827603,0.0002937353,0.000039478808,0.000006278937,0.00014679795,0.000100006015,0.00018591387],"category_scores_gemma":[0.001487183,0.00009329238,0.00025023962,0.00026569588,0.00015458438,0.00010497139,0.000029536362,0.00046278816,0.0000017941614],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8230099,0.036425464,0.021505862,0.000065184526,0.0008715955,0.0025376987,0.0114174085,0.000006613205,0.005036361,0.000017353439,0.00076377543,0.0983428],"study_design_scores_gemma":[0.17076099,0.49879363,0.30403128,0.0003819738,0.0004219468,0.000070310336,0.004711484,0.00002997256,0.0018000118,0.00038756648,0.018431887,0.00017894148],"about_ca_topic_score_codex":0.00020237411,"about_ca_topic_score_gemma":0.0007752735,"teacher_disagreement_score":0.6522489,"about_ca_system_score_codex":0.0001909276,"about_ca_system_score_gemma":0.002872334,"threshold_uncertainty_score":0.5095397},"labels":[],"label_agreement":null},{"id":"W2560003588","doi":"10.1200/jco.2012.30.5_suppl.140","title":"Patterns of referral for adjuvant radiotherapy after radical prostatectomy in men with prostate cancer: A population-based analysis.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Radiation therapy; Perineural invasion; Cancer; Internal medicine; Stage (stratigraphy); Randomized controlled trial; Urology; Gynecology; Surgery","score_opus":0.08933078052148417,"score_gpt":0.4870944906100888,"score_spread":0.3977637100886046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560003588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99221075,0.0023433052,0.00037540018,0.0039945687,0.0001426919,0.0008405155,0.000037553036,0.0000044895614,0.00005070049],"genre_scores_gemma":[0.99449444,0.00091073493,0.0033314382,0.0004759956,0.0004267006,0.00012198454,0.000026094105,0.000020242393,0.00019236335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971457,0.00029606276,0.0016154211,0.00016385595,0.00040189418,0.0003770363],"domain_scores_gemma":[0.99739605,0.0007797001,0.0009792611,0.00015126559,0.00033121576,0.0003624932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022774804,0.00013922961,0.0016660829,0.00037505003,0.00001817968,0.000004884681,0.000087641936,0.00020191736,0.00014473153],"category_scores_gemma":[0.00023466385,0.00007843326,0.00042830277,0.00033958192,0.00010485944,0.000121271485,0.000010859086,0.0004982092,3.6877614e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060973566,0.0016113179,0.9128114,0.00011316286,0.0013307515,0.00009616598,0.00022823748,0.00013126555,0.00004435506,0.0000074052164,0.00011648195,0.022535883],"study_design_scores_gemma":[0.025370233,0.008778333,0.96009105,0.00018888556,0.0009421839,0.000015990712,0.000061424165,0.0006961742,0.00016726303,0.000024167864,0.0035791309,0.00008515633],"about_ca_topic_score_codex":0.00023621242,"about_ca_topic_score_gemma":0.00026652613,"teacher_disagreement_score":0.04727965,"about_ca_system_score_codex":0.0003978264,"about_ca_system_score_gemma":0.0014688584,"threshold_uncertainty_score":0.31984153},"labels":[],"label_agreement":null},{"id":"W2560029553","doi":"10.1200/jco.2011.29.7_suppl.118","title":"Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Internal medicine; Proportional hazards model; Mitoxantrone; Chemotherapy; Oncology; Cancer; Post-hoc analysis","score_opus":0.14391705938219349,"score_gpt":0.45291083745730354,"score_spread":0.3089937780751101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560029553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990617,0.0007436326,0.000007870684,0.0074953893,0.000103908635,0.0003195942,0.00000738417,0.00000477813,0.0007004766],"genre_scores_gemma":[0.9928082,0.0044328794,0.0014930011,0.00018402869,0.00018250407,0.0000115984685,0.000002128042,0.0000152425855,0.00087039097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972408,0.0008785302,0.0010989094,0.00015983367,0.0003833917,0.00023857078],"domain_scores_gemma":[0.9964327,0.001967926,0.0009718598,0.000086296415,0.00031301435,0.00022815455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006440747,0.00011046561,0.00092844135,0.00021684833,0.000034068573,0.000011308577,0.000061803854,0.00014218927,0.00007379252],"category_scores_gemma":[0.00088338205,0.00006879068,0.00011595368,0.00021401145,0.00011880809,0.00014356937,0.000012921434,0.0006242177,7.8178533e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049931444,0.00039840935,0.93068874,0.000028628157,0.0010782891,0.00043615545,0.00092793023,0.0000014507066,0.000423008,0.000006240383,0.00028166868,0.015798038],"study_design_scores_gemma":[0.016258214,0.008816363,0.97232556,0.00015323216,0.00036034547,0.000023819468,0.00020531176,0.00001331706,0.00015435906,0.00024373013,0.0013760217,0.00006974308],"about_ca_topic_score_codex":0.00027621302,"about_ca_topic_score_gemma":0.0004136953,"teacher_disagreement_score":0.041636806,"about_ca_system_score_codex":0.00036542836,"about_ca_system_score_gemma":0.0015271328,"threshold_uncertainty_score":0.28052026},"labels":[],"label_agreement":null},{"id":"W2560077513","doi":"10.1200/jco.2011.29.7_suppl.78","title":"Long-term outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2C-T3B).","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Cancer Care Ontario; Western University","funders":"","keywords":"Medicine; Prostate cancer; Cryoablation; Prostate; Radiation therapy; Hormonal therapy; External beam radiotherapy; Randomized controlled trial; Urology; Surgery; Cancer; Internal medicine; Ablation","score_opus":0.23414840016786878,"score_gpt":0.534109479044825,"score_spread":0.2999610788769562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560077513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910075,0.0036092312,0.0010745979,0.0009854331,0.00082751823,0.00233331,0.000012951259,0.0000057639513,0.0001436806],"genre_scores_gemma":[0.98416597,0.010616243,0.0031167632,0.0002532265,0.0011894322,0.000093062685,0.0000056341914,0.000020443162,0.00053922855],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961226,0.0003646871,0.0027544932,0.00018453381,0.00033397155,0.00023969005],"domain_scores_gemma":[0.9940998,0.0026908966,0.0020830845,0.0001233931,0.00071564683,0.00028716945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004781854,0.00014689745,0.002519742,0.00013348939,0.000036811787,0.000006589202,0.00011672325,0.0002646461,0.0001116078],"category_scores_gemma":[0.0016016713,0.000084515406,0.00065302127,0.000072148374,0.00044120898,0.000136346,0.000028932971,0.00047357669,8.898584e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5707039,0.0005445968,0.28581554,0.000046363486,0.00056563906,0.000032410906,0.00015524693,9.380714e-7,0.00017697233,0.000008527058,0.00002617631,0.14192365],"study_design_scores_gemma":[0.70430326,0.01964446,0.27329156,0.00015024211,0.0004784025,0.000013436144,0.000016475926,0.000013166067,0.001140053,0.00060521404,0.00027709405,0.000066639754],"about_ca_topic_score_codex":0.000025093597,"about_ca_topic_score_gemma":0.000007695472,"teacher_disagreement_score":0.141857,"about_ca_system_score_codex":0.00009177226,"about_ca_system_score_gemma":0.0010344572,"threshold_uncertainty_score":0.34464383},"labels":[],"label_agreement":null},{"id":"W2560154122","doi":"10.1200/jco.2011.29.7_suppl.104","title":"A review of radical prostatectomy outcomes in active surveillance patients—The Sunnybrook experience.","year":2011,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Guideline; Cancer; Biochemical recurrence; Internal medicine; Biopsy; Radiation therapy; Salvage therapy; Retrospective cohort study; Surgery; Urology; Gynecology; Oncology; Pathology; Chemotherapy","score_opus":0.27411762407888474,"score_gpt":0.568808687517933,"score_spread":0.2946910634390483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560154122","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007438185,0.9942217,9.939702e-7,0.00061463757,0.00075574656,0.0018509388,0.00002475859,0.0000036477454,0.0017837936],"genre_scores_gemma":[0.00015801427,0.9984485,0.00012970029,0.0006436314,0.00025249057,0.00009544268,0.000015314201,0.000024316567,0.0002325968],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9917097,0.0019392008,0.005143547,0.00029247548,0.00054904807,0.00036599935],"domain_scores_gemma":[0.9897226,0.0042757457,0.004533008,0.00039663425,0.0007397006,0.00033229767],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0044722334,0.00032058495,0.008055777,0.000226116,0.000026364598,0.0000038748753,0.00049566734,0.0005806608,0.00024586514],"category_scores_gemma":[0.00818603,0.00014132795,0.0018421107,0.00041767888,0.0008196412,0.00007920709,0.00010376336,0.002423913,0.000014001332],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011775433,0.0019749184,0.016006608,0.021682194,0.0006582937,0.00022381406,0.00010058712,4.37625e-9,1.4282472e-8,0.000013628505,0.0017907933,0.9563716],"study_design_scores_gemma":[0.004486372,0.005659358,0.019263048,0.057199974,0.00062199996,0.00009829185,0.000021661126,9.875544e-8,4.8336074e-7,0.000030957202,0.91250324,0.00011454069],"about_ca_topic_score_codex":0.00002041967,"about_ca_topic_score_gemma":0.000011215514,"teacher_disagreement_score":0.95625705,"about_ca_system_score_codex":0.0004507147,"about_ca_system_score_gemma":0.0057057734,"threshold_uncertainty_score":0.999931},"labels":[],"label_agreement":null},{"id":"W2560318971","doi":"10.1158/0008-5472.can-16-1589","title":"RB Loss Promotes Prostate Cancer Metastasis","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; Prostate Cancer Foundation; National Institutes of Health; American Cancer Society","keywords":"Prostate cancer; Metastasis; Cancer; Medicine; Prostate; Oncology; Cancer research; Cancer metastasis; Internal medicine","score_opus":0.12574478194958472,"score_gpt":0.46633990297391104,"score_spread":0.3405951210243263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560318971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92104506,0.018381784,0.000014654425,0.055289056,0.00025663275,0.0020626609,0.00033662355,0.00012703329,0.0024864783],"genre_scores_gemma":[0.8974911,0.030793995,0.000103140635,0.00014338677,0.0006310695,0.00272461,0.000016537542,0.000083390325,0.06801275],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960038,0.00023391731,0.00027965888,0.0007015155,0.0014335082,0.0013475852],"domain_scores_gemma":[0.99752045,0.00024569666,0.000049186314,0.0006060814,0.00103181,0.0005467712],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011616633,0.00023856705,0.0004030559,0.00041343502,0.00029430265,0.00006676035,0.0002883155,0.00011305922,0.0039386563],"category_scores_gemma":[0.00021971032,0.0001283808,0.00013392477,0.0009732154,0.0008310239,0.0002237533,0.00021834775,0.0004824233,0.00041340932],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032330912,0.0004311684,0.110140026,0.00069664716,0.00081184146,0.0006359317,0.0009364437,0.0000010462763,0.35112712,0.0004066812,0.03934747,0.49223253],"study_design_scores_gemma":[0.008258779,0.0010714466,0.0137323635,0.0020798522,0.00012333572,0.0000405312,0.00024369941,0.000008659863,0.73118025,0.0011504197,0.24169233,0.00041829614],"about_ca_topic_score_codex":0.0009819178,"about_ca_topic_score_gemma":0.00015702173,"teacher_disagreement_score":0.49181423,"about_ca_system_score_codex":0.0010970556,"about_ca_system_score_gemma":0.0016914714,"threshold_uncertainty_score":0.9969719},"labels":[],"label_agreement":null},{"id":"W2560425847","doi":"10.1200/jco.2011.29.7_suppl.175","title":"ECF chemotherapy for liver metastases due to castration-resistant prostate cancer (mCRPC).","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Internal medicine; Gastroenterology; Epirubicin; Chemotherapy; Cancer; Urology; Anemia; Oncology; Breast cancer","score_opus":0.2742572706579442,"score_gpt":0.5203774591856515,"score_spread":0.24612018852770728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560425847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770065,0.0026475166,0.00032169235,0.015616969,0.0010598196,0.0012410376,0.00006972833,0.000012792604,0.0020239383],"genre_scores_gemma":[0.95807254,0.004251741,0.026842358,0.005192083,0.0016602258,0.000110600864,0.000008541025,0.00003984462,0.0038220745],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978619,0.0001507622,0.0012448754,0.00018215844,0.00027546065,0.00028482074],"domain_scores_gemma":[0.99729294,0.0006915251,0.00061650184,0.00013907971,0.0007783455,0.00048162902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018061752,0.00012555679,0.0009927455,0.000118936114,0.000051005525,0.000009022375,0.00012323831,0.00015978106,0.000631517],"category_scores_gemma":[0.0007398914,0.0000770574,0.00037890492,0.00012333257,0.00013644333,0.000097998345,0.000021167265,0.00036169746,0.000015926438],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.121925965,0.005098181,0.022602217,0.00020757526,0.002619846,0.0037117626,0.0021816937,0.000008617491,0.0046622837,0.00041330367,0.060200427,0.77636814],"study_design_scores_gemma":[0.037792787,0.07141106,0.34475747,0.0003163229,0.0011720138,0.0004360609,0.0005432981,0.000059819387,0.017709328,0.0013500162,0.52415323,0.00029862358],"about_ca_topic_score_codex":0.00011737686,"about_ca_topic_score_gemma":0.00019974522,"teacher_disagreement_score":0.7760695,"about_ca_system_score_codex":0.0001834247,"about_ca_system_score_gemma":0.002351273,"threshold_uncertainty_score":0.6914668},"labels":[],"label_agreement":null},{"id":"W2560712876","doi":"10.1200/jco.2011.29.7_suppl.93","title":"Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; External beam radiotherapy; Prostate; Urology; Androgen deprivation therapy; Radiation therapy; Cancer; Stage (stratigraphy); Surgery; Internal medicine; Nuclear medicine","score_opus":0.12285335101792888,"score_gpt":0.47119865293363894,"score_spread":0.34834530191571006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560712876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931027,0.0030355037,0.00017226538,0.0012350671,0.000798729,0.0002920824,0.00000780584,0.000015726691,0.0013400831],"genre_scores_gemma":[0.96812516,0.020827414,0.007062214,0.00085886737,0.0013753744,0.000022429233,0.0000029305647,0.00003396245,0.0016916174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99736786,0.0002685525,0.0014592075,0.00020189451,0.0003972836,0.000305227],"domain_scores_gemma":[0.99627584,0.00084382965,0.0017070523,0.0001461814,0.00058266765,0.000444401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016595896,0.00015844846,0.00106077,0.00015891063,0.000064161184,0.000009764818,0.00013328872,0.00022265733,0.00071637874],"category_scores_gemma":[0.0006520329,0.000087058645,0.00027964066,0.00015726917,0.00033293932,0.00022970475,0.00002147009,0.0012363642,0.000010832181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029610574,0.0013143368,0.65767205,0.000017819422,0.0009859324,0.0014749906,0.00055462535,0.000008526018,0.00046363988,0.000003949615,0.00083656824,0.30705696],"study_design_scores_gemma":[0.02742063,0.033183534,0.918024,0.00035412642,0.00057119475,0.0007646285,0.00023668706,0.00013656555,0.002211094,0.00017978047,0.016773151,0.00014459662],"about_ca_topic_score_codex":0.00037987522,"about_ca_topic_score_gemma":0.00007586577,"teacher_disagreement_score":0.30691236,"about_ca_system_score_codex":0.00032422083,"about_ca_system_score_gemma":0.0021394913,"threshold_uncertainty_score":0.7843845},"labels":[],"label_agreement":null},{"id":"W2560729232","doi":"10.1200/jco.2011.29.7_suppl.42","title":"Use of genetic instability to predict biochemical recurrence in intermediate-risk prostate cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Biochemical recurrence; Internal medicine; Cancer; Hormonal therapy; Oncology; Radiation therapy; Prostate; Cohort; Urology; Prostatectomy","score_opus":0.23790406165585926,"score_gpt":0.49077265823531163,"score_spread":0.2528685965794524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560729232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99687856,0.0008622944,0.000021392018,0.00092868035,0.00065972266,0.00044531925,0.0000300113,0.000004259567,0.00016973905],"genre_scores_gemma":[0.98846155,0.0072068833,0.0038182368,0.00020435231,0.00022032489,0.000018454908,0.0000015910496,0.000010107857,0.000058474692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99642855,0.00041518116,0.0023434,0.00021982582,0.00031955302,0.00027348264],"domain_scores_gemma":[0.99661285,0.0011529181,0.0010036939,0.0002135618,0.00052906456,0.00048789338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021237298,0.000115524854,0.001073655,0.00018127041,0.000012154785,0.0000033107194,0.00017968562,0.00024438364,0.00013617011],"category_scores_gemma":[0.007800721,0.00007523874,0.00023383409,0.00027105107,0.0004295658,0.00009348938,0.00010361659,0.00098871,0.0000054383345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0130989915,0.0016153839,0.82247066,0.000054541204,0.000112107286,0.00023924865,0.00059160223,0.000003941439,0.00030125765,0.0000019290555,0.001038353,0.160472],"study_design_scores_gemma":[0.004560981,0.014561566,0.97404337,0.00031852053,0.00012613417,0.000027940707,0.00007176793,0.000047459464,0.002478873,0.00020522659,0.0034931956,0.00006497719],"about_ca_topic_score_codex":0.00031233556,"about_ca_topic_score_gemma":0.00016291732,"teacher_disagreement_score":0.16040702,"about_ca_system_score_codex":0.00024663302,"about_ca_system_score_gemma":0.0023180675,"threshold_uncertainty_score":0.93387556},"labels":[],"label_agreement":null},{"id":"W2560778965","doi":"10.1200/jco.2011.29.7_suppl.2","title":"Effect of dutasteride on prostate cancer progression and cancer diagnosis on rebiopsy in the REDEEM active surveillance study.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada); University Health Network","funders":"","keywords":"Dutasteride; Medicine; Prostate cancer; Urology; Placebo; Clinical endpoint; Prostatectomy; Prostate; Internal medicine; Biopsy; Cancer; Oncology; Clinical trial; Pathology","score_opus":0.15748958612359235,"score_gpt":0.5466624502100026,"score_spread":0.3891728640864103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560778965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926481,0.0012344813,1.0733743e-7,0.0037669386,0.0004103863,0.0010706044,0.000014098619,0.000002779778,0.00085250736],"genre_scores_gemma":[0.99096394,0.008137292,0.000026058546,0.00030691098,0.00024947108,0.00023473552,8.3016073e-7,0.0000113265205,0.00006944785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996691,0.001522001,0.00095833634,0.00020181348,0.00041671772,0.00021016976],"domain_scores_gemma":[0.9955089,0.0031234403,0.0008791415,0.00016302573,0.00018797565,0.00013750451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043061343,0.00013661796,0.0010309488,0.00011601858,0.000033960598,0.0000047023896,0.00013013871,0.00014336893,0.000073982184],"category_scores_gemma":[0.0011338823,0.000060515842,0.00013937306,0.00017022403,0.0002374243,0.000052371528,0.000039456212,0.00082612736,0.0000011761834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04971653,0.001977115,0.5959903,0.000046818066,0.00017373331,0.0005083048,0.0012098722,0.0000011743057,0.000031170555,0.0000018563449,0.0003448691,0.34999827],"study_design_scores_gemma":[0.011943478,0.10259354,0.88051,0.0005668964,0.000121511875,0.000022782135,0.00030037187,0.0000056998865,0.0025737144,0.00001964492,0.0012889411,0.000053443084],"about_ca_topic_score_codex":0.00019619349,"about_ca_topic_score_gemma":0.0002540734,"teacher_disagreement_score":0.34994483,"about_ca_system_score_codex":0.0001625167,"about_ca_system_score_gemma":0.00047905528,"threshold_uncertainty_score":0.35891584},"labels":[],"label_agreement":null},{"id":"W2561061456","doi":"10.1158/1538-7445.am2015-3592","title":"Abstract 3592: Androgens interfere with enzalutamide agonism of mutant F876L androgen receptor","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Enzalutamide; Androgen receptor; LNCaP; Androgen; Cancer research; Agonist; Cell culture; Prostate cancer; Internal medicine; Endocrinology; Mutant; Receptor; Ectopic expression; Biology; Chemistry; Medicine; Hormone; Genetics; Cancer; Gene","score_opus":0.14135436479740707,"score_gpt":0.4207292355133669,"score_spread":0.2793748707159598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561061456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841465,0.005959331,0.0000064383553,0.0020304585,0.00010945435,0.0009596357,0.00013013842,0.00004395733,0.006614091],"genre_scores_gemma":[0.9946913,0.0016858568,0.00013152705,0.000038967042,0.00024161168,0.00024452963,0.000055443063,0.000056569224,0.0028541845],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969688,0.00011033654,0.00030022772,0.00045566785,0.0013816905,0.00078327034],"domain_scores_gemma":[0.9973913,0.000114302326,0.00006948397,0.00052566314,0.001228176,0.0006710617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010241164,0.00020057471,0.00043674756,0.00034349828,0.000107971195,0.00004103485,0.00025355807,0.00013074538,0.00083611143],"category_scores_gemma":[0.00013256536,0.0001326805,0.00008433624,0.0007070381,0.0006075411,0.0001279235,0.0001397191,0.00065693614,0.00012366823],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021665284,0.0011095026,0.083716996,0.0012824105,0.0014020886,0.0011917806,0.0054805214,0.000036094058,0.81787837,0.0003177296,0.02387975,0.042039473],"study_design_scores_gemma":[0.0075172056,0.0021883699,0.0040339143,0.0009611147,0.00006469371,0.00007940969,0.0024608185,0.000021547214,0.95170933,0.0001962896,0.030514993,0.0002523048],"about_ca_topic_score_codex":0.0008730983,"about_ca_topic_score_gemma":0.00014755821,"teacher_disagreement_score":0.13383096,"about_ca_system_score_codex":0.0007522141,"about_ca_system_score_gemma":0.002306373,"threshold_uncertainty_score":0.91548336},"labels":[],"label_agreement":null},{"id":"W2561387856","doi":"10.1158/1538-7445.am2015-3652","title":"Abstract 3652: Development of novel chemical inhibitors targeting the N-terminal domain (NTD) of androgen receptor variants as anti-prostate cancer agents","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Enzalutamide; Bicalutamide; Prostate cancer; Androgen receptor; Cancer research; Antiandrogens; Medicine; Cancer; Androgen; Androgen deprivation therapy; Internal medicine; Hormone","score_opus":0.12083436678818402,"score_gpt":0.4247683232650827,"score_spread":0.3039339564768987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561387856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99280316,0.0033223215,0.000004450778,0.0013491076,0.00024230922,0.0010827258,0.00011972766,0.00001712823,0.0010590963],"genre_scores_gemma":[0.9966857,0.0008006529,0.0007507908,0.000035727466,0.0003230381,0.0003513999,0.00006051949,0.000048124923,0.00094408786],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962038,0.00010365204,0.0006196348,0.0004606894,0.0017881031,0.0008241223],"domain_scores_gemma":[0.9977974,0.000121376026,0.00018179351,0.0003669829,0.0010893851,0.00044301356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022138066,0.00022192126,0.00046609205,0.00023351847,0.0001817152,0.000030061468,0.0003726575,0.00014042607,0.0005072954],"category_scores_gemma":[0.00024270418,0.00014450127,0.000098322766,0.00074870355,0.000604755,0.000114608374,0.00030492613,0.00061818206,0.0000313234],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003099136,0.0006902022,0.029219436,0.0008103964,0.0005043699,0.00013249564,0.011959896,0.000027948807,0.91995454,0.000024204224,0.016561167,0.017016217],"study_design_scores_gemma":[0.006033744,0.0002357666,0.0071127554,0.001067357,0.000036460795,0.000018343211,0.0028421255,0.000037574115,0.9680738,0.000051315117,0.014282284,0.00020848244],"about_ca_topic_score_codex":0.001006536,"about_ca_topic_score_gemma":0.00001970762,"teacher_disagreement_score":0.04811926,"about_ca_system_score_codex":0.00080099225,"about_ca_system_score_gemma":0.0048189424,"threshold_uncertainty_score":0.85485965},"labels":[],"label_agreement":null},{"id":"W2561948781","doi":"10.1158/1538-7445.am2015-732","title":"Abstract 732: Using functional and chemical genomics to identify mechanisms of Enzalutamide resistance in prostate cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Cancer research; Pharmacology; In vivo; Kinome; Cancer; Cancer cell; Signal transduction; Medicine; Biology; Internal medicine; Cell biology; Genetics","score_opus":0.1873124095930199,"score_gpt":0.46109082513293187,"score_spread":0.273778415539912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561948781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897291,0.0068432526,0.00003841586,0.001732846,0.00012687323,0.00094812206,0.000086310196,0.00001371743,0.00048136432],"genre_scores_gemma":[0.99615324,0.0009175451,0.0008265587,0.000076097764,0.00015665135,0.00030814824,0.000015688696,0.000037435293,0.0015086355],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975484,0.00006597364,0.000317505,0.00045779068,0.0009924817,0.00061785866],"domain_scores_gemma":[0.9984566,0.00008949621,0.00005099516,0.00025572837,0.0006823805,0.0004648093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011867777,0.00014655221,0.00032418725,0.00040599797,0.00006743191,0.000037550843,0.00012802337,0.000090338996,0.000156671],"category_scores_gemma":[0.00016665773,0.00012708039,0.000040104213,0.00071987754,0.00024520108,0.00011904076,0.00017640572,0.00047338984,0.000010353661],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046459707,0.00012000984,0.012733941,0.00042268672,0.000073646916,0.000114407696,0.0012075553,0.00012133631,0.97627884,0.00028266074,0.0021133323,0.0018856252],"study_design_scores_gemma":[0.007562294,0.00029255054,0.08262184,0.0015507026,0.000046939233,0.000017876982,0.0015383059,0.00016637177,0.894197,0.007552756,0.0040942444,0.00035912366],"about_ca_topic_score_codex":0.001985717,"about_ca_topic_score_gemma":0.0007735681,"teacher_disagreement_score":0.08208183,"about_ca_system_score_codex":0.0017346469,"about_ca_system_score_gemma":0.002035278,"threshold_uncertainty_score":0.5182188},"labels":[],"label_agreement":null},{"id":"W2562309431","doi":"10.1158/1538-7445.am2015-2966","title":"Abstract 2966: The mutational landscape of localized gleason 6 and 7 prostate cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Prostate cancer; Chromothripsis; Chromoplexy; Biology; Prostate; Malignancy; Cancer; Disease; Copy-number variation; Epigenetics; Genome; Genetics; Cancer research; Gene; Medicine; Pathology; Genome instability; PCA3; DNA damage","score_opus":0.1208963960530381,"score_gpt":0.45020692789471284,"score_spread":0.32931053184167475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562309431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9512298,0.034151748,0.0000022229194,0.009619554,0.000094633775,0.0009315822,0.00008813435,0.00001806931,0.0038642352],"genre_scores_gemma":[0.98977274,0.0045618326,0.00003235524,0.00008264553,0.0002172333,0.00049354415,0.000032500237,0.000023152672,0.004783991],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979263,0.00009990409,0.00019086248,0.0002648418,0.0010822858,0.00043579165],"domain_scores_gemma":[0.99834466,0.00018788558,0.000047502916,0.00023315138,0.0008936321,0.0002931692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010448499,0.00011082582,0.00022275979,0.00014799181,0.0001288487,0.000039140086,0.00013130241,0.000064743705,0.00059387676],"category_scores_gemma":[0.0001506323,0.00006339464,0.00004204709,0.00047715582,0.00056294544,0.00008464918,0.00009179057,0.00041700993,0.000019531311],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020306349,0.0007361146,0.5306929,0.002092901,0.0010997236,0.0004379595,0.013610254,0.000343785,0.03909148,0.001239565,0.22207358,0.16827543],"study_design_scores_gemma":[0.040056795,0.0026684552,0.5490034,0.0024890767,0.00027055098,0.00011989777,0.012685335,0.0018468391,0.1280308,0.0046504685,0.25742483,0.0007534919],"about_ca_topic_score_codex":0.0022727395,"about_ca_topic_score_gemma":0.00019606538,"teacher_disagreement_score":0.16752194,"about_ca_system_score_codex":0.00022296706,"about_ca_system_score_gemma":0.0017179411,"threshold_uncertainty_score":0.6502534},"labels":[],"label_agreement":null},{"id":"W2562564284","doi":"10.1158/1538-7445.am2015-727","title":"Abstract 727: Signaling redundancy between EGFR and c-Met: molecular analysis of concurrent inhibition of c-Src and therapeutic potential against prostate cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Gefitinib; DU145; Crizotinib; Cancer research; Epidermal growth factor receptor; EGFR inhibitors; Proto-oncogene tyrosine-protein kinase Src; Lapatinib; Tyrosine kinase; Dasatinib; Growth factor receptor; C-Met; Pharmacology; Biology; Medicine; Cancer; Prostate cancer; Receptor; Lung cancer; Hepatocyte growth factor; Internal medicine; Breast cancer; Trastuzumab","score_opus":0.104109410838805,"score_gpt":0.43034218822915715,"score_spread":0.32623277739035217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562564284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96521854,0.032863278,0.000024060126,0.0006670026,0.000043186898,0.0007486669,0.0002460025,0.000011790299,0.00017744854],"genre_scores_gemma":[0.9937886,0.0056988895,0.000031653515,0.000033620126,0.00008340561,0.00013008864,0.000105843246,0.000026152486,0.000101773476],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975949,0.00015220826,0.00039154265,0.00040018035,0.0010123239,0.00044887108],"domain_scores_gemma":[0.9982449,0.00009315373,0.00013272572,0.00022529237,0.0009621077,0.00034185784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010124588,0.00016311885,0.0005670097,0.0007013461,0.000083757266,0.000033068307,0.00007894762,0.00010051549,0.00006595815],"category_scores_gemma":[0.00004662918,0.0001292679,0.00010134183,0.0011344015,0.0006085605,0.00008305861,0.00010317577,0.00038191592,9.936776e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010905095,0.00017473038,0.14440648,0.000967917,0.0030406874,0.000086817665,0.002030241,0.00039019136,0.7375869,0.00006441956,0.00015512887,0.11000599],"study_design_scores_gemma":[0.009246617,0.0015607094,0.14560859,0.0015376242,0.002218388,0.0000022003987,0.0022489284,0.0007131078,0.83535606,0.00052236643,0.00060796086,0.00037743704],"about_ca_topic_score_codex":0.0009386958,"about_ca_topic_score_gemma":0.000046805584,"teacher_disagreement_score":0.10962855,"about_ca_system_score_codex":0.00028983632,"about_ca_system_score_gemma":0.0007728388,"threshold_uncertainty_score":0.5271392},"labels":[],"label_agreement":null},{"id":"W2563172800","doi":"10.1158/1538-7445.transcagen-a1-64","title":"Abstract A1-64: Molecular and clinical characterization of 1,577 primary prostate cancer tumors reveals novel clinical and biological insights into its subtypes","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Erg; Prostate cancer; Random forest; Biology; Computational biology; Gene expression profiling; Gene expression; Gene; Cancer; Oncology; Medicine; Genetics; Computer science; Artificial intelligence","score_opus":0.2103270897464328,"score_gpt":0.4836738692890444,"score_spread":0.27334677954261155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563172800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835081,0.012202114,0.0000074352697,0.002394966,0.00016259457,0.0013502792,0.0000630121,0.000028042678,0.0002834259],"genre_scores_gemma":[0.9634564,0.034905408,0.00011277359,0.0002159093,0.0003251543,0.00020811922,0.00010681562,0.00003424167,0.0006351714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99684477,0.00034597793,0.0007901104,0.0007098498,0.0007888021,0.00052050804],"domain_scores_gemma":[0.99740094,0.0003078178,0.0001624545,0.00031380335,0.0010939355,0.00072103296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025197251,0.00020962156,0.0007059523,0.00023170875,0.00010942365,0.000046165933,0.00016289933,0.0002835845,0.00005269987],"category_scores_gemma":[0.0006692718,0.00014415747,0.000085290034,0.00044895016,0.0013169307,0.0001745478,0.00029296154,0.00084456115,0.000010242613],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003777065,0.00050481333,0.5761003,0.0005800054,0.00022427137,0.00014382567,0.0005917357,7.5396423e-7,0.3930974,0.00012813603,0.00033043136,0.024521276],"study_design_scores_gemma":[0.0054558166,0.0015355084,0.96676195,0.00066821545,0.000048826707,0.0000102372505,0.00012398642,0.000049013728,0.021797244,0.0002771222,0.0030718881,0.00020019729],"about_ca_topic_score_codex":0.00032094575,"about_ca_topic_score_gemma":0.000031462754,"teacher_disagreement_score":0.39066166,"about_ca_system_score_codex":0.00021192215,"about_ca_system_score_gemma":0.0015056403,"threshold_uncertainty_score":0.58785707},"labels":[],"label_agreement":null},{"id":"W2563241643","doi":"10.1038/ncomms13719","title":"Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence","year":2016,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Helmut Horten Stiftung; Pfizer","keywords":"PTEN; Prostate cancer; Notch signaling pathway; Prostate; Cancer research; Cancer; Senescence; Medicine; Biology; Signal transduction; PI3K/AKT/mTOR pathway; Internal medicine; Cell biology","score_opus":0.019686021854037485,"score_gpt":0.3239933997795439,"score_spread":0.3043073779255064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563241643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9142867,0.058784593,0.00028775033,0.022159027,0.00024046084,0.0016372105,0.0005949489,0.00013063445,0.0018787165],"genre_scores_gemma":[0.9840851,0.013534892,0.0007677056,0.000099869765,0.000027403708,0.0002446797,0.00019170315,0.000024150866,0.0010244922],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987846,0.000084350795,0.00027914043,0.00024618907,0.00033611816,0.00026958538],"domain_scores_gemma":[0.9980476,0.00014968011,0.00014684197,0.0011476054,0.00038901187,0.000119287804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015342033,0.00015033431,0.00023348536,0.00011340231,0.00017085223,0.000010703766,0.0002900723,0.00016894401,0.000035546982],"category_scores_gemma":[0.00009489552,0.00009675438,0.00008334584,0.00037891904,0.0002475998,0.00012631367,0.00019123276,0.00044681807,0.000013574731],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016916973,0.00029513458,0.008598624,0.00006565621,0.000043447213,0.0000049786972,0.00047819293,0.0000041612375,0.96523225,0.00023556294,0.0009917795,0.023881054],"study_design_scores_gemma":[0.0037952028,0.00018190328,0.0068210885,0.0013145877,0.0000678534,0.0000052132195,0.00015898769,0.00018622691,0.9116658,0.00006605305,0.0755089,0.00022816243],"about_ca_topic_score_codex":0.000041889034,"about_ca_topic_score_gemma":0.000089771485,"teacher_disagreement_score":0.074517116,"about_ca_system_score_codex":0.0002544169,"about_ca_system_score_gemma":0.00024191978,"threshold_uncertainty_score":0.39455292},"labels":[],"label_agreement":null},{"id":"W2564057978","doi":"10.1158/1538-7445.am2015-956","title":"Abstract 956: The evolutionary history of lethal metastatic prostate cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Prostate cancer; Metastasis; Cancer; Chromoplexy; Biology; Cancer research; Prostate; Context (archaeology); Metastasis Suppressor Gene; Malignancy; Androgen receptor; Medicine; Genetics; PCA3","score_opus":0.2362246798183436,"score_gpt":0.45672844248800526,"score_spread":0.22050376266966165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564057978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8074815,0.16053988,0.000002624149,0.011857065,0.00069628353,0.0018143574,0.00013885243,0.000045637957,0.017423794],"genre_scores_gemma":[0.94096905,0.0041462537,0.00006937345,0.00011299604,0.00033181376,0.0010749691,0.00003149658,0.000042367818,0.05322165],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968026,0.00021292685,0.00029655476,0.0003470628,0.0016615673,0.0006792508],"domain_scores_gemma":[0.9975285,0.00022042812,0.00007876866,0.0004883263,0.0013111933,0.0003727891],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015470145,0.00015644028,0.0003138178,0.0002547624,0.00010533623,0.00001407734,0.0002863308,0.00006074585,0.0013959534],"category_scores_gemma":[0.00021057624,0.000094363095,0.000103459606,0.00050767296,0.0010870344,0.00013515087,0.00013935192,0.00075209996,0.00008057241],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054426687,0.0006331846,0.027885826,0.0010868991,0.0007359553,0.00048034685,0.008076155,0.00015482982,0.042396728,0.00041413444,0.8853724,0.027320856],"study_design_scores_gemma":[0.011767699,0.0016230146,0.09357806,0.0011961916,0.00027016652,0.000090179106,0.004828874,0.00035348456,0.023856388,0.0019984248,0.8599327,0.0005048099],"about_ca_topic_score_codex":0.0060458593,"about_ca_topic_score_gemma":0.00018206624,"teacher_disagreement_score":0.15639363,"about_ca_system_score_codex":0.0037804297,"about_ca_system_score_gemma":0.008419128,"threshold_uncertainty_score":0.9995169},"labels":[],"label_agreement":null},{"id":"W2565128187","doi":"10.1158/1538-7445.am2015-2853","title":"Abstract 2853: Investigating DNAPK as a biomarker and a novel therapeutic target in aggressive prostate cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"LNCaP; DU145; Prostate cancer; Cancer research; Wnt signaling pathway; Kinase; Cancer; Androgen receptor; Medicine; Signal transduction; Biology; Internal medicine; Cell biology","score_opus":0.21754230794918522,"score_gpt":0.47188783092270986,"score_spread":0.25434552297352464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565128187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9499766,0.03664518,0.000002344574,0.008052816,0.00011794205,0.0015157107,0.00006299628,0.000039277646,0.0035870862],"genre_scores_gemma":[0.9911431,0.0034144542,0.00015088524,0.00035981304,0.00017614017,0.0013353371,0.000029088096,0.000060622468,0.003330527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968315,0.00013016594,0.00030790345,0.0006042067,0.0011235531,0.0010026966],"domain_scores_gemma":[0.9980506,0.00017818932,0.00010213901,0.00031336452,0.0006364659,0.000719272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00137412,0.00023510293,0.0003745233,0.000491885,0.00015591722,0.00010558549,0.00017342599,0.00014243438,0.00037547847],"category_scores_gemma":[0.0004227825,0.0001750222,0.000046498128,0.0010468839,0.00071592454,0.00021623232,0.00018029174,0.00087537244,0.000038918155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053175054,0.00067506975,0.44426706,0.0011872499,0.0005846501,0.0013515484,0.012905728,0.000052052997,0.4279957,0.00033566653,0.010840027,0.09448771],"study_design_scores_gemma":[0.048228968,0.0026175536,0.7047666,0.009878886,0.00014295385,0.00025218155,0.0104878815,0.0032696112,0.15815416,0.0129640475,0.04768809,0.0015491126],"about_ca_topic_score_codex":0.0077634347,"about_ca_topic_score_gemma":0.0006219811,"teacher_disagreement_score":0.26984155,"about_ca_system_score_codex":0.00097199884,"about_ca_system_score_gemma":0.0033123037,"threshold_uncertainty_score":0.99884397},"labels":[],"label_agreement":null},{"id":"W2565600943","doi":"10.1136/thoraxjnl-2016-209512","title":"Androgen deprivation therapy for prostate cancer and the risk of hospitalisation for community-acquired pneumonia","year":2016,"lang":"en","type":"article","venue":"Thorax","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Prostate cancer; Community-acquired pneumonia; Androgen deprivation therapy; Pneumonia; Cohort; Internal medicine; Proportional hazards model; Incidence (geometry); Cohort study; Population; Lung cancer; Cancer","score_opus":0.040525130374274944,"score_gpt":0.3446131287056605,"score_spread":0.30408799833138556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565600943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98932433,0.0019671172,0.00064728956,0.0053157075,0.000037111946,0.002466786,0.0001934841,0.000014632636,0.000033568584],"genre_scores_gemma":[0.9915179,0.0066362354,0.00024579585,0.00005995682,0.0000481293,0.00086384657,0.00004134466,0.000013974719,0.0005728411],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994996,0.00008493175,0.00012296911,0.00008354083,0.000089773115,0.000119170705],"domain_scores_gemma":[0.9991678,0.00036696458,0.000091214744,0.00017631034,0.00016782158,0.00002989854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005995316,0.00006817497,0.00015465352,0.000030205098,0.00016248134,0.000008503747,0.000048772992,0.000032207423,0.0000055514965],"category_scores_gemma":[0.00009865519,0.00002967518,0.000050129096,0.000056420642,0.0001885005,0.000058154754,0.000015320917,0.00003187723,3.394842e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019846965,0.00017864336,0.26418707,0.00026164376,0.000521344,3.2336706e-7,0.0066711116,0.0000016549493,0.099583544,0.0008690156,0.00050061586,0.60737807],"study_design_scores_gemma":[0.07546408,0.003964879,0.42849246,0.0004806334,0.00048621453,0.0000043634454,0.001196108,0.00078638864,0.44863564,0.03033867,0.009867853,0.00028271688],"about_ca_topic_score_codex":0.00022101951,"about_ca_topic_score_gemma":0.000028666289,"teacher_disagreement_score":0.60709536,"about_ca_system_score_codex":0.0000395885,"about_ca_system_score_gemma":0.000057025056,"threshold_uncertainty_score":0.124969155},"labels":[],"label_agreement":null},{"id":"W2565952190","doi":"10.1016/j.bbrc.2016.12.153","title":"The RNA helicase DDX39B and its paralog DDX39A regulate androgen receptor splice variant AR-V7 generation","year":2016,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Androgen receptor; splice; Gene knockdown; Prostate cancer; Cancer research; Biology; RNA splicing; RNA Helicase A; RNA interference; Spliceosome; Small hairpin RNA; Messenger RNA; Cancer; RNA; Molecular biology; Gene; Genetics; Helicase","score_opus":0.12456912900378318,"score_gpt":0.39632591958879415,"score_spread":0.27175679058501095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565952190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.899058,0.011390337,0.000015126871,0.088007785,0.00002323469,0.00076454884,0.00009172739,0.00004006287,0.0006092131],"genre_scores_gemma":[0.9562875,0.040490303,0.00031135403,0.0000729431,0.00023304495,0.0002138502,0.000087677254,0.000015689397,0.0022876335],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99822503,0.00027093288,0.00021873921,0.0003580554,0.0004647455,0.00046248562],"domain_scores_gemma":[0.9973051,0.0008880336,0.000036251327,0.0009446314,0.00040714597,0.00041883125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000632754,0.00014033265,0.00018542435,0.00006255771,0.00083757757,0.00007325005,0.00035489633,0.000115731746,0.000023714569],"category_scores_gemma":[0.0005256001,0.000068436355,0.000059190395,0.0003497908,0.001179603,0.00008809738,0.0005434775,0.0003676742,0.00007669735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024978837,0.00022016795,0.00005158017,0.000023766333,0.00005893098,0.000005149332,0.000057820154,4.486179e-9,0.9699174,0.0051995777,0.0047865664,0.01942923],"study_design_scores_gemma":[0.0024522452,0.0006803849,0.0017945752,0.00022765737,0.0000628978,0.00005330812,0.0000854562,0.0015382759,0.91558903,0.0019250626,0.07533368,0.00025742318],"about_ca_topic_score_codex":0.000032866035,"about_ca_topic_score_gemma":0.00000719908,"teacher_disagreement_score":0.087934844,"about_ca_system_score_codex":0.00009947465,"about_ca_system_score_gemma":0.00014296953,"threshold_uncertainty_score":0.6442054},"labels":[],"label_agreement":null},{"id":"W2566177347","doi":"10.1016/s1470-2045(16)30641-6","title":"Can modelling of PSA dynamics accelerate drug development for prostate cancer?","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Oncology; Cancer; Retrospective cohort study; Clinical trial; Internal medicine; Mitoxantrone; Prednisone; Gynecology; Chemotherapy","score_opus":0.12021579097227539,"score_gpt":0.37582139221186084,"score_spread":0.2556056012395854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566177347","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0083542075,0.0015135738,0.00049335376,0.9840013,0.0005953672,0.0022977681,0.00083832804,0.000050735827,0.0018553619],"genre_scores_gemma":[0.02701667,0.023583645,0.008289097,0.7115027,0.025018068,0.0077558067,0.00470432,0.00045360904,0.19167612],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99786955,0.00012638299,0.00043740412,0.0003980908,0.0003059496,0.0008626096],"domain_scores_gemma":[0.9984569,0.00035339466,0.00032840806,0.00046068837,0.00033296453,0.000067651876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058132457,0.00030585146,0.0011205192,0.00012272234,0.00013851601,0.000013113644,0.00037720526,0.00039965048,0.00006319668],"category_scores_gemma":[0.000015110717,0.0001605085,0.00012555053,0.00011343763,0.00025103395,0.000025003079,0.00010924474,0.00091175095,0.0000096694075],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022731014,0.000055932254,0.0006130937,0.0018414336,0.00089319854,0.00016579716,0.0018024123,0.00010792924,0.0001000799,0.00010240216,0.9377052,0.054339375],"study_design_scores_gemma":[0.004651324,0.0003146931,0.000035301,0.0005043679,0.00021584623,0.000017292376,0.0000534513,0.0015809345,0.0015684022,0.0010919776,0.9897497,0.00021666053],"about_ca_topic_score_codex":0.00027239585,"about_ca_topic_score_gemma":0.0004673856,"teacher_disagreement_score":0.27249864,"about_ca_system_score_codex":0.0016189154,"about_ca_system_score_gemma":0.0025728128,"threshold_uncertainty_score":0.65453464},"labels":[],"label_agreement":null},{"id":"W2567705791","doi":"10.1007/s00259-016-3594-z","title":"Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI","year":2016,"lang":"en","type":"article","venue":"European Journal of Nuclear Medicine and Molecular Imaging","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Positron emission tomography; Nuclear medicine; Prostatectomy; PET-CT; Magnetic resonance imaging; Glutamate carboxypeptidase II; Standardized uptake value; Prostate; Biochemical recurrence; Radiology; Cancer; Internal medicine","score_opus":0.013348245530445575,"score_gpt":0.2882411241791203,"score_spread":0.27489287864867473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567705791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97944343,0.0039445204,0.00015024006,0.01571829,0.000044995933,0.0005038188,0.000033381115,0.000008609688,0.00015274131],"genre_scores_gemma":[0.99398744,0.0035989138,0.0010177154,0.0012366471,0.000028519113,0.0000039463375,0.0000046290093,0.00006179137,0.000060400973],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975067,0.00037120402,0.00080493453,0.00036127077,0.0005614426,0.00039449168],"domain_scores_gemma":[0.99853003,0.00015131157,0.00037947556,0.00020949697,0.00034034444,0.00038935605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083778816,0.00028061008,0.00076067384,0.00047490714,0.000040529292,0.000014315845,0.00013898654,0.000004538335,0.00009288397],"category_scores_gemma":[0.00027265825,0.0001596253,0.000059102615,0.00038668513,0.00071982277,0.00010346262,0.000106759035,0.00044641373,0.0000020185753],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033564057,0.0008706464,0.38340563,0.0012536427,0.00049380166,0.38626045,0.014969968,0.00021774227,0.118182935,0.0000073191986,0.007945909,0.052827902],"study_design_scores_gemma":[0.20076247,0.036469292,0.12862445,0.10262151,0.0026703023,0.09288897,0.03854764,0.02764647,0.10053314,0.00007445823,0.2660056,0.003155675],"about_ca_topic_score_codex":0.00022347296,"about_ca_topic_score_gemma":0.00004868427,"teacher_disagreement_score":0.2933715,"about_ca_system_score_codex":0.00016351136,"about_ca_system_score_gemma":0.0001723289,"threshold_uncertainty_score":0.650933},"labels":[],"label_agreement":null},{"id":"W2567987817","doi":"10.1038/nature20788","title":"Genomic hallmarks of localized, non-indolent prostate cancer","year":2017,"lang":"en","type":"article","venue":"Nature","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":640,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Université Laval; Centre hospitalier de l'Université Laval; University Health Network; Toronto General Hospital; University of Toronto; Ontario Institute for Cancer Research; Simon Fraser University; Princess Margaret Cancer Centre","funders":"","keywords":"Prostate cancer; Biology; Prostate; DNA methylation; Chromoplexy; Exome; Disease; Exome sequencing; Gene; Genetics; Cancer research; Computational biology; Cancer; Medicine; Pathology; Mutation; PCA3; Gene expression","score_opus":0.015022259930718058,"score_gpt":0.35126313879595106,"score_spread":0.336240878865233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567987817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.967677,0.013066583,0.000003626634,0.006840401,0.00040468242,0.000745756,0.00007339561,0.000017681743,0.011170899],"genre_scores_gemma":[0.98641086,0.002909206,0.00013235932,0.00029050696,0.00018712993,0.00004841828,0.000026278263,0.000019155148,0.0099761095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991391,0.000010101093,0.00013019044,0.00020429149,0.0002766218,0.00023973326],"domain_scores_gemma":[0.9991116,0.000011186963,0.00011109141,0.00049499265,0.00015929114,0.00011186645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001114013,0.00011270818,0.0002548305,0.000057594112,0.00013065748,0.000023967936,0.00018069496,0.00045484517,0.00017772749],"category_scores_gemma":[0.00003868473,0.00007583019,0.000088562534,0.000039273407,0.00014183063,0.000056630495,0.000086593485,0.0010144729,0.000016817465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005634219,0.00044483843,0.7451793,0.0012058791,0.0007435299,0.00045456117,0.001425826,0.000014549562,0.08949582,0.00016029929,0.03887145,0.11636974],"study_design_scores_gemma":[0.011185909,0.0004380944,0.7823639,0.0007801024,0.00017718553,0.000020623233,0.00009634581,0.00024586322,0.11804231,0.00016220678,0.086259745,0.00022771116],"about_ca_topic_score_codex":0.0002565027,"about_ca_topic_score_gemma":0.00006449735,"teacher_disagreement_score":0.116142035,"about_ca_system_score_codex":0.00012491232,"about_ca_system_score_gemma":0.00028808016,"threshold_uncertainty_score":0.44074363},"labels":[],"label_agreement":null},{"id":"W2568045406","doi":"10.5489/cuaj.4112","title":"Contemporary agents in the management of metastatic castration-resistant prostate cancer","year":2016,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Joseph's Hospital; McMaster University; St. Joseph’s Healthcare Hamilton","funders":"McMaster University; Canadian Urological Association","keywords":"Docetaxel; Enzalutamide; Cabazitaxel; Medicine; Prostate cancer; Denosumab; Abiraterone acetate; Oncology; Internal medicine; Radium-223; Chemotherapy; Cancer; Bone metastasis; Androgen deprivation therapy; Androgen receptor; Osteoporosis","score_opus":0.12593455043932428,"score_gpt":0.3829640637864259,"score_spread":0.2570295133471016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568045406","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029023213,0.98898804,8.470168e-7,0.005814664,0.00016391928,0.0013864852,0.00037092308,0.0000045929146,0.0029803014],"genre_scores_gemma":[0.005934131,0.9912162,0.000027225786,0.00034048237,0.00011764152,0.0002016725,0.000087230925,0.00001693274,0.0020585184],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99746466,0.00051509234,0.00074716785,0.00021165152,0.00060197746,0.00045947524],"domain_scores_gemma":[0.99855244,0.00018597176,0.000629839,0.00015209483,0.00017116609,0.00030847147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012551758,0.00022509145,0.0008666474,0.00030872686,0.000120939236,0.000057214405,0.00022523041,0.00016638971,0.00038965725],"category_scores_gemma":[0.00006333803,0.00010652705,0.0003071279,0.0003929248,0.000049948318,0.00006411276,0.00001630897,0.0006064642,0.000027436214],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022660979,0.00026572382,0.013590098,0.0063324496,0.004264429,0.0054429234,0.0003795291,0.0000018914095,9.591997e-7,0.00027600207,0.043872736,0.9253467],"study_design_scores_gemma":[0.001261132,0.00020101012,0.009610913,0.0044189035,0.00058515917,0.00007173425,0.00009383956,8.6958465e-7,1.834687e-7,0.00013275212,0.9835051,0.00011842827],"about_ca_topic_score_codex":0.0008131865,"about_ca_topic_score_gemma":0.00031543823,"teacher_disagreement_score":0.93963236,"about_ca_system_score_codex":0.0021259796,"about_ca_system_score_gemma":0.0024035808,"threshold_uncertainty_score":0.5559363},"labels":[],"label_agreement":null},{"id":"W2568114870","doi":"10.1007/978-3-319-42769-0_6","title":"The Clinical Genomics of Prostate Cancer","year":2017,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Prostate cancer; Disease; Medicine; Carcinogenesis; Cancer; Prostate; Oncology; Internal medicine","score_opus":0.12142284053398869,"score_gpt":0.4343532599950198,"score_spread":0.31293041946103106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568114870","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005940008,0.013078528,8.2681254e-7,0.0035254657,0.00045407857,0.0009699083,0.000092492075,0.000017994873,0.9812667],"genre_scores_gemma":[0.0010932746,0.1097042,0.00005066362,0.00007997139,0.00039142816,0.000024477646,0.000030863954,0.000038533344,0.8885866],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988794,0.00000903064,0.00039393935,0.00023909794,0.00027276902,0.00020576989],"domain_scores_gemma":[0.99854326,0.00012253258,0.00026958156,0.00070742314,0.00023285505,0.00012435218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003331361,0.00017125117,0.00045550978,0.000034650147,0.00015274402,0.000023341534,0.00019679095,0.00021879215,0.00049038697],"category_scores_gemma":[0.00003353202,0.0000838069,0.0002506872,0.000003894702,0.00063970534,0.000017906645,0.00011484187,0.00042784354,0.000080055666],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003856729,0.000112843685,0.011485055,0.0005029468,0.003175141,0.00026867478,0.00020926369,3.8267305e-7,0.00010006972,0.036659494,0.121131405,0.822498],"study_design_scores_gemma":[0.0013323525,0.00032047633,0.0009869573,0.00026539952,0.00021241933,0.0000054998336,0.000007705027,0.0000053177664,0.0002713569,0.0030136744,0.9934779,0.00010094707],"about_ca_topic_score_codex":0.00007772505,"about_ca_topic_score_gemma":0.00014334648,"teacher_disagreement_score":0.8723465,"about_ca_system_score_codex":0.00011365469,"about_ca_system_score_gemma":0.0010711772,"threshold_uncertainty_score":0.5369393},"labels":[],"label_agreement":null},{"id":"W2569288066","doi":"10.1200/jco.2015.33.7_suppl.157","title":"Genomic analysis of circulating cell-free DNA (cfDNA) to investigate mechanisms of resistance to enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Androgen receptor; Abiraterone acetate; Oncology; Progression-free survival; Cancer; Chemotherapy; Androgen deprivation therapy","score_opus":0.1701778719691283,"score_gpt":0.45910992064103445,"score_spread":0.28893204867190614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569288066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944925,0.0004724303,0.00016146421,0.003431258,0.00028041462,0.00068101264,0.00009159827,0.000003946293,0.00038541664],"genre_scores_gemma":[0.98608583,0.00013380704,0.012654047,0.00065831776,0.00007286756,0.000026409354,0.000012315662,0.000021613872,0.00033478456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99474376,0.00055497757,0.003171855,0.00030348313,0.0008604838,0.0003654498],"domain_scores_gemma":[0.9946655,0.0008378772,0.0019527652,0.0003594983,0.001363309,0.0008210593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003819352,0.00018664899,0.0020530084,0.0008140897,0.000027390877,0.0000093325125,0.00029869625,0.00014346317,0.000041276755],"category_scores_gemma":[0.003971585,0.00014022626,0.0003807428,0.0012664539,0.00014822796,0.00010588031,0.00011742963,0.00045437156,0.0000035483333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043466683,0.0052148015,0.7650545,0.0006599202,0.005688841,0.0011965632,0.0064598923,0.016733814,0.1383905,0.0003385752,0.003630502,0.013165395],"study_design_scores_gemma":[0.025071919,0.01609741,0.92863345,0.0006715497,0.0038480873,0.000006168978,0.0013157362,0.0004860579,0.01900276,0.003236445,0.0013345795,0.00029582204],"about_ca_topic_score_codex":0.00036796456,"about_ca_topic_score_gemma":0.0029205463,"teacher_disagreement_score":0.16357894,"about_ca_system_score_codex":0.00075641094,"about_ca_system_score_gemma":0.003592124,"threshold_uncertainty_score":0.63722736},"labels":[],"label_agreement":null},{"id":"W2569457561","doi":"10.5489/cuaj.4283","title":"Prostate cancer, ESMO 2016","year":2016,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Prostate cancer; Cancer; Prostate; Oncology; Medicine; Internal medicine","score_opus":0.043062134147578125,"score_gpt":0.3468073505746345,"score_spread":0.3037452164270564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569457561","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015028173,0.9814808,0.0000013087781,0.013334037,0.00074206083,0.00072171795,0.00043563536,0.000030692274,0.0032387525],"genre_scores_gemma":[0.000024822024,0.9591826,0.000016843216,0.0007595971,0.0016060023,0.00013334266,0.00009552191,0.000044663142,0.03813661],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971139,0.00031691894,0.00061769685,0.0003577425,0.00054321607,0.0010505634],"domain_scores_gemma":[0.9970181,0.0002284346,0.0005882352,0.0001803644,0.00039945453,0.0015853923],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0007326411,0.00036448482,0.0013373435,0.0004517469,0.000330996,0.00012441466,0.00022341745,0.0007577907,0.0029859277],"category_scores_gemma":[0.00044698338,0.00019286586,0.0006248705,0.000322865,0.000062603634,0.000090573696,0.000028941191,0.0013402083,0.00081047026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000023828092,0.000023868439,0.0032671983,0.0004025399,0.00061125937,0.00039220165,0.000014946958,5.551513e-8,1.1597819e-7,0.000019573317,0.09082314,0.90442127],"study_design_scores_gemma":[0.00087204616,0.00020440253,0.00070058287,0.0038375645,0.00055644184,0.00029920938,0.0000033393583,4.4673754e-7,1.8735635e-7,0.00015395315,0.99314916,0.00022268937],"about_ca_topic_score_codex":0.0008583061,"about_ca_topic_score_gemma":0.00026627525,"teacher_disagreement_score":0.9041986,"about_ca_system_score_codex":0.0072793146,"about_ca_system_score_gemma":0.00900283,"threshold_uncertainty_score":0.9999675},"labels":[],"label_agreement":null},{"id":"W2570389707","doi":"10.1002/cncr.30503","title":"Impact of ethnicity on the outcome of men with metastatic, hormone‐sensitive prostate cancer","year":2017,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Ethnic group; Oncology; Cancer; Outcome (game theory); Hormone; Internal medicine; Prostate; Gynecology","score_opus":0.09409929565671593,"score_gpt":0.43698481380852056,"score_spread":0.3428855181518046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570389707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895674,0.0012824731,0.000005278146,0.0028562117,0.000034852575,0.0008878973,0.0003711216,0.000008962936,0.0049858117],"genre_scores_gemma":[0.99418324,0.0016886006,0.000039826202,0.00007499891,0.000048850587,0.00015426091,0.000006688243,0.00002240064,0.00378113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891174,0.000046146473,0.00020198654,0.00019833651,0.00037722327,0.00026457396],"domain_scores_gemma":[0.99858856,0.00008948825,0.00029477707,0.00055923767,0.00036693754,0.00010097852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020682097,0.00016258587,0.00044583058,0.00005176915,0.00013293316,0.000013977462,0.00014544655,0.000032495413,0.0001719974],"category_scores_gemma":[0.00007093082,0.0000711814,0.00013088892,0.00009003277,0.0004954795,0.00007437764,0.00004825377,0.00020191316,0.0000038353314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014490234,0.0004135296,0.906541,0.00028285856,0.003660015,0.00012965799,0.004255386,0.00018803608,0.046542563,0.00018918904,0.006137291,0.017170258],"study_design_scores_gemma":[0.0033731814,0.001370293,0.92455244,0.0002675646,0.0002883976,0.0000033759832,0.0002552674,0.00009762073,0.06951994,0.00004650729,0.000121411606,0.00010398695],"about_ca_topic_score_codex":0.0072462033,"about_ca_topic_score_gemma":0.00024039047,"teacher_disagreement_score":0.022977376,"about_ca_system_score_codex":0.00027697108,"about_ca_system_score_gemma":0.00046549583,"threshold_uncertainty_score":0.9993646},"labels":[],"label_agreement":null},{"id":"W2570660231","doi":"10.1038/ncomms13671","title":"Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories","year":2017,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":232,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"National Health and Medical Research Council; National Breast Cancer Foundation; Prostate Cancer Canada; Government of Ontario; Prostate Cancer Foundation; Ontario Institute for Cancer Research; Medical Research Council; Movember Foundation; Canadian Institutes of Health Research; Prostate Cancer Foundation of Australia; Genome Canada","keywords":"Prostate cancer; Germline; Biology; BRCA2 Protein; Germline mutation; Genome instability; Cancer research; Genetics; Cancer; Mutation; Gene; DNA damage; DNA","score_opus":0.028230431980253063,"score_gpt":0.36514933875753064,"score_spread":0.3369189067772776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570660231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6802507,0.045215838,0.00015568837,0.15362714,0.0006469977,0.0046145744,0.0013810274,0.00056047924,0.113547534],"genre_scores_gemma":[0.9882513,0.0012742878,0.00484626,0.000113936614,0.000092841205,0.00029504974,0.00096382346,0.00002528103,0.004137197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990507,0.000047815687,0.00015719107,0.00022056089,0.0002814975,0.00024226573],"domain_scores_gemma":[0.9968095,0.00013299033,0.00013722674,0.002291872,0.00048601878,0.00014242913],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.000094367664,0.00014810768,0.00019467613,0.000087872584,0.0016934478,0.00007709016,0.00062058825,0.00013511463,0.000042818643],"category_scores_gemma":[0.00020509081,0.00010585853,0.00006405164,0.00016818602,0.0009338853,0.00022250215,0.00019042272,0.00085891795,0.000018229706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010060393,0.0006734067,0.96507466,0.00011336042,0.00077305984,0.0000840945,0.0028917035,0.000023994618,0.00094314886,0.009088482,0.011993928,0.007334103],"study_design_scores_gemma":[0.0022273876,0.00024780506,0.93618464,0.00017118738,0.00018704643,0.000050961688,0.0003000842,0.00037358966,0.00035541467,0.00031360603,0.059410386,0.00017791397],"about_ca_topic_score_codex":0.00033908075,"about_ca_topic_score_gemma":0.0026935446,"teacher_disagreement_score":0.3080006,"about_ca_system_score_codex":0.00039850257,"about_ca_system_score_gemma":0.0008149938,"threshold_uncertainty_score":0.9996062},"labels":[],"label_agreement":null},{"id":"W2573527772","doi":"10.3389/fendo.2017.00002","title":"Non-Genomic Actions of the Androgen Receptor in Prostate Cancer","year":2017,"lang":"en","type":"review","venue":"Frontiers in Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Prostate cancer; Antiandrogens; Androgen receptor; Signal transduction; Cancer research; Enzalutamide; Androgen; Androgen deprivation therapy; Biology; Cancer; Medicine; Cell biology; Internal medicine; Endocrinology; Hormone","score_opus":0.09117992957280395,"score_gpt":0.406325997364343,"score_spread":0.31514606779153903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2573527772","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011236919,0.99285126,7.789902e-7,0.00038806896,0.0020193364,0.0021202555,0.00015655743,0.000008758436,0.001331316],"genre_scores_gemma":[0.00024474916,0.992286,0.00012538179,0.000013617324,0.000101504054,0.00087438617,0.00006201744,0.000039879433,0.00625243],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983346,0.000113848655,0.00048343927,0.00038231543,0.00013476076,0.0005510406],"domain_scores_gemma":[0.99888283,0.000027402484,0.00031002128,0.00068006443,0.000040623923,0.000059041686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000093418006,0.00026403158,0.0016083919,0.00049229746,0.00006983467,0.0000075473254,0.00041174394,0.0001854433,0.00005939893],"category_scores_gemma":[0.000042909065,0.00016397612,0.00028592072,0.00026168665,0.0003960856,0.000038661117,0.0001824385,0.00076579774,0.00001296286],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011937624,0.000109967594,0.051184926,0.0045657316,0.0003704118,0.000098313365,0.00015778653,0.000001424142,0.0000050080807,0.000008223118,0.007700645,0.9356782],"study_design_scores_gemma":[0.0014184242,0.00007546283,0.0018813551,0.0049071317,0.00025594054,0.000048674374,0.000060343835,0.0000029865748,0.00004770125,0.000028657929,0.9911429,0.00013040123],"about_ca_topic_score_codex":0.00044604126,"about_ca_topic_score_gemma":0.00020803192,"teacher_disagreement_score":0.98344225,"about_ca_system_score_codex":0.0008596081,"about_ca_system_score_gemma":0.0013152915,"threshold_uncertainty_score":0.66867524},"labels":[],"label_agreement":null},{"id":"W2576982189","doi":"10.1016/j.ebiom.2017.02.022","title":"Mining Human Prostate Cancer Datasets: The “camcAPP” Shiny App","year":2017,"lang":"en","type":"article","venue":"EBioMedicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto","funders":"Academy of Medical Sciences; National Institute for Health and Care Research; Cancer Research UK","keywords":"Prostate cancer; Computer science; Prostatectomy; Annotation; Relevance (law); Cancer; Information retrieval; Bioinformatics; Medicine; Artificial intelligence; Biology; Internal medicine","score_opus":0.05564053333025964,"score_gpt":0.41037700280429046,"score_spread":0.3547364694740308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2576982189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85072124,0.0104415985,0.000010350647,0.11381524,0.0010499222,0.0020186084,0.00056278595,0.00017477917,0.021205507],"genre_scores_gemma":[0.9717418,0.0010542048,0.00010283961,0.0010304775,0.0013296448,0.00019329111,0.0009067904,0.000039196362,0.023601739],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983697,0.00002920657,0.00024488222,0.00035626182,0.0005229866,0.0004769973],"domain_scores_gemma":[0.9982743,0.00004445002,0.00015619677,0.0012110756,0.000082207895,0.00023172646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046449603,0.00019959957,0.00032616933,0.00010182936,0.0010423708,0.00008857006,0.00043322452,0.000063791864,0.0005873709],"category_scores_gemma":[0.00009829383,0.000102752616,0.00006039212,0.00012455996,0.00084235444,0.00014714249,0.00020113523,0.00027929174,0.00006096841],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095871644,0.00038692713,0.20031323,0.0005289059,0.0007893453,0.0011209727,0.004528898,7.0213866e-7,0.050913177,0.00033176495,0.61659545,0.12353195],"study_design_scores_gemma":[0.011075904,0.0009784444,0.25531334,0.0011428486,0.00040881822,0.00008555374,0.0013043309,0.00007830621,0.005969245,0.00022501776,0.7231019,0.00031624245],"about_ca_topic_score_codex":0.00092777616,"about_ca_topic_score_gemma":0.00012611508,"teacher_disagreement_score":0.123215705,"about_ca_system_score_codex":0.00011819981,"about_ca_system_score_gemma":0.00016163739,"threshold_uncertainty_score":0.8017179},"labels":[],"label_agreement":null},{"id":"W2577204283","doi":"10.5539/cco.v6n1p44","title":"Radium-223 in a Community Setting for Castration Resistant Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Cancer and Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Abiraterone acetate; Internal medicine; Neutropenia; Confidence interval; Cancer; Oncology; Urology; Surgery; Chemotherapy; Androgen deprivation therapy","score_opus":0.1904506963800432,"score_gpt":0.5484234029606013,"score_spread":0.35797270658055813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577204283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753388,0.0023976055,0.000004346987,0.018688062,0.00038518885,0.00096584024,0.00008169452,0.00001431293,0.0021241046],"genre_scores_gemma":[0.9886989,0.007385734,0.0002253709,0.000661309,0.00035702015,0.0005194625,0.00002805919,0.000014084367,0.0021100335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881154,0.00015835393,0.0004105036,0.0002303319,0.00008959441,0.00029965973],"domain_scores_gemma":[0.99869955,0.000522364,0.00019337128,0.00029033015,0.00012398406,0.00017038656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012075283,0.00010462233,0.00044455004,0.000037507154,0.0004386555,0.000033123357,0.00011138895,0.00018112772,0.00003259241],"category_scores_gemma":[0.00045714417,0.00007880422,0.00007810288,0.00003709086,0.00041148413,0.00008420153,0.000072141906,0.00054988766,0.0000013582543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077150944,0.0005905473,0.5161837,0.00027330153,0.00014743485,0.00006798087,0.00078048813,0.0000014372229,0.00092487695,0.000096075455,0.0020681561,0.4711509],"study_design_scores_gemma":[0.020414,0.0030904722,0.934915,0.0003162295,0.00015921587,0.000006174631,0.0005274193,0.00026341874,0.0004354996,0.00075659435,0.038981497,0.00013445085],"about_ca_topic_score_codex":0.003438967,"about_ca_topic_score_gemma":0.014666299,"teacher_disagreement_score":0.47101647,"about_ca_system_score_codex":0.00034810466,"about_ca_system_score_gemma":0.0010273907,"threshold_uncertainty_score":0.818414},"labels":[],"label_agreement":null},{"id":"W2579694309","doi":"10.5430/jst.v7n1p52","title":"Intravascular disseminated coagulopathy as a debut of metastatic prostate cancer: A case report","year":2017,"lang":"en","type":"article","venue":"Journal of Solid Tumors","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Coagulopathy; Medicine; Consumptive Coagulopathy; Presentation (obstetrics); Cancer; Prostate; Hormonal therapy; Intensive care medicine; Disseminated intravascular coagulation; Internal medicine; Surgery","score_opus":0.027064202743001507,"score_gpt":0.38359535500006986,"score_spread":0.35653115225706833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2579694309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944366,0.0031693778,0.000015821388,0.0013730522,0.00019474668,0.00040486213,0.000032738397,0.000007815765,0.000364977],"genre_scores_gemma":[0.9964426,0.0014304956,0.00028985203,0.000029397177,0.00011863798,0.000018280654,0.0000060331495,0.000027641954,0.0016370347],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.998064,0.000050718772,0.0008008453,0.00016825614,0.0006021079,0.0003140847],"domain_scores_gemma":[0.99706537,0.000044286327,0.0012947958,0.0004692383,0.0007880456,0.0003382769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007989038,0.0001730989,0.00075311353,0.00020876473,0.00018971425,0.000039960178,0.00018148575,0.000039120754,0.00009751857],"category_scores_gemma":[0.00063663337,0.00011418501,0.00025926155,0.00011571199,0.00027183292,0.00022356959,0.00006234742,0.00034180185,0.00000433799],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001883758,0.0004848763,0.03573436,0.00054999226,0.0012045092,0.9280936,0.0018798718,0.000019476689,0.018289551,0.0000120325985,0.0009813473,0.010866607],"study_design_scores_gemma":[0.009718337,0.0033503321,0.04574153,0.00322643,0.0016784366,0.6876341,0.0025742592,0.0002777011,0.24405774,0.00043518326,0.000992831,0.00031310855],"about_ca_topic_score_codex":0.0005208235,"about_ca_topic_score_gemma":0.00003373882,"teacher_disagreement_score":0.2404595,"about_ca_system_score_codex":0.00015975638,"about_ca_system_score_gemma":0.0009646391,"threshold_uncertainty_score":0.46563295},"labels":[],"label_agreement":null},{"id":"W2580264005","doi":"10.1016/j.eururo.2017.01.025","title":"The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer","year":2017,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; DNA repair; Gene; Prostate; Cancer research; Cancer; Internal medicine; Genetics; Biology","score_opus":0.03053900874751399,"score_gpt":0.3087893932639272,"score_spread":0.2782503845164132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2580264005","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43161663,0.042432535,0.000008640978,0.48402762,0.0029891948,0.0021661238,0.0006377033,0.0002727464,0.0358488],"genre_scores_gemma":[0.8280517,0.0038883712,0.0002345747,0.116444096,0.019120501,0.00024510178,0.0018958051,0.00048701128,0.02963285],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99667656,0.0009852594,0.00048289826,0.0007070931,0.00045602536,0.0006921858],"domain_scores_gemma":[0.9972964,0.00058866385,0.0006253034,0.0010626031,0.0003283068,0.00009875217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006702673,0.00038843512,0.0006486427,0.00010206146,0.00055577804,0.00007305656,0.0005261494,0.0002516378,0.00011284327],"category_scores_gemma":[0.001005285,0.00024336658,0.00028130182,0.00006948728,0.0007363076,0.00005606576,0.0004015272,0.0021799156,0.000045412828],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010021059,0.000059814403,0.016526945,0.00025146978,0.0015023339,0.014629763,0.009429442,0.000004162906,0.0022904926,0.0000029970035,0.9507903,0.0035101993],"study_design_scores_gemma":[0.0027711492,0.001046167,0.037866395,0.00049425935,0.0005812104,0.00009348964,0.00019115108,0.00006172711,0.0011738767,0.00007852275,0.9552548,0.0003872657],"about_ca_topic_score_codex":0.00052958255,"about_ca_topic_score_gemma":0.00005182567,"teacher_disagreement_score":0.39643505,"about_ca_system_score_codex":0.00018772704,"about_ca_system_score_gemma":0.00037620487,"threshold_uncertainty_score":0.9924201},"labels":[],"label_agreement":null},{"id":"W2581972122","doi":"10.3390/cancers9020013","title":"Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy","year":2017,"lang":"en","type":"review","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Victoria; BC Cancer Agency","funders":"Prostate Cancer Fight Foundation; Prostate Cancer Canada","keywords":"Prostate cancer; Medicine; Androgen deprivation therapy; Immunotherapy; Immune system; Radiation therapy; Immune modulation; Oncology; Prostate; Abscopal effect; Cancer; Cancer research; Immunology; Internal medicine","score_opus":0.09321449592281507,"score_gpt":0.4245187056081879,"score_spread":0.33130420968537283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581972122","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003236788,0.9927294,0.00008404188,0.0006975766,0.00017502726,0.005204132,0.00066322566,0.00006864856,0.00005422027],"genre_scores_gemma":[0.00034398044,0.9896933,0.000058052516,0.00006404903,0.00021397717,0.0055629564,0.00254894,0.00011865757,0.0013960999],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986977,0.000038603033,0.0003817089,0.00045324027,0.0001325108,0.00029625295],"domain_scores_gemma":[0.9987167,0.00006213039,0.00045666914,0.0005009936,0.00016225054,0.0001012362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017232844,0.00031083147,0.0008762721,0.00014682754,0.00029311262,0.00008733512,0.00013082995,0.00022240226,0.000015463447],"category_scores_gemma":[0.000024145718,0.00023765302,0.00022583107,0.00013680742,0.00011180884,0.00015482544,0.00001840108,0.00016416042,0.0000016211377],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015060736,0.000012991211,0.00032086048,0.0019224338,0.000493472,2.857635e-7,0.00009947357,0.0000019487904,0.00015241133,0.000014507468,0.001955598,0.99487543],"study_design_scores_gemma":[0.002453491,0.00017478003,0.0010233978,0.0017571318,0.00027600044,0.000005812916,0.0000055292253,0.00006322441,0.00008335404,0.00007952903,0.99384606,0.00023167848],"about_ca_topic_score_codex":0.0003705222,"about_ca_topic_score_gemma":0.000010159126,"teacher_disagreement_score":0.99464375,"about_ca_system_score_codex":0.0020260361,"about_ca_system_score_gemma":0.0017541047,"threshold_uncertainty_score":0.9691209},"labels":[],"label_agreement":null},{"id":"W2582197961","doi":"10.1200/jco.2012.30.5_suppl.175","title":"Validation of a genomic-clinical classifier model for predicting clinical recurrence of patients with localized prostate cancer in a high-risk population.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; University of British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Internal medicine; Concordance; Logistic regression; Cohort; Oncology; Proportional hazards model; Population; Biochemical recurrence; Cancer","score_opus":0.18252013667788702,"score_gpt":0.505684934508733,"score_spread":0.32316479783084595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582197961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995846,0.00044888808,0.0010865977,0.0005696529,0.00092334655,0.0009749394,0.00010683058,0.0000041820435,0.000039583738],"genre_scores_gemma":[0.98593384,0.0021665979,0.0110046,0.00009901232,0.0006179983,0.000030564217,0.000032994834,0.000021609123,0.000092769915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99327326,0.0008489159,0.0048320317,0.00023469175,0.00047480772,0.00033629365],"domain_scores_gemma":[0.99056387,0.0033956133,0.00432,0.00019734823,0.0011465341,0.00037664318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008763728,0.0001465969,0.0018797902,0.000163479,0.00003058662,0.0000036651822,0.0001399531,0.00043751037,0.000032899952],"category_scores_gemma":[0.005178864,0.000091854214,0.0004327154,0.00017394395,0.0003528599,0.0002178143,0.000054262055,0.0010121915,9.734963e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03206491,0.0037336133,0.87827176,0.000094089606,0.00038199034,0.000003685819,0.00017619097,0.0005936456,0.0000058044657,0.000021747343,0.00019863872,0.08445393],"study_design_scores_gemma":[0.031445846,0.011024609,0.94671917,0.00030725737,0.0005862978,0.000002289016,0.000044092456,0.00900358,0.00003141761,0.0003011427,0.00045150076,0.00008279637],"about_ca_topic_score_codex":0.00008724941,"about_ca_topic_score_gemma":0.000053708543,"teacher_disagreement_score":0.084371135,"about_ca_system_score_codex":0.00020368793,"about_ca_system_score_gemma":0.0019852424,"threshold_uncertainty_score":0.61999583},"labels":[],"label_agreement":null},{"id":"W2583311472","doi":"10.1371/journal.pone.0170544","title":"Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS)","year":2017,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Astellas Pharma; MedImmune; Princess Margaret Cancer Foundation; AstraZeneca","keywords":"Medicine; Concomitant; Prostate cancer; Proportional hazards model; Docetaxel; Internal medicine; Receiver operating characteristic; Logistic regression; Oncology; Area under the curve; Cancer","score_opus":0.49489702664078744,"score_gpt":0.4562694482195281,"score_spread":0.038627578421259356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583311472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98711526,0.004445317,0.000071269074,0.00033691878,0.000020904006,0.0017551938,0.005950471,0.000015136601,0.00028954036],"genre_scores_gemma":[0.9614329,0.0037024664,0.033395205,0.00001360347,0.000039832008,0.00008379109,0.0009159904,0.00003269225,0.00038355778],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9979277,0.000072043564,0.00036784902,0.00059975893,0.0006900544,0.0003425709],"domain_scores_gemma":[0.99752593,0.00013280255,0.00024883205,0.0018370396,0.0001562414,0.000099168225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049124757,0.00018937528,0.0005984114,0.0001621051,0.00013816432,0.00012447016,0.00054863736,0.000044763503,0.00003186546],"category_scores_gemma":[0.0004022173,0.00014536134,0.000015793003,0.00019956355,0.00021283365,0.0005606883,0.0008566263,0.00023895071,5.6756005e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002284804,0.005530732,0.81071657,0.0062590754,0.0041418443,0.0008656807,0.0013944784,0.0001272804,0.16511026,0.000066359804,0.00023660903,0.0032662987],"study_design_scores_gemma":[0.0063876384,0.0006252823,0.08340381,0.004774011,0.0026803012,0.0000036452047,0.0012141034,0.8914366,0.008793836,0.00032109587,0.000019287014,0.00034040713],"about_ca_topic_score_codex":0.0066373604,"about_ca_topic_score_gemma":0.0030864843,"teacher_disagreement_score":0.8913093,"about_ca_system_score_codex":0.000161877,"about_ca_system_score_gemma":0.0015066427,"threshold_uncertainty_score":0.9999775},"labels":[],"label_agreement":null},{"id":"W2585427049","doi":"10.1177/1078155216689381","title":"A case report of enzalutamide administration in a dialysis-dependent patient with castration-resistant prostate cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Dialysis; Internal medicine; Urology; Population; Oncology; Cancer; Clinical trial; Androgen receptor","score_opus":0.0805586320688406,"score_gpt":0.4702348691241038,"score_spread":0.38967623705526316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2585427049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829151,0.0006673728,0.00001051436,0.013036143,0.0002029127,0.00054032553,0.0000146052425,0.0000031288096,0.002609879],"genre_scores_gemma":[0.9971886,0.0010342816,0.0011471265,0.00012378873,0.00013584818,0.000046143196,0.0000043673836,0.000012846789,0.00030697466],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99805355,0.00021521513,0.00083303085,0.00017226166,0.00052149897,0.0002044365],"domain_scores_gemma":[0.9955947,0.00028675693,0.002657328,0.00025564904,0.0010309236,0.00017464711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012388991,0.00012726236,0.00043708945,0.00018559044,0.0001394902,0.000042426447,0.00009343147,0.000049337337,0.00006810247],"category_scores_gemma":[0.00090517214,0.00008643513,0.000075897995,0.00010157359,0.00014460647,0.00080873404,0.00003131525,0.00050716626,0.00000115272],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046555854,0.0020395846,0.029719738,0.00010526528,0.0007587079,0.8610963,0.002042829,0.00008810648,0.03233113,0.000007850526,0.00022367656,0.02503096],"study_design_scores_gemma":[0.03040103,0.012135656,0.010480997,0.00042037305,0.0024696558,0.8002126,0.0036537051,0.00013107224,0.105592325,0.00002314105,0.034255054,0.00022436822],"about_ca_topic_score_codex":0.0010412476,"about_ca_topic_score_gemma":0.0011958806,"teacher_disagreement_score":0.073261194,"about_ca_system_score_codex":0.00057282974,"about_ca_system_score_gemma":0.0039976924,"threshold_uncertainty_score":0.7091735},"labels":[],"label_agreement":null},{"id":"W2586949432","doi":"10.1002/cncr.30587","title":"Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel","year":2017,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Astellas Pharma; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Hazard ratio; Placebo; Docetaxel; Internal medicine; Oncology; Prostate-specific antigen; Urology; Progression-free survival; Proportional hazards model; Cancer; Chemotherapy; Confidence interval; Androgen receptor; Pathology","score_opus":0.12258591641230794,"score_gpt":0.44446357604426634,"score_spread":0.3218776596319584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586949432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97399026,0.02224921,0.0000017618538,0.0011821993,0.00011203747,0.0020607503,0.00010735584,0.00003111404,0.00026530214],"genre_scores_gemma":[0.96776056,0.02877284,0.00048158193,0.00003249194,0.0000654171,0.00055270316,0.000026672875,0.000053345106,0.0022543836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745464,0.00013950291,0.0006981027,0.0006217858,0.0005398028,0.0005461568],"domain_scores_gemma":[0.9981436,0.00024832095,0.00043743118,0.00054070435,0.0004281555,0.00020176895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071366417,0.00037484476,0.0012689008,0.00014802373,0.0002692665,0.00009205777,0.00015828184,0.000061016643,0.00002210962],"category_scores_gemma":[0.00013900634,0.000212805,0.00011855353,0.0002156808,0.0007134342,0.0003503771,0.00007612601,0.00024533665,0.0000011671117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005900023,0.00020880759,0.9830094,0.00046912968,0.0019337652,0.00056049705,0.0016605306,0.000025269163,0.0011610421,0.000013880996,0.00009923933,0.004958419],"study_design_scores_gemma":[0.016214615,0.0012283811,0.97512627,0.0016794525,0.0005465685,0.000007784966,0.0018591388,0.000029789207,0.002566141,0.000030736323,0.00042727945,0.0002838164],"about_ca_topic_score_codex":0.0030525902,"about_ca_topic_score_gemma":0.00903516,"teacher_disagreement_score":0.010314592,"about_ca_system_score_codex":0.0002371642,"about_ca_system_score_gemma":0.00077150104,"threshold_uncertainty_score":0.86779356},"labels":[],"label_agreement":null},{"id":"W2587092249","doi":"10.1200/jco.2012.30.30_suppl.90","title":"Clinical and genomic analysis of metastatic disease progression in a background of biochemical recurrence.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Genome British Columbia","funders":"","keywords":"Medicine; Biochemical recurrence; Prostate cancer; breakpoint cluster region; Prostatectomy; Internal medicine; Oncology; Disease; Confounding; Cancer; Localized disease; Stage (stratigraphy)","score_opus":0.261240829825691,"score_gpt":0.5795278070506483,"score_spread":0.3182869772249573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587092249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899298,0.008442765,0.000020582747,0.0010331364,0.00024184509,0.00017989893,0.000008508199,0.0000012463425,0.00014220201],"genre_scores_gemma":[0.9921134,0.004804357,0.00274465,0.00008473183,0.00021164425,0.000003143651,0.000007022706,0.000006046113,0.000024978217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996032,0.00063165545,0.0026571546,0.00014213406,0.00032224695,0.00021483019],"domain_scores_gemma":[0.9953685,0.0022733961,0.001316202,0.00015417355,0.00025654552,0.00063118816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055465726,0.000092434166,0.0018401385,0.0003481716,0.000009551787,0.0000022053264,0.00009805746,0.00014163702,0.000077692086],"category_scores_gemma":[0.0020331957,0.000055980294,0.0005594571,0.00042566741,0.0006807217,0.00008276188,0.000072701645,0.00059484306,0.0000013991456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007917419,0.0045108525,0.92707455,0.000097092496,0.0014673319,0.000115439594,0.000055585304,0.0000011403099,0.0002389214,0.000040596384,0.00022389785,0.05825717],"study_design_scores_gemma":[0.0063136443,0.0039742747,0.9847469,0.00018938992,0.0033072734,0.000019179164,0.00012431382,0.00018589047,0.00009865678,0.00012995029,0.0008628128,0.000047713012],"about_ca_topic_score_codex":0.0000068616387,"about_ca_topic_score_gemma":0.000005193189,"teacher_disagreement_score":0.058209457,"about_ca_system_score_codex":0.00006280764,"about_ca_system_score_gemma":0.0010492356,"threshold_uncertainty_score":0.258433},"labels":[],"label_agreement":null},{"id":"W2587256875","doi":"10.1093/annonc/mdw372.23","title":"Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomised clinical trials","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Placebo; Incidence (geometry); Adverse effect; Internal medicine; Physical therapy; Cancer; Oncology; Alternative medicine","score_opus":0.4907561625931201,"score_gpt":0.5522924709673996,"score_spread":0.061536308374279536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587256875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97828245,0.0016368459,0.000056511806,0.014974301,0.000034906283,0.0025195086,0.0010618835,0.000021329524,0.0014122896],"genre_scores_gemma":[0.9918656,0.0050956705,0.00071922765,0.0002720454,0.000096741314,0.00035671316,0.00040473923,0.000028956458,0.0011603291],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99650633,0.0012127971,0.0010794913,0.00050526654,0.00033209182,0.00036404363],"domain_scores_gemma":[0.9954214,0.0029831452,0.00050674495,0.00057042047,0.00031971882,0.00019856838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033027183,0.0002004085,0.0014623725,0.000145547,0.000031783915,0.000010219391,0.00019041455,0.00010319146,0.0003772437],"category_scores_gemma":[0.00091835525,0.000088385445,0.00007714205,0.00024487043,0.0003872288,0.00017217438,0.00004893187,0.00016405428,0.000007546122],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58278686,0.002431107,0.17396715,0.0001478159,0.0047896006,0.0018284634,0.000661773,0.000017261757,0.034393333,0.000044438893,0.014995122,0.18393707],"study_design_scores_gemma":[0.6707621,0.028203974,0.20421144,0.0026077358,0.0024679466,0.000041174444,0.0010835738,0.00039286568,0.07229341,0.0005456563,0.01671209,0.0006780233],"about_ca_topic_score_codex":0.002503676,"about_ca_topic_score_gemma":0.0039333785,"teacher_disagreement_score":0.18325904,"about_ca_system_score_codex":0.00008859352,"about_ca_system_score_gemma":0.001744607,"threshold_uncertainty_score":0.4130554},"labels":[],"label_agreement":null},{"id":"W2587472202","doi":"10.18314/gjct.v2i1.100","title":"Effect of Combination therapy of Desmopressin and Docetaxel on prostate cancer cell DU145 proliferation, migration and growth","year":2016,"lang":"en","type":"article","venue":"Journal of Cancer Biology and Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"Sunnybrook Research Institute","keywords":"Docetaxel; DU145; Medicine; Prostate cancer; Desmopressin; In vivo; Chemotherapy; Metastasis; Combination therapy; Cancer; Prostate; Internal medicine; Paclitaxel; Pharmacology; Oncology; Urology; Cancer research; Biology","score_opus":0.018228784231350284,"score_gpt":0.353905887364219,"score_spread":0.33567710313286875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587472202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9574283,0.03979454,0.000021284699,0.0023686774,0.00006618889,0.00027305854,0.000014576986,0.0000019533315,0.00003146879],"genre_scores_gemma":[0.82371897,0.17602971,0.000018739116,0.00008914786,0.00004264628,0.00001236722,0.000001636245,0.0000056163744,0.00008116902],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99938446,0.00011642148,0.00022413235,0.00008874295,0.00009593784,0.00009032169],"domain_scores_gemma":[0.9992504,0.0001411684,0.00026111628,0.000047665526,0.00025683214,0.000042779506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002866887,0.00009251736,0.00026348815,0.00006911055,0.00003653168,0.0000050499743,0.000024674719,0.000080844235,0.000010111676],"category_scores_gemma":[0.000009258228,0.00004413569,0.000027613176,0.000046006306,0.0002126138,0.00007678198,0.00000717965,0.00007731768,4.0530225e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047639366,0.00008760509,0.6787431,0.00012440504,0.00021253004,0.0000011149197,0.00037652365,2.2216015e-7,0.21411534,0.00017439168,0.0000121580315,0.10138868],"study_design_scores_gemma":[0.008869846,0.0075234915,0.20921543,0.00029109468,0.00012638021,0.000012004344,0.00001581319,0.000023169581,0.772471,0.00086464273,0.0005298692,0.000057233356],"about_ca_topic_score_codex":0.000053228374,"about_ca_topic_score_gemma":0.000023473664,"teacher_disagreement_score":0.5583557,"about_ca_system_score_codex":0.00003290461,"about_ca_system_score_gemma":0.00009605516,"threshold_uncertainty_score":0.17998013},"labels":[],"label_agreement":null},{"id":"W2587541613","doi":"10.1371/journal.pone.0171871","title":"Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models","year":2017,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Androsterone; Dihydrotestosterone; Testosterone (patch); Androgen; In vivo; Androgen receptor; Chemistry; Cancer research; Endocrinology; Internal medicine; In vitro; Cancer; Steroid; Medicine; Biology; Hormone; Biochemistry","score_opus":0.04899201021013643,"score_gpt":0.27072507134895574,"score_spread":0.2217330611388193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587541613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99554276,0.0029136448,1.2520825e-7,0.00041218146,0.000015000804,0.0008708041,0.000030570933,0.000003529063,0.00021135184],"genre_scores_gemma":[0.9986787,0.0009273054,0.000066613444,0.000028076525,0.000012238546,0.000061474166,0.0000031931365,0.000011741688,0.00021068357],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990739,0.00005139462,0.0002513537,0.00019399937,0.00024410983,0.00018521944],"domain_scores_gemma":[0.9994658,0.00002985982,0.00013182066,0.00024343102,0.00006525575,0.00006380222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022767663,0.00009760076,0.0002903763,0.0001056533,0.00003669557,0.000011026159,0.00007961352,0.00004398388,0.0000050397766],"category_scores_gemma":[0.000054826713,0.00006772132,0.000014570389,0.00015203646,0.00023094384,0.00013881836,0.00008889954,0.00013741603,2.7104778e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058086246,0.00032480297,0.24230286,0.0006057707,0.000013421789,0.0000135258015,0.002162059,0.000016037704,0.75392103,0.0000023086218,0.0000031187487,0.000054165026],"study_design_scores_gemma":[0.0034536833,0.00017281987,0.02698316,0.0011911868,0.000028782702,0.0000010652284,0.000097300755,0.006689679,0.96114177,0.00017677073,8.226923e-7,0.00006296583],"about_ca_topic_score_codex":0.0024639152,"about_ca_topic_score_gemma":0.0016812013,"teacher_disagreement_score":0.21531971,"about_ca_system_score_codex":0.000114336275,"about_ca_system_score_gemma":0.00022179548,"threshold_uncertainty_score":0.37247193},"labels":[],"label_agreement":null},{"id":"W2587966486","doi":"10.1093/annonc/mdw372.54","title":"TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Androgen deprivation therapy; Placebo; Prostate cancer; Oncology; Internal medicine; Antiandrogen; Double blind; Urology; Cancer; Pathology","score_opus":0.13255004626248107,"score_gpt":0.44675993276647247,"score_spread":0.3142098865039914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587966486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97838515,0.00496331,0.00007359238,0.0068804985,0.00014612533,0.008401024,0.000092046044,0.000017788378,0.0010404676],"genre_scores_gemma":[0.97065204,0.02617783,0.00013845087,0.00024944168,0.000115418414,0.0017853681,0.000041357445,0.000029063282,0.0008110337],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99721956,0.0005618679,0.0009842645,0.00035677192,0.00041628344,0.000461242],"domain_scores_gemma":[0.9971756,0.0012428464,0.00058968714,0.00026426915,0.0005834888,0.00014414433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020324604,0.000247557,0.0020523316,0.00045627556,0.000032879372,0.0000067231304,0.00011048966,0.00014941789,0.000083298415],"category_scores_gemma":[0.00038213385,0.00014060928,0.00033553035,0.0003375137,0.0004807697,0.00015369857,0.000038694598,0.00016927221,0.0000101341175],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9135679,0.001304007,0.00009424043,0.000045065488,0.0014828108,0.0001393207,0.0016457563,0.000012863646,0.013084826,0.00013904167,0.0003069141,0.06817723],"study_design_scores_gemma":[0.94025254,0.007685696,0.000048014514,0.00014223988,0.00024930757,0.000013378113,0.0001749974,0.00016057109,0.049420312,0.0005707023,0.0011496419,0.00013259356],"about_ca_topic_score_codex":0.00060257106,"about_ca_topic_score_gemma":0.00018633105,"teacher_disagreement_score":0.06804463,"about_ca_system_score_codex":0.0002206258,"about_ca_system_score_gemma":0.0013289887,"threshold_uncertainty_score":0.573388},"labels":[],"label_agreement":null},{"id":"W2588085167","doi":"10.1093/annonc/mdw334.19","title":"Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Logistic regression; Proportional hazards model; Internal medicine; Prostate cancer; Surgery; Cancer","score_opus":0.15251213454962662,"score_gpt":0.5233643924927793,"score_spread":0.3708522579431527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588085167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906112,0.000065761276,0.00001593689,0.0027952015,0.0001049298,0.00027275598,0.00010471591,0.0000105204645,0.0060189706],"genre_scores_gemma":[0.997616,0.0012140955,0.000112879825,0.00005714079,0.000031641226,0.00005078158,0.00012402365,0.000007101242,0.0007863148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989051,0.00012869369,0.00037764476,0.000180994,0.00022967772,0.00017789399],"domain_scores_gemma":[0.99892575,0.00016731575,0.00019539692,0.00018373533,0.00045043914,0.00007736751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031172187,0.00007858658,0.0004955716,0.00035672061,0.000011400435,0.0000035860774,0.00017044385,0.00010644281,0.00060062465],"category_scores_gemma":[0.000103621634,0.000052547948,0.00013003817,0.0004826812,0.00019409227,0.00017358012,0.00005212552,0.000074055366,0.0000017328786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018721449,0.0029467167,0.8890941,0.00002285523,0.0014233299,0.000009953576,0.00026723454,0.000005005173,0.015671737,0.000082368315,0.0010182359,0.08758633],"study_design_scores_gemma":[0.007087743,0.0032307934,0.9407502,0.00007325429,0.00027773782,0.000003887988,0.0001281594,0.00012719944,0.041266512,0.00030644744,0.006651742,0.000096355216],"about_ca_topic_score_codex":0.0007087092,"about_ca_topic_score_gemma":0.0005174056,"teacher_disagreement_score":0.08748998,"about_ca_system_score_codex":0.000074096,"about_ca_system_score_gemma":0.00020136086,"threshold_uncertainty_score":0.6576419},"labels":[],"label_agreement":null},{"id":"W2588188936","doi":"10.1093/annonc/mdw372.31","title":"Global treatment patterns for late-stage prostate cancer: Updated results from ASPIRE-PCa","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Androgen deprivation therapy; Bicalutamide; Androgen; Internal medicine; Oncology; Prostate-specific antigen; Androgen receptor; Cancer; Hormone","score_opus":0.12338188511774176,"score_gpt":0.44527526900509845,"score_spread":0.32189338388735667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588188936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94339067,0.0008114751,0.000025557614,0.0378676,0.00022772062,0.001176449,0.014111124,0.00004738259,0.0023419943],"genre_scores_gemma":[0.9781999,0.006915459,0.00016219068,0.00064099923,0.00019696455,0.00030161988,0.0008131664,0.00002171447,0.012747995],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843264,0.000066122186,0.0004165551,0.00041142185,0.00017781273,0.0004954801],"domain_scores_gemma":[0.9987366,0.00020210168,0.00020384867,0.00032554058,0.00032377703,0.00020812324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001759957,0.00019250355,0.00053270464,0.000064589054,0.000052698797,0.000006401176,0.00010395018,0.00016180199,0.00026791354],"category_scores_gemma":[0.00007007298,0.00010786596,0.00015879367,0.000120377474,0.00013421875,0.000070039896,0.000042830892,0.00004293587,0.000023841865],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033462636,0.0015163266,0.12203424,0.0000728331,0.0014501777,0.00032449924,0.00070192444,0.000018472536,0.005534127,0.00012823577,0.031026114,0.8037304],"study_design_scores_gemma":[0.044800524,0.022235803,0.10759782,0.00031639487,0.00025223137,0.000004495033,0.00014629557,0.00009126859,0.08794663,0.00068835285,0.7356347,0.00028551716],"about_ca_topic_score_codex":0.0039947387,"about_ca_topic_score_gemma":0.0015585767,"teacher_disagreement_score":0.8034449,"about_ca_system_score_codex":0.00041017286,"about_ca_system_score_gemma":0.0006946847,"threshold_uncertainty_score":0.6038877},"labels":[],"label_agreement":null},{"id":"W2588410595","doi":"10.18632/oncotarget.15237","title":"Metabolic heterogeneity signature of primary treatment-naïve prostate cancer","year":2017,"lang":"en","type":"article","venue":"Oncotarget","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Vancouver General Hospital; University of Toronto; University Health Network; University of British Columbia; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Canadian Institutes of Health Research; BC Cancer Foundation; Prostate Cancer Canada","keywords":"Prostate cancer; Medicine; Cancer; Oncology; Internal medicine; Gerontology","score_opus":0.04088886114904612,"score_gpt":0.3615637761577724,"score_spread":0.3206749150087263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588410595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96761596,0.020994917,0.0000016098234,0.0020857712,0.00022356954,0.0007465906,0.00025010662,0.000034299912,0.008047154],"genre_scores_gemma":[0.9748583,0.010517565,0.00045596497,0.00015919056,0.0002542107,0.00016124477,0.00013570173,0.000034139688,0.013423692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878633,0.00003208662,0.00019885803,0.00031087748,0.00031137568,0.0003604536],"domain_scores_gemma":[0.99875456,0.00002032324,0.00017998139,0.00070185907,0.00015198464,0.00019129671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000101407604,0.00020642964,0.000548012,0.000073482326,0.0002209255,0.000033221128,0.00016964505,0.00010772412,0.00020962529],"category_scores_gemma":[0.0000271198,0.00013455773,0.00018669169,0.00006474055,0.00020760926,0.00014902109,0.00007449973,0.00014750335,0.000025378653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013410896,0.00066307577,0.87773573,0.00021410706,0.00083200226,0.00016834297,0.000547917,0.000004455353,0.08660651,0.00006303408,0.0025801961,0.029243562],"study_design_scores_gemma":[0.005455062,0.0006558034,0.68395114,0.00012897757,0.0002638246,0.000009541086,0.000024091081,0.000020214982,0.2328582,0.000083546925,0.076391704,0.00015790956],"about_ca_topic_score_codex":0.00072380475,"about_ca_topic_score_gemma":0.00009377156,"teacher_disagreement_score":0.19378456,"about_ca_system_score_codex":0.00022819228,"about_ca_system_score_gemma":0.00048721576,"threshold_uncertainty_score":0.5487105},"labels":[],"label_agreement":null},{"id":"W2588421393","doi":"10.1093/annonc/mdw372.24","title":"Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA + P) for ≥ 4 years (yrs)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Discontinuation; Adverse effect; Abiraterone acetate; Prednisone; Gastroenterology; Peripheral edema; Androgen deprivation therapy; Placebo; Surgery; Cancer","score_opus":0.0736474234287881,"score_gpt":0.39458428387988065,"score_spread":0.32093686045109254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588421393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99341756,0.0009051224,0.00007590823,0.0021021564,0.000059719652,0.0024038076,0.00081464363,0.000012907858,0.00020816766],"genre_scores_gemma":[0.9916366,0.004660211,0.0007831187,0.000086697044,0.000032577955,0.0003816769,0.00013051162,0.00004295292,0.002245668],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99816763,0.00007873868,0.0006461153,0.00034239018,0.00033485456,0.0004302561],"domain_scores_gemma":[0.99807394,0.00017466872,0.00055184367,0.00031841136,0.0007358315,0.00014533714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022306506,0.00024523982,0.0009346194,0.00015028074,0.000036598114,0.000004216986,0.000109050896,0.000092040114,0.00016381135],"category_scores_gemma":[0.000027939184,0.00014192784,0.00015197737,0.00017016508,0.000401389,0.000104623134,0.000023942473,0.00005348758,0.000002946458],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1047102,0.0054935226,0.10246751,0.0014954713,0.0049396786,0.00011734587,0.0047887284,0.000050992483,0.18773282,0.00008090431,0.0009085885,0.58721423],"study_design_scores_gemma":[0.06511655,0.04110838,0.3255759,0.0007519336,0.00055729423,0.000010361071,0.00015181483,0.000018920497,0.5642551,0.00009324662,0.002101664,0.0002588276],"about_ca_topic_score_codex":0.00023439925,"about_ca_topic_score_gemma":0.00041530066,"teacher_disagreement_score":0.5869554,"about_ca_system_score_codex":0.00038164257,"about_ca_system_score_gemma":0.001074554,"threshold_uncertainty_score":0.578765},"labels":[],"label_agreement":null},{"id":"W2588436059","doi":"10.1093/annonc/mdw372.52","title":"ATLAS: A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Clinical endpoint; Enzalutamide; Oncology; Internal medicine; Androgen deprivation therapy; Urology; Placebo; Radiation therapy; Randomized controlled trial; Cancer; Androgen receptor; Pathology","score_opus":0.07262357971532579,"score_gpt":0.44034117849108056,"score_spread":0.3677175987757548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588436059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927181,0.0011810691,0.000025129715,0.0025913238,0.0001273709,0.0032129264,0.000055149147,0.000014540541,0.00007441225],"genre_scores_gemma":[0.9900686,0.008632513,0.00025559874,0.00025667058,0.000090229005,0.00036375184,0.000039011353,0.000026167281,0.0002674647],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978103,0.00048055223,0.00058321166,0.00029350855,0.00047224632,0.0003601527],"domain_scores_gemma":[0.99750817,0.0010703985,0.00057181006,0.00027149572,0.0004972965,0.00008082641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010283161,0.00016892776,0.000614508,0.00014838592,0.000059742448,0.0000044498365,0.00012563742,0.000102369384,0.00009645899],"category_scores_gemma":[0.000644268,0.00007279959,0.00007429245,0.00036013793,0.00027963196,0.00012146626,0.000033710392,0.00016968537,0.0000021287856],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3919849,0.0012667022,0.03480314,0.00003592223,0.00017214644,0.000005940453,0.0006482153,0.00004469612,0.0018676502,0.0000022282181,0.00007727721,0.56909114],"study_design_scores_gemma":[0.5820621,0.09548131,0.30788007,0.00076264894,0.00010582932,0.0000010884813,0.000071276,0.00007097349,0.011533262,0.00010049568,0.0017735185,0.00015740987],"about_ca_topic_score_codex":0.00038537828,"about_ca_topic_score_gemma":0.00012190782,"teacher_disagreement_score":0.5689337,"about_ca_system_score_codex":0.000231053,"about_ca_system_score_gemma":0.0013393736,"threshold_uncertainty_score":0.29686812},"labels":[],"label_agreement":null},{"id":"W2588446979","doi":"10.18632/oncotarget.15308","title":"NRIP/DCAF6 stabilizes the androgen receptor protein by displacing DDB2 from the CUL4A-DDB1 E3 ligase complex in prostate cancer","year":2017,"lang":"en","type":"article","venue":"Oncotarget","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics; University of North Carolina at Chapel Hill; National Taiwan University; National Health Research Institutes","keywords":"DDB1; Androgen receptor; Prostate cancer; Ubiquitin ligase; Cancer research; Cancer; Medicine; LNCaP; Chemistry; Biology; Ubiquitin; Internal medicine; Genetics; Gene","score_opus":0.03887675030385299,"score_gpt":0.3468921233849847,"score_spread":0.3080153730811317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588446979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95335585,0.0056824274,0.0000019699587,0.036744885,0.00015076852,0.0023171825,0.00073187606,0.000036348833,0.000978708],"genre_scores_gemma":[0.9894605,0.0015155002,0.00014373891,0.00050923764,0.00032703218,0.00086242415,0.00033888847,0.000048024936,0.006794626],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99806035,0.00015281622,0.0002981332,0.0004396059,0.0004852958,0.0005638324],"domain_scores_gemma":[0.9984788,0.00013395795,0.00017471785,0.0009441438,0.00009965722,0.00016872476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047238314,0.00025730018,0.00037248677,0.000025357827,0.0007316721,0.00019167092,0.0004747415,0.00007356543,0.0008136991],"category_scores_gemma":[0.00017980167,0.00012625523,0.00010281256,0.000116307936,0.00044152274,0.00018814093,0.00019801044,0.00043761614,0.00007738293],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019045948,0.00037822724,0.7135429,0.00011062808,0.00022431559,0.00009341939,0.004106477,0.0000066607627,0.17678598,0.00003855033,0.09647631,0.0063319565],"study_design_scores_gemma":[0.012917101,0.0006719842,0.19568782,0.0014096417,0.00016689087,0.000008388016,0.0024329575,0.00075798377,0.194907,0.0008164405,0.5895828,0.00064100587],"about_ca_topic_score_codex":0.007875493,"about_ca_topic_score_gemma":0.0014048954,"teacher_disagreement_score":0.51785505,"about_ca_system_score_codex":0.0003245099,"about_ca_system_score_gemma":0.00034171654,"threshold_uncertainty_score":0.99873114},"labels":[],"label_agreement":null},{"id":"W2588459214","doi":"10.1093/annonc/mdw372.01","title":"Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Surrogate endpoint; Randomization; Prostate cancer; Internal medicine; Randomized controlled trial; Stage (stratigraphy); Oncology; Clinical endpoint; Disease; Radiation therapy; Survival analysis; Cancer; Surgery","score_opus":0.1488525946476359,"score_gpt":0.44678848335507515,"score_spread":0.29793588870743926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588459214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89723676,0.004758375,0.000099562036,0.09014441,0.00060233567,0.0019155858,0.0013468725,0.000044354354,0.0038517255],"genre_scores_gemma":[0.96635437,0.019233882,0.0006508128,0.0018998034,0.00026007043,0.0007682629,0.00005843642,0.00007374611,0.010700614],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771976,0.00021640329,0.0005133597,0.00043940014,0.00037412878,0.0007369296],"domain_scores_gemma":[0.9980432,0.00060970517,0.00018434081,0.0004181064,0.0005313066,0.00021334086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010998846,0.00022767608,0.0009382167,0.00024060426,0.00004416922,0.000007565764,0.00021656319,0.00018119717,0.00066328264],"category_scores_gemma":[0.00032182623,0.0001425499,0.00023907125,0.00024391168,0.0002742845,0.00012250735,0.00011970288,0.00014023771,0.000019518859],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04928708,0.0030461303,0.16854574,0.0010008371,0.0026657516,0.00048987824,0.0023595751,0.0000112666785,0.025514841,0.0026600838,0.093951486,0.65046734],"study_design_scores_gemma":[0.08818218,0.0118485335,0.041009415,0.0008229421,0.00036955913,0.000018919924,0.0004276348,0.00010880131,0.14080729,0.013746069,0.7019859,0.000672761],"about_ca_topic_score_codex":0.001506508,"about_ca_topic_score_gemma":0.0019446164,"teacher_disagreement_score":0.6497946,"about_ca_system_score_codex":0.00018792828,"about_ca_system_score_gemma":0.00083644135,"threshold_uncertainty_score":0.72624797},"labels":[],"label_agreement":null},{"id":"W2588676979","doi":"10.1093/annonc/mdw372.43","title":"Prognostic factors in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or bicalutamide (BIC) in TERRAIN","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Oncology; Prostate cancer; Proportional hazards model; Enzalutamide; Prostate-specific antigen; Bicalutamide; Confidence interval; Biochemical recurrence; Androgen deprivation therapy; Gynecology; Cancer; Androgen receptor; Prostatectomy","score_opus":0.1044892592278731,"score_gpt":0.4020163358150616,"score_spread":0.29752707658718847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588676979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990318,0.0003825522,0.0000062536124,0.0063782344,0.000013218749,0.0017191014,0.000109867055,0.000026756083,0.0010460083],"genre_scores_gemma":[0.9964603,0.0006878614,0.00021349208,0.00013671345,0.000018241186,0.00052007625,0.000038649716,0.000037018857,0.0018876005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978522,0.00022390982,0.0005195439,0.0003845019,0.00036981583,0.0006500448],"domain_scores_gemma":[0.99859166,0.0005284586,0.00020410685,0.00023579063,0.00024021456,0.00019978151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003616919,0.00027624317,0.00075967785,0.0004469393,0.00003529924,0.000010084511,0.00010827959,0.00009933123,0.00019576254],"category_scores_gemma":[0.00018320348,0.0001228796,0.0000467157,0.0006846217,0.00039949518,0.00016137301,0.000027349202,0.00019105703,0.0000047333433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034749784,0.0015286489,0.8946774,0.00028788872,0.0005235545,0.0026214065,0.0030662103,0.00004354013,0.03743199,0.00005459841,0.00036124478,0.024653714],"study_design_scores_gemma":[0.023249684,0.020290852,0.88636994,0.0018660339,0.00020916764,0.00007766519,0.0023787674,0.00005570731,0.06322077,0.00014844057,0.0017607068,0.0003722799],"about_ca_topic_score_codex":0.0031308813,"about_ca_topic_score_gemma":0.01903022,"teacher_disagreement_score":0.02578878,"about_ca_system_score_codex":0.0003514304,"about_ca_system_score_gemma":0.0016746888,"threshold_uncertainty_score":0.9988699},"labels":[],"label_agreement":null},{"id":"W2588677369","doi":"10.1093/annonc/mdw372.20","title":"Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): A phase II trial in men with metastatic castrate resistant prostate cancer (mCRPC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Docetaxel; Internal medicine; Clinical endpoint; Prostate cancer; Regimen; Enzalutamide; Prednisone; Chemotherapy regimen; Oncology; Chemotherapy; Cancer; Surgery; Urology; Clinical trial; Androgen receptor","score_opus":0.10849510741443154,"score_gpt":0.4210841554450015,"score_spread":0.31258904803056997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588677369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98301744,0.0030580522,0.000034015527,0.006907478,0.00009618929,0.0020590287,0.0001649989,0.000042869968,0.004619936],"genre_scores_gemma":[0.9919002,0.0020730547,0.0003885331,0.00016484738,0.000105896805,0.00049602817,0.000018817505,0.000038714195,0.004813876],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973269,0.00029881488,0.000654111,0.00051071943,0.00042410506,0.0007853347],"domain_scores_gemma":[0.9983388,0.00034732433,0.00040355476,0.0003462281,0.00033035054,0.00023374769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010832371,0.0002810462,0.0009533438,0.00027773058,0.00012859766,0.000011815244,0.00014023605,0.000109508495,0.00015516052],"category_scores_gemma":[0.00014970834,0.00016038946,0.000114819304,0.00045345104,0.0003421961,0.00018868607,0.000068657806,0.00024097026,0.0000070204983],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58044827,0.0050681406,0.0008455591,0.0005496363,0.00085368974,0.0038090448,0.0034156812,0.000007438756,0.2346372,0.00022748145,0.0029125263,0.16722535],"study_design_scores_gemma":[0.5626662,0.07721966,0.0034665493,0.0020034832,0.0004167012,0.000102165526,0.0010431703,0.00008769869,0.32763666,0.0016678058,0.023070581,0.0006193686],"about_ca_topic_score_codex":0.00046971618,"about_ca_topic_score_gemma":0.0019298438,"teacher_disagreement_score":0.16660598,"about_ca_system_score_codex":0.0002968052,"about_ca_system_score_gemma":0.0014338526,"threshold_uncertainty_score":0.6540492},"labels":[],"label_agreement":null},{"id":"W2589159431","doi":"10.1002/adhm.201770018","title":"Cancer Therapy: Low‐Dose Prostate Cancer Brachytherapy with Radioactive Palladium–Gold Nanoparticles (Adv. Healthcare Mater. 4/2017)","year":2017,"lang":"en","type":"article","venue":"Advanced Healthcare Materials","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Brachytherapy; Prostate cancer; Cancer; Medicine; Radiation therapy; Colloidal gold; Nuclear medicine; Materials science; Prostate; Oncology; Biomedical engineering; Nanoparticle; Radiology; Internal medicine; Nanotechnology","score_opus":0.04751026316094291,"score_gpt":0.3959805922753751,"score_spread":0.34847032911443215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589159431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92603344,0.021124436,0.0000020367315,0.046471838,0.0010518963,0.0038899179,0.0011001434,0.00021854693,0.00010774557],"genre_scores_gemma":[0.9096718,0.081121534,0.00047383845,0.0024946756,0.00060168316,0.0026872216,0.00014183548,0.00017832546,0.0026291062],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957525,0.00025253007,0.0006919322,0.0010677638,0.00072627503,0.0015090046],"domain_scores_gemma":[0.9963673,0.000059168833,0.00069944997,0.0014386985,0.00070569507,0.00072968454],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038414204,0.00066284515,0.0012186245,0.00015362156,0.0010082069,0.00030388735,0.00041569743,0.00023833963,0.00033287445],"category_scores_gemma":[0.000032749038,0.00045453067,0.00011215752,0.00017214585,0.0004583302,0.00069816917,0.00010699637,0.00036717998,0.000041928324],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031739812,0.00041368147,0.06927137,0.0024485306,0.00067602517,0.0006327092,0.0035737276,0.00002564576,0.7397076,0.00022783664,0.0005640009,0.15071909],"study_design_scores_gemma":[0.014255223,0.0027058565,0.1250703,0.002531034,0.000075316224,0.000077186516,0.0004958777,0.000006418612,0.8456436,0.0003878517,0.008010191,0.0007411475],"about_ca_topic_score_codex":0.010601169,"about_ca_topic_score_gemma":0.0025106731,"teacher_disagreement_score":0.14997795,"about_ca_system_score_codex":0.00084872474,"about_ca_system_score_gemma":0.0013545267,"threshold_uncertainty_score":0.99979067},"labels":[],"label_agreement":null},{"id":"W2589166085","doi":"10.1200/jco.2014.32.4_suppl.159","title":"Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Enzalutamide; Medicine; Docetaxel; Abiraterone acetate; Prostate cancer; Discontinuation; Internal medicine; Cabazitaxel; Oncology; Urology; Chemotherapy; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.1344995534570567,"score_gpt":0.4956395757429001,"score_spread":0.3611400222858434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589166085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936072,0.00019952799,0.000011567692,0.004061717,0.00057881477,0.00093844195,0.000019108998,0.000005168354,0.0005784418],"genre_scores_gemma":[0.9972081,0.001121427,0.00034633485,0.0006742045,0.00028979284,0.000062309104,0.000005919546,0.000021506163,0.0002703973],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993857,0.0017809661,0.0028008565,0.00032931782,0.00083011744,0.00040173397],"domain_scores_gemma":[0.993843,0.0024853416,0.0023028597,0.00032452328,0.0007102404,0.0003340371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005303357,0.0002162754,0.0017220691,0.0001397639,0.00006803629,0.000020408781,0.00029123772,0.00022459442,0.00004776398],"category_scores_gemma":[0.0027802244,0.00011428568,0.0003542934,0.00021073953,0.0008291634,0.00017822404,0.000074745956,0.0012995895,0.000003160169],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026472302,0.0042000823,0.739687,0.00009847243,0.00035023622,0.0001565392,0.00060784654,0.000076044074,0.000245088,0.000024319981,0.00038093963,0.2277011],"study_design_scores_gemma":[0.017989026,0.017484024,0.95766526,0.00043407723,0.00015832509,0.0000046408,0.00021739402,0.00036876777,0.0015074282,0.00009193816,0.003969038,0.00011007724],"about_ca_topic_score_codex":0.00006852983,"about_ca_topic_score_gemma":0.00033034917,"teacher_disagreement_score":0.22759102,"about_ca_system_score_codex":0.0002758839,"about_ca_system_score_gemma":0.0017754429,"threshold_uncertainty_score":0.56461424},"labels":[],"label_agreement":null},{"id":"W2589285052","doi":"10.1200/jco.2013.31.6_suppl.141","title":"Hypofractionated radiotherapy (66Gy at 3Gy per fraction) for favorable-risk prostate cancer: Long-term outcomes.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Prostate; Genitourinary system; Toxicity; Hormonal therapy; Urology; Surgery; Cancer; Internal medicine","score_opus":0.13186805803046636,"score_gpt":0.5112920681895393,"score_spread":0.37942401015907296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589285052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95325637,0.0035927666,0.0003752064,0.03869636,0.0021886255,0.0012565766,0.000023589086,0.00002231274,0.00058821414],"genre_scores_gemma":[0.8902575,0.060979612,0.0057185176,0.006972919,0.0031517898,0.00032642815,0.000042211082,0.000093713665,0.032457337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654806,0.00031539524,0.0019608275,0.00027859482,0.00045984407,0.00043725577],"domain_scores_gemma":[0.99295557,0.0031156763,0.0018913081,0.0002188005,0.0012592588,0.000559419],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017252051,0.00020611183,0.0015407897,0.00018162672,0.00016235068,0.000025587562,0.00015330433,0.00042041193,0.0028749425],"category_scores_gemma":[0.0014796825,0.00012576928,0.000710307,0.00012882114,0.00023757364,0.00040730965,0.000034431796,0.0011132644,0.00010556277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00675449,0.0011853313,0.6686349,0.00004063261,0.0012872802,0.00009333433,0.000046368128,0.000018653218,0.00034507515,0.0000059931976,0.017193103,0.30439484],"study_design_scores_gemma":[0.019731043,0.007953185,0.76318073,0.000053253752,0.00035867334,0.00016413436,0.000037234444,0.00014231578,0.00018099455,0.00021952183,0.20785876,0.00012015458],"about_ca_topic_score_codex":0.00023358816,"about_ca_topic_score_gemma":0.00007854097,"teacher_disagreement_score":0.30427468,"about_ca_system_score_codex":0.0012330569,"about_ca_system_score_gemma":0.0020546257,"threshold_uncertainty_score":0.99803656},"labels":[],"label_agreement":null},{"id":"W2589286168","doi":"10.1200/jco.2016.34.2_suppl.168","title":"Treatment patterns after abiraterone acetate in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Abiraterone acetate; Enzalutamide; Cabazitaxel; Internal medicine; Prostate cancer; Docetaxel; Prednisone; Taxane; Post-hoc analysis; Discontinuation; Oncology; Chemotherapy; Placebo; Androgen deprivation therapy; Gastroenterology; Urology; Cancer; Androgen receptor; Breast cancer; Pathology","score_opus":0.08113460230896853,"score_gpt":0.45225686761719075,"score_spread":0.37112226530822223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589286168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99418104,0.000463583,0.000019730274,0.004290458,0.00016631771,0.0005562771,0.00026526718,0.000003839545,0.000053461536],"genre_scores_gemma":[0.9958575,0.0027127822,0.00036760583,0.0002121763,0.0000836554,0.00006260818,0.000023150906,0.000020287758,0.00066027005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996344,0.00040085957,0.0020566385,0.00027464068,0.0005707087,0.00035315874],"domain_scores_gemma":[0.99640566,0.000685161,0.0013740571,0.00023149652,0.0009677953,0.00033584802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008227405,0.00021659974,0.0018769474,0.00046979653,0.000023085186,0.000010203041,0.0001032353,0.00012431003,0.00041453989],"category_scores_gemma":[0.00018215652,0.000097484575,0.00040401265,0.00040700502,0.0002499742,0.00017571093,0.000025805717,0.000256842,0.0000061060377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06913686,0.0034622613,0.8242419,0.00005260062,0.005284336,0.0011703129,0.00042691763,0.000031850483,0.00046711517,0.0000026318555,0.000033342152,0.09568989],"study_design_scores_gemma":[0.036807206,0.048452485,0.90953726,0.00028203498,0.0035322134,0.000011712248,0.00012463398,0.000023368264,0.00038112278,0.000011613229,0.0007313021,0.00010505361],"about_ca_topic_score_codex":0.00033486224,"about_ca_topic_score_gemma":0.0038218957,"teacher_disagreement_score":0.09558483,"about_ca_system_score_codex":0.000771862,"about_ca_system_score_gemma":0.0018286057,"threshold_uncertainty_score":0.45389208},"labels":[],"label_agreement":null},{"id":"W2589343245","doi":"10.1200/jco.2015.33.7_suppl.224","title":"Dose escalation of five-fraction SABR for prostate cancer: Biochemical outcome and toxicity comparison of two prospective trials.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; SABR volatility model; Urology; Radiation therapy; Prostate; Toxicity; Nuclear medicine; Cancer; Internal medicine; Surgery","score_opus":0.3731556804267076,"score_gpt":0.6109997615838767,"score_spread":0.2378440811571691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589343245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929509,0.0015391881,0.0002651625,0.0037245064,0.000487853,0.0008256774,0.000024987605,0.0000037373734,0.00017795604],"genre_scores_gemma":[0.9956631,0.0005448494,0.0029924838,0.000069224,0.0005462976,0.00001816929,0.000006621989,0.000008513077,0.00015071615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99650055,0.00034509835,0.0025303555,0.00014470977,0.00033564825,0.00014365611],"domain_scores_gemma":[0.99358535,0.0022721945,0.00252649,0.000088650806,0.0012461672,0.00028113945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005314713,0.000095905954,0.0020071035,0.00010761622,0.000019509924,0.000003883855,0.000059186546,0.000225749,0.000013212126],"category_scores_gemma":[0.0077097286,0.000059969276,0.00030351328,0.000111923844,0.00027741905,0.00009614612,0.000031274743,0.0004551811,4.5460158e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050351568,0.002209836,0.8663955,0.0001424356,0.00048026745,0.000009530358,0.0003881975,0.00003121905,0.009626254,0.000047897545,0.0025188737,0.06779846],"study_design_scores_gemma":[0.122126885,0.05822013,0.70395243,0.00041573375,0.001962322,0.00005753676,0.0010018563,0.0028804268,0.09978401,0.004773182,0.0046243593,0.00020109965],"about_ca_topic_score_codex":0.00006541018,"about_ca_topic_score_gemma":0.000022455826,"teacher_disagreement_score":0.16244301,"about_ca_system_score_codex":0.00028254636,"about_ca_system_score_gemma":0.0013015021,"threshold_uncertainty_score":0.9229822},"labels":[],"label_agreement":null},{"id":"W2589344089","doi":"10.1200/jco.2014.32.4_suppl.265","title":"Real-world corticosteroid utilization in prostate cancer patients treated with two new oral agents.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone acetate; Docetaxel; Prostate cancer; Prednisone; Internal medicine; Corticosteroid; Cancer; Clinical trial; Urology; Gastroenterology; Androgen deprivation therapy","score_opus":0.19438999630608111,"score_gpt":0.5148497195759574,"score_spread":0.32045972326987626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589344089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932661,0.00011404589,0.000014745344,0.0028348141,0.00033410985,0.00040066076,0.0000028661666,0.000008521846,0.0030241567],"genre_scores_gemma":[0.99272823,0.0018014959,0.00039184056,0.00079080864,0.00035416379,0.000008521897,0.00001997995,0.000020524252,0.0038844172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974193,0.00035784137,0.0013728419,0.0001841151,0.00038726832,0.00027866254],"domain_scores_gemma":[0.997724,0.00036952712,0.00088455324,0.00012472908,0.0004637523,0.0004334233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000981535,0.00012876731,0.00095372734,0.00021568051,0.000025098925,0.000010652641,0.00008911515,0.00010050619,0.00017162162],"category_scores_gemma":[0.0004972535,0.000074809235,0.000120528566,0.00033829876,0.00012577772,0.00012752345,0.000027267277,0.0005483209,0.000010012049],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01049467,0.001181862,0.8118322,0.000016004988,0.00013485162,0.0001830612,0.00007770931,0.000023606222,0.000020531066,0.00001118024,0.0024525712,0.17357175],"study_design_scores_gemma":[0.034188833,0.014844432,0.92419475,0.00021637377,0.00020112496,0.0000134809015,0.00001470672,0.00028308574,0.00015696722,0.000078211924,0.02573315,0.00007485812],"about_ca_topic_score_codex":0.00072934816,"about_ca_topic_score_gemma":0.0025820332,"teacher_disagreement_score":0.1734969,"about_ca_system_score_codex":0.00039231655,"about_ca_system_score_gemma":0.001589148,"threshold_uncertainty_score":0.30506322},"labels":[],"label_agreement":null},{"id":"W2589352431","doi":"10.1200/jco.2014.32.4_suppl.39","title":"Relationship between abiraterone exposure, prostate-specific antigen (PSA) kinetics, and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) .","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Abiraterone acetate; Prostate cancer; Medicine; Proportional hazards model; Prostate-specific antigen; Hazard ratio; Urology; Oncology; Internal medicine; Chemotherapy; Docetaxel; Prostate; Cancer; Survival analysis; Androgen deprivation therapy; Confidence interval","score_opus":0.1576559576015668,"score_gpt":0.432733376269414,"score_spread":0.2750774186678472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589352431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99511963,0.0007442808,0.0000335866,0.002811574,0.0003047451,0.00069430756,0.000035358196,0.000007610783,0.00024891103],"genre_scores_gemma":[0.9969211,0.0006077748,0.0016241192,0.00012947795,0.000343206,0.00001638035,0.0000428719,0.000029183506,0.00028585762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99617106,0.00069875474,0.0018503527,0.00029363506,0.00061497174,0.00037123784],"domain_scores_gemma":[0.99606043,0.0017249378,0.0010156865,0.00018472296,0.0006126619,0.0004015656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023497513,0.00020355228,0.001229041,0.00020624939,0.000063486754,0.000034551475,0.00010205986,0.00017479701,0.00004197259],"category_scores_gemma":[0.0007875879,0.00012917366,0.00010539797,0.00019670345,0.00031950168,0.00020821259,0.000036405116,0.0008220508,0.0000050533786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012011716,0.0009130065,0.97094744,0.00007601388,0.00019618424,0.00011438377,0.00023378378,0.000030838197,0.0001003391,0.000070643546,0.00022784127,0.0150778135],"study_design_scores_gemma":[0.02476741,0.020657487,0.94916236,0.00017347654,0.00017767813,0.0000058597752,0.000059607242,0.000009933048,0.000057272013,0.00040971732,0.004390508,0.00012868411],"about_ca_topic_score_codex":0.00007019036,"about_ca_topic_score_gemma":0.00025583195,"teacher_disagreement_score":0.02178507,"about_ca_system_score_codex":0.00024041285,"about_ca_system_score_gemma":0.000799333,"threshold_uncertainty_score":0.52675486},"labels":[],"label_agreement":null},{"id":"W2589363967","doi":"10.1200/jco.2016.34.2_suppl.27","title":"Patient reported outcomes in NRG Oncology/RTOG 0938, evaluating two ultrahypofractionated regimens (UHR) for prostate cancer (CaP).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grand River Hospital; Juravinski Cancer Centre; Centre Hospitalier de l’Université de Montréal; McMaster University","funders":"","keywords":"Medicine; Clinical endpoint; Prostate cancer; Urinary system; EPIC; Cyberknife; Internal medicine; Quality of life (healthcare); Colorectal cancer; Urology; Cancer; Radiation therapy; Randomized controlled trial; Oncology; Radiosurgery","score_opus":0.2779095632377782,"score_gpt":0.5904249112582566,"score_spread":0.31251534802047837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589363967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9401674,0.00065051054,0.000048720623,0.054863926,0.0019321782,0.0011971893,0.000021377757,0.000017415274,0.0011012531],"genre_scores_gemma":[0.9863193,0.0026198963,0.00373015,0.0020806734,0.00074127474,0.00019516799,0.000008743571,0.00003843738,0.004266372],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9944761,0.0006511844,0.0033841252,0.0003694113,0.00061057816,0.00050863315],"domain_scores_gemma":[0.98857456,0.006307228,0.0028712612,0.0002504099,0.0015753865,0.00042115926],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0057120193,0.00020364167,0.0017665897,0.00027514997,0.00007044484,0.000008367997,0.00012602624,0.0003876202,0.00022183405],"category_scores_gemma":[0.011858649,0.000106710024,0.00050578057,0.00021996185,0.00026984827,0.00018566436,0.000047849477,0.00085547153,0.000012068375],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022149542,0.0024177814,0.401512,0.00003235034,0.00093319255,0.0010930495,0.00025938766,0.000024181094,0.004628363,0.000021186504,0.00533966,0.5615893],"study_design_scores_gemma":[0.12578875,0.064955935,0.57625705,0.0009279613,0.0010818529,0.0007447423,0.00060868525,0.00027229372,0.0029057849,0.0026257655,0.22345886,0.0003723126],"about_ca_topic_score_codex":0.00012975564,"about_ca_topic_score_gemma":0.00021750516,"teacher_disagreement_score":0.561217,"about_ca_system_score_codex":0.0015175327,"about_ca_system_score_gemma":0.0062410384,"threshold_uncertainty_score":0.9993926},"labels":[],"label_agreement":null},{"id":"W2589376012","doi":"10.1200/jco.2015.33.7_suppl.212","title":"The impact of time to metastasis on survival in treatment-naïve prostate cancer patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Enzalutamide; Metastasis; Prostate cancer; Docetaxel; Oncology; Internal medicine; Cancer; Overall survival","score_opus":0.23055821605102628,"score_gpt":0.5569435287405887,"score_spread":0.32638531268956245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589376012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98912674,0.0005716127,4.1675318e-7,0.0063080383,0.00037413382,0.00045688808,0.000031324795,0.0000025041488,0.003128354],"genre_scores_gemma":[0.9949691,0.0017795011,0.00009112989,0.00015833967,0.00031608585,0.000018282024,0.000004955379,0.000015123404,0.0026474453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734694,0.0005123109,0.0012952611,0.00013219447,0.00043425852,0.0002790578],"domain_scores_gemma":[0.99634457,0.0015902878,0.000678103,0.00015629463,0.00070708786,0.000523642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024903135,0.00012664429,0.0011224753,0.00014356182,0.000023569082,0.000006942829,0.00012554233,0.00012045427,0.00011113341],"category_scores_gemma":[0.0021234793,0.000054202057,0.00042427596,0.00022933705,0.00014394867,0.00005411636,0.00003410402,0.00037307854,0.000053739877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04454531,0.004893521,0.5446721,0.000006100397,0.0011678193,0.00021746312,0.00041384733,0.00021816649,0.000048324397,0.0000061851338,0.011809884,0.3920013],"study_design_scores_gemma":[0.0344674,0.16284463,0.7601197,0.00012460577,0.0002916723,0.000013086908,0.00016930181,0.00006156238,0.00040017773,0.00018608927,0.04122024,0.00010154583],"about_ca_topic_score_codex":0.00040376972,"about_ca_topic_score_gemma":0.00012542555,"teacher_disagreement_score":0.39189976,"about_ca_system_score_codex":0.0010888238,"about_ca_system_score_gemma":0.0036308644,"threshold_uncertainty_score":0.6440998},"labels":[],"label_agreement":null},{"id":"W2589397571","doi":"10.1200/jco.2016.34.2_suppl.223","title":"Correlation of a novel whole blood RT-PCR assay measuring AR-V7 expression with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Circulating tumor cell; Internal medicine; Docetaxel; Oncology; Cancer; TMPRSS2; Androgen receptor; Clinical endpoint; Urology; Clinical trial; Metastasis; Disease","score_opus":0.12199367474308939,"score_gpt":0.42064032115494554,"score_spread":0.2986466464118561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589397571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99661875,0.00021134676,0.00023352636,0.0019696285,0.00013350842,0.0006561021,0.000042125925,0.000007728056,0.00012726268],"genre_scores_gemma":[0.9965578,0.00031538357,0.0020891216,0.000063236934,0.000057211175,0.00003893109,0.000009697351,0.000027339329,0.00084128435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965005,0.00038430968,0.0018053745,0.0002590042,0.0007302044,0.0003205978],"domain_scores_gemma":[0.9957678,0.0010077365,0.0017885591,0.00017887534,0.0009894073,0.00026765137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016292752,0.00021074124,0.0013642954,0.0003653218,0.000043077896,0.000010882069,0.00010414522,0.00014394049,0.000042424595],"category_scores_gemma":[0.00071693637,0.00009215766,0.00014096606,0.00036381814,0.00026741854,0.00030549243,0.000027455557,0.00045159145,0.000002406536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027004104,0.0042528817,0.9249232,0.000077854726,0.0007372288,0.00033010982,0.00024082593,0.00018866165,0.026313972,0.0000029898008,0.00003684275,0.01589132],"study_design_scores_gemma":[0.07055585,0.018605663,0.8979244,0.0017936513,0.00070049585,0.000039974682,0.00013259126,0.000075088254,0.00986371,0.000015044607,0.00015791292,0.00013561502],"about_ca_topic_score_codex":0.00013284748,"about_ca_topic_score_gemma":0.0005357005,"teacher_disagreement_score":0.043551747,"about_ca_system_score_codex":0.00028759977,"about_ca_system_score_gemma":0.0015668505,"threshold_uncertainty_score":0.37580803},"labels":[],"label_agreement":null},{"id":"W2589457793","doi":"10.1200/jco.2005.23.16_suppl.8106","title":"Quality of life findings from a multicenter, multinational, observational study of patients with metatstatic hormone-refractory prostate cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Observational study; Prostate cancer; Clinical trial; Physical therapy; Cancer; Palliative care; Internal medicine","score_opus":0.308537723253256,"score_gpt":0.5346520422855282,"score_spread":0.2261143190322722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589457793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960567,0.00095053227,0.000014000376,0.0020178598,0.00016710395,0.0006505212,0.000102559396,0.0000032548742,0.00003750933],"genre_scores_gemma":[0.9951195,0.00060487934,0.0035069236,0.0003806853,0.00019450171,0.000019130595,0.00003327442,0.000013294259,0.00012778271],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954771,0.0004729441,0.0026902386,0.00017910209,0.0010124218,0.00016819683],"domain_scores_gemma":[0.99226016,0.0028371653,0.002470212,0.0001418483,0.0020297363,0.0002608605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017500423,0.0001284948,0.0013436659,0.00013085258,0.000031153588,0.000004044114,0.00013783628,0.00012068765,0.0001614191],"category_scores_gemma":[0.0028862336,0.00007780423,0.00020414828,0.00015404879,0.00021639894,0.00021493724,0.000043152246,0.00051997375,0.000002130923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031041007,0.018669879,0.9288972,0.000044560667,0.0014990903,0.000013731458,0.001209408,0.00008117138,0.0002211768,0.0000049322653,0.00054575125,0.017772075],"study_design_scores_gemma":[0.04826394,0.014077054,0.93493545,0.00007037863,0.00032894546,3.5587556e-7,0.000522139,0.00012347825,0.000046344187,0.000022548638,0.001544436,0.00006493642],"about_ca_topic_score_codex":0.00026718693,"about_ca_topic_score_gemma":0.00022322501,"teacher_disagreement_score":0.01770714,"about_ca_system_score_codex":0.00021463205,"about_ca_system_score_gemma":0.0020406463,"threshold_uncertainty_score":0.3620019},"labels":[],"label_agreement":null},{"id":"W2589475321","doi":"10.1200/jco.2016.34.2_suppl.12","title":"Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Internal medicine; Oncology; Radiation therapy; Clinical endpoint; Clinical trial; Proportional hazards model; Cohort; Metastasis; Retrospective cohort study; Cancer; Surgery","score_opus":0.10732402568670935,"score_gpt":0.49120371076822966,"score_spread":0.3838796850815203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589475321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952217,0.0011487256,0.00012141478,0.0024089864,0.0002296246,0.0007955987,0.000014097785,0.000003149365,0.00005675037],"genre_scores_gemma":[0.9852649,0.012901795,0.0012621226,0.00009014937,0.00033705187,0.000009265121,0.0000018743948,0.000011008536,0.000121842364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99713206,0.00041286284,0.0019387607,0.00018036833,0.00015577358,0.00018017572],"domain_scores_gemma":[0.99137366,0.006845993,0.0011389661,0.00009775549,0.00027109575,0.00027250455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004669636,0.00008529046,0.0010698078,0.00013797659,0.000019677469,0.000003936433,0.000056566063,0.0002872199,0.000012007345],"category_scores_gemma":[0.005539798,0.00004607586,0.00019618537,0.00007600854,0.00036913413,0.00007237162,0.000032797296,0.00041645224,0.0000013225249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026209448,0.00052910135,0.6612335,0.000017247246,0.00031261906,0.000043328535,0.00004654815,2.1174563e-7,0.0002473998,0.000009521224,0.00014258467,0.3112085],"study_design_scores_gemma":[0.050065737,0.024385873,0.92172,0.00009916606,0.0003619551,0.00004304843,0.00001706571,0.000054342818,0.00006772551,0.00022963338,0.0029092524,0.00004618229],"about_ca_topic_score_codex":0.000039349146,"about_ca_topic_score_gemma":0.00003902388,"teacher_disagreement_score":0.3111623,"about_ca_system_score_codex":0.00010382919,"about_ca_system_score_gemma":0.00096940895,"threshold_uncertainty_score":0.6632056},"labels":[],"label_agreement":null},{"id":"W2589500480","doi":"10.1200/jco.2014.32.4_suppl.127","title":"Association of PTEN protein loss with upgrading of prostate cancer from biopsy to radical prostatectomy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; PTEN; Prostatectomy; Prostate cancer; Biopsy; Cancer; Prostate; Prostate-specific antigen; Prostate biopsy; Oncology; Internal medicine; Urology; Pathology; Biology","score_opus":0.06205925677674814,"score_gpt":0.4518105693286346,"score_spread":0.3897513125518865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589500480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98430336,0.00024261478,0.00011841325,0.013919408,0.00023932934,0.00066280714,0.000027047194,0.0000061948926,0.00048082587],"genre_scores_gemma":[0.99292475,0.00028423924,0.0049826982,0.00022006118,0.00055698387,0.000026316478,0.0000052969554,0.00001893022,0.0009807379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967555,0.00040767112,0.0016780127,0.00018928615,0.00069354585,0.00027603147],"domain_scores_gemma":[0.9954387,0.0010555827,0.0020195849,0.00015426989,0.0009536605,0.00037817948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002874656,0.00012563897,0.0014245403,0.0001601322,0.000025225681,0.000005788816,0.00013981064,0.00026266254,0.00009702537],"category_scores_gemma":[0.0024733155,0.00007382732,0.0002251443,0.0002698969,0.00022461762,0.00008170059,0.000041144114,0.00066276325,0.0000044598987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030675534,0.0018864613,0.8594561,0.00017994919,0.0015054919,0.00023468514,0.0005247426,0.000027255817,0.015848847,0.00007300404,0.0014427451,0.08814518],"study_design_scores_gemma":[0.05427177,0.06467992,0.76234126,0.0026852926,0.0013804176,0.00010007163,0.00026840437,0.00025077135,0.06097991,0.0015586795,0.051165137,0.0003183568],"about_ca_topic_score_codex":0.00018232036,"about_ca_topic_score_gemma":0.000049357546,"teacher_disagreement_score":0.09711484,"about_ca_system_score_codex":0.00035700042,"about_ca_system_score_gemma":0.0017857456,"threshold_uncertainty_score":0.3167836},"labels":[],"label_agreement":null},{"id":"W2589518626","doi":"10.5489/cuaj.4303","title":"Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer","year":2017,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université Laval; Centre Hospitalier de l’Université de Montréal; Hôtel-Dieu de Québec; University of British Columbia; University of Ottawa; BC Cancer Agency; Ottawa Hospital; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Urological Association; Sanofi; AstraZeneca; Pfizer","keywords":"Prostate cancer; Testosterone (patch); Medicine; Oncology; Prostate; Cancer; Internal medicine; Urology","score_opus":0.10801808483072312,"score_gpt":0.3880615672728403,"score_spread":0.2800434824421172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589518626","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00086078705,0.9926508,3.1017933e-7,0.004540828,0.00017307252,0.0010549861,0.00014736524,0.0000028077168,0.0005690139],"genre_scores_gemma":[0.0018763859,0.99686795,0.00005463525,0.00011079504,0.000090658374,0.00013417072,0.00006108189,0.000012576106,0.0007917416],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981,0.00034780856,0.0004815716,0.00020873238,0.00043174363,0.00043015758],"domain_scores_gemma":[0.99871254,0.0001248479,0.00059738825,0.00017035886,0.00010372298,0.0002911209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011291173,0.00020146392,0.00085145334,0.00023993065,0.00019739695,0.0000940272,0.0002161157,0.00015894511,0.00010973202],"category_scores_gemma":[0.00009494245,0.000102700375,0.00016363585,0.00014723802,0.00006493231,0.000059127564,0.00003994228,0.0008467326,0.0000054478596],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050120805,0.0000640948,0.0072947103,0.002366861,0.00045192713,0.0005730395,0.00013280987,2.3361596e-7,9.102334e-8,0.000020537414,0.0017383922,0.9873072],"study_design_scores_gemma":[0.0010805066,0.0003424776,0.024522265,0.005194545,0.001100839,0.00019683629,0.000060231472,0.0000034714515,1.2944123e-7,0.00012279773,0.96726274,0.000113176764],"about_ca_topic_score_codex":0.0004358943,"about_ca_topic_score_gemma":0.00032288986,"teacher_disagreement_score":0.987194,"about_ca_system_score_codex":0.0009877739,"about_ca_system_score_gemma":0.0007156622,"threshold_uncertainty_score":0.41879997},"labels":[],"label_agreement":null},{"id":"W2589537108","doi":"10.1200/jco.2015.33.7_suppl.173","title":"Validation of the Decipher prostate cancer classifier in intermediate to high-risk men treated with radical prostatectomy but without additional therapy upon PSA rise.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Cohort; Biochemical recurrence; Internal medicine; Oncology; Adjuvant therapy; Cumulative incidence; Androgen deprivation therapy; Cancer; Metastasis; Biomarker; Urology","score_opus":0.10952880917681386,"score_gpt":0.4525458447130599,"score_spread":0.3430170355362461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589537108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99190414,0.0002695092,0.000015847729,0.0057325517,0.00032004772,0.0009756979,0.00015353932,0.0000075449248,0.0006211167],"genre_scores_gemma":[0.996056,0.0012550273,0.00066930876,0.00037557737,0.0005033985,0.00011404567,0.00002881695,0.000026087546,0.0009717012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963628,0.00086526223,0.0014607031,0.00023600232,0.0007723442,0.0003028962],"domain_scores_gemma":[0.9964377,0.000782196,0.0012074222,0.00020074706,0.0008850946,0.00048679035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022509699,0.00017556331,0.0010421671,0.00018172589,0.000038562324,0.000011801484,0.00019726472,0.0002464836,0.00043206164],"category_scores_gemma":[0.0012266386,0.000082606675,0.00018951912,0.00037979914,0.0004020596,0.00013502516,0.00005314583,0.001000471,0.000009023395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06480932,0.0016905494,0.8537526,0.000018801524,0.00059737574,0.00022247434,0.0004917829,0.00017271745,0.0003765188,0.000012420743,0.012800025,0.06505541],"study_design_scores_gemma":[0.041842345,0.018773673,0.90429044,0.00049243186,0.00023417313,0.0000725192,0.000286073,0.0001441726,0.0053416756,0.00043258147,0.02795304,0.00013686574],"about_ca_topic_score_codex":0.00025408296,"about_ca_topic_score_gemma":0.00015830487,"teacher_disagreement_score":0.06491854,"about_ca_system_score_codex":0.0005194208,"about_ca_system_score_gemma":0.004045915,"threshold_uncertainty_score":0.7177279},"labels":[],"label_agreement":null},{"id":"W2589548433","doi":"10.1200/jco.2013.31.6_suppl.88","title":"Association of declining PSA values with a lower risk of progression in the Canary Prostate Cancer Active Surveillance Study (PASS).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Tumor progression; Internal medicine; Oncology; Prostate biopsy; Cancer; Biopsy","score_opus":0.07824628479789668,"score_gpt":0.5009006886177039,"score_spread":0.4226544038198072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589548433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918155,0.00052291667,0.0000018636404,0.0061427,0.00023019224,0.00094608724,0.000008277141,0.0000021790643,0.0003303046],"genre_scores_gemma":[0.99719256,0.0019514732,0.00025148122,0.00010570967,0.00019991897,0.000046549776,0.0000014512591,0.00000905242,0.00024181811],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961978,0.0014917077,0.0012931256,0.0001362113,0.00067502167,0.00020613408],"domain_scores_gemma":[0.9926256,0.003118751,0.0028699148,0.0001365579,0.0011429735,0.00010623758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060367873,0.00009741211,0.0010159806,0.000104359664,0.00003183687,0.0000053631575,0.00013519356,0.00016025096,0.00005998838],"category_scores_gemma":[0.0026688536,0.00004427116,0.00014682476,0.00025857685,0.00015632714,0.000114413735,0.00003117561,0.00092175073,0.0000011180122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009275573,0.0029777368,0.92689043,0.000026475182,0.0007540028,0.00012310526,0.0017605203,0.000024718489,0.000039032013,4.956933e-7,0.001178207,0.0569497],"study_design_scores_gemma":[0.010104863,0.025520913,0.9607564,0.00023656746,0.00024111367,0.000009295454,0.0025050049,0.000073371215,0.0000695536,0.000079997815,0.00035956962,0.00004331361],"about_ca_topic_score_codex":0.0012115673,"about_ca_topic_score_gemma":0.0021766592,"teacher_disagreement_score":0.05690639,"about_ca_system_score_codex":0.00028806966,"about_ca_system_score_gemma":0.0018636667,"threshold_uncertainty_score":0.40045998},"labels":[],"label_agreement":null},{"id":"W2589561739","doi":"10.1200/jco.2014.32.4_suppl.61","title":"Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Internal medicine; Cancer; Progression-free survival; Chemotherapy; Oncology; Urology; Androgen deprivation therapy","score_opus":0.1297104336152411,"score_gpt":0.47866846514905964,"score_spread":0.34895803153381855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589561739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9571364,0.0012708337,0.000028158198,0.038520858,0.0004088713,0.0007720591,0.000013384656,0.000009173294,0.0018402473],"genre_scores_gemma":[0.9921252,0.0032299878,0.00049604394,0.0008867819,0.00045049694,0.00010963225,0.0000050013364,0.000026383785,0.0026704727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961327,0.00074445934,0.0016503095,0.00030731162,0.0006746325,0.0004905967],"domain_scores_gemma":[0.9969392,0.00077011413,0.0011578714,0.0002536034,0.00051352207,0.00036570433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002478074,0.00022110755,0.0012257572,0.000118081734,0.000095624186,0.000037365153,0.00026890368,0.00013758618,0.00025400537],"category_scores_gemma":[0.00038526402,0.00010503505,0.00016741705,0.0002983986,0.00052927085,0.00019838254,0.000053873147,0.00094173267,0.0000057128277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10147564,0.0041515646,0.57214344,0.00047372334,0.002730332,0.003743756,0.012845394,0.002607769,0.0048189084,0.00054190453,0.00818552,0.28628203],"study_design_scores_gemma":[0.05076291,0.011715632,0.8683192,0.00093945494,0.0008373631,0.00016510922,0.0036379558,0.0019248087,0.0020533348,0.0005271835,0.058735464,0.00038154054],"about_ca_topic_score_codex":0.00070511823,"about_ca_topic_score_gemma":0.003868643,"teacher_disagreement_score":0.29617578,"about_ca_system_score_codex":0.0004288984,"about_ca_system_score_gemma":0.0027851174,"threshold_uncertainty_score":0.49406785},"labels":[],"label_agreement":null},{"id":"W2589592541","doi":"10.1200/jco.2013.31.6_suppl.77","title":"Population-based impact on overall survival (OS) after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer (CRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Hazard ratio; Internal medicine; Cohort; Population; Oncology; Radiation therapy; Confidence interval; Cancer; Surgery","score_opus":0.10817203860025536,"score_gpt":0.5104333920947581,"score_spread":0.40226135349450276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589592541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9639553,0.0006909682,0.00005244866,0.033395454,0.00061457395,0.0011648347,0.000049907416,0.0000041669537,0.00007237318],"genre_scores_gemma":[0.9962517,0.00092819094,0.0006519911,0.0006038711,0.001085455,0.00009821219,0.000024281515,0.000017514734,0.00033876026],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99727464,0.00045775122,0.0013518876,0.00016603369,0.000527834,0.0002218479],"domain_scores_gemma":[0.99598354,0.0014625445,0.0011137298,0.00018234263,0.0010870425,0.00017079336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024453097,0.0001393097,0.00090480037,0.00010927859,0.000054145083,0.000021083182,0.000083640356,0.0001111652,0.0006372891],"category_scores_gemma":[0.00095372484,0.000064197106,0.00045129517,0.000109211025,0.00013389369,0.00013856537,0.000007581278,0.00043551618,0.000004241072],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5102644,0.00332635,0.25719988,0.00020959358,0.0027232664,0.000104034465,0.00039475478,0.001995714,0.0045222784,0.0002390222,0.017223164,0.20179754],"study_design_scores_gemma":[0.021104302,0.043481644,0.9234673,0.00009708678,0.00032578578,0.000019761983,0.00009119935,0.00028750146,0.0011891598,0.002207143,0.0076343636,0.000094782976],"about_ca_topic_score_codex":0.00048878015,"about_ca_topic_score_gemma":0.000108381064,"teacher_disagreement_score":0.6662674,"about_ca_system_score_codex":0.0003880172,"about_ca_system_score_gemma":0.0022539473,"threshold_uncertainty_score":0.69778687},"labels":[],"label_agreement":null},{"id":"W2589606552","doi":"10.5489/cuaj.4068","title":"Initial single-centre Canadian experience with 18F-fluoromethylcholine positron emission tomography-computed tomography (18F-FCH PET/ CT) for biochemical recurrence in prostate cancer patients initially treated with curative intent","year":2017,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Positron emission tomography; Prostatectomy; Nuclear medicine; Prostate-specific antigen; Radiology; Context (archaeology); Magnetic resonance imaging; Univariate analysis; Retrospective cohort study; Metastasis; Biochemical recurrence; Positron Emission Tomography-Computed Tomography; Bone metastasis; Prostate; Cancer; Surgery; Internal medicine; Multivariate analysis","score_opus":0.023590714572835722,"score_gpt":0.29348121915787795,"score_spread":0.2698905045850422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589606552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894337,0.0002385206,0.000007957982,0.0079862885,0.00014688227,0.0013505033,0.00044137103,0.000021513226,0.00037325648],"genre_scores_gemma":[0.9982425,0.00006710141,0.00026853493,0.00065218395,0.0001391326,0.00016512482,0.00031411968,0.00002793087,0.00012340254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971616,0.00016391955,0.0004579638,0.0005261115,0.0005663066,0.0011240704],"domain_scores_gemma":[0.99621135,0.00010988201,0.00047369578,0.00019099553,0.0013262684,0.0016878266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031762762,0.00034260785,0.00048173612,0.00064035173,0.0008307494,0.000313576,0.0002997557,0.000080016864,0.0000906359],"category_scores_gemma":[0.0004661047,0.00023238969,0.0001301156,0.0005393309,0.0002402968,0.00033490328,0.000027167822,0.0007832894,0.000001837915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018428348,0.00029239085,0.9919414,0.000015960597,0.00018272514,0.0013987048,0.0004987317,0.000006730952,0.0003110293,0.0000038002179,0.00089945534,0.0026062713],"study_design_scores_gemma":[0.010887924,0.0036067688,0.9772022,0.00062918826,0.00014099582,0.00027187876,0.00035342257,0.0002034955,0.0040559676,0.000054392083,0.0020936534,0.0005001541],"about_ca_topic_score_codex":0.043482855,"about_ca_topic_score_gemma":0.081625685,"teacher_disagreement_score":0.03814283,"about_ca_system_score_codex":0.0027794817,"about_ca_system_score_gemma":0.0018708339,"threshold_uncertainty_score":0.9628867},"labels":[],"label_agreement":null},{"id":"W2589737363","doi":"10.1200/jco.2014.32.4_suppl.30","title":"Using adjuvant radiotherapy to improve cancer-specific survival in patients with highly aggressive prostate cancer: Examining recently released criteria.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Internal medicine; Radiation therapy; Cancer; Adverse effect; Lymph node; Population; Proportional hazards model; Oncology","score_opus":0.13332308207713617,"score_gpt":0.4743767950744137,"score_spread":0.34105371299727755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589737363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902267,0.002388333,0.00010277233,0.004049557,0.0023427214,0.0007221621,0.000024103656,0.000009237568,0.00013445244],"genre_scores_gemma":[0.98527056,0.0075867972,0.0040974133,0.0011264114,0.0016332875,0.000033344928,0.0000074469845,0.00005212612,0.00019260359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961627,0.00067019084,0.0016673653,0.00037554034,0.0006178111,0.0005063534],"domain_scores_gemma":[0.99580765,0.00082229736,0.0016694542,0.00023087845,0.0008798371,0.0005898993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020099909,0.00022424076,0.0016841392,0.00025809454,0.000059484846,0.000023186849,0.00018206243,0.00023668437,0.00011689027],"category_scores_gemma":[0.0007446317,0.0001405958,0.0001438703,0.00033099653,0.00018785155,0.0001507829,0.000043428936,0.00089213107,0.0000025200197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037760705,0.0009684432,0.6102933,0.000042173386,0.00025770353,0.0003077352,0.00031951992,0.0000870793,0.0013155747,0.0000036605131,0.00065570703,0.3479884],"study_design_scores_gemma":[0.046472084,0.03173653,0.8837501,0.0012856919,0.00015463588,0.00001533318,0.00011762594,0.0003061687,0.0004682914,0.000023584704,0.035442628,0.00022735029],"about_ca_topic_score_codex":0.00024075159,"about_ca_topic_score_gemma":0.00015295608,"teacher_disagreement_score":0.34776103,"about_ca_system_score_codex":0.0011457668,"about_ca_system_score_gemma":0.0023096935,"threshold_uncertainty_score":0.5733331},"labels":[],"label_agreement":null},{"id":"W2589743040","doi":"10.5489/cuaj.3936","title":"Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: A prospective, longitudinal study","year":2017,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Lawrence College; Kingston General Hospital; Queen's University","funders":"Canadian Hemophilia Society; Prostate Cancer Canada","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Prospective cohort study; Hemostasis; Prostatectomy; Internal medicine; Cancer; Adverse effect; Thromboelastography; Oncology; Urology; Coagulation","score_opus":0.02644580744542849,"score_gpt":0.31304255457728863,"score_spread":0.2865967471318601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589743040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467397,0.00021589446,3.952523e-7,0.0033601844,0.0001446554,0.0013737212,0.000017794211,0.000006391274,0.00020697809],"genre_scores_gemma":[0.99920285,0.00028782475,0.000008595163,0.00016721986,0.00008803323,0.00009870837,0.000005364739,0.000008624699,0.00013279296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998584,0.00016182213,0.00026889,0.00022549347,0.0004169139,0.0003429244],"domain_scores_gemma":[0.99874383,0.00010369028,0.00029287892,0.00015262078,0.00043789748,0.00026905275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005373129,0.000120297824,0.0002945004,0.00016801569,0.00032255723,0.00006969692,0.00012425604,0.00009348722,0.00006528743],"category_scores_gemma":[0.0010364623,0.000082959436,0.00007128173,0.000121557976,0.000055487744,0.00013661629,0.000016012038,0.00042124698,0.0000043148575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073559565,0.0010311644,0.99237496,0.000010518699,0.000119687305,0.00007656379,0.00037040457,0.000004280048,0.000073078554,0.000009211643,0.00011633248,0.0050782007],"study_design_scores_gemma":[0.007825765,0.0024779574,0.9886384,0.000033156044,0.000026688938,0.0000023079176,0.000025693893,0.000008876861,0.0003745203,0.00030882258,0.00020497493,0.00007286063],"about_ca_topic_score_codex":0.0043468787,"about_ca_topic_score_gemma":0.0020620911,"teacher_disagreement_score":0.0070901695,"about_ca_system_score_codex":0.0018389731,"about_ca_system_score_gemma":0.00052600494,"threshold_uncertainty_score":0.65712094},"labels":[],"label_agreement":null},{"id":"W2589777133","doi":"10.1200/jco.2013.31.6_suppl.5","title":"Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Abiraterone acetate; Internal medicine; Prostate cancer; Interim analysis; Hazard ratio; Clinical endpoint; Prednisone; Placebo; Progression-free survival; Gastroenterology; Asymptomatic; Urology; Chemotherapy; Androgen deprivation therapy; Oncology; Population; Randomized controlled trial; Cancer; Confidence interval; Pathology","score_opus":0.08645765738220536,"score_gpt":0.4905051951186309,"score_spread":0.40404753773642554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589777133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949112,0.00024528085,0.00006360433,0.0009425765,0.00012041703,0.0036269159,0.00002239512,0.0000046429095,0.00006295252],"genre_scores_gemma":[0.9977916,0.00038944243,0.0010817068,0.0001479534,0.000044177832,0.00018509311,0.000020218751,0.000025313628,0.0003145051],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936103,0.0012112213,0.003825784,0.0002897031,0.00074937317,0.00031359165],"domain_scores_gemma":[0.9936492,0.0006269754,0.003487386,0.00026607464,0.0016822293,0.00028817082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00321367,0.000245814,0.004254531,0.00052683376,0.0000302063,0.000015378917,0.0001829142,0.00012404978,0.00053275283],"category_scores_gemma":[0.00042314976,0.0001364268,0.00042221305,0.00071898574,0.00048322915,0.00020890897,0.00003765364,0.0005804069,0.0000021932701],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7376649,0.024198376,0.1937487,0.00012723323,0.015107906,0.00019545882,0.0029563955,0.00018764264,0.0028582145,0.0000011962715,0.00014748907,0.022806514],"study_design_scores_gemma":[0.763641,0.041791253,0.18586175,0.00023357221,0.0051822215,0.0000075762473,0.0012344123,0.0007382163,0.001083268,0.00002346258,0.00006753142,0.00013574118],"about_ca_topic_score_codex":0.0010419482,"about_ca_topic_score_gemma":0.00097061205,"teacher_disagreement_score":0.025976118,"about_ca_system_score_codex":0.00023782792,"about_ca_system_score_gemma":0.0015061867,"threshold_uncertainty_score":0.583327},"labels":[],"label_agreement":null},{"id":"W2589842982","doi":"10.1200/jco.2016.34.2_suppl.234","title":"Pre-clinical rationale for combination PI3K and BRD4 inhibition in advanced prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"PI3K/AKT/mTOR pathway; LNCaP; Cancer research; Protein kinase B; In vivo; Apoptosis; Medicine; Prostate cancer; Oncogene; PTEN; Flow cytometry; Cell growth; Cancer; Biology; Internal medicine; Cell cycle; Immunology","score_opus":0.15111351480082363,"score_gpt":0.5444075210011432,"score_spread":0.39329400620031957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589842982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9573653,0.0008893275,0.00022529908,0.039965514,0.000584439,0.000735105,0.000012137866,0.000004695133,0.0002182086],"genre_scores_gemma":[0.9854805,0.009656559,0.0014404217,0.00073225005,0.0005453527,0.00006407676,0.00000728457,0.0000108444965,0.002062726],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975646,0.00024936307,0.0016265764,0.00017255622,0.0002144508,0.00017242227],"domain_scores_gemma":[0.9955466,0.002869172,0.0007736925,0.00007109263,0.00053120306,0.00020824815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031312604,0.0000785778,0.00072843937,0.00010433086,0.00002920529,0.000005553118,0.00003400552,0.0002146826,0.000049064463],"category_scores_gemma":[0.0032489246,0.000044105644,0.00016256687,0.00008009271,0.00022428308,0.00019280403,0.000023353876,0.00032857174,0.0000025810364],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022870792,0.0016722799,0.32454976,0.00006287529,0.00012775509,0.00011329679,0.000110041205,0.0000033075892,0.001246601,0.00028925834,0.0033234672,0.64563054],"study_design_scores_gemma":[0.06449042,0.024237435,0.8650188,0.0005240556,0.00011249128,0.00006798337,0.00006133527,0.00010820734,0.0008239317,0.006344951,0.03812077,0.00008963981],"about_ca_topic_score_codex":0.0000062329996,"about_ca_topic_score_gemma":0.00007047643,"teacher_disagreement_score":0.6455409,"about_ca_system_score_codex":0.00020131099,"about_ca_system_score_gemma":0.0014412144,"threshold_uncertainty_score":0.38895008},"labels":[],"label_agreement":null},{"id":"W2589956154","doi":"10.1200/jco.2016.34.2_suppl.3","title":"NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Urology; Bicalutamide; Prostate cancer; Prostatectomy; Internal medicine; Placebo; Hazard ratio; Salvage therapy; Clinical endpoint; Prostate; Androgen suppression; Radiation therapy; Randomized controlled trial; Oncology; Cancer; Chemotherapy; Confidence interval; Androgen receptor; Pathology","score_opus":0.05486591700445969,"score_gpt":0.45553566449555205,"score_spread":0.40066974749109235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589956154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907966,0.0031291174,0.000007817772,0.0036468278,0.00036320894,0.0019893236,0.000017678554,0.00001870654,0.000030699062],"genre_scores_gemma":[0.9709897,0.027350549,0.0001950603,0.0005938818,0.0005905064,0.00015281905,0.000009161156,0.000041227948,0.00007711044],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958533,0.0008630195,0.0017891991,0.00046136664,0.00051241694,0.0005207],"domain_scores_gemma":[0.997156,0.0008929103,0.0008935914,0.00017579312,0.0002768352,0.00060486054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023774898,0.00028008167,0.0016329841,0.00030702743,0.00008549045,0.000028970113,0.0001098169,0.00038228554,0.00007826059],"category_scores_gemma":[0.0004501274,0.0001406564,0.00020523336,0.00026162318,0.0004911705,0.00044431124,0.000040463918,0.0007806525,0.0000013586747],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36331472,0.0035000825,0.40888903,0.000016493626,0.00052210636,0.0011185522,0.00042054444,5.4743333e-7,0.0029998543,0.0000013129699,0.00003307616,0.2191837],"study_design_scores_gemma":[0.57799226,0.055085495,0.3586178,0.00028518014,0.00015372098,0.000086305845,0.00006171966,0.000026335461,0.002030894,0.00007660022,0.005392163,0.00019151579],"about_ca_topic_score_codex":0.000048762988,"about_ca_topic_score_gemma":0.000066999324,"teacher_disagreement_score":0.21899219,"about_ca_system_score_codex":0.0004816255,"about_ca_system_score_gemma":0.0019017896,"threshold_uncertainty_score":0.57358015},"labels":[],"label_agreement":null},{"id":"W2589967630","doi":"10.1200/jco.2013.31.6_suppl.113","title":"A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Sunnybrook Health Science Centre; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Docetaxel; Internal medicine; Prostate cancer; Population; Surgery; Cancer; Gastroenterology; Androgen deprivation therapy","score_opus":0.08306378935611403,"score_gpt":0.45138472523179707,"score_spread":0.36832093587568304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589967630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951219,0.00011151404,0.000025525504,0.0036248895,0.00013824878,0.0009023004,0.000006017338,0.000005535993,0.00006408425],"genre_scores_gemma":[0.99529856,0.00006285288,0.003692127,0.0005044865,0.00006766654,0.00008729937,0.000016169517,0.000018142147,0.00025269674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749047,0.00026850012,0.0012423053,0.00020242977,0.0005131897,0.00028309866],"domain_scores_gemma":[0.99767214,0.0002859606,0.00088783767,0.00013987508,0.0007427892,0.00027140704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005860813,0.00014470573,0.0007856959,0.00014700505,0.000037602345,0.000022745013,0.000079480684,0.00008241539,0.0001949229],"category_scores_gemma":[0.00023156535,0.00007509827,0.00007823774,0.00019481551,0.00016272868,0.0002985037,0.000012484864,0.00046956056,0.0000075761636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025677446,0.0015227692,0.95689255,0.00005190355,0.00016015813,0.0002390844,0.00035244992,0.00024981025,0.00013696976,0.0000016118552,0.000091018956,0.0146242175],"study_design_scores_gemma":[0.02993195,0.012376383,0.95623195,0.0003056049,0.00012855181,0.0000060073353,0.00018531558,0.00034404837,0.000137633,0.000014411409,0.0002521089,0.000086051776],"about_ca_topic_score_codex":0.0005705537,"about_ca_topic_score_gemma":0.00076602586,"teacher_disagreement_score":0.014538166,"about_ca_system_score_codex":0.0003415564,"about_ca_system_score_gemma":0.0012020434,"threshold_uncertainty_score":0.30624187},"labels":[],"label_agreement":null},{"id":"W2590021364","doi":"10.1200/jco.2012.30.5_suppl.66","title":"The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-cre PTEN knockout mice.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"PTEN; Endocrinology; Prostate; Cancer research; Growth factor; Internal medicine; Prostate cancer; Dysplasia; Insulin-like growth factor; Medicine; Biology; PI3K/AKT/mTOR pathway; Signal transduction; Cancer; Receptor; Cell biology","score_opus":0.08181889710047036,"score_gpt":0.4420071836591098,"score_spread":0.36018828655863944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590021364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883267,0.0038713145,0.0000039936076,0.005204581,0.00055765733,0.0004307461,0.00000816419,0.00000601921,0.0015907878],"genre_scores_gemma":[0.9916307,0.0068089752,0.00032065788,0.0006174556,0.00034834092,0.000011106977,0.0000019353356,0.000018081051,0.0002427989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959926,0.0005495604,0.0020900047,0.0001778282,0.00064656243,0.0005434262],"domain_scores_gemma":[0.99332494,0.0041500805,0.0012161859,0.00020030132,0.0006552459,0.00045324926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032392214,0.00017869943,0.0010705226,0.00019909833,0.00007556261,0.000009581056,0.0003159473,0.00030381334,0.000020472824],"category_scores_gemma":[0.0049252254,0.00009334737,0.00029484776,0.00031443394,0.0006080061,0.00017498317,0.00007345472,0.0013536421,0.000032894968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028069448,0.00749916,0.9162357,0.0002532334,0.0005012941,0.00058675464,0.0023323237,0.000021877946,0.004859747,0.0016629887,0.002584494,0.03539297],"study_design_scores_gemma":[0.009225904,0.013760467,0.97200626,0.00019833459,0.00014318383,0.00013998998,0.00045159555,0.000022593358,0.0006014396,0.00092151196,0.002419289,0.000109459404],"about_ca_topic_score_codex":0.000042855267,"about_ca_topic_score_gemma":0.000017703489,"teacher_disagreement_score":0.05577052,"about_ca_system_score_codex":0.00030307414,"about_ca_system_score_gemma":0.0015768759,"threshold_uncertainty_score":0.589631},"labels":[],"label_agreement":null},{"id":"W2590038753","doi":"10.1200/jco.2016.34.2_suppl.191","title":"Integration of bone scan (BS) and computerized tomography (CT) findings as an endpoint to assess bone metastasis in metastatic castration-resistant prostate cancer (mCRPC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Bone metastasis; Proportional hazards model; Metastasis; Oncology; Clinical endpoint; Internal medicine; Cancer; Radiology; Urology; Clinical trial","score_opus":0.18147378967777789,"score_gpt":0.5010028006530577,"score_spread":0.3195290109752798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590038753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98755723,0.00062563707,0.00029089153,0.010548979,0.00026906215,0.0005602571,0.000049643935,0.0000061411215,0.00009213527],"genre_scores_gemma":[0.98509675,0.001873306,0.012284413,0.0004164404,0.0001278255,0.000030573854,0.0000073680817,0.000016300812,0.00014702327],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99622416,0.00057487295,0.0021763786,0.00027010817,0.00047094177,0.00028355457],"domain_scores_gemma":[0.9967632,0.0010922775,0.0009190335,0.00016501339,0.0005608404,0.00049959496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035363247,0.00017153377,0.001549394,0.0005469822,0.000035716595,0.000020676458,0.00009502258,0.000086186024,0.00012879382],"category_scores_gemma":[0.0010258529,0.000095437674,0.00024472334,0.00037063257,0.00026537888,0.0002812404,0.00004860852,0.0003903084,0.000002109429],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039515506,0.0031358958,0.05696728,0.00019241024,0.0010440339,0.0027386055,0.0010016329,0.000009151781,0.26088545,0.00042052474,0.00066305033,0.6334264],"study_design_scores_gemma":[0.037456542,0.041149583,0.8804381,0.0014729754,0.00095558626,0.0005897608,0.0011607859,0.00011975105,0.027686292,0.0019376588,0.0067227613,0.0003102064],"about_ca_topic_score_codex":0.00031868787,"about_ca_topic_score_gemma":0.0009788993,"teacher_disagreement_score":0.82347083,"about_ca_system_score_codex":0.00025991525,"about_ca_system_score_gemma":0.0015803309,"threshold_uncertainty_score":0.38918352},"labels":[],"label_agreement":null},{"id":"W2590061441","doi":"10.1200/jco.2016.34.2_suppl.200","title":"Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Leuprorelin; Prostate cancer; Clinical endpoint; Urology; Gonadotropin-releasing hormone antagonist; Internal medicine; Interim analysis; Hormone antagonist; Prostate-specific antigen; Testosterone (patch); Prostate; Pharmacokinetics; Antagonist; Gastroenterology; Cancer; Randomized controlled trial; Gonadotropin-releasing hormone; Hormone; Luteinizing hormone; Receptor","score_opus":0.18046994721721318,"score_gpt":0.5432057560749756,"score_spread":0.36273580885776235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590061441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99325645,0.00019968324,0.00001016645,0.0040664184,0.00089458853,0.00048672938,0.0006264169,0.000005019465,0.0004545221],"genre_scores_gemma":[0.9961113,0.0013828556,0.00031737474,0.00029650948,0.00068427797,0.000014068296,0.0000752307,0.000015621808,0.0011028157],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99472386,0.0007054908,0.0034078318,0.00033638807,0.00049437786,0.00033207663],"domain_scores_gemma":[0.9952548,0.0011901059,0.0021264227,0.0002814774,0.00067979447,0.0004673808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027713762,0.00017187568,0.0020778184,0.0004075906,0.0000374617,0.0000087749595,0.00022223692,0.00027588077,0.0008334969],"category_scores_gemma":[0.0020668628,0.00009191028,0.0005732307,0.00041376648,0.0003544929,0.00023230189,0.00009377106,0.000598174,0.000004306396],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61432827,0.018513598,0.0984608,0.000014535417,0.002038322,0.000524691,0.0005763507,0.0000026283735,0.0011584294,0.0000023418431,0.0019474921,0.26243252],"study_design_scores_gemma":[0.67982364,0.14871573,0.13777235,0.00026474087,0.0015320914,0.0000061714604,0.00012690248,0.00009486132,0.0016030916,0.00020659706,0.02969211,0.00016173815],"about_ca_topic_score_codex":0.00036506323,"about_ca_topic_score_gemma":0.0017421381,"teacher_disagreement_score":0.26227078,"about_ca_system_score_codex":0.00039766365,"about_ca_system_score_gemma":0.002011295,"threshold_uncertainty_score":0.91262066},"labels":[],"label_agreement":null},{"id":"W2590128314","doi":"10.1200/jco.2016.34.2_suppl.192","title":"Combined Akt and MEK pathway blockade in pre-clinical models of enzalutamide-resistant prostate cancer.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Protein kinase B; LNCaP; Prostate cancer; Cancer research; Enzalutamide; PTEN; Medicine; Androgen receptor; PI3K/AKT/mTOR pathway; Growth inhibition; Apoptosis; Cell growth; Cancer; Internal medicine; Chemistry; Biochemistry","score_opus":0.1586946210047408,"score_gpt":0.4948424818601984,"score_spread":0.3361478608554576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590128314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801315,0.0029608577,0.000029414106,0.015221567,0.00052534364,0.00044813476,0.00002724158,0.0000065031295,0.00064943597],"genre_scores_gemma":[0.9794668,0.017461697,0.00069209526,0.0003493019,0.000379975,0.000015303458,0.0000011725672,0.000019633797,0.0016140209],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948038,0.000693026,0.0033969441,0.0002782777,0.00047033664,0.00035761515],"domain_scores_gemma":[0.9935674,0.0037020275,0.0014749689,0.00021444468,0.0005190608,0.0005220642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049620443,0.00016317973,0.0019370224,0.00017565252,0.00002450029,0.0000054371294,0.00016738202,0.00039985383,0.00008681918],"category_scores_gemma":[0.0023506812,0.00008450343,0.00035159453,0.00015891851,0.0007235496,0.00014863884,0.00009837726,0.0007962391,0.000002685725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09374927,0.0059383023,0.5403091,0.00020489353,0.0009625931,0.0017109435,0.00052896026,0.000023846214,0.007243783,0.0003650111,0.0018248707,0.34713846],"study_design_scores_gemma":[0.09035021,0.07350333,0.8028467,0.0019299457,0.00049827783,0.000114630064,0.00015653328,0.00041588832,0.004846151,0.0116391415,0.013425918,0.00027325208],"about_ca_topic_score_codex":0.000098192024,"about_ca_topic_score_gemma":0.00016758744,"teacher_disagreement_score":0.3468652,"about_ca_system_score_codex":0.00020155167,"about_ca_system_score_gemma":0.0032737649,"threshold_uncertainty_score":0.58075184},"labels":[],"label_agreement":null},{"id":"W2590130898","doi":"10.1200/jco.2012.30.5_suppl.11","title":"TMPRSS2-ERG status and biochemical recurrence following radiotherapy for intermediate-risk prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erg; TMPRSS2; Medicine; Prostate cancer; Tissue microarray; Prostate; Oncology; Immunohistochemistry; Radiation therapy; Internal medicine; Cancer; Ophthalmology","score_opus":0.11334181556799748,"score_gpt":0.5202996541605988,"score_spread":0.40695783859260126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590130898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9586335,0.035404865,0.00010987145,0.00295937,0.002321317,0.00044180613,0.000021237855,0.000007771582,0.00010025629],"genre_scores_gemma":[0.9345632,0.058525674,0.0039937124,0.00045576438,0.0021294323,0.00003440898,0.000006232241,0.000020832682,0.00027069618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757034,0.00021304884,0.0012708715,0.00016948114,0.0002600262,0.00051624473],"domain_scores_gemma":[0.99584895,0.0021731528,0.000851748,0.00011211263,0.00023634864,0.0007777128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029078862,0.00013705202,0.0010277523,0.00009640245,0.000056156157,0.00001109962,0.00009105804,0.0002591745,0.00003846953],"category_scores_gemma":[0.003022151,0.00008624162,0.00039572554,0.000102382146,0.00025898663,0.00016373266,0.000037025013,0.0007886446,0.0000018147829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008385697,0.00069481344,0.6503942,0.00005655084,0.0006677202,0.00004551465,0.00046971376,5.6329054e-7,0.0007091019,0.000012291382,0.0055045765,0.33305928],"study_design_scores_gemma":[0.046828132,0.030572204,0.52959985,0.0005444706,0.0012129782,0.00015372696,0.00046153358,0.0002267105,0.0026204484,0.00048523987,0.38697982,0.00031488022],"about_ca_topic_score_codex":0.000021557522,"about_ca_topic_score_gemma":0.000005097425,"teacher_disagreement_score":0.38147524,"about_ca_system_score_codex":0.00027392257,"about_ca_system_score_gemma":0.0013286036,"threshold_uncertainty_score":0.36180153},"labels":[],"label_agreement":null},{"id":"W2590157633","doi":"10.1200/jco.2013.31.15_suppl.e16068","title":"Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) refractory to docetaxel (D).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Internal medicine; Abiraterone acetate; Ketoconazole; Oncology; Refractory (planetary science); Progression-free survival; Urology; Cancer; Chemotherapy; Androgen deprivation therapy","score_opus":0.18282704748474443,"score_gpt":0.5120465585913472,"score_spread":0.32921951110660275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590157633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382675,0.00045086225,0.000007942199,0.003408921,0.0004596451,0.001215201,0.0000144254755,0.0000050402086,0.0006112178],"genre_scores_gemma":[0.9969669,0.00040674084,0.0017563928,0.00021584466,0.00012589326,0.000073178126,0.000010743404,0.000021001335,0.00042333058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961128,0.00040193947,0.0022682573,0.00023090112,0.0006316347,0.00035443073],"domain_scores_gemma":[0.9961142,0.0007028615,0.0014888266,0.00019238409,0.0010779948,0.00042371775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012815079,0.00017794385,0.0015520852,0.0002383474,0.000032100397,0.00001514749,0.0001412494,0.00014219058,0.00025106015],"category_scores_gemma":[0.00051838986,0.00010890221,0.00014846094,0.0002687835,0.00021143236,0.00025861876,0.00003380537,0.000773474,0.000025387275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13189028,0.007345071,0.6941115,0.00023959515,0.001039778,0.00026205435,0.0014651483,0.00034107052,0.0038778458,0.000013959766,0.0037855443,0.15562816],"study_design_scores_gemma":[0.049096253,0.054705065,0.88808507,0.00034831106,0.00032790808,0.0000058366986,0.0005647029,0.000093612114,0.0014967121,0.000038509515,0.0051051374,0.00013288314],"about_ca_topic_score_codex":0.00036977537,"about_ca_topic_score_gemma":0.00073990837,"teacher_disagreement_score":0.19397357,"about_ca_system_score_codex":0.00051549403,"about_ca_system_score_gemma":0.0019775669,"threshold_uncertainty_score":0.4440903},"labels":[],"label_agreement":null},{"id":"W2590191068","doi":"10.1200/jco.2016.34.2_suppl.106","title":"Development and validation of an ADT resistance signature to predict adjuvant hormone treatment failure.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Cohort; Gene signature; Adjuvant; Enzalutamide; Logistic regression; Metastasis; Cancer; Adjuvant therapy; Androgen receptor; Gene expression; Gene; Biology","score_opus":0.1027191597097351,"score_gpt":0.45533432049334854,"score_spread":0.35261516078361343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590191068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865895,0.0011851608,0.00013498018,0.011178698,0.00017327041,0.00028443718,0.000008447104,0.000004941222,0.0004405724],"genre_scores_gemma":[0.977505,0.0015640119,0.018486982,0.00018131884,0.0004122473,0.000009671704,0.0000043579957,0.000009960488,0.0018264501],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979571,0.00018560908,0.0011731895,0.0001690823,0.00034128618,0.0001737355],"domain_scores_gemma":[0.9978447,0.0005958254,0.00057595456,0.00013842757,0.00038093087,0.0004641445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013460811,0.0001056032,0.0008275774,0.000117429976,0.000029223947,0.0000040529835,0.000077673765,0.00021207651,0.00004101987],"category_scores_gemma":[0.0006766219,0.000050253297,0.000112659196,0.000089304456,0.000116680305,0.0001050106,0.000027321823,0.00019005725,0.000005421327],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031713597,0.0031887747,0.028820666,0.000053102303,0.0009023533,0.0007899421,0.00084226835,0.00000220553,0.03285868,0.00008373993,0.0069762664,0.8937684],"study_design_scores_gemma":[0.030292954,0.051292967,0.41601202,0.0005091474,0.00038524988,0.00011940951,0.00026904192,0.0000036735114,0.058053665,0.00030334463,0.44260576,0.0001527513],"about_ca_topic_score_codex":0.0000022388542,"about_ca_topic_score_gemma":0.00005448352,"teacher_disagreement_score":0.89361566,"about_ca_system_score_codex":0.0003007665,"about_ca_system_score_gemma":0.0014500805,"threshold_uncertainty_score":0.25723806},"labels":[],"label_agreement":null},{"id":"W2590244275","doi":"10.1200/jco.2013.31.6_suppl.16","title":"Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Docetaxel; Prostate cancer; Internal medicine; Tolerability; Oncology; Placebo; Androgen receptor; Cancer; Adverse effect; Alternative medicine","score_opus":0.09677433790762337,"score_gpt":0.4403547263729814,"score_spread":0.34358038846535804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590244275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9661481,0.00041967572,0.0000019476718,0.030404415,0.00027096958,0.0025009832,0.0001522682,0.0000076272454,0.0000940359],"genre_scores_gemma":[0.9971942,0.00041832597,0.0003528383,0.0007248566,0.00037574995,0.00017057608,0.00005833682,0.000024409706,0.00068070594],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959369,0.0007862508,0.0019448913,0.0002762511,0.00070684205,0.00034890193],"domain_scores_gemma":[0.99318427,0.003882818,0.0015643568,0.00028780743,0.0007982479,0.00028247983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017790423,0.0002275766,0.0012792267,0.0000658045,0.00010980415,0.00004873207,0.00020456495,0.00013837902,0.00018128013],"category_scores_gemma":[0.0010454829,0.00007903407,0.0001934672,0.00029423164,0.00040596433,0.00021489328,0.000028273098,0.0009821318,0.000011525844],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6918141,0.006821102,0.18011448,0.0000149407215,0.0022862449,0.00039156774,0.001463376,0.000025199737,0.00020299242,0.0000035305534,0.009065063,0.10779736],"study_design_scores_gemma":[0.62679064,0.07060729,0.2873681,0.00031114207,0.0009607846,0.000010865718,0.0012935412,0.000029226001,0.0003708317,0.000040800398,0.012036266,0.00018053259],"about_ca_topic_score_codex":0.0015949137,"about_ca_topic_score_gemma":0.0023314948,"teacher_disagreement_score":0.10761683,"about_ca_system_score_codex":0.0002793889,"about_ca_system_score_gemma":0.0020565917,"threshold_uncertainty_score":0.42669287},"labels":[],"label_agreement":null},{"id":"W2590305906","doi":"10.1016/j.euf.2017.02.007","title":"Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy","year":2017,"lang":"en","type":"article","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Systemic therapy; Tumour heterogeneity; Cancer; Biopsy; Positron emission tomography; Molecular imaging; Prostate; Targeted therapy; Systemic disease; Oncology; Internal medicine; Pathology; Radiology; Disease; In vivo; Breast cancer","score_opus":0.035696548314000126,"score_gpt":0.3448886157224765,"score_spread":0.3091920674084764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590305906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97973794,0.01322368,0.000020809792,0.0047932793,0.00027562724,0.0009165656,0.000085638894,0.000042829284,0.00090363115],"genre_scores_gemma":[0.99684185,0.0017844678,0.000093055714,0.00050130853,0.00010485919,0.00007392945,0.000005836464,0.000053568547,0.00054112996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774957,0.0007913671,0.00038109015,0.00042684368,0.00021991218,0.00043124956],"domain_scores_gemma":[0.9982984,0.00006250736,0.00025913838,0.00094950816,0.00021090044,0.00021952984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010317588,0.00020892301,0.00047472853,0.00022384987,0.00020266241,0.000038632534,0.00036218265,0.000028836626,0.000057982394],"category_scores_gemma":[0.00023915365,0.00015107071,0.00013474304,0.00009411253,0.00028386668,0.00008344953,0.00023491358,0.00019592319,0.00007815157],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023476742,0.00024719577,0.4976719,0.00007628705,0.0006510969,0.00065978896,0.0026839222,0.000012040594,0.24655725,0.00002711069,0.0011599466,0.22677673],"study_design_scores_gemma":[0.0051366524,0.0015827822,0.8613049,0.0001630904,0.00016749851,0.00013401204,0.00007001935,0.000017965052,0.11879377,0.000024523919,0.012388563,0.00021625623],"about_ca_topic_score_codex":0.00010545351,"about_ca_topic_score_gemma":0.000010223737,"teacher_disagreement_score":0.36363298,"about_ca_system_score_codex":0.00006088468,"about_ca_system_score_gemma":0.00010487016,"threshold_uncertainty_score":0.61604846},"labels":[],"label_agreement":null},{"id":"W2590316303","doi":"10.1200/jco.2013.31.6_suppl.60","title":"A genomic classifier independently prognostic of prostate cancer death in a high-risk surgical cohort.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Capra; Medicine; Concordance; Cohort; Prostate cancer; Hazard ratio; Prostatectomy; Oncology; Internal medicine; Proportional hazards model; Cancer; Confidence interval","score_opus":0.09709191774009196,"score_gpt":0.45492588546957213,"score_spread":0.3578339677294802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590316303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919789,0.0018456978,0.000003604277,0.0037233904,0.00051344204,0.0009296371,0.0000108494405,0.0000053346484,0.0009891887],"genre_scores_gemma":[0.9888327,0.0088152755,0.00049428915,0.0001720896,0.0005014659,0.00006923358,0.000003936384,0.000019555673,0.001091435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996002,0.000560042,0.0023188512,0.0002292162,0.00050992175,0.00037995545],"domain_scores_gemma":[0.9956271,0.0016754279,0.0014525296,0.0001694059,0.00063569855,0.0004398188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026246426,0.0001496389,0.0015931744,0.00023589948,0.000024494248,0.000010302959,0.00016810911,0.00039184437,0.0006228286],"category_scores_gemma":[0.0012816022,0.000091336406,0.00033477653,0.0002048907,0.0002748154,0.000121019155,0.00007561308,0.0014947752,0.000034041124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046253917,0.0015997704,0.9381304,0.000048053127,0.0005057899,0.0013396387,0.000093086004,0.000018193703,0.00008163256,0.000039458744,0.00078411464,0.0527345],"study_design_scores_gemma":[0.017180309,0.0077275946,0.96917427,0.00018002396,0.0003292406,0.00018224357,0.00006289165,0.00011784674,0.00008173355,0.00074602215,0.004136333,0.00008147898],"about_ca_topic_score_codex":0.0011350099,"about_ca_topic_score_gemma":0.00019993963,"teacher_disagreement_score":0.052653026,"about_ca_system_score_codex":0.00038005225,"about_ca_system_score_gemma":0.0033205352,"threshold_uncertainty_score":0.6819536},"labels":[],"label_agreement":null},{"id":"W2590328801","doi":"10.1200/jco.2015.33.7_suppl.9","title":"Molecular and clinical characterization of 1,577 primary prostate cancer tumors to reveal novel clinical and biological insights into its subtypes.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Prostate cancer; Prostatectomy; Medicine; Subtyping; Biochemical recurrence; Random forest; Gene expression profiling; Erg; Gene expression; Oncology; Computational biology; Gene; Internal medicine; Cancer; Biology; Genetics; Artificial intelligence","score_opus":0.18887667025605195,"score_gpt":0.4957003258065545,"score_spread":0.3068236555505025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590328801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871229,0.0020776393,0.000081514576,0.009062093,0.0008528754,0.000570698,0.000010060197,0.000008722972,0.00021351973],"genre_scores_gemma":[0.9838005,0.0099782245,0.0020858033,0.0029354095,0.00095630466,0.000010058943,0.000016015863,0.000020348125,0.00019734749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948309,0.0007459557,0.0033272274,0.00039469288,0.00043387417,0.0002673571],"domain_scores_gemma":[0.9950061,0.0011234145,0.0013322025,0.00017717083,0.0011156156,0.0012455202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053210896,0.00018606297,0.0020123634,0.00015788023,0.000033661927,0.0000120656,0.00014839698,0.0005767373,0.000012242042],"category_scores_gemma":[0.004989782,0.0001147711,0.00027335732,0.0002132849,0.0007770562,0.00013801073,0.00021445102,0.0010797527,0.0000051929305],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019094145,0.002368984,0.8460243,0.00009700383,0.00049739535,0.0006196259,0.00029215394,0.0000017601692,0.010308059,0.00008809627,0.000535161,0.12007332],"study_design_scores_gemma":[0.014103023,0.025151536,0.94335693,0.00025344617,0.00025356302,0.00012586954,0.000055930137,0.00005972617,0.000601726,0.0002146593,0.01568948,0.0001341382],"about_ca_topic_score_codex":0.000017873293,"about_ca_topic_score_gemma":0.000010312265,"teacher_disagreement_score":0.119939186,"about_ca_system_score_codex":0.00011961041,"about_ca_system_score_gemma":0.0027895174,"threshold_uncertainty_score":0.59735954},"labels":[],"label_agreement":null},{"id":"W2590413398","doi":"10.1200/jco.2013.31.6_suppl.153","title":"Results of a phase II study of sunitinib (SU) maintenance after response to docetaxel in metastatic castration-resistant prostate cancer (mCRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Medicine Hat College; BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Docetaxel; Prostate cancer; Clinical endpoint; Internal medicine; Adverse effect; Sunitinib; Oncology; Phases of clinical research; Progression-free survival; Urology; Clinical trial; Cancer; Chemotherapy","score_opus":0.1578829523383898,"score_gpt":0.5247198377054069,"score_spread":0.3668368853670171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590413398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871266,0.0004116474,0.0000034172044,0.010495137,0.00022366409,0.0014526171,0.000072704046,0.0000028796096,0.0002113307],"genre_scores_gemma":[0.99646133,0.00038505252,0.0010095765,0.00033752274,0.00010514932,0.00012164348,0.000002431606,0.000015341222,0.001561957],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9943078,0.0010715667,0.0034885933,0.00023275979,0.0005699608,0.00032931395],"domain_scores_gemma":[0.9943384,0.0020389257,0.0015564228,0.000262704,0.0014174897,0.00038607747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051699756,0.00015612566,0.0015690944,0.0003771708,0.000027051643,0.000008199127,0.00016268334,0.0001103412,0.00019507114],"category_scores_gemma":[0.00413253,0.000097738164,0.00021486645,0.00042903333,0.0002270837,0.0001479299,0.000060400314,0.0006303357,0.000005709403],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81483,0.03765571,0.027095398,0.00018948918,0.001193164,0.0043371315,0.009739073,0.00009579057,0.027123041,0.000010268322,0.004396567,0.073334344],"study_design_scores_gemma":[0.14553039,0.24178341,0.5936834,0.0008826369,0.00053621223,0.00008029929,0.006059794,0.000074333984,0.001688853,0.00017073871,0.009333178,0.00017675823],"about_ca_topic_score_codex":0.00084147917,"about_ca_topic_score_gemma":0.0011458986,"teacher_disagreement_score":0.66929966,"about_ca_system_score_codex":0.00022356994,"about_ca_system_score_gemma":0.0030666108,"threshold_uncertainty_score":0.5440036},"labels":[],"label_agreement":null},{"id":"W2590432301","doi":"10.1200/jco.2013.31.15_suppl.5033","title":"Validation of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Biochemical recurrence; breakpoint cluster region; Internal medicine; Proportional hazards model; Metastasis; Cohort; Oncology; Context (archaeology); Urology; Cancer","score_opus":0.11569438920027351,"score_gpt":0.4629404359793572,"score_spread":0.34724604677908366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590432301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98960996,0.0008932434,0.000031898868,0.007923311,0.00011696702,0.0009954388,0.000008156425,0.0000057590105,0.00041528195],"genre_scores_gemma":[0.9963616,0.00071481505,0.0024467648,0.00014443489,0.00014103102,0.000047415466,0.000022090877,0.0000142098725,0.00010762806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971215,0.00044621763,0.001364815,0.00021422068,0.0005838426,0.0002693908],"domain_scores_gemma":[0.99692255,0.00081592525,0.0009851704,0.00016548492,0.00051155005,0.0005993018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015701699,0.00013451492,0.00094830757,0.00019250678,0.000020301728,0.0000109917655,0.0001430468,0.0001348238,0.00016960272],"category_scores_gemma":[0.0013680703,0.000072552626,0.00017740083,0.00017374025,0.00052759814,0.0001878126,0.000053746786,0.00078241335,0.000012712037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06014676,0.008594826,0.7897411,0.00059042434,0.0007142961,0.0022297525,0.00036164845,0.000013045935,0.016086247,0.000038909817,0.0060977577,0.11538523],"study_design_scores_gemma":[0.02475869,0.019525629,0.94266135,0.0012022421,0.0004599241,0.00022602211,0.00022991924,0.00056484994,0.00840213,0.0005569645,0.0012731188,0.00013918514],"about_ca_topic_score_codex":0.00001381764,"about_ca_topic_score_gemma":0.0000013403417,"teacher_disagreement_score":0.15292022,"about_ca_system_score_codex":0.00020537105,"about_ca_system_score_gemma":0.002845639,"threshold_uncertainty_score":0.5048041},"labels":[],"label_agreement":null},{"id":"W2590605599","doi":"10.1200/jco.2016.34.2_suppl.213","title":"Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Placebo; Docetaxel; Internal medicine; Prostate cancer; Prednisone; Oncology; Enzalutamide; Clinical trial; Hypoalbuminemia; Cancer; Surgery; Pathology","score_opus":0.23265920659390768,"score_gpt":0.5383989148074215,"score_spread":0.3057397082135138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590605599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99677056,0.00066626765,0.000028206287,0.0015572339,0.0000713682,0.00044310826,0.00023938778,0.000002409632,0.00022145367],"genre_scores_gemma":[0.99750787,0.0017582999,0.00031622956,0.000035537272,0.00009283481,0.000010920554,0.000013173529,0.000011943207,0.00025318688],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99554574,0.0010275883,0.0024729818,0.00020225505,0.00051857845,0.00023286698],"domain_scores_gemma":[0.99408996,0.0025841931,0.0021304097,0.00017445175,0.00069875637,0.00032223467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004636686,0.0001589036,0.0027176666,0.0005002838,0.000021803638,0.000008738375,0.000088632616,0.0001044592,0.00019663615],"category_scores_gemma":[0.00149278,0.000071415765,0.00043111405,0.00034728998,0.00038981292,0.00016866124,0.000018990577,0.00024093139,2.2931245e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43016428,0.018952709,0.18454182,0.00014014865,0.023928631,0.0011079549,0.0021437916,0.00040568959,0.16048706,0.00006271322,0.0001871709,0.17787802],"study_design_scores_gemma":[0.105087586,0.17223996,0.7080608,0.0004515453,0.00707995,0.000028539176,0.0016285799,0.00028533646,0.0048359185,0.000077375786,0.00007888761,0.00014549983],"about_ca_topic_score_codex":0.0006648202,"about_ca_topic_score_gemma":0.0014949852,"teacher_disagreement_score":0.523519,"about_ca_system_score_codex":0.0003555582,"about_ca_system_score_gemma":0.0026022152,"threshold_uncertainty_score":0.4616218},"labels":[],"label_agreement":null},{"id":"W2590612794","doi":"10.1200/jco.2016.34.2_suppl.266","title":"Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Hazard ratio; Placebo; Prostate-specific antigen; Urology; Internal medicine; Proportional hazards model; Post-hoc analysis; Statistical significance; Oncology; Gynecology; Cancer; Confidence interval; Androgen receptor; Pathology","score_opus":0.1386197241547089,"score_gpt":0.4735383301453112,"score_spread":0.3349186059906023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590612794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834388,0.00069516647,0.00048557573,0.014090576,0.00037017514,0.00058931584,0.00005071235,0.0000066799125,0.00027298598],"genre_scores_gemma":[0.990307,0.004940767,0.0033851345,0.00029158912,0.00044805795,0.0000137634715,0.00001656382,0.000024572422,0.0005725797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961159,0.0003458654,0.0023809022,0.00029834957,0.00043583725,0.00042311146],"domain_scores_gemma":[0.99248445,0.004371549,0.0015100922,0.00027303078,0.0010002739,0.00036062291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046758205,0.00017945009,0.0023799317,0.0005494772,0.000027488384,0.00000858732,0.00021002139,0.00028681481,0.00015057612],"category_scores_gemma":[0.001742087,0.00008889413,0.000713051,0.00054653996,0.00035278834,0.00015266627,0.00006324679,0.00043254855,0.000003043475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09753368,0.0030131552,0.7914619,0.00005382416,0.0040293387,0.00039009535,0.000119360055,0.000029007679,0.010818538,0.00012750435,0.0008962442,0.09152738],"study_design_scores_gemma":[0.049595542,0.024517527,0.8770723,0.00021881882,0.0013583133,0.000023421291,0.000099038734,0.0002008832,0.0017531735,0.00039964588,0.04460099,0.00016037514],"about_ca_topic_score_codex":0.000048664693,"about_ca_topic_score_gemma":0.000540434,"teacher_disagreement_score":0.09136701,"about_ca_system_score_codex":0.000274327,"about_ca_system_score_gemma":0.0018975236,"threshold_uncertainty_score":0.36249974},"labels":[],"label_agreement":null},{"id":"W2590621732","doi":"10.1200/jco.2011.29.7_suppl.59","title":"Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"TMPRSS2; Prostate cancer; Medicine; Docetaxel; PCA3; Oncology; Internal medicine; Cytarabine; Cancer; Prostate; Mitoxantrone; Cancer research; Leukemia; Chemotherapy","score_opus":0.4058045400873943,"score_gpt":0.5760165026994505,"score_spread":0.17021196261205618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590621732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938072,0.0010953306,0.0000044950248,0.0031656285,0.00053760695,0.0012115747,0.000120465345,0.0000038023254,0.000053912325],"genre_scores_gemma":[0.98836243,0.009137691,0.0015546528,0.00036822935,0.00019811996,0.00005935862,0.00001010722,0.000016773603,0.00029261893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934254,0.0010350613,0.0044992245,0.00037637862,0.00029634574,0.00036758074],"domain_scores_gemma":[0.9952987,0.0011798425,0.002094744,0.00024314248,0.0006415593,0.0005420102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004687501,0.00020619907,0.0026347875,0.00083972345,0.000024968358,0.0000053513613,0.00014299645,0.00044385658,0.0002240534],"category_scores_gemma":[0.0026274624,0.00013955282,0.00034173785,0.0009889981,0.0007574417,0.00020828756,0.000103245075,0.0008751166,9.2833767e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1711747,0.005650754,0.6421304,0.0000608198,0.0013775678,0.0003294689,0.0013255253,0.000024737936,0.0032689688,0.0000067432056,0.00017156042,0.17447878],"study_design_scores_gemma":[0.14892296,0.059184134,0.78500116,0.0003088542,0.0012197489,0.000012409454,0.00014926266,0.00024187689,0.0018232751,0.00015684382,0.0028211349,0.00015831736],"about_ca_topic_score_codex":0.0020301477,"about_ca_topic_score_gemma":0.004489597,"teacher_disagreement_score":0.17432047,"about_ca_system_score_codex":0.00017846243,"about_ca_system_score_gemma":0.0034250559,"threshold_uncertainty_score":0.6075902},"labels":[],"label_agreement":null},{"id":"W2590639172","doi":"10.1200/jco.2014.32.4_suppl.21","title":"Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Abiraterone acetate; Enzalutamide; Post-hoc analysis; Prostate cancer; Internal medicine; Discontinuation; Prednisone; Population; Oncology; Androgen deprivation therapy; Cancer; Gastroenterology; Urology; Androgen receptor","score_opus":0.07136008729815171,"score_gpt":0.44600169250982996,"score_spread":0.3746416052116782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590639172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957459,0.00040760665,0.000009379693,0.0021307361,0.000071393064,0.0015485086,0.000053679083,0.000008972827,0.000023815528],"genre_scores_gemma":[0.99778664,0.0003564733,0.00091631454,0.00040369033,0.000050030918,0.0001450101,0.000017200491,0.000030779924,0.00029386958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99516124,0.0015465899,0.0017975988,0.00036343685,0.0007668482,0.0003643136],"domain_scores_gemma":[0.99581885,0.0010183052,0.001119654,0.0002778645,0.001343374,0.00042194332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026372725,0.00027364588,0.0020994488,0.00066219096,0.000047547644,0.000021989625,0.00011338105,0.00009877509,0.00014834279],"category_scores_gemma":[0.00027838894,0.0001421495,0.0002416039,0.00094648503,0.00016966663,0.00012267908,0.000021987324,0.00033046797,0.0000035987136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45054254,0.0067407466,0.50278383,0.00001691567,0.0068023703,0.0008734965,0.002521387,0.0005640646,0.0016242499,3.3024295e-7,0.000014184136,0.02751586],"study_design_scores_gemma":[0.050913785,0.22836633,0.7154357,0.00015711618,0.0027221157,0.000010740532,0.00064989715,0.00009711168,0.00084014697,0.000004065508,0.0006644513,0.0001385377],"about_ca_topic_score_codex":0.00040949465,"about_ca_topic_score_gemma":0.0031222238,"teacher_disagreement_score":0.39962876,"about_ca_system_score_codex":0.00055130647,"about_ca_system_score_gemma":0.0021124284,"threshold_uncertainty_score":0.5796688},"labels":[],"label_agreement":null},{"id":"W2590656741","doi":"10.1200/jco.2015.33.7_suppl.281","title":"A retrospective analysis of clinical factors influencing response to treatment with cabazitaxel in patients with metastatic castration resistant prostate cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Université de Montréal; Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame; London Health Sciences Centre; Grand River Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; University Health Network; University of Toronto","funders":"","keywords":"Cabazitaxel; Medicine; Docetaxel; Prostate cancer; Enzalutamide; Oncology; Internal medicine; Taxane; Prostate-specific antigen; Cancer; Urology; Androgen deprivation therapy; Breast cancer; Androgen receptor","score_opus":0.17530298368492458,"score_gpt":0.5108860198869127,"score_spread":0.33558303620198815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590656741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975491,0.0001310506,0.000012753111,0.0013017725,0.0001344368,0.00072435575,0.000055701075,0.0000042880242,0.000086512686],"genre_scores_gemma":[0.9976477,0.00013655161,0.0018147404,0.00010856214,0.00006683943,0.000020339106,0.000012573431,0.00001616645,0.00017652517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948832,0.0011052594,0.002587106,0.00030406102,0.0008330817,0.00028733784],"domain_scores_gemma":[0.994182,0.0012997655,0.0018429813,0.00023114787,0.0017498615,0.0006942399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044406937,0.00019148734,0.0025163414,0.0006309556,0.000026442873,0.000009894919,0.00009534463,0.0001437883,0.000019818315],"category_scores_gemma":[0.0028538306,0.00009735675,0.00032527873,0.0011429499,0.00023539961,0.000147309,0.000024050298,0.0005335641,0.0000011016831],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2019964,0.002326371,0.78411597,0.000010408945,0.0034984683,0.00044305305,0.0015457899,0.00037179323,0.0000353108,0.0000019551078,0.000030311083,0.0056241457],"study_design_scores_gemma":[0.026228053,0.12572561,0.8436918,0.0001491192,0.0026286205,0.000004072412,0.0010523953,0.000040004277,0.00006113848,0.000010969067,0.0003254441,0.00008272504],"about_ca_topic_score_codex":0.00064785284,"about_ca_topic_score_gemma":0.0036346642,"teacher_disagreement_score":0.17576836,"about_ca_system_score_codex":0.0016138338,"about_ca_system_score_gemma":0.0071275653,"threshold_uncertainty_score":0.9985011},"labels":[],"label_agreement":null},{"id":"W2590660342","doi":"10.1200/jco.2013.31.6_suppl.42","title":"Comparision of the risk of cardiovascular events and death in patients treated with degarelix compared with LHRH agonists.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Myocardial infarction; Prostate cancer; Proportional hazards model; Hazard ratio; Cancer; Confidence interval","score_opus":0.07728898096749841,"score_gpt":0.40521253656954564,"score_spread":0.3279235556020472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590660342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980474,0.00082231744,0.000012410028,0.00027353113,0.000059868966,0.00047353248,0.0000044277867,0.0000014664812,0.00030502962],"genre_scores_gemma":[0.99837035,0.0009867472,0.0005215344,0.00003366056,0.00003295981,0.0000042458673,0.0000027569363,0.000008625832,0.000039092363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767584,0.00050533225,0.001049744,0.00012237177,0.00049918686,0.00014755577],"domain_scores_gemma":[0.9975445,0.00046999464,0.00095920614,0.00020700834,0.0006613334,0.00015795146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000990814,0.0001003312,0.0013420541,0.00008411424,0.000026421087,0.0000026089479,0.000109777946,0.00012789045,0.000015914748],"category_scores_gemma":[0.00029432296,0.00004187296,0.00024720942,0.00016238842,0.00023856295,0.000057828835,0.000043234417,0.0005090621,8.892961e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007224623,0.0014800808,0.97999996,0.000033799843,0.0013735726,0.000027935563,0.00006877347,0.000107403335,0.000006152124,0.0000016293686,0.00013580563,0.0095402645],"study_design_scores_gemma":[0.0243309,0.0134477075,0.9602844,0.00031188148,0.0007030239,0.000022033548,0.000059014314,0.000096604475,0.00015615179,0.00003362105,0.00051351055,0.0000411639],"about_ca_topic_score_codex":0.0006022454,"about_ca_topic_score_gemma":0.00005331148,"teacher_disagreement_score":0.019715572,"about_ca_system_score_codex":0.00008995099,"about_ca_system_score_gemma":0.00049295864,"threshold_uncertainty_score":0.22116497},"labels":[],"label_agreement":null},{"id":"W2590697598","doi":"10.1200/jco.2015.33.7_suppl.4","title":"A randomized trial of 79.2Gy versus 70.2Gy radiation therapy (RT) for localized prostate cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; McMaster University; Cancer Care Ontario; Sunnybrook Health Science Centre; McGill University Health Centre; Health Sciences Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Randomized controlled trial; Urology; Surgery; Cancer; Internal medicine; Confidence interval","score_opus":0.3147061067878082,"score_gpt":0.570950177722728,"score_spread":0.25624407093491985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590697598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9597672,0.008707985,0.00027070538,0.019688934,0.006402758,0.0037179703,0.000020154452,0.000012473992,0.0014117772],"genre_scores_gemma":[0.9402362,0.04895845,0.0022994953,0.00095507514,0.005267653,0.00034119622,0.000029787347,0.00004681907,0.0018653204],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956223,0.000981071,0.0024322346,0.00017251194,0.00051904336,0.0002728901],"domain_scores_gemma":[0.99082184,0.0052994485,0.0020522818,0.00015722238,0.0012149132,0.00045430582],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008426009,0.00014340502,0.0026363176,0.00014528033,0.000028977985,0.000008178078,0.00013664416,0.00032401184,0.00007658203],"category_scores_gemma":[0.008428132,0.00008332241,0.0008849707,0.00015437926,0.00040316847,0.000096645395,0.000021819964,0.0004655967,0.0000033152803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8037469,0.0012300613,0.0004158753,0.000024886409,0.0011054686,0.00004515847,0.00023536752,0.00001683162,0.000049534192,0.000056654022,0.0060314736,0.18704182],"study_design_scores_gemma":[0.8393191,0.04983853,0.0001475822,0.00004846261,0.00044442574,0.00001123027,0.00008706722,0.0002850234,0.00048418512,0.0007474761,0.1085223,0.00006460526],"about_ca_topic_score_codex":0.00007526276,"about_ca_topic_score_gemma":0.000016644562,"teacher_disagreement_score":0.18697721,"about_ca_system_score_codex":0.00033224627,"about_ca_system_score_gemma":0.0064371247,"threshold_uncertainty_score":0.9999243},"labels":[],"label_agreement":null},{"id":"W2590710144","doi":"10.1200/jco.2013.31.6_suppl.196","title":"Evaluation of a genomic-based prognostic test for metastasis in high-risk post-prostatectomy patients: Does it impact physician decision making?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Internal medicine; Prostate cancer; Radiation oncologist; Clinical endpoint; Oncology; Referral; Nomogram; Confidence interval; Clinical trial; Cancer; Radiation therapy; Family medicine","score_opus":0.09944651828228353,"score_gpt":0.5001001007031128,"score_spread":0.4006535824208293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590710144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99527,0.00024720075,0.00013998005,0.0017988086,0.00032806746,0.0020613363,0.00009424438,0.0000037269353,0.000056651097],"genre_scores_gemma":[0.993069,0.0001289017,0.005946249,0.00048219156,0.0002336593,0.00008759283,0.000024116644,0.0000204698,0.000007813213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960425,0.0006405364,0.001989245,0.00020514266,0.0008307583,0.00029180112],"domain_scores_gemma":[0.9848376,0.008379637,0.00187363,0.0001820753,0.00452767,0.00019939298],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0064721396,0.00015234378,0.0011862683,0.0003186899,0.000035355028,0.000013769552,0.0001397493,0.0001971138,0.00020412922],"category_scores_gemma":[0.02218106,0.00007968058,0.00049971405,0.00019893727,0.0001457405,0.00016330786,0.000032751035,0.00048574744,0.000013115115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005527864,0.003408071,0.50662637,0.000038353308,0.00032121906,0.000011920049,0.00006638632,0.00016178834,0.00028842446,8.5033685e-7,0.00039090024,0.48315784],"study_design_scores_gemma":[0.031669486,0.033715505,0.9270435,0.00031369543,0.0012482824,0.0000021574062,0.00012130622,0.003231765,0.00029805407,0.0020481031,0.0002283594,0.000079811936],"about_ca_topic_score_codex":0.00012564538,"about_ca_topic_score_gemma":0.00012885917,"teacher_disagreement_score":0.48307803,"about_ca_system_score_codex":0.00065894716,"about_ca_system_score_gemma":0.0032428727,"threshold_uncertainty_score":0.9860555},"labels":[],"label_agreement":null},{"id":"W2590722959","doi":"10.1200/jco.2016.34.2_suppl.303","title":"Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Prostate cancer; Prostate; DECIPHER; Medicine; Metastasis; Adenocarcinoma; Carcinoma; Microarray; Cancer; Cancer research; Androgen deprivation therapy; Gene expression profiling; Androgen receptor; Oncology; Gene; Gene expression; Pathology; Internal medicine; Biology; Bioinformatics; Genetics","score_opus":0.14371395706064038,"score_gpt":0.47120583379404035,"score_spread":0.32749187673339997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590722959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98344773,0.0014030148,0.0004368461,0.012540828,0.0008452503,0.00034918237,0.000006736825,0.0000056866174,0.00096470217],"genre_scores_gemma":[0.9872344,0.007934766,0.0019688439,0.00043922022,0.0010248715,0.000009053739,4.0668957e-7,0.00001926568,0.0013691827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99639255,0.000499221,0.002213813,0.00022055265,0.00036203567,0.00031184405],"domain_scores_gemma":[0.9951038,0.0021471174,0.0015202224,0.00027813803,0.0006025103,0.00034825125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004469202,0.00013362417,0.0011634422,0.000055529323,0.000045493187,0.000006691719,0.00025745935,0.00024242907,0.00025721863],"category_scores_gemma":[0.00079874473,0.000051051422,0.0004952681,0.0000942407,0.0007531815,0.000054415286,0.000115176306,0.0008441371,0.000011024482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022517297,0.0013305653,0.5337723,0.000050712937,0.0006044421,0.0005253556,0.00011157609,0.000017903214,0.0020697806,0.000009320217,0.00075053144,0.43824026],"study_design_scores_gemma":[0.020796312,0.016204702,0.91855687,0.00035501682,0.00059654383,0.00016377555,0.00013307361,0.000078481484,0.0016178582,0.00021912142,0.041172847,0.00010541038],"about_ca_topic_score_codex":0.00004104051,"about_ca_topic_score_gemma":0.0000731187,"teacher_disagreement_score":0.43813485,"about_ca_system_score_codex":0.00014249684,"about_ca_system_score_gemma":0.0036091139,"threshold_uncertainty_score":0.6402413},"labels":[],"label_agreement":null},{"id":"W2590818354","doi":"10.1200/jco.2013.31.6_suppl.36","title":"Validation of a genomic classifier that predicts metastatic disease progression in men with high-risk pathologic features postprostatectomy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Genome British Columbia","funders":"","keywords":"Medicine; Internal medicine; Cohort; Population; Prostatectomy; Cumulative incidence; Prostate cancer; Oncology; Incidence (geometry); Clinical endpoint; Pathology; Clinical trial; Cancer","score_opus":0.09002796308985557,"score_gpt":0.4412508873607713,"score_spread":0.3512229242709157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590818354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99292845,0.0011904397,0.000024969338,0.004297835,0.00014754011,0.0009572809,0.0000131787665,0.000007817738,0.0004325216],"genre_scores_gemma":[0.99419725,0.0019137869,0.003228526,0.0001544673,0.00013719393,0.00004353586,0.0000185519,0.00001654097,0.00029016266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970591,0.0007699344,0.0011987975,0.00020765778,0.0005013848,0.00026308946],"domain_scores_gemma":[0.9965733,0.0008956343,0.0015060024,0.00018710403,0.00042677787,0.00041116227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019462436,0.00014616022,0.0010499082,0.00022343203,0.00003079723,0.000013204384,0.00012841125,0.00014121571,0.00013129771],"category_scores_gemma":[0.0010092265,0.00007285596,0.00018380214,0.00015461419,0.00031452216,0.00018929696,0.00005156661,0.0008492745,0.000010806926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023750726,0.0025118608,0.89031,0.00013850306,0.00040374676,0.0026790162,0.00022851497,0.000054054915,0.0013043788,0.00001620097,0.0015310743,0.077071905],"study_design_scores_gemma":[0.015114114,0.01688255,0.9642925,0.00028543585,0.00045581104,0.00014920124,0.00021849884,0.00008115176,0.0011341195,0.0010849652,0.00022813653,0.00007350025],"about_ca_topic_score_codex":0.00006212376,"about_ca_topic_score_gemma":0.000010154173,"teacher_disagreement_score":0.076998405,"about_ca_system_score_codex":0.00017453553,"about_ca_system_score_gemma":0.0014788697,"threshold_uncertainty_score":0.36897224},"labels":[],"label_agreement":null},{"id":"W2590842281","doi":"10.1200/jco.2014.32.4_suppl.7","title":"Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Clinical endpoint; Prednisone; Abiraterone acetate; Placebo; Prostate cancer; Internal medicine; Adverse effect; Population; Ketoconazole; Urology; Randomized controlled trial; Cancer; Oncology; Gastroenterology; Androgen deprivation therapy; Dermatology; Pathology","score_opus":0.18533527850798012,"score_gpt":0.4686484202466603,"score_spread":0.28331314173868016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590842281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800764,0.0005679585,0.00008251451,0.0019965302,0.0011780867,0.01596514,0.000074743635,0.0000149229145,0.000043703963],"genre_scores_gemma":[0.99624884,0.0004425348,0.0013854002,0.0001198483,0.0004942389,0.0009872519,0.000084559804,0.000048416667,0.00018891878],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9902145,0.002398248,0.005071103,0.00050914014,0.0012656297,0.0005413255],"domain_scores_gemma":[0.98671037,0.0069310465,0.004854114,0.00038021477,0.0006809968,0.00044327535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007476345,0.00041115988,0.005301778,0.0003846537,0.000107996384,0.00006498039,0.00025529877,0.0002869745,0.00006996055],"category_scores_gemma":[0.00351509,0.00021132923,0.0009905146,0.00028628274,0.0004473528,0.00027561781,0.00003180972,0.0009042467,0.0000014304973],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96640766,0.019348813,0.0017441589,0.00008338091,0.004179155,0.0005049826,0.0007098384,0.00025888285,0.00017189313,7.1113425e-7,0.00002444402,0.006566108],"study_design_scores_gemma":[0.9351259,0.058391947,0.0012782259,0.00077970116,0.0019681787,0.0000024183284,0.00011235861,0.0013691915,0.00061876094,0.000012342572,0.00014899134,0.0001919809],"about_ca_topic_score_codex":0.0003149679,"about_ca_topic_score_gemma":0.0005116258,"teacher_disagreement_score":0.039043136,"about_ca_system_score_codex":0.0004432751,"about_ca_system_score_gemma":0.0051356778,"threshold_uncertainty_score":0.91104716},"labels":[],"label_agreement":null},{"id":"W2590864636","doi":"10.1200/jco.2013.31.6_suppl.54","title":"Evaluation of the UCSF cancer of the prostate risk assessment for prediction of biochemical recurrence (CAPRA) to predict which patients need dose escalation in intermediate-risk disease.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Capra; Prostate cancer; Prostatectomy; Biochemical recurrence; Urology; Pathological; Proportional hazards model; Internal medicine; Oncology; Cancer","score_opus":0.10330693925102917,"score_gpt":0.4863514896427835,"score_spread":0.38304455039175433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590864636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99275845,0.00019639147,0.000059471266,0.0032074377,0.0010265288,0.0024586192,0.0002413579,0.0000016528329,0.000050113737],"genre_scores_gemma":[0.9985725,0.00079973217,0.00021376417,0.000044125612,0.00017456755,0.00015782157,0.000014777021,0.000008069384,0.000014595002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99579054,0.0010596584,0.0017909339,0.00015566836,0.0010465325,0.00015666732],"domain_scores_gemma":[0.99281186,0.00096034043,0.0023130057,0.00021740267,0.0035312204,0.00016619168],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0050704074,0.00009452601,0.0005803627,0.00010497755,0.000029597164,0.0000036827355,0.00018881256,0.00015918072,0.000038996553],"category_scores_gemma":[0.011173463,0.00004691062,0.00025100046,0.00033967994,0.00020573809,0.00011103718,0.00008425313,0.00054303044,3.706479e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003345789,0.0014416589,0.9077994,0.00007477383,0.00016778965,1.8583304e-7,0.00020307794,0.0003799804,0.0005500425,0.0000014440652,0.0013858007,0.08465006],"study_design_scores_gemma":[0.010705138,0.004659816,0.96881396,0.00056310644,0.0008023263,4.1866986e-7,0.00008232469,0.012228027,0.0013851542,0.0006634016,0.00006399077,0.000032339485],"about_ca_topic_score_codex":0.00010654285,"about_ca_topic_score_gemma":0.00006809754,"teacher_disagreement_score":0.08461773,"about_ca_system_score_codex":0.00042008463,"about_ca_system_score_gemma":0.0030992727,"threshold_uncertainty_score":0.99715585},"labels":[],"label_agreement":null},{"id":"W2590886987","doi":"10.1200/jco.2016.34.2_suppl.98","title":"The frequency of druggable targets in localized prostate cancer: Initial analysis from the Decipher GRID.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"DECIPHER; Druggability; Medicine; Computational biology; Prostate cancer; Population; Gene expression profiling; Bioinformatics; Cancer; Gene; Gene expression; Biology; Genetics; Internal medicine","score_opus":0.09692976115524495,"score_gpt":0.49111820894542224,"score_spread":0.3941884477901773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590886987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93606806,0.009287547,0.00009545162,0.052037463,0.001011307,0.00032546604,0.000052733718,0.000003844856,0.0011181375],"genre_scores_gemma":[0.9787527,0.018446188,0.00039893863,0.00070151145,0.000994783,0.000020134834,0.000003660921,0.00001110967,0.0006709978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963489,0.0007850705,0.0019390642,0.00016211679,0.0004670414,0.00029778745],"domain_scores_gemma":[0.9907727,0.0071024047,0.0011456594,0.0002581876,0.00052409526,0.00019693666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037332892,0.00011002559,0.0011697205,0.000097022195,0.00006816087,0.000008580779,0.00029356912,0.00019453198,0.00050133414],"category_scores_gemma":[0.0026610058,0.000037490176,0.00053318613,0.00043893105,0.0006261855,0.00008565131,0.000060917107,0.00059551274,0.000008294262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008904478,0.00061914197,0.8026068,0.0000063744124,0.0026621504,0.00034483045,0.0002580835,0.000013174431,0.00039415076,0.000055251643,0.006144846,0.1779907],"study_design_scores_gemma":[0.027239457,0.004727622,0.85149986,0.00029243765,0.0021040328,0.000016149694,0.00040392595,0.00008798996,0.0012728095,0.005996833,0.106235564,0.00012331657],"about_ca_topic_score_codex":0.0011143227,"about_ca_topic_score_gemma":0.0030262328,"teacher_disagreement_score":0.17786738,"about_ca_system_score_codex":0.00024657874,"about_ca_system_score_gemma":0.0025067586,"threshold_uncertainty_score":0.54892576},"labels":[],"label_agreement":null},{"id":"W2590900349","doi":"10.1200/jco.2013.31.6_suppl.125","title":"From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Discontinuation; Prednisone; Prostate cancer; Internal medicine; Cabazitaxel; Clinical endpoint; Proportional hazards model; Oncology; Chemotherapy; Clinical trial; Cancer; Androgen deprivation therapy","score_opus":0.09837554427195687,"score_gpt":0.49831209920109476,"score_spread":0.3999365549291379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590900349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93339634,0.00061694015,0.00027165154,0.06198592,0.00027518827,0.0031149003,0.000021836968,0.00000555206,0.00031169353],"genre_scores_gemma":[0.97813195,0.00089299557,0.01766922,0.0008037756,0.00083209947,0.00068696117,0.000006491927,0.000022116665,0.0009544173],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99770224,0.00028836768,0.0009883282,0.00025306057,0.0005034251,0.00026454794],"domain_scores_gemma":[0.9954113,0.002107078,0.0010299592,0.00017357747,0.0009225408,0.00035555515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001381956,0.00014527449,0.0007815344,0.00004783161,0.00009822417,0.00006549964,0.00013075973,0.00008747546,0.000064754284],"category_scores_gemma":[0.0014359031,0.00006247949,0.000082489176,0.00012523207,0.00032451967,0.00038357943,0.00003563006,0.00043654063,0.0000020718292],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8682802,0.003054849,0.017349327,0.00009371824,0.0023736977,0.00063285267,0.009164825,0.000034406614,0.0006860081,0.00007153547,0.0106294565,0.08762914],"study_design_scores_gemma":[0.3758936,0.29011026,0.19027339,0.0007279176,0.0030327258,0.00032820576,0.024636768,0.0003711949,0.0010759963,0.0007942249,0.11229986,0.00045586983],"about_ca_topic_score_codex":0.0005147192,"about_ca_topic_score_gemma":0.00019979142,"teacher_disagreement_score":0.49238658,"about_ca_system_score_codex":0.00015479434,"about_ca_system_score_gemma":0.0019703829,"threshold_uncertainty_score":0.34953743},"labels":[],"label_agreement":null},{"id":"W2591046237","doi":"10.1200/jco.2015.33.7_suppl.226","title":"Current era clinical outcomes of castration-resistant prostate cancer in real-life population study in Quebec, Canada.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Abiraterone acetate; Proportional hazards model; Oncology; Internal medicine; Hazard ratio; Cohort; Population; Androgen deprivation therapy; Enzalutamide; Chemotherapy; Survival analysis; Cancer; Androgen receptor; Confidence interval","score_opus":0.27694533253567555,"score_gpt":0.5697048201899734,"score_spread":0.2927594876542978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591046237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885838,0.00094353314,8.268317e-7,0.008217533,0.0014750796,0.00063223945,0.000010941528,0.000002530896,0.00013349808],"genre_scores_gemma":[0.99746495,0.001662034,0.000072623116,0.0001692445,0.00033690868,0.000015112454,0.0000068158083,0.000010442298,0.00026186323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99397254,0.0009278862,0.003950382,0.00019995356,0.00070281286,0.00024643025],"domain_scores_gemma":[0.9960777,0.0012273869,0.0014151939,0.00016055586,0.00060997513,0.00050915394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049118646,0.00012715325,0.0016854114,0.00019395213,0.000013974036,0.0000062512872,0.00011950144,0.0001685453,0.000030424982],"category_scores_gemma":[0.0038097682,0.00008235641,0.0001753436,0.00025244875,0.00010650126,0.00011557537,0.000038463746,0.0011701905,8.631904e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00865914,0.003565445,0.9488143,0.000026846472,0.0001823072,0.00061323366,0.00032435165,0.00011039355,0.0000037236139,0.000014145429,0.001487156,0.036198974],"study_design_scores_gemma":[0.018834036,0.0046158847,0.973893,0.00012355458,0.00011462321,0.0000032719656,0.0008221587,0.000054775905,0.0000021643277,0.00006178111,0.0014085481,0.000066195826],"about_ca_topic_score_codex":0.700962,"about_ca_topic_score_gemma":0.9846678,"teacher_disagreement_score":0.2837058,"about_ca_system_score_codex":0.0011747282,"about_ca_system_score_gemma":0.024906376,"threshold_uncertainty_score":0.9806215},"labels":[],"label_agreement":null},{"id":"W2591074898","doi":"10.1200/jco.2015.33.7_suppl.186","title":"Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Hazard ratio; Prostate cancer; Docetaxel; Internal medicine; Proportional hazards model; Response Evaluation Criteria in Solid Tumors; Oncology; Progressive disease; Cancer; Confidence interval; Disease","score_opus":0.22080835571266436,"score_gpt":0.4928362006397185,"score_spread":0.2720278449270541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591074898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973491,0.002155515,0.0000038488297,0.022950731,0.00038621778,0.00036100007,0.00003850803,0.0000024187743,0.0006107552],"genre_scores_gemma":[0.9945253,0.0021547612,0.00035155422,0.0001598818,0.00013423986,0.00002507759,0.000011293963,0.000011445471,0.0026264042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971172,0.0006133873,0.001169653,0.00013399712,0.00073888036,0.00022684097],"domain_scores_gemma":[0.9967394,0.00088157784,0.0011041671,0.000088548884,0.0008185278,0.0003678099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005557705,0.00009376948,0.00096048147,0.00014902154,0.000011797962,0.0000070122433,0.00007104261,0.000103227714,0.000038074304],"category_scores_gemma":[0.002834679,0.000058458067,0.00007883448,0.0002770013,0.0000943843,0.000107174856,0.0000133105195,0.00053515506,0.0000014194937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03570807,0.0019748618,0.94052637,0.00009128693,0.00033881314,0.0009052135,0.00033443814,0.000106412175,0.000521623,0.000009284177,0.004815351,0.01466828],"study_design_scores_gemma":[0.04936721,0.017489227,0.9072254,0.0007301714,0.00061068137,0.000018420844,0.0011603214,0.00017350324,0.0006661983,0.00050443865,0.021882664,0.00017180006],"about_ca_topic_score_codex":0.0006610714,"about_ca_topic_score_gemma":0.01146,"teacher_disagreement_score":0.033301003,"about_ca_system_score_codex":0.00092677487,"about_ca_system_score_gemma":0.0048026675,"threshold_uncertainty_score":0.8519726},"labels":[],"label_agreement":null},{"id":"W2591113678","doi":"10.1200/jco.2016.34.2_suppl.59","title":"Validation of the Decipher prostate cancer classifier for predicting 10-year postoperative metastasis from analysis of diagnostic needle biopsy specimens.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; DECIPHER; Prostatectomy; Prostate cancer; Biopsy; Cohort; Metastasis; Prostate; Prostate biopsy; Cancer; Oncology; Internal medicine; Pathology; Radiology; Bioinformatics","score_opus":0.14712856599949414,"score_gpt":0.47976550028385356,"score_spread":0.3326369342843594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591113678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886784,0.0005824615,0.00020229818,0.009035415,0.00046022626,0.00043097505,0.00030761203,0.000002468866,0.0003001279],"genre_scores_gemma":[0.99558276,0.0012262447,0.0015157143,0.00014399449,0.00034107285,0.000021536154,0.000010098735,0.000012535019,0.0011460403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726003,0.0003865655,0.0016110359,0.00016951363,0.00039485327,0.00017799533],"domain_scores_gemma":[0.98812824,0.008656303,0.0016676107,0.00019725312,0.0012037555,0.0001468482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016895444,0.00010577432,0.0012165353,0.0001647431,0.000041341547,0.0000047327912,0.00014582464,0.00016494584,0.0008648835],"category_scores_gemma":[0.008163274,0.000045802706,0.00071056536,0.00040569893,0.0003163138,0.00009827636,0.000051828287,0.00022178466,0.0000021528708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009540407,0.0010419711,0.8979254,0.000026366406,0.010437709,0.000024989864,0.00057903264,0.000076984616,0.016243637,0.00004024563,0.002753865,0.061309405],"study_design_scores_gemma":[0.015113223,0.0066983374,0.91102636,0.00042164876,0.011017898,0.000006584244,0.00062156067,0.00016324692,0.046160396,0.0003614601,0.008307408,0.00010185751],"about_ca_topic_score_codex":0.00008478676,"about_ca_topic_score_gemma":0.00005236148,"teacher_disagreement_score":0.061207548,"about_ca_system_score_codex":0.00018906628,"about_ca_system_score_gemma":0.0011739014,"threshold_uncertainty_score":0.97727907},"labels":[],"label_agreement":null},{"id":"W2591137227","doi":"10.1200/jco.2015.33.7_suppl.23","title":"Association of baseline perineural invasion with shorter time to progression in men with prostate cancer undergoing active surveillance: Results from the REDEEM study.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Perineural invasion; Prostatectomy; Prostate cancer; Prostate-specific antigen; Prostate; Internal medicine; Pathological; Cancer; Tumor progression; Biopsy; Oncology; Proportional hazards model; Dutasteride; Urology","score_opus":0.11224477025903523,"score_gpt":0.47127888059595635,"score_spread":0.3590341103369211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591137227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96776134,0.0001256057,0.0000034084796,0.030440459,0.00008935742,0.000853127,0.000024516788,0.000004469472,0.000697725],"genre_scores_gemma":[0.9973424,0.00024998383,0.00041910994,0.00024253315,0.00037623016,0.000020892781,0.000015133384,0.000013726763,0.0013199699],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99676526,0.0009517738,0.0011252834,0.00020374595,0.0007522462,0.00020170657],"domain_scores_gemma":[0.99474376,0.0027566229,0.0011616156,0.00015213448,0.000952847,0.00023298697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005458504,0.00011352418,0.0008388715,0.00007566046,0.000028018887,0.000009601724,0.00011060304,0.00012069219,0.00003225311],"category_scores_gemma":[0.003114054,0.00004893104,0.00006315771,0.00026158415,0.00007377125,0.00010614682,0.000057557292,0.00062866503,0.0000039567826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14648972,0.0013273549,0.8073263,0.000007192075,0.0004259935,0.000314448,0.0020753352,0.00016469895,0.00012688887,8.8370555e-8,0.006131264,0.035610713],"study_design_scores_gemma":[0.03475434,0.03697073,0.92238194,0.0005118842,0.00016255499,0.000015466261,0.0021902851,0.0002721993,0.00025641025,0.000012039719,0.0023945286,0.000077599296],"about_ca_topic_score_codex":0.0002562335,"about_ca_topic_score_gemma":0.0028879677,"teacher_disagreement_score":0.11505567,"about_ca_system_score_codex":0.00063520746,"about_ca_system_score_gemma":0.002712455,"threshold_uncertainty_score":0.4811779},"labels":[],"label_agreement":null},{"id":"W2591139416","doi":"10.1200/jco.2014.32.4_suppl.18","title":"The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Abiraterone; Prostate cancer; Internal medicine; Confounding; Oncology; Logistic regression; Gynecology; Cancer; Androgen receptor","score_opus":0.10970715604217106,"score_gpt":0.475957179631135,"score_spread":0.3662500235889639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591139416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876855,0.00011903635,0.000013700752,0.010026323,0.00013558715,0.0003833689,0.0000014299195,0.0000018870711,0.0016331415],"genre_scores_gemma":[0.9987662,0.00039679644,0.000074056086,0.0001759431,0.00018675931,0.000007565203,2.596663e-7,0.0000098685105,0.00038254703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966458,0.0016711279,0.0009498729,0.00011044365,0.00042557198,0.00019715619],"domain_scores_gemma":[0.98262835,0.015768059,0.0010340562,0.00025234293,0.00019614951,0.00012104261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007581533,0.00010309875,0.0010317242,0.00006853093,0.000039853912,0.0000059337144,0.00018114419,0.00016199677,0.00001901178],"category_scores_gemma":[0.004696214,0.000035791774,0.00020315358,0.00012870501,0.00053308136,0.00006311948,0.000040668107,0.000902532,0.0000028825068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12814571,0.0017580058,0.57328767,0.000107783555,0.00086090155,0.00018487204,0.00023287514,0.000045691977,0.005974901,0.00023177925,0.001873799,0.287296],"study_design_scores_gemma":[0.018971043,0.08963801,0.8569593,0.00033114624,0.0002456521,0.00004331576,0.000057233403,0.00017611006,0.025613757,0.00012786315,0.007780419,0.000056182922],"about_ca_topic_score_codex":0.000047486225,"about_ca_topic_score_gemma":0.00008885208,"teacher_disagreement_score":0.28723982,"about_ca_system_score_codex":0.00011511596,"about_ca_system_score_gemma":0.0005407787,"threshold_uncertainty_score":0.5622146},"labels":[],"label_agreement":null},{"id":"W2591165175","doi":"10.1200/jco.2014.32.4_suppl.70","title":"A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Abiraterone acetate; Docetaxel; Internal medicine; Prostate cancer; Proportional hazards model; Hazard ratio; Oncology; Lymph node; Cancer; Gastroenterology; Urology; Androgen deprivation therapy; Confidence interval","score_opus":0.08463559250725394,"score_gpt":0.43584952964092244,"score_spread":0.3512139371336685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591165175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923442,0.00020860272,0.00011720316,0.0054935534,0.00012147813,0.0015476284,0.00003989335,0.000011808196,0.00011562334],"genre_scores_gemma":[0.9939165,0.00024369085,0.0039745546,0.0007972543,0.0002419451,0.00011072747,0.000045198565,0.000042572166,0.00062756904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975619,0.00021887948,0.00116717,0.00024668174,0.00044690873,0.00035849397],"domain_scores_gemma":[0.99554133,0.0009331563,0.0011480704,0.00015506473,0.0018461936,0.00037616343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001024277,0.00020702965,0.0011972686,0.00011795194,0.00007352874,0.000024325609,0.0001006598,0.00010807774,0.00005660036],"category_scores_gemma":[0.0005779126,0.00010089323,0.00016907619,0.00017852864,0.00029144244,0.0001449537,0.000010971244,0.00040315124,0.0000033026822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1419896,0.003832451,0.7496652,0.00027521688,0.0020816862,0.00025226868,0.00025975896,0.000041492814,0.0005718789,0.000022454686,0.00052375183,0.100484245],"study_design_scores_gemma":[0.06466573,0.12005614,0.8077202,0.00050761976,0.0012814874,0.00005947751,0.000076692864,0.00012663225,0.00038694727,0.000077066485,0.0048784404,0.00016358514],"about_ca_topic_score_codex":0.00003694038,"about_ca_topic_score_gemma":0.00019197271,"teacher_disagreement_score":0.116223685,"about_ca_system_score_codex":0.00017674774,"about_ca_system_score_gemma":0.0019848535,"threshold_uncertainty_score":0.41143066},"labels":[],"label_agreement":null},{"id":"W2591342859","doi":"10.1200/jco.2014.32.4_suppl.97","title":"Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Docetaxel; Prostate cancer; Exact test; Internal medicine; Cancer; Oncology; Urology; Androgen deprivation therapy","score_opus":0.14492034401977447,"score_gpt":0.516104788827655,"score_spread":0.3711844448078805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591342859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590117,0.00011461573,0.000011538221,0.0028093962,0.00026606434,0.00070772506,0.000054451742,0.000002966461,0.00013210335],"genre_scores_gemma":[0.9986181,0.00031334645,0.0005737448,0.00013752327,0.00008382093,0.000019161374,0.000003255389,0.000018474086,0.00023257599],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99542356,0.0013415923,0.0020364232,0.00022592272,0.0006368485,0.00033563876],"domain_scores_gemma":[0.99489355,0.0018940938,0.0017120031,0.00023930539,0.0008405038,0.00042052908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046588485,0.00018229328,0.001663704,0.00035850715,0.00002428046,0.0000068606328,0.00014679886,0.00013986227,0.00008683325],"category_scores_gemma":[0.0034248107,0.000110977984,0.00040009854,0.00030106504,0.00020941971,0.0001229364,0.000041403906,0.00061746594,0.0000058766273],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38930959,0.009638974,0.37036163,0.00021629332,0.0010489795,0.00031595884,0.0008786017,0.00079153245,0.07680914,0.000013682128,0.00045070663,0.1501649],"study_design_scores_gemma":[0.020300448,0.058444817,0.91341054,0.00032909517,0.00018194746,0.0000086538985,0.000029470473,0.0000579756,0.006586121,0.000056923913,0.00051102735,0.00008294927],"about_ca_topic_score_codex":0.00034874387,"about_ca_topic_score_gemma":0.00032131988,"teacher_disagreement_score":0.5430489,"about_ca_system_score_codex":0.0007380706,"about_ca_system_score_gemma":0.003744296,"threshold_uncertainty_score":0.66422206},"labels":[],"label_agreement":null},{"id":"W2591457709","doi":"10.1200/jco.2013.31.6_suppl.13","title":"Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Aflibercept; Medicine; Docetaxel; Prednisone; Internal medicine; Bevacizumab; Hazard ratio; Clinical endpoint; Prostate cancer; Gastroenterology; Placebo; Oncology; Surgery; Randomized controlled trial; Urology; Cancer; Chemotherapy; Confidence interval; Pathology","score_opus":0.17351494744900267,"score_gpt":0.4880195139565482,"score_spread":0.31450456650754555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591457709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747865,0.00044383047,0.00008307202,0.020136302,0.00026194326,0.0037942706,0.00021789165,0.0000051513603,0.00027102523],"genre_scores_gemma":[0.9939321,0.0010288428,0.0032453774,0.00006974811,0.00039993352,0.00045150323,0.00015592272,0.000019468578,0.00069707626],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967409,0.0003109822,0.0019171153,0.0002442031,0.00054229534,0.00024450934],"domain_scores_gemma":[0.9903569,0.0066042193,0.0017305689,0.00017868531,0.00094204355,0.00018755822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013499196,0.0001837859,0.0011300695,0.00010661303,0.0000769534,0.000018650671,0.00011485399,0.000118280856,0.00010745019],"category_scores_gemma":[0.00086370256,0.000086804466,0.0001954397,0.00018690036,0.0002889248,0.00018564683,0.000013465242,0.00029312895,0.0000018675046],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92839754,0.008945464,0.00091494544,0.00002367573,0.0014492797,0.00010761713,0.0013683245,0.00039248329,0.00017841852,0.000030516061,0.0009114599,0.057280257],"study_design_scores_gemma":[0.845046,0.1306316,0.015722828,0.00018225811,0.0009554055,0.000011372121,0.00085106277,0.002390332,0.00042027375,0.0001722825,0.0035171097,0.00009947083],"about_ca_topic_score_codex":0.0011487168,"about_ca_topic_score_gemma":0.003333711,"teacher_disagreement_score":0.12168614,"about_ca_system_score_codex":0.0005259108,"about_ca_system_score_gemma":0.0025305287,"threshold_uncertainty_score":0.4489049},"labels":[],"label_agreement":null},{"id":"W2591496615","doi":"10.1200/jco.2014.32.4_suppl.267","title":"Prostate cancer patients' adherence to medication while on abiraterone acetate (AA) therapy.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Abiraterone acetate; Dosing; Prostate cancer; Medical prescription; Chemotherapy; Cancer; Internal medicine; Pharmacy; Oncology; Androgen deprivation therapy; Pharmacology; Family medicine","score_opus":0.16638427038625161,"score_gpt":0.5057545212422049,"score_spread":0.3393702508559533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591496615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97480875,0.00037537888,0.000033939312,0.020525979,0.0013057906,0.00045740156,0.0000055159967,0.0000101562455,0.0024770985],"genre_scores_gemma":[0.9873064,0.0039005012,0.0004636316,0.0055339895,0.00095244084,0.00003604989,0.0000069321222,0.000017812241,0.001782211],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974137,0.00036464454,0.0012099504,0.00020585253,0.00054100016,0.00026485327],"domain_scores_gemma":[0.9971374,0.0006806899,0.00078733684,0.00017942967,0.00068602356,0.0005290865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021110189,0.00012393734,0.0008161957,0.0001203876,0.000045425855,0.000010333797,0.00016136271,0.00018356368,0.0003237185],"category_scores_gemma":[0.0011626199,0.00007189219,0.00017531688,0.00014492053,0.00011761853,0.00008178222,0.00003278241,0.00063747226,0.00011224608],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01190069,0.0019884084,0.1305156,0.000021287738,0.00021651888,0.000035126995,0.00032199206,0.000014666819,0.00044151818,0.000029499066,0.01773075,0.83678395],"study_design_scores_gemma":[0.020010892,0.08058242,0.59723735,0.00025337838,0.00009486309,0.000009637166,0.00003775371,0.00005117916,0.001579429,0.0002682437,0.29975918,0.00011568013],"about_ca_topic_score_codex":0.000027643553,"about_ca_topic_score_gemma":0.000023146715,"teacher_disagreement_score":0.83666825,"about_ca_system_score_codex":0.00019402946,"about_ca_system_score_gemma":0.0009785856,"threshold_uncertainty_score":0.35444906},"labels":[],"label_agreement":null},{"id":"W2591501973","doi":"10.1200/jco.2016.34.2_suppl.34","title":"Causes of death in intermediate- and high-risk prostate cancer treated with radiotherapy with or without androgen deprivation therapy: Analysis from two phase III trials.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont; Centre Hospitalier Universitaire de Sherbrooke; McGill University Health Centre; Centre de Santé et de Services Sociaux de Chicoutimi; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Population; Cancer; Radiation therapy; Urology; Cause of death; Androgen deprivation therapy; Prostate; Oncology; Gastroenterology; Disease","score_opus":0.13076893971685674,"score_gpt":0.5009969256653771,"score_spread":0.37022798594852036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591501973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946345,0.0027721592,0.00037186063,0.0015098191,0.00006115346,0.00057503587,0.000060986764,0.000006277727,0.000008222936],"genre_scores_gemma":[0.9376315,0.060570903,0.001186469,0.00012660719,0.00027926668,0.000024178507,0.000009620696,0.000018962832,0.00015251689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965798,0.00083218765,0.0018083844,0.00024955414,0.00032537887,0.00020466911],"domain_scores_gemma":[0.9945762,0.002461189,0.0021507037,0.00017077163,0.0003919278,0.0002492189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024981424,0.00017380768,0.0025799999,0.00036184292,0.000024437817,0.000009121736,0.0000876447,0.0001596182,0.00019371675],"category_scores_gemma":[0.0006371089,0.00006366988,0.00018461881,0.00041171358,0.0003327999,0.00013915314,0.00001318499,0.0003287018,2.5080007e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17410219,0.00069399946,0.6053535,0.000005032239,0.004871806,0.00024187975,0.00022944063,0.000008834005,0.0008022589,8.03851e-7,0.000017008924,0.21367326],"study_design_scores_gemma":[0.2522786,0.04125535,0.6951632,0.00036522528,0.003247753,0.00003236904,0.00010203479,0.0001599404,0.006226731,0.000063512016,0.0009766833,0.00012864462],"about_ca_topic_score_codex":0.00195688,"about_ca_topic_score_gemma":0.003130768,"teacher_disagreement_score":0.2135446,"about_ca_system_score_codex":0.00020797433,"about_ca_system_score_gemma":0.0014671963,"threshold_uncertainty_score":0.29582304},"labels":[],"label_agreement":null},{"id":"W2591535929","doi":"10.1200/jco.2012.30.5_suppl.186","title":"Biochemical, pathologic, toxicity, and quality-of-life outcomes in a five-fraction hypofractionated accelerated radiotherapy treatment using standard linear accelerators and gold seed fiducials.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Image-guided radiation therapy; Cohort; Prospective cohort study; Quality of life (healthcare); Prostate; Cancer; Urology; Nuclear medicine; Surgery; Internal medicine","score_opus":0.353239664599931,"score_gpt":0.551250282577846,"score_spread":0.19801061797791503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591535929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992892,0.003849709,0.000041945746,0.0024813262,0.0003331965,0.00032228525,0.000014536647,0.0000078983185,0.00005709982],"genre_scores_gemma":[0.9828583,0.012101886,0.0039463136,0.00056712347,0.00041726232,0.000004734311,0.000005745736,0.0000143897505,0.00008422372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99694073,0.0006126864,0.0017087553,0.00018107891,0.00029212862,0.0002645933],"domain_scores_gemma":[0.9962706,0.0017996154,0.0010982215,0.00010895,0.00032648453,0.0003961052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021536867,0.00016954158,0.0017682619,0.00022425318,0.000041797495,0.000011795778,0.000053074982,0.00041781567,0.000049500035],"category_scores_gemma":[0.0021423332,0.000105746745,0.00018869832,0.00019580248,0.00025163905,0.00028279726,0.00003334867,0.00053453393,6.014401e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012479096,0.002966152,0.9261783,0.000041905023,0.0005034096,0.00007037478,0.00021219396,0.0000043266855,0.037338946,0.0000127400235,0.00009733727,0.020095266],"study_design_scores_gemma":[0.02826226,0.00955617,0.9503118,0.00007619611,0.00019680244,0.00011553638,0.0003976867,0.00017916155,0.0068882247,0.000050713283,0.0038228845,0.00014259094],"about_ca_topic_score_codex":0.00014319182,"about_ca_topic_score_gemma":0.000013852436,"teacher_disagreement_score":0.03045072,"about_ca_system_score_codex":0.0005206966,"about_ca_system_score_gemma":0.00093937677,"threshold_uncertainty_score":0.4312227},"labels":[],"label_agreement":null},{"id":"W2592077636","doi":"10.18632/oncotarget.15854","title":"Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression","year":2017,"lang":"en","type":"article","venue":"Oncotarget","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; University of California, San Diego; Vanderbilt University; Prostate Cancer Foundation","keywords":"Prostate cancer; Cancer research; Neuroendocrine differentiation; Alternative splicing; Prostate; Biology; Tramp; Cell growth; Cancer; Gene; Medicine; Exon; Genetics","score_opus":0.03713915101194212,"score_gpt":0.37963847355919517,"score_spread":0.342499322547253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592077636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858766,0.0015341778,0.000005016927,0.008906445,0.0003522462,0.0008435208,0.000093485585,0.000020893294,0.002367574],"genre_scores_gemma":[0.98870385,0.0017832075,0.00022088324,0.000082805156,0.00014678136,0.000110604706,0.000014401325,0.000021149477,0.008916305],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987639,0.000042163774,0.00019496596,0.0002618488,0.00042015742,0.0003169275],"domain_scores_gemma":[0.998877,0.000027194288,0.00020716166,0.0006111356,0.00017193094,0.00010559855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010382324,0.00014844586,0.00026074162,0.000042394662,0.0003262765,0.00003195202,0.00027156717,0.000019775001,0.000092130605],"category_scores_gemma":[0.00009885168,0.00007878612,0.0001044149,0.00006715799,0.0002760231,0.00011942476,0.00021619338,0.00019891666,0.000010477104],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007990939,0.00020507412,0.7378085,0.00022943412,0.00017911689,0.00016194183,0.0009796786,0.00003597421,0.24150833,0.00004628134,0.0011696374,0.0168769],"study_design_scores_gemma":[0.002941652,0.0004038458,0.22946487,0.00052990695,0.0000676238,0.000018296398,0.000059950038,0.0005158549,0.7585694,0.00042068525,0.0068945806,0.00011329111],"about_ca_topic_score_codex":0.0009360516,"about_ca_topic_score_gemma":0.000040028575,"teacher_disagreement_score":0.5170611,"about_ca_system_score_codex":0.000107759966,"about_ca_system_score_gemma":0.00017683906,"threshold_uncertainty_score":0.32128048},"labels":[],"label_agreement":null},{"id":"W2592262952","doi":"10.1111/andr.12331","title":"Changes in periprostatic adipose tissue induced by 5α‐reductase inhibitors","year":2017,"lang":"en","type":"article","venue":"Andrology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Adipose tissue; Medicine; Prostate cancer; Prostate; Urology; Cancer; Internal medicine","score_opus":0.03383095460908617,"score_gpt":0.35275869857537523,"score_spread":0.3189277439662891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592262952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800041,0.001295437,3.9976746e-7,0.016460605,0.00023251683,0.00039449433,0.000017603888,0.0000176749,0.0015772083],"genre_scores_gemma":[0.9962245,0.00042091002,0.000023416012,0.0004378335,0.00014384597,0.00008185536,0.00008538707,0.000015074103,0.0025671667],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99916065,0.000036382957,0.00011342066,0.00023823317,0.00010780247,0.0003435261],"domain_scores_gemma":[0.9994262,0.000023568868,0.00005460988,0.00033759885,0.00003288195,0.00012515963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012214342,0.00011110773,0.0002461051,0.000104603525,0.00013992813,0.000023519682,0.00010332092,0.00012386855,0.0002037152],"category_scores_gemma":[0.000081801256,0.00008661556,0.000020755604,0.000050143477,0.00017341468,0.000065579996,0.000061006904,0.00019474633,0.00007007627],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011906815,0.00050626125,0.12596966,0.00014874987,0.00012804985,0.0013733888,0.0020691426,1.4340941e-7,0.77917975,0.00007031452,0.015419684,0.07394415],"study_design_scores_gemma":[0.016822295,0.0072695706,0.20434567,0.00021161753,0.00015634691,0.0002806712,0.000410445,0.000074340984,0.6815972,0.00066374725,0.08767057,0.0004975699],"about_ca_topic_score_codex":0.00048411277,"about_ca_topic_score_gemma":0.0004164002,"teacher_disagreement_score":0.097582616,"about_ca_system_score_codex":0.0000547302,"about_ca_system_score_gemma":0.0000787133,"threshold_uncertainty_score":0.353208},"labels":[],"label_agreement":null},{"id":"W2593176248","doi":"10.1016/j.eururo.2017.02.023","title":"Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":218,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Loss of heterozygosity; Germline; Prostate cancer; Prostate; Oncology; DNA repair; Internal medicine; Cancer; Cancer research; Gynecology; DNA; Genetics; Allele; Gene","score_opus":0.03292710841914352,"score_gpt":0.33842346555120995,"score_spread":0.3054963571320664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593176248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991202,0.0010841701,7.712796e-7,0.0038566547,0.00011407449,0.0004672377,0.000038028305,0.00003086993,0.0032062002],"genre_scores_gemma":[0.9963362,0.0008604215,0.00004333674,0.00020684469,0.000043649157,0.000024226425,0.000011032581,0.000022400518,0.0024518718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988856,0.00012850775,0.00024544826,0.0003254714,0.000117031705,0.0002979606],"domain_scores_gemma":[0.99918103,0.000038062874,0.00013108901,0.00049520604,0.000049847626,0.00010476563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021058807,0.00015153261,0.0003791815,0.00009915604,0.00010529227,0.000012733424,0.00009631498,0.000024500985,0.00003962565],"category_scores_gemma":[0.00006997169,0.000100145415,0.00007859298,0.000035063793,0.00035041006,0.00004196112,0.00013948769,0.00010946563,0.000016658874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085466687,0.00034418996,0.99102294,0.000054276716,0.000098685705,0.0018511988,0.00053741253,0.000004768204,0.0013138434,0.000028850856,0.00006410421,0.0038250638],"study_design_scores_gemma":[0.005134805,0.001449525,0.9875618,0.000022536786,0.00006478121,0.00006449331,0.000016746184,0.000077591714,0.0009781471,0.000011897647,0.0045386897,0.00007898916],"about_ca_topic_score_codex":0.0003579088,"about_ca_topic_score_gemma":0.00013828615,"teacher_disagreement_score":0.005134223,"about_ca_system_score_codex":0.00008380966,"about_ca_system_score_gemma":0.000065646804,"threshold_uncertainty_score":0.40838113},"labels":[],"label_agreement":null},{"id":"W2593675800","doi":"10.1016/j.critrevonc.2017.02.026","title":"A comprehensive review of immunotherapies in prostate cancer","year":2017,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of New Brunswick; Princess Margaret Cancer Centre; Canada Research Chairs; University of Toronto","funders":"","keywords":"Prostate cancer; Medicine; Immunotherapy; Clinical trial; Cancer; Disease; Oncology; Immune system; Cancer immunotherapy; Internal medicine; Immunology","score_opus":0.25979385975926067,"score_gpt":0.5697634065239928,"score_spread":0.30996954676473215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593675800","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000033427152,0.9872759,7.865412e-7,0.0035000646,0.0004290555,0.0064620473,0.00006517669,0.000017060009,0.0022465643],"genre_scores_gemma":[0.0000030946644,0.99304575,0.0003396275,0.000930994,0.00007348461,0.004994674,0.00010863547,0.00007036716,0.0004333681],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934209,0.0016125808,0.0029443132,0.0008381021,0.0002807195,0.0009033588],"domain_scores_gemma":[0.9955382,0.0019199249,0.00082071027,0.0011766499,0.00034299924,0.0002015197],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014488222,0.0006949021,0.01225175,0.00055206136,0.00006287096,0.000010742271,0.0005856502,0.00072050875,0.0006216016],"category_scores_gemma":[0.0036423053,0.00046272165,0.00093125366,0.00053011224,0.0015398879,0.00008020511,0.00027107625,0.0016212908,0.00015849009],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006596743,0.00032877046,0.00010181431,0.40178704,0.000104345105,0.00092950696,0.00004794598,1.8436732e-9,4.9432e-7,0.00082217983,0.0016827647,0.59412915],"study_design_scores_gemma":[0.00081773597,0.00028329124,0.0000128724905,0.41435468,0.00045396408,0.00052221614,0.000010289196,2.7211215e-7,0.000001567338,0.00013778037,0.58321583,0.00018949299],"about_ca_topic_score_codex":0.000074739684,"about_ca_topic_score_gemma":0.000047225687,"teacher_disagreement_score":0.59393966,"about_ca_system_score_codex":0.0009006013,"about_ca_system_score_gemma":0.0027063142,"threshold_uncertainty_score":0.99978244},"labels":[],"label_agreement":null},{"id":"W2594049437","doi":"10.1158/1538-7445.sabcs16-p4-22-08","title":"Abstract P4-22-08: A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Sunnybrook Health Science Centre","funders":"","keywords":"Enzalutamide; Trastuzumab; Medicine; Oncology; Internal medicine; Metastatic breast cancer; Regimen; Cancer; Phases of clinical research; Breast cancer; Clinical endpoint; Prostate cancer; Androgen receptor; Clinical trial","score_opus":0.257187020499096,"score_gpt":0.5508135852009494,"score_spread":0.2936265647018534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594049437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99165565,0.0006816967,0.000032535158,0.002305842,0.00010135911,0.004491494,0.00025577878,0.000025426109,0.00045019938],"genre_scores_gemma":[0.9966879,0.0013404196,0.00017459742,0.00004588086,0.00015796488,0.00076707936,0.000007982224,0.00007387461,0.00074433273],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995404,0.00041505866,0.0006585997,0.0009780289,0.0015168154,0.0010274678],"domain_scores_gemma":[0.99647105,0.0007989721,0.00022798977,0.0010253319,0.0007559144,0.00072076014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025226763,0.00034910106,0.0011461427,0.0004343609,0.00037444616,0.00015472273,0.0005054823,0.000092215894,0.0005776803],"category_scores_gemma":[0.000557957,0.00022912849,0.000084084386,0.0006130364,0.000908824,0.00036443947,0.00035956252,0.0011731783,0.000009565855],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2011483,0.02921875,0.15319902,0.0011026097,0.0012530583,0.0023574766,0.0019105817,0.00013884171,0.043253943,0.0000067505403,0.00022959345,0.56618106],"study_design_scores_gemma":[0.06269563,0.018313421,0.89957625,0.0026725656,0.00019725712,0.000049771963,0.0017313267,0.00007803757,0.013917338,0.00001518074,0.00037636602,0.00037683724],"about_ca_topic_score_codex":0.005078137,"about_ca_topic_score_gemma":0.0110481065,"teacher_disagreement_score":0.7463772,"about_ca_system_score_codex":0.0010323024,"about_ca_system_score_gemma":0.0030885653,"threshold_uncertainty_score":0.93435884},"labels":[],"label_agreement":null},{"id":"W2594965158","doi":"10.1016/j.mce.2017.03.013","title":"Patient-derived xenografts: A platform for accelerating translational research in prostate cancer","year":2017,"lang":"en","type":"review","venue":"Molecular and Cellular Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute","keywords":"Prostate cancer; Translational research; Cancer; Medicine; Drug development; Cancer research; Personalized medicine; Prostate; Computational biology; Bioinformatics; Internal medicine; Biology; Pathology; Drug; Pharmacology","score_opus":0.2305034752407488,"score_gpt":0.45360725841506927,"score_spread":0.22310378317432047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594965158","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0058195293,0.988725,0.000041940377,0.00037786286,0.0001485711,0.0041908342,0.00012620028,0.000022672013,0.0005473546],"genre_scores_gemma":[0.004277001,0.99105567,0.00025817694,0.00002600267,0.00012082547,0.00324016,0.0007152769,0.00008045269,0.00022641863],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972735,0.00013773119,0.0005285619,0.0007057627,0.0003465747,0.0010078513],"domain_scores_gemma":[0.99893713,0.00014539843,0.00015386114,0.00041975244,0.00017858733,0.00016527697],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002521362,0.0003758044,0.0013097909,0.0006136087,0.0003082958,0.00008002924,0.0001759015,0.00025136993,0.00003734407],"category_scores_gemma":[0.00004719391,0.00029305043,0.00031314077,0.00020008984,0.00031661903,0.00007057483,0.0001333667,0.0008602503,0.000006820503],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020982952,0.00010025157,0.00010479749,0.009091457,0.00033494586,0.0014069035,0.0001772712,7.346127e-7,0.00059188565,0.00030993993,0.000040380462,0.9876316],"study_design_scores_gemma":[0.003251536,0.00064810994,0.000012948925,0.0055405577,0.0003742578,0.00019058643,0.000059755377,0.00004748346,0.00229816,0.0004799019,0.98675615,0.00034053557],"about_ca_topic_score_codex":0.0001723629,"about_ca_topic_score_gemma":0.00007917798,"teacher_disagreement_score":0.98729104,"about_ca_system_score_codex":0.00016681215,"about_ca_system_score_gemma":0.00083795865,"threshold_uncertainty_score":0.99995214},"labels":[],"label_agreement":null},{"id":"W2595209185","doi":"10.1200/jco.2014.32.15_suppl.5062","title":"Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Sanofi (Canada); CancerCare Manitoba; Hôtel-Dieu de Québec; Sunnybrook Health Science Centre; University Health Network; Moncton Hospital; University of Toronto; London Health Sciences Centre; Grand River Hospital; Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Cabazitaxel; Prostate cancer; Internal medicine; Discontinuation; Adverse effect; Neutropenia; Febrile neutropenia; Enzalutamide; Oncology; Surgery; Cancer; Chemotherapy; Androgen deprivation therapy","score_opus":0.16610965670482203,"score_gpt":0.4860665985901908,"score_spread":0.3199569418853688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595209185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962853,0.0004807347,0.000008836433,0.0020856527,0.00014644656,0.000779495,0.000044145632,0.0000029093276,0.00016648306],"genre_scores_gemma":[0.9971038,0.00066557864,0.0016288289,0.00024099112,0.00008397932,0.000015263842,0.000008107391,0.000020128648,0.00023329473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99554175,0.0008268268,0.002499457,0.00023606638,0.00051834265,0.00037758372],"domain_scores_gemma":[0.9953258,0.0009515527,0.0019201835,0.00019037271,0.0008657754,0.00074630475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037874908,0.00017261991,0.0018874437,0.00038502048,0.000040262297,0.00000924057,0.000110144545,0.00015499382,0.000050373783],"category_scores_gemma":[0.0029284493,0.00009925112,0.000101913676,0.00037276163,0.0004786158,0.00013976808,0.000027580758,0.0005280272,0.000001004079],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07731759,0.0016735358,0.86740875,0.00047631186,0.0005577649,0.000088742396,0.0009866403,0.00004570515,0.0010377239,0.000022006287,0.00008440309,0.050300833],"study_design_scores_gemma":[0.04634314,0.024031265,0.9268426,0.00046771197,0.00031246422,0.000012422309,0.00024022847,0.00011125289,0.00035331948,0.000026888163,0.0011504423,0.00010832369],"about_ca_topic_score_codex":0.037571754,"about_ca_topic_score_gemma":0.30540958,"teacher_disagreement_score":0.26783785,"about_ca_system_score_codex":0.0003589962,"about_ca_system_score_gemma":0.0066756997,"threshold_uncertainty_score":0.99895555},"labels":[],"label_agreement":null},{"id":"W2595926616","doi":"10.1200/jco.2006.24.18_suppl.10077","title":"Nuclear localization of NF-kappaB p65 in primary prostate tumors is predictive of pelvic lymph node metastases","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Lymph node; Metastasis; Univariate analysis; Oncology; Biochemical recurrence; Immunohistochemistry; Primary tumor; Prostate; Proportional hazards model; Pathology; Urology; Internal medicine; Cancer; Multivariate analysis","score_opus":0.05636035180279126,"score_gpt":0.42078726662258253,"score_spread":0.3644269148197913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595926616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918944,0.0012607524,0.0001659124,0.0020537977,0.00019602625,0.00034374875,0.000040826337,0.0000058009714,0.0040387046],"genre_scores_gemma":[0.99655086,0.001318127,0.0010851743,0.0005130715,0.00022596096,0.0000033334964,0.000020092108,0.000019091825,0.0002642993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99638253,0.00037684324,0.002346639,0.00016745197,0.0005072662,0.00021928098],"domain_scores_gemma":[0.9967336,0.0007517174,0.0015841611,0.00014965773,0.0006308333,0.00015000088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018665919,0.00011992371,0.00140023,0.0002679603,0.000019402094,0.0000033038004,0.0001202047,0.00019633614,0.000121056975],"category_scores_gemma":[0.000614305,0.00008150481,0.00031546512,0.0003024192,0.0004428989,0.00012362254,0.000054208827,0.00041356575,0.0000043938353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027195632,0.006907613,0.9281503,0.000509919,0.00058652135,0.0009838002,0.0005303529,0.00074459304,0.0015924037,0.00012871812,0.0063626794,0.02630749],"study_design_scores_gemma":[0.025498835,0.014068957,0.94535446,0.00073240564,0.00054277526,0.00016417318,0.000442501,0.0013377975,0.0038674632,0.0011581443,0.0067118416,0.000120627934],"about_ca_topic_score_codex":0.00010506978,"about_ca_topic_score_gemma":0.000008543283,"teacher_disagreement_score":0.026186863,"about_ca_system_score_codex":0.00028828604,"about_ca_system_score_gemma":0.0019096929,"threshold_uncertainty_score":0.3387713},"labels":[],"label_agreement":null},{"id":"W2596327728","doi":"10.1016/j.eururo.2017.02.038","title":"Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; BC Cancer Agency; Genome British Columbia; University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Medicine; Prostate cancer; Nomogram; Prostatectomy; Oncology; Proportional hazards model; Stromal cell; Biochemical recurrence; Receiver operating characteristic; Gene signature; Metastasis; Internal medicine; Prostate; Cancer; Gene expression; Gene; Biology","score_opus":0.043962014356619505,"score_gpt":0.34487937536754326,"score_spread":0.30091736101092376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596327728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9571143,0.0034242317,0.00076479744,0.010191814,0.0005505006,0.00219811,0.0006032101,0.00010690762,0.025046166],"genre_scores_gemma":[0.98268574,0.00067946425,0.001766818,0.0014193607,0.0004300696,0.0002034631,0.00014429085,0.0000696102,0.01260116],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987689,0.00011473813,0.00017513445,0.000383516,0.00016556677,0.00039210165],"domain_scores_gemma":[0.9990287,0.000052998268,0.00013910994,0.0005015857,0.00012423257,0.00015341066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025378892,0.00015287085,0.0002619718,0.000063723004,0.00033608562,0.000035605743,0.00019887817,0.000030221272,0.00015094459],"category_scores_gemma":[0.000085525964,0.00010957778,0.0000858527,0.00002379864,0.00022681116,0.000104161234,0.0001688689,0.00016785778,0.00005796577],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03220403,0.0012238992,0.18845846,0.00092669314,0.0019024356,0.0028810522,0.0060402206,0.00005203991,0.562228,0.00009957855,0.112498336,0.09148526],"study_design_scores_gemma":[0.022924462,0.007672727,0.7141925,0.00014373359,0.00082072924,0.0001339918,0.00009452123,0.00057221233,0.10509503,0.000352803,0.14755067,0.00044658082],"about_ca_topic_score_codex":0.000015177949,"about_ca_topic_score_gemma":0.0000017443132,"teacher_disagreement_score":0.52573407,"about_ca_system_score_codex":0.00006355742,"about_ca_system_score_gemma":0.00014764305,"threshold_uncertainty_score":0.4468452},"labels":[],"label_agreement":null},{"id":"W2596339699","doi":"10.1200/jco.2014.32.15_suppl.e16029","title":"Canadian cost comparison of different forms of androgen ablative therapies prior and during the castration-resistant prostate cancer.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Prostate cancer; Cabazitaxel; Castration; Goserelin; Docetaxel; Androgen deprivation therapy; Oncology; Internal medicine; Cancer; Androgen; Urology; Gynecology; Hormone","score_opus":0.10019757478991576,"score_gpt":0.4733046291161632,"score_spread":0.37310705432624747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596339699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915121,0.0017256481,0.0000031639252,0.0058322544,0.00012270472,0.0003681473,0.00001729039,0.0000011928253,0.0004174644],"genre_scores_gemma":[0.99778354,0.0017406557,0.0000690136,0.000074801224,0.00012484376,0.000008087865,0.0000017309501,0.000006491641,0.00019085391],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982508,0.00018915767,0.0010813174,0.00008497638,0.00022367461,0.0001700923],"domain_scores_gemma":[0.9976028,0.0008025056,0.00091092783,0.00009409216,0.00034345893,0.00024621098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091810443,0.00008223444,0.0008463129,0.00007704385,0.00006882385,0.0000057286766,0.00007991466,0.00010122013,0.000033573782],"category_scores_gemma":[0.00032236957,0.000038322436,0.00012401528,0.00006579328,0.00032030753,0.000046403035,0.000018914834,0.00035863934,2.5121042e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060792635,0.00040603767,0.8999997,0.00011904981,0.0006778249,0.00002752448,0.002052779,0.000011990174,0.0023968357,0.00016049271,0.00013019211,0.08793833],"study_design_scores_gemma":[0.006453252,0.007184232,0.9761017,0.0001714163,0.00017967775,0.000022569327,0.0010042773,0.00011912679,0.004669073,0.00031388827,0.0037344706,0.000046319205],"about_ca_topic_score_codex":0.002606665,"about_ca_topic_score_gemma":0.036598,"teacher_disagreement_score":0.08789201,"about_ca_system_score_codex":0.00019018292,"about_ca_system_score_gemma":0.0014938673,"threshold_uncertainty_score":0.9809816},"labels":[],"label_agreement":null},{"id":"W2596543726","doi":"10.1371/journal.pone.0174134","title":"Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer","year":2017,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Prostate cancer; Transactivation; Androgen receptor; Decoy; Cancer research; Androgen; Prostate; Receptor; Cancer; Testosterone (patch); Medicine; Internal medicine; Biology; Hormone; Endocrinology; Transcription factor; Gene","score_opus":0.061556269653883805,"score_gpt":0.3534919643468764,"score_spread":0.29193569469299263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596543726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931313,0.0018267964,0.000008073521,0.0030429168,0.000036526828,0.0012117552,0.00023210225,0.000021968437,0.0004885697],"genre_scores_gemma":[0.9946931,0.0013823053,0.0018191062,0.00004349327,0.0000965784,0.000665972,0.0002366215,0.00002049998,0.0010422955],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989807,0.000018993178,0.00017735796,0.0002138741,0.00039925464,0.0002097968],"domain_scores_gemma":[0.99919003,0.000009316669,0.00011852895,0.00025832912,0.0002511323,0.00017264395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008542622,0.00010576598,0.00020914615,0.00005744617,0.00015553886,0.000034613367,0.00006457499,0.000049867533,0.0001496241],"category_scores_gemma":[0.000058587073,0.00008076003,0.00003423426,0.000059953887,0.00007327885,0.00010672803,0.0000504429,0.00009248664,0.000030013924],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011403908,0.0018551468,0.049888864,0.00041962604,0.00023809733,0.000014809955,0.0006069115,7.195058e-7,0.90492195,0.000008818427,0.0052236076,0.035681084],"study_design_scores_gemma":[0.0016023203,0.0009687179,0.002900221,0.0015228725,0.000106925385,8.311601e-7,0.000041828254,0.000065806176,0.9922863,0.000021827718,0.00038950352,0.00009284885],"about_ca_topic_score_codex":0.00009382732,"about_ca_topic_score_gemma":0.000036499318,"teacher_disagreement_score":0.087364376,"about_ca_system_score_codex":0.00010824643,"about_ca_system_score_gemma":0.00017012966,"threshold_uncertainty_score":0.32932982},"labels":[],"label_agreement":null},{"id":"W2597432644","doi":"10.1016/j.ejca.2017.01.024","title":"Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Prostate cancer; Abiraterone acetate; Internal medicine; Cancer; Cmax; Oncology; Pharmacology; Pharmacokinetics; Urology; Androgen deprivation therapy","score_opus":0.07111369384903171,"score_gpt":0.3939819211044353,"score_spread":0.3228682272554036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597432644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99645036,0.0010142124,0.000003583196,0.0004652621,0.00029809255,0.0010393533,0.000076749326,0.0000075236076,0.00064483617],"genre_scores_gemma":[0.9973897,0.00059696706,0.00007039572,0.00003032488,0.00022367385,0.000021669144,0.000007425252,0.00006321484,0.0015966368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739575,0.00022100404,0.00081733137,0.00027792846,0.0008789719,0.00040901438],"domain_scores_gemma":[0.9973883,0.000029601522,0.0011593071,0.00043287536,0.00073723885,0.000252659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006459384,0.0002650382,0.0006511945,0.0002739178,0.00021027403,0.0001271125,0.00033887243,0.000025183546,0.00019460126],"category_scores_gemma":[0.00006906309,0.00015530467,0.000071714756,0.00018971025,0.00016628212,0.0004983102,0.000076558135,0.00041992203,0.0000035353987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10813438,0.004655223,0.77775663,0.00035714885,0.0013556773,0.00556025,0.013376542,0.00077966996,0.0076155667,0.0000022281374,0.0007218075,0.079684876],"study_design_scores_gemma":[0.091146626,0.011872828,0.8907031,0.0014068838,0.00029895356,0.00001337206,0.0009783518,0.000028101695,0.0025094147,0.0000014348999,0.0008376614,0.00020326675],"about_ca_topic_score_codex":0.0005415476,"about_ca_topic_score_gemma":0.0015377962,"teacher_disagreement_score":0.11294647,"about_ca_system_score_codex":0.00044110318,"about_ca_system_score_gemma":0.00082228106,"threshold_uncertainty_score":0.63331413},"labels":[],"label_agreement":null},{"id":"W2597532271","doi":"10.1200/jco.2017.35.6_suppl.140","title":"Germline DNA repair mutations in metastatic castration-resistant prostate cancer: Therapy response and applicability of circulating tumor DNA.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Prostate cancer; PALB2; Medicine; Germline; DNA repair; Androgen deprivation therapy; Oncology; Internal medicine; Germline mutation; Cancer; Cancer research; Androgen receptor; Mutation; Gene; Biology; Genetics","score_opus":0.20046546095766327,"score_gpt":0.5339502792579713,"score_spread":0.3334848183003081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597532271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905476,0.0010694392,0.000006944661,0.007493401,0.00013540087,0.00055823487,0.000020959318,0.000005603478,0.00016240543],"genre_scores_gemma":[0.9964732,0.0010340251,0.0020331908,0.00014539083,0.00013714113,0.000030163765,0.0000024867138,0.0000108860195,0.0001335293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967861,0.00061840314,0.0018922825,0.00020079382,0.0003061044,0.00019631271],"domain_scores_gemma":[0.9948533,0.0023660313,0.0017782132,0.00028892205,0.00049158954,0.00022193277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006061248,0.00010925332,0.001053181,0.00012135026,0.00010809924,0.00001529865,0.00011265415,0.00008925694,0.000040821247],"category_scores_gemma":[0.0049621686,0.000072613475,0.00023807249,0.00009050312,0.00058482244,0.00013759725,0.000036745525,0.00050910574,6.663735e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09087948,0.0031122784,0.7571555,0.0002586126,0.00080390886,0.0026794383,0.0014095225,0.000081819664,0.045552325,0.00006926548,0.00015181926,0.09784606],"study_design_scores_gemma":[0.012951924,0.0059635574,0.97706187,0.0001669731,0.00013976797,0.00011654399,0.0003955627,0.0003115368,0.0011247445,0.0005989066,0.0011035396,0.00006506718],"about_ca_topic_score_codex":0.00015874446,"about_ca_topic_score_gemma":0.00026257377,"teacher_disagreement_score":0.2199064,"about_ca_system_score_codex":0.00017762318,"about_ca_system_score_gemma":0.0030165925,"threshold_uncertainty_score":0.59405375},"labels":[],"label_agreement":null},{"id":"W2597687769","doi":"10.1200/jco.2017.35.6_suppl.96","title":"Pre-treatment PSA- progression as a negative prognostic factor in patients using 5-alpha-reductase inhibitors prior to radiotherapy for prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Cancer; Urology; Interquartile range; Univariate analysis; Tumor progression; Brachytherapy; Radiation therapy; Oncology; Prostate; Biopsy; Prostate-specific antigen; Multivariate analysis","score_opus":0.14036715576169392,"score_gpt":0.5532531567504972,"score_spread":0.41288600098880335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597687769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878534,0.00068806496,0.000013081715,0.0061711916,0.0012248245,0.003963798,0.000042654858,0.0000071331974,0.00003586485],"genre_scores_gemma":[0.99058306,0.0010378599,0.0065184557,0.00026421333,0.0010103203,0.00019439303,0.0000061528444,0.000034502867,0.00035101996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712783,0.00023347295,0.001463955,0.0003151508,0.00042303198,0.0004365572],"domain_scores_gemma":[0.99601877,0.0007917974,0.0016467787,0.00026102774,0.0006911921,0.00059044035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085096393,0.00022123432,0.0012754143,0.00019359993,0.00019117657,0.000045134024,0.00019664863,0.0002507537,0.000036278732],"category_scores_gemma":[0.0037083116,0.00013074024,0.00033203367,0.00009569049,0.00023170134,0.00022180655,0.000057809342,0.00042442745,0.0000025667919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025872901,0.0031567828,0.5981322,0.00004522182,0.00033437213,0.00016936728,0.00090314844,0.000010019764,0.00043680592,0.0000011297499,0.000241742,0.37069634],"study_design_scores_gemma":[0.044126634,0.082716994,0.85939527,0.0010954317,0.00025576414,0.000023010807,0.00009665885,0.00015769724,0.0043021934,0.00010803234,0.00755662,0.00016572441],"about_ca_topic_score_codex":0.00019970287,"about_ca_topic_score_gemma":0.00008829369,"teacher_disagreement_score":0.3705306,"about_ca_system_score_codex":0.0014327033,"about_ca_system_score_gemma":0.0039779358,"threshold_uncertainty_score":0.70566875},"labels":[],"label_agreement":null},{"id":"W2597943206","doi":"10.1200/jco.2017.35.6_suppl.e560","title":"Integrated somatic subtypes of localized intermediate-risk prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Biomarker; Prostate cancer; Medicine; Oncology; Biomarker discovery; TMPRSS2; Cancer; Prostate; Internal medicine; Bioinformatics; Disease; Biology; Gene; Genetics; Proteomics; Coronavirus disease 2019 (COVID-19)","score_opus":0.13373867607831488,"score_gpt":0.5165692708157237,"score_spread":0.38283059473740877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597943206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99011,0.0016774894,0.000035461453,0.004996158,0.0014000607,0.0002789985,0.000018733408,0.0000068326526,0.001476285],"genre_scores_gemma":[0.9832887,0.013774984,0.0009938959,0.00017083068,0.0005218327,0.000008152694,0.0000035707546,0.000015775879,0.0012222411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967607,0.00035305636,0.0021252297,0.00014918348,0.00036586373,0.00024591645],"domain_scores_gemma":[0.9935354,0.0011626293,0.0037466073,0.00033655346,0.000868092,0.00035072758],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0029184902,0.00012947552,0.0015975081,0.000119592005,0.00008776728,0.000017780685,0.00032749763,0.0002631096,0.00025181912],"category_scores_gemma":[0.009149801,0.00007301666,0.00043412118,0.00006786577,0.0008187901,0.00013982804,0.000088860135,0.0010120192,0.000015296233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012851482,0.00095733133,0.643385,0.000112611015,0.00082512555,0.00053243747,0.00021037128,0.0000035200821,0.0003239775,0.000015912938,0.0025876458,0.3381946],"study_design_scores_gemma":[0.031273272,0.02156734,0.8957801,0.0010406775,0.0010439432,0.00010788641,0.0003672517,0.00052976754,0.003297298,0.0015628644,0.043289296,0.00014031424],"about_ca_topic_score_codex":0.00026641646,"about_ca_topic_score_gemma":0.00016075629,"teacher_disagreement_score":0.3380543,"about_ca_system_score_codex":0.00016511344,"about_ca_system_score_gemma":0.0034248324,"threshold_uncertainty_score":0.9991965},"labels":[],"label_agreement":null},{"id":"W2598081978","doi":"10.1016/j.eururo.2017.03.007","title":"Clinical Outcomes from Androgen Signaling–directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302","year":2017,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Abiraterone acetate; Enzalutamide; Prednisone; Medicine; Prostate cancer; Internal medicine; Oncology; Urology; Pharmacology; Androgen deprivation therapy; Cancer; Androgen receptor","score_opus":0.03572552789192894,"score_gpt":0.32709393763645467,"score_spread":0.2913684097445257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598081978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964684,0.001348748,0.0000027551832,0.00055351533,0.000028091528,0.00096218614,0.00054353883,0.000023089695,0.00006964684],"genre_scores_gemma":[0.9977985,0.0010839676,0.0003360509,0.00013758664,0.00001682948,0.00007438883,0.00030961304,0.000040038958,0.00020304066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980996,0.00039698376,0.0004598304,0.00049883116,0.00024060019,0.0003041508],"domain_scores_gemma":[0.9986828,0.00012188239,0.00033110008,0.0004980789,0.0002177748,0.00014838894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023076683,0.00026230185,0.0008466858,0.00019804017,0.00009614278,0.000043649205,0.000098324206,0.000036690257,0.00011246045],"category_scores_gemma":[0.000021110658,0.00014541217,0.00008424357,0.00015272529,0.00041585133,0.00009435942,0.000038409875,0.00012668887,0.0000037542463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042205103,0.00071030407,0.9400357,0.000013496977,0.005455952,0.0004718309,0.0010379425,0.000028208033,0.0004693707,4.1028156e-7,0.000003186307,0.009568485],"study_design_scores_gemma":[0.024397967,0.011432461,0.96176094,0.00003171013,0.0018031668,0.0000012594114,0.00003981458,0.000080986705,0.00021581023,0.0000018867555,0.00009795785,0.00013602054],"about_ca_topic_score_codex":0.0009254462,"about_ca_topic_score_gemma":0.001944853,"teacher_disagreement_score":0.021725249,"about_ca_system_score_codex":0.00005845024,"about_ca_system_score_gemma":0.00014185849,"threshold_uncertainty_score":0.5929736},"labels":[],"label_agreement":null},{"id":"W2598322637","doi":"10.1200/jco.2015.33.15_suppl.tps5071","title":"A phase 3 randomized, placebo-controlled double-blind study of ARN-509 plus abiraterone acetate (AA) in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Enzalutamide; Placebo; Androgen receptor; Internal medicine; Population; Cancer; Clinical endpoint; Chemotherapy; Oncology; Pharmacology; Urology; Randomized controlled trial; Androgen deprivation therapy; Pathology","score_opus":0.2629922469881669,"score_gpt":0.5399140988926265,"score_spread":0.2769218519044596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598322637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845402,0.0026044147,0.000025837704,0.0063209673,0.00063794287,0.005258284,0.000010731879,0.000008350775,0.000593224],"genre_scores_gemma":[0.9950215,0.0016961134,0.0005755932,0.0002788109,0.00035467002,0.00033568018,0.000006676102,0.000033406297,0.0016975433],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9922498,0.0016669879,0.004426912,0.00032014918,0.00090747443,0.00042871654],"domain_scores_gemma":[0.99321824,0.0018922677,0.0028426924,0.00025518573,0.0011994018,0.00059218693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011547915,0.0002884984,0.005018831,0.00041410833,0.00003774148,0.000025420528,0.00020816499,0.00020057267,0.00013430322],"category_scores_gemma":[0.0015126659,0.00016887671,0.000547614,0.00036008825,0.0004146705,0.00020579982,0.00004310803,0.0010167682,0.000007267705],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9593622,0.014029077,0.0013493175,0.000072922645,0.0032755649,0.0016696306,0.004038395,0.00041104978,0.0005412824,0.00001086891,0.00051633385,0.014723322],"study_design_scores_gemma":[0.958792,0.0338029,0.0008110489,0.00016521158,0.0015385116,0.00006675476,0.0027424525,0.00078189763,0.0003976665,0.00020041238,0.0005669002,0.0001342926],"about_ca_topic_score_codex":0.000455239,"about_ca_topic_score_gemma":0.0009773908,"teacher_disagreement_score":0.01977382,"about_ca_system_score_codex":0.0005823926,"about_ca_system_score_gemma":0.0065835374,"threshold_uncertainty_score":0.99904823},"labels":[],"label_agreement":null},{"id":"W2598368982","doi":"10.1200/po.17.00127","title":"Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Enzalutamide; Taxane; Prostate cancer; Medicine; Docetaxel; Oncology; Internal medicine; Androgen receptor; Cabazitaxel; Androgen deprivation therapy; Cancer; Breast cancer","score_opus":0.16266761043451983,"score_gpt":0.4792556454121008,"score_spread":0.316588034977581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598368982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541163,0.00019968723,0.0000103770535,0.00083224324,0.00021294816,0.0013150324,0.00006511229,0.000013831813,0.0019391464],"genre_scores_gemma":[0.9953252,0.00014194276,0.0037704352,0.00005220236,0.000046494588,0.00011008327,0.00003175969,0.00001642254,0.00050545146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978701,0.00022856946,0.0007259693,0.00041041576,0.00043435424,0.0003306041],"domain_scores_gemma":[0.9976453,0.00069409626,0.0004911211,0.0005605089,0.00044303437,0.00016594362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010325212,0.00015324673,0.00064123457,0.000114256894,0.0001475717,0.000021888547,0.00017881028,0.00011508601,0.00012950957],"category_scores_gemma":[0.0012710205,0.000098171164,0.00006770511,0.00014142328,0.00040624596,0.00013991406,0.00010528904,0.00036283283,0.000007952127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059853937,0.0011973388,0.82614255,0.000072697105,0.000073902025,0.0000831184,0.00015856273,0.0000042323827,0.00021036052,0.0000060664192,0.00026667566,0.16579908],"study_design_scores_gemma":[0.011828143,0.0038488742,0.98135954,0.0003084562,0.00009172042,0.0000026355865,0.00006222046,0.00028309727,0.00046146728,0.00019764487,0.0014664944,0.00008973141],"about_ca_topic_score_codex":0.00063948636,"about_ca_topic_score_gemma":0.0010252821,"teacher_disagreement_score":0.16570935,"about_ca_system_score_codex":0.00019827996,"about_ca_system_score_gemma":0.0010339778,"threshold_uncertainty_score":0.4003304},"labels":[],"label_agreement":null},{"id":"W2598538935","doi":"10.9778/cmajo.20160082","title":"Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study","year":2017,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Prostate Cancer Canada; McGill University Health Centre; McGill University","keywords":"Docetaxel; Medicine; Abiraterone acetate; Hazard ratio; Prostate cancer; Internal medicine; Oncology; Chemotherapy; Cohort; Proportional hazards model; Population; Retrospective cohort study; Cancer; Confidence interval; Androgen deprivation therapy","score_opus":0.053119550961104135,"score_gpt":0.386359089065669,"score_spread":0.33323953810456486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598538935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465245,0.000038484686,0.0000023443822,0.0004183657,0.000012583413,0.004620754,0.00015365431,0.000005121553,0.00009626977],"genre_scores_gemma":[0.999277,0.000011588833,0.0001387965,0.000021793092,0.000007148721,0.00021229025,0.000038426027,0.000027304168,0.00026566556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883693,0.00007948729,0.00022598979,0.00024702869,0.00042361286,0.000186957],"domain_scores_gemma":[0.9986872,0.00004710729,0.00037837852,0.0005410497,0.00026265625,0.00008362353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027512526,0.00018282782,0.0004592858,0.000052362902,0.00022725115,0.00011154734,0.00020714304,0.000014212499,0.000059976992],"category_scores_gemma":[0.000024825293,0.00007961556,0.00003205103,0.00008865829,0.00015945456,0.00016576934,0.000039682847,0.00009048629,5.354647e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018107317,0.00079395383,0.9772963,0.00008424209,0.0006882499,0.000006197865,0.00088436244,0.000063998814,0.0003240758,0.0000053833433,0.000006587432,0.0017393345],"study_design_scores_gemma":[0.018706294,0.006298639,0.973135,0.0002572615,0.00018620504,3.928395e-7,0.00020682676,0.00006211371,0.0010416231,0.000007919379,0.000003095507,0.00009463304],"about_ca_topic_score_codex":0.010399151,"about_ca_topic_score_gemma":0.0029825508,"teacher_disagreement_score":0.0074165994,"about_ca_system_score_codex":0.00008860394,"about_ca_system_score_gemma":0.00044277826,"threshold_uncertainty_score":0.99619067},"labels":[],"label_agreement":null},{"id":"W2598709449","doi":"10.1200/jco.2017.35.6_suppl.66","title":"Permanent seed brachytherapy for low risk prostate cancer, long term outcome, and urinary toxicity.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Interquartile range; Brachytherapy; Prostate cancer; Urology; Urinary system; Median follow-up; Cancer; Surgery; Internal medicine; Radiation therapy; Overall survival","score_opus":0.1557918007465678,"score_gpt":0.5367211438602499,"score_spread":0.38092934311368215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598709449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791513,0.0031869505,0.000030507734,0.015554937,0.0010632707,0.0006181056,0.000026949001,0.0000067173773,0.0003612414],"genre_scores_gemma":[0.9667869,0.02703812,0.000727457,0.00083902077,0.0014581013,0.000027837736,0.000004011545,0.000021168758,0.0030973805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765956,0.00015973454,0.0014076876,0.00020936097,0.0002595188,0.00030414597],"domain_scores_gemma":[0.99592656,0.0010008791,0.0019144148,0.00026706618,0.0004565077,0.00043454728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024013575,0.00014180518,0.0011568312,0.000078432946,0.00025318048,0.00003839614,0.00019175817,0.00024132017,0.000042966985],"category_scores_gemma":[0.0019852577,0.00008741032,0.00033000528,0.00002917532,0.0004089931,0.00017002819,0.000078067606,0.000780006,0.0000032362898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010723874,0.00101076,0.77762944,0.00010638878,0.00040519747,0.00069234456,0.000091601345,0.0000011901216,0.000155429,0.0000062535787,0.00057222205,0.20860532],"study_design_scores_gemma":[0.019986551,0.015546571,0.9524474,0.00015057134,0.0003038246,0.00026826715,0.000027963812,0.00006406755,0.00018510499,0.00017008146,0.01076108,0.000088484885],"about_ca_topic_score_codex":0.000028329318,"about_ca_topic_score_gemma":0.000053887277,"teacher_disagreement_score":0.20851684,"about_ca_system_score_codex":0.00016404048,"about_ca_system_score_gemma":0.0010795242,"threshold_uncertainty_score":0.35644895},"labels":[],"label_agreement":null},{"id":"W2599238962","doi":"10.1200/jco.2015.33.15_suppl.5034","title":"Radium-223 in an international early access program (EAP): Effects of concomitant medication on overall survival in metastatic castration-resistant prostate cancer (mCRCP) patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Concomitant; Prostate cancer; Enzalutamide; Internal medicine; Docetaxel; Asymptomatic; Bone pain; Urology; Cancer; Surgery; Gastroenterology","score_opus":0.19529464890392434,"score_gpt":0.5424210881110837,"score_spread":0.34712643920715935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599238962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99394673,0.00027638368,0.0000040084647,0.002849591,0.0014293881,0.0009766738,0.000013817985,0.000005704736,0.0004977033],"genre_scores_gemma":[0.99815273,0.00073366135,0.00046525183,0.00021413936,0.00025167703,0.00006965459,0.00003217956,0.000014209742,0.00006649043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960744,0.00072025403,0.001894036,0.00021311783,0.0008565593,0.00024167565],"domain_scores_gemma":[0.99625385,0.0011895768,0.0012076978,0.00014321334,0.00081525475,0.0003904323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026558856,0.00013654877,0.0009906705,0.00031049515,0.000012979489,0.000021180036,0.00025315833,0.00015603805,0.000025940904],"category_scores_gemma":[0.0024334593,0.000092012495,0.00015893804,0.00020878836,0.00019470186,0.00039902795,0.000042033345,0.00070400164,0.0000020825346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022225045,0.008974578,0.862261,0.000099339166,0.0003020675,0.0006528131,0.0006210698,0.00006812882,0.00015341617,0.00009985637,0.00021423664,0.104328446],"study_design_scores_gemma":[0.037083555,0.025323307,0.9347827,0.00036962674,0.00011177623,0.000005458523,0.0000796182,0.00023200439,0.00028208844,0.000346298,0.0013055023,0.00007805753],"about_ca_topic_score_codex":0.00047801374,"about_ca_topic_score_gemma":0.0009892911,"teacher_disagreement_score":0.10425039,"about_ca_system_score_codex":0.0006953123,"about_ca_system_score_gemma":0.002804383,"threshold_uncertainty_score":0.49748552},"labels":[],"label_agreement":null},{"id":"W2599344293","doi":"10.1200/jco.2012.30.15_suppl.tps4695","title":"A randomized, open-label, phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Dutasteride; Bicalutamide; Urology; Androgen receptor; Prostatectomy; Internal medicine; Clinical endpoint; Oncology; Antiandrogen; Androgen; Endocrinology; Cancer; Cancer research; Hormone; Randomized controlled trial","score_opus":0.1287908155528639,"score_gpt":0.5162259652658956,"score_spread":0.3874351497130317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599344293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901959,0.0018991822,0.000004906464,0.0035766198,0.00019595155,0.0040842416,0.00000926794,0.0000031928635,0.000030789553],"genre_scores_gemma":[0.985737,0.012868647,0.00046673903,0.0003945138,0.000100948724,0.00023250961,0.000002770107,0.000019095514,0.00017773117],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959776,0.001110488,0.0020339184,0.00022428544,0.0003277817,0.0003259627],"domain_scores_gemma":[0.996336,0.001610347,0.0012585265,0.00012573822,0.00027993115,0.000389469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006735069,0.00017631725,0.002270089,0.00032429743,0.00004113958,0.000018510085,0.00012401197,0.000118393895,0.0000268792],"category_scores_gemma":[0.0015323905,0.000091236114,0.000038626196,0.00029056513,0.0002926801,0.00031001872,0.00016424421,0.0006875077,6.6678854e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5960157,0.01416733,0.16900231,0.000032244814,0.0003156851,0.00047666565,0.0049876277,0.0000030068807,0.00016079076,0.000003155367,0.0000414446,0.21479404],"study_design_scores_gemma":[0.7458112,0.15338452,0.09798306,0.0003914749,0.00017071595,0.000121187455,0.0011117095,0.000056725214,0.00032140614,0.000105337785,0.00044985994,0.00009275059],"about_ca_topic_score_codex":0.0014140166,"about_ca_topic_score_gemma":0.001442456,"teacher_disagreement_score":0.2147013,"about_ca_system_score_codex":0.00015603544,"about_ca_system_score_gemma":0.0009842846,"threshold_uncertainty_score":0.37205008},"labels":[],"label_agreement":null},{"id":"W2599386056","doi":"10.1200/jco.2017.35.6_suppl.4","title":"Evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic prostate needle biopsy specimens.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; DECIPHER; Oncology; Prostate; Metastasis; Biopsy; Internal medicine; Prostatectomy; Prostate biopsy; Cancer; Biochemical recurrence; Pathology; Bioinformatics","score_opus":0.30499408326372374,"score_gpt":0.5165378263537546,"score_spread":0.21154374309003082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599386056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98753476,0.004526109,0.0000152243365,0.005818635,0.0006149449,0.000874183,0.00037667615,0.0000023089792,0.00023716781],"genre_scores_gemma":[0.9943709,0.004628856,0.00032496406,0.00013932717,0.00032132302,0.000035202425,0.000011115993,0.000014256556,0.00015408399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958425,0.000745178,0.0017526249,0.00028666563,0.0011482451,0.00022476699],"domain_scores_gemma":[0.99338156,0.0016690308,0.0022984578,0.0006409491,0.0014686711,0.0005413301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005410493,0.00015263788,0.0014347973,0.00018585271,0.00013074196,0.00002961051,0.00028768324,0.00013250775,0.00035764824],"category_scores_gemma":[0.008159076,0.00008505357,0.0005663174,0.0002632396,0.0007624094,0.00012192211,0.00017128234,0.00038942668,0.0000020687864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038178342,0.0007473524,0.9159532,0.000025632613,0.0065185004,0.0000630717,0.00036593733,0.00028296502,0.0012453885,0.000008882141,0.0009160522,0.07005517],"study_design_scores_gemma":[0.0057395473,0.0011264633,0.9719293,0.00015002342,0.016778896,0.0000027442077,0.00011985223,0.0008629499,0.0003397292,0.0005592688,0.002318716,0.00007247021],"about_ca_topic_score_codex":0.00033058765,"about_ca_topic_score_gemma":0.00030041987,"teacher_disagreement_score":0.06998271,"about_ca_system_score_codex":0.00030613202,"about_ca_system_score_gemma":0.0030893532,"threshold_uncertainty_score":0.9767766},"labels":[],"label_agreement":null},{"id":"W2599413066","doi":"10.1038/onc.2017.50","title":"FOXA1 inhibits prostate cancer neuroendocrine differentiation","year":2017,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"FOXA1; Prostate cancer; MAPK/ERK pathway; Cancer research; Biology; Neuroendocrine differentiation; Prostate; Gene knockdown; Transcription factor; Cancer; Signal transduction; Cell biology; Cell culture; Genetics; Gene","score_opus":0.04133735093960655,"score_gpt":0.36702669750124917,"score_spread":0.3256893465616426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599413066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98690003,0.0012395296,0.00000712715,0.006688359,0.00030275833,0.00048377694,0.000034331217,0.000045413082,0.0042986637],"genre_scores_gemma":[0.9705011,0.0025511624,0.000062048915,0.00016241737,0.00029505798,0.00011510403,0.000060728922,0.000024639658,0.026227694],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990758,0.000015533084,0.00012698873,0.00023896786,0.00025232875,0.0002904397],"domain_scores_gemma":[0.99922365,0.0000092987675,0.00009027905,0.00043376553,0.000093598625,0.00014937931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000041401887,0.00011987261,0.00018351483,0.000055804012,0.00029387334,0.0000697477,0.00010189518,0.000021318408,0.0002669623],"category_scores_gemma":[0.000041555435,0.000087291875,0.00006313631,0.00003930013,0.000073303505,0.000118887845,0.00009124169,0.00011624169,0.000068472036],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010473221,0.00036980616,0.36258966,0.00020071304,0.00021617104,0.0005559721,0.00021541546,0.0000033441518,0.34555483,0.00006159052,0.0054508704,0.28373432],"study_design_scores_gemma":[0.0066967914,0.00047017346,0.35050005,0.00018251689,0.00014883031,0.000058168764,0.000021063715,0.00025552214,0.6105746,0.00010146618,0.030802215,0.00018861161],"about_ca_topic_score_codex":0.00020850972,"about_ca_topic_score_gemma":0.00008899065,"teacher_disagreement_score":0.28354573,"about_ca_system_score_codex":0.00010521582,"about_ca_system_score_gemma":0.00013032061,"threshold_uncertainty_score":0.35596594},"labels":[],"label_agreement":null},{"id":"W2599694538","doi":"10.1200/jco.2017.35.6_suppl.38","title":"Relationships between an androgen receptor output signature (ARoS), AR expression, and poor prostate cancer prognosis in RP tissues.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Prostate cancer; Androgen receptor; Medicine; Prospective cohort study; Internal medicine; Androgen deprivation therapy; Cohort; Cancer; Androgen; Oncology; Retrospective cohort study; Endocrinology; Hormone","score_opus":0.23544384171287003,"score_gpt":0.5102009271200337,"score_spread":0.2747570854071637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599694538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9703345,0.0037076215,0.000002679804,0.024618844,0.00041721607,0.00050144386,0.00002562199,0.000008060474,0.0003840297],"genre_scores_gemma":[0.9898233,0.005307755,0.001859922,0.00017436301,0.001297766,0.000027387456,0.000013937727,0.0000205402,0.0014750435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973141,0.0005353703,0.001253787,0.00026206733,0.00035127753,0.0002833921],"domain_scores_gemma":[0.9968788,0.00072038954,0.0011980882,0.00022394944,0.00038462976,0.0005941689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032151805,0.0001425974,0.0010521585,0.00013992417,0.00020706821,0.0000429531,0.00021442454,0.0005703995,0.00007780839],"category_scores_gemma":[0.0027713184,0.00009023973,0.00013765087,0.00007081519,0.00037014918,0.0003736592,0.000090553025,0.0017898553,0.000006619533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002477599,0.000506993,0.89653784,0.00003806199,0.00013746435,0.00030950183,0.0004340884,0.0000012049977,0.0003339696,0.0000055691703,0.004323238,0.094894476],"study_design_scores_gemma":[0.009625377,0.0050309654,0.9295381,0.00045297752,0.00018771818,0.00003565404,0.00019858633,0.000015238447,0.0017402179,0.00041228265,0.052653674,0.0001092538],"about_ca_topic_score_codex":0.000052192834,"about_ca_topic_score_gemma":0.000106586434,"teacher_disagreement_score":0.09478522,"about_ca_system_score_codex":0.00015350133,"about_ca_system_score_gemma":0.0011830444,"threshold_uncertainty_score":0.77761304},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2599909104","doi":"10.1200/jco.2017.35.6_suppl.158","title":"Radium-223 (Ra-223) in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Asymptomatic; Internal medicine; Prostate cancer; Adverse effect; Clinical endpoint; Surgery; Gastroenterology; Cancer; Clinical trial","score_opus":0.2218471606640261,"score_gpt":0.57124287542136,"score_spread":0.3493957147573339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599909104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930045,0.00017324204,0.0000011494386,0.0038132276,0.0008288984,0.0010807973,0.000024273539,0.000010936276,0.0010629992],"genre_scores_gemma":[0.99747294,0.00086091977,0.000652063,0.0001769271,0.00030051643,0.00011348385,0.000030796025,0.000022428567,0.0003699342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99601984,0.00045423093,0.0021964225,0.00029221707,0.0006433177,0.00039396694],"domain_scores_gemma":[0.9963657,0.00045228036,0.001785423,0.00030187485,0.00069111236,0.00040359242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019065961,0.00019166633,0.0011594964,0.00034407538,0.00008585232,0.0001597033,0.0005602537,0.00019834183,0.00013592222],"category_scores_gemma":[0.0016525221,0.00012966388,0.00021219296,0.00016577194,0.00029322112,0.0010216942,0.000092172406,0.0008690256,0.000008009014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069505945,0.0066012614,0.80311227,0.000042442,0.00027366754,0.0011843176,0.00024075713,0.000012177145,0.0000482832,0.000009986782,0.0001156329,0.1814086],"study_design_scores_gemma":[0.030885184,0.009981447,0.95642203,0.0003367116,0.0001503914,0.000018193921,0.000049806655,0.00044271923,0.00008580728,0.00018247367,0.0013328339,0.00011242356],"about_ca_topic_score_codex":0.001133502,"about_ca_topic_score_gemma":0.004165318,"teacher_disagreement_score":0.18129617,"about_ca_system_score_codex":0.0006841229,"about_ca_system_score_gemma":0.0016786188,"threshold_uncertainty_score":0.52875394},"labels":[],"label_agreement":null},{"id":"W2600014321","doi":"10.1200/jco.2013.31.15_suppl.5009","title":"Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Abiraterone acetate; Tolerability; Prostate cancer; Internal medicine; Interim analysis; Post-hoc analysis; Urology; Placebo; Adverse effect; Prednisone; Chemotherapy; Incidence (geometry); Oncology; Gastroenterology; Cancer; Randomized controlled trial; Androgen deprivation therapy; Pathology","score_opus":0.10376297802675932,"score_gpt":0.47752228994048673,"score_spread":0.3737593119137274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600014321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99072057,0.002386888,0.00007402251,0.0054212576,0.00016434677,0.0010841623,0.000025178839,0.0000069395032,0.00011665593],"genre_scores_gemma":[0.98779726,0.009174454,0.0015403511,0.00039317357,0.0001354502,0.000034054487,0.0000134233005,0.00002562958,0.0008862028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99561507,0.00045075864,0.0027157709,0.00031448036,0.00051819655,0.00038571545],"domain_scores_gemma":[0.9961062,0.0009283654,0.0016685718,0.0002423504,0.00063853693,0.00041594138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020706914,0.00022671213,0.0025210534,0.0004387017,0.000047551137,0.000026435917,0.00015048197,0.00019503891,0.0004997417],"category_scores_gemma":[0.0004357213,0.00014509277,0.0003712228,0.000566972,0.0004494836,0.00022197813,0.00004416507,0.0006777059,0.0000051042143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044026095,0.0027635116,0.7353498,0.00029060582,0.00845145,0.0005886298,0.0016038987,0.00048338843,0.007279605,0.000009706508,0.00014834882,0.19900498],"study_design_scores_gemma":[0.033181045,0.0057563744,0.95630425,0.00023001217,0.0022886493,0.00003733805,0.00013162757,0.0010660792,0.0005419334,0.00003150963,0.00030709693,0.00012411177],"about_ca_topic_score_codex":0.00035726535,"about_ca_topic_score_gemma":0.0010423909,"teacher_disagreement_score":0.22095445,"about_ca_system_score_codex":0.00039925397,"about_ca_system_score_gemma":0.0021015154,"threshold_uncertainty_score":0.59167117},"labels":[],"label_agreement":null},{"id":"W2600340656","doi":"10.1200/jco.2013.31.15_suppl.e16052","title":"International prevalence of nonmetastatic (M0) castration-resistant prostate cancer (CRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Incidence (geometry); Demography; Population; Prostate-specific antigen; Cancer; Disease; Oncology; Gynecology; Internal medicine; Environmental health","score_opus":0.1487583170269903,"score_gpt":0.5172608125796673,"score_spread":0.368502495552677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600340656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97940755,0.0012087828,0.000025957514,0.014205047,0.0010072892,0.00040795206,0.00002432633,0.000004106206,0.003708985],"genre_scores_gemma":[0.9848608,0.0064896652,0.0034212451,0.0003613027,0.00050744443,0.00002397443,0.0000033753952,0.000010425024,0.0043218085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972625,0.00018196425,0.0017195635,0.00013594546,0.0005173335,0.00018270638],"domain_scores_gemma":[0.996477,0.0007520066,0.0012453564,0.00012397642,0.0011399423,0.00026170275],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012272211,0.00009456833,0.0007176189,0.00011769034,0.000022299893,0.000010414329,0.00016871984,0.00011863206,0.0021841985],"category_scores_gemma":[0.0010894024,0.000058791033,0.0002556697,0.000102239035,0.00026707893,0.00019692797,0.000038409682,0.00048757065,0.000028464106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01232165,0.004133956,0.50512135,0.00075129943,0.0022498607,0.00077915296,0.00068575435,0.00007022474,0.02426004,0.00017978123,0.020053558,0.42939338],"study_design_scores_gemma":[0.011675735,0.011570102,0.9415698,0.00044320713,0.0004734929,0.00015077885,0.0002443976,0.00026582615,0.002140534,0.0006487093,0.030710341,0.000107094835],"about_ca_topic_score_codex":0.00009908044,"about_ca_topic_score_gemma":0.00001770421,"teacher_disagreement_score":0.43644845,"about_ca_system_score_codex":0.0001690696,"about_ca_system_score_gemma":0.001974296,"threshold_uncertainty_score":0.9987279},"labels":[],"label_agreement":null},{"id":"W2600365723","doi":"10.1200/jco.2017.35.6_suppl.252","title":"Population-based analysis of treatment toxicity among men with castration-resistant prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Cabazitaxel; Enzalutamide; Docetaxel; Medicine; Prostate cancer; Hazard ratio; Toxicity; Population; Internal medicine; Proportional hazards model; Oncology; Cohort; Chemotherapy; Cancer; Confidence interval; Androgen deprivation therapy","score_opus":0.14593400711687557,"score_gpt":0.5120480420107019,"score_spread":0.3661140348938263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600365723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938732,0.0001784426,0.000016707485,0.003642951,0.00010422609,0.00030018052,0.000032478667,0.0000036089864,0.0018482388],"genre_scores_gemma":[0.99760467,0.0004648261,0.000660521,0.00006666296,0.00019152093,0.00001380721,0.000018627727,0.000008845802,0.0009705272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783635,0.00017050043,0.0012828782,0.0001641449,0.00036632418,0.00017978545],"domain_scores_gemma":[0.99583256,0.0005560671,0.0024081888,0.0003141866,0.0006032163,0.0002857969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010278843,0.000119461874,0.0014678484,0.00020575881,0.0001261154,0.00001952002,0.00012941669,0.00014723802,0.00014393868],"category_scores_gemma":[0.00049345545,0.00006449791,0.00045466574,0.00016047715,0.00029404252,0.00011925564,0.000014161213,0.0002474545,6.482786e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011450773,0.0010224098,0.96292496,0.000021740927,0.0041255523,0.00028787673,0.00007341156,0.0008395809,0.0003023014,0.00001456431,0.00009223908,0.01884462],"study_design_scores_gemma":[0.009154631,0.016523771,0.96754205,0.00008953556,0.003898262,0.000003981843,0.0000600102,0.0014487545,0.0007279972,0.000024667157,0.00046795525,0.000058411315],"about_ca_topic_score_codex":0.0027150966,"about_ca_topic_score_gemma":0.005400061,"teacher_disagreement_score":0.018786209,"about_ca_system_score_codex":0.000572957,"about_ca_system_score_gemma":0.003051343,"threshold_uncertainty_score":0.5412951},"labels":[],"label_agreement":null},{"id":"W2600486674","doi":"10.1200/jco.2012.30.15_suppl.4644","title":"Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Prostate cancer; Oncology; Proportional hazards model; Clinical endpoint; Chemotherapy; Gastroenterology; Randomized controlled trial; Cancer","score_opus":0.19932598669651053,"score_gpt":0.5331515742694648,"score_spread":0.3338255875729543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600486674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98632073,0.0050558117,0.00014892191,0.0044874204,0.0010265748,0.0024284865,0.00007665003,0.000007711394,0.00044768522],"genre_scores_gemma":[0.9931454,0.0023952175,0.002674539,0.00020661391,0.00095193664,0.00012083926,0.00007281973,0.00001723968,0.00041537144],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939538,0.0013368033,0.0036128955,0.00017774849,0.00060900016,0.00030973981],"domain_scores_gemma":[0.99070024,0.0042363787,0.0032412633,0.00019480231,0.0011807956,0.0004465025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006828479,0.00016543793,0.0024155923,0.00016364489,0.0000453041,0.000013678969,0.000112206784,0.00018202724,0.00037821362],"category_scores_gemma":[0.0063931625,0.000098678865,0.0005909967,0.00018697703,0.0003875199,0.0002779816,0.000019482855,0.00062458124,0.000006600529],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93832386,0.005515187,0.001256769,0.00007167728,0.0015135101,0.00010399932,0.0006569806,0.0000042498896,0.008403485,0.000119475306,0.00044040117,0.043590393],"study_design_scores_gemma":[0.9691912,0.01605711,0.0065888916,0.0002177447,0.0031084777,0.000033267796,0.00042964297,0.00015701432,0.0021197505,0.0005469353,0.0014521284,0.00009782913],"about_ca_topic_score_codex":0.00025516475,"about_ca_topic_score_gemma":0.000060829985,"teacher_disagreement_score":0.043492563,"about_ca_system_score_codex":0.00023204865,"about_ca_system_score_gemma":0.0042175953,"threshold_uncertainty_score":0.76536745},"labels":[],"label_agreement":null},{"id":"W2600538636","doi":"10.1200/jco.2017.35.6_suppl.238","title":"Assessment of urologists experience with abiraterone acetate and with a real-world trial: Results obtained from a Canadian Observational Study in Metastatic Cancer of the Prostate (COSMiC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Université de Sherbrooke; Dalhousie University; Hôtel-Dieu de Québec; University of Calgary; University of Manitoba; University of Alberta; Trillium Health Centre","funders":"","keywords":"Abiraterone acetate; Medicine; Observational study; Prostate cancer; Clinical trial; Randomized controlled trial; Androgen deprivation therapy; Clinical Practice; Family medicine; Internal medicine; Oncology; Cancer","score_opus":0.3810844143040263,"score_gpt":0.5612095128641381,"score_spread":0.18012509856011183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600538636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897757,0.00009147621,0.0000023300533,0.008371901,0.00016290124,0.0011497495,0.000046856392,0.0000013165289,0.00039777954],"genre_scores_gemma":[0.9977551,0.00048936054,0.0011608375,0.0001855086,0.00007219624,0.00004843551,0.0000030607093,0.000009539058,0.0002759387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714243,0.0004874355,0.0014766196,0.00021013952,0.00047070943,0.00021266108],"domain_scores_gemma":[0.995787,0.0008513141,0.0022638212,0.0003367187,0.0005260015,0.00023509162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002430051,0.000119710916,0.0011341025,0.00012039945,0.00007639939,0.000014940687,0.00023993223,0.000059074297,0.000012288544],"category_scores_gemma":[0.00086726295,0.000055197168,0.00007036162,0.00014286986,0.00071427244,0.00012853598,0.0000567442,0.0004985342,7.8874045e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09888259,0.0010412983,0.8956084,0.000016629125,0.00046435907,0.00044875726,0.00091402297,0.00005576068,0.0000675953,0.000013190999,0.000042369822,0.002444985],"study_design_scores_gemma":[0.09957244,0.017525971,0.8815238,0.00018591569,0.00024641934,0.000008463213,0.0004502819,0.000112520145,0.000052500516,0.00006821096,0.00020516124,0.000048350354],"about_ca_topic_score_codex":0.10125573,"about_ca_topic_score_gemma":0.50337434,"teacher_disagreement_score":0.40211862,"about_ca_system_score_codex":0.00024901156,"about_ca_system_score_gemma":0.0075444537,"threshold_uncertainty_score":0.99808186},"labels":[],"label_agreement":null},{"id":"W2600594844","doi":"10.1200/jco.2017.35.6_suppl.208","title":"Effect of enzalutamide on sensitivity in prostate cancer cells to radiation by inhibition of DNA double strand break repair.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Enzalutamide; LNCaP; Prostate cancer; Clonogenic assay; Medicine; Cancer research; Androgen receptor; Cancer; Oncology; Internal medicine; Cell; Biology; Genetics","score_opus":0.0661779758453938,"score_gpt":0.48988665169817464,"score_spread":0.4237086758527808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600594844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99476606,0.00022955352,0.000003761493,0.0033387793,0.0004005464,0.0005558018,0.000027703258,0.0000032157498,0.0006745702],"genre_scores_gemma":[0.9980656,0.001248839,0.000065440254,0.00014602498,0.0002230502,0.000007650215,0.000004111477,0.0000090483545,0.00023025235],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99771553,0.0004494781,0.0011654296,0.00015251008,0.00034258215,0.00017448023],"domain_scores_gemma":[0.99679446,0.0012559486,0.0012940526,0.00019420128,0.00025888893,0.00020243322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051783053,0.0000984356,0.0010849538,0.0001313202,0.00003397897,0.000005572351,0.000054569802,0.00018057553,0.000023033903],"category_scores_gemma":[0.00092171156,0.00006464466,0.00026214324,0.00006974402,0.00017825802,0.00010825319,0.000028221175,0.0004781765,0.0000027621445],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14678921,0.0025433986,0.39086238,0.00048803096,0.00043976153,0.0010003473,0.00035154307,0.00020450201,0.20346446,0.000013463803,0.0072976598,0.24654524],"study_design_scores_gemma":[0.031978022,0.036972895,0.30264148,0.00067942037,0.0002023335,0.000022285341,0.000019954274,0.00006634723,0.62523663,0.000032996653,0.0020757364,0.00007186326],"about_ca_topic_score_codex":0.00039947126,"about_ca_topic_score_gemma":0.00024326026,"teacher_disagreement_score":0.42177218,"about_ca_system_score_codex":0.00023631094,"about_ca_system_score_gemma":0.00070437137,"threshold_uncertainty_score":0.26361328},"labels":[],"label_agreement":null},{"id":"W2600855551","doi":"10.1200/jco.2013.31.15_suppl.5002","title":"Double-blind randomized trial of aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Aflibercept; Medicine; Docetaxel; Placebo; Prednisone; Hazard ratio; Clinical endpoint; Internal medicine; Prostate cancer; Surgery; Bevacizumab; Randomized controlled trial; Urology; Oncology; Chemotherapy; Gastroenterology; Cancer; Confidence interval; Pathology","score_opus":0.24906357258083653,"score_gpt":0.5163570845611213,"score_spread":0.2672935119802847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600855551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98766255,0.0019547867,0.00004451399,0.0037053353,0.00042989026,0.005730109,0.000029722345,0.000003384497,0.00043967756],"genre_scores_gemma":[0.9851715,0.006041196,0.0061916546,0.000033988075,0.00037357208,0.0006299614,0.0000123460895,0.00002162098,0.0015241362],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966785,0.00034947827,0.002165738,0.00018735889,0.000387927,0.00023104316],"domain_scores_gemma":[0.99234253,0.004343002,0.0019754467,0.00014453549,0.00090669875,0.000287792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017682745,0.00017462861,0.0027098518,0.00013952528,0.00003538362,0.000011480335,0.00006716727,0.0001408387,0.00013833538],"category_scores_gemma":[0.00056256546,0.00008855307,0.0004470933,0.00010995585,0.0006197304,0.0001285,0.000013324561,0.0001633493,9.46765e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9593493,0.0029056766,0.00027820293,0.00013893459,0.0032725034,0.00004355678,0.000516099,0.000022994102,0.0004983057,0.000047162604,0.00021346097,0.03271382],"study_design_scores_gemma":[0.90529376,0.08834138,0.0005778053,0.00011466747,0.0026191634,0.000022499074,0.00029877163,0.000100637924,0.0012469736,0.00014274636,0.0011722865,0.00006931183],"about_ca_topic_score_codex":0.00027956505,"about_ca_topic_score_gemma":0.00016105616,"teacher_disagreement_score":0.085435696,"about_ca_system_score_codex":0.00016539027,"about_ca_system_score_gemma":0.0027067685,"threshold_uncertainty_score":0.4801691},"labels":[],"label_agreement":null},{"id":"W2600932175","doi":"10.1200/jco.2013.31.15_suppl.e16088","title":"Quality of life (QoL) of patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; Université de Montréal; Université Laval; Sanofi (Canada); Sunnybrook Health Science Centre; University of Toronto; Moncton Hospital; London Health Sciences Centre; Grand River Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Cabazitaxel; Medicine; Prostate cancer; Quality of life (healthcare); Docetaxel; Internal medicine; Cancer; Oncology; Androgen deprivation therapy","score_opus":0.1631294014390921,"score_gpt":0.48985776265248515,"score_spread":0.32672836121339305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600932175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99642605,0.000429264,0.000015675747,0.0017849456,0.00008009541,0.0007449292,0.00004489539,0.000003844637,0.00047030437],"genre_scores_gemma":[0.99692035,0.00041915436,0.001966715,0.0001376273,0.00007862402,0.000024630192,0.00001600613,0.000015870062,0.0004209996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996188,0.0005020536,0.0022304982,0.00016378265,0.0006914857,0.00022417233],"domain_scores_gemma":[0.9934755,0.00089020806,0.0026817848,0.00017855848,0.0024096046,0.0003643296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013904,0.00014208339,0.0015760491,0.00012261035,0.000026630378,0.000005912776,0.00009227456,0.00011605939,0.00022355778],"category_scores_gemma":[0.00093541417,0.000070396316,0.00017738524,0.00023342409,0.0004251829,0.00017217665,0.000017985718,0.00043729102,0.0000025641395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052382655,0.0030072883,0.92088443,0.00026781097,0.001479653,0.00007303367,0.00020908727,0.000029693572,0.0008275586,0.000020000147,0.0006612176,0.020157559],"study_design_scores_gemma":[0.02344149,0.030715086,0.9437336,0.00022348286,0.0004254262,0.0000062737004,0.00026954923,0.0000147408755,0.00062760635,0.000056010173,0.0004119586,0.00007481055],"about_ca_topic_score_codex":0.00095071236,"about_ca_topic_score_gemma":0.0004294284,"teacher_disagreement_score":0.028941166,"about_ca_system_score_codex":0.0001637739,"about_ca_system_score_gemma":0.0031841837,"threshold_uncertainty_score":0.5648605},"labels":[],"label_agreement":null},{"id":"W2600976514","doi":"","title":"The Quebec PROCURE Prostate Cancer Biobank: A unique resource for comprehensive studies of the disease","year":2016,"lang":"en","type":"article","venue":"Journal of Tissue Science & Engineering","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biobank; Prostate cancer; Disease; Resource (disambiguation); Medicine; Cancer; Business; Bioinformatics; Pathology; Computer science; Internal medicine; Biology","score_opus":0.039847385502951374,"score_gpt":0.37162281821167953,"score_spread":0.33177543270872817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600976514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.956385,0.023055337,0.0001656395,0.019152874,0.00039258157,0.0008072803,0.000021780672,0.000011720021,0.000007783586],"genre_scores_gemma":[0.99647623,0.0015373447,0.00023899307,0.00003176167,0.00014380176,0.000039722465,1.017062e-7,0.000010715158,0.0015213476],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893916,0.000014133391,0.00023052526,0.00010408261,0.00045208598,0.000260037],"domain_scores_gemma":[0.99860066,0.00018071853,0.00016285545,0.00017237755,0.00074779027,0.00013559645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042358864,0.00008927718,0.00018160256,0.000090755355,0.00018345173,0.000021793476,0.00026728006,0.000014901737,0.0000013711378],"category_scores_gemma":[0.00050628185,0.000032201828,0.00007546378,0.00035121854,0.0005158974,0.00014092031,0.000072082854,0.000101937614,2.1687684e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013255463,0.00009012144,0.009964722,0.00064526114,0.00039441147,0.00004460166,0.0036742538,0.0024389867,0.93684214,0.0016100653,0.0041535883,0.03881629],"study_design_scores_gemma":[0.0040394007,0.0014414244,0.070874654,0.0056451247,0.00027022682,0.000081226026,0.0018848098,0.00046293647,0.60452,0.00031365562,0.3102146,0.00025193256],"about_ca_topic_score_codex":0.000015302105,"about_ca_topic_score_gemma":0.000023189908,"teacher_disagreement_score":0.33232215,"about_ca_system_score_codex":0.00027858562,"about_ca_system_score_gemma":0.00075802836,"threshold_uncertainty_score":0.19008455},"labels":[],"label_agreement":null},{"id":"W2600997186","doi":"10.1200/jco.2017.35.6_suppl.26","title":"Genomic architecture of radioresistant prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Prostate cancer; Radioresistance; PTEN; Medicine; Prostate; Cancer; Radiation therapy; Genome instability; Copy-number variation; Cancer research; Oncology; Gene; Internal medicine; Biology; Genome; Genetics; DNA damage","score_opus":0.1472413046791093,"score_gpt":0.5243546875461824,"score_spread":0.3771133828670731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600997186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96831846,0.0038876373,0.000014338337,0.02108024,0.00088881596,0.00023404995,0.00001400593,0.000003238815,0.005559229],"genre_scores_gemma":[0.9868084,0.008328204,0.0014466237,0.00028719808,0.0010358229,0.000004223713,0.0000011601461,0.000013441229,0.002074889],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978274,0.00015513328,0.0013569471,0.0001302657,0.00031271856,0.0002175036],"domain_scores_gemma":[0.9963331,0.00047147583,0.0021280283,0.00031958925,0.00041784957,0.00032994893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018225736,0.00009668458,0.0012166,0.00008874542,0.00008625947,0.000011339557,0.00028705166,0.00019597713,0.00012606548],"category_scores_gemma":[0.0016004293,0.000056261997,0.00041983492,0.000034820514,0.00058987684,0.00005782479,0.00007422786,0.0007961039,0.000004669027],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020958442,0.0009080522,0.43799973,0.00012962657,0.0008771901,0.0014473507,0.00023282054,0.000014765342,0.0040209824,0.00007194809,0.0037374068,0.5296017],"study_design_scores_gemma":[0.01364469,0.010528677,0.84602565,0.0002468247,0.00036381398,0.00019344522,0.000052545456,0.000014895864,0.0013268495,0.0009079138,0.12662251,0.00007218717],"about_ca_topic_score_codex":0.000063039595,"about_ca_topic_score_gemma":0.000053893804,"teacher_disagreement_score":0.5295295,"about_ca_system_score_codex":0.00016000685,"about_ca_system_score_gemma":0.0031835486,"threshold_uncertainty_score":0.56474787},"labels":[],"label_agreement":null},{"id":"W2601129256","doi":"10.1200/jco.2013.31.15_suppl.e16070","title":"How does stereotactic body radiotherapy compare to standard external beam radiotherapy or low-dose rate brachytherapy for low-risk prostate cancer?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; External beam radiotherapy; Radiation therapy; Androgen deprivation therapy; Prospective cohort study; Hazard ratio; Univariate analysis; Cancer; Cohort; Prostate; Proportional hazards model; Urology; Oncology; Internal medicine; Multivariate analysis; Confidence interval","score_opus":0.07351191141618489,"score_gpt":0.4719658824772869,"score_spread":0.398453971061102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601129256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9473222,0.005407109,0.0021831484,0.03957038,0.0022731968,0.0030809513,0.00011161779,0.000029668232,0.00002171357],"genre_scores_gemma":[0.88069,0.07384248,0.017152576,0.00959479,0.006951525,0.00053176295,0.000013538601,0.00017837199,0.01104496],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951252,0.0007060641,0.0022321744,0.0004861111,0.0006644144,0.0007860341],"domain_scores_gemma":[0.9918804,0.0031005794,0.002027994,0.0004015001,0.0014349237,0.001154609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003071806,0.00040044705,0.0025974421,0.00027543856,0.00016682489,0.00017556886,0.000382968,0.0003108731,0.00082393014],"category_scores_gemma":[0.0012082371,0.00020520871,0.0007531585,0.00026744473,0.00032550286,0.00045304795,0.00003428101,0.0011945292,0.000008946895],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20606516,0.0027847693,0.20277412,0.00032559436,0.0035799858,0.00084173697,0.0010748332,0.000084083156,0.016691267,0.000011267399,0.020933148,0.544834],"study_design_scores_gemma":[0.14565416,0.12973888,0.29652715,0.0015543965,0.0007680758,0.00048570093,0.0007128388,0.0014471592,0.010045034,0.00074829854,0.4114534,0.00086492614],"about_ca_topic_score_codex":0.000113223025,"about_ca_topic_score_gemma":0.00010867433,"teacher_disagreement_score":0.5439691,"about_ca_system_score_codex":0.00096867373,"about_ca_system_score_gemma":0.0033861964,"threshold_uncertainty_score":0.90214574},"labels":[],"label_agreement":null},{"id":"W2601261230","doi":"10.1200/jco.2013.31.15_suppl.5059","title":"Interim safety results of a global early access protocol (EAP) of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after taxane-based chemotherapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McMaster University","funders":"","keywords":"Medicine; Internal medicine; Prostate cancer; Abiraterone acetate; Taxane; Docetaxel; Discontinuation; Adverse effect; Surgery; Cancer; Breast cancer; Androgen deprivation therapy","score_opus":0.10032107909518902,"score_gpt":0.49462519427479584,"score_spread":0.39430411517960684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601261230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787182,0.000068522815,0.000020310023,0.003113519,0.00009896443,0.017751362,0.0000591833,0.0000049400724,0.00016495217],"genre_scores_gemma":[0.992913,0.00003276063,0.0027210198,0.00021902159,0.000068806134,0.0039225095,0.0000073438446,0.000021386475,0.00009411733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952927,0.00047600688,0.0029519887,0.00026473895,0.00066293275,0.00035161633],"domain_scores_gemma":[0.99495184,0.0002619474,0.0028999718,0.00021645919,0.0014049102,0.00026484524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014063022,0.00021549432,0.0014531567,0.00013447947,0.000023326491,0.00003096321,0.00021059568,0.00013909161,0.00013115494],"category_scores_gemma":[0.00034523587,0.00012401832,0.00019967127,0.00036791136,0.0005024813,0.00036571053,0.00004860002,0.00050607114,0.0000019998063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24605872,0.0046187793,0.6285204,0.00051746867,0.00052776816,0.00025549365,0.00032083373,0.00007735044,0.0005272478,0.0000010961961,0.00017270244,0.1184021],"study_design_scores_gemma":[0.06881376,0.028519308,0.8984422,0.0014382175,0.00015342928,0.000008803946,0.00006004271,0.00009950494,0.0017495906,0.000036572546,0.00056954747,0.00010900173],"about_ca_topic_score_codex":0.00053557724,"about_ca_topic_score_gemma":0.0005194461,"teacher_disagreement_score":0.26992178,"about_ca_system_score_codex":0.00045363567,"about_ca_system_score_gemma":0.0030920883,"threshold_uncertainty_score":0.5485232},"labels":[],"label_agreement":null},{"id":"W2601275109","doi":"10.1016/j.jmoldx.2017.01.007","title":"Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay","year":2017,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Cancer Institute; Research Institute for Sustainable Humanosphere, Kyoto University","keywords":"DECIPHER; Computational biology; Prostate; Biology; Cancer research; Bioinformatics; Genetics; Cancer","score_opus":0.09526507109589125,"score_gpt":0.42648198176573593,"score_spread":0.3312169106698447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601275109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928656,0.003517173,0.0023470826,0.00056928076,0.00026100478,0.00037091883,0.00001966301,0.0000018856862,0.00004734543],"genre_scores_gemma":[0.9858426,0.0044312906,0.009402947,0.0001663204,0.00011539896,0.0000031942384,0.000005400269,0.000019676916,0.0000131583365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982035,0.00022869934,0.000705777,0.00011879064,0.0004944056,0.00024882468],"domain_scores_gemma":[0.997167,0.00081484,0.000808528,0.0003387463,0.0007286537,0.00014224905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000805659,0.0001162862,0.00040515562,0.00011012648,0.00009496174,0.00004603703,0.00019125786,0.000066286804,0.000009119164],"category_scores_gemma":[0.0036684824,0.000072996096,0.00017015789,0.000071502705,0.00027431393,0.0000906717,0.00009011753,0.0003786159,0.0000011523025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080168043,0.00053152966,0.9366357,0.00011003547,0.0001877286,0.003944107,0.00032631133,0.00013906466,0.026302015,0.00003334554,0.00016988268,0.030818652],"study_design_scores_gemma":[0.0059332103,0.0011103579,0.92189837,0.0007414337,0.00033073896,0.000263173,0.00020695075,0.0011529438,0.0662211,0.0005247012,0.0014951394,0.00012187143],"about_ca_topic_score_codex":0.000050222672,"about_ca_topic_score_gemma":0.000013738569,"teacher_disagreement_score":0.03991909,"about_ca_system_score_codex":0.00011190687,"about_ca_system_score_gemma":0.00044525557,"threshold_uncertainty_score":0.4391781},"labels":[],"label_agreement":null},{"id":"W2601358810","doi":"10.1200/jco.2017.35.6_suppl.260","title":"Early docetaxel-resistance in metastatic hormone-sensitive prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Internal medicine; Oncology; Androgen deprivation therapy; Prostate-specific antigen; Cancer; Urology","score_opus":0.17486007631299028,"score_gpt":0.5277195521479847,"score_spread":0.35285947583499444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601358810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96394163,0.0044571934,0.000009716266,0.023383206,0.00065554405,0.00035177378,0.000012504223,0.000004796429,0.007183661],"genre_scores_gemma":[0.9838715,0.008870132,0.001724201,0.00051153783,0.0005294187,0.000013418177,0.0000012817114,0.000016308752,0.004462161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971754,0.0003054871,0.0015276965,0.00020745535,0.0004331088,0.00035086303],"domain_scores_gemma":[0.9961608,0.00081884075,0.0017582703,0.00030112083,0.0005782982,0.0003826885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027939624,0.00013783126,0.001466186,0.000135801,0.000107845495,0.00003458709,0.00023586515,0.00016072256,0.00003907249],"category_scores_gemma":[0.0028760391,0.00008881189,0.00032569558,0.00008545838,0.00051154016,0.00025930122,0.00007110509,0.0011101741,0.000021044136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08749303,0.004106796,0.60616744,0.00018998075,0.0023338362,0.033299904,0.0019512401,0.000011220994,0.0014971142,0.0005362232,0.013218293,0.24919493],"study_design_scores_gemma":[0.018029168,0.005652495,0.95295393,0.0002587019,0.00026383772,0.000068121546,0.0001256656,0.000016921258,0.00025430074,0.0011817623,0.021100208,0.00009487675],"about_ca_topic_score_codex":0.0002010862,"about_ca_topic_score_gemma":0.00060424895,"teacher_disagreement_score":0.34678653,"about_ca_system_score_codex":0.00029652665,"about_ca_system_score_gemma":0.0025072698,"threshold_uncertainty_score":0.4823216},"labels":[],"label_agreement":null},{"id":"W2601377141","doi":"10.1200/jco.2017.35.6_suppl.51","title":"Predicting disease progression in men with localized high risk prostate cancer undergoing radical prostatectomy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Nomogram; Medicine; Prostate cancer; Prostatectomy; Biochemical recurrence; Cohort; Oncology; Internal medicine; Stage (stratigraphy); Cancer; Urology","score_opus":0.07481029464369106,"score_gpt":0.4920252350439141,"score_spread":0.41721494040022306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601377141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823882,0.0015475657,0.000032364307,0.0135478545,0.0003839681,0.0009324279,0.000012988071,0.000016463011,0.0011381432],"genre_scores_gemma":[0.98702145,0.00936936,0.002020828,0.00016865133,0.0007568129,0.00006024498,0.0000049452296,0.00003113334,0.0005665502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963063,0.00052119594,0.0016841778,0.0003185093,0.0007061089,0.00046373176],"domain_scores_gemma":[0.99463916,0.0012086487,0.002573015,0.00034620697,0.00037779316,0.00085518544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034274906,0.00018984206,0.0012476542,0.00014666254,0.00024332979,0.00005315152,0.00025760126,0.00023457935,0.00006548186],"category_scores_gemma":[0.0058410177,0.00010339706,0.00021379425,0.00010540647,0.000759272,0.00029450163,0.00012311069,0.0016118995,0.0000042680836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051922344,0.0011472565,0.8120274,0.0001196,0.00031412582,0.004181818,0.00011576288,0.000049038797,0.000016186641,0.000017967413,0.00033522845,0.12975326],"study_design_scores_gemma":[0.05360378,0.011443579,0.923681,0.0021930824,0.00048670554,0.0000805063,0.000124445,0.0011593025,0.00014172241,0.00076520507,0.0061823046,0.00013832009],"about_ca_topic_score_codex":0.00026456828,"about_ca_topic_score_gemma":0.0002943262,"teacher_disagreement_score":0.12961493,"about_ca_system_score_codex":0.00043318784,"about_ca_system_score_gemma":0.0062900945,"threshold_uncertainty_score":0.99934334},"labels":[],"label_agreement":null},{"id":"W2601560840","doi":"10.1200/jco.2015.33.15_suppl.e16095","title":"Meta-analysis of the impact of single agent daily prednisone on outcomes and toxicities in metastatic castration-resistant prostate cancer (mCRPC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Prostate cancer; Prednisone; Randomized controlled trial; Placebo; Oncology; Prostate-specific antigen; Enzalutamide; Clinical trial; Cancer; Surgery; Pathology","score_opus":0.501077019749078,"score_gpt":0.5555932498792532,"score_spread":0.05451623013017515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601560840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991885,0.0031039587,0.0000026986634,0.004231124,0.000107177366,0.00029064898,0.00006750768,0.0000012055608,0.00031070053],"genre_scores_gemma":[0.99838626,0.00044874547,0.00028296487,0.00014804723,0.00002986488,0.00000937641,0.000002265232,0.00000697607,0.0006854929],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968089,0.0005775216,0.00180732,0.0001258341,0.0005186294,0.00016178637],"domain_scores_gemma":[0.99631244,0.0013487285,0.0014635101,0.00018098776,0.0004901553,0.00020417977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002609129,0.00012181429,0.002473181,0.00026761598,0.000015960713,0.0000067483384,0.00010370495,0.000081976126,0.0000948396],"category_scores_gemma":[0.0012466145,0.0000519361,0.0012415702,0.00037236194,0.00030717047,0.00006945995,0.00003665049,0.00032269864,3.251479e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020554505,0.006013616,0.70349723,0.000105744766,0.24955764,0.00032582428,0.0032352859,0.0054228664,0.0033631257,0.00006373522,0.0010411852,0.0068192547],"study_design_scores_gemma":[0.008687437,0.017105523,0.8983104,0.000041998457,0.07316467,0.000013142078,0.00085053616,0.00018620242,0.0011035001,0.00032049406,0.00014887369,0.000067207904],"about_ca_topic_score_codex":0.0006654446,"about_ca_topic_score_gemma":0.00084467046,"teacher_disagreement_score":0.19481319,"about_ca_system_score_codex":0.00027957515,"about_ca_system_score_gemma":0.0021005243,"threshold_uncertainty_score":0.372624},"labels":[],"label_agreement":null},{"id":"W2601615263","doi":"10.1200/jco.2017.35.6_suppl.3","title":"Luminal and basal subtyping of prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Subtyping; Prostate; Oncology; Internal medicine; Tissue microarray; Basal (medicine); Androgen deprivation therapy; Cancer; Pathology","score_opus":0.21853675441988313,"score_gpt":0.5598049055431439,"score_spread":0.34126815112326075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601615263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773539,0.0020614043,0.0000036336662,0.017245,0.00077645085,0.00012551916,0.000004658712,0.0000017730719,0.0024276657],"genre_scores_gemma":[0.9890437,0.008129193,0.0006094061,0.00025821666,0.0009466372,0.0000023390364,6.099509e-7,0.00000737006,0.0010024912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984418,0.00010231901,0.0009628368,0.00010289493,0.0002277626,0.00016239664],"domain_scores_gemma":[0.99731976,0.0004547354,0.001394419,0.00015927784,0.00040606724,0.0002657191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001890591,0.000067979316,0.0008587048,0.00006005382,0.000079837875,0.000011044903,0.0001259126,0.00014928491,0.000060553877],"category_scores_gemma":[0.0017953747,0.00004221088,0.00017095883,0.000024688357,0.0005884449,0.00011342529,0.00007113998,0.00052490365,0.0000016399487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008097766,0.00042085952,0.7674583,0.000090711146,0.00030290385,0.0006031751,0.00012103565,5.5577357e-7,0.0005685692,0.000034704808,0.002197883,0.2201035],"study_design_scores_gemma":[0.0101875495,0.00896168,0.95853436,0.00027824118,0.00023278026,0.0001281757,0.000098030716,0.000037466052,0.0012657508,0.00043143696,0.019796433,0.000048116537],"about_ca_topic_score_codex":0.00008350935,"about_ca_topic_score_gemma":0.000043963253,"teacher_disagreement_score":0.22005539,"about_ca_system_score_codex":0.00006325167,"about_ca_system_score_gemma":0.001703687,"threshold_uncertainty_score":0.30222675},"labels":[],"label_agreement":null},{"id":"W2601829962","doi":"10.1200/jco.2012.30.15_suppl.e15177","title":"Temsirolimus (TEM) maintenance therapy after response of castration-resistant prostate cancer (CRPC) to docetaxel (TAX).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Princess Margaret Cancer Centre; Queen's University; London Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical endpoint; Docetaxel; Temsirolimus; Prostate cancer; Internal medicine; Oncology; Surrogate endpoint; Cancer; Urology; Clinical trial; Surgery; PI3K/AKT/mTOR pathway; Apoptosis","score_opus":0.15714857045649616,"score_gpt":0.5088583835759543,"score_spread":0.3517098131194581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601829962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97488034,0.0058191256,0.00001259852,0.017353006,0.0009226749,0.0005164522,0.00003285922,0.0000056789654,0.00045726617],"genre_scores_gemma":[0.9874875,0.005016805,0.0012148606,0.0019128136,0.001023906,0.000050623486,0.0000012430572,0.00002220422,0.0032700447],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9963987,0.0006011454,0.0018407411,0.00016905954,0.0005177013,0.00047267645],"domain_scores_gemma":[0.9959856,0.0012495246,0.0009878497,0.00023248064,0.0008435999,0.00070089434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047439113,0.00015980113,0.0011523009,0.00017909368,0.000035161993,0.000008428074,0.00014235386,0.00022861167,0.00027609064],"category_scores_gemma":[0.0012740993,0.00009394299,0.00037134852,0.00022664959,0.00024774755,0.00016475837,0.00003142201,0.00063084654,0.000022889197],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4975046,0.004104781,0.36072746,0.000095568284,0.0009569519,0.0010867934,0.0018862388,0.000015027429,0.032651957,0.00006395667,0.01214663,0.088760056],"study_design_scores_gemma":[0.0120400395,0.015516957,0.7980443,0.00023877747,0.00013148756,0.0001303979,0.00021159244,0.000005011078,0.0038327805,0.000059012855,0.16968198,0.00010761562],"about_ca_topic_score_codex":0.00007421593,"about_ca_topic_score_gemma":0.00005580829,"teacher_disagreement_score":0.48546454,"about_ca_system_score_codex":0.0003063787,"about_ca_system_score_gemma":0.0027743839,"threshold_uncertainty_score":0.49216378},"labels":[],"label_agreement":null},{"id":"W2601920003","doi":"10.1200/jco.2017.35.6_suppl.173","title":"Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Abiraterone acetate; Internal medicine; Taxane; Enzalutamide; Prednisone; Adverse effect; Cancer; Gastroenterology; Urology; Androgen receptor; Oncology; Androgen deprivation therapy; Breast cancer","score_opus":0.10375789579384996,"score_gpt":0.47915824735057805,"score_spread":0.3754003515567281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601920003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99613357,0.00026615022,0.000004414687,0.0021539968,0.0000976681,0.0011866101,0.000035027373,0.000003232981,0.00011930676],"genre_scores_gemma":[0.997679,0.0014138038,0.00054684264,0.00010091189,0.00005914937,0.00001778655,0.000005737877,0.000020399215,0.00015638952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972048,0.00034311195,0.0013801374,0.0002901671,0.0005166396,0.00026519314],"domain_scores_gemma":[0.99681526,0.0004539252,0.0017221201,0.00027226246,0.0004221522,0.00031425265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014937241,0.00019520959,0.0014053454,0.00014544456,0.00012009586,0.000031828287,0.000120896395,0.00008444039,0.000017196868],"category_scores_gemma":[0.00037816452,0.00010571306,0.000051774514,0.000084686406,0.00053997355,0.00020702965,0.000052861957,0.0005830906,7.743753e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28564534,0.019833846,0.53483146,0.00014603997,0.0013950912,0.0014247949,0.001319818,0.00009856799,0.00024559686,0.0000099550325,0.000047628942,0.15500188],"study_design_scores_gemma":[0.14349161,0.11690377,0.73778373,0.00035819743,0.0005323503,0.000026168576,0.00030394277,0.000056068227,0.00013851997,0.000014572193,0.00030195343,0.000089112604],"about_ca_topic_score_codex":0.00017338719,"about_ca_topic_score_gemma":0.0015236794,"teacher_disagreement_score":0.20295228,"about_ca_system_score_codex":0.00013804997,"about_ca_system_score_gemma":0.00083484355,"threshold_uncertainty_score":0.43108532},"labels":[],"label_agreement":null},{"id":"W2601947714","doi":"10.1200/jco.2017.35.6_suppl.e587","title":"Prevalence of oligoprogressive, metastatic castration-resistant prostate cancer (mCRPC) amenable to stereotactic ablative radiotherapy (SABR) in men undergoing abiraterone acetate (AA) therapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Docetaxel; SABR volatility model; Prostate cancer; Abiraterone acetate; Oncology; Chemotherapy; Internal medicine; Lymph; Radiation therapy; Metastasis; Bone metastasis; Androgen deprivation therapy; Cancer; Radiology; Pathology","score_opus":0.17010034977483687,"score_gpt":0.512485317785779,"score_spread":0.3423849680109421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601947714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837153,0.005206889,0.000024283609,0.008833063,0.00033825685,0.0010134651,0.00001776216,0.00000506878,0.00084592646],"genre_scores_gemma":[0.96836907,0.025377419,0.0031418616,0.00032047392,0.00019142588,0.0000537352,0.0000011253792,0.000027019169,0.002517857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963541,0.0005265652,0.0018833699,0.0002891959,0.0005351777,0.0004115823],"domain_scores_gemma":[0.9950567,0.0010669433,0.0025311166,0.00037013425,0.0006168095,0.00035830145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025751404,0.0002046325,0.0014325824,0.00021046064,0.00011441919,0.000048296097,0.0003268847,0.00013040351,0.00019509418],"category_scores_gemma":[0.0009807771,0.00013200447,0.00022577659,0.00014137903,0.00036015635,0.00040444933,0.000056220215,0.0006342157,0.000004130819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07863292,0.004278404,0.6735271,0.00094967696,0.0048225606,0.003176845,0.00511274,0.00048911606,0.033511538,0.00007062557,0.0011214708,0.19430697],"study_design_scores_gemma":[0.032895714,0.025384635,0.92865574,0.0013910118,0.00034998526,0.0000815479,0.0005446941,0.00022916385,0.007747044,0.00044486922,0.0020677452,0.0002078498],"about_ca_topic_score_codex":0.00023565933,"about_ca_topic_score_gemma":0.00029744674,"teacher_disagreement_score":0.2551286,"about_ca_system_score_codex":0.0004695991,"about_ca_system_score_gemma":0.0031801306,"threshold_uncertainty_score":0.5641415},"labels":[],"label_agreement":null},{"id":"W2602035838","doi":"10.1200/jco.2017.35.6_suppl.134","title":"AR nuclear localization and microtubule bundling as markers of docetaxel and cabazitaxel sensitivity in metastatic castration-resistant prostate cancer (mCRPC): Prospective biomarker analysis from TAXYNERGY.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; Université de Montréal; Sanofi (Canada)","funders":"","keywords":"Taxane; Cabazitaxel; Medicine; Docetaxel; Prostate cancer; Circulating tumor cell; Biomarker; Oncology; Internal medicine; Cancer; Breast cancer; Metastasis; Androgen deprivation therapy; Biology","score_opus":0.08197289625430612,"score_gpt":0.454776220245076,"score_spread":0.3728033239907699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602035838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950635,0.0015020858,0.00007180566,0.0025043094,0.00012546006,0.00035627812,0.000053467735,0.000002939926,0.0003201811],"genre_scores_gemma":[0.99445003,0.0037067996,0.0014745516,0.000121498415,0.000079968646,0.000005968744,0.000008074708,0.000013567784,0.00013953891],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763453,0.000365295,0.0012248348,0.00027287955,0.00030217823,0.00020027172],"domain_scores_gemma":[0.9967477,0.00074765435,0.001576563,0.00019313776,0.00049259485,0.00024237942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022412615,0.00014327874,0.0012894935,0.00025298318,0.00012445863,0.000042696272,0.00006727647,0.00015524779,0.000057092362],"category_scores_gemma":[0.0016100121,0.00010209866,0.00019952744,0.00018589466,0.00061163795,0.00022611236,0.00006759889,0.0004004259,8.2328694e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020914542,0.0009530768,0.9348612,0.000110061286,0.00435357,0.0013962194,0.000611534,0.00010416453,0.009325177,0.000045974368,0.000116245836,0.027208261],"study_design_scores_gemma":[0.00937405,0.0025058435,0.9802063,0.00022821047,0.0018824838,0.000046305264,0.0005636863,0.003623576,0.0006177126,0.00045093178,0.00039996958,0.00010092013],"about_ca_topic_score_codex":0.00467716,"about_ca_topic_score_gemma":0.0054588593,"teacher_disagreement_score":0.045345135,"about_ca_system_score_codex":0.00018894109,"about_ca_system_score_gemma":0.0008921845,"threshold_uncertainty_score":0.70704985},"labels":[],"label_agreement":null},{"id":"W2603065939","doi":"10.1200/jco.2017.35.6_suppl.42","title":"Oncologic outcomes of radiation therapy following active surveillance for low- and intermediate-risk localized prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Cohort; Radiation therapy; Brachytherapy; Cancer; Prostate; Internal medicine; Stage (stratigraphy); Oncology; Urology; Surgery","score_opus":0.12701812990568495,"score_gpt":0.5263233611163263,"score_spread":0.3993052312106413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603065939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893374,0.002325428,0.000040530962,0.0060687517,0.0013639145,0.00065492984,0.000032472508,0.000004639131,0.00017196678],"genre_scores_gemma":[0.9684235,0.03027187,0.00037948266,0.00026978835,0.00037537783,0.00003091769,0.0000040192326,0.000012715021,0.00023234519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978787,0.0002879817,0.0012040085,0.00017114516,0.00024060086,0.00021761481],"domain_scores_gemma":[0.99382216,0.0027213532,0.0026835108,0.00018706138,0.00037710596,0.0002088286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029052452,0.00012282135,0.0015467231,0.00007976966,0.00012958319,0.00001586789,0.00016734548,0.00023773756,0.000017934899],"category_scores_gemma":[0.0055565853,0.00007097557,0.00047263099,0.000036288322,0.00036876104,0.00015475965,0.00004634927,0.0004602486,6.537226e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011872371,0.00034679516,0.5522653,0.000027168955,0.0006832662,0.000049282004,0.00015563301,0.0000017039712,0.00008065373,0.0000035432508,0.0001508397,0.43436342],"study_design_scores_gemma":[0.033089172,0.013376503,0.9458129,0.00009599872,0.00016364614,0.0000068443032,0.00011315408,0.000091661714,0.0008592741,0.0004389127,0.0058850423,0.00006692607],"about_ca_topic_score_codex":0.00009120387,"about_ca_topic_score_gemma":0.00008975711,"teacher_disagreement_score":0.43429652,"about_ca_system_score_codex":0.00017476604,"about_ca_system_score_gemma":0.0014709801,"threshold_uncertainty_score":0.6652153},"labels":[],"label_agreement":null},{"id":"W2603251482","doi":"10.1200/jco.2014.32.15_suppl.5021","title":"Genomic analysis of circulating tumor DNA (ctDNA) in plasma of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (abi) and enzalutamide (enza).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Androgen receptor; Oncology; Internal medicine; Abiraterone; Comparative genomic hybridization; Cancer research; Cancer; Genetics; Chromosome; Biology; Gene","score_opus":0.08041507329046181,"score_gpt":0.4194641877961967,"score_spread":0.3390491145057349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603251482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986638,0.00029604786,0.000010766597,0.00039431063,0.00006370186,0.0003955934,0.000040420804,0.0000032740063,0.00013209604],"genre_scores_gemma":[0.9981102,0.0003706762,0.001274118,0.00008264783,0.00004633195,0.000012859842,0.000017377877,0.000018418523,0.00006742179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99613494,0.0005395259,0.0023631693,0.00024604946,0.00043654675,0.00027977332],"domain_scores_gemma":[0.99557483,0.0010804266,0.0022878447,0.00016546318,0.0006415998,0.0002498141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017833398,0.0001780864,0.0020977317,0.0005093827,0.000030973955,0.000008782472,0.00009617922,0.00009770019,0.0000476934],"category_scores_gemma":[0.0006755056,0.00011138028,0.00023362429,0.0005603709,0.0003499153,0.00011437179,0.000032480675,0.00041243774,6.400224e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013795061,0.0012252213,0.94095033,0.00019401379,0.0033236255,0.00023983969,0.00049485796,0.0014524903,0.01325029,0.000011033143,0.000013672609,0.025049545],"study_design_scores_gemma":[0.020290805,0.011052211,0.9588409,0.00025998094,0.0032591424,0.000022614871,0.0001949795,0.0032641252,0.0025837005,0.00003367766,0.00009583522,0.00010203188],"about_ca_topic_score_codex":0.00039365154,"about_ca_topic_score_gemma":0.0011209389,"teacher_disagreement_score":0.024947513,"about_ca_system_score_codex":0.00024353681,"about_ca_system_score_gemma":0.0010246634,"threshold_uncertainty_score":0.4541956},"labels":[],"label_agreement":null},{"id":"W2603425088","doi":"10.1200/jco.2013.31.15_suppl.5037","title":"Impact of concomitant bone-targeted therapies (BTT) on outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy (ctx) treated with abiraterone acetate (AA) or prednisone (P).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Concomitant; Prostate cancer; Denosumab; Internal medicine; Interim analysis; Zoledronic acid; Prednisone; Cancer; Post-hoc analysis; Oncology; Performance status; Placebo; Abiraterone acetate; Surgery; Androgen deprivation therapy; Urology; Randomized controlled trial; Osteoporosis; Pathology","score_opus":0.09356829627849418,"score_gpt":0.4638602741999951,"score_spread":0.3702919779215009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603425088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99476624,0.000528266,0.0000030937856,0.0025416499,0.00013123728,0.0018454463,0.00007305534,0.000012706987,0.00009833699],"genre_scores_gemma":[0.99604625,0.0014735918,0.0011029906,0.00038797417,0.000070624425,0.000099241064,0.000014228477,0.00005007517,0.00075502944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99552834,0.0005380255,0.0024678342,0.00031150517,0.00066928926,0.00048502322],"domain_scores_gemma":[0.9952662,0.00096220674,0.0020679922,0.00026400297,0.0010498877,0.00038973067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010216666,0.00035571805,0.0025527831,0.00029682668,0.000049086997,0.000027450691,0.00015929756,0.00019801366,0.00061658846],"category_scores_gemma":[0.00046322754,0.00016308945,0.0003833056,0.0003164864,0.0004089077,0.00026796007,0.000020970208,0.0007062795,0.000008668121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.078161255,0.0052085146,0.8665868,0.00008005114,0.0030820426,0.0002513639,0.0008541391,0.00005960485,0.003347973,0.000002254635,0.00028623725,0.04207975],"study_design_scores_gemma":[0.05558719,0.07582539,0.86600363,0.00028351886,0.00028750673,0.000023741835,0.00021839645,0.00007706009,0.0013363429,0.000039127273,0.00016307327,0.0001550013],"about_ca_topic_score_codex":0.0006479757,"about_ca_topic_score_gemma":0.00066438265,"teacher_disagreement_score":0.07061688,"about_ca_system_score_codex":0.000667386,"about_ca_system_score_gemma":0.0029201123,"threshold_uncertainty_score":0.6751211},"labels":[],"label_agreement":null},{"id":"W2603478463","doi":"10.1200/jco.2017.35.6_suppl.78","title":"Is there a relationship between testosterone levels at the end of short-term androgen deprivation therapy and outcomes in intermediate risk prostate cancer? Prospective data from a phase III trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Rimouski; Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Nova Scotia Cancer Centre; Centre hospitalier universitaire de Québec; Centre de Santé et de Services Sociaux de Chicoutimi; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Prostate cancer; Testosterone (patch); Androgen deprivation therapy; Urology; Goserelin; Antiandrogen; Bicalutamide; Androgen; Proportional hazards model; Analysis of variance; Cancer; Prostate; Internal medicine; Gynecology; Hormone; Androgen receptor","score_opus":0.4389825818582998,"score_gpt":0.5582691456226296,"score_spread":0.11928656376432983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603478463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98824376,0.0022724015,0.000008144897,0.0074377144,0.0002411513,0.0011499933,0.0005592481,0.0000028579889,0.00008475456],"genre_scores_gemma":[0.992997,0.0061137807,0.00011330707,0.0000939556,0.00040616063,0.00002811607,0.000033479668,0.000013259169,0.0002009623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722624,0.0004353845,0.0015817741,0.0002618872,0.0003208636,0.0001738433],"domain_scores_gemma":[0.9925256,0.004519241,0.002020408,0.0005927537,0.00019561147,0.00014643233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032251624,0.00013278866,0.0011483264,0.00007996259,0.00014466612,0.00002524084,0.00038104516,0.00020590844,0.00008110026],"category_scores_gemma":[0.0038320606,0.000068151865,0.0001339445,0.000055352448,0.00064884755,0.00026107774,0.00025742155,0.0007824831,0.0000014982071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045943595,0.00063645473,0.7972719,0.000007958227,0.0005811986,0.000055542216,0.0007364505,1.2054306e-7,0.000052350715,0.0000014751412,0.000086591834,0.15462634],"study_design_scores_gemma":[0.12248574,0.0058844206,0.8694899,0.00011956963,0.00028626583,0.0000052660193,0.00007809554,0.000020775564,0.00030802208,0.00081755803,0.00044954297,0.000054855773],"about_ca_topic_score_codex":0.00029971387,"about_ca_topic_score_gemma":0.00084162806,"teacher_disagreement_score":0.15457149,"about_ca_system_score_codex":0.00017786592,"about_ca_system_score_gemma":0.00090663304,"threshold_uncertainty_score":0.45876113},"labels":[],"label_agreement":null},{"id":"W2603608316","doi":"10.1056/oh201012070000001","title":"Does Androgen-Deprivation Therapy Affect Physical Function?","year":2010,"lang":"en","type":"article","venue":"Journal watch","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Androgen deprivation therapy; Medicine; Prostate cancer; Affect (linguistics); Prospective cohort study; Adverse effect; Cohort; Physical activity; Oncology; Internal medicine; Gerontology; Physical therapy; Cancer; Psychology","score_opus":0.01949068797325801,"score_gpt":0.33559210078467294,"score_spread":0.3161014128114149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603608316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802596,0.00009405549,0.000046865036,0.018206187,0.00068808533,0.00018379185,0.0000013981146,0.000026388612,0.0004936274],"genre_scores_gemma":[0.9925888,0.0009491058,0.0000932061,0.00017601975,0.0019382676,0.000010119046,0.0000074350364,0.000014494595,0.0042225095],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992824,0.0000252461,0.00009748699,0.00011020944,0.0003008692,0.00018378935],"domain_scores_gemma":[0.99951184,0.0000377713,0.00004267751,0.00013331255,0.00012362826,0.00015076784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018683384,0.000084850544,0.00013733542,0.000044735476,0.00016473077,0.000049709164,0.000049684855,0.000052789434,0.000358279],"category_scores_gemma":[0.000025277443,0.000036316476,0.00010676586,0.000113554444,0.000040316198,0.0001136591,0.000011356844,0.0005483448,0.00006155303],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016439651,0.00070284144,0.27831945,0.000021390488,0.00029649533,0.00013237096,0.0007111598,9.984172e-7,0.6067534,0.000076074575,0.012815062,0.0985268],"study_design_scores_gemma":[0.012978065,0.002957267,0.38616937,0.00008247104,0.00012912884,0.0007282511,0.00025079385,0.00018024823,0.36164126,0.010948115,0.22362031,0.0003147084],"about_ca_topic_score_codex":0.0000042417305,"about_ca_topic_score_gemma":0.000004780361,"teacher_disagreement_score":0.24511215,"about_ca_system_score_codex":0.00005125822,"about_ca_system_score_gemma":0.00008726029,"threshold_uncertainty_score":0.3922904},"labels":[],"label_agreement":null},{"id":"W2603622689","doi":"10.1200/jco.2017.35.6_suppl.22","title":"The use of five-alpha reductase inhibitors and their association with reclassification and pathologic outcomes in the Canary Prostate Active Surveillance Study (PASS).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; 5 Alpha-Reductase Inhibitor; Internal medicine; Biopsy; Prostate; Cancer; Prostate biopsy; Gynecology; Finasteride","score_opus":0.20376476232072682,"score_gpt":0.47424759404870237,"score_spread":0.27048283172797555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603622689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677794,0.00022080664,5.7784456e-7,0.031232873,0.00014785396,0.0005473888,0.000011150138,0.0000013680618,0.00005856816],"genre_scores_gemma":[0.99719137,0.00230293,0.000057140755,0.00012301,0.000087356784,0.000013137292,0.0000015478348,0.000004558539,0.00021893343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978223,0.0009809538,0.0007032793,0.00012414489,0.0002362811,0.0001330551],"domain_scores_gemma":[0.9931491,0.004542935,0.0016919276,0.00020477588,0.00034119913,0.000070064154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004877912,0.000080944235,0.0005790908,0.000043806198,0.00017320896,0.000034749497,0.00011168395,0.00010745384,8.166146e-7],"category_scores_gemma":[0.005909466,0.000029595252,0.000055669014,0.000051766747,0.00036849175,0.0001485348,0.000041560143,0.0005610656,1.3164305e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00426045,0.0007163663,0.9478764,0.0000061296637,0.00019754219,0.00017117093,0.0013181518,8.8099705e-7,0.000073376556,0.000004119026,0.00036537313,0.04501007],"study_design_scores_gemma":[0.0049996194,0.0077914395,0.98253846,0.000029201827,0.00005767373,0.0000435949,0.00310829,0.000020531254,0.000044757206,0.0000905195,0.0012440849,0.00003180904],"about_ca_topic_score_codex":0.00020805393,"about_ca_topic_score_gemma":0.001190819,"teacher_disagreement_score":0.044978265,"about_ca_system_score_codex":0.00013328662,"about_ca_system_score_gemma":0.00050039205,"threshold_uncertainty_score":0.707461},"labels":[],"label_agreement":null},{"id":"W2603697950","doi":"10.1200/jco.2017.35.6_suppl.245","title":"Eligibility criteria requirements and adherence in advanced prostate cancer trials.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Generalizability theory; Clinical trial; Population; Internal medicine; Cancer; Oncology; Intensive care medicine","score_opus":0.4552741150111095,"score_gpt":0.6662526710499402,"score_spread":0.21097855603883076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603697950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982934,0.0026225424,0.0000025504787,0.011325428,0.0011755531,0.0004346236,0.0000074501227,0.0000029946436,0.0014948341],"genre_scores_gemma":[0.9816488,0.015872821,0.00091264304,0.00036450976,0.00048966694,0.000018010687,9.91315e-7,0.0000076279844,0.00068490405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99671435,0.0005318295,0.002037044,0.0002100324,0.0002738757,0.00023284553],"domain_scores_gemma":[0.9962509,0.0009637706,0.0018319149,0.0002659702,0.0003697394,0.0003176693],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009212248,0.00010196203,0.0016073685,0.000073635725,0.00007417169,0.000028383414,0.00016642692,0.00019343487,0.00015483932],"category_scores_gemma":[0.013088963,0.00006184119,0.00019338603,0.00003929594,0.00038360542,0.00025831274,0.00009359756,0.0006479731,0.0000033318975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015935477,0.0005407305,0.57065374,0.000050633673,0.00011893797,0.00044309153,0.000096039366,3.737176e-7,0.0010387911,0.000008114521,0.0008573654,0.41025668],"study_design_scores_gemma":[0.025775557,0.008246573,0.94926715,0.00038343132,0.00012490088,0.000032010772,0.000063069594,0.000027623395,0.0005614111,0.0014017267,0.014049889,0.000066631655],"about_ca_topic_score_codex":0.000100956924,"about_ca_topic_score_gemma":0.00018922487,"teacher_disagreement_score":0.41019005,"about_ca_system_score_codex":0.0001878055,"about_ca_system_score_gemma":0.0016965701,"threshold_uncertainty_score":0.9952242},"labels":[],"label_agreement":null},{"id":"W2603826687","doi":"10.1200/jco.2018.36.6_suppl.74","title":"The diverse genomic landscape of low−risk prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Prostate; Oncology; Prostate biopsy; Quartile; Internal medicine; PTEN; Cancer; Population; Pathology; Confidence interval; Biology; Genetics","score_opus":0.11088025227615413,"score_gpt":0.5013645893553553,"score_spread":0.3904843370792012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603826687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98701996,0.0029477642,0.0000055886294,0.005948609,0.0013162068,0.00019398876,0.000011580258,0.0000034708094,0.0025528339],"genre_scores_gemma":[0.96870065,0.026868833,0.00024881013,0.00030704337,0.0018860268,0.0000037069046,9.155831e-7,0.0000096040885,0.0019744402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997831,0.0002778858,0.0012798017,0.00010545175,0.00028379165,0.00022206294],"domain_scores_gemma":[0.995976,0.0015569419,0.0013500296,0.00016323088,0.0007190561,0.00023475559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028808746,0.000077299745,0.000685071,0.00005624733,0.000100794095,0.000006280514,0.0001729622,0.00014607262,0.00021435917],"category_scores_gemma":[0.0016692126,0.00003661798,0.00028805094,0.00010977287,0.0006985909,0.000044807126,0.00006991973,0.00062067277,0.000028844232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018306993,0.0006401082,0.61047953,0.000031484753,0.00078536576,0.00022150394,0.0003579202,0.0000044720027,0.00045876874,0.000033300326,0.021961488,0.34671906],"study_design_scores_gemma":[0.015980402,0.026682634,0.6927366,0.0001519864,0.0005133426,0.00009189979,0.0005917219,0.00014542497,0.0010477912,0.0005516934,0.26142633,0.000080114005],"about_ca_topic_score_codex":0.00004700707,"about_ca_topic_score_gemma":0.000107045664,"teacher_disagreement_score":0.34663895,"about_ca_system_score_codex":0.00010511174,"about_ca_system_score_gemma":0.002183797,"threshold_uncertainty_score":0.38739622},"labels":[],"label_agreement":null},{"id":"W2604203648","doi":"10.1016/j.eururo.2017.03.020","title":"Local Therapy Improves Survival in Metastatic Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Propensity score matching; Prostatectomy; Confidence interval; Confounding; Retrospective cohort study; Urology; Hazard ratio; Prostate; Radiation therapy; Internal medicine; Proportional hazards model; Oncology; Cancer","score_opus":0.05171756802889916,"score_gpt":0.3560259746240684,"score_spread":0.3043084065951692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604203648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9604815,0.003424713,0.00004112783,0.008927686,0.00036104943,0.0005337354,0.000013115454,0.00003991609,0.026177134],"genre_scores_gemma":[0.992253,0.0023350213,0.000037249294,0.00059919007,0.00011068286,0.000032926513,0.0000134052225,0.000038079936,0.0045804507],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987856,0.00022934165,0.00017062237,0.00029100198,0.00013874599,0.00038466166],"domain_scores_gemma":[0.99928665,0.000038091977,0.00007692,0.00044090694,0.00005023399,0.00010717095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004146622,0.00013445922,0.00025278627,0.000085846885,0.00012802299,0.000034193366,0.00019447961,0.000023472427,0.0001454051],"category_scores_gemma":[0.00006119954,0.000093329334,0.000049845723,0.000046898404,0.00036442096,0.00007275348,0.00009720289,0.00025009701,0.00013689537],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006017869,0.00055242196,0.29228008,0.000084655934,0.00039037896,0.005161681,0.0017817349,0.00002764527,0.020438118,0.0002481676,0.0014120291,0.6716052],"study_design_scores_gemma":[0.00862885,0.0012043095,0.9469226,0.00001931605,0.00003499565,0.000029041152,0.000068612244,0.00027024405,0.0017115849,0.00012704042,0.04083742,0.0001459815],"about_ca_topic_score_codex":0.00032978767,"about_ca_topic_score_gemma":0.00014376451,"teacher_disagreement_score":0.67145926,"about_ca_system_score_codex":0.00005228793,"about_ca_system_score_gemma":0.00012423351,"threshold_uncertainty_score":0.38058597},"labels":[],"label_agreement":null},{"id":"W2604585592","doi":"10.1016/j.juro.2017.02.1782","title":"MP57-08 POPULATION-BASED ANALYSIS OF TREATMENT TOXICITY AMONG MEN WITH CASTRATION-RESISTANT PROSTATE CANCER","year":2017,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cabazitaxel; Enzalutamide; Medicine; Docetaxel; Prostate cancer; Oncology; Hazard ratio; Population; Internal medicine; Proportional hazards model; Abiraterone; Cohort; Cancer; Toxicity; Androgen deprivation therapy; Environmental health; Confidence interval","score_opus":0.030110048989214863,"score_gpt":0.34146473192584686,"score_spread":0.311354682936632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604585592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944432,0.0005263535,0.000028677585,0.004308522,0.0000281443,0.00025196053,0.000028817763,0.000002925812,0.00038142886],"genre_scores_gemma":[0.99889916,0.00039761365,0.00005165684,0.00005103594,0.00005287795,0.000009157867,0.000012296337,0.000007961035,0.00051821815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911076,0.0001020054,0.00029713105,0.000084996704,0.00023834164,0.0001667562],"domain_scores_gemma":[0.9985989,0.00010059916,0.0006298827,0.00031830318,0.00026582365,0.000086491535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031708254,0.00010277277,0.00041850272,0.00019154951,0.00018936403,0.000014565311,0.00013081483,0.000042635318,0.0001247134],"category_scores_gemma":[0.000032531363,0.00004753426,0.00011967963,0.00013686217,0.00020745437,0.0000709933,0.000011441027,0.000116706724,5.445443e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00771726,0.00019033288,0.972658,0.00001577838,0.0032538078,0.00007918732,0.00049417635,0.0072165425,0.006936167,0.000012332643,0.000055367374,0.0013710703],"study_design_scores_gemma":[0.0030514258,0.0033545808,0.9835407,0.000022317177,0.0040001003,0.000013751228,0.00007128174,0.0021152077,0.003684344,0.000030638595,0.00007073606,0.000044918343],"about_ca_topic_score_codex":0.0029269417,"about_ca_topic_score_gemma":0.0030300312,"teacher_disagreement_score":0.01088272,"about_ca_system_score_codex":0.00021022625,"about_ca_system_score_gemma":0.00040266186,"threshold_uncertainty_score":0.442468},"labels":[],"label_agreement":null},{"id":"W2604748372","doi":"10.1016/j.clon.2017.03.010","title":"Impact of Abiraterone Acetate and Enzalutamide on Symptom Burden of Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Amgen","keywords":"Medicine; Enzalutamide; Prostate cancer; Interquartile range; Abiraterone acetate; Repeated measures design; Internal medicine; Quality of life (healthcare); Cancer; Androgen deprivation therapy","score_opus":0.08046626259462353,"score_gpt":0.46951039922347615,"score_spread":0.3890441366288526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604748372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99714077,0.00021827959,0.0000015118607,0.0011832468,0.00007447334,0.0008610952,0.00014150227,0.000006850552,0.00037226907],"genre_scores_gemma":[0.9981225,0.0008944801,0.00025762804,0.00006185637,0.000058929858,0.000044463286,0.000030427613,0.000019895602,0.00050982577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857885,0.0001152329,0.0005466302,0.0002852561,0.00023336857,0.00024068817],"domain_scores_gemma":[0.9981691,0.00033024346,0.0006081919,0.00037207687,0.00033881917,0.00018156086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003473246,0.00015723397,0.00079164555,0.00006148791,0.000077553224,0.000011971413,0.000107328975,0.00009363787,0.00008106599],"category_scores_gemma":[0.00019434006,0.000089470785,0.00011081529,0.000048299495,0.00085779274,0.00006223545,0.00004090487,0.00020953294,0.0000028679483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025852976,0.0012151086,0.90388817,0.00015142291,0.0013312112,0.000057297177,0.00065584696,0.000025231997,0.0020957342,0.000021491454,0.00010764224,0.064597875],"study_design_scores_gemma":[0.017430613,0.019737413,0.9609372,0.00017938005,0.00023802283,0.0000015810701,0.00004839109,0.000041364277,0.0010777288,0.00007358786,0.00015346208,0.00008128431],"about_ca_topic_score_codex":0.0006891854,"about_ca_topic_score_gemma":0.00010035834,"teacher_disagreement_score":0.0645166,"about_ca_system_score_codex":0.0001546607,"about_ca_system_score_gemma":0.00078192604,"threshold_uncertainty_score":0.36485127},"labels":[],"label_agreement":null},{"id":"W2604778717","doi":"10.1016/j.ebiom.2017.04.006","title":"c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks","year":2017,"lang":"en","type":"article","venue":"EBioMedicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Norges Forskningsråd; Helse Sør-Øst RHF; University Hospitals; Seventh Framework Programme; Universitetet i Oslo; Commonwealth Foundation; Kreftforeningen; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation","keywords":"Androgen receptor; Prostate cancer; Transcription factor; Cancer research; Chromatin immunoprecipitation; Biology; Enhancer; Chromatin; Cancer; Gene; Promoter; Gene expression; Genetics","score_opus":0.03306646228514127,"score_gpt":0.33698701474401166,"score_spread":0.3039205524588704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604778717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974664,0.004730584,0.000013505382,0.018539093,0.0006053461,0.0009250684,0.00004880207,0.000013053002,0.00046058116],"genre_scores_gemma":[0.9952374,0.0025378587,0.00002574129,0.00014315279,0.0004726132,0.00007913555,0.00001861835,0.000016898133,0.0014685871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988237,0.000074487725,0.00018903679,0.00021743981,0.00038185256,0.0003134908],"domain_scores_gemma":[0.99911714,0.000078112564,0.00015813774,0.00048316503,0.00008289904,0.00008052972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048708107,0.00013991425,0.00028769142,0.00005130381,0.00037383309,0.000020209058,0.00024056846,0.000057219884,0.00012756701],"category_scores_gemma":[0.00007816954,0.00006428783,0.00008851455,0.00019893971,0.00062566606,0.000085487874,0.00006981328,0.000315426,0.0000019836473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019285909,0.0002998839,0.6138236,0.00019772198,0.0002659169,0.000044140463,0.0020630483,0.000042729353,0.32922086,0.000024796798,0.0016537982,0.05043492],"study_design_scores_gemma":[0.005407528,0.00031991658,0.89068633,0.00064095255,0.00011098901,0.00002683767,0.00019878849,0.0005310336,0.09633869,0.000033054806,0.0056013837,0.00010448146],"about_ca_topic_score_codex":0.0007937146,"about_ca_topic_score_gemma":0.00019168718,"teacher_disagreement_score":0.27686274,"about_ca_system_score_codex":0.00013351836,"about_ca_system_score_gemma":0.00021746612,"threshold_uncertainty_score":0.28752598},"labels":[],"label_agreement":null},{"id":"W2604796563","doi":"10.1210/en.2016-1926","title":"Inverse Regulation of DHT Synthesis Enzymes 5α-Reductase Types 1 and 2 by the Androgen Receptor in Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; McGill University","keywords":"Androgen receptor; Dihydrotestosterone; Endocrinology; Internal medicine; Biology; Bicalutamide; Androgen deprivation therapy; Chromatin immunoprecipitation; Androgen; Prostate cancer; Gene expression; Medicine; Promoter; Cancer; Gene; Biochemistry; Hormone","score_opus":0.027601158647128542,"score_gpt":0.3242361889916347,"score_spread":0.29663503034450617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604796563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98054624,0.0058545223,2.0213326e-7,0.012528785,0.000080781116,0.00032490317,0.00005712068,0.000008389229,0.00059905875],"genre_scores_gemma":[0.9927795,0.0052449033,0.000049940376,0.00004343411,0.00003844128,0.00011424826,0.000014744701,0.00000852867,0.0017062521],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99940526,0.00004136864,0.00011422876,0.00015616314,0.00008141442,0.00020158103],"domain_scores_gemma":[0.99953645,0.000054377724,0.00007622894,0.00025432615,0.000039289607,0.000039327944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006485182,0.00007462384,0.00017370956,0.000056917866,0.00009848704,0.000009924328,0.000079984326,0.00003152515,0.0001335749],"category_scores_gemma":[0.00012652662,0.000046457862,0.000020353633,0.00003773863,0.00037504357,0.00005922213,0.000058567344,0.00009294395,0.0000069961147],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024918155,0.0002952886,0.65811116,0.00023735693,0.00044922656,0.00012059549,0.0023810442,0.000011407219,0.16673298,0.0014711253,0.030716345,0.1369817],"study_design_scores_gemma":[0.0030724232,0.00022032265,0.103584506,0.00011392316,0.00008666554,0.000051482064,0.00039332532,0.00003605,0.86814916,0.00037420855,0.023812506,0.00010544466],"about_ca_topic_score_codex":0.0010815287,"about_ca_topic_score_gemma":0.0002518102,"teacher_disagreement_score":0.7014162,"about_ca_system_score_codex":0.000045515517,"about_ca_system_score_gemma":0.00007285584,"threshold_uncertainty_score":0.18944965},"labels":[],"label_agreement":null},{"id":"W2605172842","doi":"10.1158/1557-3125.dnarepair16-a28","title":"Abstract A28: Mutational landscape of TP53 in localized prostate cancer","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Hôtel-Dieu de Québec; Ontario Institute for Cancer Research; Université Laval; Princess Margaret Cancer Centre","funders":"","keywords":"Prostate cancer; Biology; Chromoplexy; Copy-number variation; DNA methylation; Cancer research; Copy number analysis; Context (archaeology); Gene; Cancer; Genetics; Exome sequencing; Genome; Mutation; PCA3; Gene expression","score_opus":0.07185084954382395,"score_gpt":0.4536672817665619,"score_spread":0.381816432222738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605172842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769138,0.008313947,0.000008587978,0.005965927,0.00009162912,0.0010491112,0.000101211575,0.000014343561,0.007541453],"genre_scores_gemma":[0.9940747,0.0026638778,0.00008270822,0.000058297137,0.00008349132,0.00068092585,0.000046931626,0.00003781899,0.0022712694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972496,0.00009104816,0.00029895347,0.00041689043,0.0012844705,0.0006590301],"domain_scores_gemma":[0.9984076,0.0000688811,0.00010349042,0.00060576387,0.0006058389,0.00020840936],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008265221,0.00015337353,0.0003530036,0.00038753534,0.00021696411,0.00007887441,0.00033146242,0.000107918975,0.0011347476],"category_scores_gemma":[0.00021017523,0.00012343272,0.000099521836,0.00031284307,0.0004863201,0.00012304043,0.00016445604,0.00056994666,0.000028080452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007159757,0.00080134935,0.60596055,0.0015662934,0.0005250079,0.0038733454,0.0013534295,0.00046643915,0.29841545,0.0005202324,0.003918905,0.07543925],"study_design_scores_gemma":[0.012808669,0.0004219477,0.68960303,0.0013899901,0.000049905197,0.000012745406,0.0003022088,0.00070355873,0.28746724,0.0010384455,0.005909333,0.00029293663],"about_ca_topic_score_codex":0.007192491,"about_ca_topic_score_gemma":0.00076440506,"teacher_disagreement_score":0.08364246,"about_ca_system_score_codex":0.0003313782,"about_ca_system_score_gemma":0.0015328067,"threshold_uncertainty_score":0.99977833},"labels":[],"label_agreement":null},{"id":"W2605345821","doi":"10.1200/jco.2004.22.90140.4","title":"A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC)","year":2004,"lang":"fr","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Mitoxantrone; Docetaxel; Neutropenia; Clinical endpoint; Internal medicine; Prednisone; Phases of clinical research; Gastroenterology; Toxicity; Prostate cancer; Bone pain; Estramustine; Refractory (planetary science); Urology; Surgery; Chemotherapy; Oncology; Cancer; Randomized controlled trial","score_opus":0.08013408898120648,"score_gpt":0.4882761833763798,"score_spread":0.4081420943951733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605345821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90148836,0.0892721,0.000030421957,0.006556692,0.0014716949,0.0009690404,0.00007144163,0.000003801899,0.00013644526],"genre_scores_gemma":[0.96352553,0.033652052,0.001138524,0.00023903455,0.000764766,0.000017341177,0.000012056962,0.000032424105,0.00061825855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994374,0.00049183005,0.0033954293,0.00034025527,0.00073624525,0.00066226016],"domain_scores_gemma":[0.9946048,0.0009507442,0.0026767221,0.00020983879,0.00084831624,0.00070956635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017488135,0.00029960694,0.0026858146,0.00026276687,0.00005087125,0.000014227125,0.00017703827,0.0005038201,0.00010733673],"category_scores_gemma":[0.00068345724,0.00019752872,0.0002465544,0.00025948798,0.0011636703,0.00033739864,0.00009089465,0.0018376245,0.0000060680673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14753172,0.036434162,0.51222956,0.00025989942,0.001188825,0.0005454897,0.001784421,0.000124184,0.00024891406,0.000015183335,0.000773131,0.2988645],"study_design_scores_gemma":[0.29162377,0.09619749,0.5905227,0.0018655225,0.000993728,0.00001856546,0.00063521945,0.00015579796,0.00022508147,0.000052021103,0.0175238,0.00018629423],"about_ca_topic_score_codex":0.00046468645,"about_ca_topic_score_gemma":0.00040815512,"teacher_disagreement_score":0.29867822,"about_ca_system_score_codex":0.0008785998,"about_ca_system_score_gemma":0.0034257965,"threshold_uncertainty_score":0.8054987},"labels":[],"label_agreement":null},{"id":"W2605513847","doi":"10.3390/cancers9040034","title":"AR Signaling and the PI3K Pathway in Prostate Cancer","year":2017,"lang":"en","type":"review","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Prostate cancer; Androgen receptor; PI3K/AKT/mTOR pathway; Androgen; Medicine; Signal transduction; Cancer research; Mechanism (biology); Cancer; Prostate; Disease; Bioinformatics; Internal medicine; Biology; Hormone; Genetics","score_opus":0.13123542134972735,"score_gpt":0.42829216847346946,"score_spread":0.2970567471237421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605513847","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000111003304,0.9944617,2.5470325e-7,0.00038699378,0.0002854785,0.0024506922,0.00009257274,0.000019045221,0.002192243],"genre_scores_gemma":[0.00022213263,0.98991346,0.000009258961,0.00008625951,0.00030470343,0.0015923615,0.00005166721,0.000054626773,0.007765524],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839956,0.00011618711,0.00035300816,0.0004365542,0.00025887717,0.00043580023],"domain_scores_gemma":[0.9989298,0.00014079062,0.0002499203,0.0004773093,0.000058730493,0.00014342103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004721622,0.00033315207,0.0015147194,0.00014997354,0.000177112,0.00007504263,0.0002068097,0.00014100882,0.00007290443],"category_scores_gemma":[0.000068576745,0.00016930197,0.00023520431,0.00016667732,0.0005596515,0.000059618455,0.00008740986,0.0006361047,0.000013207009],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023376998,0.0000053590206,0.000071452574,0.010296944,0.00025193812,0.00018055858,0.00038066375,0.0000025774777,6.522239e-7,0.00004135824,0.00043383584,0.9881009],"study_design_scores_gemma":[0.003098241,0.00005409239,0.0000086591945,0.025068626,0.00036431654,0.000024732015,0.000058612026,0.000012520005,0.000008400437,0.00004235896,0.9710745,0.00018493144],"about_ca_topic_score_codex":0.0014594848,"about_ca_topic_score_gemma":0.0002055987,"teacher_disagreement_score":0.98791593,"about_ca_system_score_codex":0.0020906439,"about_ca_system_score_gemma":0.0048293225,"threshold_uncertainty_score":0.8567011},"labels":[],"label_agreement":null},{"id":"W2605764624","doi":"10.18632/oncotarget.17124","title":"Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer","year":2017,"lang":"en","type":"article","venue":"Oncotarget","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Congressionally Directed Medical Research Programs; British Columbia Knowledge Development Fund; Canadian Institutes of Health Research; National Cancer Institute; Prostate Cancer Foundation; National Institutes of Health; Prostate Cancer Canada; U.S. Department of Defense","keywords":"Prostate cancer; Erg; Medicine; Cancer research; DNA damage; Computational biology; DNA; Oncology; Cancer; Internal medicine; Genetics; Biology; Ophthalmology","score_opus":0.02101844494321068,"score_gpt":0.30881705844801405,"score_spread":0.28779861350480335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605764624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639773,0.0005645451,0.000015398282,0.002100398,0.000069321635,0.0004077404,0.00007349608,0.000004248297,0.00036709843],"genre_scores_gemma":[0.9971116,0.0016297468,0.00023457641,0.000025149033,0.000045986988,0.000039309,0.00007014509,0.000012954036,0.00083049247],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992959,0.000035754656,0.00019832638,0.00014557675,0.00014952298,0.00017490037],"domain_scores_gemma":[0.9994868,0.000027036871,0.00020300961,0.00019674422,0.00005235625,0.000034075216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026163278,0.00008681659,0.00021535139,0.000061022252,0.000102757665,0.000029185014,0.000090063404,0.000033361153,0.000011310827],"category_scores_gemma":[0.00004998639,0.000053529868,0.000032444634,0.000059252838,0.00016609013,0.000147008,0.000077378405,0.00009892412,5.5673036e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024184113,0.00004690185,0.47764403,0.00015897363,0.00003029558,0.000016575974,0.001063861,0.0000012313618,0.52001554,0.000068100584,0.000015785688,0.0006968411],"study_design_scores_gemma":[0.0019258831,0.00014223991,0.79926425,0.00058270997,0.000026034731,0.0000023579983,0.00028714965,0.00016216523,0.1968374,0.00016018347,0.00053058885,0.00007905198],"about_ca_topic_score_codex":0.0002856041,"about_ca_topic_score_gemma":0.00007489084,"teacher_disagreement_score":0.32317817,"about_ca_system_score_codex":0.00005146326,"about_ca_system_score_gemma":0.0001115952,"threshold_uncertainty_score":0.21828847},"labels":[],"label_agreement":null},{"id":"W2606828564","doi":"10.1097/ede.0000000000000678","title":"Androgen Deprivation Therapy and the Risk of Anemia in Men with Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Epidemiology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Androgen deprivation therapy; Hazard ratio; Prostate cancer; Anemia; Proportional hazards model; Discontinuation; Population; Cohort; Internal medicine; Cohort study; Confidence interval; Cancer; Oncology","score_opus":0.06586851020777351,"score_gpt":0.38470521557104204,"score_spread":0.3188367053632685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606828564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769272,0.007252535,0.000008373325,0.014084642,0.000014278773,0.00059043174,0.0000075416992,0.000004592067,0.0011103732],"genre_scores_gemma":[0.9641604,0.034929268,0.00016898967,0.00019143452,0.000036119633,0.00011704991,0.000006433572,0.000006199648,0.00038412452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992329,0.00024146859,0.00016422359,0.00014788074,0.00005010249,0.00016345657],"domain_scores_gemma":[0.99900573,0.0004532863,0.0001894727,0.00027466557,0.00004163871,0.000035179524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012253935,0.00006702504,0.00032246826,0.00003301262,0.00009681148,0.0000030987546,0.00006896628,0.00004934875,0.000018912859],"category_scores_gemma":[0.0005059425,0.000028958386,0.000021394331,0.00003172575,0.00057711976,0.00003692823,0.0000289256,0.00013674043,7.5586786e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046127713,0.000016639922,0.9718576,0.000018003344,0.0000776939,0.000005653172,0.00049104856,0.000009376311,0.00013337102,0.00027626695,0.00023137423,0.02227021],"study_design_scores_gemma":[0.008670856,0.00021222011,0.98650074,0.000043603788,0.000024991645,0.000007174624,0.00005006679,0.00037797532,0.00094204646,0.0025421323,0.00059460825,0.000033570625],"about_ca_topic_score_codex":0.0031728148,"about_ca_topic_score_gemma":0.00027090404,"teacher_disagreement_score":0.027676731,"about_ca_system_score_codex":0.00002713379,"about_ca_system_score_gemma":0.00007117325,"threshold_uncertainty_score":0.4796368},"labels":[],"label_agreement":null},{"id":"W2606962296","doi":"10.1016/j.clgc.2017.04.006","title":"Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Prostate cancer; Confidence interval; Prostatectomy; Incidence (geometry); Internal medicine; Proportional hazards model; Oncology; Epidemiology; Surveillance, Epidemiology, and End Results; Confounding; Cancer; Cancer registry","score_opus":0.09925951799187302,"score_gpt":0.4456136316898717,"score_spread":0.34635411369799873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606962296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94860417,0.034644745,0.000014342208,0.0127522405,0.0005875159,0.001238893,0.0015000141,0.000047343354,0.00061073876],"genre_scores_gemma":[0.93372023,0.057607792,0.0001221432,0.0015108708,0.00046359957,0.0005786834,0.000077502424,0.00004459674,0.0058745686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99684614,0.00018210783,0.0009847531,0.000849714,0.0005963521,0.0005409449],"domain_scores_gemma":[0.99669856,0.00040983193,0.00069097686,0.0012495487,0.000406316,0.0005447396],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046952465,0.0003724441,0.0016552063,0.00021921755,0.0003143169,0.000062985455,0.00040724775,0.00009334178,0.00029749543],"category_scores_gemma":[0.00028703362,0.00027048113,0.00045910562,0.0002673801,0.001016043,0.00039294738,0.0004387182,0.00058127457,0.0000050998797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036413968,0.00042305086,0.95694935,0.00037830803,0.0034516994,0.0012087122,0.000055026518,0.00002283741,0.0011628515,0.0000021356714,0.004506909,0.028197728],"study_design_scores_gemma":[0.0097881565,0.0005957565,0.97932065,0.0002681703,0.0022923066,0.000014124742,0.000030511452,0.00046627346,0.00070997607,0.000016536884,0.0062217284,0.00027580291],"about_ca_topic_score_codex":0.004968067,"about_ca_topic_score_gemma":0.00032993226,"teacher_disagreement_score":0.027921924,"about_ca_system_score_codex":0.0001748531,"about_ca_system_score_gemma":0.0014330237,"threshold_uncertainty_score":0.9999747},"labels":[],"label_agreement":null},{"id":"W2607480359","doi":"10.1200/jco.2012.30.15_suppl.4565","title":"Validation of a genomic-clinical classifier for predicting clinical progression in high-risk prostate cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Concordance; Prostate cancer; Cohort; Oncology; Internal medicine; Proportional hazards model; Cancer","score_opus":0.24328308978344182,"score_gpt":0.5724689664462035,"score_spread":0.32918587666276167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607480359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892419,0.002112123,0.000103160106,0.00377904,0.0033695854,0.0010870635,0.000028709303,0.000009439441,0.00026898718],"genre_scores_gemma":[0.9759383,0.010744956,0.008156071,0.00025376768,0.0044846763,0.000054297634,0.000014873411,0.0000300663,0.00032296567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9911531,0.0014743112,0.0061268928,0.00027839572,0.00046455176,0.0005027365],"domain_scores_gemma":[0.98645544,0.007495072,0.0044225035,0.00022414314,0.00076446595,0.0006383832],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022544928,0.00016808334,0.002078495,0.00018030893,0.000052328574,0.000007788157,0.00018053308,0.00073036016,0.000074689386],"category_scores_gemma":[0.012210888,0.000107100146,0.0007779813,0.00017275095,0.00045557314,0.00022456769,0.000092736314,0.0017917798,0.000007022517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01564732,0.0031531593,0.69581014,0.00007469941,0.00035578833,0.000030788193,0.00012654816,0.000007539382,0.00010011019,0.000020124182,0.0013773688,0.28329644],"study_design_scores_gemma":[0.02714992,0.020235972,0.92825294,0.00040367688,0.0006381713,0.000030969906,0.00014653185,0.00026754092,0.00046314226,0.00029445448,0.022014838,0.00010183325],"about_ca_topic_score_codex":0.000041979696,"about_ca_topic_score_gemma":0.000022738303,"teacher_disagreement_score":0.2831946,"about_ca_system_score_codex":0.00026357133,"about_ca_system_score_gemma":0.0029097057,"threshold_uncertainty_score":0.99610966},"labels":[],"label_agreement":null},{"id":"W2607628501","doi":"10.1158/1078-0432.ccr-17-0257","title":"Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"Congressionally Directed Medical Research Programs; National Cancer Institute; National Institutes of Health","keywords":"Missense mutation; Prostate cancer; DU145; Biochemical recurrence; Cancer research; Immunohistochemistry; Prostate; Medicine; Prostatectomy; Pathology; Cancer; Immunostaining; Mutation; Biology; Oncology; Internal medicine; LNCaP; Genetics; Gene","score_opus":0.29749477977787564,"score_gpt":0.5982011123550526,"score_spread":0.30070633257717694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607628501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927529,0.0016741947,0.00003736451,0.002716107,0.00022056248,0.0022484919,0.000077627294,0.000009471092,0.00026325352],"genre_scores_gemma":[0.986232,0.011694154,0.00012964621,0.000025511657,0.00027708092,0.00033968795,0.000024231167,0.000027050488,0.0012506718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99657464,0.00041248227,0.0013033091,0.00056546624,0.0007089404,0.00043518847],"domain_scores_gemma":[0.99555707,0.0016696837,0.0004945664,0.00060218474,0.0014209197,0.00025555966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006662155,0.00014396319,0.00087122514,0.00030712268,0.00018178007,0.00005518046,0.0001927126,0.00020472071,0.000052081654],"category_scores_gemma":[0.0042385766,0.000111580106,0.00025534316,0.00028598463,0.0011752348,0.00021512221,0.00012721118,0.0006151946,0.0000022486724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017926954,0.00076499506,0.8110209,0.0011331167,0.00047926154,0.00004822682,0.00025031978,0.000023505489,0.007856401,0.000030720355,0.0003573493,0.16010824],"study_design_scores_gemma":[0.024687618,0.004473949,0.82127696,0.0013487857,0.0005445262,0.000007881776,0.00041077388,0.0075842356,0.13708681,0.0012324892,0.0011047019,0.00024125446],"about_ca_topic_score_codex":0.0024591926,"about_ca_topic_score_gemma":0.001174736,"teacher_disagreement_score":0.15986697,"about_ca_system_score_codex":0.00019296882,"about_ca_system_score_gemma":0.0009659678,"threshold_uncertainty_score":0.5074278},"labels":[],"label_agreement":null},{"id":"W2608461130","doi":"10.1200/jco.2017.72.8030","title":"Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Hormonal therapy; Abiraterone acetate; Oncology; Internal medicine; Clinical trial; Chemotherapy; Context (archaeology); Docetaxel; Population; Androgen deprivation therapy; Cancer; Androgen receptor","score_opus":0.45946857788749174,"score_gpt":0.6328043055020732,"score_spread":0.1733357276145815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2608461130","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004072526,0.97306424,0.00006134689,0.013021334,0.0024462221,0.0054391306,0.0005921913,0.000023386694,0.0012796285],"genre_scores_gemma":[0.0003939523,0.9776823,0.00957157,0.001135982,0.0081271995,0.00027009743,0.00022130141,0.00013040117,0.0024671797],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9832139,0.0020196221,0.011815195,0.0010059301,0.0011694971,0.0007758297],"domain_scores_gemma":[0.9644981,0.010840156,0.020250227,0.0007698747,0.0025323853,0.0011092348],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.015786326,0.0007588227,0.014473421,0.00021975479,0.00020776853,0.00004030547,0.000874815,0.0019765904,0.00022669566],"category_scores_gemma":[0.0019466011,0.00041817306,0.0059507326,0.00027474636,0.0032679993,0.0002034491,0.00013618455,0.00437495,0.000006071479],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049193628,0.0056389202,0.0028783532,0.002444996,0.007688219,0.00015657212,0.000054671214,8.54492e-7,0.0000035870648,0.000018416682,0.036703113,0.8952187],"study_design_scores_gemma":[0.030178249,0.10983291,0.009860979,0.0037480479,0.0016372134,0.00020315964,0.000070518945,0.000044583794,0.0000038024775,0.000060604565,0.84402853,0.00033139522],"about_ca_topic_score_codex":0.00006501298,"about_ca_topic_score_gemma":0.00010016501,"teacher_disagreement_score":0.89488727,"about_ca_system_score_codex":0.000655837,"about_ca_system_score_gemma":0.049417615,"threshold_uncertainty_score":0.999827},"labels":[],"label_agreement":null},{"id":"W2610715971","doi":"10.1016/j.mce.2017.05.006","title":"Genome-wide analysis of AR binding and comparison with transcript expression in primary human fetal prostate fibroblasts and cancer associated fibroblasts","year":2017,"lang":"en","type":"article","venue":"Molecular and Cellular Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Cancer Research Society; Movember Foundation; National Cancer Institute; National Institutes of Health; Prostate Cancer Canada; Vanderbilt University","keywords":"Biology; Prostate cancer; Stromal cell; Cancer research; Prostate; Mesenchyme; Androgen receptor; Transcription factor; Chromoplexy; Molecular biology; Cancer; Gene; Genetics; PCA3; Epithelium","score_opus":0.017347068952154137,"score_gpt":0.2897650567304458,"score_spread":0.2724179877782916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610715971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928774,0.006094105,0.000078056066,0.00022088084,0.000012335957,0.0004015058,0.000028737186,0.000012798482,0.00027416242],"genre_scores_gemma":[0.99866116,0.0007598395,0.00010815132,0.000019870262,0.0000054186503,0.000036157744,0.0001483593,0.000019394362,0.00024162962],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987011,0.00007826593,0.00024907713,0.00040260336,0.00017856609,0.00039040955],"domain_scores_gemma":[0.9994035,0.000024561938,0.00015329725,0.00024879182,0.00004905385,0.000120797005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008110828,0.00019087498,0.0006439924,0.00035151062,0.00018905566,0.00003485946,0.00007371392,0.00008507924,0.000013983476],"category_scores_gemma":[0.000013682221,0.00014882846,0.000057857815,0.0001482138,0.00037494543,0.00007588643,0.000100577854,0.00020898329,1.9448473e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031728778,0.00007949876,0.43377173,0.0001369084,0.00050659,0.00030853652,0.00041103901,0.00002280985,0.56371796,0.000006901622,0.0000020029986,0.0007187402],"study_design_scores_gemma":[0.004462104,0.0006409527,0.62869996,0.0002197761,0.00064217846,0.000012209957,0.00012253791,0.00025269375,0.3647076,0.000016645547,0.0000696037,0.00015377166],"about_ca_topic_score_codex":0.0002958754,"about_ca_topic_score_gemma":0.00024050692,"teacher_disagreement_score":0.19901036,"about_ca_system_score_codex":0.00006076777,"about_ca_system_score_gemma":0.00004645142,"threshold_uncertainty_score":0.60690486},"labels":[],"label_agreement":null},{"id":"W2612231787","doi":"10.3892/ol.2017.6140","title":"Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors","year":2017,"lang":"en","type":"article","venue":"Oncology Letters","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; Royal Alexandra Hospital","funders":"National Cancer Institute; Canadian Prostate Cancer Research Initiative; Prostate Cancer Canada; Movember Foundation","keywords":"Cribriform; DNA methylation; Methylation; Biology; Cancer; Prostate cancer; Pathology; Carcinoma; Cancer research; Oncology; Medicine; DNA; Gene; Genetics; Gene expression","score_opus":0.021583500276619132,"score_gpt":0.30294437059626933,"score_spread":0.2813608703196502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612231787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.954795,0.00007981627,0.00007365594,0.04393006,0.00005964777,0.00061073713,0.000035634697,0.000023449584,0.00039198078],"genre_scores_gemma":[0.99873817,0.000012997879,0.000090972906,0.00066345796,0.00009113939,0.00008568914,0.00017764166,0.000019178782,0.00012072828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900085,0.00008220233,0.000159199,0.00028170718,0.00016039613,0.0003156322],"domain_scores_gemma":[0.9993771,0.00007795932,0.00016847416,0.00022174882,0.00004770946,0.00010704826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016507851,0.00015075045,0.00029332537,0.000118641074,0.00026537455,0.00005826988,0.00007569138,0.00007750305,0.00001551704],"category_scores_gemma":[0.00010534315,0.000107383785,0.000029088265,0.00006543853,0.0003111355,0.00012593676,0.00004296344,0.00033700623,0.0000029048422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042052942,0.000119365985,0.9639825,0.00004420196,0.00007478395,0.0011012148,0.0014601027,0.0000062858344,0.0073620747,0.0000037556074,0.00031049413,0.025114672],"study_design_scores_gemma":[0.0037942757,0.00062566734,0.9930526,0.00016612755,0.000057107212,0.000084533436,0.000118125296,0.00016106268,0.001513251,0.000035148034,0.00027341407,0.000118698204],"about_ca_topic_score_codex":0.00024454086,"about_ca_topic_score_gemma":0.0018083788,"teacher_disagreement_score":0.043943178,"about_ca_system_score_codex":0.00036124274,"about_ca_system_score_gemma":0.00012387271,"threshold_uncertainty_score":0.43789837},"labels":[],"label_agreement":null},{"id":"W2612397142","doi":"10.1016/j.clgc.2017.05.014","title":"Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Institutes of Health; National Cancer Institute; Sanofi; Abbott Laboratories","keywords":"Medicine; Prostate cancer; Docetaxel; Hazard ratio; Internal medicine; Oncology; Confidence interval; Proportional hazards model; Response Evaluation Criteria in Solid Tumors; Enzalutamide; Prostate-specific antigen; Cancer; Progressive disease; Disease","score_opus":0.11292832206148902,"score_gpt":0.43059886480570775,"score_spread":0.31767054274421874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612397142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933554,0.00019402133,3.4267674e-7,0.002929856,0.00014473297,0.0019544405,0.00012487512,0.000009092479,0.0012872248],"genre_scores_gemma":[0.99266946,0.00074261293,0.0000364448,0.000023481121,0.00013734029,0.0003002739,0.000019551915,0.00002499419,0.00604586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787974,0.0003463229,0.00045958054,0.00034788126,0.00071884907,0.00024760867],"domain_scores_gemma":[0.9978631,0.00027330135,0.0007875027,0.0005647504,0.00042674347,0.00008456068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087173405,0.00018149042,0.0005741583,0.00008125007,0.00015329283,0.000025776524,0.00018486493,0.00006549146,0.000044521286],"category_scores_gemma":[0.00017789761,0.00009606101,0.000072126735,0.0002322159,0.00020546645,0.00008986868,0.00004920823,0.00028404375,0.000001097368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012120571,0.0014013469,0.9783807,0.00012506309,0.00062247936,0.00008441102,0.00058868335,0.00012576107,0.0021419323,0.0000025877823,0.00017063053,0.0042358395],"study_design_scores_gemma":[0.010551974,0.0055781673,0.9630605,0.00056659593,0.0004557405,0.0000011602681,0.000747675,0.000027998209,0.018767765,0.0000069763714,0.0001189009,0.00011652494],"about_ca_topic_score_codex":0.0024706263,"about_ca_topic_score_gemma":0.0069134138,"teacher_disagreement_score":0.01662583,"about_ca_system_score_codex":0.0003816394,"about_ca_system_score_gemma":0.000613737,"threshold_uncertainty_score":0.39172542},"labels":[],"label_agreement":null},{"id":"W2613258265","doi":"10.1101/cshperspect.a030510","title":"Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance","year":2017,"lang":"en","type":"review","venue":"Cold Spring Harbor Perspectives in Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Institutes of Health; National Cancer Institute; Prostate Cancer Foundation","keywords":"Stroma; Stromal cell; Tumor microenvironment; Biology; Prostate cancer; Prostate; Cancer research; Tumor progression; Carcinogenesis; Context (archaeology); Pathology; Cancer; Immunology; Medicine; Tumor cells; Genetics","score_opus":0.0711981809156143,"score_gpt":0.41599812685746546,"score_spread":0.34479994594185115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613258265","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0059181843,0.98455924,0.0000021665865,0.0016951475,0.0003733411,0.006947972,0.00010384742,0.000031213345,0.0003688883],"genre_scores_gemma":[0.016934348,0.9799258,0.00009494517,0.000028252325,0.00025038683,0.0009337559,0.0000046885257,0.0000712437,0.0017565696],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997,0.00020201487,0.0006797442,0.0008170499,0.00073572685,0.00056548073],"domain_scores_gemma":[0.9976805,0.00013882022,0.0005968158,0.00095209316,0.0003633561,0.00026843837],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007346627,0.0005321006,0.0021747327,0.00036011921,0.00024152691,0.000033919303,0.00042623954,0.00020201184,0.000027100696],"category_scores_gemma":[0.00054594356,0.00028867007,0.00018983087,0.00046759605,0.0013168777,0.00007744642,0.00022288243,0.0007584809,0.000002085955],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011007227,0.00337419,0.0988362,0.13614148,0.006708127,0.002941688,0.031647038,0.0000045027177,0.011908217,0.016179249,0.0034221003,0.67783],"study_design_scores_gemma":[0.005944605,0.0005637154,0.0061798072,0.12219601,0.00052907044,0.0000028573124,0.00030268016,0.0000021423475,0.00056336017,0.00001265555,0.8633443,0.00035877907],"about_ca_topic_score_codex":0.00017390048,"about_ca_topic_score_gemma":0.000039661787,"teacher_disagreement_score":0.85992223,"about_ca_system_score_codex":0.0007327179,"about_ca_system_score_gemma":0.0010218895,"threshold_uncertainty_score":0.99995655},"labels":[],"label_agreement":null},{"id":"W2613808262","doi":"10.1055/s-0033-1334833","title":"Prostatakarzinom - Progression verlangsamt bei Low-Risk-Tumoren","year":2013,"lang":"de","type":"letter","venue":"Aktuelle Urologie","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gynecology","score_opus":0.025635145587904692,"score_gpt":0.31078338390506755,"score_spread":0.28514823831716285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613808262","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18144661,0.35976458,0.000050805786,0.41030568,0.009762184,0.01882417,0.002109953,0.0014223668,0.016313652],"genre_scores_gemma":[0.17025527,0.25480157,0.0027369186,0.25853622,0.055699117,0.010727821,0.056063343,0.0023925703,0.18878718],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99117976,0.00072252785,0.001130068,0.0021851521,0.001829877,0.0029526139],"domain_scores_gemma":[0.9949587,0.00076041,0.00089066685,0.0021743302,0.0005267068,0.0006891886],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0007987337,0.0014784593,0.0017417168,0.0005697548,0.00065220013,0.0002851668,0.0011704091,0.0021625108,0.003916816],"category_scores_gemma":[0.00066123967,0.0010219028,0.00062214554,0.0005953909,0.0012141716,0.00029260787,0.00095465913,0.0056370185,0.026087228],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013213905,0.0006411806,0.07999597,0.001328466,0.0016322576,0.0057973303,0.00035463946,0.0000048416714,0.00020753214,0.000009330759,0.86259997,0.046107095],"study_design_scores_gemma":[0.0068771876,0.0050611394,0.015211816,0.0011186396,0.0022006144,0.000026136087,0.00009290871,0.00034053807,0.0024152196,0.00048662332,0.9648296,0.0013395753],"about_ca_topic_score_codex":0.00047857716,"about_ca_topic_score_gemma":0.0000069004427,"teacher_disagreement_score":0.17247353,"about_ca_system_score_codex":0.0006817627,"about_ca_system_score_gemma":0.0012685268,"threshold_uncertainty_score":0.99979645},"labels":[],"label_agreement":null},{"id":"W2614607222","doi":"","title":"Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy.","year":2017,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Enzalutamide; Abiraterone acetate; Medicine; Bicalutamide; Prostate cancer; Oncology; Internal medicine; Chemotherapy; Hazard ratio; Urology; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.03241403010915383,"score_gpt":0.33022611831923165,"score_spread":0.2978120882100778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614607222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99413157,0.000121224024,0.0000066365783,0.00023921397,0.00022585645,0.0043679955,0.00007438104,0.000044741373,0.000788374],"genre_scores_gemma":[0.99517244,0.00034526762,0.00044730803,0.00003654102,0.00005962364,0.0015310047,0.00003241035,0.000065374144,0.002310053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997378,0.00007353596,0.00048379885,0.00047044232,0.0006645875,0.0009296386],"domain_scores_gemma":[0.99838144,0.000026908303,0.00043861064,0.0006340755,0.00022572464,0.00029323125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028088354,0.0002904851,0.0006759351,0.00023209213,0.00016169062,0.000037108613,0.00023043525,0.00007250384,0.000021296855],"category_scores_gemma":[0.000025410709,0.00018322363,0.00006703506,0.00028760429,0.00016691543,0.00031878622,0.00008680092,0.00022559147,7.3280273e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048343646,0.0004537187,0.93307394,0.00058861304,0.00022532913,0.00005255853,0.00010919811,0.00017512738,0.00020668698,0.000008535071,0.000009453298,0.060262486],"study_design_scores_gemma":[0.016618896,0.00027966007,0.9801646,0.00067671435,0.00009091004,0.0000020645164,0.000051795603,0.00032547957,0.0015263809,0.0000039636006,0.000060257356,0.00019925972],"about_ca_topic_score_codex":0.0016180425,"about_ca_topic_score_gemma":0.0008114232,"teacher_disagreement_score":0.060063228,"about_ca_system_score_codex":0.0014305209,"about_ca_system_score_gemma":0.00040928615,"threshold_uncertainty_score":0.7471643},"labels":[],"label_agreement":null},{"id":"W2614821999","doi":"10.1200/jco.2013.31.15_suppl.5039","title":"A randomized phase II study of cediranib (CED) alone versus CED plus dasatinib (DAS) in patients (pts) with castration-resistant prostate cancer (CRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Dasatinib; Docetaxel; Oncology; Androgen deprivation therapy; N-terminal telopeptide; Urology; Gastroenterology; Cancer; Randomized controlled trial; Surgery; Alkaline phosphatase; Receptor; Osteocalcin; Tyrosine kinase","score_opus":0.13470984353906953,"score_gpt":0.5026620645599288,"score_spread":0.3679522210208592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614821999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99354464,0.00030417801,0.0000012004293,0.0018085436,0.0004155029,0.0029760918,0.000016384629,0.0000065003533,0.0009269715],"genre_scores_gemma":[0.99786973,0.0008522354,0.0002511468,0.00015292049,0.00023532193,0.00014702359,0.000014626947,0.000023141321,0.00045382636],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949634,0.00085472234,0.0028166194,0.00026523578,0.0007553277,0.0003446622],"domain_scores_gemma":[0.9950299,0.0020629475,0.0014963853,0.00021839648,0.0008164138,0.00037594486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018764988,0.00020982175,0.0025648568,0.00022847315,0.00006260103,0.000012726215,0.0001576251,0.0001977546,0.0008303564],"category_scores_gemma":[0.0011445832,0.00011899485,0.0002642444,0.00028038953,0.0003449675,0.00019779472,0.000037887366,0.00080867414,0.000008597068],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9078948,0.016649563,0.018141808,0.000043793418,0.001253744,0.00032907302,0.0019046664,0.0000747617,0.00012738799,0.0000026471143,0.0007083171,0.05286947],"study_design_scores_gemma":[0.83140105,0.11548852,0.050601672,0.00019202361,0.0006240462,0.000006351059,0.00076858996,0.00014302378,0.00006550047,0.000026138829,0.0005762847,0.0001068213],"about_ca_topic_score_codex":0.00089385064,"about_ca_topic_score_gemma":0.00082648144,"teacher_disagreement_score":0.098838955,"about_ca_system_score_codex":0.00030456515,"about_ca_system_score_gemma":0.002322251,"threshold_uncertainty_score":0.909182},"labels":[],"label_agreement":null},{"id":"W2616701769","doi":"10.1186/s12916-017-0854-0","title":"ING3 promotes prostate cancer growth by activating the androgen receptor","year":2017,"lang":"en","type":"article","venue":"BMC Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Alberta Innovates; Alberta Innovates - Health Solutions; University of Calgary","keywords":"Androgen receptor; Prostate cancer; LNCaP; Cancer research; H3K4me3; Medicine; Biology; Cancer; Internal medicine; Biochemistry; Gene expression; Promoter; Gene","score_opus":0.056808008670403386,"score_gpt":0.36913379891262116,"score_spread":0.3123257902422178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616701769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9186816,0.008532477,0.000026058133,0.06311913,0.00041312908,0.0016861609,0.000038550657,0.00008429405,0.0074185575],"genre_scores_gemma":[0.97735995,0.0024844345,0.00020150015,0.00051798875,0.0010083558,0.00032456603,0.00007658346,0.000042572767,0.017984038],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99853534,0.000052328287,0.00022414277,0.0003185393,0.0004792742,0.00039037474],"domain_scores_gemma":[0.99870235,0.00013784529,0.0001900247,0.0005895081,0.00018902065,0.00019128116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051508535,0.00018385549,0.0003167286,0.000048319933,0.00065223273,0.00004548311,0.00027027164,0.00006333645,0.0004754838],"category_scores_gemma":[0.0009742647,0.000087703505,0.00004860135,0.0001018898,0.0005095704,0.0001310771,0.00010152832,0.00027736783,0.00002535128],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012359682,0.00017660507,0.6927592,0.00067009544,0.00032577312,0.000037907248,0.003953119,2.1705505e-7,0.1076421,0.0001154829,0.13851316,0.05457037],"study_design_scores_gemma":[0.032609735,0.0037268393,0.20702152,0.006225663,0.0006112503,0.00010615631,0.0034643798,0.00047661702,0.52705145,0.0009236947,0.21688291,0.0008997625],"about_ca_topic_score_codex":0.0010374462,"about_ca_topic_score_gemma":0.000050901166,"teacher_disagreement_score":0.48573768,"about_ca_system_score_codex":0.00012035675,"about_ca_system_score_gemma":0.00026328335,"threshold_uncertainty_score":0.5206214},"labels":[],"label_agreement":null},{"id":"W2616922558","doi":"10.1007/s00428-017-2160-9","title":"Prostate cancer in Jordanian-Arab population: ERG status and relationship with clinicopathologic characteristics","year":2017,"lang":"en","type":"article","venue":"Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Jordan University of Science and Technology","keywords":"Erg; Prostate cancer; TMPRSS2; Medicine; Prostate; Prostatectomy; Population; Enucleation; Cancer; Oncology; Internal medicine; Surgery; Ophthalmology","score_opus":0.05488354360111877,"score_gpt":0.41497840380808115,"score_spread":0.36009486020696235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616922558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861873,0.005077068,0.00003985366,0.0036364181,0.00028549484,0.0014509448,0.00019120872,0.00014091036,0.0029907953],"genre_scores_gemma":[0.9833223,0.01229206,0.0018029622,0.0005345542,0.0003148207,0.00024588488,0.0004515755,0.000066330336,0.0009694795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99584526,0.00045641186,0.00087286596,0.0011537068,0.00050965726,0.0011620974],"domain_scores_gemma":[0.996583,0.00081430154,0.0006548843,0.0013056452,0.00016592744,0.00047626888],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001204361,0.0005895633,0.0011692442,0.00035087854,0.0007548083,0.00012685676,0.00043892738,0.0003714049,0.00006340466],"category_scores_gemma":[0.0018611494,0.00038312885,0.00013042203,0.0002931827,0.0018212879,0.00034385666,0.0003821427,0.0016421116,0.000029383333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002553614,0.00031428647,0.96535265,0.00020605727,0.00014992958,0.0011496501,0.00079295796,0.000021538794,0.0015660144,0.0010486399,0.00008678569,0.02675786],"study_design_scores_gemma":[0.0063187177,0.0017737513,0.98460793,0.00058803824,0.00031545843,0.000037830494,0.00040996843,0.00036450892,0.00032574966,0.0040390356,0.00076091045,0.0004581038],"about_ca_topic_score_codex":0.00063102436,"about_ca_topic_score_gemma":0.00027187742,"teacher_disagreement_score":0.026299756,"about_ca_system_score_codex":0.00015407507,"about_ca_system_score_gemma":0.00054126995,"threshold_uncertainty_score":0.9998621},"labels":[],"label_agreement":null},{"id":"W2617098998","doi":"10.1155/2017/8424686","title":"In Vivo 3T Magnetic Resonance Imaging Using a Biologically Specific Contrast Agent for Prostate Cancer: A Nude Mouse Model","year":2017,"lang":"en","type":"article","venue":"Journal of Nanotechnology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Health Sciences Centre; Lakehead University","funders":"","keywords":"In vivo; Magnetic resonance imaging; Nuclear magnetic resonance; Materials science; Nuclear medicine; Medicine; Biology; Radiology; Physics","score_opus":0.048935491758856746,"score_gpt":0.3482023620350881,"score_spread":0.29926687027623133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2617098998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95934147,0.023363668,0.0013737796,0.014882109,0.00019200395,0.0007298014,0.000058709647,0.000019047882,0.00003942667],"genre_scores_gemma":[0.97779614,0.013198405,0.007280087,0.0002509887,0.00013843022,0.00005395777,8.9010075e-7,0.000027718024,0.0012533596],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99863714,0.000021646027,0.00045988086,0.00023042281,0.00018155674,0.00046937575],"domain_scores_gemma":[0.99890226,0.000038183305,0.00039322427,0.00032477628,0.00026120318,0.000080347636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033688455,0.00015881797,0.0005004114,0.00033263373,0.00016874677,0.000041416082,0.0003210158,0.0001605452,0.00002994556],"category_scores_gemma":[0.0001654851,0.00011142937,0.00012353172,0.00009245301,0.0003566651,0.00014908832,0.00008764886,0.00041080322,0.0000011123917],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036750354,0.0002849541,0.018411087,0.00006768262,0.00003762859,0.0008803663,0.00017000003,0.00018928839,0.91243845,0.00025213358,0.0012043952,0.062389005],"study_design_scores_gemma":[0.053134263,0.0057956595,0.0073608942,0.0021798185,0.00029086435,0.0019926734,0.0005651633,0.083823435,0.7403378,0.012839151,0.09081846,0.0008618471],"about_ca_topic_score_codex":0.000049485185,"about_ca_topic_score_gemma":0.000030953008,"teacher_disagreement_score":0.17210065,"about_ca_system_score_codex":0.00041070092,"about_ca_system_score_gemma":0.00035101752,"threshold_uncertainty_score":0.45439577},"labels":[],"label_agreement":null},{"id":"W2617227331","doi":"10.1016/j.urology.2016.12.033","title":"The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II)","year":2017,"lang":"en","type":"review","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Clinical trial; Oncology; Disease; Internal medicine; Prostate; Cancer","score_opus":0.06331872554838497,"score_gpt":0.4141142640242684,"score_spread":0.3507955384758834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2617227331","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010707184,0.98044217,0.000030175715,0.000057106587,0.00021730372,0.007917351,0.00059946155,0.000009991403,0.000019283141],"genre_scores_gemma":[0.07072829,0.91922563,0.00016663858,0.0000037865004,0.000035688507,0.009487219,0.0001634843,0.00005046345,0.00013876731],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982131,0.00008713937,0.0005888442,0.00044373045,0.00019984404,0.0004673577],"domain_scores_gemma":[0.99810505,0.00026579355,0.00085105037,0.00038201842,0.00033364398,0.00006245141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021122645,0.00034374886,0.0011906715,0.00025659223,0.00027843236,0.000016481536,0.00016236247,0.00015377883,0.0000027550927],"category_scores_gemma":[0.000025193225,0.00019394098,0.0002488554,0.00020797111,0.00019438738,0.00008023507,0.0000295742,0.00017715969,8.286864e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005335792,0.00024012245,0.002206268,0.0028663753,0.00081718963,0.00000176256,0.00021724087,0.00011368071,0.0001915878,0.0000099625195,8.217145e-7,0.9879992],"study_design_scores_gemma":[0.02551073,0.034663048,0.003099256,0.011782861,0.0050560664,0.000007949185,0.00021714483,0.00088595436,0.001712664,0.00025072304,0.9160551,0.00075854314],"about_ca_topic_score_codex":0.000314326,"about_ca_topic_score_gemma":0.0011019991,"teacher_disagreement_score":0.9872407,"about_ca_system_score_codex":0.0003869651,"about_ca_system_score_gemma":0.00088088826,"threshold_uncertainty_score":0.79086834},"labels":[],"label_agreement":null},{"id":"W2619186549","doi":"10.1093/jnci/djx084","title":"Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry","year":2017,"lang":"en","type":"review","venue":"JNCI Journal of the National Cancer Institute","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut National de la Recherche Scientifique","funders":"National Institute on Minority Health and Health Disparities; National Institute of Environmental Health Sciences; National Cancer Institute; Cancer Research UK","keywords":"Allele; Prostate cancer; Germline; Genetics; Odds ratio; Biology; Population; Allele frequency; Haplotype; CHEK2; Single-nucleotide polymorphism; Genome-wide association study; Oncology; Germline mutation; Cancer; Internal medicine; Medicine; Gene; Genotype; Mutation","score_opus":0.32125090935337763,"score_gpt":0.5192791072035436,"score_spread":0.198028197850166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2619186549","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000363531,0.99160004,0.000009376734,0.0013672753,0.0014094131,0.001954258,0.0018389462,0.0000038772882,0.0014532973],"genre_scores_gemma":[0.004174864,0.9913796,0.00027114927,0.000050257768,0.0015410165,0.00031594626,0.000036375,0.00003262265,0.0021981557],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997077,0.00006209659,0.0011163,0.00027957073,0.0011507566,0.0003142634],"domain_scores_gemma":[0.9958192,0.00013024763,0.0020499823,0.00028309727,0.0015858895,0.00013155515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011317302,0.00030530404,0.0015815297,0.00032170216,0.00014652296,0.0000321455,0.00065991486,0.00016604588,0.00004630217],"category_scores_gemma":[0.00047700614,0.00017169093,0.0007601602,0.00036031284,0.0004307944,0.0002744194,0.00010727863,0.0007459279,7.416338e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018741218,0.00063849794,0.003647161,0.02362753,0.002027106,0.000028349401,0.00033231807,0.0005423347,0.00013133495,0.00026089948,0.006698248,0.9601921],"study_design_scores_gemma":[0.0046951342,0.00017546001,0.0012984014,0.018622786,0.0008627382,0.000073709765,0.000021563985,0.00003435381,0.00010146697,0.00026466468,0.97365624,0.00019351354],"about_ca_topic_score_codex":0.0005595379,"about_ca_topic_score_gemma":0.0010027748,"teacher_disagreement_score":0.966958,"about_ca_system_score_codex":0.0027875602,"about_ca_system_score_gemma":0.011989487,"threshold_uncertainty_score":0.99361163},"labels":[],"label_agreement":null},{"id":"W2620638487","doi":"10.1097/spc.0000000000000275","title":"Novel imaging in advanced prostate cancer","year":2017,"lang":"en","type":"review","venue":"Current Opinion in Supportive and Palliative Care","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Disease; Cancer; Pet imaging; Modalities; Pathology; Positron emission tomography; Radiology; Internal medicine","score_opus":0.2841922317817948,"score_gpt":0.5402836349025989,"score_spread":0.2560914031208041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620638487","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010314798,0.9943437,0.0000044630606,0.000099351404,0.0015295596,0.0026956694,0.00096949877,0.000015390324,0.00023920974],"genre_scores_gemma":[0.00022358709,0.9956966,0.000025850664,0.000007974646,0.00023993035,0.0014646706,0.002028707,0.000048642727,0.00026401028],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997735,0.00007929627,0.00062152086,0.0007564693,0.00028555028,0.0005221256],"domain_scores_gemma":[0.9987171,0.00007812141,0.00043774815,0.00031395172,0.00027369775,0.00017937434],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014589001,0.00049388583,0.0015373989,0.0004372304,0.00009446957,0.00004880239,0.00014887203,0.00013457394,0.0000535964],"category_scores_gemma":[0.00009605313,0.0003645775,0.00022487564,0.00025163626,0.00019988505,0.00015811477,0.0001488033,0.0007767803,0.0000097638995],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000088514156,0.00009280789,0.09924948,0.03595261,0.000046223482,0.00001980873,0.0017276501,1.8572344e-7,4.8694767e-7,0.000017753076,0.0001648409,0.86263967],"study_design_scores_gemma":[0.0026811883,0.00009070251,0.018029016,0.10710945,0.00010413551,0.0000035214393,0.0005926291,0.0000034793068,0.0000019900501,0.00001155939,0.8710294,0.00034295398],"about_ca_topic_score_codex":0.000057305315,"about_ca_topic_score_gemma":0.000031990185,"teacher_disagreement_score":0.8708645,"about_ca_system_score_codex":0.0007538408,"about_ca_system_score_gemma":0.0012072581,"threshold_uncertainty_score":0.9998806},"labels":[],"label_agreement":null},{"id":"W2620746860","doi":"10.1056/nejmoa1702900","title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1772,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Medical Research Council; Cardiff University; University of Glasgow; Swansea University; University of Sussex; King's College London; National Institute for Health and Care Research; University College London; Cancer Research UK; Royal Marsden NHS Foundation Trust","keywords":"Abiraterone acetate; Prostate cancer; Abiraterone; Androgen deprivation therapy; Medicine; Oncology; Internal medicine; Testosterone (patch); Cancer; Prostate; Hormone therapy; Prednisolone; Urology; Androgen receptor","score_opus":0.05415089647709481,"score_gpt":0.36009789211086235,"score_spread":0.30594699563376754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620746860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9447792,0.015689433,0.00009927405,0.03780944,0.00018754105,0.0009505792,0.000010939848,0.000013810896,0.00045977655],"genre_scores_gemma":[0.9601531,0.027737387,0.0003371872,0.00039349942,0.0032107346,0.00003317651,0.000013222074,0.000036600068,0.008085077],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998624,0.00003148102,0.00036245387,0.0001650814,0.000484226,0.00033274933],"domain_scores_gemma":[0.9982366,0.00007771362,0.00045822482,0.00030535125,0.00051542843,0.00040665592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000594654,0.0001953311,0.0006177158,0.00013003167,0.00019448502,0.000035238158,0.00017708862,0.000055900688,0.000095201955],"category_scores_gemma":[0.000117793796,0.00008998798,0.0000697558,0.00006235346,0.0002357963,0.00015558556,0.000013108578,0.00025335417,0.0000014642859],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.082347505,0.00022631913,0.07639642,0.00013250187,0.0011087026,0.00085446367,0.0023500214,0.000007243576,0.05721297,0.000015195155,0.01897469,0.76037395],"study_design_scores_gemma":[0.5610922,0.04500264,0.1958002,0.0023186745,0.00085619465,0.0013509756,0.00018793429,0.000056926612,0.031282548,0.00019280467,0.1615614,0.00029747488],"about_ca_topic_score_codex":0.00047289056,"about_ca_topic_score_gemma":0.000063558786,"teacher_disagreement_score":0.76007646,"about_ca_system_score_codex":0.000099709614,"about_ca_system_score_gemma":0.0004573909,"threshold_uncertainty_score":0.36696035},"labels":[],"label_agreement":null},{"id":"W2621872277","doi":"10.1016/j.ejca.2017.05.003","title":"Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44]","year":2017,"lang":"en","type":"erratum","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Abiraterone acetate; Prostate cancer; Medicine; PI3K/AKT/mTOR pathway; PTEN; Internal medicine; Androgen receptor; Cancer research; Oncology; Cancer; Chemistry; Androgen deprivation therapy; Apoptosis; Biochemistry","score_opus":0.08206746764147864,"score_gpt":0.38135374974787317,"score_spread":0.2992862821063945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621872277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9634544,0.013633673,0.000013627762,0.00075571536,0.015676739,0.0027410076,0.0009404891,0.000017025428,0.0027672702],"genre_scores_gemma":[0.9249758,0.010472474,0.00013404584,0.00013143162,0.0035636306,0.000037886588,0.00008806085,0.00040588807,0.060190767],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.991086,0.001242694,0.0030623956,0.000732567,0.002784808,0.001091551],"domain_scores_gemma":[0.98836386,0.0000509548,0.006265573,0.00092652184,0.003423077,0.0009700122],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002423671,0.0009928655,0.0025272672,0.0014214299,0.0003334742,0.00030796058,0.0013286258,0.00012379591,0.0004919045],"category_scores_gemma":[0.00021612129,0.00062877056,0.00033781104,0.000656259,0.0003074197,0.0006620789,0.00025786832,0.0026203664,0.00001017285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21909867,0.0060739736,0.08879803,0.0025387611,0.008566614,0.04350285,0.033125754,0.0025176632,0.0034665542,0.0000010733241,0.46769536,0.12461469],"study_design_scores_gemma":[0.11494308,0.042586554,0.67147434,0.023796033,0.0032002917,0.0001962561,0.0031369573,0.000034097728,0.0008782268,0.0000016989993,0.13837188,0.0013806033],"about_ca_topic_score_codex":0.001426506,"about_ca_topic_score_gemma":0.0060421275,"teacher_disagreement_score":0.5826763,"about_ca_system_score_codex":0.0021371117,"about_ca_system_score_gemma":0.0063463976,"threshold_uncertainty_score":0.99968064},"labels":[],"label_agreement":null},{"id":"W2623011265","doi":"10.4274/mirt.07769","title":"Clinical Significance of 18F-Fluorodeoxyglucose Avid Prostate Gland Incidentalomas on Positron Emission Tomography/Computed Tomography","year":2017,"lang":"en","type":"article","venue":"Molecular Imaging and Radionuclide Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Malignancy; Positron emission tomography; Standardized uptake value; Radiology; Clinical significance; Incidentaloma; Prostate-specific antigen; Fluorodeoxyglucose; Nuclear medicine; Biopsy; Cancer; Pathology; Internal medicine","score_opus":0.017794187991669885,"score_gpt":0.33858664202133143,"score_spread":0.32079245402966156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623011265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98417056,0.011663935,0.00016361989,0.0021740606,0.00020010951,0.0008419107,0.000018992558,0.00007027851,0.00069655664],"genre_scores_gemma":[0.994422,0.003720435,0.0009430329,0.00051064166,0.000104884486,0.000028571429,0.000048527654,0.000047601643,0.00017426792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803036,0.00016728374,0.00042940502,0.0005584107,0.00043125357,0.00038330894],"domain_scores_gemma":[0.9984399,0.00007569048,0.0002631957,0.0007786632,0.00014150716,0.00030104478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052298955,0.00028343187,0.00051928556,0.00025238853,0.00038832173,0.00011781054,0.0002377232,0.000074256335,0.000013360114],"category_scores_gemma":[0.000041418123,0.00020640617,0.00030021401,0.00015949168,0.0005705476,0.00012974578,0.00007094454,0.00033896498,0.0000026333068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030981733,0.0005896433,0.61412334,0.00008931163,0.00033632133,0.0006203954,0.00026188605,0.0000025454885,0.24512486,0.000034326848,0.00070567924,0.13501352],"study_design_scores_gemma":[0.012530015,0.0018181744,0.6881262,0.0007718604,0.000113039445,0.00013593283,0.00006606287,0.00047517777,0.29134002,0.000555117,0.003683161,0.0003852345],"about_ca_topic_score_codex":0.00012253312,"about_ca_topic_score_gemma":0.0000011599187,"teacher_disagreement_score":0.13462828,"about_ca_system_score_codex":0.00003704892,"about_ca_system_score_gemma":0.000090377864,"threshold_uncertainty_score":0.84169996},"labels":[],"label_agreement":null},{"id":"W2624305751","doi":"10.1200/jco.2017.35.15_suppl.1089","title":"Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast cancer (TNBC) treated with 0-1 prior lines of therapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Enzalutamide; Clinical endpoint; Internal medicine; Breast cancer; Prostate cancer; Oncology; Subgroup analysis; Triple-negative breast cancer; Phases of clinical research; Cancer; Androgen receptor; Gastroenterology; Clinical trial; Confidence interval","score_opus":0.06474043651843095,"score_gpt":0.44481990587863457,"score_spread":0.38007946936020365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624305751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959319,0.00045066056,0.0000023970763,0.00090941595,0.00019668486,0.0013880947,0.0010900412,0.0000049286646,0.000025861045],"genre_scores_gemma":[0.9962891,0.002947591,0.00010622636,0.00007561616,0.00038436364,0.00006780669,0.00005920242,0.00003383297,0.000036265163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99493784,0.0011531642,0.0021965338,0.00049220695,0.000826896,0.0003933875],"domain_scores_gemma":[0.992242,0.0022561015,0.0031797253,0.00042898286,0.0014809477,0.0004122482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013426007,0.00034021444,0.0030506493,0.000529274,0.00008145874,0.000023008008,0.00034109235,0.0002863929,0.0002037076],"category_scores_gemma":[0.0006601495,0.00019815199,0.00029335613,0.0005505732,0.00048267673,0.0003946884,0.000065254964,0.0008411166,5.334242e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15380219,0.025784632,0.7673277,0.000018751367,0.0045349877,0.00052659976,0.0014466767,0.00008008267,0.00016383933,4.321811e-7,0.000020375084,0.046293695],"study_design_scores_gemma":[0.12646376,0.041022565,0.8288234,0.0005875027,0.00156845,0.000009678304,0.00067704445,0.00008586339,0.0005769755,0.000008477327,0.0000122101565,0.00016410835],"about_ca_topic_score_codex":0.032365788,"about_ca_topic_score_gemma":0.042572394,"teacher_disagreement_score":0.061495643,"about_ca_system_score_codex":0.00060978,"about_ca_system_score_gemma":0.0021594814,"threshold_uncertainty_score":0.97489816},"labels":[],"label_agreement":null},{"id":"W2624844213","doi":"10.5489/cuaj.4608","title":"New research in prostate cancer, ASCO-GU 2017","year":2017,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Prostate; Oncology; Internal medicine; Gynecology; Urology; Cancer","score_opus":0.2708734089087019,"score_gpt":0.48124427115480306,"score_spread":0.2103708622461012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624844213","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004149114,0.9730496,3.3030568e-7,0.016853563,0.0006104733,0.0012026661,0.00015859191,0.000014384537,0.008068928],"genre_scores_gemma":[0.000096390235,0.96316445,0.000036887086,0.00017275207,0.0017769065,0.00012902822,0.000112726506,0.000042484826,0.03446837],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953251,0.00076500594,0.0007304965,0.00050155394,0.0010874855,0.0015903772],"domain_scores_gemma":[0.9960276,0.00034608762,0.0006239292,0.0003932399,0.0005231693,0.0020860063],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0033555771,0.00035504455,0.0016057651,0.001286647,0.00084416306,0.0004329253,0.0005764161,0.0008319006,0.0007260548],"category_scores_gemma":[0.001155421,0.00024466636,0.00045933237,0.00052034186,0.00010719476,0.00014920144,0.0000728232,0.004491741,0.00034024197],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00004648135,0.000034080796,0.014514677,0.00055838464,0.00027617483,0.0020936704,0.000044858545,4.4389924e-7,6.63351e-8,0.00002686239,0.10496495,0.8774393],"study_design_scores_gemma":[0.0011854124,0.00026584047,0.006102601,0.0037547313,0.0002112035,0.00032638753,0.000011586856,0.0000017191059,1.00738596e-7,0.00036922598,0.9875577,0.00021349506],"about_ca_topic_score_codex":0.021465749,"about_ca_topic_score_gemma":0.008330987,"teacher_disagreement_score":0.88259274,"about_ca_system_score_codex":0.01073815,"about_ca_system_score_gemma":0.021360427,"threshold_uncertainty_score":0.99780494},"labels":[],"label_agreement":null},{"id":"W2625579480","doi":"10.5489/cuaj.4652","title":"Taking the first steps in establishing recommendations for testosterone monitoring in men with prostate cancer on androgen-deprivation therapy","year":2017,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Prostate cancer; Testosterone (patch); Androgen deprivation therapy; Management of prostate cancer; Hormonal therapy; Medicine; Androgen; Hormone; Cancer; Oncology; Internal medicine","score_opus":0.06580961882793732,"score_gpt":0.3333644087442157,"score_spread":0.26755478991627835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625579480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8443583,0.00031943066,0.0000073185456,0.15361631,0.00013306936,0.0007421982,0.000019636478,0.000006769987,0.0007969772],"genre_scores_gemma":[0.9976422,0.0008599759,0.000086805405,0.0007000817,0.0002615189,0.00019979218,0.000013014564,0.000012220111,0.00022437729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894917,0.000062287574,0.00020865179,0.00015974292,0.00022033649,0.000399815],"domain_scores_gemma":[0.9990292,0.00021086897,0.0003185968,0.0001294775,0.00015754055,0.000154275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083266833,0.00009884148,0.00015888107,0.00016907333,0.00080690713,0.00030940073,0.00015052593,0.00009260553,0.000049145958],"category_scores_gemma":[0.0005224469,0.000058865913,0.000032342206,0.0001287954,0.000027952343,0.00025216764,0.000011201848,0.00048305714,0.0000012566044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038145715,0.000036975187,0.9611018,0.0000032059413,0.00003973356,0.00002387038,0.0006931086,0.00014052482,0.000025507623,0.000014976624,0.00040742336,0.037131447],"study_design_scores_gemma":[0.003619501,0.00034679574,0.98436284,0.00012084041,0.000010234598,0.000007738375,0.00022575169,0.00031825833,0.00010445729,0.00014275093,0.010669613,0.00007120251],"about_ca_topic_score_codex":0.0050583975,"about_ca_topic_score_gemma":0.015914334,"teacher_disagreement_score":0.15328392,"about_ca_system_score_codex":0.0018768304,"about_ca_system_score_gemma":0.00034621244,"threshold_uncertainty_score":0.8880572},"labels":[],"label_agreement":null},{"id":"W2625888083","doi":"10.1093/annonc/mdx312","title":"Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from ‘castration-resistant’ prostate cancer","year":2017,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; University of British Columbia; BC Cancer Agency","funders":"Cancer Research UK","keywords":"Medicine; Prostate cancer; Enzalutamide; Clinical trial; Oncology; Cancer; Androgen deprivation therapy; Internal medicine; Abiraterone acetate; Gynecology; Androgen receptor","score_opus":0.09460516190054016,"score_gpt":0.4550171178689679,"score_spread":0.3604119559684278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625888083","genre_codex":"empirical","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6307067,0.027744336,0.0000012455487,0.11522039,0.17485213,0.009705083,0.03466063,0.00010378983,0.0070056547],"genre_scores_gemma":[0.056262344,0.22915672,0.003057395,0.009891055,0.4135689,0.009693438,0.011528091,0.0007417593,0.2661003],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99628574,0.00019126877,0.00087829295,0.0010878776,0.0007357261,0.0008210819],"domain_scores_gemma":[0.9962549,0.00069001695,0.0006973903,0.0007285669,0.0012576365,0.00037148804],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00049694494,0.00052850624,0.0017586924,0.0003824917,0.00018315708,0.000051532486,0.00039061287,0.00095132395,0.00094615633],"category_scores_gemma":[0.00070100557,0.00043749053,0.00013341928,0.00018679842,0.000709789,0.00020269102,0.00029225278,0.00093318115,0.00005933667],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011823118,0.00028622185,0.0029830737,0.0002989797,0.00039940124,0.00025326727,0.0017176482,0.0000070433794,0.0025814916,0.0000013813958,0.8482076,0.1314408],"study_design_scores_gemma":[0.0069452645,0.0032618458,0.030817356,0.0016702393,0.00015624102,0.000002214051,0.000095849515,0.000024406236,0.0032558013,0.0007160509,0.9526533,0.00040141665],"about_ca_topic_score_codex":0.0054932293,"about_ca_topic_score_gemma":0.0054603247,"teacher_disagreement_score":0.5744444,"about_ca_system_score_codex":0.00044241414,"about_ca_system_score_gemma":0.0042855954,"threshold_uncertainty_score":0.9999671},"labels":[],"label_agreement":null},{"id":"W2626155574","doi":"10.5489/cuaj.4539","title":"Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians","year":2017,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia; Université Laval; McMaster University","funders":"","keywords":"Prostate cancer; Testosterone (patch); Medicine; Androgen deprivation therapy; Castration; Gynecology; Urology; Hormone therapy; Oncology; Cancer; Internal medicine; Hormone","score_opus":0.1857391345574365,"score_gpt":0.44003785254705075,"score_spread":0.25429871798961423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626155574","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026824066,0.99376804,3.942889e-7,0.0023559616,0.00015408052,0.0018038565,0.0014220214,0.0000034042505,0.00022401237],"genre_scores_gemma":[0.00048741532,0.9984767,0.00006208936,0.000058285106,0.00018842267,0.000198479,0.00019911387,0.00002703445,0.00030247934],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794835,0.00028433997,0.0005998408,0.00026867187,0.00035960792,0.0005391805],"domain_scores_gemma":[0.99439454,0.00040037936,0.003118902,0.00019042336,0.0011871555,0.000708604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014054067,0.00025591167,0.0016572187,0.0004563071,0.00024352147,0.000047755715,0.00018718402,0.0001866285,0.00001881742],"category_scores_gemma":[0.0022050398,0.00016699244,0.00016595119,0.0003466125,0.00007865441,0.00012658852,0.000015441286,0.00064285356,7.801643e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006782334,0.000029917563,0.062213935,0.020166999,0.0005249619,0.00002005414,0.000041799987,2.2841188e-7,5.004246e-7,0.0000016539517,0.0018780248,0.9150541],"study_design_scores_gemma":[0.0008483132,0.0006748812,0.03135851,0.05867595,0.0012038589,0.000037075395,0.000011535504,0.000001209204,0.0000015868101,0.0000041249027,0.90702236,0.00016061505],"about_ca_topic_score_codex":0.102436155,"about_ca_topic_score_gemma":0.093046516,"teacher_disagreement_score":0.9148935,"about_ca_system_score_codex":0.0015603706,"about_ca_system_score_gemma":0.007988841,"threshold_uncertainty_score":0.99763495},"labels":[],"label_agreement":null},{"id":"W2626200828","doi":"10.1200/jco.2017.35.18_suppl.lba3","title":"LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Androgen deprivation therapy; Internal medicine; Interim analysis; Docetaxel; Prednisone; Randomization; Oncology; Hypokalemia; Randomized controlled trial; Adverse effect; Progression-free survival; Cancer; Urology; Chemotherapy","score_opus":0.18564204016041563,"score_gpt":0.5032530866104884,"score_spread":0.31761104645007276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626200828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877079,0.0017134049,0.00023630643,0.004029013,0.0004732638,0.0056981123,0.000030521194,0.000009102936,0.00010235186],"genre_scores_gemma":[0.93872774,0.05743632,0.0023207564,0.00012254257,0.00044667377,0.00042525836,0.000018144856,0.000032627548,0.0004699157],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99441975,0.0011709878,0.0030117251,0.00032642542,0.0006817096,0.0003894151],"domain_scores_gemma":[0.99016863,0.0030100173,0.005355313,0.0004155848,0.00069330115,0.00035716745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069685816,0.00027746643,0.0037769505,0.00026141768,0.00013083128,0.000048009766,0.00032406524,0.00025500794,0.00007934757],"category_scores_gemma":[0.0019289178,0.00014233633,0.00039436077,0.00018594555,0.00080258976,0.00038258522,0.00006554482,0.0009757531,0.0000023257617],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89850956,0.0041672494,0.0046669506,0.000040817788,0.0028756578,0.0013306105,0.0009708041,0.00024577434,0.00018419985,0.000007790103,0.00018645341,0.08681415],"study_design_scores_gemma":[0.94306713,0.04901784,0.0039648144,0.00023526144,0.0011555462,0.000042985586,0.00012037675,0.0004260209,0.0010137436,0.00017694893,0.0006378891,0.00014143022],"about_ca_topic_score_codex":0.0013675047,"about_ca_topic_score_gemma":0.00083964074,"teacher_disagreement_score":0.086672716,"about_ca_system_score_codex":0.00031263675,"about_ca_system_score_gemma":0.005584161,"threshold_uncertainty_score":0.9906061},"labels":[],"label_agreement":null},{"id":"W2646737791","doi":"10.2147/ott.s127317","title":"The association between SPINK1 and clinical outcomes in patients with prostate cancer: a systematic review and meta-analysis","year":2017,"lang":"en","type":"review","venue":"OncoTargets and Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Medicine; Meta-analysis; Prostate cancer; Prostatectomy; Hazard ratio; Internal medicine; Confidence interval; Oncology; Publication bias; MEDLINE; Urology; Cancer","score_opus":0.15697010279596987,"score_gpt":0.4731653371547831,"score_spread":0.31619523435881325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2646737791","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044198206,0.99331534,9.0149996e-8,0.0008963417,0.000018530889,0.005116633,0.00016887522,0.0000070762526,0.000035143566],"genre_scores_gemma":[0.00014577208,0.99654955,0.000010536832,0.000116706084,0.000023300265,0.0006432327,0.00009549913,0.000025403486,0.002390016],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99774635,0.00042972574,0.0007976564,0.00040587172,0.0003611369,0.00025925715],"domain_scores_gemma":[0.99787885,0.0005207969,0.00092017616,0.00041181207,0.00013527063,0.00013310222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015901941,0.0003482377,0.0067236396,0.000105563435,0.0002079183,0.000117386735,0.000102239675,0.00015880508,0.000011321874],"category_scores_gemma":[0.00011322118,0.00012720891,0.0006169255,0.00016454543,0.000107956585,0.00006308847,0.000044413424,0.00035183685,0.0000011070854],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004918291,0.00008231294,0.5085822,0.14228407,0.25389993,0.000005394895,0.00004079624,2.0471032e-9,2.8495206e-10,0.000002023612,0.000032012013,0.09502209],"study_design_scores_gemma":[0.0022408518,0.0005652067,0.10025361,0.018359581,0.7564686,7.5746067e-7,0.0000042726456,2.800405e-7,8.682171e-9,0.000011594349,0.12185398,0.00024126728],"about_ca_topic_score_codex":0.00010952604,"about_ca_topic_score_gemma":0.00010996369,"teacher_disagreement_score":0.50256866,"about_ca_system_score_codex":0.00012674904,"about_ca_system_score_gemma":0.00016626326,"threshold_uncertainty_score":0.51874286},"labels":[],"label_agreement":null},{"id":"W2659875471","doi":"10.1016/j.clgc.2017.06.004","title":"Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Astellas Pharma; Sanofi","keywords":"Medicine; Prostate cancer; Internal medicine; Androgen receptor; Docetaxel; Hazard ratio; Androgen deprivation therapy; Prostate-specific antigen; Oncology; Taxane; Enzalutamide; Cancer; Breast cancer; Confidence interval","score_opus":0.062336598362176865,"score_gpt":0.3819573128623433,"score_spread":0.31962071450016644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2659875471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99209297,0.0020762556,6.358897e-7,0.0027169923,0.00025144863,0.0019862384,0.0008095447,0.000020819569,0.000045113407],"genre_scores_gemma":[0.9707943,0.02741355,0.0005452679,0.0001778345,0.00015928426,0.00043437566,0.00025626906,0.00006321005,0.00015590858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969233,0.00058295194,0.0010381516,0.00043374926,0.0005614144,0.00046042012],"domain_scores_gemma":[0.99668705,0.0007981732,0.00089999946,0.0009363334,0.0005077441,0.00017066565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011054078,0.0004045645,0.0010228807,0.00013713293,0.00041219394,0.00006177773,0.00038903486,0.00013419762,0.00026922964],"category_scores_gemma":[0.00018115484,0.00024223348,0.00018254365,0.00027233272,0.0006341599,0.00022027557,0.000088963105,0.00073045125,0.0000010417834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025350256,0.0011361528,0.9405163,0.0002038188,0.0009800553,0.000023645418,0.0021225295,0.0000036065226,0.00089410134,6.8277836e-7,0.0001874286,0.028581439],"study_design_scores_gemma":[0.01868363,0.0030517273,0.9723783,0.00040842846,0.00012108814,6.9593773e-7,0.00042762456,0.000021037302,0.0033252032,0.000012812262,0.0013125158,0.0002569139],"about_ca_topic_score_codex":0.001796805,"about_ca_topic_score_gemma":0.0024213106,"teacher_disagreement_score":0.031862043,"about_ca_system_score_codex":0.0001597031,"about_ca_system_score_gemma":0.00039872635,"threshold_uncertainty_score":0.98779947},"labels":[],"label_agreement":null},{"id":"W2663821008","doi":"10.1200/jco.2017.35.15_suppl.2562","title":"Patterns of failure on Ga PSMA (GaPSMA) and F18 FDG (FDG) PET CT in a prospective phase 2 trial of <sup>177</sup>Lu DKFZ PSMA 617 (LuPSMA) in men with castrate resistant metastatic prostate cancer (mCRPC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prospective cohort study; Internal medicine; Oncology; Biomarker; Nuclear medicine; Urology","score_opus":0.12194362726192376,"score_gpt":0.4982053091989315,"score_spread":0.37626168193700776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2663821008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905955,0.00032263165,0.000003006561,0.0060180114,0.00014345458,0.0017226685,0.00013706813,0.00000411945,0.0010535191],"genre_scores_gemma":[0.99644446,0.0019228131,0.0005796679,0.00008695248,0.00027335755,0.000088636654,0.000008052703,0.00003355244,0.0005625196],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950594,0.0006923695,0.0025472967,0.00043888926,0.0007630959,0.0004989689],"domain_scores_gemma":[0.99465793,0.0011611697,0.0028042844,0.00043123026,0.00055237877,0.000392983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003611652,0.00030516263,0.002605238,0.00038199514,0.00007527873,0.000030341163,0.00028930523,0.00011703592,0.00007773341],"category_scores_gemma":[0.0015456578,0.00018836102,0.00027053247,0.0001859352,0.00062829896,0.00024491872,0.000090671594,0.0014106069,0.0000013096113],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5782507,0.008417604,0.37108845,0.0005057979,0.0012808933,0.01679315,0.0015972155,0.000090887355,0.0005546989,0.000106878964,0.00039621344,0.020917522],"study_design_scores_gemma":[0.527439,0.13056874,0.32929435,0.0027844568,0.000962662,0.0006695487,0.0034327824,0.00045936505,0.0021335464,0.00065625797,0.0012758382,0.00032346445],"about_ca_topic_score_codex":0.0008210778,"about_ca_topic_score_gemma":0.0034982716,"teacher_disagreement_score":0.122151144,"about_ca_system_score_codex":0.00040071635,"about_ca_system_score_gemma":0.0031543202,"threshold_uncertainty_score":0.7681139},"labels":[],"label_agreement":null},{"id":"W2664930764","doi":"10.1016/j.eururo.2017.06.002","title":"Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017","year":2017,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":643,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Medical Research Council; Sanofi Genzyme; Astellas Pharma; National Institute for Health and Care Research; Prostate Cancer Foundation; Movember Foundation; AstraZeneca; Bristol-Myers Squibb; Swiss Cancer Research Foundation; Sanofi; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Amgen; European School of Oncology; National Health and Medical Research Council; Cancer Research UK","keywords":"Medicine; Prostate cancer; Prostate; Cancer; Management of prostate cancer; Consensus conference; Prostate disease; Oncology; Gynecology; General surgery; Internal medicine","score_opus":0.023431968039114393,"score_gpt":0.31425055469832053,"score_spread":0.2908185866592061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2664930764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97179514,0.0014694331,0.000002900492,0.007928038,0.00038145029,0.0021662745,0.00016048692,0.000022112761,0.01607417],"genre_scores_gemma":[0.9868783,0.002189267,0.00011610387,0.00015208924,0.00003156881,0.00013580908,0.000025903246,0.000040985225,0.010429984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981556,0.00018538634,0.00041728292,0.0004261102,0.0004031782,0.00041247075],"domain_scores_gemma":[0.997105,0.000042614018,0.0008664835,0.0013756014,0.0005226653,0.00008760652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032256107,0.0002212055,0.00037776324,0.000041464362,0.0003250057,0.000018402661,0.0005014164,0.000031293133,0.00005321945],"category_scores_gemma":[0.000066544824,0.00010850685,0.00007576819,0.00009587656,0.0012274326,0.00005865966,0.00035032257,0.000263358,0.0000063324123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012456044,0.00048015817,0.8637376,0.0006392959,0.001151465,0.0018572382,0.0019573206,0.00039209862,0.00196452,0.00032455887,0.002071234,0.11296845],"study_design_scores_gemma":[0.0071398905,0.0008862444,0.96029115,0.0003083692,0.00026931913,0.000029603765,0.00014980513,0.000022370543,0.0023085175,0.00004286021,0.02840417,0.00014772933],"about_ca_topic_score_codex":0.00012761795,"about_ca_topic_score_gemma":0.00007352907,"teacher_disagreement_score":0.11282072,"about_ca_system_score_codex":0.000056116085,"about_ca_system_score_gemma":0.0002552041,"threshold_uncertainty_score":0.45225266},"labels":[],"label_agreement":null},{"id":"W2691745207","doi":"10.1007/s11307-017-1102-x","title":"Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile","year":2017,"lang":"en","type":"article","venue":"Molecular Imaging and Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Glutamate carboxypeptidase II; Prostate-specific antigen; Prostate; Antigen; Prostate cancer; Cancer research; Membrane; Chemistry; Medicine; Pathology; Internal medicine; Biochemistry; Immunology; Cancer","score_opus":0.019925339032572962,"score_gpt":0.29307840238482474,"score_spread":0.27315306335225176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2691745207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927757,0.0035935657,0.000011503944,0.0024967706,0.000023567827,0.00074343715,0.000013365377,0.000021049811,0.0003210908],"genre_scores_gemma":[0.99860245,0.0006214551,0.0003247722,0.00027117372,0.00002120913,0.00004558699,0.000021825595,0.000018158153,0.00007338844],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990254,0.00006488343,0.00016182092,0.0003396078,0.00011124608,0.00029702767],"domain_scores_gemma":[0.99932635,0.000030812633,0.00013388302,0.00034019435,0.000109748726,0.000058994312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024035746,0.00015657439,0.00026593936,0.0000506724,0.00040977952,0.00007405842,0.00012428402,0.00003086707,0.000005039679],"category_scores_gemma":[0.00004578088,0.000084244006,0.000023684654,0.00005807508,0.0012013357,0.000051938678,0.00007774226,0.00019195782,0.0000024520614],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013911914,0.0000932329,0.21851811,0.00016629852,0.00007293301,0.00017677613,0.0004540506,0.000007816254,0.7745812,0.00020993057,0.00008152984,0.0042469692],"study_design_scores_gemma":[0.010819722,0.0031252874,0.7085176,0.001187653,0.00011799942,0.00063135294,0.0006448351,0.0013727132,0.26045573,0.0003786736,0.012201525,0.00054691435],"about_ca_topic_score_codex":0.00005037534,"about_ca_topic_score_gemma":0.0000015430439,"teacher_disagreement_score":0.5141254,"about_ca_system_score_codex":0.000014431453,"about_ca_system_score_gemma":0.0000550139,"threshold_uncertainty_score":0.44263715},"labels":[],"label_agreement":null},{"id":"W2694871785","doi":"10.1200/jco.2017.35.15_suppl.5032","title":"Efficacy, safety, tolerability, and pharmacokinetics of EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after enzalutamide and/or abiraterone.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Enzalutamide; Pharmacokinetics; Prostate cancer; Adverse effect; Internal medicine; Abiraterone acetate; Gastroenterology; Nausea; Pharmacology; Dosing; Androgen receptor; Oncology; Urology; Cancer; Androgen deprivation therapy","score_opus":0.10930470014158167,"score_gpt":0.4681243312694845,"score_spread":0.3588196311279028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2694871785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99127126,0.0019569427,0.000012239898,0.005483786,0.00014853623,0.00092645665,0.00005766321,0.000004732601,0.00013836878],"genre_scores_gemma":[0.9883584,0.0030351598,0.007928361,0.00012849497,0.00025746253,0.000036506295,0.000005726335,0.000026929822,0.00022298945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965679,0.00034185703,0.0019243781,0.00033131137,0.0004597002,0.000374827],"domain_scores_gemma":[0.9967076,0.0006780393,0.0015748403,0.00023262018,0.00039952976,0.00040737868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002508903,0.00023934552,0.001518256,0.00015586324,0.000109200075,0.00006481869,0.0001535818,0.00015937147,0.000064428306],"category_scores_gemma":[0.0004719026,0.0001379373,0.00011811453,0.00009857066,0.0010653883,0.00027876705,0.00013054862,0.0006835879,7.0509844e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21117848,0.0038115236,0.56973225,0.0008538744,0.0011406507,0.0045141946,0.0027065424,0.00002098249,0.021042123,0.0000081635135,0.00016894561,0.18482225],"study_design_scores_gemma":[0.07352491,0.022947883,0.889125,0.0022447773,0.00097178103,0.0009954484,0.0006150615,0.00024961692,0.0049107177,0.00013813199,0.003973946,0.00030272896],"about_ca_topic_score_codex":0.00011473858,"about_ca_topic_score_gemma":0.0005020464,"teacher_disagreement_score":0.31939274,"about_ca_system_score_codex":0.00021098171,"about_ca_system_score_gemma":0.0018753627,"threshold_uncertainty_score":0.56249195},"labels":[],"label_agreement":null},{"id":"W2726186366","doi":"10.1200/jco.2017.35.15_suppl.5002","title":"A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Clinical endpoint; Prednisone; Oncology; Urology; Gastroenterology; Cancer; Randomized controlled trial; Androgen receptor","score_opus":0.1569140365483028,"score_gpt":0.5432351185979689,"score_spread":0.3863210820496661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2726186366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99350506,0.00039941867,0.000047661943,0.0014964532,0.00058233144,0.0036750727,0.00013186342,0.0000062071626,0.00015591264],"genre_scores_gemma":[0.9956723,0.00056674023,0.0015466829,0.00014883211,0.00033659837,0.00025387466,0.000014483516,0.00003317662,0.0014273151],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99507076,0.0005375486,0.0029287066,0.00031979388,0.000765377,0.0003778057],"domain_scores_gemma":[0.9911505,0.0017374048,0.004320451,0.0004153465,0.0019859273,0.00039039453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004193506,0.00024562384,0.0029780508,0.00013570508,0.0003188285,0.000057110134,0.0002796992,0.0001557341,0.00012976635],"category_scores_gemma":[0.003638265,0.00013534282,0.00045187928,0.000073221454,0.0008284356,0.0003440004,0.00008748449,0.00052837125,0.0000013416075],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8699802,0.02337867,0.07808064,0.00015238475,0.0031931808,0.00028483872,0.001081665,0.000031412692,0.00039840268,0.000015139012,0.000577787,0.02282563],"study_design_scores_gemma":[0.7731149,0.12837249,0.09345243,0.00020770816,0.001979051,0.0000131869665,0.0002041957,0.0001412811,0.00043905532,0.00012451826,0.0018289436,0.00012224894],"about_ca_topic_score_codex":0.00031109081,"about_ca_topic_score_gemma":0.00052140665,"teacher_disagreement_score":0.10499382,"about_ca_system_score_codex":0.00023169827,"about_ca_system_score_gemma":0.0024131949,"threshold_uncertainty_score":0.551912},"labels":[],"label_agreement":null},{"id":"W2734875224","doi":"10.1200/jco.2017.35.15_suppl.5008","title":"Duration of androgen deprivation therapy in high risk prostate cancer: Final results of a randomized phase III trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Rimouski; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Centre hospitalier universitaire de Québec; Centre de Santé et de Services Sociaux de Chicoutimi; Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Randomized controlled trial; Hazard ratio; Quality of life (healthcare); Confidence interval; Radiation therapy; Internal medicine; Proportional hazards model; Urology; Surgery; Oncology; Cancer","score_opus":0.18353912180918638,"score_gpt":0.5299372098789196,"score_spread":0.34639808806973316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734875224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911975,0.0009914942,0.000029813815,0.00571995,0.000515406,0.0012521053,0.000025694198,0.0000019354952,0.00026609274],"genre_scores_gemma":[0.9565144,0.04224098,0.0005155351,0.000050147482,0.00042051147,0.000029561059,0.000009615447,0.0000069113507,0.00021233433],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947988,0.00085175666,0.0037112362,0.00013685391,0.00035970545,0.0001416897],"domain_scores_gemma":[0.9895235,0.0023578594,0.0070666415,0.00023381723,0.0007001564,0.00011804484],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0103763435,0.000092197035,0.0021260218,0.00016014607,0.000049344217,0.000007710145,0.00015008647,0.00021130354,0.000030445952],"category_scores_gemma":[0.013158084,0.00005419815,0.00041489207,0.000078103585,0.00041034012,0.00014378964,0.000026068128,0.00049251947,5.396251e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.771724,0.0021501256,0.01669228,0.000016229455,0.00045416324,0.00007846312,0.00022767212,0.000009479498,0.00038313709,0.00001555544,0.00023799026,0.20801093],"study_design_scores_gemma":[0.9406395,0.0203395,0.031778567,0.00017317437,0.0002705492,0.000008837008,0.000028474045,0.00018537237,0.004507465,0.0008365708,0.0011892549,0.00004275527],"about_ca_topic_score_codex":0.0007558424,"about_ca_topic_score_gemma":0.00012037977,"teacher_disagreement_score":0.20796816,"about_ca_system_score_codex":0.00010200581,"about_ca_system_score_gemma":0.0022358112,"threshold_uncertainty_score":0.9951545},"labels":[],"label_agreement":null},{"id":"W2736235473","doi":"10.21873/anticanres.11627","title":"68Ga-PSMA-PET/CT Ηas a Role in Detecting Prostate Cancer Lesions in Patients with Recurrent Disease","year":2017,"lang":"en","type":"review","venue":"Anticancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Glutamate carboxypeptidase II; Biochemical recurrence; Pet imaging; Prostate-specific antigen; Nuclear medicine; Positron emission tomography; Prostate; Radiology; Cancer; Internal medicine; Prostatectomy","score_opus":0.1997599564380064,"score_gpt":0.5099718881351781,"score_spread":0.31021193169717176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736235473","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034640916,0.95714444,9.3858745e-8,0.00038420147,0.00014419643,0.0066323644,0.00025497813,0.000032439446,0.00076636416],"genre_scores_gemma":[0.037285347,0.95646113,0.000023109335,0.000012359767,0.00016044048,0.0035789441,0.00025287239,0.00014840074,0.00207738],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99361134,0.0006098564,0.0007619662,0.0012806421,0.0019246611,0.0018115473],"domain_scores_gemma":[0.996925,0.00034275049,0.0002493303,0.0012780431,0.00051379704,0.00069106533],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0014417403,0.0005934107,0.001918672,0.001506938,0.00041494283,0.0001798652,0.0006197869,0.00005222935,0.00018036657],"category_scores_gemma":[0.00055129296,0.00039072605,0.00025979494,0.0014862046,0.00056709396,0.00022210891,0.00046645876,0.0027379396,0.0001013427],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015623039,0.00073100714,0.09812858,0.012113379,0.0001702225,0.0033677118,0.000096707045,0.0000010293745,1.7548024e-7,0.000007930991,0.00015011178,0.88367087],"study_design_scores_gemma":[0.008383684,0.0012470401,0.07455481,0.15110804,0.0004995958,0.00003693787,0.00012890754,0.000060290735,0.0000057662887,0.00007376706,0.7630013,0.0008998297],"about_ca_topic_score_codex":0.0030850095,"about_ca_topic_score_gemma":0.0022766774,"teacher_disagreement_score":0.882771,"about_ca_system_score_codex":0.0024265673,"about_ca_system_score_gemma":0.0065016965,"threshold_uncertainty_score":0.99985445},"labels":[],"label_agreement":null},{"id":"W2736306524","doi":"","title":"Novel Biomarkers for Prostate Cancer Progression","year":2017,"lang":"en","type":"article","venue":"Scholarship at UWindsor (University of Windsor)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Cancer; Medicine; Prostate; Oncology; Internal medicine","score_opus":0.054415596060954814,"score_gpt":0.3453868059706891,"score_spread":0.2909712099097343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736306524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882652,0.0007241203,0.00006150775,0.0068925056,0.00020677781,0.0014632591,0.0002806866,0.000054212695,0.002051698],"genre_scores_gemma":[0.9786772,0.0003263341,0.003282403,0.000051879186,0.00009264946,0.000010936374,0.000099654615,0.000035368284,0.017423587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841326,0.000027947082,0.00014312044,0.00046895552,0.00046179225,0.0004849468],"domain_scores_gemma":[0.99828374,0.000047985915,0.00029227237,0.00069508574,0.0003726148,0.0003082884],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0004457341,0.00020323691,0.0003707766,0.00019724433,0.0013634725,0.00005657529,0.00046366613,0.00019589387,0.00025977494],"category_scores_gemma":[0.00012678333,0.00019214646,0.00025149444,0.00012620247,0.00052572164,0.00057577004,0.000295958,0.0002460834,0.000027911037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009399814,0.0004532079,0.7641195,0.0005635256,0.00067135284,0.00008589001,0.0010753373,0.0000016535671,0.1824245,0.000066308494,0.0014774298,0.03966147],"study_design_scores_gemma":[0.014346218,0.00071175076,0.92918056,0.0007359247,0.0003440785,0.000020887355,0.0005818325,0.000099111545,0.036578223,0.00012920558,0.016964443,0.0003077311],"about_ca_topic_score_codex":0.00024902192,"about_ca_topic_score_gemma":0.00022633132,"teacher_disagreement_score":0.16506107,"about_ca_system_score_codex":0.00027026553,"about_ca_system_score_gemma":0.0003370979,"threshold_uncertainty_score":0.99993664},"labels":[],"label_agreement":null},{"id":"W2736533590","doi":"10.18632/oncotarget.19386","title":"Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells","year":2017,"lang":"en","type":"article","venue":"Oncotarget","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Protein kinase B; PI3K/AKT/mTOR pathway; LNCaP; Cancer research; Prostate cancer; Gene silencing; Biology; Ubiquitin ligase; Signal transduction; Cell biology; Cancer; Gene; Ubiquitin; Genetics","score_opus":0.03368710459730057,"score_gpt":0.3430149440850167,"score_spread":0.30932783948771614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736533590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98668903,0.0002564752,0.0000018236611,0.009672805,0.000043283664,0.0012569337,0.00014579229,0.00001596238,0.0019178871],"genre_scores_gemma":[0.9985705,0.00038916405,0.00010573248,0.00008665448,0.000052744235,0.00024954553,0.00006724094,0.000014230377,0.00046418724],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991105,0.00004208074,0.00019741639,0.0002721626,0.00016603766,0.00021178961],"domain_scores_gemma":[0.9992272,0.000022071708,0.00011988245,0.00042510545,0.00011455758,0.00009114325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001221622,0.00010609298,0.0001994572,0.00007929719,0.00013074603,0.0000237825,0.00005317395,0.000023112958,0.0001289442],"category_scores_gemma":[0.000044539545,0.00008498538,0.000028479708,0.00007996586,0.00016336887,0.00012832807,0.000052861466,0.00015245001,0.0000070576275],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015727957,0.00053864246,0.30585977,0.00034579396,0.00001827127,0.000048963248,0.0002387516,0.0000039023653,0.6877587,0.0002547174,0.0004229403,0.0029367395],"study_design_scores_gemma":[0.002173333,0.0005523478,0.6420082,0.00024528304,0.000013557482,0.000002308993,0.000025524763,0.000023645374,0.35362747,0.00078613375,0.0004762167,0.00006596106],"about_ca_topic_score_codex":0.00063557667,"about_ca_topic_score_gemma":0.0002169997,"teacher_disagreement_score":0.33614844,"about_ca_system_score_codex":0.00015238115,"about_ca_system_score_gemma":0.00013744533,"threshold_uncertainty_score":0.34656033},"labels":[],"label_agreement":null},{"id":"W2736905156","doi":"10.1097/rlu.0000000000001766","title":"Biopsy-Proven Diffuse Mediastinal Prostate Cancer Metastases Negative on 18F-Fluorocholine, Diagnosed on 68Ga-PSMA and 18F-PSMA PET/CT","year":2017,"lang":"en","type":"article","venue":"Clinical Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Malignancy; Radiology; Biopsy; PET-CT; Prostate; Lymph node; Mediastinal lymphadenopathy; Lymph; Cancer; Positron emission tomography; Pathology; Internal medicine","score_opus":0.09499040764099059,"score_gpt":0.4366676325262,"score_spread":0.3416772248852094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736905156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.947952,0.0009958239,7.637661e-7,0.044524785,0.000950967,0.0014467209,0.00019067214,0.00012654338,0.0038117538],"genre_scores_gemma":[0.9800069,0.009973885,0.0002697744,0.0044525973,0.0018582852,0.0001264517,0.000081339356,0.00012589038,0.0031049123],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99600965,0.00024981197,0.00092050026,0.0010921153,0.00096355524,0.0007643803],"domain_scores_gemma":[0.9953176,0.0017206284,0.0005066525,0.001067476,0.00028603044,0.0011016543],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010742047,0.0005443593,0.0013343497,0.00020631637,0.000636237,0.00009015969,0.00043602113,0.000042274467,0.00092731096],"category_scores_gemma":[0.006890265,0.00033862656,0.00022279714,0.00016865453,0.002599481,0.00018123642,0.0002644265,0.0012119276,0.0002425548],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060953356,0.011742603,0.21044968,0.0015435659,0.0038199632,0.09962456,0.0024843805,0.0000055422806,0.0068887873,0.0017730151,0.170315,0.43039954],"study_design_scores_gemma":[0.07661151,0.02224817,0.7988774,0.0058687273,0.0015549146,0.0011364118,0.0014107868,0.00079859653,0.0011756361,0.00071784214,0.08857096,0.001029024],"about_ca_topic_score_codex":0.0005880894,"about_ca_topic_score_gemma":0.000057618578,"teacher_disagreement_score":0.5884277,"about_ca_system_score_codex":0.00014797796,"about_ca_system_score_gemma":0.00022500992,"threshold_uncertainty_score":0.999986},"labels":[],"label_agreement":null},{"id":"W2737231281","doi":"10.1200/jco.2016.34.15_suppl.5006","title":"Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Cabazitaxel; Docetaxel; Medicine; Regimen; Clinical endpoint; Prostate cancer; Internal medicine; Mitoxantrone; Urology; Chemotherapy; Surgery; Cancer; Randomized controlled trial; Androgen deprivation therapy","score_opus":0.11248796443945806,"score_gpt":0.4847442914826962,"score_spread":0.37225632704323813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737231281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883244,0.0006660611,0.000055613604,0.008441307,0.0003527811,0.0018233485,0.000053752778,0.000009572401,0.000273159],"genre_scores_gemma":[0.9969047,0.0009163905,0.00056754955,0.000496363,0.00026269798,0.00008564137,0.000005371426,0.000035842626,0.0007254909],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956421,0.00039117815,0.002249356,0.0003683248,0.00086059765,0.00048840203],"domain_scores_gemma":[0.99570817,0.001056922,0.0014953272,0.0002638875,0.0009807895,0.0004949026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021334235,0.0002682098,0.0017465927,0.00026442646,0.00006998819,0.000019382975,0.00019242411,0.00014258946,0.00039270445],"category_scores_gemma":[0.00058159645,0.0001282172,0.0002473234,0.00033577485,0.0003437096,0.00027519692,0.000038416303,0.00069943856,0.000009966015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14180592,0.024567297,0.66763335,0.000053333788,0.002009321,0.0024935938,0.001060032,0.000006675574,0.00024705165,0.000018107032,0.00091721787,0.15918812],"study_design_scores_gemma":[0.24873963,0.089620814,0.6549187,0.00047035396,0.0007562405,0.000035889698,0.0006906543,0.000022619919,0.00012241237,0.0002767792,0.004134398,0.00021151888],"about_ca_topic_score_codex":0.00030717623,"about_ca_topic_score_gemma":0.0032636174,"teacher_disagreement_score":0.1589766,"about_ca_system_score_codex":0.0007595682,"about_ca_system_score_gemma":0.0035478456,"threshold_uncertainty_score":0.6293726},"labels":[],"label_agreement":null},{"id":"W2737333498","doi":"10.1016/j.clgc.2017.07.014","title":"Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Prednisone; Proportional hazards model; Hazard ratio; Internal medicine; Progression-free survival; Oncology; Chemotherapy; Univariate analysis; Urology; Cancer; Confidence interval; Gastroenterology; Multivariate analysis; Androgen deprivation therapy","score_opus":0.12033434774859395,"score_gpt":0.44305116817026297,"score_spread":0.32271682042166905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737333498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98452955,0.0026173885,0.00019073446,0.005705785,0.00027157107,0.0058469935,0.00053567,0.000087891065,0.00021443033],"genre_scores_gemma":[0.97921723,0.0033107598,0.002294669,0.00017919274,0.00043583763,0.0055764,0.00012468128,0.0001325139,0.008728719],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99633604,0.00013761266,0.00093615934,0.0009801596,0.00068895007,0.0009210878],"domain_scores_gemma":[0.99710757,0.00026059354,0.0005346541,0.0011371736,0.00050789956,0.00045211005],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006911991,0.0005064047,0.0010858185,0.000146127,0.00043621834,0.00016120893,0.00048864196,0.00019582095,0.00007770105],"category_scores_gemma":[0.0002358612,0.00034018722,0.0002134719,0.00020309455,0.0006623845,0.00033970366,0.00015893261,0.00054661196,0.0000051650727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07903076,0.0023561853,0.8510568,0.0012540385,0.0014913005,0.001191712,0.000893244,0.0034616613,0.0025379984,0.000011298098,0.0015365246,0.055178456],"study_design_scores_gemma":[0.080648616,0.006325891,0.78969634,0.0023288939,0.0009292516,0.000027162458,0.00025440034,0.1150468,0.002707904,0.00045482768,0.00063064566,0.0009492688],"about_ca_topic_score_codex":0.0005666442,"about_ca_topic_score_gemma":0.0018729909,"teacher_disagreement_score":0.11158513,"about_ca_system_score_codex":0.00050556555,"about_ca_system_score_gemma":0.0023411498,"threshold_uncertainty_score":0.999905},"labels":[],"label_agreement":null},{"id":"W2738571701","doi":"10.1101/gad.299958.117","title":"Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer","year":2017,"lang":"en","type":"article","venue":"Genes & Development","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University and Génome Québec Innovation Centre; McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute","keywords":"Library science; Gerontology; Medicine; Computer science","score_opus":0.03605307450010542,"score_gpt":0.30646727428842846,"score_spread":0.27041419978832304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738571701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995201,0.0020207872,9.772896e-7,0.0014614493,0.00016435109,0.0005419958,0.000012316868,0.000011063863,0.0005860542],"genre_scores_gemma":[0.9969185,0.00056876376,0.0003337012,0.0001013817,0.00004232463,0.00011674372,0.000010184827,0.000017688248,0.0018907113],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99897957,0.000026473892,0.00021689844,0.00019217613,0.00034096724,0.00024391228],"domain_scores_gemma":[0.999504,0.000009396852,0.00008829875,0.00020453057,0.00010785834,0.00008586115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018496202,0.00012014974,0.00018820699,0.00005714173,0.00023587725,0.00002927524,0.00017910072,0.000043159875,0.00017898544],"category_scores_gemma":[0.000024614399,0.00007180358,0.000058743695,0.00007205073,0.000099992896,0.00006335385,0.00006741961,0.00013387948,0.000016042079],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012260992,0.00030765127,0.33507788,0.00028434495,0.00031827297,0.000110111025,0.0117059,0.000017782026,0.51962644,0.00030403977,0.00013085469,0.1308906],"study_design_scores_gemma":[0.00240248,0.000094936346,0.16780213,0.00052338553,0.000019589808,0.000010842167,0.0004897219,0.000014762528,0.7353824,0.000082496,0.093044445,0.00013281465],"about_ca_topic_score_codex":0.00014239649,"about_ca_topic_score_gemma":0.00014203798,"teacher_disagreement_score":0.21575594,"about_ca_system_score_codex":0.00022223126,"about_ca_system_score_gemma":0.0011542004,"threshold_uncertainty_score":0.2928065},"labels":[],"label_agreement":null},{"id":"W2739741429","doi":"10.1158/1538-7445.am2017-lb-088","title":"Abstract LB-088: Role of histone demethylase JMJD1A in the generation of AR-V7","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Gene knockdown; Demethylase; Androgen receptor; RNA splicing; Cancer research; Histone; Alternative splicing; Chemistry; Cancer; Biology; Medicine; Messenger RNA; Gene; Internal medicine; Biochemistry; RNA","score_opus":0.22564015854489028,"score_gpt":0.5274943529837348,"score_spread":0.30185419443884454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739741429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98138815,0.008933539,0.0000015601437,0.002922847,0.000060679766,0.0006497449,0.000026436535,0.000004025315,0.0060130265],"genre_scores_gemma":[0.99587137,0.0025634987,0.000036005677,0.00002244233,0.00023517318,0.00019825887,0.000016656302,0.000014202921,0.0010423987],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99815196,0.00011959276,0.00025277125,0.00022097374,0.0008965594,0.00035813104],"domain_scores_gemma":[0.9985654,0.00010424956,0.000104092534,0.0007338318,0.00040698386,0.00008544825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017046198,0.00008702941,0.00023789609,0.00022032142,0.00020769009,0.00002974799,0.00039155147,0.000079004865,0.0002832422],"category_scores_gemma":[0.00027381646,0.000055631073,0.000064977045,0.00020189027,0.000539881,0.000106799496,0.000087591034,0.00044944923,0.0000137172065],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065304927,0.00029127672,0.02095421,0.00025271502,0.000056233326,0.000050042847,0.0012695343,0.000007967227,0.9354304,0.00025263362,0.0022110287,0.03857089],"study_design_scores_gemma":[0.0023293388,0.00031945642,0.16807687,0.00025107243,0.000020148369,0.0000032355608,0.00066977553,0.00010530989,0.8230252,0.00032944683,0.0047968556,0.00007324295],"about_ca_topic_score_codex":0.004921013,"about_ca_topic_score_gemma":0.0008107845,"teacher_disagreement_score":0.14712267,"about_ca_system_score_codex":0.00025901792,"about_ca_system_score_gemma":0.0006492586,"threshold_uncertainty_score":0.74391323},"labels":[],"label_agreement":null},{"id":"W2739748895","doi":"10.1158/1538-7445.am2017-5025","title":"Abstract 5025: EZH2 reprogramming confers intrinsic stem cell properties and developmental plasticity driving neuroendocrine prostate cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Reprogramming; Transdifferentiation; PRC2; Biology; Cancer research; Enzalutamide; EZH2; Prostate cancer; Cancer stem cell; Embryonic stem cell; Androgen receptor; Epigenome; Cancer; Cell biology; Stem cell; Cell; Histone; Genetics; DNA methylation; Gene expression; Gene","score_opus":0.13512764506508818,"score_gpt":0.3859632692914189,"score_spread":0.2508356242263307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739748895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98902273,0.0041590603,0.00000146999,0.0026976904,0.00016616189,0.001694852,0.000030239316,0.00007372839,0.0021540602],"genre_scores_gemma":[0.9804806,0.008000757,0.000068417714,0.000045767676,0.0002489707,0.00094331015,0.00000709179,0.0000647283,0.010140335],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99660814,0.0000810359,0.00033147042,0.00080666057,0.0009788333,0.0011938794],"domain_scores_gemma":[0.9983458,0.0001216816,0.00011804399,0.0003877614,0.0005148335,0.00051187084],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0004868475,0.00028543815,0.00041920005,0.00025818343,0.0013827687,0.0005206543,0.0003451276,0.000062654995,0.00026794375],"category_scores_gemma":[0.00016404616,0.0002135679,0.000063018706,0.00018431028,0.00103858,0.0003658094,0.0005927861,0.0009651059,0.0000394787],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002494306,0.00026359953,0.3607624,0.0018912834,0.00024972716,0.0013128205,0.0019148639,0.0000069851462,0.27233723,0.000023425955,0.0019037628,0.3568396],"study_design_scores_gemma":[0.007156523,0.0006695447,0.45349514,0.0020841635,0.00007940834,0.00009625001,0.0028401637,0.00011887963,0.50869083,0.00003257106,0.024198344,0.0005382046],"about_ca_topic_score_codex":0.0030562037,"about_ca_topic_score_gemma":0.0007377432,"teacher_disagreement_score":0.3563014,"about_ca_system_score_codex":0.00077526085,"about_ca_system_score_gemma":0.0015942305,"threshold_uncertainty_score":0.99991727},"labels":[],"label_agreement":null},{"id":"W2739779320","doi":"10.1158/1538-7445.am2017-3395","title":"Abstract 3395: Alternative splicing of the MEAF6 gene promotes neuroendocrine prostate cancer development","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Cancer research; Neuroendocrine differentiation; Biology; Alternative splicing; Prostate; Cancer; RNA splicing; Gene; Exon; RNA; Genetics","score_opus":0.1437343466086203,"score_gpt":0.4574495561367498,"score_spread":0.3137152095281295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739779320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825581,0.0022309371,0.0000015143734,0.010757735,0.00030566205,0.0018079007,0.00006109291,0.000020432068,0.0022566689],"genre_scores_gemma":[0.98287463,0.004055897,0.000079939724,0.00005691468,0.00030611904,0.0008153571,0.00000803184,0.00004799463,0.01175511],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99686885,0.000086929824,0.00033357833,0.0005002265,0.0013768576,0.00083358266],"domain_scores_gemma":[0.99766773,0.000086722466,0.0002001268,0.0009708772,0.0008427671,0.00023178522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006097233,0.0002055028,0.00034694627,0.00016976567,0.00095989933,0.00010673032,0.0007315985,0.000037989827,0.00034449005],"category_scores_gemma":[0.00022931269,0.00012237216,0.00009958578,0.00024718652,0.0007254366,0.00016562633,0.0005949135,0.0007304302,0.000021638833],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017804254,0.00039002835,0.20646045,0.0011330575,0.0006228379,0.00039787038,0.0031791744,0.000049647384,0.6771018,0.00007477766,0.0020451306,0.10676481],"study_design_scores_gemma":[0.0018302606,0.000116913456,0.21471214,0.00072218507,0.00002203686,0.0000103824,0.00008387491,0.00003686728,0.7765446,0.000110336456,0.0057040346,0.00010637452],"about_ca_topic_score_codex":0.0048659183,"about_ca_topic_score_gemma":0.00062969443,"teacher_disagreement_score":0.10665843,"about_ca_system_score_codex":0.00064982363,"about_ca_system_score_gemma":0.0019447149,"threshold_uncertainty_score":0.7382867},"labels":[],"label_agreement":null},{"id":"W2739917672","doi":"10.1158/1538-7445.am2017-4492","title":"Abstract 4492: Androgen receptor affects GLI activity by promoting transcriptionally active states of GLI upon androgen stimulation","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"LNCaP; Androgen receptor; Prostate cancer; Cancer research; Hedgehog signaling pathway; Smoothened; Gene knockdown; Androgen; GLI2; Hedgehog; Enzalutamide; Dihydrotestosterone; Biology; Bicalutamide; Chemistry; Endocrinology; Internal medicine; Signal transduction; Cell biology; Medicine; Cell culture; Cancer; Genetics","score_opus":0.08696871614001951,"score_gpt":0.42705944335871004,"score_spread":0.34009072721869055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739917672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99236286,0.0019410456,0.00002676985,0.0025817547,0.00010897974,0.0017134603,0.00050325895,0.000035336332,0.0007265651],"genre_scores_gemma":[0.9969233,0.0015063084,0.000081998245,0.000009949914,0.00018804554,0.0002913073,0.00014849409,0.000046843004,0.0008037146],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970509,0.0002167927,0.00022673275,0.0005363708,0.0012617733,0.0007074597],"domain_scores_gemma":[0.99796927,0.00025481448,0.00018349032,0.00054351403,0.0007087082,0.0003402136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014090108,0.00020842011,0.00040529852,0.00020540677,0.00064035715,0.00011746005,0.0003137764,0.00017170605,0.0006660102],"category_scores_gemma":[0.00030125864,0.0001719121,0.00012851876,0.00021377862,0.0004243642,0.00049093785,0.000101279744,0.0006684745,0.00001632474],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039880346,0.00041979918,0.017358867,0.00062534015,0.00031081628,0.000031972577,0.0007454605,0.000015720338,0.8985041,0.00002024679,0.0017484552,0.07623122],"study_design_scores_gemma":[0.0036421937,0.0006420074,0.07701404,0.0005272404,0.000042658776,0.0000033755584,0.000107290885,0.0004232702,0.9142826,0.00019524539,0.0029553056,0.00016473576],"about_ca_topic_score_codex":0.0013108337,"about_ca_topic_score_gemma":0.00015482726,"teacher_disagreement_score":0.07606648,"about_ca_system_score_codex":0.0006610427,"about_ca_system_score_gemma":0.00082036457,"threshold_uncertainty_score":0.72923446},"labels":[],"label_agreement":null},{"id":"W2740043261","doi":"10.1158/1538-7445.am2017-220","title":"Abstract 220: Proteomic identification of therapeutics targets for Enzalutamide resistance in Castration Resistant Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke; Université Laval","funders":"","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Androgen deprivation therapy; Context (archaeology); Cancer research; Androgen; Testosterone (patch); Medicine; Cancer; Cancer cell; Internal medicine; Oncology; Biology; Hormone","score_opus":0.13488509338651117,"score_gpt":0.46738906757130333,"score_spread":0.33250397418479216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740043261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811358,0.0077268383,0.000010490626,0.005665321,0.00014815899,0.0042382185,0.00033997177,0.00001772804,0.000717498],"genre_scores_gemma":[0.98430645,0.0050105047,0.0002077738,0.00002034042,0.00017265508,0.0034068015,0.00004937031,0.000044544246,0.0067815618],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973825,0.000083844774,0.00054681365,0.00050494575,0.00081865804,0.00066319446],"domain_scores_gemma":[0.9976236,0.00011196499,0.00029823728,0.0007865384,0.0010540654,0.00012556693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018164015,0.00016678248,0.0003396094,0.0003071054,0.00047097605,0.00013162517,0.00035529395,0.00012862614,0.00007787892],"category_scores_gemma":[0.00023847992,0.00013914682,0.000085979314,0.00024419843,0.00049174746,0.0002717286,0.000062374245,0.00044450612,0.000006163355],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007579906,0.00018645547,0.019618493,0.0014092396,0.000102029044,0.000027652526,0.0010218853,0.000015420015,0.9615861,0.00025429696,0.0006886328,0.0075098993],"study_design_scores_gemma":[0.0034508933,0.00019520884,0.37568644,0.00085908873,0.000030054935,5.658891e-7,0.00018585178,0.000053071693,0.6148503,0.0015710819,0.0029816919,0.00013576569],"about_ca_topic_score_codex":0.0017931473,"about_ca_topic_score_gemma":0.004857943,"teacher_disagreement_score":0.35606796,"about_ca_system_score_codex":0.0009328649,"about_ca_system_score_gemma":0.0015836805,"threshold_uncertainty_score":0.5674243},"labels":[],"label_agreement":null},{"id":"W2740295960","doi":"10.1158/1538-7445.am2017-1577","title":"Abstract 1577: GRK3 is a direct target of ADT-induced CREB1 activation and it promotes neuroendocrine differentiation of prostate cancer cells","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Cancer research; Neuroendocrine differentiation; Medicine; Prostate; LNCaP; CREB1; Internal medicine; Cancer; Oncology; Biology; CREB; Transcription factor; Genetics","score_opus":0.1008513406943512,"score_gpt":0.4272876459490915,"score_spread":0.3264363052547403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740295960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989359,0.0009861471,0.0000010768096,0.0066630845,0.00010927599,0.0014641584,0.00018327833,0.000015338996,0.0012186387],"genre_scores_gemma":[0.9910425,0.0055343406,0.00002845268,0.000029938314,0.00013521446,0.00034952187,0.000028519298,0.000037341764,0.0028141525],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99771637,0.00008410911,0.0003325048,0.00044357867,0.00090416,0.0005192864],"domain_scores_gemma":[0.9980371,0.00013342925,0.0002604898,0.00056843105,0.00080776535,0.00019279991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003748543,0.00018022148,0.0004315978,0.00028268588,0.0002930323,0.00006969085,0.00022005671,0.00006006797,0.0005427071],"category_scores_gemma":[0.000218123,0.00013752983,0.00007440377,0.00021719777,0.0003566922,0.00027512197,0.00017225413,0.0004198633,0.000003948522],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001469267,0.00024273513,0.06858043,0.0013533339,0.00017792197,0.000021599182,0.00092820846,0.0000018212974,0.9125279,0.0000069802404,0.0016948206,0.012994972],"study_design_scores_gemma":[0.0020211656,0.00040527224,0.2159563,0.00061961106,0.000030362713,0.0000011394535,0.00009204584,0.000092220456,0.78003377,0.000072382994,0.00058942835,0.000086287386],"about_ca_topic_score_codex":0.004749024,"about_ca_topic_score_gemma":0.00012638322,"teacher_disagreement_score":0.14737588,"about_ca_system_score_codex":0.00020491885,"about_ca_system_score_gemma":0.0006131762,"threshold_uncertainty_score":0.7179135},"labels":[],"label_agreement":null},{"id":"W2740545693","doi":"10.1016/s1470-2045(17)30573-9","title":"Androgen deprivation in prostate cancer: first do no harm","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Prostatectomy; Oncology; Radiation therapy; Cancer; Internal medicine; Prostate-specific antigen; Gynecology","score_opus":0.07795646313435715,"score_gpt":0.3914052653661275,"score_spread":0.31344880223177035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740545693","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020969283,0.00409421,4.88702e-7,0.95323163,0.00079538306,0.0015575328,0.00014202102,0.000049789825,0.019159658],"genre_scores_gemma":[0.031840812,0.06362659,0.00025816617,0.7699058,0.038804036,0.0038205532,0.0021631413,0.00022754144,0.08935335],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813557,0.00016202021,0.0002687982,0.00042417567,0.00030557477,0.00070384605],"domain_scores_gemma":[0.99848455,0.00019202588,0.00024948665,0.00087234686,0.00014689086,0.000054675667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000522236,0.0002579401,0.0008849096,0.00013237337,0.00020118142,0.000049349455,0.00048002155,0.0005114194,0.00035256203],"category_scores_gemma":[0.00010984669,0.00015472154,0.000091058944,0.00010389002,0.000299943,0.000057762412,0.00015535411,0.001958928,0.00026949975],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011084547,0.0000546117,0.029729052,0.00045656165,0.00017807388,0.0026185852,0.0004895456,0.0000018869024,0.000036001773,0.000008666624,0.95716757,0.008151017],"study_design_scores_gemma":[0.005115274,0.00040586625,0.007166506,0.00036352582,0.00010613989,0.00009403707,0.000012323894,0.000022394437,0.000119727294,0.00027527547,0.9861593,0.00015961],"about_ca_topic_score_codex":0.00075724896,"about_ca_topic_score_gemma":0.00042795626,"teacher_disagreement_score":0.18332583,"about_ca_system_score_codex":0.0009660183,"about_ca_system_score_gemma":0.0008166836,"threshold_uncertainty_score":0.85106766},"labels":[],"label_agreement":null},{"id":"W2740660726","doi":"10.1158/1538-7445.am2017-1576","title":"Abstract 1576: UGT2B17 promotes castration-resistant prostate cancer progression through enhancing ligand-independent AR signaling","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; University of British Columbia","funders":"","keywords":"LNCaP; Prostate cancer; Androgen receptor; Androgen; Cancer research; Enzalutamide; Biology; Endocrinology; Internal medicine; Androgen deprivation therapy; Prostate; Tumor progression; Cancer; Medicine; Hormone","score_opus":0.12445719061752251,"score_gpt":0.47607702450033507,"score_spread":0.35161983388281254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740660726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760503,0.010269382,0.000008390639,0.0066012344,0.00036957135,0.002951139,0.00010111891,0.000099032244,0.0035498205],"genre_scores_gemma":[0.9858109,0.0049712975,0.00025893055,0.00005201075,0.00095879525,0.0018829014,0.000049309154,0.00009415499,0.0059217336],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9946258,0.000120373836,0.0005408595,0.00097288913,0.0022541443,0.001485922],"domain_scores_gemma":[0.99681765,0.00015365031,0.00027539014,0.0010746381,0.0012011896,0.00047745783],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0016225643,0.0003716391,0.0005343802,0.00023360328,0.002244489,0.00071084744,0.0005706113,0.00022934227,0.0006927264],"category_scores_gemma":[0.00032320677,0.00027286581,0.00016171679,0.0003012126,0.0006391892,0.0006912848,0.00031011854,0.001310694,0.00009419578],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002479448,0.0003227454,0.017498955,0.001089072,0.0002607264,0.0007291796,0.0024142337,0.000018438086,0.95032835,0.00006799042,0.0012059235,0.02358494],"study_design_scores_gemma":[0.00351341,0.00064235803,0.033471834,0.003821583,0.00006586182,0.000014508516,0.0007587582,0.000038353253,0.9527582,0.00046606944,0.0041068327,0.0003422152],"about_ca_topic_score_codex":0.0046395757,"about_ca_topic_score_gemma":0.0015691733,"teacher_disagreement_score":0.023242723,"about_ca_system_score_codex":0.0011763654,"about_ca_system_score_gemma":0.002899679,"threshold_uncertainty_score":0.99997234},"labels":[],"label_agreement":null},{"id":"W2740897264","doi":"10.1158/1538-7445.am2017-130","title":"Abstract 130: Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Erg; Prostate cancer; Cancer research; Cancer; Biology; Genetics; Biochemistry","score_opus":0.06609275750511132,"score_gpt":0.39553695194516914,"score_spread":0.3294441944400578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740897264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99360234,0.0018902005,0.0000033185272,0.0029477275,0.00007232225,0.00090639654,0.00016528934,0.0000051525626,0.00040722967],"genre_scores_gemma":[0.9925673,0.006057478,0.000032260672,0.000012455905,0.000096141055,0.00025450604,0.000033087385,0.000024367984,0.00092237786],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99836296,0.00009538575,0.00029166188,0.00028234292,0.0005195259,0.00044811136],"domain_scores_gemma":[0.99898386,0.00010899711,0.00018425313,0.0003693491,0.00026686373,0.000086685046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011847472,0.00011835398,0.00028127834,0.00020139481,0.0002837811,0.000092130875,0.00023970184,0.0000605047,0.00006641453],"category_scores_gemma":[0.00014890726,0.000076143406,0.000044403696,0.00020120379,0.0006417837,0.00023462369,0.00020218024,0.00039361848,0.0000012347274],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007538832,0.00006426921,0.15930669,0.0006171404,0.000060492028,0.00004742458,0.0014022734,0.0000041620588,0.8309768,0.00007937892,0.000035608067,0.006651907],"study_design_scores_gemma":[0.0017132101,0.000114832066,0.6173874,0.0011385357,0.000012512274,0.0000015345734,0.0005752182,0.00004778229,0.37852034,0.00013728204,0.00027124299,0.000080054626],"about_ca_topic_score_codex":0.0021822029,"about_ca_topic_score_gemma":0.000524091,"teacher_disagreement_score":0.45808077,"about_ca_system_score_codex":0.00020702262,"about_ca_system_score_gemma":0.0005323987,"threshold_uncertainty_score":0.32988527},"labels":[],"label_agreement":null},{"id":"W2741366593","doi":"10.1158/1538-7445.am2017-2522","title":"Abstract 2522: MiRNA-652 induces neuroendocrine-like differentiation in LNCaP prostate cancer cells through decreased PP2A function","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Prostate cancer; LNCaP; Biochemical recurrence; microRNA; Metastasis; Cancer research; Cancer; Medicine; Oncogene; Blot; Proportional hazards model; Oncology; Prostatectomy; Transfection; Internal medicine; Biology; Cell culture; Cell cycle; Gene","score_opus":0.11484140774258013,"score_gpt":0.43149004823756554,"score_spread":0.3166486404949854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741366593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845458,0.0045754155,0.0000029830646,0.0058682524,0.00088480965,0.001880414,0.00009113387,0.000059327922,0.0020918201],"genre_scores_gemma":[0.97310203,0.01828374,0.00001852193,0.00016440966,0.0005242822,0.0013551818,0.00008837635,0.000072873816,0.006390579],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9960386,0.00017015183,0.00040793867,0.0008144885,0.0013449654,0.0012238516],"domain_scores_gemma":[0.99784416,0.00013649947,0.00017726627,0.0009312885,0.00055153447,0.00035927448],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004857732,0.00030812438,0.000446462,0.00039178043,0.0007615126,0.0003370223,0.0004476742,0.00011402494,0.0012605992],"category_scores_gemma":[0.00015107678,0.00024497,0.00012319647,0.000413701,0.00044102463,0.00066013745,0.00022984276,0.0012028837,0.00011430463],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008399086,0.00098532,0.18637529,0.001196579,0.00034395544,0.0009177657,0.00128299,0.000050960953,0.721216,0.00007693104,0.016611198,0.0625439],"study_design_scores_gemma":[0.0075247795,0.00045536365,0.7193716,0.00081787194,0.0000649649,0.000007072927,0.00031407538,0.00009023541,0.2559269,0.0004285616,0.014693229,0.00030532668],"about_ca_topic_score_codex":0.016138505,"about_ca_topic_score_gemma":0.0025037453,"teacher_disagreement_score":0.5329963,"about_ca_system_score_codex":0.00096613506,"about_ca_system_score_gemma":0.0011841514,"threshold_uncertainty_score":0.9996524},"labels":[],"label_agreement":null},{"id":"W2741693251","doi":"10.1158/1538-7445.am2017-4420","title":"Abstract 4420: Elevated glycolytic gene signature in patient-derived neuroendocrine prostate cancer xenograft models and its clinical relevance","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University","funders":"","keywords":"Prostate cancer; Cancer research; Cancer; Transdifferentiation; Metastasis; Biology; Androgen receptor; Androgen deprivation therapy; Adenocarcinoma; Prostate; Angiogenesis; Medicine; Genetics; Cell","score_opus":0.1440937020400715,"score_gpt":0.4653851312555976,"score_spread":0.3212914292155261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741693251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.962795,0.02557329,0.0000010173792,0.008116857,0.00029078723,0.002547622,0.00015511335,0.000054292002,0.0004659954],"genre_scores_gemma":[0.91488403,0.08116587,0.000035554294,0.00018666674,0.00027651523,0.0009842002,0.00003571446,0.00008041046,0.002351047],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99554604,0.00021877681,0.00062903867,0.0010464536,0.0011444344,0.0014152299],"domain_scores_gemma":[0.99714094,0.00029332738,0.00019375463,0.0009058196,0.0008277349,0.00063841796],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077121024,0.00033675454,0.000657902,0.00035373677,0.00059482077,0.0002059855,0.00046189228,0.00016823682,0.00023090077],"category_scores_gemma":[0.0006445608,0.00026665264,0.00011222813,0.0004256721,0.00066281523,0.0005124674,0.0004533735,0.0021251447,0.000027866088],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016480504,0.0011044625,0.07674192,0.0014741842,0.0004856654,0.008349192,0.0011787963,0.00041407882,0.72283804,0.00009386325,0.004970236,0.16586906],"study_design_scores_gemma":[0.038132463,0.0039255186,0.38680005,0.0040899906,0.00018258263,0.00015789343,0.00045425483,0.010441991,0.5365659,0.0022416895,0.015563848,0.0014438267],"about_ca_topic_score_codex":0.0015952544,"about_ca_topic_score_gemma":0.00067049137,"teacher_disagreement_score":0.31005815,"about_ca_system_score_codex":0.0005026076,"about_ca_system_score_gemma":0.0012617896,"threshold_uncertainty_score":0.99997854},"labels":[],"label_agreement":null},{"id":"W2741818496","doi":"10.1158/1538-7445.am2017-5220","title":"Abstract 5220: Chronic exposure to a novel AR-NTD inhibitor induces resistance via a selective metabolism pathway","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"LNCaP; Prostate cancer; Androgen receptor; Cancer research; Biology; Context (archaeology); Cancer; Pharmacology; Medicine; Chemistry; Internal medicine","score_opus":0.09116199209982083,"score_gpt":0.4191056136093095,"score_spread":0.32794362150948864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741818496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657574,0.013168849,0.000027417818,0.009782107,0.00042914567,0.0021800909,0.00017515916,0.00007428384,0.008405538],"genre_scores_gemma":[0.97507447,0.0011637995,0.00018033343,0.00011939282,0.0020509223,0.0014262367,0.000021173753,0.00008098894,0.019882662],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995567,0.00009411467,0.0003428753,0.00092726236,0.0016623043,0.0014064424],"domain_scores_gemma":[0.9964191,0.00014982138,0.00012627212,0.001296034,0.0012626993,0.00074611977],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012476587,0.00031742384,0.0005755673,0.0004576307,0.0012471738,0.0003214313,0.0007183367,0.00023128025,0.00050571363],"category_scores_gemma":[0.00051530777,0.00024779647,0.0001505167,0.0006095742,0.00054495456,0.00036985075,0.0003775193,0.0013773195,0.00031691388],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028247254,0.00042986887,0.0011350402,0.00042418696,0.00032603223,0.00025888404,0.0014243909,0.0000042283327,0.9551711,0.00019223629,0.010758663,0.027050612],"study_design_scores_gemma":[0.007235244,0.00084953493,0.14288142,0.0011394644,0.000046872636,0.000011678922,0.00025943673,0.000004915424,0.7534872,0.0003119176,0.09335792,0.00041433977],"about_ca_topic_score_codex":0.0015422096,"about_ca_topic_score_gemma":0.0020534005,"teacher_disagreement_score":0.20168388,"about_ca_system_score_codex":0.0017699281,"about_ca_system_score_gemma":0.0033052433,"threshold_uncertainty_score":0.99999744},"labels":[],"label_agreement":null},{"id":"W2741828858","doi":"10.1158/1538-7445.am2017-5497","title":"Abstract 5497: LSD1 modulates androgen receptor cistrome in prostate cancer via regulation of FOXA1 chromatin binding","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"FOXA1; Enhancer; Prostate cancer; Chromatin; Androgen receptor; Transcription factor; Epigenomics; Cancer research; Biology; Pioneer factor; Epigenetics; Epigenome; Genetics; Cancer; DNA methylation; Gene expression; Gene","score_opus":0.09032408893395469,"score_gpt":0.43229427222358596,"score_spread":0.34197018328963125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741828858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916072,0.0030431678,0.0000011993209,0.0025444825,0.00016506233,0.0013785765,0.00015500044,0.000024863573,0.0010804301],"genre_scores_gemma":[0.9913105,0.0034375358,0.000096157964,0.000008137197,0.00022897868,0.0005979966,0.00007933574,0.000049522976,0.004191876],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9971809,0.00010921906,0.00041599653,0.00049494125,0.0010081849,0.00079077814],"domain_scores_gemma":[0.9982019,0.00011841041,0.00020329833,0.00073239626,0.00050925114,0.00023471222],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014172351,0.00019156073,0.00044436977,0.0004783722,0.00039755966,0.00009925581,0.00035249133,0.00012928761,0.0013108968],"category_scores_gemma":[0.00022386966,0.0001574725,0.00008949611,0.00039681295,0.00051442225,0.00032512416,0.00017762525,0.0005545207,0.000053485368],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015850617,0.00015071858,0.166868,0.0007224711,0.0001216755,0.00005572163,0.00081961066,0.000044584605,0.7913119,0.000016716205,0.0010583436,0.03724517],"study_design_scores_gemma":[0.0031410935,0.00027021326,0.49858093,0.0014767457,0.000018203651,0.000004421769,0.00014166922,0.00031602473,0.49443308,0.00027796824,0.0011695985,0.00017002584],"about_ca_topic_score_codex":0.0058517097,"about_ca_topic_score_gemma":0.0005771066,"teacher_disagreement_score":0.33171296,"about_ca_system_score_codex":0.0011413236,"about_ca_system_score_gemma":0.00087975303,"threshold_uncertainty_score":0.999602},"labels":[],"label_agreement":null},{"id":"W2741925895","doi":"10.1158/1538-7445.am2017-1516","title":"Abstract 1516: Androgen-repressed and androgen-induced genes: challenging the traditional dogma of prostate cancer therapy","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Antiandrogens; Enzalutamide; Androgen receptor; Prostate cancer; LNCaP; Bicalutamide; Androgen; Cancer research; Antiandrogen; Internal medicine; Endocrinology; Medicine; Biology; Cancer; Hormone","score_opus":0.253175196669624,"score_gpt":0.44641369464574376,"score_spread":0.19323849797611975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741925895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93939424,0.04800451,5.81093e-7,0.009217218,0.00013841268,0.0013800195,0.00014971777,0.00002125807,0.0016940765],"genre_scores_gemma":[0.91798687,0.07966086,0.000009310717,0.00005327499,0.0003999885,0.0008654613,0.000017991311,0.000040625262,0.0009656354],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99742824,0.00009609418,0.00026941387,0.0004966777,0.0010344613,0.0006751122],"domain_scores_gemma":[0.99806905,0.0001936173,0.00013216691,0.0008003861,0.00054330745,0.00026146063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010034251,0.00020420337,0.00035685138,0.00017396203,0.0010842212,0.00015130405,0.00040848152,0.00011535505,0.00051657204],"category_scores_gemma":[0.000069891095,0.0001254497,0.00010293239,0.00017466258,0.0008375322,0.00021055496,0.00013651286,0.00058868976,0.0000068668605],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042104335,0.00049776107,0.09769668,0.0007742709,0.0011552352,0.000232318,0.0039551086,0.000020066984,0.60600007,0.000526804,0.0020247607,0.28290647],"study_design_scores_gemma":[0.009272804,0.00068042066,0.3643765,0.00080604,0.000054830693,0.000036581343,0.0009586621,0.00014759735,0.61345387,0.0007902479,0.009119396,0.0003030572],"about_ca_topic_score_codex":0.0019532056,"about_ca_topic_score_gemma":0.000114960705,"teacher_disagreement_score":0.2826034,"about_ca_system_score_codex":0.00019659621,"about_ca_system_score_gemma":0.00090365775,"threshold_uncertainty_score":0.83390623},"labels":[],"label_agreement":null},{"id":"W2741929755","doi":"10.1111/his.13330","title":"Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?","year":2017,"lang":"en","type":"article","venue":"Histopathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Chromogranin A; Neuroendocrine differentiation; Pathology; Prostate; Synaptophysin; Prostatic acid phosphatase; Immunohistochemistry; Carcinoma; Prostate cancer; Medicine; Biology; Cancer; Internal medicine","score_opus":0.022324344803682842,"score_gpt":0.2846252800755177,"score_spread":0.26230093527183485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741929755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920944,0.00082465063,0.000009365306,0.0048271203,0.00010341993,0.00051666005,0.000015128294,0.000012032243,0.0015971968],"genre_scores_gemma":[0.99676657,0.0001352927,0.00012002425,0.000057516096,0.00003336622,0.00006386048,0.000038200582,0.000024396806,0.002760749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888295,0.00008970341,0.00026347695,0.00025250384,0.00022426319,0.00028711063],"domain_scores_gemma":[0.99891937,0.00004746168,0.00031341542,0.00059571664,0.000078812525,0.000045242818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015151105,0.00014552526,0.00041858474,0.0001610052,0.00009686061,0.0000086904065,0.00016980487,0.00002602242,0.000018998888],"category_scores_gemma":[0.000069101305,0.00008355395,0.0000466788,0.00010015494,0.0004863619,0.00006144294,0.000075026386,0.00025856905,0.0000018048663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019974343,0.00019854346,0.975837,0.0003315086,0.000007060599,0.00088575657,0.0014418493,0.0000043223595,0.017853143,0.00017838612,0.000061092935,0.0012039355],"study_design_scores_gemma":[0.0034648585,0.0011997124,0.9885635,0.0001230585,0.000068043875,0.00036948454,0.00010886645,0.00001818554,0.0057512345,0.000105441475,0.00015633216,0.000071295864],"about_ca_topic_score_codex":0.0004330192,"about_ca_topic_score_gemma":0.00046189595,"teacher_disagreement_score":0.012726519,"about_ca_system_score_codex":0.00012901599,"about_ca_system_score_gemma":0.00021521575,"threshold_uncertainty_score":0.3407231},"labels":[],"label_agreement":null},{"id":"W2742205264","doi":"10.18632/oncotarget.19916","title":"Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4","year":2017,"lang":"en","type":"article","venue":"Oncotarget","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Cancer research; Androgen receptor; RNA splicing; Medicine; Prostate; Androgen; Cell culture; Cancer; Biology; RNA; Internal medicine; Gene; Hormone; Genetics","score_opus":0.03657029271439284,"score_gpt":0.3513054965656863,"score_spread":0.3147352038512935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742205264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801752,0.001225893,0.000035474655,0.0141448695,0.00015110023,0.0008029101,0.00028493453,0.000026191829,0.0031534212],"genre_scores_gemma":[0.98142034,0.0020175753,0.00017830485,0.00025714567,0.000092256254,0.000121458754,0.000036826084,0.000029746367,0.01584637],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998709,0.000022696475,0.00020939221,0.0002634195,0.00040557806,0.00038987902],"domain_scores_gemma":[0.99886096,0.00002931956,0.00017359901,0.0006651934,0.00012297006,0.0001479901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000069438815,0.00016405113,0.00029390398,0.000042470223,0.00028831876,0.00006220882,0.0002814857,0.000023179427,0.00013669423],"category_scores_gemma":[0.00005205357,0.00009454872,0.00009207654,0.000056703524,0.00018186115,0.00015825519,0.00015491985,0.0002264492,0.000008965859],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014039031,0.0006162976,0.5639413,0.00041800583,0.00043489545,0.00020331831,0.0019856303,0.00060855766,0.34558558,0.00013551033,0.06540009,0.019266928],"study_design_scores_gemma":[0.019558156,0.0020108249,0.1933642,0.00114489,0.0004964574,0.000059297487,0.00045194363,0.07752301,0.6277311,0.000701873,0.076127514,0.0008307143],"about_ca_topic_score_codex":0.0011675047,"about_ca_topic_score_gemma":0.00007148502,"teacher_disagreement_score":0.37057707,"about_ca_system_score_codex":0.00014470698,"about_ca_system_score_gemma":0.0002585042,"threshold_uncertainty_score":0.3855585},"labels":[],"label_agreement":null},{"id":"W2742342719","doi":"10.1016/j.urology.2017.04.062","title":"Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer","year":2017,"lang":"en","type":"review","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Sanofi","keywords":"Enzalutamide; Medicine; Prostate cancer; Cabazitaxel; Docetaxel; Oncology; Internal medicine; Androgen deprivation therapy; Cancer; Androgen receptor","score_opus":0.05963522754524756,"score_gpt":0.3795732764990591,"score_spread":0.3199380489538115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742342719","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.048104934,0.94864476,3.2577915e-7,0.00035873175,0.00013637812,0.0023261353,0.00017627364,0.000031477604,0.00022101171],"genre_scores_gemma":[0.005710217,0.9886658,0.00007991296,0.000039601677,0.00006753277,0.00049266795,0.000115639195,0.00007565618,0.0047529237],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978531,0.0002552065,0.0004995992,0.000617304,0.00026210124,0.00051269477],"domain_scores_gemma":[0.9984896,0.00036378088,0.00044255564,0.000433383,0.0001341914,0.00013649982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050169573,0.00036678094,0.001418922,0.00034689775,0.00020446387,0.000056262463,0.00012096544,0.00027408628,0.000021556796],"category_scores_gemma":[0.0004386063,0.0002337329,0.00008905498,0.00012863798,0.00020118883,0.00010762414,0.00008706259,0.0006048503,0.0000030083884],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014877364,0.00018776012,0.27735302,0.010280688,0.0005219388,0.00049858936,0.00041780047,4.31961e-7,0.0000028869633,0.0000032426965,0.000062216386,0.69579405],"study_design_scores_gemma":[0.014751889,0.0033850395,0.32484046,0.015915439,0.002236352,0.00003062362,0.00005400472,0.000008341112,0.000002317894,0.000015928932,0.63800323,0.00075639324],"about_ca_topic_score_codex":0.00015914369,"about_ca_topic_score_gemma":0.00096512894,"teacher_disagreement_score":0.69503766,"about_ca_system_score_codex":0.00031540208,"about_ca_system_score_gemma":0.0011231259,"threshold_uncertainty_score":0.95313513},"labels":[],"label_agreement":null},{"id":"W2742580607","doi":"10.1016/j.adro.2017.07.004","title":"Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408","year":2017,"lang":"en","type":"article","venue":"Advances in Radiation Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Hôpital Notre-Dame; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Pennsylvania Department of Health; University of Florida; AstraZeneca","keywords":"Medicine; Prostate cancer; Testosterone (patch); Radiation therapy; Randomized controlled trial; Internal medicine; Urology; Hormonal therapy; Prostate-specific antigen; Androgen; Cancer; Oncology; Gastroenterology; Hormone","score_opus":0.03116061725368722,"score_gpt":0.3993665575314002,"score_spread":0.368205940277713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742580607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817139,0.004219546,0.0000067961337,0.008892106,0.00037315278,0.0033061004,0.00008440307,0.000032128788,0.0013718492],"genre_scores_gemma":[0.96677107,0.029249517,0.00016620691,0.0006799016,0.00018152897,0.002059512,0.00029104666,0.000034879387,0.00056634226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985024,0.00011364063,0.00028444905,0.00043264416,0.00020288897,0.00046402463],"domain_scores_gemma":[0.9988433,0.0002344611,0.00036705995,0.0003036615,0.00015204801,0.000099439625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024260122,0.00021002811,0.00051983475,0.00032670784,0.0001729249,0.000018991539,0.00013149175,0.00019017309,0.00004573117],"category_scores_gemma":[0.00011511686,0.00015661799,0.00003035873,0.00017504729,0.00017330627,0.0003329977,0.00001978795,0.00021545491,0.0000072145103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007181777,0.0005587787,0.5092835,0.000029488132,0.00003143827,0.000021557798,0.0004946781,0.0001392601,0.0000890921,0.000015634676,0.00006366954,0.48209113],"study_design_scores_gemma":[0.04194179,0.015738996,0.8540229,0.00009828059,0.000026090756,0.0000027259873,0.00006987277,0.00039066648,0.003597229,0.00008784303,0.08384676,0.00017685036],"about_ca_topic_score_codex":0.00022172483,"about_ca_topic_score_gemma":0.005463516,"teacher_disagreement_score":0.48191428,"about_ca_system_score_codex":0.0017092305,"about_ca_system_score_gemma":0.00035812,"threshold_uncertainty_score":0.6386696},"labels":[],"label_agreement":null},{"id":"W2742715943","doi":"10.1016/j.ejca.2017.07.008","title":"Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut pour la Recherche en Santé Publique; Institut National Du Cancer","keywords":"Medicine; Docetaxel; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Urology; Prostate; Chemotherapy; Cancer; Toxicity; Radiation therapy","score_opus":0.04500592833654836,"score_gpt":0.3658912636773313,"score_spread":0.32088533534078295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742715943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952529,0.0019607756,0.00003884061,0.0004964397,0.000048900365,0.0017711133,0.00016659756,0.000004609398,0.00025980294],"genre_scores_gemma":[0.9965713,0.0024123557,0.0000727218,0.00009092299,0.0000810187,0.00006734544,0.00005479624,0.00003741171,0.0006121088],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99762446,0.00046489507,0.00064769766,0.0002227116,0.0007690381,0.00027121356],"domain_scores_gemma":[0.99742204,0.000070246766,0.0013338198,0.0003562951,0.0006809627,0.00013661383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000946792,0.00024199988,0.0008547085,0.00027540632,0.0001612787,0.00009929215,0.00028292654,0.000017580578,0.00015618776],"category_scores_gemma":[0.000048502137,0.00010199114,0.00015426887,0.00047277487,0.00025252314,0.00026069165,0.000014963864,0.00025961242,5.782995e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7110724,0.00097098807,0.26013714,0.000032145144,0.006066574,0.00042757578,0.0028720128,0.00010803063,0.00096091774,3.2145707e-7,0.00030117508,0.017050741],"study_design_scores_gemma":[0.826316,0.009533164,0.15417977,0.00038410514,0.004300825,0.000012779882,0.00033935744,0.0001729225,0.0036004505,0.0000013018318,0.00095981755,0.00019951092],"about_ca_topic_score_codex":0.00037650316,"about_ca_topic_score_gemma":0.00036544097,"teacher_disagreement_score":0.11524363,"about_ca_system_score_codex":0.00013395378,"about_ca_system_score_gemma":0.00047888752,"threshold_uncertainty_score":0.41590783},"labels":[],"label_agreement":null},{"id":"W2743526583","doi":"10.5489/cuaj.4842","title":"New research in prostate cancer, ASCO 2017","year":2017,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Prostate; Oncology; Medicine; Internal medicine; Gynecology; Cancer","score_opus":0.0988088300973852,"score_gpt":0.4012404932268154,"score_spread":0.30243166312943015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743526583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6680779,0.002727966,0.0000022213978,0.30119336,0.0005695943,0.0005248644,0.000040490835,0.00001468152,0.02684896],"genre_scores_gemma":[0.97428954,0.002988242,0.00008594636,0.0005804818,0.0008641699,0.000024446643,0.000009062604,0.000011851797,0.02114625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978282,0.00017021093,0.00023188473,0.00021947557,0.00063993613,0.000910307],"domain_scores_gemma":[0.9978824,0.00009571544,0.0001665454,0.00023360996,0.00038709518,0.0012346338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018036367,0.00010300241,0.00023282351,0.0003608104,0.001120721,0.0003548294,0.0002898053,0.00018214167,0.0005966241],"category_scores_gemma":[0.00090356683,0.000076947814,0.00007636764,0.00015866788,0.00008506462,0.00018883703,0.00004088515,0.0013409188,0.00011763071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015010903,0.000025104471,0.91179097,0.000004626368,0.000048124588,0.00081339345,0.00010426594,0.0000041977955,0.000059375667,0.00008724208,0.06735441,0.01955817],"study_design_scores_gemma":[0.0021511817,0.00023365015,0.85734105,0.000050507562,0.000012088722,0.000065397944,0.000042789256,0.000027618384,0.000041126903,0.001970626,0.13798895,0.000074986856],"about_ca_topic_score_codex":0.04468009,"about_ca_topic_score_gemma":0.017495112,"teacher_disagreement_score":0.30621168,"about_ca_system_score_codex":0.0031621167,"about_ca_system_score_gemma":0.0036179014,"threshold_uncertainty_score":0.97626835},"labels":[],"label_agreement":null},{"id":"W2743661585","doi":"10.1038/ng.3930","title":"TMPRSS2–ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer","year":2017,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":195,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"TMPRSS2; Biology; Notch signaling pathway; Prostate cancer; Transcription factor; Erg; Cancer research; Prostate; Transcription (linguistics); Genetics; Cancer; Computational biology; Signal transduction; Gene; Internal medicine; Neuroscience; Coronavirus disease 2019 (COVID-19); Medicine","score_opus":0.032734845802772736,"score_gpt":0.3369956480270824,"score_spread":0.3042608022243096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743661585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887151,0.008515864,0.0000031992129,0.0013085186,0.0002269576,0.000605498,0.000047984446,0.000017958751,0.0005588788],"genre_scores_gemma":[0.9919586,0.006287335,0.00024885105,0.00014145895,0.00014489258,0.000026396683,0.0000874523,0.000026478267,0.0010785427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989178,0.000023540306,0.00015248876,0.00029874864,0.0003102922,0.00029709694],"domain_scores_gemma":[0.9994477,0.000024124054,0.00007298996,0.00025488643,0.00008227118,0.0001179975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010796262,0.00017798509,0.00023614879,0.000107468215,0.00018410261,0.00007396472,0.00009597655,0.00029246553,0.000044121098],"category_scores_gemma":[0.000019495963,0.00012411208,0.000042769396,0.00005701005,0.00010042008,0.00010595012,0.00004074872,0.0005748536,0.0000018903273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046842115,0.000053812375,0.5798216,0.00017335615,0.00003316305,0.000028590668,0.0009168684,0.0000057416296,0.40381277,8.421424e-7,0.00011248113,0.014572361],"study_design_scores_gemma":[0.002171398,0.00015493241,0.6707942,0.00021438953,0.000039617065,0.000003035347,0.00008729623,0.00006288682,0.3238498,0.000032852367,0.0024715182,0.00011807585],"about_ca_topic_score_codex":0.00006268021,"about_ca_topic_score_gemma":0.00006125178,"teacher_disagreement_score":0.09097259,"about_ca_system_score_codex":0.00015365904,"about_ca_system_score_gemma":0.00014494245,"threshold_uncertainty_score":0.50611436},"labels":[],"label_agreement":null},{"id":"W2744273464","doi":"10.1158/1535-7163.mct-17-0259","title":"Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Enzalutamide; Androgen receptor; Prostate cancer; LNCaP; Chemistry; Chromatin; DNA-binding domain; Cancer research; Small molecule; Transcription factor; Pharmacology; Mechanism of action; Cancer; Biology; DNA; Biochemistry; Genetics; In vitro; Gene","score_opus":0.04388678794563423,"score_gpt":0.327327484174485,"score_spread":0.28344069622885076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744273464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9065469,0.034162316,0.021947267,0.028064827,0.00074637984,0.002816191,0.00046534894,0.00018057709,0.005070189],"genre_scores_gemma":[0.9718477,0.0029604838,0.01863237,0.0006121172,0.000061182596,0.00043361163,0.000055588065,0.00011251647,0.005284425],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99828136,0.00007470173,0.0002631295,0.00043041917,0.00049338635,0.00045700755],"domain_scores_gemma":[0.9983396,0.000024435727,0.0003787761,0.00079056836,0.00031461165,0.00015198514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014190502,0.00030411707,0.00044156174,0.000107930544,0.00038669852,0.00011331947,0.0002954293,0.00007539772,0.00020684626],"category_scores_gemma":[0.000009034207,0.00022875123,0.00013078598,0.00013791004,0.000313464,0.000139229,0.00008392734,0.00028692788,0.000004361152],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004169442,0.00048091172,0.02245323,0.00088329957,0.003118628,0.0003389406,0.0032434633,0.00019908261,0.9414623,0.0009991275,0.0007418593,0.021909764],"study_design_scores_gemma":[0.00304925,0.0001570313,0.0014580633,0.0012197183,0.00040074185,0.000009835518,0.00041672972,0.00028082306,0.9752091,0.0010104197,0.016472515,0.00031573972],"about_ca_topic_score_codex":0.00042711128,"about_ca_topic_score_gemma":0.00056838844,"teacher_disagreement_score":0.0653008,"about_ca_system_score_codex":0.0003041189,"about_ca_system_score_gemma":0.000523574,"threshold_uncertainty_score":0.93282044},"labels":[],"label_agreement":null},{"id":"W2744750409","doi":"10.1016/j.urology.2017.07.032","title":"Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer","year":2017,"lang":"en","type":"letter","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Abiraterone; Prednisolone; Castration; Abiraterone acetate; Internal medicine; Urology; Gynecology; Cancer; Androgen deprivation therapy; Hormone; Androgen receptor","score_opus":0.043300509729574665,"score_gpt":0.34738812335106545,"score_spread":0.3040876136214908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744750409","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022746868,0.0011825078,0.000005363628,0.971563,0.00059649604,0.0017852753,0.0005772311,0.00003693818,0.0015063322],"genre_scores_gemma":[0.08035344,0.0011715319,0.000058568494,0.8989279,0.0024148363,0.0008193496,0.0033924924,0.00010088155,0.012760953],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976881,0.00024241232,0.00034937737,0.00064326834,0.0003491978,0.0007276039],"domain_scores_gemma":[0.99880403,0.00016364815,0.00021193987,0.00060321245,0.0001223376,0.000094855335],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016457311,0.0003953273,0.00086916983,0.00031086017,0.00013260638,0.000036835376,0.00016988354,0.00043929776,0.00027073262],"category_scores_gemma":[0.000027739516,0.00031273783,0.00009722403,0.00007345019,0.00041892822,0.000071355666,0.000083454244,0.0019722558,0.0001234453],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003313699,0.00012524241,0.00085440214,0.00021370518,0.0005610105,0.023541292,0.0007362251,0.000063750216,0.00015801143,0.000004032683,0.9689152,0.0015133922],"study_design_scores_gemma":[0.015655886,0.005957792,0.0031030974,0.000323798,0.00069209776,0.00042762616,0.000068452995,0.00043909595,0.0012498059,0.00022765652,0.9712585,0.000596165],"about_ca_topic_score_codex":0.001279897,"about_ca_topic_score_gemma":0.000613887,"teacher_disagreement_score":0.07263504,"about_ca_system_score_codex":0.0005313181,"about_ca_system_score_gemma":0.000550387,"threshold_uncertainty_score":0.99993247},"labels":[],"label_agreement":null},{"id":"W2745176115","doi":"10.1200/cci.17.00018","title":"A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"JCO Clinical Cancer Informatics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Weill Cornell Medical College; National Institutes of Health; Alberta Innovates; Turun Yliopisto; Hebrew University of Jerusalem; Sanofi; European Commission; U.S. National Library of Medicine; University of Alberta; Brigham Young University; Memorial Sloan-Kettering Cancer Center; Åbo Akademi; Tulane University; University of California, San Francisco; Boettcher Foundation; Brigham and Women's Hospital; Celgene; AstraZeneca; Prostate Cancer Foundation","keywords":"Docetaxel; Prostate cancer; Discontinuation; Medicine; Oncology; Internal medicine; Cancer; Term (time)","score_opus":0.20254107868261487,"score_gpt":0.48367145682128726,"score_spread":0.28113037813867237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745176115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864548,0.00076150894,0.0015814739,0.0035467662,0.0004953464,0.0044924547,0.0012554692,0.000032941778,0.0013792361],"genre_scores_gemma":[0.99095154,0.003698494,0.0025402592,0.00013699601,0.00020359669,0.0016819754,0.00012982204,0.00002508084,0.0006322231],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99734765,0.000031946765,0.0015217614,0.00022111837,0.0004960828,0.00038146295],"domain_scores_gemma":[0.9981354,0.00016117847,0.0004816127,0.00053850794,0.00045067372,0.00023264326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009094531,0.00020279319,0.0006425614,0.00015468507,0.00015370555,0.000080018486,0.00021198123,0.00011303353,0.000025504882],"category_scores_gemma":[0.0002919157,0.0001535189,0.00017517895,0.00011539413,0.00016364976,0.00070553314,0.00007851881,0.0002556578,0.0000025436564],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019765954,0.0035737976,0.41185713,0.0066657336,0.0014678057,0.000035986748,0.025322326,0.01095003,0.0013184972,0.0019606606,0.0039897496,0.51309234],"study_design_scores_gemma":[0.04027949,0.010649043,0.66747135,0.0066715605,0.0017659694,0.000008134354,0.0038939035,0.25333992,0.0050918655,0.0034974695,0.0061773118,0.0011539956],"about_ca_topic_score_codex":0.00045248415,"about_ca_topic_score_gemma":0.0022632198,"teacher_disagreement_score":0.51193833,"about_ca_system_score_codex":0.0002595069,"about_ca_system_score_gemma":0.00069898984,"threshold_uncertainty_score":0.6260319},"labels":[],"label_agreement":null},{"id":"W2746932121","doi":"10.1016/j.eururo.2017.08.012","title":"Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)","year":2017,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; University of British Columbia","funders":"","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Medicine; Bicalutamide; Cancer research; Pharmacology; Cancer; TMPRSS2; Internal medicine; Oncology","score_opus":0.040856426086149006,"score_gpt":0.32843672203740637,"score_spread":0.28758029595125734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2746932121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98609024,0.002831077,0.000032153926,0.007229606,0.00047078572,0.0010305712,0.00008787298,0.000037912316,0.0021897664],"genre_scores_gemma":[0.9974765,0.0006744429,0.000431848,0.00052634464,0.00023993204,0.000025334548,0.0000143908765,0.000056031095,0.00055512827],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9977918,0.00038045386,0.00047698463,0.0004779233,0.00031627083,0.00055651384],"domain_scores_gemma":[0.99828696,0.00016569147,0.0005386129,0.0006798865,0.00019638013,0.00013244625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014822341,0.0002543046,0.00042778577,0.00008267552,0.00088464713,0.000062814725,0.00046936554,0.000118176096,0.00004469538],"category_scores_gemma":[0.00079540076,0.0001255886,0.00011540812,0.00012441096,0.00099802,0.00013588717,0.0008016191,0.0005242047,0.000006646385],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005744864,0.0002753656,0.07092478,0.00014874857,0.00042237985,0.00019069584,0.0033986329,0.00023591761,0.8761346,0.00007384068,0.0008667025,0.041583467],"study_design_scores_gemma":[0.02605048,0.007730105,0.5319996,0.00067763403,0.0015154044,0.0005846259,0.0016744006,0.008934859,0.21815224,0.0006347373,0.2008863,0.0011596591],"about_ca_topic_score_codex":0.00023707337,"about_ca_topic_score_gemma":0.000049954553,"teacher_disagreement_score":0.65798235,"about_ca_system_score_codex":0.00016249102,"about_ca_system_score_gemma":0.00036652107,"threshold_uncertainty_score":0.680408},"labels":[],"label_agreement":null},{"id":"W2747512347","doi":"10.1097/pap.0000000000000168","title":"The New Realization About Cribriform Prostate Cancer","year":2017,"lang":"en","type":"review","venue":"Advances in Anatomic Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Cribriform; Prostate cancer; Medicine; Cribriform plate; Cancer; Pathology; Oncology; Internal medicine; Carcinoma; Anatomy","score_opus":0.06864911550885064,"score_gpt":0.4805594701394373,"score_spread":0.4119103546305867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747512347","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000095285095,0.99270666,0.000015397673,0.0004170842,0.00082861737,0.0015823558,0.000070108676,0.00003756144,0.0043326966],"genre_scores_gemma":[0.000018456489,0.9864519,0.000040658404,0.0000630991,0.00029507276,0.0005263676,0.00024749912,0.00005668463,0.0123002585],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794734,0.00013954933,0.00057268084,0.0005285341,0.00021106075,0.00060083997],"domain_scores_gemma":[0.9983914,0.00015190394,0.0004673425,0.000774827,0.00007555174,0.00013897764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037119826,0.00035515748,0.0013349062,0.00022000005,0.00025452487,0.000046658603,0.00040091423,0.00030014836,0.000031690666],"category_scores_gemma":[0.00018890343,0.00020084923,0.0002207398,0.00022556694,0.0004086244,0.0001918048,0.000120781806,0.00058544223,0.00005165795],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007855385,0.00002015274,0.00031683405,0.0026853087,0.000052892756,0.00041422964,0.00007282214,7.697613e-7,3.8881353e-7,0.0006813417,0.0011039616,0.99457276],"study_design_scores_gemma":[0.00094376074,0.00008604342,0.00007372328,0.006969933,0.00022276306,0.00019998496,0.000014797636,0.000008022692,0.0000029379194,0.0011862906,0.99010426,0.00018750246],"about_ca_topic_score_codex":0.00011001917,"about_ca_topic_score_gemma":0.0006534122,"teacher_disagreement_score":0.99438524,"about_ca_system_score_codex":0.00056185736,"about_ca_system_score_gemma":0.0017105311,"threshold_uncertainty_score":0.8190394},"labels":[],"label_agreement":null},{"id":"W2748908606","doi":"10.1200/jco.2015.33.15_suppl.tps5072","title":"A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Tolerability; Oncology; Internal medicine; Clinical endpoint; Androgen receptor; Abiraterone; Phases of clinical research; Abiraterone acetate; Pharmacokinetics; Pharmacology; Adverse effect; Cancer; Androgen deprivation therapy; Clinical trial","score_opus":0.21696765625155973,"score_gpt":0.5335928390271395,"score_spread":0.31662518277557977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748908606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964986,0.0003698052,0.00003993751,0.001015378,0.00006165065,0.0018848546,0.00004017252,0.0000024994383,0.00008712071],"genre_scores_gemma":[0.99421155,0.00023824595,0.005190601,0.000045560984,0.00007306467,0.00006873963,0.0000022901916,0.000019594407,0.00015032801],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966258,0.0005257579,0.0016522208,0.00028185855,0.00064424647,0.0002701075],"domain_scores_gemma":[0.9966881,0.0004672352,0.0016328145,0.00017806236,0.000645405,0.0003883388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031616578,0.0001994065,0.0017200715,0.00018699042,0.000032088286,0.000018806126,0.00013392667,0.00009558655,0.000016371761],"category_scores_gemma":[0.0002810222,0.00009743416,0.000042948697,0.00029528307,0.0004560758,0.00034222272,0.00009707954,0.0005614307,2.4221032e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7612881,0.05752606,0.118173525,0.00033955034,0.00089031603,0.009384415,0.003120443,0.000017234217,0.009879628,0.000004350133,0.000050735292,0.03932562],"study_design_scores_gemma":[0.40689364,0.37725314,0.20263356,0.0024139339,0.0009936563,0.0008657052,0.00407276,0.00020413636,0.004047284,0.000038842576,0.0003558151,0.00022753883],"about_ca_topic_score_codex":0.00036888546,"about_ca_topic_score_gemma":0.0031911565,"teacher_disagreement_score":0.3543945,"about_ca_system_score_codex":0.00026666714,"about_ca_system_score_gemma":0.005435852,"threshold_uncertainty_score":0.96429676},"labels":[],"label_agreement":null},{"id":"W2749657614","doi":"10.1016/j.cancergen.2017.08.003","title":"Clinical utility of emerging liquid biomarkers in advanced prostate cancer","year":2017,"lang":"en","type":"review","venue":"Cancer Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Prostate cancer; Circulating tumor cell; Liquid biopsy; Medicine; Context (archaeology); Cancer; Biomarker; Disease; Prostate; Oncology; Bioinformatics; Internal medicine; Metastasis; Biology","score_opus":0.2337117974209354,"score_gpt":0.5454132912434997,"score_spread":0.3117014938225643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749657614","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034030338,0.99166036,0.0000015810882,0.00015278792,0.0010444022,0.0025265887,0.00044628553,0.000022853697,0.00074213854],"genre_scores_gemma":[0.00061734096,0.99636257,0.00019211682,0.000025523275,0.00032363844,0.00084785314,0.00012676229,0.00009425935,0.0014099153],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965518,0.0001923355,0.0013767998,0.00080684177,0.00044063147,0.00063160434],"domain_scores_gemma":[0.9974179,0.00011455983,0.00078438624,0.0011283451,0.00026960523,0.00028516658],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063518476,0.0004915672,0.0026928973,0.0002742515,0.000078426994,0.000018075063,0.00042162708,0.00044995573,0.00025575524],"category_scores_gemma":[0.00011741822,0.00037315383,0.00063514436,0.00036184318,0.00049569935,0.000047803136,0.00021848141,0.00071142503,0.00000857842],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006503791,0.0001328364,0.012257901,0.020977812,0.00083854515,0.000062892934,0.00009371185,0.0000015877758,0.000003812196,5.318223e-7,0.00049848965,0.9644815],"study_design_scores_gemma":[0.0020055128,0.0003959017,0.0021812303,0.028577484,0.0010321084,0.000004430288,0.00002275321,0.000032720593,0.00008417161,0.00000545395,0.9653379,0.00032038754],"about_ca_topic_score_codex":0.00032796199,"about_ca_topic_score_gemma":0.00035488053,"teacher_disagreement_score":0.96483934,"about_ca_system_score_codex":0.00046948952,"about_ca_system_score_gemma":0.0040239873,"threshold_uncertainty_score":0.999872},"labels":[],"label_agreement":null},{"id":"W2749663845","doi":"10.1158/1078-0432.ccr-17-1034","title":"Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Docetaxel; Prostate cancer; Androgen deprivation therapy; Medicine; Oncology; Internal medicine; Neoadjuvant therapy; Cancer; Transcriptome; Genomics; Biology; Gene; Genetics; Genome; Breast cancer; Gene expression","score_opus":0.17695288912995027,"score_gpt":0.5022077878579497,"score_spread":0.32525489872799945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749663845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863543,0.00985999,0.0000010964325,0.0016561633,0.000034897843,0.0018167543,0.00018411671,0.000012330686,0.00008035427],"genre_scores_gemma":[0.7285373,0.27089873,0.000035278077,0.000034488123,0.00008886558,0.00019952093,0.000015517979,0.000032412983,0.00015784006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997652,0.0002664313,0.00047170298,0.00059712323,0.00049091637,0.0005218269],"domain_scores_gemma":[0.99819064,0.0003569869,0.000200371,0.0005932724,0.00036651528,0.00029219393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015779304,0.00021771026,0.0006170355,0.00022059186,0.0002741332,0.000093010036,0.00019112635,0.00017135694,0.000054721182],"category_scores_gemma":[0.00015729837,0.00012745245,0.00009119051,0.0002061219,0.0010683028,0.0001413404,0.00005414805,0.00080957956,0.0000012099036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024178706,0.00035702015,0.7273858,0.000034989,0.00030652244,0.000033345772,0.00042165854,0.000013635251,0.002565631,0.000009455208,0.000054979584,0.24463825],"study_design_scores_gemma":[0.02347139,0.0064914483,0.96189463,0.0002533598,0.00002686657,0.0000033429826,0.000041561896,0.00023660355,0.006844339,0.00019877186,0.00040156403,0.00013614185],"about_ca_topic_score_codex":0.01847598,"about_ca_topic_score_gemma":0.0012504108,"teacher_disagreement_score":0.26103875,"about_ca_system_score_codex":0.0003316157,"about_ca_system_score_gemma":0.0009456444,"threshold_uncertainty_score":0.98806006},"labels":[],"label_agreement":null},{"id":"W2751687881","doi":"10.1016/j.clgc.2017.08.020","title":"The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Bayer HealthCare","keywords":"Medicine; Radium-223; Enzalutamide; Prostate cancer; Docetaxel; Radium; Oncology; Abiraterone; Internal medicine; Abiraterone acetate; Cancer; Bone metastasis; Androgen deprivation therapy","score_opus":0.3042373536338288,"score_gpt":0.49066077146474124,"score_spread":0.18642341783091243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751687881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739953,0.014323621,0.0000012534994,0.0086534945,0.00072644075,0.0012537953,0.0001760194,0.000017634004,0.00085241144],"genre_scores_gemma":[0.97028637,0.01869947,0.00015533829,0.00018974638,0.00035169424,0.00040498795,0.000019331826,0.000031221753,0.0098618595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977352,0.00019832738,0.000880814,0.0003904638,0.0003945681,0.00040060916],"domain_scores_gemma":[0.99762446,0.0006181337,0.0004451425,0.000830508,0.00025431582,0.00022746164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070397544,0.00020056312,0.00055183365,0.000065857705,0.00036937222,0.000100339814,0.00029070114,0.00008781503,0.000080464626],"category_scores_gemma":[0.00043022115,0.00012212085,0.00021499628,0.00011825317,0.00085226464,0.00027734187,0.00013278291,0.00045429048,0.000009059701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012685209,0.0010200466,0.9045857,0.0003005631,0.0006994213,0.0014292728,0.0002892675,0.00004149875,0.003595638,0.000049534978,0.016021682,0.059282172],"study_design_scores_gemma":[0.009296214,0.0010887174,0.93027395,0.0005578618,0.00015742463,0.0000094548695,0.00019568461,0.00025841477,0.0027498018,0.00017027189,0.055019733,0.0002224533],"about_ca_topic_score_codex":0.002956824,"about_ca_topic_score_gemma":0.00116982,"teacher_disagreement_score":0.05905972,"about_ca_system_score_codex":0.00016668734,"about_ca_system_score_gemma":0.0016966091,"threshold_uncertainty_score":0.49799436},"labels":[],"label_agreement":null},{"id":"W2752996975","doi":"10.1200/jco.2016.34.15_suppl.5019","title":"Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Biopsy; Enzalutamide; Prostate; Cancer; Pathology; Oncology; Internal medicine; Androgen receptor","score_opus":0.08894000060709614,"score_gpt":0.43266410679572326,"score_spread":0.34372410618862714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752996975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.960627,0.003737592,0.000015334695,0.030792022,0.0016450661,0.0015308843,0.0015896035,0.000019007262,0.00004348653],"genre_scores_gemma":[0.82876885,0.16650929,0.00024824546,0.0011717555,0.0013927473,0.00012145521,0.00005285246,0.000063897816,0.0016709259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99248976,0.0012360504,0.004236971,0.00075295963,0.000573127,0.0007111312],"domain_scores_gemma":[0.9907777,0.0038710625,0.003209843,0.0004148204,0.0009113701,0.00081522827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028264693,0.00043970448,0.0023665777,0.00015800456,0.00013041195,0.000046131663,0.0003317006,0.00022340535,0.00009986519],"category_scores_gemma":[0.0017703816,0.00022055673,0.00037721006,0.0002310923,0.0018189446,0.00027394164,0.0003378194,0.0013988016,0.000007228051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048300404,0.0009621624,0.6865506,0.00016423063,0.0009245449,0.0005866343,0.00081368315,0.0000046744876,0.015308518,0.000005594524,0.0016550288,0.2447239],"study_design_scores_gemma":[0.035150487,0.007712622,0.92267156,0.0010559481,0.0011983835,0.0001204026,0.00020523474,0.00010602084,0.0018820219,0.0001727751,0.029461533,0.00026301667],"about_ca_topic_score_codex":0.0007118394,"about_ca_topic_score_gemma":0.0013583553,"teacher_disagreement_score":0.2444609,"about_ca_system_score_codex":0.00026023263,"about_ca_system_score_gemma":0.003521118,"threshold_uncertainty_score":0.8994042},"labels":[],"label_agreement":null},{"id":"W2753531220","doi":"10.3747/co.24.3598","title":"Treatment Patterns and Trends in Patients Dying of Prostate Cancer in Quebec: A Population-Based Study","year":2017,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Population; Oncology; Cancer; Internal medicine; Bioinformatics; Environmental health; Biology","score_opus":0.11080137379099034,"score_gpt":0.4670260178344992,"score_spread":0.35622464404350884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753531220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99810916,0.0003478047,5.260685e-7,0.00040066213,0.00020903279,0.00081633125,0.000039217462,0.000005492533,0.00007175963],"genre_scores_gemma":[0.99921906,0.00014261897,0.000007635279,0.00000388082,0.000023251087,0.00027864618,0.00008775288,0.000008902212,0.00022824114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911225,0.000070866874,0.0002428921,0.00023241086,0.00013349636,0.00020808924],"domain_scores_gemma":[0.999514,0.000031234744,0.0001326707,0.00020946554,0.000049973467,0.00006269621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007946975,0.000114593,0.0003533052,0.00029837762,0.000054338932,0.000012234628,0.00005397972,0.000043986154,0.000053186344],"category_scores_gemma":[0.000016532542,0.00008350021,0.000027735341,0.000077889825,0.000034149856,0.00006266664,0.000035725196,0.00009951762,5.5553903e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000520698,0.0017810273,0.61457795,0.000039841292,0.00001757719,0.000019133451,0.0011943438,0.0000042368374,0.0000031428267,8.6895244e-7,0.0000029702771,0.3818382],"study_design_scores_gemma":[0.018766072,0.0021672226,0.9782914,0.00014296499,0.000039953662,1.6274997e-7,0.0001825017,0.00018507845,0.000044451917,0.0000039043707,0.00011335296,0.00006291579],"about_ca_topic_score_codex":0.044987056,"about_ca_topic_score_gemma":0.11523219,"teacher_disagreement_score":0.38177526,"about_ca_system_score_codex":0.0009211751,"about_ca_system_score_gemma":0.00015061646,"threshold_uncertainty_score":0.96137244},"labels":[],"label_agreement":null},{"id":"W2754374178","doi":"10.1016/j.eururo.2017.08.027","title":"Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression","year":2017,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Transcriptome; Prostate cancer; Disease; Genome; Whole genome sequencing; DNA sequencing; Cancer; Computational biology; Bioinformatics; Gene; Genetics; Internal medicine; Gene expression; Biology","score_opus":0.03928653072164747,"score_gpt":0.35225984655746123,"score_spread":0.3129733158358138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754374178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98654026,0.0058563324,0.00009039899,0.005750479,0.00013235112,0.00048740554,0.00003374396,0.000028460727,0.0010805875],"genre_scores_gemma":[0.9953636,0.0009546016,0.00022360205,0.00013451146,0.00019181526,0.000017081446,0.000034080138,0.0000307371,0.003050007],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990261,0.00010467634,0.00019647315,0.000278049,0.00014193973,0.00025275908],"domain_scores_gemma":[0.9991669,0.000014639283,0.00011077146,0.0003613725,0.00006459188,0.00028170508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014055033,0.00011512,0.00017966182,0.0000863552,0.00025531062,0.000056690267,0.00012618583,0.000022321241,0.000060903636],"category_scores_gemma":[0.000060610022,0.000089539084,0.000043224405,0.000038061582,0.00023933493,0.00010815068,0.000087489076,0.00013791196,0.000017128368],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005634858,0.00007942859,0.4734006,0.00023293297,0.0001329426,0.000977182,0.0025683397,0.00005091621,0.49138606,0.000029577352,0.00029441016,0.03028414],"study_design_scores_gemma":[0.0019070483,0.00033900217,0.9900495,0.00011200144,0.00014271606,0.000023733448,0.000020934112,0.0001751762,0.0006566433,0.00007080388,0.0064119115,0.00009052853],"about_ca_topic_score_codex":0.000043048818,"about_ca_topic_score_gemma":0.000018310218,"teacher_disagreement_score":0.5166489,"about_ca_system_score_codex":0.000037757633,"about_ca_system_score_gemma":0.00022299601,"threshold_uncertainty_score":0.3651298},"labels":[],"label_agreement":null},{"id":"W2754595731","doi":"10.1136/jclinpath-2017-204718","title":"PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; St. John’s Health Sciences Centre; Memorial University of Newfoundland","funders":"Canadian Institutes of Health Research; Research and Development Corporation of Newfoundland and Labrador","keywords":"Prostate cancer; Prostatectomy; Medicine; Tissue microarray; Prostate; Biochemical recurrence; Immunohistochemistry; Oncology; Prostate-specific antigen; Pathology; Internal medicine; Cancer; Cancer research","score_opus":0.07638628968737596,"score_gpt":0.47374119516958946,"score_spread":0.3973549054822135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754595731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908365,0.0010524606,0.0012024342,0.004648348,0.0007900123,0.0013525438,0.000016854416,0.000009573722,0.00009125851],"genre_scores_gemma":[0.9868618,0.0005071547,0.0116925,0.00010241888,0.0004886788,0.0000695332,0.000015256559,0.000026290576,0.00023634195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996864,0.00041603306,0.0015038777,0.0003587721,0.0004756305,0.00038167322],"domain_scores_gemma":[0.9971809,0.00036996533,0.0014540921,0.00044210945,0.00027698258,0.00027594788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033677034,0.00017224743,0.0008142661,0.00017733539,0.0002563773,0.000068963105,0.00025152348,0.00032997545,0.00003403075],"category_scores_gemma":[0.0030583004,0.000110560424,0.00049644825,0.000063746535,0.00033398095,0.00027260208,0.00007309448,0.00089932414,0.000005668258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012378332,0.0011079612,0.8998098,0.00016666649,0.000119783384,0.0026799792,0.00030193786,0.0000011351965,0.012038172,0.00001137632,0.0007849333,0.07059996],"study_design_scores_gemma":[0.019384272,0.0042065834,0.96625257,0.00077986415,0.0002527232,0.0003184366,0.0001186528,0.000540248,0.0049310476,0.0025522443,0.0005329787,0.00013037561],"about_ca_topic_score_codex":0.0000022709871,"about_ca_topic_score_gemma":0.0000020146022,"teacher_disagreement_score":0.07046958,"about_ca_system_score_codex":0.000070276095,"about_ca_system_score_gemma":0.000529775,"threshold_uncertainty_score":0.45085233},"labels":[],"label_agreement":null},{"id":"W2754629144","doi":"10.1097/rli.0000000000000415","title":"Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease","year":2017,"lang":"en","type":"article","venue":"Investigative Radiology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Stand Up To Cancer; Prostate Cancer Foundation; Prostate Cancer UK; Cancer Research UK; Royal Marsden NHS Foundation Trust; Medical Research Council; Movember Foundation","keywords":"Medicine; Prostate cancer; Magnetic resonance imaging; Effective diffusion coefficient; Bone marrow; Biopsy; Imaging biomarker; Bone metastasis; Pathology; Prostate; Cancer; Univariate analysis; Diffusion MRI; Nuclear medicine; Radiology; Internal medicine; Multivariate analysis","score_opus":0.043739243829184996,"score_gpt":0.34698709976547426,"score_spread":0.3032478559362893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754629144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9145694,0.076396264,0.000003065474,0.007034956,0.0001354743,0.00068239006,0.00010632193,0.000026383417,0.0010457712],"genre_scores_gemma":[0.993513,0.00250455,0.00063979806,0.00026111346,0.00010862176,0.00019637671,0.000017674247,0.000021344289,0.002737511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987536,0.00009303964,0.00024000868,0.0003576566,0.00018288674,0.00037280354],"domain_scores_gemma":[0.99870574,0.00010402822,0.00019148033,0.0004585507,0.00019898241,0.00034121244],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00016924922,0.0001613738,0.00040300246,0.00017384381,0.00019438667,0.00001684913,0.00017411941,0.00004571734,0.00008570392],"category_scores_gemma":[0.000999258,0.00012241377,0.00007584384,0.00015285103,0.0028331222,0.00011062001,0.000093454415,0.0002035731,0.000015297532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006327084,0.000072656985,0.9518868,0.00011139471,0.000030946987,0.00042144337,0.00039223538,0.0000041366293,0.011873267,0.0003073522,0.0010940724,0.033173],"study_design_scores_gemma":[0.0030695552,0.00025138457,0.9804645,0.0002350671,0.00007634524,0.00003667555,0.000038485185,0.00068627705,0.010418846,0.0022639334,0.0023331111,0.00012581212],"about_ca_topic_score_codex":0.00044897362,"about_ca_topic_score_gemma":0.000012824451,"teacher_disagreement_score":0.07894363,"about_ca_system_score_codex":0.00012175193,"about_ca_system_score_gemma":0.00050366076,"threshold_uncertainty_score":0.9998806},"labels":[],"label_agreement":null},{"id":"W2754902956","doi":"10.1177/1176935117730016","title":"Gene-Set Reduction for Analysis of Major and Minor Gleason Scores Based on Differential Gene-Set Expressions and Biological Pathways in Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Informatics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Prostate cancer; Medicine; Prostate; Microarray; Oncology; Cancer; Microarray analysis techniques; Internal medicine; Bioinformatics; Gene; Biology; Gene expression; Genetics","score_opus":0.10568508495251108,"score_gpt":0.37812123437436546,"score_spread":0.27243614942185435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754902956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996095,0.0010030445,0.000106212414,0.0002810876,0.000115144285,0.0008698182,0.001466791,0.000011255979,0.000051632698],"genre_scores_gemma":[0.9944106,0.0039798836,0.0006422137,0.000052893363,0.0000692472,0.0004566944,0.0003001903,0.000009779617,0.000078531535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899966,0.000018101233,0.00034013155,0.0001632392,0.0002263369,0.00025254945],"domain_scores_gemma":[0.9991369,0.000050349827,0.00024420096,0.0002981174,0.000141331,0.00012907313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014428311,0.00015709188,0.00041311467,0.0002691925,0.00018553463,0.00005087481,0.000091129274,0.000093327966,0.000043699623],"category_scores_gemma":[0.00008245381,0.00010333459,0.000078482284,0.00013014142,0.0002362815,0.00012932188,0.00005929547,0.00011363394,3.1634545e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074914047,0.00032496484,0.85102654,0.001815202,0.0011860385,0.000014585623,0.007439557,0.0010479656,0.06642664,0.000053537482,0.0020478785,0.061125677],"study_design_scores_gemma":[0.013184785,0.0012850233,0.7566288,0.0010529904,0.0015645324,0.0000054174693,0.0013886058,0.08733622,0.13631113,0.00007969056,0.0007203347,0.00044248204],"about_ca_topic_score_codex":0.00031275654,"about_ca_topic_score_gemma":0.00011373292,"teacher_disagreement_score":0.094397746,"about_ca_system_score_codex":0.00013806018,"about_ca_system_score_gemma":0.00019111198,"threshold_uncertainty_score":0.42138624},"labels":[],"label_agreement":null},{"id":"W2754906663","doi":"","title":"Differentially androgen regulated genes in androgen dependent (LNCaP) and independent (C4-2) prostate cancer cells","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"LNCaP; Androgen receptor; Androgen; Prostate cancer; Biology; Cancer research; Microarray analysis techniques; Microarray; Gene expression; Gene; Endocrinology; Internal medicine; Cancer; Medicine; Genetics; Hormone","score_opus":0.0512169071297593,"score_gpt":0.3791991388490173,"score_spread":0.327982231719258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754906663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95016927,0.04290149,0.0000024061505,0.0040352023,0.00013735169,0.0020299365,0.000117295065,0.00005537199,0.00055167376],"genre_scores_gemma":[0.9408583,0.045728754,0.00006923458,0.00010288868,0.00038068264,0.001030433,0.000048034806,0.00007639734,0.0117053],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9956536,0.00025324055,0.00045744496,0.000889045,0.0014402638,0.001306369],"domain_scores_gemma":[0.9983253,0.00008021014,0.00006898821,0.0004854512,0.00046038756,0.0005796452],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00088135095,0.00032589905,0.00053063245,0.00065445586,0.0002444789,0.00013363938,0.0002654438,0.00023217933,0.0010869786],"category_scores_gemma":[0.000025127923,0.00025707047,0.000083998304,0.000755873,0.0003696257,0.000211531,0.00033978603,0.00086369965,0.00005544434],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004084399,0.00068950566,0.21936758,0.0006047959,0.00049360597,0.0006592706,0.0027335696,0.00019186069,0.53739333,0.000041407442,0.0019704655,0.23177019],"study_design_scores_gemma":[0.011997448,0.00055842614,0.051440295,0.00063982274,0.00009871268,0.000059305043,0.00047170426,0.0005855765,0.9143039,0.00016752271,0.01917829,0.00049901346],"about_ca_topic_score_codex":0.0027018625,"about_ca_topic_score_gemma":0.00473664,"teacher_disagreement_score":0.37691054,"about_ca_system_score_codex":0.0012243901,"about_ca_system_score_gemma":0.0010067554,"threshold_uncertainty_score":0.99998814},"labels":[],"label_agreement":null},{"id":"W2754951041","doi":"10.1016/j.neo.2017.06.006","title":"Overexpression of MUC1 and Genomic Alterations in Its Network Associate with Prostate Cancer Progression","year":2017,"lang":"en","type":"article","venue":"Neoplasia","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Natural Science Foundation of Guangdong Province; McMaster University; Cancer Research Society","keywords":"Prostate cancer; Hazard ratio; Medicine; PTEN; Oncology; Internal medicine; Metastasis; Biochemical recurrence; Proportional hazards model; Bone metastasis; MUC1; IGFBP3; Cancer; Cancer research; Confidence interval; Biology; Prostatectomy; PI3K/AKT/mTOR pathway; Genetics; Apoptosis","score_opus":0.020974045856630014,"score_gpt":0.3458250329476747,"score_spread":0.32485098709104465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754951041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948954,0.0017427215,9.620965e-7,0.0009857566,0.000045917317,0.0006639572,0.000019967814,0.000010851772,0.0016344474],"genre_scores_gemma":[0.9965468,0.0009835666,0.00027546412,0.000023178678,0.000082838495,0.00010856998,0.000018115932,0.000014367976,0.0019470695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925554,0.000024533454,0.00013112645,0.00018237981,0.00017737695,0.00022903414],"domain_scores_gemma":[0.9994917,0.000021428104,0.00013869873,0.00019592447,0.00007150275,0.00008076637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001073048,0.000094789946,0.00019786417,0.000042568,0.0001925838,0.000038091985,0.000055746306,0.00005592514,0.00003139634],"category_scores_gemma":[0.000021919437,0.00006040583,0.000017527262,0.00005109976,0.00007647405,0.00012570256,0.00006050327,0.00013476313,0.000002333177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002095482,0.00010632313,0.9580471,0.00015772802,0.000057226654,0.000046273843,0.0008496195,0.000053044387,0.022678941,0.000035375226,0.00062528765,0.015247587],"study_design_scores_gemma":[0.0043913275,0.00040572748,0.9759329,0.0018893466,0.000034113506,0.000009265838,0.000039549715,0.0005608953,0.01574736,0.00005748118,0.00084398885,0.00008804592],"about_ca_topic_score_codex":0.00012625274,"about_ca_topic_score_gemma":0.0002538297,"teacher_disagreement_score":0.017885787,"about_ca_system_score_codex":0.00008117117,"about_ca_system_score_gemma":0.00018443778,"threshold_uncertainty_score":0.24632783},"labels":[],"label_agreement":null},{"id":"W2755644324","doi":"10.1158/0008-5472.can-17-0496","title":"LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium; University of Toronto; University Health Network; Ontario Institute for Cancer Research; Genome British Columbia; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Reprogramming; Prostate cancer; Epigenetics; Cancer research; Cancer; Chromatin; Epigenetic therapy; Androgen receptor; Biology; Androgen deprivation therapy; Regulator; Medicine; Gene expression; DNA methylation; Cell; Gene; Genetics","score_opus":0.09539327455615022,"score_gpt":0.4810607586295137,"score_spread":0.3856674840733635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755644324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95701045,0.03223682,0.000003227359,0.0072012316,0.00021693796,0.0021398421,0.00004805574,0.00008501437,0.0010584536],"genre_scores_gemma":[0.95741737,0.031459197,0.00030471748,0.000040865667,0.00043871574,0.0021226706,0.00004459987,0.000069598,0.008102263],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996376,0.00017632724,0.00027866598,0.00086438784,0.0011762988,0.0011283577],"domain_scores_gemma":[0.9974663,0.000129063,0.00014022215,0.0010206759,0.00062435464,0.0006193791],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0009404866,0.00024841848,0.00038837356,0.0002731466,0.0015635958,0.00036115534,0.0003590958,0.00017603028,0.0002870873],"category_scores_gemma":[0.0004414618,0.00017401966,0.00007109194,0.0002573489,0.001188838,0.00027296398,0.00056542904,0.0007793641,0.000034084827],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016685444,0.0001850826,0.32676685,0.00058454886,0.00009726949,0.00028701936,0.0013778262,0.0000013458335,0.34690854,0.000013091608,0.0020955647,0.3200143],"study_design_scores_gemma":[0.009761228,0.0015092446,0.32968086,0.0058395904,0.000092594586,0.00003551092,0.00088599167,0.00022850413,0.57903856,0.00036464908,0.07198029,0.0005829927],"about_ca_topic_score_codex":0.0009152832,"about_ca_topic_score_gemma":0.00012659386,"teacher_disagreement_score":0.3194313,"about_ca_system_score_codex":0.0003557564,"about_ca_system_score_gemma":0.0007896922,"threshold_uncertainty_score":0.99973625},"labels":[],"label_agreement":null},{"id":"W2755675304","doi":"10.1158/1078-0432.ccr-17-0413","title":"TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Institute of General Medical Sciences; National Cancer Institute; Memorial Sloan-Kettering Cancer Center","keywords":"Prostate cancer; Medicine; Oncology; Metastasis; Internal medicine; Prostate; Cancer; EZH2; Cancer research; Biology; Gene expression; Gene","score_opus":0.22242729292081326,"score_gpt":0.5604947531443503,"score_spread":0.338067460223537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755675304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884714,0.0056471126,0.0000024484787,0.003317916,0.0002922219,0.0014748562,0.00006761233,0.000028519022,0.0006979379],"genre_scores_gemma":[0.97949475,0.014364476,0.000052466825,0.000054832166,0.0006660251,0.00060275354,0.000008664237,0.000039225157,0.0047168196],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968834,0.00033428462,0.00050813705,0.00067742175,0.00092586107,0.00067093124],"domain_scores_gemma":[0.99695283,0.00031867213,0.0003258805,0.0009040553,0.00092805614,0.0005704983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021167048,0.00017189719,0.00051489385,0.00017549419,0.0006068042,0.00015312561,0.00034547233,0.00021636399,0.00014356646],"category_scores_gemma":[0.0011687772,0.00012503809,0.00011488389,0.0001694655,0.0018269374,0.00037033102,0.0003179541,0.0010408991,0.000013200439],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00694756,0.0003443544,0.4774749,0.00038131018,0.00018328617,0.0001967392,0.0004590655,6.0938703e-7,0.013616002,0.000025739393,0.0002592027,0.5001112],"study_design_scores_gemma":[0.0063638594,0.0041892696,0.9318888,0.0007381377,0.000081444006,0.000010768564,0.00017641443,0.00019649066,0.05072126,0.0005439278,0.0049065244,0.0001830613],"about_ca_topic_score_codex":0.0090095345,"about_ca_topic_score_gemma":0.0021497884,"teacher_disagreement_score":0.49992818,"about_ca_system_score_codex":0.00021639674,"about_ca_system_score_gemma":0.0009420913,"threshold_uncertainty_score":0.9975895},"labels":[],"label_agreement":null},{"id":"W2756387833","doi":"10.1038/s41467-017-00377-y","title":"Mitochondrial mutations drive prostate cancer aggression","year":2017,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Prostate Cancer Canada; Government of Ontario; Ontario Institute for Cancer Research; Federalno Ministarstvo Obrazovanja i Nauke; Movember Foundation; Canadian Institutes of Health Research; Genome Canada; Arvid Nilssons Fond","keywords":"Prostate cancer; Aggression; Mitochondrion; Mitochondrial DNA; Biology; Mutation; Cancer; Prostate; Medicine; Genetics; Cancer research; Bioinformatics; Gene; Psychiatry","score_opus":0.04048650326834032,"score_gpt":0.42201097625589207,"score_spread":0.38152447298755177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756387833","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36880055,0.14483956,0.000033406468,0.38042605,0.0029625916,0.005331706,0.0007160518,0.00046484012,0.09642525],"genre_scores_gemma":[0.9750742,0.014263711,0.003530597,0.00024106058,0.00020023939,0.0003942543,0.00036012215,0.000021306561,0.0059145666],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991798,0.00004934131,0.00014438499,0.00018742452,0.00023550421,0.00020354944],"domain_scores_gemma":[0.99681437,0.00008570958,0.00014574692,0.002477714,0.00034334668,0.00013311763],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00006792245,0.00011082034,0.00015787815,0.00008549753,0.0014836923,0.00009913917,0.0007125773,0.00019355743,0.000085723295],"category_scores_gemma":[0.00028785315,0.00008286764,0.00008200567,0.00009684615,0.00039529862,0.00017288516,0.00034680546,0.0008964589,0.000049328635],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014875939,0.0019063929,0.6089649,0.00017209866,0.0010099132,0.000112470996,0.006214997,0.000011194974,0.056120474,0.00947171,0.10820028,0.20632794],"study_design_scores_gemma":[0.008461764,0.00025643525,0.37284595,0.00160579,0.00043706954,0.000037386308,0.00033861684,0.000981676,0.0150933275,0.001320535,0.5981872,0.0004342744],"about_ca_topic_score_codex":0.000106604304,"about_ca_topic_score_gemma":0.00058152276,"teacher_disagreement_score":0.6062736,"about_ca_system_score_codex":0.0001349502,"about_ca_system_score_gemma":0.00031824084,"threshold_uncertainty_score":0.99981624},"labels":[],"label_agreement":null},{"id":"W2757027238","doi":"10.1016/j.ijrobp.2017.06.1270","title":"Integrative Characterization of the 12-Chemokine Gene Expression Signature in Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Biochemical recurrence; Internal medicine; Gene signature; Lymphovascular invasion; Oncology; Cancer; Metastasis; Gene expression; Gene; Prostatectomy; Biology","score_opus":0.024135781154935164,"score_gpt":0.3640475628039498,"score_spread":0.33991178164901464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757027238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989028,0.00037394365,0.0004172244,0.007841728,0.0015517425,0.00036222592,0.00011626239,0.0000064796577,0.00030239936],"genre_scores_gemma":[0.9957924,0.0022400252,0.00031460563,0.0002518578,0.0009097362,0.000023125845,0.00009091847,0.000015159828,0.00036221097],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988051,0.0001318889,0.00047560927,0.00015538953,0.0002795136,0.00015248163],"domain_scores_gemma":[0.99755394,0.00008355966,0.0013340457,0.0001963157,0.00077308156,0.00005903989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003095705,0.00013760099,0.00035417514,0.000111583926,0.000094411116,0.00002332273,0.00042740587,0.00015525054,0.000045787016],"category_scores_gemma":[0.000262426,0.00008167597,0.00014333663,0.0000798886,0.00026313023,0.0002988562,0.000099867415,0.0005044425,0.0000017904804],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088826945,0.00023464086,0.49240956,0.000009445986,0.0001702556,0.000019808615,0.0007455472,0.0000408908,0.4652912,0.00030444376,0.00014529139,0.03974065],"study_design_scores_gemma":[0.0068000713,0.0005080256,0.42905453,0.00038825735,0.00006147589,0.000036028214,0.00006670901,0.00032569843,0.55603606,0.0023314522,0.004291669,0.000100038684],"about_ca_topic_score_codex":0.000034634915,"about_ca_topic_score_gemma":0.000013148765,"teacher_disagreement_score":0.090744846,"about_ca_system_score_codex":0.000602346,"about_ca_system_score_gemma":0.0006644362,"threshold_uncertainty_score":0.33306494},"labels":[],"label_agreement":null},{"id":"W2757276454","doi":"10.1200/jco.2017.35.15_suppl.e16500","title":"Evaluating the impact of bone-targeted agents in the era of novel androgen targeted therapy for metastatic castration-resistant prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Zoledronic acid; Denosumab; Concomitant; Internal medicine; Enzalutamide; Docetaxel; Androgen deprivation therapy; Urology; Oncology; Bone metastasis; Cabozantinib; Cancer; Osteoporosis; Androgen receptor","score_opus":0.4590000686600946,"score_gpt":0.6220015272154118,"score_spread":0.16300145855531722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757276454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98819566,0.002724683,0.00001417611,0.0074613704,0.00021061374,0.0012332452,0.00008320996,0.0000012347525,0.00007580041],"genre_scores_gemma":[0.9960157,0.0020379713,0.0014497286,0.0001728943,0.0001906939,0.000049740993,0.000008052653,0.000012113319,0.00006306771],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967924,0.00048045072,0.0018466124,0.0001328524,0.0005022428,0.0002454437],"domain_scores_gemma":[0.9936026,0.0022074336,0.002942887,0.0003154341,0.0008255087,0.00010615218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007768594,0.00012483573,0.0010763783,0.000067513254,0.000132165,0.000018507393,0.00031005184,0.000099554796,0.000054454915],"category_scores_gemma":[0.0036208672,0.00005147796,0.00056709885,0.0001081151,0.00037001778,0.00011119167,0.000027482038,0.0005951179,2.6010468e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13580751,0.01084888,0.39431846,0.00029622778,0.0063264575,0.00037051534,0.0059691262,0.0017857472,0.10620936,0.00007833956,0.0029670482,0.3350223],"study_design_scores_gemma":[0.033912547,0.034764834,0.9240667,0.00022452229,0.00036869422,0.000049310715,0.00044905045,0.0031412204,0.002236019,0.0004410792,0.0002768499,0.00006912273],"about_ca_topic_score_codex":0.00056369696,"about_ca_topic_score_gemma":0.00016415582,"teacher_disagreement_score":0.52974826,"about_ca_system_score_codex":0.00014268447,"about_ca_system_score_gemma":0.0038835127,"threshold_uncertainty_score":0.6889185},"labels":[],"label_agreement":null},{"id":"W2757546831","doi":"10.1016/j.ijrobp.2017.06.1250","title":"The Risk of Second Malignancies after Seed Migration in Prostate Cancer Patients Treated With I-125 Free Seeds Brachytherapy","year":2017,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Université de Montréal; University of Calgary; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Brachytherapy; Prostate cancer; Internal medicine; Cancer; Prostate; Malignancy; Oncology; Esophageal cancer; Radiation therapy; Gastroenterology","score_opus":0.013148220136151132,"score_gpt":0.32067718655820365,"score_spread":0.3075289664220525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757546831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99468946,0.0010417933,0.000038281763,0.002940136,0.00047778495,0.00039557542,0.00022070527,0.0000072878056,0.00018894492],"genre_scores_gemma":[0.99401957,0.004798138,0.00016479057,0.00013612566,0.00039862224,0.00005909081,0.00005739364,0.000018893566,0.0003473573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986439,0.00016265,0.0005217103,0.00015994818,0.0003046551,0.00020714346],"domain_scores_gemma":[0.9969969,0.00019868516,0.0013534612,0.00023657455,0.0011447,0.00006972499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040964413,0.00015761504,0.0003489033,0.00012493736,0.00014549968,0.000047986843,0.00035689285,0.000110304165,0.000035631565],"category_scores_gemma":[0.00017929825,0.00009210277,0.000117762516,0.00009102437,0.00036278946,0.00033333772,0.000047153233,0.0003371921,0.0000025532079],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044885324,0.00033702175,0.9618167,0.000009465625,0.00066341046,0.000027947835,0.00073461025,0.000051932937,0.0015202404,0.00011535187,0.00020244111,0.030032303],"study_design_scores_gemma":[0.011884213,0.0018680344,0.97424716,0.00011804028,0.00009221981,0.000013778938,0.00006327946,0.00026009895,0.0063185175,0.0012218052,0.0038219115,0.00009095871],"about_ca_topic_score_codex":0.00024364764,"about_ca_topic_score_gemma":0.0007739421,"teacher_disagreement_score":0.029941345,"about_ca_system_score_codex":0.0005370827,"about_ca_system_score_gemma":0.00053464586,"threshold_uncertainty_score":0.3755842},"labels":[],"label_agreement":null},{"id":"W2757831167","doi":"10.1016/j.canlet.2017.09.029","title":"Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Letters","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Toronto Metropolitan University; Centre for Drug Research and Development; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; National Institutes of Health","keywords":"Cabazitaxel; Docetaxel; Prostate cancer; Medicine; Pharmacology; Neutropenia; Internal medicine; Oncology; Cancer; Chemotherapy; Androgen deprivation therapy","score_opus":0.04634897183238064,"score_gpt":0.35752188025911846,"score_spread":0.31117290842673784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757831167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93403107,0.01128485,0.000016709182,0.052532516,0.00027414522,0.0014487328,0.00026128278,0.0000508413,0.000099867764],"genre_scores_gemma":[0.98977256,0.0027449091,0.00052070094,0.0024341207,0.00021150193,0.0016020237,0.00003167085,0.00005351271,0.0026289893],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99841726,0.000025223786,0.0002541497,0.00045119348,0.00026247665,0.00058967917],"domain_scores_gemma":[0.99891555,0.000052279505,0.00017163178,0.0004538123,0.00014092392,0.00026582062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018757788,0.00023799973,0.00042784342,0.00008519366,0.0005450804,0.000175868,0.00013066293,0.000039350423,0.00009181112],"category_scores_gemma":[0.00007303483,0.00017808999,0.000096333206,0.00006903456,0.00045284626,0.00023486288,0.000065579436,0.00014100756,0.000008426523],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027982304,0.000083530824,0.029028764,0.0005548678,0.0006814709,0.00022403417,0.00067814137,0.0000117959835,0.93234724,0.00006165126,0.013728397,0.01980187],"study_design_scores_gemma":[0.03653612,0.0011165327,0.17739019,0.0015218337,0.001849712,0.00006346928,0.000408383,0.000808302,0.6909507,0.0004542236,0.08770378,0.0011967728],"about_ca_topic_score_codex":0.00091733923,"about_ca_topic_score_gemma":0.000371224,"teacher_disagreement_score":0.24139656,"about_ca_system_score_codex":0.00022874436,"about_ca_system_score_gemma":0.00023279802,"threshold_uncertainty_score":0.7262299},"labels":[],"label_agreement":null},{"id":"W2758676086","doi":"10.1016/j.ijrobp.2017.06.022","title":"Novel Associations Between the Immune Landscape of Prostate Cancer and Postoperative Radiation Response","year":2017,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Immune system; Medicine; Prostate cancer; Proportional hazards model; Oncology; Immunotherapy; Radiation therapy; Cancer; Cancer research; Internal medicine; Immunology","score_opus":0.03566857721097122,"score_gpt":0.3891128977857494,"score_spread":0.3534443205747782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2758676086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96256435,0.0021628877,0.00035741713,0.033197496,0.00069240027,0.00033439905,0.00044485423,0.000008568557,0.00023765599],"genre_scores_gemma":[0.9957124,0.0025097746,0.00032757822,0.0002008717,0.0008889819,0.000016788643,0.00010811131,0.000014532487,0.00022097022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987352,0.00017581416,0.00052018027,0.00014106631,0.0002690235,0.00015873475],"domain_scores_gemma":[0.9967608,0.00061022263,0.0013597399,0.00017080981,0.0010214722,0.00007694099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010151593,0.000124435,0.00038730606,0.0001146058,0.00026169338,0.000051811312,0.00029503583,0.00013596272,0.000022070486],"category_scores_gemma":[0.00080251275,0.00008268918,0.00012401454,0.00007327513,0.00031089032,0.00029886566,0.00007579096,0.00035380153,0.0000030695198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016955911,0.00017150826,0.86057806,0.0000046004857,0.0010127231,0.000007688845,0.001416173,0.000055286626,0.014831318,0.0009916016,0.00032520053,0.11891023],"study_design_scores_gemma":[0.007639687,0.0009454845,0.9730734,0.00005661033,0.00017767036,0.000028499026,0.00011817484,0.00031965555,0.011411607,0.00094781996,0.0051964023,0.00008495983],"about_ca_topic_score_codex":0.000102215046,"about_ca_topic_score_gemma":0.0000073546835,"teacher_disagreement_score":0.11882527,"about_ca_system_score_codex":0.0004469729,"about_ca_system_score_gemma":0.0008457448,"threshold_uncertainty_score":0.33719668},"labels":[],"label_agreement":null},{"id":"W2759672576","doi":"10.1016/j.ijrobp.2017.06.1145","title":"Prognostic Factors in Radium-223 Treatment—An Early Canadian Single-Center Experience","year":2017,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Interquartile range; Radium-223; Prostate cancer; Internal medicine; Single Center; Alkaline phosphatase; Hemoglobin; Gastroenterology; Urology; Oncology; Cancer","score_opus":0.06551991246372199,"score_gpt":0.38800558604522495,"score_spread":0.32248567358150293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759672576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942185,0.00017833147,0.00008124886,0.0023352732,0.0015124012,0.00034145283,0.00007002168,0.00001411339,0.0012486286],"genre_scores_gemma":[0.9978527,0.00029747697,0.00026234088,0.00019628934,0.0009993543,0.000023386281,0.00012457733,0.000023017443,0.00022085494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858075,0.00012125918,0.00045796405,0.00023925182,0.0002398677,0.00036089975],"domain_scores_gemma":[0.998287,0.00013701346,0.0005439791,0.00023722368,0.0004232365,0.0003715053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018628253,0.00019562883,0.00038986304,0.00027737237,0.00017430831,0.00009755423,0.00046597378,0.00019107704,0.0000805745],"category_scores_gemma":[0.00029067043,0.00014921317,0.00014826849,0.00007374282,0.00027614782,0.00058067805,0.00003479533,0.00030185122,0.000019950228],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033873136,0.00088425784,0.94620043,0.0000024255135,0.0002279163,0.00025390784,0.0018118555,0.00001139347,0.001917239,0.00036702843,0.000061347615,0.047923487],"study_design_scores_gemma":[0.013811343,0.004593732,0.95870084,0.00009386448,0.00007408099,0.00014756696,0.00028518366,0.0003254897,0.005012297,0.0009666912,0.015776817,0.00021210185],"about_ca_topic_score_codex":0.006197821,"about_ca_topic_score_gemma":0.004061619,"teacher_disagreement_score":0.047711384,"about_ca_system_score_codex":0.002772376,"about_ca_system_score_gemma":0.0012066937,"threshold_uncertainty_score":0.9369292},"labels":[],"label_agreement":null},{"id":"W2760275925","doi":"10.1016/j.ijrobp.2017.06.1262","title":"Distinct AR-Dependent Transcriptional Program in TMPRSS2-ERG Fusion Negative Tumors in African-American Men With Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Erg; TMPRSS2; Prostate cancer; Fusion gene; Medicine; Gene; Biomarker; Cancer research; Biology; Cancer; Internal medicine; Genetics; Ophthalmology","score_opus":0.026162950820427938,"score_gpt":0.3774020356508445,"score_spread":0.35123908483041655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760275925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855426,0.00032212475,0.00017001413,0.010630986,0.0004133617,0.00078722293,0.0001027652,0.000020996471,0.0020099608],"genre_scores_gemma":[0.9966594,0.0011374351,0.00090059487,0.00012338336,0.00067919545,0.00016517493,0.000074607924,0.000025515605,0.00023469911],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813056,0.00017049158,0.00059774995,0.00029371932,0.0004692672,0.0003382075],"domain_scores_gemma":[0.9979252,0.00015166907,0.0010250797,0.00016402903,0.0005819913,0.00015199586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004510715,0.00021552961,0.0005434746,0.00026793528,0.000113398724,0.000055556455,0.0003874403,0.00009984081,0.000052908257],"category_scores_gemma":[0.00015427012,0.00015609324,0.00011556757,0.00018037163,0.0005738787,0.00035639261,0.000056282024,0.000627052,0.0000055590785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004887181,0.0009414937,0.7675248,0.000011167778,0.00029263427,0.0003231037,0.0013606604,0.00025803663,0.0016756315,0.0005033399,0.00008067976,0.22214127],"study_design_scores_gemma":[0.014929301,0.0032339063,0.9717987,0.00026049415,0.000065371736,0.00008659457,0.000547066,0.0021342465,0.0012911328,0.002384039,0.0030708672,0.0001982566],"about_ca_topic_score_codex":0.000857122,"about_ca_topic_score_gemma":0.000625831,"teacher_disagreement_score":0.221943,"about_ca_system_score_codex":0.0017602749,"about_ca_system_score_gemma":0.0013622056,"threshold_uncertainty_score":0.6365298},"labels":[],"label_agreement":null},{"id":"W2760527559","doi":"10.1016/j.ijrobp.2017.06.307","title":"Significance of Testosterone Suppression in Localized Prostate Cancer Treated with Androgen Deprivation Therapy and Radiotherapy: Data from 2 Phase 3 Trials","year":2017,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université Laval; Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; McGill University; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Jewish General Hospital; Centre Hospitalier Universitaire de Sherbrooke; Nova Scotia Cancer Centre; Centre hospitalier universitaire de Québec; Centre de Santé et de Services Sociaux de Chicoutimi; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Bicalutamide; Testosterone (patch); Urology; Goserelin; Internal medicine; Proportional hazards model; Castration; Antiandrogen; Radiation therapy; Androgen; Oncology; Cancer; Hormone; Androgen receptor","score_opus":0.10386441391224362,"score_gpt":0.43608143435061525,"score_spread":0.33221702043837165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760527559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895054,0.004829685,0.0011622506,0.002915917,0.00031451733,0.0006428804,0.00059318455,0.000008655869,0.000027495213],"genre_scores_gemma":[0.9795558,0.017474141,0.0015860964,0.00013367728,0.00065036607,0.000030309347,0.000519166,0.000020717349,0.000029732448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836004,0.00030157602,0.00067424244,0.00025989182,0.00025396716,0.00015030021],"domain_scores_gemma":[0.99718285,0.00042089281,0.00155043,0.00032446408,0.0004355937,0.00008578265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008230449,0.00015709916,0.0006962177,0.00013200684,0.00006812814,0.00003842562,0.00039979225,0.00013320132,0.00006575424],"category_scores_gemma":[0.00029834508,0.00010247037,0.00005733965,0.000073672076,0.00029853982,0.00043271642,0.000057057514,0.00022974818,6.1564754e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012198852,0.00057441305,0.6131019,0.0000075565545,0.000744071,0.0000404293,0.00034091657,0.000042336505,0.07137747,0.000029908393,0.00019054403,0.3013516],"study_design_scores_gemma":[0.2364776,0.010167867,0.4627638,0.0010141297,0.00050701544,0.00009889671,0.00019123631,0.014465846,0.24303906,0.002979393,0.027797548,0.00049763476],"about_ca_topic_score_codex":0.0003858795,"about_ca_topic_score_gemma":0.000030587704,"teacher_disagreement_score":0.30085397,"about_ca_system_score_codex":0.00030903035,"about_ca_system_score_gemma":0.00058924756,"threshold_uncertainty_score":0.41786203},"labels":[],"label_agreement":null},{"id":"W2761093127","doi":"10.1093/annonc/mdx370.020","title":"Indirect comparison of abiraterone acetate and docetaxel for treatment of metastatic “hormone-sensitive” prostate cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Abiraterone acetate; Abiraterone; Oncology; Prostate cancer; Internal medicine; Population; Enzalutamide; Androgen deprivation therapy; Randomized controlled trial; Cancer","score_opus":0.2439804040378298,"score_gpt":0.5046447256598042,"score_spread":0.2606643216219744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761093127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858941,0.00849629,0.000008237797,0.003481624,0.000059050264,0.0010775474,0.00025912788,0.000005497611,0.0007185212],"genre_scores_gemma":[0.98720556,0.010977803,0.0006440082,0.00003504269,0.00002573436,0.00013297243,0.000031021144,0.000014457373,0.00093337847],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99895203,0.000058005106,0.00039331344,0.00019944669,0.00013951081,0.00025768598],"domain_scores_gemma":[0.99852586,0.00015468305,0.0005528388,0.0002581464,0.0004120657,0.000096382166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022548657,0.00014054772,0.0011159681,0.00011552559,0.00008072447,0.000005621045,0.00006666251,0.0000621429,0.000010571609],"category_scores_gemma":[0.00006566725,0.00009680537,0.00010697981,0.000044539604,0.00052486977,0.00006842868,0.00003628284,0.000039891624,7.707993e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02420472,0.004195506,0.11475107,0.0013554782,0.004189741,0.00008791318,0.011537401,0.000020569649,0.1935628,0.0001488572,0.0021310237,0.6438149],"study_design_scores_gemma":[0.014076203,0.026646012,0.15892611,0.00013901886,0.0005748969,0.000011007913,0.000574103,0.00022748263,0.79224855,0.00026667936,0.006195165,0.00011476868],"about_ca_topic_score_codex":0.00052610924,"about_ca_topic_score_gemma":0.00015212627,"teacher_disagreement_score":0.6437001,"about_ca_system_score_codex":0.000047815964,"about_ca_system_score_gemma":0.00028970634,"threshold_uncertainty_score":0.39476085},"labels":[],"label_agreement":null},{"id":"W2761180418","doi":"10.1093/annonc/mdx637","title":"Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Public Health Agency","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Cohort; Radiation therapy; Androgen deprivation therapy; Proportional hazards model; Concordance; Hazard ratio; Metastasis; Biopsy; Prostate; Prostate biopsy; Cancer; Urology","score_opus":0.08788200398846026,"score_gpt":0.42301228717324885,"score_spread":0.3351302831847886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761180418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972508,0.000155187,0.000032888995,0.0010900744,0.00002098201,0.0012728862,0.00007880298,0.000005343799,0.00009306476],"genre_scores_gemma":[0.998558,0.00055216206,0.00060907466,0.00003422609,0.000014578769,0.00009619198,0.00008002327,0.000012183039,0.00004357764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902856,0.00013095363,0.00024991593,0.00018938744,0.00022780111,0.00017338422],"domain_scores_gemma":[0.99876744,0.000057448204,0.0004453642,0.00023661391,0.00042526063,0.000067906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003538234,0.00010107093,0.0003286594,0.00017418402,0.00006727966,0.000012305107,0.00006585246,0.000050657043,0.000016071313],"category_scores_gemma":[0.00009019226,0.00006243368,0.00002434444,0.00015061391,0.00017749878,0.0001532948,0.000010262934,0.000086115484,5.9928965e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0105512645,0.0007097763,0.8368367,0.000050157145,0.00024546066,0.0000056678514,0.00078438397,0.00015714452,0.00977726,0.0000078209605,0.000023968892,0.14085038],"study_design_scores_gemma":[0.007630628,0.007975147,0.8112727,0.00009793131,0.000075830525,6.5431834e-7,0.00006674245,0.0002521989,0.17243887,0.000033334494,0.00008831069,0.00006765218],"about_ca_topic_score_codex":0.0016933887,"about_ca_topic_score_gemma":0.00011133123,"teacher_disagreement_score":0.16266161,"about_ca_system_score_codex":0.00009475252,"about_ca_system_score_gemma":0.00041927103,"threshold_uncertainty_score":0.25599083},"labels":[],"label_agreement":null},{"id":"W2761902517","doi":"10.1093/annonc/mdx370.051","title":"Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prednisone; Internal medicine; Prednisolone; Prostate cancer; Population; Oncology; Placebo; Clinical endpoint; Abiraterone acetate; Androgen deprivation therapy; Gastroenterology; Cancer; Randomized controlled trial; Pathology","score_opus":0.08097807817073079,"score_gpt":0.422389176494606,"score_spread":0.34141109832387523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761902517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98662,0.001954637,0.000008211267,0.0020470787,0.000060422724,0.008117406,0.00022971701,0.000028442006,0.00093406555],"genre_scores_gemma":[0.992177,0.004452435,0.00034540272,0.00008310657,0.000030313877,0.0014793238,0.00010961321,0.00004517925,0.0012776349],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964741,0.00061187556,0.0012946364,0.0004917945,0.00044707165,0.000680532],"domain_scores_gemma":[0.99691796,0.0006194049,0.0011957171,0.0006560066,0.00033417568,0.00027673386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001516245,0.00040306154,0.0028751886,0.00031809183,0.00014521099,0.000044613098,0.0002566985,0.00015513149,0.0001174374],"category_scores_gemma":[0.000404542,0.000241981,0.00013502174,0.0001985365,0.0011863704,0.00024544456,0.00010300208,0.00021850673,0.0000027147591],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9803103,0.0019101733,0.00042923118,0.0014974915,0.0019145618,0.0006744027,0.0032061497,0.000032176933,0.002230835,0.000020589918,0.000414508,0.007359585],"study_design_scores_gemma":[0.9557037,0.02497221,0.00091027713,0.001493799,0.0012127483,0.00006624598,0.00044370856,0.0025345627,0.012236087,0.000105234896,0.00008072995,0.00024071951],"about_ca_topic_score_codex":0.0036875315,"about_ca_topic_score_gemma":0.0017402641,"teacher_disagreement_score":0.024606617,"about_ca_system_score_codex":0.00017697224,"about_ca_system_score_gemma":0.0019746223,"threshold_uncertainty_score":0.9867699},"labels":[],"label_agreement":null},{"id":"W2762414010","doi":"10.1093/annonc/mdx370.011","title":"EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 update on safety, tolerability, pharmacokinetics and efficacy","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Enzalutamide; Prostate cancer; Pharmacokinetics; Cmax; Adverse effect; Internal medicine; Abiraterone acetate; Gastroenterology; Phases of clinical research; Urology; Nausea; Pharmacology; Oncology; Cancer; Chemotherapy; Androgen deprivation therapy; Androgen receptor","score_opus":0.08809003921003584,"score_gpt":0.43830772066008306,"score_spread":0.3502176814500472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762414010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780237,0.00079397846,0.0000058092387,0.01690588,0.00007483359,0.001596478,0.00048217276,0.0000162466,0.002100894],"genre_scores_gemma":[0.9941243,0.003362074,0.0012012998,0.00039123456,0.000102418286,0.00013937932,0.0001469075,0.00003533911,0.0004970536],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978691,0.00015341396,0.0005742234,0.0004963635,0.00037351678,0.0005333887],"domain_scores_gemma":[0.998462,0.00016760672,0.00038813165,0.00041958317,0.00028711135,0.00027553554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069469964,0.00029171014,0.0007870927,0.00020546692,0.00019132854,0.0000479225,0.00018392767,0.00009513768,0.0001440778],"category_scores_gemma":[0.00008192667,0.00020881933,0.00007023308,0.0001444262,0.00061444566,0.00018271244,0.00010916495,0.0003146444,0.0000071913505],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18886447,0.01698053,0.039802298,0.0015642053,0.0024466165,0.004370263,0.009522654,0.00015784374,0.29729423,0.00041604883,0.008518082,0.43006274],"study_design_scores_gemma":[0.28466266,0.0756943,0.13154402,0.0027286785,0.001329746,0.00064191927,0.0020787285,0.0011120841,0.34281665,0.0011478672,0.15453042,0.0017129243],"about_ca_topic_score_codex":0.00040307845,"about_ca_topic_score_gemma":0.00043460872,"teacher_disagreement_score":0.42834982,"about_ca_system_score_codex":0.00016176274,"about_ca_system_score_gemma":0.0007300571,"threshold_uncertainty_score":0.85154057},"labels":[],"label_agreement":null},{"id":"W2762652685","doi":"10.1016/j.eururo.2017.10.002","title":"Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis","year":2017,"lang":"en","type":"review","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Docetaxel; Abiraterone acetate; Internal medicine; Oncology; Hazard ratio; Randomized controlled trial; Meta-analysis; Subgroup analysis; Confidence interval; Cancer","score_opus":0.16600679951125935,"score_gpt":0.41055575600573463,"score_spread":0.24454895649447528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762652685","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027364814,0.9921299,0.000015347297,0.00024211979,0.000011838595,0.004702384,0.00011275791,0.000015018749,0.000034116092],"genre_scores_gemma":[0.010307049,0.98853844,0.00017160451,0.000097545766,0.00001851583,0.00045217946,0.00015856477,0.0000673652,0.0001887419],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99520147,0.0023528563,0.0011626849,0.0006812094,0.00023154433,0.00037024138],"domain_scores_gemma":[0.997156,0.000270105,0.001623456,0.00067850837,0.00012305568,0.00014888003],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018396934,0.0005268092,0.008948863,0.00034419954,0.00011305979,0.000050278508,0.0001667561,0.00007425981,0.000014065461],"category_scores_gemma":[0.000086935346,0.00028090196,0.00030549965,0.00045810852,0.00034956788,0.00008054548,0.00013151679,0.0004295415,0.0000029508224],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005857454,0.0001963135,0.009428541,0.63953054,0.2514142,0.00037220737,0.00069162645,0.000024847726,0.0000011082311,0.000017170145,0.00011443334,0.097623274],"study_design_scores_gemma":[0.003641138,0.0024339354,0.0035740808,0.017064743,0.9607448,0.000174351,0.000016858929,0.00005478421,9.22151e-7,0.000022087072,0.01181936,0.00045293284],"about_ca_topic_score_codex":0.00015320885,"about_ca_topic_score_gemma":0.00011310627,"teacher_disagreement_score":0.7093306,"about_ca_system_score_codex":0.000034616936,"about_ca_system_score_gemma":0.00010579021,"threshold_uncertainty_score":0.9999643},"labels":[],"label_agreement":null},{"id":"W2762701444","doi":"10.1093/annonc/mdx370.055","title":"ARASENS: A phase 3 trial of darolutamide in males with metastatic hormone-sensitive prostate cancer (mHSPC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Androgen deprivation therapy; Prostate cancer; Internal medicine; Oncology; Placebo; Androgen receptor; Randomization; Randomized controlled trial; Chemotherapy; Cancer; Pathology","score_opus":0.166572910446867,"score_gpt":0.4890637230435366,"score_spread":0.3224908125966696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762701444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892831,0.0012879331,0.0000037705072,0.005907649,0.00006160119,0.0011745712,0.00015188083,0.000006494414,0.0021229854],"genre_scores_gemma":[0.99475247,0.004055324,0.00026740407,0.00014642526,0.000056471134,0.00012897568,0.00002526589,0.000015721389,0.00055197283],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99873954,0.000108340035,0.00035290502,0.00022607116,0.00024380573,0.00032933208],"domain_scores_gemma":[0.998676,0.00014675652,0.00040041222,0.00033922333,0.00033242413,0.00010516512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042755553,0.00013631493,0.00073908764,0.00017855277,0.00004871972,0.0000071864115,0.00010280651,0.000062720515,0.000021611597],"category_scores_gemma":[0.00020669444,0.00009272635,0.00007972987,0.000098299664,0.0006277442,0.000107416825,0.000046314213,0.00016658974,0.000003250374],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8192639,0.0055687493,0.010866406,0.00037116365,0.0013916404,0.0037247802,0.0045543816,0.000026992633,0.026213905,0.00015556971,0.0014790772,0.12638344],"study_design_scores_gemma":[0.60604656,0.09804507,0.09470494,0.0008944669,0.0006246523,0.00011968735,0.0021438722,0.00028013322,0.18698789,0.0007837252,0.008971575,0.00039742293],"about_ca_topic_score_codex":0.0010436171,"about_ca_topic_score_gemma":0.00059204374,"teacher_disagreement_score":0.21321733,"about_ca_system_score_codex":0.000060954404,"about_ca_system_score_gemma":0.00087742414,"threshold_uncertainty_score":0.3781271},"labels":[],"label_agreement":null},{"id":"W2762767318","doi":"10.5489/cuaj.4415","title":"A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completion","year":2017,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Radium-223; Prostate-specific antigen; Internal medicine; Population; Urology; Androgen deprivation therapy; Cancer; Hazard ratio; Gastroenterology; Confidence interval","score_opus":0.11662927984194675,"score_gpt":0.3233274783297553,"score_spread":0.20669819848780852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762767318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950319,0.000042226857,0.0000011039288,0.0037373693,0.000072483956,0.00088586786,0.00021027854,0.0000041510543,0.000014631655],"genre_scores_gemma":[0.99961877,0.000013762826,0.00001754887,0.00005865087,0.00001826764,0.000033658114,0.000056746037,0.00000913057,0.00017345294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835104,0.00031076264,0.00040300642,0.00014670083,0.0004981437,0.00029033294],"domain_scores_gemma":[0.9981845,0.00021889158,0.0008321146,0.00018916438,0.00037220662,0.00020309332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003191316,0.00013373369,0.00039931101,0.00016655566,0.00040260653,0.00007744509,0.00010895324,0.00006816684,0.00005660256],"category_scores_gemma":[0.000672161,0.000072199466,0.0000872416,0.00018624446,0.000049106147,0.000116028736,0.000007440117,0.0002235594,2.2387493e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003002972,0.0005422718,0.99647754,0.0000057236684,0.00028434952,0.000029877101,0.00043950477,0.0015399781,0.00012829565,0.00000533605,0.00003723913,0.0002095574],"study_design_scores_gemma":[0.005854121,0.0015338161,0.9914551,0.00006652553,0.00020066777,0.000001317016,0.0002001103,0.00042404555,0.0000874829,0.00001925051,0.00009219417,0.00006536468],"about_ca_topic_score_codex":0.065063,"about_ca_topic_score_gemma":0.18096589,"teacher_disagreement_score":0.11590289,"about_ca_system_score_codex":0.0026786157,"about_ca_system_score_gemma":0.0011438769,"threshold_uncertainty_score":0.9411628},"labels":[],"label_agreement":null},{"id":"W2763177383","doi":"10.1093/annonc/mdx370","title":"Benefits of Abiraterone Acetate Plus Prednisone (AA+P) When Added to Androgen Deprivation Therapy (ADT) in LATITUDE on Patient (Pt) Reported Outcomes (PRO)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Discontinuation; Quality of life (healthcare); Abiraterone acetate; Prednisone; Internal medicine; Randomized controlled trial; Physical therapy; Urology; Oncology; Surgery; Cancer","score_opus":0.2045172065647001,"score_gpt":0.43758352072523554,"score_spread":0.23306631416053544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763177383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98693085,0.000442664,0.0000036421654,0.009647637,0.00008863202,0.0011136583,0.000027297248,0.000013200784,0.0017324137],"genre_scores_gemma":[0.9973211,0.0010085049,0.00042756664,0.00064457237,0.000025832403,0.00010446009,0.00004315585,0.000016924152,0.00040783337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985696,0.00006798317,0.0005185087,0.00027102136,0.0002946342,0.00027821507],"domain_scores_gemma":[0.9985058,0.000076344084,0.00043207515,0.0005672428,0.00031005734,0.00010848035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003475706,0.00014426553,0.00061838306,0.00020324488,0.000060624414,0.000008834285,0.00015515691,0.0001307118,0.000065998094],"category_scores_gemma":[0.00024022562,0.00010384063,0.00007714271,0.0000781727,0.00010194254,0.00008752076,0.00008345699,0.00011583161,0.000009557995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011648985,0.0019468567,0.54337,0.00010316551,0.00072956126,0.00014903904,0.005622957,0.0003127682,0.011613015,0.0001667511,0.0018921518,0.42244473],"study_design_scores_gemma":[0.008757431,0.008468273,0.8416584,0.00015433178,0.000024351584,0.000006130651,0.000070357404,0.00003573457,0.13798822,0.00030803162,0.0024267721,0.00010192703],"about_ca_topic_score_codex":0.00045323605,"about_ca_topic_score_gemma":0.00032913144,"teacher_disagreement_score":0.4223428,"about_ca_system_score_codex":0.000099735,"about_ca_system_score_gemma":0.00025067464,"threshold_uncertainty_score":0.4234498},"labels":[],"label_agreement":null},{"id":"W2763734756","doi":"10.1093/annonc/mdx370.057","title":"Stereotactic ablative radiotherapy (SABR) for oligoprogressive metastatic castration-resistant prostate cancer (mCRPC) during abiraterone therapy: A phase I study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"SABR volatility model; Medicine; Prostate cancer; Abiraterone; Clinical endpoint; Oncology; Internal medicine; Radiation therapy; Systemic therapy; Abiraterone acetate; Androgen deprivation therapy; Cancer; Clinical trial; Androgen receptor; Breast cancer","score_opus":0.19445316079601055,"score_gpt":0.5169005609501007,"score_spread":0.3224474001540902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763734756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98627377,0.0042373356,0.000006932236,0.0047379807,0.00014533916,0.0041776025,0.00016097557,0.000021715521,0.00023835627],"genre_scores_gemma":[0.9937041,0.0031384241,0.00030043183,0.00016360616,0.0001266523,0.0009901581,0.000023910461,0.000041354648,0.0015113724],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982552,0.00014662798,0.00044449876,0.00039211175,0.00027497456,0.00048658362],"domain_scores_gemma":[0.99802333,0.00014465822,0.00058986864,0.0004869195,0.00059039204,0.00016485281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041640416,0.00024069476,0.000736627,0.00014887149,0.00040017304,0.00005947659,0.00018845522,0.00006696752,0.00012807222],"category_scores_gemma":[0.00008096817,0.00017168184,0.00013524185,0.00008325188,0.00032714888,0.00024844994,0.000034996774,0.00015982926,0.0000024139692],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1609414,0.023467358,0.059706114,0.0009251267,0.019956985,0.002419546,0.039748985,0.000039119102,0.30784208,0.000105036284,0.0013072705,0.38354096],"study_design_scores_gemma":[0.20055526,0.1433212,0.2659101,0.000529449,0.0009316832,0.000098295386,0.006339787,0.0003596041,0.3701787,0.0006061503,0.010359215,0.0008105677],"about_ca_topic_score_codex":0.00040616762,"about_ca_topic_score_gemma":0.00018420303,"teacher_disagreement_score":0.3827304,"about_ca_system_score_codex":0.00015661579,"about_ca_system_score_gemma":0.0006641107,"threshold_uncertainty_score":0.7000982},"labels":[],"label_agreement":null},{"id":"W2763906206","doi":"10.1200/jco.2014.32.15_suppl.e16106","title":"Initial experience of radium-223 treatment for metastatic castrate resistant prostate cancer in community setting.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Cohort; Incidence (geometry); Cancer; Metastasis; Bone pain; Bone metastasis; Internal medicine","score_opus":0.26775158238252716,"score_gpt":0.5688397907845494,"score_spread":0.3010882084020222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763906206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99400413,0.0006910075,0.000052916635,0.0036394391,0.00039344432,0.00057209056,0.000040334387,0.0000037724565,0.00060285046],"genre_scores_gemma":[0.99534625,0.0012523021,0.0024781493,0.0002586972,0.00026418697,0.000064258755,0.000006285753,0.000013984411,0.00031587912],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963139,0.0011035994,0.0018974026,0.00013030635,0.0002619692,0.0002927923],"domain_scores_gemma":[0.99454015,0.0034402485,0.0011357617,0.00019185948,0.00043129802,0.00026068892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003928165,0.00013475007,0.001365581,0.00013978823,0.00006200351,0.000006541798,0.00014212378,0.00012356773,0.000047938513],"category_scores_gemma":[0.0019377079,0.000083138526,0.0003121536,0.00014172743,0.0003722494,0.00008273265,0.000030890285,0.0006137195,0.0000010806906],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.108963735,0.015051725,0.13170822,0.00066591403,0.0014989978,0.0010116717,0.011628677,0.00014564607,0.006802862,0.00018744831,0.0010488328,0.7212863],"study_design_scores_gemma":[0.18439308,0.24479908,0.45048568,0.0017706623,0.0016880325,0.00036295573,0.008850306,0.0016789837,0.026516361,0.003541284,0.07542633,0.00048723933],"about_ca_topic_score_codex":0.0005190699,"about_ca_topic_score_gemma":0.00082825817,"teacher_disagreement_score":0.720799,"about_ca_system_score_codex":0.00038219258,"about_ca_system_score_gemma":0.0022614903,"threshold_uncertainty_score":0.4011787},"labels":[],"label_agreement":null},{"id":"W2764016937","doi":"10.1158/1541-7786.mcr-17-0270","title":"Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome after Surgical Intervention","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Oncology; Prostatectomy; Biochemical recurrence; Cancer; Medicine; Prostate; Internal medicine; Stage (stratigraphy); Biology","score_opus":0.1327922935229924,"score_gpt":0.5163677629408397,"score_spread":0.38357546941784737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764016937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838377,0.00922469,0.0000073672586,0.0037630964,0.00029405757,0.0015538798,0.00009778134,0.000018089782,0.00120332],"genre_scores_gemma":[0.98939705,0.003262951,0.000051644645,0.00006462306,0.00018374479,0.0011851843,0.00002210425,0.00005379024,0.0057789315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99612355,0.00048278386,0.0007847937,0.000636365,0.0011254053,0.000847085],"domain_scores_gemma":[0.998079,0.000088213514,0.00017063342,0.000868448,0.00045992638,0.0003337741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002717094,0.00020444527,0.0006039774,0.0003944246,0.00014590274,0.000080070684,0.00043853212,0.00017327577,0.0006249403],"category_scores_gemma":[0.0002992216,0.0001623348,0.0003148855,0.00025621636,0.00080804375,0.00013097787,0.0004979715,0.0010152676,0.000032569886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061220545,0.00052510976,0.9602851,0.0005927656,0.00018090899,0.0030700408,0.00016599607,0.000012397106,0.00620875,0.000028882518,0.0004381416,0.022369811],"study_design_scores_gemma":[0.016657382,0.0011740208,0.9415874,0.001309378,0.000085960906,0.000016078928,0.00011323033,0.00048761696,0.031711765,0.00020633549,0.0063874954,0.00026336525],"about_ca_topic_score_codex":0.0058861477,"about_ca_topic_score_gemma":0.0019969225,"teacher_disagreement_score":0.025503015,"about_ca_system_score_codex":0.00061557896,"about_ca_system_score_gemma":0.0007061496,"threshold_uncertainty_score":0.88981336},"labels":[],"label_agreement":null},{"id":"W2764033835","doi":"10.1038/cddis.2017.437","title":"AP4 modulated by the PI3K/AKT pathway promotes prostate cancer proliferation and metastasis of prostate cancer via upregulating L-plastin","year":2017,"lang":"en","type":"article","venue":"Cell Death and Disease","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Specialized Research Fund for the Doctoral Program of Higher Education of China; Fundamental Research Funds for the Central Universities; National Natural Science Foundation of China; Sun Yat-sen University; Natural Science Foundation of Guangdong Province; Public Health Agency of Canada","keywords":"Prostate cancer; Cancer research; LNCaP; Metastasis; Downregulation and upregulation; PI3K/AKT/mTOR pathway; Protein kinase B; Biology; Transcription factor; Prostate; Cancer; Signal transduction; Cell biology; Gene","score_opus":0.02161331577784226,"score_gpt":0.29566746641721225,"score_spread":0.27405415063937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764033835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787954,0.016756624,0.000014079973,0.0018948399,0.0000585096,0.0017520195,0.0005182467,0.000027163911,0.00018308169],"genre_scores_gemma":[0.99410987,0.0019128541,0.000067286215,0.00007727313,0.00006829658,0.0004653291,0.00012314349,0.000028567505,0.0031473832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986871,0.000054635075,0.0002387641,0.000388297,0.0002857297,0.00034551256],"domain_scores_gemma":[0.99873924,0.000035420548,0.00020227258,0.0003558357,0.00018545524,0.0004817972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016437912,0.00022271705,0.0002795225,0.000046118614,0.0005507163,0.00013120851,0.00008681043,0.00004766884,0.000044230375],"category_scores_gemma":[0.000089718706,0.00013271366,0.000052075342,0.00006664294,0.00025952162,0.00020308756,0.00009155002,0.00012612593,0.0000011723799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031400032,0.00037351483,0.8204796,0.0018240516,0.00022991991,0.00006258835,0.001842305,0.000046514146,0.06869294,0.000022535196,0.00062158366,0.10266445],"study_design_scores_gemma":[0.014552911,0.0009961938,0.6108883,0.001213062,0.0014812091,0.000014452971,0.0003171693,0.031371944,0.33533362,0.0012742012,0.001804538,0.0007524123],"about_ca_topic_score_codex":0.0005639905,"about_ca_topic_score_gemma":0.000037294623,"teacher_disagreement_score":0.26664066,"about_ca_system_score_codex":0.00004626159,"about_ca_system_score_gemma":0.00036948902,"threshold_uncertainty_score":0.54119056},"labels":[],"label_agreement":null},{"id":"W2764212714","doi":"10.1093/annonc/mdx370.023","title":"Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Abiraterone acetate; Enzalutamide; Prostate cancer; Docetaxel; Hazard ratio; Oncology; Internal medicine; Androgen deprivation therapy; Confidence interval; Cohort; Cancer; Androgen receptor","score_opus":0.16848164959237202,"score_gpt":0.46569964776925504,"score_spread":0.297217998176883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764212714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97012454,0.0034163224,0.0006161636,0.013061402,0.00024501045,0.008606907,0.0038707687,0.000033279783,0.000025577328],"genre_scores_gemma":[0.97073555,0.005182897,0.0131371515,0.00064869376,0.000053316664,0.0066924603,0.00020695089,0.000086315136,0.0032566402],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965967,0.00018685145,0.0011541747,0.00073180307,0.0004336811,0.0008967922],"domain_scores_gemma":[0.99593925,0.00051761075,0.0013029578,0.0006702181,0.0013358118,0.00023416862],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009700029,0.00051889697,0.0018237415,0.00029116613,0.00019209209,0.000049551625,0.00025105148,0.00017599254,0.000049845294],"category_scores_gemma":[0.00067380455,0.00034955234,0.0003110852,0.00023553472,0.0008491067,0.00040162937,0.0000556876,0.00025914228,0.00000212485],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.527227,0.012194563,0.047131773,0.01200644,0.010009754,0.0023872487,0.018864874,0.0014868785,0.24625166,0.000105729865,0.0035411604,0.11879291],"study_design_scores_gemma":[0.12255654,0.030216426,0.27331415,0.0023042215,0.0020888268,0.000038461825,0.0020816687,0.00448116,0.55494094,0.00044910092,0.0063018855,0.0012265953],"about_ca_topic_score_codex":0.002516711,"about_ca_topic_score_gemma":0.010417126,"teacher_disagreement_score":0.40467048,"about_ca_system_score_codex":0.00039837655,"about_ca_system_score_gemma":0.003323244,"threshold_uncertainty_score":0.99989563},"labels":[],"label_agreement":null},{"id":"W2764285498","doi":"10.1111/bju.14050","title":"<scp>STAMPEDE</scp> ‐ing towards androgen biosynthesis inhibition for treatment of high‐risk hormone‐naïve prostate cancer: changing the <scp>LATITUDE</scp>","year":2017,"lang":"en","type":"review","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Gynecology; Library science; Internal medicine","score_opus":0.061582170160720304,"score_gpt":0.35573532370320626,"score_spread":0.29415315354248595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764285498","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02240172,0.97240907,0.00007153408,0.0002965907,0.0004652701,0.002743842,0.0014027291,0.000022611317,0.00018662756],"genre_scores_gemma":[0.00750084,0.9891119,0.00024823804,0.00004011423,0.0011620434,0.00048413288,0.00020080188,0.00012535002,0.0011265731],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961166,0.00042529218,0.0013764114,0.00051701814,0.0005860768,0.0009786221],"domain_scores_gemma":[0.99447536,0.0012152458,0.0028744168,0.00045921037,0.0006672385,0.00030851044],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012309374,0.000580094,0.0032339948,0.0006594647,0.00057200063,0.00014219635,0.00038385345,0.00050474587,0.000011714735],"category_scores_gemma":[0.0010334239,0.0004038943,0.0013104527,0.0003016477,0.00040593997,0.00018492206,0.00011534328,0.00056719116,0.000005090283],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000800939,0.0003340383,0.0001996581,0.0027315745,0.0030745233,0.0012992665,0.0007244406,0.000007001114,0.000020967962,0.0000107646365,0.0019975048,0.9895202],"study_design_scores_gemma":[0.0055738715,0.0045880624,0.00046697023,0.008079726,0.008434822,0.0073031406,0.00031783117,0.000017456852,0.00043792857,0.0002002761,0.9644761,0.00010382461],"about_ca_topic_score_codex":0.0006385721,"about_ca_topic_score_gemma":0.000119412456,"teacher_disagreement_score":0.98941636,"about_ca_system_score_codex":0.0006182749,"about_ca_system_score_gemma":0.0016341275,"threshold_uncertainty_score":0.9998413},"labels":[],"label_agreement":null},{"id":"W2765112157","doi":"10.1016/j.urology.2017.10.016","title":"Gene Expression Correlates of Site-specific Metastasis Among Men With Lymph Node Positive Prostate Cancer Treated With Radical Prostatectomy: A Case Series","year":2017,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Metastasis; Oncology; Lymph node; Prostate; Androgen receptor; Internal medicine; Cancer; Urology","score_opus":0.01635645417689012,"score_gpt":0.2820191098036974,"score_spread":0.26566265562680724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765112157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99472266,0.0016529737,0.000030563948,0.0009431629,0.000028170723,0.0011993999,0.0002889265,0.00005427578,0.0010798807],"genre_scores_gemma":[0.9958397,0.0008803783,0.0004917116,0.00003312055,0.00004467092,0.00035219293,0.00015353407,0.00005454932,0.00215015],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983251,0.0001112607,0.00024663864,0.00052027934,0.00028413496,0.00051254866],"domain_scores_gemma":[0.99856746,0.00006565719,0.00026820303,0.00057526317,0.0002916203,0.0002317712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012707336,0.0002964661,0.0005947283,0.00014933487,0.0003801769,0.000042004405,0.000120650395,0.00014214554,0.00015546444],"category_scores_gemma":[0.00002219691,0.00016925203,0.000059056907,0.00012767306,0.0014312695,0.00020106419,0.000093105016,0.00024288998,0.000007343114],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038487274,0.0003443593,0.8999432,0.00011870962,0.000713552,0.023661695,0.0019380343,0.00010736466,0.032219745,0.000018025044,0.00018787608,0.0022601988],"study_design_scores_gemma":[0.02817098,0.007737192,0.28008252,0.0004868355,0.0012276161,0.010926729,0.00065227965,0.00048900844,0.66894066,0.00004178691,0.0006703787,0.0005740106],"about_ca_topic_score_codex":0.0010081939,"about_ca_topic_score_gemma":0.00015693263,"teacher_disagreement_score":0.6367209,"about_ca_system_score_codex":0.0001247088,"about_ca_system_score_gemma":0.00025842292,"threshold_uncertainty_score":0.6901897},"labels":[],"label_agreement":null},{"id":"W2765682155","doi":"10.1016/j.ejca.2017.09.028","title":"Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’ metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University","keywords":"Cabazitaxel; Medicine; Prostate cancer; Prednisone; Genitourinary system; Oncology; Internal medicine; Prostate; Urology; Cancer; Gynecology; Androgen deprivation therapy","score_opus":0.07250577496601725,"score_gpt":0.4126444029825152,"score_spread":0.34013862801649797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765682155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97294515,0.014860819,0.00016327552,0.0070136166,0.0010618905,0.0026800958,0.00045043384,0.000014094639,0.0008106485],"genre_scores_gemma":[0.98662704,0.0048756637,0.0008504079,0.00019554255,0.0017780096,0.00023230832,0.000015339421,0.0000755353,0.0053501474],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99774575,0.0003230997,0.00065246044,0.00034793597,0.00047301923,0.000457754],"domain_scores_gemma":[0.99764836,0.00014189424,0.00094442983,0.00031149646,0.00056036323,0.00039344098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011130901,0.00028744354,0.0007608743,0.00015556031,0.00074035674,0.00014724601,0.00025486673,0.000043185028,0.00009511837],"category_scores_gemma":[0.00015268728,0.00021058627,0.00022034338,0.00007374923,0.00031757707,0.00035860142,0.000113730865,0.0004024685,0.0000025608913],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3781279,0.0017546073,0.00082378136,0.0007161209,0.002807074,0.005011283,0.006709527,0.00003087174,0.06652182,0.00003214578,0.0152309295,0.52223396],"study_design_scores_gemma":[0.67862767,0.12991709,0.025053095,0.0019745617,0.003839914,0.00079767447,0.002247933,0.00036067519,0.02135562,0.00022572913,0.13479239,0.0008076635],"about_ca_topic_score_codex":0.00023621075,"about_ca_topic_score_gemma":0.00023735935,"teacher_disagreement_score":0.52142626,"about_ca_system_score_codex":0.0006684959,"about_ca_system_score_gemma":0.0011306521,"threshold_uncertainty_score":0.8587459},"labels":[],"label_agreement":null},{"id":"W2766122987","doi":"10.1200/jco.2017.35.15_suppl.e16528","title":"Prostate-specific antigen (PSA) trajectories correlate with overall survival (OS) in men treated with abiraterone acetate plus prednisone (AA+P) or placebo plus prednisone: A post-hoc analysis of COU-AA-301 trial data.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Abiraterone acetate; Prednisone; Internal medicine; Prostate cancer; Placebo; Post-hoc analysis; Proportional hazards model; Randomization; Logistic regression; Prostate-specific antigen; Oncology; Univariate analysis; Randomized controlled trial; Multivariate analysis; Cancer; Androgen deprivation therapy; Pathology","score_opus":0.19509677854061214,"score_gpt":0.46550736720885977,"score_spread":0.27041058866824763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766122987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931405,0.0007443386,0.0000685645,0.002080093,0.0005277879,0.0022145081,0.0003245923,0.000023329967,0.000876276],"genre_scores_gemma":[0.9879339,0.0066383327,0.001452455,0.000071578055,0.00048155055,0.000047555775,0.00027385107,0.000070684764,0.0030301108],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931018,0.0009587718,0.0031327885,0.00076869904,0.0012757783,0.0007622031],"domain_scores_gemma":[0.9911824,0.001821546,0.0038929998,0.0013267449,0.0011503461,0.0006259599],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00468638,0.00048330377,0.0046189344,0.00058818015,0.00020370513,0.00010932702,0.0009248957,0.0005602038,0.00026885123],"category_scores_gemma":[0.001165248,0.00026357322,0.00040318465,0.0006002956,0.0012422685,0.0006956014,0.00025587133,0.0013973629,0.0000075145836],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8908747,0.0024874257,0.08430596,0.00009214574,0.008862063,0.004321906,0.0010562954,0.0005960818,0.00044002925,0.000009924296,0.0008054149,0.00614806],"study_design_scores_gemma":[0.4705895,0.11064946,0.40412965,0.00047952108,0.0050283885,0.00016842123,0.0008978014,0.0038386192,0.00018587727,0.000014555294,0.0036256784,0.0003925565],"about_ca_topic_score_codex":0.0006710778,"about_ca_topic_score_gemma":0.0030592568,"teacher_disagreement_score":0.42028522,"about_ca_system_score_codex":0.00070636795,"about_ca_system_score_gemma":0.0065777563,"threshold_uncertainty_score":0.99998164},"labels":[],"label_agreement":null},{"id":"W2766333999","doi":"10.1016/j.eursup.2017.09.005","title":"Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach","year":2017,"lang":"en","type":"article","venue":"European Urology Supplements","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Genitourinary system; Metastasectomy; Oncology; Prostate cancer; Disease; Internal medicine; Metastasis; Cancer; Renal cell carcinoma; Kidney cancer; Prostate","score_opus":0.023555073650507748,"score_gpt":0.3027742673740166,"score_spread":0.27921919372350884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766333999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97100097,0.0059550195,0.000012327575,0.0039891205,0.00015145913,0.0007154414,0.000057178415,0.00002747807,0.018090991],"genre_scores_gemma":[0.99243593,0.0056263655,0.0004326278,0.0005195829,0.0003030557,0.000041613013,0.00037097177,0.000038960217,0.00023088486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984581,0.00027701363,0.00023015979,0.00042742369,0.00020078132,0.00040651174],"domain_scores_gemma":[0.9990852,0.000047511472,0.00008546922,0.0005527474,0.000043842512,0.00018522708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023769426,0.00019373634,0.0002629382,0.0001875184,0.00021133543,0.0000466438,0.00021774681,0.000041449697,0.00019042447],"category_scores_gemma":[0.00013553488,0.00015157934,0.000037706715,0.00007276444,0.00020671356,0.000098159326,0.00034037294,0.00027181,0.000042068976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017412859,0.0021267799,0.8832411,0.00025021308,0.0005824381,0.037915528,0.0016009173,0.000007777199,0.0028820464,0.0005933438,0.009725135,0.059333414],"study_design_scores_gemma":[0.007872881,0.0012478222,0.7663707,0.00003139084,0.00011820715,0.00025489295,0.00021288017,0.00003319778,0.0010987263,0.00013743118,0.22239397,0.00022788528],"about_ca_topic_score_codex":0.000024616043,"about_ca_topic_score_gemma":0.000006077564,"teacher_disagreement_score":0.21266885,"about_ca_system_score_codex":0.000040648803,"about_ca_system_score_gemma":0.00004838761,"threshold_uncertainty_score":0.61812264},"labels":[],"label_agreement":null},{"id":"W2766420380","doi":"","title":"The influence of extracellular matrix (ECM) on penetration of anticancer drugs through solid tumor tissue","year":2004,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Extracellular matrix; Cell culture; Penetration (warfare); Cancer research; Cancer cell; Doxorubicin; Chemistry; Cell biology; Medicine; Biology; Chemotherapy; Cancer; Internal medicine","score_opus":0.017209795966273252,"score_gpt":0.3579915956067084,"score_spread":0.34078179964043515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766420380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99151045,0.002199431,0.00010078819,0.0018716725,0.000036884707,0.00047021653,0.000005123967,0.0000147714945,0.0037906421],"genre_scores_gemma":[0.9944439,0.0009557829,0.0004899997,0.00005527337,0.000038762,0.000017611354,0.000005923569,0.000009784567,0.003982944],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999004,0.000018162153,0.00024822672,0.00013721206,0.0004122089,0.00018017992],"domain_scores_gemma":[0.9993857,0.00007700994,0.00008341195,0.00025733866,0.00015372656,0.00004277302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001660783,0.000086537824,0.00017856128,0.000032901855,0.00006161129,0.000007826764,0.000085332664,0.000032797496,0.00008726791],"category_scores_gemma":[0.000041888845,0.000047534402,0.000043070944,0.0001680265,0.0002044073,0.000074588286,0.000018097695,0.00009573651,0.000026018692],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015570547,0.00061722455,0.004052844,0.0003806551,0.00017329256,0.00006433521,0.002551482,0.0021744585,0.9480116,0.036126804,0.00034538392,0.003944858],"study_design_scores_gemma":[0.002015032,0.001011362,0.012428168,0.00019504913,0.000039305913,0.000006606827,0.00035559695,0.000024309027,0.98063546,0.0015239827,0.0017017672,0.00006333142],"about_ca_topic_score_codex":0.00031044963,"about_ca_topic_score_gemma":0.000015062855,"teacher_disagreement_score":0.03460282,"about_ca_system_score_codex":0.00007058253,"about_ca_system_score_gemma":0.00023447008,"threshold_uncertainty_score":0.19383967},"labels":[],"label_agreement":null},{"id":"W2766734872","doi":"10.71781/5017","title":"Cancer de la prostate résistant à la castration métastatique : utilisation des nouveaux traitements dans un contexte réel au Québec","year":2017,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Gynecology; Cancer; Internal medicine","score_opus":0.04913786023588196,"score_gpt":0.4129663218287528,"score_spread":0.36382846159287086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766734872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9388459,0.0025639283,0.00018151593,0.0005391729,0.0004579712,0.0032814008,0.0010469232,0.000005236549,0.053077977],"genre_scores_gemma":[0.9113591,0.0023527187,0.0013024668,0.000021766933,0.00021904352,0.0009467436,0.0032254113,0.00009095569,0.08048185],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99642533,0.0007229519,0.00068146345,0.00078015553,0.00054599735,0.00084409164],"domain_scores_gemma":[0.997712,0.0003235033,0.00063030695,0.00047676975,0.0004382801,0.00041914487],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001517423,0.0005718703,0.0006602995,0.00014669652,0.0012703813,0.00075583084,0.0005392585,0.00046565934,0.002273381],"category_scores_gemma":[0.00027965562,0.00050861784,0.00015143456,0.00015985324,0.00081520557,0.0007119374,0.00006910267,0.00064126804,0.00012422871],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002841824,0.0006703995,0.08760688,0.00071509904,0.00084839435,0.0005408721,0.1895147,0.000072628536,0.040612493,0.000108450855,0.00010861763,0.67635965],"study_design_scores_gemma":[0.012531808,0.0011644264,0.7210884,0.0073469947,0.0017170783,0.0000987053,0.06595038,0.0011807681,0.15899979,0.00037698986,0.028540198,0.0010044524],"about_ca_topic_score_codex":0.3477006,"about_ca_topic_score_gemma":0.5862079,"teacher_disagreement_score":0.6753552,"about_ca_system_score_codex":0.003605594,"about_ca_system_score_gemma":0.01576398,"threshold_uncertainty_score":0.99973655},"labels":[],"label_agreement":null},{"id":"W2767125962","doi":"10.1200/jco.2017.35.15_suppl.e16529","title":"Predictors of clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or placebo: An exploratory post-hoc analysis of COU-AA-302 trial data.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Prostate cancer; Post-hoc analysis; Placebo; Internal medicine; Oncology; Abiraterone acetate; Proportional hazards model; Clinical trial; Brief Pain Inventory; Prostate-specific antigen; Urology; Cancer; Androgen deprivation therapy; Physical therapy; Pathology","score_opus":0.32248500850765155,"score_gpt":0.5471662874615635,"score_spread":0.22468127895391193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767125962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963832,0.00015397964,0.0000038310623,0.00087700697,0.0006291048,0.0012449019,0.0006508189,0.000006502514,0.000050652154],"genre_scores_gemma":[0.9967688,0.0015984082,0.0006957643,0.00011325359,0.00021864672,0.00003903822,0.0001928456,0.00002938059,0.00034387948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99141425,0.0014395667,0.0053220685,0.00047672723,0.0009727907,0.00037461697],"domain_scores_gemma":[0.9882974,0.0023037235,0.0062221303,0.0009795815,0.0016451105,0.00055206986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064367503,0.00027933464,0.0042372546,0.00048512337,0.000082972954,0.000028855871,0.00061959046,0.00028340452,0.0001551006],"category_scores_gemma":[0.004740591,0.00014812546,0.0004899304,0.0003554631,0.0009500804,0.000671853,0.00013989335,0.0008418664,0.0000015915622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39708528,0.0049184724,0.5813835,0.00005538517,0.006624758,0.0004718006,0.0002673026,0.000043714317,0.00005202479,0.0000011368395,0.00010664721,0.008989947],"study_design_scores_gemma":[0.17202282,0.06977093,0.75095266,0.00015976197,0.005954804,0.0000037484995,0.00038558946,0.00030471085,0.00006618843,0.0000047670096,0.0002561984,0.000117824646],"about_ca_topic_score_codex":0.00049312774,"about_ca_topic_score_gemma":0.009222796,"teacher_disagreement_score":0.22506247,"about_ca_system_score_codex":0.0001822363,"about_ca_system_score_gemma":0.005733924,"threshold_uncertainty_score":0.99990267},"labels":[],"label_agreement":null},{"id":"W2767584283","doi":"10.1007/s11255-017-1744-2","title":"Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study","year":2017,"lang":"en","type":"article","venue":"International Urology and Nephrology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Propensity score matching; Prostate cancer; Internal medicine; Enzalutamide; Proportional hazards model; Cabazitaxel; Docetaxel; Cohort; Population; Oncology; Progression-free survival; Survival analysis; Relative survival; Hazard ratio; Cancer; Cancer registry; Overall survival; Androgen deprivation therapy; Confidence interval","score_opus":0.04665283515612758,"score_gpt":0.34381636077950883,"score_spread":0.2971635256233813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767584283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797892,0.0017824378,0.000007073361,0.015868794,0.0008427319,0.0010147677,0.00031847126,0.000021087197,0.00035545253],"genre_scores_gemma":[0.9977284,0.00047905673,0.00003589933,0.00082903006,0.00014221686,0.0003502542,0.0001392952,0.00002147089,0.000274391],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983948,0.00018408675,0.0003516181,0.0005055524,0.00025315932,0.00031078508],"domain_scores_gemma":[0.99883634,0.00024200797,0.00020750934,0.00040522637,0.00019487645,0.00011405082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033026564,0.00021361798,0.0004593636,0.0002210174,0.00019505432,0.0000494465,0.00029932597,0.0001154322,0.00014899201],"category_scores_gemma":[0.00018613054,0.000175967,0.000042003183,0.000042348813,0.0002695385,0.00018633221,0.00024825367,0.00031859073,0.0000015085044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006200474,0.0006132321,0.98995525,0.000021526741,0.00038161286,0.0001355478,0.00025014812,0.000009766205,0.00026762547,0.0003970928,0.000346517,0.001421234],"study_design_scores_gemma":[0.021935182,0.0013060126,0.9727844,0.000014976408,0.000059684648,0.0000038625703,0.000054161836,0.00081184285,0.00002418059,0.001422163,0.0014452834,0.00013825523],"about_ca_topic_score_codex":0.007973795,"about_ca_topic_score_gemma":0.009566565,"teacher_disagreement_score":0.017939202,"about_ca_system_score_codex":0.000109291905,"about_ca_system_score_gemma":0.0001904379,"threshold_uncertainty_score":0.9986322},"labels":[],"label_agreement":null},{"id":"W2768353180","doi":"10.1186/s12885-017-3729-z","title":"Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma","year":2017,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Cancer Institute; National Institutes of Health","keywords":"Prostate cancer; Adenocarcinoma; Biology; Prostate; Cancer research; Carcinoma; Immunohistochemistry; Phenotype; Pathology; Gene; Cancer; Medicine; Genetics","score_opus":0.035077955035170215,"score_gpt":0.31585969397582025,"score_spread":0.28078173894065006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768353180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97188383,0.024731146,0.000008000884,0.0007715793,0.0002104373,0.0011987439,0.00016167735,0.000025597705,0.0010089915],"genre_scores_gemma":[0.9801939,0.006461523,0.0011375584,0.00015045988,0.00018177208,0.00044823403,0.00003245942,0.000044523178,0.011349541],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99862564,0.00003231963,0.00023473398,0.00041189883,0.00030564223,0.00038977078],"domain_scores_gemma":[0.9988446,0.000043946122,0.00022398344,0.00053098804,0.00016014089,0.00019629173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000070761875,0.00021439712,0.0003865862,0.000089766596,0.00021916564,0.00004725955,0.00015789965,0.000044256027,0.00009425931],"category_scores_gemma":[0.00003248064,0.00015244215,0.0000720159,0.000059427886,0.00024440986,0.00011870157,0.0001895214,0.00021388056,0.0000019361703],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015526298,0.00012579461,0.5470336,0.0018444875,0.000032233977,0.00014156182,0.00031747165,0.000014295214,0.4401291,0.000003121002,0.0012259521,0.0075797513],"study_design_scores_gemma":[0.0040222635,0.0002455473,0.40507632,0.00032383512,0.00009761851,0.000011198678,0.00003279514,0.00006692017,0.58900476,0.00002770653,0.0009619091,0.00012914801],"about_ca_topic_score_codex":0.0011459041,"about_ca_topic_score_gemma":0.00020336821,"teacher_disagreement_score":0.14887564,"about_ca_system_score_codex":0.00012872218,"about_ca_system_score_gemma":0.00062197464,"threshold_uncertainty_score":0.62164104},"labels":[],"label_agreement":null},{"id":"W2768780848","doi":"10.5489/cuaj.4524","title":"Case: Testicular oligometastasis from prostate cancer — Report of rare isolated recurrence after radiotherapy and intermittent androgen-deprivation therapy","year":2017,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Queen's University; Kingston General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Orchiectomy; Radiation therapy; Androgen suppression; Urology; Androgen; Metastasis; Prostate; Histopathology; Internal medicine; Oncology; Adenocarcinoma; Cancer; Pathology; Hormone","score_opus":0.028954152141054727,"score_gpt":0.3034455759589073,"score_spread":0.2744914238178526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768780848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803169,0.0072480906,0.000037353915,0.011659304,0.00017738133,0.0003323148,0.00018082315,0.000008603417,0.000039225994],"genre_scores_gemma":[0.99146324,0.0074017537,0.00022649957,0.0004616056,0.00016788226,0.000037507445,0.000033571538,0.000011837096,0.00019610039],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874866,0.00009877938,0.00033870724,0.00023051651,0.00027230414,0.00031100446],"domain_scores_gemma":[0.99836576,0.00006741182,0.0004897332,0.00021481264,0.00042813751,0.00043413663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004293857,0.0001349558,0.00030305694,0.0001264362,0.00033611333,0.00014058943,0.000091267546,0.00015082314,0.00040229445],"category_scores_gemma":[0.0004499117,0.00009496552,0.00008589153,0.00008676737,0.00009501017,0.00015470777,0.000017629223,0.00034398847,0.0000015000172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037132468,0.000038540384,0.9315386,0.0000056003123,0.00037412232,0.00940039,0.0002649115,0.000002409949,0.00042791007,0.0000014711832,0.00051124237,0.05706347],"study_design_scores_gemma":[0.0026335458,0.00049356674,0.9839719,0.000069382535,0.00009082474,0.0037096248,0.00004364827,0.00025522918,0.00040464237,0.00017328713,0.00802564,0.0001287043],"about_ca_topic_score_codex":0.004560665,"about_ca_topic_score_gemma":0.00062004157,"teacher_disagreement_score":0.056934766,"about_ca_system_score_codex":0.000639532,"about_ca_system_score_gemma":0.0004527699,"threshold_uncertainty_score":0.68943924},"labels":[],"label_agreement":null},{"id":"W2768842469","doi":"10.1016/j.critrevonc.2017.11.007","title":"Biomarkers in prostate cancer – Current clinical utility and future perspectives","year":2017,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":175,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Liquid biopsy; Medicine; Biomarker; Circulating tumor cell; Cancer; Prostate; Clinical Practice; Oncology; Internal medicine; Intensive care medicine; Metastasis; Biology","score_opus":0.30613549361765446,"score_gpt":0.6113364424185329,"score_spread":0.30520094880087845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768842469","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033103366,0.9856697,0.0000010683567,0.006166746,0.0015013397,0.0046056057,0.000066505185,0.000025011283,0.0019309252],"genre_scores_gemma":[0.00004390912,0.9964471,0.00022317235,0.00010014859,0.00056811364,0.0023672732,0.00006583797,0.000050112863,0.000134317],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924352,0.002463209,0.0023468165,0.0015055804,0.00023021769,0.0010189752],"domain_scores_gemma":[0.99619997,0.0017318506,0.00045351914,0.0009332032,0.00018133914,0.0005001167],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003468453,0.00070092094,0.007925907,0.00046612567,0.000121866826,0.000031359825,0.00039571853,0.0011709147,0.00029061525],"category_scores_gemma":[0.0052640624,0.00046029204,0.00072435604,0.00036813325,0.0027610203,0.0001001958,0.0003645397,0.0028759933,0.000081693026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019523798,0.0009528398,0.006828227,0.039242525,0.000167644,0.001210111,0.00015613712,2.3307112e-10,1.7418266e-8,0.0022875722,0.0021702596,0.94678944],"study_design_scores_gemma":[0.0017573215,0.0003674399,0.0007998581,0.042725056,0.000729829,0.00057477655,0.00015647947,0.0000029312987,9.14788e-8,0.0003590588,0.9521914,0.0003357171],"about_ca_topic_score_codex":0.000025708881,"about_ca_topic_score_gemma":0.00018057652,"teacher_disagreement_score":0.9500212,"about_ca_system_score_codex":0.00090741314,"about_ca_system_score_gemma":0.00267364,"threshold_uncertainty_score":0.9999529},"labels":[],"label_agreement":null},{"id":"W2768924090","doi":"10.1002/pros.23445","title":"Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen‐sensitive prostate cancer cells","year":2017,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Enzalutamide; LNCaP; Prostate cancer; Radiosensitizer; Medicine; Cancer research; Androgen deprivation therapy; Androgen receptor; Oncology; Androgen; Cancer; Internal medicine; Radiation therapy; Hormone","score_opus":0.021106727110201454,"score_gpt":0.3301724760680589,"score_spread":0.30906574895785743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768924090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911796,0.00024328023,0.0006483474,0.0044482034,0.00021111217,0.002250612,0.00015617887,0.000037164507,0.0008255159],"genre_scores_gemma":[0.99476707,0.00059758674,0.00031182115,0.00019366953,0.00010642159,0.00016028521,0.00005963532,0.00003328081,0.003770244],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984806,0.00007417202,0.0002995044,0.00033593556,0.00042837692,0.00038137482],"domain_scores_gemma":[0.9984653,0.000041165735,0.000259463,0.0006219823,0.0004307625,0.00018131558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035850366,0.00019553922,0.0003172205,0.00008107026,0.00040920192,0.000078335186,0.00015221976,0.000060530405,0.000030597395],"category_scores_gemma":[0.00007043594,0.00013091342,0.000074344636,0.00011883977,0.00021969699,0.00016589274,0.000098698045,0.0001689896,0.000050108272],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038852387,0.00013821246,0.001372197,0.00013191564,0.0001823962,0.00007587699,0.0035190016,0.00014691713,0.97029126,0.000051340605,0.00011313317,0.020092506],"study_design_scores_gemma":[0.0019362343,0.0005930653,0.009872798,0.00018901574,0.000117791555,0.000021858588,0.00026776284,0.0004018619,0.9861868,0.0001241817,0.0001471645,0.00014148046],"about_ca_topic_score_codex":0.00024276966,"about_ca_topic_score_gemma":0.00019275883,"teacher_disagreement_score":0.019951025,"about_ca_system_score_codex":0.00015832642,"about_ca_system_score_gemma":0.00035998033,"threshold_uncertainty_score":0.5338494},"labels":[],"label_agreement":null},{"id":"W2769065023","doi":"10.1200/jco.2013.31.15_suppl.e16025","title":"The economic burden of metastatic castration-resistant prostate cancer: U.S. Medicare perspective.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Quarter (Canadian coin); Cancer; Internal medicine","score_opus":0.10807726924368355,"score_gpt":0.4927880338695398,"score_spread":0.38471076462585624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769065023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90820664,0.008317431,0.0000042590373,0.07868533,0.0008652065,0.00057865225,0.00001586488,0.000004646855,0.0033219692],"genre_scores_gemma":[0.985791,0.011211445,0.0004590025,0.00018812851,0.0007577271,0.000028164968,0.0000017527684,0.000011866376,0.0015508652],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99740314,0.0003062125,0.001604197,0.00013023072,0.00033292023,0.00022332082],"domain_scores_gemma":[0.9954602,0.0019007782,0.0012220026,0.0001614548,0.00095412455,0.00030145288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001933529,0.000098208926,0.000875087,0.000070135306,0.000070921196,0.000015238865,0.00017366477,0.000099307195,0.0005048886],"category_scores_gemma":[0.0012548561,0.000048739363,0.00031428036,0.00007279471,0.0005333712,0.00010879896,0.000034020224,0.00057230465,0.000026460368],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025770355,0.0018452654,0.04719961,0.0003265872,0.009564557,0.00138867,0.0058782925,0.00041832682,0.0063919877,0.00465126,0.09436248,0.8022026],"study_design_scores_gemma":[0.06292736,0.07104011,0.44036856,0.0009740303,0.003554373,0.0008021151,0.05032577,0.0021119502,0.0031547993,0.022080634,0.34211084,0.00054944365],"about_ca_topic_score_codex":0.0013613974,"about_ca_topic_score_gemma":0.00028745923,"teacher_disagreement_score":0.80165315,"about_ca_system_score_codex":0.0006080089,"about_ca_system_score_gemma":0.0062503815,"threshold_uncertainty_score":0.9993833},"labels":[],"label_agreement":null},{"id":"W2769979088","doi":"10.1097/md.0000000000006817","title":"PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide","year":2017,"lang":"en","type":"article","venue":"Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Oncology; Retrospective cohort study; Overall survival; Prostate-specific antigen; Urology; Survival analysis; Medical record; Cancer; Androgen receptor","score_opus":0.03728021057896487,"score_gpt":0.3427382192892927,"score_spread":0.30545800871032786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769979088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929542,0.00083276356,0.0000033993704,0.004596654,0.00004358423,0.0009512613,0.00003358635,0.000020068954,0.00056450727],"genre_scores_gemma":[0.9977867,0.00037170772,0.00014776395,0.00006838239,0.000067742934,0.000110498826,0.00009873837,0.00002618758,0.0013222852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863756,0.00003725565,0.00022489968,0.00031474122,0.00047700584,0.00030851417],"domain_scores_gemma":[0.99906063,0.00005483533,0.00013188453,0.00034163412,0.00022698272,0.00018403961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020024453,0.0002043697,0.00044818743,0.00013784795,0.0001767912,0.00003045955,0.0000730976,0.000029141165,0.000074358024],"category_scores_gemma":[0.000086930704,0.000101257894,0.000012756822,0.00013803307,0.0004662569,0.00013858941,0.000022437542,0.00014917136,0.0000018105002],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061618625,0.00015357963,0.98712456,0.00015097119,0.00016202778,0.0002895593,0.0004329362,0.0000031181967,0.0005919072,0.000012966567,0.000071499926,0.004845012],"study_design_scores_gemma":[0.02283765,0.0021457898,0.97265255,0.0008797822,0.00023485042,0.0000060606594,0.00022833476,0.000035742552,0.00056248525,0.000016307233,0.00027947454,0.000120939316],"about_ca_topic_score_codex":0.0035594136,"about_ca_topic_score_gemma":0.004450842,"teacher_disagreement_score":0.016675789,"about_ca_system_score_codex":0.00010011015,"about_ca_system_score_gemma":0.00018034711,"threshold_uncertainty_score":0.53807926},"labels":[],"label_agreement":null},{"id":"W2770182678","doi":"10.1016/j.urology.2017.08.067","title":"Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study","year":2017,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Health Sciences Centre; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"Canadian Urological Oncology Group","keywords":"Medicine; Prostate cancer; Toxicity; Castration; Oncology; Gynecology; Internal medicine; Population; Population based study; Prostate; Cancer; Epidemiology; Hormone; Environmental health","score_opus":0.03531140747042478,"score_gpt":0.3781302381451798,"score_spread":0.34281883067475505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770182678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99716574,0.00010344534,0.000016365311,0.00078537955,0.000018158305,0.0012003443,0.00012230352,0.000018229463,0.00057006313],"genre_scores_gemma":[0.99859256,0.000027058883,0.000027207456,0.0000234355,0.000025321444,0.00027841752,0.000175484,0.00001168945,0.0008388572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989762,0.00006732601,0.00022595434,0.0003008771,0.00020022076,0.00022944587],"domain_scores_gemma":[0.99894804,0.000046604073,0.0002227346,0.0005354638,0.00013720152,0.000109953835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011276909,0.0001451362,0.00049682194,0.00024281103,0.00022278853,0.000022662696,0.0000840311,0.000048150145,0.00016790778],"category_scores_gemma":[0.000022810616,0.000091500544,0.00008658178,0.00019492625,0.00014982634,0.000059651422,0.000014733526,0.00006562938,0.0000011278513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060838377,0.0015980415,0.98386234,0.00001537274,0.002786199,0.00015069451,0.0006043932,0.0014731177,0.001765716,0.000008009377,0.0000130324115,0.0016392367],"study_design_scores_gemma":[0.012598653,0.010927973,0.9604508,0.000008176903,0.0035287982,8.766977e-7,0.00015235509,0.010747367,0.0014502923,0.000005968096,0.000045660534,0.00008302875],"about_ca_topic_score_codex":0.01493618,"about_ca_topic_score_gemma":0.020267546,"teacher_disagreement_score":0.0234115,"about_ca_system_score_codex":0.0002400148,"about_ca_system_score_gemma":0.0003236309,"threshold_uncertainty_score":0.99761003},"labels":[],"label_agreement":null},{"id":"W2772156557","doi":"10.5489/cuaj.4600","title":"A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate","year":2017,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Abbotsford Veterinary Clinic; BC Cancer Agency","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Internal medicine; Oncology; Proportional hazards model; Hazard ratio; Chemotherapy; Prostate-specific antigen; Cancer; Androgen deprivation therapy; Confidence interval","score_opus":0.07470281627912369,"score_gpt":0.36504089218843855,"score_spread":0.2903380759093149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772156557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846417,0.00007261105,0.00004096374,0.013343347,0.000086789936,0.0014584254,0.00024047098,0.000013139611,0.00010257762],"genre_scores_gemma":[0.99693567,0.00016850841,0.0005214074,0.0006097049,0.00007287049,0.0002305252,0.00006873693,0.000024532332,0.0013680533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979802,0.00011841955,0.0005519377,0.00030482997,0.0003885578,0.0006560736],"domain_scores_gemma":[0.99796927,0.00017437461,0.0005476563,0.00015626058,0.0005813535,0.0005710733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068995595,0.00021180206,0.0005282725,0.00014538132,0.00055116735,0.00027462654,0.00014699396,0.0001392134,0.00005064088],"category_scores_gemma":[0.0006855051,0.00013387973,0.0001308018,0.00008465552,0.00009501597,0.00023700071,0.000010087152,0.0004740842,0.0000036238634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012132098,0.00023710409,0.99528986,0.00001778493,0.00041121597,0.000089198606,0.00023377755,0.00018044405,0.000038787617,0.000012522688,0.00019126643,0.002084803],"study_design_scores_gemma":[0.011349815,0.0013251156,0.98134923,0.000059598002,0.00018312786,0.0000047349035,0.000050328377,0.005147861,0.000016880991,0.00024047967,0.00012091299,0.00015188666],"about_ca_topic_score_codex":0.0015586794,"about_ca_topic_score_gemma":0.012088699,"teacher_disagreement_score":0.013940627,"about_ca_system_score_codex":0.0011371486,"about_ca_system_score_gemma":0.0014447585,"threshold_uncertainty_score":0.6745778},"labels":[],"label_agreement":null},{"id":"W2772419959","doi":"10.1038/s41391-017-0018-5","title":"Germline BRCA mutation in male carriers—ripe for precision oncology?","year":2017,"lang":"en","type":"review","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Germline; Prostate cancer; Germline mutation; Oncology; Cancer; Synthetic lethality; Population; Disease; Mutation; BRCA mutation; DNA repair; Internal medicine; Genetics; Bioinformatics; Cancer research; Gene; Biology; Ovarian cancer","score_opus":0.11789031156022121,"score_gpt":0.48265006692905915,"score_spread":0.3647597553688379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772419959","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041350114,0.9836261,0.000009657779,0.0004689778,0.00036702026,0.009772138,0.0048695374,0.000047813573,0.00042522897],"genre_scores_gemma":[0.00022888868,0.9777784,0.00028301319,0.000081318045,0.00025021244,0.008876316,0.0031000362,0.00011080305,0.009291064],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99702233,0.00012969539,0.0008351789,0.0009230502,0.0003836431,0.00070608495],"domain_scores_gemma":[0.9977043,0.0004835306,0.0005290902,0.00051236997,0.00027079516,0.0004998576],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036753542,0.0006075169,0.0022284784,0.0004108216,0.00029093595,0.00016590137,0.00019063347,0.0002842342,0.00012561529],"category_scores_gemma":[0.0004001622,0.00043563213,0.00037428178,0.00023357995,0.00033999054,0.00024859584,0.00011121759,0.0003750211,0.000011155666],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013640589,0.00024279987,0.0013561931,0.04971596,0.0002881148,0.00034640747,0.0005167831,0.0000010044259,7.274129e-7,0.00001549936,0.0016195214,0.94453293],"study_design_scores_gemma":[0.0056965053,0.0011574903,0.0006146438,0.022365997,0.0025101681,0.000104019346,0.0001322339,0.00007660626,0.000005316596,0.0005351406,0.96629786,0.00050402957],"about_ca_topic_score_codex":0.00012899822,"about_ca_topic_score_gemma":0.000074252064,"teacher_disagreement_score":0.96467835,"about_ca_system_score_codex":0.0007399994,"about_ca_system_score_gemma":0.003488594,"threshold_uncertainty_score":0.99980956},"labels":[],"label_agreement":null},{"id":"W2773085872","doi":"10.1093/annonc/mdx785","title":"Prostate cancers that ‘Wnt’ respond to abiraterone","year":2017,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"UCLH Biomedical Research Centre; National Cancer Institute; Cancer Research UK; National Institutes of Health; National Institute for Health and Care Research; University College London","keywords":"Wnt signaling pathway; Prostate cancer; Medicine; Cancer research; Androgen receptor; Cancer; Prostate; Oncology; Internal medicine; Biology; Signal transduction; Genetics","score_opus":0.2095874997858294,"score_gpt":0.4678823498535755,"score_spread":0.2582948500677461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773085872","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044141833,0.0016801727,9.386122e-7,0.91982174,0.00066945964,0.001349438,0.00024037572,0.000033039618,0.032062978],"genre_scores_gemma":[0.030768609,0.004293232,0.00017008877,0.7752129,0.00312263,0.00043902846,0.00067093037,0.0001285695,0.18519406],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997593,0.00014885311,0.00035507014,0.00056066125,0.00051853334,0.0008238739],"domain_scores_gemma":[0.99797565,0.00014437163,0.00036295116,0.0008351994,0.00045447977,0.00022737154],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044104795,0.00033408776,0.0011135184,0.00042399266,0.0001269617,0.000027461092,0.0003914305,0.0008456595,0.0003424146],"category_scores_gemma":[0.00012793789,0.0002540767,0.00020445134,0.000110030465,0.0004324301,0.000076365686,0.00013247538,0.0011696571,0.00020627471],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027133008,0.00006876198,0.0005272857,0.00041536478,0.00043012245,0.0049402122,0.00061659265,8.0228074e-7,0.0006648455,0.000003484729,0.9673593,0.022259945],"study_design_scores_gemma":[0.0019454848,0.006829246,0.0013850174,0.0003915513,0.000101514226,0.00007195624,0.00003891981,5.290454e-7,0.012754935,0.00011548395,0.9761531,0.00021227988],"about_ca_topic_score_codex":0.0007641008,"about_ca_topic_score_gemma":0.00009545966,"teacher_disagreement_score":0.15313108,"about_ca_system_score_codex":0.00038870753,"about_ca_system_score_gemma":0.0024943796,"threshold_uncertainty_score":0.9999911},"labels":[],"label_agreement":null},{"id":"W2774213581","doi":"10.1200/jco.2017.74.1173","title":"Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Duke Cancer Institute; National Cancer Institute; Medical School, University of Michigan; Feinberg School of Medicine; School of Medicine; University of California, San Francisco; Brown University; Tulane University; Astellas Pharma; Erasmus Medisch Centrum; University of Oxford; Harvard T.H. Chan School of Public Health; National Institute for Health and Care Research; Perelman School of Medicine, University of Pennsylvania; Vanderbilt University Medical Center; Cedars-Sinai Medical Center; Janssen Pharmaceuticals; Prostate Cancer Foundation; Memorial Sloan-Kettering Cancer Center; Johns Hopkins University; University of Washington; Vanderbilt University; University of Chicago; University of Texas MD Anderson Cancer Center; Pfizer; Northwestern University; Ohio State University; University of California, San Diego; Yale University; University of Toronto; Cleveland Clinic; University of Pennsylvania","keywords":"Genetic testing; Medicine; Genetic counseling; Prostate cancer; Consensus conference; Family medicine; Oncology; Cancer; Internal medicine; Genetics; Biology","score_opus":0.5101277397551851,"score_gpt":0.5943517696159184,"score_spread":0.0842240298607333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774213581","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005723097,0.98690593,0.000002370181,0.0018748852,0.0012993076,0.0030216444,0.0007977961,0.000012989835,0.00036197036],"genre_scores_gemma":[0.0018638602,0.9913692,0.0027954543,0.00007207459,0.0019160194,0.00036704782,0.000028129967,0.00008628725,0.0015019522],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924309,0.0007711556,0.005011014,0.00054047373,0.00057456084,0.0006718789],"domain_scores_gemma":[0.97850066,0.0037412113,0.013270283,0.00055577554,0.0032891124,0.0006429567],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0033191056,0.0005211265,0.007309768,0.00030359442,0.00018276954,0.000038627968,0.00057211885,0.0010152232,0.000081414066],"category_scores_gemma":[0.00820917,0.00032607326,0.0014356471,0.00020741344,0.0010444071,0.00007254277,0.00015904855,0.0023996087,0.000006486339],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030829946,0.0005968796,0.016242785,0.0073993676,0.0023374858,0.00038716092,0.00013623404,0.000004390141,0.0000125624465,0.0000033768997,0.0026225739,0.9671742],"study_design_scores_gemma":[0.009009976,0.011167677,0.013285039,0.022898039,0.0068327473,0.00036892676,0.000046179957,0.00010204142,0.000005670907,0.00031585456,0.9356735,0.0002943857],"about_ca_topic_score_codex":0.00041928684,"about_ca_topic_score_gemma":0.00023831929,"teacher_disagreement_score":0.9668798,"about_ca_system_score_codex":0.0004792107,"about_ca_system_score_gemma":0.027291702,"threshold_uncertainty_score":0.9999191},"labels":[],"label_agreement":null},{"id":"W2774748297","doi":"10.1016/j.eururo.2017.11.038","title":"Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting","year":2017,"lang":"en","type":"review","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; Prostate Cancer UK; U.S. Department of Veterans Affairs","keywords":"Prostate cancer; Androgen receptor; Medicine; Androgen; Cancer; Oncology; Cancer research; Internal medicine","score_opus":0.08094570057224588,"score_gpt":0.3730374993675895,"score_spread":0.29209179879534364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774748297","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015511679,0.9804785,4.552167e-7,0.0007594993,0.0006450278,0.002057083,0.0006213944,0.00004342522,0.013843444],"genre_scores_gemma":[0.0004293699,0.9930162,0.00010988676,0.000075863514,0.00077129435,0.00008213507,0.0012728517,0.0001579384,0.004084476],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949623,0.0016363839,0.0012456183,0.0010392262,0.00040981156,0.0007067069],"domain_scores_gemma":[0.9962516,0.00033236464,0.0014265096,0.0015637145,0.00017191138,0.00025391873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019745845,0.00055775244,0.002070753,0.00020901598,0.00024671934,0.000049046746,0.00081156514,0.0002771624,0.00045466056],"category_scores_gemma":[0.0008200073,0.000338733,0.0003572639,0.00022505359,0.0003026203,0.000088068344,0.00049999775,0.00093549275,0.00028921742],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008460468,0.00025257986,0.0054244744,0.0017256996,0.001126648,0.0037144164,0.0007610947,0.0000012266696,0.0004073121,0.0000038258586,0.02062666,0.96511],"study_design_scores_gemma":[0.0016152503,0.00029535592,0.001072007,0.005900182,0.0007532626,0.00036138282,0.000028552346,0.000006974171,0.000053591728,0.000017944982,0.98961437,0.00028110467],"about_ca_topic_score_codex":0.0007571899,"about_ca_topic_score_gemma":0.00003361811,"teacher_disagreement_score":0.9689877,"about_ca_system_score_codex":0.00018244449,"about_ca_system_score_gemma":0.0013056482,"threshold_uncertainty_score":0.9999065},"labels":[],"label_agreement":null},{"id":"W2775555769","doi":"10.1101/225433","title":"Androgen receptor binding sites are highly mutated in prostate cancer","year":2017,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Türkiye Bilimsel ve Teknolojik Araştırma Kurumu","keywords":"Prostate cancer; Androgen receptor; Cancer research; Transcription factor; Carcinogenesis; Biology; Chromoplexy; Estrogen receptor; Genetics; Cancer; Breast cancer; Gene; PCA3","score_opus":0.031332551404881934,"score_gpt":0.29266436977676774,"score_spread":0.2613318183718858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2775555769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841044,0.009164618,0.0000022880224,0.0019461832,0.00092152774,0.0021897657,0.0013316164,0.0003162115,0.000023417864],"genre_scores_gemma":[0.99016273,0.0071985237,0.0005311669,0.00009875884,0.0005118783,0.0010424793,0.000009663159,0.00020240253,0.00024238485],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99632996,0.00012132089,0.00058805814,0.0013081055,0.000631394,0.0010211398],"domain_scores_gemma":[0.99674207,0.000049408514,0.00060828705,0.0014575061,0.00064400915,0.0004987485],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057226646,0.0007023513,0.0010779842,0.0006774924,0.00028152048,0.00030984537,0.0005001687,0.00053976855,0.00016723521],"category_scores_gemma":[0.00025263906,0.00063212647,0.00019661395,0.00050593115,0.00025104298,0.0002105854,0.0005329573,0.0013067215,0.00020407709],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005368728,0.0002819271,0.511763,0.0013982804,0.00046691837,0.001105597,0.000046457444,0.000015814534,0.4828649,0.000009752911,0.0014994502,0.000011052319],"study_design_scores_gemma":[0.005217983,0.00018529074,0.3120985,0.00590428,0.0003107801,7.723778e-8,0.000016721457,0.00019361285,0.6644125,0.0000016711844,0.010505847,0.0011527188],"about_ca_topic_score_codex":0.0004198873,"about_ca_topic_score_gemma":0.00003772729,"teacher_disagreement_score":0.19966447,"about_ca_system_score_codex":0.001340649,"about_ca_system_score_gemma":0.0018002237,"threshold_uncertainty_score":0.999613},"labels":[],"label_agreement":null},{"id":"W2776118692","doi":"10.1016/j.eururo.2017.11.029","title":"A Partner in Crime: Tumor-associated Stroma and Metastatic Prostate Cancer","year":2017,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Stroma; Prostate; Prostate cancer; Cancer; Oncology; Pathology; Gynecology; Internal medicine; Immunohistochemistry","score_opus":0.04801246166563941,"score_gpt":0.3424569798413135,"score_spread":0.2944445181756741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2776118692","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22567548,0.011253341,6.9273113e-7,0.7294346,0.00056437793,0.0018008361,0.00035406015,0.00012424165,0.030792385],"genre_scores_gemma":[0.34591493,0.0028380752,0.000065118285,0.5355781,0.0022288081,0.00032263764,0.0015453089,0.00042276786,0.11108429],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971843,0.00073821377,0.00034500804,0.00066490617,0.00027796734,0.00078960054],"domain_scores_gemma":[0.9988891,0.00012603536,0.00025152112,0.00051167543,0.00009805053,0.00012364406],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045391734,0.0003695655,0.0007450987,0.00027853326,0.000113905095,0.000059779857,0.00021574627,0.00014839305,0.00022730592],"category_scores_gemma":[0.00021452837,0.00028280116,0.00008713648,0.0000882269,0.00039175941,0.000057219826,0.00018606093,0.0018908607,0.00013479449],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004796116,0.00012126605,0.028812315,0.00031922548,0.0005906628,0.07192761,0.0004873616,8.629348e-7,0.00015526077,0.00000465446,0.8950907,0.002010456],"study_design_scores_gemma":[0.005705359,0.001073496,0.14818974,0.00019704491,0.0004840517,0.00028410574,0.000012178902,0.00003189067,0.000025105952,0.00007443083,0.84359896,0.00032366134],"about_ca_topic_score_codex":0.00022984791,"about_ca_topic_score_gemma":0.000050150058,"teacher_disagreement_score":0.19385652,"about_ca_system_score_codex":0.00014112702,"about_ca_system_score_gemma":0.0002875188,"threshold_uncertainty_score":0.9999624},"labels":[],"label_agreement":null},{"id":"W2776594178","doi":"10.1016/j.clgc.2017.12.012","title":"Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Enzalutamide; Medicine; Prostate cancer; Abiraterone acetate; Docetaxel; Androgen deprivation therapy; Oncology; Internal medicine; Cancer; Androgen receptor","score_opus":0.18384847412308658,"score_gpt":0.4752861645697759,"score_spread":0.2914376904466893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2776594178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96454674,0.011281667,0.00023052655,0.0074311034,0.0010862076,0.009951117,0.0053834086,0.0000732263,0.000016028884],"genre_scores_gemma":[0.88440925,0.08449872,0.0063492535,0.00096724887,0.0009909776,0.012460842,0.00032089333,0.00020477129,0.009798069],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99365604,0.00032072223,0.0027345119,0.0013949125,0.00075430307,0.0011395187],"domain_scores_gemma":[0.9929104,0.0019328399,0.0016972951,0.001205221,0.0016439839,0.0006102656],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018160907,0.0008010984,0.002559407,0.00017456849,0.00064088195,0.00015207235,0.00045433006,0.00025663787,0.0002542386],"category_scores_gemma":[0.0011426677,0.0004955778,0.00095062633,0.00026036237,0.0010336739,0.0005652482,0.00019010899,0.0005547305,0.000008889376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34922627,0.003997463,0.46510112,0.0023361382,0.011273024,0.0010349585,0.001332468,0.000307356,0.004420817,0.000007880941,0.0038099037,0.15715262],"study_design_scores_gemma":[0.096350566,0.018457023,0.83598095,0.0013967174,0.0049614594,0.00004275777,0.0005370554,0.0022613662,0.01984339,0.0005196092,0.01814885,0.0015002597],"about_ca_topic_score_codex":0.00092492206,"about_ca_topic_score_gemma":0.00435623,"teacher_disagreement_score":0.37087983,"about_ca_system_score_codex":0.0003590053,"about_ca_system_score_gemma":0.002318997,"threshold_uncertainty_score":0.9997496},"labels":[],"label_agreement":null},{"id":"W2778808609","doi":"10.1016/j.clgc.2017.12.006","title":"Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies","year":2017,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Prednisone; Medicine; Docetaxel; Prostate cancer; Internal medicine; Oncology; Placebo; Randomized controlled trial; Abiraterone acetate; Cancer; Androgen deprivation therapy; Pathology","score_opus":0.25017454742995576,"score_gpt":0.539170911552819,"score_spread":0.2889963641228633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2778808609","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1924544,0.8031826,1.4385452e-7,0.00011202829,0.00026229298,0.0030487804,0.0008281352,0.0000131858,0.00009841545],"genre_scores_gemma":[0.04495706,0.95114386,0.000039860068,0.000015775082,0.00011957337,0.001549812,0.00009648926,0.000051174608,0.0020263954],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9954272,0.00077237317,0.001953882,0.0008278485,0.0005987439,0.0004199342],"domain_scores_gemma":[0.995137,0.0022255175,0.0014139467,0.00071599457,0.0003214577,0.00018609996],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012105507,0.0006271382,0.006764534,0.00074810325,0.00010282424,0.000026432452,0.00022226102,0.0002123074,0.000039270428],"category_scores_gemma":[0.0007039268,0.0003795496,0.0011610325,0.00062181125,0.0008537866,0.000084067375,0.00017449028,0.0005529789,0.0000015482345],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063977875,0.0013026571,0.07086273,0.052720632,0.05257499,0.00057232653,0.0006844396,0.000034479606,0.000037247744,0.0000049259943,0.00013608491,0.8146717],"study_design_scores_gemma":[0.04371081,0.07979033,0.23821199,0.17083828,0.40523446,0.00003412724,0.0014958088,0.00010973332,0.00202674,0.00011024548,0.05541321,0.003024265],"about_ca_topic_score_codex":0.00031381287,"about_ca_topic_score_gemma":0.00042222845,"teacher_disagreement_score":0.8116474,"about_ca_system_score_codex":0.00066374405,"about_ca_system_score_gemma":0.0010281918,"threshold_uncertainty_score":0.99986565},"labels":[],"label_agreement":null},{"id":"W2781645346","doi":"10.1186/s13039-017-0348-y","title":"Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer","year":2018,"lang":"en","type":"article","venue":"Molecular Cytogenetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Conselho Nacional de Desenvolvimento Científico e Tecnológico; Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"PTEN; Biology; Aneuploidy; Prostate cancer; Cancer research; Transcriptome; Genome instability; Comparative genomic hybridization; Cancer; Copy number analysis; Genetics; Gene; Copy-number variation; PI3K/AKT/mTOR pathway; Genome; Gene expression; Signal transduction","score_opus":0.01716860800973375,"score_gpt":0.30861905048519195,"score_spread":0.2914504424754582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781645346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962485,0.002726807,0.000014349498,0.00045997612,0.000019540372,0.0003879872,0.000024407027,0.000004864914,0.00011357176],"genre_scores_gemma":[0.9989258,0.0006788534,0.00016928966,0.00007202567,0.000017883827,0.000022958426,0.000006159259,0.000013651865,0.00009338013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992613,0.00003689968,0.00022099512,0.00014578522,0.00017528968,0.00015972217],"domain_scores_gemma":[0.9994994,0.000036314897,0.000073361574,0.00020055853,0.00014588135,0.00004451425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013089973,0.00008846674,0.0001849254,0.00005082461,0.000024726904,0.0000052713335,0.0000717148,0.000035937825,0.000021633867],"category_scores_gemma":[0.000057956797,0.00005708268,0.000029986004,0.00015192619,0.0002678304,0.0000118983035,0.00006066921,0.00007236658,0.0000018788578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025686188,0.00003169143,0.80101496,0.000097865086,0.00003090793,0.000019515992,0.00031281722,0.000023551738,0.19683404,0.000009128681,0.0000062217655,0.0013624545],"study_design_scores_gemma":[0.0010246238,0.0004175499,0.7961711,0.0000480329,0.000054364336,0.000007669031,0.00004270408,0.000116320334,0.20187064,0.000055256205,0.00013846376,0.000053252526],"about_ca_topic_score_codex":0.0001893067,"about_ca_topic_score_gemma":0.00010073764,"teacher_disagreement_score":0.0050365846,"about_ca_system_score_codex":0.000029302759,"about_ca_system_score_gemma":0.0000925106,"threshold_uncertainty_score":0.23277642},"labels":[],"label_agreement":null},{"id":"W2781803975","doi":"10.1016/j.str.2017.12.007","title":"Order within a Disordered Structure","year":2018,"lang":"en","type":"letter","venue":"Structure","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Genome British Columbia","funders":"National Institutes of Health; National Cancer Institute; Academy of Finland","keywords":"Transactivation; Androgen receptor; Intrinsically disordered proteins; Domain (mathematical analysis); Chemistry; Cell biology; Protein structure; Biophysics; Transcriptional activity; Crystallography; Computational biology; Biology; Transcription factor; Biochemistry; Genetics; Gene","score_opus":0.014272198675235956,"score_gpt":0.29839658566797944,"score_spread":0.2841243869927435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781803975","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06034835,0.0027957894,0.000013874229,0.92336935,0.003144531,0.0023747028,0.0034641493,0.0003069245,0.0041823527],"genre_scores_gemma":[0.04229388,0.00016910667,0.003806445,0.8028364,0.032923907,0.000060808576,0.018559536,0.0004855351,0.09886435],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972116,0.000070929455,0.0003274479,0.000797405,0.0008639482,0.0007287102],"domain_scores_gemma":[0.9983093,0.000034092238,0.0001755018,0.00092042336,0.0004082688,0.00015239847],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.000039175844,0.00062301103,0.000748656,0.00024608517,0.00017158239,0.0000813632,0.00030789615,0.0017599078,0.006555362],"category_scores_gemma":[0.000079256344,0.00039903502,0.00017065485,0.00046089615,0.00037183848,0.00006224991,0.000116581534,0.0033455123,0.00006460606],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002164611,0.000008918433,0.00064317376,0.0006029488,0.00047318632,0.0008370407,0.00048154395,6.917815e-7,0.0008844244,0.000008556184,0.9949645,0.00087855366],"study_design_scores_gemma":[0.002458253,0.0004268879,0.0007654557,0.0002669094,0.0003592009,0.00033462586,0.00005447728,0.000016056747,0.0018385648,0.0040123872,0.9889605,0.0005067012],"about_ca_topic_score_codex":0.000053883978,"about_ca_topic_score_gemma":0.00007585674,"teacher_disagreement_score":0.12053289,"about_ca_system_score_codex":0.00020719602,"about_ca_system_score_gemma":0.0006990117,"threshold_uncertainty_score":0.99984616},"labels":[],"label_agreement":null},{"id":"W2782355925","doi":"10.1093/annonc/mdx361.028","title":"Treatment-induced hypoxia attenuates enzalutamide response and promotes resistance in pre-clinical models of prostate cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council","keywords":"Enzalutamide; LNCaP; Prostate cancer; Cancer research; Medicine; Hypoxia (environmental); Angiogenesis; In vivo; Androgen receptor; Cancer; Internal medicine; Biology; Chemistry","score_opus":0.2287695680566501,"score_gpt":0.4957445275805871,"score_spread":0.266974959523937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782355925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97799426,0.0043169186,3.5707325e-7,0.0153571945,0.000059149672,0.0008506489,0.00006124993,0.000009161677,0.0013510842],"genre_scores_gemma":[0.98566514,0.010405391,0.0002629229,0.000082289385,0.000041293584,0.00013656396,0.0000064709193,0.000016682323,0.0033832677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998381,0.00026699196,0.00052095193,0.000333294,0.0001658941,0.0003318613],"domain_scores_gemma":[0.9982811,0.00048709102,0.00037657,0.00046254921,0.0002560574,0.00013660388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008309536,0.00015258742,0.0007335798,0.00013209943,0.0000742155,0.000009767651,0.00013383363,0.00017345326,0.000015171679],"category_scores_gemma":[0.00051959325,0.00010999562,0.00008924656,0.00006951341,0.00051413145,0.00014325342,0.00007801679,0.00015146146,0.0000014507343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11331911,0.0030383898,0.63134754,0.00048017612,0.00077880634,0.0006484858,0.0070145447,0.0000070547408,0.066273764,0.00026875542,0.0008852008,0.17593819],"study_design_scores_gemma":[0.010980452,0.011412725,0.8900229,0.0004293519,0.00009115478,0.0000104584005,0.000114207614,0.00017914925,0.08121136,0.0030056627,0.0024004076,0.0001421872],"about_ca_topic_score_codex":0.0009276866,"about_ca_topic_score_gemma":0.0014182978,"teacher_disagreement_score":0.25867537,"about_ca_system_score_codex":0.000083812534,"about_ca_system_score_gemma":0.0008674422,"threshold_uncertainty_score":0.44854912},"labels":[],"label_agreement":null},{"id":"W2782456402","doi":"10.1038/modpathol.2017.158","title":"Treatment effects in prostate cancer","year":2018,"lang":"en","type":"review","venue":"Modern Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Radiation therapy; Prostate cancer; Disease; Androgen deprivation therapy; Ablative case; Clinical trial; Cancer; Chemotherapy; Oncology; Intensive care medicine; Surgery; Internal medicine","score_opus":0.07310665826743193,"score_gpt":0.4227359725410714,"score_spread":0.3496293142736395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782456402","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006388254,0.9947671,0.000008024025,0.00012994518,0.00032197777,0.003114076,0.000080804166,0.000052767453,0.000886464],"genre_scores_gemma":[0.00009286751,0.9853481,0.00009103167,0.000044963315,0.00026886724,0.0033413302,0.00027205216,0.00008649745,0.010454315],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99785596,0.0002418252,0.0003861137,0.0007313459,0.0001620649,0.0006226819],"domain_scores_gemma":[0.9990652,0.00010269384,0.00012320672,0.0005099373,0.000051590287,0.00014733957],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000117188094,0.0004717361,0.0020433534,0.00037134832,0.000043937725,0.0000116240235,0.000107927895,0.00034989326,0.000061316445],"category_scores_gemma":[0.000024863624,0.0002864806,0.00032702077,0.00024194173,0.00017867779,0.000026497215,0.00007211827,0.0003185682,0.0002425714],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011185611,0.00026915205,0.00047497687,0.011589363,0.00020111848,0.00645262,0.00037427127,1.9025663e-7,0.0000036808624,0.000007371383,0.00017691168,0.9803385],"study_design_scores_gemma":[0.003275303,0.0018084776,0.00015044452,0.009811333,0.0010497536,0.0007153622,0.0000033462702,0.00003609125,0.000019531448,0.00019098331,0.9826377,0.00030166563],"about_ca_topic_score_codex":0.00008231292,"about_ca_topic_score_gemma":0.00008332641,"teacher_disagreement_score":0.9824608,"about_ca_system_score_codex":0.0011503828,"about_ca_system_score_gemma":0.0009085327,"threshold_uncertainty_score":0.99995875},"labels":[],"label_agreement":null},{"id":"W2783025226","doi":"10.1093/annonc/mdx370.045","title":"Durable prostate cancer control in a randomized trial of optimal timing of dose escalated (76 Gy) radiation and 6 months ADT in prostate cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Urology; Goserelin; Radiation therapy; Context (archaeology); Proctitis; Internal medicine; Randomized controlled trial; Cancer; Oncology; Disease","score_opus":0.06274418392944638,"score_gpt":0.4282275056798431,"score_spread":0.3654833217503967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2783025226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846533,0.0047724186,0.000001030339,0.006247899,0.00012241524,0.0034971524,0.000081378035,0.0000051178527,0.00061928155],"genre_scores_gemma":[0.97970545,0.01903675,0.000051093506,0.00007315917,0.0000416144,0.0006739305,0.000014516603,0.0000143539555,0.00038912758],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99820507,0.00025516408,0.0007588783,0.00023766312,0.00020431017,0.00033894432],"domain_scores_gemma":[0.9983799,0.00031896128,0.0007056945,0.0002138888,0.00029496846,0.000086617125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013572364,0.00014483056,0.0014204395,0.00028633184,0.000041631847,0.000008185507,0.00009516234,0.0001375686,0.000056847228],"category_scores_gemma":[0.0005172498,0.00010871714,0.00010706651,0.0001315063,0.00046159138,0.0001560911,0.00004162209,0.0001888749,3.6224773e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8774269,0.0006422096,0.037975892,0.0002901642,0.0003365097,0.000071788716,0.0025260723,0.0002622276,0.008584051,0.00001448538,0.00021008578,0.07165961],"study_design_scores_gemma":[0.9340782,0.0028213249,0.040495086,0.0005189474,0.00013763382,0.0000025493223,0.00013236912,0.0061650444,0.01517625,0.000110554894,0.00025542622,0.00010657406],"about_ca_topic_score_codex":0.008547603,"about_ca_topic_score_gemma":0.00093531446,"teacher_disagreement_score":0.07155303,"about_ca_system_score_codex":0.000102104445,"about_ca_system_score_gemma":0.00087745395,"threshold_uncertainty_score":0.99805456},"labels":[],"label_agreement":null},{"id":"W2783442236","doi":"10.1530/erc-17-0493","title":"Sex steroids in the tumor microenvironment and prostate cancer progression","year":2018,"lang":"en","type":"review","venue":"Endocrine Related Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Prostate Cancer Canada; Movember Foundation","keywords":"Prostate cancer; Tumor microenvironment; Prostate; Context (archaeology); Medicine; Cancer; Tumor progression; Androgen; Sex steroid; Oncology; Testosterone (patch); Cancer research; Internal medicine; Biology; Steroid; Hormone","score_opus":0.03428621551525527,"score_gpt":0.3960438199909786,"score_spread":0.3617576044757233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2783442236","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022631227,0.9918986,8.904678e-8,0.0009221845,0.0002356073,0.0039319713,0.00011618414,0.000040408184,0.00059181295],"genre_scores_gemma":[0.00011853256,0.98592144,0.000025165762,0.00013109807,0.00028894635,0.0036214131,0.00016009802,0.00009891589,0.0096344035],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99713904,0.0002617987,0.0006324039,0.00073939277,0.0005071732,0.0007202079],"domain_scores_gemma":[0.9989496,0.00008018351,0.00026057803,0.0005058579,0.000036890575,0.0001669257],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028176766,0.00055478734,0.0012859217,0.00023732569,0.00012348816,0.000051144954,0.00021941683,0.0001440394,0.0004434618],"category_scores_gemma":[0.000014196676,0.00028712404,0.00021103749,0.0004791684,0.0003211554,0.000069808346,0.0001694237,0.0010436934,0.00005356986],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012650668,0.00018459858,0.0016513135,0.009820741,0.00049468165,0.0010559079,0.000569971,4.0958167e-7,0.000012131102,0.000003803992,0.008439593,0.97764033],"study_design_scores_gemma":[0.002109702,0.0003516999,0.0001527751,0.024607042,0.00092381553,0.00048867654,0.00005777196,0.0000050909916,0.00008692314,0.000011443197,0.97091573,0.0002892992],"about_ca_topic_score_codex":0.00025016302,"about_ca_topic_score_gemma":0.000050217543,"teacher_disagreement_score":0.97735107,"about_ca_system_score_codex":0.0008177462,"about_ca_system_score_gemma":0.0005596221,"threshold_uncertainty_score":0.9999581},"labels":[],"label_agreement":null},{"id":"W2783562181","doi":"10.1038/s41467-018-02863-3","title":"BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1","year":2018,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"Houston Methodist Research Institute; Strong; University of Texas MD Anderson Cancer Center; Cancer Prevention and Research Institute of Texas; Fred Hutchinson Cancer Research Center; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation; National Heart, Lung, and Blood Institute; U.S. Department of Defense","keywords":"BMI1; Prostate cancer; Cancer research; Androgen receptor; Enzalutamide; Cancer stem cell; Biology; Mdm2; Histone; Transcription factor; Cancer; Epigenetics; Stem cell; Cell biology; Cell culture; Gene; Genetics","score_opus":0.0426611873875686,"score_gpt":0.3812908964847689,"score_spread":0.3386297090972003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2783562181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.911361,0.02802179,5.050811e-7,0.046910785,0.00022845874,0.0016739663,0.0002690763,0.00004440725,0.011490055],"genre_scores_gemma":[0.99452466,0.0023688395,0.00049494865,0.00029356393,0.00005219269,0.00011615627,0.00009388882,0.000014760719,0.0020409655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990483,0.00013578156,0.00022183511,0.00016522115,0.00024612749,0.00018275593],"domain_scores_gemma":[0.99772155,0.00009727414,0.00012215548,0.0016141273,0.00038982363,0.000055076245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001679507,0.000096498436,0.0001869663,0.000096674135,0.00018089627,0.000010990528,0.0006187389,0.0001366588,0.00014590065],"category_scores_gemma":[0.0001280494,0.000060649338,0.00006614213,0.00055230357,0.00057493424,0.00005716459,0.00040273156,0.00067018345,0.000008936767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070426974,0.00063001027,0.8959228,0.000073036834,0.0002855601,0.0000033003562,0.004654101,0.0000024821043,0.064268894,0.0020978705,0.024286907,0.007070811],"study_design_scores_gemma":[0.0032482916,0.0001922205,0.7744633,0.000569745,0.00009201233,0.000016587535,0.00047320087,0.00022796163,0.12669806,0.00059377303,0.093255475,0.00016939268],"about_ca_topic_score_codex":0.0003239332,"about_ca_topic_score_gemma":0.0014984789,"teacher_disagreement_score":0.121459484,"about_ca_system_score_codex":0.00015332777,"about_ca_system_score_gemma":0.0002778229,"threshold_uncertainty_score":0.29116508},"labels":[],"label_agreement":null},{"id":"W2783798065","doi":"10.1038/s41588-018-0086-z","title":"Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets","year":2018,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":238,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Institute for Health and Care Research; Francis Crick Institute; Cancer Research UK; Wellcome Trust","keywords":"Prostate cancer; Biology; Chromoplexy; Cancer; Disease; Gene; Fusion gene; Mutation; Prostate; Bioinformatics; Genetics; Internal medicine; Medicine; PCA3","score_opus":0.017934515406397566,"score_gpt":0.34798363368850477,"score_spread":0.3300491182821072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2783798065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8455415,0.15295161,0.0000054154,0.0005688299,0.00024686757,0.0004261357,0.00003610972,0.000012826262,0.0002107299],"genre_scores_gemma":[0.98119307,0.012964951,0.002239735,0.00006378558,0.0003124607,0.000014929485,0.000019350864,0.000019953543,0.0031717874],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989955,0.000019176636,0.00020255196,0.00021776375,0.00034654752,0.0002184611],"domain_scores_gemma":[0.999189,0.0000177392,0.00012073289,0.00018359664,0.00036860607,0.000120312456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001058615,0.00012310625,0.00024046496,0.000093004,0.000050432172,0.000008825422,0.00007279431,0.00013368076,0.00003922824],"category_scores_gemma":[0.000022054359,0.000087069326,0.000037597154,0.000203655,0.00026265567,0.00003777347,0.000065456356,0.00019758599,7.274841e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010464808,0.00006224516,0.3425907,0.0015020787,0.00037917946,0.000029805657,0.007657435,0.000020866346,0.4440007,0.000021587643,0.008844982,0.19384393],"study_design_scores_gemma":[0.0012747883,0.0003402945,0.021229336,0.0005211079,0.00011156403,0.0000062718605,0.00024358109,0.00014521046,0.97077495,0.00018874842,0.0050670505,0.00009710891],"about_ca_topic_score_codex":0.00066428777,"about_ca_topic_score_gemma":0.00042262799,"teacher_disagreement_score":0.5267742,"about_ca_system_score_codex":0.00014416667,"about_ca_system_score_gemma":0.0008727665,"threshold_uncertainty_score":0.3550584},"labels":[],"label_agreement":null},{"id":"W2784538079","doi":"","title":"Predictive and prognostic biomarkers for next-generation hormonal agents in castration resistant prostate cancer","year":2015,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Prostate cancer; Medicine; Oncology; Hormone; Hormonal therapy; Internal medicine; Cancer","score_opus":0.17192351156637922,"score_gpt":0.37689348543715634,"score_spread":0.20496997387077712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784538079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933185,0.0015693471,0.00007973372,0.001957431,0.00007513369,0.0022147314,0.000058069734,0.000021939171,0.0007050877],"genre_scores_gemma":[0.9964617,0.00030286374,0.00069359585,0.0000577619,0.00009065412,0.00067520974,0.00023443329,0.000011160068,0.0014726456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99922776,0.000024353478,0.00014808407,0.00020966212,0.00019923504,0.00019090774],"domain_scores_gemma":[0.99957174,0.000024437415,0.0000299932,0.000060733815,0.00016908377,0.00014399944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020357581,0.0000874953,0.00011367361,0.00009820151,0.000040807525,0.000034663924,0.000017978258,0.000044856668,0.000012273022],"category_scores_gemma":[0.000069962414,0.00006266452,0.000017249222,0.0001298117,0.000051783176,0.000160552,0.000012250288,0.000049584978,0.0000011948471],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023747824,0.0007248636,0.64568347,0.0004911317,0.0005659179,0.00018265826,0.0050869854,0.00011291085,0.24257329,0.00026548837,0.03281099,0.047754437],"study_design_scores_gemma":[0.030439747,0.007747022,0.8166202,0.00043323246,0.00032060037,0.000035031437,0.0031163574,0.09482169,0.042010415,0.00070966774,0.003297444,0.0004486468],"about_ca_topic_score_codex":0.0002976696,"about_ca_topic_score_gemma":0.0005082599,"teacher_disagreement_score":0.20056288,"about_ca_system_score_codex":0.0002494898,"about_ca_system_score_gemma":0.00038932785,"threshold_uncertainty_score":0.2555385},"labels":[],"label_agreement":null},{"id":"W2784618326","doi":"10.21037/tau.2017.12.33","title":"On cribriform prostate cancer","year":2018,"lang":"en","type":"review","venue":"Translational Andrology and Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Cribriform; Prostate cancer; Medicine; Biopsy; Prostate; Cancer; Oncology; Pathology; Internal medicine; Carcinoma","score_opus":0.06358793693928325,"score_gpt":0.39502595537660434,"score_spread":0.3314380184373211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784618326","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002938293,0.9932016,0.0000054315483,0.0029073756,0.00018845336,0.00073267706,0.00018323881,0.00003150564,0.0024558702],"genre_scores_gemma":[0.00043005505,0.99551934,0.000021549997,0.0006806796,0.00028766444,0.00023115228,0.00052235136,0.000028386352,0.0022788248],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987022,0.000092288705,0.00028838712,0.0004451208,0.00012706916,0.00034492323],"domain_scores_gemma":[0.9993793,0.0002200798,0.00007728178,0.00013785594,0.000060061087,0.00012542417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013021009,0.00027944724,0.00095229014,0.0002124255,0.00012267915,0.0000061826067,0.00006018939,0.00050593965,0.00076534017],"category_scores_gemma":[0.0000099451345,0.0001800774,0.00017705005,0.00011797579,0.00046236863,0.000027756998,0.000015907888,0.00045595533,0.0001202295],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021498979,0.00017312825,0.0005327202,0.005136932,0.0010071633,0.00017205233,0.00013948385,0.0000010547702,4.235737e-7,0.0044051055,0.0027704681,0.98351157],"study_design_scores_gemma":[0.0013568476,0.0014413926,0.00031624292,0.00043801975,0.0009256057,0.00040506237,6.078309e-7,0.000015433074,4.508544e-7,0.0025875168,0.9923656,0.00014720943],"about_ca_topic_score_codex":0.000009286657,"about_ca_topic_score_gemma":0.000013783761,"teacher_disagreement_score":0.9895951,"about_ca_system_score_codex":0.000021266535,"about_ca_system_score_gemma":0.00039857122,"threshold_uncertainty_score":0.8379938},"labels":[],"label_agreement":null},{"id":"W2785712782","doi":"10.5489/cuaj.5206","title":"Supplementary data: Testosterone suppression in the treatment of recurrent or metastatic prostate cancer – A Canadian consensus statement","year":2018,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Statement (logic); Testosterone (patch); Prostate cancer; Medicine; Oncology; Cancer; Consensus conference; Prostate; Internal medicine; Gynecology; Political science","score_opus":0.09005870910743013,"score_gpt":0.3698893163997186,"score_spread":0.2798306072922885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785712782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90046346,0.0012364851,8.6112044e-7,0.091361605,0.0003846248,0.001268778,0.0050683552,0.00000454418,0.00021125919],"genre_scores_gemma":[0.99349475,0.0029104224,0.00018918187,0.0016823219,0.00027847837,0.00008756023,0.0008422498,0.0000125871875,0.00050245115],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99760795,0.00037494124,0.0005228827,0.00026455542,0.00048112104,0.00074853457],"domain_scores_gemma":[0.9982951,0.00021619449,0.0002345068,0.00027089426,0.00027999858,0.0007032539],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009556167,0.00017301552,0.00033075712,0.00031194394,0.00027407473,0.000059066486,0.00022371662,0.00007433134,0.0025878318],"category_scores_gemma":[0.0001899693,0.00008925396,0.000055531073,0.00034761237,0.000109664834,0.000061180916,0.00001735401,0.000264268,0.00001065613],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016174153,0.000664739,0.83994085,0.000029572626,0.0005710883,0.0013126667,0.0043285764,0.000009243746,0.000118029246,0.000016458676,0.116494365,0.034897007],"study_design_scores_gemma":[0.0076923682,0.007920457,0.2610706,0.00009899275,0.0003401643,0.00017919394,0.0017157954,0.00032310752,0.00021784962,0.0001566066,0.7200934,0.00019143587],"about_ca_topic_score_codex":0.3000801,"about_ca_topic_score_gemma":0.8153147,"teacher_disagreement_score":0.6035991,"about_ca_system_score_codex":0.003861324,"about_ca_system_score_gemma":0.0038167299,"threshold_uncertainty_score":0.9999627},"labels":[],"label_agreement":null},{"id":"W2786647130","doi":"10.1200/jco.2016.34.15_suppl.tps5090","title":"Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Docetaxel; Androgen deprivation therapy; Oncology; Internal medicine; Hazard ratio; Clinical endpoint; Cancer; Clinical trial; Androgen receptor; Confidence interval","score_opus":0.2290558006825888,"score_gpt":0.5371807235506563,"score_spread":0.3081249228680675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786647130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9653983,0.0019936028,0.00045172626,0.02573481,0.0012097626,0.0051041627,0.000050861032,0.0000053041126,0.000051463754],"genre_scores_gemma":[0.9705979,0.025358493,0.00073967286,0.0006124998,0.0018133465,0.00044358737,0.000008913386,0.000026523694,0.00039901427],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99499506,0.0009018076,0.003078417,0.00022423679,0.00047837466,0.00032209323],"domain_scores_gemma":[0.98630756,0.0105258385,0.002137183,0.00023899211,0.0005783355,0.00021207513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009147246,0.00017190131,0.0018620229,0.00019266,0.000054905937,0.000009253758,0.00021950495,0.00019743206,0.00013395217],"category_scores_gemma":[0.0077503948,0.00007281961,0.00072358927,0.00021674126,0.00033232413,0.00013764681,0.000027950498,0.00042227286,0.0000017358738],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69630414,0.0034273816,0.0012888848,0.000026352192,0.00061565917,0.000053536263,0.00014047665,0.0000068118093,0.000763583,0.000015695014,0.00072636147,0.2966311],"study_design_scores_gemma":[0.8962451,0.06222962,0.0007164611,0.00015589698,0.00039322238,0.000017107026,0.000042033673,0.00006962811,0.004106296,0.0013082626,0.034640666,0.00007566571],"about_ca_topic_score_codex":0.000037447153,"about_ca_topic_score_gemma":0.00008945126,"teacher_disagreement_score":0.29655543,"about_ca_system_score_codex":0.00023457043,"about_ca_system_score_gemma":0.002884775,"threshold_uncertainty_score":0.9278506},"labels":[],"label_agreement":null},{"id":"W2788020397","doi":"","title":"A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer.","year":2018,"lang":"en","type":"review","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Cabazitaxel; Guideline; Oncology; Denosumab; Internal medicine; Clinical trial; Abiraterone acetate; Cancer; Docetaxel; Nice; Disease; Family medicine; Gynecology; Intensive care medicine; Androgen deprivation therapy; Pathology","score_opus":0.411319150627699,"score_gpt":0.566350048075806,"score_spread":0.155030897448107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788020397","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.7382739e-7,0.9632211,0.0000042417105,0.0024788477,0.0004427278,0.032770153,0.00043891315,0.000029019599,0.0006148258],"genre_scores_gemma":[1.0433705e-7,0.92799985,0.0012052414,0.0007177416,0.0007786688,0.062783666,0.0003122585,0.00006193948,0.00614054],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99405086,0.0004085317,0.0038999582,0.0005239062,0.0006537299,0.00046299014],"domain_scores_gemma":[0.99082494,0.0012726815,0.002321607,0.000704131,0.004598732,0.00027789708],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005886158,0.00037394193,0.0047922526,0.000121845165,0.00005610699,0.000025684827,0.00022199168,0.00022664315,0.000018783967],"category_scores_gemma":[0.03338023,0.0002117405,0.0011180349,0.00039615264,0.0001381619,0.00009511354,0.000053134398,0.00026137612,0.00001310709],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012922435,0.00009173143,5.0532054e-7,0.6985433,0.0012575856,0.000016799837,0.0000057210777,2.5704516e-9,9.758834e-9,0.000009013297,0.026892513,0.2730536],"study_design_scores_gemma":[0.0004756401,0.000119392236,0.000002794604,0.47466412,0.010204798,0.00003278672,0.000009312105,5.6261524e-7,4.6292047e-7,0.0000025590127,0.51438755,0.00010000936],"about_ca_topic_score_codex":0.000037826172,"about_ca_topic_score_gemma":0.000008513072,"teacher_disagreement_score":0.48749503,"about_ca_system_score_codex":0.00024457506,"about_ca_system_score_gemma":0.0022729451,"threshold_uncertainty_score":0.974762},"labels":[],"label_agreement":null},{"id":"W2788051020","doi":"10.1038/nrurol.2018.22","title":"Cellular plasticity and the neuroendocrine phenotype in prostate cancer","year":2018,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":437,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Enzalutamide; Medicine; Neuroendocrine differentiation; Androgen receptor; Cancer research; Prostate; Phenotype; Reprogramming; Cancer; Oncology; Bioinformatics; Internal medicine; Cell; Biology; Genetics","score_opus":0.038228693148076975,"score_gpt":0.38455402192648164,"score_spread":0.34632532877840466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788051020","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000029920744,0.99209267,8.4421407e-7,0.0019852296,0.00042572708,0.00488437,0.000036446534,0.000020390362,0.00052438397],"genre_scores_gemma":[0.0000452889,0.9961087,0.000022004651,0.00091316557,0.00056013593,0.0010248922,0.0000877366,0.000056549878,0.0011815088],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969147,0.00091061206,0.0007220027,0.0006823147,0.00021249139,0.00055791944],"domain_scores_gemma":[0.99858284,0.0004363265,0.00032520233,0.00043916804,0.00008141725,0.00013503565],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00056439044,0.00050471345,0.0030868992,0.00022122159,0.000075754026,0.000018509258,0.00023792741,0.00033451716,0.0001507805],"category_scores_gemma":[0.00050453626,0.00022763958,0.00035702492,0.00055736373,0.0006004709,0.000030353402,0.00019330284,0.0026861755,0.00009099519],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005066977,0.00006768135,0.00010278113,0.025458524,0.0001983085,0.0005059845,0.000042464053,4.4278426e-8,6.986102e-7,0.00021806173,0.0050333817,0.96786535],"study_design_scores_gemma":[0.0021314907,0.00020416372,0.000023108669,0.0041842395,0.0015611842,0.00028736994,7.9148936e-7,0.0000066570856,0.0000010501132,0.00005859674,0.99137926,0.00016210714],"about_ca_topic_score_codex":0.00003762725,"about_ca_topic_score_gemma":0.000054419295,"teacher_disagreement_score":0.9863459,"about_ca_system_score_codex":0.00012279574,"about_ca_system_score_gemma":0.00039688457,"threshold_uncertainty_score":0.99961466},"labels":[],"label_agreement":null},{"id":"W2788130263","doi":"10.12688/f1000research.14026.1","title":"Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis","year":2018,"lang":"en","type":"preprint","venue":"F1000Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Oncology; Androgen deprivation therapy; Meta-analysis; Prostate-specific antigen; Internal medicine; Inclusion and exclusion criteria; Hazard ratio; Cochrane Library; Proportional hazards model; Cancer; Survival analysis; Prostate; Gynecology; Pathology; Confidence interval","score_opus":0.1654239611269785,"score_gpt":0.41659422464150947,"score_spread":0.251170263514531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788130263","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4047857,0.5617439,0.00002148811,0.004365461,0.000057517915,0.028118216,0.00062959973,0.000108623666,0.00016948594],"genre_scores_gemma":[0.57968616,0.3972311,0.00062912545,0.00038189488,0.00008524638,0.015345648,0.0009080518,0.00021210591,0.005520669],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99188435,0.001549354,0.0015431221,0.0017083811,0.002131588,0.0011831784],"domain_scores_gemma":[0.99556625,0.00054988643,0.00056271325,0.0015686925,0.0012335957,0.0005188453],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028862213,0.00085516163,0.004690578,0.001740668,0.00019386753,0.00038007216,0.0005732682,0.0002443777,0.0019751997],"category_scores_gemma":[0.0008295577,0.0005624404,0.00090173783,0.002647057,0.00040609637,0.0001952607,0.0007919246,0.0013063698,0.00011467538],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013798795,0.0010063269,0.1341831,0.59984076,0.25547886,0.0009971331,0.0038981775,0.000057971618,0.0011757961,0.000020971514,0.0009858087,0.00097521057],"study_design_scores_gemma":[0.009096466,0.003752986,0.1963951,0.068480834,0.70669025,0.00017790524,0.0006485823,0.0019823818,0.0058726054,0.0024635189,0.0010999336,0.0033394212],"about_ca_topic_score_codex":0.0012622086,"about_ca_topic_score_gemma":0.0002248589,"teacher_disagreement_score":0.53136,"about_ca_system_score_codex":0.0006006845,"about_ca_system_score_gemma":0.0012161678,"threshold_uncertainty_score":0.9996827},"labels":[],"label_agreement":null},{"id":"W2788160989","doi":"10.1093/annonc/mdy072","title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":250,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute for Health and Care Research; Cancer Research UK; Sanofi; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Pfizer; Royal Marsden NHS Foundation Trust; Astellas Pharma; Ipsen; Clovis Oncology; Institute of Cancer Research; Medical Research Council; National Institute on Handicapped Research; Public Health Agency; Eli Lilly and Company","keywords":"Medicine; Docetaxel; Prostate cancer; Abiraterone acetate; Androgen deprivation therapy; Oncology; Abiraterone; Prednisolone; Internal medicine; Protocol (science); Randomized controlled trial; Cancer; Androgen receptor; Pathology","score_opus":0.39583597424977157,"score_gpt":0.5256163290702124,"score_spread":0.1297803548204408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788160989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7982756,0.0017719218,0.000748313,0.008470363,0.0002505183,0.18611033,0.0040416787,0.00010022396,0.00023105447],"genre_scores_gemma":[0.52048945,0.009612642,0.01458457,0.008333503,0.0023597009,0.4227449,0.0024713927,0.00029314242,0.019110704],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997567,0.00012508211,0.0006136826,0.0006533757,0.0003092536,0.0007315969],"domain_scores_gemma":[0.9972627,0.0006396992,0.00032235577,0.00091885147,0.0005887807,0.00026760218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009881554,0.00031596894,0.00082490407,0.00011185615,0.00026677758,0.000042913824,0.0006249565,0.00017096922,0.00048561467],"category_scores_gemma":[0.00030570955,0.00016706839,0.00012035793,0.00024700898,0.00038499065,0.00022368318,0.00026994094,0.00022293338,0.00002632311],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45958364,0.003919965,0.019922856,0.00029763978,0.001986941,0.00014170357,0.0051928316,0.000004152374,0.10259876,0.000005878895,0.038199738,0.36814588],"study_design_scores_gemma":[0.33617458,0.034314897,0.07616043,0.0005702282,0.00022535937,0.000012373996,0.0005431611,0.0015487294,0.22237988,0.000024781008,0.32742885,0.000616717],"about_ca_topic_score_codex":0.0010615072,"about_ca_topic_score_gemma":0.0026264812,"teacher_disagreement_score":0.36752918,"about_ca_system_score_codex":0.00012434622,"about_ca_system_score_gemma":0.0009761278,"threshold_uncertainty_score":0.6812851},"labels":[],"label_agreement":null},{"id":"W2788449140","doi":"10.2147/rru.s157116","title":"Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens","year":2018,"lang":"en","type":"review","venue":"Research and Reports in Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Cancer Institute","keywords":"Antiandrogens; Enzalutamide; Prostate cancer; Medicine; Androgen receptor; Blocking (statistics); Drug development; Drug; Antiandrogen; Androgen; Pharmacology; Cancer; Internal medicine; Hormone","score_opus":0.11026817558250841,"score_gpt":0.41926288534232337,"score_spread":0.30899470975981497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788449140","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14606504,0.85184854,1.970882e-7,0.00034776126,0.00017018871,0.0013927113,0.000031982356,0.0000055932333,0.00013798686],"genre_scores_gemma":[0.010639763,0.9873344,0.00016024374,0.000009742137,0.00006080069,0.0002966594,0.00008964718,0.000036174457,0.0013725847],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966669,0.00048627358,0.0010543718,0.00068053143,0.0005049591,0.0006069583],"domain_scores_gemma":[0.9981657,0.0005989357,0.00040969255,0.00043458742,0.00023864827,0.00015240877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024518545,0.0002554907,0.0014309577,0.0005407355,0.00007658527,0.000006612184,0.00013592356,0.0002587172,0.00005575644],"category_scores_gemma":[0.000290513,0.00015661227,0.00008370033,0.0004005431,0.0012869657,0.00003537443,0.0003218799,0.0008944084,0.0000010221746],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007132035,0.0003287132,0.054534692,0.00886676,0.0005340191,0.0011888685,0.0062553124,8.642412e-7,0.0002650486,0.000010569522,0.001321248,0.9259807],"study_design_scores_gemma":[0.0010381863,0.00036511157,0.0017888796,0.0068021524,0.00010807044,0.0001708612,0.00024813696,0.0000031135928,0.00030921333,0.00010362707,0.9889003,0.00016237283],"about_ca_topic_score_codex":0.0009607629,"about_ca_topic_score_gemma":0.0012018725,"teacher_disagreement_score":0.98757905,"about_ca_system_score_codex":0.0006204544,"about_ca_system_score_gemma":0.0042965086,"threshold_uncertainty_score":0.7621822},"labels":[],"label_agreement":null},{"id":"W2788936567","doi":"10.1016/j.eururo.2018.01.029","title":"Is 68 Ga-Prostate-specific Membrane Antigen–ligand Positron Emission Tomography/Computed Tomography Ready To Simplify the Conundrum of Biochemically Recurrent Prostate Cancer?","year":2018,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Glutamate carboxypeptidase II; Prostate cancer; Positron emission tomography; Prostate; Positron Emission Tomography-Computed Tomography; Tomography; Computed tomography; Nuclear medicine; Prostate-specific antigen; Ligand (biochemistry); Cancer; Radiology; Internal medicine; Receptor","score_opus":0.0271435183773459,"score_gpt":0.296689163182916,"score_spread":0.2695456448055701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788936567","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4123736,0.021629678,0.00002196425,0.55343205,0.0018405565,0.0044502844,0.0016178322,0.00026506436,0.0043690023],"genre_scores_gemma":[0.37522116,0.025832336,0.0006112388,0.5648473,0.011862529,0.00040561424,0.008344146,0.0010387608,0.0118369125],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99451077,0.00074186677,0.0010224953,0.001499498,0.00086181716,0.0013635253],"domain_scores_gemma":[0.99660414,0.00023235199,0.00053160486,0.0014531406,0.0007803049,0.0003984347],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00065396045,0.00084666506,0.0011594009,0.00082467525,0.00026759037,0.00007775781,0.00085622433,0.00050568726,0.00028328274],"category_scores_gemma":[0.00004489305,0.00055990525,0.00047506488,0.0011619303,0.0010038982,0.00005112386,0.00047947015,0.0020887314,0.0002031112],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033830418,0.00019192051,0.004406628,0.0004792555,0.0007519527,0.0009064846,0.0011934587,0.000001424289,0.08315943,0.0000024664816,0.9012093,0.0043146284],"study_design_scores_gemma":[0.0025106254,0.0036908118,0.0074144225,0.00048168385,0.00031168724,0.0001038966,0.000029341763,0.000011577463,0.070363656,0.000026148216,0.9145176,0.00053855416],"about_ca_topic_score_codex":0.00007972609,"about_ca_topic_score_gemma":0.000003344102,"teacher_disagreement_score":0.037152447,"about_ca_system_score_codex":0.00011486066,"about_ca_system_score_gemma":0.00026095659,"threshold_uncertainty_score":0.9996852},"labels":[],"label_agreement":null},{"id":"W2789314039","doi":"10.1200/jco.2018.36.6_suppl.177","title":"Can free PSA be used as a biomarker in biochemical recurrence after surgery to predict castrate resistant prostate cancer?","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Biochemical recurrence; Prostatectomy; Urology; Logistic regression; Proportional hazards model; Internal medicine; Log-rank test; Metastasis; Oncology; Cancer; Gynecology","score_opus":0.17696429631986602,"score_gpt":0.4961325265548144,"score_spread":0.31916823023494834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789314039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9349647,0.0009055591,0.0000019775414,0.061939083,0.0010847095,0.00043620978,0.0000699724,0.000009054721,0.00058873696],"genre_scores_gemma":[0.99426717,0.0014071811,0.00043470334,0.002260529,0.0008501219,0.00005693963,0.0000060123907,0.000022067714,0.0006952753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959882,0.00043970323,0.002040152,0.00035171115,0.0006323123,0.000547915],"domain_scores_gemma":[0.9959072,0.0015682612,0.0006386171,0.00032563068,0.00068803196,0.0008722778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037313374,0.00019015299,0.001313345,0.0003414113,0.000035627596,0.000017617229,0.00022828348,0.00035042167,0.0003815284],"category_scores_gemma":[0.0047621727,0.00012669989,0.00032728203,0.0005183338,0.00057442643,0.00008505885,0.00012268491,0.0008798956,0.000017797323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12986186,0.0023376292,0.6606529,0.00015403678,0.0006281202,0.011026462,0.00092844013,5.335683e-7,0.008568733,0.000011441032,0.120409064,0.06542082],"study_design_scores_gemma":[0.012245882,0.018708182,0.89681995,0.001443389,0.00024805916,0.00031828013,0.00017871204,0.000035546,0.004780416,0.00056152244,0.064407155,0.00025288056],"about_ca_topic_score_codex":0.00042916485,"about_ca_topic_score_gemma":0.0017127714,"teacher_disagreement_score":0.23616712,"about_ca_system_score_codex":0.000531317,"about_ca_system_score_gemma":0.0065821237,"threshold_uncertainty_score":0.99904966},"labels":[],"label_agreement":null},{"id":"W2789372688","doi":"10.1111/bju.13923","title":"Selecting patients for prostate cancer treatment: the role of comorbidity","year":2018,"lang":"en","type":"letter","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Comorbidity; Cancer; Internal medicine; Prostate; Diabetes mellitus; Oncology; Disease; Life expectancy; Gynecology; Endocrinology; Population","score_opus":0.024086308148098708,"score_gpt":0.31009449980936055,"score_spread":0.28600819166126185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789372688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57356066,0.073945686,0.00001645695,0.3430569,0.0022357565,0.0038863264,0.0017674867,0.000025758096,0.0015049749],"genre_scores_gemma":[0.73316944,0.05591992,0.00043223097,0.17324017,0.025974011,0.00054466445,0.0011430483,0.00033864746,0.009237847],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984017,0.0001493858,0.000510128,0.00019170334,0.0003232113,0.00042384554],"domain_scores_gemma":[0.99773276,0.00023766316,0.00069491786,0.00014100793,0.0011267177,0.000066918285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025507365,0.00018076942,0.0006561065,0.0001208029,0.000137835,0.000023386203,0.000179778,0.00032469825,0.00009034882],"category_scores_gemma":[0.00012748926,0.00012403973,0.0002919494,0.000104322666,0.00026540676,0.00004647918,0.000031169944,0.0008474803,0.000002049138],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016657483,0.00033261025,0.029050035,0.00019624554,0.0014425452,0.00053930265,0.00041595445,0.0000019665072,0.00010304075,6.1353194e-7,0.7961937,0.17005822],"study_design_scores_gemma":[0.0058353706,0.006996276,0.0055478285,0.00024863906,0.0007845038,0.0015118038,0.000027961256,0.000019362504,0.00095294084,0.00029611652,0.97766805,0.00011116524],"about_ca_topic_score_codex":0.0005212068,"about_ca_topic_score_gemma":0.0001004569,"teacher_disagreement_score":0.18147433,"about_ca_system_score_codex":0.00021687875,"about_ca_system_score_gemma":0.0005706999,"threshold_uncertainty_score":0.5058193},"labels":[],"label_agreement":null},{"id":"W2789446608","doi":"10.1200/jco.2018.36.6_suppl.125","title":"Validation of a genomic risk classifier to predict metastasis and prostate cancer-specific mortality in men with positive lymph nodes.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Oncology; Internal medicine; Nomogram; Metastasis; Adjuvant; Adjuvant therapy; Logistic regression; Cohort; Lymph node; Proportional hazards model; Cancer","score_opus":0.12874924338815455,"score_gpt":0.4716844526941577,"score_spread":0.3429352093060032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789446608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948286,0.0006900249,0.00007132374,0.0023483967,0.000141057,0.00044548835,0.00005439493,0.0000029490889,0.0014177676],"genre_scores_gemma":[0.99311596,0.0047177854,0.0014544082,0.00015588565,0.00036325364,0.00001455507,0.0000041447347,0.000011996956,0.00016201736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766606,0.0004111813,0.0011846973,0.00020660582,0.00032536915,0.0002060778],"domain_scores_gemma":[0.99757934,0.0005044277,0.0008761698,0.00013569808,0.00060868147,0.00029571156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026105412,0.00010800317,0.0009535667,0.00017571666,0.00003233674,0.000007828377,0.000079384896,0.00013651437,0.00007754621],"category_scores_gemma":[0.00029787028,0.00006486326,0.000104571714,0.00019411305,0.00042449572,0.00009653608,0.000046716792,0.0003714788,0.0000036649938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018073156,0.00062532385,0.912385,0.0000260654,0.0006899032,0.00016990516,0.0006463195,0.000015830305,0.0014017776,0.000011192961,0.0004894991,0.06546603],"study_design_scores_gemma":[0.010879662,0.010089136,0.97305834,0.00015426452,0.0004032485,0.000045856512,0.00024338737,0.00008569709,0.0033617504,0.00012475932,0.001492335,0.000061532046],"about_ca_topic_score_codex":0.00026861992,"about_ca_topic_score_gemma":0.000088004585,"teacher_disagreement_score":0.0654045,"about_ca_system_score_codex":0.0003506471,"about_ca_system_score_gemma":0.0014865526,"threshold_uncertainty_score":0.26450473},"labels":[],"label_agreement":null},{"id":"W2789460069","doi":"10.1158/1078-0432.ccr-17-3771","title":"Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Prostatectomy; Histopathology; Medicine; Prostate cancer; Lymph node; Dissection (medical); Biochemical recurrence; Urology; Lymph; Cancer; Internal medicine; Pathology; Surgery","score_opus":0.08283417945246835,"score_gpt":0.45806292069891635,"score_spread":0.375228741246448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789460069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906571,0.0013907773,0.000310466,0.0015417206,0.0002689245,0.0050242227,0.00023970808,0.00007200469,0.00049510296],"genre_scores_gemma":[0.992239,0.0021873557,0.0007347713,0.00010121476,0.0003971165,0.0032416524,0.0003176654,0.00010535143,0.0006758808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946298,0.0004297104,0.0009482738,0.0010589677,0.0016304888,0.0013027759],"domain_scores_gemma":[0.9943383,0.00093281793,0.00027605862,0.0006026387,0.0032203188,0.00062989705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014332324,0.00031799808,0.00064034335,0.00032659655,0.00037732432,0.000086761494,0.0002483274,0.00024356038,0.00016562523],"category_scores_gemma":[0.0012639166,0.0002284814,0.00018018854,0.0010682573,0.0017883937,0.0002015988,0.00011324088,0.0005632028,0.000018746085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021640614,0.0021093546,0.9323837,0.0017525443,0.00050038396,0.000032333057,0.00045203403,0.000033061882,0.005057724,0.00017939688,0.00037106904,0.03548778],"study_design_scores_gemma":[0.028569033,0.007089034,0.916304,0.0022157517,0.00032104758,0.000006556505,0.0004290476,0.0019346952,0.04105086,0.00083845144,0.0007882017,0.0004533582],"about_ca_topic_score_codex":0.00057749957,"about_ca_topic_score_gemma":0.0001834118,"teacher_disagreement_score":0.035993133,"about_ca_system_score_codex":0.0010210323,"about_ca_system_score_gemma":0.0048986305,"threshold_uncertainty_score":0.9317201},"labels":[],"label_agreement":null},{"id":"W2789521745","doi":"10.1200/jco.2018.36.6_suppl.161","title":"SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Abiraterone acetate; Clinical endpoint; Randomization; Metastasis; Oncology; Urology; Randomized controlled trial; Doubling time; Cancer; Placebo; Androgen deprivation therapy; Pathology; Cell","score_opus":0.20043449565867036,"score_gpt":0.526148373794619,"score_spread":0.32571387813594865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789521745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99390286,0.00019774852,0.000011928625,0.00091274374,0.00080803887,0.0034130004,0.000013511941,0.0000052952078,0.00073485624],"genre_scores_gemma":[0.9981583,0.00032315592,0.0005184543,0.00010258632,0.00041386634,0.0001215565,0.0000087162625,0.000023975093,0.00032940166],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943275,0.0010887187,0.0030476174,0.00028688574,0.00086346775,0.00038581644],"domain_scores_gemma":[0.99306625,0.0026755894,0.0022483529,0.000234346,0.0014236325,0.00035183932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046010297,0.0002190316,0.002539105,0.00031499294,0.000063898755,0.000011246558,0.0001604172,0.00017977088,0.00021334596],"category_scores_gemma":[0.0013877103,0.00012615079,0.0002497723,0.00038409219,0.00070029846,0.00016254814,0.00004419232,0.0008603242,0.000009108842],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90423185,0.012190658,0.069582954,0.000059013222,0.0017154274,0.0004702148,0.0017931903,0.000030825446,0.00006609736,0.000008739568,0.00022114239,0.009629879],"study_design_scores_gemma":[0.8704489,0.101083934,0.02499707,0.00023325284,0.0011820786,0.000007763694,0.0011466774,0.00009250773,0.00014272967,0.000022550434,0.0005364104,0.0001061512],"about_ca_topic_score_codex":0.00041204868,"about_ca_topic_score_gemma":0.003601458,"teacher_disagreement_score":0.08889327,"about_ca_system_score_codex":0.00039008388,"about_ca_system_score_gemma":0.003117737,"threshold_uncertainty_score":0.5530731},"labels":[],"label_agreement":null},{"id":"W2789730857","doi":"10.1158/2159-8290.cd-17-0937","title":"Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":522,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Interior Health; BC Cancer Agency; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Astellas Pharma; Emil Aaltosen Säätiö; Prostate Cancer Canada; DOD Prostate Cancer Research Program; Terry Fox Research Institute; Movember Foundation; Prostate Cancer Foundation","keywords":"Enzalutamide; Prostate cancer; Abiraterone; Androgen receptor; Cancer; Liquid biopsy; Medicine; Oncology; Internal medicine; Circulating tumor cell; Cancer research; Biomarker; Cancer biomarkers; Exome sequencing; Gene; Biology; Mutation; Genetics; Metastasis","score_opus":0.018011082543391822,"score_gpt":0.29969906522039114,"score_spread":0.2816879826769993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789730857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905329,0.0053349524,0.000034815326,0.0016790043,0.00018071957,0.0009708951,0.00009863913,0.000031823824,0.0011362662],"genre_scores_gemma":[0.98890686,0.0011313013,0.00021241087,0.000838414,0.00027014813,0.0004266819,0.000013255634,0.000054027332,0.008146919],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984204,0.000028016902,0.00024786257,0.00052409177,0.00024961133,0.00053000916],"domain_scores_gemma":[0.9993083,0.000028404449,0.00008043363,0.00026517658,0.000115015006,0.00020269757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013657103,0.00022290518,0.00034427247,0.00013880775,0.00011304612,0.00008406627,0.00007755506,0.000039316707,0.000051055824],"category_scores_gemma":[0.000017239048,0.00016499365,0.000027819578,0.0003967812,0.00025395228,0.0002829635,0.00007184925,0.00019818037,0.000011424534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013819178,0.00019101806,0.8164281,0.0009844726,0.0003659961,0.0013554614,0.0089955935,0.00040759364,0.14562003,0.00019239027,0.0018431434,0.009796992],"study_design_scores_gemma":[0.012513602,0.0013620887,0.8857852,0.0054730433,0.00024413662,0.000095677984,0.0013475013,0.00036236737,0.07726351,0.0002727594,0.014288296,0.0009917725],"about_ca_topic_score_codex":0.00079679006,"about_ca_topic_score_gemma":0.0045598,"teacher_disagreement_score":0.06935712,"about_ca_system_score_codex":0.0008204933,"about_ca_system_score_gemma":0.0008316107,"threshold_uncertainty_score":0.67282456},"labels":[],"label_agreement":null},{"id":"W2789780764","doi":"10.1111/bju.14138","title":"External validation of the prostascore model in patients with metastatic hormone‐sensitive prostate cancer recruited to the CHAARTED study","year":2018,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Prostate cancer; Medicine; Oncology; Cancer; Internal medicine; Prostate; Gynecology","score_opus":0.02963295224274577,"score_gpt":0.3140381079553484,"score_spread":0.28440515571260266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789780764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959626,0.0004641127,0.00009567065,0.0015599063,0.00008199236,0.0017632982,0.00004782923,0.0000028424547,0.000021748747],"genre_scores_gemma":[0.99924445,0.00011979232,0.000125165,0.00027654745,0.00005887797,0.00004413246,0.000004554028,0.000015215673,0.000111272544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985453,0.00025392708,0.00037186564,0.00014387784,0.00045705182,0.00022799129],"domain_scores_gemma":[0.9984843,0.000038225742,0.00027455983,0.0001407471,0.0009875007,0.00007466371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046408278,0.00009626172,0.00029625566,0.00012285486,0.000081641956,0.00001695971,0.00013029463,0.000027649814,0.00001268872],"category_scores_gemma":[0.00010728956,0.000052732197,0.000045339406,0.00037267318,0.00017930017,0.00008584911,0.000051842737,0.00029839601,0.00000135882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03007468,0.0029464841,0.8888728,0.000042405773,0.0009052012,0.00060107256,0.015538836,0.0025941408,0.0026966312,0.000004913477,0.0013170058,0.054405812],"study_design_scores_gemma":[0.008751184,0.0070237797,0.9812929,0.0001929725,0.00022144866,0.00022144584,0.00039407937,0.00049353874,0.0012658987,0.000050255803,0.000031099178,0.000061410465],"about_ca_topic_score_codex":0.00022718454,"about_ca_topic_score_gemma":0.00040487738,"teacher_disagreement_score":0.09242007,"about_ca_system_score_codex":0.00008853833,"about_ca_system_score_gemma":0.0002783402,"threshold_uncertainty_score":0.21503566},"labels":[],"label_agreement":null},{"id":"W2789828078","doi":"10.1016/j.ejca.2018.01.115","title":"RE: Rydzewska et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J Cancer. 2017 Oct; 84:88–101","year":2018,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Prostate cancer; Abiraterone acetate; Androgen deprivation therapy; Medicine; Oncology; Abiraterone; Hormone therapy; Internal medicine; Cancer; Testosterone (patch); Gynecology; Androgen receptor; Breast cancer","score_opus":0.1329532489911135,"score_gpt":0.41736354855507046,"score_spread":0.28441029956395697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789828078","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013308367,0.9880377,0.00003124209,0.005688155,0.000051339764,0.0053572874,0.0003704461,0.000016215887,0.00031452856],"genre_scores_gemma":[0.0002791562,0.9930595,0.00034083737,0.003298044,0.000107408305,0.00076978165,0.000055942044,0.00016315696,0.001926135],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9929382,0.002556415,0.0021406664,0.0007304623,0.0010689526,0.0005652878],"domain_scores_gemma":[0.9949639,0.00017741337,0.00264977,0.0006194326,0.0011345673,0.00045491927],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0043287287,0.00082268787,0.0080832895,0.0008957381,0.00011288698,0.00014034104,0.00036155226,0.00005063935,0.00015618165],"category_scores_gemma":[0.0001366675,0.00043443838,0.0010029805,0.0016692281,0.00013619846,0.00029788786,0.00010482772,0.0007559836,0.000016041024],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021854115,0.00029184917,0.00012492744,0.3771465,0.5120145,0.004589186,0.003666266,0.000078526704,0.000037814774,0.000003719956,0.04697644,0.052884873],"study_design_scores_gemma":[0.0034097466,0.0018724566,0.00014254084,0.1542736,0.613596,0.00029719016,0.00017371385,0.00000879171,0.00003147664,0.0000013845121,0.22547205,0.0007210044],"about_ca_topic_score_codex":0.0002323436,"about_ca_topic_score_gemma":0.00036462274,"teacher_disagreement_score":0.2228729,"about_ca_system_score_codex":0.00078295043,"about_ca_system_score_gemma":0.0011554606,"threshold_uncertainty_score":0.99981076},"labels":[],"label_agreement":null},{"id":"W2789828472","doi":"10.1200/jco.2018.36.6_suppl.201","title":"Medical resource utilization (MRU) of abiraterone acetate plus prednisone (AAP) added to androgen deprivation therapy (ADT) in metastatic castration-naive prostate cancer: Results from LATITUDE.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Poisson regression; Abiraterone acetate; Radiation therapy; Prednisone; Internal medicine; Urology; Cancer; Population","score_opus":0.23642984274115264,"score_gpt":0.5089289953838686,"score_spread":0.27249915264271596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789828472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98626286,0.00093667716,0.0003246062,0.010907766,0.00035163658,0.0007901081,0.00007009237,0.000009362782,0.0003468841],"genre_scores_gemma":[0.9904245,0.004197424,0.0034162935,0.00090423157,0.00067190983,0.000024966808,0.000075745054,0.000021395119,0.00026349633],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99518275,0.00069601566,0.0026727484,0.00030532142,0.0008584896,0.000284683],"domain_scores_gemma":[0.9958284,0.0012633548,0.0013705735,0.00022935761,0.00087431393,0.00043400732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033875725,0.00016403131,0.001216723,0.00023955984,0.00004607079,0.0000127020785,0.00019768819,0.0002645771,0.0002485475],"category_scores_gemma":[0.0032568304,0.00011159057,0.00015188428,0.00042501587,0.0003384532,0.00015749542,0.000057654102,0.0005557996,0.000011752119],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16464476,0.0034210775,0.13881657,0.00008717729,0.0018198086,0.0010414756,0.010224297,0.0005833071,0.0044456166,0.000062011146,0.006025945,0.66882795],"study_design_scores_gemma":[0.14735894,0.047052108,0.72547626,0.0016353241,0.00059100153,0.00012642023,0.0013146017,0.006604329,0.02388747,0.0013869388,0.044164084,0.0004025171],"about_ca_topic_score_codex":0.00046254348,"about_ca_topic_score_gemma":0.001260725,"teacher_disagreement_score":0.66842544,"about_ca_system_score_codex":0.00032769062,"about_ca_system_score_gemma":0.003607288,"threshold_uncertainty_score":0.6399174},"labels":[],"label_agreement":null},{"id":"W2789877692","doi":"10.1200/jco.2018.36.6_suppl.225","title":"Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Docetaxel; Cabozantinib; Oncology; Internal medicine; Prostate cancer; Hazard ratio; Proportional hazards model; Enzalutamide; Cancer; Confidence interval; Androgen receptor","score_opus":0.3196519608841015,"score_gpt":0.6077363090943942,"score_spread":0.2880843482102927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789877692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99099976,0.0013325223,0.0005859166,0.004235842,0.001280447,0.0010360336,0.00011918343,0.000008042976,0.0004022395],"genre_scores_gemma":[0.9924675,0.0007398809,0.004660249,0.00036817274,0.00080681243,0.0000465544,0.000037024816,0.000020208669,0.0008535442],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937087,0.000767468,0.004345875,0.00025314552,0.0005675719,0.0003572095],"domain_scores_gemma":[0.9899462,0.0045521115,0.0033280847,0.00022333457,0.0015426963,0.00040755808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011111678,0.00018207911,0.0039996025,0.00049511524,0.000093024566,0.000017728637,0.00016277232,0.00014729344,0.00031490394],"category_scores_gemma":[0.005293256,0.000111906316,0.0020044069,0.000751956,0.0003597403,0.00013972832,0.000029492321,0.0004259737,0.0000020900802],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44295087,0.018470356,0.049717303,0.00043228013,0.1290286,0.0021050298,0.0023546624,0.00017973174,0.051094595,0.00094365695,0.011617144,0.29110578],"study_design_scores_gemma":[0.61198616,0.14753309,0.03899994,0.00069579965,0.119393855,0.00006377708,0.0012737827,0.0064856894,0.017983377,0.0018864837,0.053146522,0.0005515132],"about_ca_topic_score_codex":0.00017003343,"about_ca_topic_score_gemma":0.0004954592,"teacher_disagreement_score":0.29055426,"about_ca_system_score_codex":0.00015431666,"about_ca_system_score_gemma":0.003770661,"threshold_uncertainty_score":0.66889906},"labels":[],"label_agreement":null},{"id":"W2790003199","doi":"10.1097/rlu.0000000000001966","title":"Flare on Serial Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT Examinations in Castration-Resistant Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Biomedical Imaging and Bioengineering; National Cancer Institute","keywords":"Medicine; Prostate cancer; Antigen; Lymph node; Prostate; Glutamate carboxypeptidase II; Enzalutamide; Prostate-specific antigen; Oncology; Pathology; Cancer research; Urology; Internal medicine; Cancer; Androgen receptor; Immunology","score_opus":0.08254309325865937,"score_gpt":0.4070031418211946,"score_spread":0.32446004856253524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790003199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97492725,0.00097099063,6.3021656e-7,0.016673805,0.0013809546,0.0018363616,0.00009155509,0.00013479835,0.003983631],"genre_scores_gemma":[0.9869961,0.005983481,0.00019224858,0.0013052123,0.0020833174,0.000086825756,0.00027893813,0.00009241705,0.00298145],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9962624,0.00025119545,0.0011564039,0.00083648553,0.000802116,0.0006914153],"domain_scores_gemma":[0.99784344,0.00034716728,0.00020891838,0.0006067993,0.0004880644,0.000505589],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011364414,0.0003551177,0.0008297524,0.00031351158,0.00026648518,0.000036805828,0.0002084176,0.000058066693,0.003581802],"category_scores_gemma":[0.00064402714,0.0002500393,0.00013599524,0.00077023153,0.001258273,0.00014319627,0.0000677997,0.0007649903,0.000316234],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07920835,0.009759077,0.19323578,0.0018217311,0.0017528612,0.033435978,0.011621489,0.000046488778,0.2895059,0.0027660457,0.28676227,0.09008401],"study_design_scores_gemma":[0.04188607,0.018431477,0.64785403,0.003690589,0.0002735541,0.00026434497,0.0029642745,0.0009292679,0.0056414427,0.00019817201,0.27699852,0.0008682468],"about_ca_topic_score_codex":0.0003233877,"about_ca_topic_score_gemma":0.00039320142,"teacher_disagreement_score":0.45461825,"about_ca_system_score_codex":0.0002902011,"about_ca_system_score_gemma":0.00041824844,"threshold_uncertainty_score":0.9999952},"labels":[],"label_agreement":null},{"id":"W2790042221","doi":"10.1200/jco.2018.36.6_suppl.2","title":"Transcriptomic heterogeneity of androgen receptor activity in primary prostate cancer: Identification and characterization of a low AR-active subclass.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Androgen receptor; Prostate cancer; Medicine; Subclass; Cancer research; Cancer; Oncology; Androgen; Transcriptome; Internal medicine; Biomarker; Gene expression; Immunology; Biology; Hormone; Gene; Genetics; Antibody","score_opus":0.08516729541103782,"score_gpt":0.44306419021736576,"score_spread":0.3578968948063279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790042221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722236,0.0002605553,0.00004363139,0.0016255064,0.00035823122,0.0003787954,0.000048337562,0.0000023441141,0.000060217313],"genre_scores_gemma":[0.99405694,0.0054668454,0.00010249627,0.00007323814,0.00019581473,0.000009357711,0.000012750944,0.000008696751,0.000073854455],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979895,0.0003085816,0.0011926072,0.00015265067,0.00022236476,0.00013429433],"domain_scores_gemma":[0.99769104,0.0002158851,0.0013461593,0.00010016051,0.00051891676,0.00012781608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013483262,0.00008303293,0.0008854448,0.00014649688,0.000017815495,0.0000033119484,0.00006509657,0.000184869,0.00002655883],"category_scores_gemma":[0.00020960397,0.00006110462,0.0001365324,0.00016344064,0.00042386472,0.00018571176,0.000019064715,0.00031523916,9.224106e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020156408,0.0011893868,0.23282719,0.00018788356,0.00021069868,0.000013897932,0.00041365562,3.1161093e-7,0.5825733,0.0000017889987,0.000025995494,0.16239952],"study_design_scores_gemma":[0.005129641,0.0040766587,0.7046322,0.00015012687,0.00008103108,0.00001221217,0.000023471366,0.00004207312,0.28529054,0.000021795811,0.00050455844,0.00003565341],"about_ca_topic_score_codex":0.00003519213,"about_ca_topic_score_gemma":0.000060466213,"teacher_disagreement_score":0.47180507,"about_ca_system_score_codex":0.00022908473,"about_ca_system_score_gemma":0.0014124697,"threshold_uncertainty_score":0.25056607},"labels":[],"label_agreement":null},{"id":"W2790064496","doi":"10.1200/jco.2018.36.6_suppl.68","title":"A biopsy-based genomic classifier to predict biochemical failure after definitive radiation without hormone therapy in a prospective cohort of intermediate risk prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Ontario Institute for Cancer Research; Occupational Cancer Research Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Biochemical recurrence; Internal medicine; Hazard ratio; Oncology; Radiation therapy; Cohort; Prospective cohort study; Prostate; Clinical endpoint; Cancer; Androgen deprivation therapy; Prostatectomy; Hormonal therapy; Clinical trial; Confidence interval","score_opus":0.04751857577989758,"score_gpt":0.42676588052566283,"score_spread":0.37924730474576523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790064496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940707,0.0013053196,0.000066165616,0.0026700802,0.00037091228,0.0012372715,0.00007529401,0.000007860774,0.00019637524],"genre_scores_gemma":[0.9932136,0.0036971457,0.0013597541,0.0005472128,0.0009109683,0.00016599867,0.000008363673,0.000025047833,0.000071885166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99684346,0.0003986287,0.0017244782,0.0003078515,0.00039505732,0.0003305444],"domain_scores_gemma":[0.996739,0.00065221224,0.0011900357,0.0001751341,0.00086631015,0.00037733273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021112268,0.00018186617,0.0012335416,0.0003189079,0.000026429485,0.000008466906,0.00013618158,0.00037232172,0.000084104315],"category_scores_gemma":[0.001513521,0.00011757011,0.00027990964,0.0003411415,0.00067052344,0.000080016296,0.00004396057,0.00097642874,0.000013077385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07341798,0.0011262437,0.8909602,0.000017149623,0.00053243607,0.00016935695,0.0006707132,0.0000029283897,0.00447315,0.000001974314,0.0009929924,0.027634876],"study_design_scores_gemma":[0.019982098,0.029384265,0.943523,0.0002075715,0.00020069402,0.000024248746,0.00010406177,0.00013334406,0.004281899,0.00013712187,0.0019179012,0.00010381091],"about_ca_topic_score_codex":0.00008525944,"about_ca_topic_score_gemma":0.000107482505,"teacher_disagreement_score":0.05343588,"about_ca_system_score_codex":0.0006203636,"about_ca_system_score_gemma":0.0031918555,"threshold_uncertainty_score":0.5662215},"labels":[],"label_agreement":null},{"id":"W2790074491","doi":"10.1200/jco.2018.36.6_suppl.354","title":"Abiraterone or docetaxel in men with metastatic castration-sensitive prostate cancer: A pooled analysis of castration resistance-free survival and toxicity.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Western University; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Androgen deprivation therapy; Internal medicine; Hazard ratio; Subgroup analysis; Meta-analysis; Castration; Oncology; Toxicity; Cancer; Confidence interval","score_opus":0.11342769064778459,"score_gpt":0.4681460112735128,"score_spread":0.3547183206257282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790074491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923798,0.00035013066,0.00008422669,0.0051120147,0.0000927948,0.00037545327,0.000037805454,0.000003202373,0.0015645787],"genre_scores_gemma":[0.99482477,0.0011750344,0.0025954002,0.000126098,0.0001927232,0.00001002726,0.000007974546,0.00001006884,0.001057914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970876,0.00048903114,0.0015367882,0.0002126299,0.00045137093,0.00022258639],"domain_scores_gemma":[0.9965003,0.000957324,0.001145869,0.00016842893,0.0010106675,0.0002173733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023366406,0.00013235254,0.0015883038,0.0003700167,0.000038082362,0.000012807933,0.00008134443,0.000113357026,0.00007683327],"category_scores_gemma":[0.0008173055,0.00007516501,0.00013619359,0.0007227819,0.00053533353,0.00015977242,0.000028007116,0.0003803352,6.9321186e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3412297,0.005337447,0.53906715,0.00043231953,0.029254682,0.0073291394,0.0056679402,0.00023983326,0.016358914,0.00038075203,0.0018331254,0.052869003],"study_design_scores_gemma":[0.03292197,0.030313753,0.92031217,0.000350649,0.007544605,0.000121554825,0.0021284472,0.0008680883,0.004670798,0.00023726861,0.00037205074,0.00015864112],"about_ca_topic_score_codex":0.00026781758,"about_ca_topic_score_gemma":0.02343648,"teacher_disagreement_score":0.38124505,"about_ca_system_score_codex":0.00019422545,"about_ca_system_score_gemma":0.0022828083,"threshold_uncertainty_score":0.9943833},"labels":[],"label_agreement":null},{"id":"W2790076865","doi":"10.1016/j.jmir.2018.01.002","title":"Personalising Prostate Radiotherapy in the Era of Precision Medicine: A Review","year":2018,"lang":"en","type":"review","venue":"Journal of medical imaging and radiation sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Alberta Health Services","funders":"","keywords":"Prostate cancer; Medicine; Precision medicine; Radiation therapy; Prostate; Personalized medicine; Intensive care medicine; Cancer; Oncology; Radiation oncology; Internal medicine; Bioinformatics; Pathology","score_opus":0.07497786157442986,"score_gpt":0.4762117501744789,"score_spread":0.40123388860004905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790076865","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000095291274,0.9619802,0.000028997003,0.037095994,0.00026251966,0.00042416024,0.0000018269724,0.0000020349735,0.00010893602],"genre_scores_gemma":[0.00006278001,0.998181,0.00016698043,0.00083859323,0.00070851773,0.000005938134,0.0000034757384,0.0000068361064,0.000025886698],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959623,0.0004601367,0.0009549373,0.00018009712,0.002262863,0.00017967257],"domain_scores_gemma":[0.99787956,0.0008855097,0.0007899209,0.000110722925,0.0001780778,0.00015622014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010184608,0.000150367,0.0011226822,0.0003336239,0.00009409097,0.00003358567,0.00035895544,0.00007398866,0.00009840913],"category_scores_gemma":[0.0015897828,0.00005871846,0.00017921592,0.00086136156,0.0011156093,0.00015075816,0.000021120437,0.0006424895,6.2672444e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013828252,0.0000376529,0.00016132426,0.0069175446,0.000035465942,0.00006022447,0.0008870155,3.101494e-8,4.865571e-7,0.0000073132805,0.012366294,0.9795128],"study_design_scores_gemma":[0.0009310015,0.00040841557,0.00011661552,0.2028323,0.0003047607,0.0016829993,0.0004923552,0.00013246374,5.028758e-7,0.00003170522,0.7930038,0.00006305909],"about_ca_topic_score_codex":0.000017561664,"about_ca_topic_score_gemma":6.432447e-7,"teacher_disagreement_score":0.97944975,"about_ca_system_score_codex":0.000078285084,"about_ca_system_score_gemma":0.0013901581,"threshold_uncertainty_score":0.4110509},"labels":[],"label_agreement":null},{"id":"W2790188279","doi":"10.1101/cshperspect.a030437","title":"Transcriptional Regulation in Prostate Cancer","year":2018,"lang":"en","type":"review","venue":"Cold Spring Harbor Perspectives in Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Cancer Research Society; Prostate Cancer Foundation","keywords":"Prostate cancer; Cancer; Medical school; Gerontology; Medicine; Library science; Internal medicine; Medical education","score_opus":0.08568828112546277,"score_gpt":0.41056850423780306,"score_spread":0.32488022311234027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790188279","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00050055445,0.9946448,0.00000815264,0.0010767173,0.00035891152,0.0023831632,0.000022384707,0.000051752922,0.0009535208],"genre_scores_gemma":[0.0025363201,0.9934784,0.0001233344,0.000033645894,0.0010694646,0.000816191,0.000019089857,0.00008181282,0.0018417131],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972686,0.0001441918,0.0006890147,0.000802901,0.0005778694,0.0005174205],"domain_scores_gemma":[0.998948,0.000111887064,0.00017095284,0.00040958595,0.00019198905,0.00016759147],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006453835,0.00044022917,0.0017188537,0.0011099713,0.000056618148,0.000013455382,0.00017573024,0.00022566608,0.0005245131],"category_scores_gemma":[0.00017014581,0.00031943544,0.00019245128,0.0010866434,0.0005240729,0.00009843631,0.00004055335,0.00083494716,0.000026464104],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006169415,0.005943987,0.026572924,0.24116462,0.0049512475,0.0064408067,0.043842662,0.000028619157,0.003256315,0.084854305,0.0077984366,0.56897664],"study_design_scores_gemma":[0.0047308817,0.00046536475,0.017321656,0.093295984,0.0005472594,0.0000088078805,0.00041240745,0.000044835317,0.000018791312,0.000050837232,0.8826983,0.00040489793],"about_ca_topic_score_codex":0.0004041343,"about_ca_topic_score_gemma":0.0001230232,"teacher_disagreement_score":0.87489986,"about_ca_system_score_codex":0.0025597385,"about_ca_system_score_gemma":0.0008768432,"threshold_uncertainty_score":0.9999258},"labels":[],"label_agreement":null},{"id":"W2790262846","doi":"10.1200/jco.2018.36.6_suppl.71","title":"Validation of a genomic classifier to predict adverse pathology in men diagnosed with low risk prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Biochemical recurrence; Internal medicine; Logistic regression; Prostate; Gynecology; Cohort; Oncology; Cancer","score_opus":0.07545298122376336,"score_gpt":0.4602714696668144,"score_spread":0.38481848844305105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790262846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945543,0.00022639216,0.000037360776,0.0031212356,0.00036907426,0.0005760103,0.000019714533,0.000004527692,0.0010914218],"genre_scores_gemma":[0.9939606,0.0032385637,0.0013429928,0.000367329,0.00067962264,0.000030257363,0.0000038410008,0.000015373304,0.00036142886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972268,0.00049359584,0.0015216264,0.00019983137,0.00029216547,0.00026599146],"domain_scores_gemma":[0.9967934,0.0009337826,0.0011852941,0.00016792926,0.0006098332,0.00030977468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026657335,0.00010984343,0.0009989594,0.00022589178,0.000026236386,0.0000027710362,0.0001230726,0.00022620554,0.00017057442],"category_scores_gemma":[0.0015379494,0.0000663855,0.00014082404,0.00021480491,0.00040085448,0.00007987463,0.000047611582,0.0006280076,0.000018397232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030850021,0.0012118509,0.8924427,0.000038392187,0.00028632287,0.0012844148,0.0010672869,0.000080590944,0.0020709094,0.0000045191737,0.0020821507,0.06858085],"study_design_scores_gemma":[0.020471254,0.038347084,0.9308985,0.00024264194,0.0002531486,0.00008387901,0.00034290424,0.00010180686,0.0021231552,0.00009115147,0.0069709765,0.000073523755],"about_ca_topic_score_codex":0.00012232432,"about_ca_topic_score_gemma":0.00027845445,"teacher_disagreement_score":0.06850733,"about_ca_system_score_codex":0.00032587766,"about_ca_system_score_gemma":0.0025639518,"threshold_uncertainty_score":0.454834},"labels":[],"label_agreement":null},{"id":"W2790359800","doi":"10.1007/s00345-018-2236-4","title":"The impact of time to metastasis on overall survival in patients with prostate cancer","year":2018,"lang":"en","type":"article","venue":"World Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; Stornoway Diamond (Canada); BC Cancer Agency; University of British Columbia","funders":"Deutsche Forschungsgemeinschaft","keywords":"Medicine; Prostate cancer; Metastasis; Oncology; Internal medicine; Proportional hazards model; Nephrology; Cancer","score_opus":0.0146765880782751,"score_gpt":0.32717844021256814,"score_spread":0.31250185213429305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790359800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939821,0.0004091575,0.0000010277743,0.0038380444,0.00009582982,0.00025049195,0.000015066757,0.0000016904959,0.0014066398],"genre_scores_gemma":[0.99618804,0.00013603597,0.000026156124,0.00015828834,0.00009411854,0.0000044937156,0.0000017215423,0.000011010097,0.003380137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990756,0.00009537216,0.00023740933,0.00008408886,0.00026339287,0.0002441628],"domain_scores_gemma":[0.9991728,0.000103479964,0.00015518352,0.00012027195,0.00033750944,0.0001107479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003238793,0.00008780451,0.00028341362,0.0002501958,0.000029553046,0.0000060290276,0.000088981586,0.000018848017,0.00030230253],"category_scores_gemma":[0.000041480092,0.00003873103,0.000068676985,0.00025681732,0.00013058314,0.00003577959,0.000021604603,0.00019459311,0.000019787474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07157425,0.00051316706,0.88524497,0.000008558947,0.0007664502,0.00006449406,0.0004892895,0.00026521794,0.0005079502,0.00001205726,0.009281308,0.03127231],"study_design_scores_gemma":[0.006134557,0.015608759,0.97050965,0.000053854397,0.00006565823,0.0000066547695,0.0000059300396,0.000016569991,0.00021726395,0.000054324846,0.007277346,0.000049460283],"about_ca_topic_score_codex":0.00011516303,"about_ca_topic_score_gemma":0.00018752535,"teacher_disagreement_score":0.085264675,"about_ca_system_score_codex":0.00018950539,"about_ca_system_score_gemma":0.00032246622,"threshold_uncertainty_score":0.3310001},"labels":[],"label_agreement":null},{"id":"W2790489755","doi":"10.1097/rlu.0000000000002009","title":"Small Lymph Node Metastasis Detected by 68Ga–Prostate-Specific Membrane Antigen But Not 18F-Fluciclovine PET/CT in Low–Prostate-Specific Antigen Biochemical Recurrence of Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Prostatectomy; Biochemical recurrence; Prostate cancer; Lymph node; Glutamate carboxypeptidase II; Prostate-specific antigen; Urology; Androgen deprivation therapy; Prostate; Recurrent prostate cancer; PET-CT; Lymph; Radiation therapy; Metastasis; Nuclear medicine; Radiology; Cancer; Internal medicine; Pathology; Positron emission tomography","score_opus":0.07383393670138057,"score_gpt":0.358632999732036,"score_spread":0.28479906303065544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790489755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97514486,0.012961686,0.00000930231,0.0075927037,0.0009827438,0.002023302,0.00061293755,0.00018870778,0.0004837621],"genre_scores_gemma":[0.9200267,0.07571715,0.0008535194,0.0009334514,0.0007999237,0.00008421093,0.0004982542,0.00020301277,0.0008837754],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9919117,0.00044606117,0.0028851114,0.0018733961,0.0013348041,0.0015489198],"domain_scores_gemma":[0.99507105,0.00071813504,0.0007012091,0.001421893,0.001009403,0.0010783104],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022637565,0.00084219873,0.00237079,0.00053747377,0.00022207295,0.00004635077,0.00073298725,0.00013800467,0.0024586539],"category_scores_gemma":[0.0009827308,0.000630036,0.00040918437,0.0017380605,0.004059776,0.00019234985,0.00036017876,0.0012565603,0.00031324715],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03862964,0.0039478336,0.12013441,0.0016833926,0.0010520441,0.005103611,0.001555252,0.000006304936,0.7261503,0.0000435595,0.045746118,0.055947576],"study_design_scores_gemma":[0.06265989,0.011056948,0.21476309,0.009941282,0.000635677,0.00068856875,0.0023324725,0.0012501514,0.5315729,0.00011800091,0.16264156,0.00233948],"about_ca_topic_score_codex":0.00090976444,"about_ca_topic_score_gemma":0.000038383656,"teacher_disagreement_score":0.19457737,"about_ca_system_score_codex":0.0004035784,"about_ca_system_score_gemma":0.0004892251,"threshold_uncertainty_score":0.9996151},"labels":[],"label_agreement":null},{"id":"W2790707728","doi":"10.1200/jco.2018.36.6_suppl.333","title":"Loss of RSPO3 as a potential mechanism of greater invasiveness in prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Prostate cancer; Medicine; Downregulation and upregulation; Cancer research; Protein kinase B; PI3K/AKT/mTOR pathway; Prostate; Cancer; Signal transduction; Radiation therapy; Oncology; Internal medicine; Biology; Cell biology","score_opus":0.12650037536201875,"score_gpt":0.5013553112941292,"score_spread":0.3748549359321105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790707728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930724,0.0004523891,0.000024971274,0.004444378,0.0008177478,0.0002679769,0.00000893503,0.0000021949847,0.000909015],"genre_scores_gemma":[0.9958528,0.0022043646,0.0003927122,0.000307858,0.0005951823,0.000006417948,0.0000014204733,0.000012339606,0.00062688574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971782,0.00029084363,0.0017456912,0.00014958993,0.0004000956,0.0002355577],"domain_scores_gemma":[0.9971047,0.00033244575,0.0011959595,0.00014507357,0.0010106523,0.00021118243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019982231,0.000102275284,0.0012822228,0.00021201739,0.000016724196,0.000002508044,0.00015488196,0.00022508777,0.00037519203],"category_scores_gemma":[0.0007140796,0.00006489186,0.0002859312,0.00019949912,0.0005758148,0.000078665464,0.00007010304,0.0004951979,0.000008980093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10433951,0.005219203,0.739486,0.0005535278,0.0016907377,0.008991297,0.0018754331,0.000019799545,0.019535957,0.00093572057,0.0011476149,0.11620524],"study_design_scores_gemma":[0.0720686,0.11417285,0.6235392,0.002038502,0.0009972302,0.0013963865,0.0008919313,0.00014107965,0.16453896,0.01317119,0.006752421,0.0002916236],"about_ca_topic_score_codex":0.00021202637,"about_ca_topic_score_gemma":0.0000981348,"teacher_disagreement_score":0.145003,"about_ca_system_score_codex":0.0001451641,"about_ca_system_score_gemma":0.0031455492,"threshold_uncertainty_score":0.55800694},"labels":[],"label_agreement":null},{"id":"W2790762419","doi":"10.1158/1538-7445.sabcs17-ot1-05-03","title":"Abstract OT1-05-03: TRIO030: A presurgical tissue-acquisition study to evaluate molecular alterations in human breast cancer tissue following short-term exposure to the androgen receptor antagonist darolutamide","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology; University of Alberta","funders":"","keywords":"Medicine; Breast cancer; Androgen receptor; Triple-negative breast cancer; Prostate cancer; Cancer; Internal medicine; Estrogen receptor; Oncology; Androgen; Hormone","score_opus":0.07141023382588961,"score_gpt":0.46241183048143847,"score_spread":0.39100159665554884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790762419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819096,0.0015917274,0.000020434189,0.009340927,0.00032059706,0.005920073,0.00026610153,0.00005350567,0.00057704136],"genre_scores_gemma":[0.99283534,0.00014704604,0.000041330295,0.00023143104,0.0010459725,0.003556299,0.000100568985,0.000077596094,0.0019644357],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9949831,0.0005355794,0.00052404206,0.00095293333,0.0018441667,0.0011602134],"domain_scores_gemma":[0.9976912,0.00010625561,0.000040030925,0.0008379899,0.00071134296,0.00061318406],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002260728,0.00031813333,0.0004978535,0.0005149156,0.00076724077,0.00029690794,0.00048688796,0.000114027505,0.0018968009],"category_scores_gemma":[0.00007207659,0.00022869802,0.000105360436,0.0014973013,0.00022360974,0.00018426118,0.00030511688,0.00069118233,0.00022121817],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005032405,0.0012948209,0.04014796,0.00011926495,0.0004741591,0.0011555708,0.010599283,0.00020965506,0.9073837,0.000017577513,0.008098859,0.025466794],"study_design_scores_gemma":[0.012737206,0.013017403,0.4380292,0.0018693681,0.00030909528,0.00008596604,0.003429771,0.000088447705,0.50688463,0.000072501905,0.022442102,0.0010342913],"about_ca_topic_score_codex":0.004493546,"about_ca_topic_score_gemma":0.0043132924,"teacher_disagreement_score":0.40049902,"about_ca_system_score_codex":0.0014143488,"about_ca_system_score_gemma":0.0008596813,"threshold_uncertainty_score":0.9990156},"labels":[],"label_agreement":null},{"id":"W2790859354","doi":"10.15252/emmm.201808928","title":"Co‐targeting driver pathways in prostate cancer: two birds with one stone","year":2018,"lang":"en","type":"letter","venue":"EMBO Molecular Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Cancer research; Cancer; Prostate; Medicine; Biology; Internal medicine","score_opus":0.023785312331269903,"score_gpt":0.31750276568576563,"score_spread":0.29371745335449573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790859354","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15734023,0.021988103,0.0001229415,0.8034098,0.0006357099,0.004195056,0.00016487883,0.00027716826,0.011866099],"genre_scores_gemma":[0.11411938,0.012275256,0.0019591376,0.8161358,0.01894266,0.0019866426,0.009622748,0.0011345533,0.023823822],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946866,0.00022231445,0.0006942433,0.0011481005,0.0019468347,0.001301901],"domain_scores_gemma":[0.99794906,0.000091268186,0.0003065523,0.00083689374,0.0004878674,0.00032837162],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005854199,0.00077758014,0.0015402451,0.00080030866,0.00012545145,0.000026695538,0.0003090646,0.00045155428,0.0011087734],"category_scores_gemma":[0.00010675274,0.00052607444,0.00013341238,0.0008475615,0.0010218484,0.00008055341,0.00008058945,0.0027127666,0.00009916334],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015766235,0.00027975402,0.008283384,0.0019951784,0.00125645,0.05088696,0.0025243673,0.000008720358,0.06428926,0.000016135387,0.8640497,0.004833479],"study_design_scores_gemma":[0.03797101,0.007130283,0.0027317754,0.01535016,0.0015159335,0.0003514673,0.0004055236,0.000114100134,0.043466926,0.00024598514,0.8891181,0.0015987615],"about_ca_topic_score_codex":0.0015025623,"about_ca_topic_score_gemma":0.00008086076,"teacher_disagreement_score":0.050535493,"about_ca_system_score_codex":0.0007726296,"about_ca_system_score_gemma":0.0010039915,"threshold_uncertainty_score":0.9998044},"labels":[],"label_agreement":null},{"id":"W2790865280","doi":"10.1200/jco.2018.36.6_suppl.tps406","title":"Intergroup study EORTC-1532-gucg: A phase 2 randomized open-label study of oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in men with hormone naive prostate cancer (PCa).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Tolerability; Bicalutamide; Androgen deprivation therapy; Internal medicine; Endocrinology; Leuprorelin; Testosterone (patch); Clinical endpoint; Antagonist; Androgen receptor; Prostate cancer; Oncology; Urology; Adverse effect; Hormone; Randomized controlled trial; Cancer; Luteinizing hormone; Gonadotropin-releasing hormone; Receptor","score_opus":0.1541366464985643,"score_gpt":0.5221006580994223,"score_spread":0.367964011600858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790865280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98985904,0.0006697183,0.00003878617,0.0023244852,0.00017617823,0.0065662754,0.000015073102,0.000011424164,0.00033901137],"genre_scores_gemma":[0.9945227,0.0031879318,0.00073817675,0.00036775347,0.00029592417,0.00031380693,0.000010707974,0.00004901691,0.0005140108],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935729,0.0017058328,0.0029149044,0.000501922,0.00083794113,0.00046652637],"domain_scores_gemma":[0.9942639,0.0011744318,0.00248183,0.00039453237,0.001300238,0.00038505116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066858227,0.00034831002,0.0036947406,0.00031153052,0.00012391331,0.00005863662,0.00047819296,0.00020164213,0.00009215997],"category_scores_gemma":[0.00058720604,0.00016868734,0.00013450164,0.00057579944,0.000985281,0.0003699403,0.00018087635,0.00095153303,0.0000030830706],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73255455,0.045899488,0.17394653,0.000018971197,0.0033756504,0.001986656,0.0043492396,0.0000034545717,0.00033988658,0.0000032382134,0.0004994815,0.03702283],"study_design_scores_gemma":[0.68758756,0.2514203,0.054856654,0.00019851899,0.000739034,0.0001380425,0.0034738365,0.00015011414,0.0003110502,0.000038807808,0.00091828656,0.00016783176],"about_ca_topic_score_codex":0.0013563024,"about_ca_topic_score_gemma":0.004386962,"teacher_disagreement_score":0.2055208,"about_ca_system_score_codex":0.00047133162,"about_ca_system_score_gemma":0.0039787297,"threshold_uncertainty_score":0.7058096},"labels":[],"label_agreement":null},{"id":"W2790865406","doi":"10.1016/j.euf.2018.02.004","title":"Treatment of Castration-naive Metastatic Prostate Cancer","year":2017,"lang":"en","type":"review","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Castration; Oncology; Cancer; Prostate; Gynecology; Internal medicine; Hormone","score_opus":0.1742585783567916,"score_gpt":0.4393442344343329,"score_spread":0.2650856560775413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790865406","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000054873613,0.9815475,0.0000020847417,0.0003207885,0.00025419766,0.0019469262,0.0003439288,0.00003612154,0.015493631],"genre_scores_gemma":[0.0005492015,0.9844411,0.00006465698,0.000012889304,0.0002628861,0.00024767808,0.00027881374,0.00010588243,0.014036861],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99770725,0.0005179021,0.0006040767,0.00053159066,0.00021162127,0.00042756784],"domain_scores_gemma":[0.9981659,0.00011661814,0.00060819526,0.0007948166,0.00013119851,0.00018328716],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017975259,0.00046873835,0.0019823923,0.00025110308,0.00013081357,0.0000237157,0.00021502034,0.00009316408,0.00020467232],"category_scores_gemma":[0.00005107752,0.0002888625,0.00053328334,0.0001113723,0.00036656344,0.000045821696,0.0000642091,0.00025117944,0.0003212096],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016726421,0.00026627112,0.00010722292,0.0029236714,0.0016661695,0.0024989052,0.00024914363,3.9484175e-7,0.0000020180923,0.00002595472,0.00035628292,0.9917367],"study_design_scores_gemma":[0.0020800126,0.0027372718,0.00013599473,0.0010967868,0.0045348224,0.00036289849,0.000007424158,0.0000015312876,0.000012708172,0.000012958162,0.98883075,0.00018686565],"about_ca_topic_score_codex":0.00011731077,"about_ca_topic_score_gemma":0.000020220277,"teacher_disagreement_score":0.99154985,"about_ca_system_score_codex":0.00021948725,"about_ca_system_score_gemma":0.0009653156,"threshold_uncertainty_score":0.99995637},"labels":[],"label_agreement":null},{"id":"W2791077036","doi":"10.1007/s00345-018-2270-2","title":"Changes in the levels of testosterone profile over time in relation to clinical parameters in a cohort of patients with prostate cancer managed by active surveillance","year":2018,"lang":"en","type":"article","venue":"World Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Prostate cancer; Cohort; Internal medicine; Testosterone (patch); Proportional hazards model; Nephrology; Hazard ratio; Retrospective cohort study; Cancer; Urology; Oncology; Prostate-specific antigen; Confidence interval","score_opus":0.027500653494581716,"score_gpt":0.3382297711043436,"score_spread":0.3107291176097619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791077036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958968,0.00017130235,0.0000018085359,0.0029848402,0.000045361936,0.0007492948,0.00003914225,9.3167216e-7,0.00011047468],"genre_scores_gemma":[0.9992858,0.000108400855,0.00009408139,0.00026131832,0.000023154298,0.000025406747,0.000006875842,0.0000075908074,0.00018738219],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987427,0.00030958635,0.00041745993,0.000121230165,0.00023365191,0.00017535586],"domain_scores_gemma":[0.9991304,0.00026594102,0.00030336957,0.000103584876,0.00015739069,0.00003926273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008893191,0.00007506793,0.00037750733,0.0003321522,0.000008555149,0.0000019185286,0.00008258562,0.000043472784,0.000053601278],"category_scores_gemma":[0.00011084338,0.000043716154,0.000022338822,0.00046463733,0.00017373133,0.000048945432,0.00002097924,0.00029017127,0.0000011097094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010981653,0.00032297935,0.98104125,0.000016981608,0.00006554684,0.000022016357,0.00096379034,0.000016551892,0.00041161806,7.4443506e-7,0.00030724483,0.0058496417],"study_design_scores_gemma":[0.0047969404,0.0036363374,0.9907424,0.00010507964,0.000019228211,0.000002260774,0.000028730907,0.00002883229,0.00038274488,0.000014418411,0.00020554633,0.000037488382],"about_ca_topic_score_codex":0.00010408184,"about_ca_topic_score_gemma":0.0028171444,"teacher_disagreement_score":0.009701162,"about_ca_system_score_codex":0.00008925839,"about_ca_system_score_gemma":0.0000950357,"threshold_uncertainty_score":0.17826931},"labels":[],"label_agreement":null},{"id":"W2791124263","doi":"10.1200/jco.2018.36.6_suppl.320","title":"Real world patterns of treatment sequencing in Canada for metastatic castrate-resistant prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia; University of Ottawa; BC Cancer Agency; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Enzalutamide; Prostate cancer; Abiraterone acetate; Oncology; Family medicine; Internal medicine; Prednisone; Cancer; Targeted therapy; Androgen deprivation therapy; Androgen receptor","score_opus":0.2442960620736737,"score_gpt":0.5179284975572653,"score_spread":0.2736324354835916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791124263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958666,0.00032117605,0.000009494305,0.0020823814,0.00058995734,0.00053119176,0.00009036504,0.0000019409815,0.0005069027],"genre_scores_gemma":[0.99555075,0.0015283036,0.001171813,0.00019172773,0.0004519416,0.000016482943,0.0000058326013,0.000014700769,0.0010684431],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99716204,0.00020581197,0.0018647207,0.00016445476,0.0002709372,0.00033200797],"domain_scores_gemma":[0.9968277,0.0011495485,0.0010402395,0.0001284667,0.0005583908,0.00029565245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012172277,0.00012929995,0.0013104227,0.00015543382,0.000028241886,0.00000403273,0.000092614246,0.000059335092,0.0001039529],"category_scores_gemma":[0.00030117267,0.000079041165,0.00021695036,0.00016577242,0.00013340982,0.000054277978,0.000016523014,0.00027639486,6.459897e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.045809753,0.0009780313,0.772869,0.00041143142,0.0020230468,0.0037032792,0.0011245457,0.00017508473,0.003568058,0.00009108763,0.0015050463,0.16774166],"study_design_scores_gemma":[0.071607456,0.1613467,0.7093414,0.0017048075,0.0018965839,0.00019958083,0.004966346,0.0015759856,0.01727931,0.0006343184,0.029062279,0.00038522136],"about_ca_topic_score_codex":0.708936,"about_ca_topic_score_gemma":0.96725124,"teacher_disagreement_score":0.25831527,"about_ca_system_score_codex":0.007725237,"about_ca_system_score_gemma":0.05167547,"threshold_uncertainty_score":0.9960839},"labels":[],"label_agreement":null},{"id":"W2791155737","doi":"10.1200/jco.2018.36.6_suppl.tps390","title":"Intergroup study EORTC-1333-GUCG: A randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer (CRPC) patients metastatic to bone (PEACE III).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Asymptomatic; Prostate cancer; Docetaxel; Internal medicine; Placebo; Clinical endpoint; Cancer; Oncology; Randomized controlled trial; Pathology; Androgen receptor","score_opus":0.10854863363798499,"score_gpt":0.4911975984817431,"score_spread":0.3826489648437581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791155737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913281,0.0003012538,0.000107154614,0.0010985043,0.0008016129,0.006281169,0.0000104615965,0.000012088711,0.00005961457],"genre_scores_gemma":[0.9975069,0.00037828434,0.0011762693,0.000287506,0.00021067692,0.0002224291,0.000011304147,0.000029110432,0.00017747421],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9910525,0.0021424082,0.0051818145,0.00037379668,0.0008368906,0.00041260675],"domain_scores_gemma":[0.992249,0.0033562826,0.0027181162,0.00024212162,0.0010055775,0.0004289081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007793341,0.0002944829,0.003693338,0.00059687695,0.000075953576,0.000035130524,0.00017067564,0.00014905358,0.000060859707],"category_scores_gemma":[0.004682574,0.00018524045,0.00031425306,0.0004152255,0.00045648473,0.00027039018,0.00011516529,0.0006174586,0.000003670305],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9276355,0.015474547,0.034248672,0.00023161308,0.0012063766,0.0003004441,0.0054955673,0.000009209473,0.00047780282,0.000008790086,0.0001933359,0.014718177],"study_design_scores_gemma":[0.8688854,0.076330595,0.047415238,0.0012430731,0.0013880193,0.000025297191,0.0013725781,0.0027700353,0.00028011907,0.000068396046,0.00006454085,0.00015671003],"about_ca_topic_score_codex":0.0003758533,"about_ca_topic_score_gemma":0.0015685455,"teacher_disagreement_score":0.06085605,"about_ca_system_score_codex":0.0005655134,"about_ca_system_score_gemma":0.001206,"threshold_uncertainty_score":0.7553886},"labels":[],"label_agreement":null},{"id":"W2791166535","doi":"10.1200/jco.2018.36.6_suppl.59","title":"Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Prostate; Prostate-specific antigen; Urology; Internal medicine; Proportional hazards model; Oncology; Cancer; Gynecology; Confidence interval","score_opus":0.13382764347067863,"score_gpt":0.48366137987541946,"score_spread":0.3498337364047408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791166535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98946583,0.0014357576,0.000029335155,0.006422726,0.0020288115,0.00043274014,0.00003404876,0.000009011906,0.00014170926],"genre_scores_gemma":[0.93814343,0.057051133,0.00093805493,0.0005914344,0.002728331,0.0000059512945,0.000017308617,0.000025237236,0.0004991437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957323,0.0004408132,0.0028571056,0.00029234146,0.00036092827,0.00031652083],"domain_scores_gemma":[0.9959357,0.0006264487,0.0018268925,0.00021541434,0.00092717557,0.0004683624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030155487,0.00016108993,0.0015658654,0.00016100088,0.00006533231,0.0000136660965,0.00014887493,0.00037001292,0.00019518887],"category_scores_gemma":[0.0004903281,0.000107768225,0.0002927761,0.0001931645,0.0013861054,0.00014394235,0.000085671,0.00080554374,0.000018737403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018754542,0.001650519,0.67339736,0.0001064809,0.0005268651,0.00031316595,0.0003194172,7.502659e-7,0.057851836,0.00006293452,0.0014011492,0.24561496],"study_design_scores_gemma":[0.012532106,0.018518843,0.91509736,0.0002347054,0.00013998974,0.0000672254,0.00005626079,0.000045309094,0.0033219228,0.00019546437,0.049690682,0.00010015742],"about_ca_topic_score_codex":0.000024160443,"about_ca_topic_score_gemma":0.000014749918,"teacher_disagreement_score":0.2455148,"about_ca_system_score_codex":0.00010899565,"about_ca_system_score_gemma":0.0018024975,"threshold_uncertainty_score":0.5107163},"labels":[],"label_agreement":null},{"id":"W2791359474","doi":"10.1200/jco.2018.36.6_suppl.297","title":"Real-world experience with docetaxel for castration-sensitive prostate cancer from a population-based analysis.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Androgen deprivation therapy; Internal medicine; Population; Febrile neutropenia; Adverse effect; Cancer; Oncology; Neutropenia; Surgery; Chemotherapy","score_opus":0.14804286026040095,"score_gpt":0.5351239183200455,"score_spread":0.38708105805964454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791359474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922935,0.000084975785,0.00068112754,0.0055662543,0.00031578232,0.00041658664,0.00004450166,0.00000766525,0.0005896235],"genre_scores_gemma":[0.9882861,0.00016467052,0.00846251,0.0008590949,0.0013206813,0.000037243557,0.00004499945,0.000011922154,0.0008128184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792546,0.00016081032,0.0011257322,0.00022351048,0.0003458886,0.00021859622],"domain_scores_gemma":[0.9957431,0.0014423727,0.0010113207,0.0001513188,0.0013617517,0.00029015087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000806953,0.000113741175,0.0010778235,0.00021770535,0.000081749415,0.000014800382,0.00007401134,0.000119535776,0.00016996403],"category_scores_gemma":[0.00047437864,0.00006674839,0.0003173171,0.00045676727,0.00028898744,0.00010566942,0.000010188296,0.00030487133,0.0000029907262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022589605,0.00055366824,0.9583089,0.000011347715,0.0018645924,0.00020464919,0.0004849043,0.00012003296,0.00019424298,0.000035686673,0.00056025217,0.015072134],"study_design_scores_gemma":[0.009504722,0.009045642,0.97330487,0.00008866018,0.0017484365,0.0000069282355,0.00020636305,0.0018167401,0.001031038,0.000121971905,0.003039469,0.00008516042],"about_ca_topic_score_codex":0.0019607793,"about_ca_topic_score_gemma":0.009158829,"teacher_disagreement_score":0.014995984,"about_ca_system_score_codex":0.0002733853,"about_ca_system_score_gemma":0.0024885056,"threshold_uncertainty_score":0.5110842},"labels":[],"label_agreement":null},{"id":"W2791471075","doi":"10.1200/jco.2018.36.6_suppl.20","title":"Genomic variations associated with prostate cancer in large cohort of African American men.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Oncology; Cohort; Internal medicine","score_opus":0.07277079858176388,"score_gpt":0.479823935837381,"score_spread":0.4070531372556171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791471075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878968,0.00020782201,0.000030946383,0.0054604644,0.00018957656,0.00033148422,0.00003160618,0.0000047348285,0.0058465884],"genre_scores_gemma":[0.9968445,0.0011113507,0.00049971306,0.00030314547,0.00035714975,0.00001360641,0.000004818574,0.000013916839,0.00085180363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976351,0.00033934976,0.0012734056,0.0001433555,0.00032558484,0.00028315483],"domain_scores_gemma":[0.9965957,0.00077512214,0.0015020903,0.00012152214,0.00077889964,0.00022665679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026332808,0.00009188811,0.0011460801,0.00017600876,0.000032077834,0.0000037588538,0.000107160966,0.00011419948,0.00023546936],"category_scores_gemma":[0.0011310024,0.000055982717,0.00013650348,0.00043128588,0.00056107197,0.00005456283,0.000033764376,0.0005573434,0.000005436739],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072935894,0.0016770221,0.97587764,0.000007938136,0.00083597266,0.0001780461,0.00041048092,0.000005204203,0.00026196608,0.000032636144,0.0011448362,0.012274689],"study_design_scores_gemma":[0.009504969,0.015811564,0.96859956,0.00010556592,0.0002861375,0.000020267727,0.0002648527,0.0001592909,0.00009463867,0.00008339217,0.005013947,0.0000558043],"about_ca_topic_score_codex":0.00025247282,"about_ca_topic_score_gemma":0.0012331991,"teacher_disagreement_score":0.014134542,"about_ca_system_score_codex":0.00048456338,"about_ca_system_score_gemma":0.0034089999,"threshold_uncertainty_score":0.60474193},"labels":[],"label_agreement":null},{"id":"W2791503968","doi":"10.1200/jco.2018.36.6_suppl.193","title":"Influence of aggressive-variant prostate cancer (AVPC) features on outcome of metastatic hormone-sensitive prostate cancer (mHSPC) treated by chemohormonal therapy (CHT).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; William Osler Health System; Western University; Ottawa Hospital; London Health Sciences Centre","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Oncology; Internal medicine; Androgen deprivation therapy; Proportional hazards model; Cohort; Cancer","score_opus":0.1017387499189603,"score_gpt":0.49130339179874516,"score_spread":0.38956464187978485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791503968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837476,0.008479105,0.0000024153103,0.0059944037,0.0003096179,0.00085736363,0.0002871587,0.000010474216,0.00031188646],"genre_scores_gemma":[0.96683806,0.029771477,0.0003210151,0.0012846763,0.00041250975,0.000047180412,0.000017048169,0.000040566312,0.0012674461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950393,0.0005321032,0.0026280892,0.00037730328,0.0009111591,0.0005120712],"domain_scores_gemma":[0.99039394,0.0012937046,0.0051078917,0.00028628364,0.0024615135,0.00045664975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018292367,0.00033649712,0.002429126,0.00024845006,0.0000650963,0.000010809107,0.0002494289,0.0003003313,0.000087454566],"category_scores_gemma":[0.0016798401,0.00019722842,0.0004949859,0.0004072014,0.0013613114,0.00016823618,0.00006311471,0.0010861985,0.000007785538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22311324,0.008211435,0.3969606,0.0003444557,0.009199547,0.003927329,0.004235427,0.0002955069,0.10614249,0.000064025626,0.02343347,0.2240725],"study_design_scores_gemma":[0.03383509,0.05191042,0.8088185,0.0009268821,0.0009782435,0.00026311752,0.00029557073,0.00007426,0.093520865,0.00020318755,0.008862436,0.0003114327],"about_ca_topic_score_codex":0.0008443767,"about_ca_topic_score_gemma":0.0000963332,"teacher_disagreement_score":0.4118579,"about_ca_system_score_codex":0.0003341141,"about_ca_system_score_gemma":0.0024917147,"threshold_uncertainty_score":0.80427414},"labels":[],"label_agreement":null},{"id":"W2791520417","doi":"10.1200/jco.2018.36.6_suppl.tps383","title":"ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Androgen deprivation therapy; Internal medicine; Oncology; Abiraterone acetate; Enzalutamide; Clinical endpoint; Placebo; Performance status; Androgen receptor; Cancer; Randomized controlled trial; Pathology","score_opus":0.1433848701866493,"score_gpt":0.5219258120212307,"score_spread":0.37854094183458137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791520417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916878,0.0003411282,0.00034357415,0.005157646,0.00017114318,0.0016836065,0.000034870085,0.0000040450464,0.0005761829],"genre_scores_gemma":[0.99403733,0.0009082662,0.003919166,0.00025171053,0.00042501758,0.00006530711,0.000010649499,0.000019564734,0.00036300777],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99740005,0.00031089722,0.001403522,0.00018883668,0.00043004143,0.00026664216],"domain_scores_gemma":[0.9954786,0.001385822,0.0014393764,0.00012269722,0.0013630859,0.00021045202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025291252,0.00013561735,0.0014094976,0.00021312223,0.000029006747,0.00000641736,0.000073370305,0.000108032975,0.0000138933765],"category_scores_gemma":[0.0009842761,0.000073611096,0.00015985298,0.00024677752,0.0006010006,0.00013526434,0.000015828307,0.00043852467,0.0000013177101],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9372068,0.0065473984,0.002530421,0.00007164182,0.0011957187,0.00072407903,0.00091804087,0.000011722604,0.00081502565,0.000048763668,0.0012733015,0.048657067],"study_design_scores_gemma":[0.67463523,0.3017132,0.013284345,0.00035869094,0.0010752779,0.00014955725,0.00080667034,0.0008243667,0.0027829555,0.00047997397,0.0037720648,0.00011765613],"about_ca_topic_score_codex":0.00006598406,"about_ca_topic_score_gemma":0.00018591082,"teacher_disagreement_score":0.2951658,"about_ca_system_score_codex":0.00023035923,"about_ca_system_score_gemma":0.0030749994,"threshold_uncertainty_score":0.5454917},"labels":[],"label_agreement":null},{"id":"W2791572489","doi":"10.1200/jco.2018.36.6_suppl.374","title":"Retrospective analysis of fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Docetaxel; Internal medicine; Androgen deprivation therapy; Cancer; Concomitant; Univariate analysis; Oncology; Surgery; Multivariate analysis; Androgen receptor","score_opus":0.13964410447729805,"score_gpt":0.4978893387357752,"score_spread":0.3582452342584771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791572489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949844,0.00030462275,0.000044305503,0.0017435491,0.00003947738,0.00038003622,0.000025483016,0.0000040354644,0.002474118],"genre_scores_gemma":[0.99708635,0.0005644127,0.0015879057,0.00009215648,0.00012551078,0.000017315278,0.000008383579,0.000013208147,0.000504737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972218,0.00032596174,0.0014706267,0.00021430149,0.00052644446,0.00024086505],"domain_scores_gemma":[0.9963834,0.00048520864,0.0013551264,0.00016642272,0.0013834594,0.0002263554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001572885,0.00014060608,0.0017673323,0.00049178314,0.000031230593,0.0000076013052,0.00009019123,0.000103654595,0.00019975498],"category_scores_gemma":[0.00039746883,0.00007142544,0.00020499277,0.0012759174,0.00059647224,0.000114045404,0.000014303574,0.0004832558,0.0000011091441],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041234855,0.0012431813,0.9408855,0.00003263786,0.007937163,0.0011424834,0.00063731207,0.00015340335,0.0010397355,0.00004508682,0.00016701312,0.0054816348],"study_design_scores_gemma":[0.01423886,0.030741522,0.94751173,0.00021339416,0.0044928994,0.00003563728,0.0005350409,0.0004439211,0.0014277112,0.00005820503,0.00022024513,0.00008081784],"about_ca_topic_score_codex":0.00062195526,"about_ca_topic_score_gemma":0.0054064374,"teacher_disagreement_score":0.029498342,"about_ca_system_score_codex":0.0004620056,"about_ca_system_score_gemma":0.0026101216,"threshold_uncertainty_score":0.46302438},"labels":[],"label_agreement":null},{"id":"W2791716014","doi":"10.1200/jco.2018.36.6_suppl.196","title":"Real-world evidence in patient-related outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone (AA+P).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Trillium Health Centre; University of Alberta; Juravinski Cancer Centre; Dalhousie University; University of Manitoba; University of Calgary; Hôtel-Dieu de Québec; McMaster University; Université de Sherbrooke","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Prednisone; Internal medicine; Interim analysis; Enzalutamide; Cancer; Clinical endpoint; Androgen deprivation therapy; Oncology; Clinical trial; Urology; Androgen receptor","score_opus":0.1431754224399609,"score_gpt":0.4761652050253367,"score_spread":0.3329897825853758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791716014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950828,0.00070941803,0.0000022643976,0.001964937,0.00039608055,0.0011654012,0.00004181948,0.000013877139,0.00062341534],"genre_scores_gemma":[0.9945664,0.0022953264,0.00093557726,0.00017809674,0.0000819802,0.00004565396,0.00001169568,0.000040661427,0.001844624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939252,0.0007389316,0.0035263516,0.00039162388,0.0008515254,0.00056633604],"domain_scores_gemma":[0.99368334,0.0011232749,0.0027143194,0.00031267718,0.0017003439,0.00046603117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018246691,0.00031473226,0.0024399383,0.00043530902,0.000058625905,0.000016513448,0.00021489094,0.000195562,0.00023613875],"category_scores_gemma":[0.0009280849,0.00017737468,0.0002813927,0.0007568709,0.00087966584,0.0003240952,0.00007519127,0.00086192053,0.000014707576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062372796,0.002860671,0.9037668,0.00019714015,0.0013860766,0.0015909992,0.0010477396,0.000058672547,0.0010050549,0.000010769347,0.00038803503,0.025315208],"study_design_scores_gemma":[0.035033554,0.050559353,0.9081831,0.0016204674,0.00082669134,0.00003647354,0.00022110109,0.00014747422,0.0026501026,0.00007164944,0.00045943676,0.00019058655],"about_ca_topic_score_codex":0.001611504,"about_ca_topic_score_gemma":0.0033195047,"teacher_disagreement_score":0.047698684,"about_ca_system_score_codex":0.00081887876,"about_ca_system_score_gemma":0.0035575358,"threshold_uncertainty_score":0.723313},"labels":[],"label_agreement":null},{"id":"W2791796775","doi":"10.1016/s0022-5347(18)33424-4","title":"1199: Canadian Urologic Oncology Group (CUOG) Phase II Study Using Docetaxel/Prednisone in the Second Line Setting for Metastatic Androgen Independent Prostate Cancer in Patients Progressing after First Line Mitoxantrone/Prednisone","year":2006,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mitoxantrone; Medicine; Prednisone; Docetaxel; Prostate cancer; Oncology; Internal medicine; Cancer; Chemotherapy","score_opus":0.029179979846289165,"score_gpt":0.3510711161239282,"score_spread":0.32189113627763905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791796775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840843,0.005739349,0.000027057204,0.006576556,0.00020136742,0.0032226434,0.00012486421,0.0000059799777,0.000017863194],"genre_scores_gemma":[0.9983348,0.00014307679,0.00026183695,0.00065437634,0.00027515643,0.00021234155,0.000029203984,0.000035311026,0.000053896987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968207,0.00068932754,0.000977956,0.00027183632,0.00038867185,0.0008514939],"domain_scores_gemma":[0.99848646,0.00033577625,0.00055550784,0.00024022636,0.00022717791,0.00015487762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023581546,0.0002794802,0.0007080789,0.0005184382,0.00029701352,0.00003224699,0.0002968193,0.00013238976,0.00008444665],"category_scores_gemma":[0.00008214116,0.00015485084,0.00010767291,0.00041501207,0.0001998328,0.00015177288,0.00008546426,0.00081097893,8.8374094e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040800773,0.011807877,0.8921794,0.00020461608,0.0007199002,0.0028234508,0.014875501,0.0033084226,0.0012153909,0.0000039674355,0.00025326642,0.031807415],"study_design_scores_gemma":[0.2252921,0.14871477,0.57964766,0.00043531123,0.004013669,0.0022671283,0.0055892435,0.017949304,0.00076101976,0.0012956032,0.013061531,0.0009726959],"about_ca_topic_score_codex":0.0052485964,"about_ca_topic_score_gemma":0.18237549,"teacher_disagreement_score":0.3125318,"about_ca_system_score_codex":0.0006641268,"about_ca_system_score_gemma":0.0007521913,"threshold_uncertainty_score":0.832544},"labels":[],"label_agreement":null},{"id":"W2792020183","doi":"10.1111/iju.13535","title":"Local treatment for metastatic prostate cancer: A systematic review","year":2018,"lang":"en","type":"review","venue":"International Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Confounding; MEDLINE; Cancer; Meta-analysis; Prostate; Retrospective cohort study; Systematic review; Oncology; Internal medicine","score_opus":0.10135741517312598,"score_gpt":0.4688053784037032,"score_spread":0.3674479632305772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792020183","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000011781696,0.99279404,0.0003031744,0.0022438832,0.0009790673,0.003398475,0.00021885902,0.0000078184885,0.000053530715],"genre_scores_gemma":[0.000012335168,0.99601907,0.00020707517,0.0004943386,0.00053893414,0.0009382431,0.00013336907,0.00004594803,0.0016107154],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972945,0.0002363717,0.0014568742,0.00023477254,0.0005078495,0.0002696704],"domain_scores_gemma":[0.9964333,0.0004253012,0.0014609301,0.00020687628,0.0013077206,0.00016583782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058506045,0.00033431823,0.0032814667,0.00041419498,0.00002965169,0.000021808715,0.00036829995,0.00010961447,0.00013423327],"category_scores_gemma":[0.0002803112,0.00017857969,0.0011880083,0.00012171185,0.00014615788,0.000058379122,0.000040621137,0.000234732,0.00004213741],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005654138,0.0003354961,0.0000021580652,0.7190492,0.012628267,0.0009414818,0.000057496705,6.19973e-7,2.3338784e-7,0.000041399155,0.004282401,0.26209584],"study_design_scores_gemma":[0.0017862952,0.0024697722,1.7530121e-7,0.2992879,0.01556578,0.0038539409,0.0000064747614,0.000009783867,0.0000017147296,0.000055039356,0.6768644,0.00009878224],"about_ca_topic_score_codex":0.000010877022,"about_ca_topic_score_gemma":0.0000060134503,"teacher_disagreement_score":0.672582,"about_ca_system_score_codex":0.0010417419,"about_ca_system_score_gemma":0.0018706426,"threshold_uncertainty_score":0.7282269},"labels":[],"label_agreement":null},{"id":"W2792086148","doi":"10.1056/nejmoa1715546","title":"Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1326,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital; Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development; Ipsen; Sanofi; Astellas Pharma; Clovis Oncology; Genentech; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Prostate cancer; Cancer; Metastasis; Oncology; Medicine; Prostate; Internal medicine","score_opus":0.045749148091909254,"score_gpt":0.35780848779002133,"score_spread":0.31205933969811206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792086148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9530934,0.015576345,0.000015517027,0.028982172,0.00050437916,0.00028917755,0.000009140934,0.000007727855,0.001522144],"genre_scores_gemma":[0.9772782,0.015362328,0.0003125813,0.00022719092,0.0039274315,0.000006274006,0.0000048417623,0.00001896641,0.0028622204],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986588,0.000087741915,0.00040982745,0.00015455791,0.00041115098,0.0002779647],"domain_scores_gemma":[0.9989418,0.00013245162,0.00014679329,0.00017875044,0.00021377069,0.0003864545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072929455,0.00016541792,0.000579927,0.00030001104,0.000041862608,0.000008911053,0.00008420838,0.00003612154,0.0002748027],"category_scores_gemma":[0.00020566258,0.00008644672,0.000046061487,0.00023729706,0.0002681118,0.000082135426,0.000026971218,0.0002031764,0.00000243696],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0102212345,0.00024764315,0.29003057,0.00009096496,0.0006184828,0.0015029474,0.006234938,0.000003758565,0.006604133,0.0000871288,0.005564807,0.6787934],"study_design_scores_gemma":[0.49677023,0.031096235,0.22625297,0.002301797,0.0012354347,0.0026720115,0.0016823494,0.00008772193,0.010775622,0.0028010455,0.22398865,0.0003359069],"about_ca_topic_score_codex":0.001106703,"about_ca_topic_score_gemma":0.0010759069,"teacher_disagreement_score":0.6784575,"about_ca_system_score_codex":0.00021006976,"about_ca_system_score_gemma":0.00042600243,"threshold_uncertainty_score":0.35251948},"labels":[],"label_agreement":null},{"id":"W2792110199","doi":"10.1200/jco.2018.36.6_suppl.109","title":"Personalized risk stratification for patients with early prostate cancer (PRONTO): A Canadian team biomarker project.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Health Sciences Centre; Sunnybrook Health Science Centre; McGill University Health Centre; Ontario Institute for Cancer Research; McGill University; Queen's University","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Grading (engineering); Oncology; Biopsy; Cohort; Risk stratification; Prostate biopsy; Internal medicine; Cancer","score_opus":0.11807399547422467,"score_gpt":0.4874807099409833,"score_spread":0.36940671446675866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792110199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99150854,0.00030490145,0.000038988797,0.0037847126,0.0005309127,0.0016274668,0.00009807544,0.0000068260015,0.0020995864],"genre_scores_gemma":[0.99335676,0.0005261356,0.0027063128,0.00039820318,0.00080224697,0.00009992411,0.000024033348,0.000022938604,0.002063425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979344,0.00021280946,0.00094748836,0.00021239971,0.00034279146,0.00035011987],"domain_scores_gemma":[0.99612135,0.00037695115,0.00095403235,0.00013845484,0.0019158395,0.00049338856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014971069,0.00012474737,0.0006694893,0.00017532853,0.0001244093,0.000019336323,0.0001060568,0.0002177014,0.000120119985],"category_scores_gemma":[0.0009152976,0.00007040375,0.00019180491,0.00017028158,0.0004293937,0.00013247482,0.000009587929,0.00041086887,0.0000073066135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028456844,0.00093564694,0.76328486,0.000032655546,0.00068274734,0.000026690403,0.0006636007,1.2754776e-7,0.000021910955,0.000020871568,0.012532787,0.19334123],"study_design_scores_gemma":[0.02153684,0.03345239,0.81377715,0.000109068395,0.00042292813,0.00001125497,0.00014994778,0.00007430794,0.000034913013,0.00011592916,0.13022156,0.00009369625],"about_ca_topic_score_codex":0.012809153,"about_ca_topic_score_gemma":0.03676128,"teacher_disagreement_score":0.19324754,"about_ca_system_score_codex":0.0005247902,"about_ca_system_score_gemma":0.009254606,"threshold_uncertainty_score":0.99636203},"labels":[],"label_agreement":null},{"id":"W2792147494","doi":"10.1200/jco.2018.36.6_suppl.200","title":"Indirect treatment comparison (ITC) of abiraterone acetate (AA) plus prednisone (P) and docetaxel (DOC) on patient-reported outcomes (PROs) in metastatic castration-naïve prostate cancer (mCNPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Abiraterone acetate; Androgen deprivation therapy; Cabazitaxel; Internal medicine; Oncology; Prednisone; Population; Quality of life (healthcare); Urology; Chemotherapy; Cancer","score_opus":0.22694376382890014,"score_gpt":0.5203448045402858,"score_spread":0.2934010407113856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792147494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929099,0.0014749509,0.000006947729,0.0034823585,0.0006220404,0.0009981138,0.000028438033,0.000008983161,0.0004682608],"genre_scores_gemma":[0.9952591,0.0022857606,0.0011473682,0.00026952478,0.00018356288,0.000052560543,0.00000989441,0.00002311461,0.0007691007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953579,0.00045653997,0.0029394638,0.0003243842,0.00054307695,0.00037868877],"domain_scores_gemma":[0.9956446,0.00094126374,0.0022571287,0.00022563033,0.0005733463,0.00035802196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013590232,0.0002597342,0.0024409858,0.00030673807,0.000056728903,0.000016572481,0.000092403156,0.00018982688,0.000104451734],"category_scores_gemma":[0.0006938401,0.00015482705,0.000251733,0.0002467044,0.0005317065,0.00014438423,0.00004219972,0.0005457414,0.000007231235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022736276,0.0043981005,0.80902004,0.00009764923,0.0019657805,0.0009688244,0.0026348468,0.000081645914,0.000841369,0.000011313168,0.00042645083,0.15681767],"study_design_scores_gemma":[0.041477557,0.05964025,0.88735723,0.00032510023,0.0008597914,0.00014490729,0.0005639986,0.00043972538,0.0063568857,0.00015010714,0.0025241654,0.00016029246],"about_ca_topic_score_codex":0.00037127486,"about_ca_topic_score_gemma":0.000853333,"teacher_disagreement_score":0.15665738,"about_ca_system_score_codex":0.00061287737,"about_ca_system_score_gemma":0.0022987153,"threshold_uncertainty_score":0.6313664},"labels":[],"label_agreement":null},{"id":"W2792431643","doi":"10.1200/jco.2018.36.6_suppl.123","title":"Hypofractionated, dose escalation radiotherapy for high-risk prostate cancer: The primary endpoint of a group led phase III trial. (PCS5).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université du Québec à Chicoutimi; Hôpital Maisonneuve-Rosemont; Saint John Regional Hospital; Hôtel-Dieu de Québec; Hôpital Notre-Dame; Université Laval; Centre Hospitalier de l’Université de Montréal; McGill University; Cégep de Rimouski; Bausch Health (Canada); Centre Hospitalier Universitaire de Sherbrooke; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Clinical endpoint; Randomized controlled trial; Prostate; Radiation therapy; Dose fractionation; Urology; Nuclear medicine; Adjuvant; Concomitant; Internal medicine; Cancer","score_opus":0.10019377179591943,"score_gpt":0.5024123413044331,"score_spread":0.4022185695085137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792431643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707887,0.0022736804,0.0011042672,0.021211267,0.0023531793,0.001984098,0.000050490675,0.000010348095,0.00022396598],"genre_scores_gemma":[0.970706,0.016704524,0.0042581907,0.0014939995,0.005519208,0.00012384834,0.000032365602,0.000030648327,0.0011312385],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99633247,0.00054418435,0.0022508027,0.00019430157,0.00042702592,0.00025119632],"domain_scores_gemma":[0.9923272,0.0036610947,0.0026724362,0.00020452106,0.0009214539,0.0002132772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005182207,0.00013857093,0.0012930731,0.0001311707,0.00011807031,0.00001006951,0.0001527364,0.00026363053,0.00019230673],"category_scores_gemma":[0.0016223802,0.00007228453,0.0004787044,0.00018217471,0.0005280361,0.00016988737,0.000024415927,0.0007076221,0.0000029409591],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4931218,0.0034205334,0.0015972682,0.000032673815,0.001104243,0.00003219923,0.00018660707,0.0000047286326,0.0022873932,0.00007387128,0.006357568,0.49178112],"study_design_scores_gemma":[0.5593358,0.11527384,0.03641109,0.000110079556,0.001011484,0.000056114637,0.00011356558,0.00044838057,0.0013815913,0.0016464442,0.28409484,0.00011674404],"about_ca_topic_score_codex":0.00011491679,"about_ca_topic_score_gemma":0.000043581793,"teacher_disagreement_score":0.49166435,"about_ca_system_score_codex":0.00041847173,"about_ca_system_score_gemma":0.0021958235,"threshold_uncertainty_score":0.38952965},"labels":[],"label_agreement":null},{"id":"W2792470458","doi":"10.1200/jco.2018.36.6_suppl.182","title":"Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naïve prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta","funders":"","keywords":"Medicine; Prostate cancer; Hypokalemia; Abiraterone acetate; Androgen deprivation therapy; Adverse effect; Internal medicine; Prednisone; Urology; Gastroenterology; Cancer","score_opus":0.3536237821018281,"score_gpt":0.5897643233906775,"score_spread":0.23614054128884943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792470458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785775,0.00267573,0.00021738044,0.015627649,0.0011557392,0.0012134087,0.00007837014,0.00001067223,0.00044353344],"genre_scores_gemma":[0.98754376,0.0051497496,0.0027570594,0.0011638532,0.0020146049,0.000059769663,0.000032922726,0.000027055514,0.0012512073],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99452937,0.0012261743,0.0028698854,0.00032204826,0.0006233887,0.0004291153],"domain_scores_gemma":[0.99431056,0.0026708164,0.0016147944,0.00031395367,0.0007200363,0.00036984918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038193187,0.00022978387,0.0018231291,0.00014842465,0.00011980605,0.00003840245,0.00026536713,0.00020562983,0.0008172381],"category_scores_gemma":[0.0019859725,0.00012076713,0.00039510857,0.0003823456,0.0006568134,0.00023619964,0.000068521615,0.0010585072,0.000040920033],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75588185,0.007199233,0.047692902,0.00006780359,0.005637758,0.0026981332,0.003203738,0.00043837694,0.0062185363,0.00003056821,0.006477259,0.16445383],"study_design_scores_gemma":[0.7111966,0.056328256,0.18700631,0.00055813557,0.0036023967,0.000119221164,0.0010401488,0.003441993,0.0030753606,0.0010697873,0.032194212,0.00036757562],"about_ca_topic_score_codex":0.0005392787,"about_ca_topic_score_gemma":0.004251092,"teacher_disagreement_score":0.16408625,"about_ca_system_score_codex":0.00052337075,"about_ca_system_score_gemma":0.0047506248,"threshold_uncertainty_score":0.8948184},"labels":[],"label_agreement":null},{"id":"W2792485007","doi":"10.1200/jco.2018.36.6_suppl.197","title":"Luminal and basal subtyping of metastatic castration-resistant prostate cancer (mCRPC) and its clinical implications.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Subtyping; Internal medicine; Basal (medicine); Oncology; Androgen deprivation therapy; Prostatectomy; Cancer","score_opus":0.2732079752417164,"score_gpt":0.5633154662081646,"score_spread":0.2901074909664482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792485007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979158,0.0036129623,0.0000185563,0.016087068,0.00043397656,0.00030786174,0.0000215311,0.0000037051327,0.00035637323],"genre_scores_gemma":[0.9886716,0.0077279373,0.0018265535,0.0005321358,0.000924113,0.0000090748745,0.000002942073,0.000011387483,0.00029425987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99693,0.00035698205,0.0020511418,0.00020653433,0.00024490096,0.0002104565],"domain_scores_gemma":[0.9957123,0.0015658006,0.0011679188,0.00011852794,0.0010282842,0.00040720322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033062417,0.00010927408,0.0010359915,0.00010781628,0.00006850616,0.000010758276,0.00007747264,0.00015313062,0.00006921708],"category_scores_gemma":[0.0018950736,0.000071735485,0.00016274408,0.00013540756,0.00075819215,0.0001231507,0.000051649895,0.0005324674,0.0000028335005],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028416075,0.0024564553,0.6469105,0.00041839306,0.0018966697,0.00044838287,0.0005872884,0.0000013034755,0.009012372,0.00087370427,0.005031093,0.30394775],"study_design_scores_gemma":[0.0102156475,0.018032357,0.9591034,0.00022555504,0.0007050393,0.00024052006,0.00018222183,0.00014021463,0.0010037888,0.0009908512,0.009069556,0.000090848596],"about_ca_topic_score_codex":0.000033001787,"about_ca_topic_score_gemma":0.000115160154,"teacher_disagreement_score":0.3121929,"about_ca_system_score_codex":0.00006516919,"about_ca_system_score_gemma":0.002295798,"threshold_uncertainty_score":0.4072647},"labels":[],"label_agreement":null},{"id":"W2792597722","doi":"10.1111/bju.13978","title":"Prostate cancer biochemical recurrence after salvage radiotherapy: first look into risk stratification and prognosis","year":2018,"lang":"en","type":"letter","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Biochemical recurrence; Prostate cancer; Medicine; Prostatectomy; Oncology; Androgen deprivation therapy; Radiation therapy; Internal medicine; Multivariate analysis; Cohort; Salvage therapy; breakpoint cluster region; Cancer; Chemotherapy","score_opus":0.012785120573083113,"score_gpt":0.2902179701863545,"score_spread":0.27743284961327136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792597722","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29593137,0.21065806,0.000061689316,0.49140152,0.0006199706,0.0010186612,0.0002393262,0.000021271082,0.000048110167],"genre_scores_gemma":[0.27804673,0.55064076,0.0029069784,0.14872107,0.016408581,0.00062720093,0.00040830937,0.00022445388,0.0020159322],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980938,0.0001812218,0.0005392291,0.00040046897,0.00038303973,0.0004022444],"domain_scores_gemma":[0.99857736,0.000107559,0.0005062031,0.00016900273,0.00048294786,0.00015691482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034192688,0.00023716009,0.0005853512,0.00019731229,0.00010675487,0.00009119813,0.00016017683,0.00059918384,0.00031615217],"category_scores_gemma":[0.0001069609,0.00021309039,0.00013871095,0.0001352801,0.00066598656,0.00010668606,0.000038539085,0.0020132815,0.000005435945],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014870741,0.00013181876,0.03255231,0.00051201764,0.0006155065,0.0051287417,0.00042498694,2.5893684e-7,0.00037412034,1.6435648e-7,0.89296365,0.065809384],"study_design_scores_gemma":[0.0051611806,0.004055528,0.038748503,0.0018228348,0.0010266671,0.01038196,0.000023808458,0.000037927486,0.0010651079,0.0003600727,0.93684703,0.00046938963],"about_ca_topic_score_codex":0.00023397383,"about_ca_topic_score_gemma":0.0000813261,"teacher_disagreement_score":0.34268045,"about_ca_system_score_codex":0.00019118219,"about_ca_system_score_gemma":0.00041473875,"threshold_uncertainty_score":0.8746818},"labels":[],"label_agreement":null},{"id":"W2792742267","doi":"10.1200/jco.2018.36.6_suppl.80","title":"Nuclear factor-kappa B p65 evaluation on the Canadian Prostate Cancer Biomarker Network (CPCBN) TMA-series for biomarker validation.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; University of British Columbia; Princess Margaret Cancer Centre; University of Manitoba; Université de Montréal; Université Laval; McGill University Health Centre; Hôtel-Dieu de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Biomarker; Prostatectomy; Cohort; Oncology; Internal medicine; Cancer; Kappa; Immunohistochemistry; Pathology; Biology","score_opus":0.3345544202130519,"score_gpt":0.5313495037804408,"score_spread":0.1967950835673889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792742267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8680767,0.0007694414,0.000010659293,0.12005264,0.003358929,0.0016476222,0.000049862218,0.000011877789,0.006022266],"genre_scores_gemma":[0.99007386,0.0009672337,0.00050821493,0.003693363,0.003107713,0.00006765373,0.000018484185,0.000033441134,0.001530026],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997009,0.0005936113,0.0011435633,0.00022168976,0.0005885411,0.00044363024],"domain_scores_gemma":[0.99531627,0.0013761257,0.00077868445,0.00022972208,0.0018299083,0.00046929027],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0056173876,0.00015318276,0.00064239337,0.0001421895,0.0003648625,0.0000454211,0.00018237004,0.00031667203,0.0016342851],"category_scores_gemma":[0.002741869,0.000082222316,0.00029133612,0.00024253478,0.000546984,0.00014715108,0.000028805045,0.00047596256,0.00005219397],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031039102,0.00069417513,0.08490911,0.000050000373,0.0022352624,0.0001071765,0.0006745932,0.000022935688,0.00053522614,0.00096636626,0.38651747,0.49224856],"study_design_scores_gemma":[0.006516451,0.009112734,0.3589874,0.0001540268,0.0003979894,0.000040248095,0.00012925256,0.00057670823,0.00016580183,0.0016250621,0.62217736,0.00011699706],"about_ca_topic_score_codex":0.0015070294,"about_ca_topic_score_gemma":0.016873915,"teacher_disagreement_score":0.49213156,"about_ca_system_score_codex":0.00081644,"about_ca_system_score_gemma":0.0060977833,"threshold_uncertainty_score":0.9995367},"labels":[],"label_agreement":null},{"id":"W2792860007","doi":"10.1200/jco.2018.36.6_suppl.321","title":"Patterns of prostate cancer management across Canadian prostate cancer treatment specialists.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Toronto; University of Ottawa; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University of British Columbia; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Radiation oncologist; Referral; Family medicine; Cancer; Radiation therapy; Multidisciplinary approach; Palliative care; Oncology; Internal medicine; Nursing","score_opus":0.15095056708451754,"score_gpt":0.5317794849189827,"score_spread":0.3808289178344652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792860007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975667,0.0018758898,0.0000026422213,0.01508572,0.0021947045,0.00083051884,0.00025579406,0.0000075969356,0.004080104],"genre_scores_gemma":[0.95107377,0.03226435,0.00029717837,0.0011863102,0.0026960026,0.000070650734,0.000012687274,0.000032739033,0.012366337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654853,0.00019868443,0.0018148009,0.00029172347,0.00048504665,0.0006612043],"domain_scores_gemma":[0.9965555,0.00019317486,0.0011213822,0.00026700052,0.00095495314,0.0009080106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013161869,0.00021787397,0.001366715,0.00019520242,0.00010663998,0.000017153503,0.00019835071,0.00023692171,0.00091170275],"category_scores_gemma":[0.00012167289,0.0001368434,0.00041487868,0.00022026335,0.00040215332,0.000104223116,0.000060976585,0.00043166362,0.000023855151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005848268,0.0009181945,0.5913108,0.0001053375,0.0014053881,0.0014305173,0.0013031727,0.000005065536,0.0000406714,0.000037642185,0.004365675,0.3932293],"study_design_scores_gemma":[0.013585605,0.013572722,0.5710504,0.00037080146,0.00046420205,0.000054763113,0.00053368055,0.000011732342,0.00089898583,0.00009552043,0.39923388,0.00012767373],"about_ca_topic_score_codex":0.04359415,"about_ca_topic_score_gemma":0.17717573,"teacher_disagreement_score":0.39486822,"about_ca_system_score_codex":0.001722121,"about_ca_system_score_gemma":0.0049849967,"threshold_uncertainty_score":0.9982506},"labels":[],"label_agreement":null},{"id":"W2792993335","doi":"10.1200/jco.2018.36.6_suppl.84","title":"Long-term outcomes of stereotactic body radiotherapy for low- and intermediate-risk prostate adenocarcinoma: A multi-institutional consortium study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Biochemical recurrence; Radiation therapy; Internal medicine; Oncology; Prostate; Dose fractionation; Urology; Surgery; Cancer; Prostatectomy","score_opus":0.13607477495906306,"score_gpt":0.5017333499122798,"score_spread":0.36565857495321674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792993335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99480486,0.0014520307,0.0003768798,0.001112463,0.0010654517,0.0011283403,0.000023516577,0.000006201037,0.000030251222],"genre_scores_gemma":[0.9955947,0.001496811,0.0015018891,0.0002855564,0.0007146044,0.000022289372,0.000003742352,0.000016328811,0.0003641089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996999,0.00031165493,0.0019025187,0.00022169985,0.0003089544,0.00025614386],"domain_scores_gemma":[0.99520236,0.0020834554,0.0014502349,0.00016912933,0.0007696923,0.000325102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023470728,0.00016183947,0.0014812658,0.00017182433,0.00007572759,0.000011404678,0.00012967129,0.0001823165,0.00005772026],"category_scores_gemma":[0.0025912425,0.00009197274,0.0003363001,0.00007932203,0.0010593017,0.00012190995,0.0000507111,0.00052581687,0.0000029860303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01669319,0.004424321,0.95514,0.00009890605,0.0018610781,0.000417318,0.0005205448,2.4280138e-7,0.00011641239,0.000007693849,0.00013969287,0.020580579],"study_design_scores_gemma":[0.040915698,0.04413954,0.9132435,0.00010091504,0.0005676561,0.0001731535,0.00013227442,0.00009719232,0.00015407479,0.000028019254,0.00037415835,0.00007386605],"about_ca_topic_score_codex":0.000013497014,"about_ca_topic_score_gemma":0.00005132468,"teacher_disagreement_score":0.04189657,"about_ca_system_score_codex":0.00015320297,"about_ca_system_score_gemma":0.0016511669,"threshold_uncertainty_score":0.39030412},"labels":[],"label_agreement":null},{"id":"W2793000264","doi":"10.1001/jamaoncol.2017.5808","title":"Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Active Biotech; Astellas Pharma; Eisai; Ipsen; Clovis Oncology; Advanced Accelerator Applications; Endocyte; Gilead Sciences; Genentech; Valeant Pharmaceuticals International; Sanofi; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Prostate cancer; Enzalutamide; Oncology; Internal medicine; Progression-free survival; Clinical endpoint; Clinical trial; Placebo; Discontinuation; Cancer; Chemotherapy; Pathology","score_opus":0.04999381704449428,"score_gpt":0.4252381961655681,"score_spread":0.37524437912107383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793000264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.952628,0.0019436366,0.000008834462,0.027199034,0.00060678954,0.0018158967,0.00006186935,0.000077116034,0.015658788],"genre_scores_gemma":[0.99195313,0.0013984842,0.0027909717,0.001049849,0.00049673615,0.0006364164,0.000065785985,0.000042346743,0.0015663003],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970662,0.00041114926,0.0007183699,0.000542425,0.0006000032,0.0006618743],"domain_scores_gemma":[0.99808383,0.00049636763,0.00022206317,0.0004789762,0.00040617006,0.00031261402],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001573546,0.00023776774,0.000646412,0.00037312205,0.0001293205,0.000044957753,0.00022545493,0.00019033934,0.0010792601],"category_scores_gemma":[0.0008012327,0.00016959872,0.00014153082,0.00071420544,0.00067721884,0.00014960687,0.00012938539,0.0005333129,0.00007283432],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053955954,0.0045281844,0.4186831,0.0006048815,0.0015502234,0.00956274,0.01128526,0.000006428438,0.026260927,0.002692898,0.017238934,0.45363045],"study_design_scores_gemma":[0.08998401,0.056817994,0.6564928,0.0019281213,0.0009979408,0.0006874314,0.005782302,0.0007936364,0.009656895,0.016910328,0.15872104,0.0012275028],"about_ca_topic_score_codex":0.00107868,"about_ca_topic_score_gemma":0.004806214,"teacher_disagreement_score":0.45240295,"about_ca_system_score_codex":0.00048020607,"about_ca_system_score_gemma":0.002134392,"threshold_uncertainty_score":0.9998339},"labels":[],"label_agreement":null},{"id":"W2793122709","doi":"10.1016/j.clinthera.2017.12.015","title":"An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Amgen","keywords":"Medicine; Enzalutamide; Denosumab; Cabazitaxel; Prostate cancer; Zoledronic acid; Concomitant; Abiraterone acetate; Internal medicine; Oncology; Docetaxel; Cohort; Population; Cancer; Androgen deprivation therapy; Osteoporosis","score_opus":0.5229752836077713,"score_gpt":0.5422627704409436,"score_spread":0.019287486833172274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793122709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967572,0.0018377154,0.0000067728083,0.00056586496,0.000091990114,0.00070064486,0.00001890137,0.000010742638,0.000010133678],"genre_scores_gemma":[0.99435335,0.004697807,0.00037430663,0.00027480838,0.00008129708,0.00003087735,0.0000064690753,0.000017677283,0.00016339947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985822,0.0001692296,0.0006100791,0.00021928865,0.00023640034,0.000182845],"domain_scores_gemma":[0.99891615,0.000334483,0.00015062769,0.00025578504,0.00027243796,0.00007053064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004608291,0.00010980796,0.0004093985,0.000067786794,0.000038203532,0.0000105890385,0.00007984561,0.00006385771,0.00006646112],"category_scores_gemma":[0.000052891748,0.00006905657,0.000040400904,0.00021062835,0.00044538704,0.00010512159,0.000036185636,0.00017857268,5.8453276e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043936176,0.0016261608,0.95285195,0.000045223816,0.0003773166,0.000011907694,0.004300743,0.0000031971178,0.003518934,0.00002954683,0.000009085303,0.03283233],"study_design_scores_gemma":[0.009481184,0.009269141,0.97312945,0.00015944238,0.00015080253,0.0000024029487,0.0023385554,0.0013828148,0.0028080977,0.00014132155,0.0010327739,0.00010401407],"about_ca_topic_score_codex":0.00010308402,"about_ca_topic_score_gemma":0.00042563677,"teacher_disagreement_score":0.032728314,"about_ca_system_score_codex":0.00004131283,"about_ca_system_score_gemma":0.00030419338,"threshold_uncertainty_score":0.28160453},"labels":[],"label_agreement":null},{"id":"W2793288544","doi":"10.1200/jco.2018.36.6_suppl.72","title":"Impact of genomic risk scores on treatment decisions following radical prostatectomy in a prospective Medicare registry.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; DECIPHER; Prostate cancer; Logistic regression; Internal medicine; Odds ratio; Adjuvant therapy; Salvage therapy; Cancer; Oncology; Bioinformatics; Chemotherapy","score_opus":0.1278614806549402,"score_gpt":0.5342841960884889,"score_spread":0.4064227154335487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793288544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955629,0.00061724527,0.000021349957,0.0010242587,0.00043954307,0.0006246316,0.000023115323,0.0000062777613,0.0016806434],"genre_scores_gemma":[0.99580145,0.0018215514,0.0012519937,0.00006506836,0.0008235321,0.000015500085,0.0000053656145,0.00001844879,0.00019707106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965999,0.00044820516,0.0018026226,0.00027012904,0.00053733453,0.0003418162],"domain_scores_gemma":[0.994884,0.0027329857,0.0012097305,0.00028264103,0.0003792547,0.00051134627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022761766,0.00018199984,0.0016389634,0.00030801314,0.000055729117,0.0000068849645,0.00017027733,0.00031806185,0.00014971834],"category_scores_gemma":[0.007165359,0.00009349125,0.0010304335,0.00025238204,0.0006287415,0.000061205785,0.000046383953,0.00089636224,0.000020199024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026666706,0.0035476296,0.8546538,0.0000069036273,0.001280553,0.0019135864,0.00050153263,0.0000068771146,0.0002220422,0.000015238208,0.00083111745,0.11035403],"study_design_scores_gemma":[0.027295403,0.09825414,0.8708107,0.00037271672,0.00030698723,0.0001286346,0.000116713425,0.000043454562,0.00030004262,0.00076372334,0.0015390795,0.00006844327],"about_ca_topic_score_codex":0.00020638313,"about_ca_topic_score_gemma":0.00012226329,"teacher_disagreement_score":0.11028558,"about_ca_system_score_codex":0.0016663811,"about_ca_system_score_gemma":0.0057043275,"threshold_uncertainty_score":0.9999324},"labels":[],"label_agreement":null},{"id":"W2793327802","doi":"10.21037/tau.2018.01.18","title":"Stereotactic ablative body radiotherapy in patients with prostate cancer","year":2018,"lang":"en","type":"review","venue":"Translational Andrology and Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Institute for Work & Health","funders":"Association of Canadian Universities for Research in Astronomy","keywords":"SABR volatility model; Medicine; Prostate cancer; Brachytherapy; Radiation therapy; Prostate; Ablative case; Androgen deprivation therapy; Regimen; Genitourinary system; Cancer; Oncology; Urology; Internal medicine; Radiology","score_opus":0.026762299904248648,"score_gpt":0.3472730992571924,"score_spread":0.32051079935294374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793327802","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009337373,0.9880673,0.0000063217353,0.00082213327,0.000074534204,0.0013460127,0.00011344721,0.000014297741,0.0002185324],"genre_scores_gemma":[0.0046901857,0.9937369,0.00004562201,0.00022351921,0.000093441246,0.00024041695,0.000481149,0.000031870455,0.0004568801],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986095,0.00017731365,0.00029931605,0.00044177272,0.00013587243,0.00033621304],"domain_scores_gemma":[0.9994476,0.00015707164,0.000108755325,0.00011630932,0.00008182137,0.0000884457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011264389,0.0002844118,0.0010149209,0.00026853022,0.00006644736,0.00000588105,0.000052992105,0.0003502303,0.00031500345],"category_scores_gemma":[0.000003859752,0.00017421014,0.00007691851,0.00018623349,0.00043675024,0.00005865792,0.000009139398,0.0004292227,0.000008713294],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021501899,0.0008611764,0.48447907,0.0053820023,0.0039655752,0.00021997775,0.0009994201,0.0000037885577,3.1267746e-7,0.00026118688,0.00020849887,0.4821171],"study_design_scores_gemma":[0.010871241,0.0044125314,0.17316613,0.0007642091,0.0011051287,0.00010666619,0.0000016323959,0.000032460564,1.7041319e-7,0.00022666898,0.80900884,0.00030434842],"about_ca_topic_score_codex":0.000020606674,"about_ca_topic_score_gemma":0.00004492953,"teacher_disagreement_score":0.80880034,"about_ca_system_score_codex":0.000045229383,"about_ca_system_score_gemma":0.00039428615,"threshold_uncertainty_score":0.7104084},"labels":[],"label_agreement":null},{"id":"W2793366594","doi":"10.1200/jco.2018.36.6_suppl.276","title":"Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate (AA) and enzalutamide (E) in advanced prostate cancer: clinical value and cost considerations.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone acetate; Prostate cancer; Cabazitaxel; Clinical trial; Oncology; Abiraterone; Internal medicine; Cost effectiveness; Cancer; Androgen deprivation therapy","score_opus":0.13089206356827762,"score_gpt":0.526600887928451,"score_spread":0.3957088243601733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793366594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98111206,0.0015172684,0.0002266172,0.015128046,0.0005332748,0.0013193431,0.00003029818,0.0000035508817,0.0001295585],"genre_scores_gemma":[0.9787758,0.009430922,0.009776239,0.0014845487,0.00041372262,0.00003806905,0.0000015406564,0.000018888955,0.000060286864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938284,0.0012608424,0.0038071491,0.00036734718,0.00046859423,0.00026765472],"domain_scores_gemma":[0.9880158,0.0080969175,0.002173022,0.00038509403,0.0009938914,0.00033531067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008611836,0.0001804433,0.0018386716,0.000105494626,0.00008809942,0.00001371559,0.00019770494,0.0004436975,0.000015645144],"category_scores_gemma":[0.0061355224,0.00009967317,0.0002262871,0.00026082128,0.0024195518,0.00011697837,0.00023280106,0.0012452169,9.165691e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006342174,0.0009342459,0.854877,0.00011259984,0.00029967734,0.000013442943,0.00044180595,0.00011183185,0.0007475294,0.0010926098,0.0001428582,0.13488422],"study_design_scores_gemma":[0.009455526,0.007486803,0.97054625,0.0005588656,0.00039656556,0.000054954417,0.00023189606,0.00071795005,0.0019418788,0.0069584013,0.0015598811,0.00009100599],"about_ca_topic_score_codex":0.00017282435,"about_ca_topic_score_gemma":0.0003941671,"teacher_disagreement_score":0.13479322,"about_ca_system_score_codex":0.00006541295,"about_ca_system_score_gemma":0.001410029,"threshold_uncertainty_score":0.891494},"labels":[],"label_agreement":null},{"id":"W2793460136","doi":"10.1016/j.urolonc.2018.01.004","title":"External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer","year":2018,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Comorbidity; Radiation therapy; Internal medicine; Confounding; Oncology; Surveillance, Epidemiology, and End Results; Cancer; Epidemiology; Randomized controlled trial; Clinical trial; Combination therapy; Cancer registry","score_opus":0.027180621844176606,"score_gpt":0.33229612939569414,"score_spread":0.3051155075515175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793460136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995353,0.00141699,0.00013058694,0.0015756452,0.000052369436,0.0013255633,0.000039764127,0.00003847935,0.00006764296],"genre_scores_gemma":[0.9336857,0.0062369127,0.057402898,0.0011118684,0.00012153866,0.0005605042,0.00008507566,0.000033142733,0.0007623496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998609,0.00012803165,0.0002507514,0.00040771085,0.00024239303,0.00036208893],"domain_scores_gemma":[0.9991171,0.00013052508,0.00019215322,0.00017704567,0.00018447875,0.00019874767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023249447,0.00022657211,0.00039038787,0.00019003436,0.00023385527,0.000029602768,0.000077272976,0.00009728813,0.0001562514],"category_scores_gemma":[0.000034962017,0.00012094722,0.000019940373,0.00042589192,0.0009959895,0.00016505097,0.000014333606,0.00029190164,0.000003616798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064123375,0.00037511316,0.9715659,0.000016507707,0.00017608565,0.00007660285,0.0011037021,0.000030153264,0.00029802936,0.00004257907,0.00014274451,0.01976025],"study_design_scores_gemma":[0.037895545,0.098179325,0.72140515,0.00041465292,0.00054840674,0.00024592114,0.00037504415,0.00095620047,0.00586875,0.0019240773,0.13157724,0.0006096979],"about_ca_topic_score_codex":0.0006374857,"about_ca_topic_score_gemma":0.0006899467,"teacher_disagreement_score":0.25016075,"about_ca_system_score_codex":0.00020374807,"about_ca_system_score_gemma":0.0006646237,"threshold_uncertainty_score":0.49320847},"labels":[],"label_agreement":null},{"id":"W2793467041","doi":"10.1016/j.urolonc.2018.02.001","title":"Null association between androgen-deprivation therapy and nonprostate cancer mortality among older men with nonmetastatic prostate cancer","year":2018,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; University Health Network; Health Sciences Centre","funders":"Canadian Institutes of Health Research; Government of Ontario; Johns Hopkins University","keywords":"Cancer; Prostate cancer; Androgen deprivation therapy; Medicine; Oncology; Null (SQL); Internal medicine; Gerontology","score_opus":0.045676979912590523,"score_gpt":0.3573562732017739,"score_spread":0.31167929328918337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793467041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870731,0.0024053457,0.000023994646,0.008302495,0.00005965695,0.0011580322,0.000116481955,0.000056850073,0.000804047],"genre_scores_gemma":[0.96467686,0.022823248,0.005333515,0.0014420907,0.00038375257,0.00097239617,0.0002351542,0.00003993721,0.0040930496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841446,0.00013545687,0.0002774692,0.00046874944,0.00028369736,0.00042015716],"domain_scores_gemma":[0.99889386,0.00016224814,0.00025521193,0.00016112432,0.0002444374,0.00028313595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046640384,0.00023200251,0.00040346212,0.00012483993,0.0003860673,0.000048409733,0.000058417787,0.00018682948,0.00012171104],"category_scores_gemma":[0.00004774837,0.00015896218,0.00002971049,0.00034144503,0.0010103172,0.00022299383,0.000037792855,0.0003015471,0.000005587217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022548556,0.000089059205,0.98785007,0.000041522904,0.00045084613,0.000028637827,0.0017853817,0.0000052525443,0.00035922002,0.000070003465,0.001964328,0.007130175],"study_design_scores_gemma":[0.0036701418,0.002847936,0.9003093,0.00011740791,0.0006152165,0.000020805563,0.00025671316,0.00053961267,0.002778315,0.0012400671,0.08736856,0.0002358784],"about_ca_topic_score_codex":0.0009958333,"about_ca_topic_score_gemma":0.00036380414,"teacher_disagreement_score":0.087540746,"about_ca_system_score_codex":0.00034460754,"about_ca_system_score_gemma":0.0004917492,"threshold_uncertainty_score":0.648229},"labels":[],"label_agreement":null},{"id":"W2793542547","doi":"10.1200/jco.2018.36.6_suppl.242","title":"Outcomes in patients (Pts) with advanced prostate cancer and inactivating germline mutations in BRCA2 or ATM.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Germline; Prostate cancer; Internal medicine; Oncology; Androgen deprivation therapy; Cancer; Germline mutation; Androgen receptor; Mutation; Cancer research; Gene; Genetics; Biology","score_opus":0.1052536716788147,"score_gpt":0.5215393664997483,"score_spread":0.4162856948209336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793542547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99295104,0.00013901791,0.0000035913242,0.006022453,0.00020280224,0.00036234068,0.000004325405,0.0000033192637,0.0003111219],"genre_scores_gemma":[0.99598145,0.0006000671,0.0020803811,0.00057080784,0.00016472676,0.000017505554,0.0000027718377,0.00001171412,0.00057055795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998162,0.00013378735,0.0010984598,0.00015207136,0.0002338274,0.00021989658],"domain_scores_gemma":[0.9977679,0.00095164526,0.0005972106,0.000076503544,0.000434497,0.00017220674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008472563,0.00009676771,0.0008310628,0.00017302531,0.000030589345,0.0000057064904,0.00005329039,0.000117447125,0.0000565382],"category_scores_gemma":[0.0016732053,0.0000504562,0.00005174351,0.00024180008,0.000270821,0.00015979802,0.000031651194,0.00057944213,0.0000018040365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013546101,0.0010976025,0.79927266,0.000020498002,0.00008462327,0.000219351,0.00042901436,0.000006577711,0.00001999298,0.000002861295,0.00004798342,0.18525273],"study_design_scores_gemma":[0.03100925,0.01923777,0.9470815,0.0002681597,0.000045122306,0.00001687507,0.00022489547,0.000046919475,0.00006888167,0.00006696224,0.0018761561,0.00005752192],"about_ca_topic_score_codex":0.00007412133,"about_ca_topic_score_gemma":0.0009837801,"teacher_disagreement_score":0.1851952,"about_ca_system_score_codex":0.00030233618,"about_ca_system_score_gemma":0.0013336452,"threshold_uncertainty_score":0.251742},"labels":[],"label_agreement":null},{"id":"W2793652009","doi":"10.1016/j.eururo.2018.02.019","title":"Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Androgen deprivation therapy; Medicine; Androgen receptor; Gene knockdown; Cancer research; Downregulation and upregulation; Oncology; Cancer; Internal medicine; Biology; Gene","score_opus":0.03172585020511681,"score_gpt":0.2926756746891043,"score_spread":0.2609498244839875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793652009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99242425,0.001688921,0.00002765671,0.0014820357,0.00019322705,0.002863813,0.00023547045,0.000091323054,0.000993278],"genre_scores_gemma":[0.9948871,0.00043385103,0.0011780016,0.00019700534,0.0002904963,0.0005539854,0.00023708059,0.000116057294,0.002106424],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964439,0.00066993525,0.0007656869,0.0007890286,0.00054604426,0.00078538415],"domain_scores_gemma":[0.9977642,0.000051117266,0.00042501767,0.0005380191,0.0008915713,0.0003300688],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046750685,0.00040896385,0.0004698128,0.00015642094,0.0005050375,0.00006761944,0.0002972531,0.00010148957,0.00059361086],"category_scores_gemma":[0.00008978002,0.00027860256,0.0000908445,0.00032628598,0.00064546487,0.00026120257,0.00020576411,0.00034196483,0.00009366556],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006022996,0.0002697928,0.003818035,0.000080814396,0.0004763546,0.0000492137,0.023574272,0.000020913429,0.953429,0.00001650207,0.0012625825,0.01097952],"study_design_scores_gemma":[0.006135446,0.007305848,0.048083093,0.00022086756,0.00018889729,0.000020525475,0.000913675,0.00019280254,0.9208654,0.00014898044,0.01521245,0.0007119764],"about_ca_topic_score_codex":0.00042538054,"about_ca_topic_score_gemma":0.00026982182,"teacher_disagreement_score":0.044265058,"about_ca_system_score_codex":0.00025822743,"about_ca_system_score_gemma":0.0011139374,"threshold_uncertainty_score":0.9999666},"labels":[],"label_agreement":null},{"id":"W2793667186","doi":"10.1200/jco.2018.36.6_suppl.273","title":"Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Biomarker; Taxane; Context (archaeology); Cohort; Prostate cancer; Cancer; Breast cancer","score_opus":0.18636542787027024,"score_gpt":0.5069247617636963,"score_spread":0.32055933389342606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793667186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99365675,0.00019103609,0.00013288211,0.0030510714,0.00065438385,0.0009345364,0.000024401872,0.000012313771,0.001342625],"genre_scores_gemma":[0.9941562,0.00039194923,0.00390332,0.0004000933,0.0005320669,0.000038054233,0.000012615181,0.000031675318,0.0005340383],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9970421,0.0003492799,0.0016869312,0.00024599643,0.0003845597,0.00029113452],"domain_scores_gemma":[0.9960773,0.0010987313,0.0016096437,0.00013073033,0.0008506509,0.00023291557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016698305,0.00016880437,0.0010175687,0.00022905866,0.00011871493,0.000020571608,0.00007651039,0.00011293501,0.00026955552],"category_scores_gemma":[0.0007474535,0.00011206538,0.0004065062,0.00023865636,0.00023644681,0.00012731814,0.000014179973,0.00024366516,0.00001279288],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14835101,0.007210293,0.013388548,0.00063794834,0.005784325,0.000864892,0.0018066601,0.00039110755,0.34245425,0.00066277507,0.0032788774,0.4751693],"study_design_scores_gemma":[0.1569006,0.3245067,0.075100765,0.0027005016,0.008401884,0.0008759962,0.0028814513,0.021840751,0.3058377,0.007148421,0.09287423,0.00093101873],"about_ca_topic_score_codex":0.00018747884,"about_ca_topic_score_gemma":0.000057565372,"teacher_disagreement_score":0.47423828,"about_ca_system_score_codex":0.00056143274,"about_ca_system_score_gemma":0.0016594733,"threshold_uncertainty_score":0.45698938},"labels":[],"label_agreement":null},{"id":"W2793786660","doi":"10.1111/iju.13526","title":"Clinical and molecular features of treatment‐related neuroendocrine prostate cancer","year":2018,"lang":"en","type":"review","venue":"International Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Neuroendocrine differentiation; Androgen receptor; Medicine; Cancer research; Prostate; Cancer; Enzalutamide; Oncology; Androgen; Internal medicine; Neuroendocrine tumors; Androgen deprivation therapy; Chromoplexy; PCA3; Hormone","score_opus":0.052483222544606696,"score_gpt":0.4610997767461125,"score_spread":0.40861655420150583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793786660","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036035182,0.99282676,0.0000020801813,0.0016889016,0.0011735174,0.00034080294,0.00007307585,0.0000050595136,0.00028630267],"genre_scores_gemma":[0.002444314,0.99576145,0.00007142783,0.00012314715,0.000461101,0.000014163524,0.00004204895,0.000030529423,0.0010518369],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980564,0.00021596796,0.0010216499,0.00022372334,0.0003004606,0.0001817617],"domain_scores_gemma":[0.9980558,0.00018902635,0.00086421025,0.00013609673,0.00060659094,0.00014824183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018112715,0.0002296337,0.00136133,0.00041128744,0.000014339409,0.000011888982,0.00021502838,0.00013507712,0.0001186886],"category_scores_gemma":[0.00013620208,0.00013737426,0.00054075185,0.000098158336,0.00040376355,0.000042416727,0.000079154284,0.0004707161,0.000005220293],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010597305,0.0002742969,0.0020945494,0.0005981868,0.0055964943,0.0040841145,0.000040075432,6.490942e-7,0.000012058831,0.000081464226,0.0010050308,0.9851534],"study_design_scores_gemma":[0.0037850202,0.0046162466,0.00052896974,0.0016987151,0.0021696591,0.008271155,0.0000035829262,0.0000032950213,0.000028219687,0.0001863932,0.9786149,0.000093839946],"about_ca_topic_score_codex":0.000024899146,"about_ca_topic_score_gemma":0.0000034423456,"teacher_disagreement_score":0.9850595,"about_ca_system_score_codex":0.00013324826,"about_ca_system_score_gemma":0.00094046915,"threshold_uncertainty_score":0.560196},"labels":[],"label_agreement":null},{"id":"W2793806887","doi":"10.15562/tcp.46","title":"Androgen Receptor (AR) Based Diagnosis of Prostate Cancer Metastasis: A Biological Perspective","year":2017,"lang":"en","type":"article","venue":"The Cancer Press","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Androgen receptor; Prostate cancer; Metastasis; Perspective (graphical); Oncology; Cancer research; Cancer; Internal medicine; Medicine; Computer science; Artificial intelligence","score_opus":0.09921011360679244,"score_gpt":0.395786860250087,"score_spread":0.2965767466432946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793806887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8933392,0.07410729,0.0000068108557,0.026508817,0.0003521114,0.0020450852,0.0011619689,0.00005602835,0.0024226697],"genre_scores_gemma":[0.9742269,0.021561379,0.00009474486,0.00021484752,0.00021960662,0.0025225063,0.000014315643,0.0000243584,0.0011213509],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987031,0.00010471246,0.00018443177,0.0003581316,0.00030136522,0.0003482126],"domain_scores_gemma":[0.9984844,0.0000988896,0.00019898635,0.0007343855,0.00035402944,0.00012936485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028567345,0.00017917709,0.0003848743,0.000039765608,0.00030646197,0.000047290658,0.00042235942,0.00007067908,0.00075430906],"category_scores_gemma":[0.00013481957,0.00009292267,0.00014734136,0.000075056705,0.0006042067,0.00009207049,0.0001448642,0.00020323967,0.0000059075983],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011150249,0.0010925994,0.8432939,0.0006197871,0.0040374324,0.00008545812,0.0068767457,0.00011282952,0.011065802,0.00073496153,0.027838081,0.09309216],"study_design_scores_gemma":[0.010297444,0.0011912411,0.093300566,0.0010598974,0.0011866171,0.0000056551476,0.0012234454,0.00033156472,0.8305982,0.0005245427,0.059806764,0.00047408577],"about_ca_topic_score_codex":0.0060349857,"about_ca_topic_score_gemma":0.00015641951,"teacher_disagreement_score":0.8195324,"about_ca_system_score_codex":0.00027124133,"about_ca_system_score_gemma":0.00035098678,"threshold_uncertainty_score":0.91231334},"labels":[],"label_agreement":null},{"id":"W2793819981","doi":"10.1200/jco.2018.36.6_suppl.112","title":"Impact of decipher test on adjuvant and salvage treatments received following radical prostatectomy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"DECIPHER; Prostatectomy; Medicine; Adjuvant; Adjuvant therapy; Salvage therapy; Prostate cancer; Anxiety; Internal medicine; Oncology; Cancer; Bioinformatics; Psychiatry; Chemotherapy; Biology","score_opus":0.1353992134906448,"score_gpt":0.5391408966939886,"score_spread":0.4037416832033438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793819981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943356,0.00060758815,0.0000065212935,0.0012749679,0.00045988074,0.00031918794,0.000007963979,0.000006537239,0.0029817421],"genre_scores_gemma":[0.99631727,0.0010376544,0.0011092407,0.00022496044,0.0007399271,0.0000037706068,0.0000029957673,0.000018394598,0.0005457782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755275,0.00025292073,0.0013194068,0.00019345655,0.00039765576,0.00028378668],"domain_scores_gemma":[0.9959587,0.002318063,0.0007287554,0.00016588523,0.00031542755,0.00051318255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001546894,0.00015076705,0.0013409978,0.00014178311,0.000047702248,0.000007062693,0.00009339093,0.00026700238,0.00017593808],"category_scores_gemma":[0.0035920893,0.00008033958,0.00060135766,0.00014613422,0.00050889276,0.000079157166,0.000038582413,0.0005726228,0.0000165651],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018566247,0.0040982338,0.78900975,0.00001901737,0.0016832886,0.0015692608,0.00018374431,5.803286e-7,0.0030590417,0.0000049560185,0.0024449623,0.1793609],"study_design_scores_gemma":[0.024573497,0.11101345,0.8598946,0.00025644572,0.00043449996,0.00017546977,0.000039039172,0.00002904467,0.0009714483,0.00017389968,0.002370636,0.0000679876],"about_ca_topic_score_codex":0.000022720753,"about_ca_topic_score_gemma":0.0000062222125,"teacher_disagreement_score":0.17929292,"about_ca_system_score_codex":0.000299211,"about_ca_system_score_gemma":0.0016098936,"threshold_uncertainty_score":0.43003258},"labels":[],"label_agreement":null},{"id":"W2793834563","doi":"10.1016/j.urolonc.2018.01.011","title":"Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer","year":2018,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Prostate cancer; Medicine; Willingness to pay; Government (linguistics); Cancer; Family medicine; Oncology; Demographics; Internal medicine; Docetaxel; Gynecology; Demography","score_opus":0.15795684390010298,"score_gpt":0.4037151549053187,"score_spread":0.2457583110052157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793834563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92175704,0.007453169,0.00019850262,0.06449419,0.00067711604,0.0042848946,0.0007178344,0.00007099272,0.00034626195],"genre_scores_gemma":[0.9571429,0.019474441,0.010581821,0.0009821475,0.0005675156,0.006168824,0.0006169363,0.00005012445,0.0044153025],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984334,0.00015303525,0.0002730867,0.00044081375,0.00021845759,0.0004811769],"domain_scores_gemma":[0.99886936,0.0002474807,0.00019583422,0.00018408397,0.0002618927,0.0002413625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002886558,0.00025487706,0.00032485812,0.00013639874,0.0010073133,0.000078001096,0.000077614386,0.0000776809,0.00003512158],"category_scores_gemma":[0.00008564027,0.00014970494,0.00008030979,0.00031618003,0.0011718251,0.00015119839,0.00003080515,0.00021822781,0.0000039869233],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072224457,0.0033693311,0.77675104,0.0006933421,0.0020313747,0.00010164293,0.018815722,0.00047267214,0.0052730124,0.053201817,0.047197446,0.08487014],"study_design_scores_gemma":[0.006717067,0.01485655,0.0087052975,0.00024987265,0.0016558177,0.000026724565,0.0012004896,0.0028987639,0.0016171893,0.016132193,0.94560057,0.00033947502],"about_ca_topic_score_codex":0.00017278225,"about_ca_topic_score_gemma":0.0006083289,"teacher_disagreement_score":0.8984031,"about_ca_system_score_codex":0.0012195067,"about_ca_system_score_gemma":0.0011895202,"threshold_uncertainty_score":0.7747541},"labels":[],"label_agreement":null},{"id":"W2793895106","doi":"10.1007/s40336-018-0270-2","title":"PSMA diagnostics and treatments of prostate cancer become mature","year":2018,"lang":"en","type":"editorial","venue":"Clinical and Translational Imaging","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Salvage therapy; Radiation therapy; Prostate-specific antigen; Biochemical recurrence; Prostate; Cancer; Oncology; External beam radiotherapy; Urology; Internal medicine; Chemotherapy","score_opus":0.03402690492346192,"score_gpt":0.42039605098437977,"score_spread":0.3863691460609178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793895106","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19190851,0.20099778,0.00003537829,0.016806735,0.57665026,0.0032199589,0.008450929,0.00012191314,0.0018085495],"genre_scores_gemma":[0.06548546,0.20265979,0.0018101442,0.0003641788,0.7166714,0.00020418473,0.004640847,0.00015388046,0.008010107],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983748,0.000044954544,0.000495709,0.00042678972,0.0004426253,0.00021513026],"domain_scores_gemma":[0.9980351,0.001179013,0.00012917262,0.00013197213,0.00033331034,0.00019147775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023827532,0.00022382248,0.00056396256,0.00008303744,0.000080250786,0.000026681591,0.00004888645,0.00027703602,0.000070193804],"category_scores_gemma":[0.00019956607,0.00015889113,0.00011746743,0.000080005404,0.00069710106,0.00007499318,0.000031359872,0.00050825457,0.00000338896],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010782985,0.00027922262,0.6104395,0.0007739286,0.00062685716,0.00006662224,0.00020655367,1.7019099e-7,0.000011878159,0.000015017179,0.3448807,0.041621264],"study_design_scores_gemma":[0.012602447,0.00056787673,0.3211567,0.0018425729,0.0015875382,0.0000116592055,0.000025180745,0.00019284782,0.0000620488,0.0020429154,0.65956247,0.00034572673],"about_ca_topic_score_codex":0.000058358153,"about_ca_topic_score_gemma":0.000012353897,"teacher_disagreement_score":0.31468177,"about_ca_system_score_codex":0.000015026971,"about_ca_system_score_gemma":0.0004111478,"threshold_uncertainty_score":0.6479392},"labels":[],"label_agreement":null},{"id":"W2793898483","doi":"10.1111/bju.14207","title":"Molecular model for neuroendocrine prostate cancer progression","year":2018,"lang":"en","type":"review","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"","keywords":"Prostate cancer; Cancer research; Transdifferentiation; Androgen receptor; Enzalutamide; Cancer; Biology; Somatic evolution in cancer; Hedgehog signaling pathway; Medicine; Bioinformatics; Signal transduction; Cell; Cell biology; Genetics","score_opus":0.05517414577615398,"score_gpt":0.41319474782004395,"score_spread":0.35802060204388997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793898483","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001505806,0.9966979,0.00031531413,0.00063244236,0.00038606027,0.001593135,0.0001501765,0.000013261618,0.00006112322],"genre_scores_gemma":[0.00010002073,0.99689,0.00064621784,0.0001966721,0.0005746078,0.00026574498,0.00007392125,0.00009274234,0.0011600881],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794257,0.00013194961,0.00078074605,0.00031254106,0.000322475,0.0005096959],"domain_scores_gemma":[0.9982455,0.00006656879,0.0006633743,0.00016900804,0.0006014567,0.0002541235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025712926,0.00026725684,0.0016238869,0.00024261163,0.000078101686,0.00003730521,0.00021909163,0.00014964309,0.000040284525],"category_scores_gemma":[0.00015090831,0.00021033818,0.000679411,0.00015669351,0.00018640803,0.000064024825,0.00007596342,0.0006956937,0.0000045414963],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005122729,0.00016605722,0.000007890862,0.007014122,0.00047453184,0.006954629,0.000011558539,0.0000122748415,0.000004368687,0.000005347937,0.008042559,0.97679436],"study_design_scores_gemma":[0.0026744923,0.0022544798,0.0000029292084,0.010294516,0.0021643334,0.033541735,0.000001304114,0.0006525945,0.000011269812,0.00016513995,0.9480729,0.00016430658],"about_ca_topic_score_codex":0.0000064978753,"about_ca_topic_score_gemma":0.000005011769,"teacher_disagreement_score":0.9766301,"about_ca_system_score_codex":0.00013242388,"about_ca_system_score_gemma":0.0014906423,"threshold_uncertainty_score":0.8577342},"labels":[],"label_agreement":null},{"id":"W2793957208","doi":"10.1200/jco.2018.36.6_suppl.3","title":"PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Oncology; Placebo; Hazard ratio; Gynecology; Randomized controlled trial; Urology; Cancer; Confidence interval; Androgen receptor; Alternative medicine","score_opus":0.13905785457491876,"score_gpt":0.5135764442932255,"score_spread":0.3745185897183067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793957208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98777753,0.00086976873,0.000024713343,0.0024754559,0.0002804589,0.0066233794,0.000010693764,0.0000075375287,0.0019304646],"genre_scores_gemma":[0.9959574,0.0007741024,0.0008492451,0.00018264726,0.00055874564,0.00045667705,0.000004120877,0.000029837429,0.0011872549],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930856,0.0012526374,0.0039610956,0.00034439846,0.00092002656,0.00043621476],"domain_scores_gemma":[0.9926613,0.0027113312,0.002653411,0.0002719536,0.0012975658,0.00040442156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008579202,0.0002715289,0.0041965856,0.00039694933,0.00006886723,0.000022966035,0.00019813958,0.0001999229,0.00024105224],"category_scores_gemma":[0.0013897987,0.00014398665,0.0004133125,0.00041066384,0.0007890999,0.00019238463,0.000044394765,0.0009361772,0.000006776752],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9509549,0.0129760485,0.021439496,0.00007907414,0.0028906972,0.0013725961,0.0022794113,0.00005081451,0.0007501783,0.000022631672,0.0002934802,0.00689063],"study_design_scores_gemma":[0.92524815,0.06513241,0.0042401045,0.00029616585,0.0018920876,0.00008444255,0.0015319707,0.00046121335,0.00055422616,0.00008071738,0.00034830594,0.00013021125],"about_ca_topic_score_codex":0.0004327997,"about_ca_topic_score_gemma":0.0023744465,"teacher_disagreement_score":0.05215636,"about_ca_system_score_codex":0.0003424496,"about_ca_system_score_gemma":0.0046949815,"threshold_uncertainty_score":0.8328696},"labels":[],"label_agreement":null},{"id":"W2793980325","doi":"10.1016/j.euo.2018.02.009","title":"Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer","year":2018,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Prostate Cancer UK; GlaxoSmithKline; Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Voting; Delphi method; Biomarker; Consensus conference; Clinical trial; MEDLINE; Intensive care medicine; Cancer; Medical physics; Oncology; Pathology; Internal medicine; Computer science; Political science","score_opus":0.11904081778682665,"score_gpt":0.4557216727429578,"score_spread":0.3366808549561311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793980325","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039084352,0.9737749,0.000010096249,0.0017741193,0.0013281283,0.0053916713,0.0003615702,0.00013718756,0.016831446],"genre_scores_gemma":[0.000104558,0.99071383,0.0006514232,0.00095782086,0.00074074866,0.0010725049,0.00072528835,0.00023343248,0.004800371],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99541074,0.0012203841,0.001041776,0.0011088628,0.000214615,0.0010036132],"domain_scores_gemma":[0.9972641,0.00088268064,0.00071714685,0.00057419506,0.00026532655,0.0002965841],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012025569,0.0006220034,0.002063145,0.00041442268,0.000229155,0.000015455862,0.00025075127,0.00033083637,0.00019665206],"category_scores_gemma":[0.0002970887,0.00045123242,0.0004949079,0.00026632054,0.00065763644,0.000017981187,0.00016061218,0.0006262332,0.0004376132],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021582285,0.00028185945,0.00003057281,0.00563609,0.0018378664,0.0014313629,0.00015255011,0.000003105859,0.000013303571,0.000035568595,0.025420913,0.96299857],"study_design_scores_gemma":[0.005445732,0.0076597687,0.000029442124,0.001955487,0.001676975,0.00028282552,0.00002831086,0.0000136385925,0.000005234736,0.000021457401,0.9825354,0.0003456776],"about_ca_topic_score_codex":0.000007960333,"about_ca_topic_score_gemma":0.000011150438,"teacher_disagreement_score":0.9626529,"about_ca_system_score_codex":0.0010894594,"about_ca_system_score_gemma":0.0017672202,"threshold_uncertainty_score":0.99979395},"labels":[],"label_agreement":null},{"id":"W2794019020","doi":"10.1158/0008-5472.can-17-3677","title":"Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; University of Toronto; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; Prostate Cancer Canada; Cancer Research UK; Government of Canada","keywords":"Prostate cancer; Cancer; Prostate; Medicine; Biology; Internal medicine","score_opus":0.07030192512802515,"score_gpt":0.4178915228822316,"score_spread":0.34758959775420645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794019020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98476934,0.011084989,0.000003028444,0.002019303,0.000092462855,0.0015901593,0.000037564805,0.000034062217,0.00036909975],"genre_scores_gemma":[0.9894316,0.0025080603,0.00026967115,0.00004881546,0.000276204,0.0017426832,0.000018736964,0.000044136163,0.005660101],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99737626,0.00014235408,0.00032086362,0.00046721302,0.00094725087,0.00074606173],"domain_scores_gemma":[0.9983319,0.00007895479,0.00008810868,0.0002978691,0.0008931043,0.0003100655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039537295,0.00018605919,0.0003630675,0.0003201302,0.0002479175,0.000035628607,0.00017132619,0.000043455715,0.00055216864],"category_scores_gemma":[0.00012317396,0.00013465504,0.000036319005,0.0005844042,0.00096397277,0.00010256969,0.0002550764,0.00034549,0.000023661913],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033352764,0.00029977062,0.052685246,0.002494197,0.00031291612,0.00038531632,0.003354094,0.000001422809,0.7671202,0.00005912065,0.0021208576,0.1678316],"study_design_scores_gemma":[0.0025997306,0.00071298145,0.020256162,0.0014569586,0.000017375929,0.000019167168,0.0001895582,0.000033333567,0.96214604,0.00008770763,0.012345648,0.00013533261],"about_ca_topic_score_codex":0.00056201336,"about_ca_topic_score_gemma":0.00025050354,"teacher_disagreement_score":0.19502588,"about_ca_system_score_codex":0.00028141955,"about_ca_system_score_gemma":0.001245578,"threshold_uncertainty_score":0.60458595},"labels":[],"label_agreement":null},{"id":"W2794109715","doi":"10.1200/jco.2018.36.6_suppl.199","title":"Hepatic effects assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; MedDRA; Adverse effect; Placebo; Oncology; Cancer; Androgen receptor; Pharmacovigilance; Pathology; Alternative medicine","score_opus":0.2899779807679661,"score_gpt":0.5905129250429935,"score_spread":0.30053494427502736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794109715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.839893,0.121912435,0.00007285771,0.031699944,0.0017490884,0.0024575556,0.00023210702,0.000009909907,0.0019730898],"genre_scores_gemma":[0.6945779,0.29886755,0.0016591705,0.0028829605,0.0013129002,0.000028128805,0.000087915534,0.000025807904,0.000557692],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99302304,0.0019426463,0.0039653704,0.00024534014,0.00056147866,0.00026213337],"domain_scores_gemma":[0.9900459,0.005954263,0.0025149607,0.00042251617,0.0007717212,0.00029063423],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016308624,0.00014037202,0.0026459014,0.00010909057,0.000029848501,0.000006581915,0.00029544238,0.00021192411,0.00027133644],"category_scores_gemma":[0.021148996,0.000083623316,0.00025972017,0.0002915985,0.00033872697,0.00016775218,0.00008699819,0.0007061001,0.0000070630913],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07174844,0.007274652,0.14990526,0.01564005,0.002512824,0.0020607228,0.00026566096,0.0000018381188,0.022069125,0.00006271907,0.12122383,0.6072349],"study_design_scores_gemma":[0.08119395,0.06250466,0.44222653,0.059870165,0.0035374009,0.00017687022,0.000118969,0.0002832325,0.009091087,0.00051621377,0.340048,0.000432946],"about_ca_topic_score_codex":0.00021385965,"about_ca_topic_score_gemma":0.00038734486,"teacher_disagreement_score":0.6068019,"about_ca_system_score_codex":0.00029260025,"about_ca_system_score_gemma":0.0052404706,"threshold_uncertainty_score":0.9870963},"labels":[],"label_agreement":null},{"id":"W2794337388","doi":"10.1200/jco.2018.36.6_suppl.301","title":"Influence of CHAARTED, STAMPEDE, and LATITUDE eligibility criteria on utilization of abiraterone (A) and docetaxel (D).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Abiraterone; Docetaxel; Internal medicine; Oncology; Cancer; Androgen receptor","score_opus":0.2170137957382113,"score_gpt":0.5748296015047577,"score_spread":0.35781580576654637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794337388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99741256,0.0005239278,0.000035785462,0.0013231791,0.00010493354,0.00014481458,0.0000056188496,0.000002098986,0.00044709392],"genre_scores_gemma":[0.99608034,0.0027532382,0.00066108926,0.0002535909,0.00018628595,8.313558e-7,0.0000010785601,0.0000046696605,0.000058876587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982753,0.00018998847,0.0010868406,0.000121616795,0.00022023912,0.00010602605],"domain_scores_gemma":[0.9977373,0.0006006836,0.00069493405,0.00010435331,0.0006988554,0.00016390232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017068111,0.00006889676,0.00074147317,0.00008516033,0.000020683887,0.0000032635828,0.0000465172,0.0001571391,0.000043166747],"category_scores_gemma":[0.001530296,0.00004361245,0.000060104852,0.00007983852,0.0007432013,0.000083297266,0.000037124668,0.00023429534,0.000001154701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024278335,0.00245131,0.83554155,0.00039389334,0.0004376242,0.00009049731,0.0005747404,0.000008029633,0.024325294,0.00024850736,0.0007872804,0.11086291],"study_design_scores_gemma":[0.0065230746,0.023810605,0.961252,0.00017840561,0.00010575756,0.000036929796,0.00004184153,0.00010351442,0.00566682,0.00057149626,0.0016738651,0.000035728783],"about_ca_topic_score_codex":0.000019471523,"about_ca_topic_score_gemma":0.000018925024,"teacher_disagreement_score":0.12571038,"about_ca_system_score_codex":0.000030947827,"about_ca_system_score_gemma":0.00040833445,"threshold_uncertainty_score":0.2738356},"labels":[],"label_agreement":null},{"id":"W2794926679","doi":"10.1016/j.urology.2018.03.007","title":"Filling a True Unmet Need: A New Therapy for Nonmetastatic Castrate-resistant Prostate Cancer Commentary on: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer","year":2018,"lang":"en","type":"letter","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Metastasis; Cancer; Prostate; Gynecology; Internal medicine; Urology","score_opus":0.053456886519284215,"score_gpt":0.3434613527130272,"score_spread":0.290004466193743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794926679","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14186008,0.021393638,0.00001929918,0.82131207,0.0008853105,0.007837909,0.006514274,0.0000763724,0.00010106489],"genre_scores_gemma":[0.025306229,0.07709355,0.001720432,0.8420155,0.008859112,0.01597168,0.0073280507,0.0008508694,0.020854551],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954009,0.00039799875,0.00078830804,0.0013511649,0.0005086079,0.0015530385],"domain_scores_gemma":[0.9976691,0.00065327244,0.0003436149,0.00085026794,0.00016353867,0.00032017674],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004113038,0.0010043749,0.0017809224,0.00066533475,0.00019414208,0.000080073776,0.00030067383,0.00046351046,0.00036813258],"category_scores_gemma":[0.000045010554,0.0007139964,0.00028079003,0.00037658328,0.00047521532,0.000094826035,0.00010348374,0.0010922361,0.000009914746],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03805162,0.0007051996,0.0066144974,0.0009937548,0.0049092867,0.0033593115,0.0034605383,0.0001938901,0.0007655894,0.000010852105,0.9070538,0.033881653],"study_design_scores_gemma":[0.041129693,0.01849236,0.00096726144,0.00041207758,0.0014574383,0.000071522925,0.0002583109,0.00041669828,0.0015263209,0.0008618198,0.93348086,0.0009256502],"about_ca_topic_score_codex":0.011703521,"about_ca_topic_score_gemma":0.0062422673,"teacher_disagreement_score":0.11655386,"about_ca_system_score_codex":0.0010149207,"about_ca_system_score_gemma":0.001291248,"threshold_uncertainty_score":0.9995311},"labels":[],"label_agreement":null},{"id":"W2795222586","doi":"10.5489/cuaj.5108","title":"Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel","year":2018,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre; Hôpital Notre-Dame; Grand River Hospital; London Health Sciences Centre; Baker Hughes (Canada); Sanofi (Canada); Princess Margaret Cancer Centre","funders":"Sanofi","keywords":"Cabazitaxel; Docetaxel; Medicine; Prostate cancer; Oncology; Internal medicine; Logistic regression; Proportional hazards model; Cancer; Androgen deprivation therapy","score_opus":0.026530799371487456,"score_gpt":0.29891509166562635,"score_spread":0.2723842922941389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795222586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965091,0.00011057062,0.00000412708,0.0022181864,0.000047364043,0.00075483415,0.00019052858,0.000011114054,0.00015422357],"genre_scores_gemma":[0.9990912,0.00006280558,0.0000873437,0.00025748365,0.00009681119,0.00003830357,0.00008653918,0.000014318825,0.00026516127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983264,0.0001901914,0.00032835937,0.00025633594,0.00041024748,0.0004884665],"domain_scores_gemma":[0.9982141,0.00016084651,0.00020869442,0.00006863781,0.0006539422,0.00069374725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003606853,0.00016362254,0.0003171372,0.00018493565,0.0002149882,0.0000747351,0.000047123194,0.000105251296,0.00012749516],"category_scores_gemma":[0.00033662503,0.00009019652,0.00003402667,0.0003111365,0.00018323642,0.00013858017,0.0000072646594,0.0004729369,0.0000036425347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019138001,0.00013936436,0.9964272,0.0000061987002,0.00027820657,0.00011537016,0.00029070585,0.0000063452603,0.0000047850376,0.0000029659939,0.00021273879,0.0006023579],"study_design_scores_gemma":[0.005680051,0.0063915444,0.98691756,0.00006319346,0.00019455812,0.000011465349,0.00014037726,0.000065380744,0.0000107085525,0.000026342605,0.0003911116,0.000107722386],"about_ca_topic_score_codex":0.002066961,"about_ca_topic_score_gemma":0.010434433,"teacher_disagreement_score":0.009509617,"about_ca_system_score_codex":0.0009938551,"about_ca_system_score_gemma":0.0009904592,"threshold_uncertainty_score":0.58226585},"labels":[],"label_agreement":null},{"id":"W2795272919","doi":"10.1016/j.euf.2018.03.008","title":"Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8–10 Prostate Cancers Identifies Very High–risk Patients for Early Recurrence and Resistance to Castration","year":2018,"lang":"en","type":"article","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Fonds de Recherche du Québec - Santé; Canada Foundation for Innovation; Canadian Urological Association Scholarship Fund; Canadian Urological Oncology Group","keywords":"Medicine; Prostate cancer; Prostatectomy; Biochemical recurrence; Positron emission tomography; Standardized uptake value; Biopsy; Metastasis; Stage (stratigraphy); Pathological; Prostate; Fluorodeoxyglucose; Cancer; Radiology; Urology; Nuclear medicine; Pathology; Internal medicine","score_opus":0.006932126469062012,"score_gpt":0.24790692863598143,"score_spread":0.2409748021669194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795272919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854664,0.0095277075,0.00014079391,0.00047083144,0.0003511712,0.0030187445,0.00075849355,0.00012631991,0.00013952455],"genre_scores_gemma":[0.99704117,0.000900062,0.0006340575,0.00017079964,0.00015526643,0.00034666818,0.00035432907,0.00008539183,0.00031223928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99653035,0.00064505846,0.0005678707,0.001028713,0.00039773245,0.0008302747],"domain_scores_gemma":[0.9981038,0.00012330481,0.00027113082,0.00042162804,0.0006364803,0.0004436677],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005529102,0.00043992882,0.0005189253,0.00056476414,0.00032265033,0.000097798045,0.00021412085,0.00011200853,0.00002191889],"category_scores_gemma":[0.00018409477,0.00038363904,0.00010983786,0.0010448081,0.00041671353,0.0002677086,0.000109252236,0.0003727421,0.000012484287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09565779,0.0011606462,0.61615795,0.0005294759,0.000844134,0.00023867624,0.006205472,0.000021885426,0.12974305,0.00002182133,0.02683468,0.12258442],"study_design_scores_gemma":[0.013665407,0.003956592,0.87031835,0.00034262583,0.0003208977,0.0000043661453,0.00004122215,0.00014400086,0.10492255,0.00019524363,0.0055754837,0.0005132555],"about_ca_topic_score_codex":0.002195152,"about_ca_topic_score_gemma":0.0013371406,"teacher_disagreement_score":0.2541604,"about_ca_system_score_codex":0.00019712781,"about_ca_system_score_gemma":0.0002028226,"threshold_uncertainty_score":0.99986154},"labels":[],"label_agreement":null},{"id":"W2795460644","doi":"10.1158/1078-0432.ccr-18-0101","title":"Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre; Public Health Ontario; BC Cancer Agency; Centre for Addiction and Mental Health","funders":"Lietuvos Mokslo Taryba","keywords":"Prostate cancer; Abiraterone acetate; Internal medicine; Oncology; Medicine; Cancer; DNA methylation; Abiraterone; Cancer research; Biology; Genetics; Gene; Androgen deprivation therapy; Androgen receptor; Gene expression","score_opus":0.17158423012631732,"score_gpt":0.507320787629032,"score_spread":0.3357365575027147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795460644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98593605,0.0014250836,0.0000030651931,0.005689628,0.0003763907,0.0022323225,0.00023552487,0.000068254405,0.0040337066],"genre_scores_gemma":[0.9783042,0.0071910135,0.00006377493,0.00019561787,0.00052857836,0.0010955114,0.0002584655,0.00007575352,0.012287053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99515164,0.0005430877,0.0008767712,0.0009542521,0.0012777027,0.0011965502],"domain_scores_gemma":[0.9962515,0.00031364532,0.00013312213,0.00094226864,0.001832503,0.0005269503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020121194,0.00026563706,0.00056985364,0.0004362308,0.00024682004,0.00007784635,0.0005090497,0.0003046995,0.0006319859],"category_scores_gemma":[0.00048160058,0.00020440214,0.00012540628,0.0014275757,0.0012644267,0.000190056,0.00036679613,0.0012404115,0.0002939462],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061256783,0.0017308624,0.9483684,0.0002363132,0.00009336122,0.00004987606,0.0003646614,0.000003940658,0.0010368184,0.000042867563,0.014947783,0.026999453],"study_design_scores_gemma":[0.026452957,0.0045671514,0.93736005,0.00066813186,0.000082342194,0.0000012642059,0.0003488142,0.0045764325,0.018474126,0.00069175166,0.0063144783,0.0004624853],"about_ca_topic_score_codex":0.0038880075,"about_ca_topic_score_gemma":0.003546182,"teacher_disagreement_score":0.026536968,"about_ca_system_score_codex":0.0022849557,"about_ca_system_score_gemma":0.0011424068,"threshold_uncertainty_score":0.83352774},"labels":[],"label_agreement":null},{"id":"W2795475769","doi":"10.1186/s12885-018-4275-z","title":"Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial","year":2018,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"Vlaamse regering; European Society for Medical Oncology; Fonds Wetenschappelijk Onderzoek; Janssen Pharmaceuticals; American Association for Cancer Research; Waalse Gewest; European Regional Development Fund; European Organisation for Research and Treatment of Cancer","keywords":"Medicine; Prostate cancer; Prostatectomy; Urology; Placebo; Clinical endpoint; Antiandrogen; Androgen deprivation therapy; Internal medicine; Androgen receptor; Oncology; Randomized controlled trial; Cancer; Pathology","score_opus":0.024009714762740882,"score_gpt":0.3376450807353841,"score_spread":0.3136353659726432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795475769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.953991,0.005818894,0.0008700474,0.00090341235,0.00082070165,0.03683588,0.00041130898,0.00016162307,0.00018715233],"genre_scores_gemma":[0.9152542,0.0070934235,0.0015162737,0.00026276373,0.0015186741,0.05365076,0.00015196118,0.00016616064,0.020385826],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962079,0.00023850058,0.0008568586,0.0009767541,0.0006945956,0.001025397],"domain_scores_gemma":[0.99732,0.0007415406,0.0005106633,0.00041392198,0.00045837052,0.0005554943],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011430272,0.0006012437,0.0022132788,0.00023319488,0.00034706932,0.00014637018,0.00017942046,0.00021946318,0.00030382263],"category_scores_gemma":[0.00033694634,0.00032263182,0.000298952,0.0003390122,0.0012248176,0.00018811885,0.000081770886,0.0004260465,0.000010899031],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9797166,0.00028818034,0.005952389,0.00031307092,0.0014664299,0.000031276795,0.0009576824,0.000007968552,0.00038214,0.000013380585,0.0051146112,0.0057563004],"study_design_scores_gemma":[0.97655773,0.006189891,0.00006062109,0.00064443453,0.0020653566,0.000022495758,0.00014141863,0.0027017791,0.005147446,0.000064363376,0.005937234,0.00046722477],"about_ca_topic_score_codex":0.003535602,"about_ca_topic_score_gemma":0.005015802,"teacher_disagreement_score":0.038736824,"about_ca_system_score_codex":0.00044935796,"about_ca_system_score_gemma":0.0022568959,"threshold_uncertainty_score":0.9999226},"labels":[],"label_agreement":null},{"id":"W2795649325","doi":"10.4414/fms.2013.01539","title":"Du nouveau sur le traitement du carcinome prostatique métastatique","year":2013,"lang":"fr","type":"article","venue":"Forum Médical Suisse ‒ Swiss Medical Forum","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine","score_opus":0.01572133149700812,"score_gpt":0.28105061472628373,"score_spread":0.2653292832292756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795649325","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18139854,0.035553742,0.0031815835,0.76390916,0.0043546925,0.0052875928,0.0003342441,0.00034550548,0.005634938],"genre_scores_gemma":[0.9281037,0.0066989893,0.0007253292,0.012434946,0.0025953425,0.0013153274,0.000831047,0.00028866608,0.047006667],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98750657,0.0006722105,0.0019279353,0.0015287776,0.003551274,0.0048132287],"domain_scores_gemma":[0.9913369,0.0010294382,0.00032198845,0.0009160272,0.0007785005,0.0056171664],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.001857425,0.001168758,0.001683056,0.00040076993,0.00073575764,0.00027853376,0.0010178662,0.001418266,0.024667883],"category_scores_gemma":[0.0027754388,0.0009341189,0.0007101065,0.0009508096,0.002101654,0.0008236178,0.0008254413,0.0025637173,0.0030897353],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008846693,0.006589637,0.09871617,0.0019401361,0.001069007,0.0043288376,0.002196761,0.000014752892,0.0010552171,0.046775885,0.6958591,0.14056985],"study_design_scores_gemma":[0.025077937,0.007285199,0.03628173,0.004435526,0.00044551282,0.0010838237,0.008796405,0.024053607,0.0050676037,0.014256062,0.8710837,0.0021329245],"about_ca_topic_score_codex":0.018433744,"about_ca_topic_score_gemma":0.001838343,"teacher_disagreement_score":0.7514742,"about_ca_system_score_codex":0.001347264,"about_ca_system_score_gemma":0.005784591,"threshold_uncertainty_score":0.9998781},"labels":[],"label_agreement":null},{"id":"W2795732342","doi":"10.1016/j.juro.2018.02.1963","title":"PD42-10 PROGNOSTIC VALUE OF CELL CYCLE PROGRESSION SCORE IN PROSTATE CANCER PATIENTS WITH LOCALLY ADVERSE PATHOLOGY AFTER RADICAL PROSTATECTOMY: IMPLICATIONS FOR TREATMENT GUIDANCE","year":2018,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Cancer Society","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Adverse effect; Radiation therapy; Oncology; Internal medicine; Stage (stratigraphy); Biochemical recurrence; Adjuvant therapy; Disease; Adjuvant radiotherapy; Cancer; Adjuvant","score_opus":0.012717657146826468,"score_gpt":0.31637096160452505,"score_spread":0.30365330445769856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795732342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924153,0.0017426735,0.00010719982,0.0033060203,0.00007779069,0.0022497019,0.000056320638,0.000006604177,0.00003840565],"genre_scores_gemma":[0.9981064,0.00032896202,0.000760755,0.00013327981,0.00009611049,0.00038882147,0.000014769099,0.000024589,0.00014628778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986572,0.00016233651,0.0004537902,0.00017459056,0.00018372182,0.00036833444],"domain_scores_gemma":[0.99851835,0.00015241445,0.00036979842,0.00021210009,0.00063361216,0.000113736416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033034408,0.00015943965,0.0003831656,0.00015034205,0.00006628658,0.0000033690649,0.00012912594,0.00007682691,0.000040527866],"category_scores_gemma":[0.00005392371,0.000077551085,0.00006842722,0.00018785466,0.000633367,0.000063852574,0.00003524572,0.0001451555,0.0000036914648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048762143,0.0019998925,0.93544215,0.00016581951,0.0001538181,0.00008553752,0.0015654314,0.000085185835,0.0041014687,0.000016828055,0.0001653421,0.0074563893],"study_design_scores_gemma":[0.018043809,0.035637256,0.9361801,0.00029569937,0.00043929508,0.00011273111,0.00004667726,0.00014920934,0.0074729086,0.00041720254,0.0010898473,0.00011525312],"about_ca_topic_score_codex":0.000014503064,"about_ca_topic_score_gemma":0.00004123029,"teacher_disagreement_score":0.033637363,"about_ca_system_score_codex":0.00017809655,"about_ca_system_score_gemma":0.000634771,"threshold_uncertainty_score":0.31624416},"labels":[],"label_agreement":null},{"id":"W2795871827","doi":"10.37029/jcas.v4i1.169","title":"BEST VS AFFORDABLE TREATMENT OPTIONS IN PROSTATE CANCER","year":2018,"lang":"en","type":"article","venue":"Journal of Cancer & Allied Specialties","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Prostate cancer; Medicine; Oncology; Cancer; Internal medicine","score_opus":0.043219868279144306,"score_gpt":0.38186777942597727,"score_spread":0.33864791114683296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795871827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96194905,0.02235538,0.0000048566503,0.008198364,0.0010651785,0.000577192,0.00004922862,0.000014036805,0.0057866983],"genre_scores_gemma":[0.84009826,0.12223253,0.0005888114,0.00030835008,0.005368733,0.00017003443,0.00000782703,0.00004901129,0.031176433],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982873,0.000040989562,0.000530566,0.0001926965,0.0004923028,0.0004561101],"domain_scores_gemma":[0.99880123,0.000038478844,0.00026249094,0.00018025606,0.0004947824,0.00022277002],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020319592,0.00021285129,0.0005582213,0.00036337928,0.00013308675,0.000052062,0.000121159945,0.000066525994,0.001566583],"category_scores_gemma":[0.00001931265,0.00014290848,0.00016117693,0.00035540172,0.0002674241,0.0002224256,0.000026890095,0.00024582038,0.00003344808],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033523735,0.0037870966,0.6772779,0.00045688802,0.0028275312,0.0013966504,0.017362565,0.0006469551,0.01728765,0.0012511386,0.03250529,0.21167658],"study_design_scores_gemma":[0.022403806,0.01130794,0.1534289,0.0022016568,0.00073306623,0.00010835771,0.002892032,0.0000867881,0.057233047,0.0009656507,0.74810773,0.00053100137],"about_ca_topic_score_codex":0.0014364807,"about_ca_topic_score_gemma":0.007791507,"teacher_disagreement_score":0.71560246,"about_ca_system_score_codex":0.0016881119,"about_ca_system_score_gemma":0.001611617,"threshold_uncertainty_score":0.99934614},"labels":[],"label_agreement":null},{"id":"W2795941895","doi":"10.3389/fonc.2018.00093","title":"Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network","year":2018,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; RNA splicing; Androgen receptor; Cancer research; Reprogramming; Alternative splicing; Biology; Transcriptome; Cancer; RNA; Gene; Exon; Gene expression; Genetics","score_opus":0.015625780389486928,"score_gpt":0.33029363140349544,"score_spread":0.3146678510140085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795941895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97861344,0.0046085455,0.0008557837,0.0049046925,0.0020498494,0.0017483662,0.000032696244,0.000055377077,0.0071312343],"genre_scores_gemma":[0.95578647,0.0034880037,0.027047744,0.001442796,0.0006974909,0.00040763005,0.00021561986,0.00007632511,0.010837901],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983265,0.0001238722,0.00041505747,0.00031163936,0.0002359871,0.0005869427],"domain_scores_gemma":[0.9992594,0.00009663786,0.00016057187,0.0002326547,0.00013857945,0.00011214272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034250758,0.00016115811,0.00043995449,0.00011834077,0.00013265411,0.0000059953245,0.00015606829,0.000062088024,0.00007165129],"category_scores_gemma":[0.00008235476,0.00010848867,0.000043720378,0.0004966541,0.00047342002,0.000041369243,0.00009890844,0.00030821215,0.000013012978],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0097092325,0.0004664325,0.19790027,0.0002389129,0.000799878,0.0009226695,0.010239164,0.00010704432,0.011628476,0.000082406434,0.54425484,0.2236507],"study_design_scores_gemma":[0.011370697,0.0032200853,0.021540971,0.0003569709,0.00012676661,0.00012655417,0.004090994,0.0018585963,0.044960704,0.00028440056,0.9117098,0.0003534862],"about_ca_topic_score_codex":0.00017404722,"about_ca_topic_score_gemma":0.00027559992,"teacher_disagreement_score":0.36745495,"about_ca_system_score_codex":0.0011536751,"about_ca_system_score_gemma":0.0011278403,"threshold_uncertainty_score":0.44240394},"labels":[],"label_agreement":null},{"id":"W2801312275","doi":"10.1016/j.cell.2018.03.029","title":"The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression","year":2018,"lang":"en","type":"article","venue":"Cell","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":271,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Toronto General Hospital; University of Toronto; University Health Network; Princess Margaret Cancer Centre; Occupational Cancer Research Centre; Ontario Institute for Cancer Research","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Cancer Society; Prostate Cancer Canada; Canada First Research Excellence Fund; Government of Ontario; Compute Canada; Canadian Institutes of Health Research; Genome Canada; Government of Canada; Ontario Institute for Cancer Research; Terry Fox Research Institute; Movember Foundation","keywords":"Biology; Prostate cancer; Prostate; Cancer research; Point mutation; Cancer; Oncology; Gene; Mutation; Internal medicine; Genetics; Medicine","score_opus":0.028524503377508517,"score_gpt":0.36336873912406664,"score_spread":0.33484423574655814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801312275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96791404,0.014335074,0.000019131367,0.0010454637,0.0004635594,0.00050118193,0.000012600714,0.00002932849,0.015679602],"genre_scores_gemma":[0.9795698,0.008825052,0.00019391206,0.00007216483,0.00029498906,0.000019819712,0.000022138047,0.000011093673,0.010991064],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991738,0.00006239381,0.00021052525,0.00015032387,0.00020673181,0.00019623488],"domain_scores_gemma":[0.9993159,0.000121255136,0.00007921782,0.00022159773,0.00016233747,0.00009966198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002276306,0.00006861912,0.00015071206,0.00002816031,0.00013190428,0.000005755627,0.00007723959,0.00005285941,0.00014732289],"category_scores_gemma":[0.000047820282,0.00003486633,0.00007251079,0.0001182271,0.00055254484,0.000023802753,0.00004751667,0.000118446835,0.00006593457],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011575387,0.00061741343,0.6605214,0.00030948504,0.00026569125,0.000095907024,0.0016425735,0.000004497589,0.01575529,0.000060575912,0.22077897,0.08837284],"study_design_scores_gemma":[0.02361452,0.0073305597,0.17698313,0.0016336432,0.0002713787,0.000026403772,0.0019255392,0.0047249664,0.1703501,0.0007773261,0.61197716,0.00038524135],"about_ca_topic_score_codex":0.00002862766,"about_ca_topic_score_gemma":0.000007780071,"teacher_disagreement_score":0.48353824,"about_ca_system_score_codex":0.000052819032,"about_ca_system_score_gemma":0.0003799278,"threshold_uncertainty_score":0.20358746},"labels":[],"label_agreement":null},{"id":"W2801612425","doi":"10.1016/j.euo.2018.04.013","title":"Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Rochester Epidemiology Project; Epidemiology; Surveillance, Epidemiology, and End Results; Odds ratio; Confidence interval; Cohort; Incidence (geometry); Internal medicine; Population; Logistic regression; Cancer; Prostate; Cancer registry","score_opus":0.05876208115487862,"score_gpt":0.37008032226869425,"score_spread":0.3113182411138156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801612425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97511613,0.0030520929,0.00000786119,0.0126435105,0.0001227584,0.00080597703,0.0012598268,0.000010742468,0.0069810697],"genre_scores_gemma":[0.99467456,0.0015416672,0.0000873233,0.0031255751,0.000073379,0.000042297434,0.00021877671,0.000016103375,0.00022028637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9896074,0.008653962,0.00081058015,0.00043263653,0.00011284135,0.00038257483],"domain_scores_gemma":[0.9944896,0.0040503787,0.00051959284,0.0006086846,0.0002309399,0.00010078424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067513934,0.00017725662,0.00095900666,0.0003555879,0.000078356185,0.0000024288875,0.00029763207,0.000063545536,0.000039600898],"category_scores_gemma":[0.002559958,0.00009347078,0.000115811155,0.0010031292,0.0023557274,0.00005018966,0.00023143544,0.00035055575,0.000004624456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015442751,0.0006661928,0.95609176,0.00007936102,0.0019731044,0.0010828222,0.006470443,0.000045723173,0.0010147312,0.00030056486,0.0099813,0.0068512387],"study_design_scores_gemma":[0.008859992,0.0028787302,0.96436226,0.00001926165,0.00069544616,0.00004647528,0.000573442,0.0002596737,0.00009571823,0.00006975722,0.022055088,0.0000841766],"about_ca_topic_score_codex":0.0024781954,"about_ca_topic_score_gemma":0.0030752379,"teacher_disagreement_score":0.01955843,"about_ca_system_score_codex":0.000044621538,"about_ca_system_score_gemma":0.0004939824,"threshold_uncertainty_score":0.8679776},"labels":[],"label_agreement":null},{"id":"W2802403307","doi":"10.1007/978-3-319-78196-9_5","title":"Timelines of Prostate Cancer Biomarkers","year":2018,"lang":"en","type":"book-chapter","venue":"Lecture notes in social networks","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Prostate cancer; Disease; Prostate-specific antigen; Popularity; Biomarker; Timeline; Biomarker discovery; Cancer biomarkers; Medicine; Cancer; Computational biology; Bioinformatics; Oncology; Gene; Internal medicine; Biology; Proteomics; Psychology; Genetics","score_opus":0.024468752175372793,"score_gpt":0.3257551131412517,"score_spread":0.3012863609658789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802403307","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013577357,0.32582045,0.0037032191,0.01950825,0.0065125707,0.012556694,0.0011220978,0.000554436,0.6166449],"genre_scores_gemma":[0.55038315,0.04776489,0.0014154552,0.0022690643,0.029122056,0.00036320282,0.002176439,0.0007916821,0.36571407],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984319,0.000024856727,0.00038499333,0.00038823255,0.00035771664,0.00041226757],"domain_scores_gemma":[0.99910325,0.00012674382,0.00021484004,0.00020773553,0.000263574,0.00008387233],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001577209,0.0003527352,0.0007282412,0.00018197343,0.00008643947,0.0000123644495,0.000116421215,0.0008207294,0.0016805374],"category_scores_gemma":[0.000033953675,0.00027443722,0.00023345648,0.00014793317,0.00053578906,0.000023047403,0.00007328963,0.0006596224,0.000013623805],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010497101,0.00027400348,0.022664875,0.0017562633,0.0047370177,0.00053862936,0.005669326,0.0007731903,0.00036446998,0.0007523152,0.06763648,0.88433635],"study_design_scores_gemma":[0.032314397,0.004990097,0.008894416,0.021417318,0.0049207485,0.00007467955,0.000100995596,0.0082217725,0.0061328155,0.14556569,0.76176775,0.00559932],"about_ca_topic_score_codex":0.00009752458,"about_ca_topic_score_gemma":0.00027543606,"teacher_disagreement_score":0.87873703,"about_ca_system_score_codex":0.000273741,"about_ca_system_score_gemma":0.00032700223,"threshold_uncertainty_score":0.9999708},"labels":[],"label_agreement":null},{"id":"W2802666740","doi":"10.1073/pnas.1802415115","title":"Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells","year":2018,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; V Foundation for Cancer Research; U.S. Department of Veterans Affairs","keywords":"RNA splicing; Gene knockdown; Minigene; Prostate cancer; Cancer research; Demethylase; Androgen receptor; Vorinostat; Biology; Histone; Coactivator; Histone deacetylase; Cell biology; Molecular biology; Cancer; Cell culture; Transcription factor; RNA; Genetics; Gene","score_opus":0.05606306246090057,"score_gpt":0.38657085961212484,"score_spread":0.33050779715122425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802666740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99119174,0.00051064865,4.1809147e-7,0.004618034,0.000032773478,0.00055778876,0.000028193812,0.0000058522796,0.0030545457],"genre_scores_gemma":[0.9980428,0.00030079926,0.00089492137,0.000111196525,0.00010685498,0.000034377415,1.9454238e-7,0.0000059965855,0.0005028111],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99795246,0.000009329277,0.0003790807,0.00027453422,0.0011622472,0.00022233812],"domain_scores_gemma":[0.99884367,0.00007478786,0.0004161032,0.000012054218,0.0006010043,0.00005238026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012724691,0.00010688048,0.0002519717,0.0003054042,0.000100958256,0.000008765546,0.0003665835,0.000052127743,0.00003245685],"category_scores_gemma":[0.00020490903,0.00006407479,0.000058087193,0.00096730655,0.0015330417,0.00026409206,0.000119849414,0.00018596876,0.0000012570733],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021214728,0.00015781427,0.018114489,0.00026134576,0.000044390315,1.5260373e-7,0.0016375293,0.000014964149,0.9769658,0.0016045683,0.00019097868,0.0007958585],"study_design_scores_gemma":[0.0007703404,0.00026091936,0.022097109,0.00063775183,0.000024311656,0.0000058577116,0.00018292805,0.0009498591,0.96865827,0.0062694317,0.000080453145,0.00006278259],"about_ca_topic_score_codex":0.00022360253,"about_ca_topic_score_gemma":0.0000014079938,"teacher_disagreement_score":0.0083075045,"about_ca_system_score_codex":0.00015753182,"about_ca_system_score_gemma":0.0001837923,"threshold_uncertainty_score":0.5648556},"labels":[],"label_agreement":null},{"id":"W2802707364","doi":"10.1038/s41467-018-03054-w","title":"Publisher Correction: A PRDX1 mutant allele causes a MMACHC secondary epimutation in cblC patients","year":2018,"lang":"en","type":"erratum","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Genetics; Allele; Mutant; Biology; Medicine; Gene","score_opus":0.025848172248735424,"score_gpt":0.3478734755007837,"score_spread":0.32202530325204826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802707364","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003941709,0.088831514,0.000008519142,0.028611366,0.066711485,0.0062375674,0.00048576365,0.00048639986,0.80468565],"genre_scores_gemma":[0.21173507,0.021465896,0.0010583601,0.0021507053,0.0018017783,0.0014523474,0.0730858,0.0002478033,0.68700224],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977471,0.0002554419,0.0005022693,0.0004817756,0.0005986886,0.00041471698],"domain_scores_gemma":[0.9960223,0.00020664498,0.00025949246,0.0022001902,0.0011355274,0.00017586669],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0002901762,0.00034826557,0.0005192769,0.000641891,0.0003260105,0.0001239756,0.0008154161,0.0014356774,0.00043738107],"category_scores_gemma":[0.00068166683,0.00029762834,0.00015843655,0.0009462654,0.00032889043,0.0003035214,0.00042252569,0.0056202663,0.000083957486],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014307933,0.0007730224,0.011621719,0.00010944087,0.00018595897,0.000014529697,0.0006863392,2.1109615e-7,0.0000058168093,0.00003451237,0.98222876,0.0041966117],"study_design_scores_gemma":[0.0021247407,0.00030851064,0.06282318,0.00047548578,0.00013926899,0.000018352232,0.00015352944,0.00013452582,0.000014975197,0.00013555693,0.933417,0.00025485686],"about_ca_topic_score_codex":0.00028316278,"about_ca_topic_score_gemma":0.006937397,"teacher_disagreement_score":0.20779335,"about_ca_system_score_codex":0.000950441,"about_ca_system_score_gemma":0.0016008824,"threshold_uncertainty_score":0.9999476},"labels":[],"label_agreement":null},{"id":"W2803285371","doi":"10.1038/s41585-018-0020-2","title":"Translational models of prostate cancer bone metastasis","year":2018,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Prostate cancer; Medicine; Bone metastasis; Metastasis; Translational research; Disease; Cancer; Prostate; Oncology; Bioinformatics; Internal medicine; Pathology; Biology","score_opus":0.10535367727482654,"score_gpt":0.44095601796877915,"score_spread":0.3356023406939526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803285371","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000015047442,0.99323696,0.00001706056,0.0007710065,0.00031586018,0.0037740283,0.00049621,0.000024359102,0.0013630236],"genre_scores_gemma":[0.000008411525,0.9954341,0.0006431803,0.00025586024,0.00043944834,0.0008837079,0.0007694179,0.00007253748,0.0014933072],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99684876,0.00046401037,0.0011523551,0.0006571009,0.00040977763,0.00046797722],"domain_scores_gemma":[0.9981643,0.0001481026,0.00063356804,0.00057802437,0.00030419545,0.00017180105],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007812886,0.0005313713,0.0042717243,0.00040273057,0.00005077069,0.000006655316,0.00021953037,0.0011317198,0.0005671526],"category_scores_gemma":[0.00008423074,0.0003109576,0.0011998323,0.0006808528,0.00028051742,0.00006962768,0.000056203142,0.0015417923,0.00007501147],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013413062,0.00010539876,0.0000080316695,0.04110999,0.0007725638,0.000037541326,0.00004477824,4.1032385e-7,7.098862e-7,0.00025571193,0.0070821247,0.95044863],"study_design_scores_gemma":[0.0006643783,0.0003037025,0.0000017488001,0.0071899625,0.004998775,0.00018191806,6.098599e-7,0.000009927871,0.0000030618323,0.0002654643,0.98617756,0.00020287832],"about_ca_topic_score_codex":0.0000105168665,"about_ca_topic_score_gemma":0.000012063549,"teacher_disagreement_score":0.97909546,"about_ca_system_score_codex":0.000108242784,"about_ca_system_score_gemma":0.0011015632,"threshold_uncertainty_score":0.99993426},"labels":[],"label_agreement":null},{"id":"W2804058066","doi":"10.1158/1078-0432.ccr-17-2745","title":"Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aptose Biosciences (Canada)","funders":"National Cancer Institute","keywords":"Prostatectomy; Prostate cancer; Androgen deprivation therapy; Medicine; Oncology; Propensity score matching; Biochemical recurrence; Internal medicine; Metastasis; Proportional hazards model; Cancer; Urology","score_opus":0.1901585316872817,"score_gpt":0.4922202416215116,"score_spread":0.3020617099342299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804058066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879538,0.006246886,0.0000039053652,0.0023521269,0.0002888562,0.0028070952,0.00007558266,0.000056106182,0.0002156775],"genre_scores_gemma":[0.9895328,0.0039295396,0.0005865525,0.00007787009,0.00044996428,0.0011834386,0.000040804847,0.00006232273,0.0041367006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954074,0.0007601172,0.00073973415,0.0008644502,0.0013119405,0.0009163838],"domain_scores_gemma":[0.9973595,0.0007912388,0.00014830648,0.00046233658,0.00060074776,0.00063783635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003696305,0.0002886031,0.0006914488,0.00036182487,0.00036075877,0.00006557488,0.00020114696,0.00030391925,0.00022095807],"category_scores_gemma":[0.0004207313,0.00020146885,0.00018452824,0.00061821245,0.0012619877,0.00015444678,0.00022393536,0.0007609268,0.00003116889],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07433496,0.0011079079,0.7287999,0.00042926584,0.0014390073,0.00036372434,0.008380097,0.000002247318,0.04083828,0.000021319733,0.001212797,0.14307052],"study_design_scores_gemma":[0.019602273,0.00825963,0.58550435,0.0013309611,0.00021778057,0.000010920422,0.00048502468,0.00007122125,0.33090657,0.0001157976,0.053133953,0.0003614927],"about_ca_topic_score_codex":0.00045092055,"about_ca_topic_score_gemma":0.000093661365,"teacher_disagreement_score":0.2900683,"about_ca_system_score_codex":0.0010672031,"about_ca_system_score_gemma":0.004025847,"threshold_uncertainty_score":0.8215661},"labels":[],"label_agreement":null},{"id":"W2804380650","doi":"10.1016/j.ebiom.2018.05.002","title":"Roles of Alternative RNA Splicing of the Bif-1 Gene by SRRM4 During the Development of Treatment-induced Neuroendocrine Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"EBioMedicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; China Scholarship Council; National Natural Science Foundation of China","keywords":"Prostate cancer; Cancer research; RNA splicing; Biology; Cancer; Gene; Cancer cell; RNA; Genetics","score_opus":0.026695787592733475,"score_gpt":0.3297594905272423,"score_spread":0.3030637029345088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804380650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99439824,0.0012692935,0.000009036893,0.0028065466,0.00020545327,0.0009129349,0.000055945755,0.0000122639,0.00033027618],"genre_scores_gemma":[0.99622875,0.0007734271,0.00009152516,0.000050700324,0.00020879928,0.00007241624,0.000016884915,0.000024649953,0.0025328347],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983666,0.00005161323,0.00052494166,0.0002485433,0.00048490078,0.00032341006],"domain_scores_gemma":[0.99885565,0.000060044073,0.00032486286,0.00040220722,0.0002668187,0.00009042355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014569724,0.00020279872,0.00045076202,0.00014259221,0.00013018238,0.0000029710604,0.00020305648,0.000023327382,0.00008501794],"category_scores_gemma":[0.000032364413,0.00009071221,0.000083519124,0.00049495284,0.00053520343,0.000035503435,0.000111542664,0.00011142832,0.0000015389029],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067466026,0.0001969817,0.02158061,0.00016369598,0.00044696988,0.000009998188,0.0057126493,0.0000015318154,0.95374507,0.000003119841,0.00014591885,0.017318804],"study_design_scores_gemma":[0.0045908233,0.0012056977,0.033626076,0.00045799627,0.00013292089,0.000015215239,0.000561191,0.000053482785,0.95823276,0.000011655652,0.0010443782,0.0000678203],"about_ca_topic_score_codex":0.0007331414,"about_ca_topic_score_gemma":0.00014740169,"teacher_disagreement_score":0.017250983,"about_ca_system_score_codex":0.00025903172,"about_ca_system_score_gemma":0.00038641543,"threshold_uncertainty_score":0.36991367},"labels":[],"label_agreement":null},{"id":"W2804455592","doi":"10.5489/cuaj.5154","title":"Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: Expert opinion and review of the evidence","year":2018,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre; Université Laval; University of Alberta; Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Lower urinary tract symptoms; Expert opinion; Cancer; Population; Patient assessment; Intensive care medicine; Oncology; Internal medicine; Prostate","score_opus":0.08927064296835356,"score_gpt":0.4424080358760389,"score_spread":0.3531373929076853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804455592","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013304579,0.98740965,0.0000012623285,0.0086993445,0.00015459224,0.0023070667,0.000060043516,0.0000049314385,0.00003264676],"genre_scores_gemma":[0.0006020835,0.9978619,0.0002811606,0.00041281775,0.00016476902,0.000407181,0.000024658535,0.000015094591,0.00023032849],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975073,0.0005996399,0.00075553416,0.00032403064,0.00044283227,0.00037066545],"domain_scores_gemma":[0.99825305,0.0002312241,0.00060312107,0.00012529301,0.00033266167,0.00045463574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010748745,0.00025860238,0.00096092245,0.00022956432,0.00019666029,0.00006377021,0.00009249977,0.0001462618,0.000063172636],"category_scores_gemma":[0.000547886,0.00013418654,0.00015144082,0.0004510574,0.000049057737,0.00008687094,0.000031394935,0.00035029388,0.0000012291647],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006988241,0.000085296895,0.0281817,0.0075192912,0.00032891717,0.00004532508,0.00018172985,6.657257e-7,0.000018366029,0.0000061849805,0.003042136,0.9605205],"study_design_scores_gemma":[0.00081247976,0.0019228716,0.022762587,0.10315856,0.00052253617,0.0002604124,0.000020276839,0.000024856261,0.000006801262,0.000014224781,0.87030643,0.00018798451],"about_ca_topic_score_codex":0.001924661,"about_ca_topic_score_gemma":0.0027433718,"teacher_disagreement_score":0.9603325,"about_ca_system_score_codex":0.0052380157,"about_ca_system_score_gemma":0.004088052,"threshold_uncertainty_score":0.9985807},"labels":[],"label_agreement":null},{"id":"W2805054456","doi":"10.1200/jco.2018.36.18_suppl.lba5005","title":"Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Prednisone; Prostate cancer; Internal medicine; Abiraterone acetate; Regimen; Oncology; Performance status; Randomization; Clinical endpoint; Cancer; Gastroenterology; Randomized controlled trial; Surgery; Androgen deprivation therapy","score_opus":0.15815292437814457,"score_gpt":0.5027045043736905,"score_spread":0.344551579995546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805054456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97286725,0.00047630366,0.000034585577,0.01885291,0.0002108542,0.0003808059,0.000032504016,0.000009428072,0.007135382],"genre_scores_gemma":[0.9931579,0.0010873745,0.0025881946,0.00036830845,0.0012581692,0.000012655986,0.0000055536707,0.000023936836,0.0014978994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972313,0.00040132622,0.0012164728,0.00024819336,0.0005374683,0.00036525674],"domain_scores_gemma":[0.99642664,0.0010046352,0.0011023945,0.00016012139,0.00068082736,0.0006253541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017964587,0.000173378,0.0013982909,0.00013202612,0.00009037119,0.000024784833,0.00010844351,0.00008944035,0.00012880661],"category_scores_gemma":[0.00043079603,0.000099769015,0.0001445914,0.00021962957,0.0011487938,0.00013272364,0.000039706174,0.0006310991,0.0000067853925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032676935,0.0011102733,0.72065824,0.00010847172,0.0034415661,0.002405959,0.001520194,0.0000033373383,0.0007367714,0.00012621238,0.0048469296,0.2323651],"study_design_scores_gemma":[0.014656102,0.045162257,0.8925962,0.00014855244,0.0010931131,0.00018293744,0.0012603281,0.000036279478,0.0002244178,0.0002786664,0.044191435,0.00016971842],"about_ca_topic_score_codex":0.0006484198,"about_ca_topic_score_gemma":0.00097129965,"teacher_disagreement_score":0.23219538,"about_ca_system_score_codex":0.00024524026,"about_ca_system_score_gemma":0.0031750463,"threshold_uncertainty_score":0.5632396},"labels":[],"label_agreement":null},{"id":"W2805138983","doi":"","title":"Steroid derivatives as pure antagonists of the androgen receptor","year":2012,"lang":"en","type":"article","venue":"15th International & 14th European Congress of Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Natural Sciences and Engineering Research Council of Canada","funders":"","keywords":"Bicalutamide; Flutamide; LNCaP; Androgen receptor; Dihydrotestosterone; Endocrinology; Androgen; Internal medicine; In vivo; Chemistry; Antiandrogens; Antiandrogen; Prostate cancer; Pharmacology; Hormone; Biology; Medicine; Cancer","score_opus":0.03457134708597947,"score_gpt":0.33719878875530185,"score_spread":0.3026274416693224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805138983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9617481,0.0015352067,0.0000048380016,0.0024855856,0.0013523705,0.0002616415,0.00007793981,0.000018355051,0.032515947],"genre_scores_gemma":[0.9938442,0.0004814841,0.00011593391,0.00016247889,0.00025631298,0.000008796596,0.00004459192,0.000021182059,0.0050649988],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99878126,0.00016861365,0.00029918266,0.00015982648,0.00030455785,0.00028658198],"domain_scores_gemma":[0.9991155,0.000062487066,0.00020251231,0.00025762882,0.0002801535,0.00008171748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000117429474,0.00012243904,0.00022389577,0.00010344147,0.000042600313,0.0000070572855,0.00034716452,0.000026610041,0.00057815446],"category_scores_gemma":[0.00018467952,0.00007874744,0.00010537566,0.00008587155,0.00041002547,0.000096945645,0.00026059593,0.00016371641,0.00007266161],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011011101,0.00067297963,0.86411697,0.00012489567,0.0010831502,0.000070924885,0.0009922788,0.0000033599704,0.104925856,0.0109924255,0.008154036,0.0077620237],"study_design_scores_gemma":[0.0038930133,0.000483435,0.360706,0.0001868367,0.00006398585,0.00025095357,0.00030539112,0.00000900603,0.48078626,0.000061776394,0.15310611,0.00014724828],"about_ca_topic_score_codex":0.000019633624,"about_ca_topic_score_gemma":0.0000018367799,"teacher_disagreement_score":0.503411,"about_ca_system_score_codex":0.00004640951,"about_ca_system_score_gemma":0.000064498396,"threshold_uncertainty_score":0.6330386},"labels":[],"label_agreement":null},{"id":"W2806376672","doi":"10.1136/bmjopen-2018-022899","title":"Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol","year":2018,"lang":"en","type":"article","venue":"BMJ Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Alberta","funders":"National Cancer Institute; Movember Foundation","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Enzalutamide; Internal medicine; Oncology; Aerobic exercise; Disease; Quality of life (healthcare); Randomized controlled trial; Cancer; Physical therapy; Androgen receptor","score_opus":0.0934719071357001,"score_gpt":0.47132429343480686,"score_spread":0.3778523862991068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806376672","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23161383,0.000030214462,0.00004829865,0.0003863205,0.00007368606,0.765524,0.00011381519,0.000047354286,0.0021624358],"genre_scores_gemma":[0.27376324,0.000005908827,0.0003142839,0.000047146925,0.000104928884,0.70223635,0.000037072397,0.000067423454,0.023423664],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99664396,0.0003317396,0.0008705687,0.00072032894,0.00067887775,0.00075453636],"domain_scores_gemma":[0.9972521,0.00023380436,0.00042399566,0.0006408585,0.0010287722,0.000420456],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021364626,0.0004542741,0.0017175409,0.00014755581,0.00028938687,0.00029537658,0.0003813126,0.00004225852,0.00054259127],"category_scores_gemma":[0.00017854618,0.0002518076,0.00019568832,0.00028857082,0.00031988267,0.00033886734,0.00022361302,0.00016385052,0.000018643581],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9765906,0.0030290799,0.0046171458,0.0005829975,0.002327684,0.0007458349,0.0052124797,0.0000032703742,0.0011574682,0.000003223686,0.0028227076,0.0029075416],"study_design_scores_gemma":[0.9620558,0.013395353,0.0012229021,0.001594409,0.0018016219,0.000014171075,0.010503784,0.0029983772,0.0053269137,0.000014318001,0.00066458865,0.0004077464],"about_ca_topic_score_codex":0.003184415,"about_ca_topic_score_gemma":0.0043878458,"teacher_disagreement_score":0.06328771,"about_ca_system_score_codex":0.0002526399,"about_ca_system_score_gemma":0.0011301857,"threshold_uncertainty_score":0.99999344},"labels":[],"label_agreement":null},{"id":"W2806421431","doi":"10.1016/s1470-2045(18)30365-6","title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":409,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Prostate cancer; Internal medicine; Oncology; Enzalutamide; PARP inhibitor; Placebo; Clinical endpoint; Docetaxel; Population; Androgen deprivation therapy; Clinical trial; Cancer; Androgen receptor; Pathology","score_opus":0.063617209979282,"score_gpt":0.3828651709096185,"score_spread":0.3192479609303365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806421431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98121595,0.00020173941,0.000012200815,0.004527442,0.00018302698,0.012224278,0.000052876618,0.00004164697,0.0015408413],"genre_scores_gemma":[0.99354964,0.00009567144,0.00022515119,0.00035799338,0.00039556366,0.0040394845,0.00014135626,0.000035122277,0.0011600158],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99772143,0.0003794297,0.00047153435,0.00036667034,0.00042335538,0.0006375573],"domain_scores_gemma":[0.9986042,0.0002642942,0.000270338,0.0003938541,0.0003217043,0.00014561533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094779657,0.00027444592,0.0012844147,0.00014172762,0.00017457386,0.00004397904,0.0001701367,0.00007391293,0.00019312638],"category_scores_gemma":[0.00003678713,0.00012676454,0.000058273476,0.00036850292,0.00050975056,0.00010584325,0.00002481538,0.00035064743,0.000022754595],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.990548,0.0019789357,0.0029984643,0.0000622484,0.00078426645,0.00012910969,0.0011758307,0.0000160463,0.00032166517,0.00006827464,0.00054727006,0.0013698973],"study_design_scores_gemma":[0.9548543,0.041057363,0.0011545251,0.00010458466,0.0005319158,0.000008342437,0.00015341448,0.00009402092,0.0007001543,0.000039067218,0.0011464215,0.00015590953],"about_ca_topic_score_codex":0.00037165615,"about_ca_topic_score_gemma":0.0032568295,"teacher_disagreement_score":0.039078426,"about_ca_system_score_codex":0.0004132538,"about_ca_system_score_gemma":0.0011225702,"threshold_uncertainty_score":0.51693076},"labels":[],"label_agreement":null},{"id":"W2807085990","doi":"10.1016/j.clgc.2018.05.016","title":"Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Cancer; Prostate cancer; Prostate; Oncology; Internal medicine","score_opus":0.17179034212278158,"score_gpt":0.4655013243474023,"score_spread":0.2937109822246208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807085990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96314436,0.032149475,0.0000033075014,0.00095768424,0.0012042995,0.0015556492,0.00031298932,0.00003977437,0.00063245423],"genre_scores_gemma":[0.9803288,0.016456122,0.00006171768,0.00030326872,0.0010725426,0.0006876449,0.00010069215,0.00004335836,0.00094583456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99721575,0.0002679207,0.0008755827,0.000641684,0.0005347462,0.00046432408],"domain_scores_gemma":[0.997829,0.00018534625,0.00034049564,0.0004576605,0.0008968635,0.0002905985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000548085,0.0002741245,0.00075788837,0.0001730864,0.00008722047,0.00001421075,0.00017692092,0.00016762874,0.00040775648],"category_scores_gemma":[0.00010890537,0.00021457284,0.00016694357,0.00083992333,0.0007098803,0.00018846637,0.00011832114,0.0003868063,0.000021151489],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00342701,0.0015172067,0.95548385,0.0005354507,0.00030880448,0.00008179426,0.00025560663,0.0000149976095,0.0007277947,0.000005008306,0.011721029,0.025921462],"study_design_scores_gemma":[0.0074458322,0.0021626183,0.9635458,0.0011198196,0.00012459682,0.0000010096713,0.00008536743,0.00006990397,0.012493788,0.00003804021,0.012668442,0.00024479],"about_ca_topic_score_codex":0.001741633,"about_ca_topic_score_gemma":0.00069888,"teacher_disagreement_score":0.025676673,"about_ca_system_score_codex":0.00038811722,"about_ca_system_score_gemma":0.0015867748,"threshold_uncertainty_score":0.8750026},"labels":[],"label_agreement":null},{"id":"W2807345550","doi":"10.1016/j.euo.2018.04.004","title":"Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Hazard ratio; Oncology; Internal medicine; Placebo; Androgen deprivation therapy; Randomized controlled trial; Confidence interval; Prostate-specific antigen; Cancer; Urology; Androgen receptor; Pathology","score_opus":0.03979434032370471,"score_gpt":0.3766406032830469,"score_spread":0.33684626295934217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807345550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911421,0.002649276,0.000008321169,0.00079137605,0.00012843117,0.0006931584,0.000042174666,0.000036936373,0.004508214],"genre_scores_gemma":[0.99785984,0.00041952997,0.00088411116,0.0003086928,0.000094369345,0.000042006366,0.00005131508,0.00003733112,0.00030282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767154,0.0007304723,0.0005305225,0.0004573339,0.00015897528,0.00045116327],"domain_scores_gemma":[0.99904925,0.00015752147,0.00021118767,0.00026642653,0.0001297303,0.0001858824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062424794,0.00019716601,0.00065711717,0.00028410114,0.00009147054,0.00000785601,0.0001192925,0.000085759624,0.00010196459],"category_scores_gemma":[0.00009489394,0.0001660774,0.00003664407,0.0002679418,0.000836114,0.00008374452,0.00008239533,0.0003067958,0.000022788645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012801379,0.0015973675,0.55473137,0.00019967732,0.0003627131,0.0017178116,0.013936718,0.000117430885,0.22034162,0.000112889626,0.00026393318,0.19381706],"study_design_scores_gemma":[0.016867142,0.028216964,0.8933725,0.00009512881,0.0003770174,0.00026697884,0.0013282784,0.0012367046,0.039517164,0.00019228441,0.018147998,0.00038187948],"about_ca_topic_score_codex":0.00013300739,"about_ca_topic_score_gemma":0.001955466,"teacher_disagreement_score":0.33864108,"about_ca_system_score_codex":0.0001354467,"about_ca_system_score_gemma":0.00031718705,"threshold_uncertainty_score":0.677244},"labels":[],"label_agreement":null},{"id":"W2807386738","doi":"10.1002/pros.23662","title":"A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration‐resistant prostate cancer","year":2018,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute; Exelixis","keywords":"Medicine; Cabozantinib; Abiraterone acetate; Prostate cancer; Tolerability; Cohort; Internal medicine; Urology; Oncology; Cabazitaxel; Prednisone; Cancer; Adverse effect; Androgen deprivation therapy","score_opus":0.12915397296665254,"score_gpt":0.434792639625811,"score_spread":0.30563866665915845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807386738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99191684,0.00026907772,0.000006369792,0.0030601171,0.00018297619,0.004092065,0.00007172659,0.000030993982,0.00036982345],"genre_scores_gemma":[0.996382,0.00053674594,0.0003325471,0.00008573206,0.00007110164,0.00049634016,0.000060510538,0.000037401096,0.0019976331],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972271,0.0003856052,0.0009738606,0.00041200878,0.00048315898,0.0005182654],"domain_scores_gemma":[0.9986833,0.00019017045,0.00036761246,0.00038228362,0.0002606407,0.000116017756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017311214,0.00023931089,0.0006126513,0.0002584151,0.000096631404,0.000046540787,0.00014964041,0.000059792972,0.000055320903],"category_scores_gemma":[0.00011764569,0.00014045047,0.00007031759,0.00074557937,0.0006045449,0.00018479864,0.00006266152,0.00036608826,0.000013875315],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78551,0.003990905,0.1385302,0.0008093294,0.0005678978,0.0007026549,0.022543216,0.000053735934,0.015748322,0.0002531729,0.0002066414,0.031083954],"study_design_scores_gemma":[0.51683104,0.02948617,0.4184485,0.0021401993,0.00043680996,0.00005147589,0.0021462257,0.0019648052,0.025772702,0.0011901681,0.00093613093,0.0005957885],"about_ca_topic_score_codex":0.0006511307,"about_ca_topic_score_gemma":0.003154039,"teacher_disagreement_score":0.2799183,"about_ca_system_score_codex":0.00012286066,"about_ca_system_score_gemma":0.00082924264,"threshold_uncertainty_score":0.5727404},"labels":[],"label_agreement":null},{"id":"W2807985734","doi":"10.1016/j.cell.2018.05.036","title":"Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing","year":2018,"lang":"en","type":"article","venue":"Cell","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":379,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Human Genome Research Institute; Fund for Innovation in Cancer Informatics; Gerstner Family Foundation; American Cancer Society; Kreftforeningen; American Association for Cancer Research; Prostate Cancer Foundation; Movember Foundation; National Institutes of Health; Canadian Institutes of Health Research; U.S. Department of Defense","keywords":"Biology; Prostate cancer; Chromoplexy; Whole genome sequencing; Genome; Gene duplication; Genetics; Gene; Context (archaeology); Enhancer; Tandem exon duplication; Computational biology; Cancer; Cancer research; PCA3; Gene expression","score_opus":0.033263466610963514,"score_gpt":0.32183607251240054,"score_spread":0.288572605901437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807985734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918516,0.0016749937,0.00002805523,0.0010133062,0.00019038538,0.0006840204,0.00010578026,0.00005999608,0.004391815],"genre_scores_gemma":[0.9682464,0.00026018365,0.0004700129,0.0001594274,0.00047939495,0.00008032344,0.00026410157,0.000027952638,0.030012187],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879307,0.000034268884,0.00023802693,0.00030465337,0.0002461801,0.00038380933],"domain_scores_gemma":[0.99922603,0.000026643407,0.0000738487,0.00023963494,0.0002469662,0.00018687992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098876306,0.00015772737,0.00018933878,0.000070803915,0.00031415012,0.00007035787,0.00007600665,0.00006245529,0.0007799591],"category_scores_gemma":[0.000016995318,0.00012175296,0.000050209805,0.00019263524,0.00013841869,0.00013335214,0.000029851384,0.00017536298,0.00006521103],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012473296,0.000023343013,0.008206798,0.000107320884,0.000049908944,0.00004607695,0.0019396275,0.000014873417,0.9865133,0.000010328484,0.0022760548,0.0006876321],"study_design_scores_gemma":[0.014297676,0.0034336376,0.16537619,0.0010746953,0.00063870964,0.00011262997,0.002317065,0.0063977893,0.75037336,0.0005034225,0.053899594,0.0015752452],"about_ca_topic_score_codex":0.00035969686,"about_ca_topic_score_gemma":0.00029215784,"teacher_disagreement_score":0.23613995,"about_ca_system_score_codex":0.00046708438,"about_ca_system_score_gemma":0.00048796038,"threshold_uncertainty_score":0.8540005},"labels":[],"label_agreement":null},{"id":"W2808022995","doi":"10.2967/jnumed.118.214379","title":"Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies","year":2018,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Radioligand; Prostate cancer; Medicine; Glutamate carboxypeptidase II; Toxicity; Clinical significance; Oncology; Prostate; Internal medicine; Cancer; Receptor","score_opus":0.028162404030906616,"score_gpt":0.337230445021586,"score_spread":0.30906804099067936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808022995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835092,0.0082848435,0.000022240252,0.0044124,0.00015398428,0.00016140717,0.0000025412303,0.0000065245995,0.0034468602],"genre_scores_gemma":[0.9871857,0.011097566,0.00035388814,0.0002827659,0.0008114845,4.2542015e-7,0.0000010524699,0.00001611513,0.00025095677],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989738,0.000052158615,0.00034993642,0.00010296692,0.00037123729,0.00014990385],"domain_scores_gemma":[0.99901915,0.000095335585,0.00025564095,0.00012462624,0.0003501357,0.0001550988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004372128,0.0001051436,0.00043823494,0.00013382449,0.000050394236,0.0000076241167,0.000076487326,0.000055265722,0.0002568088],"category_scores_gemma":[0.000121194294,0.000059228314,0.000054518267,0.00014186584,0.0006285554,0.00013985287,0.000021093374,0.00020592457,0.0000023200923],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017202945,0.0006640132,0.020279706,0.00048483355,0.0013585346,0.0005702194,0.013638581,6.7602747e-7,0.86399084,0.00068283704,0.040450554,0.040676266],"study_design_scores_gemma":[0.06396059,0.084821105,0.5770534,0.008308887,0.0009441928,0.004610592,0.015345173,0.000143052,0.13406312,0.008360353,0.10185791,0.0005315948],"about_ca_topic_score_codex":0.000012902036,"about_ca_topic_score_gemma":0.0000021946692,"teacher_disagreement_score":0.7299277,"about_ca_system_score_codex":0.000039191404,"about_ca_system_score_gemma":0.00013043881,"threshold_uncertainty_score":0.28118762},"labels":[],"label_agreement":null},{"id":"W2808221505","doi":"10.21037/amj.2018.06.02","title":"Does increased expression of glucocorticoid receptor support application of antagonists to this receptor for the treatment of castration resistant prostate cancer?","year":2018,"lang":"en","type":"letter","venue":"AME Medical Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Cancer Institute","keywords":"Prostate cancer; Glucocorticoid receptor; Androgen receptor; Medicine; Receptor; Cancer research; Glucocorticoid; Internal medicine; Androgen deprivation therapy; Endocrinology; Receptor expression; Cancer; Pharmacology","score_opus":0.020313378997481327,"score_gpt":0.34111114994775776,"score_spread":0.32079777095027645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808221505","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2639983,0.0026803454,0.0007717374,0.7174,0.002095002,0.010103998,0.0027722393,0.00003183946,0.00014649425],"genre_scores_gemma":[0.5917424,0.15923217,0.018411864,0.10630634,0.05835271,0.011447156,0.015413441,0.00092450157,0.038169406],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99653256,0.00014252192,0.0010473477,0.00033362844,0.0015598901,0.00038406628],"domain_scores_gemma":[0.9971298,0.00042730843,0.0009352211,0.0004369893,0.00079579215,0.0002748749],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006147795,0.00027377295,0.0008173858,0.00018915831,0.00010912064,0.00001565694,0.0002597149,0.0004007216,0.0015111254],"category_scores_gemma":[0.00021144109,0.00011867665,0.00027125815,0.00019489096,0.00041204775,0.00004832497,0.00003084429,0.000498441,0.000009085298],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010451918,0.00068278064,0.0023917872,0.0014151474,0.0006451722,0.000053284515,0.0015066543,7.333483e-7,0.31389856,0.0000022814922,0.59937024,0.069581404],"study_design_scores_gemma":[0.0040906807,0.00689956,0.00051224424,0.0014514979,0.0004297881,0.000027358636,0.00016472187,0.000030693132,0.36227822,0.000018219067,0.6239585,0.00013849195],"about_ca_topic_score_codex":0.00057011365,"about_ca_topic_score_gemma":0.000035860892,"teacher_disagreement_score":0.6110937,"about_ca_system_score_codex":0.00047763388,"about_ca_system_score_gemma":0.0020042593,"threshold_uncertainty_score":0.9994016},"labels":[],"label_agreement":null},{"id":"W2808797700","doi":"10.1101/352138","title":"Epigenetic analysis identifies factors driving racial disparity in prostate cancer","year":2018,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"Prostate Cancer Foundation","keywords":"Prostate cancer; Epigenetics; Methylation; Wnt signaling pathway; DNA methylation; Biology; Cancer; Gene; Prostate; Genetics; Cancer research; Oncology; Bioinformatics; Medicine; Gene expression","score_opus":0.021967176934890652,"score_gpt":0.29597946886219567,"score_spread":0.27401229192730503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808797700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99214184,0.0045738975,0.00009090392,0.0003076794,0.000927974,0.001432909,0.00032514927,0.00019095362,0.000008700748],"genre_scores_gemma":[0.9957094,0.0027793292,0.00027693724,0.000037620626,0.00048108393,0.00052430015,0.0000043998375,0.00011018983,0.0000767267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960926,0.00017645139,0.0007033272,0.0013362187,0.0007496946,0.000941673],"domain_scores_gemma":[0.9972992,0.00007239616,0.00035230178,0.0012120692,0.00062247424,0.00044158005],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059855275,0.00065032847,0.0012161225,0.0011708422,0.00019730367,0.00025326243,0.0003857963,0.00044481806,0.0002986609],"category_scores_gemma":[0.00023135767,0.00057499466,0.00039706076,0.0018593206,0.00033993565,0.0001490388,0.00057640346,0.0009960289,0.000037389676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014518425,0.00024920277,0.9423459,0.00058466155,0.0016192622,0.00017405866,0.00011292095,0.00006917429,0.05457445,0.0000052817927,0.000117079486,0.0000028065492],"study_design_scores_gemma":[0.0008775171,0.00006177404,0.86983275,0.0006370023,0.0012826863,3.6752927e-9,0.0000088882625,0.0003548556,0.12607878,0.0000020329462,0.0003685121,0.00049519277],"about_ca_topic_score_codex":0.0014003139,"about_ca_topic_score_gemma":0.00057379453,"teacher_disagreement_score":0.07251316,"about_ca_system_score_codex":0.0010834081,"about_ca_system_score_gemma":0.0013595563,"threshold_uncertainty_score":0.99967015},"labels":[],"label_agreement":null},{"id":"W2809721154","doi":"10.1158/1538-7445.am2018-858","title":"Abstract 858: Enzalutamide versus abiraterone as a radiosensitizer in hormone-sensitive prostate cancer cells","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Enzalutamide; LNCaP; Prostate cancer; Medicine; Radiosensitizer; Oncology; Cancer research; Androgen deprivation therapy; Internal medicine; Androgen receptor; Cancer; Radiation therapy","score_opus":0.08356082446428732,"score_gpt":0.4311890294150546,"score_spread":0.3476282049507673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809721154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97493887,0.005113715,9.031686e-7,0.0043173637,0.0005058391,0.001870459,0.000118351054,0.00007417125,0.013060349],"genre_scores_gemma":[0.9760622,0.010190448,0.00005791383,0.0002576287,0.0011346005,0.0006946608,0.000035681784,0.000084090054,0.011482774],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9954024,0.00022165242,0.00040914209,0.00089357636,0.001395756,0.0016774912],"domain_scores_gemma":[0.9973357,0.00028813598,0.00007177562,0.0005805476,0.0011647098,0.00055913074],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001147478,0.0003371136,0.00055464497,0.0006662625,0.00029575426,0.000103366234,0.00022221384,0.0002201851,0.0009810281],"category_scores_gemma":[0.00013745739,0.00027535376,0.000111496716,0.0012904434,0.0011787784,0.00022386805,0.00018700704,0.0011938983,0.0009686908],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03169651,0.00031388208,0.0018869834,0.00022519416,0.0003481024,0.002112495,0.0037121882,0.000012948404,0.92028946,0.000068452704,0.020181505,0.019152291],"study_design_scores_gemma":[0.017209763,0.002438055,0.053480897,0.0006789998,0.00006400783,0.000024680772,0.0015060769,0.00008447738,0.90995914,0.00016130273,0.013914912,0.00047767718],"about_ca_topic_score_codex":0.010945897,"about_ca_topic_score_gemma":0.0018723231,"teacher_disagreement_score":0.051593915,"about_ca_system_score_codex":0.002187365,"about_ca_system_score_gemma":0.0020972933,"threshold_uncertainty_score":0.99996984},"labels":[],"label_agreement":null},{"id":"W2809806585","doi":"10.1097/spc.0000000000000357","title":"Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy","year":2018,"lang":"en","type":"review","venue":"Current Opinion in Supportive and Palliative Care","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Glutamate carboxypeptidase II; Prostate cancer; Molecular imaging; Targeted therapy; Prostate; Biodistribution; Oncology; Cancer research; Cancer; In vivo; Internal medicine","score_opus":0.18293001677416,"score_gpt":0.47005679939081046,"score_spread":0.2871267826166505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809806585","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00080958894,0.9786053,0.000054149405,0.00018780476,0.00250851,0.009345068,0.008419444,0.00004142263,0.000028714208],"genre_scores_gemma":[0.00019697387,0.9828116,0.00013398918,0.000047547397,0.0011175408,0.003681055,0.011755156,0.000117305884,0.0001388159],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967833,0.00017148681,0.00079808343,0.0011587659,0.00038596932,0.0007023527],"domain_scores_gemma":[0.9977831,0.00027735205,0.0003635679,0.00035097025,0.00090053416,0.00032443402],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017850536,0.0007254102,0.001717192,0.0003882477,0.00015839635,0.00008520494,0.00018196003,0.00017642947,0.00022783467],"category_scores_gemma":[0.000051511775,0.00050250033,0.0003558783,0.00049670605,0.00021454638,0.00010181127,0.00009617383,0.00046130762,0.000029648108],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010083383,0.00014757403,0.025746288,0.016147142,0.0003922199,0.000010879269,0.01263489,2.0734014e-7,0.000014745105,0.000009746166,0.0060794014,0.9378086],"study_design_scores_gemma":[0.0031264955,0.0005134289,0.0031794347,0.03535787,0.00012242714,6.9874255e-7,0.0011173126,0.000005165018,0.00016309907,0.00003905106,0.95583737,0.00053767185],"about_ca_topic_score_codex":0.000059138398,"about_ca_topic_score_gemma":0.000009709527,"teacher_disagreement_score":0.94975793,"about_ca_system_score_codex":0.00049825246,"about_ca_system_score_gemma":0.00094670855,"threshold_uncertainty_score":0.9997427},"labels":[],"label_agreement":null},{"id":"W2809872660","doi":"10.1177/1078155218784716","title":"Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Docetaxel; Medicine; Abiraterone; Prostate cancer; Context (archaeology); Oncology; Pharmacy; Abiraterone acetate; Internal medicine; Clinical trial; Chemotherapy; Cancer; Family medicine; Androgen deprivation therapy","score_opus":0.1885419126451846,"score_gpt":0.5200089429495252,"score_spread":0.33146703030434055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809872660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9529263,0.0037634731,0.0000051177944,0.03994021,0.00074016233,0.00073501415,0.000023926712,0.000014920692,0.0018509106],"genre_scores_gemma":[0.9671994,0.021055339,0.004035826,0.002374852,0.0006952279,0.000049543505,0.0000049388877,0.000041091847,0.0045438227],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99668294,0.00078465877,0.0010040812,0.00028514024,0.0006661339,0.00057703874],"domain_scores_gemma":[0.99474955,0.0014990655,0.0010338218,0.00020602156,0.0021184064,0.0003931504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023801355,0.00024415765,0.0006937977,0.0006073883,0.000116045994,0.00008464833,0.00019524698,0.000051561736,0.0007079155],"category_scores_gemma":[0.0013519659,0.00017299454,0.00012407848,0.00074466213,0.00034982138,0.002421927,0.00006673432,0.0011171061,0.000058792582],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23930691,0.0052868365,0.10418909,0.0005070642,0.002974414,0.045134503,0.006592746,0.000056361987,0.5237188,0.000056814006,0.021639626,0.050536826],"study_design_scores_gemma":[0.06851525,0.02688627,0.15406136,0.0027100316,0.0057793255,0.008888084,0.0042857244,0.0005187572,0.086992756,0.000103761144,0.64046293,0.0007957227],"about_ca_topic_score_codex":0.0030916422,"about_ca_topic_score_gemma":0.0013450218,"teacher_disagreement_score":0.61882335,"about_ca_system_score_codex":0.0015076833,"about_ca_system_score_gemma":0.0045735464,"threshold_uncertainty_score":0.8113275},"labels":[],"label_agreement":null},{"id":"W2810775937","doi":"10.1016/j.jval.2018.04.317","title":"Benefit Of Abiraterone Acetate Plus Prednisone (AA+P) Added To Androgen Deprivation Therapy (ADT) In Patients With High-Risk, Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): Post Hoc Analysis Of EQ-5D-5L From The Latitude Study","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Visual analogue scale; Androgen deprivation therapy; Post-hoc analysis; Internal medicine; Oncology; Urology; Cancer; Surgery","score_opus":0.04130192865995992,"score_gpt":0.315470123305977,"score_spread":0.2741681946460171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810775937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918806,0.0012711098,0.000023518134,0.00080146163,0.00004209116,0.0049415296,0.0010232187,0.000014234457,0.0000022194458],"genre_scores_gemma":[0.9964953,0.0017902713,0.00080465514,0.00021351226,0.000028695813,0.00026153785,0.00035174176,0.000034674467,0.00001960466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714035,0.0005027678,0.00075257866,0.0004774661,0.00069450506,0.0004323631],"domain_scores_gemma":[0.9980161,0.00034642254,0.00047026682,0.0004905402,0.0005209813,0.00015564697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074558234,0.00024512128,0.00095244375,0.0004871512,0.00008409426,0.000016093163,0.00014621705,0.000043906617,0.00002288459],"category_scores_gemma":[0.0000825113,0.00015070153,0.000063209154,0.0019075162,0.00013464832,0.00011334151,0.000059789836,0.00020191683,0.0000027678027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018534342,0.0012866479,0.9099711,0.00004960211,0.0020632525,0.00001622884,0.046531428,0.009750897,0.00033089932,0.0000037899995,0.000018260742,0.011443543],"study_design_scores_gemma":[0.021023836,0.009969796,0.9632783,0.00025068707,0.00041570608,1.1842071e-7,0.0017745147,0.0018582352,0.0012681271,0.000027308224,0.0000055964756,0.00012780764],"about_ca_topic_score_codex":0.16564351,"about_ca_topic_score_gemma":0.031442527,"teacher_disagreement_score":0.13420099,"about_ca_system_score_codex":0.0005136372,"about_ca_system_score_gemma":0.0005366729,"threshold_uncertainty_score":0.98623115},"labels":[],"label_agreement":null},{"id":"W2810971797","doi":"10.1016/j.brachy.2018.04.021","title":"Phase II Randomized Pilot Comparing HDR and LDR Monotherapy for Intermediate Risk Prostate Cancer: Report of Dose Escalation to Dominant Intraprostatic Lesions","year":2018,"lang":"en","type":"article","venue":"Brachytherapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; Randomized controlled trial; Prostate; Cancer; Oncology; Nuclear medicine; Urology; Internal medicine; Radiation therapy","score_opus":0.04104353501779934,"score_gpt":0.3855998170690291,"score_spread":0.3445562820512298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810971797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98626226,0.001971516,0.0041373665,0.0016643102,0.0002386902,0.0055418275,0.00008452263,0.00004477673,0.000054732478],"genre_scores_gemma":[0.9875506,0.0067456206,0.0028901158,0.00019434886,0.00026523595,0.0012993352,0.00008414813,0.00005156333,0.0009190359],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980894,0.00011597733,0.00072848884,0.00043273997,0.00025687454,0.0003765467],"domain_scores_gemma":[0.9984217,0.00030366585,0.0003816176,0.0003256054,0.00034149265,0.00022588922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001007428,0.0002416441,0.0008960528,0.000239672,0.00027269297,0.000028220256,0.00007556968,0.00005632471,0.00004680415],"category_scores_gemma":[0.00020818456,0.00016733633,0.00013256304,0.0002520094,0.0004061218,0.00011491929,0.000036497007,0.00013676746,0.0000024923088],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55111396,0.001853581,0.010862736,0.0002162261,0.0007446627,0.000047520323,0.0096736,0.000011423194,0.08958188,0.00008813248,0.00080336456,0.33500293],"study_design_scores_gemma":[0.8163284,0.02818423,0.010773868,0.0008306962,0.00044480863,0.0000874423,0.0002359116,0.011462232,0.12447109,0.0016272076,0.005094105,0.00046002274],"about_ca_topic_score_codex":0.00035794772,"about_ca_topic_score_gemma":0.000122958,"teacher_disagreement_score":0.33454293,"about_ca_system_score_codex":0.000096319425,"about_ca_system_score_gemma":0.0002165052,"threshold_uncertainty_score":0.68237776},"labels":[],"label_agreement":null},{"id":"W2811121519","doi":"10.5489/cuaj.5503","title":"CUA-AUA International Fellows Program: San Francisco 2018","year":2018,"lang":"es","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Political science; Psychology; Library science; Gerontology; Medical education; Medicine; Computer science","score_opus":0.02380896665456113,"score_gpt":0.3130985306093122,"score_spread":0.2892895639547511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811121519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71815944,0.004918494,0.00010307717,0.17516792,0.011147328,0.001584373,0.0005011694,0.0001561922,0.088262014],"genre_scores_gemma":[0.9735041,0.0012983292,0.00031843912,0.0042655077,0.0097718295,0.000035218356,0.00013058382,0.00003561338,0.010640368],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99630535,0.0002971157,0.0005987545,0.00042057774,0.0010593917,0.0013188027],"domain_scores_gemma":[0.9962888,0.00015280425,0.000413758,0.00020429863,0.0011100525,0.0018303337],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011736484,0.00030846073,0.0004379082,0.0004411591,0.00076779805,0.0006065227,0.0004429184,0.00060696993,0.01185466],"category_scores_gemma":[0.0010088205,0.00023872653,0.000243899,0.00044258437,0.0002992602,0.00023584336,0.000056942703,0.0013187564,0.0020037023],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024951738,0.0002477272,0.74799895,0.000010512125,0.0007521154,0.00038640114,0.00028453008,0.000001429526,0.00013616955,0.00019176622,0.19512837,0.054612536],"study_design_scores_gemma":[0.002070888,0.001811831,0.35401136,0.0000635,0.00012974376,0.00015929481,0.00010165109,0.00038675615,0.00004783896,0.00040823227,0.64060545,0.00020349884],"about_ca_topic_score_codex":0.0016780081,"about_ca_topic_score_gemma":0.001492213,"teacher_disagreement_score":0.44547707,"about_ca_system_score_codex":0.0040742913,"about_ca_system_score_gemma":0.0018726157,"threshold_uncertainty_score":0.9997489},"labels":[],"label_agreement":null},{"id":"W2879638111","doi":"10.2196/11191","title":"Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial","year":2018,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Prostate cancer; Abiraterone; Medicine; Abiraterone acetate; Protocol (science); Oncology; Randomized controlled trial; Androgen deprivation therapy; Internal medicine; Cancer; Alternative medicine; Androgen receptor","score_opus":0.3228273930777455,"score_gpt":0.6162267959688664,"score_spread":0.29339940289112093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2879638111","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0071678474,0.000014993792,0.000103628474,0.003928982,0.000050078528,0.9879697,0.00028945442,0.00012231703,0.0003529815],"genre_scores_gemma":[0.002251254,0.000014876497,0.0010446933,0.00008911207,0.0019118913,0.9871041,0.00014127778,0.00012595388,0.007316833],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99461627,0.0005368294,0.0009942488,0.00095777167,0.0013003473,0.0015945454],"domain_scores_gemma":[0.9944106,0.00145321,0.0002660069,0.00071838684,0.0026301884,0.0005216314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028586667,0.00046804114,0.0010465488,0.0004096313,0.0007836924,0.00029629163,0.00036115036,0.00016832497,0.00082462735],"category_scores_gemma":[0.0011444378,0.00030765406,0.00043846935,0.00051078934,0.0010078285,0.00027790287,0.00011000289,0.00048386655,0.0000556541],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94657934,0.005313372,0.00002167556,0.0017239271,0.0004449763,0.000043959706,0.0006491751,8.779889e-7,0.021508098,0.0001345894,0.008149077,0.015430913],"study_design_scores_gemma":[0.6051273,0.051045503,0.0000047481635,0.0011297963,0.00001749301,0.0000023582534,0.00004665805,0.00041378252,0.07324299,0.00029841193,0.2684842,0.00018678883],"about_ca_topic_score_codex":0.00023270487,"about_ca_topic_score_gemma":0.00021133904,"teacher_disagreement_score":0.3414521,"about_ca_system_score_codex":0.0005872887,"about_ca_system_score_gemma":0.0020626516,"threshold_uncertainty_score":0.99993753},"labels":[],"label_agreement":null},{"id":"W2881471750","doi":"10.1007/s00280-018-3632-6","title":"An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development; Cancer Research UK","keywords":"Prostate cancer; Medicine; Repolarization; Ventricular Repolarization; Internal medicine; Pharmacokinetics; Prostate; Cancer; Oncology; Electrophysiology","score_opus":0.03939307538328744,"score_gpt":0.4318884542488405,"score_spread":0.392495378865553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2881471750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408305,0.0010470465,0.0000034129375,0.0012120941,0.00008162031,0.003454752,0.000024872568,0.000012310178,0.00008082987],"genre_scores_gemma":[0.9977514,0.0005606538,0.000033474727,0.000581184,0.00015132289,0.00076477544,0.000019460924,0.000022722623,0.00011501877],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99877787,0.0002691562,0.00022990191,0.00032197492,0.00017217713,0.00022890439],"domain_scores_gemma":[0.9994169,0.00008005916,0.00014553875,0.00015454825,0.000104839375,0.00009809749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003944471,0.0001617615,0.0002932051,0.000075043725,0.00014653767,0.000027972734,0.000121977566,0.000044203844,0.00011920078],"category_scores_gemma":[0.000009115508,0.0000911821,0.000010304807,0.00030382109,0.00026939096,0.00010974048,0.000021813496,0.00017435211,4.1466518e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033832077,0.0014895055,0.20468177,0.00015587415,0.00042421598,0.000089170244,0.0047533815,0.000040198996,0.73384845,0.000003154576,0.00020224569,0.020479951],"study_design_scores_gemma":[0.07787526,0.032255966,0.027213233,0.00023119358,0.00025992558,0.0000067889146,0.00035761253,0.0033426792,0.8579044,0.000007198723,0.0004004241,0.00014534393],"about_ca_topic_score_codex":0.0011653191,"about_ca_topic_score_gemma":0.00029745608,"teacher_disagreement_score":0.17746854,"about_ca_system_score_codex":0.00014533756,"about_ca_system_score_gemma":0.0001966309,"threshold_uncertainty_score":0.3718298},"labels":[],"label_agreement":null},{"id":"W2883007085","doi":"10.1097/spc.0000000000000356","title":"Management of nonmetastatic castration-resistant prostate cancer","year":2018,"lang":"en","type":"review","venue":"Current Opinion in Supportive and Palliative Care","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Castration; MEDLINE; Gynecology; Prostate; Management of prostate cancer; Cancer; Oncology; Urology; Internal medicine; Hormone","score_opus":0.2082979686593035,"score_gpt":0.4965451768725613,"score_spread":0.2882472082132578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883007085","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023676764,0.994453,0.0000060118937,0.000022852857,0.00081954076,0.0027950366,0.0014236091,0.000009705056,0.00023347071],"genre_scores_gemma":[0.00027941845,0.9959693,0.000092730836,0.0000022890647,0.00014174495,0.0009379484,0.0022515454,0.00003405156,0.0002909825],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99786234,0.00011907087,0.00075380947,0.0005516124,0.00037618206,0.0003369884],"domain_scores_gemma":[0.99874854,0.000059974947,0.0004427001,0.00022944901,0.00037447465,0.00014487599],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013231706,0.00039903473,0.0012555997,0.00028152732,0.000053840686,0.000018073599,0.00009097093,0.00010346598,0.00014875358],"category_scores_gemma":[0.000012281975,0.00028126864,0.00023416878,0.00044245142,0.0002451403,0.000059180707,0.00009194121,0.0003022166,0.000013081904],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021307945,0.0001662827,0.005137831,0.2539187,0.0006612801,0.00003152493,0.0024382412,1.3465308e-7,3.5738643e-7,0.00016277988,0.00068760436,0.73658216],"study_design_scores_gemma":[0.0016652852,0.000548751,0.0047618574,0.13239467,0.000796431,0.0000018075223,0.0016581302,0.0000015370995,0.000009420309,0.0000316511,0.8578223,0.0003081765],"about_ca_topic_score_codex":0.00001685395,"about_ca_topic_score_gemma":0.0000062804147,"teacher_disagreement_score":0.8571347,"about_ca_system_score_codex":0.00035754708,"about_ca_system_score_gemma":0.0005782813,"threshold_uncertainty_score":0.99996394},"labels":[],"label_agreement":null},{"id":"W2883429965","doi":"10.1002/1878-0261.12359","title":"Construction of a set of novel and robust gene expression signatures predicting prostate cancer recurrence","year":2018,"lang":"en","type":"article","venue":"Molecular Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital","funders":"Natural Science Foundation of Guangdong Province; Canadian Cancer Society; Cancer Research Society","keywords":"Prostate cancer; Biochemical recurrence; breakpoint cluster region; Gene signature; Medicine; Internal medicine; Cutoff; Population; Oncology; Gene; Nomogram; Cancer; Gene expression; Biology; Genetics; Prostatectomy; Receptor","score_opus":0.03466729395876265,"score_gpt":0.3559264822144847,"score_spread":0.32125918825572203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883429965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99488646,0.002669,0.0010176814,0.00040959465,0.00013555613,0.00039673157,0.00005536784,0.000011095494,0.00041849635],"genre_scores_gemma":[0.98634154,0.0005184441,0.012898061,0.00004285055,0.00007187132,0.00003988911,0.000023139364,0.000009846021,0.000054338878],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992662,0.000044227687,0.00018509812,0.00019442018,0.00015346736,0.00015659483],"domain_scores_gemma":[0.99939054,0.000033267945,0.00013452246,0.000119696575,0.000257375,0.0000645877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012779876,0.000080926526,0.00023380047,0.000087823886,0.00003733208,0.0000023216248,0.00004024795,0.00011108322,0.000032621236],"category_scores_gemma":[0.00006566215,0.000061941086,0.000028374614,0.00013516007,0.000481987,0.00002879157,0.00005912884,0.00012480575,2.8278822e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084170717,0.000090215246,0.020395748,0.00014745479,0.00006439639,0.000024044768,0.000771131,0.000034241897,0.96423084,0.00004399954,0.00011176681,0.013244464],"study_design_scores_gemma":[0.0029206618,0.0016666884,0.0041076327,0.00028370018,0.00007091155,0.00006582889,0.00019850458,0.0007082606,0.9894935,0.000052626918,0.00037437305,0.000057351328],"about_ca_topic_score_codex":0.00010009627,"about_ca_topic_score_gemma":0.0000141115515,"teacher_disagreement_score":0.02526263,"about_ca_system_score_codex":0.00006284147,"about_ca_system_score_gemma":0.00026799747,"threshold_uncertainty_score":0.25258842},"labels":[],"label_agreement":null},{"id":"W2883516304","doi":"10.1002/pros.23689","title":"Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival","year":2018,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute; KU Leuven; China Scholarship Council; National Natural Science Foundation of China; Florida Breast Cancer Foundation; Florida Department of Health","keywords":"Transactivation; Androgen receptor; Molecular biology; Biology; Transcription factor; Transfection; Reporter gene; Prostate cancer; HEK 293 cells; Immunoprecipitation; Cancer research; Gene expression; Cell culture; Cell biology; Gene; Cancer; Biochemistry; Genetics","score_opus":0.03161316320321899,"score_gpt":0.29805217352161795,"score_spread":0.26643901031839895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883516304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911612,0.0022655595,0.000112279435,0.0014792298,0.00040884965,0.0013170389,0.00019798204,0.00006493215,0.0029928843],"genre_scores_gemma":[0.9843061,0.0027318343,0.000033181637,0.00012132871,0.0001901645,0.00009739158,0.0002655084,0.00003716803,0.012217344],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987775,0.00008140541,0.00025212168,0.00024791248,0.00034516602,0.00029585732],"domain_scores_gemma":[0.999175,0.00003944554,0.00013094909,0.00021673659,0.00035462488,0.00008323156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026070548,0.00016454491,0.00021354873,0.000052770913,0.00015873913,0.00001997678,0.000056557376,0.00006993814,0.0004801737],"category_scores_gemma":[0.000012176495,0.00010409282,0.000053332828,0.00030078038,0.00025172194,0.00019247885,0.000019450177,0.00013740335,0.00004801387],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0099123325,0.00033070025,0.0058826823,0.00030359186,0.00018680007,0.000003104409,0.004270625,0.000005831166,0.9406641,0.000017999175,0.0076445015,0.030777734],"study_design_scores_gemma":[0.003292115,0.001979437,0.00168069,0.00013773804,0.00016743214,0.000003270633,0.00068621535,0.000084723135,0.9715783,0.0002746307,0.019952772,0.00016266592],"about_ca_topic_score_codex":0.0005767566,"about_ca_topic_score_gemma":0.00012147483,"teacher_disagreement_score":0.030914214,"about_ca_system_score_codex":0.00016128007,"about_ca_system_score_gemma":0.00023697002,"threshold_uncertainty_score":0.52575654},"labels":[],"label_agreement":null},{"id":"W2884001931","doi":"10.1016/j.cell.2018.06.039","title":"Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"Cell","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":748,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia; BC Cancer Agency","funders":"V Foundation for Cancer Research; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation; Movember Foundation; Howard Hughes Medical Institute; Stand Up To Cancer; U.S. Department of Defense","keywords":"Biology; Chromothripsis; Prostate cancer; Chromoplexy; Carcinogenesis; Transcriptome; Genome instability; Genetics; Androgen receptor; Copy-number variation; Tandem exon duplication; Gene duplication; Cancer research; Structural variation; Exome; Epigenetics; Cancer; Genome; Exome sequencing; Mutation; Gene; DNA damage; DNA; Gene expression; PCA3","score_opus":0.020022567038578378,"score_gpt":0.31441287399649215,"score_spread":0.2943903069579138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884001931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952372,0.0019120785,0.0000066511448,0.0004983483,0.000087340304,0.0003645189,0.000009092135,0.000009962049,0.0018748213],"genre_scores_gemma":[0.9953925,0.0004688233,0.00034767954,0.00008981803,0.0000804802,0.000029858547,0.000014349057,0.000009693213,0.0035667713],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9994877,0.000020290603,0.00009210256,0.0001488713,0.0000835582,0.00016746769],"domain_scores_gemma":[0.9997745,0.000014320209,0.000023851395,0.00008255784,0.000042815445,0.000061943276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007751948,0.00006629062,0.00010880048,0.000065690845,0.000036025882,0.000013992085,0.000023290162,0.000020748317,0.00023664703],"category_scores_gemma":[0.0000061154783,0.000047724887,0.0000122518095,0.000086630076,0.00006935006,0.00004610753,0.000021451402,0.00007354695,0.000018095012],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020867803,0.00014933542,0.45853847,0.0007205263,0.00016916773,0.00018717446,0.0151714785,0.000018584227,0.48779386,0.00007774063,0.0013127283,0.03377415],"study_design_scores_gemma":[0.0044387477,0.0003510168,0.96851534,0.000053479336,0.00006404487,0.000010648751,0.00013227231,0.0025531629,0.021782966,0.0005349539,0.0014561324,0.000107234286],"about_ca_topic_score_codex":0.00039392838,"about_ca_topic_score_gemma":0.00013649213,"teacher_disagreement_score":0.50997686,"about_ca_system_score_codex":0.00010389106,"about_ca_system_score_gemma":0.000110292676,"threshold_uncertainty_score":0.2591119},"labels":[],"label_agreement":null},{"id":"W2884629517","doi":"10.1097/spc.0000000000000359","title":"Treatment of hormone-naïve metastatic prostate cancer","year":2018,"lang":"en","type":"review","venue":"Current Opinion in Supportive and Palliative Care","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Genentech; Astellas Pharma; Pfizer","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Docetaxel; Oncology; Androgen deprivation therapy; Randomized controlled trial; Abiraterone; Internal medicine; Chemotherapy; Clinical trial; Hormone therapy; Cancer; Androgen receptor","score_opus":0.2692263133631505,"score_gpt":0.5142860517253937,"score_spread":0.24505973836224315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884629517","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037511394,0.99284536,0.000003060239,0.000034279445,0.00087464944,0.0033723875,0.0023827984,0.000014230266,0.00009813657],"genre_scores_gemma":[0.0002277679,0.99436855,0.000035044173,0.0000022477398,0.00028783767,0.0015528072,0.003205983,0.00004806109,0.00027171292],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976121,0.00018266989,0.0007890116,0.0006561566,0.0003355978,0.0004244449],"domain_scores_gemma":[0.9983949,0.00012945385,0.0005045501,0.0002736031,0.0004864615,0.00021104503],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000076839664,0.0005646116,0.0020985804,0.0003791723,0.000056128374,0.000016873986,0.000082813734,0.00013266927,0.00008143945],"category_scores_gemma":[0.0000344002,0.00035582957,0.0004148728,0.00045847718,0.00032690866,0.00006396207,0.00006047332,0.00024328497,0.000017238897],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030617297,0.00043209657,0.013858545,0.053247407,0.0008306879,0.000020437861,0.0068720593,5.979844e-8,4.016505e-7,0.00004389365,0.0011515653,0.92323667],"study_design_scores_gemma":[0.003002149,0.0025163812,0.0022779063,0.023484673,0.0009495507,0.0000046312844,0.0008753711,0.0000021860837,0.000014679562,0.000022041995,0.9665282,0.00032225106],"about_ca_topic_score_codex":0.000046124776,"about_ca_topic_score_gemma":0.0000070130413,"teacher_disagreement_score":0.9653766,"about_ca_system_score_codex":0.0007518687,"about_ca_system_score_gemma":0.0012416438,"threshold_uncertainty_score":0.9998894},"labels":[],"label_agreement":null},{"id":"W2884876277","doi":"10.1158/1078-0432.ccr-18-0981","title":"Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":310,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Genentech; F. Hoffmann-La Roche","keywords":"PTEN; Prostate cancer; Medicine; Abiraterone; Blockade; Oncology; Cancer; Randomized controlled trial; Prostate; Internal medicine; Metastatic breast cancer; PI3K/AKT/mTOR pathway; Breast cancer; Androgen receptor; Biology; Receptor; Apoptosis","score_opus":0.18489000572405279,"score_gpt":0.5496204690412394,"score_spread":0.3647304633171866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884876277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98718953,0.00055683334,0.000011007559,0.0013786016,0.00003439306,0.010658537,0.00006117197,0.000030918905,0.00007902663],"genre_scores_gemma":[0.99438936,0.00028604764,0.00036158346,0.00008744035,0.000082443854,0.0039503835,0.000088685185,0.000087914785,0.0006661367],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99310243,0.0016773992,0.0008753008,0.0011165784,0.0021953902,0.0010328938],"domain_scores_gemma":[0.9964599,0.0006186811,0.00024878976,0.0005413256,0.0017040261,0.0004272623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058900057,0.00040099464,0.0013954899,0.0005352701,0.00032615327,0.00009962976,0.00020651842,0.000088581444,0.00013291715],"category_scores_gemma":[0.00033460237,0.00020412244,0.00003795171,0.0015360877,0.0024032611,0.00031780792,0.00016356894,0.0011918878,0.000004917354],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4399385,0.004276763,0.54506594,0.00013315138,0.00042134264,0.000111852714,0.001872556,0.000018440638,0.000016050737,0.0000020157984,0.000018780249,0.008124634],"study_design_scores_gemma":[0.6841337,0.071520045,0.2397518,0.0016148064,0.00035138763,0.0000047612216,0.00089659577,0.0010454021,0.00033406535,0.000028993954,0.000025134961,0.00029329135],"about_ca_topic_score_codex":0.004413332,"about_ca_topic_score_gemma":0.013730198,"teacher_disagreement_score":0.30531412,"about_ca_system_score_codex":0.0004598112,"about_ca_system_score_gemma":0.0018417415,"threshold_uncertainty_score":0.88549155},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2884919548","doi":"10.1002/path.5137","title":"Biallelic tumour suppressor loss and DNA repair defects in <i>de novo</i> small‐cell prostate carcinoma","year":2018,"lang":"en","type":"article","venue":"The Journal of Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Terry Fox Research Institute; Prostate Cancer Canada; Prostate Cancer Foundation","keywords":"Biology; Cancer research; Prostate cancer; PTEN; Malignancy; MSH2; Cancer; DNA repair; Gene; DNA mismatch repair; Genetics; Apoptosis; PI3K/AKT/mTOR pathway","score_opus":0.0228984618303642,"score_gpt":0.28871867406246404,"score_spread":0.26582021223209984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884919548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945236,0.0024573912,0.00001078086,0.0020376814,0.00012054335,0.00026448927,0.0000044611124,0.000010238714,0.0005708392],"genre_scores_gemma":[0.99765337,0.0008245174,0.00027582652,0.000346456,0.00028610887,0.000004485782,0.0000012801796,0.000016718077,0.0005912195],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988212,0.00028537965,0.00028498008,0.000116992036,0.00014117314,0.00035026507],"domain_scores_gemma":[0.99926716,0.00013061851,0.00013975026,0.00017060104,0.00016389659,0.00012797178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011018437,0.00011210856,0.00029000817,0.00015258334,0.000067300614,0.000008057924,0.00011446314,0.00007488544,0.000025524549],"category_scores_gemma":[0.00009637908,0.00006389119,0.00006824038,0.00013635374,0.0003550408,0.000042051226,0.000071110124,0.0003571434,0.00001037866],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004255945,0.00028971312,0.39308774,0.00015573372,0.00004367611,0.0122212805,0.006930791,0.0000032716134,0.5815922,0.000021188001,0.00095745176,0.00044098598],"study_design_scores_gemma":[0.012839329,0.00757915,0.6815501,0.0002004522,0.00027466263,0.027598321,0.0008111418,0.0000826489,0.26685616,0.0008151456,0.0012099289,0.00018297606],"about_ca_topic_score_codex":0.000025842503,"about_ca_topic_score_gemma":0.000063125735,"teacher_disagreement_score":0.31473604,"about_ca_system_score_codex":0.00007895805,"about_ca_system_score_gemma":0.00024055096,"threshold_uncertainty_score":0.26054072},"labels":[],"label_agreement":null},{"id":"W2884963065","doi":"10.1158/1078-0432.ccr-18-1187","title":"Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A <i>Post Hoc</i> Analysis of the PR.7 Trial","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Queen's University; University of Toronto; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Prostate cancer; Medicine; Androgen deprivation therapy; Internal medicine; Oncology; Androstenediol; Testosterone (patch); Hormonal therapy; Cancer; Proportional hazards model; Biochemical recurrence; Androgen; Cohort; Dehydroepiandrosterone; Endocrinology; Prostatectomy; Hormone","score_opus":0.1535565012202698,"score_gpt":0.5071333865013424,"score_spread":0.3535768852810727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884963065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98584855,0.0027494617,0.0000017427988,0.0024794582,0.00048825933,0.008024566,0.00027301308,0.000017813509,0.0001171318],"genre_scores_gemma":[0.9896526,0.0069531007,0.00003500718,0.00019025538,0.00037269644,0.0022584933,0.000109115615,0.000038429294,0.00039030626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99557674,0.000808403,0.0009500092,0.00071959326,0.0012222014,0.000723025],"domain_scores_gemma":[0.9961674,0.0010805619,0.00024910242,0.0006098784,0.0016623801,0.00023064719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003768663,0.00020060092,0.00067557,0.0005233934,0.00023411088,0.000050100254,0.00038268627,0.00018938225,0.00014220548],"category_scores_gemma":[0.0015478181,0.00012518419,0.0003783602,0.0027522815,0.000796593,0.000104812105,0.00020230567,0.00054977933,0.0000049127693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14269884,0.0008351464,0.67187697,0.000091295275,0.0013280838,0.0000014188563,0.00045205196,0.0000019145693,0.00010963618,0.0000029198402,0.00086126756,0.18174048],"study_design_scores_gemma":[0.08875803,0.021446247,0.880467,0.0006003422,0.00044926815,2.224532e-7,0.00019467784,0.00048426006,0.0038222119,0.00013323124,0.0034445084,0.00020000557],"about_ca_topic_score_codex":0.0006917309,"about_ca_topic_score_gemma":0.0019870012,"teacher_disagreement_score":0.20859003,"about_ca_system_score_codex":0.00054908486,"about_ca_system_score_gemma":0.0018219244,"threshold_uncertainty_score":0.5104863},"labels":[],"label_agreement":null},{"id":"W2884972285","doi":"10.1016/j.clgc.2018.07.007","title":"Impact of Prior Local Treatment on the Outcomes of Metastatic Hormone-Sensitive Prostate Cancer: Secondary Analysis of a Randomized Controlled Trial","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Proportional hazards model; Internal medicine; Androgen deprivation therapy; Docetaxel; Survival analysis; Prostate; Prostate-specific antigen; Progression-free survival; Performance status; Cancer; Overall survival","score_opus":0.06612133646766608,"score_gpt":0.4508892951953859,"score_spread":0.38476795872771985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884972285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873231,0.0033698147,0.000017620365,0.00091755134,0.00027564296,0.0069904067,0.00057404675,0.0000130775325,0.00051873154],"genre_scores_gemma":[0.9891386,0.0076204822,0.00006197116,0.00009753866,0.00024882454,0.0012390336,0.00003602595,0.000026984186,0.0015305534],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955275,0.0010827249,0.0020014646,0.00042382983,0.00059788657,0.0003665811],"domain_scores_gemma":[0.99252445,0.004751286,0.001150764,0.00057513715,0.0007929959,0.0002053905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016867664,0.00035455037,0.005509307,0.0003651011,0.00007237926,0.0000069580533,0.00014769411,0.00011252596,0.00065363524],"category_scores_gemma":[0.0006487573,0.00015360242,0.0039568576,0.00070334156,0.0019136838,0.000043637905,0.000058527465,0.00026211716,0.0000039818788],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89805204,0.0023024892,0.010058329,0.000033412158,0.07361093,0.00004599806,0.00065868685,0.00009233148,0.0004638919,0.000008945254,0.00025422865,0.014418706],"study_design_scores_gemma":[0.88425606,0.019785002,0.068421476,0.000091172784,0.02226311,0.000001361254,0.00022935725,0.0014437694,0.003305846,0.00003158887,0.000028474007,0.00014280666],"about_ca_topic_score_codex":0.0014676956,"about_ca_topic_score_gemma":0.00010331458,"teacher_disagreement_score":0.058363147,"about_ca_system_score_codex":0.00034391848,"about_ca_system_score_gemma":0.0019702204,"threshold_uncertainty_score":0.7156848},"labels":[],"label_agreement":null},{"id":"W2885044386","doi":"10.1158/1538-7445.am2018-2269","title":"Abstract 2269: Transcription factor relationships associated with androgen-deprivation therapy response and metastatic progression in prostate cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Androgen deprivation therapy; Prostate cancer; JUNB; Androgen receptor; Transcription factor; Cancer research; Medicine; Enzalutamide; Oncology; Metastasis; Biology; Cancer; Internal medicine; Gene; Genetics","score_opus":0.19113687417518735,"score_gpt":0.4525648911335739,"score_spread":0.2614280169583866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885044386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880835,0.0059103067,0.0000045558068,0.0035162093,0.000047971676,0.002198245,0.000078138975,0.000050061386,0.000111044385],"genre_scores_gemma":[0.9928302,0.004676649,0.00006369464,0.000041411255,0.00007673268,0.0011180394,0.000059152844,0.000046135745,0.0010879908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712384,0.0005932575,0.00027414694,0.0004798519,0.0009218173,0.00060708367],"domain_scores_gemma":[0.99841523,0.00034655796,0.00007661394,0.00023838099,0.00070376304,0.00021947897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020098807,0.00018380495,0.00027110055,0.0005223783,0.0003665152,0.0000807654,0.00008815912,0.000096381445,0.00035913824],"category_scores_gemma":[0.00029002942,0.00012360574,0.000032308126,0.0011373216,0.00053062,0.00029181142,0.000024695504,0.0007459552,0.000010496025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039777108,0.0005100373,0.5694975,0.00017153779,0.00027072695,0.00014769917,0.008156639,0.0000058710034,0.32530707,0.000021731768,0.00042152245,0.055712506],"study_design_scores_gemma":[0.00730169,0.0015002782,0.9151682,0.001151724,0.000020186386,0.0000063960283,0.00052029383,0.00010174098,0.0727215,0.00014767794,0.0011979713,0.00016231062],"about_ca_topic_score_codex":0.00048084126,"about_ca_topic_score_gemma":0.0012871661,"teacher_disagreement_score":0.34567067,"about_ca_system_score_codex":0.00080445723,"about_ca_system_score_gemma":0.0010265645,"threshold_uncertainty_score":0.5040496},"labels":[],"label_agreement":null},{"id":"W2885464001","doi":"10.1038/s41585-018-0060-7","title":"Landmarks in prostate cancer","year":2018,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Natural history; Prostatectomy; Guideline; Disease; Management of prostate cancer; Grading (engineering); Clinical trial; Clinical Practice; Intensive care medicine; Cancer; General surgery; Internal medicine; Pathology; Physical therapy","score_opus":0.05843815582600628,"score_gpt":0.4566947628077939,"score_spread":0.39825660698178766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885464001","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000027343183,0.9909995,2.2350007e-7,0.0007650001,0.0006269402,0.004256613,0.00005817317,0.000030919615,0.0032598572],"genre_scores_gemma":[0.0000018229096,0.99145687,0.000056470784,0.0007433086,0.0008024492,0.0016130448,0.00042618884,0.000072367395,0.004827472],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970374,0.00051817787,0.0008206835,0.00075089943,0.00021864366,0.0006541746],"domain_scores_gemma":[0.9986537,0.00012659046,0.00033056337,0.00061435904,0.00009924127,0.00017552439],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0007764547,0.0005345771,0.003603043,0.00045571497,0.00003908272,0.000012796337,0.0002543148,0.0013540231,0.0005694056],"category_scores_gemma":[0.00022150797,0.00030083285,0.0005947768,0.0007842185,0.00016144503,0.000035809408,0.00011278724,0.002941532,0.0004966669],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008825661,0.00007099942,0.00022785953,0.02952084,0.00014695819,0.00030951764,0.000023375276,6.7243167e-9,9.6869904e-8,0.000018023284,0.024514481,0.94507957],"study_design_scores_gemma":[0.00073767296,0.00027197573,0.000026245481,0.0147568155,0.0009879648,0.00027168458,5.9900657e-7,6.3665277e-7,2.4234103e-7,0.000022678734,0.9826983,0.00022519023],"about_ca_topic_score_codex":0.0000235451,"about_ca_topic_score_gemma":0.00009709801,"teacher_disagreement_score":0.9581838,"about_ca_system_score_codex":0.0003582213,"about_ca_system_score_gemma":0.0008789384,"threshold_uncertainty_score":0.9999444},"labels":[],"label_agreement":null},{"id":"W2885727665","doi":"10.2967/jnumed.118.215350","title":"Monosodium Glutamate Reduces <sup>68</sup>Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model","year":2018,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Biodistribution; Kidney; Chemistry; LNCaP; Saline; Prostate cancer; Endocrinology; Monosodium glutamate; Prostate; Internal medicine; Salivary gland; Medicine; Cancer; Biochemistry; In vitro","score_opus":0.05628824196678936,"score_gpt":0.3803489437144386,"score_spread":0.3240607017476492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885727665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96090287,0.004463447,0.0000023958103,0.0330826,0.00018856986,0.00039743504,0.000011538362,0.000015697029,0.00093542],"genre_scores_gemma":[0.9838022,0.01268329,0.000706508,0.0012770533,0.00087258354,0.000009871188,0.000005733176,0.00004765029,0.00059508655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749494,0.00010459996,0.0010034457,0.00030347958,0.0006216412,0.00047187117],"domain_scores_gemma":[0.9986524,0.00009803607,0.00027935675,0.00020631889,0.00027353366,0.0004903579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001254619,0.0002340848,0.0008267553,0.0005118051,0.000062343235,0.000019510764,0.0001693371,0.00015656122,0.0003551857],"category_scores_gemma":[0.00039721862,0.00014800395,0.00007790901,0.0004085415,0.0005278019,0.00022450267,0.00008019419,0.00068930606,0.000010710016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049588148,0.003251807,0.54612356,0.001649059,0.0010643314,0.0064268634,0.07466722,0.0010036544,0.063822076,0.00016291862,0.16579719,0.08644314],"study_design_scores_gemma":[0.10076555,0.021861985,0.57205504,0.021114342,0.0010394341,0.0021638602,0.009457079,0.18546157,0.0021328218,0.0019681156,0.08086415,0.0011160532],"about_ca_topic_score_codex":0.00027650638,"about_ca_topic_score_gemma":0.000052736934,"teacher_disagreement_score":0.18445791,"about_ca_system_score_codex":0.00022721075,"about_ca_system_score_gemma":0.0004815444,"threshold_uncertainty_score":0.6035426},"labels":[],"label_agreement":null},{"id":"W2885840167","doi":"10.1158/1538-7445.am2018-5878","title":"Abstract 5878: Effect of cannabinoid WIN 55,212-2 on prostate cancer cell proliferation, migration, invasion, and tumor growth","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"DU145; Prostate cancer; Angiogenesis; Cancer; Cell growth; Cancer research; Cancer cell; Medicine; Cannabinoid receptor; Cannabinoid; Cell migration; Cell; Internal medicine; Pharmacology; Receptor; Biology; LNCaP","score_opus":0.03563280715130795,"score_gpt":0.3805744399512674,"score_spread":0.34494163279995943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885840167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98412025,0.0048175678,9.770109e-7,0.0055037644,0.00015553168,0.00254961,0.00010736419,0.000039592825,0.0027053321],"genre_scores_gemma":[0.9866905,0.004727666,0.00001910486,0.00017951896,0.00062391645,0.0014012557,0.000051632047,0.00005644226,0.006249965],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968272,0.00024001753,0.00038487528,0.00062387745,0.0011857298,0.0007382978],"domain_scores_gemma":[0.9970604,0.00019868817,0.00010735581,0.00041094943,0.0018325071,0.00039007637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012889035,0.00026789753,0.0004363167,0.00033466035,0.00036321318,0.00007309346,0.00017923754,0.0001117204,0.0007953057],"category_scores_gemma":[0.00026556678,0.00018430904,0.00006915509,0.00071427,0.00076302915,0.00021904951,0.00009729781,0.0005223197,0.0000631341],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0128997,0.00051770837,0.41523832,0.004109144,0.00023674328,0.000119307064,0.0045221844,0.000006869797,0.42651296,0.00012886137,0.12556103,0.010147203],"study_design_scores_gemma":[0.004237411,0.0033307392,0.06681109,0.0006892749,0.000047937847,0.0000071132736,0.00017091409,0.000044128516,0.919346,0.00010169439,0.0050217165,0.00019202988],"about_ca_topic_score_codex":0.009122715,"about_ca_topic_score_gemma":0.0028452142,"teacher_disagreement_score":0.49283302,"about_ca_system_score_codex":0.0006465955,"about_ca_system_score_gemma":0.0015331218,"threshold_uncertainty_score":0.9974756},"labels":[],"label_agreement":null},{"id":"W2886592807","doi":"10.6004/jnccn.2018.7020","title":"DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of the National Comprehensive Cancer Network","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Cilag; National Cancer Institute; Janssen Biotech; Astellas Pharma; Celgene; University of Michigan; Valeant Pharmaceuticals International; Varian Medical Systems; Gilead Sciences","keywords":"DNA repair; PARP inhibitor; Prostate cancer; Medicine; Cancer research; Mutation; Cancer; Poly ADP ribose polymerase; Gene; Homologous recombination; DNA damage; Gene mutation; Oncology; Internal medicine; DNA; Biology; Genetics","score_opus":0.035890937354533,"score_gpt":0.3342492008840909,"score_spread":0.29835826352955785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886592807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991898,0.0034301868,0.0000051010798,0.003561326,0.0003734228,0.0006173319,0.00007769282,0.0000068422137,0.00003010885],"genre_scores_gemma":[0.99668145,0.00030569953,0.00086519826,0.0009168125,0.0008467913,0.000050533024,0.000008793498,0.000017844806,0.00030689788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820554,0.00020750573,0.00041573643,0.00017000397,0.0007734857,0.0002277181],"domain_scores_gemma":[0.9966088,0.00020614614,0.00031908843,0.00009835432,0.0026535904,0.00011405194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027336043,0.00014596303,0.00027399432,0.00013465555,0.00021500896,0.000034317014,0.000077106306,0.00003231533,0.000046558453],"category_scores_gemma":[0.00008761584,0.00008447182,0.0000768453,0.00050520396,0.00021800719,0.00016397043,0.000038288257,0.0002495809,0.0000010043763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16877614,0.0009501302,0.712639,0.0002586003,0.002811925,0.00013541227,0.0032737148,0.024637043,0.027994536,0.00018658074,0.05639335,0.0019435963],"study_design_scores_gemma":[0.007379724,0.0016762927,0.9822709,0.00075974944,0.0001682879,0.000035433117,0.000076750606,0.0004285361,0.0013692293,0.00024228398,0.0054622837,0.00013051613],"about_ca_topic_score_codex":0.000027885646,"about_ca_topic_score_gemma":0.000116240226,"teacher_disagreement_score":0.26963195,"about_ca_system_score_codex":0.0005493316,"about_ca_system_score_gemma":0.0010816038,"threshold_uncertainty_score":0.34446612},"labels":[],"label_agreement":null},{"id":"W2886703310","doi":"10.1158/1538-7445.am2018-ng06","title":"Abstract NG06: The clinico-genomics of localized, non-indolent prostate cancer: the CPC-GENE experience","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Canadian Cancer Society; Ontario Institute for Cancer Research","funders":"","keywords":"Prostate cancer; Genomics; Cancer; Medicine; Oncology; Internal medicine; Gene; Biology; Genetics; Genome","score_opus":0.12336988011150987,"score_gpt":0.47449907915610734,"score_spread":0.3511291990445975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886703310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742266,0.010038615,0.000009997745,0.010548237,0.00045694583,0.0023249367,0.000121018624,0.000024562281,0.0022490632],"genre_scores_gemma":[0.969314,0.023344727,0.000035143486,0.0003533345,0.0010868278,0.0015290366,0.000014375424,0.000052550782,0.0042700227],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962829,0.00018643963,0.0005137977,0.0005563776,0.0014103777,0.0010501047],"domain_scores_gemma":[0.996867,0.0003764178,0.00014309243,0.0011002949,0.001230789,0.00028237505],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019568163,0.00023112321,0.00039447614,0.00015228236,0.0006846826,0.00007760576,0.0008013687,0.00011993847,0.0010318161],"category_scores_gemma":[0.00015215097,0.00011528947,0.00015690102,0.00091579976,0.0031469772,0.0000988893,0.0003516114,0.00091313926,0.00011868502],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017474405,0.0009887551,0.085830405,0.0009761581,0.0010971903,0.0001909904,0.056519132,0.000103745064,0.5339885,0.000191343,0.047422756,0.25521663],"study_design_scores_gemma":[0.004734146,0.001212346,0.041556057,0.00060092856,0.000072544244,0.000015790974,0.0048390483,0.00025540346,0.81138575,0.00020572785,0.13485901,0.0002632173],"about_ca_topic_score_codex":0.0045886054,"about_ca_topic_score_gemma":0.00058115926,"teacher_disagreement_score":0.27739727,"about_ca_system_score_codex":0.00070971594,"about_ca_system_score_gemma":0.002555351,"threshold_uncertainty_score":0.9998814},"labels":[],"label_agreement":null},{"id":"W2886821920","doi":"10.1016/j.ebiom.2018.08.011","title":"A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network","year":2018,"lang":"en","type":"article","venue":"EBioMedicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Health Canada; China Scholarship Council; National Natural Science Foundation of China","keywords":"DU145; Biology; SOX2; Cellular differentiation; Transcriptome; Cancer research; Cell biology; Transdifferentiation; Stem cell; Carcinogenesis; Neuroendocrine differentiation; Cancer cell; Gene expression; Gene; Embryonic stem cell; Genetics; Cancer; Prostate cancer; LNCaP","score_opus":0.023603540055686465,"score_gpt":0.30974565360744616,"score_spread":0.28614211355175967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886821920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861852,0.0027054325,0.0019683905,0.0057088505,0.00065218966,0.0020236226,0.000016897946,0.0000842866,0.0006551225],"genre_scores_gemma":[0.9901829,0.0003662937,0.0060447645,0.00036664717,0.00080415315,0.00020477382,0.00007870416,0.000046437613,0.0019053762],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99770755,0.000028903878,0.00059060886,0.0004254797,0.00053853425,0.00070894073],"domain_scores_gemma":[0.99906164,0.000030776715,0.00015675969,0.00027693174,0.00024716652,0.00022671292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035198263,0.00023982846,0.0005175858,0.0003166188,0.00008829975,0.000005785306,0.00012647192,0.00004267524,0.00022917226],"category_scores_gemma":[0.000050775485,0.00017221353,0.00004684427,0.000985623,0.00024309526,0.00005887855,0.00012157514,0.00022554422,0.000016323054],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023095938,0.0012669447,0.035787374,0.0010302123,0.0003997114,0.0010745506,0.0069581578,0.000007451139,0.8212846,0.00014358008,0.0009095315,0.1288283],"study_design_scores_gemma":[0.030826459,0.0062264055,0.09991133,0.004413753,0.0002507387,0.0007626637,0.0002771126,0.0046856455,0.8349487,0.00094948226,0.016071727,0.00067593076],"about_ca_topic_score_codex":0.00041056587,"about_ca_topic_score_gemma":0.00016283903,"teacher_disagreement_score":0.12815237,"about_ca_system_score_codex":0.00023018324,"about_ca_system_score_gemma":0.0004940324,"threshold_uncertainty_score":0.70226645},"labels":[],"label_agreement":null},{"id":"W2886880347","doi":"10.4149/neo_2018_170822n551","title":"TMEM45B is a novel predictive biomarker for prostate cancer progression and metastasis","year":2018,"lang":"en","type":"article","venue":"Neoplasma","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"National Natural Science Foundation of China","keywords":"Prostate cancer; Medicine; Biomarker; Clinical significance; Oncology; Metastasis; Internal medicine; Biochemical recurrence; Logistic regression; Cancer; Prostatectomy; Biology","score_opus":0.046944165663513567,"score_gpt":0.3831711671102199,"score_spread":0.33622700144670636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886880347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869227,0.0021189826,0.0002705337,0.005741407,0.00024657592,0.0024793835,0.0006462506,0.00007787198,0.0014963403],"genre_scores_gemma":[0.985283,0.00081337296,0.004422691,0.00048054694,0.00030962794,0.0012613268,0.0000726216,0.000048646765,0.0073081474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99886423,0.000012625099,0.00014723127,0.000369449,0.00024913537,0.0003573431],"domain_scores_gemma":[0.9992385,0.00005299646,0.00005627241,0.0001714203,0.00029465315,0.00018614902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013899668,0.00015982802,0.00022789653,0.0001056721,0.00016372591,0.000030508247,0.000045742207,0.00007964936,0.00015347217],"category_scores_gemma":[0.000038359518,0.000104683146,0.00006075125,0.00019679798,0.00025876044,0.000094548675,0.000055713455,0.00008236616,0.000010747998],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021444354,0.0008562466,0.15199046,0.00091954437,0.0017191172,0.00003641504,0.006682101,4.063003e-7,0.070089675,0.000090005866,0.057637874,0.6885338],"study_design_scores_gemma":[0.029799158,0.008743381,0.1266465,0.0011241575,0.0010505064,0.00014583621,0.0006508473,0.01075496,0.40815896,0.00031185464,0.41203895,0.00057488115],"about_ca_topic_score_codex":0.000043203312,"about_ca_topic_score_gemma":0.000030904164,"teacher_disagreement_score":0.6879589,"about_ca_system_score_codex":0.00009042661,"about_ca_system_score_gemma":0.00021565273,"threshold_uncertainty_score":0.42688546},"labels":[],"label_agreement":null},{"id":"W2887237327","doi":"10.1158/1538-7445.am2018-773","title":"Abstract 773: A heterochromatin gene signature unveils HP1α mediating neuroendocrine prostate cancer development and aggressiveness","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"","keywords":"Biology; Transdifferentiation; Heterochromatin; Cancer research; Histone; Prostate cancer; Ectopic expression; LNCaP; Gene silencing; Cell biology; Chromatin; Genetics; Gene; Cancer; Cell","score_opus":0.06771988756278126,"score_gpt":0.41690073912139464,"score_spread":0.3491808515586134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887237327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97183853,0.022443753,0.0000047577796,0.0035813192,0.00025806084,0.0013663346,0.000074026175,0.00008028865,0.00035290906],"genre_scores_gemma":[0.986878,0.007247861,0.0004052318,0.00026943363,0.000957543,0.0013265717,0.00007019363,0.000081912476,0.0027632788],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99610335,0.00013810299,0.0003980488,0.00078084524,0.0013116673,0.0012680154],"domain_scores_gemma":[0.99784344,0.00018333658,0.000115958275,0.00038800717,0.0009047074,0.00056453526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005676531,0.00031098904,0.0004356894,0.00028289197,0.00060566835,0.00012706278,0.00024437613,0.00009494223,0.0006682665],"category_scores_gemma":[0.00017582282,0.00023308661,0.000055894543,0.0007261378,0.0006952473,0.0001821147,0.0003139778,0.0010926272,0.00005731189],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023843697,0.0002652409,0.034733,0.0015142368,0.00040823765,0.0017408056,0.0052617877,0.000009448237,0.6183803,0.000010679631,0.003912435,0.33137944],"study_design_scores_gemma":[0.004141193,0.0005155855,0.065417,0.0016175578,0.000032917545,0.00007464445,0.00033696144,0.00009953489,0.9128042,0.0000754499,0.014556606,0.00032838722],"about_ca_topic_score_codex":0.0006350078,"about_ca_topic_score_gemma":0.00025681301,"teacher_disagreement_score":0.33105105,"about_ca_system_score_codex":0.0006464636,"about_ca_system_score_gemma":0.0016397266,"threshold_uncertainty_score":0.95049965},"labels":[],"label_agreement":null},{"id":"W2887402464","doi":"10.1158/1538-7445.prca2017-a033","title":"Abstract A033: Identity fraud: Lineage plasticity as a mechanism of antiandrogen resistance and target for therapy","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Reprogramming; Enzalutamide; Cancer research; Biology; Transdifferentiation; EZH2; Prostate cancer; Androgen receptor; Epigenetics; Cancer; Genetics; Cell; Gene","score_opus":0.10144636960819897,"score_gpt":0.4559655279573779,"score_spread":0.3545191583491789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887402464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98835725,0.0063943863,0.00044068473,0.0010015047,0.00010896336,0.0014416712,0.0001944493,0.000026192793,0.0020349137],"genre_scores_gemma":[0.9893316,0.005312936,0.0006525849,0.00006819793,0.00046153864,0.0002862062,0.000019318875,0.000034971268,0.0038326336],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979186,0.00006116576,0.00024233485,0.00042059147,0.0007823158,0.00057497673],"domain_scores_gemma":[0.9981644,0.00025600256,0.000063490996,0.00026960962,0.0010016259,0.00024487643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009549957,0.00014199545,0.00032836536,0.0002247815,0.00027905518,0.000046970297,0.00018882313,0.00012397864,0.00075664197],"category_scores_gemma":[0.00025158568,0.00010892184,0.000079086225,0.00040686256,0.0006428505,0.00016295527,0.00008936535,0.00030794903,0.000023437096],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020127105,0.0006807619,0.0097354455,0.0019225306,0.0007673275,0.00013021058,0.0018242471,8.598095e-7,0.9347579,0.010495564,0.013120688,0.0064373524],"study_design_scores_gemma":[0.0050333967,0.0016805818,0.010338204,0.000365931,0.000022641416,0.0000044943527,0.00018017642,0.000047800644,0.95863694,0.00771974,0.01582878,0.00014130831],"about_ca_topic_score_codex":0.0005018859,"about_ca_topic_score_gemma":0.00029590834,"teacher_disagreement_score":0.023879036,"about_ca_system_score_codex":0.00015003677,"about_ca_system_score_gemma":0.0006799835,"threshold_uncertainty_score":0.8284699},"labels":[],"label_agreement":null},{"id":"W2887578713","doi":"10.1158/1538-7445.am2018-5736","title":"Abstract 5736: In silico analysis shows that PTEN loss and AR overexpression are associated with increased CD8+ T-cell and Treg density and earlier disease recurrence in prostate cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"PTEN; Prostate cancer; CD8; Cancer research; Immune system; Tumor microenvironment; Biology; Medicine; Internal medicine; Infiltration (HVAC); Oncology; Cancer; Immunology; Apoptosis; PI3K/AKT/mTOR pathway","score_opus":0.05045462756739969,"score_gpt":0.37018063480674057,"score_spread":0.31972600723934086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887578713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887308,0.008861291,4.5539804e-7,0.00087884895,0.000015796984,0.0011199804,0.0002025521,0.000017402552,0.0001728989],"genre_scores_gemma":[0.9898399,0.0088653425,0.000010474188,0.000060635175,0.00005875091,0.00032582722,0.000053562595,0.000028367262,0.00075711176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714583,0.00025311127,0.00022464588,0.00080295285,0.0008169507,0.0007564944],"domain_scores_gemma":[0.9983593,0.00024803422,0.00009506534,0.00032132442,0.00037388172,0.00060239166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091338507,0.00024463717,0.0005147899,0.0006638279,0.00021222184,0.000106415144,0.00010538071,0.00011465592,0.000167362],"category_scores_gemma":[0.00019086032,0.00017475711,0.00003696966,0.0012880997,0.0008106698,0.00023387461,0.00018243467,0.00066494255,0.0000019618033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047187028,0.00024706442,0.98263866,0.000358491,0.00016009394,0.00043025738,0.0009799437,0.0000033387655,0.007249227,0.0000015649983,0.00021313968,0.0029995486],"study_design_scores_gemma":[0.005031248,0.00022031563,0.9821107,0.0017290737,0.00012388705,0.0000018738108,0.00042342575,0.0005407671,0.009457658,0.000054198023,0.0001017534,0.0002051191],"about_ca_topic_score_codex":0.006999808,"about_ca_topic_score_gemma":0.020555135,"teacher_disagreement_score":0.0135553265,"about_ca_system_score_codex":0.00055555475,"about_ca_system_score_gemma":0.00063075445,"threshold_uncertainty_score":0.9996127},"labels":[],"label_agreement":null},{"id":"W2887612248","doi":"10.1158/1538-7445.am2018-5229","title":"Abstract 5229: Expression and regulation of chondroitin sulfate in prostate cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Chondroitin sulfate; Prostate cancer; Cancer research; Sulfation; Chemistry; Chondroitin; Biology; Cancer; Cell biology; Glycosaminoglycan; Biochemistry","score_opus":0.0806933443805099,"score_gpt":0.4446827894765815,"score_spread":0.3639894450960716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887612248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990529,0.004617109,9.822671e-7,0.0014836245,0.00008036791,0.000882161,0.000037451093,0.00001658923,0.002352718],"genre_scores_gemma":[0.9888395,0.004926042,0.000052932257,0.000020796397,0.00023347967,0.00031739665,0.000018296101,0.000026277787,0.005565278],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99808127,0.00008139508,0.0002635299,0.0003725267,0.00068346027,0.00051781547],"domain_scores_gemma":[0.99885225,0.0000855949,0.00005762807,0.000265374,0.0005627918,0.00017634609],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007417894,0.000116109106,0.00024905257,0.00041021928,0.00011074273,0.000024063076,0.00009386333,0.00008121343,0.0011249096],"category_scores_gemma":[0.00007793419,0.00008828631,0.000030093219,0.0006284349,0.00059711275,0.00015034268,0.00009952359,0.0003750287,0.00001459823],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023968914,0.00010378209,0.11794356,0.00044052288,0.000025843432,0.000029277786,0.0010140336,0.0000038247695,0.85022885,0.00003986586,0.0027520976,0.025021479],"study_design_scores_gemma":[0.0027239197,0.00027844476,0.44232455,0.0011536307,0.000006829436,0.0000029716355,0.0001615098,0.000058900314,0.55019456,0.00029192548,0.0027205993,0.0000821374],"about_ca_topic_score_codex":0.0023835676,"about_ca_topic_score_gemma":0.0006212321,"teacher_disagreement_score":0.324381,"about_ca_system_score_codex":0.00029919963,"about_ca_system_score_gemma":0.00060397544,"threshold_uncertainty_score":0.9997882},"labels":[],"label_agreement":null},{"id":"W2887867165","doi":"10.1007/s00432-018-2730-5","title":"Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification","year":2018,"lang":"en","type":"article","venue":"Journal of Cancer Research and Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary General Hospital; University of Saskatchewan; Prostate Cancer Canada; University of Calgary; Ontario Institute for Cancer Research","funders":"Prostate Cancer Canada; Prostate Cancer Foundation","keywords":"PTEN; Erg; Prostate cancer; Medicine; Androgen deprivation therapy; Internal medicine; Oncology; Cancer; Biochemical recurrence; Prostate; Immunohistochemistry; Cancer research; PI3K/AKT/mTOR pathway; Prostatectomy; Biology; Apoptosis; Ophthalmology","score_opus":0.23176427893924195,"score_gpt":0.621758170695836,"score_spread":0.3899938917565941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887867165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919201,0.002279926,0.00029413129,0.0032928067,0.00018049072,0.0018421086,0.00003736924,0.0000033888577,0.00014967489],"genre_scores_gemma":[0.9773199,0.011951916,0.009811037,0.000050925217,0.00052748946,0.00012635085,0.0000051397446,0.000015062651,0.00019220402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954855,0.0015943883,0.001602467,0.0003621461,0.0005685978,0.0003869233],"domain_scores_gemma":[0.99408937,0.001967416,0.00084340625,0.00016438495,0.0025559368,0.00037951814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011519278,0.00011657318,0.00083162123,0.00021491335,0.00012652703,0.000028700786,0.00012008752,0.0002547069,0.00005888023],"category_scores_gemma":[0.0030584808,0.00007277636,0.00012454206,0.0002694301,0.0011801162,0.00020387118,0.000088663015,0.0011738406,3.2628236e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016786382,0.0015008278,0.5469143,0.00018750821,0.00012702995,0.000010824434,0.00016856742,1.1285875e-7,0.0029165174,0.000009646708,0.00048819673,0.43089014],"study_design_scores_gemma":[0.01972802,0.027316524,0.93245226,0.0010870164,0.00012913684,0.0000047806993,0.00046647651,0.0009026879,0.009196328,0.0030728737,0.005544264,0.000099636876],"about_ca_topic_score_codex":0.00030943257,"about_ca_topic_score_gemma":0.00060202274,"teacher_disagreement_score":0.43079048,"about_ca_system_score_codex":0.00019416673,"about_ca_system_score_gemma":0.0028636847,"threshold_uncertainty_score":0.5099819},"labels":[],"label_agreement":null},{"id":"W2887873865","doi":"10.1016/j.eururo.2018.07.028","title":"The Promise and Perils of Sequencing Individual Prostate Cancer Nuclei","year":2018,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Cancer; Gynecology; Internal medicine","score_opus":0.04036587580997668,"score_gpt":0.3008160201691731,"score_spread":0.2604501443591964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887873865","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23723961,0.01701939,7.926368e-7,0.7242833,0.0005987621,0.0015744166,0.00023542422,0.00007390101,0.018974438],"genre_scores_gemma":[0.15061757,0.02302786,0.00023922282,0.7203642,0.016311992,0.00028069908,0.00084100134,0.0006289237,0.087688506],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980982,0.00041573666,0.00029236535,0.00040375927,0.00029072785,0.00049924216],"domain_scores_gemma":[0.9990494,0.00014121231,0.0001851381,0.0003896848,0.00015735453,0.00007719236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050237565,0.00023524824,0.00036140427,0.00010240372,0.00016958559,0.000035675224,0.00022081756,0.00017233608,0.0001278922],"category_scores_gemma":[0.00008523031,0.00013704512,0.00006881931,0.000091758935,0.0009987457,0.00002811384,0.00022835433,0.0010369443,0.000050842948],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060876954,0.000017176493,0.0035160861,0.00034557638,0.00054879545,0.0018359325,0.002320421,2.3379967e-7,0.0009793795,0.0000064449314,0.97594947,0.013871701],"study_design_scores_gemma":[0.0013175752,0.0010707903,0.0058508953,0.000081419115,0.00025746145,0.00014243292,0.000043118813,0.0000061409432,0.0002715534,0.00003083092,0.9907965,0.00013127028],"about_ca_topic_score_codex":0.000030781146,"about_ca_topic_score_gemma":0.000006814502,"teacher_disagreement_score":0.08662204,"about_ca_system_score_codex":0.00007175611,"about_ca_system_score_gemma":0.00033229237,"threshold_uncertainty_score":0.55885375},"labels":[],"label_agreement":null},{"id":"W2887898086","doi":"10.1158/1538-7445.am2018-1931","title":"Abstract 1931: Targeting master neuronal transcription factor BRN2 in neuroendocrine prostate cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cancer research; Enzalutamide; SOX2; Prostate cancer; Transcription factor; Biology; Medicine; Androgen receptor; Bioinformatics; Cancer; Internal medicine; Genetics","score_opus":0.12513314642690165,"score_gpt":0.4222211547800229,"score_spread":0.29708800835312127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887898086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98525465,0.0030510435,0.000002836656,0.007888655,0.00043429545,0.0013992023,0.00013531942,0.000063272426,0.001770709],"genre_scores_gemma":[0.9861493,0.003724411,0.000032161017,0.00027613412,0.0010308712,0.0006847433,0.00004711464,0.000075194635,0.007980067],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9962089,0.00016209975,0.0003972134,0.0007091473,0.0011657709,0.0013568875],"domain_scores_gemma":[0.9985933,0.00009424413,0.00005060139,0.00032748177,0.00056780543,0.00036661868],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043882692,0.00025013505,0.00034126846,0.00053877354,0.00023928254,0.000092532515,0.00022840226,0.00006544632,0.004935961],"category_scores_gemma":[0.00009132496,0.00019708775,0.000095334915,0.0009189984,0.00051306415,0.0002758531,0.00009749933,0.0011441531,0.0001708337],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045103086,0.00033883032,0.16113901,0.0005828444,0.000085193016,0.0006208816,0.001539773,0.000012433903,0.7639292,0.00002058229,0.009958994,0.057261966],"study_design_scores_gemma":[0.008053254,0.0013922494,0.6198372,0.0008129666,0.000027634951,0.000024193296,0.0004158101,0.00027054528,0.2874242,0.00014700375,0.08118453,0.00041035615],"about_ca_topic_score_codex":0.0024420226,"about_ca_topic_score_gemma":0.0010308722,"teacher_disagreement_score":0.47650498,"about_ca_system_score_codex":0.0007305205,"about_ca_system_score_gemma":0.000876252,"threshold_uncertainty_score":0.99597365},"labels":[],"label_agreement":null},{"id":"W2887923686","doi":"10.1158/1538-7445.am2018-1918","title":"Abstract 1918: Patient-derived hormone-naive prostate cancer xenograft models reveal <i>GRB10</i> as an AR-repressed gene driving the development of castration-resistant prostate cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Androgen deprivation therapy; Androgen receptor; Gene knockdown; Cancer research; Medicine; Cancer; Downregulation and upregulation; Oncology; Internal medicine; Biology; Gene; Genetics","score_opus":0.08406928269049439,"score_gpt":0.3961882916589949,"score_spread":0.3121190089685005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887923686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834499,0.00845811,0.000013020153,0.0022371332,0.0002476931,0.0040466045,0.0003703224,0.00007985496,0.0010973654],"genre_scores_gemma":[0.9870844,0.0051043076,0.00063831644,0.00013924547,0.0004986754,0.0042838245,0.00014568091,0.00012663867,0.0019789157],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9934728,0.00030314902,0.001010697,0.0011319111,0.002404889,0.0016765132],"domain_scores_gemma":[0.9948349,0.00016481316,0.00035145265,0.0010139733,0.0029453407,0.0006895474],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014323912,0.0005017209,0.000658394,0.00038632503,0.0011843267,0.00019118139,0.0005888125,0.00019905655,0.000573658],"category_scores_gemma":[0.00009357103,0.00034159998,0.00014725422,0.001152955,0.0013079958,0.00056544534,0.0003319573,0.00097293296,0.000035400983],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061805574,0.00040483032,0.004709201,0.00034881206,0.00057819224,0.00008525309,0.02490626,0.00025881216,0.91068065,0.000021815926,0.0028704263,0.048955202],"study_design_scores_gemma":[0.0043454664,0.0016078497,0.05044364,0.0011233138,0.00011507496,0.000009149379,0.0030787622,0.0003621471,0.9328576,0.00048277347,0.005033836,0.00054038194],"about_ca_topic_score_codex":0.009030598,"about_ca_topic_score_gemma":0.005585032,"teacher_disagreement_score":0.04841482,"about_ca_system_score_codex":0.0013673609,"about_ca_system_score_gemma":0.006738339,"threshold_uncertainty_score":0.9999036},"labels":[],"label_agreement":null},{"id":"W2888113308","doi":"10.1016/j.ejmech.2018.08.059","title":"Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor","year":2018,"lang":"en","type":"article","venue":"European Journal of Medicinal Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute","keywords":"Enzalutamide; Androgen receptor; Chemistry; Prostate cancer; Small molecule; Cancer research; Transcription factor; Androgen; Cell biology; Cancer; Hormone; Biochemistry; Biology; Genetics; Gene","score_opus":0.04066528702268219,"score_gpt":0.2871065211325999,"score_spread":0.2464412341099177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888113308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924338,0.0005379766,0.00003102835,0.0006149601,0.00006155325,0.00010139103,0.0000047714216,0.0000039286333,0.006210605],"genre_scores_gemma":[0.99891835,0.00013148558,0.000120629404,0.000030957282,0.00029340523,3.9675558e-7,0.000008612556,0.00001726342,0.00047892085],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988019,0.00008678202,0.00046866722,0.00010849797,0.00039120347,0.00014295343],"domain_scores_gemma":[0.9987882,0.000027212294,0.00044674243,0.00018488771,0.00039933683,0.00015362764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078417413,0.00011029321,0.0002702645,0.00004402493,0.000059741426,0.0000051557054,0.00016987226,0.0000337834,0.00010973018],"category_scores_gemma":[0.00016791155,0.00006000557,0.00008293119,0.00014065865,0.00026442157,0.000034330904,0.00005070154,0.0002718391,0.0000011908985],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075149693,0.000097261116,0.0013455284,0.00019805202,0.00015433827,0.00010039027,0.00042373486,6.320768e-8,0.9931666,0.000005503271,0.00028237925,0.0034746497],"study_design_scores_gemma":[0.0038378302,0.00198825,0.00494629,0.00077735586,0.0001801493,0.0006409179,0.0004474178,0.000010289012,0.9868089,0.000013580225,0.0002906767,0.000058353267],"about_ca_topic_score_codex":0.0000046226683,"about_ca_topic_score_gemma":7.7445094e-7,"teacher_disagreement_score":0.0064845434,"about_ca_system_score_codex":0.00004794035,"about_ca_system_score_gemma":0.0001681554,"threshold_uncertainty_score":0.2446956},"labels":[],"label_agreement":null},{"id":"W2888167705","doi":"10.1038/s42003-018-0128-1","title":"Frequent mutation of the FOXA1 untranslated region in prostate cancer","year":2018,"lang":"en","type":"article","venue":"Communications Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada; DOD Prostate Cancer Research Program; Movember Foundation; Academy of Finland; Prostate Cancer Foundation","keywords":"FOXA1; Untranslated region; Biology; Genetics; Three prime untranslated region; Prostate cancer; Indel; Somatic hypermutation; Coding region; Germline mutation; INDEL Mutation; Frameshift mutation; Five prime untranslated region; Cancer research; Mutation; Gene; Transcription factor; Cancer; Single-nucleotide polymorphism; Messenger RNA; Genotype","score_opus":0.08012740538966663,"score_gpt":0.409693609515579,"score_spread":0.32956620412591237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888167705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96392745,0.0065839677,0.00002665091,0.025431246,0.00008451111,0.0007428607,0.000017667368,0.000018003077,0.0031676625],"genre_scores_gemma":[0.9958233,0.00332454,0.00022176073,0.00013179447,0.000015313593,0.000111810994,0.00006084456,0.0000053949207,0.00030521853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994479,0.0001444802,0.00016435489,0.00008827035,0.000039498897,0.00011548484],"domain_scores_gemma":[0.9989819,0.000053802887,0.000059497834,0.00072759826,0.00015662723,0.00002057403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000100896315,0.000048836984,0.00010497258,0.000072270894,0.00007740322,0.0000019575084,0.0002327356,0.0000485464,0.000027792483],"category_scores_gemma":[0.000033457036,0.000029691535,0.000029240151,0.0003402805,0.00063964305,0.000020241874,0.00007545457,0.00012711373,0.000005518586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048365252,0.00042438772,0.8712803,0.000064841224,0.00013571346,0.0000039884817,0.006057941,0.000004127282,0.048368607,0.0052039595,0.00056650274,0.067405954],"study_design_scores_gemma":[0.0090635335,0.0014302463,0.82028574,0.0008424251,0.00017657256,0.000071969225,0.0009229075,0.0028507279,0.09604038,0.012599235,0.05543178,0.00028450805],"about_ca_topic_score_codex":0.00068031746,"about_ca_topic_score_gemma":0.0012366311,"teacher_disagreement_score":0.067121446,"about_ca_system_score_codex":0.000083182684,"about_ca_system_score_gemma":0.00016317754,"threshold_uncertainty_score":0.23567916},"labels":[],"label_agreement":null},{"id":"W2888204653","doi":"10.1038/s41391-018-0079-0","title":"Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations","year":2018,"lang":"en","type":"review","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":377,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Prostate-specific antigen; Orchiectomy; Internal medicine; Disease; Androgen; Cancer; Hormone","score_opus":0.0343580190018654,"score_gpt":0.37411717218706964,"score_spread":0.3397591531852042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888204653","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001064305,0.9847083,4.334802e-7,0.0027138365,0.00014330319,0.008236758,0.002550528,0.00009997586,0.000482574],"genre_scores_gemma":[0.0004674422,0.98975974,0.00031868374,0.00042510082,0.00046253114,0.0063841785,0.00074134953,0.00017042729,0.0012705512],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961714,0.0003046037,0.0007981018,0.0012384012,0.00060162426,0.0008858422],"domain_scores_gemma":[0.99729985,0.00048214797,0.00048489065,0.00045377493,0.0006306898,0.00064867194],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003084038,0.0009232396,0.001960509,0.00042101328,0.00039574906,0.00037963796,0.000101744765,0.00021763529,0.0002687487],"category_scores_gemma":[0.00013515171,0.00058974355,0.00014700576,0.0007361401,0.0006614614,0.00060846703,0.00010492834,0.00058128906,0.0000057615907],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035381725,0.00047850565,0.011164466,0.028919654,0.0017310828,0.0007622042,0.0048476444,8.4161667e-7,0.000002340947,0.000050186907,0.0054780524,0.94302684],"study_design_scores_gemma":[0.008931367,0.001906607,0.0021258912,0.021062471,0.0034050406,0.00035481458,0.0016570891,0.000052822976,0.000020837451,0.00032113364,0.9590228,0.0011391046],"about_ca_topic_score_codex":0.00049454573,"about_ca_topic_score_gemma":0.00013526842,"teacher_disagreement_score":0.9535448,"about_ca_system_score_codex":0.00040542247,"about_ca_system_score_gemma":0.0038570773,"threshold_uncertainty_score":0.9996554},"labels":[],"label_agreement":null},{"id":"W2888239073","doi":"10.1038/s41379-018-0107-6","title":"The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy","year":2018,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; McGill University; U.S. Department of Defense","keywords":"PTEN; Biochemical recurrence; Prostate cancer; Prostatectomy; Hazard ratio; Oncology; Medicine; Metastasis; Internal medicine; Confidence interval; Stage (stratigraphy); Cancer; Prostate; Proportional hazards model; Cancer research; Biology; PI3K/AKT/mTOR pathway","score_opus":0.009244705441278157,"score_gpt":0.26201389366858563,"score_spread":0.2527691882273075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888239073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973957,0.00011115306,0.000039822397,0.000575534,0.000015035727,0.0016032128,0.00013120343,0.000014072117,0.00011426493],"genre_scores_gemma":[0.9982588,0.00010278767,0.00007647028,0.000048587644,0.000010350529,0.0006922074,0.00073930057,0.000008319188,0.00006317157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990836,0.00009229986,0.00024721818,0.0001497419,0.00020686329,0.00022028967],"domain_scores_gemma":[0.9994384,0.00007629584,0.00009659773,0.000087419154,0.0002616456,0.000039609695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018815072,0.000096453856,0.00015953837,0.0001793847,0.00006371069,0.0000130003245,0.00003390059,0.00005954886,0.000022522845],"category_scores_gemma":[0.00010565843,0.000057785386,0.000011209323,0.00020138513,0.0004150311,0.00018471564,0.00002255234,0.00012851297,0.0000025493944],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004029139,0.00027882127,0.9530949,0.00009603384,0.000017522148,0.000021206051,0.0014231475,0.0000092570735,0.00019817452,0.000057502628,0.00008694909,0.040687326],"study_design_scores_gemma":[0.00821819,0.002341631,0.9797388,0.00022564833,0.000017106382,0.000015415184,0.000063965774,0.007651425,0.00092042884,0.00057437783,0.0001596496,0.00007337453],"about_ca_topic_score_codex":0.00007085815,"about_ca_topic_score_gemma":0.00017810708,"teacher_disagreement_score":0.04061395,"about_ca_system_score_codex":0.00013761398,"about_ca_system_score_gemma":0.00015232824,"threshold_uncertainty_score":0.23564197},"labels":[],"label_agreement":null},{"id":"W2888792762","doi":"10.1158/1538-7445.prca2017-b098","title":"Abstract B098: Genomic variations associated with prostate cancer in large cohort of African American men","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Race (biology); Oncology; Cohort; Internal medicine; Incidence (geometry); Health equity; Demography; Pathology; Biology; Public health","score_opus":0.04575613373163134,"score_gpt":0.41053103649439265,"score_spread":0.3647749027627613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888792762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830108,0.00083140976,0.0000042448623,0.0022163808,0.000044993118,0.0016511211,0.000448107,0.000033786142,0.011759103],"genre_scores_gemma":[0.99210715,0.0018323037,0.000036474856,0.00004214723,0.00017548837,0.0010282536,0.00006841168,0.000053111424,0.0046566264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698055,0.00016310216,0.00033458264,0.000484999,0.0010157508,0.0010210389],"domain_scores_gemma":[0.99792683,0.00017644609,0.00014063659,0.0003991382,0.001091917,0.00026503394],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013406882,0.00017802253,0.00047791205,0.00053050014,0.00019108556,0.00003137248,0.00022100723,0.00007281194,0.0014129888],"category_scores_gemma":[0.00014608893,0.00013211252,0.00005261888,0.0020365294,0.0009850839,0.000101146055,0.0001056131,0.00059398054,0.000035634603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032943764,0.0005883096,0.945772,0.00011291362,0.0006100792,0.00008026591,0.0029561373,0.000015534088,0.038599323,0.000067749315,0.0023710444,0.0055322614],"study_design_scores_gemma":[0.003422152,0.000913925,0.9826645,0.0003920428,0.000049711543,0.0000013445291,0.0008623369,0.00015287509,0.009429749,0.000053423868,0.0019072711,0.00015066714],"about_ca_topic_score_codex":0.013136283,"about_ca_topic_score_gemma":0.009390073,"teacher_disagreement_score":0.036892496,"about_ca_system_score_codex":0.0017535641,"about_ca_system_score_gemma":0.00239305,"threshold_uncertainty_score":0.99949986},"labels":[],"label_agreement":null},{"id":"W2889240474","doi":"10.1016/j.euo.2018.08.003","title":"GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Prostate Cancer Canada","keywords":"Methylation; DNA methylation; Prostate cancer; Biochemical recurrence; Oncology; Epigenetics; Medicine; breakpoint cluster region; Cancer research; Cancer; Prostatectomy; Internal medicine; Biology; Genetics; Gene; Gene expression","score_opus":0.019729878792382964,"score_gpt":0.28836486595863975,"score_spread":0.2686349871662568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889240474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960585,0.00044796875,0.00026422786,0.0010861779,0.00010483111,0.0014948607,0.0002522348,0.000019951274,0.00027121222],"genre_scores_gemma":[0.99834585,0.000069418544,0.0010468619,0.00014396991,0.00011632053,0.00009206161,0.00010629301,0.000024281582,0.000054924705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989377,0.00009433391,0.0002143501,0.00039072664,0.00009936136,0.00026352756],"domain_scores_gemma":[0.9991566,0.0001563209,0.00014813153,0.00010784261,0.0003189251,0.00011218474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017970902,0.00015336178,0.0002570935,0.00012677835,0.00008219718,0.0000065172153,0.000045078614,0.00009085945,0.0000092885575],"category_scores_gemma":[0.00016590918,0.00010470979,0.00002302788,0.00013060246,0.0013542651,0.00006269068,0.00006599617,0.00017151472,5.852241e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012469303,0.00035910687,0.8589501,0.00021202576,0.00029050547,0.000009942323,0.004813627,2.499514e-7,0.045153666,0.000011984076,0.00043407016,0.07729546],"study_design_scores_gemma":[0.006944345,0.01126496,0.9723117,0.000041772924,0.00022188107,0.00002895301,0.000055414366,0.0004133685,0.007776283,0.00008523064,0.0007674533,0.00008864806],"about_ca_topic_score_codex":0.000035385518,"about_ca_topic_score_gemma":0.00001642329,"teacher_disagreement_score":0.113361634,"about_ca_system_score_codex":0.000052154654,"about_ca_system_score_gemma":0.00013152884,"threshold_uncertainty_score":0.49898463},"labels":[],"label_agreement":null},{"id":"W2889330650","doi":"10.1002/pros.23715","title":"SRRM4 gene expression correlates with neuroendocrine prostate cancer","year":2018,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Research Institute for Sustainable Humanosphere, Kyoto University; Canadian Institutes of Health Research; China Scholarship Council","keywords":"Prostate cancer; Immunohistochemistry; Medicine; Neuroendocrine differentiation; Prostate; PCA3; Pathology; Adenocarcinoma; In situ hybridization; Tissue microarray; Prostatectomy; Cancer; Cancer research; Oncology; Biology; Gene expression; Internal medicine; Gene","score_opus":0.019903493140735175,"score_gpt":0.3109764559280193,"score_spread":0.2910729627872841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889330650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833209,0.002038028,0.000027841828,0.010443674,0.00023669619,0.0016984019,0.00005759111,0.00022223135,0.0019546687],"genre_scores_gemma":[0.96714705,0.0021778976,0.0002906167,0.0006069865,0.00031200383,0.00036536597,0.000049452556,0.000064349624,0.02898625],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983186,0.00006434896,0.00020359513,0.00038568935,0.00041492248,0.0006128411],"domain_scores_gemma":[0.998916,0.00004668999,0.00009269898,0.00049341744,0.00026040812,0.00019080941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013122839,0.00024134667,0.00024938188,0.00007623145,0.00034942082,0.000052264106,0.00015538154,0.00002403626,0.00030092977],"category_scores_gemma":[0.000021174044,0.000113151094,0.00005199766,0.00033956266,0.0005404057,0.00012674343,0.0001248874,0.00030199255,0.00017238331],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034457445,0.00083959324,0.34607518,0.00049310253,0.0007421074,0.002074889,0.012258707,0.00009710134,0.49710703,0.00014235236,0.03455285,0.071159646],"study_design_scores_gemma":[0.0083598085,0.0035770216,0.02173097,0.00057651853,0.00024859374,0.0005076373,0.00028756395,0.0006825946,0.9325032,0.00069620274,0.030448094,0.00038179665],"about_ca_topic_score_codex":0.00013891094,"about_ca_topic_score_gemma":0.00003688202,"teacher_disagreement_score":0.43539616,"about_ca_system_score_codex":0.00008472495,"about_ca_system_score_gemma":0.00022741809,"threshold_uncertainty_score":0.46141678},"labels":[],"label_agreement":null},{"id":"W2889540146","doi":"10.1016/j.canlet.2018.08.016","title":"Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Letters","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute","keywords":"Androgen receptor; Prostate cancer; Transcription factor; Cancer research; Small molecule; Androgen; Virtual screening; Chemistry; Biology; Cell biology; Cancer; Gene; Hormone; Drug discovery; Bioinformatics; Endocrinology; Biochemistry; Genetics","score_opus":0.025144141906661397,"score_gpt":0.32510476599524796,"score_spread":0.29996062408858654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889540146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855618,0.0008340542,0.00039724962,0.011806086,0.00007761205,0.0009637119,0.000061300074,0.000029750892,0.0002684349],"genre_scores_gemma":[0.99687773,0.00011764943,0.0005771006,0.00089545245,0.0002517841,0.00036964074,0.000037311358,0.000036104317,0.00083721953],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99894863,0.000050046456,0.00018910087,0.0002913531,0.00022973242,0.00029115984],"domain_scores_gemma":[0.9993402,0.000020475036,0.00010203242,0.00016554965,0.00027456903,0.00009718287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009137,0.00016202457,0.00020030816,0.000075751595,0.00019947287,0.000028862025,0.00009702753,0.000030274176,0.00013629267],"category_scores_gemma":[0.000013153051,0.00009592361,0.00003614392,0.00038906038,0.00025289532,0.00005827923,0.000025382626,0.000109627166,0.000006538646],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014066797,0.00003258402,0.013564315,0.000088788416,0.00015707346,0.000005787706,0.0039036414,0.00009029922,0.97512996,0.000009870822,0.0035616832,0.0020493204],"study_design_scores_gemma":[0.0014060778,0.0009948263,0.005411948,0.00035360805,0.000119540004,0.0000021554847,0.00040516717,0.000036859212,0.9884848,0.0000031947175,0.0026354135,0.00014640353],"about_ca_topic_score_codex":0.0010555759,"about_ca_topic_score_gemma":0.00050489086,"teacher_disagreement_score":0.013354849,"about_ca_system_score_codex":0.00029944655,"about_ca_system_score_gemma":0.00022047249,"threshold_uncertainty_score":0.39116514},"labels":[],"label_agreement":null},{"id":"W2889640189","doi":"10.1200/jco.2018.36.15_suppl.tps3126","title":"An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Docetaxel; Nivolumab; Oncology; Internal medicine; Cancer; Androgen receptor; Immunotherapy","score_opus":0.2131296219286533,"score_gpt":0.551173903580684,"score_spread":0.33804428165203065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889640189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957359,0.00021430061,0.000010675046,0.0014703809,0.00009578668,0.0018212569,0.000012521747,0.0000047685994,0.0006344513],"genre_scores_gemma":[0.99686956,0.0003341522,0.0018329333,0.00015522915,0.0001041083,0.00009037239,0.000006947492,0.00002796682,0.00057873403],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9959969,0.00079497433,0.0019863541,0.00030014347,0.0005967438,0.00032491487],"domain_scores_gemma":[0.99667233,0.00046165724,0.0014755583,0.00024785945,0.00087526615,0.00026730928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003391738,0.00019049179,0.0015172394,0.00025788211,0.000050574043,0.00003225717,0.00027464185,0.00011199177,0.0001840522],"category_scores_gemma":[0.000308953,0.00010126588,0.00003296368,0.0005424216,0.00039813487,0.0004488578,0.000045695066,0.00064581365,0.0000022488518],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4748603,0.113031216,0.31982028,0.00020171044,0.0017824592,0.005900881,0.007133311,0.00010050859,0.0050735907,0.0000675628,0.0004670303,0.07156112],"study_design_scores_gemma":[0.29834548,0.44950894,0.24172096,0.0006804207,0.0006692156,0.00015206494,0.0059637893,0.0008979482,0.001077682,0.00017285852,0.00060675247,0.0002039013],"about_ca_topic_score_codex":0.001385919,"about_ca_topic_score_gemma":0.019943273,"teacher_disagreement_score":0.33647773,"about_ca_system_score_codex":0.00039959344,"about_ca_system_score_gemma":0.0042127213,"threshold_uncertainty_score":0.9979402},"labels":[],"label_agreement":null},{"id":"W2889881016","doi":"10.1200/jco.2017.35.15_suppl.tps5095","title":"Abiraterone +/- cabazitaxel in defining complete response in prostatectomy (ACDC-RP) trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; University of British Columbia; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; London Health Sciences Centre; University Health Network; University of Toronto; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Cabazitaxel; Medicine; Prostate cancer; Clinical endpoint; Prostatectomy; Urology; Oncology; Prednisone; Docetaxel; Internal medicine; Androgen deprivation therapy; Randomized controlled trial; Cancer","score_opus":0.3262107862489707,"score_gpt":0.5600936919070783,"score_spread":0.23388290565810754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889881016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775531,0.0006168928,0.000006477663,0.018034998,0.00090549607,0.0005722717,0.0000056781073,0.0000050296967,0.0023000436],"genre_scores_gemma":[0.99655145,0.0007530348,0.00096178456,0.00051905995,0.00037476496,0.000020092191,0.0000025216516,0.00001819875,0.0007991171],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99553025,0.0010838176,0.0023686192,0.00022941075,0.00038243222,0.00040548318],"domain_scores_gemma":[0.99481237,0.0027043093,0.0015384624,0.0003630315,0.0002604141,0.00032139604],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0114682,0.00014268342,0.0016228886,0.00033404407,0.00008376587,0.00003462628,0.0003061106,0.00033180678,0.000083375155],"category_scores_gemma":[0.012277542,0.00009620859,0.00027267932,0.00011128186,0.0004025166,0.00020232628,0.00011694543,0.0015638069,0.000042821226],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.725199,0.002197649,0.22390352,0.00003379939,0.00013061534,0.0080794105,0.00024842343,0.00000853989,0.00073370297,0.000037953778,0.0008966615,0.038530733],"study_design_scores_gemma":[0.22593804,0.028253237,0.7253592,0.00031862213,0.000052402374,0.00014426264,0.0001308471,0.00006578492,0.00009221316,0.00038387877,0.019169789,0.00009173026],"about_ca_topic_score_codex":0.00011633049,"about_ca_topic_score_gemma":0.00026200947,"teacher_disagreement_score":0.50145566,"about_ca_system_score_codex":0.0004262012,"about_ca_system_score_gemma":0.002818199,"threshold_uncertainty_score":0.9960425},"labels":[],"label_agreement":null},{"id":"W2889899936","doi":"10.1200/jco.2018.36.15_suppl.tps5092","title":"A prospective phase 2/3 multicenter study of <sup>18</sup>F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Prospective cohort study; Cancer; Androgen deprivation therapy; Prostate; Tolerability; Cohort; Radiology; Nuclear medicine; Internal medicine; Adverse effect","score_opus":0.06507719558226906,"score_gpt":0.48582579872710174,"score_spread":0.4207486031448327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889899936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99694073,0.00020899365,0.0000056610656,0.00046938512,0.00020241953,0.0018837524,0.000016512891,0.000004501114,0.00026801744],"genre_scores_gemma":[0.99894935,0.00035211095,0.00024222932,0.00008608744,0.00022971175,0.00004986296,0.000005327851,0.000019961482,0.00006535017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964306,0.00053036335,0.0018944519,0.00025243437,0.0006155765,0.0002766216],"domain_scores_gemma":[0.992837,0.00311731,0.0017646118,0.00019200832,0.0018907858,0.00019824927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001865924,0.00016030906,0.0011777616,0.00026995465,0.000034825152,0.0000068237027,0.00014938902,0.000031166666,0.00011903638],"category_scores_gemma":[0.0059174793,0.00009905675,0.00012853857,0.0002958696,0.00042811266,0.0002622017,0.000069475966,0.00058321626,0.0000025352103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025583716,0.021361217,0.86344886,0.000065760185,0.00033684922,0.00082325743,0.0021048011,0.000023685423,0.000018896624,0.0000010657373,0.00012621106,0.08610571],"study_design_scores_gemma":[0.08214783,0.05127512,0.8632477,0.0004806256,0.0003553761,0.000023464048,0.001462099,0.000444333,0.00028217313,0.000016164382,0.00018816344,0.000076978],"about_ca_topic_score_codex":0.00016013937,"about_ca_topic_score_gemma":0.000114091075,"teacher_disagreement_score":0.08602873,"about_ca_system_score_codex":0.0003690863,"about_ca_system_score_gemma":0.0010538643,"threshold_uncertainty_score":0.7084203},"labels":[],"label_agreement":null},{"id":"W2890013612","doi":"10.1200/jco.2016.34.15_suppl.e16577","title":"Concomitant use of glucocorticoids in patients with metastatic castration resistant prostate cancer (mCRPC) treated with oral therapies.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Concomitant; Abiraterone acetate; Hazard ratio; Prostate cancer; Proportional hazards model; Enzalutamide; Internal medicine; Urology; Population; Cancer; Confidence interval; Androgen deprivation therapy; Androgen receptor","score_opus":0.13777576950248407,"score_gpt":0.44504356195058126,"score_spread":0.3072677924480972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890013612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963403,0.00025070034,0.000030007794,0.0026293655,0.0000780503,0.0005853747,0.000028220524,0.0000042354823,0.000053787313],"genre_scores_gemma":[0.99626625,0.00089879864,0.0022769608,0.00014278578,0.0000478575,0.000017441138,0.000004551042,0.00001886488,0.00032648715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718004,0.00038659468,0.0015232348,0.00017209638,0.00048218865,0.0002558571],"domain_scores_gemma":[0.9964309,0.0009757616,0.0012958073,0.00015304613,0.00091812573,0.00022639369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091441366,0.0001442884,0.0011803802,0.00015671573,0.000019566209,0.000008018949,0.000069416914,0.00010445129,0.000083264975],"category_scores_gemma":[0.00046518157,0.00005771319,0.00011434603,0.00022617425,0.00041979205,0.00023409227,0.000013788105,0.00032972373,0.0000012625586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.093386665,0.0017510167,0.829245,0.00003206158,0.0007420384,0.0005823037,0.00012184182,0.0000061637065,0.0008589197,0.000027864018,0.000089650996,0.07315651],"study_design_scores_gemma":[0.049309324,0.042279493,0.905164,0.0005579881,0.00037835585,0.000019703202,0.000078362216,0.0000069921743,0.0008227412,0.000057201745,0.001246698,0.00007911883],"about_ca_topic_score_codex":0.00020051532,"about_ca_topic_score_gemma":0.0007065534,"teacher_disagreement_score":0.07591906,"about_ca_system_score_codex":0.000351215,"about_ca_system_score_gemma":0.0022494067,"threshold_uncertainty_score":0.39903507},"labels":[],"label_agreement":null},{"id":"W2890026694","doi":"10.1038/s41388-018-0488-5","title":"A molecular portrait of epithelial–mesenchymal plasticity in prostate cancer associated with clinical outcome","year":2018,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Health and Medical Research Council; Prostate Cancer Foundation of Australia; Queensland Government; Queensland Health; Medical Research Council; Movember Foundation; Australian Government; Prostate Cancer Foundation","keywords":"Epithelial–mesenchymal transition; Biology; Prostate cancer; Cancer; Metastasis; Mesenchymal stem cell; Cancer research; Phenotype; Prostate; Gene; Cell biology; Genetics","score_opus":0.05650425985554934,"score_gpt":0.404606862720647,"score_spread":0.34810260286509764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890026694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99703723,0.00023942949,0.000022780434,0.00052988983,0.00008642026,0.0005301917,0.00010019208,0.000023235527,0.0014306462],"genre_scores_gemma":[0.99804366,0.00012555107,0.00025662468,0.00016699644,0.00010393343,0.000050732266,0.000028289578,0.000025404031,0.0011988148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984251,0.00007792801,0.0004662096,0.00028946533,0.0003861166,0.0003551638],"domain_scores_gemma":[0.9991708,0.00008274178,0.00014524597,0.00016251708,0.0002740259,0.00016468788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034405294,0.00014318073,0.00047979938,0.00010544001,0.000029377905,0.000005628108,0.0000755709,0.00009180029,0.00017610166],"category_scores_gemma":[0.00022650979,0.00009557196,0.000086852786,0.00036785813,0.00036091136,0.000036117253,0.00003955829,0.00021389808,0.000013211346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021174343,0.0006388217,0.9540711,0.000047939742,0.00028286924,0.00060171937,0.00019649338,0.000008399846,0.03654002,0.00001714945,0.00009047458,0.005387573],"study_design_scores_gemma":[0.012979853,0.003945262,0.829532,0.00052615826,0.00024491668,0.000020347326,0.00007136136,0.0003873479,0.15119839,0.000043888904,0.00081598683,0.00023446011],"about_ca_topic_score_codex":0.00029402,"about_ca_topic_score_gemma":0.0005410333,"teacher_disagreement_score":0.12453907,"about_ca_system_score_codex":0.00015918238,"about_ca_system_score_gemma":0.0006178115,"threshold_uncertainty_score":0.38973114},"labels":[],"label_agreement":null},{"id":"W2890224043","doi":"10.1200/jco.2017.35.15_suppl.5078","title":"A secondary analysis of PSA response in NRG Oncology/RTOG 9902: A phase III trial of adjuvant chemotherapy with androgen suppression and radiation for high-risk prostate cancer (CaP).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Hazard ratio; Estramustine; Internal medicine; Randomization; Oncology; Androgen suppression; Prostate cancer; Radiation therapy; Chemotherapy; Docetaxel; Urology; Adjuvant; Confidence interval; Etoposide; Cancer; Randomized controlled trial; Prostate disease","score_opus":0.08164844456432574,"score_gpt":0.5119246027542678,"score_spread":0.430276158189942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890224043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99151796,0.0014766138,0.000041631116,0.005396775,0.00028464044,0.0010864153,0.00013797804,0.0000022344168,0.00005575428],"genre_scores_gemma":[0.9865129,0.011924774,0.0009452148,0.00013118224,0.0002608005,0.000049488604,0.000016079866,0.000013829932,0.00014575473],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966728,0.00065112096,0.0019300552,0.0002272854,0.00030205227,0.00021669893],"domain_scores_gemma":[0.99256885,0.0025958954,0.0038556813,0.00026706068,0.0004857757,0.0002267207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058662086,0.00013430964,0.0022589662,0.00042158217,0.000072568946,0.000008626517,0.00013782518,0.0003232491,0.00007719712],"category_scores_gemma":[0.0022595664,0.000079968806,0.0003261912,0.00017815376,0.0004735683,0.00014600188,0.000035790807,0.0005469654,1.2311699e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6166106,0.0021971648,0.06589896,0.000039432165,0.002035568,0.00012048064,0.0005135104,0.000015244287,0.0013036159,0.0000023682524,0.00030133798,0.31096172],"study_design_scores_gemma":[0.544086,0.096777804,0.3450537,0.00018799798,0.0030327362,0.000019067089,0.0001808214,0.0006096961,0.0039365054,0.00013311183,0.0058942013,0.000088416724],"about_ca_topic_score_codex":0.00026119567,"about_ca_topic_score_gemma":0.00036895642,"teacher_disagreement_score":0.3108733,"about_ca_system_score_codex":0.00021085698,"about_ca_system_score_gemma":0.003681248,"threshold_uncertainty_score":0.6530376},"labels":[],"label_agreement":null},{"id":"W2890269457","doi":"10.1158/1538-7445.prca2017-b100","title":"Abstract B100: High-risk pathologic and genomic features of BRCA2-mutant prostate cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Prostate; Oncology; Germline; Internal medicine; Germline mutation; Disease; Cancer research; Pathology; Mutation; Biology; Gene; Genetics","score_opus":0.05720151627534745,"score_gpt":0.4092838500741783,"score_spread":0.3520823337988308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890269457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97345394,0.020983944,8.2552623e-7,0.0019281524,0.00018395882,0.0011610825,0.00034248873,0.000039337297,0.0019062796],"genre_scores_gemma":[0.9602283,0.034827676,0.00009192023,0.000073869094,0.000550203,0.0003768687,0.000021579874,0.000046651512,0.003782912],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973195,0.00014363544,0.00029155696,0.00059297594,0.00079949165,0.0008528196],"domain_scores_gemma":[0.9981432,0.00015018505,0.00010504574,0.00046139775,0.00081678753,0.0003233794],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010033326,0.00021126398,0.00042559937,0.00034012416,0.0003117982,0.00005116639,0.00021169875,0.00015301263,0.0011373588],"category_scores_gemma":[0.00013085124,0.00014522679,0.000069473506,0.0005423481,0.0014492236,0.000095066236,0.00021909534,0.0007854937,0.000046192526],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048853033,0.00026285095,0.14566156,0.0008076263,0.00040394184,0.00057329715,0.0026487035,0.0000061676733,0.6997322,0.00018089535,0.010339213,0.13449827],"study_design_scores_gemma":[0.0039006271,0.0015283757,0.7317479,0.00046847895,0.000078778095,0.00004318834,0.00043767985,0.000012549146,0.25492522,0.0008514002,0.005788993,0.00021678538],"about_ca_topic_score_codex":0.007583149,"about_ca_topic_score_gemma":0.0008498392,"teacher_disagreement_score":0.58608633,"about_ca_system_score_codex":0.0004552308,"about_ca_system_score_gemma":0.00097371894,"threshold_uncertainty_score":0.9997757},"labels":[],"label_agreement":null},{"id":"W2890301250","doi":"10.1200/jco.2016.34.15_suppl.5045","title":"Persistence of AR signaling in small cell neuroendocrine prostate cancer (SCNC) and intermediate atypical carcinoma (IAC): Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Adenocarcinoma; Pathology; Biopsy; Prostate cancer; Carcinoma; Cancer; Immunohistochemistry; Biology; Internal medicine","score_opus":0.1062622741420373,"score_gpt":0.40624153992301626,"score_spread":0.29997926578097894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890301250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96811783,0.0041739615,0.000004189317,0.025724715,0.0008279147,0.0006699284,0.0002867258,0.000008506165,0.00018620571],"genre_scores_gemma":[0.9732444,0.023898356,0.00020118094,0.00071584916,0.00094030006,0.00003679427,0.000008964699,0.00003280543,0.00092131423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952391,0.0006838476,0.0025481696,0.00048327207,0.0004534953,0.0005921518],"domain_scores_gemma":[0.99276316,0.004217374,0.0015966941,0.00030945562,0.0006030272,0.0005102825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017877655,0.00027909753,0.0015349339,0.00014556907,0.000069463065,0.000018631012,0.0003440359,0.00017792713,0.00007850146],"category_scores_gemma":[0.0018318561,0.00013628889,0.00032550623,0.00022664662,0.0009821287,0.00014963826,0.00021974913,0.0012505087,0.000005574969],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045412872,0.0008765528,0.8712534,0.00009415271,0.00024433166,0.0018594699,0.0013104584,0.000027319771,0.008702505,0.000003495038,0.001979022,0.06823646],"study_design_scores_gemma":[0.035468157,0.009430494,0.9374494,0.0013059612,0.0004321566,0.00014477018,0.0010367836,0.00009665438,0.005317227,0.00016320993,0.008953563,0.00020160525],"about_ca_topic_score_codex":0.0012579816,"about_ca_topic_score_gemma":0.0026601031,"teacher_disagreement_score":0.06803486,"about_ca_system_score_codex":0.00034605584,"about_ca_system_score_gemma":0.002541908,"threshold_uncertainty_score":0.55577},"labels":[],"label_agreement":null},{"id":"W2890317544","doi":"10.1200/jco.2016.34.15_suppl.10099","title":"Improving bone health in men with prostate cancer on ADT: Results of a randomized phase II trial.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Randomized controlled trial; Androgen deprivation therapy; Odds ratio; Physical therapy; Osteoporosis; Bone mineral; Psychological intervention; Confidence interval; Internal medicine; Prostate cancer; Cancer; Nursing","score_opus":0.1234740438026997,"score_gpt":0.5308560331266703,"score_spread":0.4073819893239706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890317544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8954222,0.002059765,0.000039722578,0.0984179,0.00039261775,0.0020294974,0.000028291777,0.0000059264507,0.0016040343],"genre_scores_gemma":[0.9817487,0.0130179245,0.00070482795,0.0008995887,0.0006743883,0.00006198562,0.0000029989938,0.000018804874,0.0028708086],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99469316,0.0010160693,0.0033319544,0.00020967024,0.00043081216,0.00031833633],"domain_scores_gemma":[0.9922945,0.0036442778,0.0031040784,0.00017293269,0.00041606088,0.00036818092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011654251,0.00012981765,0.003020748,0.00024271323,0.00003300523,0.0000030518886,0.0000913208,0.00016250943,0.000048448586],"category_scores_gemma":[0.0056328396,0.00005356466,0.00035171834,0.00016849906,0.00037203857,0.00008147152,0.000035148216,0.00058570865,0.0000017137891],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69194233,0.0037724671,0.00017320906,0.000030404633,0.0002738328,0.00025138343,0.00022228772,0.0000016630788,0.00023238035,0.000011082707,0.0015640603,0.3015249],"study_design_scores_gemma":[0.8766769,0.11574147,0.00051400857,0.0008314098,0.00014828332,0.000026372012,0.000057495046,0.000048204678,0.0003573621,0.00010535097,0.005439265,0.00005384172],"about_ca_topic_score_codex":0.00021972794,"about_ca_topic_score_gemma":0.00015214199,"teacher_disagreement_score":0.30147108,"about_ca_system_score_codex":0.0004216656,"about_ca_system_score_gemma":0.005426563,"threshold_uncertainty_score":0.9626489},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2890332162","doi":"10.1158/1538-7445.prca2017-a066","title":"Abstract A066: Rb and ZBTB7A cooperatively mediate the transcriptional repression function of androgen receptor","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Androgen receptor; Gene silencing; Prostate cancer; Biology; Cancer research; Psychological repression; Gene; Promoter; Gene expression; Cancer; Genetics","score_opus":0.11903039228287253,"score_gpt":0.4257675368277292,"score_spread":0.3067371445448567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890332162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850408,0.0074233473,0.000026320005,0.00415519,0.00018387522,0.0007209441,0.000069553615,0.00001696317,0.0023630245],"genre_scores_gemma":[0.9903229,0.0040767784,0.000027022845,0.00007279997,0.0005784267,0.0001901409,0.000033962653,0.000018022136,0.004679932],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99828815,0.00013134615,0.00019232577,0.00030669288,0.00074116787,0.00034030934],"domain_scores_gemma":[0.9985998,0.0001451501,0.000037225807,0.00023997591,0.00081655505,0.00016126515],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009768868,0.00010086452,0.00017893803,0.00013258657,0.00032979914,0.00003727531,0.000106621235,0.00008421131,0.0015500125],"category_scores_gemma":[0.00010061803,0.000056619057,0.000045089884,0.00037650563,0.0010005867,0.0001533881,0.000052446958,0.00038260393,0.000036346242],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006028532,0.0001580075,0.010433824,0.00022326747,0.00022210699,0.000009774134,0.0017901469,0.0000019422885,0.9220646,0.00035162442,0.016482918,0.04223326],"study_design_scores_gemma":[0.0057646767,0.002442092,0.2767599,0.0007261713,0.00007808674,0.000013150161,0.0011103194,0.00008715706,0.58558017,0.0005465241,0.12669541,0.00019636219],"about_ca_topic_score_codex":0.00017656687,"about_ca_topic_score_gemma":0.00004195182,"teacher_disagreement_score":0.33648443,"about_ca_system_score_codex":0.00012562516,"about_ca_system_score_gemma":0.00055767206,"threshold_uncertainty_score":0.9993627},"labels":[],"label_agreement":null},{"id":"W2890336344","doi":"10.1200/jco.2016.34.15_suppl.e16568","title":"Identifying candidates for prednisone to dexamethasone switch amongst patients with castration-resistant prostate cancer undergoing abiraterone therapy.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prednisone; Prostate cancer; Docetaxel; Dexamethasone; Internal medicine; Abiraterone acetate; Cancer; Chemotherapy; Urology; Corticosteroid; Oncology; Gastroenterology; Androgen deprivation therapy","score_opus":0.13415254367498405,"score_gpt":0.47188810988483837,"score_spread":0.33773556620985434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890336344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875351,0.0007597302,0.00066133164,0.009325854,0.00048377068,0.0010963294,0.0000410002,0.000010492971,0.00008635544],"genre_scores_gemma":[0.99098974,0.0020628297,0.004338086,0.00050636305,0.00048826472,0.0000892425,0.000006872611,0.00003363587,0.0014849391],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974143,0.00016148262,0.0013047063,0.00026657103,0.00046232776,0.00039060134],"domain_scores_gemma":[0.995748,0.0016326128,0.00091335754,0.00016240432,0.0010851321,0.00045853574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013651025,0.00016862781,0.0009257909,0.00014100446,0.00009323769,0.000029259101,0.00012716725,0.00016072579,0.00007814508],"category_scores_gemma":[0.00085592084,0.000079902835,0.00017798184,0.00016152691,0.00013399243,0.00022289007,0.00003124851,0.0002675359,0.0000071440554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07015362,0.0014876191,0.66507584,0.00008870001,0.0010341128,0.00012669363,0.00036543675,0.000007829954,0.0106148645,0.000018965646,0.0020609691,0.24896537],"study_design_scores_gemma":[0.057016592,0.04480556,0.8761614,0.0010526926,0.0003088498,0.000018693278,0.00016991075,0.000005956052,0.0068911067,0.0002448007,0.013126198,0.00019822572],"about_ca_topic_score_codex":0.00007715819,"about_ca_topic_score_gemma":0.0007569853,"teacher_disagreement_score":0.24876714,"about_ca_system_score_codex":0.00042477954,"about_ca_system_score_gemma":0.0024695643,"threshold_uncertainty_score":0.43809012},"labels":[],"label_agreement":null},{"id":"W2890415736","doi":"10.1200/jco.2018.36.15_suppl.5039","title":"DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Prostate cancer; MSH6; MSH2; MLH1; Medicine; Cancer; CHEK2; Cancer research; Pathology; Biology; Oncology; Internal medicine; DNA mismatch repair; Gene; Genetics; Mutation; Germline mutation; Colorectal cancer","score_opus":0.1557911161741769,"score_gpt":0.4617809647307325,"score_spread":0.3059898485565556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890415736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758035,0.0077525685,0.000006728485,0.010795175,0.0008866743,0.0018267924,0.0025959313,0.000018809144,0.0003138212],"genre_scores_gemma":[0.95487475,0.040621176,0.00090291013,0.00030243504,0.0007646708,0.00018374102,0.00029586907,0.000057787634,0.0019966648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941227,0.00085054035,0.003117983,0.0006514054,0.00069596793,0.0005614159],"domain_scores_gemma":[0.99264,0.0017307288,0.0030207573,0.00072813866,0.0013762048,0.000504144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015450648,0.00039873814,0.0017960361,0.00015732207,0.00019726045,0.000028765493,0.00038450176,0.000115376264,0.00041672678],"category_scores_gemma":[0.0009481825,0.00023021271,0.00035508486,0.00038431506,0.0012901208,0.00026943328,0.00022846521,0.00069447275,0.0000041539442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058896698,0.0068152756,0.75929105,0.0006586745,0.005089777,0.0015943701,0.0048454665,0.00011091069,0.016201854,0.000033104552,0.010663973,0.13579887],"study_design_scores_gemma":[0.040029246,0.044076923,0.8294268,0.0013978216,0.007840497,0.00024449138,0.0040544425,0.0016895467,0.014572659,0.00042219274,0.05571307,0.0005322846],"about_ca_topic_score_codex":0.01939691,"about_ca_topic_score_gemma":0.06307921,"teacher_disagreement_score":0.13526659,"about_ca_system_score_codex":0.00041300902,"about_ca_system_score_gemma":0.005747358,"threshold_uncertainty_score":0.99988914},"labels":[],"label_agreement":null},{"id":"W2890444045","doi":"10.1016/j.ejca.2018.08.010","title":"Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis","year":2018,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Abiraterone acetate; Prostate cancer; Oncology; Internal medicine; Prednisone; Hazard ratio; Randomized controlled trial; Cabazitaxel; Quality of life (healthcare); Androgen deprivation therapy; Enzalutamide; Cancer; Confidence interval; Androgen receptor","score_opus":0.2668346676253707,"score_gpt":0.4654540828694023,"score_spread":0.1986194152440316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890444045","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01045491,0.9866314,0.000020781286,0.00035898792,0.0003078129,0.0013361935,0.000764916,0.000008886436,0.000116138275],"genre_scores_gemma":[0.012678731,0.98543614,0.0004855081,0.000026780039,0.00025185852,0.00007481305,0.00006775028,0.00010539343,0.0008730504],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99282444,0.0021195184,0.0026900098,0.00053135166,0.001282135,0.0005525393],"domain_scores_gemma":[0.9937719,0.00046254226,0.0037073502,0.00048778096,0.0009572941,0.000613144],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003328396,0.000668386,0.007910979,0.0006992726,0.00007141737,0.00004215879,0.00029158118,0.000061716695,0.000085639294],"category_scores_gemma":[0.00026036933,0.00038320612,0.002190713,0.0012211431,0.00044712686,0.00017757082,0.00019671947,0.00060436176,0.0000028038498],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03800663,0.0007400258,0.00789148,0.026288038,0.6444452,0.001667893,0.002034068,0.0011617726,0.000014386201,0.00003357166,0.00047688937,0.27724007],"study_design_scores_gemma":[0.027402667,0.0032657434,0.041011713,0.012014995,0.85372126,0.000016691485,0.00027917532,0.0000721644,0.000025567866,0.00001959884,0.061070856,0.0010995374],"about_ca_topic_score_codex":0.00017289413,"about_ca_topic_score_gemma":0.0002095865,"teacher_disagreement_score":0.27614054,"about_ca_system_score_codex":0.00034747165,"about_ca_system_score_gemma":0.0015959883,"threshold_uncertainty_score":0.99986196},"labels":[],"label_agreement":null},{"id":"W2890743632","doi":"10.1111/bju.14534","title":"Impact of 5α‐reductase inhibitor and α‐blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality","year":2018,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"National Cancer Institute; National Institute on Aging; National Institutes of Health","keywords":"Medicine; Hazard ratio; Prostate cancer; Incidence (geometry); Proportional hazards model; Cohort; Internal medicine; Retrospective cohort study; Confidence interval; Urology; Gynecology; Cancer; Hyperplasia","score_opus":0.025353808806113484,"score_gpt":0.36698339168447064,"score_spread":0.34162958287835715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890743632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98697865,0.011408277,0.000005686481,0.000728531,0.00010912027,0.00061264005,0.0001303596,0.000003872718,0.000022837106],"genre_scores_gemma":[0.99087876,0.008374413,0.00020759794,0.0001579741,0.00026932076,0.00002674987,0.00000602205,0.000016280861,0.00006287621],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989975,0.00006588793,0.0003243642,0.00017405198,0.00019038617,0.0002477996],"domain_scores_gemma":[0.9989608,0.00009532108,0.00021332837,0.000083020816,0.00047122606,0.00017630968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034193965,0.000111694266,0.00037957722,0.00010304816,0.000076174634,0.000021332105,0.000048418377,0.00007121353,0.000043475175],"category_scores_gemma":[0.0001378602,0.00008545533,0.000077785684,0.00008535127,0.00048112648,0.000097572185,0.000019561336,0.00019093502,3.65513e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01400557,0.00061225466,0.82569903,0.00017257262,0.0007951838,0.0006778288,0.001176647,0.000004887651,0.03149686,0.000016102787,0.0036654335,0.1216776],"study_design_scores_gemma":[0.009156186,0.020260537,0.95705277,0.00026695474,0.00014684741,0.0048252023,0.00006249906,0.00007397945,0.0070388955,0.00055090454,0.0004574373,0.00010778701],"about_ca_topic_score_codex":0.00031617403,"about_ca_topic_score_gemma":0.00007360028,"teacher_disagreement_score":0.13135372,"about_ca_system_score_codex":0.00005399974,"about_ca_system_score_gemma":0.00040477025,"threshold_uncertainty_score":0.3484767},"labels":[],"label_agreement":null},{"id":"W2890786570","doi":"10.14740/wjon1144w","title":"DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC)","year":2018,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Germline; Prostate cancer; Medicine; DNA repair; Genetic testing; Germline mutation; Somatic cell; Oncology; Cancer; Internal medicine; Gene; Cancer research; Genetics; Mutation; Biology","score_opus":0.047534455331042454,"score_gpt":0.40175360339347505,"score_spread":0.3542191480624326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890786570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919523,0.0038923975,0.000022883647,0.0026951863,0.00026918863,0.0004370247,0.000032488282,0.000004750074,0.00069376006],"genre_scores_gemma":[0.99205863,0.0051131346,0.0019045477,0.00014194105,0.0001634736,0.000015781912,0.000004926457,0.000010069331,0.00058746384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982862,0.00043511039,0.00072714675,0.00012803063,0.00023399164,0.0001895289],"domain_scores_gemma":[0.9979748,0.00067270297,0.0005820599,0.00017002088,0.000495734,0.000104647756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014700454,0.000099321835,0.00047909727,0.00022874054,0.00008130258,0.0000077120785,0.000080603066,0.000044528602,0.00019687726],"category_scores_gemma":[0.0002588081,0.000058899044,0.000093337054,0.00031483336,0.0009753562,0.00007326859,0.00003443254,0.00044176416,0.0000017779043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016520664,0.0017784077,0.6738971,0.00027041577,0.001557029,0.0008694214,0.011820312,0.00009181598,0.0011296789,0.00042527437,0.00432009,0.2873198],"study_design_scores_gemma":[0.023211367,0.0045055686,0.9445451,0.00017891567,0.00096214865,0.0001770587,0.0013347589,0.0022087737,0.0014248666,0.003294594,0.01804265,0.00011419199],"about_ca_topic_score_codex":0.00032919244,"about_ca_topic_score_gemma":0.004857529,"teacher_disagreement_score":0.2872056,"about_ca_system_score_codex":0.00014593729,"about_ca_system_score_gemma":0.0011946866,"threshold_uncertainty_score":0.35937408},"labels":[],"label_agreement":null},{"id":"W2891085206","doi":"10.3390/cancers10100343","title":"Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models","year":2018,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"GlaxoSmithKline","keywords":"Pregnenolone; LNCaP; Endocrinology; Prostate cancer; Internal medicine; Steroid; CYP17A1; Chemistry; Backdoor; Prostate; Biology; Biochemistry; Enzyme; Hormone; Medicine; Cancer","score_opus":0.047067454353067494,"score_gpt":0.3390620688157951,"score_spread":0.2919946144627276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891085206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658185,0.0005567834,0.000027785847,0.00021329198,0.00014658557,0.00069191784,0.00007410496,0.00002107485,0.0016866317],"genre_scores_gemma":[0.994455,0.0011230458,0.000023040322,0.00008156937,0.00014078125,0.00021030716,0.000060722956,0.000022727349,0.0038828074],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99902564,0.000025414243,0.000216934,0.00023606779,0.00024101802,0.00025492796],"domain_scores_gemma":[0.9994651,0.000005346023,0.00008292773,0.0001881517,0.00017267033,0.000085808504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000096147596,0.00010969281,0.0002247202,0.00015173093,0.000042475553,0.000008200622,0.00006942834,0.000055215678,0.00018938651],"category_scores_gemma":[0.000003840127,0.00009153313,0.000037180263,0.00024446196,0.00014683635,0.00012965447,0.000027703793,0.00007492909,0.0000055225223],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009544441,0.000051893687,0.0686907,0.00022873565,0.000093197166,0.00001435709,0.0030661006,0.00017273158,0.91548526,0.00006333586,0.00009217837,0.0110870525],"study_design_scores_gemma":[0.0045070094,0.000801064,0.05306335,0.0005786749,0.00007122281,0.0000030722424,0.00020873007,0.0017116256,0.9379278,0.00018207786,0.0007474885,0.00019790867],"about_ca_topic_score_codex":0.0008057316,"about_ca_topic_score_gemma":0.00045394673,"teacher_disagreement_score":0.022442505,"about_ca_system_score_codex":0.0011936529,"about_ca_system_score_gemma":0.000597924,"threshold_uncertainty_score":0.3732613},"labels":[],"label_agreement":null},{"id":"W2891356992","doi":"10.1016/j.euf.2018.08.022","title":"ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Astellas Pharma; Physicians' Services Incorporated Foundation; Ipsen Biopharmaceuticals; Genentech; Bayer; Celgene; Meso Scale Diagnostics; Novartis; Amgen","keywords":"Medicine; Prostate cancer; CYP17A1; Androgen deprivation therapy; Castration; Androgen receptor; Oncology; Internal medicine; Dual (grammatical number); Orchiectomy; Urology; Cancer; Hormone","score_opus":0.023840325398907927,"score_gpt":0.295741604209543,"score_spread":0.2719012788106351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891356992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99237704,0.00072862627,0.000010850004,0.0014762871,0.00005446015,0.0006139585,0.000565758,0.000026141775,0.0041468693],"genre_scores_gemma":[0.9985394,0.00013009194,0.00029641244,0.000045556313,0.00025491687,0.00001994156,0.0001527407,0.00003233783,0.00052859273],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99861354,0.00014714239,0.00035676532,0.00040694405,0.00020516469,0.00027047333],"domain_scores_gemma":[0.9992909,0.00006505051,0.00014401767,0.00021773229,0.00015355893,0.00012876745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031029328,0.00015941914,0.00025018683,0.00013422019,0.0000639414,0.000017076698,0.000050490467,0.000057296143,0.000050043],"category_scores_gemma":[0.000051975967,0.000115571806,0.00002281213,0.0002030753,0.000378013,0.00010133035,0.00004717164,0.00018054315,0.00001867959],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11490771,0.0014240304,0.06258293,0.000053986438,0.00048338345,0.0008313693,0.016904972,0.000012583564,0.7710091,0.00005281695,0.0020731564,0.029663954],"study_design_scores_gemma":[0.12887923,0.025244478,0.6931319,0.00037023396,0.00038209255,0.00007422562,0.00047013673,0.0005954646,0.13959208,0.00008454095,0.010606334,0.0005692481],"about_ca_topic_score_codex":0.0010342363,"about_ca_topic_score_gemma":0.0006285115,"teacher_disagreement_score":0.63141704,"about_ca_system_score_codex":0.00005808007,"about_ca_system_score_gemma":0.00015526818,"threshold_uncertainty_score":0.47128814},"labels":[],"label_agreement":null},{"id":"W2891380948","doi":"10.1200/jco.2018.36.15_suppl.e17010","title":"Impact of intervening in high-risk nonmetastatic castration-resistant prostate cancer (HRnmCRPC) on metastatic castration-resistant prostate cancer (mCRPC) disease burden.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Cancer; Oncology; Internal medicine; Enzalutamide; Androgen deprivation therapy; Placebo; Gynecology; Androgen receptor; Confidence interval; Pathology","score_opus":0.12220646471505014,"score_gpt":0.507304079551666,"score_spread":0.38509761483661586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891380948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913881,0.002125785,0.000022847806,0.0039261747,0.000779753,0.0011238018,0.00047196372,0.000011791724,0.000149824],"genre_scores_gemma":[0.9934175,0.0034208698,0.0013094851,0.00016625425,0.0008203536,0.00010547499,0.000029175764,0.000053289503,0.00067758217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99297154,0.0010498308,0.00379849,0.0004921889,0.0010012352,0.0006867336],"domain_scores_gemma":[0.99255157,0.0016157003,0.003187694,0.00038312536,0.0013745383,0.0008873595],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033150106,0.00040292752,0.0021127625,0.0005327622,0.00012049453,0.000043376014,0.00026256984,0.00017417011,0.0006677958],"category_scores_gemma":[0.002462921,0.0002593273,0.0007926226,0.0005972583,0.000743537,0.00031936137,0.000065559245,0.0013068648,0.000016929458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2022252,0.007216766,0.5750814,0.00091229327,0.005722756,0.006409553,0.003916812,0.0051852977,0.01045732,0.00014719658,0.002923622,0.17980176],"study_design_scores_gemma":[0.02340048,0.044241454,0.9245214,0.0019332964,0.0016002965,0.000042734267,0.0005751694,0.00096778094,0.0007814077,0.0007386551,0.0008919339,0.0003054067],"about_ca_topic_score_codex":0.005140656,"about_ca_topic_score_gemma":0.0040832204,"teacher_disagreement_score":0.34943998,"about_ca_system_score_codex":0.0012727267,"about_ca_system_score_gemma":0.008905499,"threshold_uncertainty_score":0.9999859},"labels":[],"label_agreement":null},{"id":"W2891576771","doi":"10.1016/s1470-2045(18)30456-x","title":"Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Placebo; Clinical endpoint; Internal medicine; Prostate-specific antigen; Oncology; Randomized controlled trial; Urology; Cancer; Pathology","score_opus":0.046862068757382316,"score_gpt":0.4188538237009971,"score_spread":0.3719917549436148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891576771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99195045,0.00015621407,0.000002522987,0.001256332,0.00010424171,0.0061446526,0.00019864729,0.000006230302,0.00018069976],"genre_scores_gemma":[0.9992719,0.00006521642,0.000019405481,0.0001049973,0.00005773617,0.0003541944,0.0000628098,0.0000113243395,0.00005239073],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954666,0.002552219,0.0010133593,0.00022309611,0.00043879126,0.00030595742],"domain_scores_gemma":[0.9968157,0.0013362191,0.0010415941,0.00049448205,0.000219315,0.000092730465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039550895,0.00016351746,0.0022835354,0.00019355978,0.00007058162,0.0000037212094,0.00017218867,0.000058096743,0.000059656788],"category_scores_gemma":[0.00047180397,0.00007069937,0.00017890181,0.0007484143,0.00051425054,0.000032325825,0.000021199177,0.00020991956,7.2554076e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9179854,0.0012718799,0.073700055,0.00021851783,0.0019740576,0.0000023000273,0.0015924975,0.00034250622,0.00070168177,0.000021305168,0.00004034736,0.002149492],"study_design_scores_gemma":[0.8492323,0.03766044,0.10895023,0.0001391979,0.0013060858,2.2462022e-7,0.00011837169,0.0008743818,0.0016285151,0.00001630994,0.000009834429,0.00006410818],"about_ca_topic_score_codex":0.003625235,"about_ca_topic_score_gemma":0.00841355,"teacher_disagreement_score":0.068753056,"about_ca_system_score_codex":0.00024840055,"about_ca_system_score_gemma":0.000909419,"threshold_uncertainty_score":0.54802954},"labels":[],"label_agreement":null},{"id":"W2891591185","doi":"10.1200/jco.2017.35.15_suppl.tps5097","title":"A randomized study of enzalutamide in patients with localized prostate cancer undergoing active surveillance (ENACT).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Population; Internal medicine; Oncology; Randomized controlled trial; Prostate; Cancer; Clinical endpoint; Urology; Androgen receptor","score_opus":0.0972456130784421,"score_gpt":0.49013676786294486,"score_spread":0.39289115478450276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891591185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957513,0.00026197234,0.000006317576,0.0015966765,0.00035612893,0.0013455724,0.000005773329,0.0000030221622,0.0006732229],"genre_scores_gemma":[0.9979842,0.001337307,0.0001792647,0.00010193338,0.00013977522,0.00002928209,0.000001667012,0.000015513624,0.00021108128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962242,0.0010013686,0.0017766898,0.0001968995,0.0005491181,0.00025168742],"domain_scores_gemma":[0.9927334,0.0029778455,0.00298777,0.00028080962,0.00080886885,0.0002112735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038080662,0.00014021576,0.002621489,0.00014410702,0.00006764498,0.000012982074,0.0002042479,0.00014952058,0.000041322903],"category_scores_gemma":[0.005313318,0.00007501323,0.00023415443,0.00008874625,0.0004948506,0.00016492096,0.00007303046,0.0007386931,0.000001207584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41808033,0.0031637955,0.55392164,0.000027769041,0.00069802144,0.00018494888,0.00040408847,0.000019180266,0.0000027419978,0.0000021693602,0.00003340185,0.023461873],"study_design_scores_gemma":[0.44640753,0.011828343,0.54082984,0.0002029487,0.00015354334,0.0000029633418,0.00026084125,0.000023990797,0.000026467287,0.000056512366,0.00015958813,0.000047431826],"about_ca_topic_score_codex":0.0004475936,"about_ca_topic_score_gemma":0.0018921989,"teacher_disagreement_score":0.02832719,"about_ca_system_score_codex":0.00028241848,"about_ca_system_score_gemma":0.00248582,"threshold_uncertainty_score":0.6360922},"labels":[],"label_agreement":null},{"id":"W2891829898","doi":"10.1200/jco.2018.36.15_suppl.e17026","title":"A population-based analysis of the effectiveness of docetaxel for castration-sensitive prostate cancer (CSPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Internal medicine; Neutropenia; Febrile neutropenia; Population; Androgen deprivation therapy; Adverse effect; Oncology; Surgery; Cancer; Urology; Chemotherapy","score_opus":0.11679375847145256,"score_gpt":0.5280941466882085,"score_spread":0.41130038821675596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891829898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969518,0.0001483747,0.00025379643,0.0014720481,0.00040475852,0.0005260496,0.00005573118,0.000001491808,0.00018592797],"genre_scores_gemma":[0.9988059,0.00006741627,0.00058498146,0.0001484516,0.00026834826,0.000014093838,0.0000097593065,0.0000065778113,0.00009452043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773395,0.000611263,0.0011313917,0.00011246521,0.00028574778,0.00012517498],"domain_scores_gemma":[0.99243826,0.0040916833,0.0013329305,0.00013639318,0.0019054262,0.00009531348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031503756,0.000073194984,0.0011566607,0.00017160278,0.000039614708,0.0000025083084,0.000078912744,0.00013505912,0.00003369998],"category_scores_gemma":[0.0022237385,0.000038746482,0.00065380713,0.0004697669,0.00032201587,0.000040433057,0.000014510009,0.00021698777,3.278577e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028217522,0.00086449593,0.9511219,0.00015600683,0.003785781,0.0000134997135,0.00011537902,0.00045476772,0.0025234884,0.00010121858,0.000099962046,0.012545961],"study_design_scores_gemma":[0.0071941274,0.0064414614,0.97207904,0.00019350907,0.0029618803,0.0000041036574,0.00004050464,0.0012001484,0.009391045,0.00019820832,0.00026166212,0.0000343178],"about_ca_topic_score_codex":0.0002335876,"about_ca_topic_score_gemma":0.00039241815,"teacher_disagreement_score":0.021023395,"about_ca_system_score_codex":0.0001528933,"about_ca_system_score_gemma":0.0021006407,"threshold_uncertainty_score":0.37264466},"labels":[],"label_agreement":null},{"id":"W2891872117","doi":"10.1186/s12894-018-0387-7","title":"Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials","year":2018,"lang":"en","type":"article","venue":"BMC Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre","funders":"Astellas Pharma; Clovis Oncology; Genomic Health; Amgen; Pfizer; Augmenix; Sanofi","keywords":"Bicalutamide; Medicine; Enzalutamide; Prostate cancer; Oncology; Internal medicine; Prostate-specific antigen; Progression-free survival; Hazard ratio; Urology; Confidence interval; Cancer; Chemotherapy; Androgen receptor","score_opus":0.09198609631662609,"score_gpt":0.46810502331972853,"score_spread":0.37611892700310245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891872117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99709773,0.00013215291,0.000013340007,0.0010674376,0.000026951991,0.001464503,0.00008195617,0.00000416498,0.000111751535],"genre_scores_gemma":[0.9990601,0.000024163619,0.0004111402,0.00017173002,0.00002793024,0.0001794035,0.00006189658,0.000007671268,0.000055946508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977846,0.00081506645,0.00062581524,0.00028536288,0.00025879848,0.00023035401],"domain_scores_gemma":[0.99881476,0.0005719505,0.00019473632,0.00019792019,0.00014465397,0.00007596667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015606916,0.000114937575,0.0007103262,0.00028559545,0.000030812767,0.0000095900405,0.000065807806,0.000059078084,0.000087432396],"category_scores_gemma":[0.00040676998,0.000055828896,0.000062783416,0.0008092609,0.00026238913,0.000038473096,0.000026348687,0.00013350596,0.0000022401264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014410663,0.0004434015,0.9780112,0.000038894734,0.00020617618,0.00002104309,0.001986231,0.000015530499,0.00009332241,0.000009516366,0.000055998687,0.004708058],"study_design_scores_gemma":[0.007905573,0.003187961,0.9869439,0.000024076237,0.0010014366,9.930269e-7,0.0004556317,0.00018382483,0.00015809052,0.000025099256,0.00005778748,0.000055609242],"about_ca_topic_score_codex":0.00091958465,"about_ca_topic_score_gemma":0.008955731,"teacher_disagreement_score":0.0089327535,"about_ca_system_score_codex":0.00003613273,"about_ca_system_score_gemma":0.00024300696,"threshold_uncertainty_score":0.4997508},"labels":[],"label_agreement":null},{"id":"W2892139286","doi":"10.1158/1538-7445.prca2017-a072","title":"Abstract A072: Serum sex steroids as prognostic biomarkers in patients receiving androgen-deprivation therapy for recurrent prostate cancer post-radiotherapy: A post hoc analysis of the PR.7 trial","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Cancer Society; University of Toronto; Université Laval","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Androstenediol; Testosterone (patch); Internal medicine; Androgen; Dihydrotestosterone; Oncology; Estrone; Cancer; Dehydroepiandrosterone; Endocrinology; Urology; Estrogen; Hormone","score_opus":0.05896490622204424,"score_gpt":0.4162091243379175,"score_spread":0.35724421811587326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892139286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98192436,0.006252242,0.0000013689669,0.002448527,0.00034360643,0.008452821,0.00047608977,0.000022196476,0.000078804704],"genre_scores_gemma":[0.9907324,0.0058051716,0.000031509393,0.00014171869,0.00026383655,0.0023972103,0.00016029384,0.000059357888,0.00040853577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963627,0.00031314074,0.0005666945,0.0006589939,0.00128108,0.00081742124],"domain_scores_gemma":[0.99672776,0.00032118737,0.00021207,0.0005817209,0.001971035,0.00018623279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015559029,0.0002538458,0.00054659153,0.0009527698,0.0002755485,0.00007723465,0.00036023118,0.00015154517,0.00033651068],"category_scores_gemma":[0.00037049485,0.00016396478,0.00026710393,0.0028047103,0.00047569364,0.00016779308,0.00009215697,0.00040573417,0.0000033791853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17837237,0.0009091538,0.60495,0.00024847075,0.0029788963,0.0000038252065,0.0031828978,0.000009152557,0.013822849,0.000004504827,0.00073195394,0.19478594],"study_design_scores_gemma":[0.06164609,0.012217863,0.8991146,0.0007268401,0.00024861985,4.383219e-7,0.0004918453,0.00023131138,0.023352645,0.00004685521,0.0016671686,0.00025568515],"about_ca_topic_score_codex":0.0015067147,"about_ca_topic_score_gemma":0.0020218845,"teacher_disagreement_score":0.29416463,"about_ca_system_score_codex":0.0012030241,"about_ca_system_score_gemma":0.0017657197,"threshold_uncertainty_score":0.668629},"labels":[],"label_agreement":null},{"id":"W2892348984","doi":"10.1200/jco.2018.36.15_suppl.e17005","title":"The timing of docetaxel initiation in metastatic castrate sensitive prostate cancer and the rate of chemotherapy induced toxicity.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Discontinuation; Chemotherapy; Toxicity; Internal medicine; Oncology; Cancer; Neutropenia; Androgen deprivation therapy; Febrile neutropenia; Urology","score_opus":0.1890748277089229,"score_gpt":0.5159057343590882,"score_spread":0.32683090665016523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892348984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824584,0.000578498,0.000011080978,0.015831528,0.00019732528,0.00043485296,0.0000038381772,0.0000010057729,0.00048343567],"genre_scores_gemma":[0.99324334,0.005531026,0.00021454625,0.00068236294,0.00020086787,0.000007929672,4.898375e-7,0.000006742813,0.000112691116],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976461,0.0006905494,0.0012436867,0.00008779168,0.00018157107,0.00015028795],"domain_scores_gemma":[0.99481636,0.003061014,0.0012838247,0.00009021554,0.0006731105,0.00007544493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055315206,0.00007601669,0.00080558006,0.00007144531,0.000044045864,0.0000059436325,0.00006753758,0.00007936188,0.0000149344105],"category_scores_gemma":[0.0013299703,0.000033212327,0.00011960418,0.00016737056,0.0009064429,0.000067375855,0.000024034054,0.00045000005,5.4110944e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17557278,0.0021070458,0.07110741,0.00025741974,0.0035300392,0.0005456045,0.014880186,0.000024939342,0.042399775,0.00093345915,0.00073708675,0.68790424],"study_design_scores_gemma":[0.10188577,0.02864729,0.7327208,0.00088050787,0.0009402201,0.00027398992,0.0043760915,0.0024785707,0.12017777,0.005204229,0.0022378021,0.00017697697],"about_ca_topic_score_codex":0.00010833708,"about_ca_topic_score_gemma":0.00024337815,"teacher_disagreement_score":0.6877273,"about_ca_system_score_codex":0.00006621781,"about_ca_system_score_gemma":0.0012435735,"threshold_uncertainty_score":0.33398265},"labels":[],"label_agreement":null},{"id":"W2892459590","doi":"10.5489/cuaj.5142","title":"18F-fluorocholine positron emission tomography-computed tomography (18F-FCH PET/CT) for staging of high-risk prostate cancer patients","year":2018,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Positron emission tomography; Prostate cancer; Positron Emission Tomography-Computed Tomography; Computed tomography; Medicine; Nuclear medicine; PET-CT; Positron emission; Radiology; Cancer; Internal medicine","score_opus":0.009439414224652653,"score_gpt":0.2652208463495141,"score_spread":0.25578143212486143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892459590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926401,0.000590509,0.00007292342,0.0046994993,0.00048498838,0.00076731003,0.00055439654,0.000031838626,0.00015847647],"genre_scores_gemma":[0.9971444,0.00030520585,0.00063453143,0.00067966,0.00052890554,0.000046366564,0.00020354302,0.00002542703,0.000431957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997577,0.00017072356,0.00056179677,0.0003285645,0.0005685209,0.0007933914],"domain_scores_gemma":[0.9966948,0.00016443279,0.00057252735,0.00013999363,0.0015472785,0.0008809661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069439475,0.0002188571,0.00042700162,0.0005105043,0.0005374468,0.00007279782,0.00016153125,0.00005250975,0.00020467592],"category_scores_gemma":[0.00041356997,0.00016208699,0.0002622819,0.0006181749,0.000105425526,0.00013475922,0.00002602113,0.0005295164,0.0000044811377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061142887,0.00017958992,0.9826583,0.000025885032,0.00034485708,0.000059833463,0.00012301929,0.000009961235,0.0003536787,0.000012337894,0.008367543,0.0072535467],"study_design_scores_gemma":[0.0060625244,0.0025615373,0.97540134,0.00011214944,0.00025929592,0.000043663993,0.000049025337,0.00038507002,0.0026040683,0.0007749653,0.011525999,0.00022034795],"about_ca_topic_score_codex":0.0035319398,"about_ca_topic_score_gemma":0.0005824023,"teacher_disagreement_score":0.007256965,"about_ca_system_score_codex":0.0009535655,"about_ca_system_score_gemma":0.00066157,"threshold_uncertainty_score":0.6609716},"labels":[],"label_agreement":null},{"id":"W2893677139","doi":"10.1038/s41467-018-06177-2","title":"Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers","year":2018,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; American Cancer Society","keywords":"Angiogenesis; EZH2; Prostate cancer; Cancer research; Neuroendocrine differentiation; CREB; Biology; Enzalutamide; Medicine; Epigenetics; Cancer; Internal medicine; Androgen receptor; Transcription factor; Genetics","score_opus":0.03335424175532839,"score_gpt":0.3398669770452197,"score_spread":0.3065127352898913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893677139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97287077,0.011927511,0.000023497709,0.012051459,0.00007804713,0.0011125092,0.000048603033,0.0000761206,0.00181147],"genre_scores_gemma":[0.9926243,0.004638389,0.001536667,0.0002948438,0.000058444104,0.00016716939,0.00041802658,0.00002219677,0.00023998757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990257,0.00009997948,0.00020687754,0.00024630837,0.00018771636,0.00023340565],"domain_scores_gemma":[0.9987477,0.00008584035,0.000072878436,0.00079954485,0.00022397166,0.0000700752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008989397,0.000134673,0.00017673516,0.00014923915,0.00023297491,0.00003272328,0.00020248456,0.00007323218,0.000027383227],"category_scores_gemma":[0.00012113759,0.00011021128,0.000039535447,0.00053661224,0.00022662684,0.00017607113,0.0001870683,0.0003745472,0.0000064799333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000667476,0.00071891776,0.8966977,0.0001743647,0.0002622956,0.000038770664,0.0043800245,0.0000020916345,0.035050597,0.0033812406,0.0015680748,0.057058427],"study_design_scores_gemma":[0.004054762,0.00061277585,0.8631023,0.0001867467,0.000103576705,0.00008362806,0.00025055849,0.0015082258,0.0904636,0.0009967451,0.038349904,0.0002871529],"about_ca_topic_score_codex":0.00022708526,"about_ca_topic_score_gemma":0.0015275374,"teacher_disagreement_score":0.056771275,"about_ca_system_score_codex":0.00019165214,"about_ca_system_score_gemma":0.00016479944,"threshold_uncertainty_score":0.44942856},"labels":[],"label_agreement":null},{"id":"W2894741998","doi":"10.1158/1078-0432.ccr-18-0729","title":"Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Novo Nordisk Fonden; Kræftens Bekæmpelse","keywords":"Prostate cancer; Neuroendocrine differentiation; Rest (music); Prostate; Medicine; Cancer; Castration; Cancer research; Oncology; Biology; Internal medicine; Hormone","score_opus":0.08203419535733544,"score_gpt":0.4303867489776065,"score_spread":0.34835255362027107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894741998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99454486,0.000779123,0.00000104635,0.0020528026,0.00015588113,0.0022127787,0.00014536563,0.0000076127176,0.00010051025],"genre_scores_gemma":[0.9952074,0.0038346471,0.000016935968,0.000017658022,0.0002211389,0.00044929903,0.000068879264,0.000023149974,0.0001608571],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969834,0.0004952677,0.0010021576,0.00034541826,0.00078449585,0.00038923288],"domain_scores_gemma":[0.9977077,0.00023698801,0.00036037294,0.00041204604,0.0011686069,0.00011424496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006471344,0.00012885388,0.00044391895,0.00025457988,0.00008981849,0.00001242626,0.00019482123,0.00006204847,0.00018257079],"category_scores_gemma":[0.00022891114,0.00008164128,0.000100525634,0.0007288967,0.00094827317,0.000089749556,0.00011942983,0.0003754821,0.0000031531233],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063032415,0.0004936002,0.13449432,0.00023627668,0.000081089376,0.00000747523,0.0008108412,0.000002102737,0.84455776,0.000076456265,0.000023785884,0.012913023],"study_design_scores_gemma":[0.0016763164,0.0016360262,0.4605122,0.0003028262,0.000024672021,6.793496e-7,0.00012819191,0.00010020751,0.534788,0.00008560723,0.00069819175,0.00004710092],"about_ca_topic_score_codex":0.0020008753,"about_ca_topic_score_gemma":0.0011635982,"teacher_disagreement_score":0.32601786,"about_ca_system_score_codex":0.00014569325,"about_ca_system_score_gemma":0.0008471199,"threshold_uncertainty_score":0.3493952},"labels":[],"label_agreement":null},{"id":"W2895847496","doi":"10.5489/cuaj.5378","title":"Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces","year":2018,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Ottawa Hospital; University of Ottawa; McMaster University; Juravinski Cancer Centre; William Osler Health System; University of British Columbia; Princess Margaret Cancer Centre; University of Calgary; University of Toronto; Hôpital Charles-Le Moyne; SAIT Polytechnic; BC Cancer Agency","funders":"","keywords":"Cabazitaxel; Enzalutamide; Abiraterone acetate; Docetaxel; Medicine; Prostate cancer; Oncology; Prednisone; Internal medicine; Chemotherapy; Cancer; Family medicine; Androgen deprivation therapy; Androgen receptor","score_opus":0.06192193431347592,"score_gpt":0.34444990425569355,"score_spread":0.2825279699422176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895847496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96155876,0.0010199076,0.000010281735,0.03542592,0.00021159637,0.00067255646,0.00059737754,0.000007919503,0.0004956756],"genre_scores_gemma":[0.9980578,0.00018807198,0.00017033282,0.00062548066,0.00020841026,0.000084946005,0.000033306987,0.000012750377,0.0006189071],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979577,0.00012894842,0.00037714373,0.00020080176,0.00029647886,0.0010389097],"domain_scores_gemma":[0.9979829,0.00012771477,0.00022418615,0.00008370542,0.00063717226,0.00094427844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012464647,0.0001362544,0.0003307159,0.0002875347,0.00041698266,0.00013538908,0.00012805138,0.00012252251,0.00028330294],"category_scores_gemma":[0.00055355154,0.0000976363,0.00009507301,0.00038453346,0.00014968276,0.00016354177,0.000009615296,0.0003385036,0.000004186399],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029161054,0.000052410924,0.98990136,0.00003374098,0.00022916343,0.00007237794,0.0011583163,0.00000546955,0.00032401926,0.00023488904,0.0013025949,0.0063940287],"study_design_scores_gemma":[0.0026293737,0.00106708,0.95887333,0.000059453458,0.000058318004,0.00002602773,0.0011203343,0.0003061439,0.00021234903,0.0012618307,0.03422511,0.00016066233],"about_ca_topic_score_codex":0.2537368,"about_ca_topic_score_gemma":0.8988563,"teacher_disagreement_score":0.6451195,"about_ca_system_score_codex":0.0035510361,"about_ca_system_score_gemma":0.0048686243,"threshold_uncertainty_score":0.92858356},"labels":[],"label_agreement":null},{"id":"W2896060946","doi":"10.1530/erc-18-0226","title":"Neuroendocrine differentiation of prostate cancer leads to PSMA suppression","year":2018,"lang":"en","type":"article","venue":"Endocrine Related Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; University of Windsor","funders":"Academy of Medical Sciences; Korea Health Industry Development Institute; National Institute for Health and Care Research; Cancer Research UK; Government of Ontario","keywords":"Somatostatin receptor 2; Prostate cancer; Cancer research; Enzalutamide; Somatostatin receptor; Neuroendocrine differentiation; Biology; Neuroendocrine tumors; Cell biology; Cancer; Molecular biology; Medicine; Internal medicine; Endocrinology; Somatostatin; Androgen receptor","score_opus":0.019242059246432963,"score_gpt":0.34537987315157886,"score_spread":0.3261378139051459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896060946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849,0.0029429048,0.000009397742,0.0080438135,0.0008601582,0.0010403983,0.000088883695,0.00011041996,0.0020040413],"genre_scores_gemma":[0.9699094,0.003821953,0.00008069511,0.0002238985,0.0003341349,0.00033460796,0.00007232525,0.000058083235,0.025164854],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99798614,0.000056035242,0.00042745477,0.00045593097,0.000490086,0.0005843696],"domain_scores_gemma":[0.9987701,0.000032256183,0.00013231256,0.00038745406,0.00039702616,0.00028085642],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000051707797,0.00024835503,0.00041771337,0.00027567797,0.000105596235,0.000015254794,0.00012842122,0.00003922419,0.0027973026],"category_scores_gemma":[0.000053620875,0.00018305899,0.00011269197,0.0006840044,0.0001487107,0.00011721689,0.000119047,0.00029016053,0.0000870369],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004478259,0.0004977811,0.43411744,0.00048526088,0.0005187358,0.00029760247,0.0010461698,0.00011961371,0.45805407,0.00015200401,0.032859523,0.067373574],"study_design_scores_gemma":[0.0059031793,0.001342979,0.11041382,0.0007204599,0.00025316246,0.00007153172,0.000035201807,0.00037807558,0.84573686,0.000071867704,0.03482043,0.00025245693],"about_ca_topic_score_codex":0.00072786765,"about_ca_topic_score_gemma":0.000112484006,"teacher_disagreement_score":0.38768277,"about_ca_system_score_codex":0.00025216735,"about_ca_system_score_gemma":0.00023578126,"threshold_uncertainty_score":0.9981143},"labels":[],"label_agreement":null},{"id":"W2896250667","doi":"10.1158/1078-0432.ccr-18-0320","title":"Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; Université de Montréal; Sanofi (Canada)","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health","keywords":"Prostate cancer; Taxane; Medicine; Androgen receptor; Circulating tumor cell; Oncology; Cancer; Internal medicine; Prostate; Cabazitaxel; Androgen deprivation therapy; Metastatic breast cancer; Cancer research; Metastasis; Breast cancer","score_opus":0.1444049626610932,"score_gpt":0.4881122768051551,"score_spread":0.3437073141440619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896250667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99390197,0.0019127644,0.0000019502202,0.001543248,0.00002964351,0.0021707902,0.00003458361,0.000013847256,0.00039119364],"genre_scores_gemma":[0.9944171,0.002992283,0.0002490621,0.000111764784,0.000045506767,0.0009876034,0.000010793596,0.00004730514,0.0011385821],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964635,0.00052358006,0.0007406963,0.0006931537,0.0008023867,0.0007767078],"domain_scores_gemma":[0.9979135,0.00089380954,0.0001396027,0.00034634388,0.0004074861,0.00029926433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018454161,0.00024205318,0.00088268105,0.0006360591,0.000064623535,0.000029922121,0.00016336076,0.00008594396,0.00022645072],"category_scores_gemma":[0.00023585155,0.00013820978,0.000042614363,0.0015284503,0.00079300307,0.00012267425,0.00011229993,0.00076987373,0.0000053029244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013898567,0.00056051865,0.95397145,0.0001691763,0.000083369436,0.00039763728,0.0018134811,0.00009712459,0.014216876,0.000004036388,0.00012905744,0.014658681],"study_design_scores_gemma":[0.021496117,0.0065428154,0.8922902,0.0034897611,0.00002484309,0.0000064156634,0.0017207229,0.0006708511,0.073214754,0.0000732802,0.00020274655,0.00026753746],"about_ca_topic_score_codex":0.013834913,"about_ca_topic_score_gemma":0.010850053,"teacher_disagreement_score":0.061681323,"about_ca_system_score_codex":0.0003397608,"about_ca_system_score_gemma":0.00073556905,"threshold_uncertainty_score":0.99273205},"labels":[],"label_agreement":null},{"id":"W2896329990","doi":"10.1093/annonc/mdy419","title":"Developing prognostic models for advanced prostate cancer when the goal line keeps changing","year":2018,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Oncology; Docetaxel; Internal medicine; Cancer; Chemotherapy; Androgen deprivation therapy","score_opus":0.18683034033751908,"score_gpt":0.44791591836440925,"score_spread":0.26108557802689014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896329990","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005990101,0.007236144,0.0008990861,0.9798727,0.000640895,0.004052148,0.00027887794,0.0000489387,0.0009811192],"genre_scores_gemma":[0.008276531,0.0141494125,0.008460437,0.9112416,0.0111899115,0.0068951654,0.0018447059,0.00025860302,0.03768367],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975874,0.000100408695,0.00047688873,0.00048225568,0.00035839755,0.0009946399],"domain_scores_gemma":[0.9975177,0.0005173371,0.00036720914,0.000357051,0.0011649573,0.00007576264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053587224,0.00032864514,0.0008422885,0.00028953658,0.00017750471,0.00001582817,0.00028350294,0.000556584,0.000058845555],"category_scores_gemma":[0.00016550429,0.00020431464,0.00021528486,0.00022170595,0.00036563879,0.00009118421,0.00014912186,0.0007581042,0.000009919914],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018410258,0.0001081613,0.00014463584,0.0018454159,0.0009544424,0.00022581333,0.0026318692,0.000046279467,0.00016137588,0.000114691014,0.8926061,0.09932023],"study_design_scores_gemma":[0.0026804106,0.0037282973,0.000032571883,0.001085687,0.000249799,0.000029699242,0.00012139899,0.00065971195,0.0028129572,0.0059416327,0.98240936,0.00024848751],"about_ca_topic_score_codex":0.000053002517,"about_ca_topic_score_gemma":0.00003356898,"teacher_disagreement_score":0.09907175,"about_ca_system_score_codex":0.00023578633,"about_ca_system_score_gemma":0.0019246878,"threshold_uncertainty_score":0.8331709},"labels":[],"label_agreement":null},{"id":"W2896331467","doi":"10.1097/rlu.0000000000002301","title":"18F-DCFPyL PET/CT in Oncocytoma","year":2018,"lang":"en","type":"article","venue":"Clinical Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; London Health Sciences Centre; McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Lymph node; Pathology; Biopsy; PET-CT; Avidity; Oncocytoma; Antigen; Cancer; Radiology; Positron emission tomography; Internal medicine; Immunohistochemistry","score_opus":0.11534736409735795,"score_gpt":0.4773653821992178,"score_spread":0.36201801810185985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896331467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91586834,0.00048877194,0.0000017294767,0.027092986,0.0007444057,0.00041778522,0.0000023623927,0.00010617937,0.055277463],"genre_scores_gemma":[0.9864078,0.0009931515,0.00028198294,0.0057926695,0.0022850952,0.0000071658737,0.000018287908,0.00004609554,0.0041677365],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978719,0.00011959837,0.00068397523,0.0004485487,0.00043310004,0.0004429112],"domain_scores_gemma":[0.9984942,0.00033650734,0.00007848628,0.0004903301,0.0001481871,0.0004522663],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010930791,0.00017133012,0.0006430839,0.00016385301,0.00007633382,0.000007461958,0.0001701466,0.000027054984,0.004171637],"category_scores_gemma":[0.0011229364,0.00011112596,0.000118418386,0.0004027739,0.0014408034,0.00005593085,0.00009543147,0.000581896,0.0016661703],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008336183,0.0024951186,0.38590854,0.00028472306,0.00039027593,0.03328305,0.0008355332,1.63697e-7,0.001618273,0.0013575678,0.44350022,0.12199034],"study_design_scores_gemma":[0.020824283,0.011392001,0.3577434,0.001056475,0.00014736813,0.0012449572,0.00069843,0.0005790328,0.00013163744,0.0005731268,0.6053586,0.000250676],"about_ca_topic_score_codex":0.00011621311,"about_ca_topic_score_gemma":0.000044401753,"teacher_disagreement_score":0.16185836,"about_ca_system_score_codex":0.00012659191,"about_ca_system_score_gemma":0.00014392647,"threshold_uncertainty_score":0.9991112},"labels":[],"label_agreement":null},{"id":"W2896413833","doi":"10.1016/j.ijrobp.2018.06.064","title":"Results of a Phase III Trial of Optimal Sequencing of Dose Escalated Radiation (XRT) and 6 Months Androgen Deprivation Therapy (ADT) in Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northeast Cancer Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Bicalutamide; Radiation therapy; Urology; Oncology; Internal medicine; Cancer","score_opus":0.03957787268384484,"score_gpt":0.39377161885572276,"score_spread":0.35419374617187793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896413833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99661523,0.000990273,0.00027218176,0.0007962478,0.0004529388,0.00064490247,0.00012875399,0.0000065810245,0.00009288463],"genre_scores_gemma":[0.99229974,0.0062299366,0.0006683527,0.00005217159,0.0005845202,0.000018327808,0.00011518962,0.000013512979,0.00001823686],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980911,0.00018295665,0.0010907692,0.00017789604,0.00030020135,0.00015707569],"domain_scores_gemma":[0.9968772,0.00023670268,0.001557103,0.0001072252,0.0011508861,0.00007091076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007885116,0.0001336397,0.0005298626,0.00031971833,0.000027261307,0.000006492348,0.0001392102,0.00015127928,0.000015957943],"category_scores_gemma":[0.00025005627,0.000106992724,0.00010731418,0.000273625,0.0003159302,0.00023572177,0.000029866593,0.00021631432,4.5294308e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19306815,0.0014564267,0.09852669,0.000028019418,0.0010380354,0.000024824152,0.005136865,0.0006144697,0.15482654,0.0003378386,0.00011882468,0.5448233],"study_design_scores_gemma":[0.5370275,0.019345013,0.03785017,0.0003792893,0.00020335443,0.00005933516,0.000377445,0.018151231,0.38298982,0.0019142209,0.001476137,0.000226475],"about_ca_topic_score_codex":0.00023018362,"about_ca_topic_score_gemma":0.00001567098,"teacher_disagreement_score":0.54459685,"about_ca_system_score_codex":0.0005595025,"about_ca_system_score_gemma":0.00106974,"threshold_uncertainty_score":0.43630368},"labels":[],"label_agreement":null},{"id":"W2896428729","doi":"10.1016/j.ijrobp.2018.07.016","title":"A Prospective Study of F-18 Fluoro-methyl-choline (FCH) And Ga-68 HBED-CC- (PSMA) in Men being Considered for Salvage Radiation Treatment for Biochemical Failure Post Radical Prostatectomy","year":2018,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Princess Margaret Cancer Centre; University Health Network; Western University","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Urology; Androgen deprivation therapy; Prospective cohort study; Nuclear medicine; Biochemical recurrence; Salvage therapy; Cancer; Radiology; Internal medicine; Chemotherapy","score_opus":0.02958943149664471,"score_gpt":0.3874140393332041,"score_spread":0.3578246078365594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896428729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99161166,0.00054341747,0.0014672414,0.0029038745,0.00036589426,0.0027871127,0.00020361609,0.000019273979,0.000097939555],"genre_scores_gemma":[0.99401206,0.0003071451,0.0036102806,0.00014559299,0.0013540807,0.00023668213,0.00025310868,0.000032898606,0.000048127644],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980996,0.00017344816,0.0008164448,0.00035128137,0.0002655557,0.00029362965],"domain_scores_gemma":[0.9968903,0.0007609041,0.00070468866,0.0001278583,0.0013699008,0.0001463547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005949614,0.00023590356,0.00067909603,0.00032496965,0.000089566114,0.000024726083,0.00015243425,0.0002249664,0.000021136175],"category_scores_gemma":[0.00064680644,0.00018427706,0.00016664337,0.00018343706,0.00035029312,0.0001967334,0.00004403136,0.00025795275,0.0000017904854],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030493846,0.015967356,0.5217902,0.00012388697,0.0047196895,0.00010664696,0.011737725,0.000039869134,0.19403853,0.00267191,0.002921209,0.21538912],"study_design_scores_gemma":[0.3568748,0.087184995,0.15168244,0.00042600525,0.0013453594,0.00043018343,0.004613441,0.007042182,0.3542302,0.022933934,0.012448957,0.00078749977],"about_ca_topic_score_codex":0.000043102227,"about_ca_topic_score_gemma":0.000018383516,"teacher_disagreement_score":0.37010777,"about_ca_system_score_codex":0.0011021225,"about_ca_system_score_gemma":0.00070582004,"threshold_uncertainty_score":0.7514601},"labels":[],"label_agreement":null},{"id":"W2896555895","doi":"10.1016/j.ijrobp.2018.07.263","title":"PSA Bounce after Stereotactic Body Radiation Therapy for Prostate Cancer: Pooled Analysis from 4 SBRT Trials Evaluating Different Time-Dose-Fraction Schedules","year":2018,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; BC Cancer Agency; Health Sciences Centre; CancerCare Manitoba; University of Toronto; Sunnybrook Health Science Centre; University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Nadir; Urology; Cumulative incidence; Nuclear medicine; Incidence (geometry); Radiation therapy; Radiosurgery; Prostate; Statistical significance; Logistic regression; Prostate-specific antigen; Internal medicine; Cancer; Cohort","score_opus":0.054843843138234455,"score_gpt":0.4326685950586763,"score_spread":0.37782475192044185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896555895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837253,0.003118688,0.005076434,0.0042956695,0.0021882467,0.0010728656,0.00040759344,0.00003643383,0.000078759214],"genre_scores_gemma":[0.9871976,0.003911744,0.0010903296,0.000546614,0.0058107087,0.0002416131,0.0007667348,0.000038048587,0.0003966522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99691176,0.00069041643,0.0011536656,0.0003795464,0.00054681045,0.00031781395],"domain_scores_gemma":[0.99455035,0.0012228949,0.0019001745,0.00020097187,0.00196519,0.00016040323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001595624,0.00027948924,0.0010163515,0.00040539133,0.00013164736,0.00009197492,0.00024329021,0.0002358127,0.00055595767],"category_scores_gemma":[0.00079316716,0.00020386228,0.00057198526,0.00031761994,0.00018619737,0.0004210344,0.000036132213,0.0003606988,0.000033596967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017407745,0.00078530743,0.5021992,0.000011805449,0.013720548,0.00000977137,0.0007645126,0.00011233262,0.04284952,0.00011435024,0.0006692895,0.42135563],"study_design_scores_gemma":[0.06338949,0.013796146,0.7375985,0.00029917492,0.009751088,0.00003408345,0.00015342457,0.07717749,0.04758971,0.01912347,0.03032143,0.00076600583],"about_ca_topic_score_codex":0.000086422755,"about_ca_topic_score_gemma":0.000017551305,"teacher_disagreement_score":0.42058963,"about_ca_system_score_codex":0.0025132338,"about_ca_system_score_gemma":0.0011495254,"threshold_uncertainty_score":0.8313262},"labels":[],"label_agreement":null},{"id":"W2896613406","doi":"10.1016/j.adro.2019.09.004","title":"Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts","year":2019,"lang":"en","type":"article","venue":"Advances in Radiation Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Cancer Care Ontario","funders":"","keywords":"Medicine; Radiology; Nuclear medicine; Lesion; Medical physics; Pathology","score_opus":0.029605849347789332,"score_gpt":0.42025237833620865,"score_spread":0.39064652898841934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896613406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848879,0.00988492,0.00009813622,0.000498832,0.00040644244,0.0015417148,0.000007555365,0.000016082917,0.0026583956],"genre_scores_gemma":[0.9928807,0.0060503175,0.00044793007,0.00011545229,0.000051892253,0.00007155607,0.000113780894,0.000012275566,0.00025609796],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.998408,0.00020285301,0.00044212976,0.0002512312,0.00046314465,0.00023261135],"domain_scores_gemma":[0.9983996,0.00077106955,0.00020547521,0.0001949086,0.00036464146,0.00006429104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007628628,0.000115570874,0.0003592519,0.00047823982,0.000025564072,0.000004176084,0.000066872555,0.00009905864,0.00033359634],"category_scores_gemma":[0.0008669789,0.000092562186,0.000043542663,0.00071616913,0.000062159714,0.00018425811,0.000021229953,0.00018236607,0.000048246817],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021369585,0.00053550454,0.09246628,0.00022781896,0.000046495123,0.0000885882,0.0005935118,0.015150737,0.010864025,0.00012283052,0.00008549194,0.87768173],"study_design_scores_gemma":[0.0695236,0.014680073,0.09668899,0.0006027106,0.0005687217,0.0002574063,0.0014627982,0.6722202,0.102085024,0.002399677,0.038826246,0.0006846083],"about_ca_topic_score_codex":0.000041510953,"about_ca_topic_score_gemma":0.00005289512,"teacher_disagreement_score":0.8769972,"about_ca_system_score_codex":0.00068633124,"about_ca_system_score_gemma":0.00050836627,"threshold_uncertainty_score":0.37745765},"labels":[],"label_agreement":null},{"id":"W2897092653","doi":"10.3390/cancers10100379","title":"Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"National Institute of General Medical Sciences; Fonds de Recherche du Québec - Santé; National Center for Advancing Translational Sciences; Movember Foundation","keywords":"Prostate cancer; Androgen deprivation therapy; Transcription factor; Medicine; Identification (biology); Oncology; Internal medicine; Cancer research; Androgen; Cancer; Bioinformatics; Biology; Hormone; Gene; Genetics","score_opus":0.06750464039716028,"score_gpt":0.3555156017180793,"score_spread":0.28801096132091897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897092653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99650776,0.0012694245,0.000019303656,0.00096873497,0.000051209703,0.0011180473,0.00003662253,0.000014025404,0.000014886176],"genre_scores_gemma":[0.9987835,0.0006081792,0.000025489719,0.000029145654,0.000012914868,0.00019237146,0.000016697568,0.0000123922,0.0003192869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906576,0.000207035,0.00019248566,0.00016645166,0.00023825538,0.00013004],"domain_scores_gemma":[0.9994471,0.000061747225,0.00013630588,0.00013735941,0.0001782439,0.0000392268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039584658,0.00008058899,0.00012510254,0.00009608284,0.00010824939,0.000012427686,0.00003966985,0.00003327605,0.000016871372],"category_scores_gemma":[0.00010846664,0.000045984736,0.000021158228,0.00045948423,0.00022832256,0.00011597236,0.000005963701,0.000117999385,4.875253e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0084490925,0.00005590527,0.71969694,0.00005308674,0.00012776493,0.0000029441555,0.007803709,0.000036006462,0.25086978,0.000013382979,0.000039623872,0.012851739],"study_design_scores_gemma":[0.002926934,0.0003517875,0.8463618,0.00035318625,0.00003661599,0.0000018786669,0.00032701896,0.0005496812,0.1488782,0.00006087904,0.00009702384,0.00005495019],"about_ca_topic_score_codex":0.00010436689,"about_ca_topic_score_gemma":0.00038304922,"teacher_disagreement_score":0.12666488,"about_ca_system_score_codex":0.00069175597,"about_ca_system_score_gemma":0.00057259825,"threshold_uncertainty_score":0.18752031},"labels":[],"label_agreement":null},{"id":"W2897430047","doi":"10.1016/j.ijrobp.2018.06.252","title":"Development and Validation of Genomic Tools to Predict Extraprostatic Extension of Prostate Cancer, Opportunities for Personalizing Treatment","year":2018,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Nomogram; Prostate cancer; Prostatectomy; Logistic regression; Oncology; Biopsy; Internal medicine; Cohort; Cancer","score_opus":0.12106050461737296,"score_gpt":0.3939899931522071,"score_spread":0.2729294885348342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897430047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941515,0.0008966248,0.0018668346,0.0017219391,0.0004883013,0.0006287522,0.00016203229,0.000007875972,0.00007615091],"genre_scores_gemma":[0.98624665,0.0020872015,0.010532556,0.00015504884,0.00058506517,0.00006746224,0.00014032779,0.0000179576,0.00016775186],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988021,0.00006242364,0.000609603,0.00016092409,0.00020850738,0.00015640612],"domain_scores_gemma":[0.9976885,0.00020556542,0.00065757474,0.000075002834,0.0012643919,0.00010900584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003860424,0.00013199584,0.00038873224,0.00019434607,0.00005943651,0.000012285825,0.00009682958,0.00007753753,0.00001989121],"category_scores_gemma":[0.000100371486,0.00010165506,0.00009084265,0.00006839246,0.00018784522,0.00015113414,0.000030352805,0.00007149109,0.0000010995076],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038019852,0.00051576423,0.15785532,0.000090226014,0.001191208,0.000015023738,0.00804074,0.000083818624,0.11575068,0.0009835208,0.00037012546,0.71130157],"study_design_scores_gemma":[0.026726939,0.021193208,0.12744015,0.0008931125,0.0007200871,0.00017529013,0.0036601594,0.001978389,0.7307308,0.0026531122,0.08340928,0.0004195309],"about_ca_topic_score_codex":0.000020740928,"about_ca_topic_score_gemma":0.000005744076,"teacher_disagreement_score":0.71088207,"about_ca_system_score_codex":0.0007056541,"about_ca_system_score_gemma":0.00119518,"threshold_uncertainty_score":0.4145373},"labels":[],"label_agreement":null},{"id":"W2897479155","doi":"10.1016/j.ijrobp.2018.06.062","title":"Long-Term Update of NRG Oncology RTOG 94-08","year":2018,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; University of Alberta","funders":"","keywords":"Medicine; Prostate cancer; Clinical endpoint; Androgen deprivation therapy; Incidence (geometry); Proportional hazards model; Internal medicine; Log-rank test; Hazard ratio; Oncology; Urology; Radiation therapy; Prostate-specific antigen; Cancer; Clinical trial; Confidence interval","score_opus":0.03428123626591631,"score_gpt":0.3965199473721535,"score_spread":0.3622387111062372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897479155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97794104,0.0012433092,0.0044998014,0.008372397,0.0036887429,0.00032965897,0.0000813037,0.000032073778,0.0038116993],"genre_scores_gemma":[0.99016607,0.0022527042,0.0017342917,0.0010327192,0.0043291883,0.000010070849,0.00015143151,0.000027762826,0.0002957351],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801254,0.00022750559,0.0008390887,0.00023528977,0.00037903083,0.00030654328],"domain_scores_gemma":[0.9963884,0.0002899444,0.001089448,0.0001913141,0.0018511255,0.00018979942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006294194,0.00019393755,0.000621802,0.00027591301,0.00007135919,0.000014626553,0.00042826423,0.0003034584,0.0004622104],"category_scores_gemma":[0.00022967723,0.00015262194,0.00026309327,0.0002105692,0.000668177,0.00022865036,0.0001026531,0.0004896614,0.00014341227],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033182385,0.0012623888,0.6080593,0.000025694759,0.0017220186,0.0002429925,0.0006493811,0.000019750121,0.01957885,0.004980436,0.0045787184,0.35556227],"study_design_scores_gemma":[0.055636078,0.0281341,0.5049744,0.00047929265,0.0010607574,0.002351008,0.00026126133,0.0011779151,0.1422261,0.022709096,0.24022481,0.0007651735],"about_ca_topic_score_codex":0.00001345375,"about_ca_topic_score_gemma":0.000009390598,"teacher_disagreement_score":0.3547971,"about_ca_system_score_codex":0.0010773545,"about_ca_system_score_gemma":0.0014263692,"threshold_uncertainty_score":0.62237424},"labels":[],"label_agreement":null},{"id":"W2897636829","doi":"10.1016/j.eururo.2018.09.048","title":"Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency","year":2018,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Academy of Medical Sciences; Medical Research Council; National Institute for Health and Care Research; Cancer Research UK","keywords":"Carboplatin; Medicine; Prostate cancer; Poly ADP ribose polymerase; DNA repair; Prostate; Cancer; Oncology; Internal medicine; Cancer research; PARP inhibitor; Homologous recombination; Chemotherapy; DNA; Polymerase; Cisplatin; Genetics; Biology","score_opus":0.0261167313762709,"score_gpt":0.29900115618391065,"score_spread":0.27288442480763975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897636829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981022,0.00028043985,0.000057459925,0.00018201082,0.00003281997,0.00040466676,0.0001177181,0.000021975206,0.000800704],"genre_scores_gemma":[0.999106,0.000020141286,0.00041860246,0.00010314568,0.000029970148,0.00001835614,0.000062135405,0.000021687794,0.00021997723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998703,0.00021390022,0.0003158879,0.00027985958,0.00025919426,0.00022816502],"domain_scores_gemma":[0.99911076,0.00010698902,0.00018647245,0.00025385956,0.00025204025,0.00008987975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002469537,0.00012133831,0.0003583742,0.00045386108,0.00005177732,0.000003110933,0.00009818412,0.000016181515,0.00024042386],"category_scores_gemma":[0.000107672306,0.00007815646,0.00007935596,0.0005548364,0.0002777442,0.000018441526,0.00008572447,0.0000822223,0.000015657037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029428427,0.00023690348,0.9851228,0.000039878436,0.0009896349,0.000012472398,0.0012948432,0.000067899644,0.0076149222,0.000019325142,0.000035823534,0.0016226256],"study_design_scores_gemma":[0.0011766655,0.0030420737,0.9934914,0.000019957455,0.0010771841,0.0000011418291,0.000027715278,0.00018610568,0.00083115796,0.0000071119416,0.0000707113,0.00006879157],"about_ca_topic_score_codex":0.000060879243,"about_ca_topic_score_gemma":0.00014178143,"teacher_disagreement_score":0.0083685545,"about_ca_system_score_codex":0.00005174278,"about_ca_system_score_gemma":0.00010933388,"threshold_uncertainty_score":0.3187128},"labels":[],"label_agreement":null},{"id":"W2897661196","doi":"10.5489/cuaj.5399","title":"The effect of race on survival after local therapy in metastatic prostate cancer patients","year":2018,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal; McGill University Health Centre","funders":"","keywords":"Prostate cancer; Medicine; Oncology; Race (biology); Internal medicine; Overall survival; Cancer; Biology","score_opus":0.012593958330901255,"score_gpt":0.29048924830875894,"score_spread":0.2778952899778577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897661196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98984605,0.0005950814,0.0000021836547,0.008445811,0.00029311553,0.00041808296,0.00003071592,0.0000039082306,0.0003650685],"genre_scores_gemma":[0.99812853,0.000561642,0.000003325026,0.000558733,0.00014299621,0.000054698892,0.000006496203,0.000008831945,0.0005347268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983472,0.00042306338,0.00024219525,0.00012510414,0.00042578747,0.00043660295],"domain_scores_gemma":[0.99889237,0.0003358826,0.00013744704,0.000075560376,0.0002722445,0.0002865089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009816443,0.00010786732,0.00023553871,0.00011389369,0.0001626974,0.000033637247,0.0000804754,0.00007594326,0.00023070177],"category_scores_gemma":[0.00035522837,0.00005340561,0.00007889805,0.00022301107,0.00012258798,0.000041380157,0.000007897516,0.00039087806,0.000021667212],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024783018,0.000043185402,0.9582707,0.0000035684332,0.00011250606,0.000034349243,0.0001631362,0.0000068021686,0.000013142052,0.0000054003644,0.00081932143,0.038049586],"study_design_scores_gemma":[0.0044229557,0.0053949854,0.9807561,0.000026933514,0.00002562029,0.0000026756718,0.000022451624,0.00005909714,0.00043708645,0.000084783445,0.008708049,0.000059285278],"about_ca_topic_score_codex":0.0011931644,"about_ca_topic_score_gemma":0.0033555944,"teacher_disagreement_score":0.037990298,"about_ca_system_score_codex":0.0011994252,"about_ca_system_score_gemma":0.0003754274,"threshold_uncertainty_score":0.3136455},"labels":[],"label_agreement":null},{"id":"W2897796069","doi":"10.1016/j.ijrobp.2018.06.251","title":"International Multicenter Validation of an Intermediate-Risk Subclassification of Men Treated with Radical Treatment Without Hormone Therapy","year":2018,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Hormone therapy; Prostatectomy; Radiation therapy; Brachytherapy; Cumulative incidence; Oncology; Internal medicine; Cancer; Hormonal therapy; Urology; Cohort; Breast cancer","score_opus":0.033279056392439284,"score_gpt":0.37037161719143075,"score_spread":0.33709256079899147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897796069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994332,0.0002634702,0.0026982396,0.00083771686,0.00050935795,0.00044457763,0.00012604089,0.000022191096,0.0007663623],"genre_scores_gemma":[0.99121815,0.00411137,0.0025787556,0.00005748859,0.0014032495,0.000020267056,0.00049908244,0.000029799401,0.00008181707],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979341,0.00030760246,0.00083047105,0.00025838555,0.00047624126,0.00019320282],"domain_scores_gemma":[0.9960395,0.00020228802,0.0015352755,0.00020887255,0.0018657193,0.0001483356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000479084,0.00021941523,0.000532953,0.0003165777,0.000048938935,0.000018551958,0.00032859412,0.00018866612,0.000107220214],"category_scores_gemma":[0.00012579547,0.00014764565,0.00017601538,0.00018042051,0.00061497005,0.00036494347,0.000028503859,0.00023552137,0.000009403802],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014044451,0.0025502178,0.68574387,0.000006031359,0.0022874102,0.000018985524,0.0013995701,0.00005300691,0.07553876,0.00025309273,0.00014815407,0.21795644],"study_design_scores_gemma":[0.05289064,0.032673236,0.3556076,0.00014634074,0.00053831056,0.00014523679,0.00045713654,0.008609101,0.53603137,0.00079411035,0.0118038105,0.00030314273],"about_ca_topic_score_codex":0.00007361676,"about_ca_topic_score_gemma":0.0000051899933,"teacher_disagreement_score":0.46049258,"about_ca_system_score_codex":0.0008450272,"about_ca_system_score_gemma":0.000526361,"threshold_uncertainty_score":0.6020815},"labels":[],"label_agreement":null},{"id":"W2898122595","doi":"10.1093/annonc/mdy284.036","title":"Clinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study of real-world (RW) data from pts with metastatic castration-resistant prostate cancer (mCRPC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Internal medicine; Prostate cancer; Oncology; Cancer","score_opus":0.22798249949642282,"score_gpt":0.485327753437376,"score_spread":0.2573452539409532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898122595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939486,0.0002046629,0.000003466939,0.0005886893,0.000056186025,0.003986527,0.0007053791,0.000030941737,0.0004755711],"genre_scores_gemma":[0.9967922,0.000515612,0.0007469171,0.0001670678,0.00008584497,0.00029312825,0.00037844433,0.000063113046,0.0009576516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957307,0.0005642313,0.0013045318,0.0009808284,0.00077045837,0.0006492426],"domain_scores_gemma":[0.9963132,0.0003049313,0.0008821759,0.0010500604,0.0011768821,0.00027273194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088353065,0.00041156658,0.0017461817,0.0002734057,0.00008756521,0.000018832021,0.0003545957,0.00011069269,0.00018725458],"category_scores_gemma":[0.00014389183,0.00022405747,0.00005162319,0.0009442887,0.0008599057,0.0002754789,0.0001347783,0.00040640938,0.0000066999273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09046406,0.010008294,0.88924813,0.0001262416,0.0018923149,0.0005562849,0.002354074,0.0000078085195,0.000121450255,0.0000043763043,0.00058483594,0.0046321284],"study_design_scores_gemma":[0.043419328,0.09950576,0.8534672,0.00048259366,0.00073414587,0.0000056942145,0.0010413838,0.00003948489,0.00080201356,0.000014752652,0.0002578487,0.00022976499],"about_ca_topic_score_codex":0.026217477,"about_ca_topic_score_gemma":0.22341421,"teacher_disagreement_score":0.19719674,"about_ca_system_score_codex":0.00039721615,"about_ca_system_score_gemma":0.0015115342,"threshold_uncertainty_score":0.98026705},"labels":[],"label_agreement":null},{"id":"W2898155733","doi":"10.1093/annonc/mdy284.013","title":"Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Placebo; Quality of life (healthcare); Cancer; Randomized controlled trial; Oncology; Urology; Surgery; Gastroenterology; Pathology","score_opus":0.13434613337518478,"score_gpt":0.4763691454765236,"score_spread":0.3420230121013388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898155733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868461,0.002738259,0.0000014895234,0.006161363,0.000092165144,0.0034435755,0.0002642004,0.000008339041,0.00044453164],"genre_scores_gemma":[0.9982086,0.0005004131,0.0001245205,0.00012223057,0.000053475553,0.0007394588,0.00007155827,0.000020052245,0.00015973572],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967989,0.00054758287,0.0013262355,0.00035854918,0.00047935732,0.000489391],"domain_scores_gemma":[0.997733,0.00033203137,0.0008590279,0.00029711935,0.0004600489,0.00031876334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011551265,0.00020589086,0.0012161032,0.00031335256,0.000030255307,0.0000043051177,0.00009822229,0.000100572586,0.00017036892],"category_scores_gemma":[0.00032687417,0.00015254699,0.00009235902,0.0005334575,0.0007814632,0.000105715,0.000039259437,0.00021375115,0.000002098757],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96790284,0.0040083453,0.014384652,0.0007390923,0.00045991867,0.00030791556,0.004593596,0.000027953165,0.00086675095,0.000059251703,0.0003071875,0.0063425195],"study_design_scores_gemma":[0.7719162,0.07995762,0.13677084,0.0016389404,0.00025450924,0.0000049664095,0.0020003128,0.00039244807,0.0060684485,0.00024694038,0.00039463417,0.00035411742],"about_ca_topic_score_codex":0.0046996786,"about_ca_topic_score_gemma":0.008586998,"teacher_disagreement_score":0.1959866,"about_ca_system_score_codex":0.00022366378,"about_ca_system_score_gemma":0.00419608,"threshold_uncertainty_score":0.7443666},"labels":[],"label_agreement":null},{"id":"W2898214566","doi":"10.1038/s41391-018-0103-4","title":"Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer","year":2018,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Cancer Institute; Prostate Cancer Foundation; American Cancer Society","keywords":"Androgen receptor; Prostate cancer; TMPRSS2; Fusion gene; Gene; Transcriptome; Biology; Cancer research; Gene expression; Computational biology; Cancer; Genetics; Medicine; Internal medicine","score_opus":0.02060646178513444,"score_gpt":0.31552128378867295,"score_spread":0.2949148220035385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898214566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96999633,0.01801583,0.0000015952119,0.0053835292,0.00032352257,0.002689943,0.0031345987,0.00003916097,0.00041547767],"genre_scores_gemma":[0.9864858,0.0075438055,0.00009190957,0.00037621768,0.00015589737,0.0013151866,0.000118556105,0.000045843804,0.003866811],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997708,0.00011513384,0.0004979139,0.00056903204,0.0005762677,0.00053364737],"domain_scores_gemma":[0.99866587,0.00012003672,0.00018130061,0.00031165432,0.0004297124,0.00029139756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001714409,0.0003186415,0.00048516845,0.00013366294,0.00027180256,0.00004461541,0.0001402458,0.00006911285,0.0006038147],"category_scores_gemma":[0.00014115578,0.00019479053,0.00012816815,0.0006266247,0.0011452687,0.00020523033,0.00009519705,0.00021611933,0.0000054993484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063782283,0.0004845969,0.90745926,0.0013364644,0.0002316626,0.00002749062,0.010276095,0.0000046121095,0.006472497,0.00010270598,0.0018363215,0.06539009],"study_design_scores_gemma":[0.009841834,0.0010459118,0.9472928,0.0028686824,0.00039469326,0.00001539481,0.0014503199,0.00030665973,0.024956454,0.0023666653,0.008971746,0.00048886135],"about_ca_topic_score_codex":0.00092531735,"about_ca_topic_score_gemma":0.0005131818,"teacher_disagreement_score":0.064901225,"about_ca_system_score_codex":0.00023189386,"about_ca_system_score_gemma":0.0010863692,"threshold_uncertainty_score":0.79433274},"labels":[],"label_agreement":null},{"id":"W2898221500","doi":"10.1093/annonc/mdy284.052","title":"The neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of response to abiraterone acetate: A retrospective analysis of the COU302 study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Abiraterone acetate; Proportional hazards model; Internal medicine; Prednisone; Hazard ratio; Prostate cancer; Progression-free survival; Enzalutamide; Placebo; Survival analysis; Oncology; Neutrophil to lymphocyte ratio; Lymphocyte; Gastroenterology; Cancer; Chemotherapy; Androgen deprivation therapy; Confidence interval; Pathology","score_opus":0.05054912373938179,"score_gpt":0.418073508341856,"score_spread":0.3675243846024742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898221500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98623145,0.00022539182,0.000014177015,0.00996048,0.00011738093,0.001636491,0.00008226489,0.000008078589,0.0017242722],"genre_scores_gemma":[0.99667645,0.0001441058,0.00002725534,0.00055515725,0.000057835063,0.00012402932,0.000003228253,0.000014027254,0.0023979126],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9978006,0.0006184473,0.00047765815,0.0003007746,0.0004897832,0.00031276426],"domain_scores_gemma":[0.99694717,0.00046399722,0.0002744763,0.0006572709,0.0015218975,0.00013516347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016273226,0.00014352832,0.00070706196,0.0003331583,0.00012844874,0.000006592781,0.00028460147,0.000083178435,0.000094513],"category_scores_gemma":[0.00073574734,0.000075792406,0.0001954172,0.0017135036,0.0006149446,0.00003740943,0.00020980915,0.0001298438,0.000013752046],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40728885,0.004468995,0.34158877,0.000054651784,0.01893684,0.00011758967,0.038485184,0.00020780966,0.16909577,0.00024629058,0.011333863,0.008175402],"study_design_scores_gemma":[0.0030912473,0.04187852,0.9014887,0.000031895244,0.0009122483,0.0000040092013,0.0021343331,0.000103044316,0.047724158,0.000074772026,0.0024947564,0.000062266525],"about_ca_topic_score_codex":0.00032424091,"about_ca_topic_score_gemma":0.00042040195,"teacher_disagreement_score":0.5599,"about_ca_system_score_codex":0.00022688044,"about_ca_system_score_gemma":0.0009668071,"threshold_uncertainty_score":0.30907246},"labels":[],"label_agreement":null},{"id":"W2898281580","doi":"10.1093/annonc/mdy424.035","title":"ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Abiraterone acetate; Clinical endpoint; Internal medicine; Asymptomatic; Denosumab; Prednisone; Gastroenterology; Phases of clinical research; Placebo; Urology; Randomized controlled trial; Clinical trial; Surgery; Cancer; Prostate cancer; Osteoporosis; Androgen deprivation therapy; Pathology","score_opus":0.05907478505180859,"score_gpt":0.39678210894735894,"score_spread":0.33770732389555036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898281580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98894995,0.0010852683,0.0000751233,0.0020780687,0.000070919414,0.0074661695,0.00022816582,0.0000118413545,0.00003449415],"genre_scores_gemma":[0.9942664,0.0025769866,0.0011066598,0.00006961279,0.000035300487,0.0014512825,0.00008447045,0.00003860771,0.00037071377],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99777627,0.00017342641,0.00089058763,0.00035327632,0.00038582392,0.0004205998],"domain_scores_gemma":[0.9976534,0.00045233098,0.00080298533,0.00032147384,0.0006591997,0.00011061275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043244788,0.00030490366,0.00116888,0.00022861703,0.00009683925,0.000013446926,0.0001029857,0.000088004555,0.000036820114],"category_scores_gemma":[0.00004163025,0.00015609806,0.00008741187,0.00033580742,0.00076515164,0.00012920437,0.000016954122,0.000077213444,6.008247e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77350664,0.030344138,0.0030989924,0.001377107,0.0030235099,0.000051335417,0.02106981,0.000023748617,0.012078336,0.00004234313,0.00024221862,0.15514185],"study_design_scores_gemma":[0.65149474,0.25540352,0.00899593,0.0007610521,0.001012258,0.000023803566,0.0010589123,0.002670179,0.07786695,0.00013079918,0.00035257026,0.00022929035],"about_ca_topic_score_codex":0.0007471034,"about_ca_topic_score_gemma":0.0013775156,"teacher_disagreement_score":0.22505939,"about_ca_system_score_codex":0.0002106055,"about_ca_system_score_gemma":0.00084320287,"threshold_uncertainty_score":0.6365494},"labels":[],"label_agreement":null},{"id":"W2898340726","doi":"10.1093/annonc/mdy284.022","title":"Treatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Internal medicine; Hazard ratio; Randomization; Chemotherapy; Proportional hazards model; Oncology; Progression-free survival; Cancer; Surgery; Randomized controlled trial; Confidence interval","score_opus":0.21612272159089332,"score_gpt":0.5034199224800712,"score_spread":0.2872972008891779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898340726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920862,0.0036916556,0.0000016179353,0.0010302889,0.00011015965,0.0008891413,0.00033688082,0.0000062779986,0.0018478004],"genre_scores_gemma":[0.9922558,0.0060690097,0.00025121414,0.000014268311,0.000039226186,0.00008967827,0.00020720213,0.000013575648,0.0010600052],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986876,0.00013463112,0.00052727916,0.00018743199,0.0002499528,0.00021308311],"domain_scores_gemma":[0.99824756,0.00013323114,0.00049199566,0.00020035249,0.000843843,0.00008300112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014765291,0.00014515182,0.000658882,0.00012355018,0.000034468285,0.000001367111,0.000044896988,0.000077139775,0.00022686599],"category_scores_gemma":[0.000035935627,0.00009375032,0.00010258042,0.00022399805,0.0003799644,0.000046217152,0.000018237544,0.000028065417,0.0000031845532],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025091084,0.0067105233,0.0633577,0.0006474846,0.00191182,0.000049856088,0.0054376526,0.000010597749,0.7398851,0.00015834041,0.001658688,0.15508115],"study_design_scores_gemma":[0.0060373866,0.08076641,0.013612428,0.0001413145,0.0003079631,0.000005793687,0.00028293536,0.000039323248,0.8908698,0.00006556829,0.007798894,0.00007218952],"about_ca_topic_score_codex":0.0008780974,"about_ca_topic_score_gemma":0.0004125184,"teacher_disagreement_score":0.15500897,"about_ca_system_score_codex":0.00032401856,"about_ca_system_score_gemma":0.0009472891,"threshold_uncertainty_score":0.3823027},"labels":[],"label_agreement":null},{"id":"W2898365270","doi":"10.1016/j.eururo.2018.10.029","title":"Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432–31","year":2018,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Androgen; Gynecology; Oncology; Internal medicine; Gerontology; Cancer; Hormone","score_opus":0.020146190849544623,"score_gpt":0.30497478271557166,"score_spread":0.28482859186602705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898365270","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28004557,0.0030699754,0.00007131468,0.70452833,0.0027841048,0.008721222,0.00037152725,0.000066787434,0.00034116447],"genre_scores_gemma":[0.033918332,0.009119022,0.00016782165,0.92770535,0.021925231,0.0015557962,0.0009045078,0.0002747201,0.00442922],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99217725,0.0038214864,0.0013676044,0.0011718916,0.00069957395,0.0007622063],"domain_scores_gemma":[0.9968734,0.0006796663,0.0008224472,0.0010068851,0.00040745814,0.00021016052],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004485517,0.000604544,0.001453671,0.0005499333,0.00019089914,0.00009164673,0.0003915188,0.00031286204,0.00008966777],"category_scores_gemma":[0.0011623093,0.00039316874,0.00020869901,0.00043773506,0.00040114395,0.00014002435,0.0002200014,0.001497106,0.000050433653],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28949687,0.00012233669,0.0003238325,0.000038914503,0.00035536222,0.00044506925,0.0016731756,0.000005928189,0.0007718686,0.0000012038101,0.70457333,0.0021920844],"study_design_scores_gemma":[0.28719747,0.003749447,0.00015053546,0.00006619845,0.00020707627,0.000025145775,0.000014771979,0.00002165473,0.000621257,0.00002096137,0.70767134,0.00025412417],"about_ca_topic_score_codex":0.0010067857,"about_ca_topic_score_gemma":0.00010723768,"teacher_disagreement_score":0.24612725,"about_ca_system_score_codex":0.00015401634,"about_ca_system_score_gemma":0.00041051416,"threshold_uncertainty_score":0.999852},"labels":[],"label_agreement":null},{"id":"W2898372506","doi":"10.1093/annonc/mdy284.014","title":"A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Internal medicine; Doubling time; Placebo; Oncology; Randomized controlled trial; Gynecology; Urology; Cancer; Androgen receptor; Pathology","score_opus":0.08967654066231087,"score_gpt":0.42629916082557195,"score_spread":0.33662262016326105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898372506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98601854,0.0013042245,0.000005918438,0.001360222,0.000026465248,0.008891431,0.00007388983,0.000007965153,0.0023113496],"genre_scores_gemma":[0.9958244,0.0011549752,0.00010555812,0.00006365733,0.000034406174,0.0010904133,0.000043021086,0.00002021454,0.0016633375],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973654,0.0003679878,0.0011273309,0.0003834262,0.00040902052,0.00034682383],"domain_scores_gemma":[0.9978524,0.00044456313,0.0007541832,0.00027959602,0.00054335315,0.00012592769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015006377,0.00022334655,0.001843726,0.0003070083,0.00004617439,0.000008328432,0.000091740374,0.00010036863,0.00002200703],"category_scores_gemma":[0.00013412193,0.00013984332,0.00008331789,0.00034223867,0.00079456746,0.0001063357,0.000038454593,0.00016966433,4.7135455e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9625827,0.005319954,0.0010246543,0.00018607242,0.0011236632,0.00029820236,0.010292819,0.000010065462,0.015143627,0.00001971589,0.0012759396,0.0027225646],"study_design_scores_gemma":[0.93984824,0.032084707,0.00034969527,0.00027034094,0.00044897827,0.00001341492,0.0019758132,0.00015896365,0.024469538,0.00004924255,0.00021406764,0.000116984964],"about_ca_topic_score_codex":0.0033076452,"about_ca_topic_score_gemma":0.0035605226,"teacher_disagreement_score":0.026764754,"about_ca_system_score_codex":0.00007179415,"about_ca_system_score_gemma":0.00058612425,"threshold_uncertainty_score":0.5702645},"labels":[],"label_agreement":null},{"id":"W2898429292","doi":"10.1093/annonc/mdy284.006","title":"LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Oncology; Abiraterone; Internal medicine; Prednisone; Progression-free survival; Overall survival; Urology; Cancer; Androgen deprivation therapy","score_opus":0.06094733675121776,"score_gpt":0.38036372163113374,"score_spread":0.31941638487991597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898429292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99573535,0.000380606,0.000016906211,0.0014064484,0.00006386763,0.0021971958,0.00013764654,0.000019879184,0.00004207661],"genre_scores_gemma":[0.99740636,0.0011995296,0.0007999209,0.00008718642,0.00004073003,0.00013050757,0.00005800645,0.000028496725,0.00024925117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762785,0.0007293081,0.0003828913,0.00047813094,0.00036963617,0.00041220052],"domain_scores_gemma":[0.99825186,0.000614341,0.0002799585,0.00020653011,0.00045990213,0.00018740802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011295889,0.00026106206,0.00081113627,0.00016683275,0.000104399376,0.000025913141,0.000061274026,0.000104469065,0.000016217133],"category_scores_gemma":[0.00037110873,0.00015213613,0.00001502734,0.00019385098,0.0007305609,0.00017618426,0.0001399226,0.00025654206,9.825227e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2564682,0.00088928157,0.72124016,0.00009144576,0.00040748657,0.00028587505,0.006438784,0.000003958808,0.00045002432,0.000004087244,0.00008492054,0.013635805],"study_design_scores_gemma":[0.026420144,0.040435128,0.93131757,0.00026701947,0.00015798424,0.000025805777,0.00070791115,0.00021658742,0.00012586766,0.000019059447,0.00013124291,0.00017569723],"about_ca_topic_score_codex":0.00015064396,"about_ca_topic_score_gemma":0.00073637714,"teacher_disagreement_score":0.23004805,"about_ca_system_score_codex":0.00008430794,"about_ca_system_score_gemma":0.0003174144,"threshold_uncertainty_score":0.6203931},"labels":[],"label_agreement":null},{"id":"W2898480817","doi":"10.1093/annonc/mdy284.016","title":"Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: Results from the PROSPER study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Foundation for Research on Metabolic Disorders; Pfizer","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Internal medicine; Urology; Cancer; Androgen receptor","score_opus":0.0498774345410173,"score_gpt":0.37898335343399964,"score_spread":0.32910591889298235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898480817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859787,0.0006761363,0.0000012397486,0.007933091,0.0000148070585,0.003939882,0.0002311129,0.000014749863,0.0012102578],"genre_scores_gemma":[0.9978455,0.00027003782,0.0000826383,0.00032785934,0.000072018775,0.00066925446,0.000047470367,0.000023872277,0.0006614031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822146,0.00023252459,0.00040458978,0.0004338445,0.00031692313,0.00039066034],"domain_scores_gemma":[0.9985837,0.00031357753,0.0002139886,0.00031379718,0.00045803568,0.00011695165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005422184,0.00021569026,0.0005388502,0.000100043886,0.00011072405,0.000019524678,0.0000972681,0.000062539475,0.000029478633],"category_scores_gemma":[0.000052558462,0.00010614148,0.00002476326,0.0002869879,0.0005856536,0.0001021579,0.000030993837,0.00021478104,0.000003262663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12635207,0.0028524583,0.8426299,0.00006199812,0.0013164089,0.0012629797,0.014011519,0.000014952111,0.0051898607,0.000005147309,0.0012042766,0.0050984244],"study_design_scores_gemma":[0.036685146,0.042443324,0.91458124,0.0002553897,0.00029685142,0.000033812175,0.0024559072,0.00025076506,0.0025161107,0.000028159466,0.00031614033,0.0001371472],"about_ca_topic_score_codex":0.004495728,"about_ca_topic_score_gemma":0.0060275593,"teacher_disagreement_score":0.08966692,"about_ca_system_score_codex":0.00008763966,"about_ca_system_score_gemma":0.00075322454,"threshold_uncertainty_score":0.67962253},"labels":[],"label_agreement":null},{"id":"W2898625426","doi":"10.1016/j.purol.2018.07.016","title":"Association entre la qualité de vie liée à la santé (qdv) et les signes cliniques du cancer de prostate résistant à la castration non métastatique (cprcnm) : résultats de l’étude prosper","year":2018,"lang":"fr","type":"article","venue":"Progrès en Urologie","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Institute of Cancer Research","funders":"","keywords":"Medicine; Gynecology","score_opus":0.029874347406285386,"score_gpt":0.4110675446580098,"score_spread":0.38119319725172446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898625426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9475019,0.014567235,0.002022689,0.025196848,0.000397798,0.0029255012,0.00043808724,0.00035408902,0.006595829],"genre_scores_gemma":[0.9492093,0.03688135,0.006074506,0.0007192414,0.0012931079,0.0013420257,0.00017118626,0.00010661766,0.0042026914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924638,0.00395161,0.0006968834,0.00072148186,0.00059983606,0.0015663793],"domain_scores_gemma":[0.9956701,0.0025403486,0.00043833256,0.00029803463,0.00067479763,0.00037839383],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006867945,0.0005270676,0.0005947836,0.00015170104,0.00028258405,0.00034473182,0.0002717601,0.00095433375,0.00023743641],"category_scores_gemma":[0.0022495838,0.0004468767,0.00018261684,0.00034939096,0.00060673244,0.00038189074,0.00014502401,0.0011350623,0.000048226306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024376814,0.0014015984,0.75457793,0.0008863745,0.00080085173,0.0008676741,0.036627546,0.000086336324,0.014320117,0.0010728209,0.004538137,0.18238294],"study_design_scores_gemma":[0.011148582,0.00804009,0.71216834,0.0022104757,0.0018013447,0.00031652578,0.0041718935,0.0071605872,0.08395192,0.007107422,0.16044797,0.0014748765],"about_ca_topic_score_codex":0.001961653,"about_ca_topic_score_gemma":0.0021656384,"teacher_disagreement_score":0.18090807,"about_ca_system_score_codex":0.001929346,"about_ca_system_score_gemma":0.003815024,"threshold_uncertainty_score":0.9997983},"labels":[],"label_agreement":null},{"id":"W2899118664","doi":"10.1002/pros.23733","title":"Clinical effectiveness of docetaxel for castration‐sensitive prostate cancer in a real‐world population‐based analysis","year":2018,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbotsford Veterinary Clinic; University of British Columbia, Okanagan Campus; Kelowna General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Population; Adverse effect; Cancer; Neutropenia; Chemotherapy","score_opus":0.058521440726162104,"score_gpt":0.44716467496714013,"score_spread":0.388643234240978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899118664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948876,0.0001163801,0.00019544811,0.00104029,0.00009910162,0.002917006,0.0002993292,0.000026882733,0.0004179924],"genre_scores_gemma":[0.99726814,0.00015153021,0.00038967494,0.00006943755,0.00010581589,0.00044749133,0.00023044476,0.000021678079,0.0013157858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982415,0.00035080753,0.0004853019,0.00033759337,0.0002596302,0.00032517058],"domain_scores_gemma":[0.99826103,0.00061318505,0.00018893149,0.00032406053,0.0005261342,0.000086680586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016570815,0.00015499888,0.0005566404,0.0003481304,0.000111518995,0.000017437358,0.000079366524,0.000051037867,0.000032267923],"category_scores_gemma":[0.00010954764,0.00009605864,0.00021646645,0.0013803524,0.00028818278,0.000073920295,0.000028923234,0.0001596532,0.0000045332313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010891176,0.00026790643,0.9782025,0.00031196314,0.00084740977,0.000012123767,0.00072849606,0.0004916169,0.0021995325,0.00015255186,0.00003715673,0.0058575342],"study_design_scores_gemma":[0.0049895123,0.00072093593,0.9705003,0.00025789993,0.0007601743,8.222305e-7,0.00007105095,0.0063441726,0.015697379,0.00048664035,0.00006393092,0.00010716328],"about_ca_topic_score_codex":0.0032506643,"about_ca_topic_score_gemma":0.005553415,"teacher_disagreement_score":0.013497846,"about_ca_system_score_codex":0.00019098952,"about_ca_system_score_gemma":0.00036278932,"threshold_uncertainty_score":0.49140537},"labels":[],"label_agreement":null},{"id":"W2900022787","doi":"10.5489/cuaj.5586","title":"Identification of subgroups of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone plus prednisone at low- vs. high-risk of radiographic progression: An analysis of COU-AA-302","year":2018,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Yale University","keywords":"Abiraterone acetate; Medicine; Prednisone; Prostate cancer; Confidence interval; Internal medicine; Oncology; Proportional hazards model; Chemotherapy; Radiography; Cancer; Surgery; Urology; Androgen deprivation therapy","score_opus":0.011953699836178467,"score_gpt":0.26868028421196183,"score_spread":0.2567265843757834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900022787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997326,0.00033747882,0.00001706056,0.0002831863,0.000049022117,0.0006584415,0.0013092486,0.00000763303,0.0000119249435],"genre_scores_gemma":[0.99898046,0.00037857838,0.00009508028,0.000021338015,0.000033827142,0.00003686495,0.00030946886,0.00001644787,0.00012792765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704355,0.0003966801,0.0010085693,0.00027908513,0.00086156855,0.00041056395],"domain_scores_gemma":[0.9950239,0.00008399417,0.0020178792,0.00023352627,0.002178902,0.00046181737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008097121,0.000192513,0.0008579135,0.00080833863,0.00015958586,0.000020415919,0.0001457534,0.00014290266,0.00026998128],"category_scores_gemma":[0.00013783798,0.00012603859,0.00018620107,0.0015773493,0.00036969956,0.00014087284,0.000014842194,0.00021848889,8.431471e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004936989,0.00042618773,0.98089117,0.00008739145,0.0032699828,0.000020848755,0.0006884556,0.00030177901,0.008662615,0.000008603765,0.000060342907,0.00064563134],"study_design_scores_gemma":[0.00465547,0.005552797,0.97021073,0.000100887315,0.0031813567,0.0000035996804,0.00012747354,0.0011034192,0.0149233565,0.000020699077,0.000012479039,0.00010771999],"about_ca_topic_score_codex":0.008888277,"about_ca_topic_score_gemma":0.0101164235,"teacher_disagreement_score":0.010680431,"about_ca_system_score_codex":0.0009820642,"about_ca_system_score_gemma":0.0007126601,"threshold_uncertainty_score":0.9977116},"labels":[],"label_agreement":null},{"id":"W2900789716","doi":"10.1016/j.humpath.2018.11.016","title":"Evolving concepts in prostatic neuroendocrine manifestations: from focal divergent differentiation to amphicrine carcinoma","year":2018,"lang":"en","type":"review","venue":"Human Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Neuroendocrine differentiation; Medicine; Neuroendocrine carcinoma; Pathology; Neuroendocrine tumors; Prostate; Anatomical pathology; Prostatic Diseases; Carcinoma; Immunohistochemistry; Prostate cancer; Internal medicine; Cancer","score_opus":0.09669286927456215,"score_gpt":0.4207485857405662,"score_spread":0.32405571646600406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900789716","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.085622154,0.91012275,0.00003330118,0.00015423537,0.00043179045,0.0030453189,0.0002568665,0.000063118125,0.00027046047],"genre_scores_gemma":[0.041423403,0.9499934,0.00023611428,0.00013469713,0.0005159613,0.0011558775,0.0043638223,0.00010835795,0.0020683876],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99720216,0.00038270166,0.00074466685,0.0008079739,0.0002989692,0.00056352495],"domain_scores_gemma":[0.9987627,0.00014835745,0.00020398616,0.0005242859,0.00014255448,0.00021808103],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011425634,0.00043377574,0.0013782282,0.00058174727,0.00012984884,0.00002962433,0.00019682497,0.00012320041,0.00069346395],"category_scores_gemma":[0.00015035126,0.00034296984,0.00021678214,0.00031577135,0.00015599595,0.000059946247,0.00024836822,0.00046078642,0.00030984668],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072572497,0.0034250198,0.08646525,0.05174774,0.0010931591,0.083162114,0.007178302,0.0000015665814,0.0006181226,0.0011158697,0.017960876,0.7465063],"study_design_scores_gemma":[0.012944753,0.007444158,0.33369836,0.02915746,0.004229397,0.0027565623,0.0003571679,0.00007959611,0.00012261723,0.0013994528,0.6057275,0.0020829574],"about_ca_topic_score_codex":0.00014619518,"about_ca_topic_score_gemma":0.00026191273,"teacher_disagreement_score":0.7444233,"about_ca_system_score_codex":0.00048147747,"about_ca_system_score_gemma":0.00025342265,"threshold_uncertainty_score":0.99990225},"labels":[],"label_agreement":null},{"id":"W2901189223","doi":"10.1111/cas.13869","title":"Alternative <scp>RNA</scp> splicing of the <i><scp>GIT</scp>1</i> gene is associated with neuroendocrine prostate cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Science","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Alternative splicing; Prostate cancer; RNA splicing; Biology; Cancer research; Transcriptome; Downregulation and upregulation; Exon; Gene; Epigenetics; Cancer; microRNA; RNA; Androgen receptor; Gene expression; Genetics","score_opus":0.026835009137512834,"score_gpt":0.32401262040076256,"score_spread":0.2971776112632497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901189223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903351,0.0017232817,0.000029647568,0.0013538735,0.0006911514,0.0009934512,0.00017141731,0.0000522442,0.0046498436],"genre_scores_gemma":[0.98127645,0.0019031778,0.000073984535,0.0015816721,0.00032210047,0.00020084398,0.0000047245894,0.000041578525,0.014595475],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964561,0.000058200654,0.0003115446,0.0007713078,0.001388866,0.0010139924],"domain_scores_gemma":[0.9973231,0.00018259174,0.00034749598,0.000629484,0.0011966145,0.00032073387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034946852,0.0002958815,0.00041479798,0.000187704,0.00051632733,0.000081930826,0.00071591645,0.000035136476,0.00003449346],"category_scores_gemma":[0.0004333684,0.00017225894,0.00009198808,0.0024426354,0.002609284,0.0003487971,0.0003070035,0.00034853027,0.000010682806],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013880074,0.00040984954,0.39935526,0.00020627747,0.0005480002,0.00028566917,0.014733946,0.0003344803,0.55687743,0.000115989154,0.01671992,0.01027433],"study_design_scores_gemma":[0.002491208,0.0007349353,0.048390087,0.00062498223,0.00012636773,0.000038844646,0.00031700238,0.0018232067,0.9403684,0.000106194384,0.004923622,0.00005515586],"about_ca_topic_score_codex":0.0015444754,"about_ca_topic_score_gemma":0.00032307193,"teacher_disagreement_score":0.38349092,"about_ca_system_score_codex":0.0006609864,"about_ca_system_score_gemma":0.0020325452,"threshold_uncertainty_score":0.9614015},"labels":[],"label_agreement":null},{"id":"W2901194350","doi":"10.3389/fsurg.2018.00074","title":"Current Imaging Techniques for Lymph Node Staging in Prostate Cancer: A Review","year":2018,"lang":"en","type":"review","venue":"Frontiers in Surgery","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Frontiers Foundation","keywords":"Medicine; Lymph node; Prostate cancer; Cancer; Prostate; Radiology; Medical physics; Pathology; Internal medicine","score_opus":0.06509561836648589,"score_gpt":0.41189722135270485,"score_spread":0.346801602986219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901194350","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000030563149,0.992098,0.00013720006,0.0004665325,0.0016916335,0.0051560053,0.00025178678,0.00008587524,0.0001099449],"genre_scores_gemma":[5.570523e-7,0.98998,0.0015865322,0.00017166795,0.00037613837,0.006623622,0.00072649826,0.00012465792,0.0004103148],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996578,0.0002041798,0.0011776158,0.00078289636,0.0003629457,0.00089438335],"domain_scores_gemma":[0.99854326,0.00024227666,0.00039257036,0.00050463347,0.00015862592,0.0001586518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017143069,0.0005450437,0.003427458,0.0013020452,0.00005636378,0.000032740787,0.0001923098,0.00012276245,0.000024057741],"category_scores_gemma":[0.00025830363,0.00041532752,0.0007151057,0.0010519983,0.00016320898,0.00013151203,0.00009513633,0.00049010874,0.000005447082],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051226965,0.000067173125,0.025609177,0.15436997,0.00006662954,0.00008811675,0.00002311468,8.282701e-9,3.093798e-8,3.438246e-7,0.13864449,0.68107975],"study_design_scores_gemma":[0.00026927044,0.000007797052,0.000037025824,0.33162713,0.00030298467,0.000010484792,0.0000091751845,0.000009477413,0.0000026520138,0.00002397594,0.6674396,0.00026043886],"about_ca_topic_score_codex":0.00010366536,"about_ca_topic_score_gemma":0.000004020874,"teacher_disagreement_score":0.6808193,"about_ca_system_score_codex":0.002102599,"about_ca_system_score_gemma":0.0025589531,"threshold_uncertainty_score":0.9998298},"labels":[],"label_agreement":null},{"id":"W2901274396","doi":"10.3390/jcm7110444","title":"Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Cancer Institute","keywords":"Cabazitaxel; Docetaxel; Enzalutamide; Prostate cancer; Androgen receptor; Taxane; Medicine; Cancer research; Gene knockdown; Internal medicine; Androgen; Cancer; Pharmacology; Oncology; Androgen deprivation therapy; Cell culture; Biology; Breast cancer; Hormone","score_opus":0.06852718958259932,"score_gpt":0.431873109874095,"score_spread":0.3633459202914957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901274396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9636596,0.0018288313,0.000020802774,0.03312502,0.00028529484,0.00060618686,0.0000048524303,0.0000028520603,0.00046655783],"genre_scores_gemma":[0.9896995,0.007690667,0.00034387052,0.0006185099,0.0015036768,0.000008022662,0.0000035294029,0.000013881382,0.00011835036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969695,0.0003611548,0.001556457,0.00014945722,0.00076712883,0.00019626283],"domain_scores_gemma":[0.996567,0.0012011763,0.0010965022,0.00025365117,0.00076288125,0.00011880419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004265305,0.00012957204,0.000764113,0.000117077136,0.00005070289,0.000004695769,0.00024182485,0.0000876848,0.00011411078],"category_scores_gemma":[0.0017023667,0.00005214138,0.00014130051,0.00041551996,0.00093519466,0.00007004103,0.000019282945,0.0005116313,8.4397703e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059353303,0.0022772364,0.71633106,0.00063854974,0.0014923753,0.00025484472,0.027761785,0.000003328935,0.11933148,0.00040804018,0.006316881,0.06583114],"study_design_scores_gemma":[0.041311692,0.021192258,0.8794019,0.005813056,0.0007380072,0.00011206894,0.004937516,0.000117713134,0.041005205,0.0008597212,0.0043459656,0.00016484855],"about_ca_topic_score_codex":0.00021183767,"about_ca_topic_score_gemma":0.00009857927,"teacher_disagreement_score":0.16307092,"about_ca_system_score_codex":0.000047686182,"about_ca_system_score_gemma":0.0004936231,"threshold_uncertainty_score":0.34457636},"labels":[],"label_agreement":null},{"id":"W2901966045","doi":"10.1038/s41598-018-35612-z","title":"Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"Enzalutamide; LNCaP; Androgen receptor; Prostate cancer; Cancer research; STAT3; In vivo; Cyclin D1; Chemistry; Cell growth; Cell cycle; Signal transduction; Biology; Medicine; Cancer; Cell biology; Internal medicine; Biochemistry","score_opus":0.02501422461963144,"score_gpt":0.3165633665376805,"score_spread":0.2915491419180491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901966045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876604,0.0058560395,0.0000071783224,0.0020308536,0.0017892995,0.0009454811,0.000021418102,0.00006341313,0.0016258934],"genre_scores_gemma":[0.97874415,0.00024209246,0.00011060154,0.00009949922,0.00022785747,0.00009096239,0.000042570686,0.000026576623,0.02041572],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974066,0.000060465216,0.00042229582,0.00076525065,0.00080260047,0.0005427743],"domain_scores_gemma":[0.9982941,0.00006938515,0.00018303876,0.00069236016,0.00051948294,0.00024161625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012558266,0.00019327844,0.00025336546,0.00014363462,0.0007325832,0.00033557444,0.00008298623,0.0000591382,0.0005260178],"category_scores_gemma":[0.00014990484,0.000110121175,0.00006604077,0.0005403347,0.0013860528,0.00015731448,0.00012436915,0.0001780999,0.000021178266],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005985916,0.0001461939,0.036846414,0.00025330237,0.0001950713,0.001019492,0.004727282,0.0000069165394,0.9182804,0.000027414,0.031820018,0.0060788593],"study_design_scores_gemma":[0.0006913754,0.00027070558,0.005414671,0.00032899735,0.00012712722,0.00022064616,0.0005398303,0.000052179763,0.8960072,0.0013556307,0.09479992,0.0001917333],"about_ca_topic_score_codex":0.0003080304,"about_ca_topic_score_gemma":0.00015437031,"teacher_disagreement_score":0.06297991,"about_ca_system_score_codex":0.000107453314,"about_ca_system_score_gemma":0.00058635103,"threshold_uncertainty_score":0.5759526},"labels":[],"label_agreement":null},{"id":"W2902248289","doi":"","title":"Safety, tolerability, pharmacokinetic and escalating single doses of PCK3145 in patients with metastatic hormone resistant prostatic cancer (HRPC)","year":2004,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Tolerability; Pharmacokinetics; Prostate cancer; Medicine; In vivo; Toxicity; Cancer; Internal medicine; Pharmacology; Therapeutic index; Oncology; Prostate; Hormone; Adverse effect; Gastroenterology; Biology; Drug","score_opus":0.06460426671474814,"score_gpt":0.39543610236139004,"score_spread":0.33083183564664187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902248289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98749244,0.007684108,0.000009956229,0.001980292,0.00003167167,0.0022603762,0.00011260259,0.000020309435,0.000408239],"genre_scores_gemma":[0.9968726,0.0017199415,0.00047896034,0.000041542666,0.000039844705,0.00047823478,0.000031775995,0.000047514055,0.0002895855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967844,0.00019408876,0.00048650295,0.0005286916,0.0012409248,0.0007654269],"domain_scores_gemma":[0.99838877,0.0002300493,0.00009651523,0.0003151553,0.0006943988,0.0002751292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076467113,0.00022086078,0.0005495774,0.0004194851,0.0001433381,0.00003771768,0.00013898443,0.000051667077,0.00013084746],"category_scores_gemma":[0.00016036561,0.00015538822,0.000042299802,0.0011623717,0.0006757849,0.00015893768,0.00014511484,0.00052549154,0.000002732282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036806986,0.0041665975,0.6797422,0.004525194,0.00064135046,0.00023672785,0.0053407787,0.0008416372,0.21347214,0.00013086115,0.0002047024,0.0538908],"study_design_scores_gemma":[0.038752545,0.006053332,0.8801289,0.0032274898,0.00019287005,0.0000051893517,0.0007687249,0.00008188557,0.06929787,0.00078606716,0.00031577787,0.00038933623],"about_ca_topic_score_codex":0.0032606504,"about_ca_topic_score_gemma":0.0008013,"teacher_disagreement_score":0.20038669,"about_ca_system_score_codex":0.0012234969,"about_ca_system_score_gemma":0.0010091617,"threshold_uncertainty_score":0.6336547},"labels":[],"label_agreement":null},{"id":"W2902282663","doi":"10.1016/j.jchromb.2018.12.003","title":"An LC-MS/MS method for quantification of abiraterone, its active metabolites D(4)-abiraterone (D4A) and 5α-abiraterone, and their inactive glucuronide derivatives","year":2018,"lang":"en","type":"article","venue":"Journal of Chromatography B","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"Fondation CHU de Québec","keywords":"Chemistry; Chromatography; Selected reaction monitoring; Prostate cancer; Abiraterone acetate; Abiraterone; Analyte; Prodrug; CYP17A1; Pharmacology; Tandem mass spectrometry; Mass spectrometry; Androgen deprivation therapy; Androgen receptor; Biochemistry; Cancer; Enzyme; Internal medicine","score_opus":0.03459903610339165,"score_gpt":0.35802454953731117,"score_spread":0.3234255134339195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902282663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98290765,0.00593777,0.009539145,0.00049586676,0.00012522814,0.0007516038,0.00010086337,0.000019280587,0.00012260853],"genre_scores_gemma":[0.98565257,0.0017100112,0.012198147,0.00006281999,0.00024209324,0.000037458503,0.000021316067,0.000042855656,0.00003272514],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981071,0.00025253306,0.0006311687,0.0003477121,0.00030580227,0.00035572812],"domain_scores_gemma":[0.99738556,0.00024279376,0.0007087555,0.00024996122,0.0011335657,0.00027934634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007207987,0.0003100664,0.0008381872,0.00063546444,0.00017667656,0.00007228199,0.00014742499,0.0001367464,0.000028176231],"category_scores_gemma":[0.000083719686,0.00020224722,0.00017506261,0.00045256424,0.0005528125,0.00076398416,0.000038187147,0.00021897945,7.824428e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040069977,0.0004514393,0.010597723,0.00032323535,0.0011330324,0.000006966258,0.003768697,9.277675e-7,0.96619636,0.00038326668,0.00009778677,0.013033585],"study_design_scores_gemma":[0.0037553639,0.004765558,0.17838925,0.00025127325,0.0002632188,0.00011418268,0.0017140725,0.0002467653,0.8087699,0.00091902405,0.00064556126,0.00016586191],"about_ca_topic_score_codex":0.000035153076,"about_ca_topic_score_gemma":0.000014662232,"teacher_disagreement_score":0.16779153,"about_ca_system_score_codex":0.000050423947,"about_ca_system_score_gemma":0.00016789234,"threshold_uncertainty_score":0.82474023},"labels":[],"label_agreement":null},{"id":"W2902725138","doi":"10.1016/j.euo.2018.11.005","title":"Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Janssen Research and Development; Genentech; European Society for Medical Oncology; Astellas Pharma; Eisai; Bayer; Canada Millennium Scholarship Foundation; Phycological Society of America; Amgen; Boehringer Ingelheim; Gilead Sciences; AbbVie; Sanofi; Novartis; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Internal medicine; Clinical trial; Randomized controlled trial; Prostate-specific antigen; Cabazitaxel; Prostate; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.06802942518975472,"score_gpt":0.40857977959971103,"score_spread":0.3405503544099563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902725138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880523,0.00030139007,0.000031998177,0.0030272815,0.00011959632,0.0063081533,0.00003924749,0.000049950813,0.0020700495],"genre_scores_gemma":[0.995367,0.00094303826,0.0016187395,0.00031752107,0.00019739615,0.00048415214,0.000104136874,0.00007535412,0.0008926579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9896964,0.006214053,0.002096347,0.0008130232,0.000470446,0.00070975],"domain_scores_gemma":[0.9940342,0.003719901,0.0011078375,0.00036710725,0.0005641895,0.00020682262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007184417,0.0003782874,0.0024731415,0.0003963435,0.00007039379,0.000020146214,0.00017815978,0.00018451856,0.00007806328],"category_scores_gemma":[0.0013562476,0.00021102,0.00015639393,0.00063559035,0.0015936667,0.00010187431,0.00006964758,0.00077222695,0.000024404828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48469844,0.0015333154,0.5091861,0.000020348758,0.0007176731,0.0015437698,0.00046244985,0.000018757371,0.000058013,0.0000103431885,0.00007982834,0.0016709911],"study_design_scores_gemma":[0.45978618,0.025535023,0.51300496,0.00007577308,0.00044127973,0.00002892322,0.00011206299,0.00011594014,0.000032681728,0.000015717927,0.00070471334,0.00014676791],"about_ca_topic_score_codex":0.00038454344,"about_ca_topic_score_gemma":0.005813152,"teacher_disagreement_score":0.024912255,"about_ca_system_score_codex":0.00036077594,"about_ca_system_score_gemma":0.0015286652,"threshold_uncertainty_score":0.8605146},"labels":[],"label_agreement":null},{"id":"W2902972217","doi":"10.1016/j.urolonc.2018.11.013","title":"Role of serum cholinesterase in patients treated with salvage radical prostatectomy","year":2018,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Interquartile range; Biochemical recurrence; Hazard ratio; Prostate cancer; Internal medicine; Urology; Gastroenterology; Metastasis; Confidence interval; Body mass index; Surgery; Cancer","score_opus":0.016989031232288045,"score_gpt":0.30934868894041084,"score_spread":0.2923596577081228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902972217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584466,0.00028479076,0.0000014767203,0.0012362029,0.000020067253,0.0005824684,0.000031933392,0.000026508862,0.001971917],"genre_scores_gemma":[0.994326,0.000111663125,0.0046001812,0.0004061515,0.000052934014,0.00006688526,0.00007334863,0.000010705078,0.00035213298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990208,0.00007758714,0.0002250518,0.00026159652,0.00014354865,0.0002713911],"domain_scores_gemma":[0.99939394,0.00007012586,0.00008332625,0.00013715676,0.00012203704,0.00019343592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014114074,0.00013688765,0.00029558106,0.00018785751,0.000087044384,0.0000072236885,0.000054057415,0.00014019718,0.00007378062],"category_scores_gemma":[0.000054422562,0.00008927163,0.000021851196,0.00037416132,0.0013118518,0.00007738671,0.000028868342,0.00022040718,0.000008482341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009612878,0.00045941846,0.99410945,0.000024561507,0.00003502576,0.00006366877,0.00033867397,0.0000012775997,0.0006107646,0.0002718593,0.00015903622,0.002964994],"study_design_scores_gemma":[0.008581261,0.016426042,0.875183,0.00013938245,0.0001448538,0.000085257234,0.00015482168,0.00025957584,0.007689581,0.0009698249,0.090204164,0.00016226796],"about_ca_topic_score_codex":0.000052946165,"about_ca_topic_score_gemma":0.000038333106,"teacher_disagreement_score":0.118926466,"about_ca_system_score_codex":0.00009387088,"about_ca_system_score_gemma":0.00028472216,"threshold_uncertainty_score":0.48335725},"labels":[],"label_agreement":null},{"id":"W2903023839","doi":"10.1016/j.euo.2018.11.006","title":"Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials","year":2018,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute","keywords":"Medicine; Cabozantinib; Docetaxel; Prostate cancer; Oncology; Abiraterone acetate; Internal medicine; Enzalutamide; Hazard ratio; Mitoxantrone; Prednisone; Cancer; Urology; Confidence interval; Chemotherapy; Androgen receptor; Androgen deprivation therapy","score_opus":0.11050460092748174,"score_gpt":0.4826046893328425,"score_spread":0.3721000884053608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903023839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877755,0.0021799644,0.00045964585,0.002589737,0.00054461136,0.0028096433,0.0003989523,0.00006659028,0.0031753627],"genre_scores_gemma":[0.99506754,0.00008057761,0.0021074007,0.00055199454,0.0002796631,0.00033587616,0.00041424282,0.000050027025,0.0011126924],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99618185,0.0014581817,0.0010249439,0.000533112,0.00023403237,0.0005679098],"domain_scores_gemma":[0.99744016,0.0007817524,0.0006838751,0.00035531112,0.00054805056,0.00019085086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027319342,0.00025350295,0.0016187766,0.00057617674,0.0001811773,0.000016519458,0.00016820716,0.000066493434,0.00041729287],"category_scores_gemma":[0.00078614237,0.00018456028,0.0005332331,0.0008070131,0.0006066664,0.00006800263,0.00006339322,0.00019023487,0.000020275438],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1998396,0.012682442,0.039308578,0.00070572423,0.115658626,0.009585946,0.015149163,0.00025404565,0.46102983,0.0041520963,0.013076727,0.12855724],"study_design_scores_gemma":[0.42914695,0.16160312,0.047859628,0.0002524474,0.13958456,0.00020839386,0.0016532728,0.01136437,0.06912811,0.0010327084,0.13651769,0.0016487536],"about_ca_topic_score_codex":0.00006344024,"about_ca_topic_score_gemma":0.00018121388,"teacher_disagreement_score":0.3919017,"about_ca_system_score_codex":0.00010676172,"about_ca_system_score_gemma":0.00069589796,"threshold_uncertainty_score":0.752615},"labels":[],"label_agreement":null},{"id":"W2903241832","doi":"10.1016/j.eururo.2018.11.033","title":"Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint","year":2018,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Mitoxantrone; Cabozantinib; Prostate cancer; Clinical endpoint; Prednisone; Enzalutamide; Oncology; Randomized controlled trial; Internal medicine; Cancer; Anesthesia; Surgery; Chemotherapy","score_opus":0.030470491173510597,"score_gpt":0.3315535634413619,"score_spread":0.3010830722678513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903241832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853759,0.001520944,0.00021902325,0.0028715278,0.00035857302,0.00424635,0.000059110724,0.000098679266,0.0052499054],"genre_scores_gemma":[0.9964858,0.00029529745,0.00081233744,0.0004907088,0.00038927657,0.00043444848,0.00016209441,0.000071733026,0.0008582495],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953036,0.002501067,0.0006710032,0.00052149105,0.0003666197,0.00063623925],"domain_scores_gemma":[0.9982566,0.0007821307,0.00023139676,0.00038282492,0.00014690019,0.0002000948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025225715,0.0003049091,0.00095850416,0.0002803045,0.000111575544,0.000038453323,0.00013825267,0.000040622417,0.0002760426],"category_scores_gemma":[0.0004952807,0.00020271359,0.00012017322,0.0003519559,0.00070659444,0.000088444285,0.0000557205,0.00029278998,0.000075082346],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98405266,0.0008340876,0.00014345066,0.00012705076,0.000595421,0.001801385,0.0016209998,0.000006897294,0.0043231524,0.00005708259,0.00042114806,0.0060166703],"study_design_scores_gemma":[0.978439,0.015582904,0.0009045389,0.0000995421,0.00055952085,0.00004179314,0.00015846595,0.0008930241,0.0004885916,0.000022470253,0.0025916642,0.00021853147],"about_ca_topic_score_codex":0.00016337773,"about_ca_topic_score_gemma":0.00027707958,"teacher_disagreement_score":0.014748816,"about_ca_system_score_codex":0.00014964583,"about_ca_system_score_gemma":0.0006120424,"threshold_uncertainty_score":0.82664204},"labels":[],"label_agreement":null},{"id":"W2903289577","doi":"10.3389/fphar.2018.01419","title":"Structural Based Screening of Antiandrogen Targeting Activation Function-2 Binding Site","year":2018,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China; McGill University","keywords":"Antiandrogens; Antiandrogen; Pharmacophore; Androgen receptor; Prostate cancer; Binding site; Small molecule; Pharmacology; Chemistry; Medicine; Cancer research; Biology; Cancer; Stereochemistry; Internal medicine; Biochemistry","score_opus":0.024651693275117632,"score_gpt":0.3327872264177695,"score_spread":0.30813553314265185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903289577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905641,0.00036899548,0.0069758366,0.00039457876,0.0010384668,0.00031571282,0.000010512507,0.0000235794,0.0003081801],"genre_scores_gemma":[0.99174064,0.000026120932,0.007417376,0.00020688488,0.00029935132,0.000014458817,0.00011384194,0.000013056553,0.00016823754],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991839,0.00006286879,0.0001832317,0.00017977381,0.00013535212,0.0002548818],"domain_scores_gemma":[0.9996691,0.00003137092,0.00007890068,0.000061718005,0.00009921494,0.000059740403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017554383,0.00008762813,0.0002019824,0.00032988435,0.00008065711,0.0000041386247,0.00004851009,0.00007029559,0.0004225508],"category_scores_gemma":[0.000022817585,0.000075661424,0.000042381962,0.00033789297,0.00015623208,0.00009125622,0.000022970728,0.00015447567,0.0000052317896],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002329769,0.00003394028,0.6121091,0.000057537516,0.00013888226,0.000015165477,0.00017987033,0.000045085122,0.35704398,0.0000013412279,0.020412784,0.007632536],"study_design_scores_gemma":[0.010007707,0.00086308,0.06626095,0.00010036421,0.00016952262,0.00000480784,0.00031285206,0.05972426,0.8563934,0.000042888267,0.0059536416,0.00016654836],"about_ca_topic_score_codex":0.00002399611,"about_ca_topic_score_gemma":0.0000010395873,"teacher_disagreement_score":0.5458482,"about_ca_system_score_codex":0.00010460376,"about_ca_system_score_gemma":0.000093417875,"threshold_uncertainty_score":0.4626635},"labels":[],"label_agreement":null},{"id":"W2904143564","doi":"10.1002/cncr.31847","title":"Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration‐naive prostate cancer: Results from LATITUDE","year":2018,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Poisson regression; Prednisone; Abiraterone acetate; Internal medicine; Radiation therapy; Urology; Cancer; Population","score_opus":0.0805149206852465,"score_gpt":0.3812453842136295,"score_spread":0.300730463528383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904143564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99079967,0.0028376787,0.00028286403,0.003659104,0.000122055935,0.001532197,0.0004834818,0.00003631685,0.00024666052],"genre_scores_gemma":[0.99325526,0.0036514504,0.00071057584,0.0004361819,0.00022472111,0.0004102969,0.00045457145,0.000032581887,0.00082434877],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99794406,0.00011392235,0.00052979693,0.00043835695,0.0006497926,0.00032408442],"domain_scores_gemma":[0.9988891,0.00007827565,0.00016892573,0.00030222142,0.00034335998,0.000218144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033281252,0.00018426012,0.0003923716,0.00017962843,0.00007090089,0.00002027156,0.00012794568,0.00009044033,0.00048410855],"category_scores_gemma":[0.00015584112,0.00014368781,0.00004081878,0.0006007397,0.00017732104,0.00013183981,0.00004502901,0.00014949996,0.000014487334],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074513316,0.0011645756,0.19899592,0.00047206134,0.0018978922,0.00031111392,0.08435138,0.0037438683,0.14522278,0.00012664075,0.011356116,0.47784433],"study_design_scores_gemma":[0.058353428,0.0030314957,0.2961942,0.002546784,0.00025329378,0.0000109485445,0.0012692978,0.011857488,0.61064947,0.0004289794,0.014777809,0.00062682264],"about_ca_topic_score_codex":0.0036104156,"about_ca_topic_score_gemma":0.0040719323,"teacher_disagreement_score":0.4772175,"about_ca_system_score_codex":0.00042802715,"about_ca_system_score_gemma":0.000993156,"threshold_uncertainty_score":0.58594185},"labels":[],"label_agreement":null},{"id":"W2904355372","doi":"10.1016/j.ccell.2018.10.016","title":"Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories","year":2018,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":326,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; European Research Council; National Institutes of Health; H2020 European Research Council; Norges Forskningsråd; Deutsches Krebsforschungszentrum; Bundesministerium für Bildung und Forschung; Arvid Nilssons Fond","keywords":"Prostate cancer; Biology; Cancer research; Cancer; Computational biology; Genetics","score_opus":0.01616366991266653,"score_gpt":0.3444936481677012,"score_spread":0.3283299782550347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904355372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.965902,0.0314471,0.000073110816,0.00020956378,0.00042717342,0.0006240409,0.00015643411,0.000031414624,0.0011291981],"genre_scores_gemma":[0.9841273,0.013854797,0.000113350834,0.000052906384,0.00015101707,0.00011010963,0.000014128076,0.000032456574,0.0015439424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984646,0.000120321616,0.000344712,0.00040219567,0.00032750648,0.00034070245],"domain_scores_gemma":[0.9989609,0.000048537535,0.00015995013,0.0002976627,0.0003379532,0.00019500515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028741325,0.00017999197,0.00034789127,0.00007157781,0.00009008415,0.000022677768,0.000086217755,0.000117875636,0.00023129274],"category_scores_gemma":[0.000045265988,0.00014614909,0.00012609868,0.00022219335,0.0007511359,0.00010416242,0.000062057494,0.00020453069,0.000008804844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024176438,0.00013920073,0.9581848,0.0003349058,0.0004270019,0.00005913616,0.0007490149,0.00000450658,0.029130938,0.000016408712,0.0015401264,0.0069963285],"study_design_scores_gemma":[0.0050971815,0.0017944246,0.6501629,0.00037655619,0.00079488516,0.0000053438343,0.0006214102,0.0001744859,0.33856148,0.00036348353,0.0017435226,0.00030436853],"about_ca_topic_score_codex":0.0055235666,"about_ca_topic_score_gemma":0.00038242113,"teacher_disagreement_score":0.30943054,"about_ca_system_score_codex":0.0002892195,"about_ca_system_score_gemma":0.0005205625,"threshold_uncertainty_score":0.8350017},"labels":[],"label_agreement":null},{"id":"W2904732687","doi":"10.1055/a-0774-8809","title":"The Effect of Vitamin D Supplementation on Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials","year":2018,"lang":"en","type":"review","venue":"Hormone and Metabolic Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact; St. Michael's Hospital; University of Guelph","funders":"Shahid Sadoughi University of Medical Sciences","keywords":"Meta-analysis; Medicine; Prostate cancer; Internal medicine; Oncology; Clinical trial; Cancer; Prostate; Endocrinology; Urology","score_opus":0.4528327523233298,"score_gpt":0.6194372510993205,"score_spread":0.16660449877599065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904732687","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016561103,0.98452425,3.8034895e-7,0.00036776817,0.000021712005,0.014207067,0.0005972492,0.0000052896767,0.000110681016],"genre_scores_gemma":[0.00010228879,0.991642,0.000011237397,0.000020081015,0.00007104151,0.004972858,0.00019437989,0.00003262523,0.002953471],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97998637,0.01417607,0.0033731402,0.00060382637,0.0013994917,0.00046110505],"domain_scores_gemma":[0.985414,0.011415934,0.0013877451,0.0009110477,0.00061560696,0.00025564307],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.06058558,0.0003979918,0.018108081,0.00082843786,0.00016959755,0.000048113525,0.00023801028,0.00019637171,0.00008126779],"category_scores_gemma":[0.005685784,0.00015192323,0.0027703326,0.0019537644,0.00069421215,0.0000460146,0.00016477755,0.00063090783,0.0000062135027],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000544143,0.00006971695,0.000018351624,0.6420137,0.26300406,0.000006370595,0.00005320692,9.608376e-9,0.0000022237273,0.000049511193,0.0023068595,0.09193182],"study_design_scores_gemma":[0.001347784,0.0023002264,0.000039410832,0.019043213,0.88670063,0.000004437262,0.000026377393,0.00000286003,0.000056830642,0.0000038097564,0.090363026,0.00011139228],"about_ca_topic_score_codex":0.00021047382,"about_ca_topic_score_gemma":0.000018163875,"teacher_disagreement_score":0.62369657,"about_ca_system_score_codex":0.000039891573,"about_ca_system_score_gemma":0.0004959438,"threshold_uncertainty_score":0.99646914},"labels":[],"label_agreement":null},{"id":"W2904923544","doi":"10.1007/s12672-018-0353-6","title":"A Targeted Bivalent Androgen Receptor Binding Compound for Prostate Cancer Therapy","year":2018,"lang":"en","type":"article","venue":"Hormones and Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; McGill University; Montreal Neurological Institute and Hospital; Jewish General Hospital","funders":"Prostate Cancer Canada; Jewish General Hospital; Movember Foundation","keywords":"Bivalent (engine); Prostate cancer; Androgen receptor; Prostate; Oncology; Computational biology; Medicine; Internal medicine; Biology; Cancer; Chemistry","score_opus":0.04501632806562778,"score_gpt":0.349986072406982,"score_spread":0.3049697443413542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904923544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9241698,0.07076379,0.0000120630775,0.002946113,0.00029087852,0.0012232669,0.00031883531,0.00004501079,0.00023024698],"genre_scores_gemma":[0.86789995,0.119992085,0.0002780063,0.00046662323,0.0009903171,0.0014458665,0.00011856056,0.000052722222,0.008755887],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989685,0.000014470403,0.00015001364,0.00030458078,0.00018152657,0.00038089883],"domain_scores_gemma":[0.9994317,0.000022153206,0.00005424278,0.00013015067,0.00019978636,0.0001619602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010096934,0.00016400014,0.00024940277,0.000078371624,0.00023572834,0.000040502706,0.000049390906,0.00006285117,0.00040987734],"category_scores_gemma":[0.0000047740527,0.00010935202,0.00006520259,0.00017137206,0.00017747359,0.00007192413,0.000025471576,0.00007597608,0.000012339338],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009908177,0.00025666994,0.10515403,0.00034165455,0.0009113828,0.000017214757,0.003357832,0.0000010056822,0.34067747,0.000057137444,0.06392367,0.47539374],"study_design_scores_gemma":[0.010587797,0.0023413831,0.016820082,0.00028586085,0.00012675016,0.000011499273,0.00044983826,0.00028369515,0.18695058,0.000091541326,0.7816912,0.0003597614],"about_ca_topic_score_codex":0.00042822273,"about_ca_topic_score_gemma":0.00006507708,"teacher_disagreement_score":0.71776754,"about_ca_system_score_codex":0.00013493336,"about_ca_system_score_gemma":0.00019039324,"threshold_uncertainty_score":0.44878694},"labels":[],"label_agreement":null},{"id":"W2905069104","doi":"10.1016/j.euf.2018.11.011","title":"The Biology of Oligometastatic Prostate Cancer: A Different Beast than Polymetastatic Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Natural history; Oncology; Disease; Internal medicine; Population; Prostate; Cancer","score_opus":0.02161814020336634,"score_gpt":0.3150037288138915,"score_spread":0.29338558861052516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905069104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9553436,0.026569543,0.000029992398,0.012296583,0.00059633754,0.0012652325,0.0002938144,0.00008489328,0.003519981],"genre_scores_gemma":[0.98768014,0.0064590108,0.00004995779,0.00032736364,0.0003098727,0.00020990781,0.00004010953,0.00008338974,0.004840228],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99701285,0.0007002818,0.0005587703,0.0005397655,0.00027178696,0.00091654214],"domain_scores_gemma":[0.99836135,0.00021673809,0.0002925995,0.0005848503,0.00029239623,0.0002520446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051616086,0.00034822925,0.0005642678,0.00020541398,0.00033019602,0.000028033375,0.0003333023,0.0000534167,0.00023551591],"category_scores_gemma":[0.00010293785,0.00019267117,0.00015230937,0.0003971117,0.0017543641,0.00005256856,0.00022407254,0.0003598879,0.00012171481],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01190084,0.0009722083,0.4239984,0.00041198888,0.0035076384,0.00049750373,0.008947258,0.000009662713,0.06505767,0.0018213507,0.0045785145,0.478297],"study_design_scores_gemma":[0.027433207,0.024370521,0.6736524,0.00051810883,0.0027320099,0.0003561322,0.0011559998,0.00063855626,0.10207368,0.003770067,0.16188309,0.0014162478],"about_ca_topic_score_codex":0.0004443944,"about_ca_topic_score_gemma":0.00039241798,"teacher_disagreement_score":0.47688076,"about_ca_system_score_codex":0.00009648421,"about_ca_system_score_gemma":0.00028171486,"threshold_uncertainty_score":0.78569025},"labels":[],"label_agreement":null},{"id":"W2905455877","doi":"10.1051/medsci/2018224","title":"Comment limiter la progression des tumeurs prostatiques déficientes en PTEN ?","year":2018,"lang":"fr","type":"article","venue":"médecine/sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"PTEN; Chemistry","score_opus":0.059258789921632346,"score_gpt":0.41575264936183776,"score_spread":0.3564938594402054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905455877","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25907433,0.6577455,0.00030959107,0.04586564,0.0015322918,0.0021461942,0.000058098412,0.00018675378,0.03308164],"genre_scores_gemma":[0.69282585,0.2602292,0.01939828,0.002925694,0.003418319,0.0005162256,0.000057481353,0.0001241836,0.02050477],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962362,0.00058293884,0.00043256916,0.00071410567,0.00088024844,0.0011539488],"domain_scores_gemma":[0.9982581,0.0007716513,0.0001324106,0.00027968633,0.00022272124,0.00033540343],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0021932216,0.00037092812,0.00046596164,0.0003247893,0.0009566203,0.00030142665,0.0004574669,0.00017300592,0.00062708167],"category_scores_gemma":[0.000283116,0.00023354929,0.00013736311,0.0010760356,0.007171538,0.00042264987,0.00028636717,0.0003082984,0.00035056993],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028921358,0.0017917855,0.21215418,0.0008149288,0.0001282999,0.00017001804,0.006419762,0.000002467238,0.0005386648,0.00900946,0.011504361,0.7571769],"study_design_scores_gemma":[0.0041190847,0.013835181,0.033857398,0.011115937,0.00029246882,0.0002224044,0.003865617,0.002456822,0.017766157,0.0043634125,0.90743136,0.0006741369],"about_ca_topic_score_codex":0.00012912326,"about_ca_topic_score_gemma":0.000022587115,"teacher_disagreement_score":0.895927,"about_ca_system_score_codex":0.00023575535,"about_ca_system_score_gemma":0.00053851097,"threshold_uncertainty_score":0.99553037},"labels":[],"label_agreement":null},{"id":"W2905771584","doi":"10.1016/j.jval.2018.09.428","title":"PCN346 - DISEASE SPECIFIC COST ANALYSIS OF THE NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER HEALTH STATES","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Prostate cancer; Medicine; Disease; Oncology; Cancer; Radiation therapy; Prostate; Internal medicine; Cohort; Medical prescription; Metastasis; Castration; Pharmacology","score_opus":0.08198804906189198,"score_gpt":0.38275112796108274,"score_spread":0.30076307889919074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905771584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94309825,0.025644965,0.000026817534,0.02270466,0.00024389608,0.0047547515,0.0034607775,0.000032487667,0.0000333991],"genre_scores_gemma":[0.97574717,0.020995347,0.00063018105,0.000692124,0.0000862067,0.0006266352,0.0003166514,0.00005329196,0.0008523976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99547505,0.0005740978,0.0013236135,0.00073667814,0.0009454709,0.0009450655],"domain_scores_gemma":[0.99734384,0.0002416704,0.00069668284,0.00063365995,0.00037956904,0.00070455036],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012917501,0.00038399053,0.0010259011,0.000599143,0.0004559397,0.00008273286,0.00016698494,0.00003930387,0.00018125636],"category_scores_gemma":[0.00007618637,0.00025889018,0.00017106751,0.0024152908,0.00063911104,0.00018343778,0.00006572415,0.00032733087,0.0000042389383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020133642,0.0035589663,0.76731116,0.017185777,0.007265909,0.0004181986,0.061194833,0.044903636,0.009780043,0.0024225055,0.0064954325,0.059329897],"study_design_scores_gemma":[0.007155513,0.0020927002,0.95207816,0.002702181,0.0012795322,0.000008596903,0.0034377477,0.024158603,0.0011541228,0.0006621784,0.004760194,0.0005104691],"about_ca_topic_score_codex":0.042752568,"about_ca_topic_score_gemma":0.017045392,"teacher_disagreement_score":0.18476701,"about_ca_system_score_codex":0.0012301226,"about_ca_system_score_gemma":0.0047899187,"threshold_uncertainty_score":0.99998635},"labels":[],"label_agreement":null},{"id":"W2905845365","doi":"10.1016/j.eururo.2018.12.015","title":"Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial","year":2018,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Abbotsford Veterinary Clinic; Fraser Health; BC Cancer Agency","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Prednisone; Abiraterone; Randomized controlled trial; Quality of life (healthcare); Oncology; Internal medicine; Abiraterone acetate; Androgen deprivation therapy; Urology; Cancer; Androgen receptor; Nursing","score_opus":0.07043159014875042,"score_gpt":0.3704435745394552,"score_spread":0.30001198439070476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905845365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892812,0.0006777603,0.000053897453,0.0022552959,0.00036808767,0.0054836837,0.001575006,0.0000355288,0.00026959047],"genre_scores_gemma":[0.9973588,0.00007453486,0.0004429901,0.00017045262,0.000120416276,0.00019802661,0.0012887677,0.000043384982,0.00030263053],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956998,0.0016418964,0.001409595,0.0004954408,0.00031227325,0.00044097615],"domain_scores_gemma":[0.9976885,0.0007510814,0.00070601335,0.00033992605,0.00031194984,0.00020255528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001951731,0.00022289976,0.0012331101,0.00015499924,0.00012401954,0.000011017023,0.00010676434,0.00004482401,0.00006143992],"category_scores_gemma":[0.0011244939,0.00015376882,0.00009790566,0.00022087047,0.00049172953,0.00006775144,0.000049074864,0.00018288592,0.000008537301],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9919632,0.0012103994,0.00018732795,0.000065229964,0.00065285154,0.00001885157,0.0034641847,0.000033998273,0.00043680877,0.000029563054,0.00023240139,0.0017051661],"study_design_scores_gemma":[0.9558589,0.03808064,0.0049423403,0.00005789827,0.00020054939,2.967517e-7,0.00005802194,0.00023539821,0.00017062965,0.000040221534,0.00023234017,0.00012276795],"about_ca_topic_score_codex":0.0025445616,"about_ca_topic_score_gemma":0.000933298,"teacher_disagreement_score":0.03687024,"about_ca_system_score_codex":0.00017876722,"about_ca_system_score_gemma":0.0008143166,"threshold_uncertainty_score":0.62705106},"labels":[],"label_agreement":null},{"id":"W2906285891","doi":"10.23736/s0393-2249.18.03295-2","title":"Biological bases of radical prostatectomy in the management of prostate cancer patients with oligometastatic disease","year":2018,"lang":"en","type":"editorial","venue":"Minerva Urologica e Nefrologica","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Urology; Management of prostate cancer; Disease; Oncology; General surgery; Internal medicine; Cancer","score_opus":0.019730439347039257,"score_gpt":0.2981216629365001,"score_spread":0.27839122358946083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906285891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9682835,0.004273995,0.0000022996405,0.0011351146,0.018021774,0.005450772,0.0019098308,0.00006369689,0.00085903966],"genre_scores_gemma":[0.95133764,0.010456343,0.0011441286,0.00047653366,0.02867343,0.003401059,0.00361036,0.00009229712,0.00080819585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949639,0.0004952486,0.000953362,0.001052384,0.0016575651,0.0008775646],"domain_scores_gemma":[0.99690264,0.0007988068,0.0006342779,0.00080127735,0.00062020274,0.00024281818],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00080125785,0.0006739114,0.0014105816,0.0003158013,0.000094021845,0.00002332805,0.0007382649,0.00054195244,0.00038487327],"category_scores_gemma":[0.0003490936,0.00029189247,0.000259794,0.0008928466,0.0018013269,0.000063290725,0.0002937994,0.0009138838,0.00001313397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.082178086,0.01184987,0.48093373,0.0053493874,0.0023601032,0.0027092504,0.0006201741,0.000041686104,0.00011334694,0.000070213144,0.4080896,0.005684541],"study_design_scores_gemma":[0.022769101,0.031533606,0.64715433,0.0020080141,0.0022231275,0.000006124069,0.00020465384,0.00004258069,0.00012817672,0.000576842,0.29243147,0.00092194893],"about_ca_topic_score_codex":0.00007567699,"about_ca_topic_score_gemma":0.000009702152,"teacher_disagreement_score":0.16622064,"about_ca_system_score_codex":0.00012017582,"about_ca_system_score_gemma":0.00037915332,"threshold_uncertainty_score":0.9999533},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"editorial","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"editorial","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2906439904","doi":"10.1016/j.jval.2018.09.330","title":"PCN248 - USE OF CANCER DRUGS IN THE END-OF-LIFE IN MEN DYING OF CASTRATION-RESISTANT PROSTATE CANCER: POPULATION-BASED STUDY","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Prostate cancer; Abiraterone acetate; Internal medicine; Cancer; Oncology; Abiraterone; Cohort; Odds ratio; Confidence interval; Population; Drug; Enzalutamide; Androgen deprivation therapy; Pharmacology; Androgen receptor","score_opus":0.12536312144343623,"score_gpt":0.421221625974369,"score_spread":0.29585850453093276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906439904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939376,0.0014776734,7.381849e-7,0.0022703372,0.000055251978,0.0021518304,0.00007250576,0.000004270179,0.000029808984],"genre_scores_gemma":[0.9991156,0.0003945101,0.000108153814,0.000086895154,0.000033826273,0.00019487084,0.000021969196,0.000012173048,0.00003198899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979089,0.0003743782,0.00077555224,0.00019755424,0.00047079142,0.0002728269],"domain_scores_gemma":[0.99902,0.00027476784,0.00027718203,0.00024064207,0.00012512442,0.0000623086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011039122,0.00010340207,0.00040206502,0.0003093276,0.000038083148,0.0000057370685,0.00008548923,0.00003572495,0.00003403115],"category_scores_gemma":[0.00009135108,0.00007104844,0.000027879298,0.000723172,0.000084037085,0.000066400156,0.000014477504,0.00015722371,2.7088154e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012519559,0.00054268114,0.97475857,0.0006414424,0.00002203706,0.0000053193944,0.017045777,0.003385542,0.00046033473,0.000035654622,0.00002218258,0.0018285356],"study_design_scores_gemma":[0.0043111197,0.00093119737,0.98548913,0.0010692776,0.000012786944,1.3109661e-7,0.0031830505,0.0040282602,0.00086025865,0.000033464556,0.000024549392,0.00005674509],"about_ca_topic_score_codex":0.5436225,"about_ca_topic_score_gemma":0.054418184,"teacher_disagreement_score":0.48920432,"about_ca_system_score_codex":0.0005482729,"about_ca_system_score_gemma":0.0023124153,"threshold_uncertainty_score":0.9628362},"labels":[],"label_agreement":null},{"id":"W2906445288","doi":"10.1200/jco.18.01279","title":"Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel","year":2018,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; BC Cancer Agency","funders":"National Cancer Institute; U.S. Army; Regeneron Pharmaceuticals; Janssen Pharmaceuticals; AstraZeneca; Celgene; Sanofi; Duke Clinical Research Institute; Bristol-Myers Squibb","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Docetaxel; Oncology; Proportional hazards model; Regimen; Clinical endpoint; Gynecology; Cancer; Urology; Confidence interval; Clinical trial","score_opus":0.22113449729156442,"score_gpt":0.5174372183398704,"score_spread":0.296302721048306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906445288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025044508,0.9690404,0.000006485021,0.001020422,0.0001572543,0.001610401,0.00013116394,0.000008040705,0.002981356],"genre_scores_gemma":[0.0019036958,0.9931407,0.001045386,0.000048670365,0.00044783918,0.000030844523,0.00003148886,0.00005134799,0.0033000237],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99521416,0.0007507922,0.0026717575,0.00034997895,0.00067182205,0.00034150004],"domain_scores_gemma":[0.99319434,0.0012106334,0.003715631,0.0002487236,0.0011558733,0.0004748013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021222695,0.00038323345,0.005482224,0.00023133686,0.000040407005,0.000020272186,0.00015185105,0.00031396703,0.00013114286],"category_scores_gemma":[0.0002831446,0.000174145,0.00044618256,0.0002812551,0.0010220249,0.00011436742,0.000041113628,0.0010300954,0.0000039793704],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07814853,0.0042314767,0.029714856,0.031987604,0.028966384,0.008131862,0.0005630743,0.000009948968,0.000010322209,0.000058632577,0.0076684016,0.8105089],"study_design_scores_gemma":[0.034345906,0.08502337,0.015058642,0.027758967,0.023108026,0.0011888063,0.00021727751,0.000019027277,0.000008223707,0.000053064276,0.8127562,0.00046251583],"about_ca_topic_score_codex":0.00009048683,"about_ca_topic_score_gemma":0.00024167664,"teacher_disagreement_score":0.8100464,"about_ca_system_score_codex":0.00028342148,"about_ca_system_score_gemma":0.008388137,"threshold_uncertainty_score":0.9972334},"labels":[],"label_agreement":null},{"id":"W2906643453","doi":"10.1093/carcin/bgy185","title":"Modeling human prostate cancer progression in vitro","year":2018,"lang":"en","type":"review","venue":"Carcinogenesis","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health","keywords":"Prostate cancer; Cancer; In vitro; Cancer research; Prostate; Medicine; Oncology; Biology; Internal medicine; Biochemistry","score_opus":0.1317703545454383,"score_gpt":0.4480347463045131,"score_spread":0.31626439175907484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906643453","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050374274,0.9915813,0.0000013005058,0.00005214829,0.00017655827,0.0026300012,0.00009653636,0.000066803426,0.00035791163],"genre_scores_gemma":[0.0016508248,0.9931467,0.00009540873,0.00002139823,0.0005552869,0.0019130172,0.0005691751,0.00013893706,0.0019092469],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973661,0.0001308489,0.00061501027,0.00075995136,0.00045587047,0.00067224057],"domain_scores_gemma":[0.99886245,0.000023486959,0.00013010364,0.0005526412,0.00018806399,0.0002432368],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002804813,0.0005022507,0.0017372599,0.00054336275,0.00014034336,0.00003482019,0.00020219489,0.00035902776,0.00008978716],"category_scores_gemma":[0.000020090443,0.00033432178,0.00045721958,0.00062480505,0.00011427547,0.000057114048,0.00014578593,0.00038385924,0.00006185417],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017766579,0.00013393314,0.00046736462,0.027131464,0.00020816918,0.00027499397,0.00015355948,0.0000019612005,0.0003054199,0.0000015825575,0.0002055561,0.9709383],"study_design_scores_gemma":[0.0037408918,0.0005372622,0.00008015245,0.09955145,0.0035339983,0.00010872619,0.00007244408,0.0006705583,0.0031601,0.00003116029,0.8872203,0.0012929589],"about_ca_topic_score_codex":0.00023873714,"about_ca_topic_score_gemma":0.000028367336,"teacher_disagreement_score":0.9696454,"about_ca_system_score_codex":0.0008989564,"about_ca_system_score_gemma":0.0010695484,"threshold_uncertainty_score":0.9999109},"labels":[],"label_agreement":null},{"id":"W2906649083","doi":"","title":"Abstract 18939: Risk of Cardiovascular Events Amongst Patients Receiving Androgen Deprivation Therapy for Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Circulation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Internal medicine; Oncology; Cancer; Gynecology","score_opus":0.03600502626604229,"score_gpt":0.3215435317726073,"score_spread":0.285538505506565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906649083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962998,0.0013432646,0.00019016977,0.00007759988,0.0001444272,0.001694699,0.000059940183,0.000016507893,0.00017358683],"genre_scores_gemma":[0.9971716,0.0021944381,0.00007662423,0.0000062165514,0.000092875176,0.00019375558,0.00020725952,0.000021647224,0.000035630816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990879,0.000022038772,0.00019659782,0.00021832078,0.00031651813,0.00015862232],"domain_scores_gemma":[0.9988869,0.000024483124,0.00025823803,0.0004203689,0.00035484773,0.000055150274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002920633,0.000098155026,0.00021543055,0.00006278657,0.00026389447,0.000022783332,0.000073287796,0.00006707903,0.000013390313],"category_scores_gemma":[0.00014775751,0.000079512356,0.00019189875,0.000047413083,0.00004072432,0.00020835329,0.0000156883,0.0000676225,0.0000023976233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002759041,0.00008384034,0.8180798,0.000089555295,0.00049456477,6.222621e-7,0.00017244152,0.00027354035,0.0010944726,0.0000018692523,0.000018727544,0.17941466],"study_design_scores_gemma":[0.004945379,0.00006836949,0.98617953,0.00013401393,0.00014495577,2.7115797e-7,0.000010921174,0.00045019411,0.0073825726,0.0001875342,0.00041955517,0.00007667377],"about_ca_topic_score_codex":0.0004809931,"about_ca_topic_score_gemma":0.000014146775,"teacher_disagreement_score":0.179338,"about_ca_system_score_codex":0.000135401,"about_ca_system_score_gemma":0.00008210551,"threshold_uncertainty_score":0.32424197},"labels":[],"label_agreement":null},{"id":"W2907554925","doi":"10.4143/crt.2018.532","title":"Inherited NBN Mutations and Prostate Cancer Risk and Survival","year":2018,"lang":"en","type":"article","venue":"Cancer Research and Treatment","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Narodowym Centrum Nauki","keywords":"Medicine; Prostate cancer; Mutation; Oncology; Prostate; Cancer; Internal medicine; Bioinformatics; Genetics; Cancer research; Gene","score_opus":0.10169603995975803,"score_gpt":0.4436526378655186,"score_spread":0.3419565979057606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907554925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.967013,0.027199034,0.00000222803,0.0033062703,0.00007235931,0.0011597255,0.00027115564,0.00003437897,0.0009418243],"genre_scores_gemma":[0.8892687,0.102360785,0.00008736614,0.000030021067,0.00025814984,0.0009117878,0.000042222448,0.00002654671,0.007014428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983176,0.00011509983,0.00014685263,0.0004916283,0.00036262404,0.00056621863],"domain_scores_gemma":[0.9987656,0.00013768929,0.000032580698,0.00019595686,0.00037286416,0.000495294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025912898,0.00018851893,0.00027651724,0.00020333898,0.000583614,0.00009743548,0.00003556797,0.00006729886,0.00017894068],"category_scores_gemma":[0.00003864369,0.00012517201,0.000025672403,0.0003451775,0.0011972402,0.00009849528,0.000082547995,0.0002057048,0.0000105780555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025190685,0.00033951254,0.69252026,0.00012484862,0.0006378105,0.00013935493,0.0034679368,3.766186e-7,0.0022932491,0.00013719384,0.000700034,0.29712033],"study_design_scores_gemma":[0.025058853,0.013069571,0.8712753,0.0005515259,0.00042139215,0.00007096606,0.00257644,0.00039683437,0.018803772,0.002066157,0.06522518,0.00048401457],"about_ca_topic_score_codex":0.008648324,"about_ca_topic_score_gemma":0.00318002,"teacher_disagreement_score":0.2966363,"about_ca_system_score_codex":0.00035698654,"about_ca_system_score_gemma":0.00041993728,"threshold_uncertainty_score":0.9979532},"labels":[],"label_agreement":null},{"id":"W2907732987","doi":"10.1186/s12885-018-5203-y","title":"Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program","year":2019,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Cilag; Ipsen; Astellas Pharma; Public Health Agency; Sanofi; Amgen; Pfizer; Active Biotech; Bristol-Myers Squibb","keywords":"Medicine; Asymptomatic; Prostate cancer; Internal medicine; Hazard ratio; Adverse effect; Prostate-specific antigen; Surgery; Cancer; Confidence interval","score_opus":0.029792846454491664,"score_gpt":0.36508603557818087,"score_spread":0.3352931891236892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907732987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99599403,0.0008238455,4.3326358e-7,0.00020324861,0.00007848083,0.002503475,0.00017406551,0.000034909062,0.0001875093],"genre_scores_gemma":[0.9970969,0.00030735173,0.00020189547,0.000038969858,0.00003644721,0.0012883458,0.00023010916,0.000026968666,0.0007730019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986318,0.000045955378,0.00025975407,0.00036923698,0.00038394477,0.00030935262],"domain_scores_gemma":[0.9994329,0.000028635084,0.00008878058,0.00017141488,0.00015516355,0.0001230991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000097109456,0.0001771508,0.00029365454,0.0002567325,0.000027466906,0.00011174982,0.00008993975,0.00004678846,0.0002146307],"category_scores_gemma":[0.00000992962,0.00012232728,0.000023763647,0.00038365848,0.000069841975,0.000562624,0.000033876117,0.00013303821,0.0000036863635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032147125,0.0006550845,0.9808255,0.00016884739,0.00007526651,0.000036489913,0.0004255524,0.000063387095,0.0003748522,0.0000068197514,0.000022189786,0.014131284],"study_design_scores_gemma":[0.012412001,0.0008118323,0.9845315,0.0004949278,0.000046354835,0.0000017205588,0.00007195675,0.00047840836,0.00079188537,0.0000070639394,0.00020383432,0.00014847706],"about_ca_topic_score_codex":0.006959541,"about_ca_topic_score_gemma":0.021984287,"teacher_disagreement_score":0.015024746,"about_ca_system_score_codex":0.00043489665,"about_ca_system_score_gemma":0.00033907706,"threshold_uncertainty_score":0.9996532},"labels":[],"label_agreement":null},{"id":"W2907828838","doi":"10.1016/j.eururo.2018.12.035","title":"Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE)","year":2019,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Oncology; Prostate; Internal medicine; Gynecology; Cancer","score_opus":0.03232727007621445,"score_gpt":0.3181438679428259,"score_spread":0.28581659786661145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907828838","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019540307,0.01307964,0.00025493524,0.9717229,0.0012624407,0.0061243204,0.00054442266,0.00010594126,0.0049513597],"genre_scores_gemma":[0.0008061413,0.003935249,0.0006194585,0.90620774,0.0063251485,0.0008540997,0.0011842668,0.0003544827,0.079713404],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99641633,0.0007732389,0.00045504814,0.00088424433,0.00043831143,0.001032808],"domain_scores_gemma":[0.99767876,0.00087822025,0.00020941126,0.0008986057,0.00019383938,0.0001411419],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000723872,0.0005175573,0.0008595465,0.00024926857,0.00015635211,0.00006672456,0.0005420198,0.00016666476,0.00036746473],"category_scores_gemma":[0.00014902717,0.0003119991,0.00029613235,0.00023568995,0.00017387261,0.000045495544,0.0001467278,0.0014852412,0.0005608204],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015926801,0.00005559198,0.0004500095,0.0004744646,0.00066970714,0.0024063315,0.00085478195,0.000041278647,0.00033068738,0.0000030634938,0.98273,0.010391437],"study_design_scores_gemma":[0.00512922,0.00217512,0.0018257782,0.00007886477,0.00043410892,0.00006127185,0.00002784481,0.000025359213,0.000045010314,0.00001401187,0.98987335,0.00031004072],"about_ca_topic_score_codex":0.00008530103,"about_ca_topic_score_gemma":0.000028477,"teacher_disagreement_score":0.07476205,"about_ca_system_score_codex":0.0003025919,"about_ca_system_score_gemma":0.000572669,"threshold_uncertainty_score":0.9999332},"labels":[],"label_agreement":null},{"id":"W2908554893","doi":"10.1038/s41588-018-0330-6","title":"Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci","year":2019,"lang":"en","type":"erratum","venue":"Nature Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre","funders":"Medical Research Council; National Institute for Health and Care Research; Cancer Research UK","keywords":"Biology; Prostate cancer; Association (psychology); Computational biology; Genetics; Cancer; Psychology","score_opus":0.03662744868537579,"score_gpt":0.41180633990927934,"score_spread":0.3751788912239036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908554893","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21976905,0.51418704,0.000049984603,0.02401153,0.17212985,0.011912992,0.004976166,0.00048366122,0.052479737],"genre_scores_gemma":[0.066209696,0.017147748,0.0001331166,0.00014289022,0.0035173898,0.00004804321,0.0033422422,0.00009463491,0.9093642],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962546,0.00013024261,0.0005908422,0.00078019773,0.0016599521,0.0005841337],"domain_scores_gemma":[0.9968722,0.00008283945,0.0006937332,0.00082139246,0.0012546224,0.00027523102],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00041011494,0.00047741545,0.0010180972,0.00031975604,0.0000965508,0.000063521125,0.00027948327,0.002355578,0.00058740063],"category_scores_gemma":[0.00028663146,0.00037790247,0.00038249933,0.0007526491,0.000097455195,0.00006330524,0.00013222889,0.0029431859,0.000027943137],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038031262,0.0001153067,0.14565264,0.0007279709,0.0010797398,0.000015100299,0.0005936619,0.000033972203,0.00088942645,2.605169e-7,0.8464449,0.004066718],"study_design_scores_gemma":[0.003406485,0.0007961037,0.43186438,0.001073094,0.002786999,0.000008543746,0.00045913825,0.0005854357,0.022417625,0.00008895861,0.5358825,0.00063076423],"about_ca_topic_score_codex":0.001077153,"about_ca_topic_score_gemma":0.00061582687,"teacher_disagreement_score":0.8568845,"about_ca_system_score_codex":0.0017318588,"about_ca_system_score_gemma":0.0028729665,"threshold_uncertainty_score":0.9998673},"labels":[],"label_agreement":null},{"id":"W2908623381","doi":"10.1038/s41467-018-08133-6","title":"ONECUT2 is a driver of neuroendocrine prostate cancer","year":2019,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":244,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Ontario Institute for Cancer Research; University Health Network; University of Toronto; Occupational Cancer Research Centre; Vancouver General Hospital; Princess Margaret Cancer Centre; University of British Columbia","funders":"National Cancer Institute","keywords":"Prostate cancer; Cancer research; Hypoxia (environmental); Androgen receptor; Prostate; Neuroendocrine differentiation; Biology; Enzalutamide; Neuroendocrine tumors; Chromatin; Cancer; Endocrinology; Chemistry; Gene; Genetics","score_opus":0.026033200853261804,"score_gpt":0.374897263189994,"score_spread":0.3488640623367322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908623381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88440263,0.033651486,0.0000011027299,0.056834813,0.0001765454,0.0013427456,0.00016435563,0.00006126321,0.02336508],"genre_scores_gemma":[0.9768078,0.011312246,0.0006057038,0.00089724455,0.000016502534,0.000070791364,0.00008856707,0.000015617981,0.010185574],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99932176,0.000035593912,0.00014230234,0.00013813438,0.00020368841,0.00015849427],"domain_scores_gemma":[0.9982434,0.000056853223,0.00005981586,0.0013325142,0.00024156655,0.00006588489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000041873755,0.0000839148,0.00017930423,0.00009446024,0.000056849334,0.000006500259,0.00031971824,0.00005286673,0.0003388021],"category_scores_gemma":[0.000024443683,0.00006361747,0.00007158343,0.0003091168,0.00011157589,0.000056201112,0.00020375555,0.0006170443,0.0000610167],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050446484,0.0010602972,0.86874497,0.00033865357,0.00053536077,0.000022117974,0.002215023,0.000004564542,0.06660424,0.0055709356,0.038188085,0.01621129],"study_design_scores_gemma":[0.0051012896,0.00045242274,0.33611473,0.0003542108,0.00021031282,0.000037866117,0.00020438817,0.0006028397,0.047303576,0.00022213263,0.60917664,0.00021958009],"about_ca_topic_score_codex":0.00008648615,"about_ca_topic_score_gemma":0.000055550638,"teacher_disagreement_score":0.57098854,"about_ca_system_score_codex":0.00006316667,"about_ca_system_score_gemma":0.00017277511,"threshold_uncertainty_score":0.37096456},"labels":[],"label_agreement":null},{"id":"W2908866137","doi":"10.1002/cncr.31959","title":"Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer","year":2019,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Androgen receptor; Internal medicine; Cancer research; Cell-free fetal DNA; Cancer; Biology; Genetics","score_opus":0.021497342775592024,"score_gpt":0.31396893169450923,"score_spread":0.2924715889189172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908866137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958991,0.0007539771,0.0000042086995,0.00062225503,0.00012430301,0.0015247825,0.00011084897,0.000023997332,0.0009365656],"genre_scores_gemma":[0.99612874,0.000050408704,0.00019139789,0.00022310817,0.00004825394,0.0005226973,0.000106069994,0.000029325896,0.0027000012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876523,0.00003084998,0.0002257033,0.0002974755,0.00034775469,0.00033298536],"domain_scores_gemma":[0.9993839,0.000026003947,0.00007985264,0.0002003554,0.00020134347,0.000108538436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007591903,0.00015057439,0.00025088273,0.00011889334,0.000065236534,0.000036293197,0.00004718483,0.00001973114,0.0007158101],"category_scores_gemma":[0.00001167565,0.00010485178,0.00003445048,0.00033810138,0.00004619882,0.00017565563,0.000015663982,0.00015497598,0.000027275375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014605288,0.00022379936,0.98561555,0.00031341056,0.00016741872,0.00010016382,0.0011412624,0.000920352,0.006965062,0.00006215246,0.00020933567,0.0028209528],"study_design_scores_gemma":[0.010874185,0.0005698302,0.9814803,0.0008460922,0.00012017057,0.000004735285,0.00027075398,0.0006906148,0.004090022,0.000038120124,0.00076633313,0.0002488523],"about_ca_topic_score_codex":0.00058943714,"about_ca_topic_score_gemma":0.0006285353,"teacher_disagreement_score":0.009413656,"about_ca_system_score_codex":0.0005120914,"about_ca_system_score_gemma":0.0006730785,"threshold_uncertainty_score":0.78376186},"labels":[],"label_agreement":null},{"id":"W2909626878","doi":"10.1016/j.eururo.2018.12.042","title":"Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research; Business Finland; Prostate Cancer Canada; Academy of Finland; Prostate Cancer Foundation","keywords":"Prostate cancer; Medicine; Liquid biopsy; Prostate; Biopsy; Prostate biopsy; Concordance; Oncology; Cell-free fetal DNA; PCA3; Internal medicine; Androgen deprivation therapy; Cancer; Pathology; Biology","score_opus":0.020518337142015078,"score_gpt":0.30058030883879766,"score_spread":0.2800619716967826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909626878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918868,0.0014264993,0.000021504698,0.0012261753,0.000104405066,0.00048088774,0.000012128022,0.000030511452,0.004811094],"genre_scores_gemma":[0.9979087,0.00014097914,0.00014536349,0.00070282415,0.00005433071,0.000014678385,0.000011743521,0.000027763668,0.0009936092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869335,0.0002714412,0.00019268633,0.00032630813,0.000115438386,0.00040079403],"domain_scores_gemma":[0.9995784,0.000045480054,0.00005158035,0.00018025709,0.000038401413,0.00010586122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045779758,0.00011687394,0.00022930246,0.00008757534,0.000038244547,0.000014228312,0.00006221224,0.000016844162,0.00024355164],"category_scores_gemma":[0.000043580745,0.00009550206,0.0000315003,0.00012489327,0.00011971852,0.000051578947,0.00007669578,0.00024202604,0.000076664175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015670988,0.00019048921,0.9237333,0.0003365924,0.00012087214,0.0063982503,0.0020909663,0.00013763612,0.04920756,0.00006273253,0.00010771338,0.016046802],"study_design_scores_gemma":[0.0053717936,0.00047786543,0.98705214,0.00005013779,0.00006338277,0.0006204518,0.00012736143,0.0027566245,0.0006417708,0.00012641924,0.0025749134,0.0001371609],"about_ca_topic_score_codex":0.00009103246,"about_ca_topic_score_gemma":0.000026293912,"teacher_disagreement_score":0.06331883,"about_ca_system_score_codex":0.000060356404,"about_ca_system_score_gemma":0.00013373418,"threshold_uncertainty_score":0.3894461},"labels":[],"label_agreement":null},{"id":"W2909811185","doi":"10.1097/pai.0000000000000732","title":"PTEN Loss in a Prostate Cancer Cohort From Jordan","year":2019,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"PTEN; Prostate cancer; Oncology; Medicine; Cohort; Prostate; Cancer; Internal medicine; Cancer research; Biology; Apoptosis; PI3K/AKT/mTOR pathway","score_opus":0.00579752891837016,"score_gpt":0.27870761023806473,"score_spread":0.2729100813196946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909811185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98092145,0.006044632,0.000011301257,0.0007475824,0.00014378432,0.0012736558,0.00005078001,0.000055738714,0.010751052],"genre_scores_gemma":[0.9934447,0.0004902364,0.00023203554,0.0006275982,0.000043110955,0.000810612,0.00062031095,0.00006329881,0.0036680985],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99794734,0.000026301434,0.00036461314,0.0007420724,0.0003120519,0.0006076424],"domain_scores_gemma":[0.9988528,0.000030663712,0.00010530346,0.0007924852,0.00007814648,0.0001406269],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012575337,0.0003076128,0.00057979324,0.00009636787,0.000041175852,0.000014360659,0.0002324837,0.00020978593,0.0014017931],"category_scores_gemma":[0.000013428128,0.0002906757,0.00011634152,0.0002747068,0.00023890921,0.000029250468,0.00014036529,0.0005508239,0.00027726276],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012339662,0.00016929874,0.06057657,0.00009417765,0.0002451095,0.0011435368,0.00014870366,0.000013346216,0.93503493,0.00003704732,0.00030346288,0.0009998275],"study_design_scores_gemma":[0.009203564,0.00013603171,0.048477795,0.00013611137,0.00016153618,0.0001627063,0.0001465159,0.00003129446,0.9392024,0.00046946734,0.001401324,0.00047122518],"about_ca_topic_score_codex":0.0012288791,"about_ca_topic_score_gemma":9.808101e-7,"teacher_disagreement_score":0.012523225,"about_ca_system_score_codex":0.00061175117,"about_ca_system_score_gemma":0.00034475865,"threshold_uncertainty_score":0.9999545},"labels":[],"label_agreement":null},{"id":"W2909905361","doi":"10.1016/j.euf.2018.12.009","title":"What Is Oligometastatic Prostate Cancer?","year":2019,"lang":"en","type":"review","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Oncology; Gynecology; Internal medicine; Cancer; General surgery","score_opus":0.0798785485829733,"score_gpt":0.38858341791647916,"score_spread":0.3087048693335058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909905361","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002077717,0.9842449,0.0000015602682,0.0016374708,0.0012996678,0.0022809284,0.00014638789,0.00010925838,0.010259045],"genre_scores_gemma":[0.000021196696,0.9480692,0.000026137986,0.0007524567,0.00039575432,0.00015804578,0.0002400675,0.00023552307,0.050101593],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965724,0.0007123339,0.0006409512,0.0009225651,0.00034678465,0.00080497545],"domain_scores_gemma":[0.9981924,0.00016293525,0.0003252391,0.0009176834,0.00011367894,0.00028804905],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004568502,0.0006268217,0.0021452315,0.00043638534,0.00008733791,0.00010008541,0.0003608629,0.00018657483,0.0009198933],"category_scores_gemma":[0.00003246254,0.00041901047,0.0006073048,0.00046012836,0.00023431795,0.00014975168,0.00026158118,0.0009878264,0.007943733],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010013737,0.0000821531,0.000027134269,0.010333004,0.0009894005,0.0013782679,0.0002753008,1.7276831e-7,6.576807e-7,0.000012666386,0.008101733,0.9786994],"study_design_scores_gemma":[0.0013344203,0.0007668496,0.000025589457,0.0049754027,0.0032416137,0.00031496552,0.000019431463,0.0000018590425,0.0000031523653,0.000019083407,0.98896617,0.0003314381],"about_ca_topic_score_codex":0.000016526319,"about_ca_topic_score_gemma":0.0000022795714,"teacher_disagreement_score":0.98086447,"about_ca_system_score_codex":0.00021264267,"about_ca_system_score_gemma":0.00074832066,"threshold_uncertainty_score":0.9999934},"labels":[],"label_agreement":null},{"id":"W2910487244","doi":"10.3390/ijms20010216","title":"Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells","year":2019,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Université Laval","funders":"Fonds de Recherche du Québec - Santé; Movember Canada; Prostate Cancer Canada; Astellas Pharma; Canadian Urological Association; Cancer Research Society; Movember Foundation","keywords":"Prostate cancer; Androgen receptor; Cancer research; Biology; Cancer; Androgen; Promoter; Transcriptional regulation; Gene; Molecular biology; Gene expression; Endocrinology; Genetics","score_opus":0.02114334350080185,"score_gpt":0.3063290417050873,"score_spread":0.28518569820428546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910487244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99157286,0.00018208181,0.0011267576,0.005923319,0.00019380145,0.00044572292,0.000030732466,0.0000023877988,0.0005223482],"genre_scores_gemma":[0.9919613,0.000019908044,0.0076189605,0.00026814998,0.000025392887,0.000018904939,0.000003534241,0.000004149624,0.000079698],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986155,0.00005182729,0.0002326592,0.00013074854,0.0008747273,0.00009455383],"domain_scores_gemma":[0.99910265,0.00006819225,0.00015704645,0.00004663221,0.00055977463,0.00006572786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005086798,0.000070533126,0.00011882228,0.00017016105,0.000050382834,0.00003560728,0.00016466141,0.00001830166,0.0000615748],"category_scores_gemma":[0.000022755175,0.00003947378,0.00004659802,0.00014156278,0.00009984523,0.00007244595,0.000015652782,0.00007768313,0.000005463091],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012294844,0.00016181542,0.0052050836,0.000051171137,0.00026880825,0.000038357048,0.004388358,0.0008912187,0.98032475,0.0011013098,0.000059881702,0.006279758],"study_design_scores_gemma":[0.001258854,0.0006722171,0.009012956,0.00088824576,0.0000201217,0.000034380453,0.0011936704,0.0012597314,0.98450243,0.00006938769,0.0010135303,0.00007449358],"about_ca_topic_score_codex":0.000008538805,"about_ca_topic_score_gemma":0.0000010051293,"teacher_disagreement_score":0.0064922026,"about_ca_system_score_codex":0.00016412779,"about_ca_system_score_gemma":0.00051872345,"threshold_uncertainty_score":0.1609694},"labels":[],"label_agreement":null},{"id":"W2910743083","doi":"10.1530/erc-18-0465","title":"Roles of the HOXA10 gene during castrate-resistant prostate cancer progression","year":2019,"lang":"en","type":"article","venue":"Endocrine Related Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Downregulation and upregulation; Biology; Transcriptome; Transcription factor; Cancer research; LNCaP; Gene expression; Androgen receptor; Gene; Prostate; Cancer; Genetics","score_opus":0.010206905508999772,"score_gpt":0.31775176286825046,"score_spread":0.3075448573592507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910743083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710331,0.022695927,1.124082e-7,0.002593218,0.00040234072,0.0014102957,0.00008042715,0.00005872104,0.0017258832],"genre_scores_gemma":[0.9652613,0.0057635535,0.000031517884,0.000030662075,0.00008824027,0.00027734714,0.00001803203,0.000048458085,0.02848093],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981337,0.000056116714,0.00036710766,0.0003726691,0.00054889976,0.00052150374],"domain_scores_gemma":[0.99902,0.000019851459,0.00018766685,0.00044991952,0.00019015418,0.00013244597],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008103257,0.00022730039,0.0003672036,0.000098774755,0.00010891661,0.000015426065,0.00015724234,0.00007053098,0.00099426],"category_scores_gemma":[0.000013162657,0.00012886034,0.00015734196,0.00048678683,0.00013413912,0.000090586516,0.0001166654,0.00042254353,0.000027521557],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020885216,0.00016669995,0.2509274,0.00060650276,0.00048408474,0.00015867352,0.00052819756,0.00038480447,0.73696,0.000043869106,0.00037292158,0.007278352],"study_design_scores_gemma":[0.005986323,0.0002640153,0.14432248,0.0014133588,0.00017676876,0.00006627473,0.00012866463,0.00011509091,0.84283996,0.000034268367,0.004466047,0.00018675154],"about_ca_topic_score_codex":0.00058331556,"about_ca_topic_score_gemma":0.00012628578,"teacher_disagreement_score":0.106604904,"about_ca_system_score_codex":0.00036044314,"about_ca_system_score_gemma":0.0005328227,"threshold_uncertainty_score":0.99991894},"labels":[],"label_agreement":null},{"id":"W2910771120","doi":"10.1016/j.radonc.2018.12.022","title":"Reoxygenation during radiotherapy in intermediate-risk prostate cancer","year":2019,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"CNIB; National Comprehensive Cancer Network; Association pour la Recherche sur le Cancer","keywords":"Prostate cancer; Misonidazole; Radioresistance; Radiation therapy; Medicine; Hypoxia (environmental); Prostate; Oncology; Internal medicine; Cancer; Urology; Chemistry","score_opus":0.012537517386497162,"score_gpt":0.33625335042343185,"score_spread":0.3237158330369347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910771120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97580194,0.020404482,0.000010184412,0.002082234,0.00027513152,0.0009042341,0.000009442356,0.00003378801,0.00047858353],"genre_scores_gemma":[0.8723445,0.121661484,0.00036723755,0.00044637723,0.00022595085,0.00013623785,0.000015198418,0.000030989857,0.004772032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989165,0.0001046859,0.0002287931,0.00030432214,0.000126914,0.00031878034],"domain_scores_gemma":[0.9995471,0.000083643106,0.00008409935,0.00015053942,0.00003515459,0.00009946337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024714574,0.00013856583,0.0003661931,0.00021951328,0.000047087335,0.000013135221,0.000052049985,0.00014282188,0.00049950456],"category_scores_gemma":[0.000011900237,0.000105107036,0.000046213616,0.00018519029,0.000092946815,0.00009029442,0.00001172723,0.00027924727,0.000007816184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004560244,0.00019536416,0.80240375,0.0001296816,0.00017961813,0.00009900666,0.0040990813,0.000037091264,0.04695669,0.00003664336,0.00019387058,0.14110897],"study_design_scores_gemma":[0.024188781,0.0025006563,0.9048022,0.00015254923,0.00002599483,0.00008507643,0.00023319107,0.0015086753,0.0041737277,0.000094973584,0.0620132,0.00022099068],"about_ca_topic_score_codex":0.0002657933,"about_ca_topic_score_gemma":0.0002263893,"teacher_disagreement_score":0.14088799,"about_ca_system_score_codex":0.0011664083,"about_ca_system_score_gemma":0.00020391097,"threshold_uncertainty_score":0.54692245},"labels":[],"label_agreement":null},{"id":"W2910889145","doi":"10.1016/j.eururo.2018.12.038","title":"Further Evidence of Differences in Prostate Cancer Biomarkers Between Caucasian and Asian Men","year":2019,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Sinai Health System","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Prostate; Prostate disease; Gynecology; Cancer","score_opus":0.051123529249238346,"score_gpt":0.3203399666767041,"score_spread":0.26921643742746576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910889145","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20276642,0.012166869,9.789896e-7,0.7674071,0.00019922796,0.0012648387,0.00010796414,0.000031687352,0.016054872],"genre_scores_gemma":[0.9413108,0.0050327918,0.000026022082,0.04240071,0.000980266,0.00004296315,0.0001335137,0.00011463119,0.0099582635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755836,0.0006640426,0.00038566813,0.0005920089,0.00027761448,0.000522331],"domain_scores_gemma":[0.9989515,0.00032235094,0.00019392847,0.0003912111,0.00006424258,0.00007679776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037032654,0.0003063265,0.00073937903,0.0003818821,0.000024805337,0.000015647713,0.00021510385,0.00021612918,0.00017425841],"category_scores_gemma":[0.00007848103,0.00022147936,0.00007307201,0.00018901254,0.00041425627,0.000054231205,0.00015825461,0.0010082255,0.000056847133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005690255,0.000024529301,0.8545742,0.0010255498,0.0004866482,0.0022005646,0.0016093769,9.84792e-8,0.0001904298,6.368549e-7,0.12922032,0.010098627],"study_design_scores_gemma":[0.0026253122,0.0018669592,0.87937665,0.0010688348,0.0003279558,0.000050971925,0.00011871057,0.0000063439084,0.000062344065,0.000023303537,0.11415237,0.0003202224],"about_ca_topic_score_codex":0.00030926577,"about_ca_topic_score_gemma":0.000044993085,"teacher_disagreement_score":0.7385444,"about_ca_system_score_codex":0.000080214355,"about_ca_system_score_gemma":0.0002579759,"threshold_uncertainty_score":0.9031666},"labels":[],"label_agreement":null},{"id":"W2911362138","doi":"10.1016/j.euf.2019.01.016","title":"Biological Evolution of Castration-resistant Prostate Cancer","year":2019,"lang":"en","type":"review","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; Prostate Cancer Canada; National Cancer Institute; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Medicine; Prostate cancer; Castration; Oncology; Prostate; Cancer; Internal medicine; Gynecology; Hormone","score_opus":0.10062357527109016,"score_gpt":0.3775119691122691,"score_spread":0.2768883938411789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911362138","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030634948,0.9882205,0.000005257873,0.0001761759,0.00025992197,0.0013972538,0.00020320318,0.00004607915,0.009385274],"genre_scores_gemma":[0.00474255,0.9912864,0.000028671922,0.000020599828,0.00022995807,0.000068560745,0.00019840986,0.0000610962,0.0033637334],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977225,0.00061920926,0.0005772723,0.00050350145,0.00019330886,0.0003841824],"domain_scores_gemma":[0.99888855,0.00011143536,0.00033465817,0.00042167626,0.0001297578,0.00011389278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036769535,0.00032219492,0.0012929079,0.00022632022,0.000048984755,0.000008238862,0.00017826952,0.00020304501,0.00022606368],"category_scores_gemma":[0.0000672131,0.00019786309,0.00035745365,0.00026928994,0.0002688792,0.000026898024,0.00010661489,0.00049862696,0.00044759817],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006830173,0.00020827046,0.0005519948,0.0077122436,0.00075371726,0.00060864794,0.00007666523,0.0000014102005,0.00015987596,0.0003191013,0.001511251,0.9874138],"study_design_scores_gemma":[0.0010051011,0.0015424298,0.001141274,0.0015788688,0.0010575663,0.00009572673,0.0000074562986,0.0000014529277,0.000008194546,0.000021644324,0.99335736,0.00018293383],"about_ca_topic_score_codex":0.00005032833,"about_ca_topic_score_gemma":0.0000073265,"teacher_disagreement_score":0.9918461,"about_ca_system_score_codex":0.0002500344,"about_ca_system_score_gemma":0.00078082015,"threshold_uncertainty_score":0.8068623},"labels":[],"label_agreement":null},{"id":"W2911465702","doi":"10.1016/s1470-2045(18)30898-2","title":"Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Foundation for Research on Metabolic Disorders; Cancer Research UK; Ironwood Pharmaceuticals, Incorporated; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Clinical endpoint; Placebo; Quality of life (healthcare); Internal medicine; Discontinuation; Oncology; Prostate-specific antigen; Clinical trial; Visual analogue scale; Cancer; Physical therapy; Pathology; Nursing","score_opus":0.07290594750234178,"score_gpt":0.41209821916643674,"score_spread":0.33919227166409494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911465702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97908205,0.00030542765,0.000005346682,0.0032877158,0.00035472287,0.013705093,0.000038448914,0.00004795041,0.003173242],"genre_scores_gemma":[0.9907557,0.00020385713,0.0003906296,0.0004014333,0.00014642018,0.0028516205,0.00008868319,0.000044506804,0.0051171626],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972925,0.00025149263,0.00070284895,0.00047275523,0.0005219627,0.00075839605],"domain_scores_gemma":[0.998251,0.00061529205,0.0003404403,0.00050143455,0.00012924509,0.00016258848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095372705,0.00031573314,0.0012823793,0.00015474728,0.00011515177,0.00004588211,0.00015925762,0.00010051052,0.00032387546],"category_scores_gemma":[0.00010776175,0.00015264079,0.00014378552,0.0003867937,0.000120538054,0.00014319498,0.000055988403,0.00044314307,0.00003590102],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.938973,0.0011243644,0.046812262,0.000114095565,0.0010473533,0.0014622463,0.0036187163,0.00010755192,0.0035829365,0.000011456039,0.00030448122,0.0028415294],"study_design_scores_gemma":[0.984182,0.0052624526,0.0038339007,0.00018041655,0.0005358305,0.00003230719,0.0016458044,0.00052129384,0.0018962981,0.000013434766,0.0016760303,0.00022020936],"about_ca_topic_score_codex":0.0010470324,"about_ca_topic_score_gemma":0.0024447755,"teacher_disagreement_score":0.045209013,"about_ca_system_score_codex":0.00060335046,"about_ca_system_score_gemma":0.0015216569,"threshold_uncertainty_score":0.622451},"labels":[],"label_agreement":null},{"id":"W2911490798","doi":"10.1016/s1470-2045(18)30860-x","title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":397,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Bayer Fund","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Prednisone; Abiraterone; Placebo; Urology; Radium-223; Internal medicine; Castration; Prednisolone; Oncology; Cancer; Androgen deprivation therapy; Bone metastasis; Hormone; Alternative medicine; Pathology","score_opus":0.047407643392600944,"score_gpt":0.3646799658367788,"score_spread":0.31727232244417786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911490798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824536,0.0010679218,0.0000053155245,0.0028660535,0.00011002316,0.012891278,0.00042904075,0.000019477307,0.00015729356],"genre_scores_gemma":[0.9948187,0.0007931552,0.00029698078,0.00015935657,0.00014544283,0.0024057936,0.00020495117,0.00002610042,0.0011495539],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981055,0.0002792534,0.00050721184,0.00037704612,0.0003004543,0.00043048867],"domain_scores_gemma":[0.9988095,0.0003418453,0.0002694989,0.00027227047,0.00015927819,0.00014757832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008241965,0.00023621044,0.0013148803,0.00017035512,0.00007531748,0.00002988273,0.00007971226,0.00009245238,0.00014923011],"category_scores_gemma":[0.000057012843,0.00012226294,0.000042427728,0.00024656887,0.0002147948,0.00013267284,0.000052504514,0.00023109476,0.000004644142],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98655653,0.0013696029,0.0017833014,0.00020752689,0.00047441508,0.000048706625,0.0013277716,0.000036686328,0.00354208,0.000019030005,0.00036581027,0.0042685266],"study_design_scores_gemma":[0.9760144,0.017262544,0.003051037,0.00017780777,0.00039510103,0.000014558142,0.00017999836,0.000071271985,0.0017890792,0.000016018144,0.00088742375,0.00014080328],"about_ca_topic_score_codex":0.00029996634,"about_ca_topic_score_gemma":0.0009165573,"teacher_disagreement_score":0.015892942,"about_ca_system_score_codex":0.00017907892,"about_ca_system_score_gemma":0.0005482538,"threshold_uncertainty_score":0.49857378},"labels":[],"label_agreement":null},{"id":"W2911633935","doi":"10.5489/cuaj.5600","title":"Management algorithms for prostate-specific antigen progression in prostate cancer: Biochemical recurrence after definitive therapy and progression to non-metastatic castrate-resistant prostate cancer","year":2019,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; University of Ottawa; University of Toronto; Prevention of Organ Failure; Princess Margaret Cancer Centre; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; University of Alberta","funders":"Janssen Canada","keywords":"Prostate cancer; Enzalutamide; Medicine; Oncology; Genitourinary system; Internal medicine; Context (archaeology); Management of prostate cancer; Biochemical recurrence; Algorithm; Cancer; Prostate-specific antigen; Androgen receptor; Prostatectomy","score_opus":0.06954502985652687,"score_gpt":0.379445106426204,"score_spread":0.3099000765696771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911633935","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01790502,0.9634194,0.0000061770056,0.0035087569,0.00051372487,0.01259089,0.0019665975,0.000025522257,0.000063909036],"genre_scores_gemma":[0.0038406474,0.98613346,0.0012405274,0.00029319123,0.00026810824,0.0070733987,0.00046070636,0.0000928186,0.0005971563],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99503714,0.0003526303,0.0011236084,0.0010677221,0.0008417577,0.0015771282],"domain_scores_gemma":[0.99697167,0.00019957469,0.0007713862,0.00024575816,0.0005947312,0.0012168658],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011814296,0.0007394548,0.0017390273,0.00080317946,0.00029980755,0.00032826408,0.0002494876,0.00044195572,0.0001104798],"category_scores_gemma":[0.00009491871,0.00048514456,0.00033454772,0.0009021624,0.00012285927,0.00016137472,0.0000844637,0.0013320706,0.000023485074],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024420316,0.00021784066,0.01321592,0.0030850077,0.0005132034,0.0010328322,0.0005113256,0.0000027336785,0.00001912566,0.0000050768963,0.0025363702,0.97641855],"study_design_scores_gemma":[0.0060036196,0.0034131806,0.021044217,0.023310732,0.0005511628,0.000105950996,0.00018961467,0.000044244316,0.00004663808,0.00011354223,0.9442279,0.0009492143],"about_ca_topic_score_codex":0.0004271513,"about_ca_topic_score_gemma":0.00030692026,"teacher_disagreement_score":0.9754693,"about_ca_system_score_codex":0.003865718,"about_ca_system_score_gemma":0.0026338056,"threshold_uncertainty_score":0.9999583},"labels":[],"label_agreement":null},{"id":"W2911652114","doi":"10.1016/j.eururo.2018.12.036","title":"Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health; Canadian Cancer Society","keywords":"Medicine; Prostate cancer; Magnetic resonance imaging; Visibility; Multiparametric MRI; Prostate; Nuclear magnetic resonance; Cancer; Radiology; Internal medicine; Optics","score_opus":0.010268782711774994,"score_gpt":0.2895967742992548,"score_spread":0.2793279915874798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911652114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9537701,0.03109602,0.0000045360016,0.0009843239,0.00010616802,0.0006917884,0.000010604285,0.000022786668,0.013313679],"genre_scores_gemma":[0.9976096,0.0006116231,0.00012160497,0.00042069337,0.000019895018,0.000017139759,0.000010764764,0.00003211882,0.0011565182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845153,0.00030104414,0.0002983636,0.0004046753,0.00017925975,0.00036511038],"domain_scores_gemma":[0.99928254,0.000083416264,0.00006513287,0.000397265,0.00009282481,0.00007881108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046718717,0.00012888684,0.0002954543,0.0002754202,0.000013021333,0.0000054685606,0.00012426994,0.000025088839,0.00026168517],"category_scores_gemma":[0.00012933747,0.000106587766,0.000059932954,0.00046065662,0.00014608029,0.000038810038,0.000103690116,0.00026404866,0.00010384521],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010293126,0.00017737839,0.91487145,0.00009762429,0.0000107270025,0.00070326333,0.0002579073,0.000094117844,0.017789304,0.00002655791,0.00009027905,0.064852096],"study_design_scores_gemma":[0.004413952,0.00063131977,0.9833377,0.000052096224,0.000023210512,0.00002377097,0.000027221975,0.0018552557,0.0024835123,0.000033690867,0.0070116436,0.0001066436],"about_ca_topic_score_codex":0.0001706419,"about_ca_topic_score_gemma":0.000011335451,"teacher_disagreement_score":0.06846625,"about_ca_system_score_codex":0.00007434588,"about_ca_system_score_gemma":0.00009653817,"threshold_uncertainty_score":0.43465227},"labels":[],"label_agreement":null},{"id":"W2911847264","doi":"10.1530/ec-18-0476","title":"Discordance between testosterone measurement methods in castrated prostate cancer patients","year":2019,"lang":"en","type":"article","venue":"Endocrine Connections","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Université Laval; Centre hospitalier universitaire de Québec","funders":"Fonds de Recherche du Québec - Santé; Astellas Pharma; Canadian Urological Oncology Group; Sanofi; AstraZeneca; Pfizer; Amgen","keywords":"Immunoassay; Medicine; Testosterone (patch); Prostate cancer; Gold standard (test); Urology; Mass spectrometry; Internal medicine; Endocrinology; Cancer; Chromatography; Chemistry; Antibody; Immunology","score_opus":0.06672743505513323,"score_gpt":0.40200101351263506,"score_spread":0.33527357845750183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911847264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99198467,0.0006312226,0.000098129865,0.003022585,0.0003785572,0.001535991,0.000066195265,0.00006763026,0.0022150443],"genre_scores_gemma":[0.9911583,0.00013602602,0.00091280433,0.00005265934,0.000083354884,0.0003662025,0.00009369152,0.000028069358,0.007168908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984092,0.00010119213,0.00028923675,0.00034875172,0.0004272439,0.00042437617],"domain_scores_gemma":[0.99907196,0.00007704688,0.00006187336,0.0002474105,0.000399915,0.00014179472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023234326,0.00016902298,0.00031457318,0.00020226663,0.000071220136,0.000021169933,0.000066679386,0.000027760956,0.00037049956],"category_scores_gemma":[0.00014173046,0.00013464515,0.000057311347,0.00052496843,0.00004380646,0.0001226317,0.000048939393,0.0002845341,0.00007476995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016479756,0.00030796113,0.9734151,0.00008341727,0.000114311995,0.00001856053,0.00023425464,0.000030206209,0.010923869,0.000023028091,0.0004438074,0.0142406905],"study_design_scores_gemma":[0.007538977,0.0008982405,0.9470979,0.00028679165,0.000084766245,0.000009093628,0.00020707966,0.000079841644,0.030216143,0.00006916881,0.013304499,0.00020749125],"about_ca_topic_score_codex":0.0007010427,"about_ca_topic_score_gemma":0.0004590813,"teacher_disagreement_score":0.026317189,"about_ca_system_score_codex":0.00054568064,"about_ca_system_score_gemma":0.00023854504,"threshold_uncertainty_score":0.54906696},"labels":[],"label_agreement":null},{"id":"W2911937558","doi":"10.1158/1055-9965.epi-18-1002","title":"A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Université de Sherbrooke; McGill University Health Centre; Centre hospitalier universitaire de Québec","funders":"Fonds de Recherche du Québec - Santé; Prostate Cancer Canada; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Medicine; Prostate cancer; Internal medicine; Oncology; Prostatectomy; Biochemical recurrence; Metabolome; Testosterone (patch); Hazard ratio; Proportional hazards model; Cancer; Dehydroepiandrosterone; Dehydroepiandrosterone sulfate; Metastasis; Hormone; Endocrinology; Androgen; Confidence interval","score_opus":0.04032777789435959,"score_gpt":0.4037452959308506,"score_spread":0.363417518036491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911937558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93254346,0.06456372,0.00015627562,0.0010115339,0.00017854969,0.0013608804,0.000137219,0.00002104292,0.00002730026],"genre_scores_gemma":[0.961667,0.03586715,0.0012951514,0.00006334852,0.000026217702,0.00026725396,0.00025854455,0.0000181421,0.00053716137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975956,0.00061297265,0.0007776247,0.0004900591,0.00018511989,0.00033864178],"domain_scores_gemma":[0.9979918,0.00043615638,0.0008203191,0.00032528656,0.00029819505,0.00012826163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008230441,0.00020834724,0.0012313634,0.00043194133,0.000046676207,0.0000026736325,0.00007858421,0.00018856362,0.00021831745],"category_scores_gemma":[0.00010219181,0.00014866285,0.00027839802,0.00066742447,0.00044450987,0.000084652296,0.000079698024,0.00015275461,0.0000021847584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004632751,0.00012659853,0.8846908,0.00058552634,0.007069769,0.0000025654201,0.00018674684,0.00009130185,0.017657982,0.000026053249,0.00030403087,0.08462585],"study_design_scores_gemma":[0.0051288465,0.0011952074,0.97721136,0.0007900006,0.003963219,0.000002006414,0.00018474946,0.002573078,0.0074875043,0.0005826085,0.0007274942,0.00015394343],"about_ca_topic_score_codex":0.0019269099,"about_ca_topic_score_gemma":0.00014391482,"teacher_disagreement_score":0.09252051,"about_ca_system_score_codex":0.00013683064,"about_ca_system_score_gemma":0.00017497869,"threshold_uncertainty_score":0.6062295},"labels":[],"label_agreement":null},{"id":"W2912274952","doi":"","title":"A prospective, multinational comparison of multi-parametric and whole body magnetic resonance imaging (mp-MRI and WB- MRI) F-18 fluoro-methyl-choline (FCH) and Ga-68 HBED-CC- (PSMA) in high risk men being considered for salvage radiation treatment for biochemical failure post radical prostatectomy: Detection rates, management impact and treatment response.","year":2018,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Magnetic resonance imaging; Prostatectomy; Nuclear medicine; Prospective cohort study; Radiology; Prostate cancer; Internal medicine; Cancer","score_opus":0.016833614322079703,"score_gpt":0.34760018427587547,"score_spread":0.3307665699537958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912274952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98004377,0.01059979,0.001104497,0.0010130166,0.0000259249,0.006752678,0.00040027156,0.000044567158,0.000015513699],"genre_scores_gemma":[0.9765269,0.0018644887,0.020012477,0.000018446588,0.000055406563,0.00094320846,0.00022261821,0.000043239885,0.00031318126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778444,0.00016968949,0.0005227291,0.0008049873,0.000247557,0.00047059462],"domain_scores_gemma":[0.99832857,0.00078396243,0.00019128509,0.00020083776,0.0002569201,0.000238426],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051923806,0.00039367532,0.00066197966,0.0006566838,0.0002656384,0.000088158966,0.000039267128,0.00013038759,0.000012148101],"category_scores_gemma":[0.00029844735,0.0002908427,0.00007344769,0.00038246898,0.00046710917,0.00017247326,0.000060228158,0.00012924687,5.7798763e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04661481,0.0037758043,0.46454895,0.00042876432,0.0005520766,0.00004058491,0.002351292,0.000007431677,0.12337864,0.000048921105,0.00033498177,0.35791776],"study_design_scores_gemma":[0.07815099,0.010352045,0.68138635,0.0001703129,0.0004114219,0.000044105214,0.00080208003,0.068550326,0.15894714,0.00019001668,0.0006923961,0.00030282047],"about_ca_topic_score_codex":0.0005838354,"about_ca_topic_score_gemma":0.00014113702,"teacher_disagreement_score":0.35761493,"about_ca_system_score_codex":0.00072039355,"about_ca_system_score_gemma":0.00012127809,"threshold_uncertainty_score":0.99995434},"labels":[],"label_agreement":null},{"id":"W2912662942","doi":"10.1016/j.ccell.2019.01.008","title":"ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Human Genome Research Institute; Barr Foundation; National Cancer Institute; National Institutes of Health; National Science Foundation; Prostate Cancer Foundation; Novartis; U.S. Department of Veterans Affairs; National Institute of Diabetes and Digestive and Kidney Diseases; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; U.S. Department of Defense","keywords":"Prostate cancer; Suppressor; Gene; Cancer research; Biology; Tumor suppressor gene; Chromoplexy; Cancer; Genetics; PCA3; Carcinogenesis","score_opus":0.023077901777715425,"score_gpt":0.3200031459057658,"score_spread":0.2969252441280504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912662942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93436736,0.050955,5.126753e-7,0.00097412773,0.00038536443,0.0012611342,0.00011832243,0.000045304376,0.01189289],"genre_scores_gemma":[0.9617923,0.0098008085,0.00007478043,0.0002441024,0.00019208151,0.0006713863,0.00004595784,0.000042392334,0.027136216],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983577,0.000036969133,0.00028596242,0.000497301,0.0003386551,0.00048337644],"domain_scores_gemma":[0.99915665,0.000042177657,0.000090050235,0.00040647865,0.00014567458,0.00015895475],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010612264,0.00020761226,0.00034276347,0.00008277954,0.00005011516,0.000039635972,0.00011738378,0.0000653861,0.0026149745],"category_scores_gemma":[0.0000087449735,0.00016152357,0.000076403434,0.000242099,0.00007134571,0.00017631945,0.00004747829,0.00019997782,0.0000882986],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021060442,0.00028038412,0.28709108,0.0011568482,0.00009391912,0.00032666264,0.0010825911,0.0004497686,0.69827425,0.000027841534,0.004942446,0.0041681756],"study_design_scores_gemma":[0.0080392845,0.00046136347,0.10514137,0.00077950454,0.00011422211,0.000011349822,0.0008892561,0.00029301556,0.8171685,0.000057727557,0.06659537,0.00044908855],"about_ca_topic_score_codex":0.004651215,"about_ca_topic_score_gemma":0.0016787151,"teacher_disagreement_score":0.18194972,"about_ca_system_score_codex":0.00050283637,"about_ca_system_score_gemma":0.00075147324,"threshold_uncertainty_score":0.9982968},"labels":[],"label_agreement":null},{"id":"W2912835372","doi":"10.1158/1538-7445.prca2017-b012","title":"Abstract B012: Histone demethylase JMJD1A promotes the generation of androgen receptor variant 7 (AR-V7) in prostate cancer cells","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Androgen receptor; Gene knockdown; Cancer research; Demethylase; Enzalutamide; Coactivator; Histone; Cancer cell; Biology; Chemistry; Cancer; Medicine; Internal medicine; Transcription factor; Apoptosis; Gene; Genetics","score_opus":0.1178138050440875,"score_gpt":0.43600555049494644,"score_spread":0.31819174545085893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912835372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780136,0.012578429,0.0000038111011,0.0059495056,0.00033195593,0.0021715523,0.00018190575,0.00002209883,0.0007471625],"genre_scores_gemma":[0.98489046,0.0077230213,0.00012791883,0.00008676956,0.0009054614,0.0011589956,0.00005224841,0.000050536357,0.005004602],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969806,0.000259503,0.00042848906,0.0005150825,0.0010192248,0.00079708855],"domain_scores_gemma":[0.9980287,0.00013151517,0.00010358943,0.00051951804,0.0009944725,0.00022220127],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018992255,0.00019573356,0.00034836587,0.00034122565,0.00026457445,0.000046682577,0.00027419106,0.000114917144,0.0016980476],"category_scores_gemma":[0.00013478934,0.00012413136,0.00007688122,0.0010398272,0.00088671345,0.00014479343,0.0001246536,0.0006536887,0.0000834694],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013883562,0.0003082089,0.0037717454,0.00033102295,0.00013474992,0.00007875968,0.0024285987,0.000009878047,0.95410675,0.000035058343,0.013301439,0.024105417],"study_design_scores_gemma":[0.0022906375,0.000556796,0.0036792397,0.0004047838,0.000029123179,0.0000054126713,0.00023966981,0.00019042878,0.97642523,0.00006432186,0.015975075,0.000139266],"about_ca_topic_score_codex":0.005425168,"about_ca_topic_score_gemma":0.001485038,"teacher_disagreement_score":0.02396615,"about_ca_system_score_codex":0.000963822,"about_ca_system_score_gemma":0.0021541666,"threshold_uncertainty_score":0.99921453},"labels":[],"label_agreement":null},{"id":"W2913030727","doi":"10.1158/1538-7445.prca2017-b069","title":"Abstract B069: Drug response variability between luminal and basal prostate cancer tumors","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Carboplatin; Prostate cancer; Medicine; Olaparib; Internal medicine; Context (archaeology); Cancer; Oncology; Erlotinib; Prospective cohort study; Pathology; Cisplatin; Biology; Chemotherapy; Epidermal growth factor receptor","score_opus":0.0770861135182678,"score_gpt":0.4474507220578358,"score_spread":0.370364608539568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913030727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98067343,0.0018848049,0.000001812038,0.013643831,0.00018314685,0.0014773663,0.00024195653,0.000067590634,0.001826048],"genre_scores_gemma":[0.9850313,0.0011597485,0.00006487283,0.00012238476,0.0016237294,0.00067761797,0.000026626742,0.000059322967,0.011234395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957182,0.00055895356,0.0003693421,0.0008504148,0.0012777281,0.00122538],"domain_scores_gemma":[0.99674743,0.0007776971,0.0000631505,0.00060038833,0.001080754,0.0007305867],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0051698345,0.00025958658,0.00045630595,0.00037565126,0.0005420222,0.00011205895,0.0002511449,0.0001306292,0.0015803757],"category_scores_gemma":[0.00053783174,0.00019927564,0.00007730511,0.0008310183,0.0019835273,0.00020249079,0.00027525862,0.001036571,0.000114710085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029973278,0.0003160611,0.77712846,0.001010474,0.00038907598,0.0003761379,0.0048466753,9.767915e-7,0.11108809,0.000037349215,0.03394405,0.040889356],"study_design_scores_gemma":[0.0033688666,0.0008404986,0.8728856,0.00061352376,0.000055653745,0.000008878837,0.0004831487,0.000018946039,0.09878941,0.0005986102,0.022067802,0.00026904795],"about_ca_topic_score_codex":0.0032165523,"about_ca_topic_score_gemma":0.00023572728,"teacher_disagreement_score":0.09575714,"about_ca_system_score_codex":0.0010477373,"about_ca_system_score_gemma":0.0027657761,"threshold_uncertainty_score":0.9993323},"labels":[],"label_agreement":null},{"id":"W2913228817","doi":"10.1007/s12032-018-1238-9","title":"The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicity","year":2019,"lang":"en","type":"article","venue":"Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Ottawa Regional Cancer Foundation; University of Ottawa","funders":"","keywords":"Docetaxel; Medicine; Discontinuation; Toxicity; Chemotherapy; Prostate cancer; Internal medicine; Oncology; Cancer; Urology","score_opus":0.042340011160148246,"score_gpt":0.38235724981843144,"score_spread":0.3400172386582832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913228817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97878075,0.0006489452,0.0000056702565,0.018278042,0.00008861689,0.0010247134,0.000005597202,0.0000034721188,0.0011641813],"genre_scores_gemma":[0.9968686,0.0020983692,0.000029344319,0.0006012257,0.000025972404,0.00007694084,0.0000045872494,0.0000068997447,0.00028804046],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99883384,0.00030111734,0.00030494202,0.00012958534,0.00024007683,0.00019043342],"domain_scores_gemma":[0.9984808,0.0010854392,0.00014317576,0.00010967133,0.00011405679,0.00006684406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014935088,0.00007805162,0.00040780703,0.00004737885,0.00003280284,0.0000033811973,0.00005971759,0.00007017284,0.000103635],"category_scores_gemma":[0.0003063828,0.00003573851,0.000037427846,0.0001662408,0.000499501,0.000028333443,0.000032975557,0.00025653568,0.0000023381044],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05274615,0.0017680835,0.07802909,0.001424113,0.0019809145,0.0006559067,0.038393203,0.000033430933,0.1424481,0.0051635434,0.00067732343,0.67668015],"study_design_scores_gemma":[0.15042001,0.008759919,0.34810066,0.0016221984,0.0006518694,0.00023350742,0.012541295,0.02441968,0.44405195,0.0038024473,0.0049422355,0.00045421277],"about_ca_topic_score_codex":0.00048071292,"about_ca_topic_score_gemma":0.00042356196,"teacher_disagreement_score":0.67622596,"about_ca_system_score_codex":0.00009950728,"about_ca_system_score_gemma":0.000735999,"threshold_uncertainty_score":0.18404323},"labels":[],"label_agreement":null},{"id":"W2913237306","doi":"10.1016/j.eururo.2019.01.026","title":"Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit","year":2019,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Abiraterone; Prednisone; Prostate cancer; Radium-223; Urology; Abiraterone acetate; Oncology; Internal medicine; Culprit; Cancer; Bone metastasis; Androgen deprivation therapy","score_opus":0.013504451037174944,"score_gpt":0.26671526150621866,"score_spread":0.2532108104690437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913237306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83034253,0.0021538546,3.3129544e-7,0.16291131,0.00016372869,0.0018475497,0.0003671588,0.000035019464,0.002178512],"genre_scores_gemma":[0.8993489,0.0016259725,0.000010150961,0.08351862,0.0003254759,0.00008814445,0.00091289566,0.00013323179,0.01403657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969077,0.0011274318,0.00041872333,0.0006501823,0.00036130653,0.00053461816],"domain_scores_gemma":[0.9986244,0.00022169453,0.00032522003,0.0005973904,0.00016579103,0.00006550113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031780303,0.000415404,0.000750012,0.0001697659,0.00007064575,0.000021169704,0.0002182294,0.0002474073,0.00027948763],"category_scores_gemma":[0.00003820029,0.00021802734,0.00007175561,0.00018329886,0.0005983803,0.000045718512,0.00013716439,0.001759191,0.000028942244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044619283,0.00028874679,0.8476908,0.00029792608,0.00054470997,0.0006055691,0.00060234644,0.000008040263,0.000046740908,7.6833743e-7,0.14445007,0.001002365],"study_design_scores_gemma":[0.009645587,0.002677446,0.7252854,0.000079257035,0.00033183888,0.000006517387,0.00000624434,0.000009408075,0.0001447176,0.000005580444,0.26162583,0.00018219119],"about_ca_topic_score_codex":0.000869792,"about_ca_topic_score_gemma":0.00004509934,"teacher_disagreement_score":0.1224054,"about_ca_system_score_codex":0.0001011635,"about_ca_system_score_gemma":0.00011437278,"threshold_uncertainty_score":0.8890897},"labels":[],"label_agreement":null},{"id":"W2913271953","doi":"10.1007/s40261-019-00752-1","title":"Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects","year":2019,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"","keywords":"Abiraterone acetate; Pharmacokinetics; Cmax; Pharmacology; Abiraterone; Bioanalysis; Chemistry; Metabolite; Medicine; Chromatography; Oral administration; Internal medicine; Cancer; Prostate cancer","score_opus":0.1339849863886814,"score_gpt":0.4217515987455929,"score_spread":0.28776661235691153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913271953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932107,0.0005012196,0.000018227347,0.0034094737,0.0005253694,0.002160662,0.000021731401,0.000017577158,0.00013506423],"genre_scores_gemma":[0.9984807,0.00014243482,0.0005769403,0.00032224128,0.000077816876,0.000040542232,0.000058731326,0.00002801009,0.00027259724],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962672,0.0007750698,0.0012562006,0.00039578715,0.0010508508,0.00025487074],"domain_scores_gemma":[0.9977341,0.00027800005,0.0005818677,0.00043021498,0.00073283125,0.00024297748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037639942,0.00019455937,0.0006261171,0.00013280404,0.00005228287,0.000015289186,0.00013515294,0.00012210551,0.000029446317],"category_scores_gemma":[0.0006905589,0.00014051964,0.00014711395,0.00043989706,0.0003735374,0.00017099833,0.00008941132,0.00023722618,0.000010919836],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002545246,0.0005978395,0.17904213,0.00095340324,0.0003110638,0.000002777602,0.0019926368,0.00031964778,0.79568195,0.000039117025,0.0001941231,0.01832006],"study_design_scores_gemma":[0.010321119,0.0027956583,0.37109458,0.00071310246,0.00067104644,0.0000037282412,0.0002023793,0.0039148033,0.6094958,0.0005922155,0.0000464895,0.00014906596],"about_ca_topic_score_codex":0.000051296563,"about_ca_topic_score_gemma":0.000036830876,"teacher_disagreement_score":0.19205245,"about_ca_system_score_codex":0.00012649344,"about_ca_system_score_gemma":0.00069790176,"threshold_uncertainty_score":0.5730224},"labels":[],"label_agreement":null},{"id":"W2913585936","doi":"10.1158/1538-7445.prca2017-a029","title":"Abstract A029: Targeting neural transcription factor BRN2 in neuroendocrine prostate tumors","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"SOX2; Enzalutamide; Cancer research; Neuroendocrine differentiation; Prostate cancer; LNCaP; Androgen receptor; In vivo; Transcription factor; Neuroendocrine tumors; Medicine; Biology; Internal medicine; Cancer; Gene; Genetics","score_opus":0.1013053681014257,"score_gpt":0.42843080601204653,"score_spread":0.3271254379106208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913585936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896147,0.0018160891,0.0000021298692,0.0051897513,0.00023717961,0.0013264349,0.000052954452,0.000074206386,0.0016865346],"genre_scores_gemma":[0.9942473,0.0010497273,0.000031895725,0.00012940238,0.0006371035,0.00032957495,0.00004785496,0.000057860856,0.0034692765],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99666953,0.00016144819,0.00036330777,0.0005788478,0.0009866448,0.001240207],"domain_scores_gemma":[0.99870974,0.00009121552,0.000041597355,0.00031079684,0.00050300016,0.0003436435],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005363458,0.00020610493,0.0003123576,0.00053393806,0.00023698324,0.000078959674,0.00020538563,0.00004878036,0.0014513801],"category_scores_gemma":[0.00013869775,0.0001612453,0.00008541436,0.0009827174,0.0005014772,0.0002493125,0.00007595392,0.0010363172,0.00014539798],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038369356,0.00035279966,0.10159571,0.00054197107,0.00005484059,0.0016524135,0.0018660674,0.000010412437,0.844687,0.000029778308,0.0046802904,0.04069178],"study_design_scores_gemma":[0.008262564,0.0022398583,0.5477738,0.00073958654,0.000018367582,0.00007500358,0.0010188522,0.00073464087,0.422804,0.00022885978,0.015690597,0.00041391506],"about_ca_topic_score_codex":0.0016411864,"about_ca_topic_score_gemma":0.00030378395,"teacher_disagreement_score":0.44617805,"about_ca_system_score_codex":0.0005830881,"about_ca_system_score_gemma":0.0005579547,"threshold_uncertainty_score":0.9994614},"labels":[],"label_agreement":null},{"id":"W2913620859","doi":"10.1016/j.juro.2010.10.089","title":"Editorial Comment","year":2011,"lang":"es","type":"editorial","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Guideline; Gynecology; Family medicine; Internal medicine; Oncology; Urology; General surgery; Cancer; Pathology","score_opus":0.02480177670591102,"score_gpt":0.3285287474003008,"score_spread":0.3037269706943898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913620859","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005525668,0.011574752,0.000019553248,0.012276154,0.9737091,0.00034326568,0.00004455604,0.0000070449055,0.0014729812],"genre_scores_gemma":[0.0042941454,0.03445002,0.000012704857,0.0003945218,0.9595974,0.000004893294,0.000026761149,0.000050852286,0.0011686935],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99585116,0.00096570636,0.00093382946,0.00017270903,0.0014332607,0.0006433256],"domain_scores_gemma":[0.9946784,0.002134533,0.001159903,0.0004821417,0.0012409687,0.0003040823],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0031369051,0.00037736376,0.0010591112,0.00027736937,0.00019065112,0.000024804385,0.0009104762,0.0010332013,0.000741492],"category_scores_gemma":[0.00081546546,0.00019230985,0.00034785192,0.00013947302,0.00060907734,0.0000735951,0.00022496413,0.0037933397,0.0002130627],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019437717,0.00037625234,0.00012888107,0.000081036,0.0014739966,0.00018150719,0.0009508276,0.0000021455253,0.00019982224,0.00003657144,0.97600216,0.0011290618],"study_design_scores_gemma":[0.0066515123,0.010732374,0.00008952925,0.0001223724,0.0022744278,0.00017138492,0.000116609146,0.000001860953,0.00013302785,0.0004917472,0.97907466,0.00014050017],"about_ca_topic_score_codex":0.0001393768,"about_ca_topic_score_gemma":0.0000054364286,"teacher_disagreement_score":0.02287527,"about_ca_system_score_codex":0.00031255448,"about_ca_system_score_gemma":0.0018318114,"threshold_uncertainty_score":0.99850494},"labels":[],"label_agreement":null},{"id":"W2914080921","doi":"10.1101/546051","title":"The genomic landscape of metastatic castration-resistant prostate cancers using whole genome sequencing reveals multiple distinct genotypes with potential clinical impact","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Chromothripsis; Chromoplexy; Whole genome sequencing; Genome; Prostate cancer; Gene duplication; Microsatellite; Genotype; DNA sequencing","score_opus":0.03953090748665782,"score_gpt":0.31051818556792976,"score_spread":0.27098727808127193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914080921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900779,0.005056179,0.0003575682,0.000107821055,0.00037245516,0.0025763777,0.0013754659,0.00007113589,0.000005095977],"genre_scores_gemma":[0.9957744,0.00065106177,0.0029374592,0.000023114459,0.00031584015,0.00011521227,0.000009473464,0.00014331964,0.00003012612],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9963556,0.00028857525,0.0010161382,0.00089008827,0.00067013723,0.0007794592],"domain_scores_gemma":[0.9964547,0.00021946905,0.0008935929,0.0012281602,0.00084400014,0.0003600784],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013000551,0.0005713839,0.0010752241,0.00020351296,0.00030753078,0.00019133177,0.00035972893,0.00022878543,0.000026535768],"category_scores_gemma":[0.00019201277,0.00036248943,0.00032608348,0.00038200745,0.00038176056,0.00011550809,0.00025078215,0.00085139007,0.000015676016],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022820842,0.000096075586,0.125168,0.001091249,0.0016537074,0.00026060542,0.000040020816,0.005150618,0.8642207,0.0000046171886,0.000028722316,0.000003649212],"study_design_scores_gemma":[0.005751705,0.0012730594,0.9539674,0.0015370056,0.0018004916,8.115859e-7,0.00007568814,0.010811305,0.023633856,0.0000023249913,0.00026595194,0.00088040216],"about_ca_topic_score_codex":0.00080730545,"about_ca_topic_score_gemma":0.00005703535,"teacher_disagreement_score":0.8405868,"about_ca_system_score_codex":0.0015567094,"about_ca_system_score_gemma":0.0073269713,"threshold_uncertainty_score":0.9998827},"labels":[],"label_agreement":null},{"id":"W2914204946","doi":"10.1016/j.euf.2019.01.005","title":"Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer","year":2019,"lang":"en","type":"review","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Prostate cancer; Clinical trial; Cancer; Medical physics; Oncology; Internal medicine","score_opus":0.22015658388022494,"score_gpt":0.436312275547539,"score_spread":0.21615569166731405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914204946","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010654794,0.9890781,0.000019282386,0.0018828444,0.00014083981,0.0071952557,0.00024971543,0.000016158563,0.0003523011],"genre_scores_gemma":[0.010908622,0.9867263,0.000085696774,0.00015171348,0.00011793714,0.001243202,0.000017270246,0.00008354864,0.0006657358],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99686915,0.001484312,0.00043457779,0.00052325986,0.0003512421,0.0003374633],"domain_scores_gemma":[0.9968494,0.0017500728,0.00032906944,0.00044642953,0.0005358442,0.00008917326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026687335,0.00032900367,0.0011824657,0.00017559194,0.00009058133,0.000027772947,0.00017684257,0.00006258613,0.0000272024],"category_scores_gemma":[0.00097421434,0.00017217184,0.00022087102,0.00020878749,0.00020942137,0.000060548457,0.00012765238,0.00025651386,0.00004524292],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061564916,0.000029938721,0.0000063811794,0.0027447091,0.0011678117,0.0000148011595,0.0007577756,0.0000021390629,0.00015033309,0.000010362059,0.00045991328,0.9940402],"study_design_scores_gemma":[0.004476005,0.007817696,0.0018773569,0.016694566,0.06139112,0.00016216945,0.00042953837,0.0003969531,0.00090309035,0.00015292008,0.90466195,0.0010366142],"about_ca_topic_score_codex":0.0000305603,"about_ca_topic_score_gemma":0.000008721933,"teacher_disagreement_score":0.99300355,"about_ca_system_score_codex":0.00011429824,"about_ca_system_score_gemma":0.0005968089,"threshold_uncertainty_score":0.7020964},"labels":[],"label_agreement":null},{"id":"W2914471889","doi":"10.1158/1538-7445.prca2017-a041","title":"Abstract A041: LSD1 inhibition disrupts FOXA1-dependent AR cistrome","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"FOXA1; Transcription factor; Androgen receptor; Enhancer; Chromatin; Biology; Demethylase; Cancer research; Pioneer factor; Epigenetics; Epigenomics; Histone; Epigenome; Cell biology; Prostate cancer; Genetics; DNA methylation; Gene; Gene expression; Cancer","score_opus":0.12556389661233372,"score_gpt":0.4711247264731977,"score_spread":0.345560829860864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914471889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973694,0.0019394065,0.000014418004,0.004479847,0.00029222312,0.0009610018,0.00008040564,0.00008294117,0.018455748],"genre_scores_gemma":[0.98286146,0.0011523097,0.00005557358,0.00013571767,0.0016271457,0.000391434,0.000076582626,0.000051672985,0.01364812],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964701,0.00012232733,0.00026880298,0.0005712216,0.0015510711,0.0010164854],"domain_scores_gemma":[0.9978883,0.00017510711,0.00004516102,0.00055091735,0.00086525286,0.00047522513],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001285943,0.00018851981,0.0002821753,0.00037873656,0.0003975173,0.00009583909,0.00017717855,0.00014801088,0.0040884106],"category_scores_gemma":[0.0002214725,0.00014538452,0.00010245852,0.0006440567,0.0007119074,0.0001767068,0.00017167174,0.00078221946,0.0013039876],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007297258,0.0010160125,0.033367686,0.0008888968,0.00042212923,0.0016579055,0.0017102285,0.0000021027327,0.8181423,0.00056492863,0.06972456,0.06520597],"study_design_scores_gemma":[0.008334309,0.0027173292,0.23118772,0.0011443752,0.000067807465,0.00009323128,0.000819126,0.000033678454,0.6889929,0.0013387738,0.06478971,0.000481037],"about_ca_topic_score_codex":0.0006942566,"about_ca_topic_score_gemma":0.00020780569,"teacher_disagreement_score":0.19782002,"about_ca_system_score_codex":0.0010351192,"about_ca_system_score_gemma":0.00081998756,"threshold_uncertainty_score":0.99947363},"labels":[],"label_agreement":null},{"id":"W2914701766","doi":"","title":"18F-DCFPyL PET/CT in Castration-Resistant Prostate Cancer (CRPC): Imaging results prior to and following abiraterone or enzalutemide therapy","year":2018,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Abiraterone acetate; Standardized uptake value; Androgen deprivation therapy; Nuclear medicine; Biomarker; Oncology; Positron emission tomography; Radiology; Internal medicine; Cancer","score_opus":0.04073892577128708,"score_gpt":0.3740726807389786,"score_spread":0.3333337549676915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914701766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878447,0.0013525153,0.0000051715692,0.0066117565,0.00015802895,0.0014357711,0.000033946333,0.00006461558,0.002493476],"genre_scores_gemma":[0.9837135,0.0008336286,0.0011283443,0.00076496566,0.00015526568,0.00020489455,0.000021215059,0.000034754517,0.013143421],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982309,0.000047801208,0.00037927082,0.0004974761,0.00032831467,0.0005162623],"domain_scores_gemma":[0.99925613,0.000069024965,0.000050752165,0.00025914764,0.00012907236,0.00023586227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039643608,0.00021397181,0.00030495375,0.00019858612,0.00015824869,0.00009227207,0.00007593138,0.000008917645,0.00016433343],"category_scores_gemma":[0.00006305932,0.00013380371,0.000045004537,0.00037341204,0.00009854002,0.00019541672,0.000048150458,0.00013906634,0.000024810919],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054474726,0.0006170021,0.21351187,0.00029389787,0.00049361517,0.014997335,0.00967178,0.000010345395,0.5667383,0.00006191443,0.009321945,0.12980726],"study_design_scores_gemma":[0.07741854,0.0066874903,0.41366842,0.0031559055,0.00018557058,0.00086964516,0.0065160906,0.0011851894,0.44123155,0.00020293932,0.047333617,0.0015450232],"about_ca_topic_score_codex":0.0027317936,"about_ca_topic_score_gemma":0.004575587,"teacher_disagreement_score":0.20015657,"about_ca_system_score_codex":0.00027763168,"about_ca_system_score_gemma":0.00047270235,"threshold_uncertainty_score":0.5456357},"labels":[],"label_agreement":null},{"id":"W2915177933","doi":"10.1200/jco.18.02031","title":"Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Medicine; Prostate cancer; Castration; Asymptomatic; Prostate; Oncology; Cancer; Internal medicine; Urology; Gynecology; Surgery; Hormone","score_opus":0.14487688439168125,"score_gpt":0.5227371279460361,"score_spread":0.3778602435543549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915177933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99251944,0.0006406716,0.0000039721626,0.0030642673,0.00082135946,0.0021708563,0.00001629273,0.000006645495,0.0007564767],"genre_scores_gemma":[0.9946714,0.0009618908,0.001674663,0.00023013471,0.00026968538,0.00006834662,0.0000064792634,0.00002194227,0.0020954416],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942113,0.0005497544,0.0039623654,0.00022250843,0.00070821977,0.00034580866],"domain_scores_gemma":[0.9942904,0.002290983,0.0023317018,0.00023426053,0.00053809973,0.0003145368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037385263,0.00018601735,0.0023149487,0.0003083441,0.000021542337,0.000012533794,0.00017665235,0.0001848223,0.00055466266],"category_scores_gemma":[0.0018364603,0.000106675725,0.00039321365,0.0003666196,0.00020901556,0.00018692695,0.00003784421,0.00066970236,0.000017857597],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8751309,0.017804494,0.018653471,0.0010820541,0.001545449,0.0018539651,0.0010429984,0.000033174252,0.007071116,0.000054222455,0.0008482173,0.07487995],"study_design_scores_gemma":[0.7991571,0.16821201,0.024295961,0.001603655,0.0010344009,0.00018961645,0.0008133495,0.00086279796,0.0013724223,0.00029937312,0.0019636066,0.00019573396],"about_ca_topic_score_codex":0.000053695407,"about_ca_topic_score_gemma":0.00014670087,"teacher_disagreement_score":0.15040751,"about_ca_system_score_codex":0.00032255484,"about_ca_system_score_gemma":0.007903221,"threshold_uncertainty_score":0.9977211},"labels":[],"label_agreement":null},{"id":"W2915582979","doi":"10.1038/s41585-019-0164-8","title":"The influence of BRCA2 mutation on localized prostate cancer","year":2019,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Health and Medical Research Council; National Medical Research Council; State Government of Victoria; Australian Government; Victorian Cancer Agency","keywords":"Prostate cancer; Medicine; BRCA2 Protein; Disease; Genome instability; Germline mutation; Cancer; Mutation; Germline; Oncology; Prostate; Somatic evolution in cancer; Cancer research; Bioinformatics; Internal medicine; Gene; Biology; Genetics; DNA damage","score_opus":0.0458650264998618,"score_gpt":0.4344098668126594,"score_spread":0.3885448403127976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915582979","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000041216404,0.9924802,4.586593e-7,0.0009089776,0.00037616762,0.0056216563,0.000055823944,0.000018221002,0.00049723935],"genre_scores_gemma":[0.000038859842,0.9954826,0.000016247808,0.00061299506,0.00015039687,0.000979356,0.00017684307,0.00004999045,0.0024926816],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99720377,0.0006286141,0.0008748911,0.0005091016,0.0003635773,0.00042002462],"domain_scores_gemma":[0.9975386,0.0005862133,0.0007718332,0.00076655444,0.000241379,0.00009537459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000774495,0.0004253824,0.002649464,0.00017973712,0.000078073645,0.00001209531,0.00030943262,0.00089102326,0.000052072948],"category_scores_gemma":[0.00050026726,0.00019177723,0.00059502426,0.00055455964,0.00023460349,0.00003232325,0.0000666933,0.0019937612,0.00023444666],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023330047,0.000043782104,0.000024863733,0.02798771,0.0002826338,0.00003332029,0.00002368984,0.0000037633952,0.0000011551548,0.00016044536,0.0022640957,0.9689412],"study_design_scores_gemma":[0.000696826,0.00058300066,0.000041612064,0.011297992,0.0015532618,0.00007761713,0.0000011053505,0.0000020101047,0.0000025108197,0.000031940963,0.98557156,0.00014053755],"about_ca_topic_score_codex":0.000015246057,"about_ca_topic_score_gemma":0.0000127799185,"teacher_disagreement_score":0.9833075,"about_ca_system_score_codex":0.00021750182,"about_ca_system_score_gemma":0.0009336018,"threshold_uncertainty_score":0.86620116},"labels":[],"label_agreement":null},{"id":"W2916205053","doi":"10.1101/562652","title":"Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"The Wellcome Trust DBT India Alliance; Department of Biotechnology, Ministry of Science and Technology, India; Sleep Research Society Foundation; Wellcome Trust","keywords":"Prostate cancer; Transactivation; Androgen receptor; Cancer research; Androgen deprivation therapy; Biology; Corepressor; Gene silencing; Downregulation and upregulation; Transcription factor; Repressor; Carcinogenesis; Endocrinology; Cancer; Genetics","score_opus":0.015058025666056667,"score_gpt":0.249925331789508,"score_spread":0.23486730612345133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916205053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881571,0.008847526,0.0000849594,0.0003233433,0.00034555353,0.0019293511,0.00016682954,0.00013961374,0.0000057207844],"genre_scores_gemma":[0.9945062,0.0039250534,0.00081981043,0.000052964573,0.00018862926,0.00036247115,0.000003373516,0.00010109026,0.000040417217],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99743307,0.000085869775,0.00044881232,0.0009997477,0.00045138766,0.0005811403],"domain_scores_gemma":[0.9985437,0.000049217655,0.00024439223,0.00057752995,0.00031745507,0.00026774887],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025169592,0.00048049755,0.00065871206,0.00037520373,0.000100735684,0.00012873675,0.000175438,0.0004288108,0.00006740684],"category_scores_gemma":[0.00008229078,0.00041888436,0.000090954294,0.00033453913,0.00013257335,0.00016481227,0.00047382838,0.00073865644,0.000025298927],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029182687,0.00013755809,0.32042977,0.0011915613,0.000109855064,0.00014210746,0.00002570792,0.00011261483,0.67746615,0.000010814231,0.000076281794,0.0000057403013],"study_design_scores_gemma":[0.0020157923,0.00008250999,0.3112828,0.002069002,0.00011598442,3.3978935e-8,0.0000035213318,0.001189935,0.682622,0.0000031381558,0.0002577454,0.00035751835],"about_ca_topic_score_codex":0.00018890275,"about_ca_topic_score_gemma":0.000004010307,"teacher_disagreement_score":0.009146981,"about_ca_system_score_codex":0.00041634904,"about_ca_system_score_gemma":0.0006608534,"threshold_uncertainty_score":0.9998263},"labels":[],"label_agreement":null},{"id":"W2916658582","doi":"10.1038/s41388-019-0768-8","title":"A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer","year":2019,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute on Minority Health and Health Disparities; University of Illinois at Chicago; National Institute of General Medical Sciences; School of Medicine, Vanderbilt University; National Institute of Allergy and Infectious Diseases; Johns Hopkins University; National Cancer Institute; U.S. Department of Health and Human Services; National Natural Science Foundation of China; U.S. Department of Defense","keywords":"Androgen receptor; Enzalutamide; Prostate cancer; Biology; Gene knockdown; Cancer research; splice; Gene isoform; Alternative splicing; Small hairpin RNA; Gene expression; Gene; Molecular biology; Cancer; Genetics","score_opus":0.0137143682473599,"score_gpt":0.30710429159764463,"score_spread":0.29338992335028474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916658582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98854727,0.00834702,1.0201815e-7,0.00030505122,0.00002985771,0.0007865564,0.000052546544,0.00000594088,0.0019256572],"genre_scores_gemma":[0.9964345,0.0015790341,0.0001674447,0.000034722136,0.00002761345,0.000052481697,0.000023776069,0.000015178159,0.001665247],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99918306,0.000036979134,0.00017989994,0.00022295024,0.00015414403,0.00022294892],"domain_scores_gemma":[0.999686,0.000033956043,0.000050707135,0.00009548299,0.00006631697,0.000067534165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016919925,0.00009049831,0.0002516887,0.00012224176,0.000013054302,0.0000037364944,0.000034181918,0.000048752147,0.00012785902],"category_scores_gemma":[0.000017965562,0.00007383264,0.000020010231,0.000271836,0.00002100037,0.0000690119,0.000042884003,0.000100284786,0.0000124054095],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009225661,0.00010718184,0.3429464,0.00011594253,0.000040667164,0.0000264036,0.001927421,0.000013602195,0.6369724,0.00002001389,0.000011973048,0.016895382],"study_design_scores_gemma":[0.0108328285,0.0007768198,0.24978055,0.0015468515,0.000038969694,0.000028217106,0.0011140672,0.0022422785,0.73285687,0.000083542334,0.00048640397,0.00021259078],"about_ca_topic_score_codex":0.00061799685,"about_ca_topic_score_gemma":0.00017030588,"teacher_disagreement_score":0.09588446,"about_ca_system_score_codex":0.00015306516,"about_ca_system_score_gemma":0.00017615575,"threshold_uncertainty_score":0.3010808},"labels":[],"label_agreement":null},{"id":"W2916873940","doi":"10.5489/cuaj.2013","title":"What’s new in prostate cancer research? Highlights of GU-ASCO 2014","year":2014,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Prostate cancer; Medicine; Genitourinary system; Oncology; Medical physics; Gynecology; Library science; Cancer; Internal medicine; Computer science","score_opus":0.08144697785185719,"score_gpt":0.39783891272591626,"score_spread":0.3163919348740591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916873940","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002530463,0.97898436,5.5559866e-7,0.018181995,0.0008419814,0.0010112048,0.000061067854,0.000010175544,0.00065560325],"genre_scores_gemma":[0.00029632347,0.9831809,0.000024643154,0.00030864478,0.0012039071,0.00007836457,0.000100667785,0.00003963279,0.014766957],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952218,0.0011089817,0.0009982442,0.0004185674,0.0010685831,0.001183812],"domain_scores_gemma":[0.9963687,0.0005399414,0.000648225,0.00024766792,0.0006894291,0.0015060051],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030220463,0.00032312665,0.0018242692,0.0013054523,0.00018759689,0.00018860538,0.00033691613,0.000696457,0.0011533257],"category_scores_gemma":[0.00080609333,0.00021117214,0.00044294033,0.0008466917,0.00010578813,0.00018663742,0.000047349742,0.0025052151,0.00018361029],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00012065415,0.00010645462,0.008060382,0.0020326502,0.0006169458,0.00057109335,0.0002489558,0.0000036327067,0.0000016706207,0.0002172518,0.21756876,0.77045155],"study_design_scores_gemma":[0.0011435229,0.0004079591,0.0023121913,0.005294533,0.000227157,0.000075957665,0.00002649476,0.0000022081133,0.0000014432461,0.0004671851,0.9898623,0.00017901354],"about_ca_topic_score_codex":0.00811351,"about_ca_topic_score_gemma":0.007224878,"teacher_disagreement_score":0.77229357,"about_ca_system_score_codex":0.005867876,"about_ca_system_score_gemma":0.010484877,"threshold_uncertainty_score":0.99979603},"labels":[],"label_agreement":null},{"id":"W2917648822","doi":"10.3747/co.26.4203","title":"Efficacy and Safety of Combined Androgen Blockade with Antiandrogen for Advanced Prostate Cancer","year":2019,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"AstraZeneca","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Antiandrogen; Adverse effect; Subgroup analysis; Oncology; Blockade; Randomized controlled trial; Confidence interval; Urology; Gastroenterology; Cancer","score_opus":0.15551217031936584,"score_gpt":0.48352789369780036,"score_spread":0.32801572337843454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917648822","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002109156,0.9882767,0.0000071034833,0.0001611524,0.0003981114,0.00832494,0.0005537417,0.000025675898,0.00014340536],"genre_scores_gemma":[0.00010020579,0.99686253,0.00014827077,0.000008083196,0.000116244024,0.0010726321,0.00084342196,0.00006791589,0.0007806982],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981435,0.00009195823,0.0005485378,0.00055417186,0.00020271834,0.0004591244],"domain_scores_gemma":[0.9985121,0.00031099614,0.00042409005,0.00032768678,0.00023241615,0.00019271106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001757798,0.00039986937,0.002580236,0.0001965076,0.000061483195,0.0000072657735,0.00012698738,0.00024761262,0.000038690487],"category_scores_gemma":[0.00003444624,0.00024477404,0.00022283543,0.00025275486,0.00026007555,0.000035246758,0.000087614215,0.0003575138,0.000005939861],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005014827,0.00048912346,0.00066402764,0.046662915,0.00088515884,0.000017045075,0.00011200636,5.70585e-7,0.0000052175938,0.000023502787,0.00033562665,0.94579],"study_design_scores_gemma":[0.019381134,0.0040781107,0.000052717987,0.01501585,0.003247001,0.000064950254,0.000016933542,0.0000064004794,0.000055506494,0.0000073001265,0.9578353,0.00023875026],"about_ca_topic_score_codex":0.0000043347895,"about_ca_topic_score_gemma":0.0000066907937,"teacher_disagreement_score":0.95749974,"about_ca_system_score_codex":0.00033180657,"about_ca_system_score_gemma":0.0020230464,"threshold_uncertainty_score":0.9981595},"labels":[],"label_agreement":null},{"id":"W2920048684","doi":"10.1200/jco.2019.37.7_suppl.3","title":"SABR in high-risk prostate cancer: Outcomes from two prospective clinical trials with and without elective nodal irradiation.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; SABR volatility model; Prostate; Urology; Internal medicine; Prospective cohort study; Clinical trial; Prostate-specific antigen; Oncology; Cancer; Surgery; Gastroenterology","score_opus":0.14388872262186886,"score_gpt":0.545312926737813,"score_spread":0.4014242041159441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920048684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892505,0.0015564337,0.000016852344,0.0062594167,0.0009962503,0.0014237732,0.000045238987,0.000010118299,0.0004414233],"genre_scores_gemma":[0.98750246,0.007920405,0.002058978,0.000627781,0.0011606442,0.000032944852,0.0000063528537,0.000026437005,0.0006639748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99297404,0.0023392735,0.0034181245,0.00043014376,0.00049966865,0.0003387601],"domain_scores_gemma":[0.98626274,0.009673733,0.002827133,0.00020280444,0.0005913127,0.00044226774],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011511702,0.0002152556,0.0035536014,0.0001831438,0.0000417753,0.000021758575,0.00012158631,0.00034428423,0.00016918099],"category_scores_gemma":[0.008862983,0.00011546419,0.00036614074,0.00021517255,0.0003562239,0.00020073424,0.000050522223,0.0020382232,0.000017984363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043095157,0.0008724653,0.86468303,0.000012368371,0.0015264851,0.00015386769,0.00026858292,0.000022855325,0.000021146674,0.000035895788,0.00018494081,0.0891232],"study_design_scores_gemma":[0.07215936,0.017595977,0.90610343,0.00015237446,0.0006405588,0.00002755803,0.00018648063,0.000114471906,0.000042094012,0.0013592466,0.0014978896,0.000120542],"about_ca_topic_score_codex":0.0011125132,"about_ca_topic_score_gemma":0.0009719129,"teacher_disagreement_score":0.089002654,"about_ca_system_score_codex":0.00044046418,"about_ca_system_score_gemma":0.003609516,"threshold_uncertainty_score":0.9994858},"labels":[],"label_agreement":null},{"id":"W2920799111","doi":"10.1200/jco.2019.37.7_suppl.159","title":"Predictors of germline DNA damage repair gene mutations (gDDRm) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; PALB2; Prostatectomy; Cancer; Germline mutation; Gene; Mutation","score_opus":0.07643932083146604,"score_gpt":0.4478475139241071,"score_spread":0.37140819309264106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920799111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965768,0.00033581414,0.0000048345664,0.0013535594,0.00043196356,0.000785292,0.00005667999,0.0000080403115,0.00044700957],"genre_scores_gemma":[0.99633145,0.00038576123,0.0020583933,0.00016750825,0.0001595742,0.000019590725,0.000037073296,0.00002033208,0.0008202906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965321,0.0003300503,0.0020667866,0.00021138364,0.0005993424,0.00026032727],"domain_scores_gemma":[0.9964831,0.00075076893,0.0013639634,0.00020522904,0.00092856423,0.00026838886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014958265,0.00014365857,0.0011713781,0.00023818143,0.000025009094,0.0000058340183,0.00010559545,0.00012792661,0.00020652478],"category_scores_gemma":[0.00063597015,0.0000871872,0.0002477375,0.0003138787,0.00023517765,0.00016817062,0.000028924072,0.00060590176,0.0000071697564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015695244,0.0030868677,0.9733946,0.0001572515,0.0009057637,0.0004661062,0.00043272047,0.00029719295,0.0011886315,0.000012196227,0.0005004114,0.0038630248],"study_design_scores_gemma":[0.025392825,0.023561858,0.947233,0.00027707536,0.0004862562,0.000019673378,0.0002292983,0.00016609953,0.00069183804,0.000044634533,0.0018104155,0.000087026216],"about_ca_topic_score_codex":0.000095453484,"about_ca_topic_score_gemma":0.00028886454,"teacher_disagreement_score":0.026161587,"about_ca_system_score_codex":0.00030534194,"about_ca_system_score_gemma":0.0032381474,"threshold_uncertainty_score":0.57443345},"labels":[],"label_agreement":null},{"id":"W2920844027","doi":"10.1200/jco.2015.33.15_suppl.e16096","title":"Regional differences in cardiovascular status and events in prostate cancer patients treated with a gonadotrophin-releasing hormone agonist vs antagonist: Results of a pooled analysis.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Internal medicine; Incidence (geometry); Myocardial infarction; Proportional hazards model; Cumulative incidence; Cancer; Gynecology; Cohort","score_opus":0.09186731443337066,"score_gpt":0.4082371779295669,"score_spread":0.3163698634961962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920844027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99152786,0.0065487,0.0000019074203,0.0013587398,0.00006783261,0.00037351844,0.000029360179,0.0000028892366,0.00008921081],"genre_scores_gemma":[0.98974025,0.009763067,0.00020018601,0.00007605232,0.000078817335,0.0000117099935,0.000028793997,0.000011463216,0.00008967426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99625456,0.0006107321,0.0017876908,0.0002810312,0.0007260414,0.0003399178],"domain_scores_gemma":[0.9972962,0.0004047326,0.0009996959,0.00016268973,0.000691081,0.00044555738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001599898,0.0001654307,0.0022293122,0.0004848094,0.000023907625,0.0000069303023,0.000090818896,0.00016537549,0.0000024345954],"category_scores_gemma":[0.0007619269,0.00009829601,0.00032657915,0.00072774035,0.00033297774,0.000107356,0.00004138635,0.00061492884,3.6029795e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072465435,0.0018219943,0.91043705,0.000026952404,0.0033228945,0.00061833754,0.0004103496,0.0000685853,0.000018765642,0.0000014597224,0.000061364655,0.010746828],"study_design_scores_gemma":[0.05001187,0.013611682,0.9334773,0.00020779048,0.0016456343,0.000021663574,0.00017050403,0.00013670143,0.0000114530785,0.00003997322,0.00057695585,0.00008846098],"about_ca_topic_score_codex":0.002615596,"about_ca_topic_score_gemma":0.00051760895,"teacher_disagreement_score":0.023040276,"about_ca_system_score_codex":0.00048731078,"about_ca_system_score_gemma":0.0023286813,"threshold_uncertainty_score":0.41309804},"labels":[],"label_agreement":null},{"id":"W2920874600","doi":"10.1200/jco.2019.37.7_suppl.234","title":"Health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abiraterone.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Confidence interval; Placebo; Brief Pain Inventory; Randomized controlled trial; Clinical endpoint; Quality of life (healthcare); Urology; Oncology; Surgery; Cancer; Physical therapy; Pathology","score_opus":0.1149465555236373,"score_gpt":0.4599041896610921,"score_spread":0.3449576341374548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920874600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943683,0.00037149913,0.000003965954,0.003778308,0.000077010845,0.0012291585,0.000016737205,0.0000046942237,0.00015032367],"genre_scores_gemma":[0.9987823,0.00021283876,0.0004868622,0.00021026553,0.000015132265,0.000021738666,0.00003483837,0.000019617763,0.00021640696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954265,0.00082869356,0.0025717954,0.00023313664,0.00063548086,0.00030444443],"domain_scores_gemma":[0.99584794,0.00060790504,0.0023082157,0.00016384733,0.0007867212,0.0002853777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024685143,0.00016869068,0.0018823026,0.00026964807,0.000021858063,0.000008184275,0.00008393524,0.00013036838,0.00006574019],"category_scores_gemma":[0.00025889295,0.00008918515,0.00007459599,0.0005035139,0.0002177589,0.00019749414,0.00001303601,0.00073861924,0.0000026507973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09488462,0.0038728684,0.8942316,0.00022147832,0.00043519892,0.00011267495,0.00038751712,0.0002914921,0.000049421105,0.000029087358,0.000031732015,0.0054522716],"study_design_scores_gemma":[0.074475005,0.047203574,0.87706983,0.0006622156,0.00008967679,0.0000072378953,0.00022628697,0.000056168934,0.000044762957,0.000029416182,0.000049755305,0.000086093634],"about_ca_topic_score_codex":0.0023062297,"about_ca_topic_score_gemma":0.00613304,"teacher_disagreement_score":0.043330707,"about_ca_system_score_codex":0.0005829712,"about_ca_system_score_gemma":0.004687003,"threshold_uncertainty_score":0.8314542},"labels":[],"label_agreement":null},{"id":"W2921037661","doi":"10.1200/jco.2019.37.7_suppl.146","title":"Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Enzalutamide; Prostate cancer; Medicine; Oncology; Cancer; Cancer research; Transcriptome; Internal medicine; Gene; Biology; Genetics; Gene expression; Androgen receptor","score_opus":0.10582980403252615,"score_gpt":0.4651932925895905,"score_spread":0.35936348855706435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921037661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883544,0.004208329,0.0000014856013,0.0058455,0.00024348678,0.0005528563,0.000015367244,0.000002558416,0.00077604275],"genre_scores_gemma":[0.99080276,0.0051428764,0.0027021924,0.00020993024,0.00008439396,0.000011984283,0.0000020819846,0.000011440448,0.0010323395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744517,0.00026186442,0.0015809707,0.00017919201,0.0003142889,0.00021851026],"domain_scores_gemma":[0.99743396,0.00089540187,0.0010375403,0.00009725565,0.00032965242,0.00020618069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018245406,0.00010594947,0.0011136377,0.0001696222,0.000017831413,0.0000066331486,0.00008919027,0.000110632354,0.00008597518],"category_scores_gemma":[0.00050397636,0.000072105395,0.00016535695,0.0001717203,0.00023926696,0.00010465786,0.000030449713,0.00049890723,0.0000039988195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019380387,0.0009976058,0.9359823,0.00042328003,0.00057836086,0.00078121637,0.0006370267,0.000029315492,0.019649751,0.00017302379,0.00060189527,0.020765861],"study_design_scores_gemma":[0.016716052,0.008261089,0.9639339,0.00051359483,0.0003240822,0.00004040662,0.0005833741,0.000049936993,0.0016986731,0.00051493273,0.007269093,0.00009488957],"about_ca_topic_score_codex":0.000087284716,"about_ca_topic_score_gemma":0.00064792036,"teacher_disagreement_score":0.0279516,"about_ca_system_score_codex":0.0002575148,"about_ca_system_score_gemma":0.0025426492,"threshold_uncertainty_score":0.45105505},"labels":[],"label_agreement":null},{"id":"W2921079290","doi":"10.1200/jco.2019.37.7_suppl.186","title":"Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Prostate cancer; Regimen; Docetaxel; Oncology; Prednisone; Abiraterone acetate; Progression-free survival; Proportional hazards model; Cancer; Androgen deprivation therapy; Chemotherapy; Confidence interval","score_opus":0.10637759293864724,"score_gpt":0.5081206529327078,"score_spread":0.40174305999406057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921079290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679324,0.00040661727,0.0000041504077,0.025081323,0.000274062,0.00067501917,0.000015208089,0.0000073832034,0.005603807],"genre_scores_gemma":[0.9924365,0.0018754491,0.002513681,0.0006965472,0.00020745728,0.000021422939,0.0000038434378,0.000025807696,0.0022192919],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958866,0.00065004954,0.002216295,0.0003310139,0.0005155548,0.0004004479],"domain_scores_gemma":[0.99590665,0.0015235463,0.0014217197,0.00022124177,0.00032296812,0.0006038436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028839533,0.00020227711,0.0022197352,0.0002195827,0.000034737935,0.000021880247,0.00013245008,0.0001302008,0.00012965499],"category_scores_gemma":[0.00068822724,0.00011401941,0.00026560982,0.00030058256,0.0006549617,0.0001496481,0.000044321107,0.0011713514,0.000011408429],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011345464,0.0011325355,0.87382305,0.000046467056,0.0007777593,0.0015236039,0.00039546573,0.000005389896,0.000044187553,0.000031405412,0.00037292734,0.11050173],"study_design_scores_gemma":[0.016252061,0.022647966,0.9481392,0.00014454534,0.00035962195,0.00015051017,0.0024797488,0.000053277192,0.0000106315365,0.000094504954,0.009540624,0.00012733428],"about_ca_topic_score_codex":0.0005634175,"about_ca_topic_score_gemma":0.0025452273,"teacher_disagreement_score":0.11037439,"about_ca_system_score_codex":0.00026642636,"about_ca_system_score_gemma":0.0033931488,"threshold_uncertainty_score":0.60193},"labels":[],"label_agreement":null},{"id":"W2921151092","doi":"10.1200/jco.2019.37.7_suppl.280","title":"Abi1 loss drives prostate tumorigenesis through activation of EMT and noncanonical WNT signaling.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Queen's University","funders":"","keywords":"Wnt signaling pathway; Cancer research; Prostate cancer; Carcinogenesis; Biology; Cancer; Signal transduction; Cell biology","score_opus":0.10598788587465319,"score_gpt":0.48312061680180146,"score_spread":0.3771327309271483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921151092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99046504,0.0006403323,0.000046288416,0.0062932773,0.00042463862,0.00033115412,0.0000029666298,0.000004756293,0.0017915483],"genre_scores_gemma":[0.9939358,0.0024922362,0.0018690306,0.00041538203,0.00047329423,0.0000033736032,0.0000030394267,0.000013845189,0.00079395645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746424,0.00025605602,0.0014842023,0.00018145841,0.00040191464,0.0002121588],"domain_scores_gemma":[0.99638647,0.0016536943,0.0010870029,0.00013295027,0.0005223456,0.00021755887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016431703,0.00011241452,0.0011689055,0.00008230712,0.000026934038,0.000006684507,0.000097516335,0.00023836143,0.00014074444],"category_scores_gemma":[0.0008513674,0.00007015692,0.00026476558,0.00013038759,0.00033964636,0.00016487073,0.000052732557,0.0005955965,0.000010934136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026162138,0.0031497842,0.8511187,0.00038803162,0.0011442939,0.00062732626,0.0010477396,0.000042877244,0.030385297,0.00073711324,0.0010822535,0.08411444],"study_design_scores_gemma":[0.035455886,0.057377644,0.807599,0.0008531753,0.00064816314,0.00045794976,0.0008052752,0.000110810244,0.05360218,0.0043848753,0.038434554,0.0002704944],"about_ca_topic_score_codex":0.000019158953,"about_ca_topic_score_gemma":0.0000024935193,"teacher_disagreement_score":0.08384395,"about_ca_system_score_codex":0.00011785297,"about_ca_system_score_gemma":0.0019179138,"threshold_uncertainty_score":0.34022966},"labels":[],"label_agreement":null},{"id":"W2921155986","doi":"10.1200/jco.2019.37.7_suppl.42","title":"Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; DECIPHER; Prostate cancer; Subtyping; Oncology; Androgen deprivation therapy; Internal medicine; Hazard ratio; Transcriptome; Cancer; Bioinformatics; Gene; Biology; Confidence interval; Gene expression; Genetics","score_opus":0.12030030968046344,"score_gpt":0.4970611933775088,"score_spread":0.37676088369704536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921155986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995692,0.00016961998,0.0000040784225,0.0022246747,0.00028964,0.0015183099,0.000008720274,0.0000013462105,0.00009159866],"genre_scores_gemma":[0.99862224,0.00013240393,0.00055527966,0.0004203849,0.000051537,0.000037703114,0.0000016965759,0.000013994184,0.0001647767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957754,0.0011387782,0.0019148778,0.00019753561,0.0006860487,0.00028735804],"domain_scores_gemma":[0.99679387,0.0015179542,0.00097551756,0.00022009872,0.0003248014,0.00016777715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054957187,0.0001268481,0.0010894107,0.00029128755,0.000017975795,0.000012668479,0.00018548516,0.000112762165,0.000039362552],"category_scores_gemma":[0.001554543,0.00006871479,0.00015194654,0.00039144795,0.00011361048,0.00010819966,0.000031797077,0.0005770048,0.0000073013753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4005929,0.0017282008,0.5810371,0.0000749366,0.000102926606,0.0012058355,0.0009535902,0.00010114562,0.0016923405,0.000003872653,0.000045461904,0.012461681],"study_design_scores_gemma":[0.095921606,0.034357164,0.8671792,0.00058786006,0.00012454482,0.000018652663,0.00058507605,0.0000287232,0.00066472293,0.00005892219,0.00039875842,0.00007476153],"about_ca_topic_score_codex":0.000118275915,"about_ca_topic_score_gemma":0.00091470225,"teacher_disagreement_score":0.3046713,"about_ca_system_score_codex":0.0002878031,"about_ca_system_score_gemma":0.0020730111,"threshold_uncertainty_score":0.36774325},"labels":[],"label_agreement":null},{"id":"W2921196529","doi":"10.1200/jco.2019.37.7_suppl.161","title":"A retrospective observational study assessing bone metastases (mets) detection and management of patients (pts) with castration-resistant prostate cancer (CRPC) in Canada.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; St. Joseph’s Healthcare Hamilton; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Cohort; Prostate cancer; Androgen deprivation therapy; Internal medicine; Retrospective cohort study; Oncology; Guideline; Cancer; Pathology","score_opus":0.14723141278242588,"score_gpt":0.4637936837074555,"score_spread":0.31656227092502964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921196529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99792755,0.0002785726,0.000005693734,0.00062029564,0.00020429716,0.0007906703,0.000016997785,0.000001352998,0.0001545599],"genre_scores_gemma":[0.9986797,0.00042798521,0.0006496137,0.00006934421,0.000043876098,0.000018901024,0.000004321885,0.0000080434875,0.000098193676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977946,0.00021902197,0.0010833764,0.00016932092,0.00058375124,0.0001499152],"domain_scores_gemma":[0.9980341,0.00026152912,0.00089907227,0.000084934116,0.0006028967,0.00011744722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011583788,0.00009333964,0.0007572068,0.00010919202,0.000026755906,0.000008907579,0.00004135554,0.000051546158,0.00003739756],"category_scores_gemma":[0.00013845648,0.000059054084,0.000049803468,0.00022439014,0.00006113275,0.00016150648,0.000026642856,0.00037774403,2.575902e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008078516,0.0013829602,0.9650756,0.000094189854,0.0005663932,0.0003900443,0.00010495787,0.000052218038,0.00015513694,0.000007306449,0.000029097775,0.02406358],"study_design_scores_gemma":[0.014794614,0.009267012,0.97368306,0.00020426742,0.00027330537,0.0000090362255,0.0012920453,0.000056507142,0.00010845758,0.000024666948,0.0002345269,0.0000525136],"about_ca_topic_score_codex":0.04512481,"about_ca_topic_score_gemma":0.36555204,"teacher_disagreement_score":0.32042724,"about_ca_system_score_codex":0.0010768842,"about_ca_system_score_gemma":0.0033934512,"threshold_uncertainty_score":0.9612338},"labels":[],"label_agreement":null},{"id":"W2921252344","doi":"10.1200/jco.2019.37.7_suppl.201","title":"Metastasis-free survival as a predictor of overall survival in non-metastatic castration-resistant prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Saskatchewan; University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Oncology; Doubling time; Progression-free survival; Internal medicine; Cancer; Clinical endpoint; Metastasis; Urology; Population; Log-rank test; Prostate; Survival analysis; Overall survival; Clinical trial","score_opus":0.11677330585184705,"score_gpt":0.4777341261483805,"score_spread":0.3609608202965335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921252344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878517,0.0010420383,0.000007967804,0.005202312,0.0016641787,0.0007541293,0.00008017904,0.0000053096874,0.0033922072],"genre_scores_gemma":[0.9942261,0.0022214213,0.0010537357,0.0002167346,0.0003757814,0.000017023458,0.00001129952,0.000025265534,0.0018526533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949692,0.00063815474,0.0027480163,0.0002688182,0.00097433134,0.0004014928],"domain_scores_gemma":[0.99482954,0.002112124,0.0015696001,0.00034951934,0.0007364524,0.0004027437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046512387,0.00019758481,0.002154885,0.00026023143,0.00002219755,0.000011945951,0.0002922866,0.00019733285,0.0005633835],"category_scores_gemma":[0.0022178353,0.00013174977,0.00047290215,0.0002885263,0.00023645461,0.000189695,0.00009239319,0.0009901784,0.000021780634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07537113,0.0059527764,0.86768955,0.0007715337,0.0028752708,0.003378629,0.00082717615,0.00026537274,0.009087404,0.00062396,0.0027260166,0.030431153],"study_design_scores_gemma":[0.05901644,0.03310603,0.8955671,0.000644641,0.0006837588,0.00010570464,0.00073486345,0.00021752845,0.0008709133,0.0017850084,0.0070665916,0.00020142006],"about_ca_topic_score_codex":0.0005760303,"about_ca_topic_score_gemma":0.000725259,"teacher_disagreement_score":0.030229732,"about_ca_system_score_codex":0.00033671525,"about_ca_system_score_gemma":0.0055790334,"threshold_uncertainty_score":0.98969656},"labels":[],"label_agreement":null},{"id":"W2921257975","doi":"10.1200/jco.2019.37.7_suppl.233","title":"Association between urinary, bowel, and hormonal treatment-related symptoms and clinical outcomes in nonmetastatic castration-resistant prostate cancer (nmCRPC): PROSPER study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Prostate cancer; Confidence interval; Oncology; Proportional hazards model; Urinary system; Metastasis; Cancer; Gastroenterology","score_opus":0.08263281353558231,"score_gpt":0.4836826978408333,"score_spread":0.40104988430525096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921257975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99098337,0.001062467,3.6472295e-7,0.0058987355,0.00041917182,0.001379563,0.000024772116,0.0000066357616,0.00022492543],"genre_scores_gemma":[0.99176514,0.0037147782,0.00016513688,0.00012123958,0.0002131503,0.000025397452,0.0000091119455,0.000018672217,0.003967398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955744,0.00069780217,0.0025722114,0.00033451986,0.00049090595,0.00033014835],"domain_scores_gemma":[0.9950102,0.0028720156,0.0013333944,0.00013944635,0.0002725771,0.00037237964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035776198,0.00020533659,0.001851246,0.00017360604,0.00004833148,0.00002795347,0.000071488255,0.0003371711,0.000099057164],"category_scores_gemma":[0.0007862615,0.00012530739,0.00025419562,0.0001445602,0.00016527626,0.00019251781,0.000051409148,0.0008616616,0.000012568532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041400595,0.0037521073,0.9527046,0.000028199265,0.0029970414,0.0005449851,0.00036832262,0.0000021388812,0.000026146405,0.000004658886,0.00008862108,0.035343096],"study_design_scores_gemma":[0.031881053,0.050437883,0.91518456,0.00007945913,0.0011399969,0.00003681048,0.00024481936,0.000044707413,0.000004342604,0.0000977939,0.0007453626,0.00010323893],"about_ca_topic_score_codex":0.00016066806,"about_ca_topic_score_gemma":0.0002388233,"teacher_disagreement_score":0.046685774,"about_ca_system_score_codex":0.00065343553,"about_ca_system_score_gemma":0.0014911289,"threshold_uncertainty_score":0.51098865},"labels":[],"label_agreement":null},{"id":"W2921270519","doi":"10.1200/jco.2019.37.7_suppl.250","title":"Preliminary results of a two stage phase II study of <sup>18</sup>F-DCFPyL PET-MR for enabling oligometastases ablative therapy in subclinical prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre for Probe Development and Commercialization; University Health Network; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Stage (stratigraphy); Clinical endpoint; Nuclear medicine; Ablative case; SABR volatility model; Biochemical recurrence; Radiation therapy; Salvage therapy; Radiology; Urology; Cancer; Surgery; Clinical trial; Internal medicine; Chemotherapy","score_opus":0.22843948182652438,"score_gpt":0.5566189419865039,"score_spread":0.32817946015997945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921270519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266535,0.0018858856,0.0000068134946,0.0017071152,0.00035119735,0.002933852,0.00020988847,0.0000066023863,0.00023326992],"genre_scores_gemma":[0.9919481,0.0051765116,0.0008444234,0.00017226825,0.00040469068,0.000071287526,0.000020048412,0.000032293232,0.0013303597],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9928788,0.0009348953,0.0046334323,0.00042006426,0.000675315,0.00045752543],"domain_scores_gemma":[0.98736936,0.0077284994,0.0029931508,0.00036194245,0.0012197345,0.00032733748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007547876,0.00024555568,0.0028275142,0.00043242666,0.00004967987,0.0000064981045,0.0002857076,0.00019884363,0.00017012356],"category_scores_gemma":[0.0036071364,0.00015862136,0.00057628687,0.00043763814,0.00034078586,0.00019499636,0.00012631461,0.0011172206,0.0000018324547],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61798656,0.05756539,0.1853229,0.0003247709,0.0025070526,0.001235431,0.006382119,0.0019368711,0.0014044995,0.000022922626,0.001135601,0.12417587],"study_design_scores_gemma":[0.3163685,0.63585514,0.027900023,0.00068186026,0.0005198402,0.000050695216,0.006166019,0.0019575844,0.0021744526,0.0001960218,0.007921786,0.00020809867],"about_ca_topic_score_codex":0.00026069477,"about_ca_topic_score_gemma":0.000090205205,"teacher_disagreement_score":0.57828975,"about_ca_system_score_codex":0.00021257278,"about_ca_system_score_gemma":0.0031618262,"threshold_uncertainty_score":0.64683914},"labels":[],"label_agreement":null},{"id":"W2921281835","doi":"10.1200/jco.2020.38.6_suppl.102","title":"KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Western University","funders":"","keywords":"Medicine; Abiraterone; Enzalutamide; Cohort; Nausea; Prostate cancer; Cancer; Rash; Pembrolizumab; Internal medicine; Oncology; Immunotherapy","score_opus":0.10977388063207714,"score_gpt":0.43686790981130014,"score_spread":0.327094029179223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921281835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852097,0.0009309907,0.000017717688,0.010206886,0.00038317507,0.0014415714,0.0002253028,0.00003508059,0.0015495855],"genre_scores_gemma":[0.9939948,0.0019136786,0.0009869353,0.0018189412,0.0003317579,0.000058028654,0.00015422539,0.000069693866,0.0006719898],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99248016,0.0010179238,0.003917625,0.0006633081,0.0011202857,0.00080070406],"domain_scores_gemma":[0.9942128,0.0008391785,0.002129789,0.00033362448,0.0013453895,0.0011392311],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002087368,0.00044584755,0.0028064921,0.00029041365,0.000081497274,0.000043144322,0.00032958077,0.00035863527,0.00020596737],"category_scores_gemma":[0.0018152316,0.0002765075,0.0003379962,0.0008481732,0.00049823476,0.00031093592,0.000101469595,0.001957471,0.000036290432],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5481081,0.004455159,0.38999206,0.00035925803,0.003396873,0.014423774,0.0014656191,0.0011708821,0.0017786234,0.000014633988,0.0070950272,0.027739964],"study_design_scores_gemma":[0.21837878,0.070706725,0.68646526,0.00089955254,0.0019274363,0.00019701794,0.000574671,0.0014482077,0.0020210673,0.00006739911,0.01675645,0.00055745884],"about_ca_topic_score_codex":0.00061364286,"about_ca_topic_score_gemma":0.0006875538,"teacher_disagreement_score":0.32972935,"about_ca_system_score_codex":0.0013158304,"about_ca_system_score_gemma":0.0060296413,"threshold_uncertainty_score":0.9999687},"labels":[],"label_agreement":null},{"id":"W2921415341","doi":"10.1200/jco.2019.37.7_suppl.38","title":"Do elderly men (&gt;75) harbor more aggressive prostate cancer? Comparison of decipher and PAM50 TESTS among different age groups.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Genome British Columbia; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"DECIPHER; Medicine; Internal medicine; Cancer; Logistic regression; Prostate cancer; Oncology; Prostate; Population; Basal (medicine); Bioinformatics; Biology","score_opus":0.0976612869611432,"score_gpt":0.4959094721567694,"score_spread":0.3982481851956262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921415341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883069,0.0067616845,0.0000040502136,0.0027404567,0.0005746119,0.0006104613,0.000012233667,0.000007101811,0.0009824906],"genre_scores_gemma":[0.99335,0.004761443,0.00024376766,0.00016821404,0.00040761504,0.00001647421,0.000004383695,0.000023720006,0.0010243678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967738,0.00028242148,0.0017768595,0.0002627103,0.0005609862,0.00034327226],"domain_scores_gemma":[0.995134,0.0013875747,0.0022925301,0.00021936394,0.00047365855,0.00049285573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096807576,0.00019576898,0.0019917525,0.00012897285,0.000036463138,0.000016857854,0.00016796855,0.00032631523,0.0002236176],"category_scores_gemma":[0.00071752636,0.000113465954,0.00029538147,0.0001202015,0.00050307414,0.0001145189,0.00010072264,0.0009955197,0.0000059174763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005979923,0.0013492149,0.870527,0.00013110788,0.00061467447,0.0007166027,0.00066047837,0.0000066006596,0.00094509794,0.000020342914,0.0022030487,0.1168459],"study_design_scores_gemma":[0.014597306,0.0198736,0.9599933,0.000732226,0.0003716379,0.00003648871,0.0004631254,0.00015139891,0.00061542384,0.00017630735,0.0028768787,0.000112288995],"about_ca_topic_score_codex":0.00005020489,"about_ca_topic_score_gemma":0.00006263604,"teacher_disagreement_score":0.11673361,"about_ca_system_score_codex":0.00019704046,"about_ca_system_score_gemma":0.0006927914,"threshold_uncertainty_score":0.46270072},"labels":[],"label_agreement":null},{"id":"W2921451618","doi":"10.1016/j.eururo.2019.03.004","title":"Androgen Deprivation Therapy with Postprostatectomy Radiotherapy: For Whom and for How Long?","year":2019,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; National Institute for Health and Care Research; Royal Marsden NHS Foundation Trust","keywords":"Medicine; Androgen deprivation therapy; Radiation therapy; Prostatectomy; Prostate cancer; Urology; General surgery; Internal medicine; Cancer","score_opus":0.03161862020509741,"score_gpt":0.28897821149286584,"score_spread":0.2573595912877684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921451618","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.051461596,0.009457536,0.0040523345,0.9271808,0.00024669504,0.0068210703,0.00023500307,0.00010609992,0.00043885672],"genre_scores_gemma":[0.018445069,0.004334166,0.0026779673,0.9225289,0.0065075723,0.0006983346,0.006197699,0.00073342735,0.03787682],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99842626,0.00015834322,0.00015389764,0.0006060691,0.00016011142,0.0004953324],"domain_scores_gemma":[0.9989493,0.00029726993,0.00013328642,0.00037994297,0.00018349937,0.000056726214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002497424,0.00032146793,0.00049040024,0.00018457137,0.000116473224,0.00008073062,0.00012553917,0.00023834982,0.000021417607],"category_scores_gemma":[0.000029678646,0.00021150598,0.000100153135,0.0000738232,0.00021203615,0.000050485098,0.000025177458,0.00048525605,0.000008096349],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011645566,0.00007752707,0.01635971,0.0006758608,0.001429889,0.00066200516,0.00045356926,0.0000014127248,0.0013175773,0.000007778055,0.94342405,0.023945076],"study_design_scores_gemma":[0.012830268,0.008552038,0.0044194427,0.000033939068,0.00013360225,0.00020481762,0.0000051711863,0.000046412108,0.000336834,0.000019791089,0.9731881,0.00022958958],"about_ca_topic_score_codex":0.000003260259,"about_ca_topic_score_gemma":0.0000016755783,"teacher_disagreement_score":0.037437964,"about_ca_system_score_codex":0.000056813744,"about_ca_system_score_gemma":0.00016183766,"threshold_uncertainty_score":0.8624963},"labels":[],"label_agreement":null},{"id":"W2921492570","doi":"10.1200/jco.2019.37.7_suppl.253","title":"Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Retrospective cohort study; Abiraterone; Cohort; Cancer; Abiraterone acetate; Oncology; Androgen deprivation therapy; Androgen receptor","score_opus":0.17222980574543542,"score_gpt":0.5145880124233151,"score_spread":0.34235820667787964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921492570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962397,0.00017016906,0.000009306739,0.00052543054,0.00019820547,0.0026036205,0.000033207576,0.000009254003,0.00021110897],"genre_scores_gemma":[0.9964535,0.0008729058,0.0009954467,0.00009788845,0.000109385255,0.00013237502,0.000007010377,0.00003859168,0.0012928912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953006,0.00054447295,0.002288785,0.00054083805,0.0009329263,0.00039236754],"domain_scores_gemma":[0.9948692,0.0007899684,0.002295318,0.00032442197,0.0011974617,0.00052366935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010346636,0.00035288557,0.0026399286,0.00016789405,0.000072814546,0.000026012745,0.00012915151,0.000099106626,0.00010096081],"category_scores_gemma":[0.000114797425,0.00014211885,0.00011944736,0.00037069875,0.0007048098,0.00021860904,0.00003426999,0.00066253264,0.0000020153152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1214075,0.010486069,0.8525661,0.00008161877,0.0021844825,0.0011496273,0.0021227691,0.00002581072,0.00001934498,0.0000071894847,0.000023326955,0.009926107],"study_design_scores_gemma":[0.07481454,0.27270907,0.6482459,0.0003100589,0.0008839668,0.000067256886,0.0024592902,0.000021197102,0.000040246876,0.0000018116111,0.00031177193,0.00013488907],"about_ca_topic_score_codex":0.0007308767,"about_ca_topic_score_gemma":0.009980572,"teacher_disagreement_score":0.262223,"about_ca_system_score_codex":0.000646044,"about_ca_system_score_gemma":0.0030781536,"threshold_uncertainty_score":0.5795438},"labels":[],"label_agreement":null},{"id":"W2921510308","doi":"10.1200/jco.2019.37.7_suppl.295","title":"A survey to determine patients’ (pts) opinions of a clinical trial (CT) comparing intermittent (int) versus continuous (cont) androgen receptor signaling inhibitor (ARSi) therapy for the treatment of advanced prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Internal medicine; Quality of life (healthcare); Abiraterone acetate; Randomized controlled trial; Cancer; Clinical trial; Oncology; Androgen deprivation therapy; Androgen receptor","score_opus":0.28283184826699775,"score_gpt":0.5139859629778228,"score_spread":0.2311541147108251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921510308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862674,0.0021668621,0.000012015993,0.0013003434,0.00590654,0.004170172,0.0001297548,0.0000060563757,0.00004087648],"genre_scores_gemma":[0.9889141,0.008859309,0.00051684823,0.00014380403,0.0010934959,0.00014875669,0.00003992645,0.000030367655,0.00025339224],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99412477,0.0007643647,0.003955852,0.00033385438,0.00045445742,0.00036671766],"domain_scores_gemma":[0.98478097,0.010554991,0.002625527,0.0003218786,0.0013286959,0.00038796995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038685051,0.00023230459,0.0028635329,0.00012546832,0.000052501957,0.000010414067,0.00026687773,0.00018236235,0.00008118472],"category_scores_gemma":[0.0027709925,0.00012663305,0.0010902936,0.00017790572,0.00025966883,0.0000781399,0.000059278158,0.00043879487,0.0000045295233],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3948763,0.0044625425,0.26250625,0.000028452243,0.0012191758,0.000010579584,0.0002519492,0.000031098643,0.00015977667,0.0000013732039,0.000626589,0.33582592],"study_design_scores_gemma":[0.47184297,0.30414075,0.16481744,0.00042714618,0.00045443603,0.0000048777915,0.00034961835,0.00018353977,0.0026576067,0.000008129797,0.054949764,0.00016372683],"about_ca_topic_score_codex":0.0001611729,"about_ca_topic_score_gemma":0.00022534138,"teacher_disagreement_score":0.3356622,"about_ca_system_score_codex":0.00034256055,"about_ca_system_score_gemma":0.0019814128,"threshold_uncertainty_score":0.5163946},"labels":[],"label_agreement":null},{"id":"W2921550149","doi":"10.1200/jco.2019.37.7_suppl.270","title":"Assessing the real-world (RW) efficacy and toxicity of docetaxel (D) for the treatment of metastatic castrate sensitive prostate cancer (mCSPC): A single institution experience.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; Sunnybrook Hospital","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Toxicity; Internal medicine; Febrile neutropenia; Neutropenia; Androgen deprivation therapy; Oncology; Surgery; Cancer; Urology","score_opus":0.2666221390067654,"score_gpt":0.5529440095559734,"score_spread":0.28632187054920805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921550149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930947,0.0014160555,0.00006624151,0.0034643991,0.00043052304,0.0010494106,0.000015932848,0.0000023074901,0.00046042597],"genre_scores_gemma":[0.99285424,0.0057185,0.0006794,0.00011674324,0.00019195379,0.000024235294,0.0000017425144,0.00000787977,0.0004053059],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980046,0.00028665093,0.0011165154,0.0001443953,0.0002601613,0.00018767022],"domain_scores_gemma":[0.9942539,0.0037623164,0.0012220935,0.00014981588,0.00050077745,0.00011110376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013628723,0.00011452853,0.0009713059,0.0000708878,0.000071934584,0.000014244293,0.00007150738,0.000066964356,0.00002107059],"category_scores_gemma":[0.0004322504,0.00004856338,0.0002399744,0.00015865268,0.0006409639,0.00013006583,0.000019456433,0.00022231838,5.148036e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03443048,0.010799802,0.16794488,0.00041620745,0.0043717367,0.0003475971,0.013600917,0.0005752501,0.055474482,0.00042232315,0.00022230252,0.711394],"study_design_scores_gemma":[0.05503511,0.07700723,0.7386952,0.0009926152,0.0034593935,0.00023846088,0.009392665,0.0021191277,0.098129936,0.00037024918,0.014330273,0.000229741],"about_ca_topic_score_codex":0.00019182096,"about_ca_topic_score_gemma":0.00016648197,"teacher_disagreement_score":0.7111643,"about_ca_system_score_codex":0.00022825674,"about_ca_system_score_gemma":0.0014531541,"threshold_uncertainty_score":0.2577833},"labels":[],"label_agreement":null},{"id":"W2921553088","doi":"10.1097/01.ju.0000557079.17509.d9","title":"PD55-12 INCREMENTAL UTILITY OF MP-MRI PERFORMED BEFORE CONFIRMATORY BIOPSY IN REDUCING THE RISK OF PROGRESSION DURING ACTIVE SURVEILLANCE FOR MEN WITH LOW RISK PROSTATE CANCER: IS IMAGING ALWAYS USEFUL?","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Biopsy; Oncology; Radiology; Internal medicine; Cancer","score_opus":0.009282675752961949,"score_gpt":0.292236985587519,"score_spread":0.28295430983455705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921553088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99535435,0.0016266287,0.000009761315,0.0014779852,0.00007103368,0.0012278277,0.00010868453,0.0000042282577,0.00011949538],"genre_scores_gemma":[0.99762195,0.0021500525,0.00006294887,0.00002275466,0.000054599146,0.000023200335,0.0000044280805,0.000018224546,0.000041845593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832594,0.00035026096,0.0005087979,0.00015091775,0.00033707818,0.00032699128],"domain_scores_gemma":[0.99806213,0.00027916735,0.0010426417,0.00025487065,0.0003001162,0.000061081395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018407138,0.00014785853,0.00046711633,0.0001312145,0.00011606547,0.000004826524,0.00019115362,0.000050537303,0.00005378718],"category_scores_gemma":[0.00007528102,0.000067127905,0.000091312504,0.00014471253,0.00039039867,0.000115501316,0.00006805289,0.0005237475,4.873006e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024906095,0.00013175777,0.9453707,0.00023056455,0.00038331107,0.000010493819,0.007540479,0.0000944304,0.017119406,7.2054337e-7,0.000060043538,0.0041520214],"study_design_scores_gemma":[0.008303482,0.0017127556,0.9084289,0.00031729674,0.00021397788,0.0001830988,0.00253294,0.0026430702,0.0754852,0.00004979936,0.000058082343,0.00007140444],"about_ca_topic_score_codex":0.0005196232,"about_ca_topic_score_gemma":0.00010179199,"teacher_disagreement_score":0.058365792,"about_ca_system_score_codex":0.00013106278,"about_ca_system_score_gemma":0.00038478244,"threshold_uncertainty_score":0.27373967},"labels":[],"label_agreement":null},{"id":"W2921618481","doi":"10.1200/jco.2015.33.15_suppl.e16087","title":"Evaluation of a genomic classifier in primary tumor and lymph node metastases in pre- and post-radical prostatectomy tissue specimens from patients with lymph node positive prostate cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Concordance; Lymph node; Prostate; Biopsy; Biochemical recurrence; Stage (stratigraphy); Cancer; Lymph; Metastasis; Internal medicine; Pathology; Oncology; Urology","score_opus":0.0833392777891157,"score_gpt":0.43414709949767055,"score_spread":0.35080782170855485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921618481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929993,0.0035811763,0.0000030293768,0.0018489676,0.00013675334,0.0010206937,0.00014622955,0.0000028598304,0.00026097748],"genre_scores_gemma":[0.99699163,0.0008314539,0.0014831972,0.00041662922,0.00013005316,0.0000380917,0.00004999842,0.00001973394,0.00003923344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963238,0.0008444568,0.0013973461,0.00029672906,0.0008658692,0.00027177602],"domain_scores_gemma":[0.9967007,0.0007596264,0.0008712463,0.00012311939,0.0011559626,0.00038936455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003586248,0.00017170284,0.0012358958,0.00023857472,0.000019376857,0.000011755395,0.00007651909,0.00015674692,0.000030935877],"category_scores_gemma":[0.0009977836,0.000109303706,0.000058882273,0.00015347391,0.0004687918,0.000185442,0.000076169614,0.00043578,0.0000013099637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034344718,0.0019634955,0.9007173,0.000054981032,0.00037775826,0.00041379282,0.0009077522,0.000048447033,0.0017140682,0.0000025253537,0.00004622703,0.05940894],"study_design_scores_gemma":[0.055306073,0.00595228,0.93642175,0.0004028738,0.0005882224,0.000052618812,0.00018790198,0.00021893583,0.00043684087,0.00018750901,0.00014398943,0.00010100418],"about_ca_topic_score_codex":0.0006920997,"about_ca_topic_score_gemma":0.00015854478,"teacher_disagreement_score":0.059307937,"about_ca_system_score_codex":0.0011945133,"about_ca_system_score_gemma":0.0062439684,"threshold_uncertainty_score":0.9993897},"labels":[],"label_agreement":null},{"id":"W2921684231","doi":"10.1200/jco.2019.37.7_suppl.257","title":"Lessons learned from the metastatic castration-resistant prostate cancer phase I trial of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Glucuronidation; Metabolite; Pharmacokinetics; Prostate cancer; ADME; Medicine; Androgen receptor; Pharmacology; Sulfation; Internal medicine; Endocrinology; Chemistry; Cancer; In vitro; Biochemistry; Microsome","score_opus":0.29043854511582246,"score_gpt":0.5270321079671706,"score_spread":0.23659356285134814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921684231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95856166,0.0012270665,0.000019485808,0.037436157,0.0015026226,0.0009868799,0.00012718858,0.000004159119,0.000134791],"genre_scores_gemma":[0.99215066,0.003072368,0.0013803421,0.0003464173,0.0022048645,0.000031202144,0.000054568944,0.00001870996,0.00074087776],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99619144,0.00076543307,0.0019878917,0.00023245598,0.000583989,0.00023880709],"domain_scores_gemma":[0.99552774,0.0018890515,0.0016105496,0.00023282108,0.0005005827,0.00023926889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030888596,0.00014971543,0.001178073,0.00007702684,0.00008074673,0.000020889167,0.00015424633,0.00017786384,0.0005830947],"category_scores_gemma":[0.0010083437,0.000081699225,0.00041853831,0.00016062267,0.00024590746,0.00013723648,0.000035307887,0.00068047486,0.000019285526],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63203204,0.008037,0.009961429,0.0001262957,0.0026594705,0.00089623366,0.0021344482,0.000076420445,0.07068568,0.00014239282,0.0156065915,0.257642],"study_design_scores_gemma":[0.6591784,0.10862983,0.007023304,0.00073362334,0.0022532186,0.00014785687,0.0016914887,0.0005465347,0.01885452,0.0015627525,0.19903141,0.00034709097],"about_ca_topic_score_codex":0.00017334033,"about_ca_topic_score_gemma":0.00037980446,"teacher_disagreement_score":0.25729492,"about_ca_system_score_codex":0.00022055823,"about_ca_system_score_gemma":0.0034080835,"threshold_uncertainty_score":0.6384478},"labels":[],"label_agreement":null},{"id":"W2921709383","doi":"10.1200/jco.2019.37.7_suppl.141","title":"Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Clinical endpoint; Hypokalemia; Interim analysis; Internal medicine; Adverse effect; Placebo; Prostate cancer; MedDRA; Hazard ratio; Gastroenterology; Urology; Androgen deprivation therapy; Confidence interval; Randomized controlled trial; Cancer","score_opus":0.09064761430012958,"score_gpt":0.4504710675112411,"score_spread":0.35982345321111153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921709383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961986,0.00016708396,0.000081479084,0.0005979964,0.000086308646,0.002762785,0.000076849465,0.000008339737,0.000020535663],"genre_scores_gemma":[0.99684465,0.00086007424,0.0016770383,0.00015837503,0.000059237344,0.00010702343,0.000082785264,0.000028020288,0.00018279832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99573785,0.0006932171,0.002038398,0.00039882638,0.00078458333,0.00034711964],"domain_scores_gemma":[0.99566823,0.0007195802,0.0019116438,0.0003051775,0.0010645407,0.0003308463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00152631,0.00026428443,0.0022218588,0.00062363694,0.000046004847,0.000020219517,0.00015846684,0.0001232518,0.00020290271],"category_scores_gemma":[0.00022488507,0.00015009409,0.00019492769,0.0012688172,0.00012799642,0.00024343946,0.000029422754,0.0005479136,0.000004883815],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09742198,0.011279521,0.8231933,0.000021558266,0.007680543,0.00035547308,0.0014655304,0.0051927576,0.00021097748,0.0000010388029,0.00004108997,0.05313621],"study_design_scores_gemma":[0.14779305,0.08713059,0.7605113,0.000107178384,0.0029653588,0.0000044378285,0.00036603643,0.0004686681,0.00046450653,0.000006752533,0.000058137834,0.0001240153],"about_ca_topic_score_codex":0.0014958337,"about_ca_topic_score_gemma":0.0043185856,"teacher_disagreement_score":0.07585107,"about_ca_system_score_codex":0.0003313106,"about_ca_system_score_gemma":0.0014416262,"threshold_uncertainty_score":0.6120659},"labels":[],"label_agreement":null},{"id":"W2921803816","doi":"10.1200/jco.2020.38.6_suppl.103","title":"KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Sunnybrook Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Enzalutamide; Prednisone; Abiraterone; Cohort; Internal medicine; Prostate cancer; Cancer; Pembrolizumab; Pneumonitis; Oncology; Lung","score_opus":0.11685923084650794,"score_gpt":0.4364121771567669,"score_spread":0.31955294631025893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921803816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876145,0.0014814523,0.000014154622,0.008211198,0.00023168116,0.0015675153,0.00025899822,0.000029446715,0.0005910336],"genre_scores_gemma":[0.99152565,0.0045364015,0.0013154722,0.001281476,0.00023966076,0.0000615908,0.00009958024,0.0000615815,0.00087858207],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.993494,0.0008475886,0.0033934084,0.0006626846,0.0008953332,0.0007070287],"domain_scores_gemma":[0.9949008,0.0009056459,0.0018256682,0.00027782423,0.0010050444,0.0010849965],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001780539,0.00043175952,0.0026775226,0.00021341362,0.000085377615,0.0000514178,0.00024009982,0.0003282896,0.00016235124],"category_scores_gemma":[0.0018694509,0.00024558097,0.00020087013,0.00069651264,0.0005684363,0.00032601517,0.00011214887,0.0015364357,0.000012172276],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6849584,0.0033785307,0.26495233,0.0004556524,0.0027807788,0.010915934,0.0014961144,0.0003920473,0.0011535989,0.000008020219,0.0033988408,0.026109768],"study_design_scores_gemma":[0.25665095,0.083541915,0.642525,0.0009979522,0.0020809593,0.00035964954,0.00067619386,0.001691726,0.0012958518,0.000051135743,0.009611201,0.00051747647],"about_ca_topic_score_codex":0.00050061324,"about_ca_topic_score_gemma":0.0008771022,"teacher_disagreement_score":0.42830744,"about_ca_system_score_codex":0.00081391033,"about_ca_system_score_gemma":0.0050602416,"threshold_uncertainty_score":0.99999964},"labels":[],"label_agreement":null},{"id":"W2921821362","doi":"10.1200/jco.2019.37.7_suppl.217","title":"Immunogenomic landscape of neuroendocrine small cell prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Adenocarcinoma; Prostatectomy; Immunohistochemistry; Prostate; Chromogranin A; Pathology; Cancer; Cancer research; Oncology; Internal medicine","score_opus":0.09115831815454796,"score_gpt":0.45057301926428595,"score_spread":0.359414701109738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921821362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828105,0.005100687,0.0000013725071,0.00447517,0.0011577562,0.0003250721,0.000008322065,0.0000045617558,0.0061165416],"genre_scores_gemma":[0.98075324,0.012009863,0.00037910554,0.00045623299,0.0004321163,0.000003840107,0.0000034142872,0.000017521927,0.0059446404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763364,0.00019190315,0.0015294624,0.0001471204,0.00024427564,0.00025359026],"domain_scores_gemma":[0.9973183,0.00068247976,0.0011648779,0.00019224001,0.00040169683,0.00024037423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092127314,0.00010675451,0.0012049663,0.00011955151,0.000014996901,0.000004167717,0.00016460347,0.000090930465,0.00055036024],"category_scores_gemma":[0.0002507049,0.00006680971,0.00039387782,0.000121564415,0.00011192432,0.000049288537,0.00006507538,0.0007390655,0.000044880806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020141684,0.0019106376,0.88201404,0.00026047096,0.0004951587,0.001241646,0.000117801676,0.00005080667,0.015442589,0.000017318333,0.0037527839,0.07455507],"study_design_scores_gemma":[0.05424218,0.05647495,0.66783017,0.0003177043,0.0007043323,0.0007097615,0.00031309077,0.00015473337,0.017861327,0.00016881093,0.2010281,0.00019481685],"about_ca_topic_score_codex":0.00003783481,"about_ca_topic_score_gemma":0.000010434277,"teacher_disagreement_score":0.21418384,"about_ca_system_score_codex":0.000092818365,"about_ca_system_score_gemma":0.0023341458,"threshold_uncertainty_score":0.6026059},"labels":[],"label_agreement":null},{"id":"W2921866173","doi":"10.1200/jco.2019.37.7_suppl.315","title":"The association of PSA levels and survival outcomes in patients with chemotherapy-naïve, castration-resistant prostate cancer (CRPC) who were treated with androgen receptor signaling axis targeting agent (ARAT): A Japanese cohort study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Abiraterone acetate; Androgen receptor; Internal medicine; Oncology; Androgen; Androgen deprivation therapy; Overall survival; Urology; Cancer; Hormone","score_opus":0.045850744046622226,"score_gpt":0.39754535761622006,"score_spread":0.35169461356959786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921866173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651086,0.00025404262,4.2670965e-7,0.0015395493,0.00014532065,0.0014244599,0.000021294623,0.0000037369146,0.00010032184],"genre_scores_gemma":[0.9983627,0.000359995,0.00010029226,0.00006380116,0.00007259319,0.000024458546,0.0000074932727,0.000018476838,0.0009901974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970114,0.00050066196,0.0013111299,0.00021092255,0.000707012,0.00025884522],"domain_scores_gemma":[0.99613553,0.001254413,0.0015044442,0.00011931784,0.00084068335,0.00014558641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031172538,0.0001569552,0.0012391148,0.00007883715,0.00006583259,0.000020807282,0.00008309613,0.00014142464,0.0000512208],"category_scores_gemma":[0.00038382868,0.000073996904,0.00009797085,0.0001796883,0.00010269534,0.00011148096,0.0000197123,0.00047420827,0.0000010256331],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019077921,0.0013301711,0.97348285,0.000031278934,0.0015934164,0.000033621047,0.0008555125,0.00002986646,0.00024516153,7.687858e-7,0.000063250416,0.0032561906],"study_design_scores_gemma":[0.023586988,0.015346802,0.95902175,0.00014774967,0.0002373415,0.0000014778176,0.0010479862,0.00001545915,0.00018769727,0.0000024704152,0.00032320505,0.00008106303],"about_ca_topic_score_codex":0.0002489197,"about_ca_topic_score_gemma":0.00060437655,"teacher_disagreement_score":0.014461082,"about_ca_system_score_codex":0.0004472537,"about_ca_system_score_gemma":0.0009019454,"threshold_uncertainty_score":0.3017506},"labels":[],"label_agreement":null},{"id":"W2921871222","doi":"10.3390/ijms20061374","title":"Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-Analysis","year":2019,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Meta-analysis; Prostate cancer; Biochemical recurrence; Chromogranin A; Oncology; Internal medicine; Systematic review; Prostate; Urology; Pathology; Immunohistochemistry; MEDLINE; Cancer","score_opus":0.07677343720890799,"score_gpt":0.3969316689370682,"score_spread":0.3201582317281602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921871222","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016936994,0.99469924,0.000112265334,0.0007078105,0.000107212516,0.0025143223,0.00014356383,0.0000049787704,0.000016920552],"genre_scores_gemma":[0.034188792,0.9648978,0.00018563862,0.00014704418,0.000025140305,0.00019575683,0.000055197757,0.000019561565,0.00028503127],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99549866,0.0004168024,0.0015092298,0.00038067088,0.0019687542,0.0002258572],"domain_scores_gemma":[0.9969873,0.00022163322,0.0016039425,0.00019507088,0.0008216978,0.0001703812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005433901,0.00033444483,0.0038982057,0.0009804622,0.00003080388,0.00010152299,0.00045268494,0.000055917582,0.0002844604],"category_scores_gemma":[0.00039610456,0.00018098284,0.0022913115,0.0006425543,0.0003244357,0.0001723327,0.00013316642,0.00033568297,0.000008942165],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022753076,0.00051167235,0.0009855165,0.72144383,0.27124694,0.00282542,0.00008826573,0.0000030157544,0.000012856827,0.00021776796,0.000025978276,0.0024112354],"study_design_scores_gemma":[0.0011757086,0.0014526333,0.0004313515,0.060884777,0.9307236,0.003734216,0.000018935822,0.000038719198,0.000050310442,0.000110396555,0.0010909474,0.0002883786],"about_ca_topic_score_codex":0.000006393744,"about_ca_topic_score_gemma":6.8731816e-7,"teacher_disagreement_score":0.66055906,"about_ca_system_score_codex":0.00011721902,"about_ca_system_score_gemma":0.0009119739,"threshold_uncertainty_score":0.7380266},"labels":[],"label_agreement":null},{"id":"W2921882662","doi":"10.1200/jco.2019.37.7_suppl.237","title":"Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Placebo; Prostate cancer; Internal medicine; Incidence (geometry); Adverse effect; MedDRA; Clinical trial; Oncology; Cancer; Androgen receptor; Pathology","score_opus":0.35448445688229574,"score_gpt":0.5752077519366866,"score_spread":0.22072329505439087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921882662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727447,0.014365167,0.0000059929685,0.008217237,0.0013539939,0.0012737192,0.00039238232,0.0000022458098,0.0016445768],"genre_scores_gemma":[0.82375246,0.17253605,0.000619349,0.0006835529,0.0012322564,0.000008625865,0.00013108608,0.000020306175,0.001016297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932873,0.0011633735,0.00460159,0.00022315436,0.0005186678,0.00020590014],"domain_scores_gemma":[0.99304724,0.0024024886,0.0033795447,0.00038721092,0.0005816436,0.00020185224],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011025428,0.00012847864,0.0026350527,0.00012202834,0.000010593402,0.0000015623003,0.00033014503,0.00019896487,0.0010884531],"category_scores_gemma":[0.0069161872,0.00008094234,0.0003461014,0.00021836342,0.00014961949,0.00018550837,0.00011281393,0.0007242617,0.000007677422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14822753,0.0100385165,0.53315765,0.011309135,0.0027960837,0.0009005912,0.0002939996,0.00001730082,0.019946573,0.00012738664,0.059568126,0.2136171],"study_design_scores_gemma":[0.08033945,0.025078442,0.5730925,0.041374005,0.0016750729,0.000078068486,0.00045801591,0.00006624891,0.0026150327,0.00025797103,0.27466014,0.00030500916],"about_ca_topic_score_codex":0.00012698938,"about_ca_topic_score_gemma":0.00036670992,"teacher_disagreement_score":0.21509202,"about_ca_system_score_codex":0.0002807945,"about_ca_system_score_gemma":0.004664629,"threshold_uncertainty_score":0.9998247},"labels":[],"label_agreement":null},{"id":"W2921914635","doi":"10.1200/jco.2019.37.7_suppl.17","title":"Genomic validation of three-tiered sub-classification of high-risk prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Prostate; Cancer; Oncology; Prostate-specific antigen; Internal medicine; DECIPHER; Risk assessment; Bioinformatics; Biology","score_opus":0.14036873691157623,"score_gpt":0.47122851877000627,"score_spread":0.33085978185843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921914635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99456143,0.00094046805,0.000048813345,0.0027249656,0.0008185389,0.0004343014,0.000022285212,0.0000034950529,0.000445673],"genre_scores_gemma":[0.99233615,0.0062668463,0.00067726505,0.00004784558,0.00031151957,0.0000057758307,0.000011556024,0.000012510412,0.0003305229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970775,0.00026758644,0.0019922887,0.00014253079,0.00036434137,0.00015572242],"domain_scores_gemma":[0.99488205,0.00091667706,0.0030287793,0.00019720406,0.000822272,0.00015300742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023732984,0.00008719357,0.0010860643,0.000139469,0.000016785303,0.000002890116,0.00012351105,0.00022326212,0.00016505044],"category_scores_gemma":[0.00084043713,0.00005770038,0.00027168661,0.00015081643,0.00019050634,0.00008577166,0.00003052577,0.0005076091,0.000015506997],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00884185,0.00078969944,0.8255481,0.00011410651,0.00048411996,0.000016202013,0.00009760021,0.000072102834,0.03164101,0.00008294384,0.0005094099,0.13180284],"study_design_scores_gemma":[0.010703355,0.010757718,0.95245355,0.00013813969,0.00039181768,0.000014976462,0.00007022963,0.00018986162,0.022127021,0.0009502302,0.0021502208,0.000052892286],"about_ca_topic_score_codex":0.00016069962,"about_ca_topic_score_gemma":0.000040366856,"teacher_disagreement_score":0.13174994,"about_ca_system_score_codex":0.0002175198,"about_ca_system_score_gemma":0.002194808,"threshold_uncertainty_score":0.38934955},"labels":[],"label_agreement":null},{"id":"W2921920097","doi":"10.1200/jco.2019.37.7_suppl.1","title":"PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Radiation therapy; Cohort; External beam radiotherapy; Dose fractionation; Toxicity; Randomized controlled trial; Urology; Radiosurgery; Prostate cancer; Nuclear medicine; Internal medicine; Cancer; Brachytherapy","score_opus":0.09406648063087258,"score_gpt":0.5172467262077756,"score_spread":0.423180245576903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921920097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818853,0.000635326,0.004981333,0.0034480842,0.0022165284,0.0066707134,0.00007023642,0.000016448084,0.00007604581],"genre_scores_gemma":[0.98688185,0.005819101,0.0027209679,0.0011935129,0.0007047009,0.00049868494,0.0000990832,0.000040769097,0.0020413275],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99228597,0.0013122334,0.0045690434,0.00046797885,0.0009637981,0.0004009648],"domain_scores_gemma":[0.9887379,0.0051394245,0.003606772,0.0002512757,0.0017894511,0.00047517856],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0066601504,0.00032492503,0.0066850088,0.0012039928,0.00006286543,0.000052077103,0.0002866151,0.0003833605,0.0017913191],"category_scores_gemma":[0.0013018996,0.00020529995,0.0018201363,0.00069076073,0.00020164566,0.0005764585,0.000026830676,0.00085150765,0.0000020983869],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9272337,0.007537476,0.01360959,0.000026489986,0.034366485,0.00015339801,0.00021934419,0.0039015107,0.007232395,0.00003621907,0.00016343003,0.005519957],"study_design_scores_gemma":[0.83924896,0.015429019,0.00947135,0.00012812325,0.0037787694,0.000043816464,0.000051378633,0.1294929,0.00036339147,0.00006434947,0.0017541071,0.00017386563],"about_ca_topic_score_codex":0.00018797816,"about_ca_topic_score_gemma":0.00010733438,"teacher_disagreement_score":0.12559138,"about_ca_system_score_codex":0.0012497626,"about_ca_system_score_gemma":0.0032855,"threshold_uncertainty_score":0.9991212},"labels":[],"label_agreement":null},{"id":"W2921940659","doi":"10.1200/jco.2019.37.7_suppl.144","title":"Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Adverse effect; Abiraterone acetate; Internal medicine; Placebo; Enzalutamide; Randomized controlled trial; Androgen deprivation therapy; Oncology; Cancer; Androgen receptor; Confidence interval","score_opus":0.05830491259392324,"score_gpt":0.42172842444029973,"score_spread":0.3634235118463765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921940659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99673986,0.0002997747,0.0000014856553,0.0011644388,0.00007874587,0.0016218472,0.000050623534,0.0000017539629,0.00004145985],"genre_scores_gemma":[0.9978158,0.0017785019,0.00024166555,0.000048303482,0.00002607008,0.000030278658,0.000019648487,0.000012971418,0.000026752989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957432,0.000971783,0.0018638693,0.00024944567,0.0009318285,0.00023985934],"domain_scores_gemma":[0.9956751,0.0014842963,0.0018451486,0.00033149507,0.0005351682,0.00012880834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033254537,0.0001699021,0.0016722176,0.0003572376,0.000035112356,0.000009117192,0.00020016424,0.000099716,0.000066271874],"category_scores_gemma":[0.00026659365,0.00007598984,0.00011339551,0.00093288935,0.00027436716,0.00010367028,0.00003520321,0.0006085524,2.900059e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06456374,0.006475596,0.9167384,0.000048892467,0.0024545004,0.00018785868,0.0016148778,0.0010618814,0.00002372777,0.000006644543,0.000018195222,0.0068056746],"study_design_scores_gemma":[0.043192197,0.04806888,0.9057071,0.00022302965,0.0010840504,0.0000033509823,0.0014278964,0.00010590255,0.000029183286,0.000016484431,0.00006948462,0.000072394134],"about_ca_topic_score_codex":0.001672668,"about_ca_topic_score_gemma":0.044433605,"teacher_disagreement_score":0.042760935,"about_ca_system_score_codex":0.00016786419,"about_ca_system_score_gemma":0.001135082,"threshold_uncertainty_score":0.973003},"labels":[],"label_agreement":null},{"id":"W2921945934","doi":"10.1200/jco.2019.37.7_suppl.2","title":"A randomized trial comparing fluorocholine-PET/CT with conventional imaging in prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Nuclear medicine; Clinical endpoint; Clinical trial; Randomized controlled trial; Pelvis; Internal medicine; Radiology; Cancer","score_opus":0.11740091288418172,"score_gpt":0.5057142715991796,"score_spread":0.38831335871499784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921945934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857197,0.0013506794,0.00001349788,0.007163018,0.0011183915,0.0012751496,0.0000018949538,0.000006796622,0.0033508986],"genre_scores_gemma":[0.9953458,0.0012800719,0.00069778576,0.0005143796,0.00063168444,0.000040517498,0.0000057782336,0.000015315793,0.0014686793],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964928,0.000590572,0.0019697477,0.00019429295,0.00046881227,0.000283788],"domain_scores_gemma":[0.9963618,0.0017686198,0.0011166747,0.00011656847,0.0003851344,0.00025123594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005196502,0.00012983574,0.0022501496,0.00019130704,0.000022923206,0.000014031563,0.00011432451,0.00002477023,0.00030918038],"category_scores_gemma":[0.0008319283,0.00007324751,0.0004473767,0.00015436023,0.0002858671,0.00013838561,0.00003675148,0.0009952711,0.000019521052],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7760899,0.0008674351,0.21231076,0.00003400714,0.00030281628,0.003247952,0.000031956075,0.000039859224,0.000031719952,0.00004498765,0.0003356871,0.0066629243],"study_design_scores_gemma":[0.972603,0.0044556167,0.014683312,0.00040762417,0.00023783032,0.0011204898,0.000091721224,0.0012729521,0.000042851378,0.00018151275,0.004821833,0.00008125912],"about_ca_topic_score_codex":0.00008393256,"about_ca_topic_score_gemma":0.00004728697,"teacher_disagreement_score":0.19762745,"about_ca_system_score_codex":0.00027223132,"about_ca_system_score_gemma":0.0030706043,"threshold_uncertainty_score":0.544712},"labels":[],"label_agreement":null},{"id":"W2921967070","doi":"10.1200/jco.2019.37.7_suppl.81","title":"The molecular hallmarks and clinical consequences of tumor hypoxia in prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Prostate cancer; Medicine; Prostate; Prostatectomy; PTEN; Hypoxia (environmental); Oncology; Biomarker; Metastasis; Biochemical recurrence; Internal medicine; Cancer; Pathology; Biology; Genetics","score_opus":0.09635114724034834,"score_gpt":0.5072047743489597,"score_spread":0.4108536271086114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921967070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711984,0.007961063,0.0000010749294,0.018110197,0.000715064,0.0003665368,0.0000029924634,0.0000019631384,0.001642713],"genre_scores_gemma":[0.9774849,0.020747975,0.00033672462,0.00074001506,0.00016365315,0.000005206112,5.41429e-7,0.000008287435,0.00051270955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965669,0.00061634916,0.0021081853,0.00016148135,0.0003190207,0.0002280609],"domain_scores_gemma":[0.9945384,0.0036018377,0.0011112043,0.0001519454,0.00035930733,0.00023727585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005501299,0.000091441325,0.0011070755,0.000069277594,0.000022727645,0.000007891323,0.00014879,0.00015219262,0.00005198912],"category_scores_gemma":[0.002322217,0.00004641891,0.00026037998,0.00011953189,0.0010347225,0.000056137607,0.000061024282,0.000980264,0.000004586872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00943782,0.00056992605,0.88690156,0.00005001234,0.0003506264,0.0011803316,0.000053599877,0.0000044253115,0.0009686455,0.00024811077,0.00051367347,0.099721275],"study_design_scores_gemma":[0.017478,0.019131606,0.9298666,0.00037816213,0.00021382587,0.00032235892,0.00036356092,0.00009965284,0.00077594,0.0017560238,0.029525677,0.00008860033],"about_ca_topic_score_codex":0.000079113895,"about_ca_topic_score_gemma":0.00009101148,"teacher_disagreement_score":0.09963267,"about_ca_system_score_codex":0.00008295127,"about_ca_system_score_gemma":0.0031071105,"threshold_uncertainty_score":0.55118805},"labels":[],"label_agreement":null},{"id":"W2922002660","doi":"10.1200/jco.2019.37.7_suppl.98","title":"Preoperative trial of neoadjuvant abiraterone plus or minus cabazitaxel: Early results.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Cabazitaxel; Prostate cancer; Prednisone; Neoadjuvant therapy; Adverse effect; Internal medicine; Neutropenia; Randomized controlled trial; Febrile neutropenia; Hazard ratio; Surgery; Oncology; Urology; Cancer; Chemotherapy; Confidence interval; Androgen deprivation therapy; Breast cancer","score_opus":0.21133374720830636,"score_gpt":0.5171035825473507,"score_spread":0.30576983533904434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922002660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848302,0.00045450227,0.000011579142,0.005139485,0.0020249966,0.00084051554,0.000019131037,0.000005746215,0.006673867],"genre_scores_gemma":[0.9799002,0.0008662568,0.0010790153,0.00032549293,0.001254102,0.000006686371,0.0000051939487,0.000017015123,0.016546061],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99576247,0.00050642673,0.0026970303,0.00021242394,0.0005481272,0.00027352085],"domain_scores_gemma":[0.99495023,0.00212551,0.001523976,0.00025342897,0.000792853,0.0003540141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003176586,0.00013960805,0.0018897743,0.0001341102,0.000023139599,0.000008670009,0.00018092408,0.00036722486,0.00029929672],"category_scores_gemma":[0.0029083744,0.00007272283,0.00042998823,0.00015523448,0.00026949664,0.00012989748,0.00006317685,0.0009370678,0.0000757467],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94544524,0.0023310804,0.0062206183,0.00005448956,0.00079394825,0.0014456416,0.00070266996,0.000012539242,0.0006557996,0.000030956417,0.0061095706,0.036197457],"study_design_scores_gemma":[0.57219696,0.3208453,0.06668279,0.00033921024,0.00046650917,0.00027146767,0.0004212821,0.00007577227,0.0016446785,0.00010682047,0.036806222,0.00014297913],"about_ca_topic_score_codex":0.000060882237,"about_ca_topic_score_gemma":0.000031601474,"teacher_disagreement_score":0.37324828,"about_ca_system_score_codex":0.00024251519,"about_ca_system_score_gemma":0.0046481113,"threshold_uncertainty_score":0.824555},"labels":[],"label_agreement":null},{"id":"W2922115950","doi":"10.1200/jco.2019.37.7_suppl.220","title":"Next generation N-terminal domain androgen receptor inhibitors with improved potency and metabolic stability in castration-resistant prostate cancer models.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"LNCaP; Prostate cancer; Androgen receptor; Potency; In vivo; ADME; Pharmacology; Medicine; IC50; Tolerability; Cancer research; Pharmacokinetics; Cancer; In vitro; Internal medicine; Chemistry; Biology; Biochemistry; Adverse effect","score_opus":0.12400454156004478,"score_gpt":0.4240479212813577,"score_spread":0.3000433797213129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922115950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916937,0.0030299465,0.000010429885,0.0040194304,0.000347137,0.00068392645,0.000011594052,0.0000039951024,0.00019985266],"genre_scores_gemma":[0.99296314,0.0034666122,0.0026452953,0.00018399711,0.00047855132,0.000023124809,0.000008369389,0.000013583026,0.00021734474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975994,0.00031955994,0.0012797763,0.00024795398,0.0003111888,0.00024211689],"domain_scores_gemma":[0.998321,0.0002198807,0.0006357463,0.00013316312,0.0004140317,0.0002761674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019590443,0.00013449685,0.0009088043,0.00011797442,0.000034804096,0.0000220745,0.00005932047,0.00019838837,0.00010518496],"category_scores_gemma":[0.00013952542,0.000080024714,0.00011374247,0.00015718506,0.00017431729,0.00035088384,0.00002588419,0.00061027025,0.000002106312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053747583,0.002681994,0.5029567,0.00023552276,0.0006885758,0.00089427084,0.0020153832,0.00013763378,0.20695348,0.00016033938,0.00038045723,0.22914805],"study_design_scores_gemma":[0.16580328,0.11888702,0.6090832,0.0012839314,0.0015745967,0.0013400958,0.005191752,0.01437475,0.051091805,0.0030628236,0.027061198,0.0012455347],"about_ca_topic_score_codex":0.00022137963,"about_ca_topic_score_gemma":0.0007703385,"teacher_disagreement_score":0.22790252,"about_ca_system_score_codex":0.0002230485,"about_ca_system_score_gemma":0.0027860086,"threshold_uncertainty_score":0.49422595},"labels":[],"label_agreement":null},{"id":"W2922126493","doi":"10.1200/jco.2019.37.7_suppl.46","title":"The impact of intratumoral heterogeneity on prognostic biomarkers in localized prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network; Queen's University","funders":"","keywords":"Medicine; Prostate cancer; Biomarker; Prostatectomy; Oncology; Internal medicine; Biomarker discovery; Proportional hazards model; Cohort; Prostate; Cancer; Pathology; Gene; Biology; Proteomics; Genetics","score_opus":0.11123965375314998,"score_gpt":0.5247581897498865,"score_spread":0.41351853599673655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922126493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99222314,0.001814809,8.4637134e-7,0.003974098,0.00058473105,0.0006428928,0.0000071739923,0.00000314019,0.0007491377],"genre_scores_gemma":[0.99627256,0.003148347,0.00006819424,0.00014744735,0.00017853768,0.000011052128,0.0000020287123,0.000011648009,0.00016019198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706084,0.00052379776,0.0015866008,0.00015009407,0.00036471552,0.00031398222],"domain_scores_gemma":[0.99602103,0.0021591336,0.0010350103,0.00018136142,0.00033949397,0.00026398624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003162346,0.000121924575,0.0011108686,0.00011551072,0.000024806972,0.000008397963,0.00016231668,0.00018589196,0.00006850076],"category_scores_gemma":[0.0016970598,0.00005521838,0.00050451234,0.00023310457,0.00033366555,0.000057586272,0.000037480706,0.00082600565,0.000011343715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040291715,0.0012554587,0.87944674,0.000036526315,0.00087840774,0.00032749117,0.00005243995,0.000088348104,0.00045036493,0.000012625697,0.0011465795,0.076013274],"study_design_scores_gemma":[0.016626606,0.04105545,0.9388584,0.00030749547,0.000101218,0.00006248453,0.00007299145,0.00036745763,0.0006474761,0.00019713721,0.0016401062,0.0000631626],"about_ca_topic_score_codex":0.00019338897,"about_ca_topic_score_gemma":0.00010779307,"teacher_disagreement_score":0.07595011,"about_ca_system_score_codex":0.0004354499,"about_ca_system_score_gemma":0.0038861313,"threshold_uncertainty_score":0.68938303},"labels":[],"label_agreement":null},{"id":"W2922152917","doi":"10.1200/jco.2019.37.7_suppl.143","title":"Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Circulating tumor cell; Surrogate endpoint; Clinical endpoint; Oncology; Internal medicine; Clinical trial; Biomarker; Prostate-specific antigen; Overall survival; Urology; Phases of clinical research; Cancer; Metastasis","score_opus":0.3094984787866785,"score_gpt":0.5928363546640458,"score_spread":0.2833378758773673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922152917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919376,0.00022871654,0.00045547294,0.0033686685,0.00074055465,0.0023329668,0.00031648754,0.0000031659777,0.00061638944],"genre_scores_gemma":[0.99016464,0.0001828856,0.008553069,0.00018175277,0.00032599826,0.00014053608,0.000052968724,0.000019771154,0.00037837296],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948609,0.00065493956,0.0034884796,0.00022155969,0.0004729447,0.00030118471],"domain_scores_gemma":[0.9901611,0.006479949,0.0021829149,0.00010789244,0.00084663986,0.0002214789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011397132,0.00014766901,0.0022829347,0.0001247246,0.000046497837,0.00000920476,0.00008556541,0.00010624061,0.00038702652],"category_scores_gemma":[0.0017828306,0.00010064662,0.0007546422,0.00012850265,0.00009836108,0.0001132884,0.0000150464575,0.00041635692,0.0000014396094],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35468382,0.057046514,0.18932205,0.006849952,0.0072943773,0.0023404262,0.0031888182,0.003774322,0.2747515,0.004573091,0.0016615673,0.094513535],"study_design_scores_gemma":[0.5717684,0.17873761,0.19291598,0.001741907,0.0040919795,0.00030082767,0.0032992384,0.009419582,0.014369339,0.009059118,0.01365289,0.00064312917],"about_ca_topic_score_codex":0.00005947196,"about_ca_topic_score_gemma":0.00009395833,"teacher_disagreement_score":0.26038218,"about_ca_system_score_codex":0.00032575018,"about_ca_system_score_gemma":0.00678327,"threshold_uncertainty_score":0.99884737},"labels":[],"label_agreement":null},{"id":"W2922172159","doi":"10.1016/j.clgc.2019.03.005","title":"A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; CancerCare Manitoba; BC Cancer Agency; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Cancer Care Ontario; Juravinski Cancer Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Cancer; Castration; Clinical trial; Gynecology; Hormone","score_opus":0.15472136721313998,"score_gpt":0.4811174060029069,"score_spread":0.326396038789767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922172159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98238957,0.0020951477,1.7071186e-7,0.00047907635,0.0009186902,0.013139103,0.00089131587,0.000024170411,0.00006274981],"genre_scores_gemma":[0.99352944,0.0013348123,0.000051064228,0.00012387673,0.00028062914,0.0030167638,0.00011058613,0.00006971771,0.0014830837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942837,0.0009277874,0.00202663,0.0009701857,0.0009968164,0.00079492293],"domain_scores_gemma":[0.9969977,0.00041575197,0.0006812773,0.0006678658,0.00054639083,0.00069102895],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016697594,0.00046906894,0.0018929858,0.00045866228,0.00017423509,0.000034517612,0.00026790623,0.0001158273,0.0011967995],"category_scores_gemma":[0.00020504517,0.00029312476,0.00018369652,0.0009790538,0.00015063465,0.00020004867,0.00011417523,0.0007064459,0.000009389754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062934145,0.033264313,0.8377609,0.00024821342,0.0015699051,0.00052232743,0.002905403,0.00007963874,0.00008505997,5.732228e-7,0.000611015,0.06001846],"study_design_scores_gemma":[0.12695196,0.13308947,0.7317076,0.0007718299,0.0012117948,0.0000016084814,0.0043007387,0.00006109076,0.000059136302,0.000005042373,0.00139342,0.00044633314],"about_ca_topic_score_codex":0.11148261,"about_ca_topic_score_gemma":0.44081256,"teacher_disagreement_score":0.32932994,"about_ca_system_score_codex":0.0010993415,"about_ca_system_score_gemma":0.0047198324,"threshold_uncertainty_score":0.9999521},"labels":[],"label_agreement":null},{"id":"W2922292408","doi":"10.1200/jco.2019.37.7_suppl.256","title":"Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Docetaxel; Cabazitaxel; Prostate cancer; Oncology; Internal medicine; Regimen; Retrospective cohort study; Taxane; Combination therapy; Abiraterone acetate; Cancer; Chemotherapy; Androgen deprivation therapy; Breast cancer; Androgen receptor","score_opus":0.1340544811949481,"score_gpt":0.49896898248693994,"score_spread":0.3649145012919919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922292408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954055,0.00006608279,9.345341e-7,0.0018483191,0.00027272708,0.0021605266,0.000071105474,0.0000032373214,0.0001715784],"genre_scores_gemma":[0.99789673,0.0004242133,0.00023983038,0.00007703136,0.00007402141,0.000098124874,0.0000080324935,0.000016916123,0.001165102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972588,0.00028302163,0.0016320401,0.0002476491,0.00033265955,0.0002458699],"domain_scores_gemma":[0.997342,0.0007800035,0.001081225,0.00015053278,0.000470874,0.00017534784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097042625,0.00016391261,0.0015666151,0.00023661078,0.000025856438,0.000009356326,0.000062892344,0.00007428876,0.000044787703],"category_scores_gemma":[0.00028185302,0.00009204591,0.00022276159,0.00013027719,0.000073103816,0.000090943526,0.000027706685,0.00027898655,8.9609495e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011353084,0.0046380814,0.9703762,0.000088008725,0.0009896572,0.00017190751,0.0020210044,0.0000054005263,0.000032363616,0.000010344771,0.00003443943,0.010279503],"study_design_scores_gemma":[0.04047476,0.05381659,0.90351754,0.0001165062,0.00047065376,0.0000053999383,0.0011871656,0.000029291028,0.00006040872,0.00007503652,0.00017821153,0.000068446425],"about_ca_topic_score_codex":0.0014965634,"about_ca_topic_score_gemma":0.0077540865,"teacher_disagreement_score":0.06685868,"about_ca_system_score_codex":0.000583116,"about_ca_system_score_gemma":0.0008755108,"threshold_uncertainty_score":0.43269622},"labels":[],"label_agreement":null},{"id":"W2922343610","doi":"10.1016/j.ccell.2019.02.005","title":"The Proteogenomic Landscape of Curable Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of British Columbia; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Queen's University; Ontario Institute for Cancer Research","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care; Canada Foundation for Innovation; Prostate Cancer Canada; Movember Foundation; Ontario Genomics Institute; National Cancer Institute; Government of Canada; Canadian Cancer Society","keywords":"Epigenomics; Transcriptome; Proteome; Prostate cancer; Biology; Proteogenomics; Computational biology; Genome; Proteomics; Genomics; Chromoplexy; Epigenetics; Cancer; Prostate; Genetics; Gene; DNA methylation; Bioinformatics; Gene expression; PCA3","score_opus":0.013380012345909846,"score_gpt":0.29351343486164616,"score_spread":0.2801334225157363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922343610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9086413,0.05953627,5.702644e-7,0.001349404,0.0003305403,0.0016045431,0.000049423663,0.000021426684,0.028466556],"genre_scores_gemma":[0.8968014,0.022185268,0.000021154367,0.000084299754,0.00011290141,0.00045294975,0.00001178158,0.000025999694,0.080304205],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990683,0.0000198823,0.00016594901,0.00020398626,0.00021672674,0.00032513912],"domain_scores_gemma":[0.9993551,0.000034652658,0.00008413442,0.00030671462,0.00013234706,0.00008707381],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012050216,0.00011174581,0.00020422676,0.000024065012,0.000073900505,0.000015595013,0.00011537692,0.000043262047,0.001341349],"category_scores_gemma":[0.0000037683649,0.00006245511,0.000070794995,0.00013439132,0.000073572046,0.000056847643,0.00003861953,0.00013059315,0.00008142864],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032562145,0.00024227837,0.6371256,0.0016836614,0.00036814227,0.000019769319,0.0017689401,0.00018412272,0.2914318,0.0000987928,0.022906493,0.040914185],"study_design_scores_gemma":[0.008334312,0.0007983527,0.026090171,0.0004603825,0.00016688688,0.000005139339,0.0009446486,0.00053598377,0.63603765,0.00011508966,0.32621267,0.0002987036],"about_ca_topic_score_codex":0.0007268428,"about_ca_topic_score_gemma":0.00011046255,"teacher_disagreement_score":0.6110354,"about_ca_system_score_codex":0.00019145073,"about_ca_system_score_gemma":0.00057758123,"threshold_uncertainty_score":0.99957156},"labels":[],"label_agreement":null},{"id":"W2922411602","doi":"10.1200/jco.2019.37.7_suppl.44","title":"Genomic biomarkers to predict outcome in Gleason Score 9-10 disease.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Oncology; Logistic regression; Internal medicine; Microarray; Gene expression profiling; Gene; Cancer; Gene expression; Biology; Genetics","score_opus":0.17067420117990623,"score_gpt":0.5098196829870763,"score_spread":0.33914548180717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922411602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975707,0.0011882192,0.000007998594,0.018609893,0.0010878625,0.00048643653,0.0000060702646,0.0000062113813,0.002900319],"genre_scores_gemma":[0.99245,0.00044423083,0.00072806637,0.0020280122,0.0006096029,0.0000057123907,0.000004530344,0.000016570008,0.0037132674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739134,0.0002297858,0.0015327282,0.00019539411,0.00035963388,0.00029109354],"domain_scores_gemma":[0.99752367,0.0008263332,0.00044114242,0.00020482113,0.00018392556,0.00082009094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002261006,0.00010853994,0.0010377847,0.00024206366,0.000013824386,0.0000072257567,0.0001766586,0.00019291938,0.00081726344],"category_scores_gemma":[0.0018337873,0.00006938138,0.00036556437,0.00018766447,0.00009401685,0.000068544556,0.00007459534,0.0006251077,0.00034299403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018639142,0.00075130136,0.92260855,0.000047203586,0.00020241232,0.0010417526,0.000024466777,0.000013950304,0.00025918844,0.00001196866,0.008007315,0.04839277],"study_design_scores_gemma":[0.00996528,0.008124379,0.8879701,0.00015559947,0.00010602927,0.000035420035,0.000034286277,0.000053588596,0.00001671368,0.00009456839,0.093383454,0.00006060277],"about_ca_topic_score_codex":0.00001315707,"about_ca_topic_score_gemma":0.000013527843,"teacher_disagreement_score":0.085376136,"about_ca_system_score_codex":0.0004299255,"about_ca_system_score_gemma":0.0019710371,"threshold_uncertainty_score":0.8948462},"labels":[],"label_agreement":null},{"id":"W2922823095","doi":"10.1016/j.ctrv.2019.03.002","title":"Emerging therapeutic targets for patients with advanced prostate cancer","year":2019,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pfizer","keywords":"Medicine; Prostate cancer; Cancer; Clinical trial; Oncology; Cancer research; EZH2; Disease; Prostate; Internal medicine; Epigenetics","score_opus":0.09584489418431515,"score_gpt":0.4380468469586624,"score_spread":0.3422019527743473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922823095","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013984819,0.9674191,0.00001010121,0.0001716587,0.00060423935,0.030366508,0.0010170655,0.00007580871,0.00032155638],"genre_scores_gemma":[0.0000030613558,0.93587095,0.0003247078,0.00013292654,0.00032199197,0.045540906,0.002699077,0.0002619303,0.014844481],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961212,0.00015020356,0.0009976211,0.0012827642,0.00043078582,0.0010174158],"domain_scores_gemma":[0.9974384,0.00012223821,0.0008444484,0.0009744782,0.00029438606,0.0003260637],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00015469296,0.0013128251,0.0049475115,0.00025868317,0.00018839017,0.000052572206,0.00023080538,0.0002467294,0.00046160832],"category_scores_gemma":[0.000013490108,0.0006568351,0.0012675772,0.0005519352,0.00009804888,0.00015615406,0.00004517471,0.0002950915,0.0001360397],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046836596,0.00050719385,0.0011254598,0.048475254,0.0020945442,0.000009526612,0.00013419759,0.0000015225296,3.3690577e-7,0.0000040484574,0.0012440415,0.9459355],"study_design_scores_gemma":[0.006691817,0.0024088016,0.000044699827,0.04384815,0.009540933,0.0000032617972,0.000008029993,0.0000026740029,0.000005672362,0.0000037473558,0.9368059,0.00063630665],"about_ca_topic_score_codex":0.000056868677,"about_ca_topic_score_gemma":0.00003567123,"teacher_disagreement_score":0.9452992,"about_ca_system_score_codex":0.003129736,"about_ca_system_score_gemma":0.0018863712,"threshold_uncertainty_score":0.99996233},"labels":[],"label_agreement":null},{"id":"W2923110687","doi":"10.3390/cancers11040434","title":"The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis","year":2019,"lang":"en","type":"review","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital","funders":"Canadian Cancer Society; Cancer Research Society","keywords":"Prostate cancer; Cancer research; Cancer stem cell; Metastasis; PTEN; Stem cell; SOX2; Cancer; Biology; Cancer cell; Epithelial–mesenchymal transition; Cell biology; PI3K/AKT/mTOR pathway; Embryonic stem cell; Signal transduction; Genetics","score_opus":0.07674241583971482,"score_gpt":0.40533859413982587,"score_spread":0.32859617830011106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923110687","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00092239457,0.98978484,5.7380475e-7,0.00041639447,0.00050517364,0.0046441597,0.0035167485,0.000018970386,0.00019077635],"genre_scores_gemma":[0.0010194102,0.991706,0.0000060321545,0.000039991584,0.0000933816,0.0028568027,0.00015139981,0.000060020997,0.0040669716],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976308,0.0001948362,0.0007149558,0.0004933315,0.00038959444,0.0005765313],"domain_scores_gemma":[0.9983531,0.0002566925,0.0005065818,0.00039184804,0.00033073974,0.00016100873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004354794,0.0003969336,0.0015832845,0.00024676323,0.00013168587,0.000044598954,0.00015332471,0.00016699091,0.00004869336],"category_scores_gemma":[0.000022229126,0.0002361274,0.00024325364,0.00071281195,0.00038437304,0.000105920604,0.00008036488,0.00053652964,0.000009219175],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00028788,0.000021804412,0.00042789007,0.02017367,0.0008538288,0.000025877349,0.00044994758,0.00003853018,0.0000280706,0.000058201917,0.0015015722,0.97613275],"study_design_scores_gemma":[0.0022162031,0.00018042477,0.000048756592,0.01657621,0.0018116211,0.0000071508784,0.0002350804,0.000034905068,0.0008046011,0.000015720721,0.9777977,0.00027163947],"about_ca_topic_score_codex":0.0017226654,"about_ca_topic_score_gemma":0.00049595744,"teacher_disagreement_score":0.9762961,"about_ca_system_score_codex":0.0042997403,"about_ca_system_score_gemma":0.007459285,"threshold_uncertainty_score":0.99952257},"labels":[],"label_agreement":null},{"id":"W2923229075","doi":"10.1126/scitranslmed.aav0891","title":"Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer","year":2019,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Prostate cancer; Medicine; Prostate; Cancer; Cancer research; Protein expression; Oncology; Internal medicine; Biology; Gene; Genetics","score_opus":0.02745181514790422,"score_gpt":0.3441797062918262,"score_spread":0.31672789114392197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923229075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97359234,0.005152289,0.00001887609,0.01929142,0.00013389121,0.0011913156,0.0000053496415,0.000023089802,0.0005914229],"genre_scores_gemma":[0.9979235,0.00027937375,0.0002909322,0.00032695686,0.000067751746,0.00008841065,0.000015712774,0.000010845389,0.0009965221],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99826604,0.00002796219,0.00021841507,0.00038169185,0.00074938213,0.00035653182],"domain_scores_gemma":[0.9995268,0.000049155715,0.000039160168,0.00012009913,0.000112563066,0.0001522225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004088306,0.00012116227,0.00020112476,0.00027296258,0.00009780625,0.000011010905,0.00008697516,0.000013768264,0.0003542667],"category_scores_gemma":[0.00003267525,0.00007582321,0.000016721167,0.00066104485,0.0005167834,0.00017571624,0.00001897275,0.00019220906,0.0000068987665],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048489938,0.000053948857,0.2594472,0.00013659753,0.000006556333,0.000036864898,0.0010499826,0.000054425385,0.7268359,0.00026957976,0.000034421544,0.011589597],"study_design_scores_gemma":[0.01669837,0.0012429585,0.89111286,0.002248506,0.000044320743,0.000070475624,0.0007881374,0.010054894,0.07133067,0.002662879,0.0033984287,0.0003475275],"about_ca_topic_score_codex":0.00014236437,"about_ca_topic_score_gemma":0.000012726271,"teacher_disagreement_score":0.65550524,"about_ca_system_score_codex":0.000057233578,"about_ca_system_score_gemma":0.0003338379,"threshold_uncertainty_score":0.3878972},"labels":[],"label_agreement":null},{"id":"W2924849165","doi":"10.1007/s11912-019-0791-5","title":"Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer","year":2019,"lang":"en","type":"review","venue":"Current Oncology Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute for Health and Care Research; Royal Marsden NHS Foundation Trust","keywords":"Medicine; Prostate cancer; Radiation therapy; Oncology; Disease; Internal medicine; Hormone therapy; Randomized controlled trial; Primary tumor; Clinical trial; Metastasis; Population; Prostate; Systemic therapy; Hormonal therapy; Cancer; Breast cancer","score_opus":0.17654535894055629,"score_gpt":0.5022463586630724,"score_spread":0.32570099972251615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2924849165","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004778826,0.9907572,0.000001039111,0.00007846516,0.0012442704,0.0026243043,0.00008373794,0.000024713392,0.0047083725],"genre_scores_gemma":[0.00022073345,0.98926,0.00007017767,0.000005823192,0.000070420996,0.0009482751,0.00090114644,0.00005839226,0.008465013],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966869,0.00018028913,0.0013504092,0.0007803736,0.00044758493,0.000554452],"domain_scores_gemma":[0.9979742,0.00008376157,0.0010202021,0.0006044955,0.0001539732,0.00016333362],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053101254,0.0004665959,0.0032204352,0.0011262355,0.000024690902,0.0000072359926,0.000091464484,0.00025068474,0.0001253272],"category_scores_gemma":[0.000014586719,0.000328118,0.0005353441,0.0010810709,0.00018093352,0.0000487307,0.00016995425,0.0006812589,0.000032989985],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009904207,0.00066336,0.00037998296,0.042687014,0.0010178688,0.0073464136,0.00019633323,8.952396e-7,6.939107e-7,0.000010956824,0.002046466,0.945551],"study_design_scores_gemma":[0.0014078477,0.00059108326,0.0012928857,0.027719965,0.0038426376,0.00065832323,0.0000709798,0.0000022187153,0.0000036508463,0.000015549926,0.96416575,0.00022913798],"about_ca_topic_score_codex":0.000035801077,"about_ca_topic_score_gemma":0.000008242559,"teacher_disagreement_score":0.9621193,"about_ca_system_score_codex":0.0013736297,"about_ca_system_score_gemma":0.0012827602,"threshold_uncertainty_score":0.9999171},"labels":[],"label_agreement":null},{"id":"W2925184412","doi":"10.1016/j.euo.2019.02.007","title":"Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ferring; Astellas Pharma Canada; Sanofi; Merck; Bayer","keywords":"Medicine; Prostate cancer; Radium-223; Denosumab; Zoledronic acid; Androgen deprivation therapy; Oncology; Abiraterone acetate; Cancer; Internal medicine; Abiraterone; Bone metastasis; Osteoporosis; Androgen receptor","score_opus":0.06879219085183638,"score_gpt":0.359064597872905,"score_spread":0.2902724070210686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925184412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8199161,0.020807404,0.0009584737,0.09523265,0.00372915,0.009358292,0.0005921999,0.00044320797,0.048962485],"genre_scores_gemma":[0.9834044,0.0016649562,0.0053800144,0.0021994216,0.00060350006,0.0005723512,0.00085619045,0.00011639875,0.005202775],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99662936,0.0015211818,0.00054515497,0.0006185718,0.00015383062,0.00053191924],"domain_scores_gemma":[0.99812627,0.00078946055,0.00027609232,0.00050424325,0.0001283907,0.00017555308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091318344,0.00029618753,0.00046357446,0.00014607265,0.00046350682,0.000057895653,0.00023346115,0.000052882893,0.00048492654],"category_scores_gemma":[0.00009108965,0.0001926931,0.00016862844,0.00021261063,0.00023938017,0.000094086085,0.0000932213,0.00032068667,0.00026807783],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026294991,0.009816087,0.052443616,0.00022563056,0.011717058,0.004022964,0.08305591,0.0020927996,0.23359433,0.008802674,0.066048086,0.50188583],"study_design_scores_gemma":[0.028041504,0.011845098,0.04233953,0.00015677357,0.0012366967,0.00019596399,0.0039936113,0.0030119738,0.00066023634,0.00044225782,0.9074977,0.00057864166],"about_ca_topic_score_codex":0.00034503292,"about_ca_topic_score_gemma":0.00070894964,"teacher_disagreement_score":0.8414496,"about_ca_system_score_codex":0.0005852001,"about_ca_system_score_gemma":0.00036542577,"threshold_uncertainty_score":0.78577965},"labels":[],"label_agreement":null},{"id":"W2926592082","doi":"10.1016/j.eururo.2019.03.020","title":"Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Prostate Cancer Foundation; American Association for Cancer Research; U.S. National Library of Medicine; U.S. Department of Defense","keywords":"Enzalutamide; Prostate cancer; Medicine; Oncology; Wnt signaling pathway; Cancer research; Internal medicine; Cancer; Gene; Genetics; Biology; Androgen receptor","score_opus":0.020228257927322236,"score_gpt":0.28447764855202234,"score_spread":0.2642493906247001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2926592082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881995,0.0037687633,0.0000012432696,0.0018551607,0.00005658087,0.00077778974,0.00003703942,0.000015665806,0.005288301],"genre_scores_gemma":[0.9957686,0.0007775855,0.00035980283,0.00020657555,0.000018835368,0.000027196187,0.000017781338,0.000027062153,0.0027965347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881345,0.00020127972,0.00027158603,0.00030370403,0.00013706763,0.0002729076],"domain_scores_gemma":[0.99953926,0.000070202725,0.000096235286,0.0001505532,0.000064286905,0.00007943905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028187415,0.00012260712,0.00027937483,0.00015700469,0.000025310766,0.000008256802,0.000068826106,0.00002187024,0.00011309006],"category_scores_gemma":[0.00003136312,0.00009936416,0.00003447136,0.0001616046,0.00015811871,0.00004934667,0.000047577552,0.00015115613,0.000038042257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004110553,0.00020386213,0.68805504,0.00054642215,0.00023630414,0.0007243932,0.0027409373,0.000058478847,0.29993507,0.000439757,0.00043173012,0.0025174601],"study_design_scores_gemma":[0.0052874805,0.0009251169,0.9819148,0.00009720827,0.00011705649,0.000015899637,0.000237334,0.000065478176,0.0042604096,0.00008721761,0.0068506706,0.00014130933],"about_ca_topic_score_codex":0.000089109606,"about_ca_topic_score_gemma":0.00030186708,"teacher_disagreement_score":0.29567465,"about_ca_system_score_codex":0.00007072935,"about_ca_system_score_gemma":0.00014962933,"threshold_uncertainty_score":0.40519527},"labels":[],"label_agreement":null},{"id":"W2928270062","doi":"10.1158/1541-7786.mcr-18-1101","title":"Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Prostate cancer; Genome; Biology; Cancer research; Cancer; Computational biology; Gene; Genetics","score_opus":0.055921372436325445,"score_gpt":0.37122673277118434,"score_spread":0.3153053603348589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2928270062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9697523,0.025062593,0.00002320958,0.0024773995,0.000066951565,0.0016011314,0.00063891045,0.000023986337,0.0003535166],"genre_scores_gemma":[0.97921485,0.016466353,0.000077659475,0.00007587109,0.00003854698,0.00046351246,0.00035218694,0.00004703544,0.0032639594],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970545,0.00023857853,0.00038241598,0.00073594815,0.00078157656,0.000806941],"domain_scores_gemma":[0.99855524,0.000053028012,0.00007462897,0.00047328818,0.00046583088,0.00037800017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002728694,0.00028360376,0.00064812193,0.0008271439,0.000116815514,0.000046888592,0.00016615275,0.00006351847,0.0006107853],"category_scores_gemma":[0.000010571082,0.00022262642,0.0002948229,0.0016022822,0.00031187115,0.00007278082,0.000089071094,0.0003550834,0.00001537635],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010386625,0.00036508092,0.20183527,0.0003269383,0.002430681,0.0001598929,0.00026835807,0.0008490305,0.78902715,0.000054437154,0.000013950933,0.003630564],"study_design_scores_gemma":[0.009205978,0.0034745834,0.26394248,0.00015681417,0.0025877487,0.00002544494,0.0004916464,0.0037620408,0.7060032,0.00005659674,0.009815674,0.00047781927],"about_ca_topic_score_codex":0.0044901012,"about_ca_topic_score_gemma":0.0010123602,"teacher_disagreement_score":0.08302396,"about_ca_system_score_codex":0.0005872939,"about_ca_system_score_gemma":0.0009935009,"threshold_uncertainty_score":0.9078442},"labels":[],"label_agreement":null},{"id":"W2929490553","doi":"10.1097/01.ju.0000557025.09954.39","title":"MP68-10 HOXB13 EXPRESSION AND ITS ROLE IN PROSTATE CANCER PROGRESSION AND NEUROENDOCRINE DIFFERENTIATION","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Neuroendocrine differentiation; Cancer; Prostate; Expression (computer science); Oncology; Internal medicine","score_opus":0.012569293530092385,"score_gpt":0.3161166326750894,"score_spread":0.303547339144997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2929490553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97898823,0.014698429,6.878271e-7,0.005834876,0.000079885256,0.00032482337,0.0000015378009,0.0000032396363,0.00006829819],"genre_scores_gemma":[0.9905237,0.0086525595,0.0000079242745,0.000096118936,0.0000514706,0.000006276538,0.0000016575907,0.000008124271,0.0006522005],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9993188,0.00012407913,0.00017129476,0.00008219796,0.00014547956,0.00015817766],"domain_scores_gemma":[0.9996059,0.00006866556,0.00012603446,0.00006758126,0.000068253525,0.00006356383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016989895,0.00007184748,0.00018149368,0.00010363743,0.000030661427,0.000006870923,0.00004328675,0.000021076235,0.000095513344],"category_scores_gemma":[0.00002602295,0.000035711877,0.000015913103,0.00006194085,0.000038798407,0.000081392085,0.00005561552,0.00024143359,0.0000026590137],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011365604,0.000201761,0.3940299,0.00014620327,0.00005851905,0.00020096084,0.0012072758,0.00003793266,0.5662557,0.000014210852,0.00026742596,0.026214559],"study_design_scores_gemma":[0.013287122,0.0052682916,0.9095817,0.00031549856,0.0001684627,0.0016923256,0.00023553192,0.002355933,0.0630264,0.00042907835,0.0035192335,0.000120431134],"about_ca_topic_score_codex":0.000006256371,"about_ca_topic_score_gemma":0.0000049973028,"teacher_disagreement_score":0.5155518,"about_ca_system_score_codex":0.00002119675,"about_ca_system_score_gemma":0.00004561695,"threshold_uncertainty_score":0.14562881},"labels":[],"label_agreement":null},{"id":"W2929886035","doi":"10.1530/ec-19-0029","title":"Androgen deprivation therapy promotes an obesity-like microenvironment in periprostatic fat","year":2019,"lang":"en","type":"article","venue":"Endocrine Connections","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Adipose tissue; Inflammation; Cancer; Internal medicine; Androgen; Oncology; Obesity; Bioinformatics; Endocrinology; Hormone","score_opus":0.02361553658146928,"score_gpt":0.3003448636680661,"score_spread":0.27672932708659687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2929886035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950242,0.00063329993,0.000028572045,0.002116686,0.00013073246,0.0012728531,0.000010195109,0.000055878932,0.0007275782],"genre_scores_gemma":[0.9933877,0.0005679858,0.0003000472,0.0001661479,0.000060623675,0.00016195979,0.00020084485,0.00002199159,0.005132689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990207,0.00004959928,0.00016239734,0.00029071342,0.00020519967,0.00027142256],"domain_scores_gemma":[0.9994973,0.000037445512,0.000030070372,0.0002893709,0.000047666977,0.000098143384],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007793462,0.00012520334,0.00017729063,0.00016247548,0.00008398363,0.00002362349,0.00005536643,0.000026840173,0.0009448883],"category_scores_gemma":[0.000022499678,0.00010174913,0.00004801088,0.0002110355,0.000039519342,0.00014651928,0.000027075132,0.00015635068,0.00015000864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031633698,0.0012669662,0.8215872,0.00006052183,0.00008868398,0.000083418134,0.0011141365,0.000035446123,0.16695276,0.00018657949,0.00027411015,0.008033817],"study_design_scores_gemma":[0.012893138,0.0027720323,0.7606092,0.00012359969,0.000044834916,0.00023683709,0.0013591928,0.0010407936,0.1690561,0.0004663342,0.05102962,0.00036829532],"about_ca_topic_score_codex":0.00013801821,"about_ca_topic_score_gemma":0.00006195187,"teacher_disagreement_score":0.060978018,"about_ca_system_score_codex":0.00019441254,"about_ca_system_score_gemma":0.00004701698,"threshold_uncertainty_score":0.9999684},"labels":[],"label_agreement":null},{"id":"W2930367636","doi":"10.1002/med.21575","title":"ETS transcription factors as emerging drug targets in cancer","year":2019,"lang":"en","type":"review","venue":"Medicinal Research Reviews","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Terry Fox Research Institute","keywords":"ETS transcription factor family; Prostate cancer; Transcription factor; Context (archaeology); Drug discovery; Biology; Cancer; Computational biology; Drug target; Drug; Protein family; Bioinformatics; Cancer research; Genetics; Pharmacology; Gene","score_opus":0.43899126843610836,"score_gpt":0.5708010657915737,"score_spread":0.13180979735546539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2930367636","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000868607,0.98347807,0.0000024345823,0.0011485502,0.0006153026,0.009398648,0.00003771724,0.000035423083,0.0051969755],"genre_scores_gemma":[0.0000464234,0.9672354,0.000021871145,0.00008368963,0.00059716665,0.0020526894,0.0004879012,0.00013035939,0.029344542],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9906203,0.0021665895,0.0015922084,0.0012017852,0.0027133888,0.0017057403],"domain_scores_gemma":[0.9970157,0.0006195915,0.00029484127,0.0009741021,0.00034727884,0.00074845465],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.007048897,0.0007930039,0.0048726527,0.0019505998,0.00018030906,0.00005371141,0.00061365985,0.0004225774,0.0029156196],"category_scores_gemma":[0.0013117081,0.00045838967,0.000994724,0.0024518238,0.0003445019,0.00017434868,0.00015044068,0.0039858688,0.0017037912],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008958711,0.00018097128,0.00018991766,0.09472837,0.00015043425,0.00034371216,0.00068986806,4.94492e-8,0.000012542198,0.000022740849,0.015604054,0.88798773],"study_design_scores_gemma":[0.00101904,0.00040864924,0.000060896167,0.123412855,0.00054961885,0.00003435344,0.00017058085,0.0000032305127,0.000012345108,0.000024215055,0.87400156,0.00030262693],"about_ca_topic_score_codex":0.0019655053,"about_ca_topic_score_gemma":0.00028806977,"teacher_disagreement_score":0.8876851,"about_ca_system_score_codex":0.002489937,"about_ca_system_score_gemma":0.0034540747,"threshold_uncertainty_score":0.9997868},"labels":[],"label_agreement":null},{"id":"W2935899192","doi":"10.1186/s12967-019-1878-3","title":"RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Hospital; Ontario Institute for Cancer Research; University of Toronto; Sunnybrook Health Science Centre","funders":"Prostate Cancer Canada; Movember Foundation","keywords":"Mediator; Prostate cancer; Biomarker; Medicine; Cancer; Prostate; Oncology; Internal medicine; Bioinformatics; Pathology; Biology","score_opus":0.03338511098465611,"score_gpt":0.34801168937905635,"score_spread":0.3146265783944002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935899192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96366423,0.014173446,0.000008802825,0.021267062,0.0001579893,0.00046126367,0.000018139515,0.0000020064572,0.00024708244],"genre_scores_gemma":[0.99657583,0.0027252089,0.00016393242,0.00016201686,0.00010990703,0.0000087564285,0.000008817559,0.000010708448,0.00023482044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864614,0.00003431533,0.0004835646,0.00010880197,0.0005882171,0.00013895189],"domain_scores_gemma":[0.99905777,0.0002253795,0.00019000146,0.00006589279,0.0003324266,0.0001285535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042477428,0.000098169454,0.00042107882,0.00035642774,0.000011400342,0.0000024125393,0.000049918115,0.00004390563,0.00049268646],"category_scores_gemma":[0.00007625541,0.000060187325,0.000050067076,0.00028519888,0.00014465478,0.000108084045,0.000006328352,0.00017387472,0.0000016115109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002215357,0.00012227574,0.96365345,0.0005796664,0.00017834318,0.00009855452,0.00218426,0.00000777076,0.022881253,0.00003718947,0.00023084437,0.007811061],"study_design_scores_gemma":[0.012842814,0.0010535542,0.97678185,0.0027473092,0.00016444158,0.00015415142,0.00031007794,0.00017735838,0.00406539,0.00037940944,0.0012528711,0.000070786926],"about_ca_topic_score_codex":0.000037991333,"about_ca_topic_score_gemma":0.00001010291,"teacher_disagreement_score":0.032911625,"about_ca_system_score_codex":0.000042818396,"about_ca_system_score_gemma":0.0004516715,"threshold_uncertainty_score":0.53945714},"labels":[],"label_agreement":null},{"id":"W29367197","doi":"10.1158/2159-8290.cd-17-0937","title":"P1-14-1 腹膜中皮腫と卵巣癌の鑑別診断におけるp16/CDKN2A FISHの有用性の検討(Group 14 卵巣腫瘍・基礎1,一般演題,公益社団法人日本産科婦人科学会第66回学術講演会)","year":2014,"lang":"en","type":"article","venue":"日本産科婦人科學會雜誌","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Cancer Society Research Institute; Terry Fox Research Institute; Prostate Cancer Canada; Prostate Cancer Foundation","keywords":"Fish <Actinopterygii>; Group (periodic table); Computer science; Fishery; Biology; Physics","score_opus":0.02545027187228226,"score_gpt":0.32305631410547986,"score_spread":0.2976060422331976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W29367197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6682329,0.0059875967,0.0016049775,0.0185638,0.0028202212,0.0033669488,0.00015407092,0.001465348,0.2978041],"genre_scores_gemma":[0.9433517,0.000743797,0.0013686373,0.0027011386,0.0016441018,0.00027156543,0.0004291115,0.00017281601,0.04931713],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953239,0.00021756467,0.00068322895,0.001075438,0.0012429763,0.0014568752],"domain_scores_gemma":[0.99697787,0.00028354442,0.00018164722,0.0013575547,0.00032314638,0.0008762643],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008944152,0.0006404512,0.0009492935,0.00042587475,0.0004039192,0.00014363577,0.00049390196,0.00041683845,0.0020503679],"category_scores_gemma":[0.00036535444,0.0005097125,0.00043236904,0.0007245179,0.00041403502,0.00031228003,0.00024802866,0.00087470666,0.0020210207],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053816345,0.0038548901,0.12562212,0.0016712138,0.0017529984,0.0014330162,0.0026897045,0.00003989097,0.043158077,0.008927757,0.5186119,0.2868568],"study_design_scores_gemma":[0.011801437,0.002497916,0.04847881,0.00044199236,0.00039422375,0.00024112256,0.00022746707,0.00094527303,0.0120057715,0.0015235988,0.92043877,0.0010036502],"about_ca_topic_score_codex":0.00020597968,"about_ca_topic_score_gemma":0.00011922957,"teacher_disagreement_score":0.40182686,"about_ca_system_score_codex":0.0003935793,"about_ca_system_score_gemma":0.00027755913,"threshold_uncertainty_score":0.9997355},"labels":[],"label_agreement":null},{"id":"W2937090821","doi":"10.1177/1078155219842329","title":"Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice","year":2019,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre; Université de Montréal","funders":"Réseau de cancérologie Rossy","keywords":"Medicine; Docetaxel; Enzalutamide; Prostate cancer; Internal medicine; Cohort; Abiraterone acetate; Oncology; Medical prescription; Cancer; Hormonal therapy; Androgen deprivation therapy; Pharmacology","score_opus":0.11467175331138577,"score_gpt":0.49921140993396806,"score_spread":0.38453965662258227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937090821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98367566,0.0008489936,0.000003005899,0.013316661,0.0005203048,0.00077836914,0.000053643245,0.0000024797957,0.0008009006],"genre_scores_gemma":[0.9958836,0.002073133,0.00043188082,0.00014695335,0.00036228425,0.000016572143,0.000007067061,0.000014921221,0.0010635997],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998299,0.00021313132,0.0006004194,0.00014541898,0.0005424612,0.0001995494],"domain_scores_gemma":[0.99693424,0.00049720454,0.00143535,0.00018657075,0.0008310227,0.00011563234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006086232,0.00015163497,0.00047168208,0.00015872697,0.000048443082,0.000008657999,0.00011105904,0.000032798136,0.00038275262],"category_scores_gemma":[0.000312183,0.00007852469,0.00026814244,0.00026943383,0.00010072794,0.0003658627,0.000021320227,0.0003754697,0.000005086812],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057724748,0.011412775,0.086453,0.00019826871,0.0071143582,0.00015267968,0.0017124593,0.0037741454,0.79927814,0.000034754456,0.006962132,0.025182517],"study_design_scores_gemma":[0.08703526,0.048681557,0.4944979,0.00033307105,0.006620013,0.0021925978,0.0010984626,0.0009790922,0.15990034,0.000019055396,0.19837059,0.000272045],"about_ca_topic_score_codex":0.00053256005,"about_ca_topic_score_gemma":0.000013806018,"teacher_disagreement_score":0.63937783,"about_ca_system_score_codex":0.0013547613,"about_ca_system_score_gemma":0.0025540467,"threshold_uncertainty_score":0.45307693},"labels":[],"label_agreement":null},{"id":"W2937762300","doi":"10.1016/j.eururo.2019.04.005","title":"Separating the Dreadful from the Merely Bad: Towards Prognostic and Predictive Biomarkers in Metastatic Castration-resistant Prostate Cancer","year":2019,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Castration; Internal medicine; Prostate; Cancer; Gynecology; Hormone","score_opus":0.03304992946873519,"score_gpt":0.3061657694597973,"score_spread":0.2731158399910621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937762300","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17581499,0.01932717,0.000010893796,0.7929369,0.00053688383,0.004368325,0.0012635647,0.00005559498,0.0056856633],"genre_scores_gemma":[0.69414634,0.0018932747,0.00010198709,0.29380277,0.0018377108,0.0006523326,0.00244368,0.00024770646,0.004874191],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963328,0.0015367911,0.00044918928,0.000680225,0.00041181612,0.0005891341],"domain_scores_gemma":[0.99786896,0.0012274091,0.00023527576,0.00049929734,0.00011846471,0.000050621347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068237464,0.0003924049,0.000501262,0.000117633135,0.00016465699,0.000085654596,0.0002824412,0.00013841923,0.00012211512],"category_scores_gemma":[0.00027298517,0.00019851419,0.00009130277,0.00023451919,0.00053387956,0.000060608014,0.0001669269,0.0016614292,0.000066300076],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00490949,0.0001487442,0.061868608,0.00047383123,0.005502652,0.0103239985,0.012069893,0.000098475444,0.0012124382,0.000009682735,0.88971454,0.013667646],"study_design_scores_gemma":[0.0053377273,0.0020919065,0.44316265,0.00045743777,0.0020376435,0.00015688551,0.00062091526,0.0009458517,0.000074749645,0.000114191185,0.5444994,0.00050064066],"about_ca_topic_score_codex":0.0011099908,"about_ca_topic_score_gemma":0.00020475191,"teacher_disagreement_score":0.51833135,"about_ca_system_score_codex":0.00012506847,"about_ca_system_score_gemma":0.0005303706,"threshold_uncertainty_score":0.8095173},"labels":[],"label_agreement":null},{"id":"W2938206213","doi":"10.2967/jnumed.119.226381","title":"A Prospective Study on <sup>18</sup>F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Medicine; Prostatectomy; Biochemical recurrence; Nuclear medicine; Glutamate carboxypeptidase II; Prostate; Prospective cohort study; Cancer; Lesion; Prostate-specific antigen; Radiation therapy; Urology; Radiology; Pathology; Internal medicine","score_opus":0.02520874975018835,"score_gpt":0.3574776759038981,"score_spread":0.3322689261537098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2938206213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891124,0.0018718228,2.1429976e-7,0.0059916535,0.00018420961,0.0011125993,0.0000062361405,0.000010156907,0.0017107585],"genre_scores_gemma":[0.99832195,0.00074394536,0.000048302776,0.00023457647,0.0002494852,0.000011031165,0.0000021640628,0.000035399986,0.000353128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977302,0.0000865972,0.00067374174,0.0002707051,0.000910805,0.00032798116],"domain_scores_gemma":[0.9986683,0.00010628369,0.00035035078,0.00025307373,0.00041462472,0.0002073781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007390611,0.00020243751,0.0007416082,0.00045622012,0.00002934854,0.00000822524,0.00017772047,0.000014544037,0.0006622831],"category_scores_gemma":[0.00024215733,0.00012531866,0.00009882181,0.00048669116,0.0002046045,0.000121686666,0.00005467069,0.00072123966,0.000022029744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071489518,0.0018962272,0.94650894,0.00027464554,0.0002650044,0.0035949736,0.007314139,0.00003486486,0.019031279,0.000018801284,0.008993704,0.0049184575],"study_design_scores_gemma":[0.06142236,0.026952097,0.84388393,0.01401195,0.00058559276,0.002795869,0.0373762,0.0015964152,0.0059527513,0.00024204697,0.00468876,0.0004920541],"about_ca_topic_score_codex":0.00012231096,"about_ca_topic_score_gemma":0.0000023902955,"teacher_disagreement_score":0.10262504,"about_ca_system_score_codex":0.0004204179,"about_ca_system_score_gemma":0.0002617122,"threshold_uncertainty_score":0.7251535},"labels":[],"label_agreement":null},{"id":"W2938383621","doi":"10.2967/jnumed.118.225185","title":"The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of <sup>18</sup>F-Fluoromethylcholine or <sup>68</sup>Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy","year":2019,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; McMaster University; London Health Sciences Centre; University of Toronto","funders":"Foundation Medicine; University College London; Cancer Research UK; Movember Foundation; Society of Nuclear Medicine and Molecular Imaging","keywords":"Nuclear medicine; Medicine; Prostatectomy; Biochemical recurrence; Prostate cancer; Positron emission tomography; Cancer; Internal medicine","score_opus":0.006513775268215209,"score_gpt":0.2735130002849656,"score_spread":0.2669992250167504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2938383621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99218416,0.0010547291,0.000040609222,0.0051962207,0.000054148528,0.0014164154,0.000024493836,0.000008668837,0.000020580348],"genre_scores_gemma":[0.99860746,0.00031296015,0.00059841765,0.00020044502,0.000099272336,0.000013488712,0.000034779197,0.00004008855,0.00009308592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99697644,0.00017687125,0.001070973,0.0002826244,0.0011064194,0.0003866565],"domain_scores_gemma":[0.99755245,0.00046946647,0.000489508,0.00029244533,0.00085696543,0.00033915386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010340611,0.0002602961,0.00092267286,0.0007357096,0.000044508415,0.000018341761,0.0001898179,0.00005925779,0.00019260596],"category_scores_gemma":[0.0011929811,0.00012912226,0.00010350111,0.0009865445,0.00042352732,0.00019212706,0.00007757939,0.00063494296,0.000011389421],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19479989,0.007069215,0.72570044,0.001981476,0.0017648437,0.0016303336,0.008201401,0.00065602997,0.02608668,0.000043144853,0.0111404015,0.020926174],"study_design_scores_gemma":[0.19309129,0.044473402,0.6878706,0.012105914,0.0013351031,0.001536713,0.0062874104,0.026149962,0.0060342685,0.00005625835,0.020334503,0.00072453514],"about_ca_topic_score_codex":0.00003216585,"about_ca_topic_score_gemma":0.000003525238,"teacher_disagreement_score":0.037829775,"about_ca_system_score_codex":0.0002470526,"about_ca_system_score_gemma":0.00017707633,"threshold_uncertainty_score":0.5265453},"labels":[],"label_agreement":null},{"id":"W2938589827","doi":"10.1016/s1470-2045(19)30082-8","title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":813,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Janssen Research and Development","keywords":"Abiraterone acetate; Prostate cancer; Medicine; Prednisone; Internal medicine; Oncology; Androgen deprivation therapy; Urology; Cancer","score_opus":0.06476036434540433,"score_gpt":0.3773706945959527,"score_spread":0.31261033025054835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2938589827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99192536,0.00015267839,0.000056792054,0.0009216665,0.00021918083,0.006174786,0.00036993207,0.00001993979,0.00015966651],"genre_scores_gemma":[0.99717706,0.00047530074,0.00031586003,0.000099537225,0.0001271118,0.000636387,0.0005758891,0.00002493753,0.0005678997],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973656,0.0006291393,0.0005761815,0.00041094513,0.00050677516,0.0005113538],"domain_scores_gemma":[0.9981218,0.00056537543,0.0004859494,0.00041353374,0.0003065402,0.00010680996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094347476,0.000260711,0.0017603216,0.0003014013,0.00006573943,0.000022802193,0.00014196942,0.00008652164,0.0001946413],"category_scores_gemma":[0.000047263828,0.00014904134,0.00014176016,0.00074810995,0.00021415284,0.00012769073,0.000048639093,0.00038431535,0.00001178648],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8935666,0.0013527622,0.086735435,0.00007707863,0.0046561034,0.00010261063,0.0026197734,0.008883883,0.00018617416,0.00004618794,0.00004904062,0.0017243454],"study_design_scores_gemma":[0.861499,0.006639343,0.12629086,0.000058524878,0.003176355,0.0000013408561,0.00016694635,0.001604876,0.00033789908,0.000022280947,0.000055452554,0.00014712474],"about_ca_topic_score_codex":0.0038106835,"about_ca_topic_score_gemma":0.0055815713,"teacher_disagreement_score":0.039555423,"about_ca_system_score_codex":0.00046700198,"about_ca_system_score_gemma":0.00083888817,"threshold_uncertainty_score":0.60777295},"labels":[],"label_agreement":null},{"id":"W2939558853","doi":"10.1016/j.eururo.2019.03.011","title":"RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression","year":2019,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; Prostate Cancer UK; Prostate Cancer Canada","keywords":"RNA splicing; Cancer research; Biology; Transcriptome; Alternative splicing; Demethylase; Prostate cancer; Epigenetics; Long non-coding RNA; RNA; Gene; Cell biology; Cancer; Gene expression; Exon; Genetics","score_opus":0.013445044681499988,"score_gpt":0.30973899801847266,"score_spread":0.29629395333697267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939558853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716717,0.0013417416,0.000007995673,0.019298706,0.0003878401,0.0011861426,0.000016439735,0.000033652574,0.0060558096],"genre_scores_gemma":[0.9906847,0.00026862414,0.00003980367,0.0020104372,0.00009257051,0.000025284151,0.000009078645,0.00003507094,0.0068344567],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99880224,0.00019570872,0.00020900652,0.00027265417,0.00017320618,0.0003472029],"domain_scores_gemma":[0.9992928,0.000046987574,0.000079376194,0.00037940973,0.00011139188,0.000090027286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015923497,0.00012070063,0.00023640518,0.000082271064,0.000052827538,0.000007541485,0.0001659236,0.00001369935,0.00010963209],"category_scores_gemma":[0.000060566363,0.00006791964,0.000064235384,0.00024177486,0.00009152919,0.000022420973,0.00024043846,0.00019956604,0.00014136438],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018892704,0.00013666002,0.35028857,0.000103896986,0.00012091929,0.00024535117,0.00029492663,0.00013039233,0.62065876,0.00009729721,0.0029493598,0.023084624],"study_design_scores_gemma":[0.005852574,0.0021020502,0.5694937,0.00016906369,0.00013013414,0.00009724649,0.000030035948,0.0001727201,0.31220698,0.00003984417,0.10955602,0.00014961435],"about_ca_topic_score_codex":0.00002767665,"about_ca_topic_score_gemma":0.0000045957877,"teacher_disagreement_score":0.30845177,"about_ca_system_score_codex":0.000039565464,"about_ca_system_score_gemma":0.00008123211,"threshold_uncertainty_score":0.27696824},"labels":[],"label_agreement":null},{"id":"W2940012666","doi":"10.1016/s1470-2045(19)30155-x","title":"Importance of early treatment in metastatic prostate cancer: a question of life or death","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Prednisone; Oncology; Docetaxel; Cancer; Internal medicine; Prostate; Androgen deprivation therapy","score_opus":0.10795924696837893,"score_gpt":0.4141552426201033,"score_spread":0.30619599565172434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2940012666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5795115,0.005264423,0.0000017244236,0.41022357,0.0002780162,0.0030162032,0.00040427345,0.000023726609,0.0012765247],"genre_scores_gemma":[0.5112113,0.07461925,0.0017579462,0.3233933,0.006420155,0.005231552,0.0017564476,0.0003325869,0.07527754],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977941,0.0004303588,0.000590198,0.00034027285,0.00033268204,0.00051241164],"domain_scores_gemma":[0.99815637,0.0005118789,0.00053776446,0.00059750286,0.00014999232,0.000046476078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050041487,0.0002792525,0.0017996008,0.00019224607,0.000020573967,0.0000049092296,0.00021722303,0.00026117958,0.0001486844],"category_scores_gemma":[0.000092247785,0.00013973155,0.0001327533,0.00026094264,0.00021584035,0.000036198056,0.00004881677,0.00074737164,0.0000143673915],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028332762,0.0009849772,0.6144473,0.0053487904,0.0026298335,0.003496328,0.00401741,0.000045267443,0.0005149028,0.00011467462,0.32595146,0.014116306],"study_design_scores_gemma":[0.038419127,0.024822567,0.14814302,0.0022635476,0.0019226142,0.00017266988,0.00021061944,0.000112043854,0.0013923992,0.0007623773,0.7812035,0.0005755216],"about_ca_topic_score_codex":0.0031539735,"about_ca_topic_score_gemma":0.0009025831,"teacher_disagreement_score":0.46630427,"about_ca_system_score_codex":0.00091987115,"about_ca_system_score_gemma":0.0030456271,"threshold_uncertainty_score":0.5698087},"labels":[],"label_agreement":null},{"id":"W2940470962","doi":"10.5489/cuaj.5889","title":"Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer","year":2019,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; Sunnybrook Hospital; University Health Network; Cancer Care Ontario","funders":"","keywords":"Docetaxel; Oncology; Prostate cancer; Medicine; Volume (thermodynamics); Internal medicine; Prostate; Hormone; Cancer","score_opus":0.026935132816426767,"score_gpt":0.3037190993730906,"score_spread":0.2767839665566638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2940470962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99189585,0.0008144303,0.000008544628,0.00536977,0.00018574466,0.0009772646,0.0001301279,0.000007659026,0.0006106018],"genre_scores_gemma":[0.9975791,0.0005075722,0.000057154808,0.00037604535,0.00005902566,0.000054208864,0.00004028786,0.000012340575,0.0013142924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819064,0.00040604477,0.00030228868,0.00019536124,0.00038434606,0.0005213185],"domain_scores_gemma":[0.9986219,0.00023809314,0.00020570867,0.00008673423,0.00042605374,0.00042152734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011555963,0.00012959712,0.00045345022,0.00028844803,0.000063770436,0.000028830364,0.000070945214,0.00012144961,0.00036635093],"category_scores_gemma":[0.00028844125,0.00009602963,0.00009987812,0.00037423734,0.000043338026,0.00011536438,0.000013652319,0.0005519176,0.00006161725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008466958,0.000089399065,0.99362624,0.0000373612,0.00024027115,0.00024935612,0.0002119248,0.0003051041,0.0018361249,0.000083363506,0.00059022306,0.001883943],"study_design_scores_gemma":[0.0049476926,0.00062757183,0.9910015,0.000070724105,0.00007036455,0.000041317155,0.00013427234,0.0002057802,0.00045331207,0.00039129797,0.0019541834,0.00010202061],"about_ca_topic_score_codex":0.0062135877,"about_ca_topic_score_gemma":0.00095815735,"teacher_disagreement_score":0.0056832153,"about_ca_system_score_codex":0.00243701,"about_ca_system_score_gemma":0.0011297951,"threshold_uncertainty_score":0.9393127},"labels":[],"label_agreement":null},{"id":"W2940471279","doi":"10.1097/01.ju.0000555947.83770.aa","title":"MP34-04 A NEW GENERATION OF N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITORS IN CASTRATION-RESISTANT PROSTATE CANCER MODELS","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Androgen receptor; Prostate cancer; Medicine; Androgen; Cancer research; Cancer; Internal medicine; Hormone","score_opus":0.03877739971407853,"score_gpt":0.3161797054897291,"score_spread":0.2774023057756506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2940471279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98955846,0.0038166696,0.0000296824,0.0058735204,0.00019545703,0.00037274868,0.000008386198,0.00000210494,0.00014295713],"genre_scores_gemma":[0.9973724,0.0013372333,0.0002081148,0.00011571792,0.00026857687,0.000004677577,0.00000564635,0.000010370593,0.0006772692],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989376,0.00014278102,0.00040653406,0.00008375033,0.00024649518,0.00018286145],"domain_scores_gemma":[0.9993556,0.000048651258,0.00025242136,0.00011746617,0.00014550387,0.00008036372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050640624,0.00008733529,0.0002678669,0.00014710918,0.000024904004,0.0000057238713,0.00008241164,0.00006552875,0.0001478746],"category_scores_gemma":[0.000013148865,0.00005075679,0.00005607191,0.00014085941,0.00006815634,0.000110686655,0.000018442175,0.00023499208,0.0000050307613],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01298677,0.00021777024,0.019639028,0.00008014188,0.00022886811,0.00016249708,0.0060203136,0.0051208124,0.9444695,0.00015225373,0.0033918899,0.0075301556],"study_design_scores_gemma":[0.112145014,0.057217926,0.062566295,0.0017514426,0.002099511,0.006284839,0.00594809,0.019266171,0.68429095,0.019723233,0.0272881,0.0014184602],"about_ca_topic_score_codex":0.00023371246,"about_ca_topic_score_gemma":0.00019283732,"teacher_disagreement_score":0.2601786,"about_ca_system_score_codex":0.00011292971,"about_ca_system_score_gemma":0.00069675414,"threshold_uncertainty_score":0.20698018},"labels":[],"label_agreement":null},{"id":"W2940550246","doi":"10.1097/01.ju.0000555949.60899.e0","title":"MP34-07 ASSOCIATION OF PROSTATE-SPECIFIC ANTIGEN TRAJECTORIES WITH MORTALITY IN VETERANS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Castration; Prostate-specific antigen; Antigen; Prostate; Cancer; Immunology; Hormone","score_opus":0.022308913465026635,"score_gpt":0.3063933412057666,"score_spread":0.28408442774074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2940550246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960832,0.0011000027,0.000017158305,0.00179726,0.00009081775,0.0007264756,0.000032183947,0.000003677571,0.00014921576],"genre_scores_gemma":[0.99802,0.0014052022,0.000096866024,0.000050804632,0.000045140256,0.0000136949,0.000008181837,0.000016806682,0.00034328087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849176,0.00019146483,0.0004334552,0.000118588534,0.00048243735,0.00028229447],"domain_scores_gemma":[0.99867254,0.00016941222,0.0005145346,0.00016902044,0.00041269584,0.00006180758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008540347,0.00013444606,0.00045067846,0.00013717722,0.000039805276,0.000011677524,0.000096061194,0.00004524012,0.00008693118],"category_scores_gemma":[0.00001709974,0.00006698219,0.00004465141,0.00027664308,0.00012924068,0.00013294074,0.000009591434,0.00034626716,0.0000039145584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021110298,0.00023245148,0.9200426,0.00013654472,0.00058686355,0.00017887932,0.006373336,0.0010529849,0.049784422,0.000011703752,0.00007863263,0.00041131073],"study_design_scores_gemma":[0.007988277,0.0078012315,0.97609055,0.0001567757,0.00027040526,0.00010254883,0.0011900782,0.000060814917,0.0058159647,0.00005686235,0.00037217358,0.00009430603],"about_ca_topic_score_codex":0.00040951383,"about_ca_topic_score_gemma":0.00095849123,"teacher_disagreement_score":0.056047987,"about_ca_system_score_codex":0.0002033399,"about_ca_system_score_gemma":0.00060304673,"threshold_uncertainty_score":0.27314544},"labels":[],"label_agreement":null},{"id":"W2940558046","doi":"10.1097/01.ju.0000557504.00464.d6","title":"LBA-12 CALGB 90203 (ALLIANCE): RADICAL PROSTATECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOHORMONAL THERAPY IN MEN WITH CLINICALLY LOCALIZED, HIGH RISK PROSTATE CANCER","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Urology; Alliance; Oncology; Gynecology; Cancer; Internal medicine","score_opus":0.01900053374679639,"score_gpt":0.32154676448687924,"score_spread":0.30254623074008286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2940558046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860155,0.0028691196,0.000080634716,0.008768741,0.000091794645,0.0017531766,0.000015965854,0.00001786467,0.00038722478],"genre_scores_gemma":[0.9714137,0.02489708,0.0006481325,0.0009914913,0.00020599435,0.00006384321,0.0000065898757,0.000058597412,0.0017146241],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970664,0.00042802806,0.0008040083,0.0003038737,0.00073258113,0.00066515035],"domain_scores_gemma":[0.9979614,0.0004047111,0.0006685352,0.0003642351,0.0003240196,0.0002770857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001538088,0.0003146601,0.0009673322,0.00013092638,0.00008030238,0.000020595646,0.00032368372,0.00016409469,0.00042797657],"category_scores_gemma":[0.000057500136,0.00012400566,0.000087830114,0.0003276992,0.0006818272,0.00013185463,0.000050122922,0.0014462825,0.000021409858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31877393,0.0004967338,0.6599924,0.000048556176,0.00077954016,0.0008117726,0.0011618738,0.0004495989,0.0011372574,0.00000994023,0.00051698386,0.015821442],"study_design_scores_gemma":[0.22274682,0.15170331,0.57579553,0.0009787005,0.0013178725,0.005639194,0.0011204147,0.0033902372,0.004230765,0.0007448018,0.031379163,0.00095321325],"about_ca_topic_score_codex":0.0006056959,"about_ca_topic_score_gemma":0.00021825415,"teacher_disagreement_score":0.15120658,"about_ca_system_score_codex":0.00019403386,"about_ca_system_score_gemma":0.001569087,"threshold_uncertainty_score":0.62834585},"labels":[],"label_agreement":null},{"id":"W2940567933","doi":"10.1097/01.ju.0000555909.47437.02","title":"MP34-17 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER: POST HOC ANALYSIS OF PROSPER BY PROSTATE SPECIFIC-ANTIGEN PROGRESSION","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Post-hoc analysis; Placebo; Prostate; Prostate-specific antigen; Oncology; Cancer; Urology; Internal medicine; Post hoc; Pathology; Androgen receptor","score_opus":0.01571752767536278,"score_gpt":0.3285312000984466,"score_spread":0.31281367242308383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2940567933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986969,0.002643828,0.000007629708,0.0005346875,0.00006320396,0.009644706,0.00008969966,0.000004377026,0.000042869673],"genre_scores_gemma":[0.99859005,0.0008092262,0.000065698354,0.00003269704,0.000018894521,0.0001737923,0.000057707137,0.0000268211,0.0002250932],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99622726,0.0007327178,0.0014669221,0.00025089053,0.0009348773,0.00038734192],"domain_scores_gemma":[0.9964533,0.0004253389,0.0017267971,0.00035541505,0.00091573154,0.00012345327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022257224,0.0002751949,0.0021633608,0.00077574543,0.00005812926,0.00001729339,0.00021531977,0.00006893522,0.00015029458],"category_scores_gemma":[0.000049637696,0.00013071364,0.00024078101,0.0008659645,0.0002856683,0.00015441304,0.00004153439,0.0004071871,0.0000016808073],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8243409,0.004210903,0.14898916,0.00006482155,0.005736791,0.000048249123,0.0052133594,0.0011504866,0.009490635,0.0000019561014,0.000036024874,0.00071676244],"study_design_scores_gemma":[0.94135004,0.02984771,0.020469304,0.00012593222,0.005169719,0.000009431797,0.0010814868,0.000339759,0.0014435138,0.000006820587,0.000026917041,0.0001293829],"about_ca_topic_score_codex":0.00020115169,"about_ca_topic_score_gemma":0.00020454457,"teacher_disagreement_score":0.12851986,"about_ca_system_score_codex":0.000114864815,"about_ca_system_score_gemma":0.00040771716,"threshold_uncertainty_score":0.53303474},"labels":[],"label_agreement":null},{"id":"W2941182828","doi":"10.1097/01.ju.0000555600.69863.72","title":"MP22-15 DEPRESSION IN PROSTATE CANCER PATIENTS STARTING ANDROGEN DEPRIVATION THERAPY","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psychoanalysis; Chin; Medicine; Psychology; Anatomy","score_opus":0.020024361594642694,"score_gpt":0.3176816730469528,"score_spread":0.29765731145231006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941182828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928582,0.00419812,0.0000035611586,0.0023209653,0.00013568263,0.00035169796,0.0000014859073,0.000003162007,0.00012717396],"genre_scores_gemma":[0.996307,0.003005642,0.000016110347,0.0004768045,0.000056858527,0.0000047306416,0.0000029565258,0.0000094155985,0.00012049207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991895,0.00012429063,0.00024215579,0.000065939086,0.00020070896,0.0001774346],"domain_scores_gemma":[0.99944586,0.00007632298,0.0001899547,0.00009733857,0.00014724534,0.0000432829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043374565,0.00006406598,0.0001671739,0.00010341768,0.000029633491,0.0000043129853,0.00008000224,0.000037661735,0.000114730225],"category_scores_gemma":[0.000031594096,0.00003236808,0.000032522024,0.00011424098,0.000031398897,0.00007552684,0.000025373965,0.00024641128,0.0000086208065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043026023,0.00011908214,0.9639926,0.000009450366,0.000048552567,0.000014315913,0.0009075568,0.00013835232,0.01297048,0.0000010070742,0.00015804217,0.01733795],"study_design_scores_gemma":[0.010152398,0.0020175595,0.9703089,0.00006547847,0.00003834319,0.000036332392,0.00010478233,0.0002330978,0.014895998,0.00030099842,0.0017878001,0.000058302197],"about_ca_topic_score_codex":0.000038645816,"about_ca_topic_score_gemma":0.000010811444,"teacher_disagreement_score":0.017279647,"about_ca_system_score_codex":0.00006702782,"about_ca_system_score_gemma":0.0001052488,"threshold_uncertainty_score":0.1319932},"labels":[],"label_agreement":null},{"id":"W2941263603","doi":"10.1097/01.ju.0000557215.99831.87","title":"PD60-10 A PROSPECTIVE PHASE 2/3 MULTI-CENTER STUDY OF <sup>18</sup> F-DCFPYL PET/CT IMAGING IN PATIENTS WITH PROSTATE CANCER – EXAMINATION OF DIAGNOSTIC ACCURACY (OSPREY)","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"ROWE; Medicine; Art history; Psychoanalysis; Art; Psychology","score_opus":0.01559740752787822,"score_gpt":0.32824467644878014,"score_spread":0.31264726892090194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941263603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99703014,0.00051067834,0.000005924903,0.00029514486,0.000057734313,0.0020069291,0.000019069572,0.0000035451826,0.00007081633],"genre_scores_gemma":[0.99946964,0.00023725118,0.000021011154,0.000035537298,0.000026086718,0.000033441956,0.000006523645,0.000019885285,0.00015059598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984094,0.00030588848,0.00048364475,0.00014714146,0.0004037673,0.0002501893],"domain_scores_gemma":[0.9980083,0.00056527084,0.0005361288,0.00020379234,0.0006249852,0.00006148903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005885669,0.00014521119,0.00044237275,0.00026546212,0.000028586453,0.0000050201706,0.00015094965,0.000010986665,0.0001532957],"category_scores_gemma":[0.00033165998,0.00007893121,0.000045507444,0.00023380439,0.00013337664,0.00017972328,0.00005674791,0.0003242262,0.0000035083128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012849231,0.007336758,0.96829957,0.00006896555,0.00025281237,0.00020716898,0.005972218,0.0005031073,0.0003022192,6.8688195e-7,0.000039464736,0.004167791],"study_design_scores_gemma":[0.063852206,0.011621481,0.92072934,0.00017777503,0.00027637772,0.00010813098,0.0016677935,0.00088953594,0.00056301046,0.000009013111,0.000030406885,0.00007493691],"about_ca_topic_score_codex":0.00010866359,"about_ca_topic_score_gemma":0.000033267435,"teacher_disagreement_score":0.05100297,"about_ca_system_score_codex":0.00014620865,"about_ca_system_score_gemma":0.00017510234,"threshold_uncertainty_score":0.32187214},"labels":[],"label_agreement":null},{"id":"W2941377864","doi":"10.1097/01.ju.0000555449.91087.2b","title":"MP18-04 IMPACT OF PUTATIVE CHEMOPREVENTATIVE AGENTS ON PROSTATE CANCER DIAGNOSIS","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Gynecology; Internal medicine","score_opus":0.03419591214179501,"score_gpt":0.40558443841494457,"score_spread":0.37138852627314956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941377864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931093,0.0017112667,0.0000025323468,0.0040453607,0.00013314249,0.00042337252,0.000039636958,0.0000024492122,0.0005329392],"genre_scores_gemma":[0.9947235,0.004028146,0.000014690866,0.00029578313,0.00007057861,0.00001762437,0.0000040116715,0.000013212076,0.0008324668],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990131,0.00016662922,0.00026378487,0.00007916062,0.0002632027,0.00021406903],"domain_scores_gemma":[0.99889433,0.00029040893,0.0003532437,0.00012614483,0.00024714338,0.00008875072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039588232,0.00010892902,0.00036136256,0.000120998644,0.000025754367,0.0000028414445,0.00012116676,0.00004638615,0.000732653],"category_scores_gemma":[0.000052290452,0.00005168129,0.00016484225,0.00014866947,0.00013762474,0.0000554624,0.00003069543,0.00032551243,0.000029617417],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02679652,0.0008856423,0.91448534,0.000096309144,0.0032687006,0.00018458374,0.015226228,0.0019624273,0.016803384,0.00002349492,0.00629882,0.013968535],"study_design_scores_gemma":[0.010164773,0.022749996,0.90882796,0.0001460188,0.0005809877,0.00021617036,0.000716943,0.00013420384,0.05461299,0.001002651,0.00073349965,0.00011383451],"about_ca_topic_score_codex":0.00013832854,"about_ca_topic_score_gemma":0.0000026468397,"teacher_disagreement_score":0.037809603,"about_ca_system_score_codex":0.00017735458,"about_ca_system_score_gemma":0.0003050101,"threshold_uncertainty_score":0.8022037},"labels":[],"label_agreement":null},{"id":"W2941511463","doi":"10.1097/01.ju.0000555072.71167.58","title":"PD05-12 COMBINATION OF AN ANTAGONIST TO THE ANDROGEN RECEPTOR N-TERMINAL DOMAIN WITH ENZALUTAMIDE FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Medicine; Androgen; Internal medicine; Androgen deprivation therapy; Cancer; Antagonist; Cancer research; Abiraterone acetate; Endocrinology; Oncology; Receptor; Hormone","score_opus":0.021222156557138713,"score_gpt":0.3209306843503896,"score_spread":0.29970852779325086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941511463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841693,0.0014306463,0.000049143575,0.012843913,0.00011156536,0.001301094,0.000052043815,0.0000018383798,0.00004043385],"genre_scores_gemma":[0.9981064,0.0011181398,0.0001503835,0.00009405628,0.00009832653,0.000038459035,0.000009711743,0.00001120467,0.00037329277],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990656,0.0001657245,0.0002888379,0.00007883337,0.00023961785,0.00016138998],"domain_scores_gemma":[0.9989202,0.00022834724,0.0003222521,0.00020969013,0.0002689452,0.000050588656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063122046,0.000092466675,0.0002495515,0.00006061175,0.00009503679,0.0000072343787,0.00012788121,0.000034083438,0.00003249394],"category_scores_gemma":[0.000011381914,0.00003347381,0.000059934664,0.00009488965,0.00015687128,0.000048966296,0.0000087668695,0.0000888782,0.0000011045439],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25525162,0.002491291,0.03626213,0.00026414363,0.0022983172,0.00009162358,0.03216908,0.0018187977,0.6118521,0.0006009982,0.00093968655,0.055960223],"study_design_scores_gemma":[0.053226713,0.26015124,0.15263194,0.00035732993,0.0035542168,0.0020442272,0.01121699,0.0011679566,0.44984943,0.0013349977,0.0640923,0.00037267135],"about_ca_topic_score_codex":0.00014518747,"about_ca_topic_score_gemma":0.00033739046,"teacher_disagreement_score":0.25765994,"about_ca_system_score_codex":0.000114031354,"about_ca_system_score_gemma":0.00028529763,"threshold_uncertainty_score":0.13650224},"labels":[],"label_agreement":null},{"id":"W2941664380","doi":"10.1097/01.ju.0000555933.20995.42","title":"MP34-19 EFFICACY AND SAFETY OF APALUTAMIDE (APA) IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) PATIENTS (PTS) WITH OR WITHOUT PRIOR RADICAL PROSTATECTOMY (RP) AND/OR EXTERNAL RADIOTHERAPY (XRT): POST HOC ANALYSIS OF SPARTAN","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Post-hoc analysis; Urology; Prostatectomy; Post hoc; Internal medicine; Oncology; Cancer","score_opus":0.013816254231239543,"score_gpt":0.31219777203973703,"score_spread":0.2983815178084975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941664380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946503,0.0030374294,0.00004686685,0.0009208555,0.000036755613,0.0012260418,0.000068074936,0.0000033221122,0.00001034114],"genre_scores_gemma":[0.9948712,0.0041580717,0.0005912938,0.0001671266,0.000023945473,0.000011308481,0.0000077188115,0.000022590115,0.00014676053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979008,0.00031981096,0.00076806685,0.00020244566,0.00049519073,0.00031367343],"domain_scores_gemma":[0.99822485,0.00043475392,0.00066757266,0.00021502325,0.0002822846,0.00017548351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076178816,0.00020314232,0.0009886049,0.0004851276,0.0000503289,0.00001127699,0.00012946474,0.00006835224,0.00016704784],"category_scores_gemma":[0.00007199995,0.00009534287,0.000071639435,0.00054958306,0.0004904268,0.00010758201,0.000029990706,0.00033778747,3.7087804e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28987744,0.0006589009,0.67007905,0.00029263552,0.0025529675,0.00015043549,0.005230266,0.0006987801,0.020874346,0.000009957212,0.000009233484,0.009566007],"study_design_scores_gemma":[0.035756625,0.02327552,0.9351532,0.0003105591,0.0021648812,0.0002812209,0.0004154317,0.0012848454,0.0010228112,0.000013674778,0.00017359534,0.00014762003],"about_ca_topic_score_codex":0.0002943696,"about_ca_topic_score_gemma":0.00075687614,"teacher_disagreement_score":0.2650742,"about_ca_system_score_codex":0.00012727504,"about_ca_system_score_gemma":0.0006467601,"threshold_uncertainty_score":0.38879693},"labels":[],"label_agreement":null},{"id":"W2941797036","doi":"10.1016/j.eururo.2019.04.006","title":"Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"DOD Prostate Cancer Research Program; National Cancer Institute; Medical Research Council; Imperial Experimental Cancer Medicine Centre; Stand Up To Cancer; Cancer Research UK; Academy of Medical Sciences; U.S. Department of Veterans Affairs; Patrick C. Walsh Prostate Cancer Research Fund; Institute for Prostate Cancer Research; Prostate Cancer Foundation; Movember Foundation; National Institutes of Health; Prostate Cancer UK; National Institute for Health and Care Research; U.S. Department of Defense","keywords":"Medicine; Prostate cancer; Interquartile range; Circulating tumor cell; Androgen receptor; Biopsy; Internal medicine; Hazard ratio; Oncology; Liquid biopsy; Pathology; Cancer; Confidence interval; Metastasis","score_opus":0.04920556836931989,"score_gpt":0.3493108338620497,"score_spread":0.3001052654927298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941797036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855595,0.0015334169,0.000009252164,0.00039009054,0.00020284677,0.0008444202,0.00009108905,0.000023272773,0.011346082],"genre_scores_gemma":[0.99784434,0.00047574722,0.00044871963,0.00016740459,0.000062504434,0.000014499417,0.00007425278,0.000035667654,0.000876892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973782,0.00080047536,0.0006858972,0.0004510855,0.00022014616,0.00046422196],"domain_scores_gemma":[0.998946,0.00022588548,0.00021095725,0.00031876258,0.00012982017,0.00016858599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011686962,0.00015842283,0.00045923342,0.00011384835,0.000032151624,0.0000073508295,0.00010040516,0.00004430956,0.00081853993],"category_scores_gemma":[0.00012406286,0.00012842145,0.00009130851,0.00023643629,0.0001327975,0.00005880482,0.00007266928,0.0003620373,0.00015636998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034264561,0.0006603275,0.90596426,0.00042793245,0.00017297454,0.0008947669,0.0012939699,0.00008225044,0.07872262,0.000035549685,0.00041486946,0.007904031],"study_design_scores_gemma":[0.0091616465,0.0018253969,0.9766158,0.0000772901,0.00015585961,0.000036743786,0.00036493785,0.0013221261,0.0027952557,0.000036131023,0.0074037206,0.00020511595],"about_ca_topic_score_codex":0.0003212167,"about_ca_topic_score_gemma":0.00007039588,"teacher_disagreement_score":0.07592736,"about_ca_system_score_codex":0.000053823598,"about_ca_system_score_gemma":0.00040176837,"threshold_uncertainty_score":0.8962438},"labels":[],"label_agreement":null},{"id":"W2941821784","doi":"10.1097/01.ju.0000556542.78481.2b","title":"PD40-10 MORTALITY FOLLOWING RADICAL PROSTATECTOMY (RP) OR INTENSITY MODULATED RADIATION THERAPY (IMRT) FOR LOCALIZED PROSTATE CANCER (PCA) – AN ANALYSIS OF THE CDC PROSTATE CANCER DATA QUALITY AND PATTERNS OF CARE STUDY (CDC POC-BP)","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Radiation therapy; Urology; Oncology; Internal medicine; Cancer","score_opus":0.08239376686547109,"score_gpt":0.4274603932094225,"score_spread":0.34506662634395135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941821784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902482,0.0037333071,0.000037724258,0.0018328531,0.00023435283,0.0031990854,0.00070139556,0.00000975649,0.0000033242657],"genre_scores_gemma":[0.9968379,0.0025140545,0.000019850013,0.00023927462,0.00006160155,0.00005098397,0.00012590502,0.000028828224,0.00012160033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99666756,0.00093631475,0.0009834026,0.0003737578,0.0006621572,0.00037680447],"domain_scores_gemma":[0.99677795,0.00028362763,0.0010067683,0.0009301729,0.00085869455,0.00014279418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023941481,0.00024992978,0.0012773679,0.00022926606,0.00012921535,0.000018325321,0.000487274,0.00011904558,0.00010399615],"category_scores_gemma":[0.00015166852,0.00011912265,0.00024385113,0.00057485106,0.00024662542,0.00021554064,0.00018124992,0.00040480122,2.0142022e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03431815,0.00051412167,0.9374573,0.00021452933,0.006253181,0.000016449345,0.008596264,0.00081706955,0.005845817,0.0000015756101,0.000037123693,0.005928421],"study_design_scores_gemma":[0.015516177,0.0046974574,0.96389973,0.000080068974,0.004440531,0.000013760028,0.003000606,0.0049363924,0.0029998994,0.000041847106,0.00022637885,0.00014716852],"about_ca_topic_score_codex":0.0038506973,"about_ca_topic_score_gemma":0.0021328428,"teacher_disagreement_score":0.026442416,"about_ca_system_score_codex":0.00017091297,"about_ca_system_score_gemma":0.0006936225,"threshold_uncertainty_score":0.5821128},"labels":[],"label_agreement":null},{"id":"W2941842789","doi":"10.1097/01.ju.0000555948.83770.4e","title":"MP34-05 COMBINATION THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER USING ANTAGONISTS OF THE N-TERMINAL DOMAIN OF ANDROGEN RECEPTOR WITH IONIZING RADIATION","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Prostate cancer; Medicine; Androgen receptor; Cancer research; Cancer; Androgen; Radiation therapy; Internal medicine; Oncology; Hormone","score_opus":0.024895496483334566,"score_gpt":0.32087848839564354,"score_spread":0.295982991912309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941842789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994436,0.0015057655,0.000064910724,0.0031005088,0.00014992268,0.0007084655,0.000017765838,0.0000013607311,0.0000152499415],"genre_scores_gemma":[0.99876815,0.000767069,0.00023099131,0.00005915988,0.00006057356,0.000005435779,0.0000044249773,0.0000099419885,0.00009426391],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99918646,0.00013420994,0.0002796253,0.000058844904,0.0002170485,0.00012379409],"domain_scores_gemma":[0.99891347,0.00010606248,0.00052233075,0.00011109977,0.0003205635,0.00002649821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053069065,0.000069971655,0.00021215189,0.00006810167,0.00007085833,0.000004919703,0.00008703257,0.00003594864,0.000019298674],"category_scores_gemma":[0.000013313111,0.000032237804,0.000057805802,0.00011920298,0.00012607507,0.00006490243,0.000009208953,0.00011675083,1.949672e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028555665,0.00024750005,0.053888805,0.00014391897,0.0004433279,0.000010345237,0.0033731447,0.0006345766,0.9045659,0.00015108136,0.0001338005,0.00785196],"study_design_scores_gemma":[0.0466467,0.028362876,0.18725377,0.00064038386,0.00094724534,0.0017402861,0.0018049129,0.0023777778,0.7239698,0.0015448225,0.0044346033,0.0002768233],"about_ca_topic_score_codex":0.000045609282,"about_ca_topic_score_gemma":0.000011195588,"teacher_disagreement_score":0.18059607,"about_ca_system_score_codex":0.00008342401,"about_ca_system_score_gemma":0.00048395613,"threshold_uncertainty_score":0.13146195},"labels":[],"label_agreement":null},{"id":"W2941844660","doi":"10.1097/01.ju.0000555063.11964.56","title":"PD05-03 MOLECULAR HALLMARKS OF MPMRI VISIBILITY IN PROSTATE CANCER","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Visibility; Identification (biology); Prostatectomy; Disease; Gynecology; Pathology; Oncology; Internal medicine; Biology","score_opus":0.012573935921960884,"score_gpt":0.32657812409276377,"score_spread":0.3140041881708029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941844660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836524,0.0065728347,0.000007823582,0.008116501,0.00013266887,0.00031331007,0.000003345698,0.000001975428,0.0011991266],"genre_scores_gemma":[0.99728113,0.0018753939,0.000031736177,0.00034241294,0.000033643548,0.0000028426682,9.793932e-7,0.0000087380595,0.00042309583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998946,0.00019704139,0.0003465585,0.0000804624,0.00022488771,0.00020503541],"domain_scores_gemma":[0.99923617,0.00011246036,0.0001988613,0.00020655744,0.00018590983,0.00006001901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094589236,0.00007582454,0.00033391165,0.00012433661,0.000011310073,0.000002037845,0.00013435949,0.00005231397,0.00027792138],"category_scores_gemma":[0.000054984575,0.000040512572,0.000076549164,0.00014770046,0.00012705466,0.000040607927,0.00004118412,0.00037789208,0.000010665521],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018508991,0.00058333884,0.73577625,0.00025932046,0.0004918389,0.00050541473,0.0023742083,0.0011480424,0.23067997,0.00013256003,0.0006920339,0.008848028],"study_design_scores_gemma":[0.02167459,0.010875739,0.88050115,0.00029922568,0.000558548,0.0010602985,0.0006524436,0.0008581286,0.072266296,0.004308452,0.0067088436,0.00023628146],"about_ca_topic_score_codex":0.00013076159,"about_ca_topic_score_gemma":0.000029198838,"teacher_disagreement_score":0.15841366,"about_ca_system_score_codex":0.00007782671,"about_ca_system_score_gemma":0.0003003129,"threshold_uncertainty_score":0.30430442},"labels":[],"label_agreement":null},{"id":"W2942114051","doi":"10.1097/01.ju.0000555586.05782.19","title":"MP22-02 GNRH ANTAGONISTS HAVE DIRECT INHIBITORY EFFECTS ON CASTRATION-RESISTANT PROSTATE CANCER VIA INTRACRINE ANDROGEN AND AR-V7 EXPRESSION","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intracrine; Prostate cancer; Medicine; Testosterone (patch); Androgen deprivation therapy; Androgen receptor; Androgen; Cancer; Management of prostate cancer; Agonist; Internal medicine; Cancer research; Endocrinology; Receptor; Hormone; Paracrine signalling","score_opus":0.00968682037714934,"score_gpt":0.29068248601972896,"score_spread":0.2809956656425796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942114051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872676,0.006895056,0.000003708391,0.0045637633,0.00031784025,0.0004918087,0.000007888932,0.000007995397,0.00044431118],"genre_scores_gemma":[0.9958397,0.0027098074,0.000025135902,0.0003580563,0.0003172055,0.000010158537,0.0000041903595,0.000018095277,0.00071762863],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988399,0.00021496159,0.0002665847,0.00013870168,0.00027886764,0.00026098965],"domain_scores_gemma":[0.9991047,0.00025754212,0.00020410844,0.00016944388,0.00012655891,0.00013763866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043972436,0.00014404872,0.00033327608,0.00011322533,0.000092431335,0.000013549059,0.000079465615,0.000074836025,0.00006829507],"category_scores_gemma":[0.000033988024,0.000075827294,0.000053153035,0.00006375462,0.00012059711,0.000074835465,0.0000393109,0.00039632173,0.000010923023],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016487204,0.00017825417,0.03755691,0.00019277331,0.00023452661,0.0005873126,0.0011995247,0.000059123216,0.9280304,0.0000063513417,0.0015333866,0.0139342565],"study_design_scores_gemma":[0.01149149,0.012957988,0.08659272,0.00047603436,0.00042741644,0.0014042696,0.00019342873,0.00018861481,0.8781498,0.0002538068,0.0076455055,0.00021889844],"about_ca_topic_score_codex":0.000044032127,"about_ca_topic_score_gemma":0.000022803215,"teacher_disagreement_score":0.049880553,"about_ca_system_score_codex":0.000088314955,"about_ca_system_score_gemma":0.0001584709,"threshold_uncertainty_score":0.3092147},"labels":[],"label_agreement":null},{"id":"W2942128858","doi":"10.1158/1078-0432.ccr-19-0404","title":"Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute; Prostate Cancer Foundation","keywords":"Cancer; Prostate cancer; Oncology; DNA methylation; Gene signature; Transcriptome; Internal medicine; Breast cancer; Medicine; Biology; Cancer research; Gene; Gene expression; Genetics","score_opus":0.23426778806581544,"score_gpt":0.5628657953480856,"score_spread":0.3285980072822701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942128858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9684463,0.004353965,0.0000059481313,0.021960372,0.0010523548,0.002074322,0.000722964,0.000114490875,0.001269242],"genre_scores_gemma":[0.9462982,0.005934433,0.000057315377,0.0033213536,0.0007409779,0.00039158636,0.00008781301,0.0001219064,0.043046445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99304783,0.00056138245,0.001141535,0.001375653,0.0021439188,0.0017296819],"domain_scores_gemma":[0.9940617,0.0024553903,0.00019410347,0.0008876863,0.0015220975,0.0008790261],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005035189,0.000417242,0.0015038511,0.00016968537,0.00030419187,0.0001392221,0.0006367046,0.0008567582,0.0033583492],"category_scores_gemma":[0.00094640243,0.000262211,0.0006376005,0.0011025545,0.0015425055,0.00019258154,0.00018370575,0.0040436997,0.00042729592],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069788373,0.0014679942,0.9623464,0.00016527732,0.0019238564,0.00015483882,0.00035139566,0.0000057076622,0.001222579,0.000029282572,0.016727395,0.008626484],"study_design_scores_gemma":[0.027123606,0.0034048606,0.926375,0.0010309083,0.00026935028,0.000010438387,0.00034266507,0.00022194786,0.0019618338,0.000083819425,0.03864215,0.0005334674],"about_ca_topic_score_codex":0.0016063141,"about_ca_topic_score_gemma":0.0016159675,"teacher_disagreement_score":0.0417772,"about_ca_system_score_codex":0.0006897625,"about_ca_system_score_gemma":0.0027802857,"threshold_uncertainty_score":0.999983},"labels":[],"label_agreement":null},{"id":"W2942209065","doi":"10.5489/cuaj.5840","title":"Management algorithms for metastatic prostate cancer","year":2019,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia; Centre Hospitalier de l’Université de Montréal; University of Toronto; William Osler Health System; University of Alberta; McMaster University; Juravinski Cancer Centre; University of Calgary; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; University of Ottawa","funders":"Janssen Canada; Ipsen; Astellas Pharma; Eisai; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Prostate cancer; Cabazitaxel; Medicine; Docetaxel; Abiraterone acetate; Guideline; Oncology; Enzalutamide; Androgen deprivation therapy; Internal medicine; Radiation therapy; Clinical trial; Disease; Cancer; Management of prostate cancer; Intensive care medicine; Androgen receptor; Pathology","score_opus":0.09246631859956617,"score_gpt":0.38421689824399524,"score_spread":0.2917505796444291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942209065","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005881443,0.9900781,0.000021941221,0.004374983,0.0007433121,0.0029647173,0.0006788296,0.000019511921,0.0011127057],"genre_scores_gemma":[0.000008443366,0.96761984,0.0004965765,0.00065242784,0.00053896493,0.0006532542,0.00038340443,0.00004926673,0.029597815],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99745613,0.00018048161,0.00059013965,0.00037277315,0.00048749027,0.0009129638],"domain_scores_gemma":[0.99793464,0.0002144454,0.000514762,0.00016384477,0.00033396063,0.00083837245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008152734,0.0003392293,0.0014025854,0.0004615952,0.00024531185,0.00014259467,0.00019250123,0.00031508986,0.0005716797],"category_scores_gemma":[0.00013665021,0.00021895967,0.0007161885,0.00033271435,0.00002718008,0.00006405677,0.000025344492,0.0008463451,0.00016594643],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035179157,0.00004325915,0.00058474403,0.0036517193,0.0021668032,0.00030262404,0.000022952476,0.000002036576,2.0358453e-8,0.000058121062,0.024070833,0.96906173],"study_design_scores_gemma":[0.0014849711,0.0003110952,0.00025711852,0.0014753153,0.0032934283,0.00013042668,0.000018014096,0.000019370198,7.845465e-8,0.00016711648,0.9926265,0.00021656412],"about_ca_topic_score_codex":0.00023262807,"about_ca_topic_score_gemma":0.00009392982,"teacher_disagreement_score":0.9688451,"about_ca_system_score_codex":0.005025989,"about_ca_system_score_gemma":0.0025825966,"threshold_uncertainty_score":0.99879354},"labels":[],"label_agreement":null},{"id":"W2942219192","doi":"10.1097/01.ju.0000555359.59547.3e","title":"PD11-03 RESPONSE TO APALUTAMIDE (APA) AMONG PATIENTS (PTS) WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) FROM SPARTAN BY DECIPHER GENOMIC CLASSIFIER (GC) SCORE","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Oncology; DECIPHER; Urology; Cancer; Bioinformatics","score_opus":0.0176092887693129,"score_gpt":0.277263289139388,"score_spread":0.25965400037007513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942219192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99234945,0.0010267735,0.000033565106,0.005155608,0.0002318284,0.0009326249,0.000117529395,0.000007771995,0.00014485772],"genre_scores_gemma":[0.99603283,0.00026230264,0.00016369179,0.0007999532,0.00008107939,0.000025313871,0.00002243682,0.000043429223,0.002568957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786,0.00042971448,0.0004925072,0.00022835721,0.00053553475,0.00045389993],"domain_scores_gemma":[0.998274,0.0003835294,0.0003714237,0.00034206937,0.0003403044,0.0002886322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006790255,0.0002222621,0.00047390268,0.00015430976,0.00009885943,0.000028448412,0.00022567669,0.00008100881,0.0005607604],"category_scores_gemma":[0.00008098523,0.000120380646,0.00007578044,0.00020454076,0.00020695863,0.00012683832,0.000049414102,0.00045878987,0.00010239921],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12678818,0.00038127822,0.65898657,0.00003506432,0.0009673529,0.0002459814,0.003302205,0.000935963,0.19965541,0.000003606502,0.006977821,0.0017205597],"study_design_scores_gemma":[0.009483885,0.007996874,0.97135806,0.00013610635,0.0005792892,0.000058483325,0.00044202467,0.00011397983,0.0029791924,0.000076343415,0.0065830667,0.00019269862],"about_ca_topic_score_codex":0.00034345797,"about_ca_topic_score_gemma":0.00046303653,"teacher_disagreement_score":0.3123715,"about_ca_system_score_codex":0.0003152409,"about_ca_system_score_gemma":0.0005374742,"threshold_uncertainty_score":0.61399335},"labels":[],"label_agreement":null},{"id":"W2942238546","doi":"10.1097/01.ju.0000555599.69863.27","title":"MP22-14 DEFINITIVE THERAPY FOR MEN WITH NEWLY-DIAGNOSED OLIGOMETASTATIC PROSTATE CANCER: INITIAL SURGICAL OUTCOMES FROM A PHASE II STUDY","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prostate Cancer Canada","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Prostate; General surgery; Oncology; Surgery; Gynecology; Internal medicine","score_opus":0.046936833187455486,"score_gpt":0.3849337752926902,"score_spread":0.3379969421052347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942238546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98675954,0.0025577187,0.000024869923,0.007970513,0.00015807307,0.0021165134,0.00011798307,0.0000100599345,0.0002847438],"genre_scores_gemma":[0.99647677,0.0020611875,0.000096279335,0.00058667234,0.00018320039,0.00010292552,0.000019221896,0.000030250816,0.000443481],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99836844,0.00032258898,0.00040028448,0.00016521673,0.0003825735,0.00036087597],"domain_scores_gemma":[0.9977024,0.0013042479,0.00030553708,0.00020619805,0.00033999485,0.0001416055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068284024,0.00019543759,0.0007014057,0.0001504014,0.00012243209,0.000013781236,0.00017918796,0.000053617678,0.00040711486],"category_scores_gemma":[0.000054133157,0.0000883242,0.00012075762,0.0001524971,0.00015550178,0.00008410966,0.000040792856,0.0003834948,0.000008564732],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4772169,0.014060998,0.3618793,0.000068433495,0.012654133,0.0042889635,0.041669395,0.00027213356,0.0024369992,0.000070851056,0.0030036373,0.08237826],"study_design_scores_gemma":[0.56855863,0.30985278,0.08771515,0.00013000125,0.003221691,0.0009015033,0.010330943,0.00037121138,0.0025665548,0.0013700526,0.014478071,0.00050342473],"about_ca_topic_score_codex":0.00021083457,"about_ca_topic_score_gemma":0.00004684729,"teacher_disagreement_score":0.29579177,"about_ca_system_score_codex":0.00006888545,"about_ca_system_score_gemma":0.00048653968,"threshold_uncertainty_score":0.44576222},"labels":[],"label_agreement":null},{"id":"W2942262616","doi":"10.1097/01.ju.0000557222.99762.6b","title":"PD60-11 A PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF <sup>99M</sup> TC-MIP-1404 SPECT/CT IMAGING TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH BIOPSY PROVEN LOW GRADE PROSTATE CANCER WHO ARE CANDIDATES FOR ACTIVE SURVEILLANCE (PROSPECT-AS)","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Bible College","funders":"","keywords":"Medicine; Prostate cancer; Nuclear medicine; Biopsy; Radiology; Prostate; Cancer; Internal medicine","score_opus":0.015742076712275295,"score_gpt":0.3596029681992671,"score_spread":0.34386089148699184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942262616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733289,0.0013285181,0.000021144424,0.016833136,0.000072989234,0.008137618,0.00023308206,0.000011153517,0.000033481123],"genre_scores_gemma":[0.99729264,0.0015217174,0.000035660076,0.00037203805,0.000119390905,0.00025260457,0.000003888777,0.000055999863,0.0003460489],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967393,0.00064648065,0.00090128684,0.0004629329,0.0005678802,0.0006821],"domain_scores_gemma":[0.9971614,0.0009838614,0.00060131203,0.0004410665,0.0005483239,0.00026405905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030710038,0.00034508706,0.0010894409,0.00025014533,0.00013680849,0.000033322136,0.00037317228,0.000026852189,0.000049658516],"category_scores_gemma":[0.00034342668,0.00016657752,0.000103022285,0.0005434291,0.00027814897,0.00010890579,0.00013749099,0.0005534211,0.0000035579521],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20751645,0.0012187168,0.73237395,0.00020135338,0.0011911098,0.00046661362,0.01977429,0.0076046404,0.013489643,0.0000032898633,0.00025239208,0.01590758],"study_design_scores_gemma":[0.1011579,0.04790002,0.8078643,0.0012540732,0.0013097664,0.0007485469,0.013002196,0.0066000926,0.01826777,0.00023330565,0.0009173858,0.00074463326],"about_ca_topic_score_codex":0.0012302067,"about_ca_topic_score_gemma":0.0010163118,"teacher_disagreement_score":0.10635854,"about_ca_system_score_codex":0.00033299503,"about_ca_system_score_gemma":0.0009126469,"threshold_uncertainty_score":0.6792834},"labels":[],"label_agreement":null},{"id":"W2942284158","doi":"10.1097/01.ju.0000555597.85110.fb","title":"MP22-12 ONCOLOGICAL OUTCOMES IN PATIENTS WITH HIGH LYMPH NODE BURDEN AFTER RADICAL PROSTATECTOMY","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostatectomy; Lymph node; Dissection (medical); General surgery; Adjuvant therapy; Cancer; Prostate cancer; Oncology; Internal medicine; Surgery","score_opus":0.009862101562188844,"score_gpt":0.27396387791562,"score_spread":0.26410177635343113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942284158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98987246,0.00025243114,0.0000053318236,0.009004665,0.00013199965,0.0004272694,0.0000032872942,0.000005417361,0.00029714438],"genre_scores_gemma":[0.9983807,0.000082193816,0.00010269927,0.0008387803,0.000080859114,0.000008371579,0.0000031638635,0.000012440991,0.00049077865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876225,0.00018852299,0.0002849385,0.00010158431,0.00036031258,0.00030240088],"domain_scores_gemma":[0.99929523,0.0001978244,0.00012883081,0.00016404063,0.00010846393,0.000105620085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003894168,0.0001161988,0.00041921812,0.00012796829,0.000021911097,0.000005827595,0.00014253848,0.00009894326,0.00038697556],"category_scores_gemma":[0.00004612639,0.00004768786,0.000057045017,0.00009273213,0.00018741148,0.000055839457,0.000052458756,0.00042684868,0.000049330964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021860853,0.00037281084,0.9760794,0.000015100214,0.00014362046,0.00027301686,0.00023372521,0.000038270144,0.0000905924,0.000010898476,0.000066646804,0.00081507466],"study_design_scores_gemma":[0.015855445,0.0045942385,0.97809166,0.000026561458,0.00009620327,0.00011828374,0.000033151853,0.000011511959,0.000044404984,0.00012709139,0.00094614556,0.000055296743],"about_ca_topic_score_codex":0.000024502442,"about_ca_topic_score_gemma":0.0000033430053,"teacher_disagreement_score":0.0085082585,"about_ca_system_score_codex":0.00014337755,"about_ca_system_score_gemma":0.00018043311,"threshold_uncertainty_score":0.42371112},"labels":[],"label_agreement":null},{"id":"W2942309608","doi":"10.1530/jme-18-0226","title":"PEG10 is associated with treatment-induced neuroendocrine prostate cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Molecular Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Prostate Cancer Canada","keywords":"Enzalutamide; LNCaP; Gene knockdown; Androgen receptor; Prostate cancer; Cancer research; Transdifferentiation; Biology; Cell culture; Molecular biology; Cell; Cancer; Genetics","score_opus":0.021461590006205403,"score_gpt":0.3161706636645175,"score_spread":0.2947090736583121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942309608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98828036,0.0023231788,0.0000049141236,0.0075122826,0.00024179388,0.0005447709,0.000013517803,0.000022368717,0.0010568015],"genre_scores_gemma":[0.9932606,0.0018784415,0.00006912743,0.0006959727,0.00006864659,0.000024470255,0.000010948957,0.000045262856,0.003946491],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99826545,0.00009817686,0.00035878492,0.000253218,0.0004171579,0.0006072294],"domain_scores_gemma":[0.9987734,0.000050449577,0.00030735895,0.0002658309,0.0003936897,0.00020925568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004847991,0.00024033344,0.00063969713,0.00028703394,0.000040172217,0.000018246361,0.00012305405,0.00004294868,0.00039706237],"category_scores_gemma":[0.000040225124,0.00014929796,0.00020140481,0.00025813055,0.00006781548,0.000088790766,0.00003579016,0.00037706082,0.000036944548],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007337115,0.0015679863,0.31706393,0.00010651188,0.0052308585,0.057021767,0.0006003533,0.00008830818,0.5728639,0.00014548548,0.0009923778,0.0369814],"study_design_scores_gemma":[0.040072605,0.026148217,0.049291115,0.00039793132,0.0010920006,0.010955837,0.00025864496,0.00009007377,0.8562895,0.00013963493,0.014867924,0.00039650322],"about_ca_topic_score_codex":0.00006170235,"about_ca_topic_score_gemma":0.000012366695,"teacher_disagreement_score":0.28342563,"about_ca_system_score_codex":0.00038316267,"about_ca_system_score_gemma":0.00057440996,"threshold_uncertainty_score":0.6088195},"labels":[],"label_agreement":null},{"id":"W2942488123","doi":"10.1097/01.ju.0000556399.09410.ae","title":"PD40-02 ONCOLOGIC OUTCOMES AFTER RADICAL PROSTATECTOMY FOR HIGH RISK PROSTATE CANCER: IMPACT OF VARIOUS DEFINITIONS ON CANCER-SPECIFIC AND OVERALL MORTALITY","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostatectomy; Medicine; Prostate cancer; Stage (stratigraphy); Cancer; Proportional hazards model; Prostate-specific antigen; Oncology; Metastasis; Urology; Internal medicine; Gynecology","score_opus":0.041102604966776715,"score_gpt":0.35824172497801854,"score_spread":0.31713912001124184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942488123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897588,0.0048525757,0.000015414755,0.0035470705,0.00023039921,0.0011199276,0.00038635408,0.000007684302,0.00008177119],"genre_scores_gemma":[0.97823465,0.021023285,0.00008042367,0.0002897633,0.00010242276,0.000085627384,0.00000836492,0.000018953562,0.00015648459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985626,0.0002071887,0.00046307294,0.00015660051,0.00026229766,0.00034824767],"domain_scores_gemma":[0.99831927,0.0006389041,0.00045172818,0.00021645626,0.00023474928,0.0001388799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006415844,0.00017593848,0.00061498885,0.00013533376,0.00007404343,0.000009624159,0.0001144824,0.00010729954,0.00028562552],"category_scores_gemma":[0.0000721203,0.000085375206,0.00019274767,0.00009690662,0.00030031917,0.000060430073,0.00003749655,0.00049894344,0.0000041101443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024025405,0.00045496694,0.96712047,0.00009841158,0.0012683807,0.00007900206,0.0007142172,0.00045361384,0.0012926279,0.0001992987,0.00086060556,0.0034329994],"study_design_scores_gemma":[0.009701955,0.010169456,0.9736229,0.000053046442,0.0005509568,0.000116089235,0.000030093002,0.000051487732,0.0003796151,0.004373572,0.0008575809,0.00009321905],"about_ca_topic_score_codex":0.0007992427,"about_ca_topic_score_gemma":0.0000788133,"teacher_disagreement_score":0.016170708,"about_ca_system_score_codex":0.00026581498,"about_ca_system_score_gemma":0.0005078785,"threshold_uncertainty_score":0.34814999},"labels":[],"label_agreement":null},{"id":"W2943296283","doi":"10.1016/j.jsbmb.2019.04.016","title":"Functional genomic studies reveal the androgen receptor as a master regulator of cellular energy metabolism in prostate cancer","year":2019,"lang":"en","type":"review","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université Laval","funders":"Canadian Institutes of Health Research; Fondation CHU de Québec; Cancer Research Society; American Association for Cancer Research","keywords":"Prostate cancer; Androgen receptor; Biology; Androgen; Cancer; Nuclear receptor; Cancer research; Prostate; Cancer cell; Endocrinology; Hormone; Internal medicine; Transcription factor; Medicine; Genetics","score_opus":0.04438017562953991,"score_gpt":0.33902068697967674,"score_spread":0.29464051135013686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943296283","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.097438276,0.90145236,0.0000044170624,0.0005327514,0.00016596184,0.0003278515,0.000052826806,0.000001409656,0.000024129262],"genre_scores_gemma":[0.008534269,0.98942053,0.000017941235,0.000113867114,0.00022051943,0.00002974408,0.00004773369,0.000022637163,0.0015927413],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99847305,0.00028761872,0.00063296926,0.00020239201,0.00017169735,0.000232264],"domain_scores_gemma":[0.99874616,0.00009818015,0.00061919604,0.00027561752,0.0001902086,0.00007064298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005538382,0.00027290828,0.0012274788,0.00009469431,0.00004486896,0.000006964925,0.00020024739,0.00019130405,0.000029059083],"category_scores_gemma":[0.000032825097,0.00011974073,0.00027684952,0.0001383306,0.00041989615,0.000015994563,0.00015573461,0.0003985625,0.0000015928644],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026444562,0.00014432521,0.0001169594,0.012246821,0.006354831,0.00012693812,0.00048905914,0.0000019674287,0.7995377,0.00004673999,0.0012518485,0.17703833],"study_design_scores_gemma":[0.00425643,0.0010540686,0.00003466168,0.0104724625,0.0052778856,0.0019274272,0.0005544791,9.851053e-7,0.32385734,0.0002898559,0.65185505,0.00041934787],"about_ca_topic_score_codex":0.000014964235,"about_ca_topic_score_gemma":7.3597903e-7,"teacher_disagreement_score":0.65060323,"about_ca_system_score_codex":0.000106524465,"about_ca_system_score_gemma":0.00057089404,"threshold_uncertainty_score":0.48828855},"labels":[],"label_agreement":null},{"id":"W2943450776","doi":"10.5489/cuaj.6033","title":"Followup imaging studies in metastatic castration-resistant prostate cancer: An individualized approach","year":2019,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Prostate cancer; Medicine; Castration; Oncology; Prostate; Cancer; Internal medicine; Urology; Hormone","score_opus":0.05633319768062309,"score_gpt":0.34892612007788754,"score_spread":0.2925929223972644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943450776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841781,0.0035978358,0.0000028166476,0.009736278,0.00025703575,0.0006660949,0.000067231595,0.00001909343,0.0014754802],"genre_scores_gemma":[0.99599206,0.0006290372,0.0005033444,0.0011252862,0.00012542964,0.00007043202,0.0000741479,0.00001538302,0.0014648796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789536,0.0002976125,0.00039275526,0.0002700611,0.0005041585,0.000640051],"domain_scores_gemma":[0.99871963,0.00010531622,0.00020298804,0.000110657624,0.00031665142,0.0005447332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001163257,0.00016237563,0.0004149095,0.0003475307,0.00018787105,0.0001118668,0.0001053434,0.000075655495,0.00027454997],"category_scores_gemma":[0.00026920415,0.000117136806,0.00009202319,0.000376728,0.00004920952,0.0002541249,0.000014709722,0.0005597671,0.000023117726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025038328,0.00010295035,0.9925644,0.00003328075,0.00031072937,0.0003205508,0.0016062737,0.00014830474,0.0004888193,0.00008149917,0.0012190621,0.00287379],"study_design_scores_gemma":[0.009779323,0.00073665194,0.9708199,0.00010062943,0.00022765397,0.0002028198,0.005259543,0.0012315813,0.000070735936,0.001355561,0.009887371,0.00032822616],"about_ca_topic_score_codex":0.0024725928,"about_ca_topic_score_gemma":0.0025179656,"teacher_disagreement_score":0.021744452,"about_ca_system_score_codex":0.0025051038,"about_ca_system_score_gemma":0.001311117,"threshold_uncertainty_score":0.65507597},"labels":[],"label_agreement":null},{"id":"W2943886463","doi":"10.1101/629618","title":"Androgen-regulated transcription of <i>ESRP2</i> drives alternative splicing patterns in prostate cancer","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"NIHR Exeter Clinical Research Facility; University of Bristol; Biotechnology and Biological Sciences Research Council; Terry Fox Research Institute; Prostate Cancer UK; National Institute for Health and Care Research","keywords":"Prostate cancer; Alternative splicing; RNA splicing; Androgen receptor; Cancer research; Biology; Androgen; Splicing factor; Metastasis; Gene isoform; Cancer; Endocrinology; Gene; Genetics; Hormone; RNA","score_opus":0.019664694980079587,"score_gpt":0.2721852268508705,"score_spread":0.2525205318707909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943886463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99099594,0.0045697824,0.00010554144,0.0004035711,0.00067912706,0.0024394605,0.000687837,0.00010800252,0.000010731559],"genre_scores_gemma":[0.99311584,0.0058376747,0.00020497294,0.000085838794,0.00018567298,0.0003967369,0.000003862317,0.00012503176,0.000044387423],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99707866,0.00012456684,0.0006681719,0.0009322366,0.0005751702,0.00062118715],"domain_scores_gemma":[0.99800175,0.000036675727,0.00039214437,0.00081046356,0.00054031407,0.00021867525],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036038022,0.00052196765,0.00096218265,0.0005461716,0.000048620514,0.000052949963,0.0002665432,0.00033368214,0.0000703521],"category_scores_gemma":[0.000028477596,0.00047423056,0.00020109603,0.00051521533,0.00013754598,0.00015298641,0.00017771551,0.0008258508,0.000013081049],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000504187,0.00027415837,0.3486925,0.0020305,0.000415443,0.00014755694,0.00016201293,0.00026813967,0.6474341,0.000027550994,0.000028329336,0.000015511616],"study_design_scores_gemma":[0.0034294708,0.00018213579,0.31670302,0.0039086454,0.0001947426,3.515308e-8,0.000013057009,0.000888781,0.674005,0.0000016554995,0.00027236063,0.00040109045],"about_ca_topic_score_codex":0.0011789541,"about_ca_topic_score_gemma":0.00003397483,"teacher_disagreement_score":0.031989478,"about_ca_system_score_codex":0.0006732685,"about_ca_system_score_gemma":0.0009680165,"threshold_uncertainty_score":0.99977094},"labels":[],"label_agreement":null},{"id":"W2943963106","doi":"10.1007/s00520-019-04816-y","title":"Management of anticoagulation in patients with metastatic castration–resistant prostate cancer receiving abiraterone + prednisone","year":2019,"lang":"en","type":"review","venue":"Supportive Care in Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Sunnybrook Hospital; University of Toronto; University of Waterloo","funders":"","keywords":"Medicine; Prostate cancer; Intensive care medicine; Adverse effect; Prednisone; Atrial fibrillation; Cancer; Clinical trial; Randomized controlled trial; Internal medicine; Population; Oncology","score_opus":0.06040291114670563,"score_gpt":0.3966766658282167,"score_spread":0.33627375468151105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943963106","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038322225,0.95359427,0.0000017323601,0.000036475805,0.00018905064,0.0066435267,0.00092247466,0.000013735576,0.00027650563],"genre_scores_gemma":[0.048123635,0.94773966,0.0001631986,0.000008070501,0.000025257103,0.0017406341,0.0012806522,0.000082520615,0.0008363548],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970922,0.00013765681,0.0009581917,0.0006544628,0.0006617981,0.00049569627],"domain_scores_gemma":[0.9984541,0.000045823625,0.0005879254,0.00036361607,0.00045925428,0.00008927153],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017765057,0.00044953072,0.0017241607,0.00049134606,0.000027644275,0.000020912219,0.000114500785,0.00012056694,0.00022284203],"category_scores_gemma":[0.00000848247,0.00031411785,0.00014539009,0.0008434595,0.000102703234,0.00018593097,0.00006106572,0.00033876687,0.000006192719],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017972292,0.00038558478,0.12819332,0.12316699,0.0010455458,0.0002809872,0.0014935802,0.000079650286,0.0000029019595,0.0000075920884,0.00004279659,0.7435038],"study_design_scores_gemma":[0.02397931,0.0037865795,0.5461833,0.35208973,0.0067859474,0.0000053740923,0.002789079,0.0000178581,0.00017348575,0.000013377487,0.06268067,0.0014953078],"about_ca_topic_score_codex":0.00063464255,"about_ca_topic_score_gemma":0.0009783348,"teacher_disagreement_score":0.7420085,"about_ca_system_score_codex":0.0023660283,"about_ca_system_score_gemma":0.0014464516,"threshold_uncertainty_score":0.9999311},"labels":[],"label_agreement":null},{"id":"W2944552159","doi":"10.21037/tcr.2019.04.12","title":"Androgen deprivation therapy and Gleason grade: unravelling implications on survival","year":2019,"lang":"en","type":"letter","venue":"Translational Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Androgen deprivation therapy; Prostate cancer; Medicine; Randomized controlled trial; Radiation therapy; Oncology; Meta-analysis; Internal medicine; Adverse effect; Androgen; Overall survival; Urology; Cancer; Hormone","score_opus":0.28341052395282734,"score_gpt":0.4523458679723359,"score_spread":0.16893534401950855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944552159","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038659148,0.012631546,0.00006756414,0.9418254,0.00018361729,0.002750661,0.0005096321,0.00005860723,0.0033138627],"genre_scores_gemma":[0.49261296,0.13500723,0.00087998295,0.27457595,0.021380676,0.0050555347,0.021497494,0.0008898662,0.048100326],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99624735,0.00025352862,0.00028679412,0.00074592576,0.0018045596,0.00066183764],"domain_scores_gemma":[0.9979554,0.00082638615,0.000060408307,0.00045182023,0.0005876913,0.000118338394],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.000645108,0.00029102876,0.00040491548,0.0005651638,0.0003186845,0.00009208473,0.00019551169,0.0005177708,0.0005047314],"category_scores_gemma":[0.00002524227,0.00023498021,0.000127031,0.0005710825,0.00025095957,0.00009207524,0.000024828067,0.0024214585,0.000087903376],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004159443,0.00044952615,0.08376808,0.0016744352,0.001549134,0.00017904013,0.0010725958,0.0001296853,0.005714472,0.0026452574,0.8046263,0.09403206],"study_design_scores_gemma":[0.004569898,0.0006369553,0.06699905,0.0004882991,0.00006225466,0.000019315778,0.000021560716,0.00021907134,0.0020892129,0.0026534444,0.92186,0.0003809461],"about_ca_topic_score_codex":0.00038153626,"about_ca_topic_score_gemma":0.000028152223,"teacher_disagreement_score":0.66724944,"about_ca_system_score_codex":0.00032331987,"about_ca_system_score_gemma":0.0011144655,"threshold_uncertainty_score":0.99988},"labels":[],"label_agreement":null},{"id":"W2944778810","doi":"10.1158/1541-7786.mcr-19-0020","title":"Reprogramming of Isocitrate Dehydrogenases Expression and Activity by the Androgen Receptor in Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"Canadian Institutes of Health Research; American Association for Cancer Research","keywords":"Prostate cancer; Androgen receptor; Cancer research; IDH1; Biology; Cancer; Reprogramming; Isocitrate dehydrogenase; Gene knockdown; Cancer cell; Oncogene; Cell cycle; Cell; Apoptosis; Gene; Genetics; Enzyme; Mutation; Biochemistry","score_opus":0.039375212475064855,"score_gpt":0.3923505640991219,"score_spread":0.352975351624057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944778810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9664133,0.028493593,0.0000029074147,0.0028770333,0.000037494123,0.0018200995,0.00005791953,0.000014297337,0.00028332308],"genre_scores_gemma":[0.9903456,0.007013549,0.00004127134,0.000048915907,0.000022923541,0.0007756341,0.000016738475,0.000034364683,0.0017010337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99761194,0.00030580864,0.00019245905,0.00048661412,0.0008116754,0.00059148384],"domain_scores_gemma":[0.99905854,0.00010213966,0.000061081686,0.00041087667,0.00022116087,0.00014621038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008993405,0.00014897519,0.00029678608,0.00015845911,0.000102763166,0.000038278245,0.00015045788,0.00008056262,0.00019536709],"category_scores_gemma":[0.00005340507,0.00009572927,0.00006551124,0.00065409683,0.00031893182,0.00009231012,0.00017043487,0.0005280262,0.0000073411034],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00127792,0.00013189536,0.11888145,0.00029562926,0.00007482033,0.00003967081,0.0006053386,0.00001193242,0.8537035,0.000006863692,0.0007731227,0.02419787],"study_design_scores_gemma":[0.002340916,0.00029533327,0.0029673697,0.0004977605,0.000015251156,0.0000049244477,0.00036582642,0.00013108517,0.98828655,0.00003898686,0.004948433,0.00010756661],"about_ca_topic_score_codex":0.0036845047,"about_ca_topic_score_gemma":0.000119396485,"teacher_disagreement_score":0.13458306,"about_ca_system_score_codex":0.00027196298,"about_ca_system_score_gemma":0.00044913462,"threshold_uncertainty_score":0.5569894},"labels":[],"label_agreement":null},{"id":"W2944925015","doi":"10.1016/s0167-8140(19)31261-7","title":"PO-0841 Salvage SBRT for local prostate cancer recurrence after radiotherapy: a GETUG retrospective study","year":2019,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Prostate; Retrospective cohort study; Radiology; Oncology; Cancer; Internal medicine","score_opus":0.0172928047718121,"score_gpt":0.36134324861238903,"score_spread":0.3440504438405769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944925015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95906484,0.03059309,0.0010445801,0.0031229234,0.00053781294,0.005158613,0.000077917815,0.00006266259,0.0003375671],"genre_scores_gemma":[0.9762595,0.012287338,0.0010905456,0.0014488902,0.0004222069,0.0015919617,0.000018218898,0.00006439139,0.006816891],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818027,0.00013154667,0.00027038384,0.00063785916,0.00023253236,0.0005474224],"domain_scores_gemma":[0.9991571,0.00011469586,0.00009222723,0.00030353133,0.00014075407,0.00019173585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038503614,0.0002714305,0.00072132336,0.00014673814,0.00010336227,0.000028581711,0.00009871145,0.00018223014,0.000724746],"category_scores_gemma":[0.000010888953,0.00019834757,0.00011343898,0.00021084884,0.00025583152,0.00010717047,0.00002238305,0.00030974852,0.000009720945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022640245,0.0013209011,0.7726516,0.00019835698,0.0010384077,0.00018031981,0.010182847,0.000010987447,0.0026449317,0.0000667625,0.0023458858,0.18671875],"study_design_scores_gemma":[0.06522112,0.051400244,0.6814014,0.00028429306,0.00032451845,0.00023243186,0.0024542657,0.0019761769,0.001673187,0.0004448964,0.19372101,0.0008664495],"about_ca_topic_score_codex":0.00016180256,"about_ca_topic_score_gemma":0.00024806985,"teacher_disagreement_score":0.19137512,"about_ca_system_score_codex":0.001904075,"about_ca_system_score_gemma":0.00047602312,"threshold_uncertainty_score":0.8088379},"labels":[],"label_agreement":null},{"id":"W2945044964","doi":"","title":"PSA and beyond: Biomarkers in prostate cancer","year":2014,"lang":"en","type":"article","venue":"British Columbia medical journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Oncology; Cancer; Internal medicine","score_opus":0.00942085998180099,"score_gpt":0.2879464023517414,"score_spread":0.2785255423699404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945044964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807135,0.0068717212,0.000011343969,0.0080136955,0.00031060883,0.00030300103,0.000011230597,0.00002282087,0.003742068],"genre_scores_gemma":[0.97743654,0.017025696,0.00023641739,0.0016812838,0.00044992258,0.0000515259,0.0000105385425,0.000025486195,0.0030825702],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980441,0.00010821738,0.00032026946,0.00023313572,0.00083992555,0.00045435442],"domain_scores_gemma":[0.9988384,0.000070760965,0.000056702236,0.00008706332,0.00010554386,0.00084151386],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00093121594,0.000077576056,0.00029220982,0.000070793125,0.00014927625,0.00029716452,0.00009493089,0.00010871145,0.0022363984],"category_scores_gemma":[0.00043593615,0.000098447425,0.000056145574,0.00020921663,0.0002825261,0.0001031504,0.0000574188,0.000601182,0.000006450835],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000099053446,0.000115604416,0.3804058,0.000058359135,0.000089687135,0.0025551217,0.0000656073,7.612006e-8,0.00005706131,0.0000016577184,0.03525014,0.5813018],"study_design_scores_gemma":[0.012506793,0.00054426753,0.9355376,0.0017168128,0.00006610648,0.011431351,0.00018214835,0.0004954537,0.000019263704,0.0009692549,0.036323145,0.0002077992],"about_ca_topic_score_codex":0.011251221,"about_ca_topic_score_gemma":0.038734943,"teacher_disagreement_score":0.581094,"about_ca_system_score_codex":0.0001507886,"about_ca_system_score_gemma":0.000587753,"threshold_uncertainty_score":0.9986757},"labels":[],"label_agreement":null},{"id":"W2945680865","doi":"10.1200/jop.18.00626","title":"Cancer Drug Use in the Last Month of Life in Men With Castration-Resistant Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Oncology Practice","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Cancer; Drug; Abiraterone acetate; Odds ratio; Cohort; Abiraterone; Oncology; Androgen deprivation therapy; Cabazitaxel; Pharmacology","score_opus":0.041503906270618625,"score_gpt":0.3921140537411453,"score_spread":0.35061014747052666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945680865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96668893,0.0022756637,5.602523e-7,0.026841847,0.00008950404,0.0006041081,0.00000871416,0.0000015155537,0.0034891858],"genre_scores_gemma":[0.99361074,0.0040516467,0.00033906786,0.00068392325,0.000085802705,0.000039836053,0.0000016654304,0.000010797792,0.0011765131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846125,0.0003491012,0.00045009228,0.000112142465,0.00042377078,0.00020362774],"domain_scores_gemma":[0.997826,0.0008796206,0.0006394994,0.00013279277,0.0004409565,0.00008114507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012503691,0.00009486736,0.00038048203,0.0001749216,0.000023292963,0.00001788487,0.000105551044,0.00006068638,0.00008050714],"category_scores_gemma":[0.0003573584,0.000049630227,0.000037111895,0.0003246205,0.00008108014,0.0005689517,0.000016091926,0.00064128684,0.0000025501415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031674027,0.00129156,0.94279635,0.00012980358,0.0003858885,0.0014368874,0.00943564,0.0009425149,0.0049401172,0.000040682487,0.004331655,0.0025948763],"study_design_scores_gemma":[0.020981254,0.005070525,0.8934238,0.0006524096,0.00034535094,0.00036334273,0.01987376,0.00011445168,0.0007474073,0.000015823674,0.05828592,0.00012592913],"about_ca_topic_score_codex":0.004309791,"about_ca_topic_score_gemma":0.010723825,"teacher_disagreement_score":0.053954266,"about_ca_system_score_codex":0.000518517,"about_ca_system_score_gemma":0.0029944174,"threshold_uncertainty_score":0.6515144},"labels":[],"label_agreement":null},{"id":"W2945775983","doi":"10.5489/cuaj.6049","title":"Another dimension to the understanding of local therapy for metastatic prostate cancer","year":2019,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Prostate cancer; Dimension (graph theory); Medicine; Oncology; Prostate; Cancer; Internal medicine; Mathematics","score_opus":0.0528447858892584,"score_gpt":0.3126782674600904,"score_spread":0.259833481570832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945775983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85993016,0.001529467,0.0020352455,0.13368754,0.00041323435,0.0017582371,0.00010305865,0.000010412842,0.00053263083],"genre_scores_gemma":[0.993158,0.0002669318,0.000085677464,0.00448726,0.000091836504,0.000037599868,0.0000079267165,0.000011127372,0.001853676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900055,0.00007894141,0.0001819785,0.00011640364,0.00027565143,0.0003464656],"domain_scores_gemma":[0.99921876,0.0001446639,0.00011694834,0.00007479509,0.00020678459,0.0002380573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006074767,0.000080161415,0.0001944255,0.000105516876,0.00014874527,0.000029024945,0.00006907199,0.000058006557,0.000453059],"category_scores_gemma":[0.00007098476,0.00004231764,0.000094045616,0.00017939114,0.000026582757,0.000039274753,0.0000066849802,0.00019402507,0.000017602095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028293561,0.00015761767,0.89710104,0.0000444593,0.0011110386,0.000035015648,0.0022378985,0.0015408684,0.0037344745,0.001240854,0.052812196,0.03715516],"study_design_scores_gemma":[0.020199977,0.008005578,0.5279784,0.0002149032,0.000347011,0.00009358028,0.0038755753,0.0032416729,0.0038612625,0.0061466997,0.4255181,0.00051720964],"about_ca_topic_score_codex":0.00064274395,"about_ca_topic_score_gemma":0.00061423716,"teacher_disagreement_score":0.3727059,"about_ca_system_score_codex":0.0016120024,"about_ca_system_score_gemma":0.0005788266,"threshold_uncertainty_score":0.49606785},"labels":[],"label_agreement":null},{"id":"W2945903793","doi":"10.1177/1758835919846372","title":"FAM84B promotes prostate tumorigenesis through a network alteration","year":2019,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital","funders":"Cancer Research Society","keywords":"DU145; Cancer research; Carcinogenesis; Prostate cancer; Cell growth; Biology; Metastasis; Cell cycle; Cell; Cancer; Medicine; Genetics; LNCaP","score_opus":0.02679852681546533,"score_gpt":0.39975956751888975,"score_spread":0.3729610407034244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945903793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8429811,0.082782604,0.003080984,0.026072886,0.0024441285,0.00489608,0.000007141369,0.0002329946,0.03750209],"genre_scores_gemma":[0.9707373,0.019634688,0.0021023825,0.00435656,0.000582279,0.00030424344,0.000058933376,0.00003767611,0.002185965],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99783754,0.00021088062,0.00039686332,0.00038571583,0.0005774491,0.00059154775],"domain_scores_gemma":[0.9990945,0.0003335501,0.00009155299,0.00024665365,0.00007160975,0.00016214087],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060892745,0.00018129707,0.00053576165,0.000063570726,0.000056956193,0.000008677103,0.00015095029,0.0001988952,0.0012984517],"category_scores_gemma":[0.00006531684,0.00012415017,0.00006456911,0.00037910402,0.0002606335,0.0002081473,0.000055413,0.00044702666,0.00017798026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038304823,0.0010459992,0.09870948,0.0003551605,0.00015924819,0.00072691386,0.0019695729,0.00016164433,0.0010063295,0.0043825065,0.00023117168,0.8874215],"study_design_scores_gemma":[0.018060667,0.008863603,0.016480006,0.00086045003,0.00012431333,0.00035639055,0.00068501366,0.004914311,0.0030763454,0.044168737,0.9018919,0.00051830563],"about_ca_topic_score_codex":0.000018329907,"about_ca_topic_score_gemma":0.000046517802,"teacher_disagreement_score":0.9016607,"about_ca_system_score_codex":0.00033458386,"about_ca_system_score_gemma":0.0006944732,"threshold_uncertainty_score":0.9996145},"labels":[],"label_agreement":null},{"id":"W2946334745","doi":"10.1002/ijc.32430","title":"Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma","year":2019,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia; Genome British Columbia","funders":"Prostate Cancer Canada; Movember Foundation","keywords":"Prostate cancer; Prostate; Medicine; Carcinoma; Gene signature; Oncology; Cancer; Small-cell carcinoma; Cancer research; Internal medicine; Pathology; Biology; Gene; Gene expression","score_opus":0.013014601122118111,"score_gpt":0.2901017462475349,"score_spread":0.27708714512541677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946334745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99231017,0.0024265281,0.00006469403,0.0031145674,0.0009312981,0.00065172126,0.00026531494,0.0000047970507,0.0002309252],"genre_scores_gemma":[0.9950454,0.0019894345,0.00015553298,0.00047411522,0.00020515997,0.00002688189,0.00004805058,0.00002611081,0.002029294],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99835527,0.00003568598,0.00057877647,0.00015824866,0.0006856461,0.00018638962],"domain_scores_gemma":[0.9979528,0.00003102162,0.00048881036,0.000116949326,0.0012868755,0.00012354754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098470606,0.00014185486,0.00043036317,0.00038252646,0.000010914517,0.000012727864,0.00022618055,0.000032707427,0.00030868908],"category_scores_gemma":[0.00001287915,0.0001069101,0.00015319597,0.00020858615,0.000044117252,0.00014016705,0.000031193373,0.0002384027,0.0000028906534],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042293835,0.00021530435,0.149483,0.00042165522,0.00031389706,0.00014143322,0.0008105573,0.00021792583,0.8355577,0.000008404861,0.00015739081,0.00844337],"study_design_scores_gemma":[0.0059407395,0.00112636,0.34171617,0.00077510707,0.00019103297,0.00007641113,0.000067398105,0.00006214572,0.6468106,0.000026139689,0.0030938983,0.000114008275],"about_ca_topic_score_codex":0.00015728442,"about_ca_topic_score_gemma":0.000020700134,"teacher_disagreement_score":0.19223318,"about_ca_system_score_codex":0.00033833494,"about_ca_system_score_gemma":0.0008336895,"threshold_uncertainty_score":0.43596673},"labels":[],"label_agreement":null},{"id":"W2946462107","doi":"10.2147/rru.s207843","title":"&lt;p&gt;ERG expression in prostate cancer biopsies with and without high-grade prostatic intraepithelial neoplasia: a study in Jordanian Arab patients&lt;/p&gt;","year":2019,"lang":"en","type":"article","venue":"Research and Reports in Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Deanship of Research, Jordan University of Science and Technology; Jordan University of Science and Technology","keywords":"Medicine; Intraepithelial neoplasia; Prostate cancer; High-grade prostatic intraepithelial neoplasia; Erg; Prostate; Internal medicine; Urology; Oncology; Cancer; Ophthalmology","score_opus":0.017463638080717173,"score_gpt":0.32576088402968284,"score_spread":0.3082972459489657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946462107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911985,0.0025714927,3.6873064e-7,0.0012428414,0.000109061126,0.0045828894,0.000011641014,0.000020387164,0.00026282948],"genre_scores_gemma":[0.9955387,0.0023191066,0.00008003942,0.00003632554,0.000042286214,0.0008226944,0.000033953114,0.00004204622,0.0010848579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962096,0.00044264545,0.00060216855,0.00092066516,0.00079435704,0.0010305287],"domain_scores_gemma":[0.99884325,0.00015044205,0.00013024198,0.00040207463,0.00021125718,0.00026272293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013814442,0.00027657172,0.00067111256,0.0010165981,0.000098640005,0.00005040445,0.00008677405,0.00017092793,0.000039660343],"category_scores_gemma":[0.00018396406,0.00017747209,0.000019295905,0.0007832751,0.00056591776,0.00016841198,0.00020855131,0.0009369283,0.0000033617987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056275763,0.0015854302,0.9765186,0.00026851683,0.000051643725,0.0034630182,0.0037365034,0.000021819355,0.00670251,0.000016344608,0.00005787517,0.0019501988],"study_design_scores_gemma":[0.0124561535,0.00845185,0.9753539,0.00040781198,0.000017619945,0.0002529699,0.00076339574,0.00011447109,0.0010725317,0.00034773946,0.00055968744,0.00020186992],"about_ca_topic_score_codex":0.0008806617,"about_ca_topic_score_gemma":0.006074493,"teacher_disagreement_score":0.0068664197,"about_ca_system_score_codex":0.00023297447,"about_ca_system_score_gemma":0.0005808541,"threshold_uncertainty_score":0.7237102},"labels":[],"label_agreement":null},{"id":"W2946537887","doi":"10.1097/spc.0000000000000432","title":"Treating the primary in metastatic prostate cancer: where do we stand?","year":2019,"lang":"en","type":"review","venue":"Current Opinion in Supportive and Palliative Care","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Oncology; Hazard ratio; Internal medicine; Randomized controlled trial; Disease; Prostate; Radiation therapy; Prospective cohort study; Localized disease; Cancer; Confidence interval","score_opus":0.2085153265346377,"score_gpt":0.4845316130545643,"score_spread":0.2760162865199266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946537887","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001263984,0.99248224,0.0000021180797,0.00028341546,0.0008147309,0.0045174398,0.0015411652,0.000014330752,0.00021814308],"genre_scores_gemma":[0.000082480925,0.99663323,0.000011333793,0.0000056237136,0.00017435488,0.0013924735,0.0011129063,0.000054086042,0.0005334942],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972281,0.00030913384,0.0007926758,0.0007117879,0.00043467068,0.0005236238],"domain_scores_gemma":[0.99849,0.00039584422,0.00043461545,0.00030879813,0.00023711048,0.00013366513],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023926568,0.0005551438,0.0018112711,0.0003262242,0.000082017716,0.00007649773,0.0001533372,0.00013335327,0.00011637701],"category_scores_gemma":[0.000045459357,0.00031231227,0.0002831496,0.00066215586,0.0001788864,0.00012557508,0.00014078963,0.0009986295,0.00002118509],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011760464,0.00008214026,0.054378208,0.13110435,0.00017784616,0.000018928977,0.006109185,5.544763e-7,5.2985133e-8,0.000021660857,0.0008056516,0.8071838],"study_design_scores_gemma":[0.001965413,0.0002400956,0.0023846272,0.13722493,0.0003119314,0.00000298514,0.0034437038,0.00000365785,4.2704346e-7,0.00002083271,0.8541126,0.00028876547],"about_ca_topic_score_codex":0.00002324943,"about_ca_topic_score_gemma":0.000012222111,"teacher_disagreement_score":0.85330695,"about_ca_system_score_codex":0.0010340685,"about_ca_system_score_gemma":0.0018692215,"threshold_uncertainty_score":0.9999329},"labels":[],"label_agreement":null},{"id":"W2946829725","doi":"10.1158/1078-0432.ccr-18-3212","title":"Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK; Astex Pharmaceuticals","keywords":"Abiraterone acetate; Prostate cancer; Pharmacodynamics; Abiraterone; Medicine; Cancer; Prostate; Oncology; Internal medicine; Pharmacology; Pharmacokinetics; Androgen deprivation therapy; Androgen receptor","score_opus":0.15383574239290693,"score_gpt":0.5354631624239391,"score_spread":0.38162742003103217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946829725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98819137,0.0013116348,1.3895104e-7,0.004978815,0.00029685994,0.0048602633,0.00022581796,0.000013200224,0.000121908335],"genre_scores_gemma":[0.9923242,0.004853456,0.000014390467,0.00010238085,0.00014355715,0.00045306145,0.000039890936,0.000037135287,0.0020319403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99460393,0.0013568562,0.0013614831,0.00090923737,0.001172929,0.0005955709],"domain_scores_gemma":[0.997239,0.001238856,0.00023326087,0.00057553005,0.00046884245,0.00024454427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045823855,0.00020996481,0.00078576326,0.00027588822,0.00010058436,0.000028992657,0.00028752195,0.000142593,0.0001162481],"category_scores_gemma":[0.00037807308,0.00012464935,0.00008459351,0.001091954,0.00075428595,0.00014577853,0.00041394634,0.0019256979,0.000009431659],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052936558,0.0095339175,0.8965112,0.000120696495,0.00020895577,0.00011347482,0.0018475504,0.000028194756,0.0016315752,0.0000029968726,0.000258527,0.036806338],"study_design_scores_gemma":[0.14689845,0.015492312,0.8317275,0.0011922077,0.000073620635,0.0000013084497,0.0011263271,0.001769454,0.00090236735,0.0000681349,0.0005832872,0.00016504651],"about_ca_topic_score_codex":0.0077588097,"about_ca_topic_score_gemma":0.012700949,"teacher_disagreement_score":0.0939619,"about_ca_system_score_codex":0.00040867654,"about_ca_system_score_gemma":0.0012859821,"threshold_uncertainty_score":0.9988486},"labels":[],"label_agreement":null},{"id":"W2946837939","doi":"10.1200/jco.2019.37.15_suppl.5029","title":"Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Abiraterone; Enzalutamide; Prednisone; Prostate cancer; Internal medicine; Cancer; Cohort; Oncology","score_opus":0.08929796729595767,"score_gpt":0.4626246529269634,"score_spread":0.37332668563100574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946837939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99446493,0.0009343659,0.0000023537968,0.0009340959,0.0003571401,0.0028976516,0.00007608271,0.000007729491,0.00032563158],"genre_scores_gemma":[0.9961759,0.0014247826,0.00024683977,0.00018641514,0.000080814854,0.000063758605,0.000007524036,0.000039315393,0.0017746469],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99454945,0.0010401455,0.0025668803,0.00043472368,0.00091391074,0.0004949154],"domain_scores_gemma":[0.9954929,0.00096585765,0.0019352877,0.00040575463,0.0008276071,0.00037261506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023569348,0.0003149939,0.002302294,0.00019494114,0.00006234918,0.000022961569,0.00025743188,0.00019016762,0.0001392646],"category_scores_gemma":[0.0007316937,0.00014834708,0.00020411969,0.00050189765,0.0004926494,0.00020733362,0.00012121441,0.0010961972,0.000004280274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20218037,0.010953573,0.767766,0.00028022207,0.0016169052,0.0011370108,0.001009368,0.00009860679,0.00068872917,0.000003619749,0.00013940116,0.014126218],"study_design_scores_gemma":[0.18841425,0.06549771,0.7420066,0.0006481334,0.0011580893,0.00011515577,0.0007103768,0.0002405668,0.00055149687,0.00003084217,0.00046547514,0.0001613087],"about_ca_topic_score_codex":0.0005426959,"about_ca_topic_score_gemma":0.0013708301,"teacher_disagreement_score":0.05454414,"about_ca_system_score_codex":0.00063098595,"about_ca_system_score_gemma":0.004149475,"threshold_uncertainty_score":0.7360991},"labels":[],"label_agreement":null},{"id":"W2946863309","doi":"10.1200/jco.2019.37.15_suppl.5079","title":"CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Urology; Prostate cancer; Nomogram; Stage (stratigraphy); Neoadjuvant therapy; Androgen deprivation therapy; Biopsy; Survival analysis; Internal medicine; Gynecology; Surgery; Oncology; Cancer; Breast cancer","score_opus":0.06574906304178667,"score_gpt":0.4462995836944603,"score_spread":0.38055052065267364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946863309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845866,0.0021300835,0.00007135247,0.008502723,0.0004067866,0.002622472,0.000028036135,0.00003307596,0.0016188726],"genre_scores_gemma":[0.94551665,0.039239008,0.007981679,0.0020705448,0.00095856696,0.0001577018,0.000018034496,0.00010948955,0.003948331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923626,0.0008361552,0.003686655,0.000752332,0.0014110334,0.0009511991],"domain_scores_gemma":[0.9928775,0.0020667864,0.0025901208,0.0004917255,0.0009502682,0.0010236037],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004838177,0.00050440145,0.0035316152,0.0002064674,0.00007790345,0.000040149625,0.00042836176,0.00066287577,0.00079649786],"category_scores_gemma":[0.00069994514,0.00023771918,0.00038368226,0.0005948957,0.0010815075,0.00029073659,0.00008906677,0.0034398115,0.000055184384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2922983,0.002296948,0.59522694,0.000075398915,0.0010074027,0.0025808678,0.00022465922,0.00009097033,0.00010467124,0.000013418685,0.001141464,0.104938954],"study_design_scores_gemma":[0.23497723,0.18681195,0.47499427,0.001705457,0.0006899125,0.0009340127,0.00050625874,0.0013008054,0.0005970085,0.00030517168,0.0964755,0.00070241344],"about_ca_topic_score_codex":0.00055011467,"about_ca_topic_score_gemma":0.00037673392,"teacher_disagreement_score":0.184515,"about_ca_system_score_codex":0.0006598806,"about_ca_system_score_gemma":0.010766596,"threshold_uncertainty_score":0.9988593},"labels":[],"label_agreement":null},{"id":"W2946874178","doi":"10.1200/jco.2019.37.15_suppl.5024","title":"Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Post hoc analysis of SPARTAN.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Randomized controlled trial; Randomization; Placebo; Androgen deprivation therapy; Cancer; Oncology; Urology; Pathology","score_opus":0.053887843042956025,"score_gpt":0.4069688485368145,"score_spread":0.35308100549385846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946874178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997623,0.00094695936,0.000008539943,0.00044732296,0.000080913676,0.0007591348,0.00004973651,0.0000021114984,0.00008224858],"genre_scores_gemma":[0.9955317,0.0037517783,0.00052589364,0.000053420004,0.000019863419,0.0000053341105,0.000047596608,0.000013979662,0.000050451974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962966,0.00035211522,0.0024079648,0.0002078443,0.0005330405,0.0002024356],"domain_scores_gemma":[0.99527645,0.0012900553,0.0023087342,0.0001818251,0.00079152355,0.00015140435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016515006,0.00014504927,0.0018076677,0.00047487157,0.000019903691,0.0000046861933,0.00009625031,0.00016457993,0.00008073805],"category_scores_gemma":[0.00038097147,0.00009172503,0.000227468,0.0007446241,0.0003067517,0.00012616697,0.000026478821,0.0003956898,5.1696844e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.066858426,0.0016328754,0.8863805,0.00014252096,0.003526977,0.00009619653,0.0011631438,0.0015125679,0.0038623186,0.000023677752,0.000005674669,0.034795105],"study_design_scores_gemma":[0.03410509,0.018394731,0.9442808,0.0003322285,0.001138061,0.000005596517,0.00021800437,0.0005779031,0.00077799713,0.000024497023,0.00006880194,0.00007627773],"about_ca_topic_score_codex":0.00026279996,"about_ca_topic_score_gemma":0.0009407793,"teacher_disagreement_score":0.0579003,"about_ca_system_score_codex":0.00022785873,"about_ca_system_score_gemma":0.0013437885,"threshold_uncertainty_score":0.37404382},"labels":[],"label_agreement":null},{"id":"W2946986050","doi":"10.1016/j.clgc.2019.05.012","title":"Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer Canada; Bristol-Myers Squibb Canada; Orionin Tutkimussäätiö; Cilag; Astellas Pharma; Ipsen; Astellas Pharma Canada; Bristol-Myers Squibb; Bayer Corporation; Janssen Canada; Meso Scale Diagnostics; Sanofi; Roche; Novartis; Amgen; Pfizer; Johnson and Johnson; Takeda Pharmaceutical Company; Active Biotech; Bayer","keywords":"Medicine; Prostate cancer; Radium-223; Oncology; Disease; Internal medicine; Radium; Castration; Urology; Cancer; Hormone; Bone metastasis","score_opus":0.06678858482934684,"score_gpt":0.420381723733961,"score_spread":0.35359313890461413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946986050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962555,0.00019322471,4.424035e-7,0.00024700552,0.00008059125,0.0027972523,0.000371878,0.00001776649,0.00003633604],"genre_scores_gemma":[0.99732274,0.0008748964,0.00015114516,0.000033098626,0.000065164924,0.00073675107,0.00050656183,0.000027041688,0.0002825987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841255,0.00010572126,0.00049020746,0.00043057516,0.0003049877,0.00025593967],"domain_scores_gemma":[0.9990457,0.000062992476,0.0001902429,0.00022062783,0.00024377665,0.00023661813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001043524,0.00020422343,0.00047771967,0.00015469347,0.000025435847,0.00004201413,0.000091904774,0.00004292216,0.000088670924],"category_scores_gemma":[0.000010915462,0.000129087,0.000041147177,0.00024380114,0.00017108949,0.0002974572,0.000030795647,0.0001591976,0.0000014854425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02918195,0.0033885452,0.94452196,0.00014697814,0.00019642117,0.00017010105,0.00015111984,0.000048570575,0.00006658785,0.0000017054647,0.000003420804,0.02212261],"study_design_scores_gemma":[0.017544279,0.009111355,0.97197545,0.00041547412,0.00014493747,9.4113506e-7,0.00003265295,0.00044583596,0.00005280681,0.000003390882,0.00012845822,0.0001444464],"about_ca_topic_score_codex":0.0011503142,"about_ca_topic_score_gemma":0.0006316497,"teacher_disagreement_score":0.027453432,"about_ca_system_score_codex":0.00041527883,"about_ca_system_score_gemma":0.00055251585,"threshold_uncertainty_score":0.52640146},"labels":[],"label_agreement":null},{"id":"W2947006117","doi":"10.1200/jco.2019.37.15_suppl.5012","title":"Diagnostic performance of <sup>18</sup>F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of <sup>18</sup>F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Prospective cohort study; Cohort; Prostate cancer; Nuclear medicine; Biopsy; Histopathology; Radiology; Cancer; Internal medicine; Pathology","score_opus":0.07746961558481354,"score_gpt":0.4646073883673265,"score_spread":0.387137772782513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947006117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990403,0.00045384566,0.0000014826102,0.00085925957,0.00027825625,0.007683588,0.0000389359,0.000010207641,0.00027143632],"genre_scores_gemma":[0.99763507,0.0010593762,0.0002114219,0.00020765571,0.00020430394,0.0003250249,0.000013845507,0.000053589938,0.00028971673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99219036,0.0016411183,0.003666733,0.0005478679,0.0012488056,0.0007051049],"domain_scores_gemma":[0.98967946,0.006015555,0.002251518,0.00050105253,0.0012673713,0.00028503977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004203223,0.00041669904,0.0027186435,0.0005471735,0.00006126124,0.000024262386,0.00048261177,0.00006435512,0.00047409866],"category_scores_gemma":[0.004098404,0.0002147242,0.00031554364,0.00092622696,0.0004578872,0.00041906882,0.00013434749,0.0017335721,0.000010783244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22343203,0.028527426,0.7299926,0.0002461693,0.0006918664,0.002073542,0.0045449464,0.0012339681,0.000010414865,0.0000016253708,0.0002643422,0.00898105],"study_design_scores_gemma":[0.39723492,0.10645919,0.47822022,0.0012998226,0.0009769327,0.000121663856,0.007926705,0.0070456844,0.00008813602,0.000017980476,0.00036543174,0.0002433001],"about_ca_topic_score_codex":0.000522932,"about_ca_topic_score_gemma":0.00039005646,"teacher_disagreement_score":0.2517724,"about_ca_system_score_codex":0.0006901928,"about_ca_system_score_gemma":0.002532731,"threshold_uncertainty_score":0.8756199},"labels":[],"label_agreement":null},{"id":"W2947029248","doi":"10.1200/jco.2019.37.15_suppl.5044","title":"Health-related quality of life (HRQoL) and pain progression with enzalutamide (ENZ) in metastatic hormone-sensitive prostate cancer (mHSPC) from the ARCHES study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Brief Pain Inventory; Prostate cancer; Enzalutamide; Quality of life (healthcare); Internal medicine; Placebo; Androgen deprivation therapy; Proportional hazards model; Oncology; Cancer; Physical therapy; Chronic pain; Pathology","score_opus":0.18634195898994688,"score_gpt":0.5224271293812304,"score_spread":0.3360851703912835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947029248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9671466,0.008045714,0.00000604089,0.023249429,0.00012187571,0.0013631119,0.00001759657,0.0000041605244,0.00004550126],"genre_scores_gemma":[0.995258,0.0029884237,0.00060389994,0.000930465,0.00008751163,0.000019883892,0.0000055057926,0.000014482585,0.00009186742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99268776,0.0039722202,0.002279601,0.0002352167,0.0005549194,0.0002702907],"domain_scores_gemma":[0.9899604,0.007201401,0.0019871863,0.00018329076,0.00036032728,0.00030744847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012890042,0.00014311892,0.0018979426,0.000091822745,0.000033195593,0.000007713836,0.00010228299,0.00010997275,0.000022576358],"category_scores_gemma":[0.002754737,0.00006602561,0.0001322137,0.0002194952,0.00039559658,0.00008413185,0.00006157532,0.0010478005,0.000002104089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05890074,0.0020957242,0.84889036,0.000079188365,0.0009768377,0.0002411611,0.005033508,0.000023546134,0.00022867261,0.000008200056,0.0002281825,0.08329389],"study_design_scores_gemma":[0.020574288,0.02290994,0.95008296,0.0004564928,0.00015021898,0.000015097774,0.005079158,0.00012045182,0.000037823025,0.00022066715,0.0002844966,0.00006839569],"about_ca_topic_score_codex":0.0022501983,"about_ca_topic_score_gemma":0.0014050545,"teacher_disagreement_score":0.10119262,"about_ca_system_score_codex":0.00018392428,"about_ca_system_score_gemma":0.0033588891,"threshold_uncertainty_score":0.5958525},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2947030501","doi":"10.1200/jco.2019.37.15_suppl.5011","title":"Copy number analysis to identify tumor suppressor genes associated with enzalutamide (Enza) resistance and poor prognosis in metastatic castration-resistant prostate cancer (mCRPC) patients.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Enzalutamide; Prostate cancer; Copy-number variation; Gene; Cancer; Medicine; Oncology; Cancer research; Biology; Genetics; Internal medicine; Genome; Androgen receptor","score_opus":0.07740954457735694,"score_gpt":0.4699141394071012,"score_spread":0.39250459482974426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947030501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99373734,0.000892862,0.0000043874807,0.0037845296,0.00020014131,0.0010307046,0.00008350212,0.0000076169795,0.00025893524],"genre_scores_gemma":[0.9964883,0.0004572346,0.0011753957,0.0005370509,0.00006333841,0.00007631396,0.000025713654,0.000024164332,0.0011525372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99609137,0.0005590362,0.00181376,0.00037467616,0.0007481981,0.00041295498],"domain_scores_gemma":[0.9958574,0.0013074838,0.0012405429,0.00015204227,0.0010620157,0.00038052548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021112477,0.00020634003,0.0017272324,0.00032717673,0.00004960017,0.000041022446,0.0001347984,0.00012935261,0.0002421442],"category_scores_gemma":[0.0012875464,0.00013206807,0.00025968926,0.000904711,0.00016649676,0.00020682851,0.000047713496,0.0005842315,0.0000117097225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01590433,0.0015028875,0.9744216,0.00008493191,0.002999514,0.0007233931,0.00025919286,0.00007311342,0.00079308747,0.000008742701,0.0005609056,0.002668277],"study_design_scores_gemma":[0.0136207715,0.0042370833,0.97606754,0.0003420719,0.0021674794,0.000012051687,0.00021550113,0.000043682932,0.0012027294,0.000048092374,0.0018910761,0.00015192847],"about_ca_topic_score_codex":0.00016217692,"about_ca_topic_score_gemma":0.0031929857,"teacher_disagreement_score":0.0032474787,"about_ca_system_score_codex":0.00045267143,"about_ca_system_score_gemma":0.0015544321,"threshold_uncertainty_score":0.538558},"labels":[],"label_agreement":null},{"id":"W2947074678","doi":"10.1074/jbc.h119.009180","title":"Keys to unlock androgen receptor translocation","year":2019,"lang":"en","type":"letter","venue":"Journal of Biological Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"National Cancer Institute","keywords":"Androgen receptor; Chromosomal translocation; Receptor; Cell biology; Biology; Computer science; Computational biology; Genetics; Prostate cancer; Cancer","score_opus":0.0506681806247625,"score_gpt":0.3183325878486549,"score_spread":0.2676644072238924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947074678","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17741382,0.004136227,0.00004066655,0.81425977,0.0003412083,0.0004437382,0.00007999946,0.000022049522,0.0032624914],"genre_scores_gemma":[0.13573498,0.01136058,0.002226884,0.74264455,0.03617128,0.00005915335,0.0022139002,0.00014778838,0.06944089],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998642,0.00003586139,0.00042427558,0.00022282863,0.00038908754,0.00028590465],"domain_scores_gemma":[0.9990574,0.00009738518,0.00021830644,0.00019450401,0.00028028965,0.0001520771],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020179307,0.00020613232,0.0005915406,0.00005395039,0.000024666215,0.000017966186,0.00020634741,0.0008725112,0.0011171359],"category_scores_gemma":[0.00012343684,0.0001175627,0.00029860262,0.00012608255,0.00006181094,0.000022288783,0.000027381426,0.0015568223,0.000110020665],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052382005,0.00006922095,0.00077906315,0.00029260962,0.0002094395,0.0004680599,0.000027844295,7.245847e-7,0.1566565,4.967065e-8,0.8386491,0.0023235902],"study_design_scores_gemma":[0.0011342611,0.0007171158,0.0000940784,0.0003960888,0.000063562286,0.00033523698,0.000020787045,7.7270744e-7,0.21225986,0.000015080727,0.78482515,0.00013801768],"about_ca_topic_score_codex":0.0000012894534,"about_ca_topic_score_gemma":2.160722e-8,"teacher_disagreement_score":0.07161525,"about_ca_system_score_codex":0.000243561,"about_ca_system_score_gemma":0.00029501112,"threshold_uncertainty_score":0.999796},"labels":[],"label_agreement":null},{"id":"W2947105388","doi":"10.1200/jco.2019.37.15_suppl.1013","title":"Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Internal medicine; Triple-negative breast cancer; Taxane; Clinical endpoint; Cohort; Oncology; Breast cancer; Tolerability; Phases of clinical research; Paclitaxel; Cancer; Gastroenterology; Adverse effect; Toxicity; Clinical trial; Pembrolizumab","score_opus":0.11011647550504756,"score_gpt":0.505768883853412,"score_spread":0.39565240834836446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947105388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806274,0.0006396491,0.00009080395,0.009068756,0.0011679637,0.007245701,0.0006706668,0.000027964532,0.00046107123],"genre_scores_gemma":[0.9832806,0.0024147837,0.0026290026,0.0012068762,0.00061789906,0.00058692455,0.00006556133,0.00009474938,0.009103624],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.993668,0.0006804912,0.0030369929,0.00072505313,0.0010447861,0.0008446569],"domain_scores_gemma":[0.9891112,0.0044297185,0.0025367786,0.00049476465,0.0024186696,0.0010088657],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019301565,0.00057964644,0.0034947258,0.00029992335,0.00024336242,0.000029347706,0.00032423472,0.00030653863,0.0010466069],"category_scores_gemma":[0.0021783384,0.00030946237,0.00074441277,0.00045940033,0.00042721216,0.00032268622,0.00010640655,0.00086557365,0.00005557182],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47881556,0.100278005,0.057542704,0.00024434895,0.008356477,0.0011206778,0.0011312971,0.00013573213,0.00003720195,0.000023004754,0.0027601907,0.3495548],"study_design_scores_gemma":[0.34972778,0.5713697,0.02193212,0.00041428188,0.0030444746,0.00024305136,0.0012420748,0.00020732815,0.00010269192,0.00015522224,0.051227212,0.00033407443],"about_ca_topic_score_codex":0.00026173276,"about_ca_topic_score_gemma":0.0007944539,"teacher_disagreement_score":0.4710917,"about_ca_system_score_codex":0.0014262745,"about_ca_system_score_gemma":0.006238477,"threshold_uncertainty_score":0.99993575},"labels":[],"label_agreement":null},{"id":"W2947121907","doi":"10.1200/jco.2019.37.15_suppl.5021","title":"PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Regimen; Internal medicine; Abiraterone acetate; Prednisone; Logistic regression; Odds ratio; Oncology; Docetaxel; Cancer; Gynecology; Androgen deprivation therapy","score_opus":0.07261390822757398,"score_gpt":0.47254360320337413,"score_spread":0.39992969497580017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947121907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740933,0.0010706615,0.000003288119,0.023004804,0.00008345247,0.00059921085,0.000011644838,0.0000033570516,0.0011302937],"genre_scores_gemma":[0.993834,0.002607869,0.0012009672,0.0004457637,0.000099017874,0.000012517156,0.0000025526672,0.000015223524,0.0017820579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975283,0.0006321112,0.0010656025,0.00022886068,0.0003022661,0.00024284226],"domain_scores_gemma":[0.9971013,0.0014956361,0.0006170451,0.000109115805,0.000369925,0.00030697056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031742416,0.00014051858,0.0010340149,0.00018561269,0.000028500303,0.000021408085,0.000055923054,0.00011784923,0.00008498719],"category_scores_gemma":[0.0007297537,0.000080842205,0.00007062923,0.00018726497,0.00036279846,0.00015859144,0.00004183593,0.00064871734,0.000004058123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14564149,0.0005973526,0.8311932,0.00010448149,0.0005315734,0.0016717844,0.0014203133,0.00003169229,0.0016565425,0.000018770887,0.0003458251,0.016786963],"study_design_scores_gemma":[0.02203555,0.020121282,0.9523907,0.0002725332,0.00023912358,0.00021520755,0.0019474709,0.00019666315,0.0002129851,0.00028913293,0.0019873232,0.00009204876],"about_ca_topic_score_codex":0.00007467193,"about_ca_topic_score_gemma":0.00070879183,"teacher_disagreement_score":0.123605944,"about_ca_system_score_codex":0.000189676,"about_ca_system_score_gemma":0.0025252067,"threshold_uncertainty_score":0.44796082},"labels":[],"label_agreement":null},{"id":"W2947213749","doi":"10.1200/jco.2019.37.15_suppl.5055","title":"Complex biologic heterogeneity of <i>de novo</i> hormone naïve metastatic prostate cancer (HNPCa): Comparison of early progressors and prolonged responders to initial systemic treatment.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Cohort; Randomized controlled trial; Prostate cancer; Population; Oncology; Progression-free survival; Exact test; Cancer; Overall survival","score_opus":0.27531638913711065,"score_gpt":0.5496829417536255,"score_spread":0.2743665526165149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947213749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99173886,0.004226145,0.00000818605,0.0021149276,0.00022607026,0.0015074372,0.00007052215,0.000007577164,0.00010030473],"genre_scores_gemma":[0.99654764,0.0016514771,0.0013436992,0.00015494988,0.00011790977,0.00003978692,0.000008817114,0.000018095772,0.000117652504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996034,0.0008273024,0.0021367439,0.0002586751,0.00038300687,0.00036022067],"domain_scores_gemma":[0.9959169,0.0011505827,0.0017482592,0.000203112,0.00058180856,0.00039935278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019745945,0.00019849946,0.002379146,0.00022096519,0.0000315482,0.000007925245,0.00015052423,0.00021362846,0.00003280824],"category_scores_gemma":[0.00048091882,0.000119737575,0.00031435874,0.00023332855,0.00043929374,0.00007416151,0.00006525457,0.00044447574,0.0000050180843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.069785304,0.0028999206,0.8493406,0.00035900157,0.0018818973,0.00032905347,0.0016960421,0.0000504045,0.033863895,0.000013757776,0.00024092162,0.03953917],"study_design_scores_gemma":[0.04278068,0.21063933,0.72530836,0.0006701403,0.0014458747,0.00062987476,0.0013165482,0.00021919103,0.014441622,0.000107038635,0.0021966053,0.0002447192],"about_ca_topic_score_codex":0.00009927494,"about_ca_topic_score_gemma":0.000059463215,"teacher_disagreement_score":0.2077394,"about_ca_system_score_codex":0.00029852265,"about_ca_system_score_gemma":0.0017735253,"threshold_uncertainty_score":0.48827565},"labels":[],"label_agreement":null},{"id":"W2947262464","doi":"10.1200/jco.2019.37.15_suppl.5007","title":"Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Denosumab; Data monitoring committee; Interim analysis; Internal medicine; Oncology; Prostate cancer; Population; Clinical trial; Cancer; Osteoporosis; Androgen receptor","score_opus":0.18276435438651864,"score_gpt":0.5078856986522432,"score_spread":0.3251213442657246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947262464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942929,0.00093913847,0.00018661581,0.002366376,0.00064731983,0.000817136,0.0000045571205,0.0000098355895,0.0007361298],"genre_scores_gemma":[0.9965715,0.0008729199,0.0005205578,0.0012556418,0.00060115673,0.000009518735,0.000035636232,0.000018725643,0.000114360766],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99406606,0.002370477,0.0022747943,0.00036311007,0.0005101851,0.0004153728],"domain_scores_gemma":[0.9925708,0.0050153825,0.0015254021,0.00031014107,0.00019729442,0.00038093372],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.012764211,0.00022117526,0.0020121376,0.00026415024,0.00013151493,0.00005317131,0.0002743275,0.00035348974,0.00014486705],"category_scores_gemma":[0.0033645362,0.00013205562,0.0003999567,0.0004195863,0.0001749823,0.00023535336,0.00010168629,0.0023582499,0.000006173199],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72037077,0.0029776695,0.20113187,0.00007855603,0.0034681638,0.0013763882,0.002133782,0.00030998213,0.0016905703,0.000011376132,0.0012440629,0.06520684],"study_design_scores_gemma":[0.6051097,0.035658594,0.31275672,0.00039248093,0.0033840493,0.00020168601,0.0052412893,0.009652962,0.00058795616,0.000122991,0.026470322,0.00042127495],"about_ca_topic_score_codex":0.00031879934,"about_ca_topic_score_gemma":0.00036307616,"teacher_disagreement_score":0.11526106,"about_ca_system_score_codex":0.00031081194,"about_ca_system_score_gemma":0.00069297064,"threshold_uncertainty_score":0.9999434},"labels":[],"label_agreement":null},{"id":"W2947285993","doi":"10.1200/jco.2019.37.15_suppl.5025","title":"Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Androgen deprivation therapy; Internal medicine; Prostate cancer; Proportional hazards model; Oncology; Cancer","score_opus":0.04823765635962641,"score_gpt":0.40657250111632176,"score_spread":0.35833484475669536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947285993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997694,0.00064211735,0.000006992088,0.0005337898,0.00008086009,0.0008834372,0.000015509131,0.000004314058,0.0001389935],"genre_scores_gemma":[0.99730086,0.0017550485,0.00054703496,0.0001767239,0.00007045242,0.000014981347,0.00001543191,0.000019133038,0.000100348574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977194,0.00021818285,0.0011413245,0.00020511987,0.0004969685,0.00021900733],"domain_scores_gemma":[0.9975091,0.00060144876,0.0011127973,0.00012934272,0.0004600616,0.00018725039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079346984,0.00015494696,0.0010053945,0.00018999712,0.000025594645,0.00001104271,0.00007093137,0.00014504032,0.000048619797],"category_scores_gemma":[0.00017285938,0.00008174545,0.000077156525,0.00021094517,0.00019440273,0.00017439474,0.000015256478,0.00045608214,9.0762643e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03785898,0.000811141,0.9351621,0.00006961822,0.00063385814,0.0001207954,0.0005739056,0.00028605608,0.0007043107,0.0000027855613,0.000024413204,0.023752013],"study_design_scores_gemma":[0.03501523,0.026987815,0.9354254,0.00038702518,0.00017804,0.000019792082,0.00020737274,0.00009314259,0.0012323548,0.000014994114,0.0003571955,0.000081648126],"about_ca_topic_score_codex":0.00018596389,"about_ca_topic_score_gemma":0.0003858896,"teacher_disagreement_score":0.026176674,"about_ca_system_score_codex":0.00024619143,"about_ca_system_score_gemma":0.0016002889,"threshold_uncertainty_score":0.33334824},"labels":[],"label_agreement":null},{"id":"W2947314711","doi":"10.1200/jco.2020.38.6_suppl.50","title":"Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Internal medicine; Prostate cancer; Oncology; Cancer","score_opus":0.20144469297215994,"score_gpt":0.4925169662479288,"score_spread":0.29107227327576884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947314711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99295396,0.00033240035,0.000011700494,0.0028763034,0.0002817941,0.00330247,0.00014423866,0.000017657952,0.0000794535],"genre_scores_gemma":[0.9954405,0.0023801045,0.00083736185,0.00027610498,0.00021138818,0.00015603215,0.000016994796,0.000051790452,0.00062972703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929028,0.0011415894,0.0037693325,0.0006925039,0.0009645634,0.00052917015],"domain_scores_gemma":[0.9938029,0.0016611896,0.0025944794,0.0003002281,0.00083616923,0.0008050049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014419403,0.0004646593,0.0038933698,0.00022797615,0.000083394516,0.000031260028,0.00019661285,0.00019215354,0.000097859236],"category_scores_gemma":[0.0009141166,0.00022340938,0.00024734327,0.0005261819,0.00062573,0.00022313598,0.00008658031,0.000988485,0.0000022142947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18946633,0.016116645,0.7700929,0.00012398761,0.0033419796,0.002041128,0.0029076952,0.00008274742,0.0000318265,0.000004911924,0.00013379808,0.015656061],"study_design_scores_gemma":[0.12720732,0.21312277,0.6560594,0.0002528883,0.0012519632,0.000025272577,0.001487102,0.00012433369,0.00004946192,0.0000067162605,0.00024307004,0.00016969655],"about_ca_topic_score_codex":0.0013294313,"about_ca_topic_score_gemma":0.020149415,"teacher_disagreement_score":0.19700612,"about_ca_system_score_codex":0.0012777377,"about_ca_system_score_gemma":0.0050884075,"threshold_uncertainty_score":0.9977303},"labels":[],"label_agreement":null},{"id":"W2947444428","doi":"10.1200/jco.2019.37.15_suppl.5023","title":"Efficacy of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) and baseline (BL) comorbidities (CM).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Androgen deprivation therapy; Incidence (geometry); Cancer; Urology; Oncology","score_opus":0.08928748551687671,"score_gpt":0.42942383229262193,"score_spread":0.3401363467757452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947444428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966303,0.000951824,0.000013496715,0.0012938862,0.00017815645,0.00078732055,0.00001870337,0.0000038546586,0.00012247569],"genre_scores_gemma":[0.9949328,0.0035646653,0.0009348074,0.00024882215,0.00011644746,0.000011740634,0.000020266949,0.000017775115,0.00015269894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732536,0.00032748724,0.0014546836,0.00019446769,0.0004750729,0.00022294116],"domain_scores_gemma":[0.9967411,0.0013750204,0.0010684477,0.0001422199,0.00049643114,0.00017673508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016826397,0.00014222576,0.0010556938,0.00018648893,0.000029556451,0.000011036338,0.00007974383,0.00012421647,0.00008030739],"category_scores_gemma":[0.0004887711,0.000087747176,0.00010978607,0.00018408863,0.00021150327,0.00016026433,0.00002526033,0.00047190188,0.0000023418045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037794646,0.0013843345,0.8686858,0.00012615857,0.00040110867,0.00012217944,0.0006218376,0.00024791964,0.0006590672,0.0000151259055,0.00009821288,0.08984363],"study_design_scores_gemma":[0.052080527,0.016752843,0.9278311,0.0004534715,0.00014006422,0.000022121521,0.0002557097,0.0004506374,0.0007701259,0.000051349045,0.0010941245,0.00009791834],"about_ca_topic_score_codex":0.00018268115,"about_ca_topic_score_gemma":0.0003101624,"teacher_disagreement_score":0.089745715,"about_ca_system_score_codex":0.00025638062,"about_ca_system_score_gemma":0.0017944418,"threshold_uncertainty_score":0.3578226},"labels":[],"label_agreement":null},{"id":"W2947696102","doi":"10.1200/jco.2019.37.15_suppl.e16518","title":"A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa): Tolerability and geriatric asssessment (GA) results.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tolerability; Prostate cancer; Androgen deprivation therapy; Internal medicine; Androgen deficiency; Geriatric Depression Scale; Adverse effect; Urology; Cancer; Androgen; Endocrinology; Hormone","score_opus":0.08323762863015056,"score_gpt":0.4713934125413345,"score_spread":0.38815578391118394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947696102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950606,0.0009647196,0.000003848777,0.0012537539,0.00017781272,0.0022409423,0.000044114557,0.000007089281,0.00024709024],"genre_scores_gemma":[0.99663264,0.0017053506,0.0004012721,0.000099945806,0.00015591618,0.00006732693,0.0000048157895,0.000026257976,0.0009064766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952942,0.0006536806,0.002541939,0.00044556143,0.0006789128,0.00038567136],"domain_scores_gemma":[0.9958783,0.0010010768,0.0019385456,0.0003421161,0.00050162955,0.00033835674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034358667,0.00023908928,0.0021980656,0.00021572415,0.000037522906,0.00001632658,0.00016424851,0.00018473511,0.000038409096],"category_scores_gemma":[0.00037346166,0.00012880654,0.00010977565,0.00039144745,0.00023829873,0.00019967656,0.00013155176,0.0008880945,0.0000020086302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44745275,0.015382012,0.47353444,0.00037826208,0.001158323,0.0038493755,0.004357287,0.00017218335,0.0014997568,0.000001943099,0.00033950785,0.05187417],"study_design_scores_gemma":[0.13997066,0.30154285,0.55058986,0.000771804,0.00052490475,0.0006183441,0.004727564,0.0001318026,0.00010628056,0.0000117443715,0.00083066395,0.00017352267],"about_ca_topic_score_codex":0.00039519923,"about_ca_topic_score_gemma":0.0005254739,"teacher_disagreement_score":0.3074821,"about_ca_system_score_codex":0.0005137753,"about_ca_system_score_gemma":0.0036710498,"threshold_uncertainty_score":0.6512285},"labels":[],"label_agreement":null},{"id":"W2947704037","doi":"10.1200/jco.2019.37.15_suppl.e16501","title":"Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Univariate analysis; Cancer; Internal medicine; Proportional hazards model; Oncology; Chemotherapy; Retrospective cohort study; Urology; Multivariate analysis","score_opus":0.07848670944788415,"score_gpt":0.4537076069597042,"score_spread":0.37522089751182003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947704037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944185,0.00008771975,0.0000012173793,0.0020758102,0.00096656283,0.0008777145,0.000014579116,0.000005537947,0.0015523693],"genre_scores_gemma":[0.99800354,0.00019735888,0.00015362068,0.0007185491,0.0001869467,0.0000065901286,0.000009542437,0.000019911213,0.0007039379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970177,0.00061840354,0.0011156374,0.00026032503,0.0006249968,0.00036297002],"domain_scores_gemma":[0.996344,0.001627118,0.00080678484,0.00016866704,0.0007290514,0.00032439557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002276867,0.00019140028,0.0018716326,0.00015942274,0.000023307295,0.000010517068,0.00008726076,0.00014780955,0.00008644423],"category_scores_gemma":[0.0006333015,0.000102683276,0.0002473704,0.00016331286,0.0001643019,0.000117239855,0.000033334883,0.0012737594,0.00004702096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11566975,0.0018109118,0.86075383,0.000070380745,0.0006480115,0.0016605012,0.000100561956,0.00007771395,0.0000466358,0.000013511727,0.00024524433,0.018902915],"study_design_scores_gemma":[0.045251887,0.075501546,0.877588,0.0003363654,0.00023200257,0.000033011496,0.00005286124,0.000039199316,0.0002289922,0.000033965196,0.000606741,0.00009547448],"about_ca_topic_score_codex":0.00013143172,"about_ca_topic_score_gemma":0.00010579216,"teacher_disagreement_score":0.07369064,"about_ca_system_score_codex":0.00044923514,"about_ca_system_score_gemma":0.0015338009,"threshold_uncertainty_score":0.5533921},"labels":[],"label_agreement":null},{"id":"W2947748070","doi":"10.1200/jco.2019.37.15_suppl.5015","title":"Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and antagonist among patients with advanced prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Conventional PCI; Myocardial infarction; Percutaneous coronary intervention; Randomized controlled trial; Agonist; Cardiology; Oncology; Cancer; Receptor","score_opus":0.06547726952186192,"score_gpt":0.42900697231901963,"score_spread":0.3635297027971577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947748070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930678,0.0022634172,0.000006084315,0.0007371527,0.0008431204,0.0021243547,0.000004579321,0.0000058536425,0.00094766304],"genre_scores_gemma":[0.9949044,0.004104616,0.00031572813,0.00010196568,0.00028263815,0.000043515,0.000007659614,0.000016833805,0.00022263968],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99664277,0.0006951297,0.0015881008,0.00025554534,0.00052973494,0.0002887337],"domain_scores_gemma":[0.9972036,0.0010406702,0.0008940266,0.00018992602,0.00037448548,0.0002972817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004116603,0.00015754801,0.0033557424,0.00012756992,0.000041789,0.000019057097,0.00009421824,0.00017784718,0.000030025256],"category_scores_gemma":[0.000869255,0.00008993815,0.00055358495,0.00014733372,0.0005102154,0.00015931505,0.000054777185,0.00090254215,0.0000026915482],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5149784,0.00058031874,0.46814454,0.000041008498,0.00071198464,0.00016291396,0.000062517705,0.00006136776,0.000003166349,0.0000028780655,0.000030808715,0.015220085],"study_design_scores_gemma":[0.6328343,0.0065235724,0.35805172,0.00019114738,0.00036667843,0.000011071959,0.000042349817,0.000118393895,0.000016078062,0.000022779614,0.0017523667,0.000069554946],"about_ca_topic_score_codex":0.00028170942,"about_ca_topic_score_gemma":0.00014765751,"teacher_disagreement_score":0.11785589,"about_ca_system_score_codex":0.00024741082,"about_ca_system_score_gemma":0.0013096327,"threshold_uncertainty_score":0.39211467},"labels":[],"label_agreement":null},{"id":"W2947837169","doi":"10.1200/jco.2020.38.6_suppl.tps383","title":"PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development","keywords":"Medicine; Androgen deprivation therapy; Prostatectomy; Urology; Prostate cancer; Placebo; Internal medicine; Randomization; Antiandrogen; Biopsy; Prostate-specific antigen; Randomized controlled trial; Oncology; Gastroenterology; Cancer; Pathology","score_opus":0.08701395422269277,"score_gpt":0.4446149494255303,"score_spread":0.35760099520283756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947837169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96502686,0.000824092,0.0008410159,0.006147801,0.0007206082,0.026304256,0.000046054767,0.000030010982,0.000059333866],"genre_scores_gemma":[0.9878477,0.0044768774,0.0035381485,0.00090129115,0.00081578374,0.002163162,0.000045374356,0.0000812061,0.0001304531],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99060607,0.0016514586,0.0048307627,0.0006806235,0.00151718,0.0007139229],"domain_scores_gemma":[0.9902381,0.0033982939,0.0036061683,0.00033798805,0.001339548,0.0010799319],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0049160547,0.0005037175,0.0058684847,0.00039589943,0.00009614852,0.000032775275,0.00038025252,0.00053371035,0.0001665559],"category_scores_gemma":[0.0052914512,0.00027456362,0.0007093238,0.00083677564,0.0006639602,0.00029652932,0.000106519605,0.001706878,0.0000070603587],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8790337,0.004406915,0.0029352817,0.00011201125,0.0025910346,0.00046568448,0.0009127561,0.001349837,0.000052212246,0.000009888301,0.0001309921,0.10799971],"study_design_scores_gemma":[0.8887145,0.104653545,0.00040130998,0.0004403167,0.00093230006,0.000009204472,0.00013224389,0.001126755,0.0007018959,0.000034484554,0.0025852048,0.00026825428],"about_ca_topic_score_codex":0.00023124907,"about_ca_topic_score_gemma":0.00021920686,"teacher_disagreement_score":0.10773146,"about_ca_system_score_codex":0.0010022204,"about_ca_system_score_gemma":0.010560282,"threshold_uncertainty_score":0.9999707},"labels":[],"label_agreement":null},{"id":"W2947890783","doi":"10.1200/jco.2019.37.15_suppl.tps5095","title":"High dose testosterone in men with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination deficiency (HRD).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Testosterone (patch); Asymptomatic; Androgen deprivation therapy; Androgen receptor; Internal medicine; Oncology; Disease; Circulating tumor cell; Homologous recombination; Cancer; Endocrinology; Cancer research; Metastasis; Biology; DNA; Genetics","score_opus":0.08331740267119467,"score_gpt":0.4405109860249789,"score_spread":0.35719358335378426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947890783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988353,0.0022197298,0.000003815281,0.0071069323,0.00026506252,0.0006085967,0.000006437385,0.0000052876126,0.0014311494],"genre_scores_gemma":[0.99383986,0.002833005,0.0013110818,0.00023551293,0.000070886614,0.000018830828,0.0000041731496,0.000015330545,0.0016713171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758637,0.00032502128,0.0012139531,0.00023018988,0.0003478051,0.0002966456],"domain_scores_gemma":[0.99770534,0.0008077678,0.0007786459,0.00012996845,0.00033651467,0.00024174726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002098474,0.00013687147,0.0010649693,0.00020201522,0.000028842152,0.000014587452,0.00008648188,0.00013327523,0.00012299613],"category_scores_gemma":[0.0003203982,0.000079016834,0.00007807304,0.00022124847,0.00021965794,0.00015633118,0.000034715224,0.0007192521,0.000009974816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06491538,0.006159921,0.63574415,0.00049808074,0.0007866252,0.008495325,0.0011055979,0.00021530426,0.004723493,0.00035021163,0.0011155403,0.27589035],"study_design_scores_gemma":[0.042976122,0.05240818,0.8995499,0.0004003702,0.0003725198,0.00069133576,0.0006097046,0.00016467996,0.00038662364,0.0010131885,0.0012700169,0.0001573729],"about_ca_topic_score_codex":0.00030044976,"about_ca_topic_score_gemma":0.00028711164,"teacher_disagreement_score":0.27573296,"about_ca_system_score_codex":0.0003185922,"about_ca_system_score_gemma":0.0019527789,"threshold_uncertainty_score":0.3464146},"labels":[],"label_agreement":null},{"id":"W2947904765","doi":"","title":"High Potency Drug Screening in Neuroendocrine Prostate Cancer","year":2018,"lang":"en","type":"dissertation","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Saskatchewan Cancer Agency","keywords":"Potency; Prostate cancer; Medicine; Drug; Cancer; Pharmacology; Oncology; Internal medicine; Chemistry","score_opus":0.01841261880371711,"score_gpt":0.34409034797947635,"score_spread":0.32567772917575927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947904765","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718134,0.003740891,0.0000024084547,0.002513503,0.0008831353,0.0015492453,0.000051424395,0.00010966223,0.019336343],"genre_scores_gemma":[0.25420627,0.00683123,0.0009024675,0.00024411584,0.00047807352,0.00044748106,0.0030858894,0.0001051376,0.7336993],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998089,0.000032933756,0.00034945444,0.0005210374,0.0004685363,0.000539],"domain_scores_gemma":[0.99920064,0.000022585384,0.000099906036,0.00028231513,0.00023087213,0.0001636689],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007905161,0.0003139324,0.00048725723,0.00040143996,0.000071659786,0.000031329222,0.00011522862,0.00006876995,0.0018921908],"category_scores_gemma":[0.00003095483,0.00022925371,0.0000989656,0.00039517885,0.000044878,0.000090139285,0.000029245963,0.00050522946,0.00007658812],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02103502,0.0012915614,0.15734228,0.0051531694,0.0010884537,0.009536002,0.0056342166,0.000020206633,0.007375898,0.00035507925,0.111467525,0.6797006],"study_design_scores_gemma":[0.031743333,0.0021872334,0.6413821,0.009430012,0.00097164686,0.00014912289,0.0061635235,0.0005153871,0.21616307,0.0012772203,0.087790094,0.0022272323],"about_ca_topic_score_codex":0.008774691,"about_ca_topic_score_gemma":0.006845866,"teacher_disagreement_score":0.71760714,"about_ca_system_score_codex":0.0001298643,"about_ca_system_score_gemma":0.00047424086,"threshold_uncertainty_score":0.9990202},"labels":[],"label_agreement":null},{"id":"W2947946663","doi":"10.1200/jco.2019.37.15_suppl.5010","title":"Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Western University","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone; Rash; Nausea; Prostate cancer; Cohort; Internal medicine; Cancer; Oncology","score_opus":0.08409594014976089,"score_gpt":0.4644896020229624,"score_spread":0.3803936618732015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947946663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99416095,0.0005773097,0.0000026230798,0.0010514806,0.0005999778,0.0027335556,0.00006246796,0.000008632414,0.00080302433],"genre_scores_gemma":[0.9973285,0.0005947693,0.0001728695,0.00024354056,0.000106075306,0.000060820996,0.0000103765615,0.000043962587,0.0014390711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936968,0.001263449,0.0029204618,0.00042833248,0.0011395433,0.0005514038],"domain_scores_gemma":[0.99488413,0.00091051974,0.002251541,0.0004950455,0.0010866923,0.00037209256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002787823,0.00032126036,0.0023944299,0.00026240989,0.000059082173,0.00001868505,0.0003525302,0.0002035161,0.00017588664],"category_scores_gemma":[0.00068681553,0.00016307853,0.0003384856,0.0006021893,0.00043305213,0.00019327432,0.000111750116,0.0013761547,0.000011896341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12062965,0.012903394,0.84872234,0.00018808234,0.0016461612,0.0011698597,0.0008338524,0.00022810842,0.0008759749,0.0000054864317,0.00021270377,0.012584372],"study_design_scores_gemma":[0.16158491,0.055947177,0.7781969,0.0005896569,0.001058833,0.00006240423,0.00062309427,0.00019197517,0.00082180527,0.000040450384,0.00071555696,0.00016728227],"about_ca_topic_score_codex":0.00067637756,"about_ca_topic_score_gemma":0.0011376075,"teacher_disagreement_score":0.0705255,"about_ca_system_score_codex":0.0010028003,"about_ca_system_score_gemma":0.004893202,"threshold_uncertainty_score":0.868033},"labels":[],"label_agreement":null},{"id":"W2947954703","doi":"10.1200/jco.2019.37.15_suppl.tps5093","title":"A phase III, multicenter study to assess the diagnostic performance and clinical impact of <sup>18</sup>F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Nuclear medicine; Recurrent prostate cancer; Positron emission tomography; Cancer; Glutamate carboxypeptidase II; Radiology; Internal medicine; Prostatectomy","score_opus":0.13288894220568048,"score_gpt":0.5381535805383449,"score_spread":0.40526463833266446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947954703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99592304,0.0004222653,0.0000015967324,0.0010385355,0.00016578703,0.0021329245,0.00001767566,0.0000034041313,0.00029479648],"genre_scores_gemma":[0.99567354,0.0036564914,0.00012742753,0.00010165149,0.00015904356,0.000030548585,0.0000022798329,0.000016667665,0.00023233179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955777,0.0008287672,0.002441898,0.0002933697,0.00050997257,0.00034829913],"domain_scores_gemma":[0.9905152,0.0067349197,0.0013194706,0.00029639422,0.0007652003,0.00036881378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004598715,0.00019234729,0.0018461057,0.00017842713,0.000028057812,0.000009948445,0.00024540306,0.000047285575,0.00020032373],"category_scores_gemma":[0.0028893661,0.00009150575,0.00025072577,0.00035314934,0.00040742566,0.00015512464,0.000114884206,0.0012024587,0.0000035242674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043768067,0.010501395,0.9239715,0.00007318671,0.00085769396,0.00089218904,0.00084924296,0.00022903651,0.0000319657,6.799335e-7,0.00050823647,0.018316839],"study_design_scores_gemma":[0.06689472,0.09356241,0.8340773,0.00061814603,0.00039977377,0.00013401403,0.0014426926,0.002531506,0.000059299746,0.0000042413326,0.00018422701,0.00009167879],"about_ca_topic_score_codex":0.0003592555,"about_ca_topic_score_gemma":0.00017980178,"teacher_disagreement_score":0.08989417,"about_ca_system_score_codex":0.00022352758,"about_ca_system_score_gemma":0.0025194518,"threshold_uncertainty_score":0.5224152},"labels":[],"label_agreement":null},{"id":"W2947960158","doi":"10.1200/jco.2019.37.15_suppl.e16508","title":"Efficacy of bone resorption inhibitors (BRI) + abiraterone acetate + prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Baker Hughes (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Abiraterone acetate; Zoledronic acid; Concomitant; Internal medicine; Prostate cancer; Denosumab; Prednisone; Gastroenterology; Androgen deprivation therapy; Urology; Cancer; Oncology; Osteoporosis","score_opus":0.06569301104753747,"score_gpt":0.4377551408867463,"score_spread":0.37206212983920883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947960158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833812,0.0010063144,0.000028079048,0.013444367,0.00032488178,0.0016444615,0.00010849777,0.000008276619,0.000053907377],"genre_scores_gemma":[0.9927321,0.0036060363,0.0023430365,0.00024037644,0.0003470468,0.00006982786,0.00014542718,0.00003297644,0.000483193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967902,0.00022845562,0.0017920877,0.00035699585,0.0005364935,0.00029577763],"domain_scores_gemma":[0.99621123,0.00079954625,0.0016635942,0.00023069273,0.0008196592,0.00027526767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016622575,0.00021661221,0.001264811,0.00024739592,0.000039114737,0.000028429613,0.00011843851,0.00019720229,0.000108725784],"category_scores_gemma":[0.00048518687,0.0001401286,0.00018976677,0.00015628485,0.00032216072,0.00031963002,0.0000299241,0.00045876717,0.000002774291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4581096,0.011151217,0.4594513,0.00037933147,0.0013434959,0.00071278383,0.0010090581,0.0007246394,0.0250344,0.000022169033,0.0009845532,0.041077483],"study_design_scores_gemma":[0.18074295,0.089953706,0.69381726,0.0011915229,0.0004712672,0.00006869228,0.00036877065,0.001639802,0.02169813,0.00008331336,0.009667151,0.00029745884],"about_ca_topic_score_codex":0.00022577157,"about_ca_topic_score_gemma":0.00047398312,"teacher_disagreement_score":0.27736664,"about_ca_system_score_codex":0.00025248737,"about_ca_system_score_gemma":0.0012002419,"threshold_uncertainty_score":0.5714278},"labels":[],"label_agreement":null},{"id":"W2948276003","doi":"","title":"Assessing the optimal technique to determine reference SUV for tissue to reference ratios using F18-DCFPyL in Whole Body PET-MR imaging","year":2019,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Nuclear medicine; Whole body imaging; Correction for attenuation; Prostate cancer; Positron emission tomography; Biomedical engineering; Medicine; Cancer; Internal medicine","score_opus":0.08714465455382725,"score_gpt":0.4341146703099325,"score_spread":0.34697001575610525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948276003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9636077,0.000106668325,0.02217777,0.0043652537,0.00007783119,0.0042677117,0.000014792074,0.00007553686,0.0053067184],"genre_scores_gemma":[0.9511509,0.0000068900836,0.04131432,0.0006698352,0.0000714689,0.0003754746,0.000038077,0.000033121236,0.00633995],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984092,0.000052721538,0.00029193546,0.0004493179,0.00028400682,0.0005128185],"domain_scores_gemma":[0.9989806,0.0001511963,0.000048647114,0.00044689167,0.00020528557,0.00016741888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005192819,0.00019524498,0.0003012019,0.00022885256,0.00012485377,0.00015423412,0.0002086552,0.000048948117,0.00014105471],"category_scores_gemma":[0.00010855549,0.00012449804,0.000034402707,0.00038498713,0.000037596088,0.00036090764,0.00015463165,0.000246409,0.00007139049],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024090729,0.000074811345,0.0120219495,0.00009990591,0.000013861915,0.000065427776,0.00026193607,0.000100815785,0.9771603,0.0001181191,0.0005117809,0.009330215],"study_design_scores_gemma":[0.0040775356,0.0016431008,0.01951193,0.001620335,0.000090825895,0.00025952124,0.00261095,0.022483142,0.90241355,0.00013337286,0.044398535,0.0007572217],"about_ca_topic_score_codex":0.00034674857,"about_ca_topic_score_gemma":0.00007431623,"teacher_disagreement_score":0.07474674,"about_ca_system_score_codex":0.000304502,"about_ca_system_score_gemma":0.0003108014,"threshold_uncertainty_score":0.5076882},"labels":[],"label_agreement":null},{"id":"W2948326621","doi":"10.1007/s00259-019-04367-8","title":"68Ga-PSMA-11 PET/CT in a patient with non-PSA-secreting undifferentiated prostate cancer before and after treatment with cabozantinib","year":2019,"lang":"en","type":"article","venue":"European Journal of Nuclear Medicine and Molecular Imaging","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Cabozantinib; Prostate cancer; Medicine; Cancer; Multiparametric MRI; Oncology; Radiology; Internal medicine","score_opus":0.006830678089880327,"score_gpt":0.2491060068088903,"score_spread":0.24227532871900997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948326621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99235743,0.002625539,0.000006307237,0.0036371714,0.00004398759,0.0004398602,0.0000031880197,0.00000964154,0.0008768565],"genre_scores_gemma":[0.9975735,0.00093448936,0.00029793443,0.000985119,0.000049015238,0.0000039302627,0.0000067859887,0.00007172499,0.00007749369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986723,0.000109958484,0.0003224328,0.00025319326,0.0003343545,0.0003077829],"domain_scores_gemma":[0.99927586,0.000013979959,0.00019334262,0.00014288448,0.00013640124,0.00023749954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022204901,0.00023180625,0.00042306885,0.00025919525,0.000046551668,0.000034231914,0.000044054217,0.00000362295,0.000061489074],"category_scores_gemma":[0.000009429898,0.0001232888,0.000037767695,0.00016720842,0.00016102557,0.00010265892,0.000042495656,0.00023680567,0.0000024620617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004262314,0.00020641793,0.7812682,0.00030864912,0.0004122146,0.1582138,0.00884057,0.0000071917,0.01866872,0.0000044952526,0.00015625231,0.027651204],"study_design_scores_gemma":[0.099134624,0.03909931,0.7035915,0.024338795,0.0019771303,0.0570406,0.023970362,0.0016506223,0.003680464,0.000011974687,0.044435702,0.001068897],"about_ca_topic_score_codex":0.000105890664,"about_ca_topic_score_gemma":0.000024908912,"teacher_disagreement_score":0.1011732,"about_ca_system_score_codex":0.000075013595,"about_ca_system_score_gemma":0.000090257,"threshold_uncertainty_score":0.50275713},"labels":[],"label_agreement":null},{"id":"W2948601747","doi":"10.1055/a-1542-6064","title":"Clinical impact of whole-body 68Ga-PSMA I&amp;T PET/CT: lesion frequency and added benefit in lower extremities","year":2021,"lang":"en","type":"article","venue":"Nuklearmedizin - NuclearMedicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Biochemical recurrence; Lesion; Positron emission tomography; Nuclear medicine; Radiology; Cancer; Internal medicine; Pathology; Prostatectomy","score_opus":0.07356982914740201,"score_gpt":0.4135216276283063,"score_spread":0.3399517984809043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948601747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807886,0.008873175,0.0000035489152,0.004296027,0.0004558058,0.0005703537,0.0000612057,0.000074371885,0.0048769466],"genre_scores_gemma":[0.9838913,0.008225723,0.0011962893,0.0004048735,0.000537934,0.000020245223,0.00025398104,0.00009372736,0.0053759394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962645,0.00017054263,0.0010897178,0.0007953376,0.0009053321,0.0007745405],"domain_scores_gemma":[0.9974045,0.00041953652,0.00021643878,0.00091313256,0.0004115071,0.000634861],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00089101965,0.00042106016,0.0012550215,0.00040013276,0.000098187,0.000028592833,0.0002260909,0.00008720689,0.0027788074],"category_scores_gemma":[0.0007611913,0.00031091375,0.00033911696,0.00072397647,0.0011500187,0.00018199686,0.00026209722,0.0010010009,0.00010853468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030739068,0.0026458206,0.8571582,0.0007361869,0.0007049038,0.015713654,0.0009293039,0.0000025823617,0.058891773,0.0002692261,0.014123109,0.04575135],"study_design_scores_gemma":[0.024473203,0.0053364993,0.93427634,0.0034922503,0.0005097113,0.0035607715,0.0019087192,0.00040619256,0.0012781025,0.0008560617,0.02326747,0.0006346579],"about_ca_topic_score_codex":0.00044416246,"about_ca_topic_score_gemma":0.00013197196,"teacher_disagreement_score":0.07711817,"about_ca_system_score_codex":0.0003017895,"about_ca_system_score_gemma":0.00068963016,"threshold_uncertainty_score":0.9999343},"labels":[],"label_agreement":null},{"id":"W2948772049","doi":"10.1200/jco.2019.37.18_suppl.lba2","title":"Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Ottawa Hospital","funders":"","keywords":"Enzalutamide; Medicine; Docetaxel; Oncology; Internal medicine; Clinical endpoint; Prostate cancer; Hazard ratio; Cancer; Androgen receptor; Randomized controlled trial; Confidence interval","score_opus":0.12377839788157827,"score_gpt":0.5153794555294441,"score_spread":0.3916010576478658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948772049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98737675,0.00081219594,0.00043325132,0.0013059888,0.0013486418,0.0075725005,0.000850062,0.0000065993754,0.00029402517],"genre_scores_gemma":[0.9880626,0.005775794,0.004351687,0.00016779384,0.0006282491,0.0001645829,0.00012120828,0.000039763105,0.0006882766],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99218625,0.002089023,0.0039773574,0.00037827433,0.0010556203,0.0003134677],"domain_scores_gemma":[0.98310214,0.007876496,0.0046359776,0.000273725,0.003823012,0.00028867155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00855493,0.00029462724,0.0055865985,0.0002747385,0.000033917288,0.00001484915,0.00023286279,0.00022061323,0.00009626341],"category_scores_gemma":[0.004203348,0.00015235253,0.00081381307,0.00020208396,0.0007335661,0.00027002353,0.000040732724,0.00062099803,4.8474095e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9627644,0.0054413364,0.00017764643,0.00009611615,0.0059588836,0.00011873008,0.00347984,0.00004918157,0.0022345711,0.00008166197,0.00020609243,0.019391565],"study_design_scores_gemma":[0.76296127,0.22861809,0.00010494076,0.00029504253,0.0009879391,0.000015987842,0.0012961657,0.00031141014,0.0032102163,0.00007297898,0.0020059966,0.000119968725],"about_ca_topic_score_codex":0.00015366594,"about_ca_topic_score_gemma":0.0002031065,"teacher_disagreement_score":0.22317675,"about_ca_system_score_codex":0.00027625295,"about_ca_system_score_gemma":0.005596391,"threshold_uncertainty_score":0.99277574},"labels":[],"label_agreement":null},{"id":"W2949517930","doi":"10.1200/jco.2006.24.18_suppl.4638","title":"Impact of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases in a randomised placebo-control trial","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada); Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Brief Pain Inventory; Placebo; Prostate cancer; Bone pain; Zoledronic acid; Cancer; Malignancy; Internal medicine; Surgery; Physical therapy; Chronic pain; Pathology","score_opus":0.04802439274774274,"score_gpt":0.45338614372281066,"score_spread":0.40536175097506794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949517930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595124,0.000943583,0.000005921929,0.0009836005,0.00017218577,0.0017263296,0.000029112785,0.0000027925869,0.0001852302],"genre_scores_gemma":[0.99897,0.00033350528,0.00008838416,0.00013787419,0.000291418,0.00006905041,0.000010117044,0.000015444659,0.0000842432],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99546987,0.0013218008,0.002227043,0.00017353304,0.000464395,0.00034337203],"domain_scores_gemma":[0.9955592,0.0025161055,0.0013289957,0.00011803961,0.00029261113,0.00018504943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005766633,0.00016107269,0.0019902817,0.00035013893,0.000013479463,0.0000050932936,0.000083464976,0.00015788001,0.000105434214],"category_scores_gemma":[0.0016643432,0.00008386036,0.00045286815,0.00024947713,0.00016902164,0.00008380427,0.000012170055,0.00081041164,0.0000015579872],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6184879,0.005776623,0.34587774,0.000018441531,0.0003125524,0.0004511733,0.000027448328,0.00026622505,0.000043177075,0.0000013299032,0.00036337995,0.028374037],"study_design_scores_gemma":[0.6260676,0.07236197,0.3007349,0.0002185274,0.00016504609,0.000005563754,0.000011280683,0.00007181551,0.000055188797,0.000044465654,0.00020787893,0.00005576734],"about_ca_topic_score_codex":0.00039007136,"about_ca_topic_score_gemma":0.00058100035,"teacher_disagreement_score":0.06658535,"about_ca_system_score_codex":0.00066027103,"about_ca_system_score_gemma":0.003417872,"threshold_uncertainty_score":0.6063158},"labels":[],"label_agreement":null},{"id":"W2949665991","doi":"10.1101/090589","title":"Mining human prostate cancer datasets: The “camcAPP” shiny app","year":2017,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Prostate cancer; Computer science; Resource (disambiguation); Outcome (game theory); Cancer; Data science; Computational biology; Biology; Genetics","score_opus":0.03755905544459465,"score_gpt":0.31761220083224595,"score_spread":0.2800531453876513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949665991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96800923,0.016931884,0.000017661052,0.0052728294,0.0015770592,0.0036147572,0.0039036635,0.0005167461,0.00015616654],"genre_scores_gemma":[0.99212915,0.0034775552,0.0005938535,0.00038215288,0.0013955545,0.0014713084,0.000021531987,0.00021198601,0.00031693187],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9961988,0.00013699335,0.00054743333,0.001293424,0.00083461957,0.0009887805],"domain_scores_gemma":[0.99506253,0.000064707296,0.00056680595,0.0033808367,0.00046277748,0.000462345],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00091480266,0.0007235908,0.0008448803,0.00023443507,0.0009973178,0.000565303,0.0011279036,0.00046858605,0.00017413337],"category_scores_gemma":[0.00018205497,0.0005101403,0.00022819398,0.00025042892,0.0005724729,0.00020775637,0.001170735,0.0014740115,0.00008319668],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009829354,0.0010154906,0.20287009,0.005381336,0.0038271933,0.002111211,0.00036196772,0.000037694725,0.6907215,0.00066221616,0.09189643,0.0001319495],"study_design_scores_gemma":[0.007586346,0.0004620129,0.41415346,0.007508628,0.002058173,2.3508825e-7,0.000057441168,0.0002711473,0.2395178,0.0000133718095,0.32583916,0.0025322388],"about_ca_topic_score_codex":0.00058033643,"about_ca_topic_score_gemma":0.0000281685,"teacher_disagreement_score":0.4512037,"about_ca_system_score_codex":0.00061439804,"about_ca_system_score_gemma":0.0017485801,"threshold_uncertainty_score":0.999735},"labels":[],"label_agreement":null},{"id":"W2949791399","doi":"10.1186/s12885-019-5805-z","title":"A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)","year":2019,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University; Movember Foundation; Commonwealth Foundation; Astellas Pharma; Astellas Pharma US; National Cancer Institute; National Institutes of Health; Astellas Foundation for Research on Metabolic Disorders; Prostate Cancer Foundation","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Prostatectomy; Androgen deprivation therapy; Urology; Clinical endpoint; Internal medicine; Radiation therapy; Randomized controlled trial; Oncology; Cancer; Androgen receptor; Pathology","score_opus":0.031732700781238056,"score_gpt":0.35311030479330857,"score_spread":0.3213776040120705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949791399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9452064,0.015856119,0.000038516842,0.0003151336,0.0010531533,0.03695679,0.00023299611,0.00013213612,0.00020875834],"genre_scores_gemma":[0.96292996,0.005553503,0.0001175141,0.000072055744,0.00043050756,0.027352152,0.00013821367,0.00014216868,0.0032638954],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945414,0.0006717933,0.0010995369,0.0011153688,0.0015857763,0.0009860944],"domain_scores_gemma":[0.99683577,0.00070930924,0.0007768688,0.0007731401,0.00047357602,0.00043130957],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012686558,0.0007772575,0.0026206945,0.00049662235,0.00023095364,0.00008849424,0.00025463293,0.00022146833,0.0011508302],"category_scores_gemma":[0.00008470854,0.00048293578,0.0004170711,0.0007094728,0.00038270888,0.0003093577,0.00010795975,0.00075025467,0.000026619085],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96463716,0.0031061184,0.009466373,0.00033580078,0.0036659962,0.00007169459,0.007970809,0.0014061868,0.00060317066,0.000011271179,0.00025232707,0.0084730815],"study_design_scores_gemma":[0.97228616,0.013628938,0.0010783096,0.0004884666,0.0017284886,0.000005036094,0.0008059538,0.00296805,0.0056044967,0.000008995206,0.000836812,0.0005602825],"about_ca_topic_score_codex":0.004430751,"about_ca_topic_score_gemma":0.0019743035,"teacher_disagreement_score":0.017723592,"about_ca_system_score_codex":0.0017468561,"about_ca_system_score_gemma":0.0034263409,"threshold_uncertainty_score":0.99976224},"labels":[],"label_agreement":null},{"id":"W2949821396","doi":"10.1016/j.euo.2019.01.013","title":"Re: Shusuke Akamatsu, Masashi Kubota, Ryuji Uozumi, et al. Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer. Eur Urol Oncol 2019;2:320–328","year":2019,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Overall survival; Cancer; Internal medicine; Gynecology","score_opus":0.07546158276393353,"score_gpt":0.3527123459148482,"score_spread":0.2772507631509147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949821396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51626116,0.0016722135,0.0024351515,0.45257998,0.0014712868,0.018189242,0.0024843004,0.00018525314,0.0047213957],"genre_scores_gemma":[0.51679057,0.00453398,0.023813704,0.3898716,0.0021322486,0.005792658,0.020781586,0.0012716638,0.035012025],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945606,0.0012644929,0.0012888942,0.0013353415,0.0004991726,0.0010515194],"domain_scores_gemma":[0.996189,0.001780405,0.000916612,0.00044923162,0.0005016477,0.00016311281],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001481528,0.0007767183,0.0016977207,0.00058037014,0.00013914931,0.000039759892,0.00020549294,0.00045382662,0.000024564435],"category_scores_gemma":[0.0003759922,0.0006641393,0.00018033785,0.00021949688,0.00035828515,0.00017147318,0.00017539765,0.0013942997,0.000022461467],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046311636,0.01061745,0.09617826,0.0069776485,0.01557512,0.023295522,0.07195532,0.035349216,0.014635131,0.00025708947,0.6423899,0.03645774],"study_design_scores_gemma":[0.1318097,0.038085654,0.029293926,0.0015597238,0.005875311,0.0011629348,0.0012319301,0.12084862,0.0027056613,0.00012328704,0.6642474,0.0030558384],"about_ca_topic_score_codex":0.00018574398,"about_ca_topic_score_gemma":0.00045338468,"teacher_disagreement_score":0.085499406,"about_ca_system_score_codex":0.0010706423,"about_ca_system_score_gemma":0.003285012,"threshold_uncertainty_score":0.999581},"labels":[],"label_agreement":null},{"id":"W2949891038","doi":"10.1016/j.neo.2019.05.005","title":"Conditional Deletion of Eaf1 Induces Murine Prostatic Intraepithelial Neoplasia in Mice","year":2019,"lang":"en","type":"article","venue":"Neoplasia","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; National Cancer Institute; Burman University; University of Southern California","keywords":"Prostate cancer; Prostate; Intraepithelial neoplasia; Cancer research; High-grade prostatic intraepithelial neoplasia; Biology; Carcinogenesis; Pathology; Medicine; Cancer; Genetics","score_opus":0.011179344977658686,"score_gpt":0.2829684458061586,"score_spread":0.2717891008284999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949891038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946166,0.00019575622,0.000011038322,0.0009292718,0.00015306726,0.0008319646,0.0000503145,0.000024682757,0.0031872527],"genre_scores_gemma":[0.99746394,0.00009656404,0.00035189925,0.00010680682,0.00008583789,0.000052775024,0.0002749886,0.000018518182,0.0015486535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987593,0.00004465162,0.00029988546,0.00024406517,0.00037698224,0.00027511257],"domain_scores_gemma":[0.9994573,0.00009805637,0.000085205014,0.00015464741,0.00011187868,0.000092913964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015066928,0.00013818042,0.00030122098,0.00023143571,0.000023654418,0.000010141322,0.00007289286,0.000101698926,0.0006383474],"category_scores_gemma":[0.00004607731,0.00011187422,0.000058228983,0.0002885412,0.000087695786,0.00011477999,0.00002944482,0.00024376769,0.0002342225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044154576,0.001316508,0.5505143,0.0013931883,0.00030533056,0.00027994643,0.002485984,0.0000919582,0.42296213,0.0019719822,0.0022831836,0.011980053],"study_design_scores_gemma":[0.016622337,0.0023348432,0.7402005,0.00069485605,0.00010737475,0.00026338286,0.00079073064,0.00065922056,0.23327316,0.0012964205,0.0034300247,0.00032709487],"about_ca_topic_score_codex":0.000108278015,"about_ca_topic_score_gemma":0.000049122697,"teacher_disagreement_score":0.18968895,"about_ca_system_score_codex":0.00012804214,"about_ca_system_score_gemma":0.0003162361,"threshold_uncertainty_score":0.6989457},"labels":[],"label_agreement":null},{"id":"W2950337216","doi":"10.5489/cuaj.6124","title":"CUA-AUA International Fellows Program: Chicago 2019","year":2019,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medical education; Medicine; Psychology; Medical physics","score_opus":0.015512594708570216,"score_gpt":0.2902423832214952,"score_spread":0.274729788512925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950337216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8684282,0.00040628595,0.0000058764012,0.0866157,0.0012491744,0.0005960957,0.00004461877,0.000054581797,0.0425995],"genre_scores_gemma":[0.9670389,0.0002645551,0.00024337083,0.0030797222,0.0007119983,0.000017448854,0.00011930752,0.000013541602,0.0285111],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99846786,0.00007564282,0.00023511321,0.00019136602,0.0005136907,0.0005163093],"domain_scores_gemma":[0.9986631,0.00006289899,0.00013259842,0.00010359553,0.00031773737,0.00072003],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000459373,0.000114306786,0.00020817992,0.00019698666,0.00013492748,0.00012631655,0.00015879679,0.00021130434,0.0045867274],"category_scores_gemma":[0.00022992396,0.00008250029,0.00014973461,0.00017489502,0.00002721963,0.00011067246,0.000019882295,0.00067496893,0.0010667301],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000110037836,0.000105790044,0.92981,0.0000032897312,0.0002262634,0.0001277698,0.000056955814,0.000008063187,0.00022387419,0.00013825954,0.05576611,0.013423622],"study_design_scores_gemma":[0.001767498,0.00048388197,0.4938802,0.000011981644,0.000030690717,0.00013684346,0.000033950866,0.00019907112,0.00003370488,0.000297933,0.5030316,0.00009263642],"about_ca_topic_score_codex":0.00042903775,"about_ca_topic_score_gemma":0.00015438623,"teacher_disagreement_score":0.4472655,"about_ca_system_score_codex":0.0015529637,"about_ca_system_score_gemma":0.0007121157,"threshold_uncertainty_score":0.99971104},"labels":[],"label_agreement":null},{"id":"W2950755606","doi":"10.3390/cancers11060855","title":"Advancing Risk Assessment of Intermediate Risk Prostate Cancer Patients","year":2019,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba","funders":"Prostate Cancer Fight Foundation","keywords":"Prostate cancer; Medicine; Risk assessment; Prostate; Cancer; Oncology; Internal medicine; Computer science","score_opus":0.008638712924839736,"score_gpt":0.33533180757889997,"score_spread":0.3266930946540602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950755606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938742,0.0010208326,0.000012942897,0.00006962016,0.00070430496,0.0010890983,0.00031014634,0.000031516636,0.002887362],"genre_scores_gemma":[0.9878796,0.009642952,0.00020389975,0.000072102295,0.00007749386,0.00014258568,0.00006216865,0.000031692005,0.0018875514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985141,0.000055926103,0.0003039256,0.000317379,0.00040498868,0.00040368107],"domain_scores_gemma":[0.9989031,0.00006667562,0.00029808856,0.00028577563,0.00026930135,0.00017707581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002101046,0.00016300863,0.000355274,0.000118916745,0.000054275482,0.000010088814,0.00009393579,0.000054656746,0.00049535494],"category_scores_gemma":[0.000068887624,0.00012206598,0.00010609303,0.00022252265,0.00009954718,0.0001227116,0.000058659418,0.0003142115,0.000026179388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039163794,0.000048740956,0.9727134,0.00022033283,0.00020578629,0.0000043674454,0.00045604998,0.00059973175,0.0008170536,0.000003965102,0.0009599525,0.02357896],"study_design_scores_gemma":[0.0073696207,0.0013545551,0.97536296,0.0005219415,0.0002078885,4.6427473e-7,0.00032951435,0.0024795947,0.005434401,0.000048249247,0.0066996077,0.00019120506],"about_ca_topic_score_codex":0.0015054599,"about_ca_topic_score_gemma":0.000115186034,"teacher_disagreement_score":0.023387756,"about_ca_system_score_codex":0.0023306422,"about_ca_system_score_gemma":0.0014447061,"threshold_uncertainty_score":0.6094548},"labels":[],"label_agreement":null},{"id":"W2951506965","doi":"10.1038/s41598-019-44991-w","title":"Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cells","year":2019,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill Genome Centre; McGill University; Jewish General Hospital","funders":"","keywords":"LNCaP; Enzalutamide; Prostate cancer; Cancer research; Radiosensitivity; Gene signature; Biology; Cancer; Internal medicine; Oncology; Androgen receptor; Medicine; Gene; Gene expression; Radiation therapy; Genetics","score_opus":0.008283486857327516,"score_gpt":0.27205899250037713,"score_spread":0.26377550564304963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951506965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928582,0.004386162,0.000005192747,0.00032879654,0.0006493487,0.0015455261,0.00003886464,0.000022259444,0.00016566482],"genre_scores_gemma":[0.99711823,0.00023423694,0.000028222448,0.000025693822,0.000011843696,0.00004242948,0.00009285572,0.000021963286,0.0024244962],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975175,0.000089558176,0.00053845666,0.0008087004,0.0006861047,0.00035967823],"domain_scores_gemma":[0.99859715,0.00003742167,0.00033050345,0.00056112406,0.00032231808,0.0001514677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011903098,0.00018301066,0.00039003365,0.00028508197,0.0000720182,0.00007629326,0.0000459603,0.00012545663,0.0000081739445],"category_scores_gemma":[0.00006539579,0.00015049118,0.00007343332,0.00065729656,0.0002413246,0.00016777185,0.000058821206,0.00025113922,0.0000050079952],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046846905,0.00013676092,0.0016577411,0.00009869276,0.000054374355,0.0007724182,0.0009498783,0.00001331097,0.9937296,0.000007476083,0.0012592345,0.0008520266],"study_design_scores_gemma":[0.0010742598,0.00016601673,0.02444782,0.00012098857,0.00004775387,0.00004266971,0.00028838063,0.00019382298,0.97298765,0.00020135377,0.0002778015,0.00015145242],"about_ca_topic_score_codex":0.00026526948,"about_ca_topic_score_gemma":0.000026750913,"teacher_disagreement_score":0.022790078,"about_ca_system_score_codex":0.0002040283,"about_ca_system_score_gemma":0.00034097678,"threshold_uncertainty_score":0.6136852},"labels":[],"label_agreement":null},{"id":"W2952031509","doi":"10.1002/path.5315","title":"Development of a predictive model for stromal content in prostate cancer samples to improve signature performance","year":2019,"lang":"en","type":"article","venue":"The Journal of Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; University of Calgary; McGill University Health Centre","funders":"Canadian Cancer Society Research Institute; Prostate Cancer Canada; Movember Foundation","keywords":"Stromal cell; Prostate cancer; Prostate; Stroma; Metastasis; Medicine; Cancer research; Pathology; PCA3; Oncology; Cancer; Immunohistochemistry; Biology; Internal medicine","score_opus":0.05463652249882536,"score_gpt":0.3294163177374782,"score_spread":0.2747797952386528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952031509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658805,0.0007530311,0.00068277423,0.00083427894,0.00011181555,0.000950936,0.000044540342,0.0000020093419,0.00003258079],"genre_scores_gemma":[0.994386,0.00024884572,0.004355864,0.00011703121,0.000037497386,0.00005021775,0.0000029895955,0.000009501527,0.000792022],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99917835,0.000031395823,0.00032433885,0.00008348778,0.0001732794,0.00020913589],"domain_scores_gemma":[0.9993161,0.000058394267,0.00017373147,0.00009239325,0.0003005856,0.00005877772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005642376,0.00008213947,0.00029200828,0.000110814755,0.000024339382,0.0000019455879,0.00010068735,0.00004445162,0.0000112538855],"category_scores_gemma":[0.000030769275,0.00004337818,0.00004389823,0.00006883456,0.00004548728,0.00003908639,0.000037629998,0.00021685516,0.00000107145],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025171714,0.00027835032,0.06978088,0.00037117628,0.00023590671,0.00004553204,0.027703188,0.0057278457,0.85209674,0.000026478523,0.00018601555,0.018376147],"study_design_scores_gemma":[0.029244909,0.017477518,0.52768594,0.0017741446,0.00037628162,0.00047454523,0.007913671,0.039804965,0.37373644,0.0002989689,0.000858574,0.00035404656],"about_ca_topic_score_codex":0.000006621674,"about_ca_topic_score_gemma":0.00002212991,"teacher_disagreement_score":0.47836033,"about_ca_system_score_codex":0.00016165615,"about_ca_system_score_gemma":0.0005521893,"threshold_uncertainty_score":0.17689109},"labels":[],"label_agreement":null},{"id":"W2952944061","doi":"10.1016/j.ctrv.2019.05.001","title":"Androgen receptor plasticity and its implications for prostate cancer therapy","year":2019,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Medicine; Mechanism (biology); Cancer; Androgen deprivation therapy; Cancer research; Receptor; Drug resistance; Bioinformatics; Oncology; Internal medicine; Genetics; Biology","score_opus":0.2532166580661024,"score_gpt":0.4788837669870904,"score_spread":0.225667108920988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952944061","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005045044,0.9716659,0.0000030972335,0.00076979387,0.00028575544,0.023502573,0.0034704104,0.000055961013,0.00019602636],"genre_scores_gemma":[0.0000018917278,0.9330588,0.00009936254,0.000114794864,0.00048733252,0.050744504,0.0011679055,0.00013084216,0.014194557],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99720764,0.00013457732,0.0008195974,0.0010451893,0.00015646592,0.0006365065],"domain_scores_gemma":[0.99821377,0.00020749393,0.00051789137,0.00051980343,0.00018551969,0.00035550733],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015897081,0.0008795455,0.0036346824,0.00017950237,0.00019249416,0.000057170582,0.00016233863,0.00028462426,0.00034063472],"category_scores_gemma":[0.00002729984,0.00048730097,0.00089774956,0.00037751955,0.00007666837,0.00009147555,0.000046057907,0.00021018236,0.00012949784],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001491031,0.00021333797,0.00031509888,0.025832256,0.0012490377,0.0000017698685,0.000077155935,1.054644e-7,0.000014816066,0.00002544868,0.00529414,0.96682775],"study_design_scores_gemma":[0.0030399847,0.000914057,0.000037621405,0.016954456,0.0037308952,0.000016017992,0.0000029327268,0.0000022884722,0.000058336573,0.0000077084815,0.9748243,0.00041138078],"about_ca_topic_score_codex":0.0000794835,"about_ca_topic_score_gemma":0.000028998162,"teacher_disagreement_score":0.96953017,"about_ca_system_score_codex":0.0016464465,"about_ca_system_score_gemma":0.0017282505,"threshold_uncertainty_score":0.9997579},"labels":[],"label_agreement":null},{"id":"W2953072247","doi":"10.1016/j.jmir.2019.05.006","title":"Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice","year":2019,"lang":"en","type":"review","venue":"Journal of medical imaging and radiation sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Prostate cancer; Radium-223; Medicine; Radium; Castration; Cancer; Oncology; Internal medicine; Bone metastasis; Hormone; Radiochemistry","score_opus":0.266733362562831,"score_gpt":0.5274560359842569,"score_spread":0.26072267342142597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953072247","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050964877,0.9873086,0.0000063360008,0.0066724764,0.0003610093,0.00049433636,0.000005309343,0.0000028895217,0.000052511063],"genre_scores_gemma":[0.0026655663,0.9960733,0.0007777447,0.00022974938,0.00012891635,0.000014844709,0.0000074607224,0.0000085563815,0.0000938405],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963297,0.0005067241,0.0014240858,0.00028443203,0.0012328769,0.00022216263],"domain_scores_gemma":[0.9968261,0.0018543755,0.00080746744,0.000067972316,0.00012826035,0.00031583055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070981956,0.00017186574,0.0011002275,0.00059216237,0.000070156966,0.00015554036,0.00012910068,0.00009031534,0.000010872796],"category_scores_gemma":[0.0022640275,0.00009916794,0.00008042289,0.0004895466,0.00042185315,0.0006402773,0.00003997296,0.00075205276,0.0000012852745],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010859631,0.00016401809,0.014823565,0.0018292521,0.00009045607,0.0008180671,0.0005009297,8.4409095e-7,2.966911e-7,0.0000110005685,0.0006350639,0.9810179],"study_design_scores_gemma":[0.0044975984,0.00025993973,0.007257927,0.019579954,0.00028392416,0.00082927645,0.0015355696,0.00042090786,0.0000010329857,0.000010854123,0.9651521,0.00017092418],"about_ca_topic_score_codex":0.00019200148,"about_ca_topic_score_gemma":0.00004093187,"teacher_disagreement_score":0.980847,"about_ca_system_score_codex":0.0001894527,"about_ca_system_score_gemma":0.00831748,"threshold_uncertainty_score":0.99730444},"labels":[],"label_agreement":null},{"id":"W2953109302","doi":"10.1016/j.brachy.2019.04.111","title":"Efficacy Results of a Randomized Trial of Prostate HDR Monotherapy in Either One or Two Fractions for Low and Intermediate Risk Disease","year":2019,"lang":"en","type":"article","venue":"Brachytherapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Regimen; Prostate cancer; Randomized controlled trial; Fraction (chemistry); Brachytherapy; Oncology; Prostate; Internal medicine; Urology; Nuclear medicine; Cancer; Radiation therapy","score_opus":0.023867741449853683,"score_gpt":0.3528044707920732,"score_spread":0.3289367293422195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953109302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891406,0.0012304351,0.00008230723,0.00076637254,0.00012527397,0.008347034,0.00019997374,0.00001748511,0.00009048688],"genre_scores_gemma":[0.98804176,0.008638952,0.0004022645,0.00006963539,0.000111939305,0.0005914698,0.00006451458,0.00003680479,0.0020426493],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99846274,0.0001970375,0.00060317875,0.00028703804,0.000228089,0.00022191806],"domain_scores_gemma":[0.9981179,0.0010088212,0.0003296388,0.00030958405,0.000117447475,0.00011660124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000812761,0.00015657797,0.0008740219,0.0002194144,0.000025570707,0.000010394382,0.000058921836,0.00005513127,0.000087922126],"category_scores_gemma":[0.0003328638,0.000098943376,0.00020514701,0.00019498686,0.00018117522,0.00008322319,0.000011802831,0.00014329737,0.0000032552541],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9665622,0.0014836136,0.0038386039,0.00017190924,0.00041725993,0.000007395663,0.001304722,0.000017928023,0.0018360281,0.000021102811,0.00004458663,0.024294654],"study_design_scores_gemma":[0.9809049,0.002760609,0.0107269185,0.0004067038,0.00011287529,0.0000010387976,0.0000623914,0.0009496826,0.0032480569,0.00039597592,0.0003264476,0.00010440836],"about_ca_topic_score_codex":0.0001558528,"about_ca_topic_score_gemma":0.000032210246,"teacher_disagreement_score":0.024190245,"about_ca_system_score_codex":0.000038909788,"about_ca_system_score_gemma":0.00023607956,"threshold_uncertainty_score":0.40347937},"labels":[],"label_agreement":null},{"id":"W2953219593","doi":"10.1101/667832","title":"Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, <i>ETV1</i> , and <i>ETV4</i> on whole mount radical prostatectomy tissue","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"U.S. Department of Defense","keywords":"Prostate cancer; Prostatectomy; Erg; Medicine; Prostate; Prostate-specific antigen; Immunohistochemistry; Pathological; Cancer; Biochemical recurrence; Urology; Pathology; Internal medicine; Oncology; Ophthalmology","score_opus":0.02212216896932888,"score_gpt":0.30272242869224203,"score_spread":0.28060025972291314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953219593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826716,0.009128093,0.00003803485,0.00035809228,0.00040420878,0.005172155,0.0021264672,0.00008437873,0.000016928328],"genre_scores_gemma":[0.995905,0.001587456,0.001041565,0.00008128637,0.0001740373,0.0010221278,0.000017493823,0.0001323653,0.00003871044],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99536747,0.00029593348,0.00082085433,0.0011235661,0.0017902247,0.00060192676],"domain_scores_gemma":[0.996537,0.00008202253,0.00069946644,0.0009671574,0.0013777958,0.0003365574],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013778533,0.00059328135,0.0010346586,0.00033532426,0.00009849596,0.00006583371,0.0002531434,0.0005279709,0.00005462687],"category_scores_gemma":[0.00016064735,0.0004998806,0.00013067118,0.00039642016,0.00037158525,0.00014817511,0.00032598677,0.0009827039,0.000014950196],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017009093,0.00048484164,0.06382612,0.0025919655,0.00024688034,0.00001910151,0.00005376406,0.000094636125,0.93010736,0.00001799489,0.00081701885,0.000039410184],"study_design_scores_gemma":[0.004901953,0.0008435919,0.07188686,0.0037847704,0.00039403938,5.695589e-8,0.000006734158,0.00046800132,0.9159632,0.0000038480152,0.0013232965,0.00042366702],"about_ca_topic_score_codex":0.00021861443,"about_ca_topic_score_gemma":0.0000014952295,"teacher_disagreement_score":0.014144173,"about_ca_system_score_codex":0.0007502836,"about_ca_system_score_gemma":0.002601935,"threshold_uncertainty_score":0.9997453},"labels":[],"label_agreement":null},{"id":"W2953522954","doi":"10.1158/1538-7445.sabcs18-1730","title":"Abstract 1730:<i>DACH1</i>gene deletion extends portraits of human prostate cancer","year":2019,"lang":"en","type":"article","venue":"Molecular and Cellular Biology / Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Prostate cancer; PTEN; Tramp; Chromoplexy; Cancer; Cancer research; Metastasis; Biology; TMPRSS2; Population; Genetics; Oncology; Medicine; Disease; PCA3; Internal medicine; PI3K/AKT/mTOR pathway","score_opus":0.012951312564580552,"score_gpt":0.29963965353075517,"score_spread":0.2866883409661746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953522954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713953,0.026627617,0.00007561227,0.00018758165,0.00009022382,0.0005101321,0.000044966644,0.00001660715,0.0010519341],"genre_scores_gemma":[0.996024,0.0024017198,0.00021731984,0.00012274855,0.00004326453,0.000029823772,0.00038229587,0.000027511744,0.00075129606],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988842,0.00003951111,0.0002589453,0.0003479666,0.00014957502,0.00031978133],"domain_scores_gemma":[0.9993751,0.00000848382,0.000091207774,0.00027119694,0.00012760235,0.00012638076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013747685,0.0001751629,0.00030452598,0.00009508266,0.000049420494,0.000007970614,0.000073180876,0.00017406637,0.00017167677],"category_scores_gemma":[0.0000044226977,0.00014107107,0.00009042037,0.00011078408,0.00017491332,0.000013461102,0.00005531125,0.00015771718,0.000011083561],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001137592,0.00009654167,0.07690342,0.00015499203,0.00013506303,0.00006690715,0.00008770982,0.0000112368225,0.91613644,0.0000894539,0.000031549578,0.006172931],"study_design_scores_gemma":[0.0018328127,0.0007832765,0.050379295,0.000054229164,0.0000959326,0.000013468649,0.000036602778,0.000029643295,0.9452509,0.00024913237,0.0011218557,0.00015279833],"about_ca_topic_score_codex":0.00005746369,"about_ca_topic_score_gemma":0.0000043202267,"teacher_disagreement_score":0.02911451,"about_ca_system_score_codex":0.000029165229,"about_ca_system_score_gemma":0.000095364194,"threshold_uncertainty_score":0.5752711},"labels":[],"label_agreement":null},{"id":"W2953702378","doi":"10.1158/1538-7445.sabcs18-923","title":"Abstract 923: FOXA1 chromatin binding is regulated by LSD1-mediated methylation in prostate cancer cells","year":2019,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"FOXA1; Coactivator; Androgen receptor; Prostate cancer; Chromatin; Cancer research; Pioneer factor; Androgen deprivation therapy; Enhancer; Histone; Transcription factor; Chemistry; Internal medicine; Endocrinology; Biology; Medicine; Cancer; Breast cancer; Biochemistry","score_opus":0.01691111676357647,"score_gpt":0.31456635578154085,"score_spread":0.29765523901796437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953702378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908206,0.00096206885,0.00000131323,0.0019112347,0.00014349457,0.0013609915,0.0000935599,0.00008216472,0.0046245563],"genre_scores_gemma":[0.9691145,0.00082717335,0.00009069051,0.00019553334,0.00003081243,0.000078031306,0.00038813148,0.000035015473,0.029240102],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984586,0.000030777624,0.00032766716,0.00035889394,0.0003884547,0.0004355539],"domain_scores_gemma":[0.999364,0.000080595506,0.000095827454,0.0002287439,0.000090904505,0.00013990079],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002572813,0.000183051,0.00031077676,0.00023279016,0.000038567727,0.00003029047,0.00006939992,0.000115561284,0.0043297824],"category_scores_gemma":[0.00001667048,0.00013420147,0.00005658795,0.0005399868,0.000038575614,0.00017424271,0.000028938084,0.00024025977,0.0006628548],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031995508,0.00012665377,0.0444905,0.00018495883,0.00008180326,0.000027625825,0.0007414442,0.000014028404,0.9389749,0.0000021316866,0.010654005,0.0043819523],"study_design_scores_gemma":[0.0061090165,0.00023491075,0.071191736,0.00035226907,0.000030073774,0.0000021793799,0.00026625913,0.0015266646,0.9161361,0.000024737987,0.003898662,0.00022740923],"about_ca_topic_score_codex":0.0012669773,"about_ca_topic_score_gemma":0.000058684083,"teacher_disagreement_score":0.026701234,"about_ca_system_score_codex":0.00042220016,"about_ca_system_score_gemma":0.0002172987,"threshold_uncertainty_score":0.9965804},"labels":[],"label_agreement":null},{"id":"W2953737360","doi":"10.1158/1538-7445.am2019-5225","title":"Abstract 5225: Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; LNCaP; Androgen receptor; Androgen deprivation therapy; Cancer research; P-Chloroamphetamine; Gene knockdown; Corepressor; SOX2; Transcription factor; Biology; Downregulation and upregulation; Endocrinology; Gene silencing; Prostate; Cancer; Medicine; Internal medicine; Repressor; Receptor; Cell culture; Genetics","score_opus":0.043970121910423765,"score_gpt":0.3695935053490898,"score_spread":0.32562338343866604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953737360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872214,0.009503785,0.0000019623162,0.0009748411,0.00009775297,0.0016025085,0.00004122101,0.00003549714,0.000521016],"genre_scores_gemma":[0.99059206,0.005866864,0.00004824554,0.000030200516,0.00012495591,0.00040142037,0.00004966921,0.000040239065,0.0028463672],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975191,0.00008416781,0.00027074802,0.00058732275,0.0007973565,0.0007413282],"domain_scores_gemma":[0.9990037,0.00012928639,0.000054422646,0.00026078403,0.0003030556,0.0002487557],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047380792,0.00018921249,0.00031754977,0.00038633568,0.00014296464,0.00007805978,0.00013499062,0.00013174616,0.0013996544],"category_scores_gemma":[0.000058229492,0.00014450749,0.000047137808,0.0005281354,0.00020569746,0.00024024947,0.00017810802,0.00063052034,0.00007693622],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011135782,0.00010885706,0.3657197,0.00055306836,0.000043665474,0.000096936186,0.0004323669,0.00006323007,0.62601966,0.000014780115,0.0005246895,0.0053094393],"study_design_scores_gemma":[0.003955082,0.00022679291,0.31067118,0.0012984617,0.000016159418,0.000005628053,0.00022908236,0.00038500116,0.68157333,0.0002424118,0.001213038,0.00018381822],"about_ca_topic_score_codex":0.0015719994,"about_ca_topic_score_gemma":0.00014216221,"teacher_disagreement_score":0.055553682,"about_ca_system_score_codex":0.00045575888,"about_ca_system_score_gemma":0.0004672628,"threshold_uncertainty_score":0.9995132},"labels":[],"label_agreement":null},{"id":"W2954170173","doi":"10.1200/jco.2013.31.15_suppl.e16086","title":"The prevalence of cardiac risk factors in men with localized prostate cancer undergoing androgren deprivation therapy in British Columbia, Canada.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Framingham Risk Score; Risk factor; Internal medicine; Radiation therapy; Cancer; Coronary artery disease; Disease","score_opus":0.04512691384684178,"score_gpt":0.39178600714049616,"score_spread":0.3466590932936544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954170173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933118,0.004022062,0.0000012846026,0.0016648374,0.0001528482,0.00067122513,0.000011603399,0.0000017734309,0.00016252299],"genre_scores_gemma":[0.92577696,0.07328363,0.000089290435,0.00007246248,0.00006952551,0.000031118492,0.0000014319684,0.000009179353,0.0006663769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762017,0.0005083543,0.0011164706,0.00013166186,0.00038786998,0.00023549906],"domain_scores_gemma":[0.99684846,0.0016850082,0.0008421079,0.00011024808,0.00036845182,0.00014573736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015670831,0.00006698649,0.0007105845,0.000038560323,0.0000442795,0.000024512718,0.000118777265,0.00011402913,0.00006929492],"category_scores_gemma":[0.0008158951,0.000047072557,0.00008742088,0.00020263412,0.00021798766,0.00010408981,0.000021630845,0.00059679965,2.2175209e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008502724,0.00019635649,0.86816597,0.00004036964,0.00018484432,0.00005553449,0.00011535131,0.000024832414,0.00001803392,2.7216313e-7,0.0011109385,0.12923723],"study_design_scores_gemma":[0.007414265,0.0032090428,0.9859616,0.0002894165,0.000052063293,0.0000089741425,0.0003983796,0.000060444963,0.00006514697,0.00009568591,0.0023954937,0.000049494418],"about_ca_topic_score_codex":0.7531492,"about_ca_topic_score_gemma":0.94053143,"teacher_disagreement_score":0.18738227,"about_ca_system_score_codex":0.00049149705,"about_ca_system_score_gemma":0.0066881557,"threshold_uncertainty_score":0.998943},"labels":[],"label_agreement":null},{"id":"W2954232647","doi":"10.1074/mcp.ra119.001612","title":"Multi-omics Biomarker Pipeline Reveals Elevated Levels of Protein-glutamine Gamma-glutamyltransferase 4 in Seminal Plasma of Prostate Cancer Patients","year":2019,"lang":"en","type":"article","venue":"Molecular & Cellular Proteomics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Calgary; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada; Government of Canada","keywords":"Prostate cancer; Biomarker; Prostate; Biomarker discovery; Proteomics; Cancer; PCA3; Cancer biomarkers; Medicine; Oncology; Cancer research; Internal medicine; Biology; Biochemistry; Gene","score_opus":0.01792547505564822,"score_gpt":0.2764582476630557,"score_spread":0.2585327726074075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954232647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897831,0.0008958014,0.00081653555,0.00018150547,0.00007850534,0.007582131,0.0005740182,0.000028245984,0.00006014548],"genre_scores_gemma":[0.9913534,0.00016683702,0.0059463517,0.000036929654,0.000015226332,0.0003549069,0.00034889558,0.00010338889,0.0016740963],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968789,0.00016558141,0.00103086,0.00060553115,0.00067582965,0.0006432894],"domain_scores_gemma":[0.9983097,0.000028107876,0.00032630234,0.00058553956,0.0005492844,0.00020106885],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050333625,0.0004148204,0.0008834976,0.00041642686,0.000030935946,0.000014132925,0.00023222929,0.00025800453,0.00013868653],"category_scores_gemma":[0.00009946304,0.0003620074,0.00021808306,0.0006960806,0.00018652821,0.00010170718,0.00009836136,0.0003962703,0.000016517282],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026308254,0.001134233,0.08979853,0.0015879734,0.00016954227,0.00014343708,0.0003685269,0.00010327663,0.9019291,0.00001109511,0.0000066554767,0.002116825],"study_design_scores_gemma":[0.013624854,0.0006703286,0.015970064,0.0010597861,0.00010154732,0.000005756653,0.00004923934,0.006038912,0.96207947,0.000029531777,0.000054054664,0.00031647913],"about_ca_topic_score_codex":0.00020054336,"about_ca_topic_score_gemma":0.000013028726,"teacher_disagreement_score":0.07382847,"about_ca_system_score_codex":0.0002846196,"about_ca_system_score_gemma":0.00045741213,"threshold_uncertainty_score":0.9998832},"labels":[],"label_agreement":null},{"id":"W2954258258","doi":"10.1158/1538-7445.am2019-3482","title":"Abstract 3482: ZBTB7A mediates the transcriptional repression activity of androgen receptor in prostate cancer cells","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Prostate cancer; Biology; Cancer research; Androgen receptor; Zinc finger; PTEN; Transcription factor; Repressor; Cancer; Psychological repression; Tumor suppressor gene; Prostate; Gene; Genetics; Gene expression; PI3K/AKT/mTOR pathway; Carcinogenesis; Signal transduction","score_opus":0.07278021274602356,"score_gpt":0.41213069250007794,"score_spread":0.3393504797540544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954258258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832038,0.008332516,3.6358585e-7,0.004784519,0.00026201396,0.0019259336,0.00019895793,0.000016875298,0.0012750005],"genre_scores_gemma":[0.98146695,0.012018301,0.000012305514,0.000035108602,0.000165814,0.00072042044,0.000028342252,0.00003284024,0.0055198898],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99721086,0.00019335945,0.00027826376,0.00047045382,0.0011951379,0.00065190817],"domain_scores_gemma":[0.9985973,0.00030469653,0.00007445389,0.00044914577,0.00040044033,0.00017394716],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012699051,0.00016109865,0.00034808478,0.0002591409,0.00010811482,0.000026903188,0.00025423145,0.0001087723,0.0030642983],"category_scores_gemma":[0.000049258324,0.00009694554,0.00010553076,0.0006960005,0.00035823867,0.0001711122,0.00008445765,0.00085540954,0.000080454876],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034687817,0.00025368165,0.076130375,0.00053121476,0.000090751346,0.000018769671,0.0012675565,0.0000711447,0.8986639,0.000018852503,0.002525892,0.016959103],"study_design_scores_gemma":[0.0032583934,0.0002570397,0.1381654,0.0008020961,0.000015413982,0.0000017214097,0.00034292816,0.00007848902,0.8467647,0.00009832944,0.010092578,0.00012294747],"about_ca_topic_score_codex":0.0026674813,"about_ca_topic_score_gemma":0.00023550821,"teacher_disagreement_score":0.06203502,"about_ca_system_score_codex":0.00052569504,"about_ca_system_score_gemma":0.0013865543,"threshold_uncertainty_score":0.997847},"labels":[],"label_agreement":null},{"id":"W2954396039","doi":"10.1200/jco.2013.31.15_suppl.5058","title":"Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant-prostate-cancer (mCRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Internal medicine; Docetaxel; Oncology; Ketoconazole; Chemotherapy; Lactate dehydrogenase; Urology; Logistic regression; Prostate-specific antigen; Cancer; Androgen deprivation therapy","score_opus":0.11061810259442041,"score_gpt":0.45901309900368137,"score_spread":0.34839499640926097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954396039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808427,0.0003475291,0.00012259695,0.016552601,0.00016607706,0.0009503413,0.000030435694,0.0000048711636,0.0009828319],"genre_scores_gemma":[0.99022686,0.00050995237,0.0067905723,0.00047749453,0.00011412596,0.000075490294,0.0000032319047,0.000022109378,0.0017801501],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9964592,0.0005657297,0.0018694849,0.00022587222,0.00054385606,0.00033588358],"domain_scores_gemma":[0.995658,0.0017726745,0.0009861597,0.00018083898,0.0009336909,0.0004686823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032465004,0.00016370695,0.0012978365,0.00029922108,0.000026463582,0.0000126603545,0.00014592725,0.00013505902,0.00033100325],"category_scores_gemma":[0.0012860729,0.000097381395,0.000161199,0.00035520957,0.000315905,0.00022296357,0.00004210836,0.0006392855,0.000016067219],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7413746,0.00419407,0.09000299,0.00019901752,0.0025486008,0.0013972371,0.0017711562,0.00093605235,0.10717302,0.000018958423,0.0070352824,0.04334901],"study_design_scores_gemma":[0.030586718,0.056566656,0.9059232,0.0004659856,0.0003722543,0.000111104506,0.0016407435,0.00025900267,0.0018667978,0.000097310396,0.0019876214,0.000122609],"about_ca_topic_score_codex":0.0003132359,"about_ca_topic_score_gemma":0.00022305938,"teacher_disagreement_score":0.81592023,"about_ca_system_score_codex":0.00037275674,"about_ca_system_score_gemma":0.003613823,"threshold_uncertainty_score":0.6410767},"labels":[],"label_agreement":null},{"id":"W2954606714","doi":"10.1158/1538-7445.am2019-ct129","title":"Abstract CT129: Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN study","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Internal medicine; Oncology; Metastasis; Cancer; Proportional hazards model; Transcriptome; Biology; Gene; Gene expression","score_opus":0.07130469458714175,"score_gpt":0.4347156962361843,"score_spread":0.3634110016490425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954606714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921704,0.00048253883,4.1359507e-7,0.0006008201,0.000058232832,0.0064574615,0.000077203134,0.000008100432,0.00014483873],"genre_scores_gemma":[0.9976596,0.000107173204,0.00003226066,0.00005544644,0.000018277486,0.0015743743,0.000011742638,0.000046663507,0.0004944088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99530363,0.0006386633,0.0005630586,0.00061193836,0.0020111657,0.0008715671],"domain_scores_gemma":[0.99824256,0.0003371206,0.000110692046,0.000668147,0.0004518106,0.0001896654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002982396,0.0002354553,0.00049839186,0.0007929897,0.00009521359,0.00007934087,0.00036731444,0.000057857655,0.00015970228],"category_scores_gemma":[0.00014809878,0.00015162976,0.0000520867,0.001721595,0.0001647578,0.00017880106,0.000105811094,0.00063270977,0.000035369852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023802752,0.0010983857,0.89411414,0.00046383444,0.000081152146,0.0007138404,0.008077349,0.0003246489,0.06733562,0.000002285328,0.000043737095,0.0039422703],"study_design_scores_gemma":[0.008327552,0.0029782706,0.96520144,0.0012137761,0.000029634468,0.0000019992403,0.0054810345,0.000029799447,0.01648532,0.000014452477,0.000073615796,0.00016312642],"about_ca_topic_score_codex":0.0060659493,"about_ca_topic_score_gemma":0.012210557,"teacher_disagreement_score":0.07108729,"about_ca_system_score_codex":0.00083969184,"about_ca_system_score_gemma":0.0012731518,"threshold_uncertainty_score":0.91699415},"labels":[],"label_agreement":null},{"id":"W2955107320","doi":"10.1158/1538-7445.am2019-1853","title":"Abstract 1853: Association of IDH genes with prostate cancer progression and their regulation by the androgen receptor","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"IDH1; Androgen receptor; Prostate cancer; Biology; Cancer research; Isocitrate dehydrogenase; Cancer; IDH2; Gene; Genetics; Mutation; Enzyme; Biochemistry","score_opus":0.035313064518755904,"score_gpt":0.385887786181679,"score_spread":0.35057472166292314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955107320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97269535,0.018479,7.748787e-7,0.006119891,0.000060874714,0.0018913497,0.00011711417,0.00001842244,0.0006172473],"genre_scores_gemma":[0.9787388,0.009665455,0.00001917056,0.000026708505,0.000111476125,0.00054552354,0.00007428861,0.00002999426,0.010788569],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981369,0.00011989481,0.00017865338,0.0003112036,0.00082984363,0.00042353914],"domain_scores_gemma":[0.9986877,0.00016788581,0.00012193356,0.00025780336,0.0006520184,0.0001126769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009739911,0.00012872084,0.00023113274,0.000101540034,0.00016849875,0.000047123565,0.0001030557,0.00009653666,0.00046531443],"category_scores_gemma":[0.000031003136,0.00006328476,0.00003416456,0.00041983792,0.00019739493,0.00013066255,0.00006010776,0.0003435084,0.0000135831115],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031467567,0.00010547554,0.37344712,0.00047258032,0.00025534045,0.0000017512385,0.0013785595,0.000010185555,0.48457673,0.000014388392,0.010606492,0.12598464],"study_design_scores_gemma":[0.0047268206,0.0009950296,0.14279766,0.0011423229,0.000041185915,0.0000041211993,0.0009748302,0.000121626574,0.79043305,0.000086127446,0.058490425,0.00018679418],"about_ca_topic_score_codex":0.0004753606,"about_ca_topic_score_gemma":0.00009032774,"teacher_disagreement_score":0.30585632,"about_ca_system_score_codex":0.00052299787,"about_ca_system_score_gemma":0.000550672,"threshold_uncertainty_score":0.5094867},"labels":[],"label_agreement":null},{"id":"W2955120427","doi":"10.1158/1078-0432.ccr-18-2387","title":"DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; American Association for Cancer Research; Evans Medical Foundation; U.S. Department of Defense","keywords":"Prostate cancer; Wnt signaling pathway; Cancer research; Kinase; Tumor progression; Biology; Cancer; Transcription factor; Prostate; Signal transduction; Gene; Cell biology; Genetics","score_opus":0.15762695585381784,"score_gpt":0.49066662108902065,"score_spread":0.3330396652352028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955120427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97852194,0.004954527,0.0000069151865,0.010291661,0.000413646,0.004833049,0.00008866628,0.00003465981,0.0008549356],"genre_scores_gemma":[0.9831406,0.0011612971,0.0001394953,0.000092878996,0.00042822052,0.001247132,0.000031376414,0.000045141565,0.013713846],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948846,0.0007365903,0.0007743339,0.0006829752,0.0022402448,0.00068125856],"domain_scores_gemma":[0.99773806,0.0002666483,0.00019637775,0.00058117276,0.0009988997,0.00021886667],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023563297,0.00020499321,0.00048131845,0.000113598355,0.0002505673,0.000042926793,0.0003419508,0.0002218447,0.0015268037],"category_scores_gemma":[0.00021250955,0.00011829243,0.0002965087,0.00066157064,0.0009685338,0.00019529651,0.00019011559,0.0011689247,0.0000449631],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007057925,0.0010112254,0.16447298,0.0010806919,0.00024265402,0.000022576436,0.0011881791,0.00010559996,0.7850469,0.0012739019,0.0005371406,0.037960246],"study_design_scores_gemma":[0.008689349,0.0019788465,0.1612725,0.0041661523,0.000068738875,0.0000039077318,0.00046200526,0.00024528187,0.80810463,0.0031753548,0.011564858,0.00026835332],"about_ca_topic_score_codex":0.00038269017,"about_ca_topic_score_gemma":0.00008349353,"teacher_disagreement_score":0.037691895,"about_ca_system_score_codex":0.0004429654,"about_ca_system_score_gemma":0.0022050529,"threshold_uncertainty_score":0.99938595},"labels":[],"label_agreement":null},{"id":"W2955350141","doi":"10.1158/1538-7445.am2019-1292","title":"Abstract 1292: A new generation of N-terminal domain androgen receptor inhibitors, with improved pharmaceutical properties, in castration-resistant prostate cancer models","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Androgen receptor; Prostate cancer; ADME; In vivo; Androgen; Potency; Chemistry; Pharmacology; Dihydrotestosterone; Cancer research; Cancer; In vitro; Pharmacokinetics; Biology; Medicine; Internal medicine; Biochemistry; Hormone; Genetics","score_opus":0.14067697070800234,"score_gpt":0.40492058545540405,"score_spread":0.2642436147474017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955350141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850658,0.008812672,0.0000033951974,0.0025434792,0.00010205606,0.0030639875,0.00008767412,0.000019959873,0.0003009577],"genre_scores_gemma":[0.9924351,0.0026115433,0.00024683203,0.00003690483,0.0003487224,0.00076900225,0.000071416056,0.000049788527,0.0034306797],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971344,0.000115842464,0.00042738704,0.0005511451,0.0010331332,0.00073808705],"domain_scores_gemma":[0.9986928,0.000037932234,0.00008339994,0.00031936256,0.00051952904,0.00034694615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065786956,0.00021750943,0.0003904316,0.00031961888,0.000089378904,0.00006021217,0.00014495004,0.00012366129,0.000601666],"category_scores_gemma":[0.00001714343,0.00014810357,0.000057985435,0.0006314168,0.0002449009,0.00031682907,0.00006260993,0.00064559956,0.000015414826],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00842746,0.00028389835,0.011011439,0.0007675232,0.0001234094,0.0000837891,0.0014381739,0.00028701982,0.9638167,0.000032669544,0.0012604572,0.012467461],"study_design_scores_gemma":[0.013498161,0.001712295,0.0034399503,0.0019915209,0.00004341046,0.000018277895,0.0006858743,0.0025095404,0.97240907,0.00008140801,0.0032703744,0.00034012596],"about_ca_topic_score_codex":0.005315199,"about_ca_topic_score_gemma":0.0018007848,"teacher_disagreement_score":0.012127334,"about_ca_system_score_codex":0.001018099,"about_ca_system_score_gemma":0.0046493206,"threshold_uncertainty_score":0.82476956},"labels":[],"label_agreement":null},{"id":"W2955542325","doi":"10.1158/1538-7445.am2019-186","title":"Abstract 186: Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Angiogenesis; Prostate cancer; Neuroendocrine differentiation; EZH2; Cancer research; CREB; Enzalutamide; Cancer; Medicine; Androgen deprivation therapy; Biology; Androgen; Internal medicine; Androgen receptor; Epigenetics; Transcription factor; Genetics; Hormone","score_opus":0.060441497380012185,"score_gpt":0.3731030837646257,"score_spread":0.3126615863846135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955542325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893174,0.0044278805,0.0000023113453,0.0026345905,0.00009860327,0.0024314057,0.000059511378,0.000046746492,0.0009815119],"genre_scores_gemma":[0.992206,0.005047892,0.000042357173,0.00007109491,0.000114385315,0.00058048795,0.00013157379,0.00005181171,0.0017543935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973094,0.00012338591,0.00030659206,0.0006417565,0.0008193723,0.0007995011],"domain_scores_gemma":[0.99893284,0.00012753405,0.00006594119,0.00037307886,0.00031366388,0.00018691579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036856142,0.00021108436,0.00033726444,0.00037765843,0.00013977876,0.00008354168,0.00013321679,0.000057933248,0.0005388996],"category_scores_gemma":[0.00008391059,0.00016986245,0.000062943975,0.0008450862,0.00016727921,0.00031805702,0.00013282336,0.00045163409,0.00004479198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019804514,0.00024162354,0.65080833,0.0011153024,0.0001522969,0.00025653106,0.0013016975,0.000040374056,0.29895025,0.000115100156,0.00056962535,0.04446842],"study_design_scores_gemma":[0.005518123,0.000651746,0.64224577,0.00051313755,0.000019237263,0.000029438028,0.0003597339,0.00025803066,0.34613326,0.00043021166,0.0035887535,0.00025252465],"about_ca_topic_score_codex":0.0032348705,"about_ca_topic_score_gemma":0.00045416478,"teacher_disagreement_score":0.04718302,"about_ca_system_score_codex":0.00082954107,"about_ca_system_score_gemma":0.0007524766,"threshold_uncertainty_score":0.692679},"labels":[],"label_agreement":null},{"id":"W2955923959","doi":"10.5489/cuaj.6136","title":"2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC)","year":2019,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Université Laval; University of Alberta; Jewish General Hospital; McMaster University; Ontario Clinical Oncology Group; Dalhousie University; University of Toronto; McGill University Health Centre; University of British Columbia; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Oncology; Internal medicine; Management of prostate cancer; Urology; Cancer","score_opus":0.04540883360861512,"score_gpt":0.3354882470064392,"score_spread":0.29007941339782406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955923959","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40412745,0.0047930013,0.000037997324,0.5687229,0.0026826204,0.0059614573,0.0024847635,0.00005002256,0.011139766],"genre_scores_gemma":[0.97286963,0.0023073107,0.00055325293,0.010581715,0.00071299094,0.0002663351,0.00032534418,0.000040576782,0.012342822],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962764,0.00025186565,0.0008374191,0.00042206922,0.0007365126,0.0014757267],"domain_scores_gemma":[0.995223,0.00044285052,0.0005991552,0.00024662027,0.0017379657,0.0017504493],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023789566,0.0002896693,0.00055775576,0.00045031155,0.0006749704,0.00014237405,0.0003409497,0.0006023316,0.001654892],"category_scores_gemma":[0.00061326317,0.00019634912,0.00029302645,0.00047403484,0.00006589275,0.00014744213,0.000024390105,0.0007386672,0.000088901324],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008608891,0.000116518495,0.7587625,0.000068219335,0.002193827,0.0002649719,0.00031241632,0.0006402685,0.00041763257,0.0016734082,0.21586624,0.018823106],"study_design_scores_gemma":[0.0027749727,0.0010624422,0.4854707,0.000041797502,0.00035863614,0.000031356,0.00026401735,0.0005040211,0.000017284032,0.00045634515,0.50881416,0.00020425924],"about_ca_topic_score_codex":0.5130995,"about_ca_topic_score_gemma":0.79988927,"teacher_disagreement_score":0.5687422,"about_ca_system_score_codex":0.011812655,"about_ca_system_score_gemma":0.005481808,"threshold_uncertainty_score":0.99925774},"labels":[],"label_agreement":null},{"id":"W2958595932","doi":"10.1016/j.euo.2019.06.001","title":"Imaging and T Category for Prostate Cancer in the 8th Edition of the Union for International Cancer Control TNM Classification","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Oncology; Medical physics; Internal medicine; Radiology","score_opus":0.024791159646288065,"score_gpt":0.3455335534015078,"score_spread":0.32074239375521973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958595932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83874935,0.0024858494,0.00055628683,0.14507525,0.0027636373,0.004813135,0.00027645286,0.00001998223,0.005260041],"genre_scores_gemma":[0.9960031,0.00050443463,0.000019948338,0.0019767294,0.00034254437,0.0004105531,0.00005452216,0.000014741033,0.0006734651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990579,0.00031408356,0.0001842365,0.00019210739,0.00008009139,0.0001715874],"domain_scores_gemma":[0.9992662,0.00026237237,0.00013322796,0.00012757661,0.00019027597,0.000020346388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007484306,0.000073339164,0.00015082826,0.00006965714,0.000052216084,0.000005302099,0.00012388598,0.000037792484,0.000032052187],"category_scores_gemma":[0.0000751543,0.00004137181,0.00004043405,0.00006313537,0.0001873104,0.000040388302,0.00002678773,0.00014372407,0.0000021754538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057457136,0.00038000089,0.8042924,0.00019352676,0.00023695565,0.000012914795,0.0028885717,0.0001993069,0.03672616,0.0026790155,0.0167629,0.12988253],"study_design_scores_gemma":[0.012698047,0.0009502569,0.81308454,0.000029920498,0.00013291712,0.000022486942,0.0004561903,0.0061126594,0.00036664217,0.0004975252,0.16557454,0.00007424381],"about_ca_topic_score_codex":0.000060029957,"about_ca_topic_score_gemma":0.000108274355,"teacher_disagreement_score":0.1572537,"about_ca_system_score_codex":0.0001236978,"about_ca_system_score_gemma":0.00018720028,"threshold_uncertainty_score":0.16870935},"labels":[],"label_agreement":null},{"id":"W2958760191","doi":"10.1038/s41571-019-0254-9","title":"Continuing to improve outcomes of men with metastatic prostate cancer","year":2019,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Context (archaeology); Oncology; Disease; Androgen deprivation therapy; Clinical trial; Internal medicine; Androgen receptor; Overall survival; Androgen; Cancer; Hormone; Biology","score_opus":0.17349663504997226,"score_gpt":0.5694412218230142,"score_spread":0.3959445867730419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958760191","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021225815,0.98231983,0.000002952274,0.0011004896,0.0007239108,0.01300254,0.00020789892,0.000026640426,0.0025944891],"genre_scores_gemma":[0.000004438131,0.97395563,0.002048439,0.0008680218,0.00030326712,0.0017181743,0.00014165237,0.00009983451,0.020860549],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99366546,0.0011493465,0.0029959783,0.0010382764,0.0005130487,0.00063792226],"domain_scores_gemma":[0.9938364,0.0023135967,0.0019523387,0.0009792094,0.00043029687,0.00048818268],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0030400339,0.0007124691,0.013323363,0.00026966314,0.000027264972,0.000012917111,0.00041013607,0.0012174882,0.00017587857],"category_scores_gemma":[0.001797909,0.0003316109,0.0016794843,0.00065576227,0.00024278418,0.000054045642,0.00021240221,0.0033443004,0.00024909884],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004318024,0.0003930276,0.0007890033,0.044640098,0.0019451306,0.00011402372,0.000040233797,4.0014257e-8,6.611271e-7,0.000028435361,0.0051933746,0.9464242],"study_design_scores_gemma":[0.0032972891,0.004097892,0.0001383365,0.03228354,0.009534668,0.000030400017,0.000009875337,6.428083e-7,0.0000016418331,0.0000057122447,0.9502921,0.0003078994],"about_ca_topic_score_codex":0.000024483286,"about_ca_topic_score_gemma":0.000034320434,"teacher_disagreement_score":0.94611627,"about_ca_system_score_codex":0.0005064616,"about_ca_system_score_gemma":0.0027661147,"threshold_uncertainty_score":0.9999136},"labels":[],"label_agreement":null},{"id":"W2959197297","doi":"10.3389/fendo.2019.00481","title":"Insulin Enhances Migration and Invasion in Prostate Cancer Cells by Up-Regulation of FOXC2","year":2019,"lang":"en","type":"article","venue":"Frontiers in Endocrinology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Cancer Council Queensland; Prostate Cancer Foundation of Australia; Prostate Cancer Foundation; Cancer Australia; Department of Health and Aged Care, Australian Government; Movember Foundation; Cure Cancer Australia Foundation; Australian Government","keywords":"LNCaP; DU145; Cancer research; Prostate cancer; Hyperinsulinemia; Metastasis; Biology; Epithelial–mesenchymal transition; Cell migration; Insulin; PI3K/AKT/mTOR pathway; Androgen receptor; Cell; Cancer; Endocrinology; Internal medicine; Medicine; Signal transduction; Cell biology; Insulin resistance","score_opus":0.010855205845632496,"score_gpt":0.2770799542778886,"score_spread":0.26622474843225613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2959197297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885726,0.009200434,0.000026637425,0.00081547437,0.00048449595,0.0006779386,0.00001478317,0.000009088471,0.0001985317],"genre_scores_gemma":[0.9843205,0.013425215,0.0003733842,0.000036893736,0.000014697731,0.00007236378,0.00005417355,0.000009137112,0.0016936295],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991252,0.000053286487,0.00022250442,0.00023527372,0.00011439226,0.00024937457],"domain_scores_gemma":[0.9997261,0.000022661607,0.00006728502,0.00011365155,0.000037206417,0.000033051812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006646466,0.000092336355,0.00027430203,0.0002665959,0.000011966576,0.0000036662832,0.000041073952,0.000058453003,0.000043344484],"category_scores_gemma":[0.000012014422,0.00007719682,0.000018504647,0.00019245148,0.00010090738,0.00009239004,0.000028479757,0.00013743553,0.0000034304578],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079154526,0.00007567532,0.77671325,0.0001326577,0.000021917958,0.000005785491,0.0007618487,0.000026214017,0.19202274,0.000016994587,0.0022444017,0.027186971],"study_design_scores_gemma":[0.006461799,0.0005205442,0.26695815,0.00018153184,0.000017333165,0.0000056941026,0.0007534006,0.0012509443,0.71935564,0.0004566981,0.0039197044,0.000118537646],"about_ca_topic_score_codex":0.00082263973,"about_ca_topic_score_gemma":0.0003301515,"teacher_disagreement_score":0.5273329,"about_ca_system_score_codex":0.00013282271,"about_ca_system_score_gemma":0.00007953413,"threshold_uncertainty_score":0.3147995},"labels":[],"label_agreement":null},{"id":"W2960318035","doi":"10.1016/j.euo.2019.06.008","title":"Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Enzalutamide; Medicine; Abiraterone; Prostate cancer; Prostate-specific antigen; Oncology; Prostate; Internal medicine; Cancer; Urology; Androgen receptor","score_opus":0.021386679673091453,"score_gpt":0.335426463842839,"score_spread":0.31403978416974754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2960318035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863395,0.004423146,0.000006149766,0.0036662435,0.0002797419,0.0028424521,0.000611679,0.00006600504,0.0017650669],"genre_scores_gemma":[0.9752952,0.014766055,0.000623064,0.00038661488,0.00013572825,0.00040439185,0.000869893,0.000062385756,0.0074566877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997641,0.00037305025,0.00037861287,0.00092647184,0.00014456309,0.00053624803],"domain_scores_gemma":[0.99865603,0.00016330852,0.00019994075,0.00034636562,0.0003447506,0.00028962275],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024130357,0.00035775415,0.0007619548,0.00036222814,0.00019038668,0.00004071156,0.000102910875,0.000115073904,0.00017118228],"category_scores_gemma":[0.000015086089,0.00026142807,0.000099808756,0.0002566671,0.0003528316,0.00017590112,0.00010656145,0.00011734812,0.00005410611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041371297,0.0012751475,0.7153254,0.000038780992,0.00501957,0.0007164977,0.0123244,0.00017138754,0.09538753,0.00012699797,0.00009419366,0.12814876],"study_design_scores_gemma":[0.026792098,0.05955995,0.6792968,0.0000133660205,0.000930913,0.00007579268,0.00063231174,0.00026262147,0.004069477,0.000024702194,0.22800197,0.00034004071],"about_ca_topic_score_codex":0.00013737718,"about_ca_topic_score_gemma":0.00046866902,"teacher_disagreement_score":0.22790776,"about_ca_system_score_codex":0.0008753116,"about_ca_system_score_gemma":0.00025575171,"threshold_uncertainty_score":0.9999838},"labels":[],"label_agreement":null},{"id":"W2961268067","doi":"10.1016/j.eururo.2019.06.026","title":"Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019:75:285–93","year":2019,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Prostate cancer; Gynecology; San Joaquin; Cancer; Urology; Oncology; Internal medicine","score_opus":0.027174212522934563,"score_gpt":0.31210722580766087,"score_spread":0.2849330132847263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961268067","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00464461,0.007581656,0.00004890586,0.9495801,0.0016391088,0.0027900923,0.00095662207,0.00027707338,0.03248186],"genre_scores_gemma":[0.019522185,0.0061691385,0.0002612048,0.85658985,0.0016763464,0.00019059582,0.0049936944,0.0006382095,0.10995875],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99312663,0.0016567319,0.0010100909,0.0016491836,0.0009537599,0.0016036035],"domain_scores_gemma":[0.9970337,0.0004651146,0.0005793944,0.0014126891,0.0002604712,0.00024860364],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010386452,0.000979438,0.0012831731,0.0006161214,0.00023998739,0.00017337706,0.0005255431,0.00034677229,0.0012741077],"category_scores_gemma":[0.00012523108,0.0008129549,0.00032252824,0.00041299418,0.00038953742,0.00017181473,0.00037338448,0.0034236468,0.002711735],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010591008,0.00011058492,0.00065088645,0.0007687101,0.00075342524,0.023070164,0.0004801862,0.00014450017,0.0019586834,0.000022688548,0.9699461,0.0010349686],"study_design_scores_gemma":[0.0043537808,0.0016022959,0.0028105527,0.00028107717,0.0006385377,0.00028814975,0.00006157041,0.00013980671,0.00015560907,0.000044428503,0.9889082,0.0007160468],"about_ca_topic_score_codex":0.00033308732,"about_ca_topic_score_gemma":0.000076178316,"teacher_disagreement_score":0.0929902,"about_ca_system_score_codex":0.00030861585,"about_ca_system_score_gemma":0.00063500076,"threshold_uncertainty_score":0.99963886},"labels":[],"label_agreement":null},{"id":"W2961781424","doi":"10.1016/j.urolonc.2019.06.007","title":"Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis","year":2019,"lang":"en","type":"review","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Meta-analysis; Prostate cancer; Cryotherapy; Radiation therapy; Systematic review; Brachytherapy; Subgroup analysis; Extracorporeal shockwave therapy; Internal medicine; Cochrane Library; Androgen deprivation therapy; Prostatectomy; Biochemical recurrence; Oncology; Cancer; MEDLINE; Surgery","score_opus":0.11895687250595288,"score_gpt":0.4086968276717142,"score_spread":0.28973995516576134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961781424","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007737594,0.9891878,0.000003873708,0.0024174994,0.000044545595,0.006926227,0.00047020335,0.000019140174,0.0001570037],"genre_scores_gemma":[0.00011901846,0.99015564,0.0008556863,0.0019973759,0.000019060464,0.005056774,0.00038281037,0.000027828295,0.0013858079],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956249,0.0014740329,0.0012998997,0.0008580296,0.0003123488,0.00043077406],"domain_scores_gemma":[0.9972838,0.0010359318,0.00076832424,0.00046151716,0.00021175535,0.00023862705],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001420588,0.0006376344,0.0071285805,0.0005710456,0.000085093234,0.000026851118,0.00014439275,0.000524789,0.00026569908],"category_scores_gemma":[0.000118444426,0.000333633,0.0007655305,0.0015036608,0.0009410855,0.00008510664,0.000099623314,0.00091934385,0.000005692902],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029420934,0.0018590145,0.02631641,0.7110363,0.17916211,0.0016285761,0.0024519744,0.000014969352,0.0000011858001,0.00043282093,0.0006453605,0.07350919],"study_design_scores_gemma":[0.0015649007,0.0060220314,0.00012994155,0.026909983,0.31285772,0.00031274182,0.0000827951,0.000016191125,0.0000011194724,0.00008547504,0.65162057,0.00039657083],"about_ca_topic_score_codex":0.000101904305,"about_ca_topic_score_gemma":0.0001684029,"teacher_disagreement_score":0.6841263,"about_ca_system_score_codex":0.00040212987,"about_ca_system_score_gemma":0.0009447042,"threshold_uncertainty_score":0.99991155},"labels":[],"label_agreement":null},{"id":"W2962751967","doi":"10.1200/jco.2013.31.15_suppl.5013","title":"A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Docetaxel; Internal medicine; Proportional hazards model; Prostate cancer; Hazard ratio; Prednisone; Oncology; Placebo; Chemotherapy; Univariate analysis; Gastroenterology; Cancer; Androgen deprivation therapy; Multivariate analysis; Confidence interval; Pathology","score_opus":0.09891359559826622,"score_gpt":0.42143479666516726,"score_spread":0.322521201066901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2962751967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944292,0.00025563597,0.00016698972,0.0023600042,0.00014863495,0.0024306253,0.00005385745,0.00001266444,0.000142396],"genre_scores_gemma":[0.993433,0.00024414223,0.0041873204,0.0002489132,0.00016140711,0.00055805617,0.000026604568,0.00004678017,0.0010938032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964732,0.00028649718,0.001718452,0.00034298262,0.00062670076,0.0005521651],"domain_scores_gemma":[0.9961487,0.0008028098,0.0011000265,0.00016901092,0.0013528022,0.00042667243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011871085,0.0002710255,0.0014259674,0.00018029475,0.000055906243,0.00004296665,0.00011504064,0.000151937,0.00008402547],"category_scores_gemma":[0.00047462637,0.00014548529,0.00017157379,0.00019981955,0.00023350434,0.00038876434,0.000028610839,0.00067970366,0.000005104203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.070211776,0.0027574317,0.91135937,0.00023501071,0.0010865459,0.00044948008,0.00046369358,0.0015508101,0.00013730134,0.000006422527,0.00020442983,0.011537713],"study_design_scores_gemma":[0.063310355,0.033187922,0.8864639,0.0006905523,0.0009911156,0.000028157048,0.00015895705,0.014566982,0.00006476741,0.00014756006,0.00017985533,0.00020991429],"about_ca_topic_score_codex":0.00020855099,"about_ca_topic_score_gemma":0.0010084917,"teacher_disagreement_score":0.03043049,"about_ca_system_score_codex":0.00040184296,"about_ca_system_score_gemma":0.0023378953,"threshold_uncertainty_score":0.5932718},"labels":[],"label_agreement":null},{"id":"W2963560224","doi":"10.1242/dmm.039297","title":"Genome-wide analysis of androgen receptor binding and transcriptomic analysis in mesenchymal subsets during prostate development","year":2019,"lang":"en","type":"article","venue":"Disease Models & Mechanisms","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University and Génome Québec Innovation Centre; McGill University Health Centre","funders":"Canadian Cancer Society Research Institute; Prostate Cancer Canada; Movember Foundation","keywords":"Biology; Chromatin immunoprecipitation; Androgen receptor; Transcriptome; Promoter; Mesenchyme; Gene; Gene expression profiling; Sexual dimorphism; Genetics; Gene expression; Mesenchymal stem cell; Prostate cancer; Endocrinology","score_opus":0.017522761705998365,"score_gpt":0.2589702000274807,"score_spread":0.24144743832148235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963560224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648017,0.0010757629,0.0011872655,0.00010564561,0.00002466161,0.00086933584,0.00017855236,0.000028573733,0.00005004781],"genre_scores_gemma":[0.9971931,0.00038797618,0.00081763754,0.000021680093,0.000005124796,0.00009223502,0.00081709865,0.000025660736,0.0006394711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980172,0.00005881288,0.00043116332,0.00055296987,0.0004980382,0.0004418313],"domain_scores_gemma":[0.9991032,0.000024947234,0.00009306752,0.00031141043,0.00008814491,0.00037926677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029125743,0.00022967537,0.00072900474,0.0016884024,0.0000668742,0.00002459413,0.00009803951,0.000064441316,0.00022927888],"category_scores_gemma":[0.0000084497005,0.00019478038,0.00026819558,0.0019455783,0.000035286794,0.00016793613,0.0000558236,0.00011596728,0.000012854517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032802827,0.0005233304,0.78915673,0.0006888873,0.01235894,0.00017259178,0.0058191447,0.009287253,0.17796527,0.00015988838,0.0000015340046,0.00058612926],"study_design_scores_gemma":[0.007067478,0.00017273526,0.8066753,0.00020806164,0.011730023,0.0000016242607,0.00095126784,0.08070747,0.09127867,0.00056228065,0.000020476871,0.000624578],"about_ca_topic_score_codex":0.00004039162,"about_ca_topic_score_gemma":0.00004687145,"teacher_disagreement_score":0.086686596,"about_ca_system_score_codex":0.00024274594,"about_ca_system_score_gemma":0.00027090302,"threshold_uncertainty_score":0.7942914},"labels":[],"label_agreement":null},{"id":"W2963791328","doi":"10.5489/cuaj.5996","title":"Switching from a GnRH agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysis","year":2019,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Prostate cancer; Meta-analysis; Agonist; Gonadotropin-releasing hormone; Medicine; Oncology; Antagonist; Internal medicine; Cancer; Hormone; Receptor; Luteinizing hormone","score_opus":0.06540352888097847,"score_gpt":0.3539277466907096,"score_spread":0.28852421780973114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963791328","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009046599,0.9853169,0.0000017443322,0.008605519,0.00007756746,0.004419513,0.0013808486,0.000012064071,0.00009539005],"genre_scores_gemma":[0.0005891506,0.99128956,0.000027479118,0.0050224396,0.000079415506,0.000784142,0.0005595606,0.00003772973,0.0016105277],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9954921,0.0009534955,0.00147456,0.0006095201,0.0006925237,0.00077782874],"domain_scores_gemma":[0.9966459,0.000375491,0.001129296,0.00030366317,0.00041087682,0.0011347415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014302925,0.0005147353,0.007282048,0.0008396267,0.00022151161,0.00029341652,0.00025178105,0.00034807058,0.0006472918],"category_scores_gemma":[0.0009980006,0.00030114682,0.0016161394,0.0013910708,0.000021810882,0.000101824124,0.000057341487,0.0012917961,0.000075671785],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009062627,0.00036295646,0.042753067,0.50626826,0.4296147,0.00095988496,0.00061698287,0.000008728366,1.8005987e-7,0.000015176514,0.0062626367,0.013046778],"study_design_scores_gemma":[0.0007770057,0.00025135628,0.0016125351,0.018993579,0.815377,0.000033602657,0.000021362759,0.000006912428,2.6315416e-8,0.00002207755,0.16247131,0.00043325382],"about_ca_topic_score_codex":0.007108689,"about_ca_topic_score_gemma":0.006286073,"teacher_disagreement_score":0.4872747,"about_ca_system_score_codex":0.0044783987,"about_ca_system_score_gemma":0.0018315596,"threshold_uncertainty_score":0.9999441},"labels":[],"label_agreement":null},{"id":"W2963802995","doi":"10.1158/1535-7163.mct-18-1337","title":"GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Ferring; U.S. Department of Defense","keywords":"Prostate cancer; Testosterone (patch); Castration; Internal medicine; Endocrinology; Leuprorelin; Androgen deprivation therapy; LNCaP; Luteinizing hormone; Hormone; Medicine; Androgen; Enzalutamide; Chemistry; Androgen receptor; Cancer; Gonadotropin-releasing hormone","score_opus":0.01493351646129815,"score_gpt":0.30932913083751007,"score_spread":0.2943956143762119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963802995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9725848,0.022730693,0.000023565424,0.0017241669,0.00033477458,0.0016254431,0.00006489934,0.000064436455,0.0008472318],"genre_scores_gemma":[0.99166614,0.0047514276,0.0001065818,0.0012763975,0.00016780538,0.00032820026,0.000060395447,0.000075723576,0.0015673398],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99814594,0.000098767894,0.00024049854,0.0005358871,0.00051105884,0.00046785703],"domain_scores_gemma":[0.99912626,0.000053642732,0.00009858741,0.00038649922,0.0001352385,0.00019975551],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011751489,0.0003274177,0.00039729648,0.00011687781,0.0001243611,0.000058758116,0.00008367391,0.00013012494,0.00008089553],"category_scores_gemma":[0.000004696652,0.00024744423,0.00009055114,0.0001560524,0.00010649111,0.000078481564,0.000052225023,0.00030466565,0.000014903635],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021750939,0.0001465679,0.024872795,0.00046165183,0.00033754887,0.00031395824,0.0005134344,0.000042580614,0.92712855,0.000011391019,0.000102856735,0.043893542],"study_design_scores_gemma":[0.004336148,0.001006522,0.008000308,0.0007201236,0.0001996853,0.000015576055,0.00005235008,0.00024439194,0.9748994,0.000060072027,0.010171467,0.0002939273],"about_ca_topic_score_codex":0.00020895139,"about_ca_topic_score_gemma":0.000054201326,"teacher_disagreement_score":0.047770847,"about_ca_system_score_codex":0.00033953524,"about_ca_system_score_gemma":0.0002740664,"threshold_uncertainty_score":0.9999978},"labels":[],"label_agreement":null},{"id":"W2964673115","doi":"10.1158/1078-0432.ccr-19-1423","title":"The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":394,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Prostate cancer; Lineage (genetic); Cancer; Resistance (ecology); Medicine; Cancer therapy; Biology; Internal medicine; Genetics; Ecology","score_opus":0.1459517182911886,"score_gpt":0.5267830732056228,"score_spread":0.3808313549144342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964673115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9529132,0.034904804,2.946393e-7,0.0040988466,0.00021648472,0.0018349888,0.000051338848,0.000018048137,0.005961963],"genre_scores_gemma":[0.897692,0.079332754,0.000022026845,0.00008909259,0.00026123473,0.00054026465,0.0000058448118,0.000032419037,0.022024358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963215,0.00049281213,0.00071271247,0.00052434934,0.0011330774,0.0008155328],"domain_scores_gemma":[0.9961531,0.002272468,0.00011270347,0.0005258939,0.00070478674,0.00023102036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002765472,0.0001542473,0.0005032504,0.0001508555,0.00014720592,0.00003697764,0.00038111754,0.00013409986,0.00049572485],"category_scores_gemma":[0.00051229104,0.00008895103,0.00015373764,0.00087822106,0.00086107437,0.00007439348,0.00015825646,0.0013723809,0.00006975241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018340385,0.000498871,0.9152297,0.0001732034,0.00015363669,0.000034814326,0.0003384478,0.000014127524,0.0062279017,0.00035948333,0.0024615254,0.056167908],"study_design_scores_gemma":[0.013378122,0.0018529337,0.56480604,0.00117773,0.000021184549,0.0000013682836,0.0008698072,0.00048189086,0.06101418,0.0014453077,0.35468966,0.00026179035],"about_ca_topic_score_codex":0.0012415062,"about_ca_topic_score_gemma":0.0018633045,"teacher_disagreement_score":0.35222813,"about_ca_system_score_codex":0.00031822844,"about_ca_system_score_gemma":0.0016791795,"threshold_uncertainty_score":0.59623885},"labels":[],"label_agreement":null},{"id":"W2964685394","doi":"10.1158/1538-7445.am2019-3698","title":"Abstract 3698: Conditionally reprogrammed cells from patient-derived xenograft to model neuroendocrine prostate cancer development","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Transdifferentiation; Prostate cancer; Cancer research; Transcriptome; Androgen receptor; LNCaP; Prostate; Biology; Cancer; Adenocarcinoma; In vivo; Progenitor cell; Stem cell; Gene; Cell biology; Gene expression; Genetics","score_opus":0.07155811418352288,"score_gpt":0.3941500161421357,"score_spread":0.3225919019586128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964685394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98694533,0.0018229835,0.000012437634,0.005402441,0.00030406594,0.003923687,0.00046696194,0.00010941127,0.001012687],"genre_scores_gemma":[0.9839502,0.0015561228,0.0009919312,0.0007476247,0.00018271014,0.0034048161,0.00042970796,0.000102968595,0.008633901],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99503505,0.00009132993,0.00049732125,0.0010882624,0.0018563047,0.0014317043],"domain_scores_gemma":[0.9972494,0.00014943244,0.00008491702,0.0007048109,0.0009725514,0.0008388691],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00032359094,0.00033161024,0.00048052325,0.0004260626,0.00026577702,0.00012739211,0.00032768425,0.000075510674,0.0030698548],"category_scores_gemma":[0.000053067004,0.0002704671,0.00011621486,0.00073789485,0.00019112673,0.00017466675,0.00033059553,0.00083256664,0.00087204075],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038361633,0.00051030534,0.013321267,0.0003307112,0.00039013938,0.00041378158,0.0021692165,0.0013120978,0.8883485,0.000015901827,0.01405306,0.07529883],"study_design_scores_gemma":[0.00536219,0.00068172376,0.031952977,0.0007100548,0.000037750597,0.000006095269,0.0004903135,0.00051524426,0.894579,0.00019566313,0.06499016,0.00047884416],"about_ca_topic_score_codex":0.0018620265,"about_ca_topic_score_gemma":0.00034859992,"teacher_disagreement_score":0.07481999,"about_ca_system_score_codex":0.0011391714,"about_ca_system_score_gemma":0.0028155795,"threshold_uncertainty_score":0.9999747},"labels":[],"label_agreement":null},{"id":"W2964764956","doi":"10.1200/jco.2009.27.15_suppl.e16050","title":"Impact of age at diagnosis on survival of hormone-refractory prostate cancer (HRPC) patients","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Proportional hazards model; Internal medicine; Hazard ratio; Log-rank test; Multivariate analysis; Survival analysis; Prostate cancer; Oncology; Retrospective cohort study; Cancer; Gastroenterology; Confidence interval","score_opus":0.14197966551182978,"score_gpt":0.5245196824229064,"score_spread":0.3825400169110766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964764956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939699,0.002012393,5.08102e-7,0.0016795255,0.0004794673,0.0003038118,0.00004623001,0.0000034892666,0.0015046349],"genre_scores_gemma":[0.98027927,0.01862179,0.00006826061,0.00022955153,0.000347427,0.0000054735538,0.000009347321,0.000012425774,0.00042648788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968264,0.00031138145,0.0018076303,0.00015736929,0.0006219114,0.0002753251],"domain_scores_gemma":[0.9955522,0.001402859,0.0017511882,0.00018460899,0.0007230584,0.0003860944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012416366,0.00014688412,0.0015326914,0.00016724477,0.000025390847,0.0000026316304,0.00014055996,0.00025998647,0.00016670689],"category_scores_gemma":[0.0014434926,0.000084325926,0.0007439963,0.00015864638,0.00024431988,0.00007932742,0.00003734934,0.0006570383,0.000005772917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027607247,0.0069193873,0.7940816,0.000021515049,0.00060271256,0.0003121453,0.00016732143,0.000017351049,0.0006945632,0.000005284993,0.010183348,0.15938753],"study_design_scores_gemma":[0.013774489,0.08719919,0.89294857,0.00012655226,0.0002049489,0.0000051685956,0.000014340772,0.000003497268,0.00042221698,0.00007952497,0.0051598568,0.00006163926],"about_ca_topic_score_codex":0.000087854765,"about_ca_topic_score_gemma":0.00002638267,"teacher_disagreement_score":0.15932588,"about_ca_system_score_codex":0.00061309873,"about_ca_system_score_gemma":0.0014416077,"threshold_uncertainty_score":0.34387115},"labels":[],"label_agreement":null},{"id":"W2964940371","doi":"10.1016/j.jcpa.2019.07.005","title":"Histopathological Terminology Standards for the Reporting of Prostatic Epithelial Lesions in Dogs","year":2019,"lang":"en","type":"review","venue":"Journal of Comparative Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Universidade Estadual Paulista; Fundação de Amparo à Pesquisa do Estado de São Paulo; University of Queensland","keywords":"Medicine; Prostatitis; Prostatic Diseases; Pathology; Hyperplasia; Prostate; Squamous metaplasia; Metaplasia; Carcinoma; Cancer; Epithelium; Internal medicine","score_opus":0.33913064147278427,"score_gpt":0.5251882089024887,"score_spread":0.18605756742970447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964940371","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008074538,0.98816586,0.00046175884,0.0003034388,0.000492859,0.0020945927,0.00015270243,0.0000038119813,0.00025045383],"genre_scores_gemma":[0.0069893193,0.9911102,0.0010161406,0.000027643504,0.00018468754,0.0001266704,0.000022665585,0.000022087283,0.00050057535],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99531335,0.0005816991,0.003159214,0.0002494727,0.00036135083,0.000334931],"domain_scores_gemma":[0.9921436,0.0016341937,0.0051263813,0.00029488537,0.0007303462,0.00007064957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031951491,0.0002768002,0.0041074394,0.0004396236,0.00005777115,0.0000071676427,0.00024237107,0.0002846893,0.000034444354],"category_scores_gemma":[0.001439743,0.00012960697,0.000744335,0.00022312204,0.0004849704,0.000039063718,0.00007739699,0.000978452,0.0000034297823],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023957351,0.0008080214,0.0019533657,0.015968619,0.00064669765,0.005592748,0.0026082324,0.000011386918,0.00027723578,0.00051887694,0.0016735496,0.9675455],"study_design_scores_gemma":[0.005158063,0.008512357,0.0034435997,0.013376077,0.0027544294,0.016152348,0.00045093824,0.00002524484,0.0001159283,0.000683868,0.9490464,0.00028079728],"about_ca_topic_score_codex":0.00000220834,"about_ca_topic_score_gemma":0.0000042662014,"teacher_disagreement_score":0.9672647,"about_ca_system_score_codex":0.00042162006,"about_ca_system_score_gemma":0.0027507707,"threshold_uncertainty_score":0.52852184},"labels":[],"label_agreement":null},{"id":"W2965677442","doi":"10.1200/jco.2013.31.15_suppl.5089","title":"The role of advanced genetic testing in the management of prostate cancer post radical prostatectomy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Internal medicine; Oncology; ERCC1; Cancer; DNA repair","score_opus":0.07133883111346599,"score_gpt":0.46307350364163186,"score_spread":0.39173467252816585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965677442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98266786,0.006030759,0.0000016660582,0.008077927,0.00018524501,0.0009839884,0.0000031047837,0.0000023984944,0.0020470407],"genre_scores_gemma":[0.99005324,0.0064348974,0.0028179686,0.00025835066,0.00014257629,0.00007066996,8.05129e-7,0.0000106495,0.00021085016],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99704236,0.0003576717,0.0017216544,0.00012296061,0.00047880114,0.0002765321],"domain_scores_gemma":[0.9960057,0.0019537045,0.0010700554,0.00019477449,0.000648882,0.0001268811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022425505,0.00009766566,0.0006737346,0.0000708805,0.000044622026,0.000008014176,0.00027379714,0.000101690915,0.000041634587],"category_scores_gemma":[0.0007008368,0.000042241063,0.00017864123,0.0002728769,0.00048543466,0.00006249637,0.000066821034,0.00065301446,0.0000037589614],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003396805,0.0009045334,0.1826932,0.00012400425,0.00033400176,0.00021867159,0.00034189515,0.000051786417,0.0014246339,0.00008202326,0.00017004528,0.8102584],"study_design_scores_gemma":[0.009210715,0.009491149,0.9621924,0.00046882502,0.00019828138,0.00008744064,0.0023294447,0.00018463709,0.0008456804,0.002007769,0.012924348,0.000059277223],"about_ca_topic_score_codex":0.00011107911,"about_ca_topic_score_gemma":0.000024713461,"teacher_disagreement_score":0.81019914,"about_ca_system_score_codex":0.00009745972,"about_ca_system_score_gemma":0.0009104049,"threshold_uncertainty_score":0.28370592},"labels":[],"label_agreement":null},{"id":"W2966148971","doi":"10.1200/jco.2007.25.18_suppl.15598","title":"The impact of varying rectal contours on rectal dose in prostate cancer patients treated with hypofractionated radiation","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Rectum; Medicine; Prostate; Radiation therapy; Prostate cancer; Nuclear medicine; Colorectal cancer; Contouring; Cancer; Rectal examination; Radiology; Urology; Surgery; Internal medicine","score_opus":0.08003228879996803,"score_gpt":0.5004281065897211,"score_spread":0.4203958177897531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966148971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961613,0.00040267018,0.000001170382,0.0012375178,0.0002814438,0.00042021825,0.0000071482646,0.0000043076166,0.0014842687],"genre_scores_gemma":[0.99747133,0.0019255681,0.000040388506,0.00008809736,0.00022993388,0.000006099863,0.000009011773,0.00001255794,0.00021701913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770916,0.00027522387,0.0012478448,0.00012374096,0.00037951232,0.00026453164],"domain_scores_gemma":[0.9954421,0.002413538,0.0012190273,0.00008584583,0.0006324658,0.00020701025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023865134,0.00010973464,0.0006569197,0.00018431195,0.000050101695,0.000006228104,0.000069818234,0.00015437481,0.000030962445],"category_scores_gemma":[0.00137486,0.000050536393,0.00021204722,0.0003007128,0.00017040664,0.00012949471,0.000010297889,0.0007864803,0.0000017636023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07960672,0.0015235018,0.6783653,0.0000053440185,0.00039042428,0.00026124416,0.00009998194,0.000096147145,0.0002202383,0.000002120312,0.00034926113,0.23907971],"study_design_scores_gemma":[0.020959383,0.03162516,0.945537,0.0001466344,0.00008247754,0.000035843364,0.000055172954,0.0000897775,0.0008162364,0.000024035957,0.00057810405,0.000050209786],"about_ca_topic_score_codex":0.00055867084,"about_ca_topic_score_gemma":0.00015582313,"teacher_disagreement_score":0.26717165,"about_ca_system_score_codex":0.0009088133,"about_ca_system_score_gemma":0.0016931155,"threshold_uncertainty_score":0.34169096},"labels":[],"label_agreement":null},{"id":"W2966212079","doi":"10.1200/jco.2006.24.18_suppl.4637","title":"Blood-based biomarkers for detecting aggressive prostate cancer at time of biopsy","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Prostate cancer; Medicine; Biopsy; Cancer; Stage (stratigraphy); Prostate; Prostate biopsy; Oncology; PCA3; Internal medicine; Pathology; Biology","score_opus":0.08479941927181094,"score_gpt":0.47610155031681495,"score_spread":0.391302131045004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966212079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919402,0.0026982948,0.000030252484,0.0038360944,0.00042550257,0.0004651964,0.000033463035,0.000007228033,0.0005637699],"genre_scores_gemma":[0.9914468,0.0004535024,0.004525563,0.0003004987,0.0009519704,0.000029303694,0.000010520209,0.000026322294,0.002255505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751765,0.00016226052,0.0015741785,0.00016427465,0.00029832238,0.00028329113],"domain_scores_gemma":[0.99425375,0.0021722151,0.0024902634,0.00011909388,0.0007600628,0.0002046308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017567916,0.000116904455,0.001034094,0.00015711582,0.000055811463,0.000004209195,0.00009992754,0.00024409892,0.0001502103],"category_scores_gemma":[0.0015916679,0.00007418921,0.0005140975,0.00015991434,0.00031716906,0.000043613578,0.00003087571,0.00032192285,0.000004893267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072747745,0.0036666791,0.64522606,0.00048733223,0.0028682856,0.0023189536,0.00010392075,0.00013990483,0.07883336,0.00001112296,0.012167607,0.18142901],"study_design_scores_gemma":[0.15232363,0.0737276,0.4425651,0.0023842803,0.0050417366,0.0011685153,0.00015802411,0.0024750708,0.25693774,0.00097310764,0.061705112,0.00054008374],"about_ca_topic_score_codex":0.0000729681,"about_ca_topic_score_gemma":0.000034210254,"teacher_disagreement_score":0.20266096,"about_ca_system_score_codex":0.00022406987,"about_ca_system_score_gemma":0.002028489,"threshold_uncertainty_score":0.35984522},"labels":[],"label_agreement":null},{"id":"W2968796117","doi":"10.1016/j.dib.2019.104372","title":"RNA sequencing data of human prostate cancer cells treated with androgens","year":2019,"lang":"en","type":"article","venue":"Data in Brief","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Androgen receptor; Prostate cancer; Transcriptome; LNCaP; Biology; Cancer research; Androgen; Computational biology; Cancer; Gene expression; Gene; Endocrinology; Genetics; Hormone","score_opus":0.0916552379481301,"score_gpt":0.3666382353949506,"score_spread":0.27498299744682053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968796117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992231,0.0007746582,9.91304e-7,0.0002080974,0.000029144996,0.0007807195,0.0045943595,0.000020410718,0.0013605879],"genre_scores_gemma":[0.98773104,0.00065604557,0.00018604157,0.00006592067,0.00003777298,0.000017174578,0.009262507,0.00002686767,0.0020166591],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987032,0.000027921697,0.00020737972,0.00049566664,0.0002837579,0.00028211245],"domain_scores_gemma":[0.99780893,0.000026119584,0.00007389133,0.0019440192,0.000064516025,0.0000825015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023703839,0.0001238875,0.0002979075,0.00009854902,0.000028836226,0.000016144044,0.00045263013,0.000043713753,0.0002761943],"category_scores_gemma":[0.000011254108,0.00008502739,0.000011029829,0.0002962067,0.000098725,0.00029365235,0.00037519707,0.00015346434,0.000017980396],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008554117,0.00020806985,0.6085275,0.0005566259,0.00025725286,0.0003397199,0.00046143445,0.000012680337,0.3789121,0.000015528087,0.005653976,0.0041997004],"study_design_scores_gemma":[0.029684447,0.002716219,0.13896589,0.003564824,0.00060938165,0.00008098995,0.0012504824,0.0039220527,0.78555405,0.00003067931,0.032762907,0.000858054],"about_ca_topic_score_codex":0.0062151025,"about_ca_topic_score_gemma":0.00079343346,"teacher_disagreement_score":0.4695616,"about_ca_system_score_codex":0.00013351932,"about_ca_system_score_gemma":0.00034718885,"threshold_uncertainty_score":0.9395417},"labels":[],"label_agreement":null},{"id":"W2969441845","doi":"10.1158/0008-5472.can-19-0815","title":"ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Canadian Institutes of Health Research; Terry Fox Foundation; Prostate Cancer Canada; National Cancer Institute; Government of Canada; Congressionally Directed Medical Research Programs; Natural Sciences and Engineering Research Council of Canada; Princess Margaret Cancer Foundation","keywords":"Androgen receptor; Prostate cancer; Psychological repression; Cancer research; Biology; Prostate; Internal medicine; Cancer; Endocrinology; Medicine; Genetics; Gene; Gene expression","score_opus":0.07559345992792177,"score_gpt":0.41638582505105604,"score_spread":0.34079236512313427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969441845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752174,0.008049604,2.7516487e-7,0.013381639,0.00027940393,0.0020272192,0.000112193855,0.000010777241,0.0009214793],"genre_scores_gemma":[0.98346204,0.00538356,0.000004992926,0.000060275815,0.00013899733,0.00083501684,0.000009940398,0.000023355624,0.010081821],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99739647,0.00035022714,0.00020132647,0.00036156355,0.0011744377,0.00051594817],"domain_scores_gemma":[0.9987589,0.00022477805,0.00005736421,0.0005151032,0.00034081787,0.00010301546],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011177381,0.00012261853,0.0002499024,0.00013923501,0.00014833357,0.000020417598,0.0003189314,0.00007823367,0.001730478],"category_scores_gemma":[0.00008518197,0.000058098685,0.00010447739,0.0008607273,0.00043893428,0.000111448,0.00013442563,0.00078265707,0.000028496994],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026838395,0.00017742082,0.38853684,0.00031557397,0.00008799093,0.000005551311,0.0018167819,0.00005132603,0.5887141,0.00007347969,0.0029903953,0.014546713],"study_design_scores_gemma":[0.0040572654,0.00026333664,0.3691359,0.0010565583,0.000024336758,0.0000037858265,0.00048434985,0.0001721377,0.60271007,0.00026855743,0.02169883,0.00012488138],"about_ca_topic_score_codex":0.0019456877,"about_ca_topic_score_gemma":0.00051495695,"teacher_disagreement_score":0.019400936,"about_ca_system_score_codex":0.0004861856,"about_ca_system_score_gemma":0.0012276354,"threshold_uncertainty_score":0.9991821},"labels":[],"label_agreement":null},{"id":"W2969587751","doi":"10.1200/jco.2013.31.15_suppl.5048","title":"The ELDORADO study: A phase II randomised study of concurrent weekly docetaxel, IMRT, and ltadt in patients with high-risk prostate cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Capital District Health Authority; Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Prostatectomy; Urology; Randomized controlled trial; Radiation therapy; Prostate; Clinical endpoint; Internal medicine; Chemotherapy; Androgen deprivation therapy; Hazard ratio; Nomogram; Oncology; Cancer; Confidence interval","score_opus":0.05951183498378078,"score_gpt":0.4611538331424246,"score_spread":0.4016419981586438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969587751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920884,0.0011948164,9.519018e-7,0.0024256434,0.00042379793,0.003815186,0.000009112729,0.0000034743703,0.000038611564],"genre_scores_gemma":[0.99684924,0.0025372556,0.000034065637,0.00006259104,0.00017049561,0.00013111657,0.0000016165154,0.000013929832,0.00019971468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99584335,0.00093168265,0.002141796,0.00021587538,0.0005816545,0.0002856124],"domain_scores_gemma":[0.99472266,0.0021668437,0.0018000535,0.0001915231,0.000812834,0.00030610914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002917554,0.00016305661,0.0015081965,0.00011543735,0.00012218046,0.000017211565,0.00015419944,0.00009972709,0.00004927851],"category_scores_gemma":[0.0012945763,0.00007282005,0.00011238638,0.00019244157,0.00033633685,0.00012366954,0.00009322286,0.0009453807,0.0000014175791],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074179135,0.025648385,0.7065064,0.000016249696,0.0009027768,0.0001000774,0.0012900586,0.000004749599,0.0000062412455,0.0000018131548,0.0005529968,0.19079117],"study_design_scores_gemma":[0.30610055,0.150396,0.5406662,0.00006434115,0.00040057325,0.0000029499415,0.0015743821,0.000017565597,0.000006591045,0.000031493317,0.0006892416,0.000050049814],"about_ca_topic_score_codex":0.00071565475,"about_ca_topic_score_gemma":0.0004817256,"teacher_disagreement_score":0.23192142,"about_ca_system_score_codex":0.00014244662,"about_ca_system_score_gemma":0.0010479497,"threshold_uncertainty_score":0.41072613},"labels":[],"label_agreement":null},{"id":"W2970060261","doi":"10.1200/jco.2012.30.15_suppl.e15201","title":"Retrospective mathematical analysis of serial prostate specific antigen (PSA) measurements for patients with M0 prostate cancer treated with intermittent androgen suppression (IAS).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Androgen; Cancer; Prostate; Androgen suppression; Oncology; Internal medicine; Hormone","score_opus":0.1363414104488418,"score_gpt":0.45210160383356635,"score_spread":0.31576019338472455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970060261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99691767,0.0004133697,0.00006937675,0.00055214885,0.00026646856,0.0014397902,0.00011686504,0.000007755288,0.00021658448],"genre_scores_gemma":[0.9964859,0.0006653102,0.002108607,0.00004570828,0.00035177695,0.00005880388,0.000056334888,0.000031911466,0.00019565965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965602,0.00024817913,0.001606972,0.0002590135,0.0008669099,0.00045873557],"domain_scores_gemma":[0.995511,0.0003035662,0.0016637612,0.00022223058,0.0018132142,0.00048624194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017192549,0.00022355947,0.0019595844,0.00030194587,0.000065157285,0.000012434759,0.00012964057,0.00020167737,0.00015110905],"category_scores_gemma":[0.00033929426,0.000112408015,0.0004289535,0.00045832206,0.00031852847,0.00020750746,0.0000421755,0.00040284038,0.0000016552375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.071295656,0.0044281497,0.9073178,0.00008567921,0.0071490295,0.000035613735,0.00047302266,0.000014497938,0.00047082079,0.0000059319905,0.00047094355,0.008252842],"study_design_scores_gemma":[0.024445355,0.023772262,0.94322634,0.0003834952,0.0042682076,0.000013108027,0.000115312614,0.00004978991,0.0025119127,0.000025247005,0.001055031,0.00013396345],"about_ca_topic_score_codex":0.000015981828,"about_ca_topic_score_gemma":0.000015608743,"teacher_disagreement_score":0.0468503,"about_ca_system_score_codex":0.00043926467,"about_ca_system_score_gemma":0.0006968178,"threshold_uncertainty_score":0.45838657},"labels":[],"label_agreement":null},{"id":"W2970783342","doi":"10.1200/jco.2013.31.15_suppl.e16044","title":"Impact of a genomic classifier of metastatic risk on treatment recommendations post-radical prostatectomy: Report from the DECIDE study group.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Biochemical recurrence; Oncology; Internal medicine; Metastasis; Population; Cancer","score_opus":0.20661035193145635,"score_gpt":0.5353371366803238,"score_spread":0.3287267847488674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970783342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914905,0.00035218865,0.000039920167,0.006116719,0.00031152988,0.001338158,0.00007270293,0.0000043141363,0.00027398262],"genre_scores_gemma":[0.996247,0.0012771029,0.001746327,0.00015723259,0.00027774673,0.00004427723,0.00004042951,0.000018230561,0.00019164756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995068,0.0012490518,0.002791104,0.00022031844,0.0004358076,0.00023567905],"domain_scores_gemma":[0.98929167,0.0065991627,0.0026925448,0.00041533567,0.00066777744,0.00033353092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002632008,0.0001785432,0.0016237147,0.00013617439,0.00005715811,0.000009977589,0.00018109218,0.00013367807,0.0007783473],"category_scores_gemma":[0.0026636948,0.00007607901,0.00086182373,0.00014528871,0.00033751162,0.00008613863,0.000047812675,0.0007612885,0.000024552894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010681015,0.015832594,0.8131486,0.00000741027,0.0062181544,0.00088851305,0.0006637036,0.000012444568,0.0010995732,0.0000056456925,0.0031794608,0.14826289],"study_design_scores_gemma":[0.014332616,0.07960068,0.9014808,0.00005649957,0.00110145,0.00015634477,0.0008521143,0.000037918897,0.000070973154,0.0004714283,0.001784287,0.00005488033],"about_ca_topic_score_codex":0.00231428,"about_ca_topic_score_gemma":0.0001855095,"teacher_disagreement_score":0.148208,"about_ca_system_score_codex":0.0006026897,"about_ca_system_score_gemma":0.002592846,"threshold_uncertainty_score":0.85223573},"labels":[],"label_agreement":null},{"id":"W2971040096","doi":"10.1038/s41388-019-0966-4","title":"BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer","year":2019,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"National Institute of General Medical Sciences; National Cancer Institute; Houston Methodist Research Institute; University of Texas MD Anderson Cancer Center; University of Arizona; National Heart, Lung, and Blood Institute; PTC Therapeutics","keywords":"BMI1; Prostate cancer; Androgen receptor; Biology; Cancer research; Downregulation and upregulation; PTEN; Cancer; Carcinogenesis; Dihydrotestosterone; Internal medicine; Androgen; Endocrinology; Signal transduction; Gene; Medicine; Cell biology; Genetics; PI3K/AKT/mTOR pathway; Hormone","score_opus":0.015995790080157106,"score_gpt":0.3147430008322803,"score_spread":0.2987472107521232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971040096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843044,0.0049518147,0.0000012776826,0.0055802255,0.00013157894,0.0017996855,0.00022864467,0.00004366867,0.0029586938],"genre_scores_gemma":[0.82825536,0.0011219392,0.0010507657,0.00059555453,0.00009652503,0.00038146385,0.00024764918,0.000056361987,0.16819438],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985447,0.00003081291,0.00024040273,0.00043442653,0.00034267263,0.00040702027],"domain_scores_gemma":[0.999307,0.000012968113,0.000052546413,0.0002775858,0.00013636383,0.00021357283],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014901004,0.00017164626,0.0002949121,0.00010507159,0.00004278617,0.000025319394,0.00008427036,0.00007191307,0.0010400786],"category_scores_gemma":[0.000014013129,0.00013926212,0.00004873358,0.00053223135,0.000029666991,0.00008395306,0.000029904259,0.00012813053,0.00032149226],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015103576,0.00019628793,0.03787018,0.000144039,0.00010429638,0.000054117456,0.0014643646,0.000004951214,0.90547496,0.000005306277,0.03693187,0.01623926],"study_design_scores_gemma":[0.0037534279,0.00041898008,0.003890395,0.00042745954,0.000029009461,0.0000051416046,0.000060410035,0.000041337207,0.753611,0.000021908423,0.23750865,0.00023223669],"about_ca_topic_score_codex":0.0003264568,"about_ca_topic_score_gemma":0.00041793665,"teacher_disagreement_score":0.20057678,"about_ca_system_score_codex":0.00042047762,"about_ca_system_score_gemma":0.00034290532,"threshold_uncertainty_score":0.9998731},"labels":[],"label_agreement":null},{"id":"W2972441271","doi":"10.1002/cam4.2551","title":"Current trend of worsening prognosis of prostate small cell carcinoma: A population‐based study","year":2019,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"York University; National Cancer Institute; NYU Langone Medical Center","keywords":"Medicine; Prostate cancer; Incidence (geometry); Proportional hazards model; Prostate; Internal medicine; Oncology; Epidemiology; Stage (stratigraphy); Hazard ratio; Population; T-stage; Surveillance, Epidemiology, and End Results; Radiation therapy; Urology; Cancer; Cancer registry; Confidence interval","score_opus":0.05510181549834309,"score_gpt":0.3554434653858933,"score_spread":0.3003416498875502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972441271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857538,0.010501518,0.000006237282,0.0005770038,0.00034250366,0.0022297576,0.000031644686,0.00002256973,0.0005349717],"genre_scores_gemma":[0.99836606,0.00014551368,0.0000855023,0.00002954541,0.00014502068,0.00020669,0.00011241583,0.000028645838,0.00088060665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982744,0.000059632173,0.00050484284,0.00033273816,0.000536324,0.00029209294],"domain_scores_gemma":[0.99894047,0.000074515774,0.00025730324,0.0003431303,0.00022819926,0.00015638075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025890462,0.00019377582,0.00066221587,0.00032469473,0.000029160994,0.0000025224067,0.00010250448,0.00004291588,0.00045131912],"category_scores_gemma":[0.000028858978,0.00012922393,0.00008381486,0.0005898673,0.000085087624,0.000036929094,0.000036129477,0.00019589659,0.0000033475426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008577199,0.0007551309,0.97727823,0.0015083387,0.00006648064,0.000013121942,0.0023098527,0.000028986802,0.0042159655,0.0000034934837,0.00021136887,0.012751303],"study_design_scores_gemma":[0.016489124,0.0037300463,0.9582774,0.0013528543,0.00047151177,0.0000012316953,0.0014134758,0.00024142819,0.017196741,0.000008045155,0.0006782939,0.00013986033],"about_ca_topic_score_codex":0.0009616249,"about_ca_topic_score_gemma":0.00010296095,"teacher_disagreement_score":0.019000849,"about_ca_system_score_codex":0.00016829676,"about_ca_system_score_gemma":0.00031209717,"threshold_uncertainty_score":0.5269599},"labels":[],"label_agreement":null},{"id":"W2972597654","doi":"10.1016/j.ijrobp.2019.06.1882","title":"When Biochemical Failure Does Not Mean Cancer Recurrence in Men Treated by External Beam Radiotherapy and Adjuvant Hormones for Intermediate Risk Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Prostate cancer; External beam radiotherapy; Radiation therapy; Cancer; Hormonal therapy; Biochemical recurrence; Prostatectomy; Oncology; Prostate; Internal medicine; Population; Stage (stratigraphy); Urology","score_opus":0.01359482401197764,"score_gpt":0.34207267997418617,"score_spread":0.3284778559622085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972597654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842756,0.0081389025,0.00038959537,0.004882431,0.00085838797,0.0007587215,0.0006618054,0.000016692356,0.000017882752],"genre_scores_gemma":[0.9611697,0.036033954,0.0008214052,0.00034928106,0.0010034263,0.00013936148,0.00014598084,0.00003222754,0.00030462758],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983394,0.00012436791,0.0006306431,0.00033101437,0.00026487905,0.00030969016],"domain_scores_gemma":[0.9981416,0.00033172613,0.00074909214,0.00010921624,0.0005161443,0.00015224372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043395685,0.00023079208,0.0005675031,0.00018028745,0.000043227712,0.000033341857,0.00024983127,0.00020481585,0.0000808291],"category_scores_gemma":[0.00009660442,0.00015545358,0.00013819401,0.00010068983,0.00021084904,0.00024837902,0.00004350804,0.0004751731,0.0000026801172],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038949996,0.00024758346,0.71650666,0.00002420206,0.0005896775,0.000013104895,0.0013683749,0.00003661375,0.13973181,0.00004608943,0.0028140005,0.13472688],"study_design_scores_gemma":[0.106575914,0.010673255,0.27257353,0.0017282196,0.00080962776,0.00022772419,0.00087442744,0.017344503,0.527836,0.009378265,0.050649837,0.0013286817],"about_ca_topic_score_codex":0.0003195253,"about_ca_topic_score_gemma":0.000053925847,"teacher_disagreement_score":0.44393313,"about_ca_system_score_codex":0.0011061023,"about_ca_system_score_gemma":0.0004779937,"threshold_uncertainty_score":0.6339213},"labels":[],"label_agreement":null},{"id":"W2972616208","doi":"10.1200/jco.2019.37.15_suppl.11510","title":"Validating the Cancer and Aging Research Group (CARG) toxicity prediction tool in older men receiving chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) and extending it to androgen receptor targeted agents.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Common Terminology Criteria for Adverse Events; Cabazitaxel; Androgen deprivation therapy; Internal medicine; Docetaxel; Chemotherapy; Cancer; Adverse effect; Oncology; Toxicity; Gynecology; Androgen receptor","score_opus":0.17855848709716127,"score_gpt":0.5171520446218073,"score_spread":0.33859355752464604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972616208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754164,0.0026219229,0.000039549835,0.019424515,0.00037715104,0.0019571064,0.000035595847,0.0000056064337,0.00012212804],"genre_scores_gemma":[0.9846915,0.009402939,0.0031192307,0.0010676924,0.00049366616,0.00023446618,0.000009102833,0.000029296827,0.00095212646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706215,0.00052983203,0.0012026599,0.0003336353,0.00047097937,0.00040075558],"domain_scores_gemma":[0.99685836,0.0018539584,0.00046596423,0.00013801454,0.0004750743,0.00020864101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008364225,0.00013696178,0.00073231,0.00021201678,0.00015003885,0.00005525201,0.00011344679,0.00012386941,0.00013624919],"category_scores_gemma":[0.0011095931,0.00008442269,0.000102318176,0.00029778684,0.00013275917,0.00021186145,0.00006669587,0.0007265941,9.863577e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010985883,0.00082274445,0.46257293,0.00048757548,0.0008287383,0.000060812126,0.004556079,0.00009326499,0.05905248,0.000071018585,0.0067340466,0.45373443],"study_design_scores_gemma":[0.039106596,0.015224874,0.875074,0.003279572,0.00047059727,0.00010093608,0.0072029326,0.0039060488,0.008445986,0.00094786455,0.045863423,0.0003771155],"about_ca_topic_score_codex":0.00026489285,"about_ca_topic_score_gemma":0.0003170357,"teacher_disagreement_score":0.4533573,"about_ca_system_score_codex":0.00053982047,"about_ca_system_score_gemma":0.0012478799,"threshold_uncertainty_score":0.34426573},"labels":[],"label_agreement":null},{"id":"W2972750797","doi":"10.2217/ije-2019-0008","title":"Treatment-Emergent Neuroendocrine Prostate Cancer: Molecularly Driven Clinical Guidelines","year":2019,"lang":"en","type":"article","venue":"International Journal of Endocrine Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Université Laval","funders":"","keywords":"Prostate cancer; Medicine; Malignancy; Mechanism (biology); Androgen receptor; Cancer; Transdifferentiation; Prostate; Androgen deprivation therapy; Bioinformatics; Cancer research; Internal medicine; Biology","score_opus":0.0837851580259454,"score_gpt":0.4946137543436482,"score_spread":0.4108285963177028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972750797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9373639,0.0024887656,0.000038917882,0.052397408,0.004661649,0.0004946695,0.000034015193,0.000020293897,0.0025003613],"genre_scores_gemma":[0.9450559,0.035419855,0.002210142,0.0014157983,0.0021401425,0.00003876337,0.0000485856,0.0000422894,0.01362854],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975665,0.00012359493,0.0011092129,0.00025806142,0.0006122851,0.00033029565],"domain_scores_gemma":[0.9970878,0.00013485292,0.0005000359,0.00019120678,0.0018174138,0.00026872783],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014545061,0.00019886726,0.0006264322,0.0003160423,0.00002418435,0.000022917151,0.00029843012,0.00003654118,0.0009749706],"category_scores_gemma":[0.00020912357,0.00013469487,0.0004157254,0.000119327015,0.00008907526,0.00014512912,0.000102806815,0.00032932934,0.00008340062],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009100301,0.0020486398,0.6201716,0.000030105464,0.003324732,0.022432324,0.0001120422,0.0002851074,0.016329348,0.00030945623,0.01152862,0.31432775],"study_design_scores_gemma":[0.031059153,0.01489186,0.025009826,0.00017549616,0.0003871482,0.009886977,0.00020876105,0.0009397752,0.010754917,0.00017031092,0.9063004,0.0002153521],"about_ca_topic_score_codex":0.00012600342,"about_ca_topic_score_gemma":0.000026354855,"teacher_disagreement_score":0.8947718,"about_ca_system_score_codex":0.0006690766,"about_ca_system_score_gemma":0.0010940955,"threshold_uncertainty_score":0.99993825},"labels":[],"label_agreement":null},{"id":"W2972867814","doi":"10.1016/j.ijrobp.2019.06.1823","title":"Transcriptomic Heterogeneity in Pathological Grade Group 5 Prostate Cancer: Implications for Biomarker Discovery","year":2019,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Transcriptome; Pathological; Biomarker discovery; Biomarker; Oncology; Cancer; Internal medicine; Computational biology; Gene; Proteomics; Genetics; Gene expression","score_opus":0.04762069954430768,"score_gpt":0.3951542926788061,"score_spread":0.3475335931344984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972867814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822976,0.0014630301,0.002994115,0.010681281,0.0013040599,0.0008486632,0.0002973347,0.000019673786,0.00009424581],"genre_scores_gemma":[0.9945136,0.0028890083,0.00086295395,0.0006324992,0.0005561899,0.00013722171,0.00028428173,0.000022809307,0.0001014894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985407,0.0001393251,0.0005971123,0.00027289093,0.00016529074,0.00028469542],"domain_scores_gemma":[0.9987092,0.00025852484,0.00042992266,0.0001367359,0.00036191172,0.000103728744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004552414,0.0001680818,0.000442169,0.00019157674,0.000045282162,0.000029528876,0.0002604817,0.00019061752,0.000025234254],"category_scores_gemma":[0.000069055575,0.00012755924,0.0002728468,0.0001704223,0.00014641485,0.00033020796,0.000033129774,0.0003225503,0.000008339704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016006565,0.0006651729,0.8539446,0.000020298532,0.0003514322,0.000015458998,0.00018965335,0.00009528219,0.070064396,0.0034190635,0.00028999717,0.06934399],"study_design_scores_gemma":[0.017672407,0.0021105157,0.9434126,0.000101695194,0.00012504972,0.0001489755,0.000070199814,0.00094300805,0.005847139,0.013145675,0.016204989,0.00021773421],"about_ca_topic_score_codex":0.000024372674,"about_ca_topic_score_gemma":0.000021014906,"teacher_disagreement_score":0.089468025,"about_ca_system_score_codex":0.00100951,"about_ca_system_score_gemma":0.00049065973,"threshold_uncertainty_score":0.52017146},"labels":[],"label_agreement":null},{"id":"W2972890374","doi":"10.1158/1078-0432.ccr-19-1050","title":"Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":267,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Mercator Research Center Ruhr; Astellas Pharma; Gilead Sciences; Sirtex Medical; Pfizer; Deutsche Forschungsgemeinschaft; Eli Lilly and Company","keywords":"Prostate cancer; Glutamate carboxypeptidase II; Positron emission tomography; Medicine; Castration; Prostate; Antigen; Cancer; Oncology; Internal medicine; Nuclear medicine; Immunology; Hormone","score_opus":0.09734563871892155,"score_gpt":0.4529922809155325,"score_spread":0.35564664219661096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972890374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773841,0.009377801,0.0000017461632,0.0051260116,0.00015245649,0.0045456737,0.00011965646,0.000049968163,0.0032425765],"genre_scores_gemma":[0.9622724,0.025090793,0.0002170576,0.0001051317,0.0002306634,0.0009481093,0.00011864648,0.000088266526,0.010928905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942345,0.00052234164,0.0009250031,0.0011631468,0.0018439984,0.0013110022],"domain_scores_gemma":[0.997172,0.0005455901,0.0001531941,0.0007290957,0.0007496296,0.00065050105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027648325,0.00035247568,0.00085677835,0.000608495,0.00021691182,0.00014403395,0.0003043845,0.00020651433,0.0007789399],"category_scores_gemma":[0.00007807176,0.00023417089,0.00017388392,0.0018909923,0.0006279218,0.00026646582,0.00014265913,0.0015666998,0.000103639606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030126937,0.0009880897,0.8336318,0.0008319799,0.0003356781,0.0005647411,0.0011013458,0.000054596163,0.11315555,0.000034381268,0.004259956,0.01491491],"study_design_scores_gemma":[0.030159786,0.0083713485,0.825186,0.0040451214,0.00011550786,0.000021788836,0.0018693904,0.0005051193,0.10111202,0.0002439528,0.0275607,0.0008092792],"about_ca_topic_score_codex":0.001863176,"about_ca_topic_score_gemma":0.0006934695,"teacher_disagreement_score":0.023300743,"about_ca_system_score_codex":0.0005782951,"about_ca_system_score_gemma":0.0020119098,"threshold_uncertainty_score":0.9549211},"labels":[],"label_agreement":null},{"id":"W2972940023","doi":"10.1101/752709","title":"MicroRNA-194 promotes lineage plasticity in advanced prostate cancer","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Human Genome Research Institute; National Health and Medical Research Council; Medical Research Council; Northwestern University; State Government of Victoria; University of South Australia; Monash University; Australian Cancer Research Foundation; Prostate Cancer Foundation of Australia; Marshfield Clinic Research Foundation; Prostate Cancer Foundation; Movember Foundation; National Breast Cancer Foundation; Victorian Cancer Agency","keywords":"Prostate cancer; Chromoplexy; Biology; Cancer research; microRNA; Androgen receptor; Metastasis; Prostate; Transcription factor; Cancer; Gene; PCA3; Genetics","score_opus":0.0177504214290494,"score_gpt":0.27701391315312207,"score_spread":0.25926349172407265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972940023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98815167,0.0053352094,0.00004637325,0.0008365398,0.00094213657,0.003752959,0.00064004015,0.0002714084,0.00002365384],"genre_scores_gemma":[0.9930454,0.0032183584,0.0016924968,0.00018124668,0.00039920906,0.0010724171,0.0000025522327,0.00019494272,0.00019340684],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962291,0.000106540065,0.0006676708,0.0013788962,0.0005889165,0.001028874],"domain_scores_gemma":[0.9975767,0.0000944507,0.00034613145,0.0009898765,0.0005940141,0.00039881282],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003411263,0.00072231924,0.0010858481,0.0004982199,0.00009327642,0.0001227319,0.0003769499,0.00058865664,0.000120091114],"category_scores_gemma":[0.00022662025,0.00064328447,0.00019463527,0.00065057696,0.00017927532,0.00015716172,0.0005185296,0.0016335495,0.00012955115],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010339151,0.00057450985,0.2085672,0.0030104874,0.00032494837,0.00048435509,0.000053721684,0.00022593647,0.7853885,0.00001899346,0.00030358892,0.000013837232],"study_design_scores_gemma":[0.0046523893,0.00027257993,0.2945234,0.0035924974,0.00017888709,3.8014615e-8,0.0000055808796,0.0006704645,0.69156295,8.2931774e-7,0.003777162,0.00076320616],"about_ca_topic_score_codex":0.00024816874,"about_ca_topic_score_gemma":0.000022437018,"teacher_disagreement_score":0.09382553,"about_ca_system_score_codex":0.0011637014,"about_ca_system_score_gemma":0.002566459,"threshold_uncertainty_score":0.99960184},"labels":[],"label_agreement":null},{"id":"W2973096717","doi":"10.1158/1078-0432.ccr-19-1587","title":"Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"National Institutes of Health; National Cancer Institute; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Prostate cancer; Androgen receptor; Medicine; Oncology; Prostatectomy; Docetaxel; Internal medicine; Cancer; Androgen deprivation therapy; Biochemical recurrence; Androgen; Cancer research; Hormone","score_opus":0.147179231300564,"score_gpt":0.48289782879195847,"score_spread":0.33571859749139443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973096717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867038,0.0052268095,0.000001383752,0.003018658,0.00031414683,0.0032598155,0.0005623907,0.00003565505,0.0008773556],"genre_scores_gemma":[0.9659401,0.029040249,0.000058162466,0.00015278174,0.00023420418,0.0013643282,0.0000652268,0.00006751562,0.0030774088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953485,0.0007927382,0.0007234491,0.0009739261,0.0009715166,0.001189862],"domain_scores_gemma":[0.99741954,0.0007474549,0.00015228851,0.000658305,0.0005260557,0.00049637037],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017425764,0.00033549138,0.001170564,0.000320979,0.00009336769,0.00003021121,0.00027879258,0.0003195097,0.0005165472],"category_scores_gemma":[0.00013076582,0.00025118928,0.0003939762,0.0008946484,0.00070022163,0.00018463073,0.0001231413,0.0010803144,0.00006971427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031701524,0.0027514463,0.77068,0.00090566836,0.0005397347,0.00009939221,0.0007513319,0.000023174875,0.104594715,0.000007784502,0.00043354477,0.087511696],"study_design_scores_gemma":[0.026259251,0.0060983524,0.49279588,0.0012191931,0.00013148585,0.000013490234,0.0002520539,0.00019550712,0.4616331,0.000081687045,0.010868144,0.00045184718],"about_ca_topic_score_codex":0.004800032,"about_ca_topic_score_gemma":0.0021359976,"teacher_disagreement_score":0.35703838,"about_ca_system_score_codex":0.0029451798,"about_ca_system_score_gemma":0.004822368,"threshold_uncertainty_score":0.99999404},"labels":[],"label_agreement":null},{"id":"W2973229141","doi":"10.1016/j.ijrobp.2019.06.1768","title":"Use of Combined Hormone Therapy with Post-Operative Radiation Treatment for Prostate Cancer: Impact of Randomized Trials On Clinical Practice","year":2019,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Randomized controlled trial; Radiation therapy; Urology; Clinical trial; Cancer; Adjuvant; Internal medicine; Surgery","score_opus":0.10300422657517705,"score_gpt":0.4918085196979737,"score_spread":0.38880429312279663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973229141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98832226,0.0018620678,0.000699055,0.004700262,0.00073152606,0.0031428677,0.00045845704,0.0000097602,0.00007375686],"genre_scores_gemma":[0.97090423,0.025488272,0.0019645223,0.0003340706,0.0006938731,0.00012620424,0.00032378998,0.00002735834,0.00013767336],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964093,0.0012703326,0.0015644402,0.00021696577,0.00035668403,0.00018226467],"domain_scores_gemma":[0.9854475,0.007837458,0.0033220702,0.00015159675,0.0031324902,0.00010884762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025679814,0.000221636,0.00188396,0.00021031417,0.000033145203,0.000019654215,0.0001354072,0.00017747591,0.000042476946],"category_scores_gemma":[0.0024709492,0.00012142639,0.00083810696,0.00013602817,0.00024069211,0.0003562189,0.000012604422,0.00024456833,0.000003215636],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6254148,0.0028684768,0.107581936,0.000009744075,0.0121586025,0.000011053661,0.0010484988,0.0015554142,0.01175044,0.0010716195,0.00040483006,0.2361246],"study_design_scores_gemma":[0.76316774,0.14745522,0.050202973,0.00022993238,0.0015193531,0.000054070824,0.00020458797,0.0027784447,0.026509358,0.00090983714,0.006702637,0.0002658408],"about_ca_topic_score_codex":0.00017803088,"about_ca_topic_score_gemma":0.0000025154502,"teacher_disagreement_score":0.23585875,"about_ca_system_score_codex":0.0010000311,"about_ca_system_score_gemma":0.0022433912,"threshold_uncertainty_score":0.49516246},"labels":[],"label_agreement":null},{"id":"W2973708704","doi":"10.1186/s12964-019-0410-y","title":"Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling","year":2019,"lang":"en","type":"article","venue":"Cell Communication and Signaling","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Queen's University","funders":"National Cancer Institute; Memorial Sloan-Kettering Cancer Center; New York State Department of Health","keywords":"Wnt signaling pathway; Cancer research; LNCaP; Prostate cancer; Epithelial–mesenchymal transition; Biology; Signal transduction; Metastasis; Cancer; Cell biology; Genetics","score_opus":0.022578530940854227,"score_gpt":0.2997226443446721,"score_spread":0.2771441134038179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973708704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99364924,0.0028565384,0.00018016796,0.00060107786,0.000017728997,0.00054371916,0.0000029116616,0.00001913979,0.002129469],"genre_scores_gemma":[0.9941212,0.0032072456,0.0017178623,0.00007926473,0.000018288925,0.00002256439,0.000056763896,0.000017530534,0.0007592607],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990914,0.000084141786,0.0002698457,0.00020103029,0.0001874788,0.00016609079],"domain_scores_gemma":[0.9990952,0.00021902983,0.00012770132,0.0003364268,0.00014538957,0.000076229204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002845983,0.00011989608,0.00026119716,0.00006745828,0.00013771688,0.00003069937,0.000095936724,0.000067015266,0.00007299736],"category_scores_gemma":[0.000017162607,0.00009768593,0.000043156833,0.00014104892,0.00015524362,0.00015540558,0.00010133178,0.00018268032,0.000005921573],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048868114,0.00019669264,0.06897166,0.0006153513,0.00007451471,0.000002944803,0.0054249517,0.00009291858,0.92180353,0.00031109006,0.000027184047,0.0019904897],"study_design_scores_gemma":[0.0031093627,0.00036004456,0.012256384,0.00059269136,0.00007231017,0.000006440766,0.0022227417,0.0011591816,0.9788185,0.00059378,0.0006326866,0.00017590832],"about_ca_topic_score_codex":0.000077621975,"about_ca_topic_score_gemma":0.0000015100845,"teacher_disagreement_score":0.05701495,"about_ca_system_score_codex":0.000043645243,"about_ca_system_score_gemma":0.00010482123,"threshold_uncertainty_score":0.39835167},"labels":[],"label_agreement":null},{"id":"W2974579064","doi":"10.1016/j.eururo.2019.08.034","title":"Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7–expressing Metastatic Castration-resistant Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute","keywords":"Enzalutamide; Prostate cancer; Medicine; Androgen receptor; Androgen deprivation therapy; Internal medicine; Oncology; Clinical endpoint; Circulating tumor cell; Androgen; Docetaxel; Urology; Randomized controlled trial; Cancer research; Cancer; Metastasis; Hormone","score_opus":0.04215919260931933,"score_gpt":0.3414474701722842,"score_spread":0.2992882775629649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974579064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871427,0.0014714727,0.0007708204,0.0012799172,0.0006803672,0.0076480852,0.00038543862,0.000055560235,0.00056564726],"genre_scores_gemma":[0.98995245,0.0006152641,0.0066108503,0.000120943005,0.00023605456,0.00068588834,0.00051478785,0.00011756626,0.001146191],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947075,0.0025676389,0.0010630741,0.00070700137,0.00036630806,0.0005884265],"domain_scores_gemma":[0.99680823,0.0017404116,0.0005182299,0.0004929658,0.00025812932,0.00018202585],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034302557,0.00034629626,0.0012254495,0.00037115568,0.00010046211,0.000027645952,0.00018217172,0.000103704144,0.00042733544],"category_scores_gemma":[0.0009067261,0.0002846009,0.00024321265,0.00033638102,0.00020699874,0.00018914731,0.000069351794,0.00027548714,0.000045587174],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7759287,0.0005080666,0.000017545808,0.000130064,0.0005157098,0.00010647445,0.0013715561,0.00068938674,0.21886395,0.000025800515,0.00014747406,0.0016952956],"study_design_scores_gemma":[0.97160506,0.00586003,0.000064668544,0.00013220732,0.0005641953,0.000025118848,0.00013929361,0.008070175,0.009915848,0.000025624246,0.003326315,0.00027147497],"about_ca_topic_score_codex":0.00012416493,"about_ca_topic_score_gemma":0.00001819841,"teacher_disagreement_score":0.20894809,"about_ca_system_score_codex":0.00020096872,"about_ca_system_score_gemma":0.00046522697,"threshold_uncertainty_score":0.9999606},"labels":[],"label_agreement":null},{"id":"W2976281902","doi":"10.1093/annonc/mdz397","title":"Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital; Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development; Language Literacy and Culture, University of Maryland, Baltimore County","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Cancer; Gynecology","score_opus":0.0779698794022533,"score_gpt":0.4204154286154851,"score_spread":0.3424455492132318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976281902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876883,0.0013357683,7.060028e-7,0.005076903,0.000104551014,0.00063858187,0.000033537424,0.000005758415,0.0051158676],"genre_scores_gemma":[0.9945003,0.002502604,0.00010777585,0.0003347493,0.000026211106,0.00005059811,0.000020734107,0.00001069912,0.0024463776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990637,0.000060333783,0.00024581674,0.00019447358,0.00016629812,0.00026941625],"domain_scores_gemma":[0.9994596,0.00011810785,0.000080113066,0.00012448382,0.00012957571,0.00008806607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030193335,0.00009616456,0.00038333912,0.00012919428,0.000016071474,0.0000057157145,0.000039879727,0.00005243901,0.0001578791],"category_scores_gemma":[0.000029804767,0.000073895964,0.00003666466,0.00012356909,0.00009660532,0.000067846464,0.00002868605,0.00013080306,0.000013789318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010478238,0.0012984884,0.74203795,0.0013830074,0.00052252196,0.0007903586,0.0039105844,0.00013989117,0.14341861,0.0009557933,0.0025842574,0.0924803],"study_design_scores_gemma":[0.01117942,0.006250497,0.9603745,0.00028381508,0.000054029522,0.000022414362,0.000660101,0.00035827953,0.010251452,0.0009389399,0.009451497,0.0001750738],"about_ca_topic_score_codex":0.0010797135,"about_ca_topic_score_gemma":0.0007354115,"teacher_disagreement_score":0.21833654,"about_ca_system_score_codex":0.000062527295,"about_ca_system_score_gemma":0.0004503366,"threshold_uncertainty_score":0.301339},"labels":[],"label_agreement":null},{"id":"W2976350229","doi":"10.1007/s12032-019-1317-6","title":"SOX4 is activated by C-MYC in prostate cancer","year":2019,"lang":"en","type":"article","venue":"Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Natural Science Foundation of China","keywords":"SOX4; Oncogene; Cancer research; Prostate cancer; Cancer; Biology; Gene; Medicine; Gene expression; Internal medicine; Cell cycle; Promoter; Genetics","score_opus":0.020557177494425094,"score_gpt":0.3938727522268237,"score_spread":0.3733155747323986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976350229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93622893,0.0012682008,0.0000011005105,0.05236054,0.00031977257,0.0007152014,0.000018594632,0.000036067795,0.009051578],"genre_scores_gemma":[0.9339614,0.0036970046,0.000034913366,0.0074248323,0.00012734394,0.00021624428,0.000064341206,0.000024619585,0.054449286],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99844074,0.000079325866,0.00023531084,0.00029729187,0.0004895085,0.00045781472],"domain_scores_gemma":[0.9992536,0.00015917592,0.000042377604,0.00016137693,0.000052267034,0.00033125805],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002883241,0.000119044795,0.00041453628,0.000096537566,0.000021291564,0.0000044350104,0.00010601071,0.00023935284,0.0183261],"category_scores_gemma":[0.0001162128,0.000071979724,0.00004095891,0.00029845317,0.00015355065,0.000043347514,0.0000631208,0.00052613084,0.0003701973],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008539522,0.0016622974,0.40253696,0.0002993082,0.00024462203,0.0024895798,0.0019039941,6.060109e-7,0.032823022,0.00003567149,0.26074994,0.2887145],"study_design_scores_gemma":[0.017131295,0.0027779203,0.015308113,0.00029237109,0.000032380423,0.00007636072,0.00027455445,0.00023435043,0.026097795,0.00005784673,0.9375484,0.00016860414],"about_ca_topic_score_codex":0.00055766536,"about_ca_topic_score_gemma":0.00022446857,"teacher_disagreement_score":0.67679846,"about_ca_system_score_codex":0.00056960055,"about_ca_system_score_gemma":0.0017893037,"threshold_uncertainty_score":0.9825713},"labels":[],"label_agreement":null},{"id":"W2976445677","doi":"10.1200/po.19.00123","title":"Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Astellas Pharma; Prostate Cancer Canada; Emil Aaltosen Säätiö; Prostate Cancer Foundation; Jane ja Aatos Erkon Säätiö; DOD Prostate Cancer Research Program; Medical Research Council; Movember Foundation","keywords":"Prostate cancer; Androgen receptor; Oncology; Castration; Internal medicine; Medicine; Prostate; Biology; Cancer; Cancer research; Hormone","score_opus":0.02958628538235672,"score_gpt":0.3815232097330643,"score_spread":0.35193692435070756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976445677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993748,0.00093499984,0.000021988915,0.0005372631,0.00033770592,0.001794842,0.00038286144,0.000033087403,0.0022092154],"genre_scores_gemma":[0.98075384,0.0031312716,0.003053806,0.00006191954,0.000034383524,0.00027949322,0.0003616304,0.000029854824,0.012293786],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99722403,0.00023087306,0.0007451006,0.0005777144,0.0006682571,0.0005540398],"domain_scores_gemma":[0.99795926,0.00039509166,0.00033995314,0.0004833456,0.00049871113,0.0003236457],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045064426,0.00024362018,0.0009898867,0.00030286104,0.00009181119,0.0000127965595,0.0001369521,0.00014158759,0.014664332],"category_scores_gemma":[0.0001275651,0.0001794063,0.00026508447,0.0009728352,0.00014227597,0.00010966717,0.000120154626,0.00020743182,0.00042650203],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01402488,0.0008357749,0.81669855,0.00020890636,0.0041711642,0.00011379767,0.0017508653,0.00047001793,0.12930937,0.000030499476,0.0056640604,0.026722124],"study_design_scores_gemma":[0.048342027,0.011764313,0.30938816,0.00056928856,0.012903925,0.000115374954,0.003693846,0.01482165,0.44182882,0.00022522395,0.15495344,0.0013939213],"about_ca_topic_score_codex":0.0007895362,"about_ca_topic_score_gemma":0.00090568373,"teacher_disagreement_score":0.50731033,"about_ca_system_score_codex":0.0006740436,"about_ca_system_score_gemma":0.0009369663,"threshold_uncertainty_score":0.9862364},"labels":[],"label_agreement":null},{"id":"W2976879024","doi":"10.15252/emmm.201910659","title":"The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer","year":2019,"lang":"en","type":"article","venue":"EMBO Molecular Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Natural Science Foundation of China; National Cancer Institute; Foundation for the National Institutes of Health","keywords":"Mutant; Prostate cancer; Cancer research; Wild type; Cancer; Biology; Chemistry; Genetics; Gene","score_opus":0.014220274830566985,"score_gpt":0.31557352588087206,"score_spread":0.3013532510503051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976879024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9555305,0.010543839,0.0000045648785,0.030161139,0.00043348756,0.0014996954,0.00002575888,0.000027354083,0.0017736645],"genre_scores_gemma":[0.9900338,0.0033550386,0.000040581235,0.0018888032,0.00025435933,0.0000931849,0.000044980497,0.000049159546,0.0042400733],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979668,0.00005199036,0.00031527953,0.00047356883,0.00064812787,0.00054421707],"domain_scores_gemma":[0.9989918,0.000098346725,0.00008901932,0.00039535327,0.0001877869,0.00023771328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033315507,0.00026351277,0.00045654565,0.00016288638,0.000099183606,0.000019801555,0.00009847519,0.000108274646,0.00020847892],"category_scores_gemma":[0.00011590774,0.00015010254,0.000049361675,0.00052590383,0.00034620598,0.000075153876,0.00009839096,0.00046495657,0.000030052675],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00442121,0.0002643397,0.027413886,0.00032107253,0.00053569424,0.0010570246,0.0080209775,0.000008409142,0.9218176,0.00030040674,0.0026608899,0.033178497],"study_design_scores_gemma":[0.06021358,0.008709786,0.21840702,0.0049908226,0.0007608408,0.00046483302,0.007087348,0.001237508,0.56241137,0.0007873785,0.13372049,0.0012090339],"about_ca_topic_score_codex":0.00063379435,"about_ca_topic_score_gemma":0.00006541795,"teacher_disagreement_score":0.35940623,"about_ca_system_score_codex":0.00022352801,"about_ca_system_score_gemma":0.00035701637,"threshold_uncertainty_score":0.6121004},"labels":[],"label_agreement":null},{"id":"W2977464555","doi":"10.1093/annonc/mdz248.040","title":"Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prevention of Organ Failure; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Androgen receptor; Oncology; Internal medicine; Antiandrogen; Castration; Enzalutamide; Androgen; Urology; Cancer; Hormone","score_opus":0.05544022874472218,"score_gpt":0.3598241595572264,"score_spread":0.30438393081250426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977464555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947565,0.00029628584,0.000003153745,0.0014076466,0.0000289172,0.0022361877,0.00008591224,0.0000148446015,0.0011705032],"genre_scores_gemma":[0.9972878,0.00097532215,0.00027065675,0.00026658273,0.000015655885,0.00025896172,0.00037690788,0.000027016096,0.00052105763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985181,0.00015505028,0.0003563159,0.0003318645,0.00029150798,0.0003471807],"domain_scores_gemma":[0.99894166,0.0000921158,0.00019588952,0.00019314031,0.00048384542,0.000093369155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021333354,0.00018845809,0.0005249001,0.00030790677,0.000037146307,0.000010335281,0.000056699926,0.00008782102,0.00010725238],"category_scores_gemma":[0.000021690876,0.00012875818,0.00003595048,0.00059629633,0.00013047566,0.00019874732,0.000013553912,0.00017849679,0.000015297539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013228053,0.0010999694,0.9510194,0.00007316049,0.00046787132,0.00010903506,0.0034917665,0.00047588994,0.0025046219,0.00004904038,0.0002390852,0.027242117],"study_design_scores_gemma":[0.048199125,0.022686517,0.86807615,0.00054484425,0.00011634704,0.000031349602,0.0016876308,0.0006646524,0.055556595,0.000078550875,0.001955556,0.0004026849],"about_ca_topic_score_codex":0.0011616186,"about_ca_topic_score_gemma":0.0033164928,"teacher_disagreement_score":0.08294324,"about_ca_system_score_codex":0.00034811962,"about_ca_system_score_gemma":0.0008857195,"threshold_uncertainty_score":0.5250606},"labels":[],"label_agreement":null},{"id":"W2977570602","doi":"10.21769/bioprotoc.3075","title":"Ex vivo Culture and Lentiviral Transduction of Benign Prostatic Hyperplasia (BPH) Samples","year":2018,"lang":"en","type":"article","venue":"BIO-PROTOCOL","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Medical Research Council; Prostate Cancer UK; Wellcome Trust","keywords":"Ex vivo; Prostate; Transduction (biophysics); Biology; Cell culture; Cancer research; Stroma; Immunohistochemistry; Hyperplasia; Cell growth; In vivo; Viral vector; Cell biology; Pathology; Molecular biology; Gene; Immunology; Medicine; Recombinant DNA; Cancer; Genetics; Endocrinology","score_opus":0.040969522099501575,"score_gpt":0.3642650076793495,"score_spread":0.32329548557984794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977570602","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14376016,0.000040363768,0.00009405949,0.0005835594,0.00008313562,0.848137,0.000079922385,0.0000862089,0.007135558],"genre_scores_gemma":[0.22342546,0.000010318455,0.0017341903,0.000057266774,0.00040248898,0.7681919,0.000028659797,0.000032650893,0.00611708],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99900305,0.00004056867,0.00020878155,0.0002597193,0.00025842045,0.00022946294],"domain_scores_gemma":[0.99948996,0.000014109036,0.000063344196,0.00018521113,0.0001476105,0.000099785735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114044604,0.00014461424,0.0002259123,0.00008294584,0.00009132962,0.000019598141,0.00005273852,0.00009084119,0.0003751189],"category_scores_gemma":[0.000023124832,0.000095046926,0.000057920075,0.00016926345,0.0003534366,0.00010118248,0.000020566915,0.00009984816,0.000018106844],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00820506,0.001023654,0.06982363,0.0032361732,0.0002867838,0.00003937675,0.005059345,1.453542e-7,0.853574,0.0007975672,0.012998739,0.044955544],"study_design_scores_gemma":[0.010367381,0.0048480844,0.020281749,0.00038852528,0.000088952285,0.00006404142,0.0006100965,0.000032325443,0.7265047,0.000408393,0.23620208,0.00020367562],"about_ca_topic_score_codex":0.000053124488,"about_ca_topic_score_gemma":0.00001818302,"teacher_disagreement_score":0.22320333,"about_ca_system_score_codex":0.00004547711,"about_ca_system_score_gemma":0.00010658014,"threshold_uncertainty_score":0.41072887},"labels":[],"label_agreement":null},{"id":"W2977585775","doi":"10.1007/978-3-030-22254-3_16","title":"Resolution of Cellular Heterogeneity in Human Prostate Cancers: Implications for Diagnosis and Treatment","year":2019,"lang":"en","type":"review","venue":"Advances in experimental medicine and biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Prostate Cancer UK","keywords":"Tumour heterogeneity; Genetic heterogeneity; Prostate; Prostate cancer; Context (archaeology); Medicine; Cell of origin; Tumor heterogeneity; Penetrance; Pathology; Cancer research; Biology; Cancer; Phenotype; Internal medicine; Gene; Genetics","score_opus":0.19543015622668855,"score_gpt":0.51115923580372,"score_spread":0.31572907957703145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977585775","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021155175,0.9755788,0.0000027324786,0.00014948897,0.00008003695,0.0028332456,0.00009727592,0.000005576463,0.00009769286],"genre_scores_gemma":[0.025732711,0.9709509,0.000081331076,0.000021383517,0.00007851614,0.0025040621,0.0005762386,0.00001608595,0.000038759918],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99875134,0.00006953354,0.0004594702,0.00043234386,0.000040592928,0.00024670523],"domain_scores_gemma":[0.99939585,0.00017528384,0.00016010068,0.00017802807,0.00002328517,0.000067458524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000110263114,0.00024284805,0.0012703063,0.00026010175,0.000036764457,0.0000018160758,0.000049357317,0.0001479933,0.000006893426],"category_scores_gemma":[0.000017715844,0.00014867102,0.00007311626,0.00015251811,0.00040004408,0.00004855451,0.00004137254,0.00009274853,2.389644e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002411097,0.0003770376,0.026664719,0.0064606504,0.0001356983,0.0000064253773,0.00056725205,3.1016657e-7,0.0029572628,0.00041641577,0.000021982236,0.9621511],"study_design_scores_gemma":[0.008231219,0.013017371,0.0004548466,0.012198456,0.00045098626,0.000028822136,0.0005585985,0.000005260307,0.0046283677,0.00025166787,0.9598611,0.0003133066],"about_ca_topic_score_codex":0.00033858255,"about_ca_topic_score_gemma":0.00016844226,"teacher_disagreement_score":0.9618378,"about_ca_system_score_codex":0.00044967394,"about_ca_system_score_gemma":0.00010250743,"threshold_uncertainty_score":0.60626286},"labels":[],"label_agreement":null},{"id":"W2977703368","doi":"10.1016/j.urolonc.2019.09.004","title":"Efficacy and toxicity outcomes of elderly castrate-resistant prostate cancer patients treated with docetaxel—A pooled analysis of 3 randomized studies","year":2019,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Prostate cancer; Docetaxel; Proportional hazards model; Hazard ratio; Adverse effect; Survival analysis; Incidence (geometry); Cancer; Confidence interval","score_opus":0.027363252507344043,"score_gpt":0.3475226745891153,"score_spread":0.3201594220817712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977703368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99322534,0.0036737025,9.4857313e-7,0.0014127813,0.00002548611,0.001263047,0.00009604659,0.00001529977,0.00028737143],"genre_scores_gemma":[0.9946822,0.0026245757,0.0015866008,0.00011878493,0.0000056560534,0.00012715167,0.00007621597,0.000007733971,0.00077109213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865544,0.00017997128,0.00043899793,0.0003038912,0.00020271703,0.00021896031],"domain_scores_gemma":[0.9984397,0.00063819584,0.00032734204,0.00014595287,0.0003118822,0.00013690314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032990112,0.00019189696,0.0014826274,0.0003171997,0.00007880636,0.0000075309263,0.000046878104,0.00010240129,0.000041197585],"category_scores_gemma":[0.00016042595,0.0001068454,0.00009779222,0.0005733844,0.0013302639,0.00006304019,0.00003139498,0.0001417731,6.673642e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02399188,0.00040186866,0.9648172,0.00011606513,0.006834729,0.000020508198,0.0009816585,0.000055913577,0.0020468922,0.00029398795,0.00003914563,0.00040014897],"study_design_scores_gemma":[0.20275792,0.021615004,0.7301635,0.00033200695,0.03241678,0.000013435285,0.0010462435,0.0006677928,0.008141922,0.00068587734,0.0017694473,0.00039007212],"about_ca_topic_score_codex":0.0002936371,"about_ca_topic_score_gemma":0.000112574715,"teacher_disagreement_score":0.23465371,"about_ca_system_score_codex":0.00007411979,"about_ca_system_score_gemma":0.00023185163,"threshold_uncertainty_score":0.49014127},"labels":[],"label_agreement":null},{"id":"W2977827677","doi":"10.1093/annonc/mdz244.065","title":"EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Oncology; Internal medicine; Prostate; Androgen; Cancer research; Cancer; Urology; Hormone","score_opus":0.0977279940487419,"score_gpt":0.4305434687220062,"score_spread":0.33281547467326433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977827677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97007674,0.005487258,0.000006788206,0.021143049,0.0002460909,0.0021394067,0.00043884295,0.000007700954,0.00045409496],"genre_scores_gemma":[0.9696661,0.016555807,0.0009712105,0.0010414367,0.00039702878,0.001013014,0.00007909947,0.000039071874,0.010237182],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989497,0.000029173594,0.00030458,0.00022186602,0.00017618215,0.00031847693],"domain_scores_gemma":[0.99893695,0.00024422488,0.00017695341,0.00024953764,0.00030564534,0.00008667743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020814988,0.00013624715,0.0004892572,0.00005886607,0.00004264491,0.000003562807,0.000084389576,0.00010487578,0.0003496473],"category_scores_gemma":[0.000014656943,0.00007577695,0.00019696653,0.00012333134,0.0001870751,0.000036509904,0.000021770558,0.000063732245,0.000015895355],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029185966,0.0071794474,0.09330225,0.0009226884,0.002967586,0.000044445493,0.016858451,0.000009854824,0.12265595,0.00032077503,0.046310533,0.68024206],"study_design_scores_gemma":[0.011099842,0.023723844,0.0030431096,0.00011528922,0.00013881229,0.00001692007,0.0005717671,0.000039669558,0.2638674,0.00012949161,0.69715667,0.00009720878],"about_ca_topic_score_codex":0.00020740415,"about_ca_topic_score_gemma":0.000035846708,"teacher_disagreement_score":0.68014485,"about_ca_system_score_codex":0.0001221077,"about_ca_system_score_gemma":0.00053488463,"threshold_uncertainty_score":0.38283926},"labels":[],"label_agreement":null},{"id":"W2978152795","doi":"10.1093/annonc/mdz239.006","title":"Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Abiraterone acetate; Internal medicine; Enzalutamide; Oncology; Androgen receptor; Androgen deprivation therapy; Cancer","score_opus":0.08036228356401187,"score_gpt":0.3968418177278611,"score_spread":0.3164795341638492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978152795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952836,0.0001856862,6.911298e-7,0.00056542805,0.00003789877,0.0033547077,0.00012030452,0.000004777426,0.0004469039],"genre_scores_gemma":[0.9994513,0.00008597551,0.000030435876,0.000044855362,0.0000099145,0.00009571602,0.000128999,0.000014649849,0.000138204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979027,0.0005227498,0.0003620521,0.0002266475,0.00077954715,0.00020629159],"domain_scores_gemma":[0.9973894,0.000298196,0.00043125698,0.00021064046,0.0016294539,0.00004105334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010747026,0.00012823736,0.0005268312,0.000084133615,0.00002215251,0.000003526983,0.00007009379,0.00006723888,0.000066074404],"category_scores_gemma":[0.00012993197,0.000073334224,0.00003099004,0.0002853824,0.00017873223,0.000077048426,0.000027965842,0.00013971796,0.0000019211898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018932378,0.0026735605,0.94944227,0.000033927812,0.0016732835,0.000011332304,0.0102813095,0.0023905342,0.0010182499,0.0000016514429,0.000087488355,0.013454012],"study_design_scores_gemma":[0.032440264,0.014746296,0.9460975,0.0003173483,0.0003999059,3.3367905e-7,0.0015925146,0.0004513906,0.0038716702,0.0000094112875,0.000007699685,0.00006566626],"about_ca_topic_score_codex":0.0025550758,"about_ca_topic_score_gemma":0.0050179157,"teacher_disagreement_score":0.013507884,"about_ca_system_score_codex":0.0002477302,"about_ca_system_score_gemma":0.0011302761,"threshold_uncertainty_score":0.38625273},"labels":[],"label_agreement":null},{"id":"W2978592473","doi":"10.1158/1538-7445.am2015-1846","title":"Abstract 1846: Catalytic topoisomerase II inhibitors suppress the androgen receptor signaling and prostate cancer progression","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Androgen receptor; Prostate cancer; LNCaP; Cancer research; Androgen; Cell growth; Androgen Receptor Antagonists; Biology; Internal medicine; Cancer; Chemistry; Endocrinology; Medicine; Biochemistry; Hormone","score_opus":0.0919581761973258,"score_gpt":0.4281808869955901,"score_spread":0.33622271079826427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978592473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9474346,0.0353047,2.46147e-7,0.014158743,0.00027100235,0.0020222503,0.00010143722,0.00005601395,0.000651026],"genre_scores_gemma":[0.98736036,0.0049957293,0.000031298598,0.00009933614,0.0007083485,0.0014518357,0.000074001495,0.000058417798,0.0052206577],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996537,0.00015769889,0.00030385435,0.000576791,0.0014870885,0.00093751005],"domain_scores_gemma":[0.9977966,0.00015609401,0.00007168568,0.00043771023,0.0008293715,0.00070853153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015746604,0.00023886231,0.00032172078,0.0002308142,0.00067748263,0.00014802387,0.00023961565,0.00012884907,0.00029727645],"category_scores_gemma":[0.0001784991,0.00013839429,0.000067679146,0.00068047014,0.00072234747,0.00023834666,0.00035879784,0.00088659313,0.00003926193],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010385251,0.0009885007,0.12803146,0.0018517342,0.0008109603,0.00060432835,0.025381435,0.00009072517,0.41123533,0.00007141623,0.16892184,0.25162703],"study_design_scores_gemma":[0.009105236,0.0016316466,0.00567664,0.0023065088,0.00012728845,0.000046307516,0.005107698,0.00013310311,0.8360151,0.00027401056,0.1390328,0.0005436295],"about_ca_topic_score_codex":0.0017724633,"about_ca_topic_score_gemma":0.00011681963,"teacher_disagreement_score":0.4247798,"about_ca_system_score_codex":0.00070922106,"about_ca_system_score_gemma":0.0016203669,"threshold_uncertainty_score":0.5643555},"labels":[],"label_agreement":null},{"id":"W2978727884","doi":"10.1007/s12149-019-01404-2","title":"Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients","year":2019,"lang":"en","type":"article","venue":"Annals of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Royal College of Physicians and Surgeons of Canada","keywords":"Enzalutamide; Medicine; Prostate cancer; Glutamate carboxypeptidase II; Antiandrogen; Positron emission tomography; Oncology; Abiraterone acetate; Internal medicine; Nuclear medicine; Radiology; Urology; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.10402733841596169,"score_gpt":0.39113567825469575,"score_spread":0.2871083398387341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978727884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961463,0.0006380771,1.497112e-7,0.0017247614,0.000052935677,0.0011633245,0.00010338869,0.0000049604555,0.00016605745],"genre_scores_gemma":[0.99883664,0.0006921316,0.00005411551,0.00018905698,0.0000208188,0.000043355303,0.00007071551,0.000021935675,0.000071215014],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981179,0.000095796364,0.0004224359,0.0002144982,0.00097642146,0.00017293433],"domain_scores_gemma":[0.9986985,0.0000537974,0.0002875131,0.00017359802,0.00071537093,0.00007127631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079972576,0.00013805895,0.00042903403,0.0002878493,0.000016923894,0.0000030207407,0.00004528391,0.000016558459,0.00030391835],"category_scores_gemma":[0.0001323754,0.00008603468,0.000029658248,0.00022176512,0.0001294342,0.00009354705,0.000024702438,0.00008597253,0.0000015725483],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035338555,0.0036820665,0.27487192,0.0062456466,0.0007714174,0.00012632119,0.029272746,0.00015366255,0.58908904,0.000078097255,0.00061519176,0.059755344],"study_design_scores_gemma":[0.022755058,0.010795351,0.8449155,0.00799176,0.0004392537,0.000011002103,0.0025859156,0.0017598016,0.10832654,0.00009320187,0.00015274758,0.00017384438],"about_ca_topic_score_codex":0.00028086244,"about_ca_topic_score_gemma":0.0002384794,"teacher_disagreement_score":0.5700436,"about_ca_system_score_codex":0.000047565816,"about_ca_system_score_gemma":0.00014247088,"threshold_uncertainty_score":0.35083923},"labels":[],"label_agreement":null},{"id":"W2978738441","doi":"10.1093/annonc/mdz248","title":"Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the phase III SPARTAN study","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Gynecology; Cancer","score_opus":0.06691129783374594,"score_gpt":0.39689649757741396,"score_spread":0.329985199743668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978738441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931035,0.0002617179,3.926422e-7,0.0028957382,0.000096394986,0.0023381587,0.00054801116,0.000010130007,0.0007459713],"genre_scores_gemma":[0.9981638,0.0003053874,0.000035210367,0.00029027337,0.000031916537,0.000082546234,0.00040426894,0.000018503148,0.0006680829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981117,0.00025673647,0.00048593676,0.0003935067,0.0003983626,0.00035370712],"domain_scores_gemma":[0.99876565,0.00029425044,0.00023588553,0.00031941143,0.00026996725,0.00011484831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005298783,0.00018297753,0.00055714074,0.00009284632,0.000055495308,0.000016926375,0.00010034925,0.0000615135,0.00011076246],"category_scores_gemma":[0.00005378243,0.00010703062,0.000033109936,0.00021649525,0.00016086677,0.000110155204,0.00005158181,0.00022196007,0.0000083299565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10762124,0.006639713,0.85175383,0.000062349885,0.0010453939,0.00029489645,0.009205556,0.00009153334,0.002670062,0.000035005585,0.00246747,0.018112943],"study_design_scores_gemma":[0.09724481,0.02148039,0.87430346,0.00015089463,0.00016688967,0.0000018159277,0.0021762827,0.00014262836,0.0011308372,0.00006144089,0.002967607,0.00017294561],"about_ca_topic_score_codex":0.0053279414,"about_ca_topic_score_gemma":0.006883213,"teacher_disagreement_score":0.02254962,"about_ca_system_score_codex":0.00008657775,"about_ca_system_score_gemma":0.00045444528,"threshold_uncertainty_score":0.8054289},"labels":[],"label_agreement":null},{"id":"W2979191802","doi":"10.1200/jco.2013.31.15_suppl.5010","title":"Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Internal medicine; Proportional hazards model; Progression-free survival; Hazard ratio; Oncology; Enzalutamide; Population; Urology; Chemotherapy; Gastroenterology; Cancer; Androgen deprivation therapy; Confidence interval; Androgen receptor","score_opus":0.11890364267247432,"score_gpt":0.44364225741656615,"score_spread":0.3247386147440918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979191802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867862,0.00088656216,0.00004147626,0.010447674,0.00018039213,0.0012996246,0.0002757037,0.000004421579,0.00007796836],"genre_scores_gemma":[0.9867219,0.00079413294,0.011902236,0.00024207981,0.00013892855,0.00003887093,0.00006228845,0.0000220055,0.00007760171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953307,0.00059568527,0.0027009246,0.00028574455,0.00081957964,0.00026736234],"domain_scores_gemma":[0.9922492,0.0036493465,0.0018571065,0.00030717315,0.0015299699,0.00040722213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029841564,0.00019156869,0.0014126354,0.00035414536,0.000036927362,0.000010539236,0.00018290883,0.00017739327,0.000090387446],"category_scores_gemma":[0.0036719546,0.00011402607,0.00016352815,0.00051137165,0.0003666333,0.00016901654,0.000059656482,0.0006174133,0.0000015492055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046843294,0.0021255857,0.8982882,0.00007923312,0.0004892722,0.000073738775,0.0004614364,0.000041358184,0.00021215393,0.000010292748,0.00086125475,0.05051419],"study_design_scores_gemma":[0.042539746,0.01319223,0.94198173,0.00061542715,0.00029413306,0.0000044908707,0.00019292954,0.000109525354,0.00019112372,0.00048664675,0.00029128825,0.00010073486],"about_ca_topic_score_codex":0.000733967,"about_ca_topic_score_gemma":0.0014112596,"teacher_disagreement_score":0.050413456,"about_ca_system_score_codex":0.00011699588,"about_ca_system_score_gemma":0.001456492,"threshold_uncertainty_score":0.46498483},"labels":[],"label_agreement":null},{"id":"W2979280650","doi":"10.1038/s41585-019-0237-8","title":"Towards precision oncology in advanced prostate cancer","year":2019,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":233,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Prostate cancer; Medicine; PARP inhibitor; Precision medicine; Microsatellite instability; Clinical trial; Oncology; Cancer; Biomarker; Personalized medicine; Immunotherapy; Circulating tumor cell; Internal medicine; Bioinformatics; Metastasis; Gene; Biology; Poly ADP ribose polymerase; Pathology; Genetics; Polymerase; Microsatellite","score_opus":0.07866390795216621,"score_gpt":0.4931680772967944,"score_spread":0.4145041693446282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979280650","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007355721,0.98051554,9.302657e-7,0.0011803377,0.0016800343,0.009512828,0.00007581128,0.00004021448,0.006986953],"genre_scores_gemma":[0.000003042352,0.98771924,0.00022458917,0.00062219804,0.00037639283,0.0026977442,0.00048994244,0.00010384992,0.007762988],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99530154,0.0009543647,0.0013830531,0.0011472127,0.00035664043,0.00085716404],"domain_scores_gemma":[0.9977379,0.0003097969,0.0006859257,0.00088485173,0.00016410147,0.0002174168],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0010936286,0.00073959486,0.006095481,0.00066745974,0.000038849168,0.000009595739,0.00040215364,0.002657487,0.00063754624],"category_scores_gemma":[0.0004808243,0.00043711532,0.0008707242,0.0010539968,0.00012293154,0.000076565804,0.00022348914,0.004536191,0.0005977235],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033841823,0.00016586093,0.00006324742,0.03363681,0.00014787976,0.00018169533,0.000044328146,3.5863982e-7,0.0000013821044,0.000029052346,0.0048077703,0.9605832],"study_design_scores_gemma":[0.0017578836,0.0010784916,0.00003684013,0.015598849,0.0012792479,0.0001966104,0.0000021117676,0.0000019510612,0.0000010686839,0.00003348694,0.9796932,0.00032026166],"about_ca_topic_score_codex":0.000021046233,"about_ca_topic_score_gemma":0.000059699792,"teacher_disagreement_score":0.9748854,"about_ca_system_score_codex":0.0013361226,"about_ca_system_score_gemma":0.0029140776,"threshold_uncertainty_score":0.9998081},"labels":[],"label_agreement":null},{"id":"W2980026947","doi":"10.1016/j.jsbmb.2019.105498","title":"Increased androgen receptor levels and signaling in ovarian cancer cells by VEPH1 associated with suppression of SMAD3 and AKT activation","year":2019,"lang":"en","type":"article","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Sinai Health System","funders":"Canadian Institutes of Health Research","keywords":"Androgen receptor; Protein kinase B; Biology; Endocrinology; Internal medicine; PI3K/AKT/mTOR pathway; Androgen; Gene silencing; Cancer research; Dihydrotestosterone; Receptor; Signal transduction; Cell biology; Cancer; Prostate cancer; Medicine; Biochemistry; Hormone","score_opus":0.010569422952427736,"score_gpt":0.2743186936434182,"score_spread":0.26374927069099047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980026947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966705,0.002739433,0.000027021257,0.00038210914,0.00001047166,0.00012806739,0.000027325528,9.937879e-7,0.0000140843],"genre_scores_gemma":[0.99937725,0.0004448043,0.000043424396,0.000058940404,0.000011740705,0.0000014708758,0.000018953699,0.000005282213,0.00003813765],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995147,0.000078132194,0.00014701115,0.00008710253,0.00007316507,0.0000999128],"domain_scores_gemma":[0.9996007,0.00006052259,0.00015758256,0.000056626937,0.00006916882,0.00005538071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024902244,0.000076390585,0.00019478588,0.00003145672,0.000021857253,0.0000045943207,0.000034570134,0.000090654525,0.000014888722],"category_scores_gemma":[0.000021468295,0.00004235996,0.000013351861,0.00005478735,0.00011110267,0.000022292352,0.000025539939,0.00013418523,3.8640042e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013300612,0.00003867677,0.02082858,0.00006293124,0.00011777203,0.0000042061056,0.00015832692,9.156771e-7,0.9770748,3.7409995e-7,0.000020162459,0.0003631889],"study_design_scores_gemma":[0.0031227225,0.0005411983,0.0024888434,0.00037473752,0.000053231735,0.000028053444,0.00016750884,0.000008016209,0.99313617,0.0000151828,0.000018334385,0.00004598879],"about_ca_topic_score_codex":0.0000361588,"about_ca_topic_score_gemma":6.61146e-7,"teacher_disagreement_score":0.018339738,"about_ca_system_score_codex":0.000026550611,"about_ca_system_score_gemma":0.000065363834,"threshold_uncertainty_score":0.1727389},"labels":[],"label_agreement":null},{"id":"W2980027724","doi":"10.1182/blood.v110.11.1388.1388","title":"Synthetic 15-mer Peptide (PCK3145) Derived from Prostate Secretory Protein with In Vitro and In Vivo Activity Against Non-Hodgkin’s Lymphoma and Other Hematologic Malignancies.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"In vivo; Peptide; In vitro; Lymphoma; Prostate; Amino acid; Prostate cancer; Cancer research; Cytotoxic T cell; Biology; Chemistry; Cancer; Medicine; Internal medicine; Immunology; Biochemistry","score_opus":0.011777020004754299,"score_gpt":0.24793274727593909,"score_spread":0.23615572727118478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980027724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593663,0.0015301787,0.000017716033,0.00018405227,0.000012105328,0.0014548557,0.000037744936,0.000033330904,0.0007934048],"genre_scores_gemma":[0.998452,0.00011249608,0.00073287415,0.00014071047,0.000024626452,0.00017909231,0.0000073745337,0.000036924932,0.00031387853],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985322,0.00005870063,0.00020611307,0.00047258113,0.00023544043,0.0004950176],"domain_scores_gemma":[0.99940604,0.00008466396,0.00007411473,0.00023229675,0.00003579984,0.00016705964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002996305,0.0002391071,0.0004291464,0.00018454215,0.00006287943,0.000024964844,0.000055721666,0.000121195284,0.00002429875],"category_scores_gemma":[0.000033220447,0.00016850806,0.000027482549,0.0002034311,0.0002655279,0.00009294933,0.00005936601,0.00016638986,0.0000036362599],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00347459,0.0007154099,0.21242788,0.00019470796,0.00008209555,0.0014570348,0.0012377736,3.1196123e-7,0.77764356,0.0000013399416,0.0000054950333,0.0027598133],"study_design_scores_gemma":[0.011968414,0.00033750598,0.19474985,0.0006633066,0.000047992366,0.000072212824,0.00046210038,0.00005016683,0.79132444,0.000029835512,0.000089652916,0.00020453648],"about_ca_topic_score_codex":0.0007215686,"about_ca_topic_score_gemma":0.0009777492,"teacher_disagreement_score":0.017678032,"about_ca_system_score_codex":0.00011019818,"about_ca_system_score_gemma":0.00016872189,"threshold_uncertainty_score":0.68715596},"labels":[],"label_agreement":null},{"id":"W2980349656","doi":"10.1200/jco.2019.37.27_suppl.38","title":"Contemporary analysis of bone mineral density in men initiating androgen deprivation therapy for prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal General Hospital; McGill University","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Bone mineral; Internal medicine; Cohort; Odds ratio; Osteoporosis; Oncology; Cancer","score_opus":0.18803754257333605,"score_gpt":0.507475812743782,"score_spread":0.3194382701704459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980349656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99384356,0.00173262,0.000022513395,0.0029191542,0.00015789727,0.0005788658,0.000011898311,0.0000024621645,0.0007310269],"genre_scores_gemma":[0.99646723,0.0020062376,0.00067484763,0.0004345099,0.00016592708,0.000013053496,0.000021278418,0.000007977437,0.00020894455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766415,0.00021205601,0.0016048703,0.00013460248,0.00023362448,0.00015067155],"domain_scores_gemma":[0.99676806,0.0011820751,0.0012874685,0.00010461174,0.0005433424,0.000114428185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027871986,0.00007793999,0.001424579,0.0003151675,0.000014171513,0.000003579175,0.000059880786,0.00016346446,0.000043835837],"category_scores_gemma":[0.00066102005,0.000051243624,0.00040319376,0.00036746997,0.00007309338,0.0000973939,0.000020399626,0.00031486223,6.7339585e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016228816,0.00067227875,0.9377169,0.000038910668,0.0017236301,0.00008485836,0.0002547089,0.00005494953,0.0024822073,0.000008243531,0.00055416155,0.040180314],"study_design_scores_gemma":[0.022918215,0.008443718,0.9627425,0.000087122025,0.00042984754,0.000011210182,0.00018950904,0.0018122244,0.0014953048,0.00013159118,0.0016792972,0.00005944056],"about_ca_topic_score_codex":0.00011462997,"about_ca_topic_score_gemma":0.00006772814,"teacher_disagreement_score":0.040120874,"about_ca_system_score_codex":0.00014328244,"about_ca_system_score_gemma":0.001606081,"threshold_uncertainty_score":0.28491187},"labels":[],"label_agreement":null},{"id":"W2980372944","doi":"10.1200/jco.2019.37.27_suppl.40","title":"Trends in the use of novel hormonal agents at the end of life in metastatic castration-resistant prostate cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal General Hospital; McGill University","funders":"Réseau de cancérologie Rossy","keywords":"Enzalutamide; Medicine; Prostate cancer; Androgen deprivation therapy; Hormonal therapy; Cancer; Abiraterone acetate; Cohort; Internal medicine; Abiraterone; Odds ratio; Quality of life (healthcare); Logistic regression; Oncology; Androgen receptor","score_opus":0.38431432571456825,"score_gpt":0.5256426408285975,"score_spread":0.1413283151140292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980372944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852519,0.0009865855,0.0000014688866,0.012841996,0.00020845364,0.00031604702,0.00004083905,6.2278764e-7,0.00035206255],"genre_scores_gemma":[0.99672073,0.0012726482,0.00026285197,0.0006051144,0.00008226599,0.000010205052,0.000006997469,0.000006997328,0.0010321687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99686694,0.00045223415,0.0018393609,0.00011466535,0.00053757074,0.00018921518],"domain_scores_gemma":[0.9957835,0.002565239,0.0011581628,0.00017196032,0.0002179046,0.00010321327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028419795,0.00009060672,0.00089595205,0.0001778312,0.000016566708,0.00000535355,0.00016189214,0.0000904796,0.00031394814],"category_scores_gemma":[0.0008477785,0.00004034139,0.00024269552,0.0003267647,0.00031488453,0.00008964934,0.000040852283,0.0005884848,0.0000019275722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03584485,0.0053760177,0.8707858,0.00014568979,0.00085260527,0.00047724968,0.0020471434,0.0011698252,0.005645107,0.00013186903,0.005956438,0.07156746],"study_design_scores_gemma":[0.014523827,0.0063775075,0.96818745,0.00013255981,0.00016010036,0.000038197606,0.00037263255,0.0003630655,0.00013583596,0.0000328812,0.009634115,0.000041844905],"about_ca_topic_score_codex":0.00050055294,"about_ca_topic_score_gemma":0.0021988961,"teacher_disagreement_score":0.097401686,"about_ca_system_score_codex":0.00018615603,"about_ca_system_score_gemma":0.001808105,"threshold_uncertainty_score":0.34375122},"labels":[],"label_agreement":null},{"id":"W2980833355","doi":"","title":"STEAP4 expression in human islets is associated with differences in body mass index, sex, HbA1c, and inflammation","year":2017,"lang":"en","type":"book-chapter","venue":"Author eBooks","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Inflammation; Diabetes mellitus; Body mass index; Medicine; Obesity; Type 2 diabetes; Endocrinology; Insulin; Biology; Internal medicine","score_opus":0.047433136187787446,"score_gpt":0.315597765332607,"score_spread":0.2681646291448196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980833355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6314675,0.00034431237,0.00000428898,0.00027756894,0.00006250132,0.0014160919,0.00004118606,0.000048634585,0.3663379],"genre_scores_gemma":[0.57775795,0.00004575981,0.000008706278,0.000014462432,0.000050679162,0.00005009408,0.00008534736,0.000033008182,0.421954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983341,0.00004836349,0.00033811948,0.00046380985,0.0004956844,0.00031992092],"domain_scores_gemma":[0.99908614,0.00006909001,0.00028211976,0.00036582595,0.00006992865,0.0001268837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028472874,0.0003410338,0.00065183686,0.0004112509,0.000148665,0.000073701216,0.00012664353,0.00051929365,0.0000855697],"category_scores_gemma":[0.000028568067,0.0002426096,0.00004767449,0.000011449398,0.00021235773,0.000070649454,0.00008801837,0.0007187147,0.000004895293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042268136,0.00027865366,0.7027575,0.0020365166,0.0017479367,0.0076763257,0.023715096,6.0647676e-7,0.13925876,0.005206339,0.0017539934,0.11134146],"study_design_scores_gemma":[0.05090117,0.005929601,0.66042054,0.062342033,0.00095237815,0.000076631346,0.00094680965,0.0004612224,0.12576734,0.065933324,0.022331765,0.003937212],"about_ca_topic_score_codex":0.000080238104,"about_ca_topic_score_gemma":0.00025019053,"teacher_disagreement_score":0.10740425,"about_ca_system_score_codex":0.00023395597,"about_ca_system_score_gemma":0.00016953675,"threshold_uncertainty_score":0.9893332},"labels":[],"label_agreement":null},{"id":"W2980955535","doi":"10.1016/j.eururo.2019.09.036","title":"Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Metastasis; Cancer; Prostate; Androgen deprivation therapy; Androgen receptor; Cancer research","score_opus":0.030672605083990775,"score_gpt":0.3691256600384133,"score_spread":0.3384530549544225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980955535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97514355,0.0009681207,0.0000021876258,0.003748956,0.0007500962,0.00091202796,0.000022119046,0.00006561846,0.018387336],"genre_scores_gemma":[0.97685957,0.0019176601,0.000068065216,0.0020324616,0.00012522847,0.000033631062,0.000028483348,0.000054093576,0.018880809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782103,0.00041379154,0.0004963433,0.0005295843,0.00021887799,0.00052037],"domain_scores_gemma":[0.99905974,0.00016847801,0.000096669544,0.00043112732,0.00005460241,0.00018940595],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00051441614,0.00018986347,0.0004927054,0.00014035894,0.00002964287,0.000009934954,0.00015329952,0.000068488705,0.00057740323],"category_scores_gemma":[0.00011793413,0.00013493339,0.00012179209,0.00010876053,0.00012671841,0.00005711003,0.0001492042,0.0005385665,0.0012566785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00197083,0.00036529827,0.96469736,0.00003238622,0.00009433065,0.0018713626,0.0001936797,0.000044230303,0.0026823522,0.000028530625,0.00015508535,0.027864529],"study_design_scores_gemma":[0.010813367,0.0015694146,0.94751966,0.000032688138,0.000045421166,0.000026948623,0.000052553096,0.000061807455,0.00033325565,0.00003162886,0.039350394,0.00016284094],"about_ca_topic_score_codex":0.000049883598,"about_ca_topic_score_gemma":0.000086013366,"teacher_disagreement_score":0.03919531,"about_ca_system_score_codex":0.00008015681,"about_ca_system_score_gemma":0.00014067031,"threshold_uncertainty_score":0.99952096},"labels":[],"label_agreement":null},{"id":"W2981372250","doi":"","title":"Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness","year":2019,"lang":"en","type":"review","venue":"Europe PMC (PubMed Central)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Prostate cancer; Medicine; Cabazitaxel; Docetaxel; Oncology; Taxane; Androgen deprivation therapy; Internal medicine; Cancer; Abiraterone acetate; Androgen receptor; Breast cancer","score_opus":0.1355825541436659,"score_gpt":0.42778105137267697,"score_spread":0.29219849722901103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981372250","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015438976,0.96355057,0.0000072477687,0.000078120924,0.00096746243,0.03209584,0.0015875914,0.000043597163,0.00012568444],"genre_scores_gemma":[0.00012106536,0.99053556,0.00006836521,0.000043584612,0.000285824,0.006501343,0.0014470618,0.00015128219,0.0008459409],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99389774,0.0020728002,0.0014229807,0.0010672933,0.00052269525,0.0010164981],"domain_scores_gemma":[0.99643236,0.0009541516,0.0008612942,0.0005958168,0.00058716367,0.00056923344],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033690585,0.00062773074,0.0038351512,0.00016298087,0.00008375986,0.000035617315,0.00021971378,0.00028787527,0.000056079585],"category_scores_gemma":[0.0011645698,0.0004349136,0.00071739184,0.0006521057,0.00019839204,0.000112535105,0.000110193694,0.0005447412,0.000015735552],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018024349,0.0001992618,0.0015545897,0.3619569,0.0009087992,0.000038108104,0.00004674741,1.4524838e-7,0.000016332158,0.000009001552,0.0008243317,0.63264334],"study_design_scores_gemma":[0.0041306536,0.0006868181,0.007503487,0.16908483,0.0028354342,0.000019895348,0.000003303715,0.0000013375894,0.00018096312,0.0000019736917,0.8152296,0.0003217026],"about_ca_topic_score_codex":0.00003134747,"about_ca_topic_score_gemma":0.000002813845,"teacher_disagreement_score":0.81440526,"about_ca_system_score_codex":0.0005547226,"about_ca_system_score_gemma":0.0020992472,"threshold_uncertainty_score":0.9998103},"labels":[],"label_agreement":null},{"id":"W2981571673","doi":"10.23736/s0393-2249.19.03420-9","title":"Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?","year":2019,"lang":"en","type":"review","venue":"Minerva Urologica e Nefrologica","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Denosumab; Prostate cancer; Zoledronic acid; Oncology; Enzalutamide; Docetaxel; Dosing; Internal medicine; Cabozantinib; Cancer; Osteoporosis; Androgen receptor","score_opus":0.1022234460612595,"score_gpt":0.37831971787205093,"score_spread":0.27609627181079144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981571673","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033914605,0.98401624,2.4443577e-7,0.0038715955,0.0002917887,0.005954537,0.0005377507,0.00019167387,0.0017447317],"genre_scores_gemma":[0.0010193436,0.98828435,0.00012971858,0.00018918174,0.00027610196,0.0022694166,0.00031957944,0.00011242537,0.0073998906],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943295,0.0005899725,0.001340234,0.0016270566,0.00073411234,0.0013791241],"domain_scores_gemma":[0.9974158,0.00035998618,0.00063546747,0.0010219071,0.00023502472,0.0003318218],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060548104,0.0011728344,0.0038525877,0.0005429368,0.00015786321,0.00011662301,0.00052323524,0.0012459081,0.0015622028],"category_scores_gemma":[0.00007817041,0.000657999,0.0008096799,0.001128394,0.00030651162,0.00012317445,0.00018889726,0.0016044164,0.0002606055],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003260668,0.000779259,0.0021759549,0.010637783,0.00060839986,0.0023196074,0.00021064794,0.000012853835,0.00031353885,0.000020817055,0.0077636666,0.9718968],"study_design_scores_gemma":[0.003569708,0.004344677,0.0009476908,0.005636216,0.0005114209,0.000110372974,0.000047936475,0.000010785251,0.000006997767,0.000058673766,0.98411316,0.0006423633],"about_ca_topic_score_codex":0.00012343847,"about_ca_topic_score_gemma":0.000070803035,"teacher_disagreement_score":0.9763495,"about_ca_system_score_codex":0.0005512682,"about_ca_system_score_gemma":0.0014213768,"threshold_uncertainty_score":0.9995871},"labels":[],"label_agreement":null},{"id":"W2981596434","doi":"","title":"Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide.","year":2017,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Enzalutamide; Abiraterone acetate; Medicine; Prostate cancer; Hazard ratio; Oncology; Internal medicine; Proportional hazards model; Docetaxel; Urology; Pharmacology; Cancer; Androgen deprivation therapy; Confidence interval; Androgen receptor","score_opus":0.056446210655479584,"score_gpt":0.318446526543887,"score_spread":0.26200031588840744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981596434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951222,0.00037334918,0.0000017999007,0.0012748913,0.00013131404,0.0029130143,0.0000644507,0.000023532519,0.00009547013],"genre_scores_gemma":[0.9903868,0.0021417355,0.00010357929,0.000017166445,0.00004939815,0.0046483027,0.00010980097,0.000023434788,0.0025197763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985674,0.000058144473,0.00026523092,0.0003788315,0.00033732082,0.00039309435],"domain_scores_gemma":[0.9991177,0.000022285283,0.0002172997,0.00033468718,0.0001129217,0.00019510635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021971391,0.00019260721,0.000289173,0.00010911723,0.00021151829,0.000117405616,0.000068938825,0.00003894907,0.00003737529],"category_scores_gemma":[0.000051711722,0.00011236342,0.000020910684,0.00009012034,0.00013967138,0.00036191542,0.000025929581,0.00010364391,0.0000021800897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050110747,0.00031201358,0.63523245,0.00015546437,0.00017691287,0.0000505651,0.00072368846,0.0000035707699,0.00014701961,0.0000019683278,0.000027949416,0.3581573],"study_design_scores_gemma":[0.011296465,0.00069827546,0.9857119,0.00020615403,0.00014403541,0.0000060429043,0.00015894155,0.000018447283,0.0015170665,0.00001535692,0.000102578015,0.00012474677],"about_ca_topic_score_codex":0.0022099614,"about_ca_topic_score_gemma":0.0025881869,"teacher_disagreement_score":0.35803255,"about_ca_system_score_codex":0.0004789593,"about_ca_system_score_gemma":0.00019238198,"threshold_uncertainty_score":0.45820475},"labels":[],"label_agreement":null},{"id":"W2981774263","doi":"10.12688/f1000research.20824.2","title":"Case Report: A castration-resistant terminal prostate cancer patient’s survival prolonged after practicing Falun Gong","year":2020,"lang":"en","type":"preprint","venue":"F1000Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Castration; Gynecology; Internal medicine; Hormone","score_opus":0.0958299200812583,"score_gpt":0.4077035793406776,"score_spread":0.3118736592594193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981774263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97047967,0.0035555267,0.00001634923,0.014191708,0.0007333593,0.0072359275,0.0009258671,0.00021272466,0.0026488625],"genre_scores_gemma":[0.9831557,0.0006397706,0.0006484024,0.0001460316,0.0008956946,0.0052227117,0.00083295465,0.00018532996,0.00827336],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9929616,0.00056622684,0.0010403746,0.0016728397,0.002415248,0.0013437453],"domain_scores_gemma":[0.99581665,0.00027027246,0.00042085207,0.0012169824,0.0013114556,0.0009638192],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011309051,0.000657216,0.0009712871,0.00046639433,0.00036086034,0.00041827228,0.00028938256,0.0004430996,0.000899357],"category_scores_gemma":[0.00083500176,0.0005320807,0.000324965,0.0005783218,0.00039822925,0.00023354146,0.0013094742,0.0032564588,0.0000975864],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013502225,0.0005195604,0.030771807,0.003324744,0.00086761866,0.9240283,0.0048500863,0.000035547902,0.0045351037,0.000010005523,0.0032390603,0.014315975],"study_design_scores_gemma":[0.044593733,0.023292743,0.2769501,0.022177618,0.007537823,0.39626047,0.022176519,0.01590955,0.07251075,0.0024692025,0.10572357,0.0103979185],"about_ca_topic_score_codex":0.005177951,"about_ca_topic_score_gemma":0.0014650017,"teacher_disagreement_score":0.5277678,"about_ca_system_score_codex":0.0011914704,"about_ca_system_score_gemma":0.005553593,"threshold_uncertainty_score":0.99971306},"labels":[],"label_agreement":null},{"id":"W2981803158","doi":"10.1101/818880","title":"Clonal evaluation of prostate cancer molecular heterogeneity in biopsy samples by dual immunohistochemistry and dual RNA <i>in situ</i> hybridization","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"Congressionally Directed Medical Research Programs; U.S. Department of Defense","keywords":"Prostate cancer; Biopsy; In situ hybridization; Immunohistochemistry; Pathology; Prostate; Cancer; Erg; Biology; Prostate biopsy; Medicine; Gene; Gene expression; Genetics","score_opus":0.022562181284476072,"score_gpt":0.30309896069694187,"score_spread":0.2805367794124658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981803158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778364,0.019311331,0.000026932694,0.00019458421,0.00019580591,0.0017430303,0.00064856745,0.000034273256,0.000009100943],"genre_scores_gemma":[0.997037,0.0020196,0.0002953097,0.000035918427,0.000059929098,0.00046014626,0.00002092452,0.0000661611,0.000005042444],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99721795,0.00017527696,0.0005635602,0.0008104908,0.0008196138,0.00041310408],"domain_scores_gemma":[0.9982816,0.000034419463,0.0003168166,0.0005778925,0.0006488419,0.00014042703],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009928454,0.00038194205,0.00060918153,0.000259343,0.00003683742,0.000043832846,0.000110029694,0.00033151588,0.000020793448],"category_scores_gemma":[0.00013578113,0.00038879027,0.00008148977,0.0003782789,0.00016285355,0.00009066179,0.00021901508,0.00053566584,0.0000023037192],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029840905,0.00021568016,0.12346338,0.0009673779,0.00013717728,0.000053835785,0.000021535016,0.00020955107,0.8745688,0.0000054274856,0.000046284385,0.000012530938],"study_design_scores_gemma":[0.0031218457,0.00005985858,0.18839644,0.0007815199,0.00017103729,9.920382e-8,0.0000048661177,0.00047533587,0.80666184,0.0000013559019,0.000035484067,0.0002903083],"about_ca_topic_score_codex":0.00036464524,"about_ca_topic_score_gemma":0.000008204351,"teacher_disagreement_score":0.06790696,"about_ca_system_score_codex":0.0009788919,"about_ca_system_score_gemma":0.0017877233,"threshold_uncertainty_score":0.9998564},"labels":[],"label_agreement":null},{"id":"W2982121460","doi":"10.3747/co.26.5005","title":"Combining Prostate Cancer Radiotherapy with Therapies Targeting the Androgen Receptor Axis","year":2019,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Enzalutamide; Abiraterone acetate; Prostate cancer; Medicine; Androgen deprivation therapy; Radiation therapy; Clinical trial; Oncology; Androgen receptor; Internal medicine; Cancer","score_opus":0.16231893285004093,"score_gpt":0.4691370660978495,"score_spread":0.3068181332478086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982121460","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025344244,0.9928263,0.0000062761055,0.0010285636,0.0014590641,0.003881202,0.00009585604,0.000064385895,0.00038494202],"genre_scores_gemma":[0.000012301466,0.9948055,0.00012862144,0.000074687785,0.000703912,0.0015644174,0.00045678916,0.000110340115,0.0021434238],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975566,0.0004186644,0.00047674158,0.00057049195,0.00034903342,0.00062845764],"domain_scores_gemma":[0.99846995,0.00035973205,0.00041357471,0.00043480127,0.00017961432,0.0001423405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046276092,0.000502972,0.0020046378,0.00015926521,0.00019434551,0.000041276322,0.00028609773,0.0002519988,0.0005045486],"category_scores_gemma":[0.00002312759,0.00022662514,0.00032839866,0.00039740623,0.00034322956,0.000052364514,0.00007489071,0.0010544974,0.00006249709],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003329892,0.00021212993,0.0010960444,0.009132183,0.0012632107,0.00002052008,0.0014099869,4.9308613e-7,0.0000029228459,0.0000188778,0.008830316,0.9776803],"study_design_scores_gemma":[0.002490273,0.0012770072,0.000006495515,0.008986158,0.0009206713,0.000053121195,0.0001884018,0.000009230792,0.00000547064,0.0000038071867,0.98579496,0.00026440513],"about_ca_topic_score_codex":0.000024437446,"about_ca_topic_score_gemma":0.0000073767073,"teacher_disagreement_score":0.9774159,"about_ca_system_score_codex":0.0010324876,"about_ca_system_score_gemma":0.0024263877,"threshold_uncertainty_score":0.92415047},"labels":[],"label_agreement":null},{"id":"W2982561040","doi":"10.2147/cmar.s213051","title":"&lt;p&gt;Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome&lt;/p&gt;","year":2019,"lang":"en","type":"article","venue":"Cancer Management and Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Regional Municipality of Durham; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"Sanofi Genzyme; Bayer Canada; Astellas Pharma; Endocyte; Bavarian Nordic; Sanofi; Exelixis; Genentech; AstraZeneca; Amgen","keywords":"Medicine; Prostate cancer; Discontinuation; Enzalutamide; Radium-223; Proportional hazards model; Internal medicine; Cohort; Hazard ratio; Docetaxel; Prostate-specific antigen; Abiraterone acetate; Oncology; Population; Cancer; Androgen deprivation therapy; Bone metastasis; Confidence interval","score_opus":0.1496487276642577,"score_gpt":0.3775254693243324,"score_spread":0.22787674166007468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982561040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526227,0.0011980603,0.0000065579134,0.0003992434,0.000023786171,0.002724098,0.0003383016,0.000003764883,0.000043944987],"genre_scores_gemma":[0.9953075,0.0010640575,0.000078154444,0.0000083794785,0.0000034333746,0.0002527192,0.00019922463,0.000013824589,0.0030726788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832624,0.00011639612,0.00039316327,0.00030928128,0.0005750265,0.00027986852],"domain_scores_gemma":[0.9989153,0.00029355485,0.00019154171,0.00022058646,0.00030453666,0.00007445867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004130534,0.00015509571,0.00057241274,0.00060720707,0.00009196296,0.000027656866,0.000051706003,0.0000410839,0.000074758114],"category_scores_gemma":[0.000027696471,0.000089628506,0.00007211987,0.0008948414,0.00022865381,0.00008151627,0.000043373628,0.00009621826,4.193129e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015851019,0.00023962923,0.9888299,0.0005846565,0.0016497774,0.0000033873866,0.00074788113,0.0011441204,0.0031457983,0.00012424173,0.00002641406,0.0019191089],"study_design_scores_gemma":[0.0063134152,0.0006798859,0.9867155,0.00035493684,0.0009722617,8.1608526e-8,0.00019782901,0.0034396271,0.0008117124,0.000015474798,0.00041373647,0.0000855648],"about_ca_topic_score_codex":0.023877932,"about_ca_topic_score_gemma":0.19710577,"teacher_disagreement_score":0.17322783,"about_ca_system_score_codex":0.00058487756,"about_ca_system_score_gemma":0.00024122212,"threshold_uncertainty_score":0.98262215},"labels":[],"label_agreement":null},{"id":"W2983448860","doi":"10.5489/cuaj.6346","title":"Balancing efficacy and financial toxicity in the management of metastatic castration-sensitive prostate cancer","year":2019,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Prostate cancer; Toxicity; Castration; Medicine; Oncology; Prostate; Internal medicine; Cancer; Hormone","score_opus":0.01641364136681512,"score_gpt":0.2782134899128472,"score_spread":0.2617998485460321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983448860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98848194,0.0002994443,0.0000036343188,0.009810487,0.0000721496,0.00048377365,0.00002466874,0.0000024222038,0.00082150206],"genre_scores_gemma":[0.9982209,0.0003694311,0.000081697974,0.0009432146,0.000045799803,0.0000123353,0.000007952018,0.0000034348052,0.00031518887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990346,0.00012245572,0.00019651993,0.00011123762,0.00026768315,0.00026749325],"domain_scores_gemma":[0.999483,0.000104881314,0.00010920987,0.000051721196,0.00011143082,0.0001397864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064681954,0.0000716828,0.00017932599,0.00009425777,0.00008045593,0.000029798388,0.00004527447,0.000048535123,0.00008666173],"category_scores_gemma":[0.00006636318,0.00004416904,0.00003516611,0.00019897554,0.000025134921,0.000053398395,0.000008130907,0.00029743038,0.0000053873578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032185338,0.00009673494,0.98527926,0.00006141278,0.00020263711,0.0004552129,0.0018731571,0.0001263799,0.00042808705,0.00046468416,0.00061395543,0.010076598],"study_design_scores_gemma":[0.0020948437,0.0002730988,0.9956453,0.00005610473,0.00006257069,0.000047231864,0.00046359567,0.0000902599,0.00008012,0.00017035352,0.0009686516,0.0000478784],"about_ca_topic_score_codex":0.00082433526,"about_ca_topic_score_gemma":0.0009949754,"teacher_disagreement_score":0.010366004,"about_ca_system_score_codex":0.00047918918,"about_ca_system_score_gemma":0.0003237936,"threshold_uncertainty_score":0.18011612},"labels":[],"label_agreement":null},{"id":"W2983768183","doi":"10.1016/j.ijrobp.2019.11.001","title":"A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy","year":2019,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Health Sciences Centre; University of Toronto; Hamilton Health Sciences; Western University; McMaster University; London Health Sciences Centre","funders":"","keywords":"Medicine; Prostate cancer; Pelvis; Radiology; Magnetic resonance imaging; Prospective cohort study; Positron emission tomography; Radiation therapy; Abdomen; Nuclear medicine; Brachytherapy; Prostate-specific antigen; Prostate; Cancer; Pathology; Internal medicine","score_opus":0.023195807231820895,"score_gpt":0.38619681075910756,"score_spread":0.36300100352728665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983768183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206924,0.0033199468,0.00013084449,0.00088250765,0.0020330672,0.0013716555,0.000030445048,0.000019406545,0.00014290425],"genre_scores_gemma":[0.9936314,0.0040717945,0.00078207446,0.00028631632,0.00078829564,0.000081986334,0.000028288314,0.000040829647,0.00028901163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99760383,0.00026257464,0.0009126642,0.00034282389,0.0005592966,0.00031878462],"domain_scores_gemma":[0.99785864,0.00031328874,0.00097395346,0.00018068225,0.00056300114,0.000110417015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007546249,0.0002436287,0.000784385,0.00036854693,0.0000493761,0.000026983947,0.00032467055,0.000038701717,0.00009672275],"category_scores_gemma":[0.00007685271,0.00017975002,0.00023448654,0.00033387312,0.00010080489,0.0003561583,0.00005201122,0.000641326,0.000004710413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007406094,0.0021924954,0.8996199,0.000030500325,0.001224844,0.00085768226,0.0025464494,0.0004928685,0.010642659,0.00008325048,0.00007492693,0.07482834],"study_design_scores_gemma":[0.08290083,0.021629957,0.8758382,0.0011257206,0.00027427517,0.001120257,0.0018214943,0.0020686234,0.0072545432,0.0018524834,0.003600454,0.0005131702],"about_ca_topic_score_codex":0.00012945048,"about_ca_topic_score_gemma":0.00003558232,"teacher_disagreement_score":0.07549473,"about_ca_system_score_codex":0.002381406,"about_ca_system_score_gemma":0.0014159828,"threshold_uncertainty_score":0.7329993},"labels":[],"label_agreement":null},{"id":"W2984031486","doi":"10.1016/s0167-8140(19)33217-7","title":"161 PSMA-PET Guided Intensification of Radiotherapy for Prostate Cancer: Preliminary Detection Rate and Impact on Radiotherapeutic Management","year":2019,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal","funders":"","keywords":"Radiation therapy; Prostate cancer; Medicine; Radiology; Oncology; Medical physics; Management of prostate cancer; Cancer; Internal medicine","score_opus":0.028089744797846726,"score_gpt":0.3758898380919246,"score_spread":0.3478000932940779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984031486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97509843,0.017706504,0.0008420716,0.0024082384,0.00024404308,0.0034372245,0.000028816097,0.00003985512,0.00019482936],"genre_scores_gemma":[0.9270554,0.066976875,0.0018441719,0.0009935421,0.0001398822,0.00042545114,0.00003055877,0.000056477278,0.002477646],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99873775,0.00011875538,0.00029771047,0.0004108815,0.00012001047,0.00031491718],"domain_scores_gemma":[0.9991916,0.00017110615,0.00016060729,0.00025273877,0.000108910404,0.000115057854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040334146,0.00022756874,0.00055333495,0.00025358945,0.000078716024,0.000016330634,0.00006060379,0.00011203776,0.00008692449],"category_scores_gemma":[0.000005940356,0.00016158028,0.00010206994,0.00016494906,0.00016262093,0.00007155648,0.000009493187,0.00013456929,0.00000115483],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047195014,0.0005043999,0.022403674,0.00087830954,0.001923128,0.000034181754,0.0019172028,0.0001431836,0.19714911,0.00033711348,0.0007652234,0.7267495],"study_design_scores_gemma":[0.09771773,0.11002514,0.484426,0.0009447785,0.00090993085,0.0010156978,0.0012071365,0.061121006,0.097771704,0.0008409732,0.14283618,0.001183728],"about_ca_topic_score_codex":0.000079179845,"about_ca_topic_score_gemma":0.000011483418,"teacher_disagreement_score":0.72556573,"about_ca_system_score_codex":0.00082040863,"about_ca_system_score_gemma":0.00012440467,"threshold_uncertainty_score":0.6589052},"labels":[],"label_agreement":null},{"id":"W2984712394","doi":"10.1016/s1470-2045(19)30688-6","title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":352,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC; Kelowna General Hospital","funders":"","keywords":"Enzalutamide; Abiraterone acetate; Prostate cancer; Medicine; Prednisone; Open label; Oncology; Internal medicine; Abiraterone; Randomized controlled trial; Crossover study; Docetaxel; Cancer; Androgen deprivation therapy; Placebo; Androgen receptor; Pathology","score_opus":0.12050590991124985,"score_gpt":0.4350927641428153,"score_spread":0.3145868542315654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984712394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882034,0.0024086353,0.0000070600663,0.0018919099,0.00018212433,0.00656575,0.00013810176,0.000016870836,0.00058611407],"genre_scores_gemma":[0.99345267,0.002168076,0.001378401,0.00022833176,0.000109288056,0.0006488142,0.00004325965,0.000025897314,0.0019452851],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978944,0.00038720178,0.0005748714,0.00035939534,0.00025127575,0.0005328497],"domain_scores_gemma":[0.99876004,0.00039234466,0.00029077035,0.0003317654,0.00011528641,0.00010980018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012132733,0.00020579848,0.0011693926,0.000092639406,0.000077775294,0.000054000535,0.00022044378,0.00007414512,0.00013249482],"category_scores_gemma":[0.00010085403,0.00012784392,0.000039118113,0.00021520209,0.0002795868,0.00018576793,0.00014937768,0.00030871262,0.000010558882],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85709536,0.0007265379,0.0006203942,0.00035559922,0.00037271585,0.00022825583,0.0053120465,0.0006219709,0.13075444,0.00007389422,0.00015270579,0.0036860758],"study_design_scores_gemma":[0.9748497,0.0050443434,0.0005623537,0.00021947971,0.00027769827,0.000039989107,0.00103087,0.005583844,0.0110960575,0.0000716467,0.0010683456,0.00015569286],"about_ca_topic_score_codex":0.0012702949,"about_ca_topic_score_gemma":0.0007277565,"teacher_disagreement_score":0.11965838,"about_ca_system_score_codex":0.0006514315,"about_ca_system_score_gemma":0.00141965,"threshold_uncertainty_score":0.5213324},"labels":[],"label_agreement":null},{"id":"W2984785086","doi":"10.1097/01.ju.0000149989.01263.dc","title":"CELL LINES USED IN PROSTATE CANCER RESEARCH: A COMPENDIUM OF OLD AND NEW LINES—PART 2","year":2005,"lang":"en","type":"review","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cell culture; Prostate cancer; Telomerase reverse transcriptase; Computational biology; Androgen receptor; Medicine; Prostate; Prostate-specific antigen; Cancer research; In vivo; Telomerase; Cancer; Bioinformatics; Biology; Gene; Internal medicine; Genetics","score_opus":0.24988233305111796,"score_gpt":0.4732916276732366,"score_spread":0.22340929462211867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984785086","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006770013,0.9869477,5.8661493e-7,0.0051034857,0.00018535828,0.00081613555,0.000022008264,0.00000307079,0.00015162435],"genre_scores_gemma":[0.0009158582,0.99292606,0.000037217567,0.000082378836,0.0009797715,0.000014064872,0.0000091862985,0.000036375568,0.004999094],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99723643,0.0007745031,0.0009203309,0.00016500102,0.00046344913,0.00044027026],"domain_scores_gemma":[0.9978411,0.00078569393,0.00058940554,0.00026623547,0.00031013973,0.00020739817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021362095,0.00023078287,0.0016729577,0.0006693745,0.000044238997,0.00000946787,0.00029717258,0.00019825001,0.00014549034],"category_scores_gemma":[0.0001121313,0.00011571528,0.0001819833,0.00045713634,0.00036665102,0.00004691022,0.0001312301,0.0016443143,0.000009065612],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005260315,0.00072088296,0.0017057738,0.013806294,0.00095162884,0.0009766221,0.0023709324,0.00003123906,0.00021634653,0.000024984507,0.03071476,0.9432202],"study_design_scores_gemma":[0.0028275587,0.0015418325,0.000119046774,0.003391685,0.0007646915,0.000665052,0.0000513224,0.000005835837,0.000044857323,0.000054839034,0.99044526,0.000088012726],"about_ca_topic_score_codex":0.0002674691,"about_ca_topic_score_gemma":0.00014268878,"teacher_disagreement_score":0.9597305,"about_ca_system_score_codex":0.0001393372,"about_ca_system_score_gemma":0.001968994,"threshold_uncertainty_score":0.7143819},"labels":[],"label_agreement":null},{"id":"W2985130880","doi":"10.5489/cuaj.6082","title":"A A Canadian consensus forum on the management of patients with advanced prostate cancer","year":2019,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; BC Cancer Agency; Jewish General Hospital; Queen's University; William Osler Health System; University of Alberta; University of Calgary; Princess Margaret Cancer Centre; Vancouver General Hospital; University of British Columbia; Juravinski Cancer Centre; St. Joseph’s Healthcare Hamilton; McMaster University; Western University; University of Toronto; Ottawa Hospital; McGill University; Kingston Health Sciences Centre; University of Ottawa; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Consensus conference; Delphi method; Family medicine; Cancer; Oncology; Internal medicine","score_opus":0.029900381610725574,"score_gpt":0.305569207665092,"score_spread":0.27566882605436643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985130880","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003528323,0.96437776,1.6495478e-7,0.022362834,0.00038004256,0.0038705843,0.0014306812,0.000010967854,0.0040386682],"genre_scores_gemma":[0.0044822674,0.9895677,0.00002735819,0.0013048052,0.00007416552,0.00019118687,0.00018866594,0.000040133138,0.004123749],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99764365,0.00019165284,0.00044561317,0.00027846437,0.0005985177,0.00084212905],"domain_scores_gemma":[0.99774,0.00016881483,0.00056481524,0.00022257754,0.00043641563,0.00086739246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036101582,0.0003011309,0.0009113082,0.00034758265,0.00025329815,0.000051362887,0.00020442304,0.0002783447,0.0004607773],"category_scores_gemma":[0.00006669078,0.0001474789,0.00026431395,0.00041050187,0.00005201379,0.000024171533,0.00001724448,0.00095379783,0.000057063353],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035612163,0.000110488065,0.09003176,0.0021201917,0.0038294895,0.0004446826,0.000073969975,0.000014406538,1.87303e-8,0.0003051568,0.02006382,0.8826499],"study_design_scores_gemma":[0.0014713367,0.0006877205,0.0142650865,0.003093587,0.00092476286,0.000014219243,0.000052394138,0.0000016486307,8.847904e-8,0.000029710069,0.9792885,0.00017091141],"about_ca_topic_score_codex":0.014970622,"about_ca_topic_score_gemma":0.03559043,"teacher_disagreement_score":0.9592247,"about_ca_system_score_codex":0.006366682,"about_ca_system_score_gemma":0.004949127,"threshold_uncertainty_score":0.9974477},"labels":[],"label_agreement":null},{"id":"W2985290258","doi":"10.1016/j.urolonc.2019.10.006","title":"Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group","year":2019,"lang":"en","type":"review","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Survivorship curve; Prostate cancer; Medicine; Disease; Cancer survivorship; Cancer; Oncology; Prostate; Quality of life (healthcare); Gynecology; Internal medicine; Nursing","score_opus":0.354657451780228,"score_gpt":0.5029034638587878,"score_spread":0.1482460120785598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985290258","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019536003,0.95444,0.0000034013833,0.012510737,0.00077630335,0.011505008,0.00086073525,0.000058217258,0.00030960116],"genre_scores_gemma":[0.0005662702,0.9739099,0.001864293,0.00030110194,0.0007432392,0.016785627,0.0011380787,0.0001270924,0.0045643863],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98992616,0.003821239,0.0012749891,0.0017246153,0.0011195998,0.0021333792],"domain_scores_gemma":[0.9882961,0.009259759,0.00051750586,0.0007985712,0.0006172812,0.0005107912],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0121575445,0.00071818713,0.0021262837,0.0009798973,0.001108474,0.00024313932,0.00067018124,0.0008330237,0.000102233804],"category_scores_gemma":[0.0006979751,0.00044676784,0.0002807994,0.0023859076,0.002219243,0.00017683984,0.0004895697,0.004226389,0.000034327284],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013016224,0.0005049712,0.16978398,0.010775297,0.0007032567,0.00033832918,0.0033394436,0.00001607361,0.00001975711,0.0012766479,0.008575058,0.8033656],"study_design_scores_gemma":[0.0017963486,0.002069973,0.0002723557,0.010892716,0.000729545,0.000025849884,0.00093059934,0.00017919745,0.0000072984776,0.0030781475,0.97959614,0.00042183156],"about_ca_topic_score_codex":0.03613741,"about_ca_topic_score_gemma":0.027900552,"teacher_disagreement_score":0.97102106,"about_ca_system_score_codex":0.0025856893,"about_ca_system_score_gemma":0.0066574384,"threshold_uncertainty_score":0.9997984},"labels":[],"label_agreement":null},{"id":"W2985519058","doi":"10.1016/s0167-8140(19)33247-5","title":"189 Bone Scans in the Management of Metastatic Castrate-Resistant Prostate Cancer: Survey of Patterns of Practice in Canadian Radiation Oncologists, Medical Oncologists and Urologists","year":2019,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Radiation oncology; Oncology; Cancer; Medical physics; General surgery; Internal medicine; Radiation therapy","score_opus":0.028967158754834698,"score_gpt":0.38114691765856756,"score_spread":0.3521797589037329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985519058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799844,0.013495259,0.000004802996,0.0043499996,0.00006711942,0.0013873284,0.00012012729,0.0000031239997,0.00058781286],"genre_scores_gemma":[0.94059,0.058600593,0.00022849196,0.00036917848,0.000009052698,0.00008456489,0.000039217335,0.000009799775,0.00006905074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773484,0.0007754564,0.0005466377,0.00026419168,0.00032271227,0.00035614244],"domain_scores_gemma":[0.998341,0.00088678976,0.00034312325,0.0001897041,0.00009880637,0.00014056603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028732284,0.00014034176,0.0006686654,0.0002629577,0.000022764496,0.0000053413355,0.00011760872,0.00015274169,0.00007667557],"category_scores_gemma":[0.00011353703,0.000094226125,0.000030445479,0.00034973756,0.00034486287,0.0000626581,0.000021436472,0.00025347504,2.6206212e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005345965,0.0007514684,0.91016376,0.00073033426,0.00036929038,0.0010154223,0.0039898283,0.000059668648,0.00049226405,0.00045477043,0.00005503522,0.07657221],"study_design_scores_gemma":[0.008191801,0.0041068774,0.98183084,0.00017942539,0.000079941834,0.00008472309,0.0013653913,0.00029932876,0.00016399773,0.000021508285,0.0035913568,0.00008479262],"about_ca_topic_score_codex":0.44264063,"about_ca_topic_score_gemma":0.62180513,"teacher_disagreement_score":0.17916448,"about_ca_system_score_codex":0.00072903244,"about_ca_system_score_gemma":0.0015997703,"threshold_uncertainty_score":0.56107086},"labels":[],"label_agreement":null},{"id":"W2985545877","doi":"10.1016/j.bmcl.2019.126783","title":"Formation of 5α-dihydrotestosterone from 5α-androstane-3α,17β-diol in prostate cancer LAPC-4 cells – Identifying inhibitors of non-classical pathways producing the most potent androgen","year":2019,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université Laval","funders":"Faculté de Médecine, Université Laval; Mitacs","keywords":"Androstane; Dihydrotestosterone; Chemistry; Androgen; Testosterone (patch); Prostate cancer; Androgen receptor; IC50; Prostate; Endocrinology; Internal medicine; Stereochemistry; Pharmacology; Cancer; In vitro; Biochemistry; Hormone; Biology; Medicine","score_opus":0.016809240375881593,"score_gpt":0.25418402200544493,"score_spread":0.23737478162956333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985545877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99156964,0.0015995636,0.000023224951,0.0051075635,0.00023299493,0.0012334323,0.00011168226,0.00002295957,0.00009892412],"genre_scores_gemma":[0.9985516,0.0003639805,0.000053862914,0.00027349376,0.00028785906,0.000060152455,0.00017985892,0.00004117041,0.00018800973],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99736226,0.00004997595,0.0007457104,0.00048781093,0.00087071984,0.00048352],"domain_scores_gemma":[0.99871165,0.00009716465,0.00037869328,0.00052633317,0.0001241645,0.00016198609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042248023,0.0002984731,0.0006086284,0.000093791365,0.00006186511,0.0000188534,0.00023796169,0.00012557373,0.00020404304],"category_scores_gemma":[0.00005776948,0.00020315596,0.000108213746,0.0004896945,0.00026365643,0.00015402079,0.000121906945,0.00048298622,0.0000117497875],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005153246,0.00013152041,0.018519575,0.0011237725,0.000100856116,0.00009343373,0.0030602142,0.000017808032,0.9743327,1.6017157e-7,0.0006642577,0.0014403606],"study_design_scores_gemma":[0.0038833674,0.00014407927,0.0069502946,0.0018882114,0.00014141735,0.000040796313,0.0013167445,0.00031927248,0.9850092,0.000004967699,0.000118660515,0.00018301436],"about_ca_topic_score_codex":0.0007497856,"about_ca_topic_score_gemma":0.000025042762,"teacher_disagreement_score":0.011569281,"about_ca_system_score_codex":0.00044512108,"about_ca_system_score_gemma":0.00032500553,"threshold_uncertainty_score":0.828446},"labels":[],"label_agreement":null},{"id":"W2986868911","doi":"10.1016/j.ccell.2019.10.005","title":"Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors","year":2019,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; KWF Kankerbestrijding; Prostate Cancer Canada; Astellas Pharma; Government of Ontario; Movember Foundation","keywords":"Biology; Somatic cell; Transactivation; Transcription factor; Prostate cancer; Genetics; FOXA1; Cancer research; Gene; Computational biology; Cancer","score_opus":0.017686420948301654,"score_gpt":0.2647707488769897,"score_spread":0.24708432792868806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986868911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962412,0.0011765085,0.000009194411,0.00013893141,0.00009257754,0.00073521934,0.000087672204,0.000011433516,0.0015072707],"genre_scores_gemma":[0.9959021,0.0012859388,0.00009644866,0.000044403034,0.000016099193,0.000087821354,0.000057905767,0.0000137675515,0.0024954733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913627,0.000057293037,0.00023814433,0.00020659258,0.00017909976,0.00018261629],"domain_scores_gemma":[0.9995994,0.000040962917,0.000094988856,0.00014704432,0.00004583631,0.00007179232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017108402,0.000094963805,0.00022302294,0.00007485278,0.00003235189,0.000008315159,0.000031147327,0.000037387515,0.00035925643],"category_scores_gemma":[0.0000068873724,0.00007885177,0.000032156568,0.00012756974,0.0000657232,0.000117148156,0.0000087596945,0.000107704225,0.000015476262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006237137,0.00013719211,0.8945127,0.0011724898,0.000041236555,0.000017846483,0.0021122664,0.00012470593,0.10023035,0.000039300834,0.00007330478,0.0009148736],"study_design_scores_gemma":[0.0032490408,0.00040246965,0.96718585,0.00079949934,0.00006398644,0.0000033677966,0.00035739387,0.0004911977,0.027044106,0.00026520147,0.000040029452,0.000097852695],"about_ca_topic_score_codex":0.00018820762,"about_ca_topic_score_gemma":0.000022730646,"teacher_disagreement_score":0.07318624,"about_ca_system_score_codex":0.00018678959,"about_ca_system_score_gemma":0.00015198367,"threshold_uncertainty_score":0.39336058},"labels":[],"label_agreement":null},{"id":"W2987820141","doi":"10.1097/md.0000000000017748","title":"Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer","year":2019,"lang":"en","type":"review","venue":"Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Office of the Chief Medical Examiner","funders":"National Key Research and Development Program of China; Department of Science and Technology of Sichuan Province; National Natural Science Foundation of China","keywords":"Medicine; Enzalutamide; Prostate cancer; Hazard ratio; Adverse effect; Internal medicine; Randomized controlled trial; Urology; Oncology; Abiraterone; Cancer; Confidence interval; Androgen receptor","score_opus":0.10900504023077379,"score_gpt":0.4317681291000279,"score_spread":0.3227630888692541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987820141","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00088136416,0.9929127,0.000005662594,0.0010092694,0.0001497142,0.0045533315,0.0002732503,0.000015151138,0.00019955906],"genre_scores_gemma":[0.00033843095,0.9940436,0.000087215536,0.00004109274,0.0002616029,0.00031896745,0.0003952836,0.000050064617,0.0044637783],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99834514,0.00004918021,0.0006180647,0.0004216748,0.00027908312,0.0002868741],"domain_scores_gemma":[0.99881107,0.00033381203,0.0002577183,0.0002702453,0.00015017064,0.0001770148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035321308,0.00032573187,0.0019391943,0.00019871004,0.000057147365,0.000007715613,0.000059215155,0.00015631525,0.00007081394],"category_scores_gemma":[0.00010374507,0.00018478751,0.00008237948,0.00017939495,0.0003405243,0.000034125263,0.000040418705,0.00021208101,0.0000021951196],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015578058,0.00005544716,0.000089801564,0.08321429,0.0005157011,0.000022372478,0.00034064444,1.2214576e-7,0.00030031631,0.000054480373,0.00093294535,0.91291606],"study_design_scores_gemma":[0.009510379,0.0019459829,0.00054843153,0.04431554,0.0029420357,0.00004237887,0.00005647671,0.000005040074,0.000044692377,0.000014351674,0.94039387,0.00018085408],"about_ca_topic_score_codex":0.0001399978,"about_ca_topic_score_gemma":0.000022105465,"teacher_disagreement_score":0.9394609,"about_ca_system_score_codex":0.00012845146,"about_ca_system_score_gemma":0.00050973013,"threshold_uncertainty_score":0.7535416},"labels":[],"label_agreement":null},{"id":"W2987952774","doi":"10.1002/jcb.29515","title":"Comparison of the roles of estrogens and androgens in breast cancer and prostate cancer","year":2019,"lang":"en","type":"review","venue":"Journal of Cellular Biochemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Canadian Institutes of Health Research; China Postdoctoral Science Foundation; National Natural Science Foundation of China","keywords":"Prostate cancer; Cancer; Breast cancer; Prostate; Oncology; Internal medicine; Medicine; Biology; Gynecology","score_opus":0.03920681455372554,"score_gpt":0.38220274631016565,"score_spread":0.3429959317564401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987952774","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23602425,0.76326203,1.5594367e-7,0.00015298277,0.000047648246,0.00026429532,0.00022274214,7.553574e-7,0.000025122603],"genre_scores_gemma":[0.06286262,0.9366085,0.000014875262,0.000003817088,0.00008595513,0.0000080791215,0.00001149516,0.000020927055,0.0003837618],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985755,0.000040433304,0.0007096253,0.00016456333,0.0003344628,0.00017542507],"domain_scores_gemma":[0.998523,0.000040594823,0.00093552645,0.00019834713,0.00019528018,0.00010723988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019309466,0.00021594958,0.001498705,0.00009617325,0.000018828317,0.00000865376,0.0001291626,0.0001953287,0.000026066515],"category_scores_gemma":[0.000013793403,0.00011982101,0.00026445754,0.00018852708,0.00022024318,0.00002199297,0.00008371902,0.00045902803,1.2082074e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076627143,0.0006505952,0.21433769,0.14257392,0.0025379863,0.00012015642,0.00075046904,0.000005847739,0.094311,0.0000022605977,0.00066845777,0.54327536],"study_design_scores_gemma":[0.00804189,0.00053232955,0.0025011103,0.18555301,0.009582664,0.001844164,0.00091859297,0.0000414284,0.7177917,0.000012906475,0.0724634,0.00071679667],"about_ca_topic_score_codex":0.000028883345,"about_ca_topic_score_gemma":0.00000529797,"teacher_disagreement_score":0.6234807,"about_ca_system_score_codex":0.00013886765,"about_ca_system_score_gemma":0.0011417908,"threshold_uncertainty_score":0.4886159},"labels":[],"label_agreement":null},{"id":"W2988218846","doi":"10.1124/dmd.119.088229","title":"Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation","year":2019,"lang":"en","type":"article","venue":"Drug Metabolism and Disposition","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"Canadian Institutes of Health Research; Université Laval","keywords":"Glucuronidation; Pharmacology; Chemistry; Medicine; Microsome; Biochemistry; Enzyme","score_opus":0.0053481963119525935,"score_gpt":0.25130911853691823,"score_spread":0.24596092222496563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988218846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868892,0.0118957795,0.000024347535,0.00020789498,0.000058363603,0.00063575763,0.00022606191,0.000008834035,0.00005379238],"genre_scores_gemma":[0.9955239,0.0040684287,0.00003202601,0.0000383035,0.000030800093,0.00001613474,0.00019718811,0.000010010955,0.000083166735],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989621,0.00011150125,0.00030880558,0.00025204435,0.000215358,0.00015016404],"domain_scores_gemma":[0.99932736,0.00004756638,0.00023584365,0.00009515133,0.00020060218,0.00009349029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019382397,0.00015384093,0.00040100445,0.00013675698,0.000042289757,0.000013136559,0.00003996556,0.00007215689,0.000036494228],"category_scores_gemma":[0.000019519855,0.000109405235,0.000036475565,0.00015083821,0.00013802943,0.000436965,0.000057487185,0.00008754438,0.0000013272385],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001449266,0.00020183576,0.0027624918,0.00026145467,0.000117779324,0.0000010966644,0.0009505273,0.000008393617,0.9878909,0.0002979781,0.0000065014206,0.006051802],"study_design_scores_gemma":[0.002986455,0.0002524246,0.24739699,0.00008555492,0.00021016794,0.00000771086,0.0002465547,0.00023589992,0.74832386,0.00015509843,0.000023419332,0.00007585481],"about_ca_topic_score_codex":0.00009475172,"about_ca_topic_score_gemma":7.474127e-7,"teacher_disagreement_score":0.2446345,"about_ca_system_score_codex":0.000011575884,"about_ca_system_score_gemma":0.000048217884,"threshold_uncertainty_score":0.4461416},"labels":[],"label_agreement":null},{"id":"W2988378549","doi":"10.1093/annonc/mdz394.042","title":"Timing of radiotherapy (RT) after radical prostatectomy (RP): First results from the RADICALS RT randomised controlled trial (RCT) [NCT00541047]","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostatectomy; Randomized controlled trial; Radiation therapy; Urology; Oncology; Prostate cancer; Internal medicine; Cancer","score_opus":0.059280476973893166,"score_gpt":0.38696669541707635,"score_spread":0.3276862184431832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988378549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9552066,0.005765854,0.000017494318,0.025224753,0.0004433763,0.008554277,0.0001294236,0.000028260865,0.004629978],"genre_scores_gemma":[0.9912298,0.003906969,0.00031256603,0.001538185,0.00055577164,0.0006236003,0.000097395554,0.000037037968,0.0016987268],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968019,0.0005621681,0.0011267173,0.00043905774,0.0005593441,0.00051082857],"domain_scores_gemma":[0.9943702,0.0040777354,0.0004890004,0.0005942966,0.00026640616,0.00020235838],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001882387,0.00025480398,0.0017401656,0.00013619082,0.000066336084,0.0000122921965,0.00026739665,0.00031225028,0.0013514935],"category_scores_gemma":[0.00087093347,0.00014040459,0.0005355659,0.00019927548,0.0005996857,0.00007071645,0.000057791098,0.00038320743,0.00003319035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9701263,0.0010168742,0.0009671397,0.00005827881,0.0013211871,0.000094636074,0.0013093383,0.000006190955,0.0028784066,0.000021697448,0.013381585,0.008818396],"study_design_scores_gemma":[0.9115896,0.008542196,0.0024459339,0.00020066956,0.00019833475,0.000010541486,0.00010258784,0.00027248115,0.007542349,0.00013933892,0.06881635,0.00013961605],"about_ca_topic_score_codex":0.00021675078,"about_ca_topic_score_gemma":0.0000185836,"teacher_disagreement_score":0.05853667,"about_ca_system_score_codex":0.00009813666,"about_ca_system_score_gemma":0.00080516236,"threshold_uncertainty_score":0.9995614},"labels":[],"label_agreement":null},{"id":"W2989187593","doi":"10.1097/rlu.0000000000002799","title":"Early Detection of Metastatic Prostate Cancer Relapse on 68Ga-PSMA-11 PET/CT in a Patient Still Exhibiting Biochemical Response","year":2019,"lang":"en","type":"article","venue":"Clinical Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Glutamate carboxypeptidase II; Oncology; Prostate-specific antigen; Internal medicine; Prostate; Chemotherapy; Cancer","score_opus":0.04396516023417339,"score_gpt":0.37804729405805637,"score_spread":0.33408213382388297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989187593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99277556,0.00058558135,5.684465e-7,0.00467898,0.00038750377,0.0011980986,0.000016997457,0.00004765542,0.000309075],"genre_scores_gemma":[0.9976783,0.0005262107,0.00009855412,0.00084118266,0.00011380323,0.000036667152,0.000013436185,0.000056984947,0.000634902],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99694484,0.00038776273,0.0010582497,0.0005487708,0.0006403493,0.00042003093],"domain_scores_gemma":[0.9977188,0.0010775175,0.00026812832,0.00044719232,0.00017671881,0.0003116615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015083583,0.00022756628,0.0008165372,0.00028106995,0.000032500237,0.0000063122743,0.00010707031,0.00003375116,0.00047355026],"category_scores_gemma":[0.0021186543,0.00015436499,0.0001545657,0.00047648576,0.0004145333,0.00006329466,0.00007692112,0.00071460573,0.0001230075],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18180728,0.004933953,0.26904795,0.0018636661,0.0007650242,0.011903944,0.0058239633,0.000040372266,0.4423293,0.000119340555,0.004818534,0.07654669],"study_design_scores_gemma":[0.09034497,0.07336961,0.718408,0.017170945,0.0009849536,0.0009144056,0.006648936,0.0034378374,0.04960651,0.00032051723,0.037597064,0.0011962336],"about_ca_topic_score_codex":0.0003782438,"about_ca_topic_score_gemma":0.000016092756,"teacher_disagreement_score":0.44936007,"about_ca_system_score_codex":0.0002464454,"about_ca_system_score_gemma":0.00016466882,"threshold_uncertainty_score":0.6294821},"labels":[],"label_agreement":null},{"id":"W2989237601","doi":"10.1016/s0167-8140(19)33260-8","title":"20 Preliminary Results of a Two Stage Phase II Study of 18F-DCFPYL PET-MR for Enabling Oligometastases Ablative Therapy in Subclinical Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Ablative case; Prostate cancer; Medicine; Stage (stratigraphy); Subclinical infection; Nuclear medicine; Prostate; Oncology; Radiology; Cancer; Radiation therapy; Internal medicine; Biology","score_opus":0.06840227353379989,"score_gpt":0.453800764173566,"score_spread":0.3853984906397661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989237601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844848,0.010372585,0.000008257704,0.00066801574,0.00011422594,0.0039468003,0.00030347845,0.000011884284,0.000089971836],"genre_scores_gemma":[0.9825728,0.014231574,0.0004600978,0.00012471215,0.00008496288,0.00031169545,0.000051041166,0.0000270249,0.0021360912],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99824566,0.00021602889,0.00062167295,0.00040197436,0.00018851135,0.00032613153],"domain_scores_gemma":[0.9984089,0.00082081597,0.00027706166,0.00024015078,0.00015852113,0.0000945139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007805099,0.00018171243,0.0008845643,0.0002588425,0.000055441258,0.0000046006517,0.00008663582,0.00006296359,0.00010248901],"category_scores_gemma":[0.00004887376,0.0001290426,0.00008751377,0.00026838513,0.00019144757,0.00008084318,0.000028722005,0.00020077523,2.7039536e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52578086,0.02694129,0.15052864,0.000616869,0.0020646749,0.00038084455,0.04622614,0.00038820927,0.07831634,0.000091545924,0.00049020426,0.16817442],"study_design_scores_gemma":[0.43141845,0.48976955,0.013228286,0.000378732,0.00018852938,0.000040873743,0.007608268,0.0026797182,0.027200405,0.00012801215,0.026978238,0.00038093867],"about_ca_topic_score_codex":0.00056369556,"about_ca_topic_score_gemma":0.0003590165,"teacher_disagreement_score":0.46282825,"about_ca_system_score_codex":0.00022181908,"about_ca_system_score_gemma":0.0004898998,"threshold_uncertainty_score":0.52622044},"labels":[],"label_agreement":null},{"id":"W2989637365","doi":"10.1038/s41391-019-0188-4","title":"Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer","year":2019,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Prostate Cancer Foundation; U.S. Department of Health and Human Services","keywords":"Prostate cancer; Germline; Somatic cell; Biology; Androgen deprivation therapy; Cancer research; Germline mutation; Cancer; Oncology; Genetics; Internal medicine; Medicine; Gene; Mutation","score_opus":0.014099709778439133,"score_gpt":0.30703609069556975,"score_spread":0.29293638091713065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989637365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770188,0.013565444,0.0000026749697,0.0035318336,0.00016401571,0.0040359613,0.0014397972,0.00011178013,0.0001297293],"genre_scores_gemma":[0.98754513,0.0034490086,0.00012673374,0.0005163333,0.000032401407,0.0020952788,0.0004280476,0.000084559026,0.0057225227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997305,0.00010323857,0.0005253877,0.0007353686,0.0005433434,0.00078767],"domain_scores_gemma":[0.99851143,0.00025618437,0.00021408696,0.0003042819,0.0002330248,0.00048098006],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018715257,0.0004830993,0.00090598996,0.0002544331,0.00017789262,0.00014581675,0.00008284131,0.000057106532,0.00020542993],"category_scores_gemma":[0.00010988362,0.00033164976,0.00007412671,0.0005115639,0.00029051097,0.0004557334,0.0000798235,0.00024707438,0.000006614317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030008748,0.00041336502,0.9830505,0.00090899353,0.0002804566,0.00014864566,0.0023158088,0.000090850495,0.00079290284,0.00003808904,0.000059334117,0.008900141],"study_design_scores_gemma":[0.016003005,0.0009973332,0.976844,0.0017649675,0.00035872453,0.000013352589,0.00093966007,0.0015621288,0.00047428664,0.0004143408,0.00011580397,0.0005123784],"about_ca_topic_score_codex":0.0005688395,"about_ca_topic_score_gemma":0.0005377881,"teacher_disagreement_score":0.01300213,"about_ca_system_score_codex":0.00028658233,"about_ca_system_score_gemma":0.0008607182,"threshold_uncertainty_score":0.9999136},"labels":[],"label_agreement":null},{"id":"W2989651221","doi":"10.1007/s11523-019-00685-x","title":"Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Castration; Internal medicine; Prostate; Cancer; Hormone","score_opus":0.06205601479162649,"score_gpt":0.388488184776486,"score_spread":0.3264321699848595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989651221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905395,0.0006829297,0.000043246127,0.002779356,0.00032559814,0.004759546,0.00040959986,0.000041440446,0.0004187845],"genre_scores_gemma":[0.9956095,0.00015317292,0.00229343,0.00012394124,0.00014309854,0.0005167823,0.0005222168,0.000027430877,0.0006104147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826306,0.00020465253,0.00042991567,0.0004489498,0.00021657205,0.00043685842],"domain_scores_gemma":[0.9973498,0.002000702,0.00016288337,0.00024442386,0.00015858436,0.000083626546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050159235,0.00021798909,0.0006052415,0.000079164056,0.00012664574,0.000025567591,0.00007653965,0.00006285586,0.000046137],"category_scores_gemma":[0.00022203592,0.00013135013,0.0000717116,0.0001535101,0.000040980856,0.00008615873,0.000038983333,0.0001719741,0.00001842058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031326227,0.003513669,0.8071624,0.00009367232,0.002830668,0.0009144856,0.067793496,0.005845375,0.03299592,0.00021774501,0.00036919778,0.046937115],"study_design_scores_gemma":[0.09006305,0.014641116,0.835722,0.00026145225,0.0011651806,0.000018380826,0.022674683,0.023348277,0.009048719,0.0008717361,0.0017129957,0.00047236995],"about_ca_topic_score_codex":0.014506008,"about_ca_topic_score_gemma":0.012858659,"teacher_disagreement_score":0.05873682,"about_ca_system_score_codex":0.00085259095,"about_ca_system_score_gemma":0.0007449758,"threshold_uncertainty_score":0.9920565},"labels":[],"label_agreement":null},{"id":"W2989894179","doi":"10.1016/s1470-2045(19)30684-9","title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":644,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Prostate Cancer UK; Public Health Agency; Division of Research, Evaluation, and Communication; Prostate Cancer Foundation; Movember Foundation; AstraZeneca; Medical Research Council; Institute of Cancer Research; Cancer Research UK; Royal Marsden NHS Foundation Trust; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; U.S. Department of Veterans Affairs","keywords":"Olaparib; Medicine; Prostate cancer; Open label; Oncology; Internal medicine; Urology; Cancer; Randomized controlled trial; Gene; Biology; Poly ADP ribose polymerase; Genetics","score_opus":0.06985848620486315,"score_gpt":0.3983035503391584,"score_spread":0.3284450641342952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989894179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98577255,0.0003149389,0.000005262122,0.0022625683,0.00014296887,0.010059017,0.00009013608,0.00004278644,0.0013097492],"genre_scores_gemma":[0.9915929,0.00013533571,0.0019578305,0.0005485338,0.00015101947,0.0022675411,0.00033710498,0.000037107773,0.0029726448],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99797,0.00035653292,0.00041013522,0.00039715457,0.00034868415,0.0005175379],"domain_scores_gemma":[0.998748,0.00020268434,0.00022081839,0.0004906395,0.00021199527,0.00012585628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065050466,0.00022007033,0.0008185846,0.00009072928,0.00014391918,0.000047822094,0.00021126062,0.000058173395,0.00022457528],"category_scores_gemma":[0.0000498832,0.000110979185,0.0000323108,0.0003338486,0.00015791031,0.00017606796,0.0000611533,0.00031449733,0.000033027827],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9596585,0.005033165,0.0270315,0.00011363914,0.0007090644,0.00014430795,0.0026242207,0.00008611616,0.0013989221,0.000045459612,0.00112815,0.0020269298],"study_design_scores_gemma":[0.964244,0.0114346,0.015192544,0.00014105094,0.00037022217,0.000008330198,0.0002920953,0.00044641033,0.00075902836,0.000015368965,0.0069114133,0.00018494885],"about_ca_topic_score_codex":0.00032808215,"about_ca_topic_score_gemma":0.0029954626,"teacher_disagreement_score":0.011838956,"about_ca_system_score_codex":0.0004377957,"about_ca_system_score_gemma":0.001497502,"threshold_uncertainty_score":0.45255998},"labels":[],"label_agreement":null},{"id":"W2990053395","doi":"10.1038/s41467-019-13084-7","title":"The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact","year":2019,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"Johnson and Johnson; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; Astellas Pharma Europe; Astellas Pharma","keywords":"Prostate cancer; Genotype; Biology; Castration; Prostate; Medicine; Cancer research; Bioinformatics; Oncology; Genetics; Gene; Internal medicine; Cancer","score_opus":0.032103634677275894,"score_gpt":0.38278859010642097,"score_spread":0.3506849554291451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990053395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98048484,0.014198783,0.000008883918,0.0024212275,0.000085793145,0.0013255166,0.00021163905,0.00002371182,0.0012395865],"genre_scores_gemma":[0.99495625,0.0021509775,0.0015566633,0.00004368046,0.000033765707,0.00006488763,0.00032965658,0.000021394308,0.0008427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998736,0.00019948909,0.00037374563,0.00018431299,0.00027395418,0.00023245053],"domain_scores_gemma":[0.99732083,0.0006496057,0.00020640182,0.0013734812,0.00034161695,0.000108035674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004893762,0.00013408125,0.00029361635,0.00005745464,0.00025960818,0.000034188994,0.00041332014,0.000086621585,0.000040825133],"category_scores_gemma":[0.0001450375,0.00006922887,0.00013401489,0.00024875355,0.00030006788,0.000059996713,0.00010745612,0.000690789,0.00001722605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005242687,0.00040935617,0.96309686,0.0001253903,0.001510401,0.000016627426,0.00056199555,0.00019032013,0.022219317,0.00047593302,0.0023354026,0.0038157385],"study_design_scores_gemma":[0.003560772,0.0009335943,0.98799807,0.000105358784,0.00030030994,0.00002345614,0.0003638606,0.0015036699,0.00028097158,0.000061032566,0.0047420436,0.00012685625],"about_ca_topic_score_codex":0.00021783955,"about_ca_topic_score_gemma":0.0016445072,"teacher_disagreement_score":0.024901245,"about_ca_system_score_codex":0.00015420288,"about_ca_system_score_gemma":0.0008223211,"threshold_uncertainty_score":0.30011728},"labels":[],"label_agreement":null},{"id":"W2990415936","doi":"10.1016/j.eururo.2019.11.013","title":"Local Failure in High-grade Prostate Cancer: An Elusive but Important Outcome and Target for Clinical Trials","year":2019,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Clinical trial; Prostate; Oncology; Outcome (game theory); Cancer; Internal medicine; Gynecology","score_opus":0.1164952402966855,"score_gpt":0.43139707213675804,"score_spread":0.31490183184007253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990415936","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12673692,0.0059824423,0.00008499746,0.857842,0.0017140432,0.005675111,0.001649298,0.00009530182,0.00021983968],"genre_scores_gemma":[0.10551973,0.010858261,0.0010599401,0.8345828,0.015888901,0.00065721356,0.0088632135,0.00066586834,0.021904074],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99291736,0.0028841537,0.0018175658,0.0011670515,0.00029925306,0.0009146216],"domain_scores_gemma":[0.997047,0.001360008,0.0006247395,0.0006101189,0.00014478833,0.00021332159],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004371593,0.0005079654,0.0021916032,0.00032136135,0.000063305495,0.000036607962,0.0002692956,0.00071185775,0.0001451817],"category_scores_gemma":[0.00079820736,0.00035625257,0.00030358238,0.00011581383,0.00047408303,0.00006658302,0.0001751369,0.0026066005,0.000061152256],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042929756,0.00020932588,0.19064742,0.00060700363,0.0006094448,0.009230997,0.00019902967,0.000009881338,0.000105415944,0.000016867756,0.7885737,0.005497937],"study_design_scores_gemma":[0.015010446,0.0051203817,0.018581217,0.00006304895,0.00043740115,0.00010250771,0.000040136718,0.0001300237,0.000022785996,0.00010107709,0.96000636,0.0003846097],"about_ca_topic_score_codex":0.00012781782,"about_ca_topic_score_gemma":0.00007909897,"teacher_disagreement_score":0.1720662,"about_ca_system_score_codex":0.00013738242,"about_ca_system_score_gemma":0.00047343172,"threshold_uncertainty_score":0.99988896},"labels":[],"label_agreement":null},{"id":"W2991218841","doi":"10.1002/cncr.32630","title":"Impact of age at diagnosis of de novo metastatic prostate cancer on survival","year":2019,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Confidence interval; Epidemiology; Internal medicine; Cohort; Cancer; Prostate; Oncology; Gynecology","score_opus":0.05179489086910473,"score_gpt":0.4078372535696198,"score_spread":0.3560423627005151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991218841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923914,0.00448186,0.0000010335153,0.000314639,0.00017052505,0.00073954894,0.0003362634,0.000012280981,0.0015524407],"genre_scores_gemma":[0.9875584,0.0055320226,0.000034721146,0.000057987047,0.000053097046,0.00030299512,0.000030486128,0.000029908433,0.006400346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885035,0.00004368163,0.00021155452,0.00021609665,0.000335841,0.00034247397],"domain_scores_gemma":[0.99921024,0.00011563845,0.000113190225,0.00027379525,0.00014450242,0.00014265437],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013309914,0.00015034224,0.0004577014,0.00010624587,0.000021207688,0.0000043193318,0.00007945677,0.00004089069,0.0031336471],"category_scores_gemma":[0.000028018772,0.00009848044,0.00018439532,0.00023908442,0.00010652848,0.00004191039,0.000039119004,0.0001170024,0.000026632251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020004625,0.00023520697,0.963316,0.0005198419,0.0006391294,0.00006299758,0.00085311115,0.00037567163,0.024387335,0.000015626523,0.0009918747,0.006602741],"study_design_scores_gemma":[0.006734957,0.0019247999,0.84828585,0.00078292924,0.00028454445,0.0000052799896,0.00009839629,0.00010514916,0.14013328,0.000042518095,0.00142367,0.00017863064],"about_ca_topic_score_codex":0.002145207,"about_ca_topic_score_gemma":0.00028894626,"teacher_disagreement_score":0.11574593,"about_ca_system_score_codex":0.0008989151,"about_ca_system_score_gemma":0.00056401524,"threshold_uncertainty_score":0.99777764},"labels":[],"label_agreement":null},{"id":"W2991470240","doi":"10.1016/j.jsbmb.2019.105559","title":"Meta-Analysis of steroid-converting enzymes and related receptors in prostate cancer suggesting novel combined therapies","year":2019,"lang":"en","type":"review","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Fondation CHU de Québec","keywords":"Prostate cancer; Androgen receptor; Receptor; Androgen; Cancer research; Internal medicine; Endocrinology; Cancer; Prostate; Signal transduction; Steroid; Biology; Medicine; Hormone; Cell biology","score_opus":0.07877720637946682,"score_gpt":0.3751090404679978,"score_spread":0.296331834088531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991470240","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1217115,0.8774781,0.000004148159,0.0003245092,0.000046534533,0.0003643809,0.00005081025,0.000002685549,0.000017304188],"genre_scores_gemma":[0.042911593,0.95650506,0.000058027363,0.000041962405,0.000016168055,0.000014022807,0.00006131046,0.000021285214,0.00037058958],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99814856,0.0002666252,0.00094370585,0.00024498493,0.00015386095,0.00024228748],"domain_scores_gemma":[0.9981739,0.0002603489,0.0010870629,0.00023740792,0.00015983317,0.000081444596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000931305,0.00031597327,0.0027232901,0.00028237075,0.000040008457,0.000011643042,0.00016583073,0.00024312247,0.000035835674],"category_scores_gemma":[0.000064215565,0.00015872673,0.0006321408,0.00042605598,0.00032297175,0.000024820041,0.00011153596,0.00053883594,1.8788768e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019053302,0.000383843,0.0020964048,0.022615151,0.54053867,0.00016873462,0.002861276,0.0000124418,0.2784587,0.000016685643,0.000031372136,0.15091136],"study_design_scores_gemma":[0.00826687,0.002629576,0.000113264694,0.00860004,0.8456269,0.0012739205,0.0013950509,0.00005505609,0.11788642,0.00006628757,0.013143572,0.0009430559],"about_ca_topic_score_codex":0.000035154048,"about_ca_topic_score_gemma":0.0000018406547,"teacher_disagreement_score":0.3050882,"about_ca_system_score_codex":0.00006000717,"about_ca_system_score_gemma":0.00023413463,"threshold_uncertainty_score":0.64726883},"labels":[],"label_agreement":null},{"id":"W2992330814","doi":"10.1158/1535-7163.targ-19-cn06-01","title":"Abstract CN06-01: Lineage plasticity and the neuroendocrine phenotype as a resistance mechanism in prostate cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Cancer research; Prostate; Exome sequencing; Adenocarcinoma; Somatic evolution in cancer; DNA methylation; Biology; Cancer; Epigenomics; Copy number analysis; Chromoplexy; Liquid biopsy; Medicine; Phenotype; Copy-number variation; PCA3; Genetics; Gene; Genome","score_opus":0.02010044019727532,"score_gpt":0.3109422800884922,"score_spread":0.29084183989121687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992330814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677335,0.019827249,0.000028588434,0.008793175,0.00022045014,0.0016929129,0.000042894575,0.000043221098,0.001618008],"genre_scores_gemma":[0.979695,0.012728996,0.00006534903,0.003438992,0.000065168475,0.000299042,0.000010504071,0.000059726015,0.0036371984],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982464,0.00008241412,0.00028080042,0.00044173963,0.00044541009,0.00050325016],"domain_scores_gemma":[0.99925107,0.00010119323,0.00009814715,0.00033555727,0.00010134053,0.00011268913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001547742,0.0002664362,0.00040693342,0.00009453087,0.000078472054,0.00005170756,0.00015104329,0.00004850392,0.00023081782],"category_scores_gemma":[0.000017261555,0.00017279803,0.00008650989,0.00031493045,0.00019883955,0.000063100604,0.00007679997,0.00048303802,0.000024790545],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06808464,0.0012030083,0.050706614,0.0029905478,0.003030406,0.005249921,0.007642454,0.00095247733,0.7936905,0.02427369,0.00043100695,0.04174474],"study_design_scores_gemma":[0.09812719,0.0015518606,0.109363794,0.0026037148,0.0015050735,0.00013181874,0.001065978,0.005984492,0.6792601,0.013075241,0.08541703,0.0019137245],"about_ca_topic_score_codex":0.0006677799,"about_ca_topic_score_gemma":0.0004472563,"teacher_disagreement_score":0.1144304,"about_ca_system_score_codex":0.00019700402,"about_ca_system_score_gemma":0.00033808476,"threshold_uncertainty_score":0.7046499},"labels":[],"label_agreement":null},{"id":"W2993400819","doi":"10.1016/j.ijrobp.2010.07.1548","title":"Abdominal Adiposity and Testosterone Levels in Patients with Localized Prostate Cancer","year":2010,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Testosterone (patch); Prostate cancer; Urology; Body mass index; Prospective cohort study; Androgen; Internal medicine; Randomization; Cancer; Prostate; Randomized controlled trial; Hormone","score_opus":0.018368178020190182,"score_gpt":0.3404808021231723,"score_spread":0.3221126241029821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993400819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956172,0.00033210986,0.0002866036,0.0025751202,0.0006755198,0.00032845803,0.00006967089,0.000009920475,0.000105360086],"genre_scores_gemma":[0.9969306,0.0002542443,0.0018063652,0.0003500515,0.0005040938,0.00001738514,0.0000487733,0.000016652219,0.00007185081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989039,0.00007756276,0.00037946354,0.0001776551,0.0002605865,0.00020087656],"domain_scores_gemma":[0.9985686,0.00013194277,0.00039895473,0.00008579004,0.00067863165,0.00013608603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028764686,0.00014131037,0.00034580266,0.00015308472,0.00004359876,0.00002029515,0.00013931433,0.00013771786,0.00005930127],"category_scores_gemma":[0.00009032047,0.000099512814,0.00005097043,0.000120025295,0.0002552676,0.00022367,0.000041373714,0.00057057646,0.0000043821274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024857814,0.0003621263,0.8340867,0.000007790821,0.00025621493,0.000034193185,0.00032505067,0.000019210504,0.002402285,0.00017978202,0.000080633756,0.15976022],"study_design_scores_gemma":[0.023856986,0.0021688212,0.96407485,0.00008697207,0.00009742796,0.000061406136,0.000025379768,0.0002994363,0.0028018374,0.00094693905,0.005454989,0.0001249424],"about_ca_topic_score_codex":0.0000460554,"about_ca_topic_score_gemma":0.000055226115,"teacher_disagreement_score":0.15963528,"about_ca_system_score_codex":0.00039336018,"about_ca_system_score_gemma":0.0005829256,"threshold_uncertainty_score":0.40580148},"labels":[],"label_agreement":null},{"id":"W2993435426","doi":"10.5489/cuaj.6384","title":"Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer","year":2019,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; University Health Network; Dalhousie University; University of Toronto; Université de Montréal; Université Laval; University of Alberta; McGill University; University of British Columbia","funders":"","keywords":"Prostate cancer; Castration; Medicine; Guideline; Oncology; Internal medicine; Urology; Cancer; Pathology; Hormone","score_opus":0.02316492422261422,"score_gpt":0.30204903572972464,"score_spread":0.2788841115071104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993435426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77475435,0.00060126645,0.000007084297,0.21092586,0.00084630976,0.0015681254,0.00079798547,0.000042305328,0.010456687],"genre_scores_gemma":[0.97001135,0.00061080774,0.0003253129,0.024225283,0.00052192947,0.00008709769,0.00043006186,0.000035268844,0.0037528675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951986,0.0006948332,0.0008374599,0.0006742527,0.0007898229,0.0018050107],"domain_scores_gemma":[0.9939215,0.00061733014,0.0005460161,0.0002045717,0.00112867,0.0035818717],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020090882,0.00042864608,0.0007831811,0.0008675572,0.00082784524,0.00027259317,0.0001841575,0.00074501516,0.0027829057],"category_scores_gemma":[0.0012787244,0.0003425559,0.00019760612,0.0005923933,0.00008990395,0.00024818277,0.000021204929,0.0017466169,0.00041134327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00033510817,0.00009625226,0.9664449,0.000010582966,0.00065581047,0.001305029,0.00045363247,0.00035784525,0.00016586091,0.00064588635,0.024483135,0.005045965],"study_design_scores_gemma":[0.0044534993,0.0038902157,0.72514176,0.000033874483,0.00036150587,0.0005729941,0.0005911975,0.0012017176,0.000030221705,0.0010081942,0.26219302,0.0005218019],"about_ca_topic_score_codex":0.5480438,"about_ca_topic_score_gemma":0.8285884,"teacher_disagreement_score":0.2805446,"about_ca_system_score_codex":0.01711518,"about_ca_system_score_gemma":0.009325863,"threshold_uncertainty_score":0.99990267},"labels":[],"label_agreement":null},{"id":"W2993673395","doi":"10.1158/1535-7163.targ-19-b117","title":"Abstract B117: Treatment of castrated resistant prostate cancer with EPI-7386, a second generation N-terminal domain androgen receptor inhibitor","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Androgen receptor; Prostate cancer; In vivo; Cancer research; Biology; Androgen; Cancer; Chemistry; Pharmacology; Biochemistry; Genetics; Hormone","score_opus":0.031789674954218174,"score_gpt":0.3149602222976824,"score_spread":0.2831705473434642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993673395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829211,0.013595349,0.000010757422,0.0008886629,0.00016762018,0.0017006578,0.0003069107,0.000032363423,0.00037656978],"genre_scores_gemma":[0.9940747,0.0024892578,0.00035351704,0.00019258646,0.00014993703,0.00037546724,0.00017704413,0.00007486657,0.0021126203],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981926,0.00006030403,0.00035363476,0.0004635198,0.00048261468,0.00044733888],"domain_scores_gemma":[0.99895567,0.000012954384,0.00018966725,0.00039898808,0.00028328714,0.00015945379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009104587,0.00033082045,0.0004791653,0.000095122006,0.00007105064,0.00003731839,0.000078590565,0.0001285126,0.0006911352],"category_scores_gemma":[8.855521e-7,0.00022769351,0.00012483376,0.00029491782,0.00012924495,0.000078804434,0.000014230717,0.0001564017,0.000015458401],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048127132,0.00042925004,0.012131524,0.00027768032,0.0011244623,0.00031701158,0.0014016713,0.00007892426,0.9625739,0.000016207492,0.000050923714,0.016785774],"study_design_scores_gemma":[0.009125018,0.003739242,0.00544225,0.00039484922,0.00033129886,0.000030514651,0.00026541314,0.000097894364,0.9580201,0.000017774686,0.022214245,0.00032139345],"about_ca_topic_score_codex":0.00037951386,"about_ca_topic_score_gemma":0.0004625272,"teacher_disagreement_score":0.022163322,"about_ca_system_score_codex":0.0006954766,"about_ca_system_score_gemma":0.0008985742,"threshold_uncertainty_score":0.92850715},"labels":[],"label_agreement":null},{"id":"W2993693045","doi":"10.2967/jnumed.119.231068","title":"Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for <sup>18</sup>F-FDG Imaging of PSMA-Suppressed Tumors","year":2019,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Windsor","funders":"Canadian Institutes of Health Research","keywords":"Neuroendocrine tumors; Prostate cancer; Cancer research; Glucose transporter; Gene signature; Biology; Glucokinase; Gene expression; Gene; Cancer; Endocrinology; Biochemistry; Genetics; Insulin","score_opus":0.012467410056598495,"score_gpt":0.286186905227933,"score_spread":0.2737194951713345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993693045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931174,0.0029333795,0.000049298545,0.002810121,0.00006982725,0.0009276389,0.000044262593,0.000006583249,0.0000414682],"genre_scores_gemma":[0.99808645,0.0012567684,0.00032540018,0.000096350865,0.00011194808,0.000011664023,0.000008682283,0.00004427956,0.00005842905],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983946,0.00004829392,0.0005270216,0.00022882145,0.00053048314,0.0002707971],"domain_scores_gemma":[0.9987513,0.00011308297,0.00039520432,0.00014904028,0.00042098228,0.00017041326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013541599,0.00020073321,0.0008021254,0.00037826272,0.000028611728,0.000005384077,0.00010134282,0.000025282794,0.00025897403],"category_scores_gemma":[0.000069469934,0.00011835277,0.00009143921,0.00020704747,0.00021050949,0.000119995144,0.000021784786,0.0003196531,1.4329919e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027914418,0.00048395555,0.017203722,0.0011828454,0.00021161602,0.0010319604,0.004800602,0.00012965605,0.9454009,0.00004788579,0.00033991924,0.0012525116],"study_design_scores_gemma":[0.116467476,0.027289579,0.12894665,0.020605303,0.002039452,0.0021965774,0.029904192,0.009018803,0.66185474,0.0005779009,0.0005100568,0.00058928144],"about_ca_topic_score_codex":0.00012541746,"about_ca_topic_score_gemma":0.0000044685407,"teacher_disagreement_score":0.28354618,"about_ca_system_score_codex":0.000112360416,"about_ca_system_score_gemma":0.00016034167,"threshold_uncertainty_score":0.48262858},"labels":[],"label_agreement":null},{"id":"W2993844726","doi":"10.1158/1535-7163.targ-19-c128","title":"Abstract C128: Reprogramming transcription factors SOX2 and REST modulates SPINK1 expression in governing cellular plasticity in prostate cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Cancer research; Biology; Reprogramming; Transcription factor; SOX2; Androgen receptor; Cancer; Gene silencing; Androgen deprivation therapy; TMPRSS2; Prostate; Internal medicine; Genetics; Medicine; Cell","score_opus":0.032841490813874503,"score_gpt":0.3118384028705806,"score_spread":0.2789969120567061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993844726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851705,0.0130000515,0.00005765017,0.0004072918,0.00013560393,0.0010483142,0.000028293984,0.00003738792,0.000114909584],"genre_scores_gemma":[0.99512476,0.0041153464,0.0001264703,0.00012438027,0.00003179223,0.0001297325,0.000042255473,0.000054243752,0.00025102528],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99820316,0.000052674113,0.00032268694,0.00052301283,0.0003966084,0.0005018809],"domain_scores_gemma":[0.999484,0.000032976015,0.00009446279,0.00021973935,0.00005757031,0.00011123745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013204089,0.00026352867,0.0003710755,0.00017594383,0.000050814804,0.000047759557,0.000081623,0.0001479864,0.0000950862],"category_scores_gemma":[0.00000794531,0.00021528498,0.00007112308,0.000291354,0.000076186254,0.0001359612,0.00003401133,0.000486463,0.000004831844],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000516639,0.00010088022,0.3224734,0.00024971872,0.00005166603,0.00010357274,0.0014356949,0.0005893514,0.66361326,0.000003675591,0.0000015857265,0.010860537],"study_design_scores_gemma":[0.0043287533,0.00022518312,0.3588706,0.0012714089,0.000067110064,0.0000023606267,0.00043650126,0.002036367,0.6308069,0.000047056288,0.0016051334,0.00030260326],"about_ca_topic_score_codex":0.001464773,"about_ca_topic_score_gemma":0.00029266404,"teacher_disagreement_score":0.036397174,"about_ca_system_score_codex":0.00045603357,"about_ca_system_score_gemma":0.00014336177,"threshold_uncertainty_score":0.8779066},"labels":[],"label_agreement":null},{"id":"W2994033895","doi":"10.1530/erc-19-0420","title":"The epigenetic and transcriptional landscape of neuroendocrine prostate cancer","year":2019,"lang":"en","type":"review","venue":"Endocrine Related Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Health and Medical Research Council; Canadian Institutes of Health Research; Medical Research Council; Prostate Cancer Foundation","keywords":"Epigenetics; Reprogramming; Biology; Prostate cancer; Epigenome; Lineage (genetic); Cancer research; DNA methylation; Phenotype; Cancer; Transcription factor; Genetics; Gene; Gene expression","score_opus":0.043541312039840095,"score_gpt":0.37492675142322535,"score_spread":0.33138543938338527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994033895","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029527783,0.99392647,3.6202368e-7,0.0013106237,0.00067865744,0.002331235,0.00044074265,0.00004333617,0.0009732933],"genre_scores_gemma":[0.0003123564,0.9621072,0.000008401373,0.00002792192,0.00016999246,0.0008469115,0.00021135015,0.00010792481,0.036207948],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973422,0.00013786857,0.00078921847,0.00057858526,0.00050278706,0.00064930646],"domain_scores_gemma":[0.9986238,0.0002072187,0.00032683864,0.00048001294,0.00016582361,0.00019634671],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010606429,0.00050266803,0.001581636,0.00021648516,0.00013864499,0.000031982607,0.00019998958,0.00009150501,0.00059833145],"category_scores_gemma":[0.000027932472,0.00027884782,0.0004411564,0.0005327656,0.0002646719,0.000054089858,0.000088913854,0.0008576951,0.000029402443],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023619819,0.00006897627,0.00061748736,0.015050978,0.0015533157,0.00015419656,0.00005899914,0.000007916264,0.000021918702,0.00021865245,0.0014924088,0.98051894],"study_design_scores_gemma":[0.0023228338,0.0002685198,0.00029790064,0.008399187,0.0025951902,0.00040250085,0.000014561171,0.00002527853,0.000050303068,0.000034197426,0.9853394,0.0002501202],"about_ca_topic_score_codex":0.00025229764,"about_ca_topic_score_gemma":0.000042110263,"teacher_disagreement_score":0.983847,"about_ca_system_score_codex":0.00019061341,"about_ca_system_score_gemma":0.0012232331,"threshold_uncertainty_score":0.9999664},"labels":[],"label_agreement":null},{"id":"W2994621692","doi":"10.2147/rru.s231334","title":"&lt;p&gt;Fexapotide Triflutate Induces Selective Prostate Glandular Pharmaco-Ablation in the Rat&lt;/p&gt;","year":2019,"lang":"en","type":"article","venue":"Research and Reports in Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nymox (Canada)","funders":"","keywords":"Prostate; Prostate cancer; Medicine; Stroma; Pathology; Ablation; Stromal cell; Epithelium; Urology; Internal medicine; Cancer; Immunohistochemistry","score_opus":0.03781029271578451,"score_gpt":0.37507006103891705,"score_spread":0.33725976832313254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994621692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98098546,0.0046751415,0.0000013625333,0.004676704,0.00015940783,0.0022658238,0.0000041826784,0.000020827716,0.007211101],"genre_scores_gemma":[0.99375135,0.0029347525,0.000018324337,0.00015071926,0.00011623074,0.00023974996,0.00007128607,0.000022913811,0.0026946792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99651957,0.0007212693,0.0004704361,0.0006142316,0.0007642171,0.00091026],"domain_scores_gemma":[0.99865407,0.00046202226,0.00009975736,0.0003537433,0.00026965616,0.00016073439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041378075,0.00018178117,0.00038592092,0.0007094836,0.00013977863,0.000050057544,0.00012011607,0.00018419723,0.000095023584],"category_scores_gemma":[0.00031918942,0.00011100165,0.00004602885,0.0010391666,0.00036788222,0.00015414572,0.000104779574,0.0010713583,0.000025642112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057074837,0.0009794843,0.76297003,0.00026666487,0.00022469983,0.015231898,0.005161917,0.00009794781,0.19531749,0.0003477669,0.003196118,0.010498523],"study_design_scores_gemma":[0.015474119,0.007878031,0.8761438,0.00020109498,0.00008371375,0.0037384133,0.00073774456,0.0012898406,0.03087654,0.010681613,0.0523919,0.00050318235],"about_ca_topic_score_codex":0.00016618383,"about_ca_topic_score_gemma":0.00015438786,"teacher_disagreement_score":0.16444094,"about_ca_system_score_codex":0.00017111118,"about_ca_system_score_gemma":0.00056743226,"threshold_uncertainty_score":0.46545786},"labels":[],"label_agreement":null},{"id":"W2994749165","doi":"","title":"Enzymatic activity of prostate-specific antigen (PSA) in prostate cancer and human bone-metastasizing prostate cancer LNCaP cells","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Thunder Bay Regional Health Sciences Centre","funders":"","keywords":"Prostate cancer; Medicine; Prostate-specific antigen; Cancer; Prostate; PCA3; LNCaP; Prostatic acid phosphatase; Metastasis; Prostatectomy; Pathology; Internal medicine; Oncology","score_opus":0.0973781258124653,"score_gpt":0.4251718904687259,"score_spread":0.3277937646562606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994749165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9463661,0.04343532,8.627372e-7,0.004845551,0.00014147983,0.004184094,0.00043520835,0.000059988342,0.0005314501],"genre_scores_gemma":[0.93235624,0.057737675,0.00014107309,0.00006486258,0.00030541298,0.0024749944,0.000037631602,0.00012127844,0.006760858],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9942414,0.000371853,0.0007729402,0.0011246656,0.001667923,0.0018211772],"domain_scores_gemma":[0.99750406,0.0001910512,0.00024179036,0.00070251105,0.00080125214,0.0005593232],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018418976,0.0004889504,0.0010275057,0.0010309699,0.00041373912,0.0001401568,0.0003044815,0.00017140212,0.00063592],"category_scores_gemma":[0.000047408303,0.00040310743,0.00013500154,0.0016618978,0.0010203902,0.0005389467,0.00033976187,0.0013570118,0.000025597328],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037785706,0.0006849244,0.10700555,0.0022709745,0.0002908044,0.00023007693,0.0064427364,0.0001680261,0.768848,0.000064983644,0.0034696609,0.10674569],"study_design_scores_gemma":[0.0107772015,0.0010987617,0.08675095,0.0030666674,0.000092585884,0.000015263633,0.0011433992,0.0002753534,0.86036086,0.00014288744,0.03559004,0.00068604574],"about_ca_topic_score_codex":0.009220288,"about_ca_topic_score_gemma":0.003784856,"teacher_disagreement_score":0.10605964,"about_ca_system_score_codex":0.0017421612,"about_ca_system_score_gemma":0.0016599041,"threshold_uncertainty_score":0.9998421},"labels":[],"label_agreement":null},{"id":"W2995419061","doi":"10.1016/j.clgc.2019.12.002","title":"Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis","year":2019,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Hazard ratio; Meta-analysis; Oncology; Subgroup analysis; Cancer; Cochrane Library; Confidence interval","score_opus":0.2286906265936641,"score_gpt":0.496953248459781,"score_spread":0.26826262186611693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995419061","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016182858,0.9819675,0.0000016928514,0.00055010687,0.00010098882,0.015928112,0.0011863027,0.000026245962,0.0000772356],"genre_scores_gemma":[0.00018207851,0.98812604,0.00015513432,0.00039823062,0.000076426964,0.0062540085,0.00023277753,0.00009951924,0.004475765],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9918685,0.0018967071,0.0036058535,0.0012544565,0.0007271599,0.0006473504],"domain_scores_gemma":[0.99449736,0.001877147,0.001719681,0.0010869473,0.000431642,0.00038723156],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0020467096,0.00088588294,0.021535376,0.00063436123,0.000045352197,0.000025059775,0.0003012805,0.00032030515,0.00016732392],"category_scores_gemma":[0.0005936368,0.0005210424,0.004604962,0.0021754447,0.00035337682,0.00009505562,0.00026955505,0.001090623,0.000036349436],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016228209,0.0003617085,0.00013137385,0.7787763,0.21438576,0.0005015437,0.000044075943,0.0000040167242,1.487244e-7,0.000002876144,0.00028749384,0.005342398],"study_design_scores_gemma":[0.0010093373,0.00068579015,0.00012295287,0.1002503,0.8920697,0.00006181916,0.00002768702,0.000026328114,8.4879144e-7,0.000006524569,0.0053114705,0.00042725704],"about_ca_topic_score_codex":0.00025977494,"about_ca_topic_score_gemma":0.000036411835,"teacher_disagreement_score":0.67852604,"about_ca_system_score_codex":0.0004281786,"about_ca_system_score_gemma":0.0021384743,"threshold_uncertainty_score":0.9997241},"labels":[],"label_agreement":null},{"id":"W2995624503","doi":"10.1016/j.jval.2019.09.249","title":"PCN52 ABIRATERONE VERSUS ENZALUTAMIDE IN THE POST-CHEMOTHERAPY SETTING IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: POPULATION-BASED STUDY","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Enzalutamide; Abiraterone; Prostate cancer; Medicine; Oncology; Chemotherapy; Internal medicine; Docetaxel; Cancer; Urology; Androgen receptor","score_opus":0.059171874472310246,"score_gpt":0.38392891040404814,"score_spread":0.3247570359317379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995624503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98430085,0.0012097546,7.61779e-7,0.009848267,0.00013914001,0.0044137863,0.00003075971,0.00001742923,0.000039246777],"genre_scores_gemma":[0.9984101,0.00014503133,0.00019386348,0.00072217116,0.00002947418,0.00031577863,0.000088934576,0.000026082158,0.00006856149],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974212,0.0006316813,0.0006062696,0.00035288103,0.0004909354,0.000497023],"domain_scores_gemma":[0.9990163,0.00040629867,0.00013976287,0.00030397743,0.00005584967,0.00007780412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001697403,0.00017496206,0.0003749959,0.00034359208,0.00006589788,0.000032869175,0.00010783229,0.00003504394,0.000048138107],"category_scores_gemma":[0.000063561056,0.000121079414,0.000036713816,0.00069264264,0.000019656336,0.00008985542,0.000010518526,0.00034450207,0.000009402655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037974906,0.0007436517,0.9698681,0.00043319803,0.000029778443,0.000101483325,0.008898688,0.011850211,0.00049598585,0.000025790569,0.000010898939,0.0037446884],"study_design_scores_gemma":[0.017458782,0.0023771853,0.9679105,0.00048362964,0.000011165731,0.0000015685093,0.0053296364,0.0061118174,0.00010394681,0.000048973943,0.00003986759,0.00012291512],"about_ca_topic_score_codex":0.08482641,"about_ca_topic_score_gemma":0.01514232,"teacher_disagreement_score":0.069684096,"about_ca_system_score_codex":0.0010925006,"about_ca_system_score_gemma":0.0012260852,"threshold_uncertainty_score":0.9212678},"labels":[],"label_agreement":null},{"id":"W2995928704","doi":"10.1016/j.eururo.2019.11.021","title":"Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study","year":2019,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Janssen Research and Development","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Androgen deprivation therapy; Urology; Hazard ratio; Internal medicine; Prostate-specific antigen; Proportional hazards model; Prednisone; Oncology; Prostatectomy; Progression-free survival; Cancer; Overall survival; Confidence interval","score_opus":0.03699912934729221,"score_gpt":0.31919868235556953,"score_spread":0.2821995530082773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995928704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945906,0.00032953336,0.00013709968,0.00022699418,0.000027586626,0.0043468964,0.0002164289,0.000027360566,0.00009749401],"genre_scores_gemma":[0.9981792,0.0005020991,0.00054706505,0.000027569346,0.000014558168,0.000078339326,0.0004694449,0.00004259831,0.00013909908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973063,0.00086429133,0.0005277217,0.0005573393,0.0004183669,0.00032596968],"domain_scores_gemma":[0.9985674,0.00020552028,0.0003169988,0.00036687756,0.00042013178,0.00012309793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000551525,0.00028395542,0.0008831477,0.00044511928,0.00004258221,0.000020403711,0.0001024518,0.000046549972,0.000059077774],"category_scores_gemma":[0.000037364473,0.0001657874,0.00003947469,0.0008958677,0.00020044361,0.00010325685,0.0000662341,0.00017773046,0.0000025527409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18216346,0.0017788897,0.7442912,0.000060159455,0.0026042184,0.0005967256,0.008483168,0.012968669,0.042469524,0.00000935691,0.000006191657,0.004568471],"study_design_scores_gemma":[0.042667918,0.047273647,0.90225875,0.00007353904,0.0006582743,0.00002045545,0.001117957,0.003203828,0.0024670623,0.0000014547508,0.00003732566,0.00021978108],"about_ca_topic_score_codex":0.00015323945,"about_ca_topic_score_gemma":0.0007578989,"teacher_disagreement_score":0.1579676,"about_ca_system_score_codex":0.00008259537,"about_ca_system_score_gemma":0.00016085403,"threshold_uncertainty_score":0.6760614},"labels":[],"label_agreement":null},{"id":"W2996229517","doi":"10.1038/s41585-019-0270-7","title":"Progress in therapy across the spectrum of advanced prostate cancer","year":2019,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Enzalutamide; Medicine; Cabazitaxel; Prostate cancer; Androgen deprivation therapy; Oncology; Radiation therapy; Internal medicine; Abiraterone; Cancer; Androgen receptor","score_opus":0.054125700206555015,"score_gpt":0.46955102340481214,"score_spread":0.41542532319825715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996229517","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000103230464,0.9866792,9.233936e-8,0.0024042462,0.0005484815,0.009933816,0.00010117689,0.000017643886,0.00021213194],"genre_scores_gemma":[0.00007858813,0.9954657,0.000023201103,0.00039775655,0.00022857262,0.0022945611,0.00014791329,0.000074843534,0.0012888543],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967349,0.000594994,0.00096380495,0.0006586778,0.0003138605,0.0007337561],"domain_scores_gemma":[0.997972,0.00020715568,0.0007117464,0.00093178987,0.00009574405,0.00008152975],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0009533546,0.00054729724,0.0038525183,0.00017536225,0.00004667809,0.000011736385,0.00047485332,0.0009630133,0.00011747307],"category_scores_gemma":[0.00007065748,0.00024290169,0.0007233234,0.00095116836,0.00034815609,0.000044318505,0.00012568089,0.0028078952,0.000060350125],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030290204,0.0001221278,0.0008617347,0.023153361,0.00022548268,0.000045059824,0.00015446993,1.5548657e-7,6.404627e-7,0.00003197421,0.00054294587,0.9745591],"study_design_scores_gemma":[0.0014729624,0.0005213671,0.000296822,0.008852597,0.00036529964,0.00007822321,0.000006241877,5.994345e-7,0.0000045812576,0.0000201717,0.98819345,0.0001876515],"about_ca_topic_score_codex":0.000012756153,"about_ca_topic_score_gemma":0.000045988843,"teacher_disagreement_score":0.9876505,"about_ca_system_score_codex":0.00021376731,"about_ca_system_score_gemma":0.0007786493,"threshold_uncertainty_score":0.99949265},"labels":[],"label_agreement":null},{"id":"W2996247621","doi":"10.1038/s41388-019-1116-8","title":"Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer","year":2019,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Biotechnology and Biological Sciences Research Council; Engineering and Physical Sciences Research Council; Royal Society; Türkiye Bilimsel ve Teknolojik Araştırma Kurumu; Cancer Research UK; Wellcome Trust","keywords":"Biology; Prostate cancer; Demethylase; Cancer research; Cell growth; Chromatin; Histone; Gene knockdown; EZH2; Androgen deprivation therapy; Cancer; Genetics; Gene","score_opus":0.01976591917331781,"score_gpt":0.3375605088515216,"score_spread":0.3177945896782038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996247621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960304,0.0016893646,0.000007950081,0.0004878994,0.00012494711,0.0013497272,0.000034638673,0.000020138348,0.0002549698],"genre_scores_gemma":[0.9959416,0.00026634286,0.00010154065,0.00002413488,0.000044098095,0.00020711664,0.00008185647,0.000018997536,0.0033143426],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998683,0.00008080028,0.00043724055,0.00021647995,0.00037314597,0.0002093369],"domain_scores_gemma":[0.99938685,0.00005851737,0.00011671831,0.00020250348,0.00016839252,0.000066997316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026725707,0.00011388771,0.0003919035,0.0001547389,0.000032143536,0.000027645658,0.000048914975,0.00006568779,0.0001601363],"category_scores_gemma":[0.00010827908,0.00008843686,0.000050418035,0.00023520073,0.000051948922,0.00015520588,0.000021970252,0.00007740652,0.00003476564],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004376677,0.000100092635,0.0037532793,0.016484119,0.000053533164,0.00003899001,0.0011241003,0.0000053895496,0.97763515,0.00018889793,0.000008238114,0.00017056883],"study_design_scores_gemma":[0.0025300176,0.00047319193,0.036742304,0.016024405,0.00013184681,0.00002754072,0.0007998543,0.0014170187,0.9415838,0.00009115927,0.000018131079,0.00016070786],"about_ca_topic_score_codex":0.00019242488,"about_ca_topic_score_gemma":0.00005208935,"teacher_disagreement_score":0.0360513,"about_ca_system_score_codex":0.00022715423,"about_ca_system_score_gemma":0.00028546882,"threshold_uncertainty_score":0.36063504},"labels":[],"label_agreement":null},{"id":"W2996359243","doi":"10.1097/ju.0000000000000699","title":"Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Queen's University; Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Prostate cancer; Androgen receptor; Castration; Medicine; Internal medicine; Androgen; Oncology; Primary treatment; Prostate; Testosterone (patch); Androgen deprivation therapy; Endocrinology; Cancer; Hormone","score_opus":0.021185614651662788,"score_gpt":0.2992883899338862,"score_spread":0.2781027752822234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996359243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853292,0.010414328,0.000030162115,0.0034678015,0.0001106756,0.00059901486,0.000016954997,0.0000016764626,0.000030180832],"genre_scores_gemma":[0.9961383,0.003158148,0.0002499589,0.00015568851,0.000035179568,0.000020946507,0.0000025433435,0.000007610349,0.00023165857],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99905354,0.00015304706,0.00029081633,0.000099373756,0.00021700983,0.00018619413],"domain_scores_gemma":[0.99942833,0.000082673534,0.00016877374,0.000092548915,0.00015184219,0.00007583314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006506026,0.00008945489,0.00028344756,0.00009650357,0.000022755728,0.0000047740873,0.000062078994,0.00004501453,0.000053641623],"category_scores_gemma":[0.000010964944,0.000052060568,0.000022487286,0.00009351958,0.000058463393,0.00006343955,0.000021513786,0.00021059407,0.0000017820851],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12506184,0.00042812974,0.13574901,0.00018080787,0.00032779205,0.00007126711,0.009969813,0.000020108702,0.60491997,0.0000042450065,0.00036002873,0.122907005],"study_design_scores_gemma":[0.00809846,0.003210279,0.90739644,0.00017241183,0.00004331986,0.000052515898,0.00015145898,0.000006190515,0.06876886,0.000040025643,0.011944688,0.000115345356],"about_ca_topic_score_codex":0.000015333499,"about_ca_topic_score_gemma":0.00024521642,"teacher_disagreement_score":0.77164745,"about_ca_system_score_codex":0.00014919059,"about_ca_system_score_gemma":0.0005241707,"threshold_uncertainty_score":0.21229683},"labels":[],"label_agreement":null},{"id":"W2996743719","doi":"10.1007/s00345-019-03048-3","title":"Correction to: Evidence-based approach to active surveillance of prostate cancer","year":2019,"lang":"en","type":"erratum","venue":"World Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Prostate cancer; Nephrology; Internal medicine; Oncology; Cancer; Medical physics","score_opus":0.03901467668080042,"score_gpt":0.33986452792404115,"score_spread":0.3008498512432407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996743719","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025420768,0.23008133,0.0019193693,0.139946,0.40937778,0.013483421,0.00071983715,0.00012382331,0.17892765],"genre_scores_gemma":[0.19768505,0.009785713,0.00035315138,0.0023649882,0.002982823,0.00011366013,0.00008540291,0.00009810498,0.7865311],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976326,0.00025131684,0.00063420046,0.00036220625,0.00066949456,0.00045014164],"domain_scores_gemma":[0.9970365,0.0003679398,0.0007335455,0.00033098517,0.0012151896,0.00031580206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006309519,0.00028849533,0.0011751099,0.0011947745,0.00003438103,0.000013526025,0.00026711464,0.0002017485,0.0001377165],"category_scores_gemma":[0.00046008267,0.00021002445,0.00026050306,0.00083124114,0.00010980115,0.000082260514,0.00006528099,0.0015597994,0.000023056982],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015153806,0.0002586548,0.0115922885,0.00040399435,0.0004630245,0.00007136246,0.00041404,0.0014203212,0.0006252186,0.0000023276054,0.94828796,0.021306995],"study_design_scores_gemma":[0.0033685323,0.0071441582,0.043332666,0.0027047493,0.00039610246,0.00015467452,0.00007210468,0.00040340802,0.00069730787,0.000013630674,0.9413909,0.00032176846],"about_ca_topic_score_codex":0.0002037839,"about_ca_topic_score_gemma":0.00026449413,"teacher_disagreement_score":0.60760343,"about_ca_system_score_codex":0.000757917,"about_ca_system_score_gemma":0.0038751152,"threshold_uncertainty_score":0.8564548},"labels":[],"label_agreement":null},{"id":"W2997456566","doi":"10.21037/tau.2019.11.25","title":"Urinary biomarkers in prostate cancer: to the miRnome and beyond","year":2020,"lang":"en","type":"letter","venue":"Translational Andrology and Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; National Institutes of Health; Prostate Cancer Canada; Movember Foundation","keywords":"Prostate cancer; Biomarker; Transcriptome; Urinary system; Medicine; Biomarker discovery; Internal medicine; Cancer; Biology; Gene; Proteomics; Genetics","score_opus":0.021425496141293136,"score_gpt":0.29181251982577305,"score_spread":0.2703870236844799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997456566","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06538423,0.016174674,0.000002974402,0.9169957,0.00010716245,0.00074398826,0.00017372165,0.000014873002,0.00040266945],"genre_scores_gemma":[0.22208112,0.0035729648,0.00004869879,0.7720509,0.00062903785,0.00029964166,0.0005379469,0.000026828751,0.00075280963],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99873847,0.00013392202,0.00020034102,0.00045153245,0.00012788482,0.00034785055],"domain_scores_gemma":[0.99948996,0.00025440814,0.00003451219,0.00009892933,0.00003055537,0.00009162778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010640808,0.00020323847,0.00037396792,0.00018679867,0.00010376824,0.000007916483,0.000069649956,0.00033400333,0.000115251605],"category_scores_gemma":[0.000010023279,0.00013378666,0.00004209359,0.0001582601,0.00041563273,0.000028354605,0.000035684727,0.0009655052,0.000010916576],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018125406,0.00018189993,0.3645026,0.00079014734,0.0019906256,0.0109374095,0.004262009,0.000025090754,0.00024604006,0.0003314705,0.57744634,0.021160992],"study_design_scores_gemma":[0.003045984,0.0016241504,0.12555139,0.000016397616,0.00019061242,0.0007163276,0.00001240171,0.00013860702,0.0000053056906,0.0017463083,0.866781,0.00017153668],"about_ca_topic_score_codex":0.000062323175,"about_ca_topic_score_gemma":0.000065892586,"teacher_disagreement_score":0.28933465,"about_ca_system_score_codex":0.00001451113,"about_ca_system_score_gemma":0.00016458414,"threshold_uncertainty_score":0.54556614},"labels":[],"label_agreement":null},{"id":"W2998105801","doi":"10.1002/9780471420194.tnmc40.pub2","title":"Prostate","year":2010,"lang":"en","type":"other","venue":"TNM Online","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Prostate cancer; Stage (stratigraphy); Medicine; Prostate carcinoma; Oncology; Prostate; Internal medicine; Gynecology; Cancer; Biology","score_opus":0.0247513613404373,"score_gpt":0.36025543294884077,"score_spread":0.33550407160840345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998105801","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038294253,0.0028180853,0.0000018977175,0.0021962088,0.00036153753,0.000945543,0.0042522084,0.00036830996,0.98867327],"genre_scores_gemma":[0.000047126818,0.0014489859,0.001654673,0.00022257082,0.0012438318,0.000037797083,0.006689918,0.00041247933,0.9882426],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991469,0.000008869401,0.00010711106,0.0002446295,0.00023513517,0.00025740184],"domain_scores_gemma":[0.99937147,0.000010991928,0.00005754106,0.0003680433,0.000037638943,0.000154342],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000034319233,0.00018560117,0.00030747816,0.00018592336,0.000017652475,0.000008525616,0.000074698546,0.00027569337,0.043751318],"category_scores_gemma":[0.000025100338,0.00012529206,0.00007396056,0.000106473024,0.00009491737,0.000008313482,0.000040599025,0.000521064,0.00077035255],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008719033,0.00024020551,0.00025503087,0.000187782,0.00011072232,0.00020006912,0.000021372172,4.0089945e-9,0.00038885526,0.000009503286,0.97222525,0.026274022],"study_design_scores_gemma":[0.0013315487,0.00016360226,0.00035478664,0.00034068257,0.00006605734,0.000022442397,0.000007708929,0.000004643912,0.00016592823,0.000018748238,0.9974031,0.00012077277],"about_ca_topic_score_codex":0.0000980423,"about_ca_topic_score_gemma":0.00025956202,"teacher_disagreement_score":0.042980965,"about_ca_system_score_codex":0.000034456636,"about_ca_system_score_gemma":0.00023652326,"threshold_uncertainty_score":0.990158},"labels":[],"label_agreement":null},{"id":"W2998673592","doi":"10.1007/978-3-030-32656-2_5","title":"Prostate Cancer Genomic Subtypes","year":2019,"lang":"en","type":"review","venue":"Advances in experimental medicine and biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Prostate cancer; Cancer; Prostate; Medicine; Cancer research; Oncology; Internal medicine","score_opus":0.10403278605558897,"score_gpt":0.4904567799390508,"score_spread":0.3864239938834618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998673592","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009957325,0.99475,2.570402e-7,0.00021125715,0.0006128557,0.0014677929,0.000029289442,0.000020873367,0.0019119035],"genre_scores_gemma":[0.00070407067,0.9966926,0.00003755948,0.00018630605,0.0003805525,0.00048402665,0.000288465,0.000037048507,0.001189373],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983991,0.00008186367,0.00044585203,0.0005747564,0.000090853304,0.00040761102],"domain_scores_gemma":[0.9993639,0.00012405765,0.00014706256,0.00022181109,0.000023205144,0.00011996226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000112986,0.00037580662,0.0017819589,0.0002890421,0.000036607817,0.00000402138,0.00010727533,0.00022470018,0.00023871468],"category_scores_gemma":[0.000018083969,0.00020973173,0.000100450736,0.00021399434,0.00051204226,0.0000704247,0.000107714746,0.00035084976,0.000030937546],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018049573,0.000085271866,0.0017364449,0.0067101093,0.00011245575,0.00005139551,0.0003524959,5.0137306e-8,0.00030061317,0.00011989676,0.00013713918,0.99021363],"study_design_scores_gemma":[0.0018731859,0.0013679884,0.000022602742,0.009098651,0.00021475549,0.00008194406,0.00030433302,0.0000010151111,0.00007459004,0.00004169067,0.98671335,0.00020588312],"about_ca_topic_score_codex":0.000107634085,"about_ca_topic_score_gemma":0.000014356279,"teacher_disagreement_score":0.99000776,"about_ca_system_score_codex":0.00026792788,"about_ca_system_score_gemma":0.00021802814,"threshold_uncertainty_score":0.85526115},"labels":[],"label_agreement":null},{"id":"W2999004527","doi":"10.5489/cuaj.6391","title":"Antagonizing GnRH receptors: A temporary ADT salvage maneuver for prostate cancer patients experiencing PSA failure with GnRH agonist","year":2020,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Agonist; Prostate cancer; Medicine; Receptor; Internal medicine; Prostate; Urology; Oncology; Endocrinology; Cancer","score_opus":0.021786270004354246,"score_gpt":0.2625739120283413,"score_spread":0.24078764202398706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999004527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91944253,0.0005789414,0.000037441194,0.07782042,0.00026770457,0.0010703577,0.00023583185,0.000053203865,0.0004935745],"genre_scores_gemma":[0.9911074,0.00013435048,0.00034889966,0.006280734,0.0008823292,0.00014056782,0.00020881742,0.000036652356,0.0008602292],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797374,0.00010007654,0.00034218078,0.00034457297,0.0004943594,0.0007450736],"domain_scores_gemma":[0.9978544,0.00008052853,0.00027350133,0.000081900725,0.00047987505,0.0012297711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026495196,0.00021511683,0.0003485312,0.00011647849,0.00054257683,0.00017008036,0.00013024853,0.00019787706,0.00051709195],"category_scores_gemma":[0.00032234978,0.00014951508,0.00012466474,0.0003193172,0.000056004574,0.00022554788,0.00002076258,0.0006243702,0.000018512243],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056965696,0.000047798745,0.94798607,0.000035127658,0.00019080623,0.00015286557,0.0021314553,0.000014189818,0.000265251,0.00000628788,0.045872726,0.0027277875],"study_design_scores_gemma":[0.015045007,0.005448758,0.35167465,0.00021476648,0.0003073239,0.000076431184,0.003536715,0.00037054485,0.0012003793,0.00008965778,0.6212822,0.0007535691],"about_ca_topic_score_codex":0.0009764923,"about_ca_topic_score_gemma":0.0010135884,"teacher_disagreement_score":0.5963114,"about_ca_system_score_codex":0.0017668377,"about_ca_system_score_gemma":0.0013314628,"threshold_uncertainty_score":0.6097048},"labels":[],"label_agreement":null},{"id":"W2999039360","doi":"10.1038/s41467-019-14184-0","title":"Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer","year":2020,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Congressionally Directed Medical Research Programs; Science and Engineering Research Board; The Wellcome Trust DBT India Alliance; University Grants Commission; Department of Science and Technology, Ministry of Science and Technology, India; U.S. Department of Defense; Department of Biotechnology, Ministry of Science and Technology, India; Sleep Research Society Foundation; Wellcome Trust","keywords":"Downregulation and upregulation; Prostate cancer; Cancer research; Transdifferentiation; Androgen receptor; Repressor; Biology; Androgen deprivation therapy; Carcinogenesis; Corepressor; Endocrinology; Cancer; Internal medicine; Medicine; Cell biology; Gene expression; Genetics; Stem cell","score_opus":0.030185274771364356,"score_gpt":0.3266954629762737,"score_spread":0.2965101882049094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999039360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9417832,0.033854604,0.000018967105,0.02323861,0.000022979104,0.0006276525,0.00003363095,0.00005454565,0.0003658397],"genre_scores_gemma":[0.9909137,0.006894845,0.0014579184,0.0003352868,0.000031767315,0.00008893087,0.00018086939,0.000013487474,0.000083219384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993112,0.00005339059,0.00015178033,0.0001880457,0.00014625661,0.0001493131],"domain_scores_gemma":[0.9993466,0.00007104986,0.00004641734,0.00032364798,0.0000955223,0.00011675298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005337451,0.00009765753,0.000149861,0.000067800065,0.00013245313,0.000023543229,0.00017417742,0.00012775417,0.00003117677],"category_scores_gemma":[0.000093040275,0.00007710175,0.000026913549,0.00028611842,0.00010282338,0.000101727004,0.00022736452,0.00058120285,0.0000053308336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046655085,0.00026704764,0.6349181,0.00019026722,0.00008281328,0.000026831356,0.0026582074,0.000032197895,0.3546036,0.00039848243,0.0014937199,0.004862191],"study_design_scores_gemma":[0.0068517225,0.0003178745,0.48565987,0.000825728,0.00018272558,0.000016245176,0.00045192795,0.014274668,0.4670991,0.00044469154,0.023454763,0.00042065722],"about_ca_topic_score_codex":0.000041938725,"about_ca_topic_score_gemma":0.0000596365,"teacher_disagreement_score":0.14925823,"about_ca_system_score_codex":0.00005643361,"about_ca_system_score_gemma":0.000076438526,"threshold_uncertainty_score":0.31441182},"labels":[],"label_agreement":null},{"id":"W2999047517","doi":"10.1016/j.clgc.2019.12.019","title":"Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Janssen Pharmaceuticals; Bristol-Myers Squibb Canada; EMD Serono; Ipsen; Ferring Pharmaceuticals; Sanofi Genzyme; Merck Sharp and Dohme; Ferring; AstraZeneca; Invitae; Innocrin Pharmaceuticals; Astellas Pharma US; Flatiron Health; Dendreon Pharmaceuticals; Bayer Fund; Astellas Pharma Canada; F. Hoffmann-La Roche; Exelixis; Sanofi; Celgene; Novartis; Merck; Roche; American Association for Cancer Research; Amgen; Janssen Biotech; Johnson and Johnson; AcelRx Pharmaceuticals; Myovant Sciences; Pfizer; Bristol-Myers Squibb; Bayer; Calithera Biosciences; Constellation Energy Group","keywords":"Enzalutamide; Medicine; Cabazitaxel; Prostate cancer; Docetaxel; Prednisone; Abiraterone acetate; Internal medicine; Oncology; Confidence interval; Abiraterone; Clinical trial; Androgen deprivation therapy; Cancer","score_opus":0.10347877718998197,"score_gpt":0.4589470104597338,"score_spread":0.35546823326975185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999047517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96939874,0.00048696643,8.98575e-7,0.027547276,0.0000909753,0.0021372633,0.00023019064,0.000019919036,0.000087753746],"genre_scores_gemma":[0.9854743,0.010359081,0.0003262871,0.0026542386,0.00014581427,0.0006238457,0.00019234554,0.000035896403,0.00018822409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99637693,0.0008501863,0.0012006742,0.0006321368,0.0004558575,0.0004841964],"domain_scores_gemma":[0.99715334,0.0018961391,0.00026954315,0.00026699645,0.00015597299,0.0002580275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007834283,0.0002998337,0.00074989063,0.00019936913,0.00006334959,0.00004828914,0.00012334327,0.00007378314,0.000044748518],"category_scores_gemma":[0.00032142168,0.00016795134,0.00009414362,0.00079530885,0.00018596646,0.00018446123,0.00006270688,0.00069576903,0.0000031955847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009588482,0.0019740085,0.9696417,0.00012684982,0.00025206953,0.0015909312,0.002360158,0.00021633324,0.0000021329715,0.0000026272428,0.0001090533,0.01413565],"study_design_scores_gemma":[0.017293796,0.0040709744,0.97366923,0.00026709985,0.0002072847,0.0000024998035,0.0019496523,0.00061182096,0.0000066763673,0.000010407375,0.0017249722,0.00018559073],"about_ca_topic_score_codex":0.010166742,"about_ca_topic_score_gemma":0.013759393,"teacher_disagreement_score":0.024893036,"about_ca_system_score_codex":0.0003689203,"about_ca_system_score_gemma":0.000617012,"threshold_uncertainty_score":0.9964246},"labels":[],"label_agreement":null},{"id":"W2999168978","doi":"10.1016/s0923-7534(20)33514-6","title":"Association of Baseline Corticosteroid with Outcomes in a Multivariate Analysis of the Phase 3 Affirm Study of Enzalutamide (ENZA), An Androgen Receptor Signaling Inhibitor (ARSI)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Androgen receptor; Oncology; Association (psychology); Androgen; Internal medicine; Baseline (sea); Endocrinology; Prostate cancer; Psychotherapist; Psychology; Biology; Cancer; Hormone","score_opus":0.08948615067222013,"score_gpt":0.43194192441410273,"score_spread":0.34245577374188263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999168978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998283,0.00024742426,0.000009539212,0.0005801986,0.000051597268,0.00068790617,0.00010211526,0.0000041208755,0.000034077973],"genre_scores_gemma":[0.9995349,0.00005204534,0.0001694003,0.00006306343,0.000027968446,0.000025238578,0.000037269012,0.00001002196,0.00008011282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806035,0.000481273,0.0006628255,0.00014979245,0.00040026414,0.00024552102],"domain_scores_gemma":[0.9979663,0.00044464503,0.00075542036,0.00025405962,0.0004966905,0.00008292322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014079678,0.0001134183,0.000911212,0.00036092527,0.000020120364,0.0000014616841,0.00009720205,0.0000985955,0.00006601726],"category_scores_gemma":[0.00036957592,0.00006763513,0.00013248764,0.0007827827,0.00008170878,0.00009525226,0.000044859265,0.0001244022,3.64604e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030628673,0.011369488,0.88058203,0.00005197297,0.0028389487,0.0000034216378,0.005540957,0.00013382317,0.09299248,0.0000023046111,0.00003362806,0.0033880596],"study_design_scores_gemma":[0.019966818,0.016665392,0.5819336,0.00011808693,0.0026555634,0.0000011188547,0.0043540527,0.0005473291,0.37350085,0.0000056191343,0.00013822195,0.00011333399],"about_ca_topic_score_codex":0.00061074016,"about_ca_topic_score_gemma":0.00062891096,"teacher_disagreement_score":0.29864845,"about_ca_system_score_codex":0.00010375852,"about_ca_system_score_gemma":0.00018116817,"threshold_uncertainty_score":0.27580804},"labels":[],"label_agreement":null},{"id":"W2999247109","doi":"10.1038/s41391-020-0202-x","title":"GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome","year":2020,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Prostate cancer; Standardized uptake value; Prostatectomy; Biochemical recurrence; GLUT1; Positron emission tomography; Cancer; Oncology; Internal medicine; Nuclear medicine; Urology; Glucose uptake","score_opus":0.03135587439209314,"score_gpt":0.3583003405511894,"score_spread":0.3269444661590963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999247109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9694827,0.020080665,0.000022000557,0.0056659007,0.00015989352,0.0030597197,0.0013434782,0.00011706186,0.00006853669],"genre_scores_gemma":[0.95194924,0.044615313,0.00045226517,0.0008518668,0.00013171455,0.00092725584,0.00028522988,0.00007571312,0.0007114107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996877,0.00017900225,0.00081758003,0.0009553686,0.0005320595,0.0006389932],"domain_scores_gemma":[0.99805146,0.00029617577,0.00031585142,0.0002545337,0.00018121464,0.00090073847],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026146526,0.00044892178,0.00082257506,0.00013583271,0.00022277603,0.00013104505,0.0000926736,0.000025038493,0.000116004594],"category_scores_gemma":[0.00024798678,0.00030612265,0.000082692146,0.0004643479,0.00048133597,0.00040073125,0.00012562248,0.00052286417,0.000008341801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076563945,0.0002487905,0.93992394,0.0012003642,0.00015660886,0.001110433,0.0010132614,0.00009568449,0.00005990854,0.000015779326,0.00052029797,0.04799852],"study_design_scores_gemma":[0.021314336,0.0026099235,0.96490484,0.0014939161,0.00088999845,0.00008574726,0.0011105732,0.0034013528,0.00053083757,0.00043194788,0.0025527866,0.00067373505],"about_ca_topic_score_codex":0.0009417445,"about_ca_topic_score_gemma":0.00017760949,"teacher_disagreement_score":0.047324788,"about_ca_system_score_codex":0.00015469105,"about_ca_system_score_gemma":0.00061607704,"threshold_uncertainty_score":0.9999391},"labels":[],"label_agreement":null},{"id":"W2999382299","doi":"10.4081/aiua.2019.4.265","title":"Solitary prostatic cancer metastasis to the testis: A case report and lessons to learn","year":2020,"lang":"en","type":"article","venue":"Archivio Italiano di Urologia e Andrologia","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University","funders":"","keywords":"Orchiectomy; Medicine; Prostate cancer; Metastasis; Cancer; Differential diagnosis; Testicular cancer; Seminoma; Epididymis; Prostate; Urology; Radiology; Surgery; Pathology; Internal medicine; Sperm","score_opus":0.06225136245152232,"score_gpt":0.34768494860761834,"score_spread":0.28543358615609604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999382299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8024882,0.0012824737,0.00024275045,0.19319747,0.00008135729,0.001680894,0.00023333693,0.00012421045,0.0006692664],"genre_scores_gemma":[0.982119,0.00018581974,0.0011125185,0.014466082,0.0001552319,0.0006934999,0.000056341447,0.00003887338,0.0011726054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975908,0.00016225566,0.00036366307,0.00080365245,0.00032846574,0.00075120595],"domain_scores_gemma":[0.9983208,0.00024417666,0.00007442848,0.00049218704,0.00009887203,0.00076953013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038661103,0.00031520586,0.00049191486,0.00012420883,0.00031028138,0.000062846084,0.0002036229,0.00008064277,0.00008898716],"category_scores_gemma":[0.0007653409,0.00018813582,0.000109190005,0.00054883055,0.00026008647,0.00008327108,0.00039413784,0.00045078964,0.000112178204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005477176,0.0005417192,0.39594933,0.0004605365,0.001499382,0.39428702,0.012425591,0.00059406774,0.0061648777,0.00035181423,0.08018724,0.10206125],"study_design_scores_gemma":[0.00992045,0.031823844,0.66983193,0.000334079,0.003223341,0.15671632,0.004308622,0.0037440783,0.006584259,0.0014007827,0.109751955,0.0023603651],"about_ca_topic_score_codex":0.0006389292,"about_ca_topic_score_gemma":0.0002737468,"teacher_disagreement_score":0.27388257,"about_ca_system_score_codex":0.000048698526,"about_ca_system_score_gemma":0.00024535248,"threshold_uncertainty_score":0.7671956},"labels":[],"label_agreement":null},{"id":"W2999586427","doi":"10.1016/s0923-7534(20)33484-0","title":"Clinical Activity of Abiraterone Acetate (AA) after Progression on Mdv3100 in Patients with Metastatic Castration Resistant Prostate Cancer (MCRPC)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Abiraterone; Oncology; Internal medicine; Pharmacology; Castration; Cancer; Androgen receptor; Androgen deprivation therapy; Hormone","score_opus":0.12857814849242416,"score_gpt":0.48469412081688457,"score_spread":0.3561159723244604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999586427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965655,0.00050162553,0.0000012172741,0.001416727,0.00009005448,0.0009887181,0.000053065698,0.0000069377847,0.00037615144],"genre_scores_gemma":[0.9986866,0.0004420913,0.00029060853,0.00012532363,0.000036334706,0.00017268205,0.000030178044,0.000016287866,0.00019985816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838877,0.00027693532,0.00041971946,0.00020714462,0.0003366347,0.00037078653],"domain_scores_gemma":[0.9989897,0.00010614839,0.00029181474,0.00019164642,0.0002783599,0.00014234819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006603079,0.000136258,0.0005339492,0.00014132693,0.000019468258,0.0000029458388,0.000046272355,0.00008874049,0.00006840791],"category_scores_gemma":[0.000048941503,0.00008416424,0.000059492704,0.00018722937,0.000231951,0.00015732985,0.000029227358,0.00021870439,0.000005386634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052776787,0.004583835,0.79147464,0.00025458055,0.00018860196,0.000038174156,0.00060632825,0.000004644887,0.001863636,0.0000084475105,0.00024010775,0.1479602],"study_design_scores_gemma":[0.0070012202,0.014165632,0.9546701,0.00034990656,0.00006934349,9.994953e-7,0.000035401048,0.0000059801487,0.022960147,0.000016228232,0.0006486856,0.00007639938],"about_ca_topic_score_codex":0.00009804167,"about_ca_topic_score_gemma":0.00014193142,"teacher_disagreement_score":0.1631954,"about_ca_system_score_codex":0.00009065663,"about_ca_system_score_gemma":0.000333443,"threshold_uncertainty_score":0.3432118},"labels":[],"label_agreement":null},{"id":"W2999659032","doi":"10.1073/pnas.1905384117","title":"Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1","year":2020,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Congressionally Directed Medical Research Programs; National Cancer Institute; National Institutes of Health; Canary Foundation; U.S. Department of Defense","keywords":"Prostate cancer; Cancer research; Metastasis; PARP1; Prostate; Phenotype; Medicine; In vivo; Cancer; Neuroendocrine tumors; Biology; Internal medicine; Poly ADP ribose polymerase; Genetics; Gene","score_opus":0.06338112921855878,"score_gpt":0.34904970711631506,"score_spread":0.2856685778977563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999659032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9605743,0.00043290306,8.7677097e-7,0.036985364,0.0000052937858,0.0004727968,0.000042133986,0.0000073917536,0.0014789049],"genre_scores_gemma":[0.9973369,0.00020019566,0.0009444649,0.0012747108,0.000036665053,0.000024523033,3.2975444e-7,0.000004939817,0.0001772346],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980241,0.000005646332,0.00022337702,0.00020807686,0.0013851046,0.00015371265],"domain_scores_gemma":[0.99926007,0.000042516393,0.0002581833,0.0000074295026,0.00037196762,0.000059838716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020506543,0.000089519745,0.00021864535,0.00009214751,0.00006449442,0.000008124612,0.00030596933,0.000012491022,0.000051616884],"category_scores_gemma":[0.00009980015,0.000045872224,0.000057533725,0.0009196238,0.000688497,0.00021204971,0.000054185075,0.00013533402,9.3977036e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00183496,0.0003953016,0.13270985,0.0018395972,0.00032687667,8.9791155e-7,0.0051820613,0.00006950976,0.8447182,0.0041915155,0.0055836327,0.003147562],"study_design_scores_gemma":[0.0023430882,0.0014394176,0.096176684,0.00029939855,0.00020343125,0.000028886734,0.0005671091,0.0014599665,0.8925481,0.0039261077,0.00089216867,0.00011562967],"about_ca_topic_score_codex":0.000015831612,"about_ca_topic_score_gemma":5.4972315e-8,"teacher_disagreement_score":0.047829866,"about_ca_system_score_codex":0.000020986046,"about_ca_system_score_gemma":0.00010250397,"threshold_uncertainty_score":0.25367957},"labels":[],"label_agreement":null},{"id":"W2999694445","doi":"10.1101/2020.01.15.908384","title":"Deep Learning Modelling of Androgen Receptor Responses to Prostate Cancer Therapies","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Androgen receptor; Prostate cancer; Leverage (statistics); Mutant; Computational biology; Machine learning; Artificial intelligence; Artificial neural network; Phenotype; Drug; Computer science; Deep learning; Bioinformatics; Biology; Cancer; Medicine; Pharmacology; Genetics; Gene","score_opus":0.04366986498323012,"score_gpt":0.28799264920478507,"score_spread":0.24432278422155496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999694445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97535783,0.016840344,0.0020729026,0.0028431206,0.00038036352,0.0019552622,0.00023626853,0.00030400624,0.000009917713],"genre_scores_gemma":[0.9818593,0.008610613,0.008031206,0.00019548915,0.00037963866,0.0006297206,0.0000014840736,0.00018081488,0.00011169442],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970987,0.0001919564,0.00054291054,0.0009515804,0.000608918,0.0006059539],"domain_scores_gemma":[0.9976205,0.00008924669,0.00030103838,0.00067626114,0.0007985119,0.0005143925],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044889233,0.00050971285,0.00089194014,0.00036673722,0.00014841386,0.00008852607,0.00030291703,0.00032586034,0.00011249157],"category_scores_gemma":[0.00019104079,0.00045504057,0.00020474936,0.0006512153,0.00013742792,0.000084835694,0.0003985061,0.00096557196,0.000050250157],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048519745,0.0002537918,0.07774809,0.0025142373,0.0014892855,0.0001642101,0.0007997962,0.007177516,0.9045168,0.00006066043,0.00035924863,0.000064390115],"study_design_scores_gemma":[0.0033506183,0.0011244762,0.020146888,0.0037944098,0.00059379655,4.0612857e-8,0.00009301845,0.010948236,0.93263775,0.000005185269,0.025983086,0.0013224783],"about_ca_topic_score_codex":0.00016543285,"about_ca_topic_score_gemma":0.0000014565077,"teacher_disagreement_score":0.057601206,"about_ca_system_score_codex":0.000400844,"about_ca_system_score_gemma":0.0014200113,"threshold_uncertainty_score":0.99979013},"labels":[],"label_agreement":null},{"id":"W2999830727","doi":"10.1016/s0923-7534(20)33529-8","title":"Association of Progression by Prostate Cancer Working Group (PCWG)-2 Criteria and Survival in Metastatic Castration Resistant Prostate Cancer","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Prostate; Castration; Internal medicine; Hormone","score_opus":0.10801698828208837,"score_gpt":0.4628636981609387,"score_spread":0.3548467098788503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999830727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97707206,0.015254191,0.0000014662081,0.00598722,0.00020901636,0.0008726696,0.00010967298,0.000010344437,0.0004833482],"genre_scores_gemma":[0.98772854,0.010795686,0.00022220158,0.00009234044,0.00006947011,0.00027241412,0.00008374482,0.000017558437,0.0007180324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829,0.0002662458,0.00045725674,0.00019908266,0.00033223088,0.00045519602],"domain_scores_gemma":[0.99898857,0.00014643332,0.0003998343,0.000099540644,0.0002460984,0.00011952208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001204998,0.00013620006,0.0004911374,0.00014496956,0.00004182773,0.000009182841,0.00004231953,0.00010479479,0.00006305679],"category_scores_gemma":[0.00009193905,0.00010571513,0.00004212978,0.00026658294,0.000104402,0.00018205041,0.00003712697,0.00016915544,6.493983e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00425702,0.0008285486,0.7507514,0.0005400551,0.00026364278,0.000018604598,0.0035926974,0.0000020068296,0.12299257,0.000046547906,0.0032487141,0.1134582],"study_design_scores_gemma":[0.01238583,0.0057493937,0.82997173,0.0017298782,0.00037464098,0.000009409485,0.001613174,0.00013323121,0.10918872,0.00033011037,0.03814805,0.00036585235],"about_ca_topic_score_codex":0.0010424693,"about_ca_topic_score_gemma":0.0010195278,"teacher_disagreement_score":0.11309235,"about_ca_system_score_codex":0.00025495893,"about_ca_system_score_gemma":0.00027838952,"threshold_uncertainty_score":0.43109378},"labels":[],"label_agreement":null},{"id":"W2999963688","doi":"10.1101/19012237","title":"Polygenic hazard score is associated with prostate cancer in multi-ethnic populations","year":2019,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Alberta; Institut National de la Recherche Scientifique; Princess Margaret Cancer Centre; University of Toronto; Institute of Cancer Research","funders":"Norges Forskningsråd; National Institute for Health and Care Research; NIHR Bristol Biomedical Research Centre; Department of Health and Social Care; Cancer Research UK; U.S. Department of Defense","keywords":"Prostate cancer; Medicine; Proportional hazards model; Hazard ratio; Ethnic group; Internal medicine; Genotype; Oncology; Single-nucleotide polymorphism; Demography; Ancestry-informative marker; Gynecology; Cancer; Biology; Genetics; Gene","score_opus":0.131934780780114,"score_gpt":0.3952825862648995,"score_spread":0.2633478054847855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999963688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841108,0.009092926,0.00001701108,0.0028731895,0.00042900466,0.0026416234,0.00043856073,0.000099879224,0.00029701905],"genre_scores_gemma":[0.9729288,0.00229997,0.00015782367,0.00021575749,0.000072746574,0.0006259136,0.00057801895,0.00009598731,0.02302499],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748373,0.00011111424,0.00040892456,0.0007607474,0.00059856265,0.000636907],"domain_scores_gemma":[0.99858135,0.000044201854,0.00021695512,0.0006978114,0.0002582803,0.00020138828],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003029927,0.000401227,0.0007427477,0.00039059005,0.00006376402,0.000036342095,0.00020781711,0.000366335,0.0003240902],"category_scores_gemma":[0.00008959265,0.0002877586,0.00016570892,0.00056297117,0.00012121211,0.00006322365,0.00024939285,0.0012106039,0.00007072352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005502545,0.00030072825,0.99437416,0.0003203868,0.00039075347,0.00018122891,0.0013682356,0.00034049866,0.00045835928,0.0000027122232,0.00032367767,0.0013889875],"study_design_scores_gemma":[0.0046302094,0.00017816627,0.9891271,0.0024735779,0.0002313085,0.0000050137837,0.00006255788,0.0021694542,0.0006243922,0.00005654793,0.00012415295,0.00031749113],"about_ca_topic_score_codex":0.0011603702,"about_ca_topic_score_gemma":0.0049960073,"teacher_disagreement_score":0.02272797,"about_ca_system_score_codex":0.0008896908,"about_ca_system_score_gemma":0.0013466082,"threshold_uncertainty_score":0.99995744},"labels":[],"label_agreement":null},{"id":"W3000411451","doi":"10.1158/1078-0432.ccr-19-3023","title":"Diverse <i>AR</i> Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institutes of Health; Prostate Cancer Foundation of Australia; National Cancer Institute; National Institute for Health and Care Research; U.S. Department of Veterans Affairs","keywords":"Androgen receptor; Prostate cancer; Cancer research; Prostate; Cancer; Gene; Biology; Medicine; Oncology; Internal medicine; Genetics","score_opus":0.26812945031345203,"score_gpt":0.5093051652964752,"score_spread":0.24117571498302315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000411451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9209989,0.010634294,0.0000034047391,0.063012265,0.00046847214,0.0035156596,0.0004727784,0.00007511185,0.00081911316],"genre_scores_gemma":[0.9330304,0.044504113,0.0010206841,0.00562428,0.0019340292,0.003343647,0.00016257017,0.00016310181,0.010217125],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938547,0.0007408629,0.0009959213,0.0012082077,0.0018850177,0.001315266],"domain_scores_gemma":[0.9966109,0.0004629162,0.00011188772,0.00051468186,0.0006992396,0.0016003853],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002837774,0.00030462875,0.00083914155,0.00033010615,0.00019822163,0.00007307638,0.00044135016,0.00015101673,0.0012899744],"category_scores_gemma":[0.0012886239,0.00024380634,0.00019985769,0.0023616261,0.0004975674,0.00017700065,0.00048303747,0.0013947156,0.00053046516],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028392209,0.00095902494,0.579851,0.0010873898,0.00066146045,0.0013132707,0.0044328407,0.000047147532,0.018860346,0.00002140294,0.2996707,0.06470328],"study_design_scores_gemma":[0.035608865,0.0046137045,0.08058766,0.0025779894,0.00030004318,0.0000036281851,0.0029656233,0.00016838487,0.07756598,0.00027376667,0.794106,0.0012283404],"about_ca_topic_score_codex":0.0009221166,"about_ca_topic_score_gemma":0.001623019,"teacher_disagreement_score":0.4992633,"about_ca_system_score_codex":0.0007644653,"about_ca_system_score_gemma":0.0015948411,"threshold_uncertainty_score":0.999623},"labels":[],"label_agreement":null},{"id":"W3000713139","doi":"10.1016/j.annonc.2019.10.025","title":"A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Health and Medical Research Council; Bayer","keywords":"Medicine; Regimen; Prostate cancer; Hazard ratio; Clinical endpoint; Confidence interval; Surgery; Internal medicine; Urology; Cancer; Randomized controlled trial","score_opus":0.11824262257958643,"score_gpt":0.4133955550670814,"score_spread":0.29515293248749497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000713139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99169785,0.0007989914,0.000008709071,0.004766173,0.000038224352,0.00229467,0.00011344933,0.000005267709,0.00027669204],"genre_scores_gemma":[0.99902576,0.00027983807,0.00029800044,0.00013604556,0.000029226081,0.00010951228,0.00005501549,0.000013179461,0.000053395936],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99854386,0.00011277916,0.0006064817,0.00019064372,0.00031676263,0.0002294814],"domain_scores_gemma":[0.99883145,0.00013657798,0.0004210352,0.00013363978,0.00036266682,0.0001146373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032330788,0.00012090176,0.00083120156,0.00012989462,0.000026575071,0.0000020187954,0.00005590126,0.00004875763,0.000058703357],"category_scores_gemma":[0.000119897246,0.0000828949,0.00008699066,0.0003192457,0.00021271645,0.0000626146,0.00002542852,0.00011798107,3.7695293e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94642216,0.0056324215,0.0036310935,0.00040007746,0.0005596913,0.000089677524,0.0026843369,0.000029173303,0.01887369,0.00002318661,0.000482114,0.021172391],"study_design_scores_gemma":[0.8793929,0.07390271,0.0036785405,0.00026092486,0.00027738567,0.0000012106901,0.00018044816,0.00011383885,0.04146714,0.00006592895,0.0005620062,0.00009694211],"about_ca_topic_score_codex":0.0003072243,"about_ca_topic_score_gemma":0.00018471804,"teacher_disagreement_score":0.06827029,"about_ca_system_score_codex":0.000049700324,"about_ca_system_score_gemma":0.0008611468,"threshold_uncertainty_score":0.33803558},"labels":[],"label_agreement":null},{"id":"W3000919557","doi":"10.1200/jop.19.00421","title":"Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to Assess the Value of Abiraterone and Enzalutamide in Advanced Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"JCO Oncology Practice","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Enzalutamide; Medicine; Abiraterone; Prostate cancer; Clinical trial; Oncology; Internal medicine; Cancer; Androgen receptor","score_opus":0.0653993345987498,"score_gpt":0.4721282607479003,"score_spread":0.4067289261491505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000919557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94584405,0.0012356599,0.00013189987,0.05088944,0.00007283071,0.0013727318,0.000020704629,0.000005717391,0.00042693852],"genre_scores_gemma":[0.98858476,0.0025389777,0.0063851895,0.0021825696,0.00006002145,0.00017093161,0.0000027409328,0.000012855223,0.000061982515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843854,0.00036569446,0.00051959953,0.00027171167,0.00024244576,0.0001620014],"domain_scores_gemma":[0.9969878,0.0019887474,0.00042118976,0.00025910584,0.00024244546,0.00010071838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010554757,0.0001013485,0.00045994628,0.00003520632,0.00004268841,0.0000049773444,0.00013196046,0.00014967305,0.000008179355],"category_scores_gemma":[0.0016354839,0.000059076134,0.000039605566,0.00033507217,0.00034978258,0.00011237416,0.00017796895,0.00049144455,0.0000012359272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009296794,0.00082252943,0.8401074,0.00046615794,0.00023564315,0.00001165972,0.004906554,0.00048411087,0.025341816,0.00148772,0.00009663572,0.11674301],"study_design_scores_gemma":[0.0038772298,0.0021278665,0.96219814,0.00022564142,0.00033994,0.000013431588,0.0016795455,0.00066836766,0.019237423,0.0006172799,0.0089318,0.000083317704],"about_ca_topic_score_codex":0.0004938116,"about_ca_topic_score_gemma":0.00012884547,"teacher_disagreement_score":0.12209079,"about_ca_system_score_codex":0.00006436084,"about_ca_system_score_gemma":0.00034148918,"threshold_uncertainty_score":0.24090548},"labels":[],"label_agreement":null},{"id":"W3001540556","doi":"10.1038/s41467-020-14318-9","title":"Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer","year":2020,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Cure Brain Cancer Foundation; Canadian Institutes of Health Research; KWF Kankerbestrijding; Prostate Cancer Canada; Government of Ontario; Princess Margaret Cancer Foundation; Ontario Institute for Cancer Research; Movember Foundation","keywords":"FOXA1; Prostate cancer; Transactivation; Transcription factor; Biology; Cancer research; Androgen receptor; Prostate; Cancer; Medicine; Genetics; Gene","score_opus":0.04508509355294693,"score_gpt":0.3765440278336117,"score_spread":0.33145893428066475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001540556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83788306,0.038788453,0.000009112458,0.11414156,0.00017862563,0.0022703214,0.0003136219,0.00006401523,0.0063512377],"genre_scores_gemma":[0.99576366,0.0012408419,0.001540365,0.00084179826,0.000029352783,0.00017522629,0.000116524614,0.000014211296,0.0002780068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991248,0.00008673512,0.00025047577,0.00013218375,0.00024636395,0.0001594276],"domain_scores_gemma":[0.9988216,0.000089783236,0.000097189375,0.00075092673,0.00016544241,0.000075016666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012627793,0.00008574832,0.00016045502,0.000067294786,0.0001493881,0.000008164401,0.00045425526,0.00008083913,0.000058649126],"category_scores_gemma":[0.0001307551,0.00005912453,0.00006820524,0.0006611264,0.00017324656,0.00006272557,0.00024619562,0.0007320498,0.0000042636216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020305683,0.0003862066,0.9637165,0.0001450558,0.0001969294,0.00000526244,0.007835278,0.00011627685,0.01755284,0.001731634,0.0050087064,0.0031022246],"study_design_scores_gemma":[0.004333675,0.00015660768,0.9159323,0.00038985905,0.00013701338,0.0000039667225,0.0013734403,0.0036433407,0.017247014,0.00043990277,0.056146298,0.00019659296],"about_ca_topic_score_codex":0.00008121911,"about_ca_topic_score_gemma":0.00041173372,"teacher_disagreement_score":0.15788062,"about_ca_system_score_codex":0.0001478114,"about_ca_system_score_gemma":0.000347077,"threshold_uncertainty_score":0.31804326},"labels":[],"label_agreement":null},{"id":"W3001922420","doi":"10.1016/j.clon.2019.12.007","title":"Role of Para-aortic Radiotherapy in the Management of Prostate Cancer","year":2020,"lang":"en","type":"review","venue":"Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Royal Marsden NHS Foundation Trust","keywords":"Medicine; Radiation therapy; Prostate cancer; Presentation (obstetrics); Radiology; Surgery; Cancer; General surgery; Internal medicine","score_opus":0.2213060753147456,"score_gpt":0.5667423423888197,"score_spread":0.3454362670740741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001922420","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044719805,0.99360865,6.729132e-7,0.001498776,0.00013768229,0.0024579437,0.000027359954,0.000006618947,0.0018150853],"genre_scores_gemma":[0.00020073689,0.99803543,0.00024395747,0.00021286565,0.00018733683,0.0005462279,0.000036905218,0.000024686573,0.000511846],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972167,0.000561369,0.0014048294,0.00033053488,0.00024309126,0.00024350247],"domain_scores_gemma":[0.99821043,0.0007437203,0.0005394482,0.00036035993,0.000050820185,0.000095242394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091921503,0.00019234752,0.0027028462,0.00008183626,0.0000119552005,0.000002283201,0.0002882527,0.00030556272,0.00012503081],"category_scores_gemma":[0.000042218067,0.000098599376,0.00053551176,0.00040530667,0.0003606896,0.000011554556,0.00007024948,0.0006463618,0.000012419751],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045750052,0.00072127563,0.001198494,0.011193842,0.0012286383,0.00022840402,0.00017856008,1.3665283e-7,4.8849046e-7,0.0000869321,0.00040764333,0.9842981],"study_design_scores_gemma":[0.002439313,0.0022432976,0.0018428861,0.0049261865,0.0013950667,0.0000085834445,0.0001019798,0.0000062577155,0.000001001702,0.00007089549,0.986889,0.000075517564],"about_ca_topic_score_codex":0.000035122095,"about_ca_topic_score_gemma":0.0000101864225,"teacher_disagreement_score":0.98648137,"about_ca_system_score_codex":0.00023351255,"about_ca_system_score_gemma":0.0011579763,"threshold_uncertainty_score":0.40207657},"labels":[],"label_agreement":null},{"id":"W3002252031","doi":"10.1097/ppo.0000000000000419","title":"Genomic Strategies to Personalize Use of Androgen Deprivation Therapy With Radiotherapy","year":2020,"lang":"en","type":"review","venue":"The Cancer Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Androgen deprivation therapy; Prostate cancer; Medicine; Radiation therapy; Oncology; Disease; Combination therapy; Internal medicine; Intensive care medicine; Bioinformatics; Cancer; Biology","score_opus":0.15152890095522145,"score_gpt":0.40953601347966206,"score_spread":0.25800711252444064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3002252031","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016463351,0.9953994,0.00020086848,0.0014237936,0.000074479576,0.0011569402,0.00004587637,0.000012069961,0.000040223244],"genre_scores_gemma":[0.00007697842,0.99814105,0.00039093086,0.00027939497,0.0006802095,0.00007233293,0.000017552808,0.00006684669,0.00027468018],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986449,0.00015008973,0.00034809287,0.00021778961,0.00038961938,0.00024950955],"domain_scores_gemma":[0.9990084,0.00007788891,0.00030250874,0.00025822947,0.0001582709,0.00019470675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019828255,0.00027822208,0.0010341632,0.0001298984,0.00011739704,0.000120265344,0.00025755438,0.0000832662,0.00030554424],"category_scores_gemma":[0.000008107615,0.00012340996,0.00028068697,0.00036095918,0.00010282285,0.000100633515,0.000022710332,0.0005334668,0.000004999692],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001039472,0.00003538824,0.00020942627,0.0011112114,0.0020893721,0.00008128281,0.0010606349,0.0000204876,0.000092819646,0.000016519876,0.0016803271,0.99256307],"study_design_scores_gemma":[0.0013022778,0.0007561239,0.00013304694,0.0038805183,0.00051753304,0.00052131095,0.00010698519,0.000004737031,0.00004551101,0.000016314701,0.99257606,0.00013960428],"about_ca_topic_score_codex":0.00005521558,"about_ca_topic_score_gemma":0.0000057386014,"teacher_disagreement_score":0.9924235,"about_ca_system_score_codex":0.0005387969,"about_ca_system_score_gemma":0.0032286453,"threshold_uncertainty_score":0.5727478},"labels":[],"label_agreement":null},{"id":"W3003418338","doi":"10.1093/jncics/pkaa003","title":"Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel","year":2020,"lang":"en","type":"article","venue":"JNCI Cancer Spectrum","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Docetaxel; Hazard ratio; Prostate cancer; Internal medicine; Regimen; Oncology; Prednisone; Confidence interval; Gynecology; Cancer","score_opus":0.05303180458622026,"score_gpt":0.34326264101208714,"score_spread":0.2902308364258669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003418338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.960383,0.0038904524,0.000024372255,0.025217414,0.000049783375,0.0015286161,0.0005221669,0.00006246553,0.008321716],"genre_scores_gemma":[0.99610025,0.0011734514,0.00019419065,0.00013012887,0.00011295148,0.00021460878,0.000055285644,0.00003099854,0.0019881574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837434,0.00006132655,0.00029951226,0.000417269,0.00046497255,0.00038260157],"domain_scores_gemma":[0.99916893,0.000026494616,0.00016365136,0.0001721632,0.00015127753,0.00031749337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007943056,0.00026101948,0.0006847902,0.00008400478,0.00008947188,0.000035217607,0.00007348947,0.00003531716,0.00042335488],"category_scores_gemma":[0.0000066219604,0.00017350327,0.0000559076,0.000505932,0.00023220896,0.00013151043,0.000029899142,0.00020364982,0.000004546559],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03703308,0.00070768164,0.83584,0.0024192212,0.0057592345,0.0009688192,0.032204736,0.0003882717,0.072949424,0.00063855335,0.0065187337,0.00457228],"study_design_scores_gemma":[0.02646526,0.008016302,0.7540821,0.0009370402,0.0019825601,0.00004616606,0.009484099,0.0024681548,0.1915706,0.00014623879,0.0038781874,0.00092331576],"about_ca_topic_score_codex":0.0018751961,"about_ca_topic_score_gemma":0.002282902,"teacher_disagreement_score":0.11862118,"about_ca_system_score_codex":0.0002099889,"about_ca_system_score_gemma":0.000661856,"threshold_uncertainty_score":0.7075258},"labels":[],"label_agreement":null},{"id":"W3003615673","doi":"","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Post Hoc","year":2019,"lang":"en","type":"article","venue":"University of Southern Denmark Research Portal (University of Southern Denmark)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Enzalutamide; Prostate cancer; Post-hoc analysis; Placebo; Medicine; Post hoc; Oncology; Internal medicine; Double blind; Castration; Urology; Cancer; Pathology; Hormone; Androgen receptor","score_opus":0.023676655271671593,"score_gpt":0.2868734600698093,"score_spread":0.2631968047981377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003615673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98691976,0.00023141097,0.0000067895367,0.00012503253,0.00002488965,0.008904233,0.001168837,0.000016504755,0.0026025549],"genre_scores_gemma":[0.98837763,0.00012832161,0.0001629403,0.0000036803262,0.000010459437,0.000004533366,0.00013683467,0.000042032814,0.011133586],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952531,0.00072512316,0.0005320374,0.00069533836,0.0020916492,0.0007027554],"domain_scores_gemma":[0.9962421,0.00046742108,0.0006789754,0.00064486515,0.0016245637,0.00034206218],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00199388,0.00036634004,0.0017302532,0.0013291205,0.0002544426,0.00002082973,0.0005691138,0.00017321181,0.004083199],"category_scores_gemma":[0.00006626421,0.0003320975,0.00036432873,0.0011299506,0.001156925,0.00023993538,0.0002598393,0.0006338136,0.00018757205],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83400685,0.0051391404,0.12429947,0.0004342327,0.0018540787,0.00047175653,0.03207562,0.00008340781,0.00090755837,0.000012642312,0.000036412286,0.000678823],"study_design_scores_gemma":[0.70421743,0.005016492,0.0032367497,0.00047988127,0.00060489355,0.00000222027,0.2859309,0.00018054091,0.00005821543,0.000012420678,0.000020081266,0.00024014736],"about_ca_topic_score_codex":0.013425816,"about_ca_topic_score_gemma":0.009658731,"teacher_disagreement_score":0.2538553,"about_ca_system_score_codex":0.00024059947,"about_ca_system_score_gemma":0.0010951569,"threshold_uncertainty_score":0.9999131},"labels":[],"label_agreement":null},{"id":"W3005467664","doi":"10.1016/s0923-7534(20)33522-5","title":"Cabazitaxel Early Access Program (EAP) - Canadian Interim Results: Safety, QOL, and Utility Values in Metastatic Castration Resistant Prostate Cancer (MCRPC)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec; CancerCare Manitoba; La Cité Médicale; Moncton Hospital; Sanofi (Canada); Hôpital Notre-Dame; Grand River Hospital","funders":"","keywords":"Cabazitaxel; Medicine; Prostate cancer; Interim; Oncology; Docetaxel; Internal medicine; Cancer; Androgen deprivation therapy","score_opus":0.2168137851922464,"score_gpt":0.4984612779337534,"score_spread":0.281647492741507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005467664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764828,0.004387353,8.1006704e-7,0.010652648,0.00013806396,0.001473246,0.00040564872,0.000020111054,0.006439302],"genre_scores_gemma":[0.9956148,0.00279124,0.00027103216,0.00026867818,0.00006312096,0.00022751388,0.00011710983,0.000015999036,0.0006304508],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981053,0.0002191493,0.00051439437,0.0002810689,0.00020948927,0.0006706375],"domain_scores_gemma":[0.9988035,0.000113187874,0.00015586604,0.00021679343,0.0002823413,0.00042832026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010582992,0.00016245707,0.0004636504,0.00029361964,0.000074386044,0.000027079113,0.000105310144,0.00010677292,0.000066942666],"category_scores_gemma":[0.00019741333,0.00012778601,0.00005040994,0.00031395955,0.00030074394,0.00036366226,0.00006407626,0.00023813461,0.000003615485],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019369442,0.0020625566,0.32175368,0.00074204296,0.0005476637,0.0004188554,0.012085985,0.000004039019,0.0020493015,0.00019376448,0.00700613,0.63376653],"study_design_scores_gemma":[0.0044948165,0.0046254327,0.94341666,0.00025230367,0.00009365106,0.000025934354,0.00081523316,0.00005649975,0.00403016,0.0003446269,0.04167493,0.0001697784],"about_ca_topic_score_codex":0.1832626,"about_ca_topic_score_gemma":0.21740127,"teacher_disagreement_score":0.6335968,"about_ca_system_score_codex":0.00028156483,"about_ca_system_score_gemma":0.001329024,"threshold_uncertainty_score":0.8221761},"labels":[],"label_agreement":null},{"id":"W3006083633","doi":"10.1038/s41416-020-0749-2","title":"Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression","year":2020,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"Fonds de Recherche du Québec-Société et Culture; Prostate Cancer Canada; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Prostate cancer; Cancer research; Biochemical recurrence; Biology; Prostate; breakpoint cluster region; Androgen; Metastasis; Dihydrotestosterone; Internal medicine; Endocrinology; Cancer; Prostatectomy; Medicine; Gene; Hormone; Genetics","score_opus":0.01875105382115212,"score_gpt":0.34290333027836384,"score_spread":0.32415227645721173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006083633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92472345,0.06870821,0.0000027296774,0.005471065,0.0001164812,0.0007914389,0.00012781988,0.000008409504,0.00005040944],"genre_scores_gemma":[0.9598559,0.038561717,0.00002246366,0.0010020328,0.00028612875,0.00009946805,0.0000028486456,0.000022229933,0.00014718973],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984814,0.00006024927,0.00035863183,0.00023649656,0.00056611386,0.0002971124],"domain_scores_gemma":[0.999009,0.000026050215,0.00022936387,0.000051132858,0.00034406604,0.00034034517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000191853,0.00014080884,0.0003917983,0.000089449946,0.000054918408,0.00005780441,0.00010145738,0.000048063408,0.00006732461],"category_scores_gemma":[0.000083542465,0.000117018426,0.000053966505,0.00015473935,0.00007009538,0.000246029,0.000031798972,0.0004739643,0.000002347892],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011819596,0.0004909043,0.28002807,0.0006645818,0.0006342151,0.015532491,0.003962431,0.0012237001,0.018395418,0.00002214494,0.0006958916,0.66653055],"study_design_scores_gemma":[0.11097486,0.0074493587,0.6614437,0.026419418,0.0006771096,0.0041333926,0.00069060153,0.0037480923,0.16772178,0.00024848385,0.015364963,0.0011282237],"about_ca_topic_score_codex":0.0005027798,"about_ca_topic_score_gemma":0.00016046924,"teacher_disagreement_score":0.6654023,"about_ca_system_score_codex":0.00022183599,"about_ca_system_score_gemma":0.00045048224,"threshold_uncertainty_score":0.4771873},"labels":[],"label_agreement":null},{"id":"W3006239597","doi":"10.2967/jnumed.119.238071","title":"Multiphasic<sup>68</sup>Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients","year":2020,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Glutamate carboxypeptidase II; Prostate; Biochemical recurrence; Prospective cohort study; Nuclear medicine; Prostate-specific antigen; Androgen deprivation therapy; Urology; Cancer; Radiology; Internal medicine","score_opus":0.06456796728362828,"score_gpt":0.3270258436352856,"score_spread":0.2624578763516573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006239597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99688053,0.00033381584,0.0000020412208,0.0009206487,0.000054291802,0.0017341601,0.000031116822,0.0000034561556,0.000039944687],"genre_scores_gemma":[0.9995154,0.00025222916,0.000042762887,0.000071713635,0.000055365388,0.000021677568,0.0000035485361,0.000027117943,0.000010176462],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972732,0.00019137024,0.0008718289,0.00021653983,0.0012146308,0.00023240234],"domain_scores_gemma":[0.9979116,0.000099742756,0.0007916553,0.00017343387,0.0008970291,0.00012657297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048317164,0.00018950638,0.00075978704,0.00032570813,0.000033720924,0.0000048321403,0.00021116037,0.000018200111,0.000022414524],"category_scores_gemma":[0.00030065802,0.00010095977,0.00006536848,0.0008885809,0.00022804922,0.00016929106,0.000040993782,0.00056339055,6.2888375e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0126542635,0.0031976858,0.9253444,0.0003119106,0.00021317507,0.00022464659,0.050099064,0.00005474418,0.00089435163,8.8990174e-7,0.00006381877,0.006941045],"study_design_scores_gemma":[0.027023632,0.029346975,0.9247085,0.00195358,0.00017424476,0.000019629688,0.015944714,0.00021070107,0.00048997125,0.0000063036837,0.000040042898,0.00008170322],"about_ca_topic_score_codex":0.0014817702,"about_ca_topic_score_gemma":0.00024691093,"teacher_disagreement_score":0.03415435,"about_ca_system_score_codex":0.00018183856,"about_ca_system_score_gemma":0.00017888249,"threshold_uncertainty_score":0.411702},"labels":[],"label_agreement":null},{"id":"W3006609363","doi":"10.1038/s41467-020-14644-y","title":"Androgen receptor-binding sites are highly mutated in prostate cancer","year":2020,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Türkiye Bilimler Akademisi","keywords":"Prostate cancer; Androgen receptor; Biology; Transcription factor; Cancer research; Enhancer; Carcinogenesis; Chromoplexy; Germline mutation; Estrogen receptor; Genetics; Mutation; Cancer; Gene; Breast cancer; PCA3","score_opus":0.05618985222623682,"score_gpt":0.37144791078772293,"score_spread":0.31525805856148614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006609363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7971762,0.044221237,5.934994e-7,0.15487333,0.00006168172,0.0009085459,0.00025529478,0.00013471715,0.002368435],"genre_scores_gemma":[0.9869208,0.00959087,0.00072314584,0.0010600941,0.000051234714,0.00017667378,0.00086012273,0.00002317196,0.0005938987],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991263,0.000080254795,0.0001815079,0.00020270368,0.00018414829,0.00022509924],"domain_scores_gemma":[0.99894434,0.00009072971,0.00006784648,0.0005803104,0.00016030936,0.00015645222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009424131,0.000116733834,0.00020892205,0.00010874927,0.00014414405,0.000024904984,0.00033710667,0.00013762957,0.00009755979],"category_scores_gemma":[0.00013878738,0.00009519564,0.000049798095,0.00081294554,0.00010195529,0.00008905149,0.0001861454,0.0010331093,0.000081583006],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049388927,0.00032592012,0.9187608,0.0001380663,0.00020372709,0.000055670025,0.004308628,0.00001173784,0.0461842,0.0002828266,0.02565245,0.0035821095],"study_design_scores_gemma":[0.012258511,0.0005540617,0.20085287,0.0011933374,0.00026880155,0.00002636365,0.0033427132,0.0026662024,0.06923732,0.00010095278,0.708678,0.0008208729],"about_ca_topic_score_codex":0.000052800016,"about_ca_topic_score_gemma":0.00035589508,"teacher_disagreement_score":0.7179079,"about_ca_system_score_codex":0.00019559481,"about_ca_system_score_gemma":0.0001733525,"threshold_uncertainty_score":0.4488403},"labels":[],"label_agreement":null},{"id":"W3006735780","doi":"10.1200/jco.2020.38.6_suppl.131","title":"Novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A network meta-analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Mount Sinai Hospital; University of Calgary; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Enzalutamide; Meta-analysis; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Placebo; Randomized controlled trial; Adverse effect; Androgen receptor; Cancer","score_opus":0.3348648572000627,"score_gpt":0.5011682202617322,"score_spread":0.16630336306166954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006735780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81381977,0.025344377,0.00029315136,0.15725827,0.00088471745,0.0013759197,0.00011599186,0.000019983134,0.0008878044],"genre_scores_gemma":[0.98195684,0.0029338556,0.009117271,0.00409188,0.0013735788,0.000043671957,0.000020868205,0.000024294583,0.00043774932],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99570215,0.00045182573,0.002671958,0.00027796254,0.00054669636,0.00034943662],"domain_scores_gemma":[0.99640965,0.0010577213,0.0013660686,0.00013795144,0.0003989632,0.00062961975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029617108,0.00017387824,0.0031981368,0.00016888001,0.00003967648,0.000017402159,0.00013954156,0.00019206821,0.00062814576],"category_scores_gemma":[0.0010690306,0.00010583849,0.0015822358,0.0010247462,0.00016502521,0.00012163336,0.000044940916,0.000954099,0.0000138571695],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06315911,0.006824734,0.31084728,0.0003500221,0.49170113,0.0055929683,0.0025881648,0.015286802,0.006760476,0.00016708537,0.04458469,0.05213753],"study_design_scores_gemma":[0.060141385,0.051363785,0.14238891,0.00016146577,0.4696378,0.00018539143,0.0012090199,0.0032260395,0.0014594976,0.00044099867,0.2689812,0.00080452184],"about_ca_topic_score_codex":0.00010930526,"about_ca_topic_score_gemma":0.00044743516,"teacher_disagreement_score":0.22439648,"about_ca_system_score_codex":0.0002041806,"about_ca_system_score_gemma":0.0026464493,"threshold_uncertainty_score":0.68777555},"labels":[],"label_agreement":null},{"id":"W3006740553","doi":"10.1200/jco.2020.38.6_suppl.148","title":"Contribution of extragonadal steroids to the androgen receptor activity and to the castration-resistance development in recurrent prostate cancers after primary therapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Hôtel-Dieu de Québec; Université Laval","funders":"","keywords":"Castration; Testosterone (patch); Prostate cancer; Androstenedione; Dihydrotestosterone; Androgen receptor; Internal medicine; Medicine; Endocrinology; Androgen; Androstenediol; Dehydroepiandrosterone; Androsterone; Steroid; Cancer; Hormone","score_opus":0.10143218653899995,"score_gpt":0.43400993380110564,"score_spread":0.3325777472621057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006740553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.909668,0.0027088763,0.00007000958,0.086501524,0.00023389982,0.0007536412,0.000012388927,0.0000016233412,0.000050003942],"genre_scores_gemma":[0.9944673,0.0017682563,0.0005423115,0.0027979813,0.00027021416,0.000049094328,0.000002551402,0.0000057099824,0.000096538235],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982494,0.00032349126,0.0007996317,0.00014312113,0.00031568133,0.00016866204],"domain_scores_gemma":[0.99857914,0.00045992516,0.00033526676,0.00008284377,0.00029409784,0.00024872998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017285241,0.00008593911,0.00051368255,0.000036858386,0.00003865317,0.000008764134,0.000097938966,0.00007776151,0.000024171231],"category_scores_gemma":[0.000528785,0.00004134969,0.000075138625,0.00016960647,0.00008375317,0.000055824952,0.000042278985,0.00043550832,0.000002444408],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10425115,0.00067342597,0.07638752,0.000063763204,0.0003555472,0.00014901029,0.004624017,0.000032884527,0.0040298267,0.000009929198,0.006813409,0.8026095],"study_design_scores_gemma":[0.005770936,0.00676458,0.65760976,0.00012833554,0.000032753745,0.0000108149425,0.00012405125,0.0000106829975,0.0030443452,0.000009928987,0.3264333,0.000060519716],"about_ca_topic_score_codex":0.000016844802,"about_ca_topic_score_gemma":0.0008832684,"teacher_disagreement_score":0.802549,"about_ca_system_score_codex":0.00036464745,"about_ca_system_score_gemma":0.0023632138,"threshold_uncertainty_score":0.419224},"labels":[],"label_agreement":null},{"id":"W3006752870","doi":"10.1200/jco.2020.38.6_suppl.tps385","title":"DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Tolerability; Clinical endpoint; Prostate cancer; Placebo; Androgen deprivation therapy; Internal medicine; Hazard ratio; Oncology; Docetaxel; Hormonal therapy; Antiandrogen; Randomized controlled trial; Urology; Cancer; Adverse effect; Confidence interval; Pathology","score_opus":0.10058820587345277,"score_gpt":0.4669067357666523,"score_spread":0.3663185298931996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006752870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746821,0.0021715856,0.0003908982,0.0060040676,0.0005700929,0.015590117,0.0005605085,0.000010617043,0.00001999599],"genre_scores_gemma":[0.9365541,0.060810566,0.00045189826,0.0006387928,0.0004882184,0.0009534705,0.00002835408,0.000051359242,0.00002326546],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9888693,0.0038282485,0.0053853346,0.0004919251,0.0009500897,0.00047510825],"domain_scores_gemma":[0.97374326,0.017564457,0.0068120398,0.0003692411,0.0011306842,0.00038029757],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01302076,0.00041837402,0.005244651,0.00027488024,0.00014290816,0.000026653424,0.00038110605,0.00046449347,0.00007405411],"category_scores_gemma":[0.010446804,0.000189777,0.0013891741,0.0006398146,0.00090305076,0.00017837597,0.00008156276,0.0013220093,3.721186e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83740616,0.0019114874,0.016143832,0.000055851364,0.0040095877,0.000022449585,0.0014925497,0.0019376762,0.0006332644,0.00002901687,0.00020860837,0.13614954],"study_design_scores_gemma":[0.9152487,0.07158313,0.0054842415,0.00038556007,0.0010980654,0.0000035966254,0.0001806076,0.0017138926,0.0034504852,0.00038932828,0.00029431022,0.00016810994],"about_ca_topic_score_codex":0.0016016498,"about_ca_topic_score_gemma":0.00021803923,"teacher_disagreement_score":0.13598143,"about_ca_system_score_codex":0.00047442762,"about_ca_system_score_gemma":0.0067300396,"threshold_uncertainty_score":0.9989009},"labels":[],"label_agreement":null},{"id":"W3006769654","doi":"10.1200/jco.2020.38.6_suppl.88","title":"Development of a predictive model of PSA response to a switch from prednisone to dexamethasone in metastatic castrate-resistant prostate cancer patients biochemically progressing on abiraterone.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Enzalutamide; Prednisone; Prostate cancer; Docetaxel; Univariate analysis; Internal medicine; Abiraterone acetate; Logistic regression; Dexamethasone; Oncology; Cancer; Performance status; Multivariate analysis; Androgen deprivation therapy","score_opus":0.19842376105489842,"score_gpt":0.4787457829162528,"score_spread":0.28032202186135435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006769654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252176,0.0002358974,0.00029964725,0.005626531,0.000093145485,0.001075424,0.000112319096,0.0000050458607,0.000030209938],"genre_scores_gemma":[0.9383853,0.000068161055,0.06075243,0.0006172747,0.000059769118,0.0000607729,0.0000068729014,0.000022007804,0.000027376542],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9954845,0.00043576423,0.0026929441,0.00033179723,0.0007343372,0.0003206956],"domain_scores_gemma":[0.9962651,0.0009330411,0.0011363325,0.00014134485,0.00081455306,0.00070961274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018888318,0.00019039074,0.0015694315,0.00022625709,0.000021974462,0.000007176011,0.00018574606,0.00015565209,0.000018872113],"category_scores_gemma":[0.0029482457,0.00013030967,0.00016122528,0.00040359396,0.0001341081,0.00006785943,0.00010431682,0.00056744,0.0000030455851],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51271766,0.0059524197,0.050081022,0.00022599593,0.00096546207,0.00030944336,0.012348309,0.001794902,0.35295346,0.0000014875112,0.000268513,0.062381335],"study_design_scores_gemma":[0.05599521,0.1173949,0.48357162,0.00467296,0.00074951554,0.000006019136,0.0015823619,0.004559028,0.33003244,0.00012305503,0.00089308445,0.00041979927],"about_ca_topic_score_codex":0.000041683415,"about_ca_topic_score_gemma":0.000060746308,"teacher_disagreement_score":0.45672244,"about_ca_system_score_codex":0.000501161,"about_ca_system_score_gemma":0.00547838,"threshold_uncertainty_score":0.97184104},"labels":[],"label_agreement":null},{"id":"W3006826879","doi":"10.1200/jco.2020.38.6_suppl.117","title":"Analysis of prevalence and prognostic implications of early versus delayed PSA declines during radium-223 (Ra223) treatment among men with metastatic castration-resistant prostate cancer (mCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; University of Toronto; University Health Network; Regional Municipality of Durham; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Cohort; Prostate-specific antigen; Urology; Internal medicine; Cancer; Log-rank test; Overall survival; Oncology","score_opus":0.14763067976685162,"score_gpt":0.4712615864519624,"score_spread":0.3236309066851108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006826879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99200696,0.0019917174,0.000029994875,0.0050897747,0.000040822008,0.0006472406,0.00008683122,0.000005487122,0.00010116203],"genre_scores_gemma":[0.9927162,0.0059416364,0.0009959349,0.00003543986,0.00009275085,0.000046592824,0.000010256339,0.0000125572205,0.00014866689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997375,0.00023213905,0.0016141152,0.00023584784,0.00034038493,0.0002025061],"domain_scores_gemma":[0.9955849,0.0016348021,0.0015295515,0.00015387034,0.0007015794,0.00039527632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052617275,0.00015146217,0.0013662771,0.00018517717,0.000048484064,0.00000905777,0.000100233716,0.00008519615,0.00005065296],"category_scores_gemma":[0.0006806607,0.000090156725,0.00028198995,0.0005745974,0.00039872067,0.00012139412,0.000026578782,0.00024368208,4.1544195e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0469803,0.0011721491,0.92847854,0.00023480212,0.011993584,0.00020273037,0.00083581905,0.00038017682,0.0017649101,0.000013320901,0.000026707352,0.007916954],"study_design_scores_gemma":[0.016414292,0.03323609,0.93583685,0.00011160262,0.012783999,0.0000115489665,0.00020044786,0.00051751384,0.00072929874,0.000011099765,0.000072308554,0.000074919335],"about_ca_topic_score_codex":0.00029942105,"about_ca_topic_score_gemma":0.00061635167,"teacher_disagreement_score":0.03206394,"about_ca_system_score_codex":0.0001593498,"about_ca_system_score_gemma":0.0015388244,"threshold_uncertainty_score":0.36764845},"labels":[],"label_agreement":null},{"id":"W3007037485","doi":"10.1016/j.trecan.2020.01.015","title":"DNA-PK, Nuclear mTOR, and the Androgen Pathway in Prostate Cancer","year":2020,"lang":"en","type":"review","venue":"Trends in cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; PI3K/AKT/mTOR pathway; Androgen; Cancer research; Prostate; DNA; Cancer; Oncology; Medicine; Biology; Internal medicine; Signal transduction; Genetics; Hormone","score_opus":0.08417698578109488,"score_gpt":0.40754006505115276,"score_spread":0.32336307927005786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007037485","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031443062,0.9922793,2.076429e-8,0.0031739718,0.00021447505,0.0012032624,0.00031998684,0.000034727604,0.002459834],"genre_scores_gemma":[0.00033007946,0.9926971,0.000010373156,0.00024473196,0.0003045372,0.0015783068,0.000091779504,0.0001016589,0.004641436],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977173,0.00020036561,0.00054489524,0.00064548256,0.0003591227,0.0005327858],"domain_scores_gemma":[0.99915504,0.000110315435,0.00016898008,0.00034939728,0.00003562813,0.0001806122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029049747,0.00045904287,0.0018855955,0.0002845574,0.00006273977,0.000044836746,0.00020747732,0.00020467272,0.0008431118],"category_scores_gemma":[0.000021411937,0.00025159417,0.00025397856,0.00115498,0.0003335853,0.00006354119,0.00016008616,0.00090500596,0.000021685306],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005069039,0.000055294982,0.00040026184,0.004285692,0.00023998997,0.00043407248,0.001133752,5.209324e-7,6.182942e-7,0.000050357805,0.0016425205,0.99125004],"study_design_scores_gemma":[0.005315606,0.00008947382,0.00012255435,0.009029671,0.0003188253,0.000028355671,0.00005431812,0.000019657593,0.000004750524,0.00001779005,0.9847455,0.00025346802],"about_ca_topic_score_codex":0.0015627544,"about_ca_topic_score_gemma":0.001452538,"teacher_disagreement_score":0.99099654,"about_ca_system_score_codex":0.0009166478,"about_ca_system_score_gemma":0.00069681864,"threshold_uncertainty_score":0.9999936},"labels":[],"label_agreement":null},{"id":"W3007072416","doi":"10.1200/jco.2020.38.6_suppl.364","title":"The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; Grand River Hospital; Princess Margaret Cancer Centre; Université de Montréal; Université Laval; Hôtel-Dieu de Québec; McGill University; Sunnybrook Health Science Centre; Jewish General Hospital; University Health Network; Ottawa Hospital; Health Sciences Centre; Juravinski Cancer Centre; Western University; University of Toronto; Niagara Health System; London Health Sciences Centre; Queen's University; McMaster University","funders":"Prostate Cancer Canada","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Framingham Risk Score; Cohort; Risk factor; Internal medicine; Framingham Heart Study; Disease; Diabetes mellitus; Cohort study; Population; Logistic regression; Cancer; Prospective cohort study; Oncology; Endocrinology","score_opus":0.07506837579378435,"score_gpt":0.3998572973100811,"score_spread":0.32478892151629674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007072416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859947,0.012508179,0.000002891308,0.00094007474,0.000040516607,0.00045728585,0.000032948054,0.0000034257948,0.000019978279],"genre_scores_gemma":[0.9510103,0.04873157,0.000027131986,0.00004831582,0.00008689821,0.000008119287,0.0000018152966,0.000009146223,0.00007672472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844813,0.00026987048,0.00063395634,0.00015870464,0.00035667504,0.00013268818],"domain_scores_gemma":[0.9979514,0.00040941147,0.0006049491,0.000092719885,0.00047447465,0.00046702736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006351062,0.00009433297,0.00062037405,0.000026876956,0.00006863645,0.000008018398,0.00006504003,0.00007174068,0.0000072947564],"category_scores_gemma":[0.0013216027,0.00004267789,0.00014573555,0.0000971053,0.000321509,0.00009474035,0.000040200386,0.00033509525,2.1314398e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006668367,0.00017299152,0.97621816,0.00014493034,0.0018362927,0.000037529,0.00019578649,0.000029314011,0.00000593699,9.678771e-7,0.000035495555,0.014654227],"study_design_scores_gemma":[0.007551286,0.005529407,0.98298705,0.00010700897,0.0019724518,0.0000032742773,0.00004276023,0.0002483256,0.00016538647,0.000009782117,0.0013370293,0.00004626196],"about_ca_topic_score_codex":0.000038401133,"about_ca_topic_score_gemma":0.00000533784,"teacher_disagreement_score":0.03622339,"about_ca_system_score_codex":0.000037519712,"about_ca_system_score_gemma":0.0005119672,"threshold_uncertainty_score":0.17403539},"labels":[],"label_agreement":null},{"id":"W3007178895","doi":"10.1200/jco.2020.38.6_suppl.337","title":"Clinical-genomic sub-classification of high-risk prostate cancer: Implications for tailoring therapy and clinical trial design.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Genome British Columbia","funders":"","keywords":"Medicine; Internal medicine; Oncology; Prostate cancer; Hazard ratio; Cohort; Disease; Proportional hazards model; Cancer; Confidence interval","score_opus":0.4935468665260189,"score_gpt":0.5608985430108356,"score_spread":0.06735167648481671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007178895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9531985,0.0024736112,0.0018394185,0.039375786,0.0011001892,0.001910707,0.000048659676,0.000012523568,0.000040597977],"genre_scores_gemma":[0.8759012,0.11157577,0.008363314,0.0008213004,0.0031728353,0.000078375044,0.000009873899,0.000028002396,0.000049277354],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9932415,0.0011013733,0.004785416,0.00038177782,0.0002243724,0.0002655545],"domain_scores_gemma":[0.9850665,0.009510241,0.0036671641,0.000236637,0.0008590318,0.0006604574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008465824,0.00015847146,0.0019170471,0.00008348871,0.00008326775,0.000013325951,0.00021098653,0.00044006036,0.000024177942],"category_scores_gemma":[0.008040077,0.00010644139,0.00072307605,0.00017454181,0.00053900434,0.00010267805,0.000052767416,0.001068724,0.0000035141818],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18402185,0.0012461562,0.2564313,0.000029146493,0.00078461366,0.000007899769,0.00005406477,0.0000061857363,0.00057086255,0.000079189944,0.0017438392,0.55502486],"study_design_scores_gemma":[0.14153829,0.06775405,0.7676868,0.00005329409,0.00072315906,0.000009835613,0.00005383065,0.00030594572,0.00022865515,0.001098667,0.020445192,0.000102309845],"about_ca_topic_score_codex":0.000027086293,"about_ca_topic_score_gemma":0.000011260134,"teacher_disagreement_score":0.5549226,"about_ca_system_score_codex":0.000109696965,"about_ca_system_score_gemma":0.003339262,"threshold_uncertainty_score":0.96253043},"labels":[],"label_agreement":null},{"id":"W3007275864","doi":"10.1200/jco.2020.38.6_suppl.276","title":"Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hamilton Health Sciences; Genome British Columbia","funders":"National Institutes of Health","keywords":"Medicine; Prostate cancer; Prostatectomy; Internal medicine; Oncology; Randomized controlled trial; Cumulative incidence; Context (archaeology); Cohort; Radiation therapy; Cancer","score_opus":0.11965373547652233,"score_gpt":0.4640600398661545,"score_spread":0.34440630438963216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007275864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869405,0.0021972372,0.00009522431,0.0052281423,0.0007027701,0.0045289528,0.000052798434,0.000007757125,0.00024663983],"genre_scores_gemma":[0.99202675,0.0039680162,0.002687964,0.00044446604,0.0006054937,0.00017033791,0.000023416498,0.000029395029,0.000044172615],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935523,0.0015570523,0.0037691635,0.00031485985,0.0005241118,0.00028245832],"domain_scores_gemma":[0.99287957,0.0030913297,0.0027935593,0.00012587679,0.0008100621,0.0002995822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003324778,0.0001984994,0.003531989,0.00021278727,0.000021200198,0.0000063191665,0.00017795802,0.00040303572,0.00012644526],"category_scores_gemma":[0.003913856,0.00012935474,0.0006885481,0.00033381835,0.00048766084,0.00013453278,0.000027716962,0.001029797,0.0000017320455],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7315576,0.0035443765,0.23807816,0.00010325409,0.0011396062,0.000094421215,0.0025488427,0.000026056572,0.011702753,0.000013248823,0.00009349418,0.011098192],"study_design_scores_gemma":[0.883076,0.030556515,0.07660806,0.00029355506,0.0007624007,0.0000033301956,0.00021416569,0.00029708704,0.007182318,0.0003287309,0.000568083,0.0001097332],"about_ca_topic_score_codex":0.000082998165,"about_ca_topic_score_gemma":0.00001631569,"teacher_disagreement_score":0.1614701,"about_ca_system_score_codex":0.0005959976,"about_ca_system_score_gemma":0.0040844143,"threshold_uncertainty_score":0.7245575},"labels":[],"label_agreement":null},{"id":"W3007309272","doi":"10.1200/jco.2020.38.6_suppl.322","title":"Validation of biochemical definition of cure after low-dose rate prostate brachytherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; Urology; Cohort; External beam radiotherapy; Prospective cohort study; Androgen deprivation therapy; Prostate; Radiation therapy; Clinical trial; Clinical endpoint; Internal medicine; Cancer; Surgery; Nuclear medicine","score_opus":0.15663346601302502,"score_gpt":0.4747091916999229,"score_spread":0.3180757256868979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007309272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824257,0.0009577057,0.0000537239,0.015741808,0.00019731809,0.00022158238,0.000013734355,0.000003970668,0.0003844719],"genre_scores_gemma":[0.9939856,0.0026406257,0.0017510183,0.0010989731,0.00045497497,0.000004818282,0.000014144171,0.00001147619,0.000038351453],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975054,0.00030838352,0.0016253601,0.00012703762,0.00029514445,0.0001386647],"domain_scores_gemma":[0.99719465,0.00065971847,0.0011639877,0.000095186995,0.0006251806,0.00026129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012905326,0.00008896505,0.00091548194,0.00007061449,0.0000099208655,0.0000029477176,0.00007724593,0.00022804459,0.00018531403],"category_scores_gemma":[0.0012814031,0.000058302085,0.000343161,0.00017077214,0.00023984486,0.00008685206,0.000029108065,0.00054404244,0.000008837448],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23554224,0.008921495,0.30744863,0.0015728477,0.0021172648,0.0018534852,0.0025437293,0.00002148597,0.3270191,0.0002413871,0.012600283,0.100118056],"study_design_scores_gemma":[0.06963931,0.08930188,0.35406736,0.0012188337,0.0013316057,0.0002446142,0.00039648486,0.00024116307,0.46210408,0.0066598896,0.014461103,0.00033367495],"about_ca_topic_score_codex":0.0000023436232,"about_ca_topic_score_gemma":3.5672122e-7,"teacher_disagreement_score":0.16590293,"about_ca_system_score_codex":0.00004750797,"about_ca_system_score_gemma":0.0010099374,"threshold_uncertainty_score":0.237749},"labels":[],"label_agreement":null},{"id":"W3007465583","doi":"10.1097/pas.0000000000001450","title":"Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"The American Journal of Surgical Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Calgary Laboratory Services; University of Calgary","funders":"Astellas Pharma; Sanofi; Eli Lilly and Company","keywords":"Prostate cancer; Medicine; Pathology; Genitourinary system; Molecular pathology; Prostate; Anatomical pathology; Cancer; Internal medicine; Biology; Immunohistochemistry","score_opus":0.031106050604003344,"score_gpt":0.3266815382637129,"score_spread":0.29557548765970953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007465583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94898325,0.0015367966,0.00014835883,0.048608493,0.00011607373,0.00030926615,0.00010174259,0.000006228281,0.00018980022],"genre_scores_gemma":[0.99468714,0.002707365,0.00044563317,0.0020091867,0.000071601906,0.000024418865,0.000031858566,0.000014803173,0.000008005548],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975829,0.0005525989,0.00081573316,0.00030407807,0.00045849144,0.00028616496],"domain_scores_gemma":[0.9976763,0.0005232399,0.0009860065,0.00022524258,0.0004624397,0.0001267586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007373677,0.0001832481,0.0007684184,0.00007253179,0.000032148226,0.0000065061913,0.00035756858,0.00008461349,0.00008270002],"category_scores_gemma":[0.00028026837,0.00009991659,0.00029072913,0.00039468685,0.0021521829,0.00003510715,0.00011337164,0.00061586837,0.0000018519582],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027622765,0.0005733757,0.15389726,0.000042843523,0.0016622152,0.08691432,0.006527096,0.0008265572,0.6991433,0.00047396703,0.0008212494,0.021495063],"study_design_scores_gemma":[0.05711301,0.039127618,0.578871,0.0008109909,0.0021695436,0.049708515,0.02380843,0.0047431844,0.22971283,0.0065672034,0.0059356517,0.0014320088],"about_ca_topic_score_codex":0.00013541325,"about_ca_topic_score_gemma":0.0000040087193,"teacher_disagreement_score":0.46943045,"about_ca_system_score_codex":0.0001177328,"about_ca_system_score_gemma":0.00057336566,"threshold_uncertainty_score":0.79298073},"labels":[],"label_agreement":null},{"id":"W3007577807","doi":"10.1200/jco.2020.38.6_suppl.198","title":"Comprehensive genomic profiling (CGP) of metastatic castrate-sensitive prostate cancer (mCSPC) to reveal potential biomarkers and therapeutic targets.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Oncology; Androgen receptor; Internal medicine; CHEK2; ERCC1; Cancer; Cancer research; Bioinformatics; DNA repair; Gene; Biology; Genetics","score_opus":0.17458778918440596,"score_gpt":0.47428313674197203,"score_spread":0.2996953475575661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007577807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97680444,0.004686922,0.00009181831,0.017200235,0.00036228038,0.0006916306,0.00004210897,0.000005656814,0.00011488878],"genre_scores_gemma":[0.98981917,0.001972249,0.0050777528,0.0026506132,0.0003693428,0.000007797316,0.0000055680707,0.000020903926,0.00007661807],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973264,0.000414681,0.0014169024,0.00024037855,0.00031843796,0.00028321045],"domain_scores_gemma":[0.9971471,0.0005856153,0.0008341176,0.0000864893,0.0007437254,0.0006029972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081589323,0.00015670915,0.0013905134,0.000109310626,0.000040692175,0.000008740413,0.00008802558,0.00012057162,0.00004450654],"category_scores_gemma":[0.00034919317,0.00010512664,0.00025289468,0.00018654196,0.00032731425,0.00005340299,0.00007018208,0.00059016264,0.0000059099543],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15137914,0.0017633456,0.07049491,0.00112503,0.011653377,0.00881926,0.0048996047,0.00056247634,0.3664243,0.00005549521,0.0028834217,0.37993965],"study_design_scores_gemma":[0.069842435,0.13483125,0.6927645,0.00088175153,0.0063614477,0.0017664394,0.010363783,0.003757151,0.052593764,0.00073339423,0.025272027,0.0008320393],"about_ca_topic_score_codex":0.000042793195,"about_ca_topic_score_gemma":0.0000071965233,"teacher_disagreement_score":0.62226963,"about_ca_system_score_codex":0.00012239968,"about_ca_system_score_gemma":0.0018149146,"threshold_uncertainty_score":0.42869398},"labels":[],"label_agreement":null},{"id":"W3007640689","doi":"10.1007/s00345-020-03131-0","title":"68Ga-PSMA PET/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy","year":2020,"lang":"en","type":"article","venue":"World Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Lymph node; Radiology; Dissection (medical); Positron emission tomography; Nuclear medicine; PET-CT; Biochemical recurrence; Prospective cohort study; Cancer; Surgery; Internal medicine","score_opus":0.015320182963280212,"score_gpt":0.27030028418884,"score_spread":0.2549801012255598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007640689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9659247,0.0050248546,0.0006822208,0.027214881,0.00021842698,0.00026280645,0.0000044718813,0.000027907732,0.0006397664],"genre_scores_gemma":[0.995497,0.00026219236,0.0006339274,0.0029038803,0.00017545836,0.000011997497,0.000020563479,0.000017959816,0.0004770389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986582,0.00016548646,0.00037216427,0.00022871683,0.00029797832,0.0002774731],"domain_scores_gemma":[0.9991676,0.00014791492,0.00018786937,0.000088120876,0.00010027452,0.00030822164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023630557,0.00014704671,0.0003847241,0.00022438944,0.00008927822,0.000014012114,0.000056844114,0.000019485413,0.00044091674],"category_scores_gemma":[0.00009518439,0.000103793005,0.00010184794,0.00020724672,0.00022621533,0.00009117316,0.00004885517,0.00045200068,0.000012503535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045829482,0.0005165483,0.888851,0.00034082055,0.00028011188,0.038698554,0.00030361518,0.00017086096,0.010084483,0.000062953404,0.0023170917,0.012544515],"study_design_scores_gemma":[0.015369591,0.0023454481,0.93389064,0.0000785714,0.00043030814,0.013111324,0.00003564089,0.005582132,0.0004971601,0.00016673608,0.028269975,0.00022244618],"about_ca_topic_score_codex":0.0000025667555,"about_ca_topic_score_gemma":0.0000028511085,"teacher_disagreement_score":0.045039706,"about_ca_system_score_codex":0.0003296245,"about_ca_system_score_gemma":0.00020799802,"threshold_uncertainty_score":0.48277292},"labels":[],"label_agreement":null},{"id":"W3007645860","doi":"10.1200/jco.2020.38.6_suppl.349","title":"Tumor cell intrinsic androgen biosynthesis by 3β-hydroxy steroid dehydrogenase (HSD3B1) to modulate radiosensitivity in prostate cancer cells.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Radioresistance; Radiosensitivity; Cancer research; Molecular biology; Biology; DU145; Clonogenic assay; Prostate cancer; Cell culture; Internal medicine; LNCaP; Cancer; Medicine; Genetics; Radiation therapy","score_opus":0.07472776025244818,"score_gpt":0.40959738141998703,"score_spread":0.3348696211675388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007645860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9693485,0.0022378464,0.000014076824,0.026969938,0.000406603,0.0006880156,0.00005974903,0.00001529774,0.00026001068],"genre_scores_gemma":[0.9884621,0.0030258785,0.0006094958,0.006964742,0.00063242565,0.000016642665,0.000004558866,0.00003893915,0.00024521828],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99607974,0.0006043569,0.0018667427,0.00042060405,0.0004912916,0.00053728133],"domain_scores_gemma":[0.9966026,0.00082215277,0.0007420086,0.0002005985,0.00028575433,0.0013468958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017906857,0.00024776248,0.0017804117,0.00018893785,0.000044491095,0.000018259532,0.00020181388,0.0002106825,0.000119022974],"category_scores_gemma":[0.0007754913,0.00017725551,0.0003986975,0.0004556063,0.00018076201,0.00013483071,0.000120046556,0.0011118825,0.00006538717],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05639899,0.0072361687,0.17208058,0.00052459346,0.001240562,0.033635654,0.0019483782,0.00058488065,0.31767115,0.0000033774088,0.04632983,0.36234584],"study_design_scores_gemma":[0.037571076,0.029083839,0.030118365,0.0004385246,0.00071822084,0.00040648112,0.00032359033,0.0019760795,0.7692835,0.00007749342,0.12938611,0.0006167322],"about_ca_topic_score_codex":0.00010551453,"about_ca_topic_score_gemma":0.000063080864,"teacher_disagreement_score":0.45161235,"about_ca_system_score_codex":0.00042625683,"about_ca_system_score_gemma":0.001753833,"threshold_uncertainty_score":0.722827},"labels":[],"label_agreement":null},{"id":"W3007692078","doi":"10.1200/jco.2020.38.6_suppl.113","title":"Systemic therapy for nonmetastatic castrate-resistant prostate cancer (M0 CRPC): A systematic review and network meta-analysis (NMA).","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Enzalutamide; Randomized controlled trial; Meta-analysis; Oncology; Internal medicine; Prostate cancer; Hazard ratio; Adverse effect; Placebo; Confidence interval; Cancer; Alternative medicine; Pathology","score_opus":0.4606557545345176,"score_gpt":0.5830787549479421,"score_spread":0.12242300041342452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007692078","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005468441,0.9865951,0.00004950365,0.0035829295,0.00033211164,0.009145365,0.00023713555,0.000010967303,0.000041396594],"genre_scores_gemma":[0.000034657303,0.993927,0.00093672995,0.0016449662,0.00067856786,0.0015582715,0.000047612397,0.00007771067,0.0010944654],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.986264,0.0033552188,0.008511537,0.0006096948,0.00070173916,0.00055780733],"domain_scores_gemma":[0.9819192,0.006655242,0.009115877,0.00049230654,0.0009919624,0.0008254024],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.00994296,0.0006738769,0.03822728,0.00029211206,0.00009036506,0.00004840402,0.00037893472,0.0005509036,0.0001853115],"category_scores_gemma":[0.0021663273,0.00031819695,0.010335054,0.0010277043,0.00023152461,0.00008462507,0.00007230617,0.0015628042,0.000011565015],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009439121,0.00024917236,0.000007230603,0.5788712,0.36898127,0.00080608216,0.000025971167,0.0000025344352,8.627927e-8,0.000009497297,0.0021556385,0.04794739],"study_design_scores_gemma":[0.0021026214,0.005399476,0.0000031406485,0.080368936,0.65331054,0.0005067151,0.00001921257,0.000008551061,4.914598e-8,0.00002415964,0.25807542,0.00018119942],"about_ca_topic_score_codex":0.000016723256,"about_ca_topic_score_gemma":0.000025076244,"teacher_disagreement_score":0.49850228,"about_ca_system_score_codex":0.00045327062,"about_ca_system_score_gemma":0.0068514203,"threshold_uncertainty_score":0.999927},"labels":[],"label_agreement":null},{"id":"W3007782584","doi":"10.1200/jco.2020.38.6_suppl.tps260","title":"A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke; Centre Hospitalier de l’Université de Montréal; Jewish General Hospital; Université Laval; St Joseph's Health Care","funders":"Progenics Pharmaceuticals","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Internal medicine; Nuclear medicine; Cancer; Androgen receptor","score_opus":0.08489063859828656,"score_gpt":0.4675145738132983,"score_spread":0.38262393521501176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007782584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97675127,0.0076656262,0.000010167033,0.0067707216,0.000484682,0.008187864,0.000078574034,0.000014689318,0.00003641761],"genre_scores_gemma":[0.9903456,0.0074747535,0.00061560475,0.00090499065,0.0002722829,0.00022583664,0.000039452676,0.000043829008,0.000077678116],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9902475,0.002696636,0.0050594714,0.00050575775,0.0009594986,0.0005311626],"domain_scores_gemma":[0.99119735,0.0031818755,0.0032005012,0.00022393005,0.0014197481,0.0007765869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005188732,0.0004228901,0.0055327713,0.00029118915,0.0001434757,0.00003265348,0.00022125065,0.00019619988,0.000110764755],"category_scores_gemma":[0.0053477017,0.00024413712,0.00061052426,0.00035046664,0.0006419176,0.00024390443,0.00009687191,0.0010821053,0.0000017203251],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8804176,0.013781619,0.036328528,0.00013493186,0.00275502,0.0008255802,0.0042566513,0.00007528574,0.005680191,0.0000021420713,0.00013630568,0.055606138],"study_design_scores_gemma":[0.8818556,0.07121508,0.04133703,0.0005185717,0.0012450872,0.000021334312,0.0007318127,0.0010876507,0.001360258,0.000014756329,0.00041554007,0.00019728119],"about_ca_topic_score_codex":0.0001967149,"about_ca_topic_score_gemma":0.00019039473,"teacher_disagreement_score":0.05743346,"about_ca_system_score_codex":0.0003954813,"about_ca_system_score_gemma":0.0028774103,"threshold_uncertainty_score":0.99556226},"labels":[],"label_agreement":null},{"id":"W3007782755","doi":"10.1200/jco.2020.38.6_suppl.92","title":"Impact of upstream use of novel hormonal therapy on progression of patients (pts) to metastatic castration-resistant prostate cancer (mCRPC) in the United States (US).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Internal medicine; Abiraterone acetate; Regimen; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.30618120581759056,"score_gpt":0.5441349739554482,"score_spread":0.23795376813785762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007782755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994118,0.00019700047,0.00000854132,0.004633162,0.0000643459,0.00077320414,0.00018425765,0.0000016742094,0.000019866266],"genre_scores_gemma":[0.99684954,0.001624695,0.00076988875,0.00061642885,0.000064084554,0.000014186024,0.000037498623,0.000012057387,0.000011610035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967738,0.00042118636,0.0018134728,0.00013864232,0.00065762963,0.00019531064],"domain_scores_gemma":[0.995555,0.0016660887,0.0014936167,0.00013256147,0.00092109997,0.00023162458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011300556,0.0001352271,0.0010086916,0.00020740452,0.000017382557,0.000005977996,0.000155291,0.00008985277,0.00005009307],"category_scores_gemma":[0.0012301368,0.000062950625,0.00030742286,0.0005101668,0.00020327201,0.00008297265,0.000025282772,0.0004731659,5.143009e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.114260994,0.013338933,0.786697,0.00012777047,0.0011124144,0.0001349617,0.0037592868,0.00261711,0.0059570167,0.000017000064,0.0014464812,0.07053104],"study_design_scores_gemma":[0.015996415,0.086109884,0.894047,0.00029805434,0.00013527907,0.0000038023636,0.00020979298,0.00034580048,0.0014708425,0.000023702181,0.0013026772,0.000056732555],"about_ca_topic_score_codex":0.00046666845,"about_ca_topic_score_gemma":0.00006083963,"teacher_disagreement_score":0.10735003,"about_ca_system_score_codex":0.00013484292,"about_ca_system_score_gemma":0.0016423649,"threshold_uncertainty_score":0.2913485},"labels":[],"label_agreement":null},{"id":"W3007846303","doi":"10.1200/jco.2020.38.6_suppl.348","title":"Head-to-head comparison between decipher and prolaris tests: Two commercially available post-prostatectomy genomic tests.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Cohort; Internal medicine; Oncology; Biochemical recurrence; Cancer; Pathology; Prostate cancer","score_opus":0.2682881504647991,"score_gpt":0.5312368767897085,"score_spread":0.26294872632490945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007846303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93268216,0.0017618334,0.000061002993,0.06263648,0.00026519882,0.00070104207,0.00002325453,0.000022273745,0.0018467841],"genre_scores_gemma":[0.97827613,0.000397848,0.008774097,0.010213913,0.001814663,0.000009852341,0.0000148749405,0.000040562798,0.00045807855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99608946,0.00043585934,0.002188698,0.00035590623,0.00046095223,0.0004691065],"domain_scores_gemma":[0.9946013,0.002156479,0.0008308822,0.00020371469,0.000751752,0.0014558851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021203621,0.00022408363,0.0020800766,0.00013583402,0.000099571065,0.000037686783,0.00025042554,0.0003142898,0.0003037938],"category_scores_gemma":[0.0030906596,0.0001545765,0.00027904322,0.00028344843,0.00028238265,0.00013278295,0.00019389293,0.001734813,0.00025832164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008058509,0.00076145376,0.8604843,0.00006628353,0.00038724559,0.0007035909,0.00031393996,0.0000056747285,0.0017598688,0.0000040101954,0.009226269,0.11822887],"study_design_scores_gemma":[0.01713305,0.032905895,0.7963264,0.0001017225,0.00044505842,0.00009595591,0.00012277979,0.000110047775,0.0002101226,0.00007550342,0.15231928,0.00015421104],"about_ca_topic_score_codex":0.00013197846,"about_ca_topic_score_gemma":0.0001803255,"teacher_disagreement_score":0.143093,"about_ca_system_score_codex":0.0002528483,"about_ca_system_score_gemma":0.0026136292,"threshold_uncertainty_score":0.75369954},"labels":[],"label_agreement":null},{"id":"W3007870553","doi":"10.1200/jco.2020.38.6_suppl.120","title":"Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Taxane; Cabazitaxel; Prostate cancer; Docetaxel; Internal medicine; Oncology; Urology; Androgen deprivation therapy; Cancer; Breast cancer","score_opus":0.1391361220339376,"score_gpt":0.4996903683861957,"score_spread":0.3605542463522581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007870553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99242085,0.00042696644,0.000058562116,0.0054371664,0.000040190374,0.0014979108,0.000015839807,0.000002622917,0.00009987682],"genre_scores_gemma":[0.99745136,0.0010772552,0.0011156334,0.000059931575,0.0002540434,0.0000052013743,0.000016046517,0.000009350271,0.000011167925],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99689263,0.000434468,0.002008134,0.00019404855,0.0003623742,0.00010835404],"domain_scores_gemma":[0.9953154,0.0017669434,0.0020369366,0.00005643163,0.00068131665,0.0001430037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037049565,0.00010787688,0.0011825679,0.0001404555,0.00003304933,0.0000047240533,0.000032310618,0.0001555964,0.0000062153385],"category_scores_gemma":[0.0028159001,0.00007192057,0.00008424831,0.0002099692,0.00028173518,0.00011690219,0.000029833978,0.00035360394,3.8177518e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8844394,0.0032210608,0.0054206485,0.000100543424,0.00024739015,0.000025394196,0.0017954517,0.000021326647,0.017907687,0.000017475864,0.000009557247,0.086794056],"study_design_scores_gemma":[0.7630654,0.19630902,0.02828661,0.0003876804,0.00025680565,0.000020910624,0.00030787452,0.002559381,0.008589663,0.00013702355,0.00002230451,0.000057336485],"about_ca_topic_score_codex":0.00003451048,"about_ca_topic_score_gemma":0.000018558669,"teacher_disagreement_score":0.19308795,"about_ca_system_score_codex":0.000061903025,"about_ca_system_score_gemma":0.00063607295,"threshold_uncertainty_score":0.3371099},"labels":[],"label_agreement":null},{"id":"W3007937037","doi":"10.1200/jco.2020.38.6_suppl.327","title":"Association of black race with improved outcomes following definitive radiotherapy with androgen deprivation therapy for high-risk prostate cancer: A meta-analysis of eight randomized trials.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Internal medicine; Radiation therapy; Randomized controlled trial; Oncology; Clinical endpoint; Cancer; Gynecology","score_opus":0.19592806146311179,"score_gpt":0.48174656092871304,"score_spread":0.28581849946560123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007937037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9636022,0.004795225,0.0041022333,0.024869958,0.00009392522,0.002389844,0.00012122251,0.000005736734,0.000019647123],"genre_scores_gemma":[0.97207963,0.014315925,0.012192169,0.00091337477,0.00014727154,0.00013386246,0.000028894812,0.000026049964,0.00016282947],"study_design_codex":"meta_analysis","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936839,0.0021511228,0.0031586275,0.00022909313,0.000579679,0.00019758966],"domain_scores_gemma":[0.97134703,0.019020282,0.00800821,0.00013120509,0.0013068669,0.00018638569],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012812131,0.00018941448,0.009098431,0.00021258682,0.000035531433,0.000009411865,0.00010859728,0.00022570988,0.00007459774],"category_scores_gemma":[0.0093996385,0.00008445809,0.003523636,0.0005349758,0.00017393443,0.00011333163,0.000009955851,0.00040066682,1.402661e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38314524,0.00052002043,0.19825436,0.000028483437,0.4094009,0.00001494459,0.0007437503,0.00017246068,0.00029033286,0.000012180224,0.000085612875,0.0073317005],"study_design_scores_gemma":[0.55677164,0.024995975,0.032423023,0.000026019721,0.3797106,0.000001241395,0.0001823684,0.0010210238,0.0039049282,0.0001604145,0.0006749359,0.00012779601],"about_ca_topic_score_codex":0.00011888888,"about_ca_topic_score_gemma":0.00007679826,"teacher_disagreement_score":0.17362641,"about_ca_system_score_codex":0.00019338269,"about_ca_system_score_gemma":0.0016016965,"threshold_uncertainty_score":0.9989446},"labels":[],"label_agreement":null},{"id":"W3007977248","doi":"10.1200/jco.2020.38.6_suppl.23","title":"FDG and PSMA PET in metastatic castration-resistant prostate cancer (mCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Ontario Clinical Oncology Group; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; London Health Sciences Centre; McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Positron emission tomography; Nuclear medicine; Cohort; Standardized uptake value; Prospective cohort study; Cancer; Stage (stratigraphy); PET-CT; Oncology; Internal medicine; Radiology; Androgen receptor","score_opus":0.24960314223376734,"score_gpt":0.5359446657929826,"score_spread":0.28634152355921527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007977248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9309975,0.0026931816,0.00000638812,0.06507714,0.0002149574,0.00027084796,0.000010319104,0.000004160704,0.00072549254],"genre_scores_gemma":[0.9901618,0.005126354,0.0016045276,0.0023397831,0.00040092887,0.000009760968,0.0000026906405,0.000010855724,0.0003433418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777704,0.00026117635,0.001317935,0.00016031221,0.00028195517,0.00020156051],"domain_scores_gemma":[0.9980225,0.0006975066,0.00052686624,0.000065153676,0.00023081533,0.0004571722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001281403,0.00009613028,0.00092267955,0.000078256344,0.000023992787,0.000011555579,0.00006604785,0.00006835576,0.00016503558],"category_scores_gemma":[0.0012749417,0.00006078795,0.00013515072,0.0001654624,0.000176128,0.000099926634,0.00003060768,0.0007177171,0.000006822714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060108077,0.002762569,0.53547055,0.0006054995,0.0014981685,0.032240435,0.0026766623,0.00008983988,0.006611084,0.0002866771,0.013012964,0.34463745],"study_design_scores_gemma":[0.04686669,0.03620876,0.81495166,0.0003873053,0.000756252,0.0007634134,0.0013889528,0.0009308532,0.0006043225,0.0008997997,0.09601318,0.00022882379],"about_ca_topic_score_codex":0.00006046815,"about_ca_topic_score_gemma":0.00019079841,"teacher_disagreement_score":0.34440863,"about_ca_system_score_codex":0.00011697991,"about_ca_system_score_gemma":0.002315134,"threshold_uncertainty_score":0.41069484},"labels":[],"label_agreement":null},{"id":"W3007977552","doi":"10.1200/jco.2020.38.6_suppl.142","title":"IND candidate EPI-7386 as an N-terminal domain androgen receptor inhibitor in development for the treatment of prostate cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Androgen receptor; Prostate cancer; Enzalutamide; Cancer research; Androgen; Cancer; Potency; Prostate; Cell growth; Small molecule; Medicine; Biology; Pharmacology; In vitro; Internal medicine; Genetics; Hormone","score_opus":0.14780036888435702,"score_gpt":0.49613506772353744,"score_spread":0.34833469883918045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007977552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716881,0.002171642,0.000011691566,0.024629563,0.0004214904,0.0009665053,0.000026167672,0.0000036115034,0.00008121955],"genre_scores_gemma":[0.98556054,0.008704314,0.0029184332,0.0010056737,0.0013420457,0.0001249235,0.000018045695,0.000022590033,0.000303445],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99730605,0.00023900601,0.0016548545,0.00020583521,0.00031021016,0.0002840448],"domain_scores_gemma":[0.99742645,0.0008966852,0.0008232783,0.000116024545,0.00029073653,0.00044682107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013071786,0.0001468968,0.00109564,0.00006132205,0.000055612534,0.000008400066,0.00014254505,0.0001820523,0.00011534174],"category_scores_gemma":[0.00036386334,0.000076267206,0.00024339223,0.000156762,0.00020836835,0.00007889434,0.000025846432,0.00036036858,0.00000532139],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060473237,0.0037994285,0.18871659,0.00011350488,0.00095377036,0.0009261759,0.0076500988,0.000014490608,0.00074960693,0.00002201918,0.0015908434,0.73499024],"study_design_scores_gemma":[0.053391565,0.116874926,0.06148184,0.00028132967,0.00042936395,0.00013638227,0.0017821541,0.00008489639,0.01919946,0.0002448335,0.7458962,0.00019703462],"about_ca_topic_score_codex":0.00009344698,"about_ca_topic_score_gemma":0.00028152805,"teacher_disagreement_score":0.7443054,"about_ca_system_score_codex":0.0004723732,"about_ca_system_score_gemma":0.005168136,"threshold_uncertainty_score":0.91680515},"labels":[],"label_agreement":null},{"id":"W3008128954","doi":"10.1200/jco.2020.38.6_suppl.221","title":"Comparative efficacy of local versus systemic salvage therapies for recurrent prostate cancer after primary radiotherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus; University of British Columbia; Health Sciences Centre; University of Toronto; Queen's University; London Health Sciences Centre; Okanagan University College; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Medicine; Salvage therapy; Prostate cancer; Propensity score matching; Androgen deprivation therapy; Cryotherapy; Internal medicine; Oncology; Prostatectomy; Radiation therapy; Clinical endpoint; Surgery; Proportional hazards model; Cohort; Cancer; Urology; Randomized controlled trial; Chemotherapy","score_opus":0.21207700826277734,"score_gpt":0.5214015873049678,"score_spread":0.30932457904219046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008128954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.911867,0.06963088,0.0006621222,0.015144839,0.001344335,0.001079069,0.00003990503,0.000009535386,0.00022229411],"genre_scores_gemma":[0.9859989,0.010163695,0.0013448709,0.0011169848,0.0011987464,0.000049174243,0.0000063839984,0.000017856462,0.00010338645],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99743205,0.00031739983,0.0015116907,0.00018403887,0.00033066777,0.00022415302],"domain_scores_gemma":[0.995791,0.0022488213,0.0010010104,0.00010414666,0.0005269325,0.00032809106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094943604,0.00014113837,0.0017219118,0.00006253155,0.000023706254,0.00000560475,0.00012848832,0.00017876552,0.00009288582],"category_scores_gemma":[0.000259439,0.00008509406,0.00050756696,0.0001242491,0.00038590524,0.000067481065,0.000026898379,0.00057710276,0.00000296691],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51364696,0.0020211784,0.014953101,0.00068544276,0.0037418744,0.00028013342,0.0046538915,0.00006913432,0.0016685822,0.000025013096,0.008757087,0.44949758],"study_design_scores_gemma":[0.22561224,0.23780456,0.28960392,0.0018175415,0.002156291,0.00013039506,0.0029267082,0.000893926,0.003028735,0.00007796435,0.23550436,0.0004433608],"about_ca_topic_score_codex":0.0000048286047,"about_ca_topic_score_gemma":0.000006283307,"teacher_disagreement_score":0.4490542,"about_ca_system_score_codex":0.00032799065,"about_ca_system_score_gemma":0.002172252,"threshold_uncertainty_score":0.38534817},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W3008153451","doi":"10.1200/jco.2020.38.6_suppl.145","title":"ADRB2 expression in progressive metastatic castration-resistant prostate cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Biochemical recurrence; Hazard ratio; Cancer; Internal medicine; Proportional hazards model; Laser capture microdissection; Oncology; Biopsy; Prostatectomy; Perineural invasion; Prostate biopsy; Gene expression; Pathology; Biology; Gene","score_opus":0.24292302609369104,"score_gpt":0.5439417604283263,"score_spread":0.3010187343346353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008153451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94927514,0.005833428,0.0000233968,0.043088302,0.00037546043,0.0006142248,0.000011862478,0.0000087679155,0.00076940097],"genre_scores_gemma":[0.9918316,0.0017541082,0.0038613589,0.0016361336,0.00064098346,0.00003083523,0.000005153695,0.000014775949,0.00022503937],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99708194,0.00038096373,0.0016746137,0.00018728735,0.00042903886,0.00024617204],"domain_scores_gemma":[0.997453,0.00055578013,0.00099979,0.00008834885,0.00039141098,0.0005117017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011676326,0.00011533238,0.0010487401,0.00008796061,0.000029786619,0.000011439085,0.00011198598,0.00012754039,0.0002610756],"category_scores_gemma":[0.0017582336,0.00006939663,0.00022513293,0.00023072172,0.00016612427,0.00013767419,0.00003926184,0.00089684734,0.000010886257],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1424973,0.007008103,0.29902455,0.000849189,0.0014059601,0.04596166,0.004755009,0.00023042642,0.041625008,0.00013493322,0.026734155,0.4297737],"study_design_scores_gemma":[0.113636605,0.11439365,0.6177959,0.0028953785,0.0013503713,0.0006431861,0.0039150184,0.0014234968,0.023387687,0.0012181939,0.11874712,0.0005934361],"about_ca_topic_score_codex":0.000015508427,"about_ca_topic_score_gemma":0.000029910721,"teacher_disagreement_score":0.42918026,"about_ca_system_score_codex":0.0001783717,"about_ca_system_score_gemma":0.003397786,"threshold_uncertainty_score":0.6027527},"labels":[],"label_agreement":null},{"id":"W3008168710","doi":"10.1200/jco.2020.38.6_suppl.30","title":"Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Baker Hughes (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Abiraterone acetate; Zoledronic acid; Internal medicine; Hazard ratio; Prostate cancer; Denosumab; Concomitant; Proportional hazards model; Cohort; Prednisone; Docetaxel; Gastroenterology; Urology; Surgery; Cancer; Androgen deprivation therapy; Osteoporosis; Confidence interval","score_opus":0.23986552041939718,"score_gpt":0.5165605500960492,"score_spread":0.276695029676652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008168710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9712687,0.0010067262,0.00010886412,0.025004633,0.0010030445,0.0012405955,0.00032050448,0.000013266465,0.000033650198],"genre_scores_gemma":[0.981696,0.010110508,0.005665957,0.0009917454,0.0010457514,0.00007570771,0.00021431939,0.000042036565,0.00015797695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99460375,0.0004959971,0.003339112,0.0004616956,0.0007351943,0.00036422256],"domain_scores_gemma":[0.994367,0.0018245319,0.0019957635,0.00025290053,0.0010176542,0.00054213713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026564181,0.00026884093,0.0019091049,0.0002068093,0.00005210565,0.00002627233,0.00021368856,0.00024046445,0.00014949543],"category_scores_gemma":[0.0015748764,0.00017049603,0.00041425097,0.00022750099,0.00042609626,0.00050681195,0.00007021806,0.00083043403,0.0000046441887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44557294,0.0068035885,0.48427314,0.00014864902,0.0021481763,0.0010368277,0.0005063086,0.00016976037,0.0062797237,0.000018955183,0.00095590146,0.05208603],"study_design_scores_gemma":[0.22792651,0.10976205,0.628503,0.0006144313,0.0010570353,0.000055988497,0.0006103077,0.0013104314,0.007472146,0.00005895924,0.022252202,0.00037694178],"about_ca_topic_score_codex":0.00019403851,"about_ca_topic_score_gemma":0.0016278153,"teacher_disagreement_score":0.21764645,"about_ca_system_score_codex":0.00022138975,"about_ca_system_score_gemma":0.001586036,"threshold_uncertainty_score":0.6952626},"labels":[],"label_agreement":null},{"id":"W3008310950","doi":"10.32383/appdr/114329","title":"PREPARATION AND CHARACTERIZATION OF SELF-MICROEMUSIFYING DRUG DELIVERY SYSTEM (SMEDDS) OF CISPLATIN FOR ORAL USE IN OVARIAN CANCER TREATMENT","year":2020,"lang":"en","type":"article","venue":"Acta Poloniae Pharmaceutica - Drug Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cisplatin; Ovarian cancer; Drug; Drug delivery; Cancer; Medicine; Oncology; Pharmacology; Internal medicine; Chemistry; Chemotherapy","score_opus":0.15611194872975942,"score_gpt":0.4507166785985869,"score_spread":0.29460472986882746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008310950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901432,0.00066466734,0.0000066499947,0.0060829604,0.00004962283,0.0027167143,0.00025814143,0.00003133652,0.00004674538],"genre_scores_gemma":[0.99615926,0.0026347302,0.00028278815,0.00005579551,0.00007770276,0.00037521636,0.00015562472,0.000033901277,0.00022500068],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99779814,0.00032135195,0.00045490565,0.0004128919,0.00048620676,0.0005265025],"domain_scores_gemma":[0.998569,0.00040848381,0.00012651496,0.00019859214,0.00041959525,0.00027779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007557768,0.00017932524,0.00046320382,0.00032210996,0.000112789,0.000037201164,0.00011326169,0.00007605818,0.000034238416],"category_scores_gemma":[0.00007529578,0.00014813796,0.000069006666,0.00056001975,0.0001542344,0.00027378634,0.000101738966,0.00024801685,0.0000022603733],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006258737,0.00040901874,0.06845941,0.0022318042,0.0003159169,0.000028520892,0.012453806,0.0000041147377,0.9053055,0.00004205884,0.00024194625,0.0042491877],"study_design_scores_gemma":[0.011688444,0.0009212034,0.0717965,0.00061638746,0.00027090195,0.000009934055,0.0009785987,0.023759333,0.8853029,0.0000042122188,0.0044471836,0.00020438356],"about_ca_topic_score_codex":0.0013464828,"about_ca_topic_score_gemma":0.0001482159,"teacher_disagreement_score":0.023755219,"about_ca_system_score_codex":0.0005553372,"about_ca_system_score_gemma":0.0006088095,"threshold_uncertainty_score":0.6040891},"labels":[],"label_agreement":null},{"id":"W3008352324","doi":"10.1200/jco.2020.38.6_suppl.78","title":"Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Docetaxel; Medicine; Enzalutamide; Cabazitaxel; Prostate cancer; Abiraterone; Oncology; Internal medicine; Androgen deprivation therapy; Cancer; Androgen receptor","score_opus":0.20814875585988316,"score_gpt":0.5075707712043398,"score_spread":0.29942201534445667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008352324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95547795,0.0016362811,0.0002971157,0.03862436,0.0007574793,0.002592849,0.0005128422,0.000014346852,0.00008679492],"genre_scores_gemma":[0.99131083,0.0013037139,0.0037515936,0.0019520683,0.00058640266,0.00021685127,0.00006723112,0.000041285446,0.0007700333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968561,0.00020524049,0.0017383219,0.00032497026,0.0004231082,0.0004522648],"domain_scores_gemma":[0.99480546,0.0022446155,0.001012915,0.00012691895,0.00078136456,0.0010287062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007429868,0.00025362615,0.0019283231,0.000082001876,0.00010349192,0.000020364696,0.00009884145,0.00011677408,0.000014561113],"category_scores_gemma":[0.0024289258,0.00014766149,0.001398452,0.00012088159,0.00012396435,0.00013505269,0.000029256986,0.00029559704,0.0000045534616],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30936524,0.013514519,0.35523123,0.00072851486,0.019088829,0.005223122,0.0022147247,0.00013719397,0.0014788723,0.00013799052,0.013872254,0.27900752],"study_design_scores_gemma":[0.18932784,0.15352952,0.55535203,0.0002611671,0.0105902925,0.000019958516,0.0011047004,0.0014346162,0.0006934646,0.00067660684,0.08651896,0.00049085927],"about_ca_topic_score_codex":0.000029238967,"about_ca_topic_score_gemma":0.000024379839,"teacher_disagreement_score":0.27851665,"about_ca_system_score_codex":0.0005235533,"about_ca_system_score_gemma":0.0029789326,"threshold_uncertainty_score":0.6021461},"labels":[],"label_agreement":null},{"id":"W3008352325","doi":"10.1200/jco.2020.38.6_suppl.36","title":"Edmonton Prostate Interdisciplinary Cancer Clinic (EPICC): Real-world efficacy outcomes of a multidisciplinary clinic for metastatic castration-resistant prostate cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Alberta","funders":"Janssen Biotech","keywords":"Medicine; Enzalutamide; Prostate cancer; Cancer; Internal medicine; Oncology; Chemotherapy; Abiraterone acetate; Docetaxel; Pharmacy; Radiation therapy; Androgen deprivation therapy; Androgen receptor; Family medicine","score_opus":0.23205137625897612,"score_gpt":0.561041721982338,"score_spread":0.32899034572336194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008352325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9270348,0.0026620112,0.000033786535,0.06499972,0.0014756781,0.002652676,0.00029186855,0.000030411102,0.00081902766],"genre_scores_gemma":[0.9765199,0.0101594,0.004866849,0.0009827486,0.001187247,0.0002647158,0.00004980211,0.000084242645,0.0058851074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9918409,0.0005353661,0.0056718127,0.00058750587,0.00073409366,0.000630319],"domain_scores_gemma":[0.98853135,0.0047971373,0.004092839,0.00033977654,0.0012877019,0.0009511688],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034718956,0.00040393422,0.0036032777,0.00027248915,0.00015071838,0.000021718144,0.00037784432,0.00026497646,0.00046341558],"category_scores_gemma":[0.0019875704,0.00026251384,0.0014835568,0.0005029592,0.00061829394,0.00026077105,0.00029232752,0.0013403256,0.00001963215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19778737,0.008722479,0.6175331,0.0020130214,0.007146056,0.0017803749,0.0053800754,0.00019027462,0.0031953633,0.00003964598,0.02204569,0.13416652],"study_design_scores_gemma":[0.051709786,0.053728297,0.87700504,0.0010418252,0.0031714707,0.000030982927,0.0016643549,0.0006865753,0.00090793165,0.000624731,0.00902851,0.00040050075],"about_ca_topic_score_codex":0.00017200538,"about_ca_topic_score_gemma":0.0010313343,"teacher_disagreement_score":0.25947192,"about_ca_system_score_codex":0.000446252,"about_ca_system_score_gemma":0.006456487,"threshold_uncertainty_score":0.9999827},"labels":[],"label_agreement":null},{"id":"W3008368793","doi":"10.1200/jco.2020.38.6_suppl.32","title":"Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Cabazitaxel; Prostate cancer; Docetaxel; Internal medicine; Interim analysis; Radium-223; Clinical endpoint; Oncology; Cancer; Taxane; Clinical trial; Surgery; Androgen deprivation therapy; Breast cancer; Bone metastasis; Androgen receptor","score_opus":0.47194359211004633,"score_gpt":0.5657119235940941,"score_spread":0.09376833148404773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008368793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98317295,0.0008621828,0.0000015981308,0.014509656,0.00027269413,0.0010951512,0.000025894615,0.0000044751173,0.000055387103],"genre_scores_gemma":[0.99626195,0.001058718,0.0013373686,0.0010393657,0.00018871675,0.000043605956,0.000009891842,0.000015566557,0.00004480067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936736,0.0012550813,0.003867451,0.00031779046,0.00063213834,0.00025389742],"domain_scores_gemma":[0.995459,0.0020595337,0.0014073922,0.00014208081,0.00047004732,0.00046195346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003082995,0.00016932562,0.0018381674,0.00014989884,0.000028330283,0.0000114810755,0.00012929307,0.00016645034,0.000057143694],"category_scores_gemma":[0.003152422,0.00010835624,0.00019320982,0.00031498141,0.00023555299,0.00020196915,0.000057602505,0.0009986203,0.0000011765147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013157124,0.009377177,0.9290757,0.00007633207,0.00041345053,0.001089521,0.001558023,0.000055981604,0.00009664418,0.000024024992,0.00030057982,0.0447754],"study_design_scores_gemma":[0.027889976,0.031561557,0.936723,0.00010475133,0.00021365209,0.0000147241835,0.0019961663,0.0002467967,0.000023515877,0.00012781248,0.0010107473,0.00008730909],"about_ca_topic_score_codex":0.00047957752,"about_ca_topic_score_gemma":0.0020644206,"teacher_disagreement_score":0.044688094,"about_ca_system_score_codex":0.00016526107,"about_ca_system_score_gemma":0.0028484473,"threshold_uncertainty_score":0.5053023},"labels":[],"label_agreement":null},{"id":"W3008375373","doi":"10.1200/jco.2020.38.6_suppl.162","title":"Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"Decipher Biosciences; National Institutes of Health","keywords":"Medicine; Docetaxel; Prostate cancer; Internal medicine; Oncology; Androgen deprivation therapy; Clinical endpoint; Taxane; Cancer; Breast cancer; Clinical trial","score_opus":0.16326690855705658,"score_gpt":0.48476976302028324,"score_spread":0.3215028544632267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008375373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889569,0.0019933926,0.00016877246,0.005784795,0.00040644512,0.0022667795,0.00018746802,0.0000075860567,0.00022780384],"genre_scores_gemma":[0.99598557,0.0019830812,0.0007492597,0.0005029696,0.0003969732,0.00007935311,0.000014534118,0.000029567022,0.00025867933],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9958779,0.00047142926,0.002344092,0.00032272268,0.0006506995,0.00033316456],"domain_scores_gemma":[0.9905633,0.0038328469,0.0026727053,0.00014964551,0.0022472702,0.0005342711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016633577,0.00022874238,0.002397259,0.00018345712,0.0000417433,0.00000535442,0.0001473127,0.00019342176,0.000049831422],"category_scores_gemma":[0.004083068,0.00015233463,0.00051578926,0.00042966235,0.00046913375,0.00014080513,0.00007635804,0.0007552074,0.0000037886232],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6211371,0.024081143,0.14771223,0.0005914071,0.022196235,0.005299755,0.0441078,0.00035296983,0.0060503646,0.00007003275,0.008794187,0.1196068],"study_design_scores_gemma":[0.09547513,0.2986034,0.5760855,0.00041283137,0.005408845,0.00013363965,0.017112393,0.0025279126,0.0016262137,0.00038445691,0.0020008744,0.00022883156],"about_ca_topic_score_codex":0.0001976695,"about_ca_topic_score_gemma":0.00008141152,"teacher_disagreement_score":0.52566195,"about_ca_system_score_codex":0.00017861737,"about_ca_system_score_gemma":0.0026572437,"threshold_uncertainty_score":0.6212026},"labels":[],"label_agreement":null},{"id":"W3008394635","doi":"10.1200/jco.2020.38.6_suppl.333","title":"Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Montreal General Hospital; Cancer Care Ontario","funders":"National Institutes of Health","keywords":"Medicine; Docetaxel; Prostate cancer; Internal medicine; Oncology; Radiation therapy; Androgen deprivation therapy; Urology; Gynecology; Cancer","score_opus":0.14307360938030939,"score_gpt":0.5012946278380473,"score_spread":0.35822101845773796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008394635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.880832,0.0068820324,0.000557112,0.10782831,0.0016836416,0.0012902304,0.00020085435,0.000022964612,0.0007028133],"genre_scores_gemma":[0.951603,0.03291622,0.007436797,0.0053433534,0.0020814997,0.000052627565,0.00002467263,0.000042318083,0.0004995366],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951195,0.0005670098,0.0030220968,0.000327798,0.0005059579,0.00045760444],"domain_scores_gemma":[0.99272513,0.002099588,0.0028984535,0.00020334973,0.0012182405,0.0008552158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003107549,0.00021688327,0.002845204,0.0001228255,0.00006815648,0.000007824476,0.00028742198,0.00048578746,0.00030272416],"category_scores_gemma":[0.0036692198,0.00013685756,0.0007446978,0.00025880712,0.00053160224,0.000116664756,0.000102397324,0.001333067,0.000022461389],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1272389,0.003272721,0.09149726,0.00046798182,0.002979073,0.0012537135,0.0007310565,0.00010333947,0.0014774727,0.0002927596,0.054965004,0.7157207],"study_design_scores_gemma":[0.102647275,0.0984887,0.040394645,0.00032018576,0.002812016,0.00012632181,0.00048679436,0.00085800816,0.0043362505,0.0024490496,0.7468032,0.00027752473],"about_ca_topic_score_codex":0.00009606699,"about_ca_topic_score_gemma":0.000053544463,"teacher_disagreement_score":0.7154432,"about_ca_system_score_codex":0.00033239994,"about_ca_system_score_gemma":0.0059839683,"threshold_uncertainty_score":0.9996512},"labels":[],"label_agreement":null},{"id":"W3008469678","doi":"10.1200/jco.2020.38.6_suppl.195","title":"Next-generation sequencing (NGS) of tumor tissue from &gt;4000 men with metastatic castration-resistant prostate cancer (mCRPC): The PROfound phase III study experience.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Olaparib; Enzalutamide; Prostate cancer; Prostatectomy; Internal medicine; Cancer; Oncology; Biopsy; Prostate; Biomarker; Primary tumor; Pathology; Metastasis; Androgen receptor; Gene","score_opus":0.3364849534888414,"score_gpt":0.5173594748671928,"score_spread":0.18087452137835142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008469678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874676,0.0011263107,0.000084558895,0.009455493,0.00020279287,0.001385795,0.000023648436,0.000006977511,0.0002468094],"genre_scores_gemma":[0.99668336,0.00035555888,0.0010525002,0.00069599476,0.0008588183,0.000087101245,0.000011220281,0.00001833697,0.00023713386],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99636936,0.00055819494,0.0018630854,0.00026429104,0.0007107949,0.00023429094],"domain_scores_gemma":[0.9966771,0.0006815111,0.0014658474,0.000178122,0.00065759063,0.00033984077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014084644,0.00016718982,0.0011515837,0.000056122717,0.0001084667,0.00003441073,0.00018014372,0.000063026324,0.00030116565],"category_scores_gemma":[0.0006039808,0.0000830307,0.00012995684,0.0002586291,0.0003191759,0.00025171763,0.000037312027,0.00060196297,0.0000032800287],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13614585,0.01070772,0.045735538,0.00022980766,0.0060909213,0.011097137,0.08013443,0.0007290685,0.57020414,0.00006927059,0.005788945,0.13306716],"study_design_scores_gemma":[0.2694159,0.35223448,0.05666176,0.0009351129,0.008442962,0.0005082597,0.13836184,0.014106451,0.12938096,0.0003160485,0.028695548,0.0009406825],"about_ca_topic_score_codex":0.00055008614,"about_ca_topic_score_gemma":0.0005161552,"teacher_disagreement_score":0.4408232,"about_ca_system_score_codex":0.000275351,"about_ca_system_score_gemma":0.0044026924,"threshold_uncertainty_score":0.78101873},"labels":[],"label_agreement":null},{"id":"W3008508918","doi":"10.1200/jco.2020.38.6_suppl.371","title":"Determinants of biochemical failure and distant metastases-free survival in high-risk prostate cancer patients treated with external beam radiotherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Urology; External beam radiotherapy; Androgen deprivation therapy; Cumulative incidence; Prostate; Internal medicine; Nuclear medicine; Cancer; Cohort","score_opus":0.05056801024914782,"score_gpt":0.4128375472894749,"score_spread":0.3622695370403271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008508918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954038,0.001991203,0.00001157175,0.002006167,0.00011740131,0.0003483794,0.00010751025,0.0000040707805,0.000009899372],"genre_scores_gemma":[0.99260515,0.0054765805,0.0014343583,0.00019341189,0.00023142133,0.0000080135615,0.0000064257415,0.000019813546,0.000024809351],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722564,0.00031796467,0.0015199153,0.00023539527,0.00045008134,0.00025101635],"domain_scores_gemma":[0.99722254,0.00070573937,0.0011610946,0.00013370578,0.000326361,0.00045052817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090326247,0.00016319171,0.0015013649,0.00008990898,0.000020871064,0.000007366205,0.00015090713,0.000175145,0.000049603444],"category_scores_gemma":[0.0010682307,0.000091179994,0.00015773019,0.00020383135,0.00036120438,0.00008643543,0.000056895882,0.0007000273,4.1115882e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030562444,0.001218471,0.9389391,0.000077972974,0.0003448617,0.0008439113,0.00015344599,0.0000049325763,0.0011804787,0.0000014994523,0.0003695024,0.026303396],"study_design_scores_gemma":[0.04928687,0.032510653,0.9093935,0.0003205415,0.00046128282,0.000043668177,0.000081629725,0.00010862759,0.0064377175,0.00004145944,0.0011930229,0.00012103746],"about_ca_topic_score_codex":0.00024219698,"about_ca_topic_score_gemma":0.00015083844,"teacher_disagreement_score":0.031292185,"about_ca_system_score_codex":0.0001329109,"about_ca_system_score_gemma":0.0008113962,"threshold_uncertainty_score":0.37182122},"labels":[],"label_agreement":null},{"id":"W3008509746","doi":"10.1200/jco.2020.38.6_suppl.118","title":"Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Population; Circulating tumor cell; Oncology; Olaparib; Progression-free survival; Progressive disease; Cancer; Disease; Chemotherapy; Gene; Metastasis; Biology","score_opus":0.1685168687193393,"score_gpt":0.465545764366912,"score_spread":0.2970288956475727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008509746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953337,0.0009240626,0.000004271471,0.0022976329,0.0001104748,0.0012600417,0.000025144285,0.0000059561335,0.000038714847],"genre_scores_gemma":[0.99864244,0.0003520618,0.00047463927,0.00035603295,0.00006993753,0.000036208345,0.00000409019,0.000017658174,0.000046900157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99550253,0.0013659049,0.0019667032,0.00028236315,0.00061281124,0.00026967438],"domain_scores_gemma":[0.99643135,0.0013524235,0.0011294064,0.000117371215,0.00058900117,0.00038043648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029953695,0.00018233198,0.0015101574,0.00025619753,0.000044323773,0.000006900172,0.00009049727,0.00009008688,0.00002914154],"category_scores_gemma":[0.0030559893,0.00011457221,0.00015191051,0.00043532604,0.00028863654,0.00013595558,0.000054189164,0.0007630081,9.4789124e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29866034,0.00951343,0.67546546,0.000075763826,0.00062918244,0.0026388797,0.003896381,0.00011653659,0.001579242,0.0000024093424,0.00015768349,0.007264664],"study_design_scores_gemma":[0.07766936,0.15945221,0.7601026,0.00023249148,0.0003835612,0.000019113575,0.001075816,0.00013973402,0.00045390544,0.000018822699,0.00035266666,0.00009968039],"about_ca_topic_score_codex":0.00015823604,"about_ca_topic_score_gemma":0.0009947394,"teacher_disagreement_score":0.22099099,"about_ca_system_score_codex":0.00028133043,"about_ca_system_score_gemma":0.0032681613,"threshold_uncertainty_score":0.5797578},"labels":[],"label_agreement":null},{"id":"W3008524481","doi":"10.1200/jco.2020.38.6_suppl.158","title":"Intermediate atypical carcinoma (IAC): A discrete subtype of metastatic castration-resistant prostate cancer (mCRPC) suggesting that treatment-associated small cell/neuroendocrine prostate cancer (t-SCNC) may evolve from mCRPC adenocarcinoma (adeno)—Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Biopsy; Prostate; Pathology; Adenocarcinoma; Metastasis; Internal medicine; Oncology","score_opus":0.14008582028087863,"score_gpt":0.4086209625494445,"score_spread":0.2685351422685659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008524481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94411945,0.011599797,0.000007089753,0.032631073,0.001407487,0.0026843953,0.0073620006,0.000057604128,0.0001310751],"genre_scores_gemma":[0.97645426,0.01788683,0.0004628955,0.0012195552,0.0017037787,0.00034294382,0.0006417221,0.00015929295,0.0011287418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9895127,0.0017483443,0.0046780673,0.0012682463,0.0013929601,0.001399727],"domain_scores_gemma":[0.9854533,0.0058884276,0.00514737,0.00065196346,0.00140974,0.00144917],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013441042,0.0009540081,0.0037496975,0.0001947125,0.00030723968,0.00012556216,0.0007683883,0.0003367272,0.00037576564],"category_scores_gemma":[0.0029619709,0.00058043463,0.0010502714,0.000716391,0.0010797288,0.0003782164,0.00033866777,0.002407561,0.000022366876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07731406,0.0018325156,0.877179,0.00019241248,0.0032961091,0.005447157,0.007441076,0.00038014058,0.00394481,0.0000035241321,0.004346833,0.018622339],"study_design_scores_gemma":[0.0491549,0.018389711,0.9094768,0.0012769923,0.0045770407,0.000074702075,0.0035888231,0.0012494915,0.006920666,0.00009029738,0.0045872615,0.000613286],"about_ca_topic_score_codex":0.02336411,"about_ca_topic_score_gemma":0.020279858,"teacher_disagreement_score":0.032334764,"about_ca_system_score_codex":0.0015411422,"about_ca_system_score_gemma":0.008628222,"threshold_uncertainty_score":0.9998939},"labels":[],"label_agreement":null},{"id":"W3008661915","doi":"10.1200/jco.2020.38.6_suppl.9","title":"A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"Progenics Pharmaceuticals","keywords":"Medicine; Prostate cancer; Occult; Nuclear medicine; Prostatectomy; Radiology; Pelvis; Cancer; Pathology; Internal medicine","score_opus":0.059601925304202226,"score_gpt":0.45438124618992043,"score_spread":0.3947793208857182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008661915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99645793,0.0008361746,0.000017658427,0.0010861232,0.00013074311,0.0012868006,0.0001621009,0.000008462895,0.000014022421],"genre_scores_gemma":[0.99891126,0.0005264756,0.00012649801,0.00019906266,0.0000796602,0.00004967881,0.000053442724,0.000026792057,0.00002714425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99552894,0.00061917905,0.0022223156,0.0004723966,0.0007915886,0.00036559082],"domain_scores_gemma":[0.99558413,0.0008025594,0.0020739872,0.00016314573,0.0009824187,0.0003937575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012391922,0.00027305726,0.0021215545,0.00039629155,0.000108864064,0.000015193272,0.00012615311,0.000011550105,0.00007938689],"category_scores_gemma":[0.0006594177,0.00017882137,0.00032393637,0.00075924024,0.00044669933,0.00026327238,0.00013332267,0.00072389795,3.1576283e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09185722,0.010211674,0.8815595,0.00008167881,0.0047536823,0.004193975,0.0012083673,0.00007156018,0.001094352,5.0383755e-7,0.0001425818,0.004824897],"study_design_scores_gemma":[0.15815593,0.061744887,0.7519165,0.00033541577,0.009583856,0.00016690152,0.005028987,0.0043334044,0.0080236,0.000016660684,0.00034568034,0.00034813586],"about_ca_topic_score_codex":0.00045594346,"about_ca_topic_score_gemma":0.0008406245,"teacher_disagreement_score":0.12964296,"about_ca_system_score_codex":0.00046796465,"about_ca_system_score_gemma":0.00073331926,"threshold_uncertainty_score":0.72921234},"labels":[],"label_agreement":null},{"id":"W3008697319","doi":"10.1200/jco.2020.38.6_suppl.225","title":"Prognostic factors that affect survival outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Radium-223; Proportional hazards model; Internal medicine; Bone metastasis; Overall survival; Cancer; Survival analysis; Urology; Oncology","score_opus":0.21445699783522373,"score_gpt":0.4776605600352074,"score_spread":0.26320356219998364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008697319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98360395,0.00046420537,0.000016414258,0.014062681,0.0001061052,0.0010173067,0.000024032564,0.00001591423,0.00068941154],"genre_scores_gemma":[0.9979192,0.0005413925,0.0005215865,0.0003343812,0.00013040923,0.000037502246,0.000015025535,0.000032490796,0.00046803345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99683356,0.00058054767,0.0012002308,0.00029175618,0.00069394213,0.0003999448],"domain_scores_gemma":[0.99585444,0.0021531363,0.000918149,0.00012703355,0.0003292622,0.00061800797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010616966,0.00025833052,0.0019552892,0.0001381904,0.000046451078,0.00002471101,0.00013527687,0.00013117601,0.000107252614],"category_scores_gemma":[0.00087532663,0.00012161734,0.00021390778,0.00036713821,0.00028351948,0.00017889288,0.000024329287,0.0009096159,0.0000040758046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027225278,0.0012915415,0.9610478,0.00010458197,0.0013948081,0.0043281815,0.00055901404,0.000055264074,0.00019567419,0.000007622863,0.00022156196,0.0035686272],"study_design_scores_gemma":[0.028373474,0.031973064,0.9358809,0.00021777645,0.00089307403,0.000060656308,0.0010209096,0.00010076097,0.00047084322,0.000011928536,0.00085072906,0.00014587499],"about_ca_topic_score_codex":0.0003272764,"about_ca_topic_score_gemma":0.001081319,"teacher_disagreement_score":0.030681523,"about_ca_system_score_codex":0.0003092754,"about_ca_system_score_gemma":0.0030944718,"threshold_uncertainty_score":0.548946},"labels":[],"label_agreement":null},{"id":"W3008777590","doi":"10.1200/jco.2020.38.6_suppl.tps384","title":"INTREPId (INTermediate Risk Erection PreservatIon Trial): A randomized trial of radiation therapy and darolutamide for prostate cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Clinical endpoint; Prostate cancer; Androgen deprivation therapy; Brachytherapy; Internal medicine; Randomized controlled trial; Urology; Oncology; Radiation therapy; Cancer","score_opus":0.17134188640697212,"score_gpt":0.49562923973114204,"score_spread":0.3242873533241699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008777590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756641,0.0021754059,0.0002969658,0.016533256,0.0013441137,0.0038889374,0.000018657443,0.0000075991984,0.000070966336],"genre_scores_gemma":[0.92168385,0.07358484,0.00051268854,0.00058888237,0.0032533808,0.00019672142,0.0000130116205,0.000015472027,0.00015114505],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962339,0.0010390457,0.002140516,0.00016753295,0.00027412298,0.00014490342],"domain_scores_gemma":[0.992199,0.0043566795,0.002672713,0.00007797276,0.000462717,0.00023089885],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005593469,0.00010345225,0.0017371083,0.00008943839,0.000036887603,0.000009374907,0.00006668567,0.00020754371,0.000032816173],"category_scores_gemma":[0.0135178985,0.00006263124,0.00049327186,0.00011847562,0.00021788783,0.00015976085,0.000018413675,0.00045409438,5.3879296e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6568718,0.0004291215,0.0028131702,0.00003601004,0.00053583964,0.000005438069,0.00034002258,0.000008140483,0.00008767512,0.0000062879876,0.00085250236,0.338014],"study_design_scores_gemma":[0.9244633,0.05784267,0.0048107263,0.000045608722,0.0005042088,0.000003541167,0.00004202898,0.0016594068,0.0005859164,0.00068557804,0.009309164,0.000047871414],"about_ca_topic_score_codex":0.00006606494,"about_ca_topic_score_gemma":0.000014419952,"teacher_disagreement_score":0.33796614,"about_ca_system_score_codex":0.00009347778,"about_ca_system_score_gemma":0.0013626226,"threshold_uncertainty_score":0.9947917},"labels":[],"label_agreement":null},{"id":"W3008797474","doi":"10.5489/cuaj.6506","title":"A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy","year":2020,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Urological Association","keywords":"Positron emission tomography; Prostate cancer; Medicine; Nuclear medicine; Positron Emission Tomography-Computed Tomography; Medical physics; Radiology; Cancer; Internal medicine","score_opus":0.04204358212923238,"score_gpt":0.3741478394370959,"score_spread":0.3321042573078635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008797474","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000034099976,0.9715022,9.631498e-7,0.026878545,0.00011840161,0.0011123673,0.00018871533,0.00001549387,0.00014925812],"genre_scores_gemma":[0.000100706435,0.99296236,0.000034379933,0.0062850914,0.0002533837,0.000080257414,0.000107442516,0.000030081977,0.00014632563],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976865,0.00043891073,0.00063033105,0.0003081341,0.0004342187,0.0005019002],"domain_scores_gemma":[0.9975309,0.00015442318,0.00058233534,0.00011143813,0.0003340407,0.0012869131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006660225,0.00030964336,0.0014708492,0.00028275876,0.00014679624,0.000049250815,0.00013640344,0.00024056816,0.0004715407],"category_scores_gemma":[0.00027426443,0.00019190481,0.00052946224,0.0005101683,0.00007896289,0.0000464706,0.000017203054,0.0011419876,0.0000048550146],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008246934,0.00004383804,0.018617598,0.013677476,0.0004436921,0.00021417784,0.000017712171,5.014186e-8,0.0000031108405,0.0000018869479,0.020599525,0.9462985],"study_design_scores_gemma":[0.0011563903,0.0002670926,0.0007556056,0.026218098,0.00090393267,0.00012289624,0.0000019280812,0.000010903413,0.0000040037967,0.000013041974,0.97038484,0.0001612795],"about_ca_topic_score_codex":0.00026864756,"about_ca_topic_score_gemma":0.000008887654,"teacher_disagreement_score":0.9497853,"about_ca_system_score_codex":0.0012355668,"about_ca_system_score_gemma":0.0035069785,"threshold_uncertainty_score":0.7825651},"labels":[],"label_agreement":null},{"id":"W3008812155","doi":"10.1200/jco.2020.38.6_suppl.29","title":"Real-world management of advanced prostate cancer: A Canadian comparison of academic specialists and community-based prostate cancer physicians.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; University of Ottawa; McGill University; University of Alberta; BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network; Ottawa Hospital; Jewish General Hospital; University of Toronto; McMaster University; Juravinski Cancer Centre","funders":"Janssen Canada","keywords":"Medicine; Prostate cancer; Docetaxel; Cancer; Oncology; Internal medicine; Prostate; Family medicine","score_opus":0.19338242966842042,"score_gpt":0.5300743591986097,"score_spread":0.3366919295301892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008812155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9586291,0.0027215655,0.0000023681912,0.03549543,0.00035418017,0.0007407163,0.00011320853,0.0000067934075,0.0019366894],"genre_scores_gemma":[0.9747466,0.02177495,0.0008899311,0.0018046023,0.00034523112,0.000026837895,0.000017083932,0.000023082877,0.0003716691],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964576,0.0005832514,0.0019977908,0.0001791508,0.00043405994,0.0003481411],"domain_scores_gemma":[0.99621683,0.0006258045,0.0017957378,0.00017456751,0.00052773365,0.0006593359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014063503,0.00017008698,0.0017464885,0.00019158893,0.00008681919,0.000005029505,0.00023352391,0.00017138815,0.00005666864],"category_scores_gemma":[0.0001726589,0.00012956752,0.00022293584,0.00042818143,0.0005284614,0.000091231326,0.00007012547,0.0019873034,0.0000011971314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017270241,0.0010406266,0.61531824,0.0015184605,0.0010227865,0.0003012316,0.002944161,0.0004105445,0.0010220646,0.000091201044,0.0054833773,0.35357705],"study_design_scores_gemma":[0.030909756,0.01798695,0.774669,0.0030291253,0.001326655,0.000006304618,0.003183323,0.0005387622,0.00563318,0.00024786612,0.16218518,0.00028392265],"about_ca_topic_score_codex":0.015860649,"about_ca_topic_score_gemma":0.031928938,"teacher_disagreement_score":0.35329312,"about_ca_system_score_codex":0.0004422449,"about_ca_system_score_gemma":0.0033282342,"threshold_uncertainty_score":0.9906928},"labels":[],"label_agreement":null},{"id":"W3008866163","doi":"10.1200/jco.2020.38.6_suppl.122","title":"Phase Ib study of niraparib plus androgen receptor-targeted therapy (ART) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Internal medicine; Cohort; Enzalutamide; Discontinuation; Abiraterone acetate; Neutropenia; Gastroenterology; Cancer; Androgen deprivation therapy; Urology; Oncology; Androgen receptor; Chemotherapy","score_opus":0.17718702913344445,"score_gpt":0.49150643266501404,"score_spread":0.3143194035315696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008866163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994061,0.0009666968,0.000004222913,0.0033319164,0.00018404143,0.0012920382,0.000034400397,0.0000056158565,0.00012009191],"genre_scores_gemma":[0.9974047,0.0012938386,0.00041752955,0.00053292484,0.00016001124,0.000034729717,0.000021144928,0.000020914758,0.000114205635],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99628186,0.00057274394,0.001995478,0.00024070451,0.0006476196,0.00026159725],"domain_scores_gemma":[0.9969847,0.00045645895,0.0012929101,0.00013605111,0.0007233979,0.00040647783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011285854,0.00016990388,0.001497871,0.00013283057,0.000033626926,0.000009262366,0.00013516072,0.000103933526,0.00024705412],"category_scores_gemma":[0.0004686847,0.000098853176,0.00016118328,0.00038980538,0.00016383566,0.00013409457,0.000024838251,0.00069032056,0.000005520876],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2628539,0.03660387,0.580116,0.00011977476,0.002803993,0.0014714926,0.0062575154,0.00018239323,0.0014640201,0.0000041953836,0.0034673417,0.10465555],"study_design_scores_gemma":[0.35899436,0.39273304,0.229643,0.00022606317,0.00064331427,0.000016483353,0.0028014854,0.00019373647,0.0015876504,0.000023683036,0.012915069,0.00022211319],"about_ca_topic_score_codex":0.00008784159,"about_ca_topic_score_gemma":0.00023834646,"teacher_disagreement_score":0.35612917,"about_ca_system_score_codex":0.00025528704,"about_ca_system_score_gemma":0.0029256972,"threshold_uncertainty_score":0.51900613},"labels":[],"label_agreement":null},{"id":"W3009053217","doi":"10.1097/ju.0000000000000809","title":"Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer","year":2020,"lang":"en","type":"review","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Université Laval; McMaster University; Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; Health Sciences Centre; Mount Sinai Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Androgen deprivation therapy; Prostate cancer; Testosterone (patch); Castration; Medicine; Androgen; Cancer; Gerontology; Library science; Gynecology; Internal medicine; Hormone","score_opus":0.07486800764259527,"score_gpt":0.3978630865159919,"score_spread":0.3229950788733966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009053217","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008040286,0.98593676,0.00004397345,0.0040795053,0.00015158637,0.0016737535,0.00005029705,0.000008064376,0.000015792331],"genre_scores_gemma":[0.0035813597,0.99524975,0.00006172127,0.00016841873,0.0006470895,0.00006425146,0.00004750941,0.00004007353,0.00013983864],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986773,0.00025183213,0.0005132692,0.00014309285,0.00018254983,0.00023196673],"domain_scores_gemma":[0.9985097,0.0003025267,0.00065992767,0.0001265837,0.0003208651,0.00008041148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035762918,0.00021921171,0.0010233053,0.00011295125,0.00010466094,0.000014227575,0.0001060116,0.00014350638,0.00001658066],"category_scores_gemma":[0.00005943603,0.00011227509,0.0002235087,0.00017139105,0.00009843618,0.000075645046,0.000026121521,0.00045039313,0.000004295741],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00538919,0.00009016218,0.00012987047,0.002638049,0.0018529643,0.0002324043,0.0012140439,0.000010409365,0.0009569042,0.000005270793,0.000335649,0.98714507],"study_design_scores_gemma":[0.007962918,0.0065158946,0.0006812527,0.0028489179,0.0043569556,0.0077120806,0.000139487,0.000030057636,0.0024983427,0.000121842175,0.966845,0.00028724555],"about_ca_topic_score_codex":0.000013844792,"about_ca_topic_score_gemma":0.000006466455,"teacher_disagreement_score":0.98685783,"about_ca_system_score_codex":0.00017292265,"about_ca_system_score_gemma":0.00074341305,"threshold_uncertainty_score":0.45784453},"labels":[],"label_agreement":null},{"id":"W3009152633","doi":"10.1139/cjpp-2019-0668","title":"Upregulation of PACE4 in prostate cancer is not dependent on E2F transcription factors","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University; Université de Sherbrooke","funders":"Canadian Institutes of Health Research","keywords":"Gene silencing; Prostate cancer; Gene isoform; Transcription factor; Cancer research; Biology; Transcription (linguistics); Prostate; Cancer; Cell biology; Gene; Genetics","score_opus":0.049319447690459116,"score_gpt":0.3396845948168229,"score_spread":0.2903651471263638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009152633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891188,0.0010037792,0.000001240223,0.009356851,0.00023313613,0.00019246891,0.000053825446,0.000001423178,0.00003847947],"genre_scores_gemma":[0.997358,0.00073509436,0.0000058538067,0.0017021454,0.00011459966,0.000004892944,0.000008664205,0.0000063984785,0.00006434168],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99934685,0.000079495716,0.00021033797,0.00011148556,0.0000653526,0.00018650001],"domain_scores_gemma":[0.99942887,0.00003445947,0.00009968268,0.000029221179,0.00008546293,0.00032230315],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007419,0.000082428705,0.00026570007,0.00016051777,0.000034377863,0.0000019251252,0.000042455966,0.000068922964,0.0009402086],"category_scores_gemma":[0.000008124814,0.000062549225,0.000046767927,0.0001003385,0.00012647339,0.00004982124,0.0000032189153,0.00026049477,0.0000012018601],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020531456,0.000033962686,0.052574914,0.00014495598,0.00013490826,0.000086973676,0.0037619397,0.00016182433,0.9385931,0.000016319766,0.0010255304,0.0014124321],"study_design_scores_gemma":[0.004089264,0.0014747187,0.25413442,0.000052507377,0.00010010226,0.00001379155,0.00019576763,0.00013503822,0.73842555,0.000113444934,0.0011989597,0.00006646569],"about_ca_topic_score_codex":0.00081679726,"about_ca_topic_score_gemma":0.0005528312,"teacher_disagreement_score":0.2015595,"about_ca_system_score_codex":0.000093521776,"about_ca_system_score_gemma":0.00051360665,"threshold_uncertainty_score":0.99997306},"labels":[],"label_agreement":null},{"id":"W3009755741","doi":"10.1200/jco.2007.25.18_suppl.5018","title":"Results of a phase III randomized controlled trial of the safety and efficacy of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada); London Health Sciences Centre","funders":"","keywords":"Medicine; Placebo; Clinical endpoint; Hazard ratio; Urology; Prostate cancer; Internal medicine; Population; Randomized controlled trial; Surgery; Gastroenterology; Oncology; Cancer; Confidence interval; Pathology","score_opus":0.05724346998701832,"score_gpt":0.47168772083188726,"score_spread":0.4144442508448689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009755741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99077374,0.0022509627,0.000025428837,0.0019937705,0.0001836807,0.0034529916,0.000022560624,0.0000013429805,0.0012955212],"genre_scores_gemma":[0.99014145,0.009031078,0.00025496286,0.00006110112,0.00016355328,0.000015633546,0.0000023145976,0.000010081246,0.00031980735],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99310744,0.0011237732,0.0048221643,0.00014763525,0.0005793831,0.00021962881],"domain_scores_gemma":[0.9834915,0.011311235,0.004376415,0.00017324921,0.00045070628,0.00019689694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01442396,0.00013709301,0.0043614474,0.00018493258,0.000019590778,0.0000019026611,0.00011625974,0.00015711381,0.000017712808],"category_scores_gemma":[0.0050974903,0.000059090722,0.0005756983,0.00022177257,0.0010071963,0.000054670283,0.00003385677,0.0006369433,9.879868e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9593597,0.005552021,0.001368361,0.00004865724,0.0016873564,0.00016086052,0.0006298198,0.00001372637,0.001360582,0.000010503156,0.000112155045,0.029696258],"study_design_scores_gemma":[0.95529777,0.026851103,0.014795951,0.00029065215,0.0013417877,0.000021755217,0.00026727107,0.000080360755,0.0005675214,0.000036139583,0.0004005231,0.000049151273],"about_ca_topic_score_codex":0.00015467718,"about_ca_topic_score_gemma":0.00011270683,"teacher_disagreement_score":0.029647106,"about_ca_system_score_codex":0.00012740502,"about_ca_system_score_gemma":0.0022008985,"threshold_uncertainty_score":0.610254},"labels":[],"label_agreement":null},{"id":"W3009812442","doi":"10.1016/j.clgc.2020.02.005","title":"A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer","year":2020,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Health Sciences Centre; Mount Sinai Hospital; University of Calgary","funders":"Janssen Biotech; Astellas Pharma Canada; Bayer","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Meta-analysis; Oncology; Enzalutamide; Subgroup analysis; Androgen deprivation therapy; Randomized controlled trial; Placebo; Confidence interval; Androgen receptor; Cancer; Pathology","score_opus":0.22681532087135517,"score_gpt":0.4784924576525275,"score_spread":0.2516771367811723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009812442","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000781845,0.9883421,0.0000022077704,0.0008151241,0.0001978651,0.00895414,0.0015518045,0.000021227594,0.000037349866],"genre_scores_gemma":[0.00004749933,0.99153835,0.00036893936,0.00038774617,0.00031427536,0.0058436636,0.00037628834,0.000092632006,0.00103061],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9926461,0.00079244183,0.004201865,0.001121787,0.00065771246,0.0005800747],"domain_scores_gemma":[0.99560404,0.0010245453,0.0017951044,0.00074692105,0.00031711772,0.0005122954],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0016622758,0.00078365015,0.016149325,0.0004057043,0.00007075431,0.000033518412,0.00027944922,0.00029209052,0.00041420216],"category_scores_gemma":[0.0003507953,0.000487111,0.003775382,0.0031393992,0.00027383922,0.00009015411,0.00019621465,0.0009423351,0.000011047019],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019116083,0.00040958956,0.00012267285,0.7640802,0.2204892,0.00026921052,0.00006167257,0.000019407069,0.0000015883957,0.0000013233481,0.001635878,0.012718087],"study_design_scores_gemma":[0.0011673248,0.00052837736,0.00003086915,0.16650225,0.78654313,0.000016594859,0.000024562994,0.000051859937,0.0000010146457,0.0000016348788,0.044709228,0.00042318078],"about_ca_topic_score_codex":0.00021290864,"about_ca_topic_score_gemma":0.00017552837,"teacher_disagreement_score":0.5975779,"about_ca_system_score_codex":0.00037843714,"about_ca_system_score_gemma":0.001973422,"threshold_uncertainty_score":0.99975806},"labels":[],"label_agreement":null},{"id":"W3009821697","doi":"10.1200/jgo.19.00341","title":"Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets","year":2020,"lang":"en","type":"article","venue":"JCO Global Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Abiraterone; Abiraterone acetate; Medicine; Prostate cancer; Cancer; Oncology; Internal medicine; Androgen deprivation therapy","score_opus":0.06147423686653137,"score_gpt":0.419212840685115,"score_spread":0.35773860381858363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009821697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80135524,0.0037286235,0.000011570975,0.18839058,0.00016022884,0.0012745311,0.00014671196,0.000043508186,0.0048889727],"genre_scores_gemma":[0.97194797,0.0037306775,0.00054979464,0.022576472,0.00009762486,0.000112215595,0.000032288335,0.00001731652,0.0009356698],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99833816,0.00013156133,0.00027520471,0.00041827257,0.00025716462,0.0005796635],"domain_scores_gemma":[0.99918664,0.00009121445,0.0001095855,0.0001281882,0.00012197665,0.00036239024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021865609,0.0001936175,0.0004952522,0.00007676523,0.000056193265,0.000025329766,0.0000765678,0.000100118676,0.0002036685],"category_scores_gemma":[0.0001962028,0.00015206228,0.000039729184,0.00053380406,0.00013052564,0.00018315077,0.00012541527,0.0002584459,0.000111496855],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04833594,0.0055602,0.17394258,0.003951409,0.0029827554,0.024939608,0.10949051,0.00014662172,0.020663865,0.00093229645,0.12571509,0.48333913],"study_design_scores_gemma":[0.055077955,0.0153177595,0.055342916,0.0005945537,0.001023248,0.00078720413,0.019475447,0.0020924786,0.012884785,0.00041093444,0.83602434,0.00096840167],"about_ca_topic_score_codex":0.00040480297,"about_ca_topic_score_gemma":0.00015908317,"teacher_disagreement_score":0.7103092,"about_ca_system_score_codex":0.0006935507,"about_ca_system_score_gemma":0.0006970248,"threshold_uncertainty_score":0.620092},"labels":[],"label_agreement":null},{"id":"W3010040987","doi":"10.1200/jco.2007.25.18_suppl.5002","title":"Multicenter phase II study of combined neoadjuvant docetaxel and androgen ablation (ADT) prior to radical prostatectomy (RP) for patients (pts) with high risk localized prostate cancer (LCaP): Pathologic outcomes and 3-year follow-up analyses","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Urology; Prostatectomy; Internal medicine; Goserelin; Clinical endpoint; Cancer; Gynecology; Surgery; Clinical trial","score_opus":0.089814145008371,"score_gpt":0.49152939935460704,"score_spread":0.40171525434623606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010040987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951529,0.0003527498,0.000133084,0.0008643876,0.00026360786,0.003150646,0.00006137245,0.000009538238,0.000011706797],"genre_scores_gemma":[0.99516314,0.0007163384,0.0035648863,0.00023433722,0.00009253318,0.000059764057,0.000014767386,0.000023090808,0.00013114566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966201,0.00031749214,0.0018444064,0.00034670933,0.0005056721,0.0003656015],"domain_scores_gemma":[0.9957855,0.0012376333,0.001361202,0.00016214649,0.00092508964,0.0005284724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024476035,0.00022546187,0.0017269793,0.00025329916,0.00013601253,0.0000143155985,0.000092308364,0.0001941077,0.000018784684],"category_scores_gemma":[0.0015261443,0.00012210311,0.00017581544,0.00020697803,0.00029578418,0.00012332156,0.00008727638,0.00046564193,4.9148764e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16531292,0.0094448365,0.7203932,0.00006896811,0.0010562873,0.00023673466,0.0009861932,0.0000074836666,0.00015717043,0.0000026898163,0.00008720599,0.102246344],"study_design_scores_gemma":[0.24444993,0.18256184,0.5692516,0.00012199971,0.0014123536,0.000015316604,0.0007393385,0.000075807,0.00046373362,0.000053920976,0.00072884356,0.00012530135],"about_ca_topic_score_codex":0.00012298323,"about_ca_topic_score_gemma":0.00019167586,"teacher_disagreement_score":0.173117,"about_ca_system_score_codex":0.00014021459,"about_ca_system_score_gemma":0.0004508414,"threshold_uncertainty_score":0.497922},"labels":[],"label_agreement":null},{"id":"W3010077430","doi":"10.1016/j.ejca.2020.01.017","title":"Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Janssen Biotech; AstraZeneca France; Seattle Genetics; Janssen Canada; Meso Scale Diagnostics; Sanofi; AstraZeneca; Astellas Pharma; Ipsen; Clovis Oncology; Roche; Astellas Pharma US; Novartis; British Microcirculation Society; Pfizer","keywords":"Abiraterone acetate; Natural history; Prostate cancer; Medicine; Abiraterone; Oncology; Internal medicine; Cancer; Prostate; Urology; Androgen deprivation therapy; Androgen receptor","score_opus":0.04109552292384717,"score_gpt":0.30676500082791774,"score_spread":0.2656694779040706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010077430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9447435,0.0408361,0.000005527851,0.009089695,0.0001223447,0.00057222473,0.000013093206,0.000016119388,0.0046013645],"genre_scores_gemma":[0.98439664,0.007663425,0.00043702804,0.0015399761,0.00013287818,0.000013941399,0.0000026554396,0.00004494103,0.0057685194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855876,0.00018215699,0.00036295247,0.0002088949,0.00043338683,0.00025385455],"domain_scores_gemma":[0.99923784,0.000021051863,0.00021663883,0.000101518264,0.0001253891,0.00029757907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033101087,0.00018501599,0.0003664892,0.00015725996,0.000028785877,0.000021535492,0.00010476379,0.00000779924,0.00013739281],"category_scores_gemma":[0.000017784112,0.000112695365,0.000046127992,0.00015017606,0.000100357545,0.00013717593,0.00004938086,0.000379136,0.000012300976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04791662,0.000619435,0.57220685,0.0024250438,0.0028726284,0.06692349,0.013939823,0.0006848685,0.0054151234,0.00005020025,0.040580567,0.24636532],"study_design_scores_gemma":[0.03139428,0.0043483768,0.8742501,0.0016724548,0.0007578587,0.00019797316,0.0005191317,0.00045237213,0.0010580461,0.0000054047878,0.08494778,0.000396222],"about_ca_topic_score_codex":0.00008396214,"about_ca_topic_score_gemma":0.000036478523,"teacher_disagreement_score":0.30204323,"about_ca_system_score_codex":0.0005271496,"about_ca_system_score_gemma":0.0001445776,"threshold_uncertainty_score":0.45955834},"labels":[],"label_agreement":null},{"id":"W3010512320","doi":"10.1038/s41391-020-0222-6","title":"Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Hazard ratio; Meta-analysis; Oncology; Abiraterone; Prostate-specific antigen; Subgroup analysis; Systematic review; Confidence interval; MEDLINE; Cancer; Androgen receptor","score_opus":0.10707339501233894,"score_gpt":0.41024200089539536,"score_spread":0.30316860588305644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010512320","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042827943,0.9780321,7.184294e-7,0.0011039808,0.000026002152,0.013090499,0.00727047,0.000035367335,0.000012544319],"genre_scores_gemma":[0.0012357585,0.9871324,0.000048999584,0.00034515403,0.000024871573,0.009915761,0.0005781727,0.00008956576,0.0006293267],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9955086,0.00049435615,0.0017466658,0.0010967382,0.0005975909,0.0005560477],"domain_scores_gemma":[0.9975572,0.0002697802,0.00091225456,0.00045101304,0.0002663814,0.00054334],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042226067,0.00090651435,0.00887934,0.00047359933,0.00011564654,0.00015014836,0.00013700406,0.00013407433,0.00015899901],"category_scores_gemma":[0.000100818004,0.0005561612,0.00077807606,0.0012640252,0.00044591964,0.00021526265,0.00012184571,0.00035286558,0.0000014282512],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000492003,0.00014827494,0.0004324643,0.90221983,0.0667504,0.00018943021,0.00092965877,0.0000010936839,0.000009972005,0.000016166397,0.00005407848,0.028756656],"study_design_scores_gemma":[0.0029041055,0.0007782384,0.0002497126,0.09202306,0.89324504,0.000043570253,0.000207247,0.00002234742,0.000023542323,0.00010800819,0.009532329,0.00086279376],"about_ca_topic_score_codex":0.00074352656,"about_ca_topic_score_gemma":0.00017929309,"teacher_disagreement_score":0.82649463,"about_ca_system_score_codex":0.00020425911,"about_ca_system_score_gemma":0.0013958521,"threshold_uncertainty_score":0.999689},"labels":[],"label_agreement":null},{"id":"W3010571361","doi":"10.1200/jco.2007.25.18_suppl.5058","title":"A multivariate prognostic nomogram incorporating PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Nomogram; Prostate cancer; Internal medicine; Proportional hazards model; Urology; Docetaxel; Progression-free survival; Oncology; Gastroenterology; Cancer; Chemotherapy","score_opus":0.1563649281206174,"score_gpt":0.5123378466243577,"score_spread":0.35597291850374024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010571361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889138,0.0042669857,0.00030406006,0.0037656447,0.0007718058,0.0007968294,0.00000741148,0.000014403506,0.0011590567],"genre_scores_gemma":[0.98729837,0.0019213186,0.00904963,0.000582819,0.00064001704,0.000021888725,0.0000066694715,0.000030434121,0.0004488273],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9953226,0.00040542264,0.002934261,0.0002497894,0.000560349,0.000527575],"domain_scores_gemma":[0.9938525,0.0029216856,0.0018139407,0.0001677363,0.0006749949,0.0005691408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059910263,0.00020096156,0.0014210508,0.00036325716,0.000038993854,0.00001585513,0.00016180448,0.0002662077,0.000046337253],"category_scores_gemma":[0.004356955,0.00013195894,0.00030974735,0.00045239352,0.00032315648,0.00015559708,0.00007087774,0.0016785414,0.000011483749],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016200602,0.0071510244,0.4470234,0.00013295597,0.00071020133,0.009338136,0.00064832746,0.00007422056,0.0039293687,0.000043379096,0.0007670252,0.51398134],"study_design_scores_gemma":[0.026163243,0.026823962,0.92819625,0.00041377495,0.00053845765,0.0002719807,0.00043141816,0.00052089634,0.00029756752,0.0006582285,0.0154836085,0.00020063107],"about_ca_topic_score_codex":0.00016042784,"about_ca_topic_score_gemma":0.00048425526,"teacher_disagreement_score":0.5137807,"about_ca_system_score_codex":0.00050694286,"about_ca_system_score_gemma":0.0024257747,"threshold_uncertainty_score":0.72925204},"labels":[],"label_agreement":null},{"id":"W3011007230","doi":"10.1200/jco.2013.31.15_suppl.e16062","title":"Chemotherapy in hormone-refractory prostate cancer: Docetaxel with and without VT122.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Urology; Clinical endpoint; Internal medicine; Chemotherapy; Cancer; Surgery; Oncology; Gastroenterology; Randomized controlled trial","score_opus":0.08148570485158463,"score_gpt":0.47339873640916286,"score_spread":0.39191303155757823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011007230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96939886,0.006592095,0.000004174385,0.02194499,0.00014114915,0.0004296044,0.0000014034773,0.00000560184,0.0014821247],"genre_scores_gemma":[0.95937926,0.035854623,0.0010544057,0.0015427313,0.0003964107,0.000027140573,9.636098e-7,0.000017959856,0.0017265264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981676,0.00014726321,0.000976869,0.00016426171,0.00028398714,0.0002600244],"domain_scores_gemma":[0.99823666,0.0003324984,0.0006024417,0.00011199432,0.0003494639,0.0003669442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010349387,0.000121582365,0.0010035505,0.00012884567,0.000023232584,0.000013906228,0.00007885775,0.0001956616,0.00014602354],"category_scores_gemma":[0.0002062524,0.00006470802,0.000097548844,0.00012675974,0.00032256846,0.0001898768,0.000021704234,0.0008962781,0.000008995083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010046553,0.00096498017,0.68337506,0.000027776463,0.00026670765,0.00022103463,0.00025609235,0.0000016283942,0.0006135847,0.0000064677947,0.0031585507,0.30106154],"study_design_scores_gemma":[0.029377334,0.016765393,0.904111,0.00014783083,0.00008615408,0.00019244644,0.00015992504,0.000054825457,0.000093288734,0.00023333792,0.048692435,0.00008602127],"about_ca_topic_score_codex":0.00019372895,"about_ca_topic_score_gemma":0.00007435417,"teacher_disagreement_score":0.30097553,"about_ca_system_score_codex":0.0001668486,"about_ca_system_score_gemma":0.0015500362,"threshold_uncertainty_score":0.38939324},"labels":[],"label_agreement":null},{"id":"W3011518560","doi":"10.1016/j.eururo.2020.01.012","title":"Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019","year":2020,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":395,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"Medical Research Council; National Institute for Health and Care Research; Cancer Research UK","keywords":"Prostate cancer; Medicine; Management of prostate cancer; Prostate; Voting; Delphi method; Consensus conference; Cancer; Oncology; Gynecology; Internal medicine","score_opus":0.017205193418965557,"score_gpt":0.2828804490915681,"score_spread":0.2656752556726026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011518560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809373,0.0018863126,0.0000066870375,0.009572878,0.00018385137,0.0019457408,0.00023952314,0.000038473667,0.0051892465],"genre_scores_gemma":[0.9937338,0.0016606514,0.0002676164,0.000468304,0.000026494496,0.00007300971,0.000065739485,0.00004791098,0.0036564292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819374,0.00016560075,0.00045384816,0.00045376463,0.00037084884,0.0003622147],"domain_scores_gemma":[0.9985145,0.00002968502,0.0004359524,0.00043494217,0.00044386508,0.00014105497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013248634,0.00020878058,0.0004079702,0.000042996315,0.00005703863,0.000004844095,0.0001985977,0.000028182907,0.00009992679],"category_scores_gemma":[0.00003404218,0.00012540216,0.0000662003,0.00029962434,0.00043630062,0.000036809735,0.00019519553,0.0002269708,0.00000912715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027683001,0.0006315987,0.8508348,0.0015822642,0.0014180327,0.0028105832,0.0038197048,0.0017355338,0.007836719,0.00021541982,0.003921473,0.09751087],"study_design_scores_gemma":[0.016637247,0.0036475782,0.91567487,0.00043961065,0.00046077705,0.000027247826,0.0003069686,0.000078821475,0.0087408405,0.000022497226,0.053653333,0.00031020708],"about_ca_topic_score_codex":0.000041155978,"about_ca_topic_score_gemma":0.000010701188,"teacher_disagreement_score":0.09720066,"about_ca_system_score_codex":0.0000500304,"about_ca_system_score_gemma":0.00025311517,"threshold_uncertainty_score":0.5113752},"labels":[],"label_agreement":null},{"id":"W3011615314","doi":"10.1016/j.jaccao.2020.01.004","title":"Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"JACC CardioOncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; University of Alberta; Canadian VIGOUR Centre","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Myocardial infarction; Androgen deprivation therapy; Oncology; Dyslipidemia; Cancer; Urology; Randomized controlled trial; Disease","score_opus":0.05232511894660481,"score_gpt":0.35069976996871755,"score_spread":0.29837465102211275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011615314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8275866,0.08403078,0.002187341,0.043602493,0.0031441,0.012249441,0.0011501388,0.0003607229,0.02568837],"genre_scores_gemma":[0.98945224,0.0056229625,0.0015897705,0.00050577696,0.00074972503,0.0011187543,0.00013062156,0.00006340888,0.0007667618],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984233,0.00007459815,0.0002932257,0.00043842642,0.00031901855,0.0004514403],"domain_scores_gemma":[0.9988002,0.00017294115,0.00008352503,0.00033090936,0.000367596,0.00024480256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002343423,0.00018852504,0.0009799667,0.00006647091,0.000073022486,0.000005349883,0.00011299006,0.00014486308,0.000049360973],"category_scores_gemma":[0.00022008861,0.00015438069,0.00072797766,0.00026754203,0.00014554505,0.00006135982,0.00007847365,0.00018936463,0.00001128584],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21655533,0.00034156107,0.035164934,0.003243906,0.021211777,0.00071309874,0.004207078,0.008924253,0.03569241,0.00045017176,0.025998585,0.6474969],"study_design_scores_gemma":[0.048613347,0.0051280386,0.0049147825,0.000084132786,0.0017288653,0.00002564529,0.0006893507,0.00029650313,0.0409191,0.00002727564,0.89727217,0.0003007822],"about_ca_topic_score_codex":0.000067832625,"about_ca_topic_score_gemma":0.000013945137,"teacher_disagreement_score":0.8712736,"about_ca_system_score_codex":0.00034251966,"about_ca_system_score_gemma":0.00066253956,"threshold_uncertainty_score":0.62954617},"labels":[],"label_agreement":null},{"id":"W3011700050","doi":"10.1002/sctm.19-0286","title":"Propagation of human prostate tissue from induced pluripotent stem cells","year":2020,"lang":"en","type":"article","venue":"Stem Cells Translational Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Imperial Experimental Cancer Medicine Centre; European Commission; Medical Research Council Canada; Cancer Research UK; Prostate Cancer Foundation","keywords":"Induced pluripotent stem cell; Prostate; Stromal cell; Prostate cancer; Stem cell; Organoid; Medicine; Translational research; Mesenchyme; Embryonic stem cell; Pathology; Mesenchymal stem cell; Biology; Cancer research; Bioinformatics; Computational biology; Cancer; Internal medicine; Neuroscience; Cell biology","score_opus":0.06252410306357793,"score_gpt":0.3135276023556248,"score_spread":0.2510034992920469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011700050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97464854,0.0020655626,0.0005677598,0.018223858,0.00026944294,0.0023406723,0.00018604832,0.000089826586,0.0016082887],"genre_scores_gemma":[0.99746376,0.00013159041,0.00016583271,0.00027668418,0.00047493423,0.00004474768,0.00032789502,0.000037766942,0.0010767572],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976069,0.000078862875,0.0006431102,0.00042563185,0.0009796396,0.00026587647],"domain_scores_gemma":[0.99892515,0.00009959775,0.00017913332,0.00020428187,0.0002605543,0.00033129018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016869498,0.00023573193,0.00053952256,0.00011944214,0.00008281509,0.0000074959553,0.00011226617,0.00011043198,0.0005090689],"category_scores_gemma":[0.0000030770213,0.00017052284,0.0000768336,0.0003487462,0.00016619098,0.000095719945,0.00001644344,0.00025918632,0.000050544757],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007018682,0.00012351983,0.0014757848,0.00049647223,0.00015636675,0.00006494623,0.004395782,0.000029745697,0.97508293,0.00009916439,0.00046571187,0.01690769],"study_design_scores_gemma":[0.0070544686,0.002265592,0.0025461854,0.000530121,0.00023230693,0.0000029856142,0.00071025995,0.0004867081,0.98358196,0.000115079456,0.0023047458,0.0001695805],"about_ca_topic_score_codex":0.00014529942,"about_ca_topic_score_gemma":0.000008951166,"teacher_disagreement_score":0.022815252,"about_ca_system_score_codex":0.00005788495,"about_ca_system_score_gemma":0.00020140685,"threshold_uncertainty_score":0.6953719},"labels":[],"label_agreement":null},{"id":"W3011925872","doi":"10.1200/jco.2006.24.18_suppl.4516","title":"Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Mitoxantrone; Internal medicine; Quality of life (healthcare); Oncology; Cancer; Chemotherapy","score_opus":0.10289521198122166,"score_gpt":0.45506812270593255,"score_spread":0.3521729107247109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011925872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957591,0.00083349965,0.000006914049,0.0022972082,0.00002290792,0.0009965304,0.0000665295,0.0000023528855,0.000014951546],"genre_scores_gemma":[0.99841875,0.00071522215,0.0003233335,0.000077418714,0.00003988379,0.000024411704,0.000005069382,0.00001535045,0.00038057804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98863506,0.008045816,0.0019518317,0.0002072311,0.0009277469,0.00023230178],"domain_scores_gemma":[0.9839568,0.011631657,0.0030880435,0.00018302958,0.0009954531,0.00014503076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02019312,0.00016932395,0.0017266963,0.00020008461,0.000034342465,0.000006843083,0.00009301092,0.00012154423,0.000009151402],"category_scores_gemma":[0.005138477,0.00007288492,0.000069495036,0.0003930674,0.00044920648,0.00011248676,0.000024219355,0.0005367179,6.16124e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42643398,0.004539734,0.5650252,0.000064865584,0.00069928926,0.000110715584,0.0006785077,0.0000082472725,0.00039284842,7.040164e-7,0.00009853431,0.0019473701],"study_design_scores_gemma":[0.049431484,0.10540723,0.8419392,0.00015376511,0.00059994985,0.0000066926236,0.0020802016,0.000009280726,0.000052694377,0.0000062133054,0.00024345543,0.00006979528],"about_ca_topic_score_codex":0.00095890806,"about_ca_topic_score_gemma":0.0037944608,"teacher_disagreement_score":0.3770025,"about_ca_system_score_codex":0.00023275969,"about_ca_system_score_gemma":0.0022414627,"threshold_uncertainty_score":0.6998573},"labels":[],"label_agreement":null},{"id":"W3012871658","doi":"10.2967/jnumed.120.241737","title":"<sup>18</sup>F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smoothing Filter, and Partial-Volume Correction on PROMISE Criteria","year":2020,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Siemens (Canada); Women's College Hospital; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Nuclear medicine; Prostate cancer; Medicine; Lesion; Partial volume; Scintigraphy; Prostate; Cancer; Pathology; Internal medicine","score_opus":0.03632703303647738,"score_gpt":0.3436413963842489,"score_spread":0.3073143633477715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012871658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994106,0.0004970226,0.0000012931935,0.004473792,0.00019261207,0.00063784013,0.000009104576,0.0000074924696,0.00007482999],"genre_scores_gemma":[0.9983365,0.0011326427,0.000069726564,0.00020006129,0.0001743327,0.000004999056,0.000005921201,0.000026163047,0.000049653383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802536,0.00020512301,0.0007114964,0.00020951348,0.00064649415,0.00020202182],"domain_scores_gemma":[0.9985441,0.00030934723,0.0004951568,0.00012401331,0.00026987444,0.00025749125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069977914,0.00017171643,0.00080539635,0.00014221833,0.000035571287,0.0000068600066,0.000085997846,0.000025525029,0.00024743043],"category_scores_gemma":[0.0010735792,0.00009905354,0.000065683635,0.00027803823,0.00023844329,0.0001307548,0.000034735604,0.0005152954,0.0000014384055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07405812,0.00067250093,0.86892295,0.00152949,0.00020356762,0.0007012696,0.0033265813,0.00008112149,0.0029433712,0.000001174559,0.010190217,0.03736963],"study_design_scores_gemma":[0.06528966,0.11918635,0.7753566,0.019425532,0.00071395526,0.00023062759,0.00077551545,0.010145894,0.0052063055,0.000007783461,0.0033610892,0.00030069653],"about_ca_topic_score_codex":0.000075032454,"about_ca_topic_score_gemma":0.0000014811803,"teacher_disagreement_score":0.11851385,"about_ca_system_score_codex":0.00009790905,"about_ca_system_score_gemma":0.00012171101,"threshold_uncertainty_score":0.4039286},"labels":[],"label_agreement":null},{"id":"W3012895697","doi":"10.1186/s13550-020-0594-6","title":"Kinetic modeling of 68Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients","year":2020,"lang":"en","type":"article","venue":"EJNMMI Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; St Joseph's Health Care; Lawson Health Research Institute; Western University","funders":"Siemens Canada; Sociedade Beneficente Israelita Brasileira Albert Einstein; Mitacs","keywords":"Prostate cancer; Medicine; Nuclear medicine; Blood sampling; Positron emission tomography; Glutamate carboxypeptidase II; Magnetic resonance imaging; Prostate; Cancer; Imaging biomarker; Pathology; Radiology; Internal medicine","score_opus":0.24201313271510283,"score_gpt":0.5035799241456935,"score_spread":0.2615667914305907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012895697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274194,0.0009567917,0.0017554788,0.0022266982,0.00002462726,0.0020755993,0.000045667224,0.000008674982,0.0001645276],"genre_scores_gemma":[0.9944454,0.00061600417,0.00432491,0.000022162556,0.000029099694,0.00025677506,0.00016672802,0.000019802867,0.00011915238],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845445,0.0002172691,0.00033156585,0.0002900714,0.0004309226,0.00027574468],"domain_scores_gemma":[0.99863565,0.0002734993,0.000068238856,0.00015286873,0.0007562508,0.00011349149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001187796,0.00008368845,0.00028236283,0.00024570688,0.00004390134,0.000011322669,0.000081814316,0.000050094033,0.000013030272],"category_scores_gemma":[0.00049323094,0.000068311536,0.000036393478,0.00054500846,0.00011218912,0.00007838841,0.00007065442,0.00017369595,8.5229254e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009143764,0.00094662997,0.38276994,0.00801143,0.00014912862,0.000004731664,0.0065167164,0.0018454914,0.47004598,0.00041345894,0.00058403256,0.11956871],"study_design_scores_gemma":[0.013700809,0.0028052393,0.095263086,0.00073146884,0.0000868854,8.1906234e-7,0.00075888465,0.23646158,0.64783084,0.0009667497,0.0011431628,0.00025048724],"about_ca_topic_score_codex":0.00032048774,"about_ca_topic_score_gemma":0.000008865003,"teacher_disagreement_score":0.28750685,"about_ca_system_score_codex":0.00010996277,"about_ca_system_score_gemma":0.00027216368,"threshold_uncertainty_score":0.27856636},"labels":[],"label_agreement":null},{"id":"W3013021092","doi":"10.5489/cuaj.6234","title":"Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model","year":2019,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Health Sciences Centre; Princess Margaret Cancer Centre; Institute for Work & Health; Sunnybrook Health Science Centre","funders":"","keywords":"Docetaxel; Abiraterone; Prostate cancer; Oncology; Internal medicine; Medicine; Abiraterone acetate; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.023799518573076037,"score_gpt":0.2929616711750672,"score_spread":0.26916215260199117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013021092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96883845,0.0007639423,0.0003208948,0.02789655,0.00018950397,0.0012666159,0.00032948767,0.000024249748,0.00037031336],"genre_scores_gemma":[0.9895284,0.00041928422,0.0006898948,0.002869599,0.00016331566,0.00007126929,0.000113429836,0.000021942253,0.006122825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839675,0.00007991425,0.0003072041,0.00024425442,0.0003308269,0.00064102974],"domain_scores_gemma":[0.9983752,0.00011693069,0.0002198863,0.000092425005,0.00062570604,0.0005698989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005416408,0.00016030515,0.00036355623,0.00018836083,0.00023477187,0.00010185454,0.00006835384,0.0001395642,0.00012092976],"category_scores_gemma":[0.00016770401,0.000119705524,0.00015198848,0.00017259641,0.000028412762,0.0001581064,0.000010614085,0.00038682748,0.000059617578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009793349,0.0004760677,0.8284604,0.00017639236,0.0024407622,0.00028359963,0.003098271,0.033102863,0.05077115,0.0006322758,0.0570725,0.013692362],"study_design_scores_gemma":[0.033910803,0.0051775286,0.6435321,0.00013995821,0.0010589182,0.00024978974,0.00046511728,0.26033726,0.0028791376,0.0055997707,0.04568545,0.0009641576],"about_ca_topic_score_codex":0.00059393764,"about_ca_topic_score_gemma":0.0003131681,"teacher_disagreement_score":0.22723441,"about_ca_system_score_codex":0.0020299796,"about_ca_system_score_gemma":0.0011357135,"threshold_uncertainty_score":0.5308326},"labels":[],"label_agreement":null},{"id":"W3013363389","doi":"10.21037/atm.2020.03.78","title":"Biomarkers of response to immune checkpoint inhibitors for metastatic castration resistant prostate cancer: looking for the needle in the haystack","year":2020,"lang":"en","type":"letter","venue":"Annals of Translational Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Haystack; Prostate cancer; Medicine; Immune checkpoint; Immune system; Cancer; Oncology; Cancer research; Cabazitaxel; Immunotherapy; Internal medicine; Immunology","score_opus":0.1261955295419789,"score_gpt":0.4012587495394664,"score_spread":0.2750632199974875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013363389","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008752842,0.009793515,0.00032868548,0.97389317,0.00016726555,0.0059212884,0.0010997871,0.000008282543,0.000035157067],"genre_scores_gemma":[0.7307773,0.002995075,0.0024321822,0.24945985,0.003324144,0.0052790367,0.004335993,0.00020039677,0.0011959851],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99707806,0.0002048204,0.0010848428,0.0003280467,0.0009421504,0.00036205337],"domain_scores_gemma":[0.99578273,0.002878191,0.00037730986,0.00029389342,0.0006010103,0.000066864115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021628842,0.00027448538,0.0007240849,0.00036051782,0.0001026838,0.000010570082,0.00023323004,0.00011691798,0.00003102154],"category_scores_gemma":[0.0006105517,0.00014567249,0.000301496,0.00059347774,0.00031682607,0.00005787954,0.000011320503,0.00042015236,4.6759723e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.118306875,0.0002628653,0.0003348772,0.009273592,0.0031721466,0.0001850402,0.024077553,0.00041744777,0.16796915,0.000078928046,0.66233444,0.01358706],"study_design_scores_gemma":[0.028595677,0.015414613,0.015163117,0.012660874,0.0030229602,0.000037215836,0.006494278,0.0019131905,0.07645611,0.0031904571,0.83627725,0.0007742519],"about_ca_topic_score_codex":0.0004523855,"about_ca_topic_score_gemma":0.00007431623,"teacher_disagreement_score":0.72443336,"about_ca_system_score_codex":0.000048280916,"about_ca_system_score_gemma":0.0006997808,"threshold_uncertainty_score":0.59403515},"labels":[],"label_agreement":null},{"id":"W3013737316","doi":"10.1101/2020.03.27.20044941","title":"Circulating insulin-like growth factor-I, total and free testosterone concentrations and prostate cancer risk in 200,000 men in UK Biobank","year":2020,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Council Victoria; Medical Research Council; Canadian Institutes of Health Research; National Institutes of Health; University of Bristol; National Institute for Health and Care Research; Rosetrees Trust; Pancreatic Cancer UK; European Commission; Prostate Cancer Foundation of Australia; Cancer Research Institute; Royal Marsden NHS Foundation Trust; National Cancer Institute; British Heart Foundation; National Human Genome Research Institute; Wellcome Trust; Prostate Cancer Foundation; University Hospitals Bristol NHS Foundation Trust; National Cancer Research Institute; National Health and Medical Research Council; Cancer Research UK","keywords":"Prostate cancer; Mendelian randomization; Medicine; Hazard ratio; Prospective cohort study; Internal medicine; Sex hormone-binding globulin; Oncology; Testosterone (patch); Proportional hazards model; Cancer; Insulin-like growth factor; Gynecology; Endocrinology; Hormone; Androgen; Biology; Confidence interval; Genotype; Genetics; Genetic variants; Growth factor","score_opus":0.03394604510219879,"score_gpt":0.3044340241734267,"score_spread":0.2704879790712279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013737316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98191607,0.011917336,0.00000684463,0.0031882818,0.00015331079,0.0017154996,0.00066152005,0.00004337296,0.00039774118],"genre_scores_gemma":[0.9855586,0.013380757,0.00020411267,0.00008428075,0.000115728064,0.00030521536,0.00013956941,0.00004036831,0.00017134537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784267,0.00013877517,0.00047339525,0.0007518095,0.00033479647,0.00045856222],"domain_scores_gemma":[0.99903846,0.000120796285,0.0001655165,0.00031984627,0.000081272316,0.0002741232],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022691242,0.00034140685,0.0006033933,0.00022943586,0.000077531164,0.00007434628,0.000118853466,0.00022345368,0.00005991878],"category_scores_gemma":[0.00028053744,0.0002890199,0.000044131924,0.0003066241,0.00019965424,0.00007988552,0.000470311,0.001042336,0.0000023261541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023553552,0.000074218144,0.9892707,0.00042879386,0.00010082536,0.00032128172,0.004014911,0.000023999659,0.0031674288,0.0000061961955,0.0001239215,0.0022322289],"study_design_scores_gemma":[0.0051517035,0.00016752371,0.9901051,0.0007565671,0.000076016244,0.000017016333,0.0002471557,0.001939364,0.0007769332,0.00043607698,0.00005568891,0.00027084077],"about_ca_topic_score_codex":0.005832682,"about_ca_topic_score_gemma":0.0010779373,"teacher_disagreement_score":0.004916168,"about_ca_system_score_codex":0.00031440714,"about_ca_system_score_gemma":0.0003948168,"threshold_uncertainty_score":0.9999562},"labels":[],"label_agreement":null},{"id":"W3014442068","doi":"10.1038/s41379-020-0525-0","title":"Clonal evaluation of prostate cancer molecular heterogeneity in biopsy samples by dual immunohistochemistry and dual RNA in situ hybridization","year":2020,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"U.S. Department of Defense","keywords":"Biopsy; Prostate cancer; Pathology; In situ hybridization; Immunohistochemistry; Cancer; Biology; Prostate; Erg; Fluorescence in situ hybridization; Medicine; Gene expression; Gene; Genetics","score_opus":0.04376199581856844,"score_gpt":0.35606273157434615,"score_spread":0.3123007357557777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014442068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902726,0.007825146,0.00017276505,0.001102943,0.000018926445,0.00044091762,0.00009653725,0.000008953771,0.000061231185],"genre_scores_gemma":[0.9989566,0.00036517752,0.00011950749,0.000099273566,0.000015515137,0.00010824757,0.0003114141,0.000012346613,0.000011919736],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893165,0.00011407738,0.00022338837,0.0002939576,0.00025666962,0.00018025795],"domain_scores_gemma":[0.9996578,0.000014606415,0.0000616116,0.00009996035,0.00010701185,0.000058990117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026800102,0.00010190967,0.00022600136,0.000059195827,0.000016278958,0.000004251909,0.00002758277,0.00008005742,0.000016147354],"category_scores_gemma":[0.00007346302,0.000094971554,0.000023435849,0.00012464105,0.00011421679,0.00003722663,0.000044762633,0.00013294393,6.485623e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004641064,0.000089646805,0.07439041,0.00009988169,0.000020062063,0.00017382705,0.0010442062,0.00021992561,0.9178918,0.0000028860957,0.00001917469,0.005584095],"study_design_scores_gemma":[0.0063276696,0.0002586019,0.09915045,0.00006033433,0.00007490226,0.000083906794,0.00008748723,0.0087230215,0.8848401,0.00024987131,0.000010191212,0.00013350943],"about_ca_topic_score_codex":0.000087959525,"about_ca_topic_score_gemma":0.000023669994,"teacher_disagreement_score":0.033051718,"about_ca_system_score_codex":0.00014897322,"about_ca_system_score_gemma":0.00020476403,"threshold_uncertainty_score":0.38728276},"labels":[],"label_agreement":null},{"id":"W3014539959","doi":"10.1007/s00280-020-04063-7","title":"Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Internal medicine; Oncology; Univariate analysis; Proportional hazards model; Cancer; Discontinuation; Prostate-specific antigen; Chemotherapy; Retrospective cohort study; Urology; Multivariate analysis","score_opus":0.02855337228452725,"score_gpt":0.34417924829541136,"score_spread":0.3156258760108841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014539959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98921573,0.0008021569,0.000002256414,0.007936064,0.00021452531,0.0014762251,0.000107220134,0.00003162657,0.00021421886],"genre_scores_gemma":[0.9888428,0.0018531822,0.000020217896,0.008610724,0.00016764474,0.00019580063,0.00004040523,0.000036584184,0.00023268265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986155,0.00011636002,0.00017186433,0.0004613057,0.00021941318,0.0004155552],"domain_scores_gemma":[0.9993674,0.00008727114,0.00007249714,0.00007941195,0.00013702267,0.00025635425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010453372,0.00027160838,0.00059038674,0.00006895528,0.00006190594,0.000013839251,0.00005026638,0.000059105743,0.0004072363],"category_scores_gemma":[0.0000055440078,0.00018171364,0.000048614347,0.00021118211,0.00017490817,0.00007041117,0.000019368457,0.00037954634,0.0000061914416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15972793,0.00068207824,0.7635693,0.0007526652,0.0017569151,0.00056185044,0.0037707186,0.00016996618,0.035239846,0.000010446986,0.0025306363,0.031227652],"study_design_scores_gemma":[0.09439401,0.011512964,0.64005375,0.00026436665,0.0004751472,0.000007668994,0.000109469656,0.0005942015,0.24858122,0.000017460214,0.0034642725,0.0005254457],"about_ca_topic_score_codex":0.00026737526,"about_ca_topic_score_gemma":0.000038658458,"teacher_disagreement_score":0.21334137,"about_ca_system_score_codex":0.00020771132,"about_ca_system_score_gemma":0.00021035051,"threshold_uncertainty_score":0.7410067},"labels":[],"label_agreement":null},{"id":"W3015056143","doi":"10.1016/j.ebiom.2020.102741","title":"Corrigendum to ‘Roles of alternative RNA splicing of the Bif-1 gene by SRRM4 during the development of treatment-induced neuroendocrine prostate cancer’. [EBioMedicine 31 (2018) 267–275&gt;","year":2020,"lang":"en","type":"erratum","venue":"EBioMedicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Cancer research; Gene; RNA splicing; Alternative splicing; Cancer; Adenocarcinoma; Medicine; Transcriptome; Prostate; RNA; Biology; Gene expression; Exon; Internal medicine; Genetics","score_opus":0.03742654500993162,"score_gpt":0.3143960916835617,"score_spread":0.27696954667363005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015056143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9014984,0.024800945,0.00004443002,0.034792673,0.023848938,0.009722588,0.0019612068,0.0001252059,0.0032056484],"genre_scores_gemma":[0.69130003,0.020152716,0.00035969738,0.0009216723,0.004703885,0.0010399157,0.002139392,0.0004294081,0.27895325],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99408054,0.00015875854,0.0018902881,0.0010265982,0.0018410048,0.0010027969],"domain_scores_gemma":[0.9960933,0.00011587191,0.0014085415,0.0012389069,0.00058932183,0.0005540895],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031138794,0.0009750016,0.0023251001,0.00071505096,0.000265044,0.000012664998,0.0009092101,0.00019669771,0.00013440855],"category_scores_gemma":[0.00015571414,0.00049674395,0.00035668805,0.0019278931,0.00079407776,0.000061195264,0.00052725093,0.00094375876,0.000008638883],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022057479,0.00051284756,0.0016870971,0.002445616,0.0024696905,0.00018956795,0.009599069,0.000003996305,0.7675494,0.000002973697,0.19785386,0.015480154],"study_design_scores_gemma":[0.010335028,0.0049661794,0.0072455187,0.005328951,0.0012258228,0.0000758912,0.0014927825,0.000095634845,0.7693234,0.000010227954,0.19941685,0.0004837078],"about_ca_topic_score_codex":0.0016086645,"about_ca_topic_score_gemma":0.00026714613,"teacher_disagreement_score":0.27574763,"about_ca_system_score_codex":0.001328135,"about_ca_system_score_gemma":0.0028625503,"threshold_uncertainty_score":0.9997484},"labels":[],"label_agreement":null},{"id":"W3015511562","doi":"10.1016/j.annonc.2020.03.309","title":"Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer","year":2020,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; BC Cancer Agency","funders":"U.S. Army Medical Command; National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Prostate cancer; Internal medicine; Regimen; Confidence interval; Oncology; Docetaxel; Prednisone; Cancer; Gynecology","score_opus":0.452501022673367,"score_gpt":0.5787407502072579,"score_spread":0.1262397275338909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015511562","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018932062,0.9924848,6.967555e-7,0.0016382819,0.000084390966,0.0018973032,0.00032196555,0.00000984243,0.0016694875],"genre_scores_gemma":[0.00094875507,0.997005,0.00026551337,0.00012939225,0.000048280002,0.00026617135,0.0001458453,0.000034734014,0.0011563145],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970522,0.0004923871,0.0013183746,0.00041347,0.00036847198,0.00035510346],"domain_scores_gemma":[0.99771374,0.0007094687,0.0007914362,0.00029164486,0.0003003368,0.00019336584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007259169,0.00031234554,0.0038090881,0.0002556249,0.000019136618,0.000004122304,0.00017571084,0.00022948712,0.00015513998],"category_scores_gemma":[0.0001369477,0.00018486867,0.00046477118,0.0005376155,0.0004168941,0.000058183563,0.000085188476,0.0005677083,0.000011802509],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017071132,0.0008577407,0.0040801642,0.012703957,0.002641687,0.0009594505,0.0003696983,9.350337e-7,0.0000026256464,0.000047865753,0.0012034258,0.97542536],"study_design_scores_gemma":[0.0065237577,0.013137987,0.0071238065,0.008239879,0.0028632362,0.00003233277,0.0005524718,0.0000038010571,0.000013693943,0.000048587448,0.961174,0.00028643734],"about_ca_topic_score_codex":0.0005878337,"about_ca_topic_score_gemma":0.00083135086,"teacher_disagreement_score":0.9751389,"about_ca_system_score_codex":0.00016998967,"about_ca_system_score_gemma":0.004257421,"threshold_uncertainty_score":0.7552482},"labels":[],"label_agreement":null},{"id":"W3018861031","doi":"10.1136/bmjopen-2019-035959","title":"[ <sup>18</sup> F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial","year":2020,"lang":"en","type":"article","venue":"BMJ Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; McMaster University; Women's College Hospital; Centre for Probe Development and Commercialization; University of Toronto; University Health Network; Health Sciences Centre; Mount Sinai Hospital","funders":"Astellas Pharma; Terry Fox Research Institute; University of Toronto; Association of Canadian Universities for Research in Astronomy; Princess Margaret Cancer Foundation; Canadian Association of Radiation Oncology","keywords":"Medicine; Ablative case; Prostate cancer; Protocol (science); Clinical trial; Medical physics; Nuclear medicine; Radiation therapy; Cancer; Radiology; Internal medicine; Pathology; Alternative medicine","score_opus":0.2868840061302836,"score_gpt":0.5378987947938053,"score_spread":0.2510147886635217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3018861031","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.054001324,0.00007700023,0.0036252253,0.006473274,0.000087689434,0.93459773,0.00088478986,0.00007429412,0.00017867306],"genre_scores_gemma":[0.02483696,0.000021653052,0.0025666899,0.000584399,0.0003159676,0.9681374,0.00029017736,0.00012465149,0.0031221372],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99648386,0.00018062326,0.00085899857,0.0010151048,0.0005563851,0.0009050183],"domain_scores_gemma":[0.9976423,0.00025810895,0.0003981041,0.00041080278,0.0008679645,0.00042276195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010456484,0.000518411,0.0010787523,0.00012023607,0.0005400028,0.00028425344,0.00043971694,0.00003410876,0.00015664236],"category_scores_gemma":[0.00038855776,0.00035670903,0.00035947558,0.0003746107,0.00009384486,0.0003842819,0.00030149703,0.00022789893,0.000005422759],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92898035,0.0077881827,0.0003441928,0.0013186769,0.0022464094,0.00013703735,0.019504864,0.00046220035,0.0016081427,0.000052997555,0.015192204,0.02236473],"study_design_scores_gemma":[0.7166567,0.1256951,0.000013958236,0.0007211197,0.00031467734,0.00000716943,0.0052492567,0.048378844,0.023780013,0.00063358294,0.077864155,0.00068546244],"about_ca_topic_score_codex":0.00025009637,"about_ca_topic_score_gemma":0.00004456619,"teacher_disagreement_score":0.2123237,"about_ca_system_score_codex":0.00038859877,"about_ca_system_score_gemma":0.0021042349,"threshold_uncertainty_score":0.9998885},"labels":[],"label_agreement":null},{"id":"W3019962442","doi":"10.1016/j.eururo.2020.03.019","title":"Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study","year":2020,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; Pfizer","keywords":"Medicine; Enzalutamide; Placebo; Prostate cancer; Androgen deprivation therapy; Quality of life (healthcare); Internal medicine; Visual analogue scale; Oncology; Urology; Cancer; Physical therapy; Androgen receptor; Pathology","score_opus":0.0378007804806476,"score_gpt":0.34450563072495666,"score_spread":0.30670485024430905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019962442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99331045,0.000649687,0.000009810856,0.0006220759,0.00001284453,0.005253341,0.00008976365,0.0000106637,0.000041361283],"genre_scores_gemma":[0.9994337,0.00013329256,0.0000064032083,0.00024243853,0.0000068248814,0.00006657472,0.00008234243,0.000022303613,0.0000061224287],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9922708,0.006032855,0.0008172764,0.00030854286,0.00036951984,0.00020094965],"domain_scores_gemma":[0.99802446,0.00073323067,0.00068209367,0.00028647092,0.00015403732,0.0001196894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020555141,0.00017669397,0.0014564416,0.00023367608,0.000036705813,0.000002837482,0.000111755784,0.00002116043,0.000009080412],"category_scores_gemma":[0.00049674214,0.00009285835,0.00015283238,0.0007217696,0.0001787608,0.00003356677,0.00003417504,0.00019806263,6.3569325e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6476379,0.0011640163,0.32997242,0.00006325176,0.0037454043,0.0000135200635,0.009580915,0.003181521,0.0009101248,0.0000018603994,0.000002816681,0.0037262745],"study_design_scores_gemma":[0.42136782,0.031869967,0.54237366,0.00001710373,0.0008984303,1.8504957e-7,0.0002392758,0.0016370107,0.0015286267,0.0000010752451,0.000001249221,0.000065623266],"about_ca_topic_score_codex":0.0006595613,"about_ca_topic_score_gemma":0.0001049575,"teacher_disagreement_score":0.22627006,"about_ca_system_score_codex":0.00006603735,"about_ca_system_score_gemma":0.00019665353,"threshold_uncertainty_score":0.37866536},"labels":[],"label_agreement":null},{"id":"W3020273460","doi":"10.3390/cancers12051078","title":"Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Univariate analysis; Oncology; Logistic regression; Internal medicine; Radionuclide therapy; Prostate; Urology; Prostate-specific antigen; Statistical significance; Cancer; Multivariate analysis","score_opus":0.061319482152275756,"score_gpt":0.36716681962280917,"score_spread":0.3058473374705334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020273460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810011,0.0011197453,0.000041448493,0.012944957,0.00008964951,0.0032052738,0.00039946756,0.00011024575,0.0010881575],"genre_scores_gemma":[0.9905871,0.0009771746,0.0012608044,0.0011390913,0.00015239479,0.0013283668,0.00016255691,0.0000953836,0.004297132],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966795,0.00042631346,0.00062888605,0.0008470535,0.0006475473,0.0007706989],"domain_scores_gemma":[0.99793077,0.0004232521,0.00020154411,0.00037242606,0.00026026004,0.0008117453],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006321897,0.00043532628,0.0009108781,0.00018559919,0.00016264911,0.0000698727,0.00015204941,0.000098454606,0.00020048005],"category_scores_gemma":[0.00028113602,0.00028152467,0.00010705494,0.0011533118,0.00024087734,0.00015560475,0.000033981698,0.0003365012,0.000020893389],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.48585242,0.0015777659,0.35821983,0.0006931448,0.0088188825,0.011489217,0.034130424,0.027173186,0.03297136,0.000098293596,0.019134106,0.019841367],"study_design_scores_gemma":[0.1741487,0.0764432,0.5689464,0.0060643866,0.0048009404,0.0001245807,0.014556635,0.0102291815,0.029201107,0.00006441223,0.112018645,0.0034018056],"about_ca_topic_score_codex":0.0030320704,"about_ca_topic_score_gemma":0.004392245,"teacher_disagreement_score":0.31170374,"about_ca_system_score_codex":0.0053266874,"about_ca_system_score_gemma":0.0059533995,"threshold_uncertainty_score":0.9999637},"labels":[],"label_agreement":null},{"id":"W3020771563","doi":"10.1056/nejmoa1911440","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2237,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"Daiichi Sankyo Europe; Janssen Pharmaceuticals; Janssen Biotech; Foundation Medicine; Pharmacyclics; Genentech; Astellas Pharma Europe; Tulane University; Eisai; Astellas Pharma; Merck Sharp and Dohme; Radboud Universitair Medisch Centrum; EMD Serono; Radboud Universiteit; AstraZeneca; Invitae; Massachusetts Medical Society; Bayer HealthCare; Sanofi; Exelixis; Pfizer; Northwestern University; Ipsen; Clovis Oncology; F. Hoffmann-La Roche; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Olaparib; Poly ADP ribose polymerase; Prostate cancer; Homologous recombination; PARP inhibitor; DNA repair; Cancer research; Polymerase; DNA Damage Repair; Medicine; Prostate; Gene; Oncology; Cancer; Biology; Internal medicine; Genetics","score_opus":0.08227651790290585,"score_gpt":0.3739222685155358,"score_spread":0.29164575061262993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020771563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5912037,0.030760532,0.0022500053,0.37171328,0.0009862743,0.001833488,0.0000788137,0.000036489804,0.0011374326],"genre_scores_gemma":[0.98829514,0.0019465359,0.0017821159,0.0018464379,0.0044902307,0.00001537556,0.000025482785,0.000023872662,0.001574816],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998675,0.000038997732,0.00046586475,0.00012673548,0.00047290447,0.00022052295],"domain_scores_gemma":[0.99856675,0.00016339077,0.00022360773,0.000077791636,0.00040530897,0.00056318374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041628638,0.00013131893,0.00048864144,0.00009511055,0.000052251304,0.000011383007,0.00007697504,0.000025482994,0.00029603567],"category_scores_gemma":[0.00041033793,0.00007283769,0.00008588454,0.00018884042,0.00007932053,0.00008903853,0.000008679816,0.00023435049,0.000002530891],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05067164,0.00028610622,0.007623261,0.0013944271,0.0020017612,0.0019855236,0.014797289,0.00018796968,0.32627594,0.00043262597,0.18125619,0.41308728],"study_design_scores_gemma":[0.3731359,0.025253689,0.008925302,0.001714187,0.0024053717,0.0008562497,0.0018119811,0.0007323483,0.017201077,0.0013369481,0.5663215,0.00030547855],"about_ca_topic_score_codex":0.00008663678,"about_ca_topic_score_gemma":0.00003091413,"teacher_disagreement_score":0.41278177,"about_ca_system_score_codex":0.000073357034,"about_ca_system_score_gemma":0.0007466218,"threshold_uncertainty_score":0.32413828},"labels":[],"label_agreement":null},{"id":"W3020822565","doi":"","title":"Testosterone Replacement Therapy Following the Diagnosis of Prostate Cancer: Outcomes and Utilization Trends: Kaplan AL, Trinh Q-D, Sun M, et al (David Geffen School of Medicine at UCLA; Brigham and Women's Hosp, Boston, MA, USA; Univ of Montreal Health Centre, Quebec, Canada; et al) J Sex Med 2014 [Epub ahead of print] §","year":2014,"lang":"en","type":"article","venue":"Yearbook of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Gerontology; Testosterone (patch); Gynecology; Cancer; Family medicine; Oncology; Internal medicine","score_opus":0.021655395081254976,"score_gpt":0.31807864406432174,"score_spread":0.29642324898306677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020822565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9085102,0.008116237,0.0000036883175,0.082149856,0.00007169475,0.000876096,0.00009212672,0.0000075024936,0.00017259672],"genre_scores_gemma":[0.9754696,0.017343914,0.000026770032,0.005359229,0.000010658241,0.00007428967,0.00008297464,0.000027143926,0.0016054437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976004,0.00044742375,0.0007364543,0.0003530799,0.0004787408,0.00038389646],"domain_scores_gemma":[0.99805415,0.00058402924,0.00061639404,0.00040004126,0.00014147825,0.00020389319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010661742,0.00022609011,0.0010425249,0.00020474823,0.000044956647,0.0000024481665,0.000118830714,0.00006754159,0.00014806783],"category_scores_gemma":[0.00013484721,0.00014472062,0.00005749281,0.0001484655,0.00047514428,0.00005190943,0.00009436614,0.00016432519,1.9018282e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031844464,0.00022972209,0.95189136,0.00020838276,0.00057348993,0.000006096323,0.0028411879,0.000010457538,0.001848917,0.0000432668,0.02588065,0.013282028],"study_design_scores_gemma":[0.016469074,0.004598844,0.9268718,0.00025695417,0.0001280003,0.0000063594675,0.00039276856,0.00010725037,0.0066302484,0.000033466837,0.04436473,0.00014053362],"about_ca_topic_score_codex":0.39877808,"about_ca_topic_score_gemma":0.34039336,"teacher_disagreement_score":0.07679063,"about_ca_system_score_codex":0.00023264422,"about_ca_system_score_gemma":0.00067485817,"threshold_uncertainty_score":0.6716428},"labels":[],"label_agreement":null},{"id":"W3021475632","doi":"10.1016/j.ijrobp.2006.07.730","title":"2322","year":2006,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Prostate cancer; Pelvis; Prostatectomy; Abdomen; Prostate; Radiation therapy; Retrospective cohort study; Hormonal therapy; Urology; Nuclear medicine; Cancer; Surgery; Internal medicine","score_opus":0.025250728244025692,"score_gpt":0.36658756585492,"score_spread":0.3413368376108943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021475632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95367104,0.0027863819,0.0077524344,0.016239,0.0038218987,0.00035321424,0.000070084905,0.00006729509,0.015238646],"genre_scores_gemma":[0.9914264,0.0006736529,0.0017907951,0.00064240827,0.0044952626,0.000007719512,0.00014200874,0.000019994151,0.0008017469],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987727,0.00009289835,0.00048857555,0.0001462605,0.00029518895,0.00020441586],"domain_scores_gemma":[0.9984133,0.00017158205,0.00046686534,0.00010202966,0.0007491936,0.000096986114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031909443,0.00012737786,0.00031332538,0.00015714928,0.000053254105,0.000020954134,0.00021940311,0.0001537929,0.00014842587],"category_scores_gemma":[0.00009606101,0.00009865072,0.00019763563,0.00013457338,0.00015614982,0.00017428093,0.00003708528,0.00035205905,0.00006820719],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012044177,0.0011117157,0.70047736,0.000011857588,0.0008268979,0.0002935711,0.00018844547,0.00027311803,0.016641041,0.024440913,0.01865638,0.2358743],"study_design_scores_gemma":[0.028898492,0.004338505,0.21481614,0.00013917785,0.00036316068,0.0011624648,0.00013360953,0.0018259265,0.033871055,0.07564039,0.63838243,0.00042866965],"about_ca_topic_score_codex":0.000033478835,"about_ca_topic_score_gemma":0.0000031271456,"teacher_disagreement_score":0.619726,"about_ca_system_score_codex":0.00076438213,"about_ca_system_score_gemma":0.00060554116,"threshold_uncertainty_score":0.40228596},"labels":[],"label_agreement":null},{"id":"W3021588578","doi":"10.1097/ju.0000000000000954.010","title":"PD52-10 CLINICAL SIGNIFICANCE OF THE LACDINAC-GLYCOSYLATED PROSTATE-SPECIFIC ANTIGEN ASSAY FOR PROSTATE CANCER DETECTION","year":2020,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Cancer; Prostate; Internal medicine","score_opus":0.06865771004272075,"score_gpt":0.3641853003240304,"score_spread":0.29552759028130965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021588578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9533686,0.004959891,0.00040236287,0.039186634,0.00053232774,0.0013905838,0.000038566388,0.000012880013,0.00010814027],"genre_scores_gemma":[0.99296874,0.005276683,0.000053241947,0.0006294599,0.00045779577,0.000024691017,0.000002551235,0.000024615458,0.0005622404],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980781,0.00047135766,0.0006897552,0.00015787961,0.0003045446,0.00029837398],"domain_scores_gemma":[0.99796957,0.00049123704,0.00061396434,0.00020957032,0.00057794515,0.00013773327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015362705,0.00013449424,0.00045143306,0.000054046028,0.00012171317,0.00000840138,0.0002665493,0.000115938725,0.000110495916],"category_scores_gemma":[0.00033756145,0.00006403192,0.00022792982,0.00031065554,0.00036780082,0.000058279977,0.00005422444,0.000588399,0.000006996945],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14599535,0.000763431,0.0922243,0.00039220226,0.0017811059,0.00010931262,0.0051742536,0.0009826003,0.6150407,0.00004955275,0.02614289,0.11134428],"study_design_scores_gemma":[0.026952881,0.035496447,0.21273103,0.00022021687,0.0014874054,0.00036362387,0.00094581547,0.004178602,0.28430712,0.0010745722,0.4318129,0.0004293685],"about_ca_topic_score_codex":0.000022059481,"about_ca_topic_score_gemma":0.000017958499,"teacher_disagreement_score":0.40567002,"about_ca_system_score_codex":0.000067714886,"about_ca_system_score_gemma":0.00042023923,"threshold_uncertainty_score":0.2611146},"labels":[],"label_agreement":null},{"id":"W3021678061","doi":"10.1097/ju.0000000000000915.018","title":"MP53-18 PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY FOR THE IDENTIFICATION OF INTRA-PROSTATIC TUMORS: INVESTIGATING DELINEATION GUIDELINES FOR FOCAL THERAPY AND GUIDED BIOPSY","year":2020,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Positron emission tomography; Prostate cancer; Prostatectomy; Biopsy; Concordance; Glutamate carboxypeptidase II; Prostate-specific antigen; Radiology; Nuclear medicine; Cancer; Internal medicine","score_opus":0.1463956803404449,"score_gpt":0.38281098537370817,"score_spread":0.23641530503326327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021678061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8975901,0.010399864,0.01869328,0.071642496,0.000100698984,0.0015353368,0.000024265717,0.000010103107,0.0000038787243],"genre_scores_gemma":[0.9875582,0.006174824,0.00447348,0.0011976489,0.00044945301,0.000035637782,0.000032674772,0.000025561556,0.000052509382],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984589,0.00012342003,0.0008783909,0.00012964764,0.00022424594,0.00018540234],"domain_scores_gemma":[0.9975842,0.00048956135,0.0006357649,0.00013802989,0.0010553134,0.00009710269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015198494,0.00012273698,0.0002990004,0.00010203,0.00015721904,0.000019810024,0.00014979126,0.000054621778,0.0000070772317],"category_scores_gemma":[0.0006787524,0.000059828326,0.000106404455,0.00021864234,0.00023686048,0.00008150671,0.000021489437,0.0001543538,2.5724563e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055332864,0.00005332559,0.0030584745,0.00016231714,0.00023138733,0.0000032253713,0.0022579394,0.00020698151,0.96327734,0.00004613138,0.004182821,0.020986749],"study_design_scores_gemma":[0.015769327,0.010747913,0.019459901,0.00028632855,0.0007546653,0.0006562454,0.002266167,0.06869552,0.86934704,0.0046165017,0.007142001,0.00025837478],"about_ca_topic_score_codex":0.000007533945,"about_ca_topic_score_gemma":4.6405887e-7,"teacher_disagreement_score":0.09393031,"about_ca_system_score_codex":0.000016763577,"about_ca_system_score_gemma":0.00012698598,"threshold_uncertainty_score":0.24397284},"labels":[],"label_agreement":null},{"id":"W3022873668","doi":"10.1097/ju.0000000000000847.010","title":"PD13-10 THE PREVALENCE OF CARDIOVASCULAR DISEASE AND ITS RISK FACTORS AMONG PROSTATE CANCER PATIENTS TREATED WITH AND WITHOUT ANDROGEN DEPRIVATION","year":2020,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Chin; Medicine; Disease; Cancer; Classics; Gerontology; History; Pathology; Internal medicine; Anatomy","score_opus":0.018432347769329147,"score_gpt":0.2609863819417641,"score_spread":0.24255403417243496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022873668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98233837,0.01629252,0.0000053383255,0.00087451853,0.000009986473,0.00043614072,0.00003320326,0.0000031466893,0.000006750165],"genre_scores_gemma":[0.9841395,0.015724186,0.0000023625923,0.000038562044,0.000029396511,0.000005448336,0.0000022424895,0.000008953207,0.00004932429],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992012,0.00019244646,0.00015753314,0.000091903385,0.00024215943,0.000114777366],"domain_scores_gemma":[0.99931335,0.000058264875,0.0001873977,0.00009990437,0.00020665306,0.00013442691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002170438,0.000086777945,0.00021857391,0.00003138325,0.00007005262,0.0000050396347,0.00006623936,0.00002530158,0.00001551561],"category_scores_gemma":[0.00009121609,0.000034791654,0.00004469965,0.00009597263,0.00017529678,0.0000681511,0.00003239385,0.00016718474,2.1856304e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042564,0.00003273152,0.9921096,0.000110806206,0.0010438414,0.000009090394,0.0013169153,0.00021934352,0.00014955657,4.5534526e-7,0.000016273976,0.00073498546],"study_design_scores_gemma":[0.0028361971,0.0016951781,0.99083126,0.00003625169,0.00262097,0.000012393846,0.0000562232,0.00052258465,0.0012144143,0.000008067475,0.00012768111,0.000038775746],"about_ca_topic_score_codex":0.00006135521,"about_ca_topic_score_gemma":0.0000026906819,"teacher_disagreement_score":0.001801129,"about_ca_system_score_codex":0.000015031669,"about_ca_system_score_gemma":0.00007205259,"threshold_uncertainty_score":0.14187625},"labels":[],"label_agreement":null},{"id":"W3023470648","doi":"10.1007/s00432-020-03221-x","title":"Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication","year":2020,"lang":"en","type":"article","venue":"Journal of Cancer Research and Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Rockyview General Hospital; Alberta Health Services; Ontario Institute for Cancer Research; Alberta Bible College; Calgary Laboratory Services; University of Alberta; University of Calgary","funders":"Prostate Cancer Canada; Calgary Laboratory Services; Prostate Cancer Foundation","keywords":"PTEN; Erg; Prostate cancer; Population; Medicine; Incidence (geometry); Internal medicine; Cohort; Immunohistochemistry; Oncology; Cancer; Pathology; Biology; Genetics; Ophthalmology; Apoptosis; PI3K/AKT/mTOR pathway","score_opus":0.1836796043653658,"score_gpt":0.4859548952238305,"score_spread":0.3022752908584647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023470648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975312,0.00083349814,0.000046390738,0.023017772,0.000038820952,0.00070575177,0.000016734155,0.00000426934,0.000024745288],"genre_scores_gemma":[0.9953269,0.0041455408,0.00009225731,0.00009555997,0.00016092307,0.00006971294,0.00002228965,0.000013608879,0.000073245275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810696,0.00023610056,0.0006607843,0.00021148163,0.0005434949,0.00024116275],"domain_scores_gemma":[0.9982758,0.00016150874,0.00041876128,0.00008615313,0.00076949765,0.00028823325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045629535,0.00009906087,0.00051591836,0.00017662035,0.00004402488,0.00001927392,0.00008566718,0.000099865974,0.000019098989],"category_scores_gemma":[0.0000900274,0.000056991605,0.000040545703,0.00043339987,0.00023778445,0.00015912818,0.00003143673,0.0004734387,6.2644295e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0083735725,0.00039549122,0.96883553,0.00015897778,0.00013695235,0.00009720738,0.00035810037,0.000011990841,0.0045782416,0.000053605803,0.00000338394,0.016996915],"study_design_scores_gemma":[0.0044874283,0.011524002,0.9816696,0.0006078675,0.00009500542,0.000015812717,0.00009609425,0.00019302509,0.00097606657,0.00008979575,0.00018507092,0.00006022102],"about_ca_topic_score_codex":0.000408612,"about_ca_topic_score_gemma":0.0010719215,"teacher_disagreement_score":0.022922212,"about_ca_system_score_codex":0.00015785874,"about_ca_system_score_gemma":0.0008414899,"threshold_uncertainty_score":0.232405},"labels":[],"label_agreement":null},{"id":"W3023564249","doi":"10.1097/ju.0000000000000939.03","title":"MP64-03 CONTEMPORARY POPULATION-BASED ANALYSIS OF BONE MINERAL DENSITY TESTING IN MEN INITIATING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER","year":2020,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Bone mineral; Cohort; Internal medicine; Oncology; Population; Cancer; Logistic regression; Gynecology; Osteoporosis; Gerontology; Environmental health","score_opus":0.08942290690353445,"score_gpt":0.3507237455945976,"score_spread":0.2613008386910632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023564249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893315,0.0018256288,0.00017817892,0.00823875,0.000016163322,0.00036052786,0.000012484369,0.000003999195,0.000032800694],"genre_scores_gemma":[0.99860185,0.00011619604,0.0003286291,0.0008312762,0.00007033185,0.000008787879,0.000029730734,0.000008128025,0.0000050788362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990901,0.00014000112,0.00042351562,0.00007401301,0.00015093306,0.00012145875],"domain_scores_gemma":[0.9987523,0.000432566,0.00041323612,0.000065121734,0.00028561847,0.000051146395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060925155,0.00006878548,0.00037726967,0.00020238162,0.000039496186,0.0000035521616,0.00005230585,0.000039000926,0.0000103795],"category_scores_gemma":[0.00031052058,0.000041977197,0.00008318292,0.0005156235,0.00003599976,0.00005017655,0.000010992266,0.00014326356,1.1346702e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055726497,0.000057876914,0.9630629,0.00002789017,0.00053899287,0.000022240654,0.0009290848,0.004393847,0.022814792,0.000002234476,0.000053331456,0.0025241561],"study_design_scores_gemma":[0.0062739514,0.00160741,0.9321958,0.000026550799,0.00054246275,0.000012241275,0.00012667758,0.054782536,0.0042477595,0.00010194282,0.000029504277,0.00005317333],"about_ca_topic_score_codex":0.00034001996,"about_ca_topic_score_gemma":0.000050109084,"teacher_disagreement_score":0.050388686,"about_ca_system_score_codex":0.00004752064,"about_ca_system_score_gemma":0.00024976901,"threshold_uncertainty_score":0.17117804},"labels":[],"label_agreement":null},{"id":"W3023810398","doi":"10.1158/1078-0432.ccr-19-3402","title":"Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université du Québec; BC Cancer Agency","funders":"Janssen Research and Development; Cancer Research UK","keywords":"Abiraterone acetate; Prednisone; Prostate cancer; Medicine; Pharmacokinetics; Pharmacology; Adverse effect; Enzalutamide; Internal medicine; Antiandrogen; Cancer; Urology; Oncology; Androgen receptor; Androgen deprivation therapy","score_opus":0.17911497121785097,"score_gpt":0.5338944760008876,"score_spread":0.3547795047830366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023810398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98197186,0.0064349845,0.000008259477,0.0054146117,0.000070847454,0.0057102004,0.00027312557,0.000031837877,0.00008430167],"genre_scores_gemma":[0.98786694,0.010534868,0.00008084598,0.00009473047,0.00015964606,0.00073159544,0.00003811997,0.000058237085,0.00043504525],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99476683,0.0012367662,0.0010613521,0.00088019995,0.0012778342,0.0007770219],"domain_scores_gemma":[0.9974846,0.0008511619,0.00018137375,0.00034831025,0.0004834831,0.0006510264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003037877,0.00031338123,0.0012490244,0.0002361131,0.00013594877,0.000060048536,0.00022456818,0.00006565214,0.00021402426],"category_scores_gemma":[0.00039692863,0.0002063354,0.00008488099,0.0011019949,0.0009820511,0.00014735061,0.00020058115,0.0010950359,0.000008869347],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34593496,0.0033429426,0.52861303,0.0045156474,0.0017254906,0.003390483,0.0053236894,0.00056843285,0.04458682,0.000010038604,0.0006449842,0.061343465],"study_design_scores_gemma":[0.37360084,0.14718914,0.37110233,0.002757542,0.0018450489,0.000034486024,0.0030054683,0.011104197,0.08574064,0.000036514804,0.0025557384,0.001028052],"about_ca_topic_score_codex":0.0023299714,"about_ca_topic_score_gemma":0.0013053444,"teacher_disagreement_score":0.1575107,"about_ca_system_score_codex":0.000307986,"about_ca_system_score_gemma":0.0014692751,"threshold_uncertainty_score":0.84141135},"labels":[],"label_agreement":null},{"id":"W3023828971","doi":"10.1016/j.ijrobp.2006.07.091","title":"61","year":2006,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Radiation therapy; Clinical endpoint; Prostate cancer; Prospective cohort study; Toxicity; Cohort; Internal medicine; Surgery; Clinical trial; Cancer","score_opus":0.025028601646147206,"score_gpt":0.36714818589373815,"score_spread":0.3421195842475909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023828971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9597989,0.0025370077,0.0069395667,0.014751125,0.0034399778,0.00032080547,0.000062754254,0.000061142484,0.012088766],"genre_scores_gemma":[0.99180794,0.00054079597,0.0017419949,0.00062558765,0.00434292,0.000007297964,0.00013178491,0.000019305495,0.00078237755],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99879533,0.000090186135,0.00048191065,0.00014356906,0.00028827495,0.00020075812],"domain_scores_gemma":[0.9984318,0.00016958106,0.00045888868,0.00010007736,0.0007438818,0.000095784395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031070976,0.000125471,0.00030918003,0.00015431011,0.000068755646,0.000028331113,0.00021450043,0.00015318123,0.00013811859],"category_scores_gemma":[0.00009536378,0.000096850716,0.00019424333,0.00013154624,0.00019362255,0.00017118575,0.0000362025,0.0003446243,0.00006771948],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011276294,0.001040129,0.71593165,0.000011232287,0.0007820623,0.0002657161,0.00024294309,0.00023337985,0.015428192,0.022307001,0.015324733,0.22730532],"study_design_scores_gemma":[0.027946852,0.0041640964,0.20995955,0.00013797473,0.00035041253,0.0010789265,0.00014926303,0.0016922652,0.03596712,0.07301701,0.6451251,0.0004114652],"about_ca_topic_score_codex":0.000040150226,"about_ca_topic_score_gemma":0.0000035938394,"teacher_disagreement_score":0.6298003,"about_ca_system_score_codex":0.0007499072,"about_ca_system_score_gemma":0.00076948607,"threshold_uncertainty_score":0.39494574},"labels":[],"label_agreement":null},{"id":"W3023967508","doi":"10.2967/jnumed.120.246983","title":"The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study","year":2020,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation; University of British Columbia; Spinal Cord Injury BC; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Prostate cancer; Prostate; Placebo; Urology; Kidney; Nuclear medicine; Monosodium glutamate; Glutamate carboxypeptidase II; Internal medicine; Cancer; Pathology","score_opus":0.019247042679275652,"score_gpt":0.31549287041846535,"score_spread":0.2962458277391897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023967508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9439308,0.0074022356,0.0000031529116,0.038884625,0.00026821592,0.008257143,0.0000030128724,0.000018439416,0.0012323719],"genre_scores_gemma":[0.9948799,0.003934137,0.00004368542,0.00029711932,0.0004885362,0.00019213416,0.0000015538529,0.000050228286,0.00011270438],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996682,0.00036008543,0.0010631116,0.0002793781,0.0012086893,0.00040676605],"domain_scores_gemma":[0.9975731,0.00073250174,0.00078104297,0.00019820835,0.00038809804,0.00032706233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020660462,0.0003036837,0.001760759,0.00028940025,0.00011962566,0.00003348817,0.00022973545,0.000045862373,0.000047529214],"category_scores_gemma":[0.00063428667,0.0001334746,0.00017769061,0.0004740151,0.00042628957,0.00012208616,0.000043414526,0.0008874042,0.000002653862],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9545242,0.00073373626,0.007975734,0.00025843238,0.0016975347,0.0009069857,0.020488441,0.000033870667,0.001084095,0.000033514763,0.0015383383,0.010725075],"study_design_scores_gemma":[0.9685428,0.012989942,0.0077114734,0.0019692173,0.0012025348,0.00008495394,0.005582496,0.00090767856,0.00027861618,0.000027571677,0.00057081593,0.00013190138],"about_ca_topic_score_codex":0.00006598961,"about_ca_topic_score_gemma":0.00001411516,"teacher_disagreement_score":0.050949097,"about_ca_system_score_codex":0.0002880917,"about_ca_system_score_gemma":0.00033868873,"threshold_uncertainty_score":0.54429364},"labels":[],"label_agreement":null},{"id":"W3024368357","doi":"10.1038/s41391-020-0236-0","title":"Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer","year":2020,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Bayer","keywords":"Enzalutamide; Medicine; Prednisone; Prostate cancer; Abiraterone; Internal medicine; Oncology; Abiraterone acetate; Urology; Cancer; Surgery; Androgen deprivation therapy","score_opus":0.06797416319239474,"score_gpt":0.38368940349988756,"score_spread":0.3157152403074928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024368357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818233,0.0045513455,0.0000049890614,0.0033133933,0.00009447286,0.0062168026,0.0038596771,0.000097280754,0.000038690006],"genre_scores_gemma":[0.97750396,0.015639108,0.0003092464,0.00067946984,0.00006556537,0.002735058,0.0004913293,0.00010648093,0.0024697902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99633723,0.00018721026,0.00089723704,0.0010989578,0.00066215935,0.0008172281],"domain_scores_gemma":[0.9977262,0.0003414143,0.00032365546,0.00029065192,0.000281425,0.0010366746],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013569318,0.000707206,0.0013262691,0.00018241392,0.00020905203,0.00020345992,0.00009825373,0.000055026347,0.00018860806],"category_scores_gemma":[0.000067045454,0.00035966816,0.00008468156,0.000602442,0.00059103407,0.0003829069,0.000067211105,0.00025313944,0.000003761312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049844682,0.0013356099,0.8920073,0.0014056807,0.000984966,0.00048905,0.003249353,0.000031882028,0.000034831406,0.0000111259105,0.00017549185,0.050430026],"study_design_scores_gemma":[0.056322977,0.014541035,0.9230776,0.0010318002,0.0013730347,0.000006177676,0.0011100277,0.00030020566,0.00024046811,0.000023878361,0.001303564,0.00066926115],"about_ca_topic_score_codex":0.0019802232,"about_ca_topic_score_gemma":0.005337178,"teacher_disagreement_score":0.049760766,"about_ca_system_score_codex":0.00041866294,"about_ca_system_score_gemma":0.0020387268,"threshold_uncertainty_score":0.9998855},"labels":[],"label_agreement":null},{"id":"W3024540226","doi":"10.1016/j.ijrobp.2018.07.091","title":"Dosimetric Evaluation of PSMA PET-Delineated Dominant Intra-Prostatic Lesion Simultaneous In-Field Boosts","year":2018,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; University of Waterloo; Western University; Cancer Care Ontario","funders":"","keywords":"Medicine; Prostate cancer; Voxel; Prostate; Nuclear medicine; Lesion; Biopsy; Radiation treatment planning; Radiology; Cancer; Radiation therapy; Pathology; Internal medicine","score_opus":0.04659771956978382,"score_gpt":0.41277058836090985,"score_spread":0.36617286879112604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024540226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99204504,0.0009038819,0.0024667627,0.0021794513,0.0013858984,0.00050338835,0.00002518804,0.000011909359,0.00047848458],"genre_scores_gemma":[0.9961933,0.00091731973,0.0011953219,0.00034105458,0.0011783792,0.000012514337,0.00008731775,0.000019834368,0.00005498527],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99759585,0.00034456133,0.00091854774,0.00021811404,0.0006802262,0.00024267875],"domain_scores_gemma":[0.9948234,0.0008956716,0.0008627544,0.00014836906,0.0031582068,0.00011157399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001505503,0.0001701862,0.00047757928,0.0005405385,0.00004884357,0.000014577793,0.00024732543,0.00016937808,0.00016037222],"category_scores_gemma":[0.0022013474,0.00013234428,0.00014304798,0.0005008575,0.00020331984,0.00018421734,0.000050634368,0.0003906415,0.000031578562],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046318583,0.0012741933,0.21545883,0.000031727996,0.0006243236,0.000220643,0.00096462603,0.00084601116,0.050223958,0.00056322356,0.00066028215,0.7245003],"study_design_scores_gemma":[0.08740849,0.029479306,0.09425328,0.001053478,0.0014059672,0.001512878,0.0007035961,0.30302238,0.4516251,0.020905776,0.007837473,0.0007922529],"about_ca_topic_score_codex":0.000054794193,"about_ca_topic_score_gemma":0.000016495631,"teacher_disagreement_score":0.7237081,"about_ca_system_score_codex":0.0011934247,"about_ca_system_score_gemma":0.0011873195,"threshold_uncertainty_score":0.53968436},"labels":[],"label_agreement":null},{"id":"W3024601170","doi":"10.1073/pnas.1922207117","title":"Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance","year":2020,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Comprehensive Cancer Center, University of Michigan; U.S. Department of Defense; Stand Up To Cancer; Janssen Biotech; Astellas Pharma; University of Michigan","keywords":"Enzalutamide; Androgen receptor; Prostate cancer; Cancer research; Medicine; Androgen; Clinical trial; Oncology; Internal medicine; Biology; Cancer; Hormone","score_opus":0.0817403547864206,"score_gpt":0.3537562617956614,"score_spread":0.2720159070092408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024601170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99035305,0.00020295639,6.464585e-7,0.007507516,0.000008976004,0.00068821653,0.000047998015,0.000036862457,0.0011537866],"genre_scores_gemma":[0.9983512,0.00003072916,0.0009868973,0.00012342942,0.000069133246,0.00006527144,0.0000023553532,0.000007129683,0.000363817],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976602,0.000013607564,0.00021489318,0.0002980343,0.0016249146,0.00018831016],"domain_scores_gemma":[0.9990686,0.000059181337,0.0002489727,0.000007878697,0.00052444875,0.00009090655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007409038,0.00010506005,0.00020716016,0.00008753345,0.00021933524,0.00003860203,0.00033237715,0.000070876835,0.000015518963],"category_scores_gemma":[0.0003115949,0.00006166028,0.00006439074,0.00095625495,0.0008253661,0.00059722515,0.0000355405,0.00020781893,6.2661957e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008242722,0.0003215813,0.024985401,0.00039165028,0.000108476735,6.89406e-8,0.00066224847,0.000013992936,0.96935,0.002636549,0.0001745246,0.00053122855],"study_design_scores_gemma":[0.0010080513,0.0003650904,0.08076938,0.00046806535,0.00004636959,0.000002732905,0.0004935028,0.0005105226,0.91490614,0.0012227267,0.00010939404,0.000097999364],"about_ca_topic_score_codex":0.0000018148404,"about_ca_topic_score_gemma":2.8604774e-7,"teacher_disagreement_score":0.05578398,"about_ca_system_score_codex":0.00007277927,"about_ca_system_score_gemma":0.000150443,"threshold_uncertainty_score":0.3041096},"labels":[],"label_agreement":null},{"id":"W3025668491","doi":"10.1016/j.neo.2020.04.002","title":"Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4","year":2020,"lang":"en","type":"article","venue":"Neoplasia","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Biotech; Canadian Institutes of Health Research; Astellas Pharma Global Development; Lucas Foundation; U.S. Department of Defense; Gilead Sciences; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation; Institute for Prostate Cancer Research; Bayer Corporation","keywords":"Prostate cancer; Prostate; RNA splicing; Alternative splicing; Cancer; Cancer research; Biology; Immunohistochemistry; Oncology; Internal medicine; Medicine; Computational biology; Bioinformatics; Gene; Genetics; Exon","score_opus":0.024286652372565855,"score_gpt":0.32071356774352305,"score_spread":0.2964269153709572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025668491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739183,0.0013999643,0.0000044087487,0.022427239,0.00007744605,0.00062050024,0.00018896491,0.000034014523,0.0013291471],"genre_scores_gemma":[0.9940455,0.0028565447,0.000028655,0.0016257615,0.000081219325,0.00006742459,0.000075427866,0.00002886493,0.0011905889],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987457,0.000033790388,0.00025703514,0.0003050427,0.00033175308,0.00032671672],"domain_scores_gemma":[0.9994501,0.000059525926,0.00008027992,0.0001315739,0.00008231733,0.00019620812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000038425915,0.00015006226,0.0003343144,0.000086539396,0.000022514632,0.0000080237505,0.00009145585,0.000025594254,0.00030592736],"category_scores_gemma":[0.00005934886,0.00011864922,0.00005025087,0.00043086498,0.00007100357,0.00006928038,0.00005571013,0.00025899304,0.00003390858],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004127549,0.0004108905,0.5856851,0.0008224139,0.00033199825,0.001681146,0.011175815,0.0000960927,0.3363027,0.000038515587,0.04153493,0.017792892],"study_design_scores_gemma":[0.020138256,0.0023407568,0.027836148,0.00060941285,0.00014030632,0.0000519938,0.00068948854,0.010898357,0.89673805,0.000109313965,0.040047485,0.00040045337],"about_ca_topic_score_codex":0.0011544457,"about_ca_topic_score_gemma":0.00006796701,"teacher_disagreement_score":0.56043535,"about_ca_system_score_codex":0.00009481649,"about_ca_system_score_gemma":0.00016890833,"threshold_uncertainty_score":0.4838375},"labels":[],"label_agreement":null},{"id":"W3026074587","doi":"10.1016/j.jval.2020.04.1700","title":"PCN229 POPULATION BASED ANALYSIS OF RATES OF USE OF NOVEL HORMONAL AGENTS AT THE END-OF-LIFE IN MEN WITH CASTRATION-RESISTANT PROSTATE CANCER","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Odds ratio; Cohort; Abiraterone acetate; Internal medicine; Cancer; Hormonal therapy; Population; Cause of death; Logistic regression; Cohort study; Oncology; Disease; Androgen deprivation therapy","score_opus":0.1936823565217613,"score_gpt":0.40062361726868073,"score_spread":0.20694126074691943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026074587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99509186,0.000742719,0.000014840624,0.0030322564,0.0000064060787,0.00073327776,0.00036409718,0.000002097003,0.000012454079],"genre_scores_gemma":[0.998994,0.00032989768,0.0003241305,0.000088221095,0.0000065871186,0.000027739334,0.00019287587,0.000007567727,0.00002897793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986158,0.00011269617,0.0005690673,0.00014813962,0.00040688843,0.00014742115],"domain_scores_gemma":[0.99916387,0.00015350823,0.00034760553,0.00013608654,0.00011805594,0.00008087583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031731816,0.0000783796,0.00043078483,0.0002162276,0.000019209117,0.0000022041752,0.00004403081,0.000026441083,0.00004317216],"category_scores_gemma":[0.000068170026,0.000048107468,0.00005035031,0.0010732441,0.0000760772,0.000043769614,0.000014488157,0.00007646736,7.263128e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031307777,0.00019937381,0.9040653,0.00068654085,0.00021150519,0.0000024180968,0.0016071898,0.08324279,0.0065707183,0.000024217577,0.000029436038,0.00022972956],"study_design_scores_gemma":[0.0026126292,0.00052807014,0.90542156,0.00027523303,0.00010167225,1.0170104e-7,0.00018813423,0.08636661,0.0044590994,0.000001971227,0.000011119915,0.00003382185],"about_ca_topic_score_codex":0.08483866,"about_ca_topic_score_gemma":0.0051372605,"teacher_disagreement_score":0.0797014,"about_ca_system_score_codex":0.00022379593,"about_ca_system_score_gemma":0.0009998822,"threshold_uncertainty_score":0.92125547},"labels":[],"label_agreement":null},{"id":"W3026782802","doi":"10.1016/j.clon.2020.05.002","title":"Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer –5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life","year":2020,"lang":"en","type":"article","venue":"Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Department of Clinical Veterinary Medicine, University of Cambridge; Bayer Canada; Newcastle upon Tyne Hospitals NHS Foundation Trust","keywords":"Medicine; Radium-223; Prostate cancer; Oncology; Quality of life (healthcare); Sequence (biology); Internal medicine; Castration; Cancer; Urology; Hormone","score_opus":0.5800087866657432,"score_gpt":0.5833926480327449,"score_spread":0.0033838613670017503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026782802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96976745,0.000983197,0.000046977122,0.026580287,0.00016722707,0.0017998499,0.00014785667,0.000030216515,0.00047694155],"genre_scores_gemma":[0.9864011,0.0050877463,0.0053824657,0.0017861945,0.0002857952,0.0001875125,0.000048710375,0.000027205662,0.00079326925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976993,0.00031267953,0.0010371543,0.00043970154,0.00021705935,0.00029407264],"domain_scores_gemma":[0.9969824,0.0018779844,0.0003577494,0.0001895707,0.00019437031,0.00039795056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008791251,0.00018480977,0.0010488004,0.00006529238,0.000086348766,0.000015386608,0.00006432518,0.000092108065,0.000049037677],"category_scores_gemma":[0.0007019781,0.00011932706,0.00019356003,0.00018121595,0.00034687997,0.00004922674,0.0000232459,0.00019557374,0.0000032942742],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11948357,0.0050594024,0.60691786,0.0012364367,0.0028497614,0.0002289134,0.0031060462,0.00019551438,0.03020336,0.0023079317,0.0015017624,0.22690943],"study_design_scores_gemma":[0.14918259,0.098184176,0.6900136,0.00046569132,0.0013753294,0.0000068575414,0.0017191906,0.0021017015,0.02071125,0.00079403596,0.034525108,0.00092050026],"about_ca_topic_score_codex":0.0006082208,"about_ca_topic_score_gemma":0.0003551591,"teacher_disagreement_score":0.22598892,"about_ca_system_score_codex":0.00036180066,"about_ca_system_score_gemma":0.0013607418,"threshold_uncertainty_score":0.48660162},"labels":[],"label_agreement":null},{"id":"W3028042488","doi":"10.1016/j.eururo.2020.04.058","title":"Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Hôpital Saint-Luc; Juravinski Cancer Centre; University of Calgary; BC Cancer Agency; Spinal Cord Injury BC; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"AKT1; Prostate cancer; PTEN; Cancer research; Medicine; Mutation; Germline mutation; Cancer; Internal medicine; Oncology; PI3K/AKT/mTOR pathway; Biology; Gene; Genetics; Signal transduction","score_opus":0.05629279256817002,"score_gpt":0.33272519908053744,"score_spread":0.27643240651236745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028042488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97329646,0.0012227065,0.000024049401,0.019984925,0.000031422464,0.0004198631,0.000023179267,0.000037483318,0.0049599037],"genre_scores_gemma":[0.99770236,0.00018564776,0.0003526502,0.0012904151,0.00006419811,0.00002872023,0.000036811038,0.000023431176,0.0003157646],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999089,0.00016661268,0.0001863673,0.00024133167,0.00009890094,0.0002177625],"domain_scores_gemma":[0.99963236,0.00007169783,0.00004696439,0.0000766258,0.000041703748,0.00013063176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013310337,0.00009628573,0.0001625049,0.00007038365,0.00006122541,0.00001674968,0.000038189773,0.000013517644,0.000101152466],"category_scores_gemma":[0.00013049807,0.00007783374,0.00001952046,0.00019924752,0.00009302657,0.00006024083,0.000037748363,0.00019601278,0.000030081284],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009002497,0.000669589,0.24100044,0.0010901382,0.0008347759,0.012027337,0.051990274,0.0013432594,0.5301835,0.0011954097,0.0032398796,0.14742288],"study_design_scores_gemma":[0.015151323,0.0038401594,0.93026906,0.00011308014,0.00027015872,0.00014630896,0.002210921,0.004309711,0.0059578796,0.00024405433,0.037015557,0.0004717696],"about_ca_topic_score_codex":0.00006337344,"about_ca_topic_score_gemma":0.000046566187,"teacher_disagreement_score":0.68926865,"about_ca_system_score_codex":0.00003115809,"about_ca_system_score_gemma":0.000112796755,"threshold_uncertainty_score":0.3173968},"labels":[],"label_agreement":null},{"id":"W3028809236","doi":"10.1200/jco.2020.38.15_suppl.5602","title":"HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Castration; Urology; Testosterone (patch); Leuprorelin; Clinical endpoint; Internal medicine; Prostate; Hormone antagonist; Randomized controlled trial; Endocrinology; Antagonist; Cancer; Gynecology; Gonadotropin-releasing hormone; Hormone; Luteinizing hormone; Receptor","score_opus":0.3834256382585731,"score_gpt":0.576770821601796,"score_spread":0.19334518334322293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028809236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94541323,0.0011117852,0.000117752104,0.04709886,0.0035026213,0.0019055338,0.00008907815,0.000042255873,0.00071887346],"genre_scores_gemma":[0.9796398,0.005840799,0.007119239,0.0019417662,0.004251252,0.00010337217,0.000106400315,0.000062444924,0.00093491597],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99500406,0.00047135493,0.0030213755,0.0004556196,0.00048732737,0.0005602885],"domain_scores_gemma":[0.99433416,0.0015083397,0.0019752593,0.00024340513,0.00073876185,0.0012000434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003036175,0.0002500397,0.0023269178,0.00009198422,0.00013269667,0.000031736567,0.00028909298,0.00030225082,0.000057628684],"category_scores_gemma":[0.0036624481,0.000173967,0.0005708669,0.00022301072,0.0003086331,0.0003173133,0.00007291183,0.0012130627,0.000011293464],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81261426,0.0018466247,0.000516795,0.00006804887,0.0006119103,0.0003298225,0.00044703996,0.00007744506,0.0012156991,0.000013982894,0.012282702,0.16997565],"study_design_scores_gemma":[0.63664687,0.10032439,0.00022936417,0.000111686946,0.00045321407,0.000019290019,0.00037344478,0.00079266494,0.0016777399,0.000052237916,0.25916415,0.00015493005],"about_ca_topic_score_codex":0.00004180404,"about_ca_topic_score_gemma":0.00007691599,"teacher_disagreement_score":0.24688146,"about_ca_system_score_codex":0.00039512667,"about_ca_system_score_gemma":0.0033291532,"threshold_uncertainty_score":0.7094168},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W3028814746","doi":"10.1200/jco.2020.38.15_suppl.5551","title":"Prostate cancer biomarker enrichment and treatment selection (PC-BETS) study: A Canadian cancer trials group phase II umbrella trial for metastatic castration-resistant prostate cancer (mCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Kingston Health Sciences Centre; University of Ottawa; Ottawa Hospital; Saskatchewan Cancer Agency; Queen Elizabeth II Health Sciences Centre; Jewish General Hospital; Queen's University; McMaster University; London Health Sciences Centre; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Western University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Internal medicine; PTEN; Biomarker; Palbociclib; Enzalutamide; PARP inhibitor; Cancer research; Breast cancer; Androgen receptor; PI3K/AKT/mTOR pathway; Metastatic breast cancer; Biology","score_opus":0.37479070474399473,"score_gpt":0.5657168146001935,"score_spread":0.1909261098561988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028814746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94406426,0.0074731116,0.000019671568,0.03849755,0.0015168125,0.007801056,0.0005538164,0.000016686514,0.00005703413],"genre_scores_gemma":[0.9755183,0.016974224,0.0005217638,0.0014131577,0.0022646282,0.00209262,0.00004255336,0.00005536115,0.0011173853],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99360776,0.0011742328,0.0033204337,0.0005925283,0.00058712024,0.00071790884],"domain_scores_gemma":[0.9938878,0.0015564112,0.0020499963,0.00014669771,0.00081488723,0.001544249],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0047795703,0.000392754,0.0028317976,0.000282752,0.00034953677,0.00006278351,0.00012451464,0.00022744063,0.00034656044],"category_scores_gemma":[0.0015168792,0.00024734606,0.000584041,0.00041750522,0.00019162735,0.00017985338,0.00003895863,0.0005323635,0.000001967009],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4365651,0.0072707282,0.010831506,0.00015437519,0.0062894314,0.0006176417,0.0025505098,0.000050043313,0.0028768685,0.000010673621,0.007224855,0.5255583],"study_design_scores_gemma":[0.56114763,0.2457425,0.008910917,0.00023829116,0.0069226674,0.00004440939,0.001465753,0.0010725952,0.0006916012,0.0000697544,0.173309,0.00038487554],"about_ca_topic_score_codex":0.035179697,"about_ca_topic_score_gemma":0.1464067,"teacher_disagreement_score":0.52517337,"about_ca_system_score_codex":0.002050837,"about_ca_system_score_gemma":0.014245087,"threshold_uncertainty_score":0.99999785},"labels":[],"label_agreement":null},{"id":"W3028941164","doi":"10.1200/jco.2020.38.15_suppl.5530","title":"Clinical analysis of the extracellular vesicle-fingerprint score blood test to refine the prediction of clinically significant prostate cancer and avoid prostate biopsy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Calgary; University of Alberta","funders":"Alberta Cancer Foundation","keywords":"Medicine; Prostate cancer; Prostate; Rectal examination; Prostate biopsy; Biopsy; Urology; Prostatectomy; Prostate-specific antigen; PCA3; Cohort; Logistic regression; Internal medicine; Oncology; Cancer; Radiology","score_opus":0.14463887982751197,"score_gpt":0.449583885061469,"score_spread":0.30494500523395707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028941164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9359067,0.0012051167,0.000051574727,0.061324384,0.00042378786,0.0008535993,0.00011982258,0.000008410453,0.00010660607],"genre_scores_gemma":[0.99003863,0.0067611304,0.0008716465,0.0013473933,0.00065295165,0.000020423586,0.000005207504,0.000021829592,0.0002807814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924409,0.0007953398,0.0053099096,0.00041159443,0.00073120464,0.0003110891],"domain_scores_gemma":[0.98999935,0.004552922,0.0032957594,0.000433202,0.0010810266,0.00063776004],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0071346364,0.000200028,0.002121686,0.00014884523,0.00008080109,0.000013375093,0.0003845782,0.00031528148,0.00005986901],"category_scores_gemma":[0.01119058,0.00009531259,0.0009882745,0.0010886586,0.0010625399,0.000065735025,0.00024075866,0.0015533566,0.0000021714225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009276122,0.0021002323,0.93010396,0.00011704234,0.0032917054,0.00015683376,0.00055770716,0.00013225757,0.0108504575,0.000021612024,0.0006351269,0.04275696],"study_design_scores_gemma":[0.0079251025,0.023094418,0.9527167,0.00031505548,0.0070878854,0.000034900975,0.00027561217,0.0010845616,0.0016608879,0.00006396808,0.0056424607,0.000098412514],"about_ca_topic_score_codex":0.000054425545,"about_ca_topic_score_gemma":0.000021573376,"teacher_disagreement_score":0.05997699,"about_ca_system_score_codex":0.000069955335,"about_ca_system_score_gemma":0.0021412354,"threshold_uncertainty_score":0.99713856},"labels":[],"label_agreement":null},{"id":"W3029442987","doi":"10.1200/jco.2020.38.15_suppl.5507","title":"The comprehensive methylation landscape of metastatic castration-resistant prostate cancer (mCRPC) identifies new phenotypic subtypes: Results from the West Coast Prostate Cancer Dream Team (WCDT).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"DNA methylation; Epigenomics; Prostate cancer; Methylation; Epigenetics; Transcriptome; Biology; Cancer; Medicine; Epigenome; Oncology; Genetics; Gene; Gene expression","score_opus":0.15295780297870798,"score_gpt":0.4542921394863105,"score_spread":0.3013343365076025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029442987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86976016,0.018789742,0.000021309703,0.10856398,0.0010705377,0.0010558484,0.00038930768,0.000014029819,0.00033509207],"genre_scores_gemma":[0.9751228,0.01982424,0.00039915173,0.0014592541,0.0015058945,0.00003240289,0.00006144399,0.000029452509,0.0015653645],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99527824,0.00077773153,0.0025493698,0.00030668962,0.0007520197,0.00033594138],"domain_scores_gemma":[0.99005044,0.005561477,0.0024358334,0.00026847475,0.0012769763,0.0004067797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016502634,0.00022021022,0.0012033422,0.000054951644,0.00019738279,0.000053167983,0.00030703205,0.00014405597,0.00012948528],"category_scores_gemma":[0.0022169775,0.00010569861,0.0003512205,0.00035148472,0.0004800681,0.00017999046,0.00008361741,0.0009973512,0.000012519785],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22648239,0.0018447855,0.116082095,0.00043679602,0.009716304,0.0007241703,0.031745218,0.0023959186,0.02666719,0.00016044902,0.1772419,0.40650278],"study_design_scores_gemma":[0.05295495,0.015729582,0.69248146,0.0009924265,0.003999126,0.000046348014,0.015494559,0.0013918304,0.0065691825,0.0021464138,0.20776053,0.00043362065],"about_ca_topic_score_codex":0.0037386157,"about_ca_topic_score_gemma":0.0065639094,"teacher_disagreement_score":0.5763993,"about_ca_system_score_codex":0.00015160092,"about_ca_system_score_gemma":0.005141001,"threshold_uncertainty_score":0.91199154},"labels":[],"label_agreement":null},{"id":"W3029590709","doi":"10.1200/jco.2020.38.15_suppl.5550","title":"Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Sunnybrook Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Docetaxel; Abiraterone acetate; Internal medicine; Prednisone; Cohort; Oncology; Biomarker; Cancer; Urology; Androgen receptor; Androgen deprivation therapy","score_opus":0.11320174205275545,"score_gpt":0.4281859025036265,"score_spread":0.314984160450871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029590709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98634696,0.00161236,0.000024267916,0.009710722,0.00017008408,0.0016109473,0.00019074437,0.000020149186,0.0003137656],"genre_scores_gemma":[0.98965436,0.00749714,0.0012763042,0.0007551835,0.00013585955,0.00003410169,0.00006027135,0.000046753186,0.0005400505],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9943501,0.0007717676,0.002943456,0.0006080755,0.0007349903,0.00059165596],"domain_scores_gemma":[0.99534833,0.001365105,0.0015006072,0.00022977965,0.0006599426,0.0008962365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002068475,0.000377951,0.0022297762,0.0001802332,0.0001093538,0.00004855951,0.0001569455,0.00026057198,0.00006663794],"category_scores_gemma":[0.0020227204,0.00021711885,0.0001576776,0.00049567176,0.0006170619,0.0002837037,0.00011610585,0.0010240298,0.000005117284],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6949121,0.0018873666,0.22413762,0.00034373847,0.002096068,0.002900038,0.0012402328,0.00020227354,0.0006239771,0.000007488011,0.00060170004,0.071047455],"study_design_scores_gemma":[0.15708993,0.02845639,0.808353,0.00043979872,0.0009937088,0.00014187623,0.00019338509,0.0009950205,0.00020166689,0.000013562551,0.002884114,0.00023752032],"about_ca_topic_score_codex":0.0002698033,"about_ca_topic_score_gemma":0.0006276727,"teacher_disagreement_score":0.5842154,"about_ca_system_score_codex":0.0005248526,"about_ca_system_score_gemma":0.0029777817,"threshold_uncertainty_score":0.885385},"labels":[],"label_agreement":null},{"id":"W3029699663","doi":"10.1200/jco.2020.38.15_suppl.5515","title":"Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Hazard ratio; Prostate cancer; Internal medicine; Placebo; Discontinuation; Urology; Oncology; Gynecology; Cancer; Confidence interval; Androgen receptor; Alternative medicine","score_opus":0.18356915723541115,"score_gpt":0.4844959808260795,"score_spread":0.30092682359066836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029699663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852928,0.0010719948,0.000049367914,0.0065134033,0.00023196395,0.006049134,0.00004030432,0.0000093158405,0.0007417225],"genre_scores_gemma":[0.9965587,0.0009823133,0.0007111767,0.00038341523,0.0005621729,0.00034195773,0.000017444741,0.000032084714,0.00041069678],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9923109,0.0014470611,0.004267997,0.00043560853,0.001114111,0.00042436976],"domain_scores_gemma":[0.9919787,0.0038407247,0.0026850346,0.00021913,0.0006940811,0.0005822992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049896436,0.00032202626,0.00527895,0.00020672427,0.000053523192,0.000029040408,0.00023309798,0.00020746917,0.00035687163],"category_scores_gemma":[0.0013268907,0.00018323853,0.0005213576,0.00031627723,0.00036078045,0.00020924922,0.000060079983,0.0013088693,0.000004211122],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9495468,0.008961974,0.027069608,0.00007234594,0.003839173,0.0027823113,0.0030360927,0.00046167543,0.0008831197,0.000017562515,0.00028775964,0.0030415787],"study_design_scores_gemma":[0.9513817,0.035976816,0.0063325926,0.00022261812,0.0021939077,0.000021969692,0.00157651,0.0016171607,0.00020822596,0.00007436283,0.00023090276,0.00016327035],"about_ca_topic_score_codex":0.0012113691,"about_ca_topic_score_gemma":0.001838863,"teacher_disagreement_score":0.027014842,"about_ca_system_score_codex":0.00029202484,"about_ca_system_score_gemma":0.004626501,"threshold_uncertainty_score":0.8207214},"labels":[],"label_agreement":null},{"id":"W3029830108","doi":"10.1016/j.clgc.2020.05.013","title":"A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Astellas Pharma; Bayer Fund; Parker Institute for Cancer Immunotherapy; Sanofi; Exelixis; Genentech; Valeant Pharmaceuticals International; Merck; Astellas Pharma US; Society for Immunotherapy of Cancer; Prostate Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Sunitinib; Dasatinib; Prostate cancer; Hazard ratio; Internal medicine; Oncology; Abiraterone acetate; Clinical endpoint; Randomized controlled trial; Androgen deprivation therapy; Urology; Docetaxel; Confidence interval; Cancer; Tyrosine kinase","score_opus":0.12002647259925224,"score_gpt":0.45093749650814924,"score_spread":0.330911023908897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029830108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903813,0.000577254,0.00006678809,0.00367768,0.00009988642,0.0038676814,0.0010888615,0.000020239771,0.00022032799],"genre_scores_gemma":[0.9945616,0.0015821684,0.00062899635,0.00032649233,0.0002761435,0.0012725677,0.0003996551,0.000038538106,0.00091381924],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974081,0.00028488087,0.00115333,0.0004084049,0.0004644105,0.00028089923],"domain_scores_gemma":[0.9984649,0.00033770417,0.0003749894,0.00020052152,0.00030876556,0.00031315547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043310574,0.00020973948,0.0009001006,0.00010919682,0.00003801729,0.0000116178035,0.00010073175,0.00007515295,0.0006481741],"category_scores_gemma":[0.00028864504,0.0001394545,0.00012137366,0.0006547881,0.00016415825,0.00012005376,0.00003431267,0.00022559575,0.0000031609607],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93022174,0.0028794473,0.001815418,0.0004690816,0.00043736646,0.0002208743,0.0010225385,0.0001768125,0.04169658,0.0000018593362,0.009802399,0.011255891],"study_design_scores_gemma":[0.8900099,0.04993065,0.0020217565,0.00094190467,0.00074478844,0.0000044488293,0.000910258,0.00082711637,0.051305678,0.000011347424,0.0029404373,0.00035175958],"about_ca_topic_score_codex":0.00028169563,"about_ca_topic_score_gemma":0.00018078819,"teacher_disagreement_score":0.047051203,"about_ca_system_score_codex":0.000115212635,"about_ca_system_score_gemma":0.0011447085,"threshold_uncertainty_score":0.7097052},"labels":[],"label_agreement":null},{"id":"W3029994730","doi":"10.1188/20.cjon.369-378","title":"Metastatic Prostate Cancer: An Update on Treatments and a Review of Patient Symptom Management","year":2020,"lang":"en","type":"review","venue":"Clinical journal of oncology nursing","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Incidence (geometry); Cancer; International agency; Family medicine; Internal medicine","score_opus":0.16114913628226887,"score_gpt":0.555278793021193,"score_spread":0.3941296567389241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029994730","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036219123,0.9936011,0.000002221818,0.0030413892,0.000574548,0.0019154544,0.000048155587,0.0000072352836,0.0004477062],"genre_scores_gemma":[0.000029465446,0.9974163,0.0012448592,0.00089605304,0.00018752369,0.00005366508,0.00005291593,0.000044387445,0.00007480414],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99538875,0.0009823894,0.0024513511,0.0003965886,0.00047506543,0.0003058385],"domain_scores_gemma":[0.9962824,0.0004389694,0.0022020556,0.0002729017,0.00024769283,0.00055599865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009530061,0.00036917554,0.0043481737,0.00024895326,0.00005088289,0.000011040578,0.00017563235,0.0001752619,0.000052454936],"category_scores_gemma":[0.0001309971,0.00021953542,0.00074313185,0.00029089788,0.00037473536,0.00007268705,0.00005257232,0.0008974268,0.0000080672835],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008443083,0.0018418245,0.000065336026,0.041013643,0.0029564274,0.0021889154,0.00010456635,1.1113051e-7,7.779711e-8,0.0000172894,0.0019111459,0.9490563],"study_design_scores_gemma":[0.0029343064,0.013919238,0.000049044313,0.30354416,0.013607367,0.00050527364,0.00006085449,0.0000016316038,9.539878e-7,0.00005302745,0.66520715,0.000116960466],"about_ca_topic_score_codex":0.0000012648773,"about_ca_topic_score_gemma":2.3010828e-7,"teacher_disagreement_score":0.9489394,"about_ca_system_score_codex":0.00092919817,"about_ca_system_score_gemma":0.0017211208,"threshold_uncertainty_score":0.8952395},"labels":[],"label_agreement":null},{"id":"W3030001291","doi":"10.1200/jco.2020.38.15_suppl.5516","title":"Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Clinical endpoint; Abiraterone acetate; Urology; Androgen deprivation therapy; Doubling time; Tolerability; Oncology; Gastroenterology; Randomized controlled trial; Cancer; Adverse effect; Confidence interval","score_opus":0.25385446503007764,"score_gpt":0.49593352557567943,"score_spread":0.2420790605456018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030001291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417335,0.00016040895,0.0000072440916,0.003544635,0.0005117663,0.0011556782,0.00017437022,0.0000057324337,0.00026680625],"genre_scores_gemma":[0.99856377,0.00024778154,0.0004921685,0.00016592041,0.0003502137,0.000023619135,0.000040161663,0.00002076375,0.000095585245],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949059,0.00067037705,0.0028040651,0.00035619875,0.00093790446,0.00032558452],"domain_scores_gemma":[0.9945953,0.0022580032,0.0018214068,0.00019358596,0.0006374445,0.0004942435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015906795,0.00020851448,0.0017283895,0.00013066169,0.000041367424,0.000012215623,0.00017359578,0.00014244799,0.00009820738],"category_scores_gemma":[0.002015451,0.00013433857,0.00016685709,0.00034670823,0.00021799926,0.00014150061,0.00005138482,0.00095853687,0.000005041886],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7819016,0.012764948,0.17648542,0.000048672,0.0013256482,0.0021269438,0.003376748,0.0003261349,0.00020893465,0.0000026063155,0.0006120775,0.020820284],"study_design_scores_gemma":[0.48241067,0.15591286,0.35592288,0.00023925994,0.0008762528,0.0000038437847,0.0027210584,0.00034308643,0.00014627655,0.00001341992,0.0012593997,0.00015101414],"about_ca_topic_score_codex":0.0009203523,"about_ca_topic_score_gemma":0.0040528397,"teacher_disagreement_score":0.29949093,"about_ca_system_score_codex":0.00029284385,"about_ca_system_score_gemma":0.0028332176,"threshold_uncertainty_score":0.5478168},"labels":[],"label_agreement":null},{"id":"W3031020438","doi":"10.1056/nejmoa2003892","title":"Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":422,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université de Montréal","funders":"Ipsen; Astellas Pharma; Janssen Scientific Affairs; Sanofi; Genentech; PharmaMar; AstraZeneca; Amgen; Pfizer; Cilag; Northwestern University","keywords":"Enzalutamide; Prostate cancer; Medicine; Oncology; Overall survival; Internal medicine; Cancer; Urology; Androgen receptor","score_opus":0.04826896524351373,"score_gpt":0.33942236597204994,"score_spread":0.29115340072853624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031020438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9094318,0.009772859,0.000046111785,0.079801254,0.00018005053,0.00023887766,0.0000080483815,0.000005765576,0.0005152471],"genre_scores_gemma":[0.9921282,0.004910422,0.00035080593,0.0006626936,0.0015331088,0.0000027220733,0.000005857102,0.000013314191,0.00039286687],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987056,0.0000721708,0.00043524586,0.0001262325,0.00046816684,0.00019256369],"domain_scores_gemma":[0.9990573,0.00013741589,0.00014606019,0.0000603335,0.00013403942,0.0004648426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050597364,0.00012002797,0.00045609358,0.0001297966,0.00002581765,0.000009879806,0.000050859322,0.000029710016,0.00020437904],"category_scores_gemma":[0.00026686335,0.00007083268,0.000030367635,0.00021992318,0.000103312326,0.0000874563,0.000014239972,0.00032754196,0.0000014795787],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02827784,0.00021065361,0.36715406,0.00072344695,0.0005989519,0.0075850235,0.02519626,0.00015412975,0.18322927,0.00021225378,0.0086327195,0.37802538],"study_design_scores_gemma":[0.43598616,0.017410845,0.43296564,0.0032773872,0.0009619432,0.0013554674,0.005601626,0.00071592454,0.008979741,0.0010741623,0.09119768,0.00047342817],"about_ca_topic_score_codex":0.00035520925,"about_ca_topic_score_gemma":0.00021509542,"teacher_disagreement_score":0.40770832,"about_ca_system_score_codex":0.00006525661,"about_ca_system_score_gemma":0.0004293211,"threshold_uncertainty_score":0.28884727},"labels":[],"label_agreement":null},{"id":"W3031402932","doi":"10.1200/jco.2020.38.15_suppl.5525","title":"<i>HSD3B1</i> (1245A&gt;C) polymorphism and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (AA) and enzalutamide (ENZA): Results from two prospective studies.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Kelowna General Hospital; BC Cancer Agency","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Genotype; Oncology; Abiraterone acetate; Cohort; Hazard ratio; Prospective cohort study; Proportional hazards model; Androgen receptor; Cancer; Androgen deprivation therapy; Genetics; Biology; Confidence interval","score_opus":0.15767112275387948,"score_gpt":0.47544971927027724,"score_spread":0.3177785965163977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031402932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794176,0.0033637814,0.000002242921,0.015630517,0.00024421295,0.0010446847,0.00018444743,0.000014173235,0.000098292185],"genre_scores_gemma":[0.98692554,0.009488069,0.0013016126,0.001624141,0.00030823666,0.00002892069,0.000024798526,0.00003332774,0.00026536896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99459505,0.0007371704,0.003103538,0.0005957108,0.00056402996,0.00040448172],"domain_scores_gemma":[0.9939795,0.0027803823,0.0016214293,0.00017527238,0.00072841154,0.00071500713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017899398,0.00032352752,0.0025684896,0.00012623504,0.00007659199,0.000031178348,0.000113519876,0.00017690324,0.000016271695],"category_scores_gemma":[0.0028201153,0.00018602678,0.00019255721,0.00026897734,0.0008130554,0.00024140095,0.0001005355,0.0011364584,0.0000036607034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06371767,0.0011527253,0.90934396,0.00004491123,0.0025803172,0.0018228978,0.0013777522,0.000009855452,0.00015590226,0.000004907158,0.00036054786,0.019428587],"study_design_scores_gemma":[0.080598116,0.021957275,0.8943447,0.00026353623,0.0010554482,0.000025967553,0.00052142225,0.00007285955,0.00016349537,0.00013140914,0.00068948243,0.00017628273],"about_ca_topic_score_codex":0.0005012436,"about_ca_topic_score_gemma":0.0014667037,"teacher_disagreement_score":0.020804549,"about_ca_system_score_codex":0.00030154982,"about_ca_system_score_gemma":0.0013960678,"threshold_uncertainty_score":0.75859517},"labels":[],"label_agreement":null},{"id":"W3031403900","doi":"10.1200/jco.2020.38.15_suppl.e19369","title":"A cost-utility analysis of apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Hospital; University of Toronto; University Health Network; Sunnybrook Health Science Centre","funders":"","keywords":"Enzalutamide; Medicine; Androgen deprivation therapy; Prostate cancer; Quality-adjusted life year; Cost effectiveness; Oncology; Adverse effect; Clinical trial; Internal medicine; Cancer; Androgen receptor","score_opus":0.2546280226356184,"score_gpt":0.5177659532317747,"score_spread":0.26313793059615626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031403900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99081016,0.0006451226,0.00047202417,0.006347152,0.000102075384,0.0012840431,0.0002950918,0.0000019182496,0.000042437772],"genre_scores_gemma":[0.9967641,0.0015952856,0.0011005251,0.00030079333,0.00010459225,0.000040273004,0.000027933627,0.000007885429,0.000058603055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776775,0.00023505963,0.0013375041,0.0001464731,0.00035824106,0.00015495766],"domain_scores_gemma":[0.99409384,0.0027692935,0.0014149175,0.00012245741,0.0013878873,0.00021159479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070937985,0.00010805669,0.0015168114,0.000090247115,0.00003274311,0.0000033300903,0.00006657618,0.000064170905,0.00005927162],"category_scores_gemma":[0.00068715686,0.000048739552,0.00054616836,0.0003924847,0.00032884485,0.000048061884,0.000009562697,0.00017801448,3.8396743e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06471446,0.0041598375,0.7069065,0.000094933945,0.021057198,0.00008018688,0.002409394,0.00066998956,0.000052772346,0.000011520424,0.0002214436,0.19962178],"study_design_scores_gemma":[0.019281665,0.04280018,0.9143274,0.000037339392,0.014486567,0.0000023188957,0.00057523,0.0031313933,0.0007679566,0.000019132953,0.004519155,0.00005169115],"about_ca_topic_score_codex":0.00009654993,"about_ca_topic_score_gemma":0.00028942298,"teacher_disagreement_score":0.20742089,"about_ca_system_score_codex":0.00014582937,"about_ca_system_score_gemma":0.0015859241,"threshold_uncertainty_score":0.2813361},"labels":[],"label_agreement":null},{"id":"W3031458532","doi":"10.1200/jco.2020.38.15_suppl.5501","title":"Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Clinical endpoint; Nuclear medicine; Prostate cancer; Occult; Bone scintigraphy; Clinical trial; Radiology; Cancer; Internal medicine; Pathology","score_opus":0.09672968866034382,"score_gpt":0.49941317306536337,"score_spread":0.40268348440501955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031458532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944733,0.00034655005,0.000009762911,0.0017163128,0.00031444873,0.002489177,0.0003375238,0.00001393846,0.00029898947],"genre_scores_gemma":[0.9967223,0.0011343395,0.0013552369,0.00027519302,0.00030750735,0.0000403114,0.0000663201,0.00004123392,0.00005759326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934828,0.00055272516,0.0038514482,0.00065403903,0.0010232917,0.00043566062],"domain_scores_gemma":[0.99293154,0.0010733841,0.003450638,0.00037091813,0.0014601754,0.000713342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015869762,0.00035389795,0.002371829,0.0001441682,0.000042461215,0.000013201083,0.0002991356,0.000049936658,0.000106344676],"category_scores_gemma":[0.0008335621,0.00018958148,0.00055618474,0.00037168793,0.000534198,0.00013578575,0.00013312616,0.0013527565,0.0000038129704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31058386,0.025598362,0.6181983,0.00006664047,0.0042544627,0.0032024637,0.0003788307,0.000016299917,0.00007130302,5.443293e-7,0.001072961,0.036556024],"study_design_scores_gemma":[0.21296231,0.14314121,0.6398896,0.000826702,0.0013981374,0.000015491067,0.0005404706,0.00018985625,0.0004817363,0.000008003352,0.00037243802,0.00017404843],"about_ca_topic_score_codex":0.00018528546,"about_ca_topic_score_gemma":0.000040506613,"teacher_disagreement_score":0.11754284,"about_ca_system_score_codex":0.00043310775,"about_ca_system_score_gemma":0.0015802556,"threshold_uncertainty_score":0.77309084},"labels":[],"label_agreement":null},{"id":"W3031465744","doi":"10.1200/jco.2020.38.15_suppl.5545","title":"Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Western University","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Cohort; Internal medicine; Abiraterone acetate; Biomarker; Oncology; Cancer; Urology; Androgen receptor; Androgen deprivation therapy","score_opus":0.10664875430892808,"score_gpt":0.42883531223814014,"score_spread":0.3221865579292121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031465744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98335785,0.0011204653,0.000024974359,0.012864036,0.00024732173,0.0014240532,0.00014257204,0.000021460068,0.00079730013],"genre_scores_gemma":[0.9938355,0.0036055571,0.0008750762,0.00095993734,0.00016916629,0.000027802358,0.00007642491,0.000049883485,0.00040063253],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9939495,0.00083558937,0.0031539528,0.0005762147,0.0008609232,0.0006238335],"domain_scores_gemma":[0.99519086,0.0012444634,0.0016203129,0.00025014675,0.00080237637,0.0008918362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022418785,0.00036710507,0.0022115598,0.00023674787,0.00009824923,0.000042204152,0.00019467802,0.0002623859,0.000072453586],"category_scores_gemma":[0.0018270329,0.00022917883,0.00022383903,0.0005486225,0.00054111745,0.00025862586,0.00010775485,0.0011706704,0.000011517198],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.584489,0.002400741,0.3204602,0.00028640055,0.0025452166,0.0039261403,0.0012449018,0.0005063747,0.0010044024,0.000012959379,0.0012586096,0.08186508],"study_design_scores_gemma":[0.13024788,0.024250701,0.8388086,0.00039016316,0.00087745866,0.0000815387,0.0001434807,0.0007618557,0.00027893326,0.000020736441,0.003903548,0.00023508978],"about_ca_topic_score_codex":0.00030513998,"about_ca_topic_score_gemma":0.00045393294,"teacher_disagreement_score":0.5183484,"about_ca_system_score_codex":0.00072205934,"about_ca_system_score_gemma":0.0032605773,"threshold_uncertainty_score":0.9345641},"labels":[],"label_agreement":null},{"id":"W3031669561","doi":"10.1200/jco.2020.38.15_suppl.5553","title":"Primary analysis of a phase II study of metastasis-directed ablative therapy to PSMA (<sup>18</sup>F-DCFPyL) PET-MR/CT defined oligorecurrent prostate cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre for Probe Development and Commercialization; University Health Network; McMaster University; University of Toronto","funders":"Terry Fox Research Institute; University of Toronto","keywords":"Medicine; Prostate cancer; Prostatectomy; Nuclear medicine; Clinical endpoint; SABR volatility model; Ablative case; Radiation therapy; Salvage therapy; Lymph node; Biochemical recurrence; Androgen deprivation therapy; Metastasis; Stage (stratigraphy); Phases of clinical research; Radiology; Cancer; Surgery; Clinical trial; Internal medicine; Chemotherapy","score_opus":0.22933058198063608,"score_gpt":0.5298790695593609,"score_spread":0.3005484875787249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031669561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874157,0.002496125,0.00002284364,0.007976746,0.00018636633,0.0013810714,0.000118589385,0.000017659628,0.00038490628],"genre_scores_gemma":[0.9928253,0.0045961086,0.0010213115,0.000992266,0.00030257163,0.00005392785,0.000031158568,0.000026817932,0.0001504878],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99384534,0.0010901124,0.0033044566,0.000416813,0.0009546261,0.00038863916],"domain_scores_gemma":[0.9935509,0.0016101389,0.002226673,0.0002876184,0.0015167574,0.00080790534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022503473,0.00028271702,0.003933175,0.000583197,0.00005965775,0.000007656162,0.00031015195,0.00009469976,0.00044530953],"category_scores_gemma":[0.0016865548,0.00017910067,0.0009964071,0.0020623428,0.00024586284,0.00010803091,0.00015109325,0.00090274244,0.0000027790556],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16704333,0.05462851,0.22914483,0.00022343699,0.05976732,0.0026103323,0.013678303,0.0024312802,0.0030459662,0.000009987482,0.009020115,0.4583966],"study_design_scores_gemma":[0.16430952,0.5098044,0.2605153,0.0003725286,0.023995226,0.000083291285,0.005128332,0.0070035383,0.0035291486,0.00006898928,0.02463757,0.0005521149],"about_ca_topic_score_codex":0.0001831947,"about_ca_topic_score_gemma":0.000089396766,"teacher_disagreement_score":0.4578445,"about_ca_system_score_codex":0.0002942315,"about_ca_system_score_gemma":0.0026850943,"threshold_uncertainty_score":0.73035127},"labels":[],"label_agreement":null},{"id":"W3031687780","doi":"10.1200/jco.2020.38.15_suppl.5584","title":"Short-term adjuvant versus neoadjuvant hormone therapy in localized prostate cancer: A pooled individual patient analysis of two phase III trials.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Adjuvant; Oncology; Internal medicine; Neoadjuvant therapy; Androgen deprivation therapy; Randomized controlled trial; Radiation therapy; Cumulative incidence; Cancer; Cohort; Breast cancer","score_opus":0.27743583142348527,"score_gpt":0.5433279895238516,"score_spread":0.26589215810036637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031687780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795753,0.010908394,0.000037763984,0.007875331,0.0005187289,0.000872753,0.00009870925,0.000008692869,0.000104347346],"genre_scores_gemma":[0.97193915,0.026268631,0.0003142316,0.0008923837,0.00046555843,0.000033720877,0.000050811348,0.000019439685,0.000016062342],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9923357,0.0013358905,0.00474809,0.0003234265,0.0008669954,0.00038990966],"domain_scores_gemma":[0.99401975,0.0022823245,0.0022178658,0.00020073292,0.00055942824,0.0007199141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004684048,0.0002319093,0.0048215585,0.0004971643,0.00003050906,0.000012696461,0.00023666579,0.0002746195,0.00024251644],"category_scores_gemma":[0.002040982,0.00014103446,0.0012791898,0.0010775079,0.00029299062,0.00010537314,0.00008450726,0.0011098031,0.00000201668],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2697092,0.0040251184,0.04503667,0.000017568642,0.011605141,0.0016456965,0.0016923436,0.00019269163,0.0019887863,0.0000055137434,0.0007128029,0.66336846],"study_design_scores_gemma":[0.59191597,0.18808818,0.18339151,0.00023109386,0.017317558,0.000026916825,0.0011072094,0.0034378676,0.0030302992,0.000060971743,0.011018962,0.0003734744],"about_ca_topic_score_codex":0.00012001315,"about_ca_topic_score_gemma":0.000100354075,"teacher_disagreement_score":0.662995,"about_ca_system_score_codex":0.00026613876,"about_ca_system_score_gemma":0.0025750957,"threshold_uncertainty_score":0.5751218},"labels":[],"label_agreement":null},{"id":"W3031699081","doi":"10.1200/jco.2020.38.15_suppl.5542","title":"Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Taxane; Cabazitaxel; Enzalutamide; Internal medicine; Prostate cancer; Docetaxel; Oncology; Neutropenia; Interim analysis; Regimen; Clinical trial; Chemotherapy; Cancer; Androgen deprivation therapy; Breast cancer; Androgen receptor","score_opus":0.12707540710585571,"score_gpt":0.4252723192815633,"score_spread":0.29819691217570754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031699081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98560005,0.0014112775,0.000015488144,0.011512711,0.00012025018,0.0009259565,0.00004323946,0.00000975144,0.00036128543],"genre_scores_gemma":[0.99139696,0.006445015,0.00054427685,0.0009928585,0.00021176615,0.000021169613,0.000030760206,0.000031746993,0.00032541485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965804,0.0005427621,0.0015054777,0.00032790238,0.00065994106,0.00038350472],"domain_scores_gemma":[0.9971087,0.0006213396,0.000997602,0.00013133392,0.00051797077,0.0006230611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011012511,0.00024550184,0.0015528679,0.00010557248,0.000058688584,0.000023850778,0.000108903994,0.00013882243,0.00013027118],"category_scores_gemma":[0.0002775657,0.00013060131,0.00012832823,0.0002805165,0.00028034626,0.00017465132,0.000027089396,0.0008471683,0.0000027607744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2789094,0.0029817342,0.65861404,0.00011782239,0.0016149463,0.0034375356,0.00085886696,0.00024586337,0.00025823023,0.00003065146,0.00038003948,0.05255089],"study_design_scores_gemma":[0.13662982,0.056728724,0.7956087,0.00025811957,0.00041976964,0.0000660298,0.00026171733,0.00019774199,0.00018620469,0.0000215704,0.009413839,0.00020777957],"about_ca_topic_score_codex":0.00047996198,"about_ca_topic_score_gemma":0.0009264701,"teacher_disagreement_score":0.14227958,"about_ca_system_score_codex":0.0005539215,"about_ca_system_score_gemma":0.002861304,"threshold_uncertainty_score":0.5325767},"labels":[],"label_agreement":null},{"id":"W3031849367","doi":"10.1200/jco.2020.38.15_suppl.5535","title":"Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA) or placebo (PBO) to androgen deprivation therapy (ADT) in TITAN.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development","keywords":"Prostate cancer; Medicine; Population; Androgen deprivation therapy; Internal medicine; Oncology; Placebo; Androgen receptor; Proportional hazards model; Cancer; Pathology","score_opus":0.23171827487795327,"score_gpt":0.5132525809369715,"score_spread":0.2815343060590182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031849367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940284,0.00015068043,0.0005258924,0.0039632064,0.00007468898,0.0011503105,0.00007343887,0.0000024880674,0.00003093419],"genre_scores_gemma":[0.9921909,0.00043691514,0.0063513606,0.0008204162,0.00009080138,0.000050007424,0.000010697649,0.000015206091,0.000033688993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976951,0.0002078268,0.001467015,0.00015548104,0.00031006453,0.00016449895],"domain_scores_gemma":[0.9970694,0.0009528902,0.0010277893,0.00008004315,0.0006731469,0.00019669492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009683844,0.00010694559,0.001088599,0.00012313506,0.000014749192,0.0000034584987,0.000067369416,0.000092523886,0.000035313726],"category_scores_gemma":[0.0013516687,0.00006361985,0.00014900773,0.00023650186,0.00010917113,0.00009120644,0.000013998757,0.00023870658,9.152784e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26793084,0.0016787414,0.44291493,0.0004669107,0.0011955734,0.0018160667,0.0021664314,0.00096606027,0.012543787,0.00003435942,0.00033443156,0.26795188],"study_design_scores_gemma":[0.10221983,0.13381325,0.54994124,0.001235265,0.0011085006,0.00023836702,0.0016423075,0.004175791,0.20203096,0.00026949658,0.0029695875,0.0003554171],"about_ca_topic_score_codex":0.000041200692,"about_ca_topic_score_gemma":0.00033463797,"teacher_disagreement_score":0.26759648,"about_ca_system_score_codex":0.00012370627,"about_ca_system_score_gemma":0.0014486426,"threshold_uncertainty_score":0.25943422},"labels":[],"label_agreement":null},{"id":"W3032001277","doi":"10.1200/jco.2020.38.15_suppl.5578","title":"Quality of life (QOL) for the treatment sequence of abiraterone acetate plus prednisone (AAP) followed by enzalutamide (ENZ) versus the opposite sequence for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized clinical trial.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Kelowna General Hospital; BC Cancer Agency","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; Enzalutamide; Abiraterone acetate; Prostate cancer; Quality of life (healthcare); Internal medicine; Randomized controlled trial; Prednisone; Sequence (biology); Abiraterone; Urology; Gastroenterology; Surgery; Oncology; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.5228100287158628,"score_gpt":0.5821295097350553,"score_spread":0.05931948101919249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032001277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9280985,0.005332279,0.0011011305,0.052156944,0.0012277581,0.007672236,0.0043750275,0.000010886675,0.00002526382],"genre_scores_gemma":[0.97806144,0.013723938,0.004846493,0.0011535916,0.0008792679,0.0007313116,0.00019053959,0.000036043857,0.00037739865],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.988249,0.0030558717,0.007086619,0.0004826064,0.00071381003,0.00041210474],"domain_scores_gemma":[0.94203675,0.049939156,0.005897275,0.00043079394,0.0011528793,0.00054315943],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014245117,0.00031748178,0.004208661,0.000048487684,0.00018553935,0.00002406632,0.00041997156,0.00024311528,0.00003335606],"category_scores_gemma":[0.025633741,0.00014764853,0.001774879,0.00020841781,0.0012985525,0.00013956515,0.000060805767,0.00058832514,9.0245305e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94718593,0.0033360594,0.000056097157,0.00010605737,0.0060583157,0.000041675237,0.0016202478,0.00016643996,0.011327546,0.000029963325,0.0026775894,0.02739408],"study_design_scores_gemma":[0.88944316,0.08884668,0.00012044588,0.00012380921,0.00402216,0.0000025455583,0.0005126408,0.003653729,0.0027873265,0.00017621361,0.010180038,0.00013124797],"about_ca_topic_score_codex":0.0006401273,"about_ca_topic_score_gemma":0.00033316336,"teacher_disagreement_score":0.08551063,"about_ca_system_score_codex":0.00037121953,"about_ca_system_score_gemma":0.0070823203,"threshold_uncertainty_score":0.9985466},"labels":[],"label_agreement":null},{"id":"W3032046986","doi":"10.1056/nejmoa2004325","title":"Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":436,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Myovant Sciences","keywords":"Prostate cancer; Androgen deprivation therapy; Testosterone (patch); Medicine; Luteinizing hormone; Internal medicine; Androgen; Hormone antagonist; Hormone; Endocrinology; Gonadotropin-releasing hormone; Leuprorelin; Antagonist; Oncology; Cancer; Endocrine system; Receptor","score_opus":0.05957229224554349,"score_gpt":0.37050466439170665,"score_spread":0.31093237214616315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032046986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8862519,0.011815944,0.00015827532,0.10077306,0.0002233793,0.0006349407,0.0000042370184,0.000009898538,0.00012832171],"genre_scores_gemma":[0.97856945,0.015994864,0.0007777936,0.0018456716,0.0023293463,0.000018273457,0.000016349468,0.000022039185,0.00042623465],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989073,0.00002584762,0.0003960625,0.00012917815,0.00033894135,0.0002026544],"domain_scores_gemma":[0.999154,0.00006844893,0.0001709469,0.00007260188,0.00023763326,0.0002963951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039240997,0.00011491079,0.00042200534,0.00012967072,0.000025880388,0.000005323152,0.000072221694,0.000042082673,0.00011419072],"category_scores_gemma":[0.00019646718,0.000066138,0.000055553945,0.0002598027,0.000049412647,0.000102274025,0.000008185431,0.00024541048,9.902308e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028545262,0.000093844894,0.13830623,0.00011845072,0.00016585922,0.00024742153,0.0054916414,0.00010200442,0.029197302,0.00003380001,0.0089758355,0.78872234],"study_design_scores_gemma":[0.52396417,0.020201046,0.051866002,0.0013594917,0.00016893473,0.0002435529,0.00079021114,0.00055086426,0.024285188,0.0012295072,0.37511206,0.00022897484],"about_ca_topic_score_codex":0.00006240699,"about_ca_topic_score_gemma":0.000022727976,"teacher_disagreement_score":0.7884934,"about_ca_system_score_codex":0.00008613043,"about_ca_system_score_gemma":0.00035829365,"threshold_uncertainty_score":0.26970297},"labels":[],"label_agreement":null},{"id":"W3032163036","doi":"10.1200/jco.2020.38.15_suppl.tps5601","title":"RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Enzalutamide; Biochemical recurrence; Androgen deprivation therapy; Radiation therapy; Lymph node; Oncology; Nocturia; Urology; Internal medicine; Cancer; Surgery; Androgen receptor","score_opus":0.22287370133834156,"score_gpt":0.5239089853556419,"score_spread":0.30103528401730034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032163036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866749,0.0031460552,0.000012899493,0.008610644,0.0004911374,0.00091503054,0.0000035862288,0.000008432516,0.00013731947],"genre_scores_gemma":[0.9932927,0.004227759,0.0005976122,0.001037854,0.00053718395,0.00003124988,0.0000013406341,0.000030143687,0.00024415372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959344,0.0006644203,0.0021854434,0.00026322834,0.0006325481,0.0003199517],"domain_scores_gemma":[0.9961696,0.001753303,0.0012253848,0.00015079205,0.00026753446,0.00043334105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002554119,0.0001771491,0.002424775,0.00018387218,0.000026510648,0.000008487252,0.00014461763,0.00015799262,0.000106284184],"category_scores_gemma":[0.0010963003,0.000093855284,0.0003509004,0.0004698499,0.00013600932,0.000115162584,0.00003523229,0.0010122545,0.0000014161843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07098251,0.0036751323,0.8326018,0.00009684563,0.0010879604,0.003706499,0.003086614,0.000028192251,0.00031857612,7.881314e-7,0.0010248718,0.083390236],"study_design_scores_gemma":[0.0942348,0.15649135,0.71369195,0.0015514026,0.000996924,0.00016794757,0.004410144,0.00038245934,0.00047513278,0.00001688464,0.027269611,0.00031136116],"about_ca_topic_score_codex":0.00014495372,"about_ca_topic_score_gemma":0.0006413249,"teacher_disagreement_score":0.15281624,"about_ca_system_score_codex":0.00028662678,"about_ca_system_score_gemma":0.0039708624,"threshold_uncertainty_score":0.70441395},"labels":[],"label_agreement":null},{"id":"W3032259164","doi":"10.1200/jco.2020.38.15_suppl.5521","title":"Molecular determinants of prostate specific antigen (PSA) kinetics and clinical response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTAN.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Internal medicine; Basal (medicine); Population; Oncology; Androgen deprivation therapy; Urology; Cancer","score_opus":0.11356616701887173,"score_gpt":0.4601772755687373,"score_spread":0.34661110854986554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032259164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914404,0.0005062507,0.000010083454,0.0066634337,0.00016980249,0.0011317782,0.000039520564,0.0000035638325,0.000035124496],"genre_scores_gemma":[0.9947371,0.0019172304,0.0024735061,0.00068993913,0.00010037128,0.000016129306,0.000004259535,0.000028888735,0.00003257728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99449694,0.000963031,0.003132988,0.0003837765,0.00062218565,0.0004010757],"domain_scores_gemma":[0.9962545,0.0012142063,0.0011734958,0.00018620504,0.0004994212,0.0006721687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028293852,0.00021148489,0.0017211973,0.00025013584,0.000020410213,0.000014943859,0.00015021453,0.00019670655,0.000022734235],"category_scores_gemma":[0.0022498702,0.0001448678,0.00015956824,0.00047522952,0.000379385,0.00010761456,0.000075724834,0.00081692194,0.0000037245943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13621654,0.0018273724,0.8220363,0.0000996928,0.000141974,0.0031055633,0.0006415378,0.00012419466,0.0028376915,0.0000015906786,0.0001038532,0.032863684],"study_design_scores_gemma":[0.02353735,0.054962642,0.91730285,0.00050251366,0.00012208588,0.000019298099,0.00021137047,0.00015862414,0.0012404919,0.000021403257,0.0017886374,0.00013275947],"about_ca_topic_score_codex":0.00004739924,"about_ca_topic_score_gemma":0.00044054585,"teacher_disagreement_score":0.11267918,"about_ca_system_score_codex":0.00021166833,"about_ca_system_score_gemma":0.0017791975,"threshold_uncertainty_score":0.5907537},"labels":[],"label_agreement":null},{"id":"W3032621023","doi":"10.5489/cuaj.6685","title":"Optimizing screening and management of cardiovascular health in prostate cancer","year":2020,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Ottawa; Queensway-Carleton Hospital; Stornoway Diamond (Canada); University of British Columbia; Western University; St. Michael's Hospital; Centre hospitalier universitaire de Québec; Montreal Heart Institute; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Disease; Multidisciplinary approach; Multidisciplinary team; Intensive care medicine; Androgen deprivation therapy; Identification (biology); Clinical Practice; Cancer; Population; Disease management; Internal medicine; Physical therapy; Nursing","score_opus":0.06027817811171855,"score_gpt":0.3412637260419632,"score_spread":0.28098554793024466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032621023","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026071304,0.99072945,0.000012899179,0.008023126,0.00007038124,0.00086377666,0.00008368633,0.0000065680833,0.00018406093],"genre_scores_gemma":[0.00009688095,0.9986416,0.00055960985,0.0003042412,0.00012199267,0.000055358003,0.000045241395,0.000019846719,0.00015520878],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980747,0.00027709582,0.0005405377,0.00025812714,0.00035246488,0.0004970494],"domain_scores_gemma":[0.9987098,0.000047446054,0.00035702193,0.000089652596,0.00008705994,0.000709025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089994975,0.00019377125,0.0014873872,0.00030269808,0.0001077242,0.000039200815,0.00008652741,0.0001664165,0.000043626034],"category_scores_gemma":[0.000047167414,0.00014082603,0.00038905186,0.0004132844,0.000027825767,0.000040290164,0.000034797376,0.00083499466,0.0000023529517],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018727973,0.000011813033,0.0021877103,0.0028218476,0.0019994962,0.0005913885,0.00008927373,0.0000302639,7.816154e-9,0.000010354158,0.00052774145,0.9917114],"study_design_scores_gemma":[0.00097509875,0.00015415339,0.0017062424,0.004896008,0.0006647858,0.00008563793,0.000042479165,0.00001871827,3.607338e-8,0.000010920296,0.9913403,0.00010565371],"about_ca_topic_score_codex":0.0018412381,"about_ca_topic_score_gemma":0.0001879864,"teacher_disagreement_score":0.9916057,"about_ca_system_score_codex":0.002324966,"about_ca_system_score_gemma":0.0014208197,"threshold_uncertainty_score":0.6079705},"labels":[],"label_agreement":null},{"id":"W3032683499","doi":"10.1200/jco.2020.38.15_suppl.e17503","title":"Effect of androgen deprivation therapy combined with nivolumab on the systemic antitumor immune response in castration-sensitive prostate cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Conquer Cancer Foundation","keywords":"Medicine; Prostate cancer; Nivolumab; Androgen deprivation therapy; Immunotherapy; Castration; Immune system; Antigen; Oncology; Cancer; Immunology; Antibody; Internal medicine; Cancer research; Hormone","score_opus":0.08106360437378021,"score_gpt":0.4440707087000578,"score_spread":0.3630071043262776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032683499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769891,0.00066073716,0.0000059210356,0.021265505,0.00010928713,0.0008830807,0.0000049783625,0.0000038468525,0.00007754285],"genre_scores_gemma":[0.99770147,0.0015741163,0.00003151054,0.00049175776,0.00012946546,0.000017942904,0.0000025192169,0.0000107531605,0.00004045717],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9967237,0.001668863,0.0010343194,0.00012607181,0.0003093508,0.00013771147],"domain_scores_gemma":[0.9948341,0.0037218374,0.00088462024,0.00010893718,0.00033514923,0.00011530631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003780664,0.00010190867,0.0009506117,0.00007321991,0.00003122128,0.000005638983,0.00008474608,0.00010431618,0.000014966952],"category_scores_gemma":[0.0015459623,0.0000469112,0.00014369174,0.00024142074,0.00018627253,0.00005368716,0.000013804192,0.00059031247,0.000002633581],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7936522,0.0006029857,0.1469152,0.00009992992,0.00055575586,0.0014519537,0.00096958084,0.00013261946,0.020928204,0.000025009154,0.00017771457,0.03448887],"study_design_scores_gemma":[0.06265995,0.3466575,0.4907313,0.0011201667,0.00020627712,0.00032004633,0.0005146927,0.00041791005,0.09686739,0.00001749845,0.00037756137,0.000109691144],"about_ca_topic_score_codex":0.00003376297,"about_ca_topic_score_gemma":0.000009479347,"teacher_disagreement_score":0.7309922,"about_ca_system_score_codex":0.00015852354,"about_ca_system_score_gemma":0.001846619,"threshold_uncertainty_score":0.32758227},"labels":[],"label_agreement":null},{"id":"W3032886415","doi":"10.1200/jco.2020.38.15_suppl.5541","title":"Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide: Results from the TITAN and SPARTAN studies.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Hazard ratio; Urology; Confidence interval; Titan (rocket family); Internal medicine; Post-hoc analysis; Oncology; Cancer","score_opus":0.15271574737130175,"score_gpt":0.4460716657522297,"score_spread":0.2933559183809279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032886415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677726,0.00429122,0.0000014821878,0.02662319,0.00013180633,0.00088702503,0.000072871786,0.000009369259,0.00021040923],"genre_scores_gemma":[0.9758647,0.021629289,0.0007226087,0.0012374248,0.0003291881,0.000018172961,0.000026346688,0.000027259428,0.00014502284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99720746,0.00023740904,0.001390239,0.00034697252,0.00049422134,0.00032368425],"domain_scores_gemma":[0.9966517,0.0011447035,0.00094544195,0.00017840075,0.00070477516,0.00037496444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066228077,0.00020541553,0.0011927778,0.00005505425,0.00005521109,0.000017325037,0.00013026207,0.00013461265,0.0000145297],"category_scores_gemma":[0.000735339,0.00009259361,0.00007586952,0.0003420309,0.0005409687,0.000110312125,0.000057924386,0.00083795097,0.0000030635567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11553391,0.0009021704,0.8104253,0.000027525024,0.0007001486,0.00089348364,0.0022734925,0.00007297553,0.00014086762,0.0000027656708,0.002182693,0.06684469],"study_design_scores_gemma":[0.051487315,0.047022637,0.8707301,0.00046102106,0.00021026214,0.000009932483,0.0012050894,0.000036369813,0.00021571532,0.00003361161,0.028459197,0.00012872113],"about_ca_topic_score_codex":0.00005986552,"about_ca_topic_score_gemma":0.00031094826,"teacher_disagreement_score":0.06671596,"about_ca_system_score_codex":0.00024025819,"about_ca_system_score_gemma":0.0006204778,"threshold_uncertainty_score":0.37758577},"labels":[],"label_agreement":null},{"id":"W3033104501","doi":"10.1158/0008-5472.can-20-0233","title":"p300-Mediated Acetylation of Histone Demethylase JMJD1A Prevents Its Degradation by Ubiquitin Ligase STUB1 and Enhances Its Activity in Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; U.S. Department of Veterans Affairs","keywords":"Prostate cancer; Enzalutamide; SUMO protein; Cancer research; Ubiquitin ligase; Androgen receptor; Chemistry; Biology; Ubiquitin; Cancer; Biochemistry","score_opus":0.09812964589445748,"score_gpt":0.4549123753982027,"score_spread":0.3567827295037452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033104501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9601912,0.028041415,0.000006507712,0.00921306,0.00005571773,0.0020472382,0.00031524998,0.000030449275,0.00009917697],"genre_scores_gemma":[0.9707451,0.025842357,0.000021656362,0.000087178996,0.00010164235,0.0008836185,0.000109978784,0.000036825906,0.0021716561],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970322,0.0003681529,0.00035760584,0.0005899349,0.0010312947,0.00062081206],"domain_scores_gemma":[0.99856,0.00019406395,0.00013316455,0.00017760553,0.0005301927,0.00040495294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008518533,0.0002050699,0.0004379636,0.00028245596,0.00012358614,0.000029879238,0.00014631392,0.00011795206,0.00031986437],"category_scores_gemma":[0.00045498685,0.0001764628,0.000045576784,0.0011510875,0.00022400316,0.00035784958,0.00014090861,0.0006439849,0.00001662226],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031908434,0.0002720477,0.013297875,0.0012064032,0.00009199534,0.000034420194,0.0016874671,0.000008830036,0.95232505,0.0000049153423,0.002039305,0.025840852],"study_design_scores_gemma":[0.0041104984,0.0006518706,0.010834702,0.000549385,0.000033060376,0.0000011503237,0.00022250804,0.0007261078,0.9812616,0.000011169773,0.0014441367,0.00015380194],"about_ca_topic_score_codex":0.001121209,"about_ca_topic_score_gemma":0.0003365224,"teacher_disagreement_score":0.028936563,"about_ca_system_score_codex":0.00068844605,"about_ca_system_score_gemma":0.000978171,"threshold_uncertainty_score":0.7195944},"labels":[],"label_agreement":null},{"id":"W3033295541","doi":"10.3390/cells9061398","title":"Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development","year":2020,"lang":"en","type":"article","venue":"Cells","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Mitacs; Canadian Institutes of Health Research; National Cancer Institute; Prostate Cancer Foundation; National Institutes of Health; Terry Fox Research Institute","keywords":"Transdifferentiation; Prostate cancer; Cancer research; Transcriptome; Biology; Androgen receptor; Downregulation and upregulation; Adenocarcinoma; Cancer; Reprogramming; Prostate; LNCaP; Cell; Cell biology; Stem cell; Gene; Gene expression; Genetics","score_opus":0.0385939187859812,"score_gpt":0.29543637873998846,"score_spread":0.25684245995400723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033295541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871326,0.0004943855,0.00026114346,0.0093805,0.00017198994,0.0017038507,0.00030736346,0.00013903341,0.00040910442],"genre_scores_gemma":[0.98051524,0.0003693339,0.008641138,0.007042963,0.00014599942,0.00057085755,0.0005635383,0.00006435909,0.0020865519],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980348,0.00002884872,0.00036266656,0.0005935633,0.00046917103,0.0005110028],"domain_scores_gemma":[0.99877906,0.000031964242,0.000075368815,0.0002442349,0.00017237062,0.0006969963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000032858436,0.00023568542,0.00031654938,0.000066859546,0.00010166519,0.00004340755,0.00012255598,0.00003148912,0.00042995674],"category_scores_gemma":[0.000018418583,0.0001935349,0.0000810102,0.00025404678,0.000060865026,0.00006334014,0.00013787292,0.0002008222,0.0003521134],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013529088,0.00029707138,0.0011529333,0.0001174677,0.00021958408,0.0005618782,0.0042214426,0.0020004224,0.9369833,0.0000028647048,0.021591574,0.03149858],"study_design_scores_gemma":[0.002387265,0.00039278792,0.0009714581,0.00007354823,0.000055945675,0.0000020538957,0.00014642584,0.0016138917,0.9347169,0.000030920528,0.05938991,0.00021889978],"about_ca_topic_score_codex":0.00008865231,"about_ca_topic_score_gemma":0.000017240367,"teacher_disagreement_score":0.037798338,"about_ca_system_score_codex":0.00014888168,"about_ca_system_score_gemma":0.0005040633,"threshold_uncertainty_score":0.7892124},"labels":[],"label_agreement":null},{"id":"W3033494897","doi":"","title":"Prolactin and androgen R1881 induce pro-survival carboxypeptidase-D and EDD E3 ligase in triple-negative and HER2+ breast cancer.","year":2020,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Androgen receptor; Triple-negative breast cancer; Cancer research; Internal medicine; Endocrinology; Downregulation and upregulation; Androgen; Chemistry; Biology; Medicine; Cancer; Breast cancer; Prostate cancer; Hormone; Biochemistry","score_opus":0.045751623024949006,"score_gpt":0.28996800371448533,"score_spread":0.24421638068953633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033494897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800615,0.0032889994,3.2452652e-7,0.013417992,0.00004010453,0.0024292017,0.00008453602,0.000035935875,0.0006414244],"genre_scores_gemma":[0.9963026,0.0012499429,0.000025158486,0.0002944071,0.00017547733,0.0015153292,0.000009870328,0.00002486907,0.00040235516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867153,0.0000716099,0.00017964943,0.00043178233,0.00022316082,0.0004222681],"domain_scores_gemma":[0.9992011,0.00006839717,0.000052329495,0.00009888649,0.00006016788,0.00051912066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023094742,0.00018364194,0.00035260338,0.00008894791,0.00006392863,0.000048809743,0.000042753294,0.000087589164,0.000011980442],"category_scores_gemma":[0.00012790841,0.000141152,0.000021550502,0.00031464448,0.00016822007,0.00014160665,0.000090980204,0.00028642695,9.0674104e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00757162,0.00019460493,0.69605577,0.00059930154,0.00023980354,0.0003208633,0.0037973283,3.8684922e-7,0.0021139227,0.000019300613,0.00038174458,0.28870532],"study_design_scores_gemma":[0.0085361,0.00019165945,0.97805387,0.00007454704,0.000076012795,0.00006717326,0.0006811175,0.00009349242,0.011559455,0.00004780245,0.00044010373,0.00017869612],"about_ca_topic_score_codex":0.00042717013,"about_ca_topic_score_gemma":0.00016239836,"teacher_disagreement_score":0.28852662,"about_ca_system_score_codex":0.00010477348,"about_ca_system_score_gemma":0.00013945624,"threshold_uncertainty_score":0.57560116},"labels":[],"label_agreement":null},{"id":"W3033682445","doi":"10.5489/cuaj.6320","title":"Bone scan use in the management of metastatic castration-resistant prostate cancer: Survey of practice patterns among Canadian radiation oncologists, medical oncologists, and urologists","year":2020,"lang":"en","type":"letter","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"Canadian Urological Oncology Group","keywords":"Medicine; Prostate cancer; Bone scintigraphy; Positron emission tomography; Radiology; Clinical trial; Medical physics; Cancer; Nuclear medicine; Oncology; Internal medicine","score_opus":0.048607855211058905,"score_gpt":0.3237046430876417,"score_spread":0.27509678787658276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033682445","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22954854,0.002104522,0.0000044864105,0.76402766,0.00030047417,0.0016905215,0.0020109303,0.00001160043,0.00030127435],"genre_scores_gemma":[0.8660528,0.009747256,0.00012328356,0.122147396,0.00032705095,0.00012741257,0.0012319952,0.00003128598,0.00021148945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99349916,0.002285046,0.0011847107,0.0004825119,0.0016160901,0.00093248003],"domain_scores_gemma":[0.9950193,0.0017145949,0.0013419762,0.00024563083,0.0007848635,0.0008936334],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0038435683,0.00036246082,0.00095177756,0.0005523075,0.00023207566,0.00015393317,0.0003714745,0.00077892136,0.00020696853],"category_scores_gemma":[0.0032655604,0.00025203798,0.00014632319,0.0006996084,0.00033382126,0.0002163832,0.000043101383,0.0030937816,0.0000028368415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00042000352,0.00010079399,0.8628721,0.00022015905,0.00093165843,0.016196437,0.00043229337,0.000023800303,0.0000021644425,0.000019772586,0.11450145,0.0042793513],"study_design_scores_gemma":[0.0020440742,0.00095837074,0.9191773,0.00016570688,0.00052991934,0.0001895987,0.00024086027,0.00008783324,0.0000023400794,0.00003718151,0.076366656,0.00020014119],"about_ca_topic_score_codex":0.7083145,"about_ca_topic_score_gemma":0.7795605,"teacher_disagreement_score":0.6418803,"about_ca_system_score_codex":0.0040058093,"about_ca_system_score_gemma":0.0065162806,"threshold_uncertainty_score":0.9999932},"labels":[],"label_agreement":null},{"id":"W3034493697","doi":"","title":"Effects of linker modifications on tumor-to-kidney contrast of 68Ga-PSMA imaging radioligands","year":2018,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Biodistribution; LNCaP; Glutamate carboxypeptidase II; Prostate cancer; Chemistry; In vivo; Kidney; In vitro; Cancer research; Nuclear medicine; Medicine; Cancer; Internal medicine; Biochemistry","score_opus":0.014620948563071733,"score_gpt":0.3162737954387363,"score_spread":0.30165284687566457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034493697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9586126,0.00025992584,0.000738255,0.0038487015,0.00014945552,0.0010014463,0.000025641664,0.000045201807,0.035318736],"genre_scores_gemma":[0.9959121,0.00003515186,0.00044460647,0.00066560373,0.00013492984,0.00003766733,0.000013848066,0.000014027753,0.0027420807],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99920917,0.000020450456,0.00018477252,0.00016916865,0.00021734183,0.00019910086],"domain_scores_gemma":[0.9991266,0.00010538471,0.00004515683,0.00024272996,0.00024610054,0.00023403869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010814196,0.0000925665,0.00024095853,0.00016273138,0.000040995506,0.000004959362,0.00007216646,0.000017663577,0.00011382568],"category_scores_gemma":[0.00017766932,0.000062435254,0.000058901678,0.000224728,0.0001721044,0.000028577293,0.000021318185,0.000075010525,0.00006166781],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001279526,0.0008246097,0.024806319,0.0005305171,0.00023487529,0.00005411854,0.00089628005,0.0000017865929,0.9368176,0.0026336676,0.024652869,0.0072678323],"study_design_scores_gemma":[0.0033015485,0.000830101,0.037490282,0.00033462574,0.00007040145,0.00001010893,0.00005609746,0.00046538157,0.9557049,0.000070338734,0.0015968571,0.000069306356],"about_ca_topic_score_codex":0.000060086342,"about_ca_topic_score_gemma":0.0000014171669,"teacher_disagreement_score":0.037299447,"about_ca_system_score_codex":0.000048545517,"about_ca_system_score_gemma":0.00016569495,"threshold_uncertainty_score":0.2546036},"labels":[],"label_agreement":null},{"id":"W3034688971","doi":"10.1016/j.euo.2020.05.006","title":"Key Perspectives on Managing Older Patients with Prostate Cancer: What We Know About the Fit and What We Need to Know About the Frail","year":2020,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Need to know; Key (lock); Prostate cancer; Cancer; Intensive care medicine; Internal medicine; Computer science; Computer security","score_opus":0.019628359395526648,"score_gpt":0.294576433477559,"score_spread":0.27494807408203237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034688971","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014001108,0.12629712,0.0000038412745,0.85261345,0.0010219883,0.002836516,0.000046491532,0.000103815444,0.0030756537],"genre_scores_gemma":[0.013412016,0.3269674,0.00004110865,0.64244044,0.0030732667,0.00043126006,0.00019276084,0.00027436976,0.013167371],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947867,0.0017156544,0.00044880775,0.0013692867,0.00054080534,0.0011387673],"domain_scores_gemma":[0.9975269,0.00070619246,0.0003236597,0.00084949116,0.00032595513,0.00026781516],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00040762173,0.00074584375,0.0009673091,0.0003109578,0.00055760954,0.0003694346,0.00066265755,0.000361267,0.00029504317],"category_scores_gemma":[0.00008511376,0.00038437085,0.00015298095,0.00040794557,0.0013742398,0.00029945673,0.000517805,0.0036198576,0.00037502407],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045263534,0.00023016012,0.002301344,0.00022095715,0.0010510605,0.003678467,0.042702734,0.000023453313,0.0000096922395,0.00002511407,0.7295607,0.21567],"study_design_scores_gemma":[0.004907951,0.00594899,0.01141818,0.0010302789,0.000514451,0.00006772141,0.006812035,0.000018391245,0.000006327931,0.000029777453,0.96886224,0.0003836337],"about_ca_topic_score_codex":0.00004030781,"about_ca_topic_score_gemma":0.00006188131,"teacher_disagreement_score":0.2393016,"about_ca_system_score_codex":0.00045041158,"about_ca_system_score_gemma":0.00042310316,"threshold_uncertainty_score":0.9998608},"labels":[],"label_agreement":null},{"id":"W3035176085","doi":"10.21037/tau-2020-04","title":"Implications of local failure on overall prognosis in aggressive prostate cancer","year":2020,"lang":"en","type":"letter","venue":"Translational Andrology and Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Oncology; Internal medicine","score_opus":0.02490707459479573,"score_gpt":0.30650448846661055,"score_spread":0.2815974138718148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035176085","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029124308,0.0032373574,0.00002788213,0.9659683,0.000046613743,0.0007004196,0.00040743127,0.000016099037,0.00047156354],"genre_scores_gemma":[0.74402434,0.0013549747,0.000046260968,0.25232747,0.00032174657,0.00039414724,0.0012514549,0.00002369883,0.0002559145],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987615,0.00009877119,0.00028146166,0.00041802612,0.00014364651,0.00029662374],"domain_scores_gemma":[0.9994304,0.00019571757,0.00013477456,0.000094447176,0.00008309043,0.000061564155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004280745,0.00020194089,0.000490583,0.00020279866,0.000048217953,0.000002911388,0.000066919536,0.00059073995,0.00024334263],"category_scores_gemma":[0.000008117408,0.00015754887,0.00007809704,0.00012422419,0.0005077397,0.000026189504,0.000015009502,0.0011552454,0.0000066238713],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015235285,0.00069947937,0.45611876,0.0017818119,0.0017838536,0.0042430223,0.0019995107,0.00042145833,0.00060812384,0.0038338278,0.48452255,0.028752336],"study_design_scores_gemma":[0.015215262,0.0069407946,0.4195286,0.00028253722,0.0008330811,0.0006577218,0.000020599115,0.0005576851,0.00043365327,0.02686247,0.52805305,0.000614527],"about_ca_topic_score_codex":0.00004197945,"about_ca_topic_score_gemma":0.000069496244,"teacher_disagreement_score":0.7149,"about_ca_system_score_codex":0.00002235113,"about_ca_system_score_gemma":0.00027871045,"threshold_uncertainty_score":0.64246565},"labels":[],"label_agreement":null},{"id":"W3035356494","doi":"10.1016/j.eururo.2020.04.061","title":"Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial","year":2020,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pfizer","keywords":"Enzalutamide; Medicine; Hazard ratio; Prostate cancer; Placebo; Internal medicine; Docetaxel; Adverse effect; Confidence interval; Chemotherapy; Oncology; Cabazitaxel; Proportional hazards model; Survival analysis; Incidence (geometry); Urology; Surgery; Cancer; Androgen deprivation therapy; Pathology; Androgen receptor","score_opus":0.027991985900491928,"score_gpt":0.2827059940051615,"score_spread":0.2547140081046696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035356494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722863,0.0005781579,0.000029140405,0.022979636,0.00004430836,0.0016055446,0.00018954524,0.000041913674,0.0022454422],"genre_scores_gemma":[0.9972901,0.00056607655,0.0001408206,0.0009974575,0.00017051256,0.000063262385,0.0000938172,0.00004312353,0.0006348417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845827,0.0004494301,0.00024291813,0.00036281772,0.00024272368,0.00024387125],"domain_scores_gemma":[0.99937075,0.00020267526,0.000085758955,0.00017407381,0.0000535555,0.00011318952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029599632,0.00017443886,0.00031526366,0.000032775006,0.000078339865,0.000026873327,0.00008160801,0.000022854045,0.00010339135],"category_scores_gemma":[0.0000512945,0.00008855024,0.000026811655,0.00015627831,0.00019456638,0.00006536054,0.000033015644,0.00025998708,0.000009842676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45372996,0.00025927203,0.5216626,0.000080902784,0.0013125006,0.0007790957,0.013551542,0.00027261095,0.002483151,0.000069586866,0.0010179725,0.0047808303],"study_design_scores_gemma":[0.09582329,0.0044413814,0.89423245,0.00003833585,0.000283745,0.000009238256,0.00091526366,0.00029537844,0.00014609478,0.000014944833,0.0036636228,0.00013625447],"about_ca_topic_score_codex":0.00039634714,"about_ca_topic_score_gemma":0.00044413874,"teacher_disagreement_score":0.3725699,"about_ca_system_score_codex":0.000049255847,"about_ca_system_score_gemma":0.00017346263,"threshold_uncertainty_score":0.3610974},"labels":[],"label_agreement":null},{"id":"W3035392667","doi":"10.1158/1557-3265.advprecmed20-14","title":"Abstract 14: Computer-aided discovery of small-molecule inhibitors targeting neural transcription factor BRN2 in neuroendocrine prostate tumors","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; SOX2; Androgen receptor; Cancer research; LNCaP; Enzalutamide; Transcription factor; Medicine; Bioinformatics; Biology; Cancer; Internal medicine; Gene; Genetics","score_opus":0.19186769514599047,"score_gpt":0.45159321359909393,"score_spread":0.25972551845310343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035392667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849602,0.0013845167,0.000018138673,0.011589795,0.000267132,0.0015278771,0.00009236791,0.0000499632,0.000110012355],"genre_scores_gemma":[0.9969468,0.0014840944,0.000079756486,0.00035309282,0.0006908376,0.00011913686,0.00007280762,0.00005613826,0.00019732438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99570835,0.0004452639,0.0011750816,0.00078310445,0.0009946034,0.0008935964],"domain_scores_gemma":[0.99820185,0.00047925176,0.0001442433,0.00028335032,0.0003802689,0.00051106245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000839328,0.00024397338,0.00072719506,0.00024119008,0.00009049536,0.00006863297,0.0002807153,0.0000869567,0.00016001258],"category_scores_gemma":[0.00041961248,0.0001920521,0.00028267637,0.0009141628,0.0005296768,0.00024487244,0.00018997872,0.0018501832,0.000018444043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013164877,0.0015529091,0.6916604,0.0023972325,0.00020133056,0.0032736673,0.0014828392,0.0001826921,0.21555051,0.000022722104,0.003988758,0.06652203],"study_design_scores_gemma":[0.016122129,0.0067628315,0.81120473,0.00097306503,0.000046762612,0.0000149100315,0.0007473552,0.004599161,0.15795535,0.000052419975,0.0010532251,0.00046803814],"about_ca_topic_score_codex":0.0009974263,"about_ca_topic_score_gemma":0.000115443334,"teacher_disagreement_score":0.11954433,"about_ca_system_score_codex":0.00019292677,"about_ca_system_score_gemma":0.0007811283,"threshold_uncertainty_score":0.8038228},"labels":[],"label_agreement":null},{"id":"W3035885874","doi":"10.1158/1557-3265.liqbiop20-b02","title":"Abstract B02: Genomic and transcriptomic profiling of urine in prostate cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Prostate cancer; Biopsy; Liquid biopsy; Prostate; Oncology; Internal medicine; Cancer; Urology","score_opus":0.2969214302281731,"score_gpt":0.5315786752484376,"score_spread":0.23465724502026453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035885874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9655595,0.01570468,9.925631e-7,0.016472923,0.00008917832,0.0014595933,0.00009188561,0.000022888396,0.00059837947],"genre_scores_gemma":[0.96826625,0.030272614,0.000110447654,0.00028121466,0.00032719728,0.00030367324,0.00001600189,0.000038492355,0.00038410167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972206,0.00017352852,0.00074614916,0.0006069399,0.0006178434,0.00063494005],"domain_scores_gemma":[0.99856156,0.00033388173,0.00007513538,0.00023028937,0.00029309053,0.00050605054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015839263,0.00015939245,0.0006101116,0.0001820803,0.00006332603,0.00002265303,0.00018042266,0.00012356509,0.0004310493],"category_scores_gemma":[0.00029033702,0.00012335321,0.0001142156,0.00058327254,0.00064545794,0.0000843714,0.00012576378,0.0012774129,0.00001792553],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008905435,0.0003483498,0.8403761,0.001657955,0.00015616529,0.00021230038,0.00092551525,0.000019746247,0.10576283,0.000039384544,0.0008101455,0.040786076],"study_design_scores_gemma":[0.011472335,0.0014835693,0.942392,0.00067699846,0.000050752777,0.0000036596186,0.00047880982,0.0005926833,0.038399335,0.00016580144,0.0040717465,0.00021229686],"about_ca_topic_score_codex":0.0011894502,"about_ca_topic_score_gemma":0.00025993807,"teacher_disagreement_score":0.10201591,"about_ca_system_score_codex":0.00021469824,"about_ca_system_score_gemma":0.0013472078,"threshold_uncertainty_score":0.55497944},"labels":[],"label_agreement":null},{"id":"W3036173424","doi":"10.5489/cuaj.6388","title":"Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC","year":2020,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ozmosis Research (Canada); University of Alberta; Oakville-Trafalgar Memorial Hospital; Dalhousie University; Centre Hospitalier Universitaire de Sherbrooke; Hôtel-Dieu de Québec; University of Calgary; Trillium Health Centre; University of Manitoba; Victoria Hospital; McMaster University; Université de Sherbrooke; London Health Sciences Centre","funders":"","keywords":"Prostate cancer; Abiraterone acetate; Medicine; Prednisone; Enzalutamide; Internal medicine; Cancer; Oncology; Urology; Androgen deprivation therapy; Androgen receptor","score_opus":0.05692407859584777,"score_gpt":0.30787526808886273,"score_spread":0.250951189493015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036173424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987325,0.0002713288,6.812122e-7,0.010172855,0.000059570208,0.0008685734,0.0012125327,0.000010956372,0.00007851105],"genre_scores_gemma":[0.9986015,0.00028413875,0.000070997194,0.0004664468,0.000022125892,0.000046694644,0.00010797865,0.000021377213,0.0003787689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964171,0.00027019097,0.0012104947,0.0003679382,0.0009519113,0.0007823757],"domain_scores_gemma":[0.9966442,0.00020681742,0.0011782458,0.00015310764,0.0010045713,0.00081304664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004888797,0.00026749333,0.00082377787,0.00013729629,0.00013204121,0.000038503917,0.00014480788,0.0000903568,0.00007343674],"category_scores_gemma":[0.00079436926,0.00017946602,0.00009168035,0.00084427116,0.000110849716,0.00016892227,0.000026033298,0.000530109,0.0000012616388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006715681,0.00014957704,0.98755467,0.00007650806,0.000449713,0.00092729833,0.0009118263,0.00039524128,0.00071430777,0.0000011853658,0.00085468544,0.0012493316],"study_design_scores_gemma":[0.009522589,0.0022690985,0.9854513,0.00023289165,0.00018102328,0.000012095951,0.00023727865,0.00013873211,0.0014957166,0.000007629014,0.00028425787,0.00016742168],"about_ca_topic_score_codex":0.66817015,"about_ca_topic_score_gemma":0.8202166,"teacher_disagreement_score":0.15204644,"about_ca_system_score_codex":0.002800948,"about_ca_system_score_gemma":0.0040829824,"threshold_uncertainty_score":0.73243815},"labels":[],"label_agreement":null},{"id":"W3036626624","doi":"10.1158/1557-3265.liqbiop20-pr09","title":"Abstract PR09: Frequency and etiology of ctDNA-positive metastatic prostate cancer with BRCA2, ATM, or CDK12 mutations","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"PTEN; Cancer research; Prostate cancer; Mutation; Cancer; CDKN2A; Germline mutation; Biology; DNA repair; Germline; DNA damage; Somatic cell; Gene; Medicine; Genetics; DNA; PI3K/AKT/mTOR pathway; Signal transduction","score_opus":0.3145723633926266,"score_gpt":0.5531282130071178,"score_spread":0.23855584961449117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036626624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95919144,0.0057992307,0.000020636113,0.03102089,0.00007493931,0.0021769695,0.00048310505,0.0000384654,0.0011943179],"genre_scores_gemma":[0.98551697,0.01076047,0.00079592003,0.00053409446,0.00025807542,0.00075261877,0.000081147344,0.000047797475,0.0012529151],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99675876,0.0003940762,0.00067582045,0.0006994238,0.00080002967,0.0006718865],"domain_scores_gemma":[0.9962654,0.0015513445,0.00015506509,0.00027964867,0.0010721629,0.000676375],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011049483,0.00021031401,0.0007226338,0.00014608576,0.0001797768,0.00003314316,0.00017926558,0.0001282289,0.001355314],"category_scores_gemma":[0.00081873895,0.0001273607,0.00009975726,0.00084092614,0.0019493953,0.00013859362,0.00012443215,0.0011386481,0.00002959962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060539752,0.0020607559,0.7741523,0.0041788383,0.0037790628,0.002526393,0.007812994,0.00007047172,0.014511373,0.0007381183,0.008326413,0.12130354],"study_design_scores_gemma":[0.025917519,0.02337631,0.9248656,0.0020235733,0.0007673039,0.00006094161,0.0031486878,0.00039965284,0.012690231,0.0012860545,0.0048157545,0.0006483826],"about_ca_topic_score_codex":0.0018684671,"about_ca_topic_score_gemma":0.00078005716,"teacher_disagreement_score":0.1507133,"about_ca_system_score_codex":0.00018015968,"about_ca_system_score_gemma":0.0029720378,"threshold_uncertainty_score":0.99955755},"labels":[],"label_agreement":null},{"id":"W3036749792","doi":"10.1016/j.annonc.2020.06.006","title":"HSD3B1 (1245A&gt;C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbotsford Veterinary Clinic; Surrey Memorial Hospital; University of British Columbia, Okanagan Campus; Kelowna General Hospital; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Genentech; BC Cancer Foundation; Cilag; Astellas Pharma; Ministerio de Ciencia e Innovación; Instituto de Salud Carlos III; Prostate Cancer Canada; Ipsen; Clovis Oncology; Celgene; BC Cancer Agency; Prostate Cancer Foundation; Movember Foundation; Bristol-Myers Squibb; AstraZeneca; Pfizer; Sanofi; Jane ja Aatos Erkon Säätiö","keywords":"Enzalutamide; Medicine; Prostate cancer; Hazard ratio; Oncology; Internal medicine; Proportional hazards model; Genotype; Androgen deprivation therapy; Confidence interval; Cancer; Androgen receptor; Biology; Genetics","score_opus":0.17040081192395942,"score_gpt":0.46908234109873437,"score_spread":0.298681529174775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036749792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846609,0.002405082,8.7478685e-7,0.010999646,0.00003562409,0.0012192355,0.0005753998,0.000016473427,0.00008675564],"genre_scores_gemma":[0.99320346,0.0054368535,0.0003703871,0.0005745346,0.00004544322,0.000093107126,0.00010626374,0.000018127368,0.00015179528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980603,0.00020512374,0.00072394917,0.00049991655,0.00022719588,0.000283528],"domain_scores_gemma":[0.99841946,0.00052929466,0.00026981317,0.00012842589,0.0004576123,0.00019540149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034054444,0.00021007331,0.0009711063,0.00008643642,0.0000488109,0.000011890853,0.00004565788,0.000064649415,0.0000099962035],"category_scores_gemma":[0.0004240538,0.00012966468,0.00004165037,0.00020602491,0.0004334632,0.00010440847,0.00006458228,0.00021312654,0.0000014478081],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024601936,0.0008526991,0.9583079,0.000104337574,0.0017239166,0.0006375651,0.003998067,0.000009276148,0.00068575947,0.00001893973,0.00021272052,0.008846875],"study_design_scores_gemma":[0.028889641,0.01691219,0.95115083,0.00016526491,0.00031302148,0.000004313641,0.0005709364,0.00009405743,0.0014043405,0.00014757832,0.0002069373,0.00014087686],"about_ca_topic_score_codex":0.0012301658,"about_ca_topic_score_gemma":0.0023929805,"teacher_disagreement_score":0.016059492,"about_ca_system_score_codex":0.00007834811,"about_ca_system_score_gemma":0.0003217774,"threshold_uncertainty_score":0.5287572},"labels":[],"label_agreement":null},{"id":"W3037221203","doi":"10.1016/j.eururo.2020.06.002","title":"Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials","year":2020,"lang":"en","type":"review","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Agonist; Oncology; Randomized controlled trial; Gonadotropin-releasing hormone; Relative risk; Meta-analysis; Gonadotropin-releasing hormone antagonist; Adverse effect; Confidence interval; Cancer; Hormone; Luteinizing hormone; Receptor","score_opus":0.20110476670321595,"score_gpt":0.4695688075371052,"score_spread":0.2684640408338893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037221203","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011118641,0.9750405,0.00001627717,0.0004641677,0.00023089824,0.010108074,0.0024546562,0.000032728658,0.00053407426],"genre_scores_gemma":[0.043427713,0.9548184,0.000046907124,0.000086068605,0.00007459371,0.00022964178,0.0010529839,0.00009206862,0.00017158416],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97739774,0.016224692,0.0043694526,0.0008846183,0.0006661313,0.00045739248],"domain_scores_gemma":[0.980405,0.01398463,0.0044501103,0.0005603777,0.00028910505,0.00031077897],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0031872408,0.00091292674,0.04322656,0.0007464694,0.00009833502,0.00003330036,0.00023815998,0.0001558255,0.00026756144],"category_scores_gemma":[0.0046277624,0.0003733748,0.012409347,0.00057610753,0.00093750935,0.000024986693,0.00012528637,0.0007810056,0.000008935119],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5068603,0.00064815773,0.0002197146,0.0005002666,0.45212594,0.0001316181,0.000033563825,0.00001294316,5.347116e-7,0.000018166606,0.000026535385,0.039422262],"study_design_scores_gemma":[0.3505426,0.014818838,0.003665473,0.00013157305,0.62501454,0.000001760176,0.0000029966554,0.000025150403,1.7412154e-7,0.0000011166228,0.0055905688,0.00020521536],"about_ca_topic_score_codex":0.00008518351,"about_ca_topic_score_gemma":0.000007080939,"teacher_disagreement_score":0.17288859,"about_ca_system_score_codex":0.00023224679,"about_ca_system_score_gemma":0.00075513416,"threshold_uncertainty_score":0.9998718},"labels":[],"label_agreement":null},{"id":"W3037257784","doi":"10.1111/bju.15151","title":"Use of prostate‐specific membrane antigen positron‐emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer","year":2020,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"National Health and Medical Research Council; Medical Research Council","keywords":"Prostate cancer; Medicine; Library science; Management; Cancer; Internal medicine","score_opus":0.04325196834879642,"score_gpt":0.3332386196905214,"score_spread":0.28998665134172497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037257784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9671159,0.026007434,0.000014950658,0.0059332508,0.00010674923,0.0007532486,0.000040337214,0.000008021481,0.000020148424],"genre_scores_gemma":[0.9720695,0.026481587,0.0008746777,0.0003855354,0.00004646802,0.000030436953,0.000017542936,0.000031324278,0.000062924635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973431,0.0005342848,0.0008593734,0.00028436436,0.00053295045,0.0004458767],"domain_scores_gemma":[0.99894154,0.00019721485,0.0003147172,0.000111832705,0.00018722092,0.00024745017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010545898,0.00018441123,0.00077524333,0.00039127367,0.00004255669,0.000038357368,0.0001430093,0.000055296747,0.0000952616],"category_scores_gemma":[0.000113194925,0.00016371439,0.00023614171,0.0005685347,0.000114633025,0.00026085155,0.000044115208,0.00065553316,5.9992755e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039069444,0.0009649851,0.52389127,0.00011224313,0.00056578335,0.025115406,0.0014111374,0.00032048492,0.35763112,0.0000021588237,0.0007277715,0.05018816],"study_design_scores_gemma":[0.018148314,0.0052288887,0.947051,0.0006061485,0.000088985005,0.0016863758,0.00030252239,0.00034674394,0.021544233,0.00005452302,0.004723201,0.00021905865],"about_ca_topic_score_codex":0.00028407847,"about_ca_topic_score_gemma":0.000037976748,"teacher_disagreement_score":0.42315972,"about_ca_system_score_codex":0.0001903785,"about_ca_system_score_gemma":0.00077677163,"threshold_uncertainty_score":0.6676079},"labels":[],"label_agreement":null},{"id":"W3037398086","doi":"10.1097/01.cot.0000475228.53449.63","title":"Prostate Cancer Image-Guided IMRT Trial Shows Low Toxicity, Good Outcomes","year":2015,"lang":"en","type":"article","venue":"Oncology Times","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Toxicity; Medicine; Oncology; Cancer; Clinical trial; Medical physics; Prostate; Internal medicine; Radiology","score_opus":0.07130815327870853,"score_gpt":0.41902468643470503,"score_spread":0.3477165331559965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037398086","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8052501,0.0015635117,0.000007166209,0.031489395,0.0013585476,0.0025434876,0.000083117055,0.00019649789,0.15750816],"genre_scores_gemma":[0.4386508,0.0007019499,0.0017213601,0.0025299506,0.0011855472,0.0011639681,0.00016065592,0.00008971043,0.55379605],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998158,0.00013555733,0.00034512498,0.00038409565,0.00041436093,0.0005628595],"domain_scores_gemma":[0.9987326,0.00012424386,0.0001080767,0.00032248654,0.00029965024,0.0004129001],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048950576,0.00023551997,0.00066625077,0.00013791824,0.00008721987,0.000030451736,0.00015398716,0.00021024131,0.0013183146],"category_scores_gemma":[0.00020819598,0.00015826718,0.00015012761,0.00018790738,0.00028212,0.00013604245,0.00013316963,0.00030570553,0.00040939153],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058269426,0.002943536,0.13620105,0.00016935237,0.0012134756,0.0013847305,0.002552789,0.000009341767,0.008407768,0.0002901841,0.7609994,0.027558945],"study_design_scores_gemma":[0.47423795,0.017288988,0.015442462,0.00020674613,0.0009524348,0.00023734113,0.0012817979,0.0003219288,0.052639972,0.0024086367,0.43399805,0.0009836998],"about_ca_topic_score_codex":0.00027260385,"about_ca_topic_score_gemma":0.00012356225,"teacher_disagreement_score":0.41596854,"about_ca_system_score_codex":0.00076463004,"about_ca_system_score_gemma":0.002021272,"threshold_uncertainty_score":0.9995946},"labels":[],"label_agreement":null},{"id":"W3037424465","doi":"10.1097/01.cot.0000475699.81589.17","title":"Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"Oncology Times","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Radiation therapy; Prostate cancer; Bicalutamide; Placebo; Prostatectomy; Oncology; Prostate; Androgen deprivation therapy; Internal medicine; Cancer; Urology; Surgery","score_opus":0.05899662323301119,"score_gpt":0.4100825638024227,"score_spread":0.3510859405694115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037424465","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35341936,0.010283787,0.0000040244863,0.042498965,0.00050897227,0.0007121712,0.00001737293,0.00013751451,0.59241784],"genre_scores_gemma":[0.49624577,0.0010981223,0.0007986671,0.0012275933,0.00035834478,0.00024891578,0.00004472909,0.000023462695,0.4999544],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99940115,0.000029194445,0.000082728955,0.00013683431,0.00013340579,0.00021670281],"domain_scores_gemma":[0.99951524,0.000022824926,0.000023497045,0.0001116228,0.00012155763,0.00020527093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001321446,0.000067658795,0.00017154258,0.000051218354,0.00002979763,0.0000052770197,0.00003925612,0.00006959524,0.00067700754],"category_scores_gemma":[0.000030872827,0.00004543949,0.000029398505,0.00010006033,0.00010945703,0.000037884052,0.00003134892,0.00011395337,0.00040305633],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001845886,0.00041496943,0.13909736,0.00004180022,0.00022603199,0.00064088753,0.0018645759,0.000006573419,0.0017195835,0.00029924497,0.7290286,0.12481453],"study_design_scores_gemma":[0.004722217,0.0014169972,0.0070108734,0.000028240342,0.000069432404,0.000060925482,0.00032285933,0.00006359177,0.0041736094,0.00048130046,0.9815708,0.00007920074],"about_ca_topic_score_codex":0.00009758168,"about_ca_topic_score_gemma":0.000018500197,"teacher_disagreement_score":0.2525422,"about_ca_system_score_codex":0.000319211,"about_ca_system_score_gemma":0.0010239619,"threshold_uncertainty_score":0.7412758},"labels":[],"label_agreement":null},{"id":"W3038031098","doi":"10.1016/j.eururo.2020.06.016","title":"Re: Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review","year":2020,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; St Joseph's Health Centre; Western University","funders":"","keywords":"Medicine; Prostate cancer; Multidisciplinary approach; Risk assessment; Intensive care medicine; Oncology; Gynecology; Internal medicine; Cancer","score_opus":0.050697400324201794,"score_gpt":0.3438884402095829,"score_spread":0.29319103988538114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038031098","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036419768,0.37243995,0.00006942562,0.5697286,0.00063755625,0.015923453,0.0038266578,0.00016693155,0.0007876262],"genre_scores_gemma":[0.019333964,0.732419,0.0018601419,0.2330861,0.0011739216,0.0015208063,0.0076611703,0.00036138968,0.0025835189],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99728084,0.00061599433,0.0006977657,0.0007592464,0.00030244267,0.0003436921],"domain_scores_gemma":[0.9983721,0.00025539307,0.00057036954,0.00041895502,0.00022205224,0.00016117493],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003146976,0.0004000649,0.0014211762,0.00013472895,0.00009431712,0.00001646975,0.00020858359,0.00015021351,0.000021389213],"category_scores_gemma":[0.00017912092,0.00028680012,0.00010882131,0.00009471642,0.0002498506,0.0000871644,0.00022510697,0.00060912356,0.0000069698376],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013470105,0.0006865367,0.018494619,0.7715684,0.00930513,0.0060641947,0.0018547487,0.000034968518,0.0002733353,0.000025037132,0.09612584,0.082097046],"study_design_scores_gemma":[0.16331978,0.07854848,0.093488164,0.3961823,0.077072114,0.0012619412,0.00038508148,0.002447984,0.0004777648,0.00081447256,0.18085724,0.005144682],"about_ca_topic_score_codex":0.00006071826,"about_ca_topic_score_gemma":0.000008466403,"teacher_disagreement_score":0.37538615,"about_ca_system_score_codex":0.00011962206,"about_ca_system_score_gemma":0.00014787258,"threshold_uncertainty_score":0.9999584},"labels":[],"label_agreement":null},{"id":"W3038535715","doi":"10.1016/j.urology.2020.06.025","title":"Predictors of Prostate-specific Membrane Antigen (PSMA/FOLH1) Expression in a Genomic Database","year":2020,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"","keywords":"Medicine; DECIPHER; Androgen receptor; Prostatectomy; Prostate cancer; Basal (medicine); Androgen; Prostate; Internal medicine; Prostate-specific antigen; Biomarker; Glutamate carboxypeptidase II; Oncology; Cancer; Bioinformatics; Biology; Hormone; Genetics","score_opus":0.03584541259872662,"score_gpt":0.28873124141171913,"score_spread":0.2528858288129925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038535715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919775,0.0031258862,0.000045287234,0.003294217,0.000096674536,0.0006263043,0.000072344876,0.000033759556,0.00072803395],"genre_scores_gemma":[0.996786,0.0022119004,0.00015485896,0.00032889118,0.00012224611,0.000032578297,0.00021493746,0.00002075014,0.00012782693],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888617,0.00007278355,0.0002613721,0.00031938302,0.00016648193,0.00029381303],"domain_scores_gemma":[0.99945563,0.000050552677,0.000057923055,0.00023351228,0.0000373256,0.00016503433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011604668,0.00011590386,0.00031006458,0.00013065954,0.000022420574,0.0000033716278,0.000107288615,0.000086931126,0.00034529634],"category_scores_gemma":[0.000044620192,0.00008861588,0.00004386152,0.00021572936,0.00013201976,0.000052525942,0.00010641524,0.00022149665,0.000048045782],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041180933,0.00019029701,0.27760246,0.00014890423,0.000044533524,0.00040360595,0.0016271002,0.00004406558,0.71275985,0.000020921156,0.002437478,0.000602646],"study_design_scores_gemma":[0.01919965,0.005086911,0.1842072,0.00013292558,0.000089941874,0.00007575177,0.00048119362,0.0015460289,0.6541918,0.000056525692,0.13457488,0.0003571823],"about_ca_topic_score_codex":0.000018079785,"about_ca_topic_score_gemma":0.0000048359075,"teacher_disagreement_score":0.1321374,"about_ca_system_score_codex":0.000034949146,"about_ca_system_score_gemma":0.00012872527,"threshold_uncertainty_score":0.37807527},"labels":[],"label_agreement":null},{"id":"W3038542852","doi":"10.1016/j.eururo.2020.06.047","title":"Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series","year":2020,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Prostatectomy; Lymph node; Prostate cancer; Biochemical recurrence; Dissection (medical); Positron emission tomography; Radiology; Prostate; Urology; Cancer; Internal medicine","score_opus":0.051462145216867684,"score_gpt":0.3303954642954508,"score_spread":0.2789333190785831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038542852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97622365,0.00073652685,0.0001695922,0.019848656,0.00040395293,0.0010796434,0.0012213282,0.000078505574,0.0002381193],"genre_scores_gemma":[0.99655664,0.0002573654,0.00038617177,0.0004892033,0.00050464435,0.00017990678,0.00095825247,0.00005221685,0.00061558775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976539,0.00040753064,0.0005237672,0.0006608271,0.00029075454,0.0004632198],"domain_scores_gemma":[0.99896276,0.00021262979,0.00018796754,0.00024187569,0.00017193203,0.00022284663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003334685,0.0002837893,0.0003875698,0.00007905551,0.0003372194,0.00006449859,0.00014289346,0.00009523706,0.00008021715],"category_scores_gemma":[0.00021452723,0.00017666533,0.00014221479,0.00020676055,0.00064008543,0.00021206182,0.00015017754,0.00035416507,0.000013593655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14170572,0.0012540556,0.738815,0.0008637021,0.0011830898,0.005494257,0.028915921,0.0008600541,0.062329207,0.000060499522,0.0015834996,0.016934987],"study_design_scores_gemma":[0.038533784,0.0032128547,0.8740001,0.00051616743,0.0007321296,0.0009380597,0.00076096394,0.009108244,0.016543638,0.00007495832,0.054747246,0.0008318833],"about_ca_topic_score_codex":0.0003250998,"about_ca_topic_score_gemma":0.00016552956,"teacher_disagreement_score":0.13518506,"about_ca_system_score_codex":0.00021970973,"about_ca_system_score_gemma":0.00030343968,"threshold_uncertainty_score":0.7204203},"labels":[],"label_agreement":null},{"id":"W3039085269","doi":"10.1038/s41585-020-0335-7","title":"Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer","year":2020,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Randomized controlled trial; Intensive care medicine; Clinical trial; Sexual dysfunction; Androgen suppression; Oncology; Internal medicine; Cancer","score_opus":0.06996596604743258,"score_gpt":0.43721714772512454,"score_spread":0.367251181677692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039085269","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000107639635,0.9837053,0.000013497215,0.0023291598,0.001130257,0.012388171,0.00016801071,0.000066336994,0.00018854967],"genre_scores_gemma":[0.000009276687,0.98965275,0.0002711136,0.0010396694,0.00067685475,0.0064675184,0.0011798145,0.00010817987,0.00059484656],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973381,0.000264956,0.00080427335,0.0008453124,0.00021588347,0.0005314688],"domain_scores_gemma":[0.9982584,0.00026381403,0.00056948926,0.00048451373,0.00021313527,0.00021065683],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003184854,0.0006046638,0.003477461,0.0001767633,0.000076259385,0.000019899568,0.00027284023,0.00094252126,0.000090026755],"category_scores_gemma":[0.00036949568,0.00036608553,0.0009841656,0.0004214934,0.00008977812,0.000052445565,0.000078470104,0.0014618515,0.000060958253],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020805546,0.00006878043,0.00001990489,0.0113792615,0.0006726374,0.000057478694,0.000037632723,4.260561e-8,0.0000046007613,0.000032328026,0.004685558,0.9809612],"study_design_scores_gemma":[0.0050253104,0.0017492621,0.0000042651745,0.0035176068,0.0015221669,0.00006182364,0.000002520095,0.0000022916897,0.000010596622,0.000015466068,0.98781323,0.00027547448],"about_ca_topic_score_codex":0.0000025460959,"about_ca_topic_score_gemma":0.0000053725753,"teacher_disagreement_score":0.98312765,"about_ca_system_score_codex":0.00033447813,"about_ca_system_score_gemma":0.00068706815,"threshold_uncertainty_score":0.9998791},"labels":[],"label_agreement":null},{"id":"W3040062773","doi":"10.1172/jci135373","title":"LIN28B promotes the development of neuroendocrine prostate cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; China Scholarship Council; Terry Fox Research Institute; National Natural Science Foundation of China; U.S. Department of Defense","keywords":"SOX2; Prostate cancer; Cancer research; Biology; HMGA2; Carcinogenesis; Neuroendocrine differentiation; CD44; Cancer stem cell; Stem cell; Prostate; Transcription factor; Cancer; Cell; Cell biology; microRNA; Gene; Genetics","score_opus":0.20406593367824788,"score_gpt":0.45205943056501474,"score_spread":0.24799349688676686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3040062773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9329009,0.00057868456,0.000044864042,0.06594947,0.00015978901,0.00027993196,0.00000205138,0.0000059026934,0.000078408775],"genre_scores_gemma":[0.99433994,0.00055319,0.0030033947,0.0013754225,0.00051324355,0.0000074377645,0.000004239883,0.000010190303,0.00019293596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808836,0.00011456657,0.0011677471,0.000097215394,0.00041781407,0.00011431032],"domain_scores_gemma":[0.99839264,0.00021719238,0.0006321379,0.000077669094,0.0004168662,0.00026347136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006399777,0.00007452466,0.00033203518,0.00003394104,0.000042731837,0.000010608915,0.00009829036,0.00002576833,0.000039169427],"category_scores_gemma":[0.0012733748,0.000038050057,0.00012015436,0.00019691444,0.0001931661,0.0000870768,0.00003255438,0.00040606037,0.000004631363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031927405,0.00037384575,0.78166187,0.00055295374,0.00061409833,0.00014008651,0.005087413,0.000062411054,0.026660662,0.00008102914,0.0049858764,0.176587],"study_design_scores_gemma":[0.0090609575,0.0042953794,0.643304,0.00096069527,0.00040532937,0.000070659305,0.0004425436,0.0017792003,0.31007665,0.0012301586,0.028206153,0.00016829518],"about_ca_topic_score_codex":0.0000030814338,"about_ca_topic_score_gemma":0.00000270604,"teacher_disagreement_score":0.283416,"about_ca_system_score_codex":0.000024302342,"about_ca_system_score_gemma":0.0011713288,"threshold_uncertainty_score":0.2077887},"labels":[],"label_agreement":null},{"id":"W3041588796","doi":"10.1111/his.14205","title":"Gene fusion characterisation of rare aggressive prostate cancer variants—adenosquamous carcinoma, pleomorphic giant‐cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases","year":2020,"lang":"en","type":"article","venue":"Histopathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Memorial University of Newfoundland","funders":"Henry Ford Health System","keywords":"Adenosquamous carcinoma; Fusion gene; Sarcomatoid carcinoma; Erg; Carcinoma; Adenocarcinoma; Immunohistochemistry; Pathology; Biology; TMPRSS2; Gene rearrangement; Cancer; Cancer research; Medicine; Gene; Genetics; Retina","score_opus":0.033156045993831026,"score_gpt":0.282988456430602,"score_spread":0.24983241043677096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041588796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762219,0.021001738,0.000022660557,0.00091898727,0.000103072685,0.000746652,0.00089615723,0.000029653685,0.00005918264],"genre_scores_gemma":[0.99735576,0.0008708884,0.0001999456,0.00022061737,0.00008037703,0.000082175415,0.00090819254,0.00003860228,0.00024346556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774235,0.00026121823,0.00059061375,0.0006689617,0.0003410886,0.00039574716],"domain_scores_gemma":[0.9981421,0.00007932654,0.0006281661,0.00044327244,0.00033744986,0.00036965444],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016981312,0.00029388064,0.0010526312,0.0005329404,0.00013228976,0.000009060971,0.0001448027,0.00018637213,0.00023289859],"category_scores_gemma":[0.000096717,0.00025260655,0.00016199166,0.0006960677,0.000407192,0.0001200632,0.00012189374,0.00023265778,0.0000033317513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014738941,0.00021089838,0.6247512,0.00046590093,0.000045822682,0.003405813,0.008074686,0.0000131455,0.36073953,0.000006887171,0.00007814538,0.00073408836],"study_design_scores_gemma":[0.003318896,0.0018186886,0.94226784,0.00002930904,0.0015226979,0.00037155286,0.0007549973,0.0017809017,0.04786351,0.0000044873154,0.00006259026,0.0002045248],"about_ca_topic_score_codex":0.0024022174,"about_ca_topic_score_gemma":0.00016686649,"teacher_disagreement_score":0.31751665,"about_ca_system_score_codex":0.00021448368,"about_ca_system_score_gemma":0.00046378755,"threshold_uncertainty_score":0.9999926},"labels":[],"label_agreement":null},{"id":"W3042127363","doi":"10.1002/pros.24035","title":"Neuroendocrine differentiation in usual‐type prostatic adenocarcinoma: Molecular characterization and clinical significance","year":2020,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Cancer Institute; National Center for Advancing Translational Sciences; Division of Cancer Prevention, National Cancer Institute","keywords":"Neuroendocrine differentiation; Chromogranin A; PTEN; Androgen receptor; Prostate cancer; Adenocarcinoma; Cancer research; Carcinoma; Pathology; Medicine; Tissue microarray; Cellular differentiation; Prostate; Internal medicine; Biology; Cancer; Immunohistochemistry; Apoptosis; Gene; PI3K/AKT/mTOR pathway","score_opus":0.04357757958749408,"score_gpt":0.3322552039091863,"score_spread":0.2886776243216922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042127363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97853166,0.0005094529,0.00014203429,0.019268876,0.000063135085,0.0013949006,0.000015547306,0.000039523,0.000034851426],"genre_scores_gemma":[0.99699605,0.0012148094,0.000039540155,0.0010799038,0.00005947174,0.00005224273,0.00016276106,0.000023586934,0.00037162623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988138,0.00014870998,0.00029898848,0.00029706865,0.00019927035,0.00024217957],"domain_scores_gemma":[0.9995031,0.000056312136,0.000078368656,0.0001582566,0.00006639763,0.00013758574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013035127,0.00012647628,0.00022507351,0.000042353797,0.00005229024,0.000035038986,0.00006561327,0.000021098884,0.000018988922],"category_scores_gemma":[0.0001349382,0.00008188074,0.00003390661,0.00031034325,0.00011534312,0.000084426545,0.00006643064,0.00026293524,0.000018964947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029138823,0.00024218063,0.8258457,0.0003596696,0.000084363746,0.00046543436,0.0017753906,0.0000047117483,0.15153205,0.0001275725,0.00007199367,0.016577056],"study_design_scores_gemma":[0.003479571,0.0011496008,0.9760208,0.00006221071,0.00008483618,0.000020571135,0.000083197454,0.0047115507,0.0137682175,0.00010183821,0.0004055891,0.000111977744],"about_ca_topic_score_codex":0.000014024245,"about_ca_topic_score_gemma":0.0000029015468,"teacher_disagreement_score":0.15017514,"about_ca_system_score_codex":0.000030130497,"about_ca_system_score_gemma":0.000088895904,"threshold_uncertainty_score":0.33389995},"labels":[],"label_agreement":null},{"id":"W3042431606","doi":"10.1007/s00345-020-03344-3","title":"Novel PET imaging methods for prostate cancer","year":2020,"lang":"en","type":"review","venue":"World Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institutes of Health","keywords":"Prostate cancer; Medicine; Prostate; Management of prostate cancer; Pet imaging; Cancer; Positron emission tomography; Nephrology; Glutamate carboxypeptidase II; Oncology; Radiology; Internal medicine","score_opus":0.09171751003092564,"score_gpt":0.4888425863789801,"score_spread":0.39712507634805444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042431606","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.2322818e-7,0.98563945,0.0023986748,0.00943454,0.0010332703,0.0009805404,0.00006394799,0.000011322523,0.0004381107],"genre_scores_gemma":[0.0000014227392,0.9727547,0.019250108,0.0005983921,0.0010861221,0.00012962792,0.000028460407,0.00007490686,0.006076267],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808234,0.00019812192,0.0008363512,0.00027144444,0.0001825814,0.00042916043],"domain_scores_gemma":[0.9978832,0.00053622253,0.00080077775,0.00016766222,0.0003287876,0.00028333117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076556986,0.00031285526,0.0023098579,0.0005831109,0.000048323363,0.000020924717,0.00022349543,0.000066991255,0.00012678085],"category_scores_gemma":[0.0001879181,0.00019686823,0.0008036528,0.00041290195,0.00012442334,0.000053403808,0.0000721828,0.0009914846,0.0000069100347],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005301653,0.00007004826,0.000024779825,0.005245152,0.0009420412,0.0005542451,0.00006225264,5.8122663e-7,0.000029477496,0.00002829782,0.0070876474,0.9854253],"study_design_scores_gemma":[0.002157921,0.00048426745,0.0000043522955,0.0022959267,0.0033279557,0.0034118656,0.0000060687053,0.000041095802,0.0000024767976,0.00008606327,0.9880426,0.00013940509],"about_ca_topic_score_codex":0.000007730148,"about_ca_topic_score_gemma":0.0000062986414,"teacher_disagreement_score":0.9852859,"about_ca_system_score_codex":0.00037693666,"about_ca_system_score_gemma":0.0025789277,"threshold_uncertainty_score":0.80280536},"labels":[],"label_agreement":null},{"id":"W3043272467","doi":"10.1097/cco.0000000000000654","title":"Targeting defective DNA repair in prostate cancer","year":2020,"lang":"en","type":"review","venue":"Current Opinion in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research","keywords":"Prostate cancer; DNA repair; Cancer; DNA; Prostate; Cancer research; Biology; Medicine; Computational biology; Internal medicine; Genetics","score_opus":0.15727694281685112,"score_gpt":0.5062707063662129,"score_spread":0.34899376354936174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043272467","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022947319,0.9908144,0.0000011833878,0.0005517221,0.0045714127,0.003496919,0.00014357088,0.00007849981,0.00031936105],"genre_scores_gemma":[0.000007843439,0.99533945,0.00004826899,0.000024034562,0.00095943775,0.002747153,0.00068907894,0.000058133966,0.00012658464],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99700004,0.000516888,0.000862702,0.000778843,0.0002456931,0.0005958502],"domain_scores_gemma":[0.99890304,0.00030879836,0.00029305244,0.00021264295,0.00008626686,0.0001962275],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042841493,0.00041128535,0.002194899,0.00052448985,0.00003876367,0.0000073090882,0.00014679458,0.0003138512,0.00012669913],"category_scores_gemma":[0.00025450086,0.00031115947,0.00036958876,0.00094970316,0.00012455016,0.000053865475,0.00018809912,0.0015420683,0.000093585266],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002088783,0.00038675763,0.0023836258,0.033893485,0.00012088883,0.0001423977,0.0005164372,0.0000014278507,3.0634584e-7,0.000032868786,0.01287492,0.949438],"study_design_scores_gemma":[0.0021256618,0.00051568163,0.00014456033,0.029752528,0.00012480846,0.0000275111,0.00006472482,0.000035332625,4.4101606e-7,0.00002967016,0.966938,0.00024106362],"about_ca_topic_score_codex":0.00007006376,"about_ca_topic_score_gemma":0.000020378428,"teacher_disagreement_score":0.9540631,"about_ca_system_score_codex":0.0035939633,"about_ca_system_score_gemma":0.0036836797,"threshold_uncertainty_score":0.9999341},"labels":[],"label_agreement":null},{"id":"W3044054345","doi":"10.3390/cancers12071991","title":"Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants","year":2020,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Cancer research; DNA damage; DNA repair; Cancer; Radiation therapy; Cancer cell; Medicine; Ionizing radiation; Cell growth; Internal medicine; Chemistry; Biology; DNA; Genetics","score_opus":0.034887434882131606,"score_gpt":0.30217571568310714,"score_spread":0.26728828080097555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044054345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97757906,0.008461092,0.0000120877785,0.009546142,0.0005178978,0.0027386635,0.00074629375,0.00012427631,0.00027446606],"genre_scores_gemma":[0.9780774,0.014799253,0.00040555836,0.002955762,0.00052185275,0.0011804977,0.00014081698,0.000108696135,0.0018101805],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99726033,0.00011055513,0.00040182853,0.00080845394,0.0005706292,0.0008481816],"domain_scores_gemma":[0.9986508,0.00005965632,0.00015328158,0.0002922487,0.00019057946,0.0006534454],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021458068,0.00037022305,0.0005705681,0.00020614952,0.00014801508,0.000071247625,0.00016431646,0.000107253334,0.0003409105],"category_scores_gemma":[0.000048308953,0.00031920167,0.000097980046,0.0008513278,0.000098104305,0.00025830368,0.00009401203,0.00034964824,0.00006124326],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009454212,0.0000534458,0.037434258,0.0007995187,0.0003607284,0.0004558461,0.022236977,0.0082318075,0.87873423,0.000007842328,0.01946812,0.02276304],"study_design_scores_gemma":[0.012119891,0.0008645462,0.016892517,0.0019409403,0.00025218877,0.000008769808,0.0039741714,0.0030862906,0.896398,0.00002016755,0.063405514,0.0010370153],"about_ca_topic_score_codex":0.006097305,"about_ca_topic_score_gemma":0.00044552295,"teacher_disagreement_score":0.043937393,"about_ca_system_score_codex":0.0033816865,"about_ca_system_score_gemma":0.001741758,"threshold_uncertainty_score":0.99992603},"labels":[],"label_agreement":null},{"id":"W3044197599","doi":"10.1097/spc.0000000000000507","title":"The evolving options in metastatic castration-sensitive prostate cancer","year":2020,"lang":"en","type":"review","venue":"Current Opinion in Supportive and Palliative Care","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Abiraterone acetate; Docetaxel; Androgen deprivation therapy; Oncology; Internal medicine; Radiation therapy; Clinical trial; Randomized controlled trial; Guideline; Cabazitaxel; Cancer; Androgen receptor; Pathology","score_opus":0.2071644804414193,"score_gpt":0.4913508294523975,"score_spread":0.28418634901097817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044197599","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006537174,0.99462354,0.0000067338747,0.00035805436,0.0008026576,0.0031569968,0.00088113605,0.000013766114,0.000091713475],"genre_scores_gemma":[0.0006186691,0.99579793,0.000025454383,0.000009597702,0.00020044934,0.0015356999,0.0016754667,0.00003493251,0.00010180551],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99765223,0.00033961583,0.0006848326,0.0005830261,0.00031853036,0.0004217343],"domain_scores_gemma":[0.9985935,0.000375036,0.0003005588,0.00016873651,0.00038389486,0.00017825089],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018419452,0.00041469725,0.0011715854,0.00023036158,0.00016070042,0.000070271446,0.00008852128,0.000092380076,0.000036006677],"category_scores_gemma":[0.00016500441,0.0002573036,0.0002136855,0.0006864179,0.00021598703,0.00010525416,0.00008780936,0.0008648093,0.000014659076],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011591779,0.00008075897,0.0092871515,0.02405403,0.000287308,0.00006482282,0.008292486,0.0000012708359,3.069369e-7,0.00026172682,0.0006309952,0.95692325],"study_design_scores_gemma":[0.0014115224,0.00024775986,0.008039101,0.04155477,0.00032838082,0.000006543497,0.005357183,0.000035615336,0.000002172408,0.00004513335,0.9426419,0.0003298815],"about_ca_topic_score_codex":0.00004731401,"about_ca_topic_score_gemma":0.00010282678,"teacher_disagreement_score":0.95659333,"about_ca_system_score_codex":0.0007391106,"about_ca_system_score_gemma":0.0016611458,"threshold_uncertainty_score":0.9999879},"labels":[],"label_agreement":null},{"id":"W3044746299","doi":"10.3390/jcm9072308","title":"Diagnostic Performance of [18F]Fluorocholine and [68Ga]Ga-PSMA PET/CT in Prostate Cancer: A Comparative Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Cancer; PET-CT; Prostate; Nuclear medicine; Oncology; Positron emission tomography; Radiology; Internal medicine","score_opus":0.17113695386835645,"score_gpt":0.5028609603993831,"score_spread":0.3317240065310266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044746299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754282,0.006757805,0.0000017002792,0.016489951,0.00022830477,0.0008257391,0.0000070435776,0.000006130137,0.00025508663],"genre_scores_gemma":[0.9816279,0.01692031,0.00010107543,0.00053623633,0.0006705887,0.000016116914,0.000003238219,0.0000137463,0.0001108224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99672824,0.00021624769,0.0018808721,0.00023606743,0.0006959085,0.00024267196],"domain_scores_gemma":[0.99652016,0.0016784777,0.0006916387,0.00013961829,0.0004479365,0.00052216084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015202857,0.00018327618,0.0016212265,0.00016259965,0.00003089711,0.0000051584175,0.00013634488,0.000010422263,0.00012511836],"category_scores_gemma":[0.0026988082,0.000106368694,0.00009943827,0.00042618907,0.00042402188,0.00011960865,0.000062131345,0.00090301136,0.000003030368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007838438,0.0011251218,0.9716887,0.00036595765,0.00031145226,0.0058489735,0.0024244601,0.000029642943,0.00020005862,0.0000020830819,0.0011598122,0.009005294],"study_design_scores_gemma":[0.039245754,0.039982434,0.9082069,0.0028717583,0.00054406736,0.00094609824,0.004348791,0.0018126667,0.00052621786,0.000021345533,0.0013511243,0.00014284183],"about_ca_topic_score_codex":0.000079467565,"about_ca_topic_score_gemma":0.000021534564,"teacher_disagreement_score":0.0634818,"about_ca_system_score_codex":0.000050182098,"about_ca_system_score_gemma":0.00040626878,"threshold_uncertainty_score":0.43375894},"labels":[],"label_agreement":null},{"id":"W3044809055","doi":"10.1002/pros.24018","title":"Identifying and treating <i>ROBO1</i><sup>−ve</sup>/<i>DOCK1</i><sup>+ve</sup> prostate cancer: An aggressive cancer subtype prevalent in African American patients","year":2020,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"National Institute on Minority Health and Health Disparities; National Cancer Institute; U.S. Department of Defense","keywords":"Prostate cancer; Cancer; Medicine; Prostate; Oncology; Internal medicine; Gynecology","score_opus":0.03190703787725933,"score_gpt":0.32484105068247027,"score_spread":0.2929340128052109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044809055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806919,0.006702983,0.0000054016414,0.007669282,0.00007974143,0.0037081633,0.00058596913,0.00017727788,0.0003792894],"genre_scores_gemma":[0.9803059,0.0149066625,0.00018385291,0.0011793748,0.0003086927,0.0012681094,0.0002507915,0.00015868343,0.0014379128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951661,0.00043164086,0.0008052447,0.0012160729,0.0009725903,0.0014083228],"domain_scores_gemma":[0.9974345,0.00016509378,0.0006391287,0.00061911676,0.0003752596,0.0007668981],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044334348,0.0006859248,0.00097148615,0.00022552378,0.00049697765,0.00022336273,0.0004198279,0.00010034665,0.00012770295],"category_scores_gemma":[0.00017960991,0.0004763563,0.00015098906,0.0013319177,0.00069915695,0.00051039795,0.00039505935,0.0008730123,0.000031245054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005529856,0.0005900688,0.6692973,0.0010787188,0.00051302416,0.0004065718,0.13887326,0.0031336094,0.001377583,0.0000124607195,0.0011584631,0.17802908],"study_design_scores_gemma":[0.08087831,0.020357123,0.6000581,0.011389851,0.0037461838,0.0002106588,0.10598205,0.11274315,0.03518602,0.0011569662,0.02170104,0.0065905536],"about_ca_topic_score_codex":0.0047670435,"about_ca_topic_score_gemma":0.0004434259,"teacher_disagreement_score":0.17143853,"about_ca_system_score_codex":0.00060861604,"about_ca_system_score_gemma":0.00060220755,"threshold_uncertainty_score":0.9997688},"labels":[],"label_agreement":null},{"id":"W3044887114","doi":"10.1038/s41585-020-0349-1","title":"The Movember Prostate Cancer Landscape Analysis: an assessment of unmet research needs","year":2020,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Movember Foundation; Memorial Sloan-Kettering Cancer Center; Breast Cancer Alliance","keywords":"Medicine; Prostate cancer; Disease; Clinical trial; Cancer; Family medicine; Oncology; Gynecology; Internal medicine","score_opus":0.10239390735479598,"score_gpt":0.5439850750211666,"score_spread":0.4415911676663706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044887114","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000064698465,0.990033,0.0000032610355,0.0030422946,0.0002388816,0.004484939,0.00015891473,0.00002738906,0.002004856],"genre_scores_gemma":[0.000067184345,0.9943478,0.00012698506,0.00029313652,0.0005024144,0.0018129909,0.0008895558,0.000074909054,0.0018849932],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9930138,0.0030731845,0.0012614821,0.00080234173,0.0009962119,0.0008529874],"domain_scores_gemma":[0.9962921,0.0007742181,0.00065314554,0.0013263748,0.00057944824,0.00037472104],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0038084246,0.00055996655,0.0047151083,0.0010243257,0.00022752663,0.0000493011,0.00071856845,0.0011031565,0.00027443698],"category_scores_gemma":[0.0003546236,0.00026468377,0.0013193617,0.006064416,0.0003855294,0.0000592293,0.0002782361,0.005173283,0.00004913688],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001292199,0.00014952257,0.000747365,0.013257243,0.0044434336,0.00010030332,0.00009029679,0.0000010814663,0.0000012273873,0.00045033384,0.008721497,0.97190845],"study_design_scores_gemma":[0.00046453625,0.0007311736,0.00012951887,0.0018124009,0.010223557,0.000032469317,0.00002457922,0.000060295286,5.3027776e-7,0.000033829605,0.98628855,0.00019854479],"about_ca_topic_score_codex":0.000030183339,"about_ca_topic_score_gemma":0.00008979757,"teacher_disagreement_score":0.9775671,"about_ca_system_score_codex":0.00030139965,"about_ca_system_score_gemma":0.0022605106,"threshold_uncertainty_score":0.9999805},"labels":[],"label_agreement":null},{"id":"W3045600614","doi":"10.1158/1078-0432.ccr-19-2303","title":"Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Stand Up To Cancer; National Institutes of Health; U.S. National Library of Medicine; U.S. Department of Defense","keywords":"Enzalutamide; Prostate cancer; Biology; Cancer research; Transcriptome; Cancer; Internal medicine; Androgen receptor; Gene; Medicine; Genetics; Gene expression","score_opus":0.2182588947202795,"score_gpt":0.504447810987608,"score_spread":0.28618891626732856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045600614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9631809,0.004407936,0.0000017114984,0.029323611,0.000037591217,0.001996627,0.00043897872,0.000028808896,0.00058384385],"genre_scores_gemma":[0.9890906,0.006970894,0.0002349088,0.0005156694,0.000103922,0.00085846486,0.000039320294,0.000053697368,0.0021324884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99547076,0.0005943317,0.00090551254,0.00081210694,0.0014263977,0.0007908852],"domain_scores_gemma":[0.996883,0.0010447548,0.00020656222,0.0002397574,0.0010568606,0.0005690766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019375338,0.00024528799,0.00087749143,0.00013578054,0.00013338921,0.000056144632,0.00019801756,0.00013812046,0.0006157205],"category_scores_gemma":[0.0010395444,0.00017662827,0.00010631765,0.0015426425,0.0012078304,0.00015322624,0.00012229063,0.0010956393,0.000013993861],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016864298,0.0005852094,0.96989995,0.0009500684,0.0005569236,0.00070273015,0.0014893155,0.000005809427,0.0016652432,0.00006452374,0.004910037,0.0023058823],"study_design_scores_gemma":[0.03989555,0.0056746555,0.876625,0.006333154,0.00062137225,0.000015159632,0.0022585606,0.00043475645,0.058793843,0.00070391,0.007748894,0.00089512585],"about_ca_topic_score_codex":0.0013301348,"about_ca_topic_score_gemma":0.0036307182,"teacher_disagreement_score":0.09327494,"about_ca_system_score_codex":0.00038689116,"about_ca_system_score_gemma":0.0022617914,"threshold_uncertainty_score":0.7202692},"labels":[],"label_agreement":null},{"id":"W3046558242","doi":"10.1002/1878-0261.12770","title":"Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer","year":2020,"lang":"en","type":"article","venue":"Molecular Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre; Genome British Columbia","funders":"National Cancer Institute","keywords":"Enzalutamide; Androgen receptor; Prostate cancer; Antagonist; Androgen; Androgen deprivation therapy; Endocrinology; Internal medicine; Cancer research; Chemistry; Medicine; Receptor; Cancer; Pharmacology; Hormone","score_opus":0.020082743074056827,"score_gpt":0.32302589188343234,"score_spread":0.3029431488093755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046558242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98181933,0.0014556381,0.0002454826,0.014701379,0.000041271018,0.0010428247,0.00004084145,0.0000259847,0.0006272597],"genre_scores_gemma":[0.9968301,0.0011628545,0.00030185425,0.0011851018,0.00004105022,0.0002412403,0.00006370929,0.00002710831,0.00014699069],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872357,0.00020371136,0.00015211539,0.00039000463,0.00020658909,0.0003240176],"domain_scores_gemma":[0.9994635,0.00006876918,0.00007702568,0.00011507317,0.00008415541,0.00019147871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014325227,0.00018121203,0.0003816362,0.00008562119,0.00007610949,0.000020932446,0.00005774382,0.00013078826,0.000049141447],"category_scores_gemma":[0.000025735264,0.00013746577,0.000036068628,0.0002496164,0.00025558806,0.000061556064,0.000041676765,0.00030550538,0.000005016067],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018696366,0.00092941616,0.054121044,0.00018447379,0.0003862916,0.006308109,0.0040722503,0.000021733742,0.8357155,0.0003442511,0.00017065862,0.07904991],"study_design_scores_gemma":[0.031814523,0.019653408,0.07335772,0.00032905428,0.00017927484,0.00022124371,0.0006010788,0.0006690498,0.8650605,0.000451051,0.007094603,0.0005684751],"about_ca_topic_score_codex":0.0003248873,"about_ca_topic_score_gemma":0.00010987088,"teacher_disagreement_score":0.07848143,"about_ca_system_score_codex":0.00037352415,"about_ca_system_score_gemma":0.0004679908,"threshold_uncertainty_score":0.56056917},"labels":[],"label_agreement":null},{"id":"W3046876126","doi":"10.1097/01.ju.0000556885.55209.5f","title":"PD50-10 AFRICAN AMERICAN RACE IS NOT ASSOCIATED WITH RECLASSIFICATION DURING ACTIVE SURVEILLANCE: RESULTS FROM THE CANARY PROSTATE CANCER ACTIVE SURVEILLANCE STUDY (PASS)","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Race (biology); Watchful waiting; African american; Sexually active; Oncology; Cancer; Internal medicine; Gynecology; Demography; Environmental health; Population; Gender studies","score_opus":0.0233585189397084,"score_gpt":0.3044375356945601,"score_spread":0.2810790167548517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046876126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9605838,0.00035794752,0.0000012531084,0.037121017,0.00015203096,0.0010162613,0.00041044626,0.000016035472,0.00034123188],"genre_scores_gemma":[0.9962327,0.0011529331,0.0000056112785,0.00038269727,0.00018739061,0.000028600494,0.000033667624,0.000033594835,0.0019428238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99694157,0.0012206683,0.0004537917,0.00030338677,0.0006383957,0.00044218273],"domain_scores_gemma":[0.9958679,0.0016443674,0.0011561202,0.00048624267,0.0007208238,0.00012453446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001236164,0.00022599091,0.00062670815,0.00009802017,0.00021512811,0.00002022676,0.00034231774,0.000066372624,0.000109334025],"category_scores_gemma":[0.0003365803,0.00010848461,0.00007543847,0.0005697825,0.00036087347,0.000106635445,0.00006970696,0.00084106025,0.000012872854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19008002,0.00078465015,0.7387837,0.000012053943,0.004176416,0.00017419374,0.041288942,0.00034728466,0.013456485,7.940454e-7,0.002519154,0.008376258],"study_design_scores_gemma":[0.0077324472,0.0035670954,0.97725034,0.000035344427,0.0001788671,0.000037135862,0.008759406,0.000090488684,0.0014378923,0.000007491818,0.0007778274,0.00012563729],"about_ca_topic_score_codex":0.005510063,"about_ca_topic_score_gemma":0.005770038,"teacher_disagreement_score":0.23846662,"about_ca_system_score_codex":0.0005858101,"about_ca_system_score_gemma":0.0006483993,"threshold_uncertainty_score":0.83296037},"labels":[],"label_agreement":null},{"id":"W3047382221","doi":"10.1016/j.euo.2020.07.002","title":"Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cabazitaxel; Prostate cancer; Enzalutamide; Taxane; Urology; Docetaxel; Adverse effect; Prostate-specific antigen; Internal medicine; Oncology; Cancer; Surgery; Androgen deprivation therapy; Breast cancer; Androgen receptor","score_opus":0.0444505241222058,"score_gpt":0.33219623933308134,"score_spread":0.28774571521087555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047382221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809606,0.0010049045,0.000009816006,0.0114659425,0.000106831525,0.0024068195,0.00014459844,0.000018873858,0.0038816102],"genre_scores_gemma":[0.9973072,0.0012060363,0.00013446002,0.0002828502,0.000058715366,0.00007155004,0.00007216692,0.000036962007,0.0008300645],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99752295,0.00083347305,0.00060982775,0.0004175416,0.00027039915,0.00034580514],"domain_scores_gemma":[0.9989318,0.0001313944,0.00039745073,0.0002510443,0.00015754942,0.00013073142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006386561,0.00021048884,0.00062280794,0.00013913072,0.00009579471,0.000007879085,0.00015832996,0.00005551069,0.00013050511],"category_scores_gemma":[0.00006756331,0.00013625761,0.000058899914,0.0003761979,0.00076371327,0.00008460262,0.00012534876,0.00034158933,0.000003659396],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48474398,0.008677803,0.0122312885,0.00091093074,0.0010765103,0.0022717635,0.03270534,0.00032597568,0.43275768,0.0011041483,0.0016022094,0.02159237],"study_design_scores_gemma":[0.65199655,0.14380883,0.07066877,0.00017426036,0.0007130052,0.00012970866,0.002490404,0.0011750985,0.07255579,0.00010843341,0.055631936,0.00054720964],"about_ca_topic_score_codex":0.00009753203,"about_ca_topic_score_gemma":0.00012310321,"teacher_disagreement_score":0.3602019,"about_ca_system_score_codex":0.000093014736,"about_ca_system_score_gemma":0.00059533236,"threshold_uncertainty_score":0.5556424},"labels":[],"label_agreement":null},{"id":"W3047493241","doi":"10.1016/j.jmoldx.2020.07.003","title":"Design and Development of a Fully Synthetic Multiplex Ligation-Dependent Probe Amplification–Based Probe Mix for Detection of Copy Number Alterations in Prostate Cancer Formalin-Fixed, Paraffin-Embedded Tissue Samples","year":2020,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Occupational Cancer Research Centre; University of Toronto; Ontario Institute for Cancer Research; Queen's University; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; Prostate Cancer Canada; McGill University Health Centre; Movember Foundation; McGill University","keywords":"Multiplex; Multiplex ligation-dependent probe amplification; Prostate cancer; Biology; Fluorescence in situ hybridization; TaqMan; Molecular biology; Cancer research; Digital polymerase chain reaction; Cancer; Computational biology; Real-time polymerase chain reaction; Polymerase chain reaction; Genetics; Gene; Chromosome","score_opus":0.04523978381676569,"score_gpt":0.32965909890824957,"score_spread":0.2844193150914839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047493241","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37519228,0.0010478166,0.6206623,0.001169321,0.00003546485,0.0018552439,0.0000306667,0.0000054432157,0.0000014745384],"genre_scores_gemma":[0.8504616,0.00040816306,0.1487113,0.00007359688,0.000024208755,0.0002696477,0.000025877245,0.00002005243,0.0000055491428],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984738,0.000077034245,0.00074343506,0.00015828169,0.0003692122,0.00017823369],"domain_scores_gemma":[0.99816877,0.00037170408,0.00047210875,0.0000980636,0.0007477248,0.00014160879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034382686,0.00013823515,0.00034644682,0.00013086824,0.000056025186,0.000019585239,0.00007139204,0.00006010486,0.0000098664705],"category_scores_gemma":[0.0006820541,0.000114378316,0.00005263095,0.00018829766,0.00006289014,0.00007716335,0.00001839881,0.00013710094,7.9196394e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027617526,0.00069363817,0.012648068,0.0013042012,0.00026006583,0.000053645123,0.004803827,0.009310764,0.95288175,0.00006602035,0.00003930778,0.015176982],"study_design_scores_gemma":[0.0040808194,0.00081858336,0.002384854,0.0005811643,0.00015225043,0.00001813466,0.00019930243,0.0037188884,0.9876391,0.00012978724,0.00017165537,0.0001054499],"about_ca_topic_score_codex":0.000015458207,"about_ca_topic_score_gemma":0.00002156014,"teacher_disagreement_score":0.47526932,"about_ca_system_score_codex":0.000121632955,"about_ca_system_score_gemma":0.00085817307,"threshold_uncertainty_score":0.46642125},"labels":[],"label_agreement":null},{"id":"W3048274437","doi":"10.14740/jmc3545","title":"Aches and Pains in a Patient With History of Prostatectomy: Extensive Skeletal Metastasis Picked up by Diffusion-Weighted Magnetic Resonance Imaging","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Magnetic resonance imaging; Prostatectomy; Metastasis; Prostate; Cancer; Prostate-specific antigen; Radiology; Diffusion MRI; Urology; Internal medicine","score_opus":0.02280526660457107,"score_gpt":0.2757939959700701,"score_spread":0.25298872936549904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048274437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8697068,0.11985543,0.000015797177,0.010087573,0.000049647355,0.00022244726,0.000015571728,0.0000053275767,0.00004140091],"genre_scores_gemma":[0.99569154,0.003016985,0.00024612277,0.0008597744,0.000058381407,0.000008212649,0.0000063985412,0.000013381199,0.00009921781],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980335,0.00011310247,0.0004284393,0.00015949992,0.0010610558,0.00020439287],"domain_scores_gemma":[0.99883187,0.00023802622,0.00019220615,0.00007611933,0.00022166155,0.00044009078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002519272,0.00012991283,0.00046110063,0.00012211686,0.000019574785,0.0000058220003,0.00007304193,0.000046022855,0.00019222975],"category_scores_gemma":[0.0007212936,0.00007577816,0.00006251159,0.00016885762,0.00037721812,0.000075117845,0.000051463143,0.00039096863,4.657391e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0147577105,0.0014079803,0.079859704,0.0009474715,0.00023044724,0.0666926,0.0138153,3.7470275e-7,0.013275579,0.000010596938,0.05749556,0.7515067],"study_design_scores_gemma":[0.15818349,0.087048225,0.16146483,0.0147236,0.0031055757,0.038544323,0.036860816,0.0067933947,0.0389055,0.00016155947,0.45235184,0.0018568507],"about_ca_topic_score_codex":0.00009050732,"about_ca_topic_score_gemma":0.000012603429,"teacher_disagreement_score":0.7496498,"about_ca_system_score_codex":0.00018893047,"about_ca_system_score_gemma":0.0007734132,"threshold_uncertainty_score":0.30901438},"labels":[],"label_agreement":null},{"id":"W3048974830","doi":"10.1371/journal.pone.0237248","title":"Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer","year":2020,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Universitätsmedizin der Johannes Gutenberg-Universität Mainz; Astellas Pharma; Technische Universität Dresden","keywords":"Enzalutamide; Prostate cancer; STAT5; Gene knockdown; Cancer research; LNCaP; Medicine; STAT protein; Androgen receptor; Oncology; Cancer; Biology; Internal medicine; Signal transduction; Cell culture; STAT3; Cell biology; Receptor; Genetics","score_opus":0.06508019420719623,"score_gpt":0.34090398434203795,"score_spread":0.2758237901348417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048974830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855493,0.0037790802,0.0000068358127,0.008126154,0.000018270503,0.0011740105,0.0001099276,0.00003243629,0.0012040373],"genre_scores_gemma":[0.99165565,0.0053385296,0.0013041621,0.00053020136,0.00008792654,0.00020743253,0.000056562214,0.000028317994,0.0007912211],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984068,0.000057948433,0.00028233745,0.00027398657,0.00067060266,0.00030830072],"domain_scores_gemma":[0.9994073,0.000023934504,0.00007721034,0.00016023743,0.00014667794,0.0001846279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001268334,0.00013743111,0.00041259447,0.000089421424,0.000029285242,0.000012983137,0.00008305993,0.00004868813,0.00074012135],"category_scores_gemma":[0.000029799832,0.000104223516,0.000060287308,0.00029842852,0.00007368978,0.00006344292,0.00004108139,0.00023027293,0.000011547791],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034295938,0.0025940875,0.1126236,0.00052532693,0.00066438236,0.00027081632,0.0011881402,0.00003196443,0.87723374,0.000050423947,0.00014757844,0.0012403358],"study_design_scores_gemma":[0.016352823,0.0048706625,0.251137,0.0009048701,0.00020583543,0.0000016394081,0.00058636034,0.0024437192,0.7221397,0.00035299658,0.00070095755,0.0003034352],"about_ca_topic_score_codex":0.00042451735,"about_ca_topic_score_gemma":0.00001911462,"teacher_disagreement_score":0.15509404,"about_ca_system_score_codex":0.00016823194,"about_ca_system_score_gemma":0.0006667434,"threshold_uncertainty_score":0.81038094},"labels":[],"label_agreement":null},{"id":"W3049361936","doi":"10.3390/ijms21165847","title":"Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies","year":2020,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Simon Fraser University","funders":"Canadian Institutes of Health Research; U.S. Department of Defense","keywords":"Androgen receptor; Prostate cancer; Mutant; Leverage (statistics); Computational biology; Machine learning; Phenotype; Bioinformatics; Drug discovery; Artificial intelligence; Biology; Computer science; Medicine; Cancer; Genetics; Gene","score_opus":0.048826538612343776,"score_gpt":0.3732100863919719,"score_spread":0.32438354777962813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049361936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97146314,0.0054649184,0.0029962864,0.019685771,0.00012812112,0.00009342355,0.000003356748,0.0000047772596,0.00016022877],"genre_scores_gemma":[0.994956,0.0012361185,0.0031149222,0.0005090504,0.000092729395,0.000003241373,8.5093114e-7,0.0000054437855,0.00008163256],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987423,0.0000501301,0.00022968545,0.000106013635,0.0007649479,0.00010695907],"domain_scores_gemma":[0.99911344,0.000030329224,0.00012216085,0.000029012634,0.00058515003,0.00011987784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003178278,0.00005929927,0.00013837904,0.00016792996,0.000039060254,0.00003535521,0.00023510701,0.00001649451,0.00006519969],"category_scores_gemma":[0.00020000651,0.000040016414,0.000076798846,0.00021156388,0.00008644073,0.00010942557,0.000045700133,0.00011176366,0.0000028718057],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006559186,0.00014648352,0.08201911,0.00004656587,0.00089625013,0.00048023285,0.01620488,0.12920734,0.69116336,0.00017852901,0.00015545462,0.07294257],"study_design_scores_gemma":[0.008696571,0.011193261,0.0041841813,0.0018609704,0.00021367482,0.00036326156,0.013867307,0.18520126,0.75809234,0.0008835969,0.0148777645,0.0005657767],"about_ca_topic_score_codex":0.000021362528,"about_ca_topic_score_gemma":8.778857e-7,"teacher_disagreement_score":0.07783493,"about_ca_system_score_codex":0.000045858927,"about_ca_system_score_gemma":0.00033002484,"threshold_uncertainty_score":0.1631822},"labels":[],"label_agreement":null},{"id":"W3049424235","doi":"10.1017/s1460396920000552","title":"A review of the effects of tobacco smoking on the treatment of prostate cancer","year":2020,"lang":"en","type":"review","venue":"Journal of Radiotherapy in Practice","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Guelph; Grand River Hospital; University of Waterloo","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Oncology; Radiation therapy; Quality of life (healthcare); Cancer; Smoking cessation; Internal medicine; Regimen; Malignancy; Intensive care medicine; Pathology; Nursing","score_opus":0.048745263573589645,"score_gpt":0.4328459903482412,"score_spread":0.38410072677465157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049424235","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000302236,0.99008185,5.634887e-7,0.006361256,0.0003406173,0.0027056949,0.000019403658,0.0000016854924,0.00018671309],"genre_scores_gemma":[0.000035525263,0.9987455,0.000091532405,0.00063237624,0.000216836,0.0000959341,0.0000014458387,0.00004043447,0.00014043535],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99671954,0.0010388679,0.0012018721,0.00015844037,0.0007006446,0.00018064275],"domain_scores_gemma":[0.9925535,0.0032013434,0.0034131068,0.0004242652,0.00033746805,0.00007033811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096346583,0.00029051563,0.0023993398,0.00016133339,0.000027971528,0.000007685445,0.00029842547,0.00010705115,0.00005187942],"category_scores_gemma":[0.0010384801,0.0001139818,0.0008816042,0.000746936,0.0001226153,0.0000931362,0.00001573054,0.0006384327,3.6341592e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009902044,0.00090200524,0.0002717498,0.08433753,0.003692359,0.00015558876,0.0009794644,8.26772e-7,0.000042269672,0.000018720564,0.001244085,0.9073652],"study_design_scores_gemma":[0.001696632,0.0033842279,0.00002720468,0.24915457,0.0028373108,0.0001723607,0.000041285122,4.2809307e-7,0.00033610995,0.000002204666,0.7422862,0.0000614387],"about_ca_topic_score_codex":0.0000667793,"about_ca_topic_score_gemma":0.0000024443216,"teacher_disagreement_score":0.90730375,"about_ca_system_score_codex":0.0008834046,"about_ca_system_score_gemma":0.0017616029,"threshold_uncertainty_score":0.4648043},"labels":[],"label_agreement":null},{"id":"W3054021800","doi":"10.5489/cuaj.6779","title":"Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists","year":2020,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Centre hospitalier universitaire de Québec; University of Alberta; Jewish General Hospital; McGill University; University of Ottawa; Juravinski Cancer Centre; St. Joseph’s Healthcare Hamilton; University of British Columbia; Ottawa Hospital; Vancouver General Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; McMaster University","funders":"Bavarian Nordic; EMD Serono; Ipsen; Astellas Pharma; Eisai; Cancer Research Institute; Janssen Canada; Sanofi; Janssen Pharmaceuticals; AstraZeneca; Amgen; Pfizer","keywords":"Prostate cancer; Medicine; Docetaxel; Oncology; Cancer; Internal medicine; Prostate; Castration; Gynecology; Family medicine","score_opus":0.04985940857001855,"score_gpt":0.33153727313038983,"score_spread":0.2816778645603713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3054021800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9644465,0.0007430736,0.0000069377643,0.03156865,0.000093389295,0.0008037238,0.00023994815,0.00001113279,0.0020866732],"genre_scores_gemma":[0.9896554,0.0078861695,0.0005032038,0.001018296,0.00007673195,0.000058314443,0.000048475966,0.000013577158,0.0007398732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983502,0.00026055108,0.0004640155,0.00014418313,0.0004562026,0.00032482724],"domain_scores_gemma":[0.99794906,0.00007374738,0.0011614037,0.000110977184,0.00039651213,0.00030831285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000503572,0.00013657406,0.000402323,0.00018859956,0.00015373019,0.000024433464,0.000119149445,0.00006166728,0.00008368045],"category_scores_gemma":[0.00005249589,0.0001132147,0.00008652003,0.00049504725,0.000108798355,0.00013333416,0.000033822853,0.00041418878,7.5033626e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002671293,0.0003493251,0.92363936,0.0015889291,0.0012642118,0.00012530854,0.0030891187,0.00081439514,0.002840406,0.00033208114,0.0035475288,0.059738033],"study_design_scores_gemma":[0.004950695,0.0010350946,0.9725262,0.00047750585,0.00052523776,0.0000021751846,0.0018887841,0.00017851732,0.0016341705,0.0002785754,0.016354512,0.00014851798],"about_ca_topic_score_codex":0.006648652,"about_ca_topic_score_gemma":0.003862809,"teacher_disagreement_score":0.059589516,"about_ca_system_score_codex":0.0007557648,"about_ca_system_score_gemma":0.00032326477,"threshold_uncertainty_score":0.99996614},"labels":[],"label_agreement":null},{"id":"W3055220918","doi":"10.1016/j.radonc.2020.08.008","title":"Histologic validation of auto-contoured dominant intraprostatic lesions on [18F] DCFPyL PSMA-PET imaging","year":2020,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; St Joseph's Health Centre; Lawson Health Research Institute; London Health Sciences Centre; Western University","funders":"Canadian Institutes of Health Research; Ontario Institute for Cancer Research; Prostate Cancer Canada","keywords":"Positron emission tomography; Medicine; Nuclear medicine; Standardized uptake value; Prostatectomy; Concordance; Prostate cancer; Voxel; Histology; Biopsy; Gold standard (test); Glutamate carboxypeptidase II; Lesion; Radiology; Pathology; Cancer; Internal medicine","score_opus":0.03685299901205891,"score_gpt":0.35196770863068594,"score_spread":0.31511470961862703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3055220918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9574949,0.005560503,0.0010228158,0.03368325,0.00016682189,0.000775346,0.000020698928,0.000047097074,0.0012285232],"genre_scores_gemma":[0.9929593,0.002768392,0.0015822111,0.0021973865,0.00012619559,0.00003599635,0.000034696906,0.000016371656,0.0002794564],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990794,0.00011327698,0.00022809788,0.00024160287,0.00012571191,0.00021191826],"domain_scores_gemma":[0.9994198,0.00017281798,0.00009596692,0.00011635758,0.000049641487,0.00014542321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016407033,0.00012257994,0.00040904008,0.00009079918,0.000077969205,0.000006884849,0.000055160905,0.00004990213,0.00020419632],"category_scores_gemma":[0.000057170964,0.0000865321,0.000059440783,0.00013068599,0.00020172828,0.00004076152,0.000011640785,0.00017041386,0.000004070555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015008354,0.001275497,0.036072798,0.00054214784,0.0005236084,0.0020088328,0.010562765,0.00003965722,0.5133591,0.0023418467,0.01194904,0.40631628],"study_design_scores_gemma":[0.09425511,0.052260496,0.083424784,0.0007082028,0.0009172592,0.0019877679,0.0035480473,0.02775023,0.37303203,0.002723163,0.3580674,0.0013255146],"about_ca_topic_score_codex":0.000028735798,"about_ca_topic_score_gemma":0.0000033667218,"teacher_disagreement_score":0.4049908,"about_ca_system_score_codex":0.00031463156,"about_ca_system_score_gemma":0.00019080001,"threshold_uncertainty_score":0.35286763},"labels":[],"label_agreement":null},{"id":"W3080515346","doi":"10.1016/j.radonc.2020.08.011","title":"A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer","year":2020,"lang":"en","type":"review","venue":"Radiotherapy and Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Centre Hospitalier de l’Université de Montréal; Montreal General Hospital; Jewish General Hospital; Dalhousie University","funders":"","keywords":"Prostate cancer; Medicine; Oncology; Metastasis; Management of prostate cancer; Internal medicine; Cancer","score_opus":0.26325353414657754,"score_gpt":0.525352954043653,"score_spread":0.26209941989707547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080515346","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0055703647,0.9865796,0.000021492664,0.0016266335,0.00006919704,0.0059892954,0.00009461223,0.000010783872,0.00003802737],"genre_scores_gemma":[0.00008967707,0.9935601,0.0039097145,0.00028615395,0.00007427549,0.0018276882,0.00012818383,0.000021736982,0.000102513804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99773294,0.0008138527,0.00067500357,0.00039426764,0.00015959416,0.00022432461],"domain_scores_gemma":[0.9980515,0.0014088965,0.00026601646,0.00013911471,0.000060797298,0.00007362882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013635927,0.00023650186,0.0017549946,0.000113636954,0.00006161059,0.000013247463,0.00010143466,0.00017044501,0.000056827233],"category_scores_gemma":[0.00003880772,0.00011830251,0.00021982694,0.00031510033,0.0002653105,0.000019860265,0.000024418392,0.00026069957,3.5512653e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017996223,0.0003426793,0.00042080868,0.0037663854,0.0022585785,0.00004527096,0.00054734887,1.3979583e-7,0.000003386364,0.00010652735,0.00010186848,0.9906074],"study_design_scores_gemma":[0.012815595,0.010905399,0.0015219687,0.0019208231,0.0012846582,0.000038443166,0.0002252557,0.00022807729,0.0000018478676,0.00018864071,0.9706972,0.00017207068],"about_ca_topic_score_codex":0.000011297732,"about_ca_topic_score_gemma":0.000008943609,"teacher_disagreement_score":0.9904353,"about_ca_system_score_codex":0.0001835986,"about_ca_system_score_gemma":0.0003939871,"threshold_uncertainty_score":0.48242363},"labels":[],"label_agreement":null},{"id":"W3080783669","doi":"10.1200/jco.2009.27.15_suppl.9526","title":"Declines in physical function from androgen deprivation therapy (ADT) in men with nonmetastatic prostate cancer: A matched cohort study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Grip strength; Prospective cohort study; Cohort; Analysis of variance; Internal medicine; Repeated measures design; Physical therapy; Cancer","score_opus":0.09426715439337446,"score_gpt":0.47526946658727026,"score_spread":0.3810023121938958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080783669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99363554,0.0005446115,0.000019705387,0.0044131936,0.000103507555,0.0011095055,0.0000026417401,0.000006240761,0.00016505302],"genre_scores_gemma":[0.9964129,0.0022398953,0.00033855464,0.000486729,0.0003866419,0.000043312757,0.00000866923,0.0000112458365,0.000072074945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749327,0.00042536022,0.001208535,0.00022746739,0.00043206158,0.00021330424],"domain_scores_gemma":[0.99822545,0.000645031,0.0006136594,0.00013492526,0.0002246619,0.00015625027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017267825,0.00013329106,0.0012342146,0.00017636879,0.00001975129,0.000010031328,0.0000837143,0.00011002386,0.000033208325],"category_scores_gemma":[0.00023477468,0.00007638512,0.00011281175,0.00032308104,0.000073627,0.00014599349,0.000012533716,0.00066479034,0.000003382565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028878063,0.005771792,0.8033626,0.000004099268,0.00033619298,0.00072267617,0.000642907,0.000058557085,0.00023215491,0.0000015390054,0.00008452765,0.15990485],"study_design_scores_gemma":[0.031178044,0.02590735,0.9404215,0.00008543049,0.0001878157,0.000013575416,0.0004778654,0.0004494709,0.00011097434,0.0007973186,0.00030033605,0.00007030555],"about_ca_topic_score_codex":0.0003563576,"about_ca_topic_score_gemma":0.00065757765,"teacher_disagreement_score":0.15983455,"about_ca_system_score_codex":0.00027995693,"about_ca_system_score_gemma":0.0010575232,"threshold_uncertainty_score":0.31148946},"labels":[],"label_agreement":null},{"id":"W3081165226","doi":"10.1200/jco.2009.27.15_suppl.5121","title":"Five-year relapse-free survival and predictors of relapse following preoperative docetaxel and mitoxantrone for high-risk localized prostate cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Docetaxel; Mitoxantrone; Prostatectomy; Prostate cancer; Internal medicine; Oncology; Clinical endpoint; Urology; Regimen; Cancer; Febrile neutropenia; Prostate; Chemotherapy; Neutropenia; Clinical trial","score_opus":0.049772438768947075,"score_gpt":0.42451753496175637,"score_spread":0.37474509619280927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081165226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841208,0.005835712,0.000054833752,0.0077451896,0.0011302559,0.0007643401,0.00006717257,0.00000828234,0.00027341073],"genre_scores_gemma":[0.97738016,0.016317789,0.0039019901,0.0002061823,0.0008685867,0.000016494843,0.000006284753,0.000018730234,0.0012837651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971398,0.00039801773,0.0015114147,0.00025881728,0.000394123,0.0002977934],"domain_scores_gemma":[0.99587643,0.0019330137,0.0009894525,0.00018118767,0.0006199921,0.0003999245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026574957,0.00017058439,0.0016026332,0.00011822172,0.000084870066,0.000012022476,0.00011965061,0.0003044931,0.000018050307],"category_scores_gemma":[0.005744884,0.00010732456,0.0002919548,0.00012160108,0.0003423067,0.00016313042,0.000059173177,0.000744729,4.5900217e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06787652,0.0020518673,0.8454488,0.00019563231,0.0031847488,0.00039510147,0.0017145864,0.00002874397,0.0006933211,0.00046026762,0.009481095,0.06846934],"study_design_scores_gemma":[0.108488336,0.066901065,0.8063954,0.000586993,0.002478185,0.000046153044,0.0009092263,0.00014877324,0.0009056825,0.0037652124,0.009154414,0.00022057001],"about_ca_topic_score_codex":0.00009026088,"about_ca_topic_score_gemma":0.00006200049,"teacher_disagreement_score":0.06824876,"about_ca_system_score_codex":0.00011883804,"about_ca_system_score_gemma":0.0011966324,"threshold_uncertainty_score":0.68775773},"labels":[],"label_agreement":null},{"id":"W3081621064","doi":"10.1259/bjr.20200775","title":"A novel tool for improving the interpretation of isotope bone scans in metastatic prostate cancer","year":2020,"lang":"en","type":"article","venue":"British Journal of Radiology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast; Friends of the Cancer Centre; Prostate Cancer UK; Movember Foundation","keywords":"Medicine; Prostate cancer; Radiology; Radiation therapy; Cancer; Oncology; Internal medicine","score_opus":0.026951864537255767,"score_gpt":0.3138976590497197,"score_spread":0.28694579451246394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081621064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96812123,0.016844727,0.0068279244,0.0071103713,0.0001326806,0.00085058354,0.00008609287,0.000003804565,0.000022571281],"genre_scores_gemma":[0.9958259,0.0016489153,0.0017705385,0.00049229147,0.00011632759,0.000052933017,0.0000071923664,0.000011923147,0.00007398487],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99909943,0.00006184238,0.00043861655,0.00010155001,0.00012092138,0.00017763732],"domain_scores_gemma":[0.9992835,0.00014117449,0.00024627024,0.000046821213,0.00022128833,0.000060981198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042813292,0.00006492704,0.00037182207,0.00006768011,0.00002845346,0.000012204654,0.000083928055,0.000029838546,0.00002341866],"category_scores_gemma":[0.00041634843,0.000047279173,0.00010212691,0.00014313274,0.00010807087,0.00008478401,0.000017941697,0.00022296303,2.7480127e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014988204,0.000490446,0.038402244,0.0017444249,0.0009912564,0.001417982,0.009729594,0.0018306836,0.26798198,0.0000960524,0.0065879333,0.6557392],"study_design_scores_gemma":[0.16152705,0.0352166,0.43060088,0.0082613295,0.0033569832,0.13840713,0.011209494,0.15039894,0.052089646,0.0016563694,0.005935854,0.001339736],"about_ca_topic_score_codex":0.00020582537,"about_ca_topic_score_gemma":0.000084043095,"teacher_disagreement_score":0.65439945,"about_ca_system_score_codex":0.00008271824,"about_ca_system_score_gemma":0.0003639038,"threshold_uncertainty_score":0.19279887},"labels":[],"label_agreement":null},{"id":"W3081938535","doi":"10.1016/j.prro.2020.06.009","title":"American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer","year":2020,"lang":"en","type":"editorial","venue":"Practical Radiation Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"American Society for Radiation Oncology","keywords":"Medicine; Prostate cancer; Radiation therapy; Salvage therapy; Prostatectomy; Prostate; Disease; Management of prostate cancer; Oncology; Prostate-specific antigen; Cancer; Internal medicine; Radiology; Chemotherapy","score_opus":0.02291670317854523,"score_gpt":0.44492070899535835,"score_spread":0.42200400581681313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081938535","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014586232,0.004383718,0.0027181478,0.16124606,0.8204791,0.008709827,0.0010193245,0.0007764321,0.00052151445],"genre_scores_gemma":[0.0021672025,0.016650874,0.031994723,0.0011533586,0.9272219,0.014685221,0.0049060634,0.00028138774,0.00093930267],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957695,0.00021266853,0.00095369224,0.0012193781,0.0008089215,0.0010358499],"domain_scores_gemma":[0.98814666,0.008342865,0.0010679982,0.000354176,0.0017293015,0.00035898984],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011050646,0.0005491908,0.0014871199,0.0003190715,0.00035813302,0.00014799746,0.00024659568,0.0014160973,0.000035631383],"category_scores_gemma":[0.01523811,0.0005000924,0.000489101,0.00075187813,0.00042691798,0.0006076339,0.0001308614,0.0018479252,0.00002273301],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005957263,0.00023054822,0.00006422411,0.00033589036,0.0005924781,0.000018651132,0.0009469996,0.000054166587,0.001362463,0.00019205318,0.76750845,0.2227368],"study_design_scores_gemma":[0.009830132,0.0062486683,0.000032666092,0.00009680181,0.0008087407,0.000005441579,0.0036122277,0.0020799316,0.00039248436,0.0012812191,0.9751574,0.0004542786],"about_ca_topic_score_codex":0.000114427574,"about_ca_topic_score_gemma":0.000041348136,"teacher_disagreement_score":0.22228253,"about_ca_system_score_codex":0.005886943,"about_ca_system_score_gemma":0.014009062,"threshold_uncertainty_score":0.99988025},"labels":[],"label_agreement":null},{"id":"W3082090251","doi":"10.1093/jnci/djaa132","title":"Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institutes of Health; Prostate Cancer UK; National Cancer Institute; National Institute for Health and Care Research","keywords":"PALB2; Allele; Odds ratio; Prostate cancer; Germline; Genetics; Gene; Biology; DNA repair; Confidence interval; Cancer; Internal medicine; Oncology; Cancer research; Germline mutation; Medicine; Mutation","score_opus":0.06278076299310154,"score_gpt":0.3563064826831872,"score_spread":0.2935257196900857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082090251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95223194,0.016579099,0.0000063620214,0.029604066,0.00027060445,0.00052453607,0.00009592856,0.000013633917,0.0006738457],"genre_scores_gemma":[0.9868483,0.008666132,0.00044901183,0.0020359089,0.0011979368,0.000069369715,0.0000064464425,0.000021776576,0.00070512155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982878,0.000044443834,0.00036146844,0.0001954012,0.00090168434,0.00020921248],"domain_scores_gemma":[0.99831575,0.00004048408,0.0005446332,0.00006748615,0.000852938,0.00017867898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021840741,0.00015643478,0.000312187,0.000128898,0.0001173483,0.000024717738,0.00013763596,0.000052147083,0.000040322713],"category_scores_gemma":[0.00017826776,0.00008443354,0.00009269763,0.00041985637,0.0002237402,0.00032910053,0.00006744411,0.0004020588,9.321704e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020717526,0.00033643786,0.8048876,0.00133953,0.003202847,0.004373306,0.012965235,0.030852966,0.06600415,0.00042055818,0.02524924,0.029650597],"study_design_scores_gemma":[0.06880143,0.0041771983,0.5956159,0.021304062,0.0018108445,0.004531133,0.00239371,0.017235454,0.16833714,0.0015426533,0.112532854,0.0017175709],"about_ca_topic_score_codex":0.0001840402,"about_ca_topic_score_gemma":0.0002444732,"teacher_disagreement_score":0.20927165,"about_ca_system_score_codex":0.00094575796,"about_ca_system_score_gemma":0.002850509,"threshold_uncertainty_score":0.50566804},"labels":[],"label_agreement":null},{"id":"W3082091318","doi":"10.1158/1538-7445.am2020-3509","title":"Abstract 3509: Racial variation in molecularly-defined prostate cancer subtypes","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Prostate cancer; DECIPHER; Cancer; Oncology; Internal medicine; Biomarker; Medicine; Logistic regression; Prostate; Bioinformatics; Biology; Genetics","score_opus":0.08798550149882475,"score_gpt":0.42135064695053664,"score_spread":0.3333651454517119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082091318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9546078,0.007963534,0.000012292097,0.03318381,0.00012987548,0.0015091357,0.000076161225,0.00006461874,0.002452769],"genre_scores_gemma":[0.9919119,0.0045205588,0.00006533859,0.00049782335,0.0005226775,0.00091870426,0.000048555365,0.00005154967,0.0014629028],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9970836,0.0001330263,0.00030256758,0.00057975797,0.0010810173,0.00082004326],"domain_scores_gemma":[0.9987223,0.00010008046,0.000049455517,0.00024955775,0.00047191663,0.0004066522],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006155862,0.00018230842,0.00033120092,0.00029426804,0.00014301759,0.000082146464,0.00019445377,0.00013457598,0.0014822964],"category_scores_gemma":[0.0002690521,0.00015111636,0.0000784615,0.0013020242,0.00017475749,0.00017939063,0.00011123393,0.00091973046,0.00016008054],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011633262,0.0005159955,0.13391656,0.0013421495,0.0003226559,0.0013176032,0.013315662,0.00022115304,0.79404014,0.0003738959,0.008234547,0.03476638],"study_design_scores_gemma":[0.01618705,0.0015949832,0.7843762,0.0009709349,0.00008462105,0.0000067466085,0.0006821809,0.0010199758,0.15611398,0.0007595277,0.037532266,0.00067152386],"about_ca_topic_score_codex":0.0033626333,"about_ca_topic_score_gemma":0.00047254964,"teacher_disagreement_score":0.65045965,"about_ca_system_score_codex":0.0007568724,"about_ca_system_score_gemma":0.0017946521,"threshold_uncertainty_score":0.9994305},"labels":[],"label_agreement":null},{"id":"W3082264507","doi":"10.1038/s41588-020-0681-7","title":"Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer","year":2020,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Institute of General Medical Sciences; Canadian Institutes of Health Research; Terry Fox Foundation; Prostate Cancer Canada; Congressionally Directed Medical Research Programs; Princess Margaret Cancer Foundation; National Cancer Institute; U.S. Department of Health and Human Services; National Institute of Diabetes and Digestive and Kidney Diseases; U.S. Department of Defense","keywords":"FOXA1; Biology; Chromatin; Demethylation; Prostate cancer; Cancer; Cancer research; Genetics; DNA methylation; DNA; Breast cancer; Gene; Gene expression","score_opus":0.02013716219593562,"score_gpt":0.33092180122396075,"score_spread":0.3107846390280251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082264507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764026,0.016455142,0.0000051129296,0.0058885706,0.00006322971,0.00080720603,0.000205253,0.000025984484,0.00014691912],"genre_scores_gemma":[0.9955784,0.0026031423,0.00063741754,0.00050267397,0.000070663584,0.00003764856,0.00027933958,0.000024919254,0.00026580182],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989051,0.00003282734,0.00024069606,0.00023405584,0.00035497834,0.00023233812],"domain_scores_gemma":[0.9995022,0.00002937873,0.00009044705,0.000116894815,0.0001380145,0.00012308631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009405627,0.00012331683,0.00023457437,0.00009514992,0.000023415227,0.000007832276,0.0000721397,0.00017543022,0.00010674822],"category_scores_gemma":[0.00009721037,0.00009909833,0.00003804598,0.00067572953,0.00004402007,0.000028727409,0.00003361542,0.00045286398,0.000009116635],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004945473,0.00013736365,0.27279285,0.0005584196,0.00012477525,0.00004233895,0.0033316775,0.000017605977,0.6986516,0.0000011621373,0.009548511,0.014299156],"study_design_scores_gemma":[0.00396403,0.00066258275,0.04928289,0.00024462817,0.000073485535,0.0000024303988,0.00014270502,0.0039572096,0.9332975,0.000024927404,0.008177211,0.00017039129],"about_ca_topic_score_codex":0.00002552524,"about_ca_topic_score_gemma":0.000011242299,"teacher_disagreement_score":0.23464592,"about_ca_system_score_codex":0.000105099556,"about_ca_system_score_gemma":0.00020668609,"threshold_uncertainty_score":0.40411127},"labels":[],"label_agreement":null},{"id":"W3083034993","doi":"10.1158/1538-7445.am2020-2083","title":"Abstract 2083: Alternative splicing regulation by the androgen receptor in prostate cancer cells","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Alternative splicing; RNA splicing; Androgen receptor; Biology; Transcriptome; LNCaP; Splicing factor; Gene; Gene expression; Cancer research; Prostate cancer; Cell biology; RNA; Cancer; Exon; Genetics","score_opus":0.09723422705816151,"score_gpt":0.4210208239302919,"score_spread":0.3237865968721304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083034993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94978154,0.0083066635,0.0000034621255,0.03800623,0.00012466687,0.0019037959,0.0001755148,0.0000323403,0.0016657837],"genre_scores_gemma":[0.98357385,0.009208039,0.00001887882,0.00047167146,0.0004919995,0.00086066313,0.00006391864,0.000047146877,0.005263827],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973975,0.00015528958,0.0002695239,0.0005017686,0.0009723441,0.0007035869],"domain_scores_gemma":[0.9988868,0.0001602471,0.00006160397,0.00025788732,0.00033996082,0.0002934638],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006972097,0.00016679788,0.00025909804,0.00013300426,0.00020072822,0.000072647104,0.0002455475,0.000070323746,0.0017254269],"category_scores_gemma":[0.00006950471,0.00010827094,0.00006027489,0.0009275408,0.00027069045,0.00015095559,0.0001171707,0.000863661,0.00012641565],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002512988,0.000113652604,0.01640601,0.0003236478,0.00014870695,0.00007463741,0.00543865,0.00026371365,0.82198286,0.000028653469,0.11903478,0.0336717],"study_design_scores_gemma":[0.0038139855,0.00034202766,0.008878439,0.0004983284,0.00002026987,0.000002156922,0.001045508,0.00076761167,0.915671,0.00010950757,0.0686486,0.00020255518],"about_ca_topic_score_codex":0.0048060426,"about_ca_topic_score_gemma":0.00022398078,"teacher_disagreement_score":0.09368815,"about_ca_system_score_codex":0.0008548941,"about_ca_system_score_gemma":0.0006639768,"threshold_uncertainty_score":0.9991871},"labels":[],"label_agreement":null},{"id":"W3083237575","doi":"10.1158/1538-7445.am2020-3517","title":"Abstract 3517: A germline variant at 8q24 contributes to familial clustering of prostate cancer in men of African ancestry","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec","funders":"","keywords":"Prostate cancer; Family history; Allele; Population; Medicine; Genotype; Internal medicine; Genetics; Allele frequency; Genome-wide association study; Demography; Oncology; Cancer; Gynecology; Biology; Single-nucleotide polymorphism; Gene","score_opus":0.11476872701665779,"score_gpt":0.43060013953468307,"score_spread":0.31583141251802527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083237575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735678,0.0064526987,0.000014564582,0.015424828,0.000085659376,0.0019098532,0.0005828785,0.000021127364,0.0019406319],"genre_scores_gemma":[0.9939373,0.003865931,0.00007586189,0.00012835966,0.00019484138,0.0006135725,0.000023967203,0.000038004324,0.0011221245],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99711716,0.000100327605,0.000550345,0.0005085762,0.0009300684,0.0007935236],"domain_scores_gemma":[0.9983942,0.00018103342,0.00010011491,0.0003042364,0.0006067067,0.00041373906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007330124,0.00018702731,0.0006486235,0.00034825524,0.000072939656,0.000016748749,0.00027658025,0.00010489147,0.0005110251],"category_scores_gemma":[0.00023351327,0.00014978088,0.000086775166,0.0014451153,0.0003277689,0.00008094562,0.00036449535,0.0005367844,0.000012637925],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019702338,0.00033139822,0.1093486,0.0026896922,0.00033578262,0.0004648278,0.005718241,0.0011842342,0.83686006,0.000031749743,0.00486957,0.01846349],"study_design_scores_gemma":[0.01845108,0.002838273,0.3258248,0.0037641749,0.0000976979,0.000008624955,0.0032545598,0.0035415394,0.63030756,0.00011510838,0.011297851,0.00049870904],"about_ca_topic_score_codex":0.0061117634,"about_ca_topic_score_gemma":0.0012574401,"teacher_disagreement_score":0.2164762,"about_ca_system_score_codex":0.0009323712,"about_ca_system_score_gemma":0.0013435448,"threshold_uncertainty_score":0.9239199},"labels":[],"label_agreement":null},{"id":"W3083310601","doi":"10.1016/j.eururo.2020.08.011","title":"Apalutamide and Overall Survival in Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":290,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate; Prostate cancer; Oncology; Cancer; Urology; Gynecology; Internal medicine","score_opus":0.036342933274420584,"score_gpt":0.3024633613023374,"score_spread":0.26612042802791686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083310601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9510084,0.0023922836,0.0000036926729,0.028511675,0.00007291042,0.0002502436,0.000009909929,0.0000398422,0.017711058],"genre_scores_gemma":[0.99348974,0.0013021753,0.000027247774,0.0039203935,0.0001533325,0.000008051903,0.000012585536,0.000024027571,0.0010624676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991541,0.00015549916,0.00011989028,0.00024453984,0.00008662314,0.0002393645],"domain_scores_gemma":[0.9996961,0.000031010582,0.000020712294,0.00008224224,0.000020571411,0.00014941231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013244957,0.00008762539,0.00016899953,0.000044113553,0.000021607384,0.000008010077,0.00004557958,0.000017637072,0.00012160524],"category_scores_gemma":[0.000051084276,0.00006828765,0.0000192804,0.00009041612,0.0000891412,0.000028156106,0.000078884164,0.0002020595,0.00007864277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035136498,0.00010524752,0.9504241,0.0001439221,0.00010310172,0.0045307255,0.0035460019,0.000047727666,0.011516694,0.00029734548,0.0032715008,0.022499986],"study_design_scores_gemma":[0.0064198705,0.001094419,0.8987105,0.00001673463,0.000035160287,0.00003451815,0.00005970936,0.0004558199,0.0002940404,0.0000571877,0.092690066,0.00013197804],"about_ca_topic_score_codex":0.00004893629,"about_ca_topic_score_gemma":0.000018836106,"teacher_disagreement_score":0.08941857,"about_ca_system_score_codex":0.000021622334,"about_ca_system_score_gemma":0.00004837299,"threshold_uncertainty_score":0.27846897},"labels":[],"label_agreement":null},{"id":"W3083311387","doi":"10.1158/1538-7445.am2020-5425","title":"Abstract 5425: Novel molecular subtypes identified in prostate cancer: Results from the SPARTAN study","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Gene signature; Medicine; Oncology; Internal medicine; Cancer; Androgen deprivation therapy; Prostate; Hormonal therapy; Gene expression; Biology; Gene; Genetics","score_opus":0.15897740021073345,"score_gpt":0.4424666324182094,"score_spread":0.2834892322074759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083311387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9521474,0.0064381515,0.0000016961461,0.03675398,0.0001394684,0.0029956324,0.0005499464,0.000049046008,0.0009246693],"genre_scores_gemma":[0.9944203,0.0023327412,0.000014121733,0.0004630857,0.0004162403,0.0009373096,0.00010763247,0.00005598246,0.0012525787],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9960136,0.00020871412,0.00047953674,0.00087497965,0.0015397903,0.0008833972],"domain_scores_gemma":[0.99807245,0.0003898408,0.00007464036,0.00063239294,0.00043809778,0.0003926012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012617718,0.00023299703,0.000404216,0.00015153411,0.00022411029,0.0001530263,0.0004963752,0.00008013086,0.00039236486],"category_scores_gemma":[0.00046490887,0.00015297197,0.00008754266,0.0013392221,0.00029365337,0.00013054522,0.00026382957,0.0012767788,0.00011216419],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03008369,0.0019922678,0.4014424,0.000326095,0.0010156587,0.003484658,0.028317088,0.0004062243,0.49300942,0.000085596526,0.022379339,0.017457576],"study_design_scores_gemma":[0.028710986,0.0013222131,0.8272572,0.00082890963,0.00012209431,0.0000030733843,0.009573151,0.00025063613,0.11340872,0.00020362061,0.01783627,0.00048308566],"about_ca_topic_score_codex":0.02546844,"about_ca_topic_score_gemma":0.0059933737,"teacher_disagreement_score":0.42581484,"about_ca_system_score_codex":0.00048141196,"about_ca_system_score_gemma":0.0012829145,"threshold_uncertainty_score":0.98102105},"labels":[],"label_agreement":null},{"id":"W3083506489","doi":"10.1158/1538-7445.am2020-1621","title":"Abstract 1621: Contactin 1 (CNTN1) promotes prostate cancer tumorigenesis in transgenic models","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; McMaster University","funders":"","keywords":"Tramp; Prostate cancer; Cancer research; Carcinogenesis; PTEN; Genetically modified mouse; Transgene; Cre recombinase; Metastasis; Cancer; Medicine; Biology; Internal medicine; Apoptosis; Genetics; Gene","score_opus":0.2011238224896096,"score_gpt":0.4413270813062213,"score_spread":0.24020325881661167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083506489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9517217,0.013297075,0.0000061277583,0.02847626,0.000102804246,0.0027341149,0.00017051207,0.0000940555,0.0033973032],"genre_scores_gemma":[0.9844692,0.009725936,0.0000476904,0.00033142808,0.00040471257,0.0021626775,0.000042957516,0.00009065622,0.0027247916],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959853,0.0001563966,0.00044514847,0.000835725,0.0012798787,0.0012975145],"domain_scores_gemma":[0.9982391,0.00015910085,0.00005645751,0.00035184145,0.00048416277,0.0007093336],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007156948,0.00029027511,0.0005605489,0.000340785,0.00018770988,0.00008254328,0.00031962644,0.00015097848,0.0015938429],"category_scores_gemma":[0.00008767198,0.00023161333,0.0001441667,0.0014373974,0.00027837843,0.0003024906,0.000094411706,0.0012083711,0.000091431844],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01904102,0.0012091646,0.087618396,0.004638495,0.00077733485,0.0019249154,0.015917914,0.00084228435,0.7536478,0.00041466719,0.012982434,0.10098559],"study_design_scores_gemma":[0.024233747,0.0026627819,0.08373029,0.002701299,0.00016788447,0.000019178084,0.0034358993,0.0042889155,0.8474507,0.0015006016,0.028506266,0.0013024323],"about_ca_topic_score_codex":0.0033380247,"about_ca_topic_score_gemma":0.0011043228,"teacher_disagreement_score":0.09968315,"about_ca_system_score_codex":0.000963788,"about_ca_system_score_gemma":0.0023500903,"threshold_uncertainty_score":0.99931884},"labels":[],"label_agreement":null},{"id":"W3083541285","doi":"10.1158/1538-7445.am2020-776","title":"Abstract 776: Androgen receptor (AR) and non-AR aberrations associated with outcomes in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Androgen deprivation therapy; Androgen receptor; Internal medicine; Progression-free survival; Medicine; Oncology; Urology; Proportional hazards model; LNCaP; Overall survival; Cancer","score_opus":0.08397157565865523,"score_gpt":0.37833558719738425,"score_spread":0.29436401153872904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083541285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989198,0.0012510129,0.0000051993047,0.0057217563,0.000017397246,0.0032071872,0.00028474958,0.000042283737,0.00027240068],"genre_scores_gemma":[0.994119,0.0032306812,0.00009874596,0.00018892527,0.000047854723,0.0013451058,0.00033890293,0.00006767851,0.00056310825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970318,0.00022417841,0.000402754,0.00067845517,0.0009171414,0.0007456365],"domain_scores_gemma":[0.9984381,0.00026353853,0.000120553465,0.00022876379,0.00060842425,0.0003405744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056555384,0.00031437282,0.0006358882,0.00042192146,0.0002013377,0.00010760452,0.00011176858,0.00011034776,0.00015383423],"category_scores_gemma":[0.00013751305,0.00021639938,0.000042265878,0.0016926815,0.00034731283,0.00034554713,0.000038584767,0.00070694875,0.000010298615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00746456,0.00037364507,0.94301885,0.0001830364,0.00089292653,0.0007092849,0.009111469,0.0005183808,0.03136291,0.000013158126,0.0003004857,0.0060512912],"study_design_scores_gemma":[0.023135345,0.0020763816,0.9178549,0.0009870606,0.00009526299,0.000013518187,0.0033427305,0.0015677924,0.050213177,0.000029741155,0.00022030978,0.00046377344],"about_ca_topic_score_codex":0.0052778036,"about_ca_topic_score_gemma":0.01326307,"teacher_disagreement_score":0.025163945,"about_ca_system_score_codex":0.0013037847,"about_ca_system_score_gemma":0.0018412261,"threshold_uncertainty_score":0.88245106},"labels":[],"label_agreement":null},{"id":"W3083608894","doi":"10.1158/1538-7445.am2020-3731","title":"Abstract 3731: Targeting the isocitrate dehydrogenase 1 (IDH1) metabolic enzyme in prostate cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Isocitrate dehydrogenase; IDH1; Cell growth; PI3K/AKT/mTOR pathway; Cancer research; Prostate cancer; Biology; Anabolism; Cancer cell; Enzyme; Chemistry; Cancer; Biochemistry; Cell biology; Signal transduction; Mutant; Genetics","score_opus":0.10888073083183997,"score_gpt":0.4228358465801656,"score_spread":0.31395511574832563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083608894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8857392,0.06291203,0.0000011360842,0.047124032,0.00011550067,0.0018874897,0.00010941668,0.00006668235,0.0020445161],"genre_scores_gemma":[0.9757107,0.017752321,0.000029336286,0.0013303405,0.00080367527,0.0016865847,0.000039393883,0.00007522489,0.002572432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960234,0.00026900723,0.00042949268,0.00067378127,0.0012491713,0.001355148],"domain_scores_gemma":[0.9983388,0.00023174533,0.000073317926,0.00036112103,0.00043373107,0.0005612502],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014483706,0.00026394703,0.00045811382,0.00028050682,0.00036102903,0.00012057855,0.00041274691,0.00008653864,0.0021612148],"category_scores_gemma":[0.0002386408,0.00016694095,0.00014411393,0.0022263082,0.00045253072,0.00018836134,0.00020455511,0.0016834699,0.00018926527],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005130148,0.00040992454,0.0956657,0.0012383804,0.0007014034,0.0017309301,0.012756815,0.0007973219,0.7704693,0.0003992728,0.08060677,0.030094037],"study_design_scores_gemma":[0.008300811,0.00039582787,0.03136377,0.0006544443,0.000105050356,0.000009451812,0.0029596994,0.0014485138,0.72357965,0.00035020828,0.23024905,0.0005835517],"about_ca_topic_score_codex":0.0038456025,"about_ca_topic_score_gemma":0.0009968408,"teacher_disagreement_score":0.14964227,"about_ca_system_score_codex":0.00050976913,"about_ca_system_score_gemma":0.0018514993,"threshold_uncertainty_score":0.9987509},"labels":[],"label_agreement":null},{"id":"W3083638783","doi":"10.1158/1538-7445.am2020-4361","title":"Abstract 4361: A systematic study of the impact of estrogens and selective estrogen receptor modulators on prostate cancer cell proliferation","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Estrogen receptor; LNCaP; Cancer research; DU145; Prostate cancer; Estrogen; Selective estrogen receptor modulator; Androgen receptor; Cell growth; Oncogene; Receptor; Estrogen receptor alpha; Cancer; Cell; Biology; Internal medicine; Endocrinology; Cell cycle; Breast cancer; Medicine; Biochemistry","score_opus":0.0727677534753255,"score_gpt":0.4143117050873933,"score_spread":0.3415439516120678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083638783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99014866,0.0027992064,2.6253306e-7,0.00057201454,0.00003058535,0.006150828,0.0001344532,0.000014018181,0.00014998896],"genre_scores_gemma":[0.9979509,0.0007567888,0.0000055830724,0.000012981846,0.00008522003,0.0009623612,0.0000062470062,0.00003458418,0.00018533015],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975191,0.00028700015,0.0003788646,0.00038459964,0.0010277621,0.00040267708],"domain_scores_gemma":[0.99838406,0.0001287405,0.00016718106,0.00032486956,0.0007494219,0.00024570705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004939921,0.00018193558,0.00050498644,0.00011255969,0.00014140368,0.000025685353,0.00016771065,0.00006834124,0.00010094003],"category_scores_gemma":[0.0001548428,0.00010048644,0.00011809179,0.0007862397,0.00017870257,0.00008558152,0.00009278568,0.0004434582,0.0000037826833],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067402404,0.0018144891,0.6428771,0.015625684,0.0015190684,0.000017308575,0.028478505,0.0011791434,0.29940358,0.000015266734,0.001461686,0.00086795114],"study_design_scores_gemma":[0.010088226,0.014345818,0.25304064,0.0052066147,0.00032551965,0.000004399439,0.009487715,0.0013344785,0.7058197,0.000034054974,0.000010002151,0.0003028205],"about_ca_topic_score_codex":0.0042349356,"about_ca_topic_score_gemma":0.00010156445,"teacher_disagreement_score":0.40641615,"about_ca_system_score_codex":0.0007450824,"about_ca_system_score_gemma":0.001303488,"threshold_uncertainty_score":0.6401984},"labels":[],"label_agreement":null},{"id":"W3083681037","doi":"10.7554/elife.54542","title":"Regulation of stem/progenitor cell maintenance by BMP5 in prostate homeostasis and cancer initiation","year":2020,"lang":"en","type":"article","venue":"eLife","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Progenitor cell; Stem cell; Biology; Cell biology; Cancer stem cell; Adult stem cell; Progenitor; GATA3; Cellular differentiation; Cancer research; Transcription factor; Genetics","score_opus":0.03047740867168183,"score_gpt":0.29822107012672217,"score_spread":0.26774366145504036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083681037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985794,0.00918794,0.000016231255,0.004100557,0.000030200385,0.0005345314,0.00008368468,0.000015648982,0.0002371979],"genre_scores_gemma":[0.99428666,0.004713334,0.0000912095,0.00027949532,0.000051846408,0.000058626334,0.000053258827,0.000012025874,0.00045354624],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99927986,0.000025058938,0.00017497446,0.00016421961,0.00021307437,0.0001428038],"domain_scores_gemma":[0.9996516,0.000018438783,0.00006468068,0.00006932734,0.000099735335,0.0000962236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008022937,0.000072866016,0.00016085422,0.00004519464,0.000019497606,0.0000069875427,0.000025500036,0.000033034983,0.000035668007],"category_scores_gemma":[0.000015241186,0.00005823028,0.000019354484,0.00021033485,0.00004061796,0.00007513164,0.000020523164,0.00007988838,0.0000049363866],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028577985,0.0002594555,0.5707475,0.0014679572,0.000082998726,0.000044865643,0.0055836537,0.000024188364,0.30894634,0.00003047538,0.02085015,0.08910461],"study_design_scores_gemma":[0.0070293746,0.00062870566,0.17062426,0.00027182052,0.000052356758,0.0000027609199,0.00070720416,0.0011707507,0.808213,0.000019063891,0.011117763,0.0001629459],"about_ca_topic_score_codex":0.00007943687,"about_ca_topic_score_gemma":0.000008167849,"teacher_disagreement_score":0.49926665,"about_ca_system_score_codex":0.00007127441,"about_ca_system_score_gemma":0.000104233644,"threshold_uncertainty_score":0.23745617},"labels":[],"label_agreement":null},{"id":"W3083715659","doi":"10.1158/1538-7445.am2020-1953","title":"Abstract 1953: Pre-clinical development of the second-generation N-terminal domain androgen receptor inhibitor, EPI-7386, for the treatment of prostate cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Androgen receptor; LNCaP; Prostate cancer; Cancer research; Cancer; Chemistry; Computational biology; Biology; Pharmacology; Genetics","score_opus":0.18562171698225297,"score_gpt":0.460539999905851,"score_spread":0.274918282923598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083715659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787524,0.008465533,0.000009554403,0.008201897,0.00028826634,0.0038488384,0.00034119905,0.000011246615,0.000081068894],"genre_scores_gemma":[0.9864921,0.005198082,0.00038009975,0.00011614288,0.0011066796,0.002886891,0.00006962988,0.00004240541,0.0037079875],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974371,0.00016991237,0.0006499783,0.00043012292,0.00082093064,0.0004919101],"domain_scores_gemma":[0.998295,0.00034900583,0.00017423762,0.0003674756,0.0005848613,0.00022942443],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009271784,0.0001848986,0.00041595896,0.00005253129,0.00032064927,0.000026125954,0.00025848506,0.000111860034,0.0009382528],"category_scores_gemma":[0.00008412056,0.00009382984,0.00021366865,0.00040389207,0.0004937291,0.00006112427,0.0000836812,0.00032936662,0.00000812018],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013137863,0.001553267,0.07381884,0.0018957554,0.0017388816,0.00002131114,0.02584761,0.00004609828,0.42762136,0.000034224617,0.035580292,0.41870448],"study_design_scores_gemma":[0.005552452,0.0017906134,0.026000433,0.00025600265,0.000068479254,0.0000016837657,0.0004962633,0.000084488376,0.7345276,0.00002090211,0.23107672,0.00012437288],"about_ca_topic_score_codex":0.00019961684,"about_ca_topic_score_gemma":0.00078516616,"teacher_disagreement_score":0.4185801,"about_ca_system_score_codex":0.0005520993,"about_ca_system_score_gemma":0.0027122481,"threshold_uncertainty_score":0.999975},"labels":[],"label_agreement":null},{"id":"W3083758578","doi":"10.1158/1538-7445.am2020-2015","title":"Abstract 2015: A transcriptionally enhanced biosensor to detect and monitor biopsy-dissociated primary prostate cancer single cell drug responses by bioluminescence microscopy","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Enzalutamide; Prostate cancer; LNCaP; Androgen receptor; Cancer research; PCA3; Cell culture; Cancer cell; Cancer; Cell; Circulating tumor cell; Prostate; Biology; Medicine; Chemistry; Internal medicine; Metastasis; Biochemistry","score_opus":0.04859452136934901,"score_gpt":0.3828039818549057,"score_spread":0.3342094604855567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083758578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9482579,0.021680456,0.000010057009,0.026081465,0.0001387778,0.0021574253,0.001324866,0.00010983776,0.00023917986],"genre_scores_gemma":[0.9786592,0.008684219,0.0004680396,0.00073640334,0.00031365443,0.0009168393,0.00011314253,0.000093557166,0.010014905],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961871,0.00020223112,0.00040918385,0.0009822601,0.0010766874,0.0011425387],"domain_scores_gemma":[0.9976042,0.00022366228,0.00008051727,0.00029560446,0.0007843018,0.0010117118],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005337622,0.00034727593,0.0005142455,0.00028826416,0.00035657125,0.00016136773,0.00028055406,0.00015397041,0.0003013045],"category_scores_gemma":[0.00015678898,0.0002917107,0.00010174303,0.0012366131,0.0004860981,0.00017881242,0.00012305184,0.0007193409,0.00007831957],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0093144635,0.00016861591,0.002341143,0.0007454597,0.00010029591,0.00008373979,0.0021178436,0.0000013966193,0.9478902,3.0174726e-7,0.03071589,0.006520619],"study_design_scores_gemma":[0.0032265321,0.0007748909,0.018206654,0.00050166063,0.000038140257,0.0000034790698,0.00042821147,0.0000043926507,0.9646574,0.000006982071,0.011836748,0.0003148823],"about_ca_topic_score_codex":0.0014515446,"about_ca_topic_score_gemma":0.000084228326,"teacher_disagreement_score":0.030401304,"about_ca_system_score_codex":0.0009144494,"about_ca_system_score_gemma":0.001160551,"threshold_uncertainty_score":0.9999535},"labels":[],"label_agreement":null},{"id":"W3084161124","doi":"10.1016/j.adro.2020.08.010","title":"Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging","year":2020,"lang":"en","type":"article","venue":"Advances in Radiation Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network; University of Toronto; McMaster University; London Health Sciences Centre; Sunnybrook Health Science Centre; Western University","funders":"Ontario Institute for Cancer Research","keywords":"Medicine; Prostate cancer; Positron emission tomography; Radiology; Management of prostate cancer; PET-CT; Radiation therapy; Brachytherapy; Prostate; Malignancy; Nuclear medicine; Cancer; Internal medicine","score_opus":0.0462824162330975,"score_gpt":0.4267704119364332,"score_spread":0.38048799570333575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084161124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8976481,0.09640111,0.00010520452,0.0036639047,0.00017997013,0.0015004319,0.00007746042,0.00001857967,0.00040525716],"genre_scores_gemma":[0.9090366,0.09012395,0.0003551933,0.00011075853,0.000046245583,0.00020652698,0.000055328685,0.000010374136,0.000055049586],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991185,0.00007930194,0.00033905046,0.000196295,0.00012481485,0.00014203963],"domain_scores_gemma":[0.9992807,0.00022918731,0.00023102082,0.0000751576,0.00013142738,0.000052527193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019205552,0.00008172197,0.00031085114,0.00010631673,0.000026786227,0.000002849233,0.000040553736,0.000012384046,0.000011299284],"category_scores_gemma":[0.00022494422,0.00006678901,0.00002847223,0.00022776195,0.00010698748,0.00015237031,0.000014955286,0.000078034434,4.344967e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012767972,0.00031929024,0.22234567,0.004695821,0.00018529619,0.00013574689,0.016252648,0.0010859867,0.011039926,0.0027036169,0.00032740508,0.72814065],"study_design_scores_gemma":[0.101437606,0.042238757,0.10658647,0.0063300375,0.0008436538,0.00063361035,0.03806184,0.043818057,0.1470178,0.0070064394,0.5046823,0.0013434022],"about_ca_topic_score_codex":0.000042655836,"about_ca_topic_score_gemma":0.00006089441,"teacher_disagreement_score":0.7267972,"about_ca_system_score_codex":0.00017320541,"about_ca_system_score_gemma":0.0002852026,"threshold_uncertainty_score":0.27235767},"labels":[],"label_agreement":null},{"id":"W3084814365","doi":"10.1007/s10147-020-01777-9","title":"Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","year":2020,"lang":"en","type":"review","venue":"International Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"Medizinische Universität Wien; Universität Wien","keywords":"Enzalutamide; Medicine; Prostate cancer; Hazard ratio; Internal medicine; Oncology; Placebo; Adverse effect; Androgen deprivation therapy; Cancer; Confidence interval; Androgen receptor; Pathology","score_opus":0.29575869287660983,"score_gpt":0.5572556385365748,"score_spread":0.26149694565996495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084814365","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010604843,0.988101,0.00012763041,0.0068702376,0.00044894588,0.003914257,0.00045798448,0.000008484547,0.000060872815],"genre_scores_gemma":[0.00010039394,0.99355257,0.0023964902,0.0017700428,0.000710861,0.0006859151,0.00011449808,0.000047440328,0.000621814],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99185336,0.001018383,0.005433941,0.00054938137,0.000800678,0.0003442693],"domain_scores_gemma":[0.9872957,0.0054889796,0.004974695,0.00025599255,0.0014314039,0.0005532311],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.004538343,0.00049676164,0.015561972,0.00039158226,0.00006787024,0.000079641264,0.00040580696,0.00027970446,0.00009848052],"category_scores_gemma":[0.0031476251,0.00028711112,0.0041148784,0.0004929462,0.0002774364,0.00013501289,0.00014454458,0.00097634265,0.0000048523957],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000972972,0.0002736386,0.000052985026,0.35995334,0.53589636,0.0012946856,0.000048745813,0.0000081096605,2.5801248e-7,0.0000771001,0.0017376145,0.09968418],"study_design_scores_gemma":[0.0020198748,0.001841956,0.000027975086,0.039840773,0.7036754,0.00061508396,0.000016785481,0.00006712506,1.1167975e-7,0.00016362168,0.2515386,0.00019269096],"about_ca_topic_score_codex":0.00002348685,"about_ca_topic_score_gemma":0.00006837395,"teacher_disagreement_score":0.3201126,"about_ca_system_score_codex":0.00035753663,"about_ca_system_score_gemma":0.0032402582,"threshold_uncertainty_score":0.9999581},"labels":[],"label_agreement":null},{"id":"W3085312854","doi":"10.21203/rs.3.rs-67753/v1","title":"Schlafen family member 5 (SLFN5) regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer","year":2020,"lang":"en","type":"preprint","venue":"Research Square (Research Square)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Beatson Institute for Cancer Research; Medical Research Council; Ligue Contre le Cancer; European Commission; Cancer Research UK","keywords":"Prostate cancer; Androgen deprivation therapy; Cancer research; Androgen receptor; mTORC1; In vivo; PI3K/AKT/mTOR pathway; Biomarker; Cancer; Medicine; Biology; Chemistry; Signal transduction; Internal medicine; Cell biology; Biochemistry","score_opus":0.17363502871962322,"score_gpt":0.45876831626976,"score_spread":0.2851332875501368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085312854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93335456,0.0070659104,0.000011339074,0.033721257,0.0003615991,0.015788402,0.0011154064,0.0004137347,0.008167802],"genre_scores_gemma":[0.96984017,0.010419937,0.0002750733,0.0001163178,0.0013035916,0.007121,0.003209871,0.00037660153,0.0073374175],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.97459245,0.0039590113,0.0017009504,0.0032653036,0.012017849,0.004464449],"domain_scores_gemma":[0.98354596,0.0029577643,0.00031547065,0.0022173575,0.008924021,0.00203942],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.010965637,0.0011736858,0.0018585607,0.0044381777,0.0010239774,0.00096499384,0.001412567,0.0014693888,0.0014156038],"category_scores_gemma":[0.005700933,0.001011232,0.000531559,0.0062830634,0.0016461874,0.0006454675,0.0027541635,0.012040868,0.00069130067],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03307674,0.004031686,0.06670282,0.022891508,0.0020024313,0.0037702823,0.01257118,0.00096247735,0.7557431,0.00081856444,0.0771204,0.020308824],"study_design_scores_gemma":[0.030462535,0.010380532,0.6562155,0.03651062,0.00027819243,0.00003220959,0.016643511,0.01217141,0.16985448,0.013948193,0.04932076,0.004182049],"about_ca_topic_score_codex":0.023932569,"about_ca_topic_score_gemma":0.00304342,"teacher_disagreement_score":0.5895127,"about_ca_system_score_codex":0.008497151,"about_ca_system_score_gemma":0.019213099,"threshold_uncertainty_score":0.9998269},"labels":[],"label_agreement":null},{"id":"W3085395192","doi":"10.1111/bju.15236","title":"Can post‐treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer?","year":2020,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Cohort; Biochemical recurrence; Prostatectomy; Internal medicine; Prospective cohort study; Oncology; Retrospective cohort study; Proportional hazards model; Metastasis; Cancer; Radiation therapy; Urology","score_opus":0.037494714902189925,"score_gpt":0.32336041889590045,"score_spread":0.28586570399371053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085395192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8523852,0.0036248304,0.000006107911,0.1426393,0.00026606268,0.00069085986,0.00030729186,0.000014605088,0.00006574915],"genre_scores_gemma":[0.9926761,0.0035734975,0.00013224661,0.0029689972,0.00023370219,0.00006195467,0.00003280815,0.000024502113,0.00029619675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837375,0.000120054545,0.000509402,0.00023869814,0.00035865282,0.00039947047],"domain_scores_gemma":[0.9988859,0.00006613291,0.00015646353,0.00013442824,0.00025229724,0.00050477113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016377683,0.00016120767,0.0005861922,0.0001662845,0.000050442308,0.000020502735,0.00016722866,0.00008048932,0.0001839258],"category_scores_gemma":[0.00030096306,0.00013786445,0.0001455455,0.0002187021,0.00007160504,0.00008507959,0.000065519984,0.0003588038,0.0000058739447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00913957,0.001326472,0.8180636,0.00011969925,0.0009912474,0.025080603,0.007211161,0.00042368425,0.0036030149,0.00001631593,0.012635802,0.121388815],"study_design_scores_gemma":[0.039730895,0.03084098,0.8841057,0.00036009203,0.00048339745,0.0028710726,0.0008818552,0.00021190077,0.0019395768,0.000101402016,0.038101368,0.00037179323],"about_ca_topic_score_codex":0.0012626044,"about_ca_topic_score_gemma":0.0053398903,"teacher_disagreement_score":0.1402909,"about_ca_system_score_codex":0.000380222,"about_ca_system_score_gemma":0.000781139,"threshold_uncertainty_score":0.5621949},"labels":[],"label_agreement":null},{"id":"W3087357547","doi":"10.1007/s13238-020-00786-8","title":"Pioneer of prostate cancer: past, present and the future of FOXA1","year":2020,"lang":"en","type":"review","venue":"Protein & Cell","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":189,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"FOXA1; Prostate cancer; Androgen receptor; Transcription factor; Cancer research; Chromatin; Cancer; Prostate; Biology; Androgen deprivation therapy; Medicine; Breast cancer; Internal medicine; Genetics; Gene","score_opus":0.026261007975902983,"score_gpt":0.3287618782701934,"score_spread":0.3025008702942904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087357547","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000058327656,0.98781043,0.0000011279209,0.0040268754,0.00006968119,0.0071376027,0.00013646492,0.000013018205,0.00074647425],"genre_scores_gemma":[0.00011098309,0.9914541,0.000092929404,0.00001416174,0.00087067985,0.0014440317,0.00005672915,0.0000447862,0.0059116003],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983979,0.00015988457,0.000475378,0.0003141523,0.00041572948,0.00023699779],"domain_scores_gemma":[0.99895537,0.00007125521,0.00036614935,0.00034578805,0.00013732631,0.00012409993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002221072,0.00028507618,0.0015449348,0.000076645614,0.000037701528,0.000010267102,0.00016482192,0.000148539,0.00007679782],"category_scores_gemma":[0.0000075458534,0.00013603829,0.0003077271,0.00028567045,0.00029157609,0.000023724031,0.00015920396,0.0004335786,0.0000064232418],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004905171,0.00009282567,0.000025298172,0.08283424,0.00033906623,0.000027575154,0.00045937873,1.076006e-7,0.000034476336,0.00003806807,0.002344892,0.91331357],"study_design_scores_gemma":[0.0020839125,0.00026512405,0.0000037105488,0.008020411,0.000849489,0.000006797625,0.000060622093,0.0000039925367,0.0011236344,0.00004532675,0.9874256,0.00011134598],"about_ca_topic_score_codex":0.0001088605,"about_ca_topic_score_gemma":0.0000018234796,"teacher_disagreement_score":0.9850807,"about_ca_system_score_codex":0.00006637659,"about_ca_system_score_gemma":0.00057738886,"threshold_uncertainty_score":0.55474806},"labels":[],"label_agreement":null},{"id":"W3087416729","doi":"10.1056/nejmoa2022485","title":"Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":766,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"Daiichi Sankyo Europe; Pharmacyclics; Merck Sharp and Dohme; EMD Serono; Genentech; Foundation Medicine; Sierra Oncology; Bavarian Nordic; Astellas Pharma; Eisai; Celldex Therapeutics; Daiichi-Sankyo; Clovis Oncology; National Institute for Health and Care Research; AstraZeneca; Invitae; Ipsen; Vertex Pharmaceuticals; Boston Scientific Corporation; Endocyte; NRG Oncology; F. Hoffmann-La Roche; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Olaparib; Prostate cancer; Oncology; Medicine; Internal medicine; Cancer research; Cancer; Biology; Poly ADP ribose polymerase","score_opus":0.06052038105550388,"score_gpt":0.34320059801749203,"score_spread":0.28268021696198814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087416729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88914925,0.0063962014,0.00010973143,0.10279129,0.00019543043,0.0003924016,0.000008500361,0.0000097988395,0.00094739755],"genre_scores_gemma":[0.9955412,0.0014628929,0.0004333335,0.0005807184,0.0013998192,0.000004834671,0.000010027069,0.000017334714,0.00054982293],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99846333,0.00007884821,0.0004392337,0.00013340512,0.00065910915,0.00022609536],"domain_scores_gemma":[0.99892646,0.000110369205,0.00018468892,0.00007938533,0.00022584417,0.00047322497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046297951,0.00013956378,0.0005330411,0.00014043557,0.000027139435,0.000010115449,0.00007294373,0.000022784365,0.0002925131],"category_scores_gemma":[0.00016248396,0.00007176455,0.00003617167,0.00037558397,0.000099502526,0.00009909861,0.000009278901,0.00039153584,0.0000023155683],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11333422,0.0006231216,0.44484463,0.0012425069,0.002033114,0.025675744,0.034682665,0.0010464843,0.10268928,0.00033854166,0.018128369,0.2553613],"study_design_scores_gemma":[0.6512006,0.03602867,0.19695213,0.0049872166,0.0017255414,0.0019254193,0.006239423,0.00057168346,0.007868824,0.00048874016,0.09146899,0.0005427431],"about_ca_topic_score_codex":0.00046324308,"about_ca_topic_score_gemma":0.00049598695,"teacher_disagreement_score":0.5378664,"about_ca_system_score_codex":0.00009588481,"about_ca_system_score_gemma":0.00090677204,"threshold_uncertainty_score":0.32028136},"labels":[],"label_agreement":null},{"id":"W3087584857","doi":"10.1007/s13577-020-00435-6","title":"Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones","year":2020,"lang":"en","type":"article","venue":"Human Cell","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Genome British Columbia; University of British Columbia","funders":"National Cancer Institute","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; clone (Java method); Cancer research; Biology; Cell growth; Cell culture; Population; Cancer; Internal medicine; Medicine; Genetics; Gene","score_opus":0.041213091567371886,"score_gpt":0.3095000808406214,"score_spread":0.2682869892732495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087584857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971088,0.00037303826,0.00001682072,0.0013437604,0.000019122961,0.0003476796,0.00003389668,0.000016838398,0.0007400377],"genre_scores_gemma":[0.9977284,0.00039879052,0.00005153622,0.000090197034,0.00008483125,0.0000205334,0.00018605891,0.000009843276,0.0014298003],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995189,0.000013052766,0.00013372407,0.00012814341,0.00011796755,0.000088239714],"domain_scores_gemma":[0.99972945,0.0000055910086,0.00006147277,0.000056274992,0.00007519297,0.000071987226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000030381054,0.000062262785,0.00011390435,0.0000304879,0.00005388238,0.000012213835,0.000017395781,0.000026724212,0.0001509494],"category_scores_gemma":[0.000002820341,0.00005032521,0.000017792188,0.00007952321,0.00004041137,0.00006639504,0.000011505559,0.000052169125,0.0000041639173],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002646691,0.000037161648,0.023797423,0.00031809762,0.000013598963,0.0000065459403,0.0016194977,8.848974e-7,0.97322524,0.00004081704,0.0000720151,0.0006040323],"study_design_scores_gemma":[0.0028630116,0.0008605167,0.41337714,0.000105024745,0.00008554646,0.000001495689,0.00021576464,0.0005137705,0.57979697,0.00003559248,0.0020275817,0.00011755241],"about_ca_topic_score_codex":0.000045340097,"about_ca_topic_score_gemma":0.000010803933,"teacher_disagreement_score":0.39342827,"about_ca_system_score_codex":0.00002093036,"about_ca_system_score_gemma":0.000055836907,"threshold_uncertainty_score":0.20522025},"labels":[],"label_agreement":null},{"id":"W3087796427","doi":"10.1016/j.annonc.2020.08.920","title":"661P Real-world treatment (Tx) patterns of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the US","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Merck Sharp and Dohme; AstraZeneca","keywords":"Enzalutamide; Docetaxel; Medicine; Abiraterone; Prostate cancer; Internal medicine; Oncology; Cabazitaxel; Abiraterone acetate; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.1667584045785049,"score_gpt":0.44440872277820376,"score_spread":0.2776503181996989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087796427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97648525,0.00047527396,8.409137e-7,0.019249428,0.000048707894,0.0011151747,0.0002843841,0.0000073922442,0.0023335307],"genre_scores_gemma":[0.9945889,0.0033650051,0.000049364968,0.0012275368,0.000043391097,0.00021490913,0.00012349845,0.000013514002,0.00037385433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985091,0.00019549302,0.00046968606,0.0002254222,0.00030484534,0.00029547364],"domain_scores_gemma":[0.999084,0.00016549903,0.00021626228,0.00018999795,0.00023481388,0.0001094532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019260719,0.00014946252,0.0004971964,0.000120940254,0.00003206273,0.0000054961056,0.0001090638,0.000040146748,0.00016286508],"category_scores_gemma":[0.000042864962,0.00008806163,0.000105157735,0.00030846102,0.00010217474,0.000053225824,0.000025488269,0.00011633377,0.000005769944],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006423253,0.0037324326,0.88641834,0.00058568997,0.00075678807,0.00045935935,0.013597485,0.00009300861,0.0030572463,0.00023813723,0.003407517,0.08123076],"study_design_scores_gemma":[0.011052174,0.021031523,0.9215667,0.00018119407,0.0002704166,0.0000031439074,0.0011688321,0.00008101603,0.021661535,0.00012417808,0.022706691,0.0001525608],"about_ca_topic_score_codex":0.0056899404,"about_ca_topic_score_gemma":0.0067285667,"teacher_disagreement_score":0.0810782,"about_ca_system_score_codex":0.00014112155,"about_ca_system_score_gemma":0.0005418564,"threshold_uncertainty_score":0.86015254},"labels":[],"label_agreement":null},{"id":"W3087865502","doi":"10.1016/j.annonc.2020.08.896","title":"637P The prognostic value of the baseline neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving radium-223 (Ra-223): A post-hoc analysis of the ALSYMPCA phase-III trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; EMD Serono; Servier; Astellas Pharma; Constellation Pharmaceuticals; Clovis Oncology; Advanced Accelerator Applications; Endocyte; Invitae; Gilead Sciences; Genentech; Valeant Pharmaceuticals International; Bayer HealthCare; Sanofi; Active Biotech; Celgene; Bristol-Myers Squibb; AstraZeneca; Astellas Foundation for Research on Metabolic Disorders; Amgen; Pfizer","keywords":"Medicine; Prostate cancer; Oncology; Radium-223; Post-hoc analysis; Neutrophil to lymphocyte ratio; Internal medicine; Post hoc; Urology; Cancer; Overall survival","score_opus":0.060852168536440016,"score_gpt":0.38004750527603737,"score_spread":0.3191953367395973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087865502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688127,0.00091173395,0.000014984798,0.025606345,0.000111269546,0.004055142,0.00039763708,0.0000075797866,0.00008259555],"genre_scores_gemma":[0.99756444,0.00033347798,0.00010489736,0.0014499223,0.000065725806,0.00027996633,0.00007857104,0.000023538669,0.000099448545],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9967526,0.00086558016,0.0009422836,0.00035966255,0.000696872,0.00038299404],"domain_scores_gemma":[0.9972292,0.0006260406,0.0007013536,0.00046055272,0.0008442487,0.00013858196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089245744,0.00023166966,0.0009575459,0.00020704845,0.000116826275,0.000012116999,0.00034548383,0.00006821347,0.000072618284],"category_scores_gemma":[0.0006519193,0.00010627764,0.0002810713,0.002251677,0.0003637148,0.0000787663,0.000107671636,0.00023801342,9.779452e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74218386,0.011351167,0.103731364,0.00095415383,0.01189405,0.00009763579,0.025960341,0.014242684,0.027505826,0.00028629645,0.0022362797,0.059556324],"study_design_scores_gemma":[0.347361,0.071381226,0.51792413,0.000952862,0.010369297,0.0000059991107,0.002248861,0.010048198,0.03542474,0.00007775295,0.0036423292,0.00056361203],"about_ca_topic_score_codex":0.0012355208,"about_ca_topic_score_gemma":0.0013834769,"teacher_disagreement_score":0.41419277,"about_ca_system_score_codex":0.00016619322,"about_ca_system_score_gemma":0.0020462524,"threshold_uncertainty_score":0.43338767},"labels":[],"label_agreement":null},{"id":"W3087872591","doi":"10.1016/j.annonc.2020.08.882","title":"623P KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Daiichi Sankyo Europe; Pharmacyclics; Merck Sharp and Dohme; Genentech; EMD Serono; MorphoSys; PharmaMar; Astellas Pharma; Eisai; Pfizer; Incyte; BeiGene; Menarini Silicon Biosystems; Beth Israel Deaconess Medical Center; Astex Pharmaceuticals; Valeant Pharmaceuticals International; Advanced Accelerator Applications; Endocyte; Sierra Oncology; Genomic Health; Ipsen; Array BioPharma; Daiichi-Sankyo; Teva Pharmaceutical Industries; Exelixis; Sanofi; Merck; GlaxoSmithKline; Amgen; Jounce Therapeutics; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Enzalutamide; Medicine; Prostate cancer; Pembrolizumab; Internal medicine; Docetaxel; Oncology; Abiraterone; Chemotherapy; Cancer; Immunotherapy; Androgen receptor","score_opus":0.14206301833293994,"score_gpt":0.4476406662763026,"score_spread":0.3055776479433627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087872591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805003,0.00473325,0.000028200198,0.009894133,0.00009219585,0.0036693253,0.00081551046,0.00003239677,0.00023472417],"genre_scores_gemma":[0.99561644,0.0019022673,0.00037297703,0.0009853685,0.00008876865,0.00055091456,0.00012343616,0.000045598314,0.00031422198],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9972284,0.00019568157,0.0009533201,0.0005783643,0.00048399591,0.00056024024],"domain_scores_gemma":[0.9978622,0.00029019834,0.0004923931,0.0003053204,0.00066412817,0.0003857323],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005144245,0.00031439716,0.001290052,0.00019468366,0.00017946647,0.000016457048,0.00015300003,0.00010501982,0.000100111065],"category_scores_gemma":[0.00024482195,0.00025172418,0.00015364376,0.00034546762,0.00032088932,0.00011752424,0.0001254537,0.0002218571,0.0000017833188],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31685796,0.018400805,0.005388756,0.0061413962,0.008227462,0.0023312443,0.040340584,0.0006407969,0.39870378,0.0011111825,0.014724193,0.18713182],"study_design_scores_gemma":[0.24137302,0.4101464,0.016913865,0.00084428414,0.005106387,0.00011107256,0.016739491,0.0040841606,0.21223241,0.0017787635,0.08921676,0.0014533944],"about_ca_topic_score_codex":0.00071624253,"about_ca_topic_score_gemma":0.0007870888,"teacher_disagreement_score":0.3917456,"about_ca_system_score_codex":0.00013968424,"about_ca_system_score_gemma":0.0014140431,"threshold_uncertainty_score":0.9999935},"labels":[],"label_agreement":null},{"id":"W3088153386","doi":"10.1016/j.annonc.2020.08.879","title":"620P Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)–pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme","keywords":"Medicine; Enzalutamide; Prostate cancer; Docetaxel; Cohort; Prednisone; Abiraterone acetate; Internal medicine; Urology; Cancer; Oncology; Surgery; Androgen deprivation therapy; Androgen receptor","score_opus":0.06855141656529057,"score_gpt":0.3665041529986613,"score_spread":0.2979527364333707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088153386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869869,0.0019461034,0.000009848366,0.007571738,0.00005284798,0.0024953766,0.000419868,0.000050365477,0.0004669528],"genre_scores_gemma":[0.9935681,0.0033303068,0.00051560835,0.001199225,0.000038431113,0.00033831783,0.00030811326,0.00005994039,0.00064194214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969426,0.00025033666,0.0007789748,0.0006914994,0.00054480735,0.00079177646],"domain_scores_gemma":[0.99821544,0.00012843596,0.00036893462,0.00029682578,0.0005582121,0.00043217166],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032290016,0.0004077569,0.0012066221,0.0001976748,0.00009916366,0.000034043172,0.00015027633,0.00014085403,0.0002263787],"category_scores_gemma":[0.00012277467,0.00027332915,0.000072938245,0.00062938343,0.00041946798,0.00027584104,0.000107086984,0.00036229484,0.000014958726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33820876,0.0031177595,0.5797699,0.002723406,0.0040807733,0.002613849,0.007913529,0.000991129,0.0119088935,0.00010873937,0.0034418555,0.04512138],"study_design_scores_gemma":[0.09484777,0.031642877,0.8421506,0.00065497163,0.0009684166,0.0000519067,0.00059173,0.0013011467,0.022557393,0.00010310856,0.004377712,0.00075234484],"about_ca_topic_score_codex":0.000832494,"about_ca_topic_score_gemma":0.0009391224,"teacher_disagreement_score":0.26238072,"about_ca_system_score_codex":0.00025626904,"about_ca_system_score_gemma":0.0014387047,"threshold_uncertainty_score":0.99997187},"labels":[],"label_agreement":null},{"id":"W3088233867","doi":"10.1016/j.annonc.2020.08.910","title":"651P Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Androgen deprivation therapy; Prostate cancer; Hazard ratio; Subgroup analysis; Internal medicine; Prednisone; Gastroenterology; Proportional hazards model; Enzalutamide; Placebo; Urology; Cancer; Confidence interval; Pathology","score_opus":0.11606796369809859,"score_gpt":0.4462474897081508,"score_spread":0.33017952601005224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088233867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969649,0.00039086933,0.0000020092991,0.00097036705,0.000014256321,0.0013418524,0.00024596,0.000003778457,0.00006606167],"genre_scores_gemma":[0.9995186,0.00021394328,0.000060953185,0.00008282927,0.000012555433,0.000034330427,0.000031024367,0.000011421648,0.000034390683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873763,0.00021018139,0.00036904222,0.00020794821,0.00026954158,0.00020563236],"domain_scores_gemma":[0.9989954,0.000067941735,0.0002872159,0.00014214484,0.00041675058,0.00009050774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017287934,0.00013952194,0.0006589991,0.00009124462,0.000025822674,0.0000043217196,0.000063575055,0.000042387685,0.00002657543],"category_scores_gemma":[0.000045151217,0.00007549644,0.000069919355,0.0003542191,0.000268835,0.00008880879,0.00006104657,0.00012888081,3.1533617e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01242568,0.0012844471,0.96448076,0.00014860119,0.0014878251,0.000038186234,0.009563728,0.0012494429,0.0067054536,0.0000027956046,0.00009199496,0.0025210606],"study_design_scores_gemma":[0.010514995,0.017696755,0.95407575,0.00008210886,0.00024008288,0.0000013641379,0.0007471027,0.00014895668,0.016416945,0.000005932842,0.0000070866654,0.00006289681],"about_ca_topic_score_codex":0.0029668636,"about_ca_topic_score_gemma":0.0010838292,"teacher_disagreement_score":0.016412307,"about_ca_system_score_codex":0.00007424133,"about_ca_system_score_gemma":0.0005500706,"threshold_uncertainty_score":0.448503},"labels":[],"label_agreement":null},{"id":"W3088330245","doi":"10.1016/j.annonc.2020.08.884","title":"625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Merck Sharp and Dohme","keywords":"Medicine; Enzalutamide; Prostate cancer; Cohort; Abiraterone acetate; Internal medicine; Abiraterone; Cancer; Urology; Oncology; Surgery; Androgen deprivation therapy; Androgen receptor","score_opus":0.06414097661310898,"score_gpt":0.3659130848340182,"score_spread":0.3017721082209092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088330245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98539764,0.0012160435,0.0000121123685,0.009454344,0.000080825674,0.0022836307,0.0003637517,0.000059183036,0.001132477],"genre_scores_gemma":[0.9951887,0.0013928504,0.00037094677,0.0016772947,0.000047417456,0.00033315664,0.00049058837,0.00006585486,0.0004331666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99669915,0.00027853655,0.00081691996,0.00067441515,0.0006502833,0.0008806712],"domain_scores_gemma":[0.9980199,0.00010667819,0.0003867316,0.00035305953,0.00070949935,0.00042418035],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033938762,0.00040678785,0.0011871307,0.00026043563,0.00009245014,0.000026620572,0.00019980062,0.00014416297,0.00027124776],"category_scores_gemma":[0.000105677675,0.00029935443,0.00011396459,0.00074358046,0.00035237637,0.0002545331,0.00009679795,0.0004242519,0.00004164707],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18835275,0.0032730284,0.72570425,0.0018644342,0.0040676035,0.0026323968,0.00664586,0.0027356802,0.016454266,0.00017896981,0.005479009,0.042611726],"study_design_scores_gemma":[0.07040715,0.023699671,0.8590006,0.0005314182,0.0007915117,0.000023224235,0.00045652466,0.0010637006,0.03649352,0.00013708668,0.0066447,0.00075088383],"about_ca_topic_score_codex":0.0009773572,"about_ca_topic_score_gemma":0.00071250775,"teacher_disagreement_score":0.13329634,"about_ca_system_score_codex":0.00038612995,"about_ca_system_score_gemma":0.0015128463,"threshold_uncertainty_score":0.9999459},"labels":[],"label_agreement":null},{"id":"W3088332096","doi":"10.1016/j.annonc.2020.08.659","title":"545P Preclinical profile of EPI-7386, a second-generation N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Daiichi Sankyo Europe; Loxo Oncology; Chugai Pharmaceutical; Shionogi; Pfizer Japan; Genentech; Eli Lilly Japan; Eisai; Astellas Pharma; Dainippon Sumitomo Pharma; Yakult Honsha; Sanofi; Kyowa Hakko Kirin; Ignyta; Eli Lilly and Company; Ono Pharmaceutical; Pfizer; Incyte; Taiho Pharmaceutical; GlaxoSmithKline; Teijin Pharma; Daiichi-Sankyo; Amgen; Bayer Yakuhin; Rakuten Medical; AstraZeneca; Bristol-Myers Squibb","keywords":"Enzalutamide; Androgen receptor; Prostate cancer; LNCaP; Medicine; In vivo; Tolerability; Cancer research; Pharmacology; Reporter gene; Cancer; Internal medicine; Gene expression; Biology; Gene; Adverse effect; Biochemistry","score_opus":0.19861082355544013,"score_gpt":0.46233925188934605,"score_spread":0.2637284283339059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088332096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9694075,0.004525498,0.000011901922,0.02296935,0.00014614596,0.0021663469,0.0005761679,0.000007701761,0.00018937154],"genre_scores_gemma":[0.9899061,0.0058648954,0.0009835798,0.00046247983,0.00063605234,0.0009400287,0.000179869,0.000021117463,0.001005917],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99878323,0.00009866878,0.00051199883,0.00022383373,0.00016390008,0.00021835256],"domain_scores_gemma":[0.99879605,0.00028596926,0.00028743414,0.00015715878,0.00036046418,0.00011294906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025069082,0.0001204008,0.00054633693,0.000033775505,0.000040983934,0.0000026361179,0.00007369717,0.00011548043,0.00039360498],"category_scores_gemma":[0.00007787478,0.000070899136,0.00019169367,0.0001256191,0.00024246279,0.000038304086,0.000021628104,0.000075116324,0.000003107647],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02876653,0.0042312103,0.021056233,0.0011960986,0.0018763512,0.00004223431,0.013297812,0.000019971125,0.2836289,0.00013499377,0.054012556,0.5917371],"study_design_scores_gemma":[0.0072933044,0.038148336,0.0013482774,0.00006327656,0.00016210673,0.000005819863,0.00032055928,0.00021563438,0.7534506,0.000055400935,0.19885935,0.00007739053],"about_ca_topic_score_codex":0.000043776025,"about_ca_topic_score_gemma":0.000073464675,"teacher_disagreement_score":0.5916597,"about_ca_system_score_codex":0.00006038291,"about_ca_system_score_gemma":0.0006585201,"threshold_uncertainty_score":0.43096983},"labels":[],"label_agreement":null},{"id":"W3088368080","doi":"10.1016/j.annonc.2020.08.891","title":"632P Health-related quality of life (HRQoL) at final analysis of the SPARTAN study of apalutamide (APA) vs placebo (PBO) in patients (pts) with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving androgen deprivation therapy (ADT)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Placebo; Internal medicine; Repeated measures design; Urology; Analysis of variance; Quality of life (healthcare); Oncology; Cancer; Nursing","score_opus":0.17824461829542312,"score_gpt":0.4239858116542255,"score_spread":0.24574119335880237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088368080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423915,0.0005683075,0.000002268487,0.0029904821,0.00002334834,0.0019838903,0.00013940682,0.000005234408,0.000047880992],"genre_scores_gemma":[0.998994,0.00048651575,0.00005956789,0.0002442421,0.0000071545846,0.00008465295,0.0000738329,0.000014388112,0.000035652873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690187,0.00064246013,0.0012971208,0.00030581336,0.0005903323,0.00026240174],"domain_scores_gemma":[0.9973711,0.00028383365,0.0013347934,0.00029492762,0.0005878002,0.0001275491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091095775,0.00016657509,0.0012218141,0.00025179304,0.000058794445,0.0000028479183,0.00014130307,0.00006606285,0.000060372597],"category_scores_gemma":[0.00022958148,0.00010832951,0.00012870914,0.0014875465,0.00020047129,0.00006707372,0.000055316792,0.00017183,3.6699768e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029777352,0.00218351,0.943563,0.0003274859,0.0024175595,0.0000054767634,0.012742402,0.0017946528,0.003869998,0.0000057812513,0.0000769467,0.0032358503],"study_design_scores_gemma":[0.013802575,0.012731285,0.96582377,0.00013938305,0.00028934726,3.036374e-7,0.0015521809,0.0004967564,0.00505126,0.000010592847,0.000020126134,0.00008244306],"about_ca_topic_score_codex":0.0069543202,"about_ca_topic_score_gemma":0.015047961,"teacher_disagreement_score":0.02226076,"about_ca_system_score_codex":0.00016786046,"about_ca_system_score_gemma":0.0010821646,"threshold_uncertainty_score":0.99965847},"labels":[],"label_agreement":null},{"id":"W3088465353","doi":"10.1016/j.annonc.2020.08.924","title":"665P Impact of enzalutamide on patient-reported fatigue in hormone-sensitive prostate cancer (HSPC) or castration-resistant prostate cancer (CRPC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Janssen Biotech; Genentech; Active Biotech; Astellas Pharma; Incyte; Gilead Sciences; Alere; Sanofi; Genomic Health; GlaxoSmithKline; Myriad Genetics; Bristol-Myers Squibb; AstraZeneca; Astellas Foundation for Research on Metabolic Disorders; Amgen; Pfizer; Ipsen; Constellation Pharmaceuticals; Clovis Oncology; Astellas Pharma US","keywords":"Medicine; Enzalutamide; Prostate cancer; Asymptomatic; Cancer; Placebo; Internal medicine; Disease; Oncology; Androgen receptor; Pathology; Alternative medicine","score_opus":0.18446280646921684,"score_gpt":0.46331229145432057,"score_spread":0.27884948498510376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088465353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854409,0.001792832,0.0000010321111,0.009278538,0.00006899593,0.0016970672,0.00058501266,0.000021657683,0.0011139767],"genre_scores_gemma":[0.9925995,0.005695489,0.00006437327,0.000838795,0.00006580814,0.0002591767,0.00009645064,0.000034840275,0.00034557725],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976085,0.00016222626,0.00081048853,0.0004352426,0.00042651032,0.00055704865],"domain_scores_gemma":[0.998018,0.00017835575,0.0005327269,0.00022131432,0.0007488553,0.00030071416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022176513,0.0002684123,0.00086778967,0.00021947459,0.00004424236,0.000008058744,0.00008582664,0.00014731046,0.00014897129],"category_scores_gemma":[0.0002828573,0.00018088214,0.00017318713,0.00062625686,0.00025484856,0.00011864909,0.00005050871,0.0003250363,0.000004566022],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18821189,0.0028574655,0.11213641,0.000784445,0.0028519216,0.0054531065,0.039532397,0.003930123,0.46114105,0.0000544184,0.01571999,0.16732676],"study_design_scores_gemma":[0.018809577,0.07027841,0.51847553,0.0010605465,0.00029199597,0.000042392767,0.0029661641,0.0006443662,0.382306,0.00010669339,0.004453803,0.00056451425],"about_ca_topic_score_codex":0.006962079,"about_ca_topic_score_gemma":0.0015357218,"teacher_disagreement_score":0.4063391,"about_ca_system_score_codex":0.00037109773,"about_ca_system_score_gemma":0.002994961,"threshold_uncertainty_score":0.99965066},"labels":[],"label_agreement":null},{"id":"W3088562785","doi":"10.1016/j.euf.2020.09.005","title":"Prostate-specific Membrane Antigen Imaging and Theranostics Impact Patient Outcomes","year":2020,"lang":"en","type":"article","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Janssen Research and Development; Janssen Pharmaceuticals; AstraZeneca; Bayer; Roche; Astellas Pharma US; Deutsche Krebshilfe; Pfizer; Deutsche Forschungsgemeinschaft; Bristol-Myers Squibb","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Positron emission tomography; Radioligand; Prostate; Oncology; Internal medicine; Radiology; Cancer; Receptor","score_opus":0.022581061514421873,"score_gpt":0.28068129312340123,"score_spread":0.2581002316089794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088562785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95737827,0.009169128,0.000056115783,0.023439392,0.000095851974,0.00052496383,0.000033359094,0.00011787001,0.009185073],"genre_scores_gemma":[0.99602264,0.0014062903,0.000102528735,0.0021521186,0.00009563511,0.000004062121,0.000027993821,0.000052431173,0.00013632618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987517,0.00016992353,0.00020534421,0.0003445115,0.00016421889,0.00036430414],"domain_scores_gemma":[0.999335,0.000072246636,0.000052850362,0.00019766652,0.000058538706,0.0002837079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000117613905,0.00019107376,0.0002774223,0.00006536901,0.00009298182,0.000030228342,0.00007873749,0.000025373749,0.00015825985],"category_scores_gemma":[0.00006545932,0.00012454434,0.0000804534,0.00011858039,0.00018335156,0.000051631472,0.000107641274,0.00024720188,0.00018957966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023190053,0.00019008394,0.837588,0.000044384436,0.0003655525,0.0046977936,0.005591561,0.000016265707,0.030777296,0.0000492266,0.007087855,0.11127295],"study_design_scores_gemma":[0.007796903,0.0036138748,0.8595863,0.000022203558,0.00012039836,0.0002412941,0.00027136054,0.0003504541,0.0069559244,0.00006385757,0.1206,0.0003774335],"about_ca_topic_score_codex":0.000008199394,"about_ca_topic_score_gemma":3.8531272e-7,"teacher_disagreement_score":0.11351214,"about_ca_system_score_codex":0.000026238125,"about_ca_system_score_gemma":0.000042170297,"threshold_uncertainty_score":0.5078771},"labels":[],"label_agreement":null},{"id":"W3088563759","doi":"10.1016/j.annonc.2020.08.2084","title":"690TiP A phase III, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Docetaxel; Medicine; Nivolumab; Prostate cancer; Oncology; Internal medicine; Enzalutamide; Chemotherapy; Placebo; Cancer; Immunotherapy; Androgen receptor; Pathology","score_opus":0.23337521537375636,"score_gpt":0.47446785959615373,"score_spread":0.24109264422239737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088563759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.960012,0.001166113,0.00016433746,0.022523267,0.0001487137,0.0144216595,0.000388161,0.000035125908,0.0011406229],"genre_scores_gemma":[0.99100345,0.0013991018,0.0011021462,0.0005826747,0.00015753329,0.0030612433,0.00021935995,0.0000431355,0.002431355],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997581,0.00019312461,0.0009688909,0.00038225102,0.00041253958,0.0004621653],"domain_scores_gemma":[0.9973905,0.00063282694,0.00067088386,0.00022373236,0.00080294017,0.00027913245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009262885,0.00026755402,0.0019357844,0.00015753252,0.00007802377,0.000015688112,0.00013856075,0.000105696985,0.00029071668],"category_scores_gemma":[0.0002487605,0.00016162953,0.00027079045,0.00037947888,0.00049195706,0.000117672585,0.00003520079,0.00018653739,0.000002765442],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.979449,0.0020216447,0.000009058307,0.0008409267,0.002175641,0.00015100082,0.0018117893,0.00004149961,0.005664743,0.00018558836,0.003109721,0.0045394218],"study_design_scores_gemma":[0.9002389,0.047296043,0.0000033614397,0.00015009599,0.00097010296,0.0000119258575,0.000441619,0.00064087956,0.046511747,0.00010625122,0.003480611,0.00014849482],"about_ca_topic_score_codex":0.00035265533,"about_ca_topic_score_gemma":0.00029612618,"teacher_disagreement_score":0.079210095,"about_ca_system_score_codex":0.00007010798,"about_ca_system_score_gemma":0.002552761,"threshold_uncertainty_score":0.65910614},"labels":[],"label_agreement":null},{"id":"W3088602042","doi":"10.1016/j.annonc.2020.08.2250","title":"LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; PTEN; Prostate cancer; Internal medicine; Placebo; Androgen deprivation therapy; Prednisone; Gastroenterology; Asymptomatic; Clinical endpoint; Cancer; Urology; Oncology; Clinical trial; PI3K/AKT/mTOR pathway; Pathology","score_opus":0.19236414445010053,"score_gpt":0.45830870870332024,"score_spread":0.2659445642532197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088602042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874363,0.0017153946,0.000011882271,0.0068030073,0.00013711123,0.003126337,0.00040362097,0.000029168665,0.00033717335],"genre_scores_gemma":[0.9970152,0.0009691151,0.00009825354,0.0005923918,0.0000798962,0.00055969245,0.00022218766,0.00003979567,0.00042349144],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99673176,0.0003629943,0.0011575328,0.0005512275,0.00056622503,0.000630287],"domain_scores_gemma":[0.9982315,0.00015805071,0.00045957128,0.00034567175,0.00046125508,0.0003439844],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005843771,0.00031590255,0.0013595442,0.00027804376,0.00007187156,0.000014711127,0.00021692675,0.000115939445,0.0004677617],"category_scores_gemma":[0.0001223944,0.00025412798,0.00012605722,0.00061054796,0.00026208445,0.00017524035,0.000115859395,0.0003519785,0.000015517648],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49820113,0.028606847,0.020146614,0.0042398195,0.0053221444,0.009768855,0.10382039,0.005154873,0.23441567,0.0001445933,0.018892707,0.07128635],"study_design_scores_gemma":[0.48443395,0.20551172,0.03446238,0.0010693027,0.002334624,0.00007127662,0.034810737,0.007893014,0.21423748,0.00024452692,0.013507048,0.0014239525],"about_ca_topic_score_codex":0.0049336585,"about_ca_topic_score_gemma":0.0037211813,"teacher_disagreement_score":0.17690487,"about_ca_system_score_codex":0.0002819138,"about_ca_system_score_gemma":0.001974506,"threshold_uncertainty_score":0.9999911},"labels":[],"label_agreement":null},{"id":"W3088668888","doi":"10.1016/j.annonc.2020.08.2085","title":"691TiP A phase III, randomized study of enzalutamide (ENZA) plus leuprolide (LHRHa), ENZA monotherapy, and placebo plus LHRHa in men with high-risk nonmetastatic hormone-sensitive prostate cancer (nmHSPC) progressing after local therapy: EMBARK final protocol/study status","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Astellas Pharma Global Development; Pfizer","keywords":"Medicine; Prostate cancer; Enzalutamide; Placebo; Internal medicine; Oncology; Urology; Discontinuation; Hazard ratio; Androgen deprivation therapy; Gynecology; Cancer; Androgen receptor; Pathology","score_opus":0.07288615058085053,"score_gpt":0.41586888639660835,"score_spread":0.34298273581575783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088668888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89028704,0.0018095142,0.00007896286,0.00092493946,0.000017779857,0.10664448,0.00011170382,0.00003298106,0.00009256477],"genre_scores_gemma":[0.91547793,0.0010123358,0.0003396333,0.00038027324,0.00006141816,0.08254368,0.00001857406,0.0000717106,0.00009447329],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99492,0.0014689956,0.0011904627,0.0008296946,0.000736844,0.00085397245],"domain_scores_gemma":[0.9974489,0.00053175836,0.00081679417,0.0003337057,0.00048402665,0.00038478657],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012553002,0.0005422072,0.002696906,0.00035530946,0.00010384117,0.000033052333,0.0001441269,0.00014345383,0.000044602093],"category_scores_gemma":[0.00011507618,0.00035797223,0.00013585141,0.00058487,0.00089938805,0.00020199266,0.00011794049,0.00061216037,0.0000022999711],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8089375,0.0058315103,0.019250788,0.00021939172,0.0022718457,0.0016503552,0.083611146,0.0004312674,0.0009078768,0.0000010695558,0.000108688044,0.07677857],"study_design_scores_gemma":[0.8706271,0.07812036,0.019729678,0.00029261602,0.0005709199,0.000024010811,0.019910388,0.0046982323,0.005268227,0.000045709483,0.0003125953,0.00040014228],"about_ca_topic_score_codex":0.0045425645,"about_ca_topic_score_gemma":0.00096245395,"teacher_disagreement_score":0.07637843,"about_ca_system_score_codex":0.00029441452,"about_ca_system_score_gemma":0.001962878,"threshold_uncertainty_score":0.9998872},"labels":[],"label_agreement":null},{"id":"W3089050578","doi":"10.1016/j.annonc.2020.08.927","title":"668P Clinical factors that are prognostic for survival outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Biotech; European Society for Medical Oncology; Daiichi Sankyo Company; Emerson Collective; Incyte; Daiichi Sankyo Europe; Sanofi; Exelixis; GlaxoSmithKline; Society for Immunotherapy of Cancer; Astellas Pharma Global Development; Bristol-Myers Squibb; AstraZeneca; Astellas Pharma; Parker Institute for Cancer Immunotherapy; Gateway for Cancer Research; Astellas Foundation for Research on Metabolic Disorders; Amgen; Pfizer","keywords":"Medicine; Prostate cancer; Proportional hazards model; Internal medicine; Radium-223; Cohort; Oncology; Cancer; Retrospective cohort study; Urology; Surgery; Bone metastasis","score_opus":0.3090772894855692,"score_gpt":0.4777500778161739,"score_spread":0.16867278833060473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089050578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771656,0.00042716155,0.000014144785,0.019183282,0.000033819997,0.002445012,0.00026075623,0.00002964026,0.00044061773],"genre_scores_gemma":[0.9976196,0.00045839956,0.0003135461,0.00040694073,0.00003632814,0.00041293248,0.00014453675,0.00003516136,0.000572555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981615,0.00018456322,0.00048228016,0.00040185763,0.00031902472,0.00045075375],"domain_scores_gemma":[0.9981913,0.0007476709,0.00030051818,0.00015638256,0.00033314686,0.0002709948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003316614,0.0002385565,0.0010857924,0.000104764884,0.00004947956,0.000012781169,0.000097702556,0.00009154051,0.000044733486],"category_scores_gemma":[0.00021822858,0.00013292591,0.00011050619,0.00029143592,0.00027399338,0.00009480684,0.00002184136,0.00021608193,0.00000199795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014690712,0.00093747966,0.97834116,0.00029623325,0.00093875494,0.00037242915,0.00088162604,0.000023572524,0.0002074358,0.000021091462,0.0006798861,0.002609625],"study_design_scores_gemma":[0.018658256,0.021538937,0.95016676,0.00019126505,0.00040155632,0.00000606428,0.0024917102,0.00014140132,0.0041060722,0.000026931435,0.0020706742,0.00020036366],"about_ca_topic_score_codex":0.0006487923,"about_ca_topic_score_gemma":0.0022816283,"teacher_disagreement_score":0.028174387,"about_ca_system_score_codex":0.00008437835,"about_ca_system_score_gemma":0.0009567796,"threshold_uncertainty_score":0.5420561},"labels":[],"label_agreement":null},{"id":"W3089163327","doi":"10.1016/j.annonc.2020.08.2079","title":"685P A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC): Outcomes by prostate-specific antigen (PSA) response","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Astellas Pharma Global Development; EMD Serono; Genentech; Sanofi; BeiGene; Gilead Sciences; Pfizer; Amgen","keywords":"Medicine; Prostate cancer; Enzalutamide; Internal medicine; Placebo; Urology; Gynecology; Hazard ratio; Oncology; Prostate-specific antigen; Cancer; Confidence interval; Androgen receptor; Alternative medicine; Pathology","score_opus":0.1158635947186557,"score_gpt":0.4313768723674121,"score_spread":0.3155132776487564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089163327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9673176,0.002863457,0.000015652913,0.013799044,0.00004690742,0.01509911,0.0002309768,0.000031928455,0.00059531746],"genre_scores_gemma":[0.99333733,0.00195562,0.00015446485,0.00046881207,0.000031447173,0.0028497458,0.00009534187,0.000053723175,0.001053505],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949626,0.0011801842,0.0016741643,0.00067018747,0.0008237878,0.0006890739],"domain_scores_gemma":[0.9964248,0.0013685627,0.00086950115,0.0003927595,0.0005929177,0.00035144037],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025328305,0.00045091158,0.0032259908,0.0004379806,0.000091183996,0.000027639131,0.00022467913,0.00013841274,0.000180678],"category_scores_gemma":[0.00026944987,0.00029338888,0.00024092106,0.0007372216,0.00048700455,0.00019149171,0.00008886767,0.00039686385,0.0000058112787],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9330738,0.005296366,0.0050365776,0.00016305286,0.0022475747,0.00076023623,0.01573908,0.00021263742,0.033104982,0.000012534782,0.0023294783,0.0020236743],"study_design_scores_gemma":[0.94542193,0.02669211,0.0010991107,0.00014499115,0.00041750283,0.000008009806,0.0068813837,0.00029169637,0.017430155,0.000024248693,0.0013226839,0.00026617284],"about_ca_topic_score_codex":0.0011649588,"about_ca_topic_score_gemma":0.00064955006,"teacher_disagreement_score":0.026019733,"about_ca_system_score_codex":0.00017471894,"about_ca_system_score_gemma":0.0015602757,"threshold_uncertainty_score":0.99995184},"labels":[],"label_agreement":null},{"id":"W3089279818","doi":"10.1038/s41391-020-00283-3","title":"KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy","year":2020,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Urology; TMPRSS2; Biochemical recurrence; Lymph node; Prostate-specific antigen; Internal medicine; Oncology; Cancer","score_opus":0.017307091543038874,"score_gpt":0.31126726274884453,"score_spread":0.29396017120580564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089279818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95294774,0.0289665,0.00005185759,0.009345432,0.00011927993,0.005930175,0.002411708,0.00013405205,0.000093264774],"genre_scores_gemma":[0.9766764,0.015242195,0.0005624801,0.0025553964,0.00009771246,0.0038663521,0.0005422571,0.00013273199,0.00032447415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966046,0.00008803394,0.000624073,0.0010851681,0.00056170166,0.0010364183],"domain_scores_gemma":[0.9981289,0.00022041127,0.00018155633,0.0002114023,0.00028214595,0.00097556564],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015839422,0.00054604106,0.0007721729,0.00021049246,0.00024779787,0.00020273581,0.000116242256,0.000084386425,0.00005294523],"category_scores_gemma":[0.00025420162,0.00045216884,0.00011317476,0.0005140761,0.00042611134,0.00038607567,0.00016182427,0.00026697168,0.0000027610797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007200752,0.0004048437,0.92762685,0.007396397,0.00028620812,0.00019292223,0.0044678305,0.00008029598,0.001125441,0.00014263732,0.00046556874,0.05061024],"study_design_scores_gemma":[0.13273166,0.005537724,0.79644746,0.007998373,0.0022654713,0.000029817356,0.0047097066,0.013203296,0.015725581,0.007098138,0.010736159,0.0035166442],"about_ca_topic_score_codex":0.00022015658,"about_ca_topic_score_gemma":0.000020710297,"teacher_disagreement_score":0.13117944,"about_ca_system_score_codex":0.00031780792,"about_ca_system_score_gemma":0.0011473345,"threshold_uncertainty_score":0.999793},"labels":[],"label_agreement":null},{"id":"W3089292170","doi":"10.1016/j.annonc.2020.08.2088","title":"694TiP DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University; Ottawa Hospital; McGill University; Jewish General Hospital","funders":"Genentech; EUSA Pharma; Ipsen; Astellas Pharma; Eisai; Sanofi; Pfizer; Les Laboratories Pierre Fabre; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Placebo; Clinical endpoint; Internal medicine; Docetaxel; Tolerability; Oncology; Antiandrogen; Hazard ratio; Randomized controlled trial; Urology; Cancer; Adverse effect; Confidence interval; Pathology","score_opus":0.11803724377700105,"score_gpt":0.4164679729252467,"score_spread":0.29843072914824564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089292170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975127,0.0015755156,0.0003056668,0.005466277,0.00014452274,0.016641876,0.00063223543,0.000018014121,0.0000889229],"genre_scores_gemma":[0.984105,0.011859646,0.00021084526,0.0011101621,0.00016295869,0.0023493045,0.000117635354,0.000036131074,0.000048322272],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974548,0.0003940044,0.0009275224,0.00039539373,0.00046504047,0.00036320437],"domain_scores_gemma":[0.99701726,0.0010379994,0.0008995832,0.00024658628,0.0006101557,0.00018843217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011968234,0.00025521638,0.0013799669,0.00018489784,0.00012780582,0.00001377482,0.00016524554,0.00017989964,0.000066773006],"category_scores_gemma":[0.00045215467,0.00015482675,0.0002583022,0.0003879357,0.00023635376,0.000119994125,0.00004892603,0.00018832642,4.1194232e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88091713,0.00067436654,0.0010613246,0.000082539,0.0015887029,0.000006094006,0.002602249,0.00009296255,0.016546937,0.000040023366,0.00056272035,0.095824935],"study_design_scores_gemma":[0.81898946,0.021788664,0.00044375728,0.000092947266,0.0002587546,0.0000011029246,0.00016448174,0.00031845065,0.15581304,0.00012988188,0.0018814808,0.00011800242],"about_ca_topic_score_codex":0.0002270239,"about_ca_topic_score_gemma":0.00004666249,"teacher_disagreement_score":0.1392661,"about_ca_system_score_codex":0.00011507495,"about_ca_system_score_gemma":0.0013008842,"threshold_uncertainty_score":0.6313652},"labels":[],"label_agreement":null},{"id":"W3089317162","doi":"10.1101/2020.09.23.309088","title":"Mapping Isoform Abundance and Interactome of the Endogenous TMPRSS2-ERG Fusion Protein with Orthogonal Immunoprecipitation-Mass Spectrometry Assays","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"China Scholarship Council; Mitacs; National Natural Science Foundation of China; Prostate Cancer Canada","keywords":"Interactome; TMPRSS2; Erg; Fusion protein; Gene isoform; Biology; Immunoprecipitation; Prostate cancer; Chromatin immunoprecipitation; Fusion gene; Molecular biology; Computational biology; Gene; Genetics; Gene expression; Cancer; Biochemistry; Internal medicine; Medicine; Recombinant DNA","score_opus":0.021509740558577035,"score_gpt":0.23773741555076722,"score_spread":0.21622767499219017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089317162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927875,0.0026484544,0.0008048796,0.0009537738,0.0002534215,0.0022143621,0.00017479763,0.00011113008,0.000051706545],"genre_scores_gemma":[0.9931356,0.0005080323,0.005707782,0.00006829937,0.00019924628,0.0002597735,0.0000016035976,0.00009517248,0.000024508056],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99740714,0.00012969956,0.00049824436,0.0007591677,0.0007256097,0.00048015706],"domain_scores_gemma":[0.9977771,0.00009786602,0.00048676305,0.0008529954,0.0005514247,0.00023383337],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000454513,0.0004659114,0.0006849923,0.0002906091,0.00019654291,0.000097448865,0.0003618059,0.0002631699,0.000053737644],"category_scores_gemma":[0.00022636175,0.00032035453,0.00015147495,0.0008464181,0.00027735214,0.00013084995,0.00048684093,0.00092983985,0.000009416227],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062934344,0.00014430119,0.03234721,0.0014150253,0.00046895532,0.000116439056,0.000103970444,0.000004497747,0.9646351,0.00011519511,0.000012208759,0.000007794472],"study_design_scores_gemma":[0.0019375819,0.0005161821,0.38628602,0.0031795448,0.00015878388,4.7445914e-7,0.000039113238,0.00019280802,0.6068575,0.000010225638,0.00038066285,0.00044114588],"about_ca_topic_score_codex":0.00004520078,"about_ca_topic_score_gemma":0.0000022373165,"teacher_disagreement_score":0.3577776,"about_ca_system_score_codex":0.00043625146,"about_ca_system_score_gemma":0.0013206712,"threshold_uncertainty_score":0.99992484},"labels":[],"label_agreement":null},{"id":"W3089332307","doi":"10.1016/j.annonc.2020.08.890","title":"631P Darolutamide (D), enzalutamide (E) and apalutamide (A), the risk of adverse events (AEs) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC): Number needed to harm (NNH)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Research and Development; Genentech; Daiichi Sankyo Europe; Servier; Eisai; Astellas Pharma; Merck Sharp and Dohme; Cilag; Puma Biotechnology; Sierra Oncology; Pfizer; Incyte; Ipsen; Clovis Oncology; Astex Pharmaceuticals; Sanofi; Exelixis; Karyopharm Therapeutics; Teva Pharmaceutical Industries; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Number needed to harm; Enzalutamide; Adverse effect; Rate ratio; Prostate cancer; Internal medicine; Relative risk; Confidence interval; Number needed to treat; Cancer; Androgen receptor","score_opus":0.043929810108878836,"score_gpt":0.36777058779935035,"score_spread":0.3238407776904715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089332307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98688626,0.00025943876,0.0000095381865,0.0102887275,0.00004829395,0.0018040756,0.00031798225,0.000010643325,0.00037501834],"genre_scores_gemma":[0.99720305,0.0006408934,0.0003802074,0.0013731146,0.000034098262,0.00015417383,0.000042701813,0.000029492017,0.00014225529],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979694,0.0002003447,0.00057004724,0.00036683268,0.00045753655,0.00043582215],"domain_scores_gemma":[0.9985172,0.00020839428,0.0003337734,0.00024544582,0.00041553346,0.00027963083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031247447,0.00023073674,0.00065835635,0.00010695432,0.00006943601,0.0000038674902,0.0001431884,0.00007272776,0.0000783636],"category_scores_gemma":[0.00020708889,0.00014370977,0.00007982593,0.00053299865,0.0002449967,0.000121715966,0.00009203189,0.00027829406,0.000014435335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020316789,0.0008470333,0.95413303,0.0003867746,0.00067841465,0.000117584415,0.008946417,0.00062135473,0.0024839551,0.000016581442,0.0014511138,0.010000973],"study_design_scores_gemma":[0.013005294,0.0073686894,0.9665296,0.00032747124,0.00031203215,0.00000618152,0.00311498,0.00026853333,0.007239844,0.00009910519,0.0015158621,0.0002124043],"about_ca_topic_score_codex":0.00213191,"about_ca_topic_score_gemma":0.00075686665,"teacher_disagreement_score":0.012396594,"about_ca_system_score_codex":0.000098759854,"about_ca_system_score_gemma":0.0006092237,"threshold_uncertainty_score":0.58603144},"labels":[],"label_agreement":null},{"id":"W3090562759","doi":"10.1016/j.eururo.2020.08.025","title":"Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring","year":2020,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Astellas Pharma US; Pfizer","keywords":"Medicine; Prostate cancer; Enzalutamide; Prostate-specific antigen; Urology; Prostate; Antigen; Oncology; Castration; Internal medicine; Cancer; Immunology; Hormone; Androgen receptor","score_opus":0.04052337154656442,"score_gpt":0.312660925060009,"score_spread":0.27213755351344454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090562759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779157,0.010238314,0.0000064077653,0.004876248,0.0001289843,0.004093051,0.00014114844,0.00019589023,0.0024042728],"genre_scores_gemma":[0.988243,0.009139092,0.00061429973,0.0001290465,0.0002731109,0.00033138692,0.0002636555,0.00021414922,0.00079225993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99449813,0.0009152744,0.0010678953,0.0014177446,0.0007161183,0.0013848137],"domain_scores_gemma":[0.9981978,0.00010073826,0.00034825905,0.0005884658,0.0002493625,0.00051540957],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007812257,0.00066756917,0.00090207875,0.000497504,0.00021436658,0.0001296702,0.00032786006,0.000118204625,0.00013719016],"category_scores_gemma":[0.00005275069,0.0005052456,0.00009644281,0.0014208711,0.00043552433,0.0004485513,0.00018457387,0.00093142426,0.00015935884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02700464,0.00060477655,0.7652503,0.0003704002,0.00018325158,0.016940268,0.009713298,0.00046446102,0.16386853,0.000022800525,0.00078054453,0.014796679],"study_design_scores_gemma":[0.01750737,0.0078052664,0.9038752,0.00089860155,0.000083933104,0.00008536867,0.0017589045,0.00046009483,0.02611324,0.000025753887,0.04048288,0.00090340304],"about_ca_topic_score_codex":0.00025438162,"about_ca_topic_score_gemma":0.00010041765,"teacher_disagreement_score":0.13862485,"about_ca_system_score_codex":0.00040389766,"about_ca_system_score_gemma":0.0004055079,"threshold_uncertainty_score":0.99973994},"labels":[],"label_agreement":null},{"id":"W3090930865","doi":"10.1200/jco.20.01566","title":"Brachytherapy and Androgen-Deprivation Therapy in Patients With Intermediate- and High-Risk Prostate Cancer: Not Necessarily an Either/Or Decision","year":2020,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Okanagan University College; University of British Columbia; Western University","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; Androgen deprivation therapy; Oncology; Prostate; Androgen; Cancer; Internal medicine; Gynecology; Urology; Radiation therapy; Hormone","score_opus":0.0768048921112965,"score_gpt":0.4319979745032296,"score_spread":0.3551930823919331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090930865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8229798,0.0015358679,0.000010916261,0.17425212,0.00042470213,0.0007327018,0.000048937447,0.000007692037,0.0000072409034],"genre_scores_gemma":[0.5005648,0.15915622,0.0016464248,0.3341501,0.004013153,0.00004823175,0.00013937583,0.00011528303,0.00016639511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962016,0.00061804656,0.0017566794,0.00045859822,0.0006461186,0.0003189707],"domain_scores_gemma":[0.99524105,0.0018669094,0.0018864506,0.00019854151,0.0004672832,0.00033978673],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011190567,0.0003053446,0.0018661945,0.00025941434,0.000056793782,0.00004158656,0.00016302246,0.00079738075,0.00006289554],"category_scores_gemma":[0.0006524234,0.00015978428,0.000118460805,0.00019238645,0.00037074886,0.00024507858,0.000054942637,0.003329259,0.0000014276025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05871002,0.00040726984,0.46956924,0.000040179842,0.00034269714,0.00111987,0.0002078836,8.787218e-7,0.0000026710654,2.389644e-7,0.010579645,0.4590194],"study_design_scores_gemma":[0.045651294,0.06740443,0.75769943,0.0004178521,0.00020204003,0.00004098138,0.000028886132,0.000034049972,0.00002103425,0.00022757311,0.1280887,0.00018376076],"about_ca_topic_score_codex":0.00013135347,"about_ca_topic_score_gemma":0.00015564742,"teacher_disagreement_score":0.45883563,"about_ca_system_score_codex":0.00019168285,"about_ca_system_score_gemma":0.001571316,"threshold_uncertainty_score":0.9989701},"labels":[],"label_agreement":null},{"id":"W3090982321","doi":"10.1016/j.clon.2020.09.005","title":"Impact of Concomitant Medications on Biochemical Outcome in Localised Prostate Cancer Treated with Radiotherapy and Androgen Deprivation Therapy","year":2020,"lang":"en","type":"article","venue":"Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; University of Ottawa; Ottawa Hospital","funders":"AstraZeneca","keywords":"Medicine; Concomitant; Prostate cancer; Hazard ratio; Androgen deprivation therapy; Radiation therapy; Internal medicine; Confidence interval; Proportional hazards model; Oncology; Urology; Odds ratio; Cancer; Surgery","score_opus":0.12478286035883128,"score_gpt":0.4866028681537337,"score_spread":0.3618200077949024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090982321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842595,0.0015516585,0.000014531873,0.013171058,0.000017764663,0.0008167389,0.000025975289,0.000019294566,0.00012346481],"genre_scores_gemma":[0.9917454,0.0065178154,0.00017935435,0.0012983923,0.00008256946,0.000084111285,0.000046520378,0.00001584708,0.000029958126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998726,0.00013757143,0.0005225915,0.00028707916,0.0001446356,0.00018208667],"domain_scores_gemma":[0.99889576,0.00046537092,0.00014620012,0.00013844663,0.00009112166,0.00026309837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025026908,0.000121619705,0.00061912986,0.000062310995,0.000018016322,0.0000033237966,0.000059590402,0.00017728559,0.00009673013],"category_scores_gemma":[0.00015010199,0.00006842921,0.0000833946,0.0002686163,0.00043355025,0.000024690915,0.000013020754,0.00028527653,0.000001839306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013108043,0.0006741039,0.95271116,0.00001855418,0.00034288134,0.000055104807,0.0002724531,0.0000073121946,0.0040812665,0.000012014082,0.0003164158,0.028400715],"study_design_scores_gemma":[0.026011845,0.015762886,0.95386183,0.000057792084,0.00005716952,0.0000071755803,0.000038350343,0.0007041485,0.0025168434,0.000017226343,0.0008753113,0.00008943788],"about_ca_topic_score_codex":0.00013453397,"about_ca_topic_score_gemma":0.000012724735,"teacher_disagreement_score":0.028311279,"about_ca_system_score_codex":0.00025068424,"about_ca_system_score_gemma":0.0006346748,"threshold_uncertainty_score":0.27904624},"labels":[],"label_agreement":null},{"id":"W3091625344","doi":"10.7554/elife.54542.sa2","title":"Author response: Regulation of stem/progenitor cell maintenance by BMP5 in prostate homeostasis and cancer initiation","year":2020,"lang":"en","type":"peer-review","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Progenitor cell; Stem cell; Biology; Cell biology; Progenitor; Cancer stem cell; Adult stem cell; Cellular differentiation; Immunology; Genetics","score_opus":0.059470317982500215,"score_gpt":0.3711642429586265,"score_spread":0.31169392497612625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091625344","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031619933,0.5920834,0.000023992061,0.36304456,0.0006221075,0.00706421,0.0040504355,0.00008385185,0.0014074873],"genre_scores_gemma":[0.039208617,0.19547094,0.0003351577,0.0015380429,0.00020261973,0.0010792566,0.0031179183,0.000116644274,0.7589308],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975644,0.0002351893,0.0006561266,0.00055850117,0.00063940824,0.0003464156],"domain_scores_gemma":[0.998573,0.00013970549,0.00034176456,0.00029455047,0.00045727135,0.00019372108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063435046,0.000318492,0.0008844178,0.00023904181,0.000038818696,0.000019197465,0.000095520496,0.00020962534,0.00036439684],"category_scores_gemma":[0.00010930645,0.00023870188,0.0001010232,0.000584803,0.00010748078,0.000095549076,0.00007955793,0.0004118904,0.000011484869],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036355872,0.00011427991,0.001275164,0.014869538,0.00009406059,0.000043997203,0.00027858533,4.4765412e-7,0.0037948184,0.0000033548604,0.93423116,0.041659027],"study_design_scores_gemma":[0.0039201663,0.0007681871,0.0049526626,0.009787332,0.0003631165,0.000010183168,0.0001405794,0.0000843645,0.023418825,0.00002044802,0.956195,0.00033914892],"about_ca_topic_score_codex":0.00035540812,"about_ca_topic_score_gemma":0.00006145564,"teacher_disagreement_score":0.7575233,"about_ca_system_score_codex":0.0004482143,"about_ca_system_score_gemma":0.000955872,"threshold_uncertainty_score":0.97339803},"labels":[],"label_agreement":null},{"id":"W3091778672","doi":"10.7554/elife.60225","title":"RUNX1 marks a luminal castration-resistant lineage established at the onset of prostate development","year":2020,"lang":"en","type":"article","venue":"eLife","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Cancer Research UK","keywords":"Prostate; Biology; Lineage (genetic); RUNX1; Embryonic stem cell; Population; Transcription factor; Cancer research; Cell biology; Gene; Genetics; Medicine","score_opus":0.03539157641540182,"score_gpt":0.30150078311347583,"score_spread":0.26610920669807403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091778672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886061,0.0008273145,0.000010514913,0.007989068,0.00005561046,0.00066769123,0.000049825638,0.000025780771,0.0017680718],"genre_scores_gemma":[0.99187726,0.0001237683,0.0005999734,0.0007141772,0.00013064599,0.00006855809,0.00020016807,0.000016211756,0.0062692156],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987725,0.00003921737,0.00027477933,0.00019542674,0.00049098436,0.00022709827],"domain_scores_gemma":[0.99936914,0.00005746739,0.00007257954,0.00017384392,0.0001491028,0.00017787905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021907792,0.00011367286,0.00019075476,0.000032687232,0.000121363344,0.000020342533,0.00008513332,0.00003778986,0.00033510663],"category_scores_gemma":[0.000111776106,0.00006688079,0.000051625,0.00020642029,0.000112742215,0.000043533695,0.00007985235,0.00014578304,0.00006061246],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03174532,0.0013541606,0.29663566,0.0024763227,0.0015808154,0.0030983465,0.048152115,0.00006287525,0.22174682,0.00011957236,0.36801973,0.025008278],"study_design_scores_gemma":[0.00566999,0.0011310304,0.2030397,0.0002275383,0.0001321966,0.000059622373,0.0016730605,0.00026393213,0.5822938,0.0000031228637,0.2052514,0.00025456768],"about_ca_topic_score_codex":0.000037063455,"about_ca_topic_score_gemma":0.000069338486,"teacher_disagreement_score":0.36054704,"about_ca_system_score_codex":0.000109655375,"about_ca_system_score_gemma":0.00060357194,"threshold_uncertainty_score":0.36691827},"labels":[],"label_agreement":null},{"id":"W3092140209","doi":"10.1016/j.ccell.2020.09.009","title":"Dual Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancer: Just a Gambit or Real CheckMate?","year":2020,"lang":"en","type":"letter","venue":"Cancer Cell","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Pfizer Canada; AstraZeneca Canada","keywords":"Gambit; Blockade; Prostate cancer; Medicine; Cancer research; Dual (grammatical number); Oncology; Cancer; Internal medicine; Computer science; Receptor","score_opus":0.0787338536318727,"score_gpt":0.35476039912195234,"score_spread":0.27602654549007966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092140209","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.053984225,0.026055539,0.0000019846593,0.90083253,0.0012803733,0.0060984343,0.003391514,0.00027883425,0.008076565],"genre_scores_gemma":[0.06740289,0.17390224,0.001094016,0.38420114,0.017356694,0.014501503,0.008621908,0.0012754474,0.33164415],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952604,0.00015596075,0.0009824876,0.0012366305,0.0010766798,0.0012878266],"domain_scores_gemma":[0.9982475,0.00010456515,0.000393486,0.0006054368,0.00025639194,0.00039259778],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017902727,0.00082990935,0.0014096687,0.00025059452,0.0001338505,0.00012051466,0.00027030386,0.000438354,0.0031224464],"category_scores_gemma":[0.000031081458,0.0006174171,0.0002926398,0.0006978616,0.00025113634,0.00015517871,0.00012586205,0.0023216913,0.00010635455],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052815,0.00030861227,0.0009515222,0.010191987,0.0007810216,0.035855137,0.0037348578,0.000038137077,0.028147966,0.0000016765839,0.9126649,0.002042688],"study_design_scores_gemma":[0.015562892,0.0017101743,0.0012919408,0.0029046715,0.0019305384,0.00011570671,0.0013138471,0.00031996914,0.061499603,0.00004636068,0.9117595,0.0015448222],"about_ca_topic_score_codex":0.015097123,"about_ca_topic_score_gemma":0.005894298,"teacher_disagreement_score":0.51663136,"about_ca_system_score_codex":0.0027298424,"about_ca_system_score_gemma":0.005190712,"threshold_uncertainty_score":0.99998},"labels":[],"label_agreement":null},{"id":"W3092635944","doi":"10.1158/1078-0432.ccr-20-2925","title":"Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"National Cancer Institute; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Prostate cancer; Proinflammatory cytokine; Transcriptome; Immune system; Prostate; Cancer; Cancer research; Tumor microenvironment; Medicine; Biology; Immunology; Inflammation; Gene; Internal medicine; Gene expression; Genetics","score_opus":0.34410766421591554,"score_gpt":0.5275851019976024,"score_spread":0.1834774377816869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092635944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9576682,0.0038222137,0.0000049397577,0.026558146,0.000057071175,0.0028125197,0.00019516892,0.00007054259,0.008811231],"genre_scores_gemma":[0.9874835,0.007927956,0.00020054633,0.00060489087,0.0005184047,0.0016793717,0.000056043635,0.000057129644,0.0014721296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948052,0.0009147596,0.00090198946,0.0010454057,0.0010905598,0.0012420805],"domain_scores_gemma":[0.9966659,0.0010483066,0.00022608139,0.00047829727,0.00066144223,0.0009199758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001817057,0.00031584932,0.001376283,0.00019231651,0.00021603328,0.00007088792,0.0004531242,0.00012735989,0.000417542],"category_scores_gemma":[0.00042043126,0.00020921585,0.00016199576,0.002036426,0.0022210693,0.00010491997,0.0003550986,0.0020838205,0.00009103243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05003782,0.0012480624,0.8740198,0.00042955295,0.00063268305,0.0012189469,0.009527575,0.00009284055,0.007984705,0.000060122617,0.012338579,0.042409305],"study_design_scores_gemma":[0.014436746,0.014002126,0.9213706,0.0006006746,0.00012818452,0.000008875096,0.00969919,0.0014389255,0.0042169075,0.0002562787,0.03320258,0.0006388889],"about_ca_topic_score_codex":0.003211262,"about_ca_topic_score_gemma":0.0011626199,"teacher_disagreement_score":0.047350816,"about_ca_system_score_codex":0.0013665498,"about_ca_system_score_gemma":0.0030583136,"threshold_uncertainty_score":0.9053279},"labels":[],"label_agreement":null},{"id":"W3093001752","doi":"10.48083/tabr2149","title":"The Clinical Applications of Tissue Biomarkers in Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Société Internationale d’Urologie Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Prostatectomy; Medicine; Disease; Cancer; Prostate; Prostate-specific antigen; Stage (stratigraphy); Oncology; Bioinformatics; Pathology; Internal medicine; Biology","score_opus":0.10750417441802887,"score_gpt":0.4713960323661637,"score_spread":0.36389185794813483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093001752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74753714,0.0143686365,0.0005001788,0.22714347,0.0007146448,0.0016613629,0.00008363769,0.00004448563,0.007946441],"genre_scores_gemma":[0.983535,0.013252276,0.00026074552,0.0009719842,0.00047899943,0.00013843375,0.00001727644,0.000009860982,0.0013354557],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99873567,0.00009403246,0.00048783605,0.00014986304,0.00034077725,0.00019183353],"domain_scores_gemma":[0.9989338,0.00035865974,0.00020765216,0.00009612118,0.0002726288,0.0001311403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000570033,0.000080251106,0.0001889735,0.000059751488,0.00009659203,0.0000260248,0.0002246928,0.00005516635,0.00021533156],"category_scores_gemma":[0.00032034583,0.00004896381,0.00011853609,0.00020105981,0.00023814283,0.000060189795,0.000065584085,0.0004798166,0.000010634058],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019535816,0.00024542163,0.70467323,0.000040841755,0.0008111663,0.00009525895,0.00046574927,0.00003855712,0.0012634071,0.00024893536,0.012711834,0.27745205],"study_design_scores_gemma":[0.011830722,0.0017885335,0.44517136,0.00012477316,0.00016998847,0.00014045282,0.002367256,0.0012116906,0.0049054096,0.004638199,0.52740484,0.00024675496],"about_ca_topic_score_codex":0.000020457695,"about_ca_topic_score_gemma":0.000015735124,"teacher_disagreement_score":0.514693,"about_ca_system_score_codex":0.000120688775,"about_ca_system_score_gemma":0.00044632776,"threshold_uncertainty_score":0.23577295},"labels":[],"label_agreement":null},{"id":"W3093377386","doi":"10.48083/kdck6642","title":"The Clinical Applications of Serum and Urinary Biomarkers in Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Société Internationale d’Urologie Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Intensive care medicine; Management of prostate cancer; Disease; Prostate-specific antigen; Risk stratification; Cancer; Oncology; Internal medicine","score_opus":0.0962461047147377,"score_gpt":0.446562056174897,"score_spread":0.3503159514601593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093377386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89745325,0.009166731,0.000044243436,0.09103411,0.00017157533,0.00051098946,0.000046537698,0.00001378247,0.001558794],"genre_scores_gemma":[0.97696894,0.02127508,0.00013608967,0.0007149679,0.00024254696,0.00006926854,0.000006161398,0.0000067017954,0.00058022334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990037,0.000080233,0.00037335992,0.00014034515,0.00024220806,0.00016012508],"domain_scores_gemma":[0.99917287,0.00030669023,0.00015544187,0.00007190091,0.00017185227,0.00012125304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048482834,0.00007182552,0.00016051541,0.00005224094,0.00009741041,0.000023123997,0.0001375438,0.000046875564,0.000100249345],"category_scores_gemma":[0.00018460843,0.00004408501,0.00008690225,0.00013386442,0.00025948332,0.0000612582,0.000082767016,0.0004113039,0.0000024512115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009819862,0.00012775787,0.88241374,0.000028126875,0.00038227838,0.000061789935,0.00024289114,0.000006609737,0.00013898205,0.00011667718,0.0017878198,0.11371132],"study_design_scores_gemma":[0.004714361,0.0009123569,0.9489354,0.000054704557,0.000060828217,0.00013551753,0.0011800735,0.0006937668,0.00026819875,0.002013689,0.04094555,0.0000855411],"about_ca_topic_score_codex":0.000008679788,"about_ca_topic_score_gemma":0.0000062398453,"teacher_disagreement_score":0.11362577,"about_ca_system_score_codex":0.00007314121,"about_ca_system_score_gemma":0.00029508382,"threshold_uncertainty_score":0.17977345},"labels":[],"label_agreement":null},{"id":"W3093603721","doi":"10.1016/j.ijrobp.2020.07.416","title":"Outcomes Comparison Using PSA Cut-Off Values Of 0.1 Or 0.2 Ng/Ml At 6 Months In Localized High-Risk Prostate Cancer Treated With Androgen Deprivation Therapy And Radiotherapy: Prospective Data From A Phase III Trial","year":2020,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Jewish General Hospital; Centre de Santé et de Services Sociaux de Chicoutimi; McGill University; Centre Hospitalier de l’Université de Montréal; Université Laval; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Hazard ratio; Urology; Radiation therapy; Proportional hazards model; Internal medicine; Prospective cohort study; Randomized controlled trial; Oncology; Cancer; Confidence interval","score_opus":0.08290902110110325,"score_gpt":0.4194808505653395,"score_spread":0.33657182946423625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093603721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99109167,0.00338262,0.0015932694,0.0018753129,0.00023367391,0.0011621498,0.0006370092,0.000018052357,0.00000626219],"genre_scores_gemma":[0.98663026,0.009714642,0.0022198628,0.00023327845,0.0006119518,0.000031674495,0.0005127535,0.000029081757,0.000016479824],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99806064,0.0002833659,0.0007989217,0.00034239097,0.0003324492,0.00018222042],"domain_scores_gemma":[0.9976422,0.00040089717,0.0012300058,0.00016529953,0.00044021217,0.00012137505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032351312,0.0002156266,0.00086330407,0.00013846681,0.00006326374,0.000021940217,0.00025006637,0.00014276247,0.00007005517],"category_scores_gemma":[0.00016977849,0.0001376604,0.00007542933,0.00023884053,0.00023547561,0.00029987618,0.000066670305,0.0003169427,6.2993655e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1740413,0.00081802136,0.74790126,0.0000062619106,0.001988387,0.000041791347,0.0018706571,0.0005325772,0.0037794367,0.000020092226,0.00010234181,0.06889789],"study_design_scores_gemma":[0.6953517,0.016080434,0.14851464,0.0002278534,0.0007110725,0.000038324433,0.00047176846,0.106912754,0.027668828,0.00085520104,0.0027750141,0.0003924158],"about_ca_topic_score_codex":0.00080289046,"about_ca_topic_score_gemma":0.00011771939,"teacher_disagreement_score":0.59938663,"about_ca_system_score_codex":0.000841323,"about_ca_system_score_gemma":0.0007274488,"threshold_uncertainty_score":0.5613628},"labels":[],"label_agreement":null},{"id":"W3093612331","doi":"10.1016/j.chembiol.2020.10.001","title":"Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors","year":2020,"lang":"en","type":"article","venue":"Cell chemical biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Congressionally Directed Medical Research Programs; National Cancer Institute; National Institutes of Health; Ludwig Center at Harvard; Deutsche Forschungsgemeinschaft; Novartis Pharma; Deutschen Konsortium für Translationale Krebsforschung; Ono Pharma Foundation; Canada Foundation for Innovation; Ontario Ministry of Economic Development and Innovation; Eshelman Institute for Innovation, University of North Carolina at Chapel Hill; Broad Institute; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Shenzhen Gas Corporation; Wellcome Trust; U.S. Department of Defense; Genome Canada; Merck KGaA; Meso Scale Diagnostics; Cancer Prevention and Research Institute of Texas; Takeda Pharmaceuticals U.S.A.; Pfizer; Alexander and Margaret Stewart Trust; Boehringer Ingelheim; Janssen Pharmaceuticals; Prostate Cancer Foundation; National Science Foundation","keywords":"Androgen receptor; Prostate cancer; Cancer research; Transcription (linguistics); Transcription factor; In vivo; Androgen; Biology; Chemistry; Cancer; Endocrinology; Gene; Hormone; Biochemistry; Genetics","score_opus":0.022302505012197386,"score_gpt":0.28292297716042664,"score_spread":0.26062047214822925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093612331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954617,0.0008402107,0.000015630369,0.0023245665,0.00002571637,0.0005061362,0.000021330581,0.000039680952,0.0007650088],"genre_scores_gemma":[0.9985502,0.00024378322,0.00043220713,0.00025837388,0.00014364929,0.00010608041,0.00016637417,0.000017314545,0.000082054474],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99909484,0.00003395995,0.0001547805,0.0003398581,0.00007935831,0.00029721085],"domain_scores_gemma":[0.99966943,0.000020993446,0.000035983456,0.00006240684,0.000060454135,0.00015072494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000035551653,0.00012687128,0.00024284612,0.000039169467,0.000023337168,0.000004519779,0.00004643005,0.00010692534,0.0000717608],"category_scores_gemma":[0.000014549824,0.000087746244,0.000037985203,0.00028509373,0.000116251234,0.000033211323,0.000019523915,0.00028718778,0.000009694773],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012318275,0.00006196772,0.1199372,0.0000780063,0.000031625103,0.000015033073,0.0011598316,0.000019719091,0.8750868,0.000003257927,0.00018348746,0.0021912595],"study_design_scores_gemma":[0.003224203,0.0006173696,0.00047756167,0.000054327666,0.000023684652,0.0000031909374,0.00013562196,0.00059467263,0.9937994,0.000021893673,0.0009309849,0.00011709734],"about_ca_topic_score_codex":0.00007115639,"about_ca_topic_score_gemma":0.000006482797,"teacher_disagreement_score":0.11945964,"about_ca_system_score_codex":0.00016536396,"about_ca_system_score_gemma":0.00011405625,"threshold_uncertainty_score":0.3578188},"labels":[],"label_agreement":null},{"id":"W3093675505","doi":"10.1016/j.ijrobp.2020.07.2104","title":"Interim Analysis of a Phase II Multi-institution Randomized Placebo-controlled Trial the PREMIUM trial (PREvention of Metabolic Syndrome and Increased weight Using Metformin concurrent to ADT and EBRT for locally advanced adenocarcinoma of the prostate)","year":2020,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; University of Manitoba; BC Cancer Agency; CancerCare Manitoba","funders":"","keywords":"Medicine; Metformin; Waist; Metabolic syndrome; Placebo; Androgen deprivation therapy; Interim analysis; Internal medicine; Prostate cancer; Lipid profile; Weight loss; Randomized controlled trial; Urology; Endocrinology; Insulin; Body mass index; Cholesterol; Obesity; Cancer","score_opus":0.042412355931715794,"score_gpt":0.39107625007742597,"score_spread":0.3486638941457102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093675505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96855026,0.0020517886,0.022919066,0.0009718964,0.000597263,0.0047877408,0.00011252152,0.0000038755074,0.000005563554],"genre_scores_gemma":[0.9977047,0.00050922774,0.0012393327,0.000080039725,0.0002486634,0.00015018249,0.00004943188,0.000008800916,0.000009664517],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976331,0.00061513484,0.001168825,0.00017821493,0.0002780319,0.00012666604],"domain_scores_gemma":[0.9964771,0.00083128724,0.0017135427,0.00009610305,0.000784889,0.00009704109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015291552,0.00015351298,0.0013953096,0.00022850474,0.00006817866,0.000008536889,0.00018508903,0.00009994297,0.0000100558145],"category_scores_gemma":[0.0014762549,0.00008583746,0.0005478346,0.00030995905,0.00035629526,0.0001415295,0.00007887891,0.0001811845,8.232703e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9521199,0.0009115729,0.0020463825,0.000030454066,0.0060132192,0.0000027107474,0.0010747511,0.00034760693,0.014085819,0.0009853888,0.0000064033,0.022375828],"study_design_scores_gemma":[0.9405802,0.0072889742,0.000902521,0.000093193856,0.0042847157,0.000019276411,0.00010775529,0.035719637,0.010614917,0.00019540134,0.00012431435,0.000069084614],"about_ca_topic_score_codex":0.000022788588,"about_ca_topic_score_gemma":0.0000048448564,"teacher_disagreement_score":0.03537203,"about_ca_system_score_codex":0.00014860021,"about_ca_system_score_gemma":0.00076643686,"threshold_uncertainty_score":0.350035},"labels":[],"label_agreement":null},{"id":"W3093951006","doi":"10.1016/j.eururo.2020.09.048","title":"Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Cabazitaxel; Medicine; Vial; Prostate cancer; Docetaxel; Drug; Oncology; Chemotherapy; Internal medicine; Urology; Androgen deprivation therapy; Surgery; Cancer; Pharmacology","score_opus":0.059502030270270755,"score_gpt":0.31639045980587904,"score_spread":0.2568884295356083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093951006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95233756,0.0018655825,0.000060594677,0.04075007,0.000051535662,0.0015981698,0.00015800967,0.000034480345,0.0031439746],"genre_scores_gemma":[0.9963269,0.00025157677,0.00017317095,0.0016733706,0.00007378314,0.000059514474,0.000025104673,0.000035614634,0.0013809286],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99846834,0.00043633918,0.00030105657,0.00031378688,0.00019375776,0.00028671222],"domain_scores_gemma":[0.99915516,0.00024024211,0.000093174574,0.00018922899,0.000089225556,0.00023298684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035851746,0.00015799371,0.0003634274,0.00006454475,0.000088726156,0.000021210848,0.000105982814,0.000013476465,0.00008797951],"category_scores_gemma":[0.00015044134,0.000094187555,0.00005741194,0.00020925996,0.00031117574,0.00003788934,0.00007767349,0.00016866998,0.000030860254],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062165875,0.00053642975,0.020064445,0.001472771,0.0014220455,0.004649926,0.13899346,0.0009489548,0.7175909,0.0013526694,0.020408286,0.030394232],"study_design_scores_gemma":[0.23899044,0.024687963,0.24845767,0.00074669335,0.008228853,0.00049038365,0.039746676,0.00795681,0.21998335,0.00030585125,0.2073519,0.0030534088],"about_ca_topic_score_codex":0.0001548956,"about_ca_topic_score_gemma":0.00007924047,"teacher_disagreement_score":0.49760756,"about_ca_system_score_codex":0.000027105256,"about_ca_system_score_gemma":0.00012386969,"threshold_uncertainty_score":0.38408569},"labels":[],"label_agreement":null},{"id":"W3094019177","doi":"10.1101/2020.10.23.350793","title":"Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"European Commission; Lucas Foundation; National Cancer Institute; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"FOXA1; Epigenomics; Biology; Prostate cancer; Chromatin; Cancer research; Transcription factor; Histone; Chromatin immunoprecipitation; Androgen receptor; Reprogramming; Epigenetics; Enhancer; Cell biology; Cancer; Genetics; Cell; Gene; DNA methylation; Gene expression","score_opus":0.0335174096520456,"score_gpt":0.2933309260178676,"score_spread":0.259813516365822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094019177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853878,0.005574483,0.0000071405975,0.0048633288,0.00076937437,0.002913,0.00033441326,0.00013934835,0.000011136976],"genre_scores_gemma":[0.9923881,0.0054596877,0.00040791222,0.00012023702,0.0002686834,0.0011549584,0.0000012202466,0.00012602657,0.00007313982],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99677926,0.00017530826,0.0006954478,0.0010728224,0.00057060935,0.00070654956],"domain_scores_gemma":[0.99755937,0.00004436354,0.00039576332,0.001380801,0.0002984491,0.00032125134],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020906559,0.0005544687,0.0009003899,0.00022731673,0.00008962318,0.00005073384,0.00038024684,0.00014127076,0.00006390699],"category_scores_gemma":[0.00017722054,0.0003931594,0.00034130595,0.00092294224,0.00019958256,0.00006006146,0.0005413893,0.00076831627,0.000009183827],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011277186,0.00087003683,0.47081864,0.001913175,0.00074252195,0.0010882245,0.0000809791,0.00007039651,0.5228735,0.000057669906,0.00020908222,0.00014801696],"study_design_scores_gemma":[0.0039758044,0.0005007091,0.4675958,0.001324863,0.00043722067,1.1334542e-7,0.000014796918,0.0002642965,0.51796854,0.000002495796,0.007464538,0.0004508604],"about_ca_topic_score_codex":0.0007877079,"about_ca_topic_score_gemma":0.000030193276,"teacher_disagreement_score":0.0072554555,"about_ca_system_score_codex":0.0009005389,"about_ca_system_score_gemma":0.0015363396,"threshold_uncertainty_score":0.999852},"labels":[],"label_agreement":null},{"id":"W3095019291","doi":"10.5489/cuaj.6834","title":"Current attitudes of Canadian urologists towards surgical castration in the treatment of prostate cancer","year":2020,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Prostate cancer; Castration; Medicine; Gynecology; General surgery; Cancer; Oncology; Urology; Medical physics; Internal medicine; Hormone","score_opus":0.06527797528662528,"score_gpt":0.3377641105575058,"score_spread":0.27248613527088056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095019291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.921283,0.0036255072,4.9368333e-7,0.07379655,0.00009836593,0.00040843704,0.00014591815,0.0000037479424,0.00063794584],"genre_scores_gemma":[0.9916276,0.0075247353,0.000015374746,0.0005025425,0.00021998322,0.000023804905,0.000038236467,0.0000054223447,0.00004232489],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851656,0.00019469515,0.00035494237,0.00014718836,0.00037480224,0.00041179458],"domain_scores_gemma":[0.9988172,0.00007412144,0.0001726696,0.00006888284,0.00024116208,0.0006259317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035834278,0.00011446148,0.00029949954,0.0002891756,0.00008181859,0.000024761783,0.000105327745,0.00012021876,0.00022828697],"category_scores_gemma":[0.00013093207,0.00006692276,0.000119561395,0.00057412987,0.00006489351,0.000047333262,0.0000036637612,0.00030776995,0.0000048111165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019626008,0.00015332336,0.98052394,0.000013924989,0.00007787419,0.00027522157,0.0013633447,0.00008268192,0.000030541007,0.00006205377,0.0009981691,0.016222661],"study_design_scores_gemma":[0.0018813029,0.0016246648,0.90994686,0.000015514035,0.00005443295,0.000036318892,0.00009658005,0.00008574108,0.00011317567,0.000032028944,0.086053155,0.00006022218],"about_ca_topic_score_codex":0.15031713,"about_ca_topic_score_gemma":0.21264064,"teacher_disagreement_score":0.085054986,"about_ca_system_score_codex":0.0013281408,"about_ca_system_score_gemma":0.0025342493,"threshold_uncertainty_score":0.85534096},"labels":[],"label_agreement":null},{"id":"W3096058325","doi":"10.1186/s40644-020-00350-x","title":"Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels","year":2020,"lang":"en","type":"article","venue":"Cancer Imaging","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Ministero della Salute; Università degli Studi di Milano","keywords":"Medicine; Magnetic resonance imaging; Prostate cancer; Radiology; Pelvis; Metastasis; Cohen's kappa; Prostate; Kappa; Lumbosacral joint; Cancer; Nuclear medicine; Surgery; Internal medicine","score_opus":0.14738098726325058,"score_gpt":0.3857691736271766,"score_spread":0.23838818636392603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096058325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79735273,0.14925222,0.0040311636,0.042916354,0.00028354753,0.004742684,0.0010783268,0.00017692412,0.00016604114],"genre_scores_gemma":[0.9962725,0.00051028456,0.0010686859,0.00050428143,0.00035543588,0.0007713512,0.00012710101,0.00008230295,0.00030805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955484,0.00009857545,0.0018582488,0.0011316843,0.0006259285,0.0007371228],"domain_scores_gemma":[0.9958039,0.000121036115,0.0024556192,0.0009583702,0.00036762285,0.00029347272],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011189783,0.00042112914,0.0009844474,0.00009911921,0.0002851349,0.00012954806,0.00037863487,0.00003331206,0.000029077977],"category_scores_gemma":[0.00037969765,0.00025887045,0.00012355152,0.00035188114,0.00033990864,0.00036814797,0.00046665748,0.00033041753,6.311247e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006725547,0.000035331257,0.66006684,0.0023416467,0.00033986045,0.00025646712,0.0047704573,0.000011923372,0.022776332,0.000005052784,0.0021656847,0.30655786],"study_design_scores_gemma":[0.024197858,0.0016007766,0.56367904,0.025283013,0.0063157086,0.00037583313,0.055920128,0.044105094,0.23345478,0.00003172539,0.04273238,0.0023036993],"about_ca_topic_score_codex":0.0009103337,"about_ca_topic_score_gemma":0.000058752717,"teacher_disagreement_score":0.30425417,"about_ca_system_score_codex":0.00045550155,"about_ca_system_score_gemma":0.00038529906,"threshold_uncertainty_score":0.99998635},"labels":[],"label_agreement":null},{"id":"W3096464204","doi":"10.3389/fcell.2020.571677","title":"Epidermal Growth Factor Is Essential for the Maintenance of Novel Prostate Epithelial Cells Isolated From Patient-Derived Organoids","year":2020,"lang":"en","type":"article","venue":"Frontiers in Cell and Developmental Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Medicine, American University of Beirut; York University; New York University Abu Dhabi; American University of Beirut","keywords":"Organoid; Biology; Prostate cancer; Epidermal growth factor; Cancer research; Transcriptome; Cell culture; Prostate; Cell growth; Cell biology; Computational biology; Cancer; Gene expression; Gene; Genetics","score_opus":0.015852528752251092,"score_gpt":0.24259794475411672,"score_spread":0.22674541600186562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096464204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98382217,0.0011452747,0.010358463,0.0021044838,0.00045848548,0.0010238655,0.0009969276,0.000015268586,0.000075077376],"genre_scores_gemma":[0.98479205,0.0010805938,0.012770702,0.000913815,0.000053873726,0.000049914932,0.0001933476,0.000017556604,0.00012812851],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99890506,0.000027092026,0.00031406738,0.00033974432,0.00008630863,0.0003277166],"domain_scores_gemma":[0.9995648,0.00009291504,0.00008982444,0.00006801831,0.00007210867,0.000112285925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000046761532,0.0001712831,0.00035374772,0.000053404325,0.00007563693,0.000008349443,0.000098683224,0.00011644655,0.000069987174],"category_scores_gemma":[0.000031795367,0.00010649064,0.00005784319,0.00014225149,0.00026324348,0.000040664276,0.00010093903,0.00014531463,0.0000038919],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003196553,0.00013808551,0.03893402,0.00009944466,0.00016932082,0.000010637497,0.0067207995,4.6372057e-7,0.9389676,0.0000034877737,0.0055633136,0.0061963145],"study_design_scores_gemma":[0.0069226003,0.0006778421,0.0042705513,0.000028240745,0.00003650898,0.0000029628834,0.0021075003,0.00096793147,0.981445,0.000102763435,0.0032729905,0.00016511565],"about_ca_topic_score_codex":0.00010639782,"about_ca_topic_score_gemma":0.0000034300444,"teacher_disagreement_score":0.042477433,"about_ca_system_score_codex":0.000059483886,"about_ca_system_score_gemma":0.00017137174,"threshold_uncertainty_score":0.43425623},"labels":[],"label_agreement":null},{"id":"W3099469760","doi":"10.3389/fonc.2020.587981","title":"Discussion of Treatment Options for Metastatic Hormone Sensitive Prostate Cancer Patients","year":2020,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Prostate cancer; Genitourinary system; Oncology; Prostate; Cancer; Internal medicine; Gynecology","score_opus":0.03746538721116676,"score_gpt":0.3614363235667781,"score_spread":0.3239709363556113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3099469760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9572931,0.0038967729,0.0021983471,0.028714284,0.0006792652,0.0056809415,0.0009017009,0.000038888502,0.00059667724],"genre_scores_gemma":[0.97401345,0.0044256803,0.017815234,0.00037708774,0.000091938615,0.0010071815,0.00044561044,0.000030787898,0.0017930033],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99913996,0.00006646048,0.00023155675,0.00022232134,0.00009989586,0.0002397856],"domain_scores_gemma":[0.99954456,0.000043252527,0.00008406454,0.000077246514,0.00011832137,0.00013257569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006116608,0.00011431559,0.00046964086,0.00010561777,0.000036385543,0.00000239669,0.000034439407,0.000052859035,0.000011422352],"category_scores_gemma":[0.000053843567,0.00006568068,0.00008274736,0.00019179824,0.000111071975,0.0000417694,0.000022048118,0.00007614201,0.0000019418665],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041352917,0.005620725,0.34065452,0.00063469744,0.0022510744,0.00022777804,0.033578083,0.00039723638,0.011741421,0.000120582976,0.09016601,0.47325495],"study_design_scores_gemma":[0.19851834,0.15763167,0.23797402,0.0005887932,0.0033727614,0.000016058199,0.02427423,0.02682845,0.055224847,0.0021836467,0.29218268,0.0012045325],"about_ca_topic_score_codex":0.00006119634,"about_ca_topic_score_gemma":0.000021053169,"teacher_disagreement_score":0.47205043,"about_ca_system_score_codex":0.0009152021,"about_ca_system_score_gemma":0.0004302288,"threshold_uncertainty_score":0.26783803},"labels":[],"label_agreement":null},{"id":"W3101613917","doi":"10.3390/ph13110386","title":"Bioanalytical Assay Development and Validation for the Pharmacokinetic Study of GMC1, a Novel FKBP52 Co-chaperone Inhibitor for Castration Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Pharmaceuticals","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"DOD Prostate Cancer Research Program; Cancer Prevention and Research Institute of Texas; National Institute on Minority Health and Health Disparities; Lizanell and Colbert Coldwell Foundation","keywords":"Chromatography; Pharmacokinetics; Selected reaction monitoring; Chemistry; Bioanalysis; Formic acid; Albendazole; Mass spectrometry; Prostate cancer; Tandem mass spectrometry; Pharmacology; Medicine; Cancer","score_opus":0.2018792346868837,"score_gpt":0.46091861024260145,"score_spread":0.25903937555571777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101613917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96545756,0.0021498688,0.0023599567,0.020592263,0.00009931149,0.009002635,0.00022186087,0.000039044346,0.00007747981],"genre_scores_gemma":[0.9966839,0.00029631675,0.0009192753,0.00036066395,0.00018773264,0.001301297,0.000052040534,0.000024909154,0.00017389837],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859345,0.000041587693,0.0004110421,0.00031604178,0.00035707385,0.00028082708],"domain_scores_gemma":[0.99896675,0.00038705143,0.00008627105,0.00009103385,0.0002461939,0.00022266868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054151413,0.00015820572,0.00028547324,0.00005196285,0.00014800197,0.00003089057,0.000063707346,0.000037223315,0.000043516135],"category_scores_gemma":[0.00014153312,0.00010054973,0.00004918901,0.00016986713,0.000107241736,0.000060257764,0.00003331679,0.00012232871,0.0000016541156],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012322651,0.0013771162,0.0035750328,0.00119104,0.0010772035,0.00000816822,0.0060150474,0.000044359207,0.9329992,0.00009760978,0.0010314238,0.040261164],"study_design_scores_gemma":[0.021667648,0.0016972686,0.0030387526,0.00008743588,0.0012764338,0.0000036523145,0.0015051238,0.014301662,0.9190857,0.000013253286,0.037128672,0.00019443753],"about_ca_topic_score_codex":0.000008795602,"about_ca_topic_score_gemma":0.0000048288057,"teacher_disagreement_score":0.040066727,"about_ca_system_score_codex":0.00008647706,"about_ca_system_score_gemma":0.00023544114,"threshold_uncertainty_score":0.4100299},"labels":[],"label_agreement":null},{"id":"W3101819413","doi":"10.18433/jpps31003","title":"Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Abiraterone; Prostate cancer; Medicine; Oncology; Meta-analysis; Docetaxel; Cancer; Internal medicine; Androgen receptor","score_opus":0.24782864657816275,"score_gpt":0.5323740162969102,"score_spread":0.28454536971874744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101819413","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006144969,0.990211,0.0000037741818,0.00032037817,0.000032850156,0.003105249,0.00017193121,0.0000027635642,0.000007087004],"genre_scores_gemma":[0.07954931,0.92015696,0.00013913703,0.00003562325,0.0000057814373,0.00008723973,0.000007869422,0.000012773894,0.0000053222075],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99524087,0.0010287489,0.0019911563,0.00033825875,0.0011268469,0.000274128],"domain_scores_gemma":[0.99637234,0.001123741,0.0017014801,0.000119724915,0.00037229585,0.0003104267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020649324,0.00038550104,0.008525179,0.0004457227,0.00006289559,0.000031907184,0.0002180639,0.000031029827,0.00006553296],"category_scores_gemma":[0.00017286044,0.00018089889,0.0006820474,0.0015705517,0.00054144894,0.00021608624,0.000067571156,0.00042590444,3.3901975e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002595772,0.00055760413,0.015299844,0.8536133,0.10945186,0.00006167719,0.0001794792,0.000013965893,0.000017885253,0.000007712005,0.000002472797,0.018198404],"study_design_scores_gemma":[0.0074233483,0.0015235749,0.0014687494,0.03436555,0.9531487,0.000014113941,0.000062315514,0.0000717261,0.00014688067,0.0000018943911,0.0015455465,0.00022759082],"about_ca_topic_score_codex":0.00004959792,"about_ca_topic_score_gemma":0.000012921658,"teacher_disagreement_score":0.84369683,"about_ca_system_score_codex":0.00017635516,"about_ca_system_score_gemma":0.0006757564,"threshold_uncertainty_score":0.73768425},"labels":[],"label_agreement":null},{"id":"W3103659780","doi":"10.5489/cuaj.6817","title":"Diagnostic performance of 18F-DCFPyL positron emission tomography/computed tomography for biochemically recurrent prostate cancer and change-of-management analysis","year":2020,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Prostate cancer; Medicine; Positron emission tomography; Interquartile range; Lymph node; Radiology; PET-CT; Nuclear medicine; Androgen deprivation therapy; Prostate; Biochemical recurrence; Glutamate carboxypeptidase II; Prostate-specific antigen; Cancer; Pathology; Prostatectomy; Internal medicine","score_opus":0.018380003176463464,"score_gpt":0.26664084401743626,"score_spread":0.2482608408409728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103659780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98108023,0.004373379,0.00003137298,0.013567406,0.000071414805,0.0006696935,0.00015559961,0.000010671413,0.000040254057],"genre_scores_gemma":[0.9956408,0.0031047056,0.00034943142,0.00054908585,0.0001418486,0.000070252056,0.00010477305,0.000007981715,0.00003112415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872845,0.000047629506,0.0003444912,0.00021522742,0.00031083624,0.0003533615],"domain_scores_gemma":[0.9985143,0.00014177662,0.00028116067,0.00006642821,0.00036447213,0.0006318521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026951468,0.00012861389,0.0003737511,0.0004013499,0.000115436706,0.000021744365,0.00008864828,0.00009043878,0.000038364244],"category_scores_gemma":[0.00014868319,0.000096227195,0.00022305569,0.0009643612,0.000052334508,0.000058689544,0.000023396778,0.00021735848,2.9400505e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051871187,0.00007628541,0.98136616,0.0001795141,0.00122843,0.00001457537,0.0003796073,0.000026908538,0.0005042299,0.000007691356,0.0011021396,0.014595738],"study_design_scores_gemma":[0.0019997025,0.0017554994,0.98838663,0.00013404178,0.0012363542,0.0000038405437,0.00005842321,0.0025306118,0.0015353678,0.000040024563,0.0021897792,0.00012971286],"about_ca_topic_score_codex":0.00021845475,"about_ca_topic_score_gemma":0.000043836888,"teacher_disagreement_score":0.01456059,"about_ca_system_score_codex":0.00021004636,"about_ca_system_score_gemma":0.00013096748,"threshold_uncertainty_score":0.3924031},"labels":[],"label_agreement":null},{"id":"W3105765590","doi":"10.1002/ijc.33397","title":"Risk of cardiovascular disease following gonadotropin‐releasing hormone agonists vs antagonists in prostate cancer: Real‐world evidence from five databases","year":2020,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast; Ferring; NHS Health Scotland","keywords":"Prostate cancer; Medicine; Gonadotropin-releasing hormone; Disease; Hormone; Hormone antagonist; Internal medicine; Prostate; Database; Cancer; Endocrinology; Oncology; Luteinizing hormone; Endocrine system; Computer science","score_opus":0.04256306499133321,"score_gpt":0.3682275945832836,"score_spread":0.32566452959195036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3105765590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86534053,0.12657988,0.00010908068,0.006417426,0.0005430667,0.00027416472,0.0006996265,0.000009401594,0.000026788883],"genre_scores_gemma":[0.8225486,0.17601088,0.00038550387,0.00016569473,0.0007247224,0.000024683137,0.000042259326,0.000022710834,0.0000749549],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973317,0.00011616242,0.00062869303,0.00029332328,0.0013906778,0.00023944557],"domain_scores_gemma":[0.9982955,0.0001669958,0.00043040616,0.00019616052,0.00058715756,0.0003238063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020517329,0.00018413104,0.0005788501,0.00022883777,0.000044353103,0.00004144155,0.000303565,0.000024348248,0.0000826846],"category_scores_gemma":[0.000326442,0.00014708051,0.00048605673,0.00029783262,0.000096955366,0.00043524374,0.00010343365,0.0003865679,0.0000025105503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01798691,0.00018378621,0.9161139,0.00013356053,0.008762412,0.005009296,0.0014249135,0.007445352,0.008741891,0.000010156154,0.0011696211,0.03301817],"study_design_scores_gemma":[0.008845062,0.00034020413,0.95973665,0.0053686947,0.0019358541,0.000013318016,0.00017297096,0.0018568443,0.010068781,0.00008405336,0.011313421,0.0002641237],"about_ca_topic_score_codex":0.022321237,"about_ca_topic_score_gemma":0.0004262814,"teacher_disagreement_score":0.04943099,"about_ca_system_score_codex":0.00076388416,"about_ca_system_score_gemma":0.0012987077,"threshold_uncertainty_score":0.9841892},"labels":[],"label_agreement":null},{"id":"W3106786206","doi":"10.3390/ijms21239054","title":"Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Prostate cancer; Meta-analysis; Asymptomatic; Enzalutamide; Internal medicine; Adverse effect; Systematic review; Lymph node; Oncology; Cancer; MEDLINE","score_opus":0.09928725423452187,"score_gpt":0.42021252076473264,"score_spread":0.3209252665302108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106786206","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000050579045,0.99526566,0.00023565668,0.0014301534,0.000042959615,0.0027662478,0.00019496036,0.0000036902316,0.000010075888],"genre_scores_gemma":[0.000347473,0.9956749,0.0032463488,0.00026830685,0.000022225926,0.0003257383,0.00004165037,0.000017865665,0.00005546306],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99719113,0.00017815578,0.00093865104,0.0003067958,0.001211673,0.00017358009],"domain_scores_gemma":[0.9971791,0.00017551647,0.001330416,0.000119889286,0.0010368279,0.00015826887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007329765,0.00028986266,0.0034976283,0.00044612947,0.00007674423,0.00017569162,0.0003780676,0.000032339347,0.00002785517],"category_scores_gemma":[0.00012854191,0.000135194,0.0012300829,0.00063829724,0.00015545882,0.00015869582,0.000029223838,0.00016246716,4.6339252e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039395536,0.0002814252,0.000016478178,0.31848025,0.66462,0.00064010074,0.00035117622,0.000056681325,0.000008541445,0.000063995416,0.00006382323,0.0150235575],"study_design_scores_gemma":[0.001806741,0.00177575,0.0000033285678,0.041109174,0.94696134,0.00019851868,0.00005333802,0.000029294813,0.000022086906,0.000024979792,0.0077526816,0.00026275817],"about_ca_topic_score_codex":0.000009047856,"about_ca_topic_score_gemma":0.0000029319326,"teacher_disagreement_score":0.28234133,"about_ca_system_score_codex":0.00013737379,"about_ca_system_score_gemma":0.0009932419,"threshold_uncertainty_score":0.5513051},"labels":[],"label_agreement":null},{"id":"W3107140765","doi":"10.2967/jnumed.120.249029","title":"First Experiences with <sup>177</sup>Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients","year":2020,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pembrolizumab; Olaparib; Medicine; Prostate cancer; Internal medicine; Oncology; Immunotherapy; Urology; Combination therapy; Prostate-specific antigen; Cancer; DNA; Polymerase","score_opus":0.027409221719345272,"score_gpt":0.2722952437973554,"score_spread":0.24488602207801016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107140765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878737,0.0005691836,0.0000076201936,0.010508329,0.000021205009,0.0006176964,0.0000014449546,0.000011270256,0.0003895975],"genre_scores_gemma":[0.9982498,0.0004044185,0.00029291556,0.0007905501,0.00011032649,0.00003116319,0.000006735347,0.0000382428,0.00007584523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981874,0.000057862606,0.00039189382,0.00022039241,0.0008638178,0.00027862517],"domain_scores_gemma":[0.9991013,0.000059125563,0.00020772533,0.00013031246,0.0002434861,0.00025808948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000133153,0.0002155299,0.00053752924,0.00024722752,0.000045269193,0.000019756077,0.00010721644,0.00005675569,0.000399259],"category_scores_gemma":[0.000048836664,0.00009349697,0.000030046394,0.0005577438,0.00023060461,0.00023890057,0.000016334885,0.0003212088,0.0000031645284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20086628,0.0041998974,0.6114721,0.00024125158,0.00041362422,0.005239335,0.1656306,0.00021758408,0.00013062058,0.0000053170106,0.0011012824,0.010482125],"study_design_scores_gemma":[0.1909942,0.26708743,0.45831332,0.006418566,0.00023221293,0.0005797187,0.067648515,0.0013493006,0.00048271348,0.000009507853,0.006458428,0.00042609643],"about_ca_topic_score_codex":0.00005998651,"about_ca_topic_score_gemma":0.00007646238,"teacher_disagreement_score":0.26288754,"about_ca_system_score_codex":0.00033013942,"about_ca_system_score_gemma":0.00017950076,"threshold_uncertainty_score":0.4371606},"labels":[],"label_agreement":null},{"id":"W3107337141","doi":"10.1016/j.annonc.2020.10.441","title":"221P Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development; Chugai Pharmaceutical; Deutsche Krebshilfe; Astellas Pharma; Ipsen; Clovis Oncology; Eisai; Exelixis; Sanofi; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline","keywords":"Medicine; Sexual function; Prostate cancer; Androgen deprivation therapy; Urology; Internal medicine; Placebo; Cancer; Metastasis; Oncology; Pathology","score_opus":0.0956510077947232,"score_gpt":0.3548784918408807,"score_spread":0.25922748404615753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107337141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927073,0.0014084821,0.0000061200485,0.0044687325,0.0000136774315,0.0011993314,0.000022545608,0.000015401647,0.00015837688],"genre_scores_gemma":[0.99785143,0.0011941347,0.00014452335,0.00045311506,0.000022181897,0.00017013859,0.00009348225,0.000018264464,0.000052745956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866015,0.00012983459,0.00040383724,0.0003444517,0.00019641485,0.0002652901],"domain_scores_gemma":[0.9993494,0.00009796902,0.00019355006,0.00010169375,0.00012441752,0.00013294963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020497931,0.00016279527,0.0004115484,0.0001862959,0.00004308123,0.0000123087875,0.000027350408,0.000076105636,0.000033086704],"category_scores_gemma":[0.000036722402,0.00012465735,0.000016469294,0.0002864174,0.00013361091,0.00015292717,0.000022874052,0.00016258218,6.219611e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03276603,0.00046650972,0.8682558,0.00018452738,0.00029092247,0.0007250167,0.005611863,0.00008157909,0.020181742,0.000011078791,0.00010242461,0.07132253],"study_design_scores_gemma":[0.02284613,0.03164901,0.9257367,0.00023464215,0.00013451935,0.00011745382,0.0027342038,0.0014515216,0.013468599,0.00014350175,0.0012162847,0.00026741545],"about_ca_topic_score_codex":0.0010846157,"about_ca_topic_score_gemma":0.001055838,"teacher_disagreement_score":0.071055114,"about_ca_system_score_codex":0.00006344585,"about_ca_system_score_gemma":0.00036551687,"threshold_uncertainty_score":0.5083379},"labels":[],"label_agreement":null},{"id":"W3107357355","doi":"10.1016/j.annonc.2020.10.444","title":"224P Associations of pre-existing cardiovascular disease (CVD) with treatment patterns and survival outcomes in patients with localized prostate cancer: A real-world, population-based study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Astellas Pharma; Sanofi; Amgen; Pfizer; Genentech; Bayer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Prostate cancer; Interquartile range; Cancer registry; Cancer; Internal medicine; Prostatectomy; Population; Odds ratio; Proportional hazards model; Oncology; Confidence interval; Localized disease; Comorbidity; Androgen deprivation therapy","score_opus":0.10014939714745508,"score_gpt":0.408071733717063,"score_spread":0.30792233656960794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107357355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958291,0.00018224429,0.0000060769016,0.0016888046,0.000015716614,0.0018791533,0.00031449343,0.000014529144,0.000069873524],"genre_scores_gemma":[0.9991814,0.0001359146,0.000060455404,0.00008305726,0.00001548249,0.00021265472,0.00023851983,0.000018859926,0.000053640055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985702,0.00020105153,0.00032210344,0.00028260774,0.000403323,0.00022069001],"domain_scores_gemma":[0.9990391,0.00014193772,0.00018897737,0.00018730565,0.00026786877,0.00017477208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016593064,0.00015582706,0.0008150498,0.00012334973,0.00004204341,0.000005101469,0.00004162798,0.000031961583,0.000010550687],"category_scores_gemma":[0.000059375492,0.0000985437,0.00008678049,0.00027189718,0.000052382027,0.000045595734,0.00002121981,0.000075237585,1.9234454e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060185743,0.0020807013,0.9821732,0.00013553139,0.0015933785,0.000062227955,0.0011168732,0.0009835166,8.549348e-7,0.000003827877,0.0000038065916,0.0058274744],"study_design_scores_gemma":[0.01729405,0.008889194,0.9727219,0.000089208326,0.00048325298,4.9026927e-8,0.00018875865,0.00014388435,0.000037850987,0.0000036488493,0.000060637332,0.0000876187],"about_ca_topic_score_codex":0.017722324,"about_ca_topic_score_gemma":0.0069384053,"teacher_disagreement_score":0.011275474,"about_ca_system_score_codex":0.00019093213,"about_ca_system_score_gemma":0.00045750762,"threshold_uncertainty_score":0.98881876},"labels":[],"label_agreement":null},{"id":"W3107391416","doi":"10.1158/0008-5472.can-20-1965","title":"KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; Amgen (Canada); University of Toronto","funders":"National Key Research and Development Program of China; Canadian Institutes of Health Research; National Natural Science Foundation of China; Shandong University","keywords":"Enzalutamide; Prostate cancer; Cancer; Oncology; Medicine; Cancer research; Internal medicine; Androgen receptor","score_opus":0.07888420955720794,"score_gpt":0.41474316714508785,"score_spread":0.3358589575878799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107391416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.942686,0.027391747,0.000015901032,0.026864307,0.000051144863,0.0021048505,0.00031675413,0.000032340602,0.00053694856],"genre_scores_gemma":[0.98625416,0.01044448,0.000068130525,0.0005013518,0.00009599013,0.00088444434,0.000059952006,0.000038809376,0.0016526694],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974475,0.0001895732,0.00038093567,0.00053843664,0.00076646346,0.0006771127],"domain_scores_gemma":[0.9979662,0.00028440368,0.000056036297,0.00024228649,0.0010251687,0.00042595546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069578923,0.0001640692,0.00045198912,0.00036033124,0.000090421614,0.000035551006,0.00015305626,0.0000840814,0.00021160259],"category_scores_gemma":[0.0010302002,0.00013572029,0.000029994995,0.0025861182,0.00034919332,0.00010901287,0.00014638908,0.00046988323,0.000013055083],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01318327,0.0001850908,0.5295366,0.0024009023,0.00019600875,0.00017304865,0.007700538,0.000098545905,0.42626962,0.000497874,0.0143578965,0.005400622],"study_design_scores_gemma":[0.02000272,0.001635073,0.33033216,0.0040024356,0.00009393462,0.0000023148455,0.0035422903,0.00061528117,0.53584933,0.00094630494,0.102362916,0.00061524607],"about_ca_topic_score_codex":0.0012181915,"about_ca_topic_score_gemma":0.0023254305,"teacher_disagreement_score":0.19920442,"about_ca_system_score_codex":0.00069128646,"about_ca_system_score_gemma":0.0013830446,"threshold_uncertainty_score":0.55345124},"labels":[],"label_agreement":null},{"id":"W3108070988","doi":"10.1016/j.euros.2020.11.005","title":"High Serine-arginine Protein Kinase 1 Expression with PTEN Loss Defines Aggressive Phenotype of Prostate Cancer Associated with Lethal Outcome and Decreased Overall Survival","year":2020,"lang":"en","type":"article","venue":"European Urology Open Science","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta; University of Calgary","funders":"Prostate Cancer Canada; Prostate Cancer Foundation","keywords":"PTEN; Prostate cancer; Hazard ratio; Medicine; Androgen deprivation therapy; Cohort; Prostate; Proportional hazards model; Biochemical recurrence; Oncology; Internal medicine; Cancer research; Cancer; Erg; Confidence interval; Biology; Prostatectomy; Apoptosis; PI3K/AKT/mTOR pathway; Genetics","score_opus":0.038885866709223116,"score_gpt":0.31355053006929823,"score_spread":0.2746646633600751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108070988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991146,0.000247362,0.000017563101,0.0059677097,0.00003338849,0.0012736035,0.000056243916,0.000036861853,0.0012212247],"genre_scores_gemma":[0.9979602,0.000040717416,0.00064720353,0.00062682165,0.000038186197,0.000050964096,0.000032896027,0.000035519097,0.00056748284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978153,0.00026440696,0.00026825926,0.000669394,0.00053392985,0.00044870682],"domain_scores_gemma":[0.9985614,0.00006808045,0.00033770865,0.00028010804,0.0003745486,0.00037818277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006834097,0.00022549022,0.00046111117,0.00008274397,0.00019248977,0.00006719705,0.00053135445,0.000031965046,0.00008559893],"category_scores_gemma":[0.00048594695,0.00013130238,0.000020054526,0.0005524171,0.001366831,0.0002963288,0.0005903854,0.00025090977,0.0000074697214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013371831,0.00026153066,0.875691,0.00010808929,0.0001221168,0.0026503678,0.0010908104,0.00013762021,0.105320625,0.00010720315,0.00009058381,0.0010482346],"study_design_scores_gemma":[0.015902186,0.005749944,0.94766086,0.0004700555,0.00013343191,0.000048358386,0.00014451213,0.0002295772,0.028999526,0.000017237422,0.00028267104,0.00036166297],"about_ca_topic_score_codex":0.0002673887,"about_ca_topic_score_gemma":0.00004767596,"teacher_disagreement_score":0.076321095,"about_ca_system_score_codex":0.0000461919,"about_ca_system_score_gemma":0.00050000544,"threshold_uncertainty_score":0.5354356},"labels":[],"label_agreement":null},{"id":"W3108249746","doi":"10.1002/ijc.33416","title":"Circulating insulin‐like growth factor‐I, total and free testosterone concentrations and prostate cancer risk in 200 000 men in UK Biobank","year":2020,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; Medical Research Council; Medical Research Council Canada; National Institute for Health and Care Research; Wellcome Trust; British Heart Foundation; National Cancer Institute; Cancer Research UK; World Health Organization","keywords":"Prostate cancer; Medicine; Hazard ratio; Prospective cohort study; Internal medicine; Sex hormone-binding globulin; Testosterone (patch); Cancer; Risk factor; Odds ratio; Proportional hazards model; Insulin-like growth factor; Oncology; Prostate; Gynecology; Endocrinology; Hormone; Androgen; Confidence interval; Growth factor","score_opus":0.02500203288867578,"score_gpt":0.33098727275007145,"score_spread":0.3059852398613957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108249746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731518,0.013985068,0.000016433485,0.012027221,0.00019308084,0.00023805325,0.00020449588,0.000004832077,0.00017901459],"genre_scores_gemma":[0.9843068,0.014814172,0.00013675535,0.00035981246,0.00028704276,0.000020124313,0.000006744014,0.000011969849,0.000056554218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988078,0.000040121435,0.00039542548,0.00016529961,0.0004164591,0.00017487853],"domain_scores_gemma":[0.99924684,0.00007018871,0.00020443341,0.000047590704,0.0002661852,0.00016476553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011256457,0.000116034986,0.00023694793,0.00016829862,0.00002787791,0.000048885613,0.00009734694,0.000047452668,0.00014357701],"category_scores_gemma":[0.00014643154,0.00009184166,0.00003323338,0.00015847059,0.00008280781,0.00021166488,0.000060876082,0.00033976845,5.277595e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087806804,0.000049871,0.9790901,0.000027954111,0.00020871258,0.0003218217,0.0028847428,0.0001293527,0.005601748,0.000012128984,0.00035401253,0.010441481],"study_design_scores_gemma":[0.010006121,0.00027104476,0.98475224,0.0004885822,0.00004954359,0.00009447581,0.00033373365,0.0016427471,0.0016907555,0.0001986758,0.00035590772,0.00011618766],"about_ca_topic_score_codex":0.0019238865,"about_ca_topic_score_gemma":0.0005394374,"teacher_disagreement_score":0.011667408,"about_ca_system_score_codex":0.00035463294,"about_ca_system_score_gemma":0.00031714514,"threshold_uncertainty_score":0.37451944},"labels":[],"label_agreement":null},{"id":"W3108540679","doi":"10.1016/j.critrevonc.2020.103185","title":"Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications","year":2020,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Janssen Biotech; Astellas Pharma; Eisai; AstraZeneca; Pfizer","keywords":"Prostate cancer; Androgen receptor; PTEN; Cancer research; Wnt signaling pathway; Signal transduction; PI3K/AKT/mTOR pathway; Medicine; Tramp; Androgen deprivation therapy; Androgen; Prostate; Cancer; Bioinformatics; Biology; Internal medicine; Hormone; Cell biology","score_opus":0.21749076504914358,"score_gpt":0.5632320503575629,"score_spread":0.3457412853084193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108540679","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016895555,0.982842,0.000012456332,0.012267443,0.0003680503,0.0039422377,0.0001824427,0.000029493554,0.00018686318],"genre_scores_gemma":[0.0000834748,0.99422896,0.0008945996,0.0003434828,0.0005275541,0.0036998072,0.00015313065,0.000058271824,0.0000107473315],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99491835,0.001426368,0.0019069186,0.0010147537,0.00014387834,0.00058973604],"domain_scores_gemma":[0.9971995,0.0015317412,0.0003065105,0.00034978852,0.00010357501,0.00050891354],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009807542,0.00049243966,0.0042849896,0.00027641017,0.00008126331,0.000024512727,0.00017597934,0.0005813579,0.00013598237],"category_scores_gemma":[0.0010964555,0.00033771578,0.0003179019,0.00055173953,0.0006819881,0.00006148181,0.00025322652,0.0020944572,0.00004118625],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000525285,0.00031103444,0.008474327,0.014419403,0.00009608836,0.0002477451,0.00010989807,2.301598e-9,0.0000018107846,0.0031290941,0.0006464631,0.9725116],"study_design_scores_gemma":[0.0009497464,0.0003832057,0.00005927918,0.029029926,0.0006677546,0.00037743762,0.000034914774,0.0000019337735,0.0000040413265,0.0004803565,0.9677519,0.0002594655],"about_ca_topic_score_codex":0.000004437487,"about_ca_topic_score_gemma":0.000013848386,"teacher_disagreement_score":0.97225213,"about_ca_system_score_codex":0.00037678523,"about_ca_system_score_gemma":0.0010755938,"threshold_uncertainty_score":0.9999075},"labels":[],"label_agreement":null},{"id":"W3109863291","doi":"10.1016/j.jgo.2020.11.002","title":"Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: A systematic review","year":2020,"lang":"en","type":"review","venue":"Journal of Geriatric Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre; Cambridge Memorial Hospital","funders":"","keywords":"Enzalutamide; Prostate cancer; Medicine; Bicalutamide; Oncology; Internal medicine; Context (archaeology); Androgen deprivation therapy; Placebo; Androgen receptor; Cancer","score_opus":0.01645077976860411,"score_gpt":0.35330864778298626,"score_spread":0.33685786801438217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109863291","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033713598,0.9937251,0.0000011675453,0.0002660835,0.00013028846,0.0053994837,0.000021574546,0.0000059804956,0.0001131733],"genre_scores_gemma":[0.00010820691,0.99893725,0.00016350478,0.00004082812,0.00017551947,0.00039076796,0.00003463347,0.000037358943,0.000111945075],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9969622,0.0007826508,0.0013821475,0.00023965049,0.00039490563,0.00023842926],"domain_scores_gemma":[0.996565,0.0005291759,0.002192021,0.00013850181,0.0003488909,0.00022643068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007280584,0.0003007343,0.005025942,0.0004485062,0.000025859348,0.000007997096,0.00011609056,0.00023567745,0.000026057434],"category_scores_gemma":[0.00038526152,0.00015990445,0.00025503663,0.0007693655,0.00006560851,0.00007447892,0.00004922616,0.0005907219,0.0000036474623],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008810887,0.00015549142,0.00007909092,0.82735103,0.0008682616,0.0006057188,0.00024060697,3.2792858e-8,0.000012503236,2.013981e-7,0.0009804905,0.16882549],"study_design_scores_gemma":[0.0062257336,0.004045341,0.000019439254,0.91072047,0.016283812,0.0015524339,0.00008051534,0.0000017620233,0.00006242386,0.00000520039,0.06081692,0.00018596093],"about_ca_topic_score_codex":0.000013432076,"about_ca_topic_score_gemma":0.0000018457308,"teacher_disagreement_score":0.16863954,"about_ca_system_score_codex":0.0006089227,"about_ca_system_score_gemma":0.0025968445,"threshold_uncertainty_score":0.6520714},"labels":[],"label_agreement":null},{"id":"W3110045906","doi":"10.1016/bs.asn.2020.10.001","title":"Impact of prostate cancer stem cell niches on prostate cancer tumorigenesis and progression","year":2020,"lang":"en","type":"book-chapter","venue":"Advances in stem cells and their niches","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital","funders":"","keywords":"Prostate cancer; Metastasis; Cancer research; Stem cell; Cancer stem cell; Homing (biology); Carcinogenesis; Bone marrow; Biology; Bone metastasis; Oncology; Medicine; Cancer; Immunology; Internal medicine; Cell biology","score_opus":0.023689569023733766,"score_gpt":0.3207825068930225,"score_spread":0.29709293786928875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110045906","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43189833,0.5442193,6.8555346e-7,0.00046089044,0.0003145394,0.003351434,0.0014147868,0.00006626332,0.018273735],"genre_scores_gemma":[0.54996216,0.39568433,0.000022220613,0.00004138499,0.000120744306,0.00026588372,0.000033749446,0.00011438955,0.05375516],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99761736,0.0000463588,0.0005719812,0.00089037156,0.00038367722,0.00049023534],"domain_scores_gemma":[0.99860656,0.00015778538,0.0004597058,0.00034126657,0.00013920055,0.00029548488],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015343589,0.00071230234,0.0012144163,0.00020828574,0.0000967417,0.000037258073,0.00013766986,0.00022943073,0.000047610454],"category_scores_gemma":[0.000001670529,0.00042814936,0.00020128964,0.000119171025,0.0004578504,0.00018053291,0.00015434517,0.00050799013,0.0000041795697],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009958969,0.00043598883,0.11268668,0.011412173,0.00091368065,0.00036183847,0.0059678396,0.00017018328,0.012268282,0.00036473217,0.00032615184,0.8451335],"study_design_scores_gemma":[0.024660194,0.023288334,0.013874807,0.04448825,0.0014969438,0.00006938965,0.0031155907,0.00053701666,0.7025736,0.0056606443,0.17565422,0.004581003],"about_ca_topic_score_codex":0.00011172318,"about_ca_topic_score_gemma":0.00007979038,"teacher_disagreement_score":0.8405525,"about_ca_system_score_codex":0.00027353383,"about_ca_system_score_gemma":0.00043985242,"threshold_uncertainty_score":0.999817},"labels":[],"label_agreement":null},{"id":"W3110412319","doi":"10.3389/fonc.2020.562504","title":"Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Huazhong University of Science and Technology; National Natural Science Foundation of China","keywords":"Medicine; Prostate cancer; Oncology; Hazard ratio; Meta-analysis; Internal medicine; Androgen receptor; Odds ratio; Confidence interval; Cancer","score_opus":0.09477081122974979,"score_gpt":0.40919784094836986,"score_spread":0.3144270297186201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110412319","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001655946,0.9849419,0.000014631324,0.0008910264,0.00005084119,0.013446602,0.0005880755,0.000005248522,0.0000451051],"genre_scores_gemma":[0.00003946263,0.990515,0.001765822,0.00007465082,0.000011973709,0.0071283337,0.00023611789,0.000026762811,0.0002018691],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99518937,0.0018709294,0.0017662046,0.0005090546,0.000357663,0.00030679506],"domain_scores_gemma":[0.9976139,0.00064374687,0.0010455484,0.0004775318,0.000116110714,0.00010315215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009988969,0.0004387145,0.011455804,0.0005428784,0.000027318134,0.000007760867,0.00021216559,0.00014461686,0.000048229627],"category_scores_gemma":[0.00019149929,0.00021427691,0.0011181746,0.0018739689,0.00018826738,0.000033786117,0.000027348124,0.0002338601,0.0000014800266],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017317657,0.00089602504,0.00009479066,0.82110137,0.16156855,0.0007207828,0.0018449189,0.00000310979,4.085619e-7,0.000030853163,0.00036945048,0.013196544],"study_design_scores_gemma":[0.0011442482,0.0023265313,0.000007090013,0.019638274,0.91694134,0.0000781729,0.00043945538,0.000032400152,0.0000014739015,0.000022073831,0.059201367,0.00016754244],"about_ca_topic_score_codex":0.00039555316,"about_ca_topic_score_gemma":0.00018580383,"teacher_disagreement_score":0.8014631,"about_ca_system_score_codex":0.00082744134,"about_ca_system_score_gemma":0.0017416981,"threshold_uncertainty_score":0.87379587},"labels":[],"label_agreement":null},{"id":"W3110464061","doi":"10.1016/j.annonc.2020.10.437","title":"217O Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme","keywords":"Medicine; Cohort; Enzalutamide; Abiraterone acetate; Docetaxel; Abiraterone; Prostate cancer; Internal medicine; Cancer; Oncology; Androgen deprivation therapy; Androgen receptor","score_opus":0.0810000559258849,"score_gpt":0.407301675363801,"score_spread":0.32630161943791613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110464061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98871213,0.00058162183,0.0000016255959,0.0077068526,0.000053425767,0.0024974972,0.00009376354,0.000010106579,0.00034298867],"genre_scores_gemma":[0.99901646,0.00017809225,0.000032634012,0.00036933116,0.000014646912,0.0001831396,0.000045416386,0.00001786451,0.00014238844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983221,0.00024546296,0.00045814877,0.0002479435,0.00047362442,0.0002526738],"domain_scores_gemma":[0.99876404,0.0000886091,0.00030796396,0.000205092,0.0005444681,0.00008983528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024726696,0.00015829058,0.00055257,0.00010701469,0.000078597855,0.0000062522336,0.000120774894,0.00004546475,0.00006784385],"category_scores_gemma":[0.000072678326,0.00009270196,0.00006385995,0.0004443773,0.00021602132,0.000098354634,0.000055824297,0.00017958389,9.767194e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059667323,0.022349907,0.82287157,0.00058445835,0.0017295333,0.00014787544,0.035941314,0.00015764017,0.006028734,0.00018422396,0.0010995246,0.049237896],"study_design_scores_gemma":[0.05563519,0.05000671,0.8816344,0.00016212816,0.00025695685,0.0000018828767,0.0022371795,0.000105938925,0.008772057,0.00013976877,0.00090082694,0.00014695643],"about_ca_topic_score_codex":0.00044567688,"about_ca_topic_score_gemma":0.0004552171,"teacher_disagreement_score":0.05876283,"about_ca_system_score_codex":0.00008990617,"about_ca_system_score_gemma":0.00068260357,"threshold_uncertainty_score":0.37802762},"labels":[],"label_agreement":null},{"id":"W3110527171","doi":"10.1186/s13550-020-00735-w","title":"Kinetic analysis of dominant intraprostatic lesion of prostate cancer using quantitative dynamic [18F]DCFPyL-PET: comparison to [18F]fluorocholine-PET","year":2021,"lang":"en","type":"article","venue":"EJNMMI Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Centre for Probe Development and Commercialization; McMaster University; London Health Sciences Centre; Lawson Health Research Institute; Western University","funders":"Canadian Institutes of Health Research; Canada Foundation for Innovation; Ontario Institute for Cancer Research","keywords":"Prostate cancer; Medicine; Positron emission tomography; Nuclear medicine; Standardized uptake value; PET-CT; Lesion; Biopsy; Fluorodeoxyglucose; Pathology; Cancer; Internal medicine","score_opus":0.1545377986110393,"score_gpt":0.5118926992328069,"score_spread":0.35735490062176756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110527171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899217,0.0057862825,0.00040301532,0.0017899037,0.00009639744,0.0014317239,0.0002946303,0.000016778622,0.00025957738],"genre_scores_gemma":[0.99037486,0.0018022443,0.005162399,0.000035777073,0.000029660256,0.00013787714,0.00025217963,0.000053223222,0.0021517542],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9950013,0.0005862188,0.00084739766,0.0007485479,0.0018802917,0.0009362038],"domain_scores_gemma":[0.9954252,0.0005987611,0.00021334074,0.00073794345,0.0026209997,0.0004037179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014625334,0.000285135,0.0012903947,0.0018421891,0.00018946905,0.000046156074,0.000266111,0.000054323697,0.0004729484],"category_scores_gemma":[0.00066779647,0.00022769626,0.00028251685,0.0063787396,0.00052440027,0.000111790236,0.00029313774,0.0006422351,0.000021926173],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005223394,0.0015443834,0.084096946,0.0017852021,0.0029952843,0.0014466943,0.0064381203,0.004476539,0.8841765,0.00022106677,0.0007233821,0.0068724803],"study_design_scores_gemma":[0.007840639,0.003912261,0.12666045,0.002954667,0.0025972177,0.000090319016,0.013528649,0.23807171,0.60250884,0.00020388396,0.0009889487,0.00064240326],"about_ca_topic_score_codex":0.0021050852,"about_ca_topic_score_gemma":0.0012691701,"teacher_disagreement_score":0.28166768,"about_ca_system_score_codex":0.0006558401,"about_ca_system_score_gemma":0.0014313967,"threshold_uncertainty_score":0.9285184},"labels":[],"label_agreement":null},{"id":"W3110773361","doi":"10.1016/j.eururo.2020.11.038","title":"Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"National Cancer Institute; U.S. Department of Defense","keywords":"Prostate cancer; Medicine; Hazard ratio; Oncology; Transcriptome; Internal medicine; Prostatectomy; Immune system; Confidence interval; Prostate; Cancer; Immunology; Biology; Gene; Genetics","score_opus":0.09134125043236942,"score_gpt":0.3142924554285957,"score_spread":0.22295120499622628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110773361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95252264,0.0013424649,0.000065989574,0.044424,0.00020102125,0.0005825461,0.00014553491,0.0000580372,0.00065774814],"genre_scores_gemma":[0.99649733,0.00043370266,0.00007745394,0.0013249804,0.00019997048,0.00003733135,0.00007609515,0.00004753657,0.0013055905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998648,0.00016038824,0.00034515766,0.00038005522,0.00011136065,0.00035506932],"domain_scores_gemma":[0.99947476,0.00007976076,0.00006270078,0.00014922292,0.000032493725,0.00020105632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014702333,0.00018163111,0.0004199101,0.00011854832,0.000054390213,0.000016637101,0.00010349998,0.000042864558,0.00009480199],"category_scores_gemma":[0.000037421312,0.00013963712,0.00006982372,0.000109092325,0.00018504474,0.0000683169,0.00007795959,0.00051053683,0.000048182075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011130816,0.00016366686,0.7907404,0.000058886657,0.00036645014,0.00031915779,0.002289358,0.000018012928,0.20092177,0.000031401676,0.00031252546,0.0036653029],"study_design_scores_gemma":[0.0075227576,0.00068049633,0.9810867,0.000019203464,0.00013013849,0.000029823055,0.000119058685,0.0001315798,0.00078660063,0.0000054971056,0.009370586,0.000117595475],"about_ca_topic_score_codex":0.00026080172,"about_ca_topic_score_gemma":0.000054375963,"teacher_disagreement_score":0.20013517,"about_ca_system_score_codex":0.00008969427,"about_ca_system_score_gemma":0.000078670484,"threshold_uncertainty_score":0.5694236},"labels":[],"label_agreement":null},{"id":"W3111396708","doi":"10.21037/tau-20-1205","title":"A marrow-minded look at immune checkpoint blockade resistance in metastatic castration resistant prostate cancer","year":2021,"lang":"en","type":"editorial","venue":"Translational Andrology and Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Blockade; Medicine; Immune checkpoint; Oncology; Immune system; Prostate; Cancer; Internal medicine; Immunotherapy; Cancer research; Immunology; Receptor","score_opus":0.016894250190160002,"score_gpt":0.3043265856478033,"score_spread":0.2874323354576433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111396708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47854948,0.29563367,0.000028387378,0.064702265,0.15214281,0.003735392,0.0026756574,0.00011503129,0.0024173027],"genre_scores_gemma":[0.7046495,0.039479814,0.0013339416,0.0006984328,0.16776505,0.002393941,0.021156747,0.00026121788,0.062261365],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970689,0.00030881775,0.00072844065,0.0008231876,0.0004860203,0.0005846568],"domain_scores_gemma":[0.9986074,0.0005390311,0.00019963898,0.00024567344,0.00025890247,0.00014937567],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048278485,0.00039248043,0.0009404819,0.00028763612,0.00017301504,0.000017308255,0.00009133926,0.00080594904,0.00062190427],"category_scores_gemma":[0.00009879068,0.0003397708,0.00014649854,0.00023925578,0.00048470727,0.000067717425,0.00004395361,0.0011073715,0.000009588248],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36178142,0.0037312184,0.052561022,0.010388593,0.00846016,0.02549059,0.012711588,0.00048261974,0.1421379,0.0016363573,0.37560135,0.0050171725],"study_design_scores_gemma":[0.035259027,0.0023826705,0.07831278,0.00052127877,0.0019047124,0.00026331094,0.000069127964,0.0002683283,0.0026735745,0.006445363,0.8708251,0.001074699],"about_ca_topic_score_codex":0.00021232669,"about_ca_topic_score_gemma":0.009177238,"teacher_disagreement_score":0.49522376,"about_ca_system_score_codex":0.0001646084,"about_ca_system_score_gemma":0.001488365,"threshold_uncertainty_score":0.9999054},"labels":[],"label_agreement":null},{"id":"W3112404269","doi":"10.1016/j.jval.2020.08.173","title":"PCN36 Systematic Review of Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC) with DNA Damage Repair Gene Mutation (DDRm)","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Olaparib; Oncology; Internal medicine; Clinical trial; Taxane; Pembrolizumab; Prostate cancer; Cancer; Breast cancer; Immunotherapy","score_opus":0.08304421118659776,"score_gpt":0.3717929691983274,"score_spread":0.2887487580117296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112404269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85737133,0.12257957,0.000014323163,0.009509432,0.00004136429,0.010158445,0.00015727102,0.000058418333,0.0001098574],"genre_scores_gemma":[0.95260954,0.041904088,0.0021848036,0.001425502,0.000028821634,0.0012890851,0.00023674202,0.000048414135,0.00027302583],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99741024,0.00045202728,0.00096930575,0.00033301988,0.00050066,0.00033477767],"domain_scores_gemma":[0.99894834,0.00010575643,0.00035204316,0.00025716037,0.00012562472,0.00021107351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007148711,0.0001859692,0.0009224168,0.00015449274,0.000038603,0.00000781098,0.000060995448,0.000026634802,0.000031854663],"category_scores_gemma":[0.00016709915,0.00012401983,0.000067709414,0.00081896107,0.000047326834,0.00009629145,0.000013707169,0.0001512307,0.0000059960003],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010835432,0.00045398925,0.011218891,0.97922295,0.00031160965,0.0008795883,0.004649138,0.00081681163,0.0009701705,0.000052687185,0.00010172547,0.00023892],"study_design_scores_gemma":[0.021247888,0.010017007,0.055782396,0.88465685,0.0014108239,0.00010890209,0.002697415,0.016798511,0.006523082,0.00010354784,0.000061086634,0.0005925157],"about_ca_topic_score_codex":0.0046844254,"about_ca_topic_score_gemma":0.00030698365,"teacher_disagreement_score":0.0952382,"about_ca_system_score_codex":0.0006910913,"about_ca_system_score_gemma":0.0014647386,"threshold_uncertainty_score":0.7081481},"labels":[],"label_agreement":null},{"id":"W3112855317","doi":"10.7150/jca.48433","title":"Whole-exome Sequencing of Prostate Cancer in Sardinian Identify Recurrent UDP-glucuronosyltransferase Amplifications","year":2020,"lang":"en","type":"article","venue":"Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Greenfield Research (Canada); Dalhousie University","funders":"","keywords":"Prostate cancer; Exome sequencing; Cancer research; Cancer; Computational biology; Medicine; Biology; Internal medicine; Gene; Genetics; Mutation","score_opus":0.07134641586811011,"score_gpt":0.3982696856967039,"score_spread":0.32692326982859377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112855317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9579958,0.017561335,0.000070965005,0.023257442,0.00030418785,0.00043424315,0.00017631329,0.000008480575,0.000191279],"genre_scores_gemma":[0.98751676,0.011466966,0.00013841211,0.00027349137,0.0003338403,0.000042568943,0.000007950605,0.000022821041,0.00019719328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831223,0.000056072455,0.0006860891,0.00017771935,0.0004981362,0.0002697698],"domain_scores_gemma":[0.99882656,0.00003948923,0.0002775079,0.00012949543,0.00043192637,0.0002950165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024902404,0.00014095924,0.00047844934,0.00021842826,0.000037212176,0.000021112173,0.00013648556,0.00005489011,0.0003307989],"category_scores_gemma":[0.000062479034,0.00010645147,0.000169783,0.0005313982,0.000087846776,0.00019724783,0.000018693292,0.00045494523,0.000005525004],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004879861,0.00036944138,0.4642159,0.0013289175,0.00078905205,0.0005118334,0.014219024,0.0016830371,0.4324153,0.000044950928,0.003782086,0.075760596],"study_design_scores_gemma":[0.021832816,0.0032158075,0.6366309,0.0064274087,0.001040398,0.00011108043,0.0035515567,0.0008712865,0.257517,0.00025706968,0.0679033,0.0006413923],"about_ca_topic_score_codex":0.00015977553,"about_ca_topic_score_gemma":0.00014919564,"teacher_disagreement_score":0.17489828,"about_ca_system_score_codex":0.00061530183,"about_ca_system_score_gemma":0.0014958159,"threshold_uncertainty_score":0.43409652},"labels":[],"label_agreement":null},{"id":"W3114158368","doi":"10.4103/wjnm.wjnm_17_20","title":"Radiographic and metabolic evolution of prostate cancer lung metastasis detected by prostate-specific membrane antigen and fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography","year":2020,"lang":"en","type":"article","venue":"World Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph's Hospital; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Positron emission tomography; Prostate; Positron Emission Tomography-Computed Tomography; Metastasis; Radiology; Lung; Radiography; Positron emission; Nuclear medicine; Cancer; Pathology; Internal medicine","score_opus":0.012001436279315872,"score_gpt":0.2591413571162162,"score_spread":0.24713992083690034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114158368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71416426,0.27595773,0.000022294367,0.008952539,0.00011791436,0.00066523993,0.000043388183,0.00003817772,0.000038475246],"genre_scores_gemma":[0.9174661,0.08105734,0.00082345394,0.0002678633,0.00024813294,0.000007299871,0.00002377423,0.000061775696,0.00004427443],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99715745,0.00020008959,0.00089712674,0.0004188346,0.00087295263,0.000453519],"domain_scores_gemma":[0.99777526,0.00008678848,0.0005878784,0.00020981563,0.0005192682,0.0008209651],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005584564,0.00036975447,0.0011345235,0.001398492,0.00016948614,0.00003063462,0.00016258379,0.000093307295,0.00014546403],"category_scores_gemma":[0.00005198276,0.0002510807,0.00022770076,0.0026044648,0.00060012186,0.00025281945,0.00007523265,0.00060628686,4.8527534e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007023171,0.0002578307,0.12929076,0.0007491701,0.0016479483,0.00018083715,0.0026327108,0.000004322295,0.81577116,0.00003489146,0.013734121,0.02867308],"study_design_scores_gemma":[0.036734324,0.008449869,0.7005943,0.0051482017,0.0038157091,0.0005949246,0.0019595984,0.0014963424,0.1453567,0.00011866983,0.09485853,0.00087284634],"about_ca_topic_score_codex":0.0001094546,"about_ca_topic_score_gemma":0.0000066530743,"teacher_disagreement_score":0.67041445,"about_ca_system_score_codex":0.00007127125,"about_ca_system_score_gemma":0.00010580312,"threshold_uncertainty_score":0.99999416},"labels":[],"label_agreement":null},{"id":"W3115815050","doi":"10.1186/s40658-021-00369-4","title":"Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&amp;T","year":2021,"lang":"en","type":"article","venue":"EJNMMI Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of British Columbia","funders":"Ludwig-Maximilians-Universität München; Deutsche Forschungsgemeinschaft","keywords":"Medicine; Dosimetry; Prostate cancer; Nuclear medicine; Hounsfield scale; Absorbed dose; Lesion; Voxel; Homogeneous; Radiology; Cancer; Internal medicine; Surgery; Mathematics; Computed tomography","score_opus":0.03845021917348053,"score_gpt":0.3833092572006072,"score_spread":0.3448590380271267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115815050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969588,0.00030965958,0.0012412046,0.00035311506,0.00003778704,0.000692921,0.000016606607,0.000034774777,0.00035513466],"genre_scores_gemma":[0.99287057,0.0002535064,0.0060121366,0.0002915373,0.00007004591,0.000096304815,0.00016478852,0.000032582964,0.00020852369],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985509,0.00008075646,0.0002867841,0.0003820319,0.00042986995,0.00026969123],"domain_scores_gemma":[0.99887747,0.00020704331,0.00010340695,0.00045612152,0.00024258632,0.00011340091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022117661,0.00017622978,0.0003553927,0.000112568814,0.000054151875,0.000015161718,0.000094293675,0.00007709277,0.000013243108],"category_scores_gemma":[0.00014858667,0.00014553862,0.000069655835,0.0008425613,0.000036664114,0.00010116799,0.00007049225,0.0002101042,0.000049493396],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010339366,0.0017303192,0.13904381,0.00021611084,0.00007538845,0.000014932323,0.0015891508,0.0022921714,0.52275425,0.0001474328,0.00024925792,0.33085325],"study_design_scores_gemma":[0.002936495,0.00036464917,0.41132283,0.0003965146,0.000023875018,0.0000010928184,0.000060843526,0.00035470762,0.58317226,0.0007338341,0.00047821447,0.0001546531],"about_ca_topic_score_codex":0.00011457265,"about_ca_topic_score_gemma":0.000013630051,"teacher_disagreement_score":0.3306986,"about_ca_system_score_codex":0.00016970346,"about_ca_system_score_gemma":0.00012082365,"threshold_uncertainty_score":0.5934893},"labels":[],"label_agreement":null},{"id":"W3115918502","doi":"10.1016/j.eururo.2020.12.012","title":"Re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020;78:652–6","year":2020,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Terry Fox Foundation; National Cancer Institute; Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Swami; Gynecology; Oncology; Internal medicine; Cancer; Theology","score_opus":0.019905035738930103,"score_gpt":0.3054813802605399,"score_spread":0.2855763445216098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115918502","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.099044174,0.00039450778,0.00010169652,0.8910572,0.000109068664,0.0022415088,0.0005878885,0.00010136038,0.006362576],"genre_scores_gemma":[0.41316828,0.0008062084,0.0010333954,0.5676807,0.0005147211,0.00031974964,0.0036396948,0.00039808403,0.012439164],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956072,0.0014367767,0.0006459567,0.0008125451,0.00073291746,0.0007645779],"domain_scores_gemma":[0.99776375,0.0006114565,0.000672875,0.00037503333,0.0004242967,0.00015256862],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005839419,0.00053228834,0.0010764985,0.00033564976,0.00009904141,0.000044541437,0.00018291955,0.00015045764,0.000090115725],"category_scores_gemma":[0.000269614,0.00039668186,0.00011654597,0.00054641475,0.00019656385,0.00014049861,0.000073857285,0.0019416943,0.000056136967],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057094246,0.00055146025,0.20488772,0.00071170134,0.004507973,0.06717982,0.017940735,0.0018656959,0.001744079,0.00001655849,0.6940002,0.00088467303],"study_design_scores_gemma":[0.053332582,0.020206895,0.42848057,0.0013430526,0.0063188407,0.0016546272,0.0048207166,0.0025408233,0.0020409652,0.000104715145,0.476113,0.003043219],"about_ca_topic_score_codex":0.000540563,"about_ca_topic_score_gemma":0.001345079,"teacher_disagreement_score":0.32337654,"about_ca_system_score_codex":0.00058057345,"about_ca_system_score_gemma":0.0009475348,"threshold_uncertainty_score":0.9998485},"labels":[],"label_agreement":null},{"id":"W3116917655","doi":"10.1016/j.urology.2020.12.021","title":"Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary","year":2020,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Biomarker; Prostate; Internal medicine; Foundation (evidence); Gynecology","score_opus":0.04288828609753408,"score_gpt":0.3235995611506047,"score_spread":0.2807112750530706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3116917655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89480287,0.022542067,0.000119762095,0.07289144,0.000621744,0.0023655293,0.00007883583,0.00029771222,0.006280039],"genre_scores_gemma":[0.9851538,0.008268477,0.000118015465,0.00409365,0.00046687227,0.000379866,0.00024401525,0.000059945305,0.0012153381],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980366,0.00013434968,0.0003033974,0.0005828915,0.00029528336,0.0006474521],"domain_scores_gemma":[0.9991667,0.00009706792,0.00013727779,0.000166493,0.00017105245,0.00026140673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021315587,0.00024519223,0.00038876967,0.00012234879,0.00018183599,0.000035865243,0.000084261614,0.00013684541,0.00014418938],"category_scores_gemma":[0.000073380004,0.00019870733,0.000087589804,0.00044757585,0.00021089554,0.0001221067,0.00011912802,0.00036052175,0.00006504765],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029861925,0.00031171888,0.26978818,0.0004396999,0.0017359162,0.0016757629,0.013523086,0.0003398499,0.2693769,0.00016968977,0.019880313,0.39289698],"study_design_scores_gemma":[0.034380253,0.007125901,0.2563213,0.0009524901,0.0019026517,0.00016385627,0.0024476657,0.037315737,0.026348192,0.0005639617,0.6303679,0.0021101006],"about_ca_topic_score_codex":0.0006151065,"about_ca_topic_score_gemma":0.00019272802,"teacher_disagreement_score":0.6104876,"about_ca_system_score_codex":0.00022343275,"about_ca_system_score_gemma":0.0002746257,"threshold_uncertainty_score":0.810305},"labels":[],"label_agreement":null},{"id":"W3117423049","doi":"10.1017/s1460396920001168","title":"A review of current clinical biomarkers for prostate cancer: towards personalised and targeted therapy","year":2020,"lang":"en","type":"review","venue":"Journal of Radiotherapy in Practice","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Guelph; Grand River Hospital; University of Waterloo","funders":"","keywords":"Prostate cancer; Medicine; Disease; Oncology; Cancer; Biopsy; Internal medicine; Targeted therapy; Rectal examination; Prostate; Intensive care medicine","score_opus":0.16024967433341786,"score_gpt":0.5373459357728235,"score_spread":0.37709626143940567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3117423049","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001110416,0.98815936,0.000020819094,0.0078255,0.00052449334,0.0033048983,0.00011590579,0.000005636576,0.000032265452],"genre_scores_gemma":[7.473124e-7,0.9957246,0.002313135,0.0010395437,0.00063016545,0.00015655691,0.000026331994,0.00006827943,0.000040637246],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99602723,0.0009054437,0.0019387894,0.00032513062,0.0005283594,0.00027505448],"domain_scores_gemma":[0.99487925,0.0012311282,0.0027151103,0.00020634854,0.00068430556,0.000283862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003338447,0.00037100172,0.0034434195,0.00029638724,0.00003084217,0.000024499022,0.00020605428,0.00018838608,0.00006358524],"category_scores_gemma":[0.0014049063,0.00022604648,0.0009966871,0.0005772952,0.00016082491,0.00022577564,0.000017998478,0.0010638874,3.7526473e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047338516,0.00043741835,0.00009718039,0.0883001,0.003621171,0.00011568963,0.00025988225,2.2616256e-8,0.0000046163427,0.0000028392365,0.0073164683,0.8951107],"study_design_scores_gemma":[0.0062138834,0.0025319718,0.000017861923,0.1350038,0.0019167465,0.0004631452,0.000048621834,0.0000068812874,0.0000027995134,0.0000029489636,0.85363436,0.00015697931],"about_ca_topic_score_codex":0.00001759587,"about_ca_topic_score_gemma":7.2842613e-7,"teacher_disagreement_score":0.8949538,"about_ca_system_score_codex":0.00044966312,"about_ca_system_score_gemma":0.0044935746,"threshold_uncertainty_score":0.9217908},"labels":[],"label_agreement":null},{"id":"W3118582178","doi":"10.5489/cuaj.6805","title":"Urological outcomes in nonagenarians with prostate cancer","year":2021,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Calgary; Dalhousie University","funders":"","keywords":"Medicine; Interquartile range; Prostate cancer; Androgen deprivation therapy; Referral; Cancer; Cohort; Internal medicine; Prostate-specific antigen; Population; Prostate; Localized disease; Retrospective cohort study; Urology","score_opus":0.01978689418159529,"score_gpt":0.28405957463627973,"score_spread":0.26427268045468444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118582178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8531038,0.0007729401,0.0000055727965,0.14323662,0.0001262175,0.00020605666,0.0000340354,0.000016741447,0.0024980016],"genre_scores_gemma":[0.9873142,0.0005278488,0.00013385432,0.0066329143,0.00014673216,0.00004006286,0.000028777868,0.000012131689,0.0051634493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982836,0.00016689737,0.00024725965,0.00023779871,0.00040411213,0.00066033273],"domain_scores_gemma":[0.9987057,0.000106208165,0.00009764764,0.00009300567,0.00033223233,0.0006652122],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036208256,0.00013789846,0.00033458782,0.00015236059,0.00016786915,0.00008389283,0.000073580755,0.00019954288,0.0009858032],"category_scores_gemma":[0.00034779686,0.000084623025,0.0000902739,0.00037595318,0.000044262226,0.000078689234,0.00001575232,0.0007898857,0.000025203411],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022587922,0.00010433842,0.9925787,0.0000040506075,0.00014264495,0.003498106,0.00012900919,0.000062395906,0.0000821392,0.000055117624,0.0013926193,0.0017250034],"study_design_scores_gemma":[0.002658221,0.000368835,0.9667277,0.00001674582,0.000047591366,0.00028342303,0.00011982223,0.000043268312,0.0000520938,0.00020671454,0.02936832,0.00010726686],"about_ca_topic_score_codex":0.000966499,"about_ca_topic_score_gemma":0.005890884,"teacher_disagreement_score":0.13660371,"about_ca_system_score_codex":0.0015479038,"about_ca_system_score_gemma":0.001909814,"threshold_uncertainty_score":0.9999274},"labels":[],"label_agreement":null},{"id":"W3118944735","doi":"10.1158/2326-6074.tumimm18-a26","title":"Abstract A26: Immune profiling and organoids generation of a rare case of prostate cancer liver metastasis","year":2020,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Metastasis; Immunotherapy; Cancer; Pathology; Immunophenotyping; Oncology; Internal medicine; Immunology; Antigen","score_opus":0.15677542524079074,"score_gpt":0.41524590447679954,"score_spread":0.2584704792360088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118944735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88454056,0.110917024,0.0000042177703,0.0030370867,0.000067849556,0.0010759761,0.00020099238,0.000019033965,0.00013724745],"genre_scores_gemma":[0.9706897,0.028091017,0.00021911925,0.0000413856,0.00012774032,0.00035083987,0.00005913633,0.000035177338,0.00038588562],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980479,0.00018850969,0.0004470709,0.0004296966,0.00037972155,0.00050711783],"domain_scores_gemma":[0.9982102,0.00012220778,0.00013210239,0.0003026526,0.0010751373,0.00015772773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005690675,0.00017457425,0.0005456593,0.0002652813,0.00016542301,0.000016655447,0.0001365642,0.00015542665,0.00066805934],"category_scores_gemma":[0.00019709731,0.000137687,0.00008036283,0.0007432287,0.0008466162,0.00013382672,0.00020856428,0.0006567562,0.0000068042214],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024930413,0.00013760057,0.021631662,0.0012947957,0.0008730942,0.0010041539,0.0035369254,0.000009747392,0.92000616,0.000065395165,0.0003603812,0.048587065],"study_design_scores_gemma":[0.0035915892,0.001026374,0.011245718,0.00023127545,0.00013119706,0.00017274382,0.0018522188,0.00047266207,0.98066425,0.000013722991,0.0004620738,0.00013616895],"about_ca_topic_score_codex":0.002594239,"about_ca_topic_score_gemma":0.000095021525,"teacher_disagreement_score":0.08614913,"about_ca_system_score_codex":0.0001871909,"about_ca_system_score_gemma":0.0010738757,"threshold_uncertainty_score":0.7314781},"labels":[],"label_agreement":null},{"id":"W3119166731","doi":"10.1016/j.eururo.2020.12.037","title":"Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer","year":2021,"lang":"en","type":"review","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institutes of Health; Fundación Científica Asociación Española Contra el Cáncer; National Cancer Institute; Fundación Fero; “la Caixa” Foundation","keywords":"Liquid biopsy; Prostate cancer; Medicine; Circulating tumor cell; Precision medicine; Context (archaeology); Biopsy; Biomarker; Personalized medicine; Microvesicles; Prostate; Oncology; Cancer; Pathology; Bioinformatics; Internal medicine; microRNA; Metastasis; Biology; Gene","score_opus":0.15599802804801202,"score_gpt":0.5461625296701861,"score_spread":0.3901645016221741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119166731","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026180618,0.97158056,0.000034165907,0.00031963032,0.00010021889,0.0009126852,0.00025369338,0.000016792555,0.0006016381],"genre_scores_gemma":[0.00475491,0.99318296,0.0011658686,0.0003414624,0.000039643117,0.00008043056,0.00021659114,0.000053456308,0.00016468647],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954815,0.0018525224,0.0013635672,0.0006514925,0.00028296135,0.00036797448],"domain_scores_gemma":[0.99480474,0.0038724053,0.00044535258,0.0003864994,0.00032049758,0.00017048875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021159744,0.00033714948,0.002930083,0.0015319152,0.000045879005,0.000016621672,0.00016405927,0.00013063656,0.00012358784],"category_scores_gemma":[0.002012796,0.00023879501,0.0005013262,0.0026167491,0.0003652009,0.000036447014,0.0002351709,0.00054953655,0.00002076264],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004127459,0.0005561775,0.002582442,0.005285074,0.012192263,0.002529299,0.010324932,0.00009439975,0.000003568307,0.00022048251,0.00021853964,0.96186537],"study_design_scores_gemma":[0.004886423,0.01388542,0.00573845,0.024574356,0.036189664,0.000043107506,0.0019761547,0.00019337938,0.0000060296093,0.000017978457,0.91158056,0.0009084616],"about_ca_topic_score_codex":0.0000416165,"about_ca_topic_score_gemma":0.00015072235,"teacher_disagreement_score":0.96095693,"about_ca_system_score_codex":0.00006765683,"about_ca_system_score_gemma":0.0007464545,"threshold_uncertainty_score":0.97377783},"labels":[],"label_agreement":null},{"id":"W3119217389","doi":"10.1016/j.annonc.2020.12.017","title":"Have investigators forgotten how to write?","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Principal (computer security); Randomized controlled trial; Medical education; Family medicine; Pathology; Computer science","score_opus":0.17868539220082263,"score_gpt":0.450052422089461,"score_spread":0.27136702988863837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119217389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73975044,0.0011362699,0.000013054483,0.23983985,0.00010152248,0.0002105012,0.000014613367,0.00001577675,0.018917996],"genre_scores_gemma":[0.9630758,0.0006888054,0.0013948263,0.014421136,0.00018404431,0.000039959275,0.000049865128,0.000016696784,0.020128833],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99920374,0.000056135763,0.00012901731,0.00018301581,0.00016183495,0.0002662631],"domain_scores_gemma":[0.99901164,0.0000818141,0.000037903792,0.00020385938,0.00038351273,0.00028130275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016433376,0.000076316326,0.00030070328,0.00009908929,0.00002824895,0.0000060229236,0.000059086233,0.00009704242,0.00015351358],"category_scores_gemma":[0.00032312545,0.000060772272,0.00007977853,0.00019659672,0.00010690962,0.000048275415,0.00007319028,0.0001145317,0.000035716006],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009848409,0.0010324226,0.10977275,0.00027716698,0.0006265099,0.00267017,0.0017469939,0.0000035100632,0.09242756,0.0022992396,0.6292719,0.1588869],"study_design_scores_gemma":[0.0015091094,0.002898015,0.016296223,0.000060015955,0.000033952576,0.00006969329,0.0005956826,0.0000069019793,0.35527033,0.00080974936,0.6223734,0.00007695438],"about_ca_topic_score_codex":0.0000256567,"about_ca_topic_score_gemma":0.000033228007,"teacher_disagreement_score":0.26284277,"about_ca_system_score_codex":0.000042005624,"about_ca_system_score_gemma":0.0006621418,"threshold_uncertainty_score":0.24782214},"labels":[],"label_agreement":null},{"id":"W3119850026","doi":"10.1016/j.eururo.2020.12.040","title":"The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited","year":2021,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; McMaster University; Movember Foundation; National Cancer Institute; Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Castration; Oncology; Prostate; Cancer; Internal medicine; Gynecology; Hormone","score_opus":0.017893513775631104,"score_gpt":0.2964395411881939,"score_spread":0.2785460274125628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119850026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82495517,0.023584938,0.00023084677,0.084262505,0.000391593,0.0012374313,0.00020555555,0.00006188453,0.06507008],"genre_scores_gemma":[0.9926698,0.0012761065,0.000041696396,0.00083153084,0.0001292472,0.000014625291,0.000108514825,0.000018640489,0.004909828],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99829483,0.00092640467,0.00020542482,0.00018034595,0.00018234603,0.0002106316],"domain_scores_gemma":[0.9988136,0.00060987065,0.00009006101,0.00023258822,0.00020705812,0.000046808484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006599082,0.000091024536,0.00015796069,0.00003291211,0.00018077769,0.00001916986,0.00007506124,0.000012316327,0.00021048504],"category_scores_gemma":[0.00019936488,0.00004544273,0.00006358124,0.00021395556,0.00027299035,0.00002372658,0.000049106155,0.0001924722,0.00004851767],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035427358,0.0021645138,0.12024746,0.0010280537,0.0155845145,0.04056655,0.046772826,0.0023811345,0.08679106,0.32557523,0.064959206,0.2585021],"study_design_scores_gemma":[0.012227848,0.0027775175,0.8192722,0.00016093146,0.0017610763,0.0032708435,0.0065950816,0.0015613538,0.037595328,0.010552868,0.103724524,0.0005003927],"about_ca_topic_score_codex":0.000007664074,"about_ca_topic_score_gemma":0.000025736283,"teacher_disagreement_score":0.6990248,"about_ca_system_score_codex":0.00001938691,"about_ca_system_score_gemma":0.00026777203,"threshold_uncertainty_score":0.23046637},"labels":[],"label_agreement":null},{"id":"W3120098199","doi":"10.3390/ijms22020487","title":"Steroidogenesis in Peripheral and Transition Zones of Human Prostate Cancer Tissue","year":2021,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Prostate cancer; Pregnenolone; Prostate; Testosterone (patch); Dehydroepiandrosterone; Endocrinology; Internal medicine; Dihydrotestosterone; Androstenediol; Chemistry; Prostatectomy; Steroid; Cancer; Medicine; Androgen; Hormone","score_opus":0.0265261194840782,"score_gpt":0.37434048546480514,"score_spread":0.34781436598072696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120098199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893071,0.0058193407,0.0000768841,0.0044840905,0.0001074005,0.000048207537,0.0000051194274,0.0000010137085,0.0001508183],"genre_scores_gemma":[0.99807006,0.0011535656,0.00053087063,0.000099947836,0.000037011294,0.0000021468015,0.0000019450106,0.0000026429925,0.00010181345],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99915934,0.00003264504,0.00019152883,0.00008372789,0.0004598027,0.00007297581],"domain_scores_gemma":[0.9994979,0.000009883711,0.00007862445,0.000027195261,0.0003470663,0.00003934358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016951501,0.00004275333,0.00011611688,0.00014794369,0.000020743366,0.000024779398,0.000075918666,0.000016617114,0.00005884312],"category_scores_gemma":[0.000012780053,0.000031692525,0.000034263376,0.00013399508,0.00014100572,0.00010793518,0.000016606196,0.000053861182,1.2664971e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017605793,0.000118390824,0.022972776,0.000025816045,0.000082406536,0.0010160943,0.0014580162,0.00017639528,0.95474976,0.00013044641,0.000009857249,0.019083958],"study_design_scores_gemma":[0.002533321,0.00081392756,0.04835075,0.00047011586,0.00003403123,0.00047248247,0.0011447886,0.0001142492,0.9451809,0.0006510584,0.00016718481,0.000067180015],"about_ca_topic_score_codex":0.00007113186,"about_ca_topic_score_gemma":0.000040742034,"teacher_disagreement_score":0.025377976,"about_ca_system_score_codex":0.00004936,"about_ca_system_score_gemma":0.00018510263,"threshold_uncertainty_score":0.12923837},"labels":[],"label_agreement":null},{"id":"W3120799199","doi":"10.1097/mnm.0000000000001363","title":"Physiologic prostate-specific membrane antigen-targeted 18F-DCFPyL uptake in the epididymis head newly appreciated on digital PET/CT","year":2020,"lang":"en","type":"article","venue":"Nuclear Medicine Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; McGill University Health Centre","funders":"","keywords":"Epididymis; Glutamate carboxypeptidase II; Antigen; Prostate; Medicine; Internal medicine; Immunology; Andrology","score_opus":0.11942632123184543,"score_gpt":0.34504736643014267,"score_spread":0.22562104519829723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120799199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73448485,0.00560973,0.0000036977995,0.21382469,0.00009945212,0.002108028,0.00007897831,0.0002868853,0.0435037],"genre_scores_gemma":[0.983043,0.010483551,0.00022116491,0.004892051,0.00015926834,0.000071743285,0.0008395964,0.000052869123,0.00023676825],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978725,0.00026548756,0.0005042421,0.0004031587,0.0005139928,0.0004406531],"domain_scores_gemma":[0.9973983,0.00041617037,0.00012311799,0.0016735767,0.00014088246,0.00024795972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003572546,0.00027352545,0.0005085976,0.00015131127,0.0003517829,0.000049187227,0.0009989757,0.000024852776,0.00043059877],"category_scores_gemma":[0.000411422,0.0001648136,0.00011666738,0.0010818179,0.0006423655,0.00013201799,0.00020387954,0.00093084975,0.00041372486],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0142989345,0.014808184,0.03470233,0.0012169112,0.0019036141,0.006243274,0.09144163,0.00035397764,0.16744052,0.013593877,0.4871539,0.16684286],"study_design_scores_gemma":[0.009481385,0.0033719148,0.06885817,0.0006290835,0.0000830391,0.00020989722,0.009698341,0.0032389075,0.0002817216,0.00020807458,0.9035501,0.0003893775],"about_ca_topic_score_codex":0.000087233864,"about_ca_topic_score_gemma":0.000020279196,"teacher_disagreement_score":0.4163962,"about_ca_system_score_codex":0.00011855871,"about_ca_system_score_gemma":0.00010189119,"threshold_uncertainty_score":0.6720903},"labels":[],"label_agreement":null},{"id":"W3120833111","doi":"10.1158/1078-0432.ccr-20-3708","title":"<i>BRCA2</i> , <i>ATM</i> , and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Alberta Cancer Foundation; BC Cancer Agency; Spinal Cord Injury BC; University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada; Government of Canada; Prostate Cancer Foundation","keywords":"Biology; Prostate cancer; Cancer research; Context (archaeology); Cancer; Genome instability; Allele; PTEN; Primary tumor; Chromoplexy; Mutation; Copy-number variation; Genetics; DNA damage; Gene; Metastasis; Genome; DNA; Apoptosis","score_opus":0.13646479669692277,"score_gpt":0.48600994150724286,"score_spread":0.34954514481032006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120833111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96234894,0.02965768,0.000006055874,0.0051857554,0.0005251064,0.0012297655,0.00008962295,0.00006548625,0.00089160685],"genre_scores_gemma":[0.8150584,0.17631613,0.00039452917,0.0019441172,0.0012004043,0.00019016571,0.00009571306,0.000101476566,0.004699034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939791,0.0011712665,0.0010909752,0.0014768087,0.0011371594,0.0011447002],"domain_scores_gemma":[0.994834,0.0019519283,0.00016258413,0.0007215812,0.0009729653,0.0013569555],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003250598,0.0003429032,0.0010097262,0.00015154987,0.00045846857,0.00020772986,0.00023080732,0.00035199814,0.00044268183],"category_scores_gemma":[0.0013721227,0.00025746707,0.0002957062,0.00055929803,0.0019360349,0.00015578524,0.0011000357,0.0023004557,0.000069866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049206377,0.0012484728,0.79458386,0.000560486,0.00043382918,0.0022959593,0.00018049628,3.1957453e-7,0.008336329,0.0000735902,0.013392509,0.17397353],"study_design_scores_gemma":[0.034838546,0.0056449603,0.7765776,0.0035043717,0.0006548567,0.0003403365,0.00043587384,0.0009863027,0.016040776,0.001607067,0.15834494,0.0010243898],"about_ca_topic_score_codex":0.00008705969,"about_ca_topic_score_gemma":0.00018632985,"teacher_disagreement_score":0.17294914,"about_ca_system_score_codex":0.00022269128,"about_ca_system_score_gemma":0.0022237685,"threshold_uncertainty_score":0.9999878},"labels":[],"label_agreement":null},{"id":"W3120929937","doi":"10.1016/j.celrep.2020.108585","title":"Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Cell Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Health and Medical Research Council; State Government of Victoria; Prostate Cancer Foundation of Australia; National Institute for Health and Care Research; Medical Research Future Fund; Australian Government; Department of Health and Aged Care, Australian Government; Movember Foundation; Cancer Council South Australia; Victorian Cancer Agency","keywords":"Transdifferentiation; Prostate cancer; Biology; Cancer research; LNCaP; FOXA1; Neuroendocrine differentiation; Transcription factor; microRNA; Prostate; Cancer; Cell biology; Gene; Stem cell; Genetics","score_opus":0.012925985468101269,"score_gpt":0.27120485820062407,"score_spread":0.2582788727325228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120929937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888373,0.0059425565,0.000032104883,0.003842887,0.0002381891,0.0006548368,0.00004493569,0.000036950332,0.0003702218],"genre_scores_gemma":[0.9799173,0.0012790213,0.00012857883,0.00013681767,0.00006497729,0.00011644722,0.0018173632,0.000027697215,0.016511781],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998527,0.000045664357,0.00037609317,0.00041940264,0.00033781782,0.0002940233],"domain_scores_gemma":[0.9993231,0.000012932832,0.0000946165,0.00021676152,0.00024000244,0.00011256807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007676832,0.0001468198,0.00021303959,0.00009531199,0.000055879136,0.00003475394,0.000023964296,0.000033849195,0.0005035815],"category_scores_gemma":[0.00001947703,0.00012848664,0.00008138913,0.0002310315,0.000037755202,0.00013567496,0.000011891901,0.00016754566,0.0000042567026],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020093928,0.00037871112,0.059395894,0.00019313327,0.000028326458,0.003105964,0.00028026866,0.000011351719,0.9334282,0.0000022421825,0.00047183305,0.0025030822],"study_design_scores_gemma":[0.0014487273,0.000096689204,0.16624272,0.00007598957,0.000052381278,0.0005692073,0.000036288096,0.00006593171,0.82705665,0.00007825437,0.004171192,0.000105954394],"about_ca_topic_score_codex":0.00013984132,"about_ca_topic_score_gemma":0.00007882637,"teacher_disagreement_score":0.106846824,"about_ca_system_score_codex":0.00016661407,"about_ca_system_score_gemma":0.00038343162,"threshold_uncertainty_score":0.5513864},"labels":[],"label_agreement":null},{"id":"W3122268760","doi":"10.1038/s41391-020-00308-x","title":"Clinical implications of genomic alterations in metastatic prostate cancer","year":2021,"lang":"en","type":"review","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Prostate; Internal medicine; Cancer","score_opus":0.11878480565701459,"score_gpt":0.4820014845827602,"score_spread":0.3632166789257456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122268760","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026405382,0.9804667,0.0000042848696,0.0010501476,0.00024451714,0.006112492,0.009310796,0.000047300044,0.0001232111],"genre_scores_gemma":[0.0007736072,0.98501533,0.0003217177,0.00016860325,0.00014078077,0.008272656,0.0025780688,0.00013553946,0.0025936945],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99526227,0.00040487293,0.0020098346,0.0011491502,0.0004185222,0.0007553468],"domain_scores_gemma":[0.9969634,0.0005888198,0.00069798424,0.00068838446,0.00045729874,0.0006041222],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038652524,0.00071729714,0.00336692,0.00049459736,0.00015641865,0.000117778975,0.00020417842,0.00016571148,0.00031337253],"category_scores_gemma":[0.00016959883,0.00054180797,0.000620436,0.0009424675,0.0005655071,0.0001992109,0.00020194807,0.000612022,0.000011689698],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027751675,0.0007659853,0.032057364,0.042400185,0.0011696371,0.00012184458,0.00059651793,0.000006368163,0.000004606659,0.00018469887,0.0010162387,0.92139906],"study_design_scores_gemma":[0.009072367,0.000994975,0.029134369,0.0703342,0.015224322,0.0001180334,0.00054178457,0.0000746476,0.000017840102,0.001414999,0.8713985,0.0016739537],"about_ca_topic_score_codex":0.00036636516,"about_ca_topic_score_gemma":0.00015499485,"teacher_disagreement_score":0.91972506,"about_ca_system_score_codex":0.00043029926,"about_ca_system_score_gemma":0.006380564,"threshold_uncertainty_score":0.99970335},"labels":[],"label_agreement":null},{"id":"W3122929327","doi":"10.1016/j.urolonc.2020.12.006","title":"Defining oligometastatic hormone sensitive prostate cancer and clinically significant outcomes: Implications on clinical trials?","year":2021,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Hormone therapy; Clinical trial; Androgen deprivation therapy; Oncology; Clinical Practice; Internal medicine; Medical physics; Cancer; Family medicine; Breast cancer","score_opus":0.15644910506767903,"score_gpt":0.48406610435500197,"score_spread":0.3276169992873229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122929327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9237802,0.0032415423,0.000046876987,0.07033634,0.0001617672,0.0007535007,0.00021516572,0.000057043417,0.0014075469],"genre_scores_gemma":[0.83383393,0.060266227,0.076239005,0.022583883,0.00032003384,0.0009681061,0.0006337383,0.00005908423,0.0050960146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99694854,0.00084576965,0.0009856239,0.0006530681,0.00018043599,0.0003865784],"domain_scores_gemma":[0.99381715,0.0047982037,0.00033165482,0.00026813752,0.00024196644,0.0005428837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025386047,0.00023736035,0.0010236673,0.00013692905,0.0003298823,0.000044124572,0.00005587115,0.00025363077,0.000041390103],"category_scores_gemma":[0.0037089575,0.00016463488,0.00014431858,0.00033399762,0.0011367967,0.00007042156,0.00007786641,0.00067975814,0.000023837774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008456711,0.0006303399,0.95027125,0.000036705023,0.0005611585,0.0005247543,0.0005527702,0.0000132011755,0.0010522637,0.010125864,0.0040105963,0.03137545],"study_design_scores_gemma":[0.012345637,0.01623187,0.64311826,0.00025469903,0.002798874,0.0005474541,0.002330519,0.00063289027,0.00076441735,0.017205063,0.30313435,0.0006359241],"about_ca_topic_score_codex":0.000036242793,"about_ca_topic_score_gemma":0.000016220594,"teacher_disagreement_score":0.30715296,"about_ca_system_score_codex":0.00011524955,"about_ca_system_score_gemma":0.0013767837,"threshold_uncertainty_score":0.67136157},"labels":[],"label_agreement":null},{"id":"W3124546863","doi":"10.1200/jco.20.03256","title":"Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Ottawa Hospital; University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Docetaxel; Prostate cancer; Abiraterone acetate; Guideline; Oncology; Androgen deprivation therapy; Internal medicine; Cancer; Clinical trial; Radiation therapy; Management of prostate cancer; Gynecology; Pathology","score_opus":0.22149227194068663,"score_gpt":0.5749504827356309,"score_spread":0.3534582107949442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124546863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9337688,0.017968165,0.0003598131,0.035828847,0.003833531,0.000959563,0.00014794133,0.00001790452,0.007115449],"genre_scores_gemma":[0.6092141,0.26061934,0.11349803,0.003807245,0.002154921,0.00007599257,0.00012449166,0.000088766144,0.01041708],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953665,0.00037684973,0.0031051,0.00025001608,0.0005664481,0.00033504283],"domain_scores_gemma":[0.9958344,0.00048172535,0.0016627169,0.00023258377,0.0014003977,0.00038815496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022514905,0.00016784544,0.0015330539,0.00009419899,0.000039966606,0.000009471869,0.00016045531,0.000119853474,0.000788992],"category_scores_gemma":[0.0005902217,0.00010383978,0.00042713276,0.00033853782,0.00024976808,0.00013659886,0.00011173794,0.0007436312,0.000014795438],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03377062,0.0028464631,0.0034645777,0.00046504298,0.0025307527,0.017624237,0.00007077794,0.00006317481,0.00023299266,0.00015143135,0.009943947,0.928836],"study_design_scores_gemma":[0.071163505,0.035060138,0.022656724,0.0022195207,0.0036032419,0.0016523565,0.0014294946,0.00025124324,0.0063504823,0.0014096263,0.8538631,0.00034055975],"about_ca_topic_score_codex":0.000010106207,"about_ca_topic_score_gemma":0.000043466775,"teacher_disagreement_score":0.9284954,"about_ca_system_score_codex":0.00018442242,"about_ca_system_score_gemma":0.004080524,"threshold_uncertainty_score":0.8638909},"labels":[],"label_agreement":null},{"id":"W3125008730","doi":"10.1093/ehjcvp/pvab005","title":"The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer","year":2021,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; Population Health Research Institute; Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre; Hamilton Health Sciences; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Goserelin; Adverse effect; Internal medicine; Gonadotropin-releasing hormone antagonist; Hormone antagonist; Testosterone (patch); Gonadotropin-releasing hormone; Androgen deprivation therapy; Oncology; Agonist; Endocrinology; Antagonist; Hormone; Cancer; Receptor; Luteinizing hormone","score_opus":0.043209260730617864,"score_gpt":0.3677541840522094,"score_spread":0.3245449233215915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125008730","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007424652,0.99514395,0.000037314927,0.0001546617,0.0003987721,0.0030022608,0.000023253417,0.000037169095,0.00046014966],"genre_scores_gemma":[0.00020417638,0.9971191,0.00013977804,0.00006586921,0.001254228,0.0001739504,0.000032963388,0.00036709112,0.00064283767],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99090666,0.004313751,0.0011057268,0.0007835203,0.0018933901,0.0009969565],"domain_scores_gemma":[0.9972775,0.00025593292,0.00035170652,0.0012103589,0.00045611148,0.00044836244],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002469816,0.0008442157,0.004262487,0.00039921704,0.00043497916,0.0002092897,0.00043405726,0.00012880191,0.000021494376],"category_scores_gemma":[0.00004765607,0.0004741345,0.006203344,0.0010848048,0.00031670986,0.00014276219,0.0001081471,0.0020061587,0.000017880306],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053075585,0.00016341412,0.0000721196,0.007940014,0.04393846,0.010060731,0.00023633691,0.000107045096,0.00022130221,0.000001035223,0.0018621559,0.9348666],"study_design_scores_gemma":[0.008148444,0.00039691545,0.0005585957,0.020850506,0.0068706553,0.0044553783,0.00003656372,0.000004975948,0.0003114462,7.833097e-7,0.95789087,0.00047488592],"about_ca_topic_score_codex":0.000092437265,"about_ca_topic_score_gemma":0.0000010244254,"teacher_disagreement_score":0.9560287,"about_ca_system_score_codex":0.0007515095,"about_ca_system_score_gemma":0.0016184162,"threshold_uncertainty_score":0.99977106},"labels":[],"label_agreement":null},{"id":"W3125247993","doi":"10.3390/cancers13030430","title":"Effective Prediction of Prostate Cancer Recurrence through the IQGAP1 Network","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital","funders":"Canadian Cancer Society; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Prostate cancer; DU145; Tramp; PTEN; LNCaP; Medicine; Oncology; Biochemical recurrence; Gene signature; Cancer research; Cancer; Internal medicine; Biology; Prostatectomy; Gene; Gene expression; Signal transduction; PI3K/AKT/mTOR pathway","score_opus":0.027661898748887314,"score_gpt":0.3367257389326205,"score_spread":0.3090638401837332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125247993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8619414,0.10489124,0.00019831535,0.0063854977,0.0027979044,0.0031316353,0.00040535195,0.00010231502,0.02014636],"genre_scores_gemma":[0.9778949,0.016251763,0.00013734202,0.00040297423,0.00060220837,0.0006835127,0.000070202725,0.000021176356,0.0039359285],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99897105,0.00007467703,0.00015823974,0.00024406212,0.0002662069,0.0002857882],"domain_scores_gemma":[0.9992358,0.00009016735,0.00007278119,0.00025966973,0.00027948443,0.00006208949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012235406,0.00010888756,0.00021040378,0.000015248616,0.00011440227,0.00001055644,0.00006461735,0.00004982866,0.0001795527],"category_scores_gemma":[0.00004906687,0.00006772874,0.00008065948,0.00049964077,0.00021845309,0.00007591896,0.00003983024,0.00021375187,0.00000542622],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050773555,0.00019828523,0.43658003,0.0018373225,0.0026142704,0.00032769135,0.019318288,0.017391266,0.013299245,0.0015480866,0.24876377,0.25304437],"study_design_scores_gemma":[0.014679474,0.0026253152,0.28359044,0.0055235713,0.0013078765,0.0001517535,0.0047516543,0.0032515451,0.2969555,0.004108429,0.38241157,0.00064287765],"about_ca_topic_score_codex":0.00064964785,"about_ca_topic_score_gemma":0.00011120561,"teacher_disagreement_score":0.28365624,"about_ca_system_score_codex":0.0009611228,"about_ca_system_score_gemma":0.0014931378,"threshold_uncertainty_score":0.27618977},"labels":[],"label_agreement":null},{"id":"W3125752559","doi":"10.31083/jomh.2021.014","title":"The molecule that makes prostate cancer easy to find shows why it will be so difficult to cure","year":2021,"lang":"en","type":"article","venue":"Journal of Men s Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eagle Ridge Hospital; University of British Columbia","funders":"","keywords":"Prostate cancer; Prostate; Semen; Sperm; Cancer; Medicine; Biology; Internal medicine; Andrology","score_opus":0.050714520948889674,"score_gpt":0.3991457695173557,"score_spread":0.348431248568466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125752559","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.106968075,0.023627823,0.0001152045,0.86628586,0.00043143838,0.00096577755,0.00007266224,0.000012264628,0.0015208841],"genre_scores_gemma":[0.47625613,0.1382763,0.0044684457,0.21875812,0.0033295848,0.0003253259,0.000057477046,0.00022756855,0.15830104],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977936,0.00015072957,0.00041779524,0.00020044473,0.000877084,0.0005603291],"domain_scores_gemma":[0.99810004,0.00007894665,0.00019553659,0.00025137467,0.000544675,0.00082939916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008037666,0.00015475991,0.00040664294,0.0000974515,0.00034219492,0.00010454518,0.00015901972,0.00004690463,0.0001612304],"category_scores_gemma":[0.00009158072,0.00008571945,0.0001197855,0.00032269835,0.000046221136,0.00011157686,0.00007354999,0.0004094917,0.00001050917],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028640714,0.00036128183,0.0154904025,0.00037391644,0.0004999574,0.0010069241,0.011162351,0.0001152645,0.005031969,0.00009281895,0.90559906,0.057401974],"study_design_scores_gemma":[0.0023151382,0.0015763442,0.0030954054,0.00074637553,0.000053908727,0.0002086918,0.0032361767,0.000022078593,0.009362543,0.00006036799,0.9792069,0.000116032585],"about_ca_topic_score_codex":0.00023088425,"about_ca_topic_score_gemma":0.00072696985,"teacher_disagreement_score":0.64752775,"about_ca_system_score_codex":0.00063772086,"about_ca_system_score_gemma":0.0027282063,"threshold_uncertainty_score":0.48397207},"labels":[],"label_agreement":null},{"id":"W3126274126","doi":"10.1038/s41391-020-00310-3","title":"Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors","year":2021,"lang":"en","type":"review","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Bayer HealthCare","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Androgen deprivation therapy; Internal medicine; Androgen receptor; Disease; Adverse effect; Cancer","score_opus":0.059184624419738714,"score_gpt":0.3692282572156028,"score_spread":0.3100436327958641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126274126","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00805625,0.9654103,6.630336e-7,0.00048958167,0.00045775526,0.0071015363,0.018290713,0.00006623216,0.00012700252],"genre_scores_gemma":[0.0021899138,0.9790128,0.00013160476,0.00004888826,0.00041394425,0.0074299853,0.0056469133,0.00018218716,0.0049437755],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953381,0.0003072721,0.0014133324,0.0013154537,0.0008128465,0.00081303297],"domain_scores_gemma":[0.9971481,0.00027753806,0.0007926672,0.00062520197,0.00045792098,0.0006985875],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013862306,0.001116992,0.0031176417,0.00044635445,0.00028422705,0.00019248704,0.00012107126,0.00021846696,0.00070926367],"category_scores_gemma":[0.0000639373,0.00077828945,0.0006589684,0.0007547476,0.0003694115,0.00021508761,0.000064015585,0.00027623682,0.00001665242],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010722477,0.0011013336,0.0008289259,0.031467468,0.002096904,0.00027828186,0.0013988264,0.000006389479,0.00020381552,0.00006006069,0.0019439309,0.9595418],"study_design_scores_gemma":[0.009887307,0.007479399,0.00020314501,0.034010954,0.010942294,0.000081143786,0.00060793874,0.000048401347,0.00422935,0.000121893914,0.9307489,0.0016393195],"about_ca_topic_score_codex":0.00035169604,"about_ca_topic_score_gemma":0.00018913613,"teacher_disagreement_score":0.9579025,"about_ca_system_score_codex":0.0010682747,"about_ca_system_score_gemma":0.0044841105,"threshold_uncertainty_score":0.9994668},"labels":[],"label_agreement":null},{"id":"W3126881335","doi":"10.1038/s41391-021-00322-7","title":"ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development","year":2021,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Prevention of Organ Failure; BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Prostate cancer; Transcriptome; Androgen deprivation therapy; Androgen receptor; Gene knockdown; Gene expression profiling; Medicine; Oncology; Biology; Cancer research; Gene; Bioinformatics; Cancer; Gene expression; Internal medicine; Genetics","score_opus":0.022490576941124545,"score_gpt":0.3309283767807692,"score_spread":0.30843779983964464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126881335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9252924,0.068658836,0.0000026464154,0.0033053204,0.00009688721,0.0017550554,0.00070534984,0.000043993277,0.00013953423],"genre_scores_gemma":[0.96963054,0.021966869,0.00038450767,0.0005955531,0.00006163684,0.0020383564,0.0001872005,0.000053915755,0.005081393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973171,0.000077324825,0.0005715255,0.000799935,0.0005780069,0.0006561279],"domain_scores_gemma":[0.9986893,0.00007460939,0.00013866869,0.00025285836,0.00029769578,0.0005468573],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014085899,0.00038316543,0.00052043924,0.00016366177,0.00023668859,0.00018259895,0.00005966932,0.0000757241,0.0002883191],"category_scores_gemma":[0.000050517294,0.00030220766,0.00006617592,0.00037150676,0.00019744737,0.000290348,0.00012714465,0.00022889997,0.000004447803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036306386,0.0006672525,0.850569,0.0033362494,0.00031332843,0.0007743968,0.016539546,0.00001965449,0.023062536,0.000070854796,0.001066015,0.099950515],"study_design_scores_gemma":[0.00945618,0.0004766203,0.93005896,0.0044984086,0.0002505115,0.000031686235,0.001715476,0.00012588802,0.042426445,0.0010095928,0.009305375,0.0006448633],"about_ca_topic_score_codex":0.0008884363,"about_ca_topic_score_gemma":0.00030135954,"teacher_disagreement_score":0.09930565,"about_ca_system_score_codex":0.000377312,"about_ca_system_score_gemma":0.0020572224,"threshold_uncertainty_score":0.999943},"labels":[],"label_agreement":null},{"id":"W3128166013","doi":"10.3390/genes12020257","title":"Differential Expression of a Panel of Ten CNTN1-Associated Genes during Prostate Cancer Progression and the Predictive Properties of the Panel towards Prostate Cancer Relapse","year":2021,"lang":"en","type":"article","venue":"Genes","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital","funders":"Canadian Cancer Society; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Prostate cancer; LNCaP; Cancer research; Oncology; Biochemical recurrence; Cancer; Medicine; Hazard ratio; Internal medicine; Biology; Prostatectomy; Confidence interval","score_opus":0.038062952289899685,"score_gpt":0.29352848360002065,"score_spread":0.25546553131012095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128166013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9484842,0.048427265,7.553405e-7,0.0011529833,0.00016780786,0.001495461,0.00021933553,0.000018924708,0.000033281816],"genre_scores_gemma":[0.972488,0.024410587,0.00002056906,0.000010819108,0.000067607194,0.00060354656,0.000018766623,0.000028630728,0.0023514745],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99810797,0.0002320925,0.0004245621,0.00031237805,0.0006180999,0.00030489004],"domain_scores_gemma":[0.9985953,0.000033496464,0.0003645492,0.0003228478,0.0006139828,0.00006979847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016515801,0.0002071341,0.00052704586,0.000057354082,0.00017680145,0.000014876468,0.00013662045,0.000099815305,0.000038065384],"category_scores_gemma":[0.0000894691,0.0000902717,0.00013846363,0.00028980084,0.0006888446,0.00007792772,0.00032495832,0.00017534217,1.3649225e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005015949,0.0002210521,0.18775198,0.0013503544,0.00037087646,0.000009249489,0.008828613,0.000041912343,0.78300136,0.0000026914365,0.00002872122,0.01337723],"study_design_scores_gemma":[0.004857902,0.00014284535,0.20394725,0.0024881354,0.00025667073,0.0000057125285,0.0011894701,0.00018301683,0.7867984,0.00002326134,0.000026125674,0.000081205224],"about_ca_topic_score_codex":0.00071157306,"about_ca_topic_score_gemma":0.00009284601,"teacher_disagreement_score":0.024016678,"about_ca_system_score_codex":0.00010742905,"about_ca_system_score_gemma":0.00071556953,"threshold_uncertainty_score":0.3681173},"labels":[],"label_agreement":null},{"id":"W3128320272","doi":"10.5489/cuaj.7160","title":"UPDATE – 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) castration-resistant prostate cancer (CRPC) guideline: What has changed since 2019?","year":2021,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma; Sanofi; Amgen","keywords":"Guideline; Prostate cancer; Medicine; Internal medicine; Oncology; Gynecology; Urology; Cancer; Family medicine; Pathology","score_opus":0.03139039771769743,"score_gpt":0.30088881358452296,"score_spread":0.26949841586682555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128320272","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12090647,0.009486409,0.000014972163,0.8608314,0.0026091062,0.0013664849,0.0015642489,0.000057859463,0.0031630918],"genre_scores_gemma":[0.9354521,0.010714946,0.0004905198,0.04098411,0.0025197421,0.00020893945,0.002658512,0.00008106703,0.0068900855],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.993223,0.0009940298,0.0011454406,0.0008434409,0.0011357327,0.0026583436],"domain_scores_gemma":[0.9909756,0.00033379364,0.000696971,0.0003466881,0.0024160307,0.005230886],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023955961,0.0005043263,0.0008875078,0.0007654507,0.0017993972,0.0011088547,0.0003456129,0.0012776582,0.0075897626],"category_scores_gemma":[0.0021520432,0.00044293763,0.00035288482,0.0010803457,0.00013458537,0.00065701606,0.000047519825,0.0018881052,0.00036510287],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0006637011,0.00030687646,0.44647744,0.000028107494,0.0014577291,0.009829774,0.00076989905,0.0002235946,0.0020910678,0.00047348088,0.51013696,0.027541373],"study_design_scores_gemma":[0.0028110605,0.0006964978,0.19786404,0.000056058147,0.00027397374,0.0002665912,0.00038404492,0.00024718582,0.00009220981,0.00045016143,0.7964185,0.00043971435],"about_ca_topic_score_codex":0.49105605,"about_ca_topic_score_gemma":0.96598756,"teacher_disagreement_score":0.8198472,"about_ca_system_score_codex":0.028434807,"about_ca_system_score_gemma":0.026011465,"threshold_uncertainty_score":0.9999281},"labels":[],"label_agreement":null},{"id":"W3128439966","doi":"10.26434/chemrxiv.13064186.v3","title":"Identifying Potential Off-Target Protein Binders of Glutamate-Ureido-Lysine, a Prostate Cancer Specific Imaging Agent","year":2020,"lang":"en","type":"preprint","venue":"ChemRxiv","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Windsor","funders":"Canadian Institutes of Health Research; Government of Ontario; Compute Canada; Natural Sciences and Engineering Research Council of Canada; Windsor Cancer Centre Foundation","keywords":"Prostate cancer; Glutamate carboxypeptidase II; Cancer research; Chemistry; Lysine; Prostate; Computational biology; Biology; Cancer; Cell biology; Biochemistry; Medicine; Amino acid; Internal medicine","score_opus":0.047369754109590136,"score_gpt":0.3259133787967173,"score_spread":0.2785436246871271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128439966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9435635,0.038104217,0.00068072136,0.009829219,0.0010662407,0.005026836,0.00013965864,0.0002650834,0.0013245005],"genre_scores_gemma":[0.98821425,0.0051979115,0.0020661242,0.0001166608,0.0006592989,0.00072385353,0.00051146257,0.00015241225,0.0023580429],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99633455,0.000075483695,0.0007515782,0.0011209341,0.0009754212,0.0007420387],"domain_scores_gemma":[0.9979612,0.000015647853,0.00047545455,0.00074688287,0.00040768913,0.00039309415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028849716,0.00058966584,0.001045777,0.0003411903,0.00012176251,0.00012783507,0.00037614172,0.00024032396,0.00064693525],"category_scores_gemma":[0.00004090709,0.0005070528,0.0005187288,0.00044943093,0.0003076209,0.000111611575,0.00073200563,0.0011476933,0.000058379836],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032719267,0.0006803152,0.028834967,0.013700242,0.002144203,0.0022669635,0.0030711235,0.00028136245,0.91723,0.000040892945,0.010004359,0.018473616],"study_design_scores_gemma":[0.0058315457,0.00016466966,0.011734969,0.0054287184,0.00071907963,0.000035066623,0.0008066352,0.002500301,0.9636146,0.0018026234,0.006379893,0.0009819007],"about_ca_topic_score_codex":0.00023091956,"about_ca_topic_score_gemma":0.0000047933127,"teacher_disagreement_score":0.04638457,"about_ca_system_score_codex":0.0005580832,"about_ca_system_score_gemma":0.0010192737,"threshold_uncertainty_score":0.9997381},"labels":[],"label_agreement":null},{"id":"W3129039703","doi":"10.1200/jco.2015.33.7_suppl.248","title":"International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Orchiectomy; Radiation therapy; Internal medicine; Gynecology; Urology; Oncology; Cancer","score_opus":0.3006676408482751,"score_gpt":0.5581479475104603,"score_spread":0.2574803066621852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129039703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900005,0.0014376667,0.00015599832,0.0065539763,0.0009101036,0.0005355885,0.00006347049,0.000002050981,0.00034067902],"genre_scores_gemma":[0.98808557,0.0094190035,0.001223034,0.00057583116,0.00028736403,0.000027101485,0.00003011927,0.000011453352,0.00034053143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977907,0.00023285054,0.0013613517,0.00011008211,0.00035548775,0.00014954424],"domain_scores_gemma":[0.99568367,0.0015316212,0.0009131721,0.000080500904,0.0015827193,0.00020832321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056753336,0.00007512306,0.00076677586,0.0001579455,0.000010899669,0.0000057227107,0.00011926783,0.00010766244,0.00006404699],"category_scores_gemma":[0.0030988166,0.0000483243,0.00012681235,0.00014709204,0.00013798398,0.000102909806,0.000021219857,0.00027890812,0.000002137712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02812519,0.00090961455,0.8727941,0.00003002235,0.00041980256,0.00007816616,0.00030463398,0.000056026463,0.00006598247,0.000010510664,0.0053746495,0.091831304],"study_design_scores_gemma":[0.045969654,0.010150707,0.86431944,0.00011685073,0.00007239165,0.000038127753,0.00012351641,0.0006543281,0.0006262388,0.00052880263,0.07732923,0.00007069163],"about_ca_topic_score_codex":0.00033429064,"about_ca_topic_score_gemma":0.00026159597,"teacher_disagreement_score":0.09176061,"about_ca_system_score_codex":0.00030656808,"about_ca_system_score_gemma":0.0052652275,"threshold_uncertainty_score":0.9340288},"labels":[],"label_agreement":null},{"id":"W3129520566","doi":"10.1158/1078-0432.ccr-20-4573","title":"Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":380,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Cancer Institute; National Institutes of Health; Progenics Pharmaceuticals","keywords":"Prostate cancer; Medicine; Cancer; Prostate; Biochemical recurrence; Oncology; Radiology; Internal medicine; Prostatectomy","score_opus":0.14964507020304046,"score_gpt":0.5127410395060567,"score_spread":0.3630959693030162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129520566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807198,0.007864477,3.0750437e-7,0.006637994,0.00018698204,0.0035304974,0.00058388273,0.00002222905,0.0004538522],"genre_scores_gemma":[0.9695565,0.02651633,0.000041314124,0.00014471584,0.00032795334,0.0013767809,0.00021549783,0.00004327989,0.0017775911],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943357,0.0009087537,0.0012666726,0.0010445423,0.0015574618,0.0008868723],"domain_scores_gemma":[0.99144405,0.00566479,0.000205157,0.0009929626,0.00130004,0.00039298288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030659726,0.0002744923,0.0008313131,0.00012613891,0.00017342385,0.000056754096,0.0004513106,0.000034961504,0.00040597265],"category_scores_gemma":[0.0027812228,0.00015898622,0.00013331907,0.0011338096,0.0010154202,0.00010779217,0.00039091214,0.0017433595,0.000020186164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.077678405,0.008320112,0.8634253,0.00023408943,0.0007238716,0.0043467875,0.0019770896,0.000029298237,0.0013951971,0.0000021016933,0.0081634065,0.033704314],"study_design_scores_gemma":[0.31686997,0.019935979,0.5470556,0.008694903,0.00070480694,0.000054937005,0.012332016,0.004669157,0.07810613,0.000049627444,0.010618008,0.0009088471],"about_ca_topic_score_codex":0.005992009,"about_ca_topic_score_gemma":0.0026505687,"teacher_disagreement_score":0.31636968,"about_ca_system_score_codex":0.0004708965,"about_ca_system_score_gemma":0.002765632,"threshold_uncertainty_score":0.9058165},"labels":[],"label_agreement":null},{"id":"W3130535105","doi":"10.1016/j.urology.2020.11.080","title":"A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide","year":2021,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; University Health Network; University of Toronto","funders":"Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences; Astellas Pharma Canada; Princess Margaret Cancer Foundation; Merck; Janssen Pharmaceuticals; Bayer","keywords":"Medicine; Enzalutamide; Abiraterone acetate; Prostate cancer; Hazard ratio; Internal medicine; Population; Abiraterone; Retrospective cohort study; Cohort; Proportional hazards model; Medical record; Cancer; Oncology; Androgen deprivation therapy; Confidence interval","score_opus":0.053084314788000256,"score_gpt":0.36386356058019914,"score_spread":0.3107792457921989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130535105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907597,0.0002877693,0.00015849613,0.0052151307,0.00007499158,0.00309418,0.00029086534,0.00010213524,0.000016790222],"genre_scores_gemma":[0.99422634,0.00008613412,0.00044091707,0.0008110511,0.000027135673,0.001439354,0.001170524,0.0000674086,0.0017311523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969804,0.0002632194,0.0005684376,0.0007680853,0.0006601089,0.00075970666],"domain_scores_gemma":[0.99780446,0.00073136424,0.00024161175,0.00038857898,0.0004977501,0.00033621237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002863723,0.00041624418,0.0010906188,0.00012057832,0.00023337275,0.000041683223,0.00014569459,0.00012691725,0.00029194163],"category_scores_gemma":[0.00039739802,0.00020755714,0.00006317947,0.0004372918,0.00022638611,0.00007490616,0.000055703655,0.00031167903,0.0000046702735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.075636044,0.0030764444,0.9155763,0.0002281173,0.0010392497,0.0025375066,0.00022213986,0.0008294953,0.000036258443,0.0000016030408,0.00020089115,0.00061596057],"study_design_scores_gemma":[0.06436992,0.03452927,0.895764,0.00011840295,0.0012103725,0.000042350737,0.0001373171,0.0023025272,0.00032739103,0.000007747813,0.0008167329,0.00037400585],"about_ca_topic_score_codex":0.0011450408,"about_ca_topic_score_gemma":0.052487597,"teacher_disagreement_score":0.051342554,"about_ca_system_score_codex":0.00031107728,"about_ca_system_score_gemma":0.001460112,"threshold_uncertainty_score":0.964802},"labels":[],"label_agreement":null},{"id":"W3131625900","doi":"10.1016/j.euf.2021.02.003","title":"Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients","year":2021,"lang":"en","type":"article","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Oakville-Trafalgar Memorial Hospital; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Tolerability; Prostate cancer; Urology; Prostate; Antiandrogen; Prostate-specific antigen; Radiation therapy; Adverse effect; Surgery; Internal medicine; Cancer","score_opus":0.02882841669465299,"score_gpt":0.298126175067451,"score_spread":0.269297758372798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131625900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9590788,0.0051916065,0.00035358145,0.005550757,0.0003473463,0.0011639204,0.00013301964,0.000117665295,0.028063303],"genre_scores_gemma":[0.98940253,0.0004609283,0.0003427407,0.00039266175,0.00030489362,0.000027914812,0.0002860908,0.000052685275,0.008729553],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987735,0.0001562033,0.00016439916,0.00040612038,0.00011926324,0.00038052682],"domain_scores_gemma":[0.99920905,0.000087672655,0.000052663276,0.00028101972,0.00016010963,0.00020950692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000749583,0.0001666906,0.00027188266,0.000055089564,0.00009669079,0.000014111677,0.00006680999,0.00004900087,0.000111464535],"category_scores_gemma":[0.000109492226,0.00012603604,0.00013372753,0.00013272656,0.000058555164,0.000033703254,0.000052953903,0.00009275795,0.00017633305],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008436131,0.0019149816,0.29861456,0.00006535524,0.0015724767,0.0029484262,0.0014335435,0.000006062838,0.004087607,0.000116866955,0.014748733,0.66605526],"study_design_scores_gemma":[0.033580042,0.009902425,0.47229803,0.00002741646,0.00031812082,0.00021156085,0.00006472135,0.000042793476,0.056166228,0.00025012717,0.4267511,0.00038741608],"about_ca_topic_score_codex":0.000021340793,"about_ca_topic_score_gemma":0.000045030483,"teacher_disagreement_score":0.66566783,"about_ca_system_score_codex":0.000100783065,"about_ca_system_score_gemma":0.0002837505,"threshold_uncertainty_score":0.51396006},"labels":[],"label_agreement":null},{"id":"W3131780647","doi":"10.2967/jnumed.120.259069","title":"Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide","year":2021,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; McMaster University; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Glutamate carboxypeptidase II; Nuclear medicine; Urology; Prospective cohort study; Prostate-specific antigen; Clinical trial; Internal medicine; Oncology; Cancer; Androgen receptor","score_opus":0.07049986074682199,"score_gpt":0.33784679164600767,"score_spread":0.2673469308991857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131780647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99191993,0.000941716,5.239494e-7,0.004488134,0.00026144134,0.002194442,0.00004982261,0.000024257964,0.00011970544],"genre_scores_gemma":[0.99688643,0.0013474992,0.00035146993,0.00036972176,0.00050831615,0.00005604237,0.00006568413,0.00010166499,0.00031318117],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.995451,0.00029478146,0.0012970597,0.00053796294,0.0017043256,0.0007148747],"domain_scores_gemma":[0.9975537,0.00017139253,0.0007097373,0.00029931194,0.000964038,0.00030181088],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012271723,0.00041121425,0.0010726333,0.0005329285,0.00013983868,0.00006621252,0.00014127296,0.000042683143,0.0012542713],"category_scores_gemma":[0.0004639813,0.00025248947,0.00008267354,0.000918586,0.00016027429,0.0002656802,0.00004552367,0.00089905213,0.000004898432],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52533436,0.006883989,0.31413397,0.00094101886,0.000654484,0.023254639,0.012449302,0.0011930738,0.09682343,0.000008461686,0.00072689366,0.017596368],"study_design_scores_gemma":[0.30730745,0.08174522,0.5688182,0.013608194,0.00029395905,0.00033498107,0.011881655,0.00081522757,0.013066851,0.000029293784,0.001459492,0.0006394326],"about_ca_topic_score_codex":0.00014748603,"about_ca_topic_score_gemma":0.00068903127,"teacher_disagreement_score":0.25468427,"about_ca_system_score_codex":0.0011314272,"about_ca_system_score_gemma":0.0007221354,"threshold_uncertainty_score":0.9999927},"labels":[],"label_agreement":null},{"id":"W3132890685","doi":"10.3390/ijms22041994","title":"The Chemokine Receptor CCR3 Is Potentially Involved in the Homing of Prostate Cancer Cells to Bone: Implication of Bone-Marrow Adipocytes","year":2021,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fondation de France; Ligue Contre le Cancer; CNIB","keywords":"Prostate cancer; Homing (biology); Bone marrow; Bone metastasis; Cancer research; Metastasis; CCL7; Chemokine receptor; Tumor microenvironment; Bone remodeling; Chemokine; CCR3; Medicine; Cancer; Biology; Pathology; Receptor; Internal medicine","score_opus":0.019100483373508278,"score_gpt":0.3350922346581889,"score_spread":0.3159917512846806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132890685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624507,0.0059869573,0.000093248316,0.030894171,0.00023378004,0.00016487541,0.000014004998,0.0000011222496,0.00016115292],"genre_scores_gemma":[0.996174,0.0022234411,0.00095955946,0.0004224207,0.000060545008,0.000009967565,0.0000026491036,0.000004249136,0.00014319552],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99823654,0.00006496218,0.00041232194,0.00012096655,0.0010317701,0.0001334297],"domain_scores_gemma":[0.9984519,0.00009232839,0.0003104333,0.000110431516,0.000986466,0.00004844848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000913572,0.00006645371,0.0001584263,0.00015475848,0.000050422423,0.00005164327,0.0003534294,0.000022819011,0.000034364573],"category_scores_gemma":[0.00015341364,0.000035761142,0.00010594861,0.00041114073,0.00018949712,0.00009577818,0.00006220586,0.00011736687,0.0000011186568],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026944882,0.00010859363,0.005840172,0.000016415228,0.00010346575,0.000080572405,0.0012600733,0.00012844277,0.976108,0.00010766531,0.00057530496,0.015401832],"study_design_scores_gemma":[0.0008166045,0.00020686116,0.0057697683,0.0002577064,0.000025705485,0.000045924135,0.00093834935,0.000058127283,0.98972124,0.00024327426,0.0018777391,0.000038730403],"about_ca_topic_score_codex":0.00007310703,"about_ca_topic_score_gemma":0.00003496017,"teacher_disagreement_score":0.033723284,"about_ca_system_score_codex":0.00008284568,"about_ca_system_score_gemma":0.00063923927,"threshold_uncertainty_score":0.1458297},"labels":[],"label_agreement":null},{"id":"W3132915896","doi":"10.3390/cancers13040831","title":"p38 MAPK Inhibition Mitigates Hypoxia-Induced AR Signaling in Castration-Resistant Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Terry Fox Research Institute; Prostate Cancer Canada","keywords":"Hsp27; Prostate cancer; Cancer research; p38 mitogen-activated protein kinases; MAPK/ERK pathway; Androgen receptor; Heat shock protein; Kinase; Biology; Internal medicine; Chemistry; Medicine; Cell biology; Hsp70; Cancer; Biochemistry","score_opus":0.039422206957974146,"score_gpt":0.32455470126055597,"score_spread":0.2851324943025818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132915896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908578,0.0044267206,0.0000017480329,0.0024096011,0.00021922294,0.0005214101,0.000065688546,0.00004293123,0.0014549091],"genre_scores_gemma":[0.9954189,0.0012106191,0.00015998245,0.00037496514,0.00018668303,0.0002960366,0.00017035073,0.00003014277,0.0021522855],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985109,0.000050875537,0.00028310818,0.00039541212,0.00032802217,0.00043170407],"domain_scores_gemma":[0.9992996,0.000040641324,0.00006523631,0.00018976713,0.00022634726,0.00017844346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012787337,0.0001728831,0.0002724138,0.0001291111,0.00009532071,0.000045893477,0.0000378307,0.00008624569,0.00039761988],"category_scores_gemma":[0.00004390316,0.00015470789,0.000075658914,0.0005240369,0.000072580035,0.00013701514,0.000022933651,0.0002558221,0.000018340688],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005128551,0.00003981927,0.006151021,0.0002254516,0.00008218227,0.0010514982,0.0010067571,0.00040291197,0.98632234,0.000054599743,0.0006525679,0.003497983],"study_design_scores_gemma":[0.003973613,0.00020802309,0.012465955,0.0010008038,0.00006232915,0.000021972244,0.0017762706,0.0001976358,0.9783103,0.00021895174,0.0015391612,0.00022500353],"about_ca_topic_score_codex":0.0014765045,"about_ca_topic_score_gemma":0.0014975325,"teacher_disagreement_score":0.008012071,"about_ca_system_score_codex":0.0025450368,"about_ca_system_score_gemma":0.0031626902,"threshold_uncertainty_score":0.6655183},"labels":[],"label_agreement":null},{"id":"W3133576337","doi":"10.1200/jco.2021.39.6_suppl.12","title":"CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Docetaxel; Prostate cancer; Internal medicine; Nivolumab; Oncology; Abiraterone acetate; Chemotherapy; Cancer; Prednisone; Androgen deprivation therapy; Immunotherapy; Androgen receptor","score_opus":0.17478267805292091,"score_gpt":0.5093775652134046,"score_spread":0.3345948871604837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133576337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97847015,0.007215573,0.0003294153,0.012689785,0.0002821746,0.0006052291,0.00008923694,0.000005656757,0.00031276626],"genre_scores_gemma":[0.9792714,0.011379581,0.00687744,0.00046756028,0.00033324797,0.000024558705,0.00002996393,0.000016845423,0.0015994168],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99665356,0.0002678463,0.002130788,0.00026044823,0.00039826904,0.00028911044],"domain_scores_gemma":[0.99532896,0.0015401213,0.0014305726,0.00018448706,0.0011910736,0.00032477753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020928395,0.00016042197,0.0019774823,0.00017049817,0.00006808365,0.000016558572,0.00009731686,0.00015178228,0.00019506193],"category_scores_gemma":[0.0011410604,0.000109693676,0.00060913083,0.00042521147,0.0002902226,0.000089140914,0.000031898,0.00047347517,9.409834e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28813463,0.0117258085,0.050307017,0.0018502556,0.04679149,0.0034842838,0.0025851757,0.001236093,0.01530205,0.00055082515,0.0040334268,0.5739989],"study_design_scores_gemma":[0.21263936,0.046709895,0.64365804,0.00088754494,0.022587962,0.0005833315,0.0018403961,0.0036614318,0.01201713,0.0014307707,0.053477254,0.0005068762],"about_ca_topic_score_codex":0.000048235914,"about_ca_topic_score_gemma":0.00020244003,"teacher_disagreement_score":0.593351,"about_ca_system_score_codex":0.00024820617,"about_ca_system_score_gemma":0.005087714,"threshold_uncertainty_score":0.90253866},"labels":[],"label_agreement":null},{"id":"W3133638241","doi":"10.1200/jco.2021.39.6_suppl.133","title":"Real-world comparison of abiraterone (A) versus enzalutamide (E) for first-line therapy of metastatic castration-resistant prostate cancer (mCRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Abiraterone acetate; Abiraterone; Cohort; Internal medicine; Log-rank test; Exact test; Oncology; Androgen deprivation therapy; Retrospective cohort study; Docetaxel; Cancer; Survival analysis; Androgen receptor","score_opus":0.36925050314898716,"score_gpt":0.5771850649322998,"score_spread":0.20793456178331265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133638241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98500884,0.005380321,0.00006519393,0.00753274,0.0009298888,0.00052733015,0.00007484272,0.0000043888913,0.00047648727],"genre_scores_gemma":[0.97792846,0.015995696,0.004598533,0.00012186839,0.00038115887,0.000028415128,0.000024437326,0.000020793364,0.0009006559],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996125,0.00029331984,0.0026884114,0.00018828885,0.00045405948,0.000250944],"domain_scores_gemma":[0.9928423,0.0030799557,0.0020093948,0.00019522983,0.0016429672,0.00023012597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016717279,0.00014344411,0.0018739419,0.00013820849,0.000043721895,0.000006616889,0.00011416522,0.00012332936,0.0002019976],"category_scores_gemma":[0.0010285778,0.0000954002,0.00046086268,0.00026307066,0.00028019823,0.000079431746,0.000026943688,0.0004385634,0.0000011222672],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35459414,0.015321885,0.15917246,0.0013436624,0.008482062,0.0010913118,0.0018345431,0.0009355104,0.07249648,0.00067795016,0.0072263987,0.3768236],"study_design_scores_gemma":[0.1910289,0.13058387,0.317636,0.0013916594,0.0028027417,0.00006382251,0.0018369793,0.0013523268,0.25579527,0.0016671472,0.095412605,0.0004286677],"about_ca_topic_score_codex":0.00014966339,"about_ca_topic_score_gemma":0.0019925272,"teacher_disagreement_score":0.37639493,"about_ca_system_score_codex":0.00021594654,"about_ca_system_score_gemma":0.0040353774,"threshold_uncertainty_score":0.71585864},"labels":[],"label_agreement":null},{"id":"W3133767883","doi":"10.1200/jco.2021.39.6_suppl.tps180","title":"UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naïve prostate cancer (mHNPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Cabazitaxel; Androgen deprivation therapy; Oncology; Cancer; Internal medicine; Prostate; Nuclear medicine; Urology","score_opus":0.2086462485145681,"score_gpt":0.5499936979897206,"score_spread":0.34134744947515255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133767883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759134,0.016716782,0.000016847065,0.0044998275,0.001073573,0.0012629788,0.000024746329,0.0000062815143,0.00048557695],"genre_scores_gemma":[0.98165697,0.015911171,0.00089415984,0.00019128292,0.00037066193,0.00007003657,0.000009259303,0.000023565293,0.0008728724],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99346614,0.0017826665,0.0032768718,0.00036681013,0.0006932985,0.0004142141],"domain_scores_gemma":[0.99386925,0.0027983573,0.0017105109,0.00024613598,0.00091954326,0.00045622516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005538153,0.0002445482,0.0037906773,0.00027603924,0.000071447634,0.000017707547,0.00014727926,0.00020224763,0.00018003002],"category_scores_gemma":[0.0041830665,0.00015886225,0.00053126295,0.00037265843,0.0005354785,0.00019105972,0.00017575336,0.0011843984,0.0000022461302],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8736087,0.024195904,0.008045124,0.00014115346,0.0053032376,0.008845764,0.0031126805,0.00003685421,0.001396745,0.000038509683,0.0012542617,0.07402108],"study_design_scores_gemma":[0.9302632,0.051514287,0.008313255,0.00017150077,0.0030431943,0.00021871713,0.0026484176,0.00029817878,0.0004689561,0.00028708807,0.0026127226,0.00016044384],"about_ca_topic_score_codex":0.00029070853,"about_ca_topic_score_gemma":0.00056920183,"teacher_disagreement_score":0.07386064,"about_ca_system_score_codex":0.0002642918,"about_ca_system_score_gemma":0.004165306,"threshold_uncertainty_score":0.73890746},"labels":[],"label_agreement":null},{"id":"W3133928665","doi":"10.20944/preprints202102.0605.v1","title":"Molecular Profiles of Prostate Cancer in Men of Middle Eastern Ancestry Identifies Key Differences with Western Populations: A Multiethnic SNP Array Study","year":2021,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Toronto","funders":"National Institutes of Health; Prostate Cancer Canada; National Cancer Institute; Prostate Cancer Foundation","keywords":"Prostate cancer; Biology; Cancer; Genetics; Copy-number variation; SNP; Genome; Gene duplication; Copy number analysis; SNP array; Oncology; Gene; Single-nucleotide polymorphism; Medicine; Genotype","score_opus":0.25334204584389447,"score_gpt":0.4244769702046471,"score_spread":0.17113492436075262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133928665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99155396,0.003861539,0.000011341384,0.00019817107,0.00014941828,0.0037334738,0.00007850892,0.00003616068,0.0003774447],"genre_scores_gemma":[0.9953019,0.0010514115,0.000119681274,0.000006801884,0.00003347341,0.0015738403,0.00011134715,0.000048121245,0.0017534093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996688,0.00026850103,0.00084281707,0.0009682558,0.00085486134,0.00037755212],"domain_scores_gemma":[0.99773157,0.000041495692,0.00056558155,0.0010337431,0.0005054843,0.00012212759],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038779035,0.00040683747,0.0010821671,0.00030856946,0.000038518323,0.000024107763,0.0003550737,0.00018860049,0.0001150999],"category_scores_gemma":[0.0000788409,0.00031118124,0.0001515429,0.00035777662,0.00025950425,0.00012197554,0.00067022856,0.0006778775,0.000006845897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008619676,0.0014967878,0.9508692,0.0026438131,0.0007017396,0.0001356857,0.016708722,0.00058363535,0.025775226,0.0000010459353,5.1050756e-7,0.00022166617],"study_design_scores_gemma":[0.0023997482,0.00019869686,0.86476254,0.004965135,0.00024508403,0.0000031883071,0.00696484,0.00006789704,0.12010917,0.000054443542,0.0000011773944,0.00022808317],"about_ca_topic_score_codex":0.005163018,"about_ca_topic_score_gemma":0.0023995326,"teacher_disagreement_score":0.09433395,"about_ca_system_score_codex":0.00017875418,"about_ca_system_score_gemma":0.000736685,"threshold_uncertainty_score":0.999934},"labels":[],"label_agreement":null},{"id":"W3133949928","doi":"10.1016/j.eururo.2021.02.031","title":"Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis","year":2021,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Mount Sinai Hospital; McMaster University; Centre for Probe Development and Commercialization; Women's College Hospital","funders":"Terry Fox Research Institute; University of Toronto; Princess Margaret Cancer Foundation; AbbVie","keywords":"Medicine; Prostatectomy; Prostate cancer; Clinical endpoint; SABR volatility model; Urology; Radiation therapy; Biochemical recurrence; Metastasis; Prostate-specific antigen; Prostate; Stage (stratigraphy); Androgen deprivation therapy; Phases of clinical research; Oncology; Cancer; Surgery; Internal medicine; Clinical trial; Randomized controlled trial","score_opus":0.0954410268437023,"score_gpt":0.35168373391626456,"score_spread":0.25624270707256225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133949928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9077313,0.032621052,0.0010912088,0.036631767,0.0011620169,0.00924213,0.00073975284,0.00057968625,0.010201095],"genre_scores_gemma":[0.9914792,0.0011315465,0.0024485542,0.0013232902,0.00041491297,0.0014899004,0.00013187023,0.00010875693,0.001471967],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967089,0.0009636202,0.0005034418,0.0007555665,0.00034959917,0.00071885984],"domain_scores_gemma":[0.99745256,0.0007371699,0.00022771122,0.00049874396,0.0009005414,0.00018327507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068599655,0.00038471445,0.0006401657,0.00016200836,0.00055037695,0.00007496954,0.00021747088,0.00005074223,0.00015438035],"category_scores_gemma":[0.0018541615,0.0002384447,0.00031086674,0.0007524201,0.00032265318,0.00007715954,0.00020046296,0.00038915063,0.0000245954],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15056376,0.007333718,0.002039251,0.0002605146,0.008781518,0.0018953189,0.012156109,0.000038785423,0.072172455,0.0010676761,0.0060873786,0.7376035],"study_design_scores_gemma":[0.48723924,0.065487,0.011332121,0.00034962912,0.0067082206,0.00071300205,0.0031333528,0.0024875014,0.13070609,0.0028713874,0.28710446,0.0018680221],"about_ca_topic_score_codex":0.0000370833,"about_ca_topic_score_gemma":0.00002192512,"teacher_disagreement_score":0.7357355,"about_ca_system_score_codex":0.0001574167,"about_ca_system_score_gemma":0.00048964785,"threshold_uncertainty_score":0.9723493},"labels":[],"label_agreement":null},{"id":"W3133986190","doi":"10.1158/1535-7163.mct-20-0510","title":"Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University College of the North","funders":"Janssen Research and Development","keywords":"Prostate cancer; Androgen receptor; Cancer research; Antagonist; Cancer; Internal medicine; Medicine; Receptor; Endocrinology; Pharmacology; Biology","score_opus":0.06884914067294168,"score_gpt":0.3620688245716197,"score_spread":0.29321968389867803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133986190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832801,0.012718369,0.00011132943,0.0025042938,0.00016531932,0.0007978876,0.000346895,0.000014118464,0.00006168341],"genre_scores_gemma":[0.97548,0.021375952,0.0015332894,0.0004691902,0.00005850724,0.00016839764,0.0005256771,0.00004644308,0.00034250086],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811333,0.00017717462,0.00055416947,0.00044287517,0.00038652346,0.0003258983],"domain_scores_gemma":[0.9989807,0.00007753604,0.00020314481,0.00024930848,0.0003891203,0.00010021462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022119329,0.00022745467,0.00044025684,0.00013973535,0.00012433824,0.000102430764,0.00006232928,0.00008748443,0.00001685021],"category_scores_gemma":[0.000043531167,0.00019459332,0.00008516998,0.0006966843,0.0002022834,0.00020942555,0.00003951746,0.0002493047,0.0000013473103],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013395402,0.0002507559,0.0074948217,0.00016965262,0.00068775093,0.00026580432,0.0019726437,0.00016200215,0.9761092,0.000069515096,0.000014549015,0.011463776],"study_design_scores_gemma":[0.005193828,0.0005764134,0.0028605692,0.000543117,0.00049186684,0.00001615781,0.002072644,0.00078737736,0.98588055,0.00019772766,0.0010807556,0.000298962],"about_ca_topic_score_codex":0.00019494853,"about_ca_topic_score_gemma":0.00063620665,"teacher_disagreement_score":0.011164814,"about_ca_system_score_codex":0.0003475062,"about_ca_system_score_gemma":0.0016801251,"threshold_uncertainty_score":0.79352856},"labels":[],"label_agreement":null},{"id":"W3134000103","doi":"10.1200/jco.2021.39.6_suppl.47","title":"Real-world utilization of docetaxel among men with <i>de novo</i> metastatic castration-sensitive prostate cancer: A population-based study in men aged 66 or older.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McMaster University; Juravinski Cancer Centre; London Health Sciences Centre; Western University; University of Ottawa; McGill University; Princess Margaret Cancer Centre; University of Calgary; University of Alberta; Jewish General Hospital; BC Cancer Agency; Ottawa Hospital; University Health Network","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Androgen deprivation therapy; Internal medicine; Febrile neutropenia; Neutropenia; Cancer; Population; Metastatic breast cancer; Oncology; Chemotherapy; Breast cancer","score_opus":0.15116936125868657,"score_gpt":0.49948466006961684,"score_spread":0.34831529881093026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134000103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953975,0.00012319649,0.000055136363,0.0021557368,0.00008680675,0.00095280225,0.00001591609,0.000006314655,0.0012065895],"genre_scores_gemma":[0.9959097,0.0005984885,0.0015085874,0.00017849363,0.00012515318,0.000037504014,0.000033021173,0.000019693387,0.0015893868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99612707,0.0010486164,0.0018037519,0.00023426564,0.00053373893,0.0002525725],"domain_scores_gemma":[0.9957678,0.0016241154,0.0012848013,0.0001606787,0.00092877616,0.00023384645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023380406,0.00014758245,0.0013240037,0.00023386988,0.000045738412,0.000013412604,0.00006983602,0.00009356274,0.00011355],"category_scores_gemma":[0.0009140448,0.00009123698,0.00014191908,0.0006754084,0.00012474156,0.00014131222,0.000020587337,0.00058813056,6.1191247e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015283864,0.0038601283,0.96646065,0.00010382526,0.00064756494,0.0050148373,0.0010523526,0.0008268976,0.00025399122,0.000012293215,0.00017670948,0.0063069],"study_design_scores_gemma":[0.026284643,0.006936604,0.9610937,0.00039180802,0.00064721546,0.000057704216,0.0024309852,0.0009181403,0.001069646,0.000032991713,0.000051504172,0.00008504313],"about_ca_topic_score_codex":0.0014570233,"about_ca_topic_score_gemma":0.024364758,"teacher_disagreement_score":0.022907736,"about_ca_system_score_codex":0.0005153404,"about_ca_system_score_gemma":0.0067215534,"threshold_uncertainty_score":0.9989094},"labels":[],"label_agreement":null},{"id":"W3134007156","doi":"10.1200/jco.2021.39.6_suppl.62","title":"Comparative cardiotoxicity of the novel hormonal agents abiraterone and enzalutamide in metastatic castration-resistant prostate cancer using real-world data.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal General Hospital; McGill University","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Oncology; Cohort; Incidence (geometry); Population; Cancer; Cardiotoxicity; Clinical trial; Abiraterone acetate; Disease; Androgen deprivation therapy; Chemotherapy; Androgen receptor","score_opus":0.5192197711273235,"score_gpt":0.5764238078082177,"score_spread":0.05720403668089413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134007156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955285,0.0013043991,0.000020139812,0.0022606868,0.00025965972,0.0002842928,0.00011592903,0.0000012401664,0.00022512392],"genre_scores_gemma":[0.99463594,0.0018517654,0.0028906583,0.00021732366,0.0001547403,0.0000035783116,0.000009296217,0.000007486594,0.00022922804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723935,0.0005186382,0.0014417662,0.00019927562,0.00041218236,0.00018875791],"domain_scores_gemma":[0.99737096,0.00078288483,0.0009955254,0.0002277007,0.00046246013,0.00016048066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001956393,0.000105904575,0.0012498613,0.00008607461,0.000042848813,0.000010777181,0.00013576122,0.000059110178,0.000023833918],"category_scores_gemma":[0.00047651108,0.00006136503,0.00013220399,0.00031532563,0.00043792013,0.00012819585,0.00014464534,0.0006043808,2.9381337e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016567055,0.0038686004,0.8305616,0.00028855618,0.0031050516,0.0021968258,0.0014137405,0.0009877632,0.12631154,0.00013005633,0.0010264834,0.013542721],"study_design_scores_gemma":[0.008054733,0.0012874221,0.9816103,0.00028226813,0.00048995443,0.000113012386,0.00044073196,0.0012864601,0.005142362,0.00009169541,0.0011374814,0.00006359235],"about_ca_topic_score_codex":0.0007656026,"about_ca_topic_score_gemma":0.006162822,"teacher_disagreement_score":0.15104868,"about_ca_system_score_codex":0.0002692333,"about_ca_system_score_gemma":0.004307485,"threshold_uncertainty_score":0.7641294},"labels":[],"label_agreement":null},{"id":"W3134014622","doi":"10.1186/s13014-021-01935-x","title":"Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial","year":2021,"lang":"en","type":"article","venue":"Radiation Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; University of Manitoba; CancerCare Manitoba","funders":"Alberta Cancer Foundation; CancerCare Manitoba Foundation","keywords":"Medicine; Interim analysis; Prostate cancer; Placebo; Metformin; Genitourinary system; Radiation therapy; Internal medicine; Toxicity; Urology; Prostate; Randomized controlled trial; Gastroenterology; Oncology; Cancer; Pathology","score_opus":0.040392092648670434,"score_gpt":0.3883933773181183,"score_spread":0.34800128466944785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134014622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98577327,0.002125721,0.00004638452,0.0015933461,0.00014976972,0.009659171,0.00008312182,0.000020154432,0.0005490883],"genre_scores_gemma":[0.99125063,0.00299548,0.0029635823,0.0000249335,0.00012061124,0.0017408758,0.00010133228,0.000023930606,0.00077859074],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972718,0.00065408763,0.0010249693,0.00039248014,0.00031146157,0.00034520062],"domain_scores_gemma":[0.99748987,0.0010591643,0.0007279011,0.00018785492,0.00039842573,0.0001367868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015245893,0.00023141976,0.0017123721,0.0002940831,0.0000667744,0.000012508733,0.00006629781,0.000087600834,0.000059100897],"category_scores_gemma":[0.00071684696,0.00016024223,0.00014274447,0.00031206277,0.00031618567,0.00014381779,0.00005602195,0.00026457247,2.2192418e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9544112,0.0027731096,0.0008603205,0.0001835042,0.000623404,0.00022641073,0.0026244854,0.0000578049,0.027673354,0.000014349997,0.00006495105,0.010487092],"study_design_scores_gemma":[0.923702,0.018257,0.00021946887,0.00035320967,0.00026125106,0.00007589986,0.00055406423,0.0042752754,0.052060004,0.00000682944,0.00011767989,0.000117318355],"about_ca_topic_score_codex":0.0002634273,"about_ca_topic_score_gemma":0.00024190158,"teacher_disagreement_score":0.030709215,"about_ca_system_score_codex":0.00057636824,"about_ca_system_score_gemma":0.0014893421,"threshold_uncertainty_score":0.6534489},"labels":[],"label_agreement":null},{"id":"W3134153606","doi":"10.1200/jco.2021.39.6_suppl.101","title":"Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Bicalutamide; Medicine; Prostate cancer; Internal medicine; Oncology; Placebo; Androgen deprivation therapy; Androgen receptor; Clinical endpoint; Antiandrogen; Prostate-specific antigen; Clinical trial; Cancer; Pathology","score_opus":0.42566985796274126,"score_gpt":0.5246021642651568,"score_spread":0.09893230630241556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134153606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96022373,0.030099135,0.00024824782,0.0076162578,0.0004936294,0.0009700286,0.00010982041,0.0000063089583,0.00023286167],"genre_scores_gemma":[0.9868553,0.006168731,0.0056880913,0.0001995796,0.0004207942,0.00007031532,0.000026937096,0.000025877998,0.00054436096],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99448156,0.00084230874,0.0032266986,0.00037237204,0.0006428681,0.00043418378],"domain_scores_gemma":[0.9848892,0.010760445,0.0024387778,0.00041566364,0.0011491429,0.00034676102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027949195,0.00027936127,0.004619013,0.0001903559,0.00011610948,0.000021509637,0.0001710791,0.00019787336,0.0001267274],"category_scores_gemma":[0.0018285967,0.00015104112,0.0023530237,0.0007263998,0.00064533117,0.000092572736,0.00006615339,0.00033951638,8.553398e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13456503,0.009221573,0.15668371,0.00065659906,0.6013165,0.0011511451,0.0018143458,0.026274463,0.0041116355,0.0008297439,0.0012864098,0.06208881],"study_design_scores_gemma":[0.06288967,0.03606919,0.36081207,0.00013345142,0.51746917,0.000108561115,0.0010733305,0.0034283698,0.003745815,0.0010050283,0.012907846,0.00035748607],"about_ca_topic_score_codex":0.00016714259,"about_ca_topic_score_gemma":0.0009554837,"teacher_disagreement_score":0.20412837,"about_ca_system_score_codex":0.00026255363,"about_ca_system_score_gemma":0.002691045,"threshold_uncertainty_score":0.6159278},"labels":[],"label_agreement":null},{"id":"W3134158292","doi":"10.1200/jco.2021.39.6_suppl.249","title":"Investigation of a 22-gene genomic classifier (GC) for risk stratification and molecular subtyping in an Asian prostate cancer (PCa) cohort.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada); Genome British Columbia; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Subtyping; Medicine; Oncology; Prostate cancer; Cohort; Internal medicine; Radiogenomics; Cancer; Pathology; Radiomics","score_opus":0.15193007226466507,"score_gpt":0.4764153505461325,"score_spread":0.32448527828146745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134158292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916747,0.0018390552,0.00017996103,0.005566781,0.00018287566,0.0004258151,0.0000153545,0.0000022181162,0.00011323323],"genre_scores_gemma":[0.99027646,0.0036876171,0.0054560397,0.00024328938,0.00018831206,0.000026480368,0.000025604639,0.0000114974555,0.00008467485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979291,0.0003893825,0.0011800416,0.00018198762,0.00017283569,0.00014667571],"domain_scores_gemma":[0.99781513,0.00035742237,0.0009028219,0.00011828855,0.0005907747,0.00021555374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001967354,0.00007605574,0.0006415772,0.00009947566,0.000026627918,0.000009504445,0.000049643284,0.00019561865,0.000020279045],"category_scores_gemma":[0.0008336798,0.00005828634,0.000112684436,0.00013109941,0.0001740085,0.00009926676,0.00001649095,0.0004185304,3.251316e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002658522,0.00025475337,0.8321145,0.000076636454,0.00022221169,0.00013054536,0.00028922764,0.00002126854,0.09787038,0.00008419134,0.00008256793,0.066195175],"study_design_scores_gemma":[0.0069508427,0.003588015,0.96222967,0.000112240574,0.00028499297,0.000037158254,0.00026340882,0.0005644445,0.023087913,0.0022228672,0.00059927336,0.000059182395],"about_ca_topic_score_codex":0.000036175483,"about_ca_topic_score_gemma":0.00024510783,"teacher_disagreement_score":0.13011514,"about_ca_system_score_codex":0.00017535694,"about_ca_system_score_gemma":0.002860924,"threshold_uncertainty_score":0.5075156},"labels":[],"label_agreement":null},{"id":"W3134182875","doi":"10.1200/jco.2021.39.6_suppl.57","title":"Sequence decision making for cabazitaxel (Cbz) versus abiraterone (Abt) or enzalutamide (Enz) post-docetaxel (Dtx) in a publicly funded health care system.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Cabazitaxel; Enzalutamide; Medicine; Docetaxel; Prostate cancer; Internal medicine; Abiraterone acetate; Oncology; Chemotherapy; Cancer; Androgen receptor; Androgen deprivation therapy","score_opus":0.3593705298942796,"score_gpt":0.5842240712661738,"score_spread":0.22485354137189423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134182875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9664524,0.0098502645,0.000620228,0.017973261,0.003259429,0.00097292406,0.00007721977,0.000025267946,0.0007689579],"genre_scores_gemma":[0.97642565,0.0017272835,0.018206276,0.0021898444,0.0009849643,0.000033224675,0.000030977204,0.000036717465,0.0003650778],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948161,0.00067292294,0.002802426,0.00042698404,0.00064237294,0.00063918694],"domain_scores_gemma":[0.99072045,0.005127514,0.0013411999,0.0003295689,0.0019122353,0.0005690338],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0037596857,0.0002147071,0.0019531047,0.00024806638,0.0001129594,0.000045929675,0.0002501301,0.00042467847,0.00008835769],"category_scores_gemma":[0.008576314,0.00014077203,0.0004930429,0.00042006062,0.00015965928,0.00023001939,0.00011873102,0.0011038525,0.0000138992955],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22032608,0.0028799283,0.043554217,0.00190829,0.0011329676,0.016940005,0.0015442063,0.000062832376,0.0006324461,0.00067487336,0.006815286,0.7035289],"study_design_scores_gemma":[0.3276598,0.22654368,0.21038868,0.012687349,0.0014523395,0.008871904,0.048296418,0.0014792843,0.0011689736,0.0009000368,0.15934646,0.0012050903],"about_ca_topic_score_codex":0.00014952586,"about_ca_topic_score_gemma":0.0038765613,"teacher_disagreement_score":0.7023238,"about_ca_system_score_codex":0.0025535554,"about_ca_system_score_gemma":0.012046555,"threshold_uncertainty_score":0.9997749},"labels":[],"label_agreement":null},{"id":"W3134199561","doi":"10.1200/jco.2021.39.6_suppl.149","title":"Prognostic association between common laboratory tests and overall survival in men with <i>de novo</i> metastatic castration-sensitive prostate cancer: A population-based study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McMaster University; Juravinski Cancer Centre; Western University; University of Ottawa; McGill University; Princess Margaret Cancer Centre; University of Calgary; University of Alberta; Jewish General Hospital; BC Cancer Agency; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Oncology; Proportional hazards model; Prostate-specific antigen; Cohort; Population; Cancer; Relative survival; Cancer registry","score_opus":0.08136567479624043,"score_gpt":0.45968797456301114,"score_spread":0.3783222997667707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134199561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99241483,0.00027002714,0.0000072963453,0.0064911293,0.00008902706,0.00055801164,0.00003498903,0.0000055043965,0.0001291758],"genre_scores_gemma":[0.9984512,0.00018594539,0.0006308787,0.00032624218,0.00021474432,0.000020584208,0.000029100634,0.000013363768,0.00012795017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969168,0.0011669825,0.0010475251,0.00017924585,0.00046355516,0.00022594095],"domain_scores_gemma":[0.9939741,0.003996298,0.00084418117,0.00008219872,0.0008814473,0.0002217999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028449127,0.00011384576,0.0010394639,0.00009666468,0.000043844382,0.000022090966,0.00003636233,0.00011524416,0.000011220226],"category_scores_gemma":[0.0020205772,0.00007991106,0.00006688529,0.00026170313,0.00004519513,0.00011128602,0.000017117867,0.00067793665,7.347093e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024452633,0.0014422478,0.98821014,0.000045330456,0.0006127044,0.0026042482,0.0003305639,0.00010283219,0.00007156905,0.0000047046865,0.000057411253,0.0040729977],"study_design_scores_gemma":[0.015788352,0.006506701,0.97594804,0.00016690817,0.00065847515,0.000024969639,0.00045822226,0.000116260766,0.00008395843,0.00005845462,0.00011685743,0.00007277622],"about_ca_topic_score_codex":0.00028751144,"about_ca_topic_score_gemma":0.0033855936,"teacher_disagreement_score":0.013343089,"about_ca_system_score_codex":0.0007563351,"about_ca_system_score_gemma":0.0049237595,"threshold_uncertainty_score":0.87345374},"labels":[],"label_agreement":null},{"id":"W3134327766","doi":"10.1200/jco.2021.39.6_suppl.94","title":"Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the phase III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Placebo; Hazard ratio; Prostate cancer; Urology; Post-hoc analysis; Internal medicine; Proportional hazards model; Prostate-specific antigen; Oncology; Gynecology; Cancer; Confidence interval","score_opus":0.11753508138163961,"score_gpt":0.44699884395670697,"score_spread":0.3294637625750674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134327766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891259,0.003062506,0.000035414832,0.005004495,0.00015448089,0.0017848558,0.0002734758,0.000005837489,0.0005530265],"genre_scores_gemma":[0.9894122,0.008053892,0.0016143878,0.00015633786,0.00022336809,0.00006769126,0.000082510865,0.00004084612,0.00034876872],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934686,0.0013786355,0.002880207,0.00044385553,0.001347681,0.0004810234],"domain_scores_gemma":[0.993933,0.0020749196,0.0020306122,0.00045295208,0.0011779218,0.00033056168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004887649,0.00033795636,0.002532946,0.00018259142,0.00007150536,0.000036344885,0.00028010723,0.00019625183,0.000100129044],"category_scores_gemma":[0.0006862369,0.00017319106,0.00025990233,0.00056477526,0.0007554739,0.00022551185,0.000083981104,0.00088146166,5.3059836e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7878945,0.011898565,0.15551773,0.00028366037,0.0029329015,0.0035516147,0.0014192505,0.00007352167,0.014777657,0.00011133342,0.0014872819,0.020051999],"study_design_scores_gemma":[0.71608883,0.08587018,0.17009777,0.0006901098,0.0020763704,0.00036829634,0.003074347,0.00012833999,0.014061037,0.00025149097,0.006873202,0.00042004616],"about_ca_topic_score_codex":0.00052785437,"about_ca_topic_score_gemma":0.0030257963,"teacher_disagreement_score":0.073971614,"about_ca_system_score_codex":0.00018113866,"about_ca_system_score_gemma":0.003826692,"threshold_uncertainty_score":0.70625263},"labels":[],"label_agreement":null},{"id":"W3134337523","doi":"10.1200/jco.2021.39.6_suppl.40","title":"Time trends of drug specific adverse events among patients on androgen receptor antagonists: Implications for remote monitoring.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"University Health Network","keywords":"Enzalutamide; Medicine; Prostate cancer; Adverse effect; Abiraterone; Incidence (geometry); Internal medicine; Oncology; Pharmacology; Androgen receptor; Cancer","score_opus":0.11291019692692938,"score_gpt":0.4734092523733782,"score_spread":0.36049905544644884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134337523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913453,0.0003329751,0.000013131929,0.0055414946,0.0010306718,0.00020031765,0.00006356758,0.000005192537,0.0014673655],"genre_scores_gemma":[0.98070115,0.0032700642,0.0055505764,0.00016885634,0.0016025176,0.000007655665,0.00010063694,0.000029851346,0.0085686995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978031,0.00019164706,0.0013440904,0.00018715093,0.0002738175,0.0002002229],"domain_scores_gemma":[0.9966562,0.0009652112,0.00092853,0.00021988689,0.0009331313,0.00029706868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092017447,0.0001019215,0.0008361287,0.00013467173,0.000052648138,0.0000022820327,0.00011917649,0.00017880023,0.00016947972],"category_scores_gemma":[0.00084204914,0.00007287583,0.00050222786,0.00020288372,0.00015647244,0.000064743166,0.000036412344,0.0003954712,0.00001667663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007988849,0.0039584218,0.6494627,0.00004096572,0.0006218556,0.000067112895,0.00011304565,0.000005031267,0.0009076429,0.000016935333,0.025397118,0.3114203],"study_design_scores_gemma":[0.01482366,0.0075840172,0.86835426,0.00021284835,0.00020970138,0.000017759143,0.00008120052,0.000011659891,0.004030812,0.00018891034,0.1044068,0.00007837317],"about_ca_topic_score_codex":0.0000032075948,"about_ca_topic_score_gemma":0.0000018157716,"teacher_disagreement_score":0.31134194,"about_ca_system_score_codex":0.0002600745,"about_ca_system_score_gemma":0.000774109,"threshold_uncertainty_score":0.297179},"labels":[],"label_agreement":null},{"id":"W3134421833","doi":"10.1002/cncr.33487","title":"Differential treatment outcomes in <i>BRCA1/2</i>‐, <i>CDK12</i>‐, and <i>ATM</i>‐mutated metastatic castration‐resistant prostate cancer","year":2021,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; University of Calgary","funders":"Astellas Pharma; Endocyte; Mirati Therapeutics; Giannini Foundation of Agricultural Economics; Sanofi; Genentech; AstraZeneca; Daiichi Sankyo Europe; Bristol-Myers Squibb; Pfizer; A.P. Giannini Foundation","keywords":"Enzalutamide; Medicine; Docetaxel; Cabazitaxel; Prostate cancer; Carboplatin; Oncology; Internal medicine; Chemotherapy; Abiraterone; Population; Cancer; Androgen deprivation therapy; Androgen receptor; Cisplatin","score_opus":0.03828403333267071,"score_gpt":0.35558796662345515,"score_spread":0.31730393329078443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134421833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97768855,0.014526985,0.0000067327755,0.0053855823,0.0003152023,0.0010392532,0.00046552432,0.0000588279,0.000513339],"genre_scores_gemma":[0.96928704,0.013072439,0.00016042618,0.0004403912,0.00009802881,0.0011026408,0.00021532839,0.00005389909,0.015569825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787056,0.00009760153,0.0004251079,0.00062003435,0.00038478375,0.000601883],"domain_scores_gemma":[0.99901694,0.00008293107,0.00009220524,0.0003165457,0.00019993281,0.0002914379],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006562283,0.00036718804,0.0007192434,0.00014319958,0.00012359332,0.00008190111,0.000060264156,0.00007462719,0.00084044295],"category_scores_gemma":[0.000027090955,0.00026127734,0.00012919967,0.00042812602,0.0001563925,0.00014414408,0.000053429067,0.000204995,0.000011561082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033101018,0.002269425,0.66093165,0.00085295,0.0024099762,0.0051889913,0.004236474,0.00011774224,0.26434097,0.00015262274,0.0016293299,0.054559812],"study_design_scores_gemma":[0.045659225,0.0016351776,0.5464016,0.0009924483,0.0017133966,0.00017977574,0.001269108,0.00064231834,0.38132197,0.00031638826,0.018702766,0.0011658017],"about_ca_topic_score_codex":0.0016150085,"about_ca_topic_score_gemma":0.0042572087,"teacher_disagreement_score":0.11698101,"about_ca_system_score_codex":0.000795859,"about_ca_system_score_gemma":0.0010325073,"threshold_uncertainty_score":0.99998397},"labels":[],"label_agreement":null},{"id":"W3134437253","doi":"10.1200/jco.2021.39.6_suppl.51","title":"Retrospective cohort analysis of real-world clinical outcomes in nonmetastatic (M0) castration-resistant prostate cancer (CRPC) treated with novel androgen receptor pathway inhibitors (ARPI).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); Princess Margaret Cancer Centre; University of Saskatchewan; University of Calgary","funders":"","keywords":"Medicine; Proportional hazards model; Enzalutamide; Prostate cancer; Hazard ratio; Cohort; Oncology; Internal medicine; Retrospective cohort study; Abiraterone acetate; Androgen deprivation therapy; Survival analysis; Urology; Cancer; Androgen receptor; Confidence interval","score_opus":0.10002027299648605,"score_gpt":0.46719824009257044,"score_spread":0.3671779670960844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134437253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948249,0.00037570577,0.000011305016,0.0028047184,0.00037149148,0.0005608768,0.00023727679,0.000008426668,0.00080531044],"genre_scores_gemma":[0.9912769,0.0039063906,0.0021865908,0.00023704699,0.00025075796,0.000032899625,0.0000778846,0.000029021012,0.0020025007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933278,0.0007539793,0.0041758777,0.00048048559,0.00086993945,0.00039195028],"domain_scores_gemma":[0.9931632,0.0019322135,0.0023965756,0.00033056177,0.0016971801,0.0004802685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003948389,0.0002567009,0.0039108563,0.00062483735,0.000046768295,0.000016718865,0.00013448526,0.00029251387,0.0003448444],"category_scores_gemma":[0.0019778488,0.00015751125,0.000955724,0.00196805,0.00050003955,0.00014663534,0.00005208653,0.0011746754,0.000002606938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01163845,0.0042106253,0.96407264,0.000040891297,0.011248522,0.0019192104,0.00015571223,0.00007814333,0.0011976189,0.000034300894,0.00023136628,0.005172517],"study_design_scores_gemma":[0.014607859,0.007828983,0.9700893,0.00021533239,0.0042059277,0.000027055732,0.0002841585,0.00008690269,0.0014224558,0.000022883236,0.0010634242,0.00014571131],"about_ca_topic_score_codex":0.0009960684,"about_ca_topic_score_gemma":0.012588386,"teacher_disagreement_score":0.011592318,"about_ca_system_score_codex":0.0008401688,"about_ca_system_score_gemma":0.0058350344,"threshold_uncertainty_score":0.999801},"labels":[],"label_agreement":null},{"id":"W3134481849","doi":"10.5489/cuaj.7268","title":"Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer","year":2021,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; Western University; Université de Montréal; McMaster University; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Prostate cancer; Positron emission tomography; Glutamate carboxypeptidase II; Medicine; Magnetic resonance imaging; Management of prostate cancer; Clinical Practice; Radiology; Prostate; Positron emission; Cancer; Nuclear medicine; Oncology; Internal medicine","score_opus":0.011587161472156101,"score_gpt":0.26092786491611786,"score_spread":0.24934070344396175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134481849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8871645,0.023979405,0.0000011003866,0.08591107,0.00045165347,0.0008359147,0.000202294,0.000043949734,0.0014101538],"genre_scores_gemma":[0.97834486,0.014148206,0.0004336851,0.002655927,0.00036011942,0.00008947818,0.0003082669,0.000042497646,0.003616933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994798,0.0008122325,0.00089894,0.0008371357,0.0010481392,0.0016055396],"domain_scores_gemma":[0.99520665,0.0004924739,0.00060561066,0.00026551235,0.0013611616,0.0020686134],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019061652,0.00040084508,0.00067825656,0.00079627545,0.00071385637,0.00040569674,0.00018042751,0.00015291912,0.00050641067],"category_scores_gemma":[0.0019322699,0.00034277042,0.00022418694,0.0016687445,0.0000905357,0.00037868315,0.000050273793,0.0017658359,0.000017916045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036380504,0.00022928974,0.94034004,0.000022040294,0.00014816102,0.048319027,0.00020350708,0.000025808185,0.00064565026,0.00002186188,0.0053824913,0.004298314],"study_design_scores_gemma":[0.0029647863,0.0007714982,0.76000893,0.00014142376,0.00013865958,0.009014879,0.00028996074,0.00019378691,0.00026698053,0.00017247,0.22565997,0.00037667924],"about_ca_topic_score_codex":0.05115001,"about_ca_topic_score_gemma":0.06530566,"teacher_disagreement_score":0.22027747,"about_ca_system_score_codex":0.0051588123,"about_ca_system_score_gemma":0.003647473,"threshold_uncertainty_score":0.9999024},"labels":[],"label_agreement":null},{"id":"W3134531349","doi":"10.1200/jco.2021.39.6_suppl.50","title":"Geographic variation in systemic therapy in men age 66 years and older with de novo metastatic castration-sensitive prostate cancer: A population-based study in a single payer health-system.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre; Western University; University of Ottawa; McGill University; Princess Margaret Cancer Centre; University of Calgary; University of Alberta; BC Cancer Agency; University Health Network; Ottawa Hospital; Jewish General Hospital","funders":"Janssen Biotech","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Abiraterone acetate; Docetaxel; Internal medicine; Enzalutamide; Population; Oncology; Cancer; Prednisone; Systemic therapy; Gynecology; Androgen receptor; Breast cancer","score_opus":0.0956582054972567,"score_gpt":0.4575031590966921,"score_spread":0.36184495359943536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134531349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926968,0.0011945908,0.00001925345,0.0049500912,0.00008497955,0.0010308513,0.00000473609,0.000003571525,0.000015076403],"genre_scores_gemma":[0.99831134,0.00064431614,0.0005840105,0.00029526302,0.00006777733,0.000055411536,0.000007087099,0.000011827486,0.000022977843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965309,0.0014422548,0.0013232061,0.00019825797,0.00028253812,0.00022284049],"domain_scores_gemma":[0.99839586,0.0005456954,0.0006045056,0.000087816516,0.00022850739,0.00013762344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029830234,0.00009918798,0.0009707316,0.00032930807,0.000020016409,0.000015891885,0.000031917225,0.00008868942,0.0000036043657],"category_scores_gemma":[0.00021909547,0.00006930935,0.000058378064,0.00044781124,0.00002667485,0.000079127334,0.000008666464,0.0004909256,2.4491575e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004436181,0.0023556794,0.97127914,0.00010688899,0.00017036147,0.0074210856,0.0028756498,0.0004925987,0.00019216759,0.0000059666154,0.0000039808115,0.010660315],"study_design_scores_gemma":[0.02642865,0.0069215847,0.96087766,0.00078012154,0.000050787563,0.00021930654,0.0042633326,0.0003612322,0.000011902909,0.000022178045,0.000007537543,0.00005568979],"about_ca_topic_score_codex":0.0031678497,"about_ca_topic_score_gemma":0.017895786,"teacher_disagreement_score":0.021992467,"about_ca_system_score_codex":0.0008144484,"about_ca_system_score_gemma":0.0033473696,"threshold_uncertainty_score":0.9986269},"labels":[],"label_agreement":null},{"id":"W3134553248","doi":"10.1200/jco.2021.39.6_suppl.136","title":"Clinical outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving radium-223 (Ra-223) early versus late in the treatment sequence.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Bayer (Canada); McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Cohort; Docetaxel; Androgen deprivation therapy; Radium-223; Oncology; Cancer; Bone metastasis","score_opus":0.23699086339588288,"score_gpt":0.5181500086195547,"score_spread":0.28115914522367186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134553248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99096537,0.0008780637,0.00000311337,0.006337466,0.0008304815,0.00057373155,0.000043620006,0.000004187423,0.00036397926],"genre_scores_gemma":[0.9917573,0.0054989103,0.0014663766,0.00037345203,0.00021120628,0.00003071246,0.000019708112,0.000018655981,0.0006237184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948917,0.001232531,0.0025395867,0.00027635854,0.00071127585,0.00034852512],"domain_scores_gemma":[0.9925426,0.004688969,0.0014107852,0.0002763499,0.00081118505,0.00027009757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002723706,0.00019951221,0.0016674623,0.00010644927,0.000057777674,0.000020557376,0.00016941676,0.00016871485,0.00010855849],"category_scores_gemma":[0.0015234674,0.00009557576,0.00048316014,0.00033301723,0.00038076268,0.00014401152,0.000026366939,0.00081101316,0.0000045256606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024820432,0.006442846,0.8965474,0.000035778336,0.001686544,0.0020034588,0.0007665692,0.000029007537,0.000027003765,0.000018110703,0.00014187614,0.067480974],"study_design_scores_gemma":[0.046401363,0.030256826,0.9173961,0.00015578605,0.00083172694,0.000014509382,0.00035703156,0.000014680754,0.000052397074,0.0000783133,0.004351644,0.00008956745],"about_ca_topic_score_codex":0.00030924965,"about_ca_topic_score_gemma":0.0016753526,"teacher_disagreement_score":0.06739141,"about_ca_system_score_codex":0.00047412462,"about_ca_system_score_gemma":0.004293822,"threshold_uncertainty_score":0.76170564},"labels":[],"label_agreement":null},{"id":"W3134581025","doi":"10.1200/jco.2021.39.6_suppl.241","title":"Early surrogate measures for ablative therapies for intermediate-risk prostate cancer patients.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Cumulative incidence; Androgen deprivation therapy; Population; Urology; Brachytherapy; Radiation therapy; Prostate; Biochemical recurrence; Internal medicine; Cancer; Incidence (geometry); Cohort; Oncology; Nuclear medicine; Surgery; Prostatectomy","score_opus":0.13940411079361129,"score_gpt":0.49675106391983487,"score_spread":0.35734695312622355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134581025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98640794,0.0041835248,0.00019224524,0.006285302,0.001746268,0.00082969305,0.0001444438,0.0000074540794,0.0002031547],"genre_scores_gemma":[0.9820434,0.0115244035,0.0022453102,0.0007482495,0.0012348439,0.00012720928,0.000024871457,0.000029411214,0.0020223293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974277,0.00031484177,0.0014338555,0.00020361603,0.00031113843,0.00030882485],"domain_scores_gemma":[0.9918198,0.0036529407,0.0012060498,0.00010962861,0.0029346633,0.00027690607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002216898,0.00013090829,0.001086801,0.00007891192,0.00007690204,0.00001664779,0.00009945253,0.0002177663,0.000057983234],"category_scores_gemma":[0.0062542334,0.00008013673,0.0006149171,0.00010127424,0.00022592129,0.000114109724,0.000032574546,0.0005438069,0.0000028492432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02577333,0.0017550832,0.5055249,0.000084902436,0.002178126,0.00009126849,0.0013696103,0.000004640713,0.00014347878,0.0000389914,0.006554177,0.45648152],"study_design_scores_gemma":[0.044172533,0.03709761,0.6753426,0.00023019027,0.0008958845,0.000011785977,0.00048769233,0.00005002497,0.0021011152,0.0030096532,0.23645449,0.00014640683],"about_ca_topic_score_codex":0.000020810638,"about_ca_topic_score_gemma":0.00009020087,"teacher_disagreement_score":0.4563351,"about_ca_system_score_codex":0.00019612427,"about_ca_system_score_gemma":0.0028100985,"threshold_uncertainty_score":0.7487353},"labels":[],"label_agreement":null},{"id":"W3134704630","doi":"10.1200/jco.2021.39.6_suppl.117","title":"UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castrate-sensitive prostate cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Ottawa; London Health Sciences Centre; Western University; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network; University of Toronto","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Oncology; Metastasis; Internal medicine; Cancer; Urology","score_opus":0.19613867306482594,"score_gpt":0.5038224550843591,"score_spread":0.30768378201953317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134704630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95727414,0.018782768,0.000035329806,0.021376444,0.0008396564,0.0006415557,0.000037170652,0.0000056923254,0.0010072547],"genre_scores_gemma":[0.9858446,0.010377152,0.0017379941,0.000634124,0.0007239634,0.00003784181,0.0000108269915,0.000020848442,0.00061261386],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99733233,0.00046202465,0.0013245547,0.0001890505,0.0004116613,0.00028038956],"domain_scores_gemma":[0.99553436,0.0022513808,0.0008589212,0.00016187446,0.0009826407,0.00021084743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026941786,0.00013836447,0.0013167508,0.000059961887,0.00006891029,0.0000096539625,0.0001147519,0.00015611168,0.000044927478],"category_scores_gemma":[0.00095264177,0.00007483919,0.0007940642,0.00014489307,0.00021308199,0.00008106949,0.00003137483,0.00067022315,0.0000013540105],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03682955,0.004781041,0.025817214,0.00014260222,0.009833996,0.0030427657,0.0022815592,0.000029114144,0.03651809,0.0002604713,0.0030037605,0.8774598],"study_design_scores_gemma":[0.1299507,0.07728173,0.14717734,0.0013273823,0.0050582993,0.0016373703,0.020709299,0.0014009296,0.20866157,0.013998906,0.39213547,0.00066098943],"about_ca_topic_score_codex":0.000030379919,"about_ca_topic_score_gemma":0.00006538496,"teacher_disagreement_score":0.87679887,"about_ca_system_score_codex":0.0001560624,"about_ca_system_score_gemma":0.0046248236,"threshold_uncertainty_score":0.8204239},"labels":[],"label_agreement":null},{"id":"W3134768182","doi":"10.1200/jco.2021.39.6_suppl.6","title":"177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cabazitaxel; Medicine; Docetaxel; Prostate cancer; Clinical endpoint; Hazard ratio; Internal medicine; Adverse effect; Progression-free survival; Oncology; Urology; Confidence interval; Randomized controlled trial; Cancer; Overall survival; Androgen deprivation therapy","score_opus":0.19541153809071804,"score_gpt":0.513257776138573,"score_spread":0.317846238047855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134768182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97163504,0.007842597,0.000004202202,0.01743359,0.0016504487,0.00092088344,0.00007687565,0.000024207791,0.000412127],"genre_scores_gemma":[0.99242544,0.0022240598,0.0040485896,0.00039409657,0.00028936024,0.00011216711,0.000052467385,0.000050025974,0.0004037719],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99272054,0.0010267105,0.0037683712,0.0006164682,0.0011867967,0.00068113615],"domain_scores_gemma":[0.9934204,0.0017281172,0.0023510621,0.00045945324,0.0014316686,0.00060929713],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032485037,0.00037459665,0.0020573866,0.00030290082,0.00015647756,0.00009983946,0.0001877686,0.00032633787,0.000117197094],"category_scores_gemma":[0.005120313,0.0002466198,0.0003624362,0.00062027806,0.00047095207,0.00040288232,0.00024544806,0.001397077,0.0000029662103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1288361,0.0046367864,0.5493989,0.00025435165,0.0031558697,0.034805074,0.002429808,0.000033396078,0.0019132098,0.000023520583,0.0013159394,0.27319705],"study_design_scores_gemma":[0.10974488,0.013944477,0.852351,0.0016410911,0.0013476722,0.00052389153,0.0024213453,0.00021666648,0.00181557,0.0004102668,0.015058834,0.0005242995],"about_ca_topic_score_codex":0.000111547,"about_ca_topic_score_gemma":0.0013380637,"teacher_disagreement_score":0.3029521,"about_ca_system_score_codex":0.00050476595,"about_ca_system_score_gemma":0.0049208757,"threshold_uncertainty_score":0.9999986},"labels":[],"label_agreement":null},{"id":"W3134785045","doi":"10.1200/jco.2021.39.6_suppl.148","title":"5-hydroxymethylcytosine as a liquid biopsy biomarker in mCRPC.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia","funders":"National Institutes of Health; Svenska Läkaresällskapet; Prostate Cancer Foundation","keywords":"Epigenetics; DNA methylation; 5-Hydroxymethylcytosine; Gene; Liquid biopsy; Bisulfite sequencing; Biomarker; Medicine; Biology; Gene expression; Cancer; Cancer research; Genetics","score_opus":0.19257127429109278,"score_gpt":0.5391417807923622,"score_spread":0.3465705065012694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134785045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94474757,0.004303303,0.000020952162,0.03526342,0.0008990183,0.000113604234,0.0000019524925,0.0000058219343,0.014644352],"genre_scores_gemma":[0.98735565,0.0042323256,0.0019011216,0.0023799052,0.0005828636,0.0000038238154,0.0000058491046,0.00001610745,0.0035223702],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969092,0.0005202561,0.0017200575,0.00019246133,0.00037686407,0.00028117752],"domain_scores_gemma":[0.99694264,0.0013875645,0.00053563813,0.00018663683,0.0005298656,0.00041762818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029057022,0.00010852193,0.0011952386,0.00020779658,0.000022041406,0.0000078567655,0.00010815274,0.00037055725,0.00084017974],"category_scores_gemma":[0.004723563,0.00007149649,0.00042590543,0.00042699283,0.00020432487,0.000081885235,0.00007532587,0.0009830527,0.00007873652],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08759309,0.017108327,0.21578763,0.00019348823,0.0024224625,0.16426857,0.0004274617,0.000007531918,0.06459974,0.0005171647,0.020720454,0.42635408],"study_design_scores_gemma":[0.046105262,0.035976972,0.49547234,0.0005481723,0.00046053794,0.009596069,0.00042900816,0.000094598734,0.011055679,0.0013737134,0.39865205,0.00023561741],"about_ca_topic_score_codex":0.000023729515,"about_ca_topic_score_gemma":0.000023451998,"teacher_disagreement_score":0.42611846,"about_ca_system_score_codex":0.00022359133,"about_ca_system_score_gemma":0.0045653554,"threshold_uncertainty_score":0.9199379},"labels":[],"label_agreement":null},{"id":"W3134832274","doi":"10.1200/jco.2021.39.15_suppl.5023","title":"PSMA-targeted imaging with <sup>18</sup>F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Progenics Pharmaceuticals","keywords":"Medicine; Nuclear medicine; Confidence interval; Histopathology; Prostate cancer; Population; Clinical endpoint; Radiation therapy; Radiology; Cancer; Clinical trial; Pathology; Internal medicine","score_opus":0.031066895960023825,"score_gpt":0.421542854466676,"score_spread":0.3904759585066522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134832274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550843,0.0020774014,0.00019495808,0.00069776387,0.00016388085,0.0009443891,0.00033304395,0.0000052215587,0.0000748853],"genre_scores_gemma":[0.99761343,0.0017460106,0.00022486974,0.00012663317,0.000068726964,0.00002652568,0.00011488309,0.000026261981,0.000052640855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950944,0.0011921264,0.0022517934,0.00042835844,0.0007161556,0.0003171634],"domain_scores_gemma":[0.9939909,0.0011534726,0.0017871577,0.00019083059,0.0025608952,0.00031675602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020146493,0.00024373374,0.002046138,0.0002515259,0.0000440193,0.000012411687,0.00011217511,0.00005895747,0.00007351675],"category_scores_gemma":[0.0018943732,0.00016479846,0.00021728383,0.00063869887,0.00046000927,0.00016830038,0.00007443076,0.0007504319,2.5458974e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.097618505,0.010602329,0.8542582,0.00011600985,0.0022697193,0.0015324374,0.0011125405,0.00036747998,0.00054525747,0.0000016481947,0.0005955533,0.030980352],"study_design_scores_gemma":[0.30931777,0.2192596,0.3847904,0.0035539358,0.008048312,0.00038654954,0.009042778,0.02080863,0.043376923,0.00019234668,0.00050739455,0.000715366],"about_ca_topic_score_codex":0.00014653768,"about_ca_topic_score_gemma":0.00007123672,"teacher_disagreement_score":0.4694678,"about_ca_system_score_codex":0.00052829605,"about_ca_system_score_gemma":0.0027814538,"threshold_uncertainty_score":0.67202866},"labels":[],"label_agreement":null},{"id":"W3134910506","doi":"10.1200/jco.2021.39.6_suppl.239","title":"Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Discontinuation; Adverse effect; Placebo; Incidence (geometry); Internal medicine; Rash","score_opus":0.18057939522637942,"score_gpt":0.5243375010670506,"score_spread":0.3437581058406711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134910506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784377,0.0029939343,0.00022923834,0.015083207,0.0012574579,0.0013212471,0.00022304154,0.000003310675,0.0004508336],"genre_scores_gemma":[0.9909489,0.003849401,0.0024101664,0.00088532263,0.00073764054,0.000086057924,0.00006398545,0.00001797451,0.0010005467],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952106,0.00078732765,0.0028948719,0.0002447361,0.0005564825,0.00030600783],"domain_scores_gemma":[0.9923565,0.004998602,0.0014423826,0.0002612186,0.000731006,0.00021029804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041052885,0.00015232668,0.0016340027,0.00010136408,0.000060429255,0.00001523828,0.00018437069,0.00019526975,0.00023749589],"category_scores_gemma":[0.003467995,0.00008743559,0.0006021708,0.0002650081,0.00023882781,0.00010269923,0.000030413263,0.00072183,0.0000016476599],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7733226,0.007919832,0.0024152196,0.00012299462,0.0014804032,0.002394638,0.0016102477,0.000038049475,0.007766156,0.00012567543,0.0036017955,0.1992024],"study_design_scores_gemma":[0.8585524,0.038773865,0.041303813,0.00052380457,0.0020843442,0.00010304706,0.0031711005,0.00039020923,0.0036775873,0.0036896039,0.047528114,0.00020209036],"about_ca_topic_score_codex":0.00018484997,"about_ca_topic_score_gemma":0.0010238604,"teacher_disagreement_score":0.19900031,"about_ca_system_score_codex":0.00024728297,"about_ca_system_score_gemma":0.0063977847,"threshold_uncertainty_score":0.99923503},"labels":[],"label_agreement":null},{"id":"W3135006799","doi":"10.3390/ijms22052493","title":"Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor","year":2021,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Terry Fox Research Institute; Canadian Institutes of Health Research; Terry Fox Foundation; Prostate Cancer Canada","keywords":"Androgen receptor; Druggability; Prostate cancer; Chemistry; DNA-binding domain; Small molecule; Nuclear receptor; Binding domain; Biochemistry; Biology; Computational biology; Cancer research; Binding site; Transcription factor; Cancer; Genetics; Gene","score_opus":0.029136214741720887,"score_gpt":0.3275015409724375,"score_spread":0.2983653262307166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135006799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574596,0.00087878515,0.0004056045,0.0022548032,0.0003419059,0.0000583933,0.0000051179495,6.471381e-7,0.0003087821],"genre_scores_gemma":[0.98522604,0.000063947606,0.01458069,0.000035535308,0.000043148964,8.1514116e-7,0.0000013165501,0.000002745985,0.00004577615],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99833286,0.00004046362,0.0003981046,0.0000708173,0.0010743429,0.000083404506],"domain_scores_gemma":[0.99884987,0.00005625078,0.0003964805,0.000057495527,0.0006098206,0.000030109893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008759122,0.000047996567,0.00012585879,0.00010291503,0.000055668046,0.000012299863,0.00033493992,0.000018459106,0.000029041465],"category_scores_gemma":[0.00017723654,0.000023483268,0.00011335227,0.0002880276,0.00027215428,0.000054950928,0.00010608905,0.000085514686,2.6617107e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046331792,0.00010900627,0.008129444,0.0000128121255,0.00017133892,0.00001528047,0.0011935222,0.000039596158,0.98796695,0.00022068142,0.00004894127,0.002046103],"study_design_scores_gemma":[0.0006504353,0.00006177212,0.0010693846,0.00033469472,0.000013650019,0.00005305665,0.0019657942,0.000017166767,0.9948479,0.00006421287,0.0008988725,0.000023071021],"about_ca_topic_score_codex":0.0000039008437,"about_ca_topic_score_gemma":0.0000013903563,"teacher_disagreement_score":0.014175085,"about_ca_system_score_codex":0.0000565338,"about_ca_system_score_gemma":0.0009836927,"threshold_uncertainty_score":0.17450285},"labels":[],"label_agreement":null},{"id":"W3135123677","doi":"10.1200/jco.2021.39.6_suppl.9","title":"Final results from ACIS, a randomized, placebo (PBO)-controlled double-blind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versus AAP in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Clinical endpoint; Interim analysis; Internal medicine; Placebo; Progression-free survival; Androgen deprivation therapy; Prednisone; Mallinckrodt; Enzalutamide; Randomization; Randomized controlled trial; Gastroenterology; Urology; Oncology; Androgen receptor; Cancer; Chemotherapy; Pathology","score_opus":0.1758181269716558,"score_gpt":0.4757662955401537,"score_spread":0.29994816856849793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135123677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99203426,0.0016626565,0.000009588687,0.0018272407,0.0004748498,0.0036711565,0.00014137846,0.000006189888,0.00017270538],"genre_scores_gemma":[0.9962466,0.001750258,0.0009422633,0.00007991696,0.00019406047,0.00019063386,0.0000727791,0.00002826532,0.0004952374],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928658,0.0014559131,0.0038424935,0.0005076381,0.0009149819,0.00041320102],"domain_scores_gemma":[0.9908919,0.004376028,0.002731225,0.00028359253,0.0013015011,0.0004158033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039049247,0.00032391617,0.0042314525,0.00024072175,0.000068078814,0.000037520123,0.00014255058,0.00019351531,0.00008013478],"category_scores_gemma":[0.0024734864,0.00019668076,0.00030738223,0.00032626014,0.0004538124,0.00021986698,0.0000795494,0.00096277584,0.0000021201934],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96376175,0.010228234,0.0055887746,0.00007559745,0.0045709177,0.0023257374,0.0032491554,0.0003090481,0.0003245935,0.0000026708549,0.00009345179,0.009470067],"study_design_scores_gemma":[0.9419839,0.036024734,0.015324431,0.00036016706,0.0029312307,0.000022518132,0.0019426008,0.0005020121,0.0006237397,0.000036491147,0.000086715234,0.00016149817],"about_ca_topic_score_codex":0.00066868437,"about_ca_topic_score_gemma":0.0026357844,"teacher_disagreement_score":0.025796501,"about_ca_system_score_codex":0.0004621773,"about_ca_system_score_gemma":0.00423279,"threshold_uncertainty_score":0.8020409},"labels":[],"label_agreement":null},{"id":"W3135144655","doi":"10.1200/jco.2021.39.6_suppl.84","title":"PROSPER subgroup analysis by age and region: Overall survival and safety in men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy plus enzalutamide.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Androgen deprivation therapy; Hazard ratio; Internal medicine; Oncology; Post-hoc analysis; Subgroup analysis; Placebo; Adverse effect; Proportional hazards model; Multivariate analysis; Gynecology; Cancer; Androgen receptor; Confidence interval; Alternative medicine","score_opus":0.09074979996232181,"score_gpt":0.42452423312065346,"score_spread":0.33377443315833166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135144655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871034,0.005906417,0.000074919786,0.0061467155,0.00005745652,0.00035780406,0.000009822471,0.0000036469764,0.00033979138],"genre_scores_gemma":[0.9684482,0.029466229,0.0009713064,0.0002772619,0.00010698386,0.000015284912,0.000024670078,0.0000133361655,0.00067671685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759156,0.00045396184,0.0011138477,0.00027313046,0.0003592127,0.00020827523],"domain_scores_gemma":[0.9980052,0.00076010404,0.0005901364,0.00012438942,0.00029173156,0.00022840942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00164566,0.00013622601,0.0011170462,0.00013291147,0.000056940476,0.0000331631,0.000045902427,0.0001373668,0.00003948513],"category_scores_gemma":[0.0002892594,0.00008567129,0.00011571844,0.0003814549,0.00018797563,0.00016964992,0.000028072014,0.0004742729,1.9715264e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035950273,0.00054570666,0.9191216,0.000064058055,0.002169502,0.0041656564,0.0006859036,0.00008161284,0.0015350078,0.000044616525,0.00023363835,0.035402395],"study_design_scores_gemma":[0.021114323,0.005736635,0.96886075,0.0001448886,0.0006642102,0.00016673387,0.00038778476,0.00032952582,0.00029102288,0.00016607034,0.0020220352,0.00011605233],"about_ca_topic_score_codex":0.00015145386,"about_ca_topic_score_gemma":0.0021514972,"teacher_disagreement_score":0.049739085,"about_ca_system_score_codex":0.00027977373,"about_ca_system_score_gemma":0.0013595627,"threshold_uncertainty_score":0.34935737},"labels":[],"label_agreement":null},{"id":"W3135186447","doi":"10.1200/jco.2021.39.6_suppl.106","title":"Impact of concomitant prostate cancer therapy on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase III HERO study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Concomitant; Docetaxel; Urology; Clinical endpoint; Prostate; Testosterone (patch); Internal medicine; Cancer; Subgroup analysis; Oncology; Enzalutamide; Gynecology; Randomized controlled trial; Androgen receptor; Confidence interval","score_opus":0.09848423727485707,"score_gpt":0.5165458415783135,"score_spread":0.41806160430345646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135186447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98701847,0.007895012,0.0000020478294,0.0035528576,0.0001491149,0.0010950993,0.0001081685,0.0000035737514,0.00017568287],"genre_scores_gemma":[0.9498736,0.049567685,0.00009902913,0.000114635026,0.00014663281,0.00003763485,0.000013417372,0.000019146864,0.00012819165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960131,0.000808018,0.0019864363,0.00032856004,0.000555094,0.0003087878],"domain_scores_gemma":[0.9935192,0.003483158,0.0016966629,0.00032993112,0.00071068783,0.0002603874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018318455,0.00021764067,0.0023276012,0.00015838098,0.000047642454,0.000009421361,0.0001597421,0.0001431006,0.00012489829],"category_scores_gemma":[0.0005308077,0.0001044339,0.00040595434,0.0007154878,0.00040328744,0.000095225194,0.000051323812,0.00087745354,2.5742008e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35326713,0.004649599,0.5226592,0.000012706944,0.007832335,0.00061639736,0.0021046887,0.0007180347,0.0009011358,0.000002017123,0.000106072745,0.10713068],"study_design_scores_gemma":[0.19016264,0.05267238,0.7526615,0.0002484206,0.0014573385,0.000007326914,0.0012670711,0.00011244416,0.0008276744,0.000017045983,0.0004732664,0.000092868126],"about_ca_topic_score_codex":0.002198275,"about_ca_topic_score_gemma":0.0028188825,"teacher_disagreement_score":0.23000231,"about_ca_system_score_codex":0.00046313804,"about_ca_system_score_gemma":0.003769704,"threshold_uncertainty_score":0.66872925},"labels":[],"label_agreement":null},{"id":"W3135310517","doi":"10.1200/jco.2021.39.6_suppl.tps266","title":"DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University; Ottawa Hospital; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Placebo; Internal medicine; Docetaxel; Tolerability; Oncology; Randomized controlled trial; Interim analysis; Urology; Cancer; Adverse effect; Pathology","score_opus":0.11763635021972726,"score_gpt":0.4702516051159598,"score_spread":0.3526152548962326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135310517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98130924,0.0038300883,0.00095412123,0.004192741,0.00089787773,0.008561352,0.00017357986,0.000007382041,0.00007364751],"genre_scores_gemma":[0.95075065,0.04511882,0.0017727229,0.0008326925,0.0005475832,0.0006746997,0.000032958254,0.000035768877,0.00023411338],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936209,0.0017265478,0.003232516,0.00033576484,0.0007505769,0.0003337204],"domain_scores_gemma":[0.986185,0.008453257,0.0033414694,0.00027736518,0.0014549004,0.0002879708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00763009,0.0002519674,0.0036617846,0.00020772494,0.00013841415,0.000024282457,0.00018849439,0.0003181412,0.00013257159],"category_scores_gemma":[0.0047455695,0.00013045875,0.0008749743,0.00035254873,0.00042353466,0.00014831367,0.00006239065,0.0005931683,3.6836119e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8591486,0.0017688526,0.0018878579,0.000033332006,0.0041608703,0.000045123306,0.00047841817,0.00006670219,0.0010843703,0.000073147836,0.00027724577,0.13097546],"study_design_scores_gemma":[0.9610691,0.019448265,0.000652501,0.00020897068,0.0011748986,0.000016054208,0.00013779779,0.000209872,0.0128432335,0.0006034916,0.0035164373,0.000119348806],"about_ca_topic_score_codex":0.000083322106,"about_ca_topic_score_gemma":0.00005546656,"teacher_disagreement_score":0.13085611,"about_ca_system_score_codex":0.0002760524,"about_ca_system_score_gemma":0.005487106,"threshold_uncertainty_score":0.973389},"labels":[],"label_agreement":null},{"id":"W3135314217","doi":"10.1200/jco.2021.39.15_suppl.e17003","title":"A prospective phase 2/3 study of PSMA-targeted <sup>18</sup>F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"Progenics Pharmaceuticals","keywords":"Medicine; Bone scintigraphy; Nuclear medicine; Prostate cancer; Stage (stratigraphy); Radiology; Positron emission tomography; Cancer; Internal medicine","score_opus":0.09436800555742343,"score_gpt":0.4742779297651016,"score_spread":0.37990992420767816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135314217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99608314,0.00074558414,0.0000056480644,0.0014573724,0.00008614402,0.0013137431,0.00026231082,0.000004923698,0.00004114109],"genre_scores_gemma":[0.9985092,0.00072181935,0.00022773191,0.00015455311,0.000060137914,0.00012940867,0.00006859716,0.000022237027,0.0001062631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952565,0.00095933623,0.0018227258,0.00049861876,0.0010744889,0.00038834492],"domain_scores_gemma":[0.9948551,0.0011732129,0.0016785673,0.00027340354,0.00163728,0.00038241324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017096204,0.00025965594,0.002234661,0.00080309156,0.00003897253,0.000012586975,0.00015782335,0.000030203768,0.0002891602],"category_scores_gemma":[0.0013953282,0.00015160684,0.00026668338,0.0017068516,0.00036162304,0.00017194082,0.00007095958,0.0008130904,6.1834953e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.117977016,0.029413158,0.82791597,0.00014008197,0.0038241644,0.0077904826,0.0006550074,0.0007394399,0.000016208973,0.0000039551937,0.000081544764,0.011442961],"study_design_scores_gemma":[0.07655315,0.041961275,0.8721298,0.0010754109,0.0041001327,0.000028992625,0.0022156255,0.0011750509,0.00044337072,0.000026951731,0.00011552891,0.00017474192],"about_ca_topic_score_codex":0.00021049762,"about_ca_topic_score_gemma":0.00257656,"teacher_disagreement_score":0.044213794,"about_ca_system_score_codex":0.0005475875,"about_ca_system_score_gemma":0.004165108,"threshold_uncertainty_score":0.7388723},"labels":[],"label_agreement":null},{"id":"W3135328828","doi":"10.1200/jco.2021.39.6_suppl.13","title":"PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"PTEN; Medicine; Prostate cancer; Immunohistochemistry; Internal medicine; Cancer; Population; Oncology; Abiraterone acetate; Pathology; PI3K/AKT/mTOR pathway; Androgen deprivation therapy; Apoptosis; Biology","score_opus":0.200979632659316,"score_gpt":0.5116480651843357,"score_spread":0.3106684325250197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135328828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865393,0.0035695655,0.00006780381,0.008071179,0.00078043406,0.0005731331,0.00030065913,0.000003735684,0.00009416599],"genre_scores_gemma":[0.9951863,0.0029292067,0.00068307726,0.00032932925,0.00040723613,0.000032906522,0.00016521677,0.000014007772,0.00025271985],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942254,0.0012899303,0.0032303836,0.00028744814,0.00065284676,0.00031400385],"domain_scores_gemma":[0.9947806,0.002114112,0.0017810989,0.0003225064,0.00070575665,0.0002959466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003430832,0.00017341902,0.0020749187,0.00021409932,0.00006081373,0.000022690509,0.00019049969,0.00016963317,0.000536689],"category_scores_gemma":[0.0014533661,0.00009809752,0.00075225567,0.00092741026,0.0003537581,0.00012337443,0.00005909991,0.0006897896,0.0000029265696],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79486316,0.009759252,0.020605808,0.00008683015,0.019411579,0.009387434,0.0011664972,0.00034933395,0.022750527,0.00002514104,0.001849275,0.11974517],"study_design_scores_gemma":[0.8378677,0.034145866,0.08275879,0.00044101794,0.013436092,0.00006108262,0.002998725,0.0013815158,0.018309802,0.00048330915,0.0078096306,0.00030647326],"about_ca_topic_score_codex":0.0016457834,"about_ca_topic_score_gemma":0.0044899886,"teacher_disagreement_score":0.1194387,"about_ca_system_score_codex":0.00032600772,"about_ca_system_score_gemma":0.0073709036,"threshold_uncertainty_score":0.9982564},"labels":[],"label_agreement":null},{"id":"W3135535477","doi":"10.1200/jco.2021.39.6_suppl.10","title":"KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre; Sunnybrook Hospital","funders":"","keywords":"Medicine; Enzalutamide; Docetaxel; Prostate cancer; Abiraterone; Cohort; Prednisone; Cabazitaxel; Internal medicine; Oncology; Cancer; Adverse effect; Androgen deprivation therapy; Androgen receptor","score_opus":0.13968818408775974,"score_gpt":0.45052115223611805,"score_spread":0.3108329681483583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135535477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949723,0.0012666056,0.000015478025,0.0009232179,0.0002346711,0.00065065734,0.0017874155,0.000006873296,0.00014279495],"genre_scores_gemma":[0.99043995,0.0017675782,0.0044650272,0.0002680833,0.00022752718,0.0000472782,0.00095865916,0.000036488793,0.0017893983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959729,0.00051822595,0.0019016296,0.00047013414,0.0007802233,0.00035690315],"domain_scores_gemma":[0.99622506,0.00085956143,0.0009878894,0.00041771648,0.0009863354,0.0005234333],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010187504,0.0002351981,0.0015336216,0.00015162288,0.000040698877,0.000028732386,0.00018905634,0.00019528878,0.0018870013],"category_scores_gemma":[0.001229714,0.00014530007,0.0001157251,0.00032836635,0.00032616095,0.0004578962,0.00011816381,0.0006594871,0.0000035967912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28542796,0.0045612287,0.6689049,0.0003621316,0.0026035002,0.004666352,0.0005902539,0.00007188966,0.00044007754,0.0000139436925,0.005027486,0.027330285],"study_design_scores_gemma":[0.06961071,0.012135739,0.91304576,0.0006200171,0.0008239399,0.00014177657,0.00020485402,0.00017610338,0.00022895956,0.00008485558,0.0027593507,0.00016793543],"about_ca_topic_score_codex":0.0002688881,"about_ca_topic_score_gemma":0.003466753,"teacher_disagreement_score":0.24414088,"about_ca_system_score_codex":0.00035561764,"about_ca_system_score_gemma":0.0092241885,"threshold_uncertainty_score":0.9990254},"labels":[],"label_agreement":null},{"id":"W3135651958","doi":"10.1200/jco.2021.39.6_suppl.48","title":"Real-world clinical outcomes study of sequential novel antihormonal therapy (NAH) or radium-223 (Ra-223) treatment of metastatic castration-resistant prostate cancer (mCRPC) that progressed after first-line NAH.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Cohort; Prostate cancer; Internal medicine; Incidence (geometry); Abiraterone acetate; Cancer; Surgery; Gastroenterology; Oncology; Androgen deprivation therapy; Androgen receptor","score_opus":0.3834570783091499,"score_gpt":0.5611084279878157,"score_spread":0.1776513496786658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135651958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98825777,0.002822976,0.000014754514,0.0058463668,0.0010957898,0.0016479092,0.0001463148,0.000011339763,0.00015678917],"genre_scores_gemma":[0.97372067,0.020642534,0.0022575208,0.000228193,0.0006558732,0.00012750154,0.000030388603,0.000044695626,0.0022926321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921867,0.0009502814,0.004714659,0.0005056779,0.0011507722,0.00049189525],"domain_scores_gemma":[0.9916394,0.003088662,0.0028756207,0.00044797448,0.0014211034,0.00052723446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025436764,0.0003870209,0.0035912427,0.00025029993,0.00008039287,0.000024821975,0.00021335647,0.00025399373,0.00056574686],"category_scores_gemma":[0.0006889474,0.00021035863,0.0011259501,0.0004622577,0.00058617035,0.00016340837,0.00007224454,0.00069697265,0.0000028004301],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09292175,0.061342545,0.7651578,0.00014475205,0.0067827404,0.0056630694,0.0008816663,0.000026297364,0.0005415112,0.000009183484,0.000269981,0.06625866],"study_design_scores_gemma":[0.089487575,0.06898683,0.83107674,0.00023406166,0.0018672426,0.000110990906,0.00071529014,0.00005223017,0.0018086777,0.00004219744,0.005431788,0.00018637383],"about_ca_topic_score_codex":0.0006503088,"about_ca_topic_score_gemma":0.008043877,"teacher_disagreement_score":0.066072285,"about_ca_system_score_codex":0.00044830993,"about_ca_system_score_gemma":0.0070020054,"threshold_uncertainty_score":0.99862736},"labels":[],"label_agreement":null},{"id":"W3135675772","doi":"10.15252/emmm.202013427","title":"Androgen receptor (AR) antagonism triggers acute succinate‐mediated adaptive responses to reactivate AR signaling","year":2021,"lang":"en","type":"article","venue":"EMBO Molecular Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Androgen receptor; AMPK; SDHA; Cancer research; Chemistry; Signal transduction; Prostate cancer; Cell biology; Activator (genetics); Biology; Endocrinology; Receptor; Internal medicine; Succinate dehydrogenase; Kinase; Protein kinase A; Biochemistry; Medicine; Cancer; Mitochondrion","score_opus":0.0267857524373139,"score_gpt":0.32412620587846386,"score_spread":0.29734045344114995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135675772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95661634,0.006121843,0.0007235623,0.030854393,0.00045625027,0.0011448357,0.00010138179,0.00017029597,0.0038110812],"genre_scores_gemma":[0.9805043,0.0017329593,0.0019110348,0.0050854543,0.00046659558,0.000149609,0.0010405715,0.00013104866,0.008978425],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966551,0.0003182447,0.0004950542,0.0007890061,0.0009819368,0.00076062867],"domain_scores_gemma":[0.9976043,0.00027478387,0.00011607224,0.0006231603,0.00057031505,0.0008113664],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005895828,0.0004037072,0.00084242417,0.00042079025,0.00016455815,0.000024233825,0.00017449318,0.00018892415,0.0008030552],"category_scores_gemma":[0.00084692094,0.00030605754,0.00017290103,0.0012195513,0.00020418738,0.00009213769,0.000116876436,0.0005021126,0.0001871577],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004701445,0.0001784632,0.0005334588,0.000057672973,0.0009879232,0.010135891,0.0010498851,0.0000038688936,0.9750794,0.0000922106,0.004361802,0.0028179737],"study_design_scores_gemma":[0.007905319,0.0022091304,0.0009043668,0.00063577597,0.0005033656,0.00029569076,0.001196124,0.000041637646,0.9568943,0.0001024915,0.028977731,0.00033406168],"about_ca_topic_score_codex":0.000091257316,"about_ca_topic_score_gemma":0.0000025892882,"teacher_disagreement_score":0.025768938,"about_ca_system_score_codex":0.0003659657,"about_ca_system_score_gemma":0.00074697746,"threshold_uncertainty_score":0.99993914},"labels":[],"label_agreement":null},{"id":"W3135882965","doi":"10.1200/jco.2021.39.6_suppl.15","title":"Prospective randomized trial of gene expression classifier utility following radical prostatectomy (G-MINOR).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Institutes of Health","keywords":"Medicine; Prostatectomy; Randomization; Randomized controlled trial; Prostate cancer; Clinical endpoint; Internal medicine; Clinical trial; Prospective cohort study; Surgery; Cancer","score_opus":0.14080071263276195,"score_gpt":0.49748572608388647,"score_spread":0.3566850134511245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135882965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98462254,0.001832005,0.00041187368,0.0030623875,0.0020735145,0.0013029324,0.000004623188,0.000009537226,0.0066805654],"genre_scores_gemma":[0.98918533,0.0009297526,0.0072631245,0.00020788272,0.0011559174,0.00003414993,0.000007473858,0.000016611915,0.0011997437],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937884,0.0018323518,0.0029895506,0.00028945066,0.00080667844,0.00029356667],"domain_scores_gemma":[0.9928199,0.0041642804,0.0014351669,0.0002596754,0.00087882305,0.0004421331],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0074907104,0.00015776294,0.00321871,0.00011064971,0.00005191343,0.000009804478,0.00012863702,0.00045979102,0.00029260013],"category_scores_gemma":[0.013628378,0.00009211019,0.0017646082,0.00021854942,0.00059832924,0.000112990056,0.00007508096,0.0012295918,0.000004961463],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9524328,0.0041456395,0.015134999,0.000051182386,0.001110864,0.0023824405,0.00014251367,4.781153e-7,0.004771074,0.000044707376,0.00083966646,0.018943628],"study_design_scores_gemma":[0.9385546,0.008221342,0.010312763,0.00020532285,0.00073383976,0.00015347327,0.0001316661,0.000038741146,0.035819497,0.0013318696,0.0044157347,0.00008117183],"about_ca_topic_score_codex":0.000004800351,"about_ca_topic_score_gemma":0.0000019722004,"teacher_disagreement_score":0.031048425,"about_ca_system_score_codex":0.00018746142,"about_ca_system_score_gemma":0.005310743,"threshold_uncertainty_score":0.9946802},"labels":[],"label_agreement":null},{"id":"W3136190116","doi":"10.1016/j.mcpro.2021.100075","title":"Mapping Isoform Abundance and Interactome of the Endogenous TMPRSS2-ERG Fusion Protein by Orthogonal Immunoprecipitation–Mass Spectrometry Assays","year":2021,"lang":"en","type":"article","venue":"Molecular & Cellular Proteomics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary; University of Alberta","funders":"China Scholarship Council; Mitacs; National Natural Science Foundation of China; Prostate Cancer Canada","keywords":"Interactome; TMPRSS2; Fusion protein; Gene isoform; Prostate cancer; Erg; Molecular biology; Biology; Immunoprecipitation; Fusion gene; Computational biology; Chemistry; Cancer research; Gene; Cancer; Genetics; Biochemistry; Recombinant DNA; Medicine; Internal medicine","score_opus":0.012692227595657057,"score_gpt":0.23583496777187876,"score_spread":0.2231427401762217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136190116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97899634,0.0069003035,0.010845401,0.0007705624,0.00008884984,0.0015908653,0.00004039528,0.000023651395,0.0007436374],"genre_scores_gemma":[0.9889717,0.00028334733,0.008812513,0.00008540492,0.000035572608,0.00012932571,0.0001492875,0.000044440836,0.001488381],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981661,0.00016709924,0.00036779046,0.00039354083,0.00052799797,0.00037746478],"domain_scores_gemma":[0.9989291,0.00003495396,0.00017461876,0.00049501564,0.0002558114,0.000110506706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037200493,0.00022372343,0.00033629758,0.00011232741,0.00016584528,0.000050621733,0.00016837471,0.00012795934,0.00008317481],"category_scores_gemma":[0.00015235189,0.000169993,0.0001726671,0.0005200743,0.00015807158,0.00008300173,0.000203646,0.00035632864,0.0000069874745],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019494657,0.00017262337,0.0019851024,0.00027550306,0.00017211167,0.00022509597,0.00038087677,0.0000040238033,0.99557674,0.00013347964,0.000015040635,0.0008644716],"study_design_scores_gemma":[0.0015527839,0.00021927724,0.0014902576,0.00030326893,0.000045148947,0.00012038445,0.00020580826,0.00025754163,0.99464655,0.00051006104,0.0004862022,0.00016274175],"about_ca_topic_score_codex":0.000022888431,"about_ca_topic_score_gemma":0.0000018157824,"teacher_disagreement_score":0.009975393,"about_ca_system_score_codex":0.00020499557,"about_ca_system_score_gemma":0.00038111364,"threshold_uncertainty_score":0.6932114},"labels":[],"label_agreement":null},{"id":"W3136434813","doi":"10.1038/s41585-021-00455-3","title":"Building confidence in circulating tumour DNA assays for metastatic castration-resistant prostate cancer","year":2021,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Liquid biopsy; Oncology; Prostate; Internal medicine; Cancer; Cell-free fetal DNA; Cancer research; Biology","score_opus":0.10715337228298683,"score_gpt":0.46767525240603325,"score_spread":0.3605218801230464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136434813","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020885453,0.9910359,0.00008088113,0.00072421064,0.00041168366,0.007392734,0.00017668237,0.000026801506,0.0001302497],"genre_scores_gemma":[0.00011487692,0.9916814,0.002415684,0.00033355862,0.00030376163,0.0040961676,0.0005646841,0.00009180878,0.00039808927],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955752,0.0008027265,0.001460885,0.0010153974,0.00035501723,0.00079077383],"domain_scores_gemma":[0.99745184,0.0008066199,0.0007516632,0.0004940486,0.0003086233,0.00018721586],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016572971,0.0006431701,0.0043532536,0.00041038,0.00011007933,0.00005032807,0.00024061506,0.0006930692,0.00012270264],"category_scores_gemma":[0.001411605,0.00044356537,0.0008285995,0.0009205024,0.00009987492,0.00008330691,0.00007909351,0.0021001056,0.0000129114105],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007651638,0.00009916235,0.000025548437,0.06615543,0.00042611934,0.00086996634,0.00006000412,0.0000023412929,0.00022551721,0.0012589964,0.00085414504,0.92994624],"study_design_scores_gemma":[0.0010395815,0.00021037375,0.000013543562,0.027058518,0.0024219223,0.00042951654,0.000009351353,0.000024139612,0.000015247855,0.00013485497,0.9683133,0.0003296722],"about_ca_topic_score_codex":0.00004622267,"about_ca_topic_score_gemma":0.00015066279,"teacher_disagreement_score":0.96745914,"about_ca_system_score_codex":0.00059234037,"about_ca_system_score_gemma":0.0022794015,"threshold_uncertainty_score":0.99980164},"labels":[],"label_agreement":null},{"id":"W3136457463","doi":"10.5489/cuaj.7107","title":"18F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy","year":2021,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Bone scintigraphy; Positron emission tomography; Radiology; Nuclear medicine; Bone metastasis; Prostatectomy; Scintigraphy; Cancer; Internal medicine","score_opus":0.019795905779812405,"score_gpt":0.2833117341092103,"score_spread":0.2635158283293979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136457463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8878645,0.0047077388,0.0001436823,0.10485259,0.000560571,0.001053928,0.00064432336,0.0000806655,0.00009203918],"genre_scores_gemma":[0.9864869,0.00058589433,0.0024309421,0.008158231,0.00047140155,0.00015256241,0.0003328538,0.000046068755,0.0013351352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99625576,0.00025116492,0.00069070864,0.0006530368,0.0007981625,0.0013511666],"domain_scores_gemma":[0.99586505,0.00018226016,0.00036952842,0.00026620744,0.0012584873,0.0020584494],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007711102,0.0003734698,0.00073115976,0.0009409622,0.00082243583,0.00040354958,0.00020768578,0.00008388809,0.0004930058],"category_scores_gemma":[0.00023322208,0.00030808564,0.00048146304,0.0014456956,0.00006654435,0.00023787917,0.000059664046,0.0008155917,0.000011183014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010218162,0.00041476393,0.8121933,0.000096564996,0.0012065419,0.0031366197,0.0007124058,0.00017856191,0.0125035355,0.000071833434,0.16167437,0.006789698],"study_design_scores_gemma":[0.013233124,0.0013626603,0.83051527,0.0005155838,0.00072917284,0.0010061259,0.00047810448,0.0011583993,0.018589595,0.003782094,0.12758705,0.0010428579],"about_ca_topic_score_codex":0.0022704005,"about_ca_topic_score_gemma":0.0011811212,"teacher_disagreement_score":0.09862245,"about_ca_system_score_codex":0.0013460128,"about_ca_system_score_gemma":0.0014040734,"threshold_uncertainty_score":0.9999371},"labels":[],"label_agreement":null},{"id":"W3136531756","doi":"10.1038/s41467-021-21860-7","title":"A noncanonical AR addiction drives enzalutamide resistance in prostate cancer","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health; Mayo Clinic","keywords":"Enzalutamide; Prostate cancer; Addiction; Cancer research; Medicine; Resistance (ecology); Cancer; Biology; Internal medicine; Androgen receptor; Psychiatry","score_opus":0.026208722199772317,"score_gpt":0.37619154010265266,"score_spread":0.3499828179028803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136531756","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27163583,0.52783686,0.000008902849,0.12349345,0.0003094959,0.0012544619,0.00024151691,0.00016032829,0.07505914],"genre_scores_gemma":[0.94887704,0.036654886,0.0037292598,0.0006133323,0.000056159326,0.00019496477,0.00034099564,0.000018896166,0.009514471],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99896455,0.00013990124,0.00020647387,0.00023164328,0.0002275613,0.00022989628],"domain_scores_gemma":[0.9982749,0.00016689886,0.000047985573,0.0011297885,0.00028456113,0.00009584701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014018138,0.000103905855,0.00019099827,0.00010442757,0.00012726043,0.000023891303,0.00023820165,0.00015996613,0.00009811881],"category_scores_gemma":[0.00018460354,0.00009062414,0.00006560172,0.0006834681,0.00016062702,0.00008719123,0.0001650889,0.0011723279,0.000020972333],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030074755,0.0048441933,0.71934766,0.0004688385,0.0011717371,0.00102921,0.009245024,0.00005977217,0.08953624,0.043010768,0.09160586,0.036673248],"study_design_scores_gemma":[0.0028719213,0.00005126754,0.29913408,0.0006463641,0.00009315616,0.000016613925,0.00024374983,0.00016938307,0.0065025203,0.0003725683,0.6897191,0.00017927327],"about_ca_topic_score_codex":0.00005096433,"about_ca_topic_score_gemma":0.009880387,"teacher_disagreement_score":0.6772412,"about_ca_system_score_codex":0.0003651281,"about_ca_system_score_gemma":0.00085151417,"threshold_uncertainty_score":0.55134875},"labels":[],"label_agreement":null},{"id":"W3137566103","doi":"10.1016/j.eururo.2021.02.041","title":"Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?","year":2021,"lang":"en","type":"editorial","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Arnold Ventures","keywords":"Olaparib; Medicine; PARP inhibitor; Prostate cancer; Homologous recombination; Oncology; Clinical endpoint; Internal medicine; Prostate; Gene; Cancer; Randomized controlled trial; Poly ADP ribose polymerase; Genetics","score_opus":0.022213001699800724,"score_gpt":0.3445303999727195,"score_spread":0.3223173982729188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137566103","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008654294,0.051174603,0.00009594277,0.01732115,0.88947594,0.019921541,0.0038553267,0.00023622607,0.009265001],"genre_scores_gemma":[0.0018220871,0.008146956,0.00030668237,0.0010136148,0.92476225,0.004066827,0.003885001,0.00041672098,0.055579852],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967882,0.00037961558,0.0005388463,0.0009552965,0.000478848,0.0008591973],"domain_scores_gemma":[0.9965224,0.0014113613,0.0003417842,0.0006963119,0.0008736397,0.00015450199],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010283745,0.00045683072,0.00081918994,0.00009874948,0.00036433685,0.00009139173,0.00041251074,0.00037385675,0.00009445205],"category_scores_gemma":[0.0011592882,0.0002934665,0.00039755742,0.00016936602,0.00020378586,0.000051353265,0.00017215498,0.00097528164,0.000022600681],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.121155724,0.00016263145,0.000025045612,0.00043638685,0.0007378626,0.00013513798,0.0010231278,0.000006057773,0.00020628393,0.000027919055,0.8576482,0.01843565],"study_design_scores_gemma":[0.07769495,0.0047338903,0.000016377413,0.00013444552,0.0006444109,0.0000050821127,0.00015175407,0.000039394636,0.00018691133,0.0001519943,0.9159912,0.00024959448],"about_ca_topic_score_codex":0.000045436926,"about_ca_topic_score_gemma":0.00009603818,"teacher_disagreement_score":0.05834302,"about_ca_system_score_codex":0.00023436947,"about_ca_system_score_gemma":0.0018926006,"threshold_uncertainty_score":0.9999517},"labels":[],"label_agreement":null},{"id":"W3137618571","doi":"10.1007/s00280-021-04249-7","title":"Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)","year":2021,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Abiraterone acetate; Internal medicine; Prednisone; Enzalutamide; Adverse effect; Oncology; Pharmacokinetics; Urology; Discontinuation; Androgen receptor; Cancer; Androgen deprivation therapy","score_opus":0.025117111216251545,"score_gpt":0.34287421252309486,"score_spread":0.3177571013068433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137618571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98088014,0.012787798,0.0000035298017,0.0021806965,0.00013734678,0.0024822576,0.0014491396,0.000031336345,0.00004773576],"genre_scores_gemma":[0.965591,0.031652614,0.00014977832,0.0010970433,0.00011362309,0.00044721595,0.00055628933,0.00004908701,0.00034333026],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978651,0.00021287016,0.00040002388,0.00074913964,0.00032384362,0.00044902827],"domain_scores_gemma":[0.9990008,0.00011607371,0.00016261818,0.00017586736,0.00028842597,0.00025623958],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001630799,0.00035651855,0.000617534,0.00011273086,0.00015238345,0.00003761382,0.00007235835,0.000062536936,0.0010066532],"category_scores_gemma":[0.0000046929363,0.00024446798,0.00003131036,0.00046449134,0.00023604666,0.00013731979,0.000024450575,0.00031680238,9.3101403e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31841272,0.0077573303,0.45042485,0.00017103738,0.004268403,0.0005860746,0.013643585,0.00005623534,0.084066965,0.0000014418895,0.00101205,0.11959931],"study_design_scores_gemma":[0.57178324,0.013038598,0.19998193,0.00029752674,0.0008977877,0.000016920745,0.0015915651,0.0002890063,0.1951334,0.000015071799,0.01619798,0.00075695966],"about_ca_topic_score_codex":0.0009479666,"about_ca_topic_score_gemma":0.0004699596,"teacher_disagreement_score":0.25337052,"about_ca_system_score_codex":0.00020465888,"about_ca_system_score_gemma":0.0006235766,"threshold_uncertainty_score":0.99990654},"labels":[],"label_agreement":null},{"id":"W3138001976","doi":"10.1038/s41598-021-85812-3","title":"Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer","year":2021,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre; Sinai Health System; Lunenfeld-Tanenbaum Research Institute; BC Cancer Agency; University Health Network; University of Toronto","funders":"Hospital for Sick Children; Astellas Pharma; Prostate Cancer Canada; Movember Foundation","keywords":"Prostate cancer; DNA methylation; Methylation; Oncology; Cancer research; Medicine; Castration; DNA; Bioinformatics; Biology; Cancer; Internal medicine; Gene; Genetics; Gene expression; Hormone","score_opus":0.039000085955540414,"score_gpt":0.3292561057749231,"score_spread":0.29025601981938265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138001976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490595,0.0015944546,0.000017890608,0.0009793285,0.00051722885,0.0008868757,0.00005382649,0.000041973784,0.0010024738],"genre_scores_gemma":[0.96547925,0.0000810307,0.00021894666,0.000011379432,0.000022739761,0.0002718945,0.0010981823,0.00002190592,0.03279466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974694,0.00013590339,0.00048388605,0.00078143,0.000730579,0.0003987713],"domain_scores_gemma":[0.9985858,0.000056980145,0.00025656866,0.0005156369,0.00044089425,0.0001440819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007089418,0.00018817243,0.00033713918,0.00017446396,0.0002035642,0.00016819513,0.000030645653,0.000040340794,0.00015933684],"category_scores_gemma":[0.00016833296,0.00012940611,0.00006963983,0.0009602994,0.00012962132,0.00016548566,0.000017638486,0.00010713733,0.0000029797586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017594729,0.001972061,0.74787354,0.00043320167,0.0007128586,0.0496278,0.0051082317,0.00009224149,0.1828674,0.000053653217,0.0013048328,0.008194742],"study_design_scores_gemma":[0.0039136074,0.0004106409,0.79289895,0.0013610702,0.00037562568,0.00013155439,0.0006801825,0.00009120927,0.19316387,0.0013116122,0.0053150207,0.000346632],"about_ca_topic_score_codex":0.00026075647,"about_ca_topic_score_gemma":0.026783776,"teacher_disagreement_score":0.049496245,"about_ca_system_score_codex":0.0010817538,"about_ca_system_score_gemma":0.0014494387,"threshold_uncertainty_score":0.9909749},"labels":[],"label_agreement":null},{"id":"W3138359294","doi":"10.1073/pnas.2012748118","title":"A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer","year":2021,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"U.S. Army; National Institutes of Health; Congressionally Directed Medical Research Programs; National Cancer Institute; Prostate Cancer Foundation","keywords":"Glutaminase; Prostate cancer; Glutamine; Gene isoform; Androgen receptor; Cancer research; Cancer; Biology; Medicine; Internal medicine; Biochemistry; Gene; Amino acid","score_opus":0.040089625775222536,"score_gpt":0.3714131041020251,"score_spread":0.3313234783268026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138359294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97217846,0.010156941,1.2289155e-7,0.016044512,0.000008545322,0.00032109153,0.000031086798,0.0000052564737,0.0012539773],"genre_scores_gemma":[0.996271,0.0016254659,0.00040802074,0.00013618864,0.000025587571,0.000035595825,3.6597484e-7,0.000003708772,0.0014940614],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99847835,0.0000050758536,0.00020695663,0.00020590065,0.0009676228,0.00013608935],"domain_scores_gemma":[0.9991572,0.000050946066,0.00022044855,0.000009625449,0.0004816542,0.00008014135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039428272,0.00007386881,0.00015702918,0.00008488072,0.000121041136,0.000011874913,0.000151216,0.000033981756,0.000012835026],"category_scores_gemma":[0.000249393,0.000040900293,0.00004929641,0.0005941797,0.0009586069,0.00020185625,0.00009195576,0.00009871048,1.1553545e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083317666,0.00029055533,0.36609694,0.001708874,0.00008558162,3.173627e-7,0.0011001186,0.0000032026376,0.6085723,0.01174978,0.0004475581,0.009111576],"study_design_scores_gemma":[0.0007576923,0.00009163212,0.44030222,0.0011608407,0.00005328827,0.000004077853,0.00038916018,0.00015682893,0.5361048,0.020599186,0.000321745,0.00005853503],"about_ca_topic_score_codex":0.0000023495074,"about_ca_topic_score_gemma":1.8033258e-7,"teacher_disagreement_score":0.07420529,"about_ca_system_score_codex":0.000038127455,"about_ca_system_score_gemma":0.00027336282,"threshold_uncertainty_score":0.3532027},"labels":[],"label_agreement":null},{"id":"W3138851413","doi":"10.1016/j.esmoop.2021.100089","title":"An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer","year":2021,"lang":"en","type":"article","venue":"ESMO Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Merck Sharp and Dohme; Johnson and Johnson; Genentech; Astellas Pharma; Roche; National Institute for Health and Care Research; Novartis; Sanofi; GlaxoSmithKline; Merck; Bayer; AstraZeneca; Amgen; Pfizer","keywords":"Cabazitaxel; Docetaxel; Medicine; Prostate cancer; Quality of life (healthcare); Internal medicine; Oncology; Cancer; Chemotherapy; Androgen deprivation therapy","score_opus":0.14885466249602713,"score_gpt":0.4834998996692597,"score_spread":0.3346452371732326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138851413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937745,0.0032204913,0.00000211372,0.0014415932,0.000008305975,0.0013815573,0.00012253349,0.0000024722813,0.00004643257],"genre_scores_gemma":[0.9989636,0.00033884638,0.00019102103,0.00007301079,0.0000016942196,0.00013017465,0.00024303657,0.0000073151077,0.000051330677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797475,0.00053161144,0.00070252747,0.00025300644,0.00035742694,0.00018069735],"domain_scores_gemma":[0.9989384,0.00014045199,0.00032062441,0.0002522958,0.00028500753,0.0000632373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013160808,0.00010733724,0.0008097568,0.00016551327,0.0000770711,0.00003921522,0.000091137554,0.000017141698,0.000027178758],"category_scores_gemma":[0.00012888748,0.00006226633,0.00003068809,0.0012345593,0.00013513188,0.00022246843,0.000043737196,0.00011872274,5.988328e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028107888,0.0019252003,0.9702292,0.00044759343,0.0019652857,0.000042962107,0.01869791,0.00015968754,0.00019453077,0.000046480753,0.000018013781,0.0034623523],"study_design_scores_gemma":[0.013331538,0.0006457739,0.97054106,0.00030497691,0.00037223985,3.2651553e-7,0.014267038,0.00022265324,0.0002161618,0.000026008353,0.0000053131807,0.000066902],"about_ca_topic_score_codex":0.024390895,"about_ca_topic_score_gemma":0.041904446,"teacher_disagreement_score":0.01751355,"about_ca_system_score_codex":0.00013359627,"about_ca_system_score_gemma":0.0008841809,"threshold_uncertainty_score":0.9821058},"labels":[],"label_agreement":null},{"id":"W3139304883","doi":"10.1177/1758835921998586","title":"Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Myovant Sciences","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Adverse effect; Testosterone (patch); Management of prostate cancer; Internal medicine; Oncology; Gonadotropin-releasing hormone; Androgen; Androgen suppression; Cancer; Luteinizing hormone; Endocrinology; Hormone","score_opus":0.0585975078822475,"score_gpt":0.45452544383896826,"score_spread":0.39592793595672077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139304883","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003756005,0.9926577,0.00056949665,0.00037710342,0.00021484429,0.0054189735,0.0000913971,0.000022307366,0.00027257754],"genre_scores_gemma":[0.000093394265,0.9918833,0.002898432,0.00029336804,0.00007443004,0.003824704,0.0006298564,0.000075164244,0.00022738849],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99716437,0.00013682494,0.0008254837,0.00061029475,0.0007511342,0.00051190023],"domain_scores_gemma":[0.99833786,0.00039560505,0.00046520235,0.00036539114,0.00026291402,0.00017301334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040257585,0.0003976905,0.002211435,0.00020646404,0.000044887183,0.0000048136603,0.00025363397,0.00036890805,0.00015502221],"category_scores_gemma":[0.000032143693,0.00024117733,0.00022293904,0.00061416964,0.00033182368,0.000092211805,0.00007442054,0.00046428925,0.0000013717215],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022893087,0.0013616557,0.0004965016,0.0104878135,0.0008947979,0.00006989729,0.000087139684,0.0000044894923,3.782742e-7,0.0002852547,0.00001370836,0.984009],"study_design_scores_gemma":[0.0151104685,0.0021478296,0.00016802161,0.016404042,0.00058468734,0.00001107773,0.00006208831,0.000011549306,0.000009913665,0.000113622766,0.9651487,0.00022804136],"about_ca_topic_score_codex":0.000004524391,"about_ca_topic_score_gemma":0.000014572461,"teacher_disagreement_score":0.98378104,"about_ca_system_score_codex":0.00064989814,"about_ca_system_score_gemma":0.0015689244,"threshold_uncertainty_score":0.9834926},"labels":[],"label_agreement":null},{"id":"W3139707937","doi":"10.1016/j.eururo.2021.03.017","title":"Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"National Center for Advancing Translational Sciences; National Institutes of Health; National Cancer Institute; Vetenskapsrådet","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Biochemical recurrence; Positron emission tomography; Prostate; Prostatectomy; Oncology; Cancer research; Cancer; Lymph node; Internal medicine; Nuclear medicine","score_opus":0.020741619947131414,"score_gpt":0.2755894216283982,"score_spread":0.2548478016812668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139707937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9568578,0.038655043,0.000012537004,0.0020536869,0.0000655521,0.0004139636,0.000100025034,0.000036152713,0.0018052676],"genre_scores_gemma":[0.9738345,0.02241194,0.00036480112,0.0008320853,0.00007163248,0.000013563703,0.00026417937,0.00006130885,0.002145997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982974,0.00035725633,0.00032196357,0.0005032573,0.0001934161,0.00032673654],"domain_scores_gemma":[0.99912465,0.00009602618,0.00013403599,0.0002371922,0.00025092842,0.00015714398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040793113,0.0001911553,0.00052735675,0.00006838805,0.000060304574,0.000018010947,0.000057230725,0.00008338882,0.0000777323],"category_scores_gemma":[0.00004287066,0.00013600508,0.000045247907,0.00020979445,0.000396728,0.00004915125,0.000057664307,0.0002823889,0.0000020954428],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004130341,0.00043143358,0.88125,0.00031745477,0.0008074659,0.0051979665,0.00058186945,0.000016822427,0.09869431,0.000046804365,0.0008227829,0.0077027483],"study_design_scores_gemma":[0.0053339805,0.0010979337,0.968658,0.00012435051,0.00022000678,0.00015843865,0.00005289863,0.000008707581,0.012243158,0.000017107022,0.01192523,0.00016024425],"about_ca_topic_score_codex":0.000015336875,"about_ca_topic_score_gemma":0.00002690976,"teacher_disagreement_score":0.08740794,"about_ca_system_score_codex":0.000021675713,"about_ca_system_score_gemma":0.00019939289,"threshold_uncertainty_score":0.5546126},"labels":[],"label_agreement":null},{"id":"W3140070353","doi":"10.3389/fgene.2021.652747","title":"Tumor Microenvironment in Prostate Cancer: Toward Identification of Novel Molecular Biomarkers for Diagnosis, Prognosis, and Therapy Development","year":2021,"lang":"en","type":"review","venue":"Frontiers in Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Medicine, American University of Beirut; York University; New York University Abu Dhabi; American University of Beirut","keywords":"Prostate cancer; Stromal cell; Stroma; Metastasis; Tumor microenvironment; Medicine; Androgen deprivation therapy; Angiogenesis; Cancer research; Cancer; Disease; Prostate; Bioinformatics; Oncology; Pathology; Internal medicine; Biology; Immunohistochemistry","score_opus":0.05103793970388202,"score_gpt":0.34927593222184583,"score_spread":0.2982379925179638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3140070353","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006702598,0.9871407,0.00029840315,0.00013005243,0.00022950783,0.0053222096,0.000169063,0.000005213183,0.000002239074],"genre_scores_gemma":[0.00020980532,0.9735274,0.019702088,0.000021140233,0.000018698205,0.005941885,0.00045973732,0.000058724527,0.00006056604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99796677,0.00006259019,0.00082387234,0.0005399182,0.00026265535,0.0003442027],"domain_scores_gemma":[0.9993056,0.000031268406,0.00028132045,0.00023305876,0.000059693404,0.000089059715],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029379988,0.00031557013,0.0011572167,0.00036870895,0.000024904504,0.000021243297,0.00012701817,0.00012824862,0.000004409656],"category_scores_gemma":[0.000021409856,0.00026705847,0.00014461369,0.0003380588,0.00012846591,0.00001873127,0.000069602414,0.00015656289,2.0608749e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082097744,0.00052409736,0.03668705,0.0121901315,0.00053755724,0.000030890966,0.0003188747,0.0000045034585,0.00012095896,5.893698e-7,0.000417564,0.9490857],"study_design_scores_gemma":[0.0046907812,0.00024906208,0.0051182,0.017091399,0.0004910717,0.000011342365,0.00023730284,0.00007008741,0.015580421,0.0000069093126,0.9559974,0.00045601095],"about_ca_topic_score_codex":0.0000139368685,"about_ca_topic_score_gemma":0.000005557118,"teacher_disagreement_score":0.9555799,"about_ca_system_score_codex":0.00058099447,"about_ca_system_score_gemma":0.00083975645,"threshold_uncertainty_score":0.9999782},"labels":[],"label_agreement":null},{"id":"W3140212121","doi":"10.1002/cncr.33523","title":"Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen‐receptor–targeted therapy for metastatic castration‐resistant prostate cancer","year":2021,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Kingston Health Sciences Centre; University of Toronto; University Health Network","funders":"Prostate Cancer Canada","keywords":"Medicine; Prostate cancer; Enzalutamide; Internal medicine; Docetaxel; Oncology; Toxicity; Chemotherapy; Cancer; Logistic regression; Androgen deprivation therapy; Geriatric oncology; Androgen receptor","score_opus":0.08414339884429221,"score_gpt":0.39153009875965855,"score_spread":0.3073866999153663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3140212121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665333,0.020083029,0.000017631064,0.008793232,0.0001897669,0.0039845146,0.00030414434,0.000018023404,0.00007636019],"genre_scores_gemma":[0.9786153,0.012948447,0.00048097392,0.00071318046,0.0001800465,0.0048343865,0.000019956547,0.000051212497,0.0021565168],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99742925,0.00030501603,0.00043796698,0.00061905466,0.0006154921,0.00059323845],"domain_scores_gemma":[0.99822956,0.00042131048,0.0001106901,0.0004951088,0.00061077054,0.00013256574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014789226,0.0002275053,0.00043877077,0.00010728601,0.00030573015,0.00006999042,0.00020822631,0.00006867167,0.0004741442],"category_scores_gemma":[0.00022849427,0.00012115392,0.000080659185,0.001055119,0.0002745493,0.00012761977,0.00010494304,0.00035842496,3.3787796e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046471395,0.0003923644,0.23643908,0.00082356995,0.00048120524,0.000012189479,0.010399478,0.000110208166,0.5569506,0.000025538688,0.0029276826,0.18679094],"study_design_scores_gemma":[0.007946531,0.0005257446,0.6314928,0.001780416,0.00008528264,0.0000064955098,0.003817148,0.0004225066,0.3462854,0.00013006324,0.0072406153,0.00026702485],"about_ca_topic_score_codex":0.0017913802,"about_ca_topic_score_gemma":0.003389529,"teacher_disagreement_score":0.39505368,"about_ca_system_score_codex":0.0007529326,"about_ca_system_score_gemma":0.0023953575,"threshold_uncertainty_score":0.51915467},"labels":[],"label_agreement":null},{"id":"W3140398084","doi":"10.1017/s1460396921000236","title":"Review of novel tissue-based biomarkers for prostate cancer: towards personalised and targeted medicine","year":2021,"lang":"en","type":"article","venue":"Journal of Radiotherapy in Practice","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Guelph; Grand River Hospital; McMaster University; University of Waterloo","funders":"","keywords":"Overdiagnosis; Prostate cancer; Medicine; Disease; Cancer; Oncology; Internal medicine; Intensive care medicine","score_opus":0.04253322329329632,"score_gpt":0.4215111970301955,"score_spread":0.3789779737368992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3140398084","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019314792,0.8279823,0.00055525027,0.15085682,0.00022862272,0.0008058237,0.00004029675,0.0000044920844,0.00021160013],"genre_scores_gemma":[0.0120818885,0.9476655,0.030698035,0.008739589,0.0003186771,0.00003231052,0.000023822256,0.000039058636,0.00040110707],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99856323,0.00013526462,0.0005519021,0.00015023917,0.00041648003,0.00018287236],"domain_scores_gemma":[0.99753225,0.0005533136,0.0005619348,0.00013004213,0.0010844885,0.00013799954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014677043,0.00012894509,0.0006213691,0.00017686757,0.000029053528,0.000008978728,0.000064343054,0.000055128898,0.00018768922],"category_scores_gemma":[0.0013777149,0.000087573455,0.00009073406,0.00043183437,0.00012558191,0.00019413828,0.0000060459406,0.00021925406,6.161254e-8],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03673073,0.002557572,0.008333092,0.030231822,0.0046728626,0.0012491171,0.0041904175,0.000033947086,0.6071641,0.00005571176,0.04290723,0.2618734],"study_design_scores_gemma":[0.071369186,0.0075646043,0.004133874,0.046840407,0.0017446367,0.0021953317,0.0019356627,0.0010844003,0.055736404,0.000021903223,0.80704594,0.00032768256],"about_ca_topic_score_codex":0.00012495225,"about_ca_topic_score_gemma":0.0000062109343,"teacher_disagreement_score":0.7641387,"about_ca_system_score_codex":0.0002518625,"about_ca_system_score_gemma":0.0014154043,"threshold_uncertainty_score":0.3571142},"labels":[],"label_agreement":null},{"id":"W3142133875","doi":"10.1158/1538-7445.am2019-1023","title":"Abstract 1023: Combining all-trans retinoic acid therapy with androgen receptor N-terminal domain inhibitors for the treatment of castration-resistant prostate cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Androgen receptor; Transactivation; Prostate cancer; LNCaP; Cancer research; Bicalutamide; Androgen deprivation therapy; Biology; Chemistry; Cancer; Transcription factor; Biochemistry; Genetics; Gene","score_opus":0.0765473766767302,"score_gpt":0.40273880725303324,"score_spread":0.32619143057630307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3142133875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767263,0.0131715005,0.0000028230586,0.0039596525,0.00016134443,0.0053188773,0.0002589967,0.000025073414,0.0003754266],"genre_scores_gemma":[0.97383434,0.01817974,0.00012356043,0.000036573787,0.00026368754,0.0033206856,0.00010082406,0.000067367815,0.00407322],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99727285,0.000099248995,0.0003539843,0.000506072,0.0009728438,0.00079499016],"domain_scores_gemma":[0.99824727,0.00033080167,0.00011446364,0.0004804313,0.0006141996,0.00021285909],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006576988,0.0002642222,0.000435638,0.0001818908,0.00027564736,0.000065446926,0.0001968026,0.000103097154,0.0010198209],"category_scores_gemma":[0.00000992288,0.00014080839,0.00015254566,0.00044611603,0.00044174877,0.00010858136,0.000017476928,0.00026944047,0.00001802858],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033259418,0.0008563728,0.03740257,0.000594805,0.0013065578,0.00007959348,0.0071246373,0.000047982354,0.87254435,0.000052676678,0.0023309474,0.044400074],"study_design_scores_gemma":[0.01978671,0.012826501,0.0123856375,0.00092155824,0.00011616238,0.000014492602,0.0030246163,0.000034617482,0.8579753,0.0000693875,0.092540115,0.00030489557],"about_ca_topic_score_codex":0.0014301294,"about_ca_topic_score_gemma":0.00052376726,"teacher_disagreement_score":0.09020917,"about_ca_system_score_codex":0.0007536402,"about_ca_system_score_gemma":0.0015124248,"threshold_uncertainty_score":0.99989337},"labels":[],"label_agreement":null},{"id":"W3143375719","doi":"10.1038/s41416-021-01376-z","title":"Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression","year":2021,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; Centre Hospitalier de l’Université de Montréal; McGill University; Université Laval; Université de Sherbrooke; Centre hospitalier universitaire de Québec","funders":"","keywords":"Urinary system; Prostate cancer; Medicine; Urine; Prospective cohort study; Internal medicine; Metastasis; Gynecology; Cancer; Cohort study; Oncology; Physiology; Endocrinology","score_opus":0.013711611370692328,"score_gpt":0.3457214588175842,"score_spread":0.3320098474468919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143375719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9150042,0.08336553,0.000002040244,0.0007529331,0.0002271751,0.0003328858,0.0001973619,0.0000042938063,0.00011360389],"genre_scores_gemma":[0.96024805,0.03851473,0.00016255275,0.00008944488,0.00022436015,0.00003374739,0.00000714671,0.000024772296,0.00069519767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998114,0.00018961946,0.0005141197,0.00016720855,0.0007778374,0.00023725041],"domain_scores_gemma":[0.9981555,0.000029860068,0.00068173744,0.00020446179,0.0007189971,0.00020944006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031210535,0.00011221523,0.00042324237,0.00007284826,0.000079483594,0.000022581336,0.00017977876,0.000076193355,0.00046603318],"category_scores_gemma":[0.00007485701,0.00007762445,0.00021214607,0.0002924147,0.00025118087,0.00015361208,0.00007522786,0.00040174837,7.5274653e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002700082,0.0010276499,0.7328019,0.0004726332,0.0008745845,0.0017891955,0.00074898166,0.00004066877,0.022447659,0.0000045481765,0.0010363664,0.23605572],"study_design_scores_gemma":[0.008843781,0.001741333,0.6307154,0.0056008887,0.0006610824,0.0024972016,0.0005558251,0.000022018792,0.3426635,0.00018958755,0.006361437,0.00014792653],"about_ca_topic_score_codex":0.0006091385,"about_ca_topic_score_gemma":0.00016795035,"teacher_disagreement_score":0.32021585,"about_ca_system_score_codex":0.00016751431,"about_ca_system_score_gemma":0.0021166613,"threshold_uncertainty_score":0.51027364},"labels":[],"label_agreement":null},{"id":"W3143844999","doi":"10.1016/j.annonc.2021.03.205","title":"Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta; McGill University; University of Ottawa; Regional Municipality of Durham; Juravinski Cancer Centre; Canada's Michael Smith Genome Sciences Centre; Jewish General Hospital; Kelowna General Hospital; CancerCare Manitoba; Ottawa Hospital; Queen Elizabeth II Health Sciences Centre; University of Saskatchewan; Lakeridge Health; University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada; Terry Fox Research Institute; Movember Foundation; Prostate Cancer Foundation","keywords":"Cabazitaxel; Enzalutamide; Medicine; Abiraterone; Prostate cancer; Open label; Oncology; Docetaxel; Internal medicine; Phases of clinical research; Clinical trial; Chemotherapy; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.28529324821179536,"score_gpt":0.5082174511914536,"score_spread":0.2229242029796582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143844999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773959,0.0045669293,0.0000017129379,0.011628749,0.00039636134,0.004904432,0.00027147256,0.000018618408,0.00081580394],"genre_scores_gemma":[0.98281115,0.007619512,0.0016922405,0.00063677394,0.00013161216,0.0024341682,0.00026071855,0.000041230258,0.0043725856],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99726677,0.00041903774,0.0008497766,0.0004930622,0.00035802563,0.0006133322],"domain_scores_gemma":[0.9980627,0.00053060637,0.00030415624,0.0002456755,0.0006053086,0.00025156254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007034444,0.00024924203,0.0010697969,0.0001587236,0.00012472148,0.000040004456,0.00018409887,0.00011428366,0.0005727942],"category_scores_gemma":[0.00071755715,0.00018237838,0.00009487592,0.0005592681,0.00018843492,0.00021415253,0.00016623043,0.00025400738,0.000010154372],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87001836,0.014265978,0.0001260236,0.00025420028,0.0009213664,0.0028459039,0.0012812695,0.0000082291535,0.042684525,0.000036238303,0.0027339275,0.06482398],"study_design_scores_gemma":[0.8736433,0.040332343,0.0001388266,0.00024956174,0.00040559,0.000023449244,0.0010164032,0.00016637269,0.07434037,0.000042826545,0.009449295,0.0001916626],"about_ca_topic_score_codex":0.0010344008,"about_ca_topic_score_gemma":0.004830962,"teacher_disagreement_score":0.06463232,"about_ca_system_score_codex":0.00025149374,"about_ca_system_score_gemma":0.003943232,"threshold_uncertainty_score":0.7437175},"labels":[],"label_agreement":null},{"id":"W3143865899","doi":"10.4021/jcs77w","title":"Prostate Adenocarcinoma Metastasis and Papillary Thyroid Carcinoma: A Case Report of Coexisting Thyroid Tumors","year":2012,"lang":"en","type":"article","venue":"Journal of Current Surgery","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Thyroid carcinoma; Metastasis; Thyroid; Pathology; Thyroglobulin; Thyroidectomy; Carcinoma; Adenocarcinoma; Prostate; Papillary adenocarcinoma; Thyroid cancer; Immunohistochemistry; Papillary carcinoma; Cancer; Oncology; Internal medicine","score_opus":0.07970267661223941,"score_gpt":0.34657116571979985,"score_spread":0.26686848910756045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143865899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8694693,0.1292768,0.00001682361,0.00029825984,0.000545733,0.00024373045,0.000023223345,0.00000914445,0.00011701786],"genre_scores_gemma":[0.9970998,0.002029176,0.00019119172,0.000017882074,0.00050477695,0.0000078384155,0.00001918852,0.000029180794,0.00010095639],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9973728,0.0001498714,0.0011384739,0.00017583779,0.0006615793,0.0005014292],"domain_scores_gemma":[0.9973125,0.00042203447,0.001013425,0.00024008735,0.00048756273,0.0005244298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021155938,0.00022368123,0.0008800891,0.00047687147,0.00010065771,0.00002021302,0.000052727333,0.000052866224,0.000032536675],"category_scores_gemma":[0.0005286809,0.00015423358,0.00034260793,0.00031619988,0.00017064814,0.0003432806,0.00007290821,0.0004309844,0.000001956074],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006646492,0.00041221737,0.9252213,0.00072919525,0.0002563106,0.057712156,0.0008052778,4.3249153e-7,0.0017171892,0.000011398243,0.0047840793,0.007685763],"study_design_scores_gemma":[0.0033723474,0.000960836,0.3739694,0.0014909738,0.0011631085,0.590977,0.0015353753,0.000025461897,0.022472242,0.00007114744,0.0035530434,0.00040903385],"about_ca_topic_score_codex":0.00002734167,"about_ca_topic_score_gemma":7.9331727e-7,"teacher_disagreement_score":0.55125195,"about_ca_system_score_codex":0.00012467371,"about_ca_system_score_gemma":0.0005613958,"threshold_uncertainty_score":0.6289463},"labels":[],"label_agreement":null},{"id":"W3146562435","doi":"10.1158/1538-7445.am2019-923","title":"Abstract 923: FOXA1 chromatin binding is regulated by LSD1-mediated methylation in prostate cancer cells","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"FOXA1; Coactivator; Prostate cancer; Chromatin; Androgen receptor; Cancer research; Histone; Enhancer; Pioneer factor; Transcription factor; Androgen deprivation therapy; Chemistry; Cancer; Medicine; Internal medicine; Breast cancer; Biochemistry","score_opus":0.05501616584590622,"score_gpt":0.41185329665783543,"score_spread":0.3568371308119292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3146562435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98345983,0.00707298,4.8988665e-7,0.00424868,0.00024401073,0.0026892372,0.00035030363,0.00007082024,0.0018636743],"genre_scores_gemma":[0.9686596,0.0071899053,0.000026345453,0.0001283531,0.00012780813,0.00076769694,0.00032077896,0.00008488085,0.022694655],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99592525,0.00018255653,0.00047469416,0.0007577084,0.00143217,0.0012275958],"domain_scores_gemma":[0.9982713,0.0002755313,0.00011186618,0.0005005091,0.00049292255,0.00034788763],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013383996,0.00027249122,0.0004932807,0.00073637697,0.00015158701,0.00009215848,0.0002460617,0.00021357354,0.0052791415],"category_scores_gemma":[0.00007580625,0.00022305206,0.00009113428,0.0019004261,0.00020485357,0.00027536278,0.00011847911,0.0010824447,0.00080851663],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001039992,0.00016291645,0.034741607,0.00055180566,0.00012597472,0.00007306515,0.0013804617,0.000033024808,0.9290676,0.00000325215,0.024369422,0.008450857],"study_design_scores_gemma":[0.0069750776,0.0003900813,0.039694466,0.0012665085,0.000024293604,0.000002699117,0.0005003082,0.0006332666,0.93362856,0.000060893708,0.016492,0.00033183873],"about_ca_topic_score_codex":0.004993774,"about_ca_topic_score_gemma":0.00020883507,"teacher_disagreement_score":0.02083098,"about_ca_system_score_codex":0.0020443967,"about_ca_system_score_gemma":0.0013061591,"threshold_uncertainty_score":0.9999695},"labels":[],"label_agreement":null},{"id":"W3146651690","doi":"10.6000/1929-2279.2013.02.01.4","title":"An Audit to Evaluate the Clinical Safety and PSA Response of Firmagon® (Degarelix) in Patients with Advanced Metastatic Prostate Cancer -","year":2013,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Radiation therapy; Incidence (geometry); Surgery; Internal medicine","score_opus":0.05982472714688522,"score_gpt":0.4781129102995293,"score_spread":0.41828818315264404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3146651690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781522,0.0043675723,0.0000033206743,0.015306154,0.000085870975,0.0019788682,0.0000717207,0.0000046533337,0.000029624163],"genre_scores_gemma":[0.99007297,0.008512995,0.0004407557,0.00023166343,0.00008693879,0.00019927889,0.000008076482,0.00003394395,0.00041337052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99531555,0.0012367994,0.00089002366,0.00029672368,0.0016680646,0.00059282134],"domain_scores_gemma":[0.99534494,0.00078963215,0.00024548575,0.00037896322,0.0027312136,0.0005097756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005431502,0.00018497923,0.00063616957,0.00046657014,0.00012784143,0.00006690901,0.0003130344,0.00005067369,0.00042753288],"category_scores_gemma":[0.0007140838,0.0000916531,0.00007589997,0.0007895535,0.0005149754,0.00047230726,0.0001106267,0.00086138357,0.00000786919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13372527,0.0008205007,0.747123,0.00019387563,0.0005798947,0.00007170669,0.001518832,0.0004992533,0.0038893276,0.0000068896015,0.0043476145,0.10722386],"study_design_scores_gemma":[0.012474353,0.010031232,0.96906835,0.0009382254,0.00010432533,0.000006720615,0.0005977994,0.00015166622,0.0031273032,0.00014633338,0.0032305312,0.00012314005],"about_ca_topic_score_codex":0.0007019985,"about_ca_topic_score_gemma":0.00028887799,"teacher_disagreement_score":0.22194539,"about_ca_system_score_codex":0.00041569467,"about_ca_system_score_gemma":0.0018134267,"threshold_uncertainty_score":0.46811852},"labels":[],"label_agreement":null},{"id":"W3147101898","doi":"10.1038/s41467-021-22139-7","title":"Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"European Commission; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services; Prostate Cancer Foundation; Lucas Foundation; Pharmaceutical Research and Manufacturers of America Foundation; U.S. Department of Defense","keywords":"FOXA1; Epigenomics; Biology; Prostate cancer; Cancer research; Chromatin; Transcription factor; Histone; Chromatin immunoprecipitation; Androgen receptor; Reprogramming; Epigenetics; Enhancer; Cell biology; Genetics; Cancer; Cell; Gene; DNA methylation; Gene expression","score_opus":0.04600197336227593,"score_gpt":0.39576848505843476,"score_spread":0.3497665116961588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147101898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8571961,0.07795149,7.346338e-7,0.060837273,0.00019834057,0.00096246414,0.0000755511,0.00003206954,0.0027459976],"genre_scores_gemma":[0.9733992,0.02183062,0.0005655595,0.00014488034,0.000020222007,0.0002583657,0.000104252,0.000013458103,0.0036634128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910885,0.00014246875,0.0002100738,0.00017476978,0.0001742506,0.00018957538],"domain_scores_gemma":[0.9979573,0.00009275792,0.000065676984,0.00164341,0.00018788668,0.000052961368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007051729,0.00009408554,0.0001823727,0.000058986276,0.00010779567,0.000008834478,0.00026717008,0.00004350642,0.00004609197],"category_scores_gemma":[0.00013712504,0.00005951268,0.000109290966,0.000692762,0.00012389655,0.00003206086,0.00023427198,0.0004812861,0.0000015840022],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026737625,0.001787184,0.8892336,0.000098686585,0.00027577748,0.00011169283,0.0011019503,0.00001493652,0.02234509,0.0011697469,0.000822581,0.08277137],"study_design_scores_gemma":[0.004858165,0.00025931254,0.63394076,0.00036278242,0.00023384493,0.000105478844,0.0007921243,0.0002520983,0.07875584,0.00014289083,0.28013176,0.00016495955],"about_ca_topic_score_codex":0.0002339348,"about_ca_topic_score_gemma":0.0024644528,"teacher_disagreement_score":0.27930918,"about_ca_system_score_codex":0.00020963051,"about_ca_system_score_gemma":0.00036483735,"threshold_uncertainty_score":0.24268566},"labels":[],"label_agreement":null},{"id":"W3147271558","doi":"10.5489/cuaj.7260","title":"Local salvage ablation therapy after radiation therapy for prostate cancer — are we there yet?","year":2021,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Prostate cancer; Salvage therapy; Radiation therapy; Medicine; Ablation; Ablation Therapy; Cancer; Oncology; Surgery; Internal medicine; Chemotherapy","score_opus":0.025214232079702234,"score_gpt":0.29729239204040553,"score_spread":0.2720781599607033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147271558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7848943,0.039450623,0.00027404586,0.17312773,0.00058480905,0.0009861671,0.0002583751,0.00003934989,0.00038460398],"genre_scores_gemma":[0.96091,0.029387737,0.00006440919,0.00558408,0.00056672766,0.00021825788,0.00011861494,0.000026224236,0.003123914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835783,0.00017926627,0.00027829062,0.0002545152,0.00037734697,0.00055274524],"domain_scores_gemma":[0.9983865,0.00013977783,0.00021588035,0.00010878754,0.0006537151,0.0004953604],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043035785,0.00016373524,0.0002700318,0.0001249364,0.00028939452,0.00013378948,0.00006535923,0.00025893582,0.0014073803],"category_scores_gemma":[0.00014103636,0.000117211035,0.00018309786,0.00026043365,0.000037602353,0.00013934994,0.000006342474,0.00042479465,0.000017072745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012103509,0.00012074772,0.79848015,0.000013055338,0.0003735917,0.00023435485,0.00046753793,0.00008603586,0.00039376624,0.00003237585,0.017985607,0.1806024],"study_design_scores_gemma":[0.00465222,0.0004233526,0.7190171,0.000036801855,0.00003492564,0.00003392486,0.00017337828,0.00028786983,0.00086251984,0.0010221382,0.27331,0.00014577045],"about_ca_topic_score_codex":0.00036523573,"about_ca_topic_score_gemma":0.0011415675,"teacher_disagreement_score":0.2553244,"about_ca_system_score_codex":0.0017819115,"about_ca_system_score_gemma":0.0014254757,"threshold_uncertainty_score":0.99950546},"labels":[],"label_agreement":null},{"id":"W3147725646","doi":"10.1016/j.eururo.2013.08.008","title":"Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment","year":2013,"lang":"en","type":"review","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; BC Cancer Agency","funders":"Janssen Pharmaceuticals; Astellas Pharma Canada; Novartis; Bayer; Amgen","keywords":"Cabazitaxel; Medicine; Enzalutamide; Docetaxel; Clinical trial; Prostate cancer; Taxane; Abiraterone acetate; Oncology; Cancer; Internal medicine; Androgen receptor; Breast cancer; Androgen deprivation therapy","score_opus":0.0855193134577789,"score_gpt":0.3721937028405051,"score_spread":0.2866743893827262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147725646","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003763487,0.9910244,0.00001119314,0.001959285,0.000546359,0.0030948408,0.00031406534,0.00010927931,0.0025642656],"genre_scores_gemma":[0.000012009479,0.9327141,0.0005481884,0.00069788354,0.002050708,0.00023963396,0.0012250376,0.00016655936,0.06234585],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99675715,0.0005956163,0.00068178785,0.0010273458,0.0002031214,0.0007349779],"domain_scores_gemma":[0.99780864,0.0001657091,0.00024978325,0.0007844632,0.00007757831,0.00091380166],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000088172834,0.0006916556,0.0019537557,0.00025882208,0.00008557299,0.00004503577,0.00027671718,0.00020952003,0.0016767739],"category_scores_gemma":[0.000047216367,0.0004469418,0.00040895905,0.00028622325,0.00008602869,0.00004201001,0.00015222668,0.00041269223,0.00529473],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003380693,0.00009996855,0.000012444897,0.00042891785,0.0006576608,0.0009631411,0.00038586103,0.0000021467938,0.00019074246,0.0000095081605,0.039917625,0.95699394],"study_design_scores_gemma":[0.0017911913,0.0031885214,0.00017856101,0.0008059222,0.0014020023,0.000031653926,0.000008195097,7.3778705e-7,0.000010182737,0.00007855975,0.9921832,0.00032125553],"about_ca_topic_score_codex":0.0055172266,"about_ca_topic_score_gemma":0.00020896916,"teacher_disagreement_score":0.95667267,"about_ca_system_score_codex":0.00048762432,"about_ca_system_score_gemma":0.0024702826,"threshold_uncertainty_score":0.99979824},"labels":[],"label_agreement":null},{"id":"W3151414537","doi":"10.1016/j.eururo.2021.03.001","title":"Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP","year":2021,"lang":"en","type":"editorial","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Enzalutamide; Docetaxel; Cabazitaxel; Medicine; Prostate cancer; Oncology; PARP inhibitor; Internal medicine; Chemotherapy; Abiraterone; Poly ADP ribose polymerase; Androgen receptor; Olaparib; Pharmacology; Cancer research; Cancer; Androgen deprivation therapy; Polymerase","score_opus":0.018068637499209773,"score_gpt":0.303282293205035,"score_spread":0.28521365570582524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3151414537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744583,0.002228718,0.000024477911,0.0012693874,0.015236597,0.005567539,0.001056005,0.000046324967,0.0001126784],"genre_scores_gemma":[0.9305339,0.0011904989,0.006211017,0.00080649415,0.049566444,0.0033457354,0.0037296487,0.00052893447,0.0040873587],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99721736,0.00034444366,0.00040843608,0.0010561959,0.0004447429,0.0005288509],"domain_scores_gemma":[0.9985497,0.00016926412,0.00016729944,0.0002671632,0.0004196571,0.000426923],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018329086,0.00052254664,0.0006721382,0.00026062442,0.0001784065,0.0001592329,0.000054427517,0.00013661383,0.0000146519715],"category_scores_gemma":[0.00015290463,0.00034121846,0.00005011845,0.00009438719,0.000095104624,0.000073506635,0.000108496744,0.00028794562,0.0000082858805],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20728855,0.0040963506,0.06276714,0.0024853337,0.0044362475,0.0027735366,0.05296104,0.00006908258,0.002722563,0.000017113058,0.43431106,0.226072],"study_design_scores_gemma":[0.021729972,0.10830853,0.033908315,0.0007090451,0.0013140335,0.000050590545,0.00033517138,0.0000182741,0.00047901826,0.000033999928,0.8322716,0.00084146624],"about_ca_topic_score_codex":0.00005096087,"about_ca_topic_score_gemma":0.00009295043,"teacher_disagreement_score":0.39796054,"about_ca_system_score_codex":0.00024160555,"about_ca_system_score_gemma":0.00024101425,"threshold_uncertainty_score":0.999904},"labels":[],"label_agreement":null},{"id":"W3151619115","doi":"10.1016/j.euo.2021.03.005","title":"Incidental Prostate Cancer (cT1a–cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines","year":2021,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Prostate; Oncology; Medical physics; Internal medicine","score_opus":0.22262775962300127,"score_gpt":0.5128784833823907,"score_spread":0.29025072375938943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3151619115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73472214,0.0064190994,0.0000010658314,0.2549922,0.00043279718,0.0006443565,0.000087689004,0.000019368814,0.0026813329],"genre_scores_gemma":[0.92340386,0.047370896,0.00016868551,0.019943122,0.0007052882,0.00023223028,0.00009406652,0.00004821213,0.008033623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99537134,0.002009118,0.0006951691,0.0007936264,0.0005224035,0.0006083534],"domain_scores_gemma":[0.9981907,0.0005226124,0.000118745746,0.00033328167,0.00063787,0.00019680092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041120723,0.00020614544,0.0004523365,0.0002089255,0.0002040303,0.00006821364,0.0002687766,0.00015946773,0.00033563218],"category_scores_gemma":[0.0009052583,0.00013004389,0.00007268752,0.00033590602,0.0013456774,0.00010530355,0.00068375235,0.0013140312,0.000020763939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003348087,0.00059023034,0.8758079,0.00006796259,0.00027994782,0.006063924,0.006692898,0.0000032725593,0.0019062487,0.00014762366,0.059144415,0.045947522],"study_design_scores_gemma":[0.0075260876,0.0014928824,0.54511774,0.000063575026,0.00009919855,0.0005418675,0.0014298408,0.0002117171,0.00021056776,0.00031572694,0.44283614,0.00015466053],"about_ca_topic_score_codex":0.0006366826,"about_ca_topic_score_gemma":0.0031439436,"teacher_disagreement_score":0.38369173,"about_ca_system_score_codex":0.00020087739,"about_ca_system_score_gemma":0.0010548003,"threshold_uncertainty_score":0.57088846},"labels":[],"label_agreement":null},{"id":"W3151771386","doi":"10.3390/cancers13071588","title":"Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Kom op tegen Kanker; Stichting Tegen Kanker; Cancerfonden; Svenska Forskningsrådet Formas; Familjen Erling-Perssons Stiftelse","keywords":"Prostate cancer; Androgen receptor; Oncology; Medicine; Proportional hazards model; Internal medicine; Biomarker; Gene; Overall survival; Cancer research; Bioinformatics; Biology; Cancer; Genetics","score_opus":0.08999475463178652,"score_gpt":0.35909398794969544,"score_spread":0.2690992333179089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3151771386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863688,0.006909,0.000007485149,0.0029114163,0.00015272893,0.0011225744,0.00045158513,0.00004571445,0.0020307251],"genre_scores_gemma":[0.9949538,0.00077243673,0.00046090566,0.0007189249,0.000036877344,0.00058120204,0.00024851417,0.00003124228,0.0021960784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982266,0.000104886334,0.0003214904,0.0004555333,0.00040183362,0.0004896639],"domain_scores_gemma":[0.9990403,0.000075992015,0.00007492449,0.00028907828,0.00027052962,0.0002491925],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017721797,0.00020706281,0.00038063826,0.00013804485,0.00009199244,0.00004541395,0.00006811956,0.00004852742,0.0011565059],"category_scores_gemma":[0.00010069366,0.0001706913,0.00009472213,0.0007628132,0.00021243996,0.00010163005,0.000036908375,0.00020175366,0.000022974678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009466613,0.0009831492,0.48987573,0.0036180064,0.0021512648,0.013345821,0.008694093,0.00019724504,0.40489787,0.0007257246,0.015410617,0.050633863],"study_design_scores_gemma":[0.02117421,0.00072722294,0.8281492,0.0021408324,0.0005036137,0.00013774571,0.0031866885,0.004574376,0.1128975,0.001107094,0.0245211,0.00088044297],"about_ca_topic_score_codex":0.00525799,"about_ca_topic_score_gemma":0.0044822046,"teacher_disagreement_score":0.33827344,"about_ca_system_score_codex":0.0021464897,"about_ca_system_score_gemma":0.006321529,"threshold_uncertainty_score":0.9997566},"labels":[],"label_agreement":null},{"id":"W3152013950","doi":"10.1016/j.eururo.2015.03.054","title":"Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer","year":2015,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Abiraterone; Prostate cancer; Oncology; Internal medicine; Cancer; Androgen receptor","score_opus":0.034510154443889926,"score_gpt":0.30761034225910344,"score_spread":0.2731001878152135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152013950","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11711613,0.02032427,0.0000012474916,0.8438607,0.00024201645,0.0010561965,0.0001087305,0.00005668261,0.017234067],"genre_scores_gemma":[0.06443712,0.0066760965,0.00028656327,0.8224486,0.0024340786,0.00018568212,0.00029955278,0.00026305323,0.102969214],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99767375,0.0004282111,0.00031398103,0.0007309167,0.00024644745,0.0006066772],"domain_scores_gemma":[0.9991523,0.00007855696,0.00008466516,0.00036984615,0.000102705715,0.00021195276],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050463877,0.00031117327,0.00054822204,0.00030093352,0.00004523516,0.000033893928,0.00011794679,0.00017539969,0.000053945645],"category_scores_gemma":[0.00009712285,0.00024834252,0.000025921478,0.00017804414,0.00025176178,0.000041489973,0.00020628561,0.0012072759,0.00008588295],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014545671,0.000023545545,0.010642131,0.000335302,0.00007599766,0.0114893755,0.0011072902,9.566173e-7,0.00030367752,0.000003841778,0.9724279,0.0021354195],"study_design_scores_gemma":[0.0025753323,0.00063860114,0.019050704,0.00016307613,0.00006859563,0.000054035765,0.000025995467,0.0000018468356,0.000043811004,0.00009247507,0.9770581,0.00022742581],"about_ca_topic_score_codex":0.000086230764,"about_ca_topic_score_gemma":0.00034320971,"teacher_disagreement_score":0.08573514,"about_ca_system_score_codex":0.00014949644,"about_ca_system_score_gemma":0.0001676379,"threshold_uncertainty_score":0.9999969},"labels":[],"label_agreement":null},{"id":"W3152837137","doi":"10.1101/2021.04.20.440154","title":"<i>SPOP</i> mutation confers sensitivity to AR-targeted therapy in prostate cancer by reshaping the androgen-driven chromatin landscape","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"Weill Cornell Medical College; MetLife Foundation; National Cancer Institute; Damon Runyon Cancer Research Foundation; Prostate Cancer Foundation","keywords":"Prostate cancer; Chromatin; Androgen receptor; Cancer research; Biology; Carcinogenesis; Mutant; Mutation; Chromoplexy; Phenotype; Prostate; Reprogramming; Cancer; Genetics; DNA; Gene; PCA3","score_opus":0.01886942159173322,"score_gpt":0.2701182412281904,"score_spread":0.2512488196364572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152837137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821764,0.010752514,0.000046122896,0.0032822806,0.00036385003,0.0027463734,0.0004612079,0.00016165168,0.000009587583],"genre_scores_gemma":[0.9933106,0.0038148267,0.00038980102,0.0011524387,0.00020777681,0.0009730488,0.000013728917,0.00011610048,0.000021688664],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99689156,0.00036129338,0.00047876357,0.0009732155,0.0006016918,0.0006934909],"domain_scores_gemma":[0.99790996,0.000103848404,0.00023573468,0.00081612275,0.0006235373,0.00031077466],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007397244,0.00050844636,0.00071348326,0.00025078875,0.00017871648,0.00022974036,0.0001912087,0.00029047008,0.00007244059],"category_scores_gemma":[0.00012904032,0.00039670384,0.00014191408,0.0008360638,0.00012942842,0.00011934138,0.00023319482,0.00090715283,0.000015621239],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056924723,0.00024644975,0.07886136,0.0003901513,0.00041986816,0.0008634309,0.00031151288,0.0003206678,0.91588175,0.000006241273,0.0020966963,0.000032628835],"study_design_scores_gemma":[0.0037997377,0.00021830127,0.16861904,0.0017111957,0.000111475,2.4830962e-7,0.0000975577,0.0016394657,0.8203152,3.9691744e-7,0.002822802,0.00066462305],"about_ca_topic_score_codex":0.0007495045,"about_ca_topic_score_gemma":0.0001270845,"teacher_disagreement_score":0.09556658,"about_ca_system_score_codex":0.0005890349,"about_ca_system_score_gemma":0.0015970212,"threshold_uncertainty_score":0.9998485},"labels":[],"label_agreement":null},{"id":"W3154460154","doi":"10.21037/tau-20-1341","title":"Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review","year":2021,"lang":"en","type":"review","venue":"Translational Andrology and Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Daiichi Sankyo Europe; Astellas Pharma; Pfizer; Sanofi; Prostate Cancer Foundation","keywords":"Prostate cancer; Medicine; Docetaxel; Taxane; Oncology; Clinical trial; Cabazitaxel; Disease; Internal medicine; Immunotherapy; Cancer; Androgen deprivation therapy; Breast cancer","score_opus":0.14963257769129593,"score_gpt":0.44592425981304656,"score_spread":0.2962916821217506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154460154","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00068668416,0.98655176,0.0000047271687,0.010532217,0.00007051942,0.0018097383,0.00021860484,0.000010802016,0.00011495896],"genre_scores_gemma":[0.00082283106,0.9958666,0.00008607374,0.0004423176,0.00005620883,0.0011775017,0.0009561088,0.00001875762,0.000573618],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99783075,0.0005804321,0.0005594326,0.0005051985,0.00015869625,0.00036547426],"domain_scores_gemma":[0.99900305,0.0005063949,0.00015683306,0.00016924334,0.00007757042,0.00008692694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032633782,0.00035257282,0.0015299805,0.00013986969,0.00018438887,0.000012077681,0.000076367716,0.00018758728,0.00030980067],"category_scores_gemma":[0.00002045491,0.00019579288,0.00022095749,0.00032556738,0.0003712617,0.000051576728,0.00001600457,0.0004596627,0.0000057736934],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011154251,0.00045930242,0.00060669106,0.02370423,0.0030827443,0.002783963,0.0034008257,0.000101876525,0.000015002763,0.0021815572,0.00036492202,0.9621835],"study_design_scores_gemma":[0.0028263761,0.0015425684,0.0003948854,0.008132326,0.004154735,0.0018940843,0.00010049019,0.00009947476,0.0000020138732,0.00019291183,0.9803313,0.0003288117],"about_ca_topic_score_codex":0.00008458992,"about_ca_topic_score_gemma":0.0003321189,"teacher_disagreement_score":0.9799664,"about_ca_system_score_codex":0.00010405161,"about_ca_system_score_gemma":0.0015355459,"threshold_uncertainty_score":0.7984202},"labels":[],"label_agreement":null},{"id":"W3154901103","doi":"10.1016/j.euf.2021.04.003","title":"Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis","year":2021,"lang":"en","type":"review","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"Goethe-Universität Frankfurt am Main","keywords":"Docetaxel; Enzalutamide; Medicine; Oncology; Prostate cancer; Internal medicine; Abiraterone; Cancer","score_opus":0.06909828418963834,"score_gpt":0.3435124568326401,"score_spread":0.2744141726430017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154901103","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010095979,0.99042004,0.000008187331,0.00055151887,0.00024622105,0.00770442,0.0006192447,0.00006598769,0.0002834198],"genre_scores_gemma":[0.0015552562,0.98654705,0.000054356155,0.0001976913,0.00015607159,0.0030610962,0.00078705786,0.00020053024,0.0074408585],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9871137,0.0077697276,0.002010117,0.0015537168,0.00052687293,0.0010258597],"domain_scores_gemma":[0.99648255,0.00062282576,0.00094066514,0.0013068778,0.00025719078,0.0003898718],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.001578901,0.001254576,0.01654349,0.0005556379,0.000106184554,0.00008053888,0.00024764938,0.00019403621,0.0002626983],"category_scores_gemma":[0.00016562123,0.00078602455,0.002845768,0.0014482406,0.0002260258,0.000088276545,0.00027292123,0.0007425862,0.00028802312],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006882774,0.00029078734,0.00006526286,0.48709944,0.4874024,0.018703641,0.00021884384,0.00004251023,1.7777435e-7,0.000024115616,0.00048885786,0.0049756677],"study_design_scores_gemma":[0.0027431361,0.0011339105,0.00009661915,0.03182777,0.9426072,0.0003095684,0.000022473238,0.00001589411,7.626952e-8,0.0000022171414,0.020606022,0.00063508865],"about_ca_topic_score_codex":0.00038046378,"about_ca_topic_score_gemma":0.00023363935,"teacher_disagreement_score":0.45527166,"about_ca_system_score_codex":0.0008842204,"about_ca_system_score_gemma":0.000621471,"threshold_uncertainty_score":0.9994591},"labels":[],"label_agreement":null},{"id":"W3155830986","doi":"10.1158/1557-3265.radsci21-po-077","title":"Abstract PO-077: Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH) - Trial in progress","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Enzalutamide; Clinical endpoint; Prostate cancer; Radionuclide therapy; Oncology; Cabazitaxel; Internal medicine; Hormonal therapy; Docetaxel; Androgen deprivation therapy; Abiraterone acetate; Metastatic breast cancer; Clinical trial; Progression-free survival; Prednisone; Chemotherapy; Cancer; Breast cancer; Androgen receptor","score_opus":0.5805525165238268,"score_gpt":0.6232808433027445,"score_spread":0.04272832677891769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155830986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95363367,0.033502154,4.6551898e-7,0.002242406,0.0005296838,0.009335271,0.0005089057,0.00005335577,0.00019408848],"genre_scores_gemma":[0.9695365,0.014322843,0.0003477502,0.000087532564,0.0013144364,0.008816678,0.00012445166,0.00014366652,0.0053061396],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9894558,0.0022396927,0.002067946,0.0018994805,0.002382421,0.0019546319],"domain_scores_gemma":[0.99520785,0.0012602078,0.0003165711,0.0010682377,0.0013038322,0.0008433259],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004581742,0.00072911556,0.0017349563,0.0004999656,0.00041293897,0.00029379842,0.00028010012,0.00025105226,0.0037077977],"category_scores_gemma":[0.00030236007,0.0004966289,0.00054805854,0.0014883428,0.0007459231,0.00025218294,0.00018837859,0.0013321489,0.000049339367],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.4788779,0.028047265,0.18044952,0.00038057243,0.0038182468,0.014507289,0.0037215329,0.00017138729,0.0062588714,0.0000031152058,0.00023471781,0.28352958],"study_design_scores_gemma":[0.47286737,0.09893325,0.39664823,0.0017180844,0.0010609248,0.000072408446,0.005097099,0.001790212,0.015689172,0.00023568705,0.00458735,0.001300227],"about_ca_topic_score_codex":0.004673292,"about_ca_topic_score_gemma":0.011236687,"teacher_disagreement_score":0.28222936,"about_ca_system_score_codex":0.004255229,"about_ca_system_score_gemma":0.009926135,"threshold_uncertainty_score":0.9997485},"labels":[],"label_agreement":null},{"id":"W3155986965","doi":"10.22037/uj.v18i.4831","title":"5α-Reductase Inhibitors Could Prevent the Clinical and Pathological Progression of Prostate Cancer: A Meta-analysis.","year":2021,"lang":"en","type":"review","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Finasteride; Dutasteride; Prostate cancer; Cochrane Library; Meta-analysis; Internal medicine; Prostate; Pathological; 5 Alpha-Reductase Inhibitor; MEDLINE; Oncology; Cancer; Urology; Gynecology","score_opus":0.31962831407193654,"score_gpt":0.4934718880114609,"score_spread":0.17384357393952438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155986965","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040014187,0.9908746,3.5332693e-7,0.0017050275,0.000140085,0.006492379,0.00029128924,0.000021366122,0.00007477781],"genre_scores_gemma":[0.0007207831,0.97869563,0.00004980195,0.000055429962,0.00020074392,0.017746555,0.00031962668,0.000031395397,0.0021800234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958027,0.0010712716,0.0012160355,0.0007569628,0.00066387915,0.00048916676],"domain_scores_gemma":[0.9978487,0.00036416063,0.0006030776,0.00064217154,0.00020536291,0.00033653874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023269118,0.00041018342,0.004807259,0.00019004694,0.000083854786,0.000041299754,0.00017794406,0.00035075028,0.000096384516],"category_scores_gemma":[0.00031601707,0.00016603537,0.0030344222,0.0009855052,0.00063788553,0.000034774752,0.00027941243,0.0008220294,0.0000015056],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065422646,0.000452449,0.00087082095,0.0039198766,0.07457768,0.00021312664,0.000038282706,1.2005377e-7,5.5581683e-8,0.000007592668,0.0012184894,0.9186361],"study_design_scores_gemma":[0.00054810476,0.00014322117,0.0009804612,0.00062403025,0.42150402,0.000046473862,0.00002315198,7.781505e-7,0.000013409172,0.000010583749,0.57593405,0.0001717477],"about_ca_topic_score_codex":0.000019424173,"about_ca_topic_score_gemma":0.0000073667093,"teacher_disagreement_score":0.91846436,"about_ca_system_score_codex":0.00009130904,"about_ca_system_score_gemma":0.00061645865,"threshold_uncertainty_score":0.67707264},"labels":[],"label_agreement":null},{"id":"W3156322804","doi":"10.1007/s00432-021-03634-2","title":"Expression of ISL1 and its partners in prostate cancer progression and neuroendocrine differentiation","year":2021,"lang":"en","type":"article","venue":"Journal of Cancer Research and Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Rockyview General Hospital; Ontario Institute for Cancer Research; Institute of Cancer Research; Prostate Cancer Canada; Decipher Biosciences (Canada); University of Calgary","funders":"Prostate Cancer Canada; Prostate Cancer Foundation","keywords":"Prostate cancer; Downregulation and upregulation; Cancer research; Metastasis; Neuroendocrine differentiation; Internal medicine; Tumor progression; Prostate; Biomarker; Cancer; Neuroendocrine tumors; Biology; Oncology; Medicine; Gene; Genetics","score_opus":0.1710132296045032,"score_gpt":0.5829486442331917,"score_spread":0.41193541462868855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156322804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9445288,0.04248497,6.364215e-7,0.012440654,0.00012289123,0.00030307323,0.0000075554403,0.0000019633273,0.00010946038],"genre_scores_gemma":[0.7840724,0.2151602,0.000053099757,0.000062357896,0.00014101181,0.000026776712,0.000002453109,0.000007758266,0.00047392782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787205,0.00046259095,0.0006591532,0.00022838663,0.00047414223,0.0003036862],"domain_scores_gemma":[0.99802774,0.0006065591,0.00024318747,0.000078409816,0.00070245727,0.00034163796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009766197,0.00008894269,0.0005548368,0.00018929248,0.000055767374,0.000016913245,0.000048000828,0.00007354301,0.00007288031],"category_scores_gemma":[0.0005311095,0.000056477285,0.000049531664,0.00023528501,0.00032385386,0.000117948715,0.00014653304,0.00079926796,2.0356221e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010929332,0.0010041136,0.7246337,0.00045892913,0.00012094259,0.0013810435,0.00024713503,0.0000012774728,0.04555014,0.000046179848,0.00080485217,0.21482238],"study_design_scores_gemma":[0.02035274,0.011907398,0.87350637,0.0020216925,0.00011756559,0.00028076925,0.00053850055,0.00020476241,0.079182945,0.0007294874,0.011042598,0.00011516033],"about_ca_topic_score_codex":0.000039583923,"about_ca_topic_score_gemma":0.00020713886,"teacher_disagreement_score":0.21470723,"about_ca_system_score_codex":0.00011555795,"about_ca_system_score_gemma":0.0011484994,"threshold_uncertainty_score":0.3472466},"labels":[],"label_agreement":null},{"id":"W3157575440","doi":"10.1016/j.euros.2021.04.005","title":"Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)","year":2021,"lang":"en","type":"article","venue":"European Urology Open Science","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pantharei Bioscience","keywords":"Medicine; Prostate cancer; Internal medicine; Androgen deprivation therapy; Testosterone (patch); Endocrinology; Placebo; N-terminal telopeptide; Goserelin; Urology; Population; Luteinizing hormone; Cancer; Osteocalcin; Hormone; Alkaline phosphatase; Pathology","score_opus":0.11127052007068175,"score_gpt":0.4198355365680645,"score_spread":0.30856501649738277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157575440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880359,0.00049815554,0.000056586396,0.0020909298,0.00014945127,0.005167521,0.000021515389,0.0000145406675,0.003965395],"genre_scores_gemma":[0.99654806,0.00083839963,0.00091008894,0.00032786827,0.000041656902,0.00032489872,0.00006590032,0.000018647936,0.00092451205],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99717,0.0007620522,0.000629444,0.00060265005,0.00044069305,0.0003951992],"domain_scores_gemma":[0.9984315,0.00030668793,0.00027917235,0.000359578,0.00047550103,0.00014756904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002787617,0.00019069514,0.00069415587,0.00023671729,0.00027815875,0.00010596411,0.00033119658,0.000026630672,0.00011861362],"category_scores_gemma":[0.0004237464,0.00012592124,0.00007705317,0.0010951423,0.00084236934,0.00038974974,0.00027874685,0.00019347799,0.000007821155],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9500305,0.0016504815,0.0014953583,0.000011769957,0.00020354312,0.0010838322,0.0036624253,0.000111137204,0.020364298,0.00017196679,0.000022357799,0.021192353],"study_design_scores_gemma":[0.9170718,0.005851371,0.0004362639,0.00004532529,0.00010551399,0.00011653168,0.00041736662,0.00057849707,0.07504282,0.000035877132,0.0001776259,0.00012097211],"about_ca_topic_score_codex":0.0002909148,"about_ca_topic_score_gemma":0.00018937085,"teacher_disagreement_score":0.054678526,"about_ca_system_score_codex":0.000124548,"about_ca_system_score_gemma":0.002426833,"threshold_uncertainty_score":0.5134919},"labels":[],"label_agreement":null},{"id":"W3157765547","doi":"10.3389/fonc.2021.658331","title":"Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Joseph and Silvana Melara Cancer Research Fund","keywords":"Medicine; Prostate cancer; Docetaxel; Androgen deprivation therapy; Internal medicine; Oncology; Abiraterone acetate; Proportional hazards model; Hazard ratio; Progression-free survival; Clinical endpoint; Cabazitaxel; Cohort; Population; Cancer; Randomized controlled trial; Chemotherapy; Confidence interval","score_opus":0.024675362345897,"score_gpt":0.3691055581586356,"score_spread":0.3444301958127386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157765547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996352,0.0009107409,0.00012220415,0.00019310169,0.00027383817,0.0019842952,0.00009770949,0.0000057775765,0.00006032505],"genre_scores_gemma":[0.99763256,0.000102390346,0.0017671114,0.000010032538,0.00001220089,0.00033040767,0.00007456483,0.000013691172,0.00005703517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980705,0.0007768925,0.00037507858,0.00030560058,0.00026567603,0.00020628526],"domain_scores_gemma":[0.999053,0.00032942873,0.00015740356,0.00016242664,0.00023850528,0.00005924024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052714464,0.00013187119,0.0007124537,0.0002649988,0.000026289978,0.0000040375567,0.00004352881,0.000074575946,0.000014765729],"category_scores_gemma":[0.00021784724,0.000098587545,0.00002717398,0.00046681595,0.00012618769,0.00006746412,0.000041179563,0.00017279758,6.630481e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026961554,0.001853564,0.95636594,0.0005105429,0.00025014524,0.0006336354,0.0017319274,0.0007435716,0.0010910656,0.0000026100474,0.000037307185,0.009818115],"study_design_scores_gemma":[0.01873443,0.0058361413,0.9611858,0.0003868969,0.0001449136,0.0000055549785,0.006401899,0.0015873997,0.0055534034,0.00008192151,0.0000043895743,0.00007723418],"about_ca_topic_score_codex":0.00097103993,"about_ca_topic_score_gemma":0.0032444191,"teacher_disagreement_score":0.009740881,"about_ca_system_score_codex":0.0004989573,"about_ca_system_score_gemma":0.0008843151,"threshold_uncertainty_score":0.40202835},"labels":[],"label_agreement":null},{"id":"W3158859410","doi":"10.1111/cas.14935","title":"Establishment and characterization of a novel treatment‐related neuroendocrine prostate cancer cell line KUCaP13","year":2021,"lang":"en","type":"article","venue":"Cancer Science","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Japan Society for the Promotion of Science; Japanese Foundation for Prostate Research","keywords":"Cancer research; Cell culture; Prostate cancer; Biology; Gene knockdown; EZH2; Cancer; Epigenetics; Gene; Genetics","score_opus":0.029691059563170162,"score_gpt":0.33090696517907076,"score_spread":0.3012159056159006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158859410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885845,0.0054203346,0.00001973491,0.004462225,0.0003019671,0.00049983157,0.00015122564,0.000026531166,0.0005336313],"genre_scores_gemma":[0.9587302,0.032605823,0.00015504753,0.00033286825,0.00004171729,0.00016666637,0.000061530576,0.000016207765,0.0078899115],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99852437,0.000014096095,0.00022777241,0.00048635097,0.00038301657,0.0003644018],"domain_scores_gemma":[0.99900436,0.000016284115,0.00010411876,0.00025604875,0.00040008497,0.0002191016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008029838,0.00015010564,0.00025532817,0.00009551037,0.00012215294,0.000048509555,0.00008446348,0.000017741893,0.0002153488],"category_scores_gemma":[0.000019584098,0.00011194177,0.00003816922,0.0009115034,0.0003858938,0.00032563016,0.00008613939,0.00007872427,0.0000013064249],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013725756,0.00039605773,0.016923496,0.00010133477,0.000028934213,0.00006602342,0.0005962953,0.000015721156,0.95461917,0.000031202773,0.000025930885,0.027058568],"study_design_scores_gemma":[0.00511522,0.00054887077,0.049106516,0.00019173733,0.00008777024,0.000050001596,0.00012431863,0.0025830583,0.93732506,0.000006363418,0.0047283466,0.00013271108],"about_ca_topic_score_codex":0.00047287336,"about_ca_topic_score_gemma":0.000055837005,"teacher_disagreement_score":0.032183018,"about_ca_system_score_codex":0.00041830444,"about_ca_system_score_gemma":0.001632834,"threshold_uncertainty_score":0.4564853},"labels":[],"label_agreement":null},{"id":"W3159321340","doi":"10.1101/2021.04.23.441016","title":"MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Prostate cancer; Androgen receptor; Cancer research; Carcinogenesis; Transcription factor; Biology; Transcriptional regulation; Enhancer; Prostate; Cancer; Gene; Genetics","score_opus":0.015511378256763313,"score_gpt":0.26638186030422695,"score_spread":0.25087048204746365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159321340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9222953,0.06984863,0.000039796618,0.0018419062,0.0009938097,0.0017571114,0.0029241352,0.0002888367,0.000010507655],"genre_scores_gemma":[0.97033036,0.024943981,0.001450359,0.00032478277,0.000682506,0.0014942003,0.00005939242,0.00025293397,0.00046147621],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99550104,0.0002035246,0.000678119,0.001610915,0.00095405226,0.0010523556],"domain_scores_gemma":[0.9965244,0.000068225665,0.0005905659,0.0009996556,0.0009743514,0.00084283424],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003273386,0.00081611826,0.0009835521,0.00024058782,0.00040139712,0.0002295968,0.00032092753,0.0005884022,0.00071163336],"category_scores_gemma":[0.00021750023,0.00074526964,0.0003512715,0.000493989,0.0003132631,0.00022594827,0.00045542695,0.0011737895,0.0000653238],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008094072,0.0004906784,0.04863725,0.0014770571,0.0011399053,0.001015695,0.00018737762,0.000025064219,0.9408776,0.000012853703,0.0053066225,0.000020486219],"study_design_scores_gemma":[0.004323129,0.0002161696,0.03494191,0.0038150619,0.0006241236,2.905892e-7,0.000039869214,0.0001314995,0.92445576,7.090974e-7,0.030256283,0.0011951737],"about_ca_topic_score_codex":0.00018132717,"about_ca_topic_score_gemma":0.000014142799,"teacher_disagreement_score":0.0480351,"about_ca_system_score_codex":0.0015342425,"about_ca_system_score_gemma":0.0020118076,"threshold_uncertainty_score":0.99949986},"labels":[],"label_agreement":null},{"id":"W3159545343","doi":"10.2217/fon-2021-0153","title":"Real-World Genetic Testing Patterns in Metastatic Castration-Resistant Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Merck Sharp and Dohme","keywords":"Medicine; FANCA; PALB2; Prostate cancer; Oncology; Genetic testing; Internal medicine; Cancer; DNA repair; Gene; Mutation; Fanconi anemia; Genetics; Germline mutation","score_opus":0.0559407481845942,"score_gpt":0.38897862257168647,"score_spread":0.33303787438709226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159545343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98024774,0.0028567147,0.000005747272,0.007832441,0.00042246736,0.00061936653,0.000068143054,0.00003780513,0.007909553],"genre_scores_gemma":[0.9807584,0.002425174,0.005849065,0.0005777416,0.00075510994,0.00041724357,0.00016220362,0.00003893109,0.009016085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985793,0.00017035386,0.00030280376,0.00034184757,0.00020323157,0.00040243653],"domain_scores_gemma":[0.99921834,0.0001586523,0.000076689226,0.00020430304,0.00020549473,0.00013653302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016394659,0.00014639094,0.00035975873,0.00015080707,0.00006332335,0.000018064993,0.00005323199,0.000064496584,0.00052014255],"category_scores_gemma":[0.00006143994,0.00011533868,0.00004647977,0.00059542584,0.000048692465,0.000040470557,0.00003896688,0.00029670296,0.000016768738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013614069,0.0008426367,0.7506262,0.0007646057,0.00030622797,0.030041689,0.0025077595,0.00009922433,0.059343997,0.0002734513,0.0024005251,0.15143225],"study_design_scores_gemma":[0.004233366,0.0005401294,0.9706986,0.00023512877,0.00014051615,0.0001508881,0.0012487225,0.00015625937,0.00400689,0.00015234556,0.018277386,0.00015980355],"about_ca_topic_score_codex":0.0014265752,"about_ca_topic_score_gemma":0.02863272,"teacher_disagreement_score":0.22007234,"about_ca_system_score_codex":0.0006490545,"about_ca_system_score_gemma":0.0019067733,"threshold_uncertainty_score":0.98909223},"labels":[],"label_agreement":null},{"id":"W3160112606","doi":"10.1172/jci147878","title":"Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"Memorial Sloan-Kettering Cancer Center; Associazione Italiana per la Ricerca sul Cancro; Urology Care Foundation; College of Veterinary Medicine, Cornell University; MetLife Foundation; Damon Runyon Cancer Research Foundation; National Cancer Institute; Prostate Cancer Foundation; Weill Cornell Medical College; U.S. Department of Defense","keywords":"Prostate cancer; Cancer; Disease; Natural history; Biology; Prostate; Pathology; Medicine; Computational biology; Cancer research; Internal medicine; Genetics","score_opus":0.09844316615881343,"score_gpt":0.43650898699870433,"score_spread":0.3380658208398909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160112606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99092185,0.004983742,0.00000914399,0.0034640355,0.00024428955,0.00022871967,0.000006770291,0.0000047290905,0.00013672498],"genre_scores_gemma":[0.9935104,0.0030815843,0.0026738595,0.00040652778,0.00021376705,0.0000065199088,0.000021179872,0.0000131577235,0.000072966286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727786,0.00034228715,0.0016262842,0.00018941335,0.0004179709,0.00014619541],"domain_scores_gemma":[0.9977625,0.00043761282,0.0007840876,0.00012784757,0.00061221374,0.00027571028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018404422,0.00009986441,0.0006385823,0.00008355291,0.000021097474,0.000013714256,0.000052284206,0.00011055285,0.000017250084],"category_scores_gemma":[0.002501505,0.00006699212,0.00017023626,0.0002500223,0.00036437923,0.0001174426,0.00005244408,0.0005247774,9.4201744e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011483775,0.00039019543,0.9470279,0.00024668194,0.00007947524,0.0006427637,0.00006708477,0.0000024996907,0.008085889,0.000039457824,0.00014982975,0.042119842],"study_design_scores_gemma":[0.004602822,0.0012150203,0.97389406,0.0014525683,0.00013177062,0.00005936107,0.000036683665,0.00009477862,0.016757995,0.0014732479,0.00021550657,0.000066189066],"about_ca_topic_score_codex":0.000011494451,"about_ca_topic_score_gemma":0.000013858874,"teacher_disagreement_score":0.042053655,"about_ca_system_score_codex":0.000053764576,"about_ca_system_score_gemma":0.0016970801,"threshold_uncertainty_score":0.30105472},"labels":[],"label_agreement":null},{"id":"W3160325452","doi":"10.1186/s13059-021-02339-6","title":"Functional mapping of androgen receptor enhancer activity","year":2021,"lang":"en","type":"article","venue":"Genome biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"Natural Sciences and Engineering Research Council of Canada; Türkiye Bilimsel ve Teknolojik Araştırma Kurumu; Astellas Pharma; Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada; KWF Kankerbestrijding; Astellas Foundation for Research on Metabolic Disorders; Prostate Cancer Foundation","keywords":"Enhancer; Biology; Androgen receptor; Enhancer RNAs; Promoter; Transcription factor; Gene; Binding site; Regulation of gene expression; Regulatory sequence; Genetics; Transcription (linguistics); Gene expression; Molecular biology; Prostate cancer; Cancer","score_opus":0.0575315143107429,"score_gpt":0.3209653406788414,"score_spread":0.26343382636809853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160325452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991617,0.0038881896,0.00031146602,0.0010405537,0.00018543382,0.000108999295,0.000039381925,0.000012595281,0.0027963417],"genre_scores_gemma":[0.9924236,0.0007222703,0.00037026135,0.00007146036,0.00020343033,0.000019589383,0.00020811256,0.0000060776397,0.005975222],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99949545,0.00003829338,0.00008481863,0.00016788024,0.000056117104,0.00015745035],"domain_scores_gemma":[0.99965626,0.000028704852,0.000029333616,0.00012388117,0.00010967713,0.000052143143],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000070776296,0.000055786262,0.00016978574,0.000048153666,0.000030216364,0.0000016726182,0.000023709814,0.000069682625,0.0022494139],"category_scores_gemma":[0.000023039922,0.000042951146,0.000055423756,0.00013378795,0.00007852652,0.0000147001065,0.00004152222,0.000075248696,0.00007599362],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001898694,0.000079924335,0.01183188,0.000035649977,0.00014426159,0.0000096028125,0.00009646879,2.86917e-7,0.9767064,0.0000569681,0.0003218173,0.010526885],"study_design_scores_gemma":[0.0017100576,0.00033299503,0.11163702,0.000020294452,0.000026835449,0.00003737415,0.00009907472,0.0000032381874,0.72597563,0.00017820389,0.15989165,0.00008762006],"about_ca_topic_score_codex":0.000010407675,"about_ca_topic_score_gemma":0.0000018474663,"teacher_disagreement_score":0.25073075,"about_ca_system_score_codex":0.00006724161,"about_ca_system_score_gemma":0.00027753934,"threshold_uncertainty_score":0.99866265},"labels":[],"label_agreement":null},{"id":"W3160395419","doi":"10.3389/fonc.2021.659135","title":"Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies","year":2021,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Oncology; Overall survival; Logistic regression; Hormone; Gynecology; Cancer","score_opus":0.018360520533807576,"score_gpt":0.34639052559991546,"score_spread":0.32803000506610785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160395419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995941,0.00067932706,0.0000125913475,0.0017819678,0.000083872044,0.0007839236,0.00006266049,0.0000019813472,0.0006527027],"genre_scores_gemma":[0.9984044,0.00059485814,0.00043126955,0.000060703496,0.0000071801214,0.0000756257,0.00008843241,0.000007189083,0.00033036253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987751,0.00041255046,0.00026803438,0.00015439425,0.00021679749,0.00017306967],"domain_scores_gemma":[0.99944896,0.00014103403,0.00009112825,0.000107750326,0.00018590358,0.000025256639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037306524,0.000084502615,0.00037181686,0.00018719815,0.000012539136,0.0000031208249,0.000043370106,0.00004535666,0.000015234975],"category_scores_gemma":[0.00010643117,0.000057824185,0.000037932205,0.0005341394,0.00007552337,0.000044882112,0.000012077755,0.00018779412,0.0000013241681],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014147266,0.003568407,0.91264373,0.000098675184,0.00026879052,0.00032071734,0.028586637,0.00037159843,0.0073837233,0.000051542203,0.004285382,0.028273521],"study_design_scores_gemma":[0.005623111,0.0024718142,0.987539,0.00013660394,0.000018752819,8.9039656e-7,0.0017410427,0.0001307474,0.0019952888,0.0002273327,0.00006417764,0.000051251387],"about_ca_topic_score_codex":0.00055924477,"about_ca_topic_score_gemma":0.0015976089,"teacher_disagreement_score":0.07489525,"about_ca_system_score_codex":0.00077544077,"about_ca_system_score_gemma":0.00049435685,"threshold_uncertainty_score":0.23580018},"labels":[],"label_agreement":null},{"id":"W3160722971","doi":"10.1016/j.euf.2021.04.018","title":"A Clinical Trial of Prophylactic Prostatectomy for BRCA2 Mutation Carriers: Is Now the Time?","year":2021,"lang":"en","type":"editorial","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Clinical trial; Oncology; Population; Internal medicine; Intensive care medicine; Cancer","score_opus":0.03086523607533071,"score_gpt":0.36753881539600697,"score_spread":0.33667357932067626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160722971","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016427668,0.00897351,0.00013100868,0.011804988,0.9335114,0.014069758,0.0013505088,0.00018050993,0.013550671],"genre_scores_gemma":[0.018595561,0.00090719084,0.0002562772,0.00031433944,0.9468761,0.0004596773,0.0018600731,0.00028073334,0.030450039],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99595636,0.001262847,0.00089140004,0.0007623801,0.0006541909,0.00047280133],"domain_scores_gemma":[0.9956696,0.0020069908,0.00053391524,0.0007598798,0.0008704982,0.00015914196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020947866,0.0003414387,0.0009141935,0.00013471692,0.00013736484,0.000039657512,0.00031832053,0.000505496,0.00016023609],"category_scores_gemma":[0.003400862,0.00021471655,0.00054094737,0.00022469483,0.0005708394,0.000042285767,0.00015157179,0.0013318189,0.0001813596],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08612422,0.0004034624,0.00003090874,0.00030758762,0.0008492591,0.00056529074,0.00038614328,4.559176e-7,0.00007571079,0.0000022954678,0.8966082,0.014646469],"study_design_scores_gemma":[0.079868995,0.013524535,0.000059968017,0.00006473586,0.0011446363,0.0000187394,0.000028460814,0.000027707467,0.00029673107,0.00006803567,0.9047127,0.00018480935],"about_ca_topic_score_codex":0.000013429675,"about_ca_topic_score_gemma":0.000005922144,"teacher_disagreement_score":0.016899368,"about_ca_system_score_codex":0.000092526854,"about_ca_system_score_gemma":0.0017593019,"threshold_uncertainty_score":0.8755887},"labels":[],"label_agreement":null},{"id":"W3161387627","doi":"10.3390/cancers13102363","title":"Copy Number Profiles of Prostate Cancer in Men of Middle Eastern Ancestry","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Rockyview General Hospital; University of Calgary; University of Toronto","funders":"National Cancer Institute; Prostate Cancer Foundation","keywords":"Copy-number variation; Genetics; Prostate cancer; Biology; Gene duplication; Cancer; Genome; Copy number analysis; Gene","score_opus":0.05636714061464857,"score_gpt":0.3616988271034275,"score_spread":0.3053316864887789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161387627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794084,0.0064173024,0.0000012443753,0.0004261427,0.00011781271,0.00038337556,0.00012224884,0.000009540725,0.013113927],"genre_scores_gemma":[0.9865539,0.0035532352,0.00013511715,0.000043476844,0.00005423207,0.00013166157,0.000031114694,0.00001688812,0.00948034],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989937,0.00002971716,0.0002514143,0.00021823277,0.00025919217,0.00024773754],"domain_scores_gemma":[0.9993862,0.000022643888,0.00009353108,0.00019837529,0.00021475423,0.000084498344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007723141,0.00010444499,0.00033415513,0.000050682742,0.000014390857,0.000004053422,0.00006071957,0.000055953693,0.0006966919],"category_scores_gemma":[0.000019372706,0.00008559579,0.000058800815,0.00037181296,0.00016269395,0.0000602043,0.00003477217,0.00012589793,0.0000064599885],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070145325,0.00005973023,0.9777392,0.00096200017,0.00011553063,0.00010028579,0.0013314578,0.00012510411,0.012604023,0.000029469911,0.0008930782,0.0053386777],"study_design_scores_gemma":[0.007012426,0.00024037519,0.0942965,0.0025631143,0.00008845643,0.000014820098,0.0035170314,0.00038648638,0.888593,0.00011475043,0.002971974,0.00020105983],"about_ca_topic_score_codex":0.0013610553,"about_ca_topic_score_gemma":0.00021776895,"teacher_disagreement_score":0.8834427,"about_ca_system_score_codex":0.00061850855,"about_ca_system_score_gemma":0.0023656657,"threshold_uncertainty_score":0.76282877},"labels":[],"label_agreement":null},{"id":"W3161420966","doi":"10.1101/2021.05.11.21256306","title":"Exploring the extracellular transcriptome in seminal plasma for non-invasive prostate cancer diagnosis","year":2021,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Prostate cancer; PCA3; Prostate; TMPRSS2; Biomarker; Cancer; Transcriptome; Cancer research; Biology; Medicine; Internal medicine; Oncology; Disease; Gene expression; Gene; Genetics","score_opus":0.10996862432633397,"score_gpt":0.33484669569207715,"score_spread":0.22487807136574317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161420966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761262,0.01248367,0.00003393715,0.0064642713,0.0010877027,0.0034549027,0.00020989637,0.000039673687,0.00009972443],"genre_scores_gemma":[0.91987604,0.040776405,0.00023847235,0.00007829996,0.0004053802,0.035706565,0.00024398984,0.0000824079,0.0025924463],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975123,0.000086487176,0.00045013314,0.00077870645,0.00049631175,0.0006761052],"domain_scores_gemma":[0.99852073,0.00036681147,0.00011077302,0.0005839772,0.00023138004,0.00018634203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005106155,0.00039987004,0.0006724701,0.00022135943,0.00012811548,0.000091799826,0.00028671708,0.0001679842,0.00014331583],"category_scores_gemma":[0.0001418209,0.00026956538,0.00034772092,0.00031850746,0.00014360511,0.0001191701,0.00017829379,0.0009928547,0.0000061854953],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021519817,0.00084195065,0.8693508,0.008206417,0.0011898115,0.0025684065,0.03228542,0.00047171518,0.04677982,0.000016103748,0.0012422733,0.034895305],"study_design_scores_gemma":[0.011735788,0.000745192,0.27578944,0.013937709,0.0011955084,0.00004824136,0.0066909865,0.0017531463,0.66700023,0.00015104923,0.019766677,0.0011860196],"about_ca_topic_score_codex":0.00043886193,"about_ca_topic_score_gemma":0.0006530611,"teacher_disagreement_score":0.6202204,"about_ca_system_score_codex":0.00043168207,"about_ca_system_score_gemma":0.0010148535,"threshold_uncertainty_score":0.9999757},"labels":[],"label_agreement":null},{"id":"W3162099604","doi":"10.1038/s41391-021-00378-5","title":"Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease","year":2021,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; Movember Foundation; Turun Yliopistollinen Keskussairaala; Tays; Academy of Finland; Cancer Research UK; Syöpäsäätiö; National Institutes of Health; Ovarian Cancer Research Fund; Génome Québec; McGill University; Helsingin Yliopisto; Breast Cancer Research Foundation","keywords":"Odds ratio; Prostate cancer; Medicine; Single-nucleotide polymorphism; Oncology; Genome-wide association study; Germline; Internal medicine; Genetics; Population; Gene; Cancer; Bioinformatics; Biology; Genotype","score_opus":0.019750970737134946,"score_gpt":0.32454213157981127,"score_spread":0.3047911608426763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162099604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9314958,0.043588072,0.000020542282,0.005384222,0.0004547552,0.004137406,0.014653061,0.0001504955,0.000115637966],"genre_scores_gemma":[0.96136427,0.02117535,0.0005826267,0.0021624994,0.00029489284,0.0039487104,0.0022471661,0.00013348515,0.008091019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99592274,0.000092782015,0.0006038686,0.0013822423,0.0009229651,0.0010753949],"domain_scores_gemma":[0.9956432,0.00013209697,0.00024488964,0.00065142254,0.0012934261,0.0020349897],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012493976,0.0006021033,0.00073824363,0.0001796248,0.00038163632,0.00023179688,0.0001521556,0.00007810561,0.000503384],"category_scores_gemma":[0.00053667795,0.00047910953,0.00019437517,0.00072312326,0.00038073148,0.00037322944,0.00031132353,0.0002578716,0.000024204848],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073062466,0.0018422136,0.9067123,0.0022913367,0.0004167339,0.00048040168,0.0023941384,0.00007323378,0.0038872864,0.000027024593,0.0032515635,0.071317546],"study_design_scores_gemma":[0.010624513,0.0008247886,0.96628374,0.0018069672,0.0010709356,0.000014715284,0.00054215296,0.00016367139,0.010465712,0.0005528823,0.0067936108,0.0008563413],"about_ca_topic_score_codex":0.00032082968,"about_ca_topic_score_gemma":0.00014288274,"teacher_disagreement_score":0.070461206,"about_ca_system_score_codex":0.0004473791,"about_ca_system_score_gemma":0.0024097443,"threshold_uncertainty_score":0.99976605},"labels":[],"label_agreement":null},{"id":"W3162357932","doi":"10.1038/s41416-021-01410-0","title":"PALB2 mutations and prostate cancer risk and survival","year":2021,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Women's College Hospital; University of Toronto","funders":"Narodowe Centrum Nauki","keywords":"Prostate cancer; Hazard ratio; Medicine; Odds ratio; PALB2; Confidence interval; Internal medicine; Cancer; Oncology; Prostate; Gynecology; Mutation; Genetics; Biology; Germline mutation","score_opus":0.017558245570224507,"score_gpt":0.33631361155831363,"score_spread":0.3187553659880891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162357932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8056025,0.19162737,0.000011507599,0.0019877162,0.00020673934,0.00010102165,0.0001102668,0.0000045910133,0.00034831566],"genre_scores_gemma":[0.69899154,0.29729453,0.00024040314,0.00011497167,0.00027749926,0.000017154442,0.0000061449177,0.000014527209,0.003043247],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991532,0.000056889494,0.00021447868,0.00013072106,0.00026792363,0.00017676846],"domain_scores_gemma":[0.99908996,0.00005176765,0.00011841953,0.000049943934,0.00048770677,0.00020220896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017587497,0.000074118114,0.00024374972,0.000049021182,0.000116950476,0.00008064109,0.000025027664,0.000037916856,0.00030878143],"category_scores_gemma":[0.00008352332,0.00006817659,0.000049544087,0.00013933584,0.000121967954,0.00012166101,0.000025933185,0.00027673852,6.5886553e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002629002,0.000070389455,0.45818654,0.00012224005,0.00034489884,0.0026498253,0.00042878103,0.000011408059,0.0014296205,0.000009040785,0.0014751331,0.5350092],"study_design_scores_gemma":[0.0065966574,0.00021583863,0.9467345,0.0012323554,0.00042968793,0.0032030002,0.00065748265,0.00003598581,0.0041544186,0.00038737588,0.03621394,0.00013875935],"about_ca_topic_score_codex":0.0010312394,"about_ca_topic_score_gemma":0.0018571336,"teacher_disagreement_score":0.53487045,"about_ca_system_score_codex":0.00008017961,"about_ca_system_score_gemma":0.00059844484,"threshold_uncertainty_score":0.33809403},"labels":[],"label_agreement":null},{"id":"W3162712564","doi":"10.1038/s41585-021-00470-4","title":"Treatment and trials in non-metastatic castration-resistant prostate cancer","year":2021,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Internal medicine; Oncology; Androgen deprivation therapy; Metastasis; Androgen receptor; Placebo; Cancer; Disease; Pathology","score_opus":0.13577911162651235,"score_gpt":0.49222047868182495,"score_spread":0.3564413670553126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162712564","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003412642,0.9902819,6.2084257e-7,0.0010620096,0.00029743492,0.0077663874,0.0002614299,0.000013747462,0.00028239263],"genre_scores_gemma":[0.000025958649,0.9927944,0.0002019915,0.00019537454,0.00025853273,0.0037132965,0.00093021966,0.000060438746,0.0018197981],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945379,0.0020635738,0.001783596,0.00086891983,0.0002054642,0.00054058374],"domain_scores_gemma":[0.9975908,0.0008756959,0.00070356316,0.00050751166,0.00010637895,0.00021609731],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001718559,0.0006861833,0.008332672,0.00043746334,0.00005915416,0.000038958464,0.00010457798,0.0007274944,0.00023261007],"category_scores_gemma":[0.0008278347,0.00037551732,0.00085541775,0.0006827501,0.00011349904,0.000046081143,0.000054464494,0.0012791712,0.000029106015],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014097267,0.00018345335,0.00006074901,0.02043709,0.00060074386,0.0009933693,0.000073303876,9.684121e-8,0.000006476904,0.000036433383,0.0007689098,0.9766984],"study_design_scores_gemma":[0.002249455,0.00073442864,0.000034556386,0.010922855,0.0043975995,0.0004166159,0.000007728784,0.0000015533819,0.0000022234508,0.000012087955,0.98098046,0.00024042466],"about_ca_topic_score_codex":0.000098536526,"about_ca_topic_score_gemma":0.00029323035,"teacher_disagreement_score":0.98021156,"about_ca_system_score_codex":0.00064162805,"about_ca_system_score_gemma":0.0018231808,"threshold_uncertainty_score":0.9998697},"labels":[],"label_agreement":null},{"id":"W3162982128","doi":"10.1158/0008-5472.can-20-3694","title":"SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council; Beatson Institute for Cancer Research; CRUK and EPSRC Cancer Imaging Centre in Cambridge and Manchester; Ligue Contre le Cancer; European Commission; Cancer Research UK","keywords":"Prostate cancer; Androgen deprivation therapy; mTORC1; Cancer research; Androgen receptor; Amino acid transporter; PI3K/AKT/mTOR pathway; Regulator; Prostate; Cancer; Androgen; Medicine; Transporter; Internal medicine; Biology; Signal transduction; Hormone; Cell biology; Biochemistry; Gene","score_opus":0.09149100848381074,"score_gpt":0.4304945983274098,"score_spread":0.3390035898435991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162982128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801571,0.004601438,0.0000010425379,0.010999066,0.00013160058,0.0010559325,0.00007874147,0.000049509803,0.0029255685],"genre_scores_gemma":[0.97449243,0.0041302983,0.000054947137,0.000111886984,0.00028879568,0.0011627259,0.00020734148,0.000047789876,0.019503787],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966667,0.00024308905,0.00033264668,0.00058755884,0.0013184189,0.0008515608],"domain_scores_gemma":[0.99748176,0.00024332816,0.00005158951,0.0003907771,0.0015549335,0.00027761134],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007925398,0.00018304071,0.00032283316,0.00040836076,0.00020366066,0.00009703651,0.00012392063,0.00014578085,0.0018191384],"category_scores_gemma":[0.00042359656,0.00015254634,0.00006729117,0.001870425,0.00022534562,0.0002157471,0.00009494633,0.0007447061,0.0000544249],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020179779,0.00023731713,0.043611236,0.0003434283,0.00011569225,0.00029175443,0.0010098586,0.000044362445,0.9396818,0.000091408336,0.004743807,0.007811354],"study_design_scores_gemma":[0.005263382,0.00030315295,0.18993534,0.0011202998,0.000024285444,0.000007946544,0.000986021,0.00014701081,0.78845876,0.00034286105,0.013169023,0.000241908],"about_ca_topic_score_codex":0.004205585,"about_ca_topic_score_gemma":0.004245532,"teacher_disagreement_score":0.15122303,"about_ca_system_score_codex":0.002047526,"about_ca_system_score_gemma":0.005014188,"threshold_uncertainty_score":0.99909335},"labels":[],"label_agreement":null},{"id":"W3163731137","doi":"10.1016/j.euo.2021.04.008","title":"Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)","year":2021,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Clinical endpoint; Prostate cancer; Hazard ratio; Androgen deprivation therapy; Population; Prostatectomy; Internal medicine; Urology; Testosterone (patch); Prostate-specific antigen; Biochemical recurrence; Randomized controlled trial; Confidence interval; Oncology; Cancer","score_opus":0.0251811069725022,"score_gpt":0.33797486306754854,"score_spread":0.31279375609504634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163731137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858949,0.006431571,0.000035460354,0.0024447846,0.00035128978,0.004177641,0.000029367337,0.00003239826,0.00060255284],"genre_scores_gemma":[0.98145974,0.015296676,0.00028093092,0.0005595883,0.00021776384,0.0013250695,0.0001195005,0.000047010504,0.00069371465],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99486387,0.003074733,0.00090342865,0.0005058524,0.00023416468,0.00041794553],"domain_scores_gemma":[0.9975389,0.0011811941,0.00049569336,0.00031151375,0.00034070018,0.00013196513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019881134,0.0002596819,0.0022539515,0.00025654887,0.000038720817,0.000009110639,0.00008575858,0.00013457733,0.00034360314],"category_scores_gemma":[0.0007834952,0.00014575738,0.00023629719,0.00034311856,0.0005057172,0.0000454684,0.000055439607,0.00040744382,0.000010377303],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94459987,0.0034917945,0.019980276,0.000032511478,0.0010013985,0.0016863062,0.0004721218,0.0000036614892,0.0021602456,0.000005629076,0.00018555485,0.026380658],"study_design_scores_gemma":[0.9832635,0.0073901583,0.0013232719,0.000055146655,0.00046869664,0.00007895456,0.000026399019,0.00007135153,0.004539859,0.000032125434,0.0026029306,0.00014762039],"about_ca_topic_score_codex":0.000055273933,"about_ca_topic_score_gemma":0.00010481519,"teacher_disagreement_score":0.038663644,"about_ca_system_score_codex":0.00012300866,"about_ca_system_score_gemma":0.0015398298,"threshold_uncertainty_score":0.59438133},"labels":[],"label_agreement":null},{"id":"W3164251373","doi":"10.1001/jamaoncol.2021.1463","title":"Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Prostate cancer; Internal medicine; Oncology; Proportional hazards model; Enzalutamide; Cohort; Confidence interval; Cancer; Androgen receptor","score_opus":0.02506877602564506,"score_gpt":0.3563358219363845,"score_spread":0.33126704591073947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164251373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884149,0.0003287112,0.000038157144,0.009774921,0.00007728592,0.00071892847,0.00007211354,0.0000101334945,0.00056484557],"genre_scores_gemma":[0.9925085,0.00017281281,0.0011818296,0.0002224098,0.000036627596,0.00030720027,0.00009307771,0.000016092936,0.0054614614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987533,0.00013554894,0.00030433276,0.0002464675,0.00027687833,0.00028349183],"domain_scores_gemma":[0.9992972,0.00011242747,0.00011383314,0.00015029115,0.00022014903,0.00010608063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011768876,0.00012764064,0.00044668617,0.00012650232,0.000024399773,0.0000137550005,0.000034001507,0.00008652722,0.00018781592],"category_scores_gemma":[0.0000833237,0.00008898809,0.000057299447,0.00030287917,0.000031430394,0.0000397457,0.000020856118,0.00011350901,0.00000861469],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004729493,0.0013692706,0.71260977,0.00019079114,0.0007216824,0.002268237,0.0021950952,0.0002177776,0.24849476,0.0000918217,0.000170261,0.026941026],"study_design_scores_gemma":[0.017307622,0.005518838,0.7840358,0.0001665558,0.0005384517,0.000029069262,0.0007950696,0.00009987216,0.18681198,0.000089843066,0.0044103893,0.00019653217],"about_ca_topic_score_codex":0.0009467433,"about_ca_topic_score_gemma":0.008058852,"teacher_disagreement_score":0.07142599,"about_ca_system_score_codex":0.0017726549,"about_ca_system_score_gemma":0.0009867896,"threshold_uncertainty_score":0.46354312},"labels":[],"label_agreement":null},{"id":"W3164510972","doi":"10.1016/j.eururo.2021.05.016","title":"Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy","year":2021,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency; Queen's University; University of British Columbia","funders":"Astellas Pharma US","keywords":"Medicine; Enzalutamide; Prostate cancer; Hazard ratio; Androgen deprivation therapy; Oncology; Internal medicine; Hormonal therapy; Hormone therapy; Interim analysis; Prostate; Cancer; Confidence interval; Urology; Clinical trial; Breast cancer; Androgen receptor","score_opus":0.024867884516760856,"score_gpt":0.2810322654030481,"score_spread":0.25616438088628724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164510972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882573,0.005314585,0.00006778165,0.0007386274,0.000009204573,0.00048361908,0.00003713624,0.00002994339,0.005061836],"genre_scores_gemma":[0.9937801,0.0046057664,0.00031097507,0.00018063067,0.0000289453,0.000018032784,0.000117259966,0.000046184912,0.00091212423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866414,0.00039008187,0.0001683095,0.0003362318,0.00019054832,0.00025069684],"domain_scores_gemma":[0.99928063,0.0000788252,0.00009576883,0.00020045218,0.00024730864,0.00009700561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018398958,0.00017128036,0.00037906924,0.00007582678,0.00005703198,0.000012106094,0.000036019686,0.000020823436,0.000032060758],"category_scores_gemma":[0.000014236153,0.00010443484,0.000028942548,0.00018402879,0.00020770986,0.000061279105,0.000027705104,0.0001310708,0.000004025208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06311595,0.0013284639,0.46369326,0.0002530155,0.010387388,0.015352245,0.009756546,0.00042448766,0.39484638,0.00047695616,0.00034745247,0.040017843],"study_design_scores_gemma":[0.028328037,0.008249451,0.8263079,0.00006438223,0.0010197612,0.0007664883,0.00053553155,0.00034293171,0.13088207,0.00003835,0.0030906969,0.00037444086],"about_ca_topic_score_codex":0.00015629538,"about_ca_topic_score_gemma":0.00007005556,"teacher_disagreement_score":0.3626146,"about_ca_system_score_codex":0.00003967583,"about_ca_system_score_gemma":0.00022307869,"threshold_uncertainty_score":0.42587292},"labels":[],"label_agreement":null},{"id":"W3164642352","doi":"10.48083/sawc9585","title":"Urine Biomarkers for Prostate Cancer Diagnosis and Progression","year":2021,"lang":"en","type":"article","venue":"Société Internationale d’Urologie Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Urine; Medicine; Risk stratification; Biomarker; Stage (stratigraphy); Oncology; Cancer; Internal medicine","score_opus":0.06483383410715844,"score_gpt":0.42668939633660535,"score_spread":0.3618555622294469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164642352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9235882,0.022611568,0.00010646883,0.05095156,0.0007296136,0.00060918654,0.00012304574,0.000037932998,0.0012424334],"genre_scores_gemma":[0.9347437,0.047569267,0.0030491354,0.0013122669,0.0008912237,0.0012116889,0.0001979893,0.000030592055,0.010994125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989355,0.000042197396,0.00022003912,0.00021898685,0.0003192688,0.00026395894],"domain_scores_gemma":[0.9988951,0.00019751236,0.00011409683,0.000081308404,0.00055902766,0.00015293427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025697207,0.000116762276,0.00018783685,0.00009370235,0.00017778705,0.000076874356,0.000070657305,0.00007272429,0.0006365968],"category_scores_gemma":[0.00032067057,0.00008323758,0.00012739455,0.00009550658,0.00010317098,0.00011485411,0.000075485994,0.00023759526,0.000002024547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013902119,0.00034373318,0.70105743,0.0001169265,0.000943014,0.00040791195,0.00023970868,0.0000043535747,0.0025130322,0.00009303126,0.02389852,0.2689921],"study_design_scores_gemma":[0.027570482,0.0026099642,0.50482947,0.00090766436,0.00056110084,0.0019849688,0.0014031512,0.001146014,0.067647286,0.007925073,0.38288552,0.0005293205],"about_ca_topic_score_codex":0.0000064331557,"about_ca_topic_score_gemma":0.0000075326893,"teacher_disagreement_score":0.35898697,"about_ca_system_score_codex":0.0002016564,"about_ca_system_score_gemma":0.00039980348,"threshold_uncertainty_score":0.6970289},"labels":[],"label_agreement":null},{"id":"W3164777726","doi":"10.2139/ssrn.3245213","title":"Somatic Mutations and Risk-Variants Converge on Cis-Regulatory Elements to Reveal the Cancer Driver Transcription Regulators in Primary Prostate Tumors","year":2018,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Somatic cell; Prostate cancer; Biology; Transcription factor; Genetics; Gene; Cancer research; Medicine; Cancer","score_opus":0.010012872880667123,"score_gpt":0.28210019560241106,"score_spread":0.27208732272174396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164777726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994545,0.0012008344,0.000054756798,0.002964708,0.00014524495,0.00088158465,0.00002114576,0.000016745445,0.0001699822],"genre_scores_gemma":[0.9938861,0.0032104405,0.000050079325,0.00025371445,0.00020914467,0.00007359083,0.000015647067,0.000028251205,0.002273036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975143,0.00015484613,0.0003544241,0.00026930653,0.00044192802,0.0012651582],"domain_scores_gemma":[0.99937016,0.000033406213,0.00013510617,0.00019547973,0.000103427585,0.00016245103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012949809,0.00017239469,0.00022986626,0.00022864589,0.00033448255,0.000037171118,0.00011649008,0.000053915723,0.00006202511],"category_scores_gemma":[0.00002788246,0.00011123837,0.00005969343,0.00028616766,0.0001620181,0.00014314332,0.00002195305,0.0009437778,0.000022490241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073259445,0.0006889689,0.85491097,0.00017357085,0.0014682207,0.00008207883,0.012593384,0.000050746134,0.033333723,0.0035313384,0.0012828902,0.084558174],"study_design_scores_gemma":[0.0058446676,0.002690934,0.9755572,0.0003934145,0.00018920182,0.00016639898,0.0014763972,0.0001887797,0.0023102595,0.01068942,0.00029848388,0.00019485204],"about_ca_topic_score_codex":0.00017300535,"about_ca_topic_score_gemma":0.0009993379,"teacher_disagreement_score":0.12064622,"about_ca_system_score_codex":0.0019320705,"about_ca_system_score_gemma":0.0018848666,"threshold_uncertainty_score":0.5052297},"labels":[],"label_agreement":null},{"id":"W3165392750","doi":"10.1038/s41391-021-00395-4","title":"Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","year":2021,"lang":"en","type":"review","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Adverse effect; Internal medicine; Oncology; Subgroup analysis; Population; Meta-analysis; Cancer; Androgen receptor","score_opus":0.04713426913375306,"score_gpt":0.3554620909676744,"score_spread":0.3083278218339213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165392750","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014734173,0.94768906,0.000024959274,0.0005432464,0.00010153008,0.02510349,0.024989152,0.0000683767,0.0000067696305],"genre_scores_gemma":[0.0017858623,0.9372323,0.00066448236,0.00035848882,0.00010149067,0.053802222,0.0031101967,0.00023042582,0.0027145406],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9925736,0.00086197135,0.0020869707,0.002150444,0.0009778097,0.0013492005],"domain_scores_gemma":[0.9946365,0.0010988802,0.0015438128,0.0010000856,0.0006302193,0.0010905107],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0007714161,0.0018892168,0.012521852,0.0004323032,0.0005014757,0.00024156115,0.00016707166,0.00017533252,0.00015053045],"category_scores_gemma":[0.00015979235,0.0011211893,0.0015793128,0.0011834238,0.00044634906,0.00036874803,0.00016745522,0.00040924037,0.0000028029028],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029053343,0.00037013448,0.004028172,0.7858266,0.1895066,0.00047224868,0.00054099946,0.00004698226,2.8503092e-7,0.000022989529,0.00013026108,0.016149376],"study_design_scores_gemma":[0.005447187,0.0022777584,0.0011277059,0.1083084,0.87573254,0.000063716245,0.0001798274,0.000080702775,0.0000016004199,0.00015212772,0.005373487,0.0012549406],"about_ca_topic_score_codex":0.0015968303,"about_ca_topic_score_gemma":0.0012592366,"teacher_disagreement_score":0.68622595,"about_ca_system_score_codex":0.0007135307,"about_ca_system_score_gemma":0.0025678116,"threshold_uncertainty_score":0.9993852},"labels":[],"label_agreement":null},{"id":"W3165599343","doi":"10.1016/j.euo.2021.05.004","title":"Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? Eur Urol Oncol. In press","year":2021,"lang":"en","type":"letter","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre","funders":"","keywords":"Medicine; Prostate cancer; Gynecology; Cancer; Internal medicine","score_opus":0.055677404488332166,"score_gpt":0.37010723138857665,"score_spread":0.31442982690024446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165599343","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.281043,0.014450487,0.00002663966,0.68252647,0.0014986244,0.008256503,0.00034564806,0.000124236,0.011728416],"genre_scores_gemma":[0.019383712,0.013474413,0.0012650845,0.92680407,0.005029409,0.0028484745,0.0015650619,0.0005348559,0.029094934],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928191,0.0021608898,0.0014118683,0.0017309987,0.00041642995,0.0014607633],"domain_scores_gemma":[0.9973344,0.0006329838,0.00040024397,0.0007957805,0.0005014157,0.00033518404],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016523061,0.0007256585,0.0017222232,0.0008248482,0.00011985714,0.00004837437,0.00042698812,0.00084650447,0.00014651811],"category_scores_gemma":[0.0007234652,0.0006301448,0.00019518357,0.0004662867,0.00033800007,0.00010854666,0.0007198784,0.0026968475,0.000044357716],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007039647,0.00048590582,0.018721338,0.0004417373,0.0003429623,0.030641567,0.0024003359,0.00010603375,0.0009802481,0.000007047047,0.88896084,0.049872313],"study_design_scores_gemma":[0.013058012,0.004627392,0.022301678,0.00032605944,0.0003066045,0.00071201584,0.00016086872,0.00017979079,0.00009567005,0.000059408114,0.95765555,0.00051692885],"about_ca_topic_score_codex":0.0017544685,"about_ca_topic_score_gemma":0.001688801,"teacher_disagreement_score":0.26165926,"about_ca_system_score_codex":0.0010422993,"about_ca_system_score_gemma":0.0014297097,"threshold_uncertainty_score":0.999615},"labels":[],"label_agreement":null},{"id":"W3165701213","doi":"10.1158/1078-0432.ccr-21-1625","title":"Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbotsford Veterinary Clinic; University of the Fraser Valley; Interior Health; BC Cancer Agency; Spinal Cord Injury BC; Island Health; University of British Columbia","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; Canadian Cancer Society; Prostate Cancer Canada; Institute of Cancer Research; Jane ja Aatos Erkon Säätiö; Prostate Cancer Foundation; Government of Canada; Academy of Finland","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Somatic cell; Cancer research; Oncology; Biology; Genotype; Mutation; Internal medicine; Cancer; Abiraterone; Exome sequencing; Medicine; Gene; Genetics","score_opus":0.1548736304656693,"score_gpt":0.48229699450883784,"score_spread":0.3274233640431685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165701213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863022,0.00885129,0.0000023795997,0.0027817471,0.000269004,0.0009239693,0.00029027983,0.000022748265,0.0005563872],"genre_scores_gemma":[0.9878634,0.0076840953,0.00006710328,0.000021594717,0.00048562625,0.00045436577,0.00010151874,0.000031293795,0.0032909987],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962072,0.0006092866,0.0008398048,0.00062013726,0.00107176,0.0006518173],"domain_scores_gemma":[0.99779963,0.00021708549,0.000113275324,0.0003602912,0.0012246578,0.0002850553],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017429724,0.0001509062,0.00046142284,0.00027696256,0.00014948787,0.00003565354,0.00009141338,0.0002047751,0.0013231345],"category_scores_gemma":[0.00045428364,0.00012999293,0.00016341647,0.0011945469,0.00046627215,0.00015714542,0.0001451173,0.00091072894,0.000026213145],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00775181,0.0008903385,0.2740348,0.000926775,0.00015918919,0.00062601233,0.00045862573,0.00006434966,0.703849,0.00019332676,0.00069346424,0.010352323],"study_design_scores_gemma":[0.011540123,0.0009289392,0.31393215,0.0019693656,0.000046894907,0.000015560614,0.00091122976,0.00013086105,0.6673664,0.00044173858,0.0024706123,0.0002461359],"about_ca_topic_score_codex":0.0020445047,"about_ca_topic_score_gemma":0.003078786,"teacher_disagreement_score":0.03989736,"about_ca_system_score_codex":0.001492351,"about_ca_system_score_gemma":0.0047808364,"threshold_uncertainty_score":0.9995898},"labels":[],"label_agreement":null},{"id":"W3166222017","doi":"10.3390/cancers13112844","title":"Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in Canada","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia; BC Cancer Agency; Princess Margaret Cancer Centre; University of Calgary; University of Ottawa; McGill University; University of Alberta; Ottawa Hospital; Jewish General Hospital; University of Toronto; Cancer Care Ontario; McMaster University; Juravinski Cancer Centre; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Neutrophil to lymphocyte ratio; Cohort; Proportional hazards model; Population; Oncology; Prostate-specific antigen; Multivariate analysis; Cancer; Retrospective cohort study; Lymphocyte","score_opus":0.0199120178765816,"score_gpt":0.3066518634520079,"score_spread":0.2867398455754263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166222017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974772,0.00028386587,0.0000019513886,0.00076477125,0.000030228186,0.0011956879,0.00018154972,0.0000105223935,0.000054222073],"genre_scores_gemma":[0.99925894,0.000044445373,0.00005653388,0.000084846855,0.000026917587,0.00021406669,0.00020923506,0.00001804066,0.000086966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855494,0.00024052667,0.00022214431,0.00027174756,0.0003903342,0.00032031588],"domain_scores_gemma":[0.99920225,0.00026833016,0.000100066005,0.0000995307,0.00021300398,0.00011683672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002657942,0.00013932485,0.00034706498,0.00009258776,0.000049267117,0.000027376938,0.000023029397,0.000031596803,0.0000074144796],"category_scores_gemma":[0.0000905302,0.0001238168,0.000011008281,0.00046814798,0.000014436835,0.000091057,0.000009179361,0.00021464044,1.8253068e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000311258,0.000046411627,0.99410546,0.00010025046,0.00014952352,0.00084079016,0.0009702753,0.0023099466,0.0001778167,0.0000010871016,0.000019301107,0.00096785463],"study_design_scores_gemma":[0.0055548595,0.00037206893,0.9895678,0.00024650834,0.0001450253,0.0000020303273,0.0024210615,0.0010067157,0.00054633454,0.0000069255366,0.0000074757004,0.00012320784],"about_ca_topic_score_codex":0.83846986,"about_ca_topic_score_gemma":0.98793024,"teacher_disagreement_score":0.14946038,"about_ca_system_score_codex":0.015156145,"about_ca_system_score_gemma":0.015511565,"threshold_uncertainty_score":0.99006957},"labels":[],"label_agreement":null},{"id":"W3166259184","doi":"10.1158/1078-0432.ccr-21-0358","title":"Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prevention of Organ Failure; University of British Columbia","funders":"Janssen Research and Development","keywords":"Prostate cancer; Androgen receptor; Medicine; Androgen deprivation therapy; Enzalutamide; Internal medicine; Oncology; Biomarker; Proportional hazards model; Metastasis; Cancer; Androgen; Antiandrogen; Biology; Hormone","score_opus":0.07527895759064986,"score_gpt":0.42445680304503575,"score_spread":0.3491778454543859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166259184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98793477,0.0050281333,0.0000019630595,0.0031471194,0.000033293923,0.0033906326,0.00039056333,0.000032292504,0.000041236217],"genre_scores_gemma":[0.99024236,0.006343835,0.00037915897,0.00015533171,0.00005457867,0.001886814,0.00030483978,0.000071212926,0.00056185125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99544895,0.0007957002,0.0005959646,0.0009881104,0.0013925701,0.0007786816],"domain_scores_gemma":[0.99687207,0.0004791023,0.00013661475,0.00053727813,0.0011770783,0.0007978368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011758587,0.00031002925,0.0006155711,0.0003307528,0.00022644195,0.00015310963,0.00013417771,0.00006411939,0.00025710886],"category_scores_gemma":[0.00032375666,0.00018676507,0.00006504122,0.0013397894,0.00044516817,0.00017596595,0.000094976975,0.00060065946,0.000011820251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036808208,0.0018060799,0.92898667,0.00020898221,0.0008277086,0.00093138823,0.00030829245,0.000034162833,0.00018712824,0.000015779777,0.000075485,0.029810097],"study_design_scores_gemma":[0.023727274,0.0040487,0.96904576,0.0006687856,0.0003074821,0.000004830043,0.00021378318,0.000079420446,0.0013204109,0.00012233891,0.00021242787,0.00024880873],"about_ca_topic_score_codex":0.0022416152,"about_ca_topic_score_gemma":0.0030019763,"teacher_disagreement_score":0.04005905,"about_ca_system_score_codex":0.00019208775,"about_ca_system_score_gemma":0.0020668753,"threshold_uncertainty_score":0.76160586},"labels":[],"label_agreement":null},{"id":"W3166274652","doi":"10.1200/jco.2021.39.15_suppl.5002","title":"Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Denosumab; Population; Internal medicine; Adverse effect; Oncology; Randomized controlled trial; Incidence (geometry); FRAX; Asymptomatic; Surgery; Cancer; Osteoporosis; Androgen receptor; Bone mineral","score_opus":0.13460935779372213,"score_gpt":0.4848886222871188,"score_spread":0.3502792644933967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166274652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900312,0.0006475953,0.0003747467,0.007093891,0.0004187326,0.00079698465,0.00001275626,0.000015673464,0.0006084384],"genre_scores_gemma":[0.99452865,0.00047780445,0.0017709993,0.0021605836,0.000577356,0.000021468313,0.00028015545,0.000029984998,0.00015296877],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99139374,0.004290729,0.0025458767,0.0004338804,0.00081145077,0.00052433665],"domain_scores_gemma":[0.99224293,0.0044073253,0.0018744313,0.00040069292,0.00059844577,0.00047617205],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.012628425,0.00026413813,0.0021064884,0.00025407903,0.00023004352,0.00006267196,0.0002753064,0.00043000665,0.00031293143],"category_scores_gemma":[0.005597774,0.00014975618,0.00046048508,0.0011462332,0.00022035491,0.00023664995,0.00006942679,0.0030242638,0.000004291239],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8601562,0.008105811,0.04732068,0.000049595652,0.0076311817,0.016836002,0.0015284424,0.0006845872,0.0019660986,0.000013702716,0.0030511967,0.05265655],"study_design_scores_gemma":[0.7512624,0.043706164,0.14084274,0.00039935307,0.00776664,0.0006341913,0.0059079737,0.0031322716,0.0021790394,0.00016391737,0.043462947,0.0005423229],"about_ca_topic_score_codex":0.00015199641,"about_ca_topic_score_gemma":0.0005330325,"teacher_disagreement_score":0.108893715,"about_ca_system_score_codex":0.00038287003,"about_ca_system_score_gemma":0.0028858841,"threshold_uncertainty_score":0.9992758},"labels":[],"label_agreement":null},{"id":"W3166956800","doi":"10.1200/jco.2021.39.15_suppl.e17056","title":"Associations of pre-existing cardiovascular disease (CVD) with treatment patterns and survival outcomes in patients with metastatic prostate cancer: A real-world, population-based study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Interquartile range; Cancer; Internal medicine; Cancer registry; Population; Proportional hazards model; Oncology; Radiation therapy; Comorbidity; Disease","score_opus":0.13442533197162196,"score_gpt":0.476342423185486,"score_spread":0.34191709121386404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166956800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99779755,0.0002911361,0.00001105547,0.0008998605,0.00010204496,0.0007482093,0.00010667386,0.0000039281185,0.000039532464],"genre_scores_gemma":[0.998829,0.00028719328,0.0005080016,0.0000427599,0.000052234154,0.00003703512,0.000059328173,0.00001639,0.00016802529],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970913,0.00068702357,0.0011610365,0.00021886018,0.00064909866,0.00019265883],"domain_scores_gemma":[0.9969247,0.0011467739,0.00080888596,0.0001943165,0.00065880973,0.00026651283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010237518,0.00014231198,0.0016471036,0.00014841516,0.00004317875,0.000009926464,0.000043115117,0.000040773408,0.000015744263],"category_scores_gemma":[0.00060023885,0.000078644814,0.00024700098,0.00024147383,0.000056074878,0.000071423856,0.000019852465,0.00025602346,1.4413294e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00628815,0.0058957846,0.96886957,0.000060788105,0.0038482342,0.0007970095,0.00020848424,0.0007948339,1.9360307e-7,0.0000029357707,0.0000016945181,0.013232338],"study_design_scores_gemma":[0.03222561,0.009443635,0.9555465,0.00018259496,0.0022556442,0.0000012403804,0.00016777914,0.00005411721,0.000003695971,0.0000114944805,0.000036016885,0.00007166813],"about_ca_topic_score_codex":0.003211636,"about_ca_topic_score_gemma":0.010332527,"teacher_disagreement_score":0.025937459,"about_ca_system_score_codex":0.000530794,"about_ca_system_score_gemma":0.0024691785,"threshold_uncertainty_score":0.5765792},"labels":[],"label_agreement":null},{"id":"W3167099310","doi":"10.1200/jco.2021.39.15_suppl.tps5087","title":"Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using <sup>177</sup>Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Enzalutamide; Clinical endpoint; Prostate cancer; Oncology; Hormonal therapy; Radionuclide therapy; Internal medicine; Androgen deprivation therapy; Cabazitaxel; Abiraterone acetate; Chemotherapy; Clinical trial; Cancer; Androgen receptor","score_opus":0.41269038254573515,"score_gpt":0.5696239092667471,"score_spread":0.15693352672101196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167099310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805463,0.01407815,0.000007850695,0.0029385278,0.00051104143,0.0014743442,0.00011154018,0.000016214422,0.00031602813],"genre_scores_gemma":[0.9788241,0.010429899,0.0039088577,0.0005166367,0.0015149504,0.00019770514,0.000023045213,0.00007007915,0.0045147617],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9926335,0.0018136372,0.00316093,0.0006411614,0.0009964048,0.0007543417],"domain_scores_gemma":[0.9945154,0.0015833562,0.0014259662,0.00044184655,0.0012695858,0.0007638155],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027286925,0.00051234337,0.0026768402,0.00023324424,0.00017716085,0.000066570225,0.00014744596,0.00024075349,0.0015057295],"category_scores_gemma":[0.00045145967,0.00030367772,0.00091878616,0.0003893084,0.00026307857,0.00020592098,0.00006662141,0.00079575327,0.000018978302],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11470712,0.040869996,0.14787486,0.00013027148,0.018126687,0.07234017,0.0069253445,0.0024776007,0.007762697,0.000006054659,0.00042721632,0.58835196],"study_design_scores_gemma":[0.2130234,0.48470813,0.22889037,0.00085113756,0.0104392255,0.0041150884,0.014506958,0.00711261,0.008522282,0.00046541088,0.026297906,0.0010674712],"about_ca_topic_score_codex":0.00021140346,"about_ca_topic_score_gemma":0.00070218503,"teacher_disagreement_score":0.5872845,"about_ca_system_score_codex":0.002312071,"about_ca_system_score_gemma":0.010878177,"threshold_uncertainty_score":0.9999415},"labels":[],"label_agreement":null},{"id":"W3167779332","doi":"10.1200/jco.2021.39.15_suppl.5042","title":"Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"","keywords":"Enzalutamide; Medicine; Pembrolizumab; Abiraterone; Prostate cancer; Cohort; Internal medicine; Oncology; Clinical endpoint; Docetaxel; Cancer; Clinical trial; Immunotherapy; Androgen receptor","score_opus":0.17601262121427924,"score_gpt":0.48352181287242263,"score_spread":0.3075091916581434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167779332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99047875,0.002906225,0.000030704075,0.0021524564,0.00041461145,0.0008737193,0.003056773,0.0000039550755,0.00008281998],"genre_scores_gemma":[0.9955469,0.0007904437,0.0020911582,0.00027982172,0.00025929196,0.00008857305,0.00014348961,0.000023115845,0.00077720574],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99557036,0.000689404,0.0023507453,0.0003124406,0.0008096224,0.00026745422],"domain_scores_gemma":[0.9936363,0.0027055189,0.0016490896,0.00028530514,0.0014362563,0.00028751415],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013054913,0.00019101953,0.0017852858,0.00012765148,0.00007461461,0.000016828782,0.0001458356,0.00015621475,0.001511169],"category_scores_gemma":[0.0023215672,0.000117739386,0.00055501366,0.00028923346,0.0004376486,0.000106845146,0.0000918045,0.0004998262,0.0000010205962],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.515832,0.018117571,0.266507,0.0012948024,0.035809807,0.004861411,0.0041568563,0.00045247126,0.10166781,0.00028813354,0.024500612,0.026511565],"study_design_scores_gemma":[0.052943718,0.012019586,0.911163,0.000699057,0.0053725154,0.00006738616,0.0021692172,0.00013328917,0.0074101756,0.0016194991,0.0061891642,0.00021342399],"about_ca_topic_score_codex":0.0003609459,"about_ca_topic_score_gemma":0.0024493358,"teacher_disagreement_score":0.644656,"about_ca_system_score_codex":0.0002918665,"about_ca_system_score_gemma":0.006513799,"threshold_uncertainty_score":0.99940157},"labels":[],"label_agreement":null},{"id":"W3168464126","doi":"10.1200/jco.2021.39.15_suppl.5038","title":"Complementary detection of genomic alterations in metastatic castration-resistant prostate cancer (mCRPC) from CheckMate 9KD through analyses of tumor tissue and plasma DNA.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Enzalutamide; Prostate cancer; Abiraterone; Medicine; Germline; Oncology; Cancer research; Gene; Fusion gene; DNA sequencing; Internal medicine; Cancer; Computational biology; Biology; Genetics; Androgen receptor","score_opus":0.26212701438473324,"score_gpt":0.5410428733183825,"score_spread":0.2789158589336493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168464126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994093,0.0029973602,0.000062043255,0.0021792024,0.00021755256,0.00023403321,0.0001237195,0.0000017259777,0.00009134246],"genre_scores_gemma":[0.99231696,0.002783591,0.0045018406,0.00014225088,0.00013269197,0.000009611968,0.000030160267,0.000008523341,0.00007439426],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99725074,0.00036100036,0.0018498881,0.00015496506,0.00024062989,0.00014278892],"domain_scores_gemma":[0.99750876,0.00084230315,0.0010267156,0.00010515681,0.00040679253,0.000110295296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006795882,0.00009573507,0.001028346,0.00010464241,0.000031116364,0.0000072140338,0.00005122303,0.00005698934,0.00023758019],"category_scores_gemma":[0.000317731,0.000069434245,0.0001301,0.00016421205,0.00018462563,0.00011935238,0.000034230936,0.00031641647,9.987647e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007993553,0.0013834748,0.033152644,0.00019095515,0.0014198987,0.0011369862,0.001002421,0.00023950859,0.92632216,0.000025205003,0.00011615301,0.027017063],"study_design_scores_gemma":[0.017564999,0.007189929,0.47762287,0.00033960698,0.0012708502,0.00014579484,0.0018481169,0.0006423494,0.4899177,0.0009951126,0.0023521716,0.0001105161],"about_ca_topic_score_codex":0.0015403484,"about_ca_topic_score_gemma":0.0049510724,"teacher_disagreement_score":0.44447023,"about_ca_system_score_codex":0.00016005068,"about_ca_system_score_gemma":0.0016804562,"threshold_uncertainty_score":0.29810572},"labels":[],"label_agreement":null},{"id":"W3169115384","doi":"10.5489/cuaj.7347","title":"Canadian consensus forum of key controversial areas in the management of advanced prostate cancer","year":2021,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Queen's University; London Health Sciences Centre; University of Alberta; University of British Columbia; Jewish General Hospital; Kingston Health Sciences Centre; McGill University; University of Ottawa; BC Cancer Agency; Ottawa Hospital; University of Calgary; Vancouver General Hospital; Princess Margaret Cancer Centre; Western University; University of Toronto; McMaster University; St. Joseph’s Healthcare Hamilton; Juravinski Cancer Centre; Université Laval; Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma; Eisai; Sanofi; AstraZeneca; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Consensus conference; Prostate cancer; Voting; Medicine; Evidence-based practice; Family medicine; Alternative medicine; Political science; Pathology; Cancer; Internal medicine","score_opus":0.027749360905560308,"score_gpt":0.3233499761242234,"score_spread":0.2956006152186631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169115384","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001057761,0.9790287,1.9679554e-7,0.015201652,0.00026881017,0.001222825,0.0006653354,0.0000028453767,0.0025518897],"genre_scores_gemma":[0.0074199797,0.99051654,0.000038532715,0.0005837362,0.00010306208,0.00008729865,0.00015288235,0.000017356446,0.0010806242],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974221,0.00039410882,0.00070784567,0.00022927411,0.0005176508,0.0007290372],"domain_scores_gemma":[0.9980046,0.00023331025,0.00060764793,0.00017433545,0.0003887943,0.0005912684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007806438,0.0002327893,0.0012353637,0.00041895002,0.00012299443,0.000033312306,0.00022798845,0.00033049096,0.00030821792],"category_scores_gemma":[0.00018222722,0.00014519837,0.0004060714,0.00058148673,0.000065324966,0.000026707045,0.000019473602,0.00086278364,0.000004234345],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00018446559,0.00014458825,0.044507496,0.003008769,0.0032285824,0.004410837,0.000440368,0.00002874981,5.700092e-7,0.0008336574,0.020230927,0.92298096],"study_design_scores_gemma":[0.0017734953,0.00020556519,0.005575647,0.0030512868,0.0008252704,0.00012438059,0.0006028849,0.0000025005702,4.7005759e-7,0.00006743896,0.98763525,0.00013578976],"about_ca_topic_score_codex":0.07141123,"about_ca_topic_score_gemma":0.19053306,"teacher_disagreement_score":0.96740437,"about_ca_system_score_codex":0.0048042363,"about_ca_system_score_gemma":0.006953973,"threshold_uncertainty_score":0.99901617},"labels":[],"label_agreement":null},{"id":"W3169367773","doi":"10.1080/14740338.2021.1919620","title":"A drug safety evaluation of enzalutamide to treat advanced prostate cancer","year":2021,"lang":"en","type":"review","venue":"Expert Opinion on Drug Safety","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Astellas Pharma; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Clinical trial; Cancer; Internal medicine; Androgen receptor","score_opus":0.08988337752740705,"score_gpt":0.46237497673581374,"score_spread":0.3724915992084067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169367773","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045643235,0.9848222,0.0000066615853,0.002782234,0.00129261,0.0064004827,0.00069866556,0.00008168562,0.003869792],"genre_scores_gemma":[0.000041612937,0.9845607,0.00025769274,0.00025435633,0.000613441,0.0025627248,0.002805081,0.00015558761,0.008748771],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99377906,0.0009755063,0.0013511728,0.0012171121,0.0019886247,0.0006885397],"domain_scores_gemma":[0.9965809,0.00041353915,0.0004784618,0.0011553077,0.00090604596,0.00046572599],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014691419,0.00082074915,0.0028582336,0.0004936741,0.0001902102,0.00002853157,0.0002969889,0.0002576621,0.0010842071],"category_scores_gemma":[0.00032964323,0.0005870562,0.00083798106,0.001064175,0.000109164386,0.00012293886,0.00019152038,0.00059057807,0.0001033653],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011775736,0.00036501014,0.000009672245,0.004366165,0.00037763777,0.000017756307,0.0017574352,0.0000739261,0.00001715709,0.000058835816,0.013004851,0.97877395],"study_design_scores_gemma":[0.0041776155,0.00023213902,0.0000348295,0.048095375,0.00030382155,0.00001926251,0.00033596373,0.000025984797,0.0004581563,0.0000066345697,0.94581735,0.00049286307],"about_ca_topic_score_codex":0.00026026735,"about_ca_topic_score_gemma":0.00003592382,"teacher_disagreement_score":0.97828114,"about_ca_system_score_codex":0.0030905101,"about_ca_system_score_gemma":0.0038117378,"threshold_uncertainty_score":0.99982893},"labels":[],"label_agreement":null},{"id":"W3169559325","doi":"10.1530/erc-21-0116","title":"Targeting androgen receptor signaling: a historical perspective","year":2021,"lang":"en","type":"review","venue":"Endocrine Related Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; Prostate Cancer Canada; Prostate Cancer Foundation","keywords":"Prostate cancer; Medicine; Androgen deprivation therapy; Cancer; Disease; Hormonal therapy; Oncology; Prostate; Internal medicine; Androgen; Hormone","score_opus":0.05901755478858615,"score_gpt":0.3948831400957289,"score_spread":0.3358655853071427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169559325","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008318857,0.99367344,0.0000029657645,0.0009481904,0.0009173811,0.0012432252,0.00007543784,0.00015613272,0.0029749272],"genre_scores_gemma":[0.000004786787,0.94504565,0.0001760472,0.000030813822,0.0008873211,0.00064648455,0.00058542745,0.0001560701,0.052467383],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968196,0.0002261794,0.00073441176,0.0009240557,0.00055861135,0.00073714316],"domain_scores_gemma":[0.99834436,0.00015313533,0.0002872832,0.00040866263,0.0004382615,0.00036828185],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015629771,0.00059130485,0.002466348,0.00031139608,0.00014482351,0.000034147015,0.00017047976,0.0003325464,0.0046657366],"category_scores_gemma":[0.00021873455,0.00043269468,0.0009408819,0.0010406513,0.00006962101,0.000060875405,0.00013269756,0.0015665332,0.00019869444],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013647694,0.00045939945,0.00006451425,0.012586541,0.006868933,0.004634303,0.00046373182,0.0000055564064,0.00006660987,0.00034850714,0.11125836,0.8631071],"study_design_scores_gemma":[0.0012390495,0.00015895937,1.5134486e-7,0.013732565,0.0023623824,0.00033547194,0.000096222175,0.0000037820937,0.00007683339,0.000013894102,0.9815805,0.00040020706],"about_ca_topic_score_codex":0.00044504253,"about_ca_topic_score_gemma":0.0000024748615,"teacher_disagreement_score":0.8703221,"about_ca_system_score_codex":0.010113386,"about_ca_system_score_gemma":0.0025730717,"threshold_uncertainty_score":0.9998125},"labels":[],"label_agreement":null},{"id":"W3169833232","doi":"10.1016/j.euros.2021.05.004","title":"Decreased ATM Protein Expression Is Substantiated with PTEN Loss in Defining Aggressive Phenotype of Prostate Cancer Associated with Lethal Disease","year":2021,"lang":"en","type":"article","venue":"European Urology Open Science","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta; University of Calgary","funders":"Prostate Cancer Canada; Alberta Cancer Foundation; Movember Foundation; National Cancer Institute; Prostate Cancer Foundation","keywords":"PTEN; Medicine; Prostate cancer; Hazard ratio; Immunohistochemistry; Oncology; Prostate; Internal medicine; Cancer research; TMPRSS2; Cancer; Confidence interval; Disease; Biology; Apoptosis; PI3K/AKT/mTOR pathway","score_opus":0.02581577385603006,"score_gpt":0.31706438104506296,"score_spread":0.2912486071890329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169833232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99261063,0.0012861574,0.000009925134,0.0013926849,0.00002442375,0.0010009247,0.000059246016,0.000023116309,0.0035928895],"genre_scores_gemma":[0.99807656,0.0000738257,0.00038294969,0.00032796705,0.000009324498,0.00006957598,0.00006261696,0.000033916767,0.0009632654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744,0.00039138252,0.00025905,0.0007485655,0.0006012642,0.0005597728],"domain_scores_gemma":[0.9982584,0.000065186934,0.0002997202,0.000441993,0.0006040802,0.00033060793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008264977,0.0001939191,0.00035086006,0.00015146295,0.00019780637,0.00006759322,0.0005346833,0.00003184121,0.00017851795],"category_scores_gemma":[0.000518367,0.0001240482,0.00002579903,0.0015092054,0.0012045848,0.00030457028,0.00042435888,0.0002771516,0.00001364122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011139619,0.0006284727,0.8990446,0.000059689784,0.000094101,0.015314352,0.002284328,0.00012311018,0.06910583,0.000050857037,0.000075446966,0.002079647],"study_design_scores_gemma":[0.010739703,0.0011559214,0.8994583,0.00185702,0.00010628615,0.000050439565,0.00021221893,0.00036063616,0.08561141,0.00004193603,0.000121828634,0.0002843225],"about_ca_topic_score_codex":0.00015176542,"about_ca_topic_score_gemma":0.00012657203,"teacher_disagreement_score":0.016505586,"about_ca_system_score_codex":0.00012237813,"about_ca_system_score_gemma":0.0024998912,"threshold_uncertainty_score":0.50585383},"labels":[],"label_agreement":null},{"id":"W3170032553","doi":"10.5489/cuaj.7336","title":"Adding prostate-specific membrane antigen positron emission tomography (PSMA PET) to our prostate cancer armamentarium raises many questions","year":2021,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Prostate cancer; Glutamate carboxypeptidase II; Positron emission tomography; Medicine; Prostate; Cancer; Nuclear medicine; Oncology; Internal medicine","score_opus":0.019014326006000486,"score_gpt":0.2907053384549929,"score_spread":0.2716910124489924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170032553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8743759,0.0033303923,0.00001733089,0.119462475,0.00065420393,0.00066740543,0.00029287994,0.000058196274,0.0011412547],"genre_scores_gemma":[0.984722,0.004052185,0.00050764787,0.0033355234,0.00066332426,0.0000886059,0.00021797224,0.00003204496,0.0063806977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99730504,0.0002367232,0.00043114045,0.00041843174,0.00064603635,0.00096263405],"domain_scores_gemma":[0.9971065,0.000062990985,0.00018823505,0.0001623292,0.0007786213,0.0017013387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005063974,0.00024138641,0.00038189665,0.00040443538,0.00069628266,0.000273686,0.00013058752,0.00014843653,0.0007940045],"category_scores_gemma":[0.00024146779,0.0001921927,0.00021170444,0.00075932825,0.000026576228,0.00017458425,0.000041877596,0.000801289,0.000054299806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046889856,0.00018715786,0.9025995,0.000026134288,0.00036727428,0.0021246828,0.00064327853,0.00010929338,0.026428144,0.000048742677,0.06216378,0.00483311],"study_design_scores_gemma":[0.0029238681,0.00061633973,0.64726514,0.00022959316,0.00014568675,0.00054373476,0.0008976814,0.000055593537,0.0077455137,0.00014337966,0.33905622,0.00037723486],"about_ca_topic_score_codex":0.0013073089,"about_ca_topic_score_gemma":0.00090119505,"teacher_disagreement_score":0.27689245,"about_ca_system_score_codex":0.0025186304,"about_ca_system_score_gemma":0.0015920002,"threshold_uncertainty_score":0.8693792},"labels":[],"label_agreement":null},{"id":"W3170594626","doi":"10.1530/erc-21-0098","title":"Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer","year":2021,"lang":"en","type":"review","venue":"Endocrine Related Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Terry Fox Foundation; National Cancer Institute; Dan L. Duncan Cancer Center, Baylor College of Medicine; Adrienne Helis Malvin Medical Research Foundation; Prostate Cancer Foundation","keywords":"Enzalutamide; Bicalutamide; Prostate cancer; Androgen receptor; Medicine; Flutamide; Abiraterone acetate; Cyproterone acetate; Androgen; Oncology; Internal medicine; Androgen deprivation therapy; Antiandrogen; Cancer; Pharmacology; Hormone","score_opus":0.02342480583172414,"score_gpt":0.3628771149748778,"score_spread":0.33945230914315366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170594626","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011997151,0.9815074,5.578193e-7,0.002064161,0.00038120896,0.00335753,0.0003930867,0.00008648083,0.00021241758],"genre_scores_gemma":[0.00036343076,0.9871846,0.00012055381,0.00020635125,0.00048788387,0.0012523415,0.000921526,0.00021441649,0.009248886],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963403,0.00025694043,0.0009805706,0.0010920367,0.0005074178,0.00082276633],"domain_scores_gemma":[0.99836123,0.00017017522,0.0003819661,0.0003942884,0.00038427775,0.00030803797],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021498888,0.00079905294,0.0022770234,0.0004542486,0.000114480536,0.00008604772,0.00011184477,0.00039811613,0.0011076994],"category_scores_gemma":[0.000037191625,0.00062502525,0.00039542644,0.0010329974,0.000179634,0.00016392393,0.00007299555,0.0012862117,0.00002175629],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049886614,0.00022149437,0.0010298126,0.0069252304,0.002239763,0.0009967065,0.0013833249,0.000013146461,0.00069652783,0.000008731032,0.0021091024,0.9838773],"study_design_scores_gemma":[0.006530255,0.00043057202,0.00009374824,0.045392387,0.0009749259,0.00046375234,0.00018490723,0.000019647969,0.0045134095,0.000008960802,0.94056803,0.00081939093],"about_ca_topic_score_codex":0.0012591147,"about_ca_topic_score_gemma":0.0003461974,"teacher_disagreement_score":0.9830579,"about_ca_system_score_codex":0.0012593481,"about_ca_system_score_gemma":0.0024295396,"threshold_uncertainty_score":0.99980545},"labels":[],"label_agreement":null},{"id":"W3170708393","doi":"10.3390/cancers13122939","title":"Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Enzalutamide; Bicalutamide; Prostate cancer; Androgen receptor; Mutant; Cancer research; Medicine; Internal medicine; Endocrinology; Oncology; Biology; Bioinformatics; Cancer; Genetics; Gene","score_opus":0.05710852725076808,"score_gpt":0.3775610798233485,"score_spread":0.32045255257258043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170708393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422055,0.0012863876,0.0000011044003,0.0004553811,0.00035511501,0.0012529796,0.00013728412,0.000015858905,0.0022753528],"genre_scores_gemma":[0.997817,0.0006515569,0.000045466062,0.00018049437,0.000039970484,0.0002817448,0.00017510784,0.000021737438,0.00078694907],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99771416,0.00011256056,0.00035390723,0.00042075734,0.0010690199,0.00032960682],"domain_scores_gemma":[0.99840564,0.000024539942,0.0001187055,0.00031865173,0.0009681739,0.00016427791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061757345,0.00013569967,0.0002819686,0.00017329933,0.00003952864,0.000009233653,0.000064766864,0.00004828016,0.00043857264],"category_scores_gemma":[0.0004093331,0.000113864226,0.000047928555,0.00076530175,0.00005286601,0.000057612677,0.000036642727,0.00012751322,0.000019606457],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004892485,0.00088644493,0.5890143,0.00039838525,0.0006514345,0.0002857221,0.0059169666,0.011050652,0.08029149,0.000013218173,0.0057593174,0.3008396],"study_design_scores_gemma":[0.021713004,0.0021401823,0.27833238,0.002203062,0.00054327137,0.000008895891,0.0008888775,0.0038497678,0.6822348,0.000065396096,0.0075222924,0.0004980714],"about_ca_topic_score_codex":0.0005409783,"about_ca_topic_score_gemma":0.0002955153,"teacher_disagreement_score":0.6019433,"about_ca_system_score_codex":0.002706175,"about_ca_system_score_gemma":0.003947723,"threshold_uncertainty_score":0.7076553},"labels":[],"label_agreement":null},{"id":"W3170743116","doi":"10.1200/jco.2021.39.15_suppl.5064","title":"PSMA-PET/CT Registry for Recurrent Prostate Cancer (PREP): Initial findings from a single center.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Western University; University of Toronto; McMaster University","funders":"Cancer Care Ontario","keywords":"Medicine; Prostate cancer; Prostatectomy; Cohort; Glutamate carboxypeptidase II; Stage (stratigraphy); Prospective cohort study; Biochemical recurrence; Single Center; Radiation therapy; Cancer; Radiology; Nuclear medicine; Oncology; Internal medicine","score_opus":0.22626698630054612,"score_gpt":0.539504332170889,"score_spread":0.3132373458703429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170743116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96866006,0.003793961,0.00003511431,0.02238743,0.003352455,0.00036957033,0.0001749949,0.000010787949,0.0012156515],"genre_scores_gemma":[0.97953564,0.006529049,0.0049657,0.0023292967,0.0032917939,0.000048167447,0.00011075989,0.000037134996,0.0031524466],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970451,0.0002565037,0.0016535141,0.0002988488,0.00038643915,0.00035956502],"domain_scores_gemma":[0.99600834,0.0015690716,0.0008631262,0.00020793999,0.0009014087,0.00045012918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001134671,0.00015064701,0.0011979253,0.00006971914,0.00006448055,0.000025856581,0.0001445585,0.00008334626,0.0003930684],"category_scores_gemma":[0.0031321521,0.00010593001,0.00060519954,0.00013109666,0.00020050831,0.00010500342,0.0000806145,0.0009225847,0.00000926938],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061676353,0.011208669,0.20427859,0.0003111085,0.0026114848,0.037748907,0.00036177426,0.0000053860126,0.003369288,0.00004801332,0.12376948,0.55461097],"study_design_scores_gemma":[0.056882836,0.029896295,0.041594457,0.0014977946,0.0010437948,0.0043713315,0.00050159526,0.0001176641,0.011780559,0.0017798498,0.85023683,0.00029699213],"about_ca_topic_score_codex":0.00003785807,"about_ca_topic_score_gemma":0.000110926885,"teacher_disagreement_score":0.7264674,"about_ca_system_score_codex":0.0004400898,"about_ca_system_score_gemma":0.0041214805,"threshold_uncertainty_score":0.7311329},"labels":[],"label_agreement":null},{"id":"W3170806165","doi":"10.1200/jco.2021.39.15_suppl.5037","title":"Analysis of two poor prognosis subgroups in ACIS evaluating apalutamide + abiraterone acetate plus prednisone (APA + AAP) versus placebo (PBO) + AAP in metastatic castration-resistant prostate cancer (mCRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Internal medicine; Clinical endpoint; Placebo; Prednisone; Progression-free survival; Adverse effect; Population; Randomization; Enzalutamide; Randomized controlled trial; Urology; Gastroenterology; Oncology; Surgery; Cancer; Chemotherapy; Androgen deprivation therapy; Pathology","score_opus":0.24598597854768942,"score_gpt":0.5368218909530965,"score_spread":0.29083591240540707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170806165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897553,0.0034698003,0.000020820187,0.0050605442,0.00052567665,0.0008653898,0.000056808072,0.0000076097267,0.00023805762],"genre_scores_gemma":[0.9917602,0.0028378605,0.0044167424,0.00018732226,0.000172576,0.000117267904,0.000045009816,0.000029994351,0.00043302414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99180317,0.0017431384,0.0043272716,0.00048428355,0.0010464452,0.00059566594],"domain_scores_gemma":[0.99288356,0.0030832882,0.0022002775,0.00026351417,0.00118902,0.00038035927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071098134,0.00028192668,0.0030176383,0.0008039405,0.000051299994,0.000030303849,0.00020617545,0.00021975131,0.0003616476],"category_scores_gemma":[0.0037872645,0.00021122533,0.00063338224,0.0019493694,0.00031856474,0.0002499142,0.0001007478,0.0011637605,0.0000046979058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17967129,0.006723421,0.5814055,0.0006597047,0.015913323,0.0095304195,0.0043857303,0.02270976,0.034852423,0.000050630028,0.00019376093,0.143904],"study_design_scores_gemma":[0.18353383,0.022538623,0.72923243,0.0012013721,0.014087926,0.000111060275,0.0038546345,0.03437146,0.009869712,0.00025621464,0.00044955403,0.0004931992],"about_ca_topic_score_codex":0.0007262847,"about_ca_topic_score_gemma":0.014567787,"teacher_disagreement_score":0.14782688,"about_ca_system_score_codex":0.0012428848,"about_ca_system_score_gemma":0.0071527287,"threshold_uncertainty_score":0.9984758},"labels":[],"label_agreement":null},{"id":"W3171034696","doi":"10.1101/2021.06.03.21256653","title":"The Movember Global Action Plan 1 (GAP1) - Unique Prostate Cancer Tissue Microarray Resource","year":2021,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute; National Institutes of Health; DOD Prostate Cancer Research Program; Institute for Prostate Cancer Research; Movember Foundation; Johns Hopkins University; U.S. Department of Defense","keywords":"Prostate cancer; Prostatectomy; Medicine; Prostate; Oncology; Metastasis; Biomarker; Disease; Cancer; Lymph node; Internal medicine; Cancer research; Biology","score_opus":0.04218441034865411,"score_gpt":0.36068124409241453,"score_spread":0.3184968337437604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171034696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9603525,0.016470864,0.000028088754,0.013685573,0.0010848328,0.001674131,0.00021939815,0.000138899,0.006345739],"genre_scores_gemma":[0.8832689,0.024636053,0.0003028938,0.00090107246,0.001405126,0.0014462121,0.001246388,0.00013703333,0.08665633],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974555,0.00023527407,0.00036053907,0.0007334665,0.0005987736,0.0006164652],"domain_scores_gemma":[0.9982996,0.00008264719,0.00017591438,0.00091066957,0.00026473572,0.00026641128],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043104266,0.0003875114,0.00047115877,0.000054699693,0.00029097928,0.00020172245,0.0002958983,0.00035099493,0.00025392658],"category_scores_gemma":[0.0000729175,0.0002460573,0.00017021853,0.00028241402,0.00022686445,0.0000496757,0.00046198565,0.0010822999,0.000035640063],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076714423,0.0008748561,0.60770816,0.0037778441,0.0038564375,0.003528875,0.005419965,0.00041223734,0.102446035,0.00017660965,0.088966355,0.17516117],"study_design_scores_gemma":[0.002506536,0.00028522615,0.12179322,0.0016220242,0.0004015453,0.00014152595,0.001197543,0.000100554935,0.09902992,0.00037132087,0.7719318,0.00061874365],"about_ca_topic_score_codex":0.0013919015,"about_ca_topic_score_gemma":0.0011545768,"teacher_disagreement_score":0.68296546,"about_ca_system_score_codex":0.00090075436,"about_ca_system_score_gemma":0.001205915,"threshold_uncertainty_score":0.99999917},"labels":[],"label_agreement":null},{"id":"W3171441932","doi":"10.1200/jco.2021.39.15_suppl.5005","title":"A prospective validation of the genomic classifier to define high-metastasis risk in a subset of African American men with early localized prostate cancer: VanDAAM study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Institutes of Health","keywords":"Medicine; Prospective cohort study; Oncology; Prostate cancer; DECIPHER; Metastasis; Cohort; Classifier (UML); Biopsy; Internal medicine; Cancer; Artificial intelligence; Bioinformatics; Biology; Computer science","score_opus":0.06911415077130584,"score_gpt":0.43875848641769244,"score_spread":0.3696443356463866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171441932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99343044,0.00026561235,0.000023179762,0.0047728755,0.00013453157,0.0010146176,0.000056434365,0.000002667819,0.00029963074],"genre_scores_gemma":[0.9973554,0.0009083538,0.0012304623,0.00010252766,0.000099568846,0.000050305094,0.0000023203022,0.000016949465,0.00023408169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962953,0.0010969798,0.0015788327,0.00024258213,0.0005505503,0.00023579532],"domain_scores_gemma":[0.9958635,0.0007892601,0.0018572937,0.00026020425,0.0010202853,0.00020947901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021606816,0.00013457178,0.0015924987,0.00016716425,0.000032778276,0.0000069331563,0.00015885523,0.00007909786,0.000048240647],"category_scores_gemma":[0.001151953,0.00007083037,0.00022053957,0.0009343816,0.00041447426,0.00005481191,0.00009233182,0.00071734947,0.0000011329391],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026781831,0.0029034584,0.9359872,0.000027238959,0.0010621154,0.00022624216,0.0020660553,0.00015262405,0.00074899447,0.000011620565,0.00020471118,0.029827928],"study_design_scores_gemma":[0.017749647,0.025361076,0.9485733,0.00013086142,0.00069528533,0.00002328424,0.0023717298,0.000013710855,0.0041094623,0.0001283886,0.00077453227,0.00006872964],"about_ca_topic_score_codex":0.001957049,"about_ca_topic_score_gemma":0.0020764268,"teacher_disagreement_score":0.029759198,"about_ca_system_score_codex":0.00044518462,"about_ca_system_score_gemma":0.0036506124,"threshold_uncertainty_score":0.647603},"labels":[],"label_agreement":null},{"id":"W3171699641","doi":"10.5489/cuaj.7357","title":"Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies – Executive summary","year":2021,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Dalhousie University; McGill University Health Centre; Ontario Clinical Oncology Group; Université Laval; University of Manitoba; Princess Margaret Cancer Centre; McMaster University; Queen's University; Memorial University of Newfoundland; University of British Columbia; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Androgen deprivation therapy; Guideline; Medicine; Prostate cancer; Adverse effect; Disease; Management of prostate cancer; Oncology; Internal medicine; Cancer; Pathology","score_opus":0.021755459819660913,"score_gpt":0.28136021369530434,"score_spread":0.2596047538756434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171699641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8705984,0.0013960788,0.00003650658,0.10680234,0.00039518852,0.000687617,0.00015074466,0.000042689844,0.019890485],"genre_scores_gemma":[0.9788712,0.004424801,0.0002602835,0.010448856,0.00033426017,0.000029817978,0.00037590277,0.000018149516,0.005236695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976026,0.00032393483,0.00039600235,0.00034122856,0.0006045621,0.0007317052],"domain_scores_gemma":[0.9979074,0.00013055564,0.00022140918,0.00012583348,0.0005596794,0.001055138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009440691,0.00019842638,0.0002971075,0.00029612926,0.0004637743,0.00009024033,0.00009525074,0.00037019025,0.0004665162],"category_scores_gemma":[0.0004127882,0.00015773544,0.00012194931,0.00032977073,0.000022343147,0.00016312375,0.000023607596,0.00060073886,0.00003612148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021136562,0.00009432556,0.9624807,0.000006416149,0.00055979245,0.00093713525,0.00011404605,0.000070187925,0.000062948515,0.0005425009,0.02996088,0.0049597067],"study_design_scores_gemma":[0.0027945489,0.000468005,0.8129393,0.000025740732,0.0000957292,0.000089594345,0.00039970214,0.00011229365,0.000064651016,0.0020719687,0.18075891,0.00017957587],"about_ca_topic_score_codex":0.008404803,"about_ca_topic_score_gemma":0.017837558,"teacher_disagreement_score":0.15079802,"about_ca_system_score_codex":0.0053072292,"about_ca_system_score_gemma":0.0015021311,"threshold_uncertainty_score":0.9985112},"labels":[],"label_agreement":null},{"id":"W3171945717","doi":"10.1200/jco.2021.39.15_suppl.5075","title":"Impact of age on efficacy and safety of relugolix: A subgroup analysis from the randomized, phase 3 hero study versus leuprolide in men with advanced prostate cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Testosterone (patch); Urology; Randomization; Randomized controlled trial; Subgroup analysis; Internal medicine; Adverse effect; Clinical endpoint; Prostate; Cancer; Gynecology; Confidence interval","score_opus":0.093369394868022,"score_gpt":0.5226232800088864,"score_spread":0.4292538851408644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171945717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422705,0.0024251319,0.000007694591,0.001887359,0.00009009491,0.0009440034,0.000031963136,0.0000020625348,0.00038465342],"genre_scores_gemma":[0.9911966,0.008278946,0.00021327767,0.000055289544,0.00011515817,0.000019862073,0.000010812241,0.000011204922,0.000098896955],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958418,0.0013926674,0.0018783386,0.00022954088,0.0004528518,0.00020479884],"domain_scores_gemma":[0.9891879,0.008531432,0.0013825141,0.0002629434,0.00043285475,0.00020235681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031977294,0.0001494175,0.00290605,0.00015036832,0.000027716964,0.000006220705,0.000116688294,0.00011438873,0.00007875784],"category_scores_gemma":[0.0026802148,0.00006791748,0.0005504964,0.000600447,0.0004179439,0.000059857826,0.000047968704,0.0007194704,2.817786e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7504334,0.0055881087,0.19850029,0.000012734938,0.009443779,0.0014289616,0.0011046827,0.00045893138,0.00020039637,0.000002803211,0.000052344065,0.03277356],"study_design_scores_gemma":[0.5506267,0.031844813,0.41310173,0.00015225938,0.003110692,0.000007368726,0.00078995747,0.000101291116,0.0001289909,0.000024790777,0.00006271085,0.00004871111],"about_ca_topic_score_codex":0.0007451973,"about_ca_topic_score_gemma":0.0011850296,"teacher_disagreement_score":0.21460144,"about_ca_system_score_codex":0.00023728191,"about_ca_system_score_gemma":0.0018761432,"threshold_uncertainty_score":0.33281973},"labels":[],"label_agreement":null},{"id":"W3172086766","doi":"10.1200/jco.2021.39.15_suppl.lba4","title":"Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Taxane; Progression-free survival; Urology; Internal medicine; Oncology; Clinical endpoint; Abiraterone acetate; Prostate; Response Evaluation Criteria in Solid Tumors; Confidence interval; Phases of clinical research; Cancer; Nuclear medicine; Randomized controlled trial; Clinical trial; Androgen deprivation therapy; Chemotherapy; Breast cancer","score_opus":0.12652740242309743,"score_gpt":0.5251846662483957,"score_spread":0.3986572638252982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172086766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960607,0.0007007743,0.000004746111,0.0019262682,0.00034388615,0.0006911947,0.000020265297,0.000002758825,0.00024940708],"genre_scores_gemma":[0.9980524,0.0004892135,0.0006441727,0.00018173938,0.00012104608,0.000019134148,0.0000129233385,0.000014561107,0.00046482068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99609053,0.00054542883,0.0021706708,0.00022447997,0.000723659,0.00024521968],"domain_scores_gemma":[0.99618506,0.0007326471,0.0012114849,0.00019924121,0.0013911776,0.00028036363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015357905,0.00013754748,0.0014353584,0.00016645412,0.000035731977,0.0000103234015,0.00009853667,0.00009332916,0.0002038494],"category_scores_gemma":[0.00068952516,0.00008107031,0.00015928641,0.00036397864,0.00016643605,0.00013370824,0.00004254923,0.0006811483,0.0000019857416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11267852,0.08825267,0.6865283,0.00015373841,0.0019597176,0.0066932975,0.002110739,0.0001099794,0.0006208799,0.000013125101,0.0011528672,0.09972613],"study_design_scores_gemma":[0.19176911,0.09512278,0.7077525,0.00031904713,0.00070674234,0.000028597051,0.0017183032,0.000031036503,0.00034345116,0.000044846805,0.0020639524,0.00009962903],"about_ca_topic_score_codex":0.000121838566,"about_ca_topic_score_gemma":0.00096667744,"teacher_disagreement_score":0.099626504,"about_ca_system_score_codex":0.00022159552,"about_ca_system_score_gemma":0.004178946,"threshold_uncertainty_score":0.74132705},"labels":[],"label_agreement":null},{"id":"W3172271613","doi":"10.1016/j.ejca.2021.05.003","title":"Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score–weighted comparative cohort study","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Prostate Cancer Fight Foundation; Prostate Cancer Foundation","keywords":"Enzalutamide; Medicine; Tolerability; Prostate cancer; Hazard ratio; Discontinuation; Internal medicine; Retrospective cohort study; Cohort; Propensity score matching; Abiraterone acetate; Oncology; Confidence interval; Urology; Population; Cancer; Androgen deprivation therapy; Adverse effect; Androgen receptor","score_opus":0.051821641529548455,"score_gpt":0.32560697302654446,"score_spread":0.273785331496996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172271613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962376,0.0014681882,0.000018262306,0.0000324445,0.00019394692,0.0016364768,0.00012372882,0.000007068583,0.0002823211],"genre_scores_gemma":[0.9991058,0.00044266004,0.00012846652,0.0000042876623,0.00004977145,0.00003627118,0.000026323029,0.000038293805,0.00016808927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969589,0.00087820424,0.00067321357,0.00030119647,0.00094532483,0.00024315319],"domain_scores_gemma":[0.99618566,0.0001268005,0.0007905166,0.00024116425,0.002492988,0.00016285693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088327547,0.00022404002,0.0009806658,0.00014790393,0.000070708076,0.000025769463,0.0001197647,0.00001651274,0.00006440979],"category_scores_gemma":[0.000076413664,0.00015576449,0.000111777095,0.00052169716,0.00029620543,0.00018210089,0.00005579928,0.0003239841,0.0000011353741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030268399,0.001336339,0.9494327,0.00040071362,0.0030400995,0.0027418009,0.0028869172,0.0003417947,0.008668426,0.0000019355987,0.000029695266,0.0008512098],"study_design_scores_gemma":[0.019609949,0.008184715,0.92288035,0.0016969395,0.0009250205,0.000008472186,0.00039325785,0.000013197916,0.046133313,0.0000032228127,0.000019519652,0.00013202542],"about_ca_topic_score_codex":0.00041653067,"about_ca_topic_score_gemma":0.001050637,"teacher_disagreement_score":0.037464887,"about_ca_system_score_codex":0.0005128931,"about_ca_system_score_gemma":0.0006069377,"threshold_uncertainty_score":0.6351891},"labels":[],"label_agreement":null},{"id":"W3172744731","doi":"10.1096/fasebj.27.1_supplement.471.8","title":"RNAseq Analysis of FFPE Radical Prostatectomy Specimens Identifies Predictors of Biochemical Recurrence","year":2013,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Agencia de Innovación y Desarrollo de Andalucía; U.S. Department of Defense","keywords":"Prostatectomy; Biochemical recurrence; Prostate cancer; Oncology; Receiver operating characteristic; Medicine; breakpoint cluster region; Internal medicine; Urology; Cancer","score_opus":0.022189494091225198,"score_gpt":0.3005389723632895,"score_spread":0.27834947827206435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172744731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966508,0.0014785508,0.000047870242,0.0008772999,0.00012094475,0.00032326108,0.000037170652,0.000008859502,0.00045522067],"genre_scores_gemma":[0.99827474,0.0007789221,0.00010665063,0.000019985257,0.00013274177,0.000011440144,0.000026507725,0.000008779622,0.00064021157],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984523,0.000091096335,0.00044225494,0.00013466614,0.00061584107,0.0002638439],"domain_scores_gemma":[0.9988727,0.00012424999,0.00021985012,0.00026474945,0.0003167498,0.0002017312],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042332138,0.00011517199,0.0003985771,0.00032133967,0.000080146754,0.000026898488,0.0001999827,0.000055383112,0.001226545],"category_scores_gemma":[0.0001300511,0.000060942315,0.00027106242,0.0007753755,0.00056131143,0.000089803994,0.000056860994,0.00037029292,0.000016149334],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004960428,0.00032012805,0.10695148,0.000083223276,0.003375034,0.000044957425,0.00085332163,0.0000133082385,0.87992454,0.000027475739,0.006802526,0.0011079554],"study_design_scores_gemma":[0.0015705237,0.0003779989,0.1254889,0.00018457713,0.0015769136,0.00008850614,0.00045875294,0.00033330507,0.86950135,0.00023648278,0.00010378784,0.00007890529],"about_ca_topic_score_codex":0.000051698287,"about_ca_topic_score_gemma":0.0000014963449,"teacher_disagreement_score":0.018537423,"about_ca_system_score_codex":0.00007490932,"about_ca_system_score_gemma":0.00018565981,"threshold_uncertainty_score":0.9996865},"labels":[],"label_agreement":null},{"id":"W3173244755","doi":"10.1111/ajco.13595","title":"<sup>68</sup>Ga‐prostate‐specific membrane antigen (PSMA) PET/CT as a clinical decision‐making tool in biochemically recurrent prostate cancer","year":2021,"lang":"en","type":"article","venue":"Asia-Pacific Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Sanofi; AstraZeneca; Pfizer; Astellas Pharma; Bristol-Myers Squibb","keywords":"Medicine; Watchful waiting; Prostate cancer; Biochemical recurrence; Logistic regression; Radiation therapy; Prostate; Radiology; Nuclear medicine; Urology; Internal medicine; Cancer; Prostatectomy","score_opus":0.09134584371318756,"score_gpt":0.4848521792671509,"score_spread":0.39350633555396336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173244755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96130645,0.016741361,0.00003081038,0.013972339,0.002459422,0.0009531669,0.000050462164,0.000036062916,0.0044499342],"genre_scores_gemma":[0.87233216,0.11648763,0.0072419723,0.000762321,0.0013916825,0.00005278585,0.00004686728,0.00008447436,0.0016000873],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9885081,0.0015373215,0.0062124063,0.0011455994,0.0014054703,0.0011911016],"domain_scores_gemma":[0.98959535,0.005324926,0.0017398627,0.0007958995,0.001695893,0.000848088],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0077729207,0.0005425135,0.003252944,0.00046883535,0.00014573405,0.00009608313,0.0005527626,0.00031892254,0.0015953579],"category_scores_gemma":[0.006742546,0.00040275365,0.0013364139,0.0011119329,0.0008865045,0.0002887147,0.00032095585,0.0038169567,0.00023252434],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027646981,0.005849494,0.31942683,0.00015858652,0.001070405,0.06365287,0.00052181596,0.000059721056,0.0008076834,0.00011151666,0.019722108,0.560972],"study_design_scores_gemma":[0.051274944,0.017176647,0.116031736,0.005469954,0.0007433946,0.019617992,0.005152545,0.00060456863,0.0034147578,0.003827353,0.77552927,0.0011568248],"about_ca_topic_score_codex":0.000019099907,"about_ca_topic_score_gemma":0.000042150466,"teacher_disagreement_score":0.75580716,"about_ca_system_score_codex":0.00077843823,"about_ca_system_score_gemma":0.008869443,"threshold_uncertainty_score":0.9998424},"labels":[],"label_agreement":null},{"id":"W3173494220","doi":"10.1200/jco.21.00169","title":"Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Astellas Pharma; University of Wisconsin Carbone Cancer Center; U.S. Department of Defense","keywords":"Enzalutamide; Medicine; Prostate cancer; Androgen receptor; Prospective cohort study; Internal medicine; Oncology; Hazard ratio; Cancer; Prostate biopsy; Prostate; Androgen deprivation therapy; PTEN; Confidence interval; Biology; PI3K/AKT/mTOR pathway","score_opus":0.3465071294292043,"score_gpt":0.5814825905054469,"score_spread":0.23497546107624262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173494220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925053,0.0024674134,0.00013809439,0.0027320716,0.0011430314,0.00071647204,0.000020399339,0.0000053525396,0.00027182433],"genre_scores_gemma":[0.9726804,0.0015810168,0.024814138,0.0002561644,0.00027724926,0.000023560051,0.000006132875,0.000019980547,0.00034137067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99246377,0.00203909,0.0037422406,0.00034254143,0.0010895394,0.00032283674],"domain_scores_gemma":[0.99166805,0.0023998083,0.0024462852,0.00019338695,0.0030119552,0.00028050394],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014866581,0.00016575286,0.0021345192,0.00018273761,0.00004881187,0.0000084952435,0.00012176043,0.00024075754,0.00022279528],"category_scores_gemma":[0.018223811,0.00011280338,0.00062056934,0.00041409812,0.00027757106,0.00017063426,0.00009731187,0.0010307176,0.0000026594964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02726835,0.004052116,0.9377983,0.0001800264,0.001759779,0.0024175658,0.0007612059,0.0003676638,0.004507357,0.0001188311,0.00019739222,0.020571416],"study_design_scores_gemma":[0.05708764,0.007525248,0.91751957,0.0009377436,0.0024165942,0.00010165835,0.0028120207,0.0033808881,0.0043082014,0.0029291806,0.00075042556,0.0002308282],"about_ca_topic_score_codex":0.00010022799,"about_ca_topic_score_gemma":0.0004152186,"teacher_disagreement_score":0.029819293,"about_ca_system_score_codex":0.0005988903,"about_ca_system_score_gemma":0.0086858,"threshold_uncertainty_score":0.99693406},"labels":[],"label_agreement":null},{"id":"W3173857525","doi":"10.1097/ju.0000000000001946","title":"Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; University of British Columbia, Okanagan Campus; University of British Columbia; Queen's University; Université Laval","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Testosterone (patch); Queen (butterfly); Concomitant; Library science; Gerontology; Cancer; Internal medicine; Biology","score_opus":0.033504610992798216,"score_gpt":0.33019767673719375,"score_spread":0.2966930657443955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173857525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9341411,0.05620653,0.000044879678,0.008886515,0.0001839955,0.00049222895,0.000012118239,0.000006373873,0.00002623365],"genre_scores_gemma":[0.94220996,0.057046484,0.0001994278,0.00020509088,0.0001672026,0.000017392873,0.0000059886297,0.000017088389,0.00013134844],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99904233,0.00014111034,0.00031611626,0.00012345912,0.00014711432,0.0002298808],"domain_scores_gemma":[0.99907005,0.00018618675,0.00022114145,0.000116935655,0.00033330888,0.00007239374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052678917,0.0001048323,0.0002641023,0.00007128074,0.00012125556,0.00002023393,0.00006663232,0.000041088377,0.000025167043],"category_scores_gemma":[0.00006946105,0.000060356182,0.00005429585,0.000091710914,0.000119884025,0.000071573384,0.000045226065,0.0002172454,6.832162e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0351292,0.00023492506,0.18275315,0.00015484978,0.00071446795,0.0002429579,0.009996584,0.00004098278,0.67212075,0.000018727498,0.0005651022,0.09802832],"study_design_scores_gemma":[0.031269137,0.015385147,0.36256418,0.00075372896,0.00042243995,0.004170103,0.002330956,0.00059230893,0.5575483,0.0024099974,0.022165436,0.00038826538],"about_ca_topic_score_codex":0.0000040923387,"about_ca_topic_score_gemma":0.0000047285066,"teacher_disagreement_score":0.17981102,"about_ca_system_score_codex":0.00007058799,"about_ca_system_score_gemma":0.00017082342,"threshold_uncertainty_score":0.24612537},"labels":[],"label_agreement":null},{"id":"W3174022783","doi":"10.1111/bju.15507","title":"Systemic therapies for metastatic hormone‐sensitive prostate cancer: network meta‐analysis","year":2021,"lang":"en","type":"review","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Prostate cancer; Medicine; Oncology; Meta-analysis; Internal medicine; Cancer","score_opus":0.09407199595601104,"score_gpt":0.3886952149672202,"score_spread":0.29462321901120914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174022783","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002500298,0.99677503,0.00030262893,0.0004806715,0.00028504766,0.0015566647,0.00053629954,0.000012416456,0.000026231879],"genre_scores_gemma":[0.0002634384,0.9966034,0.00065576175,0.00017235921,0.0006128712,0.00042161936,0.00028582994,0.00007925873,0.0009054286],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9962399,0.00097048294,0.0013246167,0.00042032287,0.00041230742,0.00063239207],"domain_scores_gemma":[0.9962226,0.0008205073,0.0013272184,0.00023355593,0.0011516706,0.00024445172],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012333201,0.0004143676,0.008186305,0.00044980153,0.0001415339,0.000082401166,0.00019559261,0.0002409478,0.00012152029],"category_scores_gemma":[0.000120051096,0.00031156684,0.004942482,0.00095189153,0.00016733378,0.000090968184,0.000056448836,0.00083582837,0.0000031088998],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028576175,0.000111470334,0.000005351929,0.004946928,0.58003825,0.007167484,0.00011086992,0.00008661635,7.272602e-7,0.00001592539,0.0032677497,0.40396285],"study_design_scores_gemma":[0.0011677251,0.00071097404,0.000007777506,0.0019200031,0.565502,0.02094578,0.00007297003,0.000007664797,3.45737e-7,0.000030581723,0.40945444,0.0001797792],"about_ca_topic_score_codex":0.0000921534,"about_ca_topic_score_gemma":0.000073608986,"teacher_disagreement_score":0.40618667,"about_ca_system_score_codex":0.0002076895,"about_ca_system_score_gemma":0.001623928,"threshold_uncertainty_score":0.99993366},"labels":[],"label_agreement":null},{"id":"W3174319659","doi":"10.1530/erc-21-0192","title":"Celebrating the 80th anniversary of hormone ablation for prostate cancer","year":2021,"lang":"en","type":"article","venue":"Endocrine Related Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"U.S. Department of Veterans Affairs","keywords":"Prostate cancer; Medicine; Androgen; Cancer; Disease; Radiation therapy; Prostate; Ablation; Oncology; Endocrine system; Internal medicine; Hormone; Cancer research; Bioinformatics; Biology","score_opus":0.020317115866904788,"score_gpt":0.3338556181193614,"score_spread":0.3135385022524566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174319659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84988785,0.12259574,0.00006638877,0.020611955,0.00042428865,0.0017110126,0.00024119591,0.000079867714,0.0043817074],"genre_scores_gemma":[0.95103055,0.017455041,0.000290489,0.00016993491,0.0002003753,0.00046132732,0.00017253325,0.000039883533,0.030179843],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99887013,0.000038161055,0.00026532062,0.00025188056,0.00025111137,0.00032338614],"domain_scores_gemma":[0.9991001,0.00009061138,0.00012073979,0.00021967414,0.0003942282,0.000074631804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009582031,0.00013252534,0.0002470278,0.00005836029,0.00013205725,0.000012496693,0.000060551713,0.000046025416,0.00031455097],"category_scores_gemma":[0.000048192243,0.00008705732,0.00011724352,0.0004320792,0.00008654733,0.00009251545,0.000040897896,0.0002257006,0.0000036595754],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054036095,0.00073696696,0.11485158,0.0013426534,0.0044459,0.0007524669,0.007295585,0.0037965414,0.5702195,0.0019315192,0.10095701,0.18826665],"study_design_scores_gemma":[0.024300931,0.0011461722,0.060667597,0.0009421375,0.0013474616,0.0001626181,0.002180351,0.009684124,0.74196136,0.0010501721,0.15597844,0.00057864236],"about_ca_topic_score_codex":0.00045708413,"about_ca_topic_score_gemma":0.00008215368,"teacher_disagreement_score":0.18768801,"about_ca_system_score_codex":0.00021292036,"about_ca_system_score_gemma":0.00061215414,"threshold_uncertainty_score":0.35500947},"labels":[],"label_agreement":null},{"id":"W3174824255","doi":"10.5489/cuaj.7383","title":"The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre International Retreat","year":2021,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Women's College Hospital; St. Michael's Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; University Health Network; Toronto General Hospital; Princess Margaret Cancer Centre; University of British Columbia","funders":"National Institute for Health and Care Research","keywords":"Prostate cancer; Medicine; Genetic testing; Cancer; Oncology; Family medicine; Genetic counseling; Internal medicine; Gynecology; Genetics; Biology","score_opus":0.0152828792468936,"score_gpt":0.27434467011434865,"score_spread":0.25906179086745507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174824255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.910151,0.015759666,0.0000011705928,0.07229892,0.00022722768,0.00025363857,0.00007517351,0.0000055085284,0.0012276998],"genre_scores_gemma":[0.98604214,0.011333313,0.0002431279,0.00052474975,0.0002684788,0.000030027959,0.000026265061,0.000008257994,0.0015236357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987151,0.00011861155,0.0003175419,0.0001785775,0.00036421092,0.0003059279],"domain_scores_gemma":[0.99877644,0.00029166281,0.00022902351,0.00009980826,0.00042201887,0.00018104164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042394505,0.00008490825,0.00014760745,0.000046713052,0.00022334821,0.000095878655,0.00010961188,0.00005586366,0.00020815394],"category_scores_gemma":[0.00065520767,0.00004811676,0.000039958282,0.00021905024,0.00004664921,0.000044333763,0.000049830374,0.0003320574,7.506736e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042933632,0.000016647324,0.95939386,0.0000044212616,0.00019972322,0.0008691087,0.00016780733,0.000039115086,0.000085810614,0.000010710159,0.0011059624,0.03806392],"study_design_scores_gemma":[0.0007813003,0.000020348974,0.98001325,0.00008556158,0.000058524485,0.0000897808,0.00032674364,0.00074286544,0.000070380716,0.0005766186,0.017185416,0.000049218866],"about_ca_topic_score_codex":0.010819195,"about_ca_topic_score_gemma":0.02312219,"teacher_disagreement_score":0.07589115,"about_ca_system_score_codex":0.0010974337,"about_ca_system_score_gemma":0.0006228001,"threshold_uncertainty_score":0.99576783},"labels":[],"label_agreement":null},{"id":"W3174909401","doi":"10.1007/s00292-021-00956-3","title":"Das metastasierte kastrationsresistente Prostatakarzinom","year":2021,"lang":"de","type":"review","venue":"Der Pathologe","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Gynecology; Medicine","score_opus":0.10766252221844894,"score_gpt":0.42000779063680055,"score_spread":0.31234526841835164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174909401","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017872955,0.9884972,0.00009379321,0.0008029185,0.0013770673,0.0034361358,0.0019943356,0.00010301877,0.0035168168],"genre_scores_gemma":[0.0001757786,0.95924395,0.0010596064,0.00027269253,0.0009888667,0.0009442935,0.01416668,0.00017514084,0.022972997],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99358183,0.0010456762,0.00134585,0.0016280393,0.0009814312,0.0014171737],"domain_scores_gemma":[0.996335,0.0002981755,0.00049707515,0.0016744762,0.0005544159,0.0006408063],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00094837084,0.001098596,0.0031979007,0.00045978202,0.00042728876,0.00025917328,0.00046539056,0.00069106184,0.0022432252],"category_scores_gemma":[0.00036455272,0.0008233537,0.0013463313,0.001065993,0.00048367074,0.00016438865,0.0003775181,0.0015742453,0.004358957],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000191259,0.0018262245,0.0018543606,0.027696894,0.008628893,0.03733022,0.0007028241,6.0317785e-7,0.00017272576,0.0006132544,0.020639364,0.90034336],"study_design_scores_gemma":[0.0019818924,0.0004959118,0.00043946665,0.010998524,0.010534633,0.0007123883,0.00019238371,0.000004906506,0.00019469514,0.000026597032,0.973723,0.00069558714],"about_ca_topic_score_codex":0.000020405289,"about_ca_topic_score_gemma":0.000013912334,"teacher_disagreement_score":0.95308363,"about_ca_system_score_codex":0.00052041054,"about_ca_system_score_gemma":0.0031287344,"threshold_uncertainty_score":0.9994217},"labels":[],"label_agreement":null},{"id":"W3176208875","doi":"10.1056/nejmoa2107322","title":"Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2598,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institute for Health and Care Research; Advanced Accelerator Applications; Endocyte; Novartis","keywords":"Prostate cancer; Medicine; Castration; Oncology; Cancer research; Prostate; Internal medicine; Cancer; Hormone","score_opus":0.0572078347326491,"score_gpt":0.37646202383116567,"score_spread":0.31925418909851655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176208875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75948596,0.06745282,0.0013124977,0.16595116,0.0023041388,0.001292967,0.00010240173,0.000030748168,0.0020673254],"genre_scores_gemma":[0.9573889,0.009077273,0.0047216467,0.0011722787,0.006400142,0.00003671345,0.00009969737,0.00005142185,0.021051941],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822354,0.00007380524,0.0005830132,0.00017697169,0.0006307294,0.00031196105],"domain_scores_gemma":[0.99793106,0.00026965034,0.00025924307,0.00016738857,0.0009273618,0.00044528948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068109576,0.00017011643,0.0005958211,0.00016387526,0.00008404702,0.0000203533,0.0000792066,0.00003935598,0.0005808181],"category_scores_gemma":[0.00048179415,0.00010076271,0.00012575329,0.00026085213,0.00010513677,0.000103098784,0.0000143385105,0.00028683434,0.0000025685745],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022755614,0.0006904523,0.009842715,0.0015210742,0.0028830466,0.008998377,0.008915393,0.00015234336,0.3362429,0.00056529255,0.13297507,0.4744577],"study_design_scores_gemma":[0.3007304,0.009423148,0.013582181,0.0034979817,0.002874531,0.0047144447,0.0024878911,0.00019452156,0.057717342,0.0028972581,0.6015024,0.0003778531],"about_ca_topic_score_codex":0.00012845213,"about_ca_topic_score_gemma":0.00017399107,"teacher_disagreement_score":0.47407985,"about_ca_system_score_codex":0.00014929855,"about_ca_system_score_gemma":0.0017766597,"threshold_uncertainty_score":0.6359551},"labels":[],"label_agreement":null},{"id":"W3176238068","doi":"10.1002/prca.202100037","title":"A proteomic investigation of isogenic radiation resistant prostate cancer cell lines","year":2021,"lang":"en","type":"article","venue":"PROTEOMICS - CLINICAL APPLICATIONS","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute; National Heart, Lung, and Blood Institute; Prostate Cancer Canada","keywords":"DU145; Prostate cancer; Cancer research; Epithelial–mesenchymal transition; CD44; Biology; Glycolysis; Radiation therapy; Anaerobic glycolysis; Cancer cell; Cancer; Cell culture; Cell; Medicine; Metastasis; Enzyme; Internal medicine; Biochemistry; LNCaP; Genetics","score_opus":0.056106424241839536,"score_gpt":0.392463241892522,"score_spread":0.3363568176506825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176238068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982508,0.0032243414,0.0011332073,0.0071364967,0.00006763802,0.005098711,0.00017836253,0.00006768225,0.00058556424],"genre_scores_gemma":[0.935293,0.015116724,0.0339743,0.0005167751,0.0005576877,0.0097883735,0.0007057787,0.00006518661,0.0039821826],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980396,0.00011118457,0.00085321534,0.00047803388,0.00027400217,0.00024395181],"domain_scores_gemma":[0.99820536,0.00012227164,0.0003352508,0.00051359995,0.0005996644,0.00022386157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045939337,0.0001518218,0.00037841563,0.00005523776,0.00011448209,0.000022664977,0.00011462349,0.00016376325,0.00010195082],"category_scores_gemma":[0.0001406679,0.000130874,0.00018459844,0.0004812173,0.00022599458,0.00009280852,0.00007091971,0.00028676837,0.00003519356],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009847538,0.0008616439,0.14581718,0.00078729546,0.0002106827,0.000007005106,0.00028056678,0.000017227921,0.8323799,0.0006784222,0.0007561288,0.0172192],"study_design_scores_gemma":[0.0039877766,0.00038031823,0.09944045,0.0001455334,0.00026976105,0.0000055105024,0.00007357695,0.00056087546,0.88545847,0.0040503824,0.0054111485,0.00021621621],"about_ca_topic_score_codex":0.000115670206,"about_ca_topic_score_gemma":0.000035461857,"teacher_disagreement_score":0.053078562,"about_ca_system_score_codex":0.00018787032,"about_ca_system_score_gemma":0.0014780548,"threshold_uncertainty_score":0.5336887},"labels":[],"label_agreement":null},{"id":"W3177859492","doi":"10.1158/1538-7445.am2021-359","title":"Abstract 359: Molecular signatures associated with long-term response to apalutamide (APA) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in TITAN","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prevention of Organ Failure","funders":"","keywords":"Quartile; Prostate cancer; Internal medicine; Medicine; Cohort; Oncology; Population; Proportional hazards model; Androgen deprivation therapy; Hazard ratio; Placebo; Cancer; Pathology","score_opus":0.038756578742328615,"score_gpt":0.38618270671746224,"score_spread":0.3474261279751336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177859492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99284613,0.0015077266,0.000003481203,0.0026119694,0.000043379292,0.0024394146,0.00022332011,0.000025407115,0.00029915402],"genre_scores_gemma":[0.99617517,0.00032603872,0.000068175505,0.00021208974,0.000029008637,0.0010856926,0.00022916944,0.00007789055,0.0017967462],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99539196,0.0006437201,0.00036064463,0.0008002715,0.0016942824,0.0011090939],"domain_scores_gemma":[0.99715227,0.0004047823,0.000080159945,0.00040759906,0.0015552205,0.00039999213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011382285,0.00030228164,0.00053678994,0.00072968606,0.00012645965,0.00010686275,0.0001494054,0.00011388505,0.00021291751],"category_scores_gemma":[0.0005108417,0.00022616488,0.000051534847,0.002471794,0.00025909746,0.00018916768,0.000088043875,0.0010908785,0.000017583357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051416136,0.001616457,0.7626473,0.00043356398,0.00079619617,0.02078532,0.004341561,0.0018231046,0.14832723,0.000015468995,0.00035001655,0.00744766],"study_design_scores_gemma":[0.009529673,0.0013435944,0.9062132,0.00249181,0.000050274255,0.000006923229,0.000574017,0.000019455676,0.07945323,0.000013085598,0.000038093905,0.00026661012],"about_ca_topic_score_codex":0.0014486639,"about_ca_topic_score_gemma":0.018167833,"teacher_disagreement_score":0.14356595,"about_ca_system_score_codex":0.0028701415,"about_ca_system_score_gemma":0.0037538703,"threshold_uncertainty_score":0.99974805},"labels":[],"label_agreement":null},{"id":"W3178440845","doi":"10.4103/aja.aja_58_21","title":"Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer","year":2021,"lang":"en","type":"article","venue":"Asian Journal of Andrology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Interquartile range; Internal medicine; Follicle-stimulating hormone; Oncology; Prostatectomy; Proportional hazards model; Cohort; Biochemical recurrence; Endocrinology; Hormone; Gynecology; Urology; Cancer; Luteinizing hormone","score_opus":0.045513947523030764,"score_gpt":0.3596209714386616,"score_spread":0.31410702391563083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178440845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9658301,0.002037999,0.00046117094,0.029376853,0.00013082955,0.0018875839,0.00006920513,0.000023689545,0.00018255199],"genre_scores_gemma":[0.99203235,0.00020579077,0.0031904702,0.0008358717,0.00011053269,0.00016873288,0.000012500183,0.00005060672,0.003393144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781007,0.0001245711,0.0005828642,0.00038496093,0.00048108303,0.0006164312],"domain_scores_gemma":[0.99801105,0.00011548955,0.00025149208,0.00029852038,0.0008564404,0.00046703464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005768221,0.00025938798,0.0011358868,0.00024267823,0.00023538998,0.000035151563,0.00015151722,0.0001420634,0.00006499549],"category_scores_gemma":[0.00027226776,0.00015219924,0.00031886768,0.00047307514,0.00007181374,0.000116521536,0.00012696894,0.00035275254,0.0000064051487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0513198,0.00069752475,0.732491,0.0004872471,0.010185152,0.024174882,0.008620079,0.001971971,0.016563315,0.0000104651845,0.0012413425,0.15223718],"study_design_scores_gemma":[0.03107954,0.020243233,0.9282153,0.00062815036,0.0013070481,0.0032794997,0.00091905415,0.00004561527,0.010657628,0.000059896047,0.0031764295,0.00038857065],"about_ca_topic_score_codex":0.0000101737505,"about_ca_topic_score_gemma":0.000057680907,"teacher_disagreement_score":0.1957243,"about_ca_system_score_codex":0.0003077669,"about_ca_system_score_gemma":0.00093967805,"threshold_uncertainty_score":0.6206505},"labels":[],"label_agreement":null},{"id":"W3178468434","doi":"10.1158/1538-7445.am2021-lb065","title":"Abstract LB065: Prostate cancer molecular immunophenotypes in biopsies with high vs average radiation sensitivity as predicted by post-operative radiation therapy outcomes (PORTOS) scores","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"","keywords":"Prostate cancer; Medicine; Radiation therapy; Biopsy; Oncology; Prostate biopsy; Internal medicine; Cancer; Gene signature; Pathology; Prostate; Biology; Gene expression; Gene","score_opus":0.020428050638043524,"score_gpt":0.36549042134474274,"score_spread":0.3450623707066992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178468434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9674494,0.018170854,0.0000041164453,0.0113372635,0.00012742396,0.0019014586,0.00067942165,0.00006146523,0.00026855015],"genre_scores_gemma":[0.9649171,0.029888215,0.000027497255,0.00046639092,0.0001022781,0.0009766604,0.0010982583,0.00006995186,0.0024536154],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99629575,0.0004582838,0.0003556315,0.0007305261,0.001329051,0.0008307734],"domain_scores_gemma":[0.99763894,0.00024572306,0.000099613695,0.00044163424,0.0013333844,0.00024072267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072828855,0.00032128041,0.00053688674,0.0003856437,0.0002648886,0.00016359333,0.00011535554,0.00016512211,0.00074651133],"category_scores_gemma":[0.00022446821,0.00023248488,0.00008056218,0.0011391225,0.00034733073,0.00037132367,0.00007204858,0.0008355706,0.000019290033],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008877076,0.0006245445,0.3296601,0.00024587027,0.0008186087,0.0017303468,0.0036817694,0.00064399483,0.609145,0.00006340553,0.0010823879,0.043426927],"study_design_scores_gemma":[0.006039248,0.0006423525,0.51238817,0.00030630262,0.000022456952,0.000011683493,0.00037788675,0.00006689712,0.4787973,0.00004320269,0.0010804571,0.00022405366],"about_ca_topic_score_codex":0.015685283,"about_ca_topic_score_gemma":0.0011789942,"teacher_disagreement_score":0.18272807,"about_ca_system_score_codex":0.0011634862,"about_ca_system_score_gemma":0.0030582654,"threshold_uncertainty_score":0.99086934},"labels":[],"label_agreement":null},{"id":"W3178882185","doi":"10.3390/cancers13143488","title":"Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Androgen receptor; Prostate cancer; FOXA1; Cancer research; Androgen; Transcription factor; Androgen deprivation therapy; Chemistry; Prostate; Endocrinology; Internal medicine; Biology; Medicine; Cancer; Gene; Hormone; Biochemistry","score_opus":0.03430529043387877,"score_gpt":0.3280932132275991,"score_spread":0.29378792279372035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178882185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930392,0.004731814,0.000014299836,0.0003142337,0.00016894532,0.0012079504,0.00044787815,0.000009182997,0.00006647703],"genre_scores_gemma":[0.97505605,0.0019328028,0.020155527,0.000023788945,0.00025915974,0.00086274947,0.0007072947,0.000045697132,0.00095691177],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99854374,0.00006121322,0.0005231947,0.00028542467,0.00031127778,0.00027513233],"domain_scores_gemma":[0.9988914,0.00005016745,0.00027370357,0.00022487484,0.0004453483,0.00011449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023927575,0.00016610713,0.00042219608,0.000048974944,0.00011241662,0.000008293416,0.000068033885,0.00006518729,0.00011658423],"category_scores_gemma":[0.000025349953,0.00010959869,0.00011457433,0.00023719174,0.00016318339,0.00006789318,0.000018680832,0.000045720553,6.1083074e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055888067,0.00023494664,0.0022146495,0.00075224065,0.0005198914,0.000023465576,0.013523406,0.00004755274,0.91719186,0.000022486576,0.00056703587,0.059313685],"study_design_scores_gemma":[0.0038092905,0.0012062364,0.00026365896,0.00033634203,0.000108921,0.0000060403577,0.004842371,0.00003860902,0.9619413,0.00001411332,0.027328027,0.00010508698],"about_ca_topic_score_codex":0.00019412987,"about_ca_topic_score_gemma":0.00027642638,"teacher_disagreement_score":0.059208598,"about_ca_system_score_codex":0.0013788467,"about_ca_system_score_gemma":0.004308873,"threshold_uncertainty_score":0.7643755},"labels":[],"label_agreement":null},{"id":"W3178977732","doi":"10.1002/cam4.4125","title":"Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration‐resistant prostate cancer treated with Radium‐223","year":2021,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Radium-223; Internal medicine; Proportional hazards model; Prostate-specific antigen; Oncology; Cancer; Log-rank test; Survival analysis; Urology; Bone metastasis","score_opus":0.06709255880006178,"score_gpt":0.37260466825207034,"score_spread":0.3055121094520086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178977732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98179764,0.00918296,0.000003955447,0.0070181303,0.00005951259,0.0013001953,0.00009457892,0.00005768847,0.00048531962],"genre_scores_gemma":[0.98909783,0.0066208025,0.00014320033,0.00028037705,0.000039567352,0.0007190783,0.00012096962,0.00004415897,0.002934008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975903,0.00014684643,0.00040551813,0.0006585411,0.0006615728,0.0005372164],"domain_scores_gemma":[0.9986439,0.00022208433,0.00017190877,0.00029957958,0.00034980918,0.00031275678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028679176,0.00038822385,0.0010069031,0.00019220143,0.00010631644,0.000030461579,0.000083293795,0.000068606416,0.00020795639],"category_scores_gemma":[0.00009917116,0.00019797313,0.000038401242,0.00074023026,0.0005936846,0.00018419686,0.00003501938,0.0003409641,0.0000012358636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019479546,0.0002166364,0.9879648,0.0003495011,0.00035709722,0.0018324143,0.0017908054,0.00002526439,0.003681056,0.000010103522,0.00007421461,0.0017501393],"study_design_scores_gemma":[0.0148131065,0.0018099366,0.96832645,0.0013890599,0.00058797724,0.000055764434,0.0039695282,0.000036362937,0.008502068,0.000014893462,0.0002442967,0.0002505308],"about_ca_topic_score_codex":0.003598245,"about_ca_topic_score_gemma":0.004664799,"teacher_disagreement_score":0.019638337,"about_ca_system_score_codex":0.0003549799,"about_ca_system_score_gemma":0.0009312468,"threshold_uncertainty_score":0.807311},"labels":[],"label_agreement":null},{"id":"W3180162850","doi":"","title":"Detection of tumor-related DNA methylation biomarkers in liquid biopsies from metastatic castration resistant prostate cancer patients to improve treatment decisions","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Epigenetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Prostate cancer; DNA methylation; Medicine; Oncology; Liquid biopsy; Differentially methylated regions; Internal medicine; Abiraterone acetate; Epigenomics; Cancer; Bioinformatics; Biology; Androgen receptor; Gene; Androgen deprivation therapy; Genetics","score_opus":0.07046894898845477,"score_gpt":0.4172806485431296,"score_spread":0.34681169955467483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180162850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953309,0.0025271475,0.0001355389,0.00078230473,0.000550918,0.00052379764,0.00012052498,0.000004063295,0.000024757785],"genre_scores_gemma":[0.9921498,0.004571782,0.0030163776,0.000041070005,0.000075623764,0.00001687762,0.000037690013,0.000018083792,0.00007273889],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967398,0.00032108603,0.0019790395,0.00023735366,0.0005221771,0.00020051992],"domain_scores_gemma":[0.9970272,0.00077455124,0.00075450854,0.00019304696,0.0009895238,0.00026117012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007082855,0.00015022418,0.00068854395,0.00024356761,0.000038818212,0.000017207765,0.00006026352,0.00009084502,0.000041540123],"category_scores_gemma":[0.0019048911,0.00010616558,0.00025686287,0.0005198215,0.00007399296,0.00007560254,0.000028655882,0.00021617046,0.0000028151737],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019450841,0.002808058,0.073913954,0.000057376506,0.0018175513,0.00038796407,0.001115857,0.0005256091,0.6692681,0.0000022641361,0.000028251112,0.23062423],"study_design_scores_gemma":[0.00911027,0.010968142,0.43091634,0.000486939,0.0005718222,0.0000051350758,0.00039012954,0.00029370215,0.5465366,0.0002628478,0.00034519928,0.00011284161],"about_ca_topic_score_codex":0.00020856259,"about_ca_topic_score_gemma":0.0006361444,"teacher_disagreement_score":0.35700238,"about_ca_system_score_codex":0.00031765027,"about_ca_system_score_gemma":0.0009768052,"threshold_uncertainty_score":0.43293065},"labels":[],"label_agreement":null},{"id":"W3180502637","doi":"10.1097/ju.0000000000002015.19","title":"MP24-19 TYPE OF ANDROGEN DEPRIVATION THERAPY AND THE RISK OF CARDIOVASCULAR DISEASES IN PATIENTS WITH PROSTATE CANCER WITH OR WITHOUT PRE-EXISTING CARDIOVASCULAR RISK","year":2021,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Internal medicine; Cancer; Oncology; Disease; Hormonal therapy; Heart failure; Myocardial infarction","score_opus":0.022172503971312985,"score_gpt":0.2878787311951929,"score_spread":0.26570622722387993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180502637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9224101,0.076786116,0.00007185081,0.00016215222,0.000032615,0.00050395215,0.00001571717,0.000002127149,0.000015389372],"genre_scores_gemma":[0.9520073,0.047792494,0.00008021085,0.000026862836,0.000038331793,0.0000094641955,0.0000039096144,0.00001453826,0.00002689461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983178,0.0007114804,0.00027030127,0.000113214766,0.00043854263,0.00014865925],"domain_scores_gemma":[0.99853665,0.0002205253,0.00032607204,0.00030609287,0.00055620464,0.000054429205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009308938,0.00010674289,0.00061461976,0.000068959016,0.00006284328,0.000004847065,0.00008292763,0.000036073812,0.000007856474],"category_scores_gemma":[0.0002114728,0.000039732622,0.00013870791,0.00028064635,0.00034809348,0.00004893395,0.00003196926,0.0002534036,7.255846e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050347373,0.00011810855,0.9226409,0.00005122242,0.0067410097,0.000038241895,0.0016289575,0.0062460396,0.000013353335,0.0000012245016,0.000008421862,0.012165138],"study_design_scores_gemma":[0.024427239,0.0027760915,0.96686804,0.000119307355,0.0038587172,0.00010161869,0.00027299847,0.00021969891,0.00064552634,0.00005618353,0.00058924174,0.00006535231],"about_ca_topic_score_codex":0.0005892466,"about_ca_topic_score_gemma":0.00005427319,"teacher_disagreement_score":0.044227112,"about_ca_system_score_codex":0.000033934222,"about_ca_system_score_gemma":0.00045356734,"threshold_uncertainty_score":0.16202493},"labels":[],"label_agreement":null},{"id":"W3180578829","doi":"","title":"Detection of clinically significant prostate cancer with 18F-DCFPyL (PSMA) PET/MR compared to mpMR alone: preliminary results of a prospective trial","year":2019,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Biopsy; Prospective cohort study; Radiology; Cancer; Nuclear medicine; Pathology; Internal medicine","score_opus":0.030259421128167263,"score_gpt":0.34615424538236667,"score_spread":0.3158948242541994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180578829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98822206,0.00009629363,0.000041381336,0.0007537845,0.00016967658,0.007050418,0.00011916341,0.000052798976,0.00349442],"genre_scores_gemma":[0.98964536,0.00013532657,0.0007345098,0.000044221568,0.000097749245,0.00044174553,0.000038248625,0.00003254787,0.0088303005],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975153,0.00008595676,0.00083743164,0.00054475217,0.0006553203,0.0003612475],"domain_scores_gemma":[0.99806976,0.00020269727,0.0003347856,0.00046520206,0.0007109767,0.00021660059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005235111,0.00021613474,0.0007416333,0.00018230296,0.000041244144,0.000010858436,0.00011845076,0.000052670268,0.00010335471],"category_scores_gemma":[0.00013500762,0.00013561871,0.00012190049,0.0004976561,0.00017801531,0.00008333526,0.000066426815,0.00024016316,0.000025781928],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87840706,0.0011869535,0.044975,0.00033535823,0.0004280148,0.00006614862,0.0013236452,0.00010821447,0.07056851,0.000008850576,0.00042720896,0.0021650146],"study_design_scores_gemma":[0.29106608,0.11207313,0.10766091,0.0011608218,0.0004452631,0.000037359034,0.0019638378,0.0008071247,0.48379087,0.00004885413,0.0005076363,0.0004381172],"about_ca_topic_score_codex":0.0012382945,"about_ca_topic_score_gemma":0.00019270818,"teacher_disagreement_score":0.587341,"about_ca_system_score_codex":0.00020821435,"about_ca_system_score_gemma":0.00069879094,"threshold_uncertainty_score":0.5530371},"labels":[],"label_agreement":null},{"id":"W3181400059","doi":"10.4103/aja.aja_64_21","title":"Apalutamide for patients with metastatic castration-sensitive prostate cancer in East Asia","year":2021,"lang":"en","type":"article","venue":"Asian Journal of Andrology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prevention of Organ Failure","funders":"","keywords":"Prostate cancer; Medicine; Oncology; Castration; Internal medicine; Gynecology; East Asia; Prostate; Cancer; Political science; China; Hormone","score_opus":0.016223408897137363,"score_gpt":0.3057839041102319,"score_spread":0.2895604952130945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181400059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898895,0.0005606104,0.00015234655,0.008361854,0.00011917804,0.0004284183,0.000052098538,0.0000025892814,0.00043339818],"genre_scores_gemma":[0.99816656,0.000110339344,0.0011382869,0.00013033969,0.000061242,0.00001868838,0.000031186755,0.000012729595,0.0003306357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913734,0.00006807977,0.00026551957,0.00012453637,0.00017051183,0.00023402192],"domain_scores_gemma":[0.9990276,0.00003784358,0.00014510898,0.0000684127,0.00060871395,0.00011231822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013109877,0.00009325631,0.00033482566,0.00013511175,0.000034469253,0.00001062989,0.000029676688,0.00003388412,0.000049273793],"category_scores_gemma":[0.000052231193,0.00006222867,0.0000594122,0.00016843114,0.00007663379,0.00009209443,0.00000773728,0.00017832426,0.0000013585468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019395744,0.0012833602,0.8869439,0.0002506767,0.0014691728,0.0065944274,0.0057412744,0.00014580094,0.0020754312,0.00019293616,0.0005440535,0.07536322],"study_design_scores_gemma":[0.041445516,0.0109464815,0.9312135,0.00055961567,0.0006007962,0.0020582941,0.004215905,0.00010850002,0.0061474047,0.000608743,0.0018674497,0.00022776627],"about_ca_topic_score_codex":0.000006193396,"about_ca_topic_score_gemma":0.00016652807,"teacher_disagreement_score":0.075135455,"about_ca_system_score_codex":0.00009154476,"about_ca_system_score_gemma":0.00069333444,"threshold_uncertainty_score":0.25376114},"labels":[],"label_agreement":null},{"id":"W3182554615","doi":"10.1158/1538-7445.am2021-2496","title":"Abstract 2496: CD82 regulation of c-Met in metastatic prostate cells","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metastasis; Cancer research; Tetraspanin; Prostate cancer; Prostate; Biology; Cancer; Metastasis suppressor; Medicine; Cell; Internal medicine","score_opus":0.12321089482797858,"score_gpt":0.4537991853095187,"score_spread":0.3305882904815401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182554615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883446,0.0050192103,0.0000035460246,0.0016544921,0.00009082958,0.00079954363,0.000060130515,0.000014366187,0.004013276],"genre_scores_gemma":[0.98598695,0.0028925992,0.00031625276,0.00002979049,0.00006919988,0.00021256645,0.00007844506,0.000027782544,0.010386389],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99760634,0.00017178548,0.00033794402,0.00036579807,0.00096496503,0.0005531733],"domain_scores_gemma":[0.9984227,0.00019873117,0.00005183051,0.00038417132,0.00077201985,0.00017054386],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010464485,0.000114196606,0.00033381145,0.00039263253,0.00006216144,0.000027393506,0.00010271853,0.000059193826,0.0019315183],"category_scores_gemma":[0.00014230683,0.00009332276,0.000074952,0.0012736768,0.00022397032,0.00011358626,0.00008661272,0.0004893986,0.00006803055],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094256987,0.00036847405,0.012529425,0.0009654458,0.00010622379,0.00044618556,0.00079779973,0.00008365375,0.96329045,0.00015228604,0.0028006427,0.017516833],"study_design_scores_gemma":[0.0031594646,0.00023816431,0.09243517,0.00056417333,0.000021516931,0.000007972626,0.0006496902,0.000052245046,0.89817107,0.00069791893,0.003908393,0.00009424491],"about_ca_topic_score_codex":0.0005940991,"about_ca_topic_score_gemma":0.00020628235,"teacher_disagreement_score":0.07990575,"about_ca_system_score_codex":0.0004416171,"about_ca_system_score_gemma":0.0016557523,"threshold_uncertainty_score":0.9989809},"labels":[],"label_agreement":null},{"id":"W3183994644","doi":"10.1038/s41598-021-94438-4","title":"Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia","year":2021,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Biomarker; Hyperplasia; Prostate-specific antigen; Prostate biopsy; Biopsy; Urology; Oncology; Internal medicine; Rectal examination; Cancer","score_opus":0.09599983733396639,"score_gpt":0.3928507084805636,"score_spread":0.2968508711465972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183994644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99033725,0.0024861658,0.000002456705,0.000797077,0.003285754,0.0007319992,0.00014610251,0.000039093287,0.0021740908],"genre_scores_gemma":[0.9915712,0.00018843844,0.0003886831,0.00003148021,0.00007411697,0.000060840153,0.00031649682,0.000022399186,0.0073463637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962183,0.0001739884,0.0011375586,0.0011749287,0.0007869971,0.00050818955],"domain_scores_gemma":[0.9977459,0.0001269397,0.0003418343,0.00094443955,0.0005844496,0.0002564454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023798712,0.00018451524,0.0005606054,0.00014031556,0.00013656041,0.00011956552,0.00008802156,0.00011650325,0.0004036554],"category_scores_gemma":[0.0010301608,0.00014401469,0.0001826289,0.00092316215,0.0005374865,0.00014183627,0.00017355221,0.0003130643,0.0000067438614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023608308,0.00042976908,0.93306726,0.00015080052,0.00009145627,0.005204969,0.00092976715,0.0000014733533,0.010145209,0.0000014661767,0.0027238412,0.047017932],"study_design_scores_gemma":[0.0014006156,0.000052587715,0.9494564,0.00063979934,0.00007944101,0.0001194013,0.00046585096,0.0004027729,0.036910757,0.0013048309,0.009007461,0.00016011635],"about_ca_topic_score_codex":0.00077518396,"about_ca_topic_score_gemma":0.00065238413,"teacher_disagreement_score":0.046857815,"about_ca_system_score_codex":0.000108292974,"about_ca_system_score_gemma":0.0016985085,"threshold_uncertainty_score":0.58727485},"labels":[],"label_agreement":null},{"id":"W3184516018","doi":"10.1007/s12325-021-01823-6","title":"Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Merck Sharp and Dohme; AstraZeneca","keywords":"Medicine; Prostate cancer; Internal medicine; Chemotherapy; Oncology; Cancer; Overall survival; Enzalutamide; Hormonal therapy","score_opus":0.02342395738069975,"score_gpt":0.34929700075028364,"score_spread":0.3258730433695839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184516018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99455845,0.003213551,0.000001779004,0.0007267992,0.00005766577,0.0011465095,0.000119975666,0.000005101698,0.00017019441],"genre_scores_gemma":[0.97718793,0.021906862,0.00017820773,0.00009967201,0.000021162936,0.000301655,0.000053426986,0.000014450027,0.00023663245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988808,0.00010668744,0.00023725073,0.00024727941,0.0003058141,0.00022214235],"domain_scores_gemma":[0.9995036,0.0001019454,0.000065730186,0.00018242549,0.0000906963,0.000055610206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109170156,0.0001470672,0.00028385627,0.000099689234,0.000033957844,0.000016305208,0.00004450164,0.0000139892445,0.00003741638],"category_scores_gemma":[0.0000068798226,0.000078109755,0.000026553618,0.00033422254,0.000053946893,0.00012179463,0.000010673806,0.000075107026,3.4113668e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00291623,0.00054982794,0.94830275,0.00006686026,0.000072463394,0.00011014399,0.0030646895,0.0001525423,0.00053645443,0.000038492435,0.0000031520226,0.04418643],"study_design_scores_gemma":[0.008198571,0.0014392509,0.9808675,0.00023290368,0.0000226366,9.4591e-7,0.0005362435,0.0000069645093,0.0067826626,0.00007935793,0.0017355715,0.00009738666],"about_ca_topic_score_codex":0.0018898793,"about_ca_topic_score_gemma":0.0373998,"teacher_disagreement_score":0.04408904,"about_ca_system_score_codex":0.00019683327,"about_ca_system_score_gemma":0.00020383144,"threshold_uncertainty_score":0.9801651},"labels":[],"label_agreement":null},{"id":"W3184582022","doi":"10.17107/kh.2021.22.538-546","title":"A tumormarker-kutatás rövid története. A PSA, mint legismertebb urológiai tumormarker felfedezésének története","year":2021,"lang":"en","type":"article","venue":"Kaleidoscope History","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Carcinoembryonic antigen; Cancer; Prostate-specific antigen; Multiple myeloma; Disease; Tumor marker; Oncology; Internal medicine; Pathology","score_opus":0.02866105897701201,"score_gpt":0.27434242787675306,"score_spread":0.24568136889974104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184582022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48850414,0.17778182,0.00029758143,0.009736315,0.0060965815,0.0026107822,0.00013514144,0.0007992319,0.31403843],"genre_scores_gemma":[0.71142024,0.0038946387,0.003533609,0.0059281276,0.0010610125,0.0005188175,0.000617145,0.0002852336,0.2727412],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99539757,0.0003065887,0.00078896055,0.0011269554,0.0011275642,0.001252375],"domain_scores_gemma":[0.9970526,0.0001552217,0.00020352234,0.0012303327,0.000476077,0.00088225806],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00057203264,0.00062909856,0.0009650883,0.00037741504,0.00029167128,0.000063683656,0.00033877953,0.00023989376,0.006149293],"category_scores_gemma":[0.00025012717,0.0005761616,0.00047125507,0.000518054,0.0005272231,0.00035520535,0.00026300582,0.00095805986,0.0014243817],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043008816,0.0020415941,0.020943569,0.001631609,0.0011884571,0.020416621,0.0043889456,0.000014682887,0.07533577,0.0002011554,0.8409628,0.028573873],"study_design_scores_gemma":[0.0065810443,0.0007156591,0.027838282,0.0004988415,0.00037962035,0.0009658455,0.00041033718,0.0003515096,0.0067350757,0.00005780572,0.9547737,0.00069224526],"about_ca_topic_score_codex":0.00032375328,"about_ca_topic_score_gemma":0.00015786279,"teacher_disagreement_score":0.22291608,"about_ca_system_score_codex":0.0029927248,"about_ca_system_score_gemma":0.0030604133,"threshold_uncertainty_score":0.99966896},"labels":[],"label_agreement":null},{"id":"W3185280489","doi":"10.1016/j.euo.2021.07.002","title":"The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Meta-analysis; Prostate cancer; Subgroup analysis; Relative risk; Adverse effect; Randomized controlled trial; Systematic review; Internal medicine; Confidence interval; Urology; Oncology; Gynecology; MEDLINE; Cancer","score_opus":0.13708938105967342,"score_gpt":0.43064019404415815,"score_spread":0.2935508129844847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185280489","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00076172623,0.9919368,0.0000065021054,0.00046861605,0.00013009715,0.005268185,0.00015586746,0.000012490106,0.0012597297],"genre_scores_gemma":[0.0013360541,0.99660933,0.00016509792,0.0001086955,0.00005678302,0.0006164743,0.0005287709,0.000062870466,0.00051592634],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9771429,0.018449936,0.002932846,0.00066940405,0.00029495347,0.0005099645],"domain_scores_gemma":[0.9828336,0.01344098,0.0025173172,0.00059801026,0.00048371506,0.00012633052],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.008118912,0.00048200903,0.01940493,0.00045759353,0.000089643494,0.000008924931,0.00025365502,0.00020722243,0.00013116407],"category_scores_gemma":[0.0022624421,0.00022053212,0.0020971769,0.0014180344,0.0011746117,0.00002360069,0.00021171325,0.00066946703,0.0000021011251],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21856539,0.0007932737,0.0004016386,0.0018297952,0.4752109,0.0003521524,0.0005757757,0.0007372262,4.415478e-7,0.000116641306,0.0005157973,0.30090097],"study_design_scores_gemma":[0.107167706,0.0014286146,0.00035214674,0.00045709294,0.44592538,0.000011590511,0.000018492174,0.000014204441,3.1927487e-7,0.000004585976,0.44446874,0.0001511189],"about_ca_topic_score_codex":0.000051839474,"about_ca_topic_score_gemma":0.00022054664,"teacher_disagreement_score":0.44395295,"about_ca_system_score_codex":0.00015744618,"about_ca_system_score_gemma":0.0009352212,"threshold_uncertainty_score":0.995153},"labels":[],"label_agreement":null},{"id":"W3185871101","doi":"10.1038/s41585-021-00490-0","title":"Molecular events in neuroendocrine prostate cancer development","year":2021,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Prevention of Organ Failure; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Mitacs; Cancer Research UK; National Cancer Institute; Prostate Cancer Foundation","keywords":"Prostate cancer; Transdifferentiation; Drug development; Cancer research; Androgen receptor; Disease; Prostate; Biology; Adenocarcinoma; Cancer; Medicine; Bioinformatics; Internal medicine; Pharmacology; Drug; Cell biology; Stem cell","score_opus":0.04655151472358472,"score_gpt":0.42545938246356013,"score_spread":0.3789078677399754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185871101","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003663313,0.9937738,0.0000013628625,0.00094007124,0.00049998943,0.004378578,0.000018514938,0.000028302627,0.0003227389],"genre_scores_gemma":[0.000010957982,0.99342716,0.00015774652,0.0010253066,0.0001411563,0.0025780296,0.0007530961,0.00009824362,0.0018082826],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99596757,0.00077061896,0.0011244019,0.0009740221,0.0003704035,0.00079296395],"domain_scores_gemma":[0.99860024,0.00008472735,0.000346196,0.000629237,0.00011686166,0.00022276168],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0003839195,0.0006785898,0.004074181,0.0004665257,0.000043386437,0.000008277698,0.0002741796,0.00054819294,0.00024953592],"category_scores_gemma":[0.00024240513,0.00044571905,0.00061940943,0.001047009,0.00005436137,0.000034106986,0.00023231628,0.0030296696,0.00013146568],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033972636,0.00016072628,0.0002415615,0.024463402,0.00026264056,0.0033193375,0.000018173676,2.2877741e-7,0.0000013333434,0.00002567538,0.0008627205,0.9706102],"study_design_scores_gemma":[0.00085976726,0.00010608434,0.00004537449,0.015988091,0.0008089936,0.00072897784,8.2538304e-7,5.2138705e-7,0.000009693143,0.0000067837163,0.9811561,0.00028879562],"about_ca_topic_score_codex":0.000008628764,"about_ca_topic_score_gemma":0.000028839322,"teacher_disagreement_score":0.9802934,"about_ca_system_score_codex":0.0005328463,"about_ca_system_score_gemma":0.0020704123,"threshold_uncertainty_score":0.99979943},"labels":[],"label_agreement":null},{"id":"W3186286798","doi":"10.3390/cancers13143607","title":"Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer","year":2021,"lang":"en","type":"review","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Prostate cancer; Medicine; Radionuclide therapy; Neuroendocrine tumors; Oncology; Cancer; Radioligand; Targeted therapy; Tumor heterogeneity; Internal medicine; Cancer research; Receptor","score_opus":0.0724530169037287,"score_gpt":0.41771717109434175,"score_spread":0.34526415419061307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186286798","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1485013,0.8438979,0.0000010743591,0.0011781895,0.00035957573,0.005496846,0.00053636945,0.0000133369185,0.000015404874],"genre_scores_gemma":[0.0024111995,0.989341,0.00002551496,0.00025937322,0.00027555614,0.006514919,0.00015899337,0.00007706273,0.0009363648],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99746305,0.00043078398,0.0005210579,0.000701917,0.000234101,0.00064909895],"domain_scores_gemma":[0.9987603,0.00040540518,0.00013409618,0.00036630544,0.00007876598,0.00025515567],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031879955,0.0004277838,0.0017323819,0.00031359232,0.00008116797,0.000039593095,0.00018668454,0.00010988646,0.000040712912],"category_scores_gemma":[0.00014063703,0.00025653743,0.00022829059,0.00054166844,0.00018376738,0.000039493854,0.00009939733,0.00054054655,0.0000014379418],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009982905,0.00014600309,0.0033687195,0.005236427,0.00046811096,0.0010664004,0.00090889796,0.00003324865,0.00010598135,0.0000027252497,0.0016638505,0.97701675],"study_design_scores_gemma":[0.0050211246,0.0015695255,0.00076423126,0.007846235,0.00019007125,0.00008480308,0.00010999083,0.000025604615,0.0001880147,0.0000039063666,0.9839504,0.00024609402],"about_ca_topic_score_codex":0.00044829625,"about_ca_topic_score_gemma":0.00060294085,"teacher_disagreement_score":0.9822866,"about_ca_system_score_codex":0.0035735185,"about_ca_system_score_gemma":0.005606805,"threshold_uncertainty_score":0.9999887},"labels":[],"label_agreement":null},{"id":"W3187165571","doi":"10.3390/curroncol28040252","title":"Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response","year":2021,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Biochemical recurrence; Radiation therapy; Lymph node; Disease; Systematic review; Stage (stratigraphy); Watchful waiting; MEDLINE; Cancer; Internal medicine; Oncology; Urology","score_opus":0.1359682251555561,"score_gpt":0.4598819351372298,"score_spread":0.3239137099816737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187165571","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003149339,0.9819561,0.000009459973,0.000292412,0.0009981247,0.012268517,0.0012650279,0.000044647404,0.00001636358],"genre_scores_gemma":[0.00010923083,0.992168,0.00015201441,0.000036627785,0.00009548555,0.0045740823,0.0025179118,0.000053802152,0.000292839],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99424857,0.001988627,0.0019264512,0.00086601655,0.00047527545,0.0004950822],"domain_scores_gemma":[0.9959735,0.0011438632,0.0014367937,0.000502999,0.00058848213,0.00035434612],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023115613,0.0006239025,0.0067159142,0.00039878354,0.00009210676,0.000012493821,0.00017147331,0.00042999777,0.00008238969],"category_scores_gemma":[0.0010911799,0.00038492907,0.0005465738,0.00041806878,0.00076395157,0.00007513459,0.00018601667,0.0006428165,0.0000011405617],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013033574,0.0011116331,0.0013182145,0.8612755,0.0007298345,0.00009714235,0.00013461083,3.3761985e-8,0.0000066647094,0.000056478533,0.0012727936,0.13269374],"study_design_scores_gemma":[0.005017425,0.005891703,0.0009721063,0.46376455,0.011109436,0.00044224353,0.000069120884,0.000006697197,0.000008575077,0.000016855725,0.51231784,0.00038346712],"about_ca_topic_score_codex":0.0000040848204,"about_ca_topic_score_gemma":0.0000032756673,"teacher_disagreement_score":0.51104504,"about_ca_system_score_codex":0.0010579012,"about_ca_system_score_gemma":0.0034425233,"threshold_uncertainty_score":0.9998603},"labels":[],"label_agreement":null},{"id":"W3187545758","doi":"10.1136/bmjopen-2020-046588","title":"A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design","year":2021,"lang":"en","type":"article","venue":"BMJ Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Astellas Pharma; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Androgen deprivation therapy; Placebo; Internal medicine; Prostate-specific antigen; Oncology; Urology; Radiation therapy; Prostatectomy; Hormone therapy; Cancer; Breast cancer; Pathology; Androgen receptor","score_opus":0.05980164032402145,"score_gpt":0.4043480596106108,"score_spread":0.34454641928658936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187545758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95745647,0.0017850971,0.001087221,0.0001799917,0.000032031538,0.039345562,0.000056509838,0.000017276558,0.000039840463],"genre_scores_gemma":[0.9876737,0.0011376127,0.0010423309,0.0001655016,0.000037437825,0.009426699,0.000016342105,0.000080789316,0.0004195771],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99619085,0.0011540069,0.00069378695,0.00078118104,0.0006679954,0.00051221234],"domain_scores_gemma":[0.99827904,0.0003394961,0.00028927025,0.0005771535,0.00030822333,0.00020681613],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016934855,0.0004140296,0.0013563527,0.00023830569,0.00012852703,0.00013262843,0.00016240089,0.000050078987,0.000040598745],"category_scores_gemma":[0.000068840265,0.00027696532,0.00006373306,0.00064260577,0.00018075018,0.00027031027,0.00016955778,0.0003613732,0.0000026910711],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72223544,0.011765416,0.09665717,0.0001483204,0.0034045693,0.0104181105,0.070662655,0.0017234908,0.0063131163,3.9261738e-7,0.00005901858,0.0766123],"study_design_scores_gemma":[0.751318,0.025284523,0.1307437,0.0008464897,0.0008207485,0.00008866566,0.05184543,0.00423446,0.034158476,0.000054501208,0.000011251216,0.00059376593],"about_ca_topic_score_codex":0.008837108,"about_ca_topic_score_gemma":0.0029931914,"teacher_disagreement_score":0.076018535,"about_ca_system_score_codex":0.00034358344,"about_ca_system_score_gemma":0.0014298749,"threshold_uncertainty_score":0.99996823},"labels":[],"label_agreement":null},{"id":"W3188003094","doi":"10.1097/ju.0000000000002058.02","title":"PD44-02 PHARMACOGENOMIC DETERMINANTS OF SERUM STEROID HORMONE RESPONSES TO ABIRATERONE OR ENZALUTAMIDE AND HSD3B1 GENE MUTATION IN CRPC PATIENTS","year":2021,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Medicine; Abiraterone acetate; Abiraterone; Oncology; Pharmacogenomics; Pharmacogenetics; Prostate cancer; Internal medicine; Pharmacology; Cancer; Bioinformatics; Genotype; Gene; Genetics; Androgen deprivation therapy; Biology; Androgen receptor","score_opus":0.03465547636685034,"score_gpt":0.3462671067024123,"score_spread":0.31161163033556194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3188003094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948083,0.0034244435,0.000009901299,0.0014404707,0.00009094022,0.00019389974,0.000020417885,0.0000017836768,0.000009804139],"genre_scores_gemma":[0.9968455,0.0022662422,0.000113063805,0.00041284753,0.000049427075,0.0000027152257,0.0000019433776,0.000011181456,0.00029710436],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99885637,0.00031265593,0.00038507956,0.00008949027,0.00016703174,0.00018935975],"domain_scores_gemma":[0.9992488,0.00018278946,0.00017041009,0.000104511666,0.00020047525,0.00009299401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048313173,0.00008476167,0.00029318148,0.00015328225,0.000031060932,0.0000049458154,0.00007543269,0.000045080837,0.000049364975],"category_scores_gemma":[0.00013146913,0.000049306447,0.000028068602,0.00014356857,0.00007354974,0.00005637655,0.00006133359,0.00016373281,0.000004085297],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042981114,0.0003879799,0.2533299,0.000057377914,0.00016494255,0.001761933,0.002734118,0.000041378415,0.66865647,4.1613396e-7,0.00015584377,0.029728562],"study_design_scores_gemma":[0.0073223677,0.00496148,0.7836251,0.00003138088,0.00014624879,0.0011310868,0.0001651864,0.00004775145,0.20232333,0.00002897722,0.0001654893,0.000051569572],"about_ca_topic_score_codex":0.000012523064,"about_ca_topic_score_gemma":0.00003192183,"teacher_disagreement_score":0.53029525,"about_ca_system_score_codex":0.00006265944,"about_ca_system_score_gemma":0.00023890492,"threshold_uncertainty_score":0.20106587},"labels":[],"label_agreement":null},{"id":"W3189079996","doi":"10.1097/ju.0000000000002067.04","title":"MP46-04 RESULTS OF THE PCM-204 PHASE 2B TRIAL OF PARTIAL-GLAND ABLATION FOR MEN WITH INTERMEDIATE-RISK PROSTATE CANCER WITH PADELIPORFIN (WST11 OR TOOKAD) VASCULAR-TARGETED PHOTODYNAMIC THERAPY","year":2021,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Prostate cancer; Art history; Classics; Psychoanalysis; Art; Internal medicine; Psychology","score_opus":0.022578143576099125,"score_gpt":0.32499573288769906,"score_spread":0.30241758931159995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189079996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921721,0.0022320424,0.00017259165,0.0035544443,0.00016425518,0.001505559,0.00014140183,0.000004544282,0.000053060496],"genre_scores_gemma":[0.9907468,0.008330491,0.00008380273,0.00012508067,0.0002006347,0.00005835378,0.000028818447,0.000024431127,0.00040158938],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981078,0.0004178202,0.0006480862,0.00014959501,0.00041617829,0.00026050129],"domain_scores_gemma":[0.99760056,0.00040626616,0.00095413806,0.00031738513,0.00064670487,0.000074975855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001123766,0.00015742613,0.0005266289,0.00008475916,0.00008082843,0.0000074271857,0.00016864261,0.00008077512,0.00005591669],"category_scores_gemma":[0.00021079517,0.000059461516,0.00013740572,0.0002678568,0.00030260647,0.00006484913,0.000027925787,0.00033113887,2.4029657e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93828875,0.0008639895,0.0027811432,0.000071983886,0.0021489242,0.00006683065,0.0036096557,0.0010533654,0.041377652,0.0000031406112,0.00063878164,0.00909578],"study_design_scores_gemma":[0.6586222,0.06321065,0.011424233,0.00035204046,0.002667822,0.00032753288,0.0011423259,0.0031405266,0.25136566,0.00021876728,0.0072896644,0.00023857603],"about_ca_topic_score_codex":0.00015860447,"about_ca_topic_score_gemma":0.00031108942,"teacher_disagreement_score":0.27966654,"about_ca_system_score_codex":0.000063320345,"about_ca_system_score_gemma":0.0011837849,"threshold_uncertainty_score":0.24247703},"labels":[],"label_agreement":null},{"id":"W3190141894","doi":"10.1016/s1470-2045(21)00376-4","title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":277,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Centre for Mathematical Cognition, Loughborough University; Pfizer UK; Pfizer","keywords":"Medicine; Prostate cancer; Enzalutamide; Oncology; Internal medicine; PARP inhibitor; Clinical endpoint; Docetaxel; Cancer; Clinical trial; Poly ADP ribose polymerase; Androgen receptor; Biology","score_opus":0.17274289492622194,"score_gpt":0.47870194846347636,"score_spread":0.3059590535372544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190141894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97528845,0.0012325951,0.000018045643,0.01857285,0.00016187625,0.0028594967,0.00012381363,0.000058534402,0.0016843101],"genre_scores_gemma":[0.98292035,0.0016011161,0.0037840118,0.002163704,0.00058588607,0.003170527,0.00049895345,0.000051234845,0.0052242437],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99806494,0.0005065115,0.00035107174,0.0004045079,0.00023437361,0.00043860657],"domain_scores_gemma":[0.9989033,0.00014003266,0.00011856565,0.00052459456,0.00018861228,0.00012492931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006688249,0.00017706456,0.0006237661,0.00006892695,0.00018520509,0.00008682613,0.00019326364,0.00005677312,0.00028981775],"category_scores_gemma":[0.000045928275,0.000103936225,0.000029505603,0.00043244942,0.00018449206,0.00021699899,0.000055552733,0.00031601658,0.000008283193],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74544084,0.017363215,0.002992389,0.00025153876,0.0015506712,0.0061112135,0.009420419,0.00020863918,0.173393,0.0040030135,0.007933412,0.031331662],"study_design_scores_gemma":[0.86717516,0.035563875,0.0033269466,0.0002479265,0.00049763237,0.00030697713,0.0018807176,0.0024749774,0.021292975,0.0012685123,0.06549625,0.0004680229],"about_ca_topic_score_codex":0.0005419428,"about_ca_topic_score_gemma":0.008999149,"teacher_disagreement_score":0.15210001,"about_ca_system_score_codex":0.0003791163,"about_ca_system_score_gemma":0.0024840713,"threshold_uncertainty_score":0.50217366},"labels":[],"label_agreement":null},{"id":"W3190572377","doi":"10.1016/j.urolonc.2021.06.008","title":"PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy","year":2021,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Positron emission tomography; Glutamate carboxypeptidase II; Biochemical recurrence; Proportional hazards model; Propensity score matching; Hazard ratio; Nuclear medicine; Internal medicine; Oncology; Urology; PET-CT; Cancer; Confidence interval","score_opus":0.028680241360428023,"score_gpt":0.3342595366078746,"score_spread":0.3055792952474466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190572377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9614143,0.0063776406,0.0000343729,0.030083511,0.000096276184,0.00052766677,0.000063103296,0.000022303806,0.0013808509],"genre_scores_gemma":[0.93563837,0.003972465,0.055161998,0.0036969085,0.0002046087,0.00043405636,0.00018376093,0.000024814333,0.0006830183],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982891,0.00046720446,0.0003138373,0.0003152589,0.0002828431,0.0003317193],"domain_scores_gemma":[0.9988383,0.0005404002,0.00008883141,0.00030749704,0.000080509235,0.00014447376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008422131,0.0001572476,0.00039594874,0.00012365925,0.00011145158,0.000019566613,0.00013714052,0.00011463472,0.00013027238],"category_scores_gemma":[0.00032118708,0.000099322395,0.000069255526,0.00048669268,0.00082045567,0.00007321665,0.00006232188,0.0004555794,0.000002197992],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007995204,0.00062367803,0.9804764,0.0001574811,0.00019424195,0.0036059453,0.002610872,0.0000157421,0.0024122833,0.0032004232,0.0029333727,0.0029700457],"study_design_scores_gemma":[0.012635948,0.0056067957,0.25707263,0.0002741715,0.00064129604,0.0035066416,0.002837508,0.0009861117,0.0045185876,0.0139035275,0.6976422,0.00037455698],"about_ca_topic_score_codex":0.000034938224,"about_ca_topic_score_gemma":0.00007332231,"teacher_disagreement_score":0.72340375,"about_ca_system_score_codex":0.0000962559,"about_ca_system_score_gemma":0.0006721871,"threshold_uncertainty_score":0.40502498},"labels":[],"label_agreement":null},{"id":"W3190600090","doi":"10.1097/ju.0000000000002015.18","title":"MP24-18 COMPARISON OF THE CARDIOTOXICITY OF ABIRATERONE AND ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER USING REAL-WORLD DATA","year":2021,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Abiraterone acetate; Cardiotoxicity; Internal medicine; Oncology; Cancer; Cohort; Population; Androgen deprivation therapy; Chemotherapy","score_opus":0.18026519662138332,"score_gpt":0.439299224522568,"score_spread":0.2590340279011847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190600090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909648,0.0066299625,0.000014834703,0.0019627006,0.00007438942,0.00023284012,0.000058822505,9.17954e-7,0.000060764807],"genre_scores_gemma":[0.9978578,0.0017624091,0.00020585465,0.000052776453,0.00003383755,0.0000017818867,0.0000039181664,0.000007409861,0.00007422431],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99854714,0.00044704136,0.00050351024,0.00009323216,0.00025588775,0.00015320854],"domain_scores_gemma":[0.9987981,0.00020354697,0.000427561,0.00031606253,0.00021252359,0.000042254855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008564829,0.000078618,0.0004851118,0.000088728935,0.000041934585,0.0000050038107,0.00015956652,0.000020617315,0.000021898435],"category_scores_gemma":[0.00008449073,0.00004022286,0.000039015056,0.00028395077,0.00032888632,0.00006030375,0.00012137892,0.00027777624,8.472627e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043587135,0.00026868796,0.39135006,0.00023100355,0.0006499157,0.00014238022,0.0022142024,0.0023729987,0.59611386,0.000035398905,0.00019072913,0.0020720642],"study_design_scores_gemma":[0.0059120813,0.0012455645,0.7833171,0.00035467246,0.0016035473,0.00044307552,0.002056767,0.004270386,0.19995216,0.00034189824,0.0003925378,0.00011020593],"about_ca_topic_score_codex":0.0015635112,"about_ca_topic_score_gemma":0.005025753,"teacher_disagreement_score":0.3961617,"about_ca_system_score_codex":0.00006921186,"about_ca_system_score_gemma":0.0006037393,"threshold_uncertainty_score":0.2804488},"labels":[],"label_agreement":null},{"id":"W3190799048","doi":"10.1016/j.phro.2021.07.001","title":"Prostate specific membrane antigen positron emission tomography for lesion-directed high-dose-rate brachytherapy dose escalation","year":2021,"lang":"en","type":"article","venue":"Physics and Imaging in Radiation Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Cancer Care Ontario; Lawson Health Research Institute","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Prostate Cancer Canada","keywords":"Prostate cancer; Medicine; Positron emission tomography; Nuclear medicine; Brachytherapy; Glutamate carboxypeptidase II; Lesion; Histopathology; Radiology; Cancer; Radiation therapy; Pathology; Internal medicine","score_opus":0.023492991077936787,"score_gpt":0.3403729707292516,"score_spread":0.3168799796513148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190799048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876093,0.0043894267,0.00061919854,0.005840615,0.00027868836,0.00084920623,0.000029338284,0.000063242536,0.00032096426],"genre_scores_gemma":[0.9902815,0.0065165344,0.0014496137,0.00025180177,0.00028521294,0.00009125109,0.00082382525,0.00002725725,0.00027295295],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989227,0.00011765581,0.0002328882,0.00034076633,0.00012215234,0.00026385646],"domain_scores_gemma":[0.99932927,0.00015476836,0.00009855718,0.00013586857,0.00018661247,0.000094918905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002230591,0.0001356786,0.0002768116,0.00013421204,0.00012801858,0.000040558756,0.000030585128,0.000059025355,0.000020127554],"category_scores_gemma":[0.000023149942,0.00011976132,0.00006188931,0.00038710324,0.000060578383,0.00017068943,0.000017931494,0.00013741094,0.0000021548353],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015807747,0.00059255713,0.13484146,0.000121236524,0.00006623884,0.00006067724,0.0008391487,0.00006867451,0.45189017,0.00044705093,0.0009388858,0.40855312],"study_design_scores_gemma":[0.016892545,0.0006309363,0.780742,0.00016210398,0.00005903955,0.000025691334,0.00015135141,0.021802612,0.15321445,0.005104672,0.020919748,0.00029488135],"about_ca_topic_score_codex":0.000036365556,"about_ca_topic_score_gemma":0.0000048138827,"teacher_disagreement_score":0.6459005,"about_ca_system_score_codex":0.00017740444,"about_ca_system_score_gemma":0.00022624174,"threshold_uncertainty_score":0.48837247},"labels":[],"label_agreement":null},{"id":"W3190846855","doi":"10.3390/cancers13164023","title":"PSMA Theranostics: Current Landscape and Future Outlook","year":2021,"lang":"en","type":"review","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université Laval; University of Manitoba","funders":"Ipsen; Astellas Pharma; Eisai; Sanofi; AstraZeneca; Pfizer; Amgen","keywords":"Current (fluid); Data science; Computer science; Geology; Oceanography","score_opus":0.0600750673742921,"score_gpt":0.39855001418087344,"score_spread":0.33847494680658136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190846855","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006145614,0.99527407,0.0000016103852,0.00019708522,0.0011053171,0.00075286836,0.00011057168,0.000031584426,0.002520763],"genre_scores_gemma":[0.0000013531801,0.99427193,0.000027212773,0.000059286787,0.0023167417,0.00016769071,0.00051294203,0.000051524363,0.0025913417],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99874824,0.00005799391,0.00023029922,0.000416181,0.00023810288,0.00030916097],"domain_scores_gemma":[0.99922544,0.000058731282,0.00008499316,0.00031784238,0.00008656201,0.00022642549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007399498,0.00031567866,0.0012383796,0.00011059472,0.00006466554,0.00003792056,0.00008199575,0.00019420657,0.00045726128],"category_scores_gemma":[0.000015646543,0.00020042453,0.00026887475,0.00022184403,0.000083585124,0.000024581288,0.00005448838,0.00051453005,0.000035332796],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016901711,0.000010233865,0.00003447953,0.013565435,0.00032089796,0.00010916658,0.000086740816,5.0625697e-8,1.13435085e-7,0.000030080178,0.01196409,0.9738618],"study_design_scores_gemma":[0.0007527817,0.000084035986,0.00000684627,0.0130686015,0.0010761572,0.00006080598,0.00008879905,0.0000023538926,9.552725e-7,0.00000389458,0.98466784,0.00018695393],"about_ca_topic_score_codex":0.000008266045,"about_ca_topic_score_gemma":0.000003218374,"teacher_disagreement_score":0.97367483,"about_ca_system_score_codex":0.0008800707,"about_ca_system_score_gemma":0.0032688854,"threshold_uncertainty_score":0.81730753},"labels":[],"label_agreement":null},{"id":"W3190958237","doi":"10.3389/fonc.2021.722430","title":"Establishing a Provincial Registry for Recurrent Prostate Cancer: Providing Access to PSMA PET/CT in Ontario, Canada","year":2021,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Cancer Care Ontario; Women's College Hospital; London Health Sciences Centre; Mount Sinai Hospital; Western University","funders":"","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Christian ministry; Agency (philosophy); Population; Positron emission tomography; Health care; Medical physics; Cancer; Family medicine; Nuclear medicine; Environmental health; Internal medicine","score_opus":0.03560235239046635,"score_gpt":0.35339542772271937,"score_spread":0.31779307533225304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190958237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730748,0.0021031604,0.000088847635,0.015724733,0.003672725,0.0031464065,0.00010447746,0.000021986796,0.0020628609],"genre_scores_gemma":[0.9395906,0.0009963937,0.019835358,0.00334776,0.0007330958,0.0073623615,0.000665704,0.000119586366,0.027349185],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979485,0.000091435424,0.0003879984,0.0005709361,0.00027616054,0.0007249492],"domain_scores_gemma":[0.99915075,0.00010161088,0.000100388206,0.00023649287,0.00017996517,0.00023076445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033628405,0.00018645763,0.0005747258,0.00022974651,0.00008458563,0.0000655843,0.00022452945,0.00003855416,0.000054328975],"category_scores_gemma":[0.00046527223,0.00017478739,0.000053225634,0.0004787002,0.000049474795,0.00018696582,0.00016842799,0.000544705,3.8394563e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0037256668,0.00028766206,0.7171788,0.00034082067,0.00006938258,0.00842284,0.0010852303,0.00007963078,0.00010588557,0.000013665328,0.19611634,0.072574064],"study_design_scores_gemma":[0.011998141,0.0014735764,0.07268202,0.0009556452,0.000092094764,0.00030817374,0.003151105,0.00060456846,0.0042193034,0.00034152684,0.90369767,0.00047615668],"about_ca_topic_score_codex":0.8847481,"about_ca_topic_score_gemma":0.99845994,"teacher_disagreement_score":0.70758134,"about_ca_system_score_codex":0.014434475,"about_ca_system_score_gemma":0.030160021,"threshold_uncertainty_score":0.98934895},"labels":[],"label_agreement":null},{"id":"W3194097125","doi":"10.1016/j.eururo.2021.06.004","title":"Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman’s Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374–82","year":2021,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; General surgery","score_opus":0.060725641845245856,"score_gpt":0.328905315257747,"score_spread":0.26817967341250115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194097125","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00812287,0.017461203,0.00035350505,0.9549553,0.004004208,0.013088683,0.0012285947,0.0002589235,0.00052673504],"genre_scores_gemma":[0.007511828,0.002926572,0.0026419808,0.9461078,0.02398005,0.009828712,0.0009805404,0.0006660729,0.0053564543],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98997533,0.0034738071,0.001333021,0.0024448137,0.0011113235,0.0016616797],"domain_scores_gemma":[0.99376315,0.0020947335,0.00073218386,0.0017896456,0.0012265189,0.00039375856],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0026113957,0.0014333342,0.0019185893,0.0005457292,0.00085742044,0.0003775923,0.0009667775,0.0002547731,0.00016605195],"category_scores_gemma":[0.0034548976,0.00083780667,0.00061718264,0.0012721446,0.00046177616,0.00015824291,0.001010995,0.0028492815,0.00005745451],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026739797,0.00074386224,0.000059854236,0.00013996652,0.0037784618,0.0011024667,0.004253721,0.00001027614,0.0023432935,0.000007964213,0.9304137,0.03040663],"study_design_scores_gemma":[0.029471206,0.010637719,0.00025184033,0.00020267421,0.0017349181,0.00010868155,0.00018996281,0.00008391666,0.00096000195,0.000036759535,0.95553905,0.0007832769],"about_ca_topic_score_codex":0.0003622735,"about_ca_topic_score_gemma":0.00012197107,"teacher_disagreement_score":0.029623352,"about_ca_system_score_codex":0.0003769715,"about_ca_system_score_gemma":0.0005719503,"threshold_uncertainty_score":0.99984163},"labels":[],"label_agreement":null},{"id":"W3194210605","doi":"10.1016/j.eururo.2021.06.003","title":"Re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374–82","year":2021,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; London Health Sciences Centre; Western University","funders":"Ontario Institute for Cancer Research; Canadian Association of Radiation Oncology","keywords":"Medicine; Prostate cancer; Oncology; Metastasis; Prostate; Internal medicine; Clinical trial; Gynecology; Cancer; Urology","score_opus":0.09249571404793779,"score_gpt":0.3496596363935667,"score_spread":0.2571639223456289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194210605","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008293153,0.055781137,0.0004007606,0.9135599,0.0023184041,0.013950076,0.0020050693,0.00052015844,0.003171343],"genre_scores_gemma":[0.053442862,0.019494757,0.0056295083,0.87191385,0.009145272,0.016723577,0.007930022,0.0017757538,0.0139443735],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98805845,0.004759714,0.0015664506,0.0024622746,0.0012308155,0.0019222926],"domain_scores_gemma":[0.99272394,0.0025101965,0.0011999907,0.0016322249,0.0016130937,0.00032053524],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002334631,0.0016216207,0.0024554222,0.0006767752,0.0008491427,0.00030127662,0.00095587055,0.0003842714,0.00032552448],"category_scores_gemma":[0.0035251356,0.0010699028,0.0010971145,0.0014822677,0.0007292259,0.0001969329,0.0006921525,0.0037397959,0.000059455288],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052009247,0.0024770782,0.00014113917,0.0003749913,0.010984118,0.004772747,0.0034900627,0.0000132581235,0.0034424881,0.00003410395,0.8527516,0.06950914],"study_design_scores_gemma":[0.072639704,0.011281125,0.00019010698,0.00023494469,0.0035272646,0.00016364855,0.00025931618,0.00025183574,0.0017488492,0.00013321653,0.90859914,0.000970865],"about_ca_topic_score_codex":0.00021603072,"about_ca_topic_score_gemma":0.00007499203,"teacher_disagreement_score":0.06853828,"about_ca_system_score_codex":0.0005037903,"about_ca_system_score_gemma":0.0013035465,"threshold_uncertainty_score":0.9996531},"labels":[],"label_agreement":null},{"id":"W3194294343","doi":"10.3390/cancers13174257","title":"A Review on the Current Treatment Paradigm in High-Risk Prostate Cancer","year":2021,"lang":"en","type":"review","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Androgen deprivation therapy; Brachytherapy; External beam radiotherapy; Oncology; Clinical trial; Population; Internal medicine; Radiology; Cancer","score_opus":0.10993545852851275,"score_gpt":0.433025170289124,"score_spread":0.3230897117606113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194294343","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025151106,0.9907566,1.5893237e-7,0.0017132426,0.0006529254,0.0059407232,0.0005211307,0.000031696898,0.00035840383],"genre_scores_gemma":[0.00000495276,0.98679775,0.0000040336254,0.00042275072,0.00035664628,0.009879819,0.0005074314,0.00008449856,0.0019420944],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970407,0.000428043,0.0006996603,0.00078516704,0.00040708805,0.0006393311],"domain_scores_gemma":[0.99813914,0.000313464,0.00037488554,0.00087618077,0.000069704176,0.00022665068],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032942358,0.0006576164,0.002582559,0.00017317358,0.000110010595,0.000033305212,0.0002079028,0.00012371001,0.00045716602],"category_scores_gemma":[0.000101541715,0.00031680678,0.00069642166,0.00095178536,0.00013886146,0.000030977528,0.000052617208,0.0009783357,0.00010575912],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000415384,0.00007125524,0.000047267502,0.033518318,0.00053404353,0.00014958285,0.00007686662,0.0000038267385,1.0610045e-8,0.000058928254,0.017264495,0.94823384],"study_design_scores_gemma":[0.0008284207,0.0002665786,0.000008432656,0.24996231,0.0017730184,0.000008386535,0.000007376274,0.0000017609702,0.0000012485917,0.000012589226,0.74691397,0.00021590153],"about_ca_topic_score_codex":0.0016153083,"about_ca_topic_score_gemma":0.0003462749,"teacher_disagreement_score":0.94801795,"about_ca_system_score_codex":0.0138979945,"about_ca_system_score_gemma":0.010040941,"threshold_uncertainty_score":0.9999284},"labels":[],"label_agreement":null},{"id":"W3194931280","doi":"10.2217/fon-2021-0575","title":"Relugolix, An Oral Gonadotropin-Releasing Hormone Antagonist for the Treatment of Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Prostate cancer; Testosterone (patch); Gonadotropin-releasing hormone antagonist; Hormone antagonist; Internal medicine; Androgen deprivation therapy; Antagonist; Gonadotropin-releasing hormone; Endocrinology; Androgen; Agonist; Urology; Leuprorelin; Hormone; Cancer; Luteinizing hormone; Receptor","score_opus":0.04279694177607753,"score_gpt":0.39304045283617983,"score_spread":0.3502435110601023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194931280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88749033,0.07123756,0.00005509846,0.037452042,0.00097562704,0.0017749922,0.00024246027,0.00004314779,0.0007287237],"genre_scores_gemma":[0.81394243,0.16099529,0.003808236,0.0011491493,0.004093956,0.0014552831,0.00080560084,0.0000964361,0.013653604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99891144,0.00009309168,0.0002131422,0.0002845379,0.00014853977,0.0003492509],"domain_scores_gemma":[0.9990825,0.00012356612,0.000084340696,0.00031294898,0.00027340328,0.0001232586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007677958,0.00015364545,0.00041590413,0.000042388794,0.00018019507,0.000013492865,0.00006789358,0.00012934739,0.0000975922],"category_scores_gemma":[0.000016456943,0.00008564557,0.0001342811,0.00017951961,0.00017268656,0.000041476673,0.00001735874,0.00011006013,0.000003440468],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01096189,0.0035723953,0.011320353,0.00021405205,0.0012737066,0.0006299177,0.004660785,0.00001879006,0.072739154,0.001347886,0.0103900805,0.882871],"study_design_scores_gemma":[0.0105767455,0.008630226,0.035844512,0.000030880292,0.00043427158,0.00010252675,0.002133428,0.00016537461,0.01876773,0.00012171691,0.92307395,0.00011865361],"about_ca_topic_score_codex":0.00034475498,"about_ca_topic_score_gemma":0.00052251015,"teacher_disagreement_score":0.91268384,"about_ca_system_score_codex":0.0005790001,"about_ca_system_score_gemma":0.0011756124,"threshold_uncertainty_score":0.34925252},"labels":[],"label_agreement":null},{"id":"W3196173890","doi":"10.3390/curroncol28050282","title":"18F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Women's College Hospital; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Prostate cancer; Biochemical recurrence; Salvage therapy; Prostatectomy; Radiation therapy; Ablative case; Cancer; Bone scintigraphy; Internal medicine; Oncology; Nuclear medicine; Radiology; Chemotherapy","score_opus":0.14606200658788013,"score_gpt":0.5080065003187811,"score_spread":0.361944493730901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196173890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905704,0.0060842074,0.0000051988964,0.0015893887,0.00016154614,0.0005252564,0.000027406604,0.00000656148,0.0010299903],"genre_scores_gemma":[0.9874021,0.011349452,0.00026100973,0.00026568424,0.0001715082,0.0003729777,0.00009880989,0.000011455823,0.00006702197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984848,0.00022870845,0.0003970456,0.00031055306,0.00032192675,0.00025699407],"domain_scores_gemma":[0.99934596,0.00007733305,0.00010042129,0.00027802642,0.00011488426,0.00008339688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028259167,0.00012450559,0.0003826678,0.000055866316,0.00001670638,0.000003474584,0.00018186292,0.00007919587,0.0002016817],"category_scores_gemma":[0.0000075349103,0.000071277886,0.00007158145,0.00022353705,0.00043274983,0.000053890348,0.0001004056,0.00049164676,0.0000016398735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0150637645,0.007529847,0.78412867,0.0010036319,0.00055095233,0.002456551,0.007999725,0.0000010623371,0.0038374595,0.00008944846,0.0045069405,0.17283195],"study_design_scores_gemma":[0.034696404,0.0047353413,0.81670636,0.0017642856,0.00031529198,0.00035248493,0.009912888,0.000073484516,0.025912195,0.00012330609,0.10502345,0.0003845184],"about_ca_topic_score_codex":0.0000094273055,"about_ca_topic_score_gemma":0.000018571869,"teacher_disagreement_score":0.17244744,"about_ca_system_score_codex":0.0001364734,"about_ca_system_score_gemma":0.00038493663,"threshold_uncertainty_score":0.29066277},"labels":[],"label_agreement":null},{"id":"W3196289286","doi":"10.1101/2021.08.30.21262305","title":"Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment","year":2021,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"National Center for Advancing Translational Sciences; NorthShore University HealthSystem; University of Michigan; National Cancer Institute; College of Pharmacy, University of Michigan; National Institutes of Health; Vanderbilt University; U.S. Department of Defense","keywords":"Prostate cancer; Single-nucleotide polymorphism; Hazard ratio; Genome-wide association study; Medicine; Oncology; Confidence interval; Internal medicine; SNP; Decile; Cancer; Germline; Prostate-specific antigen; Genetics; Biology; Gene; Genotype","score_opus":0.04382431172953798,"score_gpt":0.31670497005740006,"score_spread":0.27288065832786207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196289286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924723,0.0024730584,0.000011055121,0.0012277779,0.00043373418,0.0019144964,0.0012373879,0.00009755961,0.0001326141],"genre_scores_gemma":[0.9916072,0.0027119466,0.000092628616,0.00009181664,0.00013121776,0.0005161659,0.0020290043,0.00007589888,0.0027441478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975318,0.00016457633,0.00025046334,0.0009529745,0.0005919574,0.00050827774],"domain_scores_gemma":[0.99830097,0.00014991956,0.00016460197,0.00058109197,0.0003967547,0.00040665892],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007308992,0.0004880008,0.0008524835,0.00013727555,0.00009674572,0.00006634895,0.00014146733,0.00024602414,0.00051165617],"category_scores_gemma":[0.000060689697,0.00031547656,0.00016660166,0.00028559138,0.00008827923,0.00003450088,0.00022218487,0.0004079679,0.000015979636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012969284,0.0003364875,0.9863934,0.00008008813,0.0019112122,0.0004631855,0.0034452055,0.00013321551,0.0028387902,7.180692e-8,0.000106997606,0.002994399],"study_design_scores_gemma":[0.0030310703,0.0006703944,0.9509698,0.0008370468,0.00028990497,9.161251e-7,0.00047245933,0.000065216285,0.042697016,0.000005726993,0.0006347766,0.0003256649],"about_ca_topic_score_codex":0.0042516226,"about_ca_topic_score_gemma":0.0021996829,"teacher_disagreement_score":0.039858226,"about_ca_system_score_codex":0.0019016161,"about_ca_system_score_gemma":0.0012475282,"threshold_uncertainty_score":0.9999297},"labels":[],"label_agreement":null},{"id":"W3196377280","doi":"10.1021/acschembio.1c00390","title":"Development of a Benzothiazole Scaffold-Based Androgen Receptor N-Terminal Inhibitor for Treating Androgen-Responsive Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"ACS Chemical Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Deutsche Forschungsgemeinschaft; Wilhelm Sander-Stiftung; Prostate Cancer Foundation","keywords":"Androgen receptor; Benzothiazole; Prostate cancer; Scaffold; Androgen; Terminal (telecommunication); Prostate; Chemistry; Cancer research; Cancer; Endocrinology; Internal medicine; Medicine; Hormone; Biochemistry; Computer science","score_opus":0.029797269844471494,"score_gpt":0.337623279651928,"score_spread":0.3078260098074565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196377280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955862,0.0023545157,0.000020572705,0.0010750627,0.000076266486,0.00058605196,0.00021530336,0.000025499034,0.000060534046],"genre_scores_gemma":[0.981078,0.00013774954,0.016084552,0.0002740096,0.00017232877,0.0005949807,0.0011151909,0.000028948907,0.0005142119],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986831,0.00003740181,0.00036747937,0.00038534604,0.00012672272,0.00039993072],"domain_scores_gemma":[0.99902827,0.00018314584,0.00010589541,0.00016695795,0.00036326202,0.00015246008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013846904,0.00017265296,0.0004177544,0.000068712114,0.0000712218,0.000006973103,0.00007210102,0.00017731571,0.00012846963],"category_scores_gemma":[0.00017470642,0.00013191422,0.00010380502,0.00019449009,0.000159557,0.000024769355,0.000067998284,0.00010736587,0.0000062637664],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025110864,0.00022811533,0.008049186,0.00025622913,0.00018836919,0.000029093942,0.0006104004,2.961963e-7,0.9542968,0.000016743503,0.00035902817,0.033454604],"study_design_scores_gemma":[0.00453245,0.00025835686,0.00009088749,0.00019806791,0.00006633873,0.000019575496,0.00014115419,0.000028562388,0.97669363,0.00003028393,0.01780558,0.0001350935],"about_ca_topic_score_codex":0.000008242142,"about_ca_topic_score_gemma":0.00000728805,"teacher_disagreement_score":0.033319514,"about_ca_system_score_codex":0.00018681816,"about_ca_system_score_gemma":0.0013284462,"threshold_uncertainty_score":0.53793055},"labels":[],"label_agreement":null},{"id":"W3196402595","doi":"10.1007/s00345-021-03810-6","title":"Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"World Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Medizinische Universität Wien","keywords":"Medicine; TMPRSS2; Prostate cancer; Internal medicine; Androgen deprivation therapy; Retrospective cohort study; Meta-analysis; Oncology; Disease; Cancer; Coronavirus disease 2019 (COVID-19)","score_opus":0.08188773506062261,"score_gpt":0.3880364907193921,"score_spread":0.30614875565876953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196402595","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032724931,0.993344,0.0000022210686,0.0012664518,0.00003886826,0.0019701056,0.000091963186,0.0000058782475,0.000008013986],"genre_scores_gemma":[0.002809787,0.9959359,0.0000054737693,0.00052016496,0.000054264507,0.00019954432,0.00015423511,0.000022834669,0.00029776094],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9970602,0.0010568069,0.0009804517,0.00028218064,0.0004222584,0.00019811514],"domain_scores_gemma":[0.9970671,0.00028944702,0.0018113363,0.00019250724,0.00047504908,0.00016453858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009795204,0.00029125798,0.0047743083,0.00062423974,0.000072604795,0.000037875147,0.000056363253,0.0001260278,0.000034640223],"category_scores_gemma":[0.00039975418,0.00017106885,0.001007093,0.0007951744,0.00004290725,0.00010456469,0.000038046943,0.00048957946,0.0000011728852],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011321345,0.0002592631,0.23899987,0.33436385,0.40129453,0.000080738675,0.00006321461,6.1652435e-7,1.8314421e-7,0.000002499577,0.0006947158,0.024127295],"study_design_scores_gemma":[0.0007419095,0.00028843744,0.014260521,0.011511088,0.94794935,0.000010644114,5.8877595e-7,0.0000013354006,9.686063e-7,0.000018144243,0.025065796,0.00015122125],"about_ca_topic_score_codex":0.0000367675,"about_ca_topic_score_gemma":0.00006673495,"teacher_disagreement_score":0.5466548,"about_ca_system_score_codex":0.0003521791,"about_ca_system_score_gemma":0.000276245,"threshold_uncertainty_score":0.6975985},"labels":[],"label_agreement":null},{"id":"W3197133628","doi":"10.1038/s42003-021-02520-4","title":"CdGAP promotes prostate cancer metastasis by regulating epithelial-to-mesenchymal transition, cell cycle progression, and apoptosis","year":2021,"lang":"en","type":"article","venue":"Communications Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; Université de Montréal; Montreal Clinical Research Institute; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; Université de Montréal; Terry Fox Research Institute; Canadian Institutes of Health Research; McGill University Health Centre; Cancer Research Society; McGill University; Prostate Cancer Foundation","keywords":"Epithelial–mesenchymal transition; Apoptosis; Metastasis; Prostate cancer; Cancer research; Mesenchymal stem cell; Cell cycle; Cancer; Cell biology; Chemistry; Oncology; Medicine; Biology; Internal medicine; Biochemistry","score_opus":0.03303879051919035,"score_gpt":0.3680322217965457,"score_spread":0.33499343127735537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197133628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90172696,0.02824744,0.00013792816,0.06688366,0.000054650543,0.0010993833,0.00043476664,0.00008588088,0.00132935],"genre_scores_gemma":[0.97628015,0.00799945,0.012596327,0.00040141563,0.0000322811,0.00062892115,0.0008755501,0.000023429233,0.0011625016],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99875486,0.00026758082,0.00025816777,0.00032385142,0.00009600233,0.00029955048],"domain_scores_gemma":[0.9984636,0.00012654021,0.000066961875,0.0008475285,0.00032130186,0.00017410865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020788274,0.00014370464,0.00027368782,0.000088623405,0.00036361782,0.000027908356,0.00018495027,0.000093588984,0.00010231796],"category_scores_gemma":[0.00007423855,0.00011212499,0.00005334576,0.00040800794,0.00030789204,0.00005904587,0.00023998675,0.00020766022,0.000012440629],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018926052,0.00074615446,0.013948484,0.00019866916,0.00024348228,0.0000038776757,0.004315355,0.0000040165455,0.8464418,0.00035609287,0.0021737975,0.131379],"study_design_scores_gemma":[0.0037239054,0.0007685303,0.0043227193,0.0004153602,0.0003465829,0.000048321912,0.0014828187,0.0008605836,0.9266394,0.0011998401,0.059768457,0.00042353212],"about_ca_topic_score_codex":0.00009272588,"about_ca_topic_score_gemma":0.000036603276,"teacher_disagreement_score":0.13095546,"about_ca_system_score_codex":0.00006724205,"about_ca_system_score_gemma":0.00022607134,"threshold_uncertainty_score":0.45723245},"labels":[],"label_agreement":null},{"id":"W3197214945","doi":"10.3389/fonc.2021.742093","title":"PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions","year":2021,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Hôpitaux Universitaires de Genève; Movember Foundation; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Medicine; Prostate cancer; Prostatectomy; Androgen deprivation therapy; Radiation therapy; Positron emission tomography; Management of prostate cancer; Biochemical recurrence; Prostate; Salvage therapy; Radiology; Cancer; Surgery; Internal medicine; Chemotherapy","score_opus":0.028242473169263333,"score_gpt":0.41306452085818146,"score_spread":0.38482204768891815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197214945","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030444472,0.9860098,0.000031487027,0.0013107592,0.0021469225,0.009228738,0.0007386164,0.00005194388,0.0001773234],"genre_scores_gemma":[0.000010302862,0.9714823,0.0049073133,0.00015200958,0.0006105148,0.018759785,0.0009588157,0.0001185753,0.0030003968],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970986,0.0003534644,0.0005625417,0.00096905726,0.00025065578,0.0007656767],"domain_scores_gemma":[0.9988414,0.00015907179,0.00019777597,0.00042838405,0.00006447099,0.00030890395],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023428425,0.0007348796,0.0027777248,0.0007511156,0.000110942805,0.00004068891,0.00010489281,0.00014491653,0.00014498214],"category_scores_gemma":[0.000009909039,0.00044677578,0.00070406264,0.00051441597,0.00022144198,0.000036776044,0.00003299713,0.0005338585,0.0000024609085],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040578903,0.0011781214,0.0006492956,0.0063273967,0.0023062746,0.0040467153,0.000144822,0.0000015289046,6.205672e-8,0.000007848077,0.014187996,0.96709204],"study_design_scores_gemma":[0.008981484,0.005892451,0.00025709998,0.005419954,0.0015660317,0.00018712496,0.00008214419,0.00005189557,0.000002708088,0.000013873543,0.9771824,0.00036283038],"about_ca_topic_score_codex":0.00003531934,"about_ca_topic_score_gemma":0.00003964729,"teacher_disagreement_score":0.9667292,"about_ca_system_score_codex":0.009803121,"about_ca_system_score_gemma":0.0020682903,"threshold_uncertainty_score":0.9997984},"labels":[],"label_agreement":null},{"id":"W3197562406","doi":"10.1038/s41556-021-00743-5","title":"An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer","year":2021,"lang":"en","type":"article","venue":"Nature Cell Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Simon Fraser University; University Health Network; University of British Columbia","funders":"CIHR Skin Research Training Centre; Terry Fox Research Institute; Prostate Cancer Canada; Government of Canada; National Cancer Institute; Prostate Cancer Foundation","keywords":"Androgen receptor; Prostate cancer; Lineage (genetic); Prostate; Biology; Cancer research; Cell biology; Androgen; Receptor; Cancer; Genetics; Endocrinology; Gene; Hormone","score_opus":0.019978334250808062,"score_gpt":0.3542477562366831,"score_spread":0.334269421985875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197562406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95545954,0.039263796,0.0000016240282,0.0023723794,0.00026803065,0.0005085217,0.00021499823,0.00004820225,0.001862927],"genre_scores_gemma":[0.9821384,0.0118314,0.00036905598,0.00049857976,0.0002005623,0.00011898904,0.0011346908,0.000023873637,0.003684424],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984882,0.0001572077,0.000250163,0.00053105154,0.00011831344,0.00045509991],"domain_scores_gemma":[0.9991396,0.00007011011,0.000056759432,0.0003598318,0.0002007485,0.00017293441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013718652,0.00021725651,0.0004128482,0.00011732337,0.00006841247,0.000018986006,0.00008261362,0.000505175,0.00047787774],"category_scores_gemma":[0.000035851375,0.00014696179,0.0000843917,0.0003625595,0.0001137972,0.00005581118,0.000036693767,0.0005120845,0.000022286406],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002444948,0.0010041189,0.212715,0.00015165636,0.0001775313,0.00044866852,0.0011259414,0.0000075732064,0.76609,0.00011536567,0.00072832446,0.014990913],"study_design_scores_gemma":[0.0072813793,0.0015969536,0.0150571335,0.00007584608,0.00008055914,0.00001193233,0.0006334567,0.00005801306,0.8169245,0.00018076513,0.1578399,0.0002595437],"about_ca_topic_score_codex":0.00040669003,"about_ca_topic_score_gemma":0.0016477328,"teacher_disagreement_score":0.19765787,"about_ca_system_score_codex":0.0004593417,"about_ca_system_score_gemma":0.0007782786,"threshold_uncertainty_score":0.59929276},"labels":[],"label_agreement":null},{"id":"W3197690873","doi":"10.1016/j.euf.2021.08.005","title":"Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy","year":2021,"lang":"en","type":"article","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Placebo; Androgen deprivation therapy; Antiandrogen; Internal medicine; Quality of life (healthcare); Randomized controlled trial; Urology; Cancer; Oncology","score_opus":0.07433959756864661,"score_gpt":0.34986856234815294,"score_spread":0.27552896477950634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197690873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98881674,0.005989539,0.00005675683,0.003830274,0.00005579129,0.0007453835,0.00027274716,0.000011523657,0.00022125992],"genre_scores_gemma":[0.9979914,0.0007030765,0.00010582471,0.0002337855,0.00001671125,0.00003935363,0.00046318735,0.000021504355,0.0004251693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763656,0.0008020669,0.0007609701,0.00029320928,0.00026202464,0.0002451975],"domain_scores_gemma":[0.9984,0.0003095343,0.00051674544,0.0003076223,0.00037441633,0.00009170521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009415975,0.00012671146,0.000525988,0.00012836377,0.00013862368,0.000007145065,0.00008006854,0.000031817275,0.00011280264],"category_scores_gemma":[0.0003301145,0.00008576597,0.00017976643,0.0006042023,0.00016148288,0.000034542798,0.000043724467,0.000111157366,0.0000028867962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063072545,0.00053351116,0.9441761,0.00017025572,0.0040863543,0.000019119716,0.0025249745,0.00076435774,0.017827064,0.00008214475,0.00031753143,0.023191359],"study_design_scores_gemma":[0.0043257503,0.0008771956,0.9883749,0.000020987525,0.00044720832,0.0000015320642,0.00006375199,0.00022426764,0.005206849,0.000049949318,0.00033354494,0.00007407615],"about_ca_topic_score_codex":0.00036900418,"about_ca_topic_score_gemma":0.0017987305,"teacher_disagreement_score":0.044198815,"about_ca_system_score_codex":0.000095071584,"about_ca_system_score_gemma":0.00033590043,"threshold_uncertainty_score":0.3497435},"labels":[],"label_agreement":null},{"id":"W3198154413","doi":"10.1161/circulationaha.121.056810","title":"Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian VIGOUR Centre; St. Michael's Hospital","funders":"Janssen Pharmaceuticals; American Regent; St. Jude Medical; Esperion Therapeutics; Idorsia Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Servier; Duke Clinical Research Institute; Astellas Pharma; Eisai; Cleveland Clinic; Bristol-Myers Squibb; CryoLife; Medicines Company; Regado Biosciences; Novo Nordisk; MyoKardia; Daiichi-Sankyo; AstraZeneca; Amarin Corporation; Ironwood Pharmaceuticals, Incorporated; Regeneron Pharmaceuticals; Boston VA Research Institute; Boston Scientific Corporation; Pfizer; York University; Eli Lilly and Company; CSL Behring; University of Toronto; Heart and Stroke Foundation of Canada; HLS Therapeutics; GlaxoSmithKline; Amgen; Sanofi; American Heart Association","keywords":"Medicine; Prostate cancer; Randomized controlled trial; Prostate; Cancer; Urology; Gynecology; Oncology; Internal medicine","score_opus":0.01695433379412681,"score_gpt":0.26261056831419655,"score_spread":0.24565623452006974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198154413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925033,0.0021658074,0.000014898744,0.00047061616,0.00017696459,0.0037805096,0.000038568767,0.0000056627446,0.00084366655],"genre_scores_gemma":[0.99921435,0.0003061108,0.000027539507,0.0000123445025,0.000040885498,0.00017052487,0.00013780856,0.000009771665,0.00008063456],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984401,0.00028975963,0.00036952086,0.00018669067,0.00058138504,0.00013258072],"domain_scores_gemma":[0.9988497,0.00016542002,0.0001664041,0.00041148037,0.0003840071,0.00002299492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006769082,0.00008654238,0.00043895532,0.000035164692,0.000050294464,0.000005695036,0.00006198194,0.000043002066,0.0000043753867],"category_scores_gemma":[0.00030023002,0.000041390485,0.00020057609,0.00036497397,0.00016280377,0.000052917145,0.00003170402,0.00012042429,3.0689668e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92357224,0.00014607771,0.0664052,0.00011811918,0.00054180756,0.0000024969904,0.000697078,0.0022583785,0.0001235716,0.000012998671,0.000013133315,0.006108865],"study_design_scores_gemma":[0.6369923,0.00009905952,0.36101335,0.00018980764,0.00025096425,3.5233282e-7,0.000033165074,0.000091852526,0.0011389006,0.000015412175,0.0001380119,0.00003687194],"about_ca_topic_score_codex":0.00025527718,"about_ca_topic_score_gemma":0.000044683242,"teacher_disagreement_score":0.29460815,"about_ca_system_score_codex":0.00025079396,"about_ca_system_score_gemma":0.0006920177,"threshold_uncertainty_score":0.16878551},"labels":[],"label_agreement":null},{"id":"W3198434193","doi":"10.17863/cam.75006","title":"Analysis of Prostate Cancer Tumor Microenvironment Identifies Reduced Stromal CD4 Effector T-cell Infiltration in Tumors with Pelvic Nodal Metastasis.","year":2021,"lang":"en","type":"article","venue":"Apollo (University of Cambridge)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Institute of Infection and Immunity","funders":"Cancer Research UK","keywords":"Stromal cell; Metastasis; Prostate cancer; Medicine; Oncology; Pathology; Cancer research; Tumor microenvironment; Cancer; Internal medicine","score_opus":0.009362407328656645,"score_gpt":0.23522286269122178,"score_spread":0.22586045536256513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198434193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99748063,0.0008192766,0.000024900457,0.0006107438,0.000026626649,0.00038659692,0.00019918961,0.000009808901,0.00044220913],"genre_scores_gemma":[0.99433935,0.0003661446,0.00023724127,0.000017344597,0.000010366626,0.0000028309328,0.00027513193,0.000011351903,0.0047402326],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987455,0.000100589146,0.00018957877,0.00032821723,0.00039582918,0.0002402658],"domain_scores_gemma":[0.99927366,0.000042644435,0.00018429411,0.00026679633,0.00012967206,0.00010292713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014194108,0.00014801622,0.0005815615,0.00045270068,0.00006302893,0.000007751153,0.00009177728,0.00003392398,0.00022594098],"category_scores_gemma":[0.000009955067,0.00013882913,0.00016454846,0.0010550685,0.00027034976,0.00015083097,0.00006031065,0.00012721687,0.000004480752],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019013258,0.00044860682,0.37853068,0.00046736916,0.0017848806,0.0006775774,0.0018787739,0.0003336186,0.6130026,0.000016797552,0.00034768914,0.000610084],"study_design_scores_gemma":[0.0042582285,0.00044690364,0.7684307,0.00020277563,0.002116801,0.000009375366,0.004486744,0.0002355672,0.21956582,8.2991033e-7,0.0001109158,0.00013535676],"about_ca_topic_score_codex":0.0038488216,"about_ca_topic_score_gemma":0.0013862159,"teacher_disagreement_score":0.39343676,"about_ca_system_score_codex":0.00023779285,"about_ca_system_score_gemma":0.00032296253,"threshold_uncertainty_score":0.58182925},"labels":[],"label_agreement":null},{"id":"W3198512485","doi":"10.1016/j.celrep.2021.109625","title":"Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity","year":2021,"lang":"en","type":"article","venue":"Cell Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"Weill Cornell Medical College; National Cancer Institute; Prostate Cancer Foundation; National Institutes of Health; MetLife Foundation; Damon Runyon Cancer Research Foundation","keywords":"Prostate cancer; Androgen receptor; Chromatin; Biology; Chromoplexy; Carcinogenesis; Prostate; Epigenomics; Phenotype; Cancer research; Mutant; Epigenetics; Genetics; Cancer; Gene; DNA methylation; PCA3; Gene expression","score_opus":0.009636414892716128,"score_gpt":0.2617658211857947,"score_spread":0.2521294062930786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198512485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99454516,0.0032238404,6.18436e-7,0.0002518061,0.0001005859,0.000515541,0.000012735512,0.0000099659155,0.001339747],"genre_scores_gemma":[0.9980403,0.00037224407,0.000009759547,0.0001030914,0.000018475497,0.000022605116,0.000013811701,0.000014069254,0.0014056128],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99894667,0.00013052463,0.00018990533,0.00025875727,0.00025971446,0.0002144366],"domain_scores_gemma":[0.9994408,0.00008265361,0.00011190693,0.00023876895,0.000057234396,0.00006867583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024497596,0.00011517502,0.0002438464,0.00004123377,0.000055159,0.000013809637,0.000019381863,0.00005661496,0.000034143755],"category_scores_gemma":[0.000016134918,0.00007299431,0.000058349127,0.00018214298,0.00009576227,0.000036895068,0.000048490198,0.00017718931,0.0000011462811],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013298183,0.000077544675,0.51817757,0.00019090222,0.00004037805,0.0016508679,0.00053490663,0.000020177533,0.47692728,4.053826e-7,0.00032521656,0.001921793],"study_design_scores_gemma":[0.0012019436,0.000260814,0.13762337,0.0002768328,0.000047678965,0.00008628896,0.00005222074,0.000117026626,0.8597762,0.0000055579544,0.0004811564,0.00007093754],"about_ca_topic_score_codex":0.00016912314,"about_ca_topic_score_gemma":0.00006409207,"teacher_disagreement_score":0.3828489,"about_ca_system_score_codex":0.00006868106,"about_ca_system_score_gemma":0.00018820014,"threshold_uncertainty_score":0.2976622},"labels":[],"label_agreement":null},{"id":"W3198678954","doi":"10.1007/s00259-021-05497-8","title":"Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting","year":2021,"lang":"en","type":"article","venue":"European Journal of Nuclear Medicine and Molecular Imaging","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; Lunds Universitet","keywords":"Contextualization; Medical physics; Medicine; Nuclear medicine; Radiology; Computer science","score_opus":0.03031287471322622,"score_gpt":0.33772391552469005,"score_spread":0.3074110408114638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198678954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98479676,0.0049294457,0.006509916,0.0030313304,0.00006849425,0.00017858113,0.0000033828708,0.000020853631,0.00046125954],"genre_scores_gemma":[0.9976695,0.00070091506,0.0012260784,0.00029957184,0.00005067628,4.4914634e-7,0.000008745291,0.000031008654,0.000013028544],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983206,0.00013076997,0.0009721574,0.00016165382,0.0002804526,0.00013439056],"domain_scores_gemma":[0.9976837,0.000048961992,0.0009016404,0.00013447275,0.001113481,0.00011772326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015095941,0.000101447666,0.00041616228,0.0002094311,0.0000748253,0.000016006627,0.000042597938,0.000010422194,0.00001181149],"category_scores_gemma":[0.0012178592,0.000078847515,0.00007168669,0.00020333368,0.0002317246,0.00009785118,0.00003125487,0.00012367577,1.5116694e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009592229,0.000059912836,0.015732998,0.00061905687,0.00022479267,0.0007227145,0.0010827404,0.000010774912,0.9512662,0.00006777561,0.0011405814,0.02811318],"study_design_scores_gemma":[0.04063263,0.0029093337,0.10410544,0.00754284,0.0025922928,0.009374581,0.013516192,0.28933948,0.507452,0.00007782442,0.02190862,0.0005487776],"about_ca_topic_score_codex":0.00000326904,"about_ca_topic_score_gemma":1.379382e-7,"teacher_disagreement_score":0.44381428,"about_ca_system_score_codex":0.000031652413,"about_ca_system_score_gemma":0.000111037145,"threshold_uncertainty_score":0.32153082},"labels":[],"label_agreement":null},{"id":"W3199016966","doi":"10.1038/s41391-021-00447-9","title":"Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials","year":2021,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Astellas Pharma; Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma US; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Clinical trial; Internal medicine; Androgen deprivation therapy; Docetaxel; Cancer-related fatigue; Disease; Oncology; Cancer; Physical therapy; Pathology; Androgen receptor","score_opus":0.15704249740024048,"score_gpt":0.46620089944171006,"score_spread":0.3091584020414696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199016966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96145487,0.015215276,0.0000018986449,0.0011062426,0.00018981677,0.003450667,0.018493824,0.00003178312,0.000055627377],"genre_scores_gemma":[0.98426104,0.00972643,0.00006989632,0.0003460985,0.00010585882,0.00059935683,0.0046310592,0.000059617316,0.00020066953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955506,0.000674725,0.0013738752,0.0009883919,0.00083815353,0.00057428883],"domain_scores_gemma":[0.9958919,0.0014163735,0.00064748205,0.0010375218,0.000569553,0.0004371215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007205988,0.00042626588,0.0012285245,0.00010170795,0.000131047,0.00010150183,0.00020730135,0.00008469364,0.0002809075],"category_scores_gemma":[0.0014991092,0.00022509944,0.00019559047,0.00056149904,0.0004547374,0.00028920214,0.00022598609,0.00038741552,0.0000023678338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022515908,0.0015457037,0.8697524,0.00022046549,0.0012077028,0.00015395989,0.0010267197,0.000055172357,0.000046952442,0.000003083865,0.0017788016,0.1016931],"study_design_scores_gemma":[0.016808055,0.0023241306,0.9768469,0.0014628757,0.0008608926,0.000002159267,0.00037808655,0.00018795315,0.00035227305,0.00016311239,0.00033020528,0.0002834005],"about_ca_topic_score_codex":0.0023489203,"about_ca_topic_score_gemma":0.00032852122,"teacher_disagreement_score":0.10709443,"about_ca_system_score_codex":0.00021137962,"about_ca_system_score_gemma":0.0027985978,"threshold_uncertainty_score":0.91792893},"labels":[],"label_agreement":null},{"id":"W3199482111","doi":"10.1016/j.clgc.2021.08.009","title":"Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Fonds de Recherche du Québec - Santé","keywords":"Medicine; Prostate cancer; Castration; Oncology; Hormone; Internal medicine; Hormonal therapy; Cancer","score_opus":0.4711515689813758,"score_gpt":0.5250952329655744,"score_spread":0.05394366398419859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199482111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786587,0.016934136,0.000045908007,0.00064796413,0.0003850509,0.00095502473,0.0016513146,0.000017531873,0.0007043919],"genre_scores_gemma":[0.97107136,0.021659471,0.004115313,0.00013717574,0.0004732727,0.00011940657,0.0006470314,0.00004152153,0.0017354592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99658495,0.0003097773,0.0011183396,0.00081091374,0.0007137496,0.00046225256],"domain_scores_gemma":[0.99775714,0.0002720761,0.00025188268,0.0009979815,0.00045943502,0.000261459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085217267,0.00026178412,0.0012636639,0.0001509812,0.00009332737,0.000021324377,0.000246749,0.00006583565,0.00021402618],"category_scores_gemma":[0.00008475453,0.00021935267,0.00033584904,0.00090140884,0.00039186355,0.00018968634,0.00032310296,0.00048401073,0.0000037311372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02597424,0.008563667,0.8331399,0.0019518494,0.017238954,0.009087508,0.0015592003,0.020291792,0.03545009,0.000062927684,0.0054501127,0.04122976],"study_design_scores_gemma":[0.0167563,0.000651651,0.9447523,0.0012119499,0.0019304351,0.00004712268,0.000795757,0.013852874,0.005536751,0.00002733641,0.013928808,0.00050874415],"about_ca_topic_score_codex":0.0041210996,"about_ca_topic_score_gemma":0.004105918,"teacher_disagreement_score":0.11161237,"about_ca_system_score_codex":0.0004793771,"about_ca_system_score_gemma":0.0031056316,"threshold_uncertainty_score":0.89449424},"labels":[],"label_agreement":null},{"id":"W3200060894","doi":"10.3390/curroncol28050315","title":"Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Urology; Renal function; Salivary gland; Scintigraphy; Regimen; Creatinine; Kidney; Prostate; Internal medicine; Cancer","score_opus":0.09317437182570543,"score_gpt":0.3839507892895523,"score_spread":0.29077641746384686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200060894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875349,0.010714911,0.000019173229,0.0006299204,0.00018337592,0.00063189864,0.00017587682,0.000007667578,0.00010230076],"genre_scores_gemma":[0.99722856,0.0018141548,0.00020090133,0.00003578082,0.000048764618,0.00028567624,0.00019011869,0.000014462137,0.00018157379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894637,0.00009187185,0.00024592844,0.00025984095,0.00022386805,0.00023211329],"domain_scores_gemma":[0.99935645,0.00007810919,0.00008332811,0.00014694927,0.00024192863,0.0000932165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009771471,0.00013450619,0.00032630822,0.00011554607,0.000043890934,0.000010969327,0.000029809878,0.000043039625,0.00016123452],"category_scores_gemma":[0.000016896616,0.00008942385,0.000036735088,0.00020967821,0.00015415378,0.00007869251,0.00002918497,0.00018626892,0.0000018412154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069405115,0.0009776182,0.93721133,0.0001603729,0.00020075873,0.00014114147,0.0004272432,0.0000067865058,0.00062894064,0.0000048985635,0.00027871793,0.05302169],"study_design_scores_gemma":[0.010924079,0.0015615174,0.98408705,0.00024952192,0.000112692505,0.0000110908695,0.00014487888,0.00002796821,0.0003738983,0.00009572852,0.0023185997,0.000092961774],"about_ca_topic_score_codex":0.0001216462,"about_ca_topic_score_gemma":0.0028002674,"teacher_disagreement_score":0.05292873,"about_ca_system_score_codex":0.00016777897,"about_ca_system_score_gemma":0.0007378048,"threshold_uncertainty_score":0.36465985},"labels":[],"label_agreement":null},{"id":"W3200352208","doi":"10.1002/ijc.33808","title":"A transcriptome‐wide association study identifies novel candidate susceptibility genes for prostate cancer risk","year":2021,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Cancer Institute; Wellcome Trust; National Human Genome Research Institute; National Institute on Aging; Canadian Institutes of Health Research; Harbin Medical University Cancer Hospital; National Institutes of Health; National Heart, Lung, and Blood Institute; Vetenskapsrådet; Cancer Research UK; Swedish Cancer Foundation; U.S. Department of Defense","keywords":"Prostate cancer; Biology; DNA methylation; Candidate gene; Prostate; CpG site; Transcriptome; Gene; Genome-wide association study; Cancer; Genetics; Genotype; Gene expression; Single-nucleotide polymorphism","score_opus":0.029006923161844753,"score_gpt":0.39233126492063686,"score_spread":0.3633243417587921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200352208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9748499,0.011567252,0.00037303142,0.009721905,0.002288522,0.00053020037,0.0006140268,0.000010379519,0.000044789776],"genre_scores_gemma":[0.9825186,0.0111050755,0.0001773365,0.00030421373,0.00084643846,0.00014127244,0.000029472103,0.000021123446,0.004856449],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980023,0.0000618699,0.0005126316,0.00021393655,0.000981553,0.00022769954],"domain_scores_gemma":[0.9955705,0.00020002022,0.00046820092,0.000110341534,0.0035354143,0.00011555223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060929084,0.00013217656,0.00032347156,0.00015120533,0.000078559286,0.00010056433,0.00015470253,0.00005445784,0.00034836095],"category_scores_gemma":[0.00038554164,0.00010177486,0.00023915584,0.00014658584,0.00003276833,0.00023225545,0.000028226046,0.00024165175,0.0000017951498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027309968,0.0007633785,0.9392957,0.00004574747,0.003582255,0.000117234275,0.0017601397,0.00014633618,0.03490159,0.0000050996805,0.0030667013,0.013584802],"study_design_scores_gemma":[0.021608258,0.0007005654,0.8472198,0.0004063212,0.0013011451,0.000030378906,0.0020416467,0.0001288283,0.08269641,0.00037908825,0.043260694,0.00022682355],"about_ca_topic_score_codex":0.0010952,"about_ca_topic_score_gemma":0.0045975065,"teacher_disagreement_score":0.09207588,"about_ca_system_score_codex":0.0014268317,"about_ca_system_score_gemma":0.0011960955,"threshold_uncertainty_score":0.41502583},"labels":[],"label_agreement":null},{"id":"W3200866809","doi":"10.1002/pros.24235","title":"Improvement in overall and cancer‐specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients","year":2021,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Propensity score matching; Hazard ratio; Proportional hazards model; Internal medicine; Prostate cancer; Chemotherapy; Epidemiology; Cancer; Oncology; Concomitant; Stage (stratigraphy); Surgery; Confidence interval","score_opus":0.05592623632028982,"score_gpt":0.32940034774818927,"score_spread":0.27347411142789946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200866809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745671,0.0143778995,0.0000013365755,0.00797611,0.00019736002,0.0023051798,0.00015704136,0.000023893872,0.00039404343],"genre_scores_gemma":[0.96817875,0.02643362,0.000045026038,0.00067838095,0.00004133323,0.0007854213,0.00011511474,0.0000469579,0.0036753728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797136,0.00014490061,0.0004408457,0.00048075954,0.00042569623,0.0005364661],"domain_scores_gemma":[0.9991969,0.00007474875,0.00011049403,0.00031126957,0.00017388328,0.00013269248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004085296,0.00025998207,0.00046911367,0.00012274894,0.000076596596,0.00006241296,0.00009666287,0.000040586732,0.00013020121],"category_scores_gemma":[0.000019140887,0.00017043242,0.000055582103,0.0004045388,0.00014678648,0.00014340536,0.00009560855,0.0003214845,0.000004838014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00527539,0.0010943251,0.84521985,0.00046181327,0.00028045152,0.00041674354,0.012138399,0.00003206763,0.029924095,0.00006492984,0.0010113365,0.104080625],"study_design_scores_gemma":[0.06386637,0.0013966114,0.8279518,0.0011284588,0.00007282764,0.00000806807,0.0024417522,0.0004639316,0.080905385,0.001418597,0.019651137,0.00069509156],"about_ca_topic_score_codex":0.0016326401,"about_ca_topic_score_gemma":0.0008356601,"teacher_disagreement_score":0.10338553,"about_ca_system_score_codex":0.0004032639,"about_ca_system_score_gemma":0.0005891597,"threshold_uncertainty_score":0.6950032},"labels":[],"label_agreement":null},{"id":"W3201585333","doi":"10.1001/jamaoncol.2021.3987","title":"Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Basal (medicine); Internal medicine; Oncology; Prostate; Pathology; Cancer; Biopsy","score_opus":0.03329409438283301,"score_gpt":0.352235723384815,"score_spread":0.318941629001982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201585333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98520905,0.0029567264,0.0000019670615,0.009739414,0.000055474196,0.00037164093,0.00004768451,0.000015515187,0.0016025357],"genre_scores_gemma":[0.99422634,0.0010440577,0.00055541476,0.000342859,0.000048589827,0.00016036052,0.00007231681,0.000015275731,0.0035347776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991079,0.00011273784,0.00015572253,0.00020328941,0.00018634388,0.00023401278],"domain_scores_gemma":[0.99919575,0.00016799671,0.00008696786,0.00008670747,0.00036150345,0.0001010479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017739489,0.000093137336,0.0003602061,0.000060288625,0.00003819469,0.000009928409,0.000027364851,0.00006634025,0.00017386218],"category_scores_gemma":[0.00014684311,0.00006222629,0.00003160512,0.0002524024,0.00021953118,0.000051988845,0.000036209076,0.00016017794,0.0000021248447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031842324,0.001240638,0.9247697,0.00043653906,0.0014291024,0.0022462714,0.0017779005,0.0000026497348,0.012953426,0.00008451222,0.003887746,0.04798729],"study_design_scores_gemma":[0.015829861,0.0057631214,0.8671627,0.0005280608,0.0010235184,0.00018599445,0.0014998824,0.00014602473,0.096189864,0.00022466213,0.011252323,0.00019396875],"about_ca_topic_score_codex":0.0001238449,"about_ca_topic_score_gemma":0.00049820996,"teacher_disagreement_score":0.08323643,"about_ca_system_score_codex":0.00016640921,"about_ca_system_score_gemma":0.0011305374,"threshold_uncertainty_score":0.25375143},"labels":[],"label_agreement":null},{"id":"W3201737725","doi":"10.1038/s41598-021-98903-y","title":"Using ex vivo culture to assess dynamic phenotype changes in human prostate macrophages following exposure to therapeutic drugs","year":2021,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Université Laval","funders":"Fonds de Recherche du Québec - Santé; Cancer Research Society; Canadian Urological Oncology Group","keywords":"Ex vivo; Phenotype; In vivo; Prostate; Medicine; Computational biology; Biology; Pharmacology; Bioinformatics; Cancer research; Internal medicine; Biotechnology; Genetics; Gene","score_opus":0.052641931352363676,"score_gpt":0.37960286053037345,"score_spread":0.3269609291780098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201737725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99200636,0.0018320412,0.000041529973,0.0014521824,0.002316284,0.0013325763,0.0000059755657,0.00005638444,0.00095668976],"genre_scores_gemma":[0.9605133,0.000014334113,0.0010327584,0.00023383574,0.00006980688,0.00008464674,0.000087138906,0.00003599378,0.037928186],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972024,0.00008009006,0.0003698375,0.0009485288,0.0008081185,0.00059105316],"domain_scores_gemma":[0.9985762,0.000014572132,0.00009122322,0.00075308856,0.00028249476,0.0002824188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000960638,0.00021080526,0.00036135135,0.000327663,0.00031958192,0.0003102371,0.00009630991,0.00008107102,0.0001461799],"category_scores_gemma":[0.00007690856,0.00016519205,0.00010816234,0.00147655,0.00006604283,0.00011476856,0.00014832904,0.00019033173,0.000014808521],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004740079,0.00014526494,0.013887561,0.00011355338,0.00006844924,0.00810965,0.0061169346,0.00007291817,0.9670502,0.000004555863,0.0007736198,0.0036099136],"study_design_scores_gemma":[0.0019483385,0.0005986592,0.016079122,0.0016538999,0.00021433998,0.00053644046,0.0068886317,0.00016455757,0.9449234,0.0013126736,0.024948727,0.00073120964],"about_ca_topic_score_codex":0.00004781801,"about_ca_topic_score_gemma":0.00030527712,"teacher_disagreement_score":0.036971495,"about_ca_system_score_codex":0.00040318965,"about_ca_system_score_gemma":0.00045535777,"threshold_uncertainty_score":0.67363364},"labels":[],"label_agreement":null},{"id":"W3201850473","doi":"10.1016/j.annonc.2021.08.1098","title":"585P Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Abiraterone; Prostate cancer; Oncology; Abiraterone acetate; Internal medicine; Cancer; Gynecology; Androgen deprivation therapy; Androgen receptor","score_opus":0.08722032634478372,"score_gpt":0.41968051344682533,"score_spread":0.3324601871020416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201850473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954522,0.0007058244,0.000011013038,0.0014092396,0.00009476131,0.001155264,0.0010126989,0.0000038209773,0.00015515552],"genre_scores_gemma":[0.9981415,0.00062430685,0.000097260265,0.00009836368,0.000015128428,0.000076546945,0.00064547715,0.000012885387,0.00028848005],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978444,0.00028256173,0.0008022164,0.00027935562,0.00048824376,0.00030324483],"domain_scores_gemma":[0.9980734,0.000107209504,0.0005098225,0.00038897397,0.00083016953,0.00009042298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041936262,0.00015441158,0.0010445118,0.00022631469,0.00004681538,0.000004696879,0.000116422154,0.00007021416,0.00043462074],"category_scores_gemma":[0.00007825189,0.0000960757,0.00020200279,0.0011171354,0.00029857954,0.000075333024,0.000060348095,0.00014942505,6.997403e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79391813,0.015864486,0.09082303,0.00079118955,0.013323449,0.00032220795,0.006534736,0.0030479736,0.023852034,0.0000745834,0.0008114506,0.050636727],"study_design_scores_gemma":[0.48541072,0.023151262,0.38553056,0.0004816554,0.0062231,0.0000027459098,0.0012749359,0.0006496192,0.09535185,0.00008518133,0.0015388156,0.00029953942],"about_ca_topic_score_codex":0.0020839248,"about_ca_topic_score_gemma":0.0059417584,"teacher_disagreement_score":0.3085074,"about_ca_system_score_codex":0.00012697515,"about_ca_system_score_gemma":0.0016925797,"threshold_uncertainty_score":0.47587922},"labels":[],"label_agreement":null},{"id":"W3201893135","doi":"10.1016/j.annonc.2021.08.1095","title":"582P Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Taxane; Population; Cancer; Quality of life (healthcare); Breast cancer","score_opus":0.1432927834102591,"score_gpt":0.4299050447486323,"score_spread":0.28661226133837314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201893135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541295,0.0023755105,2.1649093e-7,0.000977261,0.000023661722,0.0009546196,0.00016315919,0.00000407172,0.00008853244],"genre_scores_gemma":[0.9992473,0.00035333168,0.00004344837,0.00009269078,0.000002515057,0.00004484755,0.00005924329,0.00000822941,0.00014837839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972995,0.00073103874,0.0010147559,0.00026839986,0.00045689603,0.00022941596],"domain_scores_gemma":[0.99770665,0.0002666649,0.0008374761,0.00032541587,0.00076536875,0.000098413024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008023047,0.00012628021,0.0011698015,0.00023023503,0.00004408507,0.0000017147509,0.00006303176,0.00005408389,0.000054746764],"category_scores_gemma":[0.0002384745,0.00007960452,0.0001391554,0.0012072372,0.00026623922,0.000040795963,0.00007188913,0.00013086761,1.0928558e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007381424,0.003536442,0.9784033,0.00057531486,0.0033427987,0.000018263569,0.0042431112,0.00021485834,0.0013181933,0.000024375271,0.000109707624,0.00083224976],"study_design_scores_gemma":[0.008002797,0.007196977,0.97942674,0.00013155717,0.0006833965,6.7646255e-7,0.001470256,0.00003893064,0.0029494136,0.000020394968,0.000021169444,0.000057662648],"about_ca_topic_score_codex":0.0060758404,"about_ca_topic_score_gemma":0.030351428,"teacher_disagreement_score":0.024275588,"about_ca_system_score_codex":0.00011048474,"about_ca_system_score_gemma":0.0013866273,"threshold_uncertainty_score":0.9873421},"labels":[],"label_agreement":null},{"id":"W3201912392","doi":"10.5489/cuaj.7595","title":"FDG PET/CT – not PSMA trendy, but available, comfortable, and complementary","year":2021,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medical physics; Nuclear medicine; Medicine","score_opus":0.03667870936227753,"score_gpt":0.2806139531728804,"score_spread":0.2439352438106029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201912392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9106898,0.0018189673,0.0000055185806,0.07204859,0.0003074228,0.00018760515,0.00026812722,0.00002460121,0.014649378],"genre_scores_gemma":[0.967051,0.0012047803,0.0003158345,0.008635313,0.00033346724,0.000009012571,0.00024838667,0.00001375697,0.022188433],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983522,0.00014668208,0.0002793142,0.00022841519,0.00039407468,0.00059929845],"domain_scores_gemma":[0.99843097,0.00013493368,0.00011415583,0.00010370718,0.00024044476,0.00097576936],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004629879,0.00013308109,0.0002914122,0.00013373143,0.00041541408,0.0001296193,0.00006936756,0.000033800567,0.0077664093],"category_scores_gemma":[0.0002227815,0.00010497917,0.0000943112,0.00020908954,0.000047810317,0.00009530699,0.000030680803,0.00056439405,0.00009116643],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096472635,0.00007636896,0.8612893,0.000012260481,0.00029969536,0.008697968,0.000032024935,0.000002693566,0.00030104382,0.00014777336,0.12572694,0.0033174288],"study_design_scores_gemma":[0.004389144,0.0004502925,0.4585821,0.000026470969,0.00017905302,0.0071911104,0.00027072974,0.00020266724,0.00047639175,0.00038212715,0.52764344,0.00020648247],"about_ca_topic_score_codex":0.002202995,"about_ca_topic_score_gemma":0.0031941696,"teacher_disagreement_score":0.40270725,"about_ca_system_score_codex":0.0010515176,"about_ca_system_score_gemma":0.0010391827,"threshold_uncertainty_score":0.99314064},"labels":[],"label_agreement":null},{"id":"W3201918452","doi":"10.1016/j.annonc.2021.08.1117","title":"604P Predictive genomic biomarkers in non-metastatic castration resistant prostate cancer (nmCRPC) treated with androgen receptor pathway inhibitors (ARPi)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Androgen receptor; Metastasis; Cancer","score_opus":0.047387716425435746,"score_gpt":0.3588832135497775,"score_spread":0.3114954971243417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201918452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99066186,0.0026992385,0.0000030304097,0.0033947087,0.00007764323,0.0010286358,0.00026905103,0.000019051144,0.0018467623],"genre_scores_gemma":[0.9950701,0.0028815165,0.00035310345,0.00016473945,0.0000582107,0.00027764167,0.0003173349,0.000031050742,0.0008462802],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982623,0.00019313025,0.00044151116,0.00040787068,0.0002611765,0.00043402606],"domain_scores_gemma":[0.99882776,0.00009985662,0.0001947636,0.0002136682,0.0004918917,0.0001720819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003233916,0.00019664459,0.00054458744,0.00024482992,0.000053342574,0.000011065557,0.00005883505,0.0001146874,0.0001494877],"category_scores_gemma":[0.000053240623,0.00014666529,0.00007793407,0.0006114519,0.00023324684,0.00010535217,0.000035578985,0.00019125616,0.000008384153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03746131,0.002391813,0.16641757,0.00066768925,0.0028935769,0.0053326013,0.004568613,0.00014022723,0.6937176,0.000022153023,0.004963425,0.081423394],"study_design_scores_gemma":[0.01672887,0.016924528,0.13253209,0.0009439152,0.00026950554,0.00014453073,0.0036361688,0.00020998792,0.81848526,0.000089248264,0.009675031,0.00036089533],"about_ca_topic_score_codex":0.0007699624,"about_ca_topic_score_gemma":0.0012551013,"teacher_disagreement_score":0.12476761,"about_ca_system_score_codex":0.00035846475,"about_ca_system_score_gemma":0.0021602802,"threshold_uncertainty_score":0.59808373},"labels":[],"label_agreement":null},{"id":"W3201981182","doi":"10.1016/s1470-2045(21)00402-2","title":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development; National Cancer Institute","keywords":"Abiraterone acetate; Prednisone; Prostate cancer; Medicine; Placebo; Androgen deprivation therapy; Internal medicine; Oncology; Urology; Cancer; Pathology","score_opus":0.10851012393174991,"score_gpt":0.41889350831075456,"score_spread":0.31038338437900465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201981182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97213846,0.008195703,0.000033334305,0.007989517,0.00030601033,0.010484124,0.000178146,0.000065648994,0.0006090459],"genre_scores_gemma":[0.9856231,0.003760232,0.00063590374,0.00022234865,0.00026800382,0.0058377255,0.00017209596,0.000058534806,0.0034220472],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958997,0.000982314,0.00088199234,0.00082313345,0.0005617132,0.00085119886],"domain_scores_gemma":[0.9974666,0.0010960648,0.0003387323,0.00048699792,0.00034421758,0.0002673596],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019858393,0.0004770556,0.0018906458,0.00021952059,0.00031501384,0.0001481216,0.00018152151,0.00014344367,0.00016357447],"category_scores_gemma":[0.00021646147,0.00032109828,0.0000895949,0.00040886886,0.00047292092,0.00023596975,0.00020146946,0.0005936443,0.000012410365],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96739775,0.0015295601,0.0008961026,0.0002825073,0.0016035844,0.0013836719,0.010586709,0.00067845534,0.01150709,0.00008193561,0.00024648002,0.0038061822],"study_design_scores_gemma":[0.97853845,0.003926834,0.001965536,0.00012818277,0.0010187338,0.00013827521,0.0056620208,0.005183532,0.0022303103,0.00007615587,0.000811963,0.00031997447],"about_ca_topic_score_codex":0.0006236053,"about_ca_topic_score_gemma":0.0056461003,"teacher_disagreement_score":0.013484638,"about_ca_system_score_codex":0.0009200612,"about_ca_system_score_gemma":0.001699949,"threshold_uncertainty_score":0.9999241},"labels":[],"label_agreement":null},{"id":"W3202209089","doi":"10.1016/j.annonc.2021.08.1100","title":"587P Clinical and cost impact of cabazitaxel versus (vs) a second androgen receptor targeted agent (ARTA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone or enzalutamide)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Cabazitaxel; Docetaxel; Prostate cancer; Medicine; Oncology; Androgen receptor; Internal medicine; Chemotherapy; Cancer; Androgen deprivation therapy","score_opus":0.12874800077029838,"score_gpt":0.44628128748955603,"score_spread":0.3175332867192576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202209089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99187213,0.0027295381,0.0000038091491,0.0011705987,0.00006653159,0.0029641334,0.0010989384,0.000007734807,0.0000865794],"genre_scores_gemma":[0.9922841,0.005114933,0.00044171562,0.00013571199,0.000036583697,0.0005295571,0.00028627025,0.000030577343,0.0011405281],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99800885,0.00033909763,0.00058587367,0.00041542455,0.00026371374,0.0003870337],"domain_scores_gemma":[0.99721265,0.000769938,0.00045148455,0.00022376525,0.0011168168,0.00022532411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048514185,0.00025103692,0.0009694473,0.000070148526,0.00009061821,0.000021447573,0.00006862093,0.00007922664,0.00016531571],"category_scores_gemma":[0.00024531226,0.00012131373,0.000112289126,0.00022072946,0.0008598988,0.000115286624,0.000042348896,0.00016494059,7.340698e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6148012,0.003788061,0.31717837,0.0011407132,0.014213663,0.0004250694,0.00565686,0.00006284854,0.00410025,0.00007596034,0.00482718,0.03372983],"study_design_scores_gemma":[0.37362257,0.23308384,0.30984983,0.001326473,0.0040927925,0.00015419889,0.0027523183,0.00071158,0.06276969,0.00016042143,0.010629378,0.0008469094],"about_ca_topic_score_codex":0.0005840662,"about_ca_topic_score_gemma":0.0027470002,"teacher_disagreement_score":0.24117865,"about_ca_system_score_codex":0.00010425717,"about_ca_system_score_gemma":0.0014120893,"threshold_uncertainty_score":0.49470305},"labels":[],"label_agreement":null},{"id":"W3202406345","doi":"10.1186/s12929-021-00765-z","title":"Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models","year":2021,"lang":"en","type":"article","venue":"Journal of Biomedical Science","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"Prostate cancer; Downregulation and upregulation; Cancer research; Biology; Protein kinase B; Cancer; Phosphorylation; Cell biology; Gene; Genetics","score_opus":0.033834694679397655,"score_gpt":0.3509668293859904,"score_spread":0.31713213470659274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202406345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905111,0.003047328,0.00010330096,0.006056826,0.00006290086,0.00010009493,0.0000053529784,0.0000014322684,0.00011161887],"genre_scores_gemma":[0.9966728,0.0017295268,0.0013795336,0.00004481398,0.000043432676,0.0000023032871,0.0000013227582,0.0000025129063,0.00012373884],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986959,0.00002073576,0.00030917037,0.00013774457,0.00066902867,0.00016742315],"domain_scores_gemma":[0.99923146,0.000042635624,0.00010886,0.0000573705,0.00030959788,0.00025007688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064330996,0.000053874865,0.00018321157,0.00018223474,0.00005144429,0.000023353196,0.000047844303,0.000038291626,0.000025581796],"category_scores_gemma":[0.00013275763,0.00003467397,0.000020065852,0.0006366749,0.0007467093,0.0002491027,0.000037477213,0.00012888836,9.724633e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009507627,0.000318389,0.023880187,0.00022196476,0.00003351976,0.00044338685,0.0022119042,0.0000365966,0.8086205,0.00022398288,0.0001512865,0.16290754],"study_design_scores_gemma":[0.011207718,0.002971861,0.7992581,0.0024275195,0.00011858695,0.0010187196,0.0017008753,0.02092076,0.15085393,0.00812472,0.0011462497,0.00025094344],"about_ca_topic_score_codex":0.00008068188,"about_ca_topic_score_gemma":0.000041928157,"teacher_disagreement_score":0.7753779,"about_ca_system_score_codex":0.000115196235,"about_ca_system_score_gemma":0.0012766938,"threshold_uncertainty_score":0.27512816},"labels":[],"label_agreement":null},{"id":"W3202433444","doi":"10.1016/j.annonc.2021.08.1121","title":"608P Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"EMD Serono; Genentech; Astellas Pharma; Eisai; Flatiron Health; Endocyte; Sanofi; Exelixis; Genomic Health; Janssen Pharmaceuticals; Gilead Sciences; Amgen; Pfizer; Eli Lilly and Company; American Association for Cancer Research; AstraZeneca; Ipsen; Constellation Pharmaceuticals","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Androgen deprivation therapy; Overall survival; Cancer","score_opus":0.0543074712341284,"score_gpt":0.3914125880459866,"score_spread":0.33710511681185823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202433444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869823,0.000831301,0.0000038819376,0.008347195,0.000042221807,0.00064902176,0.00008638197,0.00000751806,0.0030501958],"genre_scores_gemma":[0.99686664,0.0014949382,0.00035781082,0.00048471135,0.0000213922,0.00004420227,0.00013536379,0.000013851498,0.0005810634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988677,0.00013482383,0.00025507904,0.0002564758,0.00020261572,0.00028330582],"domain_scores_gemma":[0.999049,0.00013725151,0.000098147444,0.00012687624,0.00046833168,0.00012041494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016494375,0.000119437274,0.00042406967,0.000108157736,0.00004039742,0.0000067606707,0.00002642481,0.000053404976,0.000058005568],"category_scores_gemma":[0.00008948611,0.00008814398,0.000029073042,0.0002710611,0.00019345863,0.000074500094,0.000030796666,0.00016343906,0.000003122735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017072763,0.0032085232,0.49581018,0.0004927032,0.0011722477,0.002748424,0.008366526,0.00009415394,0.0025795826,0.00035365208,0.0009054902,0.46719575],"study_design_scores_gemma":[0.013237826,0.0035342213,0.9684428,0.00025895098,0.00010595141,0.00003663606,0.00083750143,0.000024743547,0.009893538,0.000088109125,0.0034231106,0.000116641946],"about_ca_topic_score_codex":0.00019449387,"about_ca_topic_score_gemma":0.0010485842,"teacher_disagreement_score":0.4726326,"about_ca_system_score_codex":0.00008674435,"about_ca_system_score_gemma":0.0007952654,"threshold_uncertainty_score":0.3594407},"labels":[],"label_agreement":null},{"id":"W3202447968","doi":"10.1016/j.annonc.2021.08.1089","title":"576MO Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; BC Cancer Agency","funders":"Advanced Accelerator Applications; Astellas Pharma; Peter MacCallum Cancer Centre; Clovis Oncology; Endocyte; Sanofi; AstraZeneca; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Oncology; Taxane; Quality of life (healthcare); Glutamate carboxypeptidase II; Progression-free survival; Brief Pain Inventory; Randomized controlled trial; Cancer; Chemotherapy; Physical therapy; Breast cancer; Chronic pain","score_opus":0.12174853267378476,"score_gpt":0.4792702461281007,"score_spread":0.35752171345431594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202447968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901512,0.0015464262,0.0000014789591,0.0064830943,0.000022315575,0.001620029,0.00010926243,0.0000028156815,0.000063372434],"genre_scores_gemma":[0.99896276,0.0004460823,0.000047435387,0.00034621402,0.0000030269387,0.00006968248,0.000065581626,0.000008042343,0.000051174688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99664444,0.0014435743,0.0010563538,0.00022572369,0.00039680072,0.00023312861],"domain_scores_gemma":[0.9982434,0.00058580935,0.00048479054,0.00022174153,0.0003829761,0.000081290644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024969762,0.00012333861,0.0009386168,0.00014556758,0.000037997805,0.0000035367032,0.00006390608,0.0000469739,0.00003067525],"category_scores_gemma":[0.00030298438,0.00007209442,0.00004114302,0.00042814063,0.00016046228,0.00006179442,0.000033449716,0.00016102847,1.1895027e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02197513,0.014168695,0.920084,0.00052102504,0.0004457573,0.00007849407,0.017751452,0.000047919926,0.0003398195,0.000051959076,0.00014243885,0.024393322],"study_design_scores_gemma":[0.038635917,0.01991644,0.9326113,0.00017695883,0.000041544503,7.544892e-7,0.008209946,0.000023883877,0.00020423066,0.00006167091,0.00005627923,0.00006111539],"about_ca_topic_score_codex":0.005629499,"about_ca_topic_score_gemma":0.012979174,"teacher_disagreement_score":0.024332207,"about_ca_system_score_codex":0.000073526106,"about_ca_system_score_gemma":0.0010704796,"threshold_uncertainty_score":0.85101557},"labels":[],"label_agreement":null},{"id":"W3202506818","doi":"10.1016/j.annonc.2021.08.1092","title":"579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Centre hospitalier universitaire de Québec","funders":"Pharmacyclics; Genentech; Astellas Pharma; Eisai; Endocyte; Advanced Accelerator Applications; Incyte; Clovis Oncology; Exelixis; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Enzalutamide; Internal medicine; Cohort; Prostate cancer; Oncology; Nivolumab; Anemia; Docetaxel; Cancer; Immunotherapy; Androgen receptor","score_opus":0.13380879695539613,"score_gpt":0.45069543520493915,"score_spread":0.316886638249543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202506818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96822846,0.008528741,0.00014501427,0.0185055,0.00017800886,0.001571579,0.0005089541,0.000040102554,0.0022936207],"genre_scores_gemma":[0.97805065,0.006742264,0.0020577158,0.0012682996,0.00013770214,0.00079922564,0.0006651894,0.00003938136,0.010239576],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976316,0.00013674702,0.0006549753,0.00053864514,0.00040455282,0.0006334954],"domain_scores_gemma":[0.9977022,0.00019130866,0.00031823656,0.00040704984,0.001156113,0.00022511974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000578293,0.00026135854,0.0011158433,0.00027136717,0.0001311834,0.000027314629,0.00013047544,0.00009071357,0.00087472476],"category_scores_gemma":[0.000111781526,0.0002174388,0.0004403796,0.0008358379,0.0002351874,0.000108350265,0.00003788887,0.000196286,0.000009975894],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04116241,0.010791678,0.18492664,0.0042045396,0.07833803,0.005242495,0.0061610695,0.0013593473,0.2154152,0.004409008,0.08468469,0.36330488],"study_design_scores_gemma":[0.039202176,0.012997756,0.20129602,0.00048716448,0.011158158,0.00028620384,0.0029333653,0.0030279504,0.46723193,0.0036311825,0.25659016,0.0011579597],"about_ca_topic_score_codex":0.0007448268,"about_ca_topic_score_gemma":0.001110685,"teacher_disagreement_score":0.3621469,"about_ca_system_score_codex":0.00021732989,"about_ca_system_score_gemma":0.0023070893,"threshold_uncertainty_score":0.95776224},"labels":[],"label_agreement":null},{"id":"W3202877676","doi":"10.1016/j.annonc.2021.08.1134","title":"621P Efficacy and safety of relugolix vs leuprolide (LEU) in men with advanced prostate cancer (APC): Clinical subgroup analysis from the phase III HERO study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"Plexxikon; Ipsen; Astellas Pharma; Upsher-Smith; Prothena; Flatiron Health; Sunesis; Sanofi; Exelixis; Genomic Health; Medpace; AstraZeneca; Pfizer; Amgen","keywords":"Medicine; Prostate cancer; Subgroup analysis; Oncology; Internal medicine; HERO; Gynecology; Cancer; Phases of clinical research; Clinical trial; Meta-analysis","score_opus":0.0915332718256188,"score_gpt":0.4870020442695029,"score_spread":0.3954687724438841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202877676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98412895,0.0049261507,0.0000061584306,0.0089764185,0.000034929333,0.0011565203,0.00008605412,0.00000888494,0.0006759598],"genre_scores_gemma":[0.98712736,0.011509598,0.00013401116,0.00041493666,0.00005809209,0.00011152481,0.00008427498,0.000015566955,0.00054464117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766374,0.0005066402,0.0007597748,0.00045218796,0.0003008037,0.00031687348],"domain_scores_gemma":[0.99783874,0.0008883637,0.0002918678,0.00043878486,0.0004015438,0.0001406948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094469887,0.00016374,0.0011717674,0.000121529636,0.00005213925,0.0000063009024,0.00011995254,0.00010788109,0.000119958655],"category_scores_gemma":[0.00019037089,0.000096600095,0.00012346405,0.0008327022,0.00037696792,0.00006415969,0.00010823087,0.00033293222,9.418759e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07172185,0.0058365394,0.81473917,0.000044421715,0.0043571442,0.0006176973,0.0042292182,0.00014132178,0.00079985126,0.000012302707,0.0006501954,0.0968503],"study_design_scores_gemma":[0.07634407,0.01463165,0.894089,0.00016629462,0.0014907249,0.000006457014,0.0038847355,0.00017590325,0.004520112,0.00006106422,0.004484306,0.00014571667],"about_ca_topic_score_codex":0.0018467705,"about_ca_topic_score_gemma":0.004412314,"teacher_disagreement_score":0.09670458,"about_ca_system_score_codex":0.000062361316,"about_ca_system_score_gemma":0.00075901917,"threshold_uncertainty_score":0.39392376},"labels":[],"label_agreement":null},{"id":"W3202928000","doi":"10.1016/j.annonc.2021.08.1097","title":"584P Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA + AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Prednisone; Enzalutamide; Androgen deprivation therapy; Oncology; Clinical endpoint; Internal medicine; Abiraterone; Acis; Antiandrogen; Quality of life (healthcare); Cancer; Clinical trial; Androgen receptor","score_opus":0.1693330360404185,"score_gpt":0.4695793393923535,"score_spread":0.30024630335193503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202928000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98086596,0.007892791,0.0000045808392,0.009080091,0.00005882309,0.00172817,0.00022563449,0.0000082507695,0.00013571377],"genre_scores_gemma":[0.9934481,0.0053469865,0.0003313821,0.00022142779,0.000016209951,0.00020550791,0.00009729595,0.000019542536,0.0003135508],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996433,0.0007291899,0.0016207052,0.0003839643,0.00038759725,0.00044553843],"domain_scores_gemma":[0.9979838,0.00028631458,0.00079598033,0.00026716068,0.00046096087,0.00020579789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015894644,0.00020357064,0.0016649493,0.00028219065,0.00003091754,0.0000062408944,0.00007371255,0.00011047924,0.000075642885],"category_scores_gemma":[0.00027300688,0.00015680355,0.00007569268,0.000650423,0.00041901835,0.000119602446,0.00004826269,0.00026680378,5.427977e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8178714,0.010024021,0.01684841,0.0037875918,0.0015813537,0.0007494462,0.017565874,0.0002931228,0.09241182,0.00022801632,0.00030563516,0.038333338],"study_design_scores_gemma":[0.7407815,0.057468906,0.102311485,0.0019700008,0.0003125406,0.000053069467,0.005590728,0.0004077805,0.08934339,0.0007684837,0.000543873,0.00044827547],"about_ca_topic_score_codex":0.0073016095,"about_ca_topic_score_gemma":0.014347901,"teacher_disagreement_score":0.08546307,"about_ca_system_score_codex":0.00014209011,"about_ca_system_score_gemma":0.0036516457,"threshold_uncertainty_score":0.9993089},"labels":[],"label_agreement":null},{"id":"W3203295350","doi":"10.1016/j.annonc.2021.08.1131","title":"618P Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN &amp; SPARTAN","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Androgen deprivation therapy; Internal medicine; Prostate-specific antigen; Metastasis; Overall survival; Titan (rocket family); Urology; Cancer","score_opus":0.07562218545953421,"score_gpt":0.44387280410939806,"score_spread":0.36825061864986386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203295350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921996,0.0013876692,0.000010156263,0.0039805216,0.000109625944,0.000773601,0.00029490332,0.000008279418,0.0012356406],"genre_scores_gemma":[0.9938917,0.0020390765,0.0003760618,0.00038461885,0.000018370261,0.00020509411,0.0005176112,0.000016438755,0.0025510176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985978,0.00007887934,0.00046419943,0.00028446032,0.00022348367,0.00035116452],"domain_scores_gemma":[0.9983481,0.00018238231,0.00020409838,0.0002600437,0.0009000896,0.00010528777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022454401,0.00012460795,0.0008118761,0.00035211068,0.000025337335,0.000002943336,0.00007419183,0.00009124404,0.00027480297],"category_scores_gemma":[0.0001835924,0.00010507838,0.00020551193,0.0009297417,0.00012368227,0.00005457664,0.000044321478,0.000107121086,0.0000023611294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065914523,0.0037543683,0.88510585,0.0005023588,0.0029871305,0.00006322787,0.0016709528,0.0003797144,0.0119462,0.00018684605,0.0037282624,0.083083615],"study_design_scores_gemma":[0.021622444,0.004937143,0.8798279,0.00028263355,0.001136389,0.0000015253723,0.00043635268,0.00032228665,0.0646711,0.00048714565,0.026043298,0.00023177198],"about_ca_topic_score_codex":0.00015663859,"about_ca_topic_score_gemma":0.0024623838,"teacher_disagreement_score":0.08285184,"about_ca_system_score_codex":0.00012523397,"about_ca_system_score_gemma":0.00051697216,"threshold_uncertainty_score":0.42849723},"labels":[],"label_agreement":null},{"id":"W3203466135","doi":"10.3390/cancers13194982","title":"Oligometastatic Disease Detection with 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Androgen deprivation therapy; Biochemical recurrence; Oncology; Internal medicine; Hormone therapy; Urology; Cancer; Radiology; Breast cancer","score_opus":0.01432072126885634,"score_gpt":0.31825243515716894,"score_spread":0.3039317138883126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203466135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951895,0.0021680887,0.000018172717,0.00015384678,0.000100549056,0.0016749093,0.00062950567,0.00004196076,0.000023455004],"genre_scores_gemma":[0.9964942,0.002381585,0.0000862732,0.000081719016,0.000054028078,0.0005130221,0.00023924865,0.000053527074,0.00009643021],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974324,0.00016475876,0.0003686029,0.0008490154,0.0005499484,0.0006352568],"domain_scores_gemma":[0.99829686,0.00013755531,0.00013042611,0.00025850997,0.00038956935,0.00078707555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014364305,0.00039157827,0.0005948742,0.00017166961,0.00008474037,0.000050312417,0.000056062836,0.000026392408,0.00003348194],"category_scores_gemma":[0.0001652404,0.00024015871,0.0001017794,0.00073051517,0.0007533342,0.00023079016,0.00005985311,0.000547039,0.000002337749],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025525576,0.0002743617,0.96580714,0.0001992217,0.00043078282,0.0046400838,0.0005869482,0.000043956075,0.00023745348,3.8410008e-7,0.000076164,0.002177908],"study_design_scores_gemma":[0.010687928,0.0029554009,0.9761833,0.000950682,0.0004235812,0.00010713915,0.0006068874,0.00060297735,0.007025438,0.000010332724,0.0000877382,0.00035861114],"about_ca_topic_score_codex":0.000794563,"about_ca_topic_score_gemma":0.0006263127,"teacher_disagreement_score":0.014837648,"about_ca_system_score_codex":0.0022946026,"about_ca_system_score_gemma":0.0033051104,"threshold_uncertainty_score":0.97933877},"labels":[],"label_agreement":null},{"id":"W3203946083","doi":"10.1016/j.annonc.2021.08.1135","title":"622P Geographical assessment of efficacy and safety of relugolix: A subgroup analysis from the randomized, phase III HERO study vs leuprolide (LEU) in men with advanced prostate cancer (APC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Medicine; Subgroup analysis; HERO; Prostate cancer; Adverse effect; Internal medicine; Oncology; Testosterone (patch); Cancer; Gynecology; Confidence interval","score_opus":0.038564813141961446,"score_gpt":0.4342465178334426,"score_spread":0.3956817046914811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203946083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856505,0.0049528615,0.000034060507,0.0064814608,0.000019255085,0.002158891,0.0000952244,0.0000064785995,0.00060127623],"genre_scores_gemma":[0.9856837,0.013309466,0.00029773894,0.00015308577,0.000021173377,0.00031246681,0.00008503464,0.000013686612,0.00012367718],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99732447,0.0007492446,0.00079998473,0.00039771988,0.00042775387,0.00030081547],"domain_scores_gemma":[0.99735695,0.0012121781,0.0004060297,0.00039786493,0.0005138011,0.00011319641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013191905,0.00018337807,0.0018879627,0.000239234,0.00004458202,0.0000055614537,0.00011526699,0.00009305012,0.00010029598],"category_scores_gemma":[0.00014566674,0.00010389503,0.00020002847,0.0011163221,0.0005869169,0.000057650614,0.000100643134,0.000282567,1.0567265e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5340138,0.0070396913,0.41632777,0.00011090493,0.010063405,0.00030178847,0.004369949,0.00048678496,0.0024655627,0.00006608516,0.000097392076,0.024656862],"study_design_scores_gemma":[0.5995741,0.008491533,0.37833285,0.00025248984,0.0029987635,0.0000058708933,0.0032655527,0.0007922456,0.005659174,0.00014446644,0.00033735074,0.00014559904],"about_ca_topic_score_codex":0.003582162,"about_ca_topic_score_gemma":0.0029568858,"teacher_disagreement_score":0.0655603,"about_ca_system_score_codex":0.0000585474,"about_ca_system_score_gemma":0.0007557104,"threshold_uncertainty_score":0.54151815},"labels":[],"label_agreement":null},{"id":"W3203962015","doi":"10.1016/j.annonc.2021.08.1160","title":"647TiP PSMAddition: A phase III trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Daiichi Sankyo Europe; Genentech; EMD Serono; Bavarian Nordic; Astellas Pharma; Eisai; AstraZeneca; Invitae; Myriad Genetics; Menarini Silicon Biosystems; Ipsen; Bristol-Myers Squibb; Constellation Pharmaceuticals; Clovis Oncology; Sierra Oncology; Endocyte; Taiho Pharmaceutical; Advanced Accelerator Applications; Sanofi; GlaxoSmithKline; Cardinal Health; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Prostate cancer; Oncology; Standard of care; Internal medicine; Cancer","score_opus":0.09691843788467025,"score_gpt":0.4308888205358018,"score_spread":0.33397038265113155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203962015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904813,0.0017860901,0.000009676652,0.002391628,0.00011327571,0.0025836478,0.0019590035,0.000013393392,0.00066197064],"genre_scores_gemma":[0.9965633,0.0009485397,0.00045855893,0.00015643195,0.00006055873,0.00044364177,0.0011375239,0.00002798954,0.00020344352],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99801034,0.00017972877,0.00044277002,0.00040440753,0.0005218397,0.0004409039],"domain_scores_gemma":[0.9975692,0.00017000826,0.00024137723,0.00026987717,0.0015227563,0.00022678458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000120151,0.0002555949,0.0013250959,0.0001943865,0.00006153541,0.000008058482,0.00005874414,0.00005607807,0.00010952528],"category_scores_gemma":[0.000035673173,0.0001724061,0.000102646205,0.0004769612,0.00024023921,0.00007971883,0.00004191893,0.00014638629,0.0000028438735],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9419696,0.0031439895,0.0021513659,0.00016245426,0.0016700266,0.0011567924,0.011260798,0.000100639045,0.00016742248,0.000014807466,0.0016256109,0.036576543],"study_design_scores_gemma":[0.72077984,0.22470883,0.0060611386,0.00045991963,0.00072790124,0.000010245057,0.00919529,0.000012426931,0.03188311,0.000010581933,0.0058841477,0.0002665593],"about_ca_topic_score_codex":0.0006515029,"about_ca_topic_score_gemma":0.003961551,"teacher_disagreement_score":0.22156483,"about_ca_system_score_codex":0.00081030215,"about_ca_system_score_gemma":0.0028825232,"threshold_uncertainty_score":0.7030517},"labels":[],"label_agreement":null},{"id":"W3204083322","doi":"10.1007/978-3-030-78315-0_16","title":"Androgen Receptors in the Pathology of Disease","year":2021,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Androgen receptor; Androgen insensitivity syndrome; Biology; Receptor; Steroid hormone receptor; Antiandrogens; Androgen; Endocrinology; Internal medicine; Transcription factor; Alternative splicing; Polyglutamine tract; Prostate cancer; Cancer research; Cell biology; Hormone; Estrogen receptor; Cancer; Genetics; Medicine; Gene; Breast cancer; Messenger RNA; Mutant","score_opus":0.03911204487347654,"score_gpt":0.3156567700055117,"score_spread":0.27654472513203515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204083322","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036105013,0.01355376,0.0000016783165,0.003634585,0.00011246688,0.00061058404,0.000042365555,0.000010358538,0.9784237],"genre_scores_gemma":[0.009654493,0.006345193,0.00003478406,0.00034614588,0.00008788508,0.000022261687,0.00032767054,0.000020296395,0.9831613],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99932516,0.000022502994,0.00015142922,0.00017312364,0.00021175081,0.00011606452],"domain_scores_gemma":[0.9995031,0.000050449624,0.00003444769,0.0002872278,0.000058466136,0.000066341774],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001140587,0.00010768151,0.0002592464,0.00008795674,0.0000120839395,0.0000031889097,0.00006800145,0.0001038097,0.0029966207],"category_scores_gemma":[0.00001847756,0.000056702185,0.00010835449,0.000029348375,0.00011426267,0.000008502598,0.0000373603,0.0002027364,0.000027335507],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008045418,0.0018347338,0.057972413,0.004240395,0.0020679743,0.047217783,0.0043195137,0.0000018942187,0.00086246507,0.52414757,0.15049906,0.19879079],"study_design_scores_gemma":[0.0041358666,0.00089362083,0.00429393,0.0010813308,0.0005056423,0.00009590318,0.00039060702,0.000003828949,0.00089600903,0.009318763,0.9780574,0.00032713736],"about_ca_topic_score_codex":0.0000090279955,"about_ca_topic_score_gemma":0.000016814929,"teacher_disagreement_score":0.8275583,"about_ca_system_score_codex":0.000042671654,"about_ca_system_score_gemma":0.00026213063,"threshold_uncertainty_score":0.9979148},"labels":[],"label_agreement":null},{"id":"W3204415649","doi":"10.1016/j.annonc.2021.08.1094","title":"581P Patient (pt) reported pain in men with metastatic castration-resistant prostate cancer (mCRPC) receiving talazoparib (TALA): TALAPRO-1","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Novartis; AstraZeneca","keywords":"Medicine; Prostate cancer; Castration; Oncology; Internal medicine; Cancer; Hormone","score_opus":0.0881848129497501,"score_gpt":0.39892494546719337,"score_spread":0.31074013251744326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204415649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97756225,0.0032215759,0.000008654569,0.010452061,0.00006338647,0.0010206823,0.000052937747,0.000024976776,0.0075934953],"genre_scores_gemma":[0.9942561,0.0015694562,0.0007796035,0.00046992698,0.000031925865,0.00038650422,0.00018827672,0.000029816885,0.0022883972],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976442,0.00034470623,0.00066938903,0.00043199558,0.00040968595,0.0005000525],"domain_scores_gemma":[0.99830043,0.00020552773,0.0003304916,0.00031708632,0.00067043107,0.00017600178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008601812,0.0002002329,0.0006403988,0.00017677003,0.000062788975,0.000016196893,0.00006105093,0.000086755135,0.00026046584],"category_scores_gemma":[0.0003507644,0.00014774431,0.00008158347,0.00059600436,0.00017951596,0.00011332755,0.000051278254,0.00026034765,0.0000036331642],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015515064,0.0063660755,0.17022611,0.0017168914,0.0031221765,0.036185313,0.0117565375,0.00061524817,0.15759026,0.00026754042,0.021300992,0.5753378],"study_design_scores_gemma":[0.032972604,0.050047252,0.30167866,0.0037776679,0.0009463655,0.0012784926,0.017142683,0.0017120794,0.49142095,0.0015242252,0.09609814,0.0014008812],"about_ca_topic_score_codex":0.0010609032,"about_ca_topic_score_gemma":0.0025716492,"teacher_disagreement_score":0.57393694,"about_ca_system_score_codex":0.0002474412,"about_ca_system_score_gemma":0.0023025074,"threshold_uncertainty_score":0.6024838},"labels":[],"label_agreement":null},{"id":"W3205444686","doi":"10.1021/acs.jmedchem.1c00812","title":"Synthesis and Preclinical Evaluation of [<sup>18</sup>F]SiFA-PSMA Inhibitors in a Prostate Cancer Model","year":2021,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Alberta","funders":"Prostate Cancer Canada; Alberta Cancer Foundation","keywords":"LNCaP; Chemistry; In vivo; Prostate cancer; IC50; In vitro; Glutamate carboxypeptidase II; Cancer research; Cancer; Biochemistry; Internal medicine; Medicine","score_opus":0.08251600672874582,"score_gpt":0.41000643617886096,"score_spread":0.32749042945011514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205444686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979817,0.0153876925,0.0000049333203,0.00349193,0.00004086655,0.00017192877,0.000011739492,0.000003026777,0.001070902],"genre_scores_gemma":[0.9944216,0.0045124893,0.0002390304,0.00005244102,0.0003072929,0.000025895011,0.0000052174287,0.000013701707,0.00042232897],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976376,0.00008406439,0.00068862515,0.0001854112,0.0012001891,0.00020408133],"domain_scores_gemma":[0.9982234,0.00020599972,0.00028311828,0.00014395037,0.0009126533,0.0002308575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017428315,0.0001289466,0.00050868926,0.00007796058,0.000023346865,0.000007891726,0.000066057,0.00011359396,0.00033705556],"category_scores_gemma":[0.0014984991,0.00009288177,0.000104098915,0.0002065106,0.0001601358,0.00008050807,0.000039590017,0.0004966572,3.6974888e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008507051,0.0019464602,0.25226834,0.004572945,0.0010844896,0.0019281599,0.0045420565,0.007826531,0.52750087,0.0000032239689,0.005400351,0.1844195],"study_design_scores_gemma":[0.013849944,0.00040789566,0.009955412,0.006961265,0.0014348805,0.0011107093,0.0030927928,0.072490744,0.8898159,0.00039433624,0.0002845846,0.00020151434],"about_ca_topic_score_codex":0.00001881319,"about_ca_topic_score_gemma":0.0000039880897,"teacher_disagreement_score":0.36231503,"about_ca_system_score_codex":0.00029792654,"about_ca_system_score_gemma":0.0022899855,"threshold_uncertainty_score":0.40623358},"labels":[],"label_agreement":null},{"id":"W3205678578","doi":"10.5489/cuaj.7495","title":"A cost-utility analysis of apalutamide for metastatic castration-sensitive prostate cancer","year":2021,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Canadian Centre for Applied Research in Cancer Control; Health Sciences Centre; Public Health Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Prostate cancer; Castration; Oncology; Prostate; Medicine; Cancer; Urology; Internal medicine","score_opus":0.05469953845474502,"score_gpt":0.3433182507687152,"score_spread":0.2886187123139702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205678578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9689692,0.0009186788,0.00050938333,0.026772413,0.00016328391,0.0007245707,0.0014235777,0.000010746245,0.0005081378],"genre_scores_gemma":[0.99654484,0.00027648933,0.00046110753,0.0010482775,0.00008227062,0.000059767877,0.00026099864,0.000006934338,0.0012593206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853295,0.0001803269,0.00035276002,0.00019495281,0.00033310437,0.00040592687],"domain_scores_gemma":[0.99736536,0.0002943881,0.00023614446,0.000090369045,0.0015201076,0.0004936587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064585306,0.0001019976,0.00045129386,0.00026458918,0.00017956176,0.000045203633,0.000041746713,0.000090558,0.00057540037],"category_scores_gemma":[0.0009585943,0.000079394486,0.00029299431,0.000794454,0.00004527075,0.00006518983,0.000007387128,0.00026575595,0.0000026570383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042028612,0.00014019739,0.9786595,0.000029238949,0.0060864193,0.00030357923,0.0006646585,0.0005241731,0.0009173486,0.00012178499,0.0025233284,0.009609452],"study_design_scores_gemma":[0.0020451273,0.00023483428,0.9812036,0.000016721679,0.0029619916,0.000045002595,0.0004323207,0.004052716,0.0013675634,0.00036162464,0.007175434,0.000103051294],"about_ca_topic_score_codex":0.0017725849,"about_ca_topic_score_gemma":0.0129038775,"teacher_disagreement_score":0.027575625,"about_ca_system_score_codex":0.0010972245,"about_ca_system_score_gemma":0.0023332795,"threshold_uncertainty_score":0.72006667},"labels":[],"label_agreement":null},{"id":"W3206115164","doi":"10.1111/bju.15621","title":"The Triple‐Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol","year":2021,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Université de Sherbrooke; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke; Université Laval; Université de Montréal; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Merck Canada; Cancer Research Society","keywords":"Prostate cancer; Medicine; Protocol (science); Triple-negative breast cancer; Oncology; Internal medicine; Cancer; Pathology; Breast cancer","score_opus":0.038790019331964735,"score_gpt":0.37919684785272695,"score_spread":0.3404068285207622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206115164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8820198,0.027986202,0.000019628387,0.012061536,0.00071906444,0.07455785,0.000051810675,0.000031889,0.0025521838],"genre_scores_gemma":[0.95469433,0.006282133,0.00012124324,0.00080609095,0.00050894805,0.027422141,0.00001026335,0.0000598019,0.010095047],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99781394,0.0004506973,0.000616595,0.00020924221,0.00047333582,0.00043616613],"domain_scores_gemma":[0.9983973,0.00013451606,0.0002815538,0.00017384515,0.00081345753,0.0001993504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007975189,0.00013828388,0.00044115717,0.00007128663,0.00023968372,0.00012728483,0.0001524173,0.00005133539,0.0002662027],"category_scores_gemma":[0.00020607236,0.000096002565,0.0001522269,0.00026920091,0.00017115762,0.00011431871,0.00005408066,0.00068093505,0.0000075195126],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009349793,0.004486046,0.04779619,0.00024158329,0.003222891,0.09785503,0.0010074482,0.00024517885,0.0035962567,0.00003265626,0.022343123,0.8098238],"study_design_scores_gemma":[0.10859191,0.023333851,0.387378,0.0006709107,0.0019501045,0.055667274,0.008890321,0.00030612724,0.0043475023,0.0014788498,0.40663144,0.00075369456],"about_ca_topic_score_codex":0.00007436988,"about_ca_topic_score_gemma":0.0004934722,"teacher_disagreement_score":0.8090701,"about_ca_system_score_codex":0.00010212597,"about_ca_system_score_gemma":0.0014742083,"threshold_uncertainty_score":0.3914871},"labels":[],"label_agreement":null},{"id":"W3206193775","doi":"10.5489/cuaj.7437","title":"Time trends of drug-specific actionable adverse events among patients on androgen receptor antagonists: Implications for remote monitoring","year":2021,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Abiraterone; Adverse effect; Incidence (geometry); Internal medicine; Hypokalemia; Pharmacology; Androgen receptor; Cancer","score_opus":0.022185562867355627,"score_gpt":0.284077132746974,"score_spread":0.26189156987961837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206193775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860446,0.00016278471,0.000011363106,0.011618451,0.00032636483,0.00020904273,0.00032167762,0.000012740066,0.0012930168],"genre_scores_gemma":[0.988123,0.00036368443,0.0004241467,0.00017155657,0.0004069327,0.00001644966,0.0004042198,0.000015849602,0.010074181],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884355,0.00008090331,0.00027208764,0.00018692904,0.0002595364,0.00035699955],"domain_scores_gemma":[0.9984532,0.000115517556,0.00020514996,0.000113021764,0.00066148856,0.00045163662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002545352,0.000098876146,0.00020897535,0.00018499681,0.00030804836,0.000015319205,0.00006974027,0.00012897716,0.00048365988],"category_scores_gemma":[0.00023953922,0.00008348481,0.00015798818,0.00030207582,0.000026694119,0.0000824326,0.000009808544,0.00025650993,0.000025662432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016490874,0.00014198139,0.9717934,0.0000058713,0.00016126834,0.000007611672,0.00006674275,0.000022649554,0.0006599262,0.000018495486,0.016485596,0.010471555],"study_design_scores_gemma":[0.002147009,0.0002619613,0.9398219,0.00003223667,0.00004464547,0.000007768311,0.00005566086,0.00002336509,0.0013554109,0.00017937356,0.055990294,0.0000803843],"about_ca_topic_score_codex":0.00010182393,"about_ca_topic_score_gemma":0.00003848546,"teacher_disagreement_score":0.0395047,"about_ca_system_score_codex":0.0018483697,"about_ca_system_score_gemma":0.00041551454,"threshold_uncertainty_score":0.5295737},"labels":[],"label_agreement":null},{"id":"W3207089487","doi":"10.3390/curroncol28050353","title":"Single-Center Comparison of [64Cu]-DOTAGA-PSMA and [18F]-PSMA PET–CT for Imaging Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Nuclear medicine; Standardized uptake value; Prostatectomy; Positron emission tomography; Radiology; Cancer; Internal medicine","score_opus":0.188893560584501,"score_gpt":0.48966405385657913,"score_spread":0.30077049327207817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207089487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95372385,0.038240544,0.000052099997,0.004746649,0.0011136621,0.0010230364,0.00015529696,0.00003237719,0.00091250206],"genre_scores_gemma":[0.99520963,0.0022780686,0.00045725927,0.00011708958,0.00023543768,0.000284776,0.00022028634,0.000030544772,0.0011669007],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99857503,0.000072556366,0.0003563597,0.0003819965,0.00018655555,0.00042751757],"domain_scores_gemma":[0.99899364,0.00015244959,0.0001397584,0.00016260985,0.00038294963,0.00016861629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014087261,0.00017153962,0.00056536397,0.00010248714,0.00008461111,0.000018089288,0.00006367199,0.000017650209,0.00014317338],"category_scores_gemma":[0.00008078481,0.00014032287,0.00010282968,0.00015690354,0.00022906113,0.000062581545,0.00010706903,0.00022225833,0.0000047826084],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096570473,0.0021866304,0.650482,0.000991609,0.000152788,0.00028948995,0.000887054,0.0000014629135,0.01254532,0.00007243006,0.008857211,0.32256827],"study_design_scores_gemma":[0.018656109,0.0014877757,0.022770286,0.00069416437,0.00037183956,0.0006984586,0.0011698651,0.0017452353,0.042760495,0.0001764557,0.909174,0.00029530964],"about_ca_topic_score_codex":0.000017009957,"about_ca_topic_score_gemma":0.000069293834,"teacher_disagreement_score":0.9003168,"about_ca_system_score_codex":0.0003343357,"about_ca_system_score_gemma":0.00053137133,"threshold_uncertainty_score":0.57222},"labels":[],"label_agreement":null},{"id":"W3208119767","doi":"10.5772/intechopen.99483","title":"Genetic Polymorphism and Prostate Cancer: An Update","year":2021,"lang":"en","type":"book-chapter","venue":"IntechOpen eBooks","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Oncology; Bioinformatics; Biology; Internal medicine","score_opus":0.029617796630450725,"score_gpt":0.30963216375705577,"score_spread":0.28001436712660505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208119767","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012288479,0.031237148,0.000007871458,0.001687068,0.00035787746,0.0023097317,0.00027535984,0.00016002977,0.9516764],"genre_scores_gemma":[0.016556747,0.008500838,0.00036601024,0.00077999756,0.0003439415,0.00017767948,0.00016987014,0.00015483769,0.9729501],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815387,0.000020344658,0.00033441334,0.0007117144,0.00038653478,0.0003931027],"domain_scores_gemma":[0.9986367,0.000017645396,0.00012234418,0.00061481644,0.00022497831,0.0003834834],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009320945,0.00042982266,0.0006294058,0.00020583379,0.0001099779,0.000107426495,0.00016736989,0.00032230295,0.001427208],"category_scores_gemma":[0.000006768167,0.00034903656,0.00012249072,0.000017620701,0.0003284655,0.000048324684,0.00024951503,0.0006717357,0.00008659499],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012215122,0.00006953532,0.0006733843,0.00054412824,0.0012609944,0.0053492473,0.00076096895,2.7899372e-7,0.006886261,0.009644822,0.0046620844,0.9689268],"study_design_scores_gemma":[0.0042145187,0.0010735277,0.0004652603,0.0029868179,0.00078322116,0.00069665944,0.00008975152,0.000018659875,0.011439427,0.008687981,0.96860754,0.00093661714],"about_ca_topic_score_codex":0.0002842422,"about_ca_topic_score_gemma":0.00018741064,"teacher_disagreement_score":0.96799016,"about_ca_system_score_codex":0.00022272275,"about_ca_system_score_gemma":0.00071400194,"threshold_uncertainty_score":0.99989617},"labels":[],"label_agreement":null},{"id":"W3208338083","doi":"10.1016/j.ijrobp.2021.07.873","title":"Intermittent Androgen Deprivation Therapy Plus Comprehensive Stereotactic Radiotherapy for Oligometastatic Prostate Cancer (CROP)","year":2021,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Radiation therapy; Internal medicine; Stereotactic radiotherapy; Radiosurgery; Cancer","score_opus":0.05266918614678296,"score_gpt":0.3958725051633769,"score_spread":0.34320331901659396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208338083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9660141,0.011282607,0.009757246,0.009719025,0.0021540637,0.0008187882,0.00015569183,0.00002869878,0.00006977883],"genre_scores_gemma":[0.95922124,0.029144406,0.005491564,0.0029914088,0.0021492464,0.00014657364,0.00040192963,0.000059549817,0.00039406327],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982915,0.00019910141,0.00065117184,0.00027154127,0.00031035513,0.0002763482],"domain_scores_gemma":[0.99644554,0.0003802225,0.00073889724,0.00015645004,0.0021382435,0.000140643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024557856,0.00021168943,0.0005596081,0.00017884652,0.00008571214,0.00005091552,0.00021310632,0.00013477815,0.00011363031],"category_scores_gemma":[0.000112840244,0.00016761539,0.0002917702,0.0002040877,0.00014590447,0.00025117843,0.000037351423,0.00032112084,0.000006145613],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005684452,0.00089265127,0.16993423,0.000060267,0.0051940936,0.00022126234,0.0020572639,0.00077915774,0.06717644,0.0011247754,0.0016494461,0.74522597],"study_design_scores_gemma":[0.14625424,0.012259553,0.15764531,0.00072343746,0.0010472155,0.0023415678,0.0012544283,0.017578509,0.17590594,0.01695062,0.46687114,0.0011680331],"about_ca_topic_score_codex":0.000016981738,"about_ca_topic_score_gemma":0.0000034741204,"teacher_disagreement_score":0.74405795,"about_ca_system_score_codex":0.0015530715,"about_ca_system_score_gemma":0.001596202,"threshold_uncertainty_score":0.6835158},"labels":[],"label_agreement":null},{"id":"W3208564133","doi":"10.1101/2021.11.02.21265806","title":"Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence","year":2021,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Enzalutamide; Prostate cancer; Epigenomics; Circadian rhythm; Androgen deprivation therapy; Biology; Androgen receptor; Internal medicine; Cancer research; Oncology; Medicine; Pharmacology; Cancer; Genetics; DNA methylation","score_opus":0.03809364661550759,"score_gpt":0.328934425049472,"score_spread":0.29084077843396444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208564133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98802644,0.0021069571,0.00013466582,0.0041353647,0.0011262794,0.003478805,0.00013385102,0.00019385209,0.00066378916],"genre_scores_gemma":[0.99104154,0.0013891987,0.00077476806,0.00021500028,0.00063895714,0.0014247263,0.0004333001,0.0001148169,0.0039676656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953638,0.0001847634,0.000649796,0.0017285534,0.0011257605,0.000947374],"domain_scores_gemma":[0.9969908,0.000056552974,0.00026396726,0.0010776768,0.000778547,0.00083243335],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005837726,0.0005940388,0.00096369133,0.00034704668,0.00021181532,0.00020654169,0.00031058336,0.00048140343,0.000408352],"category_scores_gemma":[0.0002238621,0.0005267037,0.0003160775,0.0005631017,0.00012658267,0.00011393751,0.00070703775,0.0011631683,0.00007817285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026037376,0.00096996216,0.5688451,0.003165029,0.002300796,0.0048156935,0.022322245,0.0014771328,0.103813164,0.00005377983,0.0011117638,0.2885216],"study_design_scores_gemma":[0.0040504793,0.0005699944,0.61933285,0.0036281473,0.00068148394,0.00019031005,0.000854036,0.001214189,0.36319104,0.0003122916,0.0045693885,0.0014057641],"about_ca_topic_score_codex":0.0029517459,"about_ca_topic_score_gemma":0.0018492697,"teacher_disagreement_score":0.2871158,"about_ca_system_score_codex":0.0013791546,"about_ca_system_score_gemma":0.0029237333,"threshold_uncertainty_score":0.9997184},"labels":[],"label_agreement":null},{"id":"W3208960913","doi":"10.1177/17588359211051870","title":"Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Systemic therapy; Hormone therapy; Internal medicine; Clinical trial; Radiation therapy; Prostate-specific antigen; Disease; Cancer; Breast cancer","score_opus":0.10205391747517757,"score_gpt":0.459568545127229,"score_spread":0.35751462765205144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208960913","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018049736,0.9772992,0.000030422863,0.0009942105,0.00007106841,0.003204205,0.00004860086,0.00003115359,0.0002714192],"genre_scores_gemma":[0.0026952145,0.99412704,0.00014102404,0.00071935763,0.000082383114,0.0016761392,0.00015051456,0.000090034446,0.00031831884],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99651456,0.00061554986,0.0007460777,0.000845045,0.00065513345,0.00062365644],"domain_scores_gemma":[0.9984609,0.00059329835,0.00028133238,0.00029601526,0.00007058071,0.00029789706],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053570134,0.0005947893,0.002576159,0.00035631604,0.00007498996,0.00002258091,0.00013657277,0.000629831,0.00012633437],"category_scores_gemma":[0.000030773354,0.00034472125,0.0001052674,0.0005284166,0.0006349725,0.00013685336,0.00007207219,0.0007185525,0.0000017758616],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013229419,0.00056421285,0.01229371,0.0020596345,0.0010122884,0.0011576434,0.0010903616,0.000001161953,0.0000042606252,0.00003419768,0.0000032071646,0.98045635],"study_design_scores_gemma":[0.03469735,0.0054110666,0.00092829514,0.03447172,0.0020862708,0.0022485233,0.0017474219,0.00016786555,0.000033016742,0.00015350325,0.9172835,0.000771515],"about_ca_topic_score_codex":0.00031144771,"about_ca_topic_score_gemma":0.0005409923,"teacher_disagreement_score":0.9796849,"about_ca_system_score_codex":0.001494566,"about_ca_system_score_gemma":0.0018934289,"threshold_uncertainty_score":0.99990046},"labels":[],"label_agreement":null},{"id":"W3209315604","doi":"10.1016/j.ijrobp.2021.07.886","title":"4-Year PSA Response Rate as a Predictive Measure in Intermediate Risk Prostate Cancer Treated With Ablative Therapies: The Sprat Analysis","year":2021,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Cumulative incidence; Prostate cancer; Internal medicine; Oncology; Incidence (geometry); Proportional hazards model; Survival analysis; Log-rank test; Metastasis; Urology; Radiation therapy; Cancer; Cohort","score_opus":0.018185884388344856,"score_gpt":0.348871507486231,"score_spread":0.3306856230978862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209315604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883974,0.0018089304,0.0006926614,0.007832036,0.00034320843,0.00041827283,0.00023348872,0.000019685,0.0002543198],"genre_scores_gemma":[0.99202454,0.006214225,0.00018724542,0.00044710678,0.0005182142,0.000074225274,0.0001146637,0.000025319421,0.0003944397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99667037,0.0017456288,0.00059911207,0.00030350796,0.00040540408,0.0002759973],"domain_scores_gemma":[0.99561983,0.0012836369,0.00089840766,0.00018948513,0.0018853878,0.00012323004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016534671,0.00022343041,0.000574605,0.00033545995,0.00009627847,0.000045378045,0.00024821522,0.00016193371,0.00014531704],"category_scores_gemma":[0.0008763097,0.00013171033,0.00024825172,0.0009533177,0.00035515998,0.00024154523,0.000050726176,0.00078373315,0.000012164778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038716305,0.0004487364,0.91829693,0.0000047106505,0.009686667,0.0004654624,0.0051533123,0.0020924297,0.0029106052,0.00015297503,0.00017732916,0.021894516],"study_design_scores_gemma":[0.022688935,0.005736072,0.94005406,0.00025836614,0.002205728,0.00014258729,0.0034349721,0.0035649885,0.0124181835,0.002540298,0.0066658803,0.0002899306],"about_ca_topic_score_codex":0.00014177497,"about_ca_topic_score_gemma":0.0001693381,"teacher_disagreement_score":0.02175711,"about_ca_system_score_codex":0.0013129708,"about_ca_system_score_gemma":0.0022376447,"threshold_uncertainty_score":0.5370991},"labels":[],"label_agreement":null},{"id":"W3209394079","doi":"10.1016/j.ijrobp.2021.07.928","title":"Patterns and Predictors of Distant Failure After Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Retrospective Multi-Institutional Analysis","year":2021,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Biochemical recurrence; Prostate cancer; breakpoint cluster region; Radiation therapy; Radiosurgery; Logistic regression; Disease; Oncology; Retrospective cohort study; Salvage therapy; Internal medicine; Cancer; Chemotherapy; Prostatectomy","score_opus":0.016991825993371984,"score_gpt":0.3476437378881125,"score_spread":0.3306519118947405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209394079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97973204,0.003135451,0.012110511,0.0027756218,0.0008294923,0.0005045561,0.00088592566,0.000013455926,0.000012972831],"genre_scores_gemma":[0.9898569,0.0076473374,0.0009035058,0.00021303316,0.00071819953,0.000094576935,0.0004786521,0.00001740656,0.000070360606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984567,0.00015108107,0.0006032218,0.00027119726,0.00032340875,0.00019435925],"domain_scores_gemma":[0.9972779,0.00019935104,0.0007137989,0.000117531825,0.0015682827,0.00012310469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030327268,0.00018153594,0.0005915884,0.00023822101,0.000067049536,0.000028379052,0.00011222927,0.0001507301,0.00007523979],"category_scores_gemma":[0.00017219989,0.0001357386,0.00032024173,0.0002971,0.00017492953,0.0002382146,0.00003366723,0.0002557378,7.110919e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002955609,0.000579799,0.9648961,0.000029119079,0.005797719,0.00006043955,0.0008335197,0.00012708495,0.003100135,0.0004642382,0.0000757766,0.021080453],"study_design_scores_gemma":[0.020765344,0.0017338463,0.95346683,0.000105336665,0.0011209437,0.000072434945,0.00014930389,0.0040566823,0.010011647,0.0010040466,0.0073371395,0.00017643465],"about_ca_topic_score_codex":0.0000457936,"about_ca_topic_score_gemma":0.000048281996,"teacher_disagreement_score":0.020904018,"about_ca_system_score_codex":0.00096599135,"about_ca_system_score_gemma":0.0010687023,"threshold_uncertainty_score":0.553526},"labels":[],"label_agreement":null},{"id":"W3210019259","doi":"10.1016/j.ijrobp.2021.07.933","title":"Individual Patient Level Meta-Analysis of Prospective Trials Studying Metastasis-Directed Therapy for Metachronous Oligometastatic Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Hazard ratio; Oncology; Randomized controlled trial; Internal medicine; Clinical trial; Prospective cohort study; Cancer; Proportional hazards model; Surgery; Confidence interval","score_opus":0.216829238344314,"score_gpt":0.4542109000144464,"score_spread":0.23738166167013242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210019259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93328017,0.041633636,0.008946243,0.0057867365,0.0015879206,0.0027007188,0.0059018997,0.00004927563,0.00011341208],"genre_scores_gemma":[0.983217,0.0045495424,0.009966109,0.0005452749,0.00046135217,0.00038424862,0.00071563484,0.000036692207,0.00012413181],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9961907,0.000930985,0.0015672587,0.00036168922,0.00065596314,0.00029337153],"domain_scores_gemma":[0.99192196,0.001589383,0.0023093245,0.00019261059,0.003852393,0.00013431832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002057727,0.00027697932,0.0025692214,0.0005654391,0.000088455294,0.000041003994,0.00025500596,0.00013075327,0.00029831193],"category_scores_gemma":[0.0010363394,0.00018784184,0.0019232667,0.00086080836,0.00016417474,0.00022320608,0.00006258947,0.0003318871,0.0000016259083],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036992512,0.0024685166,0.06519401,0.000031502932,0.7141779,0.000068374284,0.0037891283,0.0022022584,0.009701667,0.0009637683,0.0004791318,0.19722448],"study_design_scores_gemma":[0.055427875,0.011681556,0.09767028,0.00007534093,0.5311985,0.00013410872,0.002190236,0.0029211596,0.27269384,0.010966411,0.014217338,0.00082335225],"about_ca_topic_score_codex":0.00005531365,"about_ca_topic_score_gemma":0.000025392086,"teacher_disagreement_score":0.26299217,"about_ca_system_score_codex":0.0007335548,"about_ca_system_score_gemma":0.0019571658,"threshold_uncertainty_score":0.7659968},"labels":[],"label_agreement":null},{"id":"W3210271201","doi":"10.1016/j.ijrobp.2021.07.189","title":"Prognostic and Predictive Performance of Routine Clinicopathologic Variables in 10,535 Men Enrolled on Randomized Phase III Trials in Localized Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Cohort; Confidence interval; Concordance; Proportional hazards model; Internal medicine; Oncology; Androgen deprivation therapy; Prognostic variable; Radiation therapy; Cancer; Retrospective cohort study; Prostate-specific antigen; Prostate; Randomized controlled trial; Metastasis","score_opus":0.040307148255296826,"score_gpt":0.4085040188536268,"score_spread":0.36819687059832995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210271201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927695,0.002584054,0.00043245842,0.0020998209,0.0004946105,0.00108812,0.0001041762,0.000008919027,0.00041838366],"genre_scores_gemma":[0.98489845,0.013569117,0.00047454206,0.0001798525,0.0004055487,0.00014304706,0.00014874418,0.0000139630465,0.0001667366],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958189,0.0017676832,0.0016561655,0.00025273432,0.00028547895,0.0002190507],"domain_scores_gemma":[0.99477166,0.0028406244,0.0013907498,0.00009664543,0.0008140057,0.000086310785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051776324,0.00018072502,0.0016885457,0.00029584533,0.000028620645,0.000013440738,0.00013249881,0.00018946911,0.000120788034],"category_scores_gemma":[0.0036491978,0.00012574787,0.00020755599,0.00027385284,0.00028606446,0.00015034841,0.000051365034,0.0004365369,0.0000018946077],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35845283,0.002671527,0.5526091,0.0000636865,0.0012552304,0.00031345926,0.0014664055,0.0021582376,0.004908739,0.00053381297,0.00013862448,0.07542839],"study_design_scores_gemma":[0.89628935,0.006508761,0.04209494,0.0009161624,0.00052050716,0.00011245476,0.00027619168,0.03641452,0.012288938,0.0038441312,0.0005288732,0.00020514676],"about_ca_topic_score_codex":0.000024540292,"about_ca_topic_score_gemma":0.0000049331356,"teacher_disagreement_score":0.53783655,"about_ca_system_score_codex":0.00055263506,"about_ca_system_score_gemma":0.0012989624,"threshold_uncertainty_score":0.5127849},"labels":[],"label_agreement":null},{"id":"W3210855075","doi":"10.1016/j.ijrobp.2021.07.190","title":"Impact of High DosE rAdioTherapy (HEAT) in Localized Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis of 15 Randomized Trials","year":2021,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Randomized controlled trial; Radiation therapy; Androgen deprivation therapy; Randomization; Clinical endpoint; Internal medicine; Oncology; Meta-analysis; Cancer; Clinical trial; Urology","score_opus":0.13547139630710078,"score_gpt":0.46643355718531265,"score_spread":0.33096216087821184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210855075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97782606,0.014457643,0.0015415131,0.0022257932,0.0006085615,0.00078229985,0.0025229813,0.000008737432,0.00002643104],"genre_scores_gemma":[0.98374486,0.010774213,0.0025185172,0.00023900732,0.00041504815,0.000047565216,0.002215101,0.000022229598,0.00002347608],"study_design_codex":"meta_analysis","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99401337,0.002584777,0.0021930458,0.0003421958,0.00062909996,0.00023749164],"domain_scores_gemma":[0.993801,0.0018570273,0.0022059337,0.0004173047,0.0015656989,0.0001530168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040124464,0.00024043162,0.0039571766,0.0006475406,0.000026966234,0.000023031407,0.0004881275,0.00019732359,0.0006982145],"category_scores_gemma":[0.0012487893,0.00015404634,0.001634274,0.0007554514,0.00031097865,0.00032943467,0.00009907195,0.00036644444,7.48436e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12145194,0.0039906404,0.1897504,0.00003053094,0.5383401,0.00019307736,0.0031616788,0.01981777,0.009546081,0.00083178707,0.0006993132,0.1121867],"study_design_scores_gemma":[0.6437249,0.008815477,0.08222628,0.00012926545,0.20696785,0.00014271468,0.00047076697,0.02915268,0.018628001,0.006795123,0.0023094246,0.0006375152],"about_ca_topic_score_codex":0.0008289698,"about_ca_topic_score_gemma":0.00007498318,"teacher_disagreement_score":0.52227294,"about_ca_system_score_codex":0.0007670067,"about_ca_system_score_gemma":0.0026343323,"threshold_uncertainty_score":0.76449597},"labels":[],"label_agreement":null},{"id":"W3211012182","doi":"10.1016/j.ijrobp.2021.07.186","title":"The Relationship Between Androgen Deprivation Therapy Duration and External Beam Radiotherapy With or Without a Brachytherapy Boost in High-Risk Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Brachytherapy; External beam radiotherapy; Cohort; Radiation therapy; Urology; Internal medicine; Oncology; Surgery; Cancer","score_opus":0.036049602042230997,"score_gpt":0.36996544483646543,"score_spread":0.3339158427942344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211012182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98068696,0.008741939,0.00330056,0.006377444,0.00034569384,0.00047026496,0.00004490932,0.000016360495,0.000015857233],"genre_scores_gemma":[0.9466675,0.04974264,0.0017186587,0.00036896413,0.0011637603,0.0000574526,0.00009028797,0.000029750576,0.00016101134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981652,0.00033487036,0.0006945778,0.00024147498,0.0003408831,0.0002229958],"domain_scores_gemma":[0.99711,0.001071624,0.0008910487,0.00014023586,0.00068590575,0.00010116107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073213165,0.00018138581,0.0003858254,0.0001345662,0.00018526029,0.00007878222,0.00015340312,0.00015426402,0.000024832065],"category_scores_gemma":[0.00029000422,0.00010784267,0.00007472683,0.00028150476,0.0002142175,0.00032930067,0.00002081912,0.00052452576,0.0000015141825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037819417,0.00014093993,0.8276771,0.0000047801846,0.00046132968,0.000043715172,0.00076846214,0.000115100425,0.0017091327,0.0004535485,0.000043551227,0.16480042],"study_design_scores_gemma":[0.018477568,0.0018383472,0.9618651,0.00013297486,0.000075952674,0.00022148123,0.0001291792,0.0005842429,0.0060960273,0.0046952446,0.0057364623,0.0001474002],"about_ca_topic_score_codex":0.000103387596,"about_ca_topic_score_gemma":0.00010453224,"teacher_disagreement_score":0.16465302,"about_ca_system_score_codex":0.0006980418,"about_ca_system_score_gemma":0.0011845845,"threshold_uncertainty_score":0.43976966},"labels":[],"label_agreement":null},{"id":"W3211226672","doi":"10.3390/curroncol28060365","title":"Prostate Cancer Metastasis to the Pituitary Gland Manifesting as Corticosteroid Withdrawal, and the Impact of the Switch from Prednisone to Dexamethasone on Survival Time","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Horizon Health Network; Moncton Hospital","funders":"","keywords":"Medicine; Prednisone; Prostate cancer; Metastasis; Dexamethasone; Abiraterone acetate; Cancer; Corticosteroid; Oncology; Internal medicine; Androgen deprivation therapy","score_opus":0.07183348431617437,"score_gpt":0.4219248477631996,"score_spread":0.35009136344702524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211226672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740914,0.0074699908,0.000010237747,0.015088128,0.0006145296,0.0016634342,0.00022492801,0.000014109833,0.0008232272],"genre_scores_gemma":[0.9971199,0.00095824036,0.00006436682,0.00034899134,0.0002288914,0.00025865054,0.000040437,0.000023976858,0.0009565538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805766,0.00051218236,0.00029533825,0.00037453213,0.00038176196,0.00037851738],"domain_scores_gemma":[0.9981466,0.00080860226,0.00012331655,0.0004910996,0.0002343091,0.00019607466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051710167,0.00020544621,0.0005246601,0.000048209233,0.00018878514,0.000032070413,0.00019696867,0.000053933967,0.00018785053],"category_scores_gemma":[0.00046329756,0.000083375795,0.00013465773,0.00039491805,0.00023280011,0.000033159035,0.00031592866,0.0003608219,0.000035053148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02880119,0.0023646571,0.4898551,0.00023892739,0.0033136848,0.00040210577,0.022310603,0.0006049419,0.03472243,0.000116402065,0.019315226,0.3979547],"study_design_scores_gemma":[0.03710279,0.009529769,0.87655485,0.0016916096,0.002453031,0.0005161971,0.0032776368,0.0012143925,0.03079556,0.00070476474,0.035485487,0.00067393656],"about_ca_topic_score_codex":0.0015474593,"about_ca_topic_score_gemma":0.00041982214,"teacher_disagreement_score":0.39728078,"about_ca_system_score_codex":0.00031969565,"about_ca_system_score_gemma":0.0008699722,"threshold_uncertainty_score":0.3399966},"labels":[],"label_agreement":null},{"id":"W3211235931","doi":"10.1038/s41467-021-26489-0","title":"Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Princess Margaret Cancer Centre; St. Michael's Hospital; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; National Cancer Institute; University of Toronto; Prostate Cancer Canada; Government of Ontario; Canadian Cancer Society Research Institute; National Institutes of Health; Ontario Genomics; Genome Canada; Cancer Research UK; Government of Canada; Ontario Institute for Cancer Research; Ontario Genomics Institute; Movember Foundation","keywords":"Prostate cancer; Biology; Somatic cell; Genome instability; Cancer research; Metastasis; Disease; Oncology; Cancer; Gene; Medicine; Genetics; Internal medicine; DNA damage; DNA","score_opus":0.02616332556755274,"score_gpt":0.3624327021093147,"score_spread":0.336269376541762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211235931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9472051,0.04322477,0.000012813705,0.006043658,0.00012371602,0.0010607585,0.00011845559,0.000043873133,0.0021668377],"genre_scores_gemma":[0.98261404,0.010634299,0.0023412155,0.000108255364,0.000011517429,0.00023552793,0.00034106657,0.000017915474,0.0036961464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859893,0.00022670881,0.00036631207,0.0002178356,0.00038864094,0.00020156223],"domain_scores_gemma":[0.9977938,0.00031503048,0.00013800732,0.0011867351,0.00048227693,0.0000841334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024656102,0.00012312268,0.00026625476,0.00018263074,0.00010670476,0.000023148226,0.00031731784,0.00010844486,0.00010158308],"category_scores_gemma":[0.0006091105,0.000106771244,0.000080007856,0.0007389718,0.00029591916,0.00018989944,0.0001806783,0.0006787862,0.000020514328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019106327,0.0055487985,0.7764995,0.011954513,0.0029112736,0.0018982292,0.07432083,0.0004742652,0.09306578,0.013171424,0.0069745127,0.011270229],"study_design_scores_gemma":[0.015639769,0.0007996529,0.83471215,0.0066583366,0.0015883811,0.00051687437,0.0076904697,0.0053179995,0.1093408,0.009596247,0.0073961676,0.0007431744],"about_ca_topic_score_codex":0.00012873928,"about_ca_topic_score_gemma":0.000897814,"teacher_disagreement_score":0.06663036,"about_ca_system_score_codex":0.00033239776,"about_ca_system_score_gemma":0.0009999193,"threshold_uncertainty_score":0.43540052},"labels":[],"label_agreement":null},{"id":"W3211295995","doi":"10.1016/j.ijrobp.2021.07.133","title":"Validation of a 22-gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Internal medicine; Prostatectomy; Interquartile range; Oncology; Prostate cancer; Randomized controlled trial; Concordance; Biopsy; Clinical endpoint; Cancer","score_opus":0.09645569716986015,"score_gpt":0.41855802989893953,"score_spread":0.3221023327290794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211295995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98339117,0.0058261496,0.0020107,0.0066709784,0.0004674323,0.0010053751,0.0005782263,0.0000066227894,0.000043336302],"genre_scores_gemma":[0.9920317,0.0039478466,0.0022545806,0.0005736365,0.00032136316,0.00023728095,0.00059393345,0.000016345784,0.000023308732],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930413,0.0038485902,0.0020323363,0.00032684262,0.0005043538,0.00024659213],"domain_scores_gemma":[0.9929349,0.0032997704,0.0025805952,0.00018403964,0.0009059716,0.000094735005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006065707,0.00023604534,0.0024605552,0.00065495266,0.000055792003,0.000036225454,0.00024373332,0.00024208741,0.00018674707],"category_scores_gemma":[0.0014646971,0.00014652463,0.00092616735,0.000737741,0.00032793925,0.0001553922,0.000059578364,0.00060349045,0.0000017461796],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17296433,0.008462916,0.27459863,0.00006199666,0.19281508,0.000934317,0.012034406,0.012803853,0.031703684,0.001643017,0.00045738879,0.2915204],"study_design_scores_gemma":[0.7809538,0.004355562,0.030776909,0.00008422428,0.11145402,0.00018102149,0.0014424156,0.008286018,0.04702022,0.011152626,0.0037666769,0.00052651396],"about_ca_topic_score_codex":0.00028708598,"about_ca_topic_score_gemma":0.00006918876,"teacher_disagreement_score":0.6079895,"about_ca_system_score_codex":0.0008249422,"about_ca_system_score_gemma":0.0018108228,"threshold_uncertainty_score":0.5975101},"labels":[],"label_agreement":null},{"id":"W3211646732","doi":"10.1007/s00259-021-05616-5","title":"68Ga-PSMA PET in prostate cancer: a systematic review and meta-analysis of the observer agreement","year":2021,"lang":"en","type":"review","venue":"European Journal of Nuclear Medicine and Molecular Imaging","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Kappa; Meta-analysis; Cohen's kappa; Nuclear medicine; Confidence interval; Radiology; Metastasis; Bone metastasis; Prostate; Cancer; Pathology; Internal medicine; Statistics; Mathematics","score_opus":0.09388987005938577,"score_gpt":0.3772895387954234,"score_spread":0.2833996687360376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211646732","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005041728,0.99151516,0.0000012425679,0.0070354706,0.000034770612,0.0010624521,0.000015539403,0.0000023987004,0.00028257593],"genre_scores_gemma":[0.00023963154,0.9962492,0.00006239203,0.003195173,0.000023128418,0.0000096320655,0.000010258017,0.000049758994,0.00016080745],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99612004,0.0014199307,0.0014194736,0.00026360853,0.0005727905,0.00020414653],"domain_scores_gemma":[0.99791944,0.00007221837,0.0011408642,0.0004174372,0.000285822,0.00016424284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021213647,0.00031686792,0.005629214,0.0004412822,0.000040879022,0.00002214745,0.00020798287,0.000010966614,0.00014275889],"category_scores_gemma":[0.00027341818,0.00014498305,0.001188883,0.000885244,0.00017716004,0.00004723099,0.00017989066,0.00050563953,9.2670956e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019403142,0.00008683037,0.000040460374,0.83882046,0.13400914,0.0124092065,0.0006951856,7.517782e-7,0.000028481067,0.000014638013,0.0029267524,0.01094872],"study_design_scores_gemma":[0.00065228937,0.00010926834,0.00002422098,0.19766808,0.6942936,0.0011945145,0.00022038701,0.00000519993,8.1952555e-7,6.030255e-7,0.10572105,0.0001099327],"about_ca_topic_score_codex":0.000019791843,"about_ca_topic_score_gemma":0.0000016964219,"teacher_disagreement_score":0.6411524,"about_ca_system_score_codex":0.00008092096,"about_ca_system_score_gemma":0.00017534361,"threshold_uncertainty_score":0.59122366},"labels":[],"label_agreement":null},{"id":"W3212220745","doi":"10.1016/j.canlet.2021.11.004","title":"Patient-derived xenograft models of neuroendocrine prostate cancer","year":2021,"lang":"en","type":"review","venue":"Cancer Letters","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Mitacs; Terry Fox Research Institute","keywords":"Prostate cancer; Cancer; Computational biology; Translational research; Neuroendocrine tumors; Biology; Precision medicine; Medicine; Cancer research; Bioinformatics; Pathology; Internal medicine","score_opus":0.07247706334073667,"score_gpt":0.3772668888360223,"score_spread":0.3047898254952856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212220745","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010510574,0.9930102,0.000011622228,0.002281479,0.00064342597,0.0021526124,0.00062462065,0.000056787754,0.00016815998],"genre_scores_gemma":[0.00010005229,0.99495006,0.000088351626,0.0011101365,0.00028841058,0.001951666,0.00047504093,0.00015128354,0.0008850111],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99703246,0.00014490417,0.00075766153,0.0007575862,0.00058670633,0.00072069955],"domain_scores_gemma":[0.9983551,0.00006519902,0.00042375427,0.00065639196,0.0002238304,0.0002757387],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00004918581,0.000600127,0.002456759,0.0003058873,0.000069071255,0.000030846975,0.00019694191,0.0000956794,0.00039481267],"category_scores_gemma":[0.000015750737,0.00044077754,0.00077676796,0.0006867311,0.00023715784,0.00011714445,0.00016935522,0.0006435643,0.000011119819],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000995587,0.000109181376,0.000050625695,0.026228854,0.0012420836,0.0009840805,0.00022287997,0.000051232535,0.0006017378,0.0000060496477,0.012871734,0.957532],"study_design_scores_gemma":[0.0012963029,0.0001557525,0.0000041579196,0.027910609,0.0019413069,0.00007479407,0.000024909137,0.000022609038,0.00091198535,0.0000035336323,0.9672669,0.00038713962],"about_ca_topic_score_codex":0.0003179555,"about_ca_topic_score_gemma":0.000016417403,"teacher_disagreement_score":0.95714486,"about_ca_system_score_codex":0.00061859365,"about_ca_system_score_gemma":0.0015149198,"threshold_uncertainty_score":0.9998044},"labels":[],"label_agreement":null},{"id":"W3212268582","doi":"10.1016/j.euo.2021.10.005","title":"Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review","year":2021,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Janssen Pharmaceuticals; National Cancer Institute; National Institutes of Health; RefleXion Medical; Ipsen; Stand Up To Cancer; Ferring Pharmaceuticals; Prostate Cancer Foundation; AstraZeneca; Movember Foundation; Merck; Bayer; Kom op tegen Kanker; Astellas Pharma US; Pfizer","keywords":"Medicine; Disease; Biomarker; Prostate cancer; Oncology; Clinical trial; Internal medicine; Cancer; Bioinformatics; Biology; Genetics","score_opus":0.06133329220559403,"score_gpt":0.3943840527493043,"score_spread":0.3330507605437103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212268582","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004780631,0.9843089,0.000017759765,0.0012656293,0.00025048712,0.012823142,0.0003420266,0.00007400984,0.00087022176],"genre_scores_gemma":[0.000012765135,0.9920997,0.0004947902,0.0014585354,0.00016508262,0.0023045465,0.00092984526,0.00020698558,0.0023277407],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99295294,0.0036435353,0.0013349333,0.0010969181,0.00018622827,0.00078546203],"domain_scores_gemma":[0.9967057,0.0011400771,0.0008733209,0.0006321851,0.00030445805,0.00034422099],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016372079,0.00072731177,0.0066991826,0.00032319382,0.00016252248,0.000025788277,0.00023184398,0.00022962627,0.000051465187],"category_scores_gemma":[0.0006198614,0.00051339326,0.00054141885,0.00034979658,0.00051507895,0.000037178765,0.00028753394,0.00061366067,0.000109741],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023358285,0.00022247365,0.0000010315583,0.8031119,0.008713188,0.006384126,0.0002163371,5.6632143e-8,0.0000886227,0.000021809157,0.0033174474,0.1776894],"study_design_scores_gemma":[0.0036181991,0.00352535,0.000007728571,0.13957682,0.06298455,0.005358751,0.000058273712,0.0000025297975,0.000007439041,0.0000048960674,0.7843922,0.00046329648],"about_ca_topic_score_codex":0.000014063784,"about_ca_topic_score_gemma":0.000009500768,"teacher_disagreement_score":0.7810747,"about_ca_system_score_codex":0.00035492197,"about_ca_system_score_gemma":0.0015462212,"threshold_uncertainty_score":0.9997318},"labels":[],"label_agreement":null},{"id":"W3212373720","doi":"10.1007/s11538-021-00953-w","title":"Intermittent Hormone Therapy Models Analysis and Bayesian Model Comparison for Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Bulletin of Mathematical Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Jayne Koskinas Ted Giovanis Foundation for Health and Policy","keywords":"Prostate cancer; Androgen deprivation therapy; Prostate; Nomogram; Bayesian inference; Bayesian probability; Cancer; Oncology; Medicine; Internal medicine; Computer science; Artificial intelligence","score_opus":0.05762424633139363,"score_gpt":0.3674308247374461,"score_spread":0.30980657840605247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212373720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78342164,0.01823326,0.17023705,0.024311474,0.000028457513,0.0014588519,0.00019998016,0.000043379176,0.0020659],"genre_scores_gemma":[0.97634846,0.0029668715,0.018064037,0.0002482977,0.000021175883,0.00024251656,0.00008169405,0.000014137233,0.0020128093],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9990819,0.00003863442,0.00030800354,0.0002554088,0.0000916176,0.00022444614],"domain_scores_gemma":[0.9993097,0.00016085077,0.00006919935,0.00018216825,0.00017736801,0.00010068333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016394525,0.00011806484,0.0006061361,0.00008051586,0.000033504522,0.0000073902156,0.000049925813,0.00009059414,0.00024690235],"category_scores_gemma":[0.00004819415,0.00007728901,0.000150069,0.000115310766,0.00016937772,0.0000063647244,0.000050922616,0.00008467444,0.0000027761064],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024086503,0.013380857,0.052334417,0.0059688315,0.031510092,0.00014947032,0.015478026,0.0032654149,0.2638664,0.12113156,0.043585114,0.42524332],"study_design_scores_gemma":[0.013121485,0.0027443739,0.002238084,0.00027881085,0.0021754731,0.00003312896,0.0007736324,0.79212296,0.05106788,0.12822998,0.0067088823,0.00050530577],"about_ca_topic_score_codex":0.000021937529,"about_ca_topic_score_gemma":0.000003773216,"teacher_disagreement_score":0.7888576,"about_ca_system_score_codex":0.00002667597,"about_ca_system_score_gemma":0.000071739836,"threshold_uncertainty_score":0.31517544},"labels":[],"label_agreement":null},{"id":"W3212481355","doi":"10.1111/iju.14743","title":"Response to Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients","year":2021,"lang":"en","type":"letter","venue":"International Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; External beam radiotherapy; Radiation therapy; Urology; External beam radiation; Oncology; Cancer; Internal medicine","score_opus":0.015795662989714698,"score_gpt":0.31410086123967557,"score_spread":0.2983051982499609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212481355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54528683,0.0010140529,0.000013309059,0.452587,0.000593101,0.00035933687,0.0001192759,0.0000059608196,0.000021117974],"genre_scores_gemma":[0.5414945,0.001961932,0.00048016664,0.44932413,0.003449608,0.00015203482,0.0003787063,0.00018082894,0.002578067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99668264,0.0005114136,0.000650899,0.000405009,0.0012811946,0.00046881713],"domain_scores_gemma":[0.9976274,0.00031956696,0.00057163945,0.0001452177,0.0011425139,0.00019371127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005912883,0.00031823304,0.0007834916,0.0008217587,0.000034476412,0.00007693825,0.00028730158,0.00042395596,0.00020523154],"category_scores_gemma":[0.0003397013,0.00023012831,0.0001236869,0.00021938805,0.00020513534,0.00011296821,0.00007977987,0.0020451334,0.0000019549225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04932593,0.000618327,0.79345554,0.000056180757,0.0023730358,0.044500988,0.0010944569,0.000023818133,0.0012604522,6.3675685e-7,0.1021322,0.0051584244],"study_design_scores_gemma":[0.024275018,0.005104109,0.7383879,0.0017144808,0.00018221444,0.00084502896,0.000056712262,0.00001615813,0.00037091164,0.000055497756,0.22860922,0.00038275984],"about_ca_topic_score_codex":0.000040538624,"about_ca_topic_score_gemma":0.00006584419,"teacher_disagreement_score":0.12647702,"about_ca_system_score_codex":0.0010007704,"about_ca_system_score_gemma":0.00080011843,"threshold_uncertainty_score":0.93843603},"labels":[],"label_agreement":null},{"id":"W3212642643","doi":"","title":"Diagnostic Performance of PSMA-Targeted 18F-DCFPyL PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the Phase 3, Multicenter CONDOR Study","year":2020,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Nuclear medicine; Biochemical recurrence; Glutamate carboxypeptidase II; Occult; Clinical endpoint; Confidence interval; Concordance; Radiology; Clinical trial; Cancer; Internal medicine; Pathology; Prostatectomy","score_opus":0.02800046455679669,"score_gpt":0.3267026296961082,"score_spread":0.2987021651393115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212642643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884059,0.0012682534,8.5475176e-7,0.006268532,0.000041536823,0.0032298574,0.00040427258,0.0000388855,0.00034191352],"genre_scores_gemma":[0.99700046,0.0015943383,0.00009458421,0.00028774329,0.00007000668,0.00031976026,0.00029745427,0.000024887979,0.00031076532],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981373,0.000087602246,0.00047958136,0.00046955037,0.00047051284,0.00035548393],"domain_scores_gemma":[0.9987118,0.00045771795,0.00013080864,0.00032092872,0.0001775622,0.00020114734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000192657,0.00022518396,0.000408412,0.000047207595,0.000054292526,0.000018628432,0.0001868927,0.000008637906,0.00014996802],"category_scores_gemma":[0.0003097029,0.00011461936,0.000046305646,0.00038667695,0.00015550487,0.00008116963,0.00008782785,0.00031518223,0.000014793066],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07271899,0.0050488897,0.8790128,0.00026935304,0.0007476148,0.0018791693,0.012453274,0.00006175212,0.013545992,0.0000011161451,0.0066610384,0.007599983],"study_design_scores_gemma":[0.30479914,0.027476575,0.23473601,0.0025088447,0.0010013037,0.000041447056,0.018714583,0.03303067,0.3742911,0.000005264506,0.0024751578,0.0009199253],"about_ca_topic_score_codex":0.0020057044,"about_ca_topic_score_gemma":0.00023849639,"teacher_disagreement_score":0.6442768,"about_ca_system_score_codex":0.00011723732,"about_ca_system_score_gemma":0.00027600894,"threshold_uncertainty_score":0.4674042},"labels":[],"label_agreement":null},{"id":"W3212987218","doi":"10.1016/j.ejca.2021.10.015","title":"Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Foundation Medicine; Sanofi Genzyme; Cilag; Astellas Pharma; Genentech; UroGen Pharma; Boston Scientific Corporation; Array BioPharma; Invitae; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Bristol-Myers Squibb; AstraZeneca; Astellas Foundation for Research on Metabolic Disorders; Amgen; Pfizer; Daiichi Sankyo Company; Ipsen; Clovis Oncology; Astellas Pharma US","keywords":"Enzalutamide; Medicine; Prostate cancer; Androgen deprivation therapy; Placebo; Internal medicine; Oncology; Adverse effect; Post-hoc analysis; Subgroup analysis; Multivariate analysis; Cancer; Androgen receptor; Confidence interval; Pathology","score_opus":0.030634154938138557,"score_gpt":0.29665330578475313,"score_spread":0.2660191508466146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212987218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97577965,0.022205433,0.00006053353,0.0011204219,0.000029636401,0.0003211976,0.00004286509,0.000003818303,0.00043646718],"genre_scores_gemma":[0.97970504,0.018753743,0.0002700409,0.000061765146,0.000044169843,0.000012642711,0.000031125503,0.000025850799,0.0010956276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983733,0.0002005596,0.00052345387,0.00021076095,0.0004957007,0.0001962111],"domain_scores_gemma":[0.998836,0.000042576852,0.0003860792,0.00015265607,0.00045175973,0.00013095826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045487357,0.00015127311,0.0005024032,0.00019701042,0.00004447457,0.0000384639,0.00006097204,0.00001807356,0.000051985986],"category_scores_gemma":[0.000018101004,0.000102026876,0.00009295434,0.0005908653,0.00011258736,0.00012475149,0.000019150062,0.00017194977,2.380971e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016754866,0.00034584725,0.83920085,0.00026432428,0.0043734526,0.0065147104,0.004220195,0.0018149304,0.08997327,0.00003367711,0.0003470763,0.03615678],"study_design_scores_gemma":[0.01866367,0.0031454482,0.92216545,0.0008593612,0.0014279692,0.00014315968,0.0012241893,0.00026999635,0.050176278,0.00002482099,0.0016290719,0.0002706074],"about_ca_topic_score_codex":0.00023018579,"about_ca_topic_score_gemma":0.0012424879,"teacher_disagreement_score":0.08296456,"about_ca_system_score_codex":0.00024881514,"about_ca_system_score_gemma":0.00042389194,"threshold_uncertainty_score":0.41605353},"labels":[],"label_agreement":null},{"id":"W3213630353","doi":"10.1038/s41467-021-27024-x","title":"G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"Cleveland Clinic; National Cancer Institute; U.S. Department of Health and Human Services; Prostate Cancer Foundation; Johns Hopkins University; Weill Cornell Medical College; U.S. Department of Defense","keywords":"Ubiquitin ligase; Ubiquitin; Biology; Prostate cancer; Cancer research; Cell biology; Cancer; Genetics; Gene","score_opus":0.04092337422996124,"score_gpt":0.3944046702502338,"score_spread":0.35348129602027256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213630353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79539794,0.10208781,0.0000148369645,0.096034884,0.0001151639,0.0012679903,0.00014977185,0.00011311365,0.0048184693],"genre_scores_gemma":[0.9790402,0.009270758,0.0059698294,0.0015114766,0.00006397378,0.00023660946,0.0002874154,0.000024548706,0.00359519],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99910146,0.000069523696,0.00015523203,0.00023985274,0.00020523569,0.00022868888],"domain_scores_gemma":[0.9983489,0.00008575476,0.000034935627,0.0009310023,0.00039741068,0.00020201564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014389507,0.00011615997,0.00019202854,0.000087422995,0.00026863854,0.00004881688,0.0001838795,0.00016188454,0.000053586708],"category_scores_gemma":[0.0001432166,0.000095307376,0.000037856295,0.0005070027,0.00009081386,0.00006516949,0.0003380982,0.0008847183,0.000019372317],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007064924,0.001654139,0.13069677,0.0006967552,0.001004698,0.00020705369,0.01923946,0.00003178996,0.6965297,0.007815278,0.02582667,0.115591206],"study_design_scores_gemma":[0.0033179524,0.00026173072,0.033559456,0.0011438794,0.00026290026,0.00011346238,0.0010355542,0.00022292728,0.18364899,0.00048348136,0.77551067,0.0004389778],"about_ca_topic_score_codex":0.000044448385,"about_ca_topic_score_gemma":0.0003052467,"teacher_disagreement_score":0.74968404,"about_ca_system_score_codex":0.000118537246,"about_ca_system_score_gemma":0.0003471804,"threshold_uncertainty_score":0.3886522},"labels":[],"label_agreement":null},{"id":"W3213812451","doi":"10.1093/jncics/pkab082","title":"Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer","year":2021,"lang":"en","type":"letter","venue":"JNCI Cancer Spectrum","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Juravinski Cancer Centre; University of British Columbia; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Calgary; University of Ottawa; McGill University; University of Alberta; University of Toronto; BC Cancer Agency; Ottawa Hospital; Jewish General Hospital","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Docetaxel; Abiraterone acetate; Interquartile range; Internal medicine; Population; Oncology; Regimen; Prednisone; Cohort; Randomized controlled trial; Cancer","score_opus":0.05167400206241337,"score_gpt":0.3179605011314767,"score_spread":0.2662864990690634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213812451","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39363015,0.0050464096,0.000027338052,0.59400076,0.00038157852,0.003987854,0.0010123249,0.00010328742,0.0018102988],"genre_scores_gemma":[0.47912425,0.10791075,0.0013913874,0.2399314,0.00553856,0.006679581,0.008828037,0.0010169556,0.14957906],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968742,0.00013322261,0.0005037868,0.00077137264,0.0007514278,0.0009659803],"domain_scores_gemma":[0.9978306,0.00007747587,0.0004016789,0.0007658321,0.00060733786,0.0003170238],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018129202,0.0005036156,0.00087278493,0.0007300152,0.00013025031,0.000106520536,0.00018091845,0.00026915464,0.00077350263],"category_scores_gemma":[0.000023672914,0.00037894235,0.00016294149,0.0010249426,0.00025679992,0.00022614915,0.000033988013,0.0011766207,0.0000050614185],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008569744,0.000117999145,0.5233222,0.0010104299,0.0028662407,0.0025737765,0.0018934092,0.00005902589,0.0009871263,0.000024858355,0.4616268,0.0046611186],"study_design_scores_gemma":[0.008926391,0.00076687336,0.43009472,0.004564862,0.0018316158,0.00013410591,0.00047941544,0.00052154093,0.062395036,0.00013247733,0.48872587,0.0014271077],"about_ca_topic_score_codex":0.5691137,"about_ca_topic_score_gemma":0.39273793,"teacher_disagreement_score":0.35406935,"about_ca_system_score_codex":0.003492147,"about_ca_system_score_gemma":0.007548505,"threshold_uncertainty_score":0.99986625},"labels":[],"label_agreement":null},{"id":"W3214676769","doi":"10.1016/s0167-8140(21)08948-9","title":"70: After ASCENDE-RT: Outcomes of Androgen Deprivation, External Beam Radiation and LDR Brachytherapy Boost for High-Tier Intermediate and High Risk Prostate Cancer Treated at BC Cancer Kelowna","year":2021,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Brachytherapy; Androgen deprivation therapy; Medicine; External beam radiation; Androgen; Oncology; Internal medicine; Cancer; Radiation therapy; Hormone","score_opus":0.012685118260670246,"score_gpt":0.3262029768565477,"score_spread":0.31351785859587744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214676769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9381437,0.057679113,0.00012227964,0.0025545796,0.0002154518,0.00090901635,0.00034761778,0.000020489122,0.000007777232],"genre_scores_gemma":[0.79746455,0.19821958,0.0005631132,0.00073681684,0.00020783546,0.00054141734,0.00010153254,0.000039004964,0.0021261165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863034,0.00010376928,0.0003576896,0.0004373136,0.00014807895,0.00032283284],"domain_scores_gemma":[0.9990848,0.00022472421,0.00020215778,0.00016233222,0.00016024495,0.00016577673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018573942,0.00023098287,0.00063417864,0.00012341829,0.00013456143,0.000023845194,0.0000391772,0.00018836874,0.00026685817],"category_scores_gemma":[0.000027812102,0.00017148358,0.00006283146,0.00012309308,0.0002620529,0.00011318533,0.000029460934,0.00014080135,3.9988265e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004777905,0.00013281486,0.7630934,0.000115073424,0.00068878155,0.0000401276,0.0015385373,0.0000042240104,0.008112567,0.000018880066,0.00024701882,0.22123069],"study_design_scores_gemma":[0.018947227,0.00150787,0.92395943,0.000093272596,0.00026372317,0.000047704118,0.00005303682,0.0002308923,0.04207338,0.00028080563,0.012340683,0.00020195043],"about_ca_topic_score_codex":0.0011760828,"about_ca_topic_score_gemma":0.00088803243,"teacher_disagreement_score":0.22102873,"about_ca_system_score_codex":0.0005050748,"about_ca_system_score_gemma":0.00032912774,"threshold_uncertainty_score":0.69928974},"labels":[],"label_agreement":null},{"id":"W3214853603","doi":"10.3390/cancers13235872","title":"The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials","year":2021,"lang":"en","type":"review","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma US; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Quality of life (healthcare); Oncology; Internal medicine; Disease; Clinical trial; Cancer; Physical therapy; Androgen receptor","score_opus":0.4305155525265233,"score_gpt":0.6165568470815892,"score_spread":0.1860412945550659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214853603","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010328907,0.98073053,1.884303e-7,0.0006642224,0.000533053,0.0058297925,0.001763054,0.000010744255,0.00013949869],"genre_scores_gemma":[0.0015553355,0.99628776,0.0000031486293,0.00022857926,0.00010179161,0.001229917,0.00020105364,0.00004975014,0.00034265447],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9846674,0.00674002,0.0063591856,0.00057038956,0.0010389865,0.0006240092],"domain_scores_gemma":[0.98700935,0.0050190883,0.005800816,0.0011906942,0.0006719681,0.00030809065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013980334,0.0004921044,0.0074593253,0.000061776445,0.00017254881,0.000014378288,0.00041046212,0.00026523264,0.00025737667],"category_scores_gemma":[0.008031492,0.0002031996,0.0031587263,0.00093865575,0.00117387,0.000037614445,0.0001602951,0.0009263313,0.0000020629334],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00098122,0.00014430756,0.00046149112,0.07739413,0.0027461238,0.000007172161,0.0013492305,0.0000053587332,0.0000022460492,0.000021502716,0.01134332,0.9055439],"study_design_scores_gemma":[0.003520855,0.0034083442,0.00062718644,0.5962504,0.0011326373,0.000008677168,0.0018980253,0.000005371467,0.000056595505,0.000012152574,0.39264023,0.00043953615],"about_ca_topic_score_codex":0.005131555,"about_ca_topic_score_gemma":0.000049658316,"teacher_disagreement_score":0.90510434,"about_ca_system_score_codex":0.0025374922,"about_ca_system_score_gemma":0.02571499,"threshold_uncertainty_score":0.97980833},"labels":[],"label_agreement":null},{"id":"W3215295275","doi":"10.1016/j.xhgg.2021.100070","title":"Genetic factors associated with prostate cancer conversion from active surveillance to treatment","year":2021,"lang":"en","type":"article","venue":"Human Genetics and Genomics Advances","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"National Center for Advancing Translational Sciences; U.S. Department of Defense; National Heart, Lung, and Blood Institute; NorthShore University HealthSystem; National Cancer Institute; National Institutes of Health; Vanderbilt University","keywords":"Prostate cancer; Medicine; Cancer; Oncology; Internal medicine; Environmental health","score_opus":0.03102467114616855,"score_gpt":0.31071044049039626,"score_spread":0.27968576934422773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215295275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97734123,0.02122729,0.000011064881,0.00026783437,0.00007242527,0.0004854197,0.0004305019,0.000018674851,0.0001455247],"genre_scores_gemma":[0.9764742,0.021287214,0.00035908955,0.00009164532,0.00007365825,0.000052859683,0.0003057321,0.00003086758,0.0013247358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890924,0.000033105836,0.0001478011,0.00044386933,0.00017267346,0.00029332718],"domain_scores_gemma":[0.99928427,0.00005205558,0.00006819606,0.00019419623,0.00017669445,0.0002245678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00002396188,0.00020687346,0.0003139793,0.00004919188,0.00018593117,0.000043372904,0.000045464225,0.00005016153,0.00008832877],"category_scores_gemma":[0.000007712867,0.00014916099,0.000040531726,0.00012602142,0.00008815631,0.000029199227,0.000048988073,0.00007001315,0.000002814583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062397576,0.0002536755,0.91589856,0.00003713596,0.00051397074,0.00013002894,0.0028895193,0.0004034284,0.046754215,0.0000050857625,0.000041644704,0.032448772],"study_design_scores_gemma":[0.0031841407,0.001135719,0.8863718,0.00007889246,0.00011336811,0.0000021820758,0.0007311772,0.00006859079,0.090653695,0.00012117295,0.017292764,0.00024648098],"about_ca_topic_score_codex":0.00014468734,"about_ca_topic_score_gemma":0.0015948009,"teacher_disagreement_score":0.04389948,"about_ca_system_score_codex":0.00033639773,"about_ca_system_score_gemma":0.00022621623,"threshold_uncertainty_score":0.6082608},"labels":[],"label_agreement":null},{"id":"W3215465802","doi":"10.5489/cuaj.7525","title":"Metastatic progression following multimodal therapy for unfavorable-risk prostate cancer","year":2021,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; North York General Hospital; Sunnybrook Health Science Centre; London Health Sciences Centre","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Hazard ratio; Proportional hazards model; Oncology; Internal medicine; Radiation therapy; Biochemical recurrence; Cancer; Prostate; Confidence interval","score_opus":0.028360490359148463,"score_gpt":0.33697266325639635,"score_spread":0.3086121728972479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215465802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9474854,0.0096310135,0.00011736314,0.0406678,0.00059405575,0.0009389479,0.00019506428,0.00003302984,0.00033734826],"genre_scores_gemma":[0.98810077,0.0036707476,0.0020946849,0.0020731853,0.00038940497,0.0002035555,0.000120865014,0.000026442152,0.0033203498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810016,0.00022706704,0.0003137139,0.0002526309,0.00042677738,0.0006796419],"domain_scores_gemma":[0.99817085,0.00024818882,0.00022544942,0.00009585695,0.00054631714,0.00071335374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008891946,0.00014979292,0.00031933555,0.00011950484,0.0005523293,0.00013640209,0.000071757706,0.00013390723,0.00039362107],"category_scores_gemma":[0.0010519028,0.00010221189,0.00027832668,0.00027686328,0.000022780016,0.00011172294,0.000010679169,0.000523217,0.00001099059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044419887,0.00015056819,0.9048972,0.000014447639,0.00078163354,0.00051298866,0.0002976219,0.00006690994,0.0008921433,0.000019870544,0.0063935625,0.08552883],"study_design_scores_gemma":[0.025351757,0.0023122383,0.5857208,0.0001963037,0.0007021936,0.00023118815,0.00057497126,0.0023256433,0.0039694807,0.0033206034,0.37474224,0.0005526323],"about_ca_topic_score_codex":0.0006751466,"about_ca_topic_score_gemma":0.00064486644,"teacher_disagreement_score":0.3683487,"about_ca_system_score_codex":0.0013563483,"about_ca_system_score_gemma":0.002424724,"threshold_uncertainty_score":0.43098748},"labels":[],"label_agreement":null},{"id":"W3216319709","doi":"10.1016/j.ejca.2021.09.043","title":"Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Docetaxel; Medicine; Prostate cancer; Chemotherapy; Oncology; Internal medicine; Nivolumab; Cancer; Immunotherapy","score_opus":0.033042106537681054,"score_gpt":0.33079038096837576,"score_spread":0.29774827443069474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216319709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830204,0.0069805873,0.00001007071,0.007755016,0.00035790334,0.0007568523,0.00048849214,0.000009230619,0.0006214322],"genre_scores_gemma":[0.99319637,0.0027805956,0.00030673368,0.0004222737,0.0005432512,0.000021537875,0.00009091033,0.00005602688,0.0025823126],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973905,0.00038420892,0.00079561776,0.00028178794,0.0008079247,0.00033997002],"domain_scores_gemma":[0.9981497,0.00008640631,0.0005634629,0.00029487806,0.0007223607,0.00018317532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006773623,0.00022463687,0.00048500823,0.00008500021,0.00015114175,0.00007977865,0.00017601835,0.000018844941,0.00027453242],"category_scores_gemma":[0.000110487745,0.00012482794,0.00012555112,0.0003829656,0.00011742145,0.0001815393,0.000041220545,0.00045176936,0.0000048994452],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80272603,0.0026184323,0.007301682,0.00009366893,0.0023101543,0.004444874,0.013165682,0.0005483106,0.0055258744,0.000006891161,0.008488495,0.15276988],"study_design_scores_gemma":[0.83621985,0.009733015,0.10699675,0.0017725184,0.0006916541,0.000025800711,0.00096908427,0.00009033138,0.009173597,0.000025176678,0.033951513,0.00035069484],"about_ca_topic_score_codex":0.00032611183,"about_ca_topic_score_gemma":0.0004063385,"teacher_disagreement_score":0.1524192,"about_ca_system_score_codex":0.00046273487,"about_ca_system_score_gemma":0.001679876,"threshold_uncertainty_score":0.5090336},"labels":[],"label_agreement":null},{"id":"W3216340305","doi":"10.2139/ssrn.3966640","title":"Autocrine Activation of MAPK-Signaling Mediates Intrinsic Tolerance to Androgen Deprivation in LY6D Prostate Cancer Cells","year":2021,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Autocrine signalling; Prostate cancer; Androgen deprivation therapy; Cancer; MAPK/ERK pathway; Androgen; Endocrinology; Cancer research; Internal medicine; Signal transduction; Medicine; Biology; Hormone; Cell biology; Receptor","score_opus":0.01327840042965383,"score_gpt":0.29591764813570576,"score_spread":0.2826392477060519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216340305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99138737,0.004559613,0.00038166862,0.0031275642,0.00008995111,0.0003779037,0.000004680247,0.000012491485,0.00005873355],"genre_scores_gemma":[0.98871154,0.010036746,0.00018137775,0.000120448705,0.00017827784,0.000041934767,0.000023202665,0.000020702659,0.00068576355],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99800795,0.00005987835,0.0003414026,0.00021139834,0.0003552823,0.0010240936],"domain_scores_gemma":[0.99930686,0.000039950075,0.000117284304,0.00012402497,0.0003092783,0.00010258179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005350296,0.00012415803,0.0002647421,0.00022703358,0.000059284914,0.000019455376,0.00007488694,0.000050613824,0.00006313549],"category_scores_gemma":[0.00006886763,0.00010389692,0.000060165945,0.0006315775,0.00002335899,0.00014712552,0.000032837568,0.00074338523,0.0000053513786],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013836898,0.00028463057,0.08483655,0.00013652569,0.00026545924,0.00006936768,0.0012468216,0.0011988104,0.8163055,0.0008547684,0.000066594825,0.09335125],"study_design_scores_gemma":[0.00360305,0.0004481257,0.015992865,0.00042759976,0.000044168733,0.00009109333,0.0008494752,0.00015617245,0.97202706,0.005807082,0.00041749235,0.0001358153],"about_ca_topic_score_codex":0.00014599788,"about_ca_topic_score_gemma":0.00041552034,"teacher_disagreement_score":0.15572153,"about_ca_system_score_codex":0.0013755206,"about_ca_system_score_gemma":0.003511705,"threshold_uncertainty_score":0.6229614},"labels":[],"label_agreement":null},{"id":"W3216437033","doi":"10.1007/s10637-021-01202-6","title":"A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer","year":2021,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Tolerability; Medicine; Prostate cancer; Nausea; Pharmacokinetics; Adverse effect; Internal medicine; Vomiting; Androgen receptor; Pharmacology; Oncology; Cancer; Gastroenterology","score_opus":0.03486849492790454,"score_gpt":0.34264569075683055,"score_spread":0.307777195828926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216437033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99018985,0.0001565267,0.000004784296,0.007273155,0.00007441469,0.0019605507,0.00031061942,0.000006362266,0.000023715613],"genre_scores_gemma":[0.99862736,0.00001727535,0.00052750966,0.00029833516,0.00006268302,0.00009252729,0.000057913378,0.000016751364,0.00029966727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828,0.00023693584,0.0002883475,0.0002969738,0.00069133873,0.00020638574],"domain_scores_gemma":[0.9990627,0.00013240501,0.00013146826,0.00019427743,0.0002859901,0.00019314299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027285772,0.00016249211,0.0002595776,0.00006776986,0.00012884516,0.000038189897,0.000087308086,0.000014247072,0.000055770535],"category_scores_gemma":[0.00007788581,0.00008956546,0.000033701268,0.00052012946,0.00022295238,0.00011419732,0.00008046518,0.00018145671,0.0000013671795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065867775,0.005118528,0.8422191,0.0002776756,0.00058348017,0.0001741182,0.011845245,0.00015924919,0.12553369,0.000098196215,0.001248976,0.0061549516],"study_design_scores_gemma":[0.03004258,0.0014394438,0.7933948,0.0005290647,0.00028393624,0.000016980573,0.0016794284,0.00007772263,0.171279,0.00023221965,0.0007930228,0.00023179752],"about_ca_topic_score_codex":0.00031939856,"about_ca_topic_score_gemma":0.00024360769,"teacher_disagreement_score":0.04882431,"about_ca_system_score_codex":0.00014851414,"about_ca_system_score_gemma":0.0015801877,"threshold_uncertainty_score":0.36523736},"labels":[],"label_agreement":null},{"id":"W3217067446","doi":"10.3390/cancers13225830","title":"Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Merck Sharp and Dohme; AstraZeneca","keywords":"Olaparib; Medicine; Prostate cancer; Oncology; Abiraterone; Internal medicine; PARP inhibitor; Germline; Homologous recombination; Germline mutation; Cancer; Cancer research; CHEK2; Urology; Mutation; Biology; Genetics; Androgen receptor; Gene","score_opus":0.028058034904881964,"score_gpt":0.3331128205273476,"score_spread":0.30505478562246563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217067446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952068,0.002277159,0.000034601013,0.0007304654,0.00022183136,0.0010968175,0.00036119804,0.000032197804,0.000038945123],"genre_scores_gemma":[0.99377126,0.002992689,0.00017412519,0.000058838104,0.000037213755,0.0004195444,0.0013789334,0.000023196466,0.0011442103],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986388,0.0001092329,0.00042166334,0.00035335848,0.00022723296,0.0002496989],"domain_scores_gemma":[0.9992967,0.000023926481,0.00018312049,0.00015744989,0.00023652554,0.000102261656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023201924,0.0001513259,0.00037610487,0.0001509049,0.00007389617,0.000016487767,0.000030756175,0.00006331343,0.00007344687],"category_scores_gemma":[0.000052374253,0.00013601987,0.000051460524,0.00045088737,0.00011150886,0.00015613493,0.00002367516,0.00012125702,7.3485796e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057006083,0.0005199245,0.00021445607,0.0003355338,0.00018364433,0.0003682075,0.0015115602,0.000025435831,0.93095344,0.000012869913,0.00009994061,0.008768909],"study_design_scores_gemma":[0.16220568,0.011929616,0.0024054688,0.00044724083,0.00031947074,0.000078407254,0.0006613378,0.0015974517,0.8194113,0.000053133364,0.0005962378,0.00029467506],"about_ca_topic_score_codex":0.00075163384,"about_ca_topic_score_gemma":0.00013856342,"teacher_disagreement_score":0.11154216,"about_ca_system_score_codex":0.0009959055,"about_ca_system_score_gemma":0.0013645748,"threshold_uncertainty_score":0.55467296},"labels":[],"label_agreement":null},{"id":"W3217747474","doi":"10.3389/fonc.2021.778858","title":"Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients","year":2021,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Oncology; Chemotherapy; Overall survival; Internal medicine; Cancer","score_opus":0.025855005602759207,"score_gpt":0.36663318764465563,"score_spread":0.3407781820418964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217747474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99007016,0.0031652008,0.000005902223,0.0012305229,0.00083677645,0.0009102648,0.000033365268,0.000008555446,0.0037392306],"genre_scores_gemma":[0.9957885,0.0016146248,0.0003315111,0.00035745764,0.000029573162,0.00018192866,0.00010691994,0.000022098788,0.0015673456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998537,0.00042051374,0.00029100903,0.00026234254,0.0002192836,0.00026982412],"domain_scores_gemma":[0.99944395,0.00017922251,0.00008206234,0.00015038897,0.00007561664,0.00006873997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003754869,0.00013690484,0.0006895426,0.00020781421,0.0000128879365,0.0000032149642,0.000058445356,0.00008378948,0.00006905806],"category_scores_gemma":[0.000098668745,0.000103664264,0.0000668158,0.00026971527,0.0001006474,0.000040964012,0.00002521268,0.00024335699,0.0000024839885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010099634,0.000997167,0.93152183,0.0002616765,0.00016742306,0.00049263204,0.00068392634,0.0000134951015,0.0003749499,0.000009957112,0.007860969,0.04751636],"study_design_scores_gemma":[0.13568118,0.024821764,0.71677595,0.0009850267,0.00012330513,0.000007643598,0.000577477,0.00046853858,0.08592699,0.0005981537,0.033600077,0.00043388168],"about_ca_topic_score_codex":0.00019737684,"about_ca_topic_score_gemma":0.00006720075,"teacher_disagreement_score":0.21474585,"about_ca_system_score_codex":0.00067234057,"about_ca_system_score_gemma":0.0006814795,"threshold_uncertainty_score":0.4227306},"labels":[],"label_agreement":null},{"id":"W3217758388","doi":"10.1200/po.21.00543","title":"Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Oncology; PTEN; Prostate cancer; Prostate; Lung; Lung cancer; Internal medicine; Pathology; Cancer; Biology; Genetics","score_opus":0.026086967435030754,"score_gpt":0.377235857640557,"score_spread":0.35114889020552625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217758388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723028,0.015292311,0.0000086765285,0.0038468577,0.00072307396,0.0013977314,0.00025388369,0.000037339418,0.006137324],"genre_scores_gemma":[0.98509985,0.0039829146,0.00023405215,0.0003171632,0.00013368824,0.000488778,0.00011891157,0.000027238828,0.009597387],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99837214,0.00021152437,0.00029820556,0.00034615738,0.00044229455,0.0003296883],"domain_scores_gemma":[0.99906915,0.00020067467,0.00015616423,0.00024844534,0.00018778814,0.00013774914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036570104,0.00014427197,0.0004586251,0.0002194928,0.00016019063,0.0000055412697,0.00012567626,0.000078629484,0.00069065427],"category_scores_gemma":[0.000051153376,0.00011010311,0.00012321476,0.00026729898,0.00012591711,0.000033942557,0.0003337094,0.00045758538,0.000015417016],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032207504,0.0017483783,0.014477994,0.00012324838,0.0006042359,0.00067907304,0.007299131,0.00019415823,0.12216752,0.00022607583,0.1926085,0.6276642],"study_design_scores_gemma":[0.016738625,0.015155084,0.44396392,0.00011422536,0.0004202292,0.00037407345,0.002163915,0.0006231896,0.029181197,0.00056695775,0.49026808,0.0004305244],"about_ca_topic_score_codex":0.00016301565,"about_ca_topic_score_gemma":0.00003380441,"teacher_disagreement_score":0.6272337,"about_ca_system_score_codex":0.0012015946,"about_ca_system_score_gemma":0.000848868,"threshold_uncertainty_score":0.756218},"labels":[],"label_agreement":null},{"id":"W367758757","doi":"10.1007/978-1-4419-0020-3_26","title":"Mining Natural Product-Derived Molecules Against Cancer Targets: The Case of the Androgen Receptor in Prostate Cancer","year":2010,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Antiandrogens; Bicalutamide; Flutamide; Prostate cancer; Androgen receptor; Antiandrogen; Medicine; Androgen; Cancer; Docetaxel; Cancer research; Internal medicine; Oncology; Pharmacology; Hormone","score_opus":0.02055483374810207,"score_gpt":0.29816215318985845,"score_spread":0.2776073194417564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W367758757","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74243796,0.12456036,4.8824705e-7,0.022906706,0.002097741,0.008036519,0.00078159064,0.000085559106,0.099093065],"genre_scores_gemma":[0.31266475,0.021777399,0.00030057738,0.0007697685,0.000661012,0.0007311294,0.00015985579,0.00017353822,0.662762],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99820167,0.000042202217,0.00042565516,0.0005233094,0.00037317272,0.0004339928],"domain_scores_gemma":[0.99862355,0.0000597896,0.00025351555,0.00063461467,0.0003261933,0.00010231282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020605254,0.0004085947,0.00054819,0.00013312572,0.00016232299,0.000022326445,0.00024765756,0.0001885822,0.00072524627],"category_scores_gemma":[0.00004739618,0.00018580159,0.00020052824,0.00011818808,0.00065295125,0.00005422289,0.00015144532,0.0011084016,0.0000064431156],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059789764,0.0006329925,0.014657313,0.0031186598,0.004949995,0.007980586,0.025048148,0.000052667776,0.45649865,0.00278113,0.040343363,0.43795753],"study_design_scores_gemma":[0.0104786,0.0004743929,0.0016499598,0.008266915,0.0010999242,0.0008884286,0.0018955836,0.00024650095,0.71423006,0.00082064286,0.258253,0.0016959572],"about_ca_topic_score_codex":0.0013012872,"about_ca_topic_score_gemma":0.005951121,"teacher_disagreement_score":0.5636689,"about_ca_system_score_codex":0.00035020924,"about_ca_system_score_gemma":0.0010961022,"threshold_uncertainty_score":0.7940938},"labels":[],"label_agreement":null},{"id":"W38329651","doi":"10.1007/3-540-27671-8_8","title":"Hormonal and Stromal Regulation of Normal and Neoplastic Prostatic Growth","year":2005,"lang":"en","type":"review","venue":"Progress in molecular and subcellular biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Stromal cell; Hormone; Medicine; Cancer research; Physiology; Internal medicine","score_opus":0.021787802176596933,"score_gpt":0.3358970032743398,"score_spread":0.3141092010977429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W38329651","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034012426,0.9647914,0.00008247157,0.000053735737,0.00002372183,0.0009574013,0.000028149503,0.000008697748,0.000041988762],"genre_scores_gemma":[0.062158585,0.9361978,0.0010479769,0.0000065420586,0.000036083442,0.00010917945,0.00038178285,0.000025686168,0.00003633083],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986252,0.00016342328,0.00039236867,0.00040233674,0.000121860015,0.00029477442],"domain_scores_gemma":[0.99949753,0.00007042902,0.0001325166,0.00012970324,0.00005394435,0.00011587545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020081043,0.00027072814,0.0009856428,0.0002771753,0.000034094242,0.000014968621,0.00005036605,0.00029684728,0.000007796747],"category_scores_gemma":[0.000031520023,0.00019504849,0.000079141704,0.00015146994,0.0005573297,0.000028725177,0.00010757,0.0002692314,6.5384506e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015930268,0.00009758575,0.019499257,0.010575461,0.00019764472,0.00017201033,0.000089280446,4.273896e-8,0.0001482273,0.0008692296,0.0000018714484,0.9681901],"study_design_scores_gemma":[0.07768171,0.051944133,0.11583208,0.112794824,0.027590618,0.014987141,0.0006061804,0.006913363,0.0070546498,0.011711032,0.5622957,0.010588591],"about_ca_topic_score_codex":0.0000075188855,"about_ca_topic_score_gemma":0.000001984209,"teacher_disagreement_score":0.9576015,"about_ca_system_score_codex":0.00003312137,"about_ca_system_score_gemma":0.00014214103,"threshold_uncertainty_score":0.79538465},"labels":[],"label_agreement":null},{"id":"W41590078","doi":"10.1016/s0090-4295(02)01559-5","title":"Overview consensus statement","year":2002,"lang":"en","type":"review","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre","funders":"","keywords":"Medicine; Androgen deprivation therapy; Consensus conference; Prostate cancer; Statement (logic); Gynecology; Library science; Family medicine; Internal medicine; Cancer; Epistemology","score_opus":0.22247363830445918,"score_gpt":0.45518199027923983,"score_spread":0.23270835197478065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W41590078","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000010959443,0.9887678,0.0000015499775,0.000877163,0.00023707486,0.0011300878,0.000058110818,0.000047995385,0.008879102],"genre_scores_gemma":[0.0000017564654,0.98489,0.00003111139,0.00031147312,0.00017032135,0.00017072562,0.0002336164,0.000044293578,0.014146709],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983987,0.00017111267,0.0004400179,0.00037334787,0.00018751374,0.00042925935],"domain_scores_gemma":[0.99909616,0.00014950542,0.00013680781,0.00040451615,0.000050717073,0.00016227145],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014501756,0.00028456375,0.0015038765,0.00018611748,0.000039617553,0.00000741706,0.00009774433,0.00028789215,0.0026078168],"category_scores_gemma":[0.00003515203,0.00018333674,0.0003256667,0.00017707066,0.000130124,0.000006143957,0.000075009644,0.00043104272,0.0017109063],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027569142,0.00010521363,0.0000036165354,0.012709028,0.0004691015,0.00093323976,0.000013652393,4.6878107e-8,5.8336774e-8,0.00011502966,0.030365443,0.955258],"study_design_scores_gemma":[0.00078072806,0.00056655006,0.000001193641,0.0012541143,0.001368587,0.0004808478,0.0000016936657,0.000004235375,1.8267862e-7,0.000028533655,0.9953849,0.00012845713],"about_ca_topic_score_codex":0.000008976769,"about_ca_topic_score_gemma":0.000002128608,"teacher_disagreement_score":0.9650194,"about_ca_system_score_codex":0.00018548849,"about_ca_system_score_gemma":0.00033915765,"threshold_uncertainty_score":0.99906635},"labels":[],"label_agreement":null},{"id":"W4200018745","doi":"10.1002/pros.24282","title":"Response to the letter to the editor: “Don't throw the baby out with the bath water” by Horsley et al.","year":2021,"lang":"en","type":"letter","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Unit (ring theory); Medicine; Library science; Gerontology; Cancer; Psychology; Internal medicine; Computer science","score_opus":0.019425423811853162,"score_gpt":0.2953386388325011,"score_spread":0.275913215020648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200018745","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0070611094,0.0018344643,0.00005639799,0.98109174,0.0026129954,0.0059643667,0.0005920462,0.00008958066,0.0006973064],"genre_scores_gemma":[0.002323202,0.0005901485,0.00001723112,0.836596,0.011485747,0.0020101396,0.00047225505,0.00019333958,0.14631195],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925495,0.0025603147,0.0004229885,0.0009193616,0.002036063,0.0015118031],"domain_scores_gemma":[0.9945422,0.0015639397,0.00015076142,0.003208146,0.0003614848,0.0001734951],"candidate_categories":["sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0046212953,0.000792859,0.00061565405,0.00009073309,0.0013600898,0.00064915296,0.001937585,0.0002626122,0.0002828414],"category_scores_gemma":[0.00017262925,0.00019363787,0.00028750667,0.00046824905,0.00075330416,0.00009339904,0.0009122593,0.0044253124,0.00087391876],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034470381,0.000043834098,0.000026763215,0.00003864312,0.0005863405,0.0003023574,0.02043797,0.00001868422,0.0022243718,0.0000020460525,0.97220325,0.00066870963],"study_design_scores_gemma":[0.0011014376,0.00081868423,0.000079075435,0.0002495927,0.00032831178,0.00007647804,0.001208454,0.000008469138,0.0048198444,0.000023449182,0.9909334,0.00035280723],"about_ca_topic_score_codex":0.00031815784,"about_ca_topic_score_gemma":0.00029637397,"teacher_disagreement_score":0.14561464,"about_ca_system_score_codex":0.00027547762,"about_ca_system_score_gemma":0.0005277089,"threshold_uncertainty_score":0.99994},"labels":[],"label_agreement":null},{"id":"W4200042354","doi":"10.1158/1535-7163.targ-21-cc06-01","title":"Abstract CC06-01: Identifying therapeutic options for patients with advanced prostate cancer through genes in liquid biopsies","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Prostate cancer; Medicine; Androgen deprivation therapy; Androgen receptor; Oncology; Prostatectomy; Internal medicine; Disease; Prostate; Circulating tumor cell; Cancer; Liquid biopsy; Metastasis; Bioinformatics; Biology","score_opus":0.04885802728738338,"score_gpt":0.3650282655748881,"score_spread":0.31617023828750473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200042354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8970764,0.09685142,0.0007457273,0.0028413418,0.00028004037,0.0018161718,0.00018150562,0.00006518363,0.0001421699],"genre_scores_gemma":[0.9606176,0.032483935,0.0024467758,0.0016634887,0.00007606085,0.0017350046,0.00027909927,0.00012428372,0.0005737777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979875,0.000047476402,0.00033324416,0.00054322334,0.00045978208,0.0006287403],"domain_scores_gemma":[0.9988304,0.000047993402,0.000117254596,0.0003915403,0.00051512674,0.00009771709],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008521275,0.00032230414,0.00041084632,0.00010898554,0.00015944168,0.00006845265,0.00012484445,0.00011814166,0.00012576526],"category_scores_gemma":[0.0000067307474,0.0002513828,0.00014529191,0.0005426399,0.00014141011,0.00019040999,0.000044732333,0.00024909384,0.0000029527237],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01325846,0.002684348,0.13369565,0.0018669562,0.0035998824,0.0004702844,0.0051880903,0.0024712912,0.62583,0.0006816149,0.000057885187,0.21019554],"study_design_scores_gemma":[0.028271168,0.002176151,0.11651467,0.002094935,0.0011544965,0.0000145059075,0.0014246143,0.0002763704,0.785613,0.0012268181,0.059993517,0.0012397479],"about_ca_topic_score_codex":0.00011508303,"about_ca_topic_score_gemma":0.0002726115,"teacher_disagreement_score":0.2089558,"about_ca_system_score_codex":0.0004208183,"about_ca_system_score_gemma":0.0007134526,"threshold_uncertainty_score":0.99999386},"labels":[],"label_agreement":null},{"id":"W4200058283","doi":"10.14740/wjon1423","title":"Early mRNA Expression of Neuroendocrine Differentiation Signals Predicts Recurrence After Radical Prostatectomy: A Transcriptomic Analysis","year":2021,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostatectomy; Transcriptome; Neuroendocrine differentiation; Messenger RNA; Urology; Internal medicine; Oncology; Prostate cancer; Gene expression; Gene; Cancer","score_opus":0.02297857817848592,"score_gpt":0.3276575201574764,"score_spread":0.3046789419789905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200058283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930056,0.003708205,0.0003851194,0.0021387632,0.0002517561,0.00022072441,0.000023480294,0.0000075388507,0.00025881312],"genre_scores_gemma":[0.997117,0.00122219,0.00059038604,0.00010382061,0.00013823736,0.000016612941,0.000023075732,0.000012265361,0.0007764457],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99807274,0.00031207444,0.0006797304,0.00019535614,0.00047175746,0.000268333],"domain_scores_gemma":[0.9986301,0.00015139546,0.00036854096,0.00016949372,0.00045027173,0.00023021708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022179107,0.00013290592,0.0007355384,0.00066988583,0.00003397389,0.000013445081,0.00009889683,0.0000445446,0.00071645953],"category_scores_gemma":[0.000096551004,0.00009386891,0.00034779182,0.00094093895,0.0001313122,0.000119654345,0.00003398997,0.00046007102,0.000002427959],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01898309,0.0028165344,0.38722217,0.00038026928,0.0024172994,0.009426897,0.0014277692,0.00006871433,0.54315466,0.000026913849,0.0016538993,0.032421768],"study_design_scores_gemma":[0.011557166,0.003889201,0.62601584,0.0006103789,0.0026938461,0.0005685674,0.00007790705,0.0001706511,0.34717068,0.00023707449,0.0068688258,0.00013987732],"about_ca_topic_score_codex":0.000006150362,"about_ca_topic_score_gemma":0.00002955065,"teacher_disagreement_score":0.23879366,"about_ca_system_score_codex":0.00018569708,"about_ca_system_score_gemma":0.000633772,"threshold_uncertainty_score":0.78447294},"labels":[],"label_agreement":null},{"id":"W4200095907","doi":"10.1200/jco.21.00941","title":"Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; University of Ottawa; Alberta Cancer Foundation; BC Cancer Agency","funders":"National Health and Medical Research Council; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Astellas Pharma","keywords":"Medicine; Enzalutamide; Quality of life (healthcare); Prostate cancer; Internal medicine; Discontinuation; Randomized controlled trial; Cancer; Oncology; Physical therapy","score_opus":0.20635219679472658,"score_gpt":0.5675658819912144,"score_spread":0.3612136851964878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200095907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.954419,0.007128731,0.00006998602,0.035224617,0.0013930543,0.001265061,0.00012370596,0.000008184711,0.0003676208],"genre_scores_gemma":[0.9671723,0.0284964,0.0011522835,0.0017323783,0.00043893975,0.000043946904,0.00013312182,0.00002214206,0.0008084425],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98650604,0.0055929148,0.006439609,0.00033742224,0.0007697545,0.00035423864],"domain_scores_gemma":[0.9880628,0.005384602,0.004226775,0.0002320621,0.0014065558,0.00068721315],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016166741,0.00020002144,0.0052348757,0.00023310506,0.00004143418,0.00001568025,0.00017354205,0.00025514018,0.00025664168],"category_scores_gemma":[0.013975627,0.0001366695,0.0007684714,0.0003321748,0.0005133611,0.0002525978,0.00006492323,0.0012465211,0.0000029618102],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94364625,0.008879023,0.0015115027,0.000044933287,0.0026666254,0.00078038446,0.0010317187,0.000013242533,0.0011142985,0.00007871783,0.0036139488,0.03661933],"study_design_scores_gemma":[0.9765884,0.014224271,0.0030448178,0.00013897248,0.00038667407,0.00005748349,0.00075152813,0.00030677515,0.00054706633,0.00033221446,0.0035035058,0.00011825092],"about_ca_topic_score_codex":0.0012230446,"about_ca_topic_score_gemma":0.00035616776,"teacher_disagreement_score":0.03650108,"about_ca_system_score_codex":0.00045923077,"about_ca_system_score_gemma":0.009163462,"threshold_uncertainty_score":0.99645364},"labels":[],"label_agreement":null},{"id":"W4200117800","doi":"10.1001/jamanetworkopen.2021.38550","title":"Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography–Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Nomogram; Positron emission tomography; Prostate-specific antigen; Prostatectomy; Biochemical recurrence; Oncology; Prostate; Androgen deprivation therapy; Glutamate carboxypeptidase II; Biopsy; Radiology; Internal medicine; Cancer","score_opus":0.01512929080133044,"score_gpt":0.2737539760530783,"score_spread":0.2586246852517478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200117800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834523,0.010084492,0.000109977926,0.0007566038,0.00031368926,0.004499317,0.0006337863,0.00006763276,0.00008218877],"genre_scores_gemma":[0.92139053,0.069915995,0.0056057586,0.00004898064,0.00037667344,0.000712868,0.0012217815,0.000063915504,0.0006634928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969029,0.000334347,0.00073560775,0.00087496504,0.00046021852,0.0006920053],"domain_scores_gemma":[0.99752563,0.0002856063,0.0006599863,0.0006600684,0.0006220298,0.00024666838],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010111856,0.0003876463,0.0007616264,0.00017528773,0.00058395637,0.0002659254,0.0002876347,0.00019363977,0.000077065066],"category_scores_gemma":[0.00006179393,0.00031011048,0.00017047352,0.0011547592,0.00020017258,0.00049365207,0.00023816834,0.00048598732,0.0000026874395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010446782,0.0003436798,0.84071726,0.0005197337,0.0007214811,0.000029013692,0.000736678,0.00079686247,0.019665558,0.000034829107,0.0031233272,0.12286479],"study_design_scores_gemma":[0.009268139,0.0013882811,0.8376035,0.0011440144,0.00038829466,0.000010586186,0.0001376154,0.003034733,0.14424734,0.00022586816,0.0021770902,0.00037451295],"about_ca_topic_score_codex":0.0010044103,"about_ca_topic_score_gemma":0.0000881124,"teacher_disagreement_score":0.12458178,"about_ca_system_score_codex":0.0001023783,"about_ca_system_score_gemma":0.00039406438,"threshold_uncertainty_score":0.9999351},"labels":[],"label_agreement":null},{"id":"W4200159367","doi":"10.1016/j.ijrobp.2021.12.005","title":"An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer","year":2021,"lang":"en","type":"review","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institutes of Health; Advanced Accelerator Applications; Bayer Fund; Penn State Hershey Cancer Institute; Janssen Pharmaceuticals; Penn State College of Medicine; AstraZeneca; Astellas Pharma US; Varian Medical Systems; American Cancer Society","keywords":"Medicine; Prostate cancer; Tolerability; Androgen deprivation therapy; Testosterone (patch); Agonist; Leuprorelin; Luteinizing hormone; Gonadotropin-releasing hormone; Internal medicine; Gonadotropin-releasing hormone antagonist; Adverse effect; Discontinuation; Oncology; Hormone antagonist; Hormone; Antagonist; Cancer; Receptor","score_opus":0.07838809019743119,"score_gpt":0.4543259764692983,"score_spread":0.3759378862718671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200159367","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004486048,0.9908934,0.00037378212,0.004713462,0.0009092627,0.002187766,0.00031799427,0.000013525446,0.00014218176],"genre_scores_gemma":[0.00112823,0.99386644,0.0003308901,0.0013426397,0.0013378789,0.00055097434,0.0013167332,0.000058092966,0.000068133406],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99733806,0.00066380715,0.00100391,0.0003118459,0.0004609855,0.00022136766],"domain_scores_gemma":[0.9938817,0.0011094084,0.0024082088,0.00024941863,0.0022503561,0.0001008804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008973018,0.0003356527,0.0015491401,0.00020268353,0.00008617538,0.00002584134,0.0003781939,0.0002687956,0.00006699919],"category_scores_gemma":[0.00030043442,0.00018584354,0.00053204485,0.00031365582,0.00020655998,0.00018020636,0.00002238721,0.0005764328,0.0000037178793],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006826111,0.0007392176,0.00062245876,0.00081167923,0.0019655607,0.000017361237,0.0002878975,0.000008351565,0.000019953692,0.004104899,0.0023678464,0.98837215],"study_design_scores_gemma":[0.0066857487,0.0065822164,0.00017709647,0.019465243,0.0008572099,0.000109967936,0.00006296474,0.00006284237,0.0003707978,0.0008499665,0.9645315,0.0002444492],"about_ca_topic_score_codex":0.000016761805,"about_ca_topic_score_gemma":0.0000020010718,"teacher_disagreement_score":0.9881277,"about_ca_system_score_codex":0.0011602009,"about_ca_system_score_gemma":0.003054533,"threshold_uncertainty_score":0.75784796},"labels":[],"label_agreement":null},{"id":"W4200163190","doi":"10.3389/fonc.2021.780507","title":"Drug Intensification in Future Postoperative Radiotherapy Practice in Biochemically-Relapsing Prostate Cancer Patients","year":2021,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Janssen Pharmaceuticals; Ipsen; Astellas Pharma; AstraZeneca","keywords":"Prostate cancer; Medicine; Prostatectomy; Radiation therapy; Prostate; Oncology; Salvage therapy; Internal medicine; Androgen receptor; Cancer; Urology; Chemotherapy","score_opus":0.009703494157577451,"score_gpt":0.3392749469431128,"score_spread":0.32957145278553535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200163190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92738503,0.024798587,0.00003104336,0.044306297,0.0013976173,0.0008980858,0.00001205929,0.000013434751,0.0011578643],"genre_scores_gemma":[0.89970374,0.06349315,0.025819268,0.006563926,0.0003247618,0.0006034397,0.00048334865,0.00006450714,0.0029438892],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985334,0.00028181684,0.0003184702,0.000373514,0.00016468923,0.00032810844],"domain_scores_gemma":[0.99929976,0.000091400194,0.0000834026,0.0001506957,0.00030453296,0.000070174625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026174058,0.00013149099,0.00038045485,0.00027612087,0.000026438862,0.000011404337,0.00006426808,0.00017044118,0.000038999442],"category_scores_gemma":[0.00030024,0.000114182454,0.00003205681,0.0006455729,0.00010141228,0.00014644407,0.000029897297,0.000535735,0.0000021833316],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052093985,0.0020250701,0.75681585,0.000058423004,0.00011273028,0.00093298056,0.026444385,0.00002867646,0.01098456,0.000028256321,0.02671148,0.1706482],"study_design_scores_gemma":[0.0656525,0.002315319,0.37042797,0.0015133208,0.00012400815,0.00010227599,0.06415445,0.0023121778,0.04508033,0.00053580204,0.44687018,0.00091166387],"about_ca_topic_score_codex":0.0002699346,"about_ca_topic_score_gemma":0.000529176,"teacher_disagreement_score":0.42015868,"about_ca_system_score_codex":0.0025128445,"about_ca_system_score_gemma":0.00088320393,"threshold_uncertainty_score":0.6571001},"labels":[],"label_agreement":null},{"id":"W4200169768","doi":"10.1158/1078-0432.ccr-21-3762","title":"Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"National Cancer Institute; U.S. Department of Defense","keywords":"Prostate cancer; DNA methylation; Methylation; DNA; Prostate; PCA3; Cancer","score_opus":0.2299962849316558,"score_gpt":0.5587790777569874,"score_spread":0.3287827928253316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200169768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9455202,0.017645277,0.00011010997,0.023587503,0.0005933159,0.001528331,0.00014007563,0.00013812915,0.010737051],"genre_scores_gemma":[0.91472155,0.050520048,0.0007198025,0.0005794413,0.00094110245,0.0007832723,0.00016445619,0.00007483911,0.03149552],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99413866,0.00074869546,0.0009887951,0.0010523632,0.0017880717,0.0012834412],"domain_scores_gemma":[0.99464244,0.0016593183,0.00016747828,0.0012348634,0.0017432389,0.0005526853],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016264401,0.00027712886,0.0008817541,0.0003947943,0.00043638906,0.0001421829,0.00039544055,0.00014240065,0.00242108],"category_scores_gemma":[0.0026211224,0.00022112147,0.00044261542,0.004331041,0.0004771828,0.0002784144,0.00061080384,0.0017122849,0.00009488864],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076826876,0.0018130105,0.46708247,0.0021871096,0.004915697,0.0044069723,0.0018233623,0.00038399553,0.0359141,0.00013092809,0.02806517,0.4455945],"study_design_scores_gemma":[0.017058004,0.002123719,0.17209256,0.00047462079,0.002279706,0.000035517834,0.00115944,0.0013667234,0.6364155,0.0015404538,0.16474788,0.00070591737],"about_ca_topic_score_codex":0.0017416724,"about_ca_topic_score_gemma":0.0028476864,"teacher_disagreement_score":0.60050136,"about_ca_system_score_codex":0.0006677393,"about_ca_system_score_gemma":0.0031602536,"threshold_uncertainty_score":0.99849087},"labels":[],"label_agreement":null},{"id":"W4200186760","doi":"10.1016/s1470-2045(21)00719-1","title":"Radiographic progression-free survival in the ACIS trial for prostate cancer","year":2021,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prednisone; Abiraterone acetate; Placebo; Clinical endpoint; Prostate cancer; Internal medicine; Enzalutamide; Oncology; Progression-free survival; Surgery; Randomized controlled trial; Cancer; Androgen deprivation therapy; Pathology; Chemotherapy","score_opus":0.11843179758308021,"score_gpt":0.4310193453638538,"score_spread":0.3125875477807736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200186760","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010042221,0.010394831,0.0000024695332,0.9681808,0.0020234517,0.0066649388,0.00037524576,0.000043255215,0.0022727917],"genre_scores_gemma":[0.0038097869,0.027574956,0.00041136704,0.8573744,0.062896386,0.028742062,0.00302659,0.00020334423,0.015961073],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99637306,0.0010725249,0.00040372866,0.00052298215,0.0006563585,0.0009713744],"domain_scores_gemma":[0.9968022,0.0015782363,0.00021649673,0.0011749323,0.00017776935,0.000050350955],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0020787627,0.0003320501,0.001257897,0.00017956764,0.00018222818,0.000054872507,0.0008916683,0.0006977667,0.00013875817],"category_scores_gemma":[0.0002788241,0.00014949267,0.00032605158,0.0005623079,0.00043642565,0.000031251933,0.00016412322,0.002558573,0.00000620018],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0376269,0.00019459685,0.0013193557,0.00046994517,0.00038850834,0.0013930477,0.0009552182,5.303238e-7,0.000016475859,0.000038214865,0.94501746,0.0125797605],"study_design_scores_gemma":[0.0910712,0.0019442649,0.00064710295,0.00025915928,0.00030763762,0.000061281185,0.00016469702,0.00000910785,0.000029025938,0.0009757341,0.9043673,0.00016343515],"about_ca_topic_score_codex":0.00018351787,"about_ca_topic_score_gemma":0.0005226428,"teacher_disagreement_score":0.11080636,"about_ca_system_score_codex":0.00035019073,"about_ca_system_score_gemma":0.0014380867,"threshold_uncertainty_score":0.99974257},"labels":[],"label_agreement":null},{"id":"W4200295032","doi":"10.1097/ju.0000000000001785.02","title":"Editorial Comment","year":2021,"lang":"es","type":"editorial","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Prostate cancer; Medicine; Adverse effect; Library science; General surgery; Family medicine; Gynecology; Cancer; Internal medicine","score_opus":0.01794646987382783,"score_gpt":0.3362784833135211,"score_spread":0.3183320134396933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200295032","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000616716,0.025894238,0.000018244624,0.036687966,0.93592095,0.00024896918,0.000048783106,0.000005155163,0.000558975],"genre_scores_gemma":[0.0024397494,0.05024914,0.000013004151,0.00057059736,0.9453121,0.0000041183725,0.00006653715,0.00004531593,0.0012994559],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952308,0.0012628142,0.00092063734,0.00018897273,0.0017892619,0.0006075116],"domain_scores_gemma":[0.9933264,0.003227285,0.0009536891,0.00048375464,0.0017254641,0.000283359],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0028657182,0.00035467176,0.0011467565,0.00021493432,0.00020127435,0.000047446243,0.0006974553,0.00097078655,0.0006674361],"category_scores_gemma":[0.0013632328,0.00019041114,0.00039573517,0.00019971757,0.00045641905,0.00006163091,0.00026408548,0.003986486,0.00008241532],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009240854,0.0003566535,0.00008992931,0.00010757029,0.0017250592,0.00052726804,0.00051726,0.00001132431,0.0005439124,0.000018679772,0.9857549,0.0011065808],"study_design_scores_gemma":[0.006773706,0.005992984,0.000043838325,0.00018926752,0.0021869561,0.00023895765,0.00024463426,0.0000041009284,0.00019308944,0.0001486137,0.9838495,0.00013433321],"about_ca_topic_score_codex":0.000062494546,"about_ca_topic_score_gemma":0.000005977281,"teacher_disagreement_score":0.03611737,"about_ca_system_score_codex":0.0004060803,"about_ca_system_score_gemma":0.0031251733,"threshold_uncertainty_score":0.99831134},"labels":[],"label_agreement":null},{"id":"W4200341258","doi":"10.1097/ju.0000000000002340.02","title":"Editorial Comment","year":2021,"lang":"es","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"","score_opus":0.02371403833183591,"score_gpt":0.341634994724132,"score_spread":0.3179209563922961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200341258","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16577207,0.085760206,0.00009449568,0.5034092,0.2407947,0.00024767919,0.000018691906,0.0000073453593,0.0038956197],"genre_scores_gemma":[0.7709092,0.028617552,0.000025302055,0.0033531801,0.19591229,0.0000010621617,0.0000045736165,0.000017243001,0.0011596446],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983711,0.0005328575,0.00033328382,0.00006555653,0.00042470093,0.0002724587],"domain_scores_gemma":[0.9984402,0.0005002546,0.00021067384,0.0002050397,0.0005128261,0.00013101178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009842665,0.00009829814,0.0003178242,0.000060148363,0.000091474096,0.000017654567,0.00017823599,0.00012198506,0.00055007736],"category_scores_gemma":[0.00020842694,0.000052121504,0.000120643635,0.00012152831,0.00018615637,0.000035190555,0.0000964353,0.0007514838,0.00006891299],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004565001,0.00041383848,0.0030757762,0.000044069482,0.0008781541,0.00076540845,0.00071721396,0.00001974415,0.008047558,0.00032367415,0.977282,0.0038675517],"study_design_scores_gemma":[0.0043042437,0.0026579716,0.0019952692,0.00004605855,0.0007067238,0.000937708,0.00030317067,0.000013320342,0.003016766,0.00045572675,0.98551553,0.000047481946],"about_ca_topic_score_codex":0.000010626765,"about_ca_topic_score_gemma":0.000001556604,"teacher_disagreement_score":0.6051371,"about_ca_system_score_codex":0.000091826754,"about_ca_system_score_gemma":0.00072093296,"threshold_uncertainty_score":0.6022961},"labels":[],"label_agreement":null},{"id":"W4200342108","doi":"10.1016/j.eururo.2021.11.020","title":"Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN","year":2021,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate-specific antigen; Prostate cancer; Placebo; Antiandrogen; Urology; Hazard ratio; Androgen deprivation therapy; Internal medicine; Confidence interval; Oncology; Cancer; Pathology","score_opus":0.06073126657511658,"score_gpt":0.3453950488027126,"score_spread":0.28466378222759603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200342108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489194,0.0029153023,0.00008557508,0.0012391151,0.00009947961,0.0004275269,0.0000071914487,0.000022153,0.00031168704],"genre_scores_gemma":[0.9967061,0.0021817565,0.00032273435,0.00042111365,0.000084511266,0.0000099742065,0.00011551253,0.000030470523,0.00012781692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824476,0.0005821003,0.00039552836,0.00037811944,0.00014700966,0.0002524826],"domain_scores_gemma":[0.99921983,0.00025868876,0.0000666061,0.00025265035,0.000080664766,0.000121546705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009770762,0.00011270985,0.0002836779,0.00016855911,0.000047556587,0.000014999291,0.00005966586,0.000054671647,0.000065655455],"category_scores_gemma":[0.00023069639,0.00010018889,0.00007070199,0.00025607727,0.00006947072,0.000054775523,0.00007818295,0.00017446361,0.000025702104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007619139,0.00018471216,0.88761026,0.000015138946,0.00007868564,0.002058772,0.00078732194,0.000018531568,0.0421041,0.00002130765,0.00004243587,0.05945961],"study_design_scores_gemma":[0.003559017,0.0013213636,0.98792326,0.000056136854,0.000014040594,0.000046538782,0.000038863436,0.000035742924,0.0049253595,0.00002510334,0.0019725824,0.00008197229],"about_ca_topic_score_codex":0.0000034336244,"about_ca_topic_score_gemma":0.00003916884,"teacher_disagreement_score":0.10031303,"about_ca_system_score_codex":0.000037570506,"about_ca_system_score_gemma":0.000067437155,"threshold_uncertainty_score":0.40855843},"labels":[],"label_agreement":null},{"id":"W4200388798","doi":"10.1158/1078-0432.ccr-21-1090","title":"The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma; National Institute for Health and Care Research; Prostate Cancer Foundation of Australia; Pfizer; National Cancer Institute; National Institutes of Health; Conquer Cancer Foundation; Prostate Cancer Foundation","keywords":"Enzalutamide; Prostate cancer; Multivariate analysis; Clinical trial; Outcome (game theory); Cancer; Phases of clinical research","score_opus":0.19438336259119904,"score_gpt":0.5706155863813225,"score_spread":0.37623222379012344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200388798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890631,0.0035707948,0.0000024906878,0.0032603052,0.00045607032,0.0032711546,0.00014885428,0.00001442955,0.00021281297],"genre_scores_gemma":[0.990914,0.0028122368,0.000010418139,0.000048993392,0.00019131828,0.0013991495,0.000028174592,0.000036153582,0.004559552],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99402505,0.0017562277,0.0011164958,0.00065128633,0.0017323813,0.00071857753],"domain_scores_gemma":[0.9928045,0.004902367,0.00029758867,0.0011371974,0.0005791147,0.00027918819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033670515,0.00026697048,0.0013727988,0.00020879682,0.00037225167,0.000049660306,0.00031866436,0.00014005376,0.00014315998],"category_scores_gemma":[0.0010710211,0.00010818077,0.0010626623,0.0022982934,0.00085026404,0.00004617679,0.00019279582,0.0007918705,0.000003345547],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35604805,0.001927149,0.5237157,0.00015486126,0.012706862,0.0002289762,0.000521809,0.00014094666,0.0043945913,0.000014435606,0.00012084667,0.1000258],"study_design_scores_gemma":[0.60446346,0.060467552,0.1722972,0.0013472221,0.012299208,0.0000038037442,0.00056913804,0.001880503,0.14130776,0.000021412234,0.0049344003,0.00040834333],"about_ca_topic_score_codex":0.0020119387,"about_ca_topic_score_gemma":0.0017054486,"teacher_disagreement_score":0.35141847,"about_ca_system_score_codex":0.0006804554,"about_ca_system_score_gemma":0.0017898834,"threshold_uncertainty_score":0.4411484},"labels":[],"label_agreement":null},{"id":"W4200390731","doi":"10.1016/j.ejca.2021.11.026","title":"Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Placebo; Abiraterone acetate; Prednisone; Post-hoc analysis; Prostate cancer; Urology; Internal medicine; Gastroenterology; Androgen deprivation therapy; Enzalutamide; Cancer; Pathology","score_opus":0.023766139638104037,"score_gpt":0.3155620819471137,"score_spread":0.2917959423090097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200390731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972483,0.0018793056,0.0000030745048,0.0000767467,0.000056074743,0.00040272635,0.00031351537,0.0000015277624,0.000018735183],"genre_scores_gemma":[0.9992203,0.00049925904,0.00006165081,0.000017422253,0.000022392813,0.0000048119787,0.000009771349,0.00002216909,0.00014218208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818814,0.00039073173,0.00052462635,0.00015540764,0.0005806639,0.00016045923],"domain_scores_gemma":[0.99796516,0.00003813688,0.00058902404,0.00018003868,0.0011391008,0.00008855432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003649354,0.00013809584,0.0006290443,0.00024859316,0.00002353427,0.000013167693,0.00007157899,0.000012796905,0.000054560693],"category_scores_gemma":[0.000038612598,0.00008077664,0.00017358536,0.0006984671,0.00012805744,0.00016181114,0.00005446216,0.00016664741,1.260199e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010171651,0.00047319417,0.95675796,0.000059364895,0.008137656,0.00030852327,0.01088541,0.0038616539,0.005618076,3.9253402e-7,0.000031701416,0.0036943848],"study_design_scores_gemma":[0.013846425,0.0030852172,0.9772885,0.00035172145,0.0018615728,0.0000036780443,0.0010698234,0.00003780792,0.0023799487,4.3973972e-7,0.0000054720913,0.00006941291],"about_ca_topic_score_codex":0.0003682152,"about_ca_topic_score_gemma":0.0013575763,"teacher_disagreement_score":0.020530488,"about_ca_system_score_codex":0.00019245943,"about_ca_system_score_gemma":0.0008013849,"threshold_uncertainty_score":0.3293976},"labels":[],"label_agreement":null},{"id":"W4200475073","doi":"10.1016/j.jbc.2021.101556","title":"Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity","year":2021,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Enzalutamide; Prostate cancer; Cancer research; Biology; SOX2; Androgen receptor; LNCaP; Vimentin; Prostate; Cancer; Cancer cell; TMPRSS2; Transcription factor; Internal medicine; Medicine; Immunohistochemistry; Immunology; Gene; Genetics; Disease","score_opus":0.03170150693655574,"score_gpt":0.3203698710191146,"score_spread":0.2886683640825589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200475073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98715967,0.009622751,0.000008428903,0.0022146814,0.000037710728,0.00011544997,0.00006261874,0.000009968764,0.00076869526],"genre_scores_gemma":[0.99356407,0.0038233653,0.00028286598,0.00012414536,0.00017182529,0.000012590429,0.000029474071,0.000008855725,0.0019827988],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99864024,0.00007223735,0.0005046912,0.0002168257,0.000255216,0.00031077742],"domain_scores_gemma":[0.99897635,0.00018635656,0.0002347288,0.000084852574,0.00029643197,0.00022126753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003851771,0.00014222215,0.0004250142,0.000024351135,0.00004198536,0.000023293402,0.000091134294,0.0001355503,0.00028087277],"category_scores_gemma":[0.000920411,0.0000903982,0.00012028066,0.00020995614,0.00013662568,0.000047493857,0.000043296553,0.00059839356,0.0000011859842],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016337922,0.0003887658,0.053956434,0.00031494143,0.00007743662,0.0025940898,0.00011249878,0.0000033254173,0.93886936,0.0000019525207,0.001357,0.00069038844],"study_design_scores_gemma":[0.0033495426,0.00015906831,0.0055025676,0.00067674095,0.0000318052,0.00015518082,0.0002410312,0.000026440084,0.98537266,0.000056274166,0.0043199765,0.00010871444],"about_ca_topic_score_codex":0.000006075022,"about_ca_topic_score_gemma":0.0000054698257,"teacher_disagreement_score":0.048453867,"about_ca_system_score_codex":0.00026069657,"about_ca_system_score_gemma":0.000500842,"threshold_uncertainty_score":0.36863315},"labels":[],"label_agreement":null},{"id":"W4200601466","doi":"10.3390/jpm12010008","title":"Oncological Response and Predictive Biomarkers for the Checkpoint Inhibitors in Castration-Resistant Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"Journal of Personalized Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Meta-analysis; Oncology; Internal medicine; Cancer; Bioinformatics; Biology","score_opus":0.17232887372998731,"score_gpt":0.4605737321403323,"score_spread":0.288244858410345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200601466","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027121989,0.97760516,0.000020956932,0.015287898,0.000055016477,0.006739994,0.00025392423,0.000004052593,0.000005847298],"genre_scores_gemma":[0.000054387903,0.99668586,0.00024648968,0.00036702817,0.000083816456,0.0015700796,0.000057966117,0.000030692834,0.0009036508],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9944946,0.0015981451,0.0023099424,0.00041209627,0.00086749974,0.00031768734],"domain_scores_gemma":[0.99306345,0.0038652716,0.0017965394,0.0002783803,0.00067768246,0.0003186889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007844748,0.0004980293,0.01065075,0.000697954,0.000106027495,0.00003378558,0.0001399017,0.00013148539,0.00021096619],"category_scores_gemma":[0.0032481928,0.00019637583,0.0019289999,0.0013142385,0.00052392646,0.000075194504,0.000046836874,0.0006045215,2.1554617e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027463841,0.00013947894,0.000005744832,0.67339224,0.31775743,0.000955488,0.0010461076,6.663018e-7,0.000012559653,0.00000814861,0.0009960437,0.0029397293],"study_design_scores_gemma":[0.0029416853,0.0015912186,0.000017620168,0.12854697,0.8375608,0.0008164313,0.0013593816,0.00001524233,9.3946505e-7,0.0000068208587,0.026999777,0.0001431354],"about_ca_topic_score_codex":0.00005228063,"about_ca_topic_score_gemma":0.00003767091,"teacher_disagreement_score":0.5448452,"about_ca_system_score_codex":0.00058193813,"about_ca_system_score_gemma":0.0016647672,"threshold_uncertainty_score":0.80079734},"labels":[],"label_agreement":null},{"id":"W4205173478","doi":"10.2217/fon-2021-1096","title":"A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Exelixis","keywords":"Cabozantinib; Medicine; Atezolizumab; Prostate cancer; Enzalutamide; Oncology; Internal medicine; Clinical trial; Cancer; Nivolumab; Immunotherapy; Androgen receptor","score_opus":0.057886474600819124,"score_gpt":0.3914232047436411,"score_spread":0.333536730142822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205173478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849012,0.0023650108,0.0000031737638,0.00066271255,0.00040163685,0.010246527,0.0005251385,0.000015722455,0.00087886455],"genre_scores_gemma":[0.99411684,0.00031873505,0.00027814138,0.00013372111,0.00006222759,0.0036918246,0.00035192916,0.000040168215,0.0010064116],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974299,0.00046978155,0.0006429495,0.00047692488,0.0005393412,0.0004410919],"domain_scores_gemma":[0.99863726,0.00025131414,0.00039333774,0.00031819925,0.0002657612,0.00013411044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008006791,0.00028089387,0.0014014331,0.0002470112,0.00018252722,0.00002384795,0.00024365632,0.000057610137,0.0007242298],"category_scores_gemma":[0.000026211053,0.00018745866,0.000061205195,0.00053884566,0.00013609692,0.00014249979,0.00014994136,0.00046629863,0.0000014125483],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95604444,0.023296535,0.0012160551,0.000043895438,0.0015326635,0.00036484003,0.008037047,0.0000175712,0.0023945104,0.00007664809,0.0005511086,0.006424685],"study_design_scores_gemma":[0.9324665,0.051189624,0.0058668368,0.000022817607,0.00030460622,0.000007738914,0.0054778373,0.00007845699,0.00018507053,0.0000060391585,0.0042082905,0.00018615316],"about_ca_topic_score_codex":0.0019225505,"about_ca_topic_score_gemma":0.0036252849,"teacher_disagreement_score":0.027893089,"about_ca_system_score_codex":0.0008830553,"about_ca_system_score_gemma":0.0021884774,"threshold_uncertainty_score":0.7929808},"labels":[],"label_agreement":null},{"id":"W4205339646","doi":"10.1016/j.eururo.2021.12.038","title":"Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer","year":2022,"lang":"en","type":"editorial","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Centre Hospitalier de l’Université de Montréal; University of British Columbia; Nova Scotia Cancer Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Biomarker; Hormone; Cancer; Prostate; Oncology; Pathology; Internal medicine; Biology","score_opus":0.07781672848737231,"score_gpt":0.41893051623557426,"score_spread":0.34111378774820195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205339646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6714579,0.026116354,0.000043100747,0.00522498,0.28230798,0.003578148,0.007034627,0.00019399186,0.0040429416],"genre_scores_gemma":[0.7377029,0.013986756,0.0009986229,0.0028889067,0.23540588,0.0011242571,0.0054922123,0.00064816687,0.0017522858],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99517256,0.0018835431,0.00072783,0.0009653975,0.00065041805,0.0006002269],"domain_scores_gemma":[0.9956427,0.002673176,0.00062984554,0.0004523301,0.00043527246,0.000166667],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025997479,0.00042937679,0.001157449,0.00037440268,0.00018290673,0.000020930487,0.00018767983,0.00008296254,0.00014095241],"category_scores_gemma":[0.0030954352,0.00035540425,0.00015674028,0.00023268165,0.0005469257,0.000047358633,0.00045512422,0.001316971,0.000017378388],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027694428,0.002289895,0.077699095,0.002286544,0.0050720223,0.008076068,0.0051146727,0.000120843375,0.022485852,0.00043246994,0.79637533,0.052352756],"study_design_scores_gemma":[0.03272611,0.021889538,0.12070001,0.00054374896,0.003936413,0.00022329153,0.0011321678,0.0005725516,0.0016046056,0.0002726212,0.81455064,0.0018482807],"about_ca_topic_score_codex":0.001284926,"about_ca_topic_score_gemma":0.00004945735,"teacher_disagreement_score":0.066245034,"about_ca_system_score_codex":0.00022312393,"about_ca_system_score_gemma":0.0006369476,"threshold_uncertainty_score":0.9998898},"labels":[],"label_agreement":null},{"id":"W4205524306","doi":"10.1016/s1470-2045(21)00723-3","title":"Radiographic progression-free survival in the ACIS trial for prostate cancer – Authors' reply","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Astellas Pharma Canada; Bayer; AstraZeneca; Bristol-Myers Squibb","keywords":"Prednisone; Prostate cancer; Abiraterone acetate; Enzalutamide; Placebo; Clinical endpoint; Acis","score_opus":0.1013740712609857,"score_gpt":0.44420525823761475,"score_spread":0.34283118697662907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205524306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6233455,0.008714954,0.000016499738,0.35643893,0.001715375,0.0049205315,0.00013353047,0.00006737249,0.004647302],"genre_scores_gemma":[0.938009,0.015044571,0.0017053426,0.012153272,0.00831381,0.012777332,0.00034315983,0.000094890514,0.011558595],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978782,0.00064306747,0.00026689644,0.000317914,0.00034036257,0.00055356853],"domain_scores_gemma":[0.99816287,0.000772751,0.0000939528,0.00075041637,0.0001508585,0.00006913886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024195474,0.0001389581,0.0005311608,0.000074340656,0.00017079756,0.000030155647,0.0003698221,0.00011425976,0.00008383333],"category_scores_gemma":[0.0005094532,0.00006439413,0.00014111874,0.00057231006,0.00024250154,0.00003585829,0.00010285095,0.00045893542,0.000004358198],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39650828,0.0025896206,0.08699053,0.0006624054,0.0009979515,0.0019277639,0.014145947,0.000012926359,0.0025172608,0.0045910203,0.29404205,0.19501425],"study_design_scores_gemma":[0.2122448,0.003996174,0.024713872,0.00018027537,0.00025941746,0.00012309519,0.0014933276,0.00012215663,0.0012790374,0.007269873,0.74812067,0.0001973366],"about_ca_topic_score_codex":0.000113531176,"about_ca_topic_score_gemma":0.0006792443,"teacher_disagreement_score":0.45407858,"about_ca_system_score_codex":0.00015729583,"about_ca_system_score_gemma":0.00086372823,"threshold_uncertainty_score":0.26259166},"labels":[],"label_agreement":null},{"id":"W4205627393","doi":"10.1002/1097-0142(20000615)88:12+<3009::aid-cncr17>3.3.co;2-5","title":"Hormone therapy for patients with prostate carcinoma","year":2000,"lang":"en","type":"review","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Androgen; Hormonal therapy; Ablation; Prostate; Prostate cancer; Population; Oncology; Hormone therapy; Urology; Internal medicine; Cancer; Hormone; Breast cancer","score_opus":0.057243424219424646,"score_gpt":0.3786345254050621,"score_spread":0.32139110118563746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205627393","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00090789876,0.9911489,8.5223115e-7,0.00006570766,0.00009584783,0.0064375848,0.00067337044,0.000037143727,0.00063271396],"genre_scores_gemma":[0.000057031048,0.98254895,0.000057818528,0.000075959375,0.0003125882,0.004902658,0.0012536184,0.000119850396,0.010671524],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855155,0.000025649428,0.00025424463,0.00044633934,0.00028082245,0.00044142216],"domain_scores_gemma":[0.9991516,0.000043236287,0.00011768121,0.00034057858,0.00017603584,0.00017090417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000047456848,0.0003794408,0.0011661127,0.00012750684,0.000080376565,0.000023461522,0.00010682089,0.0001605667,0.00023820992],"category_scores_gemma":[0.000003855015,0.00020061567,0.00026881567,0.0002426827,0.00008861175,0.000044941466,0.0000135442315,0.00022910285,0.000026953416],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001805857,0.00016744195,0.0007377697,0.005431962,0.0003937253,0.000016144742,0.00005327452,6.0262444e-8,8.484217e-8,0.0000011012628,0.006848392,0.98454416],"study_design_scores_gemma":[0.005679175,0.0016610781,0.00084286736,0.004133516,0.0006067853,0.0000034191507,0.0000022261825,5.2689427e-7,0.000002518051,0.000004040785,0.9868208,0.00024300271],"about_ca_topic_score_codex":0.000027334274,"about_ca_topic_score_gemma":0.000002138867,"teacher_disagreement_score":0.9843012,"about_ca_system_score_codex":0.00042020943,"about_ca_system_score_gemma":0.0012241022,"threshold_uncertainty_score":0.818087},"labels":[],"label_agreement":null},{"id":"W4205721076","doi":"10.1111/j.1442-2042.2012.03066.x","title":"IJU this issue","year":2012,"lang":"en","type":"article","venue":"International Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Tolerability; Androgen deprivation therapy; Testosterone (patch); Management of prostate cancer; Androgen; Castration; Androgen receptor; Gonadotropin-releasing hormone; Internal medicine; Hormone; Endocrinology; Oncology; Cancer; Adverse effect; Luteinizing hormone","score_opus":0.02895887039965204,"score_gpt":0.3824323188988153,"score_spread":0.35347344849916323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205721076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8455279,0.010586336,0.00038243193,0.08749207,0.00618501,0.00012752405,0.000008004011,0.000015352749,0.04967541],"genre_scores_gemma":[0.9921455,0.0005029653,0.00030505288,0.0014746094,0.0020982034,0.0000010722845,0.0000038407557,0.000005807564,0.0034629789],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993473,0.000025478661,0.0001690357,0.000037129612,0.0002833046,0.0001377239],"domain_scores_gemma":[0.99937946,0.000050872353,0.00009036071,0.000046602294,0.00032028617,0.000112396236],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020584834,0.00004434466,0.000111912836,0.00015475348,0.000011671773,0.0000057149095,0.00011179855,0.000043208413,0.0024317517],"category_scores_gemma":[0.000084289175,0.000029941075,0.0000706971,0.00003317033,0.000046479538,0.00010577123,0.000026883747,0.00017538376,0.00019223495],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069644903,0.0015862505,0.65898806,0.000021759171,0.0025820194,0.0019727142,0.0021400603,0.000011501525,0.023548177,0.002919642,0.17933708,0.11992821],"study_design_scores_gemma":[0.0027905318,0.00075824565,0.054733496,0.000014531265,0.00007523755,0.003888174,0.000043556895,0.000019381878,0.0041686855,0.00029618153,0.9331644,0.000047588564],"about_ca_topic_score_codex":0.0000061784503,"about_ca_topic_score_gemma":3.8127033e-7,"teacher_disagreement_score":0.7538273,"about_ca_system_score_codex":0.000072240364,"about_ca_system_score_gemma":0.00007730685,"threshold_uncertainty_score":0.99848014},"labels":[],"label_agreement":null},{"id":"W4205889656","doi":"10.3390/pharmaceutics14010195","title":"Towards Complete Tumor Resection: Novel Dual-Modality Probes for Improved Image-Guided Surgery of GRPR-Expressing Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"Pharmaceutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TRIUMF","funders":"KWF Kankerbestrijding","keywords":"Prostate cancer; Medicine; Resection; Modality (human–computer interaction); Radiology; Cancer; Surgery; Computer science; Internal medicine; Artificial intelligence","score_opus":0.20122270635383582,"score_gpt":0.4419146509168225,"score_spread":0.2406919445629867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205889656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96956384,0.004111169,0.0006472043,0.014796371,0.0013408305,0.0049582003,0.0036885147,0.00017222733,0.0007216446],"genre_scores_gemma":[0.99171156,0.0005198923,0.0026283585,0.0006680797,0.00036476005,0.0018191227,0.00035173306,0.00007791672,0.0018585628],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979683,0.00009442894,0.00051135925,0.00039328184,0.0004892016,0.0005434037],"domain_scores_gemma":[0.99859893,0.00017441064,0.00024219649,0.00028028947,0.0005145132,0.00018965155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008890216,0.00021469753,0.0004957266,0.00017605064,0.0003970185,0.000033164386,0.000112474685,0.000030600277,0.00026627077],"category_scores_gemma":[0.00011567583,0.00018799149,0.00021156235,0.00041184964,0.00020175744,0.00013068512,0.00021972183,0.0003727921,0.0000010443877],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054088254,0.0008294354,0.008544559,0.0024402512,0.00038721634,0.00003868262,0.0008387235,0.000108582266,0.9671877,0.00003140143,0.005750482,0.008434142],"study_design_scores_gemma":[0.009621274,0.00047076738,0.003066525,0.00015568509,0.00042675858,0.00010966601,0.0004326965,0.022002414,0.8823814,0.00025422062,0.080719076,0.00035954887],"about_ca_topic_score_codex":0.00029943197,"about_ca_topic_score_gemma":0.0000070459855,"teacher_disagreement_score":0.08480633,"about_ca_system_score_codex":0.00047584646,"about_ca_system_score_gemma":0.0010293899,"threshold_uncertainty_score":0.76660705},"labels":[],"label_agreement":null},{"id":"W4205918537","doi":"10.1038/s41572-020-00243-0","title":"Prostate cancer","year":2021,"lang":"en","type":"review","venue":"Nature Reviews Disease Primers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Prostate cancer; Medicine; Prostatectomy; Oncology; Cancer; Internal medicine; Radiation therapy; Androgen deprivation therapy; Olaparib; PTEN; Cancer research; Biology; PI3K/AKT/mTOR pathway","score_opus":0.06710718438827394,"score_gpt":0.4623833379955043,"score_spread":0.39527615360723034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205918537","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[4.6579268e-7,0.99129176,3.8129892e-7,0.0005500575,0.000573674,0.0060606594,0.00033881614,0.000075047945,0.0011091555],"genre_scores_gemma":[2.4529584e-7,0.9804385,0.00016604149,0.000534172,0.0005896186,0.0024615398,0.0023986935,0.00013932533,0.013271885],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996468,0.00039822867,0.0008072451,0.0010226528,0.0006458768,0.0006580157],"domain_scores_gemma":[0.9972242,0.000075652366,0.00039407727,0.0010467663,0.00022286708,0.0010364462],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035421996,0.0008022293,0.0039309105,0.0002571766,0.00010771195,0.00006109505,0.0002690853,0.0006385067,0.00112408],"category_scores_gemma":[0.00030857636,0.00048486792,0.002213688,0.0010500398,0.000121646524,0.00007818627,0.00015764756,0.0021896039,0.00034659886],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042460124,0.00014447291,0.000035348563,0.096792914,0.00066699,0.00050820044,0.000010798588,1.4626251e-8,1.7575725e-7,0.000029053002,0.03166218,0.8701074],"study_design_scores_gemma":[0.0004683487,0.000027895867,0.00001444401,0.10773774,0.0077918563,0.00002367817,0.0000026780508,2.6279665e-7,0.0000010187371,0.000003942584,0.8835352,0.00039290168],"about_ca_topic_score_codex":0.0000072955213,"about_ca_topic_score_gemma":0.000001365823,"teacher_disagreement_score":0.8697145,"about_ca_system_score_codex":0.0007905436,"about_ca_system_score_gemma":0.0048745093,"threshold_uncertainty_score":0.999789},"labels":[],"label_agreement":null},{"id":"W4205940871","doi":"10.1016/j.ijrobp.2022.01.002","title":"Determining Planning Priorities for SABR for Oligometastatic Disease: A Secondary Analysis of the SABR-COMET Phase II Randomized Trial","year":2022,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Positive Living North; Nova Scotia Health Authority; London Health Sciences Centre","funders":"Cancer Research UK","keywords":"SABR volatility model; Medicine; Randomized controlled trial; Confidence interval; Adverse effect; Malignancy; Surgery; Nuclear medicine; Internal medicine; Mathematics","score_opus":0.04555066416876718,"score_gpt":0.41682903894162515,"score_spread":0.37127837477285797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205940871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97722465,0.0014659426,0.013108207,0.002946745,0.0021207435,0.0017652977,0.0012890009,0.000012599529,0.000066839886],"genre_scores_gemma":[0.99565876,0.00013726176,0.0017866956,0.0004556117,0.00091382617,0.00040020436,0.00041938171,0.000019825766,0.00020845882],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979814,0.00038840884,0.0008804283,0.00017880212,0.00036765044,0.0002032727],"domain_scores_gemma":[0.9956239,0.0023024145,0.0012856524,0.00013352315,0.0005590683,0.00009543293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015154303,0.00014587921,0.00094749656,0.00045491048,0.00026732948,0.000016917742,0.00033300347,0.00005666607,0.000092463524],"category_scores_gemma":[0.0010293005,0.00010188088,0.0009948838,0.00035706905,0.0002293039,0.00012209183,0.00010373789,0.00030407635,1.8402967e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8455165,0.0015908455,0.021759942,0.00006839931,0.016346598,0.000026926095,0.0025770504,0.003986708,0.0017529813,0.0033853177,0.0010913445,0.10189736],"study_design_scores_gemma":[0.9350925,0.006148623,0.0018648647,0.000053801086,0.005308883,0.000025817832,0.0003789979,0.02765074,0.00082019874,0.008125213,0.01437817,0.00015215269],"about_ca_topic_score_codex":0.000004103728,"about_ca_topic_score_gemma":7.9088045e-7,"teacher_disagreement_score":0.1017452,"about_ca_system_score_codex":0.0005688934,"about_ca_system_score_gemma":0.0013960889,"threshold_uncertainty_score":0.41545817},"labels":[],"label_agreement":null},{"id":"W4205960983","doi":"10.21037/exrna-21-29","title":"How do androgens affect prostate cancer extracellular vesicles?","year":2022,"lang":"en","type":"article","venue":"ExRNA","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Prostate cancer; Extracellular vesicles; Affect (linguistics); Extracellular; Prostate; Vesicle; Chemistry; Internal medicine; Medicine; Oncology; Biology; Cancer; Cell biology; Biochemistry; Psychology; Communication","score_opus":0.027522401550559926,"score_gpt":0.31125873567085277,"score_spread":0.28373633412029287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205960983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95345163,0.03603762,0.0000069364496,0.007903358,0.00026220578,0.0008038173,0.00008257138,0.000076683165,0.0013751673],"genre_scores_gemma":[0.9439496,0.0009520951,0.00006143818,0.0001235899,0.0001732017,0.0004444987,0.000052696076,0.000032993434,0.05420993],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987235,0.0000667366,0.00009479359,0.00028601396,0.00045518493,0.0003737526],"domain_scores_gemma":[0.9994675,0.000024480656,0.000045004894,0.00025861783,0.000044043,0.00016035879],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000192016,0.00012923357,0.0001946268,0.00009195939,0.00025952273,0.000051097675,0.00009133832,0.000026832136,0.0011202341],"category_scores_gemma":[0.000013891878,0.0001022842,0.00009408271,0.00027425413,0.00006024283,0.000069309026,0.00010231101,0.0002773945,0.000022314698],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003177297,0.0011414266,0.24002923,0.0005023328,0.00090321584,0.0056124786,0.005226441,0.000100011304,0.4840932,0.00062497146,0.0752484,0.183341],"study_design_scores_gemma":[0.009318776,0.001937688,0.02351564,0.00011220096,0.00024310323,0.0002640539,0.0020793467,0.00029869066,0.1539677,0.00035096987,0.80741745,0.00049439224],"about_ca_topic_score_codex":0.00004626259,"about_ca_topic_score_gemma":0.000004561379,"teacher_disagreement_score":0.73216903,"about_ca_system_score_codex":0.00028581696,"about_ca_system_score_gemma":0.00020086148,"threshold_uncertainty_score":0.9997929},"labels":[],"label_agreement":null},{"id":"W4206146537","doi":"10.1097/ju.0000000000002384","title":"Low Serum Testosterone in Men with Newly Diagnosed Androgen-Deprivation Therapy-Naïve Prostate Cancer and Its Relationship to Cardiovascular Risk Factors: A RADICAL-PC Substudy","year":2022,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute; University of British Columbia; Grand River Hospital; Niagara Health System; Université de Montréal; Université Laval; Princess Margaret Cancer Centre; Impact; Centre hospitalier universitaire de Québec; McGill University Health Centre; University of Ottawa; McGill University; Sunnybrook Health Science Centre; Jewish General Hospital; McMaster University; Queen's University; Ottawa Hospital; Health Sciences Centre; Western University; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Testosterone (patch); Internal medicine; Odds ratio; Framingham Risk Score; Body mass index; Endocrinology; Cancer; Oncology; Disease","score_opus":0.030956465084139427,"score_gpt":0.2864020547001923,"score_spread":0.2554455896160529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206146537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754647,0.017897319,0.000017825201,0.0055866977,0.000041984284,0.0009469299,0.000019146448,0.000006724472,0.000018675739],"genre_scores_gemma":[0.99415857,0.0053679366,0.000016715476,0.00020148655,0.00005165052,0.000071839364,0.0000043474865,0.000019446865,0.0001079896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984057,0.00054382667,0.00025836597,0.00014154527,0.00041231795,0.00023825273],"domain_scores_gemma":[0.99912894,0.00031992764,0.0001530167,0.0001743258,0.000105381856,0.00011841543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011213379,0.00011970458,0.0003338924,0.00020773875,0.00018537117,0.000009087974,0.0001126007,0.000038279268,0.0000504402],"category_scores_gemma":[0.00010325674,0.000066199114,0.00005711025,0.00037615813,0.00006478128,0.00007492015,0.00005955058,0.0005785468,0.000001478474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005745985,0.00022611211,0.9731669,0.0000123439795,0.0007302079,0.00022866038,0.0084247375,0.006035746,0.0006986685,0.0000033886388,0.0001574398,0.0045698197],"study_design_scores_gemma":[0.011840582,0.004878027,0.9785996,0.00002321534,0.00029451874,0.00026573014,0.0010432837,0.00017023296,0.0012910626,0.00007595738,0.001426734,0.00009105117],"about_ca_topic_score_codex":0.00020280234,"about_ca_topic_score_gemma":0.000046558624,"teacher_disagreement_score":0.01869389,"about_ca_system_score_codex":0.00016486627,"about_ca_system_score_gemma":0.00020762207,"threshold_uncertainty_score":0.26995215},"labels":[],"label_agreement":null},{"id":"W4206244400","doi":"10.5489/cuaj.7074","title":"2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) (full-text)","year":2021,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Centre Hospitalier de l’Université de Montréal; Université Laval; Canadian Urological Association; University of Alberta; Jewish General Hospital; McMaster University; Ontario Clinical Oncology Group; Dalhousie University; University of Toronto; McGill University Health Centre; University of British Columbia","funders":"Ipsen; Astellas Pharma; Bavarian Nordic; Eisai; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Guideline; Prostate cancer; Medicine; Oncology; Internal medicine; Castration; Gynecology; Cancer; Urology; Family medicine; Hormone; Pathology","score_opus":0.021859394940724686,"score_gpt":0.30269398383130874,"score_spread":0.28083458889058405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206244400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5488386,0.0056825154,0.00003978793,0.3976269,0.0023007777,0.0022155636,0.0018602005,0.00005957141,0.04137607],"genre_scores_gemma":[0.97933,0.0031350702,0.00089978863,0.007294243,0.0008075649,0.0001356378,0.00075776887,0.000046650875,0.0075932844],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946151,0.0006220128,0.0011905549,0.0006268773,0.0010505153,0.0018949762],"domain_scores_gemma":[0.9933941,0.00022584415,0.00067483075,0.0002914343,0.0019042349,0.0035095527],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019250804,0.0003796598,0.00076834107,0.00065846904,0.0007738656,0.00020130684,0.00028572013,0.00087457814,0.0073580123],"category_scores_gemma":[0.0008328948,0.0003303379,0.00033668554,0.0010018781,0.00009109507,0.00019111887,0.000043475557,0.001203439,0.00011527931],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00070385035,0.0003607772,0.77780503,0.0000762979,0.00254014,0.009546521,0.00045762205,0.0004351381,0.0020591198,0.0015300387,0.17520912,0.029276328],"study_design_scores_gemma":[0.0033229876,0.0009846273,0.44696033,0.00006770605,0.00045302455,0.00021587254,0.0004978475,0.00023945626,0.00008967816,0.00059254747,0.54621226,0.00036365679],"about_ca_topic_score_codex":0.40651026,"about_ca_topic_score_gemma":0.9011251,"teacher_disagreement_score":0.49461484,"about_ca_system_score_codex":0.020704921,"about_ca_system_score_gemma":0.013043603,"threshold_uncertainty_score":0.9999149},"labels":[],"label_agreement":null},{"id":"W4206405356","doi":"10.1016/j.clgc.2021.11.018","title":"Establishing metastatic prostate cancer quality indicators using a modified Delphi approach","year":2022,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Princess Margaret Cancer Centre; University of Toronto","funders":"Movember Foundation","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Delphi method; Quality (philosophy); Prostate; Internal medicine; Artificial intelligence","score_opus":0.5175260287163131,"score_gpt":0.568070829747509,"score_spread":0.05054480103119585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206405356","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037762786,0.98683333,0.000027334323,0.0001294666,0.0016665778,0.004737222,0.0012209076,0.0001689761,0.0014399244],"genre_scores_gemma":[0.00015328458,0.98662233,0.0012371897,0.00028019169,0.0019559315,0.004742106,0.0010349225,0.00030258985,0.0036714734],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99016833,0.00205939,0.0029857492,0.0019532747,0.0015091237,0.0013241088],"domain_scores_gemma":[0.9944871,0.0014879102,0.0015703687,0.0013035979,0.000172487,0.0009785133],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029462199,0.0010795309,0.004969942,0.0008109879,0.0005465792,0.00014507909,0.0008122798,0.0005528537,0.0016663801],"category_scores_gemma":[0.00055114744,0.0008078989,0.0020559265,0.0022170113,0.00055757165,0.00027324492,0.0009086055,0.0036628917,0.000018903085],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007523303,0.0013234952,0.00089659257,0.030510886,0.0031457962,0.0007785367,0.00029748637,0.000093747505,8.199946e-7,0.000009338509,0.0022478295,0.9599431],"study_design_scores_gemma":[0.003061463,0.00048173225,0.00010146832,0.0051417556,0.006524592,0.0001200642,0.00035320444,0.00023796881,0.0000011379285,0.00002732563,0.9829749,0.0009743765],"about_ca_topic_score_codex":0.0009106623,"about_ca_topic_score_gemma":0.000013180395,"teacher_disagreement_score":0.9807271,"about_ca_system_score_codex":0.001997011,"about_ca_system_score_gemma":0.008587887,"threshold_uncertainty_score":0.9994372},"labels":[],"label_agreement":null},{"id":"W4206450911","doi":"10.3390/cancers14020386","title":"Differential Gene Expression Profiles between N-Terminal Domain and Ligand-Binding Domain Inhibitors of Androgen Receptor Reveal Ralaniten Induction of Metallothionein by a Mechanism Dependent on MTF1","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; University of British Columbia","keywords":"Androgen receptor; Metallothionein; Domain (mathematical analysis); Terminal (telecommunication); Mechanism (biology); Cell biology; Ligand (biochemistry); Gene; Chemistry; Gene expression; RNF4; Receptor; Biology; Genetics; Biochemistry; Physics; Transcription factor; Computer science; Zinc finger","score_opus":0.02114181641118654,"score_gpt":0.2802541078661946,"score_spread":0.259112291455008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206450911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980332,0.00041572526,0.000045741708,0.0001480275,0.00020607967,0.00073086424,0.00033517912,0.00001743028,0.000067730994],"genre_scores_gemma":[0.9981514,0.00016907304,0.00042659938,0.000010321356,0.00015002249,0.00017280896,0.00033363074,0.000026422742,0.0005597066],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99841684,0.00013546455,0.00031251708,0.00032355267,0.0005719032,0.00023974745],"domain_scores_gemma":[0.9994227,0.000035365447,0.00020536825,0.00015965938,0.000042533906,0.0001343695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002492671,0.0001654416,0.0003957911,0.00021083216,0.00016764304,0.000008594514,0.000086208194,0.0000802497,0.00016103324],"category_scores_gemma":[0.000009915185,0.00013338603,0.00007993844,0.00017900998,0.0000971137,0.00005196503,0.00012381293,0.00022444582,0.0000011581993],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012531466,0.00005291211,0.0042374623,0.0001429189,0.00015379794,0.000018706294,0.0008935329,0.0000028501272,0.9907544,0.000029422672,0.00076154934,0.0016992997],"study_design_scores_gemma":[0.0032927606,0.0013930858,0.00034852445,0.00019749481,0.00009916577,0.000018241615,0.0012795083,0.0000034381458,0.9927607,0.0002236156,0.00026188046,0.00012157494],"about_ca_topic_score_codex":0.00009327771,"about_ca_topic_score_gemma":0.0000012150781,"teacher_disagreement_score":0.0038889379,"about_ca_system_score_codex":0.00080864935,"about_ca_system_score_gemma":0.00026793877,"threshold_uncertainty_score":0.54393244},"labels":[],"label_agreement":null},{"id":"W4206534973","doi":"10.1038/s41388-021-02135-3","title":"RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition","year":2022,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"CIHR Skin Research Training Centre; U.S. Department of Defense; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; U.S. Department of Health and Human Services; Government of Canada","keywords":"Biology; Prostate cancer; Cancer research; E2F; Transcriptome; Repressor; Transcription factor; Chromatin; Androgen receptor; E2F1; Retinoblastoma protein; Cell biology; Cancer; Gene; Genetics; Cell cycle; Gene expression","score_opus":0.03822302197447547,"score_gpt":0.359781736974808,"score_spread":0.3215587150003325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206534973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902159,0.0005388462,0.0000039916476,0.006636811,0.00012991324,0.001067575,0.00024488757,0.000026959458,0.0011351374],"genre_scores_gemma":[0.99544775,0.00008956971,0.00009713751,0.00043868247,0.000073617164,0.0009767611,0.00018172218,0.000017055156,0.0026777037],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986871,0.000094045594,0.0002187038,0.00031025193,0.0003945439,0.00029535082],"domain_scores_gemma":[0.99949753,0.00002393971,0.000036456964,0.00019392163,0.00009212382,0.00015600288],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033829408,0.00010966041,0.0001917071,0.00013433593,0.00015639205,0.000017791366,0.000045168465,0.000027735332,0.000981697],"category_scores_gemma":[0.000026024518,0.00009755268,0.000044891047,0.00043303313,0.00005065813,0.000050000424,0.00006750859,0.00021591742,0.000018668447],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006087908,0.0008975028,0.1424649,0.00019202848,0.00008666689,0.0011968545,0.0035464237,0.0013801722,0.8174834,0.00016118324,0.0030631472,0.023439774],"study_design_scores_gemma":[0.030161006,0.007471961,0.27759334,0.00045228616,0.00021083902,0.00017497288,0.005503183,0.00080734194,0.51128113,0.00087767537,0.16427602,0.0011902225],"about_ca_topic_score_codex":0.00144019,"about_ca_topic_score_gemma":0.0010337279,"teacher_disagreement_score":0.3062023,"about_ca_system_score_codex":0.0011428952,"about_ca_system_score_gemma":0.0006319965,"threshold_uncertainty_score":0.9999315},"labels":[],"label_agreement":null},{"id":"W4206799085","doi":"10.1016/j.ijrobp.2021.12.164","title":"Patterns of Prostate Cancer Recurrence After Brachytherapy Determined by Prostate-Specific Membrane Antigen–Positron Emission Tomography and Computed Tomography Imaging","year":2022,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Foundation; Terry Fox Research Institute","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Brachytherapy; Positron emission tomography; Nuclear medicine; Prostate; Prostate-specific antigen; Radiology; Radiation treatment planning; Cancer; Urology; Radiation therapy; Internal medicine","score_opus":0.013441507284688679,"score_gpt":0.32017024006626466,"score_spread":0.306728732781576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206799085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812918,0.013461325,0.0006231571,0.0024952346,0.0010257539,0.000502394,0.00055411214,0.00002302732,0.000023229637],"genre_scores_gemma":[0.98851925,0.00981062,0.0004546152,0.00039503013,0.0003694119,0.00008008581,0.00029479482,0.000028893412,0.00004731363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980304,0.0002668181,0.00066383963,0.00031083275,0.0004466609,0.00028143387],"domain_scores_gemma":[0.9981261,0.00015733892,0.000823208,0.00013481788,0.0006049384,0.0001536334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042131575,0.00021872419,0.00046880584,0.0003655287,0.00012699989,0.000029486924,0.00024626448,0.00007498041,0.000108503664],"category_scores_gemma":[0.000015897958,0.0001838852,0.00020400526,0.00032666652,0.00018025485,0.0002417058,0.00010373006,0.00050450396,5.720345e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029713726,0.0004528475,0.79577625,0.000030127336,0.0003882693,0.00007430558,0.00097262784,0.000048750673,0.04675583,0.000030466199,0.00070489215,0.15179428],"study_design_scores_gemma":[0.035965413,0.008090111,0.7178117,0.00075402553,0.0003291866,0.0008734224,0.0006825525,0.0043299617,0.14684787,0.0020372695,0.08138724,0.00089122896],"about_ca_topic_score_codex":0.000043185435,"about_ca_topic_score_gemma":0.0000021611484,"teacher_disagreement_score":0.15090306,"about_ca_system_score_codex":0.00037202553,"about_ca_system_score_gemma":0.0003094028,"threshold_uncertainty_score":0.7498621},"labels":[],"label_agreement":null},{"id":"W4206931676","doi":"10.1097/rlu.0000000000004066","title":"68Ga-PSMA PET/CT Scan Leading to Diagnosis of PSMA-Positive Rectal Adenocarcinoma in a Patient With Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"Clinical Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Occult; Prostate cancer; Pathological; Colorectal cancer; Colonoscopy; Prostate; Rectum","score_opus":0.0445995323646796,"score_gpt":0.3808045861138042,"score_spread":0.33620505374912457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206931676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739887,0.0015782134,3.871863e-7,0.020920215,0.00028599412,0.0015228759,0.000075923635,0.000038386082,0.0015892866],"genre_scores_gemma":[0.99523693,0.000822776,0.00014947694,0.002486478,0.00017906392,0.00039884992,0.00004486765,0.000067622714,0.0006139038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970349,0.00026145793,0.0007935578,0.00060654926,0.00080292847,0.0005006261],"domain_scores_gemma":[0.9983818,0.0004398783,0.00019040417,0.00035991406,0.00016768328,0.00046034198],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00070810836,0.00023157694,0.000878876,0.0003086109,0.00013968056,0.000006514126,0.00017825438,0.000015516196,0.0015327875],"category_scores_gemma":[0.00037979303,0.00016027121,0.00011185459,0.0008824832,0.000457993,0.00005480177,0.00024822497,0.0007796142,0.000024334613],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015165042,0.0014115904,0.90317726,0.00019987897,0.00032861318,0.0145364925,0.0047524963,0.000055644752,0.0004393999,0.000042603217,0.01657816,0.04331281],"study_design_scores_gemma":[0.027533306,0.06865775,0.84244907,0.004506146,0.0006536553,0.0020451352,0.014434905,0.00039421406,0.0014556785,0.00006179723,0.037100267,0.0007080618],"about_ca_topic_score_codex":0.0011210609,"about_ca_topic_score_gemma":0.0001468781,"teacher_disagreement_score":0.06724616,"about_ca_system_score_codex":0.0005010344,"about_ca_system_score_gemma":0.00029694932,"threshold_uncertainty_score":0.99937993},"labels":[],"label_agreement":null},{"id":"W4206966663","doi":"10.1016/j.ijrobp.2021.07.184","title":"Association of Short-Term Patient-Reported Outcomes With Long-Term Oncologic Outcomes in Localized Prostate Cancer Treated With Radiotherapy and ADT in a Phase III Randomized Controlled Trial","year":2021,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Randomized controlled trial; Radiation therapy; Internal medicine; Oncology; Population; Stage (stratigraphy); Randomization; Cancer; Confidence interval","score_opus":0.020593535872189643,"score_gpt":0.3747323691509671,"score_spread":0.35413883327877743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206966663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99249494,0.0012266273,0.00024889794,0.0027894538,0.00039667686,0.0027365608,0.00003640861,0.000014633551,0.00005578367],"genre_scores_gemma":[0.99425524,0.0042391657,0.0003485941,0.00024447063,0.00015989649,0.0003621305,0.0001346386,0.000024061208,0.00023178481],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99662405,0.00076121854,0.0015633231,0.00028538227,0.0004909775,0.00027504627],"domain_scores_gemma":[0.99553615,0.0012499547,0.001898316,0.00011965152,0.0010877757,0.0001081435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010243963,0.00027286517,0.002588374,0.00035101298,0.000032979773,0.000026283476,0.000112878086,0.00022823337,0.00006072277],"category_scores_gemma":[0.00047170272,0.00015892819,0.00028013854,0.00028997424,0.00023141883,0.00020088092,0.000023785573,0.00041551117,2.6601006e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43023747,0.0016443969,0.5475014,0.00000905893,0.0035319792,0.0004075783,0.0004789332,0.0000736809,0.0007900843,0.000024017661,0.0000076009937,0.015293836],"study_design_scores_gemma":[0.8719204,0.0039901463,0.12126634,0.00016351431,0.00058210536,0.00006903665,0.000071259485,0.0005394707,0.0011240935,0.00009615694,0.000037202833,0.0001402428],"about_ca_topic_score_codex":0.00008111953,"about_ca_topic_score_gemma":0.00019447521,"teacher_disagreement_score":0.44168296,"about_ca_system_score_codex":0.0018056139,"about_ca_system_score_gemma":0.0014799384,"threshold_uncertainty_score":0.64809036},"labels":[],"label_agreement":null},{"id":"W4207047760","doi":"10.1148/radiol.211824","title":"Effect of <sup>18</sup>F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial","year":2022,"lang":"en","type":"article","venue":"Radiology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; University of Toronto; University Health Network; McMaster University; Women's College Hospital; Cancer Care Ontario; Thunder Bay Regional Health Sciences Centre; Mount Sinai Hospital; Western University","funders":"Cancer Care Ontario","keywords":"Medicine; Prostate cancer; Interquartile range; Prostatectomy; Prospective cohort study; Bone scintigraphy; Glutamate carboxypeptidase II; Nuclear medicine; Androgen deprivation therapy; Watchful waiting; Prostate-specific antigen; Biochemical recurrence; Radiation therapy; Urology; Internal medicine; Cancer","score_opus":0.013824783957430852,"score_gpt":0.30705641676662526,"score_spread":0.2932316328091944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4207047760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99256283,0.00040768943,5.283124e-7,0.00041402745,0.00014617051,0.0049461145,0.00048976275,0.000010046788,0.001022827],"genre_scores_gemma":[0.99765366,0.00030454036,0.000025656864,0.00001742701,0.000035191504,0.0010861179,0.00014801366,0.000017231941,0.0007121809],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981549,0.00043681986,0.00038568903,0.00032913822,0.00042936194,0.00026414177],"domain_scores_gemma":[0.9988077,0.00027457296,0.00033540733,0.0004180417,0.00011539243,0.000048841954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005724184,0.00016430022,0.0005127268,0.00009806579,0.0000724437,0.0000018506693,0.00016228587,0.00001153871,0.000104852414],"category_scores_gemma":[0.00005556114,0.00008702604,0.000106139516,0.00023647063,0.00028084766,0.000017051718,0.00011121671,0.00027287015,0.000001004815],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8796645,0.0017444119,0.10290804,0.0011322787,0.0018769394,0.0002879034,0.0011654478,0.00044327465,0.00009002619,0.00014851298,0.0025258244,0.00801286],"study_design_scores_gemma":[0.6693201,0.17680551,0.12373099,0.0015940056,0.0016334291,0.00008279333,0.001615744,0.00088682317,0.018701237,0.00008063825,0.0050891237,0.0004596329],"about_ca_topic_score_codex":0.00008608812,"about_ca_topic_score_gemma":0.000002800794,"teacher_disagreement_score":0.2103444,"about_ca_system_score_codex":0.00029173703,"about_ca_system_score_gemma":0.000101498656,"threshold_uncertainty_score":0.3548819},"labels":[],"label_agreement":null},{"id":"W4210270056","doi":"10.1016/s0140-6736(22)00148-9","title":"Improving outcomes of men with incurable prostate cancer","year":2022,"lang":"en","type":"letter","venue":"The Lancet","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Prostate cancer; Medicine; Docetaxel; Androgen deprivation therapy; Oncology; Abiraterone acetate; Internal medicine; Abiraterone; Prostatectomy; Radiation therapy; Cancer; Gynecology; Androgen receptor","score_opus":0.03686076132142103,"score_gpt":0.3231636640621434,"score_spread":0.2863029027407224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210270056","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010694981,0.0032060463,9.826324e-7,0.972726,0.0001254144,0.001317578,0.0005342498,0.00006080224,0.011333934],"genre_scores_gemma":[0.017912982,0.0053217914,0.00029647592,0.62977046,0.0065519237,0.002537297,0.0014433458,0.0002804863,0.33588526],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998368,0.00007768954,0.0001890594,0.0002639301,0.0006238846,0.00047739167],"domain_scores_gemma":[0.9988907,0.00010367248,0.00019017185,0.00069610355,0.00008525532,0.000034116805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023910975,0.00022053957,0.0008388517,0.00007845865,0.00011838393,0.000020860114,0.00032142713,0.00010296281,0.00086796656],"category_scores_gemma":[0.000018145103,0.00010188459,0.000082508945,0.00019210199,0.00015775076,0.000038503116,0.00014434561,0.00140467,0.0000071620298],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000918889,0.00002489946,0.039364632,0.000848103,0.0006297215,0.0002808205,0.00045979902,0.000004980338,0.00013680867,0.000005494357,0.95577437,0.0015514749],"study_design_scores_gemma":[0.0044563888,0.0005986878,0.007157922,0.00022623461,0.00041946204,0.000024436942,0.00014548963,0.000036146008,0.00077761244,0.0000585962,0.98589355,0.00020548647],"about_ca_topic_score_codex":0.0016732331,"about_ca_topic_score_gemma":0.000026891763,"teacher_disagreement_score":0.34295556,"about_ca_system_score_codex":0.00022064046,"about_ca_system_score_gemma":0.00043993918,"threshold_uncertainty_score":0.9503625},"labels":[],"label_agreement":null},{"id":"W4210285931","doi":"10.1101/2022.02.02.22270344","title":"PSMA-Hornet: fully-automated, multi-target segmentation of healthy organs in PSMA PET/CT images","year":2022,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; National Institutes of Health; Mitacs","keywords":"Segmentation; Image segmentation; Radiation treatment planning; Biodistribution; Nuclear medicine; Medical imaging; Artificial intelligence; Medicine; Computer science; Radiation therapy; Radiology; In vivo; Biology","score_opus":0.040035551255228036,"score_gpt":0.37335430161287103,"score_spread":0.333318750357643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210285931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989363,0.004338326,0.000053245327,0.002419671,0.000575054,0.001972112,0.00034323242,0.00024821173,0.0006871286],"genre_scores_gemma":[0.988134,0.0032755074,0.0041497676,0.00018035184,0.00009877986,0.0005508572,0.001501142,0.000091937065,0.0020176368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970499,0.0003033053,0.00070062897,0.0007045967,0.0007197646,0.00052177894],"domain_scores_gemma":[0.99860746,0.00009581782,0.00029701128,0.0006430958,0.00015498478,0.00020163516],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007361083,0.00036214167,0.0007775811,0.00056612777,0.00008752971,0.00002320623,0.00028915872,0.000050126106,0.0015783029],"category_scores_gemma":[0.000102581194,0.00031447082,0.00017645332,0.00048119196,0.0001362114,0.000061346596,0.0004689031,0.0009993283,0.00004281287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013929808,0.0016944944,0.9649099,0.003666512,0.00038576202,0.004254698,0.0014561196,0.00062968634,0.017537326,0.000006988144,0.002385133,0.0016804048],"study_design_scores_gemma":[0.018908614,0.0020430104,0.84177333,0.0011763793,0.00035435462,0.0004501946,0.003134143,0.010747591,0.11659426,0.00020903678,0.0035923827,0.0010167174],"about_ca_topic_score_codex":0.00085662934,"about_ca_topic_score_gemma":0.00009142709,"teacher_disagreement_score":0.12313659,"about_ca_system_score_codex":0.00069341884,"about_ca_system_score_gemma":0.00086093706,"threshold_uncertainty_score":0.99993074},"labels":[],"label_agreement":null},{"id":"W4210297561","doi":"10.3390/molecules27030961","title":"A Novel Docetaxel-Biotin Chemical Conjugate for Prostate Cancer Treatment","year":2022,"lang":"en","type":"article","venue":"Molecules","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"Israel Innovation Authority; Israel Cancer Association","keywords":"Docetaxel; Prostate cancer; In vivo; Cancer; Medicine; Prostate; Paclitaxel; Pharmacology; Apoptosis; Drug; Internal medicine; Cancer research; Oncology; Chemistry; Biology; Biochemistry","score_opus":0.034380847021471296,"score_gpt":0.33456355862606657,"score_spread":0.30018271160459525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210297561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97770655,0.004743137,0.00020750864,0.011594927,0.00019445857,0.0027306727,0.0011334466,0.00010990298,0.0015793936],"genre_scores_gemma":[0.97875714,0.00037597388,0.0016106245,0.0006821892,0.00014253455,0.004068081,0.00046393767,0.000053490054,0.013846031],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989151,0.000015687323,0.0001493555,0.00031436238,0.00023991792,0.00036558448],"domain_scores_gemma":[0.99955374,0.00003203753,0.000042645082,0.00017792694,0.00006390101,0.0001297402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007015955,0.00015530313,0.00023747259,0.00006473784,0.0001708655,0.00001779792,0.000071378425,0.000028652612,0.00033947924],"category_scores_gemma":[0.000013720509,0.0001161452,0.00012988383,0.00013644702,0.00006890383,0.000020180494,0.00006984112,0.00010234474,0.000007353847],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038993456,0.0014261407,0.0030653346,0.00015832434,0.000546155,0.00014190775,0.0010706857,0.00007687657,0.94583404,0.0003563569,0.0049413205,0.038483504],"study_design_scores_gemma":[0.021745237,0.0031691447,0.0014855698,0.00006114644,0.0003353466,0.000109252716,0.00043690536,0.0016810267,0.7681328,0.00019280233,0.20228107,0.0003697091],"about_ca_topic_score_codex":0.00023346687,"about_ca_topic_score_gemma":0.000009371917,"teacher_disagreement_score":0.19733976,"about_ca_system_score_codex":0.00051400636,"about_ca_system_score_gemma":0.0002902035,"threshold_uncertainty_score":0.47362638},"labels":[],"label_agreement":null},{"id":"W4210299923","doi":"10.1158/1541-7786.mcr-21-1037","title":"Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; Canadian Institutes of Health Research; Mitacs; Terry Fox Research Institute; Killam Trusts","keywords":"Prostate cancer; Dormancy; Androgen deprivation therapy; Androgen receptor; Risk stratification; Prostate; Chromoplexy","score_opus":0.2294742934641102,"score_gpt":0.5007229806420664,"score_spread":0.27124868717795625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210299923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95141375,0.031000286,0.000038126545,0.015162693,0.00008880879,0.0018963375,0.00007333502,0.000048398022,0.0002782827],"genre_scores_gemma":[0.9729308,0.02168288,0.000039430153,0.0003892225,0.000115279385,0.0039867894,0.000074899704,0.0000532056,0.000727496],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971152,0.0003831938,0.0003337452,0.0006041531,0.0009445591,0.0006191611],"domain_scores_gemma":[0.99870896,0.00005416329,0.00004351573,0.00039536756,0.0005167598,0.000281209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012671634,0.00015341751,0.00025930253,0.00031082027,0.0006920191,0.0000546351,0.00020187315,0.000072075294,0.00028661505],"category_scores_gemma":[0.00005776481,0.0001325506,0.000091690184,0.0008920211,0.00008124536,0.00009804607,0.00035764874,0.0009046311,0.000008825198],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038287886,0.0009231693,0.15047798,0.0002530138,0.0008818372,0.00027845992,0.0015812012,0.0023330846,0.5724596,0.0012508502,0.0012376013,0.26449445],"study_design_scores_gemma":[0.06002944,0.010433718,0.1459285,0.00082685694,0.00052850985,0.00033990873,0.0023833462,0.20660956,0.48324573,0.0094448645,0.07742636,0.0028032027],"about_ca_topic_score_codex":0.00090469583,"about_ca_topic_score_gemma":0.000042332995,"teacher_disagreement_score":0.26169127,"about_ca_system_score_codex":0.00048258138,"about_ca_system_score_gemma":0.0011272022,"threshold_uncertainty_score":0.5405256},"labels":[],"label_agreement":null},{"id":"W4210340087","doi":"10.3390/ijms23031476","title":"ARPC1B Is Associated with Lethal Prostate Cancer and Its Inhibition Decreases Cell Invasion and Migration In Vitro","year":2022,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"Canadian Cancer Society; Prostate Cancer Foundation","keywords":"Erg; Prostate cancer; PTEN; DU145; Cancer research; Biology; Metastasis; Prostate; Cancer; Immunohistochemistry; Medicine; PI3K/AKT/mTOR pathway; Internal medicine; Immunology; Signal transduction; Cell biology","score_opus":0.021178137878375695,"score_gpt":0.30897332911918446,"score_spread":0.28779519124080877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210340087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902048,0.0037356643,0.000007736456,0.0057724365,0.00005642219,0.00011904002,0.000017209364,0.0000022145312,0.00008447744],"genre_scores_gemma":[0.99863935,0.0008258782,0.000097662785,0.00031087716,0.000017048988,0.000011305663,0.000009872398,0.0000035650683,0.000084423635],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886864,0.000050547726,0.00014546054,0.00011654336,0.0007270618,0.00009171967],"domain_scores_gemma":[0.999548,0.000033438508,0.0001384888,0.000019021363,0.00020202732,0.000058985075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003589205,0.000055925953,0.0000952624,0.00025460473,0.0000766611,0.00004430519,0.00005863273,0.000013642944,0.000024896966],"category_scores_gemma":[0.000041071322,0.000039368522,0.000020065147,0.00018760799,0.000080954975,0.00017512318,0.000047942478,0.00012745746,1.275357e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019030577,0.00035292283,0.07012663,0.000018220573,0.00010569231,0.0020298776,0.0021672286,0.00031304394,0.9170225,0.000039071816,0.00010181538,0.005819918],"study_design_scores_gemma":[0.0057082325,0.0016863398,0.035048783,0.00034357127,0.00005233161,0.00080426014,0.0012676984,0.002120614,0.95224226,0.000414886,0.00018466315,0.0001263819],"about_ca_topic_score_codex":0.00008555948,"about_ca_topic_score_gemma":0.000025891757,"teacher_disagreement_score":0.035219718,"about_ca_system_score_codex":0.00014224865,"about_ca_system_score_gemma":0.00028063956,"threshold_uncertainty_score":0.16054018},"labels":[],"label_agreement":null},{"id":"W4210342713","doi":"10.1158/1078-0432.ccr-21-3940","title":"Tumor Genomic Testing for &amp;gt;4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; National Institute for Health and Care Research; Merck; AstraZeneca","keywords":"Olaparib; Prostate cancer; Homologous recombination; Cancer; Clinical trial; Homologous chromosome; Prostate","score_opus":0.4004069388603253,"score_gpt":0.5604908869630105,"score_spread":0.16008394810268523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210342713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97504705,0.0027848093,0.000009015417,0.007404959,0.0002011243,0.012731285,0.0007348672,0.00003491509,0.0010519713],"genre_scores_gemma":[0.96394145,0.00031670445,0.00040140355,0.00034432852,0.0007422807,0.028075859,0.00017621099,0.00007738431,0.0059243757],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99386346,0.0012958559,0.0010218796,0.0008626879,0.0017795634,0.0011765446],"domain_scores_gemma":[0.9950444,0.0031637275,0.00022168,0.000613192,0.0006547572,0.00030226202],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009197658,0.00026301757,0.0007029075,0.0002885746,0.0009853375,0.0001545717,0.0005077369,0.000050096416,0.00092429033],"category_scores_gemma":[0.0009137746,0.00016082548,0.00015753495,0.0014571806,0.0006412605,0.00012142698,0.00020433909,0.0017248661,0.000008978225],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87878126,0.0059641334,0.020249315,0.0008062629,0.000869167,0.00095983734,0.0041792607,0.00048244753,0.010852509,0.0002146484,0.020159256,0.05648193],"study_design_scores_gemma":[0.7822445,0.05378617,0.023272308,0.00074017956,0.0008541077,0.000107494045,0.009364329,0.003923767,0.00079382444,0.0012843254,0.12263087,0.0009981347],"about_ca_topic_score_codex":0.002984677,"about_ca_topic_score_gemma":0.0022088382,"teacher_disagreement_score":0.10247161,"about_ca_system_score_codex":0.0012027962,"about_ca_system_score_gemma":0.0053338152,"threshold_uncertainty_score":0.999989},"labels":[],"label_agreement":null},{"id":"W4210490878","doi":"10.5489/cuaj.7591","title":"A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant prostate cancer","year":2022,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; HEC Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Univariate analysis; Hazard ratio; Docetaxel; Internal medicine; Urology; Proportional hazards model; Oncology; Confidence interval; Cancer; Gastroenterology; Multivariate analysis","score_opus":0.02929950573912153,"score_gpt":0.28563634083126477,"score_spread":0.2563368350921432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210490878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829163,0.00059578626,0.00000494271,0.014723369,0.00007587025,0.0006475097,0.00015141495,0.000016950013,0.00086787407],"genre_scores_gemma":[0.99696344,0.00009929288,0.00013418403,0.00049934816,0.0000695339,0.00037106016,0.000047385125,0.000021344084,0.0017943853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766564,0.00022794565,0.00031053353,0.00030032892,0.0007312149,0.0007643446],"domain_scores_gemma":[0.99873626,0.00007936361,0.00021966107,0.0001077781,0.00016767868,0.00068925327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047737674,0.00018341478,0.00032264864,0.00026526628,0.0005427575,0.000082787585,0.00013501939,0.00004448997,0.00057124265],"category_scores_gemma":[0.000058089587,0.00011869169,0.00005371253,0.00058430247,0.00008358136,0.00014155635,0.00003524438,0.00079289434,0.0000034057243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038726644,0.00046048532,0.98450977,0.000012830138,0.00020199746,0.0051167556,0.002773913,0.0006303631,0.000749675,0.000011046092,0.00085245003,0.00080807303],"study_design_scores_gemma":[0.024666386,0.008488172,0.93407935,0.00013110724,0.00019184903,0.0019360696,0.009589058,0.0009919956,0.00032566683,0.00013312441,0.018940846,0.0005263735],"about_ca_topic_score_codex":0.005145771,"about_ca_topic_score_gemma":0.010481822,"teacher_disagreement_score":0.050430395,"about_ca_system_score_codex":0.0051472266,"about_ca_system_score_gemma":0.0016861387,"threshold_uncertainty_score":0.9986718},"labels":[],"label_agreement":null},{"id":"W4210818182","doi":"10.3390/cancers14030820","title":"Intraductal Carcinoma of the Prostate as a Cause of Prostate Cancer Metastasis: A Molecular Portrait","year":2022,"lang":"en","type":"review","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Metastasis; Prostate cancer; Prostate; Immunohistochemistry; Carcinoma; Cancer; Prostate carcinoma; Medicine; Pathology; Cancer research; Oncology; Internal medicine","score_opus":0.06274234231587025,"score_gpt":0.37318649194458875,"score_spread":0.31044414962871847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210818182","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009139937,0.98317295,2.1515761e-7,0.00019056526,0.00042689592,0.0044311867,0.0016309913,0.000022649854,0.0009845885],"genre_scores_gemma":[0.0039903214,0.99054366,0.000025524465,0.00007319021,0.00007129412,0.0023264217,0.00022366854,0.00012778894,0.0026180975],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99663454,0.0002493781,0.00090454426,0.00063592737,0.0009872128,0.0005883833],"domain_scores_gemma":[0.997784,0.00006656601,0.00084313995,0.0008943779,0.00019164999,0.00022024607],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030231327,0.00054369617,0.002146525,0.00029165635,0.000100385965,0.0000129253895,0.00045220513,0.00014726349,0.0008468012],"category_scores_gemma":[0.00008057518,0.00033379035,0.001008245,0.0012720281,0.0005247335,0.00005827719,0.00025808552,0.0007962703,0.0000035365986],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068660284,0.00014043065,0.00063322234,0.06491917,0.0054989397,0.0009878748,0.0018782663,0.00003498839,0.000115341616,0.0001851278,0.0021192413,0.9228008],"study_design_scores_gemma":[0.0018082511,0.0007055147,0.000060482496,0.009452746,0.0061836033,0.00022548644,0.000369739,0.0000038837065,0.0017599069,0.000037047594,0.97900885,0.00038450296],"about_ca_topic_score_codex":0.0023326618,"about_ca_topic_score_gemma":0.0000509072,"teacher_disagreement_score":0.9768896,"about_ca_system_score_codex":0.0031128551,"about_ca_system_score_gemma":0.017968707,"threshold_uncertainty_score":0.9999114},"labels":[],"label_agreement":null},{"id":"W4211075920","doi":"10.3410/f.740905744.793589416","title":"Faculty Opinions recommendation of Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.","year":2021,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Abiraterone acetate; Prednisone; Placebo; Prostate cancer; Medicine; Abiraterone; Pooled analysis; Internal medicine; Urology; Oncology; Cancer; Androgen deprivation therapy; Pathology","score_opus":0.07539069977082925,"score_gpt":0.4226541068734359,"score_spread":0.34726340710260667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211075920","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012031783,0.009307161,0.000011992868,0.06286534,0.00049110764,0.016145125,0.9099281,0.000032334592,0.000015676755],"genre_scores_gemma":[0.0009883911,0.0041546905,0.0005296474,0.00036553675,0.00014710777,0.005929401,0.98631436,0.00005346151,0.0015173929],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99271864,0.0009956956,0.0025577964,0.0012055536,0.0019180871,0.0006042249],"domain_scores_gemma":[0.99173796,0.0005054689,0.0017009339,0.0010091269,0.004538668,0.00050785195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025406487,0.000865751,0.0025077811,0.00071398215,0.00032685703,0.00029788163,0.00052644365,0.0004424703,0.00024893385],"category_scores_gemma":[0.0026589232,0.00056121283,0.00038486553,0.0017126346,0.00059212453,0.00053920347,0.00044014936,0.001156066,0.000005901786],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17452022,0.0026175654,0.000019761137,0.012510267,0.0019570685,0.000018006882,0.0017366649,0.000006842585,0.000066577624,0.000020067717,0.8043745,0.0021524404],"study_design_scores_gemma":[0.47654235,0.0012639819,0.00055243046,0.008665732,0.0014626888,0.000050237308,0.00059796055,0.0002625027,0.00007860411,0.000004286705,0.51006955,0.00044968686],"about_ca_topic_score_codex":0.00047756048,"about_ca_topic_score_gemma":0.00030996354,"teacher_disagreement_score":0.30202213,"about_ca_system_score_codex":0.0006029321,"about_ca_system_score_gemma":0.002299282,"threshold_uncertainty_score":0.9996839},"labels":[],"label_agreement":null},{"id":"W4211087830","doi":"10.1016/s0140-6736(14)61947-4","title":"Prostate cancer","year":2015,"lang":"en","type":"review","venue":"The Lancet","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":917,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Astellas Pharma; National Cancer Institute; Cancer Research UK; Prostate Cancer UK; Ipsen; National Institute for Health and Care Research; GlaxoSmithKline","keywords":"Prostate cancer; Overdiagnosis; Medicine; Docetaxel; Oncology; Internal medicine; Disease; Cancer; Prostate; Cabazitaxel; Androgen deprivation therapy","score_opus":0.22937488496165262,"score_gpt":0.4760491146759444,"score_spread":0.2466742297142918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211087830","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000034780085,0.9844163,1.2936171e-7,0.0025268425,0.00022166791,0.0014055317,0.00021358636,0.00006332841,0.01114915],"genre_scores_gemma":[9.946641e-7,0.9618892,0.00002018719,0.00019117679,0.002285727,0.000574117,0.0001842838,0.000046059933,0.03480825],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878263,0.00009433265,0.0001971011,0.00022198603,0.00031315815,0.0003907644],"domain_scores_gemma":[0.998981,0.000044248336,0.00009744656,0.0006647145,0.00008953039,0.00012308876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037911374,0.0002298409,0.001717554,0.000052943073,0.00005556182,0.000030247595,0.00026725087,0.0001096155,0.0001825362],"category_scores_gemma":[0.000024009654,0.0000957528,0.00019117817,0.0002527949,0.00010521902,0.000021283202,0.000089291076,0.00050043914,0.0004109609],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006717881,0.000017133945,0.000028254875,0.008610863,0.00024923883,0.000044963665,0.00008158817,4.1166334e-8,6.6462654e-8,0.000024625211,0.17849292,0.8123831],"study_design_scores_gemma":[0.00090054126,0.000066525725,0.000008464983,0.007943667,0.00083249365,0.000044609304,0.000008368582,7.669243e-7,6.7419705e-7,0.00006573752,0.9900197,0.000108489316],"about_ca_topic_score_codex":0.00004895795,"about_ca_topic_score_gemma":0.0000062516187,"teacher_disagreement_score":0.81227463,"about_ca_system_score_codex":0.0002780289,"about_ca_system_score_gemma":0.0010849212,"threshold_uncertainty_score":0.5282208},"labels":[],"label_agreement":null},{"id":"W4212773488","doi":"10.1200/jco.2022.40.6_suppl.224","title":"Randomized phase II trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Toronto; London Health Sciences Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Cabazitaxel; Internal medicine; Prostatectomy; Randomized controlled trial; Abiraterone acetate; Urology; Prostate; Oncology; Neoadjuvant therapy; Prednisone; Cancer; Androgen deprivation therapy; Breast cancer","score_opus":0.14061371387660235,"score_gpt":0.5090536018849796,"score_spread":0.36843988800837724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212773488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815746,0.0032117446,0.000010296956,0.009996901,0.002923622,0.0019632664,0.00010306975,0.000007811226,0.00020869198],"genre_scores_gemma":[0.9793153,0.013854901,0.0005925018,0.0004820462,0.0011623341,0.00024573688,0.000017717697,0.000029262083,0.004300244],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9916983,0.0024313224,0.004334761,0.00028195887,0.00082359964,0.00043005813],"domain_scores_gemma":[0.99164885,0.0040261243,0.0032953767,0.00024010813,0.00040110858,0.00038840174],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010843166,0.00020453356,0.0039859437,0.00034104625,0.00012437538,0.0000067551887,0.00026524675,0.00022386563,0.001023743],"category_scores_gemma":[0.004918665,0.000119013006,0.00071481644,0.00037555388,0.0004967458,0.000100272475,0.000215377,0.0019107461,0.0000030768203],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8548308,0.008111446,0.00092198723,0.000043509033,0.0008222091,0.002938744,0.00071506476,0.00016503628,0.00016819368,0.000011214171,0.0032963604,0.12797545],"study_design_scores_gemma":[0.861632,0.11517692,0.00049807684,0.00009312939,0.00072573294,0.00013240962,0.00031991123,0.0002862822,0.00019173528,0.00023973819,0.020601446,0.000102635735],"about_ca_topic_score_codex":0.00089184544,"about_ca_topic_score_gemma":0.00026622321,"teacher_disagreement_score":0.12787281,"about_ca_system_score_codex":0.0008341846,"about_ca_system_score_gemma":0.0077749803,"threshold_uncertainty_score":0.99988943},"labels":[],"label_agreement":null},{"id":"W4212776446","doi":"10.1038/s41391-021-00488-0","title":"Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)","year":2022,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Bayer HealthCare; Bayer","keywords":"Medicine; Prostate cancer; Radium-223; Oncology; Castration; Internal medicine; Cancer; Radium; Prostate; Overall survival; Urology; Hormone; Bone metastasis","score_opus":0.038605976680587344,"score_gpt":0.3466598766266834,"score_spread":0.30805389994609605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212776446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9640614,0.0031817371,0.0000017285769,0.0006455162,0.00019743839,0.008577545,0.02324469,0.00006456492,0.000025427793],"genre_scores_gemma":[0.97042954,0.0023411447,0.00012072141,0.00011562377,0.000050429448,0.020358311,0.0014277087,0.00010797329,0.0050485427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99676514,0.00019767135,0.00072585576,0.00073518784,0.00088100083,0.00069512887],"domain_scores_gemma":[0.9980691,0.00031340995,0.00044756808,0.00035301532,0.0004107319,0.00040619363],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021757704,0.0004881851,0.0009794029,0.00026661545,0.00034604833,0.000086812106,0.00009993509,0.000025868774,0.00036223332],"category_scores_gemma":[0.00006662371,0.00033255713,0.00013963062,0.0006791807,0.00028832292,0.00016140753,0.00008956853,0.0001644491,6.164928e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09890577,0.0077202725,0.80651504,0.0019070797,0.003772924,0.0014448478,0.027163913,0.00017857508,0.0005496833,0.000024396755,0.0005109565,0.051306546],"study_design_scores_gemma":[0.032530554,0.023184065,0.9207451,0.0007721044,0.0045390674,0.000011892423,0.012874836,0.00045236232,0.0007249093,0.000105717474,0.0031746728,0.00088473514],"about_ca_topic_score_codex":0.0017726243,"about_ca_topic_score_gemma":0.0017831274,"teacher_disagreement_score":0.11423005,"about_ca_system_score_codex":0.000921756,"about_ca_system_score_gemma":0.001969608,"threshold_uncertainty_score":0.9999126},"labels":[],"label_agreement":null},{"id":"W4212779820","doi":"10.1200/jco.2022.40.6_suppl.085","title":"Exposure-adjusted safety analyses of the VISION phase 3 trial of <sup>177</sup>Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Incidence (geometry); Adverse effect; Internal medicine; Clinical endpoint; Taxane; Oncology; Confidence interval; Randomized controlled trial; Cancer; Breast cancer","score_opus":0.17771800703188737,"score_gpt":0.5205111701276368,"score_spread":0.3427931630957495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212779820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956939,0.00051487726,0.000004709873,0.0021502227,0.00030011454,0.0010827843,0.00011813764,0.0000022755346,0.00013297143],"genre_scores_gemma":[0.99887055,0.00036119472,0.0003030027,0.000118638956,0.00011175062,0.000029343732,0.000021194666,0.000013863749,0.00017043539],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944325,0.0013286612,0.0027529732,0.00018909862,0.0010681257,0.00022864046],"domain_scores_gemma":[0.9953218,0.0012013215,0.0023906606,0.00024424275,0.0006732335,0.00016872116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028290255,0.0001414747,0.0014569828,0.0002140556,0.0000835087,0.0000049827718,0.0002138075,0.00008160673,0.00022824242],"category_scores_gemma":[0.0010236144,0.00007310116,0.00037239539,0.0005774347,0.00031780993,0.00010150437,0.000086735694,0.0008520308,3.0514568e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79203945,0.014809985,0.121433035,0.00012519248,0.0012771807,0.00026531826,0.00080993574,0.004663127,0.00077164173,0.000011569975,0.0004237614,0.06336982],"study_design_scores_gemma":[0.4870159,0.1391036,0.36739853,0.00028879504,0.0014198591,0.000019577259,0.0013638429,0.00044308577,0.0008690826,0.00007625101,0.0018811519,0.00012033623],"about_ca_topic_score_codex":0.00020239012,"about_ca_topic_score_gemma":0.00014956816,"teacher_disagreement_score":0.30502352,"about_ca_system_score_codex":0.0003728795,"about_ca_system_score_gemma":0.0037720336,"threshold_uncertainty_score":0.66914254},"labels":[],"label_agreement":null},{"id":"W4212819065","doi":"10.1200/jco.2022.40.6_suppl.252","title":"Real-world management of metastatic castration-resistant prostate cancer (mCRPC): A national multicenter cohort study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency; Jewish General Hospital; Ottawa Hospital; CancerCare Manitoba; Centre Hospitalier de l’Université de Montréal; Université Laval; University of Alberta; McMaster University; Juravinski Cancer Centre; University of Manitoba; St. Joseph’s Healthcare Hamilton; University of Toronto; Hôpital Charles-Le Moyne; Vancouver General Hospital; Princess Margaret Cancer Centre; University of Calgary; McGill University; University of Ottawa","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Abiraterone acetate; Cohort; Internal medicine; Cabazitaxel; Docetaxel; Cancer; Prednisone; Prospective cohort study; Oncology; Androgen deprivation therapy; Androgen receptor","score_opus":0.17470189149900983,"score_gpt":0.5368501938432154,"score_spread":0.3621483023442056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212819065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98715544,0.0003700007,0.0000041171197,0.004172491,0.0007118109,0.0013283709,0.000048085367,0.000005579994,0.00620409],"genre_scores_gemma":[0.9918572,0.001179331,0.0014996143,0.00027720077,0.00017804757,0.00016042708,0.000012356694,0.00001457936,0.004821299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956857,0.0005926911,0.0020073932,0.00020083206,0.0013032131,0.00021015963],"domain_scores_gemma":[0.9969872,0.00062568695,0.001323926,0.00013525638,0.00072654,0.00020138135],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0045398637,0.00011337381,0.000966908,0.00023651507,0.00009107382,0.0000070740366,0.00015243345,0.000031188705,0.00091856095],"category_scores_gemma":[0.00017060449,0.0000792165,0.00028108078,0.00031599496,0.00013469864,0.00007441792,0.000116041236,0.0006407685,0.0000034876905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026941799,0.012608912,0.92213315,0.0001996978,0.006271506,0.003912631,0.000516544,0.00047035317,0.00026377328,0.00032970353,0.005670325,0.020681633],"study_design_scores_gemma":[0.018078987,0.011220418,0.95086205,0.00007564043,0.0011221432,0.000034854525,0.0015422378,0.0001499585,0.000046121502,0.00021116433,0.016579868,0.00007655807],"about_ca_topic_score_codex":0.00021700664,"about_ca_topic_score_gemma":0.00028086518,"teacher_disagreement_score":0.028728925,"about_ca_system_score_codex":0.0007650835,"about_ca_system_score_gemma":0.0021880073,"threshold_uncertainty_score":0.99999475},"labels":[],"label_agreement":null},{"id":"W4212821853","doi":"10.1200/jco.2022.40.6_suppl.tps200","title":"A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Androgen deprivation therapy; Internal medicine; Oncology; Docetaxel; Adverse effect; Placebo; Tolerability; Clinical endpoint; Abiraterone acetate; Randomized controlled trial; Cancer; Androgen receptor; Pathology","score_opus":0.1408623413131093,"score_gpt":0.5041841219842379,"score_spread":0.36332178067112864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212821853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890762,0.0023522244,0.000021703632,0.0035317633,0.00042235284,0.0044517955,0.000041191415,0.0000041019016,0.000098685785],"genre_scores_gemma":[0.9948213,0.003675836,0.00019563957,0.00043992235,0.00014084058,0.0006202951,0.00001838715,0.000016723512,0.00007106951],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930187,0.0029743384,0.002814883,0.00023771309,0.0006885155,0.000265869],"domain_scores_gemma":[0.9931052,0.0046641477,0.0014708597,0.00014391793,0.0004227677,0.00019315259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0084167505,0.00015753218,0.0034287078,0.00056572,0.000046703008,0.000005859775,0.00011366887,0.000077958815,0.00013679522],"category_scores_gemma":[0.002882686,0.00010471016,0.0003943994,0.00051574426,0.0001315953,0.0001085353,0.00006157699,0.00086903217,0.000001669947],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92835367,0.010343624,0.0039266916,0.000009468294,0.001553805,0.0015449486,0.002566535,0.0008500731,0.0006764053,0.0000049907844,0.0002205578,0.049949255],"study_design_scores_gemma":[0.936552,0.047680635,0.010578069,0.000052482406,0.0004958915,0.00003482297,0.0029077106,0.0006367076,0.00022301983,0.00011355772,0.0006384332,0.00008671128],"about_ca_topic_score_codex":0.00041841556,"about_ca_topic_score_gemma":0.00048645693,"teacher_disagreement_score":0.049862545,"about_ca_system_score_codex":0.0006142949,"about_ca_system_score_gemma":0.0017245504,"threshold_uncertainty_score":0.42699564},"labels":[],"label_agreement":null},{"id":"W4212864413","doi":"10.1200/jco.2022.40.6_suppl.tps210","title":"PSMAddition: A phase 3 trial to compare treatment with <sup>177</sup>Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Clinical endpoint; Androgen deprivation therapy; Oncology; Internal medicine; Hazard ratio; Urology; Nuclear medicine; Randomized controlled trial; Cancer; Confidence interval","score_opus":0.12006038377425364,"score_gpt":0.47611275525506047,"score_spread":0.3560523714808068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212864413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99228185,0.0008411007,0.000013733213,0.0028517025,0.00032671055,0.0023753,0.0010855853,0.000008596794,0.00021542335],"genre_scores_gemma":[0.9973208,0.00052415737,0.001043553,0.00021256853,0.00029919547,0.00022925859,0.00021831856,0.000033442364,0.000118727075],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99571204,0.0007265504,0.0016264634,0.00034794395,0.0011606325,0.0004263926],"domain_scores_gemma":[0.9959282,0.0010417867,0.0011882304,0.00022575214,0.0011156839,0.0005003291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008739025,0.0002696354,0.0025222625,0.00028404416,0.00012776547,0.000011368444,0.00013749616,0.00007001959,0.00019429885],"category_scores_gemma":[0.00023663556,0.00016427734,0.00029326338,0.0004574483,0.00030089883,0.00011108024,0.00007673609,0.0008006342,0.0000021887931],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9267083,0.005543941,0.008570897,0.00005240503,0.0018786548,0.0023508042,0.0047569205,0.001683074,0.0000050928184,0.000004447415,0.0014606204,0.04698485],"study_design_scores_gemma":[0.55655825,0.41809627,0.007715148,0.0001578851,0.0011254438,0.000033733795,0.008862293,0.00006657198,0.000097115284,0.000008068461,0.0071271164,0.00015211159],"about_ca_topic_score_codex":0.00020179518,"about_ca_topic_score_gemma":0.0005981609,"teacher_disagreement_score":0.41255233,"about_ca_system_score_codex":0.0031812543,"about_ca_system_score_gemma":0.0065933154,"threshold_uncertainty_score":0.9990384},"labels":[],"label_agreement":null},{"id":"W4212879952","doi":"10.1200/jco.2022.40.6_suppl.053","title":"Patterns of care for patients with non-metastatic castration-resistant prostate cancer: Population-based study in Ontario, Canada.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McMaster University; St. Joseph’s Healthcare Hamilton; Juravinski Cancer Centre; Queen Elizabeth II Health Sciences Centre; University of British Columbia; Dalhousie University; University of Toronto; BC Cancer Agency; Ottawa Hospital; University of Calgary; Princess Margaret Cancer Centre; Jewish General Hospital; University of Ottawa; McGill University","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Internal medicine; Oncology; Population; Cancer; Enzalutamide; Disease; Androgen receptor","score_opus":0.06834058048368173,"score_gpt":0.43431885696779426,"score_spread":0.3659782764841125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212879952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971939,0.0000794397,0.000004362922,0.0007811516,0.00033079914,0.0014373708,0.00015153675,0.0000010812888,0.000020411422],"genre_scores_gemma":[0.9991154,0.0000063535276,0.00031583983,0.00016804032,0.000040291114,0.00012226826,0.00009132728,0.000011949809,0.00012853979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975146,0.00021215655,0.0013379898,0.00014519524,0.0006075932,0.00018243518],"domain_scores_gemma":[0.99746203,0.0006836194,0.0009782172,0.000107451975,0.00062365935,0.00014503468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000697359,0.00009539548,0.0008762643,0.00012391174,0.00006745366,0.0000035188673,0.000090525085,0.0000313243,0.00015012205],"category_scores_gemma":[0.0001801266,0.0000641089,0.00010412414,0.00012155154,0.000017937497,0.00003882309,0.000020405929,0.0005000868,4.099961e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021319553,0.0027765057,0.96861434,0.00009779408,0.00022208267,0.000285154,0.0007088842,0.0013482238,0.0000028856605,8.24089e-7,0.00011572904,0.0045080227],"study_design_scores_gemma":[0.026581915,0.039267123,0.93068844,0.000079412086,0.00023124355,0.0000018454662,0.0020392735,0.00003405429,0.000006430659,0.000005735958,0.0010086374,0.000055897493],"about_ca_topic_score_codex":0.7487063,"about_ca_topic_score_gemma":0.9910735,"teacher_disagreement_score":0.24236716,"about_ca_system_score_codex":0.0021543866,"about_ca_system_score_gemma":0.019343095,"threshold_uncertainty_score":0.9862163},"labels":[],"label_agreement":null},{"id":"W4212895767","doi":"10.1200/jco.2022.40.6_suppl.tps285","title":"PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Urology; Prostatectomy; Clinical endpoint; Perioperative; Lymph node; Internal medicine; Nuclear medicine; Oncology; Cancer; Surgery; Randomized controlled trial","score_opus":0.08082467148519223,"score_gpt":0.45035102151859246,"score_spread":0.36952635003340023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212895767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96813,0.0009652288,0.00034784415,0.0028710442,0.0012119901,0.026295735,0.00007687023,0.00002652142,0.00007477458],"genre_scores_gemma":[0.98555195,0.004263448,0.0027718998,0.0005210289,0.0005603488,0.005815973,0.000062847575,0.000088554,0.0003639553],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98889947,0.0027525732,0.0049651833,0.0006824105,0.0019336725,0.0007666807],"domain_scores_gemma":[0.9891829,0.0044134124,0.0040969076,0.0004239585,0.0011402059,0.00074263685],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008876495,0.00048523836,0.005254607,0.00065194076,0.00018819117,0.00002945347,0.00044374372,0.00037246934,0.0003398502],"category_scores_gemma":[0.004604301,0.00027905492,0.0007386179,0.00094833254,0.00062214234,0.00025202078,0.000178004,0.002123568,0.0000044895705],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84603554,0.0077396017,0.0027011975,0.00007917811,0.0023240088,0.0006162777,0.00072223507,0.0035228813,0.00004327494,0.000012486383,0.00014932716,0.13605401],"study_design_scores_gemma":[0.8627543,0.12768054,0.00027603735,0.00026486412,0.0008139869,0.000029229415,0.00022733407,0.0009064722,0.00043601534,0.00006298626,0.0062815915,0.0002666441],"about_ca_topic_score_codex":0.00038280414,"about_ca_topic_score_gemma":0.00032954494,"teacher_disagreement_score":0.13578737,"about_ca_system_score_codex":0.0021970682,"about_ca_system_score_gemma":0.012818695,"threshold_uncertainty_score":0.99996614},"labels":[],"label_agreement":null},{"id":"W4212943765","doi":"10.1200/jco.2022.40.6_suppl.013","title":"Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Clinical endpoint; Androgen deprivation therapy; Internal medicine; Oncology; Placebo; Adverse effect; Cancer; Urology; Randomized controlled trial; Pathology","score_opus":0.1866927260760188,"score_gpt":0.4892049602523721,"score_spread":0.3025122341763533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212943765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864141,0.00076214096,0.000046269633,0.010369049,0.00020183522,0.0020970562,0.000028685008,0.0000026884898,0.00007822057],"genre_scores_gemma":[0.9964736,0.0023816228,0.0003428773,0.00040616916,0.00010967425,0.00020184672,0.000019266367,0.000012952179,0.00005195592],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975976,0.00083637575,0.0007619022,0.00016983584,0.0004360707,0.0001982688],"domain_scores_gemma":[0.99604326,0.0029228572,0.00064301596,0.00008858546,0.00021761477,0.000084632535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040979898,0.00010903405,0.00073218404,0.00015640889,0.00007233522,0.000012409722,0.00006786227,0.000048855272,0.000010241466],"category_scores_gemma":[0.00040450037,0.000056707864,0.00007733656,0.00021900868,0.0001526453,0.000107159874,0.000017639448,0.0006482253,1.190537e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95157367,0.0037295027,0.007817898,0.000014043391,0.00045576325,0.0007797985,0.0012566629,0.00023742963,0.00013516277,0.00011093464,0.00014540175,0.033743754],"study_design_scores_gemma":[0.80918986,0.13324776,0.050167795,0.000039862316,0.00024535356,0.00011631281,0.002257184,0.0009589613,0.00008307453,0.00032276657,0.0032742221,0.000096866475],"about_ca_topic_score_codex":0.00006535578,"about_ca_topic_score_gemma":0.00028773322,"teacher_disagreement_score":0.14238381,"about_ca_system_score_codex":0.00028354937,"about_ca_system_score_gemma":0.0014017638,"threshold_uncertainty_score":0.28162524},"labels":[],"label_agreement":null},{"id":"W4212977599","doi":"10.1200/jco.2022.40.6_suppl.011","title":"PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Hazard ratio; Clinical endpoint; Placebo; Androgen deprivation therapy; Abiraterone acetate; Oncology; Interim analysis; Progression-free survival; Prednisone; Olaparib; Confidence interval; Docetaxel; Randomized controlled trial; Urology; Androgen receptor; Cancer; Chemotherapy; Pathology; Poly ADP ribose polymerase","score_opus":0.1667641359119953,"score_gpt":0.4970009066430789,"score_spread":0.3302367707310836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212977599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906515,0.0013916007,0.000014075234,0.0042793057,0.0006506784,0.0027883393,0.00010996783,0.00000524932,0.00010928806],"genre_scores_gemma":[0.9938931,0.004094461,0.00070708565,0.00020685197,0.00027973336,0.00028936387,0.0000317955,0.00002667273,0.00047096377],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99699396,0.00035002024,0.0015584027,0.00026335928,0.0005597472,0.0002744948],"domain_scores_gemma":[0.99608463,0.0015107411,0.0013835235,0.00013286105,0.0005840678,0.00030415546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020679573,0.000179425,0.0012765717,0.00013016888,0.00016709337,0.0000167947,0.00009499619,0.000089189016,0.00012812349],"category_scores_gemma":[0.00058501743,0.00010719997,0.00015005254,0.00014246174,0.00034667965,0.00012816265,0.000049610568,0.0005653065,3.6783518e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89529365,0.0062513147,0.002856368,0.00011287939,0.00118956,0.00017134349,0.0005075801,0.000036215246,0.00033610757,0.000025652187,0.0005217629,0.092697546],"study_design_scores_gemma":[0.6835711,0.2865301,0.0025154215,0.00007525712,0.00063742604,0.000036423833,0.00032392613,0.00013650695,0.00030017484,0.000092487244,0.025669005,0.0001121694],"about_ca_topic_score_codex":0.0001072449,"about_ca_topic_score_gemma":0.00018425522,"teacher_disagreement_score":0.28027877,"about_ca_system_score_codex":0.0001847706,"about_ca_system_score_gemma":0.0022816877,"threshold_uncertainty_score":0.4371488},"labels":[],"label_agreement":null},{"id":"W4212979192","doi":"10.1200/jco.2022.40.6_suppl.175","title":"Analysis of the role of PI3K-AKT and DNA damage repair (DDR) genomic biomarkers as predictors of clinical outcomes in nonmetastatic castration-resistant prostate cancer (nmCRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University of Alberta; University of Calgary","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Internal medicine; PI3K/AKT/mTOR pathway; Protein kinase B; Cancer; Proportional hazards model; Androgen deprivation therapy; Androgen receptor; Cancer research; Biology; Genetics; Signal transduction","score_opus":0.07549861582318416,"score_gpt":0.47072017186039483,"score_spread":0.39522155603721065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212979192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955793,0.0013339127,6.5431203e-7,0.0017992561,0.00038838276,0.0004584839,0.00014316005,0.0000029776993,0.0002938738],"genre_scores_gemma":[0.9980314,0.0012096916,0.00028379605,0.00014484827,0.00006250893,0.000016114709,0.000007601146,0.000012521373,0.00023153366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993382,0.0013625446,0.0041266745,0.00023755619,0.00067422766,0.00021704531],"domain_scores_gemma":[0.99315363,0.0029133577,0.0030983472,0.00030367565,0.0003209678,0.00021004923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061792443,0.00013671412,0.0022941686,0.00042352197,0.000049329978,0.0000031638538,0.0002291314,0.00013902254,0.00022782157],"category_scores_gemma":[0.0022461633,0.00008127937,0.0010661348,0.00071281404,0.0007171174,0.00006322151,0.00018070142,0.0007697862,2.7004504e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010306264,0.0021281512,0.9712741,0.00006889058,0.0073570944,0.00013489167,0.0004962157,0.00024712266,0.0021526744,0.000019067362,0.00012174858,0.005693794],"study_design_scores_gemma":[0.0072983387,0.009166802,0.9763578,0.00005624144,0.0032799835,0.000012454075,0.0014443775,0.0005728678,0.0002935138,0.00011846103,0.0013389672,0.000060197402],"about_ca_topic_score_codex":0.0005937135,"about_ca_topic_score_gemma":0.0007384208,"teacher_disagreement_score":0.0070386515,"about_ca_system_score_codex":0.00020116182,"about_ca_system_score_gemma":0.0033834372,"threshold_uncertainty_score":0.6002072},"labels":[],"label_agreement":null},{"id":"W4212987985","doi":"10.1200/jco.2022.40.6_suppl.269","title":"Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; McGill University Health Centre; Lawson Health Research Institute; Juravinski Cancer Centre; University of Alberta; Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Clinical endpoint; Internal medicine; Prostatectomy; Prostate; Randomized controlled trial; Cancer; Hormonal therapy","score_opus":0.11494132322920023,"score_gpt":0.47666074038401957,"score_spread":0.36171941715481937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212987985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818455,0.0004497246,0.0000022479271,0.012012518,0.0030330056,0.0020317554,0.000022892369,0.0000022510599,0.0006001011],"genre_scores_gemma":[0.9950515,0.002838484,0.000028383281,0.00067738525,0.0005157913,0.00018225965,0.000002424029,0.000014829235,0.00068892137],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99223745,0.003919732,0.0027823173,0.00017479021,0.000638858,0.00024683957],"domain_scores_gemma":[0.9899287,0.0056849113,0.0036891417,0.00032539954,0.00027711727,0.000094707684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012220736,0.00014080464,0.0015877471,0.000118688054,0.0001500152,0.000004871078,0.0004907782,0.00018302504,0.0005160904],"category_scores_gemma":[0.0033885846,0.0000549529,0.00076617365,0.0003462436,0.0009787576,0.00005286013,0.00022686427,0.0019900037,0.0000019652493],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9270609,0.0026939504,0.027507296,0.000019857587,0.0005295227,0.000027440294,0.0011419068,0.0003623909,0.0011642511,0.00002685365,0.0010440034,0.038421623],"study_design_scores_gemma":[0.9427719,0.015784793,0.027528455,0.00013579462,0.0006654727,0.00003714454,0.00064176234,0.0011435758,0.0024770617,0.00023052961,0.008508723,0.00007477567],"about_ca_topic_score_codex":0.0000717186,"about_ca_topic_score_gemma":0.00004170131,"teacher_disagreement_score":0.038346846,"about_ca_system_score_codex":0.0006663492,"about_ca_system_score_gemma":0.003736735,"threshold_uncertainty_score":0.8645687},"labels":[],"label_agreement":null},{"id":"W4212999409","doi":"10.1200/jco.2022.40.6_suppl.239","title":"Prostate specific antigen dynamics and prostate cancer risk: A population-based study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Prostate; Cohort; Internal medicine; Cancer; Retrospective cohort study; Population; Urology; Logistic regression; Gynecology; Oncology","score_opus":0.10090647405238626,"score_gpt":0.4847770033301339,"score_spread":0.3838705292777477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212999409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890318,0.0020814864,0.000010155086,0.006936637,0.0008110447,0.000865996,0.00006404768,0.0000104853,0.00018835394],"genre_scores_gemma":[0.99503607,0.0027216964,0.00047246995,0.00036833002,0.00035908245,0.00004810906,0.000022061626,0.000022281527,0.00094992673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99673665,0.00076740433,0.001410251,0.00023985715,0.00058209896,0.0002637702],"domain_scores_gemma":[0.9972168,0.000778973,0.0012176565,0.00016311539,0.00030963926,0.0003137867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003328685,0.00012898009,0.0009500065,0.00018957815,0.00021692144,0.000016311566,0.00011528869,0.000085411666,0.0003088689],"category_scores_gemma":[0.00041385167,0.00008947052,0.00020676991,0.0002501481,0.000106782616,0.0000706475,0.00009677663,0.001296657,0.0000024268222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011368995,0.0020968074,0.86484927,0.000018004383,0.00029257312,0.0008632193,0.00028541643,0.00024608098,0.000012244208,0.00001094016,0.0007893577,0.11916707],"study_design_scores_gemma":[0.0144330105,0.0220562,0.9455309,0.000027538981,0.00020298363,0.000050627026,0.0008392452,0.001267864,0.000005582132,0.0001725078,0.015325011,0.00008851738],"about_ca_topic_score_codex":0.000280913,"about_ca_topic_score_gemma":0.00023870109,"teacher_disagreement_score":0.119078554,"about_ca_system_score_codex":0.00064216927,"about_ca_system_score_gemma":0.0019795252,"threshold_uncertainty_score":0.5633401},"labels":[],"label_agreement":null},{"id":"W4213002141","doi":"10.1200/jco.2022.40.6_suppl.101","title":"Impact of concomitant cardiovascular therapies on efficacy and safety of relugolix verus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase 3 HERO study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Concomitant; Adverse effect; Internal medicine; Population; Clinical endpoint; Urology; Cancer; Oncology; Randomized controlled trial","score_opus":0.06994853966378729,"score_gpt":0.47151785376177063,"score_spread":0.40156931409798335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213002141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98804164,0.009442997,0.000004099089,0.0013561795,0.00006868452,0.0008845495,0.00007838911,0.000002584161,0.00012085036],"genre_scores_gemma":[0.99090403,0.008783016,0.00007333265,0.00006740142,0.00008700072,0.000031951415,0.0000070246274,0.000013632924,0.000032586544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99610555,0.0012981382,0.001481743,0.00022727024,0.00068185193,0.00020544873],"domain_scores_gemma":[0.99567103,0.0025214013,0.0010819988,0.0003292274,0.00024622105,0.00015010567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035640183,0.00014749078,0.002197952,0.00018311734,0.00006401497,0.0000042832385,0.00017851537,0.00006876293,0.00009333585],"category_scores_gemma":[0.00035996654,0.00007107921,0.00069529953,0.0005319332,0.0003053262,0.000053009462,0.00007375338,0.0008680102,1.4624725e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16285102,0.004668146,0.71277183,0.000011303288,0.02190058,0.000609912,0.0024747944,0.004031968,0.00022066146,0.0000021654562,0.00006611589,0.0903915],"study_design_scores_gemma":[0.074736126,0.06391863,0.85458827,0.00006538463,0.0028912106,0.000016094114,0.002496491,0.000113281654,0.00007681437,0.000024396808,0.0010073396,0.00006597884],"about_ca_topic_score_codex":0.0013850363,"about_ca_topic_score_gemma":0.00025324814,"teacher_disagreement_score":0.14181642,"about_ca_system_score_codex":0.00041571405,"about_ca_system_score_gemma":0.0013832332,"threshold_uncertainty_score":0.37711206},"labels":[],"label_agreement":null},{"id":"W4213017791","doi":"10.1200/jco.2022.40.6_suppl.149","title":"A microRNA-based classifier for identification of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Applied Biological Materials (Canada)","funders":"U.S. Department of Defense","keywords":"Enzalutamide; Prostate cancer; Neuroendocrine differentiation; Chromogranin A; Androgen receptor; Cancer research; LNCaP; Synaptophysin; Medicine; Androgen deprivation therapy; microRNA; Cancer; Immunohistochemistry; Biology; Pathology; Internal medicine; Gene; Genetics","score_opus":0.18065944680797397,"score_gpt":0.5010320664564488,"score_spread":0.32037261964847485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213017791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849772,0.0005596945,0.00021655868,0.0127932215,0.00061797496,0.00072413275,0.00007935504,0.0000029555963,0.000028938814],"genre_scores_gemma":[0.99814457,0.00027069708,0.0005897928,0.00025705856,0.00010490546,0.00013103303,0.00003725668,0.000011819323,0.00045284748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99683315,0.00042701833,0.0020602783,0.00014786593,0.0003613746,0.0001702968],"domain_scores_gemma":[0.99675775,0.0009421392,0.001678693,0.00011096252,0.00040406742,0.000106367785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016620561,0.00008045853,0.00072091946,0.00023559366,0.000052022802,0.000006360273,0.00009804559,0.00002855712,0.00009965135],"category_scores_gemma":[0.000821817,0.000060292085,0.00026120522,0.00022218536,0.000088877125,0.00006386179,0.00002285378,0.00044976646,4.358207e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14863624,0.016539495,0.32834923,0.0012051312,0.0014358571,0.0017158721,0.0006877818,0.005059398,0.30612317,0.00044618477,0.006467223,0.18333441],"study_design_scores_gemma":[0.049280122,0.028112799,0.8739677,0.00013087002,0.0009242191,0.000117309,0.00062763947,0.008041467,0.018260116,0.0009822109,0.019402232,0.00015331173],"about_ca_topic_score_codex":0.000039318584,"about_ca_topic_score_gemma":0.00010396651,"teacher_disagreement_score":0.5456185,"about_ca_system_score_codex":0.00033035432,"about_ca_system_score_gemma":0.0024462636,"threshold_uncertainty_score":0.43395665},"labels":[],"label_agreement":null},{"id":"W4213025187","doi":"10.1200/jco.2022.40.6_suppl.279","title":"Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; BC Cancer Agency","funders":"Janssen Research and Development","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Pharmacokinetics; Pharmacodynamics; Cancer; Oncology; Pharmacology; Urology; Gastroenterology; Androgen receptor","score_opus":0.21401462625642037,"score_gpt":0.5365450964972351,"score_spread":0.32253047024081477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213025187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97445303,0.013745303,0.00005616732,0.009281633,0.00067805813,0.0014045252,0.00028081462,0.000004177777,0.00009628095],"genre_scores_gemma":[0.9379048,0.060049728,0.00083196413,0.00011335475,0.00028219182,0.0000704315,0.000009536558,0.000022541128,0.0007154538],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995581,0.0009243903,0.002380279,0.00031771217,0.0004759387,0.00032072398],"domain_scores_gemma":[0.98992634,0.0071135256,0.0019727908,0.00025737964,0.00041367835,0.00031628943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042413957,0.0002045625,0.0020504545,0.00013350307,0.00017780835,0.000008923148,0.00014696187,0.00013408634,0.00009620364],"category_scores_gemma":[0.00058458856,0.00011182192,0.00055661454,0.0001922638,0.00096329453,0.0000792233,0.00010931575,0.0006428692,2.9129654e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2680245,0.011171659,0.11817168,0.00043144764,0.0043524047,0.0008403706,0.0010273833,0.000080912236,0.0030674296,0.0001101926,0.00095915946,0.59176284],"study_design_scores_gemma":[0.03904802,0.18129918,0.69457316,0.0001528,0.0028917259,0.00038859266,0.001290003,0.00084005966,0.0006997683,0.00029497794,0.07836161,0.0001600915],"about_ca_topic_score_codex":0.0001689104,"about_ca_topic_score_gemma":0.00008035969,"teacher_disagreement_score":0.59160274,"about_ca_system_score_codex":0.00025299602,"about_ca_system_score_gemma":0.002499045,"threshold_uncertainty_score":0.45599657},"labels":[],"label_agreement":null},{"id":"W4213038657","doi":"10.1200/jco.2022.40.6_suppl.118","title":"Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone (p) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from KEYNOTE-365 cohort D.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Abiraterone acetate; Cohort; Internal medicine; Pembrolizumab; Oncology; Urology; Cancer; Surgery; Androgen deprivation therapy","score_opus":0.06470924380485907,"score_gpt":0.412626171794028,"score_spread":0.34791692798916896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213038657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98949385,0.0010840375,0.000006392382,0.007234573,0.0003623481,0.0011967202,0.00034601183,0.000009861959,0.00026619693],"genre_scores_gemma":[0.99505144,0.0015907075,0.0013430301,0.0008014115,0.00017574932,0.00009128756,0.00010885781,0.00003776629,0.00079971884],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9953968,0.00072653196,0.00214429,0.00043781867,0.00088261685,0.000411954],"domain_scores_gemma":[0.99645615,0.0009374191,0.001522859,0.00023897031,0.0004640367,0.00038058136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018584918,0.00024308151,0.0015820677,0.0001996522,0.00012595355,0.000025926036,0.00016466886,0.000119716846,0.00020021119],"category_scores_gemma":[0.00040492733,0.00016099005,0.00015052552,0.0002821202,0.00032021123,0.0001861715,0.00009572134,0.0012246534,0.0000024816618],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47847572,0.0037510507,0.4609899,0.00007961821,0.0022630799,0.0018802993,0.0026234845,0.0008326194,0.00036232875,0.0000072422476,0.0017697526,0.04696492],"study_design_scores_gemma":[0.12866443,0.022612175,0.8433027,0.00013440692,0.00047987598,0.000041669842,0.00052571134,0.0002634707,0.00012212318,0.00011936874,0.0035656441,0.00016841236],"about_ca_topic_score_codex":0.0010324578,"about_ca_topic_score_gemma":0.0004138196,"teacher_disagreement_score":0.3823128,"about_ca_system_score_codex":0.00094903493,"about_ca_system_score_gemma":0.0031840045,"threshold_uncertainty_score":0.6564984},"labels":[],"label_agreement":null},{"id":"W4213066787","doi":"10.1200/jco.2022.40.6_suppl.tps284","title":"DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University; Ottawa Hospital; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Placebo; Internal medicine; Docetaxel; Randomization; Oncology; Randomized controlled trial; Antiandrogen; Tolerability; Urology; Cancer; Adverse effect; Pathology","score_opus":0.1202845928115184,"score_gpt":0.46894021180677387,"score_spread":0.34865561899525543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213066787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97979486,0.0026115058,0.00047600782,0.003944449,0.0009242584,0.011875917,0.0003150521,0.000007904149,0.000050062004],"genre_scores_gemma":[0.9773761,0.018385144,0.0010333224,0.0008480951,0.00040883714,0.0017141777,0.000028541617,0.000036798072,0.00016900558],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932301,0.0022240218,0.0030014664,0.0003108539,0.00090826716,0.0003252981],"domain_scores_gemma":[0.9869857,0.008039513,0.0037103,0.0002507494,0.0007642704,0.00024949003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010414128,0.00023615964,0.0032228157,0.0002866356,0.00023003129,0.000017472425,0.0002504127,0.00019209865,0.00020000344],"category_scores_gemma":[0.0031752104,0.00012486785,0.0008229181,0.0003594214,0.00039112824,0.00012297095,0.00009419996,0.0007293619,2.5652776e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8708524,0.0020333847,0.0022331835,0.000025929578,0.0034927079,0.000026578731,0.0006601898,0.00021186382,0.00052315975,0.000059765433,0.00038300705,0.11949781],"study_design_scores_gemma":[0.9488745,0.039861456,0.0005286126,0.000083900115,0.0009581118,0.000014530236,0.00018163804,0.00034421706,0.0024429876,0.0006045516,0.005992079,0.00011341709],"about_ca_topic_score_codex":0.00011319839,"about_ca_topic_score_gemma":0.000027367221,"teacher_disagreement_score":0.1193844,"about_ca_system_score_codex":0.00041428444,"about_ca_system_score_gemma":0.004302416,"threshold_uncertainty_score":0.7632301},"labels":[],"label_agreement":null},{"id":"W4213087577","doi":"10.1200/jco.2022.40.6_suppl.277","title":"Local failure, distant metastasis, and survival after definitive radiotherapy for intermediate- and high-risk prostate cancer: An individual patient-level meta-analysis of 18 randomized trials.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"Medical Research Council","keywords":"Medicine; Prostate cancer; Randomized controlled trial; Randomization; Internal medicine; Proportional hazards model; Radiation therapy; Oncology; Survival analysis; Cancer","score_opus":0.28879920908749546,"score_gpt":0.4965052661920813,"score_spread":0.20770605710458584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213087577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624431,0.02623943,0.0021239533,0.0030902259,0.0005895045,0.0016109375,0.003888917,0.0000050270087,0.000008908128],"genre_scores_gemma":[0.98038554,0.014141715,0.0042298567,0.00049216056,0.0001551946,0.0004303517,0.000099336896,0.000023686453,0.00004217579],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9888319,0.006286902,0.0035601829,0.00034285404,0.00069621,0.00028198896],"domain_scores_gemma":[0.9802376,0.015306108,0.0033347365,0.00016665598,0.0005470482,0.0004078526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021470591,0.00022773058,0.008028391,0.00045880972,0.00009599149,0.000021182586,0.00012979443,0.00016501937,0.0006365756],"category_scores_gemma":[0.0040810043,0.00012681483,0.0023290606,0.00031502405,0.00088438403,0.00011971635,0.00011074651,0.0008168254,8.015631e-8],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54767716,0.0014128636,0.014263766,0.00004133868,0.30628774,0.0001726936,0.0014112596,0.00006332047,0.000012418573,0.00008311871,0.0003489191,0.12822542],"study_design_scores_gemma":[0.3758036,0.036568232,0.030763883,0.000015363878,0.5442531,0.00004158971,0.002308033,0.00062327896,0.000145222,0.0013653887,0.007874111,0.00023820275],"about_ca_topic_score_codex":0.0002532588,"about_ca_topic_score_gemma":0.00033864664,"teacher_disagreement_score":0.23796538,"about_ca_system_score_codex":0.00015812537,"about_ca_system_score_gemma":0.0011471807,"threshold_uncertainty_score":0.7441321},"labels":[],"label_agreement":null},{"id":"W4213095052","doi":"10.1200/jco.2022.40.6_suppl.035","title":"Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"","keywords":"Medicine; Standardized uptake value; Prostate cancer; Nuclear medicine; Prostatectomy; Biopsy; Radiology; Cohort; Cancer; Positron emission tomography; Pathology; Internal medicine","score_opus":0.08366524849573825,"score_gpt":0.4622275587104839,"score_spread":0.3785623102147456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213095052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944097,0.0025158986,0.0000032001801,0.0015275775,0.00026091278,0.0005520675,0.0005113685,0.000004940031,0.00021433944],"genre_scores_gemma":[0.9930002,0.0060196877,0.00033175916,0.00025941752,0.000061421764,0.000026436213,0.000089663736,0.000015754185,0.00019567773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954406,0.00088769523,0.0022645406,0.00036451424,0.0007389403,0.0003037227],"domain_scores_gemma":[0.99668443,0.00089448446,0.001364122,0.00018814657,0.0004347778,0.00043405997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039910157,0.0001672969,0.001866549,0.00038469606,0.00008298798,0.000017954622,0.00011486462,0.00004246534,0.0001482012],"category_scores_gemma":[0.0010890499,0.00011946995,0.00024249793,0.0005774274,0.00029371853,0.00016870657,0.00010440817,0.00090039085,1.3700291e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056805406,0.0035938828,0.8811066,0.00006587018,0.0024054,0.0016840163,0.0004743356,0.0002779986,0.00035988356,0.00001511891,0.0024676102,0.050743856],"study_design_scores_gemma":[0.04265883,0.033632405,0.90958065,0.0001319411,0.0023109561,0.00010426305,0.00088549854,0.0011882436,0.00020590296,0.00013879775,0.008999429,0.00016305843],"about_ca_topic_score_codex":0.0004913002,"about_ca_topic_score_gemma":0.00059344753,"teacher_disagreement_score":0.050580796,"about_ca_system_score_codex":0.00038494548,"about_ca_system_score_gemma":0.0016260546,"threshold_uncertainty_score":0.48718432},"labels":[],"label_agreement":null},{"id":"W4213167571","doi":"10.1200/jco.2022.40.6_suppl.tps190","title":"IRONMAN: The international registry for men with advanced prostate cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Movember Foundation","keywords":"Medicine; Prostate cancer; Cancer registry; Cohort; Ethnic group; Population; Socioeconomic status; Cancer; Disease; Quality of life (healthcare); Gerontology; Demography; Environmental health; Internal medicine","score_opus":0.12151832978571304,"score_gpt":0.5171844721595642,"score_spread":0.39566614237385117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213167571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7278818,0.0024528631,0.000056513956,0.2555585,0.001701508,0.0009665286,0.000055322093,0.000009519097,0.011317475],"genre_scores_gemma":[0.96603763,0.0034399177,0.0021150527,0.0040060114,0.0016255837,0.00028233448,0.000017231161,0.000024226618,0.022452034],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843115,0.00012308075,0.00071173586,0.0001244599,0.00044430594,0.00016529324],"domain_scores_gemma":[0.9977599,0.0008630544,0.00080817076,0.00013289036,0.0003036757,0.00013232784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001840474,0.00006864859,0.00046537037,0.00004291927,0.00011999671,0.000007836519,0.0002618209,0.00004961756,0.00028507423],"category_scores_gemma":[0.0004708584,0.000033637378,0.00019265916,0.000077907636,0.00017391186,0.000054636006,0.00008246495,0.0007492001,0.0000011752842],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.124689355,0.002254272,0.121904366,0.000057763576,0.0020363093,0.0011206468,0.0006377233,0.00088615966,0.0004951372,0.00035976895,0.20357582,0.54198265],"study_design_scores_gemma":[0.017505148,0.019210337,0.028008822,0.000035401663,0.00019254643,0.00034721172,0.0010763122,0.000240565,0.00012345563,0.00036653332,0.93283886,0.000054790395],"about_ca_topic_score_codex":0.000011115132,"about_ca_topic_score_gemma":0.000013967319,"teacher_disagreement_score":0.72926307,"about_ca_system_score_codex":0.00037728963,"about_ca_system_score_gemma":0.0023488952,"threshold_uncertainty_score":0.4166839},"labels":[],"label_agreement":null},{"id":"W4213176808","doi":"10.1016/j.clgc.2022.02.004","title":"Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targets","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University Health Network; Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Oncology; Internal medicine; Androgen deprivation therapy; Cohort; Cancer; Cancer research","score_opus":0.08870405857679521,"score_gpt":0.40095933957297974,"score_spread":0.31225528099618455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213176808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97076434,0.023410706,0.000010403718,0.0008062276,0.00066658034,0.002184591,0.002025148,0.000030762447,0.00010123433],"genre_scores_gemma":[0.98646194,0.009259331,0.0012918209,0.00019416021,0.00029036272,0.0007670157,0.00020777764,0.000064812535,0.0014628092],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99635905,0.00066079496,0.0012255034,0.0006572169,0.0005375607,0.0005598845],"domain_scores_gemma":[0.99785864,0.00027111598,0.00062195613,0.0004717252,0.00053181534,0.00024472992],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003865925,0.00035424242,0.0012237283,0.00017574355,0.0002189162,0.000008766758,0.00016639836,0.00007463459,0.00059701107],"category_scores_gemma":[0.000019034467,0.00027600434,0.00044920036,0.00037167082,0.0004516658,0.00006452319,0.00016928987,0.00046297818,0.000004542203],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02061582,0.0026874696,0.06553061,0.001134632,0.005748986,0.0030856533,0.0014520753,0.0037343623,0.8730453,0.0000709607,0.00032011003,0.022573965],"study_design_scores_gemma":[0.048841935,0.058443457,0.57847935,0.0009796263,0.007902767,0.00040022362,0.009321437,0.0014826043,0.28690988,0.0025541224,0.002787991,0.0018965772],"about_ca_topic_score_codex":0.0015668918,"about_ca_topic_score_gemma":0.00002875502,"teacher_disagreement_score":0.58613545,"about_ca_system_score_codex":0.0009864194,"about_ca_system_score_gemma":0.0020519155,"threshold_uncertainty_score":0.9999692},"labels":[],"label_agreement":null},{"id":"W4213184329","doi":"10.1200/jco.2022.40.6_suppl.069","title":"First look at patient reported outcomes from IRONMAN, the international registry of men with advanced prostate cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Movember Foundation","keywords":"Medicine; Prostate cancer; Quality of life (healthcare); Cancer registry; Population; Cohort; Cancer; Internal medicine; Gynecology; Physical therapy; Environmental health","score_opus":0.09518366232032556,"score_gpt":0.45430079222864544,"score_spread":0.3591171299083199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213184329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94788796,0.0010553014,0.000002561973,0.04717736,0.00070683757,0.00032783407,0.000044186123,0.0000045239394,0.002793452],"genre_scores_gemma":[0.9914917,0.0020084463,0.000491004,0.0010839339,0.00021170233,0.0000532201,0.00001979379,0.0000142860235,0.0046259314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725366,0.00017281693,0.001461159,0.00017357069,0.00078135397,0.0001574496],"domain_scores_gemma":[0.99584,0.0010978509,0.0023146162,0.00026532603,0.000333379,0.00014882153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009884799,0.00009861946,0.0007637946,0.00005205383,0.00010453022,0.0000046137857,0.00025419667,0.00006679269,0.0008520154],"category_scores_gemma":[0.0007018413,0.00004872092,0.00023698603,0.00009062912,0.00026680602,0.00005220623,0.00021803511,0.0007294816,0.0000015132463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02901232,0.0012077788,0.9126622,0.000015077755,0.0016819069,0.0016064423,0.0006026805,0.0005656751,0.00017451105,0.000008229108,0.01863721,0.03382597],"study_design_scores_gemma":[0.017422084,0.014329855,0.665977,0.00009957854,0.00040533516,0.0002837713,0.0014453294,0.00010663205,0.0004406775,0.00016224963,0.29923952,0.00008794759],"about_ca_topic_score_codex":0.00012945467,"about_ca_topic_score_gemma":0.00015850787,"teacher_disagreement_score":0.2806023,"about_ca_system_score_codex":0.00065893936,"about_ca_system_score_gemma":0.0014979398,"threshold_uncertainty_score":0.9328971},"labels":[],"label_agreement":null},{"id":"W4213223108","doi":"10.1200/jco.2022.40.6_suppl.060","title":"Treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC) following progression on upfront androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI) for metastatic castration-sensitive prostate cancer (mCSPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Abbotsford Veterinary Clinic; BC Cancer Agency; Kelowna General Hospital; University of British Columbia","funders":"BC Cancer Foundation","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Docetaxel; Oncology; Androgen deprivation therapy; Proportional hazards model; Abiraterone acetate; Progression-free survival; Cancer; Chemotherapy; Androgen receptor","score_opus":0.13477310959720806,"score_gpt":0.4716707362161949,"score_spread":0.3368976266189868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213223108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786216,0.0022862877,0.00011067562,0.010583333,0.0011485488,0.006451038,0.0007414642,0.000025096428,0.00003195615],"genre_scores_gemma":[0.9836919,0.0018684308,0.007740849,0.0006230029,0.00043900713,0.0042197374,0.0003163019,0.00009252825,0.0010082821],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.995161,0.000646426,0.0020898296,0.0005625741,0.00094741426,0.00059276127],"domain_scores_gemma":[0.99455833,0.0018648073,0.0020539958,0.00023630015,0.0008778891,0.0004086599],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002104937,0.00042968462,0.0018503929,0.0002668238,0.00049475604,0.000052994958,0.00013270517,0.00011602061,0.00007363489],"category_scores_gemma":[0.0004033821,0.0002523378,0.00077647634,0.0003002443,0.00015990355,0.00026827332,0.00003261287,0.0005151268,0.0000014942528],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18877518,0.010796628,0.11322229,0.0003415661,0.014137538,0.0020658213,0.0055401507,0.0025979641,0.015202653,0.00013959057,0.0020069901,0.6451736],"study_design_scores_gemma":[0.26415175,0.3992081,0.050439503,0.0014375984,0.0073663057,0.00056161516,0.00984921,0.0021064328,0.09830003,0.0010063009,0.16389585,0.0016773044],"about_ca_topic_score_codex":0.00015028128,"about_ca_topic_score_gemma":0.00042187367,"teacher_disagreement_score":0.64349633,"about_ca_system_score_codex":0.001737991,"about_ca_system_score_gemma":0.00629689,"threshold_uncertainty_score":0.9999929},"labels":[],"label_agreement":null},{"id":"W4213229213","doi":"10.1200/jco.2022.40.6_suppl.104","title":"Testosterone recovery for relugolix versus leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Testosterone (patch); Prostate cancer; Androgen deprivation therapy; Urology; Population; Adverse effect; Androgen; Internal medicine; Gynecology; Cancer; Hormone","score_opus":0.17911277608448398,"score_gpt":0.5206814600689443,"score_spread":0.3415686839844604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213229213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96659386,0.0015652213,0.0000059959593,0.028300257,0.00086951896,0.0017766504,0.00017770602,0.000007299366,0.0007034591],"genre_scores_gemma":[0.9939102,0.0019663135,0.00074203854,0.00079607696,0.00070979475,0.00032931045,0.000033353568,0.000028085497,0.0014848217],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965332,0.00065311685,0.0016676966,0.00029791414,0.0005237314,0.00032430593],"domain_scores_gemma":[0.9919751,0.006058287,0.0012078043,0.0002716549,0.00028560677,0.00020153518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003865628,0.00014239858,0.0010505822,0.00008960399,0.00013242583,0.000010991221,0.00024669492,0.000084466046,0.00005817732],"category_scores_gemma":[0.002144316,0.00007666368,0.00018577125,0.00024751306,0.00014541784,0.00011499976,0.00010870173,0.0012491698,0.0000014944499],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6662197,0.0053895297,0.028538588,0.000009781178,0.0007855651,0.001257622,0.0012627936,0.00048947777,0.0001187442,0.0000020564923,0.008722731,0.2872034],"study_design_scores_gemma":[0.48131844,0.29650944,0.070619546,0.00016088605,0.0007077591,0.00006730403,0.008111762,0.00020827103,0.00014081286,0.0003082874,0.14166388,0.00018359175],"about_ca_topic_score_codex":0.00030140806,"about_ca_topic_score_gemma":0.0007629068,"teacher_disagreement_score":0.29111993,"about_ca_system_score_codex":0.0007023684,"about_ca_system_score_gemma":0.0029008857,"threshold_uncertainty_score":0.54270905},"labels":[],"label_agreement":null},{"id":"W4213247158","doi":"10.1016/s1470-2045(22)00017-1","title":"Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; National Institute for Health and Care Research; Merck; AstraZeneca","keywords":"Prostate cancer; Homologous recombination; Olaparib; Drug; Quality of life (healthcare); Hormonal therapy; Gene","score_opus":0.20043690397895775,"score_gpt":0.42880753078566086,"score_spread":0.22837062680670311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213247158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99082243,0.000544081,0.000016550688,0.0031910744,0.000082855084,0.0050917054,0.00018779236,0.000018074214,0.00004545159],"genre_scores_gemma":[0.9960564,0.000087675355,0.00084711664,0.00027989838,0.000061160645,0.001526685,0.0010519531,0.000019441191,0.00006966885],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99636906,0.00204212,0.0006085206,0.00031848904,0.00039818435,0.00026362218],"domain_scores_gemma":[0.9983331,0.00037174052,0.0006654956,0.0002716794,0.00026956317,0.0000884314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028627834,0.00015813678,0.0008145297,0.000101213016,0.0002768169,0.00002264295,0.00012647136,0.000028314033,0.00002357975],"category_scores_gemma":[0.00008140466,0.000095408024,0.000018695599,0.00041516326,0.00021752574,0.00022617963,0.00004488287,0.00027498213,1.0732217e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97066516,0.006356804,0.007749213,0.0001658119,0.00072714,0.000016389466,0.00325416,0.00074193825,0.0030895448,0.00025987186,0.00031818144,0.006655777],"study_design_scores_gemma":[0.8950447,0.07650894,0.024253303,0.00005800952,0.00024129328,0.0000030990464,0.00082447205,0.0024878965,0.00025768948,0.00006966136,0.000083848696,0.00016709362],"about_ca_topic_score_codex":0.004082114,"about_ca_topic_score_gemma":0.008301661,"teacher_disagreement_score":0.07562047,"about_ca_system_score_codex":0.0004883006,"about_ca_system_score_gemma":0.0017714634,"threshold_uncertainty_score":0.61709625},"labels":[],"label_agreement":null},{"id":"W4213250899","doi":"10.1002/pros.24312","title":"Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups","year":2022,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Chemotherapy; Confidence interval; Prostate cancer; Proportional hazards model; Cancer; Propensity score matching; Oncology","score_opus":0.022308737492848046,"score_gpt":0.3627083189889574,"score_spread":0.3403995814961093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213250899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98652846,0.0018004518,0.0000075624635,0.007583848,0.0001266622,0.0035953429,0.00009365992,0.000038584192,0.00022545374],"genre_scores_gemma":[0.9942363,0.0006902762,0.00005962653,0.00049641106,0.000031491203,0.0018499685,0.000025814405,0.00004582206,0.002564305],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997916,0.00041913366,0.0003218483,0.00031737832,0.0005260683,0.0004995977],"domain_scores_gemma":[0.99911207,0.00023824122,0.000111861045,0.00036336094,0.00006038779,0.00011408246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017516817,0.0002045501,0.0004956656,0.00020496709,0.00018228395,0.000016218783,0.00021631,0.000017055767,0.00022340383],"category_scores_gemma":[0.000061341154,0.00012264906,0.000104715284,0.0009431566,0.00010172272,0.000070024646,0.00022591182,0.00042265616,0.00001142789],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062155347,0.0010006068,0.40479472,0.0019581667,0.00091605785,0.0004260079,0.045061808,0.003736132,0.16996065,0.00011411399,0.0020923675,0.30778405],"study_design_scores_gemma":[0.056748237,0.023783913,0.10739081,0.0009909952,0.0007850513,0.00016108098,0.009000599,0.0036433535,0.77941424,0.001460895,0.015397252,0.0012235693],"about_ca_topic_score_codex":0.0007560489,"about_ca_topic_score_gemma":0.000042002972,"teacher_disagreement_score":0.6094536,"about_ca_system_score_codex":0.0003842642,"about_ca_system_score_gemma":0.0001980842,"threshold_uncertainty_score":0.5001483},"labels":[],"label_agreement":null},{"id":"W4213263260","doi":"10.26226/morressier.5cdc25c8bf4ffc620542109c","title":"A description of patients with prostate cancer seen at BC Cancer at first oncologist visit","year":2019,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Provincial Health Services Authority","funders":"","keywords":"Prostate cancer; Cancer; Medicine; Oncology; Internal medicine; Radiation oncologist; General surgery; Medical physics; Radiation therapy","score_opus":0.0397761435469621,"score_gpt":0.3283455680690814,"score_spread":0.2885694245221193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213263260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850465,0.0025446157,0.000010489188,0.0014809719,0.00048566042,0.0040458506,0.0009554515,0.00006666753,0.0053637763],"genre_scores_gemma":[0.8422399,0.005972079,0.00015112439,0.00014243634,0.00011120661,0.0010541923,0.0012656014,0.00006466215,0.14899875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756783,0.00004107405,0.00039200287,0.0007297323,0.0007718235,0.00049756165],"domain_scores_gemma":[0.99814945,0.000041540035,0.0003520544,0.00060171523,0.000652253,0.00020295464],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001170685,0.00040315127,0.00078763557,0.00016226343,0.00011712539,0.000024749274,0.0001689395,0.00031209135,0.0027811462],"category_scores_gemma":[0.000013470447,0.00024651794,0.00014775233,0.00016306066,0.00023063374,0.00007462318,0.000811975,0.00042142,0.00007636362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0094953785,0.0003616384,0.9703616,0.0021913892,0.0006662331,0.000020187827,0.00069812156,0.00056012516,0.00017157257,0.0000015595389,0.013566723,0.0019054689],"study_design_scores_gemma":[0.008647749,0.0013274308,0.9544677,0.0020343221,0.00055742904,0.0000015431011,0.000052943346,0.00025067708,0.004087031,0.000013278266,0.028146742,0.00041311161],"about_ca_topic_score_codex":0.012569233,"about_ca_topic_score_gemma":0.013484108,"teacher_disagreement_score":0.14363499,"about_ca_system_score_codex":0.004696509,"about_ca_system_score_gemma":0.0009999302,"threshold_uncertainty_score":0.9999987},"labels":[],"label_agreement":null},{"id":"W4213290660","doi":"10.1200/jco.2022.40.6_suppl.086","title":"Evolving real-world patterns of practice in metastatic castration-sensitive prostate cancer (mCSPC): The genitourinary research consortium (GURC) national multicenter cohort study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of British Columbia; BC Cancer Agency; Centre Hospitalier de l’Université de Montréal; Université Laval; University of Manitoba; Juravinski Cancer Centre; St. Joseph’s Healthcare Hamilton; Hôpital Charles-Le Moyne; University of Toronto; University of Calgary; Princess Margaret Cancer Centre; CancerCare Manitoba; Ottawa Hospital; University of Ottawa; McGill University; McMaster University; Jewish General Hospital","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Docetaxel; Cohort; Oncology; Internal medicine; Cancer; Androgen receptor","score_opus":0.21638830712805274,"score_gpt":0.5691707472062537,"score_spread":0.352782440078201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213290660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797119,0.00050746667,0.0000025642075,0.014597465,0.0005710787,0.0016819938,0.000046513902,0.0000033690787,0.0028776827],"genre_scores_gemma":[0.996089,0.0012246772,0.0002907343,0.000497059,0.00039494302,0.00018324771,0.000009566144,0.000017275017,0.0012935337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99027187,0.0050079986,0.0021111474,0.00026124125,0.0019968888,0.0003508736],"domain_scores_gemma":[0.98341495,0.0119176805,0.0013669103,0.00018100633,0.0029402399,0.00017918626],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.019983577,0.00011963538,0.0009088779,0.0004318477,0.00019178037,0.000016395872,0.00020435458,0.00005333129,0.00038821643],"category_scores_gemma":[0.006112733,0.00007633416,0.00019527406,0.0005344573,0.00030168824,0.00021236925,0.00020987276,0.0024222285,0.00000331306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012582829,0.0062809624,0.96492577,0.00003640629,0.001253694,0.0040542227,0.002737541,0.0003048021,0.00010677963,0.000037859572,0.0017103448,0.005968783],"study_design_scores_gemma":[0.00927799,0.01016776,0.96208805,0.00007467448,0.00035484042,0.00022348118,0.0123374285,0.00031270596,0.000056199904,0.00007897646,0.0049628434,0.00006507676],"about_ca_topic_score_codex":0.002059038,"about_ca_topic_score_gemma":0.0019391312,"teacher_disagreement_score":0.016377099,"about_ca_system_score_codex":0.0010822762,"about_ca_system_score_gemma":0.0059791342,"threshold_uncertainty_score":0.99987924},"labels":[],"label_agreement":null},{"id":"W4213301220","doi":"10.1038/s41391-022-00514-9","title":"Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada","year":2022,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia; BC Cancer Agency; Cancer Care Ontario; Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Calgary; University of Ottawa; McGill University; University of Alberta; Jewish General Hospital; Ottawa Hospital; University of Toronto; McMaster University; Juravinski Cancer Centre; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Tolerability; Internal medicine; Cabazitaxel; Population; Retrospective cohort study; Oncology; Cohort; Neutropenia; Febrile neutropenia; Cancer; Androgen deprivation therapy; Chemotherapy; Adverse effect","score_opus":0.017530384419952312,"score_gpt":0.31834282231287525,"score_spread":0.30081243789292295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213301220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860016,0.0033455468,0.000001239216,0.00064972544,0.00005572662,0.007352211,0.0024421297,0.00003376355,0.000118022064],"genre_scores_gemma":[0.99037886,0.0016759468,0.000042646465,0.00011542842,0.0000098835635,0.0060809436,0.00048491382,0.000058533376,0.0011528762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704826,0.0001928567,0.0005703038,0.0006995567,0.0009972107,0.0004918023],"domain_scores_gemma":[0.99870783,0.00015650812,0.00031654892,0.00027957134,0.00024001295,0.00029955283],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026186134,0.00036829477,0.00088547094,0.0003447972,0.00027381466,0.00004819899,0.00008437583,0.00001448716,0.0001303719],"category_scores_gemma":[0.000040481747,0.00027652617,0.000042781336,0.00093078695,0.00017084637,0.0002035796,0.000089681635,0.00023070224,1.4541004e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021628824,0.00056992145,0.99018425,0.0008069453,0.000507067,0.0001493628,0.0018941119,0.00064597337,0.00000649344,0.000016763179,0.00013508569,0.0029211743],"study_design_scores_gemma":[0.009100268,0.0007282549,0.98274404,0.00023922934,0.0007374468,0.0000022074155,0.003964056,0.0019921295,0.000055503508,0.00011349542,0.000019760426,0.0003036166],"about_ca_topic_score_codex":0.8479103,"about_ca_topic_score_gemma":0.7001885,"teacher_disagreement_score":0.14772174,"about_ca_system_score_codex":0.0016755153,"about_ca_system_score_gemma":0.0032178836,"threshold_uncertainty_score":0.9999687},"labels":[],"label_agreement":null},{"id":"W4213306332","doi":"10.1200/jco.2022.40.6_suppl.073","title":"Association between patient-reported outcomes (PROs) and changes in prostate-specific antigen (PSA) in patients (pts) with advanced prostate cancer treated with apalutamide (APA) in the SPARTAN and TITAN studies.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Proportional hazards model; Titan (rocket family); Placebo; Androgen deprivation therapy; Post-hoc analysis; Prostate-specific antigen; Prostate; Cancer; Urology; Pathology","score_opus":0.10570767842556247,"score_gpt":0.438367632866634,"score_spread":0.33265995444107155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213306332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98711747,0.0017999306,8.218901e-8,0.009525035,0.00009284562,0.0013837565,0.000022795517,0.000004741628,0.000053354714],"genre_scores_gemma":[0.9930403,0.0061675697,0.000076839824,0.00036368406,0.000045574758,0.00015050647,0.00002088461,0.000017513808,0.000117131836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99691534,0.0006168368,0.0011815104,0.00028155508,0.00065570214,0.00034902946],"domain_scores_gemma":[0.9973844,0.000858824,0.0012215456,0.00011952747,0.00029438277,0.00012126523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022970352,0.00017249714,0.0011927928,0.00027433853,0.000077728015,0.000013482503,0.0000778664,0.0000902152,0.000009557961],"category_scores_gemma":[0.0004359002,0.00009035933,0.00004308356,0.00049508235,0.00016765199,0.000120261255,0.000064948654,0.0009278796,1.6753536e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010395015,0.00091837917,0.93760365,0.000029430432,0.0003757254,0.00073376653,0.0028911587,0.000024869727,0.000013236797,0.000001016428,0.00011275787,0.046901017],"study_design_scores_gemma":[0.025424302,0.021897927,0.9462387,0.00016190179,0.0001293976,0.000014810687,0.0033836123,0.000005783295,0.000022226948,0.00003193773,0.002589425,0.00009997135],"about_ca_topic_score_codex":0.00012518714,"about_ca_topic_score_gemma":0.0025407437,"teacher_disagreement_score":0.046801046,"about_ca_system_score_codex":0.0009571274,"about_ca_system_score_gemma":0.00046376706,"threshold_uncertainty_score":0.40312266},"labels":[],"label_agreement":null},{"id":"W4213306983","doi":"10.1200/jco.2022.40.6_suppl.065","title":"Prevalence and natural history of non-metastatic castrate resistant prostate cancer: A population-based analysis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Interquartile range; Internal medicine; Hazard ratio; Population; Cancer; Urology; Oncology; Gynecology; Confidence interval","score_opus":0.0925722429414721,"score_gpt":0.4692166344822014,"score_spread":0.3766443915407293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213306983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854726,0.011048053,0.000008451854,0.0024609114,0.00058012136,0.00026007104,0.000032700005,0.000003165414,0.00013391917],"genre_scores_gemma":[0.99505126,0.0011766636,0.0009236872,0.00037635668,0.00008749676,0.000018278512,0.000010793166,0.0000085520405,0.00234688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99717516,0.00049381354,0.0014623262,0.00017299486,0.00051797694,0.00017772472],"domain_scores_gemma":[0.9968924,0.0009398546,0.0014762925,0.00013639183,0.00034567103,0.00020939365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023941519,0.00009563749,0.0011268611,0.00030803928,0.000046998535,0.0000029849225,0.00010371969,0.00004912938,0.00029881226],"category_scores_gemma":[0.00049426453,0.00006691035,0.00035449123,0.00030399178,0.00019915734,0.000058376452,0.000044470937,0.00075461547,3.328232e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017707983,0.0010760789,0.957702,0.00034698966,0.0018962168,0.0009598435,0.0002945543,0.0008033622,0.0006535546,0.000010162018,0.0014583763,0.017090907],"study_design_scores_gemma":[0.0069558737,0.008868553,0.9739103,0.000069067675,0.0023741003,0.000044043358,0.00010320528,0.0028619084,0.00002523706,0.000052314314,0.0046665715,0.00006883029],"about_ca_topic_score_codex":0.0003149834,"about_ca_topic_score_gemma":0.000112983864,"teacher_disagreement_score":0.017022077,"about_ca_system_score_codex":0.0009903581,"about_ca_system_score_gemma":0.004818194,"threshold_uncertainty_score":0.85472697},"labels":[],"label_agreement":null},{"id":"W4213308820","doi":"10.1200/jco.2022.40.6_suppl.075","title":"The effects of a preference-based exercise trial on outcomes in men on androgen deprivation therapy (ADT) for prostate cancer compared to an exercise randomized controlled trial of the same interventions.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Cancer Care Ontario; University Health Network; Toronto Metropolitan University; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Physical therapy; Psychological intervention; Androgen deprivation therapy; Randomization; Prostate cancer; Clinical trial; Aerobic exercise; Internal medicine; Cancer","score_opus":0.1778331054713292,"score_gpt":0.49773628455946867,"score_spread":0.3199031790881395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213308820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97106445,0.00071239145,0.000009843579,0.0064242845,0.0015091398,0.020220622,0.000017437056,0.0000033751282,0.000038449103],"genre_scores_gemma":[0.9931176,0.0017545951,0.00006808457,0.0002939688,0.00014893479,0.004260979,0.0000055304313,0.0000134670245,0.00033687957],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938154,0.002556378,0.0026532994,0.00016886204,0.0006149114,0.00019112413],"domain_scores_gemma":[0.98380274,0.013295953,0.0021652293,0.00025655684,0.0003564038,0.00012311702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008783084,0.00014009094,0.003157731,0.0001952656,0.000100571655,0.000008887918,0.0002922415,0.00010111232,0.000030206273],"category_scores_gemma":[0.00571553,0.000059123267,0.00151054,0.00018811937,0.00018417077,0.000033517194,0.0000431579,0.0005028305,2.1245012e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93926287,0.00690148,0.002020483,0.000058518388,0.0005919903,0.0000067882597,0.00034917746,0.00023678175,0.000083997365,0.000024065857,0.00028651673,0.050177317],"study_design_scores_gemma":[0.9364831,0.05593141,0.004303313,0.0005199854,0.000510972,4.407863e-7,0.000107788655,0.00029824182,0.0010269356,0.00048000136,0.00028772038,0.00005007696],"about_ca_topic_score_codex":0.00005654767,"about_ca_topic_score_gemma":0.00005505127,"teacher_disagreement_score":0.050127238,"about_ca_system_score_codex":0.00024561983,"about_ca_system_score_gemma":0.001626563,"threshold_uncertainty_score":0.6842436},"labels":[],"label_agreement":null},{"id":"W4213325738","doi":"10.1200/jco.2022.40.6_suppl.142","title":"Blood biomarkers and association with clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC): prespecified longitudinal analysis from the ACIS study of apalutamide (APA) or placebo combined with abiraterone acetate plus prednisone (AAP).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Oncology; Enzalutamide; Internal medicine; Androgen receptor; Proportional hazards model; Biomarker; Univariate analysis; Abiraterone; Population; Log-rank test; Cancer; Multivariate analysis; Androgen deprivation therapy; Biology","score_opus":0.1469827745264745,"score_gpt":0.4600745671581061,"score_spread":0.31309179263163156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213325738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992917,0.00043870282,0.000012756595,0.00475432,0.00017599326,0.001551542,0.00011634762,0.000006851479,0.000026467384],"genre_scores_gemma":[0.997497,0.00070535264,0.0008134809,0.00013389652,0.00007725827,0.00014006226,0.000019676627,0.00002132629,0.00059190457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929964,0.0023763075,0.0027068693,0.00040388957,0.0011916192,0.00032493935],"domain_scores_gemma":[0.9894202,0.0066873822,0.002888738,0.0002847241,0.00048182352,0.00023716688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062028114,0.00023077849,0.0024743457,0.000259347,0.00014126116,0.000031819138,0.00021974619,0.000111943256,0.0001825389],"category_scores_gemma":[0.0010745539,0.000110335604,0.00025850878,0.0008396951,0.00031093633,0.00013403405,0.000114505616,0.0011239477,4.2490757e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18543261,0.004927647,0.78229046,0.00002071391,0.021908771,0.0012466004,0.0012876575,0.0006762752,0.0000458931,0.0000013035558,0.00012155574,0.002040482],"study_design_scores_gemma":[0.07241511,0.048953373,0.8641083,0.00005050739,0.009839717,0.000026275844,0.004051269,0.00029808006,0.000026549385,0.000016648095,0.00010607222,0.000108097745],"about_ca_topic_score_codex":0.0014020365,"about_ca_topic_score_gemma":0.02061474,"teacher_disagreement_score":0.11301751,"about_ca_system_score_codex":0.00048839155,"about_ca_system_score_gemma":0.00256169,"threshold_uncertainty_score":0.9972565},"labels":[],"label_agreement":null},{"id":"W4213328782","doi":"10.1200/jco.2022.40.6_suppl.tps211","title":"PSMAfore: A phase 3 study to compare <sup>177</sup>Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Taxane; Glutamate carboxypeptidase II; Androgen receptor; Internal medicine; Androgen deprivation therapy; Urology; Oncology; Androgen; Cancer research; Cancer; Hormone; Breast cancer","score_opus":0.16307149764116535,"score_gpt":0.47556676565976025,"score_spread":0.3124952680185949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213328782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99161434,0.00053968845,0.0000011670302,0.0030966273,0.0001666411,0.0042257123,0.00030652192,0.000008540331,0.00004075838],"genre_scores_gemma":[0.9972145,0.00017722501,0.00056027237,0.00040743419,0.00023702979,0.0011147136,0.00008212278,0.000037702353,0.00016902256],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99529666,0.0009666941,0.0018480575,0.0004385863,0.0009349798,0.0005150143],"domain_scores_gemma":[0.9973065,0.00050283544,0.0009756751,0.00023691372,0.0004253961,0.0005526769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016351112,0.00030104944,0.0017649538,0.00044581178,0.00011400543,0.000021403117,0.00016519107,0.000050103754,0.0002475507],"category_scores_gemma":[0.00017103208,0.00017713635,0.0001512588,0.00076194305,0.00013014517,0.00016945213,0.00007933211,0.0008365943,0.000004113988],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10819262,0.03560573,0.75874674,0.000049314353,0.0007418201,0.005551854,0.011487974,0.00041115005,0.000035708534,0.0000019219144,0.00025761413,0.078917556],"study_design_scores_gemma":[0.22042194,0.44838268,0.2959678,0.0004524657,0.0006518042,0.00012388866,0.020483451,0.00028555823,0.00015569125,0.000011744201,0.012668186,0.00039478915],"about_ca_topic_score_codex":0.0014508951,"about_ca_topic_score_gemma":0.009494777,"teacher_disagreement_score":0.46277896,"about_ca_system_score_codex":0.0020414777,"about_ca_system_score_gemma":0.0038906108,"threshold_uncertainty_score":0.72234106},"labels":[],"label_agreement":null},{"id":"W4213332982","doi":"10.1200/jco.2022.40.6_suppl.tps191","title":"PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; CHEK2; PALB2; MSH2; Prostate cancer; MSH6; Genetic testing; PTEN; Oncology; Germline; MLH1; Internal medicine; Cancer; Germline mutation; Genetics; DNA mismatch repair; Mutation; Gene; Colorectal cancer; Biology","score_opus":0.1326945739031199,"score_gpt":0.507687326157604,"score_spread":0.37499275225448414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213332982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847338,0.0022331066,0.000020920215,0.0112656485,0.0003952349,0.0010902574,0.000154098,0.0000047437343,0.00010215194],"genre_scores_gemma":[0.9938202,0.0028732342,0.0010383935,0.000106833904,0.00020421366,0.00025799422,0.000020577236,0.000017188495,0.0016613986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817216,0.00034041426,0.0009490718,0.00018910281,0.00017678089,0.00017243886],"domain_scores_gemma":[0.99602777,0.0023041463,0.0010092399,0.00013188133,0.00030912878,0.00021783258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018332221,0.00011622363,0.0011921903,0.000082351085,0.00009388547,0.000006450819,0.000061531704,0.00009580135,0.000023777662],"category_scores_gemma":[0.001154775,0.00007286661,0.00023189606,0.0000857734,0.00029489465,0.000045149154,0.00005684618,0.00033238306,7.025678e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049463585,0.0034484018,0.69107735,0.00040099537,0.002269595,0.00030669218,0.0004167015,0.000024152858,0.002837365,0.00011207367,0.00048546196,0.24915764],"study_design_scores_gemma":[0.06444539,0.051205706,0.84559983,0.0001123264,0.0012069022,0.00024795256,0.0006635154,0.00030106117,0.00062433386,0.0008811068,0.034575645,0.00013623944],"about_ca_topic_score_codex":0.000111357454,"about_ca_topic_score_gemma":0.000050470328,"teacher_disagreement_score":0.2490214,"about_ca_system_score_codex":0.0002856276,"about_ca_system_score_gemma":0.0021746948,"threshold_uncertainty_score":0.38578153},"labels":[],"label_agreement":null},{"id":"W4213345473","doi":"10.1200/jco.2022.40.6_suppl.105","title":"Efficacy and safety of relugolix in black men with advanced prostate cancer: A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Subgroup analysis; Testosterone (patch); Randomized controlled trial; Internal medicine; Gynecology; Hormone antagonist; Urology; Oncology; Cancer; Hormone; Confidence interval; Endocrine system","score_opus":0.08102293201287776,"score_gpt":0.48518651769014726,"score_spread":0.4041635856772695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213345473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869011,0.0030772614,0.000008382329,0.0077513596,0.00014884994,0.0016968233,0.000032339154,0.0000037813713,0.0003800991],"genre_scores_gemma":[0.99244857,0.006761003,0.0001671367,0.00016493394,0.00015226778,0.00008657109,0.000010715007,0.0000135213395,0.00019525875],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99496275,0.0019753925,0.0019532552,0.0002588126,0.0006162549,0.00023355277],"domain_scores_gemma":[0.9904524,0.0074293907,0.0014418216,0.00024215497,0.00023430803,0.00019990755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059053577,0.00014632748,0.0025297191,0.00018872072,0.00008053732,0.0000072005855,0.00019165367,0.000073188305,0.00018424906],"category_scores_gemma":[0.0012092345,0.00007297206,0.0003498866,0.00064772647,0.00054235326,0.00007018676,0.00012382146,0.001110681,4.832359e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8120215,0.0043383497,0.1409004,0.0000092299015,0.006270466,0.0006329564,0.00228274,0.00096897426,0.000024769204,0.000005239453,0.0001942557,0.03235112],"study_design_scores_gemma":[0.81292504,0.033112627,0.14151743,0.000047563637,0.00483674,0.0000111076815,0.0048061237,0.0006635276,0.000017166361,0.000048531147,0.0019353369,0.000078816985],"about_ca_topic_score_codex":0.00074776955,"about_ca_topic_score_gemma":0.0007200351,"teacher_disagreement_score":0.032272305,"about_ca_system_score_codex":0.00030122555,"about_ca_system_score_gemma":0.0013648387,"threshold_uncertainty_score":0.48254183},"labels":[],"label_agreement":null},{"id":"W4213357340","doi":"10.1200/jco.2022.40.6_suppl.167","title":"Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Proportional hazards model; Cancer; Androgen receptor; Internal medicine; Oncology; Hazard ratio; Biopsy; Enzalutamide; Adenocarcinoma; Pathology; Cancer research; Confidence interval","score_opus":0.07253319436913555,"score_gpt":0.4405875813106236,"score_spread":0.36805438694148807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213357340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993371,0.002987273,0.0000073551814,0.0021574418,0.00035139182,0.0008997268,0.000044009565,0.0000047826447,0.0001769988],"genre_scores_gemma":[0.991926,0.0054120957,0.0020220063,0.00025728493,0.00009981597,0.000041403106,0.000025875903,0.000025487672,0.00019003845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950907,0.0011451425,0.0022593522,0.00033219132,0.000871623,0.000300995],"domain_scores_gemma":[0.99678504,0.0006744564,0.0015117838,0.00020029739,0.0005213533,0.00030708953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032456985,0.00017583086,0.0014025375,0.00023333487,0.000076421566,0.000012109414,0.00013855868,0.0001302261,0.00010241842],"category_scores_gemma":[0.0004382998,0.00011090495,0.00020598412,0.00030279296,0.00042584978,0.00013238814,0.00010470359,0.001304502,5.861963e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.105484255,0.006010225,0.7947761,0.00029561023,0.000517258,0.0027475136,0.00070793706,0.00022023772,0.009051324,0.000027583194,0.0015394564,0.07862251],"study_design_scores_gemma":[0.038322885,0.03702651,0.9117846,0.0004890689,0.00020819288,0.00008704008,0.00062382483,0.000029167462,0.0047064074,0.00013439405,0.0064307917,0.00015713504],"about_ca_topic_score_codex":0.000034244422,"about_ca_topic_score_gemma":0.00005240298,"teacher_disagreement_score":0.11700849,"about_ca_system_score_codex":0.00019991862,"about_ca_system_score_gemma":0.0017931939,"threshold_uncertainty_score":0.56674844},"labels":[],"label_agreement":null},{"id":"W4213453821","doi":"10.3390/ijms23052478","title":"On the Way for Patients with Prostate Cancer to the Best Use of PSMA","year":2022,"lang":"en","type":"editorial","venue":"International Journal of Molecular Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Prostate cancer; Cancer; Prostate; Medicine; Oncology; Internal medicine","score_opus":0.027162265398782193,"score_gpt":0.3558103974797961,"score_spread":0.3286481320810139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213453821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5646343,0.0011078599,0.00013564044,0.02702488,0.40373617,0.0019204341,0.0012353971,0.0000041990866,0.0002010562],"genre_scores_gemma":[0.7011687,0.0034129706,0.0019876463,0.0031014204,0.28243142,0.00086272805,0.0003213053,0.00013607297,0.0065776976],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99631566,0.00006135658,0.00027085622,0.00016579767,0.0030323698,0.00015398418],"domain_scores_gemma":[0.9968976,0.00069452456,0.00039447303,0.00012584044,0.0018252424,0.00006233936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005923466,0.000118859585,0.00019088143,0.00021091425,0.00013305621,0.00010086044,0.0007418734,0.000040836203,0.00007125099],"category_scores_gemma":[0.00078071316,0.000047859205,0.00013021124,0.0002093259,0.00021417969,0.00008163939,0.000096110845,0.0003440587,0.0000011130177],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008097886,0.0006225929,0.0033135721,0.000040073868,0.0012361476,0.00012022695,0.0007562205,0.0026020803,0.00026641315,0.0002764834,0.9734183,0.009249997],"study_design_scores_gemma":[0.0027539497,0.00841178,0.0007203647,0.00089306,0.00019401732,0.000007721518,0.0002885431,0.000049757644,0.0018105159,0.00020475738,0.98452973,0.00013581557],"about_ca_topic_score_codex":0.00009128846,"about_ca_topic_score_gemma":0.000016150818,"teacher_disagreement_score":0.13653438,"about_ca_system_score_codex":0.00021368312,"about_ca_system_score_gemma":0.0010802005,"threshold_uncertainty_score":0.19516417},"labels":[],"label_agreement":null},{"id":"W4214498877","doi":"10.3390/curroncol13040011","title":"In This Issue of Current Oncology","year":2006,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Clinical Oncology; Oncology; Intensive care medicine; Internal medicine; Cancer; Bioinformatics","score_opus":0.14594622537773047,"score_gpt":0.49972509461501563,"score_spread":0.3537788692372852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214498877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81952286,0.06799047,0.000059540565,0.0100594815,0.00564484,0.001569364,0.000043553013,0.00006504347,0.09504488],"genre_scores_gemma":[0.9828916,0.0076797823,0.00028824282,0.00018587003,0.0017441269,0.00027933778,0.00024460038,0.00003907188,0.006647375],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850416,0.00014191035,0.0004378319,0.00028535863,0.00021627708,0.00041447845],"domain_scores_gemma":[0.9992565,0.00014622287,0.00012518688,0.00021457943,0.00015188174,0.00010564409],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002850018,0.00014750662,0.00055985793,0.00029929265,0.000028066434,0.0000028356949,0.00011340149,0.00015064314,0.0016157619],"category_scores_gemma":[0.000054353717,0.00011566978,0.00009713312,0.00031944603,0.00024741123,0.00005145865,0.000079409016,0.00045310592,0.00021257348],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012969746,0.008070588,0.14975546,0.00060501613,0.00005238384,0.00028688044,0.0008465395,0.0000044432663,0.0031964725,0.0021963126,0.2868455,0.5468434],"study_design_scores_gemma":[0.0053935237,0.0014108206,0.015308534,0.000102623744,0.000052828356,0.000031977273,0.0000644465,0.000058179423,0.0033746464,0.0007721763,0.97333384,0.000096393815],"about_ca_topic_score_codex":0.000157525,"about_ca_topic_score_gemma":0.00013496973,"teacher_disagreement_score":0.68648833,"about_ca_system_score_codex":0.00086102827,"about_ca_system_score_gemma":0.00078948593,"threshold_uncertainty_score":0.9992969},"labels":[],"label_agreement":null},{"id":"W4214547776","doi":"10.1016/j.urolonc.2022.01.009","title":"Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada","year":2022,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of British Columbia; BC Cancer Agency; London Health Sciences Centre; University of Alberta; Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Calgary; University of Ottawa; McGill University; Western University; University of Toronto; Ottawa Hospital; Jewish General Hospital; McMaster University; Juravinski Cancer Centre; St. Joseph’s Healthcare Hamilton","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Prostate cancer; Oncology; Taxane; Docetaxel; Internal medicine; Cabazitaxel; Population; Proportional hazards model; Systemic therapy; Cohort; Cancer; Androgen deprivation therapy; Breast cancer","score_opus":0.048954909469585695,"score_gpt":0.3267261583704557,"score_spread":0.27777124890087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214547776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922178,0.0017142415,4.7304894e-7,0.0047324765,0.00003243075,0.0007815869,0.0001008873,0.000008289592,0.0004118603],"genre_scores_gemma":[0.9932971,0.002284028,0.002195724,0.00022300058,0.000008723891,0.000664439,0.00007114347,0.000009936226,0.001245899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987108,0.00025174557,0.00031783473,0.00024077133,0.00022760716,0.0002512203],"domain_scores_gemma":[0.9993707,0.0002182084,0.00014726553,0.00011884348,0.000050416424,0.00009458549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028769852,0.00012297204,0.00034485577,0.00026081357,0.000113708775,0.000007741285,0.00005212503,0.000024454355,0.000065045126],"category_scores_gemma":[0.000022009626,0.000089963985,0.000014380763,0.0006135512,0.00023913084,0.00009641386,0.000030258647,0.00029881057,1.70718e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013475673,0.00012033617,0.9879624,0.000098003926,0.00007060984,0.00079554605,0.0021836322,0.0025097046,0.0028110654,0.00094938744,0.0006388424,0.0005128942],"study_design_scores_gemma":[0.016549103,0.01312542,0.72982526,0.0011096507,0.00076141645,0.00089955097,0.03928304,0.006795324,0.0021883806,0.0025685711,0.18607543,0.0008188369],"about_ca_topic_score_codex":0.69232255,"about_ca_topic_score_gemma":0.8570643,"teacher_disagreement_score":0.25813714,"about_ca_system_score_codex":0.0015402909,"about_ca_system_score_gemma":0.004764928,"threshold_uncertainty_score":0.8452777},"labels":[],"label_agreement":null},{"id":"W4214615527","doi":"10.5489/cuaj.7739","title":"68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography for patients with favorable intermediate-risk prostate cancer","year":2022,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Positron emission tomography; Glutamate carboxypeptidase II; Lymph node; Radiology; Biochemical recurrence; Prostate-specific antigen; Prostate; Pathological; Dissection (medical); Cancer; Nuclear medicine; Internal medicine","score_opus":0.008950873795412989,"score_gpt":0.23382442528756842,"score_spread":0.22487355149215543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214615527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896112,0.0017563794,0.000024987188,0.0051642605,0.0005521634,0.001484627,0.0012065026,0.000053703447,0.0001461413],"genre_scores_gemma":[0.9959066,0.0009837856,0.00023685367,0.0007967148,0.0002485425,0.0002715198,0.00074439665,0.000042009782,0.0007695659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969714,0.00028003816,0.00046211455,0.00043935177,0.00083229353,0.0010147892],"domain_scores_gemma":[0.9975187,0.00016468634,0.00047784304,0.00016299244,0.00067586347,0.0009999125],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0007680349,0.00026907536,0.000424403,0.00060319324,0.0013703117,0.00014855138,0.0002146919,0.000115534785,0.0006324368],"category_scores_gemma":[0.00010571408,0.00019383896,0.00024719365,0.0008702691,0.0000700939,0.00015877631,0.00004849859,0.0010119624,0.0000043321565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021841223,0.0002582853,0.9759193,0.000018360644,0.00038642465,0.000081463,0.0003418587,0.00019547457,0.00016721227,0.00000602822,0.014678666,0.0057627903],"study_design_scores_gemma":[0.0077124806,0.0037614163,0.8758514,0.000043611486,0.00013580242,0.000024201734,0.00018815529,0.00020931046,0.00022071468,0.000193833,0.11136739,0.0002916851],"about_ca_topic_score_codex":0.00091661484,"about_ca_topic_score_gemma":0.00024958097,"teacher_disagreement_score":0.10006791,"about_ca_system_score_codex":0.0018518746,"about_ca_system_score_gemma":0.00085769384,"threshold_uncertainty_score":0.9999298},"labels":[],"label_agreement":null},{"id":"W4214688773","doi":"10.3390/ijms23052588","title":"Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Androgen receptor; Cancer research; Prostate; Cancer; Transcription factor; Medicine; Biology; Computational biology; Internal medicine; Genetics; Gene","score_opus":0.030274602322835627,"score_gpt":0.3573247892948708,"score_spread":0.3270501869720352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214688773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902818,0.0026755678,0.0005248674,0.0053407853,0.00065709866,0.00035639314,0.000020385793,0.00000494769,0.0001381624],"genre_scores_gemma":[0.9945265,0.00041156355,0.0040540257,0.00049262715,0.000108336884,0.00007701656,0.00000793723,0.000011087444,0.00031090385],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99795026,0.000044725886,0.00039600913,0.00017105303,0.0012399099,0.00019804761],"domain_scores_gemma":[0.9989651,0.00002501914,0.00029925536,0.00006142156,0.0005586857,0.00009053045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038957671,0.00009807081,0.00018023663,0.0003257251,0.00014893379,0.000039078386,0.00039897865,0.000009332873,0.00013619692],"category_scores_gemma":[0.000045133293,0.000072305396,0.00015400845,0.00022142523,0.0001316187,0.00007813947,0.0001234035,0.0001426771,7.4062825e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00437725,0.0007643089,0.002082151,0.000029218005,0.0006471512,0.0015903072,0.0013151922,0.0009494125,0.9099114,0.00025345833,0.0003143628,0.07776579],"study_design_scores_gemma":[0.006887013,0.003050977,0.0011796706,0.00011040527,0.00004496718,0.0010250288,0.0009047529,0.00044691633,0.9701073,0.00045864974,0.015643328,0.00014094872],"about_ca_topic_score_codex":0.00002558439,"about_ca_topic_score_gemma":0.0000029391374,"teacher_disagreement_score":0.07762484,"about_ca_system_score_codex":0.00015630662,"about_ca_system_score_gemma":0.0016083908,"threshold_uncertainty_score":0.29485285},"labels":[],"label_agreement":null},{"id":"W4220696512","doi":"10.1016/j.celrep.2022.110534","title":"The mTOR chromatin-bound interactome in prostate cancer","year":2022,"lang":"en","type":"article","venue":"Cell Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Interactome; Prostate cancer; Chromatin; PI3K/AKT/mTOR pathway; Cancer research; Computational biology; Biology; Cancer; Cell biology; Genetics; DNA; Signal transduction; Gene","score_opus":0.017945190109512812,"score_gpt":0.3196465514182275,"score_spread":0.3017013613087147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220696512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813138,0.0056459582,1.9099693e-7,0.0018071826,0.0005789524,0.0006945691,0.000005629191,0.00002673374,0.00992693],"genre_scores_gemma":[0.94303787,0.00038643935,0.000009538376,0.000095605224,0.000064423366,0.000620216,0.00003016001,0.000018542842,0.055737205],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878633,0.000044739692,0.00027600653,0.00022945082,0.000367609,0.00029588008],"domain_scores_gemma":[0.9994024,0.00005494414,0.000114854476,0.00030374154,0.000043760516,0.00008027242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036490234,0.00009105509,0.00014509632,0.00006938744,0.00025166883,0.000033010845,0.00005900486,0.000014299631,0.0007108605],"category_scores_gemma":[0.000030783307,0.00005711918,0.00005160236,0.00024065613,0.00006234419,0.000040174877,0.00012366117,0.0002914153,0.00000832224],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001575865,0.0010311248,0.76782817,0.00041101524,0.00018492778,0.040023275,0.0073375236,0.00010824108,0.081172705,0.00002794277,0.053122636,0.04717658],"study_design_scores_gemma":[0.0030256582,0.0007606726,0.11029705,0.00014856578,0.000064064945,0.0013269451,0.0016411664,0.00018929732,0.057893522,0.000687762,0.8236476,0.0003176713],"about_ca_topic_score_codex":0.00033820758,"about_ca_topic_score_gemma":0.00010061267,"teacher_disagreement_score":0.770525,"about_ca_system_score_codex":0.0005110198,"about_ca_system_score_gemma":0.00045372878,"threshold_uncertainty_score":0.77834237},"labels":[],"label_agreement":null},{"id":"W4220703997","doi":"10.1158/1541-7786.mcr-21-0780","title":"Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist–Treated Prostate Cancers","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prevention of Organ Failure; University of British Columbia","funders":"European Commission; National Institute for Health and Care Research; Cancer Research UK; Prostate Cancer UK; Movember Foundation","keywords":"Prostate; Prostate cancer; Signal transduction; Cancer; Interleukin 8","score_opus":0.04664584518569838,"score_gpt":0.364057248176534,"score_spread":0.31741140299083564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220703997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98092157,0.012620623,0.000016639302,0.0031384928,0.00006288097,0.0021621748,0.0001598001,0.000047916066,0.0008698985],"genre_scores_gemma":[0.9949419,0.0005337496,0.00009555391,0.00038085703,0.00006457559,0.002528546,0.000051301446,0.00007542468,0.0013281293],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9955533,0.00070670835,0.00034868106,0.0007611633,0.0014760229,0.00115409],"domain_scores_gemma":[0.9987439,0.0001725499,0.00008098603,0.0003498558,0.0003476573,0.00030508838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015358146,0.0002469485,0.00046152866,0.0006078753,0.00069417764,0.0000877749,0.00020626304,0.00005248843,0.00026587877],"category_scores_gemma":[0.00011509451,0.00022536085,0.000078968114,0.0013076196,0.00038073683,0.00010836962,0.00026340954,0.0014029437,0.000007029248],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014913487,0.0002959907,0.15860869,0.0003875582,0.00047038222,0.010992084,0.0034754397,0.0031678958,0.8011338,0.00017672527,0.0013703103,0.0050075985],"study_design_scores_gemma":[0.087495655,0.018530624,0.050416004,0.0034719307,0.00051836687,0.0006633981,0.03533683,0.050324578,0.7219075,0.0015718155,0.026911372,0.0028519048],"about_ca_topic_score_codex":0.01745377,"about_ca_topic_score_gemma":0.000491331,"teacher_disagreement_score":0.10819269,"about_ca_system_score_codex":0.0028251694,"about_ca_system_score_gemma":0.0018774502,"threshold_uncertainty_score":0.9890891},"labels":[],"label_agreement":null},{"id":"W4220890693","doi":"10.3390/cells11050898","title":"Androgen Receptor-Mediated Transcription in Prostate Cancer","year":2022,"lang":"en","type":"review","venue":"Cells","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"DOD Prostate Cancer Research Program; Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi; Türkiye Bilimsel ve Teknolojik Araştırma Kurumu; U.S. Department of Defense","keywords":"Prostate cancer; Androgen receptor; Transcription (linguistics); Prostate; Transcription factor; Medicine; Cancer research; Oncology; Biology; Cancer; Urology; Internal medicine; Genetics; Gene; Philosophy","score_opus":0.07935150413786046,"score_gpt":0.3701577481588787,"score_spread":0.29080624402101823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220890693","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014236897,0.9949253,1.13841764e-7,0.000094165414,0.00050065026,0.002456137,0.00043203242,0.00004569953,0.001403492],"genre_scores_gemma":[0.0000061144287,0.9808486,0.000012850601,0.00004336311,0.00012015383,0.0014983488,0.0022387772,0.00007265153,0.015159127],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99823785,0.00015520844,0.00041144752,0.00043847197,0.0003457387,0.0004112588],"domain_scores_gemma":[0.9993855,0.00007084271,0.00010828753,0.00025578024,0.000027155473,0.00015245871],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023294734,0.00029940304,0.0011258711,0.00032801295,0.00005347891,0.000016713051,0.00012245054,0.00015127618,0.0054342444],"category_scores_gemma":[0.000010825078,0.00022060955,0.00028316485,0.0006906019,0.000054848624,0.000043763644,0.000037172056,0.0006668426,0.00023501994],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115708724,0.00017375352,0.00005415489,0.016907249,0.00019024362,0.00024923557,0.0002902055,4.5306348e-7,0.0001405722,0.0000013070289,0.005274868,0.97660226],"study_design_scores_gemma":[0.0011859663,0.00014933488,0.000003395769,0.004518657,0.00028260762,0.000010832647,0.000034930723,0.0000017899906,0.00013055159,0.0000023135985,0.99348307,0.0001965458],"about_ca_topic_score_codex":0.00012049947,"about_ca_topic_score_gemma":0.0000178143,"teacher_disagreement_score":0.98820823,"about_ca_system_score_codex":0.00095387676,"about_ca_system_score_gemma":0.0009796107,"threshold_uncertainty_score":0.99547493},"labels":[],"label_agreement":null},{"id":"W4220938185","doi":"10.1016/j.annonc.2022.03.272","title":"Clinical trials for metastatic castrate-resistant prostate cancer—who is looking after the control patients? Questions for the future","year":2022,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Clinical trial; Oncology; Transparency (behavior); Prostate; Cancer; Intensive care medicine; Internal medicine","score_opus":0.1582618029126342,"score_gpt":0.5245485520031038,"score_spread":0.3662867490904696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220938185","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029565059,0.066823035,0.00015094552,0.10623077,0.74237406,0.025146356,0.05611922,0.000040598003,0.00015848418],"genre_scores_gemma":[0.012822839,0.06451168,0.000248444,0.0060069486,0.8595905,0.043712586,0.0027608096,0.00022057042,0.010125667],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99509716,0.0014306513,0.0015971526,0.00054107356,0.0007107395,0.0006232296],"domain_scores_gemma":[0.9753668,0.020777771,0.001239888,0.0005265147,0.0019389539,0.0001500973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008159351,0.00035411984,0.001991597,0.000117508105,0.0003977339,0.00003933983,0.00037114986,0.00046477266,0.0003475719],"category_scores_gemma":[0.0043950016,0.00017233331,0.0010972464,0.00016998498,0.00043998676,0.000049877115,0.00008638598,0.0010544675,0.0000017155943],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041997,0.00052477815,0.0002687893,0.00047916645,0.0030937733,0.000019912042,0.0004379361,0.000005828338,0.000004708351,0.00003761757,0.8974094,0.05572109],"study_design_scores_gemma":[0.014027498,0.011285083,0.00048194354,0.00017381286,0.0029835354,0.0000011364962,0.00042714196,0.000049641883,0.000025609119,0.0004336935,0.9699548,0.00015611306],"about_ca_topic_score_codex":0.00023110858,"about_ca_topic_score_gemma":0.00041422583,"teacher_disagreement_score":0.11721637,"about_ca_system_score_codex":0.0002216259,"about_ca_system_score_gemma":0.004255275,"threshold_uncertainty_score":0.7548675},"labels":[],"label_agreement":null},{"id":"W4220959221","doi":"10.1111/iju.14843","title":"Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study","year":2022,"lang":"en","type":"article","venue":"International Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prevention of Organ Failure","funders":"Janssen Research and Development","keywords":"Medicine; Placebo; Interim analysis; Hazard ratio; Prostate cancer; Internal medicine; Population; Randomized controlled trial; Oncology; Cancer; Confidence interval; Pathology","score_opus":0.02443639978469364,"score_gpt":0.34655502655802645,"score_spread":0.3221186267733328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220959221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99542785,0.0004247309,0.00012677372,0.0013784504,0.00012834503,0.002442217,0.000058261983,0.0000014336854,0.000011933804],"genre_scores_gemma":[0.99950355,0.00012380995,0.000025225954,0.000049134273,0.000026555994,0.00013278495,0.000071958464,0.000007904974,0.000059063153],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9978872,0.00045095698,0.0008142431,0.00013752744,0.00061272713,0.00009733599],"domain_scores_gemma":[0.9968354,0.0011072791,0.0010983021,0.000113342045,0.00081920327,0.000026469696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017412391,0.000099312274,0.00064489804,0.0003715242,0.000085060856,0.000009071458,0.00011705825,0.000017445502,0.000022629638],"category_scores_gemma":[0.00047153485,0.000050101655,0.0001730012,0.00033475622,0.00013081513,0.000079899306,0.000037856666,0.00016985212,1.4697342e-8],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6789748,0.0011833548,0.27798325,0.0000060750403,0.009056458,0.000055840323,0.007830496,0.02242803,0.00026125586,0.000013963215,0.0000025755373,0.0022038554],"study_design_scores_gemma":[0.48580158,0.0014057932,0.49930605,0.000019713327,0.0027505583,0.00011828729,0.0016726037,0.008758314,0.00006556613,0.00003781423,0.000011742823,0.000051984436],"about_ca_topic_score_codex":0.000571711,"about_ca_topic_score_gemma":0.00046860814,"teacher_disagreement_score":0.22132279,"about_ca_system_score_codex":0.00014543795,"about_ca_system_score_gemma":0.00019309841,"threshold_uncertainty_score":0.20430861},"labels":[],"label_agreement":null},{"id":"W4220976505","doi":"10.1016/j.mednuc.2022.01.006","title":"Étude de phase 3 du 177Lu-PSMA-617 dans le traitement des patients atteints d’un cancer de la prostate métastatique résistant à la castration (CPRCm) (VISION)","year":2022,"lang":"fr","type":"article","venue":"Médecine Nucléaire","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Gynecology","score_opus":0.013935808796053646,"score_gpt":0.3316032038399676,"score_spread":0.31766739504391395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220976505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804629,0.007076476,0.0009512409,0.0061288364,0.00047912673,0.0017649682,0.0014392887,0.000097697535,0.0015994657],"genre_scores_gemma":[0.9871141,0.0033072338,0.0011675892,0.0004563616,0.00040059173,0.0010875978,0.0006222616,0.00015235954,0.005691941],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9947089,0.0014794115,0.0007342378,0.0007643542,0.0010014651,0.0013116195],"domain_scores_gemma":[0.9980937,0.00026471083,0.00026887967,0.0004505041,0.00027543906,0.000646748],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015954362,0.0005468003,0.0005737727,0.00023352126,0.0012984115,0.00015865067,0.00033223664,0.00017451438,0.0022400345],"category_scores_gemma":[0.00013919009,0.00051843806,0.00022081682,0.0006401875,0.00070181035,0.00035323238,0.0002702072,0.0008845228,0.00003090636],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005973235,0.021583904,0.2641652,0.0014716549,0.001124972,0.0045429547,0.05144866,0.0030560072,0.059228413,0.0019886221,0.012143304,0.57327306],"study_design_scores_gemma":[0.08364213,0.009695268,0.7686038,0.001976727,0.0010225867,0.00058132486,0.015673717,0.010738519,0.030183343,0.0028830124,0.07360964,0.0013899145],"about_ca_topic_score_codex":0.004161217,"about_ca_topic_score_gemma":0.0009649335,"teacher_disagreement_score":0.5718832,"about_ca_system_score_codex":0.003790172,"about_ca_system_score_gemma":0.0017574436,"threshold_uncertainty_score":0.9997267},"labels":[],"label_agreement":null},{"id":"W4221041809","doi":"10.1016/j.ejca.2022.01.042","title":"Reply to comment on: Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial","year":2022,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Androgen deprivation therapy; Prostate cancer; Medicine; Radiation therapy; Oncology; Cancer; Internal medicine; Randomized controlled trial; Androgen; Urology; Hormone","score_opus":0.037241826905770825,"score_gpt":0.346108554949665,"score_spread":0.3088667280438942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221041809","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28179654,0.029947694,0.000017009173,0.68301,0.0012433154,0.0035986437,0.00016324074,0.000016314441,0.00020724643],"genre_scores_gemma":[0.009142985,0.17013972,0.00013844986,0.80953956,0.007945236,0.0005052533,0.00010918523,0.00021064158,0.0022689519],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961497,0.001134992,0.0010537391,0.000401126,0.00085690204,0.00040353558],"domain_scores_gemma":[0.9981719,0.00021059625,0.00090251345,0.00031242345,0.00018721963,0.00021535021],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018314772,0.0003658723,0.00096554024,0.00059979723,0.00010737093,0.00007221377,0.00025490692,0.000065246466,0.0009864911],"category_scores_gemma":[0.00008814776,0.00025574482,0.00024090592,0.00024297678,0.000084907086,0.00007813396,0.00004440366,0.0020164952,0.000002079555],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3699309,0.000175521,0.00048146304,0.000036700363,0.0005826945,0.0024635892,0.0023073633,0.000021184316,0.000119419536,1.0426882e-7,0.47395357,0.14992748],"study_design_scores_gemma":[0.36887383,0.007378331,0.00017235761,0.00040791984,0.000094045325,0.00002780919,0.00003673093,0.00000781556,0.0003326784,0.00000393444,0.6225121,0.000152464],"about_ca_topic_score_codex":0.00019278449,"about_ca_topic_score_gemma":0.000006976744,"teacher_disagreement_score":0.27265358,"about_ca_system_score_codex":0.0009693303,"about_ca_system_score_gemma":0.0005934188,"threshold_uncertainty_score":0.99998945},"labels":[],"label_agreement":null},{"id":"W4221085387","doi":"10.1101/2022.03.10.22271799","title":"Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancer","year":2022,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Foghorn Therapeutics; Gilead Sciences; National Cancer Institute; Genentech; Janssen Research and Development; National Institutes of Health; Sierra Oncology; V Foundation for Cancer Research; Astellas Pharma; Eisai; Prostate Cancer UK; National Institute for Health and Care Research; MacroGenics; DOD Prostate Cancer Research Program; Vertex Pharmaceuticals; Bristol-Myers Squibb; AstraZeneca; Movember Foundation; Sanofi; Pfizer; Wellcome Trust; Cancer Research UK; Doris Duke Charitable Foundation; U.S. Department of Veterans Affairs","keywords":"Prostate cancer; Androgen receptor; Biomarker; Androgen deprivation therapy; Immunohistochemistry; Oncology; Medicine; Cancer research; Prostate; splice; Internal medicine; Androgen; Messenger RNA; Cancer; Biology; Hormone; Gene","score_opus":0.08524871362891821,"score_gpt":0.4586015234323757,"score_spread":0.3733528098034575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221085387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99220645,0.00094403216,0.000007832583,0.0020260725,0.0004947331,0.0019990017,0.0006493967,0.000017584149,0.0016549153],"genre_scores_gemma":[0.9931062,0.0033587653,0.00081038993,0.000058787406,0.00007138298,0.0005093206,0.00026468074,0.000040361057,0.0017801151],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959362,0.0011667226,0.0011738709,0.00066661014,0.0007456239,0.00031094262],"domain_scores_gemma":[0.9976611,0.0006030446,0.00057499023,0.00060436944,0.0003854146,0.00017106225],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035506936,0.00025861332,0.0010549127,0.0003653265,0.000039037506,0.000007897454,0.00017104983,0.00024159146,0.0011287738],"category_scores_gemma":[0.00043687058,0.000214727,0.0002603901,0.0004325849,0.00024273591,0.00003749582,0.00042862137,0.00092171784,0.000004425107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032334536,0.0014489463,0.92412406,0.0010733218,0.0012386171,0.0013129046,0.0019018294,0.00010285138,0.03177182,0.000047879603,0.0005126,0.0041306023],"study_design_scores_gemma":[0.0045772237,0.001368841,0.98077226,0.00085924816,0.00020966052,0.000023519086,0.0006492395,0.0006510273,0.00883092,0.000059454193,0.0017880229,0.0002105667],"about_ca_topic_score_codex":0.0015041006,"about_ca_topic_score_gemma":0.00008182709,"teacher_disagreement_score":0.056648187,"about_ca_system_score_codex":0.00037211945,"about_ca_system_score_gemma":0.005428975,"threshold_uncertainty_score":0.99978435},"labels":[],"label_agreement":null},{"id":"W4221087847","doi":"10.1158/1538-7445.sabcs21-ot1-06-01","title":"Abstract OT1-06-01: A randomised trial comparing continuation or de-escalation of bone modifying agents (BMA) in patients treated for over 2 years for bone metastases from either breast or castration-resistant prostate cancer (REaCT-HOLD BMA)","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; McMaster University; University of Ottawa","funders":"","keywords":"Medicine; Breast cancer; Clinical endpoint; Denosumab; Randomized controlled trial; Internal medicine; Oncology; Clinical trial; Cancer; Surgery; Osteoporosis","score_opus":0.16422922007885143,"score_gpt":0.4298036303402548,"score_spread":0.2655744102614034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221087847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852614,0.00069877424,0.000021590995,0.00025473387,0.00011912358,0.010017018,0.003572252,0.000025690155,0.00002945687],"genre_scores_gemma":[0.9861136,0.00021757255,0.00012596969,0.000024634344,0.00017563476,0.010246487,0.0018407605,0.00007153802,0.0011837897],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964996,0.00030646275,0.0007630327,0.0005537083,0.0011493271,0.00072787993],"domain_scores_gemma":[0.99800915,0.00070172624,0.0003065719,0.0002763117,0.0005178769,0.00018838624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017505625,0.00023289381,0.000758375,0.00051624334,0.0002630625,0.00006855348,0.0001337047,0.0000913958,0.0009127343],"category_scores_gemma":[0.00031663693,0.00018292143,0.00017717347,0.0006755173,0.00012244511,0.00020988935,0.00007623115,0.0003843902,0.0000014656389],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8785362,0.0013477278,0.042603046,0.00044569388,0.0005176343,0.000052941967,0.0019447345,0.0007363478,0.06022513,0.000005109259,0.0027617821,0.010823626],"study_design_scores_gemma":[0.5544168,0.0026491124,0.42068452,0.0006801389,0.00031419154,0.0000024585015,0.0008010863,0.0061717303,0.012858951,0.00006253412,0.001016902,0.00034160638],"about_ca_topic_score_codex":0.00922429,"about_ca_topic_score_gemma":0.0028157607,"teacher_disagreement_score":0.37808144,"about_ca_system_score_codex":0.0017363703,"about_ca_system_score_gemma":0.0014152873,"threshold_uncertainty_score":0.99938005},"labels":[],"label_agreement":null},{"id":"W4223437636","doi":"10.1002/ijc.34018","title":"Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)","year":2022,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Research and Development; Medical Research Council; Takeda Oncology; Medical Research Council Canada; Astellas Pharma; University College London; Royal Marsden NHS Foundation Trust; Department of Health and Social Care; Cancer Research UK; Clovis Oncology; BeiGene; Abbott Laboratories; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Sanofi; National Institute for Health and Care Research; Novartis; Pfizer","keywords":"Medicine; Abiraterone acetate; Prednisolone; Internal medicine; Androgen deprivation therapy; Proportional hazards model; Prostate cancer; Hazard ratio; Surgery; Oncology; Confidence interval; Cancer","score_opus":0.0600295178885569,"score_gpt":0.3658253147122705,"score_spread":0.3057957968237136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223437636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98310477,0.0036848304,0.00023991244,0.007576892,0.00240857,0.0016164903,0.001297945,0.000009838202,0.000060751994],"genre_scores_gemma":[0.99451464,0.0016699281,0.00031759986,0.0006663365,0.0010390196,0.0003509878,0.0002457909,0.000033601074,0.0011620923],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99728847,0.00019189226,0.00078120286,0.00019636481,0.001295264,0.00024682845],"domain_scores_gemma":[0.99763036,0.0005834638,0.0007241218,0.00015257917,0.00080548646,0.00010398419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092078454,0.00015602869,0.00039961905,0.0001162931,0.00018633479,0.00007227305,0.00037539532,0.0000243108,0.00031152737],"category_scores_gemma":[0.0003282913,0.000093935174,0.00029910225,0.00010849109,0.00006177612,0.00015459306,0.00008987489,0.00032455678,0.0000022171646],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9630875,0.00034162548,0.00088367023,0.000004781927,0.0028975185,0.00005000368,0.0027294534,0.00048678555,0.0029690654,0.0000065562244,0.012141665,0.014401384],"study_design_scores_gemma":[0.96628743,0.0036387946,0.003035109,0.000075834396,0.00035848713,0.0000065102845,0.0007638061,0.0004596509,0.0030744383,0.0006734976,0.021487389,0.00013901874],"about_ca_topic_score_codex":0.00022869791,"about_ca_topic_score_gemma":0.000034144283,"teacher_disagreement_score":0.014262365,"about_ca_system_score_codex":0.0006809309,"about_ca_system_score_gemma":0.00067898876,"threshold_uncertainty_score":0.38305652},"labels":[],"label_agreement":null},{"id":"W4223551946","doi":"10.1038/s41598-022-09778-6","title":"PACE4-altCT isoform of proprotein convertase PACE4 as tissue and plasmatic biomarker for prostate cancer","year":2022,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aptose Biosciences (Canada); Université de Sherbrooke; Oncolytics Biotech (Canada)","funders":"Institut sur la Nutrition et les Aliments Fonctionnels; Canadian Institutes of Health Research; Université Laval","keywords":"Prostate cancer; Immunohistochemistry; Biomarker; LNCaP; Gene isoform; Cancer; Prostate; Cancer research; Medicine; Proprotein Convertases; PCA3; Internal medicine; Pathology; Biology; Gene; Biochemistry","score_opus":0.02565375407011058,"score_gpt":0.3370055720174439,"score_spread":0.31135181794733335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223551946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98952794,0.002352288,0.000010051302,0.0017715264,0.0014193209,0.0041856794,0.00009662039,0.000034849167,0.0006017364],"genre_scores_gemma":[0.93639874,0.000053227664,0.00022939031,0.000038334558,0.000022479451,0.0016833331,0.00022571482,0.000025914234,0.06132284],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979078,0.00003597415,0.0004166073,0.00057344197,0.0006852535,0.00038091844],"domain_scores_gemma":[0.9988193,0.00003731252,0.00026784494,0.000468858,0.00022007369,0.00018663157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001174609,0.00014455726,0.00030505023,0.0002157345,0.00043241595,0.00005973689,0.000056717177,0.000034023567,0.00069600955],"category_scores_gemma":[0.00012320877,0.0001068082,0.000068120804,0.00037379362,0.00036102842,0.00009273089,0.00012394416,0.00011210728,0.000003960121],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003973989,0.0013273368,0.088052705,0.0054267882,0.00069418317,0.0038634946,0.00966036,0.000028722228,0.6405455,0.0001249871,0.113161325,0.13314061],"study_design_scores_gemma":[0.0041326974,0.001863886,0.003626885,0.00033667855,0.00024388196,0.0012951263,0.001876504,0.0008301455,0.6803551,0.0039500464,0.30111533,0.00037374167],"about_ca_topic_score_codex":0.00031878066,"about_ca_topic_score_gemma":0.00004121645,"teacher_disagreement_score":0.18795402,"about_ca_system_score_codex":0.00016688115,"about_ca_system_score_gemma":0.000817042,"threshold_uncertainty_score":0.7620816},"labels":[],"label_agreement":null},{"id":"W4223609500","doi":"10.1016/j.eururo.2022.02.023","title":"Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study","year":2022,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Western University; Sunnybrook Health Science Centre","funders":"Medical Research Council; National Institute for Health and Care Research","keywords":"Medicine; Docetaxel; Enzalutamide; Prostate cancer; Prednisone; Internal medicine; Oncology; Pembrolizumab; Clinical endpoint; Cohort; Prostate-specific antigen; Cancer; Urology; Surgery; Clinical trial","score_opus":0.022785338373954987,"score_gpt":0.30158755323356945,"score_spread":0.2788022148596145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223609500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929174,0.0010401347,0.000002866585,0.0012992775,0.0000958431,0.0032119642,0.0008509514,0.00003414104,0.0005474267],"genre_scores_gemma":[0.9977778,0.0001155027,0.000018073366,0.00027548234,0.000051456336,0.00027020051,0.0007647299,0.000048164733,0.00067857496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970801,0.0009855952,0.00042170053,0.00061492727,0.0004987772,0.0003988831],"domain_scores_gemma":[0.9989819,0.00017869643,0.00016962033,0.00045540772,0.00008996474,0.00012442078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059228163,0.00022695496,0.00037830757,0.00010841167,0.00029383824,0.000039633,0.00017889243,0.000014532227,0.00009746398],"category_scores_gemma":[0.00006485546,0.0001430914,0.000030256655,0.00026542266,0.00019041273,0.000069411246,0.0002100603,0.00044600663,0.000008708373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062447637,0.0029666557,0.9217059,0.000020492782,0.0005259125,0.0022455328,0.005991935,0.00018946927,0.00009645131,0.0000030269866,0.0002844511,0.0035225116],"study_design_scores_gemma":[0.08381362,0.0079380255,0.9069525,0.000014357605,0.0003294501,0.000015751039,0.00032296905,0.00009879997,0.000010105567,0.00000409705,0.00037085754,0.00012944413],"about_ca_topic_score_codex":0.00081639306,"about_ca_topic_score_gemma":0.0006865589,"teacher_disagreement_score":0.021365987,"about_ca_system_score_codex":0.0002109645,"about_ca_system_score_gemma":0.0002598671,"threshold_uncertainty_score":0.5835098},"labels":[],"label_agreement":null},{"id":"W4223627834","doi":"10.1016/s1470-2045(22)00223-6","title":"Long-term versus short-term androgen deprivation combined with EBRT for unfavourable prostate cancer","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus","funders":"","keywords":"Prostate cancer; Androgen; Androgen deprivation therapy; Radiation therapy; Androgen suppression; Prostate; Randomized controlled trial","score_opus":0.08354481682497854,"score_gpt":0.3878135536795813,"score_spread":0.30426873685460276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223627834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98031676,0.0007461487,0.00003067853,0.014657185,0.00034436246,0.0019925705,0.00011693329,0.000064611006,0.0017307572],"genre_scores_gemma":[0.992337,0.00057865353,0.00013106132,0.00049950526,0.00031917437,0.0034927367,0.00026841648,0.000031468022,0.0023420178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987761,0.00014010991,0.00014876192,0.00025056867,0.00023625778,0.00044823243],"domain_scores_gemma":[0.999181,0.00025938256,0.00006828909,0.00030602005,0.00011039118,0.00007493951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005090528,0.0001289171,0.0003800515,0.000054389417,0.00035972212,0.000014950177,0.00018551822,0.000044170196,0.00033539842],"category_scores_gemma":[0.000028032522,0.00007757964,0.00004895337,0.00019093437,0.0001299898,0.00004574772,0.000105608546,0.00027056033,0.0000059625445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16533913,0.0006071681,0.78572124,0.0002614553,0.0009973458,0.0003033033,0.0013879538,0.00018606828,0.003398455,0.0006935371,0.008311551,0.032792784],"study_design_scores_gemma":[0.112599045,0.03735089,0.74198514,0.00016590432,0.0015425575,0.00032905748,0.0009813678,0.0007954586,0.023867602,0.0008534594,0.07877497,0.00075455534],"about_ca_topic_score_codex":0.000054723067,"about_ca_topic_score_gemma":0.00023212194,"teacher_disagreement_score":0.07046342,"about_ca_system_score_codex":0.00066417456,"about_ca_system_score_gemma":0.00062217395,"threshold_uncertainty_score":0.36723778},"labels":[],"label_agreement":null},{"id":"W4223966190","doi":"10.3390/curroncol29040226","title":"Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer According to Somatic Damage DNA Repair Gene Alterations","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Taxane; Somatic cell; Internal medicine; Oncology; Prostate cancer; Chemotherapy; Cancer; Clinical endpoint; Mutation; Disease; Gene; Clinical trial; Breast cancer; Genetics; Biology","score_opus":0.09333530194671873,"score_gpt":0.42398764240130954,"score_spread":0.3306523404545908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223966190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995648,0.00044242927,0.00003364371,0.0012071267,0.00039254385,0.0017175697,0.0004111074,0.000041423453,0.00010612428],"genre_scores_gemma":[0.9965274,0.000041858,0.0011244605,0.000100433936,0.000032062577,0.0013030134,0.00041343842,0.000022124059,0.00043525157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985002,0.00014072005,0.00036791977,0.00027315668,0.00042649554,0.0002914892],"domain_scores_gemma":[0.99911594,0.000100914855,0.0001546946,0.0002463258,0.00023625646,0.00014583541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018264171,0.00014773266,0.00042120155,0.00021522708,0.00022118696,0.00000989585,0.000088628636,0.000015086634,0.00027074412],"category_scores_gemma":[0.000054374555,0.00010572188,0.000077678145,0.00036984868,0.000065035725,0.000075545664,0.00010680504,0.00018363382,0.0000052494324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014886213,0.0019386214,0.9807904,0.00030719233,0.00045465434,0.00005804281,0.0024270564,0.00035951086,0.0031896352,0.00008067191,0.0011208338,0.0077847913],"study_design_scores_gemma":[0.011469913,0.0062780995,0.9616353,0.0001249364,0.0007146758,0.000008248988,0.002614465,0.0005450644,0.0025360617,0.00008536844,0.013690721,0.00029712816],"about_ca_topic_score_codex":0.00005341846,"about_ca_topic_score_gemma":0.00010323716,"teacher_disagreement_score":0.01915505,"about_ca_system_score_codex":0.0006434691,"about_ca_system_score_gemma":0.0007387773,"threshold_uncertainty_score":0.43112132},"labels":[],"label_agreement":null},{"id":"W4223999413","doi":"10.1016/j.urolonc.2022.03.011","title":"Variability in testosterone measurement between radioimmunoassay (RIA), chemiluminescence assay (CLIA) and liquid chromatography-tandem mass spectrometry (MS) among prostate cancer patients on androgen deprivation therapy (ADT)","year":2022,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; Princess Margaret Cancer Centre; University of Toronto","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Radioimmunoassay; Prostate cancer; Androgen deprivation therapy; Concordance; Medicine; Testosterone (patch); Internal medicine; Cancer","score_opus":0.038061561165329195,"score_gpt":0.30414934970652113,"score_spread":0.2660877885411919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223999413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99297565,0.0021272954,0.000019400632,0.0029055495,0.00010905669,0.0013674197,0.000068189984,0.00004887778,0.00037853784],"genre_scores_gemma":[0.99448997,0.002582736,0.0013928207,0.0004162909,0.000066633766,0.00078976277,0.00017609792,0.000020198704,0.000065476925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749404,0.0005142166,0.0004148487,0.0006117963,0.00052466826,0.00044044398],"domain_scores_gemma":[0.99888635,0.00032177762,0.00020537633,0.00023866918,0.00012109043,0.00022674676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019535872,0.00026237682,0.00047601789,0.0003308433,0.00041484574,0.000024941304,0.00012589431,0.00016079276,0.00008653141],"category_scores_gemma":[0.00022905559,0.00022036537,0.00005124728,0.00072911486,0.0006269844,0.00012213251,0.00009199726,0.0006195822,0.000001069112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062760164,0.0005210003,0.9894586,0.00004023755,0.00011507344,0.000032760534,0.0005092086,0.000014561688,0.006275254,0.00006166912,0.00022422525,0.0021197998],"study_design_scores_gemma":[0.00603989,0.009582423,0.95348644,0.00010837059,0.00016639727,0.000023442008,0.00017288471,0.00021157197,0.007400265,0.0012155288,0.021262605,0.00033018837],"about_ca_topic_score_codex":0.00017258115,"about_ca_topic_score_gemma":0.00003564207,"teacher_disagreement_score":0.035972174,"about_ca_system_score_codex":0.0008784223,"about_ca_system_score_gemma":0.0004124068,"threshold_uncertainty_score":0.89862394},"labels":[],"label_agreement":null},{"id":"W4224084882","doi":"10.1016/j.eururo.2022.04.002","title":"Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021","year":2022,"lang":"en","type":"review","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; University of British Columbia","funders":"National Health and Medical Research Council; Swiss Cancer Research Foundation; Astellas Pharma; Medical Research Council; Peter MacCallum Foundation; National Institute for Health and Care Research; Advanced Accelerator Applications; European School of Oncology; Prostate Cancer Foundation; Movember Foundation; AstraZeneca; Pfizer; Amgen","keywords":"Medicine; Prostate cancer; Voting; Consensus conference; Delphi method; Family medicine; Disease; Management of prostate cancer; Prostate; Cancer; Medical physics; Intensive care medicine; Gynecology; Internal medicine; Artificial intelligence; Political science","score_opus":0.03961115593197285,"score_gpt":0.33922148657362666,"score_spread":0.2996103306416538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224084882","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004510748,0.9809618,0.0000015632617,0.00089875236,0.0006139722,0.0054314397,0.0020039359,0.000054292028,0.0055235],"genre_scores_gemma":[0.0010698837,0.9855077,0.0001620078,0.00015758234,0.000109479886,0.0013905966,0.0027399063,0.00018114515,0.008681695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955705,0.0008515835,0.0010143033,0.0011610244,0.0006920544,0.0007105699],"domain_scores_gemma":[0.99685836,0.0002718315,0.0011652949,0.0011952209,0.00032221116,0.00018705906],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004025213,0.0006531235,0.0017256899,0.00012972046,0.00020296511,0.000022832872,0.00048621045,0.000081514096,0.0016832601],"category_scores_gemma":[0.00005091704,0.0003800796,0.00025297262,0.000523614,0.00051708013,0.000042727097,0.0005376426,0.0009215863,0.000037926955],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022950969,0.00023734305,0.0031405466,0.0032957075,0.0019343366,0.005500128,0.0003446196,0.00002805058,0.0000012274735,0.000015190923,0.0013586741,0.9818491],"study_design_scores_gemma":[0.004143434,0.000956301,0.004528433,0.0032153185,0.002171879,0.00004340633,0.00011687728,0.0000018438384,0.0000027097653,0.0000080176205,0.9844489,0.0003628968],"about_ca_topic_score_codex":0.00015746099,"about_ca_topic_score_gemma":0.00003980995,"teacher_disagreement_score":0.9830902,"about_ca_system_score_codex":0.00032148167,"about_ca_system_score_gemma":0.001003517,"threshold_uncertainty_score":0.9998651},"labels":[],"label_agreement":null},{"id":"W4224222846","doi":"10.3390/curroncol29040233","title":"Robot-Assisted Radical Prostatectomy for Potential Cancer Control in Patients with Metastatic Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Urology; Urinary incontinence; Prostate; Cancer; Metastasis; Surgery; Internal medicine; Oncology","score_opus":0.06719064757637482,"score_gpt":0.4129940389537049,"score_spread":0.34580339137733007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224222846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794011,0.006360033,0.00024843076,0.004276491,0.0011786575,0.0073718815,0.001059336,0.000055653807,0.00004838604],"genre_scores_gemma":[0.98492867,0.00038102784,0.00018222046,0.00025639555,0.00010725535,0.013053585,0.00057320215,0.000047150566,0.0004704924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773926,0.00022229996,0.000369862,0.00049060915,0.00049821404,0.000679736],"domain_scores_gemma":[0.99911565,0.00009001394,0.00016430859,0.00017675625,0.00024964483,0.00020364634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027531333,0.00022982637,0.0006075591,0.00024727487,0.000209004,0.00001461566,0.000120769684,0.000043937674,0.0005377768],"category_scores_gemma":[0.000023108429,0.00016618152,0.00009933032,0.00039777573,0.00019110831,0.00006984105,0.00007596616,0.0005178782,0.0000028576292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036345184,0.005556439,0.73468095,0.0005721701,0.0006067807,0.00017223724,0.0006576334,0.0009607167,0.00038476117,0.000034550314,0.0047776406,0.21525091],"study_design_scores_gemma":[0.1554999,0.009643058,0.6813974,0.00021597809,0.00086325145,0.000025896801,0.0002874911,0.0028924271,0.00016030668,0.000109374465,0.14844218,0.0004627709],"about_ca_topic_score_codex":0.00012733522,"about_ca_topic_score_gemma":0.00009234111,"teacher_disagreement_score":0.21478814,"about_ca_system_score_codex":0.0018124161,"about_ca_system_score_gemma":0.0016141909,"threshold_uncertainty_score":0.6776686},"labels":[],"label_agreement":null},{"id":"W4224674578","doi":"10.1002/cam4.4778","title":"Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance","year":2022,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institutes of Health; Canary Foundation; Congressionally Directed Medical Research Programs; National Cancer Institute; Prostate Cancer Foundation","keywords":"Germline; Germline mutation; Prostate cancer; Genetics; Cancer; Biology; Gene; Medicine; Mutation","score_opus":0.02316113072098295,"score_gpt":0.33904969071505775,"score_spread":0.3158885599940748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224674578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9448238,0.03469294,0.0000077299055,0.01709026,0.00024152135,0.0020090619,0.00047919963,0.00006112919,0.0005943619],"genre_scores_gemma":[0.9817217,0.009055741,0.00002454849,0.0004198936,0.00041470243,0.0058501787,0.00038650044,0.000060899354,0.0020658157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974191,0.00016580187,0.00042934297,0.00062127056,0.0007346716,0.00062979676],"domain_scores_gemma":[0.9989917,0.00010578214,0.00022145573,0.0002280946,0.00027082718,0.00018209113],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035217954,0.00029490702,0.0006292889,0.00046034067,0.00023582572,0.000010606048,0.00013302879,0.000058717542,0.0013160743],"category_scores_gemma":[0.00003412591,0.00021953351,0.000040825824,0.0017048918,0.0001900833,0.0001442577,0.000059747472,0.00067685137,0.000001003788],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068043205,0.00024468722,0.9392045,0.0004166428,0.00021357067,0.00062725955,0.008587619,0.008473842,0.009388929,0.0000042542097,0.0012438288,0.02479055],"study_design_scores_gemma":[0.016216096,0.0009373377,0.9624817,0.001830651,0.00013634196,0.000055379845,0.008058315,0.0030494002,0.0045596072,0.000031692867,0.0022800376,0.00036345914],"about_ca_topic_score_codex":0.013345428,"about_ca_topic_score_gemma":0.020765971,"teacher_disagreement_score":0.036897924,"about_ca_system_score_codex":0.0025288097,"about_ca_system_score_gemma":0.0011336041,"threshold_uncertainty_score":0.99959683},"labels":[],"label_agreement":null},{"id":"W4224692233","doi":"10.1016/j.bioorg.2022.105829","title":"Development of novel androgen receptor antagonists based on the structure of darolutamide","year":2022,"lang":"en","type":"article","venue":"Bioorganic Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China; McGill University","keywords":"Androgen receptor; Chemistry; Antiandrogen; Prostate cancer; Androgen; Androgen Receptor Antagonists; Receptor; Pharmacology; Biochemistry; Internal medicine; Cancer; Biology; Medicine; Hormone","score_opus":0.023956258235233372,"score_gpt":0.26730694541285943,"score_spread":0.24335068717762606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224692233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99810845,0.00015725238,0.000006028456,0.0007759496,0.00003137206,0.0001923802,0.00020438887,0.000012196673,0.0005119606],"genre_scores_gemma":[0.99848884,0.0000064314563,0.00065293856,0.0000763162,0.000031589716,0.000008320154,0.00017785958,0.000014839558,0.00054284354],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99909467,0.000009883077,0.00019105815,0.00016228251,0.0004011235,0.00014099818],"domain_scores_gemma":[0.99948937,0.000035982408,0.00009256055,0.00027933615,0.000049714974,0.00005301523],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000103048755,0.00009651188,0.0001632072,0.000019157158,0.00010877602,0.0000028983457,0.0001481052,0.000039687628,0.0029741286],"category_scores_gemma":[0.000033241147,0.00006376778,0.000048058013,0.00020742757,0.00007590935,0.0000061712817,0.000089490655,0.0001687937,0.0000012568582],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030529388,0.00024174793,0.0013386015,0.00016611407,0.00006870198,0.0000028269124,0.00020334026,0.0000029797714,0.99641854,0.0000042145975,0.0008196435,0.0004279763],"study_design_scores_gemma":[0.0014957933,0.000063559666,0.00056269317,0.000036273468,0.000019648654,0.000008753413,0.00035159284,0.000059762446,0.98976463,0.0000022482388,0.007575158,0.000059864688],"about_ca_topic_score_codex":0.0000039017896,"about_ca_topic_score_gemma":4.4471304e-7,"teacher_disagreement_score":0.0067555145,"about_ca_system_score_codex":0.00021058488,"about_ca_system_score_gemma":0.0007359049,"threshold_uncertainty_score":0.99793726},"labels":[],"label_agreement":null},{"id":"W4224880568","doi":"10.1016/j.clgc.2022.04.009","title":"Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate-Resistant Prostate Cancer: The Impact of Response to First ARPI","year":2022,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"Sanofi Genzyme; Sanofi","keywords":"Cabazitaxel; Medicine; Prostate cancer; Oncology; Internal medicine; Cancer; Androgen deprivation therapy","score_opus":0.25056824733698807,"score_gpt":0.5262210880224615,"score_spread":0.2756528406854734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224880568","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21255219,0.779298,7.260108e-8,0.0011341752,0.00033180718,0.004186672,0.0024073997,0.000025267738,0.00006439636],"genre_scores_gemma":[0.003368405,0.9831683,0.00007330066,0.00008046721,0.00018535588,0.0030547613,0.00009455472,0.0001257953,0.00984907],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99418306,0.0014574615,0.0019630485,0.0009560967,0.00064335385,0.00079700036],"domain_scores_gemma":[0.9925608,0.0050891084,0.00064103707,0.0009930208,0.00015256567,0.00056348095],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001916664,0.000723603,0.003576312,0.0006123637,0.0002002756,0.000064517124,0.000409589,0.00016269743,0.0006517516],"category_scores_gemma":[0.0007426285,0.00039332925,0.0011935505,0.0013653437,0.00043468087,0.000116368035,0.0004748608,0.0014503627,0.000009801964],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04533653,0.002661056,0.2132744,0.0195394,0.00755132,0.0076497803,0.0011003816,0.00020230931,0.000018785826,0.000004930529,0.0124829905,0.6901781],"study_design_scores_gemma":[0.004099923,0.0045443815,0.20695657,0.008359613,0.0023570273,0.000051118936,0.0001527507,0.000012743521,0.000002855638,0.000013442277,0.77282065,0.0006289173],"about_ca_topic_score_codex":0.017273802,"about_ca_topic_score_gemma":0.0044950997,"teacher_disagreement_score":0.76033765,"about_ca_system_score_codex":0.0018118205,"about_ca_system_score_gemma":0.005317294,"threshold_uncertainty_score":0.9998519},"labels":[],"label_agreement":null},{"id":"W4224882718","doi":"10.1016/j.jsxm.2022.01.044","title":"33 Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Localized Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"The Journal of Sexual Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Prostate cancer; Medicine; Androgen deprivation therapy; Testosterone (patch); Internal medicine; Oncology; Prostate; Cancer; Gynecology; Urology","score_opus":0.05194281631141111,"score_gpt":0.3494135988745512,"score_spread":0.2974707825631401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224882718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97188705,0.014654731,0.00011745538,0.012189524,0.0002472251,0.0008428229,0.000034157423,0.0000047853623,0.000022269774],"genre_scores_gemma":[0.99629974,0.0021262425,0.000068425325,0.0003719637,0.00026654184,0.000096621436,0.00003169987,0.000016909862,0.00072187826],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9985543,0.0001270991,0.00041101273,0.0000900111,0.0006606555,0.00015692304],"domain_scores_gemma":[0.99891603,0.00015340598,0.00035626488,0.00014728612,0.0003467127,0.00008029931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009837836,0.000100484554,0.00030258377,0.00014237163,0.0001189108,0.0000029116347,0.00011229802,0.000024549645,0.00032963432],"category_scores_gemma":[0.00006090985,0.000049491286,0.00003189407,0.0001934417,0.00013722807,0.0000691993,0.0000386761,0.00020270809,2.2747786e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0878818,0.000789526,0.04861239,0.0005455892,0.0010758319,0.00004610035,0.027733231,0.0007173807,0.7207061,0.0000055947935,0.01053916,0.10134729],"study_design_scores_gemma":[0.17506874,0.26160514,0.14503506,0.00310945,0.0054119607,0.0017093504,0.0582026,0.003603146,0.24516961,0.0010679422,0.09922167,0.00079532526],"about_ca_topic_score_codex":0.00006814649,"about_ca_topic_score_gemma":0.0000025448255,"teacher_disagreement_score":0.4755365,"about_ca_system_score_codex":0.00016934772,"about_ca_system_score_gemma":0.00020721291,"threshold_uncertainty_score":0.36092648},"labels":[],"label_agreement":null},{"id":"W4224950223","doi":"10.1038/s41467-022-29963-5","title":"ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Mitacs; Canadian Institutes of Health Research; Terry Fox Research Institute; National Cancer Institute; Government of Canada; Prostate Cancer Foundation","keywords":"Epigenetics; Biology; Chromatin remodeling; Chromatin; Transcription factor; Bivalent chromatin; Phenotype; Lineage (genetic); Histone; Cancer research; Neuroendocrine differentiation; Cell biology; Prostate cancer; Genetics; Cancer; Gene","score_opus":0.035731910312504785,"score_gpt":0.3452550057430522,"score_spread":0.3095230954305474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224950223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95170957,0.031948507,0.0000028612455,0.012757018,0.00016265981,0.0013766786,0.00009462833,0.000046991216,0.0019010832],"genre_scores_gemma":[0.99480647,0.0020265644,0.0012051834,0.0002548568,0.000022625058,0.00046753627,0.00010324734,0.000021747637,0.001091778],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988369,0.00020507193,0.00024194426,0.00016684853,0.00034508776,0.0002041948],"domain_scores_gemma":[0.9985892,0.0001528842,0.00012695593,0.0009919888,0.000107070286,0.000031909003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022880618,0.000104515966,0.00017818877,0.000071744325,0.00037233485,0.000013066216,0.000585726,0.0000610753,0.000038550363],"category_scores_gemma":[0.000018257919,0.00007220246,0.00007898956,0.00069476996,0.00009765393,0.00007110023,0.0006346185,0.0014993359,7.154252e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019282812,0.006179065,0.710355,0.001256122,0.00052659714,0.000035670557,0.05394806,0.007947153,0.1316283,0.0016323909,0.010735476,0.073827915],"study_design_scores_gemma":[0.015852213,0.0011901683,0.20161304,0.0014159756,0.00049386447,0.00008704877,0.020214451,0.04665622,0.110381104,0.00027385945,0.60081285,0.0010091967],"about_ca_topic_score_codex":0.00016389425,"about_ca_topic_score_gemma":0.00021313438,"teacher_disagreement_score":0.5900774,"about_ca_system_score_codex":0.00016582714,"about_ca_system_score_gemma":0.00034005372,"threshold_uncertainty_score":0.65139514},"labels":[],"label_agreement":null},{"id":"W4225014817","doi":"10.3390/ijms23094772","title":"The Expression of Proto-Oncogene ETS-Related Gene (ERG) Plays a Central Role in the Oncogenic Mechanism Involved in the Development and Progression of Prostate Cancer","year":2022,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Cancer Society; Prostate Cancer Foundation","keywords":"TMPRSS2; Erg; Prostate cancer; Cancer research; Biology; ETS transcription factor family; Fusion gene; Oncogene; Cancer; Angiogenesis; Tumor progression; Metastasis; Epithelial–mesenchymal transition; Prostate; Carcinogenesis; Transcription factor; Gene; Cell cycle; Pathology; Genetics; Medicine","score_opus":0.049801113026408154,"score_gpt":0.3884858927499842,"score_spread":0.338684779723576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225014817","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18146768,0.8161937,0.0000052202645,0.00057478057,0.00015317823,0.0015393901,0.000011522217,0.0000012455652,0.0000532968],"genre_scores_gemma":[0.10980001,0.88941574,0.00033516303,0.0000305358,0.000032043066,0.00035224296,0.00001128436,0.000009795451,0.000013187276],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962822,0.00050461746,0.00089645747,0.00019068691,0.0018995882,0.00022642581],"domain_scores_gemma":[0.9985508,0.0002149743,0.000897588,0.00012459475,0.00016735762,0.000044738917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028316732,0.00016560375,0.0004663568,0.00031500624,0.00011925706,0.00004870915,0.0009729743,0.00006556041,0.000016219092],"category_scores_gemma":[0.00009826045,0.000065383436,0.00016818297,0.00049859704,0.00025596563,0.000075710355,0.00017169885,0.00046485162,1.3899016e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000668227,0.00071862945,0.0017992373,0.0010025838,0.000540446,0.00086813857,0.013785302,0.000068942194,0.013821843,0.00029172437,0.00002463694,0.9664103],"study_design_scores_gemma":[0.018786013,0.0077473796,0.003876584,0.10232364,0.0015716278,0.0032172424,0.02664854,0.0005207854,0.386816,0.0055317027,0.44157973,0.0013807524],"about_ca_topic_score_codex":0.000031104406,"about_ca_topic_score_gemma":0.000025219106,"teacher_disagreement_score":0.96502954,"about_ca_system_score_codex":0.00024597824,"about_ca_system_score_gemma":0.0021388133,"threshold_uncertainty_score":0.3794163},"labels":[],"label_agreement":null},{"id":"W4225259757","doi":"10.1007/s00280-022-04427-1","title":"Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study","year":2022,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prostate Cancer Canada","funders":"Janssen Research and Development","keywords":"Placebo; Prostate cancer; Medicine; Internal medicine; Rash; Pharmacokinetics; Adverse effect; Antiandrogen; Oncology; Population; Pharmacology; Cancer; Pathology","score_opus":0.036061982547969766,"score_gpt":0.3577691898577706,"score_spread":0.32170720730980085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225259757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912217,0.0017875897,0.0000022432855,0.003518858,0.00007841861,0.0023384122,0.0010284267,0.000009318212,0.000015014618],"genre_scores_gemma":[0.9978383,0.0010405543,0.000026737329,0.0004202361,0.000035045425,0.0003689827,0.00010887845,0.000017053228,0.00014416673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983904,0.0006351967,0.0002827454,0.00029890705,0.00021014504,0.00018263729],"domain_scores_gemma":[0.998853,0.0007314143,0.00013571547,0.00011674289,0.00008982743,0.00007325536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005148646,0.00013860535,0.00028753548,0.000075702985,0.00023646378,0.0000074755426,0.000050849056,0.000021203703,0.00016754748],"category_scores_gemma":[0.000022014963,0.0000918585,0.000017040295,0.00027014472,0.00019054062,0.000052733023,0.000030063022,0.00032982652,1.927798e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3961925,0.0020774342,0.534747,0.000029993253,0.00096653553,0.000068221285,0.0361782,0.00032075812,0.009983614,0.0000036029364,0.0003142841,0.019117897],"study_design_scores_gemma":[0.113558695,0.0042629037,0.873493,0.00003710023,0.0002691893,0.0000029809305,0.0027364166,0.00012880415,0.0045522396,0.0000147908395,0.00082880334,0.000115080795],"about_ca_topic_score_codex":0.00063776044,"about_ca_topic_score_gemma":0.00025422126,"teacher_disagreement_score":0.338746,"about_ca_system_score_codex":0.00018958423,"about_ca_system_score_gemma":0.0003050267,"threshold_uncertainty_score":0.37458807},"labels":[],"label_agreement":null},{"id":"W4225419660","doi":"10.1038/s41388-022-02332-8","title":"RUVBL1 promotes enzalutamide resistance of prostate tumors through the PLXNA1-CRAF-MAPK pathway","year":2022,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Enzalutamide; Cancer research; Biology; Prostate cancer; Cell growth; Downregulation and upregulation; MAPK/ERK pathway; Signal transduction; Cancer; Androgen receptor; Cell biology; Genetics","score_opus":0.0282896923872465,"score_gpt":0.30235569370775317,"score_spread":0.2740660013205067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225419660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9644507,0.010096052,0.000020185618,0.0062668747,0.00017564044,0.0017387985,0.00029335998,0.00007697447,0.016881378],"genre_scores_gemma":[0.96567315,0.0002690673,0.00062353414,0.0003370514,0.00011258398,0.00044955712,0.00008782804,0.00004321854,0.032403994],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980512,0.00015414445,0.00032862677,0.00033325117,0.0007230997,0.00040963085],"domain_scores_gemma":[0.99899405,0.00010503672,0.00015308816,0.0005334225,0.00012901062,0.000085416155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041946242,0.00017613218,0.00033005007,0.000060082322,0.0003598222,0.0000144036485,0.00024109488,0.00003228433,0.00039619615],"category_scores_gemma":[0.00005921905,0.00011128748,0.00013297066,0.0005013639,0.00022323492,0.00006764311,0.00020884445,0.00027752647,0.000015121157],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009705318,0.0029780767,0.031848185,0.001535136,0.0012039393,0.002412736,0.029029584,0.00017524356,0.8584922,0.0064792717,0.03372878,0.022411538],"study_design_scores_gemma":[0.0054636477,0.0020335033,0.003315158,0.00027573667,0.00015336488,0.0001260104,0.0036222034,0.00006443288,0.691176,0.003480742,0.28992948,0.00035974378],"about_ca_topic_score_codex":0.00009357272,"about_ca_topic_score_gemma":0.00003793684,"teacher_disagreement_score":0.2562007,"about_ca_system_score_codex":0.0002604839,"about_ca_system_score_gemma":0.0005882675,"threshold_uncertainty_score":0.45381716},"labels":[],"label_agreement":null},{"id":"W4225766687","doi":"","title":"Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis","year":2022,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Canadian Cancer Society Research Institute; National Institutes of Health; Prostate Cancer Canada; National Cancer Institute; Fred Hutchinson Cancer Research Center","keywords":"Prostate cancer; Oncology; DNA methylation; Cohort; Methylation; Internal medicine; Medicine; Hazard ratio; Prostatectomy; Proportional hazards model; Cancer; CpG site; Biochemical recurrence; Prostate; Epigenetics; Biology; Gene; Genetics; Confidence interval","score_opus":0.029146572754000524,"score_gpt":0.31540646481010803,"score_spread":0.2862598920561075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225766687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750407,0.004453906,0.000013976521,0.0050053205,0.00012737031,0.0014745465,0.00012217286,0.00008031854,0.013681716],"genre_scores_gemma":[0.98083013,0.0005727674,0.00024707246,0.00018340377,0.00004267344,0.0006819462,0.00015601487,0.00001597851,0.01726999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898183,0.000048144924,0.00016913688,0.00017512497,0.00044729907,0.00017846838],"domain_scores_gemma":[0.9996348,0.0000310989,0.000058159098,0.0001047015,0.000105400184,0.000065828186],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020745906,0.00007695599,0.00018924223,0.00011408405,0.00009014037,0.0000047810854,0.000054339464,0.000019778452,0.0017351162],"category_scores_gemma":[0.000011896676,0.000055281565,0.000059147093,0.00030947838,0.00005201633,0.000056682245,0.00008425444,0.00012819543,0.0000037167272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002788597,0.0007606752,0.8128821,0.0005842909,0.00043011134,0.000037969105,0.0010767536,0.00007856991,0.07787069,0.00015194168,0.012891325,0.09044695],"study_design_scores_gemma":[0.00916111,0.00391252,0.5508501,0.00012928792,0.00047120178,0.000026296706,0.0010820063,0.0013720319,0.38344926,0.00032861324,0.048898514,0.0003190502],"about_ca_topic_score_codex":0.00033719747,"about_ca_topic_score_gemma":0.000010568501,"teacher_disagreement_score":0.30557856,"about_ca_system_score_codex":0.00024483222,"about_ca_system_score_gemma":0.00039178852,"threshold_uncertainty_score":0.99917746},"labels":[],"label_agreement":null},{"id":"W4226041390","doi":"10.1158/1055-9965.epi-21-0600","title":"The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource","year":2022,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute; National Institutes of Health; DOD Prostate Cancer Research Program; Institute for Prostate Cancer Research; Movember Foundation; Johns Hopkins University; U.S. Department of Defense","keywords":"Prostate cancer; Prostatectomy; Medicine; Tissue microarray; Prostate; Oncology; Metastasis; Biomarker; Disease; Cancer; Cancer research; Internal medicine; Biology","score_opus":0.07455425562777064,"score_gpt":0.42084376648921,"score_spread":0.3462895108614394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226041390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.706957,0.14806351,0.00050436537,0.12967639,0.003910954,0.0059701046,0.00069464854,0.00039286484,0.003830204],"genre_scores_gemma":[0.8139601,0.039993577,0.0010836996,0.0068569076,0.0015073522,0.014472372,0.0025211652,0.0001826667,0.1194222],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99605894,0.0015743016,0.00059406925,0.0006774606,0.00028740865,0.00080781354],"domain_scores_gemma":[0.9984556,0.00036089047,0.00037747232,0.00047630814,0.000108870394,0.00022085235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023264592,0.0002846635,0.00046734585,0.00008807443,0.0010065373,0.000017977762,0.0002497834,0.0001652643,0.0007644245],"category_scores_gemma":[0.0001399108,0.0002056058,0.00021273179,0.00048573868,0.0003957709,0.00009861289,0.00019946796,0.0005090197,0.00001829081],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011691768,0.00026719485,0.3750895,0.00018766952,0.0019941053,0.00006519909,0.00032231119,0.0003030115,0.013434366,0.00046226115,0.30845815,0.28772447],"study_design_scores_gemma":[0.0032045934,0.00087155966,0.13479744,0.00018391822,0.00032912294,0.00010501981,0.00081659417,0.00025560491,0.0027808836,0.0045071207,0.85181683,0.00033131006],"about_ca_topic_score_codex":0.001824347,"about_ca_topic_score_gemma":0.000976148,"teacher_disagreement_score":0.5433587,"about_ca_system_score_codex":0.0022738345,"about_ca_system_score_gemma":0.00068396726,"threshold_uncertainty_score":0.8384361},"labels":[],"label_agreement":null},{"id":"W4226065003","doi":"10.1615/critrevoncog.2022043298","title":"Genomic Alterations to Guide Treatment Selection in Metastatic Prostate Cancer","year":2022,"lang":"en","type":"review","venue":"Critical Reviews™ in Oncogenesis","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Taxane; Oncology; Precision medicine; Personalized medicine; Disease; Genotyping; Internal medicine; Cabazitaxel; Cancer; Prostate; Circulating tumor cell; Bioinformatics; Metastasis; Breast cancer; Pathology; Androgen deprivation therapy; Biology; Gene; Genotype","score_opus":0.21170501001792763,"score_gpt":0.5165287925402411,"score_spread":0.30482378252231346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226065003","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000093828894,0.9907381,0.000014047227,0.00092923245,0.00020043671,0.0072468338,0.00021377533,0.000029500827,0.0005342418],"genre_scores_gemma":[0.000008616858,0.9706515,0.0010282444,0.00028637197,0.00017392263,0.023713112,0.00027970478,0.00010092996,0.0037576144],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99541914,0.0008927752,0.001589809,0.00092904695,0.0003856909,0.0007835485],"domain_scores_gemma":[0.998336,0.00065964204,0.00011576039,0.00039944804,0.00007856726,0.00041054076],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00082991994,0.0006121581,0.0031770545,0.0008487329,0.00013660743,0.000051512972,0.00018799408,0.000120435456,0.0017400888],"category_scores_gemma":[0.00087371975,0.00043802275,0.00062188343,0.0018024533,0.00007355391,0.00007331179,0.00011008265,0.0004199053,0.00026126148],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052955904,0.0005420763,0.00024100617,0.015006865,0.00012932492,0.0002878409,0.00014483435,0.0000053129365,0.000015294612,0.00005255098,0.0008023982,0.98271954],"study_design_scores_gemma":[0.0007616911,0.000618723,0.00006027898,0.012156875,0.0016192398,0.00007671663,0.000026536154,0.000013979152,0.000011205551,0.00001852124,0.9842891,0.00034715224],"about_ca_topic_score_codex":0.0006957044,"about_ca_topic_score_gemma":0.0007876828,"teacher_disagreement_score":0.9834867,"about_ca_system_score_codex":0.008172186,"about_ca_system_score_gemma":0.0025868022,"threshold_uncertainty_score":0.9998072},"labels":[],"label_agreement":null},{"id":"W4226221611","doi":"10.1200/jco.2022.40.6_suppl.274","title":"Impact of AR-V7 and other androgen receptor splice variant expression on outcomes of post-prostatectomy salvage therapy.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"Radiological Society of North America","keywords":"Prostate cancer; Prostatectomy; Medicine; Androgen receptor; Androgen deprivation therapy; Salvage therapy; Biochemical recurrence; Oncology; Radiation therapy; Internal medicine; Cancer; Cancer research; Chemotherapy","score_opus":0.12622327562448948,"score_gpt":0.5020454190808953,"score_spread":0.3758221434564058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226221611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99533844,0.0013497418,0.000003640746,0.0020380535,0.00027646025,0.0003186561,0.00006962096,0.000003857288,0.00060154905],"genre_scores_gemma":[0.99691147,0.0014686598,0.00045794144,0.00069993065,0.00014706976,0.0000075807206,0.0000044025487,0.000018973955,0.00028396654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744225,0.0005379454,0.0012346769,0.00015299453,0.00044784482,0.00018427361],"domain_scores_gemma":[0.99666977,0.0014801353,0.0011773754,0.0001817913,0.00026639973,0.00022454945],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020739613,0.00012078151,0.0011960226,0.0001636347,0.000046222314,0.0000025374059,0.000131766,0.0001324951,0.0010253007],"category_scores_gemma":[0.0006196935,0.00006467321,0.00045673255,0.00012410905,0.00015744838,0.000046852405,0.0000846379,0.000689349,0.0000020919613],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055490237,0.0051318826,0.8342617,0.000043157917,0.0014704216,0.00038985081,0.0007548411,0.000020076599,0.04104302,0.000022575712,0.0024589503,0.058913287],"study_design_scores_gemma":[0.029247483,0.104156,0.8367812,0.0001132683,0.00016442106,0.00017659142,0.00045473926,0.000017129556,0.00731649,0.00017160793,0.021286331,0.000114704955],"about_ca_topic_score_codex":0.00006460147,"about_ca_topic_score_gemma":0.0000019301106,"teacher_disagreement_score":0.09902412,"about_ca_system_score_codex":0.0001389107,"about_ca_system_score_gemma":0.0010203541,"threshold_uncertainty_score":0.9998879},"labels":[],"label_agreement":null},{"id":"W4226321927","doi":"10.1111/ijun.12306","title":"Degarelix administration technique optimisation: Consensus findings of an international Delphi nurse panel","year":2022,"lang":"en","type":"article","venue":"International Journal of Urological Nursing","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Injection site; Delphi method; Subcutaneous injection; Internal medicine","score_opus":0.06261943864912288,"score_gpt":0.389742519065797,"score_spread":0.3271230804166741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226321927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763921,0.00013774337,0.0015616118,0.018607726,0.0009932253,0.00023442155,0.000043858952,0.000017678552,0.0020116274],"genre_scores_gemma":[0.99385077,0.000040302144,0.0052627255,0.00030697274,0.00029835248,0.0000120364375,0.00007851906,0.000010335819,0.00013996083],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980277,0.00011067566,0.0005359104,0.00015600433,0.0010290286,0.0001406736],"domain_scores_gemma":[0.99864626,0.00010804971,0.00031949693,0.00009497384,0.0007079872,0.00012321044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005092787,0.00010441827,0.00021006523,0.00031815094,0.00007766059,0.00003851314,0.00034474873,0.00006690735,0.0006044231],"category_scores_gemma":[0.00019107969,0.00008526323,0.00014091881,0.0001200733,0.00018008935,0.00019032575,0.000036256395,0.00043248347,0.0000012799359],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13350318,0.024548935,0.17654566,0.00008774393,0.0036673783,0.017365117,0.0055374177,0.010138345,0.3802692,0.021784188,0.009125313,0.21742752],"study_design_scores_gemma":[0.038486898,0.063502826,0.47648802,0.0014904275,0.0010784819,0.09658375,0.008393681,0.014815076,0.23927855,0.028896328,0.029591085,0.0013948677],"about_ca_topic_score_codex":0.000004956011,"about_ca_topic_score_gemma":2.2008646e-7,"teacher_disagreement_score":0.29994237,"about_ca_system_score_codex":0.00043562235,"about_ca_system_score_gemma":0.00027612704,"threshold_uncertainty_score":0.6618009},"labels":[],"label_agreement":null},{"id":"W4226494867","doi":"","title":"Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?","year":2022,"lang":"en","type":"article","venue":"Bern Open Repository and Information System (University of Bern)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Positron emission tomography; Glutamate carboxypeptidase II; Prostate; Cancer; Antigen; Hormone; Oncology; Positron Emission Tomography-Computed Tomography; Internal medicine; Nuclear medicine; Immunology","score_opus":0.010614023683844231,"score_gpt":0.23810398952369013,"score_spread":0.2274899658398459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226494867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99159455,0.001762549,0.000030187088,0.0002036285,0.00006645315,0.0016326718,0.00023728835,0.000026433705,0.004446208],"genre_scores_gemma":[0.9980331,0.0006394804,0.00027904176,0.000009187541,0.0000071875093,0.000016388527,0.00017872761,0.000008239919,0.00082865974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986466,0.0001636666,0.00035957163,0.00019344853,0.0004441801,0.00019252475],"domain_scores_gemma":[0.99895906,0.00003072634,0.0003994794,0.00021255604,0.00028032632,0.00011784916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003981893,0.00013788563,0.00040972437,0.0004153404,0.00048385368,0.000045644756,0.00016934433,0.00004266826,0.00001849991],"category_scores_gemma":[0.000003192527,0.00013954735,0.000083537125,0.00051879353,0.00012578386,0.0016371971,0.0002554145,0.00018043538,0.0000012937439],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021797407,0.00079675176,0.58534706,0.003846878,0.0012460933,0.0004651682,0.20977937,0.0010554596,0.16058634,0.0012164527,0.0011622693,0.012700769],"study_design_scores_gemma":[0.011519407,0.00163947,0.5210423,0.0019285462,0.00031154824,0.00030685676,0.41197187,0.0066841207,0.03824131,0.000014413553,0.0058337566,0.0005064401],"about_ca_topic_score_codex":0.003992073,"about_ca_topic_score_gemma":0.000022155506,"teacher_disagreement_score":0.2021925,"about_ca_system_score_codex":0.0002945217,"about_ca_system_score_gemma":0.00022806671,"threshold_uncertainty_score":0.60348463},"labels":[],"label_agreement":null},{"id":"W4229057515","doi":"10.1101/2022.05.04.490172","title":"Discovery and characterization of a first-in-field transcription factor BRN2 inhibitor for the treatment of neuroendocrine prostate cancer","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"DOD Prostate Cancer Research Program; Canadian Institutes of Health Research; Prostate Cancer Canada; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Cancer research; Transcription factor; Chromatin; Biology; Genetics; DNA; Gene","score_opus":0.022383058709558177,"score_gpt":0.27094494098284155,"score_spread":0.24856188227328338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229057515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888661,0.003592422,0.00009066157,0.00165986,0.00050174596,0.0034113543,0.0018487896,0.000028460661,5.9106657e-7],"genre_scores_gemma":[0.9735456,0.024037628,0.000063342355,0.00003489208,0.00015261243,0.0020552436,0.00000506812,0.000055534027,0.000050055172],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984871,0.000047891263,0.0004418681,0.0004683642,0.00027150335,0.00028324014],"domain_scores_gemma":[0.99892694,0.00011722797,0.00027118393,0.00043853905,0.00017335053,0.00007276576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009277776,0.00028704433,0.0005405486,0.00020849633,0.0000844797,0.000035805995,0.00010471723,0.000077923796,0.00003281859],"category_scores_gemma":[0.000033899043,0.00020524912,0.00014360646,0.0002559948,0.00008468588,0.00011034262,0.00006576978,0.0002134835,1.7589373e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017958372,0.0006459195,0.13143303,0.0018087428,0.00026663186,0.000026210038,0.00015163257,0.000011164389,0.8637408,0.000023037634,0.000008706334,0.00008829174],"study_design_scores_gemma":[0.0031234787,0.0012917761,0.336167,0.00042148354,0.00024765253,2.3718243e-8,0.000012663701,0.00029796155,0.6543348,5.3388675e-7,0.003930624,0.0001720442],"about_ca_topic_score_codex":0.0002919876,"about_ca_topic_score_gemma":0.000026476628,"teacher_disagreement_score":0.20940605,"about_ca_system_score_codex":0.00032780468,"about_ca_system_score_gemma":0.00037742592,"threshold_uncertainty_score":0.8369816},"labels":[],"label_agreement":null},{"id":"W4229335385","doi":"10.3390/curroncol29050275","title":"The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer—A Systematic Literature Review with Application to the Canadian Context","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université Laval; McGill University; McGill University Health Centre","funders":"Réseau Québécois de Recherche sur les Médicaments","keywords":"Enzalutamide; Medicine; Prostate cancer; Androgen deprivation therapy; Checklist; Health care; Oncology; Internal medicine; Family medicine; Cancer; Androgen receptor","score_opus":0.10035102941041374,"score_gpt":0.43767117361144725,"score_spread":0.3373201442010335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229335385","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018862356,0.9777442,0.0000089085615,0.004954381,0.00018181503,0.016044518,0.0009895675,0.0000065401678,0.000051163755],"genre_scores_gemma":[0.00021720794,0.99023926,0.000036144615,0.0003838871,0.00004852544,0.008113023,0.000764567,0.000038805316,0.0001585815],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971044,0.0008090612,0.00096271076,0.000434853,0.00025102106,0.00043797336],"domain_scores_gemma":[0.99722344,0.0006905887,0.00093767483,0.00052246306,0.00026983212,0.00035602553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014100161,0.00036474905,0.0023121047,0.00019648044,0.00050093525,0.000055277786,0.00020788623,0.000048398804,0.0000068815207],"category_scores_gemma":[0.00011186138,0.0001686774,0.00016124654,0.0006097881,0.00019727096,0.000037569032,0.000060391645,0.00062080025,0.0000062381982],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013426635,0.000059830734,0.0000017300342,0.38312307,0.0006248535,0.000032222906,0.0012116582,0.0000012465563,9.0068134e-8,0.00017676027,0.0019837506,0.6126505],"study_design_scores_gemma":[0.00055997964,0.0013184987,0.000010335529,0.12060036,0.0023096139,0.00022270643,0.0005621801,0.000025557178,1.7543817e-7,0.000007503025,0.87424225,0.00014084569],"about_ca_topic_score_codex":0.0045669693,"about_ca_topic_score_gemma":0.15366791,"teacher_disagreement_score":0.8722585,"about_ca_system_score_codex":0.0024313563,"about_ca_system_score_gemma":0.009477464,"threshold_uncertainty_score":0.99613786},"labels":[],"label_agreement":null},{"id":"W4229458535","doi":"10.1148/radiol.220701","title":"It’s Time for a Standardized MRI Assessment Scheme for Prostate Cancer Recurrence","year":2022,"lang":"en","type":"letter","venue":"Radiology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Cancer; Magnetic resonance imaging; Medical physics; Radiology; Internal medicine","score_opus":0.04009197816667138,"score_gpt":0.3943252639949523,"score_spread":0.35423328582828095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229458535","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027259934,0.0051645515,0.0006876776,0.97505456,0.0013366973,0.008252406,0.00796895,0.00009156033,0.0011709935],"genre_scores_gemma":[0.00007394407,0.011129106,0.019606022,0.6616885,0.009641671,0.05758915,0.03534713,0.00037754796,0.20454694],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972722,0.00015986477,0.00040885268,0.0008305731,0.0003839932,0.0009445404],"domain_scores_gemma":[0.9983394,0.0005701825,0.00021638375,0.00045243299,0.00031096867,0.00011060967],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00056481187,0.00038690056,0.0011137009,0.00021955122,0.00023954798,0.000024071449,0.00024675595,0.00049983815,0.0021201025],"category_scores_gemma":[0.000096320204,0.00030455602,0.00036436907,0.00015074246,0.0001982404,0.000037789807,0.00009451689,0.0012897402,0.00001212351],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027078013,0.00004967287,0.00029738972,0.0009623999,0.0008226363,0.00018290778,0.00014288284,0.0000027627614,0.00040348253,0.000014801792,0.99182594,0.0025873368],"study_design_scores_gemma":[0.007549818,0.0028263752,0.00003679555,0.00015457517,0.000326976,0.0001005025,0.000018841398,0.00047644123,0.00012588938,0.00021409578,0.98786485,0.00030484592],"about_ca_topic_score_codex":0.000032003663,"about_ca_topic_score_gemma":0.0000047531644,"teacher_disagreement_score":0.3133661,"about_ca_system_score_codex":0.001521046,"about_ca_system_score_gemma":0.0024467586,"threshold_uncertainty_score":0.99994063},"labels":[],"label_agreement":null},{"id":"W4229553565","doi":"10.12688/f1000research.20824.3","title":"Case Report: A castration-resistant terminal prostate cancer patient’s survival prolonged after practicing Falun Gong","year":2020,"lang":"en","type":"preprint","venue":"F1000Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Castration; Androgen deprivation therapy; Internal medicine; Cancer; Oncology; Urology; Hormone","score_opus":0.0958299200812583,"score_gpt":0.4077035793406776,"score_spread":0.3118736592594193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229553565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97047967,0.0035555267,0.00001634923,0.014191708,0.0007333593,0.0072359275,0.0009258671,0.00021272466,0.0026488625],"genre_scores_gemma":[0.9831557,0.0006397706,0.0006484024,0.0001460316,0.0008956946,0.0052227117,0.00083295465,0.00018532996,0.00827336],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9929616,0.00056622684,0.0010403746,0.0016728397,0.002415248,0.0013437453],"domain_scores_gemma":[0.99581665,0.00027027246,0.00042085207,0.0012169824,0.0013114556,0.0009638192],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011309051,0.000657216,0.0009712871,0.00046639433,0.00036086034,0.00041827228,0.00028938256,0.0004430996,0.000899357],"category_scores_gemma":[0.00083500176,0.0005320807,0.000324965,0.0005783218,0.00039822925,0.00023354146,0.0013094742,0.0032564588,0.0000975864],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013502225,0.0005195604,0.030771807,0.003324744,0.00086761866,0.9240283,0.0048500863,0.000035547902,0.0045351037,0.000010005523,0.0032390603,0.014315975],"study_design_scores_gemma":[0.044593733,0.023292743,0.2769501,0.022177618,0.007537823,0.39626047,0.022176519,0.01590955,0.07251075,0.0024692025,0.10572357,0.0103979185],"about_ca_topic_score_codex":0.005177951,"about_ca_topic_score_gemma":0.0014650017,"teacher_disagreement_score":0.5277678,"about_ca_system_score_codex":0.0011914704,"about_ca_system_score_gemma":0.005553593,"threshold_uncertainty_score":0.99971306},"labels":[],"label_agreement":null},{"id":"W4229871062","doi":"10.5489/cuaj.1309","title":"Podium Session 5: Prostate Cancer","year":2012,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Session (web analytics); Cancer; Medicine; Prostate cancer; Prostate; Internal medicine; Computer science; World Wide Web","score_opus":0.025100635842379638,"score_gpt":0.3052204381133153,"score_spread":0.28011980227093564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229871062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9222112,0.0029819985,0.0000048225816,0.06932314,0.00071087485,0.00023407745,0.000037750404,0.000026652415,0.0044694375],"genre_scores_gemma":[0.9863052,0.0007389744,0.000066577064,0.0033623416,0.0011105004,0.000020895895,0.000022437142,0.000010943187,0.0083621405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985136,0.000095708565,0.00017871472,0.00010253937,0.0003514624,0.00075800094],"domain_scores_gemma":[0.9982295,0.0000444029,0.00011006131,0.00006331314,0.0002247146,0.0013280313],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054438825,0.00009934357,0.00016975023,0.0001362699,0.0002709706,0.000051538587,0.000057193043,0.00016554828,0.0018915611],"category_scores_gemma":[0.00020675988,0.00006563594,0.00008585853,0.00018418941,0.000023595028,0.00016014827,0.0000116611745,0.00053031277,0.00012945413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073229035,0.00004748885,0.9622904,0.0000040691616,0.00006947133,0.000044684515,0.00026157376,0.0000022363486,0.00021766982,0.00003192961,0.028853899,0.008103347],"study_design_scores_gemma":[0.0009312316,0.00012552073,0.76638335,0.000014677697,0.000045028235,0.00010608985,0.000054018892,0.000017164784,0.00013963188,0.000101076825,0.23200788,0.000074344825],"about_ca_topic_score_codex":0.0007365234,"about_ca_topic_score_gemma":0.00016399205,"teacher_disagreement_score":0.20315398,"about_ca_system_score_codex":0.0019973232,"about_ca_system_score_gemma":0.0007317045,"threshold_uncertainty_score":0.9990209},"labels":[],"label_agreement":null},{"id":"W4230070917","doi":"10.1016/s0167-8140(02)83445-4","title":"21 Preliminary report of a multicenter canadian phase III randomized trial of 3 months vs 8 months neoadjuvant androgen deprivation prior to standard dose radiotherapy for clinically localized prostate cancer","year":2002,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Radiation therapy; Androgen deprivation therapy; Internal medicine; Androgen; Randomized controlled trial; Multicenter trial; Urology; Multicenter study; Cancer; Hormone","score_opus":0.03019391013261142,"score_gpt":0.38752976133422506,"score_spread":0.35733585120161365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230070917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9584277,0.0146395415,0.0021208334,0.008466386,0.00038826902,0.015550594,0.00024189042,0.00002724762,0.0001374854],"genre_scores_gemma":[0.9108048,0.056547463,0.022860346,0.0021472955,0.0006189326,0.0040376983,0.00015450547,0.00012200417,0.0027069228],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971969,0.00027091903,0.0012924265,0.0004803679,0.0002880753,0.00047127],"domain_scores_gemma":[0.9977283,0.00061935215,0.0004920579,0.00035560835,0.00034800242,0.00045669285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013614132,0.00025744326,0.0018525178,0.00029771103,0.00010334725,0.000012811576,0.00010975743,0.0002647704,0.00029486592],"category_scores_gemma":[0.0002964053,0.0001889293,0.00029863324,0.00020021759,0.0003561967,0.00007430643,0.000014103723,0.00016108465,3.2825176e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8002263,0.00094197446,0.0013651858,0.000117881915,0.00092840614,0.0001968679,0.00396418,0.000025432493,0.0023571842,0.000010579111,0.0014498477,0.18841621],"study_design_scores_gemma":[0.9009516,0.024195613,0.0001784448,0.00015320607,0.00030292678,0.000056677447,0.00008925747,0.0068388027,0.0025419388,0.00002415107,0.06448676,0.0001805798],"about_ca_topic_score_codex":0.006423309,"about_ca_topic_score_gemma":0.002951473,"teacher_disagreement_score":0.18823563,"about_ca_system_score_codex":0.00085284497,"about_ca_system_score_gemma":0.0010282778,"threshold_uncertainty_score":0.97101647},"labels":[],"label_agreement":null},{"id":"W4230709207","doi":"10.1186/s40658-021-00382-7","title":"Correction to: Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&amp;T","year":2021,"lang":"en","type":"article","venue":"EJNMMI Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of British Columbia","funders":"","keywords":"Dosimetry; Medicine; Nuclear medicine; Medical physics; Lesion; Radiology; Surgery","score_opus":0.033332420205386355,"score_gpt":0.37952761742559915,"score_spread":0.3461951972202128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230709207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939314,0.00013306469,0.004140033,0.00032208094,0.0001903888,0.00084712676,0.000011440746,0.000041533858,0.00038292998],"genre_scores_gemma":[0.99298656,0.00013321005,0.005709627,0.00034723934,0.000090218,0.00012852371,0.00014305864,0.00003181008,0.00042972938],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99858785,0.00008148112,0.0002770868,0.00039412527,0.00040736698,0.00025208792],"domain_scores_gemma":[0.9988572,0.00024333056,0.00009444129,0.00039541622,0.0002804744,0.00012912412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022161349,0.0001699795,0.00032303238,0.00014101803,0.00006172261,0.000017757195,0.000078524026,0.00006494371,0.000012460656],"category_scores_gemma":[0.00025853477,0.00014619902,0.00006391139,0.001074159,0.00002297281,0.00009968857,0.00006243761,0.00021263605,0.000061258404],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011571696,0.0012109753,0.09012235,0.0001048567,0.000046157016,0.000006470983,0.001562987,0.003434208,0.4686204,0.00003479872,0.0009364992,0.43276316],"study_design_scores_gemma":[0.0020224329,0.00053738744,0.40956774,0.00050468306,0.000021133275,0.0000013899138,0.00008590883,0.00071919017,0.58561844,0.0002505366,0.0005201438,0.00015100877],"about_ca_topic_score_codex":0.00022803784,"about_ca_topic_score_gemma":0.00003866842,"teacher_disagreement_score":0.43261215,"about_ca_system_score_codex":0.0002471636,"about_ca_system_score_gemma":0.0001122342,"threshold_uncertainty_score":0.5961823},"labels":[],"label_agreement":null},{"id":"W4231021439","doi":"10.1200/jco.2013.31.6_suppl.146","title":"Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel (D).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Abiraterone acetate; Internal medicine; Docetaxel; Oncology; Ketoconazole; Refractory (planetary science); Progression-free survival; Urology; Proportional hazards model; Cancer; Androgen deprivation therapy; Chemotherapy","score_opus":0.18144906861543683,"score_gpt":0.5111045380899563,"score_spread":0.3296554694745194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231021439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99361295,0.000505849,0.0000072210614,0.0035098472,0.00048993144,0.0012274178,0.000017976106,0.0000051586853,0.00062362914],"genre_scores_gemma":[0.9968941,0.00037334085,0.001763239,0.0002579818,0.00013084897,0.00008282632,0.0000102578915,0.00002237822,0.0004650199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99601865,0.000364332,0.0023480435,0.00023776572,0.0006521419,0.0003790934],"domain_scores_gemma":[0.9958911,0.00082846207,0.0014709133,0.00020155469,0.0011283241,0.0004796623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011485465,0.00019155271,0.0016680666,0.00023879623,0.000034331475,0.00001643208,0.00016128499,0.00014006654,0.00035776652],"category_scores_gemma":[0.00051603024,0.00011657355,0.00016614691,0.00027605786,0.00023788748,0.00025198117,0.00003698292,0.0007916188,0.000032185133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09734785,0.007810124,0.7553464,0.00022251239,0.0012171943,0.00027079522,0.0013685398,0.0003853701,0.0029070007,0.00001500054,0.0039640297,0.12914519],"study_design_scores_gemma":[0.051158458,0.049181636,0.89101094,0.00032451923,0.0003481467,0.000005978929,0.0005790242,0.00009068522,0.0012379304,0.00003623489,0.0058819293,0.00014451642],"about_ca_topic_score_codex":0.00040931648,"about_ca_topic_score_gemma":0.00074991485,"teacher_disagreement_score":0.13566455,"about_ca_system_score_codex":0.00047585997,"about_ca_system_score_gemma":0.0022587462,"threshold_uncertainty_score":0.47537315},"labels":[],"label_agreement":null},{"id":"W4231267067","doi":"10.5489/cuaj.2285","title":"Novel approaches in the high-risk prostate cancer patient: Summary of key research presented at AUA 2014","year":2014,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Prostate; Cancer; Medicine; Focus (optics); Key (lock); Oncology; Gynecology; Internal medicine; Computer science","score_opus":0.1146752429108696,"score_gpt":0.35474560767920316,"score_spread":0.24007036476833354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231267067","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003225167,0.9841934,0.0000016540131,0.008351382,0.0002394743,0.0020583046,0.00075847056,0.000009123066,0.0011630403],"genre_scores_gemma":[0.0040516593,0.9923227,0.000036774767,0.00020247315,0.000497955,0.00034181052,0.00036453753,0.000038404207,0.0021437053],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99358374,0.0024036444,0.0010268978,0.00043402027,0.001438356,0.0011133713],"domain_scores_gemma":[0.9959293,0.0015972956,0.0009621107,0.00033331988,0.0005488374,0.0006291291],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005093884,0.00033066073,0.0013743977,0.00077386433,0.00044798417,0.00009230064,0.0004651891,0.00068188005,0.00025385554],"category_scores_gemma":[0.0019024744,0.00017931602,0.00041648716,0.0008804922,0.00019677021,0.000067176734,0.00009868624,0.003157353,0.00004880108],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040081792,0.0005362034,0.14520401,0.003006424,0.001413981,0.0003040275,0.0013627069,0.00003909669,0.0000019587474,0.00016247242,0.15685943,0.6907089],"study_design_scores_gemma":[0.0012242917,0.0005839229,0.011112689,0.0013904016,0.000379349,0.0000866593,0.00008033375,0.000026580336,9.2189583e-7,0.00012027414,0.98482364,0.00017092045],"about_ca_topic_score_codex":0.013972205,"about_ca_topic_score_gemma":0.007836018,"teacher_disagreement_score":0.82796425,"about_ca_system_score_codex":0.004687455,"about_ca_system_score_gemma":0.0029050456,"threshold_uncertainty_score":0.9991424},"labels":[],"label_agreement":null},{"id":"W4231273774","doi":"10.3410/f.13381956.14750133","title":"Faculty Opinions recommendation of Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells.","year":2011,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"MAPK/ERK pathway; Prostate; Cell biology; Cancer research; Signaling proteins; Signal transduction; Chemistry; Biology; Genetics; Cancer","score_opus":0.05273602896165123,"score_gpt":0.3762600678715246,"score_spread":0.32352403890987336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231273774","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028107252,0.0017884873,0.000003963174,0.08240545,0.00052549224,0.004901437,0.91025084,0.00004110206,0.000055091317],"genre_scores_gemma":[0.000078613826,0.0015205534,0.00060739944,0.00148469,0.00017630514,0.000801838,0.99349314,0.00004791791,0.0017895472],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946178,0.0005344989,0.0018458219,0.0008425436,0.0015775791,0.00058173103],"domain_scores_gemma":[0.9919616,0.00011924436,0.0014334382,0.0013561758,0.0047166953,0.00041285256],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014999518,0.00063451676,0.0013487119,0.0007585956,0.00017412387,0.00007297356,0.0010140148,0.0007291434,0.00063184934],"category_scores_gemma":[0.0026446385,0.00038877796,0.00064736645,0.0028846674,0.00039561166,0.0003238963,0.00040577573,0.0017641523,0.00005909299],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019589251,0.0011272503,0.000015756312,0.014209323,0.0002894566,0.0000033556228,0.00030743435,8.501017e-8,0.0004697938,0.000016161091,0.98132104,0.0020444733],"study_design_scores_gemma":[0.0025111695,0.0004348834,0.0007886158,0.027388703,0.00026361924,0.000037372538,0.00004341242,0.0000038070375,0.004756545,0.000017448992,0.9634235,0.00033090878],"about_ca_topic_score_codex":0.00021231857,"about_ca_topic_score_gemma":0.00001055232,"teacher_disagreement_score":0.08324227,"about_ca_system_score_codex":0.00039551634,"about_ca_system_score_gemma":0.001612565,"threshold_uncertainty_score":0.9998564},"labels":[],"label_agreement":null},{"id":"W4231991130","doi":"10.1016/j.urology.2014.08.004","title":"Reply by the Authors","year":2014,"lang":"en","type":"letter","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Tolerability; Medicine; Prostate cancer; Urology; Androgen deprivation therapy; Gynecology; Adverse effect; Internal medicine; Cancer","score_opus":0.029675409740005328,"score_gpt":0.31842268977471644,"score_spread":0.2887472800347111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231991130","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013249432,0.0020296245,0.00003189441,0.9804521,0.00041252072,0.00033533512,0.00001279952,0.00004586499,0.01654737],"genre_scores_gemma":[0.0009034789,0.00012292883,0.0000057382636,0.850768,0.0025371402,0.00006646549,0.0005389348,0.000032666776,0.1450246],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877685,0.00016021654,0.00013736777,0.00030929333,0.00021530967,0.00040094292],"domain_scores_gemma":[0.9991231,0.0001895025,0.00005726768,0.0005343534,0.00004675239,0.000049036335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018803086,0.00015602726,0.0002875733,0.00006173744,0.00007030387,0.000010365578,0.0001719565,0.00054734165,0.0004865538],"category_scores_gemma":[0.000063880856,0.000080890175,0.000096243086,0.00006292468,0.0002515193,0.0000071646164,0.000047702608,0.0018211603,0.00039219973],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078062454,0.000009697615,0.00013640066,0.000035178095,0.00011318581,0.00046919187,0.00003593234,9.628344e-8,0.000030732346,0.0000101779115,0.9979185,0.0011628873],"study_design_scores_gemma":[0.0005846674,0.0005270281,0.00003391967,0.000005528055,0.00013169716,0.00025682885,0.0000017850746,0.000017265593,0.00005456155,0.00019053956,0.9981262,0.00006995486],"about_ca_topic_score_codex":0.000051476938,"about_ca_topic_score_gemma":9.19658e-7,"teacher_disagreement_score":0.12968405,"about_ca_system_score_codex":0.0000453353,"about_ca_system_score_gemma":0.000099123026,"threshold_uncertainty_score":0.79121363},"labels":[],"label_agreement":null},{"id":"W4232331073","doi":"10.5489/cuaj.3213","title":"Prostate Cancer: Summary from ASCO 2015","year":2015,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Oncology; Gynecology; Internal medicine; Medical physics","score_opus":0.06076671164679468,"score_gpt":0.36193143050564525,"score_spread":0.30116471885885054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232331073","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047968013,0.9853998,4.7301629e-7,0.0089593185,0.0008670175,0.0007996015,0.0014350275,0.00003464392,0.0024561412],"genre_scores_gemma":[0.000020019455,0.98306817,0.000042867392,0.0008600551,0.0020748714,0.000111916605,0.0011226551,0.00005151715,0.012647925],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99662703,0.0004720572,0.00068676524,0.00041438846,0.0008433784,0.00095637736],"domain_scores_gemma":[0.9959629,0.00019664393,0.0006263926,0.0002170571,0.0006515668,0.0023453978],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010237161,0.0004120275,0.0017263539,0.00039446552,0.00025042827,0.00018403388,0.00027207003,0.00089472375,0.001430268],"category_scores_gemma":[0.00043135136,0.00027059807,0.0005379669,0.00042649914,0.000056437337,0.00010923837,0.000043433156,0.0020953345,0.00040348334],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000042246793,0.00003685061,0.009277654,0.0002351291,0.000845096,0.00061997847,0.00004757638,5.6434334e-7,7.893073e-8,0.00000414937,0.3439884,0.6449023],"study_design_scores_gemma":[0.0010345974,0.00023117829,0.0008643709,0.0017635771,0.0011826489,0.00011120531,0.000015641004,0.0000029634014,1.0009262e-7,0.00024346703,0.99429107,0.00025917363],"about_ca_topic_score_codex":0.006374458,"about_ca_topic_score_gemma":0.0015033936,"teacher_disagreement_score":0.6503027,"about_ca_system_score_codex":0.0098018255,"about_ca_system_score_gemma":0.012382631,"threshold_uncertainty_score":0.9999746},"labels":[],"label_agreement":null},{"id":"W4232375200","doi":"10.1158/1538-7445.transcagen-a2-11","title":"Abstract A2-11: PLZF, a tumor suppressor genetically lost in metastatic castration resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Prostate cancer; Androgen deprivation therapy; Gene knockdown; Enzalutamide; Cancer research; Cancer; LNCaP; Suppressor; Androgen; Medicine; Biology; Androgen receptor; Internal medicine; Gene; Genetics; Hormone","score_opus":0.12344612421085763,"score_gpt":0.42362044191053555,"score_spread":0.30017431769967795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232375200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97596186,0.011417898,0.0000057837306,0.008550786,0.00009116882,0.0030401684,0.00042819537,0.000021757822,0.0004824031],"genre_scores_gemma":[0.9927391,0.0030135254,0.0005596263,0.00021506588,0.0001501717,0.0015513839,0.000055679717,0.00006322173,0.0016522477],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9955625,0.00024278555,0.00066364114,0.00068082,0.0019430596,0.000907218],"domain_scores_gemma":[0.9969338,0.00019826714,0.00013106101,0.0005730849,0.0015063442,0.0006574299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016952625,0.000257628,0.00054414384,0.00063006644,0.00009240352,0.00006777658,0.00030201828,0.0000864527,0.0004305617],"category_scores_gemma":[0.00039667732,0.00020644983,0.00008061074,0.0015222812,0.00030130398,0.00018370137,0.00009584624,0.00045003463,0.000038685375],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029560609,0.0008976147,0.06799807,0.0012246299,0.00031077216,0.0006499248,0.009925947,0.00012091797,0.86284745,0.000121058845,0.01984096,0.0065020435],"study_design_scores_gemma":[0.010370229,0.0011656353,0.08294197,0.0011071415,0.000042181393,0.0000066242087,0.0015089926,0.00007466603,0.8883485,0.0005626547,0.013544193,0.00032721876],"about_ca_topic_score_codex":0.0027171562,"about_ca_topic_score_gemma":0.0056547904,"teacher_disagreement_score":0.025501035,"about_ca_system_score_codex":0.0011649798,"about_ca_system_score_gemma":0.0037509378,"threshold_uncertainty_score":0.84187794},"labels":[],"label_agreement":null},{"id":"W4232508436","doi":"10.1200/jco.2014.32.4_suppl.29","title":"Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University Health Network; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Abiraterone acetate; Prostate cancer; Internal medicine; Proportional hazards model; Hazard ratio; Oncology; Cohort; Chemotherapy; Population; Enzalutamide; Cancer; Gastroenterology; Urology; Androgen deprivation therapy; Confidence interval; Androgen receptor","score_opus":0.15423682002521794,"score_gpt":0.4708057749667629,"score_spread":0.31656895494154497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232508436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991437,0.000092187365,0.0059596114,0.0012919332,0.00009391804,0.0009210102,0.0001522882,0.000007514073,0.00004452875],"genre_scores_gemma":[0.9876858,0.00005987579,0.011398603,0.00022112062,0.00007412912,0.00008196196,0.00016032958,0.000024268582,0.00029388643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99677503,0.00020793307,0.0019526106,0.00024543196,0.00053221895,0.00028675955],"domain_scores_gemma":[0.99439913,0.0014934633,0.0019192606,0.00018091478,0.0017090129,0.0002982348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014658027,0.00018347721,0.0018105119,0.0003801804,0.000056341403,0.000012785438,0.00010331173,0.00012565195,0.000030166666],"category_scores_gemma":[0.001180553,0.00010698697,0.00043677413,0.00050695875,0.0001515606,0.00010779062,0.000011793703,0.00028489647,5.671812e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03344255,0.005297645,0.872256,0.0002475226,0.0061266934,0.000026939244,0.00015760124,0.06374257,0.00066285505,0.00004379106,0.00008730404,0.01790854],"study_design_scores_gemma":[0.031879906,0.015211627,0.6201279,0.00017038027,0.008962162,0.0000020613593,0.00002714543,0.32318977,0.00015198195,0.000048868773,0.00011620413,0.00011198945],"about_ca_topic_score_codex":0.00016941671,"about_ca_topic_score_gemma":0.00075952325,"teacher_disagreement_score":0.2594472,"about_ca_system_score_codex":0.00023710138,"about_ca_system_score_gemma":0.0017392307,"threshold_uncertainty_score":0.4362802},"labels":[],"label_agreement":null},{"id":"W4232583537","doi":"10.1158/1538-7445.am2019-1730","title":"Abstract 1730: <i>DACH1</i> gene deletion extends portraits of human prostate cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Prostate cancer; PTEN; Tramp; Cancer; Chromoplexy; Cancer research; Metastasis; Biology; TMPRSS2; Population; Genetics; Prostate; Medicine; Disease; PCA3; Pathology; PI3K/AKT/mTOR pathway","score_opus":0.07678466906530115,"score_gpt":0.43913796638237185,"score_spread":0.36235329731707067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232583537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97755957,0.009542796,8.175319e-7,0.0013458888,0.00018199293,0.0016368666,0.00015910323,0.000048072514,0.00952492],"genre_scores_gemma":[0.9709756,0.0053768936,0.00003595492,0.00008453658,0.0003158342,0.00062051794,0.00013759009,0.00006669044,0.022386432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964302,0.00008844789,0.00042401103,0.00059916737,0.0014989374,0.0009592043],"domain_scores_gemma":[0.9978422,0.000076060154,0.0001114297,0.00056622626,0.0010609162,0.0003431792],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010126211,0.00021851572,0.00046673982,0.00041051782,0.0001793376,0.000039846123,0.000252977,0.0001518695,0.0047804727],"category_scores_gemma":[0.000033837827,0.00017226554,0.0001420069,0.0008024724,0.00035376707,0.00017010554,0.0001259741,0.00077218754,0.00014991335],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011011987,0.00027868044,0.08955181,0.00091511547,0.00019005145,0.00008974928,0.00048793497,0.00002401079,0.88153416,0.00011688221,0.006965993,0.018744446],"study_design_scores_gemma":[0.0054081683,0.0011359104,0.2878323,0.0009502565,0.00005561489,0.0000144627,0.00029624967,0.000024382183,0.69251335,0.00025605073,0.011224658,0.0002886023],"about_ca_topic_score_codex":0.0025310046,"about_ca_topic_score_gemma":0.00015697851,"teacher_disagreement_score":0.19828047,"about_ca_system_score_codex":0.00064651103,"about_ca_system_score_gemma":0.001140352,"threshold_uncertainty_score":0.9961293},"labels":[],"label_agreement":null},{"id":"W4232630202","doi":"10.1097/00005392-200204000-00021","title":"A Phase 3, Multicenter, Open Label, Randomized Study Of Abarelix Versus Leuprolide Plus Daily Antiandrogen In Men With Prostate Cancer","year":2002,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Testosterone (patch); Leuprorelin; Antiandrogen; Adverse effect; Prostate cancer; Internal medicine; Hormone antagonist; Bicalutamide; Luteinizing hormone; Urology; Endocrinology; Castration; Cyproterone acetate; Hormone; Endocrine system; Androgen; Cancer; Gonadotropin-releasing hormone; Androgen receptor","score_opus":0.07015272571455938,"score_gpt":0.3909757910611483,"score_spread":0.32082306534658894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232630202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871969,0.0063597187,0.000004238853,0.003496085,0.00007987205,0.0022003904,0.000006944847,0.000003338179,0.00065250136],"genre_scores_gemma":[0.9947656,0.00449346,0.000042281117,0.00011837487,0.000045534605,0.000054105778,0.0000014156356,0.00001704316,0.00046220777],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982596,0.0005371497,0.0005114045,0.00011817162,0.00030446603,0.0002692182],"domain_scores_gemma":[0.99880135,0.0003108908,0.00037696026,0.00019990742,0.00021419021,0.000096713215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011332716,0.00013352525,0.00082837825,0.00017088828,0.000048883914,0.000011918839,0.0003039841,0.00004127001,0.00014324591],"category_scores_gemma":[0.00008324863,0.00006376982,0.000042297015,0.0002112169,0.00020643565,0.000109514396,0.00009372454,0.00034634492,0.0000032601772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9720141,0.0043526976,0.003832857,0.000027663335,0.0013941404,0.00072098133,0.012969775,0.00018591837,0.001527712,0.0000016966344,0.00067729846,0.002295105],"study_design_scores_gemma":[0.97396845,0.0189743,0.0004855197,0.00006912938,0.0009375664,0.00015304846,0.0018049225,0.0025195207,0.00072057365,0.000010189512,0.00028673958,0.00007006404],"about_ca_topic_score_codex":0.0008539684,"about_ca_topic_score_gemma":0.00028943495,"teacher_disagreement_score":0.014621602,"about_ca_system_score_codex":0.00009835773,"about_ca_system_score_gemma":0.00017649506,"threshold_uncertainty_score":0.26004577},"labels":[],"label_agreement":null},{"id":"W4232838246","doi":"10.1200/jco.2015.33.15_suppl.tps5077","title":"Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Androgen deprivation therapy; Internal medicine; Oncology; Hazard ratio; Docetaxel; Hormone therapy; Adverse effect; Cancer; Androgen receptor; Breast cancer; Confidence interval","score_opus":0.32340789363280126,"score_gpt":0.5553874240841372,"score_spread":0.23197953045133596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232838246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742108,0.0032408554,0.00021564354,0.015427107,0.0014954477,0.0052780206,0.0000342622,0.0000053349895,0.00009255429],"genre_scores_gemma":[0.9821378,0.012900833,0.001159321,0.00075074297,0.0022981174,0.000422909,0.000023556033,0.000028226394,0.00027848137],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949731,0.00095022033,0.0030145268,0.00020562919,0.0005572985,0.00029918095],"domain_scores_gemma":[0.99059725,0.0059649134,0.0020764226,0.00022488287,0.000824581,0.0003119255],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011973934,0.00016842886,0.0019177013,0.00019281643,0.00004716668,0.000013228641,0.00021655679,0.000201813,0.000048168375],"category_scores_gemma":[0.009152535,0.00008652613,0.00061500823,0.00027002138,0.00027904942,0.00012836362,0.000029919294,0.00061776297,0.0000014194987],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.841588,0.004972188,0.0013551791,0.000032620686,0.0006710665,0.000082208484,0.00044572845,0.00006149245,0.00012094706,0.000011780761,0.001757844,0.14890091],"study_design_scores_gemma":[0.87689644,0.075767964,0.0003339621,0.00008236999,0.0004236056,0.000020881924,0.00013879081,0.0003370887,0.0013821935,0.001056354,0.043487556,0.00007280259],"about_ca_topic_score_codex":0.00007370813,"about_ca_topic_score_gemma":0.00012433212,"teacher_disagreement_score":0.1488281,"about_ca_system_score_codex":0.00026152073,"about_ca_system_score_gemma":0.0047049425,"threshold_uncertainty_score":0.9991938},"labels":[],"label_agreement":null},{"id":"W4232929949","doi":"10.1200/jco.2017.35.6_suppl.133","title":"Individual patient level meta-analysis of the performance of the Decipher genomic classifier in high-risk men post-prostatectomy to predict development of metastatic disease.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"DECIPHER; Medicine; Prostatectomy; Hazard ratio; Prostate cancer; Meta-analysis; Confidence interval; Oncology; Disease; Internal medicine; Metastasis; Bioinformatics; Cancer; Biology","score_opus":0.2852279736251007,"score_gpt":0.46173713160756474,"score_spread":0.17650915798246403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232929949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99524355,0.00043911225,0.000012514986,0.0031995957,0.00022003945,0.00059636094,0.00017941241,9.0215565e-7,0.000108529064],"genre_scores_gemma":[0.99724954,0.00019117992,0.0020618865,0.00020739884,0.000032980657,0.000021734437,0.0000041800095,0.000010547885,0.00022054632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99538016,0.0006557972,0.0026424539,0.00018343073,0.0009097877,0.00022837942],"domain_scores_gemma":[0.99398243,0.0009063455,0.003598242,0.0005998075,0.0006774414,0.00023572959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037016913,0.00014739743,0.0021138273,0.00023448121,0.0001104687,0.000007655645,0.0006631869,0.00009084815,0.00013658011],"category_scores_gemma":[0.0022482472,0.000062725354,0.0011997259,0.00029413158,0.00045275738,0.00008174661,0.00037783483,0.0005721811,0.0000014737207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050148084,0.0013257436,0.9127165,0.00006351044,0.056517337,0.000024190997,0.0010533049,0.00054109923,0.0002840107,0.0000079070605,0.00016922494,0.02228238],"study_design_scores_gemma":[0.003707628,0.002438512,0.94426495,0.00004850744,0.04702375,0.0000021180203,0.00017971448,0.00014899511,0.0015533245,0.000033223147,0.00054530695,0.000053950538],"about_ca_topic_score_codex":0.00010029815,"about_ca_topic_score_gemma":0.00028773316,"teacher_disagreement_score":0.03154849,"about_ca_system_score_codex":0.00017701322,"about_ca_system_score_gemma":0.003301275,"threshold_uncertainty_score":0.585632},"labels":[],"label_agreement":null},{"id":"W4232987374","doi":"10.1200/jco.2013.31.18_suppl.lba4510","title":"Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Jewish General Hospital; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; McGill University; Centre Hospitalier de l’Université de Montréal; Centre Hospitalier Universitaire de Sherbrooke; McGill University Health Centre; Centre de Santé et de Services Sociaux de Chicoutimi; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Randomized controlled trial; Goserelin; Hazard ratio; Urology; Randomization; Clinical endpoint; Proportional hazards model; Radiation therapy; Internal medicine; Cancer; Surgery; Confidence interval","score_opus":0.09654002515118829,"score_gpt":0.4726979184230209,"score_spread":0.3761578932718326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232987374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98727816,0.0017991879,0.000032017342,0.008372516,0.0004933221,0.0018244642,0.0000024254123,0.0000034853288,0.00019442113],"genre_scores_gemma":[0.9518407,0.046308674,0.00082219025,0.00024512922,0.00043182497,0.000105172134,0.000004609582,0.000008653508,0.00023301953],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995767,0.0010175736,0.0026594838,0.00011311242,0.0002945098,0.00014833345],"domain_scores_gemma":[0.9943393,0.0025492967,0.0022474884,0.00010601373,0.0006198347,0.00013806684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005327292,0.00008466813,0.0015953392,0.0001681845,0.000017965669,0.0000066236507,0.00007476556,0.00020688606,0.00019558845],"category_scores_gemma":[0.0042950986,0.00004702208,0.0003237522,0.0001715695,0.00018846556,0.00014463,0.0000145443255,0.00050307147,0.0000055383443],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66689736,0.0009833762,0.07490205,0.000012021188,0.00033487173,0.00002827133,0.00016116054,0.000010686,0.00024484977,0.000020705273,0.00048204508,0.25592262],"study_design_scores_gemma":[0.9113613,0.011507853,0.07173991,0.00007710363,0.00013654017,0.000010058809,0.000045319684,0.00017984545,0.0011305242,0.0023650203,0.0014026756,0.000043859567],"about_ca_topic_score_codex":0.0006907461,"about_ca_topic_score_gemma":0.00004796891,"teacher_disagreement_score":0.25587875,"about_ca_system_score_codex":0.00013628785,"about_ca_system_score_gemma":0.0016989468,"threshold_uncertainty_score":0.5141944},"labels":[],"label_agreement":null},{"id":"W4233221569","doi":"10.1200/jco.2015.33.15_suppl.lba5002","title":"A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McGill University Health Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Oncology; Clinical Oncology; Chemotherapy; Internal medicine; Prednisone; Gynecology; Cancer","score_opus":0.08920992381682366,"score_gpt":0.5058327657049976,"score_spread":0.4166228418881739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233221569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710548,0.0027451168,0.00007570154,0.0045967754,0.00022022185,0.02101848,0.00007589716,0.00001134768,0.00020164094],"genre_scores_gemma":[0.9703576,0.012015693,0.0046308334,0.0007226423,0.0007030254,0.008755605,0.00003167586,0.00009755234,0.0026853879],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969944,0.00027860122,0.0014332185,0.00039277272,0.00051669695,0.00038435264],"domain_scores_gemma":[0.99585444,0.0010226187,0.0014175926,0.00019452094,0.0006386836,0.0008721753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020335023,0.00026906905,0.0016758803,0.00011424295,0.000086790475,0.000024930518,0.0001138304,0.00026544536,0.000059646798],"category_scores_gemma":[0.00087853696,0.00015745482,0.00014738431,0.00013265149,0.00069174723,0.00019818089,0.00007337298,0.00057403604,8.1988844e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.700618,0.0044689607,0.040912498,0.00042536305,0.0020365762,0.00049950636,0.0008124583,0.0000045856127,0.0024053429,0.000024830226,0.027544878,0.22024696],"study_design_scores_gemma":[0.6227087,0.16485152,0.0011865462,0.0005582624,0.0012087441,0.00048604544,0.00049162534,0.00029829695,0.013473718,0.00079699495,0.19365528,0.00028428735],"about_ca_topic_score_codex":0.00031006965,"about_ca_topic_score_gemma":0.000054294047,"teacher_disagreement_score":0.21996267,"about_ca_system_score_codex":0.00014826252,"about_ca_system_score_gemma":0.0024224578,"threshold_uncertainty_score":0.6420821},"labels":[],"label_agreement":null},{"id":"W4233764701","doi":"10.3410/f.717950568.793455824","title":"Faculty Opinions recommendation of Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer.","year":2012,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"","keywords":"Prostate cancer; Cancer; Prostate; Medicine; Volume (thermodynamics); Oncology; Clinical significance; Internal medicine","score_opus":0.10188675452185392,"score_gpt":0.4573336569349002,"score_spread":0.3554469024130463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233764701","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037415808,0.006804781,0.000020363199,0.13756102,0.00081952114,0.0079203155,0.8468022,0.000022366221,0.00001204262],"genre_scores_gemma":[0.00016092912,0.0042016176,0.0011976638,0.00083696976,0.00041086072,0.0037584698,0.9854166,0.00004958901,0.003967325],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936917,0.00052786025,0.0029984522,0.00079390954,0.0014231225,0.000564978],"domain_scores_gemma":[0.98596394,0.00042489884,0.0027202745,0.001383535,0.008912871,0.00059447123],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001717678,0.0006081301,0.0021659012,0.00044773458,0.00017404748,0.000034478227,0.00073508197,0.00052839704,0.0003853787],"category_scores_gemma":[0.0045606457,0.0003696566,0.001021991,0.0021774769,0.0006810901,0.00021751359,0.00020117179,0.0005222324,0.000013622014],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080336584,0.0018019226,0.003423087,0.019595418,0.00059714075,3.574998e-7,0.00039008842,8.3925596e-7,0.000007976845,0.000047041405,0.96291053,0.010422236],"study_design_scores_gemma":[0.004139844,0.0016797466,0.013926562,0.01601013,0.0009299318,0.000007839907,0.00005476143,0.000015155542,0.00024569902,0.000014105886,0.9626831,0.00029316355],"about_ca_topic_score_codex":0.00050068187,"about_ca_topic_score_gemma":0.00003298775,"teacher_disagreement_score":0.1386144,"about_ca_system_score_codex":0.0004956539,"about_ca_system_score_gemma":0.0026580377,"threshold_uncertainty_score":0.99987555},"labels":[],"label_agreement":null},{"id":"W4233779081","doi":"10.1158/1078-0432.ccr-15-2119","title":"Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; U.S. Department of Defense","keywords":"Enzalutamide; PI3K/AKT/mTOR pathway; Prostate cancer; Androgen receptor; Protein kinase B; Cancer research; Everolimus; Cancer; Biology; Medicine; Pharmacology; Signal transduction; Internal medicine; Cell biology","score_opus":0.3324940879289064,"score_gpt":0.5156486817377322,"score_spread":0.18315459380882576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233779081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9484509,0.040080767,0.000016740498,0.0072693317,0.00032353125,0.0032417492,0.00044056616,0.0000216425,0.00015475886],"genre_scores_gemma":[0.96278393,0.029063998,0.00069191394,0.00008485956,0.0012061236,0.0023893823,0.000058910417,0.000055828074,0.0036650777],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971961,0.00029685925,0.00061179587,0.0005180396,0.00076240813,0.0006147994],"domain_scores_gemma":[0.9958458,0.0018745719,0.00013437425,0.00039599626,0.00126958,0.00047965802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029264393,0.00017969085,0.00048867066,0.000093895695,0.00029396894,0.000045136272,0.000174694,0.00012867474,0.00013731781],"category_scores_gemma":[0.0007658349,0.00010304183,0.00014188868,0.00036322186,0.0005827678,0.00009200835,0.00007928006,0.0003004283,0.0000071272316],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0737349,0.004023396,0.31777042,0.0015493828,0.0032163435,0.00015124422,0.011355362,0.00013695104,0.13297024,0.000341909,0.022464942,0.43228492],"study_design_scores_gemma":[0.075131826,0.044321068,0.04186906,0.0022034263,0.0010766743,0.000022383752,0.012693512,0.0048447866,0.28174898,0.0015757994,0.53340364,0.0011088545],"about_ca_topic_score_codex":0.0019723864,"about_ca_topic_score_gemma":0.00034591122,"teacher_disagreement_score":0.5109387,"about_ca_system_score_codex":0.0004638279,"about_ca_system_score_gemma":0.0023047347,"threshold_uncertainty_score":0.4201924},"labels":[],"label_agreement":null},{"id":"W4233800443","doi":"10.1200/jco.2021.39.6_suppl.33","title":"PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Progenics Pharmaceuticals","keywords":"Medicine; Nuclear medicine; Histopathology; Confidence interval; Prostate cancer; Clinical endpoint; Population; PET-CT; Radiation therapy; Radiology; Cancer; Clinical trial; Positron emission tomography; Pathology; Internal medicine","score_opus":0.02631628057664302,"score_gpt":0.41594388490857565,"score_spread":0.3896276043319326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233800443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99599516,0.0017798151,0.00024892436,0.0006348741,0.0001668142,0.0008782307,0.00023452657,0.0000044773774,0.00005715833],"genre_scores_gemma":[0.9978194,0.0016232962,0.0002251994,0.0001033837,0.000048922026,0.000023198012,0.00009356176,0.000022935219,0.00004005966],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99589163,0.0008915192,0.0018948795,0.0003841633,0.00065887446,0.0002789152],"domain_scores_gemma":[0.9943648,0.0009169214,0.0018142334,0.00016644238,0.002460364,0.00027726288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016305816,0.00021831303,0.0019086989,0.00022979049,0.000040687773,0.000010821829,0.00009230452,0.000038908653,0.00003781855],"category_scores_gemma":[0.0009546776,0.00013596113,0.00015538865,0.00063169113,0.00047070294,0.00014741535,0.000054850127,0.00063384575,1.294195e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1573218,0.009730098,0.8029262,0.00009125172,0.0023549842,0.0019762474,0.00082576025,0.00011302307,0.0006814537,0.0000017195741,0.00025889926,0.023718605],"study_design_scores_gemma":[0.35561717,0.22957449,0.34489843,0.0030163291,0.0067738355,0.0003925073,0.006244441,0.0045958613,0.04801309,0.00008814137,0.0002629649,0.00052274927],"about_ca_topic_score_codex":0.00017832949,"about_ca_topic_score_gemma":0.00018948394,"teacher_disagreement_score":0.45802772,"about_ca_system_score_codex":0.00045315738,"about_ca_system_score_gemma":0.0028868536,"threshold_uncertainty_score":0.5544334},"labels":[],"label_agreement":null},{"id":"W4234149459","doi":"10.1158/1538-7445.sabcs18-3482","title":"Abstract 3482: ZBTB7A mediates the transcriptional repression activity of androgen receptor in prostate cancer cells","year":2019,"lang":"en","type":"article","venue":"Molecular and Cellular Biology / Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Androgen receptor; Psychological repression; Prostate cancer; Cancer research; Prostate; Chemistry; Cancer; Internal medicine; Biology; Medicine; Gene; Biochemistry; Gene expression","score_opus":0.013324489466255848,"score_gpt":0.282365769719542,"score_spread":0.26904128025328616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234149459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769319,0.021521797,0.000027353617,0.0005586236,0.00011996938,0.0006036261,0.000057109264,0.0000060979914,0.00017348549],"genre_scores_gemma":[0.9946481,0.004824028,0.000072813375,0.000056056593,0.000024728417,0.000038046317,0.00007344459,0.000013567386,0.00024919317],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991368,0.0000773222,0.00016786686,0.0002676592,0.00012858771,0.00022173722],"domain_scores_gemma":[0.9995778,0.000032604312,0.000058789123,0.00021162948,0.000054097665,0.00006505048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017887709,0.00012301179,0.0002220397,0.000058427933,0.00003083971,0.0000056391123,0.0000727066,0.000116357405,0.00013473611],"category_scores_gemma":[0.000005957059,0.000076513745,0.00006579475,0.00010005844,0.00017515714,0.000014443262,0.000037170463,0.00017653302,0.000006336405],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035410732,0.00009181458,0.07247678,0.00009399149,0.00006610288,0.000014985798,0.00022239466,0.000034280718,0.92059916,0.000014718372,0.000019793271,0.0060118586],"study_design_scores_gemma":[0.0014482278,0.00024499054,0.024036169,0.00005627792,0.000035176672,0.0000027180654,0.000048852133,0.00012288586,0.97219855,0.00011449361,0.0016089014,0.0000827708],"about_ca_topic_score_codex":0.00006476721,"about_ca_topic_score_gemma":0.000007206134,"teacher_disagreement_score":0.05159937,"about_ca_system_score_codex":0.000025515308,"about_ca_system_score_gemma":0.00011931943,"threshold_uncertainty_score":0.31201398},"labels":[],"label_agreement":null},{"id":"W4234352890","doi":"10.5489/cuaj.729","title":"The pursuit of the “perfect” biomarker in prostate cancer","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Biomarker; Cancer; Prostate; Medicine; Oncology; Internal medicine; Biology; Genetics","score_opus":0.01810305119308822,"score_gpt":0.2743984691758564,"score_spread":0.2562954179827682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234352890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82841754,0.0013569366,2.08099e-7,0.16807467,0.00021783296,0.0004002523,0.000011303569,0.0000033012727,0.0015179878],"genre_scores_gemma":[0.99351317,0.00069751724,0.0000045180223,0.0014762975,0.000066639914,0.000056587025,0.0000017403418,0.0000055989053,0.004177963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987125,0.00016586256,0.00022235431,0.00008670504,0.00039710724,0.0004155118],"domain_scores_gemma":[0.9991166,0.00014594822,0.0001384965,0.00009403647,0.00025338374,0.0002515235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007355026,0.000070302965,0.00013026215,0.000069925765,0.0002543931,0.0000867468,0.00018718308,0.00008283459,0.00056443474],"category_scores_gemma":[0.00043094193,0.000030519703,0.00008575493,0.00029572917,0.00007944164,0.000055781697,0.000022204275,0.0004278107,0.000021406295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038135702,0.000018195531,0.9667722,0.000002642494,0.00006207186,0.000010764796,0.00009865791,0.0000057549432,0.00054800644,0.00003387286,0.020459611,0.011950111],"study_design_scores_gemma":[0.00075927353,0.00007312274,0.9615725,0.000016894057,0.000015373136,0.000018267885,0.00007219424,0.00008236178,0.000085229214,0.0006312287,0.036637947,0.00003559353],"about_ca_topic_score_codex":0.007424739,"about_ca_topic_score_gemma":0.0055505005,"teacher_disagreement_score":0.16659836,"about_ca_system_score_codex":0.0010964713,"about_ca_system_score_gemma":0.0008060835,"threshold_uncertainty_score":0.9991849},"labels":[],"label_agreement":null},{"id":"W4234420388","doi":"10.3410/f.1119178.575341","title":"Faculty Opinions recommendation of Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.","year":2008,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Terry Fox Foundation; Lucas Foundation; National Cancer Institute; Prostate Cancer Foundation","keywords":"Androgen receptor; Prostate cancer; Exon; Cancer research; Androgen; RNA splicing; Alternative splicing; Receptor; Prostate; Medicine; Internal medicine; Endocrinology; Oncology; Cancer; Biology; Genetics; Gene; Hormone","score_opus":0.0701607183011582,"score_gpt":0.3808318042698311,"score_spread":0.3106710859686729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234420388","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007606538,0.013015644,0.0000057225375,0.09815003,0.00058420945,0.0036951615,0.88438743,0.000033838292,0.000051873463],"genre_scores_gemma":[0.000030232966,0.044449616,0.00092512794,0.001138553,0.0002985306,0.0009215703,0.9505207,0.00004546434,0.0016701934],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99478936,0.00036621338,0.0015770829,0.00088893826,0.0018483205,0.0005300992],"domain_scores_gemma":[0.9889628,0.00021640789,0.002068589,0.0010803002,0.0072642826,0.0004075954],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00091096724,0.00070624927,0.0016789238,0.00051767245,0.00030458608,0.000059185048,0.0008492723,0.00069615507,0.0005386329],"category_scores_gemma":[0.0018728566,0.0004251752,0.0006767179,0.0021681946,0.0010962063,0.00037102055,0.00028204388,0.0009941978,0.0000120181185],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006154173,0.0009848637,0.00011589515,0.007224446,0.0009433099,8.638614e-7,0.00074080186,1.5917145e-7,0.00032799903,0.000031074935,0.9863245,0.0026906703],"study_design_scores_gemma":[0.0039291643,0.00034002142,0.0006048721,0.019980287,0.0002645971,0.00002746885,0.00012361984,0.0000034361278,0.0070618587,0.0000042259676,0.9672983,0.0003621014],"about_ca_topic_score_codex":0.00021352706,"about_ca_topic_score_gemma":0.000023108809,"teacher_disagreement_score":0.09701148,"about_ca_system_score_codex":0.00038363674,"about_ca_system_score_gemma":0.0023662755,"threshold_uncertainty_score":0.99982},"labels":[],"label_agreement":null},{"id":"W4234782197","doi":"10.21236/ada416805","title":"Signal Transduction in Prostate Cancer","year":2003,"lang":"en","type":"report","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; Novartis Pharma; U.S. Department of Defense","keywords":"Prostate cancer; Signal transduction; Transduction (biophysics); Prostate; Cancer; Cancer research; Medicine; Biology; Internal medicine; Cell biology; Biochemistry","score_opus":0.06653696141706823,"score_gpt":0.3919202604547316,"score_spread":0.3253832990376634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234782197","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.051636923,0.050153125,0.000023125462,0.0048573604,0.001959128,0.004374175,0.00015898127,0.00015145956,0.8866857],"genre_scores_gemma":[0.06686965,0.11011717,0.00014277622,0.00013790884,0.0005707226,0.0007325822,0.0004593496,0.000088895154,0.82088095],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981047,0.000034001463,0.0003091651,0.00038685004,0.00079187885,0.00037343535],"domain_scores_gemma":[0.99932575,0.000012517916,0.000060168306,0.00017775448,0.00029736143,0.00012645268],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032960196,0.00022347235,0.00046511428,0.00030215923,0.00002871665,0.000014187121,0.000038542188,0.00020097652,0.009515943],"category_scores_gemma":[0.000014219399,0.00015469796,0.00012263135,0.00030313781,0.00006106116,0.00004592465,0.000007763949,0.0005346709,0.00003215452],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002926932,0.0016499425,0.215273,0.0072943238,0.0015024206,0.0048141954,0.0012128043,0.000041430027,0.0060430695,0.000032767017,0.44859904,0.3106101],"study_design_scores_gemma":[0.0048392816,0.0005190035,0.011023051,0.0014618073,0.00030056937,0.00036552263,0.0001546913,0.000016535905,0.019528592,0.00007850825,0.9612751,0.00043730836],"about_ca_topic_score_codex":0.0024587014,"about_ca_topic_score_gemma":0.00050166505,"teacher_disagreement_score":0.51267606,"about_ca_system_score_codex":0.0013166519,"about_ca_system_score_gemma":0.004287519,"threshold_uncertainty_score":0.9913895},"labels":[],"label_agreement":null},{"id":"W4234988212","doi":"10.1200/jco.2017.35.6_suppl.47","title":"Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiotherapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Prostate cancer; Toxicity; Prostate; Acute toxicity; Radiation therapy; Urology; Genitourinary system; Regimen; Surgery; Internal medicine; Cancer","score_opus":0.05082966512565027,"score_gpt":0.4448511044698952,"score_spread":0.3940214393442449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234988212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942237,0.0011485463,0.0000012434662,0.003987152,0.00018162053,0.00033940587,0.000024799769,0.0000044905996,0.000089008514],"genre_scores_gemma":[0.96445733,0.034477387,0.00029505583,0.0001980097,0.00013135355,0.000008055801,0.0000059660274,0.000013400257,0.00041342335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984308,0.00021676815,0.0007330314,0.00019266135,0.0002294789,0.00019728376],"domain_scores_gemma":[0.99776644,0.00040249046,0.0011363333,0.00013457963,0.00027972754,0.0002804194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007656441,0.00012091053,0.0008224515,0.00010249996,0.00012791352,0.000026575279,0.00006908424,0.00020764674,0.0000388215],"category_scores_gemma":[0.0004120496,0.00006610892,0.000060454713,0.000052073334,0.00031733926,0.00027987536,0.00004043958,0.00064911187,5.9205377e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019200396,0.00067103136,0.8523006,0.000015259266,0.00048410374,0.00047385282,0.00008657804,0.0000023057955,0.00040458154,8.115637e-7,0.0001755053,0.12618501],"study_design_scores_gemma":[0.033777356,0.010669222,0.9515043,0.00015630144,0.00028148654,0.000062223495,0.000011984437,0.00012797563,0.00083384133,0.00006161319,0.002443323,0.000070379],"about_ca_topic_score_codex":0.00029360777,"about_ca_topic_score_gemma":0.00016031918,"teacher_disagreement_score":0.12611464,"about_ca_system_score_codex":0.00014514798,"about_ca_system_score_gemma":0.00046648877,"threshold_uncertainty_score":0.2820104},"labels":[],"label_agreement":null},{"id":"W4235148313","doi":"10.1016/j.eururo.2017.11.028","title":"Response to Claire Vale, David Fisher, Jayne Tierney, Ian White, Matthew Sydes, and James Carpenter's Letter to the Editor re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.10.002","year":2017,"lang":"en","type":"review","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; White (mutation); Gerontology","score_opus":0.08799935074101853,"score_gpt":0.3583162520787868,"score_spread":0.2703169013377683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235148313","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006510136,0.97108996,0.000007388077,0.013883288,0.000067389185,0.008061686,0.00025196272,0.000025578267,0.00010259946],"genre_scores_gemma":[0.0031702484,0.9870375,0.00016224282,0.0026490898,0.0001709466,0.0012315565,0.00023175034,0.00015174458,0.00519497],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98878694,0.00707116,0.0016167857,0.00131463,0.00052334234,0.00068716315],"domain_scores_gemma":[0.99630165,0.0005389973,0.0014043122,0.0012250138,0.00019768513,0.00033232197],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004984451,0.00092382194,0.006241291,0.000505346,0.00018721698,0.00017017625,0.0004610979,0.00014299605,0.00016051257],"category_scores_gemma":[0.00030963754,0.00051565486,0.0002861421,0.00061244366,0.0003870095,0.00020918716,0.00043983056,0.0010983178,0.000038657017],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018572558,0.000830402,0.0129797775,0.19576488,0.09609174,0.0019992986,0.0077311965,0.00020764495,0.000022792156,0.0000028525574,0.6364215,0.029375365],"study_design_scores_gemma":[0.0036500073,0.0030390325,0.0086722765,0.008924268,0.07536118,0.00008095163,0.00003892115,0.000040544594,0.0000013401681,0.000002185753,0.89958924,0.0006000627],"about_ca_topic_score_codex":0.00039600552,"about_ca_topic_score_gemma":0.00031282194,"teacher_disagreement_score":0.26316774,"about_ca_system_score_codex":0.00009054349,"about_ca_system_score_gemma":0.0001562133,"threshold_uncertainty_score":0.9997295},"labels":[],"label_agreement":null},{"id":"W4235175572","doi":"10.1002/cncr.23423","title":"Duration of testosterone suppression and the risk of death from prostate cancer in men treated with radiation and 6 months of hormone therapy","year":2008,"lang":"en","type":"letter","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Hormone therapy; Tamoxifen; Internal medicine; Oncology; Testosterone (patch); Androgen; Radiation therapy; Hormonal therapy; Cancer; Hormone; Androgen suppression; Breast cancer; Endocrinology","score_opus":0.01655532591462336,"score_gpt":0.28002106144171723,"score_spread":0.26346573552709385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235175572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87524074,0.10293068,0.0000018235143,0.019064838,0.000020482554,0.0019434319,0.00071274466,0.00000572487,0.00007954935],"genre_scores_gemma":[0.6321283,0.36540866,0.00003235467,0.0009474846,0.00016535439,0.0004831394,0.00029594376,0.000033710225,0.0005050512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878097,0.00013243513,0.00034658972,0.00026021636,0.00031847463,0.00016129648],"domain_scores_gemma":[0.99898666,0.00015580122,0.00045035046,0.0002170751,0.00015753215,0.000032554646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010265696,0.00020140166,0.00061909953,0.00013343178,0.00003413337,0.0000053139274,0.00004763993,0.00020027612,0.000023478144],"category_scores_gemma":[0.000014091702,0.000101269776,0.00003676444,0.00015900105,0.00036107533,0.00007148202,0.000019382216,0.00035897188,6.543879e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027119337,0.00013167865,0.86120474,0.0004318361,0.0013462041,0.00006907055,0.00786895,0.0000638465,0.024246363,0.0000010134057,0.03913702,0.03837994],"study_design_scores_gemma":[0.03838885,0.0013753135,0.8765374,0.00137328,0.0005974516,0.0000062239515,0.00012927855,0.00071505713,0.07699217,0.000046109908,0.0036115714,0.00022731558],"about_ca_topic_score_codex":0.016648235,"about_ca_topic_score_gemma":0.00017021694,"teacher_disagreement_score":0.26247796,"about_ca_system_score_codex":0.00011681587,"about_ca_system_score_gemma":0.00022639954,"threshold_uncertainty_score":0.9899},"labels":[],"label_agreement":null},{"id":"W4235183483","doi":"10.1200/jco.2019.37.7_suppl.60","title":"A phase I pilot study of preoperative radiotherapy for prostate cancer: Long-term toxicity and oncologic outcomes.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; University Health Network; Memorial University of Newfoundland; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Common Terminology Criteria for Adverse Events; Prostatectomy; Toxicity; Genitourinary system; Radiation therapy; Prostate; Surgery; Urology; Cancer; Adverse effect; Internal medicine","score_opus":0.21373529248580928,"score_gpt":0.5616994062389005,"score_spread":0.3479641137530912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235183483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913696,0.0017776106,0.000028086803,0.0034027547,0.00059340976,0.0026821785,0.00001763957,0.000005392023,0.00012330397],"genre_scores_gemma":[0.99368805,0.0035185474,0.0005229198,0.0006522467,0.00027311087,0.00006044724,0.0000021882352,0.000015306545,0.001267168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973724,0.0003534232,0.0015187286,0.00022554595,0.00029540807,0.00023451558],"domain_scores_gemma":[0.9961061,0.0018030747,0.0011005363,0.00015541703,0.00056811667,0.0002667672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020509986,0.00014801175,0.0018798837,0.00011243555,0.00003729739,0.000008328535,0.000121012636,0.00012813049,0.000121299774],"category_scores_gemma":[0.00054437143,0.000082566214,0.00020009295,0.000099000295,0.00020054597,0.000101230245,0.000038977363,0.00051631284,0.000001210253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048166562,0.03324936,0.84027433,0.00010344497,0.0013978563,0.00016416698,0.0007364844,0.000004944299,0.0013663343,0.000006354938,0.00030089568,0.07422927],"study_design_scores_gemma":[0.102942504,0.37586692,0.51955235,0.00006741007,0.0002922215,0.00003397506,0.0002371836,0.000048001184,0.00028388633,0.000027759932,0.00058410503,0.000063648156],"about_ca_topic_score_codex":0.000032859163,"about_ca_topic_score_gemma":0.00011263599,"teacher_disagreement_score":0.34261757,"about_ca_system_score_codex":0.00026028857,"about_ca_system_score_gemma":0.0016060139,"threshold_uncertainty_score":0.33669522},"labels":[],"label_agreement":null},{"id":"W4235442504","doi":"10.1158/1538-7445.sabcs18-ct129","title":"Abstract CT129: Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN study","year":2019,"lang":"en","type":"article","venue":"Clinical Trials","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Internal medicine; Oncology; Metastasis; Transcriptome; Cancer; Androgen receptor; Biology; Gene; Gene expression","score_opus":0.21659087596534435,"score_gpt":0.5220882869166081,"score_spread":0.3054974109512638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235442504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924094,0.00012369106,9.70005e-7,0.00038222593,0.00015222319,0.006809733,0.000059840677,0.000006939586,0.000054948105],"genre_scores_gemma":[0.9991948,0.00004864561,0.000090034315,0.00013263212,0.000030815558,0.0003239586,0.000010914344,0.00002496284,0.00014325006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99427485,0.0021376456,0.001917079,0.0004929635,0.0007949891,0.00038246484],"domain_scores_gemma":[0.99585897,0.002863452,0.00044708545,0.00053480815,0.00014637563,0.00014930783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013554171,0.00020357927,0.0011639207,0.00023800838,0.00003241866,0.000042342668,0.00020144867,0.0000762861,0.00006937089],"category_scores_gemma":[0.002837566,0.000114973285,0.00014274553,0.0005378107,0.0000914008,0.00009680049,0.000047541558,0.00033511582,0.00003149756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04473302,0.0020863009,0.93863624,0.00013760506,0.00012237654,0.0003875991,0.0015575613,0.00007268199,0.0051673017,0.0000010792119,0.0000180557,0.0070802015],"study_design_scores_gemma":[0.020835878,0.004826089,0.970128,0.00070991425,0.00012876652,9.112508e-7,0.0013705014,0.000017018354,0.0017986214,0.000023126058,0.000036301764,0.000124858],"about_ca_topic_score_codex":0.00038476143,"about_ca_topic_score_gemma":0.0011556221,"teacher_disagreement_score":0.0314918,"about_ca_system_score_codex":0.00012752734,"about_ca_system_score_gemma":0.00048471388,"threshold_uncertainty_score":0.46976322},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W4235536314","doi":"10.1016/j.urology.2007.06.045","title":"POD-04.08: Treatment outcome of immediate versus delayed hormone therapy in patients with lymph node metastases following radical prostatectomy","year":2007,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Prostatectomy; Lymph node; Androgen deprivation therapy; Urology; Adjuvant therapy; Hormone therapy; Adjuvant; Oncology; Internal medicine; Prostate cancer; Surgery; Cancer","score_opus":0.026426406918367007,"score_gpt":0.3204621121005079,"score_spread":0.2940357051821409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235536314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962445,0.0018185754,0.000055583787,0.0004151059,0.00014011082,0.0009208784,0.00003797414,0.000030464516,0.00033681522],"genre_scores_gemma":[0.99888444,0.00026054235,0.00028751788,0.00013965709,0.000034504123,0.000061162704,0.00022675529,0.00003107098,0.00007435148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832016,0.000074741874,0.00038169455,0.0003148635,0.00033636464,0.0005721503],"domain_scores_gemma":[0.9992132,0.00020886309,0.00009094116,0.00025374835,0.00006551185,0.0001676952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025771157,0.00022251261,0.0005358743,0.00028846733,0.000040630035,0.0000045810875,0.00007787467,0.00011366117,0.00003720424],"category_scores_gemma":[0.000037655107,0.00013618992,0.00011836026,0.00029015486,0.00016792004,0.00005443181,0.000025422647,0.00013266853,0.000012045912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09266563,0.0017291772,0.88489914,0.000012326617,0.0011171226,0.0006871106,0.00037823516,0.000012981991,0.00090603967,0.000022313563,0.000016970838,0.017552959],"study_design_scores_gemma":[0.12268386,0.022052035,0.8498477,0.000010182309,0.00028147205,0.000007761499,0.00008359614,0.000027443264,0.0038626017,0.000020594107,0.0009370645,0.00018573557],"about_ca_topic_score_codex":0.0002708874,"about_ca_topic_score_gemma":0.00004217547,"teacher_disagreement_score":0.03505148,"about_ca_system_score_codex":0.0002749611,"about_ca_system_score_gemma":0.00014608604,"threshold_uncertainty_score":0.5553664},"labels":[],"label_agreement":null},{"id":"W4235605782","doi":"10.5489/cuaj.445","title":"Stimulation of a non-functioning pituitary macroadenoma after administration of goserelin acetate for locally advanced prostate cancer causing a sustained elevation in PSA and testosterone","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Internal medicine; Endocrinology; Testosterone (patch); Luteinizing hormone; Goserelin; Context (archaeology); Androgen deprivation therapy; Androgen; Stimulation; Hormone; Cancer; Biology","score_opus":0.011582657394266156,"score_gpt":0.2750105394819506,"score_spread":0.2634278820876844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235605782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914407,0.00046080703,0.00046016992,0.006492727,0.00005835485,0.0010230405,0.000033055436,0.000004837145,0.000026277932],"genre_scores_gemma":[0.99824834,0.00013882435,0.00088213955,0.00021224451,0.00006378447,0.00014831548,0.000049672486,0.000010408882,0.00024625706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988177,0.000058107613,0.00044607103,0.00015502948,0.00021198449,0.0003111206],"domain_scores_gemma":[0.9986021,0.000112185386,0.0003135484,0.00005289155,0.0007110112,0.00020827708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003862729,0.000105024366,0.00024961558,0.00024611366,0.000083265906,0.000032621163,0.000025776402,0.00013134396,0.00009075837],"category_scores_gemma":[0.00029853985,0.00008750632,0.000045350323,0.00021578268,0.00003823741,0.0002434109,0.0000080979835,0.00020778194,8.679255e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018977124,0.0000703021,0.96486074,0.00010363785,0.00008492851,0.00002626838,0.00061464286,0.0008771775,0.010806393,0.0000074233853,0.00011541325,0.020535367],"study_design_scores_gemma":[0.0041421168,0.0011925151,0.9859495,0.00012713883,0.000056485875,0.000020434787,0.00028569656,0.0069318693,0.00072254817,0.0003995224,0.00008584337,0.00008634021],"about_ca_topic_score_codex":0.0011743108,"about_ca_topic_score_gemma":0.0016170398,"teacher_disagreement_score":0.021088755,"about_ca_system_score_codex":0.00082959625,"about_ca_system_score_gemma":0.00078302744,"threshold_uncertainty_score":0.3568404},"labels":[],"label_agreement":null},{"id":"W4236420572","doi":"10.1016/j.juro.2017.08.122","title":"Editorial Comment","year":2017,"lang":"es","type":"editorial","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Chin; Prostate cancer; Library science; Internal medicine; Cancer; Anatomy","score_opus":0.02375081332596278,"score_gpt":0.3571719090538609,"score_spread":0.33342109572789813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236420572","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043169488,0.0107795345,0.0000108516115,0.035138,0.9517988,0.00033260352,0.00005904438,0.0000053427334,0.0014441295],"genre_scores_gemma":[0.0054201507,0.03776445,0.0000071961076,0.0002682726,0.9542188,0.0000043640366,0.00003117646,0.000045837594,0.0022397486],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99589497,0.0007955769,0.0008161209,0.0001769158,0.0016821639,0.00063423923],"domain_scores_gemma":[0.9934327,0.0024098766,0.0017917386,0.00079138315,0.0012853524,0.00028895232],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0036583433,0.00037200682,0.001143209,0.00022438711,0.00047767567,0.000077043725,0.0013952246,0.00103754,0.00027816286],"category_scores_gemma":[0.0018671532,0.00019036401,0.00036589857,0.000056267483,0.00083046325,0.00010031275,0.00029212158,0.0039114854,0.00015506508],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014747421,0.00024901552,0.0001397523,0.00008589098,0.0014234427,0.0002589561,0.00040332667,0.0000044852127,0.00022151468,0.000014663399,0.9805056,0.0019459501],"study_design_scores_gemma":[0.007872763,0.007791606,0.00012205324,0.00017954834,0.0021331706,0.00017216263,0.00006755162,0.0000038905027,0.000077383556,0.00031663704,0.981125,0.00013821154],"about_ca_topic_score_codex":0.00009891878,"about_ca_topic_score_gemma":0.000007570563,"teacher_disagreement_score":0.034869727,"about_ca_system_score_codex":0.00033615233,"about_ca_system_score_gemma":0.0024986889,"threshold_uncertainty_score":0.9983865},"labels":[],"label_agreement":null},{"id":"W4236749136","doi":"10.21203/rs.3.rs-237354/v1","title":"Gastrointestinal and Genitourinary Toxicity Profiles of Metformin Versus Placebo in Men With Prostate Cancer Receiving Pelvic Radiotherapy: Interim Toxicity Results of a Double-blinded, Multicenter, Phase II Randomized Controlled Trial","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba; University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Genitourinary system; Interim analysis; Toxicity; Prostate cancer; Radiation therapy; Double blinded; Urology; Prostate; Placebo; Interim; Internal medicine; Oncology; Multicenter study; Randomized controlled trial; Cancer; Pathology","score_opus":0.08111941724918288,"score_gpt":0.4298948189562416,"score_spread":0.34877540170705873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236749136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95812374,0.0080954535,0.00003076513,0.00087692554,0.00013550952,0.03184108,0.00031844244,0.00003324489,0.00054481445],"genre_scores_gemma":[0.98137236,0.008348671,0.002142833,0.0000036911622,0.00022447034,0.0065684807,0.00026840047,0.000074641765,0.0009964813],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9921724,0.002138064,0.0016976317,0.001095671,0.0019021136,0.0009941104],"domain_scores_gemma":[0.99366325,0.002527199,0.00080116064,0.00075523846,0.0018671856,0.00038598536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0070241354,0.00059444294,0.0037579655,0.0011750051,0.00016298068,0.00009443521,0.0003358659,0.00023846044,0.00012843093],"category_scores_gemma":[0.0022205203,0.0003950411,0.00050052215,0.00067316816,0.001074446,0.00017242531,0.000875376,0.0019946066,3.001014e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9678434,0.004844834,0.00070339383,0.003944535,0.0016955157,0.00072306837,0.003907537,0.0000681584,0.013592016,0.0000044468693,0.00006390555,0.002609192],"study_design_scores_gemma":[0.9313913,0.01945436,0.00014736781,0.011014744,0.00029947172,0.00004156036,0.0027403592,0.004251758,0.0303708,0.00000901799,0.000009668184,0.0002695899],"about_ca_topic_score_codex":0.0027338231,"about_ca_topic_score_gemma":0.0006209298,"teacher_disagreement_score":0.036452096,"about_ca_system_score_codex":0.0009797307,"about_ca_system_score_gemma":0.003378329,"threshold_uncertainty_score":0.99985015},"labels":[],"label_agreement":null},{"id":"W4236803962","doi":"10.1200/jco.2016.34.2_suppl.110","title":"Risk factors for disease progression after post-prostatectomy salvage radiation: Long-term results of a large institutional experience.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Prostate-specific antigen; Proportional hazards model; Biochemical recurrence; Urology; Nomogram; Radiation therapy; Stage (stratigraphy); Surgery; Tumor progression; Pathological; Cancer; Internal medicine; Oncology","score_opus":0.08278965795689873,"score_gpt":0.49772983248354424,"score_spread":0.4149401745266455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236803962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99227166,0.0010638777,0.0004105874,0.004462644,0.0007342248,0.00058682763,0.00038974558,0.000007429725,0.00007298851],"genre_scores_gemma":[0.9968035,0.0014448578,0.00049382966,0.00018784171,0.0006735134,0.00004406468,0.000033526976,0.000010963306,0.00030787278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731034,0.00022563296,0.0015411216,0.00020559368,0.000448762,0.00026853548],"domain_scores_gemma":[0.99554694,0.0017509701,0.0012268502,0.0001716152,0.0007658711,0.00053773366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014694431,0.00012303228,0.0007050254,0.00013622503,0.00006689111,0.000006240833,0.00011568572,0.00019479431,0.0001326288],"category_scores_gemma":[0.005844287,0.000057714202,0.00046210087,0.000095089155,0.0003980277,0.00021275495,0.000048845366,0.00029537344,0.000005068697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07119689,0.0017081965,0.8261165,0.000054794386,0.00019387892,0.00046154606,0.00030024175,4.154866e-7,0.00022180208,0.000016598151,0.00037558304,0.09935353],"study_design_scores_gemma":[0.028702347,0.0094338795,0.9487378,0.00035390802,0.0001904491,0.000013894937,0.000050081402,0.000009307909,0.0010049177,0.000086826614,0.0113452235,0.0000713538],"about_ca_topic_score_codex":0.0000032396508,"about_ca_topic_score_gemma":0.0000064916644,"teacher_disagreement_score":0.12262129,"about_ca_system_score_codex":0.00019569392,"about_ca_system_score_gemma":0.0022409323,"threshold_uncertainty_score":0.699658},"labels":[],"label_agreement":null},{"id":"W4236901391","doi":"10.5489/cuaj.1306","title":"Podium Session 2: Oncology","year":2012,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Session (web analytics); Medicine; Oncology; Medical physics; Internal medicine; Computer science; World Wide Web","score_opus":0.03207778481454366,"score_gpt":0.3228794409862147,"score_spread":0.29080165617167103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236901391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8541455,0.001591386,0.000024768719,0.10457181,0.0010115445,0.00020348976,0.000015637457,0.000030349984,0.038405485],"genre_scores_gemma":[0.9897441,0.00019665425,0.00015498837,0.004588577,0.0011804671,0.0000061303017,0.000019575971,0.0000071149366,0.004102358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998692,0.00014365191,0.00016601759,0.00008161248,0.00026445635,0.0006523034],"domain_scores_gemma":[0.9982451,0.00009208287,0.00009768319,0.000056753124,0.00016843213,0.0013399234],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00073628285,0.00007657953,0.00017223874,0.00013702037,0.00023572489,0.00002804961,0.00005478127,0.00024211332,0.0018232594],"category_scores_gemma":[0.00038514737,0.000051160598,0.00008330981,0.00013982195,0.000023536091,0.00010826241,0.0000110175115,0.0005676505,0.00027254678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006949241,0.00008605927,0.9416586,0.000001971562,0.000063084335,0.00008908546,0.00013154602,7.276337e-7,0.00026195392,0.00011095448,0.04492654,0.012599972],"study_design_scores_gemma":[0.0008141003,0.00026324423,0.54797304,0.0000043982996,0.00003146349,0.00027121708,0.000058879767,0.000008147074,0.000067951885,0.00013093265,0.45033,0.000046646623],"about_ca_topic_score_codex":0.00028741828,"about_ca_topic_score_gemma":0.00008828937,"teacher_disagreement_score":0.40540347,"about_ca_system_score_codex":0.0028829991,"about_ca_system_score_gemma":0.0008309907,"threshold_uncertainty_score":0.9990892},"labels":[],"label_agreement":null},{"id":"W4237011245","doi":"10.1200/jco.2016.34.15_suppl.5079","title":"Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Internal medicine; Clinical endpoint; Oncology; Response Evaluation Criteria in Solid Tumors; Proportional hazards model; Prostate-specific antigen; Placebo; Progressive disease; Hazard ratio; Surrogate endpoint; Clinical trial; Cancer; Urology; Confidence interval; Disease; Pathology","score_opus":0.14938310484820938,"score_gpt":0.473387407952784,"score_spread":0.3240043031045746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237011245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882339,0.000062831146,0.0000029261753,0.010043946,0.00011957339,0.0007707877,0.000022126458,0.0000022573702,0.00074163266],"genre_scores_gemma":[0.99748474,0.00041144146,0.00009173318,0.00003776346,0.000093135146,0.000020583351,0.0000020506707,0.000011346766,0.0018471899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99702793,0.0009139679,0.0010116918,0.00014222867,0.0007395922,0.0001645922],"domain_scores_gemma":[0.99514484,0.0017666774,0.002036672,0.00014840985,0.00081466185,0.00008870775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032911296,0.00010699049,0.0009253941,0.00012962444,0.000025603902,0.000004376305,0.00009357982,0.000083383005,0.0000344437],"category_scores_gemma":[0.0009625831,0.00004054287,0.00008670088,0.00029748096,0.00013399494,0.00007108676,0.000014630533,0.00028776887,6.708231e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04211641,0.002916709,0.92892265,0.000043351498,0.0010300867,0.0001264982,0.00061132165,0.00003641987,0.0046866387,0.000015865033,0.00017847505,0.01931557],"study_design_scores_gemma":[0.02765857,0.044671837,0.9130027,0.00058417063,0.0006365445,0.000008307953,0.000927055,0.000005018682,0.012072981,0.00003136854,0.00034072303,0.000060680562],"about_ca_topic_score_codex":0.00025548393,"about_ca_topic_score_gemma":0.0034715948,"teacher_disagreement_score":0.04175513,"about_ca_system_score_codex":0.00053364376,"about_ca_system_score_gemma":0.001491128,"threshold_uncertainty_score":0.26451972},"labels":[],"label_agreement":null},{"id":"W4237388738","doi":"10.1007/978-1-4419-1005-9_211","title":"Prostate-Specific Antigen (PSA)","year":2013,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"","keywords":"Prostate-specific antigen; Antigen; Medicine; Prostate; Immunology; Internal medicine; Cancer","score_opus":0.05327541115173322,"score_gpt":0.2986316146357479,"score_spread":0.24535620348401466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237388738","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042318186,0.0072450805,0.0000068192803,0.0015055375,0.00018869655,0.0015976406,0.00003794175,0.00014234253,0.98885274],"genre_scores_gemma":[0.0012645777,0.015348005,0.00038437854,0.00021814824,0.0004022097,0.000050253664,0.00042690404,0.0001034662,0.98180205],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99841195,0.000005212974,0.00026153252,0.00045357234,0.0004911471,0.0003765767],"domain_scores_gemma":[0.99890465,0.000024770445,0.00006945396,0.0005052698,0.00022168142,0.00027417266],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000068222245,0.00034067128,0.000486645,0.00019676333,0.000067973684,0.00004704386,0.000102919905,0.0003095907,0.034833692],"category_scores_gemma":[0.000003512386,0.00022462168,0.00018603014,0.000028038596,0.00016436205,0.000058384663,0.00007666863,0.00042183168,0.010522018],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071069534,0.00012493107,0.00045878981,0.00039098194,0.0008104702,0.0009572244,0.00019712251,1.36151e-7,0.0018959335,0.070278764,0.8204197,0.10375521],"study_design_scores_gemma":[0.0012425806,0.0004931267,0.00042837212,0.00026976079,0.000047151163,0.000027293421,0.000013974058,0.0000031143138,0.0008558934,0.0026522963,0.99371344,0.0002530114],"about_ca_topic_score_codex":0.000026246671,"about_ca_topic_score_gemma":0.000003054293,"teacher_disagreement_score":0.1732937,"about_ca_system_score_codex":0.00018638305,"about_ca_system_score_gemma":0.00022476436,"threshold_uncertainty_score":0.9902484},"labels":[],"label_agreement":null},{"id":"W4238348367","doi":"10.5489/cuaj.719","title":"USPSTF and FDA: PSA and 5ARIs","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.01622786281586109,"score_gpt":0.2545298922207509,"score_spread":0.23830202940488981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238348367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9163933,0.0012517454,0.000005658706,0.07815533,0.00006864215,0.0001625472,0.000006812173,0.000009685645,0.003946273],"genre_scores_gemma":[0.99356055,0.000686892,0.000106223764,0.0027183746,0.0001895348,0.000008475403,0.000005795064,0.000004964381,0.002719208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992423,0.00005247212,0.00011953356,0.00010819573,0.0001620384,0.00031545493],"domain_scores_gemma":[0.9988812,0.00006885657,0.000053117543,0.00003883869,0.00014435708,0.0008135977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002355124,0.00006827722,0.00013728019,0.000094823794,0.00019651171,0.00010996097,0.000027930348,0.00013000894,0.00090021704],"category_scores_gemma":[0.00023817355,0.000046207704,0.00002801338,0.00007600103,0.00004182258,0.00009034961,0.000011241995,0.00033862548,0.000047022862],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013179243,0.000011729096,0.9618108,0.0000032073422,0.00006271038,0.00005410148,0.00007997387,2.0087056e-7,0.000102349135,0.00007208379,0.017973483,0.019816158],"study_design_scores_gemma":[0.0008916282,0.00023076567,0.9743881,0.0000055811515,0.000027614815,0.00019061498,0.00006121767,0.00009538431,0.0000151597615,0.0010386591,0.023001948,0.00005330276],"about_ca_topic_score_codex":0.0018831501,"about_ca_topic_score_gemma":0.0003111787,"teacher_disagreement_score":0.07716723,"about_ca_system_score_codex":0.00038375615,"about_ca_system_score_gemma":0.00020605944,"threshold_uncertainty_score":0.98567456},"labels":[],"label_agreement":null},{"id":"W4238715176","doi":"10.1016/j.ijrobp.2006.07.613","title":"2207","year":2006,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Proportional hazards model; Internal medicine; Radiation therapy; Cohort; Multivariate analysis; Oncology; Urology; Cancer","score_opus":0.025220226950282355,"score_gpt":0.3677817728060229,"score_spread":0.34256154585574056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238715176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95324534,0.0026669481,0.008087471,0.016143622,0.003801436,0.00035068448,0.00006921955,0.00006714379,0.01556812],"genre_scores_gemma":[0.99136347,0.0006738994,0.0018252902,0.0006413339,0.004531855,0.000007285937,0.00014013454,0.00001989726,0.0007968364],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987732,0.000091222806,0.00049013074,0.00014604696,0.00029400282,0.00020538946],"domain_scores_gemma":[0.9984012,0.0001731683,0.00046572776,0.00010173772,0.0007603338,0.00009779459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032222667,0.00012762944,0.00031364942,0.0001581184,0.00005227129,0.000020973492,0.00021807839,0.00015652948,0.00014594584],"category_scores_gemma":[0.00009590662,0.00009868544,0.00019750641,0.0001346813,0.00015713349,0.00017425237,0.000036856636,0.00035054027,0.000069592614],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011786327,0.0010781178,0.7028212,0.000011690341,0.0008058591,0.0002874542,0.00017784453,0.00025531952,0.016279751,0.02393868,0.01702649,0.23613894],"study_design_scores_gemma":[0.029264722,0.0043254024,0.22987019,0.00014554603,0.00036858884,0.0011575894,0.00013176202,0.0018220216,0.03629978,0.07634293,0.61983687,0.00043460535],"about_ca_topic_score_codex":0.000034782468,"about_ca_topic_score_gemma":0.000003167888,"teacher_disagreement_score":0.6028104,"about_ca_system_score_codex":0.000755461,"about_ca_system_score_gemma":0.00060216064,"threshold_uncertainty_score":0.40242755},"labels":[],"label_agreement":null},{"id":"W4239004166","doi":"10.1007/978-3-319-42603-7_68-1","title":"Risk Assessment Based on Molecular and Genetic Markers in Prostate Cancer","year":2018,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; TMPRSS2; Context (archaeology); Medicine; Biomarker; Biomarker discovery; Intensive care medicine; Cancer; Bioinformatics; Internal medicine; Biology; Coronavirus disease 2019 (COVID-19); Disease; Gene; Proteomics; Genetics","score_opus":0.015762178205371156,"score_gpt":0.3218823024405484,"score_spread":0.3061201242351772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239004166","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044145007,0.0038306145,0.00005465298,0.0021707942,0.00015575625,0.0030212644,0.00018560536,0.00005643275,0.9463799],"genre_scores_gemma":[0.07494096,0.013166179,0.0025063653,0.001190864,0.00014454212,0.00031612383,0.00016288027,0.00015386028,0.90741825],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985733,0.000026711901,0.00021101418,0.00048181447,0.00042463085,0.00028253446],"domain_scores_gemma":[0.99929535,0.000040915063,0.000077922676,0.00031691493,0.00009711001,0.00017178032],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012411889,0.00028995296,0.00036134967,0.00027441702,0.000036731555,0.00002407262,0.000051152594,0.00015113284,0.0031158607],"category_scores_gemma":[0.000007691162,0.00020565651,0.00007267342,0.000034867106,0.00016351147,0.000015900016,0.00004073022,0.00039781615,0.00003373383],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019705895,0.001228185,0.4122582,0.004674664,0.0035335282,0.026035234,0.0006774489,0.00036016773,0.0024746463,0.0031562424,0.06421846,0.4616773],"study_design_scores_gemma":[0.06716851,0.02237393,0.4539424,0.01554697,0.0033340787,0.000109937566,0.00017617342,0.025093975,0.007072867,0.014920213,0.38588506,0.0043758843],"about_ca_topic_score_codex":0.0002338837,"about_ca_topic_score_gemma":0.00011097187,"teacher_disagreement_score":0.45730144,"about_ca_system_score_codex":0.00042100588,"about_ca_system_score_gemma":0.00051561784,"threshold_uncertainty_score":0.9977954},"labels":[],"label_agreement":null},{"id":"W4239375149","doi":"10.5489/cuaj.2284","title":"New trends in androgen deprivation therapy: Summary of key research presented at AUA 2014","year":2014,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Androgen deprivation therapy; Key (lock); Psychology; Chemistry; Medicine; Psychotherapist; Internal medicine; Computer science; Prostate cancer; Cancer","score_opus":0.10031731773480196,"score_gpt":0.39033774074616606,"score_spread":0.2900204230113641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239375149","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000873066,0.98931575,0.0000035822127,0.0058217105,0.00016324551,0.0005936281,0.00006416887,0.000011549616,0.0031532925],"genre_scores_gemma":[0.00059847004,0.98480225,0.00004563148,0.0001332223,0.0006182655,0.000033176337,0.0005057493,0.000033676482,0.013229544],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99567693,0.0013135164,0.00081965025,0.00035491408,0.0009842723,0.0008506966],"domain_scores_gemma":[0.99723154,0.0005780694,0.00050856266,0.00024837366,0.00043748342,0.00099597],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028426542,0.00026159192,0.0013217344,0.0017886569,0.00019942291,0.000058140904,0.00029444,0.0008154155,0.0015682332],"category_scores_gemma":[0.00070880214,0.00017850999,0.00043499478,0.0011320513,0.00006252906,0.00006964375,0.00005802291,0.0016964492,0.00008233694],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013874835,0.000060705555,0.065703444,0.00025261447,0.00035688755,0.0001226978,0.00006180575,0.0000011696322,0.000002098066,0.000027261081,0.17625344,0.7570191],"study_design_scores_gemma":[0.0015837168,0.00046806,0.016412677,0.0007617682,0.00010719417,0.00007957808,0.000005468803,0.000008086185,0.0000027144692,0.00014710632,0.98028827,0.00013534699],"about_ca_topic_score_codex":0.0032414529,"about_ca_topic_score_gemma":0.0026915025,"teacher_disagreement_score":0.8040348,"about_ca_system_score_codex":0.0050496436,"about_ca_system_score_gemma":0.0028526264,"threshold_uncertainty_score":0.99934447},"labels":[],"label_agreement":null},{"id":"W4239535509","doi":"10.21037/tcr.2017.08.30","title":"The future of prostate cancer precision medicine: anti-ERG therapies","year":2017,"lang":"en","type":"article","venue":"Translational Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Erg; Prostate cancer; Medicine; Cancer; Prostate; Precision medicine; Oncology; Internal medicine; Ophthalmology; Pathology","score_opus":0.10604754354214442,"score_gpt":0.47755521389158057,"score_spread":0.37150767034943616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239535509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6385378,0.1485278,0.0000076243327,0.2047331,0.00056505593,0.0017410425,0.00016240428,0.000026894682,0.0056982487],"genre_scores_gemma":[0.90567,0.08553232,0.000042166317,0.00003897614,0.0010797844,0.0003796261,0.000026193155,0.000028218707,0.00720274],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99678487,0.00014619328,0.00030577646,0.0003245152,0.0019279924,0.0005106364],"domain_scores_gemma":[0.99761087,0.00035968472,0.00011178426,0.0006335107,0.001128467,0.00015567549],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.001456741,0.00015302545,0.0002950812,0.00015641926,0.0014766535,0.00007581797,0.0004740807,0.000094828865,0.0008344055],"category_scores_gemma":[0.00006690471,0.000080136946,0.0000950751,0.0002555438,0.0014764974,0.00018609551,0.000056459976,0.00054319104,0.000010100451],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070251934,0.00018339904,0.34519607,0.00045908822,0.00063907454,0.00003402353,0.0050324793,0.000043378303,0.02406776,0.0045274384,0.016324183,0.5964679],"study_design_scores_gemma":[0.0054359455,0.00051048753,0.77211773,0.0007611908,0.000060354174,0.000005722859,0.0007026849,0.00016801375,0.011012863,0.005217409,0.20385286,0.00015472536],"about_ca_topic_score_codex":0.0015340615,"about_ca_topic_score_gemma":0.0009394921,"teacher_disagreement_score":0.5963132,"about_ca_system_score_codex":0.00012009627,"about_ca_system_score_gemma":0.0010334108,"threshold_uncertainty_score":0.9998233},"labels":[],"label_agreement":null},{"id":"W4239731706","doi":"10.21203/rs.3.rs-641499/v1","title":"Short-Duration Dynamic [18F]DCFPyL PET and CT Perfusion Imaging to Localize Dominant Intraprostatic Lesions in Prostate Cancer: Validation Against Digital Histopathology and Comparison to [18F]DCFPyL PET/MR at 120 Minutes","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; St Joseph's Health Care; Lawson Health Research Institute; London Health Sciences Centre; Western University","funders":"","keywords":"Prostate cancer; Histopathology; Nuclear medicine; Medicine; Prostate; Cancer; Radiology; Pathology; Internal medicine","score_opus":0.04100644869141857,"score_gpt":0.3971750783086788,"score_spread":0.35616862961726026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239731706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749269,0.0085920645,0.00013853896,0.0096762385,0.00021847597,0.0057038455,0.0005380038,0.00006226849,0.0001436884],"genre_scores_gemma":[0.98274386,0.0098520415,0.0005389504,0.000085599655,0.00008475998,0.001374231,0.0034565984,0.00010394742,0.0017600257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940062,0.0005921903,0.0009528082,0.0017505409,0.0014162285,0.0012819956],"domain_scores_gemma":[0.9969132,0.00043507793,0.00014239825,0.0007564035,0.0009132076,0.000839734],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014070604,0.00060345087,0.0011182122,0.0014471196,0.0005095613,0.0005719285,0.00025243298,0.00009005562,0.000066421635],"category_scores_gemma":[0.00076671987,0.0005288166,0.00012761494,0.000894511,0.0004669882,0.00031073962,0.0020639554,0.001508514,0.000023341505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047983713,0.001178997,0.6435519,0.007033086,0.00012374269,0.016257005,0.015438858,0.001277399,0.081872575,0.000016810767,0.0027591325,0.22569214],"study_design_scores_gemma":[0.014440803,0.0048672734,0.73519045,0.03176059,0.00045755022,0.00317701,0.038967684,0.120041154,0.039537508,0.0004266735,0.0076027336,0.003530577],"about_ca_topic_score_codex":0.0010697825,"about_ca_topic_score_gemma":0.0024846585,"teacher_disagreement_score":0.22216156,"about_ca_system_score_codex":0.0033546533,"about_ca_system_score_gemma":0.0011333417,"threshold_uncertainty_score":0.99971634},"labels":[],"label_agreement":null},{"id":"W4239826291","doi":"10.5489/cuaj.1282","title":"Podium Session 1: Oncology: Prostate","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Session (web analytics); Medicine; Prostate cancer; Oncology; Internal medicine; Medical physics; Computer science; Cancer; World Wide Web","score_opus":0.020806338745550993,"score_gpt":0.2930435195762108,"score_spread":0.2722371808306598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239826291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79764783,0.00037860236,0.000007984421,0.18250494,0.00035207416,0.00046664587,0.000013367454,0.000034076482,0.018594448],"genre_scores_gemma":[0.9815977,0.00025282244,0.0002152579,0.0060384795,0.0004285217,0.00003472801,0.00003092927,0.000010529598,0.01139103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985819,0.00013841735,0.00022725976,0.00014757256,0.00031943852,0.000585401],"domain_scores_gemma":[0.99817806,0.00008214604,0.00013141887,0.0000757084,0.0004214858,0.0011111522],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044407952,0.000102283324,0.0002095743,0.00016314739,0.0002911766,0.00010044597,0.00007745452,0.00024335095,0.003371873],"category_scores_gemma":[0.00034781342,0.000066600194,0.000091646994,0.00017856962,0.000036347064,0.00014009408,0.000014590267,0.0006786734,0.0007379254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007978843,0.00009176195,0.7990581,0.0000052431647,0.00011036422,0.00028908442,0.00017391599,0.0000034398458,0.0009013462,0.000047166875,0.16156185,0.03767796],"study_design_scores_gemma":[0.0016639461,0.0007184079,0.70064676,0.000012722819,0.00003377351,0.00022949338,0.000120693905,0.000082186816,0.00009752745,0.001147867,0.2951564,0.000090266454],"about_ca_topic_score_codex":0.0013863998,"about_ca_topic_score_gemma":0.00017412555,"teacher_disagreement_score":0.18394984,"about_ca_system_score_codex":0.0026028822,"about_ca_system_score_gemma":0.0012920576,"threshold_uncertainty_score":0.99753916},"labels":[],"label_agreement":null},{"id":"W4240237991","doi":"10.5489/cuaj.7","title":"Se rapprocher avec les survivants de la cancer de la prostate","year":2012,"lang":"fr","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Canadian Urological Association","funders":"","keywords":"Humanities; Philosophy","score_opus":0.027758771132116774,"score_gpt":0.3255167224744766,"score_spread":0.29775795134235983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240237991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86659515,0.06848006,0.00007901528,0.047940664,0.0014464993,0.00036034576,0.00022825644,0.000030409497,0.014839604],"genre_scores_gemma":[0.9505435,0.011627162,0.00017538773,0.0018932093,0.0032177202,0.00004330102,0.000020605648,0.000035295576,0.032443818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99478626,0.002334449,0.00031962318,0.00019085681,0.00043767339,0.0019311337],"domain_scores_gemma":[0.9960565,0.0008807712,0.00022736423,0.00009766166,0.00024907786,0.0024886301],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0051706117,0.00023366547,0.00033228906,0.00017547543,0.00047468184,0.00020884423,0.00015782766,0.0008399166,0.0040140124],"category_scores_gemma":[0.0014900396,0.00018924112,0.00016330794,0.00027607704,0.00027952873,0.0002079937,0.000025653222,0.0018227039,0.000108534136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000119455384,0.00018588963,0.9310132,0.00003331624,0.00042109337,0.00040312967,0.0034198123,0.000041095405,0.00022679845,0.0002629434,0.034652315,0.029220909],"study_design_scores_gemma":[0.0014904154,0.00011868618,0.6466547,0.000072437884,0.00018039084,0.00032963578,0.00024503988,0.00013793248,0.00010043495,0.00059219793,0.3499246,0.00015349728],"about_ca_topic_score_codex":0.01296903,"about_ca_topic_score_gemma":0.0013455137,"teacher_disagreement_score":0.31527227,"about_ca_system_score_codex":0.007972917,"about_ca_system_score_gemma":0.0038729464,"threshold_uncertainty_score":0.99689645},"labels":[],"label_agreement":null},{"id":"W4240269857","doi":"10.5489/cuaj.3127","title":"Podium Session 4: Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"Helsingin ja Uudenmaan Sairaanhoitopiiri; University of Toronto; McMaster University; University of Minnesota; Tays; U.S. Department of Veterans Affairs","keywords":"Session (web analytics); Prostate cancer; Prostate; Cancer; Medicine; Gynecology; Internal medicine; Computer science; World Wide Web","score_opus":0.03728279693489328,"score_gpt":0.3134019161869245,"score_spread":0.2761191192520312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240269857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8506114,0.0017424473,0.0000066828234,0.13980359,0.0006447809,0.0002681936,0.000041278123,0.000034095017,0.006847558],"genre_scores_gemma":[0.9825186,0.0004102089,0.00008452023,0.0037146835,0.00065739127,0.000019712217,0.000027664091,0.000011235858,0.012555974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986108,0.00010213908,0.00018575444,0.00013924485,0.00045382525,0.0005082177],"domain_scores_gemma":[0.997705,0.000031749172,0.00011058024,0.00006809778,0.0005169104,0.0015676739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005747084,0.000097446864,0.00018034379,0.00014358827,0.00017566001,0.00007690606,0.00006977664,0.00016124929,0.00060105644],"category_scores_gemma":[0.00038406567,0.00006468766,0.00007147427,0.00020533704,0.000026466718,0.00009940715,0.000012954422,0.0005103666,0.00011293351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001716411,0.000036196572,0.89584154,0.000003220488,0.00007358902,0.00028776375,0.00031917804,0.000018770506,0.00008740621,0.00002399306,0.0953329,0.007803779],"study_design_scores_gemma":[0.0033875273,0.00054852583,0.55944985,0.000028696664,0.00006662215,0.00021858375,0.00018726787,0.00014622687,0.00013163025,0.00097286573,0.43472606,0.00013614362],"about_ca_topic_score_codex":0.0014725775,"about_ca_topic_score_gemma":0.00050224585,"teacher_disagreement_score":0.33939317,"about_ca_system_score_codex":0.0027700611,"about_ca_system_score_gemma":0.0023051014,"threshold_uncertainty_score":0.72436136},"labels":[],"label_agreement":null},{"id":"W4240426680","doi":"10.26434/chemrxiv.13064186.v2","title":"Identifying Potential Off-Target Protein Binders of Glutamate-Ureido-Lysine, a Prostate Cancer Specific Imaging Agent","year":2020,"lang":"en","type":"preprint","venue":"ChemRxiv","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Windsor","funders":"Canadian Institutes of Health Research; Government of Ontario; Compute Canada; Natural Sciences and Engineering Research Council of Canada; Windsor Cancer Centre Foundation","keywords":"Glutamate carboxypeptidase II; Prostate cancer; Cancer research; Prostate; Lysine; Chemistry; Glutamate receptor; Cancer; Biology; Receptor; Medicine; Biochemistry; Amino acid; Internal medicine","score_opus":0.047369754109590136,"score_gpt":0.3259133787967173,"score_spread":0.2785436246871271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240426680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9435635,0.038104217,0.00068072136,0.009829219,0.0010662407,0.005026836,0.00013965864,0.0002650834,0.0013245005],"genre_scores_gemma":[0.98821425,0.0051979115,0.0020661242,0.0001166608,0.0006592989,0.00072385353,0.00051146257,0.00015241225,0.0023580429],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99633455,0.000075483695,0.0007515782,0.0011209341,0.0009754212,0.0007420387],"domain_scores_gemma":[0.9979612,0.000015647853,0.00047545455,0.00074688287,0.00040768913,0.00039309415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028849716,0.00058966584,0.001045777,0.0003411903,0.00012176251,0.00012783507,0.00037614172,0.00024032396,0.00064693525],"category_scores_gemma":[0.00004090709,0.0005070528,0.0005187288,0.00044943093,0.0003076209,0.000111611575,0.00073200563,0.0011476933,0.000058379836],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032719267,0.0006803152,0.028834967,0.013700242,0.002144203,0.0022669635,0.0030711235,0.00028136245,0.91723,0.000040892945,0.010004359,0.018473616],"study_design_scores_gemma":[0.0058315457,0.00016466966,0.011734969,0.0054287184,0.00071907963,0.000035066623,0.0008066352,0.002500301,0.9636146,0.0018026234,0.006379893,0.0009819007],"about_ca_topic_score_codex":0.00023091956,"about_ca_topic_score_gemma":0.0000047933127,"teacher_disagreement_score":0.04638457,"about_ca_system_score_codex":0.0005580832,"about_ca_system_score_gemma":0.0010192737,"threshold_uncertainty_score":0.9997381},"labels":[],"label_agreement":null},{"id":"W4240634580","doi":"10.26434/chemrxiv.13064186.v1","title":"Identifying Potential Off-Target Protein Binders of Glutamate-Ureido-Lysine, a Prostate Cancer Specific Imaging Agent","year":2020,"lang":"en","type":"preprint","venue":"ChemRxiv","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Windsor","funders":"Canadian Institutes of Health Research; Government of Ontario; Compute Canada; Natural Sciences and Engineering Research Council of Canada; Windsor Cancer Centre Foundation","keywords":"Glutamate carboxypeptidase II; Prostate cancer; Cancer research; Lysine; Prostate; Chemistry; Glutamate receptor; Cancer; Receptor; Biology; Biochemistry; Medicine; Amino acid; Internal medicine","score_opus":0.047369754109590136,"score_gpt":0.3259133787967173,"score_spread":0.2785436246871271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240634580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9435635,0.038104217,0.00068072136,0.009829219,0.0010662407,0.005026836,0.00013965864,0.0002650834,0.0013245005],"genre_scores_gemma":[0.98821425,0.0051979115,0.0020661242,0.0001166608,0.0006592989,0.00072385353,0.00051146257,0.00015241225,0.0023580429],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99633455,0.000075483695,0.0007515782,0.0011209341,0.0009754212,0.0007420387],"domain_scores_gemma":[0.9979612,0.000015647853,0.00047545455,0.00074688287,0.00040768913,0.00039309415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028849716,0.00058966584,0.001045777,0.0003411903,0.00012176251,0.00012783507,0.00037614172,0.00024032396,0.00064693525],"category_scores_gemma":[0.00004090709,0.0005070528,0.0005187288,0.00044943093,0.0003076209,0.000111611575,0.00073200563,0.0011476933,0.000058379836],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032719267,0.0006803152,0.028834967,0.013700242,0.002144203,0.0022669635,0.0030711235,0.00028136245,0.91723,0.000040892945,0.010004359,0.018473616],"study_design_scores_gemma":[0.0058315457,0.00016466966,0.011734969,0.0054287184,0.00071907963,0.000035066623,0.0008066352,0.002500301,0.9636146,0.0018026234,0.006379893,0.0009819007],"about_ca_topic_score_codex":0.00023091956,"about_ca_topic_score_gemma":0.0000047933127,"teacher_disagreement_score":0.04638457,"about_ca_system_score_codex":0.0005580832,"about_ca_system_score_gemma":0.0010192737,"threshold_uncertainty_score":0.9997381},"labels":[],"label_agreement":null},{"id":"W4240674910","doi":"10.3410/f.737742310.793580830","title":"Faculty Opinions recommendation of FAM46C inhibits cell proliferation and cell cycle progression and promotes apoptosis through PTEN/AKT signaling pathway and is associated with chemosensitivity in prostate cancer.","year":2020,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"PTEN; Protein kinase B; Cancer research; Cell growth; Cell cycle progression; Apoptosis; Cell cycle; PI3K/AKT/mTOR pathway; Prostate cancer; Cell; Signal transduction; Prostate; Chemistry; Cancer; Cell biology; Medicine; Biology; Internal medicine; Biochemistry","score_opus":0.03063305660807397,"score_gpt":0.34947876166332703,"score_spread":0.31884570505525306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240674910","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013823122,0.0025861235,0.0000022021775,0.1180315,0.000059089212,0.0032490478,0.8746531,0.000022386585,0.000014259281],"genre_scores_gemma":[0.0040710084,0.0017368029,0.00042529526,0.0012898078,0.00006570972,0.00039649563,0.9918134,0.000026538975,0.00017491303],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99689174,0.00031943357,0.0008618027,0.0007018639,0.0009208971,0.00030425534],"domain_scores_gemma":[0.9961322,0.00010684499,0.0009264632,0.000349748,0.0022328508,0.00025189904],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000760029,0.00042844986,0.0008958347,0.00018478709,0.00019489983,0.000117980424,0.00016281343,0.0003983252,0.000021140668],"category_scores_gemma":[0.0011005775,0.00025152412,0.000106679836,0.0012831116,0.0003495457,0.00034530336,0.00025673854,0.0008355908,0.0000012288989],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018100462,0.00069416745,0.00056104467,0.01901343,0.00012961122,0.000001647055,0.0015410379,5.4056127e-8,0.00024544538,0.0000038464545,0.9717698,0.0058588977],"study_design_scores_gemma":[0.0047476823,0.0009474873,0.002771436,0.038531896,0.0003603275,0.000028628936,0.00015565321,0.00008450781,0.020632634,0.000020190211,0.93128186,0.0004376931],"about_ca_topic_score_codex":0.00006476603,"about_ca_topic_score_gemma":0.000011083056,"teacher_disagreement_score":0.11716035,"about_ca_system_score_codex":0.00012511009,"about_ca_system_score_gemma":0.0005724107,"threshold_uncertainty_score":0.9999937},"labels":[],"label_agreement":null},{"id":"W4240799807","doi":"10.1097/ju.0000000000000955.07","title":"PD53-07 CLINICAL SIGNIFICANCE OF THE SIAα2,3GAL-GLYCOSYLATED PROSTATE-SPECIFIC ANTIGEN ASSAY FOR PROSTATE CANCER DETECTION","year":2020,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Urology; Prostate-specific antigen; Receiver operating characteristic; Area under the curve; Prostate; Cohort; Internal medicine; Area under curve; Gastroenterology; Cancer; Oncology; Pharmacokinetics","score_opus":0.0669924007343825,"score_gpt":0.3633867955029653,"score_spread":0.2963943947685828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240799807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9544512,0.0051533445,0.00043945445,0.03776112,0.0006121858,0.0014540368,0.00003393317,0.000013588437,0.00008111126],"genre_scores_gemma":[0.9920726,0.006228627,0.000052031453,0.00081862183,0.0005231265,0.000026979835,0.0000025522186,0.000027786316,0.00024768425],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99785835,0.000518188,0.000771713,0.00017603922,0.0003465172,0.00032920705],"domain_scores_gemma":[0.9978465,0.00053033564,0.00067153043,0.00023243618,0.00056418555,0.00015503237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016413552,0.00014943966,0.0004927121,0.000058405087,0.00013109928,0.000009633041,0.00028825377,0.00013034529,0.000079674],"category_scores_gemma":[0.00034743623,0.00007179915,0.00025196487,0.00031027055,0.0004046074,0.000065244254,0.0000585971,0.0005800454,0.000008451951],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11369158,0.0007780427,0.1292036,0.00039524317,0.0019424519,0.00010995261,0.005842175,0.0012756018,0.6342661,0.00006008091,0.011646193,0.100789],"study_design_scores_gemma":[0.029292176,0.034951422,0.34621596,0.0002733203,0.0017626974,0.0003963811,0.0010931923,0.00474948,0.3390038,0.0016521533,0.24009074,0.00051866414],"about_ca_topic_score_codex":0.00002605522,"about_ca_topic_score_gemma":0.000017654376,"teacher_disagreement_score":0.29526228,"about_ca_system_score_codex":0.00007221532,"about_ca_system_score_gemma":0.00046221033,"threshold_uncertainty_score":0.29278845},"labels":[],"label_agreement":null},{"id":"W4240982908","doi":"10.26434/chemrxiv.13064186","title":"Identifying Potential Off-Target Protein Binders of Glutamate-Ureido-Lysine, a Prostate Cancer Specific Imaging Agent","year":2020,"lang":"en","type":"preprint","venue":"ChemRxiv","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Windsor","funders":"Canadian Institutes of Health Research; Government of Ontario; Compute Canada; Natural Sciences and Engineering Research Council of Canada; Windsor Cancer Centre Foundation","keywords":"Prostate cancer; Glutamate carboxypeptidase II; Cancer research; Prostate; Chemistry; Lysine; Cancer; Biology; Medicine; Biochemistry; Internal medicine; Amino acid","score_opus":0.047369754109590136,"score_gpt":0.3259133787967173,"score_spread":0.2785436246871271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240982908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9435635,0.038104217,0.00068072136,0.009829219,0.0010662407,0.005026836,0.00013965864,0.0002650834,0.0013245005],"genre_scores_gemma":[0.98821425,0.0051979115,0.0020661242,0.0001166608,0.0006592989,0.00072385353,0.00051146257,0.00015241225,0.0023580429],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99633455,0.000075483695,0.0007515782,0.0011209341,0.0009754212,0.0007420387],"domain_scores_gemma":[0.9979612,0.000015647853,0.00047545455,0.00074688287,0.00040768913,0.00039309415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028849716,0.00058966584,0.001045777,0.0003411903,0.00012176251,0.00012783507,0.00037614172,0.00024032396,0.00064693525],"category_scores_gemma":[0.00004090709,0.0005070528,0.0005187288,0.00044943093,0.0003076209,0.000111611575,0.00073200563,0.0011476933,0.000058379836],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032719267,0.0006803152,0.028834967,0.013700242,0.002144203,0.0022669635,0.0030711235,0.00028136245,0.91723,0.000040892945,0.010004359,0.018473616],"study_design_scores_gemma":[0.0058315457,0.00016466966,0.011734969,0.0054287184,0.00071907963,0.000035066623,0.0008066352,0.002500301,0.9636146,0.0018026234,0.006379893,0.0009819007],"about_ca_topic_score_codex":0.00023091956,"about_ca_topic_score_gemma":0.0000047933127,"teacher_disagreement_score":0.04638457,"about_ca_system_score_codex":0.0005580832,"about_ca_system_score_gemma":0.0010192737,"threshold_uncertainty_score":0.9997381},"labels":[],"label_agreement":null},{"id":"W4241828587","doi":"10.1200/jco.2019.37.15_suppl.5026","title":"Concurrent or layered treatment with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Internal medicine; Prostate cancer; Oncology; Cancer","score_opus":0.14063196091680283,"score_gpt":0.48479497104042457,"score_spread":0.3441630101236217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241828587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941191,0.00031843188,0.0000045779966,0.000836246,0.00046621112,0.003997499,0.00011291632,0.000013750836,0.0001312391],"genre_scores_gemma":[0.9942558,0.0023722528,0.0006265827,0.00011113636,0.00013601614,0.00015174117,0.000015947178,0.00005050522,0.0022800604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931075,0.0010830509,0.0036209174,0.0006682611,0.0009708817,0.0005493855],"domain_scores_gemma":[0.9936247,0.0018618563,0.0026873979,0.00039878147,0.00087762444,0.0005496268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019034212,0.0004537389,0.003960998,0.0003216601,0.000067169436,0.000029461404,0.00018714718,0.00020569914,0.00014122136],"category_scores_gemma":[0.00045209026,0.00021358926,0.00024154509,0.00045034615,0.0005282058,0.00024047321,0.00007757966,0.0009142236,0.0000039836705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1607388,0.019064419,0.79867524,0.000115795716,0.0031578233,0.0010788341,0.0015665742,0.00006153952,0.000035735055,0.0000055617684,0.00006466588,0.01543502],"study_design_scores_gemma":[0.13295314,0.20671201,0.6572659,0.00033988347,0.0009932163,0.000031579893,0.0012015912,0.00007694728,0.00003788422,0.000008518715,0.00021590243,0.00016345769],"about_ca_topic_score_codex":0.0018476694,"about_ca_topic_score_gemma":0.02711542,"teacher_disagreement_score":0.1876476,"about_ca_system_score_codex":0.0016231127,"about_ca_system_score_gemma":0.0050932965,"threshold_uncertainty_score":0.9906372},"labels":[],"label_agreement":null},{"id":"W4242184364","doi":"10.1200/jco.2019.37.7_suppl.170","title":"Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Docetaxel; Medicine; Enzalutamide; Abiraterone; Prostate cancer; Prednisone; Internal medicine; Pembrolizumab; Oncology; Cohort; Pneumonitis; Cancer; Lung; Immunotherapy","score_opus":0.08204740760807967,"score_gpt":0.43870798409038925,"score_spread":0.3566605764823096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242184364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99334556,0.0018226457,0.0000057682055,0.0015782132,0.0004120522,0.0017740196,0.00006320876,0.000016779995,0.0009817452],"genre_scores_gemma":[0.98892236,0.005238987,0.0010174746,0.00044153014,0.00015183858,0.00006567535,0.0000229673,0.000056914025,0.0040822644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946837,0.00070678676,0.0025215726,0.00054707384,0.00084874156,0.00069216924],"domain_scores_gemma":[0.9956047,0.0010461116,0.0015276605,0.00033303234,0.00083776034,0.0006507484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002141823,0.00037647225,0.0025352263,0.00028272494,0.00006238379,0.00004155754,0.00019908106,0.0003040899,0.00030330106],"category_scores_gemma":[0.00069922145,0.00020909724,0.00019805628,0.00044159396,0.00043591348,0.00031795452,0.00009302834,0.0013221644,0.00002240721],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21729624,0.0023238738,0.75096476,0.00041499716,0.0014680361,0.003421364,0.00048644925,0.00015996555,0.0006157808,0.000010207629,0.00040052974,0.02243778],"study_design_scores_gemma":[0.11258609,0.0432336,0.83775574,0.0009388126,0.00093289895,0.00033268507,0.00028580023,0.0004310506,0.00039734674,0.000075587996,0.0027503474,0.00028003726],"about_ca_topic_score_codex":0.0004953969,"about_ca_topic_score_gemma":0.0010672797,"teacher_disagreement_score":0.104710154,"about_ca_system_score_codex":0.00099964,"about_ca_system_score_gemma":0.0048279483,"threshold_uncertainty_score":0.8564573},"labels":[],"label_agreement":null},{"id":"W4242381048","doi":"10.1101/2020.09.17.301283","title":"Schlafen family member 5 (SLFN5) regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Beatson Institute for Cancer Research; Medical Research Council; Ligue Contre le Cancer; European Commission; Cancer Research UK","keywords":"Prostate cancer; Androgen deprivation therapy; Cancer research; Androgen receptor; mTORC1; In vivo; Biomarker; Tramp; PI3K/AKT/mTOR pathway; Medicine; Chemistry; Cancer; Biology; Signal transduction; Internal medicine; Cell biology; Biochemistry","score_opus":0.03536974441062341,"score_gpt":0.2853517655936945,"score_spread":0.2499820211830711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242381048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904797,0.0019471883,0.000012518464,0.0035914548,0.0004624718,0.0026671905,0.00042183878,0.0003510632,0.00006658667],"genre_scores_gemma":[0.9957889,0.0013859846,0.0007138346,0.00029582548,0.0005047324,0.0010470086,0.00001217224,0.00017646083,0.00007510547],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99614424,0.00014823217,0.0007435811,0.0012407824,0.0009482809,0.00077487796],"domain_scores_gemma":[0.99726534,0.00009687164,0.0003829604,0.00082924054,0.0009456061,0.00048000165],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000473334,0.00066089456,0.0008717993,0.00046842606,0.00013696952,0.00018763493,0.00027952596,0.000583868,0.000121504905],"category_scores_gemma":[0.00034761286,0.0006087021,0.00016110939,0.0010751216,0.00016223411,0.00024465748,0.00027446196,0.0012576425,0.00007005166],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011784757,0.00021609974,0.029494788,0.0010283369,0.0003542538,0.00019117864,0.00006986047,0.00006414704,0.9666303,0.0000489427,0.0007167965,0.0000068294116],"study_design_scores_gemma":[0.0030581206,0.00017145993,0.51986897,0.0017628887,0.00016188544,1.3693793e-8,0.000017370783,0.00046420417,0.47194502,0.0000045782485,0.0019389408,0.00060652185],"about_ca_topic_score_codex":0.0011447873,"about_ca_topic_score_gemma":0.00005402249,"teacher_disagreement_score":0.49468526,"about_ca_system_score_codex":0.0017138666,"about_ca_system_score_gemma":0.004081145,"threshold_uncertainty_score":0.9996364},"labels":[],"label_agreement":null},{"id":"W4242383671","doi":"10.14694/edbook_am.2013.33.e176","title":"Androgen Deprivation for Prostate Cancer: When and How, the Good and the Bad","year":2013,"lang":"en","type":"review","venue":"American Society of Clinical Oncology Educational Book","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Androgen deprivation therapy; Medicine; Prostate cancer; Prostatectomy; Radiation therapy; Oncology; Internal medicine; Randomized controlled trial; Disease; Adverse effect; Cancer","score_opus":0.14433784236185704,"score_gpt":0.5065755656683095,"score_spread":0.3622377233064525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242383671","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024696407,0.80922425,0.0000078649,0.18679366,0.00011438518,0.0032481498,0.00005875506,0.000005849978,0.00030011102],"genre_scores_gemma":[0.000043051623,0.97053295,0.0019181784,0.0039809104,0.00065288984,0.002916019,0.00014561128,0.000024613286,0.019785777],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981848,0.00036008388,0.00064385956,0.00037595534,0.00021316615,0.00022214359],"domain_scores_gemma":[0.989225,0.009111553,0.00095100806,0.0002551288,0.0003137366,0.00014360971],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.001302619,0.0002131172,0.0017084988,0.000021123285,0.00018231044,0.00002167533,0.00015997369,0.00020062149,0.00007259475],"category_scores_gemma":[0.00046840784,0.00009746204,0.000610901,0.00010962896,0.004415964,0.000054995806,0.000096110816,0.00048007295,0.000002916647],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014442275,0.0001278569,0.0017168241,0.0011647077,0.000990727,1.0685064e-7,0.00049360574,2.1934222e-8,1.5037588e-7,0.00047949198,0.065289445,0.9295926],"study_design_scores_gemma":[0.0022287837,0.00063803676,0.0014883301,0.00051926874,0.0014088054,0.000013901631,0.00039366938,0.000016962747,3.967827e-7,0.0006732151,0.9925221,0.00009653432],"about_ca_topic_score_codex":0.00015249776,"about_ca_topic_score_gemma":0.00000733356,"teacher_disagreement_score":0.9294961,"about_ca_system_score_codex":0.00015773272,"about_ca_system_score_gemma":0.0044291667,"threshold_uncertainty_score":0.99829346},"labels":[],"label_agreement":null},{"id":"W4242797105","doi":"10.1159/000079775","title":"Author Index","year":2004,"lang":"en","type":"paratext","venue":"Advances in psychosomatic medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"","keywords":"Index (typography); Computer science; World Wide Web","score_opus":0.03189481793897215,"score_gpt":0.4240139962509331,"score_spread":0.39211917831196097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242797105","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020403594,0.32159215,0.0011422615,0.016830692,0.008315083,0.0031719692,0.000044458957,0.00009319285,0.6467698],"genre_scores_gemma":[0.05036041,0.12683558,0.0014086429,0.0022297706,0.0038277183,0.0009394442,0.0014108068,0.00023555316,0.81275207],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963256,0.00007626171,0.00097590644,0.00077818416,0.0010986606,0.0007453656],"domain_scores_gemma":[0.9981036,0.00017060484,0.00031000318,0.0008926906,0.0001347536,0.00038835866],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00033452854,0.0005934412,0.001505065,0.0008469269,0.00006786426,0.0000118417975,0.00032425445,0.00045260167,0.011269924],"category_scores_gemma":[0.000178849,0.00039661262,0.00013252266,0.0009300167,0.00056022895,0.00017485644,0.00005137359,0.0011107866,0.0034658022],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019671076,0.0013491404,0.015803834,0.015318064,0.0007066925,0.0009978395,0.002317429,0.00018459979,0.00021477281,0.0005366589,0.8644207,0.09618313],"study_design_scores_gemma":[0.015261113,0.0014800025,0.0023448651,0.025037112,0.00018805984,0.00022042586,0.00040183036,0.00007587699,0.00007941812,0.0053130984,0.9490769,0.0005213209],"about_ca_topic_score_codex":0.00009817565,"about_ca_topic_score_gemma":0.000024952205,"teacher_disagreement_score":0.19475655,"about_ca_system_score_codex":0.0006872449,"about_ca_system_score_gemma":0.00058074854,"threshold_uncertainty_score":0.9998486},"labels":[],"label_agreement":null},{"id":"W4242895274","doi":"10.5489/cuaj.11067","title":"Clinical and pathological variables that predict changes in tumour grade after radical prostatectomy in patients with prostate cancer","year":2012,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostatectomy; Prostate cancer; Pathological; Medicine; Urology; Oncology; Prostate; Cancer; Internal medicine","score_opus":0.021918946075437165,"score_gpt":0.28216481261677445,"score_spread":0.2602458665413373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242895274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871549,0.0012239561,0.000001389036,0.010534506,0.0001587104,0.000732485,0.000075668046,0.000014470219,0.000103928214],"genre_scores_gemma":[0.9968425,0.0009500152,0.00013303988,0.001457572,0.00027673712,0.00015411687,0.0000328795,0.000016330203,0.00013679912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746686,0.00041432722,0.00036207333,0.00028108992,0.0004758912,0.0009997424],"domain_scores_gemma":[0.9984378,0.0001500888,0.00015128082,0.000076997756,0.00011731537,0.001066519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014348683,0.00019386459,0.0004351771,0.00028008266,0.00009720989,0.000059110185,0.000072864,0.00032717487,0.000245025],"category_scores_gemma":[0.00031885813,0.00011861234,0.00004946183,0.00028733502,0.0001680681,0.00018514151,0.000030094798,0.0011397139,0.0000050740723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013420697,0.00032322737,0.995047,0.000013242275,0.000047775262,0.00026994752,0.00023546207,0.0000017429119,0.0000036279835,0.000009492518,0.00027548693,0.0024309703],"study_design_scores_gemma":[0.0067664096,0.00083751924,0.988811,0.00008446014,0.00004275492,0.00003824296,0.000051098843,0.000017291788,0.000007314442,0.000118388445,0.0030825431,0.00014294355],"about_ca_topic_score_codex":0.0004845425,"about_ca_topic_score_gemma":0.00178794,"teacher_disagreement_score":0.009687624,"about_ca_system_score_codex":0.00092940306,"about_ca_system_score_gemma":0.0004419006,"threshold_uncertainty_score":0.4951553},"labels":[],"label_agreement":null},{"id":"W4243150695","doi":"10.21037/tcr.2018.02.05","title":"Genomic instability and circulating tumor cells in prostate cancer","year":2018,"lang":"en","type":"article","venue":"Translational Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology","funders":"","keywords":"Circulating tumor cell; Prostate cancer; Grading (engineering); Genome instability; Medicine; Prostate; Pathological; Primary tumor; Cancer; Tumor cells; Oncology; Pathology; Cancer research; Internal medicine; Biology; Metastasis; DNA; Genetics","score_opus":0.11136874793107172,"score_gpt":0.4360501692652007,"score_spread":0.324681421334129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243150695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98735917,0.004558363,0.00000399146,0.0045081587,0.00007203056,0.0011877952,0.00014810408,0.000022915552,0.002139449],"genre_scores_gemma":[0.9974525,0.0009251018,0.00018537292,0.00009273408,0.00029023542,0.00040693666,0.000024241626,0.000027342563,0.00059555634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977511,0.00014136793,0.00027077584,0.00047081555,0.0007695525,0.00059639046],"domain_scores_gemma":[0.9990079,0.00014890611,0.000026894604,0.00018221758,0.00043625236,0.00019787253],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009879642,0.00013352951,0.00022685245,0.00030630027,0.00022090612,0.000039617873,0.000087081586,0.000049384413,0.0010164536],"category_scores_gemma":[0.000025201445,0.00011210861,0.000039753744,0.00065018935,0.00064274826,0.0001313552,0.000042183165,0.0004857933,0.00002518826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024228173,0.00016675744,0.8175326,0.00044117347,0.000070146845,0.00006500912,0.0037982618,0.00006653556,0.14936434,0.00022070843,0.0001892504,0.025662385],"study_design_scores_gemma":[0.0046849386,0.00033718717,0.9564828,0.0003194904,0.000019615505,0.000014415466,0.0002382746,0.0021292935,0.029089099,0.0015237689,0.0049642245,0.00019689243],"about_ca_topic_score_codex":0.0035362018,"about_ca_topic_score_gemma":0.002441629,"teacher_disagreement_score":0.13895018,"about_ca_system_score_codex":0.0004500864,"about_ca_system_score_gemma":0.0013005118,"threshold_uncertainty_score":0.99989676},"labels":[],"label_agreement":null},{"id":"W4243521236","doi":"10.1016/j.juro.2015.02.1601","title":"MP42-16 CONTEMPORARY PATIENTS WITH BIOPSY GLEASON 3+4 PROSTATE CANCER: ELIGIBILITY FOR ACTIVE SURVEILLANCE","year":2015,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Biopsy; Prostate biopsy; Cancer; Gynecology; Internal medicine; General surgery; Urology","score_opus":0.042016164330234924,"score_gpt":0.34705964100154363,"score_spread":0.3050434766713087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243521236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858562,0.0045608995,0.0000729562,0.007994544,0.00020714501,0.0007895948,0.00007326199,0.000007997081,0.0004374101],"genre_scores_gemma":[0.99889076,0.0003497341,0.000053138097,0.00027682784,0.00014008653,0.000019135658,0.000017367534,0.000015203267,0.00023772428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989553,0.00017376107,0.00024380165,0.00011129697,0.00027847404,0.00023737493],"domain_scores_gemma":[0.99818045,0.00020173642,0.00030069065,0.00017208852,0.0009730834,0.00017197218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074406056,0.000113026916,0.00033807333,0.00006187995,0.000055075358,0.000006012154,0.00012071292,0.00005423444,0.0000115476005],"category_scores_gemma":[0.00014810487,0.0000527955,0.000057250494,0.00011615763,0.0002138872,0.000086398104,0.00002594088,0.00024027363,0.000002325096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09470845,0.00037434942,0.88668,0.000046236368,0.00045771245,0.000031721276,0.0010635307,0.000027546002,0.00023211689,0.000009045592,0.009486977,0.006882305],"study_design_scores_gemma":[0.046143863,0.026495267,0.8811732,0.000099853154,0.00033649165,0.0003174426,0.0008191479,0.0000845115,0.0026212796,0.0013687146,0.040284164,0.0002560833],"about_ca_topic_score_codex":0.00014829918,"about_ca_topic_score_gemma":0.000037603128,"teacher_disagreement_score":0.04856459,"about_ca_system_score_codex":0.00020410368,"about_ca_system_score_gemma":0.00080268085,"threshold_uncertainty_score":0.21529381},"labels":[],"label_agreement":null},{"id":"W4243551237","doi":"10.1111/j.1525-1497.2006.00506_1.x","title":"Disseminated intravascular coogulation as the presenting sign of metastatic prostate cancer","year":2006,"lang":"en","type":"article","venue":"Journal of General Internal Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Disseminated intravascular coagulation; Prostate cancer; Sepsis; Differential diagnosis; Etiology; Cancer; Prostate; Internal medicine; Pathology","score_opus":0.02216132639647258,"score_gpt":0.3575336349584125,"score_spread":0.33537230856193995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243551237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799436,0.009619486,0.0002607747,0.007994496,0.00037608587,0.00034467634,0.0000044179887,0.000006026653,0.0014504809],"genre_scores_gemma":[0.98507017,0.0010893001,0.00017772437,0.0001398035,0.0010615304,0.000009076827,0.000012524416,0.000018737168,0.012421156],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99799544,0.000108309745,0.0007653812,0.00011495707,0.00079476536,0.00022117491],"domain_scores_gemma":[0.9983619,0.000119912314,0.00056917605,0.00014345003,0.00069434586,0.00011124743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069614436,0.00014452211,0.0004636174,0.00020201894,0.00005057551,0.000012780804,0.00015229496,0.00003275279,0.00032951738],"category_scores_gemma":[0.00018504001,0.00006862814,0.0001446173,0.00026350917,0.00024399247,0.00010431289,0.000030042682,0.00031435056,0.0000020560658],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049217707,0.00060620316,0.11779121,0.00059517205,0.0025376468,0.0015902744,0.0031461057,0.0016778281,0.7917462,0.00043994887,0.0438817,0.031065958],"study_design_scores_gemma":[0.020973878,0.007233656,0.33345148,0.0064670397,0.003293831,0.0031777914,0.0018734303,0.008940145,0.5917386,0.004027707,0.018435244,0.0003872312],"about_ca_topic_score_codex":0.0022302198,"about_ca_topic_score_gemma":0.000027070919,"teacher_disagreement_score":0.21566027,"about_ca_system_score_codex":0.00011816434,"about_ca_system_score_gemma":0.00015791063,"threshold_uncertainty_score":0.36079842},"labels":[],"label_agreement":null},{"id":"W4243656983","doi":"10.1016/j.ijrobp.2020.07.836","title":"Patient Reported Outcomes in NRG Oncology/RTOG 0938, a Randomized Phase II Study Evaluating 2 Ultrahypofractionated Regimens (UHR) for Prostate Cancer (CaP)","year":2020,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grand River Hospital; Juravinski Cancer Centre; Centre Hospitalier de l’Université de Montréal; McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; EPIC; Cumulative incidence; Oncology; Quality of life (healthcare); Toxicity; Cancer; Colorectal cancer; Clinical endpoint; Randomized controlled trial; Cohort","score_opus":0.0728536635058466,"score_gpt":0.455575357103364,"score_spread":0.3827216935975174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243656983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9684167,0.0007103402,0.00080297684,0.024766438,0.0015988577,0.003345709,0.00013003044,0.000047051264,0.00018191709],"genre_scores_gemma":[0.99396664,0.0007856666,0.0016183063,0.0016885678,0.00094678457,0.00056587806,0.00023448268,0.000041328218,0.00015234841],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961949,0.0007074627,0.0017318268,0.00043463852,0.0005690094,0.00036219132],"domain_scores_gemma":[0.99415934,0.0013529703,0.0021584043,0.0001532633,0.0019425713,0.00023344105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017540312,0.00029337857,0.0013523746,0.00028172942,0.0001441019,0.000026250653,0.00023277375,0.00022369694,0.00008914386],"category_scores_gemma":[0.00287788,0.00021993669,0.0004053487,0.00033088113,0.00020438802,0.00028180773,0.000076397,0.0007048757,0.0000055205687],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26246917,0.010707413,0.27751774,0.000040390383,0.007544949,0.00056597346,0.016029231,0.0019527372,0.019160641,0.0002689647,0.0020487434,0.40169403],"study_design_scores_gemma":[0.893314,0.04662233,0.008496886,0.00017218757,0.0014016889,0.00018119371,0.002499962,0.02201482,0.005192811,0.0030944727,0.016531918,0.0004777171],"about_ca_topic_score_codex":0.00010678419,"about_ca_topic_score_gemma":0.000016990882,"teacher_disagreement_score":0.63084483,"about_ca_system_score_codex":0.001857562,"about_ca_system_score_gemma":0.002158554,"threshold_uncertainty_score":0.8968758},"labels":[],"label_agreement":null},{"id":"W4243844195","doi":"10.1097/01.ju.0000555569.70342.60","title":"PD17-09 PROSTATE-SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) IN HIGH-RISK NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) SPARTAN-LIKE PATIENTS (PTS) NEGATIVE BY CONVENTIONAL IMAGING","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Positron emission tomography; Prostate; Cancer; Castration; Oncology; Urology; Internal medicine; Nuclear medicine; Hormone","score_opus":0.00876858456905807,"score_gpt":0.26438336463728473,"score_spread":0.2556147800682267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243844195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905497,0.0045234486,0.000019320873,0.0030475666,0.000426884,0.001154256,0.00016869156,0.000010134761,0.00010002693],"genre_scores_gemma":[0.9938876,0.0049062446,0.00013815993,0.0001874509,0.0000741245,0.000024062336,0.00010314277,0.00003444445,0.000644747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972721,0.0004936515,0.00076141726,0.0002757531,0.0006661383,0.0005309947],"domain_scores_gemma":[0.99817103,0.00027489857,0.0006874395,0.0002316446,0.00044387198,0.00019111375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008416666,0.00026341822,0.00053888536,0.0003547207,0.00015035052,0.000033543434,0.00019987953,0.000056197943,0.00038144525],"category_scores_gemma":[0.000037866314,0.00016403267,0.00014161285,0.0004108932,0.00024178078,0.0002556631,0.000049952218,0.00069158047,0.000024965893],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022433758,0.0009809808,0.8417353,0.00013673058,0.0005878759,0.00031388542,0.0023960692,0.00047620188,0.12268946,0.000022584436,0.0046053706,0.0036217787],"study_design_scores_gemma":[0.03981803,0.0074842107,0.9072485,0.0005639216,0.00071875425,0.0003623318,0.0012528627,0.00084215566,0.03274899,0.0010397147,0.0073639383,0.0005566068],"about_ca_topic_score_codex":0.00039660168,"about_ca_topic_score_gemma":0.00006452936,"teacher_disagreement_score":0.08994047,"about_ca_system_score_codex":0.00023713731,"about_ca_system_score_gemma":0.00033070552,"threshold_uncertainty_score":0.6689058},"labels":[],"label_agreement":null},{"id":"W4244259592","doi":"10.1200/jco.2008.17.2494","title":"In Reply","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine","score_opus":0.3099601706094736,"score_gpt":0.5751988046111001,"score_spread":0.26523863400162645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244259592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9520434,0.00085563044,0.000007174629,0.032809343,0.0006317942,0.00007725887,2.810923e-7,0.000002425073,0.013572676],"genre_scores_gemma":[0.982807,0.0043907627,0.0013583159,0.0057486286,0.001052962,0.0000013179648,4.159192e-7,0.0000059154336,0.004634715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826765,0.00015818028,0.0011435365,0.00007675294,0.00021633545,0.00013751545],"domain_scores_gemma":[0.99837655,0.00075347145,0.0003733222,0.00008994643,0.00019039615,0.00021631163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001713207,0.000044405017,0.00069992844,0.00010744346,0.000015362511,9.715803e-7,0.00006393316,0.00013146111,0.00021214907],"category_scores_gemma":[0.0019789075,0.000026662814,0.0002105632,0.00011283706,0.00017226004,0.00006679519,0.000018676514,0.0007141681,0.000036103098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0116578415,0.0030067402,0.78086036,0.000018368455,0.00020354771,0.033309717,0.000233806,0.0000027245737,0.000181565,0.0000809345,0.1057878,0.064656585],"study_design_scores_gemma":[0.011860042,0.010165168,0.57402104,0.000038541188,0.00003405225,0.0021270844,0.000036126174,0.000010840896,0.00016601682,0.00039837506,0.40111095,0.00003175209],"about_ca_topic_score_codex":0.00001486085,"about_ca_topic_score_gemma":0.0000060903362,"teacher_disagreement_score":0.29532316,"about_ca_system_score_codex":0.0001235908,"about_ca_system_score_gemma":0.0019437044,"threshold_uncertainty_score":0.34480482},"labels":[],"label_agreement":null},{"id":"W4244355447","doi":"10.1200/jco.2015.33.7_suppl.24","title":"A novel biomarker signature to predict aggressive disease in African-American men with prostate cancer.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; GSTP1; Internal medicine; Biomarker; Oncology; TMPRSS2; Logistic regression; Cohort; Cancer; Gastroenterology; Disease; Genotype; Biology; Gene; Genetics; Coronavirus disease 2019 (COVID-19)","score_opus":0.11713033371959268,"score_gpt":0.48747712595161774,"score_spread":0.37034679223202505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244355447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92872345,0.0028495246,0.00006828601,0.0635604,0.00035822266,0.00087854866,0.00004979171,0.000011345866,0.0035004516],"genre_scores_gemma":[0.9938361,0.0010637537,0.0016047617,0.0014812024,0.00053599564,0.000056505494,0.000005494409,0.000022419155,0.0013937331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973925,0.00024603723,0.0010636444,0.00025779556,0.00065836083,0.00038171367],"domain_scores_gemma":[0.9955163,0.0005732896,0.0011904511,0.0001816712,0.000774913,0.0017633874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016539297,0.00016294689,0.0011587829,0.0002498478,0.000021923554,0.000011068922,0.00017570295,0.00013073551,0.00003606329],"category_scores_gemma":[0.0025845333,0.00008980998,0.00016298975,0.0005723238,0.00040062654,0.00010208299,0.000070001086,0.0008798939,0.000007606226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16516104,0.0031016779,0.6567502,0.000037749698,0.0006843257,0.0089535955,0.00097236375,0.00027136115,0.00021429025,0.000006193721,0.026741004,0.13710617],"study_design_scores_gemma":[0.027796337,0.028981874,0.8818787,0.0006501922,0.00035989666,0.00015414278,0.00095495186,0.00037849334,0.000046560555,0.00008600858,0.058544036,0.00016883355],"about_ca_topic_score_codex":0.00024683826,"about_ca_topic_score_gemma":0.00018803832,"teacher_disagreement_score":0.22512844,"about_ca_system_score_codex":0.00058769214,"about_ca_system_score_gemma":0.0077259387,"threshold_uncertainty_score":0.99789935},"labels":[],"label_agreement":null},{"id":"W4244585987","doi":"10.1200/jco.2007.25.18_suppl.5005","title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of the TAX 327 study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; Mitoxantrone; Prednisone; Prostate cancer; Internal medicine; Oncology; Cancer; Survival analysis; Chemotherapy","score_opus":0.14606775055517018,"score_gpt":0.5181732919384646,"score_spread":0.37210554138329444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244585987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98294854,0.002105372,0.0002625239,0.008044691,0.002850256,0.003288954,0.00009740345,0.000016349004,0.00038589316],"genre_scores_gemma":[0.9850521,0.0020780207,0.0018503504,0.0003353286,0.0012927633,0.000069179274,0.000010456379,0.000045973076,0.009265842],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9942971,0.0005024244,0.003242227,0.00036237863,0.00092978886,0.0006660646],"domain_scores_gemma":[0.9925581,0.0025176995,0.0025810846,0.00042626006,0.0014322483,0.00048459473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060948697,0.00026933895,0.0024009696,0.00015943848,0.00013404328,0.000012493817,0.00044965695,0.00035029682,0.00013715005],"category_scores_gemma":[0.0027191718,0.00013688365,0.000615094,0.0004601051,0.00051046774,0.00015148205,0.00015960832,0.0010997547,0.0000031757074],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5195846,0.014612135,0.22543956,0.00043155148,0.005441083,0.0012724708,0.0024130917,0.0005041057,0.0049140146,0.000059817437,0.0144720115,0.21085557],"study_design_scores_gemma":[0.26828793,0.114682406,0.48598734,0.0006907262,0.0032937513,0.00028133445,0.006150889,0.00056588714,0.007097386,0.00028361098,0.11220323,0.00047552318],"about_ca_topic_score_codex":0.0001033246,"about_ca_topic_score_gemma":0.0010456092,"teacher_disagreement_score":0.26054776,"about_ca_system_score_codex":0.0007922695,"about_ca_system_score_gemma":0.0070803207,"threshold_uncertainty_score":0.9985486},"labels":[],"label_agreement":null},{"id":"W4244842137","doi":"10.1016/j.eururo.2020.03.012","title":"Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77: 508–47 https://doi.org/10.1016/j.eururo.2020.01.012","year":2020,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Cancer; Management of prostate cancer; Gynecology; Urology; Radiology; Internal medicine","score_opus":0.01632491710633048,"score_gpt":0.2792461981090559,"score_spread":0.2629212810027254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244842137","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07619202,0.013524817,0.000007867124,0.85096115,0.0016823441,0.010928562,0.0030625248,0.00032182087,0.043318905],"genre_scores_gemma":[0.13744797,0.04057839,0.0011118464,0.35147917,0.0017412486,0.002123532,0.00891256,0.0016805758,0.4549247],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9913102,0.0012891699,0.0018907507,0.0022335788,0.0017632999,0.0015130184],"domain_scores_gemma":[0.99345046,0.00023545786,0.0023910603,0.0019991938,0.0015512771,0.00037256806],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00058988336,0.0012899452,0.0020623913,0.00022068595,0.0002265894,0.00004077686,0.0009991507,0.00029918272,0.0028118696],"category_scores_gemma":[0.0001900297,0.00089941255,0.0004259018,0.00088343193,0.0013824635,0.00013666114,0.0009840019,0.003446212,0.0003949432],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010258858,0.00037827156,0.011568791,0.0021424773,0.0022814607,0.017740618,0.00063044176,0.00024110581,0.00054283364,0.0000059326317,0.9470367,0.0071725147],"study_design_scores_gemma":[0.010534759,0.0026189066,0.027408127,0.0010987583,0.0011216884,0.000059557668,0.00010143944,0.000024944355,0.0006612902,0.000013518344,0.9555471,0.0008099149],"about_ca_topic_score_codex":0.00012962382,"about_ca_topic_score_gemma":0.000034591794,"teacher_disagreement_score":0.49948198,"about_ca_system_score_codex":0.0003025906,"about_ca_system_score_gemma":0.0011320766,"threshold_uncertainty_score":0.9999852},"labels":[],"label_agreement":null},{"id":"W4245222417","doi":"10.5489/cuaj.609","title":"Emerging novel therapies in the treatment of castrate-resistant prostate cancer","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Denosumab; Docetaxel; Cabazitaxel; Prostate cancer; Hormonal therapy; Oncology; Ipilimumab; Combination therapy; Internal medicine; Enzalutamide; Nivolumab; Pharmacology; Cancer; Immunotherapy; Androgen deprivation therapy; Androgen receptor; Osteoporosis","score_opus":0.02888160460853816,"score_gpt":0.29416733952495266,"score_spread":0.2652857349164145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245222417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94244266,0.002145178,0.0000013783942,0.05424,0.00007556722,0.00043402918,0.00003302281,0.0000041406365,0.0006240284],"genre_scores_gemma":[0.9963881,0.0018508842,0.000041171475,0.00066684006,0.00013003126,0.00009139188,0.000008714764,0.0000061589367,0.0008167355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988928,0.00009053645,0.000243193,0.00010426336,0.00027712947,0.00039211896],"domain_scores_gemma":[0.99930125,0.000088379464,0.00012833031,0.000072413444,0.00019785602,0.0002117694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027784175,0.0000978559,0.00019646481,0.0001333934,0.00012990822,0.000056230576,0.00007350667,0.000079252444,0.0005981911],"category_scores_gemma":[0.000046055255,0.000049735496,0.0000835896,0.00021958028,0.000038477858,0.00006624649,0.0000024086057,0.00020059606,0.000010107583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014655513,0.00030960434,0.97329354,0.0000072681855,0.00022129584,0.00009434696,0.0042216005,0.000041885392,0.0036291892,0.000075276774,0.0017009599,0.01625849],"study_design_scores_gemma":[0.002109843,0.0009605918,0.96748906,0.00001736326,0.0000372469,0.000026326978,0.0011778305,0.00007599682,0.00014664658,0.00026202458,0.027634496,0.00006256746],"about_ca_topic_score_codex":0.018412894,"about_ca_topic_score_gemma":0.005582753,"teacher_disagreement_score":0.05394542,"about_ca_system_score_codex":0.0012332753,"about_ca_system_score_gemma":0.00053418835,"threshold_uncertainty_score":0.9881236},"labels":[],"label_agreement":null},{"id":"W4245270013","doi":"10.1016/j.urology.2011.07.1002","title":"UP-02.184 Urinary PCA3 and Cancer Progression Under Active Surveillance of Prostate Cancer","year":2011,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Cancer; PCA3; Oncology; Biomarker; Retrospective cohort study; Prostate; Urinary system; Internal medicine; Cohort; Gynecology; Urology","score_opus":0.04749350058890857,"score_gpt":0.36337857303548887,"score_spread":0.3158850724465803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245270013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830251,0.012236037,0.000006891687,0.001986006,0.00024870972,0.0005763797,0.00005382548,0.000030194273,0.0018368892],"genre_scores_gemma":[0.9910814,0.006228851,0.000038192935,0.00018730415,0.00006462676,0.00021445402,0.000016143471,0.000020272382,0.002148752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990315,0.000068021,0.00015120924,0.00028403755,0.0001443518,0.0003208744],"domain_scores_gemma":[0.9994474,0.000041090207,0.00008854856,0.00016814572,0.00013997828,0.000114830604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000090371526,0.00013140049,0.00028427536,0.00008924638,0.00005041937,0.0000025334969,0.000057258323,0.00010819276,0.0005046647],"category_scores_gemma":[0.000013324307,0.00009076306,0.00003393526,0.00012732798,0.00034071392,0.000052451065,0.00007636085,0.00018168095,0.0000072898138],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012698126,0.00052013696,0.8561308,0.00031118045,0.0004540551,0.00017766244,0.0040794187,0.000008332883,0.0071780337,0.00017272541,0.0012414955,0.11702803],"study_design_scores_gemma":[0.0069184713,0.0041676788,0.9410283,0.00012245275,0.00015291292,0.000111126006,0.0003277056,0.00021475452,0.038011275,0.00089113676,0.0077859545,0.00026824573],"about_ca_topic_score_codex":0.00077085156,"about_ca_topic_score_gemma":0.00011694899,"teacher_disagreement_score":0.116759785,"about_ca_system_score_codex":0.00006637049,"about_ca_system_score_gemma":0.00023718755,"threshold_uncertainty_score":0.5525725},"labels":[],"label_agreement":null},{"id":"W4245577852","doi":"10.1200/jco.2012.30.18_suppl.4","title":"Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prostate Cancer Canada","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Bicalutamide; Goserelin; Urology; Oncology; Androgen deprivation therapy; Antiandrogen; Hazard ratio; Castration; Cancer; Androgen receptor; Hormone; Confidence interval","score_opus":0.1729421620923322,"score_gpt":0.5120540794502855,"score_spread":0.33911191735795326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245577852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934441,0.0006219124,0.00001915737,0.0018422384,0.0024052695,0.0009373596,0.00009690278,0.000006126306,0.0006269585],"genre_scores_gemma":[0.99453074,0.0035924108,0.0005045685,0.0002226187,0.0007945776,0.000026524505,0.0001027949,0.00001852907,0.00020721905],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952964,0.00063657673,0.0028317615,0.00022820351,0.00064854755,0.00035846536],"domain_scores_gemma":[0.99487585,0.0011759815,0.0021985276,0.00018254592,0.0011285009,0.00043860672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037216102,0.00017376206,0.0013245204,0.00029559268,0.000027542967,0.000010232351,0.00016661161,0.00019182524,0.00004613736],"category_scores_gemma":[0.0034070897,0.000120640965,0.00029177617,0.00018968443,0.00022315986,0.00044417073,0.00007833581,0.00072656514,0.00000547742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68147695,0.011973097,0.03601251,0.000019378656,0.0010948738,0.0002743037,0.0013385097,0.0000066521484,0.00042971558,0.000013358064,0.0013057294,0.26605493],"study_design_scores_gemma":[0.7445533,0.057390727,0.18490441,0.00022063473,0.00064184755,0.00004205645,0.0008200637,0.00019787595,0.0015401971,0.000048629856,0.009474208,0.00016602082],"about_ca_topic_score_codex":0.00015738637,"about_ca_topic_score_gemma":0.00007980786,"teacher_disagreement_score":0.2658889,"about_ca_system_score_codex":0.0005476855,"about_ca_system_score_gemma":0.0009862907,"threshold_uncertainty_score":0.49195957},"labels":[],"label_agreement":null},{"id":"W4246021409","doi":"10.1200/jco.2017.35.6_suppl.72","title":"The diverse genomic landscape of low-risk prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Quartile; Oncology; Cancer; Prostate; Internal medicine; Androgen receptor; Confidence interval","score_opus":0.1336281857188823,"score_gpt":0.5127946063853154,"score_spread":0.3791664206664331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246021409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818192,0.0031433827,0.0000021297556,0.01053718,0.0012694807,0.0001959614,0.000014037686,0.000002377835,0.003016212],"genre_scores_gemma":[0.9506743,0.045627926,0.00014770543,0.00014039122,0.00093707244,0.0000040729524,7.3337765e-7,0.000008616933,0.002459197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980343,0.00020019001,0.0011739171,0.0001032113,0.00027913612,0.00020924583],"domain_scores_gemma":[0.995152,0.0013058697,0.0025311073,0.00031359267,0.00046095852,0.0002364781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030190751,0.00007763516,0.0007513545,0.00004006958,0.00024810125,0.00001840891,0.0003246542,0.0001478453,0.0000952421],"category_scores_gemma":[0.0032617233,0.000036948117,0.00034097256,0.000029538043,0.00059254083,0.00007554537,0.00011668096,0.0007319187,0.00001325031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009001829,0.00037340008,0.7142208,0.000027047803,0.0005253211,0.00030758212,0.000119041215,0.0000065675977,0.00017733825,0.000023390454,0.0068340986,0.26838356],"study_design_scores_gemma":[0.011302043,0.006229298,0.8992973,0.00011089976,0.00032043623,0.000041664618,0.00021714385,0.000068154084,0.00027509147,0.00034747328,0.081743754,0.00004675737],"about_ca_topic_score_codex":0.000092448136,"about_ca_topic_score_gemma":0.00012737606,"teacher_disagreement_score":0.2683368,"about_ca_system_score_codex":0.00009148652,"about_ca_system_score_gemma":0.0020436114,"threshold_uncertainty_score":0.3904823},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W4246518733","doi":"10.1002/(sici)1097-0215(20000101)85:1<60::aid-ijc11>3.3.co;2-2","title":"International trends and patterns of prostate cancer incidence and mortality","year":2000,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Incidence (geometry); Prostate cancer; Demography; Medicine; Mortality rate; Developed country; Westernization; Cancer; China; Environmental health; Population; Geography; Internal medicine; Economic growth","score_opus":0.026224785538255115,"score_gpt":0.40652687657235026,"score_spread":0.3803020910340951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246518733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98724735,0.004827386,0.000007975936,0.006219548,0.0004174578,0.000060983548,0.00014248496,0.0000037253014,0.0010730658],"genre_scores_gemma":[0.95956975,0.037217233,0.0000672759,0.0001886718,0.00039460484,0.000011006993,0.000007446663,0.000008482142,0.0025355383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987883,0.000017436907,0.00033600483,0.00012100976,0.00062984857,0.00010738761],"domain_scores_gemma":[0.9990882,0.000027498414,0.00019284483,0.000059310114,0.0005238007,0.00010831486],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014679103,0.000091445785,0.00020371759,0.00019956405,0.000018008986,0.000028443552,0.00013013797,0.000034877998,0.002514112],"category_scores_gemma":[0.000015183058,0.0000667959,0.000061021507,0.00006663158,0.0000990071,0.00022207301,0.000036300302,0.00015077832,6.514517e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008627512,0.000059165955,0.6914291,0.00002216089,0.0006229972,0.00010350752,0.00038273857,0.000020934025,0.0013272985,0.0000213613,0.00020780858,0.30494016],"study_design_scores_gemma":[0.0031374064,0.00017418106,0.976972,0.00050221314,0.000114253366,0.00017645446,0.000055829078,0.0001445143,0.0045742225,0.00012959466,0.013946288,0.00007303582],"about_ca_topic_score_codex":0.0007052573,"about_ca_topic_score_gemma":0.00012831313,"teacher_disagreement_score":0.30486715,"about_ca_system_score_codex":0.00014797637,"about_ca_system_score_gemma":0.00016187518,"threshold_uncertainty_score":0.9983977},"labels":[],"label_agreement":null},{"id":"W4246701592","doi":"10.1200/jco.2020.38.15_suppl.tps5596","title":"A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Sherbrooke; Jewish General Hospital; Université Laval; St Joseph's Health Care","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Internal medicine; Cancer; Androgen receptor","score_opus":0.08489063859828656,"score_gpt":0.4675145738132983,"score_spread":0.38262393521501176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246701592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97675127,0.0076656262,0.000010167033,0.0067707216,0.000484682,0.008187864,0.000078574034,0.000014689318,0.00003641761],"genre_scores_gemma":[0.9903456,0.0074747535,0.00061560475,0.00090499065,0.0002722829,0.00022583664,0.000039452676,0.000043829008,0.000077678116],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9902475,0.002696636,0.0050594714,0.00050575775,0.0009594986,0.0005311626],"domain_scores_gemma":[0.99119735,0.0031818755,0.0032005012,0.00022393005,0.0014197481,0.0007765869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005188732,0.0004228901,0.0055327713,0.00029118915,0.0001434757,0.00003265348,0.00022125065,0.00019619988,0.000110764755],"category_scores_gemma":[0.0053477017,0.00024413712,0.00061052426,0.00035046664,0.0006419176,0.00024390443,0.00009687191,0.0010821053,0.0000017203251],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8804176,0.013781619,0.036328528,0.00013493186,0.00275502,0.0008255802,0.0042566513,0.00007528574,0.005680191,0.0000021420713,0.00013630568,0.055606138],"study_design_scores_gemma":[0.8818556,0.07121508,0.04133703,0.0005185717,0.0012450872,0.000021334312,0.0007318127,0.0010876507,0.001360258,0.000014756329,0.00041554007,0.00019728119],"about_ca_topic_score_codex":0.0001967149,"about_ca_topic_score_gemma":0.00019039473,"teacher_disagreement_score":0.05743346,"about_ca_system_score_codex":0.0003954813,"about_ca_system_score_gemma":0.0028774103,"threshold_uncertainty_score":0.99556226},"labels":[],"label_agreement":null},{"id":"W4247519426","doi":"10.1200/jco.2004.22.14_suppl.4508","title":"Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: Phase 3 study","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Abbott (Canada)","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Refractory (planetary science); Internal medicine; Cancer; Prostate; Disease; Cancer research; Biology","score_opus":0.08309949456012075,"score_gpt":0.5086345688209617,"score_spread":0.4255350742608409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247519426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918413,0.0044046547,0.0000031930947,0.0021872297,0.00008157036,0.0013776749,0.00000626168,0.000004525634,0.0000935821],"genre_scores_gemma":[0.9917096,0.007670143,0.00029944666,0.00013626405,0.00009413365,0.000046829184,0.000002781979,0.000011089313,0.00002973759],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976124,0.0005199985,0.001032986,0.00021289637,0.0003981178,0.00022358276],"domain_scores_gemma":[0.99734664,0.0012020326,0.0007087423,0.000100112804,0.00014371885,0.0004987693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014486167,0.00014333276,0.0010698385,0.0001601691,0.000026800462,0.0000048779975,0.00007293322,0.00008454732,0.00000955337],"category_scores_gemma":[0.00075349223,0.00007010199,0.00012110889,0.00015853251,0.00036079148,0.00007368155,0.00003178095,0.0006323866,7.14905e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29400435,0.037137948,0.42089444,0.00020594806,0.0008475928,0.0147189135,0.0004408907,0.00002049169,0.00091361,0.000009733872,0.0001545744,0.2306515],"study_design_scores_gemma":[0.09157045,0.15761277,0.7487476,0.0005039801,0.00045092378,0.000030954943,0.0003926345,0.000012468045,0.00022120817,0.000116740004,0.0002680615,0.00007223577],"about_ca_topic_score_codex":0.000030019859,"about_ca_topic_score_gemma":0.00001613838,"teacher_disagreement_score":0.3278531,"about_ca_system_score_codex":0.00024222737,"about_ca_system_score_gemma":0.0014788382,"threshold_uncertainty_score":0.2858676},"labels":[],"label_agreement":null},{"id":"W4247642466","doi":"10.5489/cuaj.949","title":"Guidelines for the management of castrate-resistant prostate cancer","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Prostate; Management of prostate cancer; Medicine; Cancer; Internal medicine","score_opus":0.06102732398207741,"score_gpt":0.34034975969219766,"score_spread":0.2793224357101203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247642466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55457675,0.0063557844,0.000090751695,0.4336283,0.0005046123,0.0023671887,0.00018449096,0.000018395665,0.0022737416],"genre_scores_gemma":[0.98321164,0.002339296,0.0007864216,0.0026128627,0.00031512344,0.00027993473,0.000014387356,0.000011476042,0.010428888],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9989385,0.000030778745,0.00029034328,0.000101568876,0.0002696023,0.00036919423],"domain_scores_gemma":[0.99829644,0.000080777536,0.00015732922,0.00007709997,0.00109173,0.00029662153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044913602,0.000080960104,0.000153833,0.000061084414,0.00021135839,0.000053573243,0.00009389153,0.00006967474,0.0006686914],"category_scores_gemma":[0.00010353605,0.000042256226,0.00010121822,0.00013048976,0.00003463981,0.00004990581,0.000009555548,0.00017320005,0.000013226871],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008178615,0.0001435098,0.4098911,0.0001905929,0.0032544772,0.00015138388,0.00037622105,0.0003914579,0.0018631968,0.0011921475,0.4538961,0.12783195],"study_design_scores_gemma":[0.0030016624,0.0005660939,0.8038938,0.00008284096,0.00032084674,0.000027846812,0.0006640764,0.0007189663,0.000247191,0.0016828392,0.18867022,0.00012363859],"about_ca_topic_score_codex":0.003611446,"about_ca_topic_score_gemma":0.0005722817,"teacher_disagreement_score":0.4310154,"about_ca_system_score_codex":0.0005915048,"about_ca_system_score_gemma":0.00039023548,"threshold_uncertainty_score":0.7321702},"labels":[],"label_agreement":null},{"id":"W4247695466","doi":"10.33790/jcrc1100103","title":"Utility of111In-octreotide for the Characterization of an Extra-axial Lesion with uptake of 18F-choline PET-CT in a Patient with Adenocarcinoma of the Prostate","year":2020,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate adenocarcinoma; Adenocarcinoma; Octreotide; Medicine; Lesion; Prostate cancer; Prostate; PET-CT; Radiology; Choline; Nuclear medicine; Positron emission tomography; Internal medicine; Pathology; Cancer; Somatostatin","score_opus":0.04432107178141635,"score_gpt":0.28871239475110877,"score_spread":0.2443913229696924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247695466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520266,0.00007649182,0.00013741571,0.0019844675,0.000014880646,0.0023641086,0.00011042466,0.000008305393,0.00010121759],"genre_scores_gemma":[0.9992685,0.00004251523,0.00028024992,0.00008454286,0.000018355828,0.00005802131,0.00008936793,0.0000153898,0.0001431057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887395,0.000054156873,0.00034803603,0.00020659906,0.00035488294,0.00016234806],"domain_scores_gemma":[0.9991974,0.000048189428,0.0001920191,0.00028184825,0.00021521268,0.000065284476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015569486,0.000118666445,0.00028225788,0.000040377265,0.000037225,0.0000045102224,0.00010349191,0.000009101066,0.000035203473],"category_scores_gemma":[0.000037222995,0.000047993584,0.000053504064,0.0003172457,0.00018261901,0.00007777952,0.000033284192,0.000107986896,1.6407608e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051881656,0.0019669884,0.6245286,0.0019125608,0.00031964845,0.00019501067,0.0065708994,0.00007615873,0.2676959,0.0001479351,0.000036601563,0.044668056],"study_design_scores_gemma":[0.0050103567,0.0043869056,0.67635536,0.00021296513,0.00010344907,0.0000464985,0.00089139,0.0035799928,0.30919382,0.000007646913,0.00014639516,0.000065181004],"about_ca_topic_score_codex":0.00015545762,"about_ca_topic_score_gemma":0.00013604529,"teacher_disagreement_score":0.05182681,"about_ca_system_score_codex":0.000023279981,"about_ca_system_score_gemma":0.00026612103,"threshold_uncertainty_score":0.19571215},"labels":[],"label_agreement":null},{"id":"W4247793704","doi":"10.3410/f.13450964.14826065","title":"Faculty Opinions recommendation of MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model.","year":2012,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Prostate cancer; Prostate; Cancer; Medicine; Contrast (vision); Cancer imaging; Medical physics; Oncology; Internal medicine; Computer science; Artificial intelligence","score_opus":0.030807448631231377,"score_gpt":0.371404334080362,"score_spread":0.34059688544913064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247793704","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013988896,0.009454822,0.000014828819,0.10243014,0.00019636205,0.0042379657,0.883484,0.000023390206,0.000018593819],"genre_scores_gemma":[0.00060906797,0.0045063198,0.00042731277,0.0016177177,0.00008924601,0.0018951006,0.9892976,0.00004969658,0.0015079059],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952446,0.00031445595,0.00156609,0.0006795965,0.001588698,0.00060651294],"domain_scores_gemma":[0.9917155,0.00005320646,0.00142249,0.001044171,0.005371857,0.00039280852],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009069682,0.00058916956,0.0013437361,0.0005424052,0.000106226704,0.000051412764,0.0006187445,0.0003416429,0.00030234826],"category_scores_gemma":[0.00077867665,0.0003437939,0.00040162753,0.0018816836,0.00046589642,0.00031371234,0.00026526282,0.001063423,0.0000047577246],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028525118,0.0008177396,0.0014549926,0.016626865,0.000420373,0.0000029959606,0.00060228154,0.000006142678,0.00011200534,0.000025029316,0.9769222,0.002724087],"study_design_scores_gemma":[0.0034550524,0.0001931129,0.0025027508,0.023853833,0.00043379713,0.00002009442,0.00006670834,0.00015683602,0.00065138267,0.0000061400247,0.96832114,0.00033912322],"about_ca_topic_score_codex":0.00067330484,"about_ca_topic_score_gemma":0.000065322456,"teacher_disagreement_score":0.10581362,"about_ca_system_score_codex":0.00040540154,"about_ca_system_score_gemma":0.0019419653,"threshold_uncertainty_score":0.9999014},"labels":[],"label_agreement":null},{"id":"W4247879458","doi":"10.1200/jco.2017.35.15_suppl.lba3","title":"LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Androgen deprivation therapy; Prednisone; Internal medicine; Abiraterone; Oncology; Clinical trial; Family medicine; Cancer; Androgen receptor","score_opus":0.18564204016041563,"score_gpt":0.5032530866104884,"score_spread":0.31761104645007276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247879458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877079,0.0017134049,0.00023630643,0.004029013,0.0004732638,0.0056981123,0.000030521194,0.000009102936,0.00010235186],"genre_scores_gemma":[0.93872774,0.05743632,0.0023207564,0.00012254257,0.00044667377,0.00042525836,0.000018144856,0.000032627548,0.0004699157],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99441975,0.0011709878,0.0030117251,0.00032642542,0.0006817096,0.0003894151],"domain_scores_gemma":[0.99016863,0.0030100173,0.005355313,0.0004155848,0.00069330115,0.00035716745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069685816,0.00027746643,0.0037769505,0.00026141768,0.00013083128,0.000048009766,0.00032406524,0.00025500794,0.00007934757],"category_scores_gemma":[0.0019289178,0.00014233633,0.00039436077,0.00018594555,0.00080258976,0.00038258522,0.00006554482,0.0009757531,0.0000023257617],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89850956,0.0041672494,0.0046669506,0.000040817788,0.0028756578,0.0013306105,0.0009708041,0.00024577434,0.00018419985,0.000007790103,0.00018645341,0.08681415],"study_design_scores_gemma":[0.94306713,0.04901784,0.0039648144,0.00023526144,0.0011555462,0.000042985586,0.00012037675,0.0004260209,0.0010137436,0.00017694893,0.0006378891,0.00014143022],"about_ca_topic_score_codex":0.0013675047,"about_ca_topic_score_gemma":0.00083964074,"teacher_disagreement_score":0.086672716,"about_ca_system_score_codex":0.00031263675,"about_ca_system_score_gemma":0.005584161,"threshold_uncertainty_score":0.9906061},"labels":[],"label_agreement":null},{"id":"W4247927392","doi":"10.1016/j.urolonc.2016.12.021","title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Department of Medicine; Department of Biostatistics and Computational Biology; Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston; Johns Hopkins University, Baltimore; University of Wisconsin Carbone Cancer Center; School of Medicine and Public Health; Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Mayo Clinic, Rochester, MN; University Hospitals Case Medical Center, Seidman Cancer Center; Cleveland Clinic Taussig Cancer Institute; Both in Cleveland; University of Virginia Cancer Center, Charlottesville; Comprehensive Cancer Centers of Nevada, Las Vegas; Siteman Cancer Center, Washington University School of Medicine, St. Louis; NorthShore University Health System, Evanston, IL; University of Michigan Comprehensive Cancer Center, Ann Arbor; Rutgers Cancer Institute of New Jersey, New Brunswick.N Engl J Med. 2015 Aug 20;373(8):737-46. [Epub 2015 Aug 5]. doi: 10.1056/NEJMoa1503747.","year":2017,"lang":"en","type":"letter","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Docetaxel; Androgen deprivation therapy; Medicine; Prostate cancer; Hazard ratio; Urology; Internal medicine; Combination therapy; Cancer; Oncology; Confidence interval; Surgery","score_opus":0.05452041160486256,"score_gpt":0.33954735402472885,"score_spread":0.2850269424198663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247927392","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8198419,0.020003982,0.0000773056,0.065509655,0.0012614694,0.003926039,0.08924131,0.000057666828,0.00008067414],"genre_scores_gemma":[0.49585578,0.49673256,0.00048183676,0.0018808263,0.00032735846,0.000009014017,0.003889361,0.000109661545,0.00071358314],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9900342,0.0020675957,0.002114359,0.0022660745,0.0017363884,0.001781332],"domain_scores_gemma":[0.98777425,0.00054231216,0.0059118276,0.00087128696,0.0021367357,0.0027636047],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0010818108,0.0015578214,0.005288244,0.0025540183,0.0008302862,0.000018759343,0.0013274606,0.0012100734,0.0006783976],"category_scores_gemma":[0.00012327626,0.0015897257,0.0004438443,0.001954635,0.010250285,0.0010648457,0.0010326649,0.0021298965,8.5255215e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012143438,0.0015348097,0.87835056,0.0059033334,0.0064046546,0.0024781933,0.008180744,0.00058580964,0.00019335304,0.00006399675,0.081500955,0.0026601476],"study_design_scores_gemma":[0.10163409,0.0040914626,0.23855428,0.02963991,0.003719347,0.00017684608,0.024426218,0.0009910341,0.00014998313,0.000009740352,0.59453005,0.0020770316],"about_ca_topic_score_codex":0.75491846,"about_ca_topic_score_gemma":0.6164572,"teacher_disagreement_score":0.63979626,"about_ca_system_score_codex":0.008798728,"about_ca_system_score_gemma":0.02878894,"threshold_uncertainty_score":0.999717},"labels":[],"label_agreement":null},{"id":"W4248142486","doi":"10.1038/sj.modpathol.3800876","title":"Gynecologic","year":2006,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Centre Hospitalier de l’Université de Montréal; University of Ottawa","funders":"","keywords":"Medicine; Pathology","score_opus":0.023860478610086975,"score_gpt":0.30514330037495435,"score_spread":0.28128282176486735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248142486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9533015,0.0012133777,0.0008747595,0.0020018492,0.000084520674,0.0001901663,0.000004489905,0.00007698344,0.04225239],"genre_scores_gemma":[0.98440075,0.000041352083,0.0005337389,0.0003151531,0.00009960906,0.000035496498,0.000043421518,0.000009338427,0.014521119],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994031,0.000025091278,0.000085282896,0.00017547554,0.00007948745,0.00023151792],"domain_scores_gemma":[0.99973196,0.000023428005,0.000015457716,0.00015672142,0.000033827302,0.000038619793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007051949,0.000064790824,0.00013712278,0.000056014407,0.00004140338,0.0000040709447,0.00003539416,0.00007920206,0.00021348467],"category_scores_gemma":[0.000014320219,0.000045802703,0.000041097286,0.000055585704,0.0000822907,0.00001644174,0.000025770787,0.00009515356,0.00018170004],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008258898,0.001503017,0.60006124,0.00012004352,0.00008308732,0.014637468,0.00040073678,0.000094400086,0.25726655,0.0051288023,0.020014245,0.09986451],"study_design_scores_gemma":[0.0066320817,0.0014288168,0.89831424,0.000017645447,0.00009330743,0.0012197264,0.00003364011,0.0019354183,0.021040935,0.04812923,0.02089552,0.00025946822],"about_ca_topic_score_codex":0.000016273967,"about_ca_topic_score_gemma":0.000011459094,"teacher_disagreement_score":0.29825297,"about_ca_system_score_codex":0.000053229585,"about_ca_system_score_gemma":0.00004458368,"threshold_uncertainty_score":0.23375075},"labels":[],"label_agreement":null},{"id":"W4248204712","doi":"10.1016/s0360-3016(04)01537-8","title":"Prospective assessment of the relationship between traditional prognostic factors and novel biomarkers in prostate cancer patients treated with curative intent in a phase three randomized trial","year":2004,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Biomarker; Context (archaeology); Randomized controlled trial; Prospective cohort study; Prostate; Stage (stratigraphy); Androgen deprivation therapy; Prostate-specific antigen; Cancer","score_opus":0.06346847012592743,"score_gpt":0.3928104854258067,"score_spread":0.3293420152998793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248204712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945708,0.00009844627,0.00068521843,0.0018000262,0.00025161504,0.002327364,0.00021060611,0.000005560849,0.00005035409],"genre_scores_gemma":[0.99906874,0.0000727183,0.00032597242,0.000032124677,0.00014638837,0.00017511752,0.00016186562,0.000012905853,0.0000041723324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833256,0.00021924813,0.00073987193,0.00019058786,0.00035863012,0.00015910358],"domain_scores_gemma":[0.9972771,0.0011163049,0.0008793019,0.00006238495,0.00059516355,0.00006976718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000498095,0.00016921984,0.00060300634,0.0002597318,0.000045530247,0.000013128484,0.00012509908,0.00009897935,0.000006163126],"category_scores_gemma":[0.00062997045,0.00009526885,0.00012941874,0.00033126015,0.00045410058,0.00021907326,0.000025770232,0.00044105633,1.6604709e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10312172,0.0017904622,0.8892572,0.000008920045,0.00079800637,0.0000075928037,0.0007932125,0.0001352203,0.000116470146,0.0025874716,0.0000026970893,0.0013810291],"study_design_scores_gemma":[0.4006493,0.0019320133,0.592152,0.00018884787,0.00010732445,0.0000046391892,0.00005785057,0.00013869177,0.0002888795,0.004424022,0.0000027695355,0.000053625503],"about_ca_topic_score_codex":0.00015212181,"about_ca_topic_score_gemma":0.000079426056,"teacher_disagreement_score":0.29752758,"about_ca_system_score_codex":0.0017318762,"about_ca_system_score_gemma":0.0013061898,"threshold_uncertainty_score":0.45287958},"labels":[],"label_agreement":null},{"id":"W4248218407","doi":"10.1290/0508053.1","title":"MOLECULAR ANALYSIS AND CHARACTERIZATION OF PrEC, COMMERCIALLY AVAILABLE PROSTATE EPITHELIAL CELLS","year":2006,"lang":"en","type":"article","venue":"In Vitro Cellular & Developmental Biology - Animal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"Health Canada","keywords":"Chromogranin A; Cytokeratin; Western blot; Immunohistochemistry; Prostate; Androgen receptor; Prostate cancer; Biology; Prostate-specific antigen; Antigen; Blot; Molecular biology; PCA3; Cancer research; Pathology; Cancer; Medicine; Immunology; Gene","score_opus":0.010434569915994446,"score_gpt":0.2461459252415445,"score_spread":0.23571135532555004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248218407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979996,0.0003904851,0.00009068324,0.00014618968,0.00003699828,0.0004915507,0.0001212318,0.000018090936,0.00070517766],"genre_scores_gemma":[0.9959741,0.00015241624,0.0014551315,0.00005515414,0.000025544623,0.00003538737,0.0017274847,0.000015546837,0.0005592267],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872726,0.00008446366,0.00037938493,0.0003447368,0.00013505395,0.0003290812],"domain_scores_gemma":[0.9996434,0.000021761945,0.00010127532,0.000101787606,0.00006536228,0.000066424465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019973252,0.00017397164,0.00042776766,0.00035260414,0.000051970324,0.000011927721,0.00006980469,0.00013370004,0.00011324926],"category_scores_gemma":[0.0000056975623,0.00014934698,0.00009092387,0.0005008627,0.00020655687,0.000057489626,0.00008114841,0.00013225907,0.000022516497],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012009591,0.00019079258,0.15819865,0.000040346775,0.00023998105,0.00007698327,0.000110618064,3.9211253e-7,0.83908284,0.000019335988,0.000008543053,0.000830545],"study_design_scores_gemma":[0.0015067114,0.0002283811,0.110450186,0.000014098685,0.0001537159,0.0000061396704,0.000020547404,0.00008574586,0.8868625,0.000023014569,0.00052286795,0.00012609616],"about_ca_topic_score_codex":0.00033510308,"about_ca_topic_score_gemma":0.00002467077,"teacher_disagreement_score":0.04777965,"about_ca_system_score_codex":0.00011226681,"about_ca_system_score_gemma":0.00016498494,"threshold_uncertainty_score":0.60901934},"labels":[],"label_agreement":null},{"id":"W4248307030","doi":"10.1200/jco.2011.29.7_suppl.160","title":"Phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC).","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical endpoint; Temsirolimus; Docetaxel; Prostate cancer; Internal medicine; Oncology; Everolimus; Chemotherapy; Urology; Cancer; PI3K/AKT/mTOR pathway; Clinical trial; Discovery and development of mTOR inhibitors","score_opus":0.16229527574561708,"score_gpt":0.48872050039423237,"score_spread":0.3264252246486153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248307030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98889613,0.00089265016,0.0000094096895,0.008423497,0.00020927782,0.0013831728,0.000018856848,0.0000058504643,0.0001611432],"genre_scores_gemma":[0.9943346,0.002539104,0.00071822415,0.0009676824,0.0002299448,0.00012766897,8.747512e-7,0.000029085071,0.0010528252],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9964173,0.00046143375,0.0019718637,0.00028649913,0.00049870426,0.00036419957],"domain_scores_gemma":[0.9970456,0.00055049476,0.0009978999,0.000284252,0.0007467837,0.00037501808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002965275,0.00020656211,0.001368929,0.0002776478,0.000048169004,0.0000064652204,0.00017803136,0.00017000662,0.00025408127],"category_scores_gemma":[0.0003998828,0.00011575309,0.00017688115,0.000373773,0.00021632202,0.00011698731,0.000034507102,0.00066713936,0.0000027122046],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7750222,0.035732422,0.11164879,0.000033784443,0.00064008316,0.0033032515,0.0075065205,0.00002097319,0.0030471662,0.0000021311876,0.00041087254,0.062631786],"study_design_scores_gemma":[0.1317457,0.33899033,0.5151653,0.00035452022,0.000121411365,0.00007849835,0.0010171162,0.000015606196,0.0016184105,0.000050841994,0.0106965145,0.00014575716],"about_ca_topic_score_codex":0.00037349717,"about_ca_topic_score_gemma":0.002206543,"teacher_disagreement_score":0.6432765,"about_ca_system_score_codex":0.00026216562,"about_ca_system_score_gemma":0.0019804891,"threshold_uncertainty_score":0.47202742},"labels":[],"label_agreement":null},{"id":"W4248435625","doi":"10.5489/cuaj.1414","title":"Podium Session 1: Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Session (web analytics); Medicine; Cancer; Prostate cancer; Prostate; Gynecology; Internal medicine; Computer science; World Wide Web","score_opus":0.018828056373532874,"score_gpt":0.28408440787201167,"score_spread":0.2652563514984788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248435625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.850506,0.0008040794,0.0000034290342,0.14406863,0.00031850062,0.0003661228,0.000020731257,0.000025714178,0.0038867944],"genre_scores_gemma":[0.978541,0.00064300606,0.000077004865,0.0048015695,0.00048247428,0.000059332568,0.00002149232,0.0000112292055,0.015362872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866176,0.00008225342,0.00019850666,0.00014465833,0.00034585822,0.0005669664],"domain_scores_gemma":[0.99834824,0.00004402399,0.000111798734,0.00007029965,0.00043199363,0.0009936444],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026191212,0.000102843274,0.00017755161,0.0001431407,0.00026508095,0.00012124148,0.000071551534,0.00016548022,0.005693775],"category_scores_gemma":[0.00018975764,0.00006655455,0.00008492045,0.0001856719,0.000027336884,0.00014505144,0.000012007082,0.00053750427,0.00036001587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003894448,0.000032894997,0.8939912,0.0000047907984,0.0000799968,0.00009103276,0.0001435755,0.0000057689526,0.00052605657,0.000017372324,0.08706786,0.018000506],"study_design_scores_gemma":[0.001240593,0.00022032895,0.89202905,0.000021035961,0.000033369353,0.00008348673,0.00006373087,0.00011595278,0.00012198848,0.00065705396,0.10532199,0.000091430615],"about_ca_topic_score_codex":0.0037795247,"about_ca_topic_score_gemma":0.00035217794,"teacher_disagreement_score":0.13926706,"about_ca_system_score_codex":0.0017005627,"about_ca_system_score_gemma":0.00092410215,"threshold_uncertainty_score":0.9952152},"labels":[],"label_agreement":null},{"id":"W4248808332","doi":"10.1200/jco.2017.35.6_suppl.4.2017.1.test","title":"Evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic prostate needle biopsy specimens.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; DECIPHER; Prostate cancer; Prostate; Metastasis; Disease; Pathology; Cancer; Biopsy; Oncology; Internal medicine; Bioinformatics; Biology","score_opus":0.30499408326372374,"score_gpt":0.5165378263537546,"score_spread":0.21154374309003082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248808332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98753476,0.004526109,0.0000152243365,0.005818635,0.0006149449,0.000874183,0.00037667615,0.0000023089792,0.00023716781],"genre_scores_gemma":[0.9943709,0.004628856,0.00032496406,0.00013932717,0.00032132302,0.000035202425,0.000011115993,0.000014256556,0.00015408399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958425,0.000745178,0.0017526249,0.00028666563,0.0011482451,0.00022476699],"domain_scores_gemma":[0.99338156,0.0016690308,0.0022984578,0.0006409491,0.0014686711,0.0005413301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005410493,0.00015263788,0.0014347973,0.00018585271,0.00013074196,0.00002961051,0.00028768324,0.00013250775,0.00035764824],"category_scores_gemma":[0.008159076,0.00008505357,0.0005663174,0.0002632396,0.0007624094,0.00012192211,0.00017128234,0.00038942668,0.0000020687864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038178342,0.0007473524,0.9159532,0.000025632613,0.0065185004,0.0000630717,0.00036593733,0.00028296502,0.0012453885,0.000008882141,0.0009160522,0.07005517],"study_design_scores_gemma":[0.0057395473,0.0011264633,0.9719293,0.00015002342,0.016778896,0.0000027442077,0.00011985223,0.0008629499,0.0003397292,0.0005592688,0.002318716,0.00007247021],"about_ca_topic_score_codex":0.00033058765,"about_ca_topic_score_gemma":0.00030041987,"teacher_disagreement_score":0.06998271,"about_ca_system_score_codex":0.00030613202,"about_ca_system_score_gemma":0.0030893532,"threshold_uncertainty_score":0.9767766},"labels":[],"label_agreement":null},{"id":"W4248908788","doi":"10.1200/jco.2019.37.7_suppl.195","title":"Identification, incidence and clinical outcomes of patients (pts) with hypermutated prostate cancer (PC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Juravinski Cancer Centre; BC Cancer Agency; Ottawa Hospital; University of British Columbia; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Enzalutamide; Oncology; Androgen deprivation therapy; Microsatellite instability; KRAS; Cancer; Incidence (geometry); Gastroenterology; Genetics; Androgen receptor; Biology; Allele; Microsatellite","score_opus":0.08544578536697905,"score_gpt":0.5030082362144115,"score_spread":0.41756245084743243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248908788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994127,0.00045313349,0.000006527769,0.004031614,0.0006669238,0.0004934327,0.000015016088,0.000005149257,0.00020123248],"genre_scores_gemma":[0.9939874,0.0036318365,0.000315773,0.0005960068,0.00011665524,0.0000060141297,0.0000064508827,0.000014371438,0.0013254873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99641407,0.00030214206,0.0023606864,0.000223366,0.0005032755,0.00019648936],"domain_scores_gemma":[0.99463946,0.0015338586,0.0018700539,0.00019953128,0.0014404816,0.00031664246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002393816,0.00011957283,0.001384293,0.00010997998,0.000025452082,0.000008394597,0.00013273407,0.00021656173,0.00011728161],"category_scores_gemma":[0.0016441543,0.0000653476,0.00022421798,0.00016053603,0.0004442679,0.00016270102,0.000057104193,0.00066824164,0.000015013142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006848962,0.0014421339,0.94147563,0.00005130043,0.00065310503,0.00007187783,0.000092856746,0.0000030604901,0.00004643897,0.000010934811,0.00060796406,0.048695743],"study_design_scores_gemma":[0.015290914,0.011901784,0.9682514,0.00012829454,0.00034592176,0.00002296737,0.00008054803,0.000033461125,0.000105682615,0.00008112829,0.0036904914,0.00006738835],"about_ca_topic_score_codex":0.000047950103,"about_ca_topic_score_gemma":0.00004808833,"teacher_disagreement_score":0.048628353,"about_ca_system_score_codex":0.000105217,"about_ca_system_score_gemma":0.0017602636,"threshold_uncertainty_score":0.3122632},"labels":[],"label_agreement":null},{"id":"W4249219855","doi":"10.1158/1538-7445.am2019-4389","title":"Abstract 4389: Post-translational modifications of histone demethylase JMJD1A in prostate cancer cells","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Demethylase; Cancer research; Histone; Ubiquitin; Androgen receptor; Chemistry; Interactome; Cancer; EZH2; Chromatin immunoprecipitation; Biology; Medicine; Biochemistry; Internal medicine; DNA","score_opus":0.08258141192698826,"score_gpt":0.4642664800740971,"score_spread":0.38168506814710884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249219855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97849876,0.010283168,0.0000018178613,0.0060585355,0.0001514072,0.0018293334,0.00033471506,0.000020028556,0.002822264],"genre_scores_gemma":[0.98581684,0.004375918,0.000091257425,0.00005681804,0.000091853835,0.0006686639,0.00008316219,0.000038916594,0.008776587],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972958,0.00010080907,0.0004012372,0.00046148835,0.0010891722,0.000651513],"domain_scores_gemma":[0.998113,0.00018285247,0.00007158532,0.00043023887,0.0009749251,0.00022744948],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008113566,0.00015707871,0.00034174568,0.0006314196,0.000084314954,0.000019456005,0.00020766346,0.000101175785,0.0027786875],"category_scores_gemma":[0.00004367894,0.00013164843,0.00009425388,0.0009484258,0.00032036577,0.00015668482,0.000052519248,0.000708762,0.00017028816],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017235334,0.0004248307,0.036154218,0.0007679001,0.000096887044,0.00003880301,0.0012247608,0.0003419624,0.9498285,0.00016896857,0.001126015,0.008103621],"study_design_scores_gemma":[0.00646312,0.00039465807,0.2500596,0.0009173111,0.000035795136,0.000003806432,0.0006428462,0.00026443996,0.73260564,0.0002540463,0.008087049,0.0002716825],"about_ca_topic_score_codex":0.0057252585,"about_ca_topic_score_gemma":0.00066716445,"teacher_disagreement_score":0.21722284,"about_ca_system_score_codex":0.0006799012,"about_ca_system_score_gemma":0.0023201248,"threshold_uncertainty_score":0.9981329},"labels":[],"label_agreement":null},{"id":"W4249315100","doi":"10.3410/f.2829956.793455836","title":"Faculty Opinions recommendation of Effect of dutasteride on the risk of prostate cancer.","year":2012,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Dutasteride; Prostate cancer; Medicine; Oncology; Internal medicine; Cancer","score_opus":0.037622174205259186,"score_gpt":0.3949235650281795,"score_spread":0.3573013908229203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249315100","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000048468053,0.0040151584,0.0000013893056,0.12616074,0.00051074266,0.0031670833,0.86602926,0.00001297624,0.000054187487],"genre_scores_gemma":[0.00018164844,0.003928324,0.00006189116,0.00076858775,0.00021924145,0.00056883093,0.99326605,0.00002842645,0.0009769828],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99497026,0.0009749757,0.0015134102,0.00045578642,0.0017071277,0.00037840928],"domain_scores_gemma":[0.9913614,0.0005282864,0.0022661472,0.0015118516,0.004072459,0.00025989467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002512555,0.00049290585,0.0013765004,0.0003336747,0.00015358285,0.000028774328,0.00090302894,0.0004463383,0.0006911976],"category_scores_gemma":[0.0056106388,0.0002207787,0.000772107,0.0016890708,0.00064377574,0.00014984982,0.00033658918,0.0011359423,0.00002118661],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030220914,0.0004891998,0.0003230639,0.019968847,0.0006035595,2.1893968e-7,0.00017650386,1.12765235e-7,0.000012089457,0.000041218038,0.9727887,0.005294306],"study_design_scores_gemma":[0.0016095148,0.0009294689,0.0049383286,0.023665698,0.0008089402,0.0000121860285,0.000024229343,0.000003411832,0.00095278554,0.0000061480946,0.96688277,0.00016654393],"about_ca_topic_score_codex":0.00020414691,"about_ca_topic_score_gemma":0.0000053416948,"teacher_disagreement_score":0.12723681,"about_ca_system_score_codex":0.00015537025,"about_ca_system_score_gemma":0.0006326557,"threshold_uncertainty_score":0.90030944},"labels":[],"label_agreement":null},{"id":"W4249576449","doi":"10.1200/jco.2017.35.15_suppl.e16509","title":"Prevalence of oligoprogressive, metastatic castration-resistant prostate cancer (mCRPC) amenable to stereotactic ablative radiotherapy (SABR) in men undergoing abiraterone acetate (AA) therapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Docetaxel; SABR volatility model; Prostate cancer; Oncology; Abiraterone acetate; Radiation therapy; Internal medicine; Chemotherapy; Lymph; Androgen deprivation therapy; Cancer; Radiology; Urology; Pathology","score_opus":0.17010034977483687,"score_gpt":0.512485317785779,"score_spread":0.3423849680109421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249576449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837153,0.005206889,0.000024283609,0.008833063,0.00033825685,0.0010134651,0.00001776216,0.00000506878,0.00084592646],"genre_scores_gemma":[0.96836907,0.025377419,0.0031418616,0.00032047392,0.00019142588,0.0000537352,0.0000011253792,0.000027019169,0.002517857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963541,0.0005265652,0.0018833699,0.0002891959,0.0005351777,0.0004115823],"domain_scores_gemma":[0.9950567,0.0010669433,0.0025311166,0.00037013425,0.0006168095,0.00035830145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025751404,0.0002046325,0.0014325824,0.00021046064,0.00011441919,0.000048296097,0.0003268847,0.00013040351,0.00019509418],"category_scores_gemma":[0.0009807771,0.00013200447,0.00022577659,0.00014137903,0.00036015635,0.00040444933,0.000056220215,0.0006342157,0.000004130819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07863292,0.004278404,0.6735271,0.00094967696,0.0048225606,0.003176845,0.00511274,0.00048911606,0.033511538,0.00007062557,0.0011214708,0.19430697],"study_design_scores_gemma":[0.032895714,0.025384635,0.92865574,0.0013910118,0.00034998526,0.0000815479,0.0005446941,0.00022916385,0.007747044,0.00044486922,0.0020677452,0.0002078498],"about_ca_topic_score_codex":0.00023565933,"about_ca_topic_score_gemma":0.00029744674,"teacher_disagreement_score":0.2551286,"about_ca_system_score_codex":0.0004695991,"about_ca_system_score_gemma":0.0031801306,"threshold_uncertainty_score":0.5641415},"labels":[],"label_agreement":null},{"id":"W4249594000","doi":"10.12688/f1000research.8192.1","title":"A predictive model of overall survival in patients with metastatic castration-resistant prostate cancer","year":2016,"lang":"en","type":"preprint","venue":"F1000Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Turun yliopiston tutkijakoulu; Turun Yliopisto","keywords":"Prostate cancer; Medicine; Clinical trial; Oncology; Cancer; Overall survival; Internal medicine","score_opus":0.05907445598158823,"score_gpt":0.36086231194279067,"score_spread":0.30178785596120244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249594000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98696584,0.00079270726,0.00014427908,0.0011067204,0.0000932348,0.0050012614,0.0036925839,0.00003620149,0.0021672023],"genre_scores_gemma":[0.99160403,0.0007486171,0.00043800505,0.000014746691,0.00005666218,0.0012296659,0.00049511454,0.000086217064,0.005326964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99561167,0.00022659377,0.0005465195,0.0007306835,0.0021201686,0.0007643865],"domain_scores_gemma":[0.99742186,0.00016091343,0.0001912446,0.00065057544,0.001283011,0.00029242082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006027969,0.0003662552,0.00080566976,0.00059275696,0.00005839818,0.00003983953,0.00028655241,0.00015962016,0.00018586502],"category_scores_gemma":[0.00010303473,0.00022413855,0.00011769243,0.0002948844,0.0003912144,0.00013072694,0.00044954818,0.0009048034,0.000008181209],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.066165894,0.0028353895,0.9028127,0.0049676667,0.002077598,0.00024294449,0.002725413,0.0077888723,0.0050947433,0.00038707524,0.0011985959,0.0037030727],"study_design_scores_gemma":[0.03505668,0.004484107,0.92264205,0.0068150116,0.00040870835,0.0000013054132,0.00023839918,0.018499682,0.0055144983,0.00551175,0.00008725882,0.0007405561],"about_ca_topic_score_codex":0.0011626601,"about_ca_topic_score_gemma":0.00036483462,"teacher_disagreement_score":0.03110921,"about_ca_system_score_codex":0.0009569181,"about_ca_system_score_gemma":0.004089312,"threshold_uncertainty_score":0.91401047},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"simulation_or_modeling","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"},{"model":"gpt","categories":[],"domain":null,"study_design":"simulation_or_modeling","genre":"methods","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W4249628793","doi":"10.1158/1538-7445.sabcs18-1853","title":"Abstract 1853: Association of IDH genes with prostate cancer progression and their regulation by the androgen receptor","year":2019,"lang":"en","type":"article","venue":"Molecular and Cellular Biology / Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"IDH1; Androgen receptor; Prostate cancer; Biology; Cancer research; Isocitrate dehydrogenase; Cancer; Reprogramming; IDH2; Cell; Gene; Genetics; Mutation; Enzyme; Biochemistry","score_opus":0.0067483187526321325,"score_gpt":0.2618315394891949,"score_spread":0.25508322073656275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249628793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9544032,0.043981567,0.00005375016,0.0007503267,0.00003335189,0.0006366932,0.000037964703,0.000007355486,0.00009578953],"genre_scores_gemma":[0.9949546,0.0040982068,0.00011127319,0.000045025598,0.00001916951,0.000033242653,0.00019119943,0.000013671394,0.0005336273],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99935746,0.000055298307,0.00012157706,0.00019800768,0.00010380707,0.00016383195],"domain_scores_gemma":[0.9995925,0.000021182475,0.00010293871,0.00013802794,0.00009749369,0.000047887093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015714098,0.00010904089,0.00016472703,0.000027360127,0.00005283097,0.00001094357,0.000035093013,0.00011325565,0.000026203168],"category_scores_gemma":[0.0000044737576,0.000056473,0.000025264679,0.00007075009,0.00010917493,0.000012922154,0.00003000812,0.00008391583,0.0000014168747],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023029895,0.000028918521,0.203527,0.00005971152,0.00012273135,0.0000011669796,0.00017048528,0.0000040461773,0.7688748,0.00000779338,0.000060374652,0.026912622],"study_design_scores_gemma":[0.0013717377,0.0005762473,0.015543112,0.00005572651,0.000059450438,0.000004233268,0.000091239184,0.000122052414,0.9761652,0.00006583839,0.005861179,0.00008401555],"about_ca_topic_score_codex":0.000014970549,"about_ca_topic_score_gemma":0.0000034914501,"teacher_disagreement_score":0.20729032,"about_ca_system_score_codex":0.000029767201,"about_ca_system_score_gemma":0.00005705184,"threshold_uncertainty_score":0.23029022},"labels":[],"label_agreement":null},{"id":"W4249669395","doi":"10.5489/cuaj.1276","title":"Moderated Poster Session 7: Oncology: Prostate","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Manitoba; University of Toronto; University Health Network","funders":"","keywords":"Session (web analytics); Prostate cancer; Medicine; Medical physics; Oncology; Internal medicine; Computer science; World Wide Web; Cancer","score_opus":0.023136706977284142,"score_gpt":0.2940392261699184,"score_spread":0.27090251919263425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249669395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85412085,0.00025263111,0.000008970336,0.13120903,0.00022286574,0.00045915635,0.000013959079,0.00003111964,0.0136814155],"genre_scores_gemma":[0.9843148,0.0001448752,0.000119607685,0.0069274474,0.00025758566,0.00003186202,0.000044188186,0.000011233487,0.008148415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985661,0.00016320263,0.00024095632,0.00015596363,0.00030234663,0.0005714334],"domain_scores_gemma":[0.9981751,0.00006455415,0.000126152,0.00007402609,0.0005509864,0.0010091992],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003783748,0.0001106537,0.00021789031,0.00016381315,0.00029879762,0.0001293683,0.0000690692,0.00026353824,0.0029245967],"category_scores_gemma":[0.00025148413,0.00007136632,0.00008175804,0.00017683007,0.000031843414,0.00016979426,0.000014732875,0.00066457986,0.00055895845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018324399,0.00012362249,0.8553381,0.0000064568426,0.00017855932,0.00030876423,0.00029076304,0.000013279474,0.0019021366,0.000027271595,0.11597439,0.025653403],"study_design_scores_gemma":[0.003243381,0.0012114963,0.8675686,0.00002435207,0.00005780562,0.00040694707,0.00012999673,0.00056418544,0.0002928415,0.001541471,0.12479574,0.0001632022],"about_ca_topic_score_codex":0.0012367953,"about_ca_topic_score_gemma":0.00017897398,"teacher_disagreement_score":0.13019393,"about_ca_system_score_codex":0.0023864505,"about_ca_system_score_gemma":0.0012034749,"threshold_uncertainty_score":0.99798685},"labels":[],"label_agreement":null},{"id":"W4249861497","doi":"10.1200/jco.2016.34.15_suppl.e16547","title":"The frequency of druggable targets in localized prostate cancer: Initial analysis from the Decipher GRID.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"DECIPHER; Druggability; Medicine; Prostate cancer; Computational biology; Gene expression profiling; Population; Bioinformatics; Cancer; Gene; Oncology; Gene expression; Biology; Genetics; Internal medicine","score_opus":0.09692976115524495,"score_gpt":0.49111820894542224,"score_spread":0.3941884477901773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249861497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93606806,0.009287547,0.00009545162,0.052037463,0.001011307,0.00032546604,0.000052733718,0.000003844856,0.0011181375],"genre_scores_gemma":[0.9787527,0.018446188,0.00039893863,0.00070151145,0.000994783,0.000020134834,0.000003660921,0.00001110967,0.0006709978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963489,0.0007850705,0.0019390642,0.00016211679,0.0004670414,0.00029778745],"domain_scores_gemma":[0.9907727,0.0071024047,0.0011456594,0.0002581876,0.00052409526,0.00019693666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037332892,0.00011002559,0.0011697205,0.000097022195,0.00006816087,0.000008580779,0.00029356912,0.00019453198,0.00050133414],"category_scores_gemma":[0.0026610058,0.000037490176,0.00053318613,0.00043893105,0.0006261855,0.00008565131,0.000060917107,0.00059551274,0.000008294262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008904478,0.00061914197,0.8026068,0.0000063744124,0.0026621504,0.00034483045,0.0002580835,0.000013174431,0.00039415076,0.000055251643,0.006144846,0.1779907],"study_design_scores_gemma":[0.027239457,0.004727622,0.85149986,0.00029243765,0.0021040328,0.000016149694,0.00040392595,0.00008798996,0.0012728095,0.005996833,0.106235564,0.00012331657],"about_ca_topic_score_codex":0.0011143227,"about_ca_topic_score_gemma":0.0030262328,"teacher_disagreement_score":0.17786738,"about_ca_system_score_codex":0.00024657874,"about_ca_system_score_gemma":0.0025067586,"threshold_uncertainty_score":0.54892576},"labels":[],"label_agreement":null},{"id":"W4249874770","doi":"10.1002/9781118868126.ch7","title":"Active Surveillance for Low‐Risk Prostate Cancer","year":2017,"lang":"en","type":"other","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Conservative management; Disease; Magnetic resonance imaging; Watchful waiting; Intensive care medicine; Cancer; Biomarker; Conservative treatment; Risk assessment; Internal medicine; Oncology; Surgery; Radiology","score_opus":0.02591896998058346,"score_gpt":0.37512788759827836,"score_spread":0.3492089176176949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249874770","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020239472,0.0098185465,0.000061206534,0.0010661307,0.00060135743,0.0040033404,0.00311749,0.00021429418,0.98091525],"genre_scores_gemma":[0.00069373247,0.028414687,0.00028130595,0.000068396854,0.0007577906,0.00090523326,0.00034066496,0.00036556437,0.9681726],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988327,0.000020015672,0.00010965347,0.0004187407,0.0002239177,0.00039498316],"domain_scores_gemma":[0.99892604,0.000058071608,0.00023399224,0.0005175412,0.00011734553,0.00014703111],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000105705054,0.00025702867,0.0004951752,0.00012641143,0.00010331497,0.000028420862,0.00013037084,0.00021987424,0.0025490557],"category_scores_gemma":[0.000090622125,0.00016624123,0.0001415036,0.000041032166,0.00013427984,0.000024772053,0.000040774623,0.00021340507,0.000080943726],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000857986,0.00006404741,0.00598221,0.00052550324,0.0006309591,0.000025164387,0.000051161413,1.2085535e-7,0.00004242406,0.000009151889,0.9081307,0.08368055],"study_design_scores_gemma":[0.0035907591,0.00020951444,0.0017597931,0.0006311778,0.00009143263,0.0000020251573,0.00001619308,0.00001532284,0.0012021676,0.0000299476,0.99224454,0.00020714018],"about_ca_topic_score_codex":0.0026384164,"about_ca_topic_score_gemma":0.0025240616,"teacher_disagreement_score":0.0841138,"about_ca_system_score_codex":0.00016916453,"about_ca_system_score_gemma":0.0004877484,"threshold_uncertainty_score":0.9983627},"labels":[],"label_agreement":null},{"id":"W4249931646","doi":"10.1200/jco.2019.37.7_suppl.171","title":"Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Western University","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone; Nausea; Prostate cancer; Pembrolizumab; Cancer; Cohort; Internal medicine; Oncology; Gynecology; Immunotherapy; Androgen receptor","score_opus":0.07638448730761598,"score_gpt":0.439758731083495,"score_spread":0.363374243775879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249931646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919763,0.001124812,0.000006890654,0.0018035488,0.0007057999,0.0016262925,0.000050541992,0.00001900652,0.002686812],"genre_scores_gemma":[0.99272734,0.0021643108,0.00073892664,0.00059887493,0.00020555973,0.00006190714,0.0000339023,0.00006338897,0.0034057621],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939106,0.00084095326,0.0028683164,0.0005389782,0.0010607293,0.0007804315],"domain_scores_gemma":[0.9950874,0.0009682248,0.0017629082,0.0004033059,0.0011176936,0.00066046574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025283485,0.0003836393,0.0026402874,0.00039272223,0.000057903253,0.000034172157,0.00027112907,0.00032943458,0.00040956587],"category_scores_gemma":[0.00064056605,0.00023256295,0.0003355065,0.00052792614,0.0003719536,0.00030172674,0.00008243578,0.0016744368,0.00007025866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12287876,0.0025189072,0.8473153,0.00026713614,0.0014498865,0.0035744924,0.00037185106,0.00039334688,0.00075487746,0.000015711346,0.00062510965,0.019834591],"study_design_scores_gemma":[0.08952556,0.03478691,0.8678018,0.00083052716,0.0008118322,0.00017700995,0.00022711689,0.00033987538,0.00057972444,0.0000981317,0.0045337463,0.0002877957],"about_ca_topic_score_codex":0.0006220941,"about_ca_topic_score_gemma":0.0008581684,"teacher_disagreement_score":0.033353206,"about_ca_system_score_codex":0.0016499743,"about_ca_system_score_gemma":0.005743913,"threshold_uncertainty_score":0.9998926},"labels":[],"label_agreement":null},{"id":"W4250282415","doi":"10.3410/f.1019481.220529","title":"Faculty Opinions recommendation of Physical and functional interaction of androgen receptor with calmodulin in prostate cancer cells.","year":2004,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Prostate cancer; Androgen receptor; Calmodulin; Receptor; Internal medicine; Cancer; Oncology; Cancer research; Endocrinology; Medicine; Calcium","score_opus":0.03369774291588463,"score_gpt":0.37149575335507146,"score_spread":0.33779801043918684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250282415","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010743225,0.0014252781,0.0000034755928,0.077276364,0.00027656,0.0017502338,0.91913384,0.00001109639,0.00001571766],"genre_scores_gemma":[0.00021520087,0.0015198127,0.00019658043,0.00045457392,0.0001675787,0.0003676851,0.9965227,0.000020848249,0.0005349694],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99711776,0.00018415939,0.0008890469,0.0005074177,0.0010517661,0.00024983313],"domain_scores_gemma":[0.9951826,0.00008444671,0.0008303576,0.0005338497,0.003160893,0.00020790333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004760093,0.00035357478,0.0008768395,0.00037407747,0.00007803645,0.00003093947,0.00025151327,0.00027292644,0.00021269893],"category_scores_gemma":[0.00059031707,0.00019961449,0.0002484978,0.0014209014,0.00041005595,0.00023492631,0.00016096151,0.0008418017,0.0000063128587],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003455057,0.000875444,0.0000864014,0.0113222655,0.00022566975,6.848699e-7,0.0002675651,0.0000012357737,0.00004700173,0.000022078568,0.9840658,0.002740358],"study_design_scores_gemma":[0.0025044184,0.0005405126,0.0028204147,0.021030877,0.00020831599,0.000027928065,0.000056816953,0.000013466004,0.00069671765,0.000008670299,0.97191685,0.0001750128],"about_ca_topic_score_codex":0.00028160226,"about_ca_topic_score_gemma":0.000024648105,"teacher_disagreement_score":0.077388905,"about_ca_system_score_codex":0.00027980984,"about_ca_system_score_gemma":0.0011748802,"threshold_uncertainty_score":0.81400424},"labels":[],"label_agreement":null},{"id":"W4250316970","doi":"10.21203/rs.2.17590/v1","title":"Molecular Characterization of Prostate Cancer in Middle Eastern Population Highlights Differences with Western Populations with Prognostic Implication","year":2019,"lang":"en","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Prostate cancer; Population; Oncology; Cancer; Medicine; Demography; Geography; Gynecology; Internal medicine; Political science; Environmental health; Sociology","score_opus":0.07541858581927788,"score_gpt":0.383787015059195,"score_spread":0.30836842923991714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250316970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99092704,0.000540992,0.00013084839,0.0016777279,0.000051765906,0.0062913056,0.00025803864,0.00004071522,0.00008159286],"genre_scores_gemma":[0.99310315,0.0005957239,0.000082515355,0.000006019635,0.00006171082,0.0016906275,0.0034872503,0.00006469221,0.0009083083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966687,0.00026142233,0.00042715366,0.00070845085,0.0013995359,0.0005347519],"domain_scores_gemma":[0.9978532,0.000058978614,0.00025929697,0.0006334078,0.0010392203,0.00015587531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030616447,0.00029667976,0.00056124514,0.00079791463,0.0000820391,0.00008762204,0.00018413016,0.0002234296,0.000025412297],"category_scores_gemma":[0.00003197766,0.00019479913,0.00005798602,0.00075609155,0.00014067885,0.00016313416,0.0001872829,0.0007044694,0.00000953263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001329782,0.0003414199,0.9869445,0.0035320332,0.00010535118,0.000041005478,0.00091960107,0.00037634274,0.0049274047,0.00009326471,8.9291166e-7,0.001388427],"study_design_scores_gemma":[0.0016988415,0.0009997784,0.9842543,0.008181686,0.00007391596,0.000005089272,0.00011024028,0.001460818,0.0028844478,0.000110967456,0.000013974423,0.0002059132],"about_ca_topic_score_codex":0.002721576,"about_ca_topic_score_gemma":0.0011544137,"teacher_disagreement_score":0.004649652,"about_ca_system_score_codex":0.0004788189,"about_ca_system_score_gemma":0.0007663806,"threshold_uncertainty_score":0.7943678},"labels":[],"label_agreement":null},{"id":"W4250448185","doi":"10.21203/rs.3.rs-50788/v1","title":"Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&amp;amp;T","year":2020,"lang":"en","type":"preprint","venue":"Research Square (Research Square)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Dosimetry; Absorbed dose; Nuclear medicine; Medicine; Radionuclide therapy; Medical physics","score_opus":0.1622857535009645,"score_gpt":0.49870569337710063,"score_spread":0.33641993987613616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250448185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729899,0.0027087831,0.0008421147,0.006396388,0.0001129194,0.015274968,0.00041143192,0.00022381962,0.0010396374],"genre_scores_gemma":[0.9801075,0.0058557573,0.0061823903,0.0001589751,0.0003833325,0.004434239,0.0017821182,0.00031200383,0.0007836709],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9779254,0.0042741685,0.0018208002,0.0031736302,0.009574381,0.003231575],"domain_scores_gemma":[0.9830534,0.0057439846,0.00038827382,0.0034055943,0.0055150576,0.0018937297],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01448578,0.0010692689,0.0021056246,0.005908231,0.00063915475,0.00034217417,0.001923348,0.0011656475,0.00027199293],"category_scores_gemma":[0.010825268,0.00090350595,0.0005026693,0.0069624875,0.000858808,0.000324214,0.0036154748,0.008178167,0.001029403],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036990125,0.011213339,0.26086646,0.018282002,0.0008978628,0.00047563136,0.012398155,0.009690841,0.27587965,0.00041598748,0.015790705,0.3570992],"study_design_scores_gemma":[0.015832355,0.009116487,0.8085956,0.01748559,0.00008401116,0.00001332294,0.001293536,0.0034231513,0.12233793,0.0064792754,0.013458306,0.0018804589],"about_ca_topic_score_codex":0.005775889,"about_ca_topic_score_gemma":0.00048094688,"teacher_disagreement_score":0.54772913,"about_ca_system_score_codex":0.0033608563,"about_ca_system_score_gemma":0.002985432,"threshold_uncertainty_score":0.9997484},"labels":[],"label_agreement":null},{"id":"W4251242878","doi":"10.1200/jco.2021.39.6_suppl.32","title":"A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"Progenics Pharmaceuticals","keywords":"Medicine; Bone scintigraphy; Prostate cancer; Nuclear medicine; Radiology; Stage (stratigraphy); Cancer staging; Positron emission tomography; Cancer; Internal medicine","score_opus":0.08183082847259189,"score_gpt":0.4714340660007631,"score_spread":0.3896032375281712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251242878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957515,0.0008532002,0.0000039674987,0.0019062725,0.00013251929,0.0011651005,0.0001369711,0.000004344141,0.00004613393],"genre_scores_gemma":[0.9983149,0.0008212813,0.000280742,0.00013777077,0.00006795179,0.00010993078,0.000039838826,0.000020370004,0.000207187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99579793,0.0007288619,0.0017014146,0.00044323443,0.00097262766,0.0003559521],"domain_scores_gemma":[0.9952992,0.0008128682,0.0017306976,0.00024107106,0.001567529,0.00034859285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015523961,0.00023633592,0.0018546386,0.00049659575,0.00004983868,0.000009729504,0.00014663677,0.000022237846,0.00023425036],"category_scores_gemma":[0.0010983426,0.00013686018,0.00018981843,0.0009989821,0.00035311392,0.00016537413,0.000080519065,0.0007611655,3.8721018e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14633186,0.03551125,0.7926557,0.0001307989,0.0012734598,0.00855154,0.00061277836,0.00009737982,0.000021303898,0.000004139616,0.00008700159,0.014722748],"study_design_scores_gemma":[0.12845697,0.08089221,0.78323287,0.0017381206,0.0015358699,0.000057263216,0.0026349572,0.00027469094,0.0007509413,0.00004819468,0.0001863088,0.00019160617],"about_ca_topic_score_codex":0.0002839993,"about_ca_topic_score_gemma":0.0040638777,"teacher_disagreement_score":0.04538096,"about_ca_system_score_codex":0.000502543,"about_ca_system_score_gemma":0.004514151,"threshold_uncertainty_score":0.80079097},"labels":[],"label_agreement":null},{"id":"W4251266546","doi":"10.1200/jco.2015.33.7_suppl.168","title":"A genomic classifier to identify men with adverse pathology post radical prostatectomy who benefit from adjuvant radiation therapy.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Metastasis; Internal medicine; Cumulative incidence; Adjuvant; Incidence (geometry); Radiation therapy; Oncology; Clinical endpoint; Proportional hazards model; Adjuvant radiotherapy; Adjuvant therapy; Salvage therapy; Prostate cancer; Cancer; Clinical trial; Chemotherapy; Cohort","score_opus":0.1284877817778054,"score_gpt":0.47119199044115356,"score_spread":0.34270420866334816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251266546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786994,0.0020430149,0.0000859487,0.016062541,0.0005519685,0.0006621923,0.000023465122,0.000013591863,0.0018578648],"genre_scores_gemma":[0.9888369,0.0025921639,0.002126174,0.0036279715,0.0015818733,0.000026339541,0.000035631165,0.00003730043,0.0011356411],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99687576,0.0004387452,0.0014462082,0.0003086293,0.00056516076,0.00036548765],"domain_scores_gemma":[0.99633086,0.0007267576,0.0008038229,0.00024634326,0.0008072532,0.0010849443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023295647,0.0001815912,0.0013559229,0.00021290059,0.000044215856,0.000014684271,0.00020059258,0.0003911472,0.00018304531],"category_scores_gemma":[0.00095904135,0.00010584712,0.0002618964,0.00018012198,0.00023879952,0.00014766431,0.00006641105,0.0009613222,0.00009866361],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.115630046,0.0026688145,0.3518223,0.000016317672,0.0014675668,0.009061946,0.001843327,0.000049973656,0.0048319926,0.00006464793,0.018729435,0.49381363],"study_design_scores_gemma":[0.035296764,0.032561935,0.827611,0.00008185555,0.00024321231,0.0004406251,0.00042855743,0.00006228882,0.0003485419,0.00049115723,0.10230357,0.00013045389],"about_ca_topic_score_codex":0.000072055336,"about_ca_topic_score_gemma":0.000040012852,"teacher_disagreement_score":0.4936832,"about_ca_system_score_codex":0.0005098945,"about_ca_system_score_gemma":0.003345218,"threshold_uncertainty_score":0.5934273},"labels":[],"label_agreement":null},{"id":"W4251534422","doi":"10.5489/cuaj.2788","title":"COSMiC details","year":2015,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Observational study; Prostate cancer; Abiraterone acetate; Prospective cohort study; Population; Cancer; Quality of life (healthcare); Internal medicine; Oncology; Androgen deprivation therapy; Nursing","score_opus":0.043982125714908823,"score_gpt":0.29452689646626456,"score_spread":0.2505447707513557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251534422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87222403,0.001232292,0.000035915553,0.096273385,0.00045715927,0.00021138552,0.00001713818,0.00003432134,0.029514397],"genre_scores_gemma":[0.990571,0.00007804422,0.00011560516,0.003727197,0.0004160521,0.0000048904208,0.00001550783,0.0000066283205,0.0050650495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890214,0.00008531014,0.00015078021,0.00009738068,0.00034886345,0.00041549408],"domain_scores_gemma":[0.99796504,0.0000429001,0.00007127349,0.000060588285,0.0003565933,0.0015036287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061442587,0.00007005753,0.00014907161,0.00012597964,0.00014270829,0.00006150925,0.000064722066,0.00013284163,0.00043441047],"category_scores_gemma":[0.0006453056,0.000048984282,0.00006989428,0.00015508645,0.000022842563,0.00006500269,0.0000075779367,0.00041381578,0.00030861338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008506187,0.000029633818,0.8843274,0.0000013455757,0.00008281441,0.00033492307,0.000084883024,0.0000072534312,0.000046029738,0.00010196831,0.11120936,0.0036892989],"study_design_scores_gemma":[0.00344942,0.00073446706,0.5018432,0.000009231602,0.00006780864,0.0005483078,0.00014834419,0.00011464613,0.00007346212,0.0033701605,0.48952073,0.0001202077],"about_ca_topic_score_codex":0.0005088059,"about_ca_topic_score_gemma":0.00030038666,"teacher_disagreement_score":0.3824842,"about_ca_system_score_codex":0.0022322133,"about_ca_system_score_gemma":0.0014820114,"threshold_uncertainty_score":0.583716},"labels":[],"label_agreement":null},{"id":"W4251650965","doi":"10.1200/jco.2017.35.6_suppl.142","title":"Genomic classifier to augment the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Cohort; Prostatectomy; Oncology; Internal medicine; Prostate cancer; Proportional hazards model; Radiation therapy; Adjuvant therapy; Pathological; Biochemical recurrence; Stage (stratigraphy); Cancer","score_opus":0.09438116764309755,"score_gpt":0.4466428084827843,"score_spread":0.35226164083968675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251650965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99745125,0.00055517984,0.00010374075,0.0007886962,0.00009316178,0.00097442046,0.000008643334,8.276484e-7,0.000024064359],"genre_scores_gemma":[0.99504244,0.00064133626,0.0041085323,0.00003993111,0.00004310548,0.000071333336,0.000005384596,0.0000064761825,0.00004144246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998544,0.000107445914,0.0008655035,0.00012848564,0.00020718703,0.00014739831],"domain_scores_gemma":[0.9983746,0.00029982076,0.0009020185,0.00008801308,0.00025545666,0.00008013589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014593967,0.000079033176,0.0005532073,0.00009927095,0.00004421887,0.000013196812,0.00011441706,0.000093649294,0.0000033718266],"category_scores_gemma":[0.000551295,0.000039747694,0.00004923852,0.00003691168,0.00011040961,0.00008464494,0.000049447244,0.0002521123,7.108066e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017941086,0.00062521355,0.82168776,0.00002443867,0.00009788475,0.000008985494,0.0011160009,0.00071684155,0.000710851,0.0000068139984,0.000012675093,0.15705144],"study_design_scores_gemma":[0.013290501,0.005345187,0.97525144,0.00025346904,0.000041440053,0.0000024199433,0.0001379848,0.0012887878,0.0040780245,0.000104822706,0.00016387808,0.000042023694],"about_ca_topic_score_codex":0.000070566704,"about_ca_topic_score_gemma":0.00008376878,"teacher_disagreement_score":0.15700942,"about_ca_system_score_codex":0.00019348472,"about_ca_system_score_gemma":0.00085003185,"threshold_uncertainty_score":0.1620864},"labels":[],"label_agreement":null},{"id":"W4251849256","doi":"10.1200/jco.2021.39.6_suppl.tps187","title":"A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Sherbrooke; Jewish General Hospital; Université Laval; St Joseph's Health Care","funders":"Progenics Pharmaceuticals","keywords":"Medicine; Enzalutamide; Prostate cancer; Clinical endpoint; Metastatic breast cancer; Oncology; Internal medicine; Nuclear medicine; Cancer; Clinical trial; Breast cancer; Androgen receptor","score_opus":0.06995440332410377,"score_gpt":0.47116281652960146,"score_spread":0.4012084132054977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251849256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768742,0.0128997415,0.000007707776,0.003252397,0.0007274265,0.0061004213,0.000076027536,0.000011218255,0.000050863826],"genre_scores_gemma":[0.9861608,0.011796028,0.00078073,0.00045957475,0.00021696652,0.00023363516,0.00005758607,0.000041968233,0.00025267404],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9895538,0.0033336116,0.005062378,0.0005168231,0.0009787752,0.0005545978],"domain_scores_gemma":[0.99009484,0.0038100786,0.0029963087,0.00029829264,0.0022184695,0.00058200944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006269233,0.00041117598,0.005492796,0.00034212467,0.00015977111,0.00003799786,0.00018119719,0.00021136011,0.00014819897],"category_scores_gemma":[0.005552865,0.0002430822,0.0006529037,0.000372664,0.00062546553,0.00023697707,0.00010266579,0.001041343,0.0000013007508],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8543599,0.022015017,0.04053352,0.0001238372,0.0032420445,0.0017557141,0.0025491538,0.000058268404,0.0077411993,0.0000031619459,0.00009950758,0.06751864],"study_design_scores_gemma":[0.8905936,0.041316714,0.061010245,0.0007618005,0.001355689,0.000059086866,0.00085191434,0.00046896437,0.0029440157,0.000027567054,0.00040998973,0.0002003941],"about_ca_topic_score_codex":0.00020892089,"about_ca_topic_score_gemma":0.00047684196,"teacher_disagreement_score":0.06731824,"about_ca_system_score_codex":0.00051457016,"about_ca_system_score_gemma":0.004492963,"threshold_uncertainty_score":0.99126047},"labels":[],"label_agreement":null},{"id":"W4251906053","doi":"10.1002/(sici)1097-0142(20000215)88:4<955::aid-cncr27>3.3.co;2-w","title":"Report on Prostate Cancer Tumor Marker Workshop 1999","year":2000,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Cancer; Oncology; Gynecology; Tumor marker; Internal medicine; Library science","score_opus":0.028650509830800933,"score_gpt":0.3572453819387357,"score_spread":0.32859487210793475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251906053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9359155,0.01197784,8.0707287e-7,0.010400103,0.00045390872,0.00095839414,0.00006989668,0.000121495505,0.04010204],"genre_scores_gemma":[0.5680734,0.009643692,0.000062001454,0.002660759,0.00081340433,0.0011901481,0.00007176695,0.00006989869,0.41741496],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982908,0.000026223799,0.00024918644,0.00048416894,0.00043042778,0.00051923655],"domain_scores_gemma":[0.9990894,0.000034354038,0.000058545327,0.00044639537,0.00010981234,0.00026150185],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014279004,0.000211745,0.0002983151,0.00008159219,0.00010927873,0.000029627081,0.00008550085,0.00006717682,0.01787745],"category_scores_gemma":[0.00002427769,0.00014963065,0.00010691004,0.00031880554,0.00012205081,0.000077482466,0.000019973195,0.0003047166,0.00027746675],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006969144,0.00040623368,0.25798833,0.00025883655,0.0004997394,0.0075610015,0.0005585977,0.00016286504,0.0014023538,0.000028769113,0.25489202,0.4692721],"study_design_scores_gemma":[0.0033179924,0.00021087784,0.13205107,0.0007945817,0.00012302127,0.00017183025,0.000053073476,0.0000936962,0.0067161466,0.000051918938,0.8561229,0.00029288442],"about_ca_topic_score_codex":0.00055786356,"about_ca_topic_score_gemma":0.0000925624,"teacher_disagreement_score":0.6012309,"about_ca_system_score_codex":0.0005010048,"about_ca_system_score_gemma":0.00061283796,"threshold_uncertainty_score":0.98302037},"labels":[],"label_agreement":null},{"id":"W4251923763","doi":"10.1016/j.urology.2008.08.086","title":"POD-4.10: Phase II Study of Treatment with 5-Alpha Reductase Inhibitors (5ARIs) in Low-Risk Prostate Cancer","year":2008,"lang":"en","type":"article","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Prostate cancer; 5 Alpha-Reductase Inhibitor; Prostate; Incidence (geometry); Cancer; Biopsy; Internal medicine; Urology; Surgery; Finasteride","score_opus":0.02407004107290819,"score_gpt":0.3354891709069626,"score_spread":0.31141912983405445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251923763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99499273,0.00197865,8.42656e-7,0.00071501755,0.000079173726,0.0016903329,0.000066634326,0.000029726283,0.00044687878],"genre_scores_gemma":[0.9944882,0.0019535723,0.000017538005,0.000047482547,0.00008900718,0.0004288793,0.000055355486,0.000028702058,0.0028912718],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9984706,0.00012503605,0.0003519591,0.0004091954,0.00021729225,0.00042593686],"domain_scores_gemma":[0.9992087,0.00005105199,0.0001349374,0.0003392144,0.00011254625,0.00015353179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109179346,0.00021881814,0.0004910784,0.00027861889,0.0001258843,0.0000024936542,0.0000666432,0.000085481566,0.00031335748],"category_scores_gemma":[0.000024547102,0.00013957462,0.000048608857,0.00037640097,0.00026593643,0.000053726537,0.000045231613,0.00021306731,0.00001166185],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04973668,0.037851308,0.8044062,0.000111914196,0.0012817174,0.006187488,0.044544518,0.00055445434,0.006561106,0.000006201936,0.0023753748,0.046382993],"study_design_scores_gemma":[0.26114386,0.5989487,0.06394374,0.00019179349,0.0014040909,0.0005824993,0.005478822,0.000827944,0.04581989,0.000058240097,0.02076413,0.0008362489],"about_ca_topic_score_codex":0.0040064175,"about_ca_topic_score_gemma":0.00093250454,"teacher_disagreement_score":0.7404625,"about_ca_system_score_codex":0.00029914948,"about_ca_system_score_gemma":0.0005724315,"threshold_uncertainty_score":0.60565317},"labels":[],"label_agreement":null},{"id":"W4252009923","doi":"10.1016/j.urology.2017.08.069","title":"Reply","year":2017,"lang":"en","type":"letter","venue":"Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Contextualization; Retrospective cohort study; Family medicine; General surgery; Cancer; Internal medicine","score_opus":0.04357876744025281,"score_gpt":0.3478726828009579,"score_spread":0.3042939153607051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252009923","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014991609,0.0014680134,0.0000036016004,0.93455476,0.0004916285,0.0002377688,0.000016213502,0.000041854633,0.063036256],"genre_scores_gemma":[0.0007201935,0.00019917692,0.000015824671,0.8168434,0.004789511,0.000038939346,0.0004397588,0.000030067877,0.17692314],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990439,0.000034553108,0.00009899283,0.0003094008,0.00015987709,0.0003533041],"domain_scores_gemma":[0.99902004,0.000049322654,0.00006878952,0.00075804227,0.000056817516,0.00004698948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006383467,0.00013487502,0.0003208151,0.0001053744,0.00007594793,0.000013411288,0.0001550069,0.00056131463,0.00071810314],"category_scores_gemma":[0.00007240306,0.00009621238,0.000096729236,0.000017056216,0.00019737166,0.000014344521,0.00006156206,0.0013887896,0.0007727121],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000112771195,0.000010709899,0.00037604687,0.00006587987,0.00012301681,0.011532334,0.0000143949665,2.4329678e-8,0.000015805128,0.000003340298,0.9862304,0.0015152832],"study_design_scores_gemma":[0.00083604536,0.0005067008,0.00028639365,0.000011368059,0.00011914214,0.00041401625,4.410548e-7,0.0000036883994,0.00003944937,0.00020360902,0.99750555,0.00007361866],"about_ca_topic_score_codex":0.000049116577,"about_ca_topic_score_gemma":0.0000010257721,"teacher_disagreement_score":0.11771136,"about_ca_system_score_codex":0.000046976773,"about_ca_system_score_gemma":0.00020837817,"threshold_uncertainty_score":0.9931908},"labels":[],"label_agreement":null},{"id":"W4252805818","doi":"10.1002/cncr.22803","title":"Author reply","year":2007,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Radiation therapy; Urology; Randomized controlled trial; Clinical trial; External beam radiotherapy; Cancer; Internal medicine; Surgery; Oncology","score_opus":0.063293732592509,"score_gpt":0.4271133124780612,"score_spread":0.36381957988555225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252805818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8930489,0.010304807,0.00030101297,0.020178024,0.00069834833,0.00048647192,0.0000111974705,0.00013366064,0.07483757],"genre_scores_gemma":[0.8723553,0.00022618273,0.00030374358,0.0018408875,0.00051433727,0.000031255506,0.000009094946,0.000015217651,0.12470402],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994103,0.0000039291463,0.00008274203,0.00012846148,0.00015090825,0.00022369967],"domain_scores_gemma":[0.99961805,0.000017861681,0.000015015203,0.00014795599,0.00006416551,0.00013691948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016082867,0.000052370026,0.00008878584,0.000049304967,0.0000373219,0.000005411178,0.000029728844,0.000029761308,0.0008754439],"category_scores_gemma":[0.000020552541,0.000036639456,0.000037014288,0.00013726762,0.00004432705,0.000024763394,0.0000127313715,0.00009267539,0.00008522122],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019902117,0.00019645729,0.24645254,0.0001904457,0.00024922952,0.00096578477,0.0009894571,0.0000016318052,0.046873413,0.0007346189,0.30623406,0.39512214],"study_design_scores_gemma":[0.0014906107,0.00014723574,0.13490558,0.00007515885,0.000037998634,0.000019493647,0.00009610123,0.000012058382,0.07581632,0.00009869896,0.787222,0.000078724515],"about_ca_topic_score_codex":0.00007570954,"about_ca_topic_score_gemma":0.000017425138,"teacher_disagreement_score":0.48098797,"about_ca_system_score_codex":0.00017079487,"about_ca_system_score_gemma":0.00013333834,"threshold_uncertainty_score":0.95854974},"labels":[],"label_agreement":null},{"id":"W4252885931","doi":"10.3410/f.718765369.793499659","title":"Faculty Opinions recommendation of Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.","year":2014,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Guideline; Medicine; Clinical Oncology; Clinical Practice; Oncology; Systemic therapy; Internal medicine; Cancer; Family medicine; Pathology; Breast cancer","score_opus":0.10930666882349448,"score_gpt":0.505937931464352,"score_spread":0.39663126264085746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252885931","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000057056946,0.007938852,0.000007037906,0.16971523,0.0002792744,0.00310681,0.8188418,0.0000116110305,0.000042307212],"genre_scores_gemma":[0.00009068368,0.027256329,0.0033741314,0.0038565372,0.0002275583,0.0007147927,0.9639673,0.000029266143,0.00048337327],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922533,0.0013572725,0.003765739,0.00081568485,0.0014417871,0.00036619158],"domain_scores_gemma":[0.98390466,0.00066543696,0.003966278,0.00095711567,0.010140216,0.00036627552],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004025092,0.0004887153,0.0023674965,0.00021670375,0.000118301934,0.00004515812,0.0005454422,0.0004899876,0.00011729427],"category_scores_gemma":[0.003053746,0.00026942525,0.0005743498,0.0013364282,0.0010448904,0.00023293868,0.00019549184,0.001613126,0.0000018007831],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009285487,0.0008343797,0.0011573698,0.008486564,0.0009786908,0.0000017951706,0.0009805085,5.7692523e-7,0.0000028975621,0.000010420814,0.9500439,0.036574323],"study_design_scores_gemma":[0.0053227874,0.002230629,0.010978592,0.015778258,0.0007298657,0.000043476623,0.00091334834,0.00001700505,0.0000063739712,0.0000017216497,0.96374625,0.0002316838],"about_ca_topic_score_codex":0.014443923,"about_ca_topic_score_gemma":0.0026419468,"teacher_disagreement_score":0.16585869,"about_ca_system_score_codex":0.000583587,"about_ca_system_score_gemma":0.007820113,"threshold_uncertainty_score":0.9999758},"labels":[],"label_agreement":null},{"id":"W4252918737","doi":"10.1200/jco.2013.31.6_suppl.52","title":"Validation of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Biochemical recurrence; Prostate cancer; breakpoint cluster region; Internal medicine; Population; Oncology; Cohort; Metastasis; Proportional hazards model; Disease; Context (archaeology); Localized disease; Surgery; Cancer","score_opus":0.11569438920027351,"score_gpt":0.4629404359793572,"score_spread":0.34724604677908366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252918737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98960996,0.0008932434,0.000031898868,0.007923311,0.00011696702,0.0009954388,0.000008156425,0.0000057590105,0.00041528195],"genre_scores_gemma":[0.9963616,0.00071481505,0.0024467648,0.00014443489,0.00014103102,0.000047415466,0.000022090877,0.0000142098725,0.00010762806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971215,0.00044621763,0.001364815,0.00021422068,0.0005838426,0.0002693908],"domain_scores_gemma":[0.99692255,0.00081592525,0.0009851704,0.00016548492,0.00051155005,0.0005993018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015701699,0.00013451492,0.00094830757,0.00019250678,0.000020301728,0.0000109917655,0.0001430468,0.0001348238,0.00016960272],"category_scores_gemma":[0.0013680703,0.000072552626,0.00017740083,0.00017374025,0.00052759814,0.0001878126,0.000053746786,0.00078241335,0.000012712037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06014676,0.008594826,0.7897411,0.00059042434,0.0007142961,0.0022297525,0.00036164845,0.000013045935,0.016086247,0.000038909817,0.0060977577,0.11538523],"study_design_scores_gemma":[0.02475869,0.019525629,0.94266135,0.0012022421,0.0004599241,0.00022602211,0.00022991924,0.00056484994,0.00840213,0.0005569645,0.0012731188,0.00013918514],"about_ca_topic_score_codex":0.00001381764,"about_ca_topic_score_gemma":0.0000013403417,"teacher_disagreement_score":0.15292022,"about_ca_system_score_codex":0.00020537105,"about_ca_system_score_gemma":0.002845639,"threshold_uncertainty_score":0.5048041},"labels":[],"label_agreement":null},{"id":"W4253028827","doi":"10.5489/cuaj.735","title":"HIFU ablation is not a proven standard treatment for localized prostate cancer","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Ablation; Medicine; Prostate; Urology; Cancer; Medical physics; Oncology; Radiology; Internal medicine","score_opus":0.02831282472661701,"score_gpt":0.30651006834591993,"score_spread":0.2781972436193029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253028827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7270999,0.0010323925,0.00013502542,0.2655768,0.00037286573,0.003413932,0.0006301554,0.000049964856,0.0016889649],"genre_scores_gemma":[0.9774663,0.0008531525,0.00045683884,0.005360811,0.0005521627,0.0006710112,0.000091505,0.000023997973,0.014524227],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984316,0.000069305555,0.000295227,0.00021842025,0.00036131218,0.0006241306],"domain_scores_gemma":[0.9981916,0.00009267113,0.00018509285,0.000089108195,0.00068010925,0.0007614515],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029450978,0.00015650332,0.000308455,0.00014602716,0.00031403915,0.00015080068,0.00006054398,0.00018597957,0.0022601255],"category_scores_gemma":[0.00018614712,0.00010283319,0.0001649245,0.0001494899,0.0000316339,0.00014212998,0.00000623331,0.00022534141,0.00006781916],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018763134,0.00016224847,0.67720294,0.000033136304,0.00090290175,0.000060873674,0.0010965236,0.0000372333,0.0010725426,0.00011088348,0.12678222,0.19066216],"study_design_scores_gemma":[0.013441457,0.0040291846,0.3010913,0.000048656268,0.0002698842,0.000044167875,0.00014677357,0.0013119457,0.0020413487,0.0026269655,0.6746612,0.00028707134],"about_ca_topic_score_codex":0.00443,"about_ca_topic_score_gemma":0.0009671255,"teacher_disagreement_score":0.54787904,"about_ca_system_score_codex":0.005184711,"about_ca_system_score_gemma":0.0015520132,"threshold_uncertainty_score":0.9986519},"labels":[],"label_agreement":null},{"id":"W4253470223","doi":"10.1186/s12894-018-0397-5","title":"Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials","year":2018,"lang":"en","type":"erratum","venue":"BMC Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre","funders":"","keywords":"Medicine; Mistake; Prostate cancer; Clinical trial; Section (typography); Sentence; Cancer; Medical physics; Oncology; Internal medicine; Natural language processing; Computer science","score_opus":0.06940393031988432,"score_gpt":0.44975670345590757,"score_spread":0.3803527731360232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253470223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909998,0.00043500864,0.000020224463,0.0011181891,0.0020748482,0.0043168846,0.00039751828,0.000010278814,0.0006272175],"genre_scores_gemma":[0.98993176,0.00017592148,0.00028360533,0.0003063611,0.00025360708,0.0008491866,0.0012386026,0.000035225352,0.006925718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959229,0.0014636995,0.001127461,0.00060567446,0.0005143975,0.00036582098],"domain_scores_gemma":[0.99778724,0.0009021913,0.0005142431,0.00035152058,0.00030114458,0.00014367356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002150346,0.0002813108,0.0016377346,0.0007906258,0.000047040183,0.00002267425,0.00012493959,0.00023443389,0.00011399344],"category_scores_gemma":[0.0012464945,0.00014846024,0.00014746471,0.0014002258,0.00021345654,0.000042933745,0.00005353838,0.0005731132,0.000004254777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029898185,0.00083509885,0.8930772,0.0002214493,0.0007179376,0.000053586708,0.0026763903,0.000059641443,0.00001617066,0.0000014191695,0.06560551,0.006837412],"study_design_scores_gemma":[0.0072375946,0.00657923,0.97877693,0.00024401967,0.0035649282,0.0000026672544,0.000545593,0.00030544357,0.000023749524,0.000010010623,0.0025385926,0.00017121751],"about_ca_topic_score_codex":0.0027034765,"about_ca_topic_score_gemma":0.034922138,"teacher_disagreement_score":0.08569975,"about_ca_system_score_codex":0.00014348327,"about_ca_system_score_gemma":0.0009010234,"threshold_uncertainty_score":0.982688},"labels":[],"label_agreement":null},{"id":"W4253473443","doi":"10.1200/jco.2019.37.15_suppl.tps5100","title":"PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostatectomy; Prostate cancer; Urology; Antiandrogen; Internal medicine; Placebo; Randomization; Oncology; Randomized controlled trial; Cancer; Pathology","score_opus":0.06609354285625957,"score_gpt":0.44419695264387915,"score_spread":0.3781034097876196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253473443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9648053,0.0007378448,0.00029505603,0.001960549,0.0012079552,0.030833159,0.000040938863,0.000023578457,0.00009563655],"genre_scores_gemma":[0.9895268,0.003891933,0.00308288,0.0003710785,0.00053752953,0.0020330064,0.00004302618,0.000081996266,0.00043176874],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99085355,0.0016677993,0.0045159557,0.00066283526,0.0015498415,0.00075000804],"domain_scores_gemma":[0.98970765,0.0040053222,0.0036440177,0.0004570155,0.0014445332,0.00074147666],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006543547,0.0004964757,0.005679073,0.00056693744,0.00007557576,0.00003206711,0.00036959405,0.00057996437,0.00024172157],"category_scores_gemma":[0.0035539456,0.0002653506,0.00070270617,0.0007078779,0.00056337524,0.00032363227,0.00009459838,0.0016032878,0.000015686508],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87957716,0.005479411,0.009977608,0.00011955412,0.0023956918,0.00025392647,0.00045579099,0.0012938086,0.00005696344,0.000012261739,0.00006985836,0.100307986],"study_design_scores_gemma":[0.8909419,0.102469586,0.001117249,0.0006231809,0.00074214756,0.000012104433,0.00010059826,0.00066952856,0.00063352525,0.00005088791,0.002366895,0.0002723781],"about_ca_topic_score_codex":0.0002681743,"about_ca_topic_score_gemma":0.00026675337,"teacher_disagreement_score":0.10003561,"about_ca_system_score_codex":0.0012883381,"about_ca_system_score_gemma":0.010538794,"threshold_uncertainty_score":0.99997985},"labels":[],"label_agreement":null},{"id":"W4254102689","doi":"10.1186/preaccept-1882913817126479","title":"Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer","year":2014,"lang":"en","type":"article","venue":"Genome Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada; Prostate Cancer Foundation","keywords":"Biology; Chromothripsis; Prostate cancer; Transcriptome; Chromoplexy; Tumor progression; Genetics; Computational biology; Genome instability; Cancer; Cancer research; Gene; Gene expression; DNA damage; PCA3","score_opus":0.02435837050415369,"score_gpt":0.32156558619721787,"score_spread":0.2972072156930642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254102689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955099,0.0022336063,0.00005104657,0.0012625197,0.00012006528,0.00045788888,0.00011137731,0.000010586072,0.00024300204],"genre_scores_gemma":[0.99827814,0.0009562914,0.00005517824,0.00031526654,0.00009495413,0.00011929268,0.000050393865,0.0000088522065,0.000121639394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990372,0.00020630067,0.0002146875,0.00020009068,0.00007115426,0.00027056417],"domain_scores_gemma":[0.9995449,0.0000635407,0.00006667391,0.00023446619,0.000045018794,0.000045383244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004088098,0.0000980915,0.0002627376,0.00009087595,0.000031389398,0.000003491979,0.00013488058,0.000051236464,0.00008412021],"category_scores_gemma":[0.0000319802,0.000052975614,0.00006186563,0.00014685796,0.00019097055,0.000015576374,0.000023416196,0.00016969904,0.000013169529],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014728713,0.00031476474,0.8055064,0.00019082706,0.00022016659,0.000025270954,0.0036255524,0.000010374421,0.15424177,0.00034398463,0.000105284045,0.033942737],"study_design_scores_gemma":[0.0055284807,0.0025531421,0.9266702,0.000050818002,0.000099602024,0.0000264733,0.00024557425,0.000045064,0.01493735,0.0014286063,0.048248164,0.00016650678],"about_ca_topic_score_codex":0.0015273375,"about_ca_topic_score_gemma":0.00039654734,"teacher_disagreement_score":0.13930443,"about_ca_system_score_codex":0.000056957877,"about_ca_system_score_gemma":0.00005852516,"threshold_uncertainty_score":0.23088875},"labels":[],"label_agreement":null},{"id":"W4254701901","doi":"10.1200/jco.2012.30.5_suppl.15","title":"Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Placebo; Clinical endpoint; Discontinuation; Prostate cancer; Internal medicine; Docetaxel; Tolerability; Prednisone; Randomization; Hazard ratio; Oncology; Urology; Gastroenterology; Chemotherapy; Cancer; Randomized controlled trial; Androgen deprivation therapy; Adverse effect; Confidence interval","score_opus":0.22405257462937547,"score_gpt":0.516633520639768,"score_spread":0.29258094601039253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254701901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99307275,0.0048100753,0.0000073816723,0.00052660477,0.00021622067,0.0012496231,0.000066856315,0.0000032169564,0.00004726892],"genre_scores_gemma":[0.99487185,0.0043753437,0.0002965056,0.000031496835,0.000093642455,0.00009870952,0.000011629739,0.000017677294,0.00020316569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948796,0.00070459495,0.0031706765,0.00026266035,0.0005792715,0.00040320796],"domain_scores_gemma":[0.9961268,0.0009876314,0.0018224295,0.00022920694,0.00044808743,0.00038584523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034462258,0.00023182924,0.0031464894,0.00072079897,0.000030784333,0.000008429482,0.00010617199,0.0001371335,0.0000834857],"category_scores_gemma":[0.00025429772,0.00015161867,0.00027258493,0.0007679134,0.00025477514,0.0002529111,0.00004828821,0.0004232025,6.6846127e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.085291855,0.040865317,0.75866926,0.00023011958,0.010435177,0.0011166816,0.019460013,0.00093750964,0.0046657394,0.000015795702,0.000025613883,0.07828692],"study_design_scores_gemma":[0.15135811,0.038762394,0.7914103,0.00019557805,0.006697717,0.00001809219,0.009305402,0.0009011396,0.00093603745,0.00002760643,0.0002190611,0.00016854616],"about_ca_topic_score_codex":0.001063458,"about_ca_topic_score_gemma":0.010013349,"teacher_disagreement_score":0.07811838,"about_ca_system_score_codex":0.0006488058,"about_ca_system_score_gemma":0.0019254058,"threshold_uncertainty_score":0.61828303},"labels":[],"label_agreement":null},{"id":"W4254855644","doi":"10.5489/cuaj.1287","title":"Moderated Posters 1: Oncology-Prostate","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate; Medicine; Oncology; Internal medicine; Cancer","score_opus":0.022090562570181466,"score_gpt":0.27947547801253264,"score_spread":0.2573849154423512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254855644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.837657,0.00029610132,0.000009635059,0.14696144,0.00024071678,0.00038241537,0.000016278445,0.000031992626,0.014404459],"genre_scores_gemma":[0.98470837,0.00017952608,0.00017234737,0.008445295,0.00022511506,0.000026418706,0.00003808865,0.000010906935,0.0061939443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858326,0.00013329164,0.0002366273,0.00015064151,0.00028530328,0.0006108897],"domain_scores_gemma":[0.99811316,0.000070437076,0.000117894924,0.00007592318,0.00049940526,0.001123208],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036104335,0.00010859325,0.00021965054,0.00017489002,0.0002728807,0.00012826275,0.00007913942,0.0002317265,0.0026616582],"category_scores_gemma":[0.00028708475,0.00007536081,0.00009268237,0.0001886117,0.000039132945,0.00014369887,0.000012104961,0.00063280325,0.0006391114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018581291,0.00011386517,0.80467033,0.000005884351,0.00032641232,0.000413884,0.00036789838,0.000032055705,0.0016623616,0.00007044074,0.16128457,0.030866478],"study_design_scores_gemma":[0.0035858226,0.0013595931,0.850377,0.0000148217805,0.00007117272,0.00048375985,0.00023514856,0.0008688993,0.00014630656,0.0020622066,0.14060968,0.0001855433],"about_ca_topic_score_codex":0.0020548927,"about_ca_topic_score_gemma":0.00025210745,"teacher_disagreement_score":0.1470514,"about_ca_system_score_codex":0.0026625271,"about_ca_system_score_gemma":0.0011309803,"threshold_uncertainty_score":0.99825007},"labels":[],"label_agreement":null},{"id":"W4255135550","doi":"10.1017/s1460396921000248","title":"Review of novel liquid-based biomarkers for prostate cancer: towards personalised and targeted medicine","year":2021,"lang":"en","type":"article","venue":"Journal of Radiotherapy in Practice","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Guelph; Grand River Hospital; University of Waterloo","funders":"","keywords":"Prostate cancer; Medicine; Disease; Liquid biopsy; Cancer; Precision medicine; Prostate; Narrative review; Oncology; Intensive care medicine; Prostate-specific antigen; Biomarker; Biopsy; Internal medicine; Pathology","score_opus":0.042344285094666326,"score_gpt":0.4132085591876058,"score_spread":0.3708642740929395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255135550","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03655805,0.79892707,0.00049438095,0.16277242,0.00023050196,0.00077862694,0.00004052185,0.0000047944177,0.00019363879],"genre_scores_gemma":[0.0137336515,0.9510108,0.023530977,0.011052424,0.00031322407,0.00004923129,0.000021447164,0.000038384154,0.00024981512],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985093,0.00014523794,0.00058095105,0.00015399414,0.00042086668,0.00018963846],"domain_scores_gemma":[0.99735415,0.00059954554,0.00058909866,0.0001336979,0.0011795628,0.00014394995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001629732,0.00013278492,0.0006326381,0.00018747244,0.000030018802,0.000008163287,0.00006686363,0.000058040314,0.00015531779],"category_scores_gemma":[0.0015996615,0.00008982097,0.00012042099,0.0004451368,0.00013230077,0.00020349101,0.0000066202338,0.00023462415,4.83221e-8],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.102936104,0.003348125,0.0055904677,0.035486504,0.0063031637,0.0013091308,0.005247984,0.000043116594,0.6807935,0.00007637273,0.039321918,0.11954357],"study_design_scores_gemma":[0.098635904,0.01637388,0.0030402725,0.06959966,0.0023836861,0.0026860854,0.0029809165,0.0016926224,0.073117115,0.000017535147,0.7290244,0.0004479298],"about_ca_topic_score_codex":0.000109730245,"about_ca_topic_score_gemma":0.0000064787514,"teacher_disagreement_score":0.68970245,"about_ca_system_score_codex":0.00027148752,"about_ca_system_score_gemma":0.0016922097,"threshold_uncertainty_score":0.36627927},"labels":[],"label_agreement":null},{"id":"W4255815021","doi":"10.1200/jco.2011.29.7_suppl.3","title":"A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Androgen deprivation therapy; Clinical endpoint; Prostate cancer; Interim analysis; Internal medicine; Randomized controlled trial; Goserelin; Androgen suppression; Prostatectomy; Urology; Placebo; Progression-free survival; Androgen; Oncology; Cancer; Chemotherapy; Hormone","score_opus":0.15502023248022337,"score_gpt":0.4819053568972396,"score_spread":0.3268851244170162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255815021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852321,0.00084640406,0.00025109612,0.000654899,0.005070106,0.0074284775,0.0000143328425,0.000025861535,0.00047669103],"genre_scores_gemma":[0.9947279,0.00042927818,0.0016203083,0.00022635527,0.0021851684,0.00051484676,0.000060397142,0.000050456598,0.00018529585],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99321896,0.001265805,0.0035395669,0.00048888905,0.00085555756,0.0006312189],"domain_scores_gemma":[0.99331254,0.0025209147,0.0023766966,0.00031191012,0.00069399766,0.00078397075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004272749,0.0004057757,0.0039965534,0.00026146704,0.00012903131,0.000050342005,0.00033265082,0.0005335282,0.00043069382],"category_scores_gemma":[0.002381425,0.00021216582,0.0014478957,0.00013152267,0.00096310716,0.00023354474,0.00014940796,0.0012533165,0.000006856948],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86604226,0.018885959,0.0073650894,0.000033865283,0.0017975774,0.0005488097,0.000579798,8.150223e-8,0.000033719924,0.0000052811347,0.0014584207,0.10324916],"study_design_scores_gemma":[0.8300812,0.1609655,0.0014288943,0.00045791012,0.0010391166,0.000046522426,0.0001147488,0.00008955519,0.00042163362,0.000049147966,0.005113284,0.00019247584],"about_ca_topic_score_codex":0.000017366967,"about_ca_topic_score_gemma":0.000012795648,"teacher_disagreement_score":0.14207953,"about_ca_system_score_codex":0.00027676346,"about_ca_system_score_gemma":0.0013235587,"threshold_uncertainty_score":0.8651871},"labels":[],"label_agreement":null},{"id":"W4255834306","doi":"10.5489/cuaj.742","title":"The role of resection of pulmonary metastases from prostate cancer: a case report and literature review","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Prostatectomy; Lung; Prostate; Prostate cancer; Nodule (geology); Resection; Radiology; Lobe; Urology; Surgery; Cancer; Pathology; Internal medicine","score_opus":0.012316166696984125,"score_gpt":0.2768632180870658,"score_spread":0.2645470513900817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255834306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70192105,0.2741576,4.2248124e-7,0.022794815,0.00007224805,0.00046475395,0.00017108965,0.000004132773,0.0004138646],"genre_scores_gemma":[0.90581506,0.09308452,0.000030296806,0.00031063156,0.00010831529,0.000042549873,0.00004498076,0.0000051193806,0.0005584976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989345,0.00016874076,0.00033243478,0.000111647925,0.0002403795,0.00021227177],"domain_scores_gemma":[0.99850994,0.00015592606,0.0003336416,0.00009436003,0.0006108194,0.0002952834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005821161,0.000073869676,0.0002280856,0.00006479197,0.00017905947,0.000039052746,0.0000417603,0.0000823186,0.00017386222],"category_scores_gemma":[0.00057546207,0.000040142448,0.000071618524,0.00020251103,0.00005363161,0.00009147768,0.000012043814,0.000328948,0.000001335271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026680605,0.00007476862,0.8561816,0.000193028,0.0006332732,0.022799408,0.00033116539,0.0000023376986,0.0015828391,0.000035334186,0.012863518,0.1050359],"study_design_scores_gemma":[0.0028303973,0.0019435184,0.72573054,0.003465908,0.0011066779,0.10975697,0.0012531637,0.0004682091,0.002178594,0.00828507,0.14260982,0.0003710995],"about_ca_topic_score_codex":0.009178053,"about_ca_topic_score_gemma":0.0010790959,"teacher_disagreement_score":0.20389403,"about_ca_system_score_codex":0.0002569244,"about_ca_system_score_gemma":0.0003622721,"threshold_uncertainty_score":0.9974199},"labels":[],"label_agreement":null},{"id":"W4256178155","doi":"10.1158/1538-7445.am2018-4995","title":"Abstract 4995: Identity fraud: Lineage plasticity as a mechanism of anti-androgen resistance and target for therapy","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Reprogramming; Biology; Enzalutamide; Cancer research; Transdifferentiation; Androgen receptor; EZH2; Prostate cancer; Epigenetics; Cancer; Cell biology; Cell; Stem cell; Genetics; Gene","score_opus":0.1007832456863494,"score_gpt":0.4513442733368875,"score_spread":0.3505610276505381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256178155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98975426,0.0054909666,0.0003353351,0.0009714939,0.000113881266,0.00148265,0.00020872754,0.000027370756,0.0016153014],"genre_scores_gemma":[0.98977137,0.0055591017,0.00054464774,0.00006807533,0.00047779753,0.00031250858,0.000020724307,0.000037287995,0.003208517],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977765,0.00006679768,0.00026108764,0.0004482391,0.0008378511,0.00060953177],"domain_scores_gemma":[0.9980466,0.0002775595,0.00006921155,0.00028746782,0.0010617689,0.00025741538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010308357,0.00015340874,0.00037249803,0.0002363818,0.00029608115,0.00005017836,0.00020312442,0.00013170186,0.0007338892],"category_scores_gemma":[0.00027256622,0.000117082316,0.00008564096,0.0004243777,0.0006638363,0.00017298799,0.00009799507,0.00033135992,0.000024973013],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01297504,0.000674081,0.01013978,0.001711348,0.000737769,0.0001201149,0.0016294807,0.0000012832667,0.94905865,0.008027125,0.010380287,0.0045450167],"study_design_scores_gemma":[0.0051400447,0.0015258616,0.011291643,0.00034468982,0.000024772253,0.0000045547235,0.00018667588,0.00005645982,0.9584859,0.006711543,0.016078422,0.00014946223],"about_ca_topic_score_codex":0.0005522694,"about_ca_topic_score_gemma":0.00021636469,"teacher_disagreement_score":0.009427197,"about_ca_system_score_codex":0.00016918361,"about_ca_system_score_gemma":0.00070960505,"threshold_uncertainty_score":0.8035572},"labels":[],"label_agreement":null},{"id":"W4256385293","doi":"10.1016/s1569-9056(15)60416-x","title":"423 Functional role of the kallikrein 6 region of the kallikrein locus in genetic predisposition for aggressive (Gleason ≥8) prostate cancer: Fine-mapping and methylation study in a Canadian cohort and the Swiss arm of the European Randomized Study for Prostate Cancer Screening","year":2015,"lang":"en","type":"article","venue":"European Urology Supplements","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Kallikrein; Prostate cancer; Locus (genetics); Cohort; Oncology; Methylation; Internal medicine; Cancer; Gene; Genetics; Biology","score_opus":0.02720482633445917,"score_gpt":0.29391177874392077,"score_spread":0.26670695240946163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256385293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97891873,0.0027563127,0.000035945926,0.0026089423,0.00012220809,0.015277068,0.0001825262,0.0000043790146,0.00009389108],"genre_scores_gemma":[0.99846286,0.00018413927,0.000028763525,0.00007443752,0.000057768204,0.0009539552,0.000039339113,0.000034276472,0.00016446468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958434,0.002499245,0.0006314965,0.00034954076,0.0003370577,0.00033926943],"domain_scores_gemma":[0.9985086,0.00025323356,0.00057582953,0.00031004555,0.00027194305,0.00008040517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030814817,0.00019277206,0.00047443513,0.00014850828,0.00016752035,0.000013942827,0.00021251763,0.000029265128,0.0000045872],"category_scores_gemma":[0.00033798677,0.00009466422,0.000089291534,0.00030541955,0.00040782732,0.0000512164,0.00018508785,0.00020698359,8.9185e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028615173,0.00024146073,0.9523715,0.00007277647,0.00045386574,0.000009674793,0.012803963,0.0011756149,0.00040694608,0.000014240738,0.00013782801,0.0036969795],"study_design_scores_gemma":[0.13403995,0.00082764414,0.85875654,0.00022532586,0.00047663087,0.0000056565864,0.0024613964,0.0022463966,0.00042757386,0.00017882163,0.00025889106,0.00009514818],"about_ca_topic_score_codex":0.033829015,"about_ca_topic_score_gemma":0.089980334,"teacher_disagreement_score":0.105424784,"about_ca_system_score_codex":0.00013075705,"about_ca_system_score_gemma":0.0003379976,"threshold_uncertainty_score":0.9726048},"labels":[],"label_agreement":null},{"id":"W4280518749","doi":"10.1016/j.ejca.2022.04.016","title":"Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Alberta","funders":"National Cancer Institute; Foundation Medicine; Eisai; Merck Sharp and Dohme; Ipsen; Astellas Pharma; Sanofi; Chugai Pharmaceutical; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Prostate cancer; Tolerability; Olaparib; Medicine; Adverse effect; Oncology; Internal medicine; Cancer; Gynecology","score_opus":0.04573720873806924,"score_gpt":0.3604040520670452,"score_spread":0.31466684332897593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280518749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99327356,0.003334574,0.0000027943083,0.0017087541,0.00009838308,0.0012768755,0.00008100728,0.000004304653,0.00021977103],"genre_scores_gemma":[0.9990087,0.00026252508,0.00007634737,0.00014177634,0.000043843043,0.000074342955,0.0000115352495,0.000022437755,0.0003584839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977035,0.00070832146,0.00046437356,0.00019690712,0.000739794,0.00018712811],"domain_scores_gemma":[0.9992037,0.0000470555,0.0003051186,0.00019741204,0.00015527103,0.00009148195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080862583,0.00014116622,0.00030740869,0.00008879394,0.00016190772,0.000031722746,0.00013323556,0.0000037120515,0.00025232122],"category_scores_gemma":[0.000007631436,0.00007674392,0.000051103794,0.0002617494,0.000075583455,0.0000959241,0.00009283875,0.00032040788,7.728624e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007077732,0.0010989655,0.96005213,0.000037966984,0.0012485024,0.00072003977,0.0061206836,0.0015888679,0.000078794365,0.0000013754067,0.00023127951,0.021743674],"study_design_scores_gemma":[0.010076944,0.002335535,0.9780029,0.00011543486,0.0005403947,0.000002984137,0.006919205,0.000021255404,0.000034696317,0.00001000568,0.00185544,0.000085175874],"about_ca_topic_score_codex":0.00077501364,"about_ca_topic_score_gemma":0.0011127465,"teacher_disagreement_score":0.021658497,"about_ca_system_score_codex":0.00040767997,"about_ca_system_score_gemma":0.00016847067,"threshold_uncertainty_score":0.31295264},"labels":[],"label_agreement":null},{"id":"W4280545708","doi":"10.3390/jcm11102783","title":"Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review","year":2022,"lang":"en","type":"review","venue":"Journal of Clinical Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Tolerability; Oncology; Regimen; Clinical trial; Internal medicine; Cabazitaxel; Chemotherapy; Adverse effect; Cancer; Cyclophosphamide; Androgen deprivation therapy","score_opus":0.17391117200642986,"score_gpt":0.5699307196411556,"score_spread":0.39601954763472574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280545708","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004843923,0.97935635,0.00000714001,0.014392471,0.002042914,0.0037433663,0.00010448242,0.000014086665,0.00033437097],"genre_scores_gemma":[3.467243e-7,0.9870121,0.0005739375,0.0028719348,0.004285893,0.00049588457,0.00022437965,0.0001075693,0.0044279434],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938255,0.0004105274,0.0040570083,0.00045415264,0.0008219786,0.00043082453],"domain_scores_gemma":[0.9927693,0.0022884305,0.0033394904,0.00048624,0.0005446073,0.00057195633],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0046328376,0.00050997164,0.00783132,0.00039785326,0.000078855206,0.0000122728625,0.00042681806,0.00028275693,0.0014286852],"category_scores_gemma":[0.0028803954,0.00026270378,0.0023954208,0.00075302244,0.00021727364,0.0000960213,0.000059645856,0.002422263,0.000004166874],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013186601,0.00020677451,0.000021620472,0.10359629,0.0014441139,0.00023207744,0.000034710654,6.756069e-8,2.3931236e-7,0.000004123842,0.051631927,0.8415094],"study_design_scores_gemma":[0.007576402,0.0046308003,0.0000072063453,0.27707604,0.004374279,0.00035656025,0.000011966108,6.9959805e-7,3.2781418e-7,0.00002639811,0.70579505,0.00014425804],"about_ca_topic_score_codex":0.0000017990878,"about_ca_topic_score_gemma":5.368751e-7,"teacher_disagreement_score":0.84136516,"about_ca_system_score_codex":0.0004848392,"about_ca_system_score_gemma":0.0027310175,"threshold_uncertainty_score":0.99998254},"labels":[],"label_agreement":null},{"id":"W4280562448","doi":"10.1016/j.eururo.2022.04.019","title":"TNM Staging of Prostate Cancer: Challenges in Securing a Globally Applicable Classification","year":2022,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Glutamate carboxypeptidase II; Interquartile range; Positron emission tomography; Radiation therapy; Metastasis; Population; Prostate-specific antigen; Prostate; Oncology; Disease; Cancer; Radiology; Internal medicine","score_opus":0.07091666804099069,"score_gpt":0.3162267047172977,"score_spread":0.24531003667630702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280562448","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021019205,0.029751843,0.0000032429232,0.8636356,0.00032100748,0.0015030042,0.00013184521,0.000107720065,0.083526544],"genre_scores_gemma":[0.5099403,0.13254143,0.00021529758,0.3271449,0.004720752,0.0015188339,0.0029416007,0.0006849223,0.020291941],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99751157,0.0005022946,0.00040871155,0.00063563214,0.0003960907,0.0005456934],"domain_scores_gemma":[0.99907386,0.00008202916,0.00023230385,0.00048107925,0.00007389292,0.00005684517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005297493,0.00024840355,0.00051091827,0.00034359854,0.000055249588,0.0000103888515,0.00029456898,0.0001456153,0.0003521697],"category_scores_gemma":[0.000026032454,0.0002267979,0.00008590012,0.00023483316,0.00013290603,0.000033631266,0.00025773156,0.0016336959,0.000033278735],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004147213,0.0007195445,0.05707739,0.0055163587,0.0011026048,0.018744523,0.0072239353,0.00022207547,0.0030040804,0.0004407846,0.77085674,0.13094476],"study_design_scores_gemma":[0.001656725,0.00063107314,0.011786999,0.00008654414,0.000081630846,0.000039502327,0.00013552718,0.0000653438,0.000052233685,0.000051820585,0.98524106,0.00017157377],"about_ca_topic_score_codex":0.00009869265,"about_ca_topic_score_gemma":0.000020951085,"teacher_disagreement_score":0.5364907,"about_ca_system_score_codex":0.0003171297,"about_ca_system_score_gemma":0.0002486461,"threshold_uncertainty_score":0.924855},"labels":[],"label_agreement":null},{"id":"W4280564143","doi":"10.1002/bco2.158","title":"Patterns of care for non‐metastatic castration‐resistant prostate cancer: A population‐based study","year":2022,"lang":"en","type":"article","venue":"BJUI Compass","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McMaster University; St. Joseph’s Healthcare Hamilton; Juravinski Cancer Centre; Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of British Columbia; BC Cancer Agency; University of Ottawa; McGill University; London Health Sciences Centre; University of Alberta; Western University; University of Toronto; University of Calgary; Princess Margaret Cancer Centre; Mount Sinai Hospital; Baker Hughes (Canada); Ottawa Hospital; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Population; Cancer; Urology","score_opus":0.044822417365900445,"score_gpt":0.36523857996004655,"score_spread":0.3204161625941461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280564143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936505,0.00038353793,0.00009489569,0.0006847566,0.00012657592,0.0037172406,0.0012683785,0.00002666887,0.00004743272],"genre_scores_gemma":[0.9957564,0.0000052767,0.00028971053,0.00005541446,0.000035129695,0.0023846321,0.0007649596,0.000024964747,0.0006835172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986783,0.00007560063,0.00029569588,0.00024203458,0.00047525528,0.00023308459],"domain_scores_gemma":[0.9992706,0.000067593486,0.00012101905,0.00024826243,0.00021127259,0.000081223276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014147138,0.00012731359,0.0003415749,0.00015156489,0.00025108663,0.000014757044,0.00009435928,0.000010827044,0.00021381088],"category_scores_gemma":[0.000010983968,0.00010796896,0.00009607067,0.00022078237,0.000011076304,0.000034803248,0.00004683355,0.00011029318,9.470537e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003521717,0.0012262089,0.98334724,0.0011360133,0.00024849406,0.00007373068,0.003952112,0.0019916724,0.001783843,0.00002814413,0.00050470117,0.0021861207],"study_design_scores_gemma":[0.015148444,0.0056485888,0.9571778,0.0001322005,0.00038700268,0.0000043157643,0.014579787,0.0027585905,0.002048601,0.000031429947,0.0018776557,0.00020556306],"about_ca_topic_score_codex":0.0016389274,"about_ca_topic_score_gemma":0.0010945213,"teacher_disagreement_score":0.026169421,"about_ca_system_score_codex":0.00038886894,"about_ca_system_score_gemma":0.00040357397,"threshold_uncertainty_score":0.44028464},"labels":[],"label_agreement":null},{"id":"W4280566607","doi":"10.1038/s41467-022-30257-z","title":"MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"National Institute of General Medical Sciences; Institute for Prostate Cancer Research; Canadian Institutes of Health Research; McGill University Health Centre; Cancer Research Society; Lucas Foundation; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation; McGill University; U.S. Department of Defense","keywords":"Prostate cancer; Androgen receptor; Cancer research; Carcinogenesis; Transcriptome; Biology; Enhancer; Transcriptional regulation; Prostate; Tumor progression; Cancer; Gene; Gene expression; Genetics","score_opus":0.022245069620651464,"score_gpt":0.3434167540474366,"score_spread":0.3211716844267851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280566607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54640424,0.37758553,0.0000038412963,0.06767932,0.00032323462,0.0016127898,0.0040402547,0.00016404266,0.0021867205],"genre_scores_gemma":[0.9606673,0.020890107,0.0007525248,0.0008090874,0.00006001717,0.0013757464,0.0049359114,0.000038392685,0.010470874],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99854875,0.0002056673,0.00021677942,0.00027762435,0.00044795912,0.00030322315],"domain_scores_gemma":[0.9984819,0.00013294692,0.00015258684,0.0008719221,0.00018072632,0.00017987205],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00016114941,0.00015667449,0.00019788263,0.00009787917,0.0013143087,0.000021527929,0.000457322,0.00010426767,0.0008374211],"category_scores_gemma":[0.000083995226,0.00013424183,0.00010575691,0.00037037965,0.00020684247,0.00009700743,0.0004201714,0.0012803022,0.000019606185],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003221643,0.0028992,0.1619081,0.0002093479,0.0013934255,0.00011940656,0.01668937,0.00009702228,0.26446787,0.0018522076,0.52722484,0.01991756],"study_design_scores_gemma":[0.002634637,0.0002069251,0.0053070365,0.00009045461,0.00013070847,0.00004237906,0.00069813605,0.00019870372,0.0069828425,0.000057133228,0.98342717,0.00022390284],"about_ca_topic_score_codex":0.000072383205,"about_ca_topic_score_gemma":0.00014783922,"teacher_disagreement_score":0.4562023,"about_ca_system_score_codex":0.000664508,"about_ca_system_score_gemma":0.00026654612,"threshold_uncertainty_score":0.9999859},"labels":[],"label_agreement":null},{"id":"W4280579547","doi":"10.1186/s12014-022-09352-2","title":"Transcriptome profiling and proteomic validation reveals targets of the androgen receptor signaling in the BT-474 breast cancer cell line","year":2022,"lang":"en","type":"article","venue":"Clinical Proteomics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Translational Research in Oncology; Toronto General Hospital; University Health Network; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Androgen receptor; Downregulation and upregulation; Androgen; Transcriptome; Biology; Dihydrotestosterone; Signal transduction; Cancer research; Estrogen receptor; Transcription factor; Gene expression profiling; Endocrinology; Internal medicine; Gene expression; Gene; Cell biology; Hormone; Cancer; Prostate cancer; Breast cancer; Medicine; Genetics","score_opus":0.0567407656718679,"score_gpt":0.3623710424726679,"score_spread":0.30563027680079996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280579547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877934,0.0011594982,0.000027362754,0.0062597953,0.00017169994,0.0043303487,0.0001758915,0.000013272227,0.000068724505],"genre_scores_gemma":[0.99647814,0.0006359398,0.0010032273,0.00035050084,0.00019692982,0.0008786688,0.000042515177,0.000024201323,0.00038990175],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978397,0.00055367075,0.00066048035,0.00032236538,0.00036616265,0.00025761357],"domain_scores_gemma":[0.99917656,0.00016126821,0.00021925448,0.00029940772,0.0000703181,0.000073176285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002002079,0.00013804687,0.0003474944,0.0000410367,0.00020064652,0.000016745571,0.00023996815,0.00008845949,0.00013597077],"category_scores_gemma":[0.00008333644,0.00007859893,0.00014213265,0.00026528834,0.0001567739,0.00006755144,0.00011118674,0.000712736,0.0000011242715],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025340617,0.00080310553,0.29557797,0.0003958921,0.00008349001,0.000009451042,0.0013019475,0.00017894825,0.69708645,0.00007785059,0.00015942559,0.0017913883],"study_design_scores_gemma":[0.01881303,0.002711237,0.08401024,0.0006775584,0.00044437742,0.00009470574,0.0030381246,0.0018244514,0.884563,0.0018643952,0.001381481,0.0005773612],"about_ca_topic_score_codex":0.00006478117,"about_ca_topic_score_gemma":0.0000030805652,"teacher_disagreement_score":0.21156773,"about_ca_system_score_codex":0.00012741092,"about_ca_system_score_gemma":0.00029649076,"threshold_uncertainty_score":0.32051715},"labels":[],"label_agreement":null},{"id":"W4280581878","doi":"10.1016/j.molmet.2022.101516","title":"Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion","year":2022,"lang":"en","type":"article","venue":"Molecular Metabolism","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Université Laval","keywords":"Citric acid cycle; Glutaminolysis; Citrate synthase; Tricarboxylic acid; Metabolic pathway; Biology; ATP citrate lyase; Biochemistry; Chemistry; Glutamine; Cell biology; Metabolism; Enzyme","score_opus":0.012419929781583017,"score_gpt":0.24584876474080852,"score_spread":0.2334288349592255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280581878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97450656,0.015421264,0.00006218052,0.0067698886,0.00025485683,0.0026080327,0.000072504714,0.00004011656,0.00026459465],"genre_scores_gemma":[0.9978922,0.00046347338,0.00009552208,0.00045165932,0.000049405884,0.0005292761,0.00003603922,0.000033154145,0.0004492536],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99787605,0.00045468786,0.00028871425,0.00038095724,0.0006437669,0.0003558027],"domain_scores_gemma":[0.9989891,0.000027415375,0.000126277,0.00053235976,0.00020299428,0.0001218588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007001826,0.00018723236,0.00034251274,0.00016343038,0.00032884884,0.000026753292,0.00017584642,0.000031430816,0.000029906296],"category_scores_gemma":[0.0003064926,0.00010616018,0.00013264311,0.0011559628,0.00019315898,0.000049808288,0.00024634125,0.00033313676,0.0000019010191],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088936504,0.00019251644,0.0017056895,0.00007397167,0.00023190798,0.000038716888,0.0037053563,0.00020552165,0.9852295,0.0023914347,0.00011207931,0.0052239536],"study_design_scores_gemma":[0.005275272,0.00033804777,0.07749673,0.000043482163,0.0007693398,0.00013793784,0.003473294,0.00093134126,0.8752309,0.0024056486,0.03356095,0.000337024],"about_ca_topic_score_codex":0.00015775178,"about_ca_topic_score_gemma":0.000010493828,"teacher_disagreement_score":0.109998554,"about_ca_system_score_codex":0.00006772185,"about_ca_system_score_gemma":0.0002704967,"threshold_uncertainty_score":0.43290865},"labels":[],"label_agreement":null},{"id":"W4280630044","doi":"10.17650/1726-9776-2022-18-1-77-89","title":"Apalutamide compared with darolutamide for the treatment of non-metastatic castration resistant prostate cancer: efficacy and tolerability in a matching-adjusted indirect comparison","year":2022,"lang":"en","type":"article","venue":"Cancer Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Prostate cancer; Tolerability; Oncology; Internal medicine; Urology; Cancer; Adverse effect","score_opus":0.05150558099593017,"score_gpt":0.3567398578961358,"score_spread":0.30523427690020566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280630044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846451,0.008653419,0.000041353607,0.0026009115,0.00009741274,0.0035295344,0.00039493997,0.000018251952,0.00001902174],"genre_scores_gemma":[0.99471843,0.001009578,0.00012992053,0.00009388896,0.000031724143,0.0037654978,0.00010908766,0.000023470964,0.000118387354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844164,0.00016920129,0.0003990388,0.000390778,0.00023290138,0.000366436],"domain_scores_gemma":[0.9989636,0.00041265905,0.00019303351,0.0002620758,0.00008797224,0.00008064971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022902525,0.0001935242,0.000673768,0.00013570026,0.0002125956,0.000010908724,0.00008755919,0.00002802616,0.00005173512],"category_scores_gemma":[0.000012639683,0.00012187633,0.000048363814,0.00035699425,0.0002622883,0.000034421377,0.00003141253,0.00019055369,1.9595154e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08241187,0.0024873395,0.77132446,0.0006125856,0.0011545329,0.0001100029,0.02458754,0.053592786,0.008052635,0.000019326886,0.00022583807,0.055421114],"study_design_scores_gemma":[0.021434944,0.011520463,0.94645697,0.000046826703,0.0006490355,0.00002337056,0.0019767124,0.013350314,0.0013279842,0.00005638803,0.0029831508,0.00017386282],"about_ca_topic_score_codex":0.0036121234,"about_ca_topic_score_gemma":0.01160732,"teacher_disagreement_score":0.17513251,"about_ca_system_score_codex":0.00066294265,"about_ca_system_score_gemma":0.0005955038,"threshold_uncertainty_score":0.64771575},"labels":[],"label_agreement":null},{"id":"W4281261821","doi":"10.5489/cuaj.7730","title":"Androgen deprivation therapy for prostate cancer: Prescribing behaviors and preferences among urologists","year":2022,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Ontario Ministry of Health and Long-Term Care; Princess Margaret Cancer Foundation; Cancer Care Ontario","keywords":"Medicine; Medical prescription; Androgen deprivation therapy; Prostate cancer; Odds ratio; Tolerability; Confidence interval; Logistic regression; Internal medicine; Population; Goserelin; Gynecology; Cancer; Oncology; Adverse effect; Pharmacology","score_opus":0.03587399842227536,"score_gpt":0.29303045719774146,"score_spread":0.2571564587754661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281261821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852674,0.0021101176,0.000008312225,0.011436802,0.00015180159,0.0007689514,0.00013661009,0.000019836278,0.00010019436],"genre_scores_gemma":[0.99641407,0.0014448543,0.000055977896,0.0009461205,0.00013210805,0.0003834467,0.0000751047,0.000010704828,0.00053760875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987167,0.00013825197,0.00020191266,0.00020360039,0.00032038242,0.00041912837],"domain_scores_gemma":[0.99912375,0.000085705666,0.00017015732,0.000057870908,0.000184493,0.00037802637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006400217,0.00010183883,0.00017655801,0.00014087568,0.000772036,0.000082216306,0.00008300048,0.000088940265,0.000264924],"category_scores_gemma":[0.0001417735,0.00007814849,0.00006518452,0.00015030446,0.000046057496,0.00009470566,0.000023958686,0.0004256757,6.2780373e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002845094,0.000038643528,0.974789,0.0000031369216,0.000082941,0.000023474357,0.0003021174,0.00004968479,0.00016873293,0.00001639051,0.0018086038,0.02243272],"study_design_scores_gemma":[0.0023361116,0.0012385497,0.9664045,0.0000047853714,0.000054081553,0.00004565299,0.00016569538,0.00024280633,0.0001404188,0.0005824228,0.028683443,0.00010150932],"about_ca_topic_score_codex":0.0020610285,"about_ca_topic_score_gemma":0.00079857773,"teacher_disagreement_score":0.026874838,"about_ca_system_score_codex":0.0009642312,"about_ca_system_score_gemma":0.0005821656,"threshold_uncertainty_score":0.5937955},"labels":[],"label_agreement":null},{"id":"W4281264061","doi":"10.1172/jci.insight.157164","title":"Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome","year":2022,"lang":"en","type":"article","venue":"JCI Insight","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"National Institute of General Medical Sciences; National Cancer Institute; DOD Prostate Cancer Research Program; Foundation Medicine; Janssen Research and Development; National Institutes of Health; Institute for Prostate Cancer Research; U.S. Department of Defense; Sanofi; GlaxoSmithKline; Dana-Farber Cancer Institute; Pfizer; Foghorn Therapeutics; Bristol-Myers Squibb; Prostate Cancer Foundation; Doris Duke Charitable Foundation; Gilead Sciences; Mayer Foundation; Canadian Institutes of Health Research; University of Washington; Safeway Foundation","keywords":"Androgen receptor; Prostate cancer; Transcriptome; Androgen; Androgen deprivation therapy; Testosterone (patch); Internal medicine; Transcription factor; Medicine; Cancer research; Oncology; Endocrinology; Biology; Bioinformatics; Cancer; Hormone; Gene expression; Gene; Genetics","score_opus":0.02854666256671331,"score_gpt":0.29799253479843874,"score_spread":0.26944587223172545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281264061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850364,0.000452946,0.000008825356,0.011521323,0.0001233761,0.00074379146,0.0012515663,0.000107559004,0.00075422315],"genre_scores_gemma":[0.9797685,0.000035848512,0.00017543192,0.0017711528,0.00008208255,0.00045708558,0.00074722443,0.000027515593,0.016935127],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982674,0.00025522098,0.00020232411,0.0004096499,0.00049928785,0.00036610186],"domain_scores_gemma":[0.9990928,0.00014612121,0.000038309387,0.0003431281,0.00006569623,0.00031390155],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026080382,0.00016090494,0.0002803795,0.00013157069,0.00024776996,0.00001865756,0.00014946457,0.00005581751,0.0045998935],"category_scores_gemma":[0.00015307897,0.00010465228,0.00008622955,0.00053945667,0.000078886806,0.0000410856,0.00024783242,0.00028438112,0.000094215204],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03185352,0.0010349003,0.015998881,0.00003021038,0.00016913157,0.00026682083,0.0019349279,8.4384345e-7,0.45659903,0.0000035964051,0.48950082,0.0026073349],"study_design_scores_gemma":[0.003160859,0.0069548725,0.041681014,0.000022164862,0.00003538732,0.000040437542,0.000161635,0.0000142247345,0.02101478,0.000014502079,0.92673117,0.00016892658],"about_ca_topic_score_codex":0.00001883927,"about_ca_topic_score_gemma":6.5813157e-7,"teacher_disagreement_score":0.43723038,"about_ca_system_score_codex":0.00029439057,"about_ca_system_score_gemma":0.00015011642,"threshold_uncertainty_score":0.99631006},"labels":[],"label_agreement":null},{"id":"W4281624214","doi":"10.1200/jco.2022.40.16_suppl.5044","title":"Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Tolerability; Population; Androgen deprivation therapy; Post-hoc analysis; Prostate-specific antigen; Oncology; Urology; Tumor progression; Gastroenterology; Cancer; Adverse effect","score_opus":0.18639553091805627,"score_gpt":0.5445654624035217,"score_spread":0.3581699314854654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281624214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846969,0.011523525,0.000032931322,0.0025833438,0.00045005837,0.00044091835,0.000109179804,0.00000586825,0.00015722736],"genre_scores_gemma":[0.9832232,0.014850338,0.0012360421,0.00026008458,0.00018534895,0.000008915661,0.00003769863,0.000020508774,0.00017785245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99452984,0.0011389945,0.0030481026,0.0002638151,0.00075745676,0.00026176617],"domain_scores_gemma":[0.9941035,0.0023449657,0.0023309374,0.00022782003,0.0006406183,0.0003521898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041567828,0.00015670847,0.0019277092,0.0002097458,0.00006154731,0.0000071819513,0.00020695874,0.00015021648,0.00035445538],"category_scores_gemma":[0.0009823437,0.00009834813,0.0005227308,0.00023148973,0.00057057245,0.00008930539,0.00018282891,0.00098845,0.0000020445777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030231576,0.006641241,0.6052542,0.00020999726,0.002349772,0.000758314,0.0002471019,0.000010824694,0.005031055,0.000017615937,0.0040976154,0.3451507],"study_design_scores_gemma":[0.031098206,0.19951776,0.7116613,0.0005189219,0.002058723,0.00046267486,0.0016225668,0.00020550635,0.005146865,0.00029356618,0.04713925,0.00027470585],"about_ca_topic_score_codex":0.000032274755,"about_ca_topic_score_gemma":0.0000058841433,"teacher_disagreement_score":0.344876,"about_ca_system_score_codex":0.00009313761,"about_ca_system_score_gemma":0.0012403098,"threshold_uncertainty_score":0.42943782},"labels":[],"label_agreement":null},{"id":"W4281640954","doi":"10.1016/s0302-2838(22)00609-1","title":"Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups","year":2022,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Chemotherapy; Ethnic group; Oncology; Race (biology); Prostate; Cancer; Internal medicine; Gynecology","score_opus":0.020136514418924303,"score_gpt":0.3418920798911864,"score_spread":0.32175556547226214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281640954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99220866,0.0012006013,0.000012986826,0.003562847,0.00014032269,0.00094539457,0.000020687345,0.000029079216,0.0018794385],"genre_scores_gemma":[0.99741024,0.00019531482,0.00004404181,0.0011559203,0.000045489207,0.0001522149,0.00001792738,0.0000423457,0.0009365026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790543,0.0010378893,0.00022818074,0.00028760303,0.00020612894,0.0003347672],"domain_scores_gemma":[0.99942696,0.00017118269,0.000065912216,0.00021570858,0.000027809996,0.00009241705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001235794,0.000129855,0.0003711123,0.00023157756,0.00006215769,0.0000040017408,0.00013861926,0.000011046368,0.0003894331],"category_scores_gemma":[0.00007811833,0.00010103198,0.000064074324,0.00043936956,0.000061278675,0.00002607995,0.00018331954,0.00031777943,0.000026795973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036482524,0.0007598461,0.62246466,0.0005443878,0.0005152408,0.002727502,0.008459155,0.0021464168,0.11480303,0.000072200615,0.0028837745,0.20814127],"study_design_scores_gemma":[0.06545082,0.064072676,0.6855875,0.0001586471,0.00061439344,0.0003893628,0.0014110623,0.0014431363,0.082014136,0.00013642525,0.09771785,0.0010039329],"about_ca_topic_score_codex":0.00010945927,"about_ca_topic_score_gemma":0.000010567286,"teacher_disagreement_score":0.20713733,"about_ca_system_score_codex":0.00013603174,"about_ca_system_score_gemma":0.000067355046,"threshold_uncertainty_score":0.4264019},"labels":[],"label_agreement":null},{"id":"W4281670534","doi":"10.1200/jco.2022.40.16_suppl.tps5103","title":"DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Ottawa Hospital; McGill University; Queen Elizabeth II Health Sciences Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Placebo; Internal medicine; Docetaxel; Randomization; Oncology; Randomized controlled trial; Antiandrogen; Tolerability; Prostatectomy; Urology; Cancer; Adverse effect; Pathology","score_opus":0.12138332810913034,"score_gpt":0.4691233173216555,"score_spread":0.3477399892125252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281670534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97995377,0.0026212425,0.00047823135,0.0040162317,0.0009823674,0.011575643,0.0003123342,0.000008009935,0.000052145784],"genre_scores_gemma":[0.9763156,0.019607168,0.0010196372,0.0008498494,0.00042243683,0.0015447483,0.000031462077,0.000037402468,0.0001716729],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931884,0.0022223555,0.0030285409,0.00031280683,0.00091929076,0.00032860867],"domain_scores_gemma":[0.9869311,0.008067549,0.0037304752,0.00025435412,0.0007661175,0.00025042493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010539158,0.00023831513,0.0032193346,0.00028401133,0.00023577374,0.000017501277,0.00025602512,0.00019573812,0.0001984966],"category_scores_gemma":[0.0031379564,0.00012630528,0.0008209876,0.0003609286,0.00039233064,0.00012635087,0.000095022195,0.000740085,2.571728e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8728983,0.0019958005,0.002392979,0.000025087198,0.0034133343,0.000025014819,0.00059128174,0.00022796306,0.00053232734,0.00006725335,0.00040660353,0.117424056],"study_design_scores_gemma":[0.94932145,0.038720977,0.0005808106,0.00008070202,0.0009527467,0.000013640425,0.00017509426,0.00031628148,0.002803588,0.000619532,0.0063002007,0.00011497872],"about_ca_topic_score_codex":0.00010952213,"about_ca_topic_score_gemma":0.00002659694,"teacher_disagreement_score":0.11730908,"about_ca_system_score_codex":0.000415398,"about_ca_system_score_gemma":0.0041383076,"threshold_uncertainty_score":0.734118},"labels":[],"label_agreement":null},{"id":"W4281681049","doi":"10.1200/jco.2022.40.16_suppl.5025","title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic castration-sensitive prostate cancer: A pooled analysis of the STOMP and ORIOLE trials.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Clinical endpoint; Oncology; Proportional hazards model; Progression-free survival; Androgen deprivation therapy; Cancer; Randomized controlled trial; Overall survival; Confidence interval","score_opus":0.22242967973475058,"score_gpt":0.5031369747882891,"score_spread":0.28070729505353853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281681049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924327,0.0014812865,0.000005120815,0.0049493634,0.00032862023,0.0007073252,0.00008929392,0.0000025341383,0.0000037325694],"genre_scores_gemma":[0.9970429,0.0022455743,0.00038670018,0.00017961433,0.000035775684,0.000030025943,0.000006170186,0.000007542373,0.00006569809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944029,0.0030368108,0.0018141951,0.00016132474,0.00044658364,0.00013821645],"domain_scores_gemma":[0.99250066,0.0054062414,0.0014183066,0.00013441134,0.00039834934,0.00014204411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053780163,0.00010399585,0.0017561724,0.0004873306,0.000045579734,0.0000055834043,0.000080988415,0.00006282841,0.00003848992],"category_scores_gemma":[0.0037654627,0.000059501315,0.00029550242,0.0009847551,0.00016941033,0.000046508387,0.00006133574,0.00036077143,5.0606513e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.092461884,0.0005467736,0.8638817,0.000019660103,0.0059425333,0.00011575248,0.0012205911,0.0005215072,0.0026456728,0.0000016462565,0.000022982988,0.032619286],"study_design_scores_gemma":[0.017412324,0.009157393,0.96897215,0.000035130342,0.0031852743,0.000012312521,0.00038441824,0.0002022223,0.0005090792,0.000009594937,0.00007652112,0.000043599997],"about_ca_topic_score_codex":0.00016470761,"about_ca_topic_score_gemma":0.0005501171,"teacher_disagreement_score":0.10509042,"about_ca_system_score_codex":0.00019415613,"about_ca_system_score_gemma":0.001513735,"threshold_uncertainty_score":0.45078826},"labels":[],"label_agreement":null},{"id":"W4281682623","doi":"10.1200/jco.2022.40.16_suppl.e17029","title":"DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tolerability; Prostate cancer; Internal medicine; Adverse effect; Interim analysis; Clinical endpoint; Placebo; Oncology; Cancer; Randomized controlled trial","score_opus":0.1871923208535928,"score_gpt":0.4913599537361473,"score_spread":0.30416763288255455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281682623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993785,0.00023172612,0.0000027240283,0.004384264,0.0004042495,0.00093698845,0.00004221801,0.0000043043833,0.00020848967],"genre_scores_gemma":[0.99779826,0.000067437,0.0006050447,0.00066471746,0.00016000462,0.0000919604,0.000024662739,0.000017020924,0.00057086616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99612033,0.00065671303,0.0016952278,0.0002130795,0.0010524439,0.00026219],"domain_scores_gemma":[0.99739283,0.00071806816,0.001004807,0.00014260125,0.0005090129,0.00023265922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002679335,0.0001264363,0.00091972004,0.00019345494,0.000106119085,0.000010661478,0.00014154478,0.000056121233,0.00043142057],"category_scores_gemma":[0.0004718865,0.00008169256,0.00013397502,0.00035819234,0.00011877906,0.00014125771,0.000071746545,0.0011022018,0.0000027790657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031048536,0.0078716045,0.94524306,0.000018699466,0.00043334177,0.0009973363,0.00044416395,0.00062812545,0.00002064105,0.000010387612,0.00069259177,0.012591487],"study_design_scores_gemma":[0.029926708,0.039290503,0.9253058,0.00003302188,0.00021121326,0.000016492404,0.0007647681,0.000053372463,0.0000034630038,0.00008003889,0.0042399135,0.00007472721],"about_ca_topic_score_codex":0.00012397591,"about_ca_topic_score_gemma":0.00043225868,"teacher_disagreement_score":0.031418897,"about_ca_system_score_codex":0.00071332266,"about_ca_system_score_gemma":0.0046525323,"threshold_uncertainty_score":0.82533926},"labels":[],"label_agreement":null},{"id":"W4281724494","doi":"10.1200/jco.2022.40.16_suppl.5024","title":"Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"","keywords":"Medicine; Standardized uptake value; Prostate cancer; Nuclear medicine; Prostatectomy; Biopsy; Radiology; Cohort; Prostate; Positron emission tomography; PET-CT; Cancer; Urology; Pathology; Internal medicine","score_opus":0.06375505272018468,"score_gpt":0.43579344613662657,"score_spread":0.3720383934164419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281724494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961601,0.001421099,0.000003787925,0.0010763751,0.0001458501,0.00060569163,0.00044265683,0.000004705179,0.00013975623],"genre_scores_gemma":[0.99652237,0.0025403614,0.0004689457,0.00016803617,0.00004244149,0.000021144915,0.00008865347,0.00001613332,0.00013190684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960345,0.0007124716,0.0018150946,0.00035367365,0.0007944978,0.000289782],"domain_scores_gemma":[0.9970044,0.0006600685,0.0013026675,0.00019637475,0.00041714782,0.00041932537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031568864,0.00016698838,0.0018148237,0.000344704,0.00008185805,0.0000170306,0.000105554966,0.00004017488,0.00008983199],"category_scores_gemma":[0.00051206717,0.00010964213,0.00016666613,0.00056736957,0.00030631875,0.00015729168,0.000080145306,0.0008284336,8.2638934e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09786238,0.0022024733,0.8635492,0.000040777755,0.001963195,0.0009386943,0.000255632,0.0002743659,0.00007104543,0.000006195898,0.00074504677,0.032091007],"study_design_scores_gemma":[0.0404151,0.036078557,0.91777426,0.00010134439,0.0017593183,0.00005238965,0.00044073435,0.00048782665,0.000070704475,0.000043849606,0.0026636717,0.00011224965],"about_ca_topic_score_codex":0.00038680204,"about_ca_topic_score_gemma":0.0005622362,"teacher_disagreement_score":0.057447277,"about_ca_system_score_codex":0.00032466854,"about_ca_system_score_gemma":0.0017046881,"threshold_uncertainty_score":0.44710764},"labels":[],"label_agreement":null},{"id":"W4281725891","doi":"10.1016/j.euo.2022.04.009","title":"First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature","year":2022,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Androgen deprivation therapy; Docetaxel; Oncology; Systematic review; Prostate-specific antigen; Systemic therapy; Internal medicine; Radiation therapy; Quality of life (healthcare); Cancer; Watchful waiting; MEDLINE; Intensive care medicine; Breast cancer","score_opus":0.05646314654128041,"score_gpt":0.37166315697840985,"score_spread":0.3152000104371294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281725891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000043351276,0.9862927,0.000001607631,0.0006098026,0.0006953058,0.011041378,0.0005383989,0.000033202516,0.0007442592],"genre_scores_gemma":[0.00014725201,0.99055135,0.000009891873,0.00082309375,0.00018605533,0.0041576237,0.00038649712,0.00013306474,0.0036051683],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99132836,0.0051886886,0.0018699609,0.00068906485,0.0004285436,0.00049535406],"domain_scores_gemma":[0.9962205,0.00065283454,0.001578889,0.0012172292,0.00019483855,0.00013567052],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010188078,0.0006798993,0.0054783165,0.0002633571,0.00009294492,0.000006417647,0.0005031404,0.00025735595,0.0006413739],"category_scores_gemma":[0.00013755643,0.00029767203,0.0011159175,0.00079396134,0.0004851679,0.00002561219,0.0002976525,0.00076986605,0.000027103311],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014156362,0.00076258136,0.000016494709,0.7304627,0.0015308959,0.0014232039,0.0007099323,6.358942e-7,4.5840642e-7,0.00000234276,0.00038058122,0.26329458],"study_design_scores_gemma":[0.0018892861,0.00679535,0.000018450919,0.3899044,0.004933693,0.0014295769,0.000012294395,9.453704e-7,6.701146e-7,9.221637e-7,0.59485954,0.00015486509],"about_ca_topic_score_codex":0.00001032289,"about_ca_topic_score_gemma":0.000013109811,"teacher_disagreement_score":0.59447896,"about_ca_system_score_codex":0.0017355201,"about_ca_system_score_gemma":0.0022385765,"threshold_uncertainty_score":0.99994755},"labels":[],"label_agreement":null},{"id":"W4281728851","doi":"10.1200/jco.2022.40.16_suppl.e18757","title":"Patient preferences for treatment and outcomes in hormone-sensitive prostate cancer (HSPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Concomitant; Prostate cancer; Rash; Tolerability; Oncology; Internal medicine; Adverse effect; Mixed logit; Confidence interval; Logistic regression; Androgen deprivation therapy; Cancer","score_opus":0.1687419788458399,"score_gpt":0.5115443745390501,"score_spread":0.3428023956932102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281728851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856162,0.0027439822,0.0000017667167,0.0101587055,0.00040122514,0.0007108556,0.000053246997,0.000002867558,0.0003111272],"genre_scores_gemma":[0.9918058,0.005980741,0.00044073685,0.00061633845,0.000120654346,0.00016555708,0.0000057057423,0.000008771111,0.00085569534],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99825346,0.00026312566,0.0009269702,0.00015253133,0.00020599717,0.0001979209],"domain_scores_gemma":[0.99784213,0.0012199325,0.0005157981,0.000064747976,0.00017792672,0.0001794592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089279213,0.00009501531,0.0009802222,0.00011483098,0.00006148243,0.0000051782554,0.00004082622,0.00006737558,0.00003580299],"category_scores_gemma":[0.00036074172,0.00005476233,0.00018472153,0.00007698314,0.00011233618,0.000048018508,0.0000532062,0.00029490882,5.730828e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023916714,0.0027283556,0.4734578,0.00001815704,0.00061924977,0.0005676794,0.0018965624,0.0000374342,0.00013860567,0.000020107944,0.0012895882,0.49530974],"study_design_scores_gemma":[0.030178564,0.107927985,0.783479,0.00003936928,0.000307877,0.0001114196,0.002734901,0.000086625805,0.00024902468,0.00064442994,0.07413226,0.00010857968],"about_ca_topic_score_codex":0.000111524074,"about_ca_topic_score_gemma":0.00012002073,"teacher_disagreement_score":0.49520117,"about_ca_system_score_codex":0.00048500687,"about_ca_system_score_gemma":0.0015086619,"threshold_uncertainty_score":0.26763013},"labels":[],"label_agreement":null},{"id":"W4281734550","doi":"10.1016/j.xpro.2022.101434","title":"Rapid immunoprecipitation mass spectrometry of endogenous protein (RIME) to identify chromatin-interactome in prostate cancer cells","year":2022,"lang":"en","type":"article","venue":"STAR Protocols","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"DU145; Interactome; LNCaP; Immunoprecipitation; Hard rime; Prostate cancer; Mass spectrometry; Cancer research; Chromatin immunoprecipitation; Endogeny; Chemistry; Cancer; Computational biology; Biology; Medicine; Internal medicine; Chromatography; Biochemistry; Gene; Gene expression; Physics","score_opus":0.04623498943077752,"score_gpt":0.37789173460217096,"score_spread":0.33165674517139343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281734550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81793034,0.00032511642,0.000013777088,0.0005588852,0.00007321337,0.18008476,0.00023016325,0.000043651882,0.00074011297],"genre_scores_gemma":[0.6369106,0.000018141587,0.0016463491,0.000051716524,0.000045601362,0.35947725,0.000056827896,0.00004277184,0.0017506828],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975318,0.00026832643,0.00054936385,0.00039922885,0.0007495202,0.00050178566],"domain_scores_gemma":[0.9990791,0.000044456705,0.00019755182,0.00039704193,0.00015146246,0.00013035558],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000780913,0.00020415601,0.0004508174,0.0005537427,0.00011074965,0.000031005296,0.00022205233,0.000035448145,0.0025402282],"category_scores_gemma":[0.000051541054,0.00018221032,0.000102052036,0.00095716224,0.00005030204,0.00012466835,0.0001647432,0.00039508526,0.000038853515],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040517244,0.00050005683,0.0019316234,0.00068494916,0.000096385826,0.00016704889,0.0025492993,0.000034475725,0.986215,0.000013378908,0.00022718635,0.0035288502],"study_design_scores_gemma":[0.004910005,0.0034992155,0.010623614,0.0005646878,0.000018294448,0.000013255227,0.0006785719,0.000030767947,0.9743683,0.00020046977,0.0048984974,0.00019433933],"about_ca_topic_score_codex":0.000471761,"about_ca_topic_score_gemma":0.000015829719,"teacher_disagreement_score":0.18101966,"about_ca_system_score_codex":0.001013381,"about_ca_system_score_gemma":0.000564763,"threshold_uncertainty_score":0.9983716},"labels":[],"label_agreement":null},{"id":"W4281750499","doi":"10.1200/jco.2022.40.16_suppl.5039","title":"Candidate surrogate endpoints in advanced prostate cancer: Aggregate meta-analysis of 143 randomized trials.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institutes of Health; Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Hazard ratio; Oncology; Randomized controlled trial; Surrogate endpoint; Progression-free survival; Prostate; Urology; Cancer; Confidence interval; Overall survival","score_opus":0.30810223937547704,"score_gpt":0.5556795685582354,"score_spread":0.24757732918275838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281750499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.954367,0.025664955,0.000012088635,0.016877733,0.00089241785,0.0013496298,0.0001815336,0.000007360698,0.00064732425],"genre_scores_gemma":[0.9767262,0.01930721,0.0006173674,0.00078973593,0.00014085791,0.00022486706,0.000030820032,0.00002130984,0.0021416834],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98449796,0.0076519772,0.0062296386,0.0003112736,0.0009281031,0.0003810168],"domain_scores_gemma":[0.98249704,0.010388202,0.005864724,0.00028922217,0.0005995532,0.00036124964],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.040834177,0.0002084908,0.012977802,0.00096570124,0.000061442704,0.0000072842054,0.00026300072,0.00015329795,0.0028554907],"category_scores_gemma":[0.009545863,0.00012035793,0.005869178,0.0012226212,0.00036315646,0.000108929235,0.0001428229,0.0013938646,0.000002122615],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66929615,0.0021388547,0.012940747,0.000055334192,0.26349148,0.0018731346,0.0006513359,0.002932204,0.0003179887,0.000049566235,0.0006797632,0.04557343],"study_design_scores_gemma":[0.56777114,0.008490083,0.0075219832,0.000040250834,0.39098382,0.00006901077,0.00045887366,0.0009325028,0.0010465113,0.00084760203,0.021627298,0.00021095005],"about_ca_topic_score_codex":0.00038700554,"about_ca_topic_score_gemma":0.0005567451,"teacher_disagreement_score":0.12749232,"about_ca_system_score_codex":0.00043846422,"about_ca_system_score_gemma":0.0032801335,"threshold_uncertainty_score":0.9987972},"labels":[],"label_agreement":null},{"id":"W4281750849","doi":"10.1002/pros.24373","title":"Genomic biomarkers to guide precision radiotherapy in prostate cancer","year":2022,"lang":"en","type":"review","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health","keywords":"Prostate cancer; Prostate; Medicine; Radiation therapy; Cancer; Oncology; Prostate disease; Internal medicine; Pathology","score_opus":0.07174354759623408,"score_gpt":0.4222440753397179,"score_spread":0.35050052774348384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281750849","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040833198,0.98490363,0.000001938516,0.0024849174,0.00041065196,0.010395143,0.0003852067,0.00010224677,0.0009079299],"genre_scores_gemma":[0.000004132653,0.96650416,0.00019375727,0.00040953385,0.00016493858,0.005504167,0.0002947017,0.00018688614,0.026737716],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99635124,0.00044350632,0.0008677833,0.000825859,0.0006383113,0.00087330147],"domain_scores_gemma":[0.99821866,0.00026976626,0.0002557413,0.0009349595,0.00005614779,0.0002647087],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012944652,0.00059240364,0.0016008994,0.000622966,0.0002240307,0.00007502595,0.00055432087,0.00011343544,0.0011081018],"category_scores_gemma":[0.000062229985,0.00033468712,0.0004115594,0.0013732284,0.0001324044,0.00006159968,0.0003592278,0.0008176682,0.000117485215],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009221846,0.00010134217,0.00015788249,0.0038379913,0.0005583426,0.00023628667,0.0014614133,0.000013099521,0.000028534601,0.0000028973218,0.013323979,0.97935605],"study_design_scores_gemma":[0.0016572884,0.00044412524,0.000093913244,0.0052318648,0.0003598865,0.00008071786,0.00007307821,0.000018105215,0.000010511936,0.000035646182,0.99163735,0.00035753037],"about_ca_topic_score_codex":0.0008907377,"about_ca_topic_score_gemma":0.00009514754,"teacher_disagreement_score":0.97899854,"about_ca_system_score_codex":0.0030265332,"about_ca_system_score_gemma":0.0020088248,"threshold_uncertainty_score":0.99991053},"labels":[],"label_agreement":null},{"id":"W4281754567","doi":"10.1101/2022.05.31.494200","title":"Androgen receptor inhibition induces metabolic reprogramming and increased reliance on oxidative mitochondrial metabolism in prostate cancer","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Clinical and Translational Science Institute, University of California, Los Angeles; Stop Cancer; National Center for Advancing Translational Sciences; National Institutes of Health; National Cancer Institute; Jonsson Comprehensive Cancer Center","keywords":"Androgen receptor; Prostate cancer; Oxidative phosphorylation; Blockade; Biology; Mitochondrion; Downregulation and upregulation; Metabolism; Cell biology; Bioenergetics; Cancer research; Receptor; Cancer; Pharmacology; Endocrinology; Biochemistry","score_opus":0.02124430623245595,"score_gpt":0.2789761133932537,"score_spread":0.25773180716079774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281754567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739847,0.01986362,0.000002850937,0.00096523704,0.00094606436,0.0032764978,0.00073648867,0.0002123111,0.00001220096],"genre_scores_gemma":[0.97956055,0.012248081,0.0025998452,0.00026694773,0.0007339025,0.004367325,0.000012869677,0.00017223415,0.000038222268],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957599,0.0003809099,0.0006547262,0.0016331268,0.0008032988,0.0007680537],"domain_scores_gemma":[0.997755,0.00008886465,0.0004442212,0.0009206127,0.000378756,0.00041257933],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007216454,0.0006667804,0.001083536,0.0007723394,0.00024455367,0.00017198625,0.00020564596,0.0003600986,0.00017976793],"category_scores_gemma":[0.00033072277,0.0006197922,0.00015827824,0.0011392947,0.0002287679,0.00021574459,0.00050552055,0.0016881373,0.00001479832],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002783949,0.0006737664,0.026126914,0.00072145247,0.0006224697,0.00043256185,0.00020504583,0.000023833069,0.9676797,0.0002485879,0.00035298232,0.00012876975],"study_design_scores_gemma":[0.006530989,0.00031580013,0.13623896,0.0015995232,0.000411025,1.0151793e-7,0.000047036552,0.000041912284,0.8283948,0.0000069998864,0.025519697,0.0008931965],"about_ca_topic_score_codex":0.0011030828,"about_ca_topic_score_gemma":0.000016058837,"teacher_disagreement_score":0.13928491,"about_ca_system_score_codex":0.0006703405,"about_ca_system_score_gemma":0.0013745856,"threshold_uncertainty_score":0.9996253},"labels":[],"label_agreement":null},{"id":"W4281776829","doi":"10.5489/cuaj.7802","title":"Real-world experience managing unresectable or metastatic small cell carcinoma of the prostate","year":2022,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Island Health; University of British Columbia; Abbotsford Veterinary Clinic","funders":"","keywords":"Oncology; Prostate carcinoma; Medicine; Internal medicine; Prostate cancer; Cancer","score_opus":0.03649045745914687,"score_gpt":0.2804509140927682,"score_spread":0.24396045663362131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281776829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790276,0.00026338518,0.000003308426,0.013469918,0.00023459183,0.00040834933,0.000054651267,0.000008470819,0.006529724],"genre_scores_gemma":[0.9767333,0.00006683283,0.000089484776,0.00096185505,0.00006139228,0.000057058183,0.000009830566,0.000010873049,0.022009362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982006,0.0003312997,0.00028396194,0.00016132859,0.00051418145,0.000508639],"domain_scores_gemma":[0.99894476,0.00013655148,0.00024726213,0.00014222518,0.00015882122,0.00037040102],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00067201455,0.00010060726,0.00021756532,0.000197709,0.0006659649,0.000040508367,0.0002236641,0.000028274684,0.0016956391],"category_scores_gemma":[0.00016902701,0.000058862297,0.000113691836,0.00066486077,0.000049310478,0.00005017874,0.00007532199,0.00063050544,0.0000042955294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030881274,0.000082093204,0.99235404,0.000020344653,0.000058350786,0.00036697206,0.0012299967,0.0001864462,0.00041858325,0.000076490665,0.0042817984,0.00061607367],"study_design_scores_gemma":[0.0032390533,0.0010992737,0.946432,0.000016403239,0.0001395364,0.00016121546,0.002578089,0.00052767195,0.0014506946,0.0007013066,0.043483898,0.00017084784],"about_ca_topic_score_codex":0.0063253674,"about_ca_topic_score_gemma":0.0031515874,"teacher_disagreement_score":0.045922026,"about_ca_system_score_codex":0.0019627067,"about_ca_system_score_gemma":0.0014516137,"threshold_uncertainty_score":0.999217},"labels":[],"label_agreement":null},{"id":"W4281934052","doi":"10.1002/pros.24356","title":"Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer","year":2022,"lang":"en","type":"review","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Prostate Cancer Foundation","keywords":"Prostate cancer; Androgen receptor; Medicine; Prostate; Oncology; Prostate disease; Androgen; Internal medicine; Cancer; Receptor; Cancer research; Hormone","score_opus":0.09868511844137028,"score_gpt":0.3896992534177602,"score_spread":0.2910141349763899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281934052","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011694988,0.98889357,2.6830486e-7,0.0013036518,0.00013504729,0.0067063454,0.0012721602,0.000059095477,0.00046034984],"genre_scores_gemma":[0.0000355648,0.9628357,0.00015396926,0.00006261483,0.00007850026,0.0080284,0.0008363995,0.00010201307,0.027866818],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99738896,0.00041517185,0.0006325569,0.00064806663,0.00032544672,0.00058982085],"domain_scores_gemma":[0.9987381,0.00023975693,0.00025551964,0.00055609376,0.00004056249,0.00016995223],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044357375,0.000519626,0.0014112884,0.00027686046,0.00034694953,0.00008682382,0.00017224054,0.0000617146,0.0005051128],"category_scores_gemma":[0.000026353377,0.0002900883,0.00023257732,0.00058902655,0.00020253076,0.00007992898,0.00014963644,0.0004863902,0.000043006745],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005849256,0.00026371574,0.00019118871,0.00701643,0.0010363725,0.0002478871,0.0042918944,0.0000033086455,0.000008601778,0.000071646326,0.0012129414,0.98507106],"study_design_scores_gemma":[0.0019420534,0.00033786302,0.00003325823,0.0024536808,0.0011449761,0.0000436158,0.000111160174,0.0000074296977,0.000008922422,0.00014551455,0.99349964,0.00027186575],"about_ca_topic_score_codex":0.00028110898,"about_ca_topic_score_gemma":0.0006236524,"teacher_disagreement_score":0.99228674,"about_ca_system_score_codex":0.0015541852,"about_ca_system_score_gemma":0.0014890395,"threshold_uncertainty_score":0.9999551},"labels":[],"label_agreement":null},{"id":"W4281963646","doi":"10.5489/cuaj.7954","title":"Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in Canada","year":2022,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Université Laval; Alberta Children's Hospital; University of Calgary; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre; London Health Sciences Centre; McMaster University; Queen Elizabeth II Health Sciences Centre; University of Alberta; BC Cancer Agency; Dalhousie University; University of Toronto; University of British Columbia","funders":"Canadian Institutes of Health Research; Merck Canada; Astellas Pharma; Incyte; Ipsen; Canadian Urological Association; AstraZeneca Canada; Eisai; MacroGenics; Daiichi Sankyo Europe; Janssen Canada; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Genetic testing; Geneticist; Genetic counseling; Medicine; Multidisciplinary approach; Prostate cancer; Cancer; Family medicine; Bioinformatics; Internal medicine; Genetics; Biology; Political science","score_opus":0.05152806214043363,"score_gpt":0.3344223791003647,"score_spread":0.28289431695993106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281963646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94629794,0.0003464749,0.00002961639,0.049843874,0.00029218823,0.0015978538,0.0015734425,0.0000023333785,0.000016266124],"genre_scores_gemma":[0.99718106,0.000058236386,0.0004637927,0.0012423556,0.000046580906,0.00076483865,0.0001299379,0.000007687058,0.00010551928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989576,0.000088286935,0.00031049945,0.000093110015,0.00023796524,0.0003125719],"domain_scores_gemma":[0.9987235,0.0005160178,0.00024371281,0.000039173192,0.0003435068,0.0001341088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046465214,0.00005834056,0.00013134484,0.00009286511,0.0004061575,0.000014453394,0.0000715167,0.000012974955,0.00029535792],"category_scores_gemma":[0.00030458227,0.000041562955,0.00004413059,0.00023302439,0.0000081477865,0.000028453287,0.00001126973,0.00018144048,1.0810887e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061364255,0.000023638786,0.96356016,0.000008732538,0.000080214224,0.0000023058642,0.0001733309,0.0004107164,0.0000114161785,0.000007678695,0.010326816,0.025333636],"study_design_scores_gemma":[0.0030125554,0.00054758845,0.97028583,0.0000052074197,0.00008522149,0.000004313336,0.0013243733,0.00085986586,0.000020173859,0.00025545055,0.023549244,0.0000501729],"about_ca_topic_score_codex":0.76218873,"about_ca_topic_score_gemma":0.8816437,"teacher_disagreement_score":0.11945499,"about_ca_system_score_codex":0.004805335,"about_ca_system_score_gemma":0.005123141,"threshold_uncertainty_score":0.99901503},"labels":[],"label_agreement":null},{"id":"W4282574692","doi":"10.1016/j.isci.2022.104576","title":"Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancer","year":2022,"lang":"en","type":"article","venue":"iScience","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Shanghai Rising-Star Program; National Natural Science Foundation of China","keywords":"Prostate cancer; SOX2; Biology; Transcriptome; Transcription factor; Gene; Regulation of gene expression; Cancer research; Prostate; Computational biology; Gene expression; Neuroendocrine differentiation; Cancer; Genetics","score_opus":0.027290017269517845,"score_gpt":0.28529381568630796,"score_spread":0.2580037984167901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282574692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99210334,0.005529478,0.000115396564,0.0014999934,0.00008839831,0.00026456523,0.000026122063,0.000010778922,0.00036192042],"genre_scores_gemma":[0.996695,0.00016634204,0.00021391897,0.000034560482,0.000017515928,0.000051807187,0.000006160582,0.0000043745154,0.0028103176],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992439,0.000024167251,0.00009514214,0.00016506895,0.00033960064,0.00013208344],"domain_scores_gemma":[0.9997859,0.000009893618,0.00003344888,0.00007562515,0.000046914785,0.000048236427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000048911286,0.000044709832,0.000068088666,0.0000795035,0.00012566434,0.000005841688,0.000041094485,0.0000040323102,0.00015534367],"category_scores_gemma":[0.000005521651,0.000037533104,0.000017817878,0.00026863723,0.0001416311,0.000058686554,0.000032301657,0.00006186566,6.7556476e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020427206,0.00014438623,0.05891538,0.00005800801,0.0000036150038,0.000022468746,0.00028359078,0.00049838674,0.92685086,0.00011711633,0.000117216325,0.01278468],"study_design_scores_gemma":[0.0025142864,0.0013665601,0.9106456,0.000030717,0.00004139015,0.0001820264,0.00024587865,0.0070655197,0.07122202,0.0006313807,0.0059530307,0.000101579],"about_ca_topic_score_codex":0.00008502111,"about_ca_topic_score_gemma":0.0000057136576,"teacher_disagreement_score":0.85562885,"about_ca_system_score_codex":0.00014804245,"about_ca_system_score_gemma":0.00015560784,"threshold_uncertainty_score":0.17009042},"labels":[],"label_agreement":null},{"id":"W4282915372","doi":"10.1158/1538-7445.am2022-1079","title":"Abstract 1079: Anti-cancer efficacy of TH1902, a SORT1 docetaxel peptide-drug conjugate, against ovarian and endometrial cancers xenografts alone or in combination with carboplatin","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal; Theratechnologies (Canada)","funders":"","keywords":"Docetaxel; Ovarian cancer; Cancer research; Pharmacology; Carboplatin; Cancer; Peptide; Medicine; Apoptosis; Drug; Internal medicine; Chemotherapy; Cisplatin; Chemistry; Biochemistry","score_opus":0.06753017365991106,"score_gpt":0.38683840589362406,"score_spread":0.319308232233713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282915372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98857284,0.004957156,0.0000013665278,0.0019528,0.00019345223,0.0027087291,0.00026801412,0.000036213194,0.0013094532],"genre_scores_gemma":[0.98988456,0.005720975,0.000051337673,0.00008244567,0.00020603498,0.0015732977,0.00012665064,0.000066876266,0.0022878184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99561137,0.00033603975,0.00056131853,0.0006989784,0.0018787684,0.0009135142],"domain_scores_gemma":[0.99800056,0.0006167644,0.0001900883,0.0004116918,0.00046609054,0.00031480298],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018468064,0.00027808908,0.0007487466,0.0012348011,0.00038434484,0.00004816282,0.00027187323,0.00008260938,0.001022093],"category_scores_gemma":[0.00022266195,0.0002080779,0.000083022125,0.0026788574,0.0006326712,0.00018171461,0.00025852915,0.0012388931,0.0000031332545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11128443,0.00421904,0.4846905,0.003404942,0.002306818,0.0027658204,0.0114506725,0.0055125356,0.3090538,0.0002262252,0.010379017,0.054706205],"study_design_scores_gemma":[0.17861716,0.006479692,0.62534666,0.002565519,0.00026802972,0.00006920324,0.007477138,0.0009059548,0.16427316,0.00009252397,0.012642953,0.001261993],"about_ca_topic_score_codex":0.014988858,"about_ca_topic_score_gemma":0.003093553,"teacher_disagreement_score":0.14478067,"about_ca_system_score_codex":0.0018335006,"about_ca_system_score_gemma":0.0036265776,"threshold_uncertainty_score":0.9998911},"labels":[],"label_agreement":null},{"id":"W4282915663","doi":"10.1016/j.euo.2022.04.006","title":"Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography–targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis","year":2022,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Positron emission tomography; Meta-analysis; Glutamate carboxypeptidase II; Confidence interval; Magnetic resonance imaging; Prostate; Biopsy; Prospective cohort study; Nuclear medicine; Radiology; Internal medicine; Cancer","score_opus":0.08277012584212112,"score_gpt":0.37797085764769944,"score_spread":0.2952007318055783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282915663","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014827152,0.9857621,0.000014055866,0.00024883225,0.00011674664,0.011592328,0.0006416597,0.000042848547,0.000098694945],"genre_scores_gemma":[0.0045613553,0.99099964,0.00014218873,0.00012203811,0.000037485825,0.002895753,0.00068060536,0.000105116174,0.00045583787],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9916142,0.0034384055,0.0030439873,0.0009932548,0.00036593564,0.0005442032],"domain_scores_gemma":[0.99324685,0.0025762664,0.0028001876,0.0007952969,0.00035932675,0.00022205093],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003687986,0.0006167403,0.009989658,0.0009147084,0.00016113573,0.000008509488,0.00036311627,0.0002534717,0.00026292136],"category_scores_gemma":[0.0006937215,0.00039352817,0.002272378,0.001500093,0.000492957,0.000046664805,0.00021113093,0.0007138575,0.0000047893227],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013332492,0.00062112784,0.0003008573,0.86315906,0.10933684,0.00020734442,0.00022503892,0.0000068276486,0.0002744326,0.0000023229027,0.00009272441,0.024440158],"study_design_scores_gemma":[0.0016859653,0.010639239,0.00011414992,0.0076415576,0.865097,0.00020773655,0.000028656697,0.000023926481,0.000098912424,0.0000018849302,0.11405068,0.00041028112],"about_ca_topic_score_codex":0.000020169098,"about_ca_topic_score_gemma":0.0000020927212,"teacher_disagreement_score":0.8555175,"about_ca_system_score_codex":0.00018042773,"about_ca_system_score_gemma":0.0005307327,"threshold_uncertainty_score":0.99985164},"labels":[],"label_agreement":null},{"id":"W4282916823","doi":"10.1016/j.esmoop.2022.100510","title":"Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer","year":2022,"lang":"en","type":"review","venue":"ESMO Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Sanofi Genzyme; Genentech; Takeda Pharmaceutical Company; Janssen Pharmaceuticals; Gilead Sciences; Sanofi; Merck; Bayer; Astellas Pharma Global Development; AstraZeneca; Amgen; Pfizer; Astellas Pharma; Daiichi Sankyo Company; Clovis Oncology; Astellas Pharma US","keywords":"Enzalutamide; Prostate cancer; Hazard ratio; Medicine; Placebo; Cabazitaxel; Oncology; Internal medicine; Antiandrogen; Confidence interval; Androgen deprivation therapy; Cancer; Androgen receptor","score_opus":0.270638878063148,"score_gpt":0.47585124211778135,"score_spread":0.20521236405463333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282916823","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012064715,0.96516126,0.0000019952215,0.00018683485,0.00047873147,0.019269088,0.0024613154,0.000011793683,0.00036424483],"genre_scores_gemma":[0.008565735,0.9820628,0.00016078558,0.0000050480357,0.000059679725,0.005454466,0.00065797404,0.00008038909,0.0029530865],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969651,0.0003805583,0.0011964499,0.00047017334,0.0006094266,0.00037830844],"domain_scores_gemma":[0.99519,0.0023575274,0.0012907488,0.00096030656,0.00011088885,0.00009050772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036578183,0.0005188705,0.0027809176,0.00015869956,0.0002694324,0.000031576874,0.00064754393,0.00009033902,0.00035049056],"category_scores_gemma":[0.00006320373,0.00023784822,0.00093077595,0.00059649104,0.000266326,0.0000499238,0.00016388283,0.00019191798,0.0000020771172],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006556291,0.0028803037,0.00031227566,0.007679029,0.0077855457,0.000015699798,0.0056553944,0.0001904721,0.000023055161,0.00006182689,0.00016445378,0.9686757],"study_design_scores_gemma":[0.018968942,0.010244438,0.0015655897,0.0059317388,0.01761987,0.00000936757,0.001855805,0.00004727893,0.0028103672,0.000021020409,0.9405804,0.00034513848],"about_ca_topic_score_codex":0.010124185,"about_ca_topic_score_gemma":0.0033060082,"teacher_disagreement_score":0.9683305,"about_ca_system_score_codex":0.0014587797,"about_ca_system_score_gemma":0.0024837109,"threshold_uncertainty_score":0.9964675},"labels":[],"label_agreement":null},{"id":"W4282937964","doi":"10.1148/radiol.211836","title":"Impact of <sup>18</sup>F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"Radiology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Women's College Hospital; University of Toronto; University Health Network; Mount Sinai Hospital; Western University","funders":"Ontario Ministry of Health and Long-Term Care","keywords":"Medicine; McNemar's test; Prostate cancer; Nuclear medicine; PET-CT; Radiology; Biopsy; Prospective cohort study; Cancer; Biochemical recurrence; Positron emission tomography; Prostatectomy; Internal medicine","score_opus":0.027910293903323183,"score_gpt":0.34810354658753867,"score_spread":0.3201932526842155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282937964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584746,0.002039871,0.0000013742739,0.0003634188,0.00008302208,0.00073575735,0.0007381129,0.000019733727,0.00017125942],"genre_scores_gemma":[0.98749834,0.009638768,0.0000540991,0.0000261302,0.00006731737,0.00024635255,0.00012506246,0.00002488089,0.0023190312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866074,0.00019566496,0.00029382066,0.00030439647,0.00017279727,0.0003725817],"domain_scores_gemma":[0.99917114,0.00022232062,0.00016956562,0.00025378124,0.000056230154,0.00012696412],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001815501,0.00018323571,0.0006065879,0.00022145204,0.00009813799,0.0000037081186,0.00007092043,0.000033731165,0.0009716562],"category_scores_gemma":[0.000040454168,0.000110547706,0.000106678875,0.00020205125,0.00022363474,0.000031552645,0.000061653394,0.00017175157,0.000002037382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017367093,0.0009892556,0.9173837,0.00016124581,0.0017323428,0.0006074406,0.004721076,0.004473029,0.003483674,0.000048334747,0.002537124,0.046495736],"study_design_scores_gemma":[0.04892107,0.12694874,0.7952735,0.0002883045,0.001084852,0.00072194135,0.0029331322,0.006915126,0.009246896,0.00048077025,0.006552389,0.00063327386],"about_ca_topic_score_codex":0.002986512,"about_ca_topic_score_gemma":0.000030047964,"teacher_disagreement_score":0.1259595,"about_ca_system_score_codex":0.0007057977,"about_ca_system_score_gemma":0.0004913955,"threshold_uncertainty_score":0.9999416},"labels":[],"label_agreement":null},{"id":"W4282941071","doi":"10.1158/1538-7445.am2022-5729","title":"Abstract 5729: Dynamic phase separation of the androgen receptor and its coactivators to regulate gene expression","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Coactivator; Androgen receptor; Prostate cancer; Transcription factor; FOXA1; Biology; Cancer research; Nuclear receptor coactivator 3; Androgen; Transcription (linguistics); Cell biology; Gene; Cancer; Genetics; Endocrinology; Hormone","score_opus":0.07137576185562841,"score_gpt":0.4583538856016459,"score_spread":0.3869781237460175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282941071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919489,0.0030911942,0.0000023847351,0.0030685165,0.00012141771,0.0013285641,0.0001899832,0.00001382632,0.00023522013],"genre_scores_gemma":[0.9946873,0.0006776013,0.000024558847,0.000046188998,0.000057846646,0.00055429444,0.000042629337,0.000023497703,0.0038860494],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99802583,0.00017538966,0.00017747177,0.00031423592,0.00095704413,0.0003500454],"domain_scores_gemma":[0.9991466,0.00007186394,0.00004996917,0.00030801992,0.00022519493,0.0001983561],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006746401,0.0000973426,0.00017842781,0.00019197424,0.0004501115,0.000017562003,0.00017359917,0.000041586507,0.00095091236],"category_scores_gemma":[0.000061776314,0.00006546982,0.000048669495,0.000657434,0.00010419656,0.000073131705,0.00032576526,0.0004242095,0.0000082308325],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021150701,0.00017555365,0.0011005049,0.00009865611,0.000046397035,0.00001046863,0.00072456,0.000060464175,0.9865002,0.000011808437,0.003993507,0.005162811],"study_design_scores_gemma":[0.002558812,0.000558852,0.004395952,0.000117477044,0.0000128291085,0.000007687733,0.000369436,0.00015613588,0.9813848,0.000038759794,0.010322592,0.00007668006],"about_ca_topic_score_codex":0.00009691914,"about_ca_topic_score_gemma":0.000010008545,"teacher_disagreement_score":0.0063290857,"about_ca_system_score_codex":0.0005738257,"about_ca_system_score_gemma":0.00052037893,"threshold_uncertainty_score":0.99996233},"labels":[],"label_agreement":null},{"id":"W4282946122","doi":"10.1158/1538-7445.am2022-6317","title":"Abstract 6317: Molecular subtyping in prostate cancer associate with outcomes to abiraterone and ipatasertib treatment from the phase III IPATential150 trial","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Prostate cancer; Cell cycle; Cancer research; Cancer; Transcriptome; Internal medicine; Prostate; Oncology; Medicine; Biology; Gene; Genetics; Gene expression","score_opus":0.10475146967943505,"score_gpt":0.44809907688356615,"score_spread":0.3433476072041311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282946122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97452384,0.0057527004,0.0000014763134,0.014048831,0.00016365328,0.0044196164,0.00097147294,0.00003013565,0.00008829013],"genre_scores_gemma":[0.98767626,0.0016586389,0.000015528627,0.00037660764,0.00013807211,0.008068473,0.00023904159,0.000059152764,0.0017682199],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964109,0.00034836857,0.0003510618,0.00069243734,0.0012361879,0.0009610554],"domain_scores_gemma":[0.99871916,0.00023377444,0.000078035926,0.00046523032,0.00018000211,0.00032378663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000990134,0.0002697763,0.00052941474,0.00026400122,0.0005574612,0.000120559744,0.00024105055,0.00004849185,0.000849499],"category_scores_gemma":[0.00004701321,0.00015963354,0.00007777424,0.00079148664,0.00018937759,0.00010146289,0.00026845525,0.00071279536,0.0000105973195],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5015539,0.0042302557,0.24461253,0.00017607781,0.0027763667,0.004696756,0.015676629,0.000796622,0.11618242,0.00004203209,0.004431191,0.10482522],"study_design_scores_gemma":[0.634242,0.015625373,0.21771887,0.00080020603,0.0004793939,0.000014655012,0.0067700935,0.00015699005,0.09275475,0.00021549455,0.030166723,0.0010554562],"about_ca_topic_score_codex":0.046070475,"about_ca_topic_score_gemma":0.0049587726,"teacher_disagreement_score":0.13268809,"about_ca_system_score_codex":0.0022235063,"about_ca_system_score_gemma":0.0014737275,"threshold_uncertainty_score":0.96028185},"labels":[],"label_agreement":null},{"id":"W4282959844","doi":"10.1158/1538-7445.am2022-3099","title":"Abstract 3099: Biological evaluation of a novel AKR1C3 inhibitor in patient-derived prostate cancer cell line and xenograft models","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Enzalutamide; Prostate cancer; Cancer research; Cancer; Androgen receptor; Carcinogenesis; Cell culture; Prostate; Medicine; Abiraterone acetate; Biology; Internal medicine; Oncology; Androgen deprivation therapy","score_opus":0.25092119821482306,"score_gpt":0.45414219526708133,"score_spread":0.20322099705225827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282959844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737206,0.021655066,0.0000020491007,0.0012061131,0.00009266815,0.0023834996,0.00032148717,0.000016627408,0.0006018827],"genre_scores_gemma":[0.98954165,0.006713775,0.000055243025,0.0000496391,0.000080674195,0.0032468012,0.00008862635,0.00002804658,0.00019551674],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99653184,0.00026925412,0.00037322746,0.0005024707,0.0017153791,0.0006078142],"domain_scores_gemma":[0.998589,0.00012343712,0.000088048124,0.00025330394,0.000751088,0.00019512053],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001984311,0.0001583447,0.0003284077,0.00032031437,0.00019748407,0.000020938907,0.00013298207,0.00008156397,0.0009681396],"category_scores_gemma":[0.000072246636,0.00012292387,0.000056885154,0.00071333814,0.00030014678,0.00013674035,0.0003295932,0.00071378745,0.000001450405],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043874304,0.0015996154,0.00845552,0.00039583386,0.00008875134,0.00005599722,0.005117242,0.005083191,0.8961774,0.00002088043,0.00065367593,0.07796448],"study_design_scores_gemma":[0.053958923,0.008956331,0.06288883,0.0011652487,0.00018483082,0.00003053303,0.016213859,0.0478283,0.8024321,0.0014027145,0.0040114135,0.00092692045],"about_ca_topic_score_codex":0.004576975,"about_ca_topic_score_gemma":0.00046864207,"teacher_disagreement_score":0.09374529,"about_ca_system_score_codex":0.0013596929,"about_ca_system_score_gemma":0.0017625877,"threshold_uncertainty_score":0.9999451},"labels":[],"label_agreement":null},{"id":"W4282963831","doi":"10.3390/cancers14122954","title":"A Tale of Two Cancers: A Current Concise Overview of Breast and Prostate Cancer","year":2022,"lang":"en","type":"review","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Prostate cancer; Breast cancer; Medicine; Cancer; Disease; Psychological intervention; Incidence (geometry); Quality of life (healthcare); Mortality rate; Oncology; Intensive care medicine; Gynecology; Internal medicine","score_opus":0.1365374435578623,"score_gpt":0.4553574516623561,"score_spread":0.3188200081044938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282963831","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029705203,0.99306625,5.0078296e-7,0.000036218386,0.00042626087,0.002369389,0.0033494995,0.000020155367,0.0004346479],"genre_scores_gemma":[0.00016217663,0.99680644,0.000015570466,0.000022967406,0.00015176173,0.0016514832,0.00028116416,0.00007588932,0.00083255005],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975748,0.0001295298,0.0007098616,0.0005621768,0.00057903066,0.00044459014],"domain_scores_gemma":[0.99837995,0.00010042783,0.0006374769,0.00045788885,0.00016275646,0.0002614868],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002177805,0.00044556643,0.0023952045,0.00027785025,0.00006655168,0.000010315579,0.00019652626,0.00009004606,0.0013028829],"category_scores_gemma":[0.000019547026,0.00033393232,0.00044463458,0.00073633826,0.00045382296,0.00007326046,0.00019248221,0.0005252294,0.000002173479],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00019927733,0.00003305064,0.000113927934,0.09745911,0.0005243988,0.000045208555,0.0003521201,0.0000055813234,0.0000053361705,0.000023479453,0.0015655026,0.899673],"study_design_scores_gemma":[0.0023703761,0.00029057867,0.00001396052,0.03974124,0.0020040502,0.00012291287,0.00009271781,0.000016055074,0.000022665981,0.000011359026,0.9550398,0.0002742532],"about_ca_topic_score_codex":0.0029846788,"about_ca_topic_score_gemma":0.00016790592,"teacher_disagreement_score":0.95347434,"about_ca_system_score_codex":0.0055312305,"about_ca_system_score_gemma":0.011169448,"threshold_uncertainty_score":0.99991125},"labels":[],"label_agreement":null},{"id":"W4282976653","doi":"10.1158/1538-7445.am2022-2367","title":"Abstract 2367: Characterizing the reciprocal regulation of an ABI1-dependent androgen receptor axis in prostate cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Chemistry; Androgen receptor; LNCaP; Cell biology; Molecular biology; Biology; Prostate cancer; Cancer","score_opus":0.0812202773113444,"score_gpt":0.40870092008312003,"score_spread":0.32748064277177563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282976653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878543,0.0035521928,2.9389759e-7,0.005805214,0.0001978833,0.0018431603,0.00023415366,0.000024347493,0.0004884431],"genre_scores_gemma":[0.99022377,0.0022907574,0.000018014614,0.000088955974,0.00023347654,0.0028392293,0.00014720148,0.000045246397,0.0041133394],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9964809,0.0003752736,0.00039201946,0.00049221085,0.0015722166,0.00068737724],"domain_scores_gemma":[0.9987485,0.000121875295,0.00010459266,0.00048823774,0.0003536671,0.00018313277],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023926874,0.00015275332,0.0003017861,0.00037075317,0.0004158133,0.000039174553,0.0003262938,0.00005756789,0.003973462],"category_scores_gemma":[0.000062743544,0.000108932145,0.0000700476,0.0010083565,0.00026878496,0.00019704468,0.00025054876,0.0010712456,0.0000126449295],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00880735,0.0006793146,0.068475865,0.00047053627,0.00016648107,0.00012345667,0.006203653,0.00032171077,0.79574865,0.0000848439,0.0024214515,0.11649667],"study_design_scores_gemma":[0.0075453767,0.0019410547,0.47037175,0.0006203151,0.000044415887,0.000035699235,0.005876721,0.000687232,0.46811768,0.00031397535,0.04403974,0.00040602664],"about_ca_topic_score_codex":0.004062541,"about_ca_topic_score_gemma":0.00062156335,"teacher_disagreement_score":0.40189588,"about_ca_system_score_codex":0.0015733145,"about_ca_system_score_gemma":0.0013142404,"threshold_uncertainty_score":0.99693704},"labels":[],"label_agreement":null},{"id":"W4282983478","doi":"10.21203/rs.3.rs-1520593/v2","title":"Tumour evolvability metrics predict recurrence beyond 10 years in locally-advanced prostate cancer","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre; Institute of Cancer Research","funders":"Medical Research Council; Department of Health and Social Care; National Institute for Health and Care Research; Canada's Michael Smith Genome Sciences Centre; Royal Marsden NHS Foundation Trust; National Cancer Institute; Cancer Research UK; Wellcome Trust","keywords":"Evolvability; Prostate cancer; Cancer; Prostate; Medicine; Oncology; Internal medicine; Biology; Evolutionary biology","score_opus":0.06470919462335512,"score_gpt":0.4334889433664823,"score_spread":0.3687797487431272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282983478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9332947,0.043748785,0.000007919186,0.0036888667,0.0007067601,0.010398779,0.0021678351,0.00018993998,0.005796413],"genre_scores_gemma":[0.9454359,0.032133464,0.00042453673,0.000046578396,0.00030339535,0.0075543206,0.0014502624,0.00014540607,0.012506137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9903863,0.0011347012,0.00077154033,0.0017898951,0.004143012,0.0017745581],"domain_scores_gemma":[0.9955785,0.00067213085,0.00017002768,0.0014798867,0.0014268722,0.0006725511],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004497247,0.0004982449,0.0009933843,0.0019976224,0.0002720092,0.00014171565,0.00085951743,0.00040668115,0.004813687],"category_scores_gemma":[0.0020790037,0.0004535832,0.0002984369,0.003672907,0.0005965735,0.00016354279,0.0030392637,0.006162198,0.000093904935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013849955,0.0037751177,0.6706724,0.015124849,0.0005524848,0.0042855437,0.0046599517,0.0033716452,0.0011411164,0.000103352955,0.025975756,0.2564878],"study_design_scores_gemma":[0.017245669,0.006349751,0.84259474,0.008697428,0.00018845631,0.000027916896,0.0045461585,0.0055026864,0.0029268782,0.0066256896,0.10348003,0.0018145991],"about_ca_topic_score_codex":0.0018538379,"about_ca_topic_score_gemma":0.00033139106,"teacher_disagreement_score":0.25467318,"about_ca_system_score_codex":0.005683371,"about_ca_system_score_gemma":0.0066167866,"threshold_uncertainty_score":0.99979156},"labels":[],"label_agreement":null},{"id":"W4283211705","doi":"10.1200/jco.22.00705","title":"Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Docetaxel; Cancer; Prostate; Oncology; Prostate cancer; Internal medicine; Hormone","score_opus":0.14967188929207503,"score_gpt":0.5055826342452931,"score_spread":0.3559107449532181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283211705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9611879,0.0059011616,0.000023954683,0.026272094,0.0007850393,0.0005575541,0.000060287457,0.0000065058116,0.00520549],"genre_scores_gemma":[0.97461367,0.015207468,0.0021771737,0.0020793532,0.00021307833,0.000035676967,0.000006095875,0.000018670986,0.005648812],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99678147,0.000406572,0.0016482896,0.0001755884,0.00072440866,0.00026367544],"domain_scores_gemma":[0.99726355,0.0005283627,0.0013405322,0.00016446691,0.0004316431,0.00027143265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026067817,0.000118132695,0.001273523,0.000171844,0.000074591044,0.000004361234,0.00015320127,0.000058683425,0.00044395027],"category_scores_gemma":[0.00012643506,0.00008102798,0.00045816717,0.00029660153,0.00021975867,0.00006658312,0.00017542801,0.00087609916,0.0000069449766],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081999555,0.009833176,0.023133757,0.00055881235,0.014376287,0.02452316,0.0034893171,0.00027533047,0.0012007845,0.0006954342,0.10560995,0.7343044],"study_design_scores_gemma":[0.09665092,0.11064693,0.22479025,0.0005040772,0.0074446755,0.0018248213,0.029351868,0.0006078359,0.004268781,0.0033286978,0.5200583,0.0005228758],"about_ca_topic_score_codex":0.0000829444,"about_ca_topic_score_gemma":0.0000034421942,"teacher_disagreement_score":0.7337816,"about_ca_system_score_codex":0.00034816473,"about_ca_system_score_gemma":0.0013518689,"threshold_uncertainty_score":0.48609442},"labels":[],"label_agreement":null},{"id":"W4283258055","doi":"10.1016/j.eururo.2022.05.030","title":"Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1","year":2022,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre Hospitalier de l’Université de Montréal","funders":"Medical Research Council; National Institute for Health and Care Research; Pfizer","keywords":"Medicine; Prostate cancer; Internal medicine; Quality of life (healthcare); Population; Oncology; Taxane; Visual analogue scale; Cancer; Hormonal therapy; Breast cancer; Surgery","score_opus":0.026208309276524597,"score_gpt":0.28873884592051924,"score_spread":0.2625305366439946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283258055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916274,0.00016159278,0.000004844093,0.003933024,0.00004171833,0.0013290395,0.000690332,0.00009052567,0.0021215368],"genre_scores_gemma":[0.99519116,0.000018626335,0.0002214479,0.00025679116,0.000021379285,0.00038943804,0.0008726444,0.000072193616,0.002956341],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99683946,0.0011110939,0.0005492063,0.0006205084,0.0004279183,0.000451821],"domain_scores_gemma":[0.9987471,0.0002478442,0.00024932227,0.00048014347,0.0001207997,0.00015477827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052622607,0.00026432335,0.00040376245,0.0002943323,0.00027464365,0.00004254582,0.00010550862,0.000018224222,0.00015288567],"category_scores_gemma":[0.0001230099,0.00018178733,0.00004062221,0.0005049994,0.00014980578,0.00011878369,0.000100053265,0.00040984876,0.000010511438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35069475,0.0020629908,0.4166637,0.000045408575,0.0021691183,0.054247778,0.016232446,0.008553184,0.14657348,0.000034968485,0.001309546,0.0014126085],"study_design_scores_gemma":[0.024160229,0.0075435247,0.9577543,0.00004834391,0.00040372708,0.00011687646,0.0012789695,0.00071945874,0.0037865432,0.000008510733,0.0038384967,0.0003409967],"about_ca_topic_score_codex":0.0011368073,"about_ca_topic_score_gemma":0.00059374305,"teacher_disagreement_score":0.5410906,"about_ca_system_score_codex":0.00027118274,"about_ca_system_score_gemma":0.00044516136,"threshold_uncertainty_score":0.7413072},"labels":[],"label_agreement":null},{"id":"W4283362513","doi":"10.1038/s41698-022-00282-8","title":"An appraisal of genetic testing for prostate cancer susceptibility","year":2022,"lang":"en","type":"review","venue":"npj Precision Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Sunnybrook Health Science Centre; Women's College Hospital","funders":"","keywords":"Prostate cancer; Genetic testing; Germline; Disease; Cancer; Medicine; Oncology; Prostate; Genetic predisposition; Germline mutation; Family history; Internal medicine; Bioinformatics; Biology; Genetics; Mutation; Gene","score_opus":0.18924701665809224,"score_gpt":0.5178367154979572,"score_spread":0.32858969883986494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283362513","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015255228,0.99149513,0.000038414328,0.000043377313,0.0006869917,0.0049876086,0.00048459822,0.00004951343,0.00068882236],"genre_scores_gemma":[0.00015189,0.9895519,0.005373442,0.000020791922,0.0003067666,0.0033657637,0.00049644883,0.00008309705,0.0006498836],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968138,0.0005477356,0.0009489455,0.0007928732,0.00042228366,0.0004743921],"domain_scores_gemma":[0.99494207,0.003320381,0.00053882145,0.0006751946,0.00029827977,0.0002252723],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010634303,0.00034245237,0.0021704,0.00028344698,0.00013131175,0.00001030436,0.00031874928,0.000408908,0.0012623587],"category_scores_gemma":[0.0010915885,0.00024116371,0.00039899533,0.0005054385,0.00019458834,0.000042155243,0.00019096384,0.00062149554,0.000007929497],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005774655,0.00057827093,0.0012530329,0.011690317,0.00016678235,0.000043737764,0.00016023325,0.000004264523,0.00003625402,0.0000029026965,0.0007855577,0.98470116],"study_design_scores_gemma":[0.0017785137,0.0077726906,0.00036360952,0.002085402,0.00094997324,0.00007803929,0.00006512895,0.00007226592,0.000011755076,0.000057667243,0.98657244,0.00019251122],"about_ca_topic_score_codex":0.00013212943,"about_ca_topic_score_gemma":0.00006524449,"teacher_disagreement_score":0.9857869,"about_ca_system_score_codex":0.0011375942,"about_ca_system_score_gemma":0.0043631913,"threshold_uncertainty_score":0.9996506},"labels":[],"label_agreement":null},{"id":"W4283369616","doi":"10.1136/jcp-2022-208350","title":"Gene of the month: ERG","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Erg; Biology; Gene; Transcription (linguistics); Transcription factor; ETS transcription factor family; Angiogenesis; Haematopoiesis; Cancer research; Pathology; Genetics; Medicine; Stem cell; Retinal","score_opus":0.13293177944626877,"score_gpt":0.46972369140473363,"score_spread":0.33679191195846486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283369616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877629,0.0014558764,0.000010542645,0.008602955,0.0009965901,0.000097042146,0.000008058834,0.0000018243397,0.0010641989],"genre_scores_gemma":[0.996806,0.00041596327,0.00030183815,0.0006790765,0.00032758305,0.0000026647174,0.0000010093323,0.0000062205527,0.0014596429],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983576,0.00038628132,0.0007382024,0.00007399759,0.00032902946,0.000114870185],"domain_scores_gemma":[0.9988411,0.00030088902,0.00044654185,0.00018475829,0.00014536238,0.00008132544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015824218,0.000044626107,0.0003983005,0.000050615738,0.000054614848,0.0000012023436,0.00016961459,0.000049518167,0.00031639528],"category_scores_gemma":[0.0006308426,0.00002318514,0.00034381237,0.0001185077,0.00018773547,0.000015447771,0.00013737383,0.0006907834,0.0000024653082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008467053,0.002560797,0.8841723,0.000050055885,0.00046319707,0.0047031706,0.00045459144,0.00010826208,0.019204056,0.00017687453,0.023449827,0.05618978],"study_design_scores_gemma":[0.010176171,0.008382139,0.9296889,0.00003429481,0.00025686956,0.0032584134,0.00025446387,0.00003386664,0.0051378165,0.0017757866,0.040935386,0.000065939385],"about_ca_topic_score_codex":0.0000020063235,"about_ca_topic_score_gemma":7.527198e-7,"teacher_disagreement_score":0.05612384,"about_ca_system_score_codex":0.000033912365,"about_ca_system_score_gemma":0.00035479155,"threshold_uncertainty_score":0.34643066},"labels":[],"label_agreement":null},{"id":"W4283453521","doi":"10.3390/cancers14122887","title":"The Extracellular Matrix Stiffening: A Trigger of Prostate Cancer Progression and Castration Resistance?","year":2022,"lang":"en","type":"review","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre; Université Laval; Hôtel-Dieu de Québec","funders":"Canadian Institutes of Health Research; Fonds de Recherche du Québec - Santé; Prostate Cancer Foundation","keywords":"Prostate cancer; Medicine; Cancer; Prostate; Disease; Stiffening; Oncology; Internal medicine; Extracellular matrix; Biology","score_opus":0.06857487869890601,"score_gpt":0.4143794855158802,"score_spread":0.3458046068169742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283453521","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020112404,0.99590355,9.181569e-7,0.00022189139,0.00028306205,0.0028141479,0.00014661081,0.00002668577,0.00040202288],"genre_scores_gemma":[0.000057475107,0.965881,0.000049896753,0.0000035043838,0.00013086367,0.0020374781,0.00015623537,0.000059064256,0.031624515],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793553,0.0001579378,0.00053047127,0.00043719777,0.0005575493,0.00038129662],"domain_scores_gemma":[0.99873435,0.00020030404,0.00046297067,0.00036719802,0.000089436195,0.00014575855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041071995,0.00031597793,0.00097234064,0.00013478335,0.0003394022,0.00004268404,0.00014422137,0.00013424983,0.00019314523],"category_scores_gemma":[0.000048654987,0.0001787149,0.00022973446,0.00045573316,0.00031085746,0.000053594104,0.00007620121,0.0005253905,0.0000016245746],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053789024,0.00001507486,0.000029066594,0.016646186,0.00032686235,0.00009126309,0.00027589628,0.0000017863442,0.000013999279,0.00007709478,0.0025444746,0.9794404],"study_design_scores_gemma":[0.0008828121,0.0002018865,0.0000059742492,0.00853757,0.00083803234,0.000023475328,0.00013640853,0.000010575407,0.000028497085,0.00001985407,0.9891511,0.00016379693],"about_ca_topic_score_codex":0.00007941893,"about_ca_topic_score_gemma":0.000058536458,"teacher_disagreement_score":0.98660666,"about_ca_system_score_codex":0.0021481432,"about_ca_system_score_gemma":0.0044411775,"threshold_uncertainty_score":0.78784585},"labels":[],"label_agreement":null},{"id":"W4283579922","doi":"10.3389/fonc.2022.905398","title":"The Androgen Receptor and Its Crosstalk With the Src Kinase During Castrate-Resistant Prostate Cancer Progression","year":2022,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Proto-oncogene tyrosine-protein kinase Src; Androgen receptor; Cancer research; Prostate; Medicine; Tyrosine kinase; Metastasis; Androgen; Receptor tyrosine kinase; Internal medicine; Oncology; Cancer; Receptor; Hormone","score_opus":0.0387672580639465,"score_gpt":0.38577928470851225,"score_spread":0.34701202664456576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283579922","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042947964,0.9890759,3.3218765e-7,0.0014813888,0.00060019,0.003998878,0.00014658444,0.000025701267,0.00037623727],"genre_scores_gemma":[0.00010425838,0.9889668,0.00009782028,0.000028167557,0.00014231444,0.0040139914,0.00010434809,0.000067087676,0.0064751627],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975461,0.00046912968,0.00039637007,0.0005437659,0.0003811188,0.0006635537],"domain_scores_gemma":[0.9989714,0.00018275081,0.00029701812,0.0003296339,0.000063623724,0.0001555573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056308624,0.00037758565,0.0011429221,0.00015643952,0.00071757275,0.00006254193,0.0002569697,0.00020998057,0.00009517656],"category_scores_gemma":[0.00004205883,0.0001619398,0.00012120678,0.0004947978,0.0004934098,0.000051832314,0.00021985832,0.0010376277,0.0000026765615],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003362621,0.00013505443,0.0005663096,0.005307454,0.0005364271,0.0013140441,0.0006551918,8.8051155e-7,0.000010153984,0.000009033475,0.0077890176,0.98031384],"study_design_scores_gemma":[0.0021435348,0.0011336376,0.00006607158,0.0025152985,0.00041753048,0.00015160552,0.00080256537,0.0000053888903,0.0000309564,0.0000063646266,0.99253756,0.00018949993],"about_ca_topic_score_codex":0.000044014127,"about_ca_topic_score_gemma":0.00017108746,"teacher_disagreement_score":0.98474854,"about_ca_system_score_codex":0.0017467865,"about_ca_system_score_gemma":0.0022594219,"threshold_uncertainty_score":0.6603713},"labels":[],"label_agreement":null},{"id":"W4283656267","doi":"10.1158/2159-8290.cd-21-0576","title":"Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence","year":2022,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Astellas Pharma; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; National Cancer Institute; ZonMw; Movember Foundation","keywords":"Epigenomics; Prostate cancer; Circadian rhythm; Androgen; Independence (probability theory); Biology; Melatonin; Drug; Cancer; Neuroscience; Endocrinology; Pharmacology; Hormone; Genetics","score_opus":0.03190768478287693,"score_gpt":0.31640415213052425,"score_spread":0.28449646734764733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283656267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887853,0.002504792,0.00006161844,0.0046130405,0.00074695767,0.0022279418,0.00048484487,0.00009828143,0.0004771793],"genre_scores_gemma":[0.98654574,0.00069329684,0.000053475993,0.00065024133,0.00041391965,0.0032263326,0.00015678813,0.00006650023,0.008193689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970927,0.000097789016,0.0003548262,0.00087853626,0.0008406671,0.0007354867],"domain_scores_gemma":[0.99882394,0.00004387037,0.0001454532,0.00042469602,0.00015968274,0.0004023624],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002556902,0.00029172888,0.00043045086,0.00022486394,0.00041713152,0.000106952175,0.00020599946,0.0000732854,0.00066630146],"category_scores_gemma":[0.00003238803,0.00026616038,0.00014901266,0.0007088739,0.0000950295,0.00035399917,0.00029165094,0.00045891388,0.000028486269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0109799765,0.00096611603,0.577665,0.0008691496,0.0015263102,0.0011758005,0.028313262,0.0113475565,0.12647018,0.0004316198,0.014913875,0.22534116],"study_design_scores_gemma":[0.017897943,0.0034436272,0.56232977,0.0013017189,0.0010309003,0.00031187717,0.00857241,0.0017135061,0.3101588,0.0013363675,0.08913045,0.0027726463],"about_ca_topic_score_codex":0.0034819967,"about_ca_topic_score_gemma":0.000879531,"teacher_disagreement_score":0.2225685,"about_ca_system_score_codex":0.002636292,"about_ca_system_score_gemma":0.0017573124,"threshold_uncertainty_score":0.9999791},"labels":[],"label_agreement":null},{"id":"W4283693979","doi":"10.3390/curroncol29070362","title":"Achieving Consensus for Management of Hormone-Sensitive, Low-Volume Metastatic Prostate Cancer in Italy","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Cilag","keywords":"Medicine; Prostate cancer; Systemic therapy; Oncology; Radiation therapy; Disease; Androgen deprivation therapy; Hormone therapy; Internal medicine; Metastasis; Prostate-specific antigen; Docetaxel; Cancer; Breast cancer","score_opus":0.09806637829297123,"score_gpt":0.4334130943124152,"score_spread":0.335346716019444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283693979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797595,0.013518036,0.00003939145,0.0025519133,0.00052835344,0.0024368593,0.0003544921,0.000020073148,0.0007913823],"genre_scores_gemma":[0.9941003,0.0018437733,0.0005066399,0.00004968689,0.000034744902,0.0016266552,0.00013775489,0.000022950659,0.0016775165],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99864167,0.00012789888,0.00033600023,0.0002914294,0.00024002629,0.0003629838],"domain_scores_gemma":[0.9994116,0.00011435141,0.00012980957,0.00015272526,0.00010964316,0.00008186693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033072854,0.00013010883,0.00042423524,0.0002126539,0.00008824438,0.0000037657255,0.00007677485,0.00002169956,0.00007789666],"category_scores_gemma":[0.000020717187,0.000114990224,0.00009479205,0.00030465305,0.00013013533,0.00002079514,0.00015875191,0.00021533032,0.0000033432154],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031378444,0.010489417,0.120359495,0.007206397,0.0027816007,0.0031425774,0.007888511,0.001605628,0.022573575,0.0026950652,0.047251362,0.7426279],"study_design_scores_gemma":[0.10165133,0.01875697,0.3400075,0.0013515804,0.0025999777,0.00024334955,0.027200468,0.013646747,0.0048659844,0.0011871603,0.48717293,0.001315976],"about_ca_topic_score_codex":0.00003244482,"about_ca_topic_score_gemma":0.00002174628,"teacher_disagreement_score":0.74131197,"about_ca_system_score_codex":0.0007810524,"about_ca_system_score_gemma":0.000328982,"threshold_uncertainty_score":0.46891654},"labels":[],"label_agreement":null},{"id":"W4283814976","doi":"10.1038/s41391-022-00560-3","title":"Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer","year":2022,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Ottawa Hospital; University of Ottawa; University of Toronto; Ottawa Regional Cancer Foundation; Mount Sinai Hospital","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Confidence interval; Proportional hazards model; Oncology; Prognostic variable; Multivariate statistics; Multivariate analysis; Cancer; Statistics","score_opus":0.037057405412189125,"score_gpt":0.3325120029562708,"score_spread":0.2954545975440817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283814976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870985,0.0075337645,0.000048738082,0.0007158308,0.00005447623,0.002880727,0.0015512732,0.00003706465,0.00007961836],"genre_scores_gemma":[0.9891053,0.0024022306,0.0027158814,0.00016251238,0.0000144600335,0.004160976,0.00027590038,0.000049174116,0.0011135812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99772364,0.00013231878,0.00050951284,0.0005435637,0.00049440085,0.0005965423],"domain_scores_gemma":[0.9989996,0.00014256155,0.00019179101,0.00015232094,0.00019841375,0.00031534323],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036864978,0.00030332943,0.00054909213,0.00025929807,0.0002512715,0.000050293114,0.000060857546,0.000027970242,0.000062720836],"category_scores_gemma":[0.00007710074,0.00026196576,0.0000435915,0.0004646178,0.000215742,0.00020357182,0.0001565648,0.00024346799,5.8036744e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010375599,0.0016416069,0.82836616,0.0067155147,0.0008142503,0.0008078395,0.05836212,0.017403442,0.012555036,0.00029403405,0.00012939949,0.06253499],"study_design_scores_gemma":[0.07758333,0.004651648,0.4686515,0.00637373,0.0047138617,0.00054820086,0.053681687,0.2148399,0.1533069,0.008970744,0.0028505225,0.003827972],"about_ca_topic_score_codex":0.00044951087,"about_ca_topic_score_gemma":0.00006225225,"teacher_disagreement_score":0.35971466,"about_ca_system_score_codex":0.00045428897,"about_ca_system_score_gemma":0.0023020734,"threshold_uncertainty_score":0.99998325},"labels":[],"label_agreement":null},{"id":"W4284887428","doi":"10.1016/j.euo.2022.06.003","title":"Addition of Docetaxel to Androgen Receptor Axis–targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis","year":2022,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Mount Sinai Hospital; Ottawa Hospital; University of Ottawa; University Health Network; University of Toronto; Université de Montréal","funders":"","keywords":"Docetaxel; Androgen deprivation therapy; Medicine; Prostate cancer; Oncology; Internal medicine; Hazard ratio; Clinical endpoint; Randomized controlled trial; Confidence interval; Androgen receptor; Meta-analysis; Cancer","score_opus":0.1584241569403467,"score_gpt":0.38862274295798793,"score_spread":0.23019858601764123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284887428","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0060179033,0.987935,0.000013016047,0.00079847185,0.00010339341,0.0038691205,0.0007392258,0.000040440696,0.00048340132],"genre_scores_gemma":[0.0013984231,0.99281394,0.00049044465,0.00086494826,0.00012214149,0.0013136326,0.0025748725,0.00010891315,0.00031269641],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99218875,0.004775339,0.001104584,0.0009808472,0.000325426,0.00062508],"domain_scores_gemma":[0.99762434,0.0007249833,0.0007687077,0.00049707486,0.00016671424,0.00021818912],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018687181,0.0005736153,0.0048194383,0.0010704094,0.00013213462,0.000013677743,0.00022485238,0.0001873094,0.0013306689],"category_scores_gemma":[0.00009926983,0.00040717475,0.0009900404,0.002133791,0.00025692667,0.00006058438,0.00019166167,0.0007364786,0.000026098109],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039171963,0.00055799517,0.00033889932,0.00040357516,0.1419544,0.00079882145,0.0013630355,0.0001302551,0.000034200682,0.000024237856,0.0019854319,0.84849197],"study_design_scores_gemma":[0.0032149425,0.005452052,0.0006254693,0.000038068018,0.058302294,0.00012747532,0.000054461714,0.00001564876,0.000012399491,0.000025122501,0.931822,0.00031007137],"about_ca_topic_score_codex":0.00011639602,"about_ca_topic_score_gemma":0.00009006445,"teacher_disagreement_score":0.9298366,"about_ca_system_score_codex":0.00035810235,"about_ca_system_score_gemma":0.00065132184,"threshold_uncertainty_score":0.999838},"labels":[],"label_agreement":null},{"id":"W4285495370","doi":"10.1186/s12913-022-08274-x","title":"An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective","year":2022,"lang":"en","type":"article","venue":"BMC Health Services Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Sanofi","keywords":"Cabazitaxel; Enzalutamide; Prostate cancer; Medicine; Docetaxel; Oncology; Androgen receptor; Internal medicine; Androgen deprivation therapy; Cancer","score_opus":0.08022750665785497,"score_gpt":0.43327819554680547,"score_spread":0.3530506888889505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285495370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98594123,0.0025206287,0.000001866894,0.00043779536,0.000043560736,0.009117241,0.0018922418,0.000023385548,0.000022033853],"genre_scores_gemma":[0.9909878,0.0004942875,0.0002891707,0.0000805462,0.00003947149,0.004083175,0.0037983318,0.000056952314,0.00017027454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953523,0.0014886652,0.0004196542,0.00064542657,0.0013586023,0.00073532667],"domain_scores_gemma":[0.9964194,0.0003278188,0.00027180297,0.00046729064,0.002098734,0.0004149374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027431743,0.00024428137,0.00042241492,0.00040071775,0.00091989257,0.00008780781,0.00019197837,0.00003336746,0.0003647231],"category_scores_gemma":[0.000016850918,0.00014902302,0.000037997674,0.0007127623,0.00021128786,0.00028916018,0.000057642526,0.0003190432,0.0000015141962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23558547,0.0053587444,0.5725473,0.008153628,0.0037101044,0.000021837352,0.14892818,0.017583119,0.0014339383,0.00023325787,0.0004785726,0.005965849],"study_design_scores_gemma":[0.092169814,0.08905128,0.4513534,0.00066322275,0.0010483968,0.00001192502,0.24165048,0.11830039,0.001975616,0.00022290958,0.0027792442,0.0007733147],"about_ca_topic_score_codex":0.013339029,"about_ca_topic_score_gemma":0.026667738,"teacher_disagreement_score":0.14341564,"about_ca_system_score_codex":0.0019472169,"about_ca_system_score_gemma":0.0036989178,"threshold_uncertainty_score":0.99323124},"labels":[],"label_agreement":null},{"id":"W4285594030","doi":"10.21203/rs.3.rs-1833452/v1","title":"Absence of KLK4-KLKP1 Fusion Corroborate with PTEN Loss in Characterizing Men at Higher Risk for Biochemical Recurrence in Middle Eastern Prostate Cancer Cohort","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"Prostate Cancer Canada; Prostate Cancer Foundation","keywords":"PTEN; Prostate cancer; Medicine; Prostatectomy; Biochemical recurrence; Internal medicine; Erg; Oncology; Urology; Population; Cancer; Biology","score_opus":0.07937416648846396,"score_gpt":0.39719592261603165,"score_spread":0.3178217561275677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285594030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98472106,0.00478507,0.000004642503,0.0013509012,0.00015047664,0.0068835304,0.0016249062,0.000028296396,0.00045110445],"genre_scores_gemma":[0.9703185,0.015158581,0.00014248394,0.000015409245,0.00012410534,0.006337718,0.00157484,0.00008656569,0.0062418114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948716,0.0004582754,0.000623734,0.001206002,0.0017090496,0.0011313406],"domain_scores_gemma":[0.9975418,0.00032204966,0.00029357173,0.0007721892,0.0007826174,0.00028777623],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00205289,0.00038655841,0.0008797118,0.00075649546,0.00016580988,0.000045490742,0.00045305525,0.00027877092,0.0004531179],"category_scores_gemma":[0.00016396162,0.00029880085,0.00012348873,0.0010736603,0.000445591,0.00009444221,0.0015699766,0.0022076904,0.00000964748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010806466,0.00046127773,0.971504,0.0048568933,0.00011714341,0.00034944704,0.0017843877,0.00011184085,0.0074969297,0.0000043932137,0.00041794364,0.002089304],"study_design_scores_gemma":[0.008469113,0.0017897657,0.9482822,0.015245032,0.000065601605,0.000010022386,0.001000478,0.0029807314,0.018407114,0.00016101109,0.0029547967,0.000634127],"about_ca_topic_score_codex":0.003840102,"about_ca_topic_score_gemma":0.0005196441,"teacher_disagreement_score":0.023221765,"about_ca_system_score_codex":0.002249373,"about_ca_system_score_gemma":0.0015383983,"threshold_uncertainty_score":0.9999464},"labels":[],"label_agreement":null},{"id":"W4285730177","doi":"10.3390/curroncol29070400","title":"Emerging Biomarker-Guided Therapies in Prostate Cancer","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; McMaster University; London Health Sciences Centre; Juravinski Cancer Centre; Western University","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Precision medicine; Personalized medicine; Androgen receptor; Targeted therapy; Biomarker; Enzalutamide; Cancer research; Oncology; Bioinformatics; Internal medicine; Biology; Pathology; Genetics","score_opus":0.39871769434795296,"score_gpt":0.5616530948274054,"score_spread":0.16293540047945249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285730177","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017563929,0.99278194,3.6698262e-7,0.000574755,0.0020921268,0.002475711,0.00010330538,0.00005614395,0.0017400413],"genre_scores_gemma":[0.000008254194,0.9930827,0.00001556312,0.000032008797,0.00023018796,0.0040291417,0.0006754504,0.00007123519,0.0018554737],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99730927,0.0004577013,0.0006781254,0.0005949656,0.00033164627,0.00062832003],"domain_scores_gemma":[0.99896264,0.00022168108,0.0002731793,0.0003391298,0.000055713474,0.00014767442],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004890824,0.00041137892,0.0019374209,0.0006905676,0.00010361282,0.000014222079,0.00022341123,0.00016434026,0.0029319562],"category_scores_gemma":[0.000057968395,0.00028918902,0.0003806949,0.0008499965,0.00014684301,0.000041414136,0.0002319939,0.0010511571,0.000046538207],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100372046,0.00045314507,0.001057922,0.013188883,0.00031909544,0.00033036017,0.0004765735,1.1627069e-7,5.213681e-7,0.00001535639,0.0073294314,0.9767282],"study_design_scores_gemma":[0.0019378354,0.000269773,0.00009372249,0.005682844,0.0005026401,0.000089931025,0.00011900546,0.0000066233183,4.5601178e-7,0.000028936023,0.99102247,0.00024575653],"about_ca_topic_score_codex":0.000081209924,"about_ca_topic_score_gemma":0.00004742194,"teacher_disagreement_score":0.98369306,"about_ca_system_score_codex":0.0026926394,"about_ca_system_score_gemma":0.0027884438,"threshold_uncertainty_score":0.999956},"labels":[],"label_agreement":null},{"id":"W4285741313","doi":"","title":"Sex steroid modulation of macrophages within the prostate tumor microenvironment.","year":2022,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Prostate cancer; Prostate; CD163; Tumor microenvironment; Testosterone (patch); Estrogen; Immune system; Dehydroepiandrosterone; Internal medicine; Androgen; Cancer research; Endocrinology; Ex vivo; Macrophage; Medicine; Biology; In vivo; Cancer; Immunology; Hormone; In vitro","score_opus":0.019610680624348543,"score_gpt":0.2420274388930971,"score_spread":0.22241675826874857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285741313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99487686,0.0008384481,0.0000039271185,0.00190764,0.000084183834,0.0016638673,0.0000444713,0.000016436055,0.0005641485],"genre_scores_gemma":[0.98413956,0.000036671416,0.000030821426,0.00018948743,0.00003218484,0.0022280724,0.000040157243,0.000014629561,0.013288428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990698,0.000077032244,0.0001553323,0.0001499954,0.00033885447,0.0002089512],"domain_scores_gemma":[0.99961865,0.000022223045,0.00008070491,0.00020848325,0.000013288074,0.000056672714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034887542,0.00007189806,0.00012328036,0.000048947488,0.00013267776,0.000008801531,0.00008249018,0.000008758057,0.00008778679],"category_scores_gemma":[0.000012208518,0.000045058878,0.000042135278,0.00012620131,0.00009175177,0.00003300251,0.00011083264,0.00014190939,0.0000033506478],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005707589,0.0018418928,0.5508268,0.00062299153,0.00097348506,0.00050067954,0.009696577,0.0025108638,0.13338926,0.00014766876,0.007852576,0.2859296],"study_design_scores_gemma":[0.0025895692,0.00021442791,0.9253509,0.000005872868,0.000059115773,0.0000518376,0.00087244494,0.000367151,0.06634424,0.000144926,0.003917476,0.000082038045],"about_ca_topic_score_codex":0.000023336937,"about_ca_topic_score_gemma":0.0000011781091,"teacher_disagreement_score":0.3745241,"about_ca_system_score_codex":0.00015121161,"about_ca_system_score_gemma":0.000030076622,"threshold_uncertainty_score":0.18374477},"labels":[],"label_agreement":null},{"id":"W4285792521","doi":"10.1007/s13139-022-00754-6","title":"Interval Changes in PSMA PET/CT During Radium-223 Therapy for Metastatic Bone Disease from Castration-Resistant Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"Nuclear Medicine and Molecular Imaging","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Bayer Canada","keywords":"Medicine; Prostate cancer; Radium-223; PET-CT; Disease; Oncology; Internal medicine; Cancer; Bone metastasis; Nuclear medicine; Radiology; Positron emission tomography","score_opus":0.025071100372481794,"score_gpt":0.32267240769442446,"score_spread":0.2976013073219427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285792521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.944937,0.022326576,0.000006321704,0.031373452,0.00010130259,0.0010369323,0.00010799778,0.000033832046,0.000076618286],"genre_scores_gemma":[0.9941134,0.0018635187,0.00030539586,0.0028965871,0.00007667303,0.00036950357,0.00015454786,0.000057089776,0.00016332821],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986584,0.00007360174,0.00021235066,0.00037316955,0.000351477,0.0003309981],"domain_scores_gemma":[0.99946576,0.00003841855,0.00006435051,0.00018006616,0.000049444196,0.00020198617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020641038,0.00017655484,0.00032077995,0.00021045674,0.00019910878,0.000024437282,0.00006676959,0.0000032031141,0.00034172108],"category_scores_gemma":[0.000038803213,0.0001406077,0.000057670524,0.00017595972,0.00011678722,0.0000614711,0.00006783327,0.00020588562,9.738245e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01327655,0.00059348246,0.025025848,0.00079886924,0.0005511423,0.03155083,0.007218307,0.000035744124,0.8936718,0.00012984521,0.0042083603,0.022939203],"study_design_scores_gemma":[0.2658517,0.008431871,0.32623658,0.0064321244,0.003361328,0.0027317125,0.07128735,0.028506717,0.054718237,0.0041834507,0.22488545,0.0033734753],"about_ca_topic_score_codex":0.0009707908,"about_ca_topic_score_gemma":0.00006841667,"teacher_disagreement_score":0.83895355,"about_ca_system_score_codex":0.00016648539,"about_ca_system_score_gemma":0.00011199878,"threshold_uncertainty_score":0.5733816},"labels":[],"label_agreement":null},{"id":"W4286007717","doi":"10.3390/cells11142246","title":"A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers","year":2022,"lang":"en","type":"article","venue":"Cells","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cameco (Canada); Saskatchewan Cancer Agency; University of Saskatchewan","funders":"Canadian Institutes of Health Research; Canada Foundation for Innovation; Health Research","keywords":"Prostate cancer; Cancer research; Reactive oxygen species; Fludarabine; Oncogene; Biology; Medicine; Cancer; Internal medicine; Cell biology; Cell cycle; Chemotherapy","score_opus":0.02123176121564797,"score_gpt":0.30458334591070785,"score_spread":0.2833515846950599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286007717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96892464,0.020671532,0.00024049621,0.002991198,0.0013753639,0.0040661837,0.0002842486,0.00018597055,0.0012603359],"genre_scores_gemma":[0.9416464,0.0011010187,0.00024002035,0.0011305694,0.00020760877,0.00067979173,0.00024502448,0.0000882835,0.05466129],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978292,0.000093153074,0.00031702008,0.0005353831,0.00057644304,0.0006487882],"domain_scores_gemma":[0.9991646,0.000056516074,0.00013585523,0.00037706824,0.00010488587,0.0001610953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021242605,0.00023934164,0.00033621993,0.00014985328,0.0006461132,0.0001173157,0.00017213284,0.000015862115,0.0006503795],"category_scores_gemma":[0.00001539751,0.00020856354,0.00020810749,0.0002604793,0.00011464827,0.00013614065,0.00021300418,0.00029208726,0.00001874335],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00916105,0.0004983432,0.0007845071,0.0007076415,0.00065714226,0.002303696,0.0020536575,0.0023710981,0.8962405,0.000060892562,0.031745818,0.053415664],"study_design_scores_gemma":[0.010207135,0.0013415975,0.00050365156,0.00022717468,0.0004776004,0.0002729416,0.0014334127,0.004672997,0.8532679,0.0007410012,0.12641262,0.00044195066],"about_ca_topic_score_codex":0.0005213551,"about_ca_topic_score_gemma":0.0000070089377,"teacher_disagreement_score":0.094666794,"about_ca_system_score_codex":0.00053892337,"about_ca_system_score_gemma":0.00043348255,"threshold_uncertainty_score":0.8504974},"labels":[],"label_agreement":null},{"id":"W4286293512","doi":"10.1200/jco.2022.40.16_suppl.5055","title":"Biallelic loss of TP53, PTEN, and RB1 in association to aggressive clinical features and poor outcomes in metastatic castration-resistant prostate cancer (mCRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Positive Living North; Abbotsford Veterinary Clinic; BC Cancer Agency; Kelowna General Hospital; University of British Columbia","funders":"","keywords":"PTEN; Prostate cancer; Medicine; Loss of heterozygosity; Internal medicine; Oncology; Cancer; Androgen deprivation therapy; Cancer research; Allele; Biology; Gene; Genetics; Apoptosis","score_opus":0.12466618231781888,"score_gpt":0.5212195107989226,"score_spread":0.3965533284811037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96168995,0.0025784674,8.123552e-7,0.034711443,0.0004066687,0.00050192676,0.00004225378,0.0000021380054,0.00006636815],"genre_scores_gemma":[0.9930418,0.004395021,0.00050987507,0.0012157003,0.00012777376,0.000038621813,0.0000044706144,0.000010679062,0.0006560448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99594265,0.0009806887,0.0021155782,0.00021671978,0.0005027366,0.00024165404],"domain_scores_gemma":[0.99460024,0.0030511168,0.001719164,0.000085778236,0.00028971164,0.0002540153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005100183,0.000115431,0.0014406391,0.00028485633,0.000043191856,0.000011393854,0.00008705257,0.00013498153,0.000056714875],"category_scores_gemma":[0.005096663,0.00007938592,0.00016090664,0.00025318214,0.00014048263,0.00007841812,0.00010376161,0.0010689143,5.6889354e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009470413,0.0012461009,0.9512337,0.000050393686,0.0003825148,0.0014601888,0.00053666363,0.0000496628,0.0001567944,0.000028059083,0.0012020776,0.03418342],"study_design_scores_gemma":[0.014133238,0.008213206,0.9735817,0.00011604992,0.00019176753,0.00008016464,0.0006201346,0.000041306797,0.00003383976,0.00031360943,0.0026037593,0.00007125217],"about_ca_topic_score_codex":0.00039256734,"about_ca_topic_score_gemma":0.00203554,"teacher_disagreement_score":0.034112167,"about_ca_system_score_codex":0.00044960665,"about_ca_system_score_gemma":0.0017874131,"threshold_uncertainty_score":0.610155},"labels":[],"label_agreement":null},{"id":"W4286293775","doi":"10.1200/jco.2022.40.16_suppl.5057","title":"Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cholesterol side-chain cleavage enzyme; Androgen receptor; CYP17A1; Medicine; Internal medicine; Endocrinology; Androgen; Pregnenolone; Glucocorticoid receptor; Pharmacology; Hormone; Steroid; CYP3A4; Chemistry; Receptor; Prostate cancer; Cytochrome P450; Enzyme; Cancer; Biochemistry","score_opus":0.05253178606062217,"score_gpt":0.44546713280245953,"score_spread":0.3929353467418374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99538934,0.000054480624,0.000005660474,0.0031343065,0.00012656089,0.0011018038,0.00015190935,0.0000032672428,0.000032669337],"genre_scores_gemma":[0.99847484,0.000058464306,0.0010562157,0.00018366108,0.00005308585,0.000089927555,0.000009349092,0.000018808276,0.00005566822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969828,0.00080764724,0.0011086403,0.0002761619,0.00053871865,0.00028599866],"domain_scores_gemma":[0.99544317,0.0027827732,0.00076886563,0.000106175576,0.00057777093,0.00032124564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023258182,0.00016052464,0.0009583053,0.00047971637,0.0000868356,0.000008886254,0.000058184927,0.000055185752,0.000027451446],"category_scores_gemma":[0.0025549012,0.0001108674,0.00011736365,0.00068702723,0.000089901776,0.00013844954,0.000057686735,0.00074525335,7.1253737e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.322248,0.0035986286,0.61683303,0.00003886001,0.00059586845,0.00065691996,0.004710802,0.014631713,0.010711429,0.0000027852282,0.00017837336,0.025793586],"study_design_scores_gemma":[0.020249506,0.071957275,0.9023452,0.0003255391,0.00006817351,0.000018803225,0.0006915882,0.00014971066,0.0038270329,0.000029287408,0.00022310225,0.00011481511],"about_ca_topic_score_codex":0.00026251408,"about_ca_topic_score_gemma":0.00082501967,"teacher_disagreement_score":0.3019985,"about_ca_system_score_codex":0.0016771001,"about_ca_system_score_gemma":0.0028878793,"threshold_uncertainty_score":0.5122974},"labels":[],"label_agreement":null},{"id":"W4286293820","doi":"10.1200/jco.2022.40.16_suppl.e17018","title":"Pilot trial of physical and cognitive changes related to fall risk in enzalutamide patients with castration-resistant prostate cancer (CRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Physical therapy; Montreal Cognitive Assessment; Cancer; Oncology; Internal medicine; Disease; Androgen receptor; Cognitive impairment","score_opus":0.09699072246260514,"score_gpt":0.4671761462542567,"score_spread":0.37018542379165154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958342,0.00027682257,6.654922e-7,0.0023483548,0.00025243525,0.0009908387,0.00009123613,0.0000026352616,0.00020286388],"genre_scores_gemma":[0.9988819,0.00041011948,0.00007306465,0.00020428338,0.00015160356,0.00006680205,0.000008808845,0.000011889145,0.00019153357],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9976736,0.00057629676,0.0009018344,0.00017353956,0.00048668036,0.00018805095],"domain_scores_gemma":[0.9970428,0.0014004577,0.00087475695,0.00006676062,0.00039611862,0.00021911264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001358254,0.0000992288,0.0008736687,0.0001661793,0.000050918254,0.0000040335244,0.000060436527,0.000049739312,0.000039350576],"category_scores_gemma":[0.0010582326,0.00006253203,0.000084445484,0.00024029486,0.00017267201,0.00004784337,0.00006188763,0.0008742477,6.7933235e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5573051,0.0053742924,0.37987188,0.000027597564,0.0004626906,0.0003064052,0.0014520044,0.000046722314,0.0002036384,0.000011462135,0.0001264616,0.054811746],"study_design_scores_gemma":[0.17399713,0.18780129,0.6360245,0.00015206284,0.0003603374,0.000009568759,0.00051502604,0.000026232185,0.000095664014,0.000119668875,0.0008273949,0.000071129456],"about_ca_topic_score_codex":0.0002934739,"about_ca_topic_score_gemma":0.00091305055,"teacher_disagreement_score":0.383308,"about_ca_system_score_codex":0.00019500048,"about_ca_system_score_gemma":0.0013255813,"threshold_uncertainty_score":0.379822},"labels":[],"label_agreement":null},{"id":"W4286294073","doi":"10.1200/jco.2022.40.16_suppl.tps5110","title":"CCTG PR21: A randomized phase II study of [<sup>177</sup>lu]lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lions Gate Hospital; McMaster University; Western University; Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Université Laval; Université de Montréal; University of British Columbia","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Tolerability; Taxane; Response Evaluation Criteria in Solid Tumors; Internal medicine; Oncology; Adverse effect; Progression-free survival; Chemotherapy; Population; Progressive disease; Cancer; Urology; Breast cancer","score_opus":0.068962979691834,"score_gpt":0.45872948020305576,"score_spread":0.38976650051122175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992627,0.0014374265,0.000004024112,0.0023080371,0.00017582045,0.0031496906,0.00020232555,0.0000058566434,0.00008977552],"genre_scores_gemma":[0.9981994,0.0005495957,0.0002436071,0.00024181629,0.000107266875,0.00028474614,0.000037068257,0.000026979025,0.00030949878],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99406046,0.0017123381,0.0024531882,0.00036535197,0.0010418944,0.00036674843],"domain_scores_gemma":[0.99498725,0.0018483188,0.0017078761,0.00021508778,0.0006845533,0.0005569269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033273303,0.00025149845,0.0024774515,0.00032708247,0.00018545969,0.000015859914,0.00015424569,0.000068037334,0.00017233602],"category_scores_gemma":[0.0012120508,0.00015497855,0.0002817906,0.00037199297,0.00045756146,0.00018521083,0.00014811647,0.0010402278,6.475173e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8229222,0.033388436,0.11467056,0.000113308204,0.0022675144,0.0026234512,0.0039745453,0.0005413253,0.000028049666,0.000014540564,0.00022957995,0.01922645],"study_design_scores_gemma":[0.7382433,0.09167261,0.16209759,0.00019572304,0.0025848618,0.000027841825,0.003949442,0.0005698632,0.000021247255,0.00013311826,0.00033389893,0.00017055332],"about_ca_topic_score_codex":0.0002561589,"about_ca_topic_score_gemma":0.00014301705,"teacher_disagreement_score":0.084678985,"about_ca_system_score_codex":0.00041080167,"about_ca_system_score_gemma":0.003398041,"threshold_uncertainty_score":0.63198423},"labels":[],"label_agreement":null},{"id":"W4286295779","doi":"10.1200/jco.2022.40.16_suppl.5073","title":"Efficacy and safety of relugolix in men with advanced prostate cancer based on baseline body mass index (BMI): A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide (LEU).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Overweight; Body mass index; Underweight; Internal medicine; Subgroup analysis; Testosterone (patch); Androgen deprivation therapy; Randomized controlled trial; Gynecology; Cancer; Confidence interval","score_opus":0.05860357441995731,"score_gpt":0.46429011962309996,"score_spread":0.4056865452031426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881195,0.0011070587,0.00011750924,0.008119794,0.00019981145,0.0020022683,0.00006714805,0.0000057192456,0.0002612261],"genre_scores_gemma":[0.99702704,0.0016835573,0.00031362174,0.00043528125,0.00018539086,0.0001613873,0.000028153629,0.00002066,0.00014491014],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931797,0.0031612604,0.0021430703,0.00034709775,0.00088183983,0.00028706886],"domain_scores_gemma":[0.9852921,0.012308484,0.0015236661,0.00032616,0.00029787802,0.00025171877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008960761,0.00020264779,0.0026159866,0.0003182888,0.00010036324,0.0000090060585,0.0002147847,0.00010140877,0.00029589253],"category_scores_gemma":[0.002152234,0.00010432842,0.00039130446,0.00080551207,0.00036593078,0.00006579898,0.000078115154,0.001435128,4.4193283e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7742444,0.0056649046,0.18825926,0.00001062955,0.0036220113,0.0008150385,0.0002953443,0.007198111,0.000047571146,0.000002258106,0.00013805192,0.019702418],"study_design_scores_gemma":[0.8113387,0.03685403,0.13036844,0.00008324934,0.003803732,0.000005201193,0.0015026956,0.014502797,0.00003338432,0.000026161593,0.0013730739,0.00010851794],"about_ca_topic_score_codex":0.0006273373,"about_ca_topic_score_gemma":0.000539195,"teacher_disagreement_score":0.05789081,"about_ca_system_score_codex":0.00042338547,"about_ca_system_score_gemma":0.0018682719,"threshold_uncertainty_score":0.6234997},"labels":[],"label_agreement":null},{"id":"W4286296187","doi":"10.1200/jco.2022.40.16_suppl.5056","title":"Activation of the AKT pathway and outcomes in patients (pts) treated with or without ipatasertib (ipat) in metastatic castration-resistant prostate cancer (mCRPC): Next-generation sequencing (NGS) data from the phase III IPATential150 trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"PTEN; Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Cancer; Prednisone; Placebo; Oncology; Interim analysis; Gastroenterology; Pathology; Randomized controlled trial; PI3K/AKT/mTOR pathway","score_opus":0.40071639978436796,"score_gpt":0.49403444143841113,"score_spread":0.09331804165404317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99536926,0.00017656214,0.000007431784,0.0023549956,0.0002472586,0.0015106298,0.00032162544,0.0000025713775,0.000009671882],"genre_scores_gemma":[0.9987336,0.00021156491,0.00016151088,0.00032929025,0.0001072183,0.00008533638,0.00025122054,0.000014042685,0.000106254214],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960201,0.0012115934,0.001716303,0.00025614514,0.0006054068,0.00019047737],"domain_scores_gemma":[0.9968262,0.0010532953,0.0014711665,0.00032427398,0.00023029477,0.0000948075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024387795,0.00014223675,0.00095016795,0.00010941336,0.00011735237,0.00002159486,0.00024123369,0.000067116605,0.00010352476],"category_scores_gemma":[0.0009157577,0.000061825245,0.00008023881,0.00034018728,0.00016226857,0.00030895072,0.00012740835,0.0006878942,1.85706e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3235236,0.0044631595,0.6187274,0.00003213828,0.0006800341,0.00017414185,0.0015137036,0.00033840028,0.0061883815,0.0000037367663,0.00031392853,0.04404139],"study_design_scores_gemma":[0.5258449,0.03676937,0.42012125,0.00040161808,0.0010821013,0.000018946304,0.0037064159,0.0068619633,0.0037674373,0.000061910745,0.0011340695,0.00023004755],"about_ca_topic_score_codex":0.0033196418,"about_ca_topic_score_gemma":0.007287641,"teacher_disagreement_score":0.20232126,"about_ca_system_score_codex":0.00048370636,"about_ca_system_score_gemma":0.0033154439,"threshold_uncertainty_score":0.5881455},"labels":[],"label_agreement":null},{"id":"W4286296265","doi":"10.1200/jco.2022.40.16_suppl.5000","title":"TheraP: <sup>177</sup>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Cabazitaxel; Medicine; Docetaxel; Prostate cancer; Internal medicine; Oncology; Clinical endpoint; Hazard ratio; Progression-free survival; Cancer; Overall survival; Urology; Nuclear medicine; Clinical trial; Confidence interval; Androgen deprivation therapy","score_opus":0.13108514094083001,"score_gpt":0.46336823419059714,"score_spread":0.3322830932497671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842944,0.0060332697,0.0000039892384,0.0064517017,0.0018620075,0.0007964169,0.00013508566,0.000010243116,0.00041289316],"genre_scores_gemma":[0.9946898,0.0015377827,0.0012250602,0.0004148722,0.0005608284,0.0002625787,0.000022623057,0.000052170293,0.0012342854],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9938333,0.0011889276,0.0025759768,0.0004125752,0.001342043,0.00064714625],"domain_scores_gemma":[0.9959214,0.0013740446,0.0013762076,0.0003154681,0.0005383507,0.00047457518],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037022675,0.00029319926,0.0018122221,0.00039146774,0.000084688276,0.000034235472,0.000292451,0.00019932698,0.0013081855],"category_scores_gemma":[0.00078985404,0.00021958273,0.00061828917,0.0004400877,0.00045669178,0.0002648004,0.00015680773,0.0016904982,0.0000071418262],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3818743,0.0062837475,0.3479719,0.00047464843,0.0044403537,0.024141392,0.009528857,0.00091866014,0.0010259672,0.000054430122,0.002214426,0.22107136],"study_design_scores_gemma":[0.14934494,0.039502993,0.74730283,0.000858326,0.0022059858,0.00030598397,0.0065413574,0.00075175054,0.0003253368,0.0008499588,0.051258385,0.00075216574],"about_ca_topic_score_codex":0.00033980788,"about_ca_topic_score_gemma":0.0013557728,"teacher_disagreement_score":0.39933094,"about_ca_system_score_codex":0.0008273744,"about_ca_system_score_gemma":0.0050034653,"threshold_uncertainty_score":0.99960476},"labels":[],"label_agreement":null},{"id":"W4286296857","doi":"10.1200/jco.2022.40.16_suppl.5084","title":"Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Janssen Research and Development","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Clinical endpoint; Population; Internal medicine; Bicalutamide; Urology; Oncology; Goserelin; Radiation therapy; Hormonal therapy; Randomized controlled trial; Cancer","score_opus":0.10210199417347897,"score_gpt":0.47783163263754,"score_spread":0.37572963846406104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98981154,0.0021801903,0.00001130824,0.0020179553,0.00037861874,0.0055762064,0.000009851424,0.0000058561154,0.000008502452],"genre_scores_gemma":[0.9891683,0.009489383,0.000087660024,0.00054733496,0.00015135744,0.0004695842,0.0000314046,0.000020958154,0.000034017772],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9948375,0.0017479975,0.002160289,0.00028674226,0.0007081658,0.00025927246],"domain_scores_gemma":[0.99637437,0.001324007,0.0016015584,0.00020769522,0.00033822877,0.00015412965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003627398,0.0001852955,0.0013254763,0.00038518992,0.00009839444,0.000015461472,0.00016146549,0.00013398839,0.000099642384],"category_scores_gemma":[0.00056137313,0.00010295544,0.00013227992,0.00066360884,0.000064870226,0.00013864186,0.000050175473,0.00080295786,6.5266346e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3974696,0.00402537,0.3275784,0.0000075832286,0.00023544891,0.00014487449,0.0019471716,0.0015091283,0.00012417651,0.0000017925421,0.000024052079,0.2669324],"study_design_scores_gemma":[0.44211242,0.065115996,0.49041706,0.00005546477,0.000121704536,0.000022164673,0.0009790412,0.0004479337,0.00015005209,0.000054267195,0.0004259421,0.00009795938],"about_ca_topic_score_codex":0.00067099347,"about_ca_topic_score_gemma":0.001993661,"teacher_disagreement_score":0.26683444,"about_ca_system_score_codex":0.00048618164,"about_ca_system_score_gemma":0.0011269387,"threshold_uncertainty_score":0.41984013},"labels":[],"label_agreement":null},{"id":"W4286296877","doi":"10.1200/jco.2022.40.16_suppl.5078","title":"Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Hazard ratio; Prostate-specific antigen; Internal medicine; Oncology; Population; Androgen deprivation therapy; Confidence interval; Cancer","score_opus":0.10449796444811289,"score_gpt":0.4477058098119922,"score_spread":0.3432078453638793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286296877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98761374,0.001008368,0.0000025516745,0.009259592,0.00046306965,0.0012453378,0.00037491007,0.0000034148516,0.000028993554],"genre_scores_gemma":[0.9962427,0.0027052592,0.00016606822,0.00034922187,0.00017324793,0.00003410231,0.000044096552,0.000018419933,0.00026690785],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9943662,0.0027790274,0.0014680786,0.00022535687,0.00088549335,0.00027579343],"domain_scores_gemma":[0.99158,0.005680895,0.001845093,0.00015046768,0.0005686859,0.00017487461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006396691,0.00014040948,0.0012036309,0.00013076591,0.00008073784,0.000012674995,0.00009831812,0.00008458864,0.00006803469],"category_scores_gemma":[0.001799896,0.000080358564,0.00016216123,0.00024237002,0.00019236444,0.00010680639,0.00007550553,0.00095866626,9.785492e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7199899,0.0033921562,0.26262483,0.0000070269543,0.00087071053,0.0004396755,0.0016278214,0.00004430704,0.00039702252,0.0000031775587,0.002096727,0.008506662],"study_design_scores_gemma":[0.22981434,0.04016629,0.71766824,0.000047326397,0.0002852633,0.000004555918,0.0007627594,0.000037098194,0.000079851416,0.00008145712,0.010975514,0.00007732859],"about_ca_topic_score_codex":0.00015906009,"about_ca_topic_score_gemma":0.00008915487,"teacher_disagreement_score":0.49017555,"about_ca_system_score_codex":0.0006434449,"about_ca_system_score_gemma":0.0018459813,"threshold_uncertainty_score":0.41649812},"labels":[],"label_agreement":null},{"id":"W4286298199","doi":"10.1200/jco.2022.40.16_suppl.5058","title":"Transcriptional profiling of matched biopsies reveals molecular determinants of enzalutamide resistance.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Enzalutamide; Prostate cancer; Medicine; Disease; Androgen receptor; Transcriptome; Cancer; Oncology; Bioinformatics; Cancer research; Internal medicine; Genetics; Biology; Gene; Gene expression","score_opus":0.14846742324663345,"score_gpt":0.48801363054230923,"score_spread":0.33954620729567575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99311846,0.0031472372,0.000039563303,0.0021949292,0.00040920242,0.00022034899,0.00003123115,0.0000029946568,0.0008360541],"genre_scores_gemma":[0.9925636,0.00060622266,0.005711751,0.00024023214,0.00013601575,0.000009624596,0.0000040508403,0.00001184119,0.00071663485],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9963648,0.00049412914,0.0021834306,0.00012956059,0.0006462163,0.0001818732],"domain_scores_gemma":[0.9969951,0.00079136505,0.0014545155,0.0001433651,0.00046077895,0.00015487446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003463263,0.000086877095,0.0012981112,0.00016547534,0.000039712057,0.0000016649187,0.00017091131,0.00012261765,0.00021891293],"category_scores_gemma":[0.0010075539,0.00006303611,0.00048629683,0.00019111148,0.00028753196,0.000047779755,0.00005143617,0.0006305936,8.5651374e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048822213,0.0048521976,0.45608738,0.00083617156,0.0012187614,0.0036034097,0.00059977424,0.00009085001,0.4579374,0.0010275512,0.0014939057,0.023430385],"study_design_scores_gemma":[0.04425882,0.048025418,0.6280504,0.00094306556,0.0016384468,0.0010831791,0.0029498672,0.0001344961,0.23655532,0.011765235,0.02424346,0.00035229395],"about_ca_topic_score_codex":0.0000055247574,"about_ca_topic_score_gemma":0.000004523104,"teacher_disagreement_score":0.22138207,"about_ca_system_score_codex":0.00014503713,"about_ca_system_score_gemma":0.0017703671,"threshold_uncertainty_score":0.31405553},"labels":[],"label_agreement":null},{"id":"W4286298970","doi":"10.1200/jco.2022.40.16_suppl.5047","title":"Tolerability of [<sup>177</sup>Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Clinical endpoint; Prostate cancer; Adverse effect; Taxane; Internal medicine; Urology; Gastroenterology; Clinical trial; Cancer; Breast cancer","score_opus":0.07360753000731195,"score_gpt":0.4581354245937601,"score_spread":0.38452789458644815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957408,0.00090329413,0.0000054886,0.0014686442,0.00011730775,0.0015375924,0.00015974353,0.0000053597373,0.0000617754],"genre_scores_gemma":[0.9987354,0.00026182312,0.0003006716,0.00011394672,0.000060327682,0.00014517401,0.00007050718,0.000019075353,0.00029303523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99372584,0.001589267,0.002764896,0.00040968205,0.0011574466,0.0003528895],"domain_scores_gemma":[0.99610794,0.0009800239,0.0016166014,0.00034116078,0.00062287285,0.0003314209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030414504,0.00024008467,0.002356598,0.00037387374,0.00010762502,0.000013961391,0.00017851332,0.00009207353,0.00036906052],"category_scores_gemma":[0.00030295548,0.00014309646,0.00045796295,0.0008974038,0.00021181033,0.00014493617,0.00007517838,0.0007744864,8.19558e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04185062,0.027995395,0.8950417,0.000042318024,0.0036607592,0.00051106495,0.0018061976,0.002504202,0.00005753935,0.0000016711981,0.00025670603,0.026271837],"study_design_scores_gemma":[0.038916886,0.12358579,0.8297384,0.000038998485,0.0027362905,0.00000806516,0.0036228383,0.00027158967,0.000033224496,0.000024124882,0.00090872234,0.00011512034],"about_ca_topic_score_codex":0.00079480297,"about_ca_topic_score_gemma":0.0013380246,"teacher_disagreement_score":0.09559039,"about_ca_system_score_codex":0.0013003885,"about_ca_system_score_gemma":0.0023923728,"threshold_uncertainty_score":0.5835304},"labels":[],"label_agreement":null},{"id":"W4286472044","doi":"10.5489/cuaj.8007","title":"UPDATE – Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies (Summary of changes)","year":2022,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Dalhousie University; McGill University Health Centre; Ontario Clinical Oncology Group; Université Laval; University of Manitoba; Princess Margaret Cancer Centre; McMaster University; Queen's University; Memorial University of Newfoundland; University of British Columbia; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Guideline; Androgen deprivation therapy; Adverse effect; Medicine; Association (psychology); Internal medicine; Prostate cancer; Psychology; Psychotherapist; Pathology","score_opus":0.023623904776288493,"score_gpt":0.27577356768321737,"score_spread":0.25214966290692886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286472044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90910774,0.0007419615,0.0000120491695,0.085232235,0.00029457145,0.00073287805,0.00026258588,0.000024023522,0.0035919647],"genre_scores_gemma":[0.98840725,0.0021439963,0.000102634694,0.007918424,0.00016986625,0.000053143693,0.0003068104,0.000014074648,0.00088382117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977431,0.0003385941,0.000367725,0.0002514699,0.00071807386,0.0005809819],"domain_scores_gemma":[0.99857265,0.000078903104,0.00033780147,0.00011345147,0.00024280926,0.0006543757],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001459134,0.00015810694,0.00027845838,0.00046054425,0.0005421119,0.000029465386,0.00013644679,0.0001775555,0.0010146481],"category_scores_gemma":[0.00015023763,0.00012966855,0.00008991684,0.00032901578,0.000022528562,0.00008959582,0.00003915864,0.0005770937,0.000010947656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005143511,0.00013230444,0.96118766,0.000010210242,0.0005763647,0.00026773612,0.00015872395,0.00040731046,0.000084033214,0.0006835073,0.026133228,0.009844549],"study_design_scores_gemma":[0.003182493,0.0013153977,0.71413773,0.000011382654,0.00009695039,0.00005010049,0.0003932857,0.000239402,0.000030782718,0.0014122872,0.2789635,0.0001666604],"about_ca_topic_score_codex":0.008697498,"about_ca_topic_score_gemma":0.0091786105,"teacher_disagreement_score":0.25283027,"about_ca_system_score_codex":0.0038564722,"about_ca_system_score_gemma":0.0006931119,"threshold_uncertainty_score":0.9999676},"labels":[],"label_agreement":null},{"id":"W4286472115","doi":"10.5489/cuaj.8054","title":"UPDATE – Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies (Full-text)","year":2022,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Dalhousie University; McGill University Health Centre; Ontario Clinical Oncology Group; Université Laval; University of Manitoba; Princess Margaret Cancer Centre; McMaster University; Queen's University; Memorial University of Newfoundland; University of British Columbia; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Guideline; Androgen deprivation therapy; Adverse effect; Association (psychology); Medicine; Internal medicine; Psychology; Prostate cancer; Psychotherapist; Pathology","score_opus":0.020352270237574414,"score_gpt":0.2764638196856015,"score_spread":0.2561115494480271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286472115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9013065,0.0005241965,0.000023503966,0.09306182,0.00036715265,0.0007406559,0.00016388168,0.000040013358,0.0037722762],"genre_scores_gemma":[0.9851363,0.0013738002,0.0001362585,0.011474247,0.00024655228,0.00007298586,0.00033107054,0.00001893487,0.0012098742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971667,0.00041479518,0.0004374066,0.00034126334,0.0008387941,0.00080104196],"domain_scores_gemma":[0.9982389,0.000089146015,0.0002994755,0.00013408068,0.00025165922,0.0009866877],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001618102,0.00020455668,0.00028453456,0.00047112256,0.001064562,0.000078558325,0.00016411,0.00021854122,0.0019926955],"category_scores_gemma":[0.00019758643,0.00016619719,0.00012058878,0.00037066144,0.000023644832,0.0001431964,0.000043904405,0.0008385987,0.000051585004],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006215954,0.00015355856,0.9447203,0.0000063313582,0.00065738504,0.000583249,0.00015953544,0.0009063737,0.00006006522,0.0010490671,0.041657493,0.009425018],"study_design_scores_gemma":[0.0033631886,0.0011159343,0.648404,0.0000066697844,0.0000893149,0.00011714001,0.00036180392,0.00041136597,0.00000829726,0.0019613886,0.3439592,0.00020165826],"about_ca_topic_score_codex":0.0077131763,"about_ca_topic_score_gemma":0.008258131,"teacher_disagreement_score":0.30230173,"about_ca_system_score_codex":0.006435033,"about_ca_system_score_gemma":0.0009574484,"threshold_uncertainty_score":0.9989196},"labels":[],"label_agreement":null},{"id":"W4288061296","doi":"10.1200/jco.2022.40.17_suppl.lba5004","title":"Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Medicine; Enzalutamide; Docetaxel; Hazard ratio; Oncology; Internal medicine; Prostate cancer; Cohort; Cancer; Confidence interval; Androgen receptor","score_opus":0.16276056201978895,"score_gpt":0.515166324359394,"score_spread":0.3524057623396051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288061296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99057645,0.0003625992,0.000007038684,0.006051651,0.0016149322,0.00086180406,0.00013507169,0.0000050293397,0.0003854427],"genre_scores_gemma":[0.9953574,0.002386999,0.00051099673,0.0008098576,0.00023643194,0.00006881933,0.00006910329,0.000021475096,0.00053890276],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9938629,0.0021708438,0.0025597187,0.0002849662,0.00080969546,0.00031186375],"domain_scores_gemma":[0.99588954,0.0018837716,0.0013249619,0.00016845281,0.00050547224,0.00022782269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005470246,0.0001792777,0.0020298937,0.00047143933,0.00003551169,0.000010949689,0.0002480662,0.000114904105,0.0002857575],"category_scores_gemma":[0.0019260343,0.00012725686,0.00030607302,0.0003418912,0.00024287075,0.00028932962,0.00014933436,0.0015043078,0.0000019228737],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66607964,0.016142052,0.27940336,0.000028179116,0.002291909,0.0059539834,0.003328005,0.0015003764,0.0018529281,0.00037357843,0.0009400756,0.02210589],"study_design_scores_gemma":[0.32847956,0.05773552,0.5973358,0.00007976646,0.0003541992,0.00009131553,0.0028910022,0.0008352298,0.00026036144,0.00054699084,0.011158541,0.00023171303],"about_ca_topic_score_codex":0.00071363524,"about_ca_topic_score_gemma":0.0008451249,"teacher_disagreement_score":0.3376001,"about_ca_system_score_codex":0.000858537,"about_ca_system_score_gemma":0.0024960202,"threshold_uncertainty_score":0.6535553},"labels":[],"label_agreement":null},{"id":"W4288538226","doi":"10.1007/s13139-022-00760-8","title":"Outcomes and Factors Associated with Completion of Radium-223 Therapy","year":2022,"lang":"en","type":"article","venue":"Nuclear Medicine and Molecular Imaging","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Bayer","keywords":"Medicine; Radium; Radium-223; Medical physics; Internal medicine; Radiochemistry; Cancer; Prostate cancer","score_opus":0.0361910189893373,"score_gpt":0.3074428162086575,"score_spread":0.2712517972193202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288538226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98953813,0.0029011988,0.000015823054,0.0062836274,0.00002422366,0.00022804769,0.0000056269046,0.000024839153,0.0009784834],"genre_scores_gemma":[0.9978037,0.00021737684,0.000049695976,0.0018015662,0.000007040576,0.000004901955,0.000045860324,0.000021976308,0.000047867496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992311,0.00004969486,0.000107595406,0.00015293296,0.00031916914,0.00013952304],"domain_scores_gemma":[0.9996849,0.000039143182,0.000052564916,0.00009646063,0.0000461693,0.00008077977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014998508,0.00009666656,0.00025656956,0.00011072283,0.00012490866,0.0000052671276,0.000031645934,0.000011944577,0.00013205432],"category_scores_gemma":[0.00003452057,0.00006072634,0.000023783252,0.00012537335,0.0001993411,0.00002694455,0.000042267813,0.00014156886,1.6520453e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005531303,0.00027867337,0.84634286,0.000067831475,0.00049442454,0.00027948717,0.004789704,0.00000176258,0.13739732,0.0003451935,0.0028103276,0.006639294],"study_design_scores_gemma":[0.0220487,0.0024024642,0.9447396,0.00022612413,0.0002555534,0.000081044454,0.007626657,0.0007574406,0.0023504707,0.0001572495,0.019118791,0.00023594839],"about_ca_topic_score_codex":0.000104875864,"about_ca_topic_score_gemma":8.338115e-7,"teacher_disagreement_score":0.13504684,"about_ca_system_score_codex":0.000037898688,"about_ca_system_score_gemma":0.000023321265,"threshold_uncertainty_score":0.24763483},"labels":[],"label_agreement":null},{"id":"W4289943577","doi":"10.1002/bco2.182","title":"Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer","year":2022,"lang":"en","type":"article","venue":"BJUI Compass","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Interquartile range; Prostate cancer; Lymph node; Dissection (medical); Urology; Prostate-specific antigen; Lymph; Radiology; Cancer; Surgery; Internal medicine; Pathology","score_opus":0.020722225767652674,"score_gpt":0.33894468795885213,"score_spread":0.31822246219119943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289943577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900731,0.0026358524,0.000012734464,0.0052297544,0.00025995783,0.0012802458,0.00017775895,0.000042538926,0.0002880892],"genre_scores_gemma":[0.9956602,0.00020959988,0.00013550007,0.00025021116,0.000063196516,0.001708394,0.00020804747,0.000023049855,0.0017417892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895275,0.000054443764,0.00014601424,0.00029268966,0.00021959214,0.00033451003],"domain_scores_gemma":[0.9996041,0.000070617345,0.000036546695,0.0001135362,0.000051879375,0.00012329678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018827643,0.0001277603,0.00023802757,0.00017435737,0.00022610114,0.00003244293,0.000060113594,0.000016131811,0.00005722044],"category_scores_gemma":[0.000023350263,0.00010732233,0.0000350452,0.00030943114,0.00002519168,0.000040013743,0.0000896739,0.00017630353,0.0000013878876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010276953,0.00068322045,0.88630736,0.0006376161,0.0002270138,0.0002160383,0.0059520067,0.00053485506,0.015611877,0.00020946717,0.053769145,0.02557442],"study_design_scores_gemma":[0.014768118,0.002088833,0.9287878,0.000457128,0.000126341,0.00020900783,0.002176409,0.004688128,0.00935806,0.00027822674,0.036564767,0.0004971637],"about_ca_topic_score_codex":0.0007903611,"about_ca_topic_score_gemma":0.00058657833,"teacher_disagreement_score":0.04248043,"about_ca_system_score_codex":0.00041762268,"about_ca_system_score_gemma":0.00017148192,"threshold_uncertainty_score":0.4376478},"labels":[],"label_agreement":null},{"id":"W4291035494","doi":"10.1016/j.urolonc.2022.06.018","title":"Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Cabazitaxel; Medicine; Docetaxel; Prostate cancer; Hazard ratio; Meta-analysis; Internal medicine; Oncology; Confidence interval; Subgroup analysis; Cancer; Androgen deprivation therapy","score_opus":0.1436887576997822,"score_gpt":0.41327638703670366,"score_spread":0.2695876293369215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291035494","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027471192,0.9649927,3.4439748e-7,0.00032904078,0.000008940754,0.0064051175,0.0007351859,0.00002650473,0.000030991338],"genre_scores_gemma":[0.0010426885,0.9919546,0.0005714412,0.00017977427,0.000004999142,0.0046634623,0.0011278599,0.000034277662,0.00042089156],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9967329,0.00086349744,0.00091491104,0.00073537586,0.00032088053,0.0004324341],"domain_scores_gemma":[0.9976882,0.0008893835,0.0006927764,0.0002600587,0.00010892621,0.0003606846],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060274673,0.000620768,0.0052373577,0.00067092024,0.00026866302,0.000056008266,0.00009000501,0.00015438003,0.00019339194],"category_scores_gemma":[0.00030385586,0.00032099368,0.00037853757,0.0014933007,0.00049956096,0.00012863068,0.000066186774,0.00061404053,8.448629e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015343516,0.0005447647,0.15232947,0.6882917,0.15463421,0.0013148796,0.0013193794,0.000022974937,0.000001200621,0.00006497809,0.00013644445,0.0011865181],"study_design_scores_gemma":[0.0007719577,0.0038778808,0.00047235168,0.009969567,0.9538615,0.00025956053,0.00020213431,0.000029826178,4.3197966e-7,0.00003679396,0.030098945,0.0004190652],"about_ca_topic_score_codex":0.0007656043,"about_ca_topic_score_gemma":0.0005020959,"teacher_disagreement_score":0.7992273,"about_ca_system_score_codex":0.0008267624,"about_ca_system_score_gemma":0.0015331636,"threshold_uncertainty_score":0.99992424},"labels":[],"label_agreement":null},{"id":"W4291221834","doi":"10.1038/s41467-022-32530-7","title":"Reformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prevention of Organ Failure; University of British Columbia","funders":"CIHR Skin Research Training Centre; Mitacs; Canadian Institutes of Health Research; National Cancer Institute; Government of Canada; National Institutes of Health; Prostate Cancer Canada","keywords":"Glycocalyx; Prostate cancer; Chondroitin sulfate; Cancer; Chondroitin; Cancer research; Prostate; Chemistry; Medicine; Internal medicine; Glycosaminoglycan; Biochemistry","score_opus":0.0231546228184499,"score_gpt":0.3621557010053577,"score_spread":0.33900107818690783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291221834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9291018,0.030680401,0.000002581758,0.029933985,0.000251808,0.0021413916,0.0003803905,0.000044727352,0.007462903],"genre_scores_gemma":[0.99508756,0.002537793,0.00032475326,0.00009002342,0.000013193306,0.00041627808,0.00019690141,0.000011679453,0.0013217942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987877,0.00017451028,0.00027051414,0.000104931816,0.00052212516,0.00014021563],"domain_scores_gemma":[0.9982406,0.000061258484,0.00024156256,0.0011498821,0.00026764307,0.000039074224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030877368,0.00007879917,0.00016314656,0.00010040898,0.00035792377,0.0000058212977,0.00057164667,0.000072223345,0.00008733275],"category_scores_gemma":[0.000056938323,0.00004807373,0.000087232824,0.0005560332,0.00017719404,0.00006605701,0.0006317067,0.00085110916,9.3099027e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044986876,0.005505983,0.52977616,0.0015738497,0.0011026283,0.000012837412,0.019974407,0.00045018777,0.2058701,0.018425362,0.01982753,0.19298223],"study_design_scores_gemma":[0.0094298925,0.0011844456,0.4277324,0.001268201,0.0005135947,0.00007812942,0.0049846256,0.0033279483,0.28750592,0.0012598835,0.26228863,0.00042630636],"about_ca_topic_score_codex":0.00009769981,"about_ca_topic_score_gemma":0.00011748684,"teacher_disagreement_score":0.2424611,"about_ca_system_score_codex":0.00023719348,"about_ca_system_score_gemma":0.0003275503,"threshold_uncertainty_score":0.3697693},"labels":[],"label_agreement":null},{"id":"W4291512950","doi":"10.3390/ph15080996","title":"64Cu-DOTHA2-PSMA, a Novel PSMA PET Radiotracer for Prostate Cancer with a Long Imaging Time Window","year":2022,"lang":"en","type":"article","venue":"Pharmaceuticals","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Merck Canada; Cancer Research Society","keywords":"Prostate cancer; Pet imaging; Medicine; Positron emission tomography; Nuclear medicine; Cancer; Internal medicine","score_opus":0.048192023618453164,"score_gpt":0.4002967610441008,"score_spread":0.35210473742564763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291512950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9075502,0.021570122,0.00095251563,0.052091923,0.00058294996,0.0110049555,0.0019725948,0.00046576027,0.0038089836],"genre_scores_gemma":[0.9642156,0.0005813202,0.0013157745,0.0032013778,0.00043348406,0.004155971,0.0001959368,0.00015489555,0.025745647],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99755573,0.000068165784,0.00028453823,0.0005589334,0.0006647067,0.00086795236],"domain_scores_gemma":[0.9988679,0.00018043916,0.00008654532,0.00027640624,0.00017675688,0.00041193157],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052291434,0.0002827005,0.00045154497,0.00016810847,0.0003939797,0.000057955585,0.0001680116,0.000020259087,0.0029822956],"category_scores_gemma":[0.00003398972,0.00021349838,0.00013857822,0.00039959734,0.00019385459,0.00014467382,0.0001340315,0.00047650246,0.000039951014],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041406915,0.00494808,0.4365665,0.0023766963,0.003440586,0.004090186,0.0042898036,0.00091288146,0.3425646,0.00021774572,0.040279366,0.118906625],"study_design_scores_gemma":[0.09567234,0.0025419332,0.020843921,0.00065448927,0.0031701683,0.0037049653,0.0009744131,0.08961492,0.16486557,0.00017840622,0.61580366,0.0019751964],"about_ca_topic_score_codex":0.00006936911,"about_ca_topic_score_gemma":0.000006123062,"teacher_disagreement_score":0.57552433,"about_ca_system_score_codex":0.0005102805,"about_ca_system_score_gemma":0.0005860542,"threshold_uncertainty_score":0.9979291},"labels":[],"label_agreement":null},{"id":"W4292103594","doi":"10.1136/jitc-2022-004761","title":"Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Hôtel-Dieu de Québec","funders":"Foundation Medicine; National Center for Advancing Translational Sciences; Ono Pharmaceutical; Clovis Oncology; Bristol-Myers Squibb","keywords":"Medicine; Enzalutamide; Prostate cancer; Nivolumab; Internal medicine; Oncology; Cohort; Progression-free survival; Cancer; Urology; Chemotherapy; Androgen receptor; Immunotherapy","score_opus":0.07347743674206077,"score_gpt":0.4234544933584976,"score_spread":0.34997705661643685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292103594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9094368,0.053191833,0.00025017717,0.016136775,0.0025519722,0.0064611463,0.011888783,0.000024910127,0.000057591777],"genre_scores_gemma":[0.9357943,0.027613532,0.002246888,0.00132044,0.002353568,0.010107608,0.00094790047,0.00020176683,0.019414008],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975715,0.0001226769,0.00088260695,0.00027922177,0.0006934016,0.0004505693],"domain_scores_gemma":[0.99802536,0.0004154944,0.0007217198,0.0003131067,0.00041865543,0.00010568712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010355604,0.00022572302,0.00057749206,0.00010435645,0.00090465567,0.000082420825,0.00027690828,0.000037383823,0.0005810683],"category_scores_gemma":[0.00007381844,0.00014425645,0.0004389505,0.00022877757,0.0001280725,0.0001297954,0.000026789356,0.00038292015,5.0866026e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.815492,0.0006151149,0.00003844797,0.000086076056,0.0024987033,0.00001996059,0.0053833947,0.0006558246,0.081662305,0.000043865108,0.020181166,0.07332315],"study_design_scores_gemma":[0.58750266,0.010590245,0.00021170259,0.00023715387,0.0007293828,0.000030078461,0.0025456196,0.0013213248,0.026691921,0.0013131003,0.36854607,0.0002807626],"about_ca_topic_score_codex":0.002132175,"about_ca_topic_score_gemma":0.0002993369,"teacher_disagreement_score":0.34836492,"about_ca_system_score_codex":0.0009724737,"about_ca_system_score_gemma":0.0024599964,"threshold_uncertainty_score":0.69579715},"labels":[],"label_agreement":null},{"id":"W4292178027","doi":"10.1016/j.euo.2022.08.001","title":"Erratum to “Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)” [Eur Urol Oncol 2021;4:543–52]","year":2022,"lang":"en","type":"erratum","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Androgen deprivation therapy; Prostate cancer; Oncology; Randomized controlled trial; Internal medicine; Urology; Cancer","score_opus":0.022105357981230114,"score_gpt":0.3328123005631535,"score_spread":0.3107069425819234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292178027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9087501,0.019350806,0.000034425393,0.0076468796,0.017392505,0.037219178,0.0006520715,0.00013012718,0.00882388],"genre_scores_gemma":[0.6770219,0.10904907,0.000611489,0.005700888,0.007161261,0.049072802,0.005695826,0.0010006137,0.14468612],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98605114,0.0079844715,0.002390039,0.0015546888,0.0008805771,0.001139091],"domain_scores_gemma":[0.9943751,0.0017609304,0.0019062604,0.0009352424,0.0005647586,0.00045772383],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005000034,0.0009859753,0.0067406157,0.0014107145,0.0001423368,0.000031582505,0.00046615972,0.00066339166,0.0019357023],"category_scores_gemma":[0.001626587,0.00061761256,0.00065223855,0.0009856608,0.00078340835,0.00007846536,0.00031760568,0.0028909214,0.00003917447],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8449372,0.0037185643,0.0015606135,0.00012624901,0.0023572217,0.0027120933,0.0008510058,0.000013812709,0.00023730737,0.0000019249937,0.123105615,0.020378394],"study_design_scores_gemma":[0.75616384,0.02296897,0.0003005877,0.00015864757,0.0013187546,0.000077030534,0.000036325346,0.000052398893,0.0001182369,0.000019156345,0.21831313,0.0004729033],"about_ca_topic_score_codex":0.0002995085,"about_ca_topic_score_gemma":0.00040485864,"teacher_disagreement_score":0.23172818,"about_ca_system_score_codex":0.0008036435,"about_ca_system_score_gemma":0.0063666226,"threshold_uncertainty_score":0.99962753},"labels":[],"label_agreement":null},{"id":"W4292363937","doi":"10.1101/2022.08.18.504385","title":"Rational optimization of a transcription factor activation domain inhibitor","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; Agència de Gestió d'Ajuts Universitaris i de Recerca; China Scholarship Council; Institute for Research in Biomedicine","keywords":"Transactivation; Androgen receptor; Transcription factor; Prostate cancer; Small molecule; Transcription (linguistics); Cancer research; Computational biology; Cell biology; Biology; Transcriptional activity; Chemistry; In vivo; Cancer; Genetics; Gene","score_opus":0.02485848681095191,"score_gpt":0.2650480633692302,"score_spread":0.2401895765582783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292363937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832734,0.00059531967,0.012031855,0.0008795169,0.0006616272,0.0017785347,0.00057425734,0.00017990945,0.00002559128],"genre_scores_gemma":[0.9899268,0.00033128427,0.008758618,0.00007157012,0.00035895736,0.0004263176,0.000017576147,0.00008214745,0.000026687276],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977465,0.0001351331,0.0004823953,0.0005803575,0.0007644802,0.0002910835],"domain_scores_gemma":[0.9984369,0.000041055253,0.00032606392,0.0005363657,0.00049421977,0.00016535533],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029418434,0.00031697465,0.00045946732,0.00041575305,0.00014517814,0.000050051214,0.00015356066,0.00030054053,0.00080019183],"category_scores_gemma":[0.0000767457,0.00031422268,0.0001794461,0.00043916248,0.00009260241,0.00017027931,0.0001279684,0.00062100263,0.0000055380287],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061407825,0.00043155716,0.0048425496,0.00081320025,0.00025894513,0.000017785182,0.00005195429,0.0022725242,0.9902656,0.00022944974,0.00019920067,0.0000031267],"study_design_scores_gemma":[0.0039432584,0.0004624356,0.088627495,0.0007191775,0.00020527407,2.6196124e-8,0.000023033042,0.0023505834,0.8999197,0.0000052010055,0.0031764721,0.0005673444],"about_ca_topic_score_codex":0.000028577377,"about_ca_topic_score_gemma":3.7688952e-7,"teacher_disagreement_score":0.09034593,"about_ca_system_score_codex":0.00080668076,"about_ca_system_score_gemma":0.0012159927,"threshold_uncertainty_score":0.999931},"labels":[],"label_agreement":null},{"id":"W4292397309","doi":"10.1007/s12020-022-03166-w","title":"Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question","year":2022,"lang":"en","type":"article","venue":"Endocrine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Prostate cancer; Testosterone (patch); Androgen deprivation therapy; Medicine; Androgen; Castration; Androgen receptor; Internal medicine; Oncology; Hormonal therapy; Diabetes mellitus; Hormone; Endocrinology; Cancer","score_opus":0.04785613626829492,"score_gpt":0.36423977637194377,"score_spread":0.31638364010364883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292397309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982875,0.0014645577,0.000016262942,0.013332401,0.00004611412,0.0018726798,0.00012980831,0.0000073564697,0.00025583123],"genre_scores_gemma":[0.9930088,0.004302223,0.00015765576,0.00022013849,0.000014977083,0.0007979886,0.00014449109,0.000008577098,0.0013451778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989537,0.00010062034,0.0002265955,0.0001359615,0.000429993,0.00015313919],"domain_scores_gemma":[0.99955046,0.00004715676,0.00012458,0.00020925091,0.00005435521,0.000014183027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003047048,0.000078974525,0.00011862329,0.000066203196,0.00009301011,0.000007654107,0.00011011801,0.000006057543,0.00032331923],"category_scores_gemma":[0.000003926247,0.000040075556,0.000030969815,0.00033602258,0.000052595777,0.000055182667,0.00004121876,0.00009348017,4.7885794e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031229336,0.0027762516,0.52143407,0.0019035204,0.0014606781,0.0007021009,0.03394167,0.0007211125,0.13664247,0.0038112192,0.01214811,0.25322944],"study_design_scores_gemma":[0.020518728,0.0037337637,0.55289674,0.0004211329,0.00022802895,0.00009498789,0.023446037,0.00031322573,0.3639463,0.0008267952,0.033354215,0.00022006735],"about_ca_topic_score_codex":0.00074345135,"about_ca_topic_score_gemma":0.00013302139,"teacher_disagreement_score":0.25300938,"about_ca_system_score_codex":0.00013205633,"about_ca_system_score_gemma":0.000081779326,"threshold_uncertainty_score":0.3540119},"labels":[],"label_agreement":null},{"id":"W4292466725","doi":"10.1177/10668969221116629","title":"Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumors of the Prostate Gland: A Survey among Thirty-Nine Genitourinary Pathologists","year":2022,"lang":"en","type":"article","venue":"International Journal of Surgical Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Neuroendocrine differentiation; Grading (engineering); Medicine; Neuroendocrine tumors; Prostate; Adenocarcinoma; Immunohistochemistry; Pathology; Carcinoma; Small-cell carcinoma; Surgical pathology; Oncology; Prostate cancer; Internal medicine; Cancer; Biology","score_opus":0.0808525661812582,"score_gpt":0.3848645564305988,"score_spread":0.3040119902493406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292466725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938984,0.00088123255,0.0000022914116,0.0042059203,0.00024223341,0.00013219357,0.00003635934,0.0000049406303,0.0005964392],"genre_scores_gemma":[0.9983952,0.00045520155,0.000042267573,0.00007204329,0.000087445245,0.000009580218,0.00004974924,0.000010616053,0.00087792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972231,0.0007799215,0.0010456595,0.00018029883,0.00060159515,0.00016942601],"domain_scores_gemma":[0.99661756,0.0003119767,0.0026080376,0.00012103539,0.00027647207,0.000064937725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020318457,0.00009672493,0.00033165727,0.00033578966,0.00006164899,0.0000120500945,0.00019236664,0.000025033234,0.00010635037],"category_scores_gemma":[0.0014504662,0.00006192481,0.00009318868,0.00031038688,0.00020640381,0.00009341644,0.00029877518,0.0006079527,1.6620446e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003651132,0.000340255,0.942292,0.000014572189,0.000046923265,0.047372364,0.00028424503,0.00013562322,0.0007007367,0.000016891787,0.00020791145,0.0049373596],"study_design_scores_gemma":[0.0032340237,0.0007480488,0.95363003,0.000057814854,0.000021542504,0.038040616,0.00017540691,0.00015448731,0.00038167342,0.000049792005,0.0034571544,0.000049403683],"about_ca_topic_score_codex":0.00011736234,"about_ca_topic_score_gemma":0.000036916525,"teacher_disagreement_score":0.011338052,"about_ca_system_score_codex":0.00010620994,"about_ca_system_score_gemma":0.00014582556,"threshold_uncertainty_score":0.2641286},"labels":[],"label_agreement":null},{"id":"W4292978844","doi":"10.1200/jco.22.00644","title":"Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia","funders":"National Cancer Institute; Astellas Pharma; AstraZeneca","keywords":"Medicine; Hazard ratio; Internal medicine; Oncology; Prostate cancer; Clinical endpoint; Cancer; Clinical trial; Confidence interval","score_opus":0.30776712836981457,"score_gpt":0.5398081416264104,"score_spread":0.23204101325659587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292978844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912127,0.0044988566,0.0000056002564,0.003257608,0.0003477171,0.00058581086,0.00008407701,0.0000036002482,0.000003994621],"genre_scores_gemma":[0.9902135,0.008610933,0.0008375091,0.00014989989,0.000041821633,0.00003761893,0.000008881365,0.000009740036,0.000090090485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942523,0.002578121,0.0023489548,0.00018206422,0.00047192856,0.00016661786],"domain_scores_gemma":[0.99127674,0.0065096603,0.0015313098,0.00013883061,0.0003280353,0.00021539991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077978116,0.00011293776,0.0024556844,0.00085736363,0.00003074683,0.000004851505,0.0000938704,0.00007388477,0.000106001746],"category_scores_gemma":[0.0043810215,0.00007367962,0.00030364536,0.0010014476,0.00014925198,0.000051970936,0.00006787361,0.00034985348,8.592576e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11447661,0.000706334,0.81507725,0.00003320911,0.0050427117,0.00014432253,0.00061798823,0.00028582322,0.0014421641,9.182123e-7,0.000042570548,0.062130123],"study_design_scores_gemma":[0.023090394,0.017072905,0.95634854,0.000034178265,0.0024029305,0.000007573731,0.00019722342,0.00011337887,0.000261181,0.000012484794,0.0004073868,0.000051817617],"about_ca_topic_score_codex":0.00012421144,"about_ca_topic_score_gemma":0.00019879879,"teacher_disagreement_score":0.14127132,"about_ca_system_score_codex":0.00019374843,"about_ca_system_score_gemma":0.0012549415,"threshold_uncertainty_score":0.5244809},"labels":[],"label_agreement":null},{"id":"W4293230230","doi":"10.1136/ejhpharm-2022-eahp.129","title":"4CPS-099 Clinically relevant drug–drug interaction events in patients with abiraterone, enzalutamide or apalutamide treatment","year":2022,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Rio Tinto","keywords":"Enzalutamide; Medicine; Pharmacology; Prostate cancer; Drug interaction; Internal medicine; Drug; Cancer; Androgen receptor","score_opus":0.05257616929045679,"score_gpt":0.41697915321367546,"score_spread":0.3644029839232187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293230230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934112,0.00017117141,0.000002674199,0.0021364419,0.0019449792,0.0017865231,0.00006265352,0.00014350469,0.00034084707],"genre_scores_gemma":[0.99149895,0.0009424459,0.00011396148,0.0016835366,0.0005182568,0.00042248055,0.00043774748,0.0000674771,0.004315175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99550915,0.0007806346,0.0014108814,0.0008878315,0.00086231926,0.0005491721],"domain_scores_gemma":[0.9979852,0.00053157884,0.0004710204,0.0004318683,0.00021690052,0.0003634481],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010981447,0.00037584445,0.0006951922,0.00029780634,0.0003250771,0.000032121767,0.00023372583,0.00006266462,0.0013189033],"category_scores_gemma":[0.000048956077,0.00025020947,0.00024117541,0.00064908015,0.00008042899,0.0003926481,0.00018983908,0.0010264548,0.00009356408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050601706,0.005350169,0.9268472,0.00016692537,0.0004319397,0.000100102996,0.00084083865,0.00030789306,0.00007614766,8.6775447e-7,0.0003701684,0.014906041],"study_design_scores_gemma":[0.05568903,0.0074881357,0.8534317,0.00032517387,0.00044790213,0.000029589131,0.0014433262,0.0018410865,0.0005492133,0.00006431364,0.07819221,0.00049831835],"about_ca_topic_score_codex":0.0016452154,"about_ca_topic_score_gemma":0.0009855422,"teacher_disagreement_score":0.077822044,"about_ca_system_score_codex":0.0010610089,"about_ca_system_score_gemma":0.00040575743,"threshold_uncertainty_score":0.999995},"labels":[],"label_agreement":null},{"id":"W4293235936","doi":"10.1177/20514158221090040","title":"Incidence of dural metastases in castrate-resistant prostate cancer","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital; Trillium Health Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Incidence (geometry); Cohort; Context (archaeology); Internal medicine; Logistic regression; Lactate dehydrogenase; Cancer","score_opus":0.0936555351300057,"score_gpt":0.4681465498119744,"score_spread":0.3744910146819687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293235936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876465,0.003858168,0.0000025464587,0.0077422494,0.00038457007,0.00017916363,0.00004968587,0.0000024859487,0.00013462707],"genre_scores_gemma":[0.99763536,0.0013132255,0.00013928457,0.00048389475,0.00012440559,0.000015342497,0.0000036889332,0.000008752815,0.00027606226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974059,0.00048622888,0.0013097093,0.00013824223,0.00042445608,0.00023549286],"domain_scores_gemma":[0.9983279,0.00054471253,0.00064129813,0.00012405621,0.00021448008,0.0001475689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020794622,0.00008388163,0.0007061571,0.0001911437,0.000035523924,0.0000032421026,0.00014638003,0.000050971874,0.000648199],"category_scores_gemma":[0.00055330317,0.000057543464,0.00020805975,0.0002567016,0.00022299823,0.000059974933,0.0000966172,0.0008641871,0.0000012014226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042502947,0.0015123074,0.927329,0.000097007454,0.00045978455,0.0066929064,0.00035228374,0.0009055697,0.0055362773,0.00011072323,0.0021640083,0.012337153],"study_design_scores_gemma":[0.016212055,0.021970293,0.9382626,0.00007897259,0.00039968436,0.0009697863,0.00061941845,0.00023969424,0.0017504764,0.0010298565,0.018324835,0.00014236539],"about_ca_topic_score_codex":0.00015333881,"about_ca_topic_score_gemma":0.00010188169,"teacher_disagreement_score":0.02629089,"about_ca_system_score_codex":0.00008128556,"about_ca_system_score_gemma":0.0011378749,"threshold_uncertainty_score":0.7097324},"labels":[],"label_agreement":null},{"id":"W4293255314","doi":"10.48083/lwhq7760","title":"Follicle-Stimulating Hormone (FSH) Levels During Androgen Deprivation Therapy Are Not Associated With Survival or Development of Castration-Resistant Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"Société Internationale d’Urologie Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Queen's University; Université Laval; Centre hospitalier universitaire de Québec","funders":"Prostate Cancer Canada; Movember Foundation","keywords":"Prostate cancer; Medicine; Androgen deprivation therapy; Follicle-stimulating hormone; Internal medicine; Oncology; Androgen; Hormone; Gonadotropin; Endocrinology; Cancer; Luteinizing hormone","score_opus":0.13156195486759437,"score_gpt":0.3712867066233678,"score_spread":0.23972475175577346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293255314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966821,0.000651836,0.00006879046,0.0016084795,0.0001601198,0.0004859594,0.0001782321,0.000034725777,0.00012972622],"genre_scores_gemma":[0.9970867,0.0002567459,0.0005658463,0.00011691739,0.00010740151,0.00015100498,0.000111956295,0.000025334204,0.001578098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757415,0.0001362284,0.000538781,0.00023803566,0.0011940422,0.00031879134],"domain_scores_gemma":[0.9984192,0.00019321647,0.000613092,0.00010570202,0.00057250843,0.0000962628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006925251,0.00017780959,0.00031566474,0.00018118435,0.0008729456,0.000042440206,0.00018800146,0.00005352055,0.00047457428],"category_scores_gemma":[0.00018709284,0.00012554754,0.000094568335,0.00027494415,0.000064724525,0.00015887838,0.00016554573,0.0004709999,6.1169584e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02492632,0.0011174509,0.6969809,0.00006039363,0.0033956633,0.0006535056,0.00688272,0.007859827,0.24125873,0.00002757982,0.0001445598,0.016692333],"study_design_scores_gemma":[0.012723289,0.0013289375,0.95139116,0.000113457,0.000063456304,0.000103381,0.002174545,0.0005772163,0.030864373,0.00008566034,0.0003638313,0.00021071901],"about_ca_topic_score_codex":0.00002391576,"about_ca_topic_score_gemma":0.000073965064,"teacher_disagreement_score":0.2544102,"about_ca_system_score_codex":0.0010794605,"about_ca_system_score_gemma":0.0011047904,"threshold_uncertainty_score":0.671408},"labels":[],"label_agreement":null},{"id":"W4293335427","doi":"10.1016/j.ijrobp.2022.06.080","title":"Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Mount Sinai Hospital; Princess Margaret Cancer Centre; Women's College Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Cancer; Metastasis; Medical physics","score_opus":0.04523117080794907,"score_gpt":0.4037099731063661,"score_spread":0.358478802298417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293335427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912507,0.0017587286,0.0016900245,0.0021801519,0.00079704134,0.0011813558,0.001086673,0.0000130155595,0.00004229806],"genre_scores_gemma":[0.9942261,0.0023541655,0.0023112984,0.00012179224,0.0002704017,0.00018591053,0.000456534,0.000020168314,0.00005362354],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979474,0.00034568354,0.0008892853,0.00019828968,0.00045617486,0.00016316024],"domain_scores_gemma":[0.9968051,0.00041383682,0.0014754072,0.000109989654,0.0011158455,0.000079829195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010529996,0.0001396023,0.00053951354,0.00030555486,0.00006600294,0.000010974623,0.00017531788,0.00006677339,0.000038874565],"category_scores_gemma":[0.0003386081,0.00011342704,0.00020058388,0.00023823245,0.00013179293,0.00013178504,0.000049404898,0.00024859252,2.384908e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37375888,0.0057828166,0.008884201,0.00006720027,0.0051507875,0.000049676677,0.0027054907,0.0007347201,0.15823692,0.0017014329,0.00057110307,0.44235677],"study_design_scores_gemma":[0.6700518,0.04347078,0.005852901,0.00009906478,0.00091571175,0.00014340972,0.00051075127,0.003737611,0.2513761,0.013334937,0.010204165,0.0003027498],"about_ca_topic_score_codex":0.000044264852,"about_ca_topic_score_gemma":0.0000016935892,"teacher_disagreement_score":0.44205403,"about_ca_system_score_codex":0.00042533773,"about_ca_system_score_gemma":0.0010347636,"threshold_uncertainty_score":0.46254206},"labels":[],"label_agreement":null},{"id":"W4293554373","doi":"10.5489/cuaj.8097","title":"2022 American Society of Clinical Oncology (ASCO): Meeting highlights","year":2022,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; University of Alberta; Bausch Health (Canada); Princess Margaret Cancer Centre; University of Toronto; University of British Columbia","funders":"Ipsen; Astellas Pharma; Seagen; EMD Serono; UroGen Pharma; Pfizer; Veracyte; Eisai; Sanofi; AstraZeneca; American Society of Clinical Oncology","keywords":"Clinical Oncology; Medicine; Medical physics; Internal medicine; Oncology; Cancer","score_opus":0.05442864243089597,"score_gpt":0.36843012749106974,"score_spread":0.3140014850601738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293554373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8669562,0.0005040066,0.000008110119,0.12476938,0.00051790633,0.00020657966,0.00006383,0.000013506896,0.00696052],"genre_scores_gemma":[0.99021864,0.00072343356,0.0005651471,0.005427869,0.00060577,0.000018256516,0.000037937516,0.00001090013,0.002392051],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99737877,0.0006686174,0.0006255022,0.00020330209,0.00063051085,0.00049332617],"domain_scores_gemma":[0.99782383,0.00043637562,0.00063924567,0.00009758581,0.00026515315,0.00073781656],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00293105,0.000096423755,0.00051079085,0.00012082728,0.00051047903,0.00001606255,0.00015152206,0.0001243194,0.0019597805],"category_scores_gemma":[0.00050731894,0.000074656404,0.00038629302,0.00040896272,0.00012574441,0.000037982503,0.00005827362,0.0013057922,0.000013381376],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002957043,0.00023721873,0.8605471,0.000004437949,0.00043670903,0.00019063882,0.0002490573,0.000041732943,0.00022662267,0.0000840065,0.10501548,0.032671243],"study_design_scores_gemma":[0.001890427,0.0024071266,0.32772738,0.0000038998737,0.000078417565,0.00011056074,0.00063850166,0.00023154699,0.000032681764,0.00014909027,0.66665053,0.00007981313],"about_ca_topic_score_codex":0.001768615,"about_ca_topic_score_gemma":0.0003986357,"teacher_disagreement_score":0.5616351,"about_ca_system_score_codex":0.0025224283,"about_ca_system_score_gemma":0.002676722,"threshold_uncertainty_score":0.99895257},"labels":[],"label_agreement":null},{"id":"W4293558161","doi":"10.1016/j.eururo.2022.08.005","title":"Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study","year":2022,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Medical Research Council; National Institute for Health and Care Research","keywords":"Medicine; Olaparib; Interquartile range; Prostate cancer; Internal medicine; Response Evaluation Criteria in Solid Tumors; Pembrolizumab; Oncology; Adverse effect; Cohort; Tolerability; Urology; Progressive disease; Cancer; Disease; Immunotherapy","score_opus":0.02590916212518864,"score_gpt":0.3095457383498139,"score_spread":0.2836365762246253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293558161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99241924,0.0005292127,0.0000032936894,0.0014125122,0.0001575631,0.003536282,0.0008961529,0.00004520932,0.0010005577],"genre_scores_gemma":[0.9968615,0.000049238897,0.000014000852,0.0004376657,0.00006946161,0.0003781481,0.0012977243,0.00005989605,0.00083233113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996405,0.0013081647,0.00050152006,0.00066062115,0.00063565664,0.0004890155],"domain_scores_gemma":[0.99874467,0.0002074764,0.00019800651,0.00059971766,0.000117735355,0.00013242368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000707665,0.0002526874,0.00041717457,0.00013192659,0.00032329807,0.000038941587,0.00027290283,0.000016046137,0.00019960145],"category_scores_gemma":[0.00008252466,0.00015934036,0.000049523514,0.00038507266,0.00016408466,0.00006775169,0.00021555954,0.0005920227,0.000027861211],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07506275,0.0041480884,0.90598816,0.000015259091,0.00062048755,0.0037856412,0.006260098,0.0003916108,0.000083865,0.0000039036204,0.0005777857,0.0030623435],"study_design_scores_gemma":[0.08333366,0.0085444,0.9063854,0.0000144995665,0.00034119308,0.000012196627,0.00033745816,0.00009361815,0.000010806412,0.0000036138556,0.00077494053,0.00014821035],"about_ca_topic_score_codex":0.0012151144,"about_ca_topic_score_gemma":0.001160439,"teacher_disagreement_score":0.008270912,"about_ca_system_score_codex":0.00037307615,"about_ca_system_score_gemma":0.00042427584,"threshold_uncertainty_score":0.6497711},"labels":[],"label_agreement":null},{"id":"W4293680673","doi":"10.1016/j.bmcl.2022.128952","title":"Identification of the gossypol derivatives as androgen receptor inhibitor","year":2022,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"China Postdoctoral Science Foundation; National Natural Science Foundation of China; McGill University","keywords":"LNCaP; Androgen receptor; Chemistry; Enzalutamide; Prostate cancer; Gossypol; Cancer research; Androgen; Cell growth; Cancer; Internal medicine; Endocrinology; Pharmacology; Biochemistry; Biology; Hormone; Medicine","score_opus":0.013656061513781046,"score_gpt":0.2688512947338543,"score_spread":0.2551952332200732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293680673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705166,0.000898869,0.0000067679757,0.027788822,0.00020803735,0.00032908702,0.00003538839,0.000026614236,0.00018979881],"genre_scores_gemma":[0.99744356,0.00005411601,0.000011770575,0.00087879354,0.00027954986,0.00006107194,0.000060937225,0.000020152864,0.0011900332],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985017,0.000050555358,0.00028821197,0.0002522026,0.00069308217,0.00021421009],"domain_scores_gemma":[0.9992876,0.000036876223,0.0001621089,0.00035508795,0.000058251946,0.00010008886],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023688849,0.00012662295,0.000189711,0.000022119813,0.00020259937,0.000007285315,0.00023167723,0.000037862617,0.0016054129],"category_scores_gemma":[0.00012767014,0.0000875488,0.00009293408,0.0003926148,0.0002836137,0.000031121876,0.00014480935,0.00033256755,0.000014371985],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019848149,0.000097963995,0.004253839,0.00013150557,0.000088352135,0.000015754866,0.000622421,4.2069587e-7,0.9879798,0.000002758567,0.0059701516,0.0006385285],"study_design_scores_gemma":[0.0012348958,0.00006720482,0.002651307,0.000054417975,0.000071618604,0.00009713586,0.001313489,0.000004407448,0.98744816,0.000008839198,0.00696786,0.000080674115],"about_ca_topic_score_codex":0.000021225522,"about_ca_topic_score_gemma":1.6053025e-7,"teacher_disagreement_score":0.02692696,"about_ca_system_score_codex":0.0003164613,"about_ca_system_score_gemma":0.00023914516,"threshold_uncertainty_score":0.9993073},"labels":[],"label_agreement":null},{"id":"W4293755987","doi":"10.1158/1078-0432.ccr-22-0931","title":"Detection of <i>BRCA1</i> , <i>BRCA2</i> , and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; BC Cancer Agency","funders":"MSD K.K.; Merck Sharp and Dohme; Medical Research Council; National Institute for Health and Care Research","keywords":"Medicine; Cancer; Prostate cancer; Concordance; Prostate; Oncology; Internal medicine; Cancer research; Frameshift mutation; Pathology; Gene; Mutation; Biology; Genetics","score_opus":0.07236811365894866,"score_gpt":0.42781302760158463,"score_spread":0.355444913942636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293755987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99327385,0.0021630516,0.0000014310095,0.0013353896,0.000067559,0.0029153654,0.000095506824,0.000013005183,0.00013483081],"genre_scores_gemma":[0.9968532,0.00055109395,0.0000572635,0.00018146007,0.000058958998,0.002001251,0.000036527694,0.00004011224,0.00022016652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963249,0.00064198155,0.00079139683,0.00068696233,0.0009107217,0.00064401125],"domain_scores_gemma":[0.99868554,0.00042256596,0.00013804025,0.00027016885,0.00027578263,0.00020789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023722397,0.00018112067,0.00058347575,0.00048830983,0.00018715016,0.000037942256,0.00011938081,0.000060081686,0.00007832194],"category_scores_gemma":[0.00022795073,0.00015091748,0.000031765918,0.0014748651,0.0004602154,0.00017717535,0.00027967533,0.0012753903,9.03971e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007922601,0.00074439356,0.96999997,0.00037354996,0.00003637042,0.0001302128,0.00086961454,0.00008622089,0.004610151,0.00000924159,0.000028967823,0.015188703],"study_design_scores_gemma":[0.01687388,0.00249278,0.9738167,0.000588354,0.000020482708,0.0000074308446,0.0007363914,0.00060438295,0.0041905446,0.00012411398,0.00035698726,0.0001879508],"about_ca_topic_score_codex":0.006675632,"about_ca_topic_score_gemma":0.010091564,"teacher_disagreement_score":0.015000752,"about_ca_system_score_codex":0.00067594636,"about_ca_system_score_gemma":0.0009133814,"threshold_uncertainty_score":0.999939},"labels":[],"label_agreement":null},{"id":"W4294024703","doi":"10.1016/j.euf.2022.08.007","title":"Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis","year":2022,"lang":"en","type":"review","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Docetaxel; Medicine; Oncology; Internal medicine; Androgen deprivation therapy; Prostate cancer; Randomized controlled trial; Meta-analysis; Abiraterone acetate; Cancer","score_opus":0.14261598693177288,"score_gpt":0.38142934383342275,"score_spread":0.23881335690164987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294024703","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000075827907,0.9879064,0.0000019759684,0.0005704002,0.0000620198,0.0104153175,0.0004196511,0.00004512204,0.00057155656],"genre_scores_gemma":[0.000053020965,0.99134123,0.00002858357,0.0014599271,0.000048788064,0.0033200935,0.00070119917,0.00014527015,0.0029018817],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98973,0.006447946,0.001611507,0.0010138794,0.0004796128,0.0007170653],"domain_scores_gemma":[0.9971263,0.00077563495,0.0009539458,0.0007917191,0.00013455884,0.00021785402],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025232327,0.0007926645,0.010803282,0.0006454932,0.00014291977,0.00003809748,0.0002852837,0.00008380272,0.00096873863],"category_scores_gemma":[0.00025116463,0.00041430662,0.0017530781,0.00241074,0.00016946695,0.00006359092,0.0002549695,0.0009584781,0.000053291616],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011879925,0.00054561155,0.00003051483,0.4425719,0.5014804,0.004292687,0.00046642896,0.0000071751774,3.40345e-8,0.000011962506,0.0035212722,0.04588401],"study_design_scores_gemma":[0.0020788813,0.0015758141,0.000023760898,0.0057288418,0.66324484,0.00008911596,0.000012045284,0.0000025402317,3.1332743e-8,0.000004115295,0.32688475,0.00035528452],"about_ca_topic_score_codex":0.00007153075,"about_ca_topic_score_gemma":0.00005245929,"teacher_disagreement_score":0.43684307,"about_ca_system_score_codex":0.00024588563,"about_ca_system_score_gemma":0.0003536484,"threshold_uncertainty_score":0.9999445},"labels":[],"label_agreement":null},{"id":"W4295049432","doi":"10.1111/bju.15886","title":"<scp>Low‐grade</scp> prostate cancer should still be labelled cancer","year":2022,"lang":"en","type":"letter","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; York Central Hospital; University Health Network","funders":"","keywords":"Prostate cancer; Cancer; Computer science; Information retrieval; Oncology; Medicine; Internal medicine","score_opus":0.04098180669552866,"score_gpt":0.32822750070802764,"score_spread":0.287245694012499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295049432","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.069775656,0.18904996,0.0000029343284,0.7341431,0.0032415024,0.0011281029,0.0015868223,0.00005257171,0.0010193922],"genre_scores_gemma":[0.007194442,0.22346115,0.00008499394,0.68022317,0.010642121,0.0005663151,0.00067314913,0.00032086216,0.07683383],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953193,0.00045240016,0.0009853846,0.00060164096,0.0014093602,0.0012319338],"domain_scores_gemma":[0.99729675,0.0004282234,0.000883366,0.00031766528,0.0007292474,0.00034477515],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005604608,0.00048225676,0.0015093854,0.00053024053,0.00023032892,0.00009244079,0.0005436312,0.0008563676,0.0037935253],"category_scores_gemma":[0.00026403423,0.00046309913,0.0005244417,0.00042578505,0.0003886122,0.00013733504,0.0002272015,0.0074465596,0.000011852292],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036884146,0.00022582982,0.0028055343,0.0004087064,0.0014450079,0.06664392,0.00033404146,0.000057283727,0.0001660984,9.403928e-7,0.91837096,0.009172858],"study_design_scores_gemma":[0.0063705267,0.0018445484,0.001762178,0.00041068517,0.0009879004,0.012827007,0.00007000486,0.000017736285,0.00012738559,0.00007978108,0.9753344,0.00016781855],"about_ca_topic_score_codex":0.001450715,"about_ca_topic_score_gemma":0.00024113237,"teacher_disagreement_score":0.07581443,"about_ca_system_score_codex":0.00073004735,"about_ca_system_score_gemma":0.0022582638,"threshold_uncertainty_score":0.9997821},"labels":[],"label_agreement":null},{"id":"W4295106754","doi":"10.3390/cells11182785","title":"Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors","year":2022,"lang":"en","type":"article","venue":"Cells","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Cancer Society Research Institute; European Synchrotron Radiation Facility; Canadian Cancer Society","keywords":"Androgen receptor; Morpholine; Chemistry; Prostate cancer; Receptor; Androgen; Mutation; Reactivity (psychology); Mutant; Ligand (biochemistry); Biophysics; Stereochemistry; Pharmacology; Biochemistry; Internal medicine; Biology; Medicine; Cancer; Medicinal chemistry; Hormone","score_opus":0.02944005469691364,"score_gpt":0.3348691479952535,"score_spread":0.3054290932983399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295106754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99775475,0.00008111969,0.000009843326,0.00018455832,0.00031929024,0.0011059997,0.00031295457,0.00002254819,0.00020893007],"genre_scores_gemma":[0.99809366,0.0000012061364,0.00014858462,0.000103910534,0.0000716258,0.000047174028,0.00004624033,0.000019824694,0.0014677926],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99882877,0.00004615909,0.00016862708,0.0002559782,0.000485247,0.00021520152],"domain_scores_gemma":[0.99938637,0.000053773245,0.000053399264,0.0002924343,0.00007397297,0.000140046],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019830422,0.00011114262,0.00024219463,0.00012880527,0.000113892274,0.000012142726,0.0000997801,0.000022627592,0.0009979521],"category_scores_gemma":[0.000019714755,0.000090790054,0.00006956548,0.00033965675,0.000040577102,0.000034236178,0.0001297251,0.00019235811,0.000010187669],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012779335,0.0026544812,0.17993829,0.00005845832,0.00008243392,0.00002623779,0.0011273648,0.00032931264,0.8126096,0.000002474999,0.0010048888,0.0008884943],"study_design_scores_gemma":[0.005965095,0.0023580294,0.038455993,0.000014704513,0.000041465068,0.0000021079509,0.0005111944,0.000030346055,0.9466577,0.0000055066284,0.0058387965,0.000119069],"about_ca_topic_score_codex":0.00015436843,"about_ca_topic_score_gemma":0.000008531688,"teacher_disagreement_score":0.1414823,"about_ca_system_score_codex":0.00026158497,"about_ca_system_score_gemma":0.00021237538,"threshold_uncertainty_score":0.99991524},"labels":[],"label_agreement":null},{"id":"W4295419519","doi":"10.1016/j.bioorg.2022.106145","title":"Chemical synthesis of fluorinated and iodinated 17β-HSD3 inhibitors and evaluation for imaging prostate cancer tumors and tissue biodistribution","year":2022,"lang":"en","type":"article","venue":"Bioorganic Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke; Centre hospitalier universitaire de Québec","funders":"","keywords":"Biodistribution; Prostate cancer; Chemistry; LNCaP; Cancer; Prostate; Cancer research; Molecular imaging; Pharmacology; Internal medicine; Biochemistry; Medicine; In vivo; In vitro","score_opus":0.014716511058374761,"score_gpt":0.30087090030023633,"score_spread":0.2861543892418616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295419519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919447,0.0056165564,0.0000012536626,0.0013656024,0.000023785482,0.00063606113,0.00034541453,0.000026100151,0.000040561463],"genre_scores_gemma":[0.9988384,0.0003226446,0.000034986333,0.000010283366,0.000041332103,0.00030443494,0.00028901699,0.000015955298,0.00014290173],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990591,0.000019421288,0.00018683764,0.0003068379,0.00023806788,0.00018978366],"domain_scores_gemma":[0.99950343,0.000052998952,0.00008577814,0.000102746126,0.00015257597,0.00010245349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028058395,0.00012540503,0.00020773601,0.00003483455,0.0001299836,0.000015644362,0.00003338374,0.000044369037,0.00013185073],"category_scores_gemma":[0.00014719227,0.00011505696,0.000019680878,0.00018291001,0.00016190697,0.000038869734,0.00010294779,0.00011162292,1.4950986e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003262349,0.000061513034,0.012030392,0.00056262396,0.000046764195,0.000005961756,0.00013773132,1.6876804e-7,0.96523404,0.0000015308539,0.00040707373,0.021185959],"study_design_scores_gemma":[0.002227306,0.000055100096,0.0033589234,0.00010508844,0.00017330676,0.0000674862,0.0004421265,0.0006085366,0.9923062,0.00003112578,0.0005119834,0.00011284879],"about_ca_topic_score_codex":0.000066478104,"about_ca_topic_score_gemma":4.375282e-7,"teacher_disagreement_score":0.027072122,"about_ca_system_score_codex":0.0002871896,"about_ca_system_score_gemma":0.00020444013,"threshold_uncertainty_score":0.46918866},"labels":[],"label_agreement":null},{"id":"W4295427493","doi":"10.1038/s41391-022-00529-2","title":"Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer—exploratory analysis of LATITUDE study","year":2022,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Toronto; Ottawa Regional Cancer Foundation; Mount Sinai Hospital; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Proportional hazards model; Confidence interval; Progression-free survival; Oncology; Docetaxel; Cancer; Overall survival","score_opus":0.029086505424184957,"score_gpt":0.33040945056274856,"score_spread":0.3013229451385636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295427493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873698,0.0043603447,0.000002762214,0.00047383714,0.00006177603,0.0044705602,0.0032270649,0.000021545602,0.000012308511],"genre_scores_gemma":[0.99308753,0.0017664119,0.000043745007,0.00008683291,0.0000066189364,0.004286062,0.0005192738,0.00003908886,0.00016443465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99637485,0.00076715153,0.0008209339,0.00057168165,0.0009677671,0.00049759547],"domain_scores_gemma":[0.99823,0.00030685676,0.0006611748,0.00024910958,0.00037711274,0.00017577359],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010182735,0.0003080929,0.0011123926,0.00091369305,0.00009730959,0.000022626162,0.000068648485,0.000026984708,0.00008240465],"category_scores_gemma":[0.000107148146,0.0002526595,0.00009699058,0.0027160617,0.000136406,0.00022090133,0.00009555797,0.00026069142,1.4522261e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057837996,0.0018021963,0.9364054,0.0007708974,0.0032540548,0.00066157966,0.03510924,0.0017616965,0.00024589655,0.0000026342636,0.000009642531,0.014192925],"study_design_scores_gemma":[0.008034333,0.002838175,0.95115966,0.000330329,0.0035836773,0.0000023713717,0.02768775,0.0058298167,0.00018467514,0.00004052115,0.000016764838,0.00029192492],"about_ca_topic_score_codex":0.0063514216,"about_ca_topic_score_gemma":0.012880587,"teacher_disagreement_score":0.014754224,"about_ca_system_score_codex":0.00084310235,"about_ca_system_score_gemma":0.0008749443,"threshold_uncertainty_score":0.99999255},"labels":[],"label_agreement":null},{"id":"W4295836711","doi":"10.1016/j.annonc.2022.07.1510","title":"1378P Biopsy-based basal-luminal subtyping classifier in high-risk prostate cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 randomized phase III trials","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"Chugai Pharmaceutical; Genentech; Aptitude Health; European Society for Medical Oncology; Astellas Pharma; Eisai; Incyte; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Merck KGaA; Gilead Sciences; Ipsen; BeiGene; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Celgene","keywords":"Medicine; Prostate cancer; Internal medicine; Oncology; Cumulative incidence; Subtyping; Biopsy; Basal (medicine); Proportional hazards model; Cancer; Cohort","score_opus":0.1135833553259525,"score_gpt":0.45110897388318094,"score_spread":0.33752561855722846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295836711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749858,0.004524769,0.000028042983,0.016972391,0.0003446019,0.0021580176,0.00051638315,0.000014033181,0.00045600595],"genre_scores_gemma":[0.9923715,0.004967979,0.00017005732,0.0008508068,0.000082325714,0.0008704334,0.00013526571,0.000021341275,0.00053028576],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940682,0.0030544596,0.0014573794,0.00045618007,0.0004767012,0.0004870599],"domain_scores_gemma":[0.994992,0.0028540154,0.0012963676,0.0003928249,0.0003157667,0.00014899834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008075851,0.00023589452,0.0030567793,0.000926901,0.00018882866,0.000007625668,0.00022117938,0.00017788778,0.00064277014],"category_scores_gemma":[0.0011931324,0.00015197748,0.0006332503,0.001769358,0.00089074677,0.000052138384,0.00018353933,0.0005763581,8.1494267e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74477905,0.0046156147,0.07977827,0.00025471946,0.009594527,0.00036887013,0.0033296184,0.0010289125,0.012232909,0.00025626103,0.0039595193,0.13980173],"study_design_scores_gemma":[0.8867961,0.009584194,0.031202683,0.0001853747,0.010694974,0.000020069168,0.0020179488,0.0066445894,0.021281326,0.0010826887,0.030084893,0.00040512456],"about_ca_topic_score_codex":0.0036219354,"about_ca_topic_score_gemma":0.00066414033,"teacher_disagreement_score":0.14201708,"about_ca_system_score_codex":0.00033528666,"about_ca_system_score_gemma":0.0018844265,"threshold_uncertainty_score":0.7037883},"labels":[],"label_agreement":null},{"id":"W4295836902","doi":"10.1016/j.annonc.2022.07.1521","title":"1389P Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Sunnybrook Health Science Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Abiraterone acetate; Abiraterone; Prednisone; Pembrolizumab; Prostate cancer; Oncology; Internal medicine; Cohort; Chemotherapy; Cancer; Gynecology; Androgen deprivation therapy; Androgen receptor; Immunotherapy","score_opus":0.04172470123149347,"score_gpt":0.35561525913190595,"score_spread":0.3138905579004125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295836902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937887,0.0009422404,0.000002193775,0.001995184,0.00008997321,0.0019881679,0.00035026085,0.000014340643,0.0008289426],"genre_scores_gemma":[0.996656,0.0009665395,0.00030365228,0.00024927346,0.000017321921,0.0004673631,0.00017229772,0.000040595733,0.0011269848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777406,0.00023442834,0.0005529174,0.0004144049,0.00055942417,0.00046475045],"domain_scores_gemma":[0.99873364,0.00009439333,0.00036311723,0.00026433272,0.00040298488,0.00014150552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000401762,0.0002359557,0.00086507364,0.0002663993,0.00009467422,0.000009028331,0.0001202804,0.000054614677,0.00028862458],"category_scores_gemma":[0.000025992273,0.00018518584,0.00007193592,0.0004024859,0.0003177261,0.00011764202,0.00009497474,0.00027811143,0.0000014232878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18900329,0.0035381278,0.7519393,0.0010828057,0.0029982955,0.00028362087,0.0114808595,0.0010800569,0.012883625,0.00021635965,0.0022062531,0.023287425],"study_design_scores_gemma":[0.12969263,0.029671405,0.8206724,0.00024046234,0.0004366824,0.000021898144,0.0019948427,0.00024114519,0.014186571,0.0002485559,0.002185024,0.000408422],"about_ca_topic_score_codex":0.0014112786,"about_ca_topic_score_gemma":0.0004502336,"teacher_disagreement_score":0.06873308,"about_ca_system_score_codex":0.00031038155,"about_ca_system_score_gemma":0.0010857882,"threshold_uncertainty_score":0.75516593},"labels":[],"label_agreement":null},{"id":"W4295836916","doi":"10.1016/j.annonc.2022.07.1508","title":"1376P Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer: Exploratory analysis of LATITUDE study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital; Hôpital Saint-Luc; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Hazard ratio; Confidence interval; Proportional hazards model; Prostate cancer; Internal medicine; Univariate; Univariate analysis; Brief Pain Inventory; Oncology; Cancer; Physical therapy; Multivariate analysis; Chronic pain; Multivariate statistics; Statistics","score_opus":0.10721131006997114,"score_gpt":0.4181923753401661,"score_spread":0.310981065270195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295836916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973492,0.00031046866,0.0000018328036,0.0008460274,0.000033728527,0.0012144014,0.0001855408,0.000004492162,0.000054295084],"genre_scores_gemma":[0.99898124,0.00030219278,0.000034033128,0.00007689763,0.0000033916506,0.00042027907,0.0001250356,0.0000104313585,0.000046475943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728113,0.0012086343,0.00057591667,0.00021850834,0.00047589335,0.0002399247],"domain_scores_gemma":[0.9984396,0.0002932362,0.0006727485,0.00014732426,0.00040360747,0.000043479304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002195306,0.00010691022,0.0008883636,0.00079280237,0.00002157967,0.0000013103046,0.00004521104,0.000032422962,0.000041500327],"category_scores_gemma":[0.000103535196,0.000089497174,0.00007095251,0.0017450986,0.000060491097,0.00006156524,0.00005025999,0.00018842553,1.1201242e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00317829,0.0029270158,0.9494414,0.00008423684,0.0035871007,0.00086824235,0.025477307,0.001363027,0.0010234251,0.0000026357918,0.000012488555,0.012034855],"study_design_scores_gemma":[0.0051339404,0.012911024,0.9523219,0.000053784497,0.0008806587,0.0000020116795,0.025284762,0.0023339915,0.00094554503,0.000012190554,0.000028218368,0.00009199416],"about_ca_topic_score_codex":0.005665933,"about_ca_topic_score_gemma":0.03762446,"teacher_disagreement_score":0.031958528,"about_ca_system_score_codex":0.0004661906,"about_ca_system_score_gemma":0.000573863,"threshold_uncertainty_score":0.97993636},"labels":[],"label_agreement":null},{"id":"W4295837261","doi":"10.1016/j.annonc.2022.07.1504","title":"1372P Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Clinical trial; Castration; Prostate-specific antigen; Prostate; Cancer; Urology; Hormone","score_opus":0.12480796055277366,"score_gpt":0.46891553046236173,"score_spread":0.3441075699095881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861293,0.00034369374,4.7512677e-7,0.010835245,0.00009760556,0.0022828025,0.00022505736,0.0000055975484,0.000080257945],"genre_scores_gemma":[0.997996,0.0009946957,0.00008570445,0.0003229271,0.000042649383,0.00024495294,0.00016159107,0.000012058632,0.00013942092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974787,0.00069314294,0.000695877,0.00026489323,0.00057343754,0.00029395218],"domain_scores_gemma":[0.99846065,0.00079645053,0.00034899544,0.00014894511,0.00018502442,0.000059911017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020382989,0.00012075698,0.0005763911,0.00017808792,0.000088970955,0.000014547646,0.000094164985,0.000057788664,0.00004942397],"category_scores_gemma":[0.00015432821,0.000072624396,0.00006313839,0.00035047144,0.00009776765,0.000084977895,0.00007189948,0.0003699793,9.87542e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04257614,0.0015255973,0.93192226,0.000021765609,0.00018744067,0.0000599207,0.00090474077,0.000014184845,0.000014907797,0.000007663535,0.000470085,0.02229532],"study_design_scores_gemma":[0.050589405,0.017561695,0.9275137,0.00002404758,0.000055687287,5.0621867e-7,0.0003764455,0.000008478335,0.000017471966,0.000115940624,0.003668678,0.00006794057],"about_ca_topic_score_codex":0.00042921485,"about_ca_topic_score_gemma":0.00085937715,"teacher_disagreement_score":0.02222738,"about_ca_system_score_codex":0.00022856749,"about_ca_system_score_gemma":0.0004603204,"threshold_uncertainty_score":0.2961537},"labels":[],"label_agreement":null},{"id":"W4295837302","doi":"10.1016/j.annonc.2022.07.1514","title":"1382P FDG-positive/PSMA-negative PET lesion prevalence in metastatic castration-resistant prostate cancer and its correlation with lines of systemic therapy: Results from the prospective 3TMPO imaging study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; Centre Hospitalier de l’Université de Montréal; Hôtel-Dieu de Québec; McGill University; Hôpital Fleurimont; Jewish General Hospital; Hôpital Saint-Luc; Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Prostate; Pet imaging; Internal medicine; Correlation; Prospective cohort study; Positron emission tomography; Pathology; Radiology","score_opus":0.08628769088755937,"score_gpt":0.4044144203896574,"score_spread":0.318126729502098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853847,0.0073916125,0.0000024893016,0.0033480746,0.000043607473,0.0031133792,0.0006015539,0.0000074943127,0.00010706198],"genre_scores_gemma":[0.99669755,0.002376518,0.00005092921,0.00007412585,0.000020422156,0.0005113293,0.000048542996,0.000012477428,0.00020810499],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982392,0.0005060389,0.00041397405,0.0003143556,0.0003499363,0.00017646355],"domain_scores_gemma":[0.9982371,0.00071533007,0.0003841753,0.00014532868,0.000479761,0.000038308528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071393733,0.0001317577,0.00037991643,0.00010788295,0.00012947837,0.000007246185,0.0000796417,0.000015035358,0.000017261991],"category_scores_gemma":[0.00012131827,0.00007944587,0.00002835014,0.00032626453,0.00014731303,0.00010848615,0.00005950138,0.00022522481,3.1201972e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07428976,0.0028854664,0.76199704,0.00032400075,0.0010359661,0.0006943482,0.10671352,0.002314726,0.037164513,0.00008167428,0.00021725033,0.01228175],"study_design_scores_gemma":[0.016752044,0.012634295,0.9191665,0.0007973018,0.00021009045,0.00006377201,0.033895668,0.0018786849,0.0142149655,0.00021758355,0.000023965944,0.00014510454],"about_ca_topic_score_codex":0.0026689295,"about_ca_topic_score_gemma":0.0005601551,"teacher_disagreement_score":0.15716949,"about_ca_system_score_codex":0.00015379145,"about_ca_system_score_gemma":0.00060914084,"threshold_uncertainty_score":0.4034641},"labels":[],"label_agreement":null},{"id":"W4295845829","doi":"10.3390/diagnostics12092212","title":"PSA-Stratified Performance of [18F]DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer Patients under Androgen Deprivation Therapy","year":2022,"lang":"en","type":"article","venue":"Diagnostics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"BC Cancer Foundation","keywords":"Androgen deprivation therapy; Prostate cancer; Medicine; Recurrent prostate cancer; Oncology; Cancer research; Internal medicine; Cancer; Prostatectomy","score_opus":0.027529566624267768,"score_gpt":0.30945450789922146,"score_spread":0.2819249412749537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295845829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563015,0.0024782424,7.5532995e-7,0.0005038474,0.00016037589,0.0009342238,0.00014947473,0.000016205999,0.0001267329],"genre_scores_gemma":[0.98511195,0.0135891875,0.000045940706,0.00015480033,0.000025645328,0.00042092084,0.00051667955,0.000020053476,0.0001148312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998748,0.000043437198,0.0002897762,0.00022725656,0.0004388844,0.0002526176],"domain_scores_gemma":[0.99938124,0.00011874081,0.00010140979,0.00017926189,0.00014744628,0.0000719251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013081255,0.00012845111,0.00020538647,0.00012161983,0.00007557569,0.000008324405,0.000097836935,0.000008853581,0.00016264549],"category_scores_gemma":[0.00007847469,0.000107638385,0.00004363404,0.00036291048,0.00006332841,0.00004929718,0.00006865105,0.00022926052,0.0000026651542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009363824,0.0011488457,0.98203355,0.000103981016,0.00006091505,0.00006367386,0.00032117945,0.00016887867,0.0017196068,0.00002227908,0.0008185347,0.012602172],"study_design_scores_gemma":[0.0110851405,0.0031545083,0.81426305,0.00030402772,0.000062507745,0.000023428664,0.00029839322,0.001114825,0.16679053,0.00016166519,0.0024139993,0.00032792208],"about_ca_topic_score_codex":0.00007584797,"about_ca_topic_score_gemma":0.00001487648,"teacher_disagreement_score":0.1677705,"about_ca_system_score_codex":0.0002774199,"about_ca_system_score_gemma":0.0002761453,"threshold_uncertainty_score":0.4389366},"labels":[],"label_agreement":null},{"id":"W4295988800","doi":"10.1016/j.xgen.2022.100169","title":"A patient-driven clinicogenomic partnership for metastatic prostate cancer","year":2022,"lang":"en","type":"article","venue":"Cell Genomics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Cancer Institute; Genentech; Puma Biotechnology; U.S. Department of Defense; Broad Institute; Prostate Cancer Foundation; Movember Foundation; American Society of Clinical Oncology; National Institutes of Health; National Science Foundation; Conquer Cancer Foundation; Roche","keywords":"General partnership; Prostate cancer; Economic shortage; Medicine; Lung cancer; Exome sequencing; Exome; Oncology; Internal medicine; Cancer; Biology; Political science; Gene","score_opus":0.06978238686570135,"score_gpt":0.35162122938247453,"score_spread":0.28183884251677316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295988800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99101865,0.0045982413,0.000022116052,0.00055351213,0.00020087749,0.0021135884,0.00018156161,0.000042056203,0.0012694118],"genre_scores_gemma":[0.98023695,0.00049792964,0.0015974648,0.00078960665,0.00013323055,0.0026542596,0.00043674634,0.00008118706,0.013572655],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986444,0.0000561714,0.00030426832,0.0003476637,0.00020137572,0.0004460846],"domain_scores_gemma":[0.99927384,0.0000862762,0.00012217283,0.00026860644,0.000070654816,0.00017844688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020108528,0.00015567298,0.0002816505,0.00010093321,0.00031696822,0.000020627876,0.00011112309,0.000024356157,0.0003673644],"category_scores_gemma":[0.000011435052,0.00014004756,0.00015034383,0.00013208369,0.000056817997,0.000029783332,0.00012839622,0.00020774125,0.000035709843],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037598163,0.0077324,0.13191332,0.004512921,0.0036037175,0.0009127058,0.07504772,0.017139863,0.35866454,0.0003946579,0.10846762,0.25401235],"study_design_scores_gemma":[0.010800653,0.0019000686,0.000675996,0.000023015651,0.00045048635,0.000029353023,0.0030246333,0.0034504319,0.03433858,0.00022821806,0.9446714,0.0004071718],"about_ca_topic_score_codex":0.000016529104,"about_ca_topic_score_gemma":0.0000064750857,"teacher_disagreement_score":0.83620375,"about_ca_system_score_codex":0.0006261294,"about_ca_system_score_gemma":0.0008738362,"threshold_uncertainty_score":0.5710974},"labels":[],"label_agreement":null},{"id":"W4296031411","doi":"10.1158/2159-8290.cd-22-0027","title":"Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture","year":2022,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; University of Toronto; Ontario Institute for Cancer Research","funders":"DOD Prostate Cancer Research Program; National Human Genome Research Institute; National Cancer Institute; Prostate Cancer Foundation; National Institutes of Health; Cancer Prevention and Research Institute of Texas; U.S. Department of Defense","keywords":"Germline; Somatic cell; Prostate cancer; Germline mutation; Allele; Biology; Genetics; Transcriptome; Cancer; Mutation; Computational biology; Gene; Gene expression","score_opus":0.00834741368215194,"score_gpt":0.28468239380457877,"score_spread":0.27633498012242685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296031411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9553382,0.038542863,0.00020439671,0.0030371717,0.00015877202,0.0009968295,0.0016125479,0.000019653413,0.000089599234],"genre_scores_gemma":[0.9888795,0.0057440554,0.00005386142,0.00019844848,0.000079671896,0.00079533225,0.0003099128,0.000031566615,0.003907633],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99880826,0.00012131365,0.00027116862,0.0002702657,0.00029754316,0.0002314692],"domain_scores_gemma":[0.9994464,0.000067996,0.0001588008,0.00022884617,0.00003561124,0.00006237296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017826636,0.00015423122,0.00025657276,0.000088581655,0.0002494681,0.000029794008,0.00010636569,0.000029481856,0.00033556143],"category_scores_gemma":[0.000008870353,0.00010121315,0.00007861659,0.00016940922,0.00020548575,0.00011000775,0.0000626377,0.00031472524,8.710507e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008746752,0.0007057727,0.26283914,0.001958,0.0024950802,0.0000371562,0.03322463,0.022266952,0.35283953,0.00013181168,0.021806573,0.29294857],"study_design_scores_gemma":[0.04207368,0.0037035695,0.69133437,0.0017085597,0.004900943,0.00032058638,0.013420664,0.02371938,0.08154295,0.0066203787,0.12857813,0.0020767907],"about_ca_topic_score_codex":0.0011022526,"about_ca_topic_score_gemma":0.00024404039,"teacher_disagreement_score":0.42849523,"about_ca_system_score_codex":0.00036961172,"about_ca_system_score_gemma":0.00038569485,"threshold_uncertainty_score":0.41273525},"labels":[],"label_agreement":null},{"id":"W4296031587","doi":"10.1038/s41467-022-32701-6","title":"Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; Astellas Pharma; University of Michigan Comprehensive Cancer Center; Prostate Cancer Foundation; Astellas Pharma Global Development; National Comprehensive Cancer Network; University of Michigan; National Heart, Lung, and Blood Institute; V Foundation for Cancer Research; U.S. Department of Health and Human Services; Doris Duke Charitable Foundation; Stand Up To Cancer; Rogel Cancer Center, University of Michigan; U.S. Department of Defense","keywords":"Enzalutamide; Transcriptome; Lineage (genetic); Prostate cancer; Biology; Cancer research; Transcription factor; Cancer; Androgen receptor; Bioinformatics; Oncology; Gene; Medicine; Genetics; Gene expression","score_opus":0.044580634569503154,"score_gpt":0.35118355016110797,"score_spread":0.3066029155916048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296031587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992737,0.005199714,0.000022102464,0.00077078777,0.00006253837,0.00048669975,0.00024882253,0.000020823634,0.00045154474],"genre_scores_gemma":[0.99528545,0.00020606731,0.004050502,0.000072426206,0.0000071434406,0.00013434638,0.00019234748,0.00001284528,0.00003887566],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998904,0.00013754825,0.00031757492,0.00012860177,0.00038029853,0.00013200688],"domain_scores_gemma":[0.998797,0.00016379164,0.00013414546,0.00061357504,0.00024498353,0.000046521815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015101842,0.00009211424,0.00024682915,0.00015219324,0.00018661367,0.000003990766,0.0003330654,0.00010847672,0.00004065582],"category_scores_gemma":[0.000114717346,0.000080090394,0.000106832485,0.0003237984,0.00015288393,0.000036454163,0.00022961463,0.0008048421,6.6536677e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038313106,0.0008567648,0.026571179,0.00014884425,0.00013650753,0.000010825733,0.0015301557,0.00004744843,0.9668846,0.0024113602,0.00003785041,0.0009812925],"study_design_scores_gemma":[0.0012220308,0.0005658576,0.027841058,0.0000852096,0.0001279504,0.000021075886,0.0014123181,0.0011909974,0.9664651,0.00009988891,0.000866136,0.00010238988],"about_ca_topic_score_codex":0.000037852304,"about_ca_topic_score_gemma":0.00002402238,"teacher_disagreement_score":0.004993647,"about_ca_system_score_codex":0.000083877654,"about_ca_system_score_gemma":0.0002484372,"threshold_uncertainty_score":0.34966832},"labels":[],"label_agreement":null},{"id":"W4296140011","doi":"10.1016/s0022-5347(05)64163-8","title":"Phase III Study of Mitoxantrone Plus Low Dose Prednisone Versus Low Dose Prednisone Alone in Patients With Asymptomatic Hormone Refractory Prostate Cancer","year":2002,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prednisone; Mitoxantrone; Asymptomatic; Prostate cancer; Refractory (planetary science); Urology; Internal medicine; Oncology; Cancer; Gastroenterology; Chemotherapy","score_opus":0.020374980271669008,"score_gpt":0.3035582370554601,"score_spread":0.2831832567837911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296140011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99023646,0.0067156767,0.0000040564146,0.00092819385,0.00021439292,0.0017937825,0.00002879123,0.0000128622405,0.00006580545],"genre_scores_gemma":[0.9960135,0.0033688094,0.000037195958,0.0000642888,0.00012832053,0.00004671892,0.000010385699,0.000041506548,0.00028928064],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971661,0.00038239703,0.0008635232,0.00022418311,0.0008203907,0.0005434206],"domain_scores_gemma":[0.99794877,0.0002505324,0.00075761933,0.00043933853,0.0003914402,0.00021228244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005454734,0.00028189115,0.00092806795,0.0003510855,0.00009063276,0.00001063494,0.00027661427,0.000112114874,0.0001971644],"category_scores_gemma":[0.00007357741,0.00015940712,0.00007630896,0.00042931022,0.0002991977,0.00019732647,0.0000798989,0.00068129867,0.000007953733],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7620625,0.068376295,0.07283758,0.00038546778,0.0049628136,0.0013292504,0.036732424,0.0016722215,0.012600393,0.0000016078736,0.0026238593,0.03641562],"study_design_scores_gemma":[0.5897023,0.14427106,0.25898466,0.00032777956,0.001790003,0.00010456938,0.0016465547,0.0019266153,0.0007275552,0.000012390342,0.00017706344,0.00032942492],"about_ca_topic_score_codex":0.00015513555,"about_ca_topic_score_gemma":0.00010823066,"teacher_disagreement_score":0.18614706,"about_ca_system_score_codex":0.00036837073,"about_ca_system_score_gemma":0.00026191588,"threshold_uncertainty_score":0.65004337},"labels":[],"label_agreement":null},{"id":"W4296276705","doi":"10.1002/1878-0261.13314","title":"Increased <scp> <i>MYBL2</i> </scp> expression in aggressive hormone‐sensitive prostate cancer","year":2022,"lang":"en","type":"article","venue":"Molecular Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"American College of Radiology Imaging Network; U.S. Department of Defense; ECOG-ACRIN Cancer Research Group; Sanofi; National Cancer Institute; Prostate Cancer Foundation","keywords":"LNCaP; Prostate cancer; Cancer research; Androgen deprivation therapy; Internal medicine; Docetaxel; Gene silencing; Medicine; Endocrinology; Biology; Cancer; Genetics","score_opus":0.013445213669511165,"score_gpt":0.31730876743531905,"score_spread":0.30386355376580787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296276705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98037326,0.0091813365,0.000021781263,0.0018965144,0.0001650242,0.0012816328,0.000094585506,0.000055560653,0.006930309],"genre_scores_gemma":[0.99276245,0.0009790309,0.000248049,0.0022817643,0.00006255872,0.0014807583,0.00024261721,0.00004983066,0.0018929507],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976424,0.0005066174,0.0002711435,0.0005013636,0.00047346228,0.00060502876],"domain_scores_gemma":[0.9990078,0.00017187148,0.00018849247,0.00028275707,0.00012810824,0.00022095954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003078304,0.00021319286,0.0004724837,0.00028701726,0.00017903076,0.00001058233,0.00012947171,0.00011933809,0.00009247746],"category_scores_gemma":[0.0001814014,0.00018564574,0.000106034684,0.0004963202,0.00015162137,0.000048114915,0.00034120004,0.0006637274,0.000020771413],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017659692,0.0009834395,0.012477439,0.000052028652,0.00016856428,0.029037032,0.0037626105,0.00023943828,0.9284193,0.00005488626,0.015879361,0.0071599674],"study_design_scores_gemma":[0.026628824,0.0062378007,0.036318026,0.00023013975,0.00023684994,0.0008001546,0.005457026,0.00049696583,0.78018916,0.00056782534,0.14255193,0.00028527665],"about_ca_topic_score_codex":0.00046898687,"about_ca_topic_score_gemma":0.000057836165,"teacher_disagreement_score":0.14823009,"about_ca_system_score_codex":0.0012095049,"about_ca_system_score_gemma":0.0010054066,"threshold_uncertainty_score":0.75704134},"labels":[],"label_agreement":null},{"id":"W4296311793","doi":"10.1016/j.mex.2022.101843","title":"FACS-Free isolation and purification protocol of mouse prostate epithelial cells for organoid primary culture","year":2022,"lang":"en","type":"article","venue":"MethodsX","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Organoid; Prostate cancer; Prostate; Ex vivo; Flow cytometry; Androgen receptor; Androgen; In vivo; Biology; Cancer research; Cell biology; Medicine; Cancer; Immunology; Internal medicine; Endocrinology; Hormone; Biotechnology","score_opus":0.035911892328080904,"score_gpt":0.366759050996761,"score_spread":0.3308471586686801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296311793","genre_codex":"protocol","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3199988,0.0006575153,0.06562981,0.005598183,0.00034021778,0.6027558,0.0023671621,0.00025182083,0.0024007063],"genre_scores_gemma":[0.009964021,0.000095938114,0.552369,0.00031012457,0.00023091472,0.38105345,0.0006466167,0.00009815326,0.055231784],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990128,0.00016594866,0.00020245259,0.00022011991,0.0002430206,0.00015563644],"domain_scores_gemma":[0.9993833,0.00006466455,0.00011012022,0.0002497509,0.00013358462,0.00005863194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006250472,0.00009507289,0.00019915609,0.00007987407,0.00014641619,0.000010261277,0.00008043184,0.000040951556,0.000054754004],"category_scores_gemma":[0.00008129818,0.000071485316,0.00004773833,0.00016384774,0.00006492112,0.00006077984,0.000087510816,0.00013667459,9.557134e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024050674,0.00018752717,0.00068756304,0.0006366761,0.000038832844,0.0000019797808,0.0018095447,0.000007788366,0.9723549,0.00006911687,0.001577814,0.020223184],"study_design_scores_gemma":[0.006159364,0.0013810575,0.0014457026,0.000012892962,0.000058110385,0.00000640027,0.0002491804,0.00026024683,0.92794645,0.0010924184,0.06129293,0.00009526763],"about_ca_topic_score_codex":0.000012385897,"about_ca_topic_score_gemma":5.031237e-7,"teacher_disagreement_score":0.4867392,"about_ca_system_score_codex":0.000114296236,"about_ca_system_score_gemma":0.00013706752,"threshold_uncertainty_score":0.29150864},"labels":[],"label_agreement":null},{"id":"W4296992904","doi":"10.3390/cancers14194606","title":"Change of the Neutrophil-to-Lymphocyte Ratio during Treatment: A Potential Prognostic Biomarker in Metastatic Prostate Cancer Treated with Radium-223 Dichloride","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Internal medicine; Neutrophil to lymphocyte ratio; Oncology; Cancer; Biomarker; Overall survival; Gastroenterology; Urology","score_opus":0.03399837976270846,"score_gpt":0.2929396097316706,"score_spread":0.2589412299689621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296992904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902643,0.00390718,0.0000014918618,0.0013810049,0.00017502772,0.0038561162,0.00028601495,0.000034668716,0.00009418578],"genre_scores_gemma":[0.99077773,0.00093138305,0.000024015946,0.00013858169,0.000058726626,0.005952088,0.000058315993,0.00005377412,0.0020053778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981409,0.00011787547,0.00028353572,0.000429273,0.0004982771,0.00053016195],"domain_scores_gemma":[0.99924004,0.000026342113,0.00013343655,0.00034624047,0.0000797396,0.00017421544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009779573,0.0002645448,0.0004281623,0.0002853634,0.00024036237,0.000016993486,0.00015062673,0.000024037505,0.00016898947],"category_scores_gemma":[0.000011859941,0.00015938764,0.00011175356,0.0013485734,0.0001550498,0.000091862,0.00009236648,0.00015259984,0.0000024955891],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052809156,0.0011090918,0.7327265,0.0011039084,0.0029590386,0.0032048346,0.016261464,0.023233058,0.13858552,0.00002528215,0.00027696113,0.027705187],"study_design_scores_gemma":[0.048648357,0.0045425477,0.86497486,0.0008112838,0.0013012614,0.0001875023,0.0019445737,0.0033802348,0.069830365,0.000013304372,0.0037338873,0.000631805],"about_ca_topic_score_codex":0.008825702,"about_ca_topic_score_gemma":0.00070901733,"teacher_disagreement_score":0.13224837,"about_ca_system_score_codex":0.006169088,"about_ca_system_score_gemma":0.0016900557,"threshold_uncertainty_score":0.9977746},"labels":[],"label_agreement":null},{"id":"W4296997847","doi":"10.3389/fonc.2022.963007","title":"To bind or not to bind: Cistromic reprogramming in prostate cancer","year":2022,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; FOXA1; Epigenome; Biology; Transcription factor; Chromatin remodeling; Chromatin; Reprogramming; Cancer research; Pioneer factor; Epigenetics; Cancer; Genetics; DNA methylation; Gene expression; Gene","score_opus":0.10892915621952053,"score_gpt":0.4691438975339736,"score_spread":0.3602147413144531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296997847","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011519653,0.9870754,0.000009176081,0.0013445773,0.0026366971,0.0068601114,0.00018122993,0.000045647346,0.0006952293],"genre_scores_gemma":[0.000019665731,0.97208124,0.004292779,0.0005166491,0.00023746875,0.0071216216,0.00026193648,0.00010631238,0.015362327],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962139,0.00036208585,0.00088761665,0.0010977313,0.00039421878,0.0010444407],"domain_scores_gemma":[0.9986061,0.00017776813,0.00020340012,0.00058432156,0.000042208037,0.00038622922],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00086130534,0.00046384087,0.002777866,0.0018047813,0.000077468525,0.000023760547,0.0004024238,0.00034891188,0.00063141336],"category_scores_gemma":[0.0002891835,0.00034811744,0.00023547391,0.001979806,0.00009897424,0.00004004092,0.00037711347,0.0012642221,0.00005841678],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024647228,0.0002726605,0.0016244849,0.0035556105,0.00017180045,0.003270907,0.0008859745,0.0000067688607,0.0000014069265,0.0000014235459,0.036312845,0.9514314],"study_design_scores_gemma":[0.0023413256,0.0026165382,0.00009945472,0.003102377,0.00025465508,0.00007952858,0.0004355635,0.0000042304787,0.000004507851,0.000006241152,0.99072474,0.0003308106],"about_ca_topic_score_codex":0.00064274605,"about_ca_topic_score_gemma":0.0007981546,"teacher_disagreement_score":0.9544119,"about_ca_system_score_codex":0.0094044125,"about_ca_system_score_gemma":0.0045753764,"threshold_uncertainty_score":0.99989706},"labels":[],"label_agreement":null},{"id":"W4297491134","doi":"10.5489/cuaj.8130","title":"Metastatic prostate cancer gets into the biomarker era","year":2022,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Prostate cancer; Biomarker; Medicine; Cancer; Prostate; Oncology; Internal medicine; Biology","score_opus":0.02702761862990504,"score_gpt":0.30115780231904116,"score_spread":0.2741301836891361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297491134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69932467,0.006122811,0.0000041888034,0.29164177,0.0005258531,0.00049397995,0.000086356755,0.000021424463,0.0017789163],"genre_scores_gemma":[0.9817848,0.0011886102,0.000052243147,0.008599374,0.00017027486,0.00017573073,0.000036416885,0.0000134247275,0.007979115],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981188,0.0003707005,0.0002274157,0.00016228967,0.00059586915,0.00052491407],"domain_scores_gemma":[0.998917,0.00012717662,0.0001516629,0.000100914986,0.00019412952,0.000509112],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010954812,0.00010826613,0.00018319968,0.00015713467,0.0012145181,0.000085231615,0.0001525528,0.00004274572,0.0026040813],"category_scores_gemma":[0.00021893905,0.000063606996,0.00011937372,0.00029837497,0.000049953385,0.00006027406,0.000043690437,0.0009132003,0.000038667054],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004903688,0.00013524796,0.7879893,0.000008954699,0.0009651457,0.0012299889,0.0032357462,0.00020754451,0.00041659,0.00011777745,0.11420115,0.09100215],"study_design_scores_gemma":[0.0014792284,0.0003228082,0.3545082,0.000004040367,0.00011648773,0.00016619964,0.0004320256,0.00027198842,0.00002085955,0.0011342668,0.6414488,0.000095126336],"about_ca_topic_score_codex":0.0043928656,"about_ca_topic_score_gemma":0.0019806896,"teacher_disagreement_score":0.5272476,"about_ca_system_score_codex":0.0030679835,"about_ca_system_score_gemma":0.0015624807,"threshold_uncertainty_score":0.99830765},"labels":[],"label_agreement":null},{"id":"W4297491150","doi":"10.5489/cuaj.8148","title":"UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer","year":2022,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; Dalhousie University; University of Toronto; Université de Montréal; Université Laval; University of Alberta; McGill University; University of British Columbia","funders":"","keywords":"Castration; Prostate cancer; Medicine; Guideline; Oncology; Internal medicine; Urology; Gynecology; Cancer; Pathology; Hormone","score_opus":0.023072215309117496,"score_gpt":0.29929214255468434,"score_spread":0.2762199272455668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297491150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5875505,0.0021341366,0.00002148694,0.3983659,0.0013180043,0.0019576403,0.002857741,0.00007317982,0.005721372],"genre_scores_gemma":[0.9660435,0.0007746542,0.0004780877,0.029142598,0.00052604114,0.00027322987,0.0009292291,0.00003870016,0.0017939984],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99423015,0.0012158531,0.0009412882,0.0006808724,0.0009848824,0.0019469275],"domain_scores_gemma":[0.99397135,0.0004463291,0.00063738617,0.00019151316,0.0010356467,0.003717804],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028726757,0.00041532778,0.0007457165,0.000950804,0.0024754608,0.00028114056,0.00025058354,0.0004737142,0.005047975],"category_scores_gemma":[0.0012484817,0.00036530846,0.0002103388,0.00087658525,0.00013105081,0.00026165877,0.00005667042,0.0023266948,0.00009070019],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00037058236,0.00014163439,0.89035374,0.000009470771,0.0009499947,0.003791789,0.00085091766,0.0008470187,0.00012077218,0.00076764316,0.094665766,0.007130671],"study_design_scores_gemma":[0.0034924226,0.002212075,0.3832931,0.000008104071,0.00046292343,0.0014771638,0.0012555957,0.0012230624,0.000011090209,0.0012600479,0.60481155,0.0004928452],"about_ca_topic_score_codex":0.5876924,"about_ca_topic_score_gemma":0.8184275,"teacher_disagreement_score":0.51014584,"about_ca_system_score_codex":0.02171006,"about_ca_system_score_gemma":0.013351625,"threshold_uncertainty_score":0.99997497},"labels":[],"label_agreement":null},{"id":"W4297677946","doi":"10.47102/annals-acadmedsg.v44n10p397","title":"Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"Annals of the Academy of Medicine Singapore","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"University of Toronto; National University Health System; National Cancer Centre of Singapore","keywords":"Medicine; Workgroup; Enzalutamide; Cabazitaxel; Prostate cancer; Cancer; Docetaxel; Abiraterone; Oncology; Internal medicine; Gynecology; Family medicine; Androgen deprivation therapy","score_opus":0.302261227662554,"score_gpt":0.48673871134372254,"score_spread":0.18447748368116856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297677946","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33150327,0.15867236,0.00003115359,0.5032293,0.0008004033,0.0042156368,0.00028010824,0.000036125577,0.0012316433],"genre_scores_gemma":[0.95024866,0.03565126,0.0013395896,0.004020265,0.0011411109,0.00038183798,0.00003259502,0.000074707306,0.007110002],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99698246,0.00007036659,0.0010149034,0.00032872788,0.0010552347,0.0005483318],"domain_scores_gemma":[0.997111,0.00016963507,0.0008372707,0.00040968266,0.0012726085,0.00019975124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016820509,0.00028868165,0.0007818834,0.000088468805,0.00013829628,0.0000044224867,0.0005148921,0.00012018435,0.00004404317],"category_scores_gemma":[0.00022050345,0.0001365787,0.000230038,0.000627755,0.0010123616,0.00008282139,0.00016325279,0.0003110458,3.5650427e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017250167,0.0003521656,0.009352871,0.005691667,0.004624108,0.000023385017,0.003725459,0.013845672,0.019689757,0.0020073547,0.6876233,0.23581406],"study_design_scores_gemma":[0.037637826,0.0055819806,0.0685377,0.04734472,0.00579983,0.000046703535,0.018827721,0.0026210232,0.2875627,0.01749505,0.5075121,0.0010326445],"about_ca_topic_score_codex":0.00056916574,"about_ca_topic_score_gemma":0.00003695286,"teacher_disagreement_score":0.6187454,"about_ca_system_score_codex":0.00007410485,"about_ca_system_score_gemma":0.0003935261,"threshold_uncertainty_score":0.5569518},"labels":[],"label_agreement":null},{"id":"W4297821381","doi":"10.1016/j.annonc.2022.07.1945","title":"1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Foundation Medicine; Merck Sharp and Dohme; EMD Serono; Genentech; Unicancer; Bavarian Nordic; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Pfizer; Incyte; Ipsen; Bristol-Myers Squibb; Constellation Pharmaceuticals; Clovis Oncology; American Society of Clinical Oncology; Boston Scientific Corporation; Invitae; AstraZeneca; Advanced Accelerator Applications; Endocyte; Teva Pharmaceutical Industries; Merck; Yuhan; Gilead Sciences; Exelixis; Sanofi; Amgen","keywords":"Medicine; Clinical endpoint; Placebo; Internal medicine; Interim analysis; Biomarker; Randomization; Progression-free survival; Prednisone; Oncology; Randomized controlled trial; Chemotherapy; Pathology","score_opus":0.09282910501671691,"score_gpt":0.408646793756521,"score_spread":0.3158176887398041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297821381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840085,0.0016375243,0.000006357843,0.0072463197,0.00005987687,0.0036237396,0.003355908,0.000008616369,0.000053180367],"genre_scores_gemma":[0.99363184,0.0034556307,0.0002051912,0.0002885706,0.000032906795,0.0007262774,0.001307362,0.000020288733,0.00033192334],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99808824,0.00026623427,0.00058891944,0.00042788105,0.0003443374,0.00028436395],"domain_scores_gemma":[0.9981663,0.0005065286,0.0004618967,0.00024239087,0.0004992281,0.00012364073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006675833,0.00020367022,0.00075024366,0.00018319782,0.00023862385,0.000021077705,0.000084491716,0.000056438777,0.00008799042],"category_scores_gemma":[0.0001252403,0.000117522206,0.00006889398,0.00046959738,0.00039790105,0.00008951563,0.00006850915,0.00014568017,2.5945084e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9244455,0.0027884748,0.0066571548,0.00008482805,0.004990108,0.000037815338,0.0035159206,0.000033763776,0.0036997611,0.000009158488,0.0027026492,0.051034845],"study_design_scores_gemma":[0.7956372,0.11249376,0.04049631,0.00010427637,0.0032085436,0.000009719946,0.001663328,0.0016078241,0.011273523,0.0002561181,0.032880776,0.00036863136],"about_ca_topic_score_codex":0.0025927494,"about_ca_topic_score_gemma":0.0013732379,"teacher_disagreement_score":0.12880833,"about_ca_system_score_codex":0.00005657125,"about_ca_system_score_gemma":0.0004282171,"threshold_uncertainty_score":0.47924164},"labels":[],"label_agreement":null},{"id":"W4297821452","doi":"10.1016/j.annonc.2022.07.1886","title":"1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): Initial results from SPLASH","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval; BC Cancer Agency; Princess Margaret Cancer Centre; McGill University; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Oncology; Internal medicine; Prostate-specific antigen; Cancer","score_opus":0.1391257395075549,"score_gpt":0.41543875423205257,"score_spread":0.27631301472449765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297821452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98242885,0.0062689134,9.976534e-7,0.0063033924,0.00015620695,0.0017363513,0.0019300062,0.000016114374,0.0011591875],"genre_scores_gemma":[0.96708,0.031366978,0.00023813406,0.00018448217,0.00007273986,0.00017582875,0.0005371713,0.000027770664,0.00031686976],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9972923,0.00045126988,0.0008877199,0.00046535986,0.00048301672,0.00042033574],"domain_scores_gemma":[0.99846077,0.00047203572,0.00039617097,0.0002889887,0.00025544822,0.0001266035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009160529,0.0002073854,0.0007511962,0.00029800626,0.000118356824,0.0000100148,0.00012418383,0.00007733632,0.00030102173],"category_scores_gemma":[0.00008309633,0.00017337849,0.00007813016,0.0004769767,0.0003247806,0.00010385073,0.00009533354,0.00035605667,0.0000021482078],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35139954,0.0052003646,0.01518419,0.0003717152,0.0012952578,0.0019177473,0.025633369,0.00086560985,0.32554677,0.00020806919,0.0060929228,0.26628444],"study_design_scores_gemma":[0.10700575,0.040392015,0.37864408,0.00057932193,0.00017980124,0.00008947625,0.005078112,0.00027523164,0.32103503,0.0011318502,0.14488313,0.00070623023],"about_ca_topic_score_codex":0.0017929444,"about_ca_topic_score_gemma":0.00050023186,"teacher_disagreement_score":0.3634599,"about_ca_system_score_codex":0.00015808117,"about_ca_system_score_gemma":0.00083609106,"threshold_uncertainty_score":0.707017},"labels":[],"label_agreement":null},{"id":"W4297821517","doi":"10.1016/j.annonc.2022.07.1882","title":"1396P Phase II study of AZD4635 in combination with durvalumab or oleclumab in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"EMD Serono; Genentech; CTI Biopharma; Ipsen; Mirati Therapeutics; Institute for Clinical Evaluative Sciences; Calithera Biosciences; TG Therapeutics; Novocure; Eisai; Jazz Pharmaceuticals; Puma Biotechnology; Regeneron Pharmaceuticals; Sanofi; Exelixis; GlaxoSmithKline; Amgen; Pfizer; Celgene; Boston Biomedical; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Durvalumab; Nausea; Clinical endpoint; Internal medicine; Prostate cancer; Adverse effect; Cancer; Phases of clinical research; Oncology; Urology; Chemotherapy; Immunotherapy; Clinical trial; Pembrolizumab","score_opus":0.09520743144419953,"score_gpt":0.4310226322050076,"score_spread":0.33581520076080806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297821517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958047,0.00023282101,5.7840197e-7,0.0009888133,0.000038023674,0.0025407674,0.000111681424,0.00000781409,0.0002747745],"genre_scores_gemma":[0.99842894,0.00010370766,0.00005079127,0.0000838299,0.0000048186594,0.00077275175,0.0000870248,0.000023026148,0.00044512367],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9978791,0.00034600776,0.0005137038,0.0003090631,0.0005934777,0.0003586655],"domain_scores_gemma":[0.9989726,0.0000837763,0.0003075044,0.00020926424,0.00034656745,0.000080320184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049966836,0.00016589208,0.00067322573,0.0004431457,0.000084904495,0.000003725302,0.00011100538,0.000030581497,0.00020954332],"category_scores_gemma":[0.000030733554,0.000109595945,0.000028371573,0.00081508304,0.00014067511,0.00009065123,0.00008808398,0.00027276448,4.837299e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31729895,0.15144297,0.40449944,0.0007388314,0.0012751508,0.0032253806,0.030432953,0.001551633,0.0015756321,0.000064775115,0.0006469548,0.08724736],"study_design_scores_gemma":[0.20914494,0.5230556,0.24709748,0.0002881065,0.00025100677,0.000021880964,0.01526197,0.00023492637,0.0033671637,0.000071761,0.00093497563,0.0002701647],"about_ca_topic_score_codex":0.0029652119,"about_ca_topic_score_gemma":0.007830369,"teacher_disagreement_score":0.37161267,"about_ca_system_score_codex":0.00037431694,"about_ca_system_score_gemma":0.0012831423,"threshold_uncertainty_score":0.4482533},"labels":[],"label_agreement":null},{"id":"W4297964741","doi":"10.1111/cts.13372","title":"Liquid biopsy‐based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer","year":2022,"lang":"en","type":"article","venue":"Clinical and Translational Science","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada","keywords":"Prostate cancer; Prostate; Gene; Biology; Gene signature; Cancer research; Transcriptome; Gene expression; Medicine; Cancer; Internal medicine; Genetics","score_opus":0.0262907122180303,"score_gpt":0.33163811469172405,"score_spread":0.30534740247369374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297964741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963199,0.0005084414,0.00003747408,0.0023599896,0.00007295641,0.00049227336,0.00008459191,0.000016410331,0.000107966014],"genre_scores_gemma":[0.99739844,0.000039984792,0.002043135,0.0002271428,0.000022650142,0.000079553625,0.000076722295,0.0000074328254,0.00010494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984207,0.00004211823,0.00024667053,0.00040178793,0.0006241614,0.00026455976],"domain_scores_gemma":[0.99946785,0.00008648061,0.000053967473,0.000091832204,0.00012383943,0.00017600895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039569646,0.00009369834,0.00016893563,0.00011692827,0.00030270393,0.000014138581,0.000092719296,0.000016547581,0.000117526746],"category_scores_gemma":[0.000014663775,0.00006278348,0.00003232671,0.00066467334,0.00052934955,0.00013327014,0.00002849712,0.00019853115,0.000001204735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006182393,0.0004566482,0.98763746,0.000020401381,0.000008819668,0.000027952221,0.00008684787,0.0007174408,0.0016594834,0.000036663158,0.000004904726,0.0031609726],"study_design_scores_gemma":[0.0070960005,0.0012745137,0.987717,0.000032385542,0.000015029512,9.193022e-7,0.000012805394,0.0009768846,0.0021518276,0.000035409685,0.00058681803,0.00010044113],"about_ca_topic_score_codex":0.000030579165,"about_ca_topic_score_gemma":0.0000087131575,"teacher_disagreement_score":0.0030605313,"about_ca_system_score_codex":0.000028218019,"about_ca_system_score_gemma":0.00056541397,"threshold_uncertainty_score":0.25602362},"labels":[],"label_agreement":null},{"id":"W4297982007","doi":"10.1016/j.annonc.2022.08.064","title":"LBA9 Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Radiation therapy; Duration (music); Oncology; Androgen; Internal medicine; Cancer; Hormone","score_opus":0.07871350768273673,"score_gpt":0.41203610650731365,"score_spread":0.33332259882457693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297982007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96024835,0.0027857383,0.000022886632,0.03226308,0.0001472261,0.0038132542,0.0004784277,0.000008872073,0.00023215663],"genre_scores_gemma":[0.9924067,0.00509502,0.00021077138,0.000567623,0.00012471042,0.0008629753,0.0001654094,0.000021807151,0.00054497353],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983933,0.00023788505,0.0005496323,0.00023130143,0.0003737382,0.00021413407],"domain_scores_gemma":[0.99826485,0.00030230937,0.0005389613,0.00025906766,0.0005839518,0.00005085248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007132896,0.00012546402,0.00050171174,0.0001134836,0.00016770874,0.0000036754127,0.00015078296,0.000073445226,0.00007397934],"category_scores_gemma":[0.00009403005,0.00007373495,0.0001368947,0.0003086607,0.00028127653,0.000062657986,0.000034711626,0.00014672124,1.2621288e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8085598,0.0024791306,0.008771949,0.00018936624,0.0013723329,0.000011481146,0.010234758,0.0005371195,0.053369485,0.00034386592,0.0088062845,0.105324455],"study_design_scores_gemma":[0.2305059,0.1155403,0.012854258,0.00013648251,0.00012650939,0.000025442354,0.0011145351,0.0003372422,0.5057239,0.00023648258,0.13319668,0.00020224882],"about_ca_topic_score_codex":0.00048312242,"about_ca_topic_score_gemma":0.00017715326,"teacher_disagreement_score":0.5780539,"about_ca_system_score_codex":0.00014228081,"about_ca_system_score_gemma":0.001378829,"threshold_uncertainty_score":0.3006824},"labels":[],"label_agreement":null},{"id":"W4297982023","doi":"10.1016/j.annonc.2022.08.067","title":"LBA64 Duration of androgen suppression with post-operative radiotherapy (DADSPORT): A collaborative meta-analysis of aggregate data","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Meta-analysis; Duration (music); Aggregate data; Androgen suppression; Oncology; Radiation therapy; Internal medicine; Androgen; Medical physics; Pathology; Hormone","score_opus":0.1771579412029137,"score_gpt":0.46265856988304876,"score_spread":0.28550062868013504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297982023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96752733,0.014957276,0.000053760967,0.012057483,0.000032882155,0.0011193282,0.0033312845,0.000008515805,0.0009121541],"genre_scores_gemma":[0.99448913,0.0015663271,0.0008077591,0.00036279723,0.000012273631,0.00009611218,0.0018510614,0.000012359604,0.00080219726],"study_design_codex":"meta_analysis","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99829733,0.00037517108,0.00045765136,0.000289096,0.00042156546,0.00015920558],"domain_scores_gemma":[0.9977608,0.00016405268,0.0005464042,0.0005249512,0.0009388834,0.000064953405],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006371423,0.00012226506,0.0012861325,0.0003796969,0.000067460096,0.00000269734,0.000197495,0.00005277952,0.0015436324],"category_scores_gemma":[0.000050324852,0.00007607905,0.00020688737,0.0011963912,0.00023245564,0.00011787535,0.00011582253,0.00012285242,3.8682802e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052893743,0.006187547,0.025047803,0.0002746297,0.68180674,0.0005920628,0.020282134,0.0022466616,0.17667517,0.00054914533,0.01789502,0.015549327],"study_design_scores_gemma":[0.014243132,0.07278574,0.013477703,0.00004056816,0.15996,0.00007814701,0.0103142755,0.0030940073,0.6681592,0.0000957743,0.057310123,0.00044136087],"about_ca_topic_score_codex":0.00018925323,"about_ca_topic_score_gemma":0.00010905845,"teacher_disagreement_score":0.5218468,"about_ca_system_score_codex":0.000046559533,"about_ca_system_score_gemma":0.0008904419,"threshold_uncertainty_score":0.9993691},"labels":[],"label_agreement":null},{"id":"W4297995279","doi":"10.1016/j.annonc.2022.07.1904","title":"1418P Extensive alteration of androgen precursor levels after castration in prostate cancer patients and their association with active androgen level: Importance for treatment intensification","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Androgen; Castration; Internal medicine; Endocrinology; Oncology; Cancer; Hormone","score_opus":0.10387857745286748,"score_gpt":0.3878932807247417,"score_spread":0.2840147032718742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297995279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994284,0.0006019686,0.000014767207,0.0021026258,0.000037659145,0.0019132966,0.0009847077,0.0000044815647,0.00005652734],"genre_scores_gemma":[0.99725676,0.00044380844,0.00011614723,0.0001490338,0.000017005714,0.0014328026,0.00034566227,0.000011966129,0.00022683122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910045,0.00009003005,0.00027048684,0.00021720755,0.00014737959,0.00017447806],"domain_scores_gemma":[0.998673,0.00009573657,0.00034437634,0.00008069424,0.00076588115,0.000040308496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019531176,0.000106977466,0.00032566136,0.000118834956,0.00004684214,0.0000037030982,0.000023656736,0.00004783465,0.000018076982],"category_scores_gemma":[0.00004575178,0.00007745259,0.000038821945,0.00014041968,0.000046553007,0.00010703907,0.000016087626,0.00005666329,1.3713223e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021964584,0.0017542029,0.78795516,0.00014383502,0.00064848264,0.000017377955,0.016923234,0.00008647,0.011549513,0.00003924161,0.00039154806,0.15852633],"study_design_scores_gemma":[0.011412724,0.022923678,0.6370611,0.00007668064,0.00013097802,0.000012507603,0.0022523864,0.0003196436,0.32304212,0.00035451344,0.002258227,0.00015539645],"about_ca_topic_score_codex":0.00014680135,"about_ca_topic_score_gemma":0.00041691042,"teacher_disagreement_score":0.3114926,"about_ca_system_score_codex":0.0005111106,"about_ca_system_score_gemma":0.0005081868,"threshold_uncertainty_score":0.3158425},"labels":[],"label_agreement":null},{"id":"W4298139317","doi":"10.1200/jco.2022.40.28_suppl.238","title":"Bone mineral density testing and the risk of fractures in men initiating androgen-deprivation therapy: Population-based study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Androgen deprivation therapy; Bone mineral; Incidence (geometry); Cohort; Prostate cancer; Internal medicine; Population; Retrospective cohort study; Cohort study; Osteoporosis; Surgery; Physical therapy; Cancer","score_opus":0.14026530696661274,"score_gpt":0.4744846231375586,"score_spread":0.3342193161709459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298139317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964658,0.0005954699,0.0000073620063,0.0023205532,0.00008785782,0.00037989966,0.0000019724391,0.0000024607345,0.00013862064],"genre_scores_gemma":[0.9985634,0.00012284738,0.00070230913,0.00041929915,0.00016524213,0.000009137251,0.0000024643807,0.000005768554,0.000009530535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99702924,0.0013404647,0.0011069184,0.000093803705,0.00033193076,0.00009762974],"domain_scores_gemma":[0.99202263,0.006419648,0.001215643,0.00008613782,0.00019614244,0.000059772898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064617447,0.000060341874,0.0006553793,0.00010885991,0.00010172046,0.000004439059,0.000059392758,0.000056462497,0.000031364772],"category_scores_gemma":[0.00636097,0.00003276352,0.00010540427,0.00018165197,0.00008121723,0.000037247464,0.000048589463,0.0007758137,8.3882206e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008805118,0.0009476155,0.94326365,0.0000055364903,0.00014098527,0.00013797385,0.00035113035,0.0003698017,0.00007057459,0.00000471838,0.000031236716,0.045871682],"study_design_scores_gemma":[0.024158593,0.00557671,0.96727335,0.000015544412,0.00009995175,0.00003437777,0.00048944453,0.0016647404,0.000031676,0.00057620136,0.000051385286,0.000028001226],"about_ca_topic_score_codex":0.00036480336,"about_ca_topic_score_gemma":0.00006738419,"teacher_disagreement_score":0.04584368,"about_ca_system_score_codex":0.00010000198,"about_ca_system_score_gemma":0.0005258857,"threshold_uncertainty_score":0.7615135},"labels":[],"label_agreement":null},{"id":"W4298423140","doi":"10.17615/ktmt-6886","title":"HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG)","year":2021,"lang":"en","type":"article","venue":"UNC Libraries","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Human Genome Research Institute; Medical Research Council; National Institutes of Health; Universität Ulm; Technische Universität München; Cancer Council Victoria; Cancerfonden; National Institute for Health and Care Research; National Health and Medical Research Council; Pirkanmaan Sairaanhoitopiiri; Cancer Research UK; Centers for Disease Control and Prevention; Tampereen Yliopisto; Royal Marsden NHS Foundation Trust; Huntsman Cancer Institute; European Commission; Université Laval; Northwestern University; Fred Hutchinson Cancer Research Center","keywords":"Prostate cancer; Genetics; Oncology; Medicine; Cancer; Biology; Internal medicine","score_opus":0.054710442282259464,"score_gpt":0.3303562215361277,"score_spread":0.27564577925386824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298423140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.779011,0.028687602,0.00031172438,0.14802124,0.0015892113,0.0047035646,0.03707332,0.0001336507,0.00046867377],"genre_scores_gemma":[0.7215103,0.02502794,0.040350486,0.016952733,0.005540296,0.009557623,0.018062396,0.00031648454,0.16268176],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99796444,0.00004600732,0.00044675992,0.00066065014,0.00040095166,0.00048116274],"domain_scores_gemma":[0.9979492,0.0005554006,0.00015120472,0.0005118305,0.0006789796,0.00015341486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021761602,0.00024122045,0.00034105298,0.000041542644,0.00028911472,0.00025404652,0.00024093574,0.0001038299,0.00035468882],"category_scores_gemma":[0.00031968928,0.00015871479,0.00017857878,0.00019367157,0.0003610393,0.00021161122,0.00017361277,0.00017612458,0.0000053018052],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034491282,0.0007475276,0.4301815,0.000668075,0.0032410603,0.000097814445,0.024386039,0.000104800965,0.041133527,0.0034991289,0.39148256,0.069966696],"study_design_scores_gemma":[0.014126167,0.00044693434,0.025217492,0.0002514979,0.00034357028,0.000004993072,0.0014389944,0.0014551762,0.5749169,0.02465855,0.35679078,0.00034896066],"about_ca_topic_score_codex":0.000995996,"about_ca_topic_score_gemma":0.0009930381,"teacher_disagreement_score":0.5337834,"about_ca_system_score_codex":0.00020245949,"about_ca_system_score_gemma":0.0022708515,"threshold_uncertainty_score":0.6472201},"labels":[],"label_agreement":null},{"id":"W4299907971","doi":"10.17615/k0er-5480","title":"Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27","year":2020,"lang":"en","type":"article","venue":"UNC Libraries","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Pfizer; Canadian Cancer Society Research Institute; Avon Foundation for Women","keywords":"Aromatase; Medicine; Breast cancer; Adjuvant; Aromatase inhibitor; Oncology; Gynecology; Cancer; Internal medicine","score_opus":0.05710974613826852,"score_gpt":0.3086222942155729,"score_spread":0.2515125480773044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4299907971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939615,0.00074625586,0.000008500784,0.0034761631,0.000028754184,0.0007548722,0.00046030304,0.000059532005,0.0005041192],"genre_scores_gemma":[0.99841166,0.000042868833,0.0005020397,0.00032750194,0.00013096351,0.00016967388,0.00013773823,0.000035506266,0.000242074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887866,0.00003431874,0.00022490996,0.00026804913,0.0002395063,0.00035455247],"domain_scores_gemma":[0.9994095,0.00011049205,0.000080577935,0.0001431529,0.000054327502,0.00020192715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000067697765,0.00017443352,0.00039561887,0.000117148455,0.00005230183,0.00003430739,0.00007852855,0.00005923603,0.000113029586],"category_scores_gemma":[0.000029299727,0.00011266934,0.000043859545,0.00033093998,0.00012740682,0.00018838809,0.00003817518,0.00015470681,0.0000054900565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02504514,0.00032807037,0.9560482,0.00064717646,0.0002714691,0.00018526778,0.008447398,0.000052967163,0.0014601005,0.0009683862,0.0009796702,0.005566142],"study_design_scores_gemma":[0.02566576,0.007781556,0.8331359,0.0024520373,0.00019887078,0.000018800347,0.005858474,0.00088817906,0.120355606,0.0009815104,0.0020933864,0.000569902],"about_ca_topic_score_codex":0.00049335376,"about_ca_topic_score_gemma":0.000018766163,"teacher_disagreement_score":0.122912295,"about_ca_system_score_codex":0.000117643096,"about_ca_system_score_gemma":0.00027953403,"threshold_uncertainty_score":0.4594522},"labels":[],"label_agreement":null},{"id":"W4301398333","doi":"10.1016/j.eururo.2022.09.021","title":"Reply to Yongbao Wei, Haijian Huang, and Liefu Ye’s Letter to the Editor re: George J. Netto, Mahul B. Amin, Daniel M. Berney, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs—Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022;82:469–82.","year":2022,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Cancer Research UK; Francis Crick Institute; World Health Organization","keywords":"George (robot); Medicine; Humanities; Art history; Philosophy; History","score_opus":0.01562154517120196,"score_gpt":0.2543308733572933,"score_spread":0.23870932818609136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301398333","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10985256,0.0030553204,0.000008332102,0.88018185,0.0014474557,0.003359031,0.00059761404,0.00006547234,0.0014323861],"genre_scores_gemma":[0.2002117,0.001012856,0.000045966186,0.7369292,0.006728227,0.00023932026,0.0013444772,0.00041793293,0.053070348],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99427724,0.0024769695,0.0008678028,0.0010182245,0.0007149062,0.0006448564],"domain_scores_gemma":[0.9973656,0.00035811696,0.0006397566,0.0012006662,0.00022823112,0.00020760891],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018989821,0.0004813199,0.0007057543,0.00033914746,0.0004971602,0.000069164904,0.00056392065,0.000111859954,0.00020518093],"category_scores_gemma":[0.00023339168,0.00029724673,0.00008395574,0.00084523024,0.00044133156,0.000104728475,0.0010003113,0.0019738027,0.000019569998],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057481043,0.00016925798,0.009835553,0.00044688245,0.00012667687,0.0008554448,0.0023532326,0.0000037673242,0.00083943567,0.000021585425,0.9845523,0.00022101392],"study_design_scores_gemma":[0.000960141,0.0030586836,0.09454511,0.00014594109,0.00016185871,0.0016522403,0.0004346431,0.000020684078,0.0000651983,0.000002946827,0.89871377,0.00023878823],"about_ca_topic_score_codex":0.00012843928,"about_ca_topic_score_gemma":0.00001946073,"teacher_disagreement_score":0.14325266,"about_ca_system_score_codex":0.0001803407,"about_ca_system_score_gemma":0.00030195725,"threshold_uncertainty_score":0.99994797},"labels":[],"label_agreement":null},{"id":"W4302029121","doi":"10.1016/j.esmoop.2022.100597","title":"The current role of precision surgery in oligometastatic prostate cancer","year":2022,"lang":"en","type":"review","venue":"ESMO Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Current (fluid); Oncology; Prostate; Cancer; Medical physics; Internal medicine; Geology; Oceanography","score_opus":0.14927890532467877,"score_gpt":0.46674198326922145,"score_spread":0.31746307794454265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4302029121","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008131778,0.99347967,5.9628455e-8,0.00013383287,0.00033418406,0.0043409117,0.00014489346,0.0000066013804,0.0014785202],"genre_scores_gemma":[0.000027935297,0.9928096,0.000008386951,0.000006849553,0.0000425354,0.0035473066,0.00035343567,0.00004430019,0.0031596548],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771506,0.00038031687,0.00069064525,0.00035456335,0.0005016255,0.00035781955],"domain_scores_gemma":[0.9980212,0.0010176336,0.0003245995,0.00049995864,0.00004521518,0.00009140656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013709773,0.00024269885,0.0015148325,0.00026007197,0.000119064236,0.000057764257,0.0005049792,0.00003860805,0.00074807357],"category_scores_gemma":[0.00016576072,0.00012780349,0.00028867248,0.0007879068,0.00008105195,0.00007457378,0.00065547373,0.0006255811,0.000022882532],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015088798,0.00014312853,0.00044787073,0.0055627236,0.00016686754,0.000034750585,0.000127452,4.1112685e-7,4.658288e-8,0.000011718596,0.0023103885,0.99104375],"study_design_scores_gemma":[0.0004061442,0.0000742795,0.00025340464,0.012528511,0.00027632716,0.000007938533,0.000048537786,0.0000027890524,0.0000046266096,0.00010971166,0.9861691,0.00011861622],"about_ca_topic_score_codex":0.0011734288,"about_ca_topic_score_gemma":0.00024543228,"teacher_disagreement_score":0.99092513,"about_ca_system_score_codex":0.00046950165,"about_ca_system_score_gemma":0.0026729063,"threshold_uncertainty_score":0.8190881},"labels":[],"label_agreement":null},{"id":"W4303650164","doi":"10.1038/s41391-022-00592-9","title":"Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide","year":2022,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Urology; Cancer","score_opus":0.0189712351618547,"score_gpt":0.31427866208773236,"score_spread":0.29530742692587764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303650164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859548,0.0015294251,0.0000032978492,0.00057519233,0.00006797782,0.00512074,0.006595051,0.00008429466,0.00006919698],"genre_scores_gemma":[0.9894404,0.0010512598,0.00012437993,0.00042476587,0.000035956764,0.004491098,0.0026496095,0.00012616099,0.0016564109],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959604,0.00024366543,0.0007826578,0.000957266,0.0011367662,0.0009192382],"domain_scores_gemma":[0.99781686,0.00023539206,0.0004715006,0.00036543098,0.00053588394,0.00057492097],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003105923,0.0005856273,0.0010139442,0.00027710688,0.00044101055,0.00014675705,0.00013615168,0.000048443348,0.00021012327],"category_scores_gemma":[0.000069855516,0.00037624358,0.00007291085,0.0010230625,0.0005450046,0.00030791466,0.00009193251,0.00054639496,0.0000021162903],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03244549,0.001978491,0.94597924,0.00060990517,0.00081168424,0.0006410063,0.0015164752,0.00015957654,0.000034383644,0.0000053154936,0.00014189724,0.01567652],"study_design_scores_gemma":[0.025736183,0.0077765263,0.962042,0.001153957,0.0010336033,0.000008034705,0.0009845484,0.0003200252,0.000045559023,0.000024977415,0.00030094123,0.00057369337],"about_ca_topic_score_codex":0.00070625695,"about_ca_topic_score_gemma":0.00052615185,"teacher_disagreement_score":0.016062697,"about_ca_system_score_codex":0.0006503282,"about_ca_system_score_gemma":0.0019433214,"threshold_uncertainty_score":0.9998689},"labels":[],"label_agreement":null},{"id":"W4304013933","doi":"10.1097/ju.0000000000002923.01","title":"Editorial Comment","year":2022,"lang":"es","type":"editorial","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Androgen; Androgen deprivation therapy; Castration; Gynecology; Urology; Oncology; Internal medicine; Cancer; Hormone","score_opus":0.01794442492974572,"score_gpt":0.3332479323845863,"score_spread":0.31530350745484054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304013933","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00059033395,0.013151325,0.0000071487493,0.034075785,0.9509787,0.000364256,0.00009767875,0.000006917655,0.0007278341],"genre_scores_gemma":[0.0026168309,0.030989423,0.000005733811,0.0006073973,0.9642331,0.000011185879,0.00007123508,0.000052369116,0.0014127019],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99448746,0.0015411027,0.0009081961,0.00018411136,0.0022638554,0.00061527936],"domain_scores_gemma":[0.99393207,0.003484297,0.0011213002,0.0004728766,0.0007406295,0.00024881208],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004110693,0.0003432482,0.0010069731,0.0003080217,0.00038339497,0.000030519674,0.0010136674,0.00058864633,0.002955741],"category_scores_gemma":[0.00091868866,0.000189566,0.00036643186,0.00021131324,0.0004314131,0.000060950344,0.00044677703,0.0052960212,0.00007215517],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018452793,0.00037899287,0.000106410946,0.00007141234,0.0014086877,0.00029303238,0.00071122893,0.000034406716,0.00018663633,0.000024257068,0.977396,0.0009361419],"study_design_scores_gemma":[0.0070931893,0.012347309,0.00004173043,0.00004516918,0.0019210861,0.00022248345,0.00033762484,0.0000049359446,0.00003266412,0.00022748284,0.9775925,0.00013380236],"about_ca_topic_score_codex":0.00009431577,"about_ca_topic_score_gemma":0.0000030394938,"teacher_disagreement_score":0.033468388,"about_ca_system_score_codex":0.0006997691,"about_ca_system_score_gemma":0.0023909553,"threshold_uncertainty_score":0.9979557},"labels":[],"label_agreement":null},{"id":"W4304891956","doi":"10.1016/j.clgc.2022.10.003","title":"Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Population; Hazard ratio; Prostate cancer; Proportional hazards model; Cancer; Urology","score_opus":0.05194096266369281,"score_gpt":0.39466579880682723,"score_spread":0.3427248361431344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304891956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96149224,0.03588325,0.0000035010025,0.00085256377,0.00054747134,0.000734909,0.00035810145,0.000025304424,0.00010263578],"genre_scores_gemma":[0.98308504,0.003480675,0.00032509913,0.00028856384,0.00012457749,0.0005327679,0.000110849294,0.000025773748,0.01202663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976288,0.00025567602,0.000698215,0.0005339118,0.00055064895,0.00033272375],"domain_scores_gemma":[0.9986535,0.00026183753,0.00031527027,0.00036640072,0.00017743371,0.00022556435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052504364,0.00019468684,0.0006386785,0.00027684605,0.00013120253,0.000007669242,0.00013587506,0.000041005034,0.0009125065],"category_scores_gemma":[0.000054985485,0.00016328639,0.00030415188,0.00059931446,0.00024805532,0.00006459656,0.0001183461,0.00050415477,0.0000012108509],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005515896,0.00048483288,0.98007345,0.000814641,0.0011894731,0.00036576303,0.00023691452,0.0012252482,0.0011857336,0.0000015021183,0.0016391315,0.0072673955],"study_design_scores_gemma":[0.0034692339,0.0014569064,0.9828084,0.00011875641,0.0020638348,0.0000069512143,0.000097246026,0.007138248,0.00011251515,0.000015199961,0.0025082608,0.00020445125],"about_ca_topic_score_codex":0.0016515052,"about_ca_topic_score_gemma":0.00014077961,"teacher_disagreement_score":0.03240258,"about_ca_system_score_codex":0.0010961546,"about_ca_system_score_gemma":0.0017401113,"threshold_uncertainty_score":0.9991306},"labels":[],"label_agreement":null},{"id":"W4304893762","doi":"10.1016/j.ijrobp.2022.07.026","title":"Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It?","year":2022,"lang":"en","type":"letter","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Radiation therapy; Internal medicine; Radiology","score_opus":0.045610500003330744,"score_gpt":0.3859553363625946,"score_spread":0.3403448363592639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304893762","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022300307,0.011800721,0.0017992621,0.94363225,0.014340863,0.0026990224,0.0016922745,0.00009780894,0.0016374998],"genre_scores_gemma":[0.15824993,0.059941262,0.0025267522,0.66794974,0.08917504,0.0010739168,0.015599616,0.00050454197,0.0049791983],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99658495,0.0004845203,0.0011407507,0.00047023434,0.0008222639,0.00049730187],"domain_scores_gemma":[0.9950837,0.0010694833,0.0020367166,0.00030923245,0.0013554278,0.0001454702],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093184924,0.00043596365,0.0010037113,0.000642072,0.0001818517,0.0000921577,0.00069516717,0.00070454803,0.00084636576],"category_scores_gemma":[0.0003307847,0.00036209932,0.0007332488,0.00027291602,0.00018891794,0.0003283185,0.000091493486,0.002259937,0.000032908138],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003375921,0.00070955494,0.01762817,0.00006570677,0.0062548416,0.00046911836,0.00048211584,0.000042198677,0.0004860147,0.00045920475,0.774827,0.19520013],"study_design_scores_gemma":[0.012839118,0.0048032124,0.0013616454,0.00006869174,0.00045863082,0.00035874685,0.00005941988,0.00016305104,0.0005383967,0.0029782238,0.9760807,0.00029014435],"about_ca_topic_score_codex":0.000017206305,"about_ca_topic_score_gemma":6.6428663e-7,"teacher_disagreement_score":0.2756825,"about_ca_system_score_codex":0.002947898,"about_ca_system_score_gemma":0.0020826051,"threshold_uncertainty_score":0.9998831},"labels":[],"label_agreement":null},{"id":"W4306724295","doi":"10.1200/jco.21.02947","title":"Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Novartis Institutes for BioMedical Research; EMD Serono; Genentech; Sierra Oncology; PharmaMar; Astellas Pharma; Eisai; G1 Therapeutics; National Institute of Environmental Health Sciences; MacroGenics; Silverback Therapeutics; INOVIO Pharmaceuticals; Cardinal Health; Puma Biotechnology; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; Agios Pharmaceuticals; Ipsen; Array BioPharma; Five Prime Therapeutics; Halozyme; Mirati Therapeutics; Clovis Oncology; Astex Pharmaceuticals; PTC Therapeutics; Sanofi; Exelixis; GlaxoSmithKline; Amgen; Pfizer; Invitae; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Olaparib; Medicine; Prostate cancer; Internal medicine; Hazard ratio; PARP inhibitor; Oncology; Urology; Progression-free survival; Clinical endpoint; Randomized controlled trial; Cancer; Gastroenterology; Overall survival; Poly ADP ribose polymerase; Confidence interval","score_opus":0.27304451516687994,"score_gpt":0.5330496930102513,"score_spread":0.26000517784337135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306724295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95238817,0.0015943565,0.000113253736,0.036239844,0.0028938677,0.004702331,0.0012569409,0.000008445305,0.0008027771],"genre_scores_gemma":[0.9895,0.002093617,0.0027666292,0.0008601725,0.0015788763,0.0008598447,0.000080682665,0.00002125535,0.002238934],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99502355,0.0009269883,0.0025366826,0.00022391485,0.0010664073,0.00022245875],"domain_scores_gemma":[0.9890518,0.0068389806,0.0026108597,0.0001480177,0.0011746071,0.00017574341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074472534,0.00014771496,0.0019433306,0.000108025364,0.00017778817,0.000013580901,0.00020402478,0.00007563251,0.00019072632],"category_scores_gemma":[0.0042070146,0.00006560229,0.00044463723,0.00022693846,0.00058671867,0.000118246026,0.000043878186,0.0007396054,4.4897334e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9837683,0.0012022622,0.0003802398,0.0000341587,0.0024203013,0.00011959177,0.00050718384,0.0006804765,0.00013455849,0.00015621156,0.0032694729,0.007327239],"study_design_scores_gemma":[0.92902356,0.017477859,0.0005108135,0.00010494278,0.0015752671,0.000037581995,0.0003772866,0.00065459235,0.00013100749,0.00074571266,0.049281742,0.00007963689],"about_ca_topic_score_codex":0.0009935194,"about_ca_topic_score_gemma":0.001839004,"teacher_disagreement_score":0.054744747,"about_ca_system_score_codex":0.00041025665,"about_ca_system_score_gemma":0.015284167,"threshold_uncertainty_score":0.9902983},"labels":[],"label_agreement":null},{"id":"W4306809801","doi":"10.1038/s41598-022-21593-7","title":"Efficacy of PACE4 pharmacotherapy in JHU-LNCaP-SM preclinical model of androgen independent prostate cancer","year":2022,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aptose Biosciences (Canada); Oncolytics Biotech (Canada); Université de Sherbrooke","funders":"Canadian Institutes of Health Research","keywords":"LNCaP; Prostate cancer; Cancer research; Androgen; Prostate; Medicine; Cancer; Internal medicine; Hormone","score_opus":0.06602063921055258,"score_gpt":0.40348370413369233,"score_spread":0.33746306492313977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306809801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99502856,0.0019907986,0.0000051937627,0.00042126275,0.00085246743,0.001236778,0.00004629003,0.000016814884,0.0004018506],"genre_scores_gemma":[0.9914392,0.00020973719,0.00008900707,0.000020824706,0.000027500535,0.00020200307,0.0000698428,0.00001928915,0.007922591],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972461,0.00008431636,0.0007547501,0.00057412055,0.0010234467,0.00031728233],"domain_scores_gemma":[0.9987876,0.00004635417,0.00035484452,0.0005139011,0.00015712314,0.00014018657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018146746,0.00012089844,0.00039993133,0.00030061696,0.000106657564,0.000015286201,0.00011323211,0.0000408389,0.00046500674],"category_scores_gemma":[0.000045789726,0.00009760456,0.00013785293,0.00064391276,0.0002817763,0.0000665948,0.00013603625,0.0002730113,0.0000010241572],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024384866,0.0021524413,0.7005961,0.00028289336,0.0002725085,0.00075995404,0.004740196,0.007129617,0.24863653,0.000010632683,0.005396106,0.027584538],"study_design_scores_gemma":[0.01940479,0.0012005637,0.047826048,0.00040267798,0.0002946113,0.00020780555,0.0007501324,0.013967977,0.89253414,0.003009112,0.019858675,0.00054345606],"about_ca_topic_score_codex":0.00011420318,"about_ca_topic_score_gemma":0.000011672111,"teacher_disagreement_score":0.65277004,"about_ca_system_score_codex":0.00020229342,"about_ca_system_score_gemma":0.0013804776,"threshold_uncertainty_score":0.5091498},"labels":[],"label_agreement":null},{"id":"W4306830909","doi":"10.4103/aja202263","title":"Investigation of androgen receptor-dependent alternative splicing has identified a unique subtype of lethal prostate cancer","year":2022,"lang":"en","type":"article","venue":"Asian Journal of Andrology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Calgary; Jewish General Hospital","funders":"Prostate Cancer Canada","keywords":"Exon; RNA splicing; Alternative splicing; Biology; Androgen receptor; Cancer research; Exon skipping; Prostate cancer; Exonic splicing enhancer; RNA-binding protein; Genetics; RNA; Gene; Cancer","score_opus":0.046460937818842106,"score_gpt":0.3162958746677814,"score_spread":0.26983493684893933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306830909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924691,0.0014151346,0.000035114255,0.0052307975,0.00028040333,0.0002696158,0.000035348086,0.000003432694,0.00026111054],"genre_scores_gemma":[0.9988234,0.00040386402,0.00013971371,0.00006546777,0.00008245644,0.000014783586,0.000015962965,0.000013481775,0.00044086494],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99862564,0.00022624852,0.00047673253,0.00012531421,0.00036651688,0.0001795577],"domain_scores_gemma":[0.998803,0.00003732353,0.00060732465,0.00010958899,0.0003317204,0.00011102567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057641894,0.000092570335,0.00039378158,0.00028440348,0.00007583314,0.0000054887005,0.00012215436,0.000044936976,0.00029113615],"category_scores_gemma":[0.000035989375,0.000074543874,0.00009737088,0.00021719553,0.00021916925,0.00007995258,0.00006293528,0.000351575,8.5582417e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012349992,0.00033572566,0.47282833,0.00034567158,0.0017512904,0.0010213876,0.02488816,0.00040647818,0.47209775,0.00030898734,0.0021198222,0.011546395],"study_design_scores_gemma":[0.012709588,0.012511502,0.026213871,0.0003528488,0.00042308818,0.002016307,0.00425308,0.00010754077,0.935831,0.0033187931,0.0020547542,0.00020759946],"about_ca_topic_score_codex":0.00020062637,"about_ca_topic_score_gemma":0.000022641538,"teacher_disagreement_score":0.4637333,"about_ca_system_score_codex":0.00015356146,"about_ca_system_score_gemma":0.00079874124,"threshold_uncertainty_score":0.3187737},"labels":[],"label_agreement":null},{"id":"W4306932585","doi":"10.1016/j.urolonc.2022.09.010","title":"UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer","year":2022,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; London Health Sciences Centre; Western University; Sunnybrook Health Science Centre; Health Sciences Centre; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"Joseph and Silvana Melara Cancer Research Fund","keywords":"Docetaxel; Medicine; Prostate cancer; Cabazitaxel; Androgen deprivation therapy; Oncology; Internal medicine; Prostate-specific antigen; Cancer; Urology","score_opus":0.051539667060191724,"score_gpt":0.35441702149511206,"score_spread":0.30287735443492037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306932585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9672198,0.011094403,0.000012552763,0.019242225,0.00014671881,0.0014828403,0.00018793129,0.00002505893,0.00058842264],"genre_scores_gemma":[0.9874442,0.0020597011,0.006026781,0.0010701312,0.00009987068,0.0021471805,0.00020057806,0.000017646838,0.00093391177],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988673,0.00017379159,0.00022999672,0.0002613108,0.00021198727,0.00025565948],"domain_scores_gemma":[0.9991816,0.0003629137,0.00013431795,0.00012862084,0.00009012614,0.000102391445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005137859,0.000140489,0.00031354243,0.00009084178,0.0005693868,0.000010495193,0.00007904005,0.00005288517,0.000053111686],"category_scores_gemma":[0.000047452864,0.00009254371,0.00010073524,0.0002000098,0.00040905934,0.000060813374,0.00004191377,0.00029218732,6.2318026e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01151984,0.0037270705,0.5873843,0.00027050375,0.005250045,0.000654122,0.03983609,0.0011402881,0.14665799,0.02920857,0.01534282,0.15900838],"study_design_scores_gemma":[0.0053946064,0.008396041,0.0035356393,0.00003580181,0.0006140049,0.00021529937,0.008983147,0.0027736046,0.011477927,0.018226188,0.9401298,0.00021792944],"about_ca_topic_score_codex":0.00012405279,"about_ca_topic_score_gemma":0.000039061393,"teacher_disagreement_score":0.924787,"about_ca_system_score_codex":0.00016675303,"about_ca_system_score_gemma":0.0007723108,"threshold_uncertainty_score":0.43793207},"labels":[],"label_agreement":null},{"id":"W4307146668","doi":"10.1016/j.ijrobp.2022.07.1187","title":"Development and Validation of a Multivariable Prognostic Model in De Novo Metastatic Castrate Sensitive Prostate Cancer: Exploring Potential Avenue for Risk Stratification and Treatment Personalization","year":2022,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Confidence interval; Internal medicine; Proportional hazards model; Oncology; Cancer","score_opus":0.07038823701742254,"score_gpt":0.36338405760664394,"score_spread":0.2929958205892214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307146668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818325,0.000317692,0.01637382,0.00048497296,0.0001696697,0.0006056954,0.0002030996,0.0000053784906,0.0000071417167],"genre_scores_gemma":[0.9870572,0.001262102,0.011015555,0.000020726018,0.00011078024,0.00027653313,0.00022078677,0.000012582362,0.000023747913],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99900466,0.0001370954,0.00039872754,0.00015743055,0.00016772651,0.00013438187],"domain_scores_gemma":[0.99886864,0.00014095279,0.0005391225,0.000038132664,0.0003577827,0.00005535081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047841086,0.00010322956,0.0002507327,0.0001538041,0.00010033126,0.000013595541,0.000045039716,0.000035007928,0.0000039075862],"category_scores_gemma":[0.00007707845,0.000092781935,0.00004234301,0.000096435826,0.00006030599,0.00016237856,0.000022351294,0.00013826766,1.12154446e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047888574,0.0013108779,0.5073547,0.00010704769,0.0014446947,0.00007189323,0.026696647,0.1291652,0.061436288,0.002411204,0.000010710572,0.26520193],"study_design_scores_gemma":[0.03876872,0.005275859,0.09420657,0.00027078233,0.0010052437,0.00039747616,0.0063955025,0.74427587,0.099533975,0.008565179,0.0008915956,0.00041320713],"about_ca_topic_score_codex":0.000051835013,"about_ca_topic_score_gemma":0.000011434625,"teacher_disagreement_score":0.6151107,"about_ca_system_score_codex":0.0011495997,"about_ca_system_score_gemma":0.0010504193,"threshold_uncertainty_score":0.37835374},"labels":[],"label_agreement":null},{"id":"W4307153601","doi":"10.1016/j.euo.2022.09.007","title":"Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers","year":2022,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Genitourinary system; Prospective cohort study; Clinical trial; Oncology; Radiosurgery; Radiation therapy; Cancer; Prostate; Internal medicine","score_opus":0.14529858941571672,"score_gpt":0.46872939060602287,"score_spread":0.32343080119030615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307153601","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003087839,0.986945,0.000002004107,0.0002629799,0.00026215683,0.009468956,0.00020161254,0.000026467078,0.002522042],"genre_scores_gemma":[0.00041084483,0.995847,0.000110941626,0.00021905928,0.00016762047,0.0024639962,0.0005445067,0.00009087639,0.00014518185],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9863117,0.010809801,0.0017067255,0.0005416731,0.00021889377,0.00041122857],"domain_scores_gemma":[0.99285895,0.00447858,0.0019309528,0.0005139434,0.00014058525,0.000077009136],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004624735,0.00043054656,0.0044495733,0.0005305312,0.000098024124,0.000006699253,0.0002757292,0.000117379095,0.0003530034],"category_scores_gemma":[0.0010283702,0.0002452837,0.00084343634,0.00070348824,0.00025324515,0.000048956976,0.00008391723,0.0004859468,0.000004768966],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090928044,0.000777887,0.00018532657,0.012816619,0.0031277759,0.00014927358,0.00031301455,8.4371254e-7,0.000013413816,0.00001512104,0.0001832728,0.9815082],"study_design_scores_gemma":[0.0050787274,0.00943073,0.0005775709,0.002809126,0.0055729835,0.00018416095,0.00007545735,0.0000066827556,0.000019492407,0.000031528052,0.9760621,0.00015139971],"about_ca_topic_score_codex":0.00009760906,"about_ca_topic_score_gemma":0.00000988131,"teacher_disagreement_score":0.9813568,"about_ca_system_score_codex":0.001740414,"about_ca_system_score_gemma":0.0032169477,"threshold_uncertainty_score":0.99999994},"labels":[],"label_agreement":null},{"id":"W4307291215","doi":"10.1016/j.ijrobp.2022.07.542","title":"Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival Following Stereotactic Ablative Radiation Therapy in Oligometastatic Castration-Sensitive Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University; Movember Foundation; Bayer HealthCare; RefleXion Medical; Patient-Centered Outcomes Research Institute","keywords":"Medicine; Ablative case; Prostate cancer; Oncology; Radiation therapy; Metastasis; Glutamate carboxypeptidase II; Prostate-specific antigen; Internal medicine; Cancer","score_opus":0.03467823074637733,"score_gpt":0.35568026980238715,"score_spread":0.3210020390560098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307291215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98890215,0.0016404239,0.0001610416,0.00624255,0.0013912686,0.0010283951,0.00048471344,0.000029272514,0.000120168],"genre_scores_gemma":[0.99354756,0.004279325,0.0006807954,0.00033676627,0.00038505858,0.00016485371,0.00036656403,0.000053217267,0.00018588513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960729,0.00136661,0.0008479874,0.00038801198,0.0009006945,0.00042382162],"domain_scores_gemma":[0.9964144,0.0011689971,0.0012129006,0.00020155832,0.0008584072,0.00014373919],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002155354,0.00030530768,0.00076057675,0.0005329029,0.00022879743,0.00006635338,0.00032549608,0.00007652935,0.00011578055],"category_scores_gemma":[0.0002821185,0.00024805433,0.00023646883,0.00068102824,0.00016165014,0.0005582456,0.00008308135,0.0008118557,0.0000053490858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04928787,0.0019123658,0.80698746,0.000022360147,0.0069996133,0.0026521555,0.013678663,0.006707421,0.037724104,0.0007317795,0.00044741106,0.07284878],"study_design_scores_gemma":[0.114154294,0.02282363,0.77284944,0.00033917621,0.0007674315,0.0010197699,0.009349815,0.0030623532,0.044020567,0.004996623,0.025294507,0.0013224024],"about_ca_topic_score_codex":0.0001245239,"about_ca_topic_score_gemma":0.000041411615,"teacher_disagreement_score":0.07152638,"about_ca_system_score_codex":0.0030173282,"about_ca_system_score_gemma":0.0019793976,"threshold_uncertainty_score":0.9999972},"labels":[],"label_agreement":null},{"id":"W4307294130","doi":"10.1016/j.ijrobp.2022.07.460","title":"Optimal Duration of Androgen Deprivation Therapy (ADT) with Definitive Radiotherapy for Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis from the International MARCAP Consortium","year":2022,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Radiation therapy; Clinical endpoint; Randomized controlled trial; Proportional hazards model; Internal medicine; Oncology; Cancer","score_opus":0.10322665233640119,"score_gpt":0.387631058971688,"score_spread":0.28440440663528677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307294130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96458316,0.0048670853,0.009943601,0.011261433,0.0006653526,0.0011071634,0.007519712,0.000018353825,0.00003413027],"genre_scores_gemma":[0.98071337,0.0025433407,0.0066858465,0.0014083108,0.0006774645,0.00027277772,0.007644389,0.000029695402,0.000024793682],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99752057,0.0004111616,0.0007935744,0.00035527107,0.0007326867,0.00018676578],"domain_scores_gemma":[0.99615306,0.0006479309,0.0016106666,0.0003197469,0.0011875032,0.000081092825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093811005,0.0001973527,0.0006519607,0.0002288443,0.00017452324,0.00004851953,0.0008041651,0.00008062808,0.00035961],"category_scores_gemma":[0.000099034885,0.00012676054,0.00036026273,0.00031912705,0.00021004268,0.0004084695,0.00013510478,0.00034480088,5.2779706e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017906247,0.0020436835,0.51958954,0.000006631389,0.25965932,0.000039037284,0.0064656176,0.021097276,0.005569032,0.0015506111,0.0021070999,0.16396591],"study_design_scores_gemma":[0.11438576,0.04776005,0.22251403,0.00007724019,0.14036992,0.0005703527,0.010760758,0.13332327,0.06741365,0.011508459,0.24930336,0.002013159],"about_ca_topic_score_codex":0.00018949142,"about_ca_topic_score_gemma":0.000037864167,"teacher_disagreement_score":0.29707548,"about_ca_system_score_codex":0.000605767,"about_ca_system_score_gemma":0.0012348432,"threshold_uncertainty_score":0.5169144},"labels":[],"label_agreement":null},{"id":"W4307296944","doi":"10.1016/j.ijrobp.2022.07.458","title":"Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) vs. Dose Escalated Radiation Therapy and Enhanced ADT with TAK-700 for Men with High-Risk Prostate Cancer (NRG Oncology/RTOG 1115)","year":2022,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Radiation therapy; Urology; Discontinuation; Internal medicine; Oncology; External beam radiotherapy; Randomized controlled trial; Adverse effect; Cancer","score_opus":0.023654726682152762,"score_gpt":0.3547738683533663,"score_spread":0.33111914167121353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307296944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98704356,0.0037473536,0.0014101566,0.003472344,0.00053153635,0.003191306,0.0005216968,0.000042912587,0.000039154722],"genre_scores_gemma":[0.9457256,0.050855797,0.00082507666,0.00037108458,0.0007435923,0.0005090325,0.00084913115,0.00006107692,0.0000595834],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969571,0.0005744781,0.0010080409,0.00047549515,0.00062415935,0.00036070397],"domain_scores_gemma":[0.99566144,0.0005789618,0.0021916598,0.00019126062,0.0011859719,0.00019070985],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011898921,0.0003657271,0.0009167886,0.00037671378,0.00030496673,0.000048237565,0.000229011,0.00024644964,0.00007740492],"category_scores_gemma":[0.00009423978,0.00024699143,0.00014161743,0.00042639498,0.0003474927,0.000432826,0.000041706928,0.0005877554,4.6972175e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32853,0.0014609171,0.033308335,0.000010873025,0.002304628,0.000017621067,0.0024167874,0.0006910506,0.014641927,0.00017310111,0.0002460765,0.61619866],"study_design_scores_gemma":[0.7670592,0.09308975,0.042025484,0.00009316064,0.0004799828,0.000116948424,0.00041371054,0.005114083,0.063497424,0.002373626,0.025196124,0.000540515],"about_ca_topic_score_codex":0.00015907643,"about_ca_topic_score_gemma":0.000016258133,"teacher_disagreement_score":0.61565816,"about_ca_system_score_codex":0.0012591339,"about_ca_system_score_gemma":0.0018249301,"threshold_uncertainty_score":0.9999982},"labels":[],"label_agreement":null},{"id":"W4307339801","doi":"10.1038/s41391-022-00607-5","title":"Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"European Association of Urology","keywords":"Medicine; Internal medicine; Prostate cancer; Oncology; Docetaxel; Hazard ratio; Meta-analysis; Systemic therapy; Hormone therapy; Subgroup analysis; Randomized controlled trial; Cancer; Breast cancer; Confidence interval","score_opus":0.05073892592964981,"score_gpt":0.35402135942795904,"score_spread":0.30328243349830925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307339801","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007153939,0.9673433,8.166995e-7,0.00024521767,0.000016523029,0.017172446,0.008029687,0.000031310214,0.0000068138247],"genre_scores_gemma":[0.011878353,0.97633153,0.000022441962,0.00008477141,0.00000791107,0.0086314,0.0023481776,0.00008388275,0.0006115423],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99528867,0.0009504678,0.0014242299,0.00087334635,0.00096422754,0.00049903773],"domain_scores_gemma":[0.99621856,0.001129459,0.0016293579,0.0003795439,0.00035949456,0.00028360952],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00076028705,0.0007649671,0.008258291,0.0006791221,0.00016642577,0.000106108186,0.00010695274,0.00008850464,0.000050863255],"category_scores_gemma":[0.00022981179,0.00046712597,0.0005260255,0.0014591713,0.00022208963,0.0002572289,0.00012524825,0.00037806717,5.6328315e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003887436,0.0003169751,0.01954965,0.8101162,0.15515205,0.000055817527,0.0020743597,0.0000011412025,8.505421e-8,0.000006966734,0.000028465434,0.012309549],"study_design_scores_gemma":[0.004498461,0.00091105956,0.014829906,0.045699067,0.9324802,0.000005599971,0.0003506315,0.000004261532,4.2133783e-7,0.000029009268,0.0006349784,0.00055636675],"about_ca_topic_score_codex":0.00032923062,"about_ca_topic_score_gemma":0.000036033187,"teacher_disagreement_score":0.7773282,"about_ca_system_score_codex":0.00065203273,"about_ca_system_score_gemma":0.000568071,"threshold_uncertainty_score":0.99977803},"labels":[],"label_agreement":null},{"id":"W4307460092","doi":"10.5489/cuaj.8161","title":"2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC)","year":2022,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Université Laval; University of Alberta; Jewish General Hospital; McMaster University; Ontario Clinical Oncology Group; Dalhousie University; University of Toronto; McGill University Health Centre; University of British Columbia; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Guideline; Prostate cancer; Medicine; Oncology; Internal medicine; Castration; Management of prostate cancer; Urology; Cancer; Gynecology; Hormone; Pathology","score_opus":0.022412439547602928,"score_gpt":0.29933358211096855,"score_spread":0.27692114256336564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307460092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61183774,0.0036950135,0.000014121996,0.3432743,0.002554382,0.0032741404,0.0036992715,0.00008396861,0.03156707],"genre_scores_gemma":[0.98221016,0.0009730033,0.0002878452,0.008895018,0.00044382378,0.00035710272,0.0006786541,0.000041733405,0.0061126426],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944738,0.0007521779,0.0010830361,0.00054549566,0.00133701,0.0018084939],"domain_scores_gemma":[0.9951034,0.00018485793,0.00075429544,0.0002477138,0.00081483094,0.0028948765],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029504152,0.00033335778,0.00064757053,0.0009500834,0.0014969525,0.0001185262,0.00039931398,0.00046069996,0.009600283],"category_scores_gemma":[0.00039601297,0.00030180355,0.00029038647,0.0010081502,0.00007518441,0.00015240589,0.000070446695,0.0015726123,0.000043906937],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007635897,0.00026612633,0.75171757,0.000035154335,0.0014225526,0.0031231975,0.00045866298,0.00091788644,0.00047074142,0.001149696,0.22662432,0.013050515],"study_design_scores_gemma":[0.0026780616,0.0015299018,0.35732144,0.000014772239,0.0002833667,0.00012033028,0.00060414785,0.0002644134,0.000012956046,0.0005425784,0.63635385,0.00027419673],"about_ca_topic_score_codex":0.57378167,"about_ca_topic_score_gemma":0.8040539,"teacher_disagreement_score":0.4097295,"about_ca_system_score_codex":0.035203397,"about_ca_system_score_gemma":0.0089648655,"threshold_uncertainty_score":0.99994344},"labels":[],"label_agreement":null},{"id":"W4307911408","doi":"10.1016/s0959-8049(22)00994-7","title":"Molecular characterization of next generation AR-NTD inhibitors","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"LNCaP; Androgen receptor; Enzalutamide; Prostate cancer; Cancer research; Context (archaeology); Biology; Cancer; Chemistry; Pharmacology; Genetics","score_opus":0.0435423406231177,"score_gpt":0.30436734805353705,"score_spread":0.26082500743041936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307911408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398243,0.0025198816,0.00017152457,0.0017844633,0.00042169626,0.000108083215,0.000011319462,0.000004087501,0.0009965161],"genre_scores_gemma":[0.9976256,0.0007095833,0.000079013575,0.00022982016,0.00051996595,0.0000034094608,0.000023630088,0.000020800402,0.0007881986],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893427,0.00019337115,0.00028965613,0.0000704997,0.00041950063,0.000092710696],"domain_scores_gemma":[0.9993659,0.0000045743936,0.00026313265,0.000081614555,0.00021438679,0.0000703527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037906264,0.000059749163,0.00014021371,0.00012712412,0.000056051304,0.000011223257,0.00006679262,0.0000062311474,0.000440751],"category_scores_gemma":[0.000015248531,0.000047357193,0.000079766876,0.00016784942,0.000026311485,0.00008896649,0.00003604513,0.00017547999,0.0000025548734],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027525585,0.000069425616,0.0022475885,0.00002021482,0.000085937005,0.00033060947,0.0003771643,0.00013198917,0.96220106,0.000013452939,0.0008412746,0.033406038],"study_design_scores_gemma":[0.0043656803,0.0021629026,0.03495647,0.00016236102,0.0001899029,0.00017675932,0.00020952473,0.0004094343,0.85150653,0.0000073877823,0.10571511,0.00013794984],"about_ca_topic_score_codex":0.0000031359068,"about_ca_topic_score_gemma":2.552846e-7,"teacher_disagreement_score":0.110694535,"about_ca_system_score_codex":0.00013206572,"about_ca_system_score_gemma":0.00017857253,"threshold_uncertainty_score":0.48259145},"labels":[],"label_agreement":null},{"id":"W4307947785","doi":"10.3390/biom12111590","title":"Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer","year":2022,"lang":"en","type":"review","venue":"Biomolecules","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research; U.S. Department of Defense","keywords":"Prostate cancer; Druggability; Androgen receptor; Carcinogenesis; Cancer; Tumor microenvironment; Androgen; Cancer research; Phenotype; Biology; Prostate; Bioinformatics; Medicine; Gene; Internal medicine; Genetics; Hormone","score_opus":0.06912333528311727,"score_gpt":0.3923502821749386,"score_spread":0.32322694689182135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307947785","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007951018,0.98778003,6.168785e-7,0.0004118464,0.00012071916,0.003142735,0.00034248587,0.000079751866,0.00017079113],"genre_scores_gemma":[0.00048241334,0.99123883,0.00023497027,0.000024373247,0.00012944853,0.0032786857,0.00032906275,0.000079916244,0.0042022737],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99775153,0.0002126323,0.00043278173,0.00064748205,0.0005022729,0.00045326832],"domain_scores_gemma":[0.9990636,0.00005009761,0.00020382258,0.00035467942,0.00007613772,0.00025163076],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021388302,0.00040069668,0.0011132847,0.00036427475,0.0003146347,0.00009246984,0.00010841375,0.00011972054,0.0001892827],"category_scores_gemma":[0.000058314003,0.00027541592,0.00018162472,0.0005062833,0.00013175744,0.00005266301,0.00017870119,0.00028526076,0.0000074851246],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074985274,0.00018051988,0.00010654494,0.03637891,0.00042947906,0.00056751625,0.00085148436,4.2870315e-7,0.0039335885,0.000042382173,0.00033523512,0.95642406],"study_design_scores_gemma":[0.0010570675,0.00032613496,0.00023850515,0.010060907,0.0006497678,0.0000575109,0.000559168,0.000001009911,0.0033504337,0.00000868273,0.98334247,0.00034831656],"about_ca_topic_score_codex":0.00015660716,"about_ca_topic_score_gemma":0.000071932096,"teacher_disagreement_score":0.98300725,"about_ca_system_score_codex":0.00037181424,"about_ca_system_score_gemma":0.0005988931,"threshold_uncertainty_score":0.9999698},"labels":[],"label_agreement":null},{"id":"W4307970770","doi":"10.1158/1078-0432.ccr-21-3577","title":"Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and <i>BRCA1, BRCA2</i> , or <i>ATM</i> Alterations Identified by Testing Circulating Tumor DNA","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Juravinski Cancer Centre; Institute of Cancer Research","funders":"Medical Research Council; National Institute for Health and Care Research; AstraZeneca","keywords":"Olaparib; Medicine; Enzalutamide; Hazard ratio; Internal medicine; Oncology; Cohort; Prostate cancer; Population; Cancer; Confidence interval; Progression-free survival; PARP inhibitor; Chemotherapy; Poly ADP ribose polymerase; Biology; Genetics","score_opus":0.18852185491737347,"score_gpt":0.46875579997177996,"score_spread":0.28023394505440646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307970770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921794,0.0017388995,0.0000020177679,0.0021791225,0.0001397985,0.0029718825,0.0005433431,0.000043542055,0.00020199653],"genre_scores_gemma":[0.9943897,0.00022820728,0.00021282726,0.00037669,0.00011450478,0.0022246225,0.00026669967,0.000068323694,0.0021184147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947241,0.00074249436,0.0009573887,0.00094381755,0.0016897297,0.0009424589],"domain_scores_gemma":[0.9964579,0.0017898972,0.00020094069,0.00042341283,0.00069505454,0.0004328195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025824532,0.0002622158,0.00060765265,0.0002683679,0.0009190499,0.00018832607,0.00022371463,0.000048149977,0.00044859914],"category_scores_gemma":[0.0010676319,0.00019155192,0.00006611072,0.0017363636,0.0005001222,0.00023033911,0.00030236092,0.0015035344,0.0000062427325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014472854,0.0033846179,0.9432483,0.0005882742,0.00043022388,0.0006803665,0.0013696624,0.00034921692,0.0061722607,0.000028710689,0.006795404,0.022480143],"study_design_scores_gemma":[0.05532954,0.008501424,0.92249537,0.0012576901,0.0003251297,0.00003401272,0.0014575034,0.0016441467,0.0014939876,0.00011633959,0.0065314416,0.0008134172],"about_ca_topic_score_codex":0.0024385606,"about_ca_topic_score_gemma":0.0012056569,"teacher_disagreement_score":0.040856685,"about_ca_system_score_codex":0.000805454,"about_ca_system_score_gemma":0.0025124303,"threshold_uncertainty_score":0.7811261},"labels":[],"label_agreement":null},{"id":"W4308341346","doi":"10.1200/go.22.00154","title":"IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"JCO Global Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Astellas Pharma; Sanofi; Movember Foundation; AstraZeneca; Pfizer; Amgen","keywords":"Medicine; Prostate cancer; Family medicine; Cancer registry; Cohort; Government (linguistics); Population; Veterans Affairs; Cancer; Gynecology; Internal medicine; Environmental health","score_opus":0.019972567161577685,"score_gpt":0.3717071362068913,"score_spread":0.3517345690453136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308341346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8453914,0.0015520798,0.00003114623,0.019690717,0.00043739498,0.0009823886,0.00082199497,0.000046670608,0.13104622],"genre_scores_gemma":[0.9863794,0.00035477726,0.0011674946,0.00049040676,0.00009165388,0.00047286617,0.00013218781,0.000012278802,0.010898963],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990077,0.000025727612,0.00016512959,0.00022371003,0.00035773363,0.00022000508],"domain_scores_gemma":[0.9994864,0.000019362455,0.00012606714,0.00017547468,0.00010876354,0.000083964376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000092893795,0.00009190852,0.0002429697,0.000040331477,0.00006078031,0.0000035201385,0.00014893721,0.000037889142,0.00058956124],"category_scores_gemma":[0.000015322004,0.00006871486,0.00004253429,0.0002044176,0.00014062303,0.00003982444,0.00015052049,0.00016954106,0.0000036751758],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06229516,0.0056224097,0.5957749,0.00031878072,0.0021843906,0.002031684,0.002075214,0.0026436374,0.029401483,0.005335699,0.056585953,0.23573068],"study_design_scores_gemma":[0.02445517,0.0076816,0.08559593,0.00007608845,0.00016770978,0.0005872905,0.0022608775,0.0004483737,0.0017043435,0.00021754153,0.8765827,0.00022239656],"about_ca_topic_score_codex":0.0002918793,"about_ca_topic_score_gemma":0.00007344581,"teacher_disagreement_score":0.8199967,"about_ca_system_score_codex":0.0015915143,"about_ca_system_score_gemma":0.00087955454,"threshold_uncertainty_score":0.64552826},"labels":[],"label_agreement":null},{"id":"W4308348119","doi":"10.1016/j.canlet.2022.215994","title":"UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways","year":2022,"lang":"en","type":"article","venue":"Cancer Letters","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Prostate Cancer Canada; Centre Hospitalier de l’Université de Montréal; Université Laval; Centre hospitalier de l'Université Laval; McGill University Health Centre; Centre hospitalier universitaire de Québec","funders":"Canadian Institutes of Health Research; Centre Hospitalier Universitaire de Québec","keywords":"Prostate cancer; Cancer research; Androgen receptor; Signal transducing adaptor protein; Epidermal growth factor receptor; Signal transduction; Tumor progression; Biology; Cancer; Cell growth; Endocytic cycle; Cell; Cell biology; Endocytosis","score_opus":0.042693818452301316,"score_gpt":0.3206133529855304,"score_spread":0.2779195345332291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308348119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98029786,0.005835571,0.000009397897,0.011053991,0.00018226446,0.0023715077,0.000115410854,0.000040195813,0.00009380909],"genre_scores_gemma":[0.9955245,0.00051424094,0.00018496891,0.0007779692,0.00012251329,0.002349689,0.000031101095,0.00003759,0.00045741757],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840945,0.00012511158,0.000256803,0.0003448741,0.00053029973,0.0003334688],"domain_scores_gemma":[0.9993492,0.000032381875,0.0001952728,0.0002652128,0.00009380534,0.000064121705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012815007,0.0001710457,0.00024234114,0.00005168684,0.0003656928,0.000024897083,0.00012225308,0.00003030429,0.0001757201],"category_scores_gemma":[0.000027167289,0.00011078064,0.0000637608,0.00039011968,0.0002180018,0.00014398608,0.00018278635,0.0002726946,3.888678e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000972774,0.00011161779,0.08533458,0.00064851413,0.00013098883,0.000020023932,0.0056700488,0.00060715317,0.8859984,0.00010879153,0.0019024151,0.018494667],"study_design_scores_gemma":[0.007026382,0.0006269313,0.025592666,0.0015007909,0.00016646531,0.00002425659,0.0020349214,0.0016188646,0.95036936,0.00025271627,0.010370884,0.00041573722],"about_ca_topic_score_codex":0.00023972763,"about_ca_topic_score_gemma":0.000020110854,"teacher_disagreement_score":0.06437096,"about_ca_system_score_codex":0.0007469575,"about_ca_system_score_gemma":0.00045255356,"threshold_uncertainty_score":0.45175034},"labels":[],"label_agreement":null},{"id":"W4308684837","doi":"10.1097/spc.0000000000000624","title":"Cardiometabolic side effects of androgen deprivation therapy in prostate cancer","year":2022,"lang":"en","type":"review","venue":"Current Opinion in Supportive and Palliative Care","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Adverse effect; Internal medicine; Enzalutamide; Oncology; Cancer; Bioinformatics; Intensive care medicine; Androgen receptor","score_opus":0.16039417526896937,"score_gpt":0.46823735573954534,"score_spread":0.30784318047057596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308684837","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004391437,0.990451,0.0000010986299,0.000016048194,0.0009046415,0.0037433235,0.00041844367,0.000009731888,0.00006427673],"genre_scores_gemma":[0.0013314164,0.9935659,0.000004727891,0.0000056681097,0.00012505379,0.0026816532,0.002215921,0.000037706926,0.000031908497],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99787384,0.0003208773,0.0005999136,0.0005178821,0.00036520854,0.00032227146],"domain_scores_gemma":[0.99898416,0.00021887037,0.00034538854,0.00020058484,0.00015211351,0.00009887906],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016198333,0.00036473302,0.0016153086,0.0006652317,0.000043190466,0.000010473245,0.000092792245,0.00010388099,0.000055019398],"category_scores_gemma":[0.00007747686,0.00027124325,0.00026074797,0.0009782799,0.00010250763,0.0000642681,0.00010042107,0.00054829544,0.0000014706951],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012067069,0.000111770205,0.093628325,0.047444403,0.00019209053,0.00001452789,0.0029503084,5.06526e-7,8.5107934e-7,0.000014129787,0.000048521335,0.8554739],"study_design_scores_gemma":[0.0031059894,0.00046563082,0.024973596,0.02386749,0.00016130165,0.000001881314,0.00051512197,0.0000010524291,0.000054955362,0.00001922928,0.9465634,0.00027035625],"about_ca_topic_score_codex":0.00007523986,"about_ca_topic_score_gemma":0.0000060277575,"teacher_disagreement_score":0.9465149,"about_ca_system_score_codex":0.00050182844,"about_ca_system_score_gemma":0.001006933,"threshold_uncertainty_score":0.99997395},"labels":[],"label_agreement":null},{"id":"W4308768653","doi":"10.1097/spc.0000000000000620","title":"Metastatic castrate-resistant prostate cancer: a new horizon beyond the androgen receptors","year":2022,"lang":"en","type":"review","venue":"Current Opinion in Supportive and Palliative Care","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Olaparib; Oncology; Androgen receptor; Internal medicine; Cancer research; Cancer; Poly ADP ribose polymerase; Polymerase; Biology","score_opus":0.20565123498538732,"score_gpt":0.4628617856845431,"score_spread":0.25721055069915577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308768653","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013778161,0.99106294,0.000002024341,0.00022458039,0.0023054546,0.0041537615,0.0019139646,0.000024264255,0.00017521836],"genre_scores_gemma":[0.000039578867,0.991837,0.000016443244,0.000015072725,0.00034473118,0.0020041289,0.004959646,0.000067768015,0.00071562035],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967434,0.00044856637,0.0007866474,0.00081506686,0.0006109845,0.0005953492],"domain_scores_gemma":[0.9983903,0.00028299604,0.00048446923,0.00033615995,0.00017740527,0.00032864118],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026553488,0.00063387566,0.001589516,0.0003036599,0.0002506898,0.00006710686,0.00020955721,0.00010757741,0.0009913218],"category_scores_gemma":[0.00006878324,0.00037848405,0.00040423832,0.00086928083,0.000224285,0.00008702192,0.0001950523,0.0011172071,0.000013547804],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028391342,0.00009796793,0.0021581165,0.027303325,0.00050898996,0.000046074125,0.0049636876,3.9150623e-7,2.176657e-7,0.00008468886,0.007607268,0.95694536],"study_design_scores_gemma":[0.0015441335,0.0010212861,0.00018571856,0.011163765,0.0007527221,0.0000086007985,0.0037033095,0.0000011764555,0.000003846995,0.000065564855,0.981177,0.0003728991],"about_ca_topic_score_codex":0.00014810509,"about_ca_topic_score_gemma":0.000042077074,"teacher_disagreement_score":0.9735697,"about_ca_system_score_codex":0.00094926154,"about_ca_system_score_gemma":0.0032030742,"threshold_uncertainty_score":0.9999219},"labels":[],"label_agreement":null},{"id":"W4309013737","doi":"10.3390/curroncol29110680","title":"Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone acetate; Prostate cancer; Tolerability; Taxane; Cohort; Internal medicine; Cabazitaxel; Oncology; Chemotherapy; Specialty; Retrospective cohort study; Cancer; Population; Androgen deprivation therapy; Breast cancer; Adverse effect; Family medicine; Androgen receptor","score_opus":0.2888061128264869,"score_gpt":0.4910539350213424,"score_spread":0.20224782219485554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309013737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99248445,0.0046570404,0.000012780025,0.001164278,0.00034785428,0.0005421219,0.00024928464,0.000008916883,0.00053328235],"genre_scores_gemma":[0.9969445,0.00055475073,0.000052636628,0.000024490866,0.0000231079,0.0005477031,0.00036768205,0.000011068166,0.0014740771],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987367,0.00011863963,0.00037032846,0.0002210511,0.0003024592,0.00025083622],"domain_scores_gemma":[0.9996095,0.000045816934,0.00011500777,0.000102992315,0.00006606,0.00006067749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025410857,0.00010182273,0.00029933825,0.00048694405,0.000041441665,0.000004203319,0.000068319656,0.000024931502,0.00068632903],"category_scores_gemma":[0.000023102242,0.00008945471,0.000044329627,0.0007501101,0.0000763737,0.000057611407,0.000060595194,0.00025162238,0.0000010045042],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005464704,0.008620562,0.30822465,0.00046255067,0.0001395679,0.0002995592,0.007786031,0.0021367846,0.011974676,0.00061788847,0.0022464434,0.6520266],"study_design_scores_gemma":[0.021880997,0.0020858576,0.9107336,0.00016773773,0.00012215928,0.000019359903,0.0022414187,0.009154245,0.0011133222,0.000084604835,0.052186597,0.00021010824],"about_ca_topic_score_codex":0.0044415616,"about_ca_topic_score_gemma":0.023726044,"teacher_disagreement_score":0.6518165,"about_ca_system_score_codex":0.0013740426,"about_ca_system_score_gemma":0.0010630076,"threshold_uncertainty_score":0.9940884},"labels":[],"label_agreement":null},{"id":"W4309029826","doi":"10.1016/j.ijrobp.2022.07.006","title":"PSMA PET- and mpMRI-directed Prostate Cancer Salvage","year":2022,"lang":"en","type":"letter","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Oncology; Cancer; Radiology; Internal medicine","score_opus":0.02632028065900478,"score_gpt":0.35957618169806693,"score_spread":0.33325590103906216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309029826","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.104001984,0.011707794,0.00010871635,0.87110025,0.00864594,0.0011635211,0.0013117421,0.00015341242,0.0018066533],"genre_scores_gemma":[0.14299336,0.09671883,0.0039311456,0.65299517,0.074053936,0.00068284216,0.009602739,0.0005630925,0.018458888],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972696,0.0003921601,0.0008107018,0.0004229885,0.0006771384,0.0004274227],"domain_scores_gemma":[0.9968737,0.00045852628,0.0013035135,0.00019848508,0.0010111516,0.00015467164],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0004609826,0.00037202984,0.00086123246,0.00040452697,0.00014347647,0.000054200133,0.00042773312,0.00042648125,0.00078855647],"category_scores_gemma":[0.00017738892,0.0003057345,0.00030452106,0.00023071517,0.00032188595,0.0002044976,0.00017237749,0.002869452,0.000018294908],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019565297,0.00038503198,0.09567575,0.000112577975,0.0037293734,0.0040947944,0.00076698285,0.000048426777,0.0012299749,0.0002250085,0.7685933,0.12318222],"study_design_scores_gemma":[0.0071914406,0.001818613,0.0048378506,0.00013764347,0.00040875867,0.0010419585,0.000049998933,0.00032303488,0.00036484943,0.0020119254,0.9815268,0.00028713956],"about_ca_topic_score_codex":0.00007926152,"about_ca_topic_score_gemma":0.000004526414,"teacher_disagreement_score":0.21810506,"about_ca_system_score_codex":0.002160081,"about_ca_system_score_gemma":0.0018962825,"threshold_uncertainty_score":0.9999395},"labels":[],"label_agreement":null},{"id":"W4309263961","doi":"10.1101/2022.11.16.516773","title":"Germline determinants of the prostate tumor genome","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Public Health Ontario; Lunenfeld-Tanenbaum Research Institute; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Vector Institute; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Health and Medical Research Council; Norges Forskningsråd; Prostate Cancer Canada; Prostate Cancer Foundation; Movember Foundation; Helse Sør-Øst RHF; Medical Research Council; Cancer Prevention and Research Institute of Texas; Instituto Tecnológico de Costa Rica; Cancer Association of South Africa; Universitetet i Oslo; Genome Canada; National Institutes of Health; U.S. Department of Defense","keywords":"Germline; Biology; Genetics; Genome; Prostate cancer; Germline mutation; Somatic cell; Transcriptome; Gene; Computational biology; Cancer; Mutation; Gene expression","score_opus":0.021197447391073296,"score_gpt":0.2725880257396122,"score_spread":0.2513905783485389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309263961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927033,0.0030386639,0.0000046586115,0.00041220596,0.0007850694,0.0021554339,0.0007541421,0.00012049489,0.000025991858],"genre_scores_gemma":[0.99769706,0.0005470045,0.00045846283,0.00018798235,0.00024928185,0.00054387737,8.99487e-7,0.00013159722,0.00018386621],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9970737,0.00015200007,0.0006121242,0.000771187,0.00079213537,0.00059884123],"domain_scores_gemma":[0.99704814,0.000042975917,0.00050220854,0.0017294495,0.00043077624,0.0002464305],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005686985,0.00044524125,0.0007688141,0.00023464643,0.00021869308,0.000047917045,0.00061606686,0.00017740567,0.00032496435],"category_scores_gemma":[0.00014877821,0.00032122224,0.00030996,0.00060763,0.00027139488,0.000055918845,0.0013680897,0.0010705012,0.0000206502],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005182809,0.0005813803,0.36170462,0.0025212115,0.0003905232,0.0006252227,0.000046179233,0.00003290842,0.633312,0.00003865491,0.00022435366,0.0000046761656],"study_design_scores_gemma":[0.001708389,0.0002297166,0.72447383,0.00055171316,0.00028812935,1.2313679e-7,0.000006545167,0.00011260834,0.26393852,0.0000016514905,0.008287673,0.00040113274],"about_ca_topic_score_codex":0.00006606237,"about_ca_topic_score_gemma":0.0000019902186,"teacher_disagreement_score":0.3693735,"about_ca_system_score_codex":0.00054708926,"about_ca_system_score_gemma":0.001954867,"threshold_uncertainty_score":0.999924},"labels":[],"label_agreement":null},{"id":"W4309341654","doi":"10.1016/j.clgc.2022.11.005","title":"Distinct Profiles of DNA Repair Activity Define Favorable-risk Prostate Cancer Subtypes With Divergent Outcome","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Oncology; Internal medicine; Quartile; Disease; Prospective cohort study; Proportional hazards model; Gene expression profiling; Biomarker; DNA repair; Bioinformatics; Gene; Cancer; Gene expression; Genetics; Confidence interval; Biology","score_opus":0.07357477446378567,"score_gpt":0.3947500217146571,"score_spread":0.32117524725087143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309341654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886774,0.005693955,0.0000050626936,0.0016755492,0.00065057655,0.0014719818,0.0011372889,0.00013680436,0.00055139686],"genre_scores_gemma":[0.98156637,0.005463656,0.0003331011,0.00014441895,0.0004400253,0.0013952962,0.00007709561,0.00006364143,0.010516413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99669856,0.00038088328,0.00078536203,0.00074553076,0.0008170045,0.0005726845],"domain_scores_gemma":[0.9979522,0.00033241944,0.0004987843,0.0006126982,0.00026237045,0.0003414911],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000803957,0.00031782436,0.0008407286,0.00011661595,0.00039660415,0.000010787807,0.00021949054,0.00008942743,0.0016747132],"category_scores_gemma":[0.00015857453,0.00021954584,0.00039830199,0.00052102044,0.00042650194,0.0000967879,0.00044644828,0.00093192025,0.0000110654755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012921807,0.0015181584,0.9589877,0.0003807147,0.0007545364,0.00043601284,0.00014173241,0.00012764904,0.00050234963,0.000004336839,0.0041859923,0.020039022],"study_design_scores_gemma":[0.0059423028,0.0050242036,0.96123725,0.00013353564,0.0006696615,0.000024672267,0.0001873889,0.00024452579,0.0028551412,0.00003317265,0.023299465,0.0003487053],"about_ca_topic_score_codex":0.0014776959,"about_ca_topic_score_gemma":0.00019979093,"teacher_disagreement_score":0.019690316,"about_ca_system_score_codex":0.00049564487,"about_ca_system_score_gemma":0.001208033,"threshold_uncertainty_score":0.9992379},"labels":[],"label_agreement":null},{"id":"W4309585704","doi":"10.51731/cjht.2022.498","title":"Prostate-Specific Membrane Antigen PET-CT Imaging for the Staging of Prostate Cancer in Canada","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Staffing; Context (archaeology); Glutamate carboxypeptidase II; PET-CT; Medical physics; Nuclear medicine; Cancer; Positron emission tomography; Nursing; Internal medicine","score_opus":0.03150406660229012,"score_gpt":0.31069015037118786,"score_spread":0.27918608376889775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309585704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66109586,0.22176948,0.000009634074,0.1146061,0.0005042613,0.0015274578,0.0004373541,0.00001907296,0.00003077677],"genre_scores_gemma":[0.9902647,0.009108581,0.00009992605,0.00025163323,0.000008790872,0.00012814277,0.000007942004,0.000021727865,0.00010854],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99818385,0.000056952893,0.000591055,0.00015832827,0.00033749433,0.00067234074],"domain_scores_gemma":[0.9989819,0.000121459714,0.00037989908,0.00022796287,0.00019390412,0.00009489427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089899753,0.0001279653,0.00041687678,0.0005514584,0.00043310056,0.000016301066,0.00032775066,0.000007407836,0.000059810383],"category_scores_gemma":[0.000092438655,0.000088532266,0.00006263327,0.0005831974,0.00018072872,0.00006840945,0.000042419033,0.00058853644,1.0099941e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00037064456,0.000029690635,0.45645973,0.00051653193,0.00011946945,0.0022739167,0.0011060694,0.0011694934,0.00028963978,0.000095691255,0.0075785266,0.5299906],"study_design_scores_gemma":[0.008726709,0.0012779942,0.12194608,0.0013654004,0.00006616648,0.0018713573,0.15231125,0.0012010452,0.012107478,0.0008497539,0.6977864,0.00049039174],"about_ca_topic_score_codex":0.849597,"about_ca_topic_score_gemma":0.7979102,"teacher_disagreement_score":0.69020784,"about_ca_system_score_codex":0.0040508425,"about_ca_system_score_gemma":0.02902415,"threshold_uncertainty_score":0.9997724},"labels":[],"label_agreement":null},{"id":"W4309685160","doi":"10.53350/pjmhs22169862","title":"The Subline of Metastatic Prostate Cancer Cell line, DU145 expresses Tks4 and reveals distinctive Phenotype","year":2022,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"DU145; Metastasis; Prostate cancer; Cancer; Cancer research; Biology; Cell culture; Chorioallantoic membrane; Phenotype; Cancer cell; In vitro; Cell; In vivo; Pathology; Medicine; Angiogenesis; Gene; Genetics; LNCaP","score_opus":0.02962124400278885,"score_gpt":0.32991779667854204,"score_spread":0.30029655267575317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309685160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9480402,0.03636984,0.000040422558,0.00482306,0.00015681985,0.0015624868,0.0003458759,0.00004082666,0.008620459],"genre_scores_gemma":[0.9593218,0.004440294,0.00023666692,0.00011166328,0.000039183928,0.0003645089,0.00004637996,0.000018358964,0.035421155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989338,0.00008656403,0.00021085162,0.00020011226,0.00033635172,0.0002322999],"domain_scores_gemma":[0.9992239,0.0002351154,0.00008809022,0.00020387625,0.00016125636,0.00008777462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002839905,0.00010972524,0.00022642466,0.000034746972,0.00025129062,0.000016195361,0.00008256784,0.000010880503,0.00082156877],"category_scores_gemma":[0.00005127807,0.000059495196,0.000040545983,0.00020483638,0.00014935942,0.000055610286,0.00015761817,0.00014511858,0.0000018576998],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040717278,0.0061766664,0.25839585,0.005957449,0.004117762,0.0006374748,0.024353584,0.00055249047,0.35402226,0.0067137815,0.1276021,0.17075332],"study_design_scores_gemma":[0.048220675,0.016516482,0.13724124,0.00052401127,0.0029381297,0.00011426684,0.052055363,0.004496093,0.48783135,0.010521538,0.2378137,0.001727134],"about_ca_topic_score_codex":0.00074096094,"about_ca_topic_score_gemma":0.0001220969,"teacher_disagreement_score":0.16902618,"about_ca_system_score_codex":0.00009486202,"about_ca_system_score_gemma":0.00019606539,"threshold_uncertainty_score":0.8995602},"labels":[],"label_agreement":null},{"id":"W4309731124","doi":"10.1016/j.urolonc.2022.09.028","title":"Should grade group 1 prostate cancer be reclassified as “non-cancer”? A pathology community perspective","year":2022,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Rockyview General Hospital","funders":"","keywords":"Overdiagnosis; Prostate cancer; Medicine; Prostatectomy; Cancer; Gynecology; Internal medicine; Family medicine; Oncology","score_opus":0.11459962503718452,"score_gpt":0.4104762455651094,"score_spread":0.2958766205279249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309731124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8872919,0.005489905,0.0000048229317,0.099712856,0.00035931933,0.0010056441,0.00022133507,0.000091426555,0.005822797],"genre_scores_gemma":[0.95166504,0.010429553,0.0042608134,0.017752884,0.00027588705,0.005287853,0.000394582,0.00005165137,0.009881764],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976186,0.00077576877,0.00028492569,0.00048315088,0.00029711,0.00054043665],"domain_scores_gemma":[0.99868685,0.0003535425,0.0001693873,0.000311189,0.00013302427,0.000345984],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.000722984,0.0002619196,0.00049518433,0.0002390047,0.0016484141,0.000022943088,0.00020223204,0.00020104875,0.0007311759],"category_scores_gemma":[0.00013152744,0.00021630869,0.00008886659,0.00055452733,0.0014674515,0.00010072528,0.00029485454,0.0018856727,0.000007841877],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038777867,0.0033243094,0.83150554,0.00017989389,0.0008040131,0.0027523306,0.030489866,0.00027417447,0.017357754,0.03785445,0.06295718,0.00862268],"study_design_scores_gemma":[0.0038096295,0.010369564,0.011843098,0.00004417131,0.00048023902,0.0009351542,0.015822433,0.00042976195,0.00067056215,0.024231395,0.9310366,0.00032737365],"about_ca_topic_score_codex":0.0034299102,"about_ca_topic_score_gemma":0.00042635723,"teacher_disagreement_score":0.8680794,"about_ca_system_score_codex":0.0011454877,"about_ca_system_score_gemma":0.0014683586,"threshold_uncertainty_score":0.9996513},"labels":[],"label_agreement":null},{"id":"W4309838276","doi":"10.5489/cuaj.8159","title":"UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer (Summary of changes)","year":2022,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université de Montréal; University of British Columbia","funders":"","keywords":"Guideline; Prostate cancer; Medicine; Castration; Oncology; Androgen deprivation therapy; Internal medicine; Disease; Cancer; Gynecology; Hormone; Pathology","score_opus":0.02437298614694277,"score_gpt":0.29563767080692227,"score_spread":0.2712646846599795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309838276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61425996,0.0030765692,0.000016234117,0.37024796,0.0011520827,0.00208134,0.004200998,0.00005008359,0.0049147396],"genre_scores_gemma":[0.977084,0.0012152018,0.0003995328,0.018451737,0.00039798062,0.00021486422,0.00088661775,0.000032671345,0.001317394],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99508774,0.0010751563,0.0008632065,0.0005511599,0.00090184616,0.0015208767],"domain_scores_gemma":[0.99492913,0.00043586214,0.0007733475,0.00017648435,0.0010559027,0.002629243],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026720352,0.00035402365,0.00077609724,0.0009729184,0.0014138519,0.00012285776,0.00022878809,0.0004245747,0.0030718541],"category_scores_gemma":[0.0010135624,0.00031192534,0.0001743607,0.00083334174,0.00013931759,0.00017761251,0.00005539431,0.001734597,0.000025946898],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00052555435,0.00017334872,0.90341026,0.000020592623,0.0011579262,0.0024941566,0.0010973255,0.00068628445,0.00034640206,0.0006827443,0.07977668,0.009628734],"study_design_scores_gemma":[0.0044214367,0.00391636,0.417437,0.000018706445,0.00066204456,0.0010964596,0.0017504996,0.0012233319,0.00004425873,0.0011109317,0.56776166,0.0005573416],"about_ca_topic_score_codex":0.547573,"about_ca_topic_score_gemma":0.84131545,"teacher_disagreement_score":0.48798496,"about_ca_system_score_codex":0.013566482,"about_ca_system_score_gemma":0.010284848,"threshold_uncertainty_score":0.9999333},"labels":[],"label_agreement":null},{"id":"W4310112889","doi":"10.21203/rs.3.rs-2280588/v1","title":"PSMA PET/CT Patterns of Recurrence After Mono-Brachytherapy in Men with Low and Intermediate Prostate Cancer and Subsequent Management","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; Biochemical recurrence; Androgen deprivation therapy; Prostate; Salvage therapy; Urology; Nuclear medicine; Radiology; Cancer; Radiation therapy; Internal medicine; Chemotherapy; Prostatectomy","score_opus":0.03286546745878434,"score_gpt":0.3842678016373079,"score_spread":0.35140233417852357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310112889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97952116,0.0136339655,0.0000021652652,0.0014932274,0.000055839744,0.0042913356,0.00051943696,0.000019813138,0.00046303088],"genre_scores_gemma":[0.8930223,0.099073336,0.00006607899,0.000023858705,0.00004098626,0.0050329664,0.00019503123,0.000053142456,0.0024923026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99633634,0.00033090342,0.00037779871,0.00091306365,0.0012920527,0.0007498262],"domain_scores_gemma":[0.99866515,0.00010393594,0.00011177414,0.000588721,0.00024969134,0.0002807506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010688768,0.0003310962,0.0005866224,0.0007862511,0.000087425266,0.00007868002,0.00021385918,0.000033353706,0.00038201266],"category_scores_gemma":[0.00001784067,0.00024244169,0.000061804436,0.0003787365,0.00035964657,0.00008627343,0.0012808925,0.0015127714,0.000001807328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006432314,0.0004090747,0.9323074,0.0147698615,0.00039035105,0.009000037,0.0026439081,0.00002794125,0.00004332596,0.000024083552,0.0001162361,0.033835445],"study_design_scores_gemma":[0.0067460304,0.0019778328,0.97283,0.011701605,0.00006999269,0.00008419648,0.003663711,0.000480329,0.00075219513,0.0003284815,0.0009731807,0.0003924318],"about_ca_topic_score_codex":0.0017666332,"about_ca_topic_score_gemma":0.00049944804,"teacher_disagreement_score":0.08649889,"about_ca_system_score_codex":0.0007180471,"about_ca_system_score_gemma":0.0004619845,"threshold_uncertainty_score":0.98864853},"labels":[],"label_agreement":null},{"id":"W4310353441","doi":"10.1016/j.clgc.2022.11.020","title":"Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Health Authority; Juravinski Cancer Centre; University of Calgary; St. Michael's Hospital; Princess Margaret Cancer Centre; Dalhousie University; University Health Network","funders":"","keywords":"Docetaxel; Medicine; Pandemic; Prostate cancer; Oncology; Internal medicine; Androgen deprivation therapy; Cabazitaxel; Cancer; Family medicine; Gynecology; Disease; Coronavirus disease 2019 (COVID-19)","score_opus":0.22629383110741824,"score_gpt":0.5035467576751977,"score_spread":0.2772529265677795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310353441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789114,0.015660176,4.73673e-7,0.0025808848,0.00029957958,0.0011563102,0.0013000795,0.000012066412,0.000079054436],"genre_scores_gemma":[0.98940283,0.006619112,0.000012835451,0.00023850486,0.00014749222,0.0013583886,0.00010969564,0.000026345437,0.0020848166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960839,0.0009635291,0.00081416697,0.0004283483,0.0012694248,0.000440586],"domain_scores_gemma":[0.9983165,0.0003991755,0.00034937065,0.00037269955,0.00032975015,0.00023248617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001823075,0.00020924456,0.00066989695,0.000094053525,0.00019103177,0.000004879024,0.00012922961,0.00004292698,0.0005000467],"category_scores_gemma":[0.00012689651,0.00014085304,0.00019815694,0.0007036238,0.00029210703,0.000043251002,0.00012689338,0.00032281713,4.3589665e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015107406,0.0020114218,0.72349,0.00021625317,0.0020209246,0.000942929,0.008661954,0.020364514,0.004041161,0.0000011429727,0.0018782642,0.22126403],"study_design_scores_gemma":[0.030503416,0.003719866,0.9409259,0.000055902598,0.0013913151,0.000120143195,0.00627359,0.0021460818,0.002593754,0.000040135586,0.011918522,0.000311368],"about_ca_topic_score_codex":0.30071232,"about_ca_topic_score_gemma":0.25797507,"teacher_disagreement_score":0.22095266,"about_ca_system_score_codex":0.0050808056,"about_ca_system_score_gemma":0.005484164,"threshold_uncertainty_score":0.9987385},"labels":[],"label_agreement":null},{"id":"W4310464744","doi":"10.1002/pros.24461","title":"Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey−Holden prostate cancer academy meeting","year":2022,"lang":"en","type":"review","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Center for Advancing Translational Sciences; National Institute of Biomedical Imaging and Bioengineering; National Institute of General Medical Sciences","keywords":"Prostate cancer; Medicine; Cancer; Library science; Oncology; Internal medicine; Computer science","score_opus":0.47700004588517514,"score_gpt":0.4714040633191248,"score_spread":0.005595982566050317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310464744","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031499383,0.9645916,7.5324044e-7,0.014745851,0.0016671395,0.013703723,0.0012680513,0.00017671664,0.0006961797],"genre_scores_gemma":[0.00006010395,0.9296589,0.00009186707,0.00030042906,0.0013325749,0.023267912,0.0010068888,0.0004092114,0.04387211],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9879743,0.0022197063,0.0020189593,0.0020808694,0.0030528342,0.0026533238],"domain_scores_gemma":[0.9949295,0.0014276111,0.0010571328,0.001734219,0.00024120639,0.000610316],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0067863,0.0012043347,0.00282735,0.0007631237,0.001453095,0.00034725494,0.0016881501,0.00027177067,0.0008294423],"category_scores_gemma":[0.00064759725,0.0006617387,0.00070327864,0.0038488484,0.0008017134,0.0005090785,0.0018164297,0.0073429765,0.00006947941],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012783073,0.00012687541,0.003835597,0.004406989,0.0014561663,0.0021109935,0.010994731,0.000039566286,0.000021061329,0.000008319783,0.07349671,0.90222466],"study_design_scores_gemma":[0.0022292866,0.0001663126,0.00032668948,0.016643604,0.0011398102,0.00012686904,0.002655447,0.000023945082,0.000083141786,0.00044735105,0.97545236,0.0007051888],"about_ca_topic_score_codex":0.02080889,"about_ca_topic_score_gemma":0.00065745745,"teacher_disagreement_score":0.90195566,"about_ca_system_score_codex":0.0036457055,"about_ca_system_score_gemma":0.006706298,"threshold_uncertainty_score":0.9998469},"labels":[],"label_agreement":null},{"id":"W4310639174","doi":"10.1038/s41467-022-35135-2","title":"Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"National Cancer Institute; KWF Kankerbestrijding; Prostate Cancer Foundation; Oncode Institute; U.S. Department of Defense","keywords":"Prostate cancer; Epigenetics; Enhancer; Androgen receptor; Biology; Concordance; Chromatin; Genetic heterogeneity; Tumour heterogeneity; Somatic cell; Cancer research; Prostate; Phenotype; Gene; Genetics; Gene expression; Cancer","score_opus":0.039804600359077444,"score_gpt":0.32386210838660645,"score_spread":0.284057508027529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310639174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9473231,0.042605534,0.000017220842,0.008182596,0.0001177005,0.0008496528,0.00037087986,0.00003257167,0.0005007393],"genre_scores_gemma":[0.99037516,0.0065492787,0.0011284053,0.0006347249,0.000013643851,0.00021192139,0.00065329246,0.000011929078,0.00042164064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888664,0.00020107484,0.00015145892,0.00022571228,0.00033697052,0.00019814905],"domain_scores_gemma":[0.9992025,0.00006946872,0.00004985847,0.00047019398,0.00012099741,0.000086999484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021096227,0.00011160857,0.00020053086,0.00014456372,0.0011452795,0.0000126151435,0.00025288638,0.00005300781,0.00010066611],"category_scores_gemma":[0.000017439637,0.00010342265,0.00006417965,0.00029672866,0.00024109975,0.00010262039,0.0009285454,0.0008628538,0.0000019836957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012394051,0.005198893,0.67520565,0.0009908873,0.0039272127,0.00043419606,0.048900023,0.0012778324,0.1929719,0.0058857608,0.014945602,0.037867974],"study_design_scores_gemma":[0.015223658,0.0011585933,0.8785514,0.00015196741,0.00069383817,0.0002781309,0.0058190054,0.0011902843,0.0050797,0.001159846,0.08992907,0.0007645064],"about_ca_topic_score_codex":0.00016964429,"about_ca_topic_score_gemma":0.0004577121,"teacher_disagreement_score":0.20334573,"about_ca_system_score_codex":0.0007823031,"about_ca_system_score_gemma":0.0003089833,"threshold_uncertainty_score":0.88086796},"labels":[],"label_agreement":null},{"id":"W4310655863","doi":"10.1016/j.brachy.2022.09.081","title":"PP12  Presentation Time: 11:20 AM","year":2022,"lang":"en","type":"article","venue":"Brachytherapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Quebec - Clinical Research Organization in Cancer","funders":"","keywords":"Medicine; Prostate cancer; Biochemical recurrence; Proportional hazards model; Univariate analysis; Multivariate analysis; Brachytherapy; Internal medicine; Oncology; Radiation therapy; Cancer; Prostatectomy","score_opus":0.0240072537756669,"score_gpt":0.33812779088121636,"score_spread":0.31412053710554944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310655863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976305,0.002734185,0.00003344527,0.008765396,0.00021903579,0.0011695508,0.0000301685,0.0001309102,0.010612304],"genre_scores_gemma":[0.8239208,0.00043615806,0.00032379816,0.0016019093,0.00039634845,0.0006710838,0.00049796846,0.0000516223,0.17210034],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990054,0.000080919825,0.00012445058,0.00018709575,0.0003941914,0.00020796327],"domain_scores_gemma":[0.99960166,0.000042519965,0.000038834623,0.00019741387,0.000038684186,0.00008089844],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001611752,0.0000870644,0.00016930349,0.00009151054,0.00019907372,0.000016138898,0.000068302244,0.000022057335,0.0053663347],"category_scores_gemma":[0.000008083072,0.00006948188,0.00008379172,0.00023181412,0.000035673882,0.00006308269,0.000035848712,0.00014885477,0.00013066518],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015956338,0.0031455138,0.20340744,0.0001632072,0.0009917552,0.0009468412,0.0051144827,0.00027083786,0.19421527,0.0010444076,0.36256275,0.21218117],"study_design_scores_gemma":[0.029853715,0.0029297513,0.058326546,0.0000266391,0.00009936594,0.00025458375,0.0006065237,0.001995911,0.017424693,0.0008771237,0.8872512,0.0003539258],"about_ca_topic_score_codex":0.000031019044,"about_ca_topic_score_gemma":0.0000029211753,"teacher_disagreement_score":0.5246885,"about_ca_system_score_codex":0.00013157258,"about_ca_system_score_gemma":0.000116424184,"threshold_uncertainty_score":0.9955429},"labels":[],"label_agreement":null},{"id":"W4310655868","doi":"10.1016/j.brachy.2022.09.097","title":"PSOR3  Presentation Time: 11:40 AM","year":2022,"lang":"en","type":"article","venue":"Brachytherapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université Laval","funders":"","keywords":"Medicine; Incidence (geometry); Internal medicine; Capra; Prostate cancer; Retrospective cohort study; Proportional hazards model; Metastasis; Oncology; Cancer","score_opus":0.024158970233755836,"score_gpt":0.3385549282858617,"score_spread":0.31439595805210585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310655868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808728,0.0025231242,0.000030146866,0.0065781786,0.00019602999,0.0010474437,0.000020945023,0.000117237556,0.008614092],"genre_scores_gemma":[0.8647653,0.0005157796,0.00028970174,0.0014182936,0.0003316115,0.0006104645,0.00033105648,0.000045893325,0.13169193],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989965,0.00008049551,0.00012589608,0.00019059199,0.00039789418,0.00020863907],"domain_scores_gemma":[0.9995995,0.000040607993,0.000039192462,0.00020263992,0.000038952316,0.000079114834],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016220135,0.000087868146,0.00017008635,0.00009542456,0.0001996186,0.000016490914,0.00006901823,0.00002231102,0.005587125],"category_scores_gemma":[0.000008823299,0.00007006429,0.000084958614,0.00023098747,0.000036351837,0.00006209575,0.000035455654,0.00014679797,0.00013583062],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024471344,0.003477226,0.16504133,0.00017457582,0.0010744411,0.0009947044,0.0055198953,0.0002460205,0.14219478,0.0011194368,0.3591141,0.29657215],"study_design_scores_gemma":[0.0363588,0.003486957,0.11387684,0.000032035525,0.00011814077,0.0003063575,0.00073814526,0.0023605267,0.018692277,0.0010838796,0.82252496,0.00042109977],"about_ca_topic_score_codex":0.000041331023,"about_ca_topic_score_gemma":0.0000022592621,"teacher_disagreement_score":0.46341085,"about_ca_system_score_codex":0.00013002675,"about_ca_system_score_gemma":0.00011375021,"threshold_uncertainty_score":0.9953219},"labels":[],"label_agreement":null},{"id":"W4310691331","doi":"10.1016/j.brachy.2022.09.014","title":"PP02  Presentation Time: 9:10 AM","year":2022,"lang":"en","type":"article","venue":"Brachytherapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus; University of British Columbia; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Prostate cancer; Salvage therapy; Brachytherapy; Prostate; Salvage surgery; Medical physics; Radiation therapy; Oncology; Surgery; Internal medicine; Cancer; Chemotherapy","score_opus":0.024509054934328246,"score_gpt":0.33924863033451114,"score_spread":0.3147395754001829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310691331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9550858,0.0035650632,0.000027190017,0.0075084977,0.00020147499,0.0013003336,0.000024964467,0.00014843523,0.032138214],"genre_scores_gemma":[0.5957957,0.00044637054,0.0002886717,0.0011881497,0.0003282171,0.0006385107,0.0003793449,0.00004493293,0.4008901],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991146,0.00006820693,0.00011021269,0.00016808952,0.00035699864,0.00018190763],"domain_scores_gemma":[0.9996395,0.000036760757,0.000033887656,0.00018060535,0.000039397244,0.00006982075],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001447774,0.000076417484,0.00015050844,0.00008259668,0.00017927993,0.00001425028,0.000060135942,0.000019285739,0.015778285],"category_scores_gemma":[0.000008765424,0.000060800674,0.000075565564,0.0002075317,0.00003160016,0.000053192198,0.000032275246,0.00013790512,0.00028593966],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021370932,0.0023823509,0.032433324,0.00010882115,0.0008962148,0.00063824636,0.0030521208,0.00013001225,0.1439969,0.0005462397,0.512922,0.28152284],"study_design_scores_gemma":[0.028513907,0.003849184,0.04215517,0.000020968904,0.00008570893,0.00020597938,0.00043753942,0.002027349,0.014080771,0.00082948455,0.9074806,0.0003133399],"about_ca_topic_score_codex":0.000016856919,"about_ca_topic_score_gemma":5.186823e-7,"teacher_disagreement_score":0.3945586,"about_ca_system_score_codex":0.00011649852,"about_ca_system_score_gemma":0.00010835417,"threshold_uncertainty_score":0.9851214},"labels":[],"label_agreement":null},{"id":"W4310691656","doi":"10.1016/j.brachy.2022.09.101","title":"PSOR7  Presentation Time: 12:00 PM","year":2022,"lang":"en","type":"article","venue":"Brachytherapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; Androgen deprivation therapy; Radiation therapy; Genitourinary system; Prostate; External beam radiotherapy; Stage (stratigraphy); Surgery; Radiology; Internal medicine; Cancer","score_opus":0.02701446370228931,"score_gpt":0.33511386191183556,"score_spread":0.30809939820954624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310691656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9483866,0.0050270353,0.000048981357,0.010452935,0.00031156698,0.0016445685,0.000033173583,0.00017836921,0.033916753],"genre_scores_gemma":[0.80410546,0.0009536055,0.00037683526,0.0019563022,0.00047874247,0.0007770959,0.00040792476,0.00005973652,0.19088432],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99899566,0.00008081461,0.00012650236,0.00019026849,0.0003986767,0.00020805716],"domain_scores_gemma":[0.9996069,0.00004079069,0.000038591443,0.00020210634,0.000032776006,0.00007884265],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016395787,0.00008773118,0.0001697818,0.00009276955,0.00019870447,0.000016246486,0.00006909122,0.000022837414,0.0077996138],"category_scores_gemma":[0.000008478957,0.00007000972,0.00008456337,0.00017553514,0.000034956945,0.00006185325,0.000034800974,0.00017131738,0.00016199463],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02268188,0.0029148785,0.08921056,0.00015624345,0.0012066396,0.000869062,0.005298369,0.00023521672,0.14158306,0.00075098575,0.43588558,0.29920754],"study_design_scores_gemma":[0.034960777,0.0040356433,0.074037895,0.000030461164,0.00009798558,0.00029068594,0.00057310663,0.002311178,0.01619508,0.0011823934,0.8658904,0.00039438688],"about_ca_topic_score_codex":0.00003319103,"about_ca_topic_score_gemma":0.0000013931402,"teacher_disagreement_score":0.43000484,"about_ca_system_score_codex":0.0001310114,"about_ca_system_score_gemma":0.00012302029,"threshold_uncertainty_score":0.9931074},"labels":[],"label_agreement":null},{"id":"W4310691702","doi":"10.1016/j.brachy.2022.09.013","title":"Friday, June 17, 20229:00 AM - 10:00 AM PP01  Presentation Time: 9:00 AM","year":2022,"lang":"en","type":"article","venue":"Brachytherapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; Androgen deprivation therapy; Radiation therapy; Urology; Prostate; Internal medicine; External beam radiotherapy; Oncology; Surgery; Cancer","score_opus":0.02500733105225417,"score_gpt":0.33562286330950764,"score_spread":0.31061553225725347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310691702","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.837831,0.031230329,0.00013793584,0.03058688,0.0020645126,0.0064115645,0.00038824213,0.0007487707,0.09060076],"genre_scores_gemma":[0.29891852,0.004043934,0.0004322713,0.0023331565,0.0014458795,0.001706053,0.0016141275,0.00019898404,0.6893071],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969804,0.0002614281,0.00042796525,0.00060965354,0.0010607822,0.000659771],"domain_scores_gemma":[0.99864787,0.00015501943,0.00016316706,0.0006285626,0.00014284076,0.0002625303],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044992214,0.00032554427,0.0005402231,0.0002766004,0.00049917324,0.0000760959,0.000261503,0.000104513434,0.035245005],"category_scores_gemma":[0.000034188517,0.00027354175,0.00025482674,0.00069145084,0.00014156575,0.00022000425,0.00013123572,0.0005329297,0.00065221114],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009478635,0.0019560333,0.007863469,0.00013503648,0.0009527144,0.00061485695,0.0023568978,0.00019681866,0.03123499,0.00020276534,0.8976497,0.047358103],"study_design_scores_gemma":[0.019405995,0.0026861643,0.0132386545,0.000057264795,0.00011951049,0.00014550427,0.0006226021,0.0014829407,0.008993704,0.0006649113,0.9520794,0.0005033261],"about_ca_topic_score_codex":0.00015150766,"about_ca_topic_score_gemma":0.000012693487,"teacher_disagreement_score":0.5987063,"about_ca_system_score_codex":0.00038267646,"about_ca_system_score_gemma":0.00030473855,"threshold_uncertainty_score":0.9999717},"labels":[],"label_agreement":null},{"id":"W4310753263","doi":"10.1016/j.annonc.2022.10.210","title":"173P Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Oncology; Prostate cancer; Internal medicine; Gynecology; Cancer","score_opus":0.23995173355578944,"score_gpt":0.5207115689632396,"score_spread":0.2807598354074501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310753263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804107,0.00061215885,4.1965174e-7,0.016453192,0.00007612465,0.0020125732,0.00005238217,0.0000053393705,0.0003771266],"genre_scores_gemma":[0.997085,0.001026105,0.000024160581,0.000895604,0.000018314344,0.00071709865,0.00004705689,0.000009930651,0.0001767739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704254,0.0013549532,0.00067307806,0.0002849268,0.00033299637,0.0003115362],"domain_scores_gemma":[0.9986663,0.00079851307,0.00016599493,0.00022973045,0.00009304553,0.000046433837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002768423,0.00011355527,0.0005920402,0.0002877888,0.000037614624,0.000005280803,0.00012397922,0.00003970882,0.000032348456],"category_scores_gemma":[0.00019618453,0.00007659208,0.00007427236,0.0005643679,0.00013932516,0.000052977877,0.00006212828,0.0005612332,0.0000032262246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035840073,0.0067252503,0.9552199,0.000020085025,0.0001560674,0.00146577,0.018091653,0.00012347673,0.00022219158,0.00008409806,0.0006215056,0.01368599],"study_design_scores_gemma":[0.0059480052,0.0065660765,0.96161246,0.000011199843,0.00003743842,0.000009521421,0.02469001,0.0001029696,0.00009389435,0.0003049426,0.00055613957,0.000067367764],"about_ca_topic_score_codex":0.002263581,"about_ca_topic_score_gemma":0.0075730495,"teacher_disagreement_score":0.016674273,"about_ca_system_score_codex":0.00017410083,"about_ca_system_score_gemma":0.0005745045,"threshold_uncertainty_score":0.42259392},"labels":[],"label_agreement":null},{"id":"W4310753448","doi":"10.1016/j.annonc.2022.10.194","title":"157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Olaparib; Abiraterone; Placebo; Internal medicine; Oncology; Biomarker; Prostate cancer; Pathology; Cancer; Alternative medicine; Nuclear magnetic resonance","score_opus":0.0927244702327429,"score_gpt":0.408633134894925,"score_spread":0.3159086646621821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310753448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836726,0.0016261066,0.0000064282845,0.0076672067,0.00005050535,0.0035695143,0.0033403276,0.000008667982,0.000058602025],"genre_scores_gemma":[0.99373996,0.0034056844,0.00021001935,0.00028120633,0.000028590732,0.0006980298,0.0012921732,0.000020053707,0.00032426137],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99809563,0.0002656986,0.00058639457,0.00042573514,0.0003436151,0.00028291537],"domain_scores_gemma":[0.9982885,0.0004983702,0.00045598813,0.0002409556,0.0003931765,0.00012297908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067892467,0.00020236072,0.0007460015,0.0001825175,0.0002363183,0.000021052003,0.000084064195,0.000056065674,0.000089696696],"category_scores_gemma":[0.00009876508,0.00011667544,0.00006837004,0.00046768878,0.00039626673,0.00008908247,0.00006804022,0.0001449862,2.6036025e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92290664,0.0028087585,0.0068591796,0.00008414112,0.004959192,0.00003868916,0.0036173032,0.000033390792,0.0038877241,0.000009847057,0.002256287,0.052538835],"study_design_scores_gemma":[0.7970817,0.11154165,0.041923165,0.00010360912,0.0032028998,0.000010891792,0.0016797367,0.0016711937,0.010842372,0.0002573149,0.03131823,0.0003672079],"about_ca_topic_score_codex":0.002663478,"about_ca_topic_score_gemma":0.0014044769,"teacher_disagreement_score":0.12582493,"about_ca_system_score_codex":0.00005611389,"about_ca_system_score_gemma":0.00042249978,"threshold_uncertainty_score":0.47578862},"labels":[],"label_agreement":null},{"id":"W4310995124","doi":"10.3390/ijms232314948","title":"Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Deutsche Forschungsgemeinschaft","keywords":"Paclitaxel; Ifosfamide; Prostate cancer; Cisplatin; Medicine; Oncology; Chemotherapy; Docetaxel; Castration; Internal medicine; Cancer; Cancer research","score_opus":0.02002768283043268,"score_gpt":0.34109642798664086,"score_spread":0.3210687451562082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310995124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99226636,0.003645766,0.0000913697,0.0034874629,0.00008459174,0.0001723359,0.000030009065,0.0000015198533,0.00022058486],"genre_scores_gemma":[0.99743193,0.0004977943,0.0017730221,0.0001844496,0.000015818301,0.00001588761,0.0000026524278,0.0000053804797,0.000073074654],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99839866,0.00006701495,0.00028584464,0.0001244006,0.0010081882,0.00011586648],"domain_scores_gemma":[0.99916923,0.000053976124,0.00039239298,0.000047749545,0.0002811609,0.000055502904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005152328,0.000072358736,0.00017363648,0.00029171564,0.00005360322,0.000030240084,0.0001617216,0.000008475146,0.00008315978],"category_scores_gemma":[0.000042741172,0.00004715906,0.00003891026,0.00026780125,0.0002153225,0.00011898759,0.000037609378,0.00014196664,1.0182264e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013328616,0.001531557,0.12637892,0.00017811122,0.0018408636,0.031394362,0.011338485,0.01168883,0.7445963,0.0035180873,0.000292599,0.053913295],"study_design_scores_gemma":[0.060334515,0.026039625,0.5554032,0.0035455453,0.0006393663,0.014282592,0.023850285,0.008173966,0.29014745,0.014897475,0.0016322796,0.0010537187],"about_ca_topic_score_codex":0.00013366142,"about_ca_topic_score_gemma":0.000025835858,"teacher_disagreement_score":0.45444882,"about_ca_system_score_codex":0.00011447648,"about_ca_system_score_gemma":0.0006287828,"threshold_uncertainty_score":0.19230908},"labels":[],"label_agreement":null},{"id":"W4311339051","doi":"10.1016/j.jval.2022.09.1458","title":"HSD115 Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Enzalutamide; Medicine; Abiraterone acetate; Prostate cancer; Taxane; Cohort; Internal medicine; Tolerability; Cabazitaxel; Oncology; Specialty; Population; Retrospective cohort study; Chemotherapy; Cancer; Gynecology; Androgen deprivation therapy; Family medicine; Adverse effect; Breast cancer; Androgen receptor; Environmental health","score_opus":0.20298439713475921,"score_gpt":0.4291731003992639,"score_spread":0.22618870326450466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311339051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99163973,0.0035341815,0.0000070911474,0.0034920687,0.00008599343,0.00080148317,0.00026378324,0.00000826114,0.00016739807],"genre_scores_gemma":[0.9965653,0.0008408204,0.00018317364,0.000111424844,0.000012245606,0.0003173732,0.00019086835,0.000015410846,0.0017634006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981978,0.00020399723,0.0005607694,0.0002374885,0.00046692565,0.00033301525],"domain_scores_gemma":[0.99956065,0.00005395943,0.00013396754,0.00012971878,0.000036499936,0.0000851977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007033624,0.000103099024,0.0003039229,0.0006700902,0.000049096976,0.0000062510685,0.00006186481,0.000019718174,0.0002005935],"category_scores_gemma":[0.000028413733,0.00009383337,0.000031621174,0.0012809811,0.000038424092,0.000071367875,0.000034582394,0.00023953881,5.034295e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006358526,0.00583436,0.6594664,0.0027674637,0.0001195762,0.00049516885,0.027928028,0.17181414,0.0070738466,0.0015379861,0.0008787281,0.11572578],"study_design_scores_gemma":[0.010338156,0.000999612,0.9385162,0.00045356274,0.00001404362,0.0000074663253,0.0018624208,0.045986116,0.00034631515,0.00008580161,0.0012594676,0.00013086025],"about_ca_topic_score_codex":0.27764064,"about_ca_topic_score_gemma":0.06732198,"teacher_disagreement_score":0.27904978,"about_ca_system_score_codex":0.0017445049,"about_ca_system_score_gemma":0.0019017627,"threshold_uncertainty_score":0.94969696},"labels":[],"label_agreement":null},{"id":"W4311662291","doi":"10.1097/mnm.0000000000001652","title":"Comparing digital to analog prostate-specific membrane antigen-targeted piflufolastat 18F PET/CT in prostate cancer patients in early biochemical failure","year":2022,"lang":"en","type":"article","venue":"Nuclear Medicine Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Prostate cancer; Medicine; Glutamate carboxypeptidase II; Prostate; Prostate-specific antigen; Cancer; Oncology; Internal medicine; Urology; Cancer research","score_opus":0.037788822258551465,"score_gpt":0.30916366207775825,"score_spread":0.2713748398192068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311662291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98121876,0.0020465325,4.024665e-7,0.012948608,0.00008780577,0.0016829693,0.00014451638,0.000082417864,0.0017879966],"genre_scores_gemma":[0.9955994,0.0020457008,0.00023686978,0.00037928738,0.000031899977,0.00037953223,0.001005165,0.000068328416,0.00025380572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752665,0.00019433342,0.00060672715,0.00045861627,0.00065074774,0.0005629458],"domain_scores_gemma":[0.9981924,0.00014675931,0.00011175478,0.0010797883,0.00016893832,0.0003003432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003452321,0.0002551167,0.0005387781,0.0006754445,0.00034606567,0.00004790171,0.00067948527,0.000014538343,0.00039760995],"category_scores_gemma":[0.00012400243,0.00022544716,0.00006564397,0.0017291195,0.00040011446,0.00018120982,0.0008219191,0.0010596446,0.000046221383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011120384,0.0016682283,0.96703357,0.00007861029,0.00008133742,0.00032568324,0.00833098,0.000092038026,0.008098017,0.00010907662,0.011682035,0.0013884017],"study_design_scores_gemma":[0.013690508,0.0016092887,0.8275648,0.0007326792,0.000044254106,0.000091008405,0.0061383047,0.0010619874,0.00049661146,0.00006429454,0.14800562,0.00050066353],"about_ca_topic_score_codex":0.0013428892,"about_ca_topic_score_gemma":0.00030707894,"teacher_disagreement_score":0.13946877,"about_ca_system_score_codex":0.0008711766,"about_ca_system_score_gemma":0.00016992827,"threshold_uncertainty_score":0.91934687},"labels":[],"label_agreement":null},{"id":"W4311765023","doi":"10.1016/j.eururo.2022.11.025","title":"Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26]","year":2022,"lang":"en","type":"erratum","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Olaparib; Pembrolizumab; Prostate cancer; Oncology; Internal medicine; Cohort; Urology; Gynecology; Cancer; Immunotherapy; Poly ADP ribose polymerase","score_opus":0.03189533556481511,"score_gpt":0.31042385900293107,"score_spread":0.27852852343811596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311765023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94460994,0.0040983525,0.000009443359,0.0030581958,0.012578132,0.015933365,0.009460949,0.00022449715,0.010027114],"genre_scores_gemma":[0.8526568,0.0006921308,0.000027309528,0.0019014764,0.0010530308,0.0015099485,0.016860671,0.0005139291,0.12478471],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.991577,0.002277632,0.0013269571,0.001972375,0.0015630089,0.0012830193],"domain_scores_gemma":[0.99649405,0.00025134478,0.0006696669,0.0016987585,0.00040257262,0.00048360138],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0010928801,0.0009462752,0.0014837258,0.00051116874,0.00046291447,0.0001372002,0.0008833667,0.00014466004,0.0007822323],"category_scores_gemma":[0.0003460536,0.0006352878,0.00017183767,0.0009500079,0.00027960708,0.00010633556,0.00056388055,0.0026676906,0.00023135332],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15278566,0.007471684,0.24781963,0.00020203747,0.0036350263,0.021171289,0.008957072,0.00023461584,0.00003434498,0.000003561958,0.55286,0.0048250672],"study_design_scores_gemma":[0.0724615,0.016150754,0.8034719,0.00017406831,0.0016189591,0.000026889782,0.0002674933,0.00007119741,0.0000036293584,0.0000030496942,0.10509803,0.0006525378],"about_ca_topic_score_codex":0.0033681619,"about_ca_topic_score_gemma":0.00715571,"teacher_disagreement_score":0.55565226,"about_ca_system_score_codex":0.0010550427,"about_ca_system_score_gemma":0.0021365623,"threshold_uncertainty_score":0.9996332},"labels":[],"label_agreement":null},{"id":"W4311907549","doi":"10.1016/j.euros.2022.10.020","title":"Debate on Treating Oligometastatic Metastatic Hormone-sensitive Prostate Cancer: The Argument for New-generation Hormone Therapy and Radiation Therapy to the Prostate","year":2022,"lang":"en","type":"article","venue":"European Urology Open Science","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Radiation therapy; Hormone therapy; Prostate; Medicine; Argument (complex analysis); Oncology; Hormone; Internal medicine; Cancer","score_opus":0.06818377685663576,"score_gpt":0.3496155982717208,"score_spread":0.28143182141508505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311907549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9356733,0.00474508,0.00015020857,0.051293645,0.00018014449,0.007159401,0.0000909123,0.000026910275,0.0006803869],"genre_scores_gemma":[0.9827549,0.004202857,0.00048361465,0.008489304,0.00013316573,0.0011732935,0.00005751906,0.00004079936,0.0026645337],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99728185,0.0006857376,0.00028707326,0.00067208277,0.0005461349,0.0005271015],"domain_scores_gemma":[0.9988217,0.00023552153,0.00017203121,0.0004345315,0.00015002117,0.00018624113],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0034684842,0.00021745014,0.00025521143,0.00017964057,0.0019850587,0.0002930668,0.00061746506,0.000008985641,0.000020897638],"category_scores_gemma":[0.00013509032,0.000113829075,0.000045780907,0.00083753053,0.0003694836,0.00021265136,0.00036785283,0.00023960882,0.000014668306],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0103600705,0.0003227961,0.000698891,0.000006981904,0.00032187064,0.00008966353,0.03581666,0.0052363137,0.13647795,0.000494191,0.0120257875,0.7981488],"study_design_scores_gemma":[0.05886645,0.0786059,0.32067105,0.000050903505,0.0005629037,0.0005026746,0.009568701,0.0494878,0.0671838,0.0009575054,0.4118962,0.0016461203],"about_ca_topic_score_codex":0.00023013701,"about_ca_topic_score_gemma":0.000021911821,"teacher_disagreement_score":0.7965027,"about_ca_system_score_codex":0.00019199782,"about_ca_system_score_gemma":0.00051481224,"threshold_uncertainty_score":0.99931425},"labels":[],"label_agreement":null},{"id":"W4311988438","doi":"10.1016/j.eururo.2022.11.002","title":"Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022","year":2022,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal; University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre; University of British Columbia","funders":"Medical Research Council; National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Prostate cancer; Prostate; Cancer; Hormonal therapy; Oncology; Disease; Internal medicine; Management of prostate cancer; Hormone; Gynecology","score_opus":0.005719139442093395,"score_gpt":0.24109530185721298,"score_spread":0.23537616241511958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311988438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865326,0.009424643,0.000003042151,0.00051281246,0.00019518835,0.0023179653,0.0007702451,0.000020342426,0.00022312018],"genre_scores_gemma":[0.9884845,0.0098382225,0.00011931351,0.000057025693,0.000013987809,0.00045941127,0.00016741948,0.000048113732,0.00081198826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977266,0.00034701382,0.0005304299,0.0005969646,0.00042551113,0.0003734509],"domain_scores_gemma":[0.99836546,0.0001414547,0.0006193511,0.0004522176,0.00023205533,0.00018947682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016717959,0.0002873743,0.00054305274,0.00009240559,0.00012527857,0.000004520977,0.00014114747,0.000026722455,0.000021023827],"category_scores_gemma":[0.0000662628,0.0001876686,0.00006550011,0.00026150898,0.0008919264,0.000041897343,0.0003857521,0.00026035294,2.786691e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06550206,0.0019208869,0.7067725,0.0020096926,0.0022519114,0.0030285278,0.0017512875,0.0010388093,0.011072342,0.000112146445,0.00022129019,0.20431857],"study_design_scores_gemma":[0.024529284,0.00763259,0.95576084,0.0004112935,0.0009265095,0.000029302611,0.00023195262,0.000059745857,0.007194747,0.000078264275,0.0028835617,0.00026188884],"about_ca_topic_score_codex":0.00006143598,"about_ca_topic_score_gemma":0.000016662554,"teacher_disagreement_score":0.24898838,"about_ca_system_score_codex":0.0001184579,"about_ca_system_score_gemma":0.0002670436,"threshold_uncertainty_score":0.7652903},"labels":[],"label_agreement":null},{"id":"W4312070720","doi":"10.1038/s41388-022-02498-1","title":"TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer","year":2022,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Biology; Androgen receptor; Transcription factor; Cancer research; Prostate cancer; Downregulation and upregulation; Epigenetics; SOX2; Neuroendocrine differentiation; Chromoplexy; Gene; Cancer; Genetics","score_opus":0.02835954564177687,"score_gpt":0.3144168323612484,"score_spread":0.2860572867194715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312070720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933577,0.001143003,0.0000013359685,0.003230398,0.00007596803,0.0015106722,0.00061973475,0.000027709712,0.000033450528],"genre_scores_gemma":[0.9943316,0.0018215486,0.000059603917,0.00023192374,0.0000531889,0.0006346335,0.00023474294,0.000030594292,0.0026021786],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987213,0.000069243055,0.00019093968,0.00042857352,0.00024870492,0.00034121805],"domain_scores_gemma":[0.9995184,0.000035343382,0.000049796472,0.00011750624,0.000034693658,0.00024426662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005210733,0.0001873698,0.0003077589,0.0001404761,0.00013948209,0.000028431645,0.00004471584,0.000019391027,0.00027552282],"category_scores_gemma":[0.00002306504,0.0001495079,0.000028972872,0.00025547552,0.000023409986,0.00006114614,0.000110425644,0.00013642164,0.000003043711],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026100706,0.0006249603,0.048367303,0.000070211914,0.00012540517,0.00017448685,0.001653849,0.000004156564,0.9135463,9.269715e-7,0.0015492039,0.03127311],"study_design_scores_gemma":[0.011454231,0.0034374974,0.0125164185,0.000044932858,0.000108609165,0.00003970132,0.00015060138,0.00046370493,0.9459973,0.000002866845,0.02559065,0.00019349967],"about_ca_topic_score_codex":0.00046415936,"about_ca_topic_score_gemma":0.00009264068,"teacher_disagreement_score":0.035850883,"about_ca_system_score_codex":0.00033353645,"about_ca_system_score_gemma":0.0001390016,"threshold_uncertainty_score":0.6096755},"labels":[],"label_agreement":null},{"id":"W4312072123","doi":"10.3390/curroncol29120747","title":"Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Androgen deprivation therapy; Androgen receptor; Oncology; Androgen; Hormone therapy; Internal medicine; Hormone; Cancer; Bioinformatics; Cancer research; Breast cancer; Biology","score_opus":0.151910962072151,"score_gpt":0.43752843740176445,"score_spread":0.28561747532961346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312072123","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013352332,0.9883262,0.0000038088888,0.00032047404,0.00011049433,0.00930452,0.0005652205,0.000015889069,0.000018196062],"genre_scores_gemma":[0.00005351483,0.9950895,0.00009834696,0.000071294766,0.000051561547,0.00336044,0.0011154357,0.000041972726,0.00011796865],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99657524,0.0009110562,0.0011980461,0.0006142622,0.0003810106,0.0003203729],"domain_scores_gemma":[0.9981601,0.00034351653,0.0007764351,0.00030201863,0.00015337099,0.0002645524],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00094246917,0.00042706713,0.0044804728,0.00066999043,0.00006337809,0.000014914294,0.000098594406,0.000111172085,0.00013581935],"category_scores_gemma":[0.00025200457,0.00029232018,0.00028902644,0.001197875,0.000088018736,0.00008164058,0.00010425288,0.00041471474,0.0000050189656],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001407398,0.00021468663,0.000040808667,0.3357448,0.0013952019,0.00003804644,0.0006628717,1.4405467e-7,0.000007088099,0.000006200584,0.0007559242,0.6609935],"study_design_scores_gemma":[0.003245021,0.0020806205,0.000018270131,0.18047568,0.01591766,0.00016561987,0.00028891276,0.000007162034,0.000055650107,0.000031248583,0.79727817,0.00043598574],"about_ca_topic_score_codex":0.000093782895,"about_ca_topic_score_gemma":0.000045935732,"teacher_disagreement_score":0.79652226,"about_ca_system_score_codex":0.00084902067,"about_ca_system_score_gemma":0.0013897842,"threshold_uncertainty_score":0.9999529},"labels":[],"label_agreement":null},{"id":"W4312129219","doi":"10.1002/pros.24469","title":"A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide","year":2022,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"EUSA Pharma; Instituto de Salud Carlos III; Ipsen; CRIS Cancer Foundation; Sociedad Española de Oncología Médica; Astellas Pharma; Sanofi; Eisai; Astellas Pharma Canada; Pfizer","keywords":"Enzalutamide; Prostate cancer; Medicine; Internal medicine; Oncology; TMPRSS2; Androgen receptor; Hazard ratio; Biomarker; Proportional hazards model; Cohort; Prostate-specific antigen; Cancer; Biology; Confidence interval","score_opus":0.03655410463946437,"score_gpt":0.3295290521999639,"score_spread":0.2929749475604996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312129219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882103,0.0013173138,0.000028413917,0.0024379822,0.00002464023,0.0073143877,0.00026826048,0.00005449845,0.00034419834],"genre_scores_gemma":[0.9895299,0.0002718828,0.00015867811,0.00013165639,0.000007676118,0.004490732,0.00007668035,0.00005634988,0.0052764253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977186,0.00036487795,0.0003535062,0.00051576644,0.0005681045,0.000479161],"domain_scores_gemma":[0.99908775,0.00017614462,0.0001589912,0.0002827003,0.0001720643,0.00012232953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005715244,0.00034003105,0.00046161746,0.00021885027,0.0003931126,0.000058872003,0.000118651486,0.000020524278,0.00007736301],"category_scores_gemma":[0.000034938388,0.00018061594,0.00004456879,0.00087057636,0.00030481574,0.00014217237,0.00010343814,0.0005130399,0.0000024741025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07311789,0.0050362307,0.6089414,0.00030969727,0.0032524755,0.002077234,0.258289,0.006773169,0.018716337,0.00021809479,0.00029218406,0.022976272],"study_design_scores_gemma":[0.07084948,0.018144147,0.55446464,0.0008866349,0.0021838935,0.0003082354,0.1588987,0.18468145,0.0051283007,0.0026484327,0.00031872006,0.0014873939],"about_ca_topic_score_codex":0.0011693765,"about_ca_topic_score_gemma":0.0010951933,"teacher_disagreement_score":0.17790827,"about_ca_system_score_codex":0.000499739,"about_ca_system_score_gemma":0.0006253152,"threshold_uncertainty_score":0.7365305},"labels":[],"label_agreement":null},{"id":"W4312139441","doi":"10.1136/ijgc-2022-igcs.206","title":"EP115/#640 Are all stage IA p53abn endometrial cancers the same? Seeking clarity in the management of stage IA p53abn and/or non-endometrioid endometrial cancers without myometrial invasion","year":2022,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Stage (stratigraphy); Medicine; Endometrial cancer; Oncology; Internal medicine; Chemotherapy; Adjuvant therapy; Retrospective cohort study; Adjuvant; Cancer; Gynecology; Gastroenterology; Biology","score_opus":0.0831108309517018,"score_gpt":0.39807388206524663,"score_spread":0.31496305111354483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312139441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981877,0.0054719723,0.00009329832,0.0054824413,0.0039487816,0.0018450727,0.0004881209,0.000014207319,0.0007790971],"genre_scores_gemma":[0.98313385,0.012874953,0.0003020943,0.0011880378,0.0010925733,0.00028494396,0.00002864536,0.00002896448,0.0010659195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939077,0.00063406443,0.0012476364,0.0004713804,0.0031410665,0.000598136],"domain_scores_gemma":[0.994641,0.0030023442,0.0013030593,0.00030013014,0.00053887785,0.00021458403],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0041169827,0.0003486628,0.0009435318,0.001585431,0.00028773886,0.00012875267,0.0012131603,0.00014483258,0.0033459435],"category_scores_gemma":[0.001653472,0.00018784424,0.00041898587,0.002319726,0.00035332062,0.00024230633,0.0006108561,0.0016070523,0.000002072552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19753945,0.0031096714,0.6328888,0.0007889458,0.012392019,0.011880071,0.005133958,0.014362393,0.006689026,0.0006589643,0.006457252,0.108099476],"study_design_scores_gemma":[0.17017446,0.017643135,0.6167216,0.0014462463,0.0018060666,0.00061704236,0.025504852,0.0013052771,0.0033015986,0.000648072,0.1596349,0.0011968045],"about_ca_topic_score_codex":0.002329784,"about_ca_topic_score_gemma":0.0013142561,"teacher_disagreement_score":0.15317765,"about_ca_system_score_codex":0.0050195507,"about_ca_system_score_gemma":0.0012377057,"threshold_uncertainty_score":0.9988},"labels":[],"label_agreement":null},{"id":"W4312143504","doi":"10.1016/j.clgc.2022.12.006","title":"Association of Androgen Deprivation Therapy with Metabolic Disease in Prostate Cancer Patients: An Updated Meta-Analysis","year":2022,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Internal medicine; Meta-analysis; Relative risk; Diabetes mellitus; Confidence interval; Metabolic syndrome; Oncology; Random effects model; Cancer; Endocrinology; Obesity","score_opus":0.19316705373262885,"score_gpt":0.4690140193793063,"score_spread":0.27584696564667743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312143504","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029192764,0.96561635,5.414636e-7,0.00025877918,0.0001511075,0.003048801,0.0016627703,0.000033337496,0.000035543726],"genre_scores_gemma":[0.0012380836,0.9863861,0.000042259333,0.0001517534,0.00021069098,0.003917359,0.0056699878,0.000090648595,0.0022930996],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99472994,0.0012553155,0.0015915617,0.00095461844,0.0010019108,0.00046663274],"domain_scores_gemma":[0.9968622,0.00029041685,0.0013451477,0.0007198938,0.00040090547,0.00038144147],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009777026,0.0005225838,0.0045591695,0.000644824,0.0000916439,0.000025132891,0.00028732128,0.00022255655,0.0034867048],"category_scores_gemma":[0.00008023219,0.00032333136,0.0021951103,0.0025455873,0.00010163414,0.00018484477,0.000114463975,0.0008304062,0.0000041588264],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026393055,0.0033049772,0.36354962,0.0014236494,0.22347656,0.00014222109,0.00008729043,0.0001057369,1.4943672e-7,0.000001044722,0.00060116954,0.4046683],"study_design_scores_gemma":[0.0029429644,0.0008447,0.020168468,0.00015881596,0.27477214,4.5755803e-7,0.000009365025,0.00001975216,0.000002729868,0.0000061969167,0.7007466,0.0003278381],"about_ca_topic_score_codex":0.0005042297,"about_ca_topic_score_gemma":0.00016895514,"teacher_disagreement_score":0.7001454,"about_ca_system_score_codex":0.0007502661,"about_ca_system_score_gemma":0.002433048,"threshold_uncertainty_score":0.99992186},"labels":[],"label_agreement":null},{"id":"W4312280366","doi":"10.7554/elife.77072.sa1","title":"Decision letter: The CIC-ERF co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progression","year":2022,"lang":"en","type":"peer-review","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Prostate cancer; Family member; Cancer research; Cancer; Computer science; Medicine; Internal medicine; Family medicine","score_opus":0.05809681822456377,"score_gpt":0.4140566714793321,"score_spread":0.35595985325476837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312280366","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.059004582,0.14076678,0.0009144486,0.73300683,0.006999097,0.036190037,0.0018621419,0.00039952414,0.020856565],"genre_scores_gemma":[0.035618015,0.35477328,0.0014889259,0.04228475,0.0018697396,0.012028122,0.014739637,0.00042873356,0.5367688],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942247,0.00029328425,0.0008472429,0.0008827622,0.0031829032,0.00056907785],"domain_scores_gemma":[0.99717045,0.00034468944,0.00052947213,0.00086965144,0.0008542518,0.00023150271],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00105239,0.0005537466,0.0010180229,0.00042482023,0.0003665723,0.000054478765,0.0004179536,0.00028018458,0.003913832],"category_scores_gemma":[0.0001719882,0.00030808858,0.00032486924,0.0007504975,0.0001415848,0.00012663518,0.0004873312,0.001057476,0.000048643873],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011081732,0.00025043517,0.0001727991,0.002089951,0.00023029302,0.000030034556,0.00040565216,0.000034450368,0.004209198,0.000012541832,0.7795723,0.21188417],"study_design_scores_gemma":[0.001984697,0.0008953312,0.00091559294,0.011255335,0.0003863576,0.000013637767,0.00030588222,0.000036458772,0.012239354,0.000073619594,0.97153413,0.0003595734],"about_ca_topic_score_codex":0.001123713,"about_ca_topic_score_gemma":0.00021532807,"teacher_disagreement_score":0.69072205,"about_ca_system_score_codex":0.0012535442,"about_ca_system_score_gemma":0.0011785006,"threshold_uncertainty_score":0.9999371},"labels":[],"label_agreement":null},{"id":"W4312716611","doi":"10.48083/vdnp9678","title":"Impact of Androgen Deprivation Therapy on Cardiovascular Outcomes in Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"Société Internationale d’Urologie Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Androgen deprivation therapy; Aspirin; Myocardial infarction; Disease; Androgen; Blood pressure; Cardiology; Oncology; Endocrinology; Cancer; Hormone","score_opus":0.06907323911175185,"score_gpt":0.4046130714089691,"score_spread":0.3355398322972173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312716611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99300736,0.0038428109,0.0000073865526,0.0018615249,0.00024324829,0.00038243164,0.00006794693,0.00001228273,0.0005749861],"genre_scores_gemma":[0.99453884,0.0041110376,0.000028998831,0.00020152067,0.00008476099,0.00013104001,0.000043112042,0.000012417145,0.0008482792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844176,0.00013575068,0.00028202677,0.00016118152,0.0007669245,0.0002123783],"domain_scores_gemma":[0.9993729,0.00009548729,0.00014550838,0.00014925005,0.00017810933,0.000058754926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005568463,0.00011512824,0.000317076,0.00028857047,0.000105414445,0.000015091242,0.00015667338,0.000031099327,0.0008647003],"category_scores_gemma":[0.00008538144,0.000078754216,0.0005065959,0.00017889104,0.000045771554,0.00007832143,0.00006179371,0.0004956178,0.0000016442519],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001600131,0.00042619315,0.9594379,0.000005181312,0.001762316,0.00014358104,0.00043319273,0.0064704316,0.00049429503,0.000017520912,0.00043599337,0.02877326],"study_design_scores_gemma":[0.0072254864,0.0016229115,0.98667085,0.000017186923,0.0000352196,0.00010659991,0.00017697268,0.00019027946,0.0008436823,0.00063878484,0.0023873067,0.00008470502],"about_ca_topic_score_codex":0.00019047057,"about_ca_topic_score_gemma":0.0000033497074,"teacher_disagreement_score":0.028688554,"about_ca_system_score_codex":0.0009784978,"about_ca_system_score_gemma":0.0005197564,"threshold_uncertainty_score":0.94678617},"labels":[],"label_agreement":null},{"id":"W4313199635","doi":"10.14740/wjon1476","title":"Treatment Patterns Among Patients With Advanced Prostate Cancer in Brazil: An Analysis of a Private Healthcare System Database","year":2022,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Medicine; Docetaxel; Cabazitaxel; Prostate cancer; Abiraterone; Oncology; Clinical endpoint; Internal medicine; Abiraterone acetate; Cancer; Clinical trial; Androgen deprivation therapy; Androgen receptor","score_opus":0.0211890470935008,"score_gpt":0.36938752278265385,"score_spread":0.3481984756891531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313199635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99692863,0.00079305907,0.0000062161994,0.00092390686,0.00012433396,0.00070200575,0.00046824184,0.000006780936,0.00004679951],"genre_scores_gemma":[0.99878037,0.00043102202,0.00016521689,0.000059544236,0.000030051038,0.00013518086,0.00018760952,0.000018658111,0.00019235771],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981238,0.0003117044,0.0005867805,0.00021170141,0.0004672415,0.0002987278],"domain_scores_gemma":[0.99860734,0.000058977617,0.0006289463,0.00023585539,0.00025339556,0.00021550427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027847072,0.0001437251,0.0008323208,0.0011718192,0.00007776056,0.0000049620025,0.00011974861,0.000023858169,0.00014776594],"category_scores_gemma":[0.0000065371664,0.00009420566,0.000113949194,0.0011648199,0.0000643713,0.00013434472,0.000056177265,0.0003031073,1.9243878e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008154706,0.0013980753,0.95801145,0.0001346457,0.001174645,0.0010097957,0.0013386708,0.0022950964,0.0000887332,0.00001763476,0.000009592896,0.026366927],"study_design_scores_gemma":[0.0132224215,0.0126260845,0.96980304,0.00022363309,0.00096805766,0.000026117972,0.001316332,0.00040915038,0.00017116744,0.0000013672505,0.0011463905,0.000086259104],"about_ca_topic_score_codex":0.0013426048,"about_ca_topic_score_gemma":0.010811205,"teacher_disagreement_score":0.026280668,"about_ca_system_score_codex":0.0031354234,"about_ca_system_score_gemma":0.0007375835,"threshold_uncertainty_score":0.81990236},"labels":[],"label_agreement":null},{"id":"W4313398972","doi":"10.1016/j.ijrobp.2022.12.038","title":"Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus","year":2022,"lang":"en","type":"review","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Jonsson Comprehensive Cancer Center; National Institutes of Health; Klaus Tschira Stiftung; Deutsche Forschungsgemeinschaft; Bundesministerium für Bildung und Forschung; National Institute for Health and Care Research; Veracyte; Pfizer; Royal Marsden NHS Foundation Trust; Department of Health and Social Care; Stop Cancer; Cancer Research UK; Astellas Pharma; Novocure; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Medicine; Prostate cancer; Delphi method; Systematic review; Disease; Clinical trial; Risk stratification; Radiation therapy; Medical physics; Clinical Practice; Oncology; Internal medicine; MEDLINE; Cancer; Family medicine; Artificial intelligence","score_opus":0.07962738267374248,"score_gpt":0.39922894022248573,"score_spread":0.31960155754874325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313398972","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023022927,0.98693436,0.000016926804,0.008055665,0.0013814666,0.0027093764,0.00035098975,0.000022036791,0.00029896077],"genre_scores_gemma":[0.0005431885,0.9952099,0.00016630982,0.00093927555,0.0016154683,0.0006705605,0.0006182398,0.000066195884,0.00017088043],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99614847,0.0011390528,0.0013454244,0.00050173566,0.0005783961,0.00028695213],"domain_scores_gemma":[0.9962052,0.0007708132,0.0022451077,0.00022006313,0.00040745325,0.00015136626],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012186719,0.000470578,0.0023410372,0.00065630424,0.00009075082,0.000047612484,0.0004614194,0.00032767135,0.00030125285],"category_scores_gemma":[0.0002833154,0.000341608,0.000619578,0.00035707498,0.00026248142,0.00010944148,0.000059751088,0.0012480058,0.000006677599],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014089724,0.0011851046,0.0029436091,0.04469967,0.005630035,0.0002219141,0.0020312069,0.000058731333,0.000006604799,0.0019256641,0.0011247593,0.93876374],"study_design_scores_gemma":[0.012982075,0.0016408317,0.00029645732,0.036338355,0.0026920477,0.0004492602,0.0009502253,0.0009186923,0.0000028019267,0.00024158532,0.94295806,0.0005295839],"about_ca_topic_score_codex":0.000013405144,"about_ca_topic_score_gemma":0.0000017502338,"teacher_disagreement_score":0.9418333,"about_ca_system_score_codex":0.0051148157,"about_ca_system_score_gemma":0.0028622928,"threshold_uncertainty_score":0.9999036},"labels":[],"label_agreement":null},{"id":"W4313430004","doi":"10.1002/bco2.212","title":"Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta‐analysis","year":2023,"lang":"en","type":"review","venue":"BJUI Compass","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Prevention of Organ Failure; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Sichuan University; Terry Fox Research Institute; Mitacs; National Natural Science Foundation of China","keywords":"Prostate cancer; Meta-analysis; Oncology; Biology; Computational biology; Internal medicine; Medicine; Cancer","score_opus":0.1500761195005275,"score_gpt":0.43238742868742336,"score_spread":0.28231130918689584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313430004","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000024493902,0.9896361,0.0000019061752,0.0015596759,0.000034149714,0.008267982,0.0003663462,0.00006563329,0.000065755004],"genre_scores_gemma":[0.000009358725,0.9815999,0.00002010216,0.00020885792,0.00002923131,0.008389541,0.00045254623,0.000065717446,0.00922469],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9972378,0.00042818434,0.0010651518,0.00056999875,0.00029214055,0.0004067052],"domain_scores_gemma":[0.9985547,0.00024083248,0.00032514692,0.00061156455,0.000084860796,0.00018286148],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031543142,0.00045516668,0.008320438,0.00077171304,0.00007021131,0.000059219612,0.00016894203,0.000043549462,0.00013014417],"category_scores_gemma":[0.000053292777,0.00027685886,0.0011589637,0.0019455283,0.00005357734,0.000044717257,0.00013663092,0.00039723274,0.00009180898],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005380653,0.000043453354,0.000011621751,0.9104174,0.08801452,0.0003351081,0.0000204469,0.0000019797046,5.8005853e-8,0.000016579104,0.00045807988,0.00067538477],"study_design_scores_gemma":[0.00033141187,0.000049113085,0.000013975834,0.100469805,0.8593126,0.00009979038,0.000006203525,0.000049903017,1.2281373e-7,0.000007161731,0.03944212,0.00021777808],"about_ca_topic_score_codex":0.00030081763,"about_ca_topic_score_gemma":0.00035848477,"teacher_disagreement_score":0.8099476,"about_ca_system_score_codex":0.00026806642,"about_ca_system_score_gemma":0.00041042315,"threshold_uncertainty_score":0.99996835},"labels":[],"label_agreement":null},{"id":"W4313430511","doi":"10.7759/cureus.32699","title":"Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"Cureus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Testosterone (patch); Leuprorelin; Internal medicine; Agonist; Androgen; Endocrinology; Oncology; Luteinizing hormone; Hormone; Cancer; Gonadotropin-releasing hormone; Receptor","score_opus":0.04079660287258937,"score_gpt":0.3306746327516567,"score_spread":0.28987802987906736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313430511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98565406,0.011334133,0.00002102876,0.0013886141,0.00012996973,0.0012161582,0.00013975769,0.000015743672,0.00010052323],"genre_scores_gemma":[0.99537337,0.0010949983,0.0001139684,0.00010430578,0.000051460393,0.0016267876,0.00022460455,0.000015279596,0.0013952383],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99932986,0.000025488453,0.000124022,0.00015380268,0.00022865026,0.00013814592],"domain_scores_gemma":[0.9996317,0.000020627996,0.00005959118,0.00013933126,0.0001066907,0.000042066928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010466358,0.00006884707,0.00011780488,0.0000460466,0.00009267676,0.0000056822582,0.00004573922,0.000022839022,0.0003975096],"category_scores_gemma":[0.0000094321895,0.000051532974,0.00007037568,0.0000959963,0.000027183025,0.00005836329,0.00003885659,0.000060484363,6.218196e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016492072,0.0012703252,0.70162237,0.00044927912,0.0005657076,0.000018173168,0.00871893,0.00023639119,0.17620823,0.000023393864,0.0068820366,0.08751311],"study_design_scores_gemma":[0.031518806,0.011789164,0.33152446,0.000313122,0.0004306567,0.00003604711,0.0031803374,0.002581048,0.48801562,0.0005133095,0.12957047,0.00052696775],"about_ca_topic_score_codex":0.00006750783,"about_ca_topic_score_gemma":0.0000055620576,"teacher_disagreement_score":0.37009788,"about_ca_system_score_codex":0.0001907629,"about_ca_system_score_gemma":0.0001287422,"threshold_uncertainty_score":0.43524516},"labels":[],"label_agreement":null},{"id":"W4313462518","doi":"10.1038/s41388-022-02566-6","title":"Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer","year":2023,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Comprehensive Cancer Center, University of California, Davis; National Institute of Environmental Health Sciences; U.S. Department of Health and Human Services; National Institutes of Health; National Cancer Institute; University of California, Davis; U.S. Department of Defense","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Cancer research; Biology; Cancer; Androgen; Androgen deprivation therapy; Internal medicine; Endocrinology; Medicine; Hormone","score_opus":0.025061863310749315,"score_gpt":0.32647815971864974,"score_spread":0.3014162964079004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313462518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98951775,0.007642478,0.0000030223089,0.0011498774,0.000065456006,0.0008163546,0.0004853256,0.00004710536,0.00027261866],"genre_scores_gemma":[0.96166795,0.028513353,0.00039653268,0.00005390323,0.000056015513,0.0005760604,0.00052790326,0.000038595477,0.008169709],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889237,0.000024751656,0.00024031717,0.00031020603,0.0002227846,0.00030960134],"domain_scores_gemma":[0.99955076,0.000046777073,0.000065274384,0.00014340764,0.000068174435,0.0001256007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011992318,0.00016153413,0.00033004038,0.0001750184,0.000042878226,0.000007789269,0.000027751812,0.000069894115,0.000075316246],"category_scores_gemma":[0.000021959991,0.000121624835,0.00004995559,0.00047332625,0.00009305667,0.000075350086,0.000034745106,0.00006618746,0.000014402305],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008769438,0.00027454013,0.019349769,0.000118531796,0.000096268166,0.000037198242,0.00073078246,0.00002312544,0.889293,0.000005603672,0.00079223816,0.08840198],"study_design_scores_gemma":[0.009423813,0.0011296336,0.004606785,0.00032320028,0.000057610498,0.0000082756205,0.0003931832,0.00012313909,0.97200423,0.000027292599,0.011751098,0.00015174769],"about_ca_topic_score_codex":0.000723786,"about_ca_topic_score_gemma":0.00022062889,"teacher_disagreement_score":0.088250235,"about_ca_system_score_codex":0.00035008768,"about_ca_system_score_gemma":0.00019449237,"threshold_uncertainty_score":0.49597168},"labels":[],"label_agreement":null},{"id":"W4313527677","doi":"10.1097/01.cot.0000912080.84806.bc","title":"Shorter Course of Radiation Therapy Safe &amp; Effective in Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Oncology Times","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Radiation therapy; Prostate; Cancer; Randomized controlled trial; Disease; Oncology; Internal medicine; Clinical trial","score_opus":0.027576897832261943,"score_gpt":0.4041965477424768,"score_spread":0.3766196499102149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313527677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984404,0.0032920619,9.184108e-7,0.0046723913,0.00013273425,0.0010165774,0.000024902236,0.000032934317,0.0064234394],"genre_scores_gemma":[0.9724992,0.0081908675,0.000026089823,0.00014953112,0.00007445204,0.0005044218,0.000118671225,0.000014651386,0.018422147],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993112,0.00008614615,0.00013346164,0.00015482846,0.00010611108,0.00020823098],"domain_scores_gemma":[0.99959266,0.0001501222,0.00004418927,0.00010880491,0.00005740626,0.000046829922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024965295,0.00007976235,0.0002550636,0.00015056663,0.000022720806,0.000002336169,0.00003531887,0.000074225005,0.0004194014],"category_scores_gemma":[0.00001850469,0.000055009128,0.000041284264,0.00033346875,0.00010721494,0.000036739977,0.00001591963,0.00012359145,0.00008471726],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016752953,0.0003031381,0.440867,0.000042594664,0.00019439166,0.00007310642,0.002957047,0.000023572042,0.008737041,0.00001533618,0.020710215,0.52440125],"study_design_scores_gemma":[0.0064251116,0.0011953509,0.8895789,0.00007166155,0.000033603097,0.0000059698323,0.00020555643,0.0001322932,0.020672161,0.00017830059,0.08141901,0.00008211771],"about_ca_topic_score_codex":0.00015000308,"about_ca_topic_score_gemma":0.0001333677,"teacher_disagreement_score":0.5243191,"about_ca_system_score_codex":0.00021870484,"about_ca_system_score_gemma":0.0003573419,"threshold_uncertainty_score":0.45921513},"labels":[],"label_agreement":null},{"id":"W4313627518","doi":"10.1016/j.clgc.2023.01.001","title":"Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Foundation Medicine; Ipsen; National Institute for Health and Care Research; Astellas Pharma; F. Hoffmann-La Roche; Sanofi; Pfizer; Genentech; Medical Research Council; PharmaMar; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Discontinuation; Placebo; Prostate cancer; Internal medicine; Prednisone; Rash; Adverse effect; Prednisolone; Gastroenterology; Cancer; Oncology; Urology; Pathology","score_opus":0.1045101810834043,"score_gpt":0.4297782096430927,"score_spread":0.3252680285596884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313627518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98709947,0.0039256113,0.0000060652014,0.003423666,0.0007480797,0.0028189914,0.0014394375,0.00012561903,0.00041304424],"genre_scores_gemma":[0.96972215,0.011506708,0.00036455208,0.0002892153,0.0005116776,0.0018686355,0.0007644138,0.00010192069,0.0148707125],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9955262,0.00034919125,0.0016439701,0.00083983765,0.0007159861,0.0009248084],"domain_scores_gemma":[0.9979223,0.00037903275,0.00034999568,0.00061443076,0.0003059015,0.00042832404],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010727429,0.00041609915,0.001210867,0.00032942154,0.00013680589,0.000031423006,0.0002544637,0.00019181163,0.0010322108],"category_scores_gemma":[0.00014365074,0.00032681003,0.00024303499,0.0011307921,0.00044622234,0.00021178379,0.00019561133,0.0006720566,0.00016701565],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3560484,0.0047115525,0.3196518,0.009586946,0.00404204,0.0150868725,0.006219559,0.014866488,0.10295712,0.00007684953,0.07634987,0.0904025],"study_design_scores_gemma":[0.087233074,0.008888867,0.82814264,0.0033639383,0.0010823351,0.000053716896,0.0020532683,0.010334171,0.040125713,0.00021897025,0.016956566,0.0015467235],"about_ca_topic_score_codex":0.0015607931,"about_ca_topic_score_gemma":0.0010427238,"teacher_disagreement_score":0.50849086,"about_ca_system_score_codex":0.00089440006,"about_ca_system_score_gemma":0.0028284108,"threshold_uncertainty_score":0.9999184},"labels":[],"label_agreement":null},{"id":"W4313702110","doi":"10.1093/jnci/djad001","title":"A polygenic two-hit hypothesis for prostate cancer","year":2023,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Public Health Ontario; Lunenfeld-Tanenbaum Research Institute; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Vector Institute; Ontario Institute for Cancer Research","funders":"Helse Sør-Øst RHF; Novo Nordisk Fonden; Norges Forskningsråd; Universitetet i Oslo; National Cancer Institute; National Institutes of Health; Cancer Research UK; Prostate Cancer Canada; Canadian Institutes of Health Research; Genome Canada; Movember Foundation","keywords":"Prostate cancer; Germline; Carcinogenesis; Germline mutation; Biology; Cancer; Oncology; Risk stratification; Somatic cell; Genetics; Medicine; Internal medicine; Gene; Mutation","score_opus":0.13533651695378116,"score_gpt":0.4222117836403943,"score_spread":0.2868752666866131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313702110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92015994,0.0049973475,0.000026298403,0.06688489,0.0045199483,0.001320633,0.00063748326,0.000043944015,0.0014094952],"genre_scores_gemma":[0.97148424,0.0035616157,0.00035675822,0.0017392125,0.0030350327,0.0003159445,0.000012098202,0.00003520245,0.019459883],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99825865,0.000025463722,0.00034388877,0.00013746436,0.0009574943,0.00027703444],"domain_scores_gemma":[0.9983834,0.00011175341,0.00025865535,0.00009259507,0.0010308983,0.00012272157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045233476,0.00012581382,0.00024764938,0.00024924078,0.00020980676,0.000029363866,0.00022196825,0.000046844878,0.00008338507],"category_scores_gemma":[0.00031025993,0.00007268316,0.0002933032,0.0006469059,0.00012426064,0.00020066586,0.000046808163,0.00022751965,0.000013469591],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01290738,0.00062367175,0.09686482,0.0009998489,0.005438128,0.00018045025,0.0025145733,0.017907988,0.09620941,0.0021457977,0.599189,0.16501898],"study_design_scores_gemma":[0.023626475,0.00070028764,0.21166912,0.0015445185,0.0009914578,0.0003395095,0.00016485792,0.0017572206,0.04777909,0.011269506,0.6996609,0.0004970482],"about_ca_topic_score_codex":0.000105959036,"about_ca_topic_score_gemma":0.00016183131,"teacher_disagreement_score":0.16452193,"about_ca_system_score_codex":0.0008965949,"about_ca_system_score_gemma":0.0025999767,"threshold_uncertainty_score":0.4612247},"labels":[],"label_agreement":null},{"id":"W4313816321","doi":"10.1158/1538-7755.disp22-c036","title":"Abstract C036: Correlation of Kaiso and androgen receptor expression in women of African ancestry with triple-negative breast cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Triple-negative breast cancer; Androgen receptor; Breast cancer; Tissue microarray; Cancer research; Oncology; Cancer; Immunohistochemistry; Metastasis; Transcription factor; Medicine; Internal medicine; Biology; Prostate cancer; Genetics; Gene","score_opus":0.05854476101759445,"score_gpt":0.38378851079210186,"score_spread":0.32524374977450743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313816321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919863,0.0049661184,0.000052527626,0.0017178279,0.00015190168,0.00082009536,0.00014728258,0.000027909773,0.00013008324],"genre_scores_gemma":[0.98998624,0.008547108,0.0003973794,0.000027527198,0.000049238002,0.00049568154,0.000108086555,0.000018479031,0.0003702476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829155,0.00026475938,0.00054170785,0.00038014393,0.0001530708,0.0003687638],"domain_scores_gemma":[0.9987366,0.0003790884,0.0004610905,0.00017057823,0.00012611883,0.00012652608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010972803,0.00016655658,0.0005951786,0.00029810917,0.00004453389,0.000001970481,0.00006429764,0.00017798148,0.00022226709],"category_scores_gemma":[0.00013277649,0.0001217124,0.0000651583,0.0006230949,0.00039917981,0.00014051267,0.00003788501,0.00017001266,0.0000020481093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0087520275,0.0001255492,0.9123213,0.0004560716,0.00037502445,0.000006542639,0.0008318993,0.00008288352,0.023229448,0.0000079815,0.0014020322,0.052409228],"study_design_scores_gemma":[0.0042073024,0.00039530027,0.98237264,0.0018632618,0.00006126365,0.0000050470103,0.0010393473,0.0003138605,0.008846599,0.0006771558,0.000099853845,0.000118372],"about_ca_topic_score_codex":0.0007606299,"about_ca_topic_score_gemma":0.00015383205,"teacher_disagreement_score":0.07005133,"about_ca_system_score_codex":0.0003326188,"about_ca_system_score_gemma":0.00030903413,"threshold_uncertainty_score":0.49632877},"labels":[],"label_agreement":null},{"id":"W4313857431","doi":"10.1158/1535-7163.mct-22-0159","title":"Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Research Nova Scotia; Canadian Institutes of Health Research; Li Ka Shing Foundation","keywords":"TMPRSS2; Prostate cancer; Erg; Cancer; Prostate; Medicine; Biology; Cancer research; Ophthalmology; Internal medicine; Coronavirus disease 2019 (COVID-19); Retinal; Disease","score_opus":0.03742462221571558,"score_gpt":0.35936550688908914,"score_spread":0.32194088467337356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313857431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94725406,0.00826857,0.00008456783,0.04087819,0.00042277793,0.0020227332,0.00021328162,0.00021228917,0.00064350193],"genre_scores_gemma":[0.97284853,0.009890891,0.000049223458,0.0084522115,0.00020343064,0.0012719443,0.000075666976,0.00010792729,0.007100192],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976349,0.00010779017,0.00025134248,0.0004983527,0.00072044303,0.0007872119],"domain_scores_gemma":[0.99877506,0.000094454066,0.0000735189,0.0005449884,0.00025852764,0.0002534385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020584789,0.00032551578,0.00034439465,0.00018899422,0.0002859145,0.000074058444,0.00025513416,0.00010766539,0.00020509379],"category_scores_gemma":[0.000016161423,0.00020786794,0.00017469127,0.0012785137,0.00014907675,0.00006991121,0.00017461296,0.00037747223,0.0001462931],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027749396,0.00028718825,0.041181836,0.00022198676,0.0027986222,0.0012417235,0.008762604,0.0014390203,0.78221405,0.00037124965,0.005359789,0.153347],"study_design_scores_gemma":[0.004015409,0.00079995533,0.068222195,0.000590082,0.00063497084,0.000028911587,0.00085321715,0.001122148,0.79848105,0.00071843393,0.12383389,0.00069973717],"about_ca_topic_score_codex":0.0007184405,"about_ca_topic_score_gemma":0.00013455101,"teacher_disagreement_score":0.15264727,"about_ca_system_score_codex":0.0003912543,"about_ca_system_score_gemma":0.00054113625,"threshold_uncertainty_score":0.84766084},"labels":[],"label_agreement":null},{"id":"W4313891451","doi":"10.1158/1538-7755.disp22-b131","title":"Abstract B131: Efficacy and safety of darolutamide in combination with androgen-deprivation therapy (ADT) and docetaxel in Black/African-American patients from the phase 3 ARASENS trial","year":2023,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Docetaxel; Medicine; Androgen deprivation therapy; Prostate cancer; Internal medicine; Population; Clinical endpoint; Oncology; Randomized controlled trial; Cancer","score_opus":0.06115497044165732,"score_gpt":0.39389480720932013,"score_spread":0.33273983676766283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313891451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99265724,0.0018844624,0.00003314823,0.003310294,0.000069841524,0.0019462035,0.000053119762,0.000020132024,0.00002556717],"genre_scores_gemma":[0.9896933,0.009386423,0.00008059596,0.00008824086,0.000036762387,0.0001584623,0.00052314496,0.000014379956,0.000018703113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981838,0.00047111933,0.000541911,0.00038450173,0.00014409995,0.00027457825],"domain_scores_gemma":[0.9982433,0.0010932839,0.00034237411,0.00018735013,0.00006310583,0.00007061117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013397029,0.00015762246,0.00048514665,0.00021208411,0.000056161392,0.0000052813357,0.000060465725,0.00009353658,0.000016903257],"category_scores_gemma":[0.0003218403,0.000103049606,0.000046935438,0.00055328687,0.00055460527,0.00009247177,0.000029841984,0.00017121134,0.0000011774877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06758777,0.0005346059,0.81069887,0.000027606264,0.00025114062,0.0000060476464,0.00050338794,0.000015965941,0.00092521723,0.000016132588,0.00016526341,0.11926801],"study_design_scores_gemma":[0.097969845,0.0014310037,0.8984872,0.0002441882,0.000048416416,5.2838334e-7,0.00023987172,0.00042013227,0.00025261723,0.0006773417,0.0001416963,0.00008717476],"about_ca_topic_score_codex":0.0016210207,"about_ca_topic_score_gemma":0.0005104822,"teacher_disagreement_score":0.11918083,"about_ca_system_score_codex":0.00016834341,"about_ca_system_score_gemma":0.00012173744,"threshold_uncertainty_score":0.4202241},"labels":[],"label_agreement":null},{"id":"W4315474239","doi":"10.21203/rs.3.rs-2423179/v1","title":"The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, decreases DNA damage repair, and predicts therapy responses.","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"Canada Research Chairs; Broad Institute; Thomas Jefferson University; Comprehensive Cancer Center, City of Hope","keywords":"Intraepithelial neoplasia; Prostate cancer; Cancer; Prostate; Medicine; High-grade prostatic intraepithelial neoplasia; Cancer research; Gene; Biology; Internal medicine; Genetics","score_opus":0.10045534441938575,"score_gpt":0.42196888807006466,"score_spread":0.3215135436506789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315474239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94898796,0.025711128,0.0000014863024,0.0128398705,0.00026313207,0.0095415,0.0021522478,0.0003388421,0.0001638594],"genre_scores_gemma":[0.71838605,0.25843906,0.00028588262,0.00021736087,0.0006018045,0.0075238114,0.0011517669,0.00030833352,0.013085902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99090385,0.0018209146,0.00091770483,0.0016568602,0.0026498516,0.0020508103],"domain_scores_gemma":[0.99407315,0.0021250367,0.00020141082,0.001705496,0.0010807528,0.00081417465],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0045018983,0.000673065,0.0008862304,0.0011304852,0.0008205075,0.0004536324,0.00061749876,0.00048113297,0.00008220342],"category_scores_gemma":[0.0022698739,0.00044993786,0.00028042975,0.0014284633,0.0015093285,0.00014863053,0.0010980422,0.0033440755,0.000035404886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07143181,0.0025419756,0.71547616,0.011484196,0.0037028182,0.025172763,0.028700119,0.000103695886,0.019007826,0.00025166862,0.04190137,0.080225594],"study_design_scores_gemma":[0.022319319,0.006733818,0.8984373,0.012730189,0.0002239631,0.00020051691,0.005794213,0.0072088954,0.021284817,0.0072388747,0.016380724,0.0014473493],"about_ca_topic_score_codex":0.007899412,"about_ca_topic_score_gemma":0.0026581264,"teacher_disagreement_score":0.23272794,"about_ca_system_score_codex":0.0012322927,"about_ca_system_score_gemma":0.006117661,"threshold_uncertainty_score":0.99979526},"labels":[],"label_agreement":null},{"id":"W4315606641","doi":"10.1097/rlu.0000000000004544","title":"Port-Site Metastasis Identified on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT After Robot-Assisted Laparoscopic Radical Prostatectomy","year":2023,"lang":"en","type":"article","venue":"Clinical Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Laparoscopic radical prostatectomy; Metastasis; Glutamate carboxypeptidase II; Surgical margin; Prostate-specific antigen; Biochemical recurrence; Biopsy; Prostate; Radiology; Urology; Cancer; Internal medicine","score_opus":0.07792931325361548,"score_gpt":0.3858572743243281,"score_spread":0.30792796107071263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315606641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749111,0.0016118733,0.0000033209596,0.01684275,0.0016392187,0.0024116472,0.000111188245,0.00083432964,0.0016345949],"genre_scores_gemma":[0.9772747,0.0092621595,0.00032195786,0.0027481015,0.00095636107,0.0001771107,0.0010876106,0.00023256295,0.007939427],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9930826,0.00048335863,0.0018569187,0.0015361554,0.0016991637,0.0013418195],"domain_scores_gemma":[0.9960605,0.0007176672,0.0003224459,0.0012997044,0.00033344142,0.0012662517],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0022936957,0.0006691853,0.0018885548,0.0006862073,0.0003207508,0.00008107799,0.0003651113,0.00010413673,0.004460153],"category_scores_gemma":[0.00096580613,0.00045988988,0.0005312156,0.0019122564,0.0016599115,0.00018108836,0.00023238022,0.0014971293,0.0042211325],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058190353,0.0071443757,0.14762485,0.0029580332,0.0046737646,0.18127924,0.0021394934,0.000024945393,0.058422226,0.0004948757,0.45771667,0.07933118],"study_design_scores_gemma":[0.030823775,0.005785091,0.6930441,0.001971727,0.0006416527,0.0007219659,0.0005272386,0.0003679232,0.002597826,0.00013371836,0.26261818,0.00076679327],"about_ca_topic_score_codex":0.00006340985,"about_ca_topic_score_gemma":0.000012333484,"teacher_disagreement_score":0.5454192,"about_ca_system_score_codex":0.0002169126,"about_ca_system_score_gemma":0.00026145135,"threshold_uncertainty_score":0.9997853},"labels":[],"label_agreement":null},{"id":"W4315703068","doi":"10.1016/j.urolonc.2022.11.019","title":"A real-world retrospective analysis of the management of metastatic castrate-resistant prostate cancer in Ontario, Canada from 2010 – 2018","year":2023,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Sunnybrook Health Science Centre; AstraZeneca (Canada)","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Retrospective cohort study; Internal medicine; Cancer; Oncology; Cancer registry; Cohort; Abiraterone; Survival analysis; Clinical trial; Docetaxel; Androgen receptor","score_opus":0.03914345252339676,"score_gpt":0.33293876066128486,"score_spread":0.2937953081378881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315703068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99334294,0.0003139877,4.576407e-7,0.003877504,0.0001302358,0.00050029316,0.00037379574,0.000009167991,0.0014515994],"genre_scores_gemma":[0.9841493,0.001518416,0.0024135895,0.00013760033,0.000010266693,0.00018881513,0.00013478634,0.000008681816,0.0114385495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880284,0.00008762069,0.00034000629,0.00027175428,0.0002513435,0.0002464467],"domain_scores_gemma":[0.999299,0.00012232528,0.00018796224,0.00021530042,0.00007423197,0.000101207006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023177639,0.00012556816,0.00047119753,0.00029732153,0.00008514636,0.0000048504703,0.000094747826,0.00004724076,0.00022785807],"category_scores_gemma":[0.000013610101,0.0000816907,0.00006435601,0.0018611823,0.00047341647,0.00003269841,0.0000633003,0.00024565498,7.2298093e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024021813,0.00008394122,0.9931619,0.000044787743,0.0015164578,0.00026272275,0.0007238006,0.0005423952,0.00084675895,0.0007716881,0.0016585304,0.0001467533],"study_design_scores_gemma":[0.00082615536,0.00034933703,0.9831955,0.000100131176,0.0021277757,0.0000015292708,0.00060837285,0.000561743,0.00046706453,0.0015169384,0.010174981,0.00007047167],"about_ca_topic_score_codex":0.9411167,"about_ca_topic_score_gemma":0.99220467,"teacher_disagreement_score":0.05108795,"about_ca_system_score_codex":0.0009082747,"about_ca_system_score_gemma":0.001886226,"threshold_uncertainty_score":0.3346084},"labels":[],"label_agreement":null},{"id":"W4316661384","doi":"10.1172/jci163498","title":"BMX controls 3βHSD1 and sex steroid biosynthesis in cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"IONICS Mass Spectrometry (Canada)","funders":"U.S. Army Medical Research and Development Command; Astellas Pharma; National Cancer Institute; National Institutes of Health; Case Western Reserve University; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Aromatase; Androgen; Endocrinology; Prostate cancer; Androgen receptor; Internal medicine; Testosterone (patch); Intracrine; Cancer research; Biology; Cancer; Medicine; Hormone; Receptor; Breast cancer; Paracrine signalling","score_opus":0.19641566806755484,"score_gpt":0.47652843413848117,"score_spread":0.28011276607092633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316661384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98161507,0.0007859752,0.0000043092477,0.01712364,0.00018123147,0.00016009007,0.000003882668,0.00000953285,0.00011627808],"genre_scores_gemma":[0.99358416,0.0042838138,0.00018840395,0.0006767376,0.00040496173,0.0000073748456,0.0000035720134,0.000009007296,0.00084197737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986166,0.00014173357,0.0007310942,0.00010505166,0.00026852978,0.00013704094],"domain_scores_gemma":[0.9986803,0.000650897,0.00025416195,0.000071418704,0.00011487491,0.00022835653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016365066,0.000065259956,0.0003822768,0.00018745456,0.00002275516,0.000017520877,0.00004232046,0.00009359226,0.000031882355],"category_scores_gemma":[0.0010596595,0.000043493365,0.000080177146,0.00025616845,0.00015941125,0.00011607761,0.000017355613,0.00030359472,0.00000877539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041655172,0.00006915013,0.94176984,0.000059617185,0.000102110214,0.00012233337,0.00020591995,0.000012004056,0.0058535677,0.000021150334,0.0022755954,0.04909217],"study_design_scores_gemma":[0.0054759537,0.0007629654,0.98100275,0.0005327675,0.000090608955,0.000019964344,0.0001701169,0.001268016,0.0061959093,0.001887151,0.002528796,0.00006500095],"about_ca_topic_score_codex":0.000028810116,"about_ca_topic_score_gemma":0.000018126213,"teacher_disagreement_score":0.049027167,"about_ca_system_score_codex":0.000048614347,"about_ca_system_score_gemma":0.00030089615,"threshold_uncertainty_score":0.17736079},"labels":[],"label_agreement":null},{"id":"W4317708657","doi":"10.1016/j.jare.2023.01.015","title":"IQGAP3 is relevant to prostate cancer: A detailed presentation of potential pathomechanisms","year":2023,"lang":"en","type":"article","venue":"Journal of Advanced Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital","funders":"Institute of Cancer Research; Canadian Institutes of Health Research","keywords":"Prostate cancer; Immune system; Cancer research; Immune checkpoint; Cancer; Carcinogenesis; Metastasis; LNCaP; Immunotherapy; Biology; Medicine; Oncology; Internal medicine; Immunology","score_opus":0.05507475768451321,"score_gpt":0.4325019568175112,"score_spread":0.377427199132998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317708657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865067,0.0014153331,0.0001816071,0.010092464,0.00029881092,0.0011687437,0.000051967967,0.000022232485,0.00026213337],"genre_scores_gemma":[0.97268623,0.012536167,0.0025293315,0.00007351342,0.00030716357,0.00010889523,0.000014408065,0.0000506537,0.011693651],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962558,0.00017839186,0.0006018927,0.0002486412,0.002073479,0.0006417908],"domain_scores_gemma":[0.9967602,0.00016216758,0.0002102444,0.00026500455,0.0021862022,0.00041621554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016796475,0.00013490593,0.00044370745,0.0012017391,0.00013760688,0.00003094745,0.00022579837,0.00007615526,0.00014948983],"category_scores_gemma":[0.00040836653,0.00009512338,0.00017647818,0.0019150387,0.000116783354,0.00021888858,0.00014884197,0.00061965635,0.00005844447],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0081994105,0.00026186297,0.002301755,0.00043807278,0.00023424707,0.0008776059,0.002871753,0.0011837544,0.8986714,0.00003381688,0.0100382585,0.074888065],"study_design_scores_gemma":[0.012407323,0.008895497,0.029727546,0.0017784272,0.00012679926,0.00019120875,0.006169737,0.0012300427,0.9256392,0.00375274,0.009819487,0.00026197778],"about_ca_topic_score_codex":0.000035317746,"about_ca_topic_score_gemma":0.000010457288,"teacher_disagreement_score":0.07462609,"about_ca_system_score_codex":0.00030443384,"about_ca_system_score_gemma":0.0008122553,"threshold_uncertainty_score":0.3879019},"labels":[],"label_agreement":null},{"id":"W4317888223","doi":"10.1002/1878-0261.13382","title":"Preclinical patient‐derived modeling of castration‐resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease","year":2023,"lang":"en","type":"article","venue":"Molecular Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Deutscher Akademischer Austausch Dienst Kairo; Bundesministerium für Bildung und Forschung; Deutscher Akademischer Austauschdienst","keywords":"Olaparib; Prostate cancer; Homologous recombination; LNCaP; Cisplatin; Medicine; Cancer research; RAD51; PARP inhibitor; Ex vivo; Oncology; Internal medicine; Cancer; In vivo; Biology; Poly ADP ribose polymerase; Chemotherapy; Gene; Genetics; Polymerase","score_opus":0.059766335992744404,"score_gpt":0.41586184937122633,"score_spread":0.35609551337848194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317888223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99547815,0.0010794966,0.00021399003,0.0012488943,0.00013465577,0.0011933675,0.0001956681,0.00007649349,0.00037925274],"genre_scores_gemma":[0.9967738,0.00053300284,0.0016427676,0.00005402207,0.000007024911,0.00040499037,0.00043128862,0.00001825184,0.00013486271],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9980027,0.00029026193,0.0006232641,0.00034747797,0.00044219205,0.0002940868],"domain_scores_gemma":[0.99882436,0.00013117598,0.00020008278,0.00027299122,0.00042142117,0.00014998025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004527733,0.00013866059,0.00043238857,0.00023681327,0.00005748531,0.000005032262,0.00007313568,0.00010518418,0.000054458622],"category_scores_gemma":[0.00023844065,0.00011570175,0.00018066113,0.0003903103,0.0001688699,0.000037276408,0.00009126751,0.00016159496,0.0000031882955],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010847988,0.0059968117,0.08926456,0.0030380513,0.0019444379,0.0026636964,0.007905482,0.053046316,0.7845113,0.0012334012,0.00072212296,0.038825776],"study_design_scores_gemma":[0.039416794,0.027645739,0.33329883,0.0015118711,0.0023074422,0.000040927553,0.005292276,0.4134904,0.16777767,0.0065556625,0.001539555,0.0011227956],"about_ca_topic_score_codex":0.00014470183,"about_ca_topic_score_gemma":0.00002088723,"teacher_disagreement_score":0.6167337,"about_ca_system_score_codex":0.00030740423,"about_ca_system_score_gemma":0.0012244703,"threshold_uncertainty_score":0.47181803},"labels":[],"label_agreement":null},{"id":"W4318263140","doi":"10.18632/oncotarget.28344","title":"Correction: IGF-1 and hyperglycaemia-induced FOXA1 and IGFBP-2 affect epithelial to mesenchymal transition in prostate epithelial cells","year":2023,"lang":"en","type":"erratum","venue":"Oncotarget","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal College of Physicians and Surgeons of Canada","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Epithelial–mesenchymal transition; Medicine; FOXA1; Affect (linguistics); Mesenchymal stem cell; Prostate cancer; Prostate; Cancer research; Internal medicine; Endocrinology; Oncology; Pathology; Psychology; Cancer","score_opus":0.020489135219173664,"score_gpt":0.3043679655191457,"score_spread":0.283878830299972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318263140","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9466015,0.0020067287,0.00001767624,0.0067739426,0.03204144,0.0039095622,0.0009295178,0.00026402206,0.0074555976],"genre_scores_gemma":[0.197349,0.016245615,0.00045818466,0.0010592764,0.0088642,0.0010685524,0.003370115,0.00051827834,0.7710668],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969299,0.0001764172,0.0004537853,0.0009980582,0.0006463309,0.00079553196],"domain_scores_gemma":[0.9987349,0.00017901331,0.000105188345,0.0003447032,0.00013516031,0.00050105783],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051465427,0.00057459355,0.0010476758,0.00066364027,0.00017462112,0.00008867653,0.00010824747,0.0005747539,0.00008967525],"category_scores_gemma":[0.00011785372,0.0004816267,0.0001487907,0.0006401137,0.00012883473,0.00013087434,0.00010828024,0.0014249219,0.00015392256],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047710384,0.00036978532,0.0019527117,0.0014687749,0.00032823766,0.002623077,0.0053786966,0.000012144009,0.080947906,0.000007443037,0.89080435,0.011335831],"study_design_scores_gemma":[0.035812646,0.019597573,0.0994394,0.010382385,0.0014007178,0.0010371596,0.002730866,0.0031372223,0.09195867,0.0005346697,0.7299463,0.0040223654],"about_ca_topic_score_codex":0.0008847679,"about_ca_topic_score_gemma":0.0007405471,"teacher_disagreement_score":0.7636112,"about_ca_system_score_codex":0.0004669424,"about_ca_system_score_gemma":0.00077996036,"threshold_uncertainty_score":0.99976355},"labels":[],"label_agreement":null},{"id":"W4318542616","doi":"10.1016/j.ctro.2023.100583","title":"18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer","year":2023,"lang":"en","type":"article","venue":"Clinical and Translational Radiation Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; St. Joseph’s Healthcare Hamilton; McMaster University; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"Hamilton Health Sciences Foundation","keywords":"DU145; LNCaP; Prostate cancer; Cancer research; Medicine; Metastasis; Glutamate carboxypeptidase II; Radiation therapy; Cancer; Pathology; Internal medicine","score_opus":0.0831643943369621,"score_gpt":0.512966007548175,"score_spread":0.4298016132112129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318542616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9434419,0.0013227289,0.00005016936,0.05362459,0.00022139914,0.0008582579,0.00006630815,0.000048257163,0.0003663455],"genre_scores_gemma":[0.98216915,0.011932647,0.0012435961,0.0012624161,0.00017619379,0.0003835149,0.00022937576,0.00002037825,0.0025827212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980575,0.000501503,0.0005573263,0.00033598964,0.0002844182,0.00026329895],"domain_scores_gemma":[0.99782944,0.0017803073,0.00008057355,0.00010234319,0.000078071644,0.00012928598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017306011,0.0001229577,0.00039431552,0.00024264332,0.000078922945,0.000015994026,0.00004372941,0.00006790862,0.00042398504],"category_scores_gemma":[0.00016704609,0.00009792231,0.000095531235,0.00043849892,0.00021346835,0.000094792165,0.000009128212,0.0002996925,0.00003835121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016909195,0.0007894226,0.74793327,0.00008863933,0.00038715935,0.00091524934,0.0009456369,0.00037649408,0.00050356996,0.0023665496,0.0014387101,0.22734609],"study_design_scores_gemma":[0.012984211,0.0012910248,0.9185861,0.000033782304,0.000058530062,0.00004611433,0.00007100025,0.00843888,0.000015902355,0.0032092084,0.055159923,0.00010534555],"about_ca_topic_score_codex":0.000042859545,"about_ca_topic_score_gemma":0.00005498643,"teacher_disagreement_score":0.22724074,"about_ca_system_score_codex":0.00012726917,"about_ca_system_score_gemma":0.0016709339,"threshold_uncertainty_score":0.4642339},"labels":[],"label_agreement":null},{"id":"W4318930619","doi":"10.1093/nar/gkad043","title":"SMAD3 promotes expression and activity of the androgen receptor in prostate cancer","year":2023,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Prostate Cancer Foundation; U.S. Department of Veterans Affairs","keywords":"Gene knockdown; Androgen receptor; Prostate cancer; Biology; Cancer research; Downregulation and upregulation; Context (archaeology); Chromatin immunoprecipitation; Cancer; Gene expression; Gene; Genetics; Promoter","score_opus":0.07159902401572289,"score_gpt":0.3942083275326719,"score_spread":0.322609303516949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318930619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920334,0.0006990569,1.6254661e-7,0.0051428596,0.000048376267,0.0012314924,0.000031625397,0.000030584495,0.0007824476],"genre_scores_gemma":[0.9915582,0.0023156696,0.000029203951,0.000010523147,0.000045661636,0.00023098181,0.000007253107,0.00002417844,0.005778306],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980169,0.00024196133,0.00014500416,0.00030458873,0.00078994536,0.00050161243],"domain_scores_gemma":[0.9991852,0.00014464854,0.000031757892,0.00032799196,0.00018490915,0.00012547901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010165769,0.00009995936,0.0002127899,0.00027720994,0.00015799506,0.000021687083,0.0001540897,0.00008021501,0.00015807248],"category_scores_gemma":[0.0002258,0.000057585057,0.000042992364,0.0013370767,0.00042292866,0.00009365512,0.0003713224,0.00051266374,0.0000266074],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093526475,0.00014583084,0.37269375,0.0003531399,0.000027751987,0.000026913962,0.0017699699,0.0000012742169,0.5888816,0.000010932497,0.002868747,0.0322848],"study_design_scores_gemma":[0.0024419702,0.00035123315,0.35713986,0.0006750428,0.000007194766,0.000004398979,0.00051019713,0.0003729243,0.63482696,0.0002279029,0.0033590419,0.00008328149],"about_ca_topic_score_codex":0.0003583322,"about_ca_topic_score_gemma":0.0000519925,"teacher_disagreement_score":0.045945305,"about_ca_system_score_codex":0.00016029403,"about_ca_system_score_gemma":0.0003401334,"threshold_uncertainty_score":0.23482504},"labels":[],"label_agreement":null},{"id":"W4319322968","doi":"10.1016/j.clon.2022.11.028","title":"Retrospective Real-world Evaluation of Enzalutamide in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) during the COVID-19 Pandemic Compared to Docetaxel in mHSPC Pre-COVID-19","year":2023,"lang":"en","type":"article","venue":"Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"","keywords":"Docetaxel; Medicine; Enzalutamide; Oncology; Internal medicine; Clinical endpoint; Retrospective cohort study; Coronavirus disease 2019 (COVID-19); Adverse effect; Prostate cancer; Cancer; Clinical trial; Androgen receptor; Disease","score_opus":0.30493027194052685,"score_gpt":0.5597495843243966,"score_spread":0.25481931238386973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319322968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97929275,0.0005292478,0.0000072273965,0.014255426,0.00022998978,0.0048737093,0.00014118142,0.0000953705,0.0005751228],"genre_scores_gemma":[0.99027437,0.0041835015,0.00011738456,0.002197194,0.00014048684,0.0015150075,0.00009974706,0.000031249565,0.0014410855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99427676,0.0022053758,0.0013471419,0.00073975144,0.00077769224,0.00065326574],"domain_scores_gemma":[0.99481875,0.0034043246,0.00038967718,0.00043115782,0.00037939788,0.00057671074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008647261,0.00023976319,0.00124954,0.0006111221,0.00009544174,0.000010641966,0.00019014838,0.0001670157,0.000096776545],"category_scores_gemma":[0.0074878572,0.00016882732,0.00016000721,0.0020538934,0.00057323877,0.00007479036,0.00017242045,0.00085415633,0.00003792529],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016104167,0.0008519567,0.9547051,0.00023313983,0.00037394158,0.0006291721,0.011466139,0.006370867,0.001985978,0.000046511374,0.0020434987,0.0051894966],"study_design_scores_gemma":[0.01937464,0.001495847,0.96976584,0.00009111181,0.00029016915,0.000017411388,0.0013998358,0.003817297,0.00013404987,0.001216708,0.0022357388,0.00016133072],"about_ca_topic_score_codex":0.0094048735,"about_ca_topic_score_gemma":0.0497865,"teacher_disagreement_score":0.04038163,"about_ca_system_score_codex":0.0066231927,"about_ca_system_score_gemma":0.0059672375,"threshold_uncertainty_score":0.999668},"labels":[],"label_agreement":null},{"id":"W4319602588","doi":"10.21203/rs.3.rs-2488586/v1","title":"Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"DOD Prostate Cancer Research Program; John Black Charitable Foundation; Veracyte; National Institute for Health and Care Research; Pfizer; Astellas Pharma; Clovis Oncology; Medical Research Council; Sanofi; Prostate Cancer UK; Cancer Research UK; Prostate Cancer Foundation","keywords":"Prostate cancer; Medicine; Androgen deprivation therapy; Abiraterone acetate; PTEN; Oncology; Internal medicine; Radiation therapy; Androgen receptor; Transcriptome; Cancer; Context (archaeology); Metastasis; Androgen; Biochemical recurrence; Clinical trial; Hormone; Biology; Prostatectomy; Gene expression; PI3K/AKT/mTOR pathway; Gene","score_opus":0.26230117298664046,"score_gpt":0.4977309854548535,"score_spread":0.23542981246821304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319602588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827521,0.0027445257,0.000014228459,0.0002692504,0.00014618979,0.013541714,0.00048185693,0.00004691219,0.000003220391],"genre_scores_gemma":[0.9926285,0.004703479,0.0004256651,0.000007826342,0.0001216833,0.0017988405,0.00016447635,0.0000809203,0.00006859821],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99132663,0.0037856072,0.0014778982,0.00089519296,0.0018669154,0.0006477365],"domain_scores_gemma":[0.99588305,0.0014752075,0.0005773633,0.0008505731,0.0009840613,0.0002297519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00740034,0.0003293035,0.0011370649,0.00055592717,0.00022774997,0.00005994565,0.00032470375,0.0002073112,0.000022649627],"category_scores_gemma":[0.0022455407,0.0002012296,0.00013594852,0.001066107,0.00043978263,0.00013978565,0.00051669194,0.0016725239,5.34933e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07293821,0.005689476,0.8581416,0.0025079765,0.0003928689,0.00008265024,0.0086307395,0.00029066968,0.018259076,7.612174e-7,0.00003402102,0.033031926],"study_design_scores_gemma":[0.30069232,0.028063053,0.57483816,0.008805841,0.00034775352,0.0000015327039,0.01946134,0.004053743,0.06209424,0.0011244346,0.000036267764,0.00048129345],"about_ca_topic_score_codex":0.0070011513,"about_ca_topic_score_gemma":0.00084942573,"teacher_disagreement_score":0.28330344,"about_ca_system_score_codex":0.00023249185,"about_ca_system_score_gemma":0.0015940438,"threshold_uncertainty_score":0.9996113},"labels":[],"label_agreement":null},{"id":"W4319656461","doi":"10.1097/ju.0000000000003084","title":"Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial","year":2023,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Daiichi Sankyo Europe; Pfizer; Astellas Pharma; Bristol-Myers Squibb","keywords":"Medicine; Post-hoc analysis; Prostate-specific antigen; Nadir; Post hoc; Randomized controlled trial; Oncology; Internal medicine; Prostate; Cancer","score_opus":0.06791236110017541,"score_gpt":0.40176139246044695,"score_spread":0.33384903136027155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319656461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99182606,0.00071054266,0.000009692947,0.0051610717,0.0007710903,0.0013533506,0.00004247567,0.0000093184935,0.00011639943],"genre_scores_gemma":[0.99617314,0.002889195,0.000014390816,0.00013675244,0.0002163838,0.000011507943,0.000017138154,0.000017081793,0.000524416],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99507564,0.002219027,0.0014223427,0.0001602165,0.00083108904,0.00029165577],"domain_scores_gemma":[0.9960116,0.0018211359,0.0009412359,0.0004861263,0.0005903875,0.00014949118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009150731,0.00015116048,0.0017192097,0.00043407737,0.00007044514,0.000008352419,0.00043229028,0.00015288961,0.0001848897],"category_scores_gemma":[0.0010752637,0.00006140969,0.00094486674,0.0008683855,0.0007461846,0.00005887033,0.00011315252,0.0005625377,0.0000069987454],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84742737,0.0005837743,0.14162424,0.000016725011,0.0060490477,0.000060321352,0.0018327367,0.00007117361,0.0014743931,0.00006776606,0.00017105076,0.0006213967],"study_design_scores_gemma":[0.5028801,0.0109969,0.47952598,0.000022090562,0.004470739,0.000043549375,0.00057247677,0.00031803868,0.00028726202,0.00032704687,0.00047733265,0.00007847437],"about_ca_topic_score_codex":0.000068010406,"about_ca_topic_score_gemma":0.000048952654,"teacher_disagreement_score":0.34454727,"about_ca_system_score_codex":0.000040402334,"about_ca_system_score_gemma":0.0005568557,"threshold_uncertainty_score":0.3171479},"labels":[],"label_agreement":null},{"id":"W4319917387","doi":"10.1016/j.bpj.2022.11.1515","title":"The androgen receptor as a potential regulator of prostate cancer contractility","year":2023,"lang":"en","type":"article","venue":"Biophysical Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Prostate cancer; Regulator; Androgen receptor; Contractility; Prostate; Internal medicine; Cancer research; Endocrinology; Biology; Chemistry; Medicine; Cancer; Genetics; Gene","score_opus":0.02057801423047956,"score_gpt":0.3334614718739677,"score_spread":0.3128834576434881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319917387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904436,0.0004375828,0.0000015837132,0.008277107,0.0003260674,0.00028483698,0.00003509114,0.000026303762,0.0001678285],"genre_scores_gemma":[0.99296826,0.002533439,0.00001477302,0.000042301144,0.00061290653,0.000025092888,0.000009055945,0.000013976394,0.0037801776],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987842,0.000059919515,0.00022129944,0.00013199891,0.00048306191,0.00031954877],"domain_scores_gemma":[0.9992249,0.00006479073,0.000105443156,0.00015375692,0.00023676113,0.00021437273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025715356,0.0000942846,0.00020576963,0.000044685847,0.00023879326,0.00004076876,0.00009727579,0.000045508674,0.0001235677],"category_scores_gemma":[0.00006559267,0.00004929702,0.00016992906,0.0002836984,0.0002246396,0.00006566679,0.00003993859,0.00027808055,0.000089400004],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047293934,0.00026465775,0.0061420877,0.000054596967,0.0004912713,0.00021482013,0.0002600443,0.000005209434,0.9223845,0.00014618588,0.011989615,0.053317636],"study_design_scores_gemma":[0.008282519,0.0016658593,0.16800551,0.00029147314,0.00030032007,0.00027727277,0.00075898063,0.00078922877,0.7680105,0.0012944024,0.050062805,0.0002611104],"about_ca_topic_score_codex":0.000039425468,"about_ca_topic_score_gemma":0.0000014905494,"teacher_disagreement_score":0.16186343,"about_ca_system_score_codex":0.00009189785,"about_ca_system_score_gemma":0.00036641903,"threshold_uncertainty_score":0.20102742},"labels":[],"label_agreement":null},{"id":"W4319962834","doi":"10.3390/curroncol30020170","title":"An Updated Systematic and Comprehensive Review of Cytoreductive Prostatectomy for Metastatic Prostate Cancer","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"European Association of Urology","keywords":"Medicine; Prostatectomy; Prostate cancer; Randomized controlled trial; Perioperative; Oncology; Internal medicine; Population; Confounding; Cancer; Radiation therapy; Prostate; Prostate-specific antigen; Urology; Surgery","score_opus":0.3513704116450944,"score_gpt":0.5636975421348582,"score_spread":0.21232713048976382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319962834","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005201428,0.97342557,0.0000060806497,0.00014776016,0.00062462233,0.024201712,0.001455069,0.000070217124,0.00001695658],"genre_scores_gemma":[0.000002576768,0.9833663,0.00014855388,0.000027358294,0.00012222647,0.012382348,0.0035748456,0.000106671,0.00026912216],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964957,0.00067581737,0.0013115463,0.0006908909,0.00032288674,0.00050316215],"domain_scores_gemma":[0.9967738,0.00048349486,0.0010327726,0.00046087103,0.0009789612,0.00027010808],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000571373,0.0005429156,0.005562535,0.0003945098,0.00008241966,0.000014279935,0.00018144565,0.00015804017,0.00004037237],"category_scores_gemma":[0.00015791661,0.00034095705,0.00041776354,0.0006621487,0.00033444873,0.000076402495,0.00009284899,0.0004442319,0.00001659803],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011801362,0.00028989752,0.0000048982056,0.76387566,0.0013068797,0.000030566647,0.00016419931,4.4629193e-8,0.0000020524765,0.00002739279,0.0024019822,0.23177843],"study_design_scores_gemma":[0.0015588916,0.001207646,0.0000031754228,0.4757177,0.008690101,0.00008136821,0.0001445639,0.000013051177,0.000004735631,0.000038499216,0.51233935,0.00020093464],"about_ca_topic_score_codex":0.000015234061,"about_ca_topic_score_gemma":0.0000042382917,"teacher_disagreement_score":0.50993735,"about_ca_system_score_codex":0.00065979455,"about_ca_system_score_gemma":0.0023725566,"threshold_uncertainty_score":0.9999042},"labels":[],"label_agreement":null},{"id":"W4320507004","doi":"","title":"Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it.","year":2023,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of British Columbia; Western University","funders":"","keywords":"Medicine; Glutamate carboxypeptidase II; Prostate cancer; Positron emission tomography; Population; PET-CT; Clinical trial; Molecular imaging; Protocol (science); Medical physics; Nuclear medicine; Radiology; Oncology; Cancer; Internal medicine; Pathology; In vivo","score_opus":0.02969382222280446,"score_gpt":0.3001137066801611,"score_spread":0.2704198844573566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320507004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9697103,0.0013252086,0.00007396776,0.021966077,0.00021197285,0.0013110017,0.000056700344,0.000114834096,0.005229969],"genre_scores_gemma":[0.992667,0.0017881533,0.00009779374,0.00007860637,0.000065136795,0.0005217853,0.000102906604,0.000016619624,0.0046619526],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991032,0.000035485027,0.00012648347,0.00019742346,0.00025042673,0.00028698726],"domain_scores_gemma":[0.9994998,0.00008530523,0.000050426363,0.00014169185,0.000094505995,0.00012825438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026089637,0.000095065705,0.00018482421,0.00019711067,0.000042930234,0.000039674404,0.000042337277,0.000008414015,0.000056524605],"category_scores_gemma":[0.000085957516,0.00007362774,0.000051461655,0.00029789022,0.00010793268,0.00016247193,0.000052201874,0.000087729924,0.000023410608],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031228252,0.00035986607,0.03001891,0.0023544505,0.00063251186,0.0027136272,0.0025910807,0.0000040090176,0.013702728,0.00016475534,0.123688765,0.82064646],"study_design_scores_gemma":[0.012707322,0.0007268019,0.91610485,0.0006030159,0.00043502625,0.00062278676,0.004987782,0.0058057294,0.03943312,0.00198274,0.016080964,0.00050985004],"about_ca_topic_score_codex":0.000010722264,"about_ca_topic_score_gemma":0.000003770475,"teacher_disagreement_score":0.8860859,"about_ca_system_score_codex":0.000073961346,"about_ca_system_score_gemma":0.000030913667,"threshold_uncertainty_score":0.30024523},"labels":[],"label_agreement":null},{"id":"W4320717817","doi":"10.1016/j.ctrv.2023.102525","title":"nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives","year":2023,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"Cilag","keywords":"Medicine; Prostate cancer; Incidence (geometry); Clinical trial; Metastasis; Oncology; Adverse effect; Internal medicine; Cancer","score_opus":0.05666846989924946,"score_gpt":0.40249026250732234,"score_spread":0.3458217926080729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320717817","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00094040734,0.98651016,5.4564982e-8,0.00026145478,0.00015854137,0.010364181,0.0013170483,0.00001810915,0.00043006067],"genre_scores_gemma":[0.000037356032,0.98950094,0.000017268967,0.000023493685,0.00021612426,0.0070481678,0.0004912066,0.00007844442,0.0025869731],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99694407,0.00039115842,0.0011366942,0.0006723826,0.00041063086,0.00044504867],"domain_scores_gemma":[0.99803996,0.00012567303,0.0008177645,0.0006067458,0.00029112937,0.00011871773],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026474104,0.0006804602,0.0039123655,0.00030957354,0.00005504381,0.000019930716,0.00019635288,0.00014596609,0.00007848324],"category_scores_gemma":[0.000024724783,0.00032194293,0.00067049405,0.00084971945,0.00026528002,0.000065666005,0.000060879054,0.00031148666,0.00001791645],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000117521406,0.00047631862,0.00311357,0.05019952,0.00072350656,0.000038877843,0.009645677,1.3154578e-7,2.687643e-7,0.0000068118547,0.0011192224,0.9345586],"study_design_scores_gemma":[0.002400053,0.0013083493,0.00060716714,0.03776922,0.0024919563,0.000004621357,0.0016090712,1.7846185e-7,0.000006875649,0.00000511895,0.9535626,0.00023478197],"about_ca_topic_score_codex":0.0004264125,"about_ca_topic_score_gemma":0.00048122325,"teacher_disagreement_score":0.95244336,"about_ca_system_score_codex":0.0012058215,"about_ca_system_score_gemma":0.0010075858,"threshold_uncertainty_score":0.9999233},"labels":[],"label_agreement":null},{"id":"W4320726232","doi":"10.1038/s41585-023-00726-1","title":"Preclinical models of prostate cancer — modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo","year":2023,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre hospitalier de l'Université Laval; Université Laval","funders":"","keywords":"Medicine; Ex vivo; Prostate cancer; In vivo; Androgen; Castration; Oncology; Prostate; Internal medicine; Cancer; Hormone; Biology","score_opus":0.12768011545531127,"score_gpt":0.43586794597930356,"score_spread":0.3081878305239923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320726232","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00053007004,0.99507076,0.000010431042,0.00022943589,0.00008830153,0.0036885047,0.00014453862,0.000014202749,0.00022377356],"genre_scores_gemma":[0.0005275531,0.99758124,0.00041772332,0.000049915543,0.00007774237,0.0006035037,0.00006658425,0.000052610656,0.0006231513],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99679506,0.00049366505,0.0012716334,0.00077893,0.00023912052,0.00042156555],"domain_scores_gemma":[0.9987283,0.000314331,0.00042261786,0.0003279598,0.00008138255,0.00012542607],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011474512,0.0003979154,0.00284609,0.00043217314,0.000026312759,0.000010785402,0.000119903874,0.0010873233,0.000015160619],"category_scores_gemma":[0.00013079864,0.0002792216,0.00018532136,0.00059076346,0.00014238758,0.000096290634,0.00008931792,0.0016874712,0.000001962645],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021039585,0.00023966857,0.0006877974,0.14272694,0.00033576696,0.0005892722,0.0004965032,0.00007819477,0.000049629296,0.00021916487,0.00031105618,0.85216206],"study_design_scores_gemma":[0.0031671594,0.00033595957,0.000022985296,0.03625399,0.0014830435,0.00016117835,0.000011293333,0.0020841204,0.000041716747,0.0021951813,0.9536853,0.00055807334],"about_ca_topic_score_codex":0.000066555345,"about_ca_topic_score_gemma":0.000891463,"teacher_disagreement_score":0.95337427,"about_ca_system_score_codex":0.00014562997,"about_ca_system_score_gemma":0.0005280535,"threshold_uncertainty_score":0.99996597},"labels":[],"label_agreement":null},{"id":"W4320879153","doi":"10.1016/j.biopha.2023.114392","title":"RETRACTED: Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies","year":2023,"lang":"en","type":"review","venue":"Biomedicine & Pharmacotherapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":115,"is_retracted":true,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Docetaxel; Medicine; Paclitaxel; Cancer research; Cancer; Prostate; Cabazitaxel; PTEN; Tumor progression; Oncology; Malignancy; Internal medicine; Androgen deprivation therapy; Biology; PI3K/AKT/mTOR pathway; Apoptosis","score_opus":0.07215196674417287,"score_gpt":0.4411357784564033,"score_spread":0.3689838117122304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320879153","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00087391783,0.9931007,0.000016052378,0.0017611735,0.0002599154,0.0033113053,0.00021148016,0.00015684658,0.00030859484],"genre_scores_gemma":[0.0003435404,0.99339616,0.00020219389,0.00039397305,0.00022509055,0.0008680178,0.00019043271,0.00019798012,0.0041826246],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966314,0.00021111801,0.00078708713,0.00094255735,0.00065564126,0.00077224174],"domain_scores_gemma":[0.9986885,0.00015932147,0.0002944691,0.0003813854,0.0001057159,0.00037061432],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00065906596,0.0007451383,0.0020757574,0.0009626193,0.00010556654,0.00010116187,0.00018610728,0.0003276045,0.00010687184],"category_scores_gemma":[0.000012216686,0.00050296396,0.00017451185,0.0014618557,0.00041118078,0.00015494078,0.000058914848,0.0009204828,0.000011255911],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074658333,0.00026209597,0.000089571804,0.039459847,0.0014978573,0.0017776313,0.0007319518,9.340897e-8,0.005834775,0.0005516054,0.0009226672,0.9481253],"study_design_scores_gemma":[0.010659885,0.0009766355,0.0003497575,0.037696965,0.0017154565,0.00013994695,0.00037269562,0.000019161445,0.0004352739,0.0025451118,0.94420946,0.0008796302],"about_ca_topic_score_codex":0.00021506907,"about_ca_topic_score_gemma":0.000054156157,"teacher_disagreement_score":0.9472457,"about_ca_system_score_codex":0.00030042938,"about_ca_system_score_gemma":0.001024092,"threshold_uncertainty_score":0.9997422},"labels":[],"label_agreement":null},{"id":"W4320893540","doi":"10.6004/jnccn.2022.7083","title":"Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk","year":2023,"lang":"en","type":"article","venue":"Journal of the National Comprehensive Cancer Network","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Internal medicine; Hazard ratio; Interquartile range; Proportional hazards model; Vitamin K antagonist; Oncology; Cancer; Confidence interval","score_opus":0.035489812507363626,"score_gpt":0.28799455768787524,"score_spread":0.25250474518051164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320893540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96128565,0.037499133,0.000016941294,0.00020402714,0.00013927874,0.00068212237,0.00015617344,0.0000041640296,0.000012482363],"genre_scores_gemma":[0.9626285,0.036963865,0.000093247654,0.00006453259,0.00016712933,0.000040300973,0.000012146038,0.000017663064,0.000012628367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756765,0.00026059934,0.00033966708,0.00017992409,0.0014761438,0.00017599453],"domain_scores_gemma":[0.9973637,0.00018573318,0.00041517275,0.00020881905,0.0017361027,0.00009045778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044967627,0.00013812215,0.00047234204,0.00017796514,0.00008340046,0.0000072606344,0.00011350544,0.000038459446,0.000006646365],"category_scores_gemma":[0.00009479074,0.00007995582,0.0003692153,0.00076059165,0.0001390521,0.000068990805,0.00003301577,0.0002603133,2.0775416e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036941187,0.000055316406,0.51498485,0.00005291931,0.0022677088,0.0000047808776,0.00006712407,0.4740637,0.000004298204,0.000001978828,0.00012349105,0.0046797064],"study_design_scores_gemma":[0.0075352625,0.00036585072,0.98334384,0.0008156363,0.00066742586,6.977613e-7,0.000018056991,0.004716093,0.0002106257,0.00018548161,0.002060107,0.000080942475],"about_ca_topic_score_codex":0.00021214806,"about_ca_topic_score_gemma":0.0000055673404,"teacher_disagreement_score":0.4693476,"about_ca_system_score_codex":0.000225501,"about_ca_system_score_gemma":0.0004766166,"threshold_uncertainty_score":0.32605037},"labels":[],"label_agreement":null},{"id":"W4320916985","doi":"10.3390/curroncol30020178","title":"Underlying Features of Prostate Cancer—Statistics, Risk Factors, and Emerging Methods for Its Diagnosis","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Fundação para a Ciência e a Tecnologia; Agência Regional para o Desenvolvimento da Investigação, Tecnologia e Inovação","keywords":"Medicine; Prostate cancer; Context (archaeology); Cancer; Intensive care medicine; Quality of life (healthcare); Oncology; Internal medicine","score_opus":0.46554215157190443,"score_gpt":0.619720821106571,"score_spread":0.15417866953466658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320916985","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008877848,0.9911392,0.0003848329,0.00009031726,0.0015290987,0.0035068446,0.0031889617,0.00004971007,0.00002229743],"genre_scores_gemma":[0.0000054855445,0.9925275,0.0029444955,0.0000034685797,0.00018794306,0.002631223,0.0010703937,0.000089301706,0.00054019253],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771374,0.0004356125,0.0006340083,0.00054506393,0.00017274667,0.0004988126],"domain_scores_gemma":[0.995458,0.0030829739,0.00078604056,0.00021123936,0.00025895686,0.00020277879],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000613573,0.0004193457,0.0023835334,0.00039569766,0.00014283463,0.000016752645,0.00013012982,0.0002886946,0.000035913876],"category_scores_gemma":[0.0011412845,0.00027745945,0.00030416602,0.00033961685,0.00016956951,0.000033110493,0.00014186367,0.00063744426,0.0000029842288],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000599268,0.00012759509,0.0028543768,0.061428044,0.00083811994,0.000008882734,0.0003941038,1.729793e-7,5.9005237e-7,0.00008405471,0.004544559,0.92965955],"study_design_scores_gemma":[0.0011926591,0.0006810204,0.00050535705,0.011214433,0.0041239373,0.000007227113,0.000114591436,0.000022982194,0.000022648735,0.00023655004,0.98164755,0.00023105132],"about_ca_topic_score_codex":0.00008004175,"about_ca_topic_score_gemma":0.000060575632,"teacher_disagreement_score":0.977103,"about_ca_system_score_codex":0.0005262958,"about_ca_system_score_gemma":0.0011185838,"threshold_uncertainty_score":0.99996775},"labels":[],"label_agreement":null},{"id":"W4321018302","doi":"10.1200/jco.23.00041","title":"Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Bayer HealthCare","keywords":"Medicine; Prostate cancer; Docetaxel; Internal medicine; Hazard ratio; Androgen deprivation therapy; Placebo; Oncology; Hormone therapy; Cancer; Pathology; Confidence interval; Breast cancer","score_opus":0.13009900985133552,"score_gpt":0.4793231230773755,"score_spread":0.34922411322603997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321018302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814925,0.0064938134,0.000008895338,0.010627133,0.00017094091,0.0011078451,0.0000721722,0.0000061199617,0.000020586613],"genre_scores_gemma":[0.9024942,0.09653679,0.000045130364,0.00048103297,0.00023275534,0.000047866684,0.000022360935,0.000012061466,0.00012777971],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9969644,0.00097022596,0.0011975514,0.00022795414,0.00035779644,0.00028209807],"domain_scores_gemma":[0.9970301,0.0017990378,0.00063868257,0.00011816539,0.00013322878,0.000280808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004487393,0.00013716659,0.0009434316,0.0002056533,0.00005919768,0.000021255753,0.00007068708,0.00010571666,0.000009220934],"category_scores_gemma":[0.0013349373,0.00007740729,0.00012574643,0.00035761806,0.0003215752,0.00013658473,0.000033313787,0.0008165777,0.0000019891547],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59571505,0.0028460827,0.19611366,0.000035874957,0.00066793466,0.005104761,0.0034967114,0.000044065255,0.0004101517,0.000013738387,0.004342862,0.19120912],"study_design_scores_gemma":[0.4199222,0.014064035,0.55420595,0.00007991456,0.00040076437,0.00006767528,0.001203221,0.0035568834,0.000041954358,0.0006761822,0.005653342,0.00012786803],"about_ca_topic_score_codex":0.00023243931,"about_ca_topic_score_gemma":0.00016979457,"teacher_disagreement_score":0.35809228,"about_ca_system_score_codex":0.00015454795,"about_ca_system_score_gemma":0.0010697956,"threshold_uncertainty_score":0.35476694},"labels":[],"label_agreement":null},{"id":"W4321079951","doi":"10.1056/nejmoa2214676","title":"Rucaparib or Physician’s Choice in Metastatic Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":414,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; Health Sciences Centre; CancerCare Manitoba; Sunnybrook Health Science Centre; Research Institute in Oncology and Hematology","funders":"National Cancer Institute; Clovis Oncology","keywords":"Prostate cancer; Medicine; Oncology; Cancer; Prostate; Internal medicine","score_opus":0.0689749689444052,"score_gpt":0.3971037382452716,"score_spread":0.32812876930086643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321079951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94106966,0.006152329,0.000011847332,0.050612222,0.00072267797,0.00043964514,0.000008161357,0.000028270557,0.0009551819],"genre_scores_gemma":[0.96274865,0.011392731,0.00017253084,0.0014279452,0.0047561787,0.000022210366,0.000025153564,0.000042370222,0.019412227],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982798,0.000078934856,0.00049087266,0.00014265781,0.0006479805,0.000359733],"domain_scores_gemma":[0.9988328,0.00033168608,0.00019120035,0.00013278084,0.00018336507,0.00032815064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007864899,0.00015398557,0.0006026896,0.0004968876,0.000035276033,0.000008681503,0.000106536485,0.00003167352,0.00033967325],"category_scores_gemma":[0.00040153548,0.000078565674,0.00006130425,0.00095294876,0.00010129835,0.0001140312,0.000021797785,0.0004322373,0.000020131554],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011029345,0.0003073571,0.13062409,0.000538756,0.00068189314,0.007964754,0.007125877,0.00020914589,0.013349514,0.000043119064,0.11223894,0.7158872],"study_design_scores_gemma":[0.34255517,0.008510736,0.24739331,0.0061670495,0.0009196312,0.0010551566,0.0022383758,0.0005700956,0.003944132,0.0014472659,0.38483053,0.00036857015],"about_ca_topic_score_codex":0.00069601,"about_ca_topic_score_gemma":0.0004483042,"teacher_disagreement_score":0.71551865,"about_ca_system_score_codex":0.00015674852,"about_ca_system_score_gemma":0.0007535296,"threshold_uncertainty_score":0.3719184},"labels":[],"label_agreement":null},{"id":"W4321096820","doi":"10.3390/cancers15041247","title":"Editorial for the Special Edition of Advanced Prostate Cancer: From Bench to Bedside","year":2023,"lang":"en","type":"editorial","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Bench to bedside; Cancer; Oncology; Internal medicine; Medical physics","score_opus":0.01635914170586426,"score_gpt":0.3439745427750197,"score_spread":0.32761540106915543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321096820","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044841613,0.001883902,0.000014641953,0.0016063517,0.97810256,0.0033235063,0.014380217,0.00007332949,0.00016705807],"genre_scores_gemma":[0.000047297483,0.008879234,0.000096422926,0.000047196303,0.9780692,0.0034919917,0.0038266208,0.00013224318,0.0054098223],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965757,0.000032660544,0.00049020234,0.00069511624,0.0015561383,0.00065018417],"domain_scores_gemma":[0.995873,0.0019390965,0.00028282683,0.00053272926,0.0011074261,0.0002649419],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030834068,0.0003938349,0.000801,0.00017730768,0.00019339002,0.000041146784,0.00035655417,0.00057505805,0.00018626977],"category_scores_gemma":[0.0012242367,0.0002765591,0.00030085735,0.0004671019,0.00019648802,0.00008534047,0.00010613842,0.00073012535,0.000032220967],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0066183982,0.000016200149,0.00001649729,0.00030249613,0.0005264185,0.0000070484157,0.0007292673,0.00039855295,0.00054981495,0.000002764171,0.97642285,0.014409714],"study_design_scores_gemma":[0.004808706,0.0008691489,0.00004713543,0.00082859414,0.0005455496,6.7271955e-8,0.00033848625,0.000023559338,0.0021410645,0.00015973105,0.98997486,0.00026308233],"about_ca_topic_score_codex":0.0048688245,"about_ca_topic_score_gemma":0.0019033711,"teacher_disagreement_score":0.0141466325,"about_ca_system_score_codex":0.004041867,"about_ca_system_score_gemma":0.0076534394,"threshold_uncertainty_score":0.99996865},"labels":[],"label_agreement":null},{"id":"W4321457844","doi":"10.3389/fcell.2023.1156392","title":"Editorial: The development of lethal prostate cancer","year":2023,"lang":"en","type":"editorial","venue":"Frontiers in Cell and Developmental Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Guangdong Science and Technology Department; Basic and Applied Basic Research Foundation of Guangdong Province; Natural Science Foundation of Shandong Province; Science, Technology and Innovation Commission of Shenzhen Municipality; National Natural Science Foundation of China","keywords":"Prostate cancer; Prostate; Medicine; Cancer; Cancer research; Biology; Internal medicine","score_opus":0.014949491652039508,"score_gpt":0.3026258678116852,"score_spread":0.2876763761596457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321457844","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0072472906,0.0050429245,0.000008482143,0.00015156972,0.9857509,0.0006994481,0.000176344,0.000030180385,0.00089284463],"genre_scores_gemma":[0.00087377423,0.013679988,0.0059009865,0.00002171337,0.96553594,0.0006567019,0.0018906824,0.00008556585,0.011354635],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99792343,0.00007362637,0.00055738067,0.0005010253,0.0004299601,0.00051459053],"domain_scores_gemma":[0.9991275,0.0003173339,0.00015909033,0.00013887351,0.0001479994,0.00010921066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005561282,0.00031909408,0.0006776755,0.000268583,0.00012460204,0.00001394931,0.00019637431,0.000718426,0.000024583289],"category_scores_gemma":[0.00014234125,0.00019727994,0.000060429214,0.0003017394,0.00038243315,0.000028143715,0.00025946417,0.00074935856,0.000016657557],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006927573,0.00006628136,0.0111630745,0.00042652534,0.00019357167,0.000013700026,0.0024769446,1.618505e-7,0.0005239788,5.1117985e-7,0.97378445,0.01065805],"study_design_scores_gemma":[0.0022578496,0.00013567829,0.00056883536,0.00024251372,0.0000404395,7.800962e-7,0.0011202134,0.0000019069547,0.002802391,0.00008005395,0.9925242,0.00022512194],"about_ca_topic_score_codex":0.00016049277,"about_ca_topic_score_gemma":0.00010262887,"teacher_disagreement_score":0.020214964,"about_ca_system_score_codex":0.0004843654,"about_ca_system_score_gemma":0.0028516813,"threshold_uncertainty_score":0.80448425},"labels":[],"label_agreement":null},{"id":"W4322213285","doi":"10.14740/wjon1425","title":"Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Cancer Antigen 125, Prostate-Specific Antigen and Other Cancer Markers: A Primer on Commonly Used Cancer Markers","year":2023,"lang":"en","type":"review","venue":"World Journal of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Carcinoembryonic antigen; Antigen; Prostate-specific antigen; Cancer; Primer (cosmetics); Prostate cancer; Oncology; Immunology; Internal medicine","score_opus":0.14078001429621284,"score_gpt":0.4374348935498289,"score_spread":0.29665487925361606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322213285","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.047964193,0.9410856,0.0000014460663,0.002353509,0.0027403869,0.0035849523,0.0007757549,0.0000815353,0.0014126564],"genre_scores_gemma":[0.0012918613,0.9852535,0.00011004199,0.00070167164,0.0019347372,0.0005426502,0.00009312579,0.0004367337,0.009635693],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921231,0.0010951201,0.002406072,0.0012603954,0.0013058255,0.0018094763],"domain_scores_gemma":[0.99425995,0.00070412096,0.0024341096,0.0008528293,0.0006450779,0.0011039267],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0017762642,0.0013828132,0.00554982,0.0023830263,0.00043018564,0.00014596788,0.0007822269,0.0007828323,0.0014239945],"category_scores_gemma":[0.000066654924,0.0009845789,0.001170612,0.0022549543,0.00082430785,0.00021060492,0.000294297,0.0026861501,0.00007612885],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068183,0.00080778473,0.13664189,0.010551859,0.012202812,0.0056650266,0.0012340973,0.000032694617,0.00044090787,0.000030858555,0.09014426,0.7354295],"study_design_scores_gemma":[0.0050620907,0.0017084492,0.022657845,0.022323962,0.0016448575,0.00023436351,0.00017038964,0.000011686613,0.0000658593,0.000017733535,0.9452384,0.0008643236],"about_ca_topic_score_codex":0.0045328857,"about_ca_topic_score_gemma":0.005507266,"teacher_disagreement_score":0.8550942,"about_ca_system_score_codex":0.003800065,"about_ca_system_score_gemma":0.010325759,"threshold_uncertainty_score":0.99989223},"labels":[],"label_agreement":null},{"id":"W4322505162","doi":"10.1016/j.annonc.2023.02.009","title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prostate Cancer Canada; St. Thomas Hospital","funders":"Cilag; Janssen Research and Development; BeiGene","keywords":"Medicine; Prostate cancer; Placebo; Androgen deprivation therapy; Hazard ratio; Prostate-specific antigen; Enzalutamide; Antiandrogen; Urology; Internal medicine; Proportional hazards model; Oncology; Cancer; Androgen receptor; Pathology; Confidence interval","score_opus":0.10048833024176645,"score_gpt":0.39972854692055465,"score_spread":0.2992402166787882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322505162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944902,0.0005187597,0.000012201352,0.002843267,0.00003320134,0.0019026002,0.00011417637,0.000027313767,0.000058265858],"genre_scores_gemma":[0.9909783,0.0077318107,0.0003351691,0.0003302805,0.000017878216,0.00013433989,0.0002650879,0.000036131758,0.00017102947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981356,0.0002084657,0.00046756465,0.0004400722,0.0003349203,0.00041337387],"domain_scores_gemma":[0.99832153,0.0004159071,0.0002943334,0.00016167935,0.00066093897,0.00014560374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060863467,0.00022757042,0.0007952089,0.00020324651,0.00008068481,0.000023116783,0.00004537091,0.000099527155,0.00001738551],"category_scores_gemma":[0.00007466861,0.00013487348,0.00003460057,0.0005072145,0.0003838003,0.00016409843,0.000035354686,0.0002072077,0.0000014061338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013865955,0.0004892044,0.96012515,0.000040899246,0.00094888883,0.00023907988,0.0018241801,0.00002757879,0.00019740066,0.0000042228608,0.00008386373,0.022153586],"study_design_scores_gemma":[0.020959133,0.009686901,0.96674854,0.000112509195,0.00006736233,0.000007392283,0.0007575819,0.0004532024,0.00084792264,0.000034461264,0.00016198143,0.00016299705],"about_ca_topic_score_codex":0.00037086985,"about_ca_topic_score_gemma":0.002038905,"teacher_disagreement_score":0.02199059,"about_ca_system_score_codex":0.0000868725,"about_ca_system_score_gemma":0.00050807395,"threshold_uncertainty_score":0.5499981},"labels":[],"label_agreement":null},{"id":"W4322617782","doi":"10.1002/pros.24501","title":"Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy","year":2023,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Fonds de Recherche du Québec - Santé; Sanofi Genzyme; Centre Hospitalier Universitaire de Québec; Université Laval","keywords":"Testosterone (patch); Prostate cancer; Medicine; Androgen deprivation therapy; Castration; Hazard ratio; Internal medicine; Urology; Androgen; Proportional hazards model; Prostate; Endocrinology; Confidence interval; Cancer; Oncology; Hormone","score_opus":0.035275392121092285,"score_gpt":0.31533727444557486,"score_spread":0.2800618823244826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322617782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883788,0.0016692744,0.0000050881445,0.007162241,0.00013314626,0.0018497409,0.00005595204,0.00015383975,0.0005918696],"genre_scores_gemma":[0.9847333,0.0107264565,0.00018587484,0.0002473218,0.000080672806,0.00042870906,0.00023421858,0.00005940646,0.003304067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998137,0.00006815637,0.0003108149,0.00037678928,0.00047016304,0.00063706195],"domain_scores_gemma":[0.99924767,0.0001119541,0.00009756722,0.0003286283,0.00011754628,0.000096609045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039910502,0.00022584494,0.0002710438,0.00031771915,0.00017527133,0.000062497485,0.00014981636,0.00005569762,0.00005915862],"category_scores_gemma":[0.000055340806,0.00013989587,0.00006194744,0.0013104003,0.00012064881,0.00016607625,0.00009585121,0.0002702678,0.000079670564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019045048,0.0001935477,0.9659814,0.00010913851,0.00013498776,0.000085491774,0.0024282883,0.00026640715,0.017969701,0.00003982519,0.00075834815,0.010128351],"study_design_scores_gemma":[0.01793227,0.0021026595,0.91544205,0.00052752474,0.00006410463,0.000017134927,0.0007483019,0.0011681857,0.05716488,0.0030475073,0.0013120308,0.00047335896],"about_ca_topic_score_codex":0.00012412843,"about_ca_topic_score_gemma":0.000065044114,"teacher_disagreement_score":0.05053937,"about_ca_system_score_codex":0.00026456275,"about_ca_system_score_gemma":0.00022454513,"threshold_uncertainty_score":0.5704788},"labels":[],"label_agreement":null},{"id":"W4322761313","doi":"10.1016/j.ejca.2023.02.018","title":"Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","year":2023,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; University of British Columbia","funders":"Astellas Pharma; Advanced Accelerator Applications; Medical Research Council; Sanofi; Movember Foundation; AstraZeneca; Chugai Pharmaceutical; Daiichi-Sankyo; Pfizer; Amgen","keywords":"Cancer; Medicine; Prostate cancer; Prostate; Oncology; Castration; Internal medicine; Hormone","score_opus":0.06118626479028528,"score_gpt":0.3776068249279193,"score_spread":0.31642056013763403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322761313","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0416478,0.94655293,0.0000023345524,0.00096524804,0.0009786984,0.0062275254,0.0032775588,0.00003212756,0.00031575197],"genre_scores_gemma":[0.0064316113,0.9762073,0.00042482567,0.000038791717,0.00012999558,0.0007525035,0.00009807421,0.00025443325,0.015662462],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928687,0.0006591794,0.002912727,0.00083463377,0.0019032285,0.0008215143],"domain_scores_gemma":[0.9904866,0.00016322407,0.0056938883,0.0007810829,0.0024675885,0.00040762383],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010923485,0.00091009954,0.002864069,0.00041633623,0.00021546733,0.00006665038,0.0005390899,0.00007198357,0.00021285709],"category_scores_gemma":[0.00009838688,0.00049340853,0.0004640671,0.0013731244,0.0007383727,0.00020519733,0.00027184468,0.0009662273,0.0000025671386],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00998623,0.00035476196,0.0042195795,0.050473157,0.005740361,0.00571447,0.0013729192,0.00044648635,0.00011577978,0.000013846454,0.00148109,0.9200813],"study_design_scores_gemma":[0.022746189,0.004684345,0.0232647,0.24930936,0.012420674,0.0003851365,0.0015719705,0.000017409404,0.00061202655,0.000025721823,0.6835072,0.0014552537],"about_ca_topic_score_codex":0.00031760105,"about_ca_topic_score_gemma":0.0005256349,"teacher_disagreement_score":0.91862607,"about_ca_system_score_codex":0.00087963307,"about_ca_system_score_gemma":0.0055120615,"threshold_uncertainty_score":0.99975175},"labels":[],"label_agreement":null},{"id":"W4323049014","doi":"10.1016/j.mednuc.2023.01.006","title":"Relation entre la baisse du PSA et résultats cliniques chez les patients atteints d’un cancer de la prostate métastatique résistant à la castration – VISION","year":2023,"lang":"fr","type":"article","venue":"Médecine Nucléaire","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Gynecology; Prostate disease; Prostate cancer; Cancer; Internal medicine","score_opus":0.017010832154840647,"score_gpt":0.35890139986103936,"score_spread":0.3418905677061987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323049014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97389066,0.0032752813,0.00020104356,0.015451729,0.00062067667,0.0015115784,0.0004678911,0.00029325107,0.004287911],"genre_scores_gemma":[0.9653969,0.020783924,0.00064908544,0.00023725546,0.00047709627,0.00025874085,0.0014070333,0.0001483188,0.010641655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949704,0.0018740479,0.00077626103,0.00074065995,0.0007741357,0.00086454186],"domain_scores_gemma":[0.99734885,0.0010853247,0.0003176196,0.000359364,0.00047052273,0.00041832592],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002134568,0.00051997474,0.0005426123,0.00031834398,0.00037723937,0.0002046004,0.00017330964,0.0005484143,0.0006978303],"category_scores_gemma":[0.0005902132,0.00045111182,0.00018435298,0.00082279544,0.00048809603,0.0005030835,0.00014101663,0.0009096679,0.00021524423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019883383,0.0018126532,0.6023225,0.00096992316,0.00036360283,0.0015066912,0.015739262,0.0003868997,0.007032067,0.0015584824,0.0264992,0.33982038],"study_design_scores_gemma":[0.011143486,0.0010371784,0.9276412,0.0032826916,0.00033178393,0.00005465653,0.001662425,0.0050434624,0.0039191768,0.001739129,0.043658838,0.00048596426],"about_ca_topic_score_codex":0.001328376,"about_ca_topic_score_gemma":0.00039100874,"teacher_disagreement_score":0.33933443,"about_ca_system_score_codex":0.00083770003,"about_ca_system_score_gemma":0.0008452553,"threshold_uncertainty_score":0.99979407},"labels":[],"label_agreement":null},{"id":"W4323351274","doi":"10.1016/j.eururo.2023.02.017","title":"Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial","year":2023,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University Health Network; University of Toronto; Ottawa Regional Cancer Foundation; Mount Sinai Hospital; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Hazard ratio; Prostate cancer; Prednisone; Abiraterone acetate; Internal medicine; Docetaxel; Oncology; Proportional hazards model; Confidence interval; Progression-free survival; Placebo; Enzalutamide; Randomized controlled trial; Androgen deprivation therapy; Cancer; Chemotherapy; Androgen receptor; Pathology","score_opus":0.02746914410844194,"score_gpt":0.33184445217358816,"score_spread":0.30437530806514623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323351274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922977,0.001279988,0.0000037193456,0.003033563,0.00015848894,0.002719643,0.00037530594,0.000034652534,0.000096952914],"genre_scores_gemma":[0.99736845,0.0013578902,0.000008817998,0.0003061982,0.000040279592,0.00017601761,0.00008752424,0.000048910882,0.0006059022],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9953333,0.0028832129,0.0005651014,0.0004301594,0.00036993707,0.00041824748],"domain_scores_gemma":[0.99819595,0.0008736502,0.00018808547,0.00050526543,0.00011201708,0.00012501524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024812429,0.000246061,0.0008220027,0.00070871896,0.00006980524,0.000007872481,0.00022933933,0.00005055116,0.00036014893],"category_scores_gemma":[0.00026130214,0.00013993814,0.00027054228,0.0023120702,0.00025337073,0.00002343382,0.00006652473,0.00029611227,0.000030291352],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86063653,0.00041732928,0.00726603,0.000084766085,0.002403756,0.00037213485,0.002986141,0.0021370098,0.06028801,0.0000019727065,0.00061619707,0.0627901],"study_design_scores_gemma":[0.25507995,0.14615649,0.3717843,0.0001969173,0.0013609336,0.000013608174,0.00021511821,0.0020029487,0.20152241,0.0000121881485,0.021137524,0.000517631],"about_ca_topic_score_codex":0.00024830308,"about_ca_topic_score_gemma":0.0002154304,"teacher_disagreement_score":0.6055566,"about_ca_system_score_codex":0.000116723175,"about_ca_system_score_gemma":0.00033419806,"threshold_uncertainty_score":0.5706512},"labels":[],"label_agreement":null},{"id":"W4323361737","doi":"10.3390/medicines10030021","title":"Effect of Dexamethasone on Abiraterone Pharmacokinetics in Mice: Determined by LC/MS Analysis","year":2023,"lang":"en","type":"article","venue":"Medicines","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Vancouver General Hospital","funders":"","keywords":"CYP17A1; Dexamethasone; Abiraterone acetate; Abiraterone; Pharmacology; Pharmacokinetics; Chemistry; Medicine; Prostate cancer; Corticosteroid; Endocrinology; Internal medicine; Androgen deprivation therapy; Cancer; Androgen receptor; Biochemistry; Enzyme","score_opus":0.020070921410618878,"score_gpt":0.37947986615731566,"score_spread":0.35940894474669677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323361737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959306,0.0010766933,0.000011346497,0.0017794988,0.0001204243,0.0005076875,0.000020150677,0.000054632168,0.00049895246],"genre_scores_gemma":[0.9960833,0.00090934435,0.000016252205,0.00014371258,0.000107321575,0.00006890758,0.00020625975,0.000020454041,0.0024444244],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985519,0.00012942083,0.00029206715,0.00026045577,0.00045061603,0.00031554812],"domain_scores_gemma":[0.99907285,0.0004683822,0.00006282347,0.00021075775,0.00005486281,0.00013030486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006794478,0.0001707708,0.00062517246,0.0007394501,0.000021815013,0.00000409407,0.00009062951,0.00006742341,0.00017877655],"category_scores_gemma":[0.00018669681,0.000106174804,0.00010200321,0.002098158,0.00012988095,0.000022859773,0.000028874701,0.0001637028,0.000037511003],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030813243,0.0002820301,0.4082381,0.0009018052,0.0010275196,0.00052329025,0.00064768625,0.00006654342,0.51979834,0.0000010370067,0.016638678,0.048793618],"study_design_scores_gemma":[0.015770294,0.0060159713,0.114563376,0.0004252368,0.0020761485,0.0000056325484,0.000094679905,0.004810206,0.8545232,0.00000870533,0.0015193273,0.00018724005],"about_ca_topic_score_codex":0.00013406987,"about_ca_topic_score_gemma":0.000020763744,"teacher_disagreement_score":0.33472484,"about_ca_system_score_codex":0.00006443481,"about_ca_system_score_gemma":0.0000311264,"threshold_uncertainty_score":0.4329683},"labels":[],"label_agreement":null},{"id":"W4323568840","doi":"10.1101/2023.03.03.530998","title":"Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Prostate cancer; Wnt signaling pathway; Biology; Context (archaeology); Prostate; Castration; Cancer research; Androgen receptor; Progenitor cell; Computational biology; Stem cell; Bioinformatics; Signal transduction; Cell biology; Endocrinology; Cancer; Genetics; Hormone","score_opus":0.035424643404157,"score_gpt":0.2581570250175795,"score_spread":0.2227323816134225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323568840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933444,0.0024083355,0.00020741147,0.00078627485,0.00051125436,0.0015980417,0.00092316006,0.00020347723,0.000017600603],"genre_scores_gemma":[0.99659,0.0010435496,0.0014371887,0.00004403566,0.0001930705,0.00032051568,0.0000075263765,0.00012512643,0.00023894971],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996633,0.00021022331,0.0008312039,0.00092472177,0.00077215966,0.00062871166],"domain_scores_gemma":[0.9964017,0.00018208724,0.0005213881,0.001420307,0.00119727,0.0002772107],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006891008,0.00056370406,0.0009689948,0.0007578789,0.00017760372,0.00014794277,0.00042000075,0.00034647717,0.00008054226],"category_scores_gemma":[0.00014190719,0.00039898284,0.0004740178,0.0025316349,0.00035667972,0.000054363958,0.00028192115,0.000718297,0.00005814311],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003639071,0.00042373143,0.01894642,0.00101217,0.0017872453,0.00018573286,0.000047403988,0.0002425987,0.9766149,0.000013072287,0.00035857368,0.000004258928],"study_design_scores_gemma":[0.00092694315,0.00030171484,0.090714805,0.0004455813,0.0030368827,1.5125368e-8,0.000038322025,0.00048318887,0.903088,0.0000014407252,0.000588537,0.00037462596],"about_ca_topic_score_codex":0.00063728564,"about_ca_topic_score_gemma":0.00006415696,"teacher_disagreement_score":0.07352694,"about_ca_system_score_codex":0.00040135795,"about_ca_system_score_gemma":0.0014878325,"threshold_uncertainty_score":0.9998462},"labels":[],"label_agreement":null},{"id":"W4323842692","doi":"10.1038/s41391-023-00656-4","title":"Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","year":2023,"lang":"en","type":"review","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Meta-analysis; Oncology; Internal medicine; Adverse effect; Urology; Cancer; Androgen receptor","score_opus":0.05492487006638911,"score_gpt":0.35954915034050244,"score_spread":0.3046242802741133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323842692","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009288625,0.95110685,0.000023053944,0.00045472514,0.00025769082,0.027127288,0.019965334,0.00012867952,0.000007513167],"genre_scores_gemma":[0.0011423669,0.92658573,0.00025901047,0.00023693452,0.00012956421,0.062345427,0.002275106,0.00025802868,0.006767816],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.993124,0.00068392,0.0020148044,0.001972712,0.0009331097,0.0012714157],"domain_scores_gemma":[0.99470884,0.001403167,0.0015389596,0.00085853366,0.00051653245,0.0009739605],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008105476,0.0017485992,0.010464136,0.0005321903,0.0005630871,0.00021003553,0.00015759634,0.00016895313,0.000095740186],"category_scores_gemma":[0.00018295286,0.0010414445,0.0013392599,0.0014446434,0.00042655432,0.00035315542,0.00014258602,0.00041446908,0.0000067192805],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004112862,0.00027260123,0.0037764292,0.80113125,0.17494167,0.000318779,0.00057677267,0.00008664391,1.5237113e-7,0.000010479759,0.00039153587,0.014380846],"study_design_scores_gemma":[0.004926815,0.0027746854,0.0019650348,0.10873518,0.87579674,0.00005757015,0.00019406536,0.00023712324,9.788362e-7,0.00019113107,0.003907577,0.0012131043],"about_ca_topic_score_codex":0.0022016051,"about_ca_topic_score_gemma":0.002034587,"teacher_disagreement_score":0.7008551,"about_ca_system_score_codex":0.0007514488,"about_ca_system_score_gemma":0.0019851427,"threshold_uncertainty_score":0.99952596},"labels":[],"label_agreement":null},{"id":"W4324136162","doi":"10.1200/jco.2023.41.6_suppl.15","title":"Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) by disease volume and disease risk in the phase 3 ARASENS study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Disease; Prostate cancer; Proportional hazards model; Androgen deprivation therapy; Oncology; Cancer","score_opus":0.08111143485991455,"score_gpt":0.4650320885907761,"score_spread":0.38392065373086154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98831284,0.002190602,0.000013050831,0.0085567525,0.00004167381,0.0008403383,0.000025738822,0.0000040939613,0.000014924262],"genre_scores_gemma":[0.98525286,0.014403913,0.000026318718,0.00019263926,0.000056549863,0.00001156164,0.000014471659,0.000008469575,0.000033196524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778426,0.0006910257,0.0008625425,0.00018638572,0.0003224545,0.00015335265],"domain_scores_gemma":[0.99736154,0.0015876574,0.0004811311,0.00012965054,0.00011578629,0.0003242093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029775072,0.00010250807,0.0006081852,0.00017554233,0.000049515646,0.000011864193,0.000061742125,0.00006877162,0.000006310531],"category_scores_gemma":[0.0016086829,0.000056093657,0.00004790835,0.00028368496,0.00031635768,0.0001057264,0.000031276493,0.00046047563,4.4493106e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04535007,0.0049401526,0.88596565,0.00002702724,0.00012501053,0.0006801335,0.0005488471,0.000009380772,0.000041586023,0.000011187882,0.00028379943,0.062017154],"study_design_scores_gemma":[0.07246203,0.010926702,0.913882,0.00007577386,0.00016767648,0.000014759894,0.0004435399,0.00065800454,0.000004621502,0.00041809864,0.00089639716,0.000050370505],"about_ca_topic_score_codex":0.000029918336,"about_ca_topic_score_gemma":0.000029010804,"teacher_disagreement_score":0.061966784,"about_ca_system_score_codex":0.000050509225,"about_ca_system_score_gemma":0.00049464166,"threshold_uncertainty_score":0.2287433},"labels":[],"label_agreement":null},{"id":"W4324136173","doi":"10.1200/jco.2023.41.6_suppl.45","title":"Patterns of failure after radiotherapy (RT) in patients with prostate cancer re-staged with <sup>18</sup>F-DCFPyL PSMA-PET: A regional cohort analysis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Western University; St. Joseph’s Healthcare Hamilton; Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Lymph node; Biochemical recurrence; Radiation therapy; Stage (stratigraphy); Cohort; Adjuvant; Internal medicine; Urology; Nuclear medicine; Cancer; Oncology; Prostatectomy","score_opus":0.06048129559350125,"score_gpt":0.43402948002501357,"score_spread":0.37354818443151233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99096066,0.00031338082,0.000023749044,0.0077995146,0.00007901238,0.00070370064,0.000050540442,0.00001117709,0.00005825785],"genre_scores_gemma":[0.99473965,0.0023129273,0.00066213,0.00082103495,0.00028653888,0.000076491844,0.000053154716,0.000035695302,0.0010123837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962109,0.0004336167,0.0016469002,0.0003384261,0.00094052014,0.00042965927],"domain_scores_gemma":[0.9968468,0.00068090373,0.0010870895,0.00027998097,0.00075186737,0.0003533773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018711223,0.00021836093,0.0019482147,0.00063281506,0.000031929172,0.000010328634,0.00016889666,0.00019947121,0.0005461999],"category_scores_gemma":[0.00016403031,0.00011984481,0.0003817627,0.0010901889,0.00026261967,0.0001357239,0.000034137698,0.0010133641,0.000003702741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053517047,0.0013073195,0.9308487,0.000072443836,0.0043656933,0.0018675575,0.00045699775,0.0010532193,0.000005507885,0.0000013667559,0.0021945653,0.0043095867],"study_design_scores_gemma":[0.024778163,0.012742389,0.95491385,0.00033283624,0.0010273306,0.00002108348,0.0002508461,0.00027286215,0.000011499409,0.0000117794025,0.005510941,0.00012642103],"about_ca_topic_score_codex":0.0001573276,"about_ca_topic_score_gemma":0.00096450903,"teacher_disagreement_score":0.028738884,"about_ca_system_score_codex":0.00038041722,"about_ca_system_score_gemma":0.0018113579,"threshold_uncertainty_score":0.5980506},"labels":[],"label_agreement":null},{"id":"W4324136183","doi":"10.1200/jco.2023.41.6_suppl.300","title":"Testosterone recovery in patients with prostate cancer treated with radiotherapy and different ADT duration: Long-term data from two randomized trials.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Cégep de Rimouski; Hôpital Maisonneuve-Rosemont; Centre Hospitalier de l’Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Cégep de l'Outaouais; Centre hospitalier universitaire de Québec; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"AstraZeneca Canada","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Radiation therapy; Cancer; Urology; Stage (stratigraphy); Logistic regression; Internal medicine; Surgery","score_opus":0.2033276439089874,"score_gpt":0.4985545941071959,"score_spread":0.2952269501982085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912292,0.0020877346,0.000023252749,0.004955195,0.00027055782,0.0013167837,0.00008163564,0.000011556398,0.000024127314],"genre_scores_gemma":[0.9733914,0.024109574,0.000467518,0.00035255338,0.000703818,0.000048687063,0.00037267752,0.00003189142,0.00052184623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99575615,0.0013454332,0.001948633,0.00030171953,0.00041440848,0.0002336434],"domain_scores_gemma":[0.9926692,0.005176859,0.001362155,0.00027080753,0.00026130097,0.000259662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037672166,0.0001774694,0.0028867635,0.00019124652,0.000032542015,0.000025085914,0.00013590019,0.00014759015,0.00012428054],"category_scores_gemma":[0.0015206828,0.00007996596,0.0001279096,0.00022169037,0.00028860112,0.0002073153,0.000053147447,0.0005408465,0.000002270914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40461835,0.0005025773,0.53269583,0.000014553362,0.0009819906,0.00032785724,0.00005898406,0.0000050604576,0.000015552936,1.9898658e-7,0.00030618263,0.06047285],"study_design_scores_gemma":[0.37997955,0.007932613,0.61093765,0.00031499326,0.00047861875,0.000008726163,0.000010889748,0.00010445917,0.000019326357,0.000017179047,0.00013430287,0.00006170351],"about_ca_topic_score_codex":0.00012939994,"about_ca_topic_score_gemma":0.0006135257,"teacher_disagreement_score":0.07824182,"about_ca_system_score_codex":0.00021419297,"about_ca_system_score_gemma":0.0008910658,"threshold_uncertainty_score":0.3260917},"labels":[],"label_agreement":null},{"id":"W4324136309","doi":"10.1200/jco.2023.41.6_suppl.19","title":"Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Clinical endpoint; Enzalutamide; Placebo; Interim analysis; Internal medicine; Pembrolizumab; Randomization; Abiraterone acetate; Oncology; Prednisone; Randomized controlled trial; Androgen deprivation therapy; Surgery; Cancer","score_opus":0.21805030031091002,"score_gpt":0.538259259351251,"score_spread":0.32020895904034097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879789,0.00052446884,0.00008092022,0.0044281958,0.0008920458,0.005728362,0.00007841203,0.000024942403,0.00026377323],"genre_scores_gemma":[0.99438596,0.001056214,0.0007970362,0.0002495708,0.00059168634,0.00062103535,0.00007463136,0.000045383236,0.0021784885],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949591,0.0005694353,0.0026732401,0.0003538971,0.00092691946,0.0005173687],"domain_scores_gemma":[0.9925087,0.0032342377,0.0017599023,0.00023852596,0.001721201,0.0005374001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046587996,0.0002665655,0.002756926,0.0003411428,0.00014273408,0.000040528994,0.00018712008,0.00015715588,0.00011881602],"category_scores_gemma":[0.0015215733,0.00014520557,0.00062020356,0.00046918847,0.00037620735,0.00021138729,0.000048358248,0.00074084784,0.000017653083],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9564133,0.0067371135,0.008569205,0.0001379909,0.0031661908,0.0009657637,0.0005924656,0.00013762305,0.000019904872,0.00003424853,0.001969626,0.021256559],"study_design_scores_gemma":[0.93775994,0.043979254,0.009901082,0.0001447451,0.0026054138,0.000028117662,0.0005167478,0.00036369002,0.000038113692,0.0001831141,0.004325646,0.0001541173],"about_ca_topic_score_codex":0.00008706662,"about_ca_topic_score_gemma":0.00020291367,"teacher_disagreement_score":0.03724214,"about_ca_system_score_codex":0.00042010527,"about_ca_system_score_gemma":0.005305507,"threshold_uncertainty_score":0.9411742},"labels":[],"label_agreement":null},{"id":"W4324136398","doi":"10.1200/jco.2023.41.6_suppl.22","title":"Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Ipilimumab; Cabazitaxel; Nivolumab; Docetaxel; Abiraterone acetate; Prostate cancer; Cohort; Prednisone; Randomized controlled trial; Oncology; Taxane; Chemotherapy; Clinical trial; Cancer; Androgen deprivation therapy; Breast cancer; Immunotherapy","score_opus":0.2058361179828932,"score_gpt":0.5215913805671609,"score_spread":0.3157552625842677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8843901,0.0046380716,0.00004844168,0.094455205,0.0017687224,0.006257697,0.008245488,0.000021451748,0.00017482367],"genre_scores_gemma":[0.87043655,0.101957165,0.0026219403,0.0028547966,0.006410008,0.0026166034,0.0025982969,0.00011229757,0.010392358],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951853,0.00084333506,0.0028191644,0.00024619338,0.00059449364,0.0003114956],"domain_scores_gemma":[0.96406525,0.03242926,0.002103156,0.0002868059,0.00092453224,0.0001909701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00446789,0.00020367983,0.0019925851,0.00009546932,0.0001634526,0.000023060664,0.00019957557,0.0001405275,0.00070191995],"category_scores_gemma":[0.00441867,0.00008443536,0.0011965085,0.00024258035,0.0006144302,0.00007647073,0.00001601568,0.00033814294,0.000009433057],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8844651,0.0024215186,0.000008326997,0.000017164464,0.0038757783,0.00013478316,0.00093871437,0.00006679007,0.00034829404,0.000030989308,0.02147735,0.0862152],"study_design_scores_gemma":[0.8709097,0.03232145,0.00088694395,0.00011718381,0.0017509493,0.000013988558,0.00063385017,0.0014103258,0.00041736016,0.0006451143,0.09081685,0.000076286684],"about_ca_topic_score_codex":0.00036378065,"about_ca_topic_score_gemma":0.00028014756,"teacher_disagreement_score":0.0973191,"about_ca_system_score_codex":0.0003892407,"about_ca_system_score_gemma":0.0049913856,"threshold_uncertainty_score":0.88545036},"labels":[],"label_agreement":null},{"id":"W4324136455","doi":"10.1200/jco.2023.41.6_suppl.363","title":"Biochemical disease control outcomes of stereotactic body radiation therapy (SBRT) or moderate hypo-fractionation (HFRT) for low- and intermediate-risk prostate cancer (PrCa): Retrospective analysis of 12 years of experience at two Canadian cancer centers.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Dose fractionation; Urology; Retrospective cohort study; Toxicity; Radiosurgery; Radiation therapy; Cancer; Internal medicine; Nuclear medicine","score_opus":0.06902400250732574,"score_gpt":0.4753972413860362,"score_spread":0.40637323887871046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99591064,0.0008100879,0.000017872206,0.0018111739,0.00037677767,0.0005629795,0.0004990512,0.0000037339303,0.0000076498045],"genre_scores_gemma":[0.9829595,0.01641686,0.000040447325,0.00018554102,0.00012606494,0.00007046793,0.000032983287,0.000012828998,0.00015527068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99772865,0.00018505126,0.001308627,0.00020372219,0.00035245108,0.00022152768],"domain_scores_gemma":[0.9955355,0.0015576672,0.0017206009,0.0001258597,0.000692217,0.00036814492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008795617,0.00011376995,0.0012030822,0.00049515656,0.000038294675,0.000005627441,0.000086496664,0.00012004468,0.000090145775],"category_scores_gemma":[0.0020906306,0.00007709195,0.0003502887,0.0003982798,0.000272739,0.0001273427,0.000020789483,0.00024726242,3.518952e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027668677,0.0003475808,0.9514229,0.000050704642,0.0032199332,0.000042069143,0.0007159012,0.00016525183,0.0007896153,0.000003584168,0.00022662696,0.015347099],"study_design_scores_gemma":[0.013473729,0.0021406715,0.9751079,0.00007125227,0.0013304407,0.0000015436613,0.00013168278,0.006321273,0.0010748575,0.00004974014,0.0002324634,0.000064412015],"about_ca_topic_score_codex":0.0045986003,"about_ca_topic_score_gemma":0.006846165,"teacher_disagreement_score":0.023684978,"about_ca_system_score_codex":0.00078656856,"about_ca_system_score_gemma":0.002095253,"threshold_uncertainty_score":0.6951739},"labels":[],"label_agreement":null},{"id":"W4324136525","doi":"10.1200/jco.2023.41.6_suppl.89","title":"Multicenter population-level analysis of systemic therapy use in metastatic or recurrent prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of the Fraser Valley; University of British Columbia; University of Alberta; Abbotsford Veterinary Clinic","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Androgen deprivation therapy; Multivariate analysis; Univariate analysis; Oncology; Population; Radiation therapy; Metastasis; Cancer; Urology; Surgery","score_opus":0.46024789426579193,"score_gpt":0.5820325619540767,"score_spread":0.12178466768828478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574083,0.0012172068,0.000009071554,0.0019910254,0.00055240863,0.00042144634,0.000046519097,0.000006168155,0.000015307629],"genre_scores_gemma":[0.9750951,0.023267683,0.0004644494,0.00018114182,0.000113525566,0.000020775773,0.000028616867,0.000011588027,0.0008171504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964029,0.0005366046,0.0022530945,0.00016034234,0.00041911955,0.00022790868],"domain_scores_gemma":[0.9956807,0.0022723258,0.0012251864,0.00014843883,0.00048343386,0.00018992372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026375968,0.00010490598,0.0016450492,0.00076583325,0.000018011851,0.0000073626156,0.000102659724,0.00011184227,0.00015475611],"category_scores_gemma":[0.0018020935,0.000057318066,0.00045726355,0.0013254728,0.00008686567,0.000114449664,0.000028703484,0.00046023005,0.0000057985176],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017337916,0.0010462739,0.8704661,0.0000840501,0.0033690939,0.0006472036,0.0004419778,0.0004760677,0.00013428576,0.0000046407768,0.000553086,0.10543928],"study_design_scores_gemma":[0.012101341,0.0042326194,0.9781299,0.0003756526,0.0012278154,0.000017718217,0.0003004591,0.0025897885,0.000037309823,0.00002145976,0.0009102519,0.000055634304],"about_ca_topic_score_codex":0.0004144278,"about_ca_topic_score_gemma":0.0009902784,"teacher_disagreement_score":0.10766383,"about_ca_system_score_codex":0.00027097677,"about_ca_system_score_gemma":0.001156581,"threshold_uncertainty_score":0.23373629},"labels":[],"label_agreement":null},{"id":"W4324136563","doi":"10.1200/jco.2023.41.6_suppl.85","title":"First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Ottawa Hospital; University of British Columbia; McMaster University; BC Cancer Agency","funders":"Movember Foundation","keywords":"Medicine; Prostate cancer; Cancer registry; Ethnic group; Socioeconomic status; Cohort; Disease; Cancer; Disease registry; Quality of life (healthcare); Internal medicine; Demography; Gerontology; Environmental health; Population","score_opus":0.16263299207011864,"score_gpt":0.5039225942459716,"score_spread":0.341289602175853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9103731,0.00035702187,0.000011377039,0.088005126,0.00038477863,0.000479386,0.000053954787,0.0000036766357,0.00033157523],"genre_scores_gemma":[0.98362154,0.008212741,0.00017167146,0.0006913062,0.00057162135,0.00009234691,0.00002027655,0.000014260842,0.0066042445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809015,0.00012240362,0.0011084955,0.00012068091,0.0003269491,0.00023130166],"domain_scores_gemma":[0.9957229,0.002674124,0.00095411245,0.0001686231,0.00037050797,0.00010975369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030433454,0.00007942796,0.0005775309,0.00005242186,0.000051940155,0.000005750281,0.00021408097,0.000085620406,0.000079199715],"category_scores_gemma":[0.0023095391,0.000033452856,0.00013558989,0.00014166761,0.00033403514,0.00004644937,0.000074645606,0.00040446484,0.0000045581655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057627704,0.0009946224,0.7737721,0.0001545817,0.0007857801,0.00055608817,0.0007844297,0.000491551,0.00042321504,0.000036207824,0.036948744,0.12742493],"study_design_scores_gemma":[0.017240983,0.006985232,0.77003855,0.00041800266,0.00026733952,0.000040476134,0.0007061801,0.0033743114,0.000530473,0.00015301019,0.20017041,0.0000750484],"about_ca_topic_score_codex":0.000021993672,"about_ca_topic_score_gemma":0.0004060216,"teacher_disagreement_score":0.16322167,"about_ca_system_score_codex":0.00021978925,"about_ca_system_score_gemma":0.0010458806,"threshold_uncertainty_score":0.2764901},"labels":[],"label_agreement":null},{"id":"W4324136570","doi":"10.1200/jco.2023.41.6_suppl.61","title":"Changes in planned disease management after piflufolastat F<sup>18</sup> PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Nuclear medicine; Prostate; Cancer; Radiology; Internal medicine","score_opus":0.09118491147118293,"score_gpt":0.4418453356488163,"score_spread":0.3506604241776333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844564,0.0012019161,3.2083875e-7,0.012757121,0.00006511576,0.00091961405,0.0004498959,0.000005351392,0.00014424365],"genre_scores_gemma":[0.9938049,0.0050835456,0.00006941737,0.00035806073,0.00010341392,0.000119294695,0.000056721277,0.000013244059,0.00039143045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969939,0.00045731384,0.0014191188,0.00034639364,0.0004807205,0.00030253516],"domain_scores_gemma":[0.9968635,0.0018384964,0.000607218,0.00023088307,0.00017410728,0.0002858081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024757544,0.00016627752,0.0012330248,0.0004596303,0.00002279082,0.000012729231,0.00015587076,0.000033771703,0.00010213883],"category_scores_gemma":[0.00048407266,0.00008710038,0.00015439828,0.0008702477,0.00024805337,0.000060784696,0.0001430953,0.0006660047,0.000001751148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.122251466,0.0023025356,0.8084442,0.000110527086,0.004189879,0.01776199,0.0017876324,0.00016911482,0.00002036998,8.143204e-7,0.0020362372,0.040925223],"study_design_scores_gemma":[0.027126068,0.0056491643,0.9595568,0.00051961746,0.0016679352,0.000010013411,0.0032265305,0.0011827081,0.000027597043,0.000041927335,0.0008989363,0.00009269402],"about_ca_topic_score_codex":0.00016032251,"about_ca_topic_score_gemma":0.0030898023,"teacher_disagreement_score":0.1511126,"about_ca_system_score_codex":0.00018885724,"about_ca_system_score_gemma":0.0008041893,"threshold_uncertainty_score":0.35518503},"labels":[],"label_agreement":null},{"id":"W4324136600","doi":"10.1200/jco.2023.41.6_suppl.209","title":"Prognostic biomarkers and clinical outcomes in neuroendocrine prostate cancer (NEPC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Stage (stratigraphy); Internal medicine; Proportional hazards model; Androgen deprivation therapy; Immunohistochemistry; Cancer; Adenocarcinoma; Oncology; Biopsy; Prostate; Log-rank test; Pathology; Gastroenterology","score_opus":0.18071229396248417,"score_gpt":0.5528733898621524,"score_spread":0.3721610958996682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95458746,0.00088315,0.0000010365758,0.04231554,0.0013502319,0.00046379006,0.0000071591253,0.000019511428,0.0003721093],"genre_scores_gemma":[0.9679557,0.02810461,0.00027180617,0.0012782381,0.00049487734,0.000021224017,0.000004512518,0.000023151415,0.0018458881],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99612737,0.0005160336,0.0023343824,0.00025841003,0.00036149358,0.00040230254],"domain_scores_gemma":[0.994095,0.004341916,0.00068371877,0.00014099035,0.00023650861,0.00050185027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031257407,0.00014117456,0.0014794796,0.0003106276,0.000031285203,0.0000115944285,0.0001168882,0.0001465792,0.00006304002],"category_scores_gemma":[0.0065176524,0.000085553715,0.0003650036,0.00040508388,0.00041758467,0.00009658467,0.000110851004,0.0011014567,0.000024973375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004406084,0.0008532996,0.8136939,0.00004111084,0.0004872752,0.006378569,0.000030447129,0.0000018704125,0.0000152346,0.000007815048,0.0035520159,0.17053238],"study_design_scores_gemma":[0.014989391,0.008741783,0.95652086,0.00012493238,0.00023477981,0.0002014654,0.000090853806,0.00017026452,0.000010267611,0.00026838496,0.018574456,0.00007256649],"about_ca_topic_score_codex":0.000058238522,"about_ca_topic_score_gemma":0.00011699099,"teacher_disagreement_score":0.17045982,"about_ca_system_score_codex":0.000106072264,"about_ca_system_score_gemma":0.0017171619,"threshold_uncertainty_score":0.78027093},"labels":[],"label_agreement":null},{"id":"W4324136629","doi":"10.1200/jco.2023.41.6_suppl.309","title":"Patterns of failure with <sup>18</sup>F-DCFPyL PSMA PET/CT in the post-prostatectomy setting: A regional cohort analysis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; St. Joseph’s Healthcare Hamilton; Princess Margaret Cancer Centre; University of Toronto; McMaster University; Juravinski Cancer Centre","funders":"Cancer Care Ontario","keywords":"Medicine; Prostatectomy; Prostate cancer; Biochemical recurrence; Lymph node; Cohort; Stage (stratigraphy); Prospective cohort study; Pathological; Cancer registry; Incidence (geometry); Urology; Proportional hazards model; Cancer; Nuclear medicine; Radiology; Internal medicine","score_opus":0.09783272336616256,"score_gpt":0.4596731295079382,"score_spread":0.36184040614177565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96067804,0.000117029536,0.000013509275,0.03812223,0.00006668222,0.00044321537,0.000020506099,0.000010692645,0.0005280854],"genre_scores_gemma":[0.99648196,0.0006908807,0.00034768184,0.0014819435,0.00034741638,0.000021524209,0.00006259863,0.000017676131,0.0005483213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958828,0.00078540324,0.0017708289,0.00026184207,0.00090931647,0.000389821],"domain_scores_gemma":[0.9947074,0.0030272303,0.0010191704,0.00031127577,0.00069003116,0.00024485815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005733935,0.00016886776,0.0015624153,0.00056497904,0.000050509898,0.000013654583,0.000312284,0.00007606705,0.00025422042],"category_scores_gemma":[0.0011400009,0.00008341581,0.0006358554,0.0011940011,0.0002565001,0.000093028124,0.00006326898,0.0013477313,0.000019318319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043457025,0.00085169706,0.96855444,0.000059879225,0.002367631,0.013961424,0.00032758556,0.00038733846,0.00002087524,0.000021671336,0.005883739,0.003218045],"study_design_scores_gemma":[0.009394585,0.008326698,0.961594,0.00015603368,0.0014467564,0.0013408269,0.0023403305,0.00068810594,0.000023344026,0.000085741165,0.014509972,0.00009362707],"about_ca_topic_score_codex":0.00012142186,"about_ca_topic_score_gemma":0.00029505586,"teacher_disagreement_score":0.036640283,"about_ca_system_score_codex":0.00013900409,"about_ca_system_score_gemma":0.0018195377,"threshold_uncertainty_score":0.5855297},"labels":[],"label_agreement":null},{"id":"W4324136640","doi":"10.1200/jco.2023.41.6_suppl.332","title":"Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"Bayer HealthCare","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Adverse effect; Oncology; Cancer; Androgen receptor; Clinical trial","score_opus":0.24014668830663125,"score_gpt":0.5210510775349937,"score_spread":0.28090438922836247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916468,0.0004328,0.000028407112,0.0059098415,0.00060178724,0.00092439156,0.00012928486,0.000015273812,0.00031137062],"genre_scores_gemma":[0.9733061,0.013189321,0.005804959,0.00042216905,0.0005757194,0.000070537804,0.000027501952,0.00004407378,0.006559572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631494,0.00023887966,0.002304319,0.00025938082,0.00047951093,0.00040297507],"domain_scores_gemma":[0.99269617,0.004405557,0.0013962872,0.00019743058,0.000877597,0.00042693556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029828516,0.00017667405,0.0015297448,0.00041856687,0.00007289929,0.000022080532,0.00010923686,0.00015180779,0.000046192377],"category_scores_gemma":[0.0023900904,0.00011995535,0.0003663485,0.0004958008,0.00041482365,0.00021324899,0.000059020473,0.00054509594,0.0000052445466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.073551185,0.0027234196,0.5321557,0.0019837974,0.0041276836,0.00330378,0.001195115,0.00059109076,0.03196168,0.0006511114,0.044311658,0.30344376],"study_design_scores_gemma":[0.021356288,0.016252909,0.90667176,0.00066018925,0.0011623404,0.00008692823,0.00035817164,0.0019988199,0.0016521908,0.0015381072,0.048055395,0.00020687829],"about_ca_topic_score_codex":0.0003649929,"about_ca_topic_score_gemma":0.0008603515,"teacher_disagreement_score":0.37451607,"about_ca_system_score_codex":0.00019496627,"about_ca_system_score_gemma":0.0030951833,"threshold_uncertainty_score":0.54907227},"labels":[],"label_agreement":null},{"id":"W4324136665","doi":"10.1200/jco.2023.41.6_suppl.316","title":"Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: A post hoc analysis of the PROPS trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre; Princess Margaret Cancer Centre; Université Laval","funders":"","keywords":"Medicine; Prostatectomy; Nomogram; Prostate cancer; Androgen deprivation therapy; Radiation therapy; Salvage therapy; Biochemical recurrence; Oncology; Internal medicine; Urology; Odds ratio; Post-hoc analysis; Surgery; Cancer; Chemotherapy","score_opus":0.08919680025866426,"score_gpt":0.49517546282303976,"score_spread":0.4059786625643755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98169595,0.00028057123,0.00008272942,0.014580383,0.00021079928,0.0030966497,0.00004153377,0.000005364632,0.000006048135],"genre_scores_gemma":[0.996931,0.0016247437,0.0002988427,0.000637623,0.000107200285,0.00031303964,0.000017622036,0.000011505936,0.000058417674],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980143,0.00019907,0.0012047326,0.00016026753,0.00026905385,0.00015261119],"domain_scores_gemma":[0.99604875,0.00094536954,0.0012842498,0.00013752065,0.001489491,0.00009461016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012380686,0.00008967001,0.0007955717,0.00035444385,0.000044497825,0.000004588281,0.000075709606,0.00007949498,0.0000027060742],"category_scores_gemma":[0.0017310691,0.000047766305,0.00054990867,0.00075743254,0.000066932575,0.000041938278,0.000011257531,0.00010515758,3.6572263e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2484084,0.0015223572,0.031997256,0.000043590237,0.0022262456,0.000004915836,0.0009954463,0.006205884,0.030383442,0.000021984522,0.0003061737,0.6778843],"study_design_scores_gemma":[0.11772894,0.19021909,0.5801898,0.00024658084,0.0035124496,0.0000051082193,0.00040270545,0.006699137,0.08845678,0.00018377755,0.012214844,0.00014077222],"about_ca_topic_score_codex":0.00006540483,"about_ca_topic_score_gemma":0.00003296979,"teacher_disagreement_score":0.67774355,"about_ca_system_score_codex":0.00039634074,"about_ca_system_score_gemma":0.0013752991,"threshold_uncertainty_score":0.24397215},"labels":[],"label_agreement":null},{"id":"W4324136676","doi":"10.1200/jco.2023.41.6_suppl.148","title":"Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Dosing; Pharmacokinetics; Discontinuation; Internal medicine","score_opus":0.0895156565479519,"score_gpt":0.4494159933776046,"score_spread":0.35990033682965267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938486,0.0011162848,0.000005839743,0.003521876,0.000059795813,0.0013979839,0.000014075258,0.0000041749126,0.000031357547],"genre_scores_gemma":[0.97227633,0.027198035,0.000105731735,0.00031399034,0.000040623472,0.000018822571,0.000010971186,0.000015351914,0.000020138757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974849,0.0006396194,0.000970837,0.00018912862,0.00050934276,0.00020612674],"domain_scores_gemma":[0.9976133,0.0010369638,0.000741562,0.00010427014,0.00040878836,0.00009511397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023853043,0.00014301903,0.00083814317,0.00026174655,0.000038434813,0.000012824417,0.00006843336,0.00006516654,0.0000032659648],"category_scores_gemma":[0.00015412283,0.00007072709,0.00004468946,0.00050437223,0.00030233178,0.0001244998,0.000023478744,0.0005210601,2.7050362e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05139629,0.0030357158,0.88050926,0.000020814086,0.0004898216,0.00036195814,0.004271286,0.00007632304,0.00015032866,0.0000076442,0.000045057393,0.05963549],"study_design_scores_gemma":[0.06569961,0.026639134,0.9054821,0.00009734299,0.0001276946,0.000022898505,0.0010911829,0.00018865279,0.00016644566,0.00009626071,0.00031944143,0.00006923903],"about_ca_topic_score_codex":0.00008415809,"about_ca_topic_score_gemma":0.00012232459,"teacher_disagreement_score":0.059566252,"about_ca_system_score_codex":0.00009245349,"about_ca_system_score_gemma":0.0004680523,"threshold_uncertainty_score":0.28841668},"labels":[],"label_agreement":null},{"id":"W4324136691","doi":"10.1200/jco.2023.41.6_suppl.366","title":"Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): Individual patient data meta-analysis from the MARCAP Consortium.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Testosterone (patch); Radiation therapy; Urology; Androgen; Internal medicine; Randomized controlled trial; Prostate; Oncology; Gynecology; Cancer; Hormone","score_opus":0.3237556577422082,"score_gpt":0.48914129670789985,"score_spread":0.16538563896569164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96288395,0.0150980465,0.000028387178,0.020675758,0.00043422342,0.00042240813,0.00037881106,0.000013242018,0.00006518107],"genre_scores_gemma":[0.983283,0.010965847,0.0019455862,0.002406652,0.00039347034,0.000015277194,0.0004983239,0.000025901909,0.0004659411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963842,0.0007080354,0.0016401605,0.0003382087,0.0006569802,0.00027242868],"domain_scores_gemma":[0.9939843,0.00419377,0.0008698768,0.0005164002,0.00013309527,0.00030256063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043293745,0.00015582178,0.0020111022,0.0001704538,0.00009469337,0.00002449084,0.00029983209,0.00020706601,0.00027958513],"category_scores_gemma":[0.0008106058,0.00007409809,0.0010287487,0.00043668857,0.00022033301,0.00019771139,0.00016082951,0.000693797,0.000005372162],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008290849,0.0008933329,0.516104,0.000020712074,0.3289575,0.003308973,0.0009083759,0.00004602026,0.00036963442,0.0000017666322,0.021874005,0.11922487],"study_design_scores_gemma":[0.0130831525,0.01069833,0.6303033,0.00004911066,0.26225427,0.00009363327,0.00058719213,0.000294525,0.0002213192,0.00032258095,0.08189339,0.00019915459],"about_ca_topic_score_codex":0.00007704414,"about_ca_topic_score_gemma":0.00006847465,"teacher_disagreement_score":0.11902571,"about_ca_system_score_codex":0.000043658507,"about_ca_system_score_gemma":0.000747442,"threshold_uncertainty_score":0.3061261},"labels":[],"label_agreement":null},{"id":"W4324136720","doi":"10.1200/jco.2023.41.6_suppl.72","title":"Outcomes of first subsequent taxane (FST) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel intensification (DI) for metastatic castration-sensitive prostate cancer (mCSPC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Docetaxel; Taxane; Cabazitaxel; Prostate cancer; Oncology; Clinical endpoint; Internal medicine; Cancer; Androgen deprivation therapy; Clinical trial; Breast cancer","score_opus":0.16528388220811646,"score_gpt":0.46729792203362736,"score_spread":0.3020140398255109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98405623,0.00086210086,0.000033290253,0.010679528,0.0004696442,0.0035828569,0.0002619323,0.000016593385,0.000037816648],"genre_scores_gemma":[0.9859834,0.010817702,0.0011707775,0.00033242189,0.00012589413,0.0005326419,0.00014000782,0.000052917523,0.0008442677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946974,0.0005427537,0.0029274472,0.00044646394,0.0008163809,0.00056954165],"domain_scores_gemma":[0.9914203,0.0019780342,0.0028087015,0.0002724661,0.0031839134,0.00033653982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027266545,0.00033994456,0.002194736,0.0004254949,0.00010366125,0.000029673583,0.00016594211,0.00014715106,0.000045810564],"category_scores_gemma":[0.0016476822,0.00021037352,0.00036661027,0.000686561,0.0004023945,0.00030397685,0.000028669889,0.0006496853,0.0000039526067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061992366,0.0034770924,0.83886695,0.00065749686,0.0037125621,0.0005947006,0.004672209,0.0015353513,0.0010812304,0.0000429335,0.0014517034,0.08191543],"study_design_scores_gemma":[0.03964828,0.02036721,0.9322902,0.0008564082,0.0008574565,0.000024792453,0.0015922438,0.0008440986,0.0014989411,0.00015348078,0.0016209101,0.00024597993],"about_ca_topic_score_codex":0.0008530911,"about_ca_topic_score_gemma":0.0058491887,"teacher_disagreement_score":0.09342327,"about_ca_system_score_codex":0.000751849,"about_ca_system_score_gemma":0.0035753176,"threshold_uncertainty_score":0.8578783},"labels":[],"label_agreement":null},{"id":"W4324136759","doi":"10.1200/jco.2023.41.6_suppl.129","title":"Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Docetaxel; Medicine; Placebo; Prostate cancer; Randomization; Population; Internal medicine; Urology; Gynecology; Oncology; Cancer; Clinical trial; Alternative medicine","score_opus":0.1430674295185643,"score_gpt":0.48837286328871127,"score_spread":0.345305433770147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091357,0.0003343,0.000018528399,0.00567558,0.0008173416,0.0018459286,0.00007344254,0.000025056614,0.00029622807],"genre_scores_gemma":[0.9951144,0.00088566676,0.0014487177,0.0005375444,0.00018165766,0.00024710112,0.000065577595,0.00004631678,0.001473037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948865,0.00030185757,0.0029641057,0.00037856665,0.00085860083,0.0006103804],"domain_scores_gemma":[0.99432874,0.0018115827,0.001925045,0.00024932175,0.0012303289,0.00045501275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017897144,0.00027169997,0.0018975917,0.00042037954,0.00009031436,0.000027065142,0.00014705781,0.0002079598,0.00007126122],"category_scores_gemma":[0.0024735285,0.00015954599,0.0004259687,0.00057458435,0.00023534523,0.0002229892,0.00005361315,0.00077786954,0.000012113029],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10479498,0.004471401,0.77313584,0.00041221522,0.0022978408,0.0038773683,0.0011254871,0.00051495456,0.00021267576,0.00005037206,0.0047237473,0.10438313],"study_design_scores_gemma":[0.10474855,0.03335952,0.84729195,0.00038876076,0.0008538845,0.00008120968,0.0005678393,0.00051953556,0.00014728034,0.00042729668,0.011361596,0.00025260632],"about_ca_topic_score_codex":0.00017801294,"about_ca_topic_score_gemma":0.0005831424,"teacher_disagreement_score":0.10413053,"about_ca_system_score_codex":0.0007352019,"about_ca_system_score_gemma":0.0052288715,"threshold_uncertainty_score":0.92757934},"labels":[],"label_agreement":null},{"id":"W4324136820","doi":"10.1200/jco.2023.41.6_suppl.76","title":"Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre; Western University; University of Toronto; University of Calgary; Mount Sinai Hospital; Princess Margaret Cancer Centre; Ottawa Hospital; Jewish General Hospital; McGill University; University of Ottawa; McMaster University; University of Alberta; Juravinski Cancer Centre; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Enzalutamide; Medicine; Abiraterone acetate; Docetaxel; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Population; Cohort; Cabazitaxel; Cancer; Androgen receptor","score_opus":0.1275548431199656,"score_gpt":0.4888571245861799,"score_spread":0.36130228146621435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994231,0.00009095059,0.000007699259,0.0049003805,0.00018307354,0.00046797955,0.000026060703,0.0000039773545,0.00008889628],"genre_scores_gemma":[0.9961892,0.0030990613,0.00033997028,0.00012446617,0.000082063576,0.00001409479,0.000023067383,0.000008582774,0.00011954296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982606,0.00027868175,0.00094782753,0.00012698039,0.00024937248,0.0001365237],"domain_scores_gemma":[0.9967322,0.0012858253,0.00087813404,0.00007698018,0.0008822418,0.00014464156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009767581,0.00008299316,0.00067526224,0.0001672774,0.000016317796,0.000004245005,0.00002654157,0.00006500965,0.0000071226486],"category_scores_gemma":[0.0010889242,0.000046987636,0.000064193766,0.00020803596,0.00013778942,0.00013699465,0.0000129208665,0.00024877893,0.0000014952191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012612705,0.0011409009,0.93213207,0.000039763483,0.00061450765,0.00033162892,0.0010033911,0.00003437014,0.000029261946,0.0000073426104,0.00010390137,0.05195017],"study_design_scores_gemma":[0.013236674,0.027437316,0.956533,0.00016269187,0.00040416955,0.00002891722,0.0012417219,0.00007479256,0.00014049275,0.000014382152,0.0006891057,0.000036711383],"about_ca_topic_score_codex":0.0002111582,"about_ca_topic_score_gemma":0.00018790421,"teacher_disagreement_score":0.05191346,"about_ca_system_score_codex":0.0002758746,"about_ca_system_score_gemma":0.0013249542,"threshold_uncertainty_score":0.2350412},"labels":[],"label_agreement":null},{"id":"W4324136858","doi":"10.1200/jco.2023.41.6_suppl.tps287","title":"CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Clinical endpoint; Oncology; Internal medicine; Enzalutamide; Taxane; Chemotherapy; Cancer; Clinical trial; Androgen receptor; Breast cancer","score_opus":0.250652462958183,"score_gpt":0.5513524197459858,"score_spread":0.3006999567878028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99262184,0.0029128545,0.0000010632095,0.0029532462,0.00037500556,0.00094655657,0.000021482107,0.000007683636,0.00016024116],"genre_scores_gemma":[0.9918226,0.0072866697,0.0001646631,0.00007311375,0.00014251852,0.00003708983,0.0000054039847,0.000015604775,0.00045230685],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996602,0.0004381277,0.0019359726,0.0002577575,0.00045468623,0.00031145566],"domain_scores_gemma":[0.9962404,0.0020150188,0.0008935096,0.00014723594,0.0003239239,0.000379922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002839923,0.00016465028,0.0014600867,0.00033770618,0.00005351889,0.000015081736,0.00008854068,0.00011844357,0.000051037732],"category_scores_gemma":[0.0011104341,0.000111057176,0.00011916014,0.00039355713,0.0003067718,0.00013629015,0.00006519072,0.00066045224,0.0000023586133],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5387797,0.022306513,0.19528016,0.0009182162,0.0052496768,0.020372761,0.01671161,0.00022927167,0.009647687,0.00011080205,0.003552877,0.18684076],"study_design_scores_gemma":[0.5533216,0.12712651,0.28928393,0.00050999346,0.002270939,0.00024346034,0.021605616,0.0012169715,0.0007283336,0.0004559177,0.0029150276,0.0003216779],"about_ca_topic_score_codex":0.0006178428,"about_ca_topic_score_gemma":0.0020691394,"teacher_disagreement_score":0.18651909,"about_ca_system_score_codex":0.00014116718,"about_ca_system_score_gemma":0.0016922479,"threshold_uncertainty_score":0.45287803},"labels":[],"label_agreement":null},{"id":"W4324136905","doi":"10.1200/jco.2023.41.6_suppl.338","title":"Pelvic clinical node-positive prostate cancer: Impact of radiotherapy and nodal disease burden.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Context (archaeology); Radiation therapy; Internal medicine; Hazard ratio; Oncology; Univariate analysis; Prostate; Proportional hazards model; Population; Cancer; Multivariate analysis; Urology; Confidence interval","score_opus":0.12091008707411777,"score_gpt":0.554328276363233,"score_spread":0.43341818928911524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97866595,0.005017371,0.000008062608,0.014901065,0.0007087423,0.00038379923,0.00006417154,0.000013519367,0.00023732717],"genre_scores_gemma":[0.93398356,0.06222879,0.00038972465,0.00044515304,0.0018533702,0.000008841592,0.000011482432,0.00002676608,0.0010523326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99632496,0.0005639111,0.0020742,0.00024810727,0.00043859717,0.00035022406],"domain_scores_gemma":[0.99460727,0.0026229566,0.001119836,0.00018420209,0.00048239809,0.0009833407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032846835,0.00016315327,0.0016668012,0.00020625863,0.000045595043,0.00001030884,0.00013293629,0.0002591186,0.00016760005],"category_scores_gemma":[0.0015052627,0.00009715949,0.0008803326,0.0002982355,0.0006883731,0.00010488449,0.000063024636,0.000958787,0.000008736902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033236895,0.00095801253,0.7617868,0.00007309009,0.001579065,0.0019512416,0.00026909544,0.000051425606,0.00027400276,0.000011055394,0.0072922735,0.192517],"study_design_scores_gemma":[0.01774757,0.018477416,0.95653576,0.00024168864,0.0004232355,0.00008115037,0.00008812536,0.0007269912,0.000027290454,0.00020767293,0.005350384,0.0000927296],"about_ca_topic_score_codex":0.00011165304,"about_ca_topic_score_gemma":0.000008861794,"teacher_disagreement_score":0.19474891,"about_ca_system_score_codex":0.00027414804,"about_ca_system_score_gemma":0.0048427503,"threshold_uncertainty_score":0.85908306},"labels":[],"label_agreement":null},{"id":"W4324136907","doi":"10.1200/jco.2023.41.6_suppl.tps283","title":"NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"SABR volatility model; Medicine; Prostate cancer; Androgen deprivation therapy; Placebo; Radiation therapy; Oncology; Prostate; Internal medicine; Urology; Prostatectomy; Cancer; Surgery; Pathology","score_opus":0.1913529550231457,"score_gpt":0.5169976281634783,"score_spread":0.3256446731403326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98262614,0.0015659772,0.000050692506,0.0058111176,0.00055423874,0.009190277,0.00002486705,0.000034064742,0.00014263553],"genre_scores_gemma":[0.96703583,0.025483977,0.003076251,0.00042009293,0.0005580876,0.0011751073,0.000023800134,0.00009160267,0.002135233],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9926749,0.0010857787,0.0038923637,0.0004721438,0.0011712917,0.00070352206],"domain_scores_gemma":[0.9930998,0.0022090052,0.002935287,0.00036793985,0.00090409897,0.00048385814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008456009,0.00039823004,0.00403298,0.0012319527,0.00009844962,0.000028263737,0.0002840332,0.0002954803,0.00022641126],"category_scores_gemma":[0.00100107,0.00020964682,0.00052258803,0.001835338,0.00046590393,0.00030233664,0.00005146523,0.0011061999,0.0000058225423],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8318784,0.0071950904,0.016373059,0.00016961031,0.0027157192,0.0008192067,0.0020898874,0.00016007418,0.0010403635,0.000008488144,0.00023331068,0.13731675],"study_design_scores_gemma":[0.8556812,0.13494606,0.0021273755,0.0004126765,0.0005483678,0.00013355345,0.00037036344,0.00096440996,0.0013964006,0.0002035485,0.0030076166,0.00020842215],"about_ca_topic_score_codex":0.00010405577,"about_ca_topic_score_gemma":0.00016050016,"teacher_disagreement_score":0.13710833,"about_ca_system_score_codex":0.0004354041,"about_ca_system_score_gemma":0.007281517,"threshold_uncertainty_score":0.99834627},"labels":[],"label_agreement":null},{"id":"W4324136961","doi":"10.1200/jco.2023.41.6_suppl.lba16","title":"Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Clinical endpoint; Prostate cancer; Internal medicine; Hazard ratio; Abiraterone acetate; Placebo; Progression-free survival; Interim analysis; Oncology; Prednisone; Confidence interval; Androgen deprivation therapy; Cancer; Surgery; Randomized controlled trial; Chemotherapy; Pathology","score_opus":0.31049066337092945,"score_gpt":0.5159334548274083,"score_spread":0.2054427914564788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775956,0.002322041,0.000010288487,0.017690692,0.00085043296,0.0013123159,0.000058652313,0.000016318147,0.00014365281],"genre_scores_gemma":[0.9722468,0.023976931,0.0009688081,0.00038921274,0.0005604217,0.000162333,0.00003330282,0.000043526285,0.001618646],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9967788,0.00035909208,0.0015894811,0.00035761629,0.0004317627,0.00048325298],"domain_scores_gemma":[0.9961047,0.0022900105,0.00067536195,0.00014450369,0.0004004156,0.00038501027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031156025,0.0002374431,0.0013352975,0.00022802567,0.000105263476,0.00004545525,0.000106520085,0.00021235443,0.000087642926],"category_scores_gemma":[0.001022061,0.00015501722,0.00015487162,0.0002260974,0.00033291374,0.0002082857,0.00005610674,0.00070823525,0.000013718774],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.652523,0.0037038578,0.10499051,0.0008642571,0.0026651644,0.004016977,0.0018402273,0.00035763843,0.006430954,0.00031404538,0.0062089497,0.21608444],"study_design_scores_gemma":[0.30102357,0.099494934,0.5214996,0.0006543318,0.0007494215,0.00020677003,0.0007945013,0.0017369173,0.0011159581,0.0024416924,0.069766924,0.00051538774],"about_ca_topic_score_codex":0.00020117882,"about_ca_topic_score_gemma":0.0014323946,"teacher_disagreement_score":0.41650906,"about_ca_system_score_codex":0.00023142394,"about_ca_system_score_gemma":0.0018757858,"threshold_uncertainty_score":0.6321419},"labels":[],"label_agreement":null},{"id":"W4324136969","doi":"10.1200/jco.2023.41.6_suppl.tps396","title":"DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University; Ottawa Hospital; Centre Hospitalier Universitaire de Sherbrooke; Sunnybrook Health Science Centre; Health Sciences Centre; McGill University; Jewish General Hospital","funders":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Cancer Australia","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Docetaxel; Placebo; Internal medicine; Salvage therapy; Randomization; Prostatectomy; Oncology; Randomized controlled trial; Antiandrogen; Urology; Surgery; Cancer; Chemotherapy; Pathology","score_opus":0.2047591432241928,"score_gpt":0.5064863245693975,"score_spread":0.30172718134520465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989336,0.0014899197,0.0004948129,0.004501131,0.00049508316,0.003551018,0.000070729366,0.000015016201,0.000046274297],"genre_scores_gemma":[0.9152064,0.081959315,0.00119799,0.00026692887,0.0007548872,0.0003124632,0.00006970018,0.00002998582,0.00020238366],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964735,0.00063735753,0.0019696373,0.0002366278,0.0004251864,0.00025770822],"domain_scores_gemma":[0.9894129,0.0073659797,0.0021967038,0.00013357912,0.0006527643,0.00023806399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00623136,0.00016274986,0.0020231514,0.00026193797,0.00007449718,0.000014974504,0.0000815331,0.00026923147,0.00003313367],"category_scores_gemma":[0.003066335,0.00008587003,0.0003266792,0.00036760754,0.0004873311,0.00014673197,0.000023102088,0.0004982855,0.0000013627322],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7745846,0.001143256,0.0022127198,0.00004728083,0.0014248918,0.00012916522,0.00027213412,0.00002214646,0.0000979929,0.00006065544,0.00033611283,0.21966907],"study_design_scores_gemma":[0.9410628,0.04970524,0.0012859859,0.00013439305,0.00090070633,0.000030945936,0.000119228294,0.0005459678,0.0013445917,0.0008085546,0.0039724545,0.00008913009],"about_ca_topic_score_codex":0.00009937502,"about_ca_topic_score_gemma":0.000038052713,"teacher_disagreement_score":0.21957995,"about_ca_system_score_codex":0.0001240347,"about_ca_system_score_gemma":0.0028427227,"threshold_uncertainty_score":0.5042868},"labels":[],"label_agreement":null},{"id":"W4324136974","doi":"10.1200/jco.2023.41.6_suppl.169","title":"Comparative outcomes of metastatic prostate cancer (mPC) patients (pts) with DNA damage response gene alterations (DDR-a): A single-center experience.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Ottawa","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Internal medicine; Clinical endpoint; Oncology; Cancer; Progression-free survival; Overall survival; Clinical trial; Androgen receptor","score_opus":0.2792048131138515,"score_gpt":0.5362127304498683,"score_spread":0.2570079173360168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936668,0.00011774095,0.000019986908,0.004813027,0.00047719164,0.00060380035,0.00007029237,0.0000115998655,0.00021952714],"genre_scores_gemma":[0.99586904,0.00029593435,0.0015393277,0.0005191505,0.00011386746,0.000057987458,0.00002489805,0.000017269467,0.0015625028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99652785,0.00072538573,0.0016335347,0.00020560285,0.00060012663,0.00030749082],"domain_scores_gemma":[0.9953515,0.0020033782,0.0011383558,0.0001929381,0.0009850537,0.00032875492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014683947,0.0001614775,0.0014735155,0.00026957973,0.00006953294,0.000013507209,0.00014235856,0.000090920556,0.0001430218],"category_scores_gemma":[0.0009511418,0.00009050651,0.0002566625,0.00042160947,0.00047910478,0.00017963712,0.00006087414,0.00045639413,0.000016188329],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051555872,0.006455421,0.920007,0.00005439735,0.0016707605,0.0010978067,0.0056604315,0.00010522537,0.003526962,0.00000799326,0.00398464,0.0058734794],"study_design_scores_gemma":[0.031888627,0.032883856,0.9176225,0.00023117966,0.00043091807,0.000051297735,0.0016094523,0.0001900387,0.0043619303,0.000043416647,0.010542132,0.00014466581],"about_ca_topic_score_codex":0.000017479075,"about_ca_topic_score_gemma":0.000064414315,"teacher_disagreement_score":0.026428433,"about_ca_system_score_codex":0.0002459841,"about_ca_system_score_gemma":0.0017091805,"threshold_uncertainty_score":0.36907482},"labels":[],"label_agreement":null},{"id":"W4324136985","doi":"10.1200/jco.2023.41.6_suppl.177","title":"Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Enzalutamide; Adverse effect; Pharmacokinetics; Internal medicine; Oncology; Pharmacodynamics; Antiandrogen; Pharmacology; Abiraterone acetate; Abiraterone; Tolerability; Cancer; Androgen deprivation therapy","score_opus":0.1872818187061182,"score_gpt":0.5233139718776647,"score_spread":0.3360321531715465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908303,0.00023423895,0.0000024310634,0.007705114,0.00038256854,0.00040916048,0.000015781407,0.000009342575,0.00041108255],"genre_scores_gemma":[0.9967707,0.0007890138,0.0007684856,0.00035660717,0.00016506578,0.000019269708,0.000018703371,0.000016265658,0.0010959349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740726,0.00028197435,0.0013427674,0.00015766363,0.00050550187,0.00030480957],"domain_scores_gemma":[0.9977656,0.0006916486,0.00064931693,0.000111566944,0.0004943601,0.00028748915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019354096,0.00010929202,0.00095172116,0.00022354837,0.000033023687,0.00000999912,0.000088314395,0.00009693932,0.00011065052],"category_scores_gemma":[0.00075455493,0.00006170643,0.00014373157,0.0004726935,0.00017170691,0.0001222042,0.000026271518,0.00064287113,0.000024484236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024369478,0.0015029153,0.88580877,0.00006388858,0.00043783005,0.0022588538,0.00019400366,0.00008696539,0.0000458023,0.000023986766,0.0034593425,0.081748195],"study_design_scores_gemma":[0.023667201,0.016815504,0.9509384,0.00016221605,0.00018520474,0.000013057568,0.00014595562,0.000054386786,0.000035205754,0.00018488133,0.007731421,0.00006655315],"about_ca_topic_score_codex":0.000084401174,"about_ca_topic_score_gemma":0.00039832795,"teacher_disagreement_score":0.08168164,"about_ca_system_score_codex":0.0002665847,"about_ca_system_score_gemma":0.0027878033,"threshold_uncertainty_score":0.49454433},"labels":[],"label_agreement":null},{"id":"W4324137009","doi":"10.1200/jco.2023.41.6_suppl.tps274","title":"PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; CHEK2; Prostate cancer; MSH2; PALB2; MSH6; Genetic testing; Oncology; PTEN; Germline; MLH1; Internal medicine; Cancer; Germline mutation; Genetics; DNA mismatch repair; Mutation; Gene; Colorectal cancer; Biology","score_opus":0.16414880134387766,"score_gpt":0.5276381257444269,"score_spread":0.36348932440054926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324137009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98491234,0.0010859211,0.000017670158,0.012443071,0.00036042056,0.0009851535,0.00009211693,0.000010117677,0.00009316442],"genre_scores_gemma":[0.98686796,0.009049832,0.0009307814,0.00006922055,0.0003178624,0.00014956864,0.000026317553,0.000021423668,0.0025670305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832195,0.00019781351,0.0009515285,0.0001880736,0.00014203042,0.00019862822],"domain_scores_gemma":[0.99537104,0.0030257844,0.0008187558,0.0001314571,0.00040407098,0.0002488933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017323784,0.00012245304,0.0012355131,0.00010722235,0.000048379432,0.000008148158,0.000050537637,0.00017151189,0.000006609193],"category_scores_gemma":[0.0020517798,0.00007184919,0.00022734606,0.00013117124,0.00034603418,0.00005388646,0.00003206099,0.00022579056,4.1529742e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025599118,0.0014110588,0.6903384,0.00056872144,0.0019972953,0.00030510154,0.00030266962,0.000008537823,0.003264093,0.00007639458,0.00066464837,0.27546397],"study_design_scores_gemma":[0.036281183,0.018317662,0.93263257,0.0002052569,0.0007065041,0.00006426121,0.00024711207,0.00028485036,0.0007331167,0.0007151785,0.009726233,0.00008607846],"about_ca_topic_score_codex":0.00008430369,"about_ca_topic_score_gemma":0.00007350055,"teacher_disagreement_score":0.2753779,"about_ca_system_score_codex":0.0001449232,"about_ca_system_score_gemma":0.0016759986,"threshold_uncertainty_score":0.29731497},"labels":[],"label_agreement":null},{"id":"W4324137016","doi":"10.1200/jco.2023.41.6_suppl.136","title":"Radiographic progression-free survival (rPFS) and time to radiographic progression (TTrP) as surrogate endpoints in docetaxel-naïve metastatic castrate resistant prostate cancer (mCRPC): A pooled analysis of COU-AA-302 and ACIS.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Mount Sinai Hospital; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Docetaxel; Placebo; Internal medicine; Enzalutamide; Progression-free survival; Oncology; Prostate cancer; Population; Clinical endpoint; Proportional hazards model; Randomized controlled trial; Cancer; Overall survival; Pathology","score_opus":0.08520076043534967,"score_gpt":0.4857800125696871,"score_spread":0.4005792521343374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324137016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835807,0.0065477095,0.0000024787716,0.007980975,0.00024024834,0.0012793008,0.00012532948,0.000024772158,0.0002184766],"genre_scores_gemma":[0.9801556,0.017812386,0.0010303598,0.00019254822,0.00013488707,0.00010262924,0.000037585465,0.00004200465,0.00049201335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935624,0.0012570869,0.0027458214,0.0005830189,0.0011653516,0.0006863108],"domain_scores_gemma":[0.9942193,0.0021519968,0.001575561,0.0003997317,0.00069106114,0.0009623618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0079481965,0.0003467832,0.0031037712,0.0027659582,0.00009728962,0.000040492665,0.00027977893,0.0002972153,0.00018296458],"category_scores_gemma":[0.002099669,0.00022448874,0.0006350057,0.0044127144,0.0007518794,0.00019408565,0.00021721957,0.0009973891,0.0000102990025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.063584074,0.0037983176,0.69130534,0.0007255025,0.016587105,0.012030386,0.0014824711,0.00011929541,0.008092885,0.000046984755,0.0020310218,0.20019664],"study_design_scores_gemma":[0.028001796,0.021672726,0.93554467,0.0015172438,0.0074234186,0.00019187137,0.00053356535,0.001306588,0.0005172167,0.0007190226,0.0022295786,0.00034230895],"about_ca_topic_score_codex":0.00013998881,"about_ca_topic_score_gemma":0.000446341,"teacher_disagreement_score":0.24423935,"about_ca_system_score_codex":0.00013930869,"about_ca_system_score_gemma":0.0015009892,"threshold_uncertainty_score":0.91543853},"labels":[],"label_agreement":null},{"id":"W4324137050","doi":"10.1200/jco.2023.41.6_suppl.166","title":"Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone acetate; Prostate cancer; Internal medicine; Cohort; Clinical endpoint; Docetaxel; Androgen receptor; Oncology; Cancer; Androgen deprivation therapy; Clinical trial","score_opus":0.08534680067596,"score_gpt":0.4606475781123941,"score_spread":0.3753007774364341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324137050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934285,0.00051985186,0.0000063985376,0.0026626012,0.0004636646,0.0025579908,0.0003387899,0.00001009399,0.000012082214],"genre_scores_gemma":[0.99579537,0.00234719,0.00058899896,0.00031514192,0.00033809993,0.00020671047,0.00008836091,0.00004388749,0.000276247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962814,0.00034405402,0.0017837912,0.00042781455,0.00081578246,0.0003471661],"domain_scores_gemma":[0.9957371,0.0015402592,0.0014762143,0.00016562412,0.0007910715,0.00028974662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015877149,0.00026164058,0.001185627,0.00037251363,0.00006120252,0.000029323059,0.0001577569,0.00011752407,0.00019538177],"category_scores_gemma":[0.0008127401,0.00016365582,0.00018420733,0.0002881774,0.00020700663,0.00022929882,0.00006992124,0.0005716863,0.000005315089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42655453,0.013549963,0.49205768,0.00026991538,0.0027535923,0.0018699021,0.0035351673,0.00031906736,0.000777156,0.00000836643,0.000666646,0.057638012],"study_design_scores_gemma":[0.19433953,0.1486555,0.63436574,0.005786911,0.0006139431,0.000033405333,0.0015895845,0.0009602814,0.0037603134,0.0000950802,0.009375045,0.00042465836],"about_ca_topic_score_codex":0.00006446762,"about_ca_topic_score_gemma":0.0005288971,"teacher_disagreement_score":0.232215,"about_ca_system_score_codex":0.00023553958,"about_ca_system_score_gemma":0.00070303975,"threshold_uncertainty_score":0.66736907},"labels":[],"label_agreement":null},{"id":"W4327747210","doi":"10.1186/s40644-023-00543-0","title":"Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy","year":2023,"lang":"en","type":"article","venue":"Cancer Imaging","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Research (Canada); University of British Columbia","funders":"Canadian Institutes of Health Research; BC Cancer Foundation; Terry Fox Research Institute","keywords":"Medicine; Biochemical recurrence; Prostate cancer; Radiation therapy; Lymph node; Positron emission tomography; Glutamate carboxypeptidase II; Prostate; Prostate-specific antigen; Prospective cohort study; Cancer; Radiology; Oncology; Surgery; Internal medicine; Prostatectomy","score_opus":0.03465301132967854,"score_gpt":0.3512546453765467,"score_spread":0.3166016340468682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327747210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814151,0.016448215,0.0000044894277,0.00039673442,0.00027838026,0.0010533254,0.0002569508,0.0001256925,0.000021125481],"genre_scores_gemma":[0.98814917,0.010021043,0.000095469004,0.00012801593,0.0000778071,0.0006868014,0.00007610863,0.000066677625,0.0006989356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980301,0.000060199996,0.0004931491,0.00041221353,0.0005312134,0.0004731146],"domain_scores_gemma":[0.9986861,0.00011917594,0.00023620759,0.0003419476,0.00047675695,0.00013984014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020561747,0.0002594999,0.0007149591,0.00029349054,0.000044340162,0.000015032281,0.00011547467,0.000014939046,0.0002343426],"category_scores_gemma":[0.000036584457,0.00015810975,0.000116472744,0.00097171916,0.00027764053,0.00011986978,0.000030821622,0.00017990025,0.000002892684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062936954,0.00011409827,0.970485,0.0009087778,0.0002532827,0.00015398268,0.00047718934,0.000005254607,0.0051770387,1.9234572e-7,0.0015180507,0.014613472],"study_design_scores_gemma":[0.010629844,0.00027030657,0.9062179,0.0056239017,0.00016004275,0.00006427286,0.0002732131,0.0005745321,0.07427249,0.000003942613,0.001407689,0.0005019039],"about_ca_topic_score_codex":0.00040509005,"about_ca_topic_score_gemma":0.000015118136,"teacher_disagreement_score":0.069095455,"about_ca_system_score_codex":0.00030906312,"about_ca_system_score_gemma":0.0006128047,"threshold_uncertainty_score":0.64475286},"labels":[],"label_agreement":null},{"id":"W4360600957","doi":"10.1097/ju.0000000000003370.03","title":"Editorial Comment","year":2023,"lang":"es","type":"editorial","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Prostate cancer; Specialty; MEDLINE; Family medicine; General surgery; Cancer; Gynecology; Library science; Internal medicine","score_opus":0.023923238848170332,"score_gpt":0.35000906664099835,"score_spread":0.326085827792828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360600957","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045855998,0.0051385453,0.000009877239,0.039608877,0.9541051,0.00030715126,0.00007322256,0.000015472748,0.00028322602],"genre_scores_gemma":[0.0012961284,0.040292088,0.000004805212,0.0002764558,0.9561843,0.0000063180414,0.000050752493,0.000072616655,0.001816505],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99541354,0.000924019,0.00093054696,0.00017818376,0.0018434454,0.0007102746],"domain_scores_gemma":[0.99070996,0.0064846687,0.0009654082,0.00044165133,0.0011105695,0.0002877639],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0039730566,0.00035432933,0.0010425899,0.000341068,0.00021422513,0.000036487483,0.0008382459,0.0009565061,0.00023169219],"category_scores_gemma":[0.0021562942,0.00018542196,0.000351901,0.00026930583,0.000491086,0.00005853797,0.00026725055,0.0037678592,0.00048140172],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01168678,0.00019761275,0.000070141075,0.000104055754,0.0015267094,0.0003174462,0.00051909214,0.000018766272,0.00022151573,0.00001579316,0.9843569,0.00096520374],"study_design_scores_gemma":[0.006179538,0.0076268404,0.00007958747,0.00015515578,0.0018373897,0.00007421122,0.00017504352,0.000007911359,0.000052060386,0.000311829,0.98336977,0.00013064944],"about_ca_topic_score_codex":0.000099864665,"about_ca_topic_score_gemma":0.0000077433215,"teacher_disagreement_score":0.03933242,"about_ca_system_score_codex":0.0003873199,"about_ca_system_score_gemma":0.0018372993,"threshold_uncertainty_score":0.9985305},"labels":[],"label_agreement":null},{"id":"W4360605497","doi":"10.1097/ju.0000000000003271.07","title":"PD16-07 POST-PROSTATECTOMY ADJUVANT ANDROGEN DEPRIVATION THERAPY-- PATIENT OPINIONS AND GOALS OF CARE","year":2023,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostatectomy; Prostate cancer; Adjuvant therapy; Adjuvant; Clinical trial; Cancer; Oncology; Gynecology; Urology; General surgery; Internal medicine; Family medicine","score_opus":0.024652219999217073,"score_gpt":0.31657621334799746,"score_spread":0.2919239933487804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360605497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835447,0.009907419,0.0000071529635,0.0060672434,0.00009679905,0.0002645968,0.00002401346,0.0000075962894,0.000080489895],"genre_scores_gemma":[0.99229044,0.007342694,0.000029803661,0.0002195476,0.000050217222,0.000003906324,0.000025799105,0.000009481974,0.000028087847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992396,0.00011428989,0.00024633863,0.000061018345,0.00018440935,0.00015431638],"domain_scores_gemma":[0.99921846,0.00013981249,0.00013827108,0.00012018277,0.00031920758,0.00006407542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002541393,0.00006832654,0.00021869845,0.00014888255,0.000058017722,0.000003343671,0.00006968759,0.000046374153,0.000038561266],"category_scores_gemma":[0.000058588113,0.000035790243,0.00005203991,0.00015529444,0.00011651952,0.000035912595,0.000043404445,0.00016260598,0.000008015418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031801153,0.0005599757,0.37580782,0.00039980357,0.00200251,0.00058164564,0.06119133,0.00057287706,0.22151808,0.00017011886,0.003823194,0.3015715],"study_design_scores_gemma":[0.017123083,0.032114442,0.8476785,0.00016626206,0.00043326966,0.0011602772,0.009786592,0.00025267314,0.071149774,0.0010321176,0.018886127,0.00021691213],"about_ca_topic_score_codex":0.000023163982,"about_ca_topic_score_gemma":0.000005057998,"teacher_disagreement_score":0.47187066,"about_ca_system_score_codex":0.000024185994,"about_ca_system_score_gemma":0.00012313217,"threshold_uncertainty_score":0.14594838},"labels":[],"label_agreement":null},{"id":"W4360607214","doi":"10.1097/ju.0000000000003361.01","title":"LBA02-01 BIOCHEMICAL RECURRENCE OF LOCALIZED PROSTATE CANCER ORIGINATING FROM THE TRANSITION VERSUS PERIPHERAL ZONE: A SYSTEMATIC REVIEW AND META-ANALYSIS","year":2023,"lang":"en","type":"review","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Prostate cancer; Cochrane Library; Confidence interval; Subgroup analysis; Internal medicine; Biochemical recurrence; Oncology; Relative risk; Cancer; Prostatectomy","score_opus":0.13714400252223832,"score_gpt":0.4280386918619044,"score_spread":0.2908946893396661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360607214","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000077843615,0.9933819,0.00004733863,0.0046277763,0.0000797109,0.0016098862,0.00016431279,0.000005610032,0.000005608161],"genre_scores_gemma":[0.0002454741,0.9991366,0.00003054432,0.0001940447,0.00007745046,0.0001387734,0.000041043902,0.000022970453,0.00011305817],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9964154,0.0015252606,0.0012273263,0.0001811483,0.00042901209,0.00022190162],"domain_scores_gemma":[0.99636513,0.0015812414,0.0013447604,0.0003487457,0.00027601633,0.00008409591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020597961,0.00027489307,0.0052045723,0.00013942311,0.00006658222,0.000011659894,0.00029602816,0.00013416482,0.00018725896],"category_scores_gemma":[0.00029478734,0.00010247963,0.0013549785,0.00081262435,0.0002783763,0.000034685992,0.00004604549,0.00072495756,0.000002940049],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012616025,0.000085133106,0.0000019825463,0.6038059,0.3871888,0.00010919018,0.0010686973,0.000010498893,0.000006936419,0.000008778341,0.00086135085,0.0055911085],"study_design_scores_gemma":[0.0008837901,0.00044184766,8.090034e-7,0.0201989,0.9728043,0.00014715466,0.00006748565,0.000031675343,0.0000028983302,0.000017999017,0.0053119245,0.00009122913],"about_ca_topic_score_codex":0.0001340524,"about_ca_topic_score_gemma":0.000022789969,"teacher_disagreement_score":0.5856155,"about_ca_system_score_codex":0.00011233916,"about_ca_system_score_gemma":0.00040385377,"threshold_uncertainty_score":0.41789982},"labels":[],"label_agreement":null},{"id":"W4360607263","doi":"10.1097/ju.0000000000003245.07","title":"MP20-07 NPTX1 IS A NOVEL SERUM BIOMARKER INDUCED BY ARPI TREATED PROSTATE CANCER AND ENRICHED IN LINEAGE PLASTICITY WITH BRN2 HIGH","year":2023,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Cancer research; Medicine; Biomarker; Transcription factor; Cancer; Internal medicine; Biology; Gene; Genetics","score_opus":0.0333906914227646,"score_gpt":0.31614433554126764,"score_spread":0.282753644118503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360607263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98271227,0.00081862655,0.000011876175,0.015972152,0.00005950821,0.00031620817,0.000052874097,0.00001530963,0.000041152864],"genre_scores_gemma":[0.99627995,0.0021088528,0.000021449774,0.0005777243,0.00006176678,0.000013321308,0.000007150128,0.000022595754,0.0009071885],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988508,0.00009737569,0.0002954425,0.00014538378,0.00024171344,0.0003692394],"domain_scores_gemma":[0.999202,0.00024575926,0.0001723418,0.00010883295,0.00014027687,0.00013077674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045977105,0.00015400273,0.0003738267,0.00025143247,0.000061664025,0.000010725683,0.00009907054,0.00010484215,0.00007201546],"category_scores_gemma":[0.000055620367,0.000077600496,0.000031382187,0.0005293199,0.00016737956,0.000061084276,0.000050482246,0.0004511408,0.000008451883],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02930281,0.00056587375,0.31038123,0.00011284157,0.0011867494,0.0008797766,0.0041567585,0.00007284051,0.6415176,0.000007807626,0.0057492135,0.006066523],"study_design_scores_gemma":[0.018025225,0.00415316,0.9614235,0.00009200527,0.00039926474,0.00056288776,0.00029321076,0.0011498663,0.012551839,0.00004632776,0.0011437483,0.00015892713],"about_ca_topic_score_codex":0.00044972333,"about_ca_topic_score_gemma":0.0001252783,"teacher_disagreement_score":0.6510423,"about_ca_system_score_codex":0.00007724382,"about_ca_system_score_gemma":0.00022368187,"threshold_uncertainty_score":0.31644562},"labels":[],"label_agreement":null},{"id":"W4360607547","doi":"10.1097/ju.0000000000003237.16","title":"MP17-16 COMPARING INTRADUCTAL CARCINOMA OF THE PROSTATE TO GRADE AND STAGE: A COPY NUMBER ALTERATION CHARACTERIZATION STUDY","year":2023,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Stage (stratigraphy); Medicine; Prostate cancer; Prostate; Carcinoma; Oncology; Cancer; Internal medicine; Biology","score_opus":0.04184097696490283,"score_gpt":0.33929652287053574,"score_spread":0.2974555459056329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360607547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99289984,0.00005143985,0.000036759673,0.006322144,0.00014450794,0.0005096927,0.000003688333,0.0000045219927,0.000027387185],"genre_scores_gemma":[0.99938726,0.00010852391,0.0000053870385,0.00011124535,0.00009370816,0.000005020459,0.0000040129075,0.000007663424,0.00027714844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992099,0.00019110176,0.00022605683,0.000059779268,0.00018697394,0.00012621937],"domain_scores_gemma":[0.999535,0.000055399152,0.00014570821,0.00010797721,0.00010649342,0.000049386268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045924427,0.000059938648,0.00017881794,0.00007259859,0.00007300249,0.00000869417,0.000078227386,0.0000198044,0.0000125206025],"category_scores_gemma":[0.000035380297,0.000029408446,0.000024363168,0.00021603587,0.00006933014,0.00005023843,0.00005995088,0.00017745448,0.0000038373064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019085886,0.00012378917,0.9279541,0.000023810917,0.00009749566,0.000031452128,0.008543946,0.000036485788,0.060327347,0.00003218259,0.00014251948,0.0007783224],"study_design_scores_gemma":[0.0020745562,0.0015464749,0.988275,0.00001395343,0.00009783634,0.0001657488,0.0005244379,0.00023803933,0.00679915,0.000059169302,0.00017750022,0.00002815405],"about_ca_topic_score_codex":0.000035660734,"about_ca_topic_score_gemma":0.000012261983,"teacher_disagreement_score":0.06032092,"about_ca_system_score_codex":0.00003351149,"about_ca_system_score_gemma":0.00006445563,"threshold_uncertainty_score":0.11992416},"labels":[],"label_agreement":null},{"id":"W4360608257","doi":"10.1200/jco.22.01649","title":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":319,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Enzalutamide; Cohort; Placebo; Hazard ratio; Internal medicine; Prednisone; Oncology; Clinical endpoint; Urology; Progression-free survival; Androgen deprivation therapy; Androgen receptor; Cancer; Chemotherapy; Randomized controlled trial; Pathology","score_opus":0.2899895319608854,"score_gpt":0.5543641495000348,"score_spread":0.26437461753914937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360608257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97131693,0.0018402648,0.000039824514,0.025302764,0.00065391924,0.00058096566,0.00003776594,0.000014046944,0.00021351078],"genre_scores_gemma":[0.97882336,0.010215785,0.0036042437,0.00084844814,0.0006614148,0.000082876235,0.000018836765,0.000027237676,0.005717766],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978606,0.00015745699,0.0012843146,0.00016255937,0.0002562234,0.00027884523],"domain_scores_gemma":[0.997283,0.0011940922,0.0006442029,0.0000907738,0.00046727786,0.00032067538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025866996,0.00010487194,0.00094696827,0.00014535498,0.00006408044,0.000016932694,0.00006303902,0.000103282015,0.00004602591],"category_scores_gemma":[0.00087969645,0.00006448111,0.00020728784,0.00018608393,0.0002110673,0.00010301504,0.00002766956,0.00036483354,0.00000993173],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06785408,0.0019887844,0.07667806,0.0010136135,0.004141139,0.0037954082,0.0014564367,0.00012511421,0.020284515,0.00044055824,0.057602428,0.7646199],"study_design_scores_gemma":[0.078267634,0.057575203,0.5324579,0.00051819254,0.0023512424,0.00041975512,0.0012689208,0.001206166,0.0029207622,0.0054346398,0.3172293,0.00035031227],"about_ca_topic_score_codex":0.000024047933,"about_ca_topic_score_gemma":0.00008096982,"teacher_disagreement_score":0.76426953,"about_ca_system_score_codex":0.00009670948,"about_ca_system_score_gemma":0.0017041327,"threshold_uncertainty_score":0.30230582},"labels":[],"label_agreement":null},{"id":"W4360809196","doi":"10.1002/pros.24531","title":"Response to RL‐225Ac in prostate cancer: Effect of prior treatment with RL‐177Lu: A systematic review of the literature","year":2023,"lang":"en","type":"review","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Radionuclide therapy; Systematic review; Meta-analysis; Oncology; Internal medicine; Cancer; MEDLINE","score_opus":0.030614448440881185,"score_gpt":0.39074690937623374,"score_spread":0.36013246093535256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360809196","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00249525,0.95581174,7.8026105e-8,0.0019694928,0.00009626068,0.038834136,0.0007148143,0.000040798426,0.000037420996],"genre_scores_gemma":[0.00013331894,0.9748087,0.000010407751,0.00009650912,0.000030491441,0.011487061,0.00009480598,0.00013516631,0.013203523],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99396425,0.002593145,0.0013863554,0.00058473763,0.000856671,0.0006148469],"domain_scores_gemma":[0.9958176,0.0011881837,0.00092897017,0.0016208118,0.00027582518,0.00016861182],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030430795,0.0007678307,0.004726098,0.00037009455,0.00009862301,0.000035078367,0.00051503535,0.00013419973,0.000012104627],"category_scores_gemma":[0.00050691055,0.00025832257,0.00070513977,0.0029837256,0.00021482877,0.000049318238,0.00020823731,0.0005620783,0.000033251494],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040784124,0.000107148655,0.0000548598,0.9565606,0.0010872983,0.00021027344,0.0026715256,0.0000010246554,0.000015300524,0.0000020832458,0.00016587581,0.035045583],"study_design_scores_gemma":[0.002231331,0.0037954294,0.00002549543,0.95978546,0.005274072,0.00010676489,0.000044944332,0.0000013702604,0.00025522092,0.0000042115257,0.028242223,0.00023346483],"about_ca_topic_score_codex":0.00017971189,"about_ca_topic_score_gemma":0.000061111234,"teacher_disagreement_score":0.03481212,"about_ca_system_score_codex":0.00092276465,"about_ca_system_score_gemma":0.0017902652,"threshold_uncertainty_score":0.9999869},"labels":[],"label_agreement":null},{"id":"W4360874540","doi":"10.1016/j.clgc.2023.03.009","title":"Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Myovant Sciences","keywords":"Medicine; Enzalutamide; Docetaxel; Concomitant; Prostate cancer; Urology; Testosterone (patch); Internal medicine; Oncology; Prostate; Adverse effect; Cancer; Androgen receptor","score_opus":0.06496777092265317,"score_gpt":0.45894922739006777,"score_spread":0.3939814564674146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360874540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98694617,0.0056997784,4.0071106e-7,0.0033388585,0.00024299056,0.002161565,0.00054399314,0.00005574246,0.0010105128],"genre_scores_gemma":[0.9025129,0.09423971,0.00006740541,0.0000528104,0.00019912019,0.0008668502,0.00007210165,0.000057488167,0.0019316087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970694,0.00015468642,0.0009858701,0.00063795573,0.00055182504,0.00060025405],"domain_scores_gemma":[0.99761426,0.00078870024,0.00039456147,0.0004867755,0.000331503,0.00038419597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005218294,0.00031756217,0.0009485906,0.00027986558,0.00008085251,0.000007915749,0.00016755161,0.00015891033,0.00015854603],"category_scores_gemma":[0.00017602356,0.00021045192,0.00017401091,0.0010110898,0.0007028369,0.000110937355,0.00011633404,0.0005690355,0.0000065694903],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11958092,0.00095849234,0.7839369,0.00048048317,0.0014243912,0.0002859994,0.0013394082,0.0027382243,0.0028144706,0.000012239502,0.0027407063,0.083687745],"study_design_scores_gemma":[0.038507447,0.0076557198,0.9477957,0.0017298012,0.00029151165,0.000004617793,0.00031756455,0.0004121851,0.0017785378,0.000026284848,0.0012116202,0.00026900152],"about_ca_topic_score_codex":0.0012159027,"about_ca_topic_score_gemma":0.0003004501,"teacher_disagreement_score":0.16385879,"about_ca_system_score_codex":0.00052696717,"about_ca_system_score_gemma":0.0021255056,"threshold_uncertainty_score":0.858198},"labels":[],"label_agreement":null},{"id":"W4361026527","doi":"10.1016/s1470-2045(23)00063-3","title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Alberta; Ottawa Hospital; Queen's University; Kingston Health Sciences Centre; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Enzalutamide; Clinical endpoint; Prostate cancer; Internal medicine; Antiandrogen; Population; Flutamide; Oncology; Interim analysis; Bicalutamide; Testosterone (patch); Urology; Randomized controlled trial; Cancer; Androgen receptor","score_opus":0.20026769745623704,"score_gpt":0.4825725563967049,"score_spread":0.28230485894046786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361026527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9704241,0.0019579742,0.000090913265,0.011946645,0.0019991728,0.011205296,0.0016891675,0.00018148989,0.0005052234],"genre_scores_gemma":[0.95942205,0.020572308,0.0019176218,0.0015349148,0.0022476905,0.0069737514,0.0032312458,0.0001930495,0.0039073857],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963876,0.000741692,0.00060714135,0.0007278841,0.0006259655,0.00090973324],"domain_scores_gemma":[0.99676114,0.0015056436,0.0003550971,0.0006990023,0.00040455005,0.00027454435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020235118,0.00040615577,0.0014799468,0.00022813134,0.00041408298,0.00014673857,0.000694857,0.00017198295,0.00014639385],"category_scores_gemma":[0.000411005,0.00024386849,0.0001176357,0.00040805034,0.00035501242,0.00042898676,0.00037310837,0.0004446875,0.00003370228],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87559247,0.0008568862,0.000037866095,0.000059780814,0.0009386254,0.00027476947,0.0031023596,0.00006834698,0.06420645,0.000023470862,0.020184139,0.034654807],"study_design_scores_gemma":[0.8860794,0.02597481,0.00013611026,0.00016366984,0.00043087467,0.00004026199,0.0009549119,0.0030654806,0.0311203,0.00017324212,0.05157603,0.0002849268],"about_ca_topic_score_codex":0.00019955415,"about_ca_topic_score_gemma":0.0000959909,"teacher_disagreement_score":0.034369882,"about_ca_system_score_codex":0.00094011496,"about_ca_system_score_gemma":0.0013997329,"threshold_uncertainty_score":0.99446684},"labels":[],"label_agreement":null},{"id":"W4361228771","doi":"10.1016/j.clgc.2023.03.012","title":"Toward Precision Medicine: Development and Validation of A Machine Learning Based Decision Support System for Optimal Sequencing in Castration-Resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Research Foundation of Korea","keywords":"Medicine; Prostate cancer; Precision medicine; Decision support system; Oncology; Cancer; Internal medicine; Machine learning; Artificial intelligence; Pathology; Computer science","score_opus":0.1484363886325666,"score_gpt":0.4358126648759478,"score_spread":0.28737627624338113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361228771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99544173,0.0015465129,0.00030152377,0.00077831873,0.00034784232,0.00140273,0.000060566537,0.00006361304,0.000057181096],"genre_scores_gemma":[0.9923803,0.0020875295,0.0035785362,0.000036819933,0.00023202649,0.00066685735,0.00025031273,0.000035339894,0.0007322503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975615,0.00011486832,0.0010173916,0.00048046984,0.00047719188,0.00034853665],"domain_scores_gemma":[0.99837184,0.0007451968,0.00023412493,0.0001609829,0.00029347301,0.00019438469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001574548,0.00019285179,0.0005510698,0.00029931936,0.00011482165,0.0000135959845,0.0000821313,0.0001347216,0.00005824362],"category_scores_gemma":[0.00032896246,0.00014281648,0.00008598224,0.00046958463,0.000120914614,0.00008969843,0.00006666996,0.0002739659,0.000003712457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037657846,0.00037812156,0.4483916,0.0059951385,0.00044511672,0.0012504249,0.0054916115,0.032982174,0.048268914,0.000011802556,0.0018902905,0.41723698],"study_design_scores_gemma":[0.07491468,0.016540872,0.41530663,0.019878453,0.00090086134,0.00008667691,0.0079942765,0.20733365,0.23052645,0.000097904944,0.024909077,0.0015104742],"about_ca_topic_score_codex":0.00024394381,"about_ca_topic_score_gemma":0.000065873915,"teacher_disagreement_score":0.4157265,"about_ca_system_score_codex":0.0006940553,"about_ca_system_score_gemma":0.0016977603,"threshold_uncertainty_score":0.5823887},"labels":[],"label_agreement":null},{"id":"W4361283772","doi":"10.51731/cjht.2023.610","title":"Darolutamide (Nubeqa)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Docetaxel; Prostate cancer; Medicine; Drug; Drug class; Family medicine; Cancer; Pharmacology; Political science; Internal medicine; Health care","score_opus":0.06536889916657437,"score_gpt":0.3642351572893772,"score_spread":0.2988662581228029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361283772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6617738,0.0759788,0.000030420755,0.2596406,0.00056989276,0.00039334266,0.000025475292,0.00035101696,0.0012366759],"genre_scores_gemma":[0.99591994,0.0026939723,0.00015344605,0.0003147585,0.000015838319,0.0000052702776,0.000005629984,0.000012684063,0.0008784773],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888736,0.00002223006,0.00030475375,0.0000891407,0.00017597566,0.00052053353],"domain_scores_gemma":[0.999375,0.000034453235,0.0001234715,0.00018075357,0.00013680692,0.00014952385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005375515,0.000077825236,0.00028174755,0.0010363674,0.00017872709,0.000016931923,0.00016497765,0.00009008936,0.00002924007],"category_scores_gemma":[0.0003572631,0.000056389,0.00006738685,0.0007314262,0.0001941349,0.000057908237,0.000016054459,0.00037078687,0.000060798615],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052312917,0.000015244912,0.031880327,0.000204544,0.00009849038,0.0023797336,0.00033218175,0.0000070212022,0.00021605485,0.00044812265,0.07348886,0.8908771],"study_design_scores_gemma":[0.0028242888,0.002261757,0.1840581,0.0008753897,0.000036169215,0.0012519823,0.009172295,0.000045154797,0.0042155813,0.008323395,0.7867271,0.00020878304],"about_ca_topic_score_codex":0.001401095,"about_ca_topic_score_gemma":0.00090154895,"teacher_disagreement_score":0.89066833,"about_ca_system_score_codex":0.00049871556,"about_ca_system_score_gemma":0.0045394083,"threshold_uncertainty_score":0.8052715},"labels":[],"label_agreement":null},{"id":"W4361815417","doi":"10.1158/1078-0432.22480055.v1","title":"Supplementary Data from Diverse &lt;i&gt;AR&lt;/i&gt; Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Androgen receptor; Prostate cancer; Cancer research; Gene; Medicine; Internal medicine; Oncology; Cancer; Biology; Genetics","score_opus":0.08892914349343341,"score_gpt":0.35893256307367194,"score_spread":0.27000341958023855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361815417","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8184329,0.012093822,0.000035436424,0.01860657,0.003009147,0.010015254,0.13683732,0.00029318305,0.0006763551],"genre_scores_gemma":[0.17216557,0.14350526,0.043335706,0.0029093272,0.003663242,0.011494105,0.4571132,0.0011471784,0.16466641],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931757,0.00028916993,0.0011669922,0.0023777534,0.0017381578,0.00125225],"domain_scores_gemma":[0.99601847,0.00019326838,0.00030162066,0.0024605081,0.00026964484,0.00075648475],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011354991,0.0008141076,0.0013029985,0.00079459033,0.00015855045,0.00012496006,0.0011443109,0.00024602888,0.0064271567],"category_scores_gemma":[0.00017335368,0.0006811123,0.00018086594,0.0008938728,0.00017485763,0.00022087584,0.0044584335,0.00076197175,0.0005157844],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045526167,0.0007233355,0.057669375,0.0014042925,0.0034773664,0.0017458064,0.0036027224,0.000102939135,0.049206506,0.000010379389,0.872626,0.004878636],"study_design_scores_gemma":[0.028898902,0.00075315736,0.03697308,0.0074301464,0.0029959367,0.0000048067427,0.0017929964,0.0005689992,0.07456903,0.0011629341,0.84177077,0.003079262],"about_ca_topic_score_codex":0.0066526844,"about_ca_topic_score_gemma":0.06437099,"teacher_disagreement_score":0.64626735,"about_ca_system_score_codex":0.0014614373,"about_ca_system_score_gemma":0.0012674854,"threshold_uncertainty_score":0.9999621},"labels":[],"label_agreement":null},{"id":"W4361815691","doi":"10.1158/1078-0432.c.6530771","title":"Data from Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Prostate Cancer Canada; Astellas Pharma; BC Cancer Foundation; Prostate Cancer Foundation; Jane ja Aatos Erkon Säätiö; Movember Foundation","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Cancer research; Somatic cell; Biology; Mutation; Internal medicine; Medicine; Cancer; Oncology; Gene; Genetics","score_opus":0.09788726340219778,"score_gpt":0.35848957905175444,"score_spread":0.26060231564955666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361815691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794273,0.002129805,0.000032001724,0.0009156924,0.00043525724,0.0016354797,0.015121528,0.000093789604,0.0002091655],"genre_scores_gemma":[0.97867376,0.0021926665,0.00032209957,0.0000055760243,0.00031006205,0.00028564146,0.015240013,0.000049501363,0.0029207],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99764854,0.00008855185,0.0005979775,0.00078884437,0.0005492892,0.00032679024],"domain_scores_gemma":[0.9986573,0.000034576486,0.00021244916,0.00079387694,0.00018924993,0.00011254379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002959632,0.00024678235,0.00046271028,0.000313529,0.000053905922,0.00003554786,0.00016891542,0.00025382906,0.0006118334],"category_scores_gemma":[0.000050282426,0.00020779742,0.00007806597,0.0002775189,0.00009305263,0.00015769892,0.00069079065,0.00047833723,0.000034997487],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004056979,0.00038251185,0.055914685,0.0021435802,0.0005798939,0.00033848474,0.00092502986,0.00043602052,0.932424,0.000043339624,0.001483859,0.0012716284],"study_design_scores_gemma":[0.012448005,0.00036887857,0.26439485,0.00869866,0.00040580155,0.0000072050125,0.001519738,0.0034214472,0.70544434,0.0019366592,0.000528395,0.00082603685],"about_ca_topic_score_codex":0.019819545,"about_ca_topic_score_gemma":0.012960304,"teacher_disagreement_score":0.22697966,"about_ca_system_score_codex":0.0011768589,"about_ca_system_score_gemma":0.0016727323,"threshold_uncertainty_score":0.98670757},"labels":[],"label_agreement":null},{"id":"W4361815711","doi":"10.1158/1078-0432.22480055","title":"Supplementary Data from Diverse &lt;i&gt;AR&lt;/i&gt; Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Androgen receptor; Prostate cancer; Cancer research; Prostate; Gene; Internal medicine; Endocrinology; Androgen; Medicine; Chemistry; Cancer; Biology; Genetics; Hormone","score_opus":0.08892914349343341,"score_gpt":0.35893256307367194,"score_spread":0.27000341958023855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361815711","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8184329,0.012093822,0.000035436424,0.01860657,0.003009147,0.010015254,0.13683732,0.00029318305,0.0006763551],"genre_scores_gemma":[0.17216557,0.14350526,0.043335706,0.0029093272,0.003663242,0.011494105,0.4571132,0.0011471784,0.16466641],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931757,0.00028916993,0.0011669922,0.0023777534,0.0017381578,0.00125225],"domain_scores_gemma":[0.99601847,0.00019326838,0.00030162066,0.0024605081,0.00026964484,0.00075648475],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011354991,0.0008141076,0.0013029985,0.00079459033,0.00015855045,0.00012496006,0.0011443109,0.00024602888,0.0064271567],"category_scores_gemma":[0.00017335368,0.0006811123,0.00018086594,0.0008938728,0.00017485763,0.00022087584,0.0044584335,0.00076197175,0.0005157844],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045526167,0.0007233355,0.057669375,0.0014042925,0.0034773664,0.0017458064,0.0036027224,0.000102939135,0.049206506,0.000010379389,0.872626,0.004878636],"study_design_scores_gemma":[0.028898902,0.00075315736,0.03697308,0.0074301464,0.0029959367,0.0000048067427,0.0017929964,0.0005689992,0.07456903,0.0011629341,0.84177077,0.003079262],"about_ca_topic_score_codex":0.0066526844,"about_ca_topic_score_gemma":0.06437099,"teacher_disagreement_score":0.64626735,"about_ca_system_score_codex":0.0014614373,"about_ca_system_score_gemma":0.0012674854,"threshold_uncertainty_score":0.9999621},"labels":[],"label_agreement":null},{"id":"W4361823014","doi":"10.1158/0008-5472.c.6499368.v1","title":"Data from Osteoblast-Derived Factors Induce an Expression Signature that Identifies Prostate Cancer Metastasis and Hormonal Progression","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"Canadian Institutes of Health Research; National Institutes of Health","keywords":"Prostate cancer; Gene signature; Osteoblast; Cancer research; Metastasis; Biology; Cancer; Gene expression; Gene; Prostate; In vitro; Genetics","score_opus":0.20015487142943328,"score_gpt":0.41861394981671607,"score_spread":0.2184590783872828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361823014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97113293,0.01350937,0.000025836463,0.0016241466,0.0007075309,0.0024384775,0.010140242,0.00035892933,0.00006256089],"genre_scores_gemma":[0.9431184,0.011978936,0.001126184,0.000061661485,0.00035465733,0.0004892624,0.03864624,0.00015087388,0.004073797],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958444,0.00019681516,0.0004013026,0.001803187,0.0011680659,0.0005861906],"domain_scores_gemma":[0.997243,0.00016151709,0.00027278718,0.0016083334,0.00021091336,0.0005034912],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033831788,0.00064698106,0.00083734904,0.00029906176,0.000246328,0.00035944936,0.0006278174,0.00063056906,0.00046621505],"category_scores_gemma":[0.00008398796,0.00039572068,0.000107467924,0.00018758712,0.00024357352,0.00056611607,0.0040043755,0.0014438041,0.000015077511],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003996017,0.0007220287,0.17684555,0.0020513246,0.002562004,0.00065866526,0.0067578373,0.000019404255,0.74135375,0.0000023058392,0.024604008,0.04042708],"study_design_scores_gemma":[0.0037273257,0.0005434842,0.23114082,0.0044473205,0.0011327683,0.0000062472836,0.005569989,0.0008308457,0.7490395,0.00074291916,0.0018146214,0.001004205],"about_ca_topic_score_codex":0.0019500244,"about_ca_topic_score_gemma":0.00064410636,"teacher_disagreement_score":0.05429527,"about_ca_system_score_codex":0.00016509375,"about_ca_system_score_gemma":0.00060956704,"threshold_uncertainty_score":0.99984944},"labels":[],"label_agreement":null},{"id":"W4361824073","doi":"10.1158/0008-5472.c.6512985.v1","title":"Data from SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Beatson Institute for Cancer Research; Medical Research Council; Ligue Contre le Cancer; European Commission; Cancer Research UK","keywords":"Prostate cancer; mTORC1; Androgen deprivation therapy; Cancer research; Androgen receptor; Androgen; Amino acid transporter; PI3K/AKT/mTOR pathway; In vivo; Chemistry; Cancer; Endocrinology; Transporter; Internal medicine; Medicine; Biology; Signal transduction; Hormone; Biochemistry; Gene","score_opus":0.1581112529985208,"score_gpt":0.40014599255929256,"score_spread":0.24203473956077176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361824073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97994465,0.0008398249,0.0000128448255,0.009858812,0.00050078746,0.0024547344,0.004845611,0.00028993294,0.0012527924],"genre_scores_gemma":[0.92800623,0.0029717016,0.0005781104,0.00010545439,0.00047938066,0.0006328839,0.045190502,0.00010065518,0.021935053],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972552,0.00007593573,0.00051094004,0.0010115389,0.00072208326,0.00042430364],"domain_scores_gemma":[0.99794954,0.00024197288,0.00017193759,0.0012037164,0.00026975462,0.00016304868],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037466185,0.0003281361,0.0005184456,0.00032262635,0.000060628074,0.00009797835,0.00034024476,0.00033272928,0.000753541],"category_scores_gemma":[0.00026768152,0.00025102092,0.000059525504,0.0003907727,0.000081339946,0.00018034456,0.00073515094,0.0007302889,0.00012003797],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01102009,0.0011718959,0.27845764,0.002645167,0.0028390328,0.0008105471,0.0033983665,0.0008464563,0.59086496,0.000058618793,0.09745555,0.010431658],"study_design_scores_gemma":[0.007533358,0.00023721262,0.9147821,0.0040559145,0.00030650283,0.0000014123824,0.00075101556,0.010382462,0.05458373,0.0022457484,0.0043218257,0.00079869333],"about_ca_topic_score_codex":0.035125528,"about_ca_topic_score_gemma":0.017997354,"teacher_disagreement_score":0.63632447,"about_ca_system_score_codex":0.00083255226,"about_ca_system_score_gemma":0.0021302737,"threshold_uncertainty_score":0.9999942},"labels":[],"label_agreement":null},{"id":"W4361824410","doi":"10.1158/0008-5472.c.6512761.v1","title":"Data from KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of Toronto; University of British Columbia","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China; Shandong University","keywords":"Enzalutamide; Prostate cancer; Cancer research; Androgen receptor; Cancer; Medicine; Chemistry; Internal medicine","score_opus":0.10939206919804949,"score_gpt":0.3924212058606515,"score_spread":0.283029136662602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361824410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94575834,0.019586416,0.00020876982,0.009551792,0.00034660572,0.0036845298,0.020292548,0.00013128326,0.00043968967],"genre_scores_gemma":[0.9174264,0.035787612,0.001612746,0.0003940249,0.00016674984,0.0009162679,0.02810184,0.0001245199,0.015469835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976075,0.000090344634,0.0005807781,0.00092248037,0.00042635066,0.0003725082],"domain_scores_gemma":[0.9978548,0.00039004322,0.00015662138,0.0010236592,0.00040125335,0.00017361763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047432282,0.00026810836,0.0007324887,0.00033994904,0.000031595264,0.00004001452,0.0002909081,0.0001904923,0.00012454849],"category_scores_gemma":[0.0008558959,0.00021165964,0.00002763255,0.00066224055,0.00013674216,0.000081423,0.0011011591,0.00040495498,0.000015262856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067117666,0.0003304513,0.93242925,0.0032040132,0.000953034,0.00025739436,0.0023283982,0.00021385492,0.020109095,0.00014194686,0.03175407,0.0015667131],"study_design_scores_gemma":[0.012151162,0.00022719822,0.9171489,0.009655061,0.00047784837,7.1578734e-7,0.0014306813,0.003307944,0.030782484,0.0060672653,0.01797896,0.0007718035],"about_ca_topic_score_codex":0.007963903,"about_ca_topic_score_gemma":0.03422992,"teacher_disagreement_score":0.02833196,"about_ca_system_score_codex":0.00040099106,"about_ca_system_score_gemma":0.001036155,"threshold_uncertainty_score":0.99864215},"labels":[],"label_agreement":null},{"id":"W4361878305","doi":"10.1158/0008-5472.22430878","title":"Supplementary Data from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Government of Ontario; University of Toronto; Movember Foundation; Princess Margaret Cancer Foundation; Prostate Cancer Foundation","keywords":"Genome; Prostate; Primary (astronomy); Prostate cancer; Computational biology; Computer science; Biology; Medicine; Internal medicine; Genetics; Gene; Cancer","score_opus":0.08416846191711036,"score_gpt":0.3294360659031509,"score_spread":0.24526760398604053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361878305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9656542,0.00037080795,0.00019493495,0.0041241916,0.0006098714,0.0034346448,0.023869468,0.00007611619,0.0016657942],"genre_scores_gemma":[0.87963635,0.0032558746,0.0052944333,0.00020906802,0.0002585164,0.00004823049,0.10340968,0.0001272917,0.007760571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791974,0.00007622213,0.00053664367,0.000566688,0.0006619045,0.0002388062],"domain_scores_gemma":[0.9977497,0.0000820946,0.00031974795,0.0015598629,0.00021167916,0.000076940945],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034078374,0.00021091149,0.0005316824,0.00015167924,0.000056743083,0.000013529763,0.0006878779,0.000108908935,0.001311664],"category_scores_gemma":[0.00006110066,0.00013693076,0.0000856899,0.0003114557,0.00018484182,0.00006386511,0.0037477869,0.00037117704,0.000013278335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012094537,0.00065109134,0.81811553,0.0054168236,0.0027579274,0.0001848387,0.005483258,0.00019592204,0.13974158,0.000031509564,0.023989625,0.0022224141],"study_design_scores_gemma":[0.00819474,0.0004504803,0.8471447,0.0042204564,0.0015783715,0.000010348979,0.002531559,0.0015487915,0.12985349,0.0011793119,0.002642627,0.0006451105],"about_ca_topic_score_codex":0.0027251372,"about_ca_topic_score_gemma":0.00016068379,"teacher_disagreement_score":0.08601784,"about_ca_system_score_codex":0.0003557732,"about_ca_system_score_gemma":0.00097519817,"threshold_uncertainty_score":0.99960124},"labels":[],"label_agreement":null},{"id":"W4361879260","doi":"10.1158/0008-5472.22430854","title":"Supplementary Table 2 from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors","year":2023,"lang":"en","type":"supplementary-materials","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Government of Ontario; University of Toronto; Movember Foundation; Princess Margaret Cancer Foundation; Prostate Cancer Foundation","keywords":"Table (database); Primary (astronomy); Prostate; Genome; Computational biology; Computer science; Oncology; Biology; Medicine; Genetics; Gene; Data mining; Physics; Cancer","score_opus":0.01955502646491496,"score_gpt":0.2722659956118515,"score_spread":0.2527109691469365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361879260","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58555895,0.0010373474,0.000025789157,0.004907844,0.0033352557,0.009496485,0.3921026,0.00011288008,0.0034228317],"genre_scores_gemma":[0.0709235,0.011343285,0.0030677496,0.0008160738,0.0011759397,0.00024338816,0.8204102,0.0004313269,0.09158852],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969961,0.00012037254,0.0009283835,0.00050736975,0.0009817423,0.00046600425],"domain_scores_gemma":[0.99831265,0.00010430358,0.00052327866,0.0006468082,0.00030702975,0.000105908926],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036587886,0.00035984107,0.0010108236,0.0002833507,0.00011705368,0.000021138863,0.00035349093,0.0001597692,0.043956496],"category_scores_gemma":[0.000037039514,0.00023699837,0.00014078495,0.0006566506,0.00020840063,0.00009381236,0.00055685075,0.0002564562,0.00002425049],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012377063,0.00043509583,0.05960669,0.005331524,0.0024287207,0.00015851148,0.0028488194,0.000011364814,0.5455427,0.000018289547,0.38172323,0.0006573275],"study_design_scores_gemma":[0.009020139,0.0009254157,0.017304266,0.0029796904,0.0014615247,0.000011222318,0.0022798022,0.000009405605,0.85500115,0.00018336483,0.11024093,0.000583068],"about_ca_topic_score_codex":0.019387534,"about_ca_topic_score_gemma":0.0006896418,"teacher_disagreement_score":0.51463544,"about_ca_system_score_codex":0.0007369294,"about_ca_system_score_gemma":0.0011548123,"threshold_uncertainty_score":0.98714244},"labels":[],"label_agreement":null},{"id":"W4361942791","doi":"10.1158/1078-0432.c.6517041","title":"Data from A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Celgene; Sanofi; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Prostate cancer; Docetaxel; Hazard ratio; Mitoxantrone; Oncology; Gastroenterology; Cancer; Chemotherapy; Confidence interval","score_opus":0.20305270549404053,"score_gpt":0.42071995937138845,"score_spread":0.21766725387734792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361942791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82625943,0.035825655,0.0028446873,0.005414452,0.00035639963,0.059483685,0.066982344,0.0012767925,0.0015565631],"genre_scores_gemma":[0.9165243,0.002375901,0.0026820076,0.00007184775,0.00021043312,0.013229344,0.0483254,0.000190998,0.016389767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99511766,0.0001998518,0.00080105895,0.0021026651,0.0010838704,0.00069486117],"domain_scores_gemma":[0.99527913,0.00062527735,0.00045736312,0.002681148,0.00052230357,0.0004348032],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008137875,0.0007181741,0.001939508,0.00077268615,0.00015534775,0.00021958456,0.00081645715,0.00015964569,0.00013612385],"category_scores_gemma":[0.0001680297,0.00045093094,0.0003094463,0.0011114319,0.00018346147,0.00019649946,0.0014497865,0.0007954898,0.000031123374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015505035,0.006322643,0.76374716,0.0015629785,0.13375807,0.0020566124,0.0037393754,0.00023826912,0.00013685711,0.0000024754922,0.067651026,0.0052795056],"study_design_scores_gemma":[0.06371289,0.019175906,0.66062856,0.0021912933,0.13662708,0.000007031858,0.026239218,0.070881404,0.00015482976,0.0006999295,0.016391177,0.0032906488],"about_ca_topic_score_codex":0.024500104,"about_ca_topic_score_gemma":0.0076540923,"teacher_disagreement_score":0.103118576,"about_ca_system_score_codex":0.00034469969,"about_ca_system_score_gemma":0.0029313883,"threshold_uncertainty_score":0.99979424},"labels":[],"label_agreement":null},{"id":"W4361947369","doi":"10.1158/1078-0432.c.6530510","title":"Data from Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Androgen receptor; Androgen deprivation therapy; Medicine; Internal medicine; Androgen; Oncology; Metastasis; Biomarker; Enzalutamide; Cancer; Proportional hazards model; Biology; Hormone","score_opus":0.04876792389667443,"score_gpt":0.32519738535499904,"score_spread":0.2764294614583246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361947369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978896,0.0017692957,0.000017691355,0.0011097162,0.000044718978,0.006883699,0.011138547,0.00012466687,0.000015631955],"genre_scores_gemma":[0.97262615,0.0023707813,0.0019468159,0.00007090451,0.000030536215,0.0017225972,0.020677608,0.00013509065,0.00041952825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99629897,0.00021315512,0.000529851,0.0014625542,0.0009630224,0.000532447],"domain_scores_gemma":[0.99749005,0.00014588206,0.0002954243,0.0012753385,0.00030286887,0.00049044087],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030509438,0.0006138647,0.00078075536,0.00045837276,0.000119554206,0.00021305983,0.00028324025,0.000078803685,0.00012649005],"category_scores_gemma":[0.00005956077,0.00035022508,0.000041291773,0.0005277678,0.00014421577,0.00021198014,0.0003602949,0.00037661777,0.000015245687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023980433,0.001082993,0.9651051,0.00033813555,0.00288042,0.00058857724,0.00051619,0.00017632537,0.00007358467,0.0000035601238,0.00009497721,0.005159695],"study_design_scores_gemma":[0.018538615,0.001455482,0.9749796,0.0012493295,0.0016455627,0.0000018182104,0.00019909277,0.00086993916,0.00033206888,0.0002290195,0.000027831382,0.00047163828],"about_ca_topic_score_codex":0.013403431,"about_ca_topic_score_gemma":0.008876286,"teacher_disagreement_score":0.009874495,"about_ca_system_score_codex":0.0001339632,"about_ca_system_score_gemma":0.00088731747,"threshold_uncertainty_score":0.999895},"labels":[],"label_agreement":null},{"id":"W4361948427","doi":"10.1158/1078-0432.c.6517041.v1","title":"Data from A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Celgene; Sanofi; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Prostate cancer; Docetaxel; Hazard ratio; Mitoxantrone; Oncology; Gastroenterology; Cancer; Chemotherapy; Confidence interval","score_opus":0.20305270549404053,"score_gpt":0.42071995937138845,"score_spread":0.21766725387734792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361948427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82625943,0.035825655,0.0028446873,0.005414452,0.00035639963,0.059483685,0.066982344,0.0012767925,0.0015565631],"genre_scores_gemma":[0.9165243,0.002375901,0.0026820076,0.00007184775,0.00021043312,0.013229344,0.0483254,0.000190998,0.016389767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99511766,0.0001998518,0.00080105895,0.0021026651,0.0010838704,0.00069486117],"domain_scores_gemma":[0.99527913,0.00062527735,0.00045736312,0.002681148,0.00052230357,0.0004348032],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008137875,0.0007181741,0.001939508,0.00077268615,0.00015534775,0.00021958456,0.00081645715,0.00015964569,0.00013612385],"category_scores_gemma":[0.0001680297,0.00045093094,0.0003094463,0.0011114319,0.00018346147,0.00019649946,0.0014497865,0.0007954898,0.000031123374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015505035,0.006322643,0.76374716,0.0015629785,0.13375807,0.0020566124,0.0037393754,0.00023826912,0.00013685711,0.0000024754922,0.067651026,0.0052795056],"study_design_scores_gemma":[0.06371289,0.019175906,0.66062856,0.0021912933,0.13662708,0.000007031858,0.026239218,0.070881404,0.00015482976,0.0006999295,0.016391177,0.0032906488],"about_ca_topic_score_codex":0.024500104,"about_ca_topic_score_gemma":0.0076540923,"teacher_disagreement_score":0.103118576,"about_ca_system_score_codex":0.00034469969,"about_ca_system_score_gemma":0.0029313883,"threshold_uncertainty_score":0.99979424},"labels":[],"label_agreement":null},{"id":"W4361949841","doi":"10.1158/1078-0432.c.6520059.v1","title":"Data from &lt;i&gt;PTEN&lt;/i&gt; Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Calgary; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Cancer Society Research Institute; Terry Fox Foundation; Prostate Cancer Canada; AstraZeneca","keywords":"PTEN; DU145; Prostate cancer; Cancer research; Cancer; Internal medicine; Biology; Medicine; Apoptosis; PI3K/AKT/mTOR pathway; Genetics","score_opus":0.05519559558885521,"score_gpt":0.34776998189791297,"score_spread":0.29257438630905774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361949841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90697366,0.008903407,0.0059718424,0.045871075,0.00072374183,0.009457903,0.02155958,0.00027597562,0.00026282613],"genre_scores_gemma":[0.73062885,0.19555664,0.010966027,0.0014470251,0.0013429953,0.005917455,0.019472813,0.00047234408,0.034195844],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99761444,0.00006584656,0.00049961614,0.001042406,0.00035001215,0.00042765404],"domain_scores_gemma":[0.99787694,0.00026459794,0.00031796066,0.0010702959,0.00032923187,0.00014098211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004654553,0.0003733213,0.0007954435,0.00024441432,0.0000987918,0.0000602573,0.00029157262,0.00026355224,0.00016783422],"category_scores_gemma":[0.000020976193,0.00023914172,0.000094296396,0.00028035493,0.0002144472,0.00011711442,0.00019539424,0.00032881217,0.000003012277],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029395329,0.0016985927,0.21772008,0.0035375662,0.00886251,0.00004668092,0.0029880397,0.0004059444,0.6229695,0.0004302897,0.03623589,0.07570959],"study_design_scores_gemma":[0.04814421,0.0019794747,0.7597865,0.002919829,0.0015143211,0.000009730991,0.00022914573,0.007831129,0.09570083,0.006401057,0.07379526,0.001688501],"about_ca_topic_score_codex":0.0008902163,"about_ca_topic_score_gemma":0.0038296499,"teacher_disagreement_score":0.54206645,"about_ca_system_score_codex":0.00048321058,"about_ca_system_score_gemma":0.0007013913,"threshold_uncertainty_score":0.97519165},"labels":[],"label_agreement":null},{"id":"W4361953266","doi":"10.1158/1078-0432.c.6529157.v1","title":"Data from Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A &lt;i&gt;Post Hoc&lt;/i&gt; Analysis of the PR.7 Trial","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Androgen deprivation therapy; Androstenediol; Internal medicine; Testosterone (patch); Dehydroepiandrosterone; Oncology; Endocrinology; Androgen; Cancer; Hormone","score_opus":0.07606319221624269,"score_gpt":0.35969701303851453,"score_spread":0.28363382082227184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361953266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9681601,0.004088642,0.00002576185,0.0012672066,0.00091406977,0.014361822,0.011036453,0.000082039965,0.0000638901],"genre_scores_gemma":[0.9503013,0.013181909,0.0003174382,0.00008497938,0.00021350128,0.0032054738,0.03156848,0.00012200976,0.0010049001],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99553883,0.00034633672,0.0010792743,0.0013931586,0.0010686667,0.00057371455],"domain_scores_gemma":[0.9962517,0.00051356497,0.00065469154,0.001874623,0.00054418464,0.00016121984],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010756756,0.0004970134,0.0011493879,0.0008071709,0.00012784643,0.00009863036,0.00088177714,0.0003365237,0.000105152496],"category_scores_gemma":[0.0006307835,0.0003206632,0.00041355038,0.0015551744,0.00014350271,0.00014484476,0.0012596947,0.00040259943,0.000004768402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09345215,0.0014512043,0.7716181,0.00056387956,0.016280074,0.000008092053,0.0016803985,0.000118422155,0.0010488586,0.0000045233023,0.002750952,0.1110233],"study_design_scores_gemma":[0.08634273,0.0035290434,0.8887966,0.0021152007,0.0044956957,2.826012e-7,0.0001910164,0.009393159,0.0021214955,0.00033983152,0.0020232091,0.0006517174],"about_ca_topic_score_codex":0.00080865907,"about_ca_topic_score_gemma":0.0068648085,"teacher_disagreement_score":0.11717847,"about_ca_system_score_codex":0.0006513437,"about_ca_system_score_gemma":0.0014436061,"threshold_uncertainty_score":0.99992454},"labels":[],"label_agreement":null},{"id":"W4361953986","doi":"10.1158/1078-0432.c.6531348.v1","title":"Data from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"Imperial Experimental Cancer Medicine Centre; Royal Marsden NHS Foundation Trust; Department of Health and Social Care; National Institute for Health and Care Research; Prostate Cancer Canada; Medical Research Council; Prostate Cancer Foundation; Movember Foundation; Prostate Cancer UK; Cancer Council NSW; Cancer Research UK; U.S. Department of Defense","keywords":"Enzalutamide; Prostate cancer; In vivo; Cancer research; Gene knockdown; Cell culture; Viability assay; Biology; Cancer; Chemistry; Medicine; Internal medicine; Androgen receptor; Genetics","score_opus":0.13927326066883577,"score_gpt":0.38500962572652936,"score_spread":0.24573636505769358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361953986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95947945,0.020520119,0.000015039153,0.0039423713,0.00017416614,0.0015374852,0.01283595,0.000098224504,0.0013971763],"genre_scores_gemma":[0.8958148,0.04860364,0.0008561586,0.00012231903,0.000061873696,0.00030145215,0.003919752,0.00007827122,0.05024176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975254,0.00006944493,0.000436512,0.00092006876,0.00067156117,0.00037704254],"domain_scores_gemma":[0.99825275,0.0001724312,0.00022320983,0.0009972265,0.00023244548,0.000121953526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039786362,0.0002840839,0.00069190457,0.00018426351,0.000040790233,0.000027471806,0.00036067062,0.00017753706,0.00051866804],"category_scores_gemma":[0.00018076466,0.00019697353,0.000035895344,0.00036760562,0.00020658068,0.00010282577,0.0010462423,0.0005629055,0.000006655844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023121536,0.00024984323,0.9582805,0.001393743,0.0015108901,0.00066615496,0.003413477,0.00002465657,0.0013007573,0.000015216505,0.029993676,0.00083891524],"study_design_scores_gemma":[0.006647006,0.000250569,0.96339494,0.012250265,0.0006464609,0.0000022014233,0.0021552704,0.0011569791,0.007870841,0.0029301902,0.0019415584,0.0007537143],"about_ca_topic_score_codex":0.009946157,"about_ca_topic_score_gemma":0.21057086,"teacher_disagreement_score":0.2006247,"about_ca_system_score_codex":0.00013192097,"about_ca_system_score_gemma":0.0009454925,"threshold_uncertainty_score":0.9966467},"labels":[],"label_agreement":null},{"id":"W4361954301","doi":"10.1158/1078-0432.c.6532551.v1","title":"Data from Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Natural Sciences and Engineering Research Council of Canada; Institute for Prostate Cancer Research; Lucas Foundation; Pharmaceutical Research and Manufacturers of America Foundation; Dana-Farber Cancer Institute; National Cancer Institute; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Prostate cancer; DNA methylation; Biology; Methylated DNA immunoprecipitation; Internal medicine; Medicine; Cancer; Genetics; Gene; Gene expression","score_opus":0.15026611409719481,"score_gpt":0.43035617458411013,"score_spread":0.2800900604869153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361954301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8772163,0.01703978,0.008680521,0.03510672,0.003936906,0.010558933,0.023418749,0.002776128,0.021265987],"genre_scores_gemma":[0.74075365,0.05333398,0.014193356,0.0005760798,0.0016772521,0.0012667073,0.06961637,0.000362233,0.11822038],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99613947,0.00009822942,0.0007136853,0.0014213349,0.0009398198,0.00068748894],"domain_scores_gemma":[0.9954185,0.00032231808,0.00034501718,0.00343986,0.0002534138,0.00022090488],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002433175,0.0004981636,0.0010039706,0.0004898969,0.00016146495,0.00015883814,0.00095848186,0.00015218537,0.0010512433],"category_scores_gemma":[0.00038224706,0.00037995115,0.00023732099,0.0012181287,0.00008482806,0.0002891797,0.004017743,0.0009734126,0.00014698564],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009832868,0.0019903972,0.2938664,0.015521895,0.07582888,0.008442627,0.012930505,0.0153430635,0.056064222,0.000058293073,0.23029985,0.279821],"study_design_scores_gemma":[0.023330487,0.0010768999,0.13621737,0.0019961528,0.045145225,0.000020088384,0.0026445454,0.100419104,0.5846769,0.009064635,0.09200278,0.0034057905],"about_ca_topic_score_codex":0.018166741,"about_ca_topic_score_gemma":0.012307777,"teacher_disagreement_score":0.5286127,"about_ca_system_score_codex":0.0004152539,"about_ca_system_score_gemma":0.0008807636,"threshold_uncertainty_score":0.99986523},"labels":[],"label_agreement":null},{"id":"W4361958475","doi":"10.1158/1078-0432.c.6530510.v1","title":"Data from Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Androgen receptor; Medicine; Androgen deprivation therapy; Internal medicine; Oncology; Metastasis; Androgen; Biomarker; Enzalutamide; Cancer; Proportional hazards model; Antiandrogen; Biology; Hormone","score_opus":0.04876792389667443,"score_gpt":0.32519738535499904,"score_spread":0.2764294614583246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361958475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978896,0.0017692957,0.000017691355,0.0011097162,0.000044718978,0.006883699,0.011138547,0.00012466687,0.000015631955],"genre_scores_gemma":[0.97262615,0.0023707813,0.0019468159,0.00007090451,0.000030536215,0.0017225972,0.020677608,0.00013509065,0.00041952825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99629897,0.00021315512,0.000529851,0.0014625542,0.0009630224,0.000532447],"domain_scores_gemma":[0.99749005,0.00014588206,0.0002954243,0.0012753385,0.00030286887,0.00049044087],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030509438,0.0006138647,0.00078075536,0.00045837276,0.000119554206,0.00021305983,0.00028324025,0.000078803685,0.00012649005],"category_scores_gemma":[0.00005956077,0.00035022508,0.000041291773,0.0005277678,0.00014421577,0.00021198014,0.0003602949,0.00037661777,0.000015245687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023980433,0.001082993,0.9651051,0.00033813555,0.00288042,0.00058857724,0.00051619,0.00017632537,0.00007358467,0.0000035601238,0.00009497721,0.005159695],"study_design_scores_gemma":[0.018538615,0.001455482,0.9749796,0.0012493295,0.0016455627,0.0000018182104,0.00019909277,0.00086993916,0.00033206888,0.0002290195,0.000027831382,0.00047163828],"about_ca_topic_score_codex":0.013403431,"about_ca_topic_score_gemma":0.008876286,"teacher_disagreement_score":0.009874495,"about_ca_system_score_codex":0.0001339632,"about_ca_system_score_gemma":0.00088731747,"threshold_uncertainty_score":0.999895},"labels":[],"label_agreement":null},{"id":"W4361959397","doi":"10.1158/1078-0432.c.6529904","title":"Data from Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"DOD Prostate Cancer Research Program; Congressionally Directed Medical Research Programs; University of California, San Francisco; National Cancer Institute; Prostate Cancer Foundation; National Institutes of Health; University of Alberta; UVA Cancer Center; U.S. Department of Defense","keywords":"DU145; Prostate cancer; Chemistry; Biodistribution; Cancer research; Cancer; Nuclear medicine; LNCaP; Medicine; Internal medicine; In vitro; Biochemistry","score_opus":0.1199775596978336,"score_gpt":0.41697022728167765,"score_spread":0.29699266758384407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361959397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94560105,0.03963286,0.00085456204,0.0034044986,0.0010244204,0.0018963452,0.006184705,0.00024283773,0.0011587106],"genre_scores_gemma":[0.93614584,0.0128529,0.020177057,0.0002965041,0.00060146913,0.00018722095,0.023810698,0.00032393675,0.0056043616],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99751586,0.00006814269,0.00051848154,0.00087541004,0.00056656386,0.0004555388],"domain_scores_gemma":[0.9978245,0.000064175394,0.00023709203,0.001478718,0.0002715724,0.0001239497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004128134,0.0003110444,0.0006440042,0.000197248,0.00006366258,0.000058176898,0.0005347624,0.0001246174,0.0004713192],"category_scores_gemma":[0.00010279656,0.00024468044,0.00011927661,0.00021052033,0.00013082182,0.00010115356,0.0033646328,0.0006472137,0.000025445326],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013858214,0.00038864458,0.35452437,0.003874807,0.0044826404,0.0022990361,0.0015298728,0.0024069562,0.5959778,0.000021868305,0.023073072,0.010035138],"study_design_scores_gemma":[0.015022977,0.0002216192,0.033824958,0.022290189,0.0046593277,0.000026962249,0.0043384368,0.35380933,0.5466816,0.0046024164,0.011673183,0.002848999],"about_ca_topic_score_codex":0.021675799,"about_ca_topic_score_gemma":0.0000666478,"teacher_disagreement_score":0.35140237,"about_ca_system_score_codex":0.000267801,"about_ca_system_score_gemma":0.0011420369,"threshold_uncertainty_score":0.9977779},"labels":[],"label_agreement":null},{"id":"W4361959558","doi":"10.1158/1078-0432.c.6529157","title":"Data from Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A &lt;i&gt;Post Hoc&lt;/i&gt; Analysis of the PR.7 Trial","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Androgen deprivation therapy; Androstenediol; Internal medicine; Testosterone (patch); Androgen; Endocrinology; Oncology; Dehydroepiandrosterone; Proportional hazards model; Cancer; Hormone","score_opus":0.07606319221624269,"score_gpt":0.35969701303851453,"score_spread":0.28363382082227184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361959558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9681601,0.004088642,0.00002576185,0.0012672066,0.00091406977,0.014361822,0.011036453,0.000082039965,0.0000638901],"genre_scores_gemma":[0.9503013,0.013181909,0.0003174382,0.00008497938,0.00021350128,0.0032054738,0.03156848,0.00012200976,0.0010049001],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99553883,0.00034633672,0.0010792743,0.0013931586,0.0010686667,0.00057371455],"domain_scores_gemma":[0.9962517,0.00051356497,0.00065469154,0.001874623,0.00054418464,0.00016121984],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010756756,0.0004970134,0.0011493879,0.0008071709,0.00012784643,0.00009863036,0.00088177714,0.0003365237,0.000105152496],"category_scores_gemma":[0.0006307835,0.0003206632,0.00041355038,0.0015551744,0.00014350271,0.00014484476,0.0012596947,0.00040259943,0.000004768402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09345215,0.0014512043,0.7716181,0.00056387956,0.016280074,0.000008092053,0.0016803985,0.000118422155,0.0010488586,0.0000045233023,0.002750952,0.1110233],"study_design_scores_gemma":[0.08634273,0.0035290434,0.8887966,0.0021152007,0.0044956957,2.826012e-7,0.0001910164,0.009393159,0.0021214955,0.00033983152,0.0020232091,0.0006517174],"about_ca_topic_score_codex":0.00080865907,"about_ca_topic_score_gemma":0.0068648085,"teacher_disagreement_score":0.11717847,"about_ca_system_score_codex":0.0006513437,"about_ca_system_score_gemma":0.0014436061,"threshold_uncertainty_score":0.99992454},"labels":[],"label_agreement":null},{"id":"W4361961286","doi":"10.1158/1078-0432.c.6520059","title":"Data from &lt;i&gt;PTEN&lt;/i&gt; Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Calgary; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Cancer Society Research Institute; Terry Fox Foundation; Prostate Cancer Canada; AstraZeneca","keywords":"PTEN; DU145; Prostate cancer; Cancer research; Cancer; Medicine; Biology; Internal medicine; Apoptosis; PI3K/AKT/mTOR pathway; Genetics","score_opus":0.05519559558885521,"score_gpt":0.34776998189791297,"score_spread":0.29257438630905774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361961286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90697366,0.008903407,0.0059718424,0.045871075,0.00072374183,0.009457903,0.02155958,0.00027597562,0.00026282613],"genre_scores_gemma":[0.73062885,0.19555664,0.010966027,0.0014470251,0.0013429953,0.005917455,0.019472813,0.00047234408,0.034195844],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99761444,0.00006584656,0.00049961614,0.001042406,0.00035001215,0.00042765404],"domain_scores_gemma":[0.99787694,0.00026459794,0.00031796066,0.0010702959,0.00032923187,0.00014098211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004654553,0.0003733213,0.0007954435,0.00024441432,0.0000987918,0.0000602573,0.00029157262,0.00026355224,0.00016783422],"category_scores_gemma":[0.000020976193,0.00023914172,0.000094296396,0.00028035493,0.0002144472,0.00011711442,0.00019539424,0.00032881217,0.000003012277],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029395329,0.0016985927,0.21772008,0.0035375662,0.00886251,0.00004668092,0.0029880397,0.0004059444,0.6229695,0.0004302897,0.03623589,0.07570959],"study_design_scores_gemma":[0.04814421,0.0019794747,0.7597865,0.002919829,0.0015143211,0.000009730991,0.00022914573,0.007831129,0.09570083,0.006401057,0.07379526,0.001688501],"about_ca_topic_score_codex":0.0008902163,"about_ca_topic_score_gemma":0.0038296499,"teacher_disagreement_score":0.54206645,"about_ca_system_score_codex":0.00048321058,"about_ca_system_score_gemma":0.0007013913,"threshold_uncertainty_score":0.97519165},"labels":[],"label_agreement":null},{"id":"W4362457702","doi":"10.1158/1078-0432.ccr-22-2998","title":"Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Cilag; Astellas Pharma; Killam Trusts; ZonMw; Prostate Cancer Foundation","keywords":"Enzalutamide; Abiraterone; Prostate cancer; Medicine; Oncology; Cancer; Internal medicine; Prostate; Androgen receptor","score_opus":0.3526424261395648,"score_gpt":0.5554773306580965,"score_spread":0.20283490451853164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362457702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806573,0.0006339941,4.0432343e-7,0.015719997,0.00012532678,0.002645875,0.00010792135,0.000048906357,0.00006031614],"genre_scores_gemma":[0.9890419,0.0033031574,0.00005674777,0.00026123683,0.00018358558,0.0031788452,0.000022162372,0.000052200172,0.0039001382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99565285,0.0010136775,0.00065643544,0.0008228807,0.00089654006,0.00095763616],"domain_scores_gemma":[0.9965497,0.0023227553,0.00007828296,0.00035755034,0.00024467538,0.00044701164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041850125,0.0002422891,0.00061784,0.0010028298,0.00016415124,0.000093887764,0.00010914799,0.00009210764,0.0002025857],"category_scores_gemma":[0.0013566107,0.00016485655,0.000059576185,0.0020248704,0.00023513357,0.00011150234,0.00010346319,0.00070906995,0.00009107001],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1885377,0.0014741098,0.50849956,0.00067974307,0.00034922487,0.009617701,0.007438469,0.00043598944,0.14318323,0.000025406676,0.00084817735,0.13891068],"study_design_scores_gemma":[0.008395419,0.006941693,0.97339624,0.0011794878,0.00003027117,0.0000070006504,0.0014216352,0.00039461174,0.006248586,0.000103765466,0.0016762614,0.00020505155],"about_ca_topic_score_codex":0.008262617,"about_ca_topic_score_gemma":0.024028575,"teacher_disagreement_score":0.46489665,"about_ca_system_score_codex":0.002050305,"about_ca_system_score_gemma":0.0017886342,"threshold_uncertainty_score":0.99834144},"labels":[],"label_agreement":null},{"id":"W4362461330","doi":"10.1158/0008-5472.22379841.v1","title":"Supplementary Table 2 from Osteoblast-Derived Factors Induce an Expression Signature that Identifies Prostate Cancer Metastasis and Hormonal Progression","year":2023,"lang":"en","type":"supplementary-materials","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"Canadian Institutes of Health Research; National Institutes of Health","keywords":"Prostate cancer; Metastasis; Osteoblast; Prostate; Table (database); Hormone; Signature (topology); Oncology; Internal medicine; Cancer; Cancer research; Medicine; Biology; Computer science; Database; Genetics","score_opus":0.049802219651797,"score_gpt":0.35592116892573056,"score_spread":0.30611894927393357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362461330","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7579955,0.007988523,0.0000015410131,0.0017162029,0.0016227276,0.003772313,0.2267177,0.00015374475,0.000031743333],"genre_scores_gemma":[0.15401092,0.031362303,0.0009080067,0.000347959,0.0013202573,0.0020143392,0.78863585,0.00041370277,0.020986656],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99471307,0.00028795915,0.0007170393,0.001530731,0.0016540862,0.0010971116],"domain_scores_gemma":[0.997926,0.0001791806,0.00039354264,0.00066642684,0.00023099803,0.00060387794],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036792737,0.0010087213,0.0013880628,0.0005242107,0.00046767332,0.00039977935,0.0003333349,0.0006154856,0.05062954],"category_scores_gemma":[0.000027052449,0.0006503876,0.00016016234,0.00034233736,0.00023913111,0.00061417953,0.0007558869,0.00086465955,0.00001486426],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021337522,0.00029111005,0.017555915,0.001070774,0.0014607593,0.00032088818,0.002199408,5.6613885e-7,0.6419468,6.460279e-7,0.32847747,0.0045419447],"study_design_scores_gemma":[0.0040939855,0.00096971774,0.0035500494,0.0017983237,0.0009906279,0.000005338435,0.0061187106,0.000004166218,0.90474975,0.0000827904,0.07694292,0.0006935984],"about_ca_topic_score_codex":0.037520196,"about_ca_topic_score_gemma":0.005657629,"teacher_disagreement_score":0.6039846,"about_ca_system_score_codex":0.00041591993,"about_ca_system_score_gemma":0.00066080334,"threshold_uncertainty_score":0.99959475},"labels":[],"label_agreement":null},{"id":"W4362473019","doi":"10.6004/jnccn.2022.7109","title":"CLO23-025: Comparison of Outcomes Using NCCN Classification in Two Concurrent Phase III Trials in Intermediate and High Risk Prostate Cancer: Long-Term Data","year":2023,"lang":"en","type":"article","venue":"Journal of the National Comprehensive Cancer Network","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont; Nova Scotia Cancer Centre; Centre hospitalier universitaire de Québec; McGill University Health Centre; Centre Intégré de Santé et de Services Sociaux du Bas-Saint-Laurent; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Prostate cancer; Term (time); Oncology; Cancer; Internal medicine; Clinical trial; Prostate","score_opus":0.32030928530987374,"score_gpt":0.5348290192169047,"score_spread":0.214519733907031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362473019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832048,0.012260729,0.000028577322,0.0019911358,0.0013038628,0.00083744683,0.00036160942,0.0000063101415,0.0000055546716],"genre_scores_gemma":[0.9870034,0.012029581,0.0000610018,0.00012011313,0.00060491706,0.000029390721,0.00009340249,0.000016734217,0.000041499992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966925,0.0005385071,0.0014636012,0.00024261232,0.000785628,0.00027716337],"domain_scores_gemma":[0.995973,0.0012595142,0.0016581671,0.00018730815,0.00082477037,0.00009726319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015974964,0.00017895178,0.0010650009,0.00035093536,0.0000867851,0.000027011578,0.00029911724,0.000054924647,0.000029591172],"category_scores_gemma":[0.00047429014,0.000114005714,0.00012752772,0.00069386483,0.00019715045,0.00018462293,0.0002165793,0.0005604625,7.0639993e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002719625,0.0002265837,0.9485725,0.00012445042,0.00046653033,0.00001693319,0.00054579723,0.018254263,0.0012486371,0.000028114002,0.002635546,0.025161019],"study_design_scores_gemma":[0.0213582,0.00017568424,0.93720526,0.0015043146,0.0002768035,0.000008691149,0.00021114243,0.038104776,0.00035420904,0.00027923106,0.0004069681,0.00011471958],"about_ca_topic_score_codex":0.00032202865,"about_ca_topic_score_gemma":0.000444766,"teacher_disagreement_score":0.0250463,"about_ca_system_score_codex":0.000616811,"about_ca_system_score_gemma":0.00072527863,"threshold_uncertainty_score":0.46490183},"labels":[],"label_agreement":null},{"id":"W4362479416","doi":"10.1158/1535-7163.c.6535299.v1","title":"Data from Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression &lt;i&gt;In vivo&lt;/i&gt;","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Gene knockdown; LNCaP; Transactivation; Cancer research; Androgen receptor; Prostate cancer; Androgen deprivation therapy; STAT5; MG132; Biology; Transcription factor; Chemistry; Apoptosis; Medicine; Internal medicine; Signal transduction; Proteasome inhibitor; Cell biology; Cancer; Proteasome","score_opus":0.0884125551900787,"score_gpt":0.36440373471725546,"score_spread":0.2759911795271768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362479416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9579554,0.014526539,0.00024872084,0.00267615,0.00077439065,0.0044061895,0.018839918,0.00025856882,0.0003140805],"genre_scores_gemma":[0.864616,0.072050825,0.004428427,0.00006121671,0.0005671806,0.0020186654,0.038685042,0.00019217514,0.017380472],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99564624,0.00019451758,0.00085847126,0.0016517399,0.0009955652,0.0006534522],"domain_scores_gemma":[0.99794704,0.0001386308,0.00031021168,0.0009827315,0.00027703177,0.0003443594],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004473696,0.00059632276,0.0007810733,0.00038630317,0.00019511755,0.00023766684,0.00036139326,0.00045254204,0.0013532916],"category_scores_gemma":[0.000071105074,0.00044872053,0.00010012854,0.0003540504,0.0001888365,0.00047899137,0.00039546867,0.00060201454,0.000037868922],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029575771,0.0002954409,0.0070411987,0.001074502,0.00051704136,0.00010639726,0.0020000788,0.000020803596,0.9509312,0.000028931787,0.0089677,0.026059128],"study_design_scores_gemma":[0.021905208,0.0025374151,0.11552531,0.014459933,0.001729963,0.000019306284,0.0018322206,0.0155667905,0.7242789,0.001666261,0.09704566,0.0034329991],"about_ca_topic_score_codex":0.0016977539,"about_ca_topic_score_gemma":0.022278704,"teacher_disagreement_score":0.22665226,"about_ca_system_score_codex":0.0005711371,"about_ca_system_score_gemma":0.0012389654,"threshold_uncertainty_score":0.99979645},"labels":[],"label_agreement":null},{"id":"W4362479968","doi":"10.1158/1535-7163.22499358","title":"Supplementary Materials and Methods from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Androgen receptor; Androgen Receptor Antagonists; Characterization (materials science); Class (philosophy); Cancer research; Internal medicine; Medicine; Oncology; Pharmacology; Cancer; Computer science; Materials science; Nanotechnology; Artificial intelligence","score_opus":0.03043099368249273,"score_gpt":0.37776043020916594,"score_spread":0.3473294365266732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362479968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98900306,0.0005117606,0.0019820493,0.0019084507,0.00013441431,0.0027511814,0.0036817617,0.00002216803,0.00000517701],"genre_scores_gemma":[0.9426409,0.01337911,0.019391943,0.00006784387,0.00013345382,0.00096704846,0.022166768,0.00008005508,0.0011729043],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998587,0.00010717789,0.00045516485,0.00043453308,0.00023149031,0.00018463649],"domain_scores_gemma":[0.9992103,0.00002759492,0.00030576225,0.00027124016,0.00011090693,0.00007418375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021844436,0.00020242148,0.0005948008,0.00016797638,0.00001694927,0.000015425447,0.000077232944,0.00012905619,0.00032874712],"category_scores_gemma":[0.0000035720723,0.00014539433,0.000034135475,0.0001659661,0.00007977988,0.000047083973,0.00014481378,0.00013568635,6.6046414e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039241654,0.00008795347,0.033221804,0.0006842049,0.00034014112,0.0000041346766,0.0006996335,0.000010874339,0.9149895,0.000005905501,0.000021391836,0.046010334],"study_design_scores_gemma":[0.0037640403,0.00028245535,0.07205508,0.0005570151,0.00020871688,0.0000012786896,0.00016910398,0.00015070576,0.9218867,0.0002898269,0.00049254985,0.00014255483],"about_ca_topic_score_codex":0.008381294,"about_ca_topic_score_gemma":0.00029966034,"teacher_disagreement_score":0.04636216,"about_ca_system_score_codex":0.00011986476,"about_ca_system_score_gemma":0.00050502573,"threshold_uncertainty_score":0.998222},"labels":[],"label_agreement":null},{"id":"W4362480054","doi":"10.1158/1535-7163.22499358.v1","title":"Supplementary Materials and Methods from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Androgen receptor; Class (philosophy); Characterization (materials science); Cancer research; Medicine; Oncology; Cancer; Computer science; Internal medicine; Materials science; Nanotechnology; Artificial intelligence","score_opus":0.03043099368249273,"score_gpt":0.37776043020916594,"score_spread":0.3473294365266732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362480054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98900306,0.0005117606,0.0019820493,0.0019084507,0.00013441431,0.0027511814,0.0036817617,0.00002216803,0.00000517701],"genre_scores_gemma":[0.9426409,0.01337911,0.019391943,0.00006784387,0.00013345382,0.00096704846,0.022166768,0.00008005508,0.0011729043],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998587,0.00010717789,0.00045516485,0.00043453308,0.00023149031,0.00018463649],"domain_scores_gemma":[0.9992103,0.00002759492,0.00030576225,0.00027124016,0.00011090693,0.00007418375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021844436,0.00020242148,0.0005948008,0.00016797638,0.00001694927,0.000015425447,0.000077232944,0.00012905619,0.00032874712],"category_scores_gemma":[0.0000035720723,0.00014539433,0.000034135475,0.0001659661,0.00007977988,0.000047083973,0.00014481378,0.00013568635,6.6046414e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039241654,0.00008795347,0.033221804,0.0006842049,0.00034014112,0.0000041346766,0.0006996335,0.000010874339,0.9149895,0.000005905501,0.000021391836,0.046010334],"study_design_scores_gemma":[0.0037640403,0.00028245535,0.07205508,0.0005570151,0.00020871688,0.0000012786896,0.00016910398,0.00015070576,0.9218867,0.0002898269,0.00049254985,0.00014255483],"about_ca_topic_score_codex":0.008381294,"about_ca_topic_score_gemma":0.00029966034,"teacher_disagreement_score":0.04636216,"about_ca_system_score_codex":0.00011986476,"about_ca_system_score_gemma":0.00050502573,"threshold_uncertainty_score":0.998222},"labels":[],"label_agreement":null},{"id":"W4362531944","doi":"10.1016/j.compbiomed.2023.106882","title":"Automatic segmentation of prostate cancer metastases in PSMA PET/CT images using deep neural networks with weighted batch-wise dice loss","year":2023,"lang":"en","type":"article","venue":"Computers in Biology and Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; National Institutes of Health; University of British Columbia; Mitacs; Microsoft","keywords":"Dice; Prostate cancer; Segmentation; Sørensen–Dice coefficient; Convolutional neural network; Context (archaeology); Artificial intelligence; Computer science; Deep learning; Pattern recognition (psychology); Prostate; Artificial neural network; Nuclear medicine; Image segmentation; Medicine; Cancer; Internal medicine; Mathematics","score_opus":0.025586363736270955,"score_gpt":0.36437897502501054,"score_spread":0.3387926112887396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362531944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99223554,0.004638487,0.0006452326,0.0016621847,0.00019937797,0.00056205946,0.000009615445,0.000034212404,0.000013311687],"genre_scores_gemma":[0.99512666,0.0029317683,0.0014314577,0.0001749997,0.00006834578,0.000046100824,0.00018602789,0.0000116582605,0.000022960989],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9989428,0.00012512063,0.00028027556,0.00025110823,0.00010364418,0.00029705474],"domain_scores_gemma":[0.9994611,0.00020930536,0.0000896793,0.00010932361,0.000049993556,0.000080554564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028777204,0.0001471849,0.00043967355,0.000348077,0.000041604697,0.0000031927088,0.000053742595,0.000018887376,0.000024822295],"category_scores_gemma":[0.000015853311,0.00008975277,0.000017898292,0.00063915714,0.00050258986,0.000055531847,0.000047689708,0.0001704804,3.467783e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009786617,0.00011198637,0.9179434,0.0004325182,0.00018966783,0.0024935163,0.0011056456,0.0011152781,0.0021861477,0.000031704338,0.00016669594,0.073244765],"study_design_scores_gemma":[0.016263971,0.0019333067,0.2631575,0.0019252882,0.00024131253,0.0005762269,0.0010131648,0.7129049,0.0014487975,0.000271544,0.000037861166,0.0002261438],"about_ca_topic_score_codex":0.00046024198,"about_ca_topic_score_gemma":0.000115076306,"teacher_disagreement_score":0.7117896,"about_ca_system_score_codex":0.000075397,"about_ca_system_score_gemma":0.000053918222,"threshold_uncertainty_score":0.3660012},"labels":[],"label_agreement":null},{"id":"W4362540678","doi":"10.1158/1538-7445.am2023-3315","title":"Abstract 3315: Evaluating biomarker potential of germline genomic factors for predicting clinical outcomes in prostate cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Prostate cancer; Germline; Medicine; Cancer; Oncology; Biomarker; Internal medicine; Gene; Genetics; Biology","score_opus":0.3323757829996484,"score_gpt":0.571522447385508,"score_spread":0.23914666438585958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362540678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282384,0.001492412,0.000002809535,0.0017579233,0.00046029597,0.0028318916,0.0004615047,0.000066801054,0.000102508355],"genre_scores_gemma":[0.9918994,0.0030536398,0.00007826487,0.00002279551,0.00028494914,0.0012669388,0.00016244575,0.00007252158,0.003159073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99603045,0.00020112825,0.0008927877,0.0006297214,0.0011412699,0.0011046497],"domain_scores_gemma":[0.9972244,0.0012432048,0.0001578856,0.0003709976,0.000732162,0.00027134657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046019815,0.00021539233,0.0006627045,0.0007490818,0.00018812905,0.000036244885,0.00024394374,0.00015453857,0.00038455674],"category_scores_gemma":[0.0011330472,0.000158728,0.0002745819,0.0010585027,0.0003706395,0.00011475069,0.00020967217,0.00070128456,0.000017931996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024642702,0.00020745813,0.8722662,0.00069633865,0.000350532,0.00006151062,0.0005911184,0.00018415756,0.09271542,0.0000034115124,0.0012001924,0.029259408],"study_design_scores_gemma":[0.0062413365,0.00052228884,0.9815449,0.00047181107,0.00005573661,0.0000010837874,0.0008808801,0.0029241787,0.0068108337,0.000096411786,0.00030481792,0.0001457381],"about_ca_topic_score_codex":0.0025920835,"about_ca_topic_score_gemma":0.00043414492,"teacher_disagreement_score":0.1092787,"about_ca_system_score_codex":0.0005971127,"about_ca_system_score_gemma":0.0018200474,"threshold_uncertainty_score":0.64727396},"labels":[],"label_agreement":null},{"id":"W4362541846","doi":"10.1158/1538-7445.am2023-4730","title":"Abstract 4730: ASCL1 activates neuronal stem cell-like lineage programming through the remodeling of the chromatin landscape in prostate cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"EZH2; Biology; Chromatin; Cancer research; PRC2; Transcription factor; Gene knockdown; Epigenetics; Polycomb-group proteins; Histone; Chromatin remodeling; Cell biology; Repressor; Cell culture; Genetics","score_opus":0.10345213902859018,"score_gpt":0.4124139236962895,"score_spread":0.3089617846676993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362541846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846925,0.004845189,9.601963e-7,0.0071496014,0.00022232237,0.0021144596,0.000062442385,0.0000612697,0.00085121987],"genre_scores_gemma":[0.9866089,0.005535866,0.00002516727,0.00007769642,0.00024921529,0.0011330147,0.000022888542,0.000061621766,0.006285579],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99647784,0.00023296064,0.00042196215,0.00047960473,0.0013850265,0.001002593],"domain_scores_gemma":[0.9983941,0.00042307714,0.000112524314,0.00058722275,0.0003702284,0.000112887414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013220621,0.00020958835,0.00033420816,0.00020931178,0.0003682811,0.00007593842,0.0004843134,0.00009377454,0.00019424746],"category_scores_gemma":[0.000058795427,0.000110466535,0.00013348201,0.0022130434,0.00040505463,0.0001565797,0.0003362174,0.0012496533,0.000025204945],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047017788,0.0009510471,0.19859008,0.0057463134,0.00047753102,0.00036478124,0.033555645,0.011148357,0.54430294,0.000086984706,0.027055904,0.17301862],"study_design_scores_gemma":[0.009546103,0.0007402931,0.27878693,0.0045409976,0.000100608275,0.000015801526,0.01547877,0.0075650397,0.6352394,0.00024317676,0.047130425,0.0006124282],"about_ca_topic_score_codex":0.0031828997,"about_ca_topic_score_gemma":0.00059629715,"teacher_disagreement_score":0.1724062,"about_ca_system_score_codex":0.00035287722,"about_ca_system_score_gemma":0.0014415793,"threshold_uncertainty_score":0.5429191},"labels":[],"label_agreement":null},{"id":"W4362593389","doi":"10.1158/1538-7445.am2023-4011","title":"Abstract 4011: Preferential cytotoxicity of ESK981 in neuroendocrine prostate cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Cancer research; Population; Prostate; Apoptosis; Pathology; Internal medicine; Biology","score_opus":0.13775562520555845,"score_gpt":0.46056723938636646,"score_spread":0.322811614180808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362593389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915682,0.0018799478,3.8555075e-7,0.0029252765,0.00018019344,0.0015377658,0.00018690802,0.00008136252,0.0016399374],"genre_scores_gemma":[0.9777059,0.012288197,0.0000076466295,0.00003274356,0.00021530836,0.0011721887,0.00006825281,0.00005185448,0.008457914],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.996575,0.00013247291,0.0003999586,0.0005321695,0.0012385917,0.0011217966],"domain_scores_gemma":[0.9986231,0.00016661016,0.000060136557,0.00042967504,0.0004427345,0.0002777914],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00066513347,0.00018693316,0.00042612717,0.0008862524,0.00010811049,0.000030187863,0.00025535788,0.00006145561,0.0015894034],"category_scores_gemma":[0.00014365494,0.00014876995,0.000100935606,0.0022014647,0.00036362457,0.00012842973,0.00024400285,0.0009038089,0.00011124743],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005944121,0.0006211184,0.32245487,0.0020578313,0.00022180004,0.0013604619,0.0010239169,0.00022004334,0.61277205,0.00009635993,0.018273871,0.03495357],"study_design_scores_gemma":[0.0049856706,0.000438758,0.5977423,0.0007346937,0.000020021713,0.0000073663114,0.00025385807,0.00017631885,0.39175406,0.00029039042,0.0034239627,0.00017256853],"about_ca_topic_score_codex":0.004927507,"about_ca_topic_score_gemma":0.0012156841,"teacher_disagreement_score":0.27528745,"about_ca_system_score_codex":0.0005768847,"about_ca_system_score_gemma":0.0013705278,"threshold_uncertainty_score":0.9993233},"labels":[],"label_agreement":null},{"id":"W4362594416","doi":"10.1158/1538-7445.am2023-4729","title":"Abstract 4729: LSD1 activates oncogenic super-enhancers in castration-resistant prostate cancer by forming nuclear condensates with BRD4","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"FOXA1; Androgen receptor; Cancer research; Coactivator; Prostate cancer; BRD4; Transcription factor; Demethylase; Enhancer; Enzalutamide; EZH2; Chromatin; Transactivation; Biology; Chemistry; Histone; Cancer; Bromodomain; Gene; Genetics","score_opus":0.07513378526280544,"score_gpt":0.41479220041049364,"score_spread":0.3396584151476882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362594416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868078,0.0042997063,1.4240068e-7,0.0056094136,0.00009550895,0.0017120426,0.00025056273,0.00013606153,0.0010887436],"genre_scores_gemma":[0.9816837,0.0076363767,0.000022001095,0.000089941524,0.00016345872,0.0012908046,0.0001616761,0.00011703077,0.008835059],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99586797,0.00009948814,0.00039749668,0.0007570706,0.0013744447,0.0015035077],"domain_scores_gemma":[0.9983394,0.00026501526,0.000074668096,0.00040975376,0.0005090782,0.00040207471],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00087064813,0.00030846288,0.00047585033,0.00061168656,0.00039847437,0.00015252094,0.0002637083,0.00015928083,0.0011210057],"category_scores_gemma":[0.00008273333,0.00023129862,0.000085352076,0.002027339,0.0005137716,0.00038371055,0.00011197984,0.0010377764,0.00016455431],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004927561,0.0001526889,0.016474143,0.00058130466,0.0002512579,0.00057867216,0.0028061646,0.00006519927,0.9488984,0.000024447138,0.013934657,0.011305526],"study_design_scores_gemma":[0.012777679,0.0020014585,0.07390447,0.0030952631,0.00008535692,0.000025562278,0.012456303,0.0002810853,0.86334884,0.00024047517,0.03091273,0.0008707547],"about_ca_topic_score_codex":0.010410043,"about_ca_topic_score_gemma":0.003271401,"teacher_disagreement_score":0.08554952,"about_ca_system_score_codex":0.0018240481,"about_ca_system_score_gemma":0.0020660958,"threshold_uncertainty_score":0.9997921},"labels":[],"label_agreement":null},{"id":"W4362594519","doi":"10.1158/1538-7445.am2023-4305","title":"Abstract 4305: Germline structural variants shape prostate cancer clinical and molecular evolution","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Prostate cancer; Germline; Cancer; Single-nucleotide polymorphism; Germline mutation; Medicine; Oncology; Internal medicine; Genetics; Biology; Genotype; Gene; Mutation","score_opus":0.12908124149744687,"score_gpt":0.5054803646120697,"score_spread":0.3763991231146228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362594519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809086,0.008433586,0.0000018298377,0.008309225,0.00033173256,0.001186111,0.00016192265,0.00012500734,0.00054203125],"genre_scores_gemma":[0.9824118,0.012080628,0.000037831047,0.000117287964,0.00055509864,0.0004940493,0.00009292753,0.000058033238,0.0041523394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654007,0.00018166107,0.0004082649,0.00071317283,0.0011085358,0.0010482873],"domain_scores_gemma":[0.99823135,0.00018407819,0.00005577072,0.00039227845,0.00060955365,0.00052696164],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015485168,0.0002067843,0.00038919094,0.00041349282,0.0003046068,0.00008442542,0.0001795846,0.00018538076,0.0009856196],"category_scores_gemma":[0.00023762869,0.0001574103,0.000103711754,0.0012058247,0.0007069771,0.00016189822,0.00024543947,0.0010198017,0.00015049858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005061876,0.00018725968,0.60544753,0.0012676169,0.0007790933,0.002258274,0.00077223347,0.000070837275,0.17956488,0.00052653113,0.021774177,0.18228967],"study_design_scores_gemma":[0.004637454,0.00034788725,0.9831336,0.0004148719,0.000051598145,0.000017947976,0.00020165884,0.0017998824,0.0045164824,0.0013967905,0.003257284,0.00022450136],"about_ca_topic_score_codex":0.0012092814,"about_ca_topic_score_gemma":0.00008348374,"teacher_disagreement_score":0.37768608,"about_ca_system_score_codex":0.00043397816,"about_ca_system_score_gemma":0.0013163254,"threshold_uncertainty_score":0.99992764},"labels":[],"label_agreement":null},{"id":"W4362595462","doi":"10.1158/1538-7445.am2023-3997","title":"Abstract 3997: Preclinical characterization of ARX517, a next-generation anti-PSMA antibody drug conjugate for the treatment of metastatic castration-resistant prostate cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Prostate cancer; Cancer research; Cancer; Medicine; Antibody-drug conjugate; Cancer cell; Antibody; Prostate; Antigen; Internal medicine; Immunology; Monoclonal antibody","score_opus":0.2840586282121687,"score_gpt":0.49573328824091406,"score_spread":0.21167466002874535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362595462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98645675,0.003273035,0.000020100757,0.004454729,0.00026236178,0.004292283,0.0011733385,0.00003316262,0.00003424432],"genre_scores_gemma":[0.95639336,0.036598682,0.00004266076,0.000019666792,0.0003529678,0.0025025907,0.0011044026,0.000046146382,0.0029395465],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99728936,0.00016283244,0.00066401716,0.0004485561,0.0008561818,0.00057906494],"domain_scores_gemma":[0.99746364,0.0006278367,0.00022459214,0.00043160623,0.0010990574,0.00015328475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011716225,0.00020408552,0.00052569405,0.00031078374,0.00028303877,0.00006492897,0.00015959788,0.000067465524,0.00022504422],"category_scores_gemma":[0.00012410755,0.00012651832,0.00018504691,0.0009391385,0.00042793772,0.00017941125,0.00003214075,0.00019152938,0.000012040927],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022626908,0.00048364268,0.0052116034,0.0007653137,0.0005375077,0.000020828267,0.001767473,0.00013405627,0.96858335,0.00006300647,0.00061927317,0.019551253],"study_design_scores_gemma":[0.0067072003,0.001945216,0.14151394,0.00053286046,0.00031727957,0.0000022586087,0.0007318913,0.005002244,0.83634245,0.000069544665,0.0066432427,0.0001918603],"about_ca_topic_score_codex":0.0014459401,"about_ca_topic_score_gemma":0.00045235865,"teacher_disagreement_score":0.13630234,"about_ca_system_score_codex":0.00032696378,"about_ca_system_score_gemma":0.0014842071,"threshold_uncertainty_score":0.5159267},"labels":[],"label_agreement":null},{"id":"W4362595513","doi":"10.1158/1538-7445.am2023-3441","title":"Abstract 3441: A multivalent peptoid conjugate that inhibits therapy-resistant prostate cancer cell proliferation by modulating androgen receptor transcriptional activity","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Division of Chemistry; National Science Foundation; National Cancer Institute; School of Medicine, New York University; National Institutes of Health; New York State Department of Health","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Cancer research; Cell growth; Chemistry; Cancer; Dihydrotestosterone; Cancer cell; Bicalutamide; Androgen; Pharmacology; Biology; Internal medicine; Medicine; Biochemistry; Hormone","score_opus":0.12261233080071712,"score_gpt":0.40126300467570625,"score_spread":0.2786506738749891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362595513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780126,0.011548904,0.0000039266524,0.0051516662,0.00020389026,0.0032847363,0.0009790106,0.00017949384,0.00063577516],"genre_scores_gemma":[0.9492087,0.03380996,0.000021536387,0.000071330134,0.00032083516,0.003156658,0.0004063216,0.000095803334,0.012908861],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9954485,0.000253011,0.00033346278,0.00083734473,0.0019066083,0.0012210498],"domain_scores_gemma":[0.99827003,0.0001591134,0.00010263566,0.00036292334,0.00066170836,0.00044358577],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012609406,0.00033192997,0.0004139457,0.00028430135,0.00062299875,0.00015578399,0.00019268008,0.00018309515,0.0016010371],"category_scores_gemma":[0.00004210419,0.00025889298,0.00015653645,0.0008972541,0.00029958604,0.0004207758,0.00008252947,0.00083343784,0.00011924213],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054079164,0.0003848096,0.0104347,0.0005221168,0.00017900557,0.00003372994,0.0018463385,0.00006283247,0.9432726,0.0000054392267,0.01359705,0.024253456],"study_design_scores_gemma":[0.0064737177,0.00050821126,0.025421664,0.0004910255,0.000019433546,0.000001851321,0.00056420354,0.0006433895,0.9499336,0.000035428933,0.015603822,0.00030365982],"about_ca_topic_score_codex":0.0028016295,"about_ca_topic_score_gemma":0.00032760875,"teacher_disagreement_score":0.028803904,"about_ca_system_score_codex":0.0014010306,"about_ca_system_score_gemma":0.0012856919,"threshold_uncertainty_score":0.99998635},"labels":[],"label_agreement":null},{"id":"W4362596323","doi":"10.1158/1538-7445.am2023-4753","title":"Abstract 4753: LSD1 &amp;8211mediated FOXA2/AP1 transcription program drives lineage plasticity in prostate cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"FOXA2; FOXA1; Transcription factor; Biology; Chromatin; Cancer research; Carcinogenesis; Cell biology; Computational biology; Genetics; Cancer; Gene","score_opus":0.14919442325819343,"score_gpt":0.4747075890183594,"score_spread":0.325513165760166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362596323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98832566,0.0025703127,0.0000027400727,0.0037850144,0.00027243452,0.0035407825,0.00021796171,0.00039132862,0.0008937911],"genre_scores_gemma":[0.9644759,0.016840713,0.00006691983,0.000048714843,0.0004629733,0.005653504,0.00042174596,0.00009526067,0.011934245],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9952743,0.00018537704,0.0004929379,0.0008196719,0.0015284477,0.0016992687],"domain_scores_gemma":[0.9981641,0.00027464586,0.00006392779,0.00037616424,0.00060123357,0.00051988446],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010176521,0.0003100053,0.0004995115,0.0010668801,0.00027128437,0.00012030258,0.00028450793,0.00020729066,0.0012353726],"category_scores_gemma":[0.00024174285,0.00024942428,0.00013827842,0.003219599,0.00053306756,0.00024960906,0.00011059258,0.0014945864,0.00040961624],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008750764,0.0020351922,0.1923586,0.003994948,0.00052446977,0.0016625691,0.008342905,0.0008225374,0.58152074,0.000050031955,0.05000893,0.14992829],"study_design_scores_gemma":[0.014481933,0.0014426969,0.7525935,0.0029362747,0.000093865,0.000012189286,0.0012860958,0.0017606181,0.117128216,0.00023518226,0.107262805,0.0007665949],"about_ca_topic_score_codex":0.0034829476,"about_ca_topic_score_gemma":0.0047254744,"teacher_disagreement_score":0.5602349,"about_ca_system_score_codex":0.0010983773,"about_ca_system_score_gemma":0.0015139633,"threshold_uncertainty_score":0.9999958},"labels":[],"label_agreement":null},{"id":"W4362603664","doi":"10.1117/12.2654527","title":"State-of-the-art object detection algorithms for small lesion detection in PSMA PET: use of rotational maximum intensity projection (MIP) images","year":2023,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Maximum intensity projection; Projection (relational algebra); Computer vision; Object detection; Artificial intelligence; Computer science; Intensity (physics); Algorithm; Physics; Pattern recognition (psychology); Optics; Radiology; Medicine","score_opus":0.08314146853818812,"score_gpt":0.33428353108189107,"score_spread":0.25114206254370297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362603664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98811024,0.000015811362,0.009326898,0.00030438477,0.00031941655,0.0017515509,0.000027053693,0.00006914257,0.00007548277],"genre_scores_gemma":[0.99344337,0.00009739022,0.0014681956,0.000017845958,0.000045963363,0.0002035696,0.00006287319,0.000020910278,0.0046398714],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99892366,0.00005511134,0.000299209,0.00023684031,0.00027229718,0.00021290124],"domain_scores_gemma":[0.99915606,0.00013502338,0.00010790847,0.00015389515,0.00040736477,0.000039739993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034674146,0.00011366212,0.00021228999,0.0003871314,0.00008216751,0.000012373429,0.000042071984,0.000050152517,0.000009793518],"category_scores_gemma":[0.00023119371,0.00007856697,0.00012101506,0.00075081555,0.0000773067,0.00012505772,0.00004192384,0.00014426588,0.0000081852595],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044084834,0.0003043982,0.026969103,0.0004402357,0.0001095185,0.00001489155,0.0004252073,0.00023140573,0.58225644,0.0000038536423,0.0003626592,0.3844738],"study_design_scores_gemma":[0.0019605989,0.000733643,0.1921143,0.000102393926,0.000033042503,0.0000251143,0.00017171746,0.016964601,0.78727007,0.0003249682,0.00022781071,0.000071737275],"about_ca_topic_score_codex":0.00069539127,"about_ca_topic_score_gemma":0.0013486061,"teacher_disagreement_score":0.38440207,"about_ca_system_score_codex":0.00022524883,"about_ca_system_score_gemma":0.00013090266,"threshold_uncertainty_score":0.3203868},"labels":[],"label_agreement":null},{"id":"W4362733357","doi":"10.3390/jpm13040641","title":"Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"Journal of Personalized Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Prostatectomy; Androgen receptor; Medicine; Urology; Oncology; Androgen; Internal medicine; Prostate; Cancer research; Cancer; Hormone","score_opus":0.06183051192493523,"score_gpt":0.4156451597868229,"score_spread":0.3538146478618877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362733357","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005559877,0.9774057,0.000032977725,0.002833473,0.0009188988,0.018331831,0.00034534017,0.00006016855,0.000015991245],"genre_scores_gemma":[0.000002836081,0.98823214,0.0009905513,0.000366343,0.0014325388,0.0032132687,0.0005299793,0.000289782,0.004942546],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9916147,0.0004400106,0.0042106733,0.00067879446,0.002070063,0.0009857756],"domain_scores_gemma":[0.99240935,0.0009494271,0.0038039337,0.00049233803,0.0013706824,0.00097424904],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0039107967,0.0010522029,0.011265534,0.0010417183,0.00018979145,0.000035246332,0.00045591316,0.00027344862,0.0002552985],"category_scores_gemma":[0.002487524,0.00055821607,0.002056154,0.0015338311,0.00048537628,0.0001810107,0.00007241007,0.0013396097,0.000034377517],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007816202,0.0001464997,0.000002950664,0.8916617,0.0038818584,0.00085003884,0.00078355096,3.427437e-7,0.00004048291,0.0000060071616,0.009128214,0.09271673],"study_design_scores_gemma":[0.008538708,0.0028740037,1.3748758e-7,0.68729675,0.021115705,0.0010407529,0.00037629274,0.00000928702,0.000016063279,0.000026836477,0.27839726,0.00030823032],"about_ca_topic_score_codex":0.000013833702,"about_ca_topic_score_gemma":0.0000025546528,"teacher_disagreement_score":0.26926905,"about_ca_system_score_codex":0.0013827402,"about_ca_system_score_gemma":0.003903611,"threshold_uncertainty_score":0.99968696},"labels":[],"label_agreement":null},{"id":"W4363673817","doi":"10.3390/cancers15082217","title":"Leukocytic Infiltration of Intraductal Carcinoma of the Prostate: An Exploratory Study","year":2023,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec; Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Centre Hospitalier Universitaire de Québec; Prostate Cancer Canada; Canadian Institutes of Health Research; Université Laval","keywords":"Infiltration (HVAC); Prostate; Carcinoma; Medicine; Prostate carcinoma; Pathology; Internal medicine; Materials science; Cancer","score_opus":0.05210833995826518,"score_gpt":0.33245383330349865,"score_spread":0.28034549334523345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4363673817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99828374,0.00019991603,6.499189e-7,0.00014403102,0.00017645102,0.000873305,0.000017181312,0.000023778392,0.0002809271],"genre_scores_gemma":[0.9993361,0.000068503214,0.0000051792604,0.00001833651,0.00005665679,0.00008669885,0.000020503738,0.000012667344,0.0003953027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991867,0.00005601588,0.00017492566,0.00014164708,0.0002907269,0.00015001948],"domain_scores_gemma":[0.9994553,0.000018424347,0.00006672341,0.00028185386,0.0001172743,0.000060426988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001632255,0.00007330313,0.00016300741,0.00008632816,0.000043611366,0.0000040413115,0.000086466905,0.000025749945,0.000022122316],"category_scores_gemma":[0.00002935433,0.000046363468,0.00004218548,0.00053604436,0.00015805264,0.00008560877,0.000029903464,0.00009314511,0.0000036848733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013953365,0.0002500264,0.8388677,0.0005067583,0.00024315927,0.00006613248,0.0472554,0.00054336124,0.10072386,0.00008948635,0.0024702467,0.007588497],"study_design_scores_gemma":[0.0056030974,0.0035463015,0.6919457,0.00014512947,0.00015236047,0.000006294595,0.042322647,0.0009060999,0.25487787,0.00009568988,0.0002588372,0.00014001229],"about_ca_topic_score_codex":0.0002169,"about_ca_topic_score_gemma":0.00013729469,"teacher_disagreement_score":0.154154,"about_ca_system_score_codex":0.00050132873,"about_ca_system_score_gemma":0.0014527623,"threshold_uncertainty_score":0.2577138},"labels":[],"label_agreement":null},{"id":"W4364374948","doi":"10.1200/jco.22.02661","title":"External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of British Columbia; BC Cancer Agency","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation; Yale University; Celgene; AstraZeneca; Active Biotech; Bristol-Myers Squibb","keywords":"Docetaxel; Medicine; Prostate cancer; Oncology; Internal medicine; Overall survival; Chemotherapy; Cancer; Prognostic model; Castration; Hormone","score_opus":0.19259416196254225,"score_gpt":0.49401133627255367,"score_spread":0.3014171743100114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364374948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543786,0.00024599236,0.00013045596,0.0030884396,0.000114256465,0.0005020173,0.0000215899,0.000004712422,0.0004546511],"genre_scores_gemma":[0.9954552,0.0017198689,0.0019854787,0.000055537002,0.00010493728,0.000023030889,0.0000073287015,0.000016459426,0.0006321815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971598,0.00025771884,0.0016278299,0.00014599814,0.00059550896,0.00021319183],"domain_scores_gemma":[0.9970124,0.0009079767,0.0012238261,0.00011034176,0.0005971432,0.00014835833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023443399,0.00011095709,0.0010825054,0.00021345534,0.000014619213,0.0000050822864,0.00009513192,0.000093728275,0.00004882824],"category_scores_gemma":[0.0005104236,0.00006801786,0.00016440681,0.00028581056,0.00018267272,0.00011009488,0.000019902065,0.0003915836,0.0000014809418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08914637,0.004836266,0.78172106,0.00088378636,0.0021070472,0.0013570677,0.0026863664,0.020036776,0.054151785,0.0003364224,0.0006779473,0.042059112],"study_design_scores_gemma":[0.051008653,0.026193522,0.8834365,0.0013522793,0.000809496,0.000050495575,0.0007827509,0.020502253,0.012449926,0.0030478926,0.00017297655,0.00019323122],"about_ca_topic_score_codex":0.000107125285,"about_ca_topic_score_gemma":0.000105637315,"teacher_disagreement_score":0.10171547,"about_ca_system_score_codex":0.00015416533,"about_ca_system_score_gemma":0.0031195343,"threshold_uncertainty_score":0.553392},"labels":[],"label_agreement":null},{"id":"W4364377547","doi":"10.1016/j.euf.2023.03.024","title":"Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume","year":2023,"lang":"en","type":"article","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Docetaxel; Medicine; Oncology; Androgen deprivation therapy; Prostate cancer; Internal medicine; Regimen; Cancer","score_opus":0.08434937998810367,"score_gpt":0.340308173405026,"score_spread":0.25595879341692235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364377547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89525443,0.04787393,0.0001219621,0.04626535,0.00024435544,0.0043453914,0.0020266015,0.000630881,0.0032370917],"genre_scores_gemma":[0.9675812,0.004941248,0.00004836235,0.0012128021,0.00009813211,0.00024892125,0.0016931079,0.00008602644,0.02409017],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9961904,0.0012667954,0.000541647,0.0007545578,0.0003788648,0.0008676969],"domain_scores_gemma":[0.99862933,0.00015612273,0.00016372293,0.000539354,0.00013659096,0.00037490105],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010490775,0.0003695955,0.0012291318,0.00044838182,0.00013876453,0.000048617585,0.00018913463,0.000049641116,0.0009312503],"category_scores_gemma":[0.000055955246,0.00023494127,0.0005085958,0.0027714823,0.0002281043,0.000095010684,0.00009018492,0.00041521763,0.0003396957],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.085347414,0.0013820473,0.032739494,0.00007225888,0.34365368,0.041235276,0.002888892,0.009406376,0.0033564328,0.000097615535,0.46467716,0.015143357],"study_design_scores_gemma":[0.05134427,0.009490393,0.42972594,0.000019661215,0.29234052,0.0000628127,0.00058848335,0.014667932,0.0012678283,0.00060386735,0.19772679,0.002161512],"about_ca_topic_score_codex":0.00027196977,"about_ca_topic_score_gemma":0.00021957552,"teacher_disagreement_score":0.39698645,"about_ca_system_score_codex":0.00007602747,"about_ca_system_score_gemma":0.00025327786,"threshold_uncertainty_score":0.99998206},"labels":[],"label_agreement":null},{"id":"W4365450907","doi":"10.1016/j.urolonc.2023.03.003","title":"Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide","year":2023,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Enzalutamide; Prostate cancer; Medicine; Urology; Oncology; Prostate-specific antigen; Internal medicine; Proportional hazards model; Hazard ratio; Cancer; Androgen receptor; Confidence interval","score_opus":0.09863561196560236,"score_gpt":0.4006963273397584,"score_spread":0.302060715374156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365450907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99562156,0.0005162485,0.0000036303968,0.0018779697,0.000078836056,0.0015084909,0.00024463667,0.00003705546,0.00011159828],"genre_scores_gemma":[0.99479926,0.001981195,0.002244858,0.00015871783,0.000014578712,0.0002750555,0.00028156955,0.000018576147,0.00022620943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977392,0.00045844156,0.0006658587,0.0003889138,0.0003454803,0.00040213738],"domain_scores_gemma":[0.99821925,0.0008628986,0.00032537812,0.00018152203,0.00022774385,0.00018319837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006364259,0.00022117063,0.00065299537,0.00046428395,0.00012568488,0.000010862908,0.00007479046,0.00012608236,0.000035631285],"category_scores_gemma":[0.0002716994,0.00016356002,0.000052594973,0.0010237327,0.0008237614,0.000088563465,0.000050288418,0.00032028815,0.000010629523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024761533,0.00091010355,0.95385593,0.0001265821,0.00015081541,0.00039698745,0.008861552,0.0013439882,0.0055835107,0.00023099434,0.00039361572,0.003384384],"study_design_scores_gemma":[0.007854577,0.031381965,0.9181185,0.0004682284,0.00020675322,0.000019694664,0.0044549834,0.002619581,0.020433307,0.00074779853,0.013401182,0.0002934747],"about_ca_topic_score_codex":0.00017044839,"about_ca_topic_score_gemma":0.00014676481,"teacher_disagreement_score":0.035737477,"about_ca_system_score_codex":0.00028319663,"about_ca_system_score_gemma":0.0007560375,"threshold_uncertainty_score":0.6669784},"labels":[],"label_agreement":null},{"id":"W4366259777","doi":"10.1002/pros.24512","title":"Implications of metastatic stage at presentation in docetaxel naïve metastatic castrate resistant prostate cancer","year":2023,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Ottawa; University Health Network; University of Toronto; Ottawa Hospital; Ottawa Regional Cancer Foundation; Mount Sinai Hospital","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Oncology; Stage (stratigraphy); Internal medicine; Prostate; Cancer","score_opus":0.08633119737678237,"score_gpt":0.40273691542072254,"score_spread":0.3164057180439402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366259777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821612,0.0016125303,0.00000885689,0.010488999,0.00007708646,0.0033705488,0.0011102894,0.00012557638,0.0010448894],"genre_scores_gemma":[0.9616202,0.0033478392,0.00020139021,0.00009903571,0.000020917958,0.0014833733,0.00039300445,0.000056312696,0.03277792],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975432,0.0002165632,0.0006345573,0.0004146064,0.00052720297,0.0006638596],"domain_scores_gemma":[0.99853015,0.0002503792,0.00026432367,0.0005581585,0.00024340805,0.00015359711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082492596,0.00024981028,0.00045925254,0.00035237955,0.00019353558,0.000036818434,0.00018978452,0.000029384259,0.00019920824],"category_scores_gemma":[0.00008654601,0.00015881484,0.00011515007,0.00161502,0.00030960853,0.00017065201,0.00014814902,0.00025000132,0.00009907847],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02029402,0.0018415683,0.21494895,0.0075197658,0.0031872485,0.0015458514,0.06136653,0.0083013205,0.6280523,0.0033069546,0.015492393,0.034143128],"study_design_scores_gemma":[0.019023374,0.0016507194,0.8103734,0.0009788718,0.0011608397,0.00008136062,0.007601919,0.0055293315,0.13336907,0.0129069695,0.0065018786,0.0008222406],"about_ca_topic_score_codex":0.0012286135,"about_ca_topic_score_gemma":0.0011578925,"teacher_disagreement_score":0.5954245,"about_ca_system_score_codex":0.0003421051,"about_ca_system_score_gemma":0.00047082582,"threshold_uncertainty_score":0.6476281},"labels":[],"label_agreement":null},{"id":"W4366351773","doi":"10.1002/cjp2.319","title":"Cell‐by‐cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression","year":2023,"lang":"en","type":"article","venue":"The Journal of Pathology Clinical Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Prostate Cancer Canada; McGill University","keywords":"Prostate cancer; Androgen receptor; Androgen deprivation therapy; Medicine; Prostate; Androgen; Hormonal therapy; Cancer research; Immunohistochemistry; Prostatectomy; Cancer; Internal medicine; Pathology; Endocrinology; Hormone","score_opus":0.3156840177308059,"score_gpt":0.5111032720403144,"score_spread":0.19541925430950846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366351773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9645809,0.0013399281,0.000022996837,0.0330813,0.000072135124,0.000850133,0.000026853084,0.0000024480446,0.000023334811],"genre_scores_gemma":[0.9910762,0.008432034,0.000085736036,0.00011442376,0.00005112691,0.000027684837,0.0000043098944,0.000009629312,0.0001988866],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99757266,0.0010098359,0.00052264606,0.0001616725,0.00046583466,0.0002673462],"domain_scores_gemma":[0.99804294,0.0011015604,0.00021210389,0.00017795521,0.00033264182,0.00013278158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007981025,0.00007218088,0.0003016006,0.00031380745,0.00008877231,0.000009284234,0.000143789,0.00010864783,0.000010860272],"category_scores_gemma":[0.00068771007,0.000036066514,0.00003720059,0.000664091,0.00040646238,0.00003516414,0.00016952994,0.00052515336,0.000002759162],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037337835,0.00022407348,0.34520808,0.00024880454,0.000026913167,0.000036395486,0.004798768,0.0000074119766,0.63375837,0.000013301043,0.00345325,0.00849088],"study_design_scores_gemma":[0.008642293,0.0124407625,0.5712112,0.002655174,0.00015480407,0.00005785288,0.007203222,0.00019397135,0.39521813,0.0012393666,0.00079176837,0.0001914481],"about_ca_topic_score_codex":0.000017168697,"about_ca_topic_score_gemma":0.00003628825,"teacher_disagreement_score":0.23854022,"about_ca_system_score_codex":0.00008697328,"about_ca_system_score_gemma":0.00021424703,"threshold_uncertainty_score":0.276608},"labels":[],"label_agreement":null},{"id":"W4366416287","doi":"10.1016/j.urolonc.2023.03.013","title":"Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study","year":2023,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Urology; Oncology; Proportional hazards model; Prostate-specific antigen; Internal medicine; Hazard ratio; Enzalutamide; Biochemical recurrence; Cohort; Androgen deprivation therapy; Cancer; Androgen receptor; Prostatectomy; Confidence interval","score_opus":0.0770773440475049,"score_gpt":0.3936441231716296,"score_spread":0.31656677912412473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366416287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943625,0.00012548505,0.0000012195854,0.0013996188,0.00007010965,0.0037129354,0.00017603986,0.0000641279,0.00008797342],"genre_scores_gemma":[0.99722487,0.00036924507,0.00088002306,0.00012662062,0.00001508981,0.00063461706,0.0002952719,0.000025412995,0.0004288641],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975315,0.0005336074,0.0005148942,0.00056124735,0.00042993765,0.00042884212],"domain_scores_gemma":[0.99858224,0.00041190948,0.00026562615,0.00021439583,0.00034361362,0.00018219475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077561225,0.0002714118,0.0007906325,0.00050679035,0.0002024764,0.000023239536,0.00006744865,0.000102677404,0.00003947811],"category_scores_gemma":[0.00017600221,0.0001780955,0.00002944466,0.001327732,0.00077229535,0.00012782036,0.000040925854,0.00043148163,0.000013961572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03451954,0.0014967886,0.9549537,0.000034261113,0.00026969155,0.0005776346,0.006509671,0.00052223244,0.00047917684,0.000040813826,0.00030055037,0.00029596314],"study_design_scores_gemma":[0.0072511574,0.033157796,0.95371056,0.00014333098,0.00017719473,0.000010098527,0.0030755016,0.00029281413,0.0010181189,0.00009804606,0.0008947729,0.00017062316],"about_ca_topic_score_codex":0.00017108941,"about_ca_topic_score_gemma":0.00028765557,"teacher_disagreement_score":0.031661008,"about_ca_system_score_codex":0.0004485232,"about_ca_system_score_gemma":0.0007319097,"threshold_uncertainty_score":0.72625244},"labels":[],"label_agreement":null},{"id":"W4366586230","doi":"10.1186/s12885-023-10851-0","title":"The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).","year":2023,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Lawson Health Research Institute; London Health Sciences Centre; Western University","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; London Health Sciences Foundation","keywords":"Medicine; Prostate cancer; Brachytherapy; Radiation therapy; Radionuclide therapy; Prostate; Oncology; Cancer; Radiology; Nuclear medicine; Internal medicine","score_opus":0.08026402452094256,"score_gpt":0.36129736294256143,"score_spread":0.2810333384216189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366586230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9454734,0.03710715,0.0002578342,0.0014929386,0.00052627164,0.014550598,0.00047465166,0.00010470922,0.00001244177],"genre_scores_gemma":[0.870998,0.107045025,0.00011897922,0.000334981,0.00036514134,0.019081414,0.00015830151,0.00008939414,0.0018087444],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972041,0.00043290362,0.0006453174,0.0006075231,0.00049214676,0.00061800895],"domain_scores_gemma":[0.99754936,0.0007337529,0.00037843126,0.00047386243,0.0007009846,0.00016364265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009034746,0.0004313026,0.0008876314,0.0002059105,0.0004201143,0.0001185492,0.00014327155,0.0000925495,0.000057643014],"category_scores_gemma":[0.00009770075,0.00022781736,0.00025195512,0.0007059884,0.0005183863,0.00026107286,0.000035038727,0.00020567302,0.0000039281917],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7082693,0.002086546,0.008255018,0.000145384,0.0018552755,0.00004145502,0.007990797,0.00049316796,0.0017292836,0.000029811166,0.0011026303,0.26800132],"study_design_scores_gemma":[0.89120334,0.020595642,0.01238655,0.0011125113,0.0006993698,0.000016246091,0.0005390057,0.0016349738,0.01824536,0.00013852684,0.05271567,0.00071281515],"about_ca_topic_score_codex":0.000624805,"about_ca_topic_score_gemma":0.0009914192,"teacher_disagreement_score":0.2672885,"about_ca_system_score_codex":0.0004106015,"about_ca_system_score_gemma":0.0012983216,"threshold_uncertainty_score":0.92901224},"labels":[],"label_agreement":null},{"id":"W4366742703","doi":"10.1002/1878-0261.13441","title":"Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic–mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer","year":2023,"lang":"en","type":"article","venue":"Molecular Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; Université Laval","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Institute of Cancer Research; Canada Foundation for Innovation","keywords":"Isocitrate dehydrogenase; Citric acid cycle; Tricarboxylic acid; Prostate cancer; Mitochondrion; IDH1; Cytoplasm; Cancer research; Biochemistry; Chemistry; Biology; Enzyme; Cancer; Medicine; Internal medicine; Gene","score_opus":0.03511277330948553,"score_gpt":0.3543559853976431,"score_spread":0.3192432120881576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366742703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97555673,0.002842444,0.000094651616,0.016983425,0.00034009956,0.0035072644,0.0002666172,0.00015466126,0.00025407702],"genre_scores_gemma":[0.99124205,0.0014367503,0.00015458002,0.0017341053,0.00012754074,0.0031687056,0.0004784445,0.00008535155,0.0015724659],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99758804,0.0001910362,0.00031866334,0.00056930404,0.00031292657,0.0010200591],"domain_scores_gemma":[0.99907684,0.00012949794,0.000103833205,0.00030313194,0.00014585479,0.00024085878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023138475,0.0002859356,0.00058991986,0.00044333327,0.00012494113,0.000028494094,0.00016616286,0.0001548143,0.00004482233],"category_scores_gemma":[0.000079574966,0.00024088255,0.00021025894,0.0007800296,0.00017641232,0.00005286123,0.00007693886,0.00032378585,0.000011735648],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008057549,0.00079396093,0.0078095417,0.00035657117,0.0009893314,0.0096878065,0.0024886732,0.00059737824,0.9442647,0.00025976606,0.0036771635,0.021017557],"study_design_scores_gemma":[0.026708687,0.003197292,0.0020769907,0.00007895013,0.0003728056,0.00011356848,0.0009796888,0.0052096965,0.9275642,0.0024374838,0.03072577,0.0005348638],"about_ca_topic_score_codex":0.00036397701,"about_ca_topic_score_gemma":0.0004977126,"teacher_disagreement_score":0.027048606,"about_ca_system_score_codex":0.0010136975,"about_ca_system_score_gemma":0.0016672,"threshold_uncertainty_score":0.98229057},"labels":[],"label_agreement":null},{"id":"W4366754119","doi":"10.1016/j.clgc.2023.04.007","title":"Association between RCT methodology and disease indication with mineralocorticoid-related toxicity for patients receiving abiraterone acetate for advanced prostate cancer: A meta-analysis of RCTs","year":2023,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Medicine; Hypokalemia; Cardiotoxicity; Internal medicine; Prostate cancer; Randomized controlled trial; Placebo; Abiraterone acetate; Odds ratio; Meta-analysis; Cancer; Gastroenterology; Androgen deprivation therapy; Chemotherapy; Pathology","score_opus":0.36135703015794335,"score_gpt":0.5240024488816203,"score_spread":0.16264541872367694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366754119","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05038734,0.93231666,0.00013550036,0.00117113,0.0002620751,0.009814934,0.0058404505,0.000067696186,0.0000042305282],"genre_scores_gemma":[0.00094277173,0.9771315,0.0018830969,0.000068537665,0.00024394326,0.010612768,0.0036032952,0.00012885303,0.005385251],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99494296,0.000860493,0.0020170973,0.0010988425,0.00047504605,0.0006055776],"domain_scores_gemma":[0.9911095,0.004658941,0.0024253663,0.00046691805,0.0008223725,0.0005169026],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019062153,0.0005557398,0.0058739022,0.00055540167,0.00013883995,0.000029477967,0.00018213675,0.00047571817,0.00003228364],"category_scores_gemma":[0.0019267999,0.00036043694,0.0020783332,0.0012827738,0.00018801542,0.00015158109,0.000109548404,0.00046395688,0.0000016037116],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003074296,0.00049393356,0.06954593,0.020345787,0.3586547,0.000013909301,0.00011888625,0.000060447837,0.000004597874,0.000001907729,0.00064288767,0.54704267],"study_design_scores_gemma":[0.00697487,0.0027887928,0.038215872,0.0020986882,0.90008587,4.9334545e-7,0.000013758168,0.000077652316,0.000013962119,0.00011941055,0.049032893,0.0005777181],"about_ca_topic_score_codex":0.00006676909,"about_ca_topic_score_gemma":0.00010102155,"teacher_disagreement_score":0.546465,"about_ca_system_score_codex":0.00062007544,"about_ca_system_score_gemma":0.0013146538,"threshold_uncertainty_score":0.9998848},"labels":[],"label_agreement":null},{"id":"W4366775212","doi":"10.3390/curroncol30040332","title":"Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Princess Margaret Cancer Centre; University of Toronto","funders":"EMD Serono; Ipsen; Sanofi; AstraZeneca; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Docetaxel; Medicine; Androgen deprivation therapy; Prostate cancer; Oncology; Abiraterone acetate; Clinical trial; Cancer; Internal medicine; Chemotherapy","score_opus":0.2695851696005563,"score_gpt":0.5303513720860599,"score_spread":0.2607662024855036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366775212","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009295358,0.9915233,0.000005364882,0.00021496393,0.0014054081,0.00415768,0.0015916028,0.000041949388,0.0001301407],"genre_scores_gemma":[0.00012932255,0.99652785,0.000056358578,0.000010480139,0.00033341834,0.0005244416,0.0012200044,0.00009112994,0.0011069686],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99687284,0.00049454224,0.000914402,0.00060984294,0.00046737114,0.00064098166],"domain_scores_gemma":[0.99840075,0.00019118362,0.0004761973,0.00031108604,0.0003664988,0.00025427446],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032463574,0.00049826707,0.0035145583,0.0006321128,0.00004335825,0.00001475083,0.00015307206,0.00024289337,0.00013820775],"category_scores_gemma":[0.0000572299,0.00034501497,0.0005142904,0.00086049584,0.00020855191,0.000044865104,0.00009258074,0.0009059974,0.00003961407],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017954244,0.00018602093,0.00006448652,0.021821376,0.0007570252,0.0010573466,0.0013875737,0.000003066067,0.0000028477757,0.0000105993195,0.0017798782,0.97113436],"study_design_scores_gemma":[0.007560351,0.0034665118,0.000054197986,0.016791234,0.001443358,0.00007456228,0.00061375165,0.0000051577113,0.000039048195,0.000041588148,0.9696242,0.0002859987],"about_ca_topic_score_codex":0.0002723124,"about_ca_topic_score_gemma":0.00044246783,"teacher_disagreement_score":0.9708484,"about_ca_system_score_codex":0.0016441231,"about_ca_system_score_gemma":0.009801912,"threshold_uncertainty_score":0.99990016},"labels":[],"label_agreement":null},{"id":"W4366814658","doi":"10.1016/j.clgc.2023.04.008","title":"Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Chemotherapy; Internal medicine; Oncology; Taxane; Cancer; Breast cancer","score_opus":0.10718751538685452,"score_gpt":0.4346031280357007,"score_spread":0.3274156126488462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366814658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465483,0.0016682815,0.0000013534171,0.0011300276,0.00020394972,0.0019657488,0.00032070623,0.000042624484,0.00001245525],"genre_scores_gemma":[0.98927283,0.006668261,0.00019524677,0.000121196965,0.00007506357,0.00078002317,0.00006939703,0.000032129352,0.00278584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981083,0.00014584814,0.0005762664,0.0004377102,0.00031650515,0.00041535345],"domain_scores_gemma":[0.99911124,0.00017468979,0.00012356573,0.00023939555,0.00014390133,0.00020720807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017952993,0.0002616878,0.0006970298,0.00020291728,0.00007823701,0.000009198006,0.00007844047,0.000026175876,0.00015591407],"category_scores_gemma":[0.00004787515,0.00015256043,0.0000994267,0.0004599143,0.00025086096,0.00008217476,0.00007840641,0.00020170235,0.000004011132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004361321,0.0044566677,0.96018267,0.00010410146,0.001032398,0.00090932386,0.0005409834,0.00014078009,0.000055002536,0.0000010366629,0.00006322742,0.028152486],"study_design_scores_gemma":[0.02851667,0.0059695463,0.9637524,0.00007664919,0.00023917125,0.00000576021,0.00045182716,0.00017105439,0.00013675127,0.0000068065283,0.00053735095,0.0001360078],"about_ca_topic_score_codex":0.00043653543,"about_ca_topic_score_gemma":0.001278845,"teacher_disagreement_score":0.02801648,"about_ca_system_score_codex":0.00020574649,"about_ca_system_score_gemma":0.00060957106,"threshold_uncertainty_score":0.62212336},"labels":[],"label_agreement":null},{"id":"W4366820616","doi":"10.1007/978-3-031-26163-3_16","title":"The “Ins and Outs” of Prostate Specific Membrane Antigen (PSMA) as Specific Target in Prostate Cancer Therapy","year":2023,"lang":"en","type":"article","venue":"Advances in experimental medicine and biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Prostate; Medicine; Cancer research; Glutamate carboxypeptidase II; Antibody; Antigen; PCA3; Prostate-specific antigen; Androgen deprivation therapy; Cancer; Internal medicine; Pathology; Immunology","score_opus":0.05405772778079242,"score_gpt":0.4101962047419896,"score_spread":0.35613847696119716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366820616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7236173,0.271359,2.6613475e-7,0.0029749458,0.00022555847,0.00071814965,0.000011991084,0.00001598393,0.001076784],"genre_scores_gemma":[0.5960361,0.40322393,0.000029561472,0.00009620173,0.00008008328,0.00012679587,0.000038911494,0.000010977453,0.00035745054],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99862087,0.00007857883,0.00035963542,0.00037718358,0.0001447425,0.00041897869],"domain_scores_gemma":[0.99946296,0.00016635057,0.00008067529,0.00016451192,0.000035193625,0.0000902953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031561663,0.0001898426,0.00043334233,0.00021961442,0.00008329448,0.0000061921564,0.00008437365,0.000058060865,0.000107298176],"category_scores_gemma":[0.000019069055,0.00010192388,0.000024671928,0.00045850145,0.0011124841,0.00009479207,0.00006807554,0.00017984785,0.0000049473783],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043588,0.000216517,0.41541,0.00009432772,0.00006210038,0.00019029487,0.010160472,0.0000037056727,0.4767973,0.00063965225,0.0005477408,0.09151906],"study_design_scores_gemma":[0.021054043,0.0072504883,0.07763091,0.0008077264,0.0000098998735,0.00007625796,0.030348724,0.000066940214,0.4213324,0.0025994885,0.43841553,0.00040760922],"about_ca_topic_score_codex":0.00019106967,"about_ca_topic_score_gemma":0.000049304548,"teacher_disagreement_score":0.4378678,"about_ca_system_score_codex":0.00005916494,"about_ca_system_score_gemma":0.00004966014,"threshold_uncertainty_score":0.4156335},"labels":[],"label_agreement":null},{"id":"W4367367470","doi":"10.1038/s41416-023-02289-9","title":"Precision medicine for prostate cancer—improved outcome prediction for low-intermediate risk disease using a six-gene copy number alteration classifier","year":2023,"lang":"en","type":"editorial","venue":"British Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Prostate cancer; Classifier (UML); Medicine; Oncology; Cohort; Internal medicine; Pathology; Artificial intelligence; Computer science; Cancer","score_opus":0.03510274844559041,"score_gpt":0.39934056784165556,"score_spread":0.36423781939606514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367367470","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03604871,0.020965375,0.0034769175,0.000929416,0.9077478,0.005465696,0.025271151,0.00008389094,0.000011050524],"genre_scores_gemma":[0.008775945,0.11509285,0.000723701,0.00009669401,0.86283153,0.0020330485,0.0028187525,0.00036369756,0.007263774],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99526685,0.00012765067,0.0017021799,0.0006486741,0.0015226648,0.0007319477],"domain_scores_gemma":[0.9929742,0.0009426735,0.001642806,0.00026216672,0.0035141974,0.00066395145],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013501392,0.00047856887,0.0013523492,0.00031244036,0.0003464023,0.00017661812,0.00024708323,0.0005326223,0.00016964546],"category_scores_gemma":[0.0032160026,0.00041339092,0.0005944838,0.00029639393,0.00020643482,0.00036749232,0.00006048829,0.0011297433,0.0000026020373],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019120043,0.00018144441,0.009617141,0.002445467,0.0011942333,0.00034678075,0.00018401322,0.000257304,0.0010904442,2.7042248e-7,0.9103509,0.05521192],"study_design_scores_gemma":[0.06333162,0.004160891,0.010777278,0.036947995,0.009274068,0.00014701576,0.00016289276,0.01726048,0.0018015062,0.00045040585,0.8545939,0.0010919513],"about_ca_topic_score_codex":0.0012127635,"about_ca_topic_score_gemma":0.000781044,"teacher_disagreement_score":0.094127476,"about_ca_system_score_codex":0.0019210184,"about_ca_system_score_gemma":0.0033759668,"threshold_uncertainty_score":0.9998318},"labels":[],"label_agreement":null},{"id":"W4367675055","doi":"10.1016/j.euros.2023.03.016","title":"Oligometastasis in Prostate Cancer: Can We Learn from Those “Excluded” from a Phase 2 Trial?","year":2023,"lang":"en","type":"article","venue":"European Urology Open Science","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Mount Sinai Hospital; University of Toronto; University Health Network; Princess Margaret Cancer Centre; Women's College Hospital","funders":"Terry Fox Research Institute; University of Toronto; Princess Margaret Cancer Foundation; Canadian Association of Radiation Oncology","keywords":"Medicine; Prostate cancer; Prostatectomy; Glutamate carboxypeptidase II; Interquartile range; Positron emission tomography; Radiation therapy; Oncology; Population; Prostate; Metastasis; Cancer; Disease; Prostate-specific antigen; Internal medicine; Radiology","score_opus":0.11280095259054927,"score_gpt":0.4241051715384329,"score_spread":0.3113042189478836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367675055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9693973,0.0013106011,0.0000025838565,0.018419694,0.00048083978,0.001735517,0.00046707538,0.00010188017,0.008084484],"genre_scores_gemma":[0.9883409,0.003472239,0.000209709,0.0012263125,0.00019260544,0.00016610767,0.00019949216,0.000046705303,0.006145891],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965969,0.00050259643,0.0004014855,0.001084321,0.0005592546,0.0008554975],"domain_scores_gemma":[0.9984697,0.00019977425,0.00011961823,0.00071827194,0.00011099914,0.00038161056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002207554,0.0002255558,0.0004711489,0.00052733114,0.00029360334,0.00020597233,0.0014672835,0.00003598048,0.0006253251],"category_scores_gemma":[0.00038589237,0.00017181822,0.000060584563,0.0025234052,0.00096188963,0.00031121343,0.0013239367,0.00043018773,0.0007732844],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.103964984,0.0023322552,0.07157528,0.00004307001,0.0004185713,0.016007282,0.02371076,0.0001982259,0.10747114,0.00012291415,0.017598256,0.65655726],"study_design_scores_gemma":[0.4042442,0.009486877,0.23631735,0.00045918993,0.00041323472,0.000042861793,0.0030863849,0.0027831385,0.021501126,0.0022982738,0.317996,0.0013713748],"about_ca_topic_score_codex":0.005428413,"about_ca_topic_score_gemma":0.000742512,"teacher_disagreement_score":0.6551859,"about_ca_system_score_codex":0.00018650485,"about_ca_system_score_gemma":0.0010543059,"threshold_uncertainty_score":0.99392647},"labels":[],"label_agreement":null},{"id":"W4368341762","doi":"10.21203/rs.3.rs-2859809/v1","title":"RETRACTED: SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":true,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Androgen receptor; Prostate cancer; Androgen; Domain (mathematical analysis); Cancer research; Terminal (telecommunication); Cancer; Castration; Medicine; Internal medicine; Oncology; Endocrinology; Hormone; Computer science","score_opus":0.07692367466402927,"score_gpt":0.41840432878780964,"score_spread":0.34148065412378037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4368341762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698365,0.0060361386,0.0000024356593,0.016076623,0.00029637717,0.005321049,0.0018091586,0.00012388556,0.00049787416],"genre_scores_gemma":[0.97604716,0.008431158,0.000111305075,0.00003349323,0.00067517365,0.003050859,0.0016068233,0.00014701832,0.009896983],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9925789,0.0011807989,0.000616953,0.0012427513,0.0027488729,0.0016317193],"domain_scores_gemma":[0.9969489,0.000622832,0.00020726093,0.00085733325,0.0009166204,0.0004470818],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004752929,0.00048747228,0.00070574606,0.0006479652,0.00058355636,0.000324328,0.00046802455,0.0006419517,0.00033427676],"category_scores_gemma":[0.00064685114,0.00033203195,0.00022136798,0.0014335434,0.0005420873,0.00017933114,0.0009195974,0.0054689306,0.00012615517],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016101042,0.002040415,0.13460849,0.012207254,0.0010554397,0.004736034,0.01079766,0.0001472499,0.61060315,0.00006141154,0.17872447,0.02891737],"study_design_scores_gemma":[0.02375296,0.005724537,0.27333668,0.040705614,0.00037514538,0.00012781828,0.020795722,0.0020279025,0.5269614,0.004283839,0.09800023,0.0039081713],"about_ca_topic_score_codex":0.0061888946,"about_ca_topic_score_gemma":0.001779278,"teacher_disagreement_score":0.13872817,"about_ca_system_score_codex":0.0021519284,"about_ca_system_score_gemma":0.003192908,"threshold_uncertainty_score":0.99991316},"labels":[],"label_agreement":null},{"id":"W4368361249","doi":"10.1158/1535-7163.mct-22-0237","title":"Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Androgen receptor; Transactivation; Prostate cancer; Enzalutamide; Cancer research; Androgen; Chemistry; Transcription factor; Biology; Cell biology; Cancer; Endocrinology; Gene; Genetics; Biochemistry; Hormone","score_opus":0.0386941703284861,"score_gpt":0.33365179603329276,"score_spread":0.29495762570480666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4368361249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816803,0.009467356,0.0003957363,0.0057954057,0.00024980077,0.0018211498,0.0004709498,0.000052498915,0.00006682861],"genre_scores_gemma":[0.9915415,0.0028574842,0.0006608567,0.0006764211,0.00027009536,0.0016015527,0.00024536424,0.0000926823,0.0020540182],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983707,0.00007476814,0.00034388225,0.0003335355,0.00038980713,0.00048728072],"domain_scores_gemma":[0.9991746,0.000069730966,0.0001472331,0.0002898253,0.00024374637,0.0000748541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029719033,0.00022233224,0.0003013603,0.00009860847,0.00018268713,0.0000573596,0.0001527392,0.000084871295,0.000021511341],"category_scores_gemma":[0.00001459077,0.00014692561,0.00020012814,0.00049919536,0.00018540991,0.000062155596,0.000054407956,0.00016701859,0.0000038194344],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018711975,0.00008894777,0.0019902154,0.00035743098,0.0005999216,0.00007911877,0.0014503397,0.000068341375,0.9876775,0.00013664251,0.0006167588,0.005063567],"study_design_scores_gemma":[0.0034453236,0.00060531945,0.0006818479,0.00032193708,0.00034459136,0.000006443259,0.00094487437,0.0005040013,0.97876745,0.00028716962,0.0138452565,0.00024576052],"about_ca_topic_score_codex":0.00017597376,"about_ca_topic_score_gemma":0.00007421999,"teacher_disagreement_score":0.013228498,"about_ca_system_score_codex":0.0002018982,"about_ca_system_score_gemma":0.0006705265,"threshold_uncertainty_score":0.59914523},"labels":[],"label_agreement":null},{"id":"W4376271805","doi":"10.1101/2023.05.10.540238","title":"Ultrastructural analysis of prostate cancer tissue provides insights into androgen-dependent adaptations to membrane contact site establishment","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Council South Australia; Queen's University; Prostate Cancer Foundation of Australia; Queen's University Belfast; Rosetrees Trust; Government of South Australia; Movember Foundation; Prostate Cancer Foundation","keywords":"Prostate cancer; Enzalutamide; Organelle; Mitochondrion; Cancer; Prostate; Biology; Cancer research; Pathology; Internal medicine; Cell biology; Medicine; Androgen receptor","score_opus":0.022782018898508314,"score_gpt":0.2904580115097456,"score_spread":0.26767599261123726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376271805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99056256,0.0031169744,0.00012917421,0.00097293855,0.00057414564,0.0031435646,0.0012249772,0.0002710344,0.0000046495593],"genre_scores_gemma":[0.99397427,0.0026398941,0.0014857337,0.00010242588,0.00018699234,0.0013236369,0.000023117074,0.00013377753,0.0001301794],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961346,0.00012652793,0.0008337468,0.0012309453,0.0010166621,0.00065753097],"domain_scores_gemma":[0.9964221,0.00010514147,0.0004264381,0.0011442965,0.0012688347,0.00063319405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033867566,0.00061813544,0.0013292579,0.0016125705,0.00017588671,0.00016757929,0.0003446796,0.0003232494,0.00011603691],"category_scores_gemma":[0.00016900068,0.000527886,0.0002850011,0.002552161,0.00012255112,0.00018120675,0.00038788829,0.0005921671,0.000037280006],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059205206,0.00020289997,0.078628585,0.0012014138,0.0050719366,0.0002326021,0.00064073293,0.0017839829,0.91143876,0.000051869512,0.000119639095,0.000035512876],"study_design_scores_gemma":[0.001331748,0.0003363018,0.36082104,0.00073834416,0.0031321882,1.9123283e-8,0.000042458854,0.00060425367,0.631484,0.0000017013042,0.0009967606,0.0005112236],"about_ca_topic_score_codex":0.0040753903,"about_ca_topic_score_gemma":0.00067392585,"teacher_disagreement_score":0.28219244,"about_ca_system_score_codex":0.0010228952,"about_ca_system_score_gemma":0.0016935196,"threshold_uncertainty_score":0.9997173},"labels":[],"label_agreement":null},{"id":"W4376286734","doi":"10.1016/j.eururo.2023.04.031","title":"Re: Darolutamide plus Androgen-deprivation Therapy and Docetaxel in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial","year":2023,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Hazard ratio; Prostate cancer; Docetaxel; Prednisone; Abiraterone acetate; Internal medicine; Oncology; Proportional hazards model; Confidence interval; Androgen deprivation therapy; Enzalutamide; Cancer","score_opus":0.03953950541478287,"score_gpt":0.3162875686684111,"score_spread":0.2767480632536283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376286734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8129657,0.01164572,0.000005947501,0.17138737,0.0001379451,0.0029022952,0.0008154917,0.00004333982,0.0000961798],"genre_scores_gemma":[0.79893154,0.0897151,0.000016823942,0.10338418,0.0014119056,0.0005457451,0.0033158357,0.00024033165,0.0024385129],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956071,0.0020736805,0.0005106081,0.0008089728,0.00037162867,0.0006280129],"domain_scores_gemma":[0.9986808,0.00046727344,0.00024707481,0.00040830649,0.00006037778,0.00013619725],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011719317,0.00041313758,0.00070952455,0.00036703487,0.00011931837,0.00006153934,0.00013989717,0.00013884991,0.000016468102],"category_scores_gemma":[0.00020662892,0.0002792538,0.00007964528,0.00037745293,0.00043452342,0.00008134931,0.00009736664,0.0016596939,0.000020026899],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2513721,0.00071009714,0.015478413,0.00025373252,0.0012123743,0.052141324,0.012523928,0.000030760562,0.00045175885,0.0000042046754,0.6455844,0.020236878],"study_design_scores_gemma":[0.49026528,0.00818101,0.09715789,0.00017414957,0.0015122787,0.00014297749,0.00076932565,0.0026048876,0.00004359252,0.00025485124,0.39777488,0.0011188652],"about_ca_topic_score_codex":0.00059702125,"about_ca_topic_score_gemma":0.0001558899,"teacher_disagreement_score":0.24780954,"about_ca_system_score_codex":0.00012966421,"about_ca_system_score_gemma":0.00020882682,"threshold_uncertainty_score":0.99996597},"labels":[],"label_agreement":null},{"id":"W4376636211","doi":"10.1002/minf.202300026","title":"Novel Inhibitors of androgen receptor's DNA binding domain identified using an ultra‐large virtual screening","year":2023,"lang":"en","type":"article","venue":"Molecular Informatics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"DOD Prostate Cancer Research Program; Canadian Cancer Society Research Institute; U.S. Department of Defense","keywords":"Androgen receptor; Virtual screening; Computational biology; Chemistry; Domain (mathematical analysis); DNA; Computer science; Biology; Genetics; Drug discovery; Biochemistry; Prostate cancer; Mathematics","score_opus":0.04133740417371557,"score_gpt":0.3232444522595325,"score_spread":0.28190704808581696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376636211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98482347,0.0000366314,0.0138315465,0.000049292044,0.00013889122,0.00042496622,0.00008698259,0.00008924104,0.00051898713],"genre_scores_gemma":[0.99098617,0.000035472716,0.007934826,0.00008069023,0.0000580633,0.000012102114,0.00067543663,0.000040739087,0.00017651908],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99827355,0.000028012995,0.0005290399,0.00011909469,0.0006087825,0.0004415479],"domain_scores_gemma":[0.9992027,0.000027931997,0.00016330194,0.00029631876,0.00012233606,0.00018741043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005669258,0.00016437212,0.0002845143,0.0004336893,0.00014010142,0.000047673966,0.00012396468,0.00011448332,0.000026945156],"category_scores_gemma":[0.000065206994,0.00014415802,0.00011759855,0.0008162015,0.00008077099,0.00030844324,0.000070031674,0.0001802696,0.000040488758],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000121514386,0.00012569678,0.0020334052,0.00023346137,0.00019824604,0.000049863396,0.0043078526,0.00029061013,0.99051166,0.00015867426,0.00023028244,0.0017387457],"study_design_scores_gemma":[0.0039886246,0.000359453,0.00025472284,0.0003929258,0.00008990113,0.000042581516,0.010372184,0.0078087174,0.97519934,0.00002472397,0.0012420956,0.00022475237],"about_ca_topic_score_codex":0.00001469858,"about_ca_topic_score_gemma":0.0000012532427,"teacher_disagreement_score":0.01531233,"about_ca_system_score_codex":0.00009010464,"about_ca_system_score_gemma":0.0001532535,"threshold_uncertainty_score":0.58785933},"labels":[],"label_agreement":null},{"id":"W4376877160","doi":"10.1038/s41388-023-02718-2","title":"Palmitoyl acyltransferase ZDHHC7 inhibits androgen receptor and suppresses prostate cancer","year":2023,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Prostate Cancer Foundation; Center for Scientific Review; U.S. Department of Health and Human Services; U.S. Department of Defense","keywords":"Biology; Prostate cancer; Androgen receptor; Cancer research; Transcription factor; Cell cycle; Palmitoylation; Zinc finger; Cell biology; Cell growth; Enzalutamide; Cell; Endocrinology; Cancer; Gene; Genetics; Biochemistry","score_opus":0.031084195036626766,"score_gpt":0.335926174998719,"score_spread":0.3048419799620923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376877160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863944,0.007062696,0.0000020661196,0.004401703,0.00017003523,0.0006938225,0.00028743845,0.00015773205,0.00083008443],"genre_scores_gemma":[0.9496946,0.034842335,0.00012860584,0.00022811916,0.00031679956,0.00032215557,0.00036526346,0.000054602664,0.014047536],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872684,0.000032378357,0.00016848491,0.00034880798,0.0002929251,0.00043055695],"domain_scores_gemma":[0.9993702,0.000049288137,0.000022833872,0.0001809086,0.00010250093,0.0002742483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013543744,0.00016929237,0.00025832516,0.00013581089,0.0001238188,0.000032478874,0.000055222496,0.00007901287,0.0004132944],"category_scores_gemma":[0.000028284263,0.00012619406,0.000055728215,0.00045681908,0.00011124298,0.00008592147,0.00005433687,0.0001346292,0.00015767149],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010042562,0.00013729402,0.07312924,0.00041183396,0.00026727578,0.0003356267,0.0013529217,0.0000040445093,0.81021106,0.000012919149,0.020614358,0.092519194],"study_design_scores_gemma":[0.004293599,0.0004267002,0.0050186194,0.00022975447,0.000106377294,0.000034999677,0.00022645798,0.000043438034,0.90983623,0.000045723293,0.07952801,0.00021007267],"about_ca_topic_score_codex":0.00012102515,"about_ca_topic_score_gemma":0.00004532994,"teacher_disagreement_score":0.09962521,"about_ca_system_score_codex":0.00007713217,"about_ca_system_score_gemma":0.0002453794,"threshold_uncertainty_score":0.5146045},"labels":[],"label_agreement":null},{"id":"W4377016738","doi":"10.1016/j.eclinm.2023.101993","title":"Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer","year":2023,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Bayer HealthCare; Bayer Corporation","keywords":"Medicine; Radium-223; Prostate cancer; Adverse effect; Interquartile range; Interim analysis; Internal medicine; Androgen deprivation therapy; Observational study; Surgery; Clinical trial; Cancer; Bone metastasis","score_opus":0.31907941033991166,"score_gpt":0.5217164345302625,"score_spread":0.20263702419035085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377016738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99491304,0.00017800453,9.139255e-7,0.0031070402,0.00009916846,0.0014240752,0.00020356859,0.000019288162,0.00005487639],"genre_scores_gemma":[0.99535906,0.002824278,0.00006943193,0.00007665417,0.00004191492,0.00024536453,0.00038394143,0.000017079963,0.000982264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964638,0.00030930896,0.0019403163,0.0004717905,0.0005277553,0.00028705923],"domain_scores_gemma":[0.9972385,0.0017487954,0.00035458943,0.00035901685,0.00013332514,0.0001657745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015981443,0.00021042433,0.0016725446,0.0010792532,0.000022276663,0.000005439418,0.0000863248,0.000059116912,0.00010632361],"category_scores_gemma":[0.00043634247,0.00013685555,0.00017353676,0.0022453032,0.0001800245,0.00005395768,0.000052513595,0.0002226491,0.0000013616574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038054192,0.003450214,0.9839678,0.000110515895,0.0027221579,0.00036697043,0.0016459719,0.000083405146,0.0000885389,0.000011700302,0.000069130496,0.0036781924],"study_design_scores_gemma":[0.01865326,0.0050631436,0.971285,0.000320064,0.001546514,5.989801e-7,0.0016679703,0.0012923889,0.00002202598,0.000025371915,0.000032706652,0.00009096922],"about_ca_topic_score_codex":0.017035186,"about_ca_topic_score_gemma":0.09311145,"teacher_disagreement_score":0.07607626,"about_ca_system_score_codex":0.00016779713,"about_ca_system_score_gemma":0.00033868017,"threshold_uncertainty_score":0.9895105},"labels":[],"label_agreement":null},{"id":"W4377087661","doi":"10.1200/edbk_390384","title":"Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair","year":2023,"lang":"en","type":"article","venue":"American Society of Clinical Oncology Educational Book","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; DNA repair; Genetic testing; Precision medicine; Disease; Personalized medicine; Clinical trial; Cancer; MSH2; Germline; Microsatellite instability; Oncology; DNA mismatch repair; Bioinformatics; Internal medicine; Biology; Gene; Genetics; Pathology; Colorectal cancer; Microsatellite","score_opus":0.10653805387541397,"score_gpt":0.486012156683782,"score_spread":0.379474102808368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377087661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.929271,0.0018370392,0.0000055245596,0.06659575,0.00017835124,0.00081446796,0.000050480907,0.000055544977,0.0011918736],"genre_scores_gemma":[0.67311746,0.029835766,0.15451439,0.03156569,0.0037502435,0.002687334,0.0003473182,0.00012723323,0.104054555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986123,0.00005988033,0.00056055235,0.0003404215,0.000155173,0.00027166435],"domain_scores_gemma":[0.99551564,0.0035309053,0.00029787736,0.00014512253,0.00030837976,0.00020208072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059414346,0.00010373494,0.0005247271,0.00003471566,0.0001064037,0.0000037585874,0.00006339288,0.00008150438,0.000072051145],"category_scores_gemma":[0.0005178218,0.00008675917,0.00027330767,0.0002532279,0.0013361878,0.000030675303,0.000055581306,0.00018184254,0.000012068627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035113184,0.0003131195,0.6560584,0.00014547413,0.00037335165,0.0000019698393,0.0005897998,0.000007501948,0.0012806202,0.000064449574,0.11103691,0.22977729],"study_design_scores_gemma":[0.0018251927,0.0023274051,0.866362,0.00003720917,0.00014165565,0.0000064247347,0.000657088,0.0007540736,0.00004488178,0.0006229202,0.12713471,0.00008646166],"about_ca_topic_score_codex":0.00014202343,"about_ca_topic_score_gemma":0.0000058152004,"teacher_disagreement_score":0.2561535,"about_ca_system_score_codex":0.0001772777,"about_ca_system_score_gemma":0.0038921759,"threshold_uncertainty_score":0.69045526},"labels":[],"label_agreement":null},{"id":"W4377096713","doi":"10.51731/cjht.2023.655","title":"Lutetium (¹⁷⁷Lu) Vipivotide Tetraxetan (Pluvicto)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Cabazitaxel; Prostate cancer; Medicine; Taxane; Oncology; Clinical trial; Drug; Internal medicine; Cancer; Androgen deprivation therapy; Pharmacology; Political science; Breast cancer; Health care","score_opus":0.05330637484045283,"score_gpt":0.3480798382205606,"score_spread":0.2947734633801078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377096713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49933067,0.095425196,0.000069502756,0.39776394,0.0015785808,0.00092554645,0.00007406387,0.0007664522,0.004066044],"genre_scores_gemma":[0.99388117,0.0043024234,0.00024209288,0.00040477756,0.000031154206,0.000008500766,0.000009988492,0.000022524302,0.0010973805],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983315,0.00003632075,0.0004584874,0.00014462604,0.00026244923,0.000766627],"domain_scores_gemma":[0.9990443,0.00005691225,0.00018176592,0.00026885953,0.00020493445,0.00024325163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006711725,0.00013136883,0.00041091512,0.0022686091,0.00024811825,0.000029561048,0.00025859667,0.00013536311,0.000060373146],"category_scores_gemma":[0.0004524883,0.00009686007,0.000107748274,0.0011741531,0.00027111755,0.00008737041,0.00002359974,0.0005775538,0.000091119444],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001264471,0.000053797627,0.075180545,0.0005997664,0.00028522636,0.0057054753,0.00084581034,0.0000150964615,0.0008961702,0.0012979816,0.17739648,0.7375972],"study_design_scores_gemma":[0.0025707558,0.002062532,0.13625084,0.0008991028,0.00004591672,0.0011741526,0.00782665,0.00003590101,0.004609828,0.004210626,0.84006536,0.00024833198],"about_ca_topic_score_codex":0.0019686902,"about_ca_topic_score_gemma":0.0015655819,"teacher_disagreement_score":0.73734885,"about_ca_system_score_codex":0.0007215683,"about_ca_system_score_gemma":0.0059970235,"threshold_uncertainty_score":0.9996381},"labels":[],"label_agreement":null},{"id":"W4377141187","doi":"10.1016/j.jmir.2023.04.005","title":"The diagnostic accuracy of 68Ga-PSMA PET/CT versus 99mTc-MDP bone scintigraphy for identifying bone metastases in persons with prostate cancer: A systematic review","year":2023,"lang":"en","type":"review","venue":"Journal of medical imaging and radiation sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Bone scintigraphy; Medicine; Prostate cancer; Radiology; Positron emission tomography; Nuclear medicine; PET-CT; Scintigraphy; Diagnostic accuracy; Cancer; Internal medicine","score_opus":0.10621957543935343,"score_gpt":0.4678512976362443,"score_spread":0.3616317221968909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377141187","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002870937,0.9896776,0.000011859024,0.007560901,0.00042538214,0.001981806,0.000041456056,0.0000081396765,0.000005780896],"genre_scores_gemma":[0.00048235006,0.9988903,0.000088676636,0.00005938739,0.00013077671,0.00027193877,0.000008955633,0.000017244307,0.000050405168],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9957453,0.0003529259,0.0013727255,0.00026604492,0.0019097778,0.00035322426],"domain_scores_gemma":[0.98938966,0.008223997,0.0016959725,0.00015562857,0.0002686494,0.00026611303],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0075070006,0.0002335631,0.0019958245,0.00067090377,0.00029595912,0.00014747882,0.00031764366,0.000015441457,0.000008764201],"category_scores_gemma":[0.012217277,0.00010145748,0.00035666348,0.0014819559,0.00075470534,0.00025535584,0.000047339425,0.00044276004,9.356246e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013531014,0.00008958598,0.0002324805,0.7456096,0.00070915476,0.0015271119,0.00023480892,0.0000018428631,3.8739003e-7,0.00002722328,0.003643247,0.2477893],"study_design_scores_gemma":[0.0028516925,0.00040085512,0.000044825603,0.9558413,0.0054197293,0.003020221,0.0021291985,0.0002840386,0.000001994919,0.000023901444,0.029803317,0.00017894949],"about_ca_topic_score_codex":0.00007872139,"about_ca_topic_score_gemma":0.000037725393,"teacher_disagreement_score":0.24761035,"about_ca_system_score_codex":0.00012583999,"about_ca_system_score_gemma":0.0024272304,"threshold_uncertainty_score":0.9961032},"labels":[],"label_agreement":null},{"id":"W4378084815","doi":"10.3390/cancers15102867","title":"Serrate RNA Effector Molecule (SRRT) Is Associated with Prostate Cancer Progression and Is a Predictor of Poor Prognosis in Lethal Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prostate Cancer Canada; University of Alberta; University of Calgary","funders":"National Institutes of Health; Prostate Cancer Canada; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Prostate cancer; Cancer; Effector; Prostate; Medicine; PCA3; Oncology; Internal medicine; Cancer research; RNA; Biology; Immunology; Gene; Genetics","score_opus":0.0202209302734129,"score_gpt":0.33232823578701226,"score_spread":0.31210730551359933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378084815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98630863,0.0052460385,3.3060235e-7,0.003581944,0.00015078067,0.0034074448,0.0009668246,0.00013623461,0.00020176408],"genre_scores_gemma":[0.98608315,0.0057053687,0.000028161827,0.00027759006,0.00007071111,0.0033778432,0.0001427214,0.000091272734,0.0042231935],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997284,0.00009286308,0.00038411655,0.00068854535,0.00072043535,0.0008300443],"domain_scores_gemma":[0.9988563,0.00006519846,0.00024102801,0.00020752409,0.00032395366,0.00030600358],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002983443,0.0003678655,0.0006544518,0.00033185165,0.000107422406,0.000037087593,0.00011628742,0.00016140944,0.00015731106],"category_scores_gemma":[0.000051947874,0.00025797362,0.00008197354,0.0015556782,0.0003577872,0.00017182966,0.00008849435,0.0003667407,0.0000068660065],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00794661,0.00018274722,0.8933245,0.002163436,0.0011166139,0.0006476316,0.013055006,0.00014541534,0.046733327,0.0000020226078,0.016261902,0.018420823],"study_design_scores_gemma":[0.026044738,0.0044926917,0.4545402,0.012520826,0.0006422481,0.00001759812,0.0011399762,0.007483044,0.49036184,0.000036259647,0.0017975378,0.00092303136],"about_ca_topic_score_codex":0.0021998545,"about_ca_topic_score_gemma":0.0005809003,"teacher_disagreement_score":0.44362852,"about_ca_system_score_codex":0.0016460676,"about_ca_system_score_gemma":0.0021815363,"threshold_uncertainty_score":0.99998724},"labels":[],"label_agreement":null},{"id":"W4378515762","doi":"10.3390/molecules28104022","title":"Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Molecules","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TRIUMF","funders":"","keywords":"Biodistribution; Linker; Internalization; Prostate cancer; Chemistry; Glutamate carboxypeptidase II; Cancer research; DOTA; In vivo; Radionuclide therapy; Cancer; Biophysics; In vitro; Chelation; Biochemistry; Medicine; Nuclear medicine; Receptor; Biology; Internal medicine","score_opus":0.08820287676201533,"score_gpt":0.4379384843395997,"score_spread":0.3497356075775844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378515762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955509,0.0015985217,0.000274816,0.000889211,0.000039320792,0.0013841257,0.000049452472,0.000035546243,0.00017815482],"genre_scores_gemma":[0.9928385,0.00017486939,0.0059002475,0.00002981966,0.000045329263,0.0004997666,0.00019866935,0.000027542967,0.0002852259],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9988582,0.00007267702,0.00023720691,0.00020718481,0.0004253978,0.00019932118],"domain_scores_gemma":[0.99895495,0.00007870917,0.0001034411,0.00015346282,0.00064659043,0.00006286502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080310483,0.00008734115,0.00023235515,0.00010372243,0.000036223475,0.00000656938,0.000047741487,0.000032482032,0.000037092977],"category_scores_gemma":[0.00014943411,0.000058927144,0.00006205733,0.00021475907,0.000101903526,0.000055192075,0.00002177719,0.00006993293,0.0000013896953],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031974733,0.0015875305,0.43937218,0.002855961,0.0015490408,0.000069732996,0.008687009,0.027103864,0.25720456,0.00011514894,0.0036473093,0.22583292],"study_design_scores_gemma":[0.033161014,0.0022990422,0.07798138,0.00096432434,0.0014554544,0.0000048352604,0.0013682113,0.5912221,0.29022485,0.0006907595,0.00031132755,0.00031669522],"about_ca_topic_score_codex":0.000078190445,"about_ca_topic_score_gemma":0.000007767114,"teacher_disagreement_score":0.5641182,"about_ca_system_score_codex":0.0000411545,"about_ca_system_score_gemma":0.00036270986,"threshold_uncertainty_score":0.24029793},"labels":[],"label_agreement":null},{"id":"W4378800385","doi":"10.1016/s1470-2045(23)00158-4","title":"Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; BC Cancer Agency","funders":"National Cancer Institute; Medical Research Council; Advanced Accelerator Applications; Astellas Pharma; Clovis Oncology; AstraZeneca; National Institute for Health and Care Research; Novartis; Pfizer","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Radioligand; Quality of life (healthcare); Oncology; Internal medicine; Lutetium; Cancer; Nursing; Receptor","score_opus":0.09987168394441787,"score_gpt":0.45554696749601414,"score_spread":0.3556752835515963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378800385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985691,0.0025096785,0.0000035993846,0.0025590982,0.00011200633,0.0066729393,0.0023521355,0.00001865084,0.00008089553],"genre_scores_gemma":[0.99801236,0.0007302831,0.00040111115,0.00006246586,0.000017764387,0.00033044087,0.0003715453,0.00002546982,0.000048562426],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99634826,0.0012847919,0.0009586252,0.00032059822,0.00065677526,0.00043092892],"domain_scores_gemma":[0.99690837,0.0011683638,0.00075470074,0.000367118,0.0006475784,0.00015387623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020301526,0.00022471718,0.0023248827,0.00015181853,0.000096819764,0.0000138064925,0.00018061949,0.00007089797,0.00002720294],"category_scores_gemma":[0.0004759456,0.00012052561,0.000048283015,0.0005138837,0.00042966317,0.00008193899,0.00008945658,0.0002460838,3.4310762e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94144374,0.0005027154,0.03075646,0.0017154856,0.0007092972,0.000031223368,0.014596183,0.00010717728,0.00004065536,0.00003691485,0.00016761497,0.009892553],"study_design_scores_gemma":[0.8982659,0.06603287,0.021420825,0.0005049818,0.00023870789,3.803966e-7,0.013002641,0.000049277278,0.00016152363,0.000013432202,0.00018046479,0.00012902246],"about_ca_topic_score_codex":0.0023397012,"about_ca_topic_score_gemma":0.018385375,"teacher_disagreement_score":0.06553015,"about_ca_system_score_codex":0.0006714017,"about_ca_system_score_gemma":0.0033803117,"threshold_uncertainty_score":0.99952656},"labels":[],"label_agreement":null},{"id":"W4378840569","doi":"10.1016/j.euf.2023.05.005","title":"Lymphotropic Pattern of Prostate-specific Membrane Antigen–detected Metastases Among Biochemically Recurrent Radical Prostatectomy Patients with Cribriform Disease","year":2023,"lang":"en","type":"article","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"Fundação para a Ciência e a Tecnologia","keywords":"Medicine; Prostatectomy; Cribriform; Prostate-specific antigen; Prostate cancer; Urology; Glutamate carboxypeptidase II; Disease; Oncology; Internal medicine; Pathology; Cancer; Immunohistochemistry","score_opus":0.013056254131272644,"score_gpt":0.2417692995057725,"score_spread":0.22871304537449985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378840569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958068,0.0011294747,0.000033357708,0.0004735523,0.00012273964,0.0014240275,0.00034615444,0.00025332207,0.00041058025],"genre_scores_gemma":[0.9976628,0.0006891497,0.000052836745,0.000058752696,0.0000758609,0.0000611498,0.0011121035,0.000097893244,0.00018945221],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732584,0.0002923525,0.00047496767,0.0006429939,0.0005602299,0.00070363225],"domain_scores_gemma":[0.998477,0.000082486804,0.00017331763,0.00053235475,0.00026107865,0.00047379205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023904898,0.00033271985,0.00046474207,0.00035513323,0.00010756423,0.000023064993,0.00021270032,0.000057689987,0.00015118375],"category_scores_gemma":[0.000091715905,0.0002260707,0.00013421882,0.0006945609,0.0007192232,0.00008891575,0.00016949253,0.00029536083,0.00017852052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012188266,0.0012219968,0.9306284,0.000379646,0.00057468377,0.0024838562,0.0004774948,0.000009907576,0.0076331375,0.000009799938,0.0020357773,0.042357016],"study_design_scores_gemma":[0.010401653,0.0027139583,0.9624561,0.00013202228,0.00018315086,0.000011469956,0.000026813466,0.000061028015,0.019711452,0.000015634192,0.004015984,0.00027070113],"about_ca_topic_score_codex":0.000016349646,"about_ca_topic_score_gemma":0.0000030948688,"teacher_disagreement_score":0.042086314,"about_ca_system_score_codex":0.00007322966,"about_ca_system_score_gemma":0.00015275841,"threshold_uncertainty_score":0.92188954},"labels":[],"label_agreement":null},{"id":"W4378965338","doi":"10.1016/j.jgo.2023.101520","title":"Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"DOD Prostate Cancer Research Program; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Enzalutamide; Medicine; Prostate cancer; Propensity score matching; Veterans Affairs; Internal medicine; Abiraterone; Oncology; Adverse effect; Cancer; Androgen receptor","score_opus":0.07188525461126993,"score_gpt":0.39308343008243707,"score_spread":0.32119817547116714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378965338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963304,0.00090303237,0.000047136917,0.0015689818,0.0001886093,0.0007867949,0.00007651127,0.000020711386,0.00007783779],"genre_scores_gemma":[0.99139285,0.0028267454,0.0012316955,0.000049142964,0.00028547723,0.00012538105,0.000028625609,0.000034571753,0.0040255096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998639,0.000111801404,0.00046136917,0.00017835757,0.00026573206,0.00034377212],"domain_scores_gemma":[0.99866384,0.00035228374,0.00031138945,0.00009218332,0.00037348567,0.00020682739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005346577,0.00015789826,0.00059687713,0.00026666524,0.00010316693,0.000030252742,0.000058368623,0.00006997896,0.00007819633],"category_scores_gemma":[0.0000742283,0.000086896,0.00007282064,0.000500108,0.00012963776,0.000134354,0.000015277148,0.00018889512,0.0000025092038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2659963,0.0019813245,0.2963657,0.0030237366,0.007620712,0.020238876,0.00850349,0.0006525115,0.24294151,0.00006924256,0.01315811,0.13944848],"study_design_scores_gemma":[0.06719853,0.051000725,0.8461799,0.00045716664,0.003168011,0.0012388782,0.0036625874,0.00065533223,0.008745593,0.0001910752,0.017016206,0.00048596243],"about_ca_topic_score_codex":0.00018938127,"about_ca_topic_score_gemma":0.00061041536,"teacher_disagreement_score":0.5498142,"about_ca_system_score_codex":0.00028732215,"about_ca_system_score_gemma":0.0011285368,"threshold_uncertainty_score":0.35435158},"labels":[],"label_agreement":null},{"id":"W4379046167","doi":"10.1016/j.ijrobp.2022.12.002","title":"Passing the Kool-Aid Point: mRNA Expression–Based Risk Classifiers in Localized Prostate Cancer Treatment Decision Making","year":2023,"lang":"en","type":"letter","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Popularity; Androgen deprivation therapy; Disease; Cancer; Artificial intelligence; Internal medicine; Computer science; Social psychology; Psychology","score_opus":0.0427000420403029,"score_gpt":0.3894830946834092,"score_spread":0.34678305264310627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379046167","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1349397,0.007064538,0.0074398657,0.8327763,0.013135888,0.002811621,0.0011581702,0.0001728882,0.00050099345],"genre_scores_gemma":[0.64937717,0.052058976,0.009275049,0.23468244,0.047111847,0.00119585,0.00300377,0.00068015937,0.0026147333],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960846,0.00077018497,0.0012392227,0.00050854345,0.000823893,0.0005735603],"domain_scores_gemma":[0.9946088,0.0021940486,0.0019989985,0.0003355641,0.0007423177,0.00012022641],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0009060121,0.00048218455,0.0009891536,0.0006162327,0.00020180587,0.00009484624,0.0005708868,0.0008237228,0.00012839487],"category_scores_gemma":[0.0004518883,0.00029490035,0.0005509799,0.00042044415,0.0003721153,0.00021432614,0.00010168505,0.0024718258,0.000039835482],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046998,0.0005504063,0.21115091,0.00005947356,0.0019347455,0.0023282364,0.0012109319,0.0039603994,0.00067162444,0.00004516767,0.21613155,0.55725676],"study_design_scores_gemma":[0.03457025,0.003166853,0.015293862,0.003420219,0.00090746663,0.00019009464,0.0002940336,0.012755912,0.0025571852,0.011200041,0.91495067,0.00069343083],"about_ca_topic_score_codex":0.00013432455,"about_ca_topic_score_gemma":0.000038625298,"teacher_disagreement_score":0.6988191,"about_ca_system_score_codex":0.0054487423,"about_ca_system_score_gemma":0.0026301455,"threshold_uncertainty_score":0.9999503},"labels":[],"label_agreement":null},{"id":"W4379107137","doi":"10.1158/1538-7445.prca2023-b048","title":"Abstract B048: Performance of diagnostic biomarkers in the Canary Prostate cancer Active Surveillance Study (PASS)","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Biomarker; Prostate cancer; Medicine; Prostate biopsy; Receiver operating characteristic; Biopsy; Oncology; Proportional hazards model; Internal medicine; Prostate; Cancer","score_opus":0.0954286920670956,"score_gpt":0.44263827012801205,"score_spread":0.34720957806091646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379107137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873129,0.0030376988,3.1326834e-8,0.0048108473,0.00015917096,0.0034106022,0.00019193394,0.00004055162,0.0010362339],"genre_scores_gemma":[0.97877914,0.016789377,0.0000015547354,0.00004353709,0.00013933571,0.003177353,0.00005170671,0.000041231124,0.0009767833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99606615,0.00039466325,0.00037871816,0.0005286174,0.0015982442,0.0010336306],"domain_scores_gemma":[0.9968339,0.0018238019,0.0000799339,0.0005725129,0.00051870587,0.00017110926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002797472,0.00021033591,0.0004031179,0.00065936707,0.0002395962,0.00003620978,0.00044452926,0.00008041601,0.00026537516],"category_scores_gemma":[0.00053737435,0.0001349367,0.0000728311,0.0034546293,0.00046623708,0.0001461813,0.00016148986,0.00084128225,0.00005542326],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030725107,0.00055057544,0.94275904,0.00060291233,0.0003916472,0.00060283643,0.006333415,0.00011830996,0.006484804,0.0000033117494,0.0076050772,0.031475544],"study_design_scores_gemma":[0.0028417238,0.0007656062,0.9839152,0.0004321853,0.000019530436,0.0000034547795,0.0068608196,0.000111553796,0.0037831108,0.000015069445,0.0011146315,0.00013710916],"about_ca_topic_score_codex":0.02028825,"about_ca_topic_score_gemma":0.007980916,"teacher_disagreement_score":0.041156147,"about_ca_system_score_codex":0.0007615743,"about_ca_system_score_gemma":0.0016651204,"threshold_uncertainty_score":0.98623574},"labels":[],"label_agreement":null},{"id":"W4379142547","doi":"10.1158/1538-7445.prca2023-b012","title":"Abstract B012: Genomic and epigenomic drivers of double-negative metastatic prostate cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Epigenomics; Prostate cancer; PTEN; Androgen receptor; DNA methylation; Cancer research; Epigenome; Biology; Copy number analysis; Epigenetics; Cancer; Genetics; Gene; Genome; PI3K/AKT/mTOR pathway; Copy-number variation; Gene expression","score_opus":0.14173364227613844,"score_gpt":0.4509753376702075,"score_spread":0.30924169539406904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379142547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880844,0.005854172,5.24028e-7,0.0026646126,0.00011924428,0.0017797594,0.0002665098,0.000057572506,0.0011732563],"genre_scores_gemma":[0.9630777,0.027314056,0.000053639193,0.000026015023,0.000112730646,0.0008243577,0.00005554442,0.000056595945,0.0084793465],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99734825,0.00009195949,0.0003231754,0.00052378187,0.0008161913,0.000896653],"domain_scores_gemma":[0.9984215,0.00029640546,0.00008398663,0.00033815915,0.0005047584,0.00035520774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009929342,0.00020015158,0.00045577346,0.0006713391,0.00022932733,0.000042047126,0.00018584638,0.00006982275,0.0007627757],"category_scores_gemma":[0.000056736266,0.00015734059,0.00008838307,0.0011758206,0.0007956687,0.00013037768,0.00020819825,0.000558681,0.00016696239],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00824096,0.00024309191,0.08974308,0.0029466487,0.0015977359,0.0006078476,0.01170716,0.00025889484,0.8348844,0.00033317046,0.01285754,0.036579475],"study_design_scores_gemma":[0.0218087,0.001056475,0.6199989,0.001257892,0.00025506606,0.000016545946,0.0061796336,0.00023069029,0.3361816,0.0015826041,0.010878517,0.0005534014],"about_ca_topic_score_codex":0.0036531228,"about_ca_topic_score_gemma":0.0003416359,"teacher_disagreement_score":0.5302558,"about_ca_system_score_codex":0.00069445005,"about_ca_system_score_gemma":0.001595687,"threshold_uncertainty_score":0.83518595},"labels":[],"label_agreement":null},{"id":"W4379144020","doi":"10.1158/1538-7445.prca2023-a037","title":"Abstract A037: Kinase GRK3 connects angiogenesis and neuroendocrine differentiation in prostate cancer progression by enhancing epigenetic activity of HDAC2","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Angiogenesis; Cancer research; Cancer; Biology; Medicine; Epigenetics; Bioinformatics; Internal medicine; Genetics; Gene","score_opus":0.059532009574431645,"score_gpt":0.42324376671507125,"score_spread":0.3637117571406396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379144020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858796,0.009746493,0.000001268452,0.002601763,0.00009351186,0.0014578504,0.00011815863,0.000046841207,0.000054523796],"genre_scores_gemma":[0.9725693,0.025298584,0.000006481637,0.000013742021,0.000071182374,0.00097370514,0.00006729156,0.000044325454,0.0009553878],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973889,0.00017456683,0.0002755672,0.00052892615,0.0008350704,0.0007969407],"domain_scores_gemma":[0.9988939,0.00023626725,0.00008162744,0.0002696533,0.00027353657,0.00024500597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005106417,0.00018403906,0.00036598975,0.00058718823,0.00014227981,0.00003459793,0.00010887802,0.00005136713,0.00015909757],"category_scores_gemma":[0.00014273445,0.00014688238,0.000057904334,0.0013199992,0.0002470521,0.00012462446,0.00016274578,0.00038651968,0.00000883554],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012732574,0.00019989263,0.131565,0.001138708,0.000057645924,0.00021260437,0.00036733627,0.0000121049,0.7945053,0.000002991797,0.0008129896,0.069852136],"study_design_scores_gemma":[0.001962642,0.00027539342,0.35322165,0.0006149199,0.00001973116,0.0000026059306,0.00010215283,0.00015638543,0.64325,0.00003985247,0.0002580797,0.000096608164],"about_ca_topic_score_codex":0.0023064131,"about_ca_topic_score_gemma":0.0007387427,"teacher_disagreement_score":0.22165667,"about_ca_system_score_codex":0.00035735255,"about_ca_system_score_gemma":0.0004616565,"threshold_uncertainty_score":0.5989689},"labels":[],"label_agreement":null},{"id":"W4379144155","doi":"10.3390/cancers15113033","title":"An Aminosteroid Derivative Shows Higher In Vitro and In Vivo Potencies than Gold Standard Drugs in Androgen-Dependent Prostate Cancer Models","year":2023,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Ministère de l'Économie, de la Science et de l'Innovation - Québec; Université Laval","keywords":"In vivo; Prostate cancer; Prostate; In vitro; Androgen; Gold standard (test); Cancer; Medicine; Pharmacology; Derivative (finance); Androgen receptor; Oncology; Chemistry; Cancer research; Internal medicine; Biology; Hormone; Biochemistry","score_opus":0.032374073694016015,"score_gpt":0.31699062457783755,"score_spread":0.28461655088382154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379144155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99391735,0.0030448083,0.0000015379572,0.0009260385,0.00013333293,0.0010571306,0.00031726132,0.000051645206,0.00055091013],"genre_scores_gemma":[0.99195534,0.0045177555,0.000035665926,0.00017083943,0.00004689604,0.00056130433,0.00004402261,0.00003892538,0.0026292333],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980957,0.00007499408,0.00028425152,0.0005072602,0.000404189,0.00063361035],"domain_scores_gemma":[0.99943525,0.00003993993,0.000051241914,0.0002180012,0.00006755059,0.0001880178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028034684,0.00022855953,0.00042801615,0.0004748167,0.000036405672,0.000036136065,0.000102801234,0.00009844073,0.000054320488],"category_scores_gemma":[0.000008935912,0.00019079336,0.00003265783,0.0007657375,0.00016338372,0.00031894966,0.000068894326,0.00029115687,0.0000022789432],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01991883,0.00016823178,0.55824214,0.0007360833,0.00020879647,0.0018797569,0.06604789,0.012276233,0.30766687,0.00005669501,0.0011676127,0.031630874],"study_design_scores_gemma":[0.042471528,0.0019447658,0.2735167,0.00229366,0.00010087996,0.000020833517,0.03346379,0.02544599,0.61483115,0.0022723011,0.002071628,0.001566732],"about_ca_topic_score_codex":0.0055073667,"about_ca_topic_score_gemma":0.0072204294,"teacher_disagreement_score":0.30716428,"about_ca_system_score_codex":0.0031669491,"about_ca_system_score_gemma":0.0007946908,"threshold_uncertainty_score":0.83255273},"labels":[],"label_agreement":null},{"id":"W4379160459","doi":"10.1158/1538-7445.prca2023-ia006","title":"Abstract IA006: Overcoming complex polyclonality for accurate clinical genotyping in metastatic prostate cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Primary tumor; Genotyping; PTEN; Metastasis; Oncology; Cancer; Exome sequencing; Internal medicine; Biology; Gene; Genotype; Mutation; Genetics","score_opus":0.48387487464407114,"score_gpt":0.5867622778331104,"score_spread":0.10288740318903927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379160459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825875,0.003438444,0.000012073624,0.009426332,0.0003024055,0.0031433136,0.00043726005,0.00010421988,0.00054841384],"genre_scores_gemma":[0.98291725,0.0077269436,0.00021602112,0.00023708402,0.00049476046,0.0029632836,0.00022745517,0.00008040385,0.005136808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957546,0.0002846458,0.00072388386,0.0007624298,0.0009789253,0.0014955037],"domain_scores_gemma":[0.9972274,0.0012608189,0.000098486955,0.0004407442,0.0005670793,0.00040552026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046768393,0.00023376176,0.0006354482,0.00058770954,0.00032296864,0.00009491489,0.0002845919,0.000115300354,0.0007353766],"category_scores_gemma":[0.00056746544,0.00018922365,0.00020585199,0.0016541696,0.00042671728,0.00018468681,0.00021163771,0.0009936837,0.000115390685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01859838,0.0010385199,0.54193425,0.0053723757,0.0013284788,0.0011579891,0.002947972,0.00051138416,0.10646858,0.00049141975,0.086304404,0.23384622],"study_design_scores_gemma":[0.011015024,0.00043399175,0.92994297,0.0010198809,0.00007118444,0.000005578182,0.00085979287,0.0026756355,0.005786903,0.0014441392,0.04637241,0.00037247973],"about_ca_topic_score_codex":0.0034871066,"about_ca_topic_score_gemma":0.0015259334,"teacher_disagreement_score":0.3880087,"about_ca_system_score_codex":0.0009422471,"about_ca_system_score_gemma":0.0020751806,"threshold_uncertainty_score":0.80518585},"labels":[],"label_agreement":null},{"id":"W4379160699","doi":"10.1158/1538-7445.prca2023-b015","title":"Abstract B015: HOXA9 promotes enzalutamide resistance in RB-p53 deficient prostate cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children’s Health Research Institute; Lawson Health Research Institute; Western University","funders":"","keywords":"LNCaP; Enzalutamide; Biology; Cancer research; Prostate cancer; CRISPR; Gene; Cancer; Androgen receptor; Genetics","score_opus":0.11796973676142204,"score_gpt":0.4522466675357946,"score_spread":0.3342769307743726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379160699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9616845,0.01925738,5.001834e-7,0.010727955,0.00024267896,0.0024123609,0.00020361197,0.00019085423,0.0052801324],"genre_scores_gemma":[0.9432074,0.015102518,0.00004750785,0.00010570199,0.00030417374,0.003285878,0.00011006737,0.00009737268,0.037739374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99458385,0.000179008,0.00047997618,0.0009411956,0.0018954014,0.0019205722],"domain_scores_gemma":[0.99783295,0.00030728598,0.00007145057,0.0006638545,0.0006704366,0.0004540195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021417604,0.00029892646,0.0004891373,0.0010953008,0.00032842325,0.0001185312,0.00037298625,0.00017467387,0.00081131794],"category_scores_gemma":[0.00026467326,0.00023845745,0.000119692995,0.0037502148,0.00051215873,0.00019067599,0.00025062743,0.0012681049,0.00048234392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010546645,0.0013386791,0.4325301,0.006845983,0.0004898897,0.004437788,0.0119004315,0.00034196748,0.3576652,0.00096043595,0.118784264,0.054158606],"study_design_scores_gemma":[0.009072237,0.0005638046,0.75592935,0.0052859974,0.000050082515,0.00000873453,0.0019417488,0.00018793167,0.116560414,0.002285475,0.107340075,0.00077412743],"about_ca_topic_score_codex":0.002699314,"about_ca_topic_score_gemma":0.0057755904,"teacher_disagreement_score":0.32339928,"about_ca_system_score_codex":0.0019024011,"about_ca_system_score_gemma":0.0023478216,"threshold_uncertainty_score":0.97240126},"labels":[],"label_agreement":null},{"id":"W4379160843","doi":"10.1158/1538-7445.prca2023-a047","title":"Abstract A047: Panorama of complex structural variants in primary localized prostate cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Prostate cancer; Chromothripsis; PTEN; Cancer; Biology; Computational biology; Disease; Chromoplexy; Genetics; Medicine; Internal medicine; PCA3; DNA; DNA damage; Genome instability","score_opus":0.13376762748070392,"score_gpt":0.4569883562943501,"score_spread":0.32322072881364616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379160843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98951745,0.0027523756,4.6787886e-7,0.0030880326,0.00015861953,0.0015512137,0.00025281485,0.00007023657,0.002608773],"genre_scores_gemma":[0.9882713,0.004613951,0.00004551936,0.00008241055,0.0001718635,0.00065303274,0.0002190062,0.000053940028,0.005888997],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9964008,0.00015910275,0.00045443396,0.0005202714,0.0013537132,0.0011117344],"domain_scores_gemma":[0.9984381,0.00021053161,0.0000745934,0.00043803983,0.0005578457,0.0002808401],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010495236,0.00020203125,0.0005584284,0.0007594344,0.00016601046,0.000054637418,0.0002761774,0.00013107587,0.002335231],"category_scores_gemma":[0.00010013506,0.00015481931,0.000094326075,0.002356123,0.0006478666,0.00013854173,0.00022315008,0.0007524436,0.00009719947],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008328584,0.00025999793,0.37921235,0.0034088467,0.0003806077,0.0011378566,0.0028812748,0.00028401724,0.4817713,0.00012293123,0.024717491,0.097494744],"study_design_scores_gemma":[0.0068773828,0.00027248595,0.9682239,0.0007686327,0.000019243296,0.000005052636,0.00039230456,0.00045490332,0.016471315,0.00043255746,0.005895819,0.00018635753],"about_ca_topic_score_codex":0.006303698,"about_ca_topic_score_gemma":0.00052238215,"teacher_disagreement_score":0.5890116,"about_ca_system_score_codex":0.0010486386,"about_ca_system_score_gemma":0.0023743904,"threshold_uncertainty_score":0.99857676},"labels":[],"label_agreement":null},{"id":"W4379281725","doi":"10.1200/jco.2023.41.16_suppl.e17095","title":"Darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: Second interim analysis.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Tolerability; Prostate cancer; Clinical endpoint; Internal medicine; Adverse effect; Interim analysis; Incidence (geometry); Cancer; Oncology; Clinical trial","score_opus":0.21190454391267297,"score_gpt":0.5100699996184069,"score_spread":0.29816545570573394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963432,0.00008984721,0.000005103125,0.002423505,0.00025708848,0.000655212,0.000042607382,0.000008543229,0.00017491357],"genre_scores_gemma":[0.99809813,0.0001111793,0.00037244204,0.00030877517,0.0001392945,0.000033793574,0.000056518817,0.000014410661,0.0008654541],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964291,0.00041657142,0.0019306835,0.0002387664,0.0006980688,0.0002868048],"domain_scores_gemma":[0.997058,0.000886865,0.00097187946,0.00016331438,0.00065411953,0.00026581995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026618547,0.00014021838,0.001344388,0.000537906,0.00004486034,0.000017669061,0.0001280774,0.00010108241,0.0002952933],"category_scores_gemma":[0.0005877226,0.00008623602,0.00023670438,0.0012363942,0.0001391291,0.00017354432,0.00004462379,0.00069455104,0.000011569355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014857196,0.0030431363,0.96936834,0.000030190376,0.002561385,0.0008764548,0.0004311872,0.00037819316,0.000029091549,0.0000041406142,0.0006225498,0.007798127],"study_design_scores_gemma":[0.018590424,0.019136643,0.95926905,0.00005552899,0.00095170684,0.0000034460666,0.00051568536,0.00020923004,0.000007713723,0.000053965246,0.001130427,0.00007616675],"about_ca_topic_score_codex":0.000082664505,"about_ca_topic_score_gemma":0.0027542112,"teacher_disagreement_score":0.016093506,"about_ca_system_score_codex":0.00034741274,"about_ca_system_score_gemma":0.0024306234,"threshold_uncertainty_score":0.43118215},"labels":[],"label_agreement":null},{"id":"W4379281728","doi":"10.1200/jco.2023.41.16_suppl.e17112","title":"Biochemical recurrence (BCR) and outcomes in patients (pts) with prostate cancer (PC) following radical prostatectomy (RP).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"Bayer","keywords":"Medicine; Biochemical recurrence; Prostate cancer; Prostatectomy; Internal medicine; breakpoint cluster region; Urology; Oncology; Hazard ratio; Cohort; Metastasis; Cancer; Surgery; Confidence interval","score_opus":0.08702810657634075,"score_gpt":0.4838215263645555,"score_spread":0.39679341978821475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900905,0.00064248656,0.0000017297848,0.0079268385,0.0005202397,0.0005744856,0.000009631373,0.00001675252,0.00021736171],"genre_scores_gemma":[0.9961203,0.002377412,0.0004220587,0.00040949893,0.0001682556,0.00003705613,0.000010795373,0.0000210004,0.0004336429],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714935,0.0002217996,0.001327331,0.00028490872,0.000581997,0.00043460907],"domain_scores_gemma":[0.9976521,0.0010157357,0.0004971196,0.00012885508,0.00024666026,0.0004595347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018322808,0.00016785598,0.001275723,0.00024984762,0.00004247092,0.000014103034,0.000118408076,0.00024826315,0.000025837113],"category_scores_gemma":[0.0016245741,0.00009505329,0.00021050681,0.0004473902,0.0003459566,0.00013220265,0.00008554236,0.0010997656,0.000010059665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009277122,0.0010279628,0.91944593,0.000060164126,0.0002936458,0.0011158752,0.00017193054,0.0000019031789,0.00004892152,0.000005628351,0.0015878644,0.06696307],"study_design_scores_gemma":[0.029921608,0.009961846,0.95246327,0.00045416973,0.00015417513,0.00002754078,0.00009199473,0.000040054292,0.00020264355,0.00014844777,0.006414192,0.00012004406],"about_ca_topic_score_codex":0.000028737959,"about_ca_topic_score_gemma":0.000019260693,"teacher_disagreement_score":0.066843025,"about_ca_system_score_codex":0.0002473716,"about_ca_system_score_gemma":0.0015741984,"threshold_uncertainty_score":0.47779956},"labels":[],"label_agreement":null},{"id":"W4379281805","doi":"10.1200/jco.2023.41.16_suppl.5047","title":"Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Cabazitaxel; Internal medicine; Progression-free survival; Confidence interval; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Oncology; Hormonal therapy; Cancer; Progressive disease; Urology; Surgery; Androgen deprivation therapy","score_opus":0.11962850468057874,"score_gpt":0.46088185585892416,"score_spread":0.34125335117834543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99471396,0.002629692,0.0000056482486,0.0014248375,0.000226357,0.00072072947,0.00024384298,0.000006243379,0.000028703069],"genre_scores_gemma":[0.98898,0.010493751,0.00024086543,0.000052511383,0.000061170635,0.000035023633,0.000039915463,0.000020329067,0.00007644659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946867,0.001743267,0.0019645134,0.0003529862,0.0008872324,0.0003652669],"domain_scores_gemma":[0.99254304,0.0042807017,0.0016623393,0.00021390073,0.0009736675,0.00032635283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067439694,0.0002464893,0.0021125632,0.00094569894,0.00005580784,0.000014615878,0.00014643196,0.00015851631,0.00003546047],"category_scores_gemma":[0.0017217011,0.00015134156,0.00032853166,0.0012900536,0.0007617317,0.00015150357,0.00007769185,0.00065489183,2.9444806e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15240641,0.0018821245,0.803553,0.00011669582,0.0047191284,0.0004244114,0.00082912226,0.00011623575,0.001885702,0.000019418694,0.00012883986,0.03391891],"study_design_scores_gemma":[0.03481465,0.019212835,0.9431195,0.00026706714,0.0010689251,0.000009410828,0.00035404804,0.00037972978,0.00033770007,0.000099534846,0.00020693598,0.00012965036],"about_ca_topic_score_codex":0.0002826668,"about_ca_topic_score_gemma":0.0008935338,"teacher_disagreement_score":0.13956651,"about_ca_system_score_codex":0.00018293489,"about_ca_system_score_gemma":0.0022576558,"threshold_uncertainty_score":0.617153},"labels":[],"label_agreement":null},{"id":"W4379281896","doi":"10.1200/jco.2023.41.16_suppl.5013","title":"Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Placebo; Prostate cancer; Internal medicine; Quality of life (healthcare); Cancer; Oncology; Alternative medicine; Androgen receptor; Nursing; Pathology","score_opus":0.19302331313074272,"score_gpt":0.5105133045419311,"score_spread":0.3174899914111884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98316705,0.0004799259,0.000014678651,0.00847995,0.0012332322,0.005442623,0.0007409922,0.00007934187,0.00036219333],"genre_scores_gemma":[0.991014,0.0015550534,0.0007858489,0.00026019115,0.0006121197,0.00092433725,0.00035419446,0.00008558155,0.0044086976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9910708,0.0007336522,0.0053113895,0.000842896,0.0011885496,0.00085270114],"domain_scores_gemma":[0.9867749,0.006995498,0.003693568,0.0005683601,0.001084325,0.00088331907],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0041649356,0.0005474313,0.0030107812,0.000431159,0.00031110138,0.00007737985,0.00023626845,0.0003119638,0.00015409982],"category_scores_gemma":[0.008112264,0.00035091137,0.00089048437,0.0005711981,0.00031393557,0.00033334934,0.000115894036,0.0008510888,0.000026576081],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34251767,0.03155621,0.40162185,0.00019763673,0.016220514,0.017619396,0.009256061,0.0009034386,0.0018260909,0.000010695728,0.006675484,0.17159493],"study_design_scores_gemma":[0.33621016,0.17892757,0.43860734,0.0007736881,0.006648872,0.00014197803,0.0070837378,0.002869188,0.0029153798,0.000692857,0.024395851,0.0007334017],"about_ca_topic_score_codex":0.0021135367,"about_ca_topic_score_gemma":0.003290425,"teacher_disagreement_score":0.17086153,"about_ca_system_score_codex":0.0012413412,"about_ca_system_score_gemma":0.0038904792,"threshold_uncertainty_score":0.99989426},"labels":[],"label_agreement":null},{"id":"W4379282075","doi":"10.1200/jco.2023.41.16_suppl.5027","title":"AI-enabled analysis of H&amp;E-stained prostate cancer tissue images: Assessing risk for metastasis prior to apalutamide (APA) treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Metastasis; Prostatectomy; Oncology; Internal medicine; Androgen deprivation therapy; Cancer; Prostate; Placebo; Disease; Urology; Pathology","score_opus":0.11432942091504984,"score_gpt":0.5153988634597378,"score_spread":0.401069442544688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99051356,0.0007304546,0.000471478,0.0039446,0.00028016954,0.0025666705,0.001447973,0.0000142522795,0.000030828996],"genre_scores_gemma":[0.983153,0.0038493655,0.01051721,0.0001877223,0.00017762174,0.00042556855,0.00019248539,0.000058979713,0.0014380488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99460745,0.00046406258,0.0029795298,0.00045700502,0.0008914606,0.00060048676],"domain_scores_gemma":[0.9909219,0.002073192,0.003141423,0.00035620388,0.0029700582,0.00053722254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022639043,0.0003395851,0.0031855903,0.0010298413,0.00013146052,0.000034251058,0.00017062151,0.00014833387,0.00012189845],"category_scores_gemma":[0.001208963,0.0002030908,0.00081831426,0.0020324118,0.00029065894,0.00025273158,0.000043992335,0.00034737313,0.0000029439032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07237062,0.0058418377,0.56507385,0.00080673833,0.03219397,0.00036021456,0.003091405,0.010385724,0.0049064816,0.0000045753845,0.0017304908,0.3032341],"study_design_scores_gemma":[0.038504954,0.044912465,0.867841,0.000538255,0.029165609,0.0000042069705,0.0011737535,0.000840301,0.0057184245,0.00008308288,0.010894974,0.0003229594],"about_ca_topic_score_codex":0.00092852756,"about_ca_topic_score_gemma":0.001748396,"teacher_disagreement_score":0.30291113,"about_ca_system_score_codex":0.0008080582,"about_ca_system_score_gemma":0.004921697,"threshold_uncertainty_score":0.8730879},"labels":[],"label_agreement":null},{"id":"W4379282239","doi":"10.1200/jco.2023.41.16_suppl.tps5116","title":"PSMAddition: A phase 3 trial to compare treatment with <sup>177</sup>Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Oncology; Internal medicine; Enzalutamide; Urology; Cancer; Randomized controlled trial; Androgen receptor","score_opus":0.11165875529990572,"score_gpt":0.47914637269810373,"score_spread":0.367487617398198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99322164,0.00066442764,0.000011753641,0.0033224532,0.0001175599,0.0019719924,0.00057569944,0.0000114273635,0.00010303804],"genre_scores_gemma":[0.9965178,0.0018096368,0.00084322836,0.00017032966,0.00025304407,0.00009795733,0.00014058602,0.000028053539,0.00013940273],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968361,0.00038308714,0.00137925,0.00030651386,0.00071334705,0.0003816519],"domain_scores_gemma":[0.996572,0.0008998337,0.00080280023,0.00016575992,0.0010551555,0.00050443655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007783045,0.00023749952,0.0023211557,0.00030093838,0.00006507449,0.000013461717,0.00007490352,0.00009419854,0.000035268295],"category_scores_gemma":[0.00025679174,0.0001332351,0.00017545697,0.0004683158,0.00035339216,0.00011400015,0.000043296805,0.00046471157,0.0000034460782],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86568826,0.0026514118,0.034610182,0.000117404335,0.0015214831,0.0025210427,0.0057287845,0.00036350611,0.000010118457,0.000003817651,0.0016516838,0.08513227],"study_design_scores_gemma":[0.5805897,0.336958,0.06970036,0.00061509246,0.0011524641,0.000045875826,0.0070550027,0.00013621344,0.0001937425,0.000025939706,0.0033408161,0.00018680446],"about_ca_topic_score_codex":0.00013501565,"about_ca_topic_score_gemma":0.0005984125,"teacher_disagreement_score":0.33430657,"about_ca_system_score_codex":0.00095444935,"about_ca_system_score_gemma":0.0034411214,"threshold_uncertainty_score":0.6104402},"labels":[],"label_agreement":null},{"id":"W4379282240","doi":"10.1200/jco.2023.41.16_suppl.5096","title":"Testosterone recovery following androgen suppression and prostate radiotherapy (TRANSPORT): Updated individual patient data meta-analyses from the MARCAP consortium.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Sunnybrook Health Science Centre; McGill University Health Centre; University of Ottawa; Ottawa Hospital; Health Sciences Centre","funders":"","keywords":"Medicine; Prostate cancer; Testosterone (patch); Androgen deprivation therapy; Androgen; Randomized controlled trial; Radiation therapy; Urology; Prostate; Internal medicine; Cancer; Hormone","score_opus":0.4338375755924066,"score_gpt":0.5274865139207717,"score_spread":0.09364893832836513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96763694,0.011077559,0.000017861115,0.019757943,0.00061673945,0.00045176997,0.0003496418,0.00001736879,0.0000741811],"genre_scores_gemma":[0.9816887,0.011709484,0.0021340828,0.0026164455,0.0004878517,0.000013730528,0.0008272304,0.000033881348,0.0004885945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99621147,0.00078893447,0.001737471,0.00033305408,0.00063989626,0.00028919757],"domain_scores_gemma":[0.9947808,0.0033618324,0.00091430196,0.00048208397,0.0001546784,0.00030633432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003698362,0.0001738632,0.0016121692,0.00011730147,0.00010070355,0.000026331132,0.00031098034,0.00021886305,0.00028310332],"category_scores_gemma":[0.0009889466,0.000080407895,0.0005136145,0.00026077684,0.0002500415,0.0002375348,0.00017005486,0.0007532781,0.0000073931633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021432307,0.0017748085,0.44948474,0.00004133872,0.07890999,0.0076230518,0.0012247172,0.000045217104,0.005772286,0.0000027388755,0.1464197,0.28726912],"study_design_scores_gemma":[0.02976274,0.020912481,0.65490204,0.0002182316,0.039680112,0.00031469698,0.0010710747,0.00035251534,0.0022168406,0.00071920065,0.24949993,0.00035012641],"about_ca_topic_score_codex":0.00007684601,"about_ca_topic_score_gemma":0.00003645185,"teacher_disagreement_score":0.28691897,"about_ca_system_score_codex":0.0000470899,"about_ca_system_score_gemma":0.00093952083,"threshold_uncertainty_score":0.32789388},"labels":[],"label_agreement":null},{"id":"W4379282338","doi":"10.1200/jco.2023.41.16_suppl.e17111","title":"Biochemical recurrence (BCR) among patients (pts) with prostate cancer (PC) after radiation therapy (RT).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"Bayer","keywords":"Medicine; Prostate cancer; Biochemical recurrence; Androgen deprivation therapy; Internal medicine; Radiation therapy; Oncology; breakpoint cluster region; Prostate-specific antigen; Cohort; Retrospective cohort study; Urology; Cancer; Prostatectomy","score_opus":0.0962726000690626,"score_gpt":0.47961277484898784,"score_spread":0.3833401747799252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915533,0.0015447832,0.0000030627225,0.005357233,0.0007415478,0.00042362665,0.000013239476,0.000016506287,0.00034668934],"genre_scores_gemma":[0.97878486,0.018824175,0.00011753204,0.0006440977,0.00072911865,0.000057443922,0.00002125933,0.000019753103,0.00080173474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977285,0.00020964403,0.0010195446,0.00021184213,0.00051588315,0.0003145691],"domain_scores_gemma":[0.99765414,0.0005537547,0.00068342796,0.00013897697,0.0006002765,0.00036941134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011826333,0.00013129026,0.0007221947,0.00015430128,0.00003659577,0.0000118684275,0.00011030652,0.00023757557,0.00017028062],"category_scores_gemma":[0.0005752362,0.00007302083,0.00020153356,0.00037095085,0.00030303677,0.00013664647,0.000033384706,0.00076788454,0.000033613644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016935777,0.0007357682,0.724632,0.00002085907,0.0002365987,0.0003013861,0.00017757263,0.0000030291892,0.000048278038,0.0000011526391,0.011032164,0.24587539],"study_design_scores_gemma":[0.0148786465,0.011100807,0.9336455,0.00019069,0.00009403092,0.0000118766875,0.00003401665,0.000045183016,0.00062053243,0.00006343187,0.039227046,0.000088265646],"about_ca_topic_score_codex":0.00002518975,"about_ca_topic_score_gemma":0.000014156099,"teacher_disagreement_score":0.24578711,"about_ca_system_score_codex":0.00023232476,"about_ca_system_score_gemma":0.0014134418,"threshold_uncertainty_score":0.3336119},"labels":[],"label_agreement":null},{"id":"W4379282451","doi":"10.1200/jco.2023.41.16_suppl.5033","title":"Prevalence of intra-patient inter-metastatic heterogeneity in mCRPC patients based on triple-tracer PET imaging: The 3TMPO study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Centre Hospitalier Universitaire de Sherbrooke; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Hospitalier de l’Université de Montréal; Hôtel-Dieu de Québec; Jewish General Hospital; Université de Sherbrooke; Université Laval","funders":"Cancer Research Society","keywords":"Medicine; Prostate cancer; Nuclear medicine; Imaging biomarker; Positron emission tomography; Lesion; Pet imaging; Biopsy; Radiology; Target lesion; Cancer; Internal medicine; Magnetic resonance imaging; Pathology","score_opus":0.1359790741629398,"score_gpt":0.5024908946381167,"score_spread":0.3665118204751769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938181,0.00012189018,0.000010120953,0.004174371,0.000817229,0.00078207254,0.000013845623,0.000006395928,0.00025595335],"genre_scores_gemma":[0.9986169,0.00026424322,0.0001354948,0.00071942765,0.00009982335,0.000020816638,0.0000036060856,0.000013222548,0.00012651592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99577,0.0011490504,0.0019536263,0.00020465678,0.0006542309,0.0002684819],"domain_scores_gemma":[0.9954301,0.002730351,0.0009777357,0.0002643607,0.00040163274,0.00019579454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037968901,0.00013160497,0.00088064204,0.00028178538,0.000032116997,0.000006788543,0.00022959715,0.00005426961,0.00009621202],"category_scores_gemma":[0.0034947363,0.000069467635,0.000312655,0.00036017617,0.00024409876,0.00006396853,0.00007793259,0.0008608609,0.000017279555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0078336755,0.0077244686,0.9089874,0.00010054906,0.00016862301,0.0009649245,0.00033902147,0.00007280205,0.000026190157,0.0000015626051,0.0016071761,0.07217361],"study_design_scores_gemma":[0.015674677,0.029370744,0.9512074,0.00023230167,0.0001983563,0.000019754409,0.00039920126,0.0013936537,0.0001833193,0.00005218652,0.0012076326,0.000060795242],"about_ca_topic_score_codex":0.0000148891895,"about_ca_topic_score_gemma":0.000023865683,"teacher_disagreement_score":0.07211281,"about_ca_system_score_codex":0.0002088157,"about_ca_system_score_gemma":0.0008687545,"threshold_uncertainty_score":0.41837782},"labels":[],"label_agreement":null},{"id":"W4379282877","doi":"10.1200/jco.2023.41.16_suppl.5002","title":"Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University; London Health Sciences Centre","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Proportional hazards model; Internal medicine; Randomization; Oncology; Radiation therapy; Stage (stratigraphy); Surrogate endpoint; Randomized controlled trial; Clinical endpoint; Hazard ratio; Urology; Survival analysis; Cancer; Confidence interval","score_opus":0.2661617005470177,"score_gpt":0.553959838353273,"score_spread":0.2877981378062553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98402673,0.005891011,0.00023251396,0.0023738632,0.00038359684,0.003176993,0.0038994304,0.000007171636,0.000008695782],"genre_scores_gemma":[0.9901258,0.006261727,0.0022377037,0.00018228574,0.00034699254,0.0001706791,0.0006169141,0.000025763882,0.000032174572],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98893356,0.0045826933,0.0050817095,0.00030522174,0.00081503176,0.00028178174],"domain_scores_gemma":[0.9685347,0.02258821,0.006215609,0.0004902197,0.0019059009,0.00026533325],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018547928,0.00021546583,0.0064110286,0.0004278909,0.000044930715,0.000015131447,0.0004014192,0.00028422207,0.00024615368],"category_scores_gemma":[0.01493834,0.00010466284,0.0015290886,0.0012354746,0.0008396839,0.00016990886,0.000075747244,0.0004307086,4.0835369e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7031616,0.001983129,0.20592938,0.00008851121,0.044589575,0.000055509903,0.004362567,0.0009824655,0.0012733851,0.0000088816305,0.004057975,0.033507038],"study_design_scores_gemma":[0.45876497,0.036330808,0.44677362,0.00058853545,0.031495754,0.00000606368,0.0016644272,0.021141114,0.00090038095,0.0005546027,0.001555315,0.00022439238],"about_ca_topic_score_codex":0.0009974769,"about_ca_topic_score_gemma":0.0007735184,"teacher_disagreement_score":0.2443966,"about_ca_system_score_codex":0.00017464574,"about_ca_system_score_gemma":0.004130104,"threshold_uncertainty_score":0.99335927},"labels":[],"label_agreement":null},{"id":"W4379282910","doi":"10.1200/jco.2023.41.16_suppl.3089","title":"Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Theratechnologies (Canada)","funders":"","keywords":"Medicine; Docetaxel; Tolerability; Pharmacokinetics; Oncology; Adverse effect; Internal medicine; Drug; Pharmacology; Cancer","score_opus":0.17533644675191873,"score_gpt":0.4953780951590365,"score_spread":0.3200416484071178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945125,0.00010574106,0.000015645695,0.0024475888,0.0006237183,0.0016610106,0.00018373245,0.000025030653,0.00042502378],"genre_scores_gemma":[0.99478835,0.0004007385,0.0029691034,0.00026558977,0.00050923973,0.000050911895,0.00021517019,0.000053628126,0.0007472617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919388,0.0005657571,0.005271225,0.00059634045,0.0010006637,0.0006271774],"domain_scores_gemma":[0.99162793,0.0027290275,0.003529287,0.0003987417,0.0011382852,0.0005767363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050970307,0.00031754843,0.0025624325,0.00039498386,0.00009007638,0.00002942125,0.0004764486,0.00023349801,0.00012479817],"category_scores_gemma":[0.0066622137,0.00021486367,0.00023732724,0.0008352139,0.00029607004,0.00046592267,0.0002748007,0.0013575692,0.000053069893],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18163665,0.0665109,0.6515449,0.0000716979,0.0014824651,0.0014818774,0.0016112598,0.00021538167,0.0025116277,0.00000498081,0.0065860418,0.086342216],"study_design_scores_gemma":[0.33720127,0.054148823,0.598874,0.0010848372,0.00043472814,0.000010334082,0.0017946989,0.00074431003,0.0010887707,0.00007640318,0.0042358143,0.0003060667],"about_ca_topic_score_codex":0.00022962484,"about_ca_topic_score_gemma":0.00034966067,"teacher_disagreement_score":0.15556462,"about_ca_system_score_codex":0.0002946199,"about_ca_system_score_gemma":0.002507986,"threshold_uncertainty_score":0.8761886},"labels":[],"label_agreement":null},{"id":"W4379283341","doi":"10.1200/jco.2023.41.16_suppl.5028","title":"Building a predictive model for outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Proportional hazards model; Univariate; Logistic regression; Univariate analysis; Oncology; Predictive value; Internal medicine; Multivariate analysis; Multivariate statistics; Cancer; Statistics","score_opus":0.24238683400862732,"score_gpt":0.5266294923762522,"score_spread":0.2842426583676249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927554,0.00018573656,0.0013361933,0.0034500905,0.00014285414,0.0015590533,0.0005214855,0.000016678667,0.00003249978],"genre_scores_gemma":[0.97326386,0.00032529182,0.025498228,0.00019213917,0.000174056,0.00006111312,0.00015376974,0.000044013832,0.00028753164],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9961754,0.0002578279,0.0018773612,0.00045581016,0.0007649113,0.00046869437],"domain_scores_gemma":[0.9954107,0.0018818895,0.0012095828,0.00034360294,0.0008420295,0.00031224324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002849604,0.00022845408,0.0013362913,0.00033484056,0.00010640452,0.000027024413,0.00023311771,0.00015820436,0.000003988389],"category_scores_gemma":[0.001489042,0.00012622078,0.00014310151,0.00042082687,0.0002466337,0.00051225384,0.0001238428,0.0007248614,8.628607e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4371894,0.0037674906,0.35264513,0.00036585677,0.0021679127,0.0013844795,0.0017943567,0.16497836,0.00007859465,0.000022018881,0.002161989,0.033444427],"study_design_scores_gemma":[0.06544279,0.05367884,0.40019292,0.0011928324,0.0012610132,0.000029617753,0.0009869939,0.47634217,0.000024841105,0.00027592434,0.00036431296,0.00020775251],"about_ca_topic_score_codex":0.00008951946,"about_ca_topic_score_gemma":0.00017239078,"teacher_disagreement_score":0.3717466,"about_ca_system_score_codex":0.00047480143,"about_ca_system_score_gemma":0.003993588,"threshold_uncertainty_score":0.7084453},"labels":[],"label_agreement":null},{"id":"W4379283397","doi":"10.1200/jco.2023.41.16_suppl.5097","title":"Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"Bayer","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Adverse effect; Proportional hazards model; Cohort; Oncology; Cancer; Androgen receptor","score_opus":0.2668486127059642,"score_gpt":0.5243409152184116,"score_spread":0.2574923025124474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873609,0.00034417433,0.000017139677,0.009996718,0.00022856997,0.0017210164,0.00009569772,0.00001536656,0.00022042205],"genre_scores_gemma":[0.98918366,0.007356212,0.00068845274,0.0016680862,0.0002187778,0.00018400716,0.000081071536,0.000029278763,0.0005904587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99552435,0.0009477501,0.0017915786,0.00036939498,0.00083443406,0.0005325102],"domain_scores_gemma":[0.9869689,0.0105165085,0.0011479795,0.00024400667,0.0007953943,0.00032721827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004129899,0.00026482105,0.001379431,0.0005555679,0.00014936012,0.00004466771,0.0002269009,0.00013061542,0.000020884125],"category_scores_gemma":[0.001627744,0.00014124216,0.00018088729,0.0010713673,0.0005153093,0.0002084864,0.000043739787,0.000983887,0.000008929111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1510177,0.0051471824,0.7657062,0.00075978896,0.0019877688,0.0025878535,0.012727734,0.005206988,0.00042144218,0.00035598027,0.016635532,0.03744583],"study_design_scores_gemma":[0.021364912,0.038013734,0.9195725,0.0015905588,0.00056609506,0.000030378133,0.003161735,0.0021937578,0.00014682412,0.0006551265,0.012478317,0.00022609744],"about_ca_topic_score_codex":0.00068474095,"about_ca_topic_score_gemma":0.004329845,"teacher_disagreement_score":0.15386626,"about_ca_system_score_codex":0.00048248353,"about_ca_system_score_gemma":0.0020056567,"threshold_uncertainty_score":0.57596874},"labels":[],"label_agreement":null},{"id":"W4379283675","doi":"10.1200/jco.2023.41.16_suppl.5010","title":"Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Positron emission tomography; Proportional hazards model; Internal medicine; Nuclear medicine; Oncology; Cancer; Radiology","score_opus":0.04646587833407486,"score_gpt":0.40587083656753464,"score_spread":0.3594049582334598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593776,0.00023536652,0.0000025926893,0.001462059,0.00070684205,0.0014557865,0.00014600217,0.000016416097,0.000037157188],"genre_scores_gemma":[0.99385464,0.005145121,0.00028098148,0.00007166922,0.00026731953,0.000047463032,0.00008987883,0.00003327691,0.00020964892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960629,0.0005947425,0.0014784189,0.0004933499,0.0009912639,0.00037936677],"domain_scores_gemma":[0.997072,0.00035295813,0.0009699719,0.00021519761,0.00074202265,0.0006478943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018961084,0.00024912227,0.0010005117,0.00041834472,0.00010708281,0.000059222315,0.00015396411,0.00008719738,0.00004527031],"category_scores_gemma":[0.00035569223,0.00015692906,0.00015738799,0.00035783078,0.000219322,0.00040684428,0.000078185854,0.000800283,0.000003457181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06566353,0.0055323984,0.9176953,0.000045964436,0.00062599237,0.0023267348,0.00081103377,0.00008724482,0.00043536702,0.0000062056833,0.00011434146,0.006655883],"study_design_scores_gemma":[0.036043193,0.018487237,0.9435798,0.00026593768,0.0002642574,0.000007675552,0.00052829774,0.00021585067,0.00010182951,0.00007369473,0.0002808074,0.00015144884],"about_ca_topic_score_codex":0.00025617125,"about_ca_topic_score_gemma":0.0004348453,"teacher_disagreement_score":0.029620338,"about_ca_system_score_codex":0.00042515792,"about_ca_system_score_gemma":0.00075505755,"threshold_uncertainty_score":0.6399381},"labels":[],"label_agreement":null},{"id":"W4379330912","doi":"10.1200/jco.2023.41.16_suppl.5012","title":"Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Brief Pain Inventory; Prostate cancer; Hazard ratio; Confidence interval; Clinical endpoint; Placebo; Quality of life (healthcare); Internal medicine; Randomized controlled trial; Cancer; Physical therapy; Chronic pain","score_opus":0.266717536119669,"score_gpt":0.528010711439331,"score_spread":0.261293175319662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379330912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738275,0.0008376914,0.0000048677416,0.0222533,0.00022750055,0.0027370425,0.00008252431,0.0000060763296,0.000023525028],"genre_scores_gemma":[0.99548244,0.0032130603,0.00038055447,0.00049195194,0.00006626722,0.00013808909,0.000028047381,0.0000170416,0.00018255715],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99475104,0.0018376482,0.0024128484,0.00025773578,0.0004251621,0.00031556652],"domain_scores_gemma":[0.99118733,0.0063320245,0.0016529158,0.00013363227,0.00037515681,0.00031896337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010032139,0.00017423843,0.0018105523,0.00015323187,0.000099574296,0.000022433442,0.0000811492,0.00013443117,0.000009885529],"category_scores_gemma":[0.0046512824,0.00008879741,0.00010294232,0.00024122352,0.0004220676,0.00012887814,0.000030818966,0.00053166255,4.7612608e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8084542,0.0024983054,0.11615857,0.00052893424,0.0010140393,0.000080120655,0.0026836349,0.000010509107,0.000053068256,0.0000268757,0.0014518063,0.0670399],"study_design_scores_gemma":[0.5565403,0.07844234,0.36058345,0.0002949657,0.00034816234,0.000006516691,0.0017976257,0.0002930833,0.000010165985,0.00015308423,0.0014100561,0.00012022742],"about_ca_topic_score_codex":0.00038649654,"about_ca_topic_score_gemma":0.001216471,"teacher_disagreement_score":0.25191393,"about_ca_system_score_codex":0.00014151988,"about_ca_system_score_gemma":0.0019145099,"threshold_uncertainty_score":0.55683553},"labels":[],"label_agreement":null},{"id":"W4379535139","doi":"10.4103/aja202320","title":"Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial","year":2023,"lang":"en","type":"article","venue":"Asian Journal of Andrology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Hazard ratio; Medicine; Internal medicine; Oncology; Placebo; Clinical endpoint; Androgen deprivation therapy; Proportional hazards model; Prostate-specific antigen; Gynecology; Confidence interval; Randomized controlled trial; Urology; Cancer; Pathology","score_opus":0.06994841603903562,"score_gpt":0.3869726003384941,"score_spread":0.3170241842994585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379535139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774639,0.00012137207,0.000059613252,0.02121867,0.0001673287,0.00074592506,0.000044761902,0.0000024315718,0.00017599088],"genre_scores_gemma":[0.9993925,0.00009035703,0.000062246414,0.00008971567,0.00009650268,0.00002921795,0.000033831522,0.0000059800254,0.00019963089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888855,0.0001821316,0.00040429324,0.000092803435,0.00024643488,0.00018580785],"domain_scores_gemma":[0.99924475,0.0001335453,0.0002878804,0.00011406477,0.00018131657,0.000038449238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077167706,0.0000756898,0.0003727976,0.00039958244,0.00006640987,0.00000960219,0.000090846355,0.000037831025,0.000015719408],"category_scores_gemma":[0.00011101474,0.000038496633,0.00023096817,0.001035514,0.000102506776,0.000055083743,0.000008913407,0.00017402552,6.8523343e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23042612,0.0012869178,0.54635704,0.00038624072,0.015763571,0.001806795,0.067587934,0.0063819042,0.0067620915,0.0025240588,0.0034535597,0.11726376],"study_design_scores_gemma":[0.04094346,0.0043901196,0.93792486,0.00009000537,0.0037816437,0.00019971168,0.0069371467,0.0022559226,0.00086331106,0.002092167,0.0004298237,0.0000918369],"about_ca_topic_score_codex":0.000057238256,"about_ca_topic_score_gemma":0.0008681123,"teacher_disagreement_score":0.3915678,"about_ca_system_score_codex":0.000060565824,"about_ca_system_score_gemma":0.0002634024,"threshold_uncertainty_score":0.15698472},"labels":[],"label_agreement":null},{"id":"W4379537570","doi":"10.37018/xrxp2904","title":"Androgen receptor (AR) expression in different Gleason scores of prostatic adenocarcinoma by immunohistochemistry","year":2022,"lang":"en","type":"article","venue":"Journal of Fatima Jinnah Medical University","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Continental (Canada)","funders":"","keywords":"Immunohistochemistry; Medicine; Androgen receptor; Prostate cancer; Adenocarcinoma; Grading (engineering); Prostatic adenocarcinoma; Prostate; Urology; Internal medicine; Pathology; Oncology; Cancer; Biology","score_opus":0.012430397314463625,"score_gpt":0.26883679241999575,"score_spread":0.25640639510553215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379537570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936826,0.003839095,0.000057923444,0.0018958154,0.00008701956,0.0001967819,0.000042271582,0.0000050409612,0.00019344667],"genre_scores_gemma":[0.9983105,0.0004914231,0.00018906611,0.000037925784,0.00003939524,0.000001271654,0.00003912537,0.0000084619005,0.0008827966],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99805164,0.00015096883,0.0003232257,0.0001374231,0.0011403454,0.00019641077],"domain_scores_gemma":[0.9990842,0.00010322388,0.0002713616,0.00013400248,0.00011889582,0.00028832414],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032478498,0.00011115898,0.00039585456,0.00017636208,0.000094541465,0.000003465,0.00025231982,0.00006933202,0.0017524526],"category_scores_gemma":[0.00016761698,0.00008379747,0.00012985524,0.00024518938,0.00017130199,0.000075236945,0.00017279918,0.0006332865,9.696839e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012141188,0.003032698,0.4443272,0.00061721035,0.00030149487,0.0027685105,0.0020798526,0.000008679564,0.4612558,0.000012421001,0.06649171,0.0069632325],"study_design_scores_gemma":[0.07100592,0.012644,0.23873918,0.005063264,0.0006522008,0.0012975064,0.019493004,0.0009782322,0.6240307,0.00017775234,0.025045948,0.0008722822],"about_ca_topic_score_codex":0.000032650427,"about_ca_topic_score_gemma":6.1019455e-7,"teacher_disagreement_score":0.20558803,"about_ca_system_score_codex":0.00070781924,"about_ca_system_score_gemma":0.00054652954,"threshold_uncertainty_score":0.99916005},"labels":[],"label_agreement":null},{"id":"W4379791997","doi":"10.1200/jco.23.00233","title":"Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Olaparib; Prostate cancer; Pembrolizumab; Oncology; Internal medicine; Randomized controlled trial; Biomarker; Open label; PARP inhibitor; Metastatic breast cancer; Cancer; Immunotherapy; Breast cancer; Poly ADP ribose polymerase","score_opus":0.18578888301456287,"score_gpt":0.51321039237129,"score_spread":0.3274215093567271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379791997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984359,0.0010565576,0.000027227074,0.0054141073,0.000475629,0.008432508,0.000082090846,0.000019556168,0.0001332913],"genre_scores_gemma":[0.9913104,0.004638003,0.00058113295,0.00035624093,0.00031238844,0.0008160268,0.00016569062,0.000040936942,0.0017791406],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953399,0.0010929919,0.002277609,0.0003179305,0.00050854863,0.0004630392],"domain_scores_gemma":[0.99082685,0.005648832,0.0017174416,0.00020126619,0.0011997832,0.0004058252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004965931,0.00024049828,0.0024713753,0.00018136557,0.00022427867,0.00008390643,0.00024219048,0.00016261822,0.000048946],"category_scores_gemma":[0.0028510885,0.000110378896,0.0002406238,0.0005058957,0.00057323836,0.00019809714,0.000065659755,0.0005534405,0.0000025444624],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9354349,0.003082188,0.00048364082,0.000075335345,0.0026217096,0.00024917055,0.00029569317,0.0000036813258,0.00011093732,0.00002811852,0.004214456,0.053400204],"study_design_scores_gemma":[0.9307252,0.057041273,0.0023488866,0.00016849839,0.0024746342,0.000040739687,0.000094375384,0.0010382842,0.000035441997,0.00016793165,0.0057443334,0.000120401375],"about_ca_topic_score_codex":0.0001848044,"about_ca_topic_score_gemma":0.00027682862,"teacher_disagreement_score":0.053959087,"about_ca_system_score_codex":0.00025680166,"about_ca_system_score_gemma":0.004660472,"threshold_uncertainty_score":0.8267477},"labels":[],"label_agreement":null},{"id":"W4379983944","doi":"10.1158/1055-9965.epi-22-1324","title":"Diabetes and Prostate Cancer Outcomes in Men with Nonmetastatic Castration-Resistant Prostate Cancer: Results from the SEARCH Cohort","year":2023,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Prostate cancer; Diabetes mellitus; Proportional hazards model; Internal medicine; Oncology; Cancer; Cohort; Gynecology; Veterans Affairs; Prostate; Endocrinology","score_opus":0.05847743160792718,"score_gpt":0.38618403351944536,"score_spread":0.3277066019115182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379983944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.939085,0.013921946,0.0000056649606,0.042413764,0.00020243919,0.0031900627,0.000993632,0.00008519575,0.000102260135],"genre_scores_gemma":[0.95501184,0.03263395,0.00031347974,0.00046344244,0.00012219678,0.0041990434,0.0013085359,0.000060824143,0.005886674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960677,0.0008848871,0.00083550776,0.0009223603,0.00035720647,0.0009323058],"domain_scores_gemma":[0.9973405,0.0015295633,0.00030372545,0.00044060804,0.00016684884,0.00021873701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002903548,0.0003627646,0.00084459846,0.00023116545,0.00025151472,0.00003220808,0.00016006507,0.00015011642,0.00008630508],"category_scores_gemma":[0.000315672,0.00021431323,0.0001115148,0.00076156086,0.00061998883,0.00019042888,0.0001020123,0.00038777164,0.000012398895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004039702,0.00007342364,0.9683423,0.0001470602,0.0016595669,0.00004622491,0.0011362489,0.00020952862,0.0022586554,0.000014388904,0.0051167742,0.016956102],"study_design_scores_gemma":[0.006350495,0.0003789423,0.98697364,0.0009908129,0.0003909455,0.0000016180551,0.00078461063,0.0018268364,0.0007433777,0.0008085872,0.00051053806,0.00023958039],"about_ca_topic_score_codex":0.015235036,"about_ca_topic_score_gemma":0.010100395,"teacher_disagreement_score":0.041950323,"about_ca_system_score_codex":0.00055840646,"about_ca_system_score_gemma":0.00076694373,"threshold_uncertainty_score":0.9913226},"labels":[],"label_agreement":null},{"id":"W4380029485","doi":"10.1158/1538-7445.am2023-2105","title":"Abstract 2105: Implications of metastatic stage at presentation in docetaxel naïve metastatic castrate resistant prostate cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Ottawa Hospital","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Abiraterone acetate; Prednisone; Internal medicine; Oncology; Enzalutamide; Stage (stratigraphy); Placebo; Regimen; Cancer; Prostate; Androgen deprivation therapy; Urology; Androgen receptor; Pathology","score_opus":0.20828137408403608,"score_gpt":0.4999385068985145,"score_spread":0.2916571328144784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380029485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839171,0.004462171,0.000002480951,0.0056203073,0.000090917885,0.0028474252,0.0013622614,0.000067815105,0.00162948],"genre_scores_gemma":[0.9624017,0.009224564,0.0001012807,0.000034692177,0.00005967069,0.0033959998,0.00034306524,0.00007181469,0.024367245],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99579245,0.00028192377,0.00070971274,0.0006803784,0.0013691594,0.0011663918],"domain_scores_gemma":[0.9975366,0.00048680673,0.00017623583,0.00062465033,0.0008249819,0.000350701],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017273352,0.00025591053,0.00056690816,0.0011395455,0.00024851254,0.000057170368,0.00027755162,0.00006425284,0.0014363512],"category_scores_gemma":[0.00020976408,0.00020734762,0.00013000461,0.0032758247,0.00049120793,0.0002418408,0.00020011423,0.00062608457,0.00013628759],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062559424,0.0007265233,0.079949185,0.0051151067,0.00089718134,0.0009809312,0.005199654,0.0014994703,0.8697701,0.00054794364,0.015223256,0.013834684],"study_design_scores_gemma":[0.00918865,0.00072010874,0.793528,0.0012138712,0.00018868949,0.000013671802,0.0042556073,0.00044356578,0.18274091,0.0014848114,0.0057913717,0.00043069007],"about_ca_topic_score_codex":0.0075513106,"about_ca_topic_score_gemma":0.006254465,"teacher_disagreement_score":0.7135789,"about_ca_system_score_codex":0.0014265223,"about_ca_system_score_gemma":0.0019326623,"threshold_uncertainty_score":0.9994765},"labels":[],"label_agreement":null},{"id":"W4380079012","doi":"10.1021/acsmedchemlett.3c00087","title":"<i>N</i>-Alkyl Carbamoylimidazoles as Versatile Synthons for the Synthesis of Urea-Based PSMA Inhibitors","year":2023,"lang":"en","type":"article","venue":"ACS Medicinal Chemistry Letters","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Alberta Cancer Foundation","keywords":"Synthon; Urea; Radioligand; Chemistry; Potency; Combinatorial chemistry; Prostate cancer; IC50; Alkyl; Glutamate carboxypeptidase II; Biochemistry; Stereochemistry; In vitro; Cancer; Medicine; Organic chemistry; Internal medicine","score_opus":0.020873351303562382,"score_gpt":0.2956149721120725,"score_spread":0.2747416208085101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380079012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9396779,0.0006196122,0.000034873003,0.057581075,0.00018490969,0.00061192043,0.00007757967,0.00010639302,0.001105725],"genre_scores_gemma":[0.997348,0.00014888251,0.000057286656,0.0011348393,0.00048039888,0.00033017248,0.00011255394,0.000038197813,0.0003496629],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99832225,0.000022153354,0.000282212,0.0002991217,0.000628736,0.00044553776],"domain_scores_gemma":[0.99768615,0.0014958513,0.00010545839,0.00043160206,0.00010622821,0.00017470731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039254382,0.00020777935,0.00034736723,0.00007568784,0.00014751813,0.000011390667,0.0002170304,0.0001012647,0.000114618146],"category_scores_gemma":[0.00056129316,0.0001336123,0.00018774156,0.0004095704,0.00046878582,0.00003179921,0.00004323659,0.0002348347,0.000019384737],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008698245,0.00008027716,0.0028760417,0.0010876706,0.00033013473,0.0001519477,0.00035923973,0.000057034176,0.9399265,0.000003745347,0.04870151,0.005556095],"study_design_scores_gemma":[0.0016983367,0.000082434904,0.0008947706,0.0004946862,0.0004622334,0.000022197624,0.0012841937,0.00028762294,0.98839605,0.000012238078,0.0062341094,0.00013110819],"about_ca_topic_score_codex":0.000114454946,"about_ca_topic_score_gemma":0.000001941242,"teacher_disagreement_score":0.057670094,"about_ca_system_score_codex":0.0001272702,"about_ca_system_score_gemma":0.0002865013,"threshold_uncertainty_score":0.5448551},"labels":[],"label_agreement":null},{"id":"W4380085777","doi":"10.20944/preprints202306.0605.v1","title":"Synthesis and Evaluation of 99mTc-labeled PSMA-targeted Tracers Based on the Lys-urea-Aad Pharmacophore for Detecting Prostate Cancer with Single Photon Emission Computed Tomography","year":2023,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Terry Fox Research Institute","funders":"","keywords":"LNCaP; Prostate cancer; Chemistry; Biodistribution; Pharmacophore; Urea; In vivo; Glutamate carboxypeptidase II; Positron emission tomography; Imaging agent; In vitro; Cancer; Cancer research; Nuclear medicine; Biochemistry; Medicine; Internal medicine; Biology","score_opus":0.19778142927809567,"score_gpt":0.40944822258926994,"score_spread":0.21166679331117427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380085777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892714,0.000938541,0.000031576506,0.0018005644,0.00022734543,0.007168856,0.00019723483,0.00016504643,0.00019945085],"genre_scores_gemma":[0.99461854,0.00036609976,0.00024864892,0.00006577269,0.00008916078,0.0041440777,0.00016106125,0.00010638178,0.0002002764],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99644214,0.00038814524,0.00050825684,0.0010520638,0.0011404685,0.00046894446],"domain_scores_gemma":[0.9968156,0.0007679667,0.0004920619,0.00075365,0.00097450765,0.00019621321],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002352287,0.00046107257,0.00068072876,0.00042860585,0.00024701125,0.000029178867,0.00023496663,0.00024497186,0.00019654476],"category_scores_gemma":[0.00055205234,0.00029729964,0.00023203707,0.0005606007,0.00021021685,0.00004612819,0.00022593765,0.0006685701,0.000005499037],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011757639,0.00085181673,0.41838974,0.003404212,0.0020413706,0.000019852761,0.0025843359,0.006918679,0.52672446,0.0000011957096,0.00014062865,0.027166087],"study_design_scores_gemma":[0.0045677098,0.00029654236,0.072145,0.0034004874,0.0013776913,0.000002007825,0.00028061226,0.07399956,0.84350854,0.00007871542,0.00006147121,0.00028165657],"about_ca_topic_score_codex":0.00040597186,"about_ca_topic_score_gemma":0.00004330336,"teacher_disagreement_score":0.34624472,"about_ca_system_score_codex":0.00048175556,"about_ca_system_score_gemma":0.00082133,"threshold_uncertainty_score":0.9999479},"labels":[],"label_agreement":null},{"id":"W4380485489","doi":"10.3390/curroncol30060432","title":"Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Immunotherapy; Oncology; Androgen deprivation therapy; Disease; Cancer; Internal medicine; Prostate","score_opus":0.2826990660185457,"score_gpt":0.5315123769176361,"score_spread":0.24881331089909037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380485489","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029693608,0.9964679,0.0000016348787,0.00042661454,0.00039822818,0.0020946257,0.00007886241,0.000033941535,0.00020127269],"genre_scores_gemma":[0.00001479107,0.9945063,0.000014829932,0.000009031915,0.00012164722,0.00042079677,0.00008854124,0.00006157397,0.004762504],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99827206,0.00018830872,0.00052860373,0.00043354725,0.00018931735,0.00038816064],"domain_scores_gemma":[0.99909943,0.00020042123,0.00025456556,0.00023186972,0.00008560815,0.00012809152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025301293,0.00030962983,0.0018903937,0.0004769139,0.00002523246,0.0000093875315,0.00011202918,0.000120845056,0.000085232154],"category_scores_gemma":[0.000021547005,0.00021097533,0.00020003204,0.0005272535,0.00024170094,0.000033657525,0.00006730856,0.0005949599,0.000035998153],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026241064,0.00026941116,0.00044799194,0.010903896,0.00045379138,0.000051522435,0.0017816729,1.4454528e-7,0.0000023890905,0.000030471776,0.00092481024,0.9848715],"study_design_scores_gemma":[0.0025581303,0.00075067533,0.00042101103,0.011187777,0.00030839245,0.000024561874,0.00015309046,0.0000031105003,0.00000259615,0.00026242115,0.98416585,0.00016236157],"about_ca_topic_score_codex":0.00008684888,"about_ca_topic_score_gemma":0.00009453933,"teacher_disagreement_score":0.98470914,"about_ca_system_score_codex":0.0007739749,"about_ca_system_score_gemma":0.002837576,"threshold_uncertainty_score":0.8603324},"labels":[],"label_agreement":null},{"id":"W4380730771","doi":"10.5489/cuaj.8417","title":"Poster Session 9: Oncology - Prostate (Part 2)","year":2023,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Research Nova Scotia; Peter MacCallum Cancer Centre; Dalhousie University; Dalhousie Medical Research Foundation; McMaster University; School of Medicine, Duke University; University of Washington; Syracuse University; Bayer","keywords":"Session (web analytics); Prostate; Medicine; Medical physics; Oncology; Internal medicine; Computer science; World Wide Web; Cancer","score_opus":0.03635699526410044,"score_gpt":0.32140045201621076,"score_spread":0.2850434567521103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380730771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7945216,0.00020769503,0.0000015633095,0.18714793,0.00070638105,0.00030964855,0.000045688124,0.00007979536,0.016979741],"genre_scores_gemma":[0.9684455,0.0006036967,0.000029473009,0.005749029,0.00072237785,0.000021986601,0.00012827353,0.00001531229,0.024284357],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984595,0.00015890635,0.00023328728,0.00016001248,0.0003458912,0.0006423891],"domain_scores_gemma":[0.9985801,0.00011546731,0.00011429651,0.000075980824,0.00024759123,0.0008665472],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00080796715,0.000096375516,0.00020947859,0.00027323564,0.0003058099,0.00006026876,0.000071881026,0.00023418451,0.0011789806],"category_scores_gemma":[0.0004081655,0.000065651744,0.00009677055,0.00040305944,0.000032328768,0.00008072225,0.000020663358,0.00058693916,0.00084941176],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019867116,0.00004762394,0.7042359,0.0000063593347,0.00011656367,0.0013872619,0.00023615095,0.000006354333,0.00035256892,0.000033839668,0.27882475,0.014553959],"study_design_scores_gemma":[0.0013942595,0.0006207572,0.41351524,0.000014417721,0.00003102473,0.00019461937,0.000073371135,0.00004132455,0.00006406025,0.000415956,0.5835647,0.00007025262],"about_ca_topic_score_codex":0.00022807835,"about_ca_topic_score_gemma":0.00022134255,"teacher_disagreement_score":0.30473995,"about_ca_system_score_codex":0.0019279928,"about_ca_system_score_gemma":0.0012260812,"threshold_uncertainty_score":0.99992853},"labels":[],"label_agreement":null},{"id":"W4380730790","doi":"10.5489/cuaj.8411","title":"Poster Session 3: Oncology - Prostate (Part 1)","year":2023,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"BC Cancer Agency; Université de Montréal; University of Toronto; Dalhousie University; Janssen Canada; Bayer HealthCare; Queen's University; McMaster University; Jewish General Hospital; McGill University; University of Ottawa; University of Alberta; Université Laval; Bayer","keywords":"Session (web analytics); Medicine; Medical physics; Prostate cancer; Oncology; Internal medicine; Computer science; World Wide Web; Cancer","score_opus":0.036814596790499796,"score_gpt":0.32131306408279026,"score_spread":0.28449846729229045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380730790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79717606,0.00020781363,0.0000015522284,0.18557428,0.00069431274,0.00030461524,0.000044873395,0.00007855164,0.015917927],"genre_scores_gemma":[0.96899295,0.00061125925,0.000029524499,0.0056173205,0.00071431254,0.000021750791,0.00012775962,0.000015151355,0.023869982],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99845845,0.00015883474,0.00023443824,0.00016032031,0.00034581643,0.00064216455],"domain_scores_gemma":[0.9985881,0.00011536432,0.000114814415,0.00007598399,0.0002480288,0.00085773115],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008130026,0.000096360345,0.00020936775,0.0002729502,0.00030569988,0.00006037734,0.000071885275,0.00023414918,0.0011488998],"category_scores_gemma":[0.00040315636,0.00006564244,0.00009674313,0.0004024293,0.000032318578,0.00008065707,0.000020669946,0.0005868598,0.0008505528],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019781677,0.000047109123,0.70936704,0.000006283306,0.0001151597,0.0013690658,0.00023705346,0.000006194344,0.00036235488,0.00003408555,0.2735386,0.014719276],"study_design_scores_gemma":[0.0014091266,0.00063378445,0.4153159,0.000014787399,0.00003134058,0.00020285034,0.0000761726,0.000040617153,0.00006538082,0.0004227138,0.58171636,0.000071007795],"about_ca_topic_score_codex":0.00022582947,"about_ca_topic_score_gemma":0.00021834242,"teacher_disagreement_score":0.30817774,"about_ca_system_score_codex":0.0019276324,"about_ca_system_score_gemma":0.0012234016,"threshold_uncertainty_score":0.9999274},"labels":[],"label_agreement":null},{"id":"W4381162988","doi":"10.1016/j.modpat.2023.100241","title":"Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study","year":2023,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University Health Network; Queen's University; Princess Margaret Cancer Centre; University of British Columbia; Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health; Canary Foundation","keywords":"PTEN; Medicine; Tensin; Hazard ratio; Prostate cancer; Internal medicine; Metastasis; Oncology; Tissue microarray; Cancer; Pathology; Biology","score_opus":0.061643567711367274,"score_gpt":0.38491510160279613,"score_spread":0.3232715338914289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381162988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593216,0.00015796929,0.00042898246,0.00092482526,0.00024786938,0.0017661768,0.0003750377,0.000118499345,0.000048469017],"genre_scores_gemma":[0.99762374,0.00010575902,0.000159559,0.00009176007,0.000093314506,0.001333532,0.00012195213,0.000051924533,0.00041843357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99737626,0.0003266526,0.0004907735,0.00067006244,0.00057046127,0.0005657923],"domain_scores_gemma":[0.998729,0.00009250296,0.00013587596,0.00049492,0.0003528462,0.00019489198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070585107,0.00024744347,0.00065901683,0.0004310947,0.000076505974,0.000025018757,0.00011497733,0.00011078337,0.00028073814],"category_scores_gemma":[0.000071705,0.00018887663,0.00015993243,0.000494612,0.00026518045,0.00011341078,0.00009261627,0.00028872452,0.000045032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043044346,0.0017811693,0.9666949,0.0000879486,0.00033957994,0.0028095094,0.0054646814,0.00006748298,0.001925436,0.000015076212,0.000029659988,0.016480152],"study_design_scores_gemma":[0.0012363995,0.0027354266,0.9783015,0.000086750246,0.00033417728,0.000008802441,0.0008731726,0.0070585078,0.007970748,0.0011781335,0.000014667453,0.00020171075],"about_ca_topic_score_codex":0.00039410245,"about_ca_topic_score_gemma":0.00026420518,"teacher_disagreement_score":0.01627844,"about_ca_system_score_codex":0.00027218353,"about_ca_system_score_gemma":0.0004763471,"threshold_uncertainty_score":0.7702166},"labels":[],"label_agreement":null},{"id":"W4381614970","doi":"10.2967/jnumed.123.265759","title":"The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy","year":2023,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Prostate cancer; Interquartile range; Prostate-specific antigen; Prostate; Urology; Internal medicine; Antigen; Oncology; Cancer; Immunology","score_opus":0.049338327281968485,"score_gpt":0.32482347439206005,"score_spread":0.2754851471100916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381614970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8894737,0.008152646,0.000001724753,0.100932166,0.00027758224,0.0008401337,0.000009670844,0.000051924177,0.00026049276],"genre_scores_gemma":[0.8920414,0.102050245,0.000103382714,0.0011152468,0.00077056326,0.000023252493,0.00001592435,0.000101241385,0.0037787834],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99649066,0.00043604107,0.000891796,0.00034462323,0.0010843948,0.0007525041],"domain_scores_gemma":[0.997795,0.0006211292,0.0002439274,0.00054137636,0.00027042624,0.00052813167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026898526,0.00032977012,0.000822889,0.000990991,0.0002617907,0.000047563222,0.00033951682,0.000120919416,0.00053846644],"category_scores_gemma":[0.00032892346,0.00017341632,0.00018209215,0.0015656397,0.00036074407,0.00012767015,0.00006205267,0.0005299654,0.00027627617],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36346114,0.0011442199,0.0069436044,0.00008968375,0.0014227271,0.012334138,0.046378896,0.000980668,0.18342136,0.00013081328,0.18039432,0.20329842],"study_design_scores_gemma":[0.033999898,0.030296335,0.08605507,0.00088769384,0.00009993753,0.0004889859,0.026317552,0.0006762446,0.00095168845,0.00026474477,0.8196257,0.00033615297],"about_ca_topic_score_codex":0.000060118648,"about_ca_topic_score_gemma":0.0000043548857,"teacher_disagreement_score":0.6392314,"about_ca_system_score_codex":0.0009415862,"about_ca_system_score_gemma":0.000395008,"threshold_uncertainty_score":0.7071712},"labels":[],"label_agreement":null},{"id":"W4382794886","doi":"10.1016/j.annonc.2023.06.009","title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"Janssen Research and Development; National Cancer Institute; Genentech; Astellas Pharma; Ipsen; Clovis Oncology; Taiho Pharmaceutical; Gilead Sciences; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Takeda Oncology; Amgen; Pfizer; Daiichi Sankyo Europe; Sanofi; Abbott Laboratories","keywords":"Medicine; Abiraterone acetate; Interim analysis; Prednisone; Prostate cancer; Hazard ratio; Internal medicine; Progression-free survival; Urology; Oncology; Chemotherapy; Confidence interval; Gastroenterology; Androgen deprivation therapy; Randomized controlled trial; Cancer","score_opus":0.0673827402915172,"score_gpt":0.3994581347533062,"score_spread":0.332075394461789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382794886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99486256,0.00039322968,0.000010199798,0.0012227135,0.000060664654,0.0031701485,0.00018672225,0.000017863,0.000075924734],"genre_scores_gemma":[0.99740195,0.00052572467,0.00023768753,0.00008132388,0.0000096075755,0.00070052827,0.00034778038,0.000013453466,0.0006819143],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99820507,0.00038120124,0.00063444587,0.00027585917,0.00026997578,0.00023346505],"domain_scores_gemma":[0.99858665,0.00022414015,0.00043097377,0.00021662854,0.00048024743,0.00006134578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080772676,0.00015232446,0.0010384094,0.00048506475,0.00006198056,0.000011694305,0.00006417847,0.00005233069,0.000062329345],"category_scores_gemma":[0.000090269335,0.000084572785,0.00011347429,0.0010516661,0.0003850435,0.000113940056,0.000037015358,0.00012461098,4.2290796e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.976165,0.0016574905,0.0063430336,0.00018024333,0.005400755,0.000059060312,0.0034813108,0.0006426948,0.0018138618,0.000027540957,0.0001616837,0.0040673306],"study_design_scores_gemma":[0.92627704,0.014877748,0.04738759,0.00013373919,0.0020479134,0.0000034198963,0.00033316095,0.0021359117,0.0065408465,0.00008636175,0.000050434024,0.00012581308],"about_ca_topic_score_codex":0.000427061,"about_ca_topic_score_gemma":0.0025297394,"teacher_disagreement_score":0.04988793,"about_ca_system_score_codex":0.00009839766,"about_ca_system_score_gemma":0.0006179163,"threshold_uncertainty_score":0.3448778},"labels":[],"label_agreement":null},{"id":"W4382862739","doi":"10.1101/2023.06.29.547118","title":"RNF185 control of COL3A1 expression limits prostate cancer migration and metastatic potential","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Cancer research; Metastasis; Ubiquitin ligase; Prostate; Cancer; Downregulation and upregulation; Carcinogenesis; Cell migration; Small hairpin RNA; Biology; Medicine; Gene knockdown; Ubiquitin; Cell culture; Internal medicine; Gene","score_opus":0.027155313720980106,"score_gpt":0.28407331440768135,"score_spread":0.25691800068670123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382862739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864257,0.007425795,0.0004953664,0.0015032741,0.0006327689,0.0024682935,0.000760927,0.00028630873,0.0000015970179],"genre_scores_gemma":[0.99133515,0.006333369,0.00097542687,0.00007226383,0.00022402914,0.0008367992,0.0000022183995,0.00014836689,0.00007238305],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99747694,0.00014017106,0.00053829513,0.0007641104,0.00060562696,0.00047484628],"domain_scores_gemma":[0.9978941,0.00007581199,0.00039408176,0.000613303,0.0007124916,0.00031023286],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004381362,0.00041993594,0.00079863064,0.00035293293,0.00011569975,0.00008405477,0.00015253738,0.0002642286,0.00003455028],"category_scores_gemma":[0.00014463802,0.0003535747,0.00014156096,0.000355515,0.00019444214,0.000113533766,0.00018058698,0.00052921375,0.000017741975],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007999513,0.00019662458,0.037284818,0.0021271184,0.0005369937,0.00019511415,0.000040443007,0.000098644865,0.9582084,0.00001902726,0.0004816267,0.000011257552],"study_design_scores_gemma":[0.0054059573,0.00034544835,0.24054208,0.0026779722,0.0009466347,5.8074885e-8,0.000015203225,0.0019713263,0.7469719,0.0000048618163,0.00064151234,0.00047704455],"about_ca_topic_score_codex":0.0003126154,"about_ca_topic_score_gemma":0.000014687265,"teacher_disagreement_score":0.21123648,"about_ca_system_score_codex":0.00022209286,"about_ca_system_score_gemma":0.0009958253,"threshold_uncertainty_score":0.99989164},"labels":[],"label_agreement":null},{"id":"W4382940377","doi":"10.3390/curroncol30070464","title":"Head-to-Head Comparison of [18F]F-choline and Imaging of Prostate-Specific Membrane Antigen, Using [18F]DCFPyL PET/CT, in Patients with Biochemical Recurrence of Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Biochemical recurrence; Medicine; Prostate cancer; Choline; Stage (stratigraphy); Nuclear medicine; Prostate; Radiology; Prostatectomy; Cancer; Internal medicine; Biology","score_opus":0.1394238333813858,"score_gpt":0.46525614572381946,"score_spread":0.32583231234243365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382940377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917912,0.0058396175,0.000005173616,0.00035972364,0.00029420006,0.0014594543,0.00019900694,0.000020600562,0.00003105994],"genre_scores_gemma":[0.9967339,0.002605472,0.00029930865,0.000008891026,0.00003266514,0.000065808475,0.00020608865,0.000027423477,0.000020419922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977982,0.000094422256,0.000721987,0.0004649685,0.00042800503,0.00049241114],"domain_scores_gemma":[0.99866134,0.00011328905,0.00031631006,0.00025453937,0.00047370067,0.0001808513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029065015,0.00022917095,0.00090963545,0.0005093546,0.00003999574,0.000005640894,0.00011861184,0.000020258674,0.000025010631],"category_scores_gemma":[0.000064490676,0.0001768686,0.00005294407,0.0010860895,0.0004843006,0.00007651879,0.00014177043,0.00033402728,0.0000021043027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003342822,0.0013834578,0.95077527,0.0010799033,0.000049956965,0.00007136615,0.0011384146,0.00007043707,0.015004943,0.0000041889616,0.0003095555,0.02676968],"study_design_scores_gemma":[0.018585986,0.002995064,0.8415528,0.004100798,0.00013503611,0.000044194807,0.0008528985,0.0032172466,0.124719076,0.000027753278,0.0033795673,0.0003895723],"about_ca_topic_score_codex":0.00017495985,"about_ca_topic_score_gemma":0.00005879667,"teacher_disagreement_score":0.109714136,"about_ca_system_score_codex":0.0002603617,"about_ca_system_score_gemma":0.00043325336,"threshold_uncertainty_score":0.7212492},"labels":[],"label_agreement":null},{"id":"W4383059223","doi":"10.1002/cncr.34910","title":"Enzalutamide shows sustained overall survival improvement in patients with metastatic hormone‐sensitive prostate cancer","year":2023,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Bicalutamide; Flutamide; Oncology; Antiandrogen; Testosterone (patch); Docetaxel; Internal medicine; Cancer; Interim analysis; Randomized controlled trial; Gynecology; Androgen receptor","score_opus":0.020878392012435947,"score_gpt":0.3122442329283145,"score_spread":0.2913658409158785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383059223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943692,0.0007879624,0.0000044998446,0.00164021,0.00019825106,0.0021362847,0.00033806174,0.00009672927,0.00042881578],"genre_scores_gemma":[0.98663074,0.0014330614,0.000038705846,0.0003771742,0.0000956348,0.00076203124,0.00027015072,0.00006517535,0.010327343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774516,0.000055401168,0.00027785407,0.00048640146,0.0006536622,0.0007815415],"domain_scores_gemma":[0.99901044,0.00006102055,0.00008762857,0.00026043213,0.00036632133,0.0002141365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002127662,0.00027637352,0.00046507604,0.00026586355,0.00008038318,0.000027987415,0.000078004865,0.000049487222,0.00015054691],"category_scores_gemma":[0.000031064505,0.00019019913,0.000065867345,0.0007058891,0.00014192646,0.00014818965,0.00007809159,0.000258925,0.000026994527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02106693,0.0008160391,0.90322334,0.00076331437,0.0015852315,0.0012207722,0.006267995,0.0007579646,0.012541494,0.00012723521,0.008360302,0.043269373],"study_design_scores_gemma":[0.027263353,0.0018752948,0.9557928,0.00038686988,0.00025258574,0.0000010117693,0.002037317,0.00050704315,0.0093330275,0.00010599588,0.0019666702,0.0004780756],"about_ca_topic_score_codex":0.00153363,"about_ca_topic_score_gemma":0.00085675245,"teacher_disagreement_score":0.052569408,"about_ca_system_score_codex":0.0011849846,"about_ca_system_score_gemma":0.0007200267,"threshold_uncertainty_score":0.77560955},"labels":[],"label_agreement":null},{"id":"W4383199021","doi":"10.3389/fgene.2023.1184704","title":"Comprehensive analysis of the progression mechanisms of CRPC and its inhibitor discovery based on machine learning algorithms","year":2023,"lang":"en","type":"article","venue":"Frontiers in Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Dali University; Yunnan Provincial Department of Education","keywords":"KEGG; Prostate cancer; Computational biology; Microarray analysis techniques; Biology; Bioinformatics; Machine learning; Cancer; Gene ontology; Gene; Gene expression; Computer science; Genetics","score_opus":0.022245147119586247,"score_gpt":0.3093047040893795,"score_spread":0.28705955696979324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383199021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99391204,0.0029187899,0.0019789168,0.00036908424,0.00022841875,0.00046585387,0.00006172999,0.000012657707,0.0000524836],"genre_scores_gemma":[0.99602014,0.00094717194,0.002512032,0.000024762869,0.000014446086,0.000012904957,0.00007009951,0.000011914529,0.00038655297],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99912363,0.00007320788,0.00016940656,0.00015783867,0.00033310454,0.00014279796],"domain_scores_gemma":[0.9996237,0.00004279168,0.0000775029,0.00014984606,0.00006742503,0.00003872492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000110251305,0.00008609179,0.0002850924,0.00037914183,0.000038438007,0.000005519994,0.000060533675,0.00005452077,0.0000041103976],"category_scores_gemma":[0.000031793057,0.00005320449,0.000080117345,0.0010358666,0.000078687255,0.000015024614,0.00006690921,0.000139936,2.8010692e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011739744,0.0003611232,0.8851525,0.00060327514,0.0010896027,0.000048043417,0.0009881373,0.023818254,0.05219169,0.000033955308,0.0005824893,0.033956952],"study_design_scores_gemma":[0.0018238012,0.00064216583,0.17511667,0.00023832818,0.00044916844,3.5046128e-7,0.00041785327,0.656883,0.16408224,0.000084065236,0.0001871051,0.00007523657],"about_ca_topic_score_codex":0.000006381931,"about_ca_topic_score_gemma":0.0000021607711,"teacher_disagreement_score":0.71003586,"about_ca_system_score_codex":0.000030780277,"about_ca_system_score_gemma":0.00005393799,"threshold_uncertainty_score":0.21696162},"labels":[],"label_agreement":null},{"id":"W4383302397","doi":"10.1158/1541-7786.mcr-23-0086","title":"Hierarchical Phosphorylation of HOXB13 by mTOR Dictates Its Activity and Oncogenic Function in Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; Terry Fox Research Institute; Génome Québec; McGill University; Canadian Institutes of Health Research; Cancer Research Society; Université Laval","keywords":"Prostate cancer; PI3K/AKT/mTOR pathway; Cancer research; Biology; Transcription factor; Cancer; Cell biology; Gene; Signal transduction; Genetics","score_opus":0.04432699187842464,"score_gpt":0.38935397516614645,"score_spread":0.3450269832877218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383302397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97917384,0.014936284,0.000011593875,0.004238484,0.00007001823,0.001203812,0.00011352199,0.000042058546,0.00021036205],"genre_scores_gemma":[0.98125994,0.014917885,0.00000956435,0.000036065114,0.00004164647,0.00087739376,0.00007676103,0.000040136943,0.002740626],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974531,0.00023315055,0.00021352999,0.00047357386,0.000989988,0.0006366724],"domain_scores_gemma":[0.99911505,0.00011583216,0.000044923854,0.0002170131,0.00029651055,0.00021067426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007865247,0.00015207613,0.00029764904,0.00050121435,0.00010656522,0.000028418128,0.00009014515,0.00010281338,0.00014368485],"category_scores_gemma":[0.00010177439,0.00012835176,0.00006110695,0.0016255497,0.00025480395,0.000112601294,0.00013786835,0.0005973426,0.000017505718],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032407555,0.00015732477,0.04558541,0.00041576067,0.00013684403,0.00012902795,0.0004928435,0.0000413535,0.8942318,0.00003517708,0.0019303241,0.053603373],"study_design_scores_gemma":[0.004349555,0.00091655465,0.15486935,0.0003894193,0.00004658541,0.0000034951092,0.00014799107,0.0023685026,0.8331714,0.00035077365,0.0031990113,0.00018732507],"about_ca_topic_score_codex":0.002414568,"about_ca_topic_score_gemma":0.00017899605,"teacher_disagreement_score":0.10928394,"about_ca_system_score_codex":0.00045049013,"about_ca_system_score_gemma":0.0006214645,"threshold_uncertainty_score":0.5234033},"labels":[],"label_agreement":null},{"id":"W4384500426","doi":"10.3389/fonc.2023.1217741","title":"Ultrastructural analysis of prostate cancer tissue provides insights into androgen-dependent adaptations to membrane contact site establishment","year":2023,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Council South Australia; Queen's University; Prostate Cancer Foundation of Australia; Queen's University Belfast; Rosetrees Trust; Government of South Australia; Movember Foundation; Prostate Cancer Foundation","keywords":"Prostate cancer; Enzalutamide; Organelle; Prostate; Mitochondrion; Cancer; Cancer cell; Biology; Pathology; Cancer research; Medicine; Internal medicine; Cell biology; Androgen receptor","score_opus":0.01914477600425131,"score_gpt":0.3440688740405791,"score_spread":0.3249240980363278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384500426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99328446,0.0018196375,0.00014177915,0.0024161548,0.00054166274,0.0013348503,0.000090523106,0.000047273268,0.00032366923],"genre_scores_gemma":[0.9921993,0.0022642643,0.0022393358,0.00015234844,0.00004769396,0.00047006502,0.00039930549,0.000019160825,0.0022085449],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838793,0.00010569699,0.00040077066,0.00038240248,0.00033422894,0.00038895351],"domain_scores_gemma":[0.99920106,0.00008747659,0.000104527826,0.00022531838,0.00017772923,0.00020386101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001907825,0.00016382463,0.00071526103,0.001489146,0.000067179746,0.000014002763,0.00011451292,0.00011220943,0.00010119524],"category_scores_gemma":[0.000074814874,0.00012863672,0.000087958004,0.002448228,0.00009829146,0.00010633363,0.00006278639,0.00017464791,0.000010656081],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036255869,0.00033334567,0.72626454,0.00024021314,0.0031983715,0.0006161776,0.03361065,0.0053444044,0.08462289,0.000060283946,0.007575885,0.13450766],"study_design_scores_gemma":[0.010905935,0.0049464186,0.78989947,0.00022482895,0.0028071778,0.000012624071,0.012202716,0.008456622,0.11594249,0.00048793288,0.05356401,0.0005497772],"about_ca_topic_score_codex":0.0023188945,"about_ca_topic_score_gemma":0.005199968,"teacher_disagreement_score":0.13395788,"about_ca_system_score_codex":0.0009795242,"about_ca_system_score_gemma":0.0005685111,"threshold_uncertainty_score":0.5245653},"labels":[],"label_agreement":null},{"id":"W4384626656","doi":"10.1111/bju.16130","title":"Poly(adenosine diphosphate‐ribose) polymerase inhibitor combinations in first‐line metastatic castrate‐resistant prostate cancer setting: a systematic review and m <scp>eta‐analysis</scp>","year":2023,"lang":"en","type":"review","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University Health Network; SickKids Foundation; University of Toronto; Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"Astellas Pharma; AstraZeneca; Pfizer","keywords":"Medicine; Hazard ratio; Internal medicine; Oncology; Cohort; Prostate cancer; Cochrane Library; Adverse effect; Meta-analysis; Placebo; Breast cancer; Relative risk; Cohort study; Confidence interval; Cancer; Pathology","score_opus":0.03988174622267645,"score_gpt":0.35716425593178075,"score_spread":0.3172825097091043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384626656","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020131908,0.993968,0.000007967435,0.0017111099,0.00014940825,0.0032542485,0.0006555761,0.00002634106,0.000026000514],"genre_scores_gemma":[0.00082228094,0.99569935,0.000041448333,0.00023281043,0.000112007634,0.00054190034,0.00030223423,0.00010676812,0.0021411795],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99403757,0.0009958885,0.0029855052,0.0005509199,0.0006643951,0.0007657504],"domain_scores_gemma":[0.99547285,0.0011489483,0.0020750305,0.00031281754,0.0005182932,0.00047204984],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019536389,0.0005725959,0.0066182856,0.0013236626,0.00016682417,0.00012821864,0.00029661172,0.00024470247,0.00004879796],"category_scores_gemma":[0.0013507059,0.00046446783,0.0008947207,0.0024554161,0.00023780495,0.00015559222,0.00012723291,0.0013389819,0.000015674777],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057775684,0.000671069,0.000100621175,0.9388902,0.013732556,0.022169888,0.00016274139,0.0000041138637,0.0000015957077,0.000011600474,0.0023615751,0.021836221],"study_design_scores_gemma":[0.0067592915,0.001825527,0.0004053456,0.73967856,0.20586824,0.020065589,0.00017233058,0.00005901921,0.000006211523,0.00008741845,0.024667626,0.00040480573],"about_ca_topic_score_codex":0.0004777186,"about_ca_topic_score_gemma":0.0006625097,"teacher_disagreement_score":0.19921166,"about_ca_system_score_codex":0.00036758633,"about_ca_system_score_gemma":0.0013465715,"threshold_uncertainty_score":0.9997807},"labels":[],"label_agreement":null},{"id":"W4384665016","doi":"10.1002/pros.24599","title":"Real‐world evidence of outcomes of oligometastatic hormone‐sensitive prostate cancer patients treated with metastasis‐directed therapy","year":2023,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Androgen deprivation therapy; Prostatectomy; Oncology; Docetaxel; Internal medicine; Radiation therapy; Urology; Lymph node; External beam radiotherapy; Hormone therapy; Metastasis; Cancer; Breast cancer; Androgen receptor","score_opus":0.053400976008500356,"score_gpt":0.3566562870622521,"score_spread":0.30325531105375175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384665016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99298763,0.001347809,8.014587e-7,0.0018779542,0.00004043507,0.002891961,0.00040297402,0.00017150752,0.000278949],"genre_scores_gemma":[0.97575974,0.017353619,0.00010090557,0.00007448365,0.000012411799,0.00039540257,0.00014391523,0.00006455182,0.006094963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974718,0.00021146423,0.0005416825,0.00038713458,0.00082186575,0.00056603434],"domain_scores_gemma":[0.99761957,0.00046022853,0.00038533108,0.00050739065,0.0008861608,0.00014129537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052041217,0.0003323487,0.00084158184,0.00043600352,0.000118952295,0.000017964381,0.00017149819,0.00003561807,0.000033668013],"category_scores_gemma":[0.00009325686,0.00016309725,0.00014341973,0.002394761,0.00048202023,0.00016601989,0.000081484795,0.0002109292,0.000019031371],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021184342,0.00077196315,0.89441377,0.0005668017,0.0036005536,0.000115628136,0.010489671,0.000082526596,0.049816865,0.000030906274,0.0009958068,0.017931143],"study_design_scores_gemma":[0.005831466,0.0023770644,0.85033196,0.00060078234,0.0004398657,0.000002148166,0.0004099634,0.00013065853,0.13953187,0.00007125391,0.00007925605,0.00019373279],"about_ca_topic_score_codex":0.002863004,"about_ca_topic_score_gemma":0.000224629,"teacher_disagreement_score":0.089715,"about_ca_system_score_codex":0.00013328074,"about_ca_system_score_gemma":0.0003378803,"threshold_uncertainty_score":0.6650913},"labels":[],"label_agreement":null},{"id":"W4384926921","doi":"10.1016/j.ccell.2023.06.010","title":"Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"University of Texas Southwestern Medical Center; Cancer Prevention and Research Institute of Texas; Terry Fox Foundation; Welch Foundation; Damon Runyon Cancer Research Foundation; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation; Howard Hughes Medical Institute; U.S. Department of Defense","keywords":"APOBEC; Mutagenesis; Biology; Cancer research; Prostate cancer; Cytosine deaminase; Mutation; Targeted therapy; Cancer; Genetics; Gene; Genetic enhancement; Genome","score_opus":0.03132180917794032,"score_gpt":0.3249537764548714,"score_spread":0.2936319672769311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384926921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9119495,0.085188776,7.579168e-7,0.0010461933,0.00015671091,0.00088632427,0.00018271811,0.00006502631,0.0005239744],"genre_scores_gemma":[0.89964026,0.096560694,0.00005907356,0.00016647176,0.00008480829,0.000485496,0.00003958751,0.00005021817,0.0029133833],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99825466,0.000070031885,0.00032198022,0.0004819215,0.00034478743,0.00052662357],"domain_scores_gemma":[0.99920726,0.000054185675,0.000112894624,0.00030958137,0.00013754569,0.0001785338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016732789,0.00023951604,0.00047271416,0.00016361948,0.000070386195,0.000018317685,0.00013049941,0.000063264815,0.00013941414],"category_scores_gemma":[0.000010785941,0.00019090934,0.00008143496,0.00065074454,0.00022113069,0.0001014077,0.000071773895,0.00015965017,0.000010555914],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022869417,0.00020197955,0.8661928,0.0012239037,0.00017525749,0.0004926808,0.0015800718,0.00010243852,0.1214616,0.000018637242,0.002199807,0.004063849],"study_design_scores_gemma":[0.007268272,0.0002870533,0.47850448,0.00072751567,0.000053150874,0.0000050830877,0.00041868628,0.00018229806,0.503054,0.0001199632,0.009041363,0.0003381469],"about_ca_topic_score_codex":0.0016813519,"about_ca_topic_score_gemma":0.0039005226,"teacher_disagreement_score":0.38768837,"about_ca_system_score_codex":0.0003137162,"about_ca_system_score_gemma":0.00041799192,"threshold_uncertainty_score":0.77850574},"labels":[],"label_agreement":null},{"id":"W4384937683","doi":"10.1016/j.euo.2023.06.010","title":"Efficacy and Effectiveness: Bridging the Gap Between Clinical Trials and Real-world Practice","year":2023,"lang":"en","type":"editorial","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Clinical trial; Oncology; Androgen deprivation therapy; Internal medicine; Cancer","score_opus":0.19224935275203967,"score_gpt":0.5299734068866627,"score_spread":0.33772405413462303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384937683","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024830129,0.0069979215,0.000035530502,0.025897512,0.90784585,0.004291468,0.0002509561,0.00042561468,0.029424986],"genre_scores_gemma":[0.010380692,0.029715378,0.00007609835,0.0006465978,0.9545496,0.000101315454,0.0007087715,0.0002441458,0.0035774042],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.96824926,0.02840342,0.0011945078,0.0010753581,0.00041330032,0.00066417654],"domain_scores_gemma":[0.8520632,0.14617372,0.0006840653,0.0005128006,0.0002559544,0.00031026878],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.036889236,0.00042637312,0.0022603602,0.00030734396,0.00029491156,0.000054991793,0.0002741795,0.00077732536,0.000020840573],"category_scores_gemma":[0.058877543,0.00026770632,0.00019845822,0.00028617177,0.0014073728,0.00005993176,0.00064296706,0.0032816592,0.00022707619],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009693817,0.00019669335,0.0042139622,0.00017853506,0.0018831317,0.0029022114,0.00018804267,3.6994788e-7,0.000024967609,0.000035042518,0.9223797,0.058303554],"study_design_scores_gemma":[0.012138231,0.0051400964,0.086153544,0.00009724364,0.0027611814,0.000051815332,0.000027587976,0.000003926952,0.0000030242657,0.00004317794,0.8933939,0.00018628628],"about_ca_topic_score_codex":0.00014322554,"about_ca_topic_score_gemma":0.000042150015,"teacher_disagreement_score":0.11777029,"about_ca_system_score_codex":0.00017975639,"about_ca_system_score_gemma":0.0008965401,"threshold_uncertainty_score":0.9999775},"labels":[],"label_agreement":null},{"id":"W4384942558","doi":"10.1111/bju.15796","title":"Table of Contents","year":2023,"lang":"fr","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Table of contents; Table (database); Citation; Information retrieval; Library science; World Wide Web; Database; Computer science","score_opus":0.041535382158415624,"score_gpt":0.3263736972979674,"score_spread":0.28483831513955177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384942558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56358767,0.41254848,0.000052462565,0.014504355,0.005154723,0.00021554473,0.0001360759,0.000011474506,0.0037892084],"genre_scores_gemma":[0.8661117,0.0995175,0.000051549607,0.0002358219,0.0008739064,0.0000022943445,0.000013699118,0.00002111593,0.03317239],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839,0.00016433513,0.0005261949,0.00010848938,0.00031374057,0.00049720454],"domain_scores_gemma":[0.9987505,0.00017756801,0.00026470277,0.00008765326,0.00050248206,0.00021708105],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00067206146,0.00008445331,0.00048972596,0.00020052206,0.000047013884,0.0000136592,0.00014852543,0.00015767282,0.0010928215],"category_scores_gemma":[0.00039089812,0.00008955631,0.00014745152,0.00039676338,0.00035046137,0.00010056305,0.000058888174,0.0004613518,0.00013650995],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023242,0.0010465926,0.062338997,0.0007123764,0.0017896928,0.0692879,0.00042955467,0.00016772801,0.010091386,0.00038863556,0.3859975,0.46542543],"study_design_scores_gemma":[0.02362609,0.010414512,0.2848062,0.002586003,0.001003669,0.054987207,0.0008603348,0.000545441,0.004161594,0.002319222,0.61442757,0.0002621688],"about_ca_topic_score_codex":0.00030313584,"about_ca_topic_score_gemma":0.000029229011,"teacher_disagreement_score":0.46516326,"about_ca_system_score_codex":0.00005348631,"about_ca_system_score_gemma":0.00033999336,"threshold_uncertainty_score":0.9998203},"labels":[],"label_agreement":null},{"id":"W4385196540","doi":"10.1158/1535-7163.mct-23-0196","title":"A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Division of Chemistry; National Cancer Institute; National Science Foundation; National Institutes of Health; School of Medicine, New York University; KU Leuven; New York State Department of Health","keywords":"Enzalutamide; Androgen receptor; Prostate cancer; Cancer research; Chemistry; Cancer; Biology; Cell biology; Genetics","score_opus":0.05644194386507937,"score_gpt":0.3467204731395425,"score_spread":0.2902785292744631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385196540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.967693,0.012276008,0.00008001751,0.016643561,0.0003140189,0.0020671927,0.0005616866,0.00023932052,0.0001252289],"genre_scores_gemma":[0.97376335,0.017718446,0.00013807388,0.0021281296,0.00015008159,0.0014497255,0.00012129726,0.00012440557,0.0044064787],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99739254,0.00011177872,0.0002848665,0.00064502825,0.0007808912,0.0007849111],"domain_scores_gemma":[0.99886405,0.000031784137,0.000075905984,0.000398123,0.0002915409,0.00033862007],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021641083,0.00039073805,0.00044610663,0.00024824933,0.000200912,0.000064634885,0.00016590406,0.00013836741,0.000384637],"category_scores_gemma":[0.000006406534,0.00031007585,0.00023964002,0.00087065157,0.00014425644,0.00009039865,0.000058238234,0.00031082446,0.00010175601],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004497935,0.0002517337,0.0038552945,0.00011658951,0.00094829337,0.00010230076,0.0017425845,0.0004382093,0.9342128,0.000028865892,0.00043171976,0.053373694],"study_design_scores_gemma":[0.005792536,0.0007249111,0.01519942,0.00029049476,0.0001532947,0.000004350311,0.00013491132,0.0009399322,0.87957895,0.00012489443,0.09660816,0.00044811913],"about_ca_topic_score_codex":0.00041365033,"about_ca_topic_score_gemma":0.00006800079,"teacher_disagreement_score":0.09617644,"about_ca_system_score_codex":0.00052408164,"about_ca_system_score_gemma":0.0005267996,"threshold_uncertainty_score":0.99993515},"labels":[],"label_agreement":null},{"id":"W4385235870","doi":"10.1200/cci.23.00057","title":"Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"JCO Clinical Cancer Informatics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Oncology; Enzalutamide; Logistic regression; Internal medicine; Medicine; Androgen deprivation therapy; Cohort; Cancer; Machine learning; Artificial intelligence; Computer science; Androgen receptor","score_opus":0.1937656149995228,"score_gpt":0.4384379232149948,"score_spread":0.244672308215472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385235870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648094,0.0013843292,0.00012538655,0.00028501928,0.00015463894,0.0012554621,0.00021747068,0.00007405661,0.000022716298],"genre_scores_gemma":[0.9901359,0.0051108906,0.00364568,0.00026198558,0.000050277933,0.00021288221,0.00024189055,0.000042151456,0.00029835833],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9974435,0.00014893604,0.001428092,0.0002044459,0.00034930478,0.00042571753],"domain_scores_gemma":[0.99851775,0.00036357582,0.00056763797,0.00017856722,0.00021439661,0.0001580985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012703491,0.0002308164,0.00075084646,0.0003644312,0.000084706706,0.000032734315,0.00010048998,0.00010690597,0.000032497654],"category_scores_gemma":[0.00038989045,0.00017669477,0.00012714052,0.0006339798,0.00020831965,0.00024078223,0.00008802934,0.00063202844,0.000005557597],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022660058,0.0007165995,0.8666712,0.0023177692,0.00067080715,0.000045999037,0.0056767873,0.09328318,0.014225604,0.000017760754,0.000114663446,0.013993597],"study_design_scores_gemma":[0.01068596,0.00038565908,0.04050282,0.00091865397,0.00036542138,0.000002589167,0.00059866416,0.9438032,0.002464571,0.00004964954,0.000043828826,0.00017896836],"about_ca_topic_score_codex":0.0017843827,"about_ca_topic_score_gemma":0.00075269525,"teacher_disagreement_score":0.85052,"about_ca_system_score_codex":0.000289946,"about_ca_system_score_gemma":0.0009938398,"threshold_uncertainty_score":0.72054034},"labels":[],"label_agreement":null},{"id":"W4385283982","doi":"10.1158/1541-7786.c.6760431.v1","title":"Data from Hierarchical Phosphorylation of HOXB13 by mTOR Dictates Its Activity and Oncogenic Function in Prostate Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Prostate cancer; PI3K/AKT/mTOR pathway; Cancer research; Biology; Transcription factor; Cancer; Cell biology; Gene; Signal transduction; Genetics","score_opus":0.08840808824431272,"score_gpt":0.37014682022613943,"score_spread":0.2817387319818267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385283982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813246,0.008870769,0.00006866185,0.0024403532,0.00030544295,0.0013625808,0.0054282728,0.00007177895,0.00012753006],"genre_scores_gemma":[0.9659973,0.020995958,0.0001054162,0.000029601733,0.0001137871,0.00023080678,0.0071400353,0.000043254473,0.0053438563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981355,0.00008319371,0.00030687937,0.00078978547,0.00041834978,0.0002662904],"domain_scores_gemma":[0.9988759,0.00018575735,0.00013640817,0.00056793686,0.0000960745,0.00013793615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028185453,0.0002332923,0.0005014409,0.00016741268,0.00003554627,0.000028012924,0.00015642756,0.00021700005,0.00025105462],"category_scores_gemma":[0.00008027846,0.00017913074,0.000047803154,0.00019980922,0.000109107794,0.00013623248,0.000843791,0.0006892304,0.000013707072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018513525,0.0013693031,0.54895645,0.0029319897,0.0022647243,0.00013450287,0.0015573937,0.00008747029,0.25542375,0.000017816272,0.034042407,0.13470067],"study_design_scores_gemma":[0.007420802,0.0006361066,0.8634383,0.0015870441,0.00059389987,0.000001951373,0.00018560298,0.0235001,0.09793959,0.0015986535,0.0025798806,0.00051807903],"about_ca_topic_score_codex":0.0090207895,"about_ca_topic_score_gemma":0.0015570347,"teacher_disagreement_score":0.31448185,"about_ca_system_score_codex":0.00023817676,"about_ca_system_score_gemma":0.0005313487,"threshold_uncertainty_score":0.9975782},"labels":[],"label_agreement":null},{"id":"W4385295238","doi":"10.1097/mou.0000000000001114","title":"Poly-ADP ribose polymerase inhibitor and androgen receptor signaling inhibitor for all comers for first-line treatment of metastatic castration-resistant prostate cancer: is gene sequencing out?","year":2023,"lang":"en","type":"review","venue":"Current Opinion in Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Olaparib; Medicine; Enzalutamide; Prostate cancer; Oncology; PARP inhibitor; Clinical endpoint; Internal medicine; Clinical trial; Biomarker; Androgen receptor; Cancer; Cancer research; Polymerase; Genetics; Gene; Poly ADP ribose polymerase; Biology","score_opus":0.24660583862963545,"score_gpt":0.457347030506748,"score_spread":0.21074119187711257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385295238","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014876843,0.9793956,0.00004968528,0.0010394808,0.002819043,0.007742947,0.0074238256,0.000040644994,0.0000010571222],"genre_scores_gemma":[0.000252404,0.9867847,0.00035166903,0.00002133287,0.00109157,0.0060041836,0.0052256593,0.00012392366,0.00014458667],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965368,0.00016085914,0.0014063709,0.0008832053,0.0002798739,0.00073291466],"domain_scores_gemma":[0.9978452,0.00071096537,0.0006415742,0.00031569137,0.00020996336,0.00027661741],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037573924,0.00063802965,0.0022623444,0.00065029564,0.00013226303,0.000028112896,0.00011302945,0.0002502249,0.000029308545],"category_scores_gemma":[0.00009688616,0.00048912194,0.00047998817,0.00035275464,0.00020102099,0.00007173313,0.000057254427,0.00023540715,0.0000053009157],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038916352,0.0010019748,0.00021799904,0.10535087,0.002643644,0.000026338628,0.002974331,0.000014766806,0.00075740996,0.0000400637,0.0023894152,0.8806915],"study_design_scores_gemma":[0.012238224,0.0064826175,0.0000032631435,0.010258726,0.0024047338,0.000028589762,0.00014130575,0.0002818952,0.0028181805,0.000087433844,0.9646672,0.0005878539],"about_ca_topic_score_codex":0.00012878985,"about_ca_topic_score_gemma":0.00006243778,"teacher_disagreement_score":0.96227777,"about_ca_system_score_codex":0.0008888092,"about_ca_system_score_gemma":0.001513027,"threshold_uncertainty_score":0.99975604},"labels":[],"label_agreement":null},{"id":"W4385303851","doi":"10.1200/jco.2023.41.36_suppl.427956","title":"Long-term follow up of selinexor maintenance in patients with <i>TP53</i>wt advanced or recurrent endometrial cancer: A pre-specified subgroup analysis from the phase 3 ENGOT-EN5/GOG-3055/SIENDO study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Placebo; Clinical endpoint; Subgroup analysis; Internal medicine; Oncology; Endometrial cancer; Maintenance therapy; Phases of clinical research; Surrogate endpoint; Clinical trial; Cancer; Chemotherapy; Confidence interval; Pathology","score_opus":0.14961426728585525,"score_gpt":0.4993738082871081,"score_spread":0.34975954100125284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385303851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99369323,0.00089938,0.000063515006,0.0018617847,0.00169034,0.0015903715,0.00014741086,0.0000146550465,0.00003933513],"genre_scores_gemma":[0.9929753,0.00506713,0.00021903942,0.00018630608,0.00085863634,0.00008708001,0.000070206086,0.00002783631,0.00050848845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940698,0.0009362963,0.002895492,0.00045762453,0.0011194455,0.00052132504],"domain_scores_gemma":[0.9903074,0.0058188257,0.0020500778,0.0004676731,0.0009769097,0.0003791365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033857333,0.0002674736,0.0025970922,0.00060533156,0.000066612316,0.000016965412,0.00045860402,0.00021392084,0.00027307234],"category_scores_gemma":[0.004364868,0.0001272093,0.00069276534,0.0028094675,0.00027520122,0.00014939823,0.00012903569,0.0012356964,0.000005821398],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20153673,0.0060933344,0.62934834,0.000019655456,0.0029617294,0.0006381383,0.0006127185,0.000044065357,0.000022335424,0.0000011319005,0.0007300622,0.15799178],"study_design_scores_gemma":[0.14305353,0.037102267,0.814671,0.00024711806,0.0020950395,0.0000037362051,0.00041030155,0.00007095436,0.00006138913,0.0000131885345,0.0021515328,0.00011997596],"about_ca_topic_score_codex":0.00019183742,"about_ca_topic_score_gemma":0.002865557,"teacher_disagreement_score":0.18532266,"about_ca_system_score_codex":0.0004478972,"about_ca_system_score_gemma":0.0017544891,"threshold_uncertainty_score":0.53685546},"labels":[],"label_agreement":null},{"id":"W4385336122","doi":"10.1016/j.eururo.2023.07.007","title":"Prostate-specific Membrane Antigen Imaging Remains True to its Name in Primary Staging of Prostate Cancer: The Time To Characterize its Impact on Clinical Outcomes Is Now","year":2023,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Prostate; Glutamate carboxypeptidase II; Cancer; Oncology; Gynecology; Internal medicine","score_opus":0.050803671160479666,"score_gpt":0.35969614631802294,"score_spread":0.30889247515754326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385336122","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40909004,0.00068028114,6.488821e-7,0.58319503,0.00054208725,0.0031661605,0.0011728107,0.00012078393,0.002032166],"genre_scores_gemma":[0.06740756,0.009454983,0.000047390044,0.83200544,0.003702509,0.0003643896,0.0019058257,0.0008669456,0.08424496],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9938317,0.0013385762,0.0013163143,0.0013305296,0.0007674437,0.0014154671],"domain_scores_gemma":[0.99709505,0.0008062677,0.00041426162,0.0010858593,0.00027746038,0.00032110102],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020150146,0.0007366487,0.001673166,0.00085092365,0.00011657331,0.00006782,0.0007166394,0.00022934767,0.00063984224],"category_scores_gemma":[0.0002635326,0.00046164065,0.0004334538,0.0007488047,0.00020673143,0.00010803564,0.00053116796,0.0026010629,0.004379871],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00536314,0.0002551038,0.15515159,0.0005297496,0.00078182167,0.010852807,0.0029132757,0.00004428046,0.0064103077,9.405642e-7,0.80571324,0.011983775],"study_design_scores_gemma":[0.0023412711,0.0015064914,0.49977165,0.00037929686,0.00008043259,0.000027235432,0.00001283581,0.000029023337,0.00028963224,0.0000017566983,0.49518827,0.00037212783],"about_ca_topic_score_codex":0.00003492812,"about_ca_topic_score_gemma":0.000005194497,"teacher_disagreement_score":0.34462005,"about_ca_system_score_codex":0.00044691173,"about_ca_system_score_gemma":0.0005280863,"threshold_uncertainty_score":0.9997835},"labels":[],"label_agreement":null},{"id":"W4385344648","doi":"10.5489/cuaj.8490","title":"PSMA-PET in Canada: More questions than answers","year":2023,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Psychology","score_opus":0.02112711080161026,"score_gpt":0.27799766848472857,"score_spread":0.2568705576831183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385344648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8777823,0.00015329482,0.0000011357405,0.12004924,0.00025134848,0.00014057283,0.00006070795,0.00002096307,0.0015404589],"genre_scores_gemma":[0.99488807,0.00027123166,0.000023432076,0.0022359875,0.00017482611,0.000013610535,0.00006479656,0.000008641286,0.002319401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985689,0.00009300121,0.00020743583,0.00013600952,0.0003857223,0.0006089243],"domain_scores_gemma":[0.9988681,0.00010140436,0.00006656925,0.00007201482,0.00013872639,0.0007531844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043185745,0.00008856873,0.00018074167,0.00028967104,0.00017766548,0.000033224573,0.00008303203,0.000076375305,0.00033441855],"category_scores_gemma":[0.0004724483,0.00006902519,0.00005596895,0.00061341695,0.000021447835,0.000053826498,0.000009956761,0.0005694469,0.00006067366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000024453662,0.000010601991,0.96680593,0.0000024789738,0.000042041826,0.0019815778,0.00007093237,0.0000910503,0.00002061974,0.00003870244,0.029911634,0.0009999552],"study_design_scores_gemma":[0.0008039963,0.000074405325,0.9725393,0.000014254119,0.000015486421,0.00012283404,0.00031602493,0.0003614677,0.00000602129,0.0002262466,0.025450293,0.000069649235],"about_ca_topic_score_codex":0.84439385,"about_ca_topic_score_gemma":0.9590642,"teacher_disagreement_score":0.11781325,"about_ca_system_score_codex":0.0071641235,"about_ca_system_score_gemma":0.00678676,"threshold_uncertainty_score":0.99884385},"labels":[],"label_agreement":null},{"id":"W4385444287","doi":"10.1016/j.jaccao.2023.05.011","title":"Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"JACC CardioOncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre; Population Health Research Institute; University of Alberta; Canadian VIGOUR Centre; Hamilton Health Sciences; University of Toronto; St. Michael's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Adverse effect; Internal medicine; Clinical endpoint; Gonadotropin-releasing hormone; Myocardial infarction; Oncology; Randomized controlled trial; Cancer; Hormone; Luteinizing hormone","score_opus":0.020024918186158237,"score_gpt":0.3196703169562287,"score_spread":0.29964539877007046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385444287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98781484,0.00669823,0.0000061474097,0.0012081596,0.0003444364,0.0016491704,0.00003098884,0.000098607336,0.002149429],"genre_scores_gemma":[0.99383724,0.003650425,0.00008148644,0.00006337094,0.00013723352,0.0006845945,0.000088268825,0.000039955186,0.0014174146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981623,0.00016921313,0.00023860215,0.00041380798,0.00044917216,0.0005669034],"domain_scores_gemma":[0.9990153,0.00016791461,0.00006453292,0.00044650532,0.00016342656,0.00014234555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034670997,0.0002008912,0.001097506,0.0003284304,0.000053663407,0.00000924001,0.00010136629,0.00010958401,0.0000136447115],"category_scores_gemma":[0.000045610483,0.00014722331,0.00028215352,0.0009907142,0.00027951505,0.000048674552,0.00008252961,0.00024492733,0.000032297274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046990416,0.00033571856,0.91742593,0.0026978012,0.004456437,0.014023498,0.0022151393,0.0017864007,0.011841363,0.00004146195,0.005494748,0.034982473],"study_design_scores_gemma":[0.023304693,0.0018505047,0.8712539,0.00058616494,0.00075222715,0.00026476564,0.00046580553,0.00021276965,0.041551854,0.000034355275,0.059373133,0.00034980447],"about_ca_topic_score_codex":0.0006686578,"about_ca_topic_score_gemma":0.00016787766,"teacher_disagreement_score":0.05387838,"about_ca_system_score_codex":0.0004106065,"about_ca_system_score_gemma":0.00059295486,"threshold_uncertainty_score":0.6003592},"labels":[],"label_agreement":null},{"id":"W4385462195","doi":"10.3390/curroncol30080529","title":"PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Radioligand; Prostate; Oncology; Targeted therapy; Population; Internal medicine; Cancer; Receptor","score_opus":0.1524831101070856,"score_gpt":0.4957781962975051,"score_spread":0.3432950861904195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385462195","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042525963,0.9878687,0.000004551099,0.0008061762,0.00059553754,0.005969878,0.00040739344,0.000073305164,0.000021853477],"genre_scores_gemma":[0.00002627105,0.99366444,0.00015888357,0.000029039085,0.0002798154,0.004570722,0.0007559132,0.00009560823,0.00041933186],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980148,0.00012982228,0.0004496682,0.0006907809,0.00016224822,0.00055265834],"domain_scores_gemma":[0.9990218,0.00016864426,0.00020852704,0.00021792119,0.00012294848,0.00026012203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013844909,0.000503601,0.0018149014,0.0002658983,0.00012477703,0.000038451795,0.00006652659,0.00016643103,0.000015163129],"category_scores_gemma":[0.00002573041,0.00032165943,0.00024247372,0.00018831884,0.00022269145,0.000036734717,0.0000764497,0.00023708647,0.0000052175733],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036171253,0.00027558906,0.00026478167,0.006081873,0.00071194227,0.00016102572,0.00066191744,2.928458e-7,0.000010191242,0.00001160782,0.0016837295,0.98977536],"study_design_scores_gemma":[0.004659896,0.0028472072,0.00002421193,0.0038322515,0.0009907938,0.00008396363,0.0000879768,0.000067371744,0.00007434775,0.000029381103,0.98703223,0.00027034772],"about_ca_topic_score_codex":0.00005273505,"about_ca_topic_score_gemma":0.0000056781787,"teacher_disagreement_score":0.989505,"about_ca_system_score_codex":0.0007252799,"about_ca_system_score_gemma":0.0008834527,"threshold_uncertainty_score":0.9999235},"labels":[],"label_agreement":null},{"id":"W4385604057","doi":"10.1016/j.ebiom.2023.104738","title":"BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype","year":2023,"lang":"en","type":"article","venue":"EBioMedicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Cancer Council Tasmania; Cancer Council Victoria; National Health and Medical Research Council; Medical Research Council; Victorian Cancer Agency; Astellas Pharma; Killam Trusts; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation","keywords":"Prostate cancer; Oncology; Proportional hazards model; Medicine; Internal medicine; Hazard ratio; Cancer; CHEK2; Cancer research; Biology; Gene; Mutation; Germline mutation; Genetics; Confidence interval","score_opus":0.062018650215557476,"score_gpt":0.3522206422589288,"score_spread":0.2902019920433713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385604057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841967,0.0035863123,0.000009259021,0.009911328,0.00027039988,0.0012930715,0.000118054544,0.00022042864,0.00039441366],"genre_scores_gemma":[0.9915474,0.0013201174,0.00017932177,0.00027072098,0.00024890338,0.00031178037,0.00052079716,0.00005117508,0.0055497806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814546,0.000048549617,0.00029043513,0.00048701468,0.00046607378,0.0005624685],"domain_scores_gemma":[0.9990312,0.000057928155,0.00007292762,0.00028739864,0.0001224557,0.00042810044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038825342,0.00023285775,0.0004099529,0.00036388193,0.0002076522,0.000026374473,0.00008766353,0.000043251985,0.00033497837],"category_scores_gemma":[0.00005278911,0.00015574563,0.00005147766,0.0008731666,0.0005135439,0.00009122084,0.00009018773,0.00017725094,0.000137719],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004315957,0.0019213498,0.529957,0.002957399,0.0015423604,0.003155511,0.018779429,0.000036816546,0.12420811,0.00014641446,0.031227587,0.28175208],"study_design_scores_gemma":[0.013988814,0.0040891324,0.9135621,0.00064395176,0.00093692465,0.000089169116,0.002746316,0.0029608107,0.0025636796,0.0002348063,0.05769965,0.0004846132],"about_ca_topic_score_codex":0.00042458813,"about_ca_topic_score_gemma":0.000076668366,"teacher_disagreement_score":0.38360515,"about_ca_system_score_codex":0.00017769025,"about_ca_system_score_gemma":0.00030128306,"threshold_uncertainty_score":0.6351122},"labels":[],"label_agreement":null},{"id":"W4385611986","doi":"10.1002/mp.16658","title":"PSMA‐Hornet: Fully‐automated, multi‐target segmentation of healthy organs in PSMA PET/CT images","year":2023,"lang":"en","type":"article","venue":"Medical Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research; National Institutes of Health; Mitacs","keywords":"Segmentation; Computer science; Artificial intelligence; Radiation treatment planning; Image segmentation; Deep learning; Medical imaging; Nuclear medicine; Pattern recognition (psychology); Medicine; Radiation therapy; Radiology","score_opus":0.03438858697881648,"score_gpt":0.38208537783008517,"score_spread":0.3476967908512687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385611986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907128,0.00039081823,0.00046862857,0.006602755,0.00023074429,0.0006796415,0.000065735316,0.00033999205,0.00050884],"genre_scores_gemma":[0.9969741,0.0008481137,0.00039485743,0.0003680068,0.000181192,0.000059030335,0.0004905973,0.00003267622,0.00065141526],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981163,0.00007149059,0.0003300433,0.00025581958,0.0008242658,0.0004020726],"domain_scores_gemma":[0.9992635,0.00012219715,0.0000666033,0.0002010159,0.00008438336,0.00026230188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037053344,0.00014267118,0.00034528182,0.000120731194,0.0000465419,0.0000073766373,0.00011063764,0.000025831678,0.00025712838],"category_scores_gemma":[0.00015205993,0.00011011585,0.00006974407,0.0008202468,0.0001811071,0.0000726667,0.000063562366,0.00029730043,0.00020257052],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028174613,0.007727077,0.6420384,0.0058466718,0.00079930166,0.015724806,0.005482331,0.0002291956,0.041160464,0.0001522589,0.11071388,0.16730817],"study_design_scores_gemma":[0.0458232,0.0033971625,0.31745794,0.0018823185,0.00022956556,0.00031698094,0.0029272484,0.05908957,0.5631775,0.0022165924,0.0025262947,0.00095559447],"about_ca_topic_score_codex":0.00018529064,"about_ca_topic_score_gemma":0.000020603462,"teacher_disagreement_score":0.52201706,"about_ca_system_score_codex":0.00014726042,"about_ca_system_score_gemma":0.00044334208,"threshold_uncertainty_score":0.4490394},"labels":[],"label_agreement":null},{"id":"W4385618080","doi":"10.1073/pnas.2220472120","title":"SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1","year":2023,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Genentech; Ontario Genomics Institute; National Cancer Institute; European Federation of Pharmaceutical Industries and Associations; University of Massachusetts Boston; Canadian HIV Trials Network, Canadian Institutes of Health Research; Merck KGaA; National Institutes of Health; Ontario Genomics; Genome Canada; Pfizer; Bristol-Myers Squibb; Prostate Cancer Foundation; U.S. Army Medical Command; Terry Fox Research Institute; Bayer; DOD Prostate Cancer Research Program; McGill University; U.S. Department of Defense","keywords":"FOXA1; Transcription factor; Repressor; Cancer research; Epigenetics; Biology; Histone methyltransferase; Pioneer factor; Prostate cancer; Histone; Methyltransferase; Chromatin; Histone methylation; EZH2; Chromatin remodeling; DNA methylation; Methylation; Genetics; Cancer; Gene expression; Gene","score_opus":0.08599431929938028,"score_gpt":0.39646885836862505,"score_spread":0.31047453906924477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385618080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979948,0.0003466067,2.6788015e-7,0.014379922,0.000023895753,0.00043818227,0.000018646171,0.000022955963,0.0048215413],"genre_scores_gemma":[0.9966511,0.00032287024,0.0001399817,0.00011491566,0.000047929843,0.00010273423,7.794557e-7,0.000004648803,0.002615044],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99836594,0.0000065430495,0.00025407027,0.00022310845,0.0009670069,0.0001833322],"domain_scores_gemma":[0.9995093,0.00006813292,0.00015027059,0.0000070532014,0.00022882408,0.000036468784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011501606,0.000069657064,0.00014166978,0.00033138046,0.00014476995,0.000012015673,0.0001742548,0.00004720572,0.00003115245],"category_scores_gemma":[0.00028670212,0.00004317112,0.00006454836,0.0019373855,0.0003657399,0.00028937653,0.000046987312,0.00018227576,0.0000042181],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016674021,0.0000617442,0.06353962,0.00021010434,0.00003624805,8.006325e-8,0.0015257715,0.00021463002,0.92799884,0.0010885156,0.00070152065,0.0044561913],"study_design_scores_gemma":[0.0014005192,0.00020175788,0.39751258,0.0006071714,0.000046945614,0.000013537772,0.0011438406,0.004935998,0.55710256,0.03637002,0.00055472704,0.0001103204],"about_ca_topic_score_codex":0.00008178527,"about_ca_topic_score_gemma":6.544011e-7,"teacher_disagreement_score":0.37089625,"about_ca_system_score_codex":0.00008427316,"about_ca_system_score_gemma":0.00008783069,"threshold_uncertainty_score":0.17604671},"labels":[],"label_agreement":null},{"id":"W4385648026","doi":"10.1053/j.semnuclmed.2023.07.007","title":"How to Report PSMA PET","year":2023,"lang":"en","type":"review","venue":"Seminars in Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Prostate cancer; Positron emission tomography; Glutamate carboxypeptidase II; Radioligand; Medical physics; Harmonization; Clinical trial; Management of prostate cancer; PET-CT; Disease; Pet imaging; Cancer; Nuclear medicine; Internal medicine","score_opus":0.09610444012482708,"score_gpt":0.42319703634350453,"score_spread":0.3270925962186775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385648026","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000048060774,0.9793372,5.917872e-7,0.011810751,0.00059061236,0.0021366535,0.000016540134,0.00018316059,0.005876426],"genre_scores_gemma":[0.0000073005554,0.91301197,0.00018479167,0.00027357772,0.0009505117,0.00013468186,0.00032561735,0.00022320179,0.08488835],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99675685,0.00009615676,0.00075185054,0.0008333524,0.0008803832,0.0006813891],"domain_scores_gemma":[0.99800193,0.00016033408,0.00022318067,0.0009920977,0.000105124636,0.0005173066],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009601149,0.00051694544,0.0026665553,0.0010871349,0.000064841326,0.000026373826,0.00031404305,0.00025904708,0.00022620383],"category_scores_gemma":[0.0012074579,0.00033461413,0.0002846194,0.0016686097,0.00022589315,0.00004531354,0.00024271438,0.0009420809,0.00065596425],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008098631,0.00007994422,0.000023010523,0.02457748,0.00024077477,0.054654945,0.00039487964,3.2991643e-8,0.000005378656,0.000039742,0.15094039,0.76896244],"study_design_scores_gemma":[0.00077736366,0.00070304185,0.000016128135,0.12151962,0.0005709711,0.003630454,0.00034291254,0.0000017367084,4.922229e-7,0.000022995191,0.8721804,0.00023386955],"about_ca_topic_score_codex":0.00006609639,"about_ca_topic_score_gemma":0.000012418371,"teacher_disagreement_score":0.76872855,"about_ca_system_score_codex":0.0006645608,"about_ca_system_score_gemma":0.0003669616,"threshold_uncertainty_score":0.9999106},"labels":[],"label_agreement":null},{"id":"W4385684657","doi":"10.1016/j.celrep.2023.112937","title":"RETRACTED: ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer","year":2023,"lang":"en","type":"article","venue":"Cell Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":true,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute","keywords":"Biology; Transcription factor; Cancer research; Receptor tyrosine kinase; Signal transduction; MAPK/ERK pathway; Prostate cancer; Lineage (genetic); Cell biology; Genetics; Cancer; Gene","score_opus":0.027687154381262517,"score_gpt":0.3091537289409558,"score_spread":0.28146657455969326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385684657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943911,0.000070171925,0.0000011312782,0.000589791,0.0002865433,0.0010372398,0.00006283724,0.00006502349,0.0034961803],"genre_scores_gemma":[0.9815909,0.00013421546,0.000022762586,0.00012571143,0.00008190829,0.000102494865,0.00006714239,0.00003181384,0.017842999],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997971,0.000037955593,0.0005327973,0.00041250698,0.0005927472,0.00045301052],"domain_scores_gemma":[0.9989416,0.000078504396,0.0002170859,0.00038486312,0.00018973707,0.00018822015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000343082,0.0001789714,0.00035532538,0.0002028733,0.00007022984,0.000015266638,0.0000851329,0.000116482406,0.00037631587],"category_scores_gemma":[0.00017328655,0.00011357623,0.00011042054,0.0011894185,0.000067197885,0.000062133826,0.00010813847,0.0003958865,0.000019776982],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039501674,0.00025483323,0.17512518,0.00030409786,0.000059994905,0.0032307638,0.0016852722,0.00027341722,0.81024635,6.674811e-7,0.0049695177,0.0034548847],"study_design_scores_gemma":[0.0007163302,0.00022926401,0.053186595,0.00032696113,0.000029891902,0.000035111763,0.00016606659,0.0000502608,0.9389348,0.000012079675,0.0061977278,0.00011487894],"about_ca_topic_score_codex":0.0006425141,"about_ca_topic_score_gemma":0.0000654904,"teacher_disagreement_score":0.12868848,"about_ca_system_score_codex":0.00019927016,"about_ca_system_score_gemma":0.0008303726,"threshold_uncertainty_score":0.46315044},"labels":[],"label_agreement":null},{"id":"W4385697376","doi":"10.21203/rs.3.rs-3221881/v1","title":"Characteristics of incidental prostate cancer in the United States","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Proportional hazards model; Prostatectomy; Radiation therapy; Epidemiology; Internal medicine; Cancer; Urology; Oncology","score_opus":0.115132777776865,"score_gpt":0.46129307571227784,"score_spread":0.34616029793541286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98580265,0.0015700419,0.00000121719,0.007385911,0.00016348889,0.003146959,0.0016746994,0.00004769549,0.00020734557],"genre_scores_gemma":[0.95496345,0.036388993,0.000013376843,0.000053192605,0.00020380819,0.0012700552,0.0038599274,0.00006585051,0.0031813264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956494,0.00061586825,0.00048723648,0.00048134514,0.0019756814,0.00079046754],"domain_scores_gemma":[0.9974253,0.00059662963,0.00011975825,0.00072898215,0.0009734545,0.00015587296],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002448576,0.00023859795,0.0005188156,0.0012923558,0.00011578553,0.00008628006,0.00047648264,0.00023068782,0.00015740152],"category_scores_gemma":[0.00040569625,0.00014902739,0.00013745498,0.0016562096,0.00046275606,0.000038177397,0.0009027465,0.0023517231,0.000056277542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024992197,0.0008866642,0.94718343,0.011190605,0.00037899418,0.0021012672,0.01858009,0.00020815578,0.0005717628,0.000108110835,0.009093005,0.007198706],"study_design_scores_gemma":[0.0019699268,0.0007061314,0.9771409,0.0054554106,0.000055722743,0.000008722603,0.0068217576,0.0014864414,0.0010556094,0.0012007786,0.003882362,0.00021621722],"about_ca_topic_score_codex":0.011621893,"about_ca_topic_score_gemma":0.0006043303,"teacher_disagreement_score":0.03481895,"about_ca_system_score_codex":0.0006289573,"about_ca_system_score_gemma":0.0012978712,"threshold_uncertainty_score":0.9999499},"labels":[],"label_agreement":null},{"id":"W4385711723","doi":"10.7150/ijbs.85209","title":"Therapeutic implications for localized prostate cancer by multiomics analyses of the ageing microenvironment landscape","year":2023,"lang":"en","type":"article","venue":"International Journal of Biological Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"China Postdoctoral Science Foundation; National Natural Science Foundation of China","keywords":"Prostate cancer; Tumor microenvironment; In vivo; Medicine; Cancer; Cancer research; Immunotherapy; Oncology; Computational biology; Internal medicine; Biology; Genetics","score_opus":0.1511751259054142,"score_gpt":0.4554426813982692,"score_spread":0.304267555492855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385711723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9765403,0.0019973756,0.00024306393,0.020749846,0.0001552626,0.00018572729,0.000081628015,0.0000043092746,0.00004246569],"genre_scores_gemma":[0.99545306,0.003858523,0.00021199744,0.00020959931,0.00005616571,0.000017576309,0.000008381118,0.0000018843378,0.00018282855],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9993302,0.000028882132,0.00021503466,0.00008903461,0.00022520544,0.00011163721],"domain_scores_gemma":[0.99945307,0.00014812734,0.00017795143,0.000040986895,0.00014354107,0.000036305806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003097736,0.000047759462,0.00011548334,0.00006814048,0.00007427233,0.000017040782,0.00026342255,0.000024008057,0.000032144093],"category_scores_gemma":[0.00006944025,0.000020228968,0.00011518971,0.00020312383,0.00028902502,0.0000366319,0.000044393644,0.000053688884,8.99243e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003002075,0.00012391714,0.3828505,0.0000064331903,0.00024084421,0.0000030828187,0.000110714995,0.0002883374,0.5855956,0.000080483835,0.0012545384,0.02914536],"study_design_scores_gemma":[0.002982226,0.0008845445,0.8381662,0.00016765801,0.00009575544,0.000034854795,0.0004450673,0.0017345126,0.13902433,0.003142923,0.013220802,0.000101165046],"about_ca_topic_score_codex":0.000021345555,"about_ca_topic_score_gemma":0.0000023441146,"teacher_disagreement_score":0.45531568,"about_ca_system_score_codex":0.00005283083,"about_ca_system_score_gemma":0.000081275946,"threshold_uncertainty_score":0.106492475},"labels":[],"label_agreement":null},{"id":"W4385722927","doi":"10.2217/fon-2023-0135","title":"Plain Language Summary: Can Declines in Prostate-Specific Antigen Level Indicate How Long Patients with Advanced Prostate Cancer Will Live When Treated with Enzalutamide?","year":2023,"lang":"en","type":"review","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Prostate-specific antigen; Prostate; Cancer; Oncology; Urology; Internal medicine; Androgen receptor","score_opus":0.049068405312900805,"score_gpt":0.35826136092005,"score_spread":0.3091929556071492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385722927","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.064682044,0.9206663,7.4936065e-7,0.0020496976,0.00031468057,0.009128813,0.002830162,0.00020069956,0.00012688927],"genre_scores_gemma":[0.00063860964,0.9773909,0.00027642064,0.000091509515,0.00058732997,0.0030816782,0.009303251,0.0003402753,0.008290035],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954182,0.00043056833,0.0007361384,0.0013720822,0.000716042,0.0013269783],"domain_scores_gemma":[0.9975092,0.00024819942,0.00077845715,0.00066580996,0.00038017958,0.000418197],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029991372,0.0010883095,0.0032532003,0.00096065074,0.0001647305,0.00006351312,0.0003726352,0.000684429,0.00010105272],"category_scores_gemma":[0.000040861036,0.00062804867,0.0002127224,0.0014502235,0.0003873244,0.00019949756,0.00015875875,0.0014361538,0.00003907918],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072853914,0.00077344384,0.071768306,0.011758539,0.0017547663,0.0104074925,0.0050638234,0.000003987713,0.000005404306,0.00000505889,0.0036433686,0.88753045],"study_design_scores_gemma":[0.0138677005,0.004427408,0.023649324,0.023528654,0.0009652665,0.00007187505,0.001397979,0.0000010370308,0.000019845213,0.000004852932,0.9310978,0.00096826674],"about_ca_topic_score_codex":0.0009200466,"about_ca_topic_score_gemma":0.018255215,"teacher_disagreement_score":0.9274544,"about_ca_system_score_codex":0.002274417,"about_ca_system_score_gemma":0.0030958585,"threshold_uncertainty_score":0.99965906},"labels":[],"label_agreement":null},{"id":"W4385728690","doi":"10.21203/rs.3.rs-3211140/v1","title":"Clinical Predictors of Germline DNA Damage Repair Gene Mutations in Patients with Advanced Prostate Cancer","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Germline; DNA Damage Repair; Germline mutation; DNA repair; DNA damage; Gene; Genetics; Cancer research; Mutation; Medicine; Biology; Cancer; DNA; Oncology","score_opus":0.07819197233126352,"score_gpt":0.4623198848996688,"score_spread":0.3841279125684053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385728690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897659,0.0010281452,0.0000030371395,0.00096966524,0.0002834712,0.005894312,0.0016752057,0.00017905555,0.00020122652],"genre_scores_gemma":[0.983423,0.0049368623,0.0006670269,0.000014653907,0.00026560476,0.0019954024,0.003941927,0.00014771734,0.0046077934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99413884,0.00058925303,0.0009923975,0.0010729393,0.002254783,0.00095181883],"domain_scores_gemma":[0.99549043,0.00053561135,0.00023142275,0.001119802,0.002182346,0.00044037285],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0019908082,0.00034255965,0.00092715275,0.0010657393,0.00011854706,0.000029625147,0.00030806824,0.00037743803,0.00011377273],"category_scores_gemma":[0.0008466248,0.0002497929,0.00027388055,0.0013623025,0.0007240728,0.00010218034,0.00081747724,0.002364368,0.00002805943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004502975,0.0013533791,0.9849068,0.0028628742,0.0005044366,0.0002814751,0.00072667195,0.0005873221,0.000073132,0.000005253045,0.001137872,0.0030578063],"study_design_scores_gemma":[0.007995432,0.0025787745,0.98324835,0.0041107386,0.000087354834,4.377914e-7,0.00028257637,0.00036649688,0.00053534954,0.00010886978,0.0004704995,0.0002151114],"about_ca_topic_score_codex":0.00065631996,"about_ca_topic_score_gemma":0.00046120022,"teacher_disagreement_score":0.0063428693,"about_ca_system_score_codex":0.00074521435,"about_ca_system_score_gemma":0.0029088797,"threshold_uncertainty_score":0.9999954},"labels":[],"label_agreement":null},{"id":"W4385752997","doi":"10.1016/j.clgc.2023.08.004","title":"Overall Survival of Metastatic Prostate Cancer Patients According to Location of Visceral Metastatic Sites","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Concomitant; Lung; Lymph node; Prostate cancer; Lymph; Internal medicine; Prostate; Proportional hazards model; Oncology; Gastroenterology; Cancer; Pathology","score_opus":0.13186869164170348,"score_gpt":0.45688983475261163,"score_spread":0.32502114311090813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385752997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949022,0.0015199014,0.000015951666,0.0011345149,0.0006884825,0.0013133092,0.0002472502,0.00005403263,0.00012438542],"genre_scores_gemma":[0.9928488,0.0031819332,0.0004086069,0.00019406788,0.00024351635,0.00034633485,0.0001735218,0.000051505038,0.0025516895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715227,0.00020232744,0.0010243752,0.0004685566,0.00067125284,0.00048124042],"domain_scores_gemma":[0.9976319,0.00046022708,0.00031368082,0.00034878912,0.0009319578,0.0003134575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006265723,0.00023738814,0.0008533553,0.00028675425,0.00006506868,0.000012359282,0.0001771739,0.000059698297,0.00017771438],"category_scores_gemma":[0.00043969654,0.00018517056,0.00022553724,0.0012533442,0.00017904514,0.00013252006,0.00018438952,0.00025099632,0.00004847539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038425701,0.0011223943,0.95788884,0.0015909107,0.0009390044,0.00007725735,0.0005647435,0.0009742046,0.005328197,0.000013660787,0.004152823,0.023505382],"study_design_scores_gemma":[0.009892268,0.0041305586,0.96977985,0.0011013373,0.0008037057,0.0000021236601,0.0006274553,0.0010670844,0.010582138,0.00022147462,0.0014021731,0.0003898426],"about_ca_topic_score_codex":0.0003361531,"about_ca_topic_score_gemma":0.000044344968,"teacher_disagreement_score":0.02311554,"about_ca_system_score_codex":0.00017457615,"about_ca_system_score_gemma":0.00071791175,"threshold_uncertainty_score":0.75510365},"labels":[],"label_agreement":null},{"id":"W4385755852","doi":"10.1016/j.ejca.2023.113290","title":"Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Internal medicine; Androgen deprivation therapy; Bone metastasis; Oncology; Urology; Post-hoc analysis; Prostate-specific antigen; Metastasis; Antiandrogen; Cancer; Androgen receptor","score_opus":0.06086182586563502,"score_gpt":0.38923981250666795,"score_spread":0.3283779866410329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385755852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749374,0.0005580725,0.000018872708,0.00031913118,0.00015587539,0.001330579,0.000061964485,0.000005611053,0.00005613261],"genre_scores_gemma":[0.99713403,0.002521605,0.000047185553,0.000057384284,0.00007807525,0.000017060096,0.00001849636,0.000026737393,0.00009943996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99571913,0.0015273963,0.0015590357,0.0002164683,0.00077816745,0.00019976865],"domain_scores_gemma":[0.9972737,0.00037759804,0.0011339418,0.00024964637,0.0008511045,0.000114009745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003400088,0.0001518843,0.00094015343,0.00038450395,0.00004372482,0.000012869852,0.000158356,0.000021607373,0.00003408788],"category_scores_gemma":[0.00021898953,0.00008099054,0.00036155412,0.0015866171,0.0002138744,0.00009910078,0.000037135997,0.0003437276,0.0000010598793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02758011,0.00066109,0.94634914,0.000025494193,0.004689445,0.0001634519,0.002245576,0.0012265863,0.00014564194,9.939821e-7,0.00005640926,0.016856043],"study_design_scores_gemma":[0.05531003,0.0024005794,0.9388691,0.00018074611,0.0016214567,0.0000014312828,0.00074317894,0.00040983813,0.00035466836,0.0000025549873,0.00003485577,0.000071522656],"about_ca_topic_score_codex":0.00012559374,"about_ca_topic_score_gemma":0.00057785836,"teacher_disagreement_score":0.02772992,"about_ca_system_score_codex":0.00014088288,"about_ca_system_score_gemma":0.00059017586,"threshold_uncertainty_score":0.33026984},"labels":[],"label_agreement":null},{"id":"W4385857165","doi":"10.1016/j.eururo.2023.08.005","title":"Reply to Xiao Li, Zicheng Xu, and Feng Qi’s Letter to the Editor re: Soumyajit Roy, Yilun Sun, Scott C. Morgan, et al. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. Eur Urol 2023;83:571–9","year":2023,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Traditional medicine","score_opus":0.02342679446478732,"score_gpt":0.3060219935002427,"score_spread":0.2825951990354554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385857165","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4893605,0.0017967386,0.000010160604,0.50001925,0.0011046244,0.0063722744,0.0012541742,0.000047511476,0.000034714434],"genre_scores_gemma":[0.21726216,0.0029410783,0.00006443784,0.76678663,0.0040097465,0.0018146641,0.00072687696,0.00058716885,0.0058072517],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98742664,0.0075455843,0.0013705298,0.0015358479,0.001103881,0.0010174919],"domain_scores_gemma":[0.9944746,0.0026283346,0.0005497411,0.0016882798,0.00036106198,0.00029796307],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005747052,0.0008827462,0.0020742528,0.0013737173,0.00020031267,0.00007128484,0.00080972805,0.00026010073,0.0004209474],"category_scores_gemma":[0.0010818122,0.0005033895,0.0004968952,0.0028466498,0.00037815518,0.000059711434,0.0003478594,0.002324501,0.000079930025],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2204329,0.00018085218,0.0007906473,0.00016829402,0.003255456,0.0009776013,0.0024056626,0.0009429329,0.007984778,1.6387455e-7,0.75875396,0.0041067544],"study_design_scores_gemma":[0.02894492,0.026724294,0.011107595,0.00030578516,0.0010091059,0.000011766704,0.000058542148,0.00011627293,0.0053409906,0.0000016433391,0.9258471,0.00053195696],"about_ca_topic_score_codex":0.0012786011,"about_ca_topic_score_gemma":0.0008851345,"teacher_disagreement_score":0.27209836,"about_ca_system_score_codex":0.00031000611,"about_ca_system_score_gemma":0.0006356979,"threshold_uncertainty_score":0.9999772},"labels":[],"label_agreement":null},{"id":"W4385949345","doi":"10.3390/cancers15164143","title":"Editorial: The Application of Proteogenomics to Urine Analysis for the Identification of Novel Biomarkers of Prostate Cancer: An Exploratory Study","year":2023,"lang":"en","type":"editorial","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Rockyview General Hospital; University of Calgary","funders":"","keywords":"Proteogenomics; Prostate cancer; Context (archaeology); Computational biology; Identification (biology); Proteomics; Medicine; Bioinformatics; Cancer; Biology; Genomics; Genome; Internal medicine; Genetics; Gene","score_opus":0.0387185778181406,"score_gpt":0.37351667266080374,"score_spread":0.33479809484266315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385949345","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03274962,0.0010839811,0.0010747894,0.00034978447,0.944653,0.01471037,0.0053371093,0.000037143185,0.0000041971416],"genre_scores_gemma":[0.08865855,0.0023980378,0.00008441983,0.000007072874,0.8882237,0.018461827,0.0015888965,0.00013378743,0.00044367515],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972876,0.00006873819,0.0008623553,0.00048815735,0.0010435608,0.0002495919],"domain_scores_gemma":[0.995477,0.0006100959,0.0009766788,0.0010123274,0.0018300556,0.00009383177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016962568,0.00023190917,0.00070007745,0.0003692541,0.00010886996,0.000016986132,0.00049138354,0.00019794701,0.000003049664],"category_scores_gemma":[0.00046326016,0.00014060782,0.00024594273,0.0016641872,0.00024194737,0.00005862137,0.00008248182,0.00022746743,6.528033e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073713018,0.00044770443,0.0021261757,0.0015503139,0.011254583,4.398982e-7,0.008245777,0.009596055,0.03265587,0.0000055431183,0.9213341,0.005412138],"study_design_scores_gemma":[0.013638591,0.005260371,0.003420799,0.0005137142,0.020314302,1.1666175e-7,0.022996329,0.0067824456,0.04745918,0.000033743974,0.8788422,0.0007382466],"about_ca_topic_score_codex":0.004005158,"about_ca_topic_score_gemma":0.0023201134,"teacher_disagreement_score":0.05642927,"about_ca_system_score_codex":0.0012340671,"about_ca_system_score_gemma":0.0031928697,"threshold_uncertainty_score":0.60546273},"labels":[],"label_agreement":null},{"id":"W4385955695","doi":"10.1053/j.semnuclmed.2023.07.004","title":"Bone Metastasis in Prostate Cancer: Bone Scan Versus PET Imaging","year":2023,"lang":"en","type":"review","venue":"Seminars in Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"","keywords":"Medicine; Prostate cancer; Bone metastasis; Positron emission tomography; Metastasis; Bone scintigraphy; Cancer; Prostate; Malignancy; Radiology; Nuclear medicine; Bone imaging; Pathology; Internal medicine","score_opus":0.07410440496656998,"score_gpt":0.4141834193224207,"score_spread":0.34007901435585075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385955695","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005268466,0.98889667,4.6488136e-8,0.0041379235,0.0009438036,0.0025113202,0.00013408503,0.00016414245,0.0026851476],"genre_scores_gemma":[0.000099050354,0.99322855,0.00010845841,0.00013804102,0.00048408893,0.0004424635,0.0004992192,0.0003272554,0.0046728454],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951887,0.00024170332,0.0013378252,0.0010519456,0.0010083269,0.0011714736],"domain_scores_gemma":[0.9979343,0.00040531077,0.000369894,0.0007793303,0.0001045863,0.0004065763],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014627015,0.00077916414,0.0037443852,0.0020615996,0.00009257814,0.000025919926,0.00031190255,0.00016690204,0.00073706056],"category_scores_gemma":[0.00046641298,0.00056537415,0.00033643545,0.0027962977,0.00054987165,0.00011099208,0.00028878066,0.0015980144,0.00023546723],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000870103,0.00015236234,0.00019146292,0.02134306,0.00032288235,0.016771857,0.0008869038,7.4190046e-7,0.0000074031445,0.000023110508,0.022340488,0.9370896],"study_design_scores_gemma":[0.0068841456,0.0005026589,0.000053403826,0.1369277,0.0012925591,0.00041129324,0.0011612094,0.0000414681,0.0000012232862,0.000023403258,0.85228103,0.00041988998],"about_ca_topic_score_codex":0.0015911903,"about_ca_topic_score_gemma":0.00034975875,"teacher_disagreement_score":0.9366697,"about_ca_system_score_codex":0.002076446,"about_ca_system_score_gemma":0.0008167087,"threshold_uncertainty_score":0.99967974},"labels":[],"label_agreement":null},{"id":"W4385969830","doi":"10.36648/2386-5180.22.10.403","title":"Generally Speaking Survival of Men with Metachronous Metastatic Hormone-Touchy Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy","year":2023,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Enzalutamide; Prostate cancer; Medicine; Androgen deprivation therapy; Oncology; Internal medicine; Androgen; Testosterone (patch); Hormone therapy; Hormone; Cancer; Endocrinology; Androgen receptor","score_opus":0.04590219548175064,"score_gpt":0.2832529385812143,"score_spread":0.23735074309946366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385969830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903678,0.0009227708,0.00015553771,0.00048792755,0.00000777328,0.001151318,0.00014796668,0.00034354278,0.006415341],"genre_scores_gemma":[0.99205583,0.0046438565,0.00027387988,0.000025055411,0.000042278625,8.6196235e-7,0.0013461361,0.0007066636,0.0009054437],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99837977,0.0001860713,0.00020624766,0.00037393198,0.0004970346,0.00035693642],"domain_scores_gemma":[0.99888444,0.000025493333,0.00011385358,0.00027123757,0.00054690026,0.00015807676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004188794,0.00017318368,0.00027890774,0.0002995598,0.0006242247,0.00015958564,0.00017985963,0.000030268684,0.0004953174],"category_scores_gemma":[0.000040627154,0.00011806381,0.000029592682,0.00096176454,0.00021729348,0.0001925927,0.00014343525,0.00014746918,0.00008759317],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0237364,0.0011425151,0.014661889,0.0011056463,0.0055400413,0.00096155534,0.01809615,0.001265577,0.41633156,0.001050353,0.011603274,0.50450504],"study_design_scores_gemma":[0.060714435,0.019657807,0.31645676,0.0009909377,0.001404618,0.0011329199,0.0069488147,0.008776492,0.17319152,0.00024783955,0.40855986,0.0019179927],"about_ca_topic_score_codex":0.00020266014,"about_ca_topic_score_gemma":0.0000054249695,"teacher_disagreement_score":0.502587,"about_ca_system_score_codex":0.00013342443,"about_ca_system_score_gemma":0.000030508381,"threshold_uncertainty_score":0.5423378},"labels":[],"label_agreement":null},{"id":"W4386121882","doi":"10.3389/fonc.2023.1185013","title":"Genome-wide studies in prostate cancer poised liquid biopsy as a molecular discovery tool","year":2023,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Liquid biopsy; Epigenome; Prostate cancer; Biopsy; Computational biology; Disease; Genome; Whole genome sequencing; DNA sequencing; Biology; Cancer; Bioinformatics; Medicine; Pathology; Gene; Genetics; DNA methylation","score_opus":0.08350769139115434,"score_gpt":0.4471172401514934,"score_spread":0.3636095487603391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386121882","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054090377,0.98713166,0.000009288641,0.0007489732,0.0019228304,0.0040530004,0.00011713604,0.00006143835,0.00054665934],"genre_scores_gemma":[0.000029942534,0.98221886,0.00034955045,0.00019744097,0.00017594823,0.004274629,0.00032750165,0.00013146467,0.012294632],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964911,0.0004232282,0.0009476586,0.0008620379,0.00034814217,0.00092784554],"domain_scores_gemma":[0.99877423,0.00026042174,0.0002774234,0.00045822907,0.00009584767,0.00013387043],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005867528,0.00056046975,0.0035647051,0.0013243577,0.000049229686,0.000021393806,0.0002868004,0.0004807849,0.0000266442],"category_scores_gemma":[0.00041637506,0.0004133039,0.00038574988,0.0013992842,0.0004491189,0.00010227284,0.00029867917,0.0009790367,0.00007329626],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006385732,0.0012141506,0.010171689,0.09092796,0.008431798,0.07808167,0.004138683,0.000027399072,0.00003576288,0.000055680423,0.015683362,0.7848461],"study_design_scores_gemma":[0.0036272423,0.0014727907,0.00018955479,0.016174294,0.0008514071,0.000063047264,0.0009247675,0.0000025789307,0.000010087281,0.00028954167,0.975915,0.00047967993],"about_ca_topic_score_codex":0.00018969453,"about_ca_topic_score_gemma":0.00010305548,"teacher_disagreement_score":0.96023166,"about_ca_system_score_codex":0.005606673,"about_ca_system_score_gemma":0.0040512593,"threshold_uncertainty_score":0.99983186},"labels":[],"label_agreement":null},{"id":"W4386127056","doi":"10.1038/s41391-023-00683-1","title":"Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide","year":2023,"lang":"en","type":"erratum","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Urology; Cancer","score_opus":0.022149767776735517,"score_gpt":0.3300304014083722,"score_spread":0.3078806336316367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386127056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96674556,0.002075388,0.0000055641353,0.00079093064,0.0031081503,0.011786497,0.014945594,0.0002708518,0.00027144805],"genre_scores_gemma":[0.75195396,0.013974668,0.00015720056,0.00088972034,0.00068440527,0.012473821,0.032817345,0.0008764532,0.18617246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99400574,0.00023167503,0.0012427607,0.0016582237,0.0014996531,0.0013619256],"domain_scores_gemma":[0.9957698,0.000438432,0.0008310036,0.0005623375,0.0013567131,0.001041692],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003403057,0.0011838039,0.0020175956,0.0006456826,0.0003095312,0.00033921294,0.00018406093,0.00023225081,0.00007553455],"category_scores_gemma":[0.0003514593,0.00075664674,0.00012998446,0.0017788198,0.00059175707,0.00032999204,0.00009167767,0.0012489943,0.000016193853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032356624,0.0014019688,0.89610493,0.0023346357,0.0017685973,0.00087005505,0.0013799338,0.00007127054,0.000006257316,6.878716e-7,0.04476878,0.01893627],"study_design_scores_gemma":[0.016662579,0.008853917,0.95202917,0.015966322,0.0024381378,0.0000054029115,0.00048619264,0.00037567518,0.000018047795,0.000010198244,0.0020757022,0.0010786297],"about_ca_topic_score_codex":0.0021062396,"about_ca_topic_score_gemma":0.005332356,"teacher_disagreement_score":0.21479164,"about_ca_system_score_codex":0.001069141,"about_ca_system_score_gemma":0.004554498,"threshold_uncertainty_score":0.9994885},"labels":[],"label_agreement":null},{"id":"W4386153705","doi":"10.1093/hmg/ddad139","title":"Identification of blood protein biomarkers associated with prostate cancer risk using genetic prediction models: analysis of over 140,000 subjects","year":2023,"lang":"en","type":"article","venue":"Human Molecular Genetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Division of Cancer Epidemiology and Genetics, National Cancer Institute; National Cancer Institute; National Heart, Lung, and Blood Institute; NIHR Cambridge Biomedical Research Centre; Cancer Council Victoria; Canadian Institutes of Health Research; Vetenskapsrådet; Breast Cancer Research Foundation; British Heart Foundation; National Institute on Aging; NHS Blood and Transplant; National Institute for Health and Care Research; National Institutes of Health; Rosetrees Trust; European Commission; U.S. Department of Defense; Pancreatic Cancer UK; Prostate Cancer Foundation; Royal Marsden NHS Foundation Trust; National Cancer Research Institute; Department of Health and Social Care; Medical Research Council; Swedish Cancer Foundation; Prostate Cancer Foundation of Australia; Ovarian Cancer Research Fund; Cancer Research Institute; National Health and Medical Research Council; NIHR BioResource; Cancer Research UK","keywords":"Prostate cancer; Biomarker; Computational biology; Gene; Biomarker discovery; Biology; Cancer; Bioinformatics; Medicine; Oncology; Internal medicine; Genetics; Proteomics","score_opus":0.02895777087250574,"score_gpt":0.3098569119617456,"score_spread":0.28089914108923986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386153705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960991,0.0017627772,0.00065891264,0.000010291577,0.000017268534,0.0010647664,0.00031765687,0.000042537486,0.000026698457],"genre_scores_gemma":[0.9985042,0.0006933442,0.00020468519,0.0000037161187,0.000011008202,0.00009652937,0.00027369038,0.000041539617,0.00017125809],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982212,0.00011979939,0.0004428527,0.00032824298,0.000619727,0.0002681868],"domain_scores_gemma":[0.99876124,0.000013474245,0.00038067083,0.00037820096,0.00038229994,0.00008414685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002524241,0.00015760654,0.00034197822,0.0006710409,0.00008497934,0.000016056852,0.00008294991,0.00009446853,0.000022633154],"category_scores_gemma":[0.00002760289,0.00013638788,0.00013444124,0.00206697,0.0001535727,0.00003344839,0.000037766367,0.000098376535,4.6058832e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019821651,0.00019000299,0.17414838,0.00011414647,0.0062231314,0.000036508456,0.00044313422,0.07392856,0.74446356,0.000004701773,0.0000062345885,0.00024339338],"study_design_scores_gemma":[0.0018732538,0.00037649213,0.6025556,0.00018076322,0.007510178,8.17527e-7,0.00006672713,0.15771973,0.22947118,0.0001326885,9.867551e-7,0.00011159812],"about_ca_topic_score_codex":0.00033367143,"about_ca_topic_score_gemma":0.00011726633,"teacher_disagreement_score":0.5149924,"about_ca_system_score_codex":0.0001015312,"about_ca_system_score_gemma":0.000171643,"threshold_uncertainty_score":0.5561736},"labels":[],"label_agreement":null},{"id":"W4386169359","doi":"10.11606/d.17.2023.tde-08082023-145937","title":"A expressão dos marcadores de transição epitélio-mesenquimal SNAI1 e o ZEB1 resulta em alterações transcricionais para promover progressão tumoral e evasão imune no câncer de próstata","year":2023,"lang":"pt","type":"dissertation","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gynecology; Molecular biology; Cancer research; Biology","score_opus":0.046105197115236904,"score_gpt":0.3721879973342912,"score_spread":0.3260828002190543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386169359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95514756,0.016524307,0.00031196987,0.0035762195,0.0018996283,0.014701685,0.0030887753,0.001189364,0.0035604625],"genre_scores_gemma":[0.7864084,0.008756974,0.0014031174,0.00038006273,0.0014780121,0.0062447703,0.013551197,0.0008204716,0.18095697],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.98629886,0.000994735,0.0022927271,0.0028857018,0.003182495,0.0043454957],"domain_scores_gemma":[0.9937662,0.00075161067,0.00063800986,0.0017141183,0.0014115645,0.001718517],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0018462633,0.002277837,0.002581134,0.001334441,0.0008337974,0.00057566375,0.0014462811,0.0014360556,0.004191515],"category_scores_gemma":[0.0005105929,0.0018325337,0.0012945512,0.0019296594,0.00065648375,0.00074471335,0.00016360296,0.0028084277,0.0011252641],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1646815,0.012905332,0.06267876,0.043785453,0.014482633,0.025035439,0.28270084,0.00028389064,0.20336083,0.0005536811,0.0932131,0.09631856],"study_design_scores_gemma":[0.09980496,0.021209858,0.37488565,0.03954591,0.011508856,0.00087935315,0.10627874,0.03209135,0.2746971,0.0010051422,0.025876228,0.012216869],"about_ca_topic_score_codex":0.0025910914,"about_ca_topic_score_gemma":0.0014498793,"teacher_disagreement_score":0.3122069,"about_ca_system_score_codex":0.001049845,"about_ca_system_score_gemma":0.0045641665,"threshold_uncertainty_score":0.9998603},"labels":[],"label_agreement":null},{"id":"W4386223953","doi":"10.3390/jcm12175604","title":"Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Regional Municipality of Durham; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"Sanofi Genzyme; Bayer Canada; Astellas Pharma; Endocyte; Bavarian Nordic; Sanofi; Exelixis; Genentech; AstraZeneca; Amgen","keywords":"Medicine; Prostate cancer; Radium-223; Oncology; Cancer; Internal medicine; Radium; Castration; Overall survival; Urology; Gynecology; Hormone; Bone metastasis","score_opus":0.0984310549185754,"score_gpt":0.4515137259980013,"score_spread":0.3530826710794259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386223953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98654485,0.0030975924,0.0000075632533,0.009088001,0.00006656634,0.00087320653,0.000024791563,0.000015556845,0.00028185922],"genre_scores_gemma":[0.97741914,0.020209065,0.00020787262,0.000021911204,0.0002624193,0.00006670055,0.000010739938,0.000017561311,0.0017846073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778575,0.00012912294,0.001131689,0.0002083228,0.0005113442,0.00023377183],"domain_scores_gemma":[0.99768674,0.0006749232,0.0006687436,0.000187234,0.00045337906,0.00032895373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092325197,0.00015123296,0.00072019245,0.00021149851,0.000073149145,0.000008730595,0.00007241951,0.000045326127,0.000046098525],"category_scores_gemma":[0.0006580067,0.00007679614,0.000085531174,0.00039604778,0.00048223473,0.00011967953,0.000019462563,0.0002310772,0.0000011331487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041247704,0.00036411092,0.97613376,0.0009279641,0.0007646075,0.00039761557,0.00095550326,0.000019903737,0.006376066,0.000014175068,0.00038404574,0.009537495],"study_design_scores_gemma":[0.011061411,0.007886379,0.9751481,0.0022237706,0.0011235335,0.00011543855,0.0004882821,0.000078124496,0.0016050612,0.00010205683,0.00010107281,0.00006681642],"about_ca_topic_score_codex":0.00009378282,"about_ca_topic_score_gemma":0.00005507536,"teacher_disagreement_score":0.01711147,"about_ca_system_score_codex":0.000102103455,"about_ca_system_score_gemma":0.00046468832,"threshold_uncertainty_score":0.31316558},"labels":[],"label_agreement":null},{"id":"W4386251893","doi":"10.5489/cuaj.8538","title":"2023 American Society of Clinical Oncology (ASCO) Symposium: Meeting highlights","year":2023,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia; University of Toronto; Dalhousie University; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; University of Alberta","funders":"","keywords":"Clinical Oncology; Medicine; Engineering ethics; Medical physics; Oncology; Internal medicine; Political science; Engineering; Cancer","score_opus":0.0647379652961401,"score_gpt":0.3797929743945967,"score_spread":0.31505500909845663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386251893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80072683,0.00015070153,0.000005402349,0.18863752,0.00048676922,0.00019463435,0.000038988233,0.000034171648,0.00972497],"genre_scores_gemma":[0.98496825,0.0040473295,0.00046521888,0.003061674,0.0011687868,0.000010936319,0.000059348924,0.000016164062,0.0062022894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763465,0.00034984938,0.00067647366,0.00022128591,0.00048610178,0.0006316588],"domain_scores_gemma":[0.9973868,0.00065634836,0.00051621237,0.00010518721,0.0004067309,0.0009286816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025915036,0.00011516024,0.00057294796,0.0001739696,0.00023488977,0.000026445414,0.00012866032,0.00028694991,0.00029670744],"category_scores_gemma":[0.00070608966,0.00008251464,0.00039634615,0.0007080035,0.0001633834,0.000052696945,0.00003039746,0.0007846256,0.00017465117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015057997,0.000093405564,0.8089486,0.000010055424,0.00047603183,0.00021917863,0.00020069229,0.000027913811,0.00057685794,0.000050903313,0.17292364,0.01632216],"study_design_scores_gemma":[0.0017970778,0.0013599279,0.60936797,0.000022162201,0.00009615875,0.00004259738,0.00030761148,0.00047408327,0.00008969599,0.00016720204,0.38617855,0.00009697472],"about_ca_topic_score_codex":0.0018292859,"about_ca_topic_score_gemma":0.00062982505,"teacher_disagreement_score":0.21325491,"about_ca_system_score_codex":0.0011636104,"about_ca_system_score_gemma":0.0019457586,"threshold_uncertainty_score":0.34516922},"labels":[],"label_agreement":null},{"id":"W4386348930","doi":"10.3390/curroncol30090591","title":"A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS)","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital; Bayer (Canada); University of Calgary","funders":"Bayer Canada","keywords":"Medicine; Enzalutamide; Prostate cancer; Androgen deprivation therapy; Cohort; Population; Internal medicine; Abiraterone acetate; Docetaxel; Retrospective cohort study; Cancer registry; Oncology; Cohort study; Cancer; Androgen receptor","score_opus":0.5148381493508316,"score_gpt":0.5510062763612852,"score_spread":0.03616812701045358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386348930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98995036,0.00010943319,0.00012892525,0.0009741836,0.00076963543,0.0067678853,0.0012315444,0.000059291924,0.000008757675],"genre_scores_gemma":[0.9921539,0.00025002938,0.0003115603,0.00005329252,0.00015951633,0.0020644984,0.0045303716,0.000042934873,0.00043393316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976491,0.00022254257,0.00045914517,0.00076282374,0.00036743385,0.0005389537],"domain_scores_gemma":[0.99777883,0.00081914454,0.00016220078,0.0005393864,0.00044713728,0.00025331508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030426562,0.00027634227,0.00057227246,0.00040096385,0.00023348244,0.0000364305,0.00015464073,0.000036611636,0.000043141532],"category_scores_gemma":[0.00023620756,0.00021165528,0.0000752133,0.00067834737,0.00003627624,0.00018541662,0.00011679124,0.00010644948,0.000022591797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014784251,0.002078366,0.96308523,0.00022361855,0.00027709376,0.00005538648,0.0023988907,0.0005029588,0.00010898909,0.0000032650178,0.0005015344,0.029286219],"study_design_scores_gemma":[0.009900027,0.005616064,0.95561266,0.00073756673,0.001206129,0.0000020885395,0.0011201124,0.023085644,0.00048938673,0.000012488357,0.0019051215,0.0003127334],"about_ca_topic_score_codex":0.024154784,"about_ca_topic_score_gemma":0.06548944,"teacher_disagreement_score":0.04133466,"about_ca_system_score_codex":0.0020433785,"about_ca_system_score_gemma":0.0015241217,"threshold_uncertainty_score":0.98234344},"labels":[],"label_agreement":null},{"id":"W4386408793","doi":"10.3390/cancers15174392","title":"Prognostic Role of Dynamic Changes in Serological Markers in Metastatic Hormone Naïve Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Ottawa; University Health Network; University of Toronto; Ottawa Hospital; Mount Sinai Hospital","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Oncology; Prostate-specific antigen; Cancer","score_opus":0.02907924400724044,"score_gpt":0.33626900404600096,"score_spread":0.30718976003876053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386408793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894529,0.007056225,3.4155863e-7,0.0017016499,0.00006901679,0.0012361443,0.00007054357,0.00004796033,0.00036521908],"genre_scores_gemma":[0.98761225,0.010162298,0.000047806232,0.000085107145,0.000016516242,0.0009817405,0.00007483366,0.000024358797,0.0009951222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857086,0.000062391904,0.00023732014,0.00031509434,0.00028459614,0.00052974396],"domain_scores_gemma":[0.99951047,0.00009643837,0.00006458003,0.00015905965,0.000057027977,0.000112443835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002859309,0.00015672487,0.00039529367,0.0004207241,0.000021693178,0.0000065840836,0.000089856265,0.00006142573,0.00008914024],"category_scores_gemma":[0.00007895821,0.0001205878,0.00004721621,0.0012383461,0.00016469683,0.00004989272,0.000049989023,0.00023042341,0.000014759597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007332917,0.00019493628,0.8241906,0.0010902319,0.00040246,0.0013042799,0.0055859326,0.002137714,0.054364737,0.00003320168,0.0011904947,0.10217247],"study_design_scores_gemma":[0.0054191723,0.0010759896,0.97412723,0.00051725813,0.00008131979,0.000006899791,0.0032646484,0.012542421,0.0018645875,0.00030835593,0.00059442734,0.00019768173],"about_ca_topic_score_codex":0.0017136777,"about_ca_topic_score_gemma":0.0040150643,"teacher_disagreement_score":0.14993662,"about_ca_system_score_codex":0.0014684225,"about_ca_system_score_gemma":0.0007536101,"threshold_uncertainty_score":0.49174276},"labels":[],"label_agreement":null},{"id":"W4386448969","doi":"10.21203/rs.3.rs-3296899/v1","title":"Genomic Classifiers and Prognosis of Localized Prostate Cancer: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Quality Enhancement Research Initiative; U.S. Department of Veterans Affairs","keywords":"Prostate cancer; Computational biology; Cancer; Biology; Oncology; Medicine; Genetics","score_opus":0.2004413197481581,"score_gpt":0.4977441307057345,"score_spread":0.2973028109575764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386448969","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014826308,0.9751051,2.8369544e-7,0.00046739448,0.00004709677,0.023719013,0.0003715465,0.00007901894,0.00019573202],"genre_scores_gemma":[0.000008412984,0.98009837,0.000020765816,0.000017745073,0.00007485071,0.012614623,0.0002910152,0.00015536947,0.0067188507],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99406,0.0012908776,0.001292994,0.0007673101,0.0016292294,0.0009596206],"domain_scores_gemma":[0.9966725,0.0008591489,0.00039040486,0.00081316195,0.0007803274,0.0004844704],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003159573,0.00047529937,0.004996831,0.0009457503,0.0001605317,0.000056256336,0.00032284987,0.00030190297,0.00009437532],"category_scores_gemma":[0.00097081775,0.00028908544,0.0006251279,0.002277511,0.0005342477,0.000053987227,0.00037020148,0.0011091611,0.00015960661],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005889766,0.000084812506,0.00009195367,0.9234005,0.0011514392,0.00018484962,0.00008842257,1.7001723e-8,0.0000012888985,0.000022913016,0.0023812635,0.07253363],"study_design_scores_gemma":[0.0006678056,0.00047256454,0.000010424984,0.861112,0.0029373327,0.000041881405,0.00011992958,0.0000067017127,0.0000027883298,0.000014540173,0.13441661,0.00019745708],"about_ca_topic_score_codex":0.00019236207,"about_ca_topic_score_gemma":0.000017896582,"teacher_disagreement_score":0.13203534,"about_ca_system_score_codex":0.0009045265,"about_ca_system_score_gemma":0.003022587,"threshold_uncertainty_score":0.99995613},"labels":[],"label_agreement":null},{"id":"W4386516247","doi":"10.1093/jnci/djad184","title":"Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial","year":2023,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; National Cancer Institute; Prostate Cancer Foundation; National Institutes of Health; Alliance for Clinical Trials in Oncology Foundation; Sanofi; U.S. Department of Defense","keywords":"Prostate cancer; Prostatectomy; Docetaxel; Androgen deprivation therapy; Oncology; Internal medicine; Neoadjuvant therapy; Medicine; Prostate; Cancer; Cancer research","score_opus":0.0746175617359197,"score_gpt":0.4332613411584046,"score_spread":0.3586437794224849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386516247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9703844,0.0068253716,0.0000017550419,0.019986095,0.001361765,0.0008712781,0.00014347564,0.0000057363814,0.00042010346],"genre_scores_gemma":[0.9923769,0.0043788324,0.000021079724,0.0013798958,0.000867168,0.00020953374,0.000012156159,0.000013533614,0.00074088515],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977351,0.0001016756,0.0004237851,0.00012418375,0.0013971933,0.000218063],"domain_scores_gemma":[0.9988796,0.00006727653,0.00027062255,0.00012694868,0.00059280166,0.00006272049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007222718,0.00013308311,0.0002787817,0.00024007184,0.000072868665,0.000023110113,0.00028849053,0.00005207105,0.000060590966],"category_scores_gemma":[0.00012786787,0.000061759674,0.0002346433,0.00078082574,0.00018135697,0.00015537147,0.00003620097,0.00044072035,0.0000017077349],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48867914,0.0038085454,0.031353626,0.00053071073,0.0033879061,0.002583761,0.01743527,0.014882487,0.106376156,0.0013812437,0.12656318,0.20301798],"study_design_scores_gemma":[0.3805543,0.0043602916,0.2030311,0.0023722555,0.000519394,0.00040350083,0.0005837889,0.00042953566,0.12628092,0.0042561926,0.2766135,0.00059523573],"about_ca_topic_score_codex":0.00019123622,"about_ca_topic_score_gemma":0.00014712408,"teacher_disagreement_score":0.20242274,"about_ca_system_score_codex":0.00036427705,"about_ca_system_score_gemma":0.0016622536,"threshold_uncertainty_score":0.29487666},"labels":[],"label_agreement":null},{"id":"W4386631299","doi":"10.1016/s1470-2045(23)00382-0","title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":288,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; Genentech; EMD Serono; Bavarian Nordic; Astellas Pharma; Sanofi; Exelixis; Advanced Accelerator Applications; Endocyte; Janssen Pharmaceuticals; Invitae; Gilead Sciences; Merck; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Ipsen; BeiGene; Constellation Pharmaceuticals","keywords":"Abiraterone; Prostate cancer; Medicine; Placebo; Olaparib; Urology; Abiraterone acetate; Internal medicine; Oncology; Double blind; Androgen deprivation therapy; Cancer; Androgen receptor; Poly ADP ribose polymerase","score_opus":0.313893449351758,"score_gpt":0.459480059444977,"score_spread":0.145586610093219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386631299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980681,0.0006786395,0.0000064121004,0.0071531795,0.0011066269,0.0072148996,0.00042918697,0.00008702447,0.0026430152],"genre_scores_gemma":[0.9869397,0.0016967594,0.00010827395,0.000086427586,0.0008448023,0.0024830948,0.0005420058,0.000053453106,0.0072454773],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99610233,0.00076248473,0.001046533,0.000558023,0.00063142244,0.00089921954],"domain_scores_gemma":[0.9976671,0.0009552161,0.0004112541,0.00058347057,0.00021359889,0.00016940877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026968054,0.00034085134,0.0015055079,0.0002748669,0.00013284177,0.000046749326,0.0003219721,0.00015565664,0.00016605179],"category_scores_gemma":[0.00019966361,0.00021578876,0.00014122161,0.00066765485,0.00037149902,0.00012992231,0.00012532421,0.0005805042,0.000058190548],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9770636,0.0006104671,0.000024514879,0.00023225919,0.00055655406,0.000659377,0.0029939045,0.0010493773,0.010952597,0.00013625328,0.0037960839,0.001925003],"study_design_scores_gemma":[0.98073053,0.0071332688,0.00046341115,0.00013153243,0.00031329016,0.000011007838,0.00051064155,0.0012036037,0.004080847,0.00008565359,0.005126976,0.00020922637],"about_ca_topic_score_codex":0.0019168123,"about_ca_topic_score_gemma":0.0041475995,"teacher_disagreement_score":0.007066752,"about_ca_system_score_codex":0.0009975213,"about_ca_system_score_gemma":0.0023218184,"threshold_uncertainty_score":0.879961},"labels":[],"label_agreement":null},{"id":"W4386753000","doi":"10.1016/j.euo.2023.08.004","title":"Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer","year":2023,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"AstraZeneca","keywords":"Medicine; Prostate cancer; Genetic testing; Guideline; Molecular diagnostics; Disease; Clinical trial; Cancer; Bioinformatics; Homologous recombination; Intensive care medicine; Internal medicine; Pathology; Gene; Genetics","score_opus":0.19306534459357183,"score_gpt":0.4938495154396637,"score_spread":0.3007841708460919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386753000","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0063461936,0.95080614,0.00085148186,0.0073869806,0.001727427,0.029234434,0.0006097556,0.00039994722,0.002637645],"genre_scores_gemma":[0.0004118356,0.9177436,0.06592834,0.0016853542,0.00042003425,0.010427659,0.0020624674,0.00044569618,0.00087497203],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927727,0.0035524755,0.0015812595,0.0011140098,0.00024195411,0.0007375792],"domain_scores_gemma":[0.9849632,0.01286286,0.0009528783,0.00040796268,0.00066680554,0.00014628822],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045681032,0.0004312775,0.0017586964,0.0006208121,0.00012107682,0.000034503995,0.00017896859,0.00028313967,0.000004126388],"category_scores_gemma":[0.021012582,0.00032522425,0.00025515386,0.00076544273,0.00021108385,0.00018392438,0.000114300004,0.0011561803,0.000023896957],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046436195,0.004406313,0.0026375703,0.0059135742,0.00084094127,0.005360933,0.00023179506,0.00009593396,8.5343623e-7,0.00037202868,0.0015773621,0.9739191],"study_design_scores_gemma":[0.013147508,0.026046833,0.0016538035,0.0036797188,0.0019058434,0.00017948747,0.00005828356,0.00049504737,0.0000012178645,0.0001290058,0.9522715,0.00043173984],"about_ca_topic_score_codex":0.000039366554,"about_ca_topic_score_gemma":0.00016939439,"teacher_disagreement_score":0.9734873,"about_ca_system_score_codex":0.0007471921,"about_ca_system_score_gemma":0.0025763134,"threshold_uncertainty_score":0.99992},"labels":[],"label_agreement":null},{"id":"W4386757238","doi":"10.1007/s12325-023-02634-7","title":"Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer","keywords":"Medicine; Prostate cancer; Concomitant; Internal medicine; Adverse effect; Urology; Population; Cancer","score_opus":0.02484750801981962,"score_gpt":0.37897592618127074,"score_spread":0.35412841816145113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386757238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92521566,0.072855644,0.0000029945868,0.000095485484,0.000047364076,0.0015976186,0.000095902,0.000024915364,0.00006442362],"genre_scores_gemma":[0.8457339,0.1539167,0.000039622835,0.000012193938,0.000019492763,0.00017368713,0.000036550857,0.000024275181,0.000043592423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980669,0.00020406515,0.0004921845,0.00045170152,0.00045526001,0.00032985967],"domain_scores_gemma":[0.998869,0.0003328913,0.00013976693,0.0004952079,0.00009430287,0.00006885822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048729643,0.00023591155,0.0011266454,0.0005440911,0.00003265584,0.0000069197695,0.00012046435,0.00005828771,0.000039698054],"category_scores_gemma":[0.000036256668,0.0001564229,0.00029066158,0.0018928358,0.00016915498,0.00015655819,0.00003134378,0.00020117262,9.898566e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020071577,0.0005665991,0.8596393,0.00003782987,0.0038558138,0.00007036846,0.0053227786,0.012392059,0.002075838,0.0000036243114,0.0000020188443,0.095962174],"study_design_scores_gemma":[0.021619905,0.002896032,0.9705652,0.0001992804,0.00017576768,4.0385973e-7,0.0012359915,0.00016549636,0.002654048,0.00014696278,0.00019867442,0.00014222277],"about_ca_topic_score_codex":0.002258021,"about_ca_topic_score_gemma":0.00071412546,"teacher_disagreement_score":0.1109259,"about_ca_system_score_codex":0.00022398622,"about_ca_system_score_gemma":0.0001203173,"threshold_uncertainty_score":0.63787407},"labels":[],"label_agreement":null},{"id":"W4386800011","doi":"10.1016/j.ctrv.2023.102626","title":"Managing postoperative biochemical relapse in prostate cancer, from the perspective of the Francophone group of Urological radiotherapy (GFRU)","year":2023,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital; Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Androgen deprivation therapy; Radiological weapon; Disease; Positron emission tomography; Clinical trial; Management of prostate cancer; Prostate; Biochemical recurrence; Cancer; Oncology; Radiology; Internal medicine; Prostatectomy","score_opus":0.08208481369047983,"score_gpt":0.4076436679264487,"score_spread":0.32555885423596886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386800011","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012275053,0.9855976,0.0000011560388,0.0028287892,0.00043353095,0.008943644,0.00078517065,0.000025288999,0.0001572934],"genre_scores_gemma":[0.00011031476,0.99248177,0.000060786184,0.0001631763,0.00029935638,0.0055725924,0.00016673908,0.00008985362,0.0010554391],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961571,0.0007803638,0.0012535402,0.00088057405,0.00043566644,0.00049272634],"domain_scores_gemma":[0.99746233,0.00046372318,0.00080541807,0.0010179075,0.00013334768,0.00011726377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039998099,0.0007474295,0.0038339049,0.00012237993,0.00010271271,0.000015866084,0.00047679053,0.00025355557,0.0002441306],"category_scores_gemma":[0.00008050305,0.00029844145,0.0012823174,0.0016719842,0.0005492597,0.000047185746,0.00013213995,0.0006608146,0.00001659062],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005547816,0.000608176,0.0025589445,0.006341281,0.0024475588,0.0000766999,0.0033668175,0.0000028532477,0.00012853058,0.000054554715,0.002694346,0.98116547],"study_design_scores_gemma":[0.0038965633,0.0008477558,0.00088255847,0.052042637,0.0023078262,0.000012764174,0.0004066306,0.000008432268,0.00019376178,0.00012446822,0.93891007,0.0003665203],"about_ca_topic_score_codex":0.006730221,"about_ca_topic_score_gemma":0.00048779824,"teacher_disagreement_score":0.98079896,"about_ca_system_score_codex":0.0027803879,"about_ca_system_score_gemma":0.0011085321,"threshold_uncertainty_score":0.9999468},"labels":[],"label_agreement":null},{"id":"W4386815910","doi":"10.1016/j.ejca.2023.113342","title":"Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Orion Corporation; Astellas Pharma; Genentech; UroGen Pharma; Daiichi Sankyo Europe; Sanofi; Bayer HealthCare; Incyte; MacroGenics; Invitae; Bayer; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Prostate cancer; Placebo; Medicine; Oncology; Internal medicine; Overall survival; Crossover; Crossover study; Cancer; Pathology; Alternative medicine","score_opus":0.038797972953451436,"score_gpt":0.4012976965375424,"score_spread":0.36249972358409094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386815910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955766,0.0006726626,0.00002390218,0.0010343088,0.00016140332,0.0017119583,0.0003487239,0.000012539664,0.0004578686],"genre_scores_gemma":[0.9983142,0.0005355025,0.000024467203,0.00012600758,0.00026536852,0.000040524985,0.000018819755,0.00005196144,0.0006231494],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99602664,0.0018796945,0.0005507706,0.0002886782,0.00091779087,0.00033645565],"domain_scores_gemma":[0.9974228,0.0014871064,0.000364861,0.00030056437,0.00022014201,0.00020453549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027365936,0.0002619869,0.0008738135,0.0002075855,0.00007369771,0.000051360905,0.00015980403,0.00001377736,0.00010208188],"category_scores_gemma":[0.0002473827,0.0001315935,0.00015418754,0.0005388458,0.00009873477,0.000097870456,0.000060329625,0.00041158617,0.000015357959],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61682916,0.0010013388,0.22526121,0.00009864793,0.004484987,0.010680334,0.014152292,0.01823312,0.07112419,1.3444274e-7,0.004827552,0.033307012],"study_design_scores_gemma":[0.3365866,0.01206627,0.5984755,0.0017056202,0.0014383467,0.000007622831,0.0012241404,0.0011572852,0.046512228,0.000004156759,0.00055148586,0.00027075535],"about_ca_topic_score_codex":0.003307056,"about_ca_topic_score_gemma":0.00067298056,"teacher_disagreement_score":0.3732143,"about_ca_system_score_codex":0.00024394337,"about_ca_system_score_gemma":0.0003196341,"threshold_uncertainty_score":0.53662264},"labels":[],"label_agreement":null},{"id":"W4386854629","doi":"10.1101/2023.09.18.558190","title":"Estradiol propionate reduction of nuclear size in prostate cancer lines lacking DHRS7 suggests DHRS7 absence as a biomarker for the effectiveness of estrogen therapy","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Medical Research Council; Darwin Trust of Edinburgh; Sigrid Juséliuksen Säätiö","keywords":"LNCaP; Prostate cancer; Cancer research; Prostate; Estrogen; Grading (engineering); Androgen; Cancer; Biology; Internal medicine; Endocrinology; Oncology; Medicine; Hormone","score_opus":0.036114061758775906,"score_gpt":0.3137035796311357,"score_spread":0.2775895178723598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386854629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98394877,0.008722036,0.0000105888275,0.0006578726,0.00085833244,0.005399919,0.0002855539,0.00011471199,0.0000022210033],"genre_scores_gemma":[0.9822875,0.015054129,0.0003914212,0.000014882547,0.00020613486,0.0018766174,0.0000015201241,0.00015353312,0.000014240436],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974332,0.00025245527,0.00058291864,0.00076120906,0.00047968535,0.0004905203],"domain_scores_gemma":[0.9971823,0.0006394807,0.00043748156,0.00076293224,0.0008554103,0.00012239658],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014860575,0.00042048842,0.0007719205,0.00028694415,0.00010023097,0.000044599896,0.0003288553,0.0002845772,0.0000151080185],"category_scores_gemma":[0.0004679207,0.00030183356,0.0002318001,0.00078424474,0.00034642033,0.0000932917,0.00016710405,0.00047532283,0.000004128609],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059423773,0.0003698168,0.06887158,0.0048042727,0.0009331601,0.00006401655,0.00010072911,0.0002753283,0.9183324,0.00015426021,0.000054418586,0.00009764916],"study_design_scores_gemma":[0.0032418082,0.0003374389,0.5526522,0.0043017194,0.0001459504,8.688769e-8,0.000021015869,0.00067543087,0.4378595,0.00001827631,0.00044530933,0.0003012381],"about_ca_topic_score_codex":0.00094364234,"about_ca_topic_score_gemma":0.0000057274865,"teacher_disagreement_score":0.48378062,"about_ca_system_score_codex":0.00038138346,"about_ca_system_score_gemma":0.0014346824,"threshold_uncertainty_score":0.9999434},"labels":[],"label_agreement":null},{"id":"W4386909796","doi":"10.1001/jamaoncol.2023.3352","title":"Rare Genetic Drivers of Lethal Prostate Cancer","year":2023,"lang":"en","type":"letter","venue":"JAMA Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"","keywords":"Medicine; Otorhinolaryngology; Family medicine; MEDLINE; Neurology; Psychiatry","score_opus":0.042841644843669154,"score_gpt":0.36716397033839254,"score_spread":0.3243223254947234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386909796","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.059117,0.0026436215,0.0000011107235,0.92923355,0.0012871828,0.0013192835,0.0004689304,0.00009761525,0.0058317115],"genre_scores_gemma":[0.010361727,0.020271055,0.00084176124,0.6310699,0.014809257,0.0017820041,0.0032171214,0.00041800272,0.31722918],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979533,0.0001475041,0.0003563782,0.0004659568,0.00046930768,0.0006075687],"domain_scores_gemma":[0.9987936,0.00023916498,0.00021311275,0.0003689109,0.00027943598,0.00010577499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012711102,0.0002663903,0.0008257679,0.00033398464,0.000047434252,0.00001078304,0.00019146048,0.0011780178,0.00075454847],"category_scores_gemma":[0.00006332994,0.00020613006,0.00020770605,0.00030456288,0.0003634845,0.0000311155,0.00013170631,0.0017517263,0.00020723502],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040890984,0.000054144064,0.008849871,0.00095159945,0.00043843084,0.013549792,0.0005282181,0.000003995139,0.00040768244,0.0000014737404,0.94513613,0.029669736],"study_design_scores_gemma":[0.0038657624,0.0013587548,0.011173974,0.00033939502,0.0003251339,0.00011278024,0.00008118756,0.000013693202,0.0006836837,0.00007299677,0.9817949,0.00017774927],"about_ca_topic_score_codex":0.00052820914,"about_ca_topic_score_gemma":0.00006630534,"teacher_disagreement_score":0.3113975,"about_ca_system_score_codex":0.0008307347,"about_ca_system_score_gemma":0.0019388336,"threshold_uncertainty_score":0.9085952},"labels":[],"label_agreement":null},{"id":"W4386930636","doi":"10.3389/fonc.2023.1268309","title":"Can PSMA PET/CT help in dose-tailoring in post-prostatectomy radiotherapy?","year":2023,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostatectomy; Medicine; Radiation therapy; Prostate cancer; Medical physics; Radiology; Nuclear medicine; Internal medicine; Cancer","score_opus":0.025975611435722693,"score_gpt":0.34431451882520825,"score_spread":0.31833890738948556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386930636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98395646,0.0021326842,0.000007242559,0.009515757,0.0010672332,0.00096487865,0.000015139453,0.00007288704,0.0022677386],"genre_scores_gemma":[0.987969,0.004462034,0.0018370601,0.00052954984,0.00013941637,0.00039718059,0.00012341885,0.00005387122,0.004488482],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811035,0.00016689548,0.00034930572,0.00040448102,0.00020421625,0.0007647698],"domain_scores_gemma":[0.99945796,0.00009782718,0.00004875564,0.00022968417,0.000038820832,0.00012698377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055312086,0.0001786327,0.0005750758,0.001290833,0.00003550069,0.00001078003,0.00014856856,0.00005201812,0.00008124066],"category_scores_gemma":[0.000096077485,0.00015854723,0.00005940282,0.00131398,0.00014572356,0.00006889118,0.00006036429,0.00054526026,0.00002548388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020099608,0.00027427127,0.9104399,0.00009875854,0.00006962328,0.022238007,0.0020845507,0.00009410704,0.0013080792,0.0000217845,0.0063689626,0.054991957],"study_design_scores_gemma":[0.040084682,0.0032172636,0.8744994,0.00038216522,0.00003080916,0.0003469114,0.010596468,0.00407805,0.0019895262,0.0013013526,0.062940575,0.0005328386],"about_ca_topic_score_codex":0.0013224994,"about_ca_topic_score_gemma":0.0026045493,"teacher_disagreement_score":0.056571614,"about_ca_system_score_codex":0.0024444477,"about_ca_system_score_gemma":0.00071607035,"threshold_uncertainty_score":0.6465368},"labels":[],"label_agreement":null},{"id":"W4386986411","doi":"10.1016/j.brachy.2023.06.075","title":"PP03  Presentation Time: 11:18 AM","year":2023,"lang":"en","type":"article","venue":"Brachytherapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital de l'Enfant-Jésus","funders":"","keywords":"Medicine; Prostate cancer; Regimen; Prostatectomy; Brachytherapy; Radiation therapy; Prostate; Prospective cohort study; Nuclear medicine; Cohort; Urology; Image-guided radiation therapy; Cancer; Surgery; Internal medicine","score_opus":0.04833410704757621,"score_gpt":0.3838494781560979,"score_spread":0.3355153711085217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386986411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98205674,0.0007730389,0.000021579934,0.0058389185,0.00016237848,0.00084211887,0.000009168571,0.0003231455,0.009972891],"genre_scores_gemma":[0.692717,0.0032389788,0.0003126493,0.00092647714,0.0007969092,0.00033926804,0.00059515814,0.00007834318,0.3009952],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.999119,0.000035997688,0.0001240004,0.00018568558,0.00028307535,0.00025225748],"domain_scores_gemma":[0.99955094,0.000061896986,0.000028342134,0.0002050951,0.000058572095,0.00009518149],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014958785,0.00009293253,0.00017594713,0.0001358234,0.00007315423,0.0000229204,0.0000510243,0.000051360326,0.001524427],"category_scores_gemma":[0.000021421056,0.000067272966,0.00008023502,0.0004307458,0.000045814777,0.00007840076,0.000015221197,0.0000806098,0.0018156294],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040018386,0.00056405086,0.15086223,0.00018156989,0.0005455544,0.000632999,0.0017831753,0.000029689698,0.119613394,0.0003333679,0.5194125,0.20203958],"study_design_scores_gemma":[0.034655713,0.0017497289,0.57483214,0.0001745833,0.00011851348,0.00009403333,0.00037962742,0.004349922,0.058159612,0.0018873174,0.32311976,0.00047905996],"about_ca_topic_score_codex":0.00002569997,"about_ca_topic_score_gemma":0.0000030063725,"teacher_disagreement_score":0.4239699,"about_ca_system_score_codex":0.000048776,"about_ca_system_score_gemma":0.00007757753,"threshold_uncertainty_score":0.99938834},"labels":[],"label_agreement":null},{"id":"W4386986448","doi":"10.1016/j.brachy.2023.06.050","title":"PL02  Presentation Time: 1:45 PM","year":2023,"lang":"en","type":"article","venue":"Brachytherapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Brachytherapy; Prostate; Urology; Randomized controlled trial; Biopsy; Androgen deprivation therapy; Randomization; Nuclear medicine; Radiation therapy; Cancer; Internal medicine","score_opus":0.03688887991007488,"score_gpt":0.36730931608995865,"score_spread":0.33042043617988376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386986448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759545,0.0010313558,0.000027713224,0.007916513,0.00016482336,0.00091711443,0.000009572695,0.00036433345,0.013614127],"genre_scores_gemma":[0.65636814,0.0039560553,0.00034573962,0.0010053987,0.00092239387,0.00035832307,0.00060453056,0.00008020532,0.33635923],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.999187,0.00003270394,0.000113552494,0.00016951734,0.000265254,0.0002319604],"domain_scores_gemma":[0.9995924,0.00005765716,0.000025021913,0.00018131438,0.00005163208,0.00009192125],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014351623,0.000084025414,0.00016250768,0.00012973457,0.000067502886,0.00002023821,0.00004548546,0.000049806513,0.00095041125],"category_scores_gemma":[0.000020030368,0.000060419454,0.00007376097,0.00039838318,0.000039775437,0.000072044706,0.00001387226,0.000091050584,0.0024593242],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006515478,0.00058968744,0.061617017,0.00019552199,0.00077030045,0.0007468456,0.0026564742,0.00003864216,0.15774016,0.00033328964,0.38967004,0.37912655],"study_design_scores_gemma":[0.0459625,0.0025993127,0.57481366,0.0002176681,0.00014389298,0.0001242917,0.00037104383,0.0064923745,0.0826298,0.0028092004,0.28324178,0.0005944877],"about_ca_topic_score_codex":0.000023000774,"about_ca_topic_score_gemma":0.000001776787,"teacher_disagreement_score":0.51319665,"about_ca_system_score_codex":0.000044394525,"about_ca_system_score_gemma":0.00007458005,"threshold_uncertainty_score":0.99996287},"labels":[],"label_agreement":null},{"id":"W4386997696","doi":"10.1053/j.semnuclmed.2023.08.004","title":"Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [18F]F-FDG Tracers - Part I. PSMA, Choline, and DOTA Radiotracers","year":2023,"lang":"en","type":"review","venue":"Seminars in Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Magnetic resonance imaging; Positron emission tomography; Nuclear medicine; Molecular imaging; Radiomics; Radiology; Artificial intelligence; In vivo; Computer science","score_opus":0.05836267653970659,"score_gpt":0.4172595825504569,"score_spread":0.3588969060107503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386997696","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025238315,0.99030125,0.000008794399,0.0040830486,0.0001670774,0.0037807988,0.000020591551,0.00004536354,0.0013406937],"genre_scores_gemma":[0.0002106363,0.9980837,0.00021173172,0.00047582918,0.00014594877,0.00031708798,0.00023814701,0.00009851003,0.00021836869],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99643743,0.00031481974,0.0013467022,0.0008365078,0.0005880719,0.0004764523],"domain_scores_gemma":[0.99821454,0.00041505403,0.00048459976,0.0005689763,0.00009689297,0.00021994897],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015739257,0.0005219718,0.0026736823,0.0008306785,0.000051154955,0.000008018269,0.00027049184,0.00018336585,0.00012482922],"category_scores_gemma":[0.0006839701,0.00037161435,0.0001950862,0.0017336488,0.0007158846,0.00005068849,0.00008767472,0.00113491,0.00003696041],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018089675,0.00021937012,0.000015091036,0.032598212,0.000102938015,0.0009904074,0.0010829375,0.000002272815,0.000024537258,0.00023087762,0.0026108064,0.96194166],"study_design_scores_gemma":[0.0010699283,0.0017067224,0.000025108937,0.32113436,0.0010933565,0.00034706376,0.0025478527,0.0006763402,0.000010368289,0.00040583345,0.6705019,0.00048116528],"about_ca_topic_score_codex":0.00008080086,"about_ca_topic_score_gemma":0.000017524804,"teacher_disagreement_score":0.9614605,"about_ca_system_score_codex":0.00070467877,"about_ca_system_score_gemma":0.00031792573,"threshold_uncertainty_score":0.9998736},"labels":[],"label_agreement":null},{"id":"W4387002108","doi":"10.1097/mou.0000000000001132","title":"Prognostic impact of serum testosterone in metastatic hormone-naive prostate cancer: a systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"Current Opinion in Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Testosterone (patch); Oncology; Internal medicine; Biomarker; Cochrane Library; Cancer; Meta-analysis","score_opus":0.27868391082783905,"score_gpt":0.5051461330706385,"score_spread":0.22646222224279944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387002108","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000032858512,0.9870537,0.000001472547,0.00030730208,0.00015095175,0.011287043,0.0011388191,0.000024504929,0.0000033846773],"genre_scores_gemma":[0.00023682056,0.9917859,0.000007608647,0.000013848305,0.000020350924,0.0071812365,0.0006029054,0.000058317284,0.000093023344],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99502444,0.0012372195,0.0020192033,0.00075244036,0.00037293902,0.0005937716],"domain_scores_gemma":[0.9972873,0.00079797726,0.0009842076,0.00058986037,0.00015960187,0.0001811038],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011954778,0.0006349143,0.0118465535,0.0018036634,0.00002356739,0.000014594364,0.00021700963,0.00016247197,0.00009066655],"category_scores_gemma":[0.0004996112,0.00036472955,0.0016656283,0.003166554,0.00017202873,0.00006366096,0.0001764139,0.00071617035,0.000021789578],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003266615,0.00020832263,0.0010866367,0.91929233,0.07550377,0.000026893184,0.00011386027,0.0000055547953,3.0731297e-8,0.000004467915,0.0001410832,0.0035843581],"study_design_scores_gemma":[0.0011563358,0.0011617468,0.0014185772,0.110473275,0.8834369,0.000071397226,0.000013736732,0.000057019188,2.8279688e-8,0.000030658037,0.0018191909,0.00036110374],"about_ca_topic_score_codex":0.00014477111,"about_ca_topic_score_gemma":0.000030997453,"teacher_disagreement_score":0.80881906,"about_ca_system_score_codex":0.0003490433,"about_ca_system_score_gemma":0.00087608513,"threshold_uncertainty_score":0.9998805},"labels":[],"label_agreement":null},{"id":"W4387033134","doi":"10.1172/jci169200","title":"The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Genentech; Sierra Oncology; Astellas Pharma; Eisai; Newcastle University; Prostate Cancer UK; National Institute for Health and Care Research; Wellcome Trust; JGW Patterson Foundation; Prostate Cancer Foundation; Movember Foundation; AstraZeneca; Pfizer; Amgen; Sanofi; Cancer Research UK; Vertex Pharmaceuticals","keywords":"Prostate cancer; Androgen receptor; RNA splicing; Signalling; Cancer research; Protein subunit; Alternative splicing; Function (biology); Prostate; Receptor; Medicine; Cancer; Cell biology; Chemistry; Biology; Computational biology; Internal medicine; Genetics; Gene isoform; Gene","score_opus":0.10274179390173648,"score_gpt":0.42657928142334484,"score_spread":0.32383748752160835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387033134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99209666,0.0010790701,0.000001861528,0.0064073806,0.00013985191,0.0002376609,0.0000043934915,0.0000041719363,0.000028918774],"genre_scores_gemma":[0.99036735,0.0090324115,0.00009696687,0.000037642538,0.00007462699,0.000005513378,0.00000779036,0.000007882295,0.00036981786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984201,0.0000992897,0.0009930141,0.00008595412,0.00028227936,0.00011935598],"domain_scores_gemma":[0.9985642,0.00045379292,0.0005135063,0.000092507355,0.00027418789,0.00010181899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017042629,0.00006247091,0.00033687122,0.00013755867,0.000031827803,0.0000067267915,0.000051723528,0.000060108894,0.0000028941258],"category_scores_gemma":[0.00056124973,0.000037169804,0.00007973178,0.00037667408,0.00032549925,0.00013615093,0.000011236886,0.0002429987,5.626706e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002978436,0.00011570378,0.60547,0.00056540477,0.00018189315,0.000030071407,0.0024638078,0.00057809724,0.32035217,0.00013333972,0.000310574,0.066820495],"study_design_scores_gemma":[0.004416373,0.0009928943,0.8394975,0.0014500003,0.00011587164,0.000009915419,0.00059412414,0.0018589677,0.14688863,0.0038571926,0.00026505537,0.00005347195],"about_ca_topic_score_codex":0.000061780906,"about_ca_topic_score_gemma":0.000064641914,"teacher_disagreement_score":0.2340275,"about_ca_system_score_codex":0.00003758967,"about_ca_system_score_gemma":0.00028322198,"threshold_uncertainty_score":0.15157406},"labels":[],"label_agreement":null},{"id":"W4387100171","doi":"10.3390/curroncol30100636","title":"Identification of Early Biochemical Recurrence Predictors in High-Risk Prostate Cancer Patients Treated with Carbon-Ion Radiotherapy and Androgen Deprivation Therapy","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Japan Society for the Promotion of Science","keywords":"Biochemical recurrence; Medicine; Prostate cancer; Androgen deprivation therapy; breakpoint cluster region; Oncology; Internal medicine; Radiation therapy; Multivariate analysis; Cancer; Prostatectomy","score_opus":0.0396234503776412,"score_gpt":0.3646032501323118,"score_spread":0.3249797997546706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387100171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946597,0.003758049,0.0000028158197,0.00017900969,0.00016447583,0.0011267782,0.00006464615,0.000038285485,0.000006194933],"genre_scores_gemma":[0.96701616,0.032332882,0.000009219018,0.000003735047,0.000044175515,0.00029045282,0.0002593881,0.000015710579,0.000028260261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988554,0.000098894365,0.00030969316,0.00030249203,0.00021581606,0.00021768962],"domain_scores_gemma":[0.99936813,0.000066427456,0.00018720188,0.00013442559,0.00016820859,0.0000756319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019453395,0.00012449015,0.00026483828,0.00025345376,0.000031072588,0.0000071297914,0.000052446514,0.00009055446,0.000005842916],"category_scores_gemma":[0.000038909715,0.00008807695,0.00002125692,0.0006228231,0.00016042651,0.00005512878,0.00001749745,0.00016653047,8.811538e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019692995,0.0003929282,0.9112241,0.00006139175,0.00006556823,0.000003594434,0.0010822653,0.0000036094043,0.0074882037,0.0000026292703,0.00007410757,0.077632286],"study_design_scores_gemma":[0.008135734,0.0019528278,0.95610267,0.00014369778,0.000037195885,0.0000010527148,0.000031491832,0.00051830936,0.0326608,0.000033213622,0.00029667254,0.00008631871],"about_ca_topic_score_codex":0.00029669076,"about_ca_topic_score_gemma":0.000026698479,"teacher_disagreement_score":0.07754596,"about_ca_system_score_codex":0.000289731,"about_ca_system_score_gemma":0.0001668665,"threshold_uncertainty_score":0.3591674},"labels":[],"label_agreement":null},{"id":"W4387160528","doi":"10.1016/j.ijrobp.2023.06.1527","title":"Prophylactic Α-Blockers for Radiotherapy-Induced LUTS in Men with Prostate Cancer: A Phase III Randomized Trial Analysis","year":2023,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Oncology; Randomized controlled trial; Internal medicine; Prostate; Urology; Cancer","score_opus":0.0307217318267184,"score_gpt":0.4061242567387481,"score_spread":0.3754025249120297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387160528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823667,0.00063077227,0.0021769116,0.010918498,0.00077798386,0.0028797546,0.00007802961,0.00004236363,0.00012897699],"genre_scores_gemma":[0.9942213,0.0019060599,0.0010202023,0.00022856065,0.0013889434,0.00057504734,0.00024357466,0.000032751042,0.00038356037],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978738,0.00031501398,0.000831756,0.00027569773,0.0003778677,0.00032587358],"domain_scores_gemma":[0.9973577,0.0006896759,0.0009451065,0.00012645335,0.000743346,0.00013771204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013340326,0.00020667892,0.0011497182,0.00075936026,0.000066483226,0.000031657382,0.00021793306,0.00015736377,0.000041785523],"category_scores_gemma":[0.00023702352,0.00013975956,0.0004272835,0.0009170898,0.00018031563,0.00019051532,0.000021116546,0.0003527579,0.0000032504101],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89730096,0.000852908,0.014684537,0.000020963509,0.006911155,0.00011323028,0.0014972019,0.0007450699,0.0037248177,0.00025533282,0.0004790246,0.07341481],"study_design_scores_gemma":[0.9661146,0.004689628,0.00078263687,0.00004469902,0.0011983449,0.000018722858,0.00015954938,0.021613076,0.002116633,0.0010786287,0.002024326,0.00015916878],"about_ca_topic_score_codex":0.00010345575,"about_ca_topic_score_gemma":0.000021908641,"teacher_disagreement_score":0.07325564,"about_ca_system_score_codex":0.0012687483,"about_ca_system_score_gemma":0.0014909958,"threshold_uncertainty_score":0.569923},"labels":[],"label_agreement":null},{"id":"W4387206587","doi":"10.1016/j.ijrobp.2023.06.1562","title":"Association of Prostate Specific Antigen Kinetics after Testosterone Recovery with Subsequent Recurrence: Secondary Analysis of a Phase III Randomized Controlled Trial","year":2023,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"National Institute for Health and Care Research","keywords":"Medicine; Prostate cancer; Urology; Prostate-specific antigen; Androgen deprivation therapy; Biochemical recurrence; Prostate; Testosterone (patch); Randomized controlled trial; Radiation therapy; Clinical endpoint; Adjuvant; Internal medicine; Prostatectomy; Cancer","score_opus":0.021986515246371945,"score_gpt":0.3495782848673044,"score_spread":0.32759176962093245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387206587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99334514,0.00092525256,0.0008833572,0.0015446034,0.001116407,0.0016686434,0.00025164575,0.000016563528,0.00024838283],"genre_scores_gemma":[0.99237233,0.0054670153,0.0004531704,0.00007908788,0.00062116096,0.00012194259,0.00054187956,0.000018606048,0.0003247782],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968583,0.0005462206,0.001524609,0.00021063886,0.00063002994,0.00023021823],"domain_scores_gemma":[0.9936758,0.0014215495,0.0028764228,0.00014568315,0.0017838817,0.000096608266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021096386,0.0001905306,0.001998089,0.0007878193,0.000028875505,0.000018155974,0.00018132145,0.00018497596,0.00015482662],"category_scores_gemma":[0.00055383635,0.00012964742,0.0006846167,0.0007926906,0.00024208613,0.00017225744,0.000036041052,0.00034784302,0.000004937695],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90752274,0.0012748006,0.04138422,0.000016873018,0.01610245,0.000061203325,0.0006888474,0.00035658092,0.0077321604,0.00009755105,0.00042317572,0.024339428],"study_design_scores_gemma":[0.9753387,0.006593422,0.0076465933,0.00010107178,0.0026933656,0.000010436144,0.00007794475,0.0014886147,0.0041008065,0.0007296622,0.0010945555,0.00012485558],"about_ca_topic_score_codex":0.000011851515,"about_ca_topic_score_gemma":0.0000060272914,"teacher_disagreement_score":0.06781597,"about_ca_system_score_codex":0.0007369494,"about_ca_system_score_gemma":0.00082160183,"threshold_uncertainty_score":0.5286868},"labels":[],"label_agreement":null},{"id":"W4387206699","doi":"10.1016/j.ijrobp.2023.06.1189","title":"Longitudinal Profiling of Tumor RNA Expression Signatures Reveal Key Biological Features Associated with Response to Neoadjuvant Stereotactic Body Radiation Therapy in High-Risk Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Immune system; Biopsy; Transcriptome; Prostatectomy; Prostate; Radiation therapy; Tumor microenvironment; Cancer research; Oncology; Cancer; Pathology; Internal medicine; Gene expression; Gene; Immunology; Biology","score_opus":0.029777652400543527,"score_gpt":0.3625320083308198,"score_spread":0.33275435593027625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387206699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99458456,0.0010597886,0.00005845061,0.0025830977,0.000680679,0.00074149127,0.00022334259,0.0000415623,0.000027042342],"genre_scores_gemma":[0.99559474,0.00270752,0.00046633786,0.0002294921,0.0005800897,0.000079979916,0.00021518221,0.000030290135,0.00009634305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973405,0.0007447496,0.0007434723,0.00032473027,0.0004923426,0.00035418087],"domain_scores_gemma":[0.99656343,0.0010745383,0.00117505,0.00013736595,0.000897407,0.00015219381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014043199,0.00023750134,0.00061499095,0.0005181561,0.0000805977,0.00002551088,0.00026494215,0.00022610012,0.00002315343],"category_scores_gemma":[0.0011987935,0.00015651343,0.00013716768,0.0006133985,0.00015360414,0.00020542488,0.000060708702,0.000731784,0.00000524055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023469687,0.00047173694,0.79781735,0.00001008027,0.0005631895,0.00025867904,0.0008432058,0.0012294544,0.14792025,0.00010682878,0.00038921458,0.026920304],"study_design_scores_gemma":[0.012298257,0.006180366,0.9073656,0.00033408977,0.000058037793,0.000034309218,0.000118642,0.00030217392,0.07193191,0.0008207457,0.0003822912,0.00017353287],"about_ca_topic_score_codex":0.0000822943,"about_ca_topic_score_gemma":0.000013921873,"teacher_disagreement_score":0.10954827,"about_ca_system_score_codex":0.0011286599,"about_ca_system_score_gemma":0.00090117985,"threshold_uncertainty_score":0.63824326},"labels":[],"label_agreement":null},{"id":"W4387206840","doi":"10.1016/j.ijrobp.2023.06.1620","title":"Multi-Institutional Analysis of Metastasis Directed Therapy with or without Androgen Deprivation Therapy in Oligometastatic Castration Sensitive Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"School of Medicine, Duke University; European Society for Medical Oncology; Astellas Pharma; Genentech; Janssen Scientific Affairs; Ipsen; Varian Medical Systems; RefleXion Medical; NRG Oncology; International Association for the Study of Lung Cancer; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Bayer HealthCare; ViewRay; U.S. Department of Defense; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Proportional hazards model; Internal medicine; Oncology; Univariate analysis; Cohort; Retrospective cohort study; Cancer; Metastasis; Urology; Multivariate analysis","score_opus":0.060353724335108404,"score_gpt":0.40016299405995687,"score_spread":0.3398092697248485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387206840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995062,0.0004704999,0.002186677,0.0011916274,0.00024811493,0.0005503101,0.00022863946,0.00003530769,0.00002684812],"genre_scores_gemma":[0.98752797,0.008440486,0.0029238022,0.00016982152,0.00019244802,0.00006122992,0.00059934356,0.000019819026,0.00006506877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998198,0.0002576342,0.0006548183,0.0002387944,0.0004331399,0.00021762756],"domain_scores_gemma":[0.9974291,0.0002880992,0.0007665158,0.000110112225,0.0013203981,0.0000858204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005822648,0.00019561719,0.00070833054,0.00095037755,0.000059584345,0.000018901108,0.00013738243,0.00010742308,0.00005165867],"category_scores_gemma":[0.00012054629,0.00012240648,0.00018370032,0.0017231898,0.0002176416,0.00028039783,0.00001948188,0.00025388485,0.0000035174642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006754461,0.00068931427,0.7924905,0.000010636316,0.007883125,0.00013348016,0.0019580834,0.009177652,0.026055971,0.000107075575,0.000031495965,0.15470822],"study_design_scores_gemma":[0.027013775,0.0032847188,0.864914,0.00014325039,0.00091258046,0.00010033863,0.0005007732,0.055921625,0.0457167,0.0002627978,0.0009733961,0.00025607433],"about_ca_topic_score_codex":0.00021101593,"about_ca_topic_score_gemma":0.00022762417,"teacher_disagreement_score":0.15445215,"about_ca_system_score_codex":0.00065200217,"about_ca_system_score_gemma":0.0013143041,"threshold_uncertainty_score":0.4991591},"labels":[],"label_agreement":null},{"id":"W4387206982","doi":"10.1016/j.ijrobp.2023.06.1576","title":"Biochemical Failure in Intermediate Risk Prostate Cancer: Then What? Long-Term Data from a Phase III Trial","year":2023,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Cancer Centre; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Jewish General Hospital; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Hospitalier de l’Université de Montréal; Hôtel-Dieu de Québec; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Prostate cancer; Term (time); Oncology; Prostate; Internal medicine; Cancer","score_opus":0.053206088653152135,"score_gpt":0.4189186170212683,"score_spread":0.3657125283681162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387206982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869133,0.0020165495,0.00023888389,0.0059613404,0.0031190964,0.0006451748,0.0010321628,0.00004601863,0.000027439357],"genre_scores_gemma":[0.96160805,0.029624173,0.00019827121,0.0002843424,0.004310987,0.00006226724,0.003789219,0.000034310855,0.000088348745],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976409,0.00026584422,0.0009236074,0.00040499552,0.00041147164,0.00035316477],"domain_scores_gemma":[0.99756056,0.0005966577,0.0009196442,0.00032087974,0.0004162627,0.00018601866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008293544,0.0002234562,0.0006006116,0.00032488324,0.0000553617,0.00007635817,0.00074943644,0.00025377833,0.00016762971],"category_scores_gemma":[0.0004520681,0.00017388946,0.00016949787,0.0003503077,0.00025022245,0.00068152125,0.00027492727,0.00082930917,0.000059004673],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0638912,0.0017018049,0.4247845,0.00001847812,0.0020033137,0.0006939887,0.0021734445,0.000066750355,0.009085432,0.00007551417,0.008491166,0.48701438],"study_design_scores_gemma":[0.79211706,0.008211661,0.124058366,0.001342654,0.00103692,0.00015089159,0.0013371041,0.013184687,0.013768835,0.010436027,0.033485934,0.00086987606],"about_ca_topic_score_codex":0.00011892066,"about_ca_topic_score_gemma":0.00006619629,"teacher_disagreement_score":0.7282258,"about_ca_system_score_codex":0.00082974194,"about_ca_system_score_gemma":0.001175734,"threshold_uncertainty_score":0.70910066},"labels":[],"label_agreement":null},{"id":"W4387207664","doi":"10.1016/j.ijrobp.2023.06.210","title":"Long-Term Outcomes of NRG/RTOG 0126, a Randomized Trial of High Dose (79.2 Gy) vs. Standard Dose (70.2 Gy) Radiation Therapy (RT) for Men with Localized Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; McGill University Health Centre; Hôtel-Dieu de Québec; Centre Hospitalier de l’Université de Montréal; University of Calgary; Health Sciences Centre","funders":"","keywords":"Medicine; Prostate cancer; Nuclear medicine; Randomized controlled trial; Urology; Cumulative incidence; Radiation therapy; Prostate; Stage (stratigraphy); Log-rank test; Cancer; Survival analysis; Internal medicine; Cohort","score_opus":0.03298171401997095,"score_gpt":0.3911303933848121,"score_spread":0.3581486793648411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387207664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852148,0.0010913585,0.0021367585,0.006456101,0.0013684448,0.0030829217,0.00049192883,0.00004369575,0.00011394814],"genre_scores_gemma":[0.9830401,0.013465853,0.00075161725,0.000245364,0.0011279134,0.00038762487,0.0005152584,0.000053144566,0.00041315326],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99696106,0.00041729189,0.0012981109,0.00029274795,0.0006901812,0.00034060716],"domain_scores_gemma":[0.99465966,0.0012930597,0.00198904,0.0001990122,0.0017113371,0.00014787161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015863061,0.0002917679,0.0016198081,0.00044253803,0.00007238964,0.000023844916,0.00031214327,0.00023015954,0.00008181986],"category_scores_gemma":[0.0004492931,0.00018974741,0.00050466385,0.000375556,0.00045890207,0.0002527311,0.00004337964,0.00032151517,0.0000036560718],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7580936,0.0006959594,0.12974946,0.000057090947,0.004343109,0.000034474153,0.0009010097,0.00042057413,0.0016954498,0.0012283528,0.0009385405,0.10184236],"study_design_scores_gemma":[0.94079757,0.007785685,0.03000797,0.00016304152,0.0005173731,0.000017806005,0.00006566076,0.00092762185,0.013011422,0.004382128,0.0021118245,0.00021191279],"about_ca_topic_score_codex":0.00009540188,"about_ca_topic_score_gemma":0.00001032627,"teacher_disagreement_score":0.18270393,"about_ca_system_score_codex":0.0008272538,"about_ca_system_score_gemma":0.0018170428,"threshold_uncertainty_score":0.77376753},"labels":[],"label_agreement":null},{"id":"W4387207688","doi":"10.1016/j.ijrobp.2023.06.2464","title":"F18-DCFPyL PSMA-PET/CT vs. mpMRI for Localizing the Gross Target Volume for Radiotherapy in Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca; Astellas Pharma; Bristol-Myers Squibb; Foundation Medicine; Amgen","keywords":"Medicine; Prostate cancer; Radiation therapy; Pathological; Prostate; Biopsy; Radiology; Biochemical recurrence; Nuclear medicine; Cancer; Oncology; Internal medicine; Prostatectomy","score_opus":0.034129459755140444,"score_gpt":0.39816564249195696,"score_spread":0.36403618273681654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387207688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88655484,0.005215315,0.016882407,0.080746435,0.0063302326,0.00317065,0.0007990428,0.00010260138,0.00019849905],"genre_scores_gemma":[0.9809048,0.007924404,0.0029195775,0.002093019,0.0038287018,0.00054019305,0.00044096424,0.00007045935,0.0012778902],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983186,0.00012887552,0.00062747183,0.0002464322,0.0002683679,0.0004102428],"domain_scores_gemma":[0.99787694,0.00062906486,0.0005384407,0.00012698432,0.00072715385,0.000101400816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010554563,0.00018840158,0.00047174175,0.00023405293,0.00013726477,0.000038666894,0.00034281056,0.000051684234,0.00003862057],"category_scores_gemma":[0.00019991724,0.00012985342,0.00027552253,0.00031619886,0.00022181969,0.00019917956,0.000036998703,0.00036037253,0.000009882355],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00790366,0.00064571854,0.7147058,0.00010497472,0.002074972,0.00037957012,0.00186519,0.0073321713,0.005116496,0.0057043764,0.03991872,0.21424834],"study_design_scores_gemma":[0.033358607,0.003941412,0.029824892,0.0002414097,0.00018135611,0.00047570642,0.0004731273,0.089125566,0.0057352297,0.021096313,0.81516355,0.00038281758],"about_ca_topic_score_codex":0.000062106636,"about_ca_topic_score_gemma":0.000020883612,"teacher_disagreement_score":0.77524483,"about_ca_system_score_codex":0.0012543302,"about_ca_system_score_gemma":0.00095451827,"threshold_uncertainty_score":0.5295269},"labels":[],"label_agreement":null},{"id":"W4387207885","doi":"10.1016/j.ijrobp.2023.06.209","title":"Long-Term Follow-Up Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Non-Inferiority Study Comparing Two Fractionation Schedules in Patients with Favorable-Risk Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; London Health Sciences Centre; Juravinski Cancer Centre; Western University","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Prostate cancer; Oncology; Cumulative incidence; Dose fractionation; Urology; Cancer; Radiation therapy; Confidence interval; Cohort","score_opus":0.029095348111079496,"score_gpt":0.40560320845007025,"score_spread":0.37650786033899075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387207885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99458355,0.00018753848,0.0020168072,0.0005174285,0.001044425,0.0014142956,0.00012720817,0.00002855411,0.00008017993],"genre_scores_gemma":[0.997107,0.0012945588,0.00028066317,0.00006165158,0.00035144298,0.00014291746,0.00068728166,0.000024889196,0.000049560327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967665,0.0006412912,0.0013134017,0.00033742792,0.0006294378,0.00031196317],"domain_scores_gemma":[0.99485874,0.0008829505,0.002074972,0.00017328809,0.0018724597,0.0001375612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001786844,0.00025063887,0.0015908157,0.0012086162,0.00010213021,0.000026833639,0.00025912726,0.00016100502,0.00006199124],"category_scores_gemma":[0.00041259849,0.00018834203,0.00034371272,0.0012746394,0.00026667616,0.0003738479,0.00007777512,0.0006410023,0.0000064977285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08992157,0.0028829777,0.84941447,0.000013459757,0.008173233,0.000053546206,0.0016618152,0.0052606096,0.00020494146,0.000092148424,0.00002352827,0.04229769],"study_design_scores_gemma":[0.34449837,0.0022227247,0.6386936,0.00007412201,0.0018816614,0.0000029129035,0.00023348814,0.011711885,0.0002492136,0.00024543432,0.000056952198,0.00012966173],"about_ca_topic_score_codex":0.0005336381,"about_ca_topic_score_gemma":0.00049830065,"teacher_disagreement_score":0.2545768,"about_ca_system_score_codex":0.0017153178,"about_ca_system_score_gemma":0.0012088037,"threshold_uncertainty_score":0.76803654},"labels":[],"label_agreement":null},{"id":"W4387207940","doi":"10.1016/j.ijrobp.2023.06.428","title":"Patient Reported Outcomes in High-Risk Prostate Cancer Patients with or without Testosterone Recovery after Androgen Deprivation Therapy","year":2023,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Jewish General Hospital; Centre de Santé et de Services Sociaux de Chicoutimi; Centre Hospitalier de l’Université de Montréal; Université Laval; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Randomization; Testosterone (patch); Quality of life (healthcare); Randomized controlled trial; Internal medicine; Androgen; Urology; Cancer; Oncology; Hormone","score_opus":0.023398249988943562,"score_gpt":0.3391938299052176,"score_spread":0.31579557991627405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387207940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961325,0.00025791553,0.00008390164,0.0017694175,0.0008633053,0.00070634775,0.00012621365,0.00003663692,0.000023775156],"genre_scores_gemma":[0.994398,0.0037692946,0.00048978726,0.0004482155,0.00030167113,0.00013839845,0.00026931133,0.000034721652,0.00015060476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981325,0.00016145213,0.0007577718,0.0002549612,0.00043180442,0.00026146302],"domain_scores_gemma":[0.99760526,0.0002602596,0.0010414051,0.00014297113,0.0008488417,0.000101284655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003384755,0.00019677922,0.00048195582,0.0003303157,0.00004851417,0.00002438607,0.00012859408,0.00014196637,0.000055316035],"category_scores_gemma":[0.0002497936,0.000121327386,0.00009589208,0.00037216037,0.00010465032,0.00030462447,0.000044357053,0.00035694093,0.000012210567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008928019,0.00055140664,0.8181595,0.0000054636726,0.0007441191,0.00011524303,0.0005598612,0.00023642369,0.00018428722,0.000007729196,0.00013370659,0.17037421],"study_design_scores_gemma":[0.017960176,0.0049204216,0.97225934,0.000109366185,0.00008011925,0.000022844473,0.000056872796,0.00020247094,0.0012859004,0.0007201706,0.0022356075,0.00014669595],"about_ca_topic_score_codex":0.00012587207,"about_ca_topic_score_gemma":0.000055362856,"teacher_disagreement_score":0.17022751,"about_ca_system_score_codex":0.00089072034,"about_ca_system_score_gemma":0.0006935805,"threshold_uncertainty_score":0.49475873},"labels":[],"label_agreement":null},{"id":"W4387207951","doi":"10.1016/j.ijrobp.2023.06.403","title":"Impact of Testosterone Recovery on Clinical Outcomes of Patients Treated with Salvage Radiotherapy and Androgen Suppression: A Secondary Analysis of the NRG/RTOG 0534 Sport Phase 3 Trial","year":2023,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre; McGill University Health Centre; Juravinski Cancer Centre; Université Laval","funders":"Genentech; Astellas Pharma; Foundation Medicine; MacroGenics; Puma Biotechnology; Sanofi; Exelixis; Plexxikon; RefleXion Medical; Varian Medical Systems; Boston Scientific Corporation; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Androgen deprivation therapy; Hazard ratio; Radiation therapy; Androgen suppression; Prostate cancer; Cumulative incidence; Proportional hazards model; Urology; Clinical endpoint; Testosterone (patch); Internal medicine; Oncology; Confidence interval; Clinical trial; Cohort; Cancer","score_opus":0.041643517396011936,"score_gpt":0.42745357608030515,"score_spread":0.3858100586842932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387207951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99814254,0.00012372798,0.000028981542,0.00043418477,0.00036861654,0.0003850815,0.00045510757,0.0000069066136,0.000054855693],"genre_scores_gemma":[0.998384,0.00088472886,0.000085980326,0.000088587636,0.00021036886,0.0000059993804,0.00028129108,0.000014045648,0.00004498234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982412,0.00020179004,0.0008999785,0.00016639114,0.00035588123,0.0001347492],"domain_scores_gemma":[0.9973009,0.00060258503,0.0013912315,0.00017326188,0.00044508386,0.00008689905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005303932,0.00014588298,0.0009063759,0.00036784954,0.000028657225,0.0000052021833,0.00018597071,0.00014850365,0.000059772003],"category_scores_gemma":[0.00016961947,0.00007815099,0.0005205554,0.0004813376,0.00029530685,0.00010373734,0.00003531278,0.0002704542,4.8549265e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045477703,0.001656135,0.9026846,0.0000070964015,0.008748926,0.00001575962,0.00016019195,0.00014489992,0.0009766102,0.000018904982,0.00028906047,0.039820075],"study_design_scores_gemma":[0.076424405,0.016617076,0.9039604,0.000048303125,0.0007991583,0.000006695828,0.000018196895,0.00026629787,0.0015555349,0.000067921515,0.00017537782,0.000060607683],"about_ca_topic_score_codex":0.000025916508,"about_ca_topic_score_gemma":0.0000031476989,"teacher_disagreement_score":0.03975947,"about_ca_system_score_codex":0.0002642886,"about_ca_system_score_gemma":0.00058309926,"threshold_uncertainty_score":0.31869048},"labels":[],"label_agreement":null},{"id":"W4387208082","doi":"10.1016/j.ijrobp.2023.06.300","title":"Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Oncology; Internal medicine; Prostate cancer; Docetaxel; Radiation therapy; Biopsy; Prostatectomy; Proportional hazards model; Cancer","score_opus":0.03658173849104125,"score_gpt":0.3993739773706397,"score_spread":0.36279223887959844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387208082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921027,0.00085874373,0.0013954904,0.0035574061,0.0005636792,0.0012449113,0.00023870985,0.000009070074,0.000029332055],"genre_scores_gemma":[0.9890436,0.008816662,0.0009266811,0.00013218861,0.0006690895,0.00013316875,0.00021179488,0.000019686551,0.00004716315],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99825865,0.000344985,0.00074034726,0.00018547277,0.00028095845,0.00018957132],"domain_scores_gemma":[0.9973193,0.0007624587,0.0012012514,0.00011377978,0.0005415528,0.000061701634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011919247,0.00014293521,0.0005724251,0.00025243513,0.000052841246,0.000011498189,0.00018500583,0.0001676875,0.000023263861],"category_scores_gemma":[0.00013309033,0.00008675045,0.00012340397,0.00023009075,0.00028067382,0.00013765528,0.000025088648,0.00028220544,6.903458e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31144527,0.002710827,0.17666404,0.000088331406,0.0026590691,0.00007103941,0.00652565,0.0018621061,0.09063577,0.0011449713,0.001927911,0.40426502],"study_design_scores_gemma":[0.8302219,0.032074567,0.022334127,0.0003155398,0.0008468371,0.00013556928,0.0010692438,0.009707796,0.06637855,0.008387552,0.028213028,0.0003152927],"about_ca_topic_score_codex":0.00008784641,"about_ca_topic_score_gemma":0.000011781524,"teacher_disagreement_score":0.51877666,"about_ca_system_score_codex":0.00046828706,"about_ca_system_score_gemma":0.00095156685,"threshold_uncertainty_score":0.35375807},"labels":[],"label_agreement":null},{"id":"W4387263732","doi":"10.1158/1078-0432.24229199","title":"Supplementary Material 1 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Amgen Canada; Sanofi; Amgen","keywords":"Abiraterone acetate; Cabazitaxel; Prostate cancer; Medicine; Abiraterone; Prostate; Oncology; Cancer; Urology; Internal medicine; Androgen deprivation therapy","score_opus":0.02782642088623507,"score_gpt":0.3241552700205218,"score_spread":0.29632884913428675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387263732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.901293,0.0001580792,0.0000070516753,0.0019621756,0.0031863612,0.010454309,0.082697004,0.00020809751,0.00003393974],"genre_scores_gemma":[0.8950761,0.0029872782,0.0009781003,0.00018665491,0.0013547965,0.0035513241,0.08946506,0.0003038886,0.006096772],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99399,0.0002529978,0.0013522097,0.0017547754,0.0012990644,0.0013509535],"domain_scores_gemma":[0.9974757,0.00008670894,0.00059341086,0.0010926193,0.000269838,0.00048173883],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044039116,0.0010191655,0.0017935407,0.0005491587,0.00022888154,0.00017510317,0.0004494116,0.00043276453,0.003810498],"category_scores_gemma":[0.00003754072,0.00070040405,0.00021499075,0.00030453765,0.00022855833,0.00017304481,0.0014347761,0.0013653795,0.000050680854],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8301204,0.0048276093,0.121179976,0.00078434934,0.003348304,0.0012639888,0.0038629198,0.00066099426,0.0006505083,0.0000037481343,0.017260067,0.016037168],"study_design_scores_gemma":[0.9101845,0.020354202,0.040282637,0.002079251,0.0018280776,0.0000021333117,0.00050257746,0.0004577332,0.01906577,0.0006457883,0.0029062203,0.0016911358],"about_ca_topic_score_codex":0.13769212,"about_ca_topic_score_gemma":0.011493626,"teacher_disagreement_score":0.1261985,"about_ca_system_score_codex":0.001910891,"about_ca_system_score_gemma":0.0018165093,"threshold_uncertainty_score":0.9995447},"labels":[],"label_agreement":null},{"id":"W4387263860","doi":"10.1158/1078-0432.24229199.v1","title":"Supplementary Material 1 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Amgen Canada; Sanofi; Amgen","keywords":"Abiraterone acetate; Cabazitaxel; Abiraterone; Prostate cancer; Medicine; Oncology; Prostate; Internal medicine; Cancer; Urology; Androgen deprivation therapy","score_opus":0.02782642088623507,"score_gpt":0.3241552700205218,"score_spread":0.29632884913428675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387263860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.901293,0.0001580792,0.0000070516753,0.0019621756,0.0031863612,0.010454309,0.082697004,0.00020809751,0.00003393974],"genre_scores_gemma":[0.8950761,0.0029872782,0.0009781003,0.00018665491,0.0013547965,0.0035513241,0.08946506,0.0003038886,0.006096772],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99399,0.0002529978,0.0013522097,0.0017547754,0.0012990644,0.0013509535],"domain_scores_gemma":[0.9974757,0.00008670894,0.00059341086,0.0010926193,0.000269838,0.00048173883],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044039116,0.0010191655,0.0017935407,0.0005491587,0.00022888154,0.00017510317,0.0004494116,0.00043276453,0.003810498],"category_scores_gemma":[0.00003754072,0.00070040405,0.00021499075,0.00030453765,0.00022855833,0.00017304481,0.0014347761,0.0013653795,0.000050680854],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8301204,0.0048276093,0.121179976,0.00078434934,0.003348304,0.0012639888,0.0038629198,0.00066099426,0.0006505083,0.0000037481343,0.017260067,0.016037168],"study_design_scores_gemma":[0.9101845,0.020354202,0.040282637,0.002079251,0.0018280776,0.0000021333117,0.00050257746,0.0004577332,0.01906577,0.0006457883,0.0029062203,0.0016911358],"about_ca_topic_score_codex":0.13769212,"about_ca_topic_score_gemma":0.011493626,"teacher_disagreement_score":0.1261985,"about_ca_system_score_codex":0.001910891,"about_ca_system_score_gemma":0.0018165093,"threshold_uncertainty_score":0.9995447},"labels":[],"label_agreement":null},{"id":"W4387327072","doi":"10.1007/s00345-023-04635-1","title":"Association of PSA kinetics after testosterone recovery with subsequent recurrence: secondary analysis of a phase III randomized controlled trial","year":2023,"lang":"en","type":"article","venue":"World Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Urology; Testosterone (patch); Biochemical recurrence; Incidence (geometry); Androgen; Prostate-specific antigen; Randomized controlled trial; Androgen deprivation therapy; Surgery; Internal medicine; Cancer; Prostatectomy; Hormone","score_opus":0.016393315680617058,"score_gpt":0.31677436773114653,"score_spread":0.30038105205052945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387327072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99194777,0.0026653362,0.000086180655,0.0033081104,0.0003211335,0.0012010658,0.000030370997,0.0000060010666,0.00043403427],"genre_scores_gemma":[0.9952961,0.0017280254,0.000093999166,0.000099859964,0.00013045495,0.00006683864,0.000035075016,0.000010020026,0.0025395944],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99747616,0.0005044719,0.0011602793,0.00012235066,0.0005128912,0.00022383369],"domain_scores_gemma":[0.99628174,0.0014250057,0.0014654284,0.00014109234,0.0005912903,0.000095461255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023635144,0.00012448481,0.0024178785,0.0015267761,0.000016724542,0.0000061879873,0.000075713055,0.00008072302,0.00048474345],"category_scores_gemma":[0.00058946223,0.00007396022,0.00060756184,0.0012289247,0.00014491192,0.000053344327,0.000019977428,0.00031743248,0.0000015696514],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97822744,0.00062061904,0.0032236332,0.000028733224,0.012322081,0.00016914873,0.0002298225,0.000087576336,0.0019956087,0.000004202515,0.00061367353,0.0024774866],"study_design_scores_gemma":[0.9782399,0.0066919457,0.0021321096,0.000051121027,0.011602777,0.000014513885,0.000026424746,0.00029930935,0.00040431626,0.000075745294,0.00040437272,0.000057477933],"about_ca_topic_score_codex":0.000008563789,"about_ca_topic_score_gemma":0.00007192312,"teacher_disagreement_score":0.006071327,"about_ca_system_score_codex":0.0001235518,"about_ca_system_score_gemma":0.00033994435,"threshold_uncertainty_score":0.5307601},"labels":[],"label_agreement":null},{"id":"W4387340449","doi":"10.5489/cuaj.8578","title":"NS-AUA 2023 Annual Meeting Abstracts – Oncology – Prostate","year":2023,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Prostate; Medical physics; Cancer","score_opus":0.026587448307058437,"score_gpt":0.3107900922945003,"score_spread":0.2842026439874418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387340449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8598177,0.0003122423,8.9280155e-7,0.10702529,0.00059180433,0.0003282403,0.00013854317,0.00008742854,0.031697884],"genre_scores_gemma":[0.97855854,0.0005586353,0.00007041502,0.0025067462,0.0007937281,0.000023208271,0.00011956003,0.000018220542,0.017350957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978872,0.00016607357,0.00036102938,0.00021111913,0.0004627228,0.0009118877],"domain_scores_gemma":[0.9979681,0.00024731684,0.00021031186,0.000083694846,0.00040486635,0.001085726],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015521193,0.00012988651,0.00027623697,0.00035322408,0.00039917257,0.00007321438,0.000106500534,0.00029721842,0.0004761106],"category_scores_gemma":[0.0012446609,0.000098401826,0.00012023288,0.0005603798,0.00004625762,0.00010727806,0.00002524205,0.00083554897,0.0009180958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002938194,0.00009828024,0.6006645,0.00001701566,0.0003403269,0.0045406176,0.00084309175,0.0002636807,0.00072315556,0.00004708198,0.37007272,0.022095686],"study_design_scores_gemma":[0.0015049899,0.00061805465,0.62818277,0.000018062769,0.000042020456,0.0001951186,0.00041519845,0.00008894658,0.00005745157,0.00051045447,0.36826032,0.0001065917],"about_ca_topic_score_codex":0.0012990545,"about_ca_topic_score_gemma":0.0012315547,"teacher_disagreement_score":0.11874086,"about_ca_system_score_codex":0.0022276402,"about_ca_system_score_gemma":0.0016302709,"threshold_uncertainty_score":0.9998598},"labels":[],"label_agreement":null},{"id":"W4387341485","doi":"10.5489/cuaj.8588","title":"2023 Canadian Urological Association guideline: Genetic testing in prostate cancer","year":2023,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McMaster University; Queen Elizabeth II Health Sciences Centre; Université de Montréal; University of Alberta; McGill University; University of British Columbia; University of Toronto; Dalhousie University","funders":"EMD Serono; Bavarian Nordic; Ipsen; Astellas Pharma; Eisai; UroGen Pharma; Seagen; Advanced Accelerator Applications; F. Hoffmann-La Roche; Incyte; Boston Scientific Corporation; Daiichi Sankyo Europe; Sanofi; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Guideline; Prostate cancer; Medicine; Association (psychology); Oncology; Internal medicine; Cancer; Pathology; Psychology","score_opus":0.038158985145895406,"score_gpt":0.31031757468158655,"score_spread":0.27215858953569116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387341485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85176516,0.00076668913,0.0000014544563,0.14295453,0.0005622952,0.0005667755,0.0001901225,0.00007472613,0.0031182272],"genre_scores_gemma":[0.9836412,0.0008703622,0.0002069801,0.006375665,0.0008450668,0.000101252546,0.00012890255,0.000030810417,0.007799728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99624455,0.00029671637,0.0006828689,0.00037945455,0.0007246464,0.0016717502],"domain_scores_gemma":[0.99679345,0.000354526,0.00029826997,0.00012673014,0.000747541,0.0016794723],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020501774,0.00022429421,0.00040577393,0.0008588213,0.00045018876,0.00015769429,0.00018247524,0.0004478451,0.0011141206],"category_scores_gemma":[0.0042644036,0.00018305109,0.000127169,0.0017460843,0.000033283206,0.0001111545,0.000028501123,0.0012230976,0.00040531458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040401257,0.000020551732,0.9180979,0.0000052174755,0.00008462166,0.0009978337,0.00008952115,0.00073884096,0.00007666857,0.0000066795087,0.07424801,0.0055937474],"study_design_scores_gemma":[0.0014849185,0.0002456284,0.9006003,0.000025943238,0.000049913047,0.000065574226,0.000074313226,0.002363459,0.0000068096356,0.0004686195,0.09443662,0.00017787662],"about_ca_topic_score_codex":0.1923726,"about_ca_topic_score_gemma":0.21387929,"teacher_disagreement_score":0.13657886,"about_ca_system_score_codex":0.010652131,"about_ca_system_score_gemma":0.0044203927,"threshold_uncertainty_score":0.999799},"labels":[],"label_agreement":null},{"id":"W4387373458","doi":"10.3390/cancers15194854","title":"Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Myovant Sciences; Astellas Pharma; Sanofi; American Association for Cancer Research; AstraZeneca; Pfizer; Amgen; Bristol-Myers Squibb","keywords":"Medicine; Prostate cancer; Population; Prostate; Urology; Castration; Internal medicine; Oncology; Clinical endpoint; Cancer; Orchiectomy; Randomized controlled trial; Hormone","score_opus":0.028765587184346516,"score_gpt":0.35557669904175887,"score_spread":0.32681111185741235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387373458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883111,0.0009881419,0.0000012269484,0.0046485066,0.00022397988,0.0034518715,0.00013645097,0.0001140101,0.0021247226],"genre_scores_gemma":[0.99062145,0.001044447,0.000025615596,0.00022302596,0.0002498098,0.001950747,0.0001190274,0.000055404587,0.005710476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978664,0.00015876646,0.00023993211,0.0005437861,0.0006715653,0.00051953533],"domain_scores_gemma":[0.99873227,0.00029198272,0.00009028033,0.0006423459,0.0000992403,0.00014387423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003191059,0.00025437062,0.0003850442,0.00011852855,0.00015954385,0.000039361992,0.00020448527,0.000054852804,0.00003522857],"category_scores_gemma":[0.00009043547,0.00015285346,0.00004671731,0.0008916251,0.00011147434,0.00012237599,0.000045850415,0.00035657105,0.00002105811],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20657714,0.0010955683,0.54408264,0.00084916764,0.0020409934,0.006557184,0.038990587,0.011439104,0.018320587,0.00009350935,0.08673299,0.08322055],"study_design_scores_gemma":[0.18783367,0.013727183,0.7006997,0.003812079,0.0005698018,0.000004400417,0.019799149,0.0010330939,0.055360015,0.00055305427,0.0155004375,0.001107441],"about_ca_topic_score_codex":0.00404993,"about_ca_topic_score_gemma":0.019960482,"teacher_disagreement_score":0.15661706,"about_ca_system_score_codex":0.0020772088,"about_ca_system_score_gemma":0.0011447181,"threshold_uncertainty_score":0.99792266},"labels":[],"label_agreement":null},{"id":"W4387380166","doi":"10.1210/jendso/bvad114.1761","title":"SAT023 The Role Of Cysteine Residues In The Binding Of Inhibitors Of The N-Terminal Domain Of The Androgen Receptor","year":2023,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cysteine; Iodoacetamide; Androgen receptor; Chemistry; Binding site; Docking (animal); Biochemistry; Prostate cancer; Biology; Cancer; Medicine; Genetics; Enzyme","score_opus":0.016782910314312307,"score_gpt":0.30320146216209604,"score_spread":0.28641855184778375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387380166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854796,0.0015105433,3.5368507e-7,0.011985387,0.00024388822,0.0004707578,0.000040746596,0.0000028355903,0.0002658758],"genre_scores_gemma":[0.9979861,0.000873636,0.000051529256,0.00006072502,0.00022373056,0.0000066734633,0.0000013672964,0.000014993991,0.00078129105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99759614,0.00039345294,0.00068296876,0.00009361959,0.0009838411,0.00024998325],"domain_scores_gemma":[0.9979341,0.00039845955,0.00093963306,0.00049017917,0.00020442576,0.000033176104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016339101,0.00012995694,0.00039434817,0.00005700093,0.0001412978,0.0000071872173,0.0007611921,0.00004407672,0.000020577487],"category_scores_gemma":[0.00025035036,0.000041962016,0.00078459416,0.0009820511,0.0005347471,0.0000532236,0.00030000723,0.0005367562,6.855858e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089186965,0.00044583276,0.37831295,0.0005454707,0.00103602,0.000028534812,0.026038136,0.00010332362,0.56538445,0.00023536276,0.024380973,0.002597071],"study_design_scores_gemma":[0.004116416,0.0006813314,0.085532054,0.0016494093,0.00032675813,0.00030095363,0.03603423,0.000042656364,0.8645464,0.0012946367,0.0053853733,0.0000897839],"about_ca_topic_score_codex":0.0001088599,"about_ca_topic_score_gemma":0.000025434038,"teacher_disagreement_score":0.2991619,"about_ca_system_score_codex":0.000098576806,"about_ca_system_score_gemma":0.00028286903,"threshold_uncertainty_score":0.23319684},"labels":[],"label_agreement":null},{"id":"W4387380294","doi":"10.1210/jendso/bvad114.1760","title":"SAT022 A Mechanism Of Resistance To Novel Inhibitors Of The N-Terminal Domain Of Androgen Receptor","year":2023,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Androgen receptor; Prostate cancer; Cancer research; Enzalutamide; Point mutation; Mutant; Mutagenesis; Mutation; Chemistry; Medicine; Biology; Pharmacology; Cancer; Genetics; Gene","score_opus":0.022362985061710656,"score_gpt":0.3093445944139809,"score_spread":0.28698160935227024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387380294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902318,0.00035221025,0.000027987702,0.0085122865,0.00034524337,0.00031726432,0.000060777398,0.0000042779193,0.00014813355],"genre_scores_gemma":[0.99344796,0.00035790497,0.0016954418,0.0001118173,0.00018312303,0.000005145727,0.0000012436524,0.000016664602,0.004180705],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984737,0.000056548404,0.0004827634,0.00008922547,0.000697923,0.00019983875],"domain_scores_gemma":[0.9988168,0.00008828808,0.00045680598,0.00027409339,0.00028521442,0.00007883345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053989317,0.000097100456,0.0003611475,0.000052831627,0.000063945976,0.0000033544288,0.00029095425,0.000031432166,0.000034914734],"category_scores_gemma":[0.00011958848,0.0000481323,0.0006135514,0.0006349088,0.00014465128,0.0000381721,0.00018953135,0.00024894366,0.0000013117751],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011816298,0.0004195805,0.008879095,0.0005954034,0.000712555,0.00003081562,0.00498464,0.000019396139,0.9117939,0.0004993044,0.070365496,0.0005182124],"study_design_scores_gemma":[0.0046536326,0.0005300653,0.0064814473,0.0010441046,0.00016886723,0.00014455242,0.0033398115,0.000011696834,0.973078,0.00094330736,0.009528508,0.00007600201],"about_ca_topic_score_codex":0.000012122343,"about_ca_topic_score_gemma":0.0000044308053,"teacher_disagreement_score":0.06128413,"about_ca_system_score_codex":0.00011999838,"about_ca_system_score_gemma":0.00031515022,"threshold_uncertainty_score":0.19627783},"labels":[],"label_agreement":null},{"id":"W4387392976","doi":"10.1530/erc-23-0010","title":"Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells","year":2023,"lang":"en","type":"article","venue":"Endocrine Related Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); Vancouver General Hospital; University of British Columbia","funders":"Terry Fox Research Institute; Terry Fox Foundation; Michael Smith Health Research BC; Prostate Cancer Canada; Cancer Research Society; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Prostate cancer; Semaphorin; Androgen; LNCaP; Androgen receptor; Androgen deprivation therapy; Endocrinology; Internal medicine; Cancer research; Biology; Enzalutamide; Downregulation and upregulation; Cancer; Medicine; Hormone; Receptor; Biochemistry; Gene","score_opus":0.02375680841031348,"score_gpt":0.34380338944090805,"score_spread":0.3200465810305946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387392976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98065025,0.009876923,7.2561437e-7,0.006254877,0.00040635915,0.001194723,0.00010011258,0.00028046797,0.001235557],"genre_scores_gemma":[0.9097947,0.033356734,0.00006569585,0.00015077686,0.00018493118,0.0014522705,0.00008042993,0.00010028537,0.05481421],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976133,0.000074021176,0.00038086055,0.00051094854,0.0003974955,0.0010233539],"domain_scores_gemma":[0.99918425,0.000061473125,0.000073619034,0.0003139702,0.00011106853,0.00025560625],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020748856,0.00027646747,0.00041582074,0.000445382,0.000082459665,0.0000269598,0.00012971275,0.00008530224,0.00095047976],"category_scores_gemma":[0.000027926479,0.00022292182,0.00011306127,0.0016630731,0.00008921412,0.000106603125,0.000097566604,0.00045482384,0.00022080062],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015936864,0.00045199474,0.49364495,0.0010410567,0.000883048,0.008939618,0.0034420223,0.0017091298,0.41474217,0.000046575446,0.012053217,0.061452538],"study_design_scores_gemma":[0.013764536,0.00052380847,0.0866568,0.0014793877,0.00027237055,0.00021559825,0.00045547585,0.0017011159,0.8547172,0.00028173352,0.039260197,0.00067178666],"about_ca_topic_score_codex":0.0023806738,"about_ca_topic_score_gemma":0.000549225,"teacher_disagreement_score":0.43997502,"about_ca_system_score_codex":0.00087731035,"about_ca_system_score_gemma":0.0006828139,"threshold_uncertainty_score":0.9999628},"labels":[],"label_agreement":null},{"id":"W4387441861","doi":"","title":"Serum Adipokines as Predictors for the Outcome of Prostate Biopsies at Early Stage Prostate Cancer Diagnosis","year":2019,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Adipokine; Stage (stratigraphy); Prostate cancer; Prostate; Medicine; Oncology; Internal medicine; Cancer; Obesity; Biology; Leptin","score_opus":0.22034101741926537,"score_gpt":0.559942406884325,"score_spread":0.3396013894650596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387441861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95326763,0.037170354,0.0000025342204,0.0017941704,0.0007256585,0.0049045873,0.0014286126,0.00003741848,0.0006690336],"genre_scores_gemma":[0.91388816,0.054026056,0.000029834926,0.00021860041,0.00014099022,0.0015728535,0.000042543656,0.00009572071,0.029985216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966149,0.00012986662,0.0010191038,0.0004843645,0.001065166,0.000686621],"domain_scores_gemma":[0.9965593,0.0007568684,0.0008834962,0.0006925388,0.0007838908,0.00032389196],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010704515,0.000422506,0.0011126389,0.0005642855,0.00029043667,0.00039377142,0.0013378456,0.0001248187,0.010416156],"category_scores_gemma":[0.00028584484,0.00025292084,0.00036902353,0.00085404696,0.00035091196,0.0011557417,0.000817365,0.00036934644,0.000028133527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031783965,0.0002649156,0.96189594,0.000959856,0.0011300696,0.000024962643,0.0009606588,0.00007924808,0.015232701,0.000015721866,0.010795413,0.0054621245],"study_design_scores_gemma":[0.0030814293,0.00017846093,0.8588659,0.00078891206,0.0003602186,0.0000059100344,0.00024284016,0.00003509004,0.109767966,0.00016139682,0.026249573,0.00026227313],"about_ca_topic_score_codex":0.0037869385,"about_ca_topic_score_gemma":0.00019065366,"teacher_disagreement_score":0.10303,"about_ca_system_score_codex":0.00029866083,"about_ca_system_score_gemma":0.00039374133,"threshold_uncertainty_score":0.9999923},"labels":[],"label_agreement":null},{"id":"W4387449548","doi":"10.1093/oncolo/oyad254","title":"Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Institute on Minority Health and Health Disparities; Astellas Pharma; Foundation Medicine; Bayer HealthCare; Pfizer; American Association for Cancer Research; Invitae; Eli Lilly and Company; Lantheus Medical Imaging","keywords":"Docetaxel; Medicine; Placebo; Internal medicine; Clinical endpoint; Androgen deprivation therapy; Prostate cancer; Population; Adverse effect; Enzalutamide; Oncology; Randomized controlled trial; Chemotherapy; Cancer; Androgen receptor","score_opus":0.04382962024491794,"score_gpt":0.32801834829904825,"score_spread":0.2841887280541303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387449548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929966,0.00028667026,0.000003280504,0.0036823903,0.000027403772,0.0028015063,0.0000125949055,0.000011637355,0.00017793073],"genre_scores_gemma":[0.9964083,0.003269671,0.00001536354,0.00006600227,0.000022009875,0.00007170614,0.00008955558,0.000006241177,0.000051151863],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99906313,0.0003018877,0.00021666894,0.00013149038,0.00017181378,0.000115010625],"domain_scores_gemma":[0.9983727,0.0013493496,0.00008876482,0.00013099528,0.000037338894,0.000020865109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000929051,0.00007597755,0.00030822758,0.000058626836,0.000048387315,0.000010478931,0.00005024754,0.000043912176,0.0000058438395],"category_scores_gemma":[0.00026912542,0.000032411728,0.000020096037,0.00026804756,0.00051303644,0.000030601805,0.0000308287,0.00012104853,0.0000013994546],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8384291,0.00043231016,0.14637914,0.000009656338,0.00008656542,0.000009570141,0.0024281226,0.000023116347,0.00020365536,0.00010492266,0.000065784516,0.011828053],"study_design_scores_gemma":[0.5242274,0.0006734331,0.47383216,0.00004144568,0.000021842183,2.9786744e-7,0.00019057174,0.0003667933,0.00017696703,0.00039938453,0.000042896274,0.000026797685],"about_ca_topic_score_codex":0.00051573577,"about_ca_topic_score_gemma":0.00020047059,"teacher_disagreement_score":0.32745302,"about_ca_system_score_codex":0.00006237096,"about_ca_system_score_gemma":0.000061848135,"threshold_uncertainty_score":0.18903042},"labels":[],"label_agreement":null},{"id":"W4387458056","doi":"10.1016/j.celrep.2023.113221","title":"MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer","year":2023,"lang":"en","type":"article","venue":"Cell Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"DOD Prostate Cancer Research Program; Clinical and Translational Science Institute, University of California, Los Angeles; National Cancer Institute; Common Fund; University of California, Los Angeles; National Institutes of Health; National Center for Advancing Translational Sciences; American Cancer Society; Doris Duke Charitable Foundation; Stop Cancer; National Institute of General Medical Sciences; Jonsson Comprehensive Cancer Center; Israel National Road Safety Authority; National Institute of Diabetes and Digestive and Kidney Diseases; U.S. Department of Defense","keywords":"Regulator; Prostate cancer; Androgen receptor; Master regulator; Prostate; Androgen; Cancer research; Cancer; Receptor; Internal medicine; Endocrinology; Biology; Medicine; Transcription factor; Gene; Genetics; Hormone","score_opus":0.04311233261856113,"score_gpt":0.3372869732590737,"score_spread":0.2941746406405126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387458056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939075,0.0019992224,1.422494e-7,0.00075010763,0.00023007763,0.00094964367,0.000023642384,0.000055067183,0.002084577],"genre_scores_gemma":[0.9814837,0.0020162226,0.000037586877,0.00008084179,0.0000670238,0.00024916723,0.00012337884,0.000032141303,0.015909951],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998267,0.000029039476,0.00050182646,0.00037368108,0.00046620457,0.0003622251],"domain_scores_gemma":[0.99910873,0.00001473052,0.00020000074,0.00036971807,0.0001589895,0.00014785213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036395332,0.0001420124,0.00035965172,0.00029132952,0.00004020171,0.000009626035,0.00003163972,0.00006924528,0.0003616662],"category_scores_gemma":[0.000041293926,0.0001142699,0.00009011919,0.0008634557,0.000052153882,0.00008934035,0.000057320634,0.00012023034,0.000037826823],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035037578,0.00030504706,0.30820474,0.0004902358,0.00013920861,0.0024266213,0.0021666205,0.0000038629946,0.6626997,0.0000060398147,0.016740475,0.006467082],"study_design_scores_gemma":[0.0017021752,0.00013213084,0.030236285,0.00030429495,0.000054933906,0.000029805236,0.00016797229,0.000015708296,0.9525861,0.00013957657,0.0145112695,0.000119747165],"about_ca_topic_score_codex":0.0003135802,"about_ca_topic_score_gemma":0.00001415873,"teacher_disagreement_score":0.28988642,"about_ca_system_score_codex":0.00012806217,"about_ca_system_score_gemma":0.0005234652,"threshold_uncertainty_score":0.46597913},"labels":[],"label_agreement":null},{"id":"W4387589984","doi":"10.1016/j.ijrobp.2023.08.027","title":"5-Year Outcomes from PACE B: An International Phase III Randomized Controlled Trial Comparing Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Fractionated or Moderately Hypo Fractionated External Beam Radiotherapy for Localized Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Randomized controlled trial; Clinical endpoint; Radiation therapy; External beam radiotherapy; Androgen deprivation therapy; Hazard ratio; Nuclear medicine; Urology; Radiosurgery; Cancer; Prostate; Dose fractionation; Surgery; Internal medicine; Confidence interval","score_opus":0.048207625373086385,"score_gpt":0.4247409801308115,"score_spread":0.37653335475772515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387589984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95285964,0.0010151496,0.025373073,0.0066506597,0.008362728,0.0050110077,0.0004659225,0.00017830146,0.00008352984],"genre_scores_gemma":[0.9752145,0.0107465675,0.003081159,0.0013006197,0.0048166327,0.001286743,0.002072168,0.00011630969,0.001365304],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952826,0.0007237254,0.0019996539,0.0005605747,0.000959792,0.00047366685],"domain_scores_gemma":[0.99195904,0.0028417937,0.0024153362,0.00023244588,0.0022485815,0.00030281962],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017836959,0.00048430255,0.0024569354,0.0006373532,0.00023003637,0.0001852298,0.0005334616,0.0003599573,0.0010244683],"category_scores_gemma":[0.0007758732,0.00034579603,0.000969498,0.00032801396,0.00031393926,0.00095543434,0.000044522498,0.0007098036,0.000016891045],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9297769,0.0023077629,0.030290803,0.0000113960405,0.012016253,0.000100411395,0.00053594616,0.0023717056,0.0073017464,0.0006044533,0.00093371794,0.013748876],"study_design_scores_gemma":[0.85846186,0.0027186624,0.004551672,0.00009980958,0.00055583694,0.00004913379,0.00009292921,0.122397125,0.0009729668,0.0021445681,0.0076538036,0.00030166056],"about_ca_topic_score_codex":0.0001522849,"about_ca_topic_score_gemma":0.000010979778,"teacher_disagreement_score":0.12002542,"about_ca_system_score_codex":0.0021469253,"about_ca_system_score_gemma":0.0018590764,"threshold_uncertainty_score":0.9998994},"labels":[],"label_agreement":null},{"id":"W4387590052","doi":"10.1016/j.ijrobp.2023.08.030","title":"Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in Men with High-Risk Biochemically Recurrent Prostate Cancer and Prior Radiotherapy: EMBARK Subgroup Analysis","year":2023,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Placebo; Clinical endpoint; Prostate cancer; Subgroup analysis; Hazard ratio; Internal medicine; Oncology; Radiation therapy; Urology; Confidence interval; Gynecology; Randomized controlled trial; Cancer; Pathology","score_opus":0.018825873450472885,"score_gpt":0.34849590660753205,"score_spread":0.3296700331570592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387590052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900164,0.0037154886,0.00048263697,0.0047396696,0.00022501055,0.00062298455,0.00012648007,0.00003777461,0.00003352758],"genre_scores_gemma":[0.93282723,0.06392425,0.0017674518,0.00033896093,0.0005460916,0.00010278578,0.00012377083,0.00004176319,0.0003276668],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980566,0.00023088093,0.00063117454,0.000383219,0.0003491013,0.00034902163],"domain_scores_gemma":[0.9981534,0.0004536611,0.000696444,0.00013789753,0.0003671577,0.00019146033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007553004,0.00026200217,0.0007401971,0.0005966477,0.00008000228,0.000048227594,0.00019274517,0.00017449357,0.000038265964],"category_scores_gemma":[0.00010991766,0.00017624041,0.000117378535,0.0006917707,0.00029002357,0.00021620186,0.000051902065,0.0005148714,0.0000025548447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022449214,0.00021368581,0.69350123,0.000032217507,0.004675053,0.00020618294,0.0025819703,0.0019617102,0.00940084,0.0001532583,0.00032095768,0.2645037],"study_design_scores_gemma":[0.11750364,0.008154294,0.78643054,0.00052141084,0.002238412,0.00034522614,0.0009608195,0.04829953,0.02109518,0.004119079,0.009409635,0.0009222493],"about_ca_topic_score_codex":0.0002588914,"about_ca_topic_score_gemma":0.00015782478,"teacher_disagreement_score":0.26358145,"about_ca_system_score_codex":0.0011722825,"about_ca_system_score_gemma":0.0008604777,"threshold_uncertainty_score":0.71868753},"labels":[],"label_agreement":null},{"id":"W4387701134","doi":"10.1093/jnci/djad215","title":"Loss of feedback regulation between FAM3B and androgen receptor driving prostate cancer progression","year":2023,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; Johns Hopkins University; School of Medicine, Duke University; University of Washington; Tulane University; Vanderbilt University; National Institute on Minority Health and Health Disparities; Canadian Institutes of Health Research; U.S. Department of Veterans Affairs; U.S. Department of Defense","keywords":"TMPRSS2; Prostate cancer; Biology; Cancer research; Fusion gene; Androgen receptor; Prostate; Epigenetics; Cancer; Internal medicine; Genetics; Gene; Medicine","score_opus":0.06664239225078174,"score_gpt":0.3980868318259597,"score_spread":0.331444439575178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387701134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98830605,0.0016702747,0.0000054963502,0.008661386,0.00066967856,0.00038501856,0.00010015609,0.00001148841,0.00019045822],"genre_scores_gemma":[0.9944993,0.0028416933,0.00015999272,0.000060145823,0.0008903126,0.000028208466,0.00002197015,0.000013968218,0.001484373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982782,0.000040326322,0.00038300012,0.00012499522,0.0010043981,0.00016910335],"domain_scores_gemma":[0.9985032,0.000052388976,0.0004036261,0.00007227108,0.0008655742,0.00010292215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004825364,0.00010529066,0.0002498889,0.00020231001,0.00014174671,0.000019297966,0.00011905324,0.00006451376,0.000048114693],"category_scores_gemma":[0.00013284296,0.000062044885,0.00009688283,0.0005559263,0.00020411432,0.00028779844,0.000072694944,0.00021873983,0.0000026785642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053934037,0.00005268954,0.9244064,0.0002542063,0.0004197311,0.000009944705,0.0007279035,0.000675514,0.01910256,0.000072960174,0.009214545,0.044524223],"study_design_scores_gemma":[0.0040707057,0.00023733385,0.9068836,0.002190903,0.00019545303,0.00004833733,0.00007207106,0.00019645253,0.051133875,0.0008269311,0.03400968,0.00013467539],"about_ca_topic_score_codex":0.00003529305,"about_ca_topic_score_gemma":0.000021184118,"teacher_disagreement_score":0.044389546,"about_ca_system_score_codex":0.0004126997,"about_ca_system_score_gemma":0.00093474245,"threshold_uncertainty_score":0.25301167},"labels":[],"label_agreement":null},{"id":"W4387729233","doi":"10.1007/s00345-023-04649-9","title":"Impact of sequencing of androgen receptor-signaling inhibition and radiotherapy in prostate cancer: importance of homologous recombination disruption","year":2023,"lang":"en","type":"article","venue":"World Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"U.S. Army","keywords":"Prostate cancer; Androgen receptor; Cancer research; Prostate; Medicine; Biology; Internal medicine; Oncology; Cancer","score_opus":0.026025552330812454,"score_gpt":0.3458175289149613,"score_spread":0.3197919765841489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387729233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99156135,0.007344786,0.000011724898,0.0007768857,0.00006309457,0.00020309353,0.000013558198,0.0000037616503,0.00002173019],"genre_scores_gemma":[0.9879496,0.011791551,0.00012932005,0.000012383975,0.000032562257,0.0000051274874,0.000013222935,0.000009673628,0.000056543573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998989,0.00009678177,0.00052158814,0.00009147406,0.00015289082,0.0001483088],"domain_scores_gemma":[0.9990518,0.0000837573,0.00054444466,0.000063970336,0.00020923652,0.00004678257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006366131,0.00007379779,0.0003848799,0.000663361,0.000014468346,0.0000018820564,0.000030617302,0.000043301774,0.00004657162],"category_scores_gemma":[0.000043037708,0.000055776072,0.00007903155,0.0005544627,0.000115047325,0.00008771764,0.000010274707,0.00016644885,1.3284556e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020720332,0.00007612474,0.6394734,0.00011801961,0.00013990734,0.000077303645,0.0010178239,0.00058342324,0.34285727,0.000017472428,0.000072820236,0.013494402],"study_design_scores_gemma":[0.015762627,0.01017182,0.8269358,0.00097234495,0.00018116484,0.0005352869,0.0004158915,0.0012101688,0.14103013,0.002514388,0.000090386355,0.0001799558],"about_ca_topic_score_codex":0.00012291291,"about_ca_topic_score_gemma":0.00005571162,"teacher_disagreement_score":0.20182714,"about_ca_system_score_codex":0.00024149475,"about_ca_system_score_gemma":0.0003000939,"threshold_uncertainty_score":0.22744823},"labels":[],"label_agreement":null},{"id":"W4387735431","doi":"10.1056/nejmoa2303974","title":"Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":291,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia","funders":"Astellas Pharma US; Pfizer","keywords":"Medicine; Enzalutamide; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Randomization; Internal medicine; Urology; Placebo; Oncology; Metastasis; Prostate-specific antigen; Combination therapy; Confidence interval; Randomized controlled trial; Surgery; Cancer; Androgen receptor; Pathology","score_opus":0.028063204050988517,"score_gpt":0.3483904114940708,"score_spread":0.3203272074430823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387735431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9501423,0.0038068972,0.000009698561,0.045144927,0.00031991946,0.00031693536,0.000004670612,0.000020852167,0.0002337626],"genre_scores_gemma":[0.988319,0.0069471356,0.00019606603,0.00032514802,0.001231046,0.000014024552,0.000017918412,0.000025753938,0.0029239447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985083,0.000039867824,0.00044067763,0.00014977102,0.000536542,0.00032485207],"domain_scores_gemma":[0.9989984,0.00014514857,0.00017299157,0.00013016089,0.00021187797,0.00034142187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006473492,0.00015671275,0.00053309626,0.00040859115,0.000023675137,0.0000068493905,0.0000947572,0.00004765226,0.000110579655],"category_scores_gemma":[0.00024091161,0.00007545181,0.000051930558,0.0005739226,0.000110807334,0.00006219631,0.0000220558,0.00044006083,0.0000039321935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012882965,0.00017780496,0.5438302,0.00022996552,0.00042519643,0.0022681546,0.0035144275,0.00002370925,0.066073634,0.000012471024,0.010765475,0.359796],"study_design_scores_gemma":[0.4230884,0.013068578,0.48548663,0.0070751105,0.0006430095,0.0011555959,0.0014913795,0.00038583172,0.023665015,0.00063833647,0.04283359,0.00046850092],"about_ca_topic_score_codex":0.00023865374,"about_ca_topic_score_gemma":0.00015129113,"teacher_disagreement_score":0.41020545,"about_ca_system_score_codex":0.00015886505,"about_ca_system_score_gemma":0.00056738214,"threshold_uncertainty_score":0.30768356},"labels":[],"label_agreement":null},{"id":"W4387774217","doi":"10.3390/curroncol30100669","title":"A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Enzalutamide; Oncology; Internal medicine; Hazard ratio; Meta-analysis; Subgroup analysis; Androgen deprivation therapy; Randomized controlled trial; Confidence interval; Cancer; Androgen receptor","score_opus":0.7893025843549145,"score_gpt":0.6733208505523148,"score_spread":0.11598173380259968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387774217","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00063532114,0.9902062,0.000010391421,0.00038069134,0.0007000286,0.007605352,0.0003999048,0.000015009196,0.00004713047],"genre_scores_gemma":[0.0005403516,0.99542624,0.00006218061,0.0000073984525,0.00015456128,0.003002908,0.00053044496,0.000040255083,0.00023563323],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9744127,0.017283386,0.0066293227,0.00060006604,0.00067591364,0.00039866145],"domain_scores_gemma":[0.9574477,0.03740383,0.0040922407,0.0005341924,0.00038600407,0.00013601489],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.032977123,0.00045085984,0.02368854,0.0012223558,0.00004803835,0.000024475738,0.00024599815,0.00025229919,0.00021923067],"category_scores_gemma":[0.009067222,0.00020038603,0.009587685,0.0027354558,0.0007521959,0.00004639854,0.0001057716,0.00090407225,0.0000057039506],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007986193,0.0012721008,0.00011883353,0.012703585,0.4051443,0.00006539758,0.0003963026,0.000020073141,0.0000017589167,0.00004403698,0.0002984331,0.57194895],"study_design_scores_gemma":[0.049019396,0.00022760397,0.000077345125,0.00279181,0.8576234,0.0000022404129,0.000121278725,0.00010139555,0.000003538146,0.00003602465,0.08984247,0.0001535067],"about_ca_topic_score_codex":0.00021542473,"about_ca_topic_score_gemma":0.00025726776,"teacher_disagreement_score":0.57179546,"about_ca_system_score_codex":0.00037728235,"about_ca_system_score_gemma":0.004728695,"threshold_uncertainty_score":0.9992798},"labels":[],"label_agreement":null},{"id":"W4387784546","doi":"10.1136/jitc-2023-007354","title":"Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"Boehringer Ingelheim Fonds","keywords":"Prostate cancer; Transcriptome; Medicine; Oncology; Internal medicine; Cancer; Cancer research; Biology; Gene; Gene expression","score_opus":0.04261554050152196,"score_gpt":0.3952922527049947,"score_spread":0.35267671220347274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387784546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9611273,0.03199116,0.00004705875,0.00474301,0.0004608439,0.0013779913,0.00018399967,0.000017452854,0.000051190756],"genre_scores_gemma":[0.94861287,0.047974046,0.00013503047,0.00028038435,0.00026691367,0.00023395008,0.000008981294,0.000059636128,0.0024281717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99805725,0.00005987064,0.0006888569,0.00017425184,0.0006369942,0.0003827934],"domain_scores_gemma":[0.99846935,0.00015602227,0.00040026446,0.0002847485,0.000587496,0.0001020907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006916612,0.00018381239,0.00062838587,0.00037527859,0.00013822572,0.000017790553,0.00025766724,0.000047730173,0.00024174912],"category_scores_gemma":[0.000027858656,0.000103359474,0.00048533987,0.00094740203,0.00018783768,0.00008599944,0.000012411195,0.00021948494,8.058741e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018926285,0.000246148,0.02421968,0.00025074565,0.0025431174,0.0000077675795,0.006577862,0.0008385781,0.7557225,0.000010664391,0.0027939233,0.18786268],"study_design_scores_gemma":[0.025360081,0.00398656,0.1956867,0.0017316069,0.00038461603,0.000024309178,0.0014252167,0.00037565938,0.71725506,0.00021270914,0.053303696,0.00025378773],"about_ca_topic_score_codex":0.00037397564,"about_ca_topic_score_gemma":0.000028140154,"teacher_disagreement_score":0.1876089,"about_ca_system_score_codex":0.00015205365,"about_ca_system_score_gemma":0.0006502036,"threshold_uncertainty_score":0.42148772},"labels":[],"label_agreement":null},{"id":"W4387797966","doi":"10.1158/2159-8290.cd-23-0984","title":"AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Avidity; Prostate cancer; Immune system; Cancer; Prostate; Cancer research; Medicine; Cancer therapy; Immunology; Biology; Internal medicine; Antibody","score_opus":0.03907725534016136,"score_gpt":0.338504388889675,"score_spread":0.2994271335495136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387797966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98480093,0.008541536,0.0000083566365,0.0020047452,0.00074579543,0.0015809917,0.0003603091,0.00036626402,0.0015910869],"genre_scores_gemma":[0.9389472,0.040499512,0.000021995895,0.00022533958,0.000625554,0.0009055215,0.00023029924,0.00013746874,0.018407084],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99670804,0.00013899292,0.00032754472,0.00093109667,0.0008757167,0.0010185943],"domain_scores_gemma":[0.9984568,0.00008309304,0.00020668522,0.0007365868,0.00020426913,0.00031258023],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004234388,0.00047401898,0.00067954604,0.00026036781,0.00039916142,0.00020474345,0.00024737144,0.0001477248,0.00010553643],"category_scores_gemma":[0.00001552983,0.0003349155,0.00017045917,0.0009135976,0.0002330286,0.0010119667,0.00012448661,0.0006360097,0.000038655944],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077084154,0.001343637,0.27258593,0.00082627946,0.0009342695,0.0010171651,0.0035296609,0.0012156363,0.5935082,0.00000883204,0.0023637696,0.11495824],"study_design_scores_gemma":[0.017149346,0.0018827948,0.42127106,0.0014653134,0.00025754413,0.000024130963,0.0020624,0.00066276966,0.54798824,0.000047162954,0.0060816277,0.0011076104],"about_ca_topic_score_codex":0.0028688698,"about_ca_topic_score_gemma":0.00059568055,"teacher_disagreement_score":0.14868514,"about_ca_system_score_codex":0.0008255688,"about_ca_system_score_gemma":0.0015435423,"threshold_uncertainty_score":0.9999103},"labels":[],"label_agreement":null},{"id":"W4387810257","doi":"10.1016/j.annonc.2023.09.2714","title":"1764O Timing of radiotherapy (RT) after radical prostatectomy (RP): Final results of RADICALS RT randomised controlled trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Urology; Prostate-specific antigen; Surgery; Internal medicine; Cancer","score_opus":0.12425507802609304,"score_gpt":0.4441995365997397,"score_spread":0.3199444585736467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791783,0.0025619483,0.00001793016,0.008293535,0.00025874184,0.0050261426,0.00009208788,0.00004054652,0.004530775],"genre_scores_gemma":[0.9908294,0.004608849,0.00035830354,0.00030700525,0.00030269322,0.00063306536,0.00008120777,0.000031868116,0.0028475733],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99702454,0.0003724027,0.001249852,0.00032186453,0.0005398933,0.0004914246],"domain_scores_gemma":[0.996975,0.0016622394,0.0004891077,0.00032488996,0.0003480697,0.00020067238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021935871,0.00019986255,0.0018503725,0.00042451252,0.00003519833,0.0000040438413,0.00015553815,0.00027122622,0.00035335615],"category_scores_gemma":[0.0010466059,0.00013733882,0.00049863703,0.00043143058,0.0006911002,0.00005095196,0.00004464147,0.00025264782,0.000009705434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94538975,0.0011462399,0.00023316154,0.0002079914,0.0009894624,0.00028070566,0.0007297841,0.0000064932005,0.011030346,0.000026027139,0.015433475,0.02452658],"study_design_scores_gemma":[0.93076265,0.013823197,0.0012515618,0.00019800209,0.00016844373,0.000016610522,0.00007364587,0.0002841415,0.039481618,0.00016880744,0.013658209,0.000113132155],"about_ca_topic_score_codex":0.00004621201,"about_ca_topic_score_gemma":0.0000030148399,"teacher_disagreement_score":0.028451271,"about_ca_system_score_codex":0.00006038138,"about_ca_system_score_gemma":0.001000102,"threshold_uncertainty_score":0.56005144},"labels":[],"label_agreement":null},{"id":"W4387810259","doi":"10.1016/j.annonc.2023.09.2734","title":"1784P Prostate-specific antigen (PSA) outcomes with darolutamide (DARO): Androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with high- and low-volume metastatic hormone-sensitive prostate cancer (mHSPC) in ARASENS","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Medicine; Docetaxel; Androgen deprivation therapy; Prostate cancer; Prostate-specific antigen; Oncology; Internal medicine; Cancer; Urology","score_opus":0.05247597282564745,"score_gpt":0.35081602817611146,"score_spread":0.29834005535046404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99196273,0.0016229078,0.0000018997765,0.003988915,0.000036545578,0.002116259,0.00017712521,0.000034340323,0.000059271788],"genre_scores_gemma":[0.9789153,0.019935226,0.00017099742,0.00029767706,0.0000163363,0.00021820763,0.00019297683,0.000044585395,0.00020872238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978541,0.00016350682,0.00045089194,0.00054204336,0.00039912836,0.00059033476],"domain_scores_gemma":[0.99888355,0.00016327946,0.00022798289,0.00022458036,0.00033783566,0.00016275804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003466471,0.00029819913,0.0008848725,0.0005608141,0.00006382406,0.000022925247,0.000063513144,0.00009705818,0.000008811242],"category_scores_gemma":[0.000036748537,0.00019967297,0.000035261695,0.00079815334,0.000447988,0.00022617893,0.000058819158,0.00025951836,0.0000053173044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013879119,0.00072633923,0.9529665,0.00012323027,0.00037921654,0.000707833,0.0042009647,0.00008811835,0.002706669,0.000023609744,0.00034323568,0.023855157],"study_design_scores_gemma":[0.019274557,0.007928375,0.96622914,0.00019692804,0.000033611206,0.000012581746,0.00079245976,0.00011231862,0.0043152403,0.00014673908,0.00074001245,0.0002180127],"about_ca_topic_score_codex":0.0007938351,"about_ca_topic_score_gemma":0.00059029297,"teacher_disagreement_score":0.023637144,"about_ca_system_score_codex":0.00013217724,"about_ca_system_score_gemma":0.00036572816,"threshold_uncertainty_score":0.8142427},"labels":[],"label_agreement":null},{"id":"W4387810275","doi":"10.1016/j.annonc.2023.09.2761","title":"1813P Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"Astellas Pharma; AstraZeneca; Chugai Pharmaceutical; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Androgen receptor; Oncology; Pharmacology; Pharmacokinetics; Clinical endpoint; Androgen deprivation therapy; Antiandrogens; Clinical trial; Cancer","score_opus":0.2061185689696446,"score_gpt":0.5020156712325335,"score_spread":0.29589710226288896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877167,0.0007120587,0.0000063723974,0.0075647198,0.0001882702,0.0030242,0.00055667147,0.000025893974,0.00020511671],"genre_scores_gemma":[0.9971901,0.0010589589,0.00016262216,0.000093842995,0.000036084515,0.0005712793,0.0006454184,0.000022662158,0.00021902745],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971733,0.00032714268,0.001042976,0.00040827531,0.0005121564,0.000536135],"domain_scores_gemma":[0.9983877,0.00030251846,0.00036909193,0.00026255994,0.0004891148,0.00018904886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013429557,0.00021869253,0.00097649905,0.0008571439,0.000052963947,0.0000089257,0.00012426106,0.000072645205,0.00003334526],"category_scores_gemma":[0.00035048937,0.00017257885,0.000076711935,0.0015040006,0.00019510732,0.00013287013,0.0000570384,0.00025970736,0.000006256372],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7841515,0.023337321,0.0013430391,0.0005746918,0.00038065735,0.0009508625,0.010161728,0.00067663455,0.03760387,0.00014511307,0.00495669,0.1357179],"study_design_scores_gemma":[0.7942623,0.094476186,0.009665916,0.0011901577,0.00022606428,0.000012296477,0.0017688967,0.0015214515,0.0851167,0.0005191678,0.010852332,0.00038853727],"about_ca_topic_score_codex":0.0024450656,"about_ca_topic_score_gemma":0.007856668,"teacher_disagreement_score":0.13532937,"about_ca_system_score_codex":0.0002771427,"about_ca_system_score_gemma":0.0014700744,"threshold_uncertainty_score":0.7037561},"labels":[],"label_agreement":null},{"id":"W4387810278","doi":"10.1016/j.annonc.2023.09.2742","title":"1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta; University of Ottawa","funders":"","keywords":"PTEN; Enzalutamide; Medicine; Oncology; Prostate cancer; Internal medicine; Proportional hazards model; Docetaxel; Multivariate analysis; Survival analysis; Overall survival; Cancer; Cancer research; Apoptosis; Androgen receptor; PI3K/AKT/mTOR pathway; Biology; Genetics","score_opus":0.2944132847888312,"score_gpt":0.4697874629469143,"score_spread":0.1753741781580831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941885,0.00013993785,0.0000016359539,0.0028474615,0.0005176907,0.0010233095,0.00004460839,0.000034690438,0.0012021745],"genre_scores_gemma":[0.9975971,0.00044902813,0.000021548984,0.00035798133,0.00009388148,0.00017993416,0.00003535688,0.000037367165,0.0012278305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99689084,0.0005426248,0.00057824707,0.00046968999,0.0005135578,0.0010050285],"domain_scores_gemma":[0.99759316,0.0014549899,0.000149118,0.00039326047,0.00012644098,0.0002830201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011509105,0.00026485886,0.0010371873,0.00074319565,0.000033640055,0.000009775884,0.00023272063,0.0002485677,0.000059000904],"category_scores_gemma":[0.00080118066,0.00019638798,0.00014373365,0.0008133004,0.00019491749,0.00009273853,0.00015818732,0.00036866826,0.0000771799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12558655,0.0035491842,0.75326097,0.0013118876,0.001124954,0.0081821615,0.01755731,0.00030382906,0.053756442,0.000498193,0.005179555,0.029688993],"study_design_scores_gemma":[0.019859103,0.0220642,0.82360977,0.00055832876,0.00007190557,0.000003469114,0.000617154,0.000029330333,0.13220724,0.00023609203,0.000511615,0.00023176846],"about_ca_topic_score_codex":0.0022899953,"about_ca_topic_score_gemma":0.0033506546,"teacher_disagreement_score":0.10572744,"about_ca_system_score_codex":0.00018769086,"about_ca_system_score_gemma":0.00042347176,"threshold_uncertainty_score":0.80084693},"labels":[],"label_agreement":null},{"id":"W4387810283","doi":"10.1016/j.annonc.2023.09.2758","title":"1810P Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"Medical Research Council","keywords":"Medicine; Prostate cancer; Imputation (statistics); Quality of life (healthcare); Progression-free survival; Log-rank test; Oncology; Internal medicine; Missing data; Urology; Gynecology; Cancer; Overall survival; Statistics","score_opus":0.15551892457803307,"score_gpt":0.48387834134422975,"score_spread":0.3283594167661967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928288,0.00017890587,3.8366431e-7,0.0050969245,0.000021643018,0.0017134162,0.00009649208,0.0000055984788,0.00005783606],"genre_scores_gemma":[0.999515,0.00014719457,0.000020658228,0.00006581315,0.0000023454593,0.00006670612,0.000068133886,0.000008142625,0.000106014966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997461,0.00069679983,0.00086999085,0.00014398864,0.0006322196,0.00019600608],"domain_scores_gemma":[0.9974199,0.0006785987,0.0010660068,0.00017635534,0.0006188597,0.000040294326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018648289,0.00009274311,0.0007951975,0.00018032941,0.000029703973,0.0000018383553,0.000072392155,0.00004008868,0.0000127525855],"category_scores_gemma":[0.00029083446,0.000048020804,0.000043060187,0.00065797666,0.000092479866,0.000047576515,0.000018312916,0.000115332485,5.191841e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062626204,0.004929884,0.9730032,0.00033197182,0.00066464045,0.0000060791535,0.010801055,0.00019215632,0.00018497577,0.000017015263,0.00021186331,0.0033945371],"study_design_scores_gemma":[0.011905881,0.018876579,0.96498793,0.00010960693,0.00006708487,8.736361e-8,0.0037378455,0.00000910611,0.00022589981,0.000022410224,0.000020150144,0.000037395403],"about_ca_topic_score_codex":0.004048802,"about_ca_topic_score_gemma":0.0033298356,"teacher_disagreement_score":0.013946694,"about_ca_system_score_codex":0.0000890345,"about_ca_system_score_gemma":0.0007559928,"threshold_uncertainty_score":0.6120604},"labels":[],"label_agreement":null},{"id":"W4387810341","doi":"10.1016/j.annonc.2023.09.2772","title":"1824P Treatment patterns among novel hormonal therapy-experienced patients with metastatic castration-resistant prostate cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Bristol-Myers Squibb","keywords":"Medicine; Prostate cancer; Hormonal therapy; Castration; Oncology; Internal medicine; Cancer; Hormone; Prostate; Gynecology","score_opus":0.13838977258649449,"score_gpt":0.4246881495505144,"score_spread":0.28629837696401994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961497,0.00033275588,0.000004245744,0.0016320532,0.0000694525,0.0011178363,0.0002813173,0.000038747894,0.00037387738],"genre_scores_gemma":[0.9950722,0.0024832748,0.000081995124,0.00015120485,0.000037441045,0.00065512495,0.00032908618,0.000024495886,0.001165188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858046,0.00004852794,0.0002863664,0.00029091857,0.00036796773,0.00042578843],"domain_scores_gemma":[0.99902034,0.00008840517,0.00015221449,0.00019394062,0.00038370362,0.00016138621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011732089,0.00019304885,0.00042718512,0.00017245003,0.00008519083,0.0000114888735,0.00007216911,0.00005366968,0.00015743518],"category_scores_gemma":[0.0000128692545,0.000112609734,0.000085425796,0.0003507267,0.00020987324,0.00010013229,0.000022088001,0.00008559204,0.000009932872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009928704,0.0035494128,0.85348123,0.000107176915,0.0015312883,0.00031783234,0.009838891,0.00008827319,0.012702319,0.000045237513,0.0008596065,0.10755002],"study_design_scores_gemma":[0.010648754,0.016840715,0.9502919,0.00008615357,0.000070604074,0.0000030163105,0.0010636052,0.000057133813,0.018391429,0.000024250983,0.0023876687,0.00013479852],"about_ca_topic_score_codex":0.0011604767,"about_ca_topic_score_gemma":0.00049420557,"teacher_disagreement_score":0.10741522,"about_ca_system_score_codex":0.00014371933,"about_ca_system_score_gemma":0.00064626086,"threshold_uncertainty_score":0.45920917},"labels":[],"label_agreement":null},{"id":"W4387810343","doi":"10.1016/j.annonc.2023.09.2731","title":"1781P Health-related quality of life (HRQoL) deterioration-free survival (DetFS) by prostate-specific antigen (PSA) decline in darolutamide (DARO)-treated patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from ARAMIS","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Cancer; Quality of life (healthcare); Urology; Oncology; Gastroenterology","score_opus":0.11302744526953401,"score_gpt":0.4023910409696842,"score_spread":0.2893635957001502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825509,0.0025891308,0.0000069621237,0.008777564,0.00013805518,0.0021577037,0.0036400347,0.00006116974,0.00007845835],"genre_scores_gemma":[0.991258,0.003976722,0.00029487192,0.00028695888,0.00003052395,0.00020578018,0.0036444217,0.00005589999,0.0002467984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99531424,0.00063515396,0.0017915927,0.0006282286,0.0008800089,0.00075076544],"domain_scores_gemma":[0.99674624,0.00049582694,0.0010071755,0.00057739014,0.00082528486,0.0003480961],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012296431,0.00035081117,0.0014474945,0.00038609232,0.000112433474,0.000021391115,0.00023929743,0.00019296372,0.00015926895],"category_scores_gemma":[0.00030056227,0.00027619887,0.00011585518,0.0012622497,0.0004186973,0.00019736002,0.00011481459,0.0003210459,0.000015497488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03408226,0.0024124943,0.8981369,0.0005385225,0.0009036458,0.00014078009,0.0031773963,0.00026594274,0.034849964,0.00002142508,0.006461239,0.01900943],"study_design_scores_gemma":[0.016819071,0.0076818615,0.9675951,0.00031693061,0.00004794827,9.22296e-7,0.0006283181,0.00013808717,0.0045713247,0.00033355047,0.0015915448,0.00027534773],"about_ca_topic_score_codex":0.019709246,"about_ca_topic_score_gemma":0.012008358,"teacher_disagreement_score":0.069458194,"about_ca_system_score_codex":0.0002763587,"about_ca_system_score_gemma":0.0017817265,"threshold_uncertainty_score":0.999969},"labels":[],"label_agreement":null},{"id":"W4387810347","doi":"10.1016/j.annonc.2023.09.2728","title":"1778P Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Clinical endpoint; Urology; Placebo; Internal medicine; Gynecology; Oncology; Gastroenterology; Randomized controlled trial; Cancer; Pathology","score_opus":0.04619213243928624,"score_gpt":0.3734757764249406,"score_spread":0.32728364398565435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99201155,0.0015822296,0.000003081387,0.003980043,0.0000664083,0.0010028926,0.00039623622,0.00003725282,0.0009203048],"genre_scores_gemma":[0.98649496,0.011646185,0.000329939,0.000087262415,0.00003414669,0.0003561861,0.0004294555,0.0000332418,0.00058861345],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982106,0.00019406895,0.00043464845,0.00040574078,0.0003338475,0.00042107512],"domain_scores_gemma":[0.9986765,0.0002878318,0.00033055776,0.0002701699,0.00029486167,0.00014008739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033011186,0.00023111604,0.0007209806,0.0003245311,0.000035937708,0.0000063476737,0.00010137067,0.00014061308,0.00008953227],"category_scores_gemma":[0.000045261415,0.00015022383,0.000072168215,0.00048937,0.0003415202,0.00008393573,0.0000491399,0.00026426036,0.000009990882],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047127817,0.004113354,0.26640385,0.00051566097,0.0022681267,0.0011590652,0.0073282975,0.00020395285,0.03577818,0.00011888344,0.0025516553,0.63243115],"study_design_scores_gemma":[0.03116746,0.023057533,0.38673005,0.0008492055,0.0003033488,0.00002206141,0.00069774955,0.0001374849,0.550928,0.0015337368,0.004296004,0.00027739443],"about_ca_topic_score_codex":0.0033821634,"about_ca_topic_score_gemma":0.0017337472,"teacher_disagreement_score":0.63215375,"about_ca_system_score_codex":0.00025132805,"about_ca_system_score_gemma":0.001176128,"threshold_uncertainty_score":0.612595},"labels":[],"label_agreement":null},{"id":"W4387810358","doi":"10.1016/j.annonc.2023.09.2716","title":"1766MO Health-related quality of life (HRQoL) in nonmetastatic hormone-sensitive prostate cancer (nmHSPC) patients (pts) with high-risk biochemical recurrence (BCR) from the EMBARK study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"Ipsen; Astellas Foundation for Research on Metabolic Disorders; Eisai; Sanofi; Clovis Oncology; PharmaMar; AstraZeneca; Pfizer","keywords":"Medicine; Prostate cancer; Quality of life (healthcare); Internal medicine; Prostatectomy; Biochemical recurrence; Placebo; Urology; Population; Oncology; Radiation therapy; Visual analogue scale; Gynecology; Cancer; Physical therapy; Pathology","score_opus":0.11017685590830867,"score_gpt":0.42880239856157587,"score_spread":0.3186255426532672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882647,0.0019473224,0.0000010333727,0.006941647,0.00009622776,0.0019067592,0.00076467916,0.00002180537,0.000055826087],"genre_scores_gemma":[0.99463665,0.004381014,0.000051900603,0.00035011824,0.000025617062,0.00017706947,0.00028738024,0.000020663509,0.00006955519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99680096,0.0009281907,0.0008739388,0.00041296383,0.0005132222,0.00047072757],"domain_scores_gemma":[0.9974247,0.00095073535,0.0006228026,0.0003400138,0.00047744124,0.00018430648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013289264,0.00019326128,0.00097009254,0.00015583141,0.000069710535,0.000004627206,0.00014892666,0.0000980781,0.00002419255],"category_scores_gemma":[0.000612894,0.00011726686,0.00007285465,0.0009288597,0.0004079907,0.000056149587,0.000108470784,0.00043310394,0.000015220812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016116736,0.0037692273,0.91370165,0.000148771,0.0011289823,0.00008969342,0.020653836,0.00005487197,0.00070998055,0.000013474152,0.009719943,0.03389283],"study_design_scores_gemma":[0.010200582,0.010013036,0.9733612,0.00019010952,0.000078238045,6.0173625e-7,0.0041367607,0.000041872707,0.001553929,0.00020695412,0.00010085712,0.00011584119],"about_ca_topic_score_codex":0.025994666,"about_ca_topic_score_gemma":0.0019252046,"teacher_disagreement_score":0.05965956,"about_ca_system_score_codex":0.00014182915,"about_ca_system_score_gemma":0.001033672,"threshold_uncertainty_score":0.98049134},"labels":[],"label_agreement":null},{"id":"W4387810382","doi":"10.1016/j.annonc.2023.09.2727","title":"1777P Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Shanghai Municipal Health Commission","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Biochemical recurrence; Internal medicine; Clinical endpoint; Cancer; Clinical trial; Androgen receptor","score_opus":0.08273213936567804,"score_gpt":0.41819373290201484,"score_spread":0.3354615935363368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980982,0.0070356037,0.0000117846375,0.009216541,0.00015082293,0.0016261906,0.0006342248,0.00003286177,0.0003099871],"genre_scores_gemma":[0.92367643,0.072176546,0.00033342335,0.00038089708,0.00015461599,0.001127154,0.00013491741,0.00003730226,0.0019786984],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99860865,0.00007975209,0.00033341983,0.00031839282,0.0002265109,0.00043328851],"domain_scores_gemma":[0.99838316,0.0006179004,0.00023802038,0.00032736428,0.0003215338,0.00011200712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003539944,0.00018964443,0.0005325215,0.00013612723,0.00008469397,0.000005017929,0.00014079934,0.00011886126,0.00011542517],"category_scores_gemma":[0.00005348787,0.00010218587,0.00014648987,0.00034432372,0.00041331153,0.000042144053,0.000027754226,0.0001658348,0.0000076126053],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026699623,0.0016239007,0.03469882,0.0004222636,0.0027516335,0.00009313594,0.004783324,0.0000837776,0.02419036,0.00015531827,0.037990823,0.866507],"study_design_scores_gemma":[0.014693752,0.028449262,0.038886268,0.00026227097,0.000346283,0.00001513534,0.0007223989,0.00019905083,0.81707954,0.00108228,0.09805038,0.00021338057],"about_ca_topic_score_codex":0.0006680955,"about_ca_topic_score_gemma":0.00014294739,"teacher_disagreement_score":0.8662936,"about_ca_system_score_codex":0.0001168622,"about_ca_system_score_gemma":0.00089302904,"threshold_uncertainty_score":0.41670188},"labels":[],"label_agreement":null},{"id":"W4387811984","doi":"10.1016/j.annonc.2023.09.1543","title":"41P Evaluation of ARX517: A next-generation anti-PSMA antibody drug conjugate for prostate cancer treatment, in preclinical enzalutamide-resistant and enzalutamide-sensitive pharmacology models and in toxicology models","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; Servier; European Society for Medical Oncology; CRIS Cancer Foundation; Astellas Pharma; Sierra Oncology; Incyte; Regeneron Pharmaceuticals; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Eisai; Sociedad Española de Oncología Médica; BeiGene; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; PharmaMar; Celgene","keywords":"Enzalutamide; Medicine; Prostate cancer; Pharmacology; Drug; Cancer; Internal medicine","score_opus":0.39245533324299103,"score_gpt":0.526931954523353,"score_spread":0.13447662128036192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98758596,0.00342005,0.000027122576,0.005021024,0.00015442395,0.0033723298,0.00019765485,0.000017724658,0.00020368083],"genre_scores_gemma":[0.9728509,0.025416788,0.00014854482,0.0002927245,0.00007977098,0.0008247981,0.00021164553,0.000025439756,0.00014934172],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99723506,0.00063624006,0.00083114894,0.0005510546,0.00024762758,0.0004988759],"domain_scores_gemma":[0.9980963,0.00072968984,0.00030400063,0.0001466835,0.00059844094,0.0001248982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022221068,0.00022549096,0.0009871579,0.00055568205,0.00005171996,0.00000823008,0.00005486175,0.00024376558,0.000012750688],"category_scores_gemma":[0.00015001434,0.00018995012,0.00008205888,0.0003759415,0.0004051742,0.00022855132,0.00006522808,0.00016538517,7.411946e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019047381,0.0020250203,0.027328992,0.0004919576,0.0007413718,0.00017487133,0.009565982,0.024260296,0.8201082,0.00046058017,0.0007634906,0.095031895],"study_design_scores_gemma":[0.030669298,0.008827057,0.029565664,0.00024204823,0.0005217968,0.000023775523,0.0011417913,0.74668294,0.17392623,0.007859493,0.00025668167,0.000283218],"about_ca_topic_score_codex":0.0009933616,"about_ca_topic_score_gemma":0.0021601622,"teacher_disagreement_score":0.72242266,"about_ca_system_score_codex":0.00023600564,"about_ca_system_score_gemma":0.0011509662,"threshold_uncertainty_score":0.7745941},"labels":[],"label_agreement":null},{"id":"W4387891738","doi":"10.21203/rs.3.rs-3295914/v1","title":"Unravelling the Role of Iroquois Homeobox 4 and its Interplay with Androgen Receptor in Prostate Cancer","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Cancer Institute; Advance Queensland; Medical Research Council; Canadian Institutes of Health Research; Manchester Biomedical Research Centre; Cancer Council Victoria; Cancer Australia; National Institute for Health and Care Research; Australian Government; Rosetrees Trust; Pancreatic Cancer UK; Breast Cancer Research Foundation; European Commission; Prostate Cancer Foundation of Australia; Cancer Research Institute; Royal Marsden NHS Foundation Trust; Prostate Cancer Foundation; National Cancer Research Institute; National Institutes of Health; Ovarian Cancer Research Fund; National Health and Medical Research Council; Cancer Research UK","keywords":"Homeobox; Prostate cancer; Androgen receptor; Biology; Cancer; Cancer research; Computational biology; Genetics; Gene; Transcription factor","score_opus":0.05849800656156946,"score_gpt":0.4067577705350652,"score_spread":0.34825976397349573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387891738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9541163,0.0373622,0.0000014105841,0.0039381087,0.000071036535,0.0035904236,0.0004025292,0.00004711301,0.00047092087],"genre_scores_gemma":[0.9520269,0.04129934,0.000043247004,0.000010220447,0.00012899378,0.0012859501,0.00016912214,0.00008052339,0.0049556987],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967558,0.00029799156,0.0003356734,0.0006469154,0.0012159143,0.00074772746],"domain_scores_gemma":[0.9981264,0.00037517183,0.000093436065,0.0005012976,0.00068454875,0.00021917744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014881344,0.00025968073,0.00053612137,0.0006502658,0.00012949613,0.00007103933,0.00028305172,0.00018564377,0.0001209359],"category_scores_gemma":[0.00016093208,0.0001471709,0.00007758073,0.00085295696,0.0003531207,0.000053833173,0.0008268804,0.0017975033,0.000027484728],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012017236,0.00069787115,0.8707315,0.015271105,0.0015450284,0.00079812686,0.030423062,0.0006413713,0.014164219,0.00031528488,0.0017932601,0.051601972],"study_design_scores_gemma":[0.025536261,0.011298482,0.28105003,0.10622548,0.00057832646,0.00013279554,0.06813007,0.020314083,0.43100944,0.008478693,0.044583242,0.0026630864],"about_ca_topic_score_codex":0.0024658719,"about_ca_topic_score_gemma":0.00078963046,"teacher_disagreement_score":0.58968145,"about_ca_system_score_codex":0.00041691982,"about_ca_system_score_gemma":0.0012473961,"threshold_uncertainty_score":0.7809357},"labels":[],"label_agreement":null},{"id":"W4387902598","doi":"10.3390/curroncol30110683","title":"Introduction of Androgen Receptor Targeting shRNA Inhibits Tumor Growth in Patient-Derived Prostate Cancer Xenografts","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"DOD Prostate Cancer Research Program; Prostate Cancer Foundation of Australia; U.S. Department of Defense; Australian Government; University of Washington; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation","keywords":"Prostate cancer; Androgen receptor; Cancer research; Cancer; Medicine; In vivo; Prostate; Cancer cell; Cell culture; Small hairpin RNA; Organoid; Biology; Internal medicine; Cell biology; Gene knockdown; Genetics","score_opus":0.05402131964323693,"score_gpt":0.37855951049202213,"score_spread":0.3245381908487852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387902598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98754436,0.0053725797,9.515079e-7,0.004535096,0.0014465492,0.00088992785,0.000048331585,0.000066277964,0.0000959046],"genre_scores_gemma":[0.9901902,0.0076716766,0.000092662405,0.00003601143,0.00084022706,0.00043557823,0.00053527567,0.000030554715,0.00016779394],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984806,0.000116581614,0.00039295983,0.0003429648,0.00023156707,0.0004353265],"domain_scores_gemma":[0.99931985,0.00004554009,0.00015103575,0.00011319187,0.00025201126,0.000118368414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027362243,0.00014228321,0.00037848396,0.00035706154,0.00005137485,0.0000055055293,0.000060722956,0.00006573491,0.00019540045],"category_scores_gemma":[0.0001809015,0.00011493542,0.00006254576,0.0008480232,0.00013698988,0.00008073343,0.000094006,0.00028092758,0.0000572909],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00313799,0.0014603299,0.36522293,0.0012662988,0.00017025672,0.0001585384,0.008248055,0.000029499355,0.25510693,0.000046363028,0.104624584,0.2605282],"study_design_scores_gemma":[0.010175722,0.0030420006,0.01988807,0.00051698566,0.00010271646,0.000027620323,0.0021338698,0.00024507084,0.623927,0.00016960692,0.3394197,0.00035163225],"about_ca_topic_score_codex":0.000068377354,"about_ca_topic_score_gemma":0.000022791592,"teacher_disagreement_score":0.3688201,"about_ca_system_score_codex":0.0004353507,"about_ca_system_score_gemma":0.00042701935,"threshold_uncertainty_score":0.46869305},"labels":[],"label_agreement":null},{"id":"W4387953947","doi":"10.3389/fonc.2023.1280943","title":"Identification of tumor-agnostic biomarkers for predicting prostate cancer progression and biochemical recurrence","year":2023,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto; Ontario Institute for Cancer Research","funders":"Conselho Nacional de Desenvolvimento Científico e Tecnológico; Government of Ontario; Fundação de Amparo à Pesquisa do Estado de São Paulo; Ontario Institute for Cancer Research","keywords":"Prostate cancer; Biochemical recurrence; Oncology; Medicine; Breast cancer; Prostate; Internal medicine; Proportional hazards model; Cancer; Biomarker; Cancer research; Biology; Prostatectomy","score_opus":0.025126004654286917,"score_gpt":0.3859449110950516,"score_spread":0.36081890644076464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387953947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911008,0.0045043733,0.00014448482,0.0020294038,0.000642968,0.0014186346,0.00006154623,0.000036224144,0.000061582476],"genre_scores_gemma":[0.9939942,0.0028402542,0.0018304028,0.00002513734,0.000059154376,0.00087135995,0.000105812345,0.000014499514,0.000259192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99908906,0.000038061986,0.00026576692,0.00024478525,0.000120599325,0.00024170776],"domain_scores_gemma":[0.9995061,0.00013539488,0.00011174433,0.000092760725,0.00008767187,0.000066297594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039980598,0.000075379816,0.00023072309,0.000239936,0.000039976505,0.000004631858,0.00005087433,0.00007888613,0.0000029569708],"category_scores_gemma":[0.0003915047,0.000061282706,0.000027078275,0.00039559955,0.00023110119,0.000039493967,0.000040324096,0.00009756611,7.8195797e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021540974,0.00014680326,0.78513265,0.0007100948,0.00009089856,0.000037989037,0.0008252399,0.0000047687895,0.041775916,0.000008978015,0.026284112,0.14282846],"study_design_scores_gemma":[0.020908315,0.004584898,0.54343385,0.0028261014,0.0004005109,0.00005386132,0.0038345149,0.049213734,0.3581561,0.0028909189,0.013211974,0.0004852199],"about_ca_topic_score_codex":0.000014132206,"about_ca_topic_score_gemma":0.000003614317,"teacher_disagreement_score":0.3163802,"about_ca_system_score_codex":0.00023269038,"about_ca_system_score_gemma":0.00027404912,"threshold_uncertainty_score":0.24990363},"labels":[],"label_agreement":null},{"id":"W4388015891","doi":"10.1002/cnr2.1922","title":"Targeting androgen receptor (<scp>AR</scp>) with a synthetic peptide increases apoptosis in triple negative breast cancer and <scp>AR</scp>‐expressing prostate cancer cell lines","year":2023,"lang":"en","type":"article","venue":"Cancer Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"LNCaP; Androgen receptor; Prostate cancer; Apoptosis; Dihydrotestosterone; Cancer research; Cancer cell; Triple-negative breast cancer; Peptide; Transactivation; Chemistry; Receptor; Cancer; Breast cancer; Endocrinology; Biology; Molecular biology; Internal medicine; Androgen; Medicine; Biochemistry; Gene expression; Hormone","score_opus":0.017042172430199308,"score_gpt":0.2897623010575832,"score_spread":0.27272012862738393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388015891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96717304,0.027935062,0.00000292767,0.00068297243,0.00040087706,0.002175981,0.00051576,0.00025259022,0.0008608033],"genre_scores_gemma":[0.9378027,0.04172375,0.0002637284,0.00022599722,0.0006373853,0.003819026,0.00022723654,0.00021166785,0.015088549],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99553025,0.00014350179,0.00084156345,0.0013161603,0.00083101017,0.0013374947],"domain_scores_gemma":[0.997298,0.00044355696,0.0006307966,0.0005074003,0.0005191493,0.0006010857],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005941864,0.0006436761,0.0010054706,0.00038347696,0.0003819251,0.00016318214,0.0001408009,0.00021179489,0.00012355244],"category_scores_gemma":[0.00043680734,0.00048764452,0.00013450062,0.001387009,0.0003919203,0.00048990146,0.0001975418,0.000511537,0.000008808918],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006185273,0.00046707474,0.8562707,0.0020817118,0.0007295172,0.0021131143,0.009963435,0.0011318586,0.079230495,0.0000016798613,0.035643935,0.011747962],"study_design_scores_gemma":[0.016579883,0.0010456067,0.16109143,0.017931854,0.0016133268,0.00093085517,0.025569726,0.0021068866,0.73576504,0.00017043961,0.036187414,0.0010075052],"about_ca_topic_score_codex":0.021355098,"about_ca_topic_score_gemma":0.0016765137,"teacher_disagreement_score":0.6951792,"about_ca_system_score_codex":0.0010578037,"about_ca_system_score_gemma":0.0017440633,"threshold_uncertainty_score":0.9997575},"labels":[],"label_agreement":null},{"id":"W4388034243","doi":"10.1503/cmaj.230555","title":"Hypothyroidism caused by apalutamide","year":2023,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Computer science; Medicine; World Wide Web","score_opus":0.016294923471841447,"score_gpt":0.2876510097257472,"score_spread":0.2713560862539057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388034243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72419804,0.0012690605,0.00001631414,0.25891072,0.0010587013,0.00028151146,0.00010536484,0.00011799044,0.014042275],"genre_scores_gemma":[0.91150147,0.003282281,0.000029420102,0.017548773,0.0027441403,0.000030466932,0.0002396728,0.000056823053,0.06456693],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99738324,0.00008210404,0.00024697962,0.00013268506,0.0015131277,0.00064187584],"domain_scores_gemma":[0.9970955,0.00012209415,0.000069423855,0.00008473569,0.00022785558,0.002400359],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011468551,0.00009332266,0.00018833944,0.00025720516,0.0002566986,0.000058397167,0.00010851118,0.00026739648,0.0030081167],"category_scores_gemma":[0.0011658127,0.00007517183,0.000090521804,0.0005058941,0.000037776557,0.0000664123,0.000011668613,0.00078115537,0.0013343642],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009664862,0.000016293863,0.043205783,0.0000060186326,0.00012934126,0.0015275247,0.00013677469,3.8343427e-7,0.00027093696,0.000021404083,0.93950665,0.015169218],"study_design_scores_gemma":[0.0030528544,0.00011406157,0.07607173,0.000060642877,0.000037494603,0.0002084805,0.00034314668,0.00022874739,0.00024372771,0.00019043572,0.91932577,0.00012293055],"about_ca_topic_score_codex":0.0010796218,"about_ca_topic_score_gemma":0.0030934152,"teacher_disagreement_score":0.24136193,"about_ca_system_score_codex":0.001555475,"about_ca_system_score_gemma":0.0035789518,"threshold_uncertainty_score":0.99944323},"labels":[],"label_agreement":null},{"id":"W4388116074","doi":"10.55730/1300-0152.2667","title":"Androgen receptor contributes to repairing DNA damage induced by inflammation and oxidative stress in prostate cancer","year":2023,"lang":"en","type":"article","venue":"TURKISH JOURNAL OF BIOLOGY","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"Ege Üniversitesi","keywords":"DNA damage; Prostate cancer; Oxidative stress; Androgen receptor; Cancer research; Inflammation; Reactive oxygen species; Tumor microenvironment; Biology; DNA repair; Cancer; Cell biology; Endocrinology; Immunology; DNA; Biochemistry","score_opus":0.02645399158456286,"score_gpt":0.34127965178150016,"score_spread":0.3148256601969373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388116074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920041,0.0014804077,0.0000022781057,0.0059212474,0.00011442257,0.00035045622,0.00007356703,0.000013358013,0.0000401874],"genre_scores_gemma":[0.9974795,0.0020038385,0.000038382295,0.000068161826,0.00009517457,0.000025299803,0.00007302241,0.000008800515,0.00020781218],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99918514,0.00008681914,0.00028758627,0.00012763195,0.00008821604,0.00022457694],"domain_scores_gemma":[0.99944425,0.00008894784,0.00012512457,0.00006169774,0.00017279357,0.000107163614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004096094,0.00008491965,0.00027713762,0.00029698916,0.000033983644,0.000013307585,0.000052407533,0.00006668918,0.000023346089],"category_scores_gemma":[0.00017627548,0.00005997433,0.0000271275,0.0003543153,0.000051748222,0.000081000166,0.000047060577,0.00019645413,0.0000052335663],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092736253,0.000027153266,0.16722223,0.000036513335,0.00013475657,0.00006506296,0.001075036,0.0000034593554,0.81532943,0.0000113519545,0.001868367,0.013299258],"study_design_scores_gemma":[0.006088305,0.0015944691,0.0954716,0.0006213026,0.000049050588,0.000025399255,0.0012358763,0.00005475266,0.8860933,0.00027417595,0.008354377,0.0001373988],"about_ca_topic_score_codex":0.000072142495,"about_ca_topic_score_gemma":0.000049735943,"teacher_disagreement_score":0.071750626,"about_ca_system_score_codex":0.00013683656,"about_ca_system_score_gemma":0.000121406425,"threshold_uncertainty_score":0.24456823},"labels":[],"label_agreement":null},{"id":"W4388199885","doi":"10.1200/op.2023.19.11_suppl.333","title":"Quality of life comparison based on testosterone recovery after androgen deprivation therapy in patients cured from high-risk prostate cancer: Long term data from a phase III trial.","year":2023,"lang":"en","type":"article","venue":"JCO Oncology Practice","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Rimouski; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Cégep de l'Outaouais; Centre hospitalier universitaire de Québec; Centre de Santé et de Services Sociaux de Chicoutimi; Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Prostate cancer; Medicine; Androgen deprivation therapy; Quality of life (healthcare); Testosterone (patch); Radiation therapy; Urology; Internal medicine; Randomized controlled trial; Prostate; Androgen; Cancer; Hormone","score_opus":0.14006825893587663,"score_gpt":0.4621977555985976,"score_spread":0.32212949666272095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388199885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989802,0.0009710938,0.000023788358,0.0035022153,0.00045320872,0.0026143482,0.0025159062,0.000054283453,0.00006315717],"genre_scores_gemma":[0.98629093,0.003086384,0.00045068387,0.0008414634,0.00017754541,0.00044604458,0.008622457,0.00003162002,0.000052852116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964266,0.0011771936,0.0008808863,0.00065047,0.0005441016,0.0003207665],"domain_scores_gemma":[0.9940975,0.0037133258,0.00092664646,0.0009041721,0.00021114803,0.00014723887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011583279,0.00021352243,0.00079364085,0.00022661402,0.00006802814,0.00002425118,0.00023036973,0.00022509237,0.00020998542],"category_scores_gemma":[0.002538454,0.00017287808,0.00005573434,0.00046519274,0.00009559444,0.00047791188,0.00014295409,0.0005091669,0.000037171958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3862723,0.004831243,0.5342236,0.000019885978,0.00030693237,0.000047329726,0.00050055404,0.000020767278,0.00034118825,1.3923798e-7,0.0010563348,0.0723797],"study_design_scores_gemma":[0.25667265,0.00791539,0.7306662,0.00011340309,0.00019960833,1.2185171e-7,0.00016426582,0.0008458868,0.0008627838,0.000020883956,0.0023870624,0.00015169752],"about_ca_topic_score_codex":0.010296099,"about_ca_topic_score_gemma":0.0013383983,"teacher_disagreement_score":0.19644263,"about_ca_system_score_codex":0.0004542183,"about_ca_system_score_gemma":0.0009400785,"threshold_uncertainty_score":0.99629444},"labels":[],"label_agreement":null},{"id":"W4388448664","doi":"10.1016/j.euo.2023.10.008","title":"Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate–Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Western University","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Abiraterone acetate; Pembrolizumab; Internal medicine; Oncology; Cohort; Interquartile range; Adverse effect; Clinical endpoint; Androgen deprivation therapy; Cancer; Clinical trial; Androgen receptor; Immunotherapy","score_opus":0.024215989961962586,"score_gpt":0.33157935936329525,"score_spread":0.3073633694013327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388448664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513274,0.0002629322,7.524714e-7,0.0009293513,0.00012565886,0.002562611,0.000074227835,0.00005155272,0.000860154],"genre_scores_gemma":[0.99850744,0.00015617223,0.000020516021,0.00015182735,0.000019860092,0.00014299163,0.000092112045,0.00004766659,0.0008613929],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99721557,0.0010866895,0.00047289615,0.0004718606,0.00028617727,0.00046678004],"domain_scores_gemma":[0.99900854,0.00014214622,0.00020519897,0.0003510615,0.00017519938,0.00011783647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006129117,0.00023303131,0.0005674788,0.0002609937,0.000113650785,0.000010666247,0.00014618733,0.000048903315,0.000038093945],"category_scores_gemma":[0.00007804168,0.00013953012,0.000037922116,0.0006435946,0.00050336757,0.000061444465,0.00013760464,0.00034188572,0.000020510835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017591145,0.0029230725,0.96669424,0.00007056316,0.000524418,0.0012305382,0.0029928207,0.00010972551,0.0023332636,0.0000073925476,0.0001887573,0.0053340537],"study_design_scores_gemma":[0.05103817,0.013207689,0.9340544,0.000027856191,0.0003930281,0.000020459402,0.00031884018,0.00008317509,0.00031840755,0.000011630325,0.00041363615,0.00011276115],"about_ca_topic_score_codex":0.00020915338,"about_ca_topic_score_gemma":0.0005889733,"teacher_disagreement_score":0.033447027,"about_ca_system_score_codex":0.00017090199,"about_ca_system_score_gemma":0.00034949015,"threshold_uncertainty_score":0.5689873},"labels":[],"label_agreement":null},{"id":"W4388480675","doi":"10.3390/ijms242216022","title":"Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Need for Early Treatment in Prostate Cancer Patients Managed with Active Surveillance","year":2023,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University; Niagara Health System; McMaster University","funders":"","keywords":"Prostate cancer; Medicine; GLUT1; Immunohistochemistry; Prostate; Glutamate carboxypeptidase II; Oncology; Internal medicine; Cancer; Univariate analysis; Biopsy; Prostate-specific antigen; Pathology; Cancer research; Glucose transporter; Multivariate analysis","score_opus":0.026435209110444977,"score_gpt":0.3277031738927832,"score_spread":0.3012679647823382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388480675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99611413,0.00038961394,0.000040630293,0.0020573193,0.0003070109,0.000853198,0.00007424194,0.000014162101,0.00014968171],"genre_scores_gemma":[0.9968836,0.002166589,0.000376328,0.000039133505,0.000067695415,0.00009572867,0.00003722068,0.000014118419,0.00031961777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809116,0.000054082993,0.000289932,0.00024622725,0.001037067,0.00028151888],"domain_scores_gemma":[0.99890846,0.000071680646,0.00022651973,0.0000762639,0.00060989533,0.000107151915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033131492,0.00013656414,0.00022951922,0.0005077847,0.000076351454,0.00007588229,0.00023684774,0.000029038301,0.000012982295],"category_scores_gemma":[0.0000370705,0.0000823304,0.00008085076,0.0004936668,0.0001620395,0.00025997387,0.00003669453,0.0000989482,0.000002588637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009853005,0.00067615754,0.88671964,0.00004527875,0.00042105225,0.0013368166,0.0035939603,0.0019104924,0.067238234,0.000022690489,0.00028586166,0.027896808],"study_design_scores_gemma":[0.014638253,0.0045968452,0.7080176,0.00076045137,0.000023020051,0.000032896143,0.00081739726,0.00039598413,0.2689212,0.00015755741,0.0014478535,0.00019097915],"about_ca_topic_score_codex":0.00006568595,"about_ca_topic_score_gemma":0.000024525092,"teacher_disagreement_score":0.20168296,"about_ca_system_score_codex":0.00028537496,"about_ca_system_score_gemma":0.00035074266,"threshold_uncertainty_score":0.33573362},"labels":[],"label_agreement":null},{"id":"W4388495240","doi":"10.1136/ijgc-2023-igcs.6","title":"PO006LBA/#1520  Selinexor maintenance for patients with TP53WT advanced or recurrent endometrial cancer: long-term follow up of efficacy and safety subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Placebo; Endometrial cancer; Internal medicine; Medicine; Nausea; Vomiting; Adverse effect; Neutropenia; Tolerability; Oncology; Cancer; Chemotherapy; Pathology","score_opus":0.04446913692738484,"score_gpt":0.3860501588021604,"score_spread":0.34158102187477557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388495240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945883,0.0007244593,0.000077901255,0.0011804254,0.0013670535,0.0014963639,0.0005351236,0.00001036612,0.000019974177],"genre_scores_gemma":[0.9957616,0.0030950245,0.00011280372,0.00007207675,0.00021655533,0.00014369455,0.000045945257,0.000017058417,0.00053528865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724954,0.00011431917,0.00087400584,0.000301896,0.0011514024,0.00030882936],"domain_scores_gemma":[0.99544317,0.0013703887,0.00085822714,0.0001800091,0.0019971335,0.0001510714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005477533,0.00021004927,0.0008455449,0.0005428906,0.0000787264,0.000020830896,0.00041972272,0.000076532866,0.00035327635],"category_scores_gemma":[0.001476194,0.00010026176,0.0003554058,0.0012746662,0.00019108824,0.00011869316,0.00014293443,0.00027750796,4.6035447e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056424778,0.001488653,0.8710563,0.000060928625,0.005923471,0.00006391596,0.00038922223,0.00047617796,0.00036973777,0.000016371801,0.00024462424,0.06348581],"study_design_scores_gemma":[0.037172865,0.005218555,0.9542973,0.00030230597,0.0015087979,0.0000049719515,0.00017238913,0.0001374059,0.00051400386,0.000012560462,0.00054483983,0.00011397837],"about_ca_topic_score_codex":0.00005826132,"about_ca_topic_score_gemma":0.0005667025,"teacher_disagreement_score":0.08324102,"about_ca_system_score_codex":0.00054297596,"about_ca_system_score_gemma":0.00043456012,"threshold_uncertainty_score":0.4088556},"labels":[],"label_agreement":null},{"id":"W4388577100","doi":"10.1016/s0167-8140(23)89998-4","title":"114 Stereotactic Body Radiation Therapy (SBRT) and Hypo-Fractionated Radiation Therapy (HFRT) Outcomes for Low and Intermediate-Risk Prostate Cancer (PRCA): Experience at Two Ontario Centres","year":2023,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Radiology; Oncology; Cancer; Internal medicine","score_opus":0.02537860592520599,"score_gpt":0.36598629743685906,"score_spread":0.3406076915116531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388577100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97644746,0.01824962,0.000011985857,0.0027185215,0.00046076224,0.0019334516,0.000055893,0.00008881323,0.000033510467],"genre_scores_gemma":[0.73253727,0.26289782,0.00006316231,0.0007499515,0.00019364669,0.0006739691,0.00013809325,0.000040243183,0.002705868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834824,0.00014753666,0.0003331287,0.0005140839,0.00019862718,0.0004583943],"domain_scores_gemma":[0.9986948,0.0006242171,0.00021858317,0.00017287165,0.000085854605,0.00020368103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002957848,0.0002789515,0.0005155259,0.00024585443,0.0003517681,0.0000624531,0.0000607399,0.00016289043,0.00020113586],"category_scores_gemma":[0.000047103807,0.00020206664,0.00006929561,0.00020489236,0.0002434619,0.00024975973,0.00002461136,0.00021936363,0.0000030201534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051779966,0.00014413403,0.70268,0.000038693182,0.00039971012,0.000024154413,0.012510957,0.0000050650115,0.0036920472,0.000011245217,0.0006697364,0.27464625],"study_design_scores_gemma":[0.023424443,0.0022935627,0.86830395,0.00003155081,0.000047255235,0.000037110734,0.0002798422,0.0013419572,0.0023393699,0.00010957809,0.10156207,0.00022928641],"about_ca_topic_score_codex":0.0032103185,"about_ca_topic_score_gemma":0.0038043046,"teacher_disagreement_score":0.27441695,"about_ca_system_score_codex":0.0013897378,"about_ca_system_score_gemma":0.00033987602,"threshold_uncertainty_score":0.8240039},"labels":[],"label_agreement":null},{"id":"W4388600581","doi":"10.1093/eurheartj/ehad655.2677","title":"Androgen deprivation therapy for prostate cancer, measures of adiposity and strength, and adverse cardiovascular outcomes: observations from 3000 men in 5 countries in the RADICAL PC study","year":2023,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of British Columbia; Population Health Research Institute; Université Laval; Université de Montréal; Jewish General Hospital","funders":"Prostate Cancer Canada","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Adverse effect; Internal medicine; Myocardial infarction; Stroke (engine); Weight change; Hazard ratio; Weight loss; Physical therapy; Cardiology; Obesity; Cancer; Confidence interval","score_opus":0.11962518695451932,"score_gpt":0.35044877169190564,"score_spread":0.23082358473738632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388600581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99056536,0.0062899846,0.0000042709457,0.0020018276,0.00003092846,0.001034789,0.000043608547,0.000008872341,0.000020368238],"genre_scores_gemma":[0.99067587,0.009017998,0.000054172782,0.00008776956,0.00006219804,0.000035947596,0.000017284961,0.000013546452,0.00003520093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870986,0.00039281684,0.00023239359,0.00014875767,0.00035386227,0.0001623376],"domain_scores_gemma":[0.99951124,0.00017391235,0.000043124215,0.00013544544,0.000074785814,0.00006149594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016563188,0.00008963734,0.0002616907,0.00012464603,0.0001277739,0.000029087207,0.000059604663,0.000017649614,0.0000046074356],"category_scores_gemma":[0.0000885861,0.00005401701,0.00006416614,0.00020868135,0.00007509647,0.000091399794,0.000024629913,0.000183854,6.305956e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041226565,0.00012651649,0.98834956,0.00001642821,0.00034222912,0.000087041204,0.0060560866,0.000038705064,0.00021158664,0.0000022728289,0.00031156174,0.0040457766],"study_design_scores_gemma":[0.0068755276,0.0003400638,0.98719877,0.00007587139,0.000071851384,0.000013913544,0.0017226674,0.00007925549,0.00012787078,0.00003605735,0.0034083938,0.0000497295],"about_ca_topic_score_codex":0.00032049415,"about_ca_topic_score_gemma":0.00013265182,"teacher_disagreement_score":0.006463262,"about_ca_system_score_codex":0.000047573758,"about_ca_system_score_gemma":0.00010417731,"threshold_uncertainty_score":0.22027497},"labels":[],"label_agreement":null},{"id":"W4388600728","doi":"10.1038/s41416-023-02492-8","title":"Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN","year":2023,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development; European Society for Medical Oncology","keywords":"Medicine; Hazard ratio; Prostate cancer; Internal medicine; Enzalutamide; Proportional hazards model; Post-hoc analysis; Androgen deprivation therapy; Placebo; Antiandrogen; Oncology; Confidence interval; Cancer; Pathology; Androgen receptor","score_opus":0.027072574063498757,"score_gpt":0.39766135972430433,"score_spread":0.37058878566080555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388600728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94598114,0.05195445,0.0000024969875,0.0008877049,0.00022126385,0.0007783991,0.00013408605,0.000012827518,0.000027611557],"genre_scores_gemma":[0.7975895,0.20161568,0.00011190448,0.00011691654,0.00017775754,0.000039589777,0.000020370899,0.00002631335,0.0003019874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983362,0.00009663386,0.00062088197,0.0002595254,0.00038253135,0.00030421946],"domain_scores_gemma":[0.99884516,0.00030063005,0.00024166096,0.00007790039,0.00030815694,0.00022649804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004620698,0.00014878926,0.00070503994,0.00012012418,0.00009261804,0.000040047697,0.0000512463,0.000054593816,0.000049404778],"category_scores_gemma":[0.00018504518,0.00011438797,0.00006340898,0.00025012222,0.00023487014,0.00017789275,0.000043604192,0.00036163494,7.5997934e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03201673,0.00027084703,0.51827985,0.000100400015,0.0005954354,0.0010565153,0.0007084044,0.00003888074,0.00011344607,3.5487466e-7,0.00057413505,0.446245],"study_design_scores_gemma":[0.17300345,0.0006474081,0.81938386,0.0035468687,0.00021084643,0.000028397866,0.00036194624,0.00004649384,0.00017122761,0.000023995959,0.0024440766,0.00013141513],"about_ca_topic_score_codex":0.00026090344,"about_ca_topic_score_gemma":0.0011377151,"teacher_disagreement_score":0.4461136,"about_ca_system_score_codex":0.00016348594,"about_ca_system_score_gemma":0.00024346869,"threshold_uncertainty_score":0.4664606},"labels":[],"label_agreement":null},{"id":"W4388680071","doi":"","title":"Evaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasis","year":2016,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostatectomy; Classifier (UML); Lymph node metastasis; Medicine; Lymph node; Metastasis; Prostate cancer; Oncology; Internal medicine; Computer science; Artificial intelligence; Cancer","score_opus":0.045719685454848065,"score_gpt":0.32708142069744695,"score_spread":0.2813617352425989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388680071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99488765,0.00014881551,0.00008842301,0.00058748195,0.000016868662,0.0008980898,0.000016788668,0.000011578656,0.0033443028],"genre_scores_gemma":[0.99871826,0.000041239626,0.00047269402,0.000031934338,0.00001074987,0.00010756079,0.00001915798,0.000012335398,0.0005860703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985633,0.000094923256,0.00017624912,0.00018531503,0.0007852173,0.00019500816],"domain_scores_gemma":[0.99933076,0.000037854956,0.000042195195,0.00016857729,0.00034132824,0.000079265905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005497743,0.00008529201,0.00018597317,0.00015028955,0.00001411732,0.000003634291,0.000038826365,0.000037408052,0.0007385507],"category_scores_gemma":[0.000059251117,0.000037772825,0.000030679996,0.00014526711,0.000110416055,0.00006817095,0.000019600337,0.000038755345,0.000029893781],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016098078,0.00050944276,0.8822481,0.000042591968,0.00017755863,0.0000062862705,0.00009455826,0.0000025315076,0.0062539177,0.000036216243,0.00009142134,0.10892757],"study_design_scores_gemma":[0.025891887,0.00032188743,0.9605211,0.00014210722,0.00019240307,0.0000016258942,0.00003263063,0.00015173535,0.012386142,0.00011147607,0.00017808509,0.000068891335],"about_ca_topic_score_codex":0.000051897412,"about_ca_topic_score_gemma":0.000016115984,"teacher_disagreement_score":0.108858675,"about_ca_system_score_codex":0.00045829438,"about_ca_system_score_gemma":0.00050546374,"threshold_uncertainty_score":0.8086612},"labels":[],"label_agreement":null},{"id":"W4388794355","doi":"10.1038/s41416-023-02487-5","title":"Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)","year":2023,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Bristol-Myers Squibb Canada; Gateway for Cancer Research; National Cancer Institute; Celgene; Prostate Cancer Foundation","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Rash; Adverse effect; PI3K/AKT/mTOR pathway; Oncology; Cancer; Urology; Pharmacology; Gastroenterology; Clinical trial; Androgen receptor","score_opus":0.034558653523682564,"score_gpt":0.36477653629771967,"score_spread":0.3302178827740371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388794355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844245,0.013661755,0.0000021606506,0.00046493436,0.00009418967,0.0010321403,0.00017255513,0.0000131482575,0.00013463515],"genre_scores_gemma":[0.9910336,0.0073784813,0.0000749473,0.000035024477,0.00016703861,0.00016970436,0.000011460481,0.000037176855,0.001092578],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99771255,0.00011702376,0.0006829538,0.00025099932,0.00085314224,0.00038331235],"domain_scores_gemma":[0.998784,0.00007633237,0.00034801546,0.00011459019,0.00044343865,0.00023360201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051906507,0.00018442393,0.00064628164,0.00033217136,0.00008575242,0.00006810975,0.00007594135,0.000040148305,0.000056828685],"category_scores_gemma":[0.00004235306,0.00015134034,0.00005963376,0.00067946315,0.00014822544,0.00026173957,0.000037653415,0.00035009955,8.739267e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.076685034,0.045770086,0.109190956,0.0038008923,0.008062128,0.12397301,0.049375515,0.0018988369,0.12104493,0.000031847536,0.019142382,0.4410244],"study_design_scores_gemma":[0.6554853,0.029087963,0.21850595,0.012824346,0.0025072396,0.003983199,0.037995912,0.00069274683,0.031997684,0.0001405801,0.005754557,0.001024579],"about_ca_topic_score_codex":0.0057443692,"about_ca_topic_score_gemma":0.016945155,"teacher_disagreement_score":0.5788002,"about_ca_system_score_codex":0.0004287323,"about_ca_system_score_gemma":0.0015647921,"threshold_uncertainty_score":0.9455794},"labels":[],"label_agreement":null},{"id":"W4388799870","doi":"10.14740/wjon1685","title":"Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis","year":2023,"lang":"en","type":"review","venue":"World Journal of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Fakultas Kedokteran, Universitas Indonesia; Universitas Indonesia; University College London","keywords":"Olaparib; Medicine; Oncology; Hazard ratio; Internal medicine; Prostate cancer; PARP inhibitor; Adverse effect; Regimen; Meta-analysis; Cochrane Library; Confidence interval; Cancer; Poly ADP ribose polymerase; Polymerase","score_opus":0.22518533162341023,"score_gpt":0.47223811530394105,"score_spread":0.24705278368053082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388799870","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[5.672648e-7,0.9819903,0.00004823447,0.010683379,0.00006940064,0.0065400586,0.00062314165,0.000004793304,0.00004015901],"genre_scores_gemma":[0.0000067066912,0.9850027,0.00075585855,0.0003300147,0.00010231129,0.0014897648,0.00012367875,0.000033371096,0.012155591],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9962614,0.0006111681,0.0020765,0.000252681,0.0005218614,0.00027634867],"domain_scores_gemma":[0.9952836,0.0010639447,0.002486412,0.0003206736,0.0005691644,0.00027622693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023284308,0.00031857248,0.008157309,0.00082717725,0.000077816585,0.000025041421,0.00022293162,0.000064672065,0.0002161604],"category_scores_gemma":[0.0003353463,0.00014659764,0.0021922826,0.0015325852,0.00007024067,0.000051642837,0.000049070364,0.00035509275,0.000006413137],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026055778,0.00010733977,2.0291631e-7,0.6327404,0.30226597,0.00015737831,0.00018333158,0.000008031817,0.0000013816622,0.000075885626,0.046226397,0.017973125],"study_design_scores_gemma":[0.000495906,0.00093727297,0.0000013023105,0.0256725,0.63542867,0.0001317781,0.000034882723,0.0000016141867,8.2718833e-7,0.000036266112,0.33718023,0.00007878652],"about_ca_topic_score_codex":0.00006013408,"about_ca_topic_score_gemma":0.00078906876,"teacher_disagreement_score":0.6070679,"about_ca_system_score_codex":0.00056574837,"about_ca_system_score_gemma":0.0027105124,"threshold_uncertainty_score":0.59780777},"labels":[],"label_agreement":null},{"id":"W4388803204","doi":"10.1016/j.heliyon.2023.e22604","title":"Multi-omic diagnostics of prostate cancer in the presence of benign prostatic hyperplasia","year":2023,"lang":"en","type":"article","venue":"Heliyon","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation","funders":"Punjab Educational Endowment Fund; Blood Cancer UK; University of Washington","keywords":"Prostate cancer; Medicine; Lipidome; Hyperplasia; Biomarker; Prostate; Confounding; Biomarker discovery; Cancer; Prostatitis; Internal medicine; Prostatic Diseases; Omics; Benign prostatic hyperplasia (BPH); Oncology; Bioinformatics; Proteomics; Biology; Lipid metabolism","score_opus":0.04095925865536154,"score_gpt":0.35709220378273915,"score_spread":0.3161329451273776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388803204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99040276,0.0064295647,0.0000015921548,0.0015928211,0.000085414074,0.0011964261,0.00012187299,0.000020558728,0.00014897186],"genre_scores_gemma":[0.9673545,0.031084811,0.00011459442,0.000045245528,0.000026538146,0.00027959183,0.000032778462,0.000016724825,0.0010452477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988615,0.00007007513,0.00026655348,0.00017057655,0.00035975254,0.00027156502],"domain_scores_gemma":[0.9990558,0.00045793838,0.0000757754,0.00025122202,0.00011340862,0.00004586751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029173464,0.00010031953,0.00023960909,0.00015914965,0.000028016111,0.0000058872556,0.00012103839,0.000045531357,0.000034146287],"category_scores_gemma":[0.00035745685,0.000060636346,0.000047029203,0.0006461172,0.00014733929,0.00004222175,0.000043441374,0.00015454931,0.000020025313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010734637,0.0008374694,0.8952823,0.00631805,0.00012339195,0.00034429197,0.024004517,0.00053466845,0.056162607,0.000115898925,0.0021619522,0.013041355],"study_design_scores_gemma":[0.006147647,0.0008135411,0.90671825,0.0036244607,0.000115791016,0.000017005103,0.0037699575,0.0020065682,0.07484974,0.00007624228,0.0016878025,0.0001729796],"about_ca_topic_score_codex":0.00009806775,"about_ca_topic_score_gemma":0.00018537801,"teacher_disagreement_score":0.024655247,"about_ca_system_score_codex":0.000048955993,"about_ca_system_score_gemma":0.00021919444,"threshold_uncertainty_score":0.24726784},"labels":[],"label_agreement":null},{"id":"W4389022891","doi":"10.1096/fasebj.31.1_supplement.669.18","title":"Steroid Metabolism in Human Prostate Cancer Tissue: Effect of CYP17 Inhibitors","year":2017,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Prostate cancer; Prostate; Testosterone (patch); Dihydrotestosterone; Medicine; CYP17A1; Prostatectomy; Androgen deprivation therapy; Internal medicine; Endocrinology; Cancer research; Chemistry; Cancer; Pharmacology; Androgen; Hormone; Biochemistry; Enzyme","score_opus":0.023586008464454158,"score_gpt":0.36289344242534727,"score_spread":0.33930743396089313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389022891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992113,0.004229472,7.8377974e-7,0.0017835124,0.00029914602,0.00047056668,0.000012253224,0.000006096194,0.0010851937],"genre_scores_gemma":[0.9952454,0.0010883736,0.000010896489,0.000025356832,0.0004071796,0.000027963571,0.0000030969134,0.000017009792,0.003174739],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99882853,0.00013925442,0.00025611126,0.00011326783,0.0003694224,0.00029340162],"domain_scores_gemma":[0.9991704,0.00004177766,0.00023914097,0.00034827166,0.000077974684,0.00012243816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000899367,0.00012708799,0.00034516415,0.0001135887,0.00039895365,0.00007446109,0.00024171956,0.000043814278,0.00014705084],"category_scores_gemma":[0.00005844046,0.00006308912,0.00008777783,0.000062162624,0.00023339991,0.0001399416,0.00007569088,0.0004597204,0.0000076888955],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013883547,0.000071201895,0.157876,0.00010840977,0.00016073117,0.00019183967,0.0011183204,0.00000720009,0.81388855,0.00001234414,0.0007422906,0.024434762],"study_design_scores_gemma":[0.006601291,0.00070234825,0.13737376,0.0003916848,0.000117843476,0.00007588715,0.00006733967,0.0000063574735,0.853518,0.00009726854,0.00097278535,0.00007542079],"about_ca_topic_score_codex":0.00040249992,"about_ca_topic_score_gemma":0.000069528,"teacher_disagreement_score":0.03962946,"about_ca_system_score_codex":0.00009878401,"about_ca_system_score_gemma":0.00012356583,"threshold_uncertainty_score":0.30684692},"labels":[],"label_agreement":null},{"id":"W4389240136","doi":"10.1158/2326-6074.tumimm23-a025","title":"Abstract A025: Combination of anti-CTLA4 and radiation induce synergistic tumor control in radiorecurrent prostate cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Tramp; Immune system; Cancer; Immunotherapy; Cancer research; Radiation therapy; Immune checkpoint; Oncology; Immunology; Internal medicine","score_opus":0.05905890052005738,"score_gpt":0.4087926179580436,"score_spread":0.34973371743798626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389240136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96642745,0.027180728,0.0000011073062,0.004412919,0.00029773018,0.0013518548,0.00009530823,0.000039009625,0.00019386811],"genre_scores_gemma":[0.9692524,0.029043218,0.0000025380652,0.000033408396,0.000068331865,0.0009394245,0.00008354011,0.000026866719,0.00055028195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781066,0.0002335511,0.00037350334,0.00040102136,0.00048953557,0.00069174176],"domain_scores_gemma":[0.99870694,0.0003787235,0.000099565405,0.00024999125,0.00045887887,0.0001058747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011454736,0.00015511726,0.00044966952,0.0009817625,0.00012610719,0.000023573011,0.00013939358,0.00014255384,0.00013873885],"category_scores_gemma":[0.00027708517,0.00013139598,0.00004391761,0.0013215147,0.00063792296,0.00013050779,0.00008179831,0.00085901807,0.000024244611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002972513,0.00048595946,0.4905991,0.0009363049,0.0004539511,0.0002775345,0.0018505276,0.00008180117,0.3764082,0.00035532657,0.0025128908,0.12306591],"study_design_scores_gemma":[0.009428162,0.0005177328,0.9586018,0.0005138986,0.00003239259,0.0000069726143,0.00045821586,0.0008812485,0.02794435,0.0002398309,0.0012451299,0.00013030897],"about_ca_topic_score_codex":0.001621219,"about_ca_topic_score_gemma":0.00010051639,"teacher_disagreement_score":0.46800268,"about_ca_system_score_codex":0.0006065254,"about_ca_system_score_gemma":0.0010513194,"threshold_uncertainty_score":0.53581727},"labels":[],"label_agreement":null},{"id":"W4389243136","doi":"10.1016/j.eururo.2023.11.015","title":"Reply to Lin Ding, Bin Yang, and Xudong Yao’s Letter to the Editor re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094–108","year":2023,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; AstraZeneca","keywords":"Medicine; Abiraterone; Olaparib; Placebo; Internal medicine; Prostate cancer; Cancer; Pathology; Alternative medicine","score_opus":0.1495319722172449,"score_gpt":0.3815436196601418,"score_spread":0.23201164744289687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243136","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16981316,0.0013867029,0.000045218432,0.7907016,0.009778474,0.022680907,0.003644855,0.00017884329,0.0017702013],"genre_scores_gemma":[0.047288045,0.005149893,0.0010588964,0.73803496,0.06541251,0.01377251,0.010598287,0.0017356718,0.116949245],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9895595,0.0033837818,0.002161295,0.0019962979,0.0013543218,0.0015448149],"domain_scores_gemma":[0.9952743,0.0015568235,0.000873097,0.0014759577,0.00041434448,0.00040549558],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004867405,0.0010366748,0.0023071931,0.0008876886,0.00021158047,0.00025252125,0.0007505744,0.0003784931,0.00015358783],"category_scores_gemma":[0.00087936583,0.0007477967,0.00027025217,0.00079552154,0.00035880183,0.00018552478,0.0005172572,0.00317018,0.00020438874],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48549506,0.00015091398,0.000007136099,0.0001840287,0.0004647708,0.0026964236,0.0011056551,0.0004593962,0.0013745584,9.129529e-7,0.50782615,0.00023499805],"study_design_scores_gemma":[0.46499133,0.0053229257,0.00014321135,0.0002590089,0.00035607076,0.000012865539,0.000053133568,0.00013757736,0.00018900083,0.0000019415352,0.52810735,0.00042560953],"about_ca_topic_score_codex":0.0030502575,"about_ca_topic_score_gemma":0.0032899727,"teacher_disagreement_score":0.12252511,"about_ca_system_score_codex":0.0006997667,"about_ca_system_score_gemma":0.0010830614,"threshold_uncertainty_score":0.9994973},"labels":[],"label_agreement":null},{"id":"W4389244749","doi":"10.1158/2326-6074.tumimm23-a027","title":"Abstract A027: Exploring autoantibody response to proteins encoded by prostate cancer driver genes","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"KEGG; Prostate cancer; Gene; Cancer; Biology; Computational biology; Autoantibody; Immunogenicity; Candidate gene; Genetics; Immune system; Transcriptome; Antibody; Gene expression","score_opus":0.15501005347750768,"score_gpt":0.44437593238393897,"score_spread":0.2893658789064313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389244749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9540369,0.017213026,0.0000027414621,0.024067158,0.00051731995,0.0030302007,0.00025548134,0.00034439567,0.0005327992],"genre_scores_gemma":[0.87664384,0.041956272,0.00006785013,0.00016986468,0.00032492075,0.013499122,0.00014540581,0.00014307692,0.06704966],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99502784,0.00043528693,0.00042751027,0.000969811,0.0011078718,0.0020316737],"domain_scores_gemma":[0.99742967,0.00039848397,0.000064334745,0.00081760157,0.0008428658,0.00044702884],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002071857,0.0003401231,0.00054918573,0.0011834833,0.00062072463,0.00009003541,0.000510598,0.00024060822,0.0012623136],"category_scores_gemma":[0.00036597074,0.00028007795,0.00012897258,0.0026429077,0.0006764468,0.00026955715,0.00051838584,0.0012367455,0.0013385791],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012759867,0.00016388259,0.019667946,0.00018719645,0.00048683365,0.00051243877,0.0025303136,0.00003049066,0.88636404,0.000013405503,0.025096074,0.052187525],"study_design_scores_gemma":[0.0047738515,0.0013971821,0.22446294,0.0007255016,0.000039775125,0.000016997728,0.0017113949,0.000057695783,0.5328733,0.00006781135,0.23343469,0.00043886644],"about_ca_topic_score_codex":0.002267885,"about_ca_topic_score_gemma":0.00011971766,"teacher_disagreement_score":0.35349074,"about_ca_system_score_codex":0.0013084452,"about_ca_system_score_gemma":0.0021561407,"threshold_uncertainty_score":0.99996513},"labels":[],"label_agreement":null},{"id":"W4389306433","doi":"10.1038/s41556-023-01274-x","title":"Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment","year":2023,"lang":"en","type":"article","venue":"Nature Cell Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; University of Toronto","funders":"DOD Prostate Cancer Research Program; Clinical and Translational Science Institute, University of California, Los Angeles; Jonsson Comprehensive Cancer Center; National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; Stop Cancer; Cancer Research Coordinating Committee; Fonds Wetenschappelijk Onderzoek; National Cancer Institute; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles; Fonds pour la Formation à la Recherche dans l’Industrie et dans l’Agriculture; U.S. Department of Health and Human Services; National Institutes of Health; Prostate Cancer Foundation; Fonds De La Recherche Scientifique - FNRS; U.S. Department of Defense","keywords":"Prostate; Biology; Lineage (genetic); Prostate cancer; Cell biology; Chromatin; Epigenetics; Transcription factor; Cancer research; Endocrinology; Biochemistry; Gene; Genetics; Cancer","score_opus":0.017362891140109568,"score_gpt":0.3151947303963084,"score_spread":0.2978318392561988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389306433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880651,0.0072001256,0.0000057506836,0.0030544568,0.00035798806,0.000738382,0.00015165714,0.0000855242,0.00034099497],"genre_scores_gemma":[0.9850152,0.0048670233,0.0001190492,0.00017007762,0.0002716622,0.0000777674,0.0005060087,0.000021316742,0.008951899],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99883866,0.00012352577,0.00014818471,0.00040270537,0.00012570687,0.00036120575],"domain_scores_gemma":[0.99937046,0.00011988159,0.000038441554,0.00021302617,0.00007266659,0.00018550936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019771473,0.00017485449,0.00029801577,0.00023087833,0.00008979381,0.000017763123,0.00005415069,0.00028042117,0.000054987897],"category_scores_gemma":[0.000039991726,0.00011386686,0.0000665621,0.00036656347,0.00006706259,0.00002527002,0.00005886911,0.00023972797,0.00013745531],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011440239,0.00026089782,0.023609424,0.0000589625,0.00019489936,0.000283969,0.0018226339,0.0000018230278,0.9386935,0.000076524375,0.0047959327,0.018761188],"study_design_scores_gemma":[0.0052557513,0.0018343473,0.20291299,0.000024912646,0.00010811851,0.000021897731,0.0001997426,0.00005944587,0.32464892,0.00004403842,0.46470007,0.00018976389],"about_ca_topic_score_codex":0.000013254314,"about_ca_topic_score_gemma":0.000007690421,"teacher_disagreement_score":0.6140446,"about_ca_system_score_codex":0.00012873975,"about_ca_system_score_gemma":0.000084474006,"threshold_uncertainty_score":0.4643356},"labels":[],"label_agreement":null},{"id":"W4389307256","doi":"10.3390/curroncol30120751","title":"Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"West China Hospital, Sichuan University; Sichuan University; National Key Research and Development Program of China; Jiangsu Development and Reform Commission; National Natural Science Foundation of China","keywords":"Olaparib; Medicine; PARP inhibitor; Prostate cancer; Oncology; Internal medicine; Taxane; Clinical trial; Placebo; BRCA mutation; Poly ADP ribose polymerase; Cancer; Polymerase; Ovarian cancer; Breast cancer; Pathology; Biology","score_opus":0.381377987920487,"score_gpt":0.5228773061164178,"score_spread":0.1414993181959308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389307256","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035699157,0.9906647,0.000104535946,0.001420659,0.0011239852,0.005232459,0.0009494337,0.00012421285,0.000022996674],"genre_scores_gemma":[0.00018397489,0.9896776,0.00060872786,0.000034220717,0.00082183874,0.0065676994,0.0009065543,0.00015629579,0.0010430743],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964703,0.00019224848,0.00097421394,0.000862711,0.00059261307,0.00090791535],"domain_scores_gemma":[0.99711615,0.0011251278,0.0006729287,0.00037330802,0.00038655385,0.00032591875],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005959073,0.00069124805,0.0023648185,0.0005175344,0.00030769437,0.00007596242,0.00023971751,0.0001804073,0.000048410697],"category_scores_gemma":[0.00016698288,0.00044771924,0.00044282773,0.00078526704,0.00032242676,0.00016471696,0.00010382068,0.00075095275,0.000021378853],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016281868,0.0006230377,0.00006769242,0.034700237,0.0018452727,0.00018426504,0.0010226713,7.903324e-7,0.00013490913,0.000111370944,0.0016676374,0.95801395],"study_design_scores_gemma":[0.0051232227,0.003682388,0.00003389652,0.05321076,0.004251728,0.00012665981,0.00047378594,0.000054209035,0.000045930374,0.000025973788,0.9324271,0.0005443296],"about_ca_topic_score_codex":0.00012689884,"about_ca_topic_score_gemma":0.00016728646,"teacher_disagreement_score":0.9574696,"about_ca_system_score_codex":0.0011775518,"about_ca_system_score_gemma":0.0065654623,"threshold_uncertainty_score":0.99979746},"labels":[],"label_agreement":null},{"id":"W4389328383","doi":"10.1016/j.annonc.2023.11.017","title":"Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Janssen Pharmaceuticals; National Cancer Institute; Genentech; Ipsen; European Society for Medical Oncology; Cilag; Sanofi Australia; Astellas Pharma; European School of Oncology; Advanced Accelerator Applications; Daiichi Sankyo Europe; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Sanofi; Exelixis; Prostate Cancer Foundation; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; AstraZeneca; Astellas Pharma US; Takeda Oncology; Amgen; Pfizer","keywords":"Medicine; Docetaxel; Prostate cancer; Oncology; Clinical endpoint; Internal medicine; Surrogate endpoint; Cancer; Metastasis; Prostate; Survival analysis; Clinical trial; Urology","score_opus":0.13930166921387518,"score_gpt":0.4525994068801056,"score_spread":0.31329773766623037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389328383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97426647,0.0012684559,0.0000118945145,0.018004555,0.00020580609,0.0036550832,0.002347178,0.00001220404,0.00022835698],"genre_scores_gemma":[0.99182427,0.0049683377,0.00019507225,0.000137043,0.000055354158,0.0019951367,0.0003512772,0.000029005612,0.00044451596],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99755764,0.00031459375,0.0008552154,0.00031929652,0.00044943285,0.0005038283],"domain_scores_gemma":[0.99755967,0.0008976762,0.000424684,0.00030910733,0.000741906,0.00006697034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025301187,0.00019049596,0.0008586319,0.0002808773,0.000041113326,0.000008721349,0.00020813289,0.000113531074,0.000053385324],"category_scores_gemma":[0.0004485968,0.00013309442,0.00019361182,0.000624142,0.0002123264,0.00010985078,0.000055240285,0.0001844454,8.286508e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25804627,0.00793108,0.15395431,0.014258184,0.004337089,0.00045040128,0.04946206,0.011805091,0.30969802,0.014520738,0.014005106,0.16153166],"study_design_scores_gemma":[0.09180528,0.021175519,0.21116793,0.001546046,0.0007175532,0.000009360727,0.008084083,0.0022062873,0.615335,0.024236284,0.023006804,0.0007098846],"about_ca_topic_score_codex":0.0060930396,"about_ca_topic_score_gemma":0.008573607,"teacher_disagreement_score":0.30563694,"about_ca_system_score_codex":0.00013377846,"about_ca_system_score_gemma":0.0015722963,"threshold_uncertainty_score":0.92108935},"labels":[],"label_agreement":null},{"id":"W4389335664","doi":"10.1148/radiol.231407","title":"Association of PSMA PET-derived Parameters and Outcomes of Patients Treated for Oligorecurrent Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Radiology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Women's College Hospital; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"Princess Margaret Cancer Foundation; Canadian Association of Radiation Oncology","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Standardized uptake value; Nuclear medicine; Biochemical recurrence; Cohort; Retrospective cohort study; Positron emission tomography; Internal medicine; Oncology; Proportional hazards model; Cancer; Radiology; Prostatectomy","score_opus":0.02925140243558811,"score_gpt":0.3410086739506362,"score_spread":0.3117572715150481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389335664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754775,0.00023011465,0.000001538449,0.0011146044,0.000120172146,0.00073589757,0.00021341765,0.000017833016,0.000018688692],"genre_scores_gemma":[0.99708605,0.0015165544,0.00006438474,0.00002208365,0.000010737376,0.00016393175,0.0002999973,0.000009469617,0.0008268036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993528,0.00003919692,0.00018512335,0.00013211524,0.000094132665,0.00019664622],"domain_scores_gemma":[0.99942267,0.00019653996,0.0001250332,0.00007139315,0.00013958542,0.00004477263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109902445,0.000074047544,0.00034276897,0.000108826825,0.000020361998,0.0000014243724,0.000025434832,0.000046618465,0.000009208498],"category_scores_gemma":[0.0001411409,0.00005148254,0.000055725686,0.0001243808,0.000064924185,0.000017361785,0.000015261721,0.000042367563,0.0000011274665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053068163,0.00006459782,0.98942196,0.00014622924,0.0003890637,0.0000020169891,0.00036601062,0.000004473328,0.0023577902,0.000007941818,0.0013140352,0.0053951754],"study_design_scores_gemma":[0.004723797,0.0007996021,0.9849259,0.000026118018,0.0001262439,7.0949187e-7,0.000048156504,0.00020984141,0.008779873,0.000057021938,0.00025643548,0.000046268393],"about_ca_topic_score_codex":0.00007652083,"about_ca_topic_score_gemma":0.000014202443,"teacher_disagreement_score":0.006422083,"about_ca_system_score_codex":0.000109735745,"about_ca_system_score_gemma":0.000049675178,"threshold_uncertainty_score":0.20993972},"labels":[],"label_agreement":null},{"id":"W4389506762","doi":"10.1016/j.euo.2023.11.015","title":"Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Titan (rocket family); Post-hoc analysis; Hazard ratio; Androgen deprivation therapy; Prostate-specific antigen; Oncology; Internal medicine; Proportional hazards model; Urology; Cancer; Confidence interval","score_opus":0.03240159015732779,"score_gpt":0.33411530116144855,"score_spread":0.30171371100412075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389506762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867171,0.009502734,0.0000011089388,0.0023499464,0.000052142397,0.001033584,0.00012907168,0.000032792836,0.00018148513],"genre_scores_gemma":[0.98796314,0.0110872565,0.0001467888,0.00034116948,0.0000068332965,0.000025926161,0.00035927756,0.0000307443,0.000038889957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971903,0.0007004046,0.0009872739,0.00051504245,0.00020275453,0.00040422328],"domain_scores_gemma":[0.9984122,0.00021458586,0.0006171824,0.00023963925,0.0002831303,0.00023325616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006898709,0.00019366654,0.0010284588,0.0006290114,0.000066554705,0.0000049004525,0.000054052543,0.00008336643,0.000033422053],"category_scores_gemma":[0.00014443256,0.00014668643,0.00004016099,0.0010117317,0.000649762,0.00005907481,0.0001433558,0.00022797535,0.0000013568317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013583195,0.0003353205,0.9096872,0.00011019854,0.0008046687,0.0001862987,0.003682181,0.000055337157,0.00087954244,0.000009512298,0.000039295363,0.07062723],"study_design_scores_gemma":[0.010283051,0.010359888,0.9773641,0.000027619477,0.00016862573,0.000006547046,0.00042133074,0.00011126713,0.000025154357,0.000011843459,0.0011063386,0.00011423742],"about_ca_topic_score_codex":0.0003051976,"about_ca_topic_score_gemma":0.0009963745,"teacher_disagreement_score":0.07051299,"about_ca_system_score_codex":0.00006876656,"about_ca_system_score_gemma":0.00022284708,"threshold_uncertainty_score":0.5981699},"labels":[],"label_agreement":null},{"id":"W4389951586","doi":"10.5489/cuaj.8688","title":"2023 European Society for Medical Oncology (ESMO) Congress","year":2023,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal; University of Calgary; University of Ottawa; Prevention of Organ Failure; Ottawa Hospital; University of British Columbia","funders":"Daiichi Sankyo Europe; EMD Serono; Ipsen; Astellas Pharma; Seagen; Gilead Sciences; Eisai; Sanofi; AstraZeneca; Pfizer","keywords":"Medicine; Oncology; Internal medicine; Political science; Family medicine","score_opus":0.0378433144790374,"score_gpt":0.3327518511399191,"score_spread":0.29490853666088174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389951586","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40296516,0.00070418214,0.000107881584,0.56050783,0.0025716492,0.00090625935,0.00023282792,0.00019083565,0.031813353],"genre_scores_gemma":[0.9376377,0.0018478372,0.000282846,0.02031508,0.0031792119,0.000067191766,0.0004089698,0.000048512695,0.036212686],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99809176,0.0001912616,0.00028608285,0.00018876632,0.00052146596,0.0007206572],"domain_scores_gemma":[0.9977635,0.0004403884,0.00012265694,0.000076463286,0.00034149006,0.0012554768],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026135866,0.00010619844,0.00025521248,0.00013482888,0.00040037133,0.00005522181,0.0001492972,0.0003066243,0.0013544804],"category_scores_gemma":[0.0016625976,0.00007739331,0.00031040117,0.00033073834,0.00007337573,0.000046698195,0.000027792672,0.00068226445,0.00040860596],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115949624,0.000053333657,0.13810505,0.0000119880615,0.00040659565,0.0009296613,0.00017064129,0.000006141904,0.00005442959,0.00015040717,0.838946,0.02104979],"study_design_scores_gemma":[0.0030537148,0.00061849604,0.19239463,0.000015357882,0.0000658363,0.00016426016,0.00015544059,0.00058302435,0.000011341396,0.00043499243,0.8024105,0.00009245594],"about_ca_topic_score_codex":0.00021564709,"about_ca_topic_score_gemma":0.000458513,"teacher_disagreement_score":0.5401928,"about_ca_system_score_codex":0.0015488451,"about_ca_system_score_gemma":0.0018425918,"threshold_uncertainty_score":0.9995584},"labels":[],"label_agreement":null},{"id":"W4390051577","doi":"10.2217/fon-2023-0649","title":"Prostate-Specific Antigen (PSA) Decline with Apalutamide Therapy is Associated with Longer Survival and Improved Outcomes in Individuals with Metastatic Prostate Cancer: A Plain Language Summary of the TITAN Study","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Placebo; Prostate cancer; Androgen deprivation therapy; Prostate-specific antigen; Internal medicine; Oncology; Prostatectomy; Post-hoc analysis; Urology; Cancer; Pathology","score_opus":0.027742835420446907,"score_gpt":0.3413039054678971,"score_spread":0.31356107004745015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390051577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98768866,0.0019304148,5.100688e-7,0.005713557,0.00009156568,0.0040295925,0.00035078812,0.0000561421,0.00013879502],"genre_scores_gemma":[0.99488443,0.0017832523,0.00013641943,0.0002693895,0.0000584728,0.0005455986,0.00015015283,0.00006583731,0.0021064754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779737,0.00030332358,0.00034214588,0.00046673228,0.00055713416,0.000533321],"domain_scores_gemma":[0.99883425,0.00028148037,0.00025309192,0.00034951366,0.00016909152,0.00011259388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073050836,0.00031472094,0.00089799945,0.00024519884,0.00010878841,0.000025095322,0.0001634766,0.000100327044,0.000039347236],"category_scores_gemma":[0.000024767602,0.00014181655,0.00004405745,0.0011545588,0.00031511454,0.000079732,0.000096693766,0.0004089192,0.0000015646663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005566367,0.0009829163,0.9657058,0.00006391756,0.001451208,0.0006227362,0.019913092,0.0000066998014,0.0012686088,0.000006239917,0.00030723735,0.004105177],"study_design_scores_gemma":[0.024085362,0.0084048,0.9431115,0.00018499586,0.00016394086,0.000016036069,0.021819126,0.000020935133,0.00079814036,0.000015281863,0.0011810681,0.00019885115],"about_ca_topic_score_codex":0.000571465,"about_ca_topic_score_gemma":0.010489514,"teacher_disagreement_score":0.022594336,"about_ca_system_score_codex":0.00023935578,"about_ca_system_score_gemma":0.0006372387,"threshold_uncertainty_score":0.5853395},"labels":[],"label_agreement":null},{"id":"W4390069932","doi":"10.21037/cco-23-87","title":"Triplet therapy for metastatic hormone sensitive prostate cancer—looking beyond volume of disease","year":2023,"lang":"en","type":"editorial","venue":"Chinese Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Disease; Hormone therapy; Oncology; Cancer; Prostate; Hormone; Volume (thermodynamics); Internal medicine; Breast cancer","score_opus":0.0631983416209183,"score_gpt":0.4781362510231089,"score_spread":0.4149379094021906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390069932","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.090765916,0.012214019,0.00003554664,0.007670899,0.8739718,0.006231566,0.008703658,0.00017895976,0.00022764804],"genre_scores_gemma":[0.01181086,0.09311993,0.00059453625,0.0005458472,0.84803957,0.0029666123,0.010979685,0.00040069985,0.031542253],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951435,0.00050490524,0.0017171741,0.0010277475,0.00084413396,0.0007625911],"domain_scores_gemma":[0.9834765,0.012834513,0.00095291884,0.0005977456,0.0014318737,0.0007064474],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023195972,0.00057814736,0.0031911314,0.0002966434,0.00012359445,0.000019341172,0.0002726955,0.00089027314,0.000053010106],"category_scores_gemma":[0.011610542,0.0003789792,0.0010329313,0.00051711284,0.00079929305,0.000069301306,0.00017695167,0.0015001138,0.00003732008],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053934474,0.001457319,0.0027430397,0.00080369535,0.0024567863,0.000612968,0.00029333198,0.000006820232,0.00008398569,0.0000047663634,0.90385145,0.03375135],"study_design_scores_gemma":[0.037582386,0.014922935,0.012080666,0.00040867267,0.0017037083,0.000001856811,0.0000798363,0.00046748345,0.000023911081,0.0011620804,0.93109477,0.00047170537],"about_ca_topic_score_codex":0.00017257378,"about_ca_topic_score_gemma":0.00009391435,"teacher_disagreement_score":0.08090591,"about_ca_system_score_codex":0.0005165794,"about_ca_system_score_gemma":0.0073563177,"threshold_uncertainty_score":0.9998662},"labels":[],"label_agreement":null},{"id":"W4390106584","doi":"10.5489/cuaj.8537","title":"Addressing controversial areas in the management of advanced prostate cancer in Canada","year":2023,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Queen's University; Vancouver General Hospital; University of Calgary; Princess Margaret Cancer Centre; London Health Sciences Centre; University of Toronto; Western University; University of Alberta; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Jewish General Hospital; Kingston Health Sciences Centre; McGill University; University of Ottawa; Ottawa Hospital; BC Cancer Agency; McMaster University; St. Joseph’s Healthcare Hamilton; Juravinski Cancer Centre; University of British Columbia; Université Laval; Centre Hospitalier de l’Université de Montréal","funders":"Ipsen; Sun Pharma; Seagen; EMD Serono; Bavarian Nordic; Eisai; Daiichi Sankyo Europe; Sanofi; AstraZeneca; Amgen; Pfizer; Astellas Pharma; F. Hoffmann-La Roche","keywords":"Prostate cancer; Medicine; Consensus conference; Management of prostate cancer; Family medicine; Gynecology; Oncology; Cancer; Medical physics; Internal medicine","score_opus":0.02977685283423935,"score_gpt":0.30208608802205394,"score_spread":0.2723092351878146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390106584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96060187,0.00047341626,2.2426414e-7,0.036934003,0.0001531387,0.0003391249,0.000055353346,0.0000037270788,0.0014391309],"genre_scores_gemma":[0.99773246,0.00083154574,0.000008320402,0.0009048141,0.000051727508,0.000033297303,0.00001514578,0.0000045483393,0.00041812073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987112,0.00010788362,0.00022876017,0.000104049635,0.00040696314,0.00044109905],"domain_scores_gemma":[0.99948406,0.00009874245,0.000106912536,0.000057394434,0.000080348545,0.00017255382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005465206,0.00006971804,0.00017498406,0.00016368029,0.00007578339,0.000018659837,0.000095825766,0.000047743415,0.00012420036],"category_scores_gemma":[0.00007014195,0.00004518916,0.000036564237,0.0005506752,0.000016801028,0.00004551599,0.000010515101,0.00035382278,0.00000268125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019671585,0.00001707711,0.976673,0.00001916868,0.00007537251,0.0013318189,0.00030536065,0.0008379717,0.000026362275,0.00004059942,0.0035885572,0.016887974],"study_design_scores_gemma":[0.0025120103,0.000059593804,0.98879814,0.00007905708,0.00002043199,0.000009351507,0.001559393,0.00019092784,0.000011196766,0.00014554024,0.0065677394,0.000046640638],"about_ca_topic_score_codex":0.5649735,"about_ca_topic_score_gemma":0.88591206,"teacher_disagreement_score":0.32093856,"about_ca_system_score_codex":0.003896461,"about_ca_system_score_gemma":0.0020982346,"threshold_uncertainty_score":0.9999274},"labels":[],"label_agreement":null},{"id":"W4390126628","doi":"10.1016/j.jval.2023.09.207","title":"CO135 A Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of Pharmaceutical Interventions for First-Line (1L) Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer (MCRPC)","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Prostate cancer; Asymptomatic; Oncology; Internal medicine; First line; Psychological intervention; Cancer; Psychiatry","score_opus":0.17517301786223566,"score_gpt":0.4448476951343678,"score_spread":0.2696746772721321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390126628","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15159847,0.8071821,0.0004975607,0.013804042,0.00014281773,0.024997883,0.0016323747,0.00012774057,0.000017014481],"genre_scores_gemma":[0.8073885,0.174062,0.005109847,0.0010516376,0.000067371904,0.00969903,0.0017034666,0.00011521321,0.00080296426],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99641865,0.00047941905,0.0015152683,0.00041461398,0.0006281269,0.0005439125],"domain_scores_gemma":[0.997469,0.0008879052,0.0005836953,0.00037861604,0.00041091625,0.00026988605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019895376,0.00029545408,0.002455632,0.00047898386,0.00014628083,0.00004120448,0.00010017589,0.000046647478,0.000051898296],"category_scores_gemma":[0.00028803,0.00017919474,0.0006049527,0.0028101988,0.00008822724,0.00011346132,0.000038634094,0.00019971924,0.0000027170106],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048426312,0.000569735,0.010014095,0.9368166,0.045404997,0.000039367078,0.0011969268,0.00435927,0.0000034591635,0.00021939658,0.0006427562,0.00024918155],"study_design_scores_gemma":[0.0150981555,0.005718106,0.030739443,0.5208408,0.3273994,0.000032170195,0.0003686877,0.09801402,0.000048166337,0.0008303624,0.0001447807,0.0007658614],"about_ca_topic_score_codex":0.00016746878,"about_ca_topic_score_gemma":0.00026539725,"teacher_disagreement_score":0.65579003,"about_ca_system_score_codex":0.00022419484,"about_ca_system_score_gemma":0.00033956498,"threshold_uncertainty_score":0.73073494},"labels":[],"label_agreement":null},{"id":"W4390127158","doi":"10.1016/j.jval.2023.09.132","title":"CO60 Predicting Treatment Effects from Surrogate Endpoints in First-Line (1L) Metastatic Castration-Resistant Prostate Cancer (MCRPC)","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Prostate cancer; Medicine; Oncology; Internal medicine; Surrogate endpoint; Cancer","score_opus":0.09172677733241291,"score_gpt":0.3858182695491741,"score_spread":0.2940914922167612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390127158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850782,0.004974001,0.0000028204845,0.0062887,0.0003033308,0.0028124365,0.0003519966,0.00011468385,0.00007383766],"genre_scores_gemma":[0.9866788,0.010603884,0.00024987813,0.000103306935,0.00011642205,0.00088367786,0.0004553476,0.000047457448,0.00086123525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972071,0.00032349516,0.0006663411,0.0005283132,0.00046047106,0.000814283],"domain_scores_gemma":[0.99845695,0.00074564014,0.00015166732,0.00029267458,0.00005461823,0.00029845975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073097285,0.00026635986,0.0006236315,0.0004153233,0.00013607989,0.000027974585,0.0000738835,0.0000595259,0.000054434964],"category_scores_gemma":[0.00016145573,0.00020525788,0.00007428568,0.0009750244,0.0000582985,0.00009741392,0.00003627155,0.00025954898,0.00005401452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046916394,0.0017710032,0.8779268,0.004975568,0.00054728147,0.00520916,0.022413163,0.027408767,0.004141051,0.000074611664,0.00048145768,0.050359495],"study_design_scores_gemma":[0.035836827,0.005829157,0.863712,0.007862076,0.00016700219,0.00001872363,0.0015077341,0.07007975,0.011554164,0.001053319,0.0018538336,0.0005254278],"about_ca_topic_score_codex":0.09496929,"about_ca_topic_score_gemma":0.017122423,"teacher_disagreement_score":0.07784686,"about_ca_system_score_codex":0.0019547052,"about_ca_system_score_gemma":0.0012579064,"threshold_uncertainty_score":0.95547146},"labels":[],"label_agreement":null},{"id":"W4390129341","doi":"10.1016/j.jval.2023.09.2917","title":"SA7 Emerging Biomarkers in Metastatic Castration Resistant Prostate Cancer As Evaluated in Early Phase Clinical Trials: A Targeted Literature Review","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVRAZ (Canada)","funders":"","keywords":"Prostate cancer; Medicine; Oncology; Clinical trial; Cancer; Internal medicine","score_opus":0.33183232689851033,"score_gpt":0.574591972933008,"score_spread":0.24275964603449768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390129341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7895887,0.181358,8.6560107e-7,0.023316951,0.00025302218,0.0052519743,0.00014749166,0.000051726714,0.000031281797],"genre_scores_gemma":[0.5002218,0.49608204,0.000261347,0.0009601673,0.0001013033,0.0010538226,0.00087105075,0.00005245841,0.00039603966],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99124026,0.0046594325,0.0022410862,0.00056377077,0.0005987878,0.00069666444],"domain_scores_gemma":[0.9982181,0.00071646593,0.00036480036,0.00028699654,0.00014014813,0.00027344975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021570655,0.000222068,0.0011788534,0.0008606986,0.000054136297,0.000032456966,0.000086642045,0.00009728129,0.00007702116],"category_scores_gemma":[0.0032955823,0.0001668535,0.00013935678,0.004092101,0.00005800189,0.00014215139,0.000027388462,0.00066642615,0.000024334118],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.064204566,0.0057548555,0.21790484,0.07814852,0.0016485917,0.019034915,0.03478369,0.0019073241,0.0078010755,0.00018931352,0.022895133,0.5457272],"study_design_scores_gemma":[0.17672512,0.016111618,0.34118447,0.3442084,0.00069576176,0.00010888834,0.00317608,0.100046925,0.0008584352,0.0028143157,0.012453447,0.001616564],"about_ca_topic_score_codex":0.009956621,"about_ca_topic_score_gemma":0.001013834,"teacher_disagreement_score":0.5441106,"about_ca_system_score_codex":0.00080378837,"about_ca_system_score_gemma":0.0027197439,"threshold_uncertainty_score":0.99663615},"labels":[],"label_agreement":null},{"id":"W4390147069","doi":"10.1016/j.euo.2023.11.024","title":"Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer","keywords":"Medicine; Testosterone (patch); Prostate cancer; Discontinuation; Urology; Internal medicine; Adverse effect; Androgen; Endocrinology; Hormone; Cancer","score_opus":0.06108210601142114,"score_gpt":0.3852625919943143,"score_spread":0.3241804859828932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390147069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679688,0.0007143315,0.0000057643056,0.01867681,0.00040890992,0.003505085,0.00028880226,0.00014566694,0.008285831],"genre_scores_gemma":[0.9912847,0.0011005632,0.00014575369,0.000834967,0.00034628875,0.0008005262,0.00047671972,0.000089554655,0.00492091],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99720234,0.0007618128,0.00045483804,0.00071350246,0.00018829397,0.00067920773],"domain_scores_gemma":[0.9974549,0.0015983746,0.00017671518,0.0005289568,0.00011340635,0.00012769383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011157464,0.00024224621,0.0005000899,0.00016469348,0.00015886495,0.000013936594,0.0002502802,0.00008096811,0.000024727882],"category_scores_gemma":[0.00043308118,0.00015015951,0.000053974465,0.0004771927,0.00027065567,0.00007431845,0.00015615547,0.00046797062,0.0001189997],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6414617,0.0030798747,0.03398021,0.00003614926,0.0011682853,0.007755734,0.013786008,0.000975011,0.0035634371,0.000012447898,0.03630903,0.25787213],"study_design_scores_gemma":[0.42778233,0.12890343,0.20516062,0.00009378384,0.00066007266,0.000057118,0.006251406,0.00061618024,0.0005247519,0.00015682721,0.22928748,0.00050601194],"about_ca_topic_score_codex":0.00028090403,"about_ca_topic_score_gemma":0.0014047943,"teacher_disagreement_score":0.25736612,"about_ca_system_score_codex":0.0002911548,"about_ca_system_score_gemma":0.00041381747,"threshold_uncertainty_score":0.6123327},"labels":[],"label_agreement":null},{"id":"W4390231963","doi":"10.1002/cncr.35173","title":"Charles Brenton Huggins: A historical review of the Nobel laureate’s pioneering discoveries","year":2023,"lang":"en","type":"review","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Université de Montréal","keywords":"Nobel laureate; Prostate cancer; Medicine; Testosterone (patch); Orchiectomy; Context (archaeology); Androgen deprivation therapy; Prostatic acid phosphatase; Androgen; Prostate; Internal medicine; Gynecology; Endocrinology; Cancer; Hormone; Biology","score_opus":0.1437514521852642,"score_gpt":0.42572230910158465,"score_spread":0.28197085691632046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390231963","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000029153296,0.99611294,0.000001041538,0.00095393567,0.0007969394,0.0014785355,0.00018135835,0.00004783302,0.00042450766],"genre_scores_gemma":[0.0000012134286,0.9676317,0.000004456474,0.00008645443,0.00037758218,0.0009822028,0.00009209016,0.00007270409,0.030751588],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983638,0.000066884,0.0004905378,0.00032113856,0.00046556853,0.00029206503],"domain_scores_gemma":[0.9989493,0.000066305336,0.00025522526,0.0005318955,0.00009904522,0.00009822339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015744857,0.00030622038,0.0016902107,0.000096180695,0.000064025706,0.000010032276,0.0002425628,0.00014002506,0.00024626998],"category_scores_gemma":[0.000099481476,0.00015340713,0.0006890653,0.00063632114,0.00009802401,0.000041443476,0.00015536822,0.00038727096,0.00004250757],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011123402,0.00003276677,0.000051301562,0.3961744,0.00035298296,0.000021231706,0.00004413241,5.5681667e-8,0.0000014158803,0.000022116632,0.039938774,0.5633497],"study_design_scores_gemma":[0.00015311745,0.000026489413,0.000026606409,0.30406746,0.0010625611,0.000009489483,0.0000027909998,2.3926356e-7,0.000006117853,0.0000035584899,0.6945416,0.00010001578],"about_ca_topic_score_codex":0.00026586428,"about_ca_topic_score_gemma":0.00002818542,"teacher_disagreement_score":0.65460277,"about_ca_system_score_codex":0.0018631484,"about_ca_system_score_gemma":0.00092541304,"threshold_uncertainty_score":0.62557614},"labels":[],"label_agreement":null},{"id":"W4390267056","doi":"10.3390/cells13010057","title":"Reduction in Nuclear Size by DHRS7 in Prostate Cancer Cells and by Estradiol Propionate in DHRS7-Depleted Cells","year":2023,"lang":"en","type":"article","venue":"Cells","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"European Research Council; Medical Research Council; Canadian Institutes of Health Research; Sigrid Juséliuksen Säätiö; Academy of Finland; Darwin Trust of Edinburgh; Wellcome Trust","keywords":"LNCaP; Prostate cancer; Prostate; Cancer research; Cancer; Grading (engineering); Cancer cell; Biology; Estrogen; Internal medicine; Endocrinology; Oncology; Medicine; Chemistry","score_opus":0.01250126032434544,"score_gpt":0.27759319873218047,"score_spread":0.265091938407835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390267056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927933,0.0025259026,1.4381273e-7,0.0021441844,0.00026181093,0.0015887914,0.0001368693,0.00007393178,0.000475062],"genre_scores_gemma":[0.9661093,0.024059681,0.00004591977,0.000110549445,0.00005783138,0.00020994557,0.000095236384,0.00007039058,0.009241173],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980511,0.00009847362,0.00037146988,0.00055419403,0.0002955311,0.00062923017],"domain_scores_gemma":[0.9994379,0.000073346484,0.00006635845,0.00021016298,0.000038664115,0.00017355762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026996626,0.00023128321,0.00037842212,0.00028999714,0.000044424825,0.000035975878,0.000092971386,0.00013934373,0.00012099147],"category_scores_gemma":[0.000015214501,0.00019969021,0.0000388479,0.0009483192,0.00014259553,0.0001347873,0.000055926794,0.00044399258,0.000098567274],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000593918,0.00027822496,0.007450134,0.00033053866,0.000023769157,0.00032215382,0.0019605306,0.00006415495,0.94644564,0.0000022894399,0.03655784,0.0059707924],"study_design_scores_gemma":[0.012395205,0.00057939306,0.01407698,0.0007966978,0.000036386195,0.000008757859,0.0017508916,0.001602776,0.93119985,0.00015002994,0.036854845,0.00054818584],"about_ca_topic_score_codex":0.0017013837,"about_ca_topic_score_gemma":0.00011541727,"teacher_disagreement_score":0.02668403,"about_ca_system_score_codex":0.0004105958,"about_ca_system_score_gemma":0.00016422289,"threshold_uncertainty_score":0.81431305},"labels":[],"label_agreement":null},{"id":"W4390405183","doi":"10.1007/s12254-023-00945-7","title":"Metastasis-directed therapy: new standard or too early to change paradigm?","year":2023,"lang":"en","type":"article","venue":"memo - Magazine of European Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"Medizinische Universität Wien","keywords":"Medicine; Clinical trial; Tolerability; Context (archaeology); Prostate cancer; Disease; Intensive care medicine; Metastasis; Oncology; Internal medicine; Cancer; Adverse effect","score_opus":0.12546084868647786,"score_gpt":0.398598524580373,"score_spread":0.27313767589389515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390405183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73776805,0.0033058242,0.00017236738,0.16131419,0.0013797282,0.0030856216,0.00013078349,0.001056329,0.09178711],"genre_scores_gemma":[0.6477082,0.03844785,0.009387287,0.041879497,0.010484231,0.00048484482,0.0009857359,0.0008212046,0.24980119],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968102,0.0004923719,0.0005343921,0.00044920458,0.0010432282,0.00067062606],"domain_scores_gemma":[0.9977744,0.00033982086,0.00010181378,0.00042711323,0.00015484217,0.0012019707],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014636288,0.0002466569,0.0008257863,0.0003816519,0.00006143551,0.0000143915695,0.00033627724,0.00012310671,0.0041957498],"category_scores_gemma":[0.0011308577,0.00015509332,0.00014110417,0.0012131744,0.0002402999,0.00006292297,0.00023347826,0.0003941949,0.0021653636],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007596496,0.00037460175,0.0014777499,0.00009238116,0.00039815815,0.0075766784,0.0014564934,4.8858976e-7,0.0017149992,0.00009164969,0.3570987,0.6221216],"study_design_scores_gemma":[0.008857179,0.010169565,0.06225742,0.00016592482,0.00010077138,0.000094072726,0.000046012177,0.00003115735,0.0012953928,0.000056329296,0.9167544,0.00017172509],"about_ca_topic_score_codex":0.000049269238,"about_ca_topic_score_gemma":0.000054705215,"teacher_disagreement_score":0.62194985,"about_ca_system_score_codex":0.00016442947,"about_ca_system_score_gemma":0.0010613046,"threshold_uncertainty_score":0.99861157},"labels":[],"label_agreement":null},{"id":"W4390451997","doi":"10.1016/j.urolonc.2023.11.022","title":"A systematic review of nanocarriers for treatment of urologic cancers","year":2023,"lang":"en","type":"review","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Natural Sciences and Engineering Research Council of Canada; Deutsche Forschungsgemeinschaft","keywords":"Medicine; Clinical trial; Prostate cancer; Bladder cancer; Cancer; Kidney cancer; Urologic disease; Intensive care medicine; Oncology; Internal medicine; Urinary system","score_opus":0.1198387692680881,"score_gpt":0.43646663794154794,"score_spread":0.3166278686734598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390451997","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000087710556,0.9917925,0.0000047098465,0.0006948227,0.00014677357,0.0065418216,0.00041206,0.000040634142,0.0002789599],"genre_scores_gemma":[0.000001403494,0.9904782,0.0031262604,0.00023045641,0.00005988772,0.0038308725,0.000493792,0.000034804452,0.0017443281],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99750495,0.00029637013,0.0011805298,0.00045637705,0.00020205157,0.00035970382],"domain_scores_gemma":[0.99695444,0.001266697,0.000978552,0.0003865871,0.00017280647,0.000240936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005707102,0.00040423797,0.0043557053,0.00033033578,0.00010656772,0.0000048449515,0.00014787134,0.00044105755,0.000027168046],"category_scores_gemma":[0.0006302856,0.00024085598,0.00059936143,0.00059898756,0.0008946,0.000028106118,0.000035767775,0.00014828498,0.000007813772],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000587319,0.000141921,0.00013347893,0.98404264,0.0013959282,0.00007152311,0.00011390946,6.268006e-7,0.0000012298929,0.0007184579,0.0014713415,0.011850194],"study_design_scores_gemma":[0.0006023192,0.0069848956,4.3055456e-7,0.25774556,0.012327237,0.00015187617,0.000050025526,0.000011336221,0.0000060755365,0.00031637136,0.7216721,0.00013176363],"about_ca_topic_score_codex":0.000049981427,"about_ca_topic_score_gemma":0.000009253703,"teacher_disagreement_score":0.7262971,"about_ca_system_score_codex":0.000666917,"about_ca_system_score_gemma":0.0030052299,"threshold_uncertainty_score":0.9821822},"labels":[],"label_agreement":null},{"id":"W4390499343","doi":"10.7759/cureus.51518","title":"Intensifying the Hormonal and Radiation Treatment in Prostate Cancer Presenting With Bulky Pelvic Lymph Nodes: An Opportunity for a New Paradigm","year":2024,"lang":"en","type":"article","venue":"Cureus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Dalhousie University","funders":"","keywords":"Medicine; Prostate cancer; Hormonal therapy; Radiation therapy; Hormone; Lymph; Enzalutamide; Hormone therapy; Prostate; Oncology; Cancer; Urology; Internal medicine; Pathology","score_opus":0.07386101689163548,"score_gpt":0.3674789398696578,"score_spread":0.2936179229780223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390499343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96191907,0.02894028,0.00004956169,0.007201144,0.000095198484,0.0014891723,0.00003699019,0.000051644252,0.00021695299],"genre_scores_gemma":[0.9906845,0.005616915,0.0000993226,0.000100237114,0.00024783728,0.0004686389,0.00010410245,0.000027356147,0.0026510546],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991629,0.00002038119,0.00013074587,0.0002706121,0.00014430334,0.0002710478],"domain_scores_gemma":[0.99951106,0.00008854875,0.000027915348,0.00015083431,0.000040909435,0.00018071006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014695733,0.00013684186,0.00016562015,0.00006702177,0.0000966936,0.00009076941,0.000041428568,0.000033836848,0.000021849379],"category_scores_gemma":[0.000025442561,0.00007156124,0.000033483928,0.00015206938,0.00006457636,0.00016968326,0.000017215383,0.00008726535,0.0000011439954],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032218248,0.00048206493,0.32761988,0.000840562,0.0010382874,0.0006645739,0.03157608,0.00011091871,0.0022362052,0.00077253097,0.0020258683,0.6294112],"study_design_scores_gemma":[0.03288788,0.006140709,0.71511173,0.002527391,0.0015528019,0.0006812086,0.01160259,0.12987553,0.009515959,0.0059981532,0.08292633,0.0011797376],"about_ca_topic_score_codex":0.0021815635,"about_ca_topic_score_gemma":0.0004769459,"teacher_disagreement_score":0.62823147,"about_ca_system_score_codex":0.00038705108,"about_ca_system_score_gemma":0.0009386891,"threshold_uncertainty_score":0.3297886},"labels":[],"label_agreement":null},{"id":"W4390547860","doi":"10.1056/nejmc2313228","title":"Enzalutamide in Biochemically Recurrent Prostate Cancer","year":2024,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Cancer; Oncology; Internal medicine; Androgen receptor","score_opus":0.03259846505699081,"score_gpt":0.3493602767517381,"score_spread":0.31676181169474726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390547860","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01821172,0.10241955,0.000002559707,0.87560666,0.0022586433,0.00042338585,0.000026265567,0.000016464513,0.0010347569],"genre_scores_gemma":[0.023160972,0.14904839,0.00041961015,0.567721,0.18416846,0.00007153012,0.000561992,0.00033171207,0.07451633],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969194,0.00010037599,0.0009557727,0.00032284204,0.0011953277,0.000506302],"domain_scores_gemma":[0.9985715,0.00021078167,0.00033862432,0.00023299696,0.0003156599,0.00033042944],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00077613373,0.00037395844,0.00113652,0.00087661814,0.000019367033,0.000020301733,0.00020934627,0.00038829268,0.00055433396],"category_scores_gemma":[0.0002581422,0.00020772853,0.0001806702,0.00044767215,0.00018601684,0.000054362325,0.000047977734,0.004437716,0.000020005624],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016052648,0.000039880033,0.001181339,0.0009261501,0.00034688917,0.015943645,0.0008805236,0.000001074839,0.0013937248,0.0000016004121,0.86799705,0.10968286],"study_design_scores_gemma":[0.035732254,0.0019953675,0.00026472672,0.0130581325,0.0006104101,0.0015177014,0.00003993415,0.000008094679,0.0007135133,0.0005729646,0.9453099,0.0001770212],"about_ca_topic_score_codex":0.00025650646,"about_ca_topic_score_gemma":0.000040076302,"teacher_disagreement_score":0.30788565,"about_ca_system_score_codex":0.00059585075,"about_ca_system_score_gemma":0.0016515278,"threshold_uncertainty_score":0.99785906},"labels":[],"label_agreement":null},{"id":"W4390581782","doi":"10.1038/s43018-023-00692-y","title":"Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping","year":2024,"lang":"en","type":"article","venue":"Nature Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Prostate cancer; Genotyping; Biology; Primary tumor; Prostate; Genotype; Oncology; Cancer; Metastasis; Gene; Medicine; Genetics","score_opus":0.14920475517979087,"score_gpt":0.5113790386103236,"score_spread":0.36217428343053276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390581782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88520026,0.10925701,0.000090549416,0.003916803,0.0004453278,0.0006966493,0.00022208651,0.0000802414,0.00009106045],"genre_scores_gemma":[0.9817402,0.013554595,0.0023236373,0.0007250914,0.00032527198,0.00012057433,0.000044659224,0.000046162462,0.0011198261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841356,0.00008901856,0.00038521533,0.00041568317,0.0003351536,0.00036133965],"domain_scores_gemma":[0.99915975,0.00020722263,0.00008291518,0.00018063367,0.00017126031,0.00019824156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054497854,0.0001759356,0.0004339596,0.0001106983,0.00006000301,0.000029080284,0.00007153447,0.00017131749,0.000108328015],"category_scores_gemma":[0.000091282236,0.00012710528,0.00011921838,0.0002901736,0.00019667887,0.00008180268,0.000058245456,0.0007180818,0.0000018126657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030123459,0.0003012884,0.65467477,0.006043432,0.0022886912,0.00035436466,0.0022202195,0.000039923994,0.08275374,0.0005229549,0.0059353746,0.24185288],"study_design_scores_gemma":[0.0069766063,0.0004286723,0.9148138,0.005261124,0.0012285511,0.00010829026,0.00018369156,0.0027819823,0.010036544,0.001582313,0.056124292,0.0004741002],"about_ca_topic_score_codex":0.0004148214,"about_ca_topic_score_gemma":0.00009126305,"teacher_disagreement_score":0.26013905,"about_ca_system_score_codex":0.0003568333,"about_ca_system_score_gemma":0.0005889433,"threshold_uncertainty_score":0.51832026},"labels":[],"label_agreement":null},{"id":"W4390584787","doi":"10.1038/s41598-023-50215-z","title":"High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker","year":2024,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Jonsson Comprehensive Cancer Center; National Institutes of Health; Canary Foundation; U.S. Department of Defense","keywords":"Prostate cancer; Medicine; Prostatectomy; Biomarker; Tissue microarray; Prostate; Oncology; PCA3; Cancer; Internal medicine; Cohort; Biology","score_opus":0.017594418228934684,"score_gpt":0.3131174638973548,"score_spread":0.2955230456684201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390584787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98717225,0.009726455,0.0000052897826,0.0011463935,0.0007884743,0.00072717,0.00010732572,0.0000536817,0.00027297018],"genre_scores_gemma":[0.9815519,0.00044925426,0.00008453932,0.000061429964,0.000024620049,0.000111892994,0.00021420726,0.000023386992,0.017478786],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977854,0.000043443368,0.00032573412,0.0007186463,0.00080277346,0.00032403425],"domain_scores_gemma":[0.99890184,0.00003345991,0.0002350493,0.00041440033,0.0002554616,0.00015980139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005394025,0.00017105309,0.00031989088,0.0002680054,0.0001484864,0.00015019235,0.000048295904,0.00007362776,0.0003515109],"category_scores_gemma":[0.000045817564,0.000100104706,0.00006660271,0.0007254072,0.0004406509,0.0001498401,0.000053650267,0.00012820872,0.000003360862],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003486389,0.0012386122,0.12851031,0.0025672195,0.001407334,0.093548395,0.022780338,0.0000034068776,0.3521643,0.000013842902,0.36949402,0.024785837],"study_design_scores_gemma":[0.0059104953,0.0017305166,0.030792793,0.01465254,0.0008860795,0.0030549269,0.00083715294,0.0005829284,0.8923165,0.0019575919,0.0466309,0.00064753037],"about_ca_topic_score_codex":0.00022654857,"about_ca_topic_score_gemma":0.0000104751525,"teacher_disagreement_score":0.54015225,"about_ca_system_score_codex":0.000109453664,"about_ca_system_score_gemma":0.000563173,"threshold_uncertainty_score":0.40821517},"labels":[],"label_agreement":null},{"id":"W4390598352","doi":"10.21203/rs.3.rs-3626834/v1","title":"Loss of ERRγ promotes lineage plasticity towards neuroendocrine prostate cancer","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Fonds de Recherche du Québec - Santé; Génome Québec; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Prostate cancer; Cancer research; PTEN; Neuroendocrine differentiation; Biology; Prostate; Neuroendocrine cell; Reprogramming; Cancer; Cell biology; PI3K/AKT/mTOR pathway; Signal transduction; Cell; Immunology; Genetics; Immunohistochemistry","score_opus":0.08058086854069708,"score_gpt":0.44510314032314896,"score_spread":0.3645222717824519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390598352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9569106,0.020266986,0.00000814891,0.010302382,0.0005770567,0.0056388364,0.0024981655,0.00022796044,0.00356984],"genre_scores_gemma":[0.96525246,0.0139818285,0.00014383625,0.000024225863,0.00079837145,0.001455185,0.00040307947,0.00015253888,0.017788496],"study_design_codex":"systematic_review","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9937957,0.0003544897,0.00065741857,0.0012035269,0.0026422392,0.0013466207],"domain_scores_gemma":[0.99640095,0.0002964244,0.00012340183,0.0008445624,0.0017667661,0.00056788],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007821962,0.0005047593,0.0010031399,0.001003874,0.00014583429,0.00014411818,0.0004712426,0.00022592852,0.00069602823],"category_scores_gemma":[0.0007246581,0.00036361182,0.0003970065,0.0010352834,0.0007907872,0.000054471897,0.003194945,0.004350654,0.0001279048],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026440203,0.008851964,0.17864417,0.41553468,0.008140388,0.0563583,0.011161861,0.0009378488,0.044955485,0.0018414152,0.06700182,0.18013188],"study_design_scores_gemma":[0.013662215,0.012085291,0.09456749,0.062014442,0.001446546,0.00045257868,0.0013486663,0.014204297,0.7455243,0.01321275,0.039233234,0.0022481682],"about_ca_topic_score_codex":0.0023612732,"about_ca_topic_score_gemma":0.00012677968,"teacher_disagreement_score":0.70056885,"about_ca_system_score_codex":0.0007483863,"about_ca_system_score_gemma":0.004625746,"threshold_uncertainty_score":0.99988157},"labels":[],"label_agreement":null},{"id":"W4390640719","doi":"10.1016/j.eururo.2023.12.004","title":"Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Medical Research Council; Advanced Accelerator Applications; Novartis; Endocyte; Genentech; Novartis Pharmaceuticals Corporation; Pfizer; Amgen","keywords":"Medicine; Prostate cancer; Oncology; Castration; Internal medicine; Prostate; Urology; Cancer; Hormone","score_opus":0.042122753653104035,"score_gpt":0.38826281951437036,"score_spread":0.34614006586126633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390640719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955982,0.0010520595,0.000010414274,0.0008375597,0.00015795867,0.00094027125,0.0001389021,0.0000118652715,0.0012527856],"genre_scores_gemma":[0.9992052,0.00013472425,0.00003990566,0.0000484371,0.000035791712,0.000014677623,0.000057031004,0.000022653277,0.00044159841],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9985325,0.00038412825,0.00038894074,0.00022731848,0.00028241536,0.0001847045],"domain_scores_gemma":[0.9994009,0.00009581029,0.00010853506,0.00023694361,0.00011021113,0.000047583846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033182622,0.000116407005,0.00028529594,0.00015598061,0.000032262113,0.000008467561,0.00008946415,0.000017582604,0.000090481444],"category_scores_gemma":[0.000057392197,0.000059418267,0.00007089278,0.00041077656,0.000202177,0.000050400922,0.000043861557,0.00016830732,0.000004986618],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7750349,0.0060447175,0.060809307,0.0013610205,0.0024005524,0.0011031481,0.0057706186,0.0013409855,0.066947214,0.00028148104,0.0014323912,0.07747366],"study_design_scores_gemma":[0.34062526,0.03465327,0.59780645,0.000793002,0.0017473708,0.000011887648,0.00024533513,0.00095774373,0.0146679245,0.00008301961,0.008069358,0.00033935983],"about_ca_topic_score_codex":0.000120549164,"about_ca_topic_score_gemma":0.00007476869,"teacher_disagreement_score":0.5369972,"about_ca_system_score_codex":0.00005265695,"about_ca_system_score_gemma":0.0002557425,"threshold_uncertainty_score":0.24230066},"labels":[],"label_agreement":null},{"id":"W4390711108","doi":"10.48083/vbff8907","title":"Proceedings From the 5th B2B Uro-Oncology: GU Cancers Triad Meeting: Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Société Internationale d’Urologie Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Triad (sociology); Medicine; Oncology; Internal medicine; Cancer; Psychology","score_opus":0.09533127094800892,"score_gpt":0.42396633915315685,"score_spread":0.32863506820514793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390711108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8881543,0.0030832333,0.0000049337946,0.09344926,0.0018252362,0.0007144414,0.00014996354,0.00016834964,0.012450246],"genre_scores_gemma":[0.95001465,0.02158981,0.00019471315,0.0040421262,0.0034942606,0.0004370024,0.00017531587,0.000052604606,0.019999506],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758947,0.000084481515,0.0004721734,0.00036263248,0.00088775693,0.0006034726],"domain_scores_gemma":[0.99806446,0.0005580072,0.0003575328,0.00014045683,0.00066573697,0.00021381422],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010519718,0.00023254816,0.0003673887,0.00017770521,0.00044701638,0.00014651338,0.0004608178,0.00016493529,0.0009361914],"category_scores_gemma":[0.0007123067,0.0001402825,0.00025779524,0.00043914767,0.0002684371,0.00020407038,0.00018057873,0.00095618394,0.0000724504],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038362234,0.00017583223,0.50194955,0.00003854675,0.0019866137,0.00051542243,0.00532696,0.00021926245,0.0075646495,0.00018573955,0.4283928,0.049808394],"study_design_scores_gemma":[0.016814388,0.0016450069,0.23698463,0.0004253113,0.0005401229,0.00029691312,0.011239512,0.0024350036,0.0049000904,0.0073568374,0.71686333,0.0004988525],"about_ca_topic_score_codex":0.0003852446,"about_ca_topic_score_gemma":0.00008719477,"teacher_disagreement_score":0.28847054,"about_ca_system_score_codex":0.0015869557,"about_ca_system_score_gemma":0.0015701136,"threshold_uncertainty_score":0.9999771},"labels":[],"label_agreement":null},{"id":"W4390747174","doi":"10.1002/bco2.318","title":"Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies","year":2024,"lang":"en","type":"article","venue":"BJUI Compass","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Debiopharm","keywords":"Triptorelin; Medicine; Prostate cancer; Testosterone (patch); Urology; Internal medicine; Nadir; Prostate; Post-hoc analysis; Prospective cohort study; Androgen deprivation therapy; Endocrinology; Gynecology; Cancer; Hormone; Luteinizing hormone; Gonadotropin-releasing hormone","score_opus":0.039394978322710016,"score_gpt":0.4204418987218071,"score_spread":0.3810469203990971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390747174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985336,0.012021401,0.0000022829825,0.0012812035,0.00014114147,0.00089098245,0.00026241658,0.00003766702,0.000026925327],"genre_scores_gemma":[0.9954744,0.003394526,0.00012539516,0.00008160417,0.0000200819,0.00009900833,0.00015349954,0.000020382437,0.00063111505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983896,0.00006507683,0.00053522165,0.00039516212,0.00033468523,0.00028025164],"domain_scores_gemma":[0.9990124,0.00026070775,0.0000959111,0.00022167292,0.00027075066,0.00013852374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024211277,0.00019581913,0.001001243,0.00044993273,0.000039857347,0.0000190497,0.00006195833,0.000047375008,0.000024227053],"category_scores_gemma":[0.000050726292,0.000117420794,0.00012095798,0.0008447927,0.00023578659,0.00010134521,0.00006343147,0.00020579575,0.0000022465151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007900025,0.0008598756,0.94713223,0.00021561909,0.00484967,0.000076278535,0.00083519897,0.000014753144,0.00006376625,0.000006412512,0.00021529596,0.03783088],"study_design_scores_gemma":[0.024904383,0.004449251,0.9664502,0.0004700181,0.0017628309,6.011534e-7,0.00037267667,0.00065575936,0.0000898579,0.000006926178,0.00068725576,0.00015020728],"about_ca_topic_score_codex":0.00018346251,"about_ca_topic_score_gemma":0.000621728,"teacher_disagreement_score":0.037680674,"about_ca_system_score_codex":0.00016061333,"about_ca_system_score_gemma":0.0001724818,"threshold_uncertainty_score":0.4788281},"labels":[],"label_agreement":null},{"id":"W4390797003","doi":"10.1101/2024.01.10.575110","title":"Increased chromatin accessibility mediated by nuclear factor I drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancer","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; DOD Prostate Cancer Research Program; Movember Foundation; Türkiye Bilimsel ve Teknolojik Araştırma Kurumu; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; American Society of Clinical Oncology; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation","keywords":"Chromatin; Gene knockdown; Prostate cancer; Androgen receptor; Biology; Enzalutamide; Cancer research; splice; Cell biology; Cancer; Genetics; Gene","score_opus":0.01666166503427942,"score_gpt":0.277455020966448,"score_spread":0.26079335593216857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390797003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98569834,0.0031215786,0.00001613056,0.0020256618,0.00037961267,0.0032968214,0.005114945,0.00033873576,0.00000814955],"genre_scores_gemma":[0.996113,0.001331222,0.00095805887,0.00022708242,0.00019382956,0.0009876442,0.000018564671,0.00015734578,0.000013276913],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99596095,0.00022981274,0.0007837218,0.0015136912,0.00078469433,0.0007271254],"domain_scores_gemma":[0.99772584,0.00008581486,0.00022165153,0.00085159583,0.00045904587,0.0006560696],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005603855,0.0006366044,0.0008039771,0.0004249715,0.00013465677,0.00023668038,0.00035234576,0.00051375886,0.00042376388],"category_scores_gemma":[0.00018814002,0.000571396,0.00014523932,0.0010031569,0.00012965183,0.00019666646,0.0002891284,0.0010887131,0.00012330801],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010669214,0.00037406085,0.0038063861,0.0017993867,0.00028305862,0.00038439583,0.00034279868,0.000012720608,0.99138725,0.000011075899,0.00051882496,0.000013144118],"study_design_scores_gemma":[0.004117685,0.00063730904,0.20645797,0.0055337595,0.00041480598,1.6778137e-7,0.00007470818,0.0012687751,0.7783083,0.000005741745,0.0017643938,0.0014164323],"about_ca_topic_score_codex":0.0021052589,"about_ca_topic_score_gemma":0.00017024687,"teacher_disagreement_score":0.21307898,"about_ca_system_score_codex":0.0015840404,"about_ca_system_score_gemma":0.002221364,"threshold_uncertainty_score":0.9996737},"labels":[],"label_agreement":null},{"id":"W4390986151","doi":"10.1038/s42003-023-05741-x","title":"DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2","year":2024,"lang":"en","type":"article","venue":"Communications Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Pohjois-Savon Rahasto; Biocenter Finland; Syöpäsäätiö; Sigrid Juséliuksen Säätiö; Suomen Kulttuurirahasto; Itä-Suomen Yliopisto","keywords":"Prostate cancer; EZH2; Neuroendocrine differentiation; Cancer research; PRC2; Androgen receptor; Biology; Prostate; Cancer; Epigenetics; Gene; Genetics","score_opus":0.07093808830371232,"score_gpt":0.39157944494261143,"score_spread":0.32064135663889914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390986151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96155703,0.014516405,0.000013954741,0.022133568,0.000088956665,0.0009496314,0.00018816076,0.00012913268,0.00042313174],"genre_scores_gemma":[0.9700862,0.027313348,0.00038111108,0.00015843353,0.000049311315,0.000668899,0.00022347477,0.000026203616,0.0010929992],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989034,0.00012307875,0.00025085697,0.0003484547,0.000058167738,0.00031603503],"domain_scores_gemma":[0.9988206,0.00031236315,0.00003486,0.00066137244,0.00006301076,0.00010777362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006030519,0.00018055135,0.0002914709,0.00022781982,0.000114755014,0.00003159468,0.00020129622,0.000060814786,0.00005331744],"category_scores_gemma":[0.000044450197,0.00012770135,0.000047601836,0.00033261516,0.00026617647,0.0000704733,0.00022427038,0.0002827177,0.000024093733],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069695653,0.0012955924,0.09420033,0.0003352289,0.0005250264,0.00023912452,0.004126133,0.0000015955592,0.7126312,0.0011346913,0.00060217595,0.18421192],"study_design_scores_gemma":[0.017945768,0.007966666,0.07512353,0.0014373788,0.0006231638,0.00034652435,0.00055995054,0.044977862,0.5351358,0.003234709,0.31150356,0.0011450922],"about_ca_topic_score_codex":0.0008203919,"about_ca_topic_score_gemma":0.00038920567,"teacher_disagreement_score":0.31090137,"about_ca_system_score_codex":0.00017362688,"about_ca_system_score_gemma":0.00021560339,"threshold_uncertainty_score":0.520751},"labels":[],"label_agreement":null},{"id":"W4391103359","doi":"10.1101/2024.01.17.576106","title":"Differential response to LSD1 inhibition in prostate cancer reveals a YAP1 vulnerability in the neuroendocrine subtype","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Genentech; MacroGenics; Sanofi; Foghorn Therapeutics; Gilead Sciences; Pfizer; Bristol-Myers Squibb","keywords":"Prostate cancer; Cancer research; Androgen receptor; Gene silencing; Neuroendocrine differentiation; Enzalutamide; Demethylase; YAP1; Biology; Mediator; Prostate; Cancer; Pharmacology; Transcription factor; Endocrinology; Histone; Gene; Genetics","score_opus":0.02383207901484171,"score_gpt":0.3044800858827344,"score_spread":0.2806480068678927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391103359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98005354,0.0017100787,0.0000033241588,0.013186369,0.0007055715,0.0037817848,0.0004077885,0.00014430593,0.0000072318153],"genre_scores_gemma":[0.9956237,0.0006815382,0.00007371225,0.0005106509,0.00033539027,0.0025936395,0.0000019245713,0.00010799304,0.000071423354],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9958737,0.00077673455,0.00067451596,0.0012110561,0.00066972105,0.00079428515],"domain_scores_gemma":[0.99799746,0.00017949422,0.00013135502,0.001158178,0.00027452712,0.00025897083],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012028608,0.0005232205,0.0007014272,0.00075189216,0.00008157407,0.00018911748,0.00024571357,0.00016516873,0.000089847104],"category_scores_gemma":[0.00051877456,0.00038658606,0.00014119552,0.0014228148,0.00012704822,0.00006817211,0.00060779176,0.0019538482,0.00006235308],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008355599,0.00075211324,0.08162336,0.0022653835,0.00011829279,0.005517327,0.00025373697,0.00005890759,0.899809,0.0000766621,0.0011517598,0.000017861157],"study_design_scores_gemma":[0.002768461,0.0004286517,0.8459999,0.0029802495,0.00014910204,3.3016806e-7,0.000014813701,0.00012767893,0.14554018,0.000027326572,0.0014317591,0.00053154415],"about_ca_topic_score_codex":0.0005367981,"about_ca_topic_score_gemma":0.00009760265,"teacher_disagreement_score":0.7643765,"about_ca_system_score_codex":0.0011688271,"about_ca_system_score_gemma":0.0013425397,"threshold_uncertainty_score":0.9998586},"labels":[],"label_agreement":null},{"id":"W4391234973","doi":"10.1016/j.clgc.2023.12.006","title":"Corrigendum","year":2024,"lang":"en","type":"erratum","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine","score_opus":0.15522069340825687,"score_gpt":0.4697687129662767,"score_spread":0.3145480195580198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391234973","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002079915,0.2854688,0.0000028777786,0.010137062,0.34964302,0.001497765,0.0006689929,0.00045481644,0.35004675],"genre_scores_gemma":[0.00042316594,0.11702592,0.0000688783,0.0013158136,0.03664708,0.00031976023,0.00095213903,0.00018262622,0.8430646],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996346,0.00011502145,0.0009125964,0.0011439102,0.0007349778,0.0007474743],"domain_scores_gemma":[0.9979399,0.000094569004,0.00016361692,0.0008654237,0.00026041633,0.0006761172],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.000373584,0.00054082746,0.0012153113,0.00024104038,0.0001051694,0.000067274195,0.00031205456,0.0013244217,0.003877982],"category_scores_gemma":[0.00010690147,0.00039231998,0.0010149103,0.00039899486,0.0003943665,0.000050434668,0.0003471121,0.004518363,0.0029353371],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063091563,0.00034867125,0.0018678984,0.0012310072,0.0010567545,0.005657826,0.000027369933,1.6348953e-7,0.000010453337,0.0000060554908,0.95042807,0.038734797],"study_design_scores_gemma":[0.0012777387,0.0011629667,0.003254807,0.0017282263,0.0010132109,0.00007866421,0.00002387636,0.00006900488,0.000029826993,0.00016505929,0.9907985,0.00039812477],"about_ca_topic_score_codex":0.00006865327,"about_ca_topic_score_gemma":0.000021068547,"teacher_disagreement_score":0.49301788,"about_ca_system_score_codex":0.00052257604,"about_ca_system_score_gemma":0.0041751857,"threshold_uncertainty_score":0.99997205},"labels":[],"label_agreement":null},{"id":"W4391301902","doi":"10.1200/jco.2024.42.4_suppl.116","title":"Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of patients with novel hormonal therapy (NHT) pretreatment in the TALAPRO-2 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Oncology; Hormonal therapy; Internal medicine; Subgroup analysis; Cancer; Pathology; Alternative medicine; Androgen receptor","score_opus":0.0822781094013292,"score_gpt":0.43054497577940876,"score_spread":0.3482668663780796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391301902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933037,0.0010956638,0.000036025147,0.0015258514,0.000103069804,0.0036453197,0.00011657037,0.000011821674,0.00016196314],"genre_scores_gemma":[0.9980402,0.00041568128,0.00059501117,0.00020498103,0.000044543376,0.00042506258,0.000069004775,0.00004156729,0.00016393102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938389,0.00062103575,0.002725975,0.00055337464,0.0017492493,0.0005114683],"domain_scores_gemma":[0.9953124,0.0017081298,0.001650075,0.00038788767,0.0006856624,0.0002558374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023025966,0.00042755815,0.002515432,0.0007664729,0.00006848942,0.000058387464,0.00022132442,0.00014993918,0.00005949429],"category_scores_gemma":[0.00022446574,0.00018439507,0.00034373076,0.0017251027,0.00040727094,0.0002813837,0.00004357239,0.00106371,6.532644e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11080472,0.008273557,0.8490464,0.000081163205,0.013506675,0.0036529296,0.0054193847,0.0023854407,0.000052225256,0.000015602907,0.000048197067,0.0067137023],"study_design_scores_gemma":[0.055022,0.05077218,0.8855529,0.00029557463,0.0041363533,0.000046708145,0.0026906112,0.00096493325,0.00006263974,0.000011695026,0.00024889395,0.00019553998],"about_ca_topic_score_codex":0.0010952922,"about_ca_topic_score_gemma":0.0074367044,"teacher_disagreement_score":0.05578272,"about_ca_system_score_codex":0.0012123361,"about_ca_system_score_gemma":0.0051870323,"threshold_uncertainty_score":0.92015725},"labels":[],"label_agreement":null},{"id":"W4391301992","doi":"10.1200/jco.2024.42.4_suppl.106","title":"Safety outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223 following external beam radiation therapy: REASSURE US subset.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Radium-223; External beam radiation; Radiation therapy; External beam radiotherapy; Oncology; Radium; Internal medicine; Prostate; Cancer; Urology; Bone metastasis; Radiochemistry","score_opus":0.0628498156280137,"score_gpt":0.4379534022943611,"score_spread":0.37510358666634736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391301992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99193186,0.0034701654,0.00002082768,0.0032409804,0.00040229372,0.00076018943,0.000033150736,0.000015255991,0.00012527469],"genre_scores_gemma":[0.9964408,0.0018510537,0.00056746375,0.00029086662,0.00016407616,0.00003020547,0.000030673185,0.000033151668,0.0005916861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969732,0.00033356834,0.0014189121,0.00026265153,0.00069591374,0.0003157138],"domain_scores_gemma":[0.99787253,0.00084528705,0.0005589931,0.0001377196,0.0003091601,0.00027628115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014967327,0.00020813527,0.0012043157,0.00024091227,0.000058060177,0.000040199226,0.000092505215,0.00013553712,0.00007014738],"category_scores_gemma":[0.00020392465,0.00010339736,0.00026788563,0.0003654419,0.00011881085,0.0002811396,0.000010795443,0.0007789864,0.0000034459006],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033209134,0.0013942848,0.9044232,0.00004104988,0.0017378399,0.0023540433,0.00019792771,0.00009727108,0.00009764824,0.0000060449124,0.00012601944,0.056315545],"study_design_scores_gemma":[0.03406002,0.015884941,0.94552976,0.0004924128,0.0005433771,0.00003291671,0.00005061307,0.00007669268,0.00015032613,0.000027259302,0.0030370774,0.000114589],"about_ca_topic_score_codex":0.00025347972,"about_ca_topic_score_gemma":0.00034149812,"teacher_disagreement_score":0.05620096,"about_ca_system_score_codex":0.00059425033,"about_ca_system_score_gemma":0.0027200866,"threshold_uncertainty_score":0.48253167},"labels":[],"label_agreement":null},{"id":"W4391302082","doi":"10.1200/jco.2024.42.4_suppl.15","title":"Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Internal medicine; Cancer; Androgen receptor","score_opus":0.10673379587228134,"score_gpt":0.5226580841497942,"score_spread":0.4159242882775129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808421,0.0051461975,0.000004112424,0.012014088,0.00030102785,0.0012178986,0.000029788685,0.000007968453,0.00043681392],"genre_scores_gemma":[0.9819087,0.016520452,0.00021887066,0.00021033996,0.0003157389,0.00008930047,0.000004472213,0.000021176646,0.0007109924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99657315,0.0006967535,0.0016447728,0.00025868948,0.00055449095,0.0002721342],"domain_scores_gemma":[0.9967292,0.0019283149,0.00067279034,0.00023694933,0.00024556433,0.00018719926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002590561,0.0002003086,0.00148392,0.0001903535,0.00003050983,0.00001810893,0.00019140741,0.00014275553,0.00011069247],"category_scores_gemma":[0.00029321466,0.000081739505,0.00031905167,0.0002990213,0.00023179028,0.0000732637,0.000023531655,0.00081849186,0.000002970366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037765432,0.014040013,0.56531906,0.000056114786,0.003534365,0.0025361627,0.004118629,0.0000136914405,0.0003105429,0.000040005405,0.0018673051,0.37039867],"study_design_scores_gemma":[0.11303853,0.20312005,0.6528098,0.00063096225,0.0023363573,0.00012464848,0.003557012,0.00020647954,0.0031982919,0.0008397242,0.019894922,0.00024323903],"about_ca_topic_score_codex":0.00043362577,"about_ca_topic_score_gemma":0.0004021036,"teacher_disagreement_score":0.37015542,"about_ca_system_score_codex":0.00047126692,"about_ca_system_score_gemma":0.0024386975,"threshold_uncertainty_score":0.43261448},"labels":[],"label_agreement":null},{"id":"W4391302371","doi":"10.1200/jco.2024.42.4_suppl.109","title":"Patient reported outcomes (PROs) among patients with metastatic castration-resistant prostate cancer (mCRPC) by homologous recombination repair mutations (HRRm) gene clusters: Findings from the phase 3 TALAPRO-2 study cohort 2.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Homologous recombination; Cohort; Oncology; Internal medicine; Gene; Cancer; Genetics; Biology","score_opus":0.07261226795548535,"score_gpt":0.45086850354280084,"score_spread":0.37825623558731547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99105316,0.000915999,0.000029262092,0.004031289,0.0010428869,0.0026435195,0.00017505317,0.000042694573,0.00006614289],"genre_scores_gemma":[0.99758786,0.00027141944,0.0005737255,0.00032753285,0.00010694584,0.00023835128,0.0002305728,0.00003538622,0.00062821695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99519384,0.00063864863,0.0025037578,0.00043631328,0.00092184974,0.0003055953],"domain_scores_gemma":[0.99527496,0.001911654,0.0012365469,0.00028990486,0.0010019032,0.00028503904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021895058,0.00024054572,0.0010923,0.00015194474,0.00017620884,0.000072880146,0.00012505947,0.0001400447,0.00012007614],"category_scores_gemma":[0.001394689,0.00012167924,0.00034374243,0.00037161994,0.00032715284,0.00030225737,0.000047682075,0.00092899206,0.000004852973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005981064,0.0076690703,0.94948137,0.000033996337,0.004899728,0.0025401006,0.0020363894,0.000026683125,0.00008376493,0.0000026625808,0.005984958,0.021260187],"study_design_scores_gemma":[0.021522585,0.02897362,0.9426563,0.0002137537,0.002982317,0.000045576253,0.0013635622,0.00026417826,0.00013327754,0.00012854871,0.0015617958,0.00015453622],"about_ca_topic_score_codex":0.0005834188,"about_ca_topic_score_gemma":0.00033949685,"teacher_disagreement_score":0.02130455,"about_ca_system_score_codex":0.000581866,"about_ca_system_score_gemma":0.0019220368,"threshold_uncertainty_score":0.49619353},"labels":[],"label_agreement":null},{"id":"W4391302427","doi":"10.1200/jco.2024.42.4_suppl.328","title":"Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Centre Hospitalier Universitaire de Sherbrooke; Sunnybrook Health Science Centre; Health Sciences Centre; McGill University; University of Ottawa; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Oncology; Internal medicine; Cancer; Disease; Prostate; Androgen; Hormone","score_opus":0.09829980145780604,"score_gpt":0.49146646231312974,"score_spread":0.3931666608553237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844229,0.006192673,0.000074319185,0.0057933894,0.00112096,0.0016450366,0.0007175406,0.000013388437,0.000019794374],"genre_scores_gemma":[0.9621487,0.03593111,0.00064337254,0.0002800172,0.00051481253,0.00010621569,0.000040105795,0.000038838643,0.00029679792],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.990956,0.0030566643,0.0044969223,0.00042754205,0.0006157869,0.0004470815],"domain_scores_gemma":[0.9856272,0.010369086,0.0023681733,0.00026518517,0.00063252496,0.00073784793],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011372695,0.00029627598,0.003942618,0.00035479467,0.000041961157,0.00001693945,0.00015760338,0.00033271642,0.00027974404],"category_scores_gemma":[0.016700985,0.00016897655,0.00049294817,0.00038043523,0.0005541158,0.00013038579,0.000073123185,0.0010866828,0.000006623137],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38299197,0.0036006568,0.09834753,0.001054369,0.001890076,0.00231259,0.0004171775,0.000063851796,0.0032497533,0.000051870134,0.0010136525,0.5050065],"study_design_scores_gemma":[0.16873513,0.09476549,0.6550683,0.011154766,0.0052831597,0.00006086739,0.00034685462,0.0033231229,0.019616287,0.0010434478,0.039929062,0.00067354867],"about_ca_topic_score_codex":0.00010505793,"about_ca_topic_score_gemma":0.00006587182,"teacher_disagreement_score":0.55672073,"about_ca_system_score_codex":0.0003273088,"about_ca_system_score_gemma":0.004496297,"threshold_uncertainty_score":0.99158174},"labels":[],"label_agreement":null},{"id":"W4391302496","doi":"10.1200/jco.2024.42.4_suppl.320","title":"Long-term results of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy (sRT) post prostatectomy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Radiation therapy; Salvage therapy; Prostate; Urology; Surgery; Oncology; Internal medicine; Cancer; Chemotherapy","score_opus":0.06960715960634782,"score_gpt":0.45225148390489134,"score_spread":0.3826443242985435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942107,0.0015193125,0.000012845926,0.0023968334,0.00053312373,0.0010964584,0.000026491523,0.000016908909,0.00018732769],"genre_scores_gemma":[0.9908099,0.00799148,0.00025158506,0.00018360463,0.00031722672,0.000012406742,0.000074921,0.000033257133,0.00032558132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963727,0.00044074774,0.0020462656,0.00028265483,0.00055606716,0.00030155593],"domain_scores_gemma":[0.9968886,0.001046667,0.0010832549,0.00017542737,0.00057961163,0.00022645765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025771454,0.00017538026,0.0011529628,0.0004036128,0.000033485074,0.000026747937,0.000108346154,0.00025231027,0.000030431951],"category_scores_gemma":[0.0012397364,0.000095766634,0.00020187178,0.0004804677,0.00018050203,0.00028439955,0.000024076113,0.0007936989,0.000005325535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04287332,0.0010855191,0.6517233,0.00011058322,0.00033778482,0.00044869058,0.0007301112,0.0000068874706,0.00033602543,0.0000012795646,0.00015046084,0.302196],"study_design_scores_gemma":[0.03919473,0.03322443,0.9220322,0.00074273185,0.00014733567,0.000051681614,0.000050290513,0.00012711805,0.003054678,0.000015828346,0.0012538175,0.00010517651],"about_ca_topic_score_codex":0.000035087967,"about_ca_topic_score_gemma":0.00009988138,"teacher_disagreement_score":0.30209082,"about_ca_system_score_codex":0.00036308597,"about_ca_system_score_gemma":0.002747347,"threshold_uncertainty_score":0.48736757},"labels":[],"label_agreement":null},{"id":"W4391302647","doi":"10.1200/jco.2024.42.4_suppl.208","title":"Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Prostate cancer; Oncology; Castration; Internal medicine; Cancer; Hormone","score_opus":0.2339183130763819,"score_gpt":0.5423661705284767,"score_spread":0.3084478574520948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882728,0.0010390093,0.004684287,0.0037608547,0.0003356238,0.0013777545,0.00047549207,0.0000123075015,0.00004186557],"genre_scores_gemma":[0.95942366,0.00029402407,0.039597113,0.0001457033,0.00017444325,0.00003803745,0.00006586477,0.000034947683,0.0002262007],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9969059,0.00017873863,0.0015955105,0.00040451816,0.00059027533,0.00032505777],"domain_scores_gemma":[0.99662375,0.0015607282,0.0007086315,0.0002522813,0.000615951,0.00023864824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022547983,0.0001879348,0.0010678286,0.00024723884,0.00006293432,0.000037594313,0.0001657655,0.00012534518,0.0000040630243],"category_scores_gemma":[0.0007970738,0.00009705182,0.00012776894,0.000246368,0.00020250923,0.0005310979,0.00007478061,0.0007133125,3.9056468e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.637482,0.005525719,0.22525033,0.00096776185,0.00408717,0.0027583167,0.0018429077,0.034985434,0.0001814068,0.00008710909,0.0022856356,0.0845462],"study_design_scores_gemma":[0.06702447,0.09824536,0.35196775,0.0037778998,0.0027300706,0.00007793546,0.00046992514,0.47357476,0.00005314411,0.0005362952,0.0012611724,0.00028121533],"about_ca_topic_score_codex":0.00006794573,"about_ca_topic_score_gemma":0.00019283064,"teacher_disagreement_score":0.5704575,"about_ca_system_score_codex":0.0005089382,"about_ca_system_score_gemma":0.005015042,"threshold_uncertainty_score":0.88964695},"labels":[],"label_agreement":null},{"id":"W4391302671","doi":"10.1200/jco.2024.42.4_suppl.209","title":"11-Ketotestosterone and time to castration resistance in patients with recurrent non-metastatic prostate cancer receiving androgen deprivation therapy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Sherbrooke; Centre Hospitalier de l’Université de Montréal; McGill University; Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Enzalutamide; Prostate cancer; Medicine; Androgen deprivation therapy; Testosterone (patch); Internal medicine; Androgen receptor; Androgen; Dihydrotestosterone; Endocrinology; Bicalutamide; Cohort; Urology; Oncology; Cancer; Hormone","score_opus":0.07317815419877942,"score_gpt":0.4411291755949603,"score_spread":0.36795102139618086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894666,0.0026427023,0.000022667786,0.006903839,0.00019708757,0.0005994711,0.00000747694,0.0000054565353,0.00015471934],"genre_scores_gemma":[0.9955711,0.0014308468,0.0019318908,0.00026638733,0.00015611641,0.000023069853,0.000007920465,0.000015872823,0.0005968372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834263,0.0001628695,0.0008431712,0.00018966194,0.00029631364,0.00016532734],"domain_scores_gemma":[0.9987272,0.00046290414,0.00027013075,0.000079180085,0.0002699715,0.00019062098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012414671,0.000099254736,0.000530657,0.00017220143,0.000024305797,0.000023862141,0.000044936947,0.00007265659,0.00005245431],"category_scores_gemma":[0.00030832476,0.000060050897,0.000050920924,0.00025370752,0.000056456345,0.00016494787,0.000018014362,0.00037863114,0.000008645472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014532229,0.000628082,0.5829659,0.00011271049,0.00020246676,0.0002992254,0.0005301175,0.000012979539,0.0002159517,0.0000048425845,0.0011306092,0.3993649],"study_design_scores_gemma":[0.008464101,0.011467265,0.97009045,0.0011354559,0.00008404503,0.000015675034,0.000021304602,0.000094131035,0.00008477976,0.00010119042,0.008364769,0.0000768404],"about_ca_topic_score_codex":0.000012619026,"about_ca_topic_score_gemma":0.00018356842,"teacher_disagreement_score":0.39928806,"about_ca_system_score_codex":0.00024835856,"about_ca_system_score_gemma":0.00096819876,"threshold_uncertainty_score":0.24488045},"labels":[],"label_agreement":null},{"id":"W4391302681","doi":"10.1200/jco.2024.42.4_suppl.323","title":"Long-term treatment outcomes from the International Multi-Institutional Stereotactic Body Radiation Therapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Bristol-Myers Squibb Foundation","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Radiation therapy; Cohort; Oncology; Prostate; Internal medicine; Radiosurgery; Prospective cohort study; Randomized controlled trial; Clinical trial; Cancer","score_opus":0.14295998657361347,"score_gpt":0.47687874480035325,"score_spread":0.3339187582267398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699352,0.0036984459,0.00021291283,0.021663094,0.0032475109,0.0009602623,0.00022373023,0.000007694198,0.00005117417],"genre_scores_gemma":[0.9921718,0.005167452,0.0003275374,0.0006441101,0.00084667,0.000046669156,0.00004913687,0.000014067616,0.0007325156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975837,0.00033487054,0.0013051308,0.00019143698,0.00042120885,0.00016365074],"domain_scores_gemma":[0.99424374,0.004268921,0.0008113042,0.00019559507,0.00036149027,0.00011897233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012035641,0.0001488149,0.00074764894,0.00006921182,0.000094310286,0.00003060677,0.00023137173,0.00015358103,0.00015969906],"category_scores_gemma":[0.0011416172,0.000056988785,0.00068110874,0.00008712565,0.00034783038,0.000107265936,0.000038822167,0.00044627188,0.0000063535676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066228886,0.0012825646,0.84642327,0.000015483542,0.0024875442,0.00013743085,0.00023511802,0.0000073352544,0.00012401193,0.00013345332,0.0005900182,0.14194085],"study_design_scores_gemma":[0.023915222,0.004972929,0.9549199,0.000094576084,0.0005665235,0.00004506416,0.000031136093,0.00054549857,0.00075481914,0.00023983656,0.013861243,0.00005327361],"about_ca_topic_score_codex":0.00019234522,"about_ca_topic_score_gemma":0.00007094844,"teacher_disagreement_score":0.14188758,"about_ca_system_score_codex":0.0004732103,"about_ca_system_score_gemma":0.002826806,"threshold_uncertainty_score":0.50146323},"labels":[],"label_agreement":null},{"id":"W4391302763","doi":"10.1200/jco.2024.42.4_suppl.325","title":"Every-other-day or once-a-week: Long-term efficacy outcomes of the multicenter randomised PATRIOT prostate SBRT trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; BC Cancer Agency; CancerCare Manitoba","funders":"","keywords":"Medicine; Term (time); Prostate cancer; Prostate; Randomized controlled trial; Internal medicine; Cancer","score_opus":0.19466731613974858,"score_gpt":0.524018911751432,"score_spread":0.3293515956116834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97596395,0.0022120124,0.00003544162,0.0144781545,0.004475084,0.0019399651,0.000014874055,0.000016794887,0.0008637514],"genre_scores_gemma":[0.981534,0.0024242983,0.00016750158,0.0010563179,0.0012736096,0.000021683481,0.000002384834,0.0000353606,0.013484862],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950237,0.0010222715,0.0027053386,0.00024512224,0.0006669646,0.00033655026],"domain_scores_gemma":[0.9895067,0.008429989,0.0010551864,0.0003186854,0.00037289498,0.00031650244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049364637,0.00020057785,0.0019026425,0.00014993889,0.000050766128,0.000025784864,0.00030976345,0.00031910997,0.0005131983],"category_scores_gemma":[0.006142046,0.00008122324,0.0014036114,0.00024442893,0.00042969547,0.00010703665,0.000096722215,0.0012367867,0.000036966536],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6445016,0.0059236838,0.17032464,0.0002299302,0.0024985622,0.0017787309,0.00051649445,0.00000492781,0.00020332684,0.00001224962,0.00639066,0.16761515],"study_design_scores_gemma":[0.58364713,0.018508816,0.35199404,0.0008647353,0.0014557933,0.0001064889,0.000060307284,0.00008023228,0.00064544566,0.00005057705,0.042453185,0.0001332826],"about_ca_topic_score_codex":0.000010591858,"about_ca_topic_score_gemma":0.000025157407,"teacher_disagreement_score":0.1816694,"about_ca_system_score_codex":0.0002559522,"about_ca_system_score_gemma":0.003196571,"threshold_uncertainty_score":0.7353046},"labels":[],"label_agreement":null},{"id":"W4391302877","doi":"10.1200/jco.2024.42.4_suppl.156","title":"Enzalutamide combination treatment (tx) suspension in men with high-risk biochemically recurrent (BCR) prostate cancer: Outcomes from EMBARK.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Cancer; Internal medicine; breakpoint cluster region; Androgen receptor; Receptor","score_opus":0.08249207575034151,"score_gpt":0.4634647410781154,"score_spread":0.3809726653277739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97274965,0.005786381,0.00000776744,0.019400544,0.0008711528,0.0005671913,0.00003909283,0.000020512327,0.00055768894],"genre_scores_gemma":[0.97117233,0.026374076,0.00085311657,0.00019229743,0.00042796976,0.00003553434,0.000042397445,0.000025980937,0.0008763217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99691975,0.00040123795,0.0015438003,0.00033398517,0.000500542,0.00030068783],"domain_scores_gemma":[0.99668425,0.0018855756,0.0006090232,0.00017628551,0.00031417175,0.00033071553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013408951,0.00021016963,0.0013166192,0.00023620536,0.000035482855,0.00002623047,0.00010863091,0.00026638716,0.00015570778],"category_scores_gemma":[0.0005427565,0.000109912085,0.00028660736,0.00023899427,0.0001770522,0.00012626367,0.00004183948,0.0009475436,0.000019336476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015644442,0.0028175812,0.56561756,0.000047018133,0.0012547529,0.0026561006,0.00046704191,0.000018501309,0.000826862,0.00005388294,0.002654876,0.40794137],"study_design_scores_gemma":[0.03984851,0.041192774,0.892213,0.0011982962,0.0012436452,0.00007289266,0.00028125427,0.0005563787,0.004980808,0.0021724268,0.016015299,0.00022474512],"about_ca_topic_score_codex":0.0009551246,"about_ca_topic_score_gemma":0.000527313,"teacher_disagreement_score":0.40771663,"about_ca_system_score_codex":0.0013361704,"about_ca_system_score_gemma":0.002546344,"threshold_uncertainty_score":0.4517105},"labels":[],"label_agreement":null},{"id":"W4391303024","doi":"10.1200/jco.2024.42.4_suppl.151","title":"Radiographic progression without PSA progression in metastatic hormone-sensitive prostate cancer (mHSPC): A retrospective analysis from the ENZAMET trial (ANZUP 1304).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta; University of British Columbia; Ottawa Hospital","funders":"Cancer Council Australia; Pfizer","keywords":"Medicine; Oncology; Prostate cancer; Internal medicine; Cancer; Gynecology","score_opus":0.10347654656899868,"score_gpt":0.5266114866556074,"score_spread":0.42313494008660874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9605425,0.023117607,0.00007645012,0.013085162,0.0012119225,0.0016961758,0.00006456077,0.0000257803,0.00017983263],"genre_scores_gemma":[0.9820181,0.013849324,0.0018986176,0.0003623949,0.0014046805,0.00014118107,0.00003066619,0.0000326309,0.00026242048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942014,0.0016266985,0.0021858688,0.0005064258,0.0010307294,0.000448856],"domain_scores_gemma":[0.9947551,0.002878415,0.0011412821,0.00028893386,0.00056232535,0.0003739767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057202633,0.0002662528,0.0022644722,0.0006654304,0.00008205192,0.000069960704,0.00020965928,0.00029689018,0.00008818937],"category_scores_gemma":[0.0018677366,0.00012658186,0.0011664244,0.0020563602,0.00060463743,0.00022212414,0.00008622239,0.002253482,0.000008314561],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2644105,0.0026460958,0.43399712,0.00005355566,0.012374173,0.006300963,0.0025196716,0.000022874157,0.00041089067,0.000030259627,0.004017232,0.27321666],"study_design_scores_gemma":[0.10348218,0.033705056,0.83260846,0.0015575956,0.011646395,0.00011651056,0.0008909071,0.0030370925,0.00029905478,0.0016170413,0.010749852,0.00028987892],"about_ca_topic_score_codex":0.00019138747,"about_ca_topic_score_gemma":0.00030695804,"teacher_disagreement_score":0.39861134,"about_ca_system_score_codex":0.0005618057,"about_ca_system_score_gemma":0.0028914884,"threshold_uncertainty_score":0.97903824},"labels":[],"label_agreement":null},{"id":"W4391303131","doi":"10.1200/jco.2024.42.4_suppl.126","title":"Differential treatment effect on overall survival (OS) based on early prostate-specific antigen (PSA) response in metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of TITAN trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Centre Hospitalier de l’Université de Montréal; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Prostate-specific antigen; Prostate cancer; Oncology; Internal medicine; Prostate; Hormone; Cancer","score_opus":0.10834649701347598,"score_gpt":0.47152638440485967,"score_spread":0.3631798873913837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992426,0.0013018344,0.000017432365,0.0029813864,0.001109456,0.0015519297,0.00025413063,0.000015393834,0.00034243788],"genre_scores_gemma":[0.9959621,0.0027141469,0.00009667719,0.00015734196,0.00033311482,0.00007354902,0.000049825256,0.000040630166,0.00057262974],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99295956,0.003002187,0.002212799,0.00050201925,0.0008672869,0.00045617172],"domain_scores_gemma":[0.98895097,0.009236534,0.0008130508,0.00030777798,0.00030493154,0.00038671438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042222166,0.00035412997,0.003127678,0.0014282601,0.000039631457,0.000039267714,0.00012696034,0.00024503045,0.0002509853],"category_scores_gemma":[0.0008732493,0.00020500446,0.0013503789,0.00088707864,0.000275773,0.000106737214,0.000029578521,0.0011151383,0.00001554245],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9034572,0.0042977794,0.009464962,0.0000809829,0.0074694837,0.007227041,0.0008129125,0.00035679314,0.003922833,0.000018390108,0.00035224837,0.06253935],"study_design_scores_gemma":[0.14515822,0.27832767,0.5627129,0.00049755775,0.003953294,0.000011496815,0.00010225847,0.0024670472,0.0024165863,0.00004400752,0.0040873243,0.0002216302],"about_ca_topic_score_codex":0.00015998413,"about_ca_topic_score_gemma":0.0001078648,"teacher_disagreement_score":0.758299,"about_ca_system_score_codex":0.0012013022,"about_ca_system_score_gemma":0.0031796978,"threshold_uncertainty_score":0.83598393},"labels":[],"label_agreement":null},{"id":"W4391303197","doi":"10.1200/jco.2024.42.4_suppl.131","title":"Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Urology; Androgen deprivation therapy; Biochemical recurrence; Radiation therapy; Clinical endpoint; Enzalutamide; Internal medicine; Surgery; Oncology; Randomized controlled trial; Cancer; Androgen receptor","score_opus":0.047664306498826095,"score_gpt":0.40599287676845164,"score_spread":0.35832857026962556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465543,0.0011174561,0.00014120761,0.0024963391,0.0007635406,0.00047208538,0.0000505761,0.000018657043,0.00028472464],"genre_scores_gemma":[0.99487793,0.00071744097,0.0033764318,0.00014820205,0.0006724253,0.000009274356,0.00012749719,0.00003095691,0.000039823077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99600595,0.0004841464,0.0021601438,0.00036487196,0.00070723664,0.00027762062],"domain_scores_gemma":[0.9934678,0.0045452057,0.000962666,0.00021728381,0.00050922355,0.00029780297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020133113,0.00018089423,0.0011287313,0.00029850387,0.000035382385,0.000020179275,0.00013043387,0.00036474175,0.000019618567],"category_scores_gemma":[0.0059771077,0.00010725523,0.00024098676,0.0004470163,0.00033850316,0.00022219744,0.00004251808,0.0015528848,0.000006586208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15382698,0.004029462,0.71675175,0.00022683687,0.0027715266,0.0050088083,0.0016306218,0.000085399115,0.0012226035,0.00013588987,0.0024532315,0.11185688],"study_design_scores_gemma":[0.096429355,0.0265296,0.8617504,0.0033787608,0.0012814072,0.000058727226,0.00044603625,0.00034598762,0.0050997455,0.0006881964,0.0037178486,0.00027391856],"about_ca_topic_score_codex":0.00012943408,"about_ca_topic_score_gemma":0.00006427413,"teacher_disagreement_score":0.14499865,"about_ca_system_score_codex":0.00044727864,"about_ca_system_score_gemma":0.0028780664,"threshold_uncertainty_score":0.71555877},"labels":[],"label_agreement":null},{"id":"W4391303198","doi":"10.1200/jco.2024.42.4_suppl.141","title":"Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McMaster University; Juravinski Cancer Centre","funders":"ESSA Pharma","keywords":"Medicine; Enzalutamide; Prostate cancer; Androgen receptor; Internal medicine; Urology; Regimen; Oncology; Pharmacology; Metastatic breast cancer; Concomitant; Pharmacokinetics; Docetaxel; Tolerability; Chemotherapy; Cancer; Adverse effect; Breast cancer","score_opus":0.17280411001997317,"score_gpt":0.5116431645062401,"score_spread":0.33883905448626694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931866,0.0006028183,0.00024353457,0.0030770055,0.0002935402,0.0023764728,0.00016900795,0.000008728058,0.0000422933],"genre_scores_gemma":[0.9955481,0.00031913054,0.0036159756,0.0001415171,0.00009509764,0.00007796136,0.000076021584,0.000026757529,0.00009943359],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99529,0.0007615391,0.0025302116,0.0003593321,0.00070659973,0.00035236313],"domain_scores_gemma":[0.99619114,0.0017387348,0.0008916081,0.00016190024,0.0006057206,0.00041091788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034839245,0.00023176162,0.0016068766,0.0005858281,0.000036328685,0.000033165998,0.00010417341,0.00012861332,0.00003172762],"category_scores_gemma":[0.0010375857,0.00014116964,0.00010510228,0.00068938476,0.0002779078,0.00029734222,0.00002694785,0.0007527486,0.0000015384235],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8638802,0.026837043,0.0034232808,0.00015171879,0.0005878738,0.002393749,0.0011267324,0.00018896106,0.0008292046,0.00001757022,0.00039703597,0.10016664],"study_design_scores_gemma":[0.785791,0.19693393,0.011087466,0.0011152243,0.00063041266,0.00003480236,0.00026486765,0.0014254636,0.0009030115,0.000114780494,0.0015254398,0.00017364202],"about_ca_topic_score_codex":0.0002604831,"about_ca_topic_score_gemma":0.0009456674,"teacher_disagreement_score":0.17009687,"about_ca_system_score_codex":0.00045118298,"about_ca_system_score_gemma":0.0030648534,"threshold_uncertainty_score":0.5756731},"labels":[],"label_agreement":null},{"id":"W4391303316","doi":"10.1200/jco.2024.42.4_suppl.313","title":"EMBARK post hoc analysis of sexual activity (SA) patient-reported outcome (PRO) measures.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"","keywords":"Medicine; Post-hoc analysis; Post hoc; Oncology; Internal medicine","score_opus":0.29736328481147134,"score_gpt":0.543237928412474,"score_spread":0.24587464360100264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98824143,0.0020918625,0.000085115054,0.0066677686,0.0011493443,0.00020304612,0.000020497395,0.00001532291,0.0015255791],"genre_scores_gemma":[0.997408,0.0005262734,0.00031541457,0.00036633605,0.00040335636,0.0000034129364,0.000009136982,0.00001568717,0.00095243],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99576944,0.00043365,0.0024338483,0.00025661645,0.00084184046,0.00026459162],"domain_scores_gemma":[0.9953953,0.0018044983,0.0011441279,0.00026484046,0.00096822355,0.00042301498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036351006,0.00014513319,0.0020179125,0.00077844254,0.00003133092,0.000013738183,0.0001289432,0.000351757,0.00027559898],"category_scores_gemma":[0.0032075506,0.00008757421,0.0008924002,0.0010448489,0.00026271955,0.00012795886,0.00006273212,0.0011657858,0.0000110201],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015259553,0.002679426,0.30606118,0.00015062641,0.018514479,0.005187244,0.00032747842,0.00002393783,0.0038039319,0.000028967108,0.0022528807,0.6457103],"study_design_scores_gemma":[0.007166624,0.04825209,0.8905778,0.00012217388,0.015926335,0.0003163173,0.0003403171,0.0006863206,0.0007217436,0.000076012475,0.03564959,0.00016468643],"about_ca_topic_score_codex":0.000052509822,"about_ca_topic_score_gemma":0.000073376286,"teacher_disagreement_score":0.6455456,"about_ca_system_score_codex":0.00028190666,"about_ca_system_score_gemma":0.0026749827,"threshold_uncertainty_score":0.50648236},"labels":[],"label_agreement":null},{"id":"W4391303387","doi":"10.1200/jco.2024.42.4_suppl.78","title":"Clinical outcomes with systemic therapy given after progression on prostate specific membrane antigen radioligand therapy (PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Radioligand; Glutamate carboxypeptidase II; Oncology; Internal medicine; Prostate; Circulating tumor cell; Prostate-specific antigen; Urology; Cancer; Metastasis; Receptor","score_opus":0.09463349629339564,"score_gpt":0.46919856485776784,"score_spread":0.3745650685643722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816904,0.0103315655,0.0000052596683,0.0045051994,0.00081644254,0.0024668316,0.00004390753,0.000024826457,0.00011554167],"genre_scores_gemma":[0.96686316,0.030876786,0.0006801877,0.00047471185,0.00041858098,0.0001553108,0.000021799468,0.000068015936,0.00044144315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943214,0.0008836935,0.002658261,0.0005596373,0.0010576457,0.0005193813],"domain_scores_gemma":[0.99615586,0.0014512351,0.0010202082,0.00030989054,0.0006183989,0.00044442996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003033525,0.00038430715,0.0020869595,0.00034070792,0.00006372213,0.0000766659,0.00018030708,0.00024483536,0.00011488391],"category_scores_gemma":[0.00013736135,0.0001735482,0.00039129253,0.00041768068,0.00045726923,0.00026102114,0.00002379028,0.0014792177,0.000014609042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12314913,0.0027687794,0.73951143,0.00014846143,0.0014812228,0.003636412,0.000523317,0.000027081014,0.000093205264,0.0000055317823,0.00033400516,0.12832141],"study_design_scores_gemma":[0.04011145,0.05318727,0.89322335,0.002533511,0.00016532971,0.00008871347,0.0001278456,0.000022272961,0.00021068804,0.000031096843,0.010084095,0.00021438395],"about_ca_topic_score_codex":0.000029212548,"about_ca_topic_score_gemma":0.00007509824,"teacher_disagreement_score":0.1537119,"about_ca_system_score_codex":0.0003960718,"about_ca_system_score_gemma":0.0030775885,"threshold_uncertainty_score":0.707709},"labels":[],"label_agreement":null},{"id":"W4391303394","doi":"10.1200/jco.2024.42.4_suppl.296","title":"Weight variation during androgen deprivation therapy in patients with localized prostate cancer: Data from two prospective randomized trials.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Cégep de Rimouski; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont; Cégep de l'Outaouais; Centre de Santé et de Services Sociaux de Chicoutimi; Centre hospitalier universitaire de Québec; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Oncology; Randomized controlled trial; Androgen; Internal medicine; Cancer; Urology; Hormone","score_opus":0.13856799279096224,"score_gpt":0.49214647304898723,"score_spread":0.35357848025802496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879582,0.00545046,0.00019965213,0.0035966774,0.0008720595,0.0017646862,0.00005565254,0.000014404984,0.000088242174],"genre_scores_gemma":[0.9838056,0.013358406,0.0013279305,0.00013541021,0.0010857928,0.000050372815,0.0001161691,0.000022545912,0.00009775498],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99532783,0.0015059735,0.0021713933,0.00031992284,0.00048633348,0.00018854534],"domain_scores_gemma":[0.99401575,0.0041504414,0.0010187865,0.0002313432,0.00042368256,0.00015999578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077235876,0.00013868813,0.0021620705,0.00019511806,0.000031873107,0.000031345688,0.0001552117,0.00016981424,0.00017995093],"category_scores_gemma":[0.003571239,0.00007027367,0.0002306014,0.0002748803,0.00014364616,0.0003298577,0.000053532654,0.000723017,0.000005257304],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49786943,0.00068218954,0.43001655,0.000021702355,0.0017062128,0.00019770824,0.0003084449,0.000016208605,0.0000420892,0.000015994568,0.00014245379,0.06898099],"study_design_scores_gemma":[0.55280524,0.0030106667,0.43857214,0.00041189225,0.0005416677,0.000005651848,0.000014599712,0.0010319687,0.00021790012,0.0012060407,0.0021044142,0.00007781614],"about_ca_topic_score_codex":0.00020791923,"about_ca_topic_score_gemma":0.00008415917,"teacher_disagreement_score":0.06890318,"about_ca_system_score_codex":0.00041673073,"about_ca_system_score_gemma":0.0021239521,"threshold_uncertainty_score":0.4275365},"labels":[],"label_agreement":null},{"id":"W4391303641","doi":"10.1200/jco.2024.42.4_suppl.90","title":"Trends in local therapy utilization and survival of patients with de-novo metastatic prostate cancer treated by hormone therapy with or without systemic therapy intensification with chemotherapy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Systemic therapy; Prostate cancer; Oncology; Chemotherapy; Hormone therapy; Internal medicine; Hormonal therapy; Cancer; Overall survival; Breast cancer","score_opus":0.13566366543201502,"score_gpt":0.46693036480939226,"score_spread":0.33126669937737724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98207533,0.014824117,0.00042865434,0.0017860861,0.00006882418,0.0007396743,0.000020708065,0.00001523976,0.000041368556],"genre_scores_gemma":[0.93721145,0.06177475,0.00025802653,0.0002314675,0.000061827195,0.00004883114,0.000035001678,0.000047449037,0.0003311959],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975157,0.000406788,0.0010467517,0.0002850767,0.00048169948,0.00026400844],"domain_scores_gemma":[0.99784267,0.00041937234,0.0006612022,0.00015067027,0.0007347345,0.00019135108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011835666,0.00023304379,0.0012628834,0.0003090738,0.000027783302,0.00002136469,0.00008601646,0.0001535579,0.000050191997],"category_scores_gemma":[0.000034187462,0.0000994983,0.00008222377,0.00065205985,0.00046075485,0.00016677921,0.00000631963,0.0004931552,3.135038e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12805071,0.0013389308,0.41860777,0.000045664874,0.0010390884,0.00011843778,0.0008401846,0.000009547804,0.00046298458,0.0000028004595,0.00010881329,0.44937506],"study_design_scores_gemma":[0.0964084,0.10516739,0.7884602,0.0010653214,0.00029447637,0.0002754618,0.0008092172,0.0011310419,0.0018046233,0.00001926805,0.0043078484,0.00025676988],"about_ca_topic_score_codex":0.00013552903,"about_ca_topic_score_gemma":0.00014701592,"teacher_disagreement_score":0.4491183,"about_ca_system_score_codex":0.00027202294,"about_ca_system_score_gemma":0.0014631042,"threshold_uncertainty_score":0.4057423},"labels":[],"label_agreement":null},{"id":"W4391303668","doi":"10.1200/jco.2024.42.4_suppl.76","title":"Impact of exposure to clinical trials and standard-of-care therapy in metastatic or recurrent prostate cancer: An update.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of the Fraser Valley; University of Alberta; Abbotsford Veterinary Clinic; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Clinical trial; Cancer; Internal medicine; Standard of care","score_opus":0.38987340184040364,"score_gpt":0.6506472274266518,"score_spread":0.2607738255862482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9577575,0.03638462,0.000010675842,0.0037621886,0.0010498075,0.0008457137,0.00014999065,0.0000052459004,0.000034269146],"genre_scores_gemma":[0.9121394,0.0858457,0.0012533886,0.00014301226,0.0005176832,0.000016549537,0.000007556754,0.000018858502,0.000057838075],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99238795,0.0023195927,0.004338869,0.00025820863,0.00044709712,0.00024828565],"domain_scores_gemma":[0.99280226,0.0046860906,0.0011009304,0.00018037244,0.00068555435,0.0005447771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014736923,0.00016119755,0.0033006964,0.00025222122,0.000014678456,0.000015324504,0.00013219602,0.00021226707,0.0002684523],"category_scores_gemma":[0.0050591193,0.000077343575,0.0007006569,0.00033536844,0.00025117688,0.00012787717,0.000042508258,0.0009257318,0.0000014809256],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12301365,0.0010827613,0.15264262,0.00019511298,0.0011781296,0.0006459857,0.000874902,0.0000167892,0.00009430927,0.000011517398,0.0012967761,0.7189474],"study_design_scores_gemma":[0.03963293,0.48229474,0.44591886,0.0018772349,0.00095561217,0.00012120565,0.0010493592,0.00006224896,0.00039331484,0.00046721165,0.02705857,0.00016871434],"about_ca_topic_score_codex":0.000048061458,"about_ca_topic_score_gemma":0.00017080993,"teacher_disagreement_score":0.7187787,"about_ca_system_score_codex":0.00023994785,"about_ca_system_score_gemma":0.007937187,"threshold_uncertainty_score":0.99768686},"labels":[],"label_agreement":null},{"id":"W4391303703","doi":"10.1200/jco.2024.42.4_suppl.31","title":"Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Centre Hospitalier Universitaire de Sherbrooke; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Hospitalier de l’Université de Montréal; Hôtel-Dieu de Québec; Jewish General Hospital; Hôpital Fleurimont; Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Positron emission tomography; Pet imaging; Internal medicine; Radiology","score_opus":0.12331357639596299,"score_gpt":0.5106027960481183,"score_spread":0.38728921965215535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782883,0.008619403,0.00000866925,0.011290474,0.0006645737,0.00044832256,0.00003005087,0.0000076260303,0.00064261275],"genre_scores_gemma":[0.99261814,0.0051455675,0.001195084,0.00029113746,0.00021335288,0.000020538177,0.0000050752383,0.000019352126,0.0004917629],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970907,0.0002970103,0.0017243982,0.00022424376,0.00040234847,0.00026127958],"domain_scores_gemma":[0.9970428,0.0018667757,0.0004824587,0.00010475478,0.00025823608,0.00024499238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025282486,0.00013804874,0.0009317988,0.00028179874,0.000025226056,0.00002327254,0.00007560248,0.00004367022,0.00006938531],"category_scores_gemma":[0.0011499464,0.00008615909,0.00018439724,0.00023495093,0.00027303013,0.0001339138,0.000028740971,0.0007729151,0.000005160133],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025408316,0.0034045458,0.26246065,0.0018057454,0.0016723681,0.052624878,0.0016875976,0.00034023222,0.0073704654,0.0017072071,0.002833631,0.63868433],"study_design_scores_gemma":[0.018578328,0.020158129,0.9226952,0.0038811592,0.0014110169,0.0016368369,0.0008931334,0.0045602145,0.0007476166,0.0034820046,0.021712659,0.00024366115],"about_ca_topic_score_codex":0.000105173385,"about_ca_topic_score_gemma":0.00013618341,"teacher_disagreement_score":0.6602346,"about_ca_system_score_codex":0.0001947629,"about_ca_system_score_gemma":0.0029294977,"threshold_uncertainty_score":0.5196803},"labels":[],"label_agreement":null},{"id":"W4391303716","doi":"10.1200/jco.2024.42.4_suppl.287","title":"Detection and delineation of intraprostatic lesions (IPLs) using multiparametric magnetic resonance imaging (mpMRI) and prostate specific membrane antigen positron emission tomography (PSMA PET) for patients with prostate cancer: A systematic review and meta-analysis.","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Cancer Care Ontario; Western University","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Magnetic resonance imaging; Positron emission tomography; Nuclear medicine; Meta-analysis; Prostate; Radiation therapy; Radiology; Histopathology; Cancer; Receiver operating characteristic; Internal medicine; Pathology","score_opus":0.1506478707525152,"score_gpt":0.4812907334608733,"score_spread":0.3306428627083581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303716","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009088261,0.9837944,0.00012602367,0.0002896837,0.00009508331,0.0064368397,0.00016018792,0.000007999458,0.0000015430282],"genre_scores_gemma":[0.002796787,0.9936267,0.0030027237,0.000064418935,0.00005994443,0.00023381907,0.000039282324,0.000051130864,0.000125173],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9939688,0.000843611,0.0038009405,0.0005634255,0.000515397,0.00030786602],"domain_scores_gemma":[0.993284,0.001687109,0.003353446,0.0002510488,0.001085176,0.000339246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003077622,0.00045073018,0.009130111,0.0011641679,0.000102845544,0.00004900212,0.00010016547,0.00019200315,0.000007579096],"category_scores_gemma":[0.0009279189,0.0002315764,0.0012425991,0.0014610492,0.00030849883,0.00015612521,0.000069277834,0.00075647444,2.2056683e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001738163,0.0004915394,0.0021931904,0.5431887,0.02511491,0.000122069716,0.00009022184,0.000001955289,0.0000070372416,9.725354e-7,0.00003938013,0.42701185],"study_design_scores_gemma":[0.004499283,0.007080706,0.0013847714,0.0818619,0.89272475,0.0004005294,0.00004005997,0.0008250992,0.0000061463447,0.00001662161,0.010835968,0.00032414912],"about_ca_topic_score_codex":0.000025510999,"about_ca_topic_score_gemma":0.0000125180195,"teacher_disagreement_score":0.86760986,"about_ca_system_score_codex":0.00019008797,"about_ca_system_score_gemma":0.0008070454,"threshold_uncertainty_score":0.9443411},"labels":[],"label_agreement":null},{"id":"W4391303726","doi":"10.1200/jco.2024.42.4_suppl.59","title":"A real-world observational study characterizing patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with or without androgen receptor pathway inhibitors (ARPIs).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); University of Calgary; University of Alberta","funders":"AstraZeneca Canada","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Internal medicine; Docetaxel; Logistic regression; Cohort; Cancer; Referral; Oncology; Retrospective cohort study; Family medicine","score_opus":0.20658985672378094,"score_gpt":0.47709178138388847,"score_spread":0.27050192466010753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948132,0.00013522657,0.000005554897,0.0026467333,0.00044323574,0.0015484764,0.000083993415,0.000030362347,0.00029323596],"genre_scores_gemma":[0.99354494,0.000556198,0.0012702178,0.00030695234,0.00068459567,0.000109530905,0.00008594181,0.000053021962,0.0033885974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99625164,0.00052037055,0.001649626,0.00039268695,0.0008340908,0.000351588],"domain_scores_gemma":[0.9961361,0.001026972,0.00093568687,0.00015170268,0.0013300783,0.0004194036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00145306,0.00027392016,0.0014376647,0.00028870263,0.000098312885,0.000059684884,0.00008582233,0.00010769181,0.00015990812],"category_scores_gemma":[0.00027674434,0.00013412804,0.00017218376,0.0006582103,0.00023965581,0.00039061636,0.000030381196,0.0008878649,0.000012988936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04403533,0.0034416523,0.8981788,0.00012253757,0.0030224083,0.005161842,0.0013056422,0.000009329063,0.0003971929,0.000008018755,0.00060689653,0.043710344],"study_design_scores_gemma":[0.034439575,0.08839498,0.8553559,0.0018938471,0.002054645,0.00037077593,0.0015685465,0.00023209918,0.0017501671,0.0000122910205,0.013580539,0.00034659755],"about_ca_topic_score_codex":0.00030499627,"about_ca_topic_score_gemma":0.0016985629,"teacher_disagreement_score":0.08495332,"about_ca_system_score_codex":0.00062582054,"about_ca_system_score_gemma":0.0055611203,"threshold_uncertainty_score":0.98651886},"labels":[],"label_agreement":null},{"id":"W4391303738","doi":"10.1200/jco.2024.42.4_suppl.69","title":"Understanding variation in treatment intensification for de novo metastatic castration-sensitive prostate cancer (mCSPC): A population-based cohort study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Ottawa Hospital; University of Ottawa; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cohort; Internal medicine; Population; Cancer; Gynecology","score_opus":0.371127075384124,"score_gpt":0.5450453315106891,"score_spread":0.17391825612656514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98125,0.00028220983,0.0072246855,0.00863021,0.000616246,0.0018871137,0.000020898873,0.000011866587,0.00007680726],"genre_scores_gemma":[0.99698377,0.00032286346,0.0018393351,0.00018205642,0.00029688355,0.0001502891,0.00003144486,0.000016188185,0.00017715125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977924,0.0003456786,0.001213783,0.00020686397,0.00025049766,0.00019075722],"domain_scores_gemma":[0.9967062,0.0022628915,0.000414777,0.00008423292,0.0003916025,0.00014032096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027606718,0.000110236746,0.000723643,0.0002809112,0.000045156357,0.000027273809,0.00003308253,0.00010126302,0.000022180166],"category_scores_gemma":[0.0009343766,0.00007412114,0.0001975832,0.0002396867,0.0000457879,0.000113307404,0.0000049341024,0.00029305022,0.0000017730433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009034711,0.002619348,0.9575928,0.00011265025,0.0014673182,0.0010925931,0.0019576496,0.0014287282,0.00037878085,0.00043511757,0.00013859571,0.023741705],"study_design_scores_gemma":[0.011089224,0.011765975,0.9545022,0.0002455018,0.0010806615,0.00006957155,0.0010832517,0.018510964,0.000081613245,0.0011842281,0.00030900483,0.0000777807],"about_ca_topic_score_codex":0.0004331944,"about_ca_topic_score_gemma":0.0011868133,"teacher_disagreement_score":0.023663925,"about_ca_system_score_codex":0.003520836,"about_ca_system_score_gemma":0.0038047621,"threshold_uncertainty_score":0.9206863},"labels":[],"label_agreement":null},{"id":"W4391303761","doi":"10.1200/jco.2024.42.4_suppl.166","title":"Overall survival with darolutamide vs placebo in combination with androgen-deprivation therapy (ADT) and docetaxel: A sensitivity analysis from ARASENS accounting for subsequent therapy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Androgen deprivation therapy; Placebo; Oncology; Internal medicine; Prostate cancer; Chemotherapy; Cancer; Pathology","score_opus":0.1025656710349568,"score_gpt":0.44005449297768734,"score_spread":0.33748882194273055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98987466,0.00153214,0.0016079933,0.0062086736,0.0001610401,0.00052504375,0.000014352233,0.0000125303695,0.000063591724],"genre_scores_gemma":[0.99419504,0.0037425207,0.0012815765,0.0003417723,0.00033210448,0.000012913744,0.000035135294,0.000018330302,0.000040603838],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979764,0.00039058464,0.000790523,0.00026352308,0.000374373,0.00020459041],"domain_scores_gemma":[0.9957418,0.0032229724,0.0004384524,0.000114106515,0.00034704106,0.00013563967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033989171,0.00013919664,0.0010263145,0.00029639865,0.000042286643,0.000045715657,0.000042221836,0.00017655767,0.000016179862],"category_scores_gemma":[0.000279325,0.00007785652,0.00019809495,0.000355462,0.00012854565,0.00019795573,0.000013416934,0.0005349731,5.8170957e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06758786,0.0011559414,0.8541718,0.000033905588,0.0041987156,0.0012416532,0.00036906818,0.00018820676,0.0009942995,0.00009245509,0.00007296047,0.06989312],"study_design_scores_gemma":[0.040414426,0.013191959,0.9317584,0.00019263466,0.00078919675,0.00010246593,0.00014489476,0.008761946,0.000651868,0.0006164925,0.0032425881,0.0001331146],"about_ca_topic_score_codex":0.0001671224,"about_ca_topic_score_gemma":0.0006314019,"teacher_disagreement_score":0.0775866,"about_ca_system_score_codex":0.00021075922,"about_ca_system_score_gemma":0.00094869355,"threshold_uncertainty_score":0.31748968},"labels":[],"label_agreement":null},{"id":"W4391362379","doi":"10.3390/jcm13030734","title":"Prostate Cancer Liver Metastasis: An Ominous Metastatic Site in Need of Distinct Management Strategies","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Metastasis; Prostate cancer; PTEN; Oncology; Cancer; Internal medicine; Incidence (geometry); PI3K/AKT/mTOR pathway; Apoptosis","score_opus":0.1302594057326382,"score_gpt":0.4919585873290085,"score_spread":0.36169918159637027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391362379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.951678,0.03724841,0.00012662676,0.007488914,0.000842548,0.0006190648,0.00002562212,0.000018120625,0.0019527014],"genre_scores_gemma":[0.97803307,0.019340381,0.0009201044,0.00020581885,0.00055182935,0.000017372995,0.000013611039,0.000025334879,0.00089245994],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965365,0.00024420494,0.0018688318,0.0002444148,0.00081723556,0.0002888487],"domain_scores_gemma":[0.99825275,0.0005488282,0.0003939935,0.0002180012,0.00029342083,0.0002929788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028330404,0.0001911151,0.0011943904,0.00049924926,0.000020347628,0.000022535914,0.00014538514,0.00005792214,0.00039848243],"category_scores_gemma":[0.00026920898,0.00010419961,0.00023038348,0.0005420171,0.00036210872,0.00028231074,0.000041932057,0.00065307866,0.0000071016584],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015229089,0.003060132,0.13191819,0.008398588,0.005733466,0.03226978,0.006393501,0.00013588791,0.0014953081,0.0010741304,0.007730293,0.7865616],"study_design_scores_gemma":[0.042803075,0.03084394,0.83529556,0.023426447,0.009244468,0.000810941,0.014724238,0.0039406703,0.00090599724,0.0036997858,0.033749387,0.00055551913],"about_ca_topic_score_codex":0.00020662465,"about_ca_topic_score_gemma":0.00009885627,"teacher_disagreement_score":0.7860061,"about_ca_system_score_codex":0.00009896839,"about_ca_system_score_gemma":0.0005274097,"threshold_uncertainty_score":0.43631032},"labels":[],"label_agreement":null},{"id":"W4391482149","doi":"10.1016/j.euf.2024.01.008","title":"Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202","year":2024,"lang":"en","type":"article","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Cancer Care Ontario","funders":"National Cancer Institute; NRG Oncology","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Hazard ratio; Internal medicine; Proportional hazards model; Radiation therapy; Oncology; Cancer; Myocardial infarction; Confidence interval; Urology","score_opus":0.02094416256630198,"score_gpt":0.3031418986192054,"score_spread":0.2821977360529034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391482149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9546121,0.043471422,0.00021916893,0.0005001747,0.00009488049,0.0005319658,0.000023932174,0.00003004929,0.00051634555],"genre_scores_gemma":[0.9922428,0.007444098,0.000044401648,0.000028135386,0.00004208691,0.000022326187,0.000056063636,0.000024929586,0.00009514636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987889,0.00019036485,0.00033834504,0.00031069093,0.00018759233,0.00018413915],"domain_scores_gemma":[0.99951917,0.00002639228,0.0000609668,0.00025009076,0.00008621143,0.000057155583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004788219,0.00011584469,0.00030353264,0.0001558377,0.000020357209,0.000007791386,0.00005782384,0.000042839132,0.000019690675],"category_scores_gemma":[0.000036758738,0.000093961295,0.00008573792,0.00024459595,0.00016963745,0.000092414055,0.00006287429,0.00015562761,0.0000066555267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011974495,0.000111522175,0.7887581,0.00075808837,0.00096870674,0.0012925429,0.0006786648,0.00022879537,0.012410875,0.00013231914,0.000045860517,0.19341709],"study_design_scores_gemma":[0.0037466285,0.0006334013,0.96926385,0.0002072612,0.00036016843,0.000055823766,0.000015312507,0.0003915281,0.02354406,0.00011904564,0.0015379603,0.00012498774],"about_ca_topic_score_codex":0.00007574636,"about_ca_topic_score_gemma":0.00005946027,"teacher_disagreement_score":0.1932921,"about_ca_system_score_codex":0.000047716985,"about_ca_system_score_gemma":0.00012747633,"threshold_uncertainty_score":0.38316303},"labels":[],"label_agreement":null},{"id":"W4391553342","doi":"10.19080/jpcr.2018.06.555685","title":"177Lutetium-PSMA in Advanced Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of pharmacology & clinical research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Oncology; Internal medicine; Cancer research; Cancer","score_opus":0.23960962581298476,"score_gpt":0.6354514016565741,"score_spread":0.39584177584358937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391553342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9669411,0.0033562249,0.0000034871616,0.026253687,0.001384473,0.0006853435,0.000005965623,0.000009527766,0.0013602003],"genre_scores_gemma":[0.97206503,0.018396646,0.00040714673,0.0010377413,0.0026243192,0.000055227774,0.0000018459773,0.000028495135,0.0053835367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956072,0.0009572415,0.0011735869,0.00033920727,0.0010241979,0.00089855114],"domain_scores_gemma":[0.99530345,0.0014932406,0.00024264398,0.00017969887,0.0022467722,0.00053417403],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0076929065,0.00014618615,0.00066943467,0.00066327624,0.00012575228,0.000019438472,0.00035474208,0.00020686514,0.0019606962],"category_scores_gemma":[0.0012165958,0.0001003689,0.00021921594,0.0009104046,0.0013968694,0.00017182864,0.00018543213,0.002698998,0.00014826989],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042842466,0.002844331,0.5435206,0.00015776156,0.0006883877,0.0038626366,0.00073894794,0.000008593346,0.13221028,0.0000349916,0.122559234,0.15053172],"study_design_scores_gemma":[0.05861927,0.02582187,0.56128114,0.00095055497,0.00027705522,0.00030860203,0.00078397273,0.0005233224,0.11388373,0.00091005623,0.23629332,0.00034710084],"about_ca_topic_score_codex":0.000043370084,"about_ca_topic_score_gemma":0.00003930727,"teacher_disagreement_score":0.15018462,"about_ca_system_score_codex":0.000442234,"about_ca_system_score_gemma":0.0023341773,"threshold_uncertainty_score":0.99960184},"labels":[],"label_agreement":null},{"id":"W4391604914","doi":"10.1002/uro2.32","title":"Current and emerging tissue‐based molecular biomarkers for prostate cancer management: A narrative review","year":2023,"lang":"en","type":"review","venue":"UroPrecision","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Prostate cancer; Risk stratification; Medicine; Management of prostate cancer; Disease; Narrative review; Prostate; Cancer; Molecular biomarkers; Intensive care medicine; Bioinformatics; Oncology; Internal medicine; Biology","score_opus":0.08869330912029576,"score_gpt":0.47359477264466565,"score_spread":0.3849014635243699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391604914","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005088622,0.9886109,0.0001404182,0.00051654957,0.00033076006,0.0099402955,0.00020003392,0.000083568455,0.00017238333],"genre_scores_gemma":[7.637087e-7,0.9941236,0.00038917677,0.00007415987,0.00007108608,0.002419673,0.0008272163,0.00012065944,0.001973661],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99756473,0.00013633013,0.000581997,0.0007786772,0.0004990277,0.00043923542],"domain_scores_gemma":[0.99880743,0.00015404577,0.00024314101,0.00042515318,0.00016450734,0.00020569499],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004880931,0.0004664529,0.0014675135,0.0004375164,0.00013813184,0.000037126414,0.00014627482,0.00011005867,0.00006915054],"category_scores_gemma":[0.00009496876,0.00031057862,0.0003570964,0.00082125684,0.00007177524,0.000045514153,0.00014979471,0.00025929013,0.000045099107],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008486586,0.000037006146,0.000001256084,0.1912947,0.00047143424,0.00011450161,0.00005189357,2.3482384e-7,0.000002069833,0.00000566174,0.00908441,0.79885197],"study_design_scores_gemma":[0.00093757466,0.00016824213,0.0000015933219,0.24628684,0.0021613564,0.00000569913,0.000016659002,0.00003164831,0.000010009748,0.00003196379,0.7501303,0.0002181038],"about_ca_topic_score_codex":0.000009119305,"about_ca_topic_score_gemma":0.0000014412531,"teacher_disagreement_score":0.7986339,"about_ca_system_score_codex":0.0002681803,"about_ca_system_score_gemma":0.00028560593,"threshold_uncertainty_score":0.9999346},"labels":[],"label_agreement":null},{"id":"W4391720110","doi":"10.1002/cncr.35221","title":"Safety and effectiveness of the radium‐223–taxane treatment sequence in patients with metastatic castration‐resistant prostate cancer in a global observational study (REASSURE)","year":2024,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal General Hospital","funders":"Bayer HealthCare","keywords":"Taxane; Medicine; Cabazitaxel; Docetaxel; Prostate cancer; Radium-223; Internal medicine; Oncology; Chemotherapy; Cancer; Surgery; Androgen deprivation therapy; Breast cancer","score_opus":0.052982418825094774,"score_gpt":0.36887829863575383,"score_spread":0.31589587981065903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391720110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99139637,0.0045908424,0.0000021442281,0.00044393173,0.00009349665,0.0027834403,0.000627791,0.000010104488,0.000051888583],"genre_scores_gemma":[0.9985729,0.00041133587,0.000024146886,0.000015178656,0.000013988276,0.00070404314,0.00003491005,0.000012613061,0.00021091467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987068,0.00017501203,0.00023545261,0.000314263,0.0003597931,0.00020866517],"domain_scores_gemma":[0.99952155,0.00010139811,0.000049340004,0.00015199384,0.00011758192,0.000058156846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023414241,0.00016337218,0.00031067367,0.00006417197,0.000039675022,0.000019342055,0.00004974791,0.000024346775,0.000029940966],"category_scores_gemma":[0.0000164756,0.00008747874,0.000031331972,0.00066028204,0.000117204916,0.000105901294,0.000021529411,0.00010052959,4.5482903e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053100805,0.00059656304,0.9841547,0.0004527662,0.00030281147,0.00008667844,0.0008290634,0.0005633374,0.0004519924,0.00006799191,0.0000039674132,0.0071800184],"study_design_scores_gemma":[0.009423792,0.0009291825,0.98726505,0.0011932736,0.00016536185,0.0000023369628,0.00015375821,0.00018626072,0.00047207007,0.00004372606,0.00007962502,0.00008553756],"about_ca_topic_score_codex":0.0042639496,"about_ca_topic_score_gemma":0.0065737967,"teacher_disagreement_score":0.0071765087,"about_ca_system_score_codex":0.0017918004,"about_ca_system_score_gemma":0.001197309,"threshold_uncertainty_score":0.6445845},"labels":[],"label_agreement":null},{"id":"W4391743861","doi":"10.1016/j.clgc.2024.02.003","title":"Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; University of Toronto; Occupational Cancer Research Centre; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; CHEK2; Genetic testing; Germline mutation; Prostate cancer; PMS2; Oncology; Germline; Internal medicine; Cancer; Malignancy; Gynecology; Mutation; DNA mismatch repair; Genetics; Gene; Colorectal cancer; Biology","score_opus":0.09665042977454873,"score_gpt":0.4267790101597776,"score_spread":0.33012858038522885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391743861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93158907,0.059000876,0.00009867688,0.0033832705,0.0010797874,0.0019438615,0.002306474,0.00015052155,0.00044745026],"genre_scores_gemma":[0.9174687,0.026226409,0.0034905996,0.00092312874,0.002450918,0.002172655,0.00011851003,0.00018210997,0.04696694],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99694574,0.00006476764,0.0008830711,0.00083844614,0.00040877907,0.0008592173],"domain_scores_gemma":[0.9982141,0.0004259751,0.0001539023,0.00040492482,0.00038395944,0.00041712815],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033052795,0.0003455088,0.0006564358,0.00014001117,0.00015762859,0.000028327962,0.00018111308,0.00022434325,0.0004521667],"category_scores_gemma":[0.00010570019,0.00026083284,0.0004287949,0.00037948432,0.00024028645,0.00009796755,0.00022258809,0.00042419368,0.00001847996],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026646273,0.00074298104,0.7437101,0.0031860743,0.0010001863,0.00038839597,0.00047020227,0.0020022998,0.009254837,0.000010128391,0.032512564,0.20405763],"study_design_scores_gemma":[0.022315513,0.0034802642,0.20709153,0.009784155,0.0034837017,0.00007571305,0.00031570034,0.6196493,0.020358587,0.0008220045,0.110903434,0.0017201188],"about_ca_topic_score_codex":0.00027328174,"about_ca_topic_score_gemma":0.00023451292,"teacher_disagreement_score":0.617647,"about_ca_system_score_codex":0.000557193,"about_ca_system_score_gemma":0.0019913123,"threshold_uncertainty_score":0.9999844},"labels":[],"label_agreement":null},{"id":"W4391847508","doi":"10.1007/s11307-024-01900-6","title":"Pre-treatment 68 Ga-PSMA-11 PET/CT Prognostic Value in Predicting Response to 177Lu-PSMA-I&amp;T Therapy and Patient Survival","year":2024,"lang":"en","type":"article","venue":"Molecular Imaging and Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"Paracelsus Medizinische Privatuniversität","keywords":"Medicine; Prostate cancer; Nuclear medicine; Progressive disease; Standardized uptake value; Lesion; Positron emission tomography; Stage (stratigraphy); Internal medicine; Radiology; Oncology; Cancer; Disease; Surgery","score_opus":0.029045628926223283,"score_gpt":0.34009099961901457,"score_spread":0.31104537069279126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391847508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9697137,0.022731185,0.00007625338,0.0062325913,0.00017619663,0.0008665557,0.000026582838,0.000082271516,0.0000946472],"genre_scores_gemma":[0.997751,0.0010368596,0.00042409825,0.00030304526,0.00004057068,0.00014746014,0.000051928462,0.000028353772,0.00021668249],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842834,0.00030384562,0.00020502499,0.00053086336,0.00011122332,0.00042067858],"domain_scores_gemma":[0.999365,0.00021895685,0.000021426813,0.00018660107,0.000037707236,0.00017032686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000320514,0.00021739243,0.00028158905,0.00025143547,0.00007356495,0.000058250826,0.00004396841,0.000019730936,0.00001196793],"category_scores_gemma":[0.00011862017,0.00014546371,0.00005267795,0.00021872083,0.00013057767,0.000031829168,0.00007706371,0.00014367545,0.000007716548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027656178,0.0002927733,0.68123156,0.00011325563,0.00022565128,0.0046835295,0.0023457697,0.000012832841,0.21168037,0.00007225338,0.00011065479,0.09646572],"study_design_scores_gemma":[0.019631965,0.01590931,0.5323323,0.0028558725,0.0004982413,0.007736412,0.0023940406,0.009962144,0.06868946,0.0011022883,0.3371923,0.0016957106],"about_ca_topic_score_codex":0.00053651206,"about_ca_topic_score_gemma":0.00002488382,"teacher_disagreement_score":0.33708164,"about_ca_system_score_codex":0.00012936097,"about_ca_system_score_gemma":0.000145201,"threshold_uncertainty_score":0.5931838},"labels":[],"label_agreement":null},{"id":"W4391872533","doi":"10.3390/curroncol31020078","title":"Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in Oncology","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Grand River Hospital","funders":"","keywords":"Medicine; Prostate cancer; Systemic therapy; Disease; Oncology; Hormonal therapy; Cancer; Internal medicine; Prostate; Androgen deprivation therapy; Metastasis; Intensive care medicine; Breast cancer","score_opus":0.4555569369407522,"score_gpt":0.5848932609584662,"score_spread":0.12933632401771394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391872533","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009942586,0.9680011,0.000030357933,0.004560471,0.0030176276,0.023355845,0.0006891087,0.000067790745,0.00026770032],"genre_scores_gemma":[0.00000576812,0.93976444,0.00013469238,0.00030977992,0.00084382173,0.05215145,0.0052450052,0.00009778885,0.0014472315],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969012,0.00038960055,0.0012195576,0.00080978574,0.00017749974,0.00050237135],"domain_scores_gemma":[0.9977747,0.00051080616,0.00065717427,0.0003391736,0.00055768795,0.00016043545],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010808175,0.00047716836,0.0031339643,0.00047472236,0.000058985173,0.000018201157,0.00017650738,0.00045830122,0.000022795417],"category_scores_gemma":[0.00021650744,0.00031427143,0.00068800605,0.0004675862,0.000136538,0.00006990261,0.000049054695,0.0007465284,0.00003456483],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00045553836,0.0003232835,0.000009189808,0.17490476,0.00034724246,0.000032412237,0.000120383665,3.888559e-8,0.000002923633,0.00007431453,0.13436879,0.6893611],"study_design_scores_gemma":[0.0031461648,0.0017168428,7.940419e-7,0.11056146,0.0015065116,0.0001887333,0.00005541515,0.000030750547,0.0000015670473,0.000057033743,0.8825014,0.00023330352],"about_ca_topic_score_codex":0.000032106116,"about_ca_topic_score_gemma":0.000014620784,"teacher_disagreement_score":0.74813265,"about_ca_system_score_codex":0.0039459905,"about_ca_system_score_gemma":0.009346261,"threshold_uncertainty_score":0.9999309},"labels":[],"label_agreement":null},{"id":"W4391945432","doi":"10.1007/978-3-030-74720-6_80","title":"Prostate Cancer","year":2024,"lang":"en","type":"book-chapter","venue":"Geriatric medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Prostate cancer; Medicine; Urology; Cancer; Oncology; Internal medicine","score_opus":0.032489980521287175,"score_gpt":0.3334530899060476,"score_spread":0.30096310938476045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391945432","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011496803,0.17250203,0.0000017094576,0.018238243,0.0018117679,0.0012973262,0.00012122347,0.00020878259,0.80570394],"genre_scores_gemma":[0.00076135254,0.06936628,0.00003188939,0.0004933717,0.00475783,0.00012939936,0.00040936747,0.00016627288,0.9238842],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997407,0.0000073581177,0.00051750545,0.0007069687,0.0008803852,0.00048077074],"domain_scores_gemma":[0.9986196,0.00006113323,0.00014205751,0.0005300395,0.00022828649,0.00041888028],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002374801,0.0005227504,0.00098157,0.00063345744,0.0000684308,0.000017645296,0.00013082265,0.00036642738,0.013248887],"category_scores_gemma":[0.00002901225,0.00032533464,0.0002070544,0.00017759766,0.00029766033,0.000031929754,0.00010484182,0.00088251743,0.0014280812],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013031879,0.00005719116,0.00022844483,0.0053744023,0.00221497,0.0056467894,0.0010286592,9.2078926e-7,0.0005369125,0.029247496,0.8470987,0.1072623],"study_design_scores_gemma":[0.0025335655,0.0007754985,0.0000894676,0.0028583957,0.0017296873,0.00012888103,0.000024671,0.000010521121,0.00005248735,0.010345257,0.9811418,0.00030975722],"about_ca_topic_score_codex":0.000120126235,"about_ca_topic_score_gemma":0.000010195053,"teacher_disagreement_score":0.13404308,"about_ca_system_score_codex":0.00047160764,"about_ca_system_score_gemma":0.0006742564,"threshold_uncertainty_score":0.9999199},"labels":[],"label_agreement":null},{"id":"W4392021861","doi":"10.1038/s41391-024-00805-3","title":"Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration","year":2024,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Genomic Health; Foundation Medicine; Genentech; EMD Serono; Bausch Health; Astellas Pharma; Eisai; Seagen; Calithera Biosciences; Advanced Accelerator Applications; Endocyte; Sanofi; Exelixis; Clovis Oncology; Sanofi Genzyme; Pfizer; Incyte; F. Hoffmann-La Roche; Prostate Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; Cardinal Health; Amgen","keywords":"Prostate cancer; Medicine; Context (archaeology); Internal medicine; Oncology; Androgen receptor; Bioinformatics; Cancer; Biology","score_opus":0.03927864963026682,"score_gpt":0.4294667207368856,"score_spread":0.39018807110661874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392021861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.872833,0.10124883,0.00014910285,0.014616565,0.00047261114,0.004149173,0.0061811833,0.00013872812,0.00021079334],"genre_scores_gemma":[0.949953,0.042544138,0.0010131309,0.00024120683,0.00010213915,0.0033930738,0.0006947855,0.000037728572,0.0020207919],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979397,0.000075870674,0.00071417645,0.0005991117,0.00029380852,0.00037734478],"domain_scores_gemma":[0.9987837,0.00018532926,0.00010915251,0.00023054717,0.00038595867,0.0003052888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020570215,0.0002605628,0.00047222606,0.00027422773,0.00016075412,0.000112279,0.00007146561,0.00006792855,0.0000810785],"category_scores_gemma":[0.000120536366,0.00019617873,0.0001063297,0.00087999663,0.00043574517,0.0004445945,0.00004898657,0.00022474077,0.000006058791],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002303016,0.00094922626,0.71412814,0.0031921898,0.0003441958,0.000094678915,0.0034264408,0.00049542024,0.0024373978,0.0026209431,0.0011330491,0.2688753],"study_design_scores_gemma":[0.013803355,0.0012537905,0.9360468,0.005162202,0.00087415933,0.000030063118,0.0014130533,0.011687884,0.0025770937,0.0048528654,0.021543019,0.00075575034],"about_ca_topic_score_codex":0.00023162646,"about_ca_topic_score_gemma":0.00040702205,"teacher_disagreement_score":0.26811957,"about_ca_system_score_codex":0.0002616649,"about_ca_system_score_gemma":0.0026778043,"threshold_uncertainty_score":0.7999937},"labels":[],"label_agreement":null},{"id":"W4392111107","doi":"10.3390/curroncol31030086","title":"Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Germline mutation; Context (archaeology); Oncology; Overdiagnosis; BRCA mutation; Disease; Breast cancer; Cancer; Genetic testing; Germline; Internal medicine; Risk stratification; Population; Bioinformatics; Gynecology; Mutation; Gene; Genetics; Biology","score_opus":0.12718616228562118,"score_gpt":0.46136193539116027,"score_spread":0.3341757731055391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392111107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6395882,0.35749853,0.000004843357,0.0018062519,0.000061944455,0.00061877124,0.000047490525,0.0000051771194,0.00036883148],"genre_scores_gemma":[0.77066773,0.22903854,0.000028113102,0.000015759246,0.000022936832,0.00014941748,0.000030909505,0.0000047362223,0.00004183512],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994583,0.000084096646,0.00018741979,0.000116647716,0.000070309645,0.00008318682],"domain_scores_gemma":[0.99961615,0.00015618531,0.000063362895,0.000087251836,0.000053110587,0.000023918305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026228218,0.00004966019,0.00015901549,0.000075294294,0.000020187643,0.0000029310722,0.000030457106,0.000022235527,0.00005102801],"category_scores_gemma":[0.000045833316,0.000029406867,0.0000265092,0.00017079571,0.00010242437,0.000019264931,0.00001366502,0.00016650296,0.0000024780172],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012127067,0.00016276799,0.08367758,0.0017622678,0.00006799529,0.000002814664,0.0012987084,0.000010680926,0.0030276387,0.0009659274,0.0005058571,0.9083965],"study_design_scores_gemma":[0.00574358,0.0038142148,0.54412556,0.03887713,0.001597264,0.00003044588,0.0032713918,0.010772715,0.02490543,0.007401579,0.35909992,0.00036075094],"about_ca_topic_score_codex":0.000085226355,"about_ca_topic_score_gemma":0.00006463885,"teacher_disagreement_score":0.90803576,"about_ca_system_score_codex":0.000084876796,"about_ca_system_score_gemma":0.0002461114,"threshold_uncertainty_score":0.11991772},"labels":[],"label_agreement":null},{"id":"W4392125982","doi":"10.1093/oncolo/oyae019","title":"Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Bayer HealthCare; Bayer","keywords":"Tolerability; Medicine; Adverse effect; Placebo; Prostate cancer; Internal medicine; Androgen deprivation therapy; Oncology; Cancer","score_opus":0.02509620189157084,"score_gpt":0.3702472411746977,"score_spread":0.34515103928312685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392125982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983877,0.006014505,0.000026572263,0.007487451,0.00005729913,0.0018344385,0.00033342247,0.000019235007,0.0003500867],"genre_scores_gemma":[0.9954763,0.0013136263,0.0002316452,0.000044856366,0.000023951645,0.00018762998,0.000029989673,0.000009845172,0.0026821357],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991328,0.000058391153,0.00027127104,0.00021647762,0.00013492646,0.00018612725],"domain_scores_gemma":[0.99937886,0.00031533532,0.00004921082,0.00014101747,0.00005350336,0.0000620641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007033068,0.00010061276,0.00027203548,0.000039231658,0.000060075323,0.00001271506,0.00003831745,0.0000361302,0.000044226494],"category_scores_gemma":[0.00006811148,0.00005803084,0.000039380135,0.0001212725,0.00042686381,0.000047796213,0.000029404286,0.000114696304,0.0000017270464],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07465139,0.004070791,0.091885306,0.012789771,0.002434722,0.0012197695,0.02165874,0.0013991451,0.14606905,0.0035231602,0.00447715,0.635821],"study_design_scores_gemma":[0.012256387,0.0046633207,0.93303984,0.0012055124,0.00093726354,0.00006827616,0.0025707388,0.027940746,0.0047918228,0.0033206933,0.008856457,0.0003489167],"about_ca_topic_score_codex":0.00038817019,"about_ca_topic_score_gemma":0.0005471714,"teacher_disagreement_score":0.8411546,"about_ca_system_score_codex":0.0002319153,"about_ca_system_score_gemma":0.0004565396,"threshold_uncertainty_score":0.2366429},"labels":[],"label_agreement":null},{"id":"W4392164936","doi":"10.1503/cmaj.230555-f","title":"Hypothyroïdie causée par l’apalutamide","year":2024,"lang":"fr","type":"article","venue":"Canadian Medical Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Gynecology","score_opus":0.01708779338394239,"score_gpt":0.29529713403824465,"score_spread":0.27820934065430225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392164936","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030009048,0.31869233,0.000064944485,0.5777726,0.02752519,0.0003585476,0.00029898784,0.00007428047,0.04520403],"genre_scores_gemma":[0.48842236,0.08174345,0.00018272786,0.021964828,0.061088048,0.00004390159,0.00011732531,0.00018015357,0.3462572],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99438363,0.00035034635,0.0006298543,0.0003337855,0.0025832888,0.0017191193],"domain_scores_gemma":[0.9926488,0.00052604853,0.00009638647,0.00015438377,0.00045885902,0.006115521],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.003243503,0.00026588218,0.00041136186,0.0004974298,0.00045122122,0.00046082406,0.00023977541,0.00095965766,0.03859614],"category_scores_gemma":[0.0022532823,0.0002289048,0.00029725712,0.00069421774,0.00019786102,0.00027793465,0.00002738605,0.0031962376,0.0064227176],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000015737933,0.000045456567,0.016675763,0.00016168173,0.0008994968,0.025848443,0.00054378953,0.00000225323,0.000021599153,0.0010544533,0.6885554,0.2661759],"study_design_scores_gemma":[0.0013304946,0.00018277443,0.011460359,0.0019427032,0.0002713607,0.0024286963,0.00045878638,0.001236542,0.00006368487,0.0007404591,0.9796611,0.00022302543],"about_ca_topic_score_codex":0.0068739946,"about_ca_topic_score_gemma":0.025304252,"teacher_disagreement_score":0.5558078,"about_ca_system_score_codex":0.009711527,"about_ca_system_score_gemma":0.025556648,"threshold_uncertainty_score":0.9997393},"labels":[],"label_agreement":null},{"id":"W4392246504","doi":"10.1016/j.esmoop.2024.102352","title":"21P Polymerase theta inhibition in homologous recombination-deficient prostate cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Homologous recombination; Homologous chromosome; Prostate cancer; Polymerase; Recombination; Cancer research; Biology; Cancer; Chemistry; Genetics; DNA; Gene","score_opus":0.03352979029464611,"score_gpt":0.3799532532632377,"score_spread":0.3464234629685916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392246504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9532511,0.004594438,0.0000021798228,0.015317339,0.0003552651,0.0015757601,0.000048062997,0.00005878377,0.024797058],"genre_scores_gemma":[0.964232,0.0011825941,0.000026895936,0.00024455314,0.00004477199,0.00050943356,0.00015712183,0.000021828322,0.033580773],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99903446,0.000047413378,0.00016979931,0.00030604022,0.0001895017,0.00025280702],"domain_scores_gemma":[0.99965835,0.000033676693,0.00002018818,0.00016849421,0.000042004114,0.0000772883],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028555814,0.00010571213,0.00016689704,0.00019105744,0.000063996034,0.00013365131,0.000074879004,0.000043325203,0.0009404514],"category_scores_gemma":[0.000016986398,0.000076358236,0.00003913503,0.00043453326,0.000054440996,0.00019191758,0.00011921936,0.00020626625,0.00015479715],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035274602,0.003732962,0.15820588,0.0015576483,0.0007016812,0.017509956,0.01773186,0.00012607065,0.010767886,0.012176796,0.07674204,0.6972197],"study_design_scores_gemma":[0.029562175,0.0038435222,0.41994184,0.008802902,0.0004294848,0.000638325,0.0026452064,0.0045298133,0.3359426,0.020224215,0.17193395,0.0015059861],"about_ca_topic_score_codex":0.004607469,"about_ca_topic_score_gemma":0.00057503907,"teacher_disagreement_score":0.69571376,"about_ca_system_score_codex":0.00034150956,"about_ca_system_score_gemma":0.0004033576,"threshold_uncertainty_score":0.9999728},"labels":[],"label_agreement":null},{"id":"W4392302540","doi":"10.1016/j.xgen.2024.100511","title":"Genomic evolution shapes prostate cancer disease type","year":2024,"lang":"en","type":"article","venue":"Cell Genomics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; Cancer Research UK Cambridge Institute, University of Cambridge; NIHR Cambridge Biomedical Research Centre; Canadian Institutes of Health Research; Syöpäjärjestöt; National Institutes of Health; H2020 Marie Skłodowska-Curie Actions; Masonic Charitable Foundation; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Prostate Cancer Canada; Prostate Cancer UK; National Institute for Health and Care Research; Sigrid Juséliuksen Säätiö; National Cancer Research Institute; Royal Marsden NHS Foundation Trust; National Health and Medical Research Council; University of St Andrews; Horizon 2020 Framework Programme; Academy of Finland; University of Cambridge; Wellcome Trust; Cancer Research UK; Hutchison Whampoa Limited; Ontario Institute for Cancer Research; Francis Crick Institute; Medical Research Council; Cancer Prevention and Research Institute of Texas","keywords":"Prostate cancer; Cancer; Biology; Disease; Computational biology; Prostate; Somatic evolution in cancer; Androgen receptor; Chromoplexy; Evolutionary biology; Cancer research; Genetics; Medicine; Internal medicine; PCA3","score_opus":0.020686882607022884,"score_gpt":0.3005653964888934,"score_spread":0.2798785138818705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392302540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89614606,0.09853942,0.000039240207,0.0012451155,0.00054301956,0.00058888074,0.00007892843,0.0001232447,0.002696084],"genre_scores_gemma":[0.95548844,0.0098643275,0.00013364134,0.000118695534,0.0004270734,0.000061014027,0.00009297546,0.000048397942,0.033765454],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99914515,0.000013002821,0.00012866568,0.00029689205,0.00012847886,0.00028781325],"domain_scores_gemma":[0.9995157,0.000016965174,0.00001677767,0.00015318517,0.00006304516,0.00023432226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007256871,0.00012739161,0.00012940718,0.00010204869,0.000068566915,0.000054231314,0.00006332383,0.000044187018,0.00033911265],"category_scores_gemma":[0.0000060940715,0.00010064462,0.000072714094,0.00019030689,0.000060484002,0.000053995922,0.000048144622,0.00015135942,0.00057357573],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004870377,0.00051797176,0.10661458,0.0041342922,0.0006447216,0.001602173,0.0033912298,0.0012293144,0.77715725,0.0010777072,0.039073125,0.05968724],"study_design_scores_gemma":[0.0039578862,0.0007237867,0.16401383,0.0006005952,0.0010659463,0.00004075303,0.00043042062,0.033647906,0.017093148,0.0024850077,0.775088,0.00085269054],"about_ca_topic_score_codex":0.000053129268,"about_ca_topic_score_gemma":0.000005935008,"teacher_disagreement_score":0.7600641,"about_ca_system_score_codex":0.00082255097,"about_ca_system_score_gemma":0.0010763681,"threshold_uncertainty_score":0.73723465},"labels":[],"label_agreement":null},{"id":"W4392303266","doi":"10.1136/bmjonc-2023-000198","title":"Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review","year":2024,"lang":"en","type":"review","venue":"BMJ Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute for Health and Care Research","keywords":"Enzalutamide; Prostate cancer; Medicine; Oncology; Cancer; Internal medicine; Androgen receptor","score_opus":0.2122101569469165,"score_gpt":0.5358499228968534,"score_spread":0.32363976594993693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392303266","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006393844,0.9836818,0.0000015081521,0.0008308146,0.0002405664,0.012757219,0.0012893835,0.000054503656,0.0005048033],"genre_scores_gemma":[0.00018308032,0.99089766,0.00090390234,0.000056861332,0.0001305859,0.004402624,0.0003777243,0.0001548037,0.002892791],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99475884,0.00067903445,0.002146747,0.00097084255,0.000748898,0.00069560553],"domain_scores_gemma":[0.9964271,0.00061618246,0.0013684427,0.0008144487,0.00040767793,0.00036613553],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007948695,0.0009343398,0.008853991,0.0005715226,0.00006810826,0.000018147075,0.00019741787,0.00029973127,0.00032698078],"category_scores_gemma":[0.0001614113,0.00047095533,0.0005832073,0.0010867117,0.00080429256,0.00006896412,0.00013843892,0.0005228812,0.000017727118],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003917351,0.00079619035,0.00007586625,0.21855336,0.0038879311,0.0011219824,0.00057258917,5.621952e-7,0.000013125269,0.000017983199,0.0029431093,0.76809996],"study_design_scores_gemma":[0.0056111044,0.01694559,0.00003798784,0.13132423,0.027635569,0.0009876936,0.00018827783,0.000010210875,0.00007095955,0.000016645929,0.8167736,0.00039816095],"about_ca_topic_score_codex":0.00017682913,"about_ca_topic_score_gemma":0.00022266681,"teacher_disagreement_score":0.81383044,"about_ca_system_score_codex":0.0017354755,"about_ca_system_score_gemma":0.010525094,"threshold_uncertainty_score":0.9997742},"labels":[],"label_agreement":null},{"id":"W4392347499","doi":"10.5489/cuaj.8620","title":"Real-world evaluation of access-driven Canadian treatment sequences in progressive prostate cancer (REACTIVATE)","year":2024,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia; University of Alberta; Bayer (Canada); BC Cancer Agency; McMaster University; Spinal Cord Injury BC; University of Calgary; Impact; Abbotsford Veterinary Clinic","funders":"","keywords":"Medicine; Hazard ratio; Prostate cancer; Confidence interval; Internal medicine; Cohort; Cancer; Health care; Overall survival; Retrospective cohort study; Oncology","score_opus":0.07621281862408386,"score_gpt":0.3938477291184254,"score_spread":0.31763491049434156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392347499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95425934,0.003382123,1.9115673e-7,0.035004977,0.00040989928,0.00096974405,0.00016372735,0.000018310522,0.0057917032],"genre_scores_gemma":[0.9956981,0.0019807282,0.000019204255,0.00022362376,0.00024332234,0.0002011231,0.000076248165,0.000014546198,0.0015431365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978657,0.00025953134,0.00035765197,0.00025903905,0.0006438712,0.0006142503],"domain_scores_gemma":[0.99830234,0.00010297088,0.00015239177,0.00008751162,0.0005606165,0.00079417415],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009125188,0.00015760095,0.0002996183,0.00092625234,0.00013876185,0.00015367108,0.00011076555,0.00015299628,0.0012845757],"category_scores_gemma":[0.00018869787,0.00010799155,0.00010453072,0.000788618,0.000055157197,0.0002477183,0.000008772188,0.00041062562,0.000014827832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00008135147,0.000050166716,0.9557391,0.000021511014,0.00030744245,0.00061231887,0.0006640455,0.00040315045,0.00015077315,0.00008423277,0.0018785297,0.040007427],"study_design_scores_gemma":[0.0020278296,0.0004991155,0.9677794,0.00029400288,0.00030364248,0.00004808413,0.00014171116,0.0033010805,0.00051315746,0.0012157563,0.023706,0.00017021378],"about_ca_topic_score_codex":0.51075655,"about_ca_topic_score_gemma":0.7612177,"teacher_disagreement_score":0.25046122,"about_ca_system_score_codex":0.017923912,"about_ca_system_score_gemma":0.013517023,"threshold_uncertainty_score":0.99962837},"labels":[],"label_agreement":null},{"id":"W4392512541","doi":"10.2196/54086","title":"Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Somatic or Germline Homologous Recombination Repair Gene Mutations: Phase II Single-Arm Trial","year":2024,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Carboplatin; Medicine; Homologous recombination; Germline; Somatic cell; Germline mutation; Oncology; Gene; Internal medicine; Mutation; Genetics; Cancer; Biology; Cisplatin; Chemotherapy","score_opus":0.18757520809691763,"score_gpt":0.5174424609602524,"score_spread":0.32986725286333474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392512541","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61647683,0.00011022998,0.0000068713266,0.00076562533,0.000030802887,0.38217986,0.00010969674,0.0001835586,0.0001365171],"genre_scores_gemma":[0.2908725,0.000009538002,0.00089557556,0.00001203326,0.00011363999,0.7050344,0.00027183868,0.00006941932,0.0027210517],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955041,0.00049857167,0.0007949981,0.0007531275,0.0015804996,0.00086869666],"domain_scores_gemma":[0.9980225,0.00036957758,0.00012204889,0.00046010411,0.00075710804,0.00026867355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014203943,0.00031044762,0.0004936953,0.0009875214,0.0003547409,0.00023770164,0.00015675796,0.000101663914,0.00036106253],"category_scores_gemma":[0.00035526193,0.00020453273,0.00010247042,0.0018243223,0.000243457,0.00046985334,0.0000976385,0.00079861813,0.000021061986],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71403533,0.070242785,0.0076474627,0.015423337,0.0015209308,0.0075447555,0.010714713,0.00018478284,0.041631702,0.00028662704,0.0027749534,0.12799262],"study_design_scores_gemma":[0.6460178,0.24106957,0.01598138,0.03037781,0.00023374704,0.0000611155,0.0009771865,0.008061357,0.045116235,0.0014520563,0.009310459,0.0013412832],"about_ca_topic_score_codex":0.000201813,"about_ca_topic_score_gemma":0.0002472466,"teacher_disagreement_score":0.32560432,"about_ca_system_score_codex":0.0014210731,"about_ca_system_score_gemma":0.0024513556,"threshold_uncertainty_score":0.83406025},"labels":[],"label_agreement":null},{"id":"W4392561550","doi":"10.1002/pros.24682","title":"Defining the challenges and opportunities for using patient‐derived models in prostate cancer research","year":2024,"lang":"en","type":"review","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"DOD Prostate Cancer Research Program; National Cancer Institute; Marshfield Clinic Research Foundation; Cancer Council NSW; National Health and Medical Research Council; Medical Research Council; Johns Hopkins University; Prostate Cancer Foundation; Advance Queensland; Tour de Cure; National Science Foundation; Krebsliga Beider Basel; Universitätsspital Basel; Australian Government; PA Research Foundation; Swiss Cancer Research Foundation; Pancreatic Cancer UK; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Cancer Council Victoria; Partenariat Canadien Contre Le Cancer; Cancer Australia; National Institutes of Health; U.S. Department of Health and Human Services; Movember Foundation","keywords":"Prostate cancer; Translational research; Standardization; Cancer; Medicine; Prostate; Variety (cybernetics); Medical physics; Computer science; Data science; Pathology; Internal medicine; Artificial intelligence","score_opus":0.5227608348091353,"score_gpt":0.486277422487123,"score_spread":0.03648341232201224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392561550","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00094062486,0.98607385,9.914719e-7,0.0048880694,0.00015569033,0.0068817465,0.00039171643,0.000042120417,0.0006251654],"genre_scores_gemma":[0.0007136901,0.99221885,0.000052481824,0.00006019064,0.000102635575,0.0047903685,0.0000884055,0.00014174469,0.0018316474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99693704,0.0005056524,0.0005488659,0.00059344765,0.0005427969,0.0008722076],"domain_scores_gemma":[0.9983601,0.0006206854,0.00014403103,0.00048753302,0.00025907284,0.00012856688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019353621,0.0004388041,0.0010598385,0.0004184328,0.00037862486,0.00015059476,0.00023551605,0.00013922072,0.0000055078935],"category_scores_gemma":[0.000056163688,0.00019454418,0.00020214904,0.0003474365,0.00059826934,0.00012593405,0.00041342052,0.0011390505,0.0000061384103],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025883917,0.00003770501,6.1190076e-7,0.02579277,0.0003625491,0.00013968135,0.01066758,0.000006738151,0.0000028034556,0.003853722,0.00023273267,0.9586443],"study_design_scores_gemma":[0.0015589803,0.0007662224,0.0000019031784,0.06977739,0.0020029778,0.00019303532,0.0122302165,0.0017030877,0.00003955252,0.013041434,0.89811385,0.0005713679],"about_ca_topic_score_codex":0.00016047856,"about_ca_topic_score_gemma":0.00007727439,"teacher_disagreement_score":0.9580729,"about_ca_system_score_codex":0.00039749395,"about_ca_system_score_gemma":0.0016281884,"threshold_uncertainty_score":0.79332817},"labels":[],"label_agreement":null},{"id":"W4392587677","doi":"10.3390/curroncol31030106","title":"177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université de Montréal; London Health Sciences Centre; McMaster University; Juravinski Cancer Centre; Queen Elizabeth II Health Sciences Centre; Centre Hospitalier de l’Université de Montréal; Université Laval; Centre hospitalier universitaire de Québec; Dalhousie University; Western University; University of Toronto; Jewish General Hospital; University of Calgary; McGill University; University of British Columbia","funders":"Ipsen; Astellas Pharma; Seagen; Advanced Accelerator Applications; Eisai; Sanofi; Genentech; AstraZeneca; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Prostate cancer; Taxane; Clinical trial; Oncology; Internal medicine; Adverse effect; Clinical Practice; Cabazitaxel; Observational study; Cancer; Androgen deprivation therapy; Breast cancer; Family medicine","score_opus":0.5473004949041903,"score_gpt":0.6469422352170666,"score_spread":0.09964174031287631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392587677","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010855776,0.97237724,0.0000010848204,0.018519463,0.0007213438,0.0074403896,0.000788026,0.0000075228004,0.00013409571],"genre_scores_gemma":[0.000018636949,0.99475867,0.00018757943,0.00023059137,0.00013884483,0.0042233397,0.00015341715,0.00002935555,0.0002595531],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99717647,0.0005665979,0.0012135403,0.00050812203,0.00017343553,0.00036181937],"domain_scores_gemma":[0.996613,0.0017644225,0.00051105814,0.0004344568,0.00042488502,0.00025217392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017165851,0.00026127973,0.0016476836,0.00020197178,0.00008254953,0.000018230616,0.00020265408,0.00013812406,0.000019782137],"category_scores_gemma":[0.0027079915,0.00014667911,0.00035941345,0.00064148067,0.0002617599,0.00007295113,0.000080491285,0.00073669874,0.000006742383],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046172176,0.00014901203,0.00019122858,0.18270539,0.0002252098,0.000016913396,0.000068884954,1.9097687e-8,1.9054156e-7,0.00026953532,0.010648804,0.80567867],"study_design_scores_gemma":[0.0004048583,0.00031764113,0.00027056897,0.17713,0.0052027144,0.00008247217,0.000022190072,0.0000022983218,1.0591939e-7,0.00007289925,0.81639946,0.0000948042],"about_ca_topic_score_codex":0.0032990142,"about_ca_topic_score_gemma":0.02246515,"teacher_disagreement_score":0.80575067,"about_ca_system_score_codex":0.001186794,"about_ca_system_score_gemma":0.017860448,"threshold_uncertainty_score":0.9953723},"labels":[],"label_agreement":null},{"id":"W4392691906","doi":"10.1016/j.eururo.2024.01.003","title":"Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study","year":2024,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Ottawa; University of Toronto; University Health Network; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal","funders":"Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Prostate; Oncology; Internal medicine; Urology; Cancer","score_opus":0.014299875810108546,"score_gpt":0.3156597686273024,"score_spread":0.30135989281719383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392691906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9094599,0.0021270395,0.0000013677679,0.08227663,0.00016772053,0.004830398,0.00068597554,0.000054676842,0.00039630654],"genre_scores_gemma":[0.9627558,0.0003604103,0.000007574246,0.03156808,0.00011798369,0.0002518592,0.0001836954,0.00015059905,0.004603991],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99095106,0.0063227215,0.0007184044,0.0008383435,0.00061423605,0.00055521895],"domain_scores_gemma":[0.99743813,0.0011964763,0.00027808355,0.0008032933,0.00019137475,0.00009265023],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022531927,0.00050051016,0.0016171726,0.0015781792,0.00004885664,0.00001546351,0.00026893863,0.00012164505,0.000043700777],"category_scores_gemma":[0.00023028997,0.00028404166,0.00037324763,0.0023219942,0.00038188804,0.000022155657,0.000206252,0.001818484,0.00003643841],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4774885,0.0023511434,0.021789487,0.002203901,0.057097524,0.065867916,0.06381124,0.0014523038,0.033579346,0.0000017842377,0.14957465,0.12478222],"study_design_scores_gemma":[0.02497847,0.09487355,0.7818811,0.00080533285,0.016171414,0.00008040872,0.00045550676,0.00084268907,0.01138521,0.000010684261,0.06757385,0.00094180054],"about_ca_topic_score_codex":0.0003282834,"about_ca_topic_score_gemma":0.0001450686,"teacher_disagreement_score":0.7600916,"about_ca_system_score_codex":0.00032029656,"about_ca_system_score_gemma":0.00039707718,"threshold_uncertainty_score":0.9999612},"labels":[],"label_agreement":null},{"id":"W4392712374","doi":"10.1177/12034754241239278","title":"Cutaneous Eruptions Associated With Androgen Receptor Inhibitors for Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials","year":2024,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Randomized controlled trial; Meta-analysis; Androgen receptor; Oncology; Internal medicine; Castration; Androgen; Androgen deprivation therapy; Androgen Receptor Antagonists; Cancer; Hormone","score_opus":0.17081736833183833,"score_gpt":0.42140439417500675,"score_spread":0.2505870258431684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392712374","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00064919924,0.99017143,0.000009159378,0.0021125833,0.00040139758,0.005692849,0.00089011836,0.000018188899,0.000055088884],"genre_scores_gemma":[0.0011746358,0.99386626,0.00005167045,0.000059015605,0.000524879,0.00077455904,0.0004483854,0.00007877304,0.0030218153],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9898271,0.0017375832,0.0063225105,0.00037223898,0.0013203888,0.0004201766],"domain_scores_gemma":[0.96550196,0.025990034,0.006172094,0.00025410875,0.0016884101,0.0003933965],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.011063494,0.00073369936,0.044899814,0.0028903256,0.00010777718,0.000058917583,0.00010320348,0.0003312836,0.00036724802],"category_scores_gemma":[0.008827947,0.00029187516,0.013849729,0.0014955853,0.0004627469,0.000063453896,0.000017347194,0.00059670117,6.847003e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11781992,0.00020897515,0.000008454447,0.008346959,0.8420903,0.0020862725,0.00048428378,0.000009267346,0.000028378048,0.000011248101,0.008450425,0.020455519],"study_design_scores_gemma":[0.04107409,0.0010664769,7.193526e-8,0.013306529,0.87003505,0.0017980468,0.00019001572,0.00002786026,0.0000064526726,0.000025123916,0.072242565,0.00022773248],"about_ca_topic_score_codex":0.00006987338,"about_ca_topic_score_gemma":0.00005874785,"teacher_disagreement_score":0.07674583,"about_ca_system_score_codex":0.00029634993,"about_ca_system_score_gemma":0.003268638,"threshold_uncertainty_score":0.9999533},"labels":[],"label_agreement":null},{"id":"W4392807621","doi":"10.1016/j.urolonc.2024.01.079","title":"LONGITUDINAL CHANGES IN PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH HIGH-RISK BIOCHEMICALLY RECURRENT (BCR) NONMETASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) FROM THE EMBARK STUDY","year":2024,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Castration; Oncology; Biochemical recurrence; Gynecology; Internal medicine; Cancer; Urology; Prostatectomy; Hormone","score_opus":0.026127470129433072,"score_gpt":0.32334838313691466,"score_spread":0.2972209130074816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392807621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98887473,0.0014021791,0.0000018872588,0.007208298,0.00019004762,0.0020452086,0.00021619342,0.00003414393,0.000027308351],"genre_scores_gemma":[0.9967138,0.0006286679,0.0012391405,0.00030890037,0.000042471158,0.0006701387,0.00029465376,0.000017039862,0.00008517556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981562,0.00023292188,0.0003793587,0.0005719099,0.00030528166,0.00035433707],"domain_scores_gemma":[0.99892455,0.00047537053,0.00014514737,0.00019438876,0.00011641008,0.00014414646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029585414,0.00025356087,0.00042689836,0.00019784374,0.00014941595,0.000049910435,0.00006878522,0.000104886356,0.00003720091],"category_scores_gemma":[0.00014447854,0.0001424396,0.000031050004,0.0005764452,0.00047448804,0.00010177871,0.000053952564,0.0005922056,0.00000507641],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082272675,0.00078722544,0.9866443,0.000023529974,0.00028340376,0.00078254467,0.0045088693,0.00003452338,0.000050630508,0.000041674662,0.0002314455,0.005789076],"study_design_scores_gemma":[0.0034338895,0.005911936,0.9855742,0.00023277168,0.00048243065,0.000017132468,0.001506436,0.00017152115,0.00020937118,0.0005469514,0.0017416511,0.00017169636],"about_ca_topic_score_codex":0.0023202342,"about_ca_topic_score_gemma":0.0064337556,"teacher_disagreement_score":0.007839078,"about_ca_system_score_codex":0.0003191292,"about_ca_system_score_gemma":0.0005163746,"threshold_uncertainty_score":0.58085185},"labels":[],"label_agreement":null},{"id":"W4392821325","doi":"10.1016/j.urolonc.2024.01.249","title":"ASSOCIATION OF PROTON PUMP INHIBITORS CUMULATIVE USE WITH PROSTATE CANCER RISK AND ADVERSE OUTCOMES: A POPULATION-BASED ANALYSIS","year":2024,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; University of Toronto","funders":"","keywords":"Prostate cancer; Medicine; Oncology; Internal medicine; Adverse effect; Population; Cancer; Environmental health","score_opus":0.025568557512638146,"score_gpt":0.3465742573761265,"score_spread":0.32100569986348837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392821325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992403,0.000707837,0.000037227885,0.005498273,0.000044869037,0.0010295367,0.00016811902,0.000050000806,0.00006114232],"genre_scores_gemma":[0.9911966,0.0009143418,0.0050940504,0.00023560278,0.000031182517,0.00042971203,0.0002149185,0.000012856391,0.0018707385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988383,0.00013694148,0.0002626223,0.00032837727,0.00022741864,0.00020631574],"domain_scores_gemma":[0.9988646,0.00054725574,0.00019208771,0.000106228305,0.0001378628,0.0001519963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033555902,0.00015796002,0.0003894271,0.0003907069,0.00014933704,0.000026739724,0.000025627349,0.00015197469,0.0000396125],"category_scores_gemma":[0.00019166584,0.0001009318,0.00007009877,0.0008185445,0.00027198723,0.00017305512,0.000017177417,0.0002745405,0.0000013256022],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031527827,0.00008845326,0.9958349,0.00011460401,0.0010011063,0.000044929977,0.0007425954,0.0009412192,0.000046712117,0.00011465765,0.00013035571,0.0006252096],"study_design_scores_gemma":[0.00201589,0.0023283747,0.92936915,0.0002025705,0.005382647,0.000008917959,0.00024189695,0.017140085,0.000547166,0.0007773877,0.041793976,0.00019196603],"about_ca_topic_score_codex":0.0016547984,"about_ca_topic_score_gemma":0.00057434954,"teacher_disagreement_score":0.06646576,"about_ca_system_score_codex":0.0003374452,"about_ca_system_score_gemma":0.0004563993,"threshold_uncertainty_score":0.41158795},"labels":[],"label_agreement":null},{"id":"W4392859762","doi":"10.1016/j.eururo.2024.01.019","title":"Prostate-specific Membrane Antigen Positron Emission Tomography–detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study","year":2024,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Positron emission tomography; Glutamate carboxypeptidase II; Prostate-specific antigen; Proportional hazards model; Oncology; Internal medicine; Confidence interval; Biochemical recurrence; Urology; Cancer; Radiology; Prostatectomy","score_opus":0.010660183176227822,"score_gpt":0.2671901839905229,"score_spread":0.2565300008142951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392859762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959485,0.0008734466,0.000012877983,0.0002534686,0.0002843668,0.0017485538,0.0007342257,0.00006827136,0.00007628335],"genre_scores_gemma":[0.9980985,0.00092177035,0.00010265482,0.000018680297,0.000076208744,0.000045915516,0.00046453395,0.00005918699,0.00021253782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777925,0.0004452707,0.00034559163,0.0006421144,0.0004902732,0.00029752537],"domain_scores_gemma":[0.9990068,0.00004444073,0.00012864452,0.00027932946,0.00028784867,0.00025295207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027140646,0.00024343187,0.00029624256,0.00025659986,0.000102575104,0.00006631598,0.000105882646,0.000023419718,0.00008995179],"category_scores_gemma":[0.000028546654,0.00016565574,0.000051988805,0.00020592539,0.00017596716,0.0002023731,0.000075714386,0.00026402847,0.0000044843596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018300483,0.0013448312,0.96632385,0.000106867454,0.00061582995,0.0007091632,0.0021279424,0.00004109136,0.008213271,0.000015910478,0.000026182228,0.0021745483],"study_design_scores_gemma":[0.0067614554,0.005094543,0.9865469,0.000087875975,0.0002686522,0.000002123168,0.00013541181,0.00027984017,0.00043254392,0.000011833337,0.00022744559,0.0001514237],"about_ca_topic_score_codex":0.00016005164,"about_ca_topic_score_gemma":0.00005343526,"teacher_disagreement_score":0.020222973,"about_ca_system_score_codex":0.00010235107,"about_ca_system_score_gemma":0.000088495566,"threshold_uncertainty_score":0.6755245},"labels":[],"label_agreement":null},{"id":"W4392956841","doi":"10.3390/curroncol31030118","title":"Ductal Adenocarcinoma of the Prostate with Novel Genetic Alterations Characterized by Next-Generation Sequencing","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Adenocarcinoma; Prostate adenocarcinoma; Cancer; Disease; Oncology; Pathology; Bioinformatics; Internal medicine; Biology","score_opus":0.1850736776166834,"score_gpt":0.3867953159175965,"score_spread":0.20172163830091314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392956841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824833,0.012970296,0.00063975976,0.0019100659,0.0006944158,0.0010366142,0.00010190863,0.000031131254,0.00013246933],"genre_scores_gemma":[0.99754643,0.00056544767,0.00023983915,0.000048056616,0.00036663224,0.0002417608,0.00022155239,0.000017899616,0.00075237156],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99913615,0.00005025414,0.00020142096,0.0002313545,0.00018591307,0.00019490968],"domain_scores_gemma":[0.9995806,0.00003103851,0.00005241026,0.00016053994,0.0001093381,0.000066048604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008347411,0.000109309476,0.00018465669,0.000068933936,0.0000813365,0.000031892818,0.00006366555,0.000047364298,0.00006682055],"category_scores_gemma":[0.000011141536,0.000061027637,0.000053757372,0.00022408333,0.00014851171,0.00008528136,0.000033962984,0.00021318588,0.0000074738136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023634592,0.00028851218,0.01958508,0.0003912073,0.0001439671,0.000044022043,0.0014364432,0.000006803168,0.9379849,0.00012310292,0.0015955148,0.038164098],"study_design_scores_gemma":[0.02240438,0.010215453,0.15724552,0.0023947419,0.001986422,0.0027273237,0.0011699436,0.05168766,0.43020812,0.00019012649,0.31873187,0.0010384183],"about_ca_topic_score_codex":0.000014104476,"about_ca_topic_score_gemma":0.000013884203,"teacher_disagreement_score":0.5077768,"about_ca_system_score_codex":0.0003501439,"about_ca_system_score_gemma":0.00089549617,"threshold_uncertainty_score":0.24886347},"labels":[],"label_agreement":null},{"id":"W4393034252","doi":"10.1101/2024.03.20.585990","title":"<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Institute of Cancer Research","funders":"University of Texas MD Anderson Cancer Center","keywords":"PTEN; Prostate cancer; Cancer research; Synthetic lethality; Prostate; Biology; Context (archaeology); Cancer; Medicine; DNA repair; PI3K/AKT/mTOR pathway; Signal transduction; Cell biology; Genetics; Gene","score_opus":0.02861495551088399,"score_gpt":0.28389727041023044,"score_spread":0.25528231489934644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393034252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97840613,0.009771937,0.00014788152,0.005110229,0.0012333466,0.003953286,0.000607124,0.00074068067,0.000029375948],"genre_scores_gemma":[0.98862255,0.00031894253,0.0056599383,0.00049590896,0.0004418658,0.004072396,0.0000036629592,0.0002548344,0.00012992088],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995041,0.0001770987,0.00083292474,0.0018048133,0.0009560816,0.0011880866],"domain_scores_gemma":[0.99671334,0.00012224045,0.00020948159,0.0013942638,0.0008239797,0.00073671574],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001033644,0.0009081455,0.0010555122,0.0004934996,0.0003027303,0.0003771968,0.00040137206,0.00047482827,0.00014404496],"category_scores_gemma":[0.00019536862,0.00077914965,0.00024448303,0.00073308253,0.000310717,0.00008578548,0.0007625955,0.0014110688,0.00019347828],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002095943,0.0020984188,0.08642465,0.032814834,0.002531429,0.0022950007,0.0012187547,0.00077060785,0.8662467,0.0003001633,0.0029273282,0.000276147],"study_design_scores_gemma":[0.0013291603,0.0002602724,0.019128488,0.0091961585,0.00040513248,1.0514951e-7,0.0000168343,0.00022040831,0.9544259,0.00001119275,0.013822102,0.0011842593],"about_ca_topic_score_codex":0.000271884,"about_ca_topic_score_gemma":0.000020059892,"teacher_disagreement_score":0.088179156,"about_ca_system_score_codex":0.0020394702,"about_ca_system_score_gemma":0.005795145,"threshold_uncertainty_score":0.9998411},"labels":[],"label_agreement":null},{"id":"W4393072330","doi":"10.1158/1538-7445.am2024-1448","title":"Abstract 1448: Investigating the effects of estrogen on the initiation of prostate cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Newfoundland and Labrador Centre for Applied Health Research; Government of Newfoundland and Labrador; Memorial University of Newfoundland","funders":"","keywords":"Prostate cancer; Cancer; Medicine; Estrogen; Prostate; Internal medicine; Oncology","score_opus":0.10785178043211657,"score_gpt":0.4464590085819904,"score_spread":0.3386072281498738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393072330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96326166,0.02311942,5.402763e-7,0.010136293,0.000222774,0.0014951058,0.000049547332,0.000022108607,0.0016925631],"genre_scores_gemma":[0.992732,0.004835718,0.0000063955003,0.000108103304,0.000271822,0.0009445897,0.000010889551,0.000029264003,0.0010612466],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99797213,0.00017711738,0.00023466785,0.00024180402,0.0009903853,0.00038387382],"domain_scores_gemma":[0.9975649,0.001577469,0.000054769032,0.00033337632,0.00037605912,0.00009340229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001136659,0.000113832575,0.00018813468,0.00017294957,0.00016052542,0.000041283958,0.00020043642,0.000059026144,0.00023485979],"category_scores_gemma":[0.0004999359,0.000053526415,0.00008467905,0.0008449698,0.0006131765,0.000068212,0.00007652489,0.00072892726,0.000017680533],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009933716,0.00023686989,0.03780886,0.010589248,0.000979315,0.0001416386,0.010734584,0.00008963606,0.80220515,0.006967307,0.02806817,0.10118584],"study_design_scores_gemma":[0.0008887554,0.00064820214,0.028955268,0.0054125786,0.00006839875,0.0000026076118,0.00055611745,0.00019506767,0.9580172,0.0012488996,0.00392122,0.00008569153],"about_ca_topic_score_codex":0.0011320887,"about_ca_topic_score_gemma":0.00004848558,"teacher_disagreement_score":0.15581204,"about_ca_system_score_codex":0.00028298906,"about_ca_system_score_gemma":0.0013516692,"threshold_uncertainty_score":0.3166867},"labels":[],"label_agreement":null},{"id":"W4393073484","doi":"10.1158/1538-7445.am2024-1274","title":"Abstract 1274: Investigating PLOD2 as a therapeutic target to overcome metastasis in radiorecurrent prostate cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Cancer; Prostate cancer; Metastasis; Medicine; Prostate; Oncology; Internal medicine","score_opus":0.1563689354340288,"score_gpt":0.4845338166096226,"score_spread":0.3281648811755938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393073484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8871545,0.09039014,0.0000038055505,0.01755967,0.00043719038,0.0023891574,0.00018189567,0.00009149558,0.0017921488],"genre_scores_gemma":[0.9799936,0.009971201,0.00015143433,0.00039686752,0.00050914014,0.0034337523,0.000047235844,0.000103746395,0.0053930306],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995639,0.00020177102,0.0004221891,0.00087670446,0.0015118658,0.0013484157],"domain_scores_gemma":[0.9982286,0.000287903,0.000030034493,0.0004317336,0.00033157162,0.000690121],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016211073,0.00030048442,0.00047911113,0.0010827316,0.00017843918,0.00024636736,0.0002846502,0.0001143472,0.0033787484],"category_scores_gemma":[0.00017658548,0.000225261,0.00013518699,0.0026026233,0.00029284618,0.00024087541,0.0001835204,0.001459723,0.0004552716],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002594113,0.0006174014,0.072617404,0.0046629957,0.0013640622,0.0024633103,0.02154417,0.00049039285,0.25385287,0.0008288388,0.028327381,0.61063707],"study_design_scores_gemma":[0.009720893,0.0029101018,0.13276632,0.018422334,0.00029714793,0.00007939148,0.003704591,0.001976638,0.34385574,0.009319729,0.47516978,0.0017773265],"about_ca_topic_score_codex":0.005752052,"about_ca_topic_score_gemma":0.000511466,"teacher_disagreement_score":0.6088597,"about_ca_system_score_codex":0.0023793853,"about_ca_system_score_gemma":0.003337064,"threshold_uncertainty_score":0.9975323},"labels":[],"label_agreement":null},{"id":"W4393085783","doi":"10.1158/1538-7445.am2024-61","title":"Abstract 61: A novel immunotherapy for metastatic prostate cancer: A monoclonal antibody that can bind both STEAP1 and STEAP2","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Monoclonal antibody; Immunotherapy; Prostate cancer; Medicine; Cancer; Prostate; Cancer research; Antibody; Oncology; Monoclonal; Internal medicine; Immunology","score_opus":0.1437745693739447,"score_gpt":0.47844501829862335,"score_spread":0.3346704489246787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393085783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88411635,0.09792522,0.00006830459,0.011467452,0.00032989756,0.0038846985,0.001756509,0.00010554044,0.00034599847],"genre_scores_gemma":[0.942301,0.038738966,0.000385434,0.00017880481,0.0004023545,0.003510339,0.00021153185,0.00015434437,0.014117234],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963984,0.00007378789,0.000328693,0.0008567972,0.0011140195,0.001228293],"domain_scores_gemma":[0.9982941,0.00045167125,0.000050202776,0.00039831447,0.00038483908,0.00042084797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001257367,0.00033404925,0.0005273766,0.0006087674,0.00044384546,0.00047260433,0.00021892149,0.000106546526,0.00044755448],"category_scores_gemma":[0.000042526855,0.00024176865,0.00016070597,0.0007463752,0.0006202843,0.00022780891,0.00010466274,0.0008315403,0.000013965991],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007976898,0.0006135187,0.020809092,0.006668594,0.0029646044,0.00058786105,0.007166782,0.000026223186,0.7484043,0.00064833614,0.009086821,0.19504693],"study_design_scores_gemma":[0.044175692,0.0058425665,0.12410372,0.010751496,0.00076699595,0.00030194302,0.00635962,0.004953685,0.21005985,0.0023460037,0.5882086,0.0021298134],"about_ca_topic_score_codex":0.004605695,"about_ca_topic_score_gemma":0.00055410934,"teacher_disagreement_score":0.57912177,"about_ca_system_score_codex":0.0008765996,"about_ca_system_score_gemma":0.003610362,"threshold_uncertainty_score":0.9859039},"labels":[],"label_agreement":null},{"id":"W4393086058","doi":"10.1158/1538-7445.am2024-5561","title":"Abstract 5561: Whole slide Imaging Mass Cytometry allows the rapid profiling of the immune landscape of histopathologically aggressive prostate tumors","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Mass cytometry; Pathology; Prostate; Medicine; Immune system; Biology; Immunology; Cancer; Internal medicine","score_opus":0.043471730883069895,"score_gpt":0.37962980912157046,"score_spread":0.3361580782385006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393086058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8826479,0.10077187,0.000011849782,0.0096186055,0.0002838116,0.0018038383,0.00017299103,0.00004831718,0.0046408214],"genre_scores_gemma":[0.99315363,0.0030116595,0.000081612416,0.000038591537,0.00016339344,0.000377613,0.000024467265,0.000043491713,0.0031055238],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99687123,0.00024560018,0.00048071519,0.00043577203,0.0012898253,0.0006768327],"domain_scores_gemma":[0.99797654,0.00044036243,0.00016584464,0.0006517772,0.00064672896,0.00011875411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022209527,0.00018948741,0.00039156486,0.00033995186,0.00023796801,0.000064833424,0.0005348231,0.00007335798,0.00041333592],"category_scores_gemma":[0.00038063398,0.00008964498,0.00023497679,0.0013912268,0.0009816017,0.00010808525,0.00028153,0.0011764307,0.000022559414],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086964126,0.0000979082,0.03928816,0.001614921,0.00015726876,0.00065010815,0.0012318505,0.000026261196,0.9350068,0.00010524787,0.0017950718,0.019156778],"study_design_scores_gemma":[0.0019163765,0.00043179598,0.13051137,0.0050304737,0.00009691638,0.00008267847,0.0024727474,0.0004724458,0.85367364,0.00045485338,0.00464449,0.00021218322],"about_ca_topic_score_codex":0.00016976755,"about_ca_topic_score_gemma":0.000005312449,"teacher_disagreement_score":0.11050575,"about_ca_system_score_codex":0.00033814425,"about_ca_system_score_gemma":0.0013349483,"threshold_uncertainty_score":0.51110715},"labels":[],"label_agreement":null},{"id":"W4393086094","doi":"10.1158/1538-7445.am2024-7525","title":"Abstract 7525: Investigating B7-H3 as a checkpoint and antibody drug conjugate target across prostate cancer variants- both androgen receptor dependent and independent","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Androgen receptor; Conjugate; Antibody-drug conjugate; Medicine; Cancer; Drug; Cancer research; Prostate; Antibody; Oncology; Internal medicine; Monoclonal antibody; Pharmacology; Immunology; Mathematics","score_opus":0.0526785314060331,"score_gpt":0.43040853946832364,"score_spread":0.3777300080622905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393086094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92695254,0.06159388,0.0000030841586,0.007564097,0.0003435064,0.0020003805,0.00055967964,0.00012804894,0.00085480436],"genre_scores_gemma":[0.95502067,0.033519763,0.00013387168,0.00019298594,0.00043306142,0.00091997394,0.00012160238,0.00011758506,0.009540465],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99504906,0.00019649878,0.00051245803,0.001235032,0.0015302408,0.0014767227],"domain_scores_gemma":[0.9978974,0.0002352672,0.00007903407,0.00041007515,0.0004248588,0.0009533793],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002553895,0.0004047565,0.00055623055,0.00032332054,0.0006066919,0.0006809757,0.00021730442,0.00019940706,0.0009936322],"category_scores_gemma":[0.00019253803,0.00031179716,0.00008856657,0.00070353266,0.00093149574,0.00042748105,0.0005051472,0.0014366821,0.00008028482],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002090305,0.0002774914,0.20192285,0.0054807914,0.0013513576,0.0022114245,0.019573167,0.000019508216,0.7214123,0.0002922167,0.006476184,0.03889243],"study_design_scores_gemma":[0.018571364,0.001943072,0.15026137,0.013326296,0.00033027845,0.00062430557,0.013128999,0.0019131781,0.7220757,0.0040236744,0.071688265,0.0021134918],"about_ca_topic_score_codex":0.0083039785,"about_ca_topic_score_gemma":0.0006643675,"teacher_disagreement_score":0.06521208,"about_ca_system_score_codex":0.00086397404,"about_ca_system_score_gemma":0.0020941067,"threshold_uncertainty_score":0.9999334},"labels":[],"label_agreement":null},{"id":"W4393087263","doi":"10.1158/1538-7445.am2024-948","title":"Abstract 948: A novel combinatorial therapy for lethal neuroendocrine prostate cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Prostate; Oncology; Internal medicine","score_opus":0.12911341980746494,"score_gpt":0.4749412569118677,"score_spread":0.3458278371044028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393087263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9213891,0.048652884,0.000018124667,0.020888036,0.0024708412,0.0043241093,0.0006180388,0.00021627093,0.0014226042],"genre_scores_gemma":[0.9628938,0.016429543,0.00004650645,0.00015081432,0.0021754722,0.0054447423,0.00009456442,0.0001272748,0.012637293],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967336,0.000049616858,0.0002758287,0.00072548934,0.0010548006,0.0011606289],"domain_scores_gemma":[0.9982642,0.00036270963,0.00002579659,0.0003692618,0.0006209723,0.00035706826],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063730194,0.00024392369,0.00034944265,0.00039202964,0.0002787168,0.00021442225,0.00023339495,0.00007140017,0.0010236779],"category_scores_gemma":[0.00008769532,0.00017660431,0.00018729563,0.0008243312,0.00032555312,0.00017825095,0.00009605734,0.0009165774,0.000059195816],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017735338,0.001289166,0.0074554393,0.0034526505,0.0011590951,0.0015687168,0.0012044962,0.000036728386,0.5933201,0.003330787,0.11212516,0.25732237],"study_design_scores_gemma":[0.018748173,0.0025158406,0.0084474,0.001345031,0.00007273274,0.000075222124,0.00016323211,0.00067617826,0.2523551,0.0025695486,0.71256196,0.00046955672],"about_ca_topic_score_codex":0.0017138019,"about_ca_topic_score_gemma":0.0000566451,"teacher_disagreement_score":0.6004368,"about_ca_system_score_codex":0.00071922946,"about_ca_system_score_gemma":0.0024053864,"threshold_uncertainty_score":0.9998895},"labels":[],"label_agreement":null},{"id":"W4393088097","doi":"10.1158/1538-7445.am2024-3046","title":"Abstract 3046: The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Cancer research; Cancer; Prostate cancer; Disease; Cell metabolism; Prostate; Estrogen; Cell growth; Signal transduction; Medicine; Biology; Internal medicine; Metabolism; Cell biology; Genetics","score_opus":0.04946783977888265,"score_gpt":0.4088317890626978,"score_spread":0.35936394928381515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393088097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7718252,0.21697637,0.0000018086091,0.008232458,0.00012312771,0.002424515,0.00008620283,0.00008199412,0.00024834904],"genre_scores_gemma":[0.9697889,0.023888338,0.000047070786,0.00007481069,0.00052605744,0.0029265569,0.000072702656,0.000057780115,0.0026177808],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99721426,0.00013823372,0.00025421713,0.000722612,0.00096538686,0.0007052666],"domain_scores_gemma":[0.9985347,0.00012749691,0.00003839443,0.00033958675,0.00031823883,0.0006416063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012789225,0.00021449458,0.00023338394,0.00012953229,0.00045921406,0.0004649586,0.00010223841,0.000083740044,0.00023860062],"category_scores_gemma":[0.00006898094,0.0001207332,0.00006540254,0.00041997395,0.00045937352,0.0002905243,0.00015209704,0.00065133226,0.000008927077],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034097652,0.00036856416,0.06523906,0.00504697,0.000387384,0.0015205656,0.005648132,0.000016295047,0.19456743,0.00054628093,0.0048920885,0.71835744],"study_design_scores_gemma":[0.008346508,0.0015447148,0.09481328,0.008280079,0.0008386479,0.00012478768,0.0033904677,0.0026444595,0.59634,0.004383953,0.27798682,0.0013062811],"about_ca_topic_score_codex":0.0005329171,"about_ca_topic_score_gemma":0.00004883706,"teacher_disagreement_score":0.7170512,"about_ca_system_score_codex":0.0002488869,"about_ca_system_score_gemma":0.0018011393,"threshold_uncertainty_score":0.4923357},"labels":[],"label_agreement":null},{"id":"W4393090123","doi":"10.1158/1538-7445.am2024-1264","title":"Abstract 1264: A targeted methylation-based multi-cancer early detection blood test preferentially detects high-grade prostate cancer and minimizes overdiagnosis","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Overdiagnosis; Prostate cancer; Cancer; Medicine; Cancer detection; Blood test; Oncology; Methylation; Internal medicine; Cancer research; Biology; Gene; Genetics","score_opus":0.0675508575601891,"score_gpt":0.39294347940809304,"score_spread":0.32539262184790396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393090123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93906116,0.053373918,0.0000345462,0.0037304212,0.00040761195,0.0024337715,0.0006349996,0.0002700909,0.000053488613],"genre_scores_gemma":[0.9668765,0.023053594,0.00023342279,0.00006925413,0.00058436586,0.005780446,0.00006820741,0.00013539517,0.003198825],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99579626,0.00016601561,0.0004438346,0.0011074707,0.0013479668,0.0011384252],"domain_scores_gemma":[0.9972129,0.0010184603,0.00008085132,0.00041694325,0.00073612045,0.0005347201],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007194371,0.0004129617,0.0005127669,0.0008616693,0.00044603768,0.0004025682,0.00019874952,0.000279246,0.0010000675],"category_scores_gemma":[0.00029837948,0.00032689824,0.00016090031,0.0014385734,0.00044221463,0.00034302767,0.00011807955,0.0012312754,0.00004261009],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018082301,0.00075266574,0.052228633,0.0026689437,0.0011538662,0.00025318784,0.0011340012,0.00020183691,0.8336169,0.000007790359,0.0013336102,0.1048403],"study_design_scores_gemma":[0.006973706,0.0008321505,0.20139912,0.0018357638,0.00038688045,0.000003413976,0.00009028306,0.0016560308,0.783538,0.00007244579,0.0028261743,0.0003860706],"about_ca_topic_score_codex":0.012086818,"about_ca_topic_score_gemma":0.0033571802,"teacher_disagreement_score":0.14917049,"about_ca_system_score_codex":0.0008803781,"about_ca_system_score_gemma":0.0020640476,"threshold_uncertainty_score":0.9999183},"labels":[],"label_agreement":null},{"id":"W4393093306","doi":"10.1158/1538-7445.am2024-6962","title":"Abstract 6962: Shed Trop2 drives prostate cancer progression and Trop2 is a novel tissue prognostic biomarker and a candidate urinary marker for prostate cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Biomarker; Cancer; Prostate; Oncology; Urinary system; Internal medicine; Biology","score_opus":0.06089445035445586,"score_gpt":0.44515856457292385,"score_spread":0.384264114218468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393093306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8608576,0.112912096,0.000014099325,0.01523979,0.00025309832,0.008215319,0.0019530231,0.00012923357,0.00042575857],"genre_scores_gemma":[0.9304226,0.043730997,0.0003551803,0.00028052242,0.0005184603,0.017123004,0.000253143,0.00015908244,0.007157025],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9947231,0.00016824041,0.00049851445,0.0014892031,0.0014879921,0.001632988],"domain_scores_gemma":[0.9978208,0.0004048005,0.00008527388,0.00045945126,0.00063153036,0.0005981307],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013717547,0.0005475696,0.0006429291,0.0007741613,0.0005159547,0.0006121438,0.00026461898,0.00024613802,0.00056063896],"category_scores_gemma":[0.000110951536,0.00038379047,0.00012315273,0.0010861458,0.000759963,0.000462858,0.00018643079,0.0008793212,0.000014033844],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015221067,0.0013902452,0.10402118,0.02033052,0.0013715952,0.002158576,0.019229071,0.0000014562146,0.2378645,0.00010151766,0.05137699,0.5469333],"study_design_scores_gemma":[0.02078337,0.007901616,0.529859,0.016845666,0.001019393,0.0005414467,0.002839981,0.0023807387,0.031102704,0.0006413833,0.3842994,0.0017853351],"about_ca_topic_score_codex":0.0015570727,"about_ca_topic_score_gemma":0.00023071976,"teacher_disagreement_score":0.54514796,"about_ca_system_score_codex":0.00055487955,"about_ca_system_score_gemma":0.0019145138,"threshold_uncertainty_score":0.9998614},"labels":[],"label_agreement":null},{"id":"W4393095401","doi":"10.1158/1538-7445.am2024-1353","title":"Abstract 1353: Potentiating salvage radiotherapy in radiorecurrent prostate cancer through anti-CTLA4 therapy: Implications from a syngeneic model","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Radiation therapy; Prostate cancer; Medicine; Cancer; Salvage therapy; Oncology; Prostate; Internal medicine; Cancer research; Chemotherapy","score_opus":0.14604115314615207,"score_gpt":0.47460272396079645,"score_spread":0.3285615708146444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393095401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7600297,0.2216697,0.000120399585,0.014821961,0.00024954553,0.0019052601,0.0005164538,0.00012888519,0.0005581386],"genre_scores_gemma":[0.7877779,0.20728932,0.00030048768,0.000219797,0.00051574374,0.0025001972,0.00015288142,0.00011088033,0.0011327678],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9962714,0.00014257591,0.0004627482,0.0009977934,0.0009600353,0.0011654812],"domain_scores_gemma":[0.99849784,0.00023334267,0.00005243021,0.00061990356,0.00032536846,0.00027111982],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006923131,0.0003238212,0.00049188925,0.000504885,0.00029423533,0.0002492248,0.00034416188,0.00016868838,0.0008425456],"category_scores_gemma":[0.000033447996,0.00024683526,0.0001799736,0.0015115977,0.00030309838,0.0003543958,0.00009298081,0.0012571086,0.000043478507],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012197421,0.00067617814,0.03463773,0.00085001584,0.0010139593,0.0003659464,0.010505168,0.002088538,0.66363245,0.0003252439,0.016015982,0.268669],"study_design_scores_gemma":[0.027967148,0.0014480508,0.46752444,0.014241813,0.00031164373,0.000055758206,0.0023051612,0.07286296,0.27446124,0.0112049915,0.12483306,0.0027837292],"about_ca_topic_score_codex":0.007482934,"about_ca_topic_score_gemma":0.00040235286,"teacher_disagreement_score":0.43288672,"about_ca_system_score_codex":0.0019242206,"about_ca_system_score_gemma":0.0025493044,"threshold_uncertainty_score":0.9999984},"labels":[],"label_agreement":null},{"id":"W4393095529","doi":"10.1158/1538-7445.am2024-3665","title":"Abstract 3665: Stratifying prostate cancer patients through circulating genes related to prostate cell subtypes, drug targets, and therapeutic resistance","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Concordia University; McGill University Health Centre","funders":"","keywords":"Prostate cancer; Medicine; Drug resistance; Prostate; Oncology; Cancer; Drug; Internal medicine; Cancer research; Biology; Pharmacology; Genetics","score_opus":0.05768977247174798,"score_gpt":0.3993755486917812,"score_spread":0.3416857762200332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393095529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82619536,0.16297999,0.0000021929459,0.004944478,0.00030987343,0.0025996773,0.00019527397,0.00014231449,0.0026308151],"genre_scores_gemma":[0.95416254,0.020753393,0.00014705282,0.00014391752,0.00016410497,0.0011386023,0.00008852997,0.00012956279,0.023272272],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9956279,0.00016265713,0.00049984676,0.001075284,0.0013737436,0.0012606131],"domain_scores_gemma":[0.9982015,0.00022489631,0.00006540276,0.00041178317,0.00068466587,0.00041175992],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00097058516,0.00035405223,0.00041666275,0.00034100394,0.0005332651,0.00036002975,0.00021896047,0.00013529381,0.0003818265],"category_scores_gemma":[0.00004902406,0.00027474455,0.000091546295,0.0013623141,0.0003055823,0.00030696302,0.00017296986,0.0010905004,0.00008042872],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064095967,0.0010069017,0.28419015,0.01957677,0.0016491397,0.0019116981,0.062569864,0.00043363668,0.40493417,0.00090793293,0.029662462,0.18674769],"study_design_scores_gemma":[0.016746363,0.0020916173,0.279366,0.018478945,0.00056689105,0.00003044588,0.0070657725,0.0009891344,0.33894646,0.0089229895,0.32363346,0.003161947],"about_ca_topic_score_codex":0.0014279031,"about_ca_topic_score_gemma":0.00043201874,"teacher_disagreement_score":0.293971,"about_ca_system_score_codex":0.0009758168,"about_ca_system_score_gemma":0.0013203202,"threshold_uncertainty_score":0.9999705},"labels":[],"label_agreement":null},{"id":"W4393180802","doi":"10.3390/cells13070575","title":"Microfluidics-Based Technologies for the Assessment of Castration-Resistant Prostate Cancer","year":2024,"lang":"en","type":"review","venue":"Cells","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Prostate cancer; Medicine; Cancer; Tumor microenvironment; Cancer research; Internal medicine","score_opus":0.08782709882514926,"score_gpt":0.45319864679485605,"score_spread":0.3653715479697068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393180802","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005550621,0.9931667,0.000038041646,0.0010401875,0.00032674902,0.004231851,0.0009708831,0.000070708666,0.00014932701],"genre_scores_gemma":[0.0000610946,0.99174446,0.0003798476,0.000013677463,0.000070677874,0.0023982646,0.00019491615,0.000051318602,0.00508576],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987385,0.000024830797,0.00040717478,0.0003178434,0.00024671256,0.00026493575],"domain_scores_gemma":[0.99899447,0.00024433355,0.0001608454,0.00041614787,0.0001490692,0.00003512451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022552567,0.00026976914,0.0008657936,0.00016978785,0.000072980445,0.0000383005,0.0001859049,0.0001814693,0.00003500775],"category_scores_gemma":[0.000014459411,0.00012690717,0.00042509864,0.00031963518,0.00021236339,0.000014279434,0.000048994927,0.00033140724,0.000009545798],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005701893,0.00010297797,0.0000054061898,0.10072925,0.00094939495,0.000040410763,0.0000323179,0.0000013348201,0.0031740824,0.00010448339,0.024121294,0.870682],"study_design_scores_gemma":[0.00044338853,0.0002565676,0.0000016733851,0.01334197,0.0032093101,0.000002216669,0.000068971654,0.000029507826,0.008427967,0.00002320025,0.9740772,0.000118003685],"about_ca_topic_score_codex":0.000032656364,"about_ca_topic_score_gemma":0.000006629623,"teacher_disagreement_score":0.94995594,"about_ca_system_score_codex":0.00034830163,"about_ca_system_score_gemma":0.0028490354,"threshold_uncertainty_score":0.5175124},"labels":[],"label_agreement":null},{"id":"W4393191283","doi":"10.1038/s41388-024-02944-2","title":"SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain","year":2024,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"Androgen receptor; Prostate cancer; Cancer research; Antiandrogens; Androgen; Biology; Androgen deprivation therapy; Apoptosis; Internal medicine; Endocrinology; Cancer; Medicine; Hormone; Biochemistry; Genetics","score_opus":0.02124417290310311,"score_gpt":0.33184726504831924,"score_spread":0.31060309214521614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393191283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754383,0.016599607,0.0000065907275,0.0059945653,0.00019502344,0.00077837915,0.00022452828,0.000047069152,0.0007159558],"genre_scores_gemma":[0.99201953,0.0016837936,0.00018077191,0.000095646516,0.00028046744,0.00029483958,0.00012163219,0.00003410492,0.0052891932],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985849,0.00008922863,0.00021124938,0.0003573683,0.00035520172,0.00040205542],"domain_scores_gemma":[0.99954575,0.00006713146,0.000040916035,0.00016331318,0.00005913969,0.00012376852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043773884,0.00017198594,0.00021118746,0.000085595355,0.00013370578,0.000080131045,0.00007494116,0.00007287721,0.0002533665],"category_scores_gemma":[0.000021382006,0.000105426356,0.00007029705,0.00041976979,0.000105981664,0.00012790455,0.00004295999,0.00029905312,0.000045630466],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078885036,0.00012407455,0.0032546087,0.00019468469,0.000096151096,0.00041898148,0.0010943318,0.0000039434485,0.9455336,0.000013459745,0.010232701,0.03824466],"study_design_scores_gemma":[0.0024866406,0.000473336,0.0012771788,0.0007758866,0.000084909116,0.00006207071,0.0005551993,0.0003035372,0.8830355,0.000087816676,0.11058422,0.00027374146],"about_ca_topic_score_codex":0.0005107967,"about_ca_topic_score_gemma":0.00030959956,"teacher_disagreement_score":0.10035152,"about_ca_system_score_codex":0.00046521085,"about_ca_system_score_gemma":0.000590885,"threshold_uncertainty_score":0.4299162},"labels":[],"label_agreement":null},{"id":"W4393203777","doi":"10.1016/j.eururo.2024.02.022","title":"Re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3–7","year":2024,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Gynecology; Cancer; Prostate; General surgery; Internal medicine","score_opus":0.051854780727103145,"score_gpt":0.33072354745379556,"score_spread":0.2788687667266924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393203777","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027570676,0.095291734,0.00015286442,0.88770026,0.002367665,0.007687439,0.00082482793,0.00022294691,0.0029952207],"genre_scores_gemma":[0.2219268,0.015230355,0.00008674983,0.6439711,0.011767119,0.003885691,0.0012394354,0.0012449279,0.100647874],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957358,0.0008572539,0.0005792303,0.0012530639,0.00032963313,0.0012449897],"domain_scores_gemma":[0.9974087,0.0007533206,0.00022475648,0.0012691665,0.00020326977,0.00014082347],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0014480462,0.0006876044,0.00074779027,0.00022371438,0.0006916061,0.00018824234,0.0006527492,0.00036858695,0.0001829143],"category_scores_gemma":[0.00008020177,0.00036555462,0.00044129128,0.0002333234,0.00056312565,0.00008505143,0.00022122706,0.0025033972,0.000118024065],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012562586,0.00009337355,0.00006712912,0.0019239736,0.0015145985,0.02255523,0.002683792,0.000060061422,0.00010058183,0.000077412325,0.9451598,0.024507808],"study_design_scores_gemma":[0.0023768798,0.0028970314,0.00006395254,0.00018738878,0.0014953513,0.0059757666,0.00026755058,0.0013262128,0.000022939501,0.00027887453,0.98471117,0.0003969111],"about_ca_topic_score_codex":0.000091620626,"about_ca_topic_score_gemma":0.000094563016,"teacher_disagreement_score":0.24372917,"about_ca_system_score_codex":0.00018261983,"about_ca_system_score_gemma":0.00031409378,"threshold_uncertainty_score":0.99987966},"labels":[],"label_agreement":null},{"id":"W4393236273","doi":"10.1097/rlu.0000000000005163","title":"Complete Resolution of Locally Advanced Prostate Cancer After Molecular Endoradiotherapy With 177Lu-PSMA","year":2024,"lang":"en","type":"article","venue":"Clinical Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Prostate; Urology; Anemia; Oncology; Cancer; Internal medicine","score_opus":0.03498939392981877,"score_gpt":0.3947042933425704,"score_spread":0.35971489941275164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393236273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90981233,0.04436335,0.00030303822,0.040683527,0.0005580327,0.0015600887,0.00007630126,0.00021551878,0.0024278369],"genre_scores_gemma":[0.9837581,0.010456389,0.0012381704,0.0026789783,0.00043657466,0.00007601635,0.00004607017,0.000095819654,0.0012138787],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979055,0.00009759269,0.0006027572,0.00048853556,0.0005489544,0.00035668781],"domain_scores_gemma":[0.99884313,0.00018019388,0.00008202213,0.0003875634,0.00020783406,0.0002992377],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045376527,0.00021127425,0.00065643707,0.00013760784,0.000037301084,0.000011001805,0.00010557581,0.00011650125,0.0009950333],"category_scores_gemma":[0.00009154179,0.00012346279,0.00013639397,0.000408527,0.0009942999,0.00007406931,0.00003625766,0.0004801978,0.000045916684],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.086426504,0.0015960295,0.043180294,0.004697735,0.0038259523,0.009724319,0.0043655043,0.00012857631,0.14237817,0.0022420005,0.03232134,0.6691136],"study_design_scores_gemma":[0.035739522,0.027529417,0.073515095,0.015961723,0.0011424789,0.00020591637,0.0006230007,0.007405117,0.0014350195,0.000541019,0.83521646,0.000685229],"about_ca_topic_score_codex":0.00006657275,"about_ca_topic_score_gemma":0.000010542559,"teacher_disagreement_score":0.8028951,"about_ca_system_score_codex":0.00011592458,"about_ca_system_score_gemma":0.00024362329,"threshold_uncertainty_score":0.99991816},"labels":[],"label_agreement":null},{"id":"W4393237791","doi":"10.1016/j.radonc.2024.110256","title":"Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials","year":2024,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Rimouski; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont; Nova Scotia Cancer Centre; Centre de Santé et de Services Sociaux de Chicoutimi; Centre hospitalier universitaire de Québec; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Prostate cancer; Androgen deprivation therapy; Medicine; Testosterone (patch); Oncology; Androgen; Internal medicine; Term (time); Urology; Cancer; Hormone","score_opus":0.08082167211733769,"score_gpt":0.4100663405271465,"score_spread":0.3292446684098088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393237791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8040681,0.18981142,0.00019279227,0.00344176,0.00033211376,0.0018334677,0.00022428659,0.000048490085,0.000047602753],"genre_scores_gemma":[0.6996402,0.295177,0.0004776358,0.0013636556,0.00094725686,0.0006750321,0.0009020921,0.00006158258,0.0007555169],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980417,0.00042253212,0.00048389213,0.0005788575,0.00016610665,0.00030691156],"domain_scores_gemma":[0.99854803,0.00082905183,0.000077967634,0.00039242857,0.000032787637,0.000119723074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010963444,0.00020711277,0.00080162316,0.00020625739,0.00004094875,0.000070420705,0.00012406155,0.00016244627,0.00078404625],"category_scores_gemma":[0.00005358645,0.00014021553,0.0000774194,0.00022540003,0.00013340467,0.00022562382,0.000038037833,0.00023654956,0.0000068338995],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.091935486,0.00019639333,0.15007621,0.00009063608,0.0007912775,0.0007609919,0.0010199937,0.000005981194,0.015726663,0.0000026702132,0.00069131353,0.73870236],"study_design_scores_gemma":[0.5259328,0.009375796,0.32509497,0.0019977489,0.0007039424,0.00023011715,0.00012329154,0.0073208394,0.018736197,0.0010330009,0.10840198,0.0010493633],"about_ca_topic_score_codex":0.00041610355,"about_ca_topic_score_gemma":0.00068140903,"teacher_disagreement_score":0.737653,"about_ca_system_score_codex":0.00056620844,"about_ca_system_score_gemma":0.0005597262,"threshold_uncertainty_score":0.8584757},"labels":[],"label_agreement":null},{"id":"W4393282851","doi":"10.1200/po.23.00654","title":"Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Prostate Cancer Foundation","keywords":"Context (archaeology); Personalized medicine; Precision medicine; Overdiagnosis; Cancer; Germline; Genetic testing; Prostate cancer; Medicine; Genotyping; Bioinformatics; Computational biology; Biology; Genetics; Gene; Internal medicine; Genotype","score_opus":0.0799215156848305,"score_gpt":0.49077883953531504,"score_spread":0.41085732385048457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393282851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99250907,0.0031415229,0.000048361326,0.0015451428,0.00042463833,0.00061945023,0.0000075576113,0.000028463,0.0016757796],"genre_scores_gemma":[0.99159163,0.006723236,0.00051269605,0.000082494225,0.00008399985,0.00009969644,0.000015070738,0.000010521553,0.0008806538],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99891996,0.00008572782,0.0004883247,0.00022475423,0.00012958376,0.00015167112],"domain_scores_gemma":[0.9991453,0.0005570267,0.000064570624,0.00006803209,0.00008928386,0.000075728225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053407723,0.00007770824,0.0003241087,0.00025560157,0.000013868498,0.0000113526585,0.00003440897,0.00012802296,0.000117631505],"category_scores_gemma":[0.00027836824,0.000054972676,0.000049295686,0.00024263961,0.00007852445,0.00009880187,0.00004967389,0.0002683562,0.000014915326],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029117696,0.00011469427,0.11850128,0.00023263623,0.000057479443,0.00005192412,0.0019106633,0.000021849859,0.0026917756,0.000030526393,0.0007799953,0.8726954],"study_design_scores_gemma":[0.0065149055,0.0053995787,0.89928097,0.0011181129,0.00010779229,0.00012295117,0.0003136471,0.03956303,0.0030757892,0.0010688587,0.043285236,0.00014913378],"about_ca_topic_score_codex":0.00013423315,"about_ca_topic_score_gemma":0.00040794088,"teacher_disagreement_score":0.87254626,"about_ca_system_score_codex":0.0003544071,"about_ca_system_score_gemma":0.0010743743,"threshold_uncertainty_score":0.22417207},"labels":[],"label_agreement":null},{"id":"W4393334670","doi":"10.1002/ijc.34937","title":"Use of 5‐alpha reductase inhibitors and risk of gastrointestinal cancers in men with benign prostatic hyperplasia: <scp>A</scp> population‐based cohort study","year":2024,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"Cancer Research UK","keywords":"Medicine; Internal medicine; Hazard ratio; Colorectal cancer; Cancer; Cohort; Population; Cohort study; Oncology; Proportional hazards model; Lower risk; Retrospective cohort study; Gastroenterology; Gynecology; Confidence interval","score_opus":0.019306338045714987,"score_gpt":0.332772437357097,"score_spread":0.31346609931138203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393334670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971156,0.0016510396,0.000038157552,0.0003066058,0.00016407066,0.00051888434,0.0001184841,0.000005521375,0.00008161579],"genre_scores_gemma":[0.9981851,0.0005483146,0.0008561716,0.000011841684,0.00013417212,0.0000307755,0.000015219628,0.000018853489,0.00019956846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982197,0.00006731504,0.0005302412,0.00016721903,0.0008754992,0.00014002674],"domain_scores_gemma":[0.9985443,0.00029435582,0.0003338984,0.000083163606,0.0006430513,0.00010126145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034412276,0.00012854428,0.00033243923,0.00052683416,0.000016960716,0.000033470307,0.00008649811,0.000023834657,0.000026815642],"category_scores_gemma":[0.00022674669,0.00008728284,0.000064929416,0.00025919965,0.0001027615,0.0002307858,0.000021496797,0.00027561717,2.5478684e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001094026,0.00024385413,0.99043274,0.00010051489,0.0009497296,0.00055922515,0.0006300598,0.002148864,0.0015798545,0.000013009287,0.000557329,0.0016907889],"study_design_scores_gemma":[0.00401291,0.001743029,0.9833151,0.0026270645,0.00046187575,0.00030859176,0.0008825562,0.0017969235,0.0046028616,0.00004353947,0.00016086409,0.000044685075],"about_ca_topic_score_codex":0.0037255525,"about_ca_topic_score_gemma":0.0006224101,"teacher_disagreement_score":0.007117646,"about_ca_system_score_codex":0.0006045156,"about_ca_system_score_gemma":0.00096790004,"threshold_uncertainty_score":0.5631946},"labels":[],"label_agreement":null},{"id":"W4393461632","doi":"10.5281/zenodo.1445571","title":"Screening Compounds Of Interest Against Usp5 Zf-Ubd By Spr #2","year":2018,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Computer science","score_opus":0.08487300609717766,"score_gpt":0.30778838264906255,"score_spread":0.2229153765518849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393461632","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018908551,0.000497084,0.00009164541,0.0005388766,0.00015432613,0.0008671859,0.9837093,0.00026895019,0.0119817965],"genre_scores_gemma":[0.004478339,0.0012139425,0.00010340039,0.00016722009,0.0003487852,1.0231949e-7,0.99079764,0.0011344546,0.0017560914],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974156,0.00028964758,0.00047717078,0.00061979116,0.0006385405,0.0005592259],"domain_scores_gemma":[0.9974873,0.000038471007,0.00026283658,0.0009352018,0.0009103971,0.00036576323],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00063034176,0.00031980395,0.00050366955,0.0005022525,0.0010090539,0.00034752404,0.0011029219,0.00023201585,0.010992067],"category_scores_gemma":[0.000440316,0.000291448,0.00013859662,0.0005979634,0.0006359662,0.00013868886,0.0016162434,0.00073647924,0.00329515],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048920396,0.00034103022,0.0000031384734,0.0005144944,0.0002829185,0.00006314798,0.0000895973,4.5033536e-7,0.002713898,0.000013600465,0.9856326,0.009855929],"study_design_scores_gemma":[0.0016991115,0.0011124465,0.000046172703,0.00050760707,0.00009855179,0.00008419911,0.000101235906,0.00002352073,0.0013882649,0.000008549127,0.9946919,0.0002384433],"about_ca_topic_score_codex":0.000078414334,"about_ca_topic_score_gemma":0.0000017576424,"teacher_disagreement_score":0.010225706,"about_ca_system_score_codex":0.000282365,"about_ca_system_score_gemma":0.00002184382,"threshold_uncertainty_score":0.99995375},"labels":[],"label_agreement":null},{"id":"W4393573099","doi":"10.5281/zenodo.1445570","title":"Screening Compounds Of Interest Against Usp5 Zf-Ubd By Spr #2","year":2018,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Computer science","score_opus":0.08487300609717766,"score_gpt":0.30778838264906255,"score_spread":0.2229153765518849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393573099","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018908551,0.000497084,0.00009164541,0.0005388766,0.00015432613,0.0008671859,0.9837093,0.00026895019,0.0119817965],"genre_scores_gemma":[0.004478339,0.0012139425,0.00010340039,0.00016722009,0.0003487852,1.0231949e-7,0.99079764,0.0011344546,0.0017560914],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974156,0.00028964758,0.00047717078,0.00061979116,0.0006385405,0.0005592259],"domain_scores_gemma":[0.9974873,0.000038471007,0.00026283658,0.0009352018,0.0009103971,0.00036576323],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00063034176,0.00031980395,0.00050366955,0.0005022525,0.0010090539,0.00034752404,0.0011029219,0.00023201585,0.010992067],"category_scores_gemma":[0.000440316,0.000291448,0.00013859662,0.0005979634,0.0006359662,0.00013868886,0.0016162434,0.00073647924,0.00329515],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048920396,0.00034103022,0.0000031384734,0.0005144944,0.0002829185,0.00006314798,0.0000895973,4.5033536e-7,0.002713898,0.000013600465,0.9856326,0.009855929],"study_design_scores_gemma":[0.0016991115,0.0011124465,0.000046172703,0.00050760707,0.00009855179,0.00008419911,0.000101235906,0.00002352073,0.0013882649,0.000008549127,0.9946919,0.0002384433],"about_ca_topic_score_codex":0.000078414334,"about_ca_topic_score_gemma":0.0000017576424,"teacher_disagreement_score":0.010225706,"about_ca_system_score_codex":0.000282365,"about_ca_system_score_gemma":0.00002184382,"threshold_uncertainty_score":0.99995375},"labels":[],"label_agreement":null},{"id":"W4393680407","doi":"10.5281/zenodo.3601388","title":"GDSC1 PSet","year":2020,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Environmental science","score_opus":0.05231809588784944,"score_gpt":0.2949711565827425,"score_spread":0.24265306069489304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393680407","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004668352,0.00030053494,0.000028398395,0.002918229,0.0001437449,0.0009310853,0.97923243,0.00053500134,0.015863907],"genre_scores_gemma":[0.00023356511,0.0016754186,0.000050883154,0.0005346204,0.00056402927,1.0299149e-7,0.99358183,0.0014220668,0.0019374758],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974754,0.00024135018,0.00030980344,0.0006729712,0.00076405855,0.0005364308],"domain_scores_gemma":[0.99799734,0.000022683098,0.00012306382,0.0007722239,0.0005577883,0.00052688125],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003431856,0.0002894467,0.00040165518,0.0003452108,0.0013381223,0.00053819164,0.00093050883,0.00021177469,0.03456928],"category_scores_gemma":[0.0006152791,0.00026185228,0.0001363023,0.0006502112,0.00023522352,0.00010382528,0.0014606889,0.00092981383,0.0707897],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037173758,0.0002042582,4.2631999e-7,0.0004946695,0.0001924572,0.00031606675,0.0001031162,6.571906e-7,0.00022382879,0.000026151893,0.9851023,0.012964359],"study_design_scores_gemma":[0.0014028678,0.00083839544,0.00005089583,0.00013461219,0.00012527964,0.000266472,0.000066690765,0.000012116279,0.000124367,0.000022794236,0.99672246,0.00023306745],"about_ca_topic_score_codex":0.000029076482,"about_ca_topic_score_gemma":2.884039e-7,"teacher_disagreement_score":0.03622042,"about_ca_system_score_codex":0.00034515088,"about_ca_system_score_gemma":0.000025178577,"threshold_uncertainty_score":0.9999834},"labels":[],"label_agreement":null},{"id":"W4393902181","doi":"10.1016/j.euo.2024.03.010","title":"Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Movember Foundation","keywords":"Androgen deprivation therapy; Medicine; Prostate cancer; Oncology; Castration; Metastasis; Internal medicine; Cancer therapy; Cancer; Hormone","score_opus":0.06196786233524793,"score_gpt":0.3735454185204336,"score_spread":0.3115775561851857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393902181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927148,0.0036718904,0.00042310086,0.0012533913,0.0000944632,0.0009546495,0.00009796708,0.00009253747,0.0006972077],"genre_scores_gemma":[0.99258053,0.0040730983,0.0019706443,0.00042328265,0.000044954668,0.00011278694,0.000293704,0.00003411292,0.00046690748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979469,0.00068073854,0.00039159297,0.0004647901,0.00020681476,0.00030916164],"domain_scores_gemma":[0.99915093,0.00022442073,0.00011173964,0.00018845935,0.0002365786,0.00008789204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054986187,0.00021744361,0.000680265,0.00094113214,0.000063887695,0.000014594246,0.00007679573,0.00006753418,0.00021781397],"category_scores_gemma":[0.000042050622,0.00012530843,0.00010119905,0.0017264198,0.0004218928,0.0000947801,0.000022697157,0.00027831222,0.00001465048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047085475,0.0030663714,0.54033315,0.00016980065,0.0293801,0.011304586,0.01556313,0.005873699,0.07939159,0.00019982406,0.00020436,0.2674279],"study_design_scores_gemma":[0.019313533,0.009566125,0.92149657,0.000089718145,0.0023114346,0.00041442752,0.00040132174,0.027052179,0.009547313,0.000014558054,0.009445913,0.0003469195],"about_ca_topic_score_codex":0.00025427135,"about_ca_topic_score_gemma":0.0016937559,"teacher_disagreement_score":0.3811634,"about_ca_system_score_codex":0.00020108942,"about_ca_system_score_gemma":0.000985954,"threshold_uncertainty_score":0.51099294},"labels":[],"label_agreement":null},{"id":"W4393988592","doi":"10.1158/1538-7445.am2024-lb196","title":"Abstract LB196: An atlas of accessible chromatin in advanced prostate cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Prostate cancer; Atlas (anatomy); Medicine; Prostate; Cancer; Internal medicine; Anatomy","score_opus":0.1021333569105468,"score_gpt":0.5019406697516867,"score_spread":0.3998073128411399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393988592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95655674,0.03515303,8.9180264e-7,0.0022732618,0.00022534125,0.0012754773,0.00012025269,0.000071626586,0.0043233596],"genre_scores_gemma":[0.97747624,0.012009256,0.00007382817,0.00002650256,0.0002612052,0.0012937965,0.000053619897,0.00006313535,0.008742439],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969857,0.00011181445,0.0003954303,0.00060400786,0.0010508911,0.00085215794],"domain_scores_gemma":[0.99867314,0.0001689354,0.000039926592,0.00042800634,0.00039466313,0.0002953277],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010212624,0.00018980185,0.00038987325,0.000744853,0.000091275855,0.00009604893,0.0002733477,0.00013032868,0.0024498466],"category_scores_gemma":[0.000070217306,0.00014198318,0.00008046344,0.0017483283,0.0003284054,0.0004581988,0.000119140175,0.0009639997,0.00006231818],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026241066,0.00049087533,0.053720985,0.0049791816,0.00019761531,0.00081243704,0.0031953019,0.00019656892,0.6659514,0.00018467614,0.0056613954,0.26198548],"study_design_scores_gemma":[0.0062778015,0.0014608415,0.25828612,0.009001049,0.00005212344,0.00001489558,0.0016655781,0.0010689944,0.6859281,0.0010412632,0.03472896,0.00047426095],"about_ca_topic_score_codex":0.0040508737,"about_ca_topic_score_gemma":0.0015796111,"teacher_disagreement_score":0.2615112,"about_ca_system_score_codex":0.0009038959,"about_ca_system_score_gemma":0.0024926616,"threshold_uncertainty_score":0.998462},"labels":[],"label_agreement":null},{"id":"W4393988883","doi":"10.1158/1538-7445.am2024-ct232","title":"Abstract CT232: Intense exercise for survival among men with metastatic prostate cancer: 12-month feasibility results from the INTERVAL-GAP4 trial pilot site at Edith Cowan University, Australia","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Alberta","funders":"","keywords":"Prostate cancer; Medicine; Gerontology; Oncology; Internal medicine; Cancer; Physical therapy","score_opus":0.21762359674858828,"score_gpt":0.43057351046672354,"score_spread":0.21294991371813526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393988883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739899,0.0024080144,0.0000073874035,0.007623389,0.00081007223,0.008344908,0.0056784763,0.00012386832,0.0010139697],"genre_scores_gemma":[0.92967147,0.0027999205,0.00004207781,0.000021944945,0.00085974776,0.0007654153,0.0007318511,0.00008745603,0.065020144],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951847,0.00040038468,0.0004873029,0.0011451341,0.0015792224,0.0012032546],"domain_scores_gemma":[0.9960154,0.0015156087,0.00011429005,0.000893701,0.0009076056,0.0005533894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029095404,0.00040250848,0.0006945954,0.00033425447,0.00056914386,0.0002762283,0.00051103614,0.00010843747,0.00064203393],"category_scores_gemma":[0.0002172836,0.00023902325,0.00022520882,0.0009858706,0.0012031848,0.0004046059,0.000377602,0.0011376692,0.00006188595],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78365237,0.00051559904,0.034311686,0.0010960095,0.0016668335,0.0010581078,0.007975137,0.000035915415,0.004246919,0.00003603831,0.16000083,0.0054045483],"study_design_scores_gemma":[0.46621048,0.027263446,0.27834395,0.018428447,0.0038619714,0.000026082573,0.022644075,0.0016402232,0.037202217,0.001195235,0.14078623,0.0023976373],"about_ca_topic_score_codex":0.046260353,"about_ca_topic_score_gemma":0.034466673,"teacher_disagreement_score":0.31744188,"about_ca_system_score_codex":0.003025238,"about_ca_system_score_gemma":0.0019708537,"threshold_uncertainty_score":0.9831518},"labels":[],"label_agreement":null},{"id":"W4393993561","doi":"10.3390/bios14040175","title":"An Extracellular Matrix Overlay Model for Bioluminescence Microscopy to Measure Single-Cell Heterogeneous Responses to Antiandrogens in Prostate Cancer Cells","year":2024,"lang":"en","type":"article","venue":"Biosensors","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Fonds de Recherche du Québec - Santé; Fonds de recherche du Québec; Fondation CHU de Québec","keywords":"Extracellular matrix; Prostate cancer; Antiandrogens; Cell biology; Cell; Intracellular; Single-cell analysis; 3D cell culture; Chemistry; Cell culture; Biology; Cancer research; Androgen receptor; Cancer; Biochemistry; Genetics","score_opus":0.04495999010135,"score_gpt":0.35650488065002817,"score_spread":0.3115448905486782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393993561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828603,0.011281149,0.00033738572,0.0018349036,0.00027553635,0.0025589229,0.0007147052,0.00012231589,0.000014774449],"genre_scores_gemma":[0.97879016,0.000368668,0.004626097,0.0001631252,0.000113697875,0.00026272438,0.00003698919,0.000092356175,0.015546207],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99785846,0.00005931891,0.00031850176,0.00075095595,0.0003179356,0.0006948085],"domain_scores_gemma":[0.998914,0.000064931126,0.00002972121,0.00039050763,0.00015642903,0.00044438415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027192204,0.0002946784,0.00034705285,0.000446445,0.00008102145,0.00011282373,0.00014289183,0.000116828276,0.000025424162],"category_scores_gemma":[0.000032307045,0.00024216919,0.00012891981,0.00058347627,0.000060065697,0.00008170843,0.00003776751,0.00013963084,0.000072249844],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003412078,0.000305645,0.0019416568,0.00036257762,0.00004155965,0.00048139464,0.0016193937,0.0012956529,0.98794234,0.0000030033368,0.0013989682,0.0011957533],"study_design_scores_gemma":[0.0011537131,0.0010750486,0.00012431452,0.00051148667,0.0000649011,0.000025006779,0.000104083105,0.019080965,0.97205687,0.0000063337557,0.0054911426,0.00030611412],"about_ca_topic_score_codex":0.00011719683,"about_ca_topic_score_gemma":0.000104311956,"teacher_disagreement_score":0.017785313,"about_ca_system_score_codex":0.0003647719,"about_ca_system_score_gemma":0.000388354,"threshold_uncertainty_score":0.9875373},"labels":[],"label_agreement":null},{"id":"W4394008668","doi":"10.1016/j.modpat.2024.100489","title":"Somatic Tumor Testing in Prostate Cancer: Experience of a Tertiary Care Center Including Pathologist-Driven Reflex Testing of Localized Tumors at Diagnosis","year":2024,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Janssen Canada; AstraZeneca Canada","keywords":"Prostate cancer; Medicine; Genetic testing; Cancer; Oncology; Pathology; Internal medicine; Primary tumor; Metastasis","score_opus":0.07643797035752352,"score_gpt":0.37382606655097594,"score_spread":0.2973880961934524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394008668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896644,0.008702933,0.000045543882,0.00024901988,0.00009941905,0.0007981702,0.00010559131,0.00008963263,0.00024532137],"genre_scores_gemma":[0.9959376,0.0002130243,0.0027964194,0.00006873696,0.000032119497,0.00080005947,0.00003376688,0.000044201966,0.00007409637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788684,0.00014959292,0.0006327747,0.00054980634,0.00027152314,0.0005094623],"domain_scores_gemma":[0.99888927,0.00036707093,0.00016410962,0.00030469074,0.00018181006,0.00009303505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021593805,0.00023128463,0.00060443213,0.0003190831,0.000070997696,0.000010770692,0.00014676347,0.000078260135,0.000028863897],"category_scores_gemma":[0.0004716273,0.00018000866,0.000084349784,0.0005080011,0.00038987614,0.0000915238,0.00032556886,0.00026369584,0.0000042376523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001539917,0.00012058025,0.8135866,0.0019105547,0.000021001895,0.0050650216,0.017570885,0.00016629246,0.14052953,0.000001919859,0.000009054373,0.020864563],"study_design_scores_gemma":[0.007730533,0.001988481,0.58393914,0.017722989,0.00023164215,0.0019236981,0.0054681697,0.060752507,0.31874722,0.00068295794,0.000088005196,0.000724629],"about_ca_topic_score_codex":0.00037613662,"about_ca_topic_score_gemma":0.00009377005,"teacher_disagreement_score":0.22964746,"about_ca_system_score_codex":0.00047119553,"about_ca_system_score_gemma":0.00029371105,"threshold_uncertainty_score":0.73405397},"labels":[],"label_agreement":null},{"id":"W4394014670","doi":"10.1007/s10147-024-02485-4","title":"Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis","year":2024,"lang":"en","type":"review","venue":"International Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Medizinische Universität Wien; Universität Wien","keywords":"Docetaxel; Medicine; Oncology; Enzalutamide; Internal medicine; Meta-analysis; Androgen deprivation therapy; Prostate cancer; Subgroup analysis; Randomized controlled trial; Cancer; Androgen receptor","score_opus":0.39014495282469785,"score_gpt":0.597948044489085,"score_spread":0.20780309166438715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394014670","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000112789094,0.991501,0.00013384013,0.0019686949,0.0003216049,0.0035338085,0.0024046819,0.0000050520107,0.00001852544],"genre_scores_gemma":[0.0023000245,0.995225,0.00031538977,0.0002196245,0.0003388272,0.00039405463,0.00033148765,0.00004442127,0.0008311391],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98842084,0.0028908057,0.0064801616,0.00053727155,0.0013696033,0.0003013038],"domain_scores_gemma":[0.97972345,0.009434039,0.0073297005,0.0004564599,0.0026067782,0.00044957417],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.008382865,0.0005707731,0.029691692,0.0012011186,0.0000256559,0.000029335837,0.0004622661,0.00020820014,0.00023856414],"category_scores_gemma":[0.0030508367,0.00025833643,0.041289587,0.001303189,0.00029123633,0.00007005529,0.00008997934,0.0008231195,0.0000038517646],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056722555,0.0010681855,0.00005203231,0.048502143,0.93437207,0.0003176156,0.00002720928,0.000105004,8.847485e-8,0.000025505155,0.001095661,0.008762256],"study_design_scores_gemma":[0.002524183,0.0049633,0.0002727759,0.0071665714,0.97636515,0.000028223993,0.0000058877636,0.000090096706,1.9149154e-7,0.000066733395,0.008353737,0.0001631579],"about_ca_topic_score_codex":0.00006793528,"about_ca_topic_score_gemma":0.000022451639,"teacher_disagreement_score":0.0419931,"about_ca_system_score_codex":0.00037623354,"about_ca_system_score_gemma":0.0032991807,"threshold_uncertainty_score":0.9999869},"labels":[],"label_agreement":null},{"id":"W4394015334","doi":"10.1016/j.euo.2024.03.006","title":"Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Tolerability; Prostate cancer; Placebo; Adverse effect; Abiraterone; Internal medicine; Oncology; Enzalutamide; Prednisone; Common Terminology Criteria for Adverse Events; Cancer; Pathology","score_opus":0.03318067851103599,"score_gpt":0.32747253788979147,"score_spread":0.29429185937875546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394015334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98778147,0.00056989485,0.000007302824,0.0069882176,0.00019621509,0.0027483774,0.0004288665,0.000041273935,0.0012384062],"genre_scores_gemma":[0.9985388,0.000046269048,0.00014476605,0.00024005599,0.000083577615,0.00013714332,0.000378443,0.000042170912,0.00038877584],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972344,0.0010541063,0.0005805376,0.00052239356,0.0002585232,0.00035003875],"domain_scores_gemma":[0.99877316,0.00040173,0.0001679365,0.0003845967,0.00018063714,0.00009195842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007961994,0.00021461606,0.00052437105,0.000095745876,0.000057742105,0.000020467816,0.00014222167,0.000050469484,0.000097433105],"category_scores_gemma":[0.000086065855,0.000104266976,0.000042284635,0.0003133619,0.0006002117,0.00007331667,0.000048966336,0.00043539843,0.000021464128],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9464095,0.0036593894,0.02584494,0.00008755164,0.00075615844,0.0012569522,0.006083884,0.00008744943,0.0010509368,0.00003480098,0.00068544026,0.014042992],"study_design_scores_gemma":[0.5570963,0.114523694,0.315161,0.00021765714,0.00083103403,0.000015213079,0.000383727,0.00026611006,0.0005587144,0.00008025492,0.010576377,0.00028990637],"about_ca_topic_score_codex":0.00043474408,"about_ca_topic_score_gemma":0.0011404149,"teacher_disagreement_score":0.38931316,"about_ca_system_score_codex":0.00017992093,"about_ca_system_score_gemma":0.0008148052,"threshold_uncertainty_score":0.42518836},"labels":[],"label_agreement":null},{"id":"W4394091467","doi":"10.6084/m9.figshare.20921256","title":"Additional file 4 of Accumulation of copy number alterations and clinical progression across advanced prostate cancer","year":2022,"lang":"en","type":"dataset","venue":"Open MIND","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Prostate cancer; Prostate; Oncology; Copy-number variation; Cancer; Cancer research; Biology; Internal medicine; Computational biology; Medicine; Genetics; Gene; Genome","score_opus":0.12960741431610975,"score_gpt":0.5443089059212464,"score_spread":0.4147014916051366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394091467","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021298872,0.00011270024,7.430215e-8,0.000097389544,0.00007528269,0.0014652377,0.99592566,7.6232317e-7,0.00019300479],"genre_scores_gemma":[0.00004464453,0.0006141015,0.001459329,0.000013440611,0.00006798008,0.0012383991,0.99225295,0.000012237643,0.004296892],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99852705,0.00008262827,0.00048275257,0.0003510648,0.00038436704,0.00017211647],"domain_scores_gemma":[0.9984319,0.0005698889,0.00041701258,0.00027251514,0.00021144864,0.000097187854],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017562331,0.00014346647,0.00043907724,0.00004144885,0.00012482227,0.00003187567,0.00014916576,0.00012242906,0.9615299],"category_scores_gemma":[0.00025103087,0.00011261189,0.00007170246,0.00015842174,0.00020977293,0.00014095749,0.00035316017,0.00030869708,0.00004078371],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011017526,0.00036440464,0.0005879691,0.0001188058,0.00013606137,0.000017078393,0.00006346314,0.0000029821097,0.0000066566936,5.299072e-8,0.9428314,0.054769352],"study_design_scores_gemma":[0.0019117423,0.00047008487,0.0022212293,0.0009327478,0.00008456537,0.000007545817,0.00007808883,0.00001939597,0.00012938143,0.0000030143426,0.9940432,0.00009903714],"about_ca_topic_score_codex":0.00008030494,"about_ca_topic_score_gemma":0.00015818058,"teacher_disagreement_score":0.96148914,"about_ca_system_score_codex":0.00007639982,"about_ca_system_score_gemma":0.0008254469,"threshold_uncertainty_score":0.45921797},"labels":[],"label_agreement":null},{"id":"W4394098316","doi":"10.6084/m9.figshare.16847362","title":"Data from the Phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer by Bruchovsky et al (2006).","year":2021,"lang":"en","type":"dataset","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Androgen suppression; Radiation therapy; Medicine; Oncology; Internal medicine; Biochemical recurrence; Androgen; Prostate; Recurrent prostate cancer; Cancer; Urology; Prostatectomy; Hormone","score_opus":0.06694952915799901,"score_gpt":0.4200603921061215,"score_spread":0.3531108629481225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394098316","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005804069,0.031974275,0.0000022163326,0.002563488,0.00017016314,0.0057933107,0.9589063,0.000008638876,0.0000012187762],"genre_scores_gemma":[0.000036899997,0.0054170615,0.00010741599,0.0009431626,0.00022672112,0.008818485,0.9842362,0.00004004147,0.00017401592],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99785775,0.00008354779,0.00048260958,0.0007987399,0.00038416704,0.00039316158],"domain_scores_gemma":[0.99792665,0.0004279979,0.00024118816,0.0010552469,0.00022336926,0.00012555646],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015978885,0.00032788794,0.00064409757,0.00005964579,0.000054137177,0.00003785165,0.00062818476,0.00022223087,0.010712512],"category_scores_gemma":[0.0007196585,0.00020920436,0.00014908501,0.00014052533,0.000037732618,0.00011569997,0.0004087594,0.00040607824,0.0000038492476],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0850297,0.00082551746,0.0000036339827,0.00054055924,0.00022364625,0.000024937495,0.000055437686,2.9547454e-7,0.0009522447,5.1606417e-9,0.90012294,0.0122210765],"study_design_scores_gemma":[0.08186766,0.0017134285,0.0000046415557,0.009471218,0.000089447414,0.0000017780984,0.000021125743,0.00013872175,0.0061319713,0.0000020599634,0.9003587,0.00019929644],"about_ca_topic_score_codex":0.00011621912,"about_ca_topic_score_gemma":0.00011174292,"teacher_disagreement_score":0.026557213,"about_ca_system_score_codex":0.00017824236,"about_ca_system_score_gemma":0.00096344406,"threshold_uncertainty_score":0.9901918},"labels":[],"label_agreement":null},{"id":"W4394303630","doi":"10.6084/m9.figshare.19767724","title":"Additional file 3 of Transcriptome profiling and proteomic validation reveals targets of the androgen receptor signaling in the BT-474 breast cancer cell line","year":2022,"lang":"en","type":"dataset","venue":"Open MIND","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto","funders":"","keywords":"Androgen receptor; Transcriptome; Profiling (computer programming); Computational biology; Breast cancer; Biology; Cancer research; Bioinformatics; Cancer; Computer science; Genetics; Gene; Prostate cancer; Gene expression","score_opus":0.03685935519273966,"score_gpt":0.3215903951983559,"score_spread":0.2847310400056163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394303630","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009061572,0.00042362403,4.6276647e-8,0.00035906577,0.00003992712,0.0027012678,0.98732936,3.9364573e-7,0.0000847635],"genre_scores_gemma":[0.00040964584,0.00025609398,0.00030940198,0.000026905242,0.00008105025,0.0016570024,0.99602985,0.000012549611,0.001217496],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985592,0.00020783418,0.00035472005,0.00027718022,0.0004324867,0.00016859743],"domain_scores_gemma":[0.9990912,0.00022097066,0.000280086,0.00027521735,0.00009380131,0.00003870405],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004181847,0.00015398259,0.0003479414,0.00006733969,0.00009393936,0.000024970554,0.00037096257,0.00009520836,0.8248106],"category_scores_gemma":[0.000058666792,0.00008857415,0.00007115835,0.00021564381,0.00007440505,0.00008309511,0.0001305888,0.0003493621,0.00000650004],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040029784,0.00020252535,0.000049840262,0.00032634588,0.00006942289,0.0000060676143,0.00022342974,0.000005050148,0.010542201,5.5975917e-8,0.9873936,0.00078114244],"study_design_scores_gemma":[0.001467203,0.00022635673,0.0002969216,0.0012636171,0.00014718986,0.000019802901,0.000545729,0.0000053816075,0.02933436,0.0000060712305,0.9665584,0.00012895287],"about_ca_topic_score_codex":0.00041602444,"about_ca_topic_score_gemma":0.000060599887,"teacher_disagreement_score":0.8248041,"about_ca_system_score_codex":0.0001289558,"about_ca_system_score_gemma":0.000644632,"threshold_uncertainty_score":0.36119488},"labels":[],"label_agreement":null},{"id":"W4394340193","doi":"10.6084/m9.figshare.16847362.v1","title":"Data from the Phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer by Bruchovsky et al (2006).","year":2021,"lang":"en","type":"dataset","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Androgen suppression; Radiation therapy; Medicine; Oncology; Biochemical recurrence; Internal medicine; Urology; Recurrent prostate cancer; Androgen; Cancer; Prostatectomy; Hormone","score_opus":0.06694952915799901,"score_gpt":0.4200603921061215,"score_spread":0.3531108629481225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394340193","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005804069,0.031974275,0.0000022163326,0.002563488,0.00017016314,0.0057933107,0.9589063,0.000008638876,0.0000012187762],"genre_scores_gemma":[0.000036899997,0.0054170615,0.00010741599,0.0009431626,0.00022672112,0.008818485,0.9842362,0.00004004147,0.00017401592],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99785775,0.00008354779,0.00048260958,0.0007987399,0.00038416704,0.00039316158],"domain_scores_gemma":[0.99792665,0.0004279979,0.00024118816,0.0010552469,0.00022336926,0.00012555646],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015978885,0.00032788794,0.00064409757,0.00005964579,0.000054137177,0.00003785165,0.00062818476,0.00022223087,0.010712512],"category_scores_gemma":[0.0007196585,0.00020920436,0.00014908501,0.00014052533,0.000037732618,0.00011569997,0.0004087594,0.00040607824,0.0000038492476],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0850297,0.00082551746,0.0000036339827,0.00054055924,0.00022364625,0.000024937495,0.000055437686,2.9547454e-7,0.0009522447,5.1606417e-9,0.90012294,0.0122210765],"study_design_scores_gemma":[0.08186766,0.0017134285,0.0000046415557,0.009471218,0.000089447414,0.0000017780984,0.000021125743,0.00013872175,0.0061319713,0.0000020599634,0.9003587,0.00019929644],"about_ca_topic_score_codex":0.00011621912,"about_ca_topic_score_gemma":0.00011174292,"teacher_disagreement_score":0.026557213,"about_ca_system_score_codex":0.00017824236,"about_ca_system_score_gemma":0.00096344406,"threshold_uncertainty_score":0.9901918},"labels":[],"label_agreement":null},{"id":"W4394370738","doi":"10.6084/m9.figshare.21359444","title":"The current role of local treatment in metastatic prostate cancer: systematic review and meta-analysis","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Meta-analysis; Oncology; Current (fluid); Medicine; Cancer; Internal medicine; Geology; Oceanography","score_opus":0.10355729734729782,"score_gpt":0.3980368876920415,"score_spread":0.2944795903447437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394370738","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.7919673e-7,0.4730937,4.6829634e-9,0.00019551946,0.0000053897547,0.0027386283,0.52395993,0.000003368443,0.0000033222877],"genre_scores_gemma":[0.000011406364,0.11756754,7.378014e-7,0.00005718926,0.0000055495484,0.019190764,0.86258906,0.000014137383,0.00056363415],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976771,0.0003738685,0.00068917597,0.00039040268,0.00057402754,0.0002954388],"domain_scores_gemma":[0.9982242,0.00033290713,0.00045100084,0.0007468122,0.00012876175,0.00011629292],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002329675,0.0003468193,0.0030905134,0.00024514715,0.00009391966,0.00002593215,0.0002145025,0.00003567789,0.20313418],"category_scores_gemma":[0.00018639796,0.00016415298,0.0007780992,0.00077776413,0.000028997221,0.000029890405,0.000164616,0.0003415529,0.000036951933],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027209928,0.00012243768,0.0000010157523,0.27130753,0.064209945,0.000044957833,0.000028170705,0.0000047667204,2.5418096e-8,1.1107314e-7,0.66393965,0.00031417256],"study_design_scores_gemma":[0.00034459875,0.0001804574,0.0000058425026,0.008780943,0.4326474,0.0000049399036,0.00006308976,0.000010769924,0.0000049173036,0.000002490482,0.55784714,0.00010741353],"about_ca_topic_score_codex":0.0004927497,"about_ca_topic_score_gemma":0.0009412002,"teacher_disagreement_score":0.36843747,"about_ca_system_score_codex":0.0004413524,"about_ca_system_score_gemma":0.0005416011,"threshold_uncertainty_score":0.79759425},"labels":[],"label_agreement":null},{"id":"W4394568191","doi":"10.1038/s41388-024-03024-1","title":"PDIA2 has a dual function in promoting androgen deprivation therapy induced venous thrombosis events and castrate resistant prostate cancer progression","year":2024,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Cancer research; Biology; Androgen receptor; Tissue factor; Tumor progression; Downregulation and upregulation; Cancer; Internal medicine; Medicine; Coagulation","score_opus":0.08023037926753677,"score_gpt":0.3758285136075628,"score_spread":0.295598134340026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394568191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983495,0.0131390765,0.0000030924396,0.0017745714,0.00015313661,0.0012753066,0.000022810253,0.000070272996,0.000066740344],"genre_scores_gemma":[0.99581873,0.0032566055,0.00009464304,0.0000348287,0.0001339033,0.00036313426,0.00007565053,0.000035817306,0.00018668598],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987171,0.000063454136,0.00022365071,0.00038610597,0.00030536237,0.00030430962],"domain_scores_gemma":[0.9996312,0.000021763597,0.000048512193,0.00012593338,0.00006904035,0.00010354359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002958954,0.00015900757,0.0002117943,0.00017323282,0.00012404805,0.000071672344,0.000028154001,0.00009342564,0.00003255699],"category_scores_gemma":[0.00001378056,0.00011383382,0.00003710702,0.0004273826,0.000040932056,0.00014722858,0.000030900756,0.0001956915,0.000006333149],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013476494,0.00031786703,0.049995147,0.00029108065,0.0001750423,0.00022004578,0.002869707,0.0000016903095,0.663137,0.000004538365,0.000041170853,0.28159904],"study_design_scores_gemma":[0.010785426,0.007707546,0.41027486,0.0048752446,0.00025569403,0.00012214256,0.00053234014,0.0017680253,0.55727255,0.00051842845,0.005336365,0.00055135775],"about_ca_topic_score_codex":0.00026802698,"about_ca_topic_score_gemma":0.0001572809,"teacher_disagreement_score":0.3602797,"about_ca_system_score_codex":0.0002919984,"about_ca_system_score_gemma":0.0004720425,"threshold_uncertainty_score":0.46420082},"labels":[],"label_agreement":null},{"id":"W4394576101","doi":"10.3390/cancers16071436","title":"Exploring The Prognostic Significance of SET-Domain Containing 2 (SETD2) Expression in Advanced and Castrate-Resistant Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta; University of Calgary","funders":"Prostate Cancer Canada; Cumming School of Medicine, University of Calgary; Prostate Cancer Foundation","keywords":"Prostate cancer; Expression (computer science); Domain (mathematical analysis); Cancer; Prostate; Set (abstract data type); Medicine; Oncology; Cancer research; Internal medicine; Computer science; Programming language; Mathematics","score_opus":0.07196252587057507,"score_gpt":0.34076644529229716,"score_spread":0.2688039194217221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394576101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764595,0.020820606,0.000013691811,0.0007602152,0.00024776967,0.0012353593,0.00006600456,0.00004310425,0.00035373523],"genre_scores_gemma":[0.99290556,0.0050600744,0.00016075837,0.000036702244,0.0000694183,0.0013470233,0.000012854634,0.000032069755,0.00037554523],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986284,0.00006085224,0.00027467785,0.0003729692,0.0002758806,0.0003872264],"domain_scores_gemma":[0.99939245,0.0001892391,0.00005396594,0.00018461894,0.00006567555,0.00011402569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027143315,0.00017404086,0.00028193602,0.00012807026,0.00007872937,0.000035721474,0.00007725439,0.000033019343,0.000027530568],"category_scores_gemma":[0.000041377025,0.00010922477,0.000045280194,0.00044306074,0.00023405436,0.00020686955,0.00004134588,0.0002810384,0.000001565166],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073635504,0.000045460005,0.05785455,0.0037577134,0.00026711336,0.0012028452,0.028067512,0.0021593475,0.8167517,0.000300643,0.00041951615,0.081810005],"study_design_scores_gemma":[0.014947246,0.004290312,0.23054181,0.033767577,0.00041355158,0.00007878178,0.062402677,0.004135787,0.6211089,0.0010913494,0.025919432,0.001302594],"about_ca_topic_score_codex":0.00059529167,"about_ca_topic_score_gemma":0.0002731673,"teacher_disagreement_score":0.19564286,"about_ca_system_score_codex":0.00092309364,"about_ca_system_score_gemma":0.0011449421,"threshold_uncertainty_score":0.4454057},"labels":[],"label_agreement":null},{"id":"W4394801095","doi":"10.1097/01.ju.0001008744.60568.e8.07","title":"MP68-07 PROPORTION OF GLEASON 8-10 PROSTATE CANCER FOUND ON BIOPSY AND TUMOR AGGRESSIVENESS IN MATCHED COHORTS OF MEN IN ASIA AND WESTERN COUNTRIES","year":2024,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Prostate biopsy; Biopsy; Cancer; Prostate; Oncology; Urology; Demography; Internal medicine; Gynecology","score_opus":0.01587702530836168,"score_gpt":0.32917912329420773,"score_spread":0.3133020979858461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394801095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97721016,0.018633803,0.0000015658234,0.0037262663,0.000059105732,0.00031109265,0.000008301951,0.0000020811879,0.000047601116],"genre_scores_gemma":[0.99363905,0.006127548,0.0000063495677,0.000027435823,0.000030525563,0.000008480688,0.0000014421724,0.000008645839,0.00015052206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991705,0.000102745886,0.00032051295,0.00008377263,0.00019050241,0.00013199274],"domain_scores_gemma":[0.9994811,0.000108189844,0.00020611825,0.00006683118,0.000100807425,0.0000369776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062433485,0.00007781341,0.00033133395,0.00019082472,0.000012919856,0.0000065023396,0.00004096121,0.000042489617,0.000030212817],"category_scores_gemma":[0.000028991617,0.000042594176,0.000018399816,0.00011620827,0.00025210736,0.000060281473,0.000023403838,0.00019308987,6.290143e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014451574,0.00018122073,0.9559431,0.00094612804,0.00020658907,0.0011983744,0.0035579295,0.00006583178,0.018988611,0.00004799264,0.00007553784,0.004337116],"study_design_scores_gemma":[0.0034631132,0.0029395083,0.9808633,0.0013443404,0.00018803345,0.0011864402,0.000402013,0.00020179023,0.008329733,0.00058009406,0.0004377413,0.00006391354],"about_ca_topic_score_codex":0.00016302285,"about_ca_topic_score_gemma":0.00008328076,"teacher_disagreement_score":0.024920182,"about_ca_system_score_codex":0.000060738388,"about_ca_system_score_gemma":0.00021799403,"threshold_uncertainty_score":0.17369401},"labels":[],"label_agreement":null},{"id":"W4394823979","doi":"10.1097/ju9.0000000000000138","title":"Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2","year":2024,"lang":"en","type":"article","venue":"JU Open Plus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Biotech; Foundation Medicine; National Cancer Institute; Cancer Center, University of Colorado; National Institutes of Health; Astellas Pharma; Daiichi-Sankyo; Invitae; National Center for Advancing Translational Sciences; Seagen; UroGen Pharma; Clovis Oncology; Sanofi; Exelixis; Advanced Accelerator Applications; Regeneron Pharmaceuticals; Prostate Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; Myriad Genetics; Celgene; Amgen; Pfizer","keywords":"Prostate cancer; Medicine; Narrative review; Narrative; Oncology; Cancer; Management of prostate cancer; Gynecology; Internal medicine; Intensive care medicine; Art","score_opus":0.05177091720800439,"score_gpt":0.39195939030769744,"score_spread":0.340188473099693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394823979","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35150298,0.47854576,0.0000015100421,0.12958385,0.0005338547,0.017561441,0.0006277679,0.000045281537,0.021597566],"genre_scores_gemma":[0.81196815,0.15539624,0.000051501705,0.00082550274,0.000031945703,0.002405237,0.000025293708,0.000023964985,0.029272156],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.99854475,0.000070276306,0.00035587465,0.00045388145,0.0003302064,0.0002450163],"domain_scores_gemma":[0.99927676,0.0000763559,0.00012499391,0.00028235966,0.00017244866,0.00006705749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030854333,0.00019053288,0.000475063,0.000075859345,0.00012231195,0.000111626054,0.00014405897,0.000023299488,0.00022395529],"category_scores_gemma":[0.00005800281,0.000110119654,0.000057900274,0.00035641744,0.00023185973,0.00018027295,0.0001344293,0.00018180741,0.000002557313],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018872766,0.0017934067,0.028990991,0.05778612,0.010707151,0.018240381,0.5424325,0.00032640848,0.0035319678,0.015662955,0.26893693,0.03271843],"study_design_scores_gemma":[0.025371796,0.0027344483,0.07750041,0.118350044,0.0032755248,0.00033577686,0.15178515,0.00091692805,0.0076507605,0.0008125628,0.60972357,0.0015430149],"about_ca_topic_score_codex":0.0031879982,"about_ca_topic_score_gemma":0.002902539,"teacher_disagreement_score":0.4604652,"about_ca_system_score_codex":0.00048015764,"about_ca_system_score_gemma":0.0006995183,"threshold_uncertainty_score":0.4819321},"labels":[],"label_agreement":null},{"id":"W4394823988","doi":"10.1097/ju9.0000000000000137","title":"Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1","year":2024,"lang":"en","type":"article","venue":"JU Open Plus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Biotech; Foundation Medicine; National Cancer Institute; Cancer Center, University of Colorado; National Institutes of Health; Astellas Pharma; Daiichi-Sankyo; Invitae; National Center for Advancing Translational Sciences; Seagen; UroGen Pharma; Clovis Oncology; Sanofi; Exelixis; Advanced Accelerator Applications; Regeneron Pharmaceuticals; Prostate Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; Myriad Genetics; Celgene; Amgen; Pfizer","keywords":"Prostate cancer; Cancer; Prostate; Narrative; Narrative review; Medicine; Management of prostate cancer; Castration; Gynecology; Internal medicine; Intensive care medicine; Art; Hormone; Literature","score_opus":0.03931946968918519,"score_gpt":0.3789558317343568,"score_spread":0.3396363620451716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394823988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51311266,0.25394952,0.0000013329011,0.16672012,0.0006719893,0.018267505,0.0005527649,0.000050016268,0.04667412],"genre_scores_gemma":[0.8310636,0.13986738,0.00002003976,0.00095654296,0.00004543293,0.0013175216,0.000020897654,0.000018012199,0.026690554],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872357,0.000059039827,0.00027630106,0.0004454722,0.00027158836,0.00022404513],"domain_scores_gemma":[0.99931926,0.00006794369,0.000102748214,0.00023683121,0.00021409361,0.000059126458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002348749,0.00017371685,0.0004198179,0.00006483838,0.00011557956,0.000087344466,0.000104264385,0.00003372132,0.00012595116],"category_scores_gemma":[0.00004760114,0.00010353116,0.000050262475,0.00030620277,0.00024784118,0.00017241618,0.00014062921,0.00019511106,0.0000029262567],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011217745,0.0009634325,0.044294402,0.020752717,0.0056982976,0.013485803,0.6429393,0.0001790264,0.0015696113,0.009125708,0.21675554,0.03301841],"study_design_scores_gemma":[0.023625646,0.0025273033,0.15107137,0.13233027,0.0020003952,0.00057205674,0.21689874,0.00094021286,0.015858019,0.0004355529,0.45213732,0.0016031086],"about_ca_topic_score_codex":0.002928958,"about_ca_topic_score_gemma":0.0021878453,"teacher_disagreement_score":0.42604056,"about_ca_system_score_codex":0.0004808656,"about_ca_system_score_gemma":0.0005770621,"threshold_uncertainty_score":0.44277278},"labels":[],"label_agreement":null},{"id":"W4394832756","doi":"10.1097/01.ju.0001008744.60568.e8.09","title":"MP68-09 THE ASSOCIATION BETWEEN 5-ALPHA REDUCTASE INHIBITORS AND PROSTATE CANCER MORTALITY","year":2024,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Finasteride; Dutasteride; Oncology; Gynecology; Cancer; Hazard ratio; Internal medicine; Proportional hazards model; Prostate; Overdiagnosis; Confidence interval","score_opus":0.029670518311140405,"score_gpt":0.35789689291564936,"score_spread":0.32822637460450893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394832756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91287374,0.021370105,0.0000025981315,0.06496009,0.00035263415,0.0001908886,0.000019349516,0.000008250957,0.00022235274],"genre_scores_gemma":[0.9909763,0.006915898,0.0000039332817,0.0002498088,0.00083835534,0.0000051361217,0.0000032230978,0.000009529206,0.0009978542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990335,0.00021535756,0.00023045605,0.00007180822,0.00026429121,0.00018459071],"domain_scores_gemma":[0.99927634,0.00031739016,0.00012924816,0.00009975984,0.00010778329,0.00006945815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014976584,0.00007343754,0.000179485,0.00006308344,0.00009240784,0.000022826373,0.00007473758,0.000059988964,0.000037545196],"category_scores_gemma":[0.00008825726,0.00003117143,0.00005522853,0.00014578058,0.00013277846,0.000058077127,0.000034549124,0.00050680083,0.0000057587285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017711056,0.00011421986,0.86687386,0.00020752741,0.004184019,0.0005188574,0.009835616,0.000031642,0.013861648,0.00016597818,0.04404997,0.05838558],"study_design_scores_gemma":[0.0035310355,0.002731681,0.8658338,0.00020262777,0.0044221147,0.00085549476,0.00083001936,0.00015658727,0.009432508,0.0049314057,0.106897265,0.00017545624],"about_ca_topic_score_codex":0.0000953744,"about_ca_topic_score_gemma":0.000016543267,"teacher_disagreement_score":0.07810253,"about_ca_system_score_codex":0.00014615561,"about_ca_system_score_gemma":0.00024587775,"threshold_uncertainty_score":0.22018255},"labels":[],"label_agreement":null},{"id":"W4394853712","doi":"10.1172/jci170809","title":"The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Estrogen receptor; Cancer research; Biology; Estrogen receptor beta; Cell growth; Androgen receptor; Estrogen; Estrogen receptor alpha; Nuclear receptor; Cancer; Endocrinology; Breast cancer; Transcription factor; Genetics","score_opus":0.06051771547079411,"score_gpt":0.4157072906028091,"score_spread":0.355189575132015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394853712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.930051,0.057165608,0.00001599276,0.0118644675,0.00030559607,0.0005499617,0.000005324104,0.000018308512,0.000023700997],"genre_scores_gemma":[0.9865328,0.011385692,0.0007237552,0.00017715202,0.0007242598,0.000044818,0.000015068727,0.000016417851,0.0003800348],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99836636,0.0001616879,0.0007274363,0.0001975537,0.00039260252,0.00015436897],"domain_scores_gemma":[0.9985684,0.00024760357,0.0002724677,0.00009833327,0.00025018377,0.000562981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018758216,0.00010246025,0.00023530172,0.000039714912,0.00013910815,0.000200461,0.000035135832,0.00006687904,0.0000068851014],"category_scores_gemma":[0.00049237546,0.000051839164,0.00009378874,0.00010807809,0.00027481248,0.0003141982,0.00002684477,0.00034199262,7.798184e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002098342,0.00017334057,0.39072266,0.0006435328,0.0002587796,0.00038201996,0.0010128422,0.000010216524,0.009291665,0.0005548278,0.0011668168,0.593685],"study_design_scores_gemma":[0.018832045,0.008314255,0.5478918,0.011930241,0.004568458,0.00064217206,0.0014854736,0.025905643,0.16001672,0.06688679,0.15246718,0.0010592603],"about_ca_topic_score_codex":0.000006886011,"about_ca_topic_score_gemma":0.00000245312,"teacher_disagreement_score":0.5926257,"about_ca_system_score_codex":0.000034434663,"about_ca_system_score_gemma":0.00096741185,"threshold_uncertainty_score":0.21139398},"labels":[],"label_agreement":null},{"id":"W4394873139","doi":"10.1111/ajco.14064","title":"Management of advanced prostate cancer in the Asia‐Pacific region: Summary of the Asia‐Pacific Advanced Prostate Cancer Consensus Conference 2023","year":2024,"lang":"en","type":"article","venue":"Asia-Pacific Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Astellas Pharma Canada; Bayer; AstraZeneca; Pfizer","keywords":"Prostate cancer; Consensus conference; Reimbursement; Asia pacific; Medicine; Cancer; Political science; Gynecology; Internal medicine; Business; Health care","score_opus":0.08370714508975953,"score_gpt":0.4454766813636823,"score_spread":0.3617695362739228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394873139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62305146,0.06862987,0.000025217656,0.21779066,0.007872353,0.006333654,0.00042983412,0.00006500817,0.07580196],"genre_scores_gemma":[0.9102684,0.06387193,0.0004030379,0.00009796453,0.00033734797,0.0002378328,0.00001492153,0.00005908052,0.024709467],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.992715,0.0012079282,0.0032645322,0.0007120471,0.0012395039,0.000860991],"domain_scores_gemma":[0.99437857,0.0017000654,0.0017576033,0.00084689795,0.0009869251,0.00032994463],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034830861,0.00048317897,0.0019597406,0.00038038415,0.00013295097,0.00004563884,0.00076250976,0.00039154012,0.00018251245],"category_scores_gemma":[0.00033626362,0.00026680113,0.00076188636,0.0014405898,0.001774737,0.0002107744,0.00019740037,0.0022178453,0.000012939617],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032011263,0.003092465,0.0766758,0.0029303804,0.0036306644,0.0102221025,0.0062923254,0.0004886973,0.0030247923,0.0029792055,0.057336044,0.80131626],"study_design_scores_gemma":[0.027587248,0.012471015,0.124846175,0.014744693,0.002123736,0.001382065,0.08639491,0.00039320986,0.004367944,0.004368757,0.7204288,0.0008914039],"about_ca_topic_score_codex":0.00006710548,"about_ca_topic_score_gemma":0.00014724767,"teacher_disagreement_score":0.8004249,"about_ca_system_score_codex":0.0005689719,"about_ca_system_score_gemma":0.0040903813,"threshold_uncertainty_score":0.9999784},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"other","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W4394933306","doi":"10.2967/jnumed.123.267014","title":"Development of a Visually Calculated SUV<sub>mean</sub>(HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to<sup>177</sup>Lu-PSMA Therapy: Comparison with Quantitative SUV<sub>mean</sub>and Patient Outcomes","year":2024,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Prostate cancer; Glutamate carboxypeptidase II; Medicine; Nuclear medicine; Taxane; Standardized uptake value; Prostate; Cancer; Positron emission tomography; Internal medicine; Breast cancer","score_opus":0.05954034430934468,"score_gpt":0.35803817741343363,"score_spread":0.29849783310408895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394933306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852507,0.0022799848,0.00013026281,0.01035097,0.0001786649,0.0015867637,0.00003176631,0.00007904644,0.00011182679],"genre_scores_gemma":[0.99523884,0.00079158036,0.0026228975,0.00091963424,0.00013655699,0.000027804012,0.000026696118,0.00014780434,0.00008816031],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9947774,0.00035682163,0.0015162105,0.00064103195,0.001987694,0.0007208421],"domain_scores_gemma":[0.99676156,0.00071152905,0.00045579785,0.00039968485,0.0006458324,0.0010256033],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013112683,0.0006681444,0.0016702232,0.0013687634,0.00023786408,0.00007165433,0.00022379357,0.00006704102,0.00006740669],"category_scores_gemma":[0.00029585898,0.0003842873,0.00024296272,0.00095306436,0.00030162372,0.0001778791,0.00010092976,0.00066516834,0.00003739044],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16107908,0.0034557136,0.021686833,0.0005961702,0.008825382,0.015328084,0.124740504,0.0015785336,0.42020845,0.00008752508,0.008551431,0.2338623],"study_design_scores_gemma":[0.064271696,0.23698704,0.22658062,0.03547269,0.0026337346,0.0039880453,0.059108436,0.009173345,0.30839607,0.000039090322,0.051331673,0.0020175707],"about_ca_topic_score_codex":0.00006080699,"about_ca_topic_score_gemma":0.000047600875,"teacher_disagreement_score":0.23353131,"about_ca_system_score_codex":0.00094866764,"about_ca_system_score_gemma":0.00082121394,"threshold_uncertainty_score":0.9998609},"labels":[],"label_agreement":null},{"id":"W4394987934","doi":"10.1016/j.eururo.2024.03.036","title":"Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study","year":2024,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Prostate-specific antigen; Hazard ratio; Internal medicine; Androgen deprivation therapy; Oncology; Population; Enzalutamide; Placebo; Subgroup analysis; Urology; Cancer; Confidence interval; Pathology; Androgen receptor","score_opus":0.04008932985786196,"score_gpt":0.35940546595417244,"score_spread":0.3193161360963105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394987934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99105716,0.001299617,0.00015812267,0.0017431305,0.00003474126,0.0055390517,0.00013315758,0.000029312656,0.000005725807],"genre_scores_gemma":[0.99730456,0.0015494062,0.00042918613,0.00017000204,0.000020007332,0.00016463967,0.000044062454,0.000049485487,0.00026867847],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99728817,0.0012328883,0.00040889913,0.0005036546,0.00029990493,0.00026646498],"domain_scores_gemma":[0.99796134,0.0011795196,0.00022115899,0.00020569967,0.00031182883,0.00012047663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013650227,0.00023120739,0.00076114765,0.00016034361,0.00014002106,0.000062114705,0.000048100665,0.00002991954,0.000003522772],"category_scores_gemma":[0.00030566103,0.000101075464,0.00004465487,0.00031086762,0.00031261868,0.000103785496,0.000044614415,0.00016378745,8.517998e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5200025,0.0004816144,0.47145912,0.000040094477,0.0020964306,0.00013446304,0.0027390833,0.00003707807,0.0008775265,0.0000020765963,0.000047308993,0.0020827372],"study_design_scores_gemma":[0.17665629,0.0145277595,0.80658257,0.000056263943,0.00080490456,0.000011280411,0.00032709198,0.00034238296,0.00032672109,0.0000066759,0.0002192993,0.00013878188],"about_ca_topic_score_codex":0.000055632183,"about_ca_topic_score_gemma":0.00005813809,"teacher_disagreement_score":0.34334618,"about_ca_system_score_codex":0.000052919673,"about_ca_system_score_gemma":0.00014312193,"threshold_uncertainty_score":0.41217378},"labels":[],"label_agreement":null},{"id":"W4395075142","doi":"10.3390/curroncol31050178","title":"Mixed Adenosquamous Cell Carcinoma of the Prostate with Paired Sequencing on the Primary and Liver Metastasis","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Metastasis; Oncology; Prostate; Docetaxel; Targeted therapy; Androgen deprivation therapy; Radiation therapy; Cancer research; Internal medicine; Cancer","score_opus":0.12918851304388637,"score_gpt":0.34296707632103335,"score_spread":0.21377856327714698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395075142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9702666,0.02379498,0.000007564149,0.002879975,0.00039745186,0.0009332083,0.00003257825,0.000023377597,0.001664304],"genre_scores_gemma":[0.99801207,0.0007559546,0.000041925032,0.000099922196,0.00007914355,0.00009288906,0.000013944469,0.000017087727,0.0008870611],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989689,0.00017964325,0.00014769287,0.00024136956,0.00023594017,0.00022648441],"domain_scores_gemma":[0.9992799,0.00028093296,0.000049677492,0.00022848297,0.00009519388,0.00006577288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026586055,0.00012900558,0.00023244375,0.00006791392,0.000088939814,0.000013912755,0.00008923262,0.00004508601,0.000056623154],"category_scores_gemma":[0.000029854042,0.00005248222,0.00006579635,0.00022233507,0.00032134238,0.000030575284,0.00008411278,0.00033447967,0.000012955911],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066211824,0.0023575313,0.14975439,0.010819854,0.0010741155,0.0019599556,0.027890297,0.00002126387,0.03190196,0.0023145142,0.075671695,0.6896132],"study_design_scores_gemma":[0.016497409,0.020158753,0.37178293,0.0031048914,0.0033604999,0.00076106447,0.006773448,0.0033103013,0.29980597,0.0005489266,0.27304223,0.0008535947],"about_ca_topic_score_codex":0.000019994735,"about_ca_topic_score_gemma":0.000014198487,"teacher_disagreement_score":0.6887596,"about_ca_system_score_codex":0.00036119125,"about_ca_system_score_gemma":0.00070943066,"threshold_uncertainty_score":0.21401629},"labels":[],"label_agreement":null},{"id":"W4395084982","doi":"10.1016/j.euo.2024.04.004","title":"The State of Intermediate Clinical Endpoints as Surrogates for Overall Survival in Prostate Cancer in 2024","year":2024,"lang":"en","type":"review","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"European Association of Urology; Pfizer","keywords":"Medicine; Prostate cancer; Cancer; Oncology; Prostate; Internal medicine; Intensive care medicine","score_opus":0.09682521397665769,"score_gpt":0.4804949331967629,"score_spread":0.3836697192201052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395084982","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046912227,0.9819792,4.1816702e-7,0.0011048304,0.0034142954,0.0029408482,0.00030498256,0.000030187688,0.005534005],"genre_scores_gemma":[0.0009243404,0.9825287,0.000010916838,0.00015075969,0.00036975555,0.00050381257,0.00014889071,0.00013642419,0.015226423],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99343866,0.0028334076,0.0018605262,0.0008295484,0.00019220308,0.0008456432],"domain_scores_gemma":[0.9960421,0.0027760381,0.0004625133,0.00043580588,0.00011807297,0.00016548156],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0043432293,0.0004655633,0.002569907,0.00049140817,0.00004131904,0.000018367564,0.00043483305,0.00025928422,0.00008561572],"category_scores_gemma":[0.0006649741,0.0002697998,0.0005496689,0.00037618878,0.0008824225,0.000032617823,0.00042345806,0.0018701797,0.00026846761],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028165209,0.0003693432,0.0017558805,0.005712804,0.0007835982,0.0030165045,0.00038673953,0.000002428362,0.0000010426243,0.00008713832,0.0034108083,0.9816572],"study_design_scores_gemma":[0.0039485726,0.003420635,0.001845033,0.0023533457,0.0007784222,0.00007944408,0.000025379813,0.00002340189,8.411085e-7,0.0005050508,0.986823,0.00019688052],"about_ca_topic_score_codex":0.000077871126,"about_ca_topic_score_gemma":0.0013794267,"teacher_disagreement_score":0.9834122,"about_ca_system_score_codex":0.00045370896,"about_ca_system_score_gemma":0.002245208,"threshold_uncertainty_score":0.99997544},"labels":[],"label_agreement":null},{"id":"W4395445932","doi":"10.1016/j.cpet.2024.03.009","title":"Treatment Response Imaging in Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"PET Clinics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Cancer imaging; Cancer; Functional imaging; Medical imaging; Radiology; Oncology; Internal medicine","score_opus":0.04618394811621717,"score_gpt":0.44390406984883546,"score_spread":0.3977201217326183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395445932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96236,0.017756829,0.0000020300708,0.017704533,0.00039629175,0.00051733985,0.000056881443,0.000107070766,0.001098983],"genre_scores_gemma":[0.95829624,0.0123970555,0.000119895696,0.00019066664,0.00014589648,0.00022726429,0.000032173746,0.000032526885,0.028558293],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895996,0.00006427709,0.00022491383,0.0002935292,0.00016476386,0.0002925804],"domain_scores_gemma":[0.99939865,0.00025142264,0.0000166769,0.00019073479,0.000038272527,0.00010425202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033395938,0.0001213329,0.00019418709,0.00017587436,0.000030072117,0.000041272117,0.000038399237,0.000019407364,0.00017374802],"category_scores_gemma":[0.00006693789,0.000082210994,0.00008617501,0.0002659059,0.00005842696,0.00006505661,0.000024462759,0.00016184959,0.00013242895],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012497979,0.0006279929,0.48526034,0.000327976,0.00021443325,0.022358539,0.004050176,0.000024223167,0.0024525528,0.0001106216,0.0032449134,0.46883026],"study_design_scores_gemma":[0.016269531,0.002601739,0.22066125,0.0020233989,0.00037650391,0.0005903706,0.0010996568,0.023795282,0.004757018,0.0010549974,0.7261775,0.0005927165],"about_ca_topic_score_codex":0.00017009465,"about_ca_topic_score_gemma":0.00006110513,"teacher_disagreement_score":0.72293264,"about_ca_system_score_codex":0.0005814127,"about_ca_system_score_gemma":0.00076455175,"threshold_uncertainty_score":0.3352467},"labels":[],"label_agreement":null},{"id":"W4396213546","doi":"10.1101/2024.04.27.591428","title":"Deciphering the Transcription Factor Landscape in Neuroendocrine Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Prostate Cancer UK; BC Cancer Foundation; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Prostate cancer; Transdifferentiation; Transcription factor; Prostate; Biology; Cancer; Medicine; Internal medicine; Cell biology; Genetics; Gene","score_opus":0.03756100779636008,"score_gpt":0.2908539033908093,"score_spread":0.25329289559444923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396213546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824407,0.006814614,0.0014089255,0.003724844,0.00084162265,0.0040798094,0.00039511922,0.0002695355,0.000024822857],"genre_scores_gemma":[0.99560785,0.0015160007,0.0008267024,0.0001380131,0.0003481005,0.001361234,0.000003330166,0.00015259633,0.000046188517],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99698085,0.00008464721,0.00050607004,0.0010581057,0.00067271275,0.0006976195],"domain_scores_gemma":[0.9986555,0.000032309184,0.000116632174,0.0006769204,0.0002075121,0.00031113057],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022844352,0.0005515219,0.00058676046,0.00040434784,0.00012966697,0.00027183976,0.0002750421,0.00018562579,0.00004229286],"category_scores_gemma":[0.000031378197,0.00037966625,0.00017824332,0.00092699775,0.00008252357,0.00009265243,0.00020029067,0.0012663248,0.000011515668],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017761221,0.0011816422,0.020560713,0.005503221,0.00065594324,0.0002632292,0.0011412324,0.0007014586,0.9675238,0.00024887163,0.00025960983,0.00018416558],"study_design_scores_gemma":[0.0127915945,0.0008514437,0.66035104,0.009791575,0.0013009291,8.897725e-7,0.00028812222,0.01919125,0.28934205,0.000020471643,0.0038894238,0.0021812185],"about_ca_topic_score_codex":0.00007929922,"about_ca_topic_score_gemma":0.000026378426,"teacher_disagreement_score":0.67818177,"about_ca_system_score_codex":0.0006444899,"about_ca_system_score_gemma":0.00077244686,"threshold_uncertainty_score":0.99986553},"labels":[],"label_agreement":null},{"id":"W4396229173","doi":"10.34133/cbsystems.0129","title":"Advances in Prostate Cancer Biomarkers and Probes","year":2024,"lang":"en","type":"review","venue":"Cyborg and Bionic Systems","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Prostate cancer; Biomarker; Medicine; Biomarker discovery; Cancer; Circulating tumor cell; Precision medicine; TMPRSS2; Cancer biomarkers; Molecular biomarkers; Prostate; Targeted therapy; Diagnostic biomarker; Bioinformatics; Computational biology; Oncology; Internal medicine; Metastasis; Pathology; Biology; Proteomics; Disease; Gene; Coronavirus disease 2019 (COVID-19)","score_opus":0.04606720693423651,"score_gpt":0.4071215601277716,"score_spread":0.3610543531935351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396229173","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001760575,0.996038,1.0628021e-7,0.00016397653,0.0005022119,0.0023161788,0.00010301996,0.000043072083,0.0006573607],"genre_scores_gemma":[0.00043272952,0.9944257,0.0000036404617,0.000005117515,0.00019256504,0.0008455477,0.00008152979,0.00003998243,0.0039731525],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998518,0.000074710384,0.0003943526,0.0005132554,0.00018270109,0.00031699365],"domain_scores_gemma":[0.9995292,0.000042768337,0.00008970782,0.00016132892,0.00003616892,0.00014087083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025225623,0.0003218802,0.0011277758,0.00032942556,0.000047886853,0.00009102364,0.000052015555,0.0001673707,0.000006239558],"category_scores_gemma":[0.000011256347,0.00017247681,0.00009505401,0.00044747855,0.00015511547,0.00007414038,0.00006539857,0.00025984613,0.000016460503],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003339322,0.000024352415,0.0005026118,0.119822845,0.00022749508,0.00017921516,0.00010229784,2.4056188e-8,0.0000012187122,0.00003547393,0.0004948124,0.8785763],"study_design_scores_gemma":[0.00051153766,0.0001333397,0.000020852085,0.088150576,0.0006191046,0.00022997444,0.00016665012,0.000013685163,0.0000012365682,0.000008528144,0.9099629,0.00018163976],"about_ca_topic_score_codex":0.00023765738,"about_ca_topic_score_gemma":0.00004895019,"teacher_disagreement_score":0.90946805,"about_ca_system_score_codex":0.00022229039,"about_ca_system_score_gemma":0.00051830465,"threshold_uncertainty_score":0.70334},"labels":[],"label_agreement":null},{"id":"W4396633436","doi":"10.1186/s13039-024-00680-6","title":"Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cytogenetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto; Ontario Institute for Cancer Research","funders":"Fundação de Amparo à Pesquisa do Estado de São Paulo; Government of Ontario","keywords":"Biology; Loss of heterozygosity; Immune system; Major histocompatibility complex; Cancer research; Tumor microenvironment; Prostate cancer; Immunology; Immunotherapy; Cancer; Genetics; Gene; Allele","score_opus":0.018583683332788304,"score_gpt":0.3047483747267482,"score_spread":0.2861646913939599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396633436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759498,0.02014328,0.00003662793,0.00277286,0.000080358026,0.0008001731,0.000052745836,0.000019196905,0.0001449324],"genre_scores_gemma":[0.99474317,0.004549033,0.00007490973,0.00015269447,0.00001896654,0.0000842748,0.00003730091,0.00003695738,0.00030268193],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99869937,0.00008441074,0.0002516657,0.00027339562,0.00037108368,0.0003201065],"domain_scores_gemma":[0.9994445,0.000033414235,0.00004074058,0.00036036797,0.000030545183,0.000090474874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015630474,0.00017328362,0.00021615636,0.000111870744,0.00003795803,0.000022726026,0.00010689099,0.00007019379,0.00009767252],"category_scores_gemma":[0.000015285317,0.00010516124,0.00010248553,0.00024827762,0.00013915254,0.000017430264,0.000093025425,0.00023755606,0.000019778203],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043516362,0.00019139302,0.030806433,0.00022313702,0.00010948225,0.0008125283,0.00062501634,0.00039743888,0.9642114,0.000014795473,0.00013365451,0.0020395312],"study_design_scores_gemma":[0.0009619796,0.00040204343,0.021354891,0.0008749769,0.000051346437,0.000013877867,0.00004543175,0.00013633519,0.9751322,0.00005175396,0.0008780563,0.0000970498],"about_ca_topic_score_codex":0.00007120221,"about_ca_topic_score_gemma":0.0000063712223,"teacher_disagreement_score":0.018793356,"about_ca_system_score_codex":0.00024080671,"about_ca_system_score_gemma":0.00012972453,"threshold_uncertainty_score":0.4288351},"labels":[],"label_agreement":null},{"id":"W4396769281","doi":"10.1001/jamaoncol.2024.0591","title":"Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes","year":2024,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Prostate; Internal medicine; Hormone therapy; Gynecology; Breast cancer","score_opus":0.041834624394988744,"score_gpt":0.3974128393724129,"score_spread":0.35557821497742415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396769281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9371781,0.010807401,0.000010841714,0.04690872,0.0002559945,0.0009350531,0.000071929426,0.00009005777,0.0037419526],"genre_scores_gemma":[0.9743192,0.008021559,0.00022801102,0.0004984697,0.00006757602,0.0003371941,0.000080685844,0.000020932559,0.01642637],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991597,0.00006091334,0.00014609864,0.00025998167,0.00013844106,0.0002348972],"domain_scores_gemma":[0.99945754,0.00022424704,0.0000260165,0.00009358418,0.00008233438,0.00011629921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013025122,0.0001362064,0.0003360123,0.000148382,0.000058418485,0.000040264244,0.000018998084,0.00006626059,0.00004382822],"category_scores_gemma":[0.00002858749,0.00008372421,0.00006038928,0.00014678064,0.00012246758,0.00009851601,0.000025386566,0.00013250389,0.000045798573],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017735126,0.0008741649,0.023204109,0.00027274358,0.0020380463,0.004049715,0.007487482,0.0000027246977,0.0056040944,0.002976066,0.008041512,0.9436758],"study_design_scores_gemma":[0.03225344,0.019566488,0.5372493,0.00033201955,0.0021988193,0.00067432085,0.003021114,0.0041113426,0.012770462,0.0032848064,0.3840139,0.00052396156],"about_ca_topic_score_codex":0.00033675454,"about_ca_topic_score_gemma":0.00008887071,"teacher_disagreement_score":0.9431519,"about_ca_system_score_codex":0.0008127265,"about_ca_system_score_gemma":0.00042929425,"threshold_uncertainty_score":0.34141743},"labels":[],"label_agreement":null},{"id":"W4396776424","doi":"10.1016/j.clgc.2024.102115","title":"A Real World Observational Study Characterizing Patients With Advanced Prostate Cancer Treated With or Without Androgen Receptor-Pathway-Inhibitor Therapies in Alberta, Canada","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; AstraZeneca (Canada); University of Alberta; University of Calgary","funders":"AstraZeneca","keywords":"Medicine; Prostate cancer; Androgen receptor; Observational study; Oncology; Management of prostate cancer; Internal medicine; Androgen; Cancer; Androgen Receptor Antagonists; Hormone","score_opus":0.07166703167350277,"score_gpt":0.3801032690257118,"score_spread":0.30843623735220904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396776424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927654,0.0011728753,1.6877487e-7,0.002005766,0.00041943684,0.003059443,0.00027128716,0.000080379046,0.00022520278],"genre_scores_gemma":[0.9750109,0.0017095747,0.0001407626,0.00032930833,0.0006144105,0.0019929158,0.00028873034,0.00011244838,0.019800998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99682534,0.00017003277,0.00071362354,0.00090817723,0.00075279234,0.0006300374],"domain_scores_gemma":[0.9985118,0.00032688532,0.00015097843,0.00035015028,0.00032406359,0.00033615273],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021208862,0.0004386267,0.00078948896,0.00017990005,0.00013420459,0.000065868255,0.00014538727,0.00008813796,0.0003946594],"category_scores_gemma":[0.000026448583,0.00024962708,0.00007955756,0.00097532436,0.00016580385,0.00028954176,0.000064582,0.00060143135,0.0000068138024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024734493,0.0010363049,0.95026475,0.00018634756,0.0007664204,0.0007412339,0.0006954005,0.00001600597,0.00016276939,9.958806e-7,0.00081423565,0.020581031],"study_design_scores_gemma":[0.012140028,0.0049330983,0.9597851,0.001627338,0.00018578274,0.000004608588,0.00040627876,0.000095843054,0.0006331355,0.0000017727108,0.019745132,0.0004418953],"about_ca_topic_score_codex":0.22694048,"about_ca_topic_score_gemma":0.73550475,"teacher_disagreement_score":0.50856423,"about_ca_system_score_codex":0.0011096974,"about_ca_system_score_gemma":0.0049963533,"threshold_uncertainty_score":0.9999956},"labels":[],"label_agreement":null},{"id":"W4396778056","doi":"10.1177/10781552241238198","title":"Review of drug-drug interactions in patients with prostate cancer","year":2024,"lang":"en","type":"review","venue":"Journal of Oncology Pharmacy Practice","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Polypharmacy; Prostate cancer; Drug; Cancer drugs; Cancer; Drug-drug interaction; Intensive care medicine; Pharmacology; Oncology; Internal medicine","score_opus":0.1037906823693015,"score_gpt":0.5476061643329013,"score_spread":0.4438154819635998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396778056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008529627,0.9877228,2.412494e-7,0.007187747,0.0009883879,0.0018185513,0.0000641496,0.000006945508,0.0021258758],"genre_scores_gemma":[0.000025534304,0.9962193,0.00027098082,0.0008739245,0.00030529447,0.00014230721,0.000043516833,0.000059102706,0.0020600366],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965833,0.0007593945,0.0015558674,0.0002580699,0.0005507706,0.0002926255],"domain_scores_gemma":[0.99483144,0.0008989516,0.0025704287,0.00020354205,0.0012902684,0.00020537434],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0015163266,0.00034077803,0.0024245947,0.0006539028,0.000031094805,0.000015116857,0.00020801976,0.000044006152,0.00032437977],"category_scores_gemma":[0.0004733352,0.00018869698,0.0004262135,0.0008541096,0.000112102854,0.00057658594,0.0000855154,0.0026348382,0.00003840101],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030992592,0.0016819615,0.0005209524,0.16259558,0.002531603,0.0012168074,0.00026761615,3.3583225e-7,3.848625e-7,0.0000014071021,0.07593946,0.75214463],"study_design_scores_gemma":[0.0036985236,0.00040366198,0.000019458901,0.22505842,0.012924503,0.00070747663,0.000046147703,4.930486e-7,0.000002582388,0.0000012601322,0.7570273,0.00011013179],"about_ca_topic_score_codex":0.000091953305,"about_ca_topic_score_gemma":0.000019587416,"teacher_disagreement_score":0.7520345,"about_ca_system_score_codex":0.0016954495,"about_ca_system_score_gemma":0.006484958,"threshold_uncertainty_score":0.9996661},"labels":[],"label_agreement":null},{"id":"W4396780056","doi":"10.2967/jnumed.123.267208","title":"Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection","year":2024,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Nuclear medicine; Medical physics; Radiology","score_opus":0.04762486483833449,"score_gpt":0.3840586717180612,"score_spread":0.3364338068797267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396780056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91558874,0.0100718,0.0000784769,0.072742835,0.0006254317,0.00017004296,0.0000010565916,0.00004349369,0.0006781038],"genre_scores_gemma":[0.99545175,0.0002634629,0.00065695826,0.0015579909,0.0011452927,0.000002199557,9.1908385e-7,0.000056482317,0.0008649295],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984674,0.00012026823,0.0002980459,0.0001777037,0.00066928414,0.0002673241],"domain_scores_gemma":[0.99914324,0.0001682816,0.00006636524,0.00012811755,0.00015784313,0.00033615576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086178066,0.00015292765,0.00033202424,0.00051330833,0.00007772544,0.000085115294,0.000065947956,0.000032538665,0.0007653205],"category_scores_gemma":[0.000121792895,0.00008360285,0.000084086045,0.00041187613,0.00019298328,0.00027637684,0.000031580676,0.00045619754,0.00003937755],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08438131,0.00037962318,0.018456895,0.0003367498,0.00094418187,0.029194824,0.012369531,0.000017597833,0.72126883,0.000011945564,0.05266615,0.07997235],"study_design_scores_gemma":[0.022099975,0.030774895,0.2690046,0.02067413,0.002205927,0.05354708,0.015596601,0.0010287407,0.017230354,0.00012417196,0.56699425,0.00071926403],"about_ca_topic_score_codex":0.0000062319764,"about_ca_topic_score_gemma":0.000001274861,"teacher_disagreement_score":0.7040385,"about_ca_system_score_codex":0.0007119158,"about_ca_system_score_gemma":0.00016106681,"threshold_uncertainty_score":0.8379723},"labels":[],"label_agreement":null},{"id":"W4396804144","doi":"10.1097/mnm.0000000000001858","title":"A phase 2, single-arm trial evaluating 131I-PSMA-1095 targeted radioligand therapy for metastatic castration-resistant prostate cancer","year":2024,"lang":"en","type":"article","venue":"Nuclear Medicine Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Tolerability; Clinical endpoint; Internal medicine; Adverse effect; Oncology; Enzalutamide; Phases of clinical research; Urology; Cancer; Clinical trial","score_opus":0.24338995944191363,"score_gpt":0.48760392716282036,"score_spread":0.24421396772090673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396804144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.719362,0.13232332,0.0001690675,0.12799573,0.0010832645,0.012582284,0.0005259967,0.000637313,0.005321016],"genre_scores_gemma":[0.9793376,0.010209267,0.0048949015,0.0007106678,0.00054637954,0.0015692633,0.000842796,0.00012308348,0.0017660715],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978838,0.00020797952,0.000611406,0.00038801352,0.00050549535,0.00040328552],"domain_scores_gemma":[0.9974939,0.0006740573,0.00012647982,0.0010776517,0.00039091625,0.00023696445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009200797,0.00025865692,0.0004961947,0.00027370462,0.0005426671,0.00008898729,0.0003507087,0.00006925903,0.00059758587],"category_scores_gemma":[0.00036980942,0.00018153385,0.00016040045,0.0006001504,0.00045388774,0.00015525526,0.00006840375,0.00040649064,0.00002243462],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0803744,0.00687924,0.000024275598,0.0008350497,0.0022019094,0.00006691025,0.022603672,0.000009838402,0.5629849,0.0032807929,0.035155322,0.2855837],"study_design_scores_gemma":[0.34110892,0.055812582,0.00014407893,0.0029488555,0.0020909815,0.00007564033,0.0045946087,0.04575294,0.004387411,0.0016262699,0.54080695,0.0006507681],"about_ca_topic_score_codex":0.00022500515,"about_ca_topic_score_gemma":0.000056462846,"teacher_disagreement_score":0.55859745,"about_ca_system_score_codex":0.00033033633,"about_ca_system_score_gemma":0.00071364245,"threshold_uncertainty_score":0.74027354},"labels":[],"label_agreement":null},{"id":"W4396825992","doi":"10.1016/j.jmir.2024.03.044","title":"MRL Prostate GTV Focal Boost: Is Prep Relevant?","year":2024,"lang":"en","type":"article","venue":"Journal of medical imaging and radiation sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate; Internal medicine","score_opus":0.025202219937809217,"score_gpt":0.39187316147639967,"score_spread":0.3666709415385905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396825992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43403998,0.14796412,0.000661163,0.41353962,0.001604888,0.00019799192,0.000005749121,0.00004117248,0.0019453077],"genre_scores_gemma":[0.9683906,0.028102234,0.00036129868,0.0012397903,0.0007744111,0.0000022239046,0.0000013112323,0.000006867879,0.00112127],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979111,0.000040817118,0.00029171404,0.00015828262,0.0014076508,0.00019046658],"domain_scores_gemma":[0.99927163,0.00018623179,0.000071026494,0.00004792751,0.00009958366,0.0003236016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001821404,0.00007039145,0.0001603051,0.00024948598,0.0001288766,0.00017635031,0.00010291058,0.000038425507,0.00019987859],"category_scores_gemma":[0.00039123598,0.000038252427,0.00006355221,0.00033171318,0.00046901303,0.00033138043,0.000027013304,0.0003012115,0.000010254111],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000102728525,0.00007787467,0.029198451,0.00018467993,0.00008446768,0.00092168147,0.0027512386,0.0000025103816,0.00067393575,0.00022767346,0.10337202,0.86240274],"study_design_scores_gemma":[0.006965216,0.0022193536,0.054334182,0.00522216,0.00038283464,0.009973403,0.006147113,0.18343075,0.006522639,0.0055295695,0.7188452,0.00042761347],"about_ca_topic_score_codex":0.000013101352,"about_ca_topic_score_gemma":4.2916773e-7,"teacher_disagreement_score":0.86197513,"about_ca_system_score_codex":0.000050575312,"about_ca_system_score_gemma":0.00084750255,"threshold_uncertainty_score":0.21885303},"labels":[],"label_agreement":null},{"id":"W4396996859","doi":"10.1200/jco.23.02445","title":"Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McMaster University; Cancer Care Ontario","funders":"National Cancer Institute","keywords":"Medicine; Clinical endpoint; Hazard ratio; Prostate cancer; Internal medicine; Cumulative incidence; Randomized controlled trial; Radiation therapy; Oncology; Dose fractionation; Clinical trial; Cancer; Urology; Confidence interval; Cohort","score_opus":0.08089638849077009,"score_gpt":0.5309293230211334,"score_spread":0.4500329345303633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396996859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584943,0.0010288757,0.00023241177,0.0007319502,0.00064683735,0.0013266038,0.000018037717,0.0000106001235,0.00015526247],"genre_scores_gemma":[0.99729407,0.0018775692,0.0003405211,0.00006120728,0.0002528379,0.00005993111,0.000031784144,0.000015595539,0.000066487104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946408,0.0013230675,0.0028358938,0.00029870056,0.00064448797,0.00025699637],"domain_scores_gemma":[0.99334687,0.0034622343,0.0018096955,0.0001636875,0.00097616686,0.0002413342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005966092,0.00017748478,0.003433868,0.00088993716,0.00004823806,0.00001924221,0.00011826169,0.00019368654,0.00017347842],"category_scores_gemma":[0.001391074,0.00010512915,0.0005562364,0.0009165122,0.00035634803,0.00021622532,0.00005455348,0.001352553,0.000002703952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2774708,0.008943829,0.6432717,0.000048337515,0.00746288,0.00042106444,0.00050195487,0.00039097806,0.000006932324,0.000007916352,0.000011686868,0.06146195],"study_design_scores_gemma":[0.35882518,0.010296122,0.621227,0.00020900623,0.0059336,0.0000041420617,0.0001258386,0.0031972558,0.000016030574,0.000024179386,0.00007404701,0.00006758441],"about_ca_topic_score_codex":0.00046740944,"about_ca_topic_score_gemma":0.0020323927,"teacher_disagreement_score":0.08135438,"about_ca_system_score_codex":0.0007819578,"about_ca_system_score_gemma":0.0028662556,"threshold_uncertainty_score":0.58762455},"labels":[],"label_agreement":null},{"id":"W4396998115","doi":"10.1681/asn.20203110s1672a","title":"CKD After 225Ac-PSMA617 Therapy in Patients with Advanced Metastatic Prostate Cancer: A Report of Two Cases","year":2020,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Urology; Oncology; Prostate; Cancer; Nephrology","score_opus":0.02378758134733808,"score_gpt":0.334525598526573,"score_spread":0.3107380171792349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396998115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985657,0.0012800599,0.000009181224,0.012561127,0.000027115519,0.00043112587,0.00002204412,0.0000030500735,0.000009325814],"genre_scores_gemma":[0.99120355,0.002084325,0.0023980436,0.0041815005,0.00004982088,0.000019497782,0.0000024678402,0.00001777043,0.00004301301],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986045,0.00010850225,0.00051024056,0.0001422754,0.0004101048,0.00022440725],"domain_scores_gemma":[0.99808633,0.00008900296,0.0011637661,0.00018502443,0.00037535772,0.00010053814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017897249,0.00013189428,0.000724329,0.000043576656,0.000023006482,0.0000027566168,0.00014002406,0.000018456149,0.000030233141],"category_scores_gemma":[0.000034696495,0.00006932974,0.00026754732,0.00045716547,0.0007088264,0.000072245966,0.000045950528,0.0002836141,2.3158373e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023141641,0.0005231101,0.9363077,0.0001143684,0.0012420951,0.00037020957,0.003525851,0.0001711251,0.01573593,5.550245e-7,0.0024287337,0.016438656],"study_design_scores_gemma":[0.01383135,0.012053686,0.9659196,0.00016907969,0.00023586572,0.000253753,0.0010599566,0.00004274881,0.003825675,0.00003877116,0.0024630665,0.00010641988],"about_ca_topic_score_codex":0.00021758495,"about_ca_topic_score_gemma":0.000014058721,"teacher_disagreement_score":0.029611902,"about_ca_system_score_codex":0.00009187193,"about_ca_system_score_gemma":0.000441723,"threshold_uncertainty_score":0.28271848},"labels":[],"label_agreement":null},{"id":"W4398594239","doi":"10.7910/dvn/fmk6sq/zhikbu","title":"650388_1.roi","year":2020,"lang":"en","type":"dataset","venue":"Harvard Dataverse","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Computer science","score_opus":0.036222855917921876,"score_gpt":0.31214378912756324,"score_spread":0.2759209332096414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398594239","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007866058,0.000009719796,0.0000025861557,0.00014059982,0.00036589202,0.0005962802,0.99792534,0.00006970834,0.0008820126],"genre_scores_gemma":[0.000005898976,0.002996702,0.00012039513,0.0012468398,0.0007011542,0.000050135743,0.9922554,0.000032854245,0.0025906481],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981768,0.000044073986,0.00024723535,0.0005569667,0.0005684307,0.00040647748],"domain_scores_gemma":[0.99820566,0.00004191197,0.00008962317,0.0011377267,0.00007460082,0.0004504795],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010207964,0.0003191302,0.00052704936,0.00015749084,0.00008190193,0.00005428254,0.00033814597,0.00026163767,0.03780212],"category_scores_gemma":[0.00016996276,0.00025242782,0.00017009744,0.00021372843,0.00012933617,0.00010270078,0.00038286566,0.000693929,0.4476419],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005305609,0.00013703581,0.000019917767,0.00052048155,0.00028835534,0.0024996705,0.000012973979,8.881513e-8,0.00004812734,0.000003293824,0.995487,0.0004525388],"study_design_scores_gemma":[0.0019841823,0.00031912292,0.000060346847,0.00018907,0.00044298483,0.000060925442,0.000030720486,0.000004873062,0.00011021856,0.0000057960738,0.99656516,0.00022660302],"about_ca_topic_score_codex":0.00018850749,"about_ca_topic_score_gemma":0.000019162033,"teacher_disagreement_score":0.4098398,"about_ca_system_score_codex":0.00018559341,"about_ca_system_score_gemma":0.0005318969,"threshold_uncertainty_score":0.9999928},"labels":[],"label_agreement":null},{"id":"W4399048033","doi":"10.17650/1726-9776-2024-20-1-79-93","title":"Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study","year":2024,"lang":"en","type":"article","venue":"Cancer Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Subgroup analysis; Clinical trial; Cancer; Meta-analysis","score_opus":0.04692491571705633,"score_gpt":0.3929498133133948,"score_spread":0.3460248975963385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399048033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99414486,0.0019331257,0.00003202348,0.00049103453,0.0002141542,0.0029660356,0.00018494704,0.000014092697,0.00001972526],"genre_scores_gemma":[0.99758685,0.0016921967,0.000019676714,0.00013715621,0.000047525165,0.00036302613,0.00008365496,0.000021678345,0.000048258982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972045,0.000714485,0.0009889569,0.0004614483,0.00037951267,0.00025114298],"domain_scores_gemma":[0.9982601,0.0007218046,0.00027674652,0.00033395257,0.00032520108,0.00008218825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009001136,0.00017565365,0.0009917748,0.00030412988,0.000036226724,0.00000989176,0.00011428019,0.000079204314,0.000061727405],"category_scores_gemma":[0.00012334777,0.000098600525,0.00025940718,0.0014011245,0.0004011277,0.00006809641,0.000037084523,0.00034999283,7.928287e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02717568,0.00075511466,0.9541853,0.00005486638,0.0056728474,0.000045972734,0.0016581479,0.0006104299,0.00004989134,0.000009216788,0.000021218208,0.009761324],"study_design_scores_gemma":[0.02913057,0.0025321748,0.9620222,0.000047427173,0.002632479,8.102314e-7,0.00022468757,0.0031298075,0.00015039936,0.000012981757,0.00003283636,0.0000836481],"about_ca_topic_score_codex":0.0007593628,"about_ca_topic_score_gemma":0.0061713597,"teacher_disagreement_score":0.0096776765,"about_ca_system_score_codex":0.00017815347,"about_ca_system_score_gemma":0.0009124908,"threshold_uncertainty_score":0.40208128},"labels":[],"label_agreement":null},{"id":"W4399137413","doi":"10.1007/978-3-030-80962-1_375-1","title":"Metastasis Inhibition in Cancer","year":2024,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Research Institute; Lakehead University","funders":"","keywords":"Cancer metastasis; Metastasis; Cancer; Medicine; Oncology; Internal medicine","score_opus":0.0687460325148159,"score_gpt":0.3666448832732375,"score_spread":0.2978988507584216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399137413","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028078858,0.018800555,0.0000016809419,0.003678502,0.00015463415,0.0004675149,0.000091947346,0.000058144564,0.97646624],"genre_scores_gemma":[0.0038519707,0.009478284,0.0000396332,0.00020895163,0.00019444973,0.00007017284,0.00017830511,0.00004912998,0.98592913],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991353,0.0000025480947,0.00016670441,0.00027743692,0.00025382958,0.00016415631],"domain_scores_gemma":[0.999697,0.000013512765,0.000020058207,0.00014338836,0.00004784523,0.00007814238],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006592783,0.00017238481,0.0002956725,0.00033809707,0.000012012357,0.000014854983,0.000016405986,0.00016214314,0.008440105],"category_scores_gemma":[0.0000021306255,0.00011603808,0.00011672155,0.000046109035,0.000047799018,0.000026539457,0.000039876424,0.0003776893,0.00070461334],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013295809,0.00028538014,0.00042526858,0.005011665,0.0031568925,0.01905192,0.00060057116,0.0000051404713,0.001960437,0.55315953,0.22024135,0.19477224],"study_design_scores_gemma":[0.0017066251,0.00028295504,0.00007306355,0.003314848,0.0005434341,0.000054554348,0.000025711744,0.000021905225,0.0051089367,0.03019394,0.9583757,0.00029830905],"about_ca_topic_score_codex":0.00021361739,"about_ca_topic_score_gemma":0.0003765929,"teacher_disagreement_score":0.7381344,"about_ca_system_score_codex":0.00043570265,"about_ca_system_score_gemma":0.0002191551,"threshold_uncertainty_score":0.99246633},"labels":[],"label_agreement":null},{"id":"W4399281058","doi":"10.1200/jco.2024.42.16_suppl.11098","title":"Quality of life and testosterone recovery after androgen deprivation therapy in patients with high-risk prostate cancer: Long-term data from a phase III trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Rimouski; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Cégep de l'Outaouais; Centre hospitalier universitaire de Québec; Centre de Santé et de Services Sociaux de Chicoutimi; Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Testosterone (patch); Quality of life (healthcare); Oncology; Androgen; Internal medicine; Prostate; Cancer; Term (time); Antiandrogen; Hormone","score_opus":0.17770989970535347,"score_gpt":0.4998605126675258,"score_spread":0.3221506129621723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98954225,0.0074316734,0.000022994655,0.0014613121,0.00044510496,0.0007572722,0.0003264296,0.000004717851,0.0000082481065],"genre_scores_gemma":[0.9786579,0.02022886,0.0003029253,0.0002275906,0.0003871806,0.000019573974,0.00012410326,0.0000140599495,0.000037790134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99695253,0.00047665634,0.0017891264,0.0002686645,0.00036179446,0.00015122394],"domain_scores_gemma":[0.99664444,0.0017275533,0.00093183503,0.0002651216,0.00022570656,0.0002053755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024072302,0.000113123526,0.0010836968,0.00012558201,0.0000151732,0.000016132622,0.00011860509,0.00016947479,0.00010105244],"category_scores_gemma":[0.0010405726,0.000064269785,0.00008176503,0.00014607834,0.00016729705,0.0002653478,0.00007462311,0.0005631295,0.0000011541886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29686958,0.0016133393,0.4914881,0.000029976542,0.00045146825,0.0000859439,0.000066574605,4.8232783e-7,0.000015882912,2.2960334e-7,0.000108192966,0.20927024],"study_design_scores_gemma":[0.21581037,0.028338691,0.7548482,0.00025387312,0.00014441655,0.0000016680929,0.000010659619,0.000014543606,0.00003548602,0.000080736165,0.00040712036,0.000054272758],"about_ca_topic_score_codex":0.0003527132,"about_ca_topic_score_gemma":0.0003779828,"teacher_disagreement_score":0.26336005,"about_ca_system_score_codex":0.00011749915,"about_ca_system_score_gemma":0.0016720685,"threshold_uncertainty_score":0.29661778},"labels":[],"label_agreement":null},{"id":"W4399359154","doi":"10.5489/cuaj.8823","title":"Podium Session 4: Oncology – Prostate","year":2024,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Positron emission tomography; Magnetic resonance imaging; Prostate; Prostatectomy; Stage (stratigraphy); Radiology; Histopathology; Nuclear medicine; Cancer; Oncology; Internal medicine; Pathology","score_opus":0.02237851458553485,"score_gpt":0.31855326081337026,"score_spread":0.2961747462278354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399359154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57553613,0.005646238,0.0000427492,0.37771064,0.0019763063,0.00049317273,0.00006993093,0.00014016658,0.038384657],"genre_scores_gemma":[0.9804657,0.0006860039,0.00010705121,0.0030045575,0.0007550846,0.00001355844,0.00004054149,0.000013153192,0.014914366],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99870014,0.00012236564,0.00020284869,0.00017067693,0.00030218804,0.00050177245],"domain_scores_gemma":[0.9987885,0.000117606745,0.000052117586,0.00005842636,0.00018198804,0.0008013627],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006410198,0.000095464595,0.00018222438,0.00023743328,0.00021138096,0.00013662572,0.00006046994,0.0002319152,0.0013119704],"category_scores_gemma":[0.0002380873,0.00006192284,0.00010916744,0.0002568958,0.000031116142,0.00009627014,0.000012183497,0.0007988269,0.000349595],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037714562,0.00014898794,0.44153312,0.00005433363,0.0005259691,0.008185022,0.00079223065,0.0000144075175,0.0017330499,0.0008544119,0.36992213,0.17585921],"study_design_scores_gemma":[0.0008136323,0.00073053094,0.1101584,0.000039983388,0.00006247103,0.0006579282,0.000070137205,0.0002419857,0.000085247826,0.0012196285,0.88583714,0.00008289191],"about_ca_topic_score_codex":0.00031477545,"about_ca_topic_score_gemma":0.00017825472,"teacher_disagreement_score":0.51591504,"about_ca_system_score_codex":0.003262842,"about_ca_system_score_gemma":0.0023012527,"threshold_uncertainty_score":0.99960095},"labels":[],"label_agreement":null},{"id":"W4399380898","doi":"10.1200/jco.2024.42.16_suppl.5055","title":"Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [<sup>177</sup>Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Endocyte; Australian Nuclear Science and Technology Organisation","keywords":"Cabazitaxel; Medicine; Prostate cancer; Oncology; Prostate; Fraction (chemistry); Internal medicine; Urology; Cancer research; Cancer; Androgen deprivation therapy","score_opus":0.14565426119267283,"score_gpt":0.5184293515209151,"score_spread":0.37277509032824224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399380898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98758584,0.0068101627,0.000018955689,0.0017661063,0.00070639467,0.0028779004,0.000047808764,0.00001309625,0.00017370356],"genre_scores_gemma":[0.9953777,0.0025411125,0.00085268175,0.00003682974,0.00064614834,0.00034786641,0.000020181646,0.000038845195,0.00013863418],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99264354,0.0015291912,0.0042412267,0.00040563018,0.0007371145,0.00044333073],"domain_scores_gemma":[0.9921125,0.0050996076,0.0018386275,0.00020341326,0.000446375,0.00029947702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004691878,0.00031840196,0.0032627073,0.0006418681,0.00003886768,0.000038612627,0.000116013485,0.0002621104,0.0001684787],"category_scores_gemma":[0.0030793825,0.00020382678,0.0009231673,0.00056686276,0.00043885893,0.000305405,0.00002922706,0.0009168163,0.0000026680073],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8619763,0.007883595,0.0015904907,0.00036002288,0.0022098827,0.0038381494,0.0025514285,0.00042865312,0.0035122123,0.000012985779,0.000025070101,0.1156112],"study_design_scores_gemma":[0.9442705,0.036400314,0.005170263,0.0022577096,0.0020891433,0.00011267775,0.0011998101,0.006660881,0.0009873813,0.0001941864,0.0004802857,0.00017686842],"about_ca_topic_score_codex":0.0004696974,"about_ca_topic_score_gemma":0.00026687726,"teacher_disagreement_score":0.11543433,"about_ca_system_score_codex":0.0012819576,"about_ca_system_score_gemma":0.0070425565,"threshold_uncertainty_score":0.9985866},"labels":[],"label_agreement":null},{"id":"W4399394556","doi":"10.1200/jco.2024.42.16_suppl.5089","title":"A phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI) as an androgen deprivation therapy (ADT)–sparing approach for older men with castration-sensitive prostate cancer (CSPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Medicine; Androgen deprivation therapy; Prostate cancer; Castration; Internal medicine; Oncology; Androgen; Clinical trial; Androgen receptor; Urology; Cancer; Gynecology; Hormone","score_opus":0.12210646872439937,"score_gpt":0.4901304543807966,"score_spread":0.36802398565639727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931404,0.0010538992,0.00043654608,0.0024304036,0.0002821001,0.0021091423,0.000033613265,0.000015487774,0.000498392],"genre_scores_gemma":[0.99204504,0.0014531662,0.00424749,0.00016739356,0.0014812687,0.00013899666,0.00006417589,0.000038888586,0.0003635669],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973059,0.00026568066,0.0013122299,0.00033697695,0.0005000277,0.00027914805],"domain_scores_gemma":[0.99730617,0.00059399306,0.00081441196,0.00016773104,0.000800534,0.000317151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020936413,0.00019306508,0.0010396761,0.00020393323,0.000097004166,0.00002858804,0.00008824709,0.0002259684,0.00002354834],"category_scores_gemma":[0.0002657689,0.00010809244,0.00021541573,0.00027492928,0.00030184252,0.0003212892,0.00002128798,0.00063404825,4.6474085e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6900534,0.010836851,0.003082399,0.00019301541,0.0027698365,0.0007699959,0.003553513,0.0001662054,0.0057926113,0.000120329416,0.0012368767,0.28142497],"study_design_scores_gemma":[0.540026,0.3826308,0.002630726,0.0009925582,0.0016944852,0.00091701024,0.0022446238,0.0033859708,0.058132686,0.0003853545,0.006591785,0.00036800053],"about_ca_topic_score_codex":0.00013307045,"about_ca_topic_score_gemma":0.00004195538,"teacher_disagreement_score":0.37179396,"about_ca_system_score_codex":0.00023516302,"about_ca_system_score_gemma":0.0047334423,"threshold_uncertainty_score":0.83969235},"labels":[],"label_agreement":null},{"id":"W4399394761","doi":"10.1200/jco.2024.42.16_suppl.tps5123","title":"Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Placebo; Homologous recombination; Oncology; Hormonal therapy; Internal medicine; Cancer; Hormone; Cohort; Prostate; Urology; Pathology; Gene","score_opus":0.0818484846970013,"score_gpt":0.4552824990079004,"score_spread":0.3734340143108991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99042493,0.0003658354,0.00014650973,0.0008350737,0.00017753635,0.007907335,0.000009080617,0.000015300624,0.000118399454],"genre_scores_gemma":[0.99792725,0.0004015763,0.0009361816,0.00005155733,0.000048848466,0.00030527153,0.00006339201,0.000030242833,0.00023567936],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995194,0.00093338307,0.002340639,0.00041389992,0.00083109376,0.00028693778],"domain_scores_gemma":[0.9957301,0.0013619125,0.0015249674,0.000130357,0.0010133781,0.00023926554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043429085,0.00027047005,0.0025394289,0.0006708835,0.00004544658,0.00003571547,0.00006201248,0.0001413803,0.000021399746],"category_scores_gemma":[0.00035199893,0.00014908945,0.00013664647,0.0005531492,0.0003299369,0.00044454174,0.000020896883,0.0008529926,6.0431074e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7181968,0.007962873,0.25726205,0.00007668062,0.0022600722,0.0009985219,0.0020694877,0.00035800936,0.000004879353,0.000018215987,0.000037831956,0.010754582],"study_design_scores_gemma":[0.7691241,0.058231212,0.16723973,0.0005161633,0.0017137495,0.00010660513,0.00090794265,0.001889826,0.000040645857,0.00009655505,0.0000065648096,0.00012694321],"about_ca_topic_score_codex":0.0009138781,"about_ca_topic_score_gemma":0.0018981004,"teacher_disagreement_score":0.09002234,"about_ca_system_score_codex":0.0004619447,"about_ca_system_score_gemma":0.0029251943,"threshold_uncertainty_score":0.60796916},"labels":[],"label_agreement":null},{"id":"W4399394762","doi":"10.1200/jco.2024.42.16_suppl.5079","title":"Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta; University of British Columbia; Ottawa Hospital","funders":"Cancer Council Australia","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Cancer; Internal medicine; Androgen receptor","score_opus":0.1389513501519841,"score_gpt":0.49574053834411713,"score_spread":0.356789188192133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98919725,0.0050899494,0.00005698237,0.004296081,0.00007583437,0.00061511464,0.0002419279,0.0000081148855,0.00041875461],"genre_scores_gemma":[0.9947999,0.0035483527,0.0008242326,0.000099379584,0.00007029718,0.000043240405,0.00003072629,0.000019583418,0.0005642714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965977,0.00043698776,0.0020157795,0.00026504064,0.00040893958,0.00027555175],"domain_scores_gemma":[0.9942798,0.0034414078,0.0010061093,0.00020552507,0.00082026544,0.000246916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018720119,0.00016672707,0.0020672076,0.00076000526,0.000024392053,0.000007534722,0.00010801995,0.00015219193,0.00009493352],"category_scores_gemma":[0.0010136749,0.00009601929,0.00047822317,0.0015487795,0.0003927917,0.000103361155,0.00004512193,0.0005761412,0.000002726084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015452125,0.0019200062,0.9119206,0.00023540627,0.015223253,0.0016523696,0.0010548652,0.0005288356,0.0048019006,0.00007082145,0.00067481847,0.046464983],"study_design_scores_gemma":[0.005859652,0.007518799,0.97318184,0.0003856372,0.009212207,0.00008570766,0.0002339445,0.00093126186,0.0015577404,0.000119020064,0.0008185473,0.00009566117],"about_ca_topic_score_codex":0.00031554388,"about_ca_topic_score_gemma":0.0010069056,"teacher_disagreement_score":0.061261207,"about_ca_system_score_codex":0.00043276936,"about_ca_system_score_gemma":0.0024104216,"threshold_uncertainty_score":0.42759845},"labels":[],"label_agreement":null},{"id":"W4399394822","doi":"10.1200/jco.2024.42.16_suppl.5046","title":"Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Secondary analysis of the SPARTAN trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; University of Ottawa; Princess Margaret Cancer Centre; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Concomitant; Prostate cancer; Oncology; Internal medicine; Prostate; Cancer","score_opus":0.09275739901400289,"score_gpt":0.5132912379548935,"score_spread":0.42053383894089064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98742646,0.0027498102,0.0000015034592,0.008091557,0.0005680114,0.00075408764,0.00009985223,0.0000024188384,0.0003063152],"genre_scores_gemma":[0.99484754,0.0044737705,0.000040075607,0.000052163956,0.00008997718,0.00003323719,0.000004105256,0.000009884092,0.00044925124],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99519545,0.0021408845,0.001892117,0.00019094911,0.00040500038,0.00017557846],"domain_scores_gemma":[0.986981,0.011645182,0.00080672605,0.0002140387,0.00016335427,0.00018970916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0082001295,0.00013714982,0.0018714252,0.00044103013,0.000027374721,0.000007296956,0.000100117,0.00011430399,0.000070662674],"category_scores_gemma":[0.0015759346,0.000062409395,0.00054853683,0.00073917944,0.00043822522,0.000039201375,0.000026157637,0.00055369077,7.300503e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78032684,0.0021219286,0.0853696,0.00037699455,0.011735701,0.0017363603,0.0011160458,0.00009946539,0.0031672483,0.00005610185,0.00030633813,0.1135874],"study_design_scores_gemma":[0.11214992,0.14221093,0.72518283,0.0010472027,0.011265777,0.00003743805,0.00036624682,0.0007922725,0.0036627953,0.000093609306,0.0030886088,0.0001023825],"about_ca_topic_score_codex":0.00017154646,"about_ca_topic_score_gemma":0.0007419944,"teacher_disagreement_score":0.6681769,"about_ca_system_score_codex":0.0004062207,"about_ca_system_score_gemma":0.004086704,"threshold_uncertainty_score":0.7249637},"labels":[],"label_agreement":null},{"id":"W4399394859","doi":"10.1200/jco.2024.42.16_suppl.5083","title":"Post-progression survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide or placebo: Post hoc analysis of ARASENS.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Post-hoc analysis; Oncology; Prostate cancer; Internal medicine; Placebo; Cancer; Pathology","score_opus":0.07924704356902992,"score_gpt":0.4753456979310896,"score_spread":0.3960986543620597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992754,0.0024214238,0.00002240963,0.0031914304,0.00044768036,0.0005973324,0.0003874268,0.000009610788,0.00016871523],"genre_scores_gemma":[0.9923416,0.0053727683,0.0011374804,0.00020715497,0.00015031513,0.000011026201,0.000097630786,0.000031451058,0.00065060356],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99552274,0.00072883535,0.0021427567,0.00031141753,0.00095881335,0.00033545602],"domain_scores_gemma":[0.9918365,0.003184325,0.0015946758,0.00021500967,0.0027907211,0.0003787812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022367612,0.00022104903,0.0025859904,0.00064171973,0.00003399298,0.000012864357,0.00012864174,0.0001884358,0.00015641263],"category_scores_gemma":[0.0016954712,0.00011254453,0.0006267791,0.000990729,0.00055705593,0.00016506515,0.00006291951,0.0008140546,0.000003956114],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5451511,0.004155667,0.18076529,0.00058013515,0.033206433,0.004616871,0.0025051814,0.0002809382,0.0021552935,0.000013824724,0.0011860321,0.22538324],"study_design_scores_gemma":[0.024328118,0.07519064,0.8801348,0.0011719605,0.01388177,0.000039061113,0.0011827017,0.0010646473,0.0009602234,0.000028466633,0.001818178,0.00019938374],"about_ca_topic_score_codex":0.00008551536,"about_ca_topic_score_gemma":0.00024832672,"teacher_disagreement_score":0.69936955,"about_ca_system_score_codex":0.00026564984,"about_ca_system_score_gemma":0.0036821533,"threshold_uncertainty_score":0.6531982},"labels":[],"label_agreement":null},{"id":"W4399394886","doi":"10.1200/jco.2024.42.16_suppl.5008","title":"Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with <sup>177</sup>Lu-PSMA-617 versus change of ARPI in PSMAfore.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Taxane; Medicine; Oncology; Internal medicine; Baseline (sea); Cancer; Breast cancer","score_opus":0.24683755409119756,"score_gpt":0.5178091961761405,"score_spread":0.27097164208494295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490726,0.00069172186,0.000011114221,0.0033601995,0.000077941244,0.00046203172,0.000059012546,0.000008330023,0.00042237018],"genre_scores_gemma":[0.9978737,0.0007720292,0.0007518666,0.00017476954,0.0001611788,0.000020506006,0.000047730253,0.00002200523,0.00017618563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99741226,0.0003440491,0.0011951794,0.00024522637,0.0005149623,0.00028829862],"domain_scores_gemma":[0.995924,0.0025904335,0.0006404543,0.00013676158,0.00046887939,0.00023946301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012863305,0.000187948,0.0014790595,0.0005151076,0.000026453486,0.000013256712,0.00008672922,0.00022174066,0.000044864853],"category_scores_gemma":[0.00095922936,0.000093305556,0.00013056681,0.0006272347,0.00028708586,0.00019240592,0.000029914292,0.0008175238,0.0000018809687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017250579,0.0018134193,0.96297944,0.000059276572,0.0012000449,0.0012365824,0.0004755436,0.000060016788,0.000004635843,0.000010017887,0.00013282968,0.014777639],"study_design_scores_gemma":[0.033584423,0.02803482,0.9354502,0.0005167678,0.00072588935,0.000019256087,0.00062753086,0.00042782593,0.00003335528,0.000017124354,0.00045753786,0.000105277984],"about_ca_topic_score_codex":0.0003741997,"about_ca_topic_score_gemma":0.0017080703,"teacher_disagreement_score":0.027529225,"about_ca_system_score_codex":0.00034287255,"about_ca_system_score_gemma":0.0010602851,"threshold_uncertainty_score":0.38048902},"labels":[],"label_agreement":null},{"id":"W4399394935","doi":"10.1200/jco.2024.42.16_suppl.tps5122","title":"Darolutamide plus androgen-deprivation therapy in patients with high-risk biochemical recurrence of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Placebo; Oncology; Internal medicine; Randomized controlled trial; Double blind; Cancer; Urology; Pathology; Alternative medicine","score_opus":0.0748434723450314,"score_gpt":0.45902999504555264,"score_spread":0.3841865227005212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888148,0.0043500857,0.000030445723,0.0012561214,0.00062146224,0.004837514,0.000022569671,0.000011326265,0.000055684715],"genre_scores_gemma":[0.9912562,0.007812044,0.00021067467,0.0000647246,0.0002983195,0.0002396849,0.000015896954,0.00002332547,0.00007912297],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99495584,0.0009673178,0.0027211325,0.00033399384,0.00073073397,0.00029100364],"domain_scores_gemma":[0.99469316,0.002707834,0.0014364955,0.00019585917,0.00071309815,0.00025356858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057208315,0.00021676223,0.0029678743,0.00037558848,0.000031774132,0.000020077901,0.00016425466,0.00023318116,0.000059303882],"category_scores_gemma":[0.001126081,0.00011346741,0.0003895686,0.00045454444,0.0003678513,0.00015966974,0.00004028036,0.001205012,0.0000029660016],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7596215,0.0061644707,0.16879384,0.000043392636,0.0019575637,0.0002415477,0.00049042533,0.00003895297,0.000029139685,0.000006936496,0.000144803,0.062467437],"study_design_scores_gemma":[0.95001197,0.035071407,0.012298397,0.00041739165,0.0008699742,0.000011094136,0.00012200174,0.00038887528,0.00039314883,0.00010703707,0.00020345647,0.00010527656],"about_ca_topic_score_codex":0.0001664232,"about_ca_topic_score_gemma":0.000047394253,"teacher_disagreement_score":0.19039044,"about_ca_system_score_codex":0.00036611303,"about_ca_system_score_gemma":0.0032547533,"threshold_uncertainty_score":0.5773793},"labels":[],"label_agreement":null},{"id":"W4399394956","doi":"10.1200/jco.2024.42.16_suppl.5022","title":"Association between prostate-specific antigen (PSA) level &lt;0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Internal medicine; Oncology; Urology; Castration; Gynecology; Prostate; Cancer; Hormone","score_opus":0.12286845051297596,"score_gpt":0.45675678728374486,"score_spread":0.3338883367707689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948308,0.0028253582,0.000045488396,0.000983158,0.0002352941,0.0007246296,0.00029161648,0.0000065870113,0.000057067256],"genre_scores_gemma":[0.9874858,0.010704304,0.0013438227,0.000017798102,0.00012385423,0.000020693702,0.00007251221,0.000016771812,0.00021440248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995444,0.00071792473,0.0023518365,0.00033144662,0.0008371342,0.00031763013],"domain_scores_gemma":[0.9948479,0.0019227884,0.0020581954,0.00014710544,0.00078014296,0.00024384806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003691533,0.00019129961,0.0019757862,0.0005444157,0.000044942757,0.000020958796,0.000103798324,0.00029892477,0.000050473773],"category_scores_gemma":[0.0009959892,0.00010922787,0.0003539113,0.000932807,0.00029439526,0.00016232552,0.00003871992,0.00082317257,0.0000010378354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0115382075,0.00088610966,0.88292176,0.00014679827,0.0058564176,0.00016601307,0.000607275,0.000075388954,0.0003648088,0.000006407355,0.00029768748,0.09713312],"study_design_scores_gemma":[0.010689053,0.015889334,0.9673399,0.00051350973,0.0037365134,0.0000030979115,0.00013959859,0.0002891228,0.00024996072,0.000069930305,0.0009783327,0.00010167388],"about_ca_topic_score_codex":0.00010162221,"about_ca_topic_score_gemma":0.0002994945,"teacher_disagreement_score":0.09703145,"about_ca_system_score_codex":0.0005180922,"about_ca_system_score_gemma":0.0013456658,"threshold_uncertainty_score":0.44541833},"labels":[],"label_agreement":null},{"id":"W4399504518","doi":"10.1158/1538-8514.synthleth24-pr005","title":"Abstract PR005: CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate cancer to PARP inhibition","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Poly ADP ribose polymerase; Cancer research; PARP inhibitor; DNA repair; DNA damage; Medicine; Cancer; In vivo; Internal medicine; Biology; Oncology; Polymerase; DNA; Genetics","score_opus":0.03612750988906618,"score_gpt":0.3464587231508978,"score_spread":0.31033121326183166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9610215,0.023441553,0.00012635955,0.010925413,0.0005761652,0.0017950056,0.00040506606,0.00041936061,0.0012895878],"genre_scores_gemma":[0.9906889,0.0026292852,0.0002742919,0.0024874392,0.0002500832,0.0005814183,0.0001287891,0.00013160624,0.0028281817],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997167,0.000070381786,0.00042046732,0.00077281555,0.0007902058,0.0007791605],"domain_scores_gemma":[0.9987676,0.000035090736,0.00006321609,0.0005051843,0.00029195403,0.00033696604],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028782402,0.0004085265,0.00039555685,0.0002561867,0.00016302023,0.00017241374,0.00009323539,0.00015484134,0.00026287846],"category_scores_gemma":[0.000008024248,0.00032417275,0.00026235654,0.0007155307,0.00015292919,0.00010629353,0.00007074188,0.00044946725,0.000084453284],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013463795,0.00017512396,0.0005473747,0.00087731093,0.00089167256,0.0038308625,0.0017926694,0.00036488796,0.97208786,0.00020924622,0.0016530053,0.01622362],"study_design_scores_gemma":[0.002160603,0.0008428518,0.009421268,0.0021472403,0.0007381613,0.000044546956,0.00059701514,0.0015805921,0.90600026,0.000199622,0.075592004,0.00067586126],"about_ca_topic_score_codex":0.00065909594,"about_ca_topic_score_gemma":0.00022446827,"teacher_disagreement_score":0.073938996,"about_ca_system_score_codex":0.00088644336,"about_ca_system_score_gemma":0.000994325,"threshold_uncertainty_score":0.999921},"labels":[],"label_agreement":null},{"id":"W4399505170","doi":"10.1158/1538-8514.synthleth24-pr010","title":"Abstract PR010: <i>CDK12</i> loss promotes prostate cancer development while exposing vulnerabilities to paralog-based synthetic lethality","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"PTEN; Prostate cancer; Synthetic lethality; Cancer research; Prostate; Biology; Cancer; Context (archaeology); Medicine; DNA repair; PI3K/AKT/mTOR pathway; Signal transduction; Cell biology; Genetics; Gene","score_opus":0.048963146014998474,"score_gpt":0.34636403839556645,"score_spread":0.297400892380568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9306507,0.04821765,0.0012162885,0.016026126,0.0005728908,0.0022898023,0.00015747536,0.000331238,0.00053780555],"genre_scores_gemma":[0.99227583,0.00089102756,0.0013258538,0.0025537815,0.00013849683,0.0016651467,0.0000658008,0.00012643248,0.0009576057],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99716645,0.00007862553,0.000451644,0.0007627855,0.0007372775,0.00080322806],"domain_scores_gemma":[0.9988224,0.00008997331,0.000058669168,0.0004922469,0.00024430602,0.0002924256],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003826677,0.00043471484,0.00044374357,0.00019679705,0.00020542409,0.00019542573,0.00018843272,0.00014504687,0.00031227383],"category_scores_gemma":[0.000013575917,0.000339216,0.00017317057,0.0005008214,0.00021107946,0.00009791071,0.00006330777,0.00045831798,0.000049910508],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020263088,0.0009706634,0.017100483,0.005681739,0.0024833824,0.0017265847,0.0122093,0.0023919542,0.5538167,0.00022047765,0.00061527477,0.40075716],"study_design_scores_gemma":[0.0014330541,0.00034773603,0.0040778387,0.002849122,0.00033049035,0.00001862354,0.00017912898,0.0006149091,0.88738513,0.00023444099,0.10189866,0.00063088053],"about_ca_topic_score_codex":0.00036603629,"about_ca_topic_score_gemma":0.000110372115,"teacher_disagreement_score":0.40012628,"about_ca_system_score_codex":0.0010453368,"about_ca_system_score_gemma":0.00203901,"threshold_uncertainty_score":0.999906},"labels":[],"label_agreement":null},{"id":"W4399553470","doi":"10.1080/14796694.2024.2343647","title":"Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamide","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Prostate cancer; Castration; Oncology; Internal medicine; Overall survival; Cancer; Hormone","score_opus":0.04179467252351697,"score_gpt":0.4186372159170123,"score_spread":0.3768425433934953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399553470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833647,0.0003190756,0.000010003367,0.004775687,0.0011432135,0.0012459777,0.00012677364,0.0001282005,0.008886357],"genre_scores_gemma":[0.9905838,0.00056063203,0.0013581875,0.0005707228,0.00073829945,0.00024457625,0.00032391364,0.00005007403,0.0055697914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817365,0.00020458913,0.0004377717,0.00044479631,0.00033297876,0.00040621049],"domain_scores_gemma":[0.9987871,0.0004508695,0.00011303147,0.00017880002,0.00026350218,0.0002067204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032204407,0.00022222992,0.0005823937,0.0001849434,0.00010613091,0.000038804137,0.000053122738,0.00010465334,0.00015463495],"category_scores_gemma":[0.000050914932,0.00013288646,0.000119962155,0.00040766818,0.00024741437,0.0001533012,0.000037388403,0.0005856085,0.000040614214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093601726,0.00027304303,0.9648642,0.00013913613,0.00096771243,0.0012897664,0.0011469112,0.0000059517965,0.0000111678855,0.000547915,0.0025065527,0.027311634],"study_design_scores_gemma":[0.004012404,0.0015046649,0.98199666,0.00023282263,0.00047500874,0.000012141241,0.00061132177,0.00010527305,0.000056758905,0.00006259147,0.010776753,0.00015361582],"about_ca_topic_score_codex":0.0006008893,"about_ca_topic_score_gemma":0.004925802,"teacher_disagreement_score":0.027158018,"about_ca_system_score_codex":0.00048114732,"about_ca_system_score_gemma":0.0010795005,"threshold_uncertainty_score":0.5418953},"labels":[],"label_agreement":null},{"id":"W4399556172","doi":"10.1016/j.clgc.2024.102137","title":"Predicting Treatment Effects from Surrogate Endpoints in Historical Trials in First-Line Metastatic Castration-Resistant Prostate Cancer","year":2024,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Medicine; Prostate cancer; Surrogate endpoint; Oncology; Internal medicine; Clinical trial; Castration; Clinical endpoint; Cancer; Hormone","score_opus":0.3290512161179735,"score_gpt":0.5274228000287672,"score_spread":0.19837158391079368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399556172","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021741329,0.9656445,7.6436123e-7,0.00096392335,0.0033141924,0.006764221,0.0013867468,0.00009578288,0.000088534616],"genre_scores_gemma":[0.001503324,0.9810951,0.0001475789,0.0000519139,0.002611941,0.00800407,0.0006968162,0.00019236968,0.005696927],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98971486,0.0022134243,0.004608693,0.001752186,0.0007155484,0.0009952881],"domain_scores_gemma":[0.99169546,0.006007328,0.00092898234,0.0006729489,0.00012065648,0.0005746049],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026166248,0.0011124244,0.007710295,0.0007210577,0.00009546133,0.00008115274,0.00027534948,0.00059717393,0.00028972345],"category_scores_gemma":[0.0012594404,0.00071119977,0.0018856172,0.0010971759,0.00015529012,0.00012478452,0.00017569982,0.0017585612,0.00010024155],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003278495,0.0021418342,0.006665601,0.027656185,0.0031452,0.016200969,0.00037147428,0.00002876151,0.000009848088,0.000001250149,0.0017968714,0.93870354],"study_design_scores_gemma":[0.016434744,0.0044145784,0.001875789,0.095117845,0.0149628725,0.00004259452,0.000048188725,0.00018959587,0.000042734886,0.0001388126,0.86566305,0.0010692173],"about_ca_topic_score_codex":0.007836732,"about_ca_topic_score_gemma":0.007747005,"teacher_disagreement_score":0.9376343,"about_ca_system_score_codex":0.010046654,"about_ca_system_score_gemma":0.004606789,"threshold_uncertainty_score":0.9995339},"labels":[],"label_agreement":null},{"id":"W4399559341","doi":"10.1097/ju.0000000000004069","title":"The Genomics and Natural History of MRI-Visible vs MRI-Invisible Prostate Cancers: Clinical Implications","year":2024,"lang":"en","type":"editorial","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Natural history; Prostate cancer; Genomics; Magnetic resonance imaging; Medicine; Prostate; Oncology; Radiology; Internal medicine; Cancer; Biology; Genome; Gene; Genetics","score_opus":0.027086568961334687,"score_gpt":0.3615176231256073,"score_spread":0.3344310541642726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399559341","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006327452,0.31125098,0.000015546426,0.040147908,0.6406434,0.0007691786,0.00012116612,0.000015846948,0.0007085031],"genre_scores_gemma":[0.01713986,0.480522,0.00014498888,0.0004722887,0.47691342,0.00003170808,0.00006856414,0.000110934976,0.02459623],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977905,0.00032146057,0.0009045828,0.00020596453,0.0004348462,0.00034262874],"domain_scores_gemma":[0.99562734,0.002400666,0.0007210099,0.00043950748,0.0006648505,0.00014661529],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0023184365,0.00020763112,0.0006905906,0.00016897295,0.000112055954,0.00001948167,0.00042814363,0.00038137933,0.000016518561],"category_scores_gemma":[0.00044056677,0.000099466386,0.00023372262,0.00012106891,0.0010377973,0.00005012342,0.00017504898,0.0026047234,0.000008762469],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004598291,0.000044715693,0.00023023535,0.00013167091,0.00083403423,0.000038833492,0.00047215007,0.000007952195,0.00019590862,0.000052942083,0.9908952,0.002498029],"study_design_scores_gemma":[0.0016635017,0.0024264986,0.000455715,0.00008204693,0.0010364848,0.00017946314,0.000059124977,0.000062372805,0.000019999381,0.0010953773,0.9928381,0.00008130667],"about_ca_topic_score_codex":0.0000925167,"about_ca_topic_score_gemma":0.0000838884,"teacher_disagreement_score":0.16927099,"about_ca_system_score_codex":0.000968168,"about_ca_system_score_gemma":0.0059537883,"threshold_uncertainty_score":0.9996963},"labels":[],"label_agreement":null},{"id":"W4399597402","doi":"10.1016/j.euo.2024.05.011","title":"Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institutes of Health; Movember Foundation; National Cancer Institute; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Castration; Cancer; Prostate; Hormone","score_opus":0.021770141579877285,"score_gpt":0.3371124047456912,"score_spread":0.31534226316581393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399597402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963503,0.0019221271,0.000018069662,0.000542781,0.000038643877,0.00056005985,0.000076427474,0.000018706616,0.00047288256],"genre_scores_gemma":[0.99897987,0.00049814925,0.00017527911,0.000058889655,0.000019618978,0.000033206517,0.000037278995,0.000028618713,0.00016906313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986623,0.00042137914,0.00029175193,0.00027754993,0.00010346362,0.00024355354],"domain_scores_gemma":[0.9994556,0.00017141225,0.00012236749,0.000098224926,0.00009277419,0.000059634378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003504429,0.0001312216,0.0004410265,0.00023773278,0.000022890594,0.00000517362,0.00004264014,0.000059754442,0.000016780425],"category_scores_gemma":[0.000031816042,0.00008875674,0.00002953077,0.00016328828,0.0002846156,0.000047633766,0.00004812987,0.00021996557,0.000002707708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040324996,0.00083547976,0.74646497,0.0009307519,0.0011690359,0.010358944,0.009185012,0.00022086226,0.11389766,0.00009007843,0.000055750497,0.11275895],"study_design_scores_gemma":[0.006077236,0.009560054,0.9664894,0.0006141202,0.0005545114,0.000350816,0.0005953243,0.0022748304,0.01299386,0.000032194657,0.00029032194,0.0001673816],"about_ca_topic_score_codex":0.000055600158,"about_ca_topic_score_gemma":0.00066980004,"teacher_disagreement_score":0.22002438,"about_ca_system_score_codex":0.00011830962,"about_ca_system_score_gemma":0.00035723738,"threshold_uncertainty_score":0.3619395},"labels":[],"label_agreement":null},{"id":"W4399670903","doi":"10.1016/j.stem.2024.05.008","title":"Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells","year":2024,"lang":"en","type":"article","venue":"Cell stem cell","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; Prostate Cancer Foundation; National Institutes of Health; Roswell Park Alliance Foundation, Roswell Park Cancer Institute; Roswell Park Cancer Institute; U.S. Department of Defense","keywords":"Biology; Prostate cancer; Wnt signaling pathway; Castration; Prostate; Context (archaeology); Cancer research; Androgen receptor; Progenitor cell; Stem cell; Computational biology; Bioinformatics; Signal transduction; Cell biology; Endocrinology; Cancer; Genetics","score_opus":0.027012352453310188,"score_gpt":0.2629062096005985,"score_spread":0.23589385714728833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399670903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635862,0.018510021,0.00015388423,0.00042516866,0.00027595874,0.000909515,0.00015195196,0.00007189589,0.015915373],"genre_scores_gemma":[0.9507128,0.0008192448,0.00022641289,0.00002859783,0.00007562017,0.000053654832,0.00014409158,0.00004097392,0.04789859],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979884,0.00012388332,0.0005064277,0.00047317747,0.000483384,0.00042472963],"domain_scores_gemma":[0.9987749,0.00022095122,0.00011639041,0.00047919713,0.00024020585,0.00016838158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003048068,0.0002808426,0.00044808895,0.0003467505,0.00011780091,0.00010674244,0.00017776627,0.000100885074,0.0003468116],"category_scores_gemma":[0.0000034009627,0.00016653811,0.00035270178,0.0016410534,0.00019417546,0.00005724884,0.000049982442,0.0002637489,0.00013027094],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003812152,0.0005546211,0.0020515001,0.0015941325,0.00042668602,0.0002536632,0.001561554,0.00018510288,0.98757154,0.000007211423,0.0019685985,0.0034442022],"study_design_scores_gemma":[0.00084899284,0.0006951714,0.0006513393,0.00013049801,0.0019586068,0.0000040537466,0.0016340627,0.0014564992,0.9846041,0.000012180688,0.0078294305,0.00017502492],"about_ca_topic_score_codex":0.0002760126,"about_ca_topic_score_gemma":0.00008661658,"teacher_disagreement_score":0.03198322,"about_ca_system_score_codex":0.00017464338,"about_ca_system_score_gemma":0.0004029212,"threshold_uncertainty_score":0.67912275},"labels":[],"label_agreement":null},{"id":"W4399722033","doi":"10.1016/j.ejca.2024.114183","title":"Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Pharmaceuticals; AstraZeneca; Pfizer; Amgen; Astellas Pharma; Abbott Laboratories","keywords":"Abiraterone acetate; Prednisone; Medicine; Prostate cancer; Oncology; Covariate; Internal medicine; Placebo; Cancer; Statistics; Androgen deprivation therapy; Mathematics; Pathology","score_opus":0.04673604915791438,"score_gpt":0.3859914848494938,"score_spread":0.33925543569157945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399722033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99082214,0.0044936636,0.000029885627,0.0018307795,0.00016439173,0.0025235638,0.00010905681,0.0000033000017,0.000023193008],"genre_scores_gemma":[0.997285,0.0020607908,0.00009253652,0.00012490837,0.00007533307,0.00016735154,0.000027665707,0.00003145988,0.00013495346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742514,0.00056323485,0.0010005885,0.00021302138,0.0005377614,0.00026024514],"domain_scores_gemma":[0.9988848,0.00021059565,0.00035793192,0.00015196603,0.0003383499,0.000056330082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029240334,0.00017767349,0.0005415297,0.00024820754,0.000022573706,0.00004033691,0.00017617969,0.0000138817895,0.00002070475],"category_scores_gemma":[0.00005705321,0.00007951022,0.000046297366,0.000478884,0.00012886578,0.00014852732,0.000023311388,0.00045989733,5.8526206e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02769841,0.00433084,0.8638662,0.00036861916,0.0003752418,0.0007200918,0.010431426,0.00071390293,0.000047379806,0.000007649033,0.00009268836,0.09134756],"study_design_scores_gemma":[0.054076485,0.009967481,0.9311367,0.0018027583,0.00022815689,0.0000052520736,0.0013093749,0.0009374221,0.000059689082,0.000009451096,0.00037119782,0.000095977],"about_ca_topic_score_codex":0.00017063953,"about_ca_topic_score_gemma":0.0014486169,"teacher_disagreement_score":0.09125158,"about_ca_system_score_codex":0.00026395704,"about_ca_system_score_gemma":0.00043716928,"threshold_uncertainty_score":0.32423323},"labels":[],"label_agreement":null},{"id":"W4399765233","doi":"10.1016/j.eururo.2024.06.009","title":"Corrigendum to “Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial” [Eur. Eurol. 84(2) (2023) 156–163]","year":2024,"lang":"en","type":"erratum","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McGill University; London Health Sciences Centre; Alberta Cancer Foundation","funders":"","keywords":"Medicine; Oncology; Internal medicine; Docetaxel; Radiation therapy; Prostate cancer; Androgen deprivation therapy; Randomized controlled trial; Androgen; Gynecology; Cancer; Hormone","score_opus":0.037080387710922744,"score_gpt":0.33309836633480194,"score_spread":0.2960179786238792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399765233","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35279003,0.2814322,0.01517357,0.071826175,0.15869676,0.10203902,0.0075518037,0.0014829617,0.009007489],"genre_scores_gemma":[0.033217564,0.12240836,0.0019824388,0.015158767,0.02130238,0.008765418,0.011186987,0.0017617096,0.7842164],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925603,0.0027860648,0.0011178397,0.0018137936,0.0006338658,0.0010881153],"domain_scores_gemma":[0.99610883,0.0012219303,0.0007049009,0.0010689845,0.0004092903,0.00048607713],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002075884,0.0010164782,0.0030322818,0.0003903568,0.00038209706,0.00018410421,0.000601279,0.0005746405,0.00047438484],"category_scores_gemma":[0.00077456946,0.00053651934,0.00044113206,0.0005240238,0.00082160847,0.00008038769,0.00027855422,0.0018541522,0.00012720957],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6273099,0.00015982326,0.002161978,0.00020445211,0.0035314339,0.00089719536,0.0010995287,0.0000039572847,0.00006853261,0.000017400405,0.34932518,0.015220632],"study_design_scores_gemma":[0.45052868,0.007955471,0.00085658923,0.00024346802,0.003560663,0.000113659386,0.00003083526,0.00024637507,0.000035638077,0.000058561003,0.53591996,0.00045007156],"about_ca_topic_score_codex":0.0009169413,"about_ca_topic_score_gemma":0.001990588,"teacher_disagreement_score":0.7752089,"about_ca_system_score_codex":0.0004132434,"about_ca_system_score_gemma":0.0019390031,"threshold_uncertainty_score":0.99970865},"labels":[],"label_agreement":null},{"id":"W4399882468","doi":"10.1002/cncr.35438","title":"Correlation analyses of radiographic progression‐free survival with clinical and health‐related quality of life outcomes in metastatic castration‐resistant prostate cancer: Analysis of the phase 3 VISION trial","year":2024,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"EMD Serono; Genentech; National Cancer Institute; Sirtex Medical; Astellas Pharma; Invitae; Seagen; Bayer Vital; Advanced Accelerator Applications; Endocyte; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Medical Research Council; Celgene; Bayer; Prostate Cancer Foundation; Eli Lilly and Company; AstraZeneca; Lantheus Medical Imaging; Boston Scientific Corporation","keywords":"Medicine; Prostate cancer; Correlation; Quality of life (healthcare); Internal medicine; Prostate; Post-hoc analysis; Population; Oncology; Progression-free survival; Cancer; Overall survival","score_opus":0.1994552131271834,"score_gpt":0.5489076594610065,"score_spread":0.3494524463338231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399882468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750655,0.020661114,0.000029731316,0.0023121918,0.00019134072,0.001329445,0.00038473555,0.000011056641,0.000014854329],"genre_scores_gemma":[0.9964577,0.0031481462,0.00008432706,0.00001634421,0.000016458625,0.00010620386,0.00005703113,0.000011782743,0.00010202387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971833,0.0004556776,0.0012805238,0.00029412413,0.0006182864,0.00016804916],"domain_scores_gemma":[0.99847454,0.00035720604,0.000529824,0.0003175051,0.00020834286,0.000112563066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015359969,0.00014067162,0.0011122411,0.00048826748,0.0000420929,0.000011397883,0.00008216426,0.00005709037,0.000053713386],"category_scores_gemma":[0.00016925024,0.000071816066,0.00027355438,0.0024756186,0.00045860367,0.0000844563,0.00003121348,0.00021317194,5.7902948e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03278253,0.0007334863,0.94845897,0.0009146606,0.0051639485,0.000008705039,0.00081597484,0.0007241434,0.001088689,0.000083842504,0.00006043097,0.009164623],"study_design_scores_gemma":[0.04339565,0.0018290314,0.94457006,0.00092811085,0.0025435104,4.5207412e-7,0.00026882207,0.005749012,0.00054820854,0.00006529748,0.00001296602,0.00008887968],"about_ca_topic_score_codex":0.0045145624,"about_ca_topic_score_gemma":0.003889736,"teacher_disagreement_score":0.021392152,"about_ca_system_score_codex":0.00009020649,"about_ca_system_score_gemma":0.001357945,"threshold_uncertainty_score":0.68246984},"labels":[],"label_agreement":null},{"id":"W4400019582","doi":"10.1016/j.euo.2024.05.013","title":"Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Sunnybrook Hospital; Jewish General Hospital","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone acetate; Prostate cancer; Prednisone; Internal medicine; Pembrolizumab; Clinical endpoint; Oncology; Interquartile range; Cohort; Urology; Cancer; Clinical trial; Surgery; Androgen deprivation therapy","score_opus":0.017376358492093395,"score_gpt":0.2946632417206965,"score_spread":0.2772868832286031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400019582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854437,0.0032246083,0.00001783583,0.0059225657,0.00022811804,0.0015593622,0.00042155685,0.00010883534,0.0030733834],"genre_scores_gemma":[0.99500513,0.0012404236,0.00034571413,0.0006873473,0.00010685032,0.00011473047,0.0006132985,0.00008815299,0.001798348],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99723333,0.0005431203,0.000542668,0.0008510633,0.00026161107,0.00056821597],"domain_scores_gemma":[0.99900913,0.0002236189,0.00012729883,0.00031876826,0.000121475096,0.00019972044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048185352,0.00032094837,0.00062802446,0.00024754266,0.00008836895,0.000049060647,0.000115946445,0.00009309214,0.00008918525],"category_scores_gemma":[0.000046032175,0.00022963365,0.00004287469,0.0002822815,0.00045629195,0.00012465689,0.000078313555,0.0005141521,0.00006663224],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40741938,0.0030292694,0.33766708,0.00080044154,0.0062979995,0.0253415,0.03281772,0.0009419764,0.010630693,0.00019843713,0.0062443623,0.16861114],"study_design_scores_gemma":[0.052347906,0.008061105,0.926034,0.00013752862,0.00046870922,0.00006116886,0.0001506928,0.000758531,0.0002918826,0.00009296151,0.011297455,0.00029811042],"about_ca_topic_score_codex":0.0006840601,"about_ca_topic_score_gemma":0.0005891262,"teacher_disagreement_score":0.58836687,"about_ca_system_score_codex":0.00045842235,"about_ca_system_score_gemma":0.00064409897,"threshold_uncertainty_score":0.93641883},"labels":[],"label_agreement":null},{"id":"W4400192544","doi":"10.1001/jamaoncol.2024.3196","title":"Fluorine-18 Prostate-Specific Membrane Antigen–1007 PET/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Prostate Cancer Canada; University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Prostate; Prostate-specific antigen; Multiparametric MRI; Nuclear medicine; Cancer; Urology; Radiology; Oncology; Internal medicine","score_opus":0.05833779788555239,"score_gpt":0.38914261966567226,"score_spread":0.3308048217801199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400192544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95953774,0.019765876,0.00016535251,0.011921165,0.0015015589,0.004348527,0.0005056884,0.0001909635,0.00206313],"genre_scores_gemma":[0.95950574,0.02115403,0.003436768,0.00034039782,0.00073880405,0.0014485111,0.00040282187,0.00010987729,0.012863058],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973893,0.00008661923,0.0005674873,0.00069887197,0.00047924247,0.0007784819],"domain_scores_gemma":[0.99811876,0.0006769654,0.00013969687,0.0003297803,0.00048417237,0.0002506557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060768344,0.00030492299,0.0007367923,0.00073812157,0.00012265769,0.000056492772,0.00017182172,0.000064039545,0.0005081383],"category_scores_gemma":[0.000100204896,0.00023017306,0.00024392689,0.0011188441,0.0003764037,0.00018322196,0.00009432712,0.00048086714,0.000049475926],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03379959,0.002847823,0.129108,0.010940343,0.002830823,0.016496044,0.004796938,0.00064740254,0.073861465,0.003201502,0.25410402,0.46736607],"study_design_scores_gemma":[0.0108564915,0.0031313747,0.0074259555,0.00065162167,0.00018837878,0.0005475598,0.00058844057,0.005105528,0.06452223,0.00023474602,0.906397,0.0003507181],"about_ca_topic_score_codex":0.00027869342,"about_ca_topic_score_gemma":0.000033641154,"teacher_disagreement_score":0.65229297,"about_ca_system_score_codex":0.00085978705,"about_ca_system_score_gemma":0.0015421242,"threshold_uncertainty_score":0.9386185},"labels":[],"label_agreement":null},{"id":"W4400412464","doi":"10.1200/jco.2024.42.16_suppl.e17030","title":"Association of baseline characteristics with adverse events (AEs) in the PROpel trial of olaparib (ola) plus abiraterone (abi) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Olaparib; Abiraterone; Internal medicine; Adverse effect; Oncology; Abiraterone acetate; Cancer; Androgen deprivation therapy; Androgen receptor","score_opus":0.15646342875329372,"score_gpt":0.48990033029688707,"score_spread":0.33343690154359334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400412464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824967,0.00067311246,0.00008884807,0.013494248,0.0006684114,0.0022837194,0.00021914486,0.000004619374,0.00007122096],"genre_scores_gemma":[0.9938999,0.0028731117,0.0008055229,0.00011749382,0.0005675943,0.0001784068,0.00005827258,0.000020698028,0.001479032],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99618924,0.0005017144,0.00226228,0.00019466317,0.0006050218,0.0002470956],"domain_scores_gemma":[0.99470633,0.0026119337,0.0016258435,0.00014901384,0.0007787107,0.00012817135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004124954,0.0001681676,0.0013411654,0.00015678865,0.000036740214,0.000008228864,0.00010990433,0.00015098418,0.000049485174],"category_scores_gemma":[0.0016823072,0.00008152361,0.00031623332,0.00024136626,0.00010975404,0.00012108116,0.000014111526,0.00041938917,0.0000026532462],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8573639,0.012882654,0.029032512,0.001436909,0.005624396,0.0014023859,0.0030525194,0.00045850186,0.0013227975,0.00011299858,0.0011978258,0.08611264],"study_design_scores_gemma":[0.564394,0.29431987,0.07556093,0.0030044706,0.008722782,0.00014755646,0.0016014742,0.005048035,0.0023925765,0.0006059401,0.043831825,0.0003705508],"about_ca_topic_score_codex":0.00016881945,"about_ca_topic_score_gemma":0.0008898518,"teacher_disagreement_score":0.29296988,"about_ca_system_score_codex":0.0009146884,"about_ca_system_score_gemma":0.004771332,"threshold_uncertainty_score":0.8464138},"labels":[],"label_agreement":null},{"id":"W4400530775","doi":"10.1158/0008-5472.can-24-0890","title":"An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"National Cancer Institute; Canadian Institutes of Health Research; University of California, San Francisco; American Association for Cancer Research; Prostate Cancer Foundation; Movember Foundation; U.S. Department of Defense; Princess Margaret Cancer Foundation; National Institutes of Health; Ontario Institute for Cancer Research; Government of Ontario; Stand Up To Cancer","keywords":"Prostate cancer; Chromatin; Epigenetics; Androgen receptor; Biology; Transcriptome; Epigenetic therapy; Cancer research; Computational biology; Transcription factor; Enzalutamide; Cancer; Bioinformatics; Gene; Genetics; DNA methylation; Gene expression","score_opus":0.049833216991354255,"score_gpt":0.4701664521484493,"score_spread":0.4203332351570951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400530775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93500894,0.05991279,0.0000026471948,0.0022885182,0.00017557124,0.0022148013,0.000047776117,0.00005684045,0.00029212746],"genre_scores_gemma":[0.9877424,0.006240645,0.00006571748,0.000012031966,0.0002759542,0.0027932478,0.0000190194,0.00005216105,0.002798806],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99680847,0.00031441878,0.00039099267,0.00055141014,0.0010731106,0.0008615945],"domain_scores_gemma":[0.9987646,0.00012778146,0.000058892005,0.0004858517,0.00035639416,0.00020651196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012578263,0.00017491479,0.00031085667,0.00050127966,0.00021512857,0.00008850983,0.00030584208,0.0000727675,0.0003433275],"category_scores_gemma":[0.00008728782,0.00010471227,0.000067709494,0.0018587651,0.00037879008,0.00029366376,0.00013858805,0.00071375637,0.000019927134],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001641987,0.0001967072,0.1348695,0.0030091726,0.000069026755,0.00021759287,0.0017760168,0.00024183124,0.82878214,0.00006630624,0.00044887813,0.028680822],"study_design_scores_gemma":[0.0026543764,0.00086139934,0.41099373,0.008596784,0.00003703701,0.000017165983,0.0008675786,0.0013898687,0.5726689,0.0006851577,0.0010245898,0.00020340295],"about_ca_topic_score_codex":0.0009943463,"about_ca_topic_score_gemma":0.00042910682,"teacher_disagreement_score":0.27612424,"about_ca_system_score_codex":0.0014042174,"about_ca_system_score_gemma":0.0017430093,"threshold_uncertainty_score":0.42700425},"labels":[],"label_agreement":null},{"id":"W4400803404","doi":"10.1016/j.jsbmb.2024.106588","title":"PSA, an outdated biomarker for prostate cancer: In search of a more specific biomarker, citrate takes the spotlight","year":2024,"lang":"en","type":"review","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Overdiagnosis; Biomarker; Prostate-specific antigen; Context (archaeology); False positive paradox; Medicine; Biomarker discovery; Prostate; Cancer; PCA3; Oncology; Internal medicine; Computer science; Biology; Artificial intelligence; Proteomics","score_opus":0.05753500703239338,"score_gpt":0.404248503552679,"score_spread":0.3467134965202856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400803404","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060362093,0.9368896,0.000016253038,0.001138522,0.00012722459,0.0010227883,0.00041023648,0.0000050947397,0.000028184011],"genre_scores_gemma":[0.0146652935,0.9845546,0.00004482936,0.000038552287,0.0001207505,0.000053687236,0.00017078078,0.000042966516,0.00030853535],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980749,0.00028343132,0.00077579817,0.00030103538,0.000193297,0.00037157227],"domain_scores_gemma":[0.9987593,0.00012232814,0.00038716642,0.0003712297,0.00022963247,0.00013032202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001157083,0.00035803212,0.0011219871,0.00021011409,0.00006449976,0.000028808316,0.00037942908,0.00030729533,0.000014089161],"category_scores_gemma":[0.000026435962,0.00015399257,0.00034347715,0.00039973223,0.0006854773,0.000024492456,0.00008955241,0.0005760002,7.5108915e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003256966,0.00023419998,0.000074427095,0.019470824,0.0026268912,0.0003689266,0.0006854657,4.1221858e-7,0.39341503,0.000011308561,0.0008131454,0.57904243],"study_design_scores_gemma":[0.00851988,0.0040196492,0.00016342608,0.042127173,0.008723444,0.0051425877,0.002395754,0.000092812414,0.26235306,0.00030044816,0.66507274,0.0010889999],"about_ca_topic_score_codex":0.000019805455,"about_ca_topic_score_gemma":0.0000028715374,"teacher_disagreement_score":0.6642596,"about_ca_system_score_codex":0.00010113984,"about_ca_system_score_gemma":0.00062118925,"threshold_uncertainty_score":0.6279635},"labels":[],"label_agreement":null},{"id":"W4400912534","doi":"10.1016/j.steroids.2024.109482","title":"Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer","year":2024,"lang":"en","type":"review","venue":"Steroids","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Genome British Columbia","funders":"National Cancer Institute; National Institutes of Health","keywords":"Transactivation; Prostate cancer; Androgen receptor; Androgen deprivation therapy; Cancer research; Antiandrogens; Medicine; Dihydrotestosterone; Internal medicine; Cancer; Androgen; Transcription factor; Endocrinology; Oncology; Biology; Hormone; Gene; Genetics","score_opus":0.04952714266088189,"score_gpt":0.3917475626483191,"score_spread":0.34222041998743724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400912534","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031308758,0.99098593,0.0000038427474,0.00036819695,0.0003584731,0.0044233026,0.0005699332,0.00001260792,0.00014684016],"genre_scores_gemma":[0.00030632282,0.9934141,0.000039288716,0.000016158587,0.00014608045,0.0011137769,0.00010458905,0.000056694764,0.0048029954],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998807,0.00006926669,0.00042197725,0.00024323315,0.00027866472,0.00017986231],"domain_scores_gemma":[0.99934334,0.000052463598,0.00019155514,0.00025642017,0.000110929555,0.000045312256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019336287,0.0002216894,0.000871546,0.00012596673,0.000030971645,0.000008522936,0.000111426205,0.00015210694,0.00005380793],"category_scores_gemma":[0.000008664934,0.00010436088,0.0005494239,0.00037362904,0.0001174095,0.00002878777,0.000017666911,0.00019763014,0.0000035250346],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041479972,0.00008193045,0.00002947043,0.030717267,0.0008258977,0.0000011447523,0.0009770099,4.989967e-8,0.0004489583,0.000015256815,0.0014481908,0.96504],"study_design_scores_gemma":[0.0014594604,0.0007304341,0.0000031046543,0.022031022,0.00069914706,0.000004261157,0.00006967024,4.011705e-7,0.0077344277,0.00013926443,0.9670264,0.00010241249],"about_ca_topic_score_codex":0.000047501657,"about_ca_topic_score_gemma":0.0000046137648,"teacher_disagreement_score":0.9655782,"about_ca_system_score_codex":0.00016775209,"about_ca_system_score_gemma":0.001080101,"threshold_uncertainty_score":0.42557132},"labels":[],"label_agreement":null},{"id":"W4400959505","doi":"10.1080/14796694.2024.2363131","title":"The TALAPRO-3 study design: a plain language summary","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Cancer; Internal medicine; Family medicine; Androgen receptor","score_opus":0.02806034429463618,"score_gpt":0.3820710198024786,"score_spread":0.35401067550784243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400959505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5610472,0.21611552,0.00015146431,0.109012425,0.00717018,0.007984084,0.000044010972,0.0008069591,0.09766813],"genre_scores_gemma":[0.9157517,0.0014776196,0.00036572415,0.0006594778,0.0040320395,0.00060619536,0.000055479653,0.000054713524,0.07699708],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99902344,0.0001821446,0.00011969074,0.00021760074,0.00017988369,0.0002772447],"domain_scores_gemma":[0.99933386,0.0003187991,0.000014074601,0.00021607178,0.00003038395,0.00008679369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048577634,0.000103696795,0.00017523971,0.00006606889,0.00014376818,0.000035844405,0.00009739035,0.00009790462,0.00014113146],"category_scores_gemma":[0.000028419416,0.000051099087,0.000057137768,0.00021863829,0.00008253316,0.00002891177,0.000053246353,0.00035371416,0.0001620362],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034002247,0.0010991861,0.0027085247,0.0001661563,0.0010391562,0.017295381,0.016673835,0.0000014011944,0.0058997446,0.0010196662,0.48049957,0.47019717],"study_design_scores_gemma":[0.0026227685,0.0049167336,0.0034932634,0.000054860066,0.00017115039,0.00021102348,0.01585862,0.000117762844,0.0008670969,0.00014446843,0.97143817,0.000104053164],"about_ca_topic_score_codex":0.000023823764,"about_ca_topic_score_gemma":0.00009733207,"teacher_disagreement_score":0.49093863,"about_ca_system_score_codex":0.0002490856,"about_ca_system_score_gemma":0.00045904983,"threshold_uncertainty_score":0.20837602},"labels":[],"label_agreement":null},{"id":"W4400974209","doi":"10.3390/curroncol31080311","title":"Prostate-Specific Membrane Antigen Expression in Patients with Primary Prostate Cancer: Diagnostic and Prognostic Value in Positron Emission Tomography-Prostate-Specific Membrane Antigen","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Glutamate carboxypeptidase II; Medicine; Prostate cancer; Positron emission tomography; Prostate; Antigen; Prostate-specific antigen; PCA3; Oncology; Cancer; Pathology; Internal medicine; Nuclear medicine; Immunology","score_opus":0.056232251580207775,"score_gpt":0.3725693857336937,"score_spread":0.3163371341534859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400974209","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15621343,0.8287655,0.0000011340384,0.00018103939,0.0012105695,0.01281946,0.00052959204,0.00013372813,0.00014555095],"genre_scores_gemma":[0.004349765,0.98661095,0.00013217372,0.000019371926,0.00028491372,0.0033269152,0.0047226856,0.00028660914,0.00026664158],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921357,0.0007933633,0.0018289831,0.0023760346,0.0011403194,0.0017255833],"domain_scores_gemma":[0.9967446,0.0008062163,0.00064663304,0.0008151453,0.00031751863,0.0006699212],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000765476,0.0015011049,0.0039237067,0.0020927486,0.00020007488,0.0001523337,0.00043074987,0.00076539256,0.000075621654],"category_scores_gemma":[0.000114877825,0.0009868876,0.00037401842,0.0023176386,0.00059045217,0.00031701688,0.0005076915,0.0024905554,0.00004419752],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030678702,0.003118231,0.21152176,0.051821314,0.00028915372,0.0013563165,0.0014859628,0.000005817199,0.00011761386,0.000007409537,0.0018867671,0.72532177],"study_design_scores_gemma":[0.0114218835,0.0033495417,0.0519528,0.12008593,0.0009195587,0.00006645289,0.00010222183,0.000013277037,0.00019748336,0.00003381347,0.8105718,0.0012852453],"about_ca_topic_score_codex":0.000058585636,"about_ca_topic_score_gemma":0.000029987552,"teacher_disagreement_score":0.808685,"about_ca_system_score_codex":0.0022893234,"about_ca_system_score_gemma":0.0020795383,"threshold_uncertainty_score":0.99981076},"labels":[],"label_agreement":null},{"id":"W4401078733","doi":"10.1158/2159-8290.26396714.v1","title":"Supplementary Figures S1-S10 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Epigenetics; Cancer research; Gene; Prostate cancer; Biology; Cancer; Genetics","score_opus":0.02826481954135859,"score_gpt":0.3317955219752537,"score_spread":0.3035307024338951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401078733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.927965,0.053433906,0.000010645964,0.0044651437,0.00048495858,0.0028791598,0.008603267,0.00012368901,0.0020342215],"genre_scores_gemma":[0.9131666,0.06673401,0.0017345725,0.0004020844,0.00035478373,0.0010563858,0.0043644705,0.00011012859,0.012076963],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99658316,0.000111960195,0.00064801774,0.0012781157,0.0006587037,0.000720044],"domain_scores_gemma":[0.99878395,0.00024152511,0.0001330013,0.0004385314,0.0001328393,0.00027017778],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019226536,0.00058567827,0.0008596019,0.0004247438,0.00010349704,0.0001292821,0.00023717455,0.00027452066,0.004043961],"category_scores_gemma":[0.000045048026,0.00041292844,0.00016804524,0.00037678183,0.0002542591,0.000052242824,0.0004943442,0.0014500072,0.000029517332],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038553897,0.004216076,0.62407553,0.013516181,0.005063969,0.008300161,0.027983826,0.00089260953,0.06321646,0.00036291184,0.19088604,0.022932319],"study_design_scores_gemma":[0.06512515,0.0031833423,0.32271317,0.022778824,0.002244013,0.000026422713,0.0048533254,0.008864694,0.40713927,0.018486707,0.13896637,0.0056187348],"about_ca_topic_score_codex":0.011712762,"about_ca_topic_score_gemma":0.012443865,"teacher_disagreement_score":0.34392282,"about_ca_system_score_codex":0.0006467186,"about_ca_system_score_gemma":0.0011258239,"threshold_uncertainty_score":0.9998323},"labels":[],"label_agreement":null},{"id":"W4401103832","doi":"10.1158/2159-8290.26396714","title":"Supplementary Figures S1-S10 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Epigenetics; Cancer research; Gene; Prostate cancer; Biology; Cancer; Genetics; Cell biology","score_opus":0.02826481954135859,"score_gpt":0.3317955219752537,"score_spread":0.3035307024338951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401103832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.927965,0.053433906,0.000010645964,0.0044651437,0.00048495858,0.0028791598,0.008603267,0.00012368901,0.0020342215],"genre_scores_gemma":[0.9131666,0.06673401,0.0017345725,0.0004020844,0.00035478373,0.0010563858,0.0043644705,0.00011012859,0.012076963],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99658316,0.000111960195,0.00064801774,0.0012781157,0.0006587037,0.000720044],"domain_scores_gemma":[0.99878395,0.00024152511,0.0001330013,0.0004385314,0.0001328393,0.00027017778],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019226536,0.00058567827,0.0008596019,0.0004247438,0.00010349704,0.0001292821,0.00023717455,0.00027452066,0.004043961],"category_scores_gemma":[0.000045048026,0.00041292844,0.00016804524,0.00037678183,0.0002542591,0.000052242824,0.0004943442,0.0014500072,0.000029517332],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038553897,0.004216076,0.62407553,0.013516181,0.005063969,0.008300161,0.027983826,0.00089260953,0.06321646,0.00036291184,0.19088604,0.022932319],"study_design_scores_gemma":[0.06512515,0.0031833423,0.32271317,0.022778824,0.002244013,0.000026422713,0.0048533254,0.008864694,0.40713927,0.018486707,0.13896637,0.0056187348],"about_ca_topic_score_codex":0.011712762,"about_ca_topic_score_gemma":0.012443865,"teacher_disagreement_score":0.34392282,"about_ca_system_score_codex":0.0006467186,"about_ca_system_score_gemma":0.0011258239,"threshold_uncertainty_score":0.9998323},"labels":[],"label_agreement":null},{"id":"W4401210425","doi":"10.2967/jnumed.124.267881","title":"Utility of<sup>64</sup>Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on<sup>68</sup>Ga-PSMA-11 PET/CT","year":2024,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Prostate cancer; Nuclear medicine; Prostate; Medicine; Cancer; Internal medicine","score_opus":0.029955191148199015,"score_gpt":0.33912083777391866,"score_spread":0.30916564662571966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401210425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705447,0.0072276797,0.0000020254008,0.020058423,0.00012568255,0.00084671687,0.00006407399,0.000035449008,0.0010952351],"genre_scores_gemma":[0.99094075,0.006466857,0.0004107339,0.00037752313,0.00036109285,0.000018058185,0.000017723742,0.000087896085,0.0013193582],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962764,0.00015040529,0.0010474125,0.00055618194,0.0013226229,0.00064699026],"domain_scores_gemma":[0.9979969,0.0004292662,0.0002672306,0.00031277866,0.0004139538,0.00057983154],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011098718,0.00046668792,0.0012335795,0.0006794264,0.00008829252,0.000044864555,0.00024832707,0.000023051032,0.0011965882],"category_scores_gemma":[0.00045880495,0.0002560631,0.00015408294,0.0009150217,0.00085235416,0.00025598117,0.00011352159,0.0012660415,0.000015426025],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13252275,0.005830985,0.120179355,0.013948237,0.0065597356,0.24913356,0.03922726,0.00033744398,0.027105736,0.00045065337,0.31008402,0.09462027],"study_design_scores_gemma":[0.15783754,0.08729365,0.13295624,0.13831948,0.006640496,0.09679761,0.050388914,0.12145148,0.03155919,0.0012997309,0.17186709,0.0035885917],"about_ca_topic_score_codex":0.0003962941,"about_ca_topic_score_gemma":0.000032266107,"teacher_disagreement_score":0.15233596,"about_ca_system_score_codex":0.00044474163,"about_ca_system_score_gemma":0.0009217547,"threshold_uncertainty_score":0.99998915},"labels":[],"label_agreement":null},{"id":"W4401274290","doi":"10.1158/2159-8290.26466973.v1","title":"Supplementary Figures S1-S10 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Epigenetics; Cancer research; Gene; Prostate cancer; Biology; Genetics; Cancer","score_opus":0.02826481954135859,"score_gpt":0.3317955219752537,"score_spread":0.3035307024338951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401274290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.927965,0.053433906,0.000010645964,0.0044651437,0.00048495858,0.0028791598,0.008603267,0.00012368901,0.0020342215],"genre_scores_gemma":[0.9131666,0.06673401,0.0017345725,0.0004020844,0.00035478373,0.0010563858,0.0043644705,0.00011012859,0.012076963],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99658316,0.000111960195,0.00064801774,0.0012781157,0.0006587037,0.000720044],"domain_scores_gemma":[0.99878395,0.00024152511,0.0001330013,0.0004385314,0.0001328393,0.00027017778],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019226536,0.00058567827,0.0008596019,0.0004247438,0.00010349704,0.0001292821,0.00023717455,0.00027452066,0.004043961],"category_scores_gemma":[0.000045048026,0.00041292844,0.00016804524,0.00037678183,0.0002542591,0.000052242824,0.0004943442,0.0014500072,0.000029517332],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038553897,0.004216076,0.62407553,0.013516181,0.005063969,0.008300161,0.027983826,0.00089260953,0.06321646,0.00036291184,0.19088604,0.022932319],"study_design_scores_gemma":[0.06512515,0.0031833423,0.32271317,0.022778824,0.002244013,0.000026422713,0.0048533254,0.008864694,0.40713927,0.018486707,0.13896637,0.0056187348],"about_ca_topic_score_codex":0.011712762,"about_ca_topic_score_gemma":0.012443865,"teacher_disagreement_score":0.34392282,"about_ca_system_score_codex":0.0006467186,"about_ca_system_score_gemma":0.0011258239,"threshold_uncertainty_score":0.9998323},"labels":[],"label_agreement":null},{"id":"W4401274326","doi":"10.1158/2159-8290.26466973","title":"Supplementary Figures S1-S10 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Epigenetics; Gene; Cancer research; Biology; Genetics","score_opus":0.02826481954135859,"score_gpt":0.3317955219752537,"score_spread":0.3035307024338951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401274326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.927965,0.053433906,0.000010645964,0.0044651437,0.00048495858,0.0028791598,0.008603267,0.00012368901,0.0020342215],"genre_scores_gemma":[0.9131666,0.06673401,0.0017345725,0.0004020844,0.00035478373,0.0010563858,0.0043644705,0.00011012859,0.012076963],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99658316,0.000111960195,0.00064801774,0.0012781157,0.0006587037,0.000720044],"domain_scores_gemma":[0.99878395,0.00024152511,0.0001330013,0.0004385314,0.0001328393,0.00027017778],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019226536,0.00058567827,0.0008596019,0.0004247438,0.00010349704,0.0001292821,0.00023717455,0.00027452066,0.004043961],"category_scores_gemma":[0.000045048026,0.00041292844,0.00016804524,0.00037678183,0.0002542591,0.000052242824,0.0004943442,0.0014500072,0.000029517332],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038553897,0.004216076,0.62407553,0.013516181,0.005063969,0.008300161,0.027983826,0.00089260953,0.06321646,0.00036291184,0.19088604,0.022932319],"study_design_scores_gemma":[0.06512515,0.0031833423,0.32271317,0.022778824,0.002244013,0.000026422713,0.0048533254,0.008864694,0.40713927,0.018486707,0.13896637,0.0056187348],"about_ca_topic_score_codex":0.011712762,"about_ca_topic_score_gemma":0.012443865,"teacher_disagreement_score":0.34392282,"about_ca_system_score_codex":0.0006467186,"about_ca_system_score_gemma":0.0011258239,"threshold_uncertainty_score":0.9998323},"labels":[],"label_agreement":null},{"id":"W4401379890","doi":"10.1200/jco.2024.42.4_suppl.18","title":"CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Centre Hospitalier de l’Université de Montréal","funders":"Exelixis","keywords":"Medicine; Docetaxel; Clinical endpoint; Internal medicine; Prostate cancer; Oncology; Hormonal therapy; Metastatic breast cancer; Enzalutamide; Androgen deprivation therapy; Taxane; Urology; Cancer; Randomized controlled trial; Breast cancer; Androgen receptor","score_opus":0.15264072572719684,"score_gpt":0.5031225171413383,"score_spread":0.35048179141414143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401379890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945292,0.0020018634,0.000009700291,0.0012225749,0.00052277563,0.0012902898,0.00009592806,0.000007684656,0.00031999094],"genre_scores_gemma":[0.9977053,0.0010787466,0.0002740832,0.00019871337,0.00017735685,0.000048318983,0.000015224959,0.000029317895,0.00047297907],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99603397,0.0003045783,0.00225536,0.00030704628,0.00075793755,0.00034110906],"domain_scores_gemma":[0.9969071,0.0009841918,0.0009208896,0.0001700578,0.0007185067,0.00029923263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001600656,0.00021967177,0.0016017295,0.00030515878,0.000040424893,0.000027274975,0.00014625848,0.00013445305,0.00032738154],"category_scores_gemma":[0.00022191675,0.00012568774,0.00021804837,0.00036488182,0.00018462565,0.00022121487,0.000029506351,0.0009951693,0.0000035600049],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4442075,0.05987224,0.25477985,0.0005744766,0.0073675616,0.008842922,0.008247887,0.00015306174,0.00429293,0.00010251958,0.0020568494,0.20950224],"study_design_scores_gemma":[0.21681333,0.20989886,0.55888426,0.0005766005,0.0006385199,0.00010101762,0.001678881,0.00038775854,0.0004954746,0.000038743754,0.010279222,0.00020731692],"about_ca_topic_score_codex":0.00027572236,"about_ca_topic_score_gemma":0.0011511861,"teacher_disagreement_score":0.30410442,"about_ca_system_score_codex":0.00042724982,"about_ca_system_score_gemma":0.005881177,"threshold_uncertainty_score":0.99975455},"labels":[],"label_agreement":null},{"id":"W4401515835","doi":"10.1038/s41391-024-00865-5","title":"Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study","year":2024,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"Medical Research Council","keywords":"Enzalutamide; Medicine; Prostate cancer; Pembrolizumab; Clinical endpoint; Internal medicine; Cohort; Oncology; Response Evaluation Criteria in Solid Tumors; Cancer; Phases of clinical research; Urology; Surgery; Clinical trial; Immunotherapy; Androgen receptor","score_opus":0.04024679531211643,"score_gpt":0.39768706055211306,"score_spread":0.3574402652399966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401515835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9184117,0.062307056,0.00001305479,0.0025214148,0.00033720152,0.010818882,0.005438352,0.00010452177,0.00004781868],"genre_scores_gemma":[0.9870609,0.0041413754,0.00011739511,0.00024758276,0.00011311539,0.0061981636,0.00016549927,0.000101795726,0.0018541489],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9966947,0.00015994663,0.0007225678,0.0009385272,0.00078713574,0.000697159],"domain_scores_gemma":[0.9981417,0.00044263803,0.00023056992,0.00041049437,0.0003058856,0.0004687057],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037170152,0.00052876933,0.00080565707,0.00023818096,0.00047177673,0.00034191986,0.0001305863,0.000055051587,0.000060317816],"category_scores_gemma":[0.00017730841,0.00032801752,0.00017326769,0.00054204057,0.00062653114,0.00030336544,0.00010407682,0.00027903862,0.0000011669446],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08059613,0.0061841537,0.21252349,0.046582818,0.0057798256,0.0013113125,0.054939907,0.0006209764,0.015085445,0.00091138633,0.0046638143,0.5708007],"study_design_scores_gemma":[0.26600617,0.058370154,0.3863459,0.045140855,0.037549015,0.0004827018,0.04087819,0.04168852,0.06377395,0.02020214,0.03283578,0.0067266044],"about_ca_topic_score_codex":0.00047760902,"about_ca_topic_score_gemma":0.00020602408,"teacher_disagreement_score":0.56407416,"about_ca_system_score_codex":0.00038979796,"about_ca_system_score_gemma":0.002277152,"threshold_uncertainty_score":0.9999172},"labels":[],"label_agreement":null},{"id":"W4401605481","doi":"10.1007/978-3-031-64388-0_3","title":"Diagnostic Advances: Innovative Techniques and Biomarkers for Prostate Cancer Diagnosis","year":2024,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Prostate cancer; Medicine; Cancer biomarkers; Cancer; Medical physics; Internal medicine","score_opus":0.028782509701505737,"score_gpt":0.353880483677687,"score_spread":0.32509797397618123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401605481","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018022768,0.2553451,0.000025410232,0.00812313,0.0003834941,0.008792336,0.002470221,0.00046242317,0.72421765],"genre_scores_gemma":[0.0004743601,0.22908051,0.0007494495,0.00021756766,0.00032736515,0.008437699,0.0003805622,0.00013446892,0.760198],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984774,0.0000040984473,0.0003063736,0.0006215685,0.00025658787,0.00033398182],"domain_scores_gemma":[0.9986195,0.0005160816,0.00008910341,0.00021251281,0.00041745213,0.0001453529],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001175081,0.0004128108,0.00053419126,0.00037890123,0.000074127056,0.00004743889,0.000064259475,0.00024970516,0.0004979461],"category_scores_gemma":[0.00006796164,0.0002787335,0.00011080136,0.00012843989,0.00031484046,0.000093494185,0.00009585128,0.00029994122,0.000020726424],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013242611,0.00008494593,0.004381958,0.0070655323,0.0027394895,0.0008100412,0.00034002887,5.2710995e-8,0.0000627614,0.04339858,0.09353312,0.84625924],"study_design_scores_gemma":[0.0011368233,0.0009686095,0.00004105341,0.004212003,0.0004322799,0.000023101145,0.000040277275,0.0000038600388,0.004868963,0.017729584,0.97020113,0.0003423359],"about_ca_topic_score_codex":0.00006321016,"about_ca_topic_score_gemma":0.000058263136,"teacher_disagreement_score":0.876668,"about_ca_system_score_codex":0.0003070952,"about_ca_system_score_gemma":0.00031221434,"threshold_uncertainty_score":0.9999665},"labels":[],"label_agreement":null},{"id":"W4401660144","doi":"10.1016/j.euf.2024.07.015","title":"Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No","year":2024,"lang":"en","type":"article","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; PARP inhibitor; Prostate cancer; Androgen receptor; Oncology; Internal medicine; Cancer research; Poly ADP ribose polymerase; Castration; Prostate; Cancer; Gene; Hormone; Polymerase; Genetics","score_opus":0.02205771521350204,"score_gpt":0.280704198087813,"score_spread":0.25864648287431097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401660144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928733,0.0010860885,0.000027880084,0.0027652278,0.0000835839,0.0021561403,0.0006969962,0.000058481804,0.0002523178],"genre_scores_gemma":[0.9979901,0.0000617052,0.00026884413,0.00019473601,0.00008003103,0.00017558616,0.0005259331,0.00006662703,0.00063649396],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984875,0.00022920774,0.00029256515,0.00042230458,0.00030031832,0.00026811822],"domain_scores_gemma":[0.99903476,0.000111709305,0.00012039571,0.0001980358,0.00041971248,0.00011535515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029454846,0.0002192889,0.00026123467,0.00013560822,0.00014041022,0.000057145087,0.00006122482,0.00004092154,0.000039081486],"category_scores_gemma":[0.000029842886,0.000118691714,0.000041097148,0.00024538607,0.00026550164,0.00018194874,0.000020014879,0.00017010889,0.0000065717395],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17137578,0.008122405,0.2153739,0.0048387004,0.00932235,0.0030425023,0.062391024,0.00013599017,0.10251418,0.0015713241,0.015946377,0.40536547],"study_design_scores_gemma":[0.12395148,0.21603595,0.3176125,0.0021157071,0.0067646466,0.0004793334,0.0030193878,0.006508788,0.2283141,0.0004658549,0.09228706,0.0024451776],"about_ca_topic_score_codex":0.00008681138,"about_ca_topic_score_gemma":0.00015817213,"teacher_disagreement_score":0.40292028,"about_ca_system_score_codex":0.000070522125,"about_ca_system_score_gemma":0.00029870743,"threshold_uncertainty_score":0.48401076},"labels":[],"label_agreement":null},{"id":"W4401698523","doi":"10.36469/jheor.2024.121233","title":"Real-World Clinical Outcomes and Treatment Patterns Among Black and Non-Black Patients With Prostate Cancer Initiated on Apalutamide in a Urology Setting","year":2024,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Urology; Androgen deprivation therapy; Bicalutamide; Cohort; Oncology; Cancer; Androgen receptor","score_opus":0.0954274413607885,"score_gpt":0.4685944567940695,"score_spread":0.373167015433281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401698523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98501414,0.0006075744,4.3389974e-7,0.013098314,0.00009773769,0.0009911023,0.000057974517,0.0000058496753,0.00012685554],"genre_scores_gemma":[0.9354759,0.0635672,0.000037952213,0.00034341466,0.000065788205,0.000025571728,0.000012544827,0.000031793727,0.00043983827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976005,0.00027970536,0.0009250557,0.0003756523,0.00023041226,0.0005886685],"domain_scores_gemma":[0.99806136,0.0010083397,0.0002063867,0.00014423161,0.00014234477,0.00043734553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020863416,0.00020713772,0.0008720001,0.0008002708,0.000114374234,0.00010902011,0.000059394093,0.00008567974,0.000013020811],"category_scores_gemma":[0.00006318361,0.00012130508,0.00007310957,0.00016373144,0.00037225574,0.00014731161,0.000073481955,0.00075625937,0.0000021607852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014989461,0.00021388583,0.96204185,0.00029817445,0.00032525728,0.00016385177,0.0015180224,0.000022829974,2.5924047e-7,0.000015148666,0.000060572052,0.03384117],"study_design_scores_gemma":[0.007571049,0.004357291,0.98525107,0.00042609297,0.00003359993,0.000006743427,0.00041409145,0.0013925557,0.000002955283,0.00006012106,0.00038829297,0.000096112584],"about_ca_topic_score_codex":0.00193434,"about_ca_topic_score_gemma":0.0037588687,"teacher_disagreement_score":0.06295962,"about_ca_system_score_codex":0.00063820806,"about_ca_system_score_gemma":0.0009454835,"threshold_uncertainty_score":0.49466774},"labels":[],"label_agreement":null},{"id":"W4401729249","doi":"10.1080/14796694.2024.2384257","title":"Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Placebo; Androgen deprivation therapy; Oncology; Internal medicine; Prostate-specific antigen; Cancer; Pathology; Alternative medicine","score_opus":0.04384379995837404,"score_gpt":0.3853748239425174,"score_spread":0.3415310239841433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401729249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8366715,0.15354967,1.4083301e-7,0.007973167,0.00005882413,0.0013868979,0.00016341438,0.00002320758,0.00017321503],"genre_scores_gemma":[0.97603023,0.022893667,0.00017418902,0.00010938186,0.00004161503,0.00014414769,0.000055482542,0.000024573923,0.00052671565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848616,0.00022271552,0.00043835086,0.00033372227,0.00023245437,0.00028661644],"domain_scores_gemma":[0.9993076,0.0001192155,0.00019288063,0.00018091161,0.00009642411,0.000102974576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005393265,0.00018239506,0.00076137687,0.0001504255,0.00005856056,0.000007985358,0.000053051288,0.00009815045,0.00001208247],"category_scores_gemma":[0.000021394386,0.00009017313,0.000025972451,0.00056869414,0.0005199268,0.000063702944,0.00005434899,0.00029895804,2.6529247e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042926786,0.0001940059,0.9426504,0.0018304212,0.00062807894,0.0001428389,0.027668534,0.00000917139,0.002761641,0.00026488968,0.00080072717,0.018756643],"study_design_scores_gemma":[0.008832482,0.0040418054,0.95990056,0.0019962462,0.000080941776,0.000036117144,0.018738318,0.000009690498,0.0013514108,0.000056176723,0.004796622,0.0001596473],"about_ca_topic_score_codex":0.0006840905,"about_ca_topic_score_gemma":0.0047910446,"teacher_disagreement_score":0.13935876,"about_ca_system_score_codex":0.00023325559,"about_ca_system_score_gemma":0.0007317225,"threshold_uncertainty_score":0.36771536},"labels":[],"label_agreement":null},{"id":"W4401977145","doi":"10.3390/siuj5040044","title":"The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Metastatic Castrate-Sensitive Prostate Cancer Patients Treated with Abiraterone Acetate","year":2024,"lang":"en","type":"article","venue":"Société Internationale d’Urologie Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Abiraterone acetate; Prostate cancer; Medicine; Biomarker; Oncology; Abiraterone; Cancer; Internal medicine; Cancer research; Chemistry; Androgen deprivation therapy; Androgen receptor","score_opus":0.03975641214283772,"score_gpt":0.3598659111627649,"score_spread":0.3201094990199272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401977145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98414886,0.0022213412,0.000031979824,0.010868793,0.00045542768,0.0009407808,0.00008971134,0.00005082483,0.001192253],"genre_scores_gemma":[0.98765296,0.0028920537,0.000074554446,0.00055267155,0.00010717811,0.00022643157,0.00008047559,0.000037109057,0.008376557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978212,0.00018345189,0.00043511376,0.00035969898,0.00068059546,0.0005199482],"domain_scores_gemma":[0.99869823,0.00026245983,0.00012463864,0.00014122413,0.0005677764,0.00020569074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043820788,0.00026437562,0.00030819935,0.000320473,0.0002263175,0.0003269407,0.00016649059,0.00005727529,0.00017437624],"category_scores_gemma":[0.000102790815,0.00014232525,0.00011976563,0.0004742983,0.00018988531,0.00025642078,0.00006267057,0.0005263979,0.00006781052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08124912,0.0025973737,0.47124058,0.00047010332,0.015977466,0.03271016,0.013870924,0.0034325074,0.03718517,0.000885955,0.018216118,0.3221645],"study_design_scores_gemma":[0.028132603,0.007521384,0.91210914,0.0014580087,0.0007814121,0.0019376811,0.0026245643,0.011118915,0.014321658,0.0013115725,0.017816165,0.0008668862],"about_ca_topic_score_codex":0.00021692416,"about_ca_topic_score_gemma":0.00016719017,"teacher_disagreement_score":0.44086856,"about_ca_system_score_codex":0.0010515467,"about_ca_system_score_gemma":0.0009805863,"threshold_uncertainty_score":0.58038557},"labels":[],"label_agreement":null},{"id":"W4401993452","doi":"10.3390/curroncol31090375","title":"Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"American Society of Clinical Oncology","keywords":"Docetaxel; Medicine; Taxane; Prostate cancer; Castration; Oncology; Cabazitaxel; Internal medicine; Cancer; Prostate; Androgen deprivation therapy; Breast cancer; Hormone","score_opus":0.12145610882621281,"score_gpt":0.4254142455777143,"score_spread":0.30395813675150146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401993452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770457,0.009720761,0.00007973741,0.00395579,0.0005924889,0.007543079,0.0009831797,0.000047428653,0.000031832424],"genre_scores_gemma":[0.9861323,0.007615628,0.0005069656,0.00006591024,0.000054847438,0.0040817996,0.0009377914,0.00006194429,0.0005427965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972269,0.00019177888,0.00083689566,0.0006677074,0.00049060374,0.00058614335],"domain_scores_gemma":[0.99752116,0.0003568195,0.0003745533,0.00028186777,0.0012941142,0.00017148019],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044567112,0.0003931352,0.0009641893,0.00038079766,0.000107617365,0.000050987503,0.00010206149,0.00006758614,0.00006727778],"category_scores_gemma":[0.00012144371,0.00026069942,0.00014228171,0.000580006,0.00029113403,0.0002501836,0.000023675757,0.0003347909,0.000004251236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022578446,0.0039974046,0.76683676,0.004902572,0.0032211377,0.00019159459,0.022338014,0.0005255576,0.0028106326,0.0003164401,0.0017319083,0.17054951],"study_design_scores_gemma":[0.03727856,0.010956475,0.9176989,0.0039330837,0.0017055778,0.000020266254,0.0029423302,0.0037441405,0.008419233,0.00029785218,0.01217996,0.00082362094],"about_ca_topic_score_codex":0.00084501813,"about_ca_topic_score_gemma":0.0052460283,"teacher_disagreement_score":0.1697259,"about_ca_system_score_codex":0.0012538065,"about_ca_system_score_gemma":0.0016710468,"threshold_uncertainty_score":0.9999845},"labels":[],"label_agreement":null},{"id":"W4402026311","doi":"10.1186/s40644-024-00752-1","title":"Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Imaging","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research; BC Cancer Foundation","keywords":"Medicine; Prostate cancer; Biochemical recurrence; Prostatectomy; Androgen deprivation therapy; Positron emission tomography; Glutamate carboxypeptidase II; Concomitant; Nuclear medicine; Prostate; Population; Proportional hazards model; PET-CT; Radiation therapy; Prospective cohort study; Radiology; Internal medicine; Cancer","score_opus":0.028091302787256134,"score_gpt":0.36497529320017946,"score_spread":0.33688399041292333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402026311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93260914,0.06374909,0.000016006996,0.0014621847,0.00026404165,0.0010468138,0.0001760178,0.00004153416,0.00063515134],"genre_scores_gemma":[0.99461645,0.0039339536,0.00022862977,0.000051496398,0.00007651874,0.0006157716,0.000015312566,0.000028985201,0.00043286633],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985017,0.000037822912,0.0003599355,0.00041501137,0.00031752614,0.00036799297],"domain_scores_gemma":[0.9992681,0.00015942552,0.00008428403,0.00018448547,0.00020233709,0.00010132364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017238565,0.0001745914,0.00037256008,0.00022934392,0.00002070594,0.000017483779,0.000111299414,0.000009149685,0.00014071728],"category_scores_gemma":[0.00011314976,0.00013822535,0.00008465498,0.0008686696,0.00037865332,0.00013300597,0.000051929135,0.0002987196,0.0000037867155],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008489553,0.00022861786,0.7388171,0.005174918,0.00020684778,0.0014473028,0.002949858,0.000043168227,0.17197204,0.00006602416,0.002142411,0.07610279],"study_design_scores_gemma":[0.0031176528,0.00021424405,0.037828255,0.015428748,0.00024059729,0.00011831516,0.0010274994,0.005985108,0.9332374,0.00052830664,0.0019001999,0.00037369312],"about_ca_topic_score_codex":0.0010521266,"about_ca_topic_score_gemma":0.00003419971,"teacher_disagreement_score":0.76126534,"about_ca_system_score_codex":0.00037349662,"about_ca_system_score_gemma":0.0011610235,"threshold_uncertainty_score":0.56366664},"labels":[],"label_agreement":null},{"id":"W4402092930","doi":"10.5489/cuaj.8691","title":"Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer","year":2024,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre; Jewish General Hospital; University of Calgary; Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network; Ottawa Hospital; McGill University; University of Ottawa; University of Alberta; Western University; University of Toronto; Alberta Health Services; McMaster University; Juravinski Cancer Centre; St. Joseph’s Healthcare Hamilton","funders":"EMD Serono; Ipsen; Seagen; Exelixis; Eisai; Sanofi; AstraZeneca; Amgen; Pfizer; Astellas Pharma; F. Hoffmann-La Roche","keywords":"Medicine; Enzalutamide; Prostate cancer; Androgen deprivation therapy; Abiraterone acetate; Docetaxel; Internal medicine; Oncology; Cohort; Retrospective cohort study; Population; Cancer registry; Cancer; Androgen receptor","score_opus":0.017720007428435203,"score_gpt":0.28430712435019134,"score_spread":0.26658711692175613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402092930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98733205,0.00039576684,0.0000106826055,0.011460753,0.00009458593,0.0004278557,0.000153953,0.0000077278355,0.00011662605],"genre_scores_gemma":[0.99871814,0.00063918915,0.00006449737,0.0002293009,0.00005343383,0.000026923068,0.00007064977,0.000008226832,0.00018963199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906963,0.000114644485,0.00021564768,0.00015218931,0.00022648301,0.00022138662],"domain_scores_gemma":[0.9989994,0.00015829683,0.00011116118,0.000043518285,0.0004453365,0.00024227332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002496148,0.00009395289,0.00018283179,0.00021028235,0.000055385288,0.000053150798,0.0000179582,0.000053613472,0.000039032173],"category_scores_gemma":[0.00019504612,0.000058022866,0.00002894857,0.00019707087,0.000032168275,0.00016679827,0.0000034317343,0.00022096549,0.000002115767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033546364,0.000074492586,0.9923486,0.000017273856,0.00033304596,0.00012466383,0.0010628238,0.000027129774,0.000019159002,0.000027096186,0.00012108614,0.0055091665],"study_design_scores_gemma":[0.0017223019,0.001539061,0.99404895,0.0000874085,0.00019983477,0.00003633292,0.00040918135,0.0001676063,0.00004726152,0.000023681629,0.0016627704,0.00005562134],"about_ca_topic_score_codex":0.004464226,"about_ca_topic_score_gemma":0.0028480971,"teacher_disagreement_score":0.011386098,"about_ca_system_score_codex":0.002027453,"about_ca_system_score_gemma":0.00089823967,"threshold_uncertainty_score":0.6748604},"labels":[],"label_agreement":null},{"id":"W4402118789","doi":"10.3390/cancers16173039","title":"From Oncogenesis to Theranostics: The Transformative Role of PSMA in Prostate Cancer","year":2024,"lang":"en","type":"review","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Biomarker; Targeted therapy; Prostate; Cancer research; Precision medicine; Tumor microenvironment; Oncology; Bioinformatics; Internal medicine; Pathology; Biology","score_opus":0.04898928737239225,"score_gpt":0.40377285167629023,"score_spread":0.354783564303898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402118789","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008682973,0.9927117,9.78872e-7,0.00047168214,0.00031794637,0.0028586248,0.0016778277,0.000021533975,0.001071363],"genre_scores_gemma":[0.0005962633,0.9957695,0.000020427226,0.00009549227,0.0002684322,0.0018172731,0.0001344124,0.000069276284,0.0012288939],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99837565,0.00008718418,0.00048905547,0.00036670367,0.00033336208,0.00034805087],"domain_scores_gemma":[0.9992223,0.0001376439,0.00009930491,0.0003277588,0.00008023314,0.00013275546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014713472,0.00034319152,0.0012640217,0.0002382479,0.000033530338,0.000020167754,0.00022228724,0.00012828414,0.00015711573],"category_scores_gemma":[0.000017398952,0.00017361046,0.00033872083,0.00078810216,0.00012585465,0.000035933375,0.000041569077,0.00043131202,0.00006521505],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020488095,0.00001330692,0.000025400072,0.0077639683,0.0007998004,0.00003989521,0.008084031,0.000015977947,0.000019035277,0.00000576025,0.0011783098,0.9818496],"study_design_scores_gemma":[0.0005819414,0.00017020473,0.000014237943,0.032276966,0.0018862528,0.0000032648638,0.0013000306,0.00001942935,0.00036310335,0.00007267968,0.96311605,0.00019583396],"about_ca_topic_score_codex":0.0057940534,"about_ca_topic_score_gemma":0.0007314944,"teacher_disagreement_score":0.9816538,"about_ca_system_score_codex":0.0029893199,"about_ca_system_score_gemma":0.0042581833,"threshold_uncertainty_score":0.8758914},"labels":[],"label_agreement":null},{"id":"W4402171758","doi":"10.1080/17501911.2024.2391729","title":"The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions","year":2024,"lang":"en","type":"article","venue":"Epigenomics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; University of British Columbia","funders":"Institute of Cancer Research; National Cancer Institute; Prostate Cancer Foundation","keywords":"Prostate cancer; Context (archaeology); Cancer research; Cancer; Androgen receptor; Neuroendocrine tumors; Epigenetics; Biology; Medicine; Bioinformatics; Internal medicine; Genetics","score_opus":0.019159485479763996,"score_gpt":0.3038996671570229,"score_spread":0.2847401816772589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402171758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9004894,0.047646675,3.9095127e-7,0.044242453,0.0014540452,0.000910367,0.000046367393,0.00015256087,0.005057727],"genre_scores_gemma":[0.53517175,0.42880914,0.000014773414,0.00022928699,0.0015801548,0.0003337806,0.000041999538,0.00005782243,0.03376132],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990698,0.00003432314,0.00013912341,0.0003226536,0.00013071812,0.00030339885],"domain_scores_gemma":[0.9994514,0.00010383829,0.000020636531,0.00024321461,0.000035388526,0.00014554104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000038599308,0.00018528865,0.00017463246,0.000091180824,0.00040642856,0.00012603852,0.000050236013,0.000029818004,0.000016752625],"category_scores_gemma":[0.0000045665674,0.000094368195,0.0000738388,0.00019784224,0.000066994995,0.000053778745,0.000027553006,0.00021033626,0.0000365313],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019419165,0.00034157504,0.0024598346,0.00019929298,0.0011251873,0.0014383966,0.007119049,0.000010653094,0.022159638,0.0040307357,0.003037868,0.95613587],"study_design_scores_gemma":[0.00095810386,0.001039953,0.0028141867,0.000053480864,0.00012573275,0.000060977756,0.00021744559,0.00025628743,0.010374338,0.00020209822,0.9837912,0.000106195046],"about_ca_topic_score_codex":0.00017236419,"about_ca_topic_score_gemma":0.00020079536,"teacher_disagreement_score":0.98075336,"about_ca_system_score_codex":0.00042181622,"about_ca_system_score_gemma":0.00027119956,"threshold_uncertainty_score":0.3848223},"labels":[],"label_agreement":null},{"id":"W4402282016","doi":"10.1038/s41391-024-00886-0","title":"Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis","year":2024,"lang":"en","type":"review","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Innovációs és Technológiai Minisztérium; Medizinische Universität Wien; European Association of Urology; Universität Wien","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Heart failure; Androgen deprivation therapy; Atrial fibrillation; Meta-analysis; Relative risk; Oncology; Androgen receptor; Cardiology; Cancer; Confidence interval","score_opus":0.06336574411383952,"score_gpt":0.34931513731522806,"score_spread":0.28594939320138857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402282016","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010163007,0.9707586,0.000011602249,0.00028046704,0.00003099855,0.020846864,0.0077627967,0.0001734627,0.00003355357],"genre_scores_gemma":[0.00035773483,0.9454417,0.00013716605,0.0001463587,0.00011480072,0.043913003,0.0032324786,0.00028897132,0.0063677826],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99078614,0.0011934345,0.0021324311,0.0026040191,0.0019779443,0.0013060311],"domain_scores_gemma":[0.9950532,0.00036448668,0.0012450631,0.0014371258,0.0007452618,0.0011548774],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001357057,0.0021727828,0.022796348,0.0010986918,0.00039159556,0.0004638562,0.00027881443,0.00024349014,0.00041674936],"category_scores_gemma":[0.000059213224,0.0010213556,0.008882259,0.0065203425,0.00052183785,0.0003859405,0.00020890421,0.000702355,0.000010022822],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002963507,0.00008148412,0.0012498741,0.4078334,0.5880088,0.00025000336,0.00021139548,0.00007995174,5.5781484e-8,0.000001073777,0.00034216003,0.001645437],"study_design_scores_gemma":[0.0010345606,0.00042597708,0.000024591573,0.06545702,0.9231559,0.000034610486,0.00010828013,0.000046174,0.000004571052,0.000014179424,0.00856866,0.0011254556],"about_ca_topic_score_codex":0.0012028643,"about_ca_topic_score_gemma":0.00020860275,"teacher_disagreement_score":0.34237638,"about_ca_system_score_codex":0.00044924536,"about_ca_system_score_gemma":0.0013763275,"threshold_uncertainty_score":0.9992237},"labels":[],"label_agreement":null},{"id":"W4402311649","doi":"10.1016/j.eururo.2024.08.021","title":"Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial","year":2024,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of British Columbia","funders":"National Cancer Institute; Medical Research Council; Novartis Pharmaceuticals Corporation; Novartis","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Oncology; Prostate; Prostate-specific antigen; Internal medicine; Antigen; Castration; Clinical trial; Urology; Cancer; Immunology; Hormone","score_opus":0.07192577697083756,"score_gpt":0.40374225212492254,"score_spread":0.33181647515408497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402311649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945508,0.0005004422,0.00001669846,0.0022220053,0.00024248686,0.0020086484,0.00009595237,0.000028788374,0.0003341365],"genre_scores_gemma":[0.99870443,0.00029136054,0.00019827804,0.00015064394,0.00008362145,0.0000667448,0.00011150017,0.000047387577,0.00034601174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964913,0.0012503272,0.0008430008,0.0004752703,0.0005329157,0.00040718092],"domain_scores_gemma":[0.9983996,0.0008476109,0.00027379792,0.00025663985,0.00015214537,0.000070202346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026894098,0.00021080555,0.0005227514,0.0002548052,0.00006655885,0.00006155363,0.00012984981,0.000052314484,0.00004487156],"category_scores_gemma":[0.00026417,0.00011352122,0.0000743799,0.00051460287,0.00014019191,0.00015678752,0.000036815934,0.00054394576,0.000012304092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07269971,0.0013294985,0.90449154,0.000089544024,0.00035629058,0.0007121111,0.0041833795,0.00007617179,0.0002746964,0.0000145172135,0.00029500196,0.015477511],"study_design_scores_gemma":[0.068806924,0.009930166,0.91873324,0.00022594321,0.00013390952,0.0000026384578,0.00027452887,0.000092915456,0.000042281004,0.000014194289,0.0016128819,0.00013039244],"about_ca_topic_score_codex":0.00007315634,"about_ca_topic_score_gemma":0.00037839526,"teacher_disagreement_score":0.0153471185,"about_ca_system_score_codex":0.00016485083,"about_ca_system_score_gemma":0.0003385156,"threshold_uncertainty_score":0.46292612},"labels":[],"label_agreement":null},{"id":"W4402316935","doi":"10.5489/cuaj.8980","title":"NS-AUA 2024 Annual Meeting Abstracts – Oncology – Prostate","year":2024,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Astellas Pharma; Pfizer","keywords":"Medicine; Prostate; Prostate cancer; Oncology; Medical physics; Internal medicine; Cancer","score_opus":0.0193238215394723,"score_gpt":0.3067412186440065,"score_spread":0.2874173971045342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402316935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67864215,0.005914943,0.0000050499452,0.23654868,0.0023122681,0.0004960421,0.0002151929,0.0001184315,0.07574724],"genre_scores_gemma":[0.9741606,0.00063202175,0.00019344556,0.002381882,0.0012065178,0.000017554958,0.000044117507,0.000020182006,0.021343678],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814576,0.00013488064,0.000349356,0.00023977313,0.00041142796,0.0007188222],"domain_scores_gemma":[0.9982246,0.00028786145,0.00010156822,0.00009507143,0.0002962488,0.0009946552],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012179743,0.00013718283,0.00024779787,0.00029731716,0.00025793887,0.00017990278,0.00011700176,0.00029439744,0.0010282368],"category_scores_gemma":[0.0011066177,0.00009741327,0.0001398398,0.00032216046,0.000046043,0.0001445743,0.000025349555,0.0011662922,0.00041648955],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034139256,0.00015680787,0.30128658,0.000075233205,0.0008779161,0.012319613,0.0017968582,0.000115996234,0.00089641963,0.00022327664,0.5981139,0.083795995],"study_design_scores_gemma":[0.00087349955,0.00078501453,0.16343673,0.00006643174,0.000099227735,0.00072448706,0.00028026602,0.00012343166,0.00007243553,0.0013661778,0.83204395,0.00012833408],"about_ca_topic_score_codex":0.0009326921,"about_ca_topic_score_gemma":0.000779302,"teacher_disagreement_score":0.29551843,"about_ca_system_score_codex":0.0031997422,"about_ca_system_score_gemma":0.0024788436,"threshold_uncertainty_score":0.99988496},"labels":[],"label_agreement":null},{"id":"W4402325549","doi":"10.1136/spcare-2024-anzspm.61","title":"P-13 Genomic variation in symptom expression in men with castrate resistant prostate cancer","year":2024,"lang":"en","type":"article","venue":"Poster presentations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Variation (astronomy); Prostate cancer; Cancer; Expression (computer science); Oncology; Internal medicine; Medicine; Computer science; Astrophysics; Physics","score_opus":0.025017071869834435,"score_gpt":0.34068416980180116,"score_spread":0.31566709793196673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402325549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863767,0.0018508979,0.000035830155,0.004842094,0.00006980624,0.0012601173,0.00007056511,0.00004819329,0.005445822],"genre_scores_gemma":[0.99010104,0.00044014712,0.0001547508,0.000038628757,0.00005650102,0.00060517306,0.00011014748,0.000027275044,0.008466313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989075,0.0000672422,0.00022543594,0.00030578903,0.00022750217,0.00026651126],"domain_scores_gemma":[0.99962384,0.00006164022,0.000027257982,0.00015798536,0.000052232135,0.00007706618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001199417,0.00011912676,0.00014576898,0.00033920648,0.000043714925,0.00008299711,0.000049955055,0.000043264034,0.00014804838],"category_scores_gemma":[0.0000071380255,0.00008441454,0.000025424919,0.000451074,0.00003951519,0.0002501323,0.000032484822,0.00019125782,0.000025211455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004049182,0.00042851208,0.5049692,0.0008628776,0.0002156295,0.0016622462,0.035868652,0.0012300062,0.44435078,0.00011960205,0.0032587647,0.0029845827],"study_design_scores_gemma":[0.00336415,0.00020760679,0.97973937,0.00090183486,0.00005665221,0.00001957946,0.00078339246,0.0020235856,0.012005991,0.00020312781,0.0005519012,0.00014280848],"about_ca_topic_score_codex":0.001776272,"about_ca_topic_score_gemma":0.0017322352,"teacher_disagreement_score":0.4747702,"about_ca_system_score_codex":0.0002750831,"about_ca_system_score_gemma":0.00036562732,"threshold_uncertainty_score":0.3442325},"labels":[],"label_agreement":null},{"id":"W4402365478","doi":"10.3390/curroncol31090391","title":"The Relationship between D’Amico and ISUP Risk Classifications and 68Ga-PSMA PET/CT SUVmax Values in Newly Diagnosed Prostate Cancers","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Metastasis; Pathological; Prostate gland; Standardized uptake value; Radiology; Prostate-specific antigen; PET-CT; Positron emission tomography; Cancer; Oncology; Urology; Internal medicine","score_opus":0.16121385561318716,"score_gpt":0.4564473767590373,"score_spread":0.2952335211458501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402365478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9527187,0.03747076,0.000016981312,0.007935691,0.00042348038,0.00085143425,0.00008607059,0.000053354477,0.0004435545],"genre_scores_gemma":[0.98370814,0.014930819,0.00006188578,0.00001780208,0.00014089559,0.0003055651,0.00010580966,0.00001782332,0.00071124715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873906,0.00021552801,0.0002528198,0.0003367134,0.00014811134,0.0003077783],"domain_scores_gemma":[0.99712235,0.0024534897,0.000053417913,0.00017913629,0.000052058916,0.00013956077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004913553,0.00013421291,0.00022423192,0.00017886222,0.00026250537,0.00006481834,0.000065790926,0.000018346713,0.000010406524],"category_scores_gemma":[0.00039001115,0.00008730157,0.000038750542,0.00032120748,0.00044565686,0.00007688285,0.000047658577,0.0005701926,0.000016140371],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008353972,0.000054047996,0.9238988,0.00014360776,0.00004370075,0.00018893309,0.0005168858,0.0000031613233,0.000007142836,0.00072053366,0.0022869038,0.072052754],"study_design_scores_gemma":[0.002292278,0.0003658917,0.8948818,0.00023633668,0.00015898138,0.00006163126,0.0005351649,0.0016893196,0.000022612543,0.0027629996,0.09689067,0.00010232786],"about_ca_topic_score_codex":0.00019028904,"about_ca_topic_score_gemma":0.00046023985,"teacher_disagreement_score":0.09460377,"about_ca_system_score_codex":0.0005827877,"about_ca_system_score_gemma":0.0008336701,"threshold_uncertainty_score":0.35600546},"labels":[],"label_agreement":null},{"id":"W4402510624","doi":"10.1016/j.ijrobp.2024.08.045","title":"Evolving Paradigms in Prostate Cancer: The Integral Role of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging and Therapeutic Decision-Making","year":2024,"lang":"en","type":"review","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Prostate cancer; Medicine; Prostate; Oncology; Medical physics; Cancer; Radiology; Internal medicine","score_opus":0.023396692124817754,"score_gpt":0.3706007541340059,"score_spread":0.34720406200918813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402510624","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057554398,0.9396434,0.00008694173,0.00044105412,0.00090702524,0.0011446804,0.0001076231,0.000020514368,0.000094399],"genre_scores_gemma":[0.17274998,0.8259685,0.00053913775,0.000065335065,0.00044012596,0.00006238237,0.000114048846,0.00005069196,0.000009776612],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996758,0.00044211917,0.0014852863,0.0004461448,0.00048287623,0.00038561254],"domain_scores_gemma":[0.9971574,0.00088583265,0.0012280754,0.0002013003,0.00042453737,0.000102867074],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010552716,0.00042906837,0.0015394797,0.0012725156,0.00006758242,0.00007355362,0.00047588858,0.0002949279,0.000014034701],"category_scores_gemma":[0.000057071346,0.0002631177,0.0005058916,0.0010483504,0.0002967636,0.00020654642,0.00015319254,0.001425914,0.0000015112751],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064620073,0.00025674445,0.114666626,0.0006951768,0.00091867795,0.00012106538,0.0011357144,0.000048428956,0.00026575805,0.00025641714,0.00005998352,0.88092923],"study_design_scores_gemma":[0.022415912,0.0054248925,0.112101056,0.1580824,0.003535432,0.0014868495,0.0014815964,0.007123413,0.0009629808,0.040095337,0.64517194,0.0021182094],"about_ca_topic_score_codex":0.000041467138,"about_ca_topic_score_gemma":0.000008929175,"teacher_disagreement_score":0.878811,"about_ca_system_score_codex":0.0013552251,"about_ca_system_score_gemma":0.0013996258,"threshold_uncertainty_score":0.9999821},"labels":[],"label_agreement":null},{"id":"W4402555565","doi":"10.1200/jco-24-01798","title":"Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Docetaxel; Medicine; Androgen deprivation therapy; Prostate cancer; Oncology; Internal medicine; Chemotherapy; Enzalutamide; Cancer; Androgen receptor","score_opus":0.09170646046613255,"score_gpt":0.46258325047132764,"score_spread":0.3708767900051951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402555565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894312,0.0015504945,0.00006165429,0.0072756694,0.0002905862,0.0013165849,0.000020570249,0.0000056871754,0.00004752511],"genre_scores_gemma":[0.99623185,0.0027485804,0.00020425621,0.00047269842,0.00020567607,0.000039056944,0.00003410448,0.000016104903,0.00004765056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976447,0.00047871683,0.0010428235,0.00018968085,0.00045984596,0.00018423701],"domain_scores_gemma":[0.99753726,0.0014910444,0.00046084754,0.00010381052,0.0003086827,0.00009836668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016999283,0.000120361416,0.000774662,0.00015229074,0.00002751689,0.000020627938,0.00007076997,0.00009454267,0.000019011466],"category_scores_gemma":[0.0002711034,0.000053966432,0.00009518802,0.00035276622,0.00017721935,0.00018607915,0.000013469964,0.000807124,0.0000018504029],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6427826,0.0039629256,0.10208215,0.000009387315,0.0007697291,0.000919291,0.0012732912,0.000038373237,0.00006809295,0.000016823686,0.00020448725,0.2478728],"study_design_scores_gemma":[0.4812862,0.05257807,0.4627832,0.0003306838,0.00023287904,0.000009553088,0.00019900294,0.00045600068,0.00015301131,0.00036406668,0.001527312,0.00008005435],"about_ca_topic_score_codex":0.0002330472,"about_ca_topic_score_gemma":0.00033571207,"teacher_disagreement_score":0.36070102,"about_ca_system_score_codex":0.0003236257,"about_ca_system_score_gemma":0.0017894366,"threshold_uncertainty_score":0.3506597},"labels":[],"label_agreement":null},{"id":"W4402560244","doi":"10.1016/j.annonc.2024.08.1699","title":"1618P Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Ottawa","funders":"National Health and Medical Research Council; Astellas Pharma US","keywords":"Medicine; Oncology; Prostate cancer; Internal medicine; Cancer","score_opus":0.14052973065755486,"score_gpt":0.46424179152199413,"score_spread":0.32371206086443927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97703934,0.007900554,0.0000075018256,0.012963723,0.00036732602,0.0012164275,0.00019677645,0.000027037937,0.00028130287],"genre_scores_gemma":[0.9936868,0.004095832,0.00017207673,0.00042621166,0.00009058265,0.00013038152,0.000069204885,0.000030642706,0.001298301],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975608,0.00041526227,0.0008381206,0.0003844012,0.0003813654,0.00042004563],"domain_scores_gemma":[0.9975836,0.0014256253,0.00023483032,0.0002628185,0.00035218455,0.0001409121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001596619,0.00020356609,0.0008894624,0.00023461398,0.000031472337,0.000012910124,0.00013985534,0.00013591151,0.00006690086],"category_scores_gemma":[0.0006027255,0.00011789184,0.0001935985,0.000571878,0.0007299504,0.00009479776,0.00009208225,0.0005629109,0.000017827171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018930756,0.0061673834,0.6990286,0.0029002563,0.007852202,0.005936874,0.042641982,0.00020016404,0.022458969,0.0029888505,0.049497314,0.14139667],"study_design_scores_gemma":[0.007977327,0.026173485,0.8830269,0.0012805306,0.0012471086,0.000097684206,0.005320538,0.0018244543,0.05102779,0.0033171729,0.0182411,0.00046593876],"about_ca_topic_score_codex":0.0018726118,"about_ca_topic_score_gemma":0.0004952845,"teacher_disagreement_score":0.18399829,"about_ca_system_score_codex":0.000111083566,"about_ca_system_score_gemma":0.0013878031,"threshold_uncertainty_score":0.48074895},"labels":[],"label_agreement":null},{"id":"W4402560269","doi":"10.1016/j.annonc.2024.08.1680","title":"1599P Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Taxane; Prostate cancer; Oncology; Internal medicine; Quality of life (healthcare); Castration; Phases of clinical research; Clinical trial; Cancer; Hormone; Nursing","score_opus":0.07814622430017823,"score_gpt":0.44859140634268474,"score_spread":0.37044518204250654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99330485,0.0028427842,0.000008659229,0.0008555726,0.000030646854,0.0022516637,0.0006644678,0.000007931966,0.000033451874],"genre_scores_gemma":[0.9989109,0.00048523894,0.00006788966,0.000053129945,0.0000039578226,0.00016218206,0.00027226197,0.000015362746,0.000029081682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99601096,0.0010897974,0.0017544662,0.0003655066,0.00046117086,0.0003181258],"domain_scores_gemma":[0.9977449,0.0005361194,0.00089865946,0.00022039124,0.00045929514,0.00014060459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020140698,0.00021298282,0.0018196417,0.000989703,0.000025627003,0.0000045163442,0.00009161979,0.0000766646,0.000031493877],"category_scores_gemma":[0.00021759038,0.00015533596,0.00012435201,0.0015735814,0.0002732249,0.00011163753,0.000051937117,0.00023197204,1.7968e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031550948,0.023093307,0.7815728,0.0059219184,0.015981354,0.00024228357,0.07719839,0.0004108096,0.0019186352,0.00011485048,0.0001436025,0.06185108],"study_design_scores_gemma":[0.035434496,0.063670106,0.8716679,0.0021142066,0.0013218446,0.0000025918082,0.022176202,0.002239652,0.0009907521,0.0001455729,0.000007640457,0.00022903233],"about_ca_topic_score_codex":0.015561238,"about_ca_topic_score_gemma":0.01523846,"teacher_disagreement_score":0.09009509,"about_ca_system_score_codex":0.00019300838,"about_ca_system_score_gemma":0.0011893607,"threshold_uncertainty_score":0.9909942},"labels":[],"label_agreement":null},{"id":"W4402560272","doi":"10.1016/j.annonc.2024.08.1692","title":"1611P Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Astellas Pharma; American Society of Clinical Oncology; Amgen; Stand Up To Cancer; Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Castration; Cancer; Hormone","score_opus":0.1697050343098413,"score_gpt":0.4788614098846602,"score_spread":0.3091563755748189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918636,0.0040358766,3.5618166e-7,0.0020633284,0.00011380772,0.0011528424,0.00024582364,0.00001274421,0.00051161804],"genre_scores_gemma":[0.9983524,0.0010608762,0.00006815058,0.000048886996,0.000021574995,0.00024083746,0.000101282334,0.000018610219,0.000087347085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855983,0.00009525592,0.00041594342,0.0002637238,0.00026621853,0.00039900013],"domain_scores_gemma":[0.99922764,0.00015597057,0.00013035235,0.00016733295,0.00022380818,0.00009491719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026936104,0.00017125279,0.0006283316,0.000423533,0.000016431282,0.000007400813,0.0000761218,0.00008572891,0.00016097892],"category_scores_gemma":[0.000051564788,0.00010712341,0.000095352174,0.00052876497,0.0001864185,0.0001378572,0.000029875613,0.00021146832,0.000004695243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04015546,0.0023739336,0.8712369,0.0018502248,0.0011986024,0.0020411038,0.0069696554,0.00015097075,0.00079236296,0.0003848015,0.00091632234,0.07192963],"study_design_scores_gemma":[0.013453685,0.021785296,0.96044016,0.00096860895,0.0001304345,0.000009835844,0.00043684326,0.0002456708,0.0017561164,0.00031641382,0.00029266498,0.00016424946],"about_ca_topic_score_codex":0.002916684,"about_ca_topic_score_gemma":0.0035165206,"teacher_disagreement_score":0.08920325,"about_ca_system_score_codex":0.00027452552,"about_ca_system_score_gemma":0.000980506,"threshold_uncertainty_score":0.4409173},"labels":[],"label_agreement":null},{"id":"W4402565585","doi":"10.1016/j.annonc.2024.08.2311","title":"LBA68 Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Bayer HealthCare; Exelixis; American Society of Clinical Oncology; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Oncology; Internal medicine; Cancer","score_opus":0.06839710869532524,"score_gpt":0.4041756379512355,"score_spread":0.3357785292559103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871797,0.007089583,0.000015372198,0.0030699288,0.00007880618,0.0021740338,0.00029752436,0.000011519267,0.000083548824],"genre_scores_gemma":[0.9912651,0.008074631,0.000058278805,0.00022382171,0.00005279501,0.000085336695,0.00017007043,0.000017708204,0.000052230498],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99870104,0.00017379907,0.00038044743,0.00025919545,0.00026180703,0.00022373878],"domain_scores_gemma":[0.998911,0.000516946,0.00014062686,0.0001650051,0.00020370758,0.00006271809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036831,0.00014117821,0.0005290619,0.00011612749,0.00003448907,0.00000872558,0.00005678622,0.00006048651,0.000020034386],"category_scores_gemma":[0.000058078207,0.00007849576,0.000052534626,0.0002843318,0.00028257968,0.00008796109,0.000029961539,0.00018038656,0.0000011555745],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.669998,0.0013577482,0.0037194532,0.000059303682,0.0013691499,0.0001445873,0.009248777,0.00004147101,0.002941135,0.00004349378,0.00044177374,0.3106351],"study_design_scores_gemma":[0.70544523,0.04163317,0.21784227,0.00067648286,0.000472837,0.000007848014,0.0007372472,0.00088206906,0.023722159,0.0005081134,0.0077934097,0.00027919674],"about_ca_topic_score_codex":0.0007426474,"about_ca_topic_score_gemma":0.000095113195,"teacher_disagreement_score":0.3103559,"about_ca_system_score_codex":0.000089313,"about_ca_system_score_gemma":0.0006213148,"threshold_uncertainty_score":0.32009643},"labels":[],"label_agreement":null},{"id":"W4402565608","doi":"10.1016/j.annonc.2024.08.2310","title":"LBA67 Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Centre Hospitalier de l’Université de Montréal","funders":"Movember Foundation","keywords":"Medicine; Atezolizumab; Cabozantinib; Prostate cancer; Oncology; Hormonal therapy; Internal medicine; Randomized controlled trial; Cancer; Immunotherapy; Nivolumab","score_opus":0.15150180573280111,"score_gpt":0.43960817400768887,"score_spread":0.2881063682748878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893174,0.0021128438,0.000004004803,0.0022441028,0.00039545272,0.0039763493,0.00063027354,0.000015382842,0.0013041546],"genre_scores_gemma":[0.9971044,0.0014786004,0.000044474767,0.00008266514,0.00004746152,0.000345665,0.000117559735,0.000028740216,0.0007504073],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99704224,0.00039394587,0.00092447083,0.0004437536,0.0007408943,0.000454697],"domain_scores_gemma":[0.99784905,0.00081623456,0.0003644842,0.00031346778,0.0005442656,0.00011248652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011135121,0.00028526236,0.0012254878,0.00022105315,0.00007144936,0.000023639092,0.00017454427,0.00008422741,0.00008525389],"category_scores_gemma":[0.00015076365,0.00015781086,0.0001974977,0.00042722482,0.0003551236,0.0001377326,0.000056105073,0.00035460934,0.0000017259299],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97076356,0.0053036893,0.0019520724,0.00014348685,0.0021889654,0.00027930402,0.005165958,0.00011484631,0.0017817013,0.00018713126,0.0008102077,0.011309058],"study_design_scores_gemma":[0.9363436,0.02905769,0.026613161,0.0003576036,0.00038839455,0.0000068383756,0.0009568481,0.00045068367,0.002843547,0.000038967653,0.0027391058,0.00020356681],"about_ca_topic_score_codex":0.0048263976,"about_ca_topic_score_gemma":0.003298173,"teacher_disagreement_score":0.034419987,"about_ca_system_score_codex":0.0002255475,"about_ca_system_score_gemma":0.0023939135,"threshold_uncertainty_score":0.7296102},"labels":[],"label_agreement":null},{"id":"W4402565679","doi":"10.1016/j.annonc.2024.08.2307","title":"LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Radium-223; Asymptomatic; Open label; Prostate cancer; Internal medicine; Oncology; Phases of clinical research; Urology; Randomized controlled trial; Clinical trial; Bone metastasis; Cancer; Androgen receptor","score_opus":0.09570365100150162,"score_gpt":0.42806967115118466,"score_spread":0.33236602014968303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98741335,0.0023855066,0.000015723806,0.0016049565,0.00013681277,0.007901132,0.00027247527,0.000022155606,0.00024787386],"genre_scores_gemma":[0.9965269,0.0012555416,0.0007404825,0.000083111736,0.000020038884,0.0007894849,0.00022240586,0.000036868838,0.00032519334],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961259,0.00056044076,0.0018547924,0.00046029093,0.0005650664,0.00043352236],"domain_scores_gemma":[0.99638337,0.0018200452,0.00083129515,0.00029177513,0.0005075539,0.00016595343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002030418,0.0003134285,0.0021805975,0.00055039645,0.00006531131,0.00004299485,0.00018115886,0.00010481887,0.000037873073],"category_scores_gemma":[0.00060825516,0.00020521971,0.00011161028,0.000586657,0.0005046794,0.00032033108,0.00012090054,0.00023067211,0.0000014419221],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96884733,0.00755442,0.0019566047,0.0031181618,0.0015711236,0.00018693846,0.006593485,0.00004423233,0.0015760474,0.00009177767,0.0003939389,0.008065932],"study_design_scores_gemma":[0.9585831,0.015281785,0.0029679227,0.0041724527,0.0008588,0.000011212287,0.00043411908,0.011918319,0.005252065,0.00011753216,0.00019206395,0.00021058474],"about_ca_topic_score_codex":0.002113691,"about_ca_topic_score_gemma":0.0021704796,"teacher_disagreement_score":0.011874087,"about_ca_system_score_codex":0.00021658189,"about_ca_system_score_gemma":0.0010314949,"threshold_uncertainty_score":0.83686167},"labels":[],"label_agreement":null},{"id":"W4402565848","doi":"10.1016/j.annonc.2024.08.2308","title":"LBA65 Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; BC Cancer Agency; Jewish General Hospital; Canadian Cancer Society; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Splash; Androgen receptor; Pharmacology; Androgen; Oncology; Cancer research; Internal medicine; Cancer; Prostate cancer; Hormone","score_opus":0.0703037373994569,"score_gpt":0.43976374096153664,"score_spread":0.36946000356207975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879274,0.003973032,0.000002430864,0.0029400145,0.00045606744,0.00078922376,0.000061389306,0.000041917374,0.00380853],"genre_scores_gemma":[0.9982407,0.000481599,0.00021404967,0.00017014651,0.0002528012,0.0000616759,0.00011244427,0.000031491727,0.00043510788],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982154,0.00019526356,0.00043442348,0.00039099774,0.00035973868,0.00040420098],"domain_scores_gemma":[0.9990223,0.0003431449,0.000092723596,0.0002239987,0.00013854241,0.00017929295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005327803,0.0001856671,0.00057228113,0.00039320285,0.000039665247,0.000010377542,0.00010615069,0.00023638284,0.00010170345],"category_scores_gemma":[0.00011728569,0.00013545204,0.00020436602,0.00043289913,0.00016141757,0.00012570538,0.00005976187,0.00031977793,0.000045039083],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010499079,0.0077764774,0.0136587415,0.00072052353,0.0008158472,0.0026125594,0.0059060357,0.000016401154,0.2534504,0.0008212589,0.008101475,0.6956212],"study_design_scores_gemma":[0.0074787447,0.031570245,0.011012983,0.0029670717,0.000090328766,0.000033206594,0.0004441489,0.00016981717,0.91984415,0.00020726449,0.025939044,0.00024297832],"about_ca_topic_score_codex":0.00004247874,"about_ca_topic_score_gemma":0.00001929074,"teacher_disagreement_score":0.69537824,"about_ca_system_score_codex":0.00013104443,"about_ca_system_score_gemma":0.0005490541,"threshold_uncertainty_score":0.5523574},"labels":[],"label_agreement":null},{"id":"W4402682826","doi":"10.1016/j.eururo.2024.09.008","title":"Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Oncology; Castration; Internal medicine; Gynecology; Cancer; Hormone","score_opus":0.22348597990205626,"score_gpt":0.39060099558399125,"score_spread":0.167115015681935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402682826","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003090938,0.9922024,0.000001251481,0.00060450385,0.00007898026,0.0061977184,0.00007073458,0.00005344675,0.0007600778],"genre_scores_gemma":[0.00030789594,0.99567753,0.00005171669,0.00013333937,0.00005739519,0.0015144489,0.0003509232,0.00009574914,0.0018110147],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9966391,0.0011704289,0.0010028435,0.00066979165,0.00017506562,0.00034279333],"domain_scores_gemma":[0.9989374,0.00014499939,0.00029478787,0.00043482412,0.000060546558,0.00012741981],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008098036,0.00046751823,0.0025371665,0.000362808,0.000044186578,0.00004342383,0.00009847705,0.000060905797,0.0000142287145],"category_scores_gemma":[0.00014731329,0.00026772183,0.00022779024,0.00042179704,0.000117214346,0.00004083303,0.00005947119,0.00037512818,0.0001344073],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036243287,0.00003482622,0.0000019525073,0.9230182,0.0007932131,0.0017443888,0.00045903402,6.596379e-7,0.000003253828,0.000065044325,0.00010996236,0.07373318],"study_design_scores_gemma":[0.0010229581,0.0012403532,0.000008604022,0.8147246,0.031431526,0.0015202357,0.00019862907,0.00011775949,0.0000011378879,0.000017389517,0.14926532,0.00045144025],"about_ca_topic_score_codex":0.0000848867,"about_ca_topic_score_gemma":0.00006762611,"teacher_disagreement_score":0.14915535,"about_ca_system_score_codex":0.0014012983,"about_ca_system_score_gemma":0.0010696946,"threshold_uncertainty_score":0.99997747},"labels":[],"label_agreement":null},{"id":"W4402690505","doi":"10.1080/10985549.2024.2401465","title":"A Genome Wide CRISPR Screen Reveals That HOXA9 Promotes Enzalutamide Resistance in Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Biology; Enzalutamide; CRISPR; Prostate cancer; Genetics; Genome editing; Genome; Computational biology; Cancer research; Cancer; Gene","score_opus":0.01818317752483063,"score_gpt":0.30418243847063375,"score_spread":0.28599926094580314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402690505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82445675,0.17053638,0.000290182,0.002988083,0.00006527858,0.00072603044,0.000056958874,0.000050370763,0.0008299729],"genre_scores_gemma":[0.9908564,0.0036741525,0.00026233454,0.00032630446,0.00004838724,0.00017492594,0.00020641183,0.000035741377,0.004415351],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985364,0.00012595984,0.00020389725,0.0005336132,0.00013281383,0.00046730082],"domain_scores_gemma":[0.9995169,0.000045796813,0.000027853874,0.00023176458,0.00004218512,0.00013549028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029154037,0.00020010392,0.00033099332,0.00019769365,0.000051172326,0.00003921529,0.00008042063,0.00012068165,0.00006131128],"category_scores_gemma":[0.000027455877,0.00014829879,0.000079115795,0.00027194177,0.00019104128,0.000042647254,0.000074441225,0.00026531302,0.000015621596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042598913,0.000062432715,0.083630934,0.00066998805,0.00019976385,0.0023971808,0.00070875115,9.3232484e-7,0.90922743,0.00059218146,0.000114389855,0.0019700353],"study_design_scores_gemma":[0.005317356,0.0012303052,0.07585411,0.002189985,0.00037664387,0.000096231925,0.00028314238,0.00013301033,0.8018877,0.015840998,0.095820025,0.00097050716],"about_ca_topic_score_codex":0.0001779588,"about_ca_topic_score_gemma":0.00010330671,"teacher_disagreement_score":0.16686223,"about_ca_system_score_codex":0.000107851876,"about_ca_system_score_gemma":0.00016080473,"threshold_uncertainty_score":0.6047449},"labels":[],"label_agreement":null},{"id":"W4402695128","doi":"10.1016/j.eururo.2024.09.009","title":"Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium","year":2024,"lang":"en","type":"review","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Randomized controlled trial; Prostate; Meta-analysis; Testosterone (patch); Urology; Oncology; Radiation therapy; Androgen; Internal medicine; Androgen suppression; Gynecology; Cancer; Hormone","score_opus":0.13272871580031698,"score_gpt":0.4104758447527413,"score_spread":0.2777471289524243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402695128","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011075288,0.9718589,0.000043803273,0.0009866465,0.0002440299,0.011810021,0.0038854135,0.000015899117,0.00007995875],"genre_scores_gemma":[0.010290777,0.98676074,0.00009783748,0.00013740822,0.00006125107,0.0008512736,0.00086276775,0.000095173826,0.00084279757],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9429058,0.048492227,0.0066433186,0.0009007249,0.000650038,0.00040790517],"domain_scores_gemma":[0.96262777,0.0312182,0.0048150453,0.0010264997,0.00020720455,0.00010525299],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.043518294,0.0007368463,0.042758513,0.0016871347,0.000057737005,0.000026828799,0.00042412645,0.00024065952,0.0005085833],"category_scores_gemma":[0.007480545,0.0002833253,0.021197228,0.0030179466,0.0009901415,0.000055771714,0.00015381006,0.000627547,8.7224294e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2617915,0.00013565316,0.00013884672,0.0014301158,0.7238567,0.00008776875,0.0015124468,0.00039017876,0.00011989052,0.0000032941382,0.00008549601,0.0104481485],"study_design_scores_gemma":[0.21982874,0.00015323662,0.000052158182,0.00083878584,0.7752693,0.0000022786792,0.000028187958,0.0003393712,0.000047938833,0.000020872427,0.0032503982,0.00016869731],"about_ca_topic_score_codex":0.00114204,"about_ca_topic_score_gemma":0.00019378355,"teacher_disagreement_score":0.051412664,"about_ca_system_score_codex":0.00007917023,"about_ca_system_score_gemma":0.00069927535,"threshold_uncertainty_score":0.9999619},"labels":[],"label_agreement":null},{"id":"W4402704907","doi":"10.1016/j.annonc.2024.08.1685","title":"1604P PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre; Princess Margaret Cancer Centre; Université Laval","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Radioligand; Internal medicine; Chemotherapy; Urology; Androgen receptor; Cancer; Receptor","score_opus":0.07466563848155026,"score_gpt":0.3938245005664609,"score_spread":0.3191588620849106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97345245,0.013452608,0.000007913836,0.008097918,0.00031594982,0.0036714058,0.0003773438,0.00011542139,0.0005090032],"genre_scores_gemma":[0.98604155,0.008872265,0.00044212682,0.0016193906,0.00015941971,0.0011047573,0.00039653172,0.00014713104,0.0012168591],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9955849,0.00036243015,0.0010029868,0.0009911482,0.00090615795,0.0011523794],"domain_scores_gemma":[0.99778974,0.00034111127,0.0003635126,0.00052338943,0.0005984806,0.0003837603],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00069519714,0.00066160894,0.0014526581,0.00065130746,0.00014700255,0.000091834445,0.00025201074,0.00023836504,0.00036454567],"category_scores_gemma":[0.000063662425,0.00045829578,0.00019643895,0.0009817638,0.0005445479,0.00032236587,0.00004320433,0.0006577027,0.000032158325],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26266104,0.0152847795,0.07278562,0.004351978,0.008896072,0.0072348933,0.034513604,0.0012223424,0.19469935,0.00022586551,0.032376803,0.36574766],"study_design_scores_gemma":[0.09247048,0.08603698,0.13864063,0.004259539,0.0005990355,0.00011830633,0.0014409341,0.0013660033,0.6148589,0.0006303695,0.057835884,0.0017429049],"about_ca_topic_score_codex":0.000969064,"about_ca_topic_score_gemma":0.001100799,"teacher_disagreement_score":0.42015958,"about_ca_system_score_codex":0.0007683076,"about_ca_system_score_gemma":0.002399358,"threshold_uncertainty_score":0.99978685},"labels":[],"label_agreement":null},{"id":"W4402704908","doi":"10.1016/j.annonc.2024.08.1741","title":"1660TiP First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"EMD Serono; Genentech; Astellas Pharma; Moderna; Jounce Therapeutics; SK Life Science; Incyte; MacroGenics; Aptitude Health; AbbVie; Sanofi; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Prostate cancer; Oncology; Antibody-drug conjugate; Conjugate; Internal medicine; Antibody; Cancer; Monoclonal antibody; Immunology","score_opus":0.05999168936279459,"score_gpt":0.41973923162184845,"score_spread":0.35974754225905387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941017,0.0013495814,0.0000011914246,0.001312497,0.00010484831,0.0018606383,0.00013147632,0.000017371423,0.0011206941],"genre_scores_gemma":[0.998083,0.00050472515,0.00009455096,0.00007666318,0.000025731451,0.0002430517,0.00010406734,0.000028830222,0.0008393954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978865,0.00017186732,0.00067082635,0.00040272644,0.00042117518,0.00044690463],"domain_scores_gemma":[0.99897,0.00017590262,0.00016726235,0.0002331366,0.0003460048,0.00010772649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058236095,0.00020659526,0.00073857466,0.0004356562,0.000049446702,0.000016273467,0.00009219912,0.00006000534,0.00015830285],"category_scores_gemma":[0.00003892461,0.00014772947,0.000049819326,0.00068913127,0.00015129698,0.00015258121,0.00005022046,0.00027280895,0.0000041425506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019038215,0.022634609,0.88938785,0.0044982675,0.0025936696,0.0044676503,0.030548116,0.0016032662,0.0108115375,0.0009153934,0.003921532,0.009579884],"study_design_scores_gemma":[0.057332214,0.07502158,0.8326052,0.004015326,0.000797898,0.000030237894,0.0075666234,0.0007973275,0.011014956,0.0009116574,0.009219953,0.0006870449],"about_ca_topic_score_codex":0.0070209503,"about_ca_topic_score_gemma":0.008774845,"teacher_disagreement_score":0.056782678,"about_ca_system_score_codex":0.00018735882,"about_ca_system_score_gemma":0.0009213887,"threshold_uncertainty_score":0.9995914},"labels":[],"label_agreement":null},{"id":"W4402704918","doi":"10.1016/j.annonc.2024.08.1722","title":"1641P Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Internal medicine; Abiraterone; Urology; Cancer; Androgen receptor","score_opus":0.1336092074318502,"score_gpt":0.4620167032676954,"score_spread":0.32840749583584516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876314,0.0015737598,0.000010076298,0.0076652584,0.00014619275,0.002279102,0.0001491863,0.000019914927,0.0005251212],"genre_scores_gemma":[0.9978678,0.00046191702,0.000391113,0.00017227362,0.000030870815,0.000401913,0.000157307,0.000024268451,0.000492504],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99799466,0.00021657375,0.0006607667,0.00033421195,0.00039183276,0.00040194855],"domain_scores_gemma":[0.9989923,0.00023337734,0.00014584485,0.00018186019,0.00030968475,0.0001369263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007707154,0.00018601703,0.0007909868,0.0006896222,0.00003239728,0.0000134651245,0.00009377722,0.00007800879,0.00009342755],"category_scores_gemma":[0.00010855927,0.00014117938,0.00006850424,0.00096030853,0.00015705547,0.00014075957,0.00004079205,0.00023242536,0.000004517485],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66074705,0.01934635,0.0063925707,0.0021616158,0.001398626,0.004142016,0.0213371,0.00088667247,0.14810775,0.0013886939,0.004002083,0.13008946],"study_design_scores_gemma":[0.5539202,0.16047025,0.030155212,0.0034997908,0.0006948819,0.00008108243,0.0036424443,0.003051323,0.22325754,0.0022243073,0.018190615,0.0008123093],"about_ca_topic_score_codex":0.003491159,"about_ca_topic_score_gemma":0.010151672,"teacher_disagreement_score":0.1411239,"about_ca_system_score_codex":0.0002648721,"about_ca_system_score_gemma":0.0014672097,"threshold_uncertainty_score":0.5757128},"labels":[],"label_agreement":null},{"id":"W4402704931","doi":"10.1016/j.annonc.2024.08.1697","title":"1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council; U.S. Army; EMD Serono; Genentech; National Institutes of Health; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Cilag; Astellas Pharma; Eisai; Prostate Cancer Foundation; Bristol-Myers Squibb; Eli Lilly and Company; UK Research and Innovation; AstraZeneca; American Society of Clinical Oncology; Ipsen; Peter MacCallum Cancer Centre; University of New South Wales; BeiGene; Sanofi; Amgen; Pfizer; Prostate Cancer UK","keywords":"Medicine; Prostate cancer; Lutetium; Oncology; Cancer; Nuclear medicine; Prostate; Cancer research; Internal medicine","score_opus":0.1693996611291912,"score_gpt":0.4659190459110379,"score_spread":0.2965193847818467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98866534,0.0025298728,0.000011443577,0.0055092988,0.00010387095,0.002489496,0.00012132321,0.000033908145,0.00053544325],"genre_scores_gemma":[0.9983009,0.0003218436,0.00030861192,0.00012071209,0.000053379656,0.00039511753,0.000037667633,0.00004414222,0.00041762678],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968222,0.0005764618,0.00077334314,0.00055128266,0.00071605423,0.00056065124],"domain_scores_gemma":[0.9983815,0.0003357925,0.00023561246,0.0002535685,0.00054654223,0.00024700342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020668795,0.00028867176,0.00089339213,0.00064350304,0.00007569858,0.00003698111,0.00010357566,0.00005046902,0.00007591497],"category_scores_gemma":[0.00034156945,0.0002174212,0.00009809826,0.00070330227,0.00022072787,0.00016467705,0.0000579955,0.0002468567,0.0000033341273],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6071837,0.001237583,0.0031366146,0.0010175536,0.0009220087,0.003943122,0.0053343647,0.00047968322,0.3431744,0.000021791906,0.00024872695,0.033300474],"study_design_scores_gemma":[0.58986735,0.08235638,0.052657764,0.007501961,0.0025024088,0.000981924,0.004299011,0.01517004,0.23977995,0.00033464708,0.0033012764,0.0012473039],"about_ca_topic_score_codex":0.00091349875,"about_ca_topic_score_gemma":0.0005595055,"teacher_disagreement_score":0.10339445,"about_ca_system_score_codex":0.0004898853,"about_ca_system_score_gemma":0.003033057,"threshold_uncertainty_score":0.88661796},"labels":[],"label_agreement":null},{"id":"W4402704938","doi":"10.1016/j.annonc.2024.08.1719","title":"1638P Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; University of British Columbia","funders":"Astellas Pharma; Pfizer","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Post-hoc analysis; Internal medicine; Cancer; Gynecology","score_opus":0.030439442080964475,"score_gpt":0.37673672785490003,"score_spread":0.34629728577393554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895913,0.004988506,0.00001383917,0.003106336,0.00008602417,0.0011805246,0.0005750607,0.000056870194,0.00040153356],"genre_scores_gemma":[0.9899846,0.006345313,0.000362849,0.00051698595,0.00006469738,0.00033845287,0.00062476704,0.00005613598,0.0017062288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732393,0.00015872126,0.00053114805,0.0007131931,0.0005862249,0.00068680523],"domain_scores_gemma":[0.99848,0.00014977097,0.00022224033,0.00037390794,0.00049237086,0.0002817126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036656164,0.00034768923,0.0010441116,0.00060038,0.00005762083,0.000032886608,0.0001762956,0.0001920081,0.000169363],"category_scores_gemma":[0.00006280763,0.00019918996,0.00013799517,0.0016018718,0.00054828177,0.00013256645,0.000075217344,0.000519327,0.000012023715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.073078476,0.002815467,0.7307641,0.0007777824,0.0062235417,0.0012170384,0.0026494234,0.000059137175,0.003185495,0.000023475885,0.013301825,0.16590427],"study_design_scores_gemma":[0.078281924,0.25603098,0.3767712,0.006165306,0.0120970905,0.00009588684,0.0019326329,0.0011025176,0.158484,0.00038720897,0.10579733,0.0028539165],"about_ca_topic_score_codex":0.0016536806,"about_ca_topic_score_gemma":0.0031347345,"teacher_disagreement_score":0.35399285,"about_ca_system_score_codex":0.0003598354,"about_ca_system_score_gemma":0.001146157,"threshold_uncertainty_score":0.8122731},"labels":[],"label_agreement":null},{"id":"W4402704946","doi":"10.1016/j.annonc.2024.08.1698","title":"1617P Multi-gene copy number variation risk-score for prediction of survival and therapy response outcome in treatment-naïve metastatic castrate resistant prostate cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"Merck Sharp and Dohme; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Cancer Australia; Genentech; AstraZeneca; National Health and Medical Research Council; Amgen; Pfizer; Astellas Pharma; Peter MacCallum Cancer Centre","keywords":"Medicine; Oncology; Prostate cancer; Internal medicine; Cancer","score_opus":0.24638739276222485,"score_gpt":0.4860402514209991,"score_spread":0.23965285865877425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98869765,0.005240407,0.00007870486,0.0023475345,0.00019740104,0.0014707127,0.0018957034,0.0000194547,0.000052441348],"genre_scores_gemma":[0.97874635,0.018619914,0.000869629,0.00003187468,0.000040076528,0.00040913705,0.0001166064,0.000024134128,0.0011422575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850696,0.00032647874,0.00047514393,0.00028194452,0.0001541197,0.0002553478],"domain_scores_gemma":[0.998817,0.00057899294,0.00016265603,0.00013815075,0.00022544796,0.00007774993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010354266,0.00015093174,0.00052477064,0.00019534428,0.0000368524,0.000009215461,0.00003477592,0.00009076461,0.00004205722],"category_scores_gemma":[0.00010045416,0.00010521366,0.000094089715,0.00023500399,0.00012608434,0.000081230915,0.00001211664,0.000105716244,0.000001172709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11303781,0.0016240182,0.67221403,0.00082893786,0.0020738272,0.00033789442,0.009267222,0.00007782806,0.120909475,0.00012426129,0.00037325095,0.07913147],"study_design_scores_gemma":[0.02123653,0.017441014,0.8759121,0.00025505034,0.00037946578,0.00002648403,0.0006192109,0.0024680689,0.07633776,0.0005280688,0.0046399445,0.0001563015],"about_ca_topic_score_codex":0.0013319372,"about_ca_topic_score_gemma":0.0003954348,"teacher_disagreement_score":0.20369808,"about_ca_system_score_codex":0.0001803391,"about_ca_system_score_gemma":0.0006951857,"threshold_uncertainty_score":0.42904884},"labels":[],"label_agreement":null},{"id":"W4402741886","doi":"10.1016/j.eururo.2024.09.003","title":"Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial","year":2024,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Oncology; Randomized controlled trial; Internal medicine; Castration; Prostate; Orchiectomy; Gynecology; Urology; Cancer; Hormone","score_opus":0.038508235026473915,"score_gpt":0.3445376374984897,"score_spread":0.30602940247201577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402741886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887482,0.0027017235,0.00037010512,0.0035461376,0.0001980669,0.0036182208,0.0006652255,0.00004376256,0.00010853933],"genre_scores_gemma":[0.9959452,0.00021488026,0.000586992,0.0004713035,0.00011019266,0.00059098133,0.0015028168,0.000033562897,0.0005440297],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982317,0.00042121398,0.0004676755,0.00040409976,0.00023824828,0.00023703772],"domain_scores_gemma":[0.9985394,0.0008237825,0.00012909596,0.0002280917,0.00018941249,0.000090247944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041505342,0.0001891528,0.00052987976,0.00015003358,0.00015539318,0.00010417645,0.000052565018,0.00001926652,0.000110839814],"category_scores_gemma":[0.00025061122,0.00009366898,0.00015630524,0.00027662885,0.00019813531,0.00007293327,0.00002769041,0.00013549728,0.00000559472],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9511102,0.0008160099,0.014691504,0.00005614127,0.015611309,0.0005482815,0.002473583,0.00009105831,0.00048406055,0.00008994814,0.000702505,0.013325438],"study_design_scores_gemma":[0.9452643,0.0043393825,0.031044133,0.000030257568,0.012708642,0.0000072633875,0.00007638959,0.0018628032,0.00010604545,0.00011231688,0.004243244,0.00020524664],"about_ca_topic_score_codex":0.00018166346,"about_ca_topic_score_gemma":0.00012237963,"teacher_disagreement_score":0.01635263,"about_ca_system_score_codex":0.0000357616,"about_ca_system_score_gemma":0.00020934865,"threshold_uncertainty_score":0.38197103},"labels":[],"label_agreement":null},{"id":"W4402757248","doi":"10.1016/j.ijrobp.2024.03.038","title":"A Wolf in Sheep's Clothing?","year":2024,"lang":"en","type":"editorial","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus; Kelowna General Hospital","funders":"","keywords":"Clothing; Geography; Archaeology","score_opus":0.020255948238512612,"score_gpt":0.38339886113165283,"score_spread":0.3631429128931402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402757248","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009609623,0.008767094,0.00040449054,0.007074307,0.97017497,0.00050060987,0.00039916512,0.00006918107,0.0030005611],"genre_scores_gemma":[0.033109397,0.011383936,0.0008057558,0.000470994,0.95098686,0.000045617955,0.0011706969,0.00011643865,0.0019102809],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970461,0.00022607346,0.0010826052,0.0004027837,0.000869785,0.000372621],"domain_scores_gemma":[0.9963786,0.0010395224,0.00087972643,0.00019589579,0.0013237871,0.00018246072],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0010134809,0.0003478979,0.000935461,0.0006415312,0.00004087997,0.00007265574,0.0005624593,0.0011540131,0.00012477057],"category_scores_gemma":[0.0010604594,0.0002783067,0.00043606578,0.00030352373,0.00022101137,0.00022071083,0.00013743197,0.0028137867,0.00014190827],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015744742,0.0006165641,0.012473703,0.00009339122,0.0016998616,0.0011550146,0.0007062861,0.000055348177,0.00037075512,0.0010942421,0.8946832,0.08547715],"study_design_scores_gemma":[0.0072108945,0.0015525898,0.00047033193,0.0005763639,0.00025888052,0.00009744763,0.000050477374,0.00032906723,0.00024814476,0.008860679,0.9801231,0.00022203597],"about_ca_topic_score_codex":0.00006210918,"about_ca_topic_score_gemma":0.000015337306,"teacher_disagreement_score":0.085439876,"about_ca_system_score_codex":0.0035048027,"about_ca_system_score_gemma":0.004204302,"threshold_uncertainty_score":0.9999669},"labels":[],"label_agreement":null},{"id":"W4402885818","doi":"10.2967/jnumed.124.267877","title":"Association of Free-to-Total PSA Ratio and<sup>18</sup>F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study","year":2024,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Fundação para a Ciência e a Tecnologia","keywords":"Glutamate carboxypeptidase II; Prostatectomy; Biochemical recurrence; Prostate-specific antigen; Medicine; Urology; Single Center; Prostate; Prospective cohort study; Nuclear medicine; Internal medicine; Cancer","score_opus":0.01251509008330144,"score_gpt":0.2670180060825025,"score_spread":0.25450291599920105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402885818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934412,0.00069876417,0.0000030045512,0.0035761695,0.00013816002,0.00199734,0.000036444326,0.000020689678,0.00008821868],"genre_scores_gemma":[0.9990748,0.00021838429,0.00019733752,0.00007989965,0.00018801361,0.000027348095,0.000016138902,0.000047808666,0.00015028099],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714535,0.00010846906,0.0007375874,0.00037420672,0.0012626174,0.00037175464],"domain_scores_gemma":[0.9987092,0.00012407925,0.00019992585,0.00019319249,0.00048538262,0.0002882289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000771629,0.0002509236,0.0007051849,0.00057727186,0.000045705907,0.000045614717,0.00012243344,0.000036746627,0.00022784313],"category_scores_gemma":[0.00034337505,0.00015447062,0.000073507894,0.0007420286,0.00021045182,0.00024395094,0.00008088892,0.0007013547,0.0000069681682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016437825,0.0031507632,0.950762,0.00044866645,0.00064469146,0.0027978602,0.010714232,0.0000043546474,0.0060989587,0.0000060685074,0.007813965,0.0011206279],"study_design_scores_gemma":[0.039174154,0.028143903,0.916803,0.0071426323,0.00036791965,0.0006657241,0.0025536562,0.00024027326,0.0019417552,0.000038538074,0.0025879233,0.00034054206],"about_ca_topic_score_codex":0.0000118189655,"about_ca_topic_score_gemma":0.0000025661463,"teacher_disagreement_score":0.03395901,"about_ca_system_score_codex":0.0007289316,"about_ca_system_score_gemma":0.00016903479,"threshold_uncertainty_score":0.6299129},"labels":[],"label_agreement":null},{"id":"W4402885837","doi":"10.2967/jnumed.124.268020","title":"Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study","year":2024,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke; Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"","keywords":"Cohort; Pet imaging; Correlation; Medicine; Nuclear medicine; Medical physics; Positron emission tomography; Internal medicine; Mathematics","score_opus":0.01606083640714754,"score_gpt":0.3335210770440191,"score_spread":0.31746024063687156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402885837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908076,0.0008633035,0.000025609845,0.0065284376,0.0007015095,0.0009408949,0.000005797918,0.000011336063,0.00011549211],"genre_scores_gemma":[0.9989723,0.0002976007,0.000040207073,0.00043943914,0.00011456421,0.000008117389,0.000008781298,0.000027647498,0.00009135156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998264,0.00016397872,0.0005599983,0.00018601563,0.0006298193,0.00019614732],"domain_scores_gemma":[0.9992265,0.00016363845,0.00011847476,0.00013290632,0.00016502902,0.0001934456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011049175,0.00014324179,0.00038664226,0.00031666819,0.00005380391,0.000035863424,0.000092524366,0.000018148043,0.00007596994],"category_scores_gemma":[0.00025917156,0.00007556736,0.00005083498,0.00029257004,0.00010155785,0.00013135682,0.00004965955,0.00036443834,0.0000068338454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001338157,0.0005901772,0.94234985,0.00009630745,0.0002605264,0.00067290146,0.007099686,0.0000054465827,0.0020143557,0.000002662567,0.014921553,0.030648379],"study_design_scores_gemma":[0.006566686,0.0046160906,0.97688985,0.0008088239,0.00037344673,0.00018580774,0.0029833075,0.0028311666,0.000041041152,0.000015033814,0.0045868354,0.00010189017],"about_ca_topic_score_codex":0.00005994642,"about_ca_topic_score_gemma":0.000021149517,"teacher_disagreement_score":0.034540024,"about_ca_system_score_codex":0.00021540311,"about_ca_system_score_gemma":0.000046922134,"threshold_uncertainty_score":0.30815476},"labels":[],"label_agreement":null},{"id":"W4402906432","doi":"10.1016/j.ijrobp.2024.07.023","title":"Patient-Reported Functional Decline Following Active Surveillance (AS), Radical Prostatectomy (RP), External Beam Radiation without Androgen Deprivation Therapy (EBRT w/o ADT), or Low-Dose-Rate Brachytherapy (LDR-BR) for Favorable-Risk Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Androgen deprivation therapy; External beam radiation; Brachytherapy; Urology; Prostatectomy; Medicine; Prostate cancer; External beam radiotherapy; Radiation therapy; Nuclear medicine; Internal medicine; Cancer","score_opus":0.02742524049999932,"score_gpt":0.36650777756632663,"score_spread":0.3390825370663273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402906432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97261655,0.0062604398,0.011836299,0.0027958504,0.003993839,0.0019244353,0.000413178,0.00011839112,0.000041027695],"genre_scores_gemma":[0.9780771,0.015204961,0.0012118607,0.00086391426,0.0028981953,0.0004100092,0.00097556337,0.00009903269,0.0002593275],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964245,0.00037274367,0.0013320934,0.00061725214,0.00074148446,0.00051194115],"domain_scores_gemma":[0.99578935,0.0009767071,0.001399511,0.00020727828,0.0013652494,0.00026189614],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012929363,0.00042788245,0.0007567941,0.0003952057,0.00024653831,0.00014475593,0.00025701395,0.00033201036,0.00014213852],"category_scores_gemma":[0.0006201676,0.0003160239,0.0005021607,0.00047997068,0.00021086643,0.00075959036,0.000053575237,0.00078033074,0.000015412441],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022221323,0.0006927594,0.42884198,0.000044706,0.0037992403,0.00019875256,0.00093857676,0.0013152421,0.032556478,0.00018971832,0.00059895,0.50860226],"study_design_scores_gemma":[0.123644784,0.020825092,0.41387856,0.0017339408,0.0012865397,0.0016374044,0.0005033702,0.043340657,0.21452683,0.025205644,0.1514425,0.001974682],"about_ca_topic_score_codex":0.000097288495,"about_ca_topic_score_gemma":0.000018056802,"teacher_disagreement_score":0.5066276,"about_ca_system_score_codex":0.0017583213,"about_ca_system_score_gemma":0.003359982,"threshold_uncertainty_score":0.9999292},"labels":[],"label_agreement":null},{"id":"W4402907077","doi":"10.1016/j.ijrobp.2024.07.1252","title":"Biochemical Recurrence is Not a Surrogate for Overall Survival in Localized Prostate Cancer: Data from 2 Phase III Trials","year":2024,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Capital District Health Authority; Centre de Santé et de Services Sociaux de Chicoutimi; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Jewish General Hospital; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Hospitalier de l’Université de Montréal; Université Laval; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Prostate cancer; Surrogate endpoint; Oncology; Biochemical recurrence; Prostate; Cancer; Medicine; Clinical trial; Internal medicine; Overall survival; Urology; Prostatectomy","score_opus":0.1263104900649967,"score_gpt":0.4745134765161035,"score_spread":0.3482029864511068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402907077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92862725,0.015626531,0.0077800313,0.028701043,0.008304776,0.0013719024,0.009419482,0.000054879984,0.000114114344],"genre_scores_gemma":[0.97214,0.017492212,0.0015123961,0.000877109,0.004751164,0.00009567711,0.0029037762,0.00003881061,0.00018882842],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975724,0.00029493443,0.0010745703,0.0004219613,0.00035523283,0.00028085377],"domain_scores_gemma":[0.9969549,0.0015778049,0.0005571684,0.00021483793,0.00054975547,0.0001454996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018137319,0.00020232334,0.00082771777,0.00020454661,0.000036747122,0.000059764276,0.0004879205,0.00020959257,0.00018791041],"category_scores_gemma":[0.00077304355,0.00015376727,0.00023664988,0.00019193048,0.00016831518,0.00033348097,0.0001134681,0.0005040478,0.000013427648],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042716045,0.002265861,0.049296696,0.00012746808,0.004953538,0.00041750274,0.002209635,0.00009729976,0.061759982,0.002737764,0.049940404,0.7834778],"study_design_scores_gemma":[0.16447672,0.0043637245,0.0022789084,0.0018098548,0.001170957,0.00010095547,0.00020929282,0.08428806,0.07862996,0.028810443,0.6331665,0.0006946277],"about_ca_topic_score_codex":0.00019108578,"about_ca_topic_score_gemma":0.000016970762,"teacher_disagreement_score":0.78278315,"about_ca_system_score_codex":0.00093302224,"about_ca_system_score_gemma":0.0018498533,"threshold_uncertainty_score":0.62704474},"labels":[],"label_agreement":null},{"id":"W4402907203","doi":"10.1016/j.ijrobp.2024.07.1253","title":"Quality of Life and Weight Variation during Androgen Deprivation Therapy in Patients with High-Risk Prostate Cancer: Long-Term Data from a Phase III Trial","year":2024,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Jewish General Hospital; Centre de Santé et de Services Sociaux de Chicoutimi; Centre Hospitalier de l’Université de Montréal; Université Laval; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Androgen deprivation therapy; Prostate cancer; Quality of life (healthcare); Oncology; Term (time); Medicine; Androgen; Internal medicine; Cancer; Hormone","score_opus":0.04041542188378534,"score_gpt":0.3853712934887312,"score_spread":0.3449558716049459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402907203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940604,0.0019931903,0.00085513043,0.0008004745,0.00084364903,0.00063316466,0.0007929007,0.000014852513,0.0000062275817],"genre_scores_gemma":[0.99001265,0.007274091,0.00031540022,0.00005246212,0.0009846214,0.000022785693,0.0013113999,0.000017731794,0.000008842465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823797,0.00023792872,0.0007664888,0.0002748721,0.00034388385,0.00013887504],"domain_scores_gemma":[0.9981492,0.00035109866,0.0008073236,0.00016617912,0.0004398644,0.00008630167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000561418,0.00014033515,0.00042586404,0.00019544915,0.000040432624,0.000030709347,0.00020021723,0.00012228226,0.000046515393],"category_scores_gemma":[0.00018362219,0.000100652265,0.00005456619,0.00017812227,0.00010401482,0.00046202587,0.00006094022,0.00031650945,0.000001270542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06040089,0.00084116036,0.8257661,0.000019549021,0.0011156797,0.000014748948,0.0005942914,0.00004025768,0.0012958304,0.00009863137,0.000026254493,0.109786615],"study_design_scores_gemma":[0.16412598,0.002093383,0.8305241,0.00012692223,0.000093232986,0.00000266789,0.000012384725,0.00070693507,0.0011769732,0.0009033455,0.00013864446,0.00009545831],"about_ca_topic_score_codex":0.00030918152,"about_ca_topic_score_gemma":0.000041368225,"teacher_disagreement_score":0.10969116,"about_ca_system_score_codex":0.0004645054,"about_ca_system_score_gemma":0.00076990365,"threshold_uncertainty_score":0.41044804},"labels":[],"label_agreement":null},{"id":"W4402907250","doi":"10.1016/j.ijrobp.2024.07.1248","title":"A Randomized Phase II Trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) Brachytherapy as Monotherapy in Localized Prostate Cancer: Analysis of Initial Arms of Canadian Cancer Trials Group PR19 (NCT02960087)","year":2024,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; University of British Columbia, Okanagan Campus; University of British Columbia; Princess Margaret Cancer Centre; University Health Network; Université Laval; University of Calgary; McGill University; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Brachytherapy; Prostate cancer; Cancer; Medicine; Randomized controlled trial; Dose rate; Oncology; Prostate; Nuclear medicine; Internal medicine; Urology; Radiation therapy; Medical physics","score_opus":0.04219455877582974,"score_gpt":0.42934789258580064,"score_spread":0.3871533338099709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402907250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832615,0.007073995,0.00031419608,0.0053385887,0.0014732006,0.0016153483,0.00085586746,0.000012276503,0.000054996064],"genre_scores_gemma":[0.95337725,0.044666223,0.00022269177,0.00031712785,0.0008647707,0.00017905682,0.0002691431,0.00003286428,0.00007089485],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99535775,0.0014101114,0.0021921787,0.00033753208,0.0003885788,0.00031382512],"domain_scores_gemma":[0.99522686,0.001596224,0.0019331182,0.00015733481,0.0008732057,0.0002132422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038594867,0.000289441,0.0025405108,0.0020655098,0.000047054127,0.000027723105,0.00024301167,0.00027592052,0.00024460646],"category_scores_gemma":[0.00049666583,0.00020932664,0.00066777976,0.0013132174,0.0005334885,0.00025393337,0.000029477515,0.00044420038,8.5797274e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7347658,0.0016129195,0.006641186,0.000095742216,0.018523429,0.00014256754,0.0040780823,0.002068911,0.024976097,0.0024355405,0.00016703861,0.20449267],"study_design_scores_gemma":[0.94426227,0.007921988,0.0019053909,0.000517862,0.0026971488,0.000018453451,0.00014354482,0.014527938,0.018035844,0.0069623757,0.0027468675,0.0002603416],"about_ca_topic_score_codex":0.028179092,"about_ca_topic_score_gemma":0.0049143364,"teacher_disagreement_score":0.20949644,"about_ca_system_score_codex":0.0008736025,"about_ca_system_score_gemma":0.0037478984,"threshold_uncertainty_score":0.97829235},"labels":[],"label_agreement":null},{"id":"W4402907342","doi":"10.1016/j.ijrobp.2024.07.1273","title":"PSMA MRI Guided Prostate SBRT: Acute Toxicity and Early Results from the ARGOS-Climber Phase I/II Trial","year":2024,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Western University; Sunnybrook Health Science Centre; St. Joseph's Hospital; London Health Sciences Centre","funders":"","keywords":"Toxicity; Medicine; Prostate cancer; Acute toxicity; Oncology; Internal medicine","score_opus":0.04175381891187565,"score_gpt":0.4030814183298109,"score_spread":0.3613275994179353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402907342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96186775,0.0017834159,0.0007841382,0.030467344,0.0031464205,0.00060088333,0.0006274227,0.000043222186,0.00067938794],"genre_scores_gemma":[0.9883546,0.0035666453,0.00072438,0.0008838457,0.005294283,0.00002672354,0.00030214695,0.000028550096,0.00081883173],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980342,0.00022274353,0.00080086547,0.00030981808,0.00038202794,0.00025034737],"domain_scores_gemma":[0.9978837,0.0007853405,0.00046741377,0.00016974805,0.0005401545,0.00015368122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008319382,0.0001989861,0.00042539815,0.00012320676,0.00014234155,0.00009623262,0.00027593755,0.00019434665,0.00005271259],"category_scores_gemma":[0.00032435174,0.00012348693,0.00022239411,0.00017874957,0.00028722384,0.000300205,0.000109314606,0.00065083214,0.00003245665],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18817317,0.004987347,0.037563756,0.000032639455,0.012275932,0.001826159,0.012944691,0.00009298082,0.041282967,0.008737334,0.09359587,0.59848714],"study_design_scores_gemma":[0.4308266,0.029365499,0.015062236,0.00053178973,0.0016454807,0.0007902029,0.00025193236,0.0054146177,0.023018686,0.04289854,0.44958833,0.0006060564],"about_ca_topic_score_codex":0.000052732492,"about_ca_topic_score_gemma":0.000005031929,"teacher_disagreement_score":0.5978811,"about_ca_system_score_codex":0.0005626407,"about_ca_system_score_gemma":0.0007986534,"threshold_uncertainty_score":0.5035651},"labels":[],"label_agreement":null},{"id":"W4402907433","doi":"10.1016/j.ijrobp.2024.07.1209","title":"PSMAddition: Phase 3 Trial of [177lu]Lu-PSMA-617 Plus Standard of Care (SoC) vs. Soc Alone in Patients with Metastatic Hormone-Sensitive Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Standard of care; Oncology; Internal medicine; Cancer","score_opus":0.021402124891671002,"score_gpt":0.37115576807336564,"score_spread":0.34975364318169466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402907433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911454,0.0024131865,0.0005924035,0.0017666611,0.0011551575,0.00091429753,0.0018543042,0.000015708278,0.00014291063],"genre_scores_gemma":[0.9957124,0.0020690833,0.00066058355,0.00009571151,0.0006533614,0.000045461275,0.00068881334,0.00002910957,0.000045450055],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99788773,0.00020276867,0.0008351262,0.00023706736,0.0006088077,0.00022850919],"domain_scores_gemma":[0.99686474,0.0003023206,0.00076530175,0.00011404496,0.0018470681,0.00010652659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037376047,0.00020273145,0.00083271356,0.00034651248,0.000035835714,0.000017984185,0.00015729951,0.00012056677,0.00005502189],"category_scores_gemma":[0.00011625367,0.00014800699,0.00019959251,0.0003143967,0.00031870688,0.00027692548,0.000038533177,0.0004452192,0.0000031577842],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57311916,0.0033907557,0.069459476,0.0003681322,0.0063082725,0.00061201915,0.012820687,0.0012117374,0.0027369144,0.0017801239,0.0030677132,0.32512504],"study_design_scores_gemma":[0.79841536,0.09651512,0.043431878,0.0022221473,0.0019979367,0.00010761759,0.0031241619,0.001958598,0.036300838,0.004016073,0.011199485,0.00071080384],"about_ca_topic_score_codex":0.000054644333,"about_ca_topic_score_gemma":0.000023993724,"teacher_disagreement_score":0.32441422,"about_ca_system_score_codex":0.0016967597,"about_ca_system_score_gemma":0.002335759,"threshold_uncertainty_score":0.603555},"labels":[],"label_agreement":null},{"id":"W4402945549","doi":"10.1016/j.ijrobp.2024.07.243","title":"Examination of Decipher Prostate Genomic Classifier in Patients with De Novo Metastatic Disease from a Large Scale Real-World Clinical and Transcriptomic Data Linkage","year":2024,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"ECOG-ACRIN Cancer Research Group; American College of Radiology Imaging Network","keywords":"DECIPHER; Transcriptome; Prostate cancer; Classifier (UML); Computational biology; Disease; Linkage (software); Biology; Medicine; Bioinformatics; Pathology; Computer science; Genetics; Artificial intelligence; Cancer; Gene; Gene expression","score_opus":0.04808952624135667,"score_gpt":0.39267029314152435,"score_spread":0.3445807669001677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402945549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943916,0.0009487889,0.0018512816,0.0010321026,0.0004877572,0.00035939497,0.0008271225,0.000012190073,0.000089764755],"genre_scores_gemma":[0.994648,0.0016549885,0.002133748,0.00015595635,0.0003957705,0.00001034344,0.0008965501,0.000023964518,0.00008071455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982892,0.00030786043,0.00068307493,0.00028083374,0.00025453503,0.00018449598],"domain_scores_gemma":[0.99865013,0.00041326167,0.00031124012,0.00017095031,0.0003004402,0.00015398896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009175248,0.00013489358,0.00039292255,0.00023662185,0.0000240248,0.000026360762,0.00022471827,0.000072236566,0.00004059841],"category_scores_gemma":[0.00010288396,0.0000992413,0.00007864546,0.0001748259,0.0002172053,0.00032167067,0.000060722963,0.00040639687,0.0000042179713],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022483645,0.000796637,0.935951,0.000034642093,0.0006084081,0.000117978016,0.00065368484,0.00002423947,0.00031270765,0.00032314193,0.00011073505,0.058818497],"study_design_scores_gemma":[0.01138799,0.0007481505,0.9764288,0.00023152767,0.0003066634,0.00000780734,0.00006741469,0.0072222226,0.00009693427,0.0016490672,0.0017639217,0.00008947025],"about_ca_topic_score_codex":0.00003263827,"about_ca_topic_score_gemma":0.000084746345,"teacher_disagreement_score":0.058729026,"about_ca_system_score_codex":0.00045336498,"about_ca_system_score_gemma":0.0009446414,"threshold_uncertainty_score":0.40469426},"labels":[],"label_agreement":null},{"id":"W4402968553","doi":"10.1172/jci178604","title":"Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Movember Foundation; National Cancer Institute; Stand Up To Cancer; Prostate Cancer Foundation","keywords":"Prostate cancer; Androgen receptor; Transcriptome; Cancer research; Medicine; Receptor; Castration; Biology; Bioinformatics; Oncology; Internal medicine; Cancer; Genetics; Gene; Hormone; Gene expression","score_opus":0.08180279273391518,"score_gpt":0.39974987060513373,"score_spread":0.31794707787121856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402968553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96556747,0.029449197,0.000009624812,0.0042651277,0.00029892716,0.00032777627,0.000033463017,0.000007012403,0.00004141475],"genre_scores_gemma":[0.9923495,0.0038006173,0.0030099421,0.000088788285,0.0002551642,0.000011145893,0.000011866469,0.000016986942,0.0004560112],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99794227,0.00017397945,0.001233459,0.00017890117,0.00032747476,0.00014394609],"domain_scores_gemma":[0.9988846,0.0003286705,0.00031677552,0.000075668286,0.00020840722,0.00018583515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014210021,0.0001124751,0.0004812773,0.00021919615,0.000027638536,0.000040536983,0.000049624232,0.00007396973,0.000024410207],"category_scores_gemma":[0.0002630636,0.00007937479,0.00013278582,0.00027006285,0.00023332094,0.00020785678,0.000007928179,0.00043983568,0.0000010371473],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005798401,0.0001843243,0.07913361,0.0020317778,0.0005859943,0.00028818194,0.0035573295,0.00006631727,0.89378864,0.00040305965,0.0026116536,0.01155075],"study_design_scores_gemma":[0.016077138,0.0036455004,0.5834237,0.015216304,0.001378135,0.0001239194,0.0013403283,0.0006058619,0.35778117,0.012836883,0.007079711,0.0004913978],"about_ca_topic_score_codex":0.000040427938,"about_ca_topic_score_gemma":0.00013051544,"teacher_disagreement_score":0.53600746,"about_ca_system_score_codex":0.00011422352,"about_ca_system_score_gemma":0.0012021994,"threshold_uncertainty_score":0.323681},"labels":[],"label_agreement":null},{"id":"W4402986892","doi":"10.1200/op.2024.20.10_suppl.399","title":"US real-world utilization and outcomes of darolutamide, enzalutamide, and apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): DEAR-EXT study.","year":2024,"lang":"en","type":"article","venue":"JCO Oncology Practice","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"","keywords":"Enzalutamide; Prostate cancer; Medicine; Oncology; Internal medicine; Cancer; Androgen receptor","score_opus":0.07738946556382287,"score_gpt":0.4619376274253936,"score_spread":0.38454816186157076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402986892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97737324,0.0075711585,0.00007646018,0.008149787,0.00031608052,0.00377726,0.00018754121,0.000077708435,0.0024707448],"genre_scores_gemma":[0.9833084,0.00712068,0.0028461684,0.0003521704,0.000082659426,0.00069742,0.00006300365,0.00005149217,0.00547806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979125,0.00026267322,0.0005606573,0.0005412157,0.0003566841,0.00036626533],"domain_scores_gemma":[0.9966702,0.0023431147,0.0002376907,0.00023965484,0.00033696933,0.00017240124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010851133,0.0002483204,0.00062007696,0.00033647355,0.00017066569,0.00007770711,0.00006375678,0.000101901926,0.000047156627],"category_scores_gemma":[0.00068598246,0.00018916083,0.0000637914,0.0004371342,0.00025811928,0.00048589372,0.000073883384,0.0002942386,0.000004531865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017890615,0.0035769849,0.68939024,0.004094591,0.005359274,0.0016557142,0.013238149,0.000073956246,0.016772123,0.0035092023,0.0028780762,0.24156107],"study_design_scores_gemma":[0.012073075,0.007840842,0.8473822,0.0003724643,0.0044851066,0.0001913471,0.0072986824,0.0031243542,0.0017488463,0.0006199713,0.11441628,0.00044685145],"about_ca_topic_score_codex":0.0018507633,"about_ca_topic_score_gemma":0.003616682,"teacher_disagreement_score":0.24111423,"about_ca_system_score_codex":0.00036738475,"about_ca_system_score_gemma":0.00096437347,"threshold_uncertainty_score":0.7713755},"labels":[],"label_agreement":null},{"id":"W4402991972","doi":"10.3390/cancers16193336","title":"Drug Interactions between Androgen Receptor Axis-Targeted Therapies and Antithrombotic Therapies in Prostate Cancer: Delphi Consensus","year":2024,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada); Moncton Hospital; Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network; Ottawa Hospital; Regional Municipality of Durham; University of Ottawa; McMaster University; University of Toronto; St. John’s Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Population Health Research Institute; Dalhousie University; Hamilton Health Sciences; Memorial University of Newfoundland","funders":"Bayer Canada","keywords":"Medicine; Antithrombotic; Enzalutamide; Drug; Drug class; Intensive care medicine; Prostate cancer; Pharmacology; Cancer; Internal medicine; Androgen receptor","score_opus":0.03391202796129243,"score_gpt":0.344313592045964,"score_spread":0.31040156408467157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402991972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87156075,0.11850172,0.0000017493197,0.008214319,0.00043178495,0.0006859654,0.00017987475,0.00011360819,0.00031023173],"genre_scores_gemma":[0.9610674,0.035491146,0.00012118877,0.00011715184,0.00020006581,0.00020332876,0.00006608962,0.0000434488,0.0026902219],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987382,0.000061581646,0.00023721551,0.0003901442,0.00019599765,0.00037683733],"domain_scores_gemma":[0.99942875,0.00014809376,0.000037197886,0.00016220864,0.00007620146,0.00014753263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015532186,0.00020642148,0.0003480085,0.0002627416,0.000103729595,0.00007697403,0.00006076081,0.000038656446,0.0003442145],"category_scores_gemma":[0.000016152768,0.0001549464,0.00006521316,0.00045919936,0.00030662338,0.00011643366,0.000028151602,0.00032440902,0.000020967462],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011885319,0.00006151178,0.7877195,0.0012315662,0.0026256214,0.00040114668,0.042097025,0.000085386106,0.018820442,0.00013336889,0.025601886,0.120034054],"study_design_scores_gemma":[0.018243575,0.0016151606,0.28336346,0.010503277,0.001191504,0.00026324924,0.041374963,0.0039282725,0.052944053,0.0018967385,0.5824068,0.0022689549],"about_ca_topic_score_codex":0.0025741395,"about_ca_topic_score_gemma":0.00092382036,"teacher_disagreement_score":0.5568049,"about_ca_system_score_codex":0.0011562671,"about_ca_system_score_gemma":0.0009883079,"threshold_uncertainty_score":0.6318531},"labels":[],"label_agreement":null},{"id":"W4403047214","doi":"10.1093/jnci/djae200","title":"When is prostate cancer really cancer?","year":2024,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University of Texas Health Science Center at San Antonio; University of Oxford; National Cancer Institute; University of Toronto; University College London; University of California, San Francisco; Vanderbilt University Medical Center; Vanderbilt University; Moffitt Cancer Center; York University; Prostate Cancer Foundation; Movember Foundation; University of Pittsburgh; Imperial College London; University of Washington; University of California, Davis; Harvard University; Fred Hutchinson Cancer Research Center; Northwestern University; Memorial Sloan-Kettering Cancer Center; Peter MacCallum Cancer Centre; Washington University in St. Louis","keywords":"Medicine; Malignancy; Cancer; Prostate cancer; Disease; Medical diagnosis; Biopsy; Autopsy; Intensive care medicine; Internal medicine; Oncology; Pathology","score_opus":0.0762406372329153,"score_gpt":0.41391055435897844,"score_spread":0.33766991712606315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403047214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.513183,0.11875177,0.00004222775,0.33778292,0.017691035,0.0014023228,0.0014108428,0.000083631654,0.009652277],"genre_scores_gemma":[0.9037926,0.033764903,0.00033382975,0.0069763083,0.0072392994,0.0002611014,0.000014292065,0.000062613166,0.04755501],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975034,0.000033042186,0.00044621178,0.0002146626,0.0015215849,0.00028111943],"domain_scores_gemma":[0.9982535,0.000043309257,0.00020311677,0.00011856095,0.0012088001,0.00017266546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003806522,0.0001802339,0.00028809515,0.00023817921,0.00016940455,0.00009628435,0.00028440324,0.000081276376,0.00080834783],"category_scores_gemma":[0.00006995185,0.00010104484,0.00027937588,0.00048110756,0.00019027536,0.0004637317,0.00006872661,0.00059915433,0.000015573249],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021154133,0.00020193987,0.025862196,0.0009228113,0.00291535,0.00033487406,0.004581701,0.0016603719,0.013236346,0.0013513227,0.84262854,0.104189135],"study_design_scores_gemma":[0.0024289235,0.00017052556,0.013678658,0.0027295535,0.00043213836,0.0002561072,0.000038218877,0.00052864273,0.014036633,0.004851779,0.96065205,0.00019674117],"about_ca_topic_score_codex":0.0008355017,"about_ca_topic_score_gemma":0.0003816529,"teacher_disagreement_score":0.39060965,"about_ca_system_score_codex":0.0020886352,"about_ca_system_score_gemma":0.0064861123,"threshold_uncertainty_score":0.99914616},"labels":[],"label_agreement":null},{"id":"W4403049869","doi":"10.52843/cassyni.b3jrfx","title":"Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Institutes of Health; Prostate Cancer Foundation","keywords":"Prostate cancer; Cancer research; Medicine; Neuroendocrine tumors; Cancer; Internal medicine","score_opus":0.022490783990712786,"score_gpt":0.3253854478165219,"score_spread":0.3028946638258091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403049869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.904545,0.08609959,0.0000036992456,0.0046382933,0.0002810572,0.0012037056,0.000052242256,0.00006390726,0.0031125003],"genre_scores_gemma":[0.9630426,0.025825527,0.0004498253,0.0001771704,0.000072771254,0.00021615245,0.000065705484,0.00007030977,0.010079913],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984073,0.000049012666,0.0004118718,0.00053878024,0.00018805049,0.00040498417],"domain_scores_gemma":[0.99940854,0.00004964489,0.00009079373,0.00027069714,0.00009385146,0.00008646145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016051432,0.00028380053,0.00050447386,0.00033546853,0.000024087885,0.000045738656,0.000098627446,0.000028277815,0.00017256895],"category_scores_gemma":[0.00001154839,0.0002088404,0.00009603238,0.00018551567,0.000111019355,0.000022516931,0.0006915496,0.000889934,0.0000061314804],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031858203,0.0010514597,0.6011152,0.045704044,0.0011471596,0.014449916,0.0064986185,0.00025640245,0.22660764,0.00018902836,0.0018306045,0.0979641],"study_design_scores_gemma":[0.050435822,0.0020093378,0.10882315,0.033922795,0.0037689805,0.0018080993,0.008227842,0.074832015,0.67457163,0.021982942,0.015218345,0.004399029],"about_ca_topic_score_codex":0.0025927804,"about_ca_topic_score_gemma":0.00009272493,"teacher_disagreement_score":0.49229205,"about_ca_system_score_codex":0.00016064657,"about_ca_system_score_gemma":0.00047288527,"threshold_uncertainty_score":0.85162646},"labels":[],"label_agreement":null},{"id":"W4403091795","doi":"10.1038/s41420-024-02152-7","title":"TRIB3 inhibition by palbociclib sensitizes prostate cancer to ferroptosis via downregulating SOX2/SLC7A11 expression","year":2024,"lang":"en","type":"article","venue":"Cell Death Discovery","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China","keywords":"Palbociclib; Prostate cancer; SOX2; Cancer; Cancer research; Apoptosis; Prostate; Medicine; Internal medicine; Chemistry; Gene; Embryonic stem cell","score_opus":0.016978739249240864,"score_gpt":0.3053688328334792,"score_spread":0.28839009358423834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403091795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842067,0.008522722,0.0006985676,0.0024145658,0.00035882916,0.0010438559,0.00026207732,0.00019906148,0.0022936333],"genre_scores_gemma":[0.96394444,0.0013063152,0.00026801656,0.00041462382,0.0003165489,0.00027339553,0.00047177583,0.00007305487,0.032931816],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99800086,0.000059355523,0.00030050403,0.00061324245,0.0004732003,0.0005528467],"domain_scores_gemma":[0.9992396,0.00008195527,0.00004515845,0.00027602268,0.0000782027,0.0002790083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016364196,0.00028448435,0.0003248803,0.00017914057,0.00019354152,0.00024643884,0.000054796077,0.000118133365,0.00018124028],"category_scores_gemma":[0.000017599801,0.00020598393,0.00016003847,0.0003841867,0.00006124529,0.00045898583,0.00010961649,0.00026895152,0.00011457902],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068608986,0.00014660702,0.0036791225,0.0007338178,0.0000680581,0.0002607562,0.0012289374,0.000057705733,0.9503605,0.000014426676,0.032766677,0.009997335],"study_design_scores_gemma":[0.0016737265,0.00032500853,0.0017037927,0.0017766437,0.00013797925,0.000017179782,0.0003619977,0.00062571914,0.9861724,0.00014626843,0.0067453687,0.00031394887],"about_ca_topic_score_codex":0.00021064244,"about_ca_topic_score_gemma":0.000008323887,"teacher_disagreement_score":0.0358119,"about_ca_system_score_codex":0.00036848403,"about_ca_system_score_gemma":0.00022493111,"threshold_uncertainty_score":0.8399781},"labels":[],"label_agreement":null},{"id":"W4403116752","doi":"10.1016/j.ccl.2024.09.003","title":"Cardiovascular Risk in Prostate Cancer","year":2024,"lang":"en","type":"review","venue":"Cardiology Clinics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Oncology; Cancer","score_opus":0.09942773193954904,"score_gpt":0.4563563592740563,"score_spread":0.35692862733450725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403116752","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007168222,0.99353147,0.000002170642,0.00006276052,0.0018872063,0.002267573,0.0004883263,0.00009270401,0.001596098],"genre_scores_gemma":[0.000022413713,0.9930483,0.00002789127,0.000034404995,0.0011920949,0.0013558798,0.00039799817,0.00013143112,0.0037895818],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965197,0.0006329072,0.00089278957,0.0010081121,0.00029583895,0.00065068534],"domain_scores_gemma":[0.99828166,0.00026981672,0.00015096567,0.000998857,0.00010766393,0.00019101419],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0014429002,0.0005424786,0.0050988114,0.00045137486,0.000047822417,0.000020072132,0.00020040636,0.0007939302,0.000024755005],"category_scores_gemma":[0.00023926467,0.0003453269,0.0034307586,0.0006769678,0.0002621563,0.000026605963,0.0001966818,0.0023700232,0.0005323983],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049632454,0.000020457646,0.0022346466,0.01890273,0.008523887,0.0040555736,0.00004268319,0.0000112831885,7.58863e-9,0.0000070929163,0.003789934,0.96236205],"study_design_scores_gemma":[0.00097518915,0.00015393527,0.000091486196,0.011100597,0.016264325,0.00025031806,0.000016946058,0.000005004583,7.6896576e-8,0.00007607982,0.9707807,0.00028538136],"about_ca_topic_score_codex":0.000059108563,"about_ca_topic_score_gemma":0.000007831063,"teacher_disagreement_score":0.9669907,"about_ca_system_score_codex":0.0006428967,"about_ca_system_score_gemma":0.0020270436,"threshold_uncertainty_score":0.9999316},"labels":[],"label_agreement":null},{"id":"W4403134216","doi":"10.1016/j.eclinm.2024.102862","title":"Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial","year":2024,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Medical Research Council; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Novartis","keywords":"Medicine; Multivariable calculus; Phase (matter)","score_opus":0.08934195670110737,"score_gpt":0.4776879771663681,"score_spread":0.3883460204652608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403134216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98431677,0.0017848229,0.0012287903,0.0076197037,0.0004867733,0.0012718721,0.00008640841,0.00005069905,0.003154138],"genre_scores_gemma":[0.99434465,0.0002880689,0.00041395883,0.00018223554,0.00017732594,0.000030753195,0.00006562219,0.00002108462,0.0044763065],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977337,0.000095360236,0.0007939514,0.00035209907,0.0007912173,0.00023368065],"domain_scores_gemma":[0.9978467,0.0010093768,0.00015701806,0.00065044034,0.00018617122,0.00015026056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096020004,0.00016997902,0.0010439218,0.00032539153,0.000041980788,0.000007743226,0.00016866495,0.00011038334,0.00039331915],"category_scores_gemma":[0.00039785446,0.000071486174,0.00042466636,0.0016090274,0.00043405296,0.000074508935,0.00007658362,0.00033838398,0.000004111947],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4873871,0.02443601,0.22488378,0.0037455428,0.076721,0.00095760875,0.006942847,0.003943035,0.020603271,0.005993526,0.024250282,0.120136],"study_design_scores_gemma":[0.57070327,0.03327199,0.05740587,0.0050681783,0.04025483,0.000020982905,0.0010740625,0.27203366,0.010026675,0.0019397066,0.0076098153,0.00059093785],"about_ca_topic_score_codex":0.0001628829,"about_ca_topic_score_gemma":0.000015106002,"teacher_disagreement_score":0.26809064,"about_ca_system_score_codex":0.000053830347,"about_ca_system_score_gemma":0.00038017955,"threshold_uncertainty_score":0.43065688},"labels":[],"label_agreement":null},{"id":"W4403195121","doi":"10.1038/s41391-024-00902-3","title":"Publisher Correction: Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis","year":2024,"lang":"en","type":"erratum","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Meta-analysis; Prostate cancer; Medicine; Androgen receptor; Oncology; Benign prostatic hyperplasia (BPH); Internal medicine; Urology; Cancer; Bioinformatics; Biology","score_opus":0.0332910402351508,"score_gpt":0.29902909023236957,"score_spread":0.2657380499972188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403195121","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00049176125,0.9781066,0.00002084592,0.0014709441,0.0008241704,0.014584104,0.0037601162,0.0002448255,0.0004965913],"genre_scores_gemma":[0.008448429,0.4346752,0.00018682104,0.00081360486,0.0007379105,0.059545126,0.012789722,0.0005899105,0.4822133],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9908341,0.00087223673,0.0017032196,0.0027037023,0.0025455838,0.0013411607],"domain_scores_gemma":[0.99463135,0.00025958847,0.0010893649,0.0014204046,0.0014242815,0.0011749947],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013010147,0.0018976628,0.01266195,0.00112435,0.00049208506,0.0008775699,0.00026855821,0.00033911222,0.0008291802],"category_scores_gemma":[0.00009615014,0.0010039323,0.005190656,0.0061693755,0.0005735816,0.00068958045,0.00019913835,0.0011388909,0.000006779127],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001035243,0.00012735599,0.01227799,0.13362569,0.7145512,0.0002930111,0.0004934493,0.00043510963,3.2993617e-7,6.335475e-7,0.13705938,0.00010057276],"study_design_scores_gemma":[0.0015437382,0.0006189757,0.00048144558,0.01367359,0.9762812,0.000029834659,0.000329578,0.00030426597,0.0000149963025,0.000033859356,0.005494674,0.0011938338],"about_ca_topic_score_codex":0.0032345145,"about_ca_topic_score_gemma":0.00088365714,"teacher_disagreement_score":0.54343146,"about_ca_system_score_codex":0.0005207967,"about_ca_system_score_gemma":0.0015935355,"threshold_uncertainty_score":0.9993767},"labels":[],"label_agreement":null},{"id":"W4403213466","doi":"10.1016/j.euo.2024.09.013","title":"Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Medicine; Abiraterone; Prostate cancer; Abiraterone acetate; Olaparib; Asymptomatic; Placebo; Internal medicine; Oncology; Urology; Cancer; Androgen deprivation therapy; Pathology","score_opus":0.06115839959823703,"score_gpt":0.3709653573860134,"score_spread":0.30980695778777634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403213466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98663396,0.0055047856,0.000027078708,0.0024167236,0.00017829993,0.0047319494,0.0002608054,0.00003618463,0.00021023184],"genre_scores_gemma":[0.9978355,0.0011431153,0.0001634837,0.00011484181,0.00008170534,0.00031043903,0.00023445241,0.000046536654,0.00006990383],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99667656,0.0011706846,0.0009110387,0.0005010719,0.00034360122,0.000397049],"domain_scores_gemma":[0.99714154,0.0019030784,0.0003259569,0.00041624575,0.00010851344,0.000104641476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000632962,0.00036950625,0.0009778821,0.0001961559,0.0001434247,0.00004275414,0.00017622011,0.00007120162,0.000046756108],"category_scores_gemma":[0.000102028505,0.00017636188,0.0000691019,0.00037481092,0.0008303196,0.000095179916,0.00006864672,0.00022824947,0.000007046338],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8848756,0.006244117,0.00796964,0.0013071776,0.0067352336,0.0014205113,0.04160585,0.0010519668,0.0020571663,0.000100985024,0.00028050158,0.046351247],"study_design_scores_gemma":[0.7284094,0.09770995,0.155013,0.000657414,0.0060787457,0.00006233542,0.0012763712,0.008149227,0.00052100286,0.00005542931,0.0016436776,0.00042344697],"about_ca_topic_score_codex":0.000351538,"about_ca_topic_score_gemma":0.0006798616,"teacher_disagreement_score":0.1564662,"about_ca_system_score_codex":0.00033945506,"about_ca_system_score_gemma":0.0005815984,"threshold_uncertainty_score":0.7191829},"labels":[],"label_agreement":null},{"id":"W4403229322","doi":"10.5489/cuaj.8859","title":"Patterns of failure with 18F-DCFPyL PSMA-PET/CT in the post-prostatectomy setting","year":2024,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre; University of Toronto; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Prostatectomy; Medicine; Prostate cancer; Internal medicine; Cancer","score_opus":0.010911943415863165,"score_gpt":0.2588427557900971,"score_spread":0.24793081237423392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403229322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92736894,0.0004337559,0.000006652977,0.07100956,0.000081212434,0.00025691482,0.00007523615,0.000013777664,0.0007539665],"genre_scores_gemma":[0.9976308,0.000080053425,0.00005314187,0.0016011259,0.00016113812,0.000014931614,0.00004475037,0.000010864495,0.00040320063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985789,0.00017778655,0.0002356521,0.00015340412,0.0004214246,0.00043280533],"domain_scores_gemma":[0.9991711,0.00022644819,0.000083745836,0.000085438594,0.00019034934,0.00024296189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089194183,0.00010722459,0.00018494418,0.00022993084,0.00012287933,0.00011607518,0.000115490606,0.0000252237,0.0003781236],"category_scores_gemma":[0.00020635953,0.000055393168,0.00008224492,0.00033752414,0.000026056248,0.000088657835,0.000008731334,0.0008219969,0.000021996351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066475855,0.00003072005,0.9867795,0.000035265894,0.00012437785,0.008017728,0.0004615234,0.000015075701,0.000076746415,0.00008976609,0.002348711,0.0019541201],"study_design_scores_gemma":[0.0017142453,0.0008988834,0.9573154,0.0001992516,0.00009700164,0.003371887,0.0015383188,0.000202436,0.00009149788,0.0002803146,0.03415888,0.00013191362],"about_ca_topic_score_codex":0.0018853829,"about_ca_topic_score_gemma":0.005044771,"teacher_disagreement_score":0.070261866,"about_ca_system_score_codex":0.0007319603,"about_ca_system_score_gemma":0.0008805745,"threshold_uncertainty_score":0.4140188},"labels":[],"label_agreement":null},{"id":"W4403425493","doi":"10.1001/jamanetworkopen.2024.39434","title":"Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Centre Hospitalier de l’Université de Montréal; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Prostate cancer; Medicine; Hazard ratio; Androgen deprivation therapy; Placebo; Oncology; Antiandrogen; Internal medicine; Proportional hazards model; Prostatectomy; Post-hoc analysis; Urology; Enzalutamide; Cancer; Androgen receptor; Confidence interval; Pathology","score_opus":0.026988362601479503,"score_gpt":0.31596504296543654,"score_spread":0.288976680363957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403425493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841514,0.0083242785,0.000040643168,0.004209012,0.00008508457,0.0027029244,0.000050991745,0.000025159889,0.00041049198],"genre_scores_gemma":[0.9939118,0.0030145748,0.00040491857,0.0002712683,0.00012125223,0.00039852137,0.00011947757,0.00003675492,0.001721402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872726,0.0000529588,0.00022764361,0.00035452345,0.0002806539,0.00035695272],"domain_scores_gemma":[0.999515,0.000082418934,0.00003789159,0.00016905085,0.000066733395,0.0001289251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029961293,0.00017001641,0.0002784954,0.00006806878,0.00009510666,0.00025139077,0.0000970175,0.000042351916,0.00014156933],"category_scores_gemma":[0.0000076073584,0.00010340531,0.000022426271,0.0004188107,0.00010740287,0.00026035056,0.00007486027,0.00023085938,0.000009782631],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0149257425,0.00030750647,0.5187327,0.00036254062,0.00041152554,0.0005072351,0.0014031655,0.0017449344,0.000018853192,0.0000909161,0.0022577278,0.45923713],"study_design_scores_gemma":[0.012119285,0.0017538307,0.96960515,0.0020712148,0.00006920199,0.000006123735,0.00008948988,0.004971391,0.00008199046,0.00016911814,0.008860059,0.0002031355],"about_ca_topic_score_codex":0.00074880256,"about_ca_topic_score_gemma":0.0017099804,"teacher_disagreement_score":0.459034,"about_ca_system_score_codex":0.00020324027,"about_ca_system_score_gemma":0.00032453248,"threshold_uncertainty_score":0.42167464},"labels":[],"label_agreement":null},{"id":"W4403537585","doi":"10.1016/j.esmoop.2024.103818","title":"77P Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"DOD Prostate Cancer Research Program; National Cancer Institute; Medical Research Council; Genentech; Sierra Oncology; Astellas Pharma; Eisai; Prostate Cancer UK; Cancer Research UK; National Center for Advancing Translational Sciences; Wellcome Trust; Prostate Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; Movember Foundation; Daiichi Sankyo Europe; U.S. Department of Defense; Sanofi; Amgen; Pfizer; Vertex Pharmaceuticals; National Institutes of Health; Menarini Silicon Biosystems","keywords":"Prostate cancer; MCL1; Cancer; Medicine; Prostate; Cancer research; Internal medicine; Biology; Genetics; Gene","score_opus":0.0645400951627398,"score_gpt":0.3920523083365812,"score_spread":0.32751221317384144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403537585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9405072,0.019072415,0.0029861326,0.0139152305,0.0006013887,0.007130413,0.000142439,0.00022149744,0.0154233035],"genre_scores_gemma":[0.993104,0.00021302441,0.00078194716,0.00014580601,0.00008021294,0.0004982842,0.00019226645,0.000037308764,0.0049471785],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989635,0.00004278421,0.00019157714,0.00033590116,0.0001797193,0.00028655145],"domain_scores_gemma":[0.99955904,0.000083583676,0.000038533883,0.00012033694,0.00011655529,0.000081955404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033455266,0.0001422063,0.00019335389,0.00006647208,0.00018812035,0.0007655466,0.00011108286,0.0000440848,0.000106463674],"category_scores_gemma":[0.000026273645,0.0001077817,0.000041167463,0.0001585383,0.0000734762,0.0004191851,0.00007742471,0.00014941834,0.000005415684],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023431368,0.001005774,0.01357763,0.004628353,0.002683571,0.00093314686,0.019576533,0.00008824799,0.57073486,0.04331934,0.010154794,0.33095458],"study_design_scores_gemma":[0.025197674,0.006510245,0.032498166,0.004381843,0.0013288773,0.0001586139,0.022201603,0.019323898,0.74240184,0.044413064,0.09961891,0.0019652923],"about_ca_topic_score_codex":0.0006322011,"about_ca_topic_score_gemma":0.000069011985,"teacher_disagreement_score":0.3289893,"about_ca_system_score_codex":0.00010254561,"about_ca_system_score_gemma":0.00042101878,"threshold_uncertainty_score":0.7382183},"labels":[],"label_agreement":null},{"id":"W4403563661","doi":"10.1016/j.ejca.2024.115078","title":"Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Cilag; Foundation Medicine; Chugai Pharmaceutical; Genentech; MacroGenics; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Astellas Pharma; Eisai; Seagen; GlaxoSmithKline; UroGen Pharma; Advanced Accelerator Applications; Pfizer; Incyte; Ipsen; Clovis Oncology; Boston Scientific Corporation; AstraZeneca; Invitae; Daiichi Sankyo Europe; Gilead Sciences; Merck KGaA; Sanofi; Exelixis; Amgen; Myriad Genetics; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Oncology; Internal medicine; Cancer; Urology; Pathology","score_opus":0.055486289193787,"score_gpt":0.40743188139701186,"score_spread":0.35194559220322486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403563661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85573465,0.13276109,0.00017251444,0.0053621107,0.00071331795,0.0036375963,0.00020971324,0.000029788605,0.001379234],"genre_scores_gemma":[0.9866821,0.0089107575,0.000101511534,0.00016735312,0.00064205413,0.00019313804,0.000019480092,0.00006264145,0.0032209267],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950359,0.0017905241,0.0014968417,0.00034736708,0.000931884,0.00039747154],"domain_scores_gemma":[0.9977923,0.00091359415,0.000464566,0.00027495093,0.00033648204,0.00021807599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039473893,0.00033126978,0.0014249885,0.0002961075,0.00014888331,0.00021972206,0.00025598606,0.000019362351,0.0005610866],"category_scores_gemma":[0.00026721624,0.00016572284,0.00046324512,0.00055708166,0.00022073022,0.00025588126,0.000055059052,0.0007253647,0.00001515074],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91794217,0.00066160545,0.0009717153,0.000104904626,0.0074825934,0.011534734,0.012654773,0.0043553202,0.009339742,0.000019991694,0.0022791969,0.032653246],"study_design_scores_gemma":[0.97345906,0.0014033554,0.002364937,0.0017308509,0.004822382,0.00007484552,0.004506913,0.0032332274,0.0016065293,0.000053997996,0.006461192,0.00028269624],"about_ca_topic_score_codex":0.0016748835,"about_ca_topic_score_gemma":0.0011952936,"teacher_disagreement_score":0.1309475,"about_ca_system_score_codex":0.00066124334,"about_ca_system_score_gemma":0.0016361674,"threshold_uncertainty_score":0.6757981},"labels":[],"label_agreement":null},{"id":"W4403565766","doi":"10.1093/oncolo/oyae237","title":"Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer","year":2024,"lang":"en","type":"review","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Oncology; Adverse effect; Population; Cancer; Androgen receptor","score_opus":0.2252177205887461,"score_gpt":0.48773709342720395,"score_spread":0.26251937283845783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403565766","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001119114,0.98871106,0.000006364847,0.0005671501,0.00009596452,0.006778181,0.002275455,0.000025286337,0.0004214007],"genre_scores_gemma":[0.0019997437,0.98991895,0.00018307888,0.00003066157,0.00008762985,0.0016580959,0.00023991737,0.000045637335,0.0058362987],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99836534,0.00013222656,0.00057656225,0.0004225459,0.00020594477,0.00029737045],"domain_scores_gemma":[0.99846256,0.00077596516,0.0003024334,0.00025690408,0.00009122192,0.00011092875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034915245,0.000408381,0.0018523387,0.0001030416,0.00017736344,0.000041765914,0.00009824118,0.000104129795,0.0000295435],"category_scores_gemma":[0.00004727301,0.000191462,0.00018419471,0.00021852464,0.00066717906,0.000030433424,0.0000807447,0.00024811635,0.0000061572255],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012190096,0.0012444863,0.000098703604,0.09019083,0.018323,0.00028267177,0.0061407024,0.000048554954,0.0000766038,0.0010174167,0.0034867786,0.86690015],"study_design_scores_gemma":[0.008515986,0.003372801,0.00018743896,0.014101822,0.020305954,0.00008674699,0.00031177374,0.000100758276,0.000053422053,0.0001706424,0.9524722,0.0003204373],"about_ca_topic_score_codex":0.00044307797,"about_ca_topic_score_gemma":0.00072062213,"teacher_disagreement_score":0.94898546,"about_ca_system_score_codex":0.00058345974,"about_ca_system_score_gemma":0.0009901419,"threshold_uncertainty_score":0.78075933},"labels":[],"label_agreement":null},{"id":"W4403646020","doi":"10.3390/curroncol31110480","title":"Clinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Victoria Hospital; London Health Sciences Centre; Abbotsford Veterinary Clinic; Western University","funders":"","keywords":"Medicine; Prostate cancer; Radium-223; Oncology; Castration; Internal medicine; Prostate; Cancer; Bone metastasis; Hormone","score_opus":0.2805092291255388,"score_gpt":0.516904618025127,"score_spread":0.23639538889958822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403646020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995856,0.0019612962,0.000019971341,0.00036536335,0.0005553672,0.00089710904,0.000306863,0.000012468962,0.000025580157],"genre_scores_gemma":[0.9985271,0.0007691603,0.00016255108,0.00001653523,0.00003816727,0.00009302626,0.00013943881,0.00001635882,0.00023766373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844664,0.00013061451,0.000669741,0.00025394902,0.00027260502,0.00022642052],"domain_scores_gemma":[0.9991699,0.00025185107,0.00012977466,0.00016272596,0.0001884985,0.00009728038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002514942,0.00012314157,0.000526737,0.00018811542,0.000012151332,0.000007791677,0.000053138883,0.000049125963,0.00009753968],"category_scores_gemma":[0.000063507345,0.00007740228,0.0000821305,0.00023221917,0.00015023793,0.00008738899,0.000030330853,0.00027546118,0.000003825895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019258457,0.0015985777,0.9494688,0.001016571,0.00018290234,0.00007153634,0.00037598904,0.0000074015256,0.000051347582,0.0000498739,0.00020647632,0.04504467],"study_design_scores_gemma":[0.00718896,0.0026256172,0.98183167,0.00067852973,0.0002213534,0.0000015972141,0.000064529086,0.000119848155,0.00014656801,0.000016028744,0.007027803,0.00007749066],"about_ca_topic_score_codex":0.00021332661,"about_ca_topic_score_gemma":0.00036800714,"teacher_disagreement_score":0.044967182,"about_ca_system_score_codex":0.00025043637,"about_ca_system_score_gemma":0.00064374116,"threshold_uncertainty_score":0.31563732},"labels":[],"label_agreement":null},{"id":"W4403680662","doi":"10.1016/j.dib.2024.111053","title":"Bulk mRNA-sequencing data of the estrogen and androgen responses in the human prostate cancer cell line VCaP","year":2024,"lang":"en","type":"article","venue":"Data in Brief","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"Canadian Institutes of Health Research; Canada Foundation for Innovation","keywords":"Prostate cancer; Androgen; Estrogen; Messenger RNA; Cancer cell lines; Biology; Line (geometry); Cell culture; Cancer research; Cancer; Medicine; Bioinformatics; Oncology; Computational biology; Endocrinology; Cancer cell; Hormone; Genetics; Gene","score_opus":0.12758488274615795,"score_gpt":0.3998389715828743,"score_spread":0.2722540888367163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403680662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95716774,0.03303696,7.1034316e-7,0.004461123,0.000061451625,0.0007225842,0.0042281365,0.000012394938,0.00030890093],"genre_scores_gemma":[0.9923529,0.004924404,0.000055013053,0.00018414103,0.000088386005,0.000041180654,0.0016459659,0.000017751256,0.000690264],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987661,0.00011446371,0.00022928235,0.00039236306,0.00027702717,0.00022074128],"domain_scores_gemma":[0.9982897,0.0001452979,0.00003527017,0.0014695979,0.000022403778,0.00003773969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000953051,0.00010439793,0.00016759409,0.00006365668,0.00005643428,0.000052187923,0.00070151873,0.000040262603,0.000044106986],"category_scores_gemma":[0.00009582013,0.000054312415,0.000014817928,0.00032260834,0.00023212389,0.00023875666,0.00073915254,0.00025316744,0.0000017035828],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027793634,0.0009564699,0.6531623,0.005176639,0.00059824646,0.0033190746,0.022774477,0.000046735393,0.1829705,0.0010772982,0.050141133,0.07699778],"study_design_scores_gemma":[0.020247517,0.0015412812,0.24299566,0.010172602,0.0012035329,0.00065809785,0.010520654,0.011492867,0.17656107,0.002442138,0.5208606,0.0013039912],"about_ca_topic_score_codex":0.009281826,"about_ca_topic_score_gemma":0.0031663906,"teacher_disagreement_score":0.47071946,"about_ca_system_score_codex":0.000099205085,"about_ca_system_score_gemma":0.00045883152,"threshold_uncertainty_score":0.99731547},"labels":[],"label_agreement":null},{"id":"W4403759868","doi":"10.1016/j.brachy.2024.08.117","title":"PSOR07 Presentation Time: 12:00 PM","year":2024,"lang":"en","type":"article","venue":"Brachytherapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Presentation (obstetrics); Medical physics; Surgery","score_opus":0.027416610708863153,"score_gpt":0.3595933904297926,"score_spread":0.33217677972092946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403759868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79813427,0.057647638,0.00045876027,0.028967306,0.0010527367,0.0026846237,0.000035258472,0.00091918214,0.11010025],"genre_scores_gemma":[0.67973477,0.0060490407,0.0006389617,0.001048165,0.0014353254,0.0002589423,0.00026151308,0.00009004422,0.31048325],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99916667,0.000030479701,0.00012584012,0.00021731347,0.00025713837,0.00020258706],"domain_scores_gemma":[0.99963325,0.00006141394,0.00001335886,0.00016765123,0.000035724428,0.00008859664],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000122067075,0.000101447054,0.00016156166,0.00011292167,0.000048455455,0.000061864455,0.000042782685,0.000055043314,0.0022931122],"category_scores_gemma":[0.000009524341,0.00006899878,0.00009834281,0.00018152459,0.000043966655,0.00011717441,0.000009890974,0.00013455364,0.0010706892],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041759866,0.00053611776,0.008853963,0.0005198953,0.0011438881,0.001082517,0.002473159,0.000010028932,0.10753107,0.0012577014,0.34527886,0.5271368],"study_design_scores_gemma":[0.0126643665,0.0017483903,0.02791999,0.00046674584,0.00016326031,0.00024745433,0.00012346913,0.0066829263,0.041812893,0.0022402199,0.9055498,0.00038044454],"about_ca_topic_score_codex":0.000021886788,"about_ca_topic_score_gemma":0.0000019659792,"teacher_disagreement_score":0.56027097,"about_ca_system_score_codex":0.00007409539,"about_ca_system_score_gemma":0.00013441121,"threshold_uncertainty_score":0.9997071},"labels":[],"label_agreement":null},{"id":"W4403850277","doi":"","title":"Side effect management algorithms for niraparib/abiraterone acetate in prostate cancer.","year":2024,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Hôpital Maisonneuve-Rosemont; Abbotsford Veterinary Clinic; University of British Columbia; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Abiraterone acetate; Abiraterone; Prostate cancer; Computer science; Algorithm; Oncology; Medicine; Internal medicine; Cancer","score_opus":0.03545981244035655,"score_gpt":0.3297744839990087,"score_spread":0.29431467155865215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403850277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91423386,0.03580556,0.00014698497,0.014679647,0.0018124327,0.02308744,0.00020479798,0.000490289,0.009538975],"genre_scores_gemma":[0.9046193,0.003155224,0.00025653018,0.00016907018,0.00022159917,0.0493403,0.00010725554,0.00006540185,0.042065322],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983656,0.000036921207,0.00021458376,0.00042818373,0.00024760223,0.0007071104],"domain_scores_gemma":[0.9995233,0.0000746304,0.00002054017,0.00018516806,0.00003281462,0.0001635772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005339527,0.00018444202,0.0002910448,0.00025930806,0.000045002867,0.0000770927,0.000077642355,0.000044585224,0.000016490701],"category_scores_gemma":[0.000015317833,0.00012917316,0.00009497383,0.00040073672,0.000058325193,0.00010743935,0.00005285132,0.00016369956,0.000022791657],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012541069,0.00008888334,0.006863708,0.0023049861,0.0004324546,0.0007284927,0.00021961454,0.000018100083,0.00016215624,0.00006977603,0.0032697073,0.984588],"study_design_scores_gemma":[0.03359313,0.0015199619,0.64672494,0.001626301,0.0010993058,0.0000723102,0.00023020816,0.005196617,0.06561226,0.0015949671,0.24173905,0.0009909673],"about_ca_topic_score_codex":0.00010011917,"about_ca_topic_score_gemma":0.00004292777,"teacher_disagreement_score":0.98359704,"about_ca_system_score_codex":0.00044847393,"about_ca_system_score_gemma":0.000055168985,"threshold_uncertainty_score":0.5267528},"labels":[],"label_agreement":null},{"id":"W4403923137","doi":"10.2967/jnumed.124.267606","title":"Comparison of Posttherapy 4- and 24-Hour [<sup>177</sup>Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Prostate cancer; Medicine; Nuclear medicine; Radiology; Cancer; Internal medicine","score_opus":0.03935819650395596,"score_gpt":0.4020554164010729,"score_spread":0.36269721989711695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403923137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9717115,0.01799989,0.0000026104371,0.009363968,0.00004373091,0.00066490675,0.00002962371,0.0000071352943,0.00017659955],"genre_scores_gemma":[0.9887111,0.010497358,0.0004464633,0.00008331013,0.00007081931,0.000010482274,0.000007652096,0.000039795472,0.00013302674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978207,0.00013974,0.00082025916,0.00023045896,0.0007441378,0.00024474162],"domain_scores_gemma":[0.99897075,0.0001597046,0.00029584928,0.00014982994,0.00015845826,0.00026538962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070710725,0.00021391053,0.00088279764,0.0005145758,0.000031332933,0.00002277912,0.00007917288,0.000006543898,0.00016021312],"category_scores_gemma":[0.00003490444,0.00012607628,0.000055528744,0.00041453118,0.00030639255,0.00017331375,0.00001842806,0.00045212742,2.2542962e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029385807,0.002186031,0.8351698,0.0052916785,0.0022983465,0.02981946,0.018010473,0.0011491491,0.049402773,0.0003437313,0.0030085596,0.023934202],"study_design_scores_gemma":[0.04502471,0.023586098,0.82775086,0.01917326,0.0014255615,0.0025170902,0.03245242,0.04226176,0.00218094,0.0004901568,0.0026556102,0.0004815074],"about_ca_topic_score_codex":0.00046348083,"about_ca_topic_score_gemma":0.0001291717,"teacher_disagreement_score":0.047221836,"about_ca_system_score_codex":0.00023080532,"about_ca_system_score_gemma":0.0005875567,"threshold_uncertainty_score":0.51412416},"labels":[],"label_agreement":null},{"id":"W4403961654","doi":"10.58931/cot.2024.1326","title":"Prostate-specific Membrane Antigen (PSMA): A Diagnostic and Therapeutic Target in Advanced Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Glutamate carboxypeptidase II; Prostate cancer; Prostate-specific antigen; Medicine; Prostate; Antigen; Cancer; Cancer research; Oncology; Internal medicine; Immunology","score_opus":0.021559119780432432,"score_gpt":0.32790311552643636,"score_spread":0.3063439957460039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403961654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8268143,0.13905956,0.0000019507152,0.026853604,0.0006356152,0.0020617559,0.00020567125,0.00008534348,0.0042822263],"genre_scores_gemma":[0.95544267,0.036416654,0.00014547101,0.0011586227,0.00015082759,0.0007451629,0.000109945126,0.00006436496,0.00576627],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979551,0.00009065704,0.0002910903,0.0005956121,0.00017446258,0.00089307176],"domain_scores_gemma":[0.99866796,0.00030452033,0.000031031203,0.0002295346,0.00008111794,0.00068585586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026846016,0.0002574225,0.00044984298,0.00058216153,0.00012123734,0.00005572569,0.00009814416,0.00020259152,0.0007093151],"category_scores_gemma":[0.000060980026,0.00020998594,0.000056311845,0.0006095347,0.00029887346,0.0001096257,0.00002933975,0.0004997146,0.000083527244],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013901044,0.00026635558,0.38132757,0.0009856707,0.0005090567,0.02155863,0.010381556,0.000104091596,0.011484147,0.001072768,0.0130333835,0.55788666],"study_design_scores_gemma":[0.0040063597,0.0010644016,0.11235884,0.0007717273,0.00006726721,0.00020253443,0.0006391653,0.00042021638,0.0023191036,0.00069984875,0.87707454,0.0003759835],"about_ca_topic_score_codex":0.014050164,"about_ca_topic_score_gemma":0.088143766,"teacher_disagreement_score":0.86404115,"about_ca_system_score_codex":0.0018040271,"about_ca_system_score_gemma":0.0038645049,"threshold_uncertainty_score":0.9925154},"labels":[],"label_agreement":null},{"id":"W4404055367","doi":"10.1016/j.radonc.2024.110618","title":"Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer","year":2024,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; Movember Foundation; National Cancer Institute; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Prostate cancer; Medicine; Oncology; Biomarker; Internal medicine; Cancer; Biology","score_opus":0.035601677725708464,"score_gpt":0.3611546695657179,"score_spread":0.3255529918400094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404055367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996861,0.00086011866,0.000479838,0.00072698237,0.00007264376,0.00091017433,0.000034126024,0.000016438871,0.000038669197],"genre_scores_gemma":[0.99834543,0.0002350026,0.001089191,0.0000631255,0.000025024343,0.00008903978,0.000107822365,0.000014204828,0.000031128107],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992179,0.00009464071,0.00019288764,0.00020580224,0.00013476155,0.00015398268],"domain_scores_gemma":[0.9996195,0.000120408054,0.000038969985,0.00006652241,0.00009337129,0.00006123362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016287182,0.00009469584,0.00021913354,0.00023002512,0.00002554019,0.000016795575,0.000018455732,0.000054412994,0.000058222835],"category_scores_gemma":[0.00001027808,0.00006368466,0.000018614954,0.00031547522,0.00015792195,0.00008686254,0.0000026562734,0.0000911806,8.216551e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011726867,0.0013861334,0.18181776,0.0005127721,0.0003796587,0.00026337645,0.005485825,0.00039771598,0.01088668,0.00033722847,0.000015701717,0.7867903],"study_design_scores_gemma":[0.008252941,0.025078801,0.8258759,0.0011741848,0.00036090735,0.00003738092,0.0010014327,0.04304272,0.093259044,0.00084869686,0.00063473353,0.0004332598],"about_ca_topic_score_codex":0.00010391722,"about_ca_topic_score_gemma":0.00014676597,"teacher_disagreement_score":0.78635705,"about_ca_system_score_codex":0.00027855163,"about_ca_system_score_gemma":0.0004971402,"threshold_uncertainty_score":0.2596985},"labels":[],"label_agreement":null},{"id":"W4404108697","doi":"10.1038/s41467-024-52472-6","title":"A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer","year":2024,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University of Toronto","funders":"Instituto de Salud Carlos III; Cancer Council Queensland; Medical Research Council; Rosetrees Trust; National Institutes of Health; Vedecká Grantová Agentúra MŠVVaŠ SR a SAV; Sigrid Juséliuksen Säätiö; Queensland Government; U.S. Department of Defense; Umeå Universitet; National Institute for Health and Care Research; Magnus Ehrnroothin Säätiö; Cancerfonden; Fundación Mutua Madrileña; Prostate Cancer Foundation of Australia; Royal Marsden NHS Foundation Trust; Advance Queensland; Prostate Cancer Foundation; Australian Prostate Cancer Research; Movember Foundation; National Health and Medical Research Council; Cancer Research UK; Mater Foundation; Vetenskapsrådet; Australian Government; National Cancer Institute; Knut och Alice Wallenbergs Stiftelse","keywords":"Prostate cancer; SNP; Outcome (game theory); Function (biology); Cancer; Prostate; Oncology; Medicine; Biology; Internal medicine; Bioinformatics; Single-nucleotide polymorphism; Genetics; Gene; Genotype","score_opus":0.05414978222780471,"score_gpt":0.4199889258446361,"score_spread":0.3658391436168314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404108697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7862818,0.13792576,0.00002177766,0.06327063,0.00012883225,0.001751016,0.0000744232,0.00020348463,0.010342264],"genre_scores_gemma":[0.9877997,0.00791831,0.00054864085,0.00021210023,0.000042967014,0.00019082631,0.00013567356,0.000022881799,0.0031288771],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991266,0.000091635055,0.00019579372,0.00021822924,0.00019368388,0.00017405463],"domain_scores_gemma":[0.9989949,0.00023297798,0.00003705733,0.0005364883,0.00011442614,0.000084167674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003311853,0.00011035367,0.00020644792,0.000119899414,0.00010363082,0.00004963222,0.00012805518,0.00016684359,0.000017943697],"category_scores_gemma":[0.0000357152,0.00006503864,0.00003309965,0.00044544617,0.00019303817,0.00009810797,0.00008549207,0.0012825005,0.0000065527847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005405348,0.00018963443,0.9923045,0.00007529699,0.00030184217,0.000027453889,0.00037493638,0.0000010797298,0.00015586289,0.0006452865,0.0011416071,0.0042419564],"study_design_scores_gemma":[0.003507886,0.0007074621,0.9494526,0.0006268576,0.00042845553,0.0000109592675,0.00038812496,0.0012763559,0.000108301494,0.00018825059,0.043132998,0.00017178067],"about_ca_topic_score_codex":0.00014751057,"about_ca_topic_score_gemma":0.0016428314,"teacher_disagreement_score":0.20151791,"about_ca_system_score_codex":0.00017118013,"about_ca_system_score_gemma":0.00025328647,"threshold_uncertainty_score":0.55718976},"labels":[],"label_agreement":null},{"id":"W4404165262","doi":"10.1158/1078-0432.ccr-24-1612","title":"Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; University of Toronto; Sunnybrook Hospital; Kingston Health Sciences Centre; Canadian Cancer Society; CancerCare Manitoba; University of Manitoba; Juravinski Cancer Centre; Hamilton Health Sciences; Baker Hughes (Canada); Canadian Centre for Applied Research in Cancer Control; University Health Network; Saskatchewan Cancer Agency; Occupational Cancer Research Centre; Ottawa Hospital; Sunnybrook Health Science Centre; Kelowna General Hospital; London Health Sciences Centre; Interior Health; Princess Margaret Cancer Centre; BC Cancer Agency; Queen's University; Spinal Cord Injury BC","funders":"Canadian Cancer Society","keywords":"Durvalumab; Tremelimumab; Prostate cancer; Medicine; Oncology; Castration; Internal medicine; Prostate; Flutamide; Cancer; Randomized controlled trial; Immunotherapy; Hormone; Androgen receptor; Nivolumab","score_opus":0.2214674561537067,"score_gpt":0.5506320744122234,"score_spread":0.32916461825851673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404165262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864623,0.0027332457,0.000003827657,0.0011098227,0.00012056543,0.009172242,0.00014158507,0.000045893634,0.00021052158],"genre_scores_gemma":[0.9905972,0.0013842378,0.00010728153,0.00003025028,0.000107708,0.0033708038,0.000053176253,0.00007957639,0.0042697503],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935813,0.0012561544,0.0012131138,0.0009134299,0.002259022,0.0007769963],"domain_scores_gemma":[0.99642175,0.0013209772,0.00014775996,0.0005462261,0.0011985061,0.0003648054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040916246,0.00031740355,0.0015692608,0.00057806243,0.000189935,0.00008495752,0.0002154784,0.00008353249,0.00067533035],"category_scores_gemma":[0.00041774777,0.00015617037,0.00013509476,0.0018475666,0.0010504908,0.00020852497,0.00011647788,0.0011518489,0.000008306093],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8489047,0.009737201,0.11299577,0.00083928695,0.0017004709,0.00056981196,0.0032955557,0.00003585391,0.00006899284,0.000014041915,0.00031943255,0.021518877],"study_design_scores_gemma":[0.90168506,0.0610268,0.029090557,0.0028330737,0.000856546,0.0000035406752,0.002273198,0.0010919143,0.0002973759,0.00004068545,0.00048921426,0.00031203026],"about_ca_topic_score_codex":0.0043088463,"about_ca_topic_score_gemma":0.0090253325,"teacher_disagreement_score":0.08390521,"about_ca_system_score_codex":0.00052704866,"about_ca_system_score_gemma":0.004297327,"threshold_uncertainty_score":0.7623273},"labels":[],"label_agreement":null},{"id":"W4404186630","doi":"10.1530/erc-24-0208","title":"Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer","year":2024,"lang":"en","type":"review","venue":"Endocrine Related Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Prostate cancer; Androgen receptor; Action (physics); Medicine; Androgen; Oncology; Cancer research; Internal medicine; Cancer; Hormone; Physics","score_opus":0.07290575837906706,"score_gpt":0.43238443650603164,"score_spread":0.3594786781269646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404186630","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000597473,0.9838773,0.000007564364,0.00093817554,0.0025445758,0.009658258,0.0019428422,0.0003023113,0.00013148328],"genre_scores_gemma":[0.000015719927,0.9287719,0.00020016031,0.00007821246,0.001160856,0.01511531,0.00060121616,0.00040219043,0.05365441],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958901,0.00009022337,0.0009358793,0.0013574392,0.00053703546,0.0011893698],"domain_scores_gemma":[0.9981243,0.00012330625,0.00028573794,0.00062297896,0.00028303903,0.0005606345],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002267434,0.0009570097,0.0021074198,0.00052653183,0.00020807023,0.0001234582,0.00026901806,0.00039140915,0.0016498842],"category_scores_gemma":[0.000062344865,0.00058502285,0.0008216012,0.0013992698,0.00007824321,0.00016331862,0.000146884,0.0010265138,0.00020990736],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015185461,0.00010161354,0.000034159613,0.014586819,0.0039675557,0.00018658506,0.00027199968,0.000003897516,0.00027207113,0.000008051489,0.014851316,0.9641974],"study_design_scores_gemma":[0.003370165,0.0010955768,0.0000013380322,0.014985269,0.0028209235,0.00013709362,0.00004448026,0.000021955417,0.0028401352,0.00001863375,0.974019,0.0006454429],"about_ca_topic_score_codex":0.0005889559,"about_ca_topic_score_gemma":0.00016943773,"teacher_disagreement_score":0.96355194,"about_ca_system_score_codex":0.002167525,"about_ca_system_score_gemma":0.002674137,"threshold_uncertainty_score":0.99966013},"labels":[],"label_agreement":null},{"id":"W4404240656","doi":"10.1002/cam4.70029","title":"Darolutamide in Japanese patients with metastatic hormone‐sensitive prostate cancer: Phase 3 <scp>ARASENS</scp> subgroup analysis","year":2024,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Astellas Pharma; Sanofi","keywords":"Subgroup analysis; Prostate cancer; Oncology; Medicine; Internal medicine; Hormone; Cancer; Endocrinology; Meta-analysis","score_opus":0.01871598017410731,"score_gpt":0.34244654817723724,"score_spread":0.32373056800312994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404240656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9537787,0.039882712,0.000037413938,0.0029296572,0.00029782782,0.001705382,0.000503764,0.0001388595,0.0007256825],"genre_scores_gemma":[0.9852935,0.008025872,0.000052248695,0.00047764427,0.00033461404,0.0006398084,0.0009474462,0.00008633199,0.0041425545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99640095,0.00012249593,0.0005883337,0.00090865913,0.0010988859,0.0008806527],"domain_scores_gemma":[0.9980921,0.00035870532,0.00013293175,0.00045544613,0.00043279649,0.0005279843],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041270241,0.00049745594,0.0012388449,0.0012433914,0.00009713226,0.00004011591,0.00012759783,0.00008840179,0.00019782806],"category_scores_gemma":[0.00014982434,0.0003059868,0.00015891521,0.0040171463,0.0005269161,0.00023400971,0.000049011396,0.00058858906,0.000024174658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011507915,0.0035982693,0.6914055,0.004340468,0.03041514,0.01726315,0.08847838,0.0012558578,0.018714944,0.00008367546,0.043553147,0.089383565],"study_design_scores_gemma":[0.116864406,0.013688039,0.75164837,0.008980162,0.032787636,0.00009406597,0.020027118,0.019103589,0.008106722,0.00013593335,0.027486762,0.0010772098],"about_ca_topic_score_codex":0.003637151,"about_ca_topic_score_gemma":0.0011680124,"teacher_disagreement_score":0.105356485,"about_ca_system_score_codex":0.0010680313,"about_ca_system_score_gemma":0.0006723157,"threshold_uncertainty_score":0.9999392},"labels":[],"label_agreement":null},{"id":"W4404249561","doi":"10.1002/pros.24820","title":"pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post‐Initiation of Androgen Deprivation Therapy","year":2024,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"DOD Prostate Cancer Research Program; National Cancer Institute; National Institutes of Health; Vetenskapsrådet; U.S. Department of Defense; Kungliga Fysiografiska Sällskapet i Lund; Johns Hopkins University; Lunds Universitet; Swedish Cancer Foundation; Fonds de Recherche du Québec - Santé; Sidney Kimmel Comprehensive Cancer Center; Cancerfonden; Movember Foundation; Skånes universitetssjukhus","keywords":"Androgen deprivation therapy; Prostate cancer; Medicine; Prostate; Cancer; Androgen; Internal medicine; Oncology; Endocrinology; Cancer research; Hormone","score_opus":0.02239563330732968,"score_gpt":0.3418290004464757,"score_spread":0.319433367139146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404249561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817234,0.010764957,0.0000064319993,0.0051829107,0.00007313219,0.0017969614,0.0001345775,0.00004429595,0.00027332536],"genre_scores_gemma":[0.9865684,0.011981492,0.000074432945,0.00027731693,0.00002780691,0.00042655968,0.000118743854,0.000031673128,0.0004935538],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99867994,0.0001002622,0.0003378897,0.00028535852,0.0003030145,0.00029356338],"domain_scores_gemma":[0.99942935,0.00009393349,0.00007042187,0.0002291911,0.00012269424,0.000054423257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004040242,0.00015238271,0.00022448387,0.0002735881,0.000041839376,0.000026662341,0.00008387631,0.000055247743,0.00011715941],"category_scores_gemma":[0.00003410396,0.000091886235,0.000052057992,0.0006514013,0.000076853226,0.00023525755,0.000038483246,0.0002332561,0.00001015143],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008521694,0.00033656816,0.1657235,0.0005672996,0.0001008429,0.00014051696,0.026675845,0.0001622811,0.59689534,0.000064741405,0.00025435627,0.20055702],"study_design_scores_gemma":[0.007685406,0.00060787436,0.18558486,0.0018266528,0.00002998594,0.0000096657695,0.0008174674,0.00213468,0.79742223,0.002013663,0.0016632758,0.0002042444],"about_ca_topic_score_codex":0.00061784853,"about_ca_topic_score_gemma":0.00009497956,"teacher_disagreement_score":0.2005269,"about_ca_system_score_codex":0.00019358622,"about_ca_system_score_gemma":0.00043007475,"threshold_uncertainty_score":0.3747012},"labels":[],"label_agreement":null},{"id":"W4404282772","doi":"10.1111/bju.16577","title":"Real‐world use of androgen‐deprivation therapy intensification for metastatic hormone‐sensitive prostate cancer: a systematic review","year":2024,"lang":"en","type":"review","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bayer HealthCare","keywords":"Enzalutamide; Androgen deprivation therapy; Prostate cancer; Medicine; Oncology; Internal medicine; Docetaxel; Family medicine; Cancer; Androgen receptor","score_opus":0.11376011404035327,"score_gpt":0.40329150278041803,"score_spread":0.2895313887400648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404282772","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000070770664,0.9925129,0.000052242078,0.00062951917,0.00020446282,0.006157195,0.00034999682,0.000013274696,0.0000096411395],"genre_scores_gemma":[0.00008147171,0.9977683,0.00028146245,0.00020748896,0.000118302356,0.0005927827,0.0002557333,0.00007514591,0.0006193075],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99657136,0.0005390988,0.001950229,0.00029940633,0.00036051744,0.00027940123],"domain_scores_gemma":[0.9956158,0.0005196702,0.0018969298,0.00024602277,0.001595151,0.00012643448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011745346,0.00030071673,0.0040642945,0.00052453886,0.000043752716,0.00004469605,0.00013763343,0.00012254494,0.000008973973],"category_scores_gemma":[0.00068274245,0.00021455977,0.00087055773,0.0005857008,0.0001301197,0.00012646982,0.000030251102,0.0005510881,0.000004624036],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036300215,0.0001303906,0.0000020599978,0.70324916,0.003665064,0.00083726994,0.00007470854,3.9290353e-7,0.000011427485,0.000022985329,0.0061456338,0.2854979],"study_design_scores_gemma":[0.0017052293,0.0017053562,0.000016574086,0.78023094,0.029985815,0.011428239,0.000025493184,0.000024422243,0.000013484355,0.00008652833,0.17454666,0.00023128607],"about_ca_topic_score_codex":0.00011232313,"about_ca_topic_score_gemma":0.000025765943,"teacher_disagreement_score":0.28526664,"about_ca_system_score_codex":0.0002725078,"about_ca_system_score_gemma":0.0011806844,"threshold_uncertainty_score":0.8749494},"labels":[],"label_agreement":null},{"id":"W4404332734","doi":"10.1177/10668969241295687","title":"Unconventional Histopathological Features With <i>KIAA1549::BRAF</i> Fusion in Advanced Prostatic Adenocarcinoma","year":2024,"lang":"en","type":"article","venue":"International Journal of Surgical Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Pathology; Medicine; Prostate; Adenocarcinoma; Prostate cancer; Cancer; Cancer research; Internal medicine","score_opus":0.015653184558430795,"score_gpt":0.32736695041062175,"score_spread":0.31171376585219096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404332734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97716516,0.01043058,0.00011614277,0.009600482,0.0008080348,0.00019749693,0.000016427075,0.000022486052,0.001643184],"genre_scores_gemma":[0.99573964,0.0012611594,0.0010441982,0.00019047868,0.00032818728,0.000015701731,0.000039274124,0.000016143329,0.0013651955],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99829274,0.00010488513,0.00044631018,0.00025366672,0.00067290844,0.0002294926],"domain_scores_gemma":[0.9991471,0.00019760877,0.00010516502,0.00008374736,0.00033494324,0.0001314162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041610975,0.00014639717,0.00033556644,0.00044531588,0.000024148507,0.000035104742,0.00016620131,0.00011184571,0.00024817203],"category_scores_gemma":[0.00005397725,0.000087233646,0.00016054175,0.00020612545,0.00021433365,0.00016227279,0.00005407685,0.00062361005,0.00002352701],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019934278,0.0015110101,0.21764942,0.0002029531,0.00036450708,0.6864778,0.0009044553,0.00023143194,0.011489144,0.005577196,0.002288528,0.05336928],"study_design_scores_gemma":[0.02547552,0.00867572,0.6478902,0.0028434559,0.00020456493,0.24218312,0.00045822776,0.00025421847,0.0035985305,0.0071327593,0.060788464,0.0004952249],"about_ca_topic_score_codex":0.0000034203065,"about_ca_topic_score_gemma":0.0000047178596,"teacher_disagreement_score":0.44429466,"about_ca_system_score_codex":0.00031786904,"about_ca_system_score_gemma":0.00031166826,"threshold_uncertainty_score":0.3557285},"labels":[],"label_agreement":null},{"id":"W4404367273","doi":"10.1016/j.prnil.2024.11.001","title":"Concurrent antiandrogen therapy in the salvage radiotherapy setting for recurrent prostate cancer: a literature review","year":2024,"lang":"en","type":"review","venue":"Prostate International","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Salvage therapy; Prostate cancer; Radiation therapy; Antiandrogen; Recurrent prostate cancer; Prostatectomy; Oncology; Internal medicine; Cancer; Chemotherapy","score_opus":0.06130048351684187,"score_gpt":0.45614122306571303,"score_spread":0.39484073954887117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404367273","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010942681,0.97487354,0.00000439791,0.009625547,0.0015162282,0.011064147,0.002680608,0.00006020213,0.0001643898],"genre_scores_gemma":[0.000007502804,0.9821549,0.000084281055,0.0010112703,0.00085622224,0.008746653,0.004845108,0.00011657332,0.002177482],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967245,0.00023433997,0.0009464051,0.00079427345,0.00075491564,0.0005455703],"domain_scores_gemma":[0.9986644,0.00020504941,0.00034154663,0.00035872494,0.0003242377,0.00010603907],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001099089,0.00063385407,0.0013692979,0.00040368692,0.00008421344,0.00028546865,0.00051948655,0.00018254807,0.000104783845],"category_scores_gemma":[0.00006785214,0.00032721885,0.00083433563,0.0007234823,0.00009348741,0.00012735932,0.00007068605,0.0010829109,0.000023654406],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015486091,0.00017050833,0.000040316692,0.06655311,0.0009305359,0.00024305789,0.001155604,1.0697854e-7,0.0000015306344,0.00006718637,0.030065449,0.9006177],"study_design_scores_gemma":[0.0015199501,0.00039076718,0.000004731576,0.20197567,0.00046845182,0.00021548214,0.000016159538,0.000043455773,0.00000367447,0.000041533087,0.7950664,0.00025369687],"about_ca_topic_score_codex":0.000009412728,"about_ca_topic_score_gemma":0.0000073512924,"teacher_disagreement_score":0.90036404,"about_ca_system_score_codex":0.0007058453,"about_ca_system_score_gemma":0.0009765178,"threshold_uncertainty_score":0.999918},"labels":[],"label_agreement":null},{"id":"W4404409907","doi":"10.1097/ju.0000000000004333","title":"High 11-Ketotestosterone Linked to Shorter Time to Castration Resistance in Recurrent Nonmetastatic Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; Centre Hospitalier de l’Université de Montréal; Université Laval; Centre hospitalier de l'Université Laval; McGill University Health Centre; Centre hospitalier universitaire de Québec","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada; McGill University Health Centre; Movember Foundation; McGill University","keywords":"Medicine; Prostate cancer; Oncology; Castration; Prostate; Internal medicine; Urology; Cancer; Hormone","score_opus":0.023708821423251952,"score_gpt":0.3295794174932467,"score_spread":0.3058705960699948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404409907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91145885,0.005197848,0.000102378515,0.082272574,0.00029946916,0.00054761005,0.00001714768,0.000008773251,0.00009536743],"genre_scores_gemma":[0.99288726,0.00049513375,0.0004778745,0.0009363666,0.00022741499,0.000029982792,0.000004514902,0.000019137635,0.0049222936],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988344,0.00015113592,0.00036673935,0.00012944739,0.00025343001,0.00026485347],"domain_scores_gemma":[0.9994029,0.00013991454,0.000060668106,0.00013728326,0.000116568306,0.00014268463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006753411,0.00010850539,0.00026896913,0.00027074313,0.000029287032,0.000019666755,0.00010541722,0.00003950044,0.00028827402],"category_scores_gemma":[0.000050924027,0.000062282976,0.000041141226,0.00033922086,0.000044647146,0.000068361995,0.00003184459,0.000333373,0.00013849727],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.083010264,0.0013186372,0.014380071,0.0012976276,0.00188767,0.009689601,0.04894131,0.0067551434,0.42305052,0.00034114197,0.15691757,0.25241044],"study_design_scores_gemma":[0.018157378,0.042515915,0.57160115,0.0051687863,0.002883558,0.003099761,0.0006829093,0.0025126513,0.010849543,0.0042154207,0.33707094,0.0012419693],"about_ca_topic_score_codex":0.00004353845,"about_ca_topic_score_gemma":0.0004875766,"teacher_disagreement_score":0.5572211,"about_ca_system_score_codex":0.00020993991,"about_ca_system_score_gemma":0.00025940948,"threshold_uncertainty_score":0.31563985},"labels":[],"label_agreement":null},{"id":"W4404524148","doi":"10.2196/59480","title":"Medication Prescription Policy for US Veterans With Metastatic Castration-Resistant Prostate Cancer: Causal Machine Learning Approach","year":2024,"lang":"en","type":"article","venue":"JMIR Medical Informatics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Docetaxel; Medicine; Prostate cancer; Oncology; Internal medicine; Mitoxantrone; Cabazitaxel; Medical prescription; Cancer; Veterans Affairs; Abiraterone acetate; Androgen deprivation therapy; Chemotherapy; Androgen receptor; Pharmacology","score_opus":0.03404942358098799,"score_gpt":0.3655782055431681,"score_spread":0.3315287819621801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404524148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8883049,0.008701271,0.056404226,0.022904502,0.000692482,0.012934488,0.00085020886,0.001192528,0.008015382],"genre_scores_gemma":[0.9767387,0.0020686674,0.009630973,0.00066353247,0.0005769224,0.003220115,0.0027246457,0.0000747761,0.0043016695],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99762535,0.000046077712,0.0005568759,0.00018758584,0.0011483808,0.00043572934],"domain_scores_gemma":[0.9990281,0.00010566899,0.000104562896,0.00017839574,0.0001648586,0.00041840764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048993074,0.00022023657,0.0003194991,0.00029151203,0.00015874616,0.00011951148,0.000109298766,0.000110854555,0.00011045761],"category_scores_gemma":[0.00010593978,0.00013638315,0.00008044082,0.00045725986,0.00019845208,0.00035041053,0.000028486573,0.00052832597,0.000015301031],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017750246,0.0029205976,0.012562317,0.07953768,0.006751626,0.00086321734,0.18605787,0.0030030787,0.0058954316,0.012911852,0.027550455,0.6441956],"study_design_scores_gemma":[0.01142623,0.0039618667,0.002439334,0.0027409233,0.0007340241,0.00048056457,0.0041679684,0.8652365,0.0009719478,0.00019400573,0.107097544,0.0005490579],"about_ca_topic_score_codex":0.00035167148,"about_ca_topic_score_gemma":0.000067965986,"teacher_disagreement_score":0.86223346,"about_ca_system_score_codex":0.0003374189,"about_ca_system_score_gemma":0.0018179528,"threshold_uncertainty_score":0.5561544},"labels":[],"label_agreement":null},{"id":"W4404527351","doi":"10.1073/pnas.2406239121","title":"Small-molecule disruption of androgen receptor–dependent chromatin clusters","year":2024,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institutes of Health; Institute for Bioengineering and Biosciences; Kaleida Health Foundation; U.S. Department of Defense; Georgia Institute of Technology; Case Comprehensive Cancer Center, Case Western Reserve University; University at Buffalo; University of Washington; National Cancer Institute; Case Western Reserve University; Itä-Suomen Yliopisto; Perelman School of Medicine, University of Pennsylvania; Universitat de Barcelona; University of Pennsylvania; Prostate Cancer Foundation; School of Medicine, Case Western Reserve University","keywords":"Androgen receptor; Enzalutamide; Chromatin; Enhancer; Epigenome; Prostate cancer; Cancer research; Biology; Chromatin immunoprecipitation; Promoter; Cell biology; Androgen; Gene; Chemistry; Computational biology; Gene expression; Cancer; Endocrinology; Genetics; DNA methylation; Hormone","score_opus":0.06388224321569005,"score_gpt":0.35603052625958104,"score_spread":0.29214828304389096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404527351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870343,0.001058538,9.726342e-7,0.005527993,0.000024939842,0.00025812036,0.000018180162,0.000011482083,0.006065478],"genre_scores_gemma":[0.99848676,0.00017595621,0.00040275158,0.00005063624,0.000050903414,0.000011185116,6.1682704e-7,0.0000037060054,0.00081746787],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99857193,0.0000041494854,0.00022387193,0.0001651966,0.00092747784,0.000107393054],"domain_scores_gemma":[0.9996178,0.000049990762,0.00011963221,0.0000060417506,0.00017329045,0.000033210723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007514007,0.000060977185,0.00012476464,0.00016726246,0.000061471495,0.000014619849,0.00021911153,0.000049942108,0.000032808708],"category_scores_gemma":[0.00012948926,0.000034836994,0.00007412295,0.00057484524,0.0004958459,0.00015471975,0.00007736487,0.00010806368,0.0000024393532],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000074087744,0.00007250466,0.004628552,0.0006736378,0.0000679947,4.4045674e-8,0.000495347,0.000009547727,0.98632985,0.004959838,0.0010719957,0.0016166203],"study_design_scores_gemma":[0.00031584932,0.0001653526,0.008165916,0.0005527161,0.000032325082,0.000013384933,0.00026481805,0.0012229349,0.98630685,0.0027175206,0.0001984848,0.000043871238],"about_ca_topic_score_codex":0.000006425151,"about_ca_topic_score_gemma":3.6789928e-8,"teacher_disagreement_score":0.011452481,"about_ca_system_score_codex":0.00006521785,"about_ca_system_score_gemma":0.00008891929,"threshold_uncertainty_score":0.1826965},"labels":[],"label_agreement":null},{"id":"W4404535143","doi":"10.21203/rs.3.rs-5301479/v1","title":"Long-Term Control of Recurrent Metastatic Castrate Sensitive Prostate Cancer with Radiotherapy: A Case Report.","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Radiation therapy; Metastasis; Cancer; Oncology; Prostate; Internal medicine","score_opus":0.06787272389665133,"score_gpt":0.44536439796914523,"score_spread":0.3774916740724939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404535143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91882426,0.06505606,0.0001469518,0.003915092,0.00029606788,0.00883311,0.002379325,0.000105041014,0.00044406563],"genre_scores_gemma":[0.98212546,0.009714914,0.0002701284,0.000021644079,0.00031385684,0.001965074,0.0004926561,0.00015862037,0.0049376395],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9940465,0.00071948784,0.0007313135,0.00126454,0.002102333,0.0011358275],"domain_scores_gemma":[0.9951492,0.00037614987,0.00027861146,0.0010859948,0.0025306458,0.000579398],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0019575378,0.0005544636,0.0013137028,0.0009237696,0.00016142227,0.00016382907,0.00016559829,0.00021889256,0.00021135903],"category_scores_gemma":[0.0001395114,0.0003611932,0.0003325823,0.0008467501,0.00080319034,0.00005909295,0.00039566387,0.003028722,0.000019026487],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011487133,0.00074287504,0.013923427,0.02477377,0.005848246,0.90788484,0.003999112,0.00016423351,0.0013617879,0.000041682048,0.00073495327,0.029037949],"study_design_scores_gemma":[0.09081506,0.05269582,0.06644103,0.22262108,0.013762508,0.419192,0.015618543,0.020296114,0.08609868,0.0027593467,0.0033384946,0.006361344],"about_ca_topic_score_codex":0.0023447669,"about_ca_topic_score_gemma":0.00092932105,"teacher_disagreement_score":0.48869285,"about_ca_system_score_codex":0.0013575823,"about_ca_system_score_gemma":0.0057288343,"threshold_uncertainty_score":0.99990773},"labels":[],"label_agreement":null},{"id":"W4404538688","doi":"10.1007/s11136-024-03843-5","title":"Quality of life and testosterone recovery after androgen deprivation therapy in high-risk prostate cancer patients: long-term data from a phase III trial","year":2024,"lang":"en","type":"article","venue":"Quality of Life Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Centre Hospitalier de l’Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Université Laval; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Centre Intégré de Santé et de Services Sociaux du Bas-Saint-Laurent; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Prostate cancer; Androgen deprivation therapy; Quality of life (healthcare); Quality of Life Research; Medicine; Testosterone (patch); Oncology; Cancer; Prostate; Public health; Term (time); Internal medicine; Androgen; Gynecology; Hormone; Nursing","score_opus":0.2633037543308094,"score_gpt":0.4913525972191437,"score_spread":0.22804884288833432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404538688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97397465,0.017868914,0.000018803028,0.001294767,0.00013007197,0.002635811,0.004034382,0.00002343869,0.000019163635],"genre_scores_gemma":[0.97874403,0.01880754,0.00007756344,0.000052912947,0.00022616368,0.0002891657,0.0016146393,0.00003192643,0.00015606632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994338,0.0015923319,0.0012962277,0.0007588027,0.0015499153,0.00046476838],"domain_scores_gemma":[0.99620134,0.0018619391,0.00023698257,0.00091631606,0.00048009117,0.00030333575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062082047,0.00019955816,0.00080936344,0.00041514545,0.000067878675,0.000070947855,0.00028156067,0.00016256428,0.00030447217],"category_scores_gemma":[0.0023044175,0.0001515729,0.00008041259,0.00065325055,0.0004371872,0.00041289435,0.00036154804,0.0005823081,0.000007220107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2110828,0.0018904483,0.71926576,0.0009513684,0.00045130646,0.000012292949,0.0012686941,3.8975145e-7,0.0019463707,0.0000061872297,0.0003468993,0.062777475],"study_design_scores_gemma":[0.1335524,0.0039320933,0.8587925,0.00068602967,0.00003417392,1.6814046e-7,0.00021317638,0.000080126076,0.0019723435,0.0003963915,0.00014754057,0.00019308673],"about_ca_topic_score_codex":0.020440122,"about_ca_topic_score_gemma":0.001642222,"teacher_disagreement_score":0.1395267,"about_ca_system_score_codex":0.00020973379,"about_ca_system_score_gemma":0.0012975275,"threshold_uncertainty_score":0.98608285},"labels":[],"label_agreement":null},{"id":"W4404544358","doi":"10.1007/978-981-97-5357-4_9","title":"Management of Intermediate Risk Prostate Cancer","year":2024,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"","keywords":"Prostate cancer; Management of prostate cancer; Medicine; Oncology; Risk analysis (engineering); Internal medicine; Cancer","score_opus":0.022981151218957246,"score_gpt":0.3259340041858538,"score_spread":0.30295285296689656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404544358","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00065730314,0.020959921,0.0000028929708,0.00043291386,0.00041824015,0.0011166693,0.00035591738,0.00007960865,0.9759765],"genre_scores_gemma":[0.004766479,0.11489681,0.00008733112,0.000028341796,0.0001270168,0.00008821137,0.000106122505,0.000070689195,0.879829],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99866664,0.0000035525734,0.0003349143,0.00036832932,0.0003995954,0.00022696787],"domain_scores_gemma":[0.9993299,0.00001819622,0.000113850576,0.00031902464,0.00010005782,0.0001189358],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001008569,0.0002615159,0.0004246667,0.00021337511,0.000020321715,0.00001274704,0.00008547849,0.00013359947,0.0034925814],"category_scores_gemma":[0.0000014673993,0.00016859331,0.0002070472,0.00003901838,0.00014990357,0.000020855658,0.00016410451,0.000399039,0.000471718],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031087284,0.00022550536,0.0026288247,0.023978489,0.020165777,0.008827646,0.0010170587,0.000004524898,0.00010424669,0.17893052,0.07395171,0.68705696],"study_design_scores_gemma":[0.002814928,0.00076918135,0.0009687645,0.009926456,0.0032430862,0.000013366893,0.00010873887,0.000042424665,0.0013207789,0.02524937,0.9551138,0.00042905082],"about_ca_topic_score_codex":0.00007373882,"about_ca_topic_score_gemma":0.000020733478,"teacher_disagreement_score":0.88116217,"about_ca_system_score_codex":0.000207891,"about_ca_system_score_gemma":0.00012401195,"threshold_uncertainty_score":0.99741834},"labels":[],"label_agreement":null},{"id":"W4404580937","doi":"10.1016/s0140-6736(24)01967-6","title":"Prostate radiotherapy in the era of intensified systemic treatment of metastatic prostate cancer","year":2024,"lang":"en","type":"article","venue":"The Lancet","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Prostate cancer; Medicine; Radiation therapy; Oncology; Prostate; Systemic therapy; Internal medicine; Cancer","score_opus":0.06540950572072782,"score_gpt":0.3752258190372895,"score_spread":0.3098163133165617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404580937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90481526,0.07499433,0.000006631624,0.017715657,0.0001345791,0.0018373978,0.00014437539,0.000027378102,0.00032441682],"genre_scores_gemma":[0.9676622,0.030294504,0.000077441786,0.00017959076,0.00015947792,0.00039536614,0.000021724238,0.00002058503,0.0011890859],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988487,0.00015300635,0.0002899067,0.00017224002,0.00026907778,0.0002671028],"domain_scores_gemma":[0.9992235,0.00018826855,0.000064832406,0.00042320174,0.00007220782,0.000028001574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043330874,0.0001396698,0.00056125596,0.00007340326,0.000026710175,0.000020537436,0.00014605856,0.000022237462,0.000040193707],"category_scores_gemma":[0.000013938789,0.000055280005,0.00009503726,0.0004058854,0.000169478,0.000037979487,0.00001120249,0.00016619342,0.0000045402367],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02182132,0.0019952683,0.121799365,0.012845707,0.006428384,0.0015412406,0.28477317,0.0005238353,0.176481,0.0035249237,0.021141978,0.34712383],"study_design_scores_gemma":[0.12409874,0.029000515,0.24241214,0.037815288,0.0054629557,0.002339345,0.047048394,0.024745831,0.3167731,0.007049151,0.1612666,0.0019879744],"about_ca_topic_score_codex":0.00069202075,"about_ca_topic_score_gemma":0.000060851533,"teacher_disagreement_score":0.34513587,"about_ca_system_score_codex":0.00018273498,"about_ca_system_score_gemma":0.00026006548,"threshold_uncertainty_score":0.22542532},"labels":[],"label_agreement":null},{"id":"W4404587979","doi":"10.1007/s10439-024-03650-6","title":"A Comparative Analysis of Alpha and Beta Therapy in Prostate Cancer Using a 3D Image-Based Spatiotemporal Model","year":2024,"lang":"en","type":"article","venue":"Annals of Biomedical Engineering","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Prostate cancer; BETA (programming language); Alpha (finance); Cancer; Medicine; Computer science; Internal medicine; Surgery","score_opus":0.09847831914485602,"score_gpt":0.4166684225087245,"score_spread":0.31819010336386844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404587979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853273,0.0095377555,0.0035202885,0.0012204881,0.000022741018,0.00023182516,0.0001047851,0.000019685216,0.000015153172],"genre_scores_gemma":[0.9962172,0.0013094272,0.0023252768,0.000034358338,0.000016556072,0.000020304768,0.00005004687,0.0000096187405,0.00001722704],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99910015,0.000013107967,0.00026011665,0.00017203315,0.00026813406,0.00018647141],"domain_scores_gemma":[0.9996266,0.00006115401,0.00003231085,0.00008846782,0.000083311636,0.000108175605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021681114,0.00010669955,0.00044387055,0.000760045,0.000008823559,0.000009196653,0.000035921614,0.000044359953,0.000024446394],"category_scores_gemma":[0.000011697258,0.00007874283,0.000088424225,0.0011409865,0.00013439976,0.00006457004,0.000016727534,0.00011970675,1.5264668e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002440738,0.0012460237,0.02776634,0.0048230737,0.0112132225,0.00047977702,0.009835817,0.19834924,0.67769223,0.00016463273,0.00039107958,0.0655978],"study_design_scores_gemma":[0.0007481553,0.00019039282,0.0051913057,0.0004903758,0.00013967544,7.0015795e-7,0.000025915828,0.9601371,0.032917216,0.000007101074,0.000085649895,0.0000663808],"about_ca_topic_score_codex":0.00036882778,"about_ca_topic_score_gemma":0.000008897636,"teacher_disagreement_score":0.7617879,"about_ca_system_score_codex":0.000030067777,"about_ca_system_score_gemma":0.00022788165,"threshold_uncertainty_score":0.32110396},"labels":[],"label_agreement":null},{"id":"W4404630453","doi":"10.1016/j.clgc.2024.102274","title":"Real-world Clinical Outcomes and Prognostic Factors in Neuroendocrine Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Alberta Cancer Foundation; University of Calgary; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Neuroendocrine tumors; Cancer; Prostate","score_opus":0.11318034506068382,"score_gpt":0.48364685449129363,"score_spread":0.3704665094306098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404630453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97589016,0.010412122,6.768667e-7,0.008781494,0.0023389834,0.0013629016,0.00010552692,0.00019143977,0.00091666967],"genre_scores_gemma":[0.8954165,0.08050398,0.0000787254,0.00051059254,0.0010217152,0.00043264686,0.000041802406,0.00007977705,0.021914262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99642766,0.00025484135,0.0012129619,0.0010028481,0.0003932719,0.0007084153],"domain_scores_gemma":[0.9973959,0.0014656809,0.000094532035,0.0003792448,0.000096965916,0.00056770403],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005003681,0.00037101668,0.0009362595,0.0003089535,0.00007822493,0.00007528676,0.00014580622,0.00011144403,0.00038030103],"category_scores_gemma":[0.00029894675,0.00024894008,0.00035993822,0.00063755485,0.0004764026,0.00016679462,0.00021767947,0.0012563621,0.00003758327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086856185,0.00047065012,0.93539506,0.00038547706,0.00032452072,0.0038642657,0.000088607754,0.0000042139814,0.00003397791,0.000020026911,0.004071592,0.054473035],"study_design_scores_gemma":[0.0030689354,0.00093613594,0.96961594,0.0005990923,0.000249205,0.000020039495,0.000054260698,0.00029310174,0.00008974811,0.00013022998,0.02468814,0.00025515427],"about_ca_topic_score_codex":0.0010973407,"about_ca_topic_score_gemma":0.0008939262,"teacher_disagreement_score":0.080473684,"about_ca_system_score_codex":0.00022468201,"about_ca_system_score_gemma":0.0009476017,"threshold_uncertainty_score":0.9999963},"labels":[],"label_agreement":null},{"id":"W4404631067","doi":"10.1097/rlu.0000000000005552","title":"A Case Report","year":2024,"lang":"en","type":"article","venue":"Clinical Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; McMaster University","funders":"","keywords":"Medicine","score_opus":0.16112203751881246,"score_gpt":0.49984508996878046,"score_spread":0.33872305244996803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404631067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79212314,0.0075543122,0.00004277445,0.104743056,0.0028331038,0.00068607036,0.000006578538,0.00068915274,0.09132179],"genre_scores_gemma":[0.9755438,0.0009198673,0.00027768136,0.002551659,0.0025156557,0.000007853124,0.000031503972,0.00005249962,0.01809947],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.99845564,0.000048388625,0.00054921303,0.00040559538,0.00030097898,0.00024016378],"domain_scores_gemma":[0.9987465,0.0003322972,0.00003069538,0.00039794663,0.00008142972,0.00041111963],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010105061,0.00011826162,0.0003822989,0.00010344813,0.00006085657,0.00001537544,0.000052559953,0.00012349925,0.0029935038],"category_scores_gemma":[0.0008481132,0.0000690361,0.00015379077,0.0002781024,0.00049943157,0.00004566679,0.00005079204,0.0005310307,0.0008170537],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021285062,0.0001080934,0.0010639947,0.00015326115,0.00016625498,0.75999534,0.00017677154,2.5993215e-8,0.0001264606,0.0004991414,0.1921873,0.045310494],"study_design_scores_gemma":[0.0021416557,0.0017016304,0.0017895206,0.0006307181,0.0002797147,0.2418577,0.0002604633,0.0005952984,0.000010820409,0.00029709394,0.7503413,0.00009409678],"about_ca_topic_score_codex":0.000040404237,"about_ca_topic_score_gemma":0.0000018061572,"teacher_disagreement_score":0.558154,"about_ca_system_score_codex":0.000056913133,"about_ca_system_score_gemma":0.00013404452,"threshold_uncertainty_score":0.9999609},"labels":[],"label_agreement":null},{"id":"W4404711423","doi":"10.1093/oncolo/oyae321","title":"Systematic literature review and meta-analysis of health state utility values in metastatic castration-resistant prostate cancer","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Medicine; EQ-5D; Meta-analysis; Prostate cancer; Observational study; Internal medicine; Systematic review; MEDLINE; Visual analogue scale; Oncology; Pooled analysis; Cancer; Health related quality of life; Surgery","score_opus":0.13686046811730865,"score_gpt":0.4540249715358743,"score_spread":0.3171645034185656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404711423","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011009429,0.963188,0.000011359358,0.022334425,0.000025652278,0.0027948956,0.00048063236,0.000023963268,0.0001316288],"genre_scores_gemma":[0.73577434,0.25742403,0.0001672252,0.0007946862,0.00000711935,0.0008289883,0.00010294969,0.000015232374,0.0048854374],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9977806,0.0007287594,0.0007038168,0.00027091155,0.00029624547,0.00021965074],"domain_scores_gemma":[0.9989659,0.00034092268,0.00017880417,0.00032187768,0.00012713,0.00006536291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002909319,0.00015801119,0.0017692379,0.00019576964,0.00006230406,0.000051047446,0.00007948063,0.00002229978,0.00012078119],"category_scores_gemma":[0.000110111534,0.000069043526,0.00030548702,0.0014571209,0.00020796714,0.00006794033,0.000031940912,0.00020643063,0.0000019294062],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046071882,0.00044657188,0.0010759257,0.7479312,0.23360093,0.0005458345,0.010435595,0.00008813828,0.00023153776,0.0004209591,0.0023760295,0.002386583],"study_design_scores_gemma":[0.0013126866,0.0013571719,0.01837373,0.025391253,0.9478131,0.000054356206,0.0013277137,0.002072224,0.0002034589,0.0010923999,0.0006789099,0.00032302632],"about_ca_topic_score_codex":0.0007260317,"about_ca_topic_score_gemma":0.0011627178,"teacher_disagreement_score":0.72476494,"about_ca_system_score_codex":0.00021011304,"about_ca_system_score_gemma":0.0004892274,"threshold_uncertainty_score":0.28155133},"labels":[],"label_agreement":null},{"id":"W4404717357","doi":"10.1093/jbmrpl/ziae157","title":"Administration and cancer-control outcomes of bone-modifying agents in real-world patients with metastatic castration-resistant prostate cancer","year":2024,"lang":"en","type":"article","venue":"JBMR Plus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Castration; Oncology; Internal medicine; Hormone","score_opus":0.04798047445184556,"score_gpt":0.3886623334258226,"score_spread":0.34068185897397707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404717357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943685,0.0022570672,0.0000059448703,0.0013538781,0.000097402444,0.0012449132,0.00028137094,0.000027727954,0.0003632288],"genre_scores_gemma":[0.9964832,0.0007702243,0.00008824052,0.000051033705,0.000023120223,0.00034597894,0.000082569284,0.000022693861,0.002132916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873644,0.00003504906,0.00032721958,0.00027806358,0.00037740674,0.00024580982],"domain_scores_gemma":[0.99952203,0.00006682174,0.00007998123,0.00012547016,0.00010420885,0.000101473626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012839172,0.00015945772,0.00037492847,0.00024369125,0.00004447484,0.00004368831,0.000029333205,0.000027131977,0.000050970233],"category_scores_gemma":[0.000015249978,0.00010437097,0.00003880093,0.0003287724,0.00007247202,0.0001585262,0.000012362756,0.00013620188,0.0000016172316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024938365,0.00017324464,0.98383474,0.0011854686,0.00039164332,0.00029400786,0.0012328501,0.00011720683,0.0007745799,0.00012938038,0.00014032266,0.009232705],"study_design_scores_gemma":[0.0077579417,0.0005325794,0.9876554,0.0008068006,0.00028315885,0.0000021080969,0.00013279774,0.0016189478,0.0007819567,0.000051112842,0.00024339744,0.00013377196],"about_ca_topic_score_codex":0.0033647213,"about_ca_topic_score_gemma":0.009302534,"teacher_disagreement_score":0.009098934,"about_ca_system_score_codex":0.00041049276,"about_ca_system_score_gemma":0.0007703472,"threshold_uncertainty_score":0.5191032},"labels":[],"label_agreement":null},{"id":"W4404749160","doi":"10.1158/1078-0432.ccr-24-2061","title":"Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies","year":2024,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"DOD Prostate Cancer Research Program; National Cancer Institute; Genentech; National Institutes of Health; Astellas Pharma; Institute for Prostate Cancer Research; Celgene; U.S. Department of Defense; Sanofi; Prostate Cancer Foundation; Eli Lilly and Company; Bristol-Myers Squibb; Pfizer; V Foundation for Cancer Research; Intuitive Surgical; Doris Duke Charitable Foundation; Amgen","keywords":"Prostate cancer; Neuroendocrine differentiation; Medicine; Adenocarcinoma; Pathology; Context (archaeology); Enzalutamide; Prostate; Androgen deprivation therapy; Androgen receptor; Chromogranin A; Lineage markers; Neuroendocrine tumors; Synaptophysin; Cancer; Immunohistochemistry; Cancer research; Phenotype; Internal medicine; Biology","score_opus":0.6165722208737369,"score_gpt":0.6663704275781906,"score_spread":0.049798206704453785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404749160","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010866042,0.98448825,0.000029928035,0.004871738,0.0012562991,0.0073160185,0.0017845583,0.000041680203,0.00010285704],"genre_scores_gemma":[0.00015766766,0.9768903,0.0006441614,0.000073345356,0.0013753591,0.012209913,0.00015353454,0.00015577827,0.008339934],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935956,0.001008424,0.001922681,0.0011083945,0.0012432557,0.0011216383],"domain_scores_gemma":[0.9862815,0.010746918,0.0003845531,0.0010833608,0.001155849,0.0003478142],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005703399,0.0005094217,0.0027926005,0.00046785595,0.00030482316,0.00012075053,0.00066109106,0.00057314895,0.00047726763],"category_scores_gemma":[0.0022944226,0.000252072,0.0013708927,0.0017958111,0.0021432396,0.000052256404,0.00034805707,0.0034822107,0.000083429266],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001593065,0.00027592148,0.000092933915,0.059600484,0.0029280826,0.00027793637,0.00020094312,0.0000013844676,0.0000045192673,0.0013881767,0.014671684,0.91896486],"study_design_scores_gemma":[0.0010546345,0.0012836521,0.00006935836,0.037691414,0.004806771,0.000018886629,0.00023336931,0.000020773947,0.000014391429,0.0025916551,0.95196044,0.00025464525],"about_ca_topic_score_codex":0.00036843505,"about_ca_topic_score_gemma":0.00023329827,"teacher_disagreement_score":0.93728876,"about_ca_system_score_codex":0.00056662486,"about_ca_system_score_gemma":0.008394221,"threshold_uncertainty_score":0.99999315},"labels":[],"label_agreement":null},{"id":"W4404754406","doi":"10.3390/pharma3040026","title":"Cardiovascular Adverse Events Associated with Prostate Cancer Treatment: A Disproportionality Analysis from the Food and Drug Administration Adverse Event Reporting System Database","year":2024,"lang":"en","type":"article","venue":"Pharmacoepidemiology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Adverse Event Reporting System; Food and drug administration; Adverse effect; Prostate cancer; Medicine; Event (particle physics); Adverse drug event; Database; Cancer; Intensive care medicine; Oncology; Internal medicine; Pharmacology; Computer science","score_opus":0.06557377598040294,"score_gpt":0.39687139128344034,"score_spread":0.3312976153030374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404754406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9655106,0.026425302,0.00033300568,0.0039674127,0.00020377661,0.0013127759,0.0020729965,0.00013539131,0.000038737813],"genre_scores_gemma":[0.9912559,0.0026181976,0.0000807754,0.00012008423,0.00022993721,0.00048613423,0.0048634876,0.000025082389,0.00032040817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966428,0.0008187787,0.0009032132,0.00087156735,0.00037606386,0.000387567],"domain_scores_gemma":[0.9978867,0.0006648802,0.00047894748,0.00063006976,0.00013062672,0.00020878026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031016716,0.0002642442,0.00081408495,0.00010164687,0.00020111092,0.000009003331,0.00010564822,0.00006474794,0.00006228955],"category_scores_gemma":[0.0005104903,0.00014084707,0.0003673261,0.000561008,0.00014034276,0.00017140395,0.00008967784,0.00025569779,0.0000051921797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013468879,0.0002235368,0.94117916,0.00027157585,0.04932379,0.0010601957,0.0006602575,0.0007529884,0.00017950588,0.000038657196,0.0005819306,0.004381492],"study_design_scores_gemma":[0.008840484,0.0008598408,0.81721485,0.001470238,0.070870474,0.00019089591,0.0017189704,0.08754286,0.0016265471,0.0000872967,0.008957401,0.0006201389],"about_ca_topic_score_codex":0.0034792346,"about_ca_topic_score_gemma":0.0010739191,"teacher_disagreement_score":0.12396433,"about_ca_system_score_codex":0.0005718795,"about_ca_system_score_gemma":0.0005944274,"threshold_uncertainty_score":0.5743577},"labels":[],"label_agreement":null},{"id":"W4404860848","doi":"10.5489/cuaj.9053","title":"Addressing an urgent treatment gap in advanced prostate cancer","year":2024,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Cancer; Medicine; Prostate; Oncology; Internal medicine","score_opus":0.07448721333895536,"score_gpt":0.36657048591036145,"score_spread":0.2920832725714061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404860848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9439852,0.009111335,0.0000022367315,0.044221535,0.0004937425,0.00040272338,0.00006805747,0.000043550783,0.0016716225],"genre_scores_gemma":[0.99198675,0.0026843378,0.00006704217,0.001136254,0.0003849816,0.000079888414,0.00004677291,0.000017238426,0.0035967159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849784,0.00012174104,0.00024965897,0.00024348816,0.00028874644,0.0005985272],"domain_scores_gemma":[0.99841595,0.000059114587,0.000057420177,0.00007659115,0.000115683666,0.0012752404],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003675236,0.00013849972,0.00022809397,0.00030902863,0.00016168827,0.00016652374,0.00005523563,0.00013947078,0.0013652523],"category_scores_gemma":[0.00016215228,0.000093014474,0.00009429041,0.0003140881,0.000023869785,0.00018211303,0.0000062913696,0.00044263114,0.00003313598],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033790036,0.00018373168,0.79132366,0.000027525248,0.00025393502,0.0029208402,0.0013087287,0.00033175276,0.00087669905,0.00012195839,0.0033170776,0.19899616],"study_design_scores_gemma":[0.0045074746,0.0020964653,0.66390383,0.00031709688,0.00015320047,0.00025291185,0.00034563543,0.0025111963,0.0003658026,0.0011672376,0.3240553,0.00032382528],"about_ca_topic_score_codex":0.0022386538,"about_ca_topic_score_gemma":0.0050195265,"teacher_disagreement_score":0.32073823,"about_ca_system_score_codex":0.006432383,"about_ca_system_score_gemma":0.0027516233,"threshold_uncertainty_score":0.99954766},"labels":[],"label_agreement":null},{"id":"W4404888857","doi":"10.1002/cncr.35612","title":"Implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024","year":2024,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Center for Advancing Translational Sciences; AstraZeneca; Bayer HealthCare; U.S. Department of Defense","keywords":"Medicine; Prostate cancer; Clinical trial; Consensus conference; Cancer; Evidence-based medicine; Intensive care medicine; Oncology; Gynecology; Medical physics; Alternative medicine; Internal medicine; Pathology","score_opus":0.07672598528469975,"score_gpt":0.41482106223430826,"score_spread":0.3380950769496085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404888857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57063085,0.30187318,0.00019062601,0.115037166,0.0007530442,0.005344316,0.0055713123,0.00018538562,0.0004141267],"genre_scores_gemma":[0.8972688,0.08299546,0.0015915242,0.0009219577,0.000520736,0.01125631,0.00046055054,0.00010006283,0.004884615],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978954,0.00006520791,0.00034750102,0.00069993554,0.000317764,0.00067415426],"domain_scores_gemma":[0.9984053,0.0005430483,0.00012062941,0.00027535605,0.0004698755,0.00018582221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032055506,0.00031726045,0.00034787436,0.000074685166,0.0003202124,0.00031175025,0.0001318824,0.00006492623,0.00056211324],"category_scores_gemma":[0.00004775618,0.00018762311,0.00007347004,0.00035771268,0.00032074272,0.00022391498,0.00007622723,0.0003369016,0.0000026451946],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0089687975,0.00014651068,0.04876799,0.0028608097,0.0024875763,0.00008920942,0.006772863,0.0002543385,0.08039893,0.00063500635,0.1015917,0.74702626],"study_design_scores_gemma":[0.01710278,0.0025376326,0.010493594,0.041594684,0.0038262405,0.000019025154,0.011750826,0.034969393,0.124536954,0.002212339,0.7491297,0.0018268059],"about_ca_topic_score_codex":0.0028731856,"about_ca_topic_score_gemma":0.002923375,"teacher_disagreement_score":0.74519944,"about_ca_system_score_codex":0.00045503798,"about_ca_system_score_gemma":0.0035294425,"threshold_uncertainty_score":0.76510483},"labels":[],"label_agreement":null},{"id":"W4404890434","doi":"10.1007/978-3-031-66754-1_23","title":"Patient Selection: What Tumors Should Be Treated Based on Grade, Size, Location, Genetics and Risk Category?","year":2024,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Selection (genetic algorithm); Evolutionary biology; Genetics; Biology; Computer science; Artificial intelligence","score_opus":0.036885727735005036,"score_gpt":0.2963327931636554,"score_spread":0.25944706542865037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404890434","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023063345,0.07651928,0.00012452682,0.017691797,0.0012306009,0.007732094,0.0003558988,0.0010418455,0.8722406],"genre_scores_gemma":[0.09466062,0.030404253,0.00013514484,0.00095606694,0.00026600616,0.00011356077,0.00057203165,0.00016556558,0.87272674],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99820685,0.0000205105,0.0003155889,0.0006195428,0.00056357885,0.0002739209],"domain_scores_gemma":[0.9988969,0.00012599102,0.0000902728,0.00031840694,0.0003146103,0.00025385045],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008384224,0.00042659967,0.0004195118,0.00029176264,0.00012379965,0.00012400583,0.00004793675,0.00031867647,0.001004608],"category_scores_gemma":[0.000017766031,0.00029590554,0.00011187437,0.00013942487,0.00014988483,0.000054455635,0.00003458479,0.000612581,0.00009235728],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012397111,0.0035490764,0.0473296,0.011065743,0.013246763,0.005630232,0.0037570049,0.0019984802,0.0006259183,0.06651069,0.28375435,0.550135],"study_design_scores_gemma":[0.015607614,0.025138963,0.006639133,0.0092327995,0.007793726,0.00034065652,0.0010111594,0.023820799,0.028407197,0.018115511,0.8603895,0.0035029654],"about_ca_topic_score_codex":0.00017317779,"about_ca_topic_score_gemma":0.00011896273,"teacher_disagreement_score":0.5766351,"about_ca_system_score_codex":0.00037038917,"about_ca_system_score_gemma":0.00036357352,"threshold_uncertainty_score":0.99994934},"labels":[],"label_agreement":null},{"id":"W4404943437","doi":"","title":"ERG expression in prostate cancer biopsies with and without high-grade prostatic intraepithelial neoplasia: a study in Jordanian Arab patients","year":2019,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intraepithelial neoplasia; Prostate cancer; Medicine; Erg; High-grade prostatic intraepithelial neoplasia; Prostate; Oncology; Internal medicine; Cancer; Urology; Ophthalmology","score_opus":0.09814597874995121,"score_gpt":0.504254695592642,"score_spread":0.4061087168426908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404943437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898323,0.004809019,0.000001189627,0.00023163442,0.0001800424,0.0046900944,0.000055209854,0.000018106855,0.00018240618],"genre_scores_gemma":[0.99196935,0.0067938315,0.000120758246,0.0000769198,0.000042252326,0.00043498297,0.00002194488,0.00006200566,0.000477928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969878,0.00027850058,0.0007100594,0.00060686446,0.0008757316,0.00054101855],"domain_scores_gemma":[0.9986316,0.00009348818,0.00042101697,0.00035285228,0.00023619062,0.00026483598],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006238192,0.0003737898,0.0010053273,0.0010632448,0.0000988045,0.00038079088,0.00051271176,0.000081045015,0.0006468695],"category_scores_gemma":[0.00007647261,0.00024546913,0.00004472665,0.0010484203,0.00015861791,0.001265591,0.0003910045,0.00061689207,0.000005059304],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005866997,0.0017474185,0.9646949,0.00034163048,0.00015486771,0.00014197631,0.0028258292,0.00005296897,0.019437188,0.0000013904628,0.00025324145,0.0044815596],"study_design_scores_gemma":[0.013610888,0.00040472974,0.9673677,0.0027712733,0.000073470386,0.00001015282,0.0010053992,0.000044861183,0.014172112,0.00014370537,0.000108489774,0.00028719573],"about_ca_topic_score_codex":0.0033333648,"about_ca_topic_score_gemma":0.0013439116,"teacher_disagreement_score":0.0077438913,"about_ca_system_score_codex":0.0002844485,"about_ca_system_score_gemma":0.00038734486,"threshold_uncertainty_score":0.99999976},"labels":[],"label_agreement":null},{"id":"W4404960577","doi":"10.3390/cells13231999","title":"Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer","year":2024,"lang":"en","type":"review","venue":"Cells","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; Medical Research Council; Prostate Cancer Foundation","keywords":"Transdifferentiation; Prostate cancer; Cancer research; Neuroendocrine differentiation; Biology; LNCaP; Androgen receptor; Medicine; SOX2; Cancer; Transcription factor; Internal medicine; Cell; Genetics; Gene","score_opus":0.07328815464932636,"score_gpt":0.39599584760987283,"score_spread":0.32270769296054647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404960577","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008420275,0.996912,0.0000017034888,0.00011824438,0.0003273662,0.0015389354,0.00007429675,0.000022848313,0.00016259655],"genre_scores_gemma":[0.0015596539,0.99332815,0.0000070093524,0.000011289521,0.00004705362,0.00030141757,0.0001989036,0.000048174905,0.004498325],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988596,0.00006818857,0.000364734,0.00027975705,0.00021949301,0.00020827157],"domain_scores_gemma":[0.999611,0.000039849416,0.00009486637,0.0001587343,0.000042092517,0.00005344643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000048858106,0.00021833679,0.00080237776,0.00037016903,0.000011385263,0.000011853897,0.000063674524,0.000045186487,0.00012742408],"category_scores_gemma":[0.0000025523277,0.00014367787,0.00024171935,0.00042192588,0.00004406228,0.000040821833,0.000014689957,0.00029338908,0.00004053359],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049594324,0.00010081401,0.0000412122,0.051937316,0.000246935,0.00014702014,0.00045701038,0.0000011458364,0.0001994169,0.000013113878,0.00023253,0.9465739],"study_design_scores_gemma":[0.0019556133,0.00037902413,0.000113413786,0.036513377,0.004304013,0.00001894613,0.000112483365,0.00006492097,0.0018821936,0.00007346882,0.95428646,0.00029608083],"about_ca_topic_score_codex":0.00003324572,"about_ca_topic_score_gemma":0.000012581691,"teacher_disagreement_score":0.95405394,"about_ca_system_score_codex":0.00021893898,"about_ca_system_score_gemma":0.00034744787,"threshold_uncertainty_score":0.5859013},"labels":[],"label_agreement":null},{"id":"W4405076942","doi":"10.1016/j.euf.2024.11.004","title":"Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE Data","year":2024,"lang":"en","type":"article","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Meta-analysis; Prostate cancer; Oncology; Hormone therapy; Internal medicine; Cancer; Breast cancer","score_opus":0.19031728068552534,"score_gpt":0.3958050187199457,"score_spread":0.2054877380344204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405076942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8868751,0.088588506,0.0004136639,0.013601133,0.00053421396,0.0037757969,0.0022421435,0.00048532724,0.0034841402],"genre_scores_gemma":[0.9900917,0.003212378,0.0002678636,0.0011445726,0.00018135589,0.00007447412,0.0032327138,0.00009853647,0.0016964293],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9959374,0.0013490879,0.00057862577,0.001057453,0.00036952936,0.0007079016],"domain_scores_gemma":[0.9984117,0.00019700037,0.00011774466,0.00091723766,0.0001517372,0.0002045656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001543746,0.00036947496,0.0011585292,0.0005551785,0.00013092709,0.000094486226,0.0003675661,0.00005862297,0.0006221503],"category_scores_gemma":[0.000056330537,0.00022067034,0.00028614185,0.002019862,0.0001808605,0.00034131412,0.0003062351,0.00056133914,0.000095070085],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06366174,0.0030675244,0.024538545,0.00015133788,0.693731,0.035079975,0.01108943,0.004996108,0.0021114338,0.00022311562,0.062190674,0.09915911],"study_design_scores_gemma":[0.046518188,0.019338863,0.13130897,0.00007403943,0.45202252,0.00017797691,0.000496846,0.043215048,0.0013512146,0.00060276035,0.30227175,0.002621836],"about_ca_topic_score_codex":0.00034124972,"about_ca_topic_score_gemma":0.00054947747,"teacher_disagreement_score":0.24170849,"about_ca_system_score_codex":0.00012119566,"about_ca_system_score_gemma":0.00023871564,"threshold_uncertainty_score":0.89986753},"labels":[],"label_agreement":null},{"id":"W4405128969","doi":"10.1038/s41391-024-00924-x","title":"Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison","year":2024,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Abiraterone acetate; Medicine; Enzalutamide; Olaparib; Prostate cancer; Oncology; Internal medicine; Confidence interval; Hazard ratio; Urology; Cancer; Androgen deprivation therapy; Poly ADP ribose polymerase; Chemistry","score_opus":0.060146084737071254,"score_gpt":0.3616965064831839,"score_spread":0.3015504217461127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405128969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8342215,0.14219695,0.00020338566,0.0037017826,0.0011623624,0.00894963,0.008929802,0.00052412035,0.00011050343],"genre_scores_gemma":[0.9594755,0.022181021,0.0011035119,0.00033077158,0.0002653363,0.008428306,0.002188937,0.00029726597,0.0057293293],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.993615,0.00024494933,0.0014176989,0.0018876821,0.0010324086,0.001802266],"domain_scores_gemma":[0.99662864,0.0006610557,0.0004294829,0.0005744679,0.000515023,0.001191355],"candidate_categories":["metaepi_narrow","scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.00058944046,0.0012369606,0.0020551067,0.00056169403,0.0007968795,0.0011909236,0.00025090633,0.00017680973,0.00014247555],"category_scores_gemma":[0.00012649017,0.0009880554,0.000278005,0.00091868656,0.00090479763,0.0009912759,0.00023071989,0.0006693546,0.000021136288],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28821892,0.002233097,0.041860588,0.09558862,0.019312063,0.0037717891,0.122506596,0.010744342,0.040849432,0.0018227537,0.017912578,0.35517922],"study_design_scores_gemma":[0.37310776,0.030206634,0.11552184,0.03058877,0.04600435,0.0007226806,0.041356083,0.20810562,0.0558524,0.01359454,0.07070676,0.014232559],"about_ca_topic_score_codex":0.0021242138,"about_ca_topic_score_gemma":0.0015061047,"teacher_disagreement_score":0.34094667,"about_ca_system_score_codex":0.0014658439,"about_ca_system_score_gemma":0.0035858783,"threshold_uncertainty_score":0.9998459},"labels":[],"label_agreement":null},{"id":"W4405134893","doi":"10.1016/j.annonc.2024.10.365","title":"346P High genomic risk is associated with clinically significant prostate cancer (csPCa) recurrences following focal therapy (FT)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"Association of Schools and Colleges of Optometry","keywords":"Medicine; Prostate cancer; Oncology; Prostate; Internal medicine; Cancer; Urology","score_opus":0.11955148465602199,"score_gpt":0.45380816955871633,"score_spread":0.33425668490269433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405134893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731311,0.011199563,0.0000071090153,0.0129162,0.00044903893,0.00073974545,0.0001990517,0.0000800673,0.001278108],"genre_scores_gemma":[0.9557795,0.040986147,0.00011074626,0.00084613985,0.00016234077,0.0001531964,0.000057949503,0.000034680947,0.001869291],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979651,0.00022029967,0.0004907197,0.00046576138,0.00035780398,0.0005002912],"domain_scores_gemma":[0.9985719,0.0005878773,0.00019478396,0.00020893433,0.00026013455,0.000176413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009690624,0.00020359858,0.0006657674,0.0001442698,0.00008836898,0.0000266425,0.00014185955,0.00020176824,0.00028166588],"category_scores_gemma":[0.000119606346,0.00012686214,0.00022687994,0.00037407508,0.00027843355,0.000081144426,0.000040015442,0.0004676064,0.0000268681],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008861272,0.0011775292,0.24654375,0.00013504218,0.005368607,0.0013640876,0.0042356323,0.000016355625,0.0041182954,0.00006559882,0.027556956,0.7005569],"study_design_scores_gemma":[0.030482063,0.13229172,0.55273736,0.0038961892,0.0015613912,0.000036904137,0.0018486627,0.0011574295,0.041569326,0.006785644,0.22618403,0.0014493264],"about_ca_topic_score_codex":0.00068418763,"about_ca_topic_score_gemma":0.000094180235,"teacher_disagreement_score":0.6991075,"about_ca_system_score_codex":0.00015709458,"about_ca_system_score_gemma":0.0018054505,"threshold_uncertainty_score":0.5173288},"labels":[],"label_agreement":null},{"id":"W4405182706","doi":"10.1158/0008-5472.can-24-2052","title":"Plasma Cell–Free DNA Chromatin Immunoprecipitation Profiling Depicts Phenotypic and Clinical Heterogeneity in Advanced Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Canada's Michael Smith Genome Sciences Centre; Occupational Cancer Research Centre; BC Cancer Agency; University of British Columbia","funders":"Intramural Research Program; National Institutes of Health","keywords":"Prostate cancer; Cancer research; Immunoprecipitation; Phenotype; Biology; Medicine; Cancer; Internal medicine; Genetics; Gene","score_opus":0.08307303704932385,"score_gpt":0.4592454300956394,"score_spread":0.37617239304631556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95410013,0.04065672,0.000004260286,0.0019331446,0.00042335573,0.0020913936,0.00009036705,0.00009272252,0.00060790894],"genre_scores_gemma":[0.97236675,0.022577954,0.00042961884,0.000042215794,0.00029981756,0.001511753,0.000056016797,0.00006912875,0.0026467561],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99662197,0.0003435527,0.00052439614,0.0008219785,0.0008119816,0.0008761396],"domain_scores_gemma":[0.9984203,0.00046495197,0.000046129484,0.00046263705,0.0003053918,0.0003006151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001630392,0.00022987327,0.00041547974,0.00044977164,0.00018123334,0.00013930675,0.00021779914,0.00017468819,0.00014348983],"category_scores_gemma":[0.00024175154,0.00018338714,0.00009239346,0.00094945607,0.00038520416,0.00027220292,0.00026008984,0.0011498587,0.000042821517],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005091984,0.00049043103,0.2223292,0.0041121454,0.0003740506,0.0005895948,0.0028002819,0.00009096215,0.48065934,0.00012251147,0.0020629505,0.28127655],"study_design_scores_gemma":[0.015912028,0.0020546794,0.23636647,0.0045519844,0.000134592,0.00002481756,0.0011886961,0.0060524507,0.7254873,0.0010013683,0.0065957475,0.0006298568],"about_ca_topic_score_codex":0.0006060208,"about_ca_topic_score_gemma":0.0011473952,"teacher_disagreement_score":0.2806467,"about_ca_system_score_codex":0.0010643117,"about_ca_system_score_gemma":0.0016078267,"threshold_uncertainty_score":0.747831},"labels":[],"label_agreement":null},{"id":"W4405188907","doi":"10.1111/iju.15615","title":"Prostate‐specific antigen kinetics in Asian patients with metastatic castration‐sensitive prostate cancer treated with apalutamide in the <scp>TITAN</scp> trial: A post hoc analysis","year":2024,"lang":"en","type":"article","venue":"International Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Post-hoc analysis; Oncology; Glutamate carboxypeptidase II; Post hoc; Urology; Internal medicine; Cancer","score_opus":0.016909614682407252,"score_gpt":0.31429435254111704,"score_spread":0.2973847378587098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405188907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992134,0.0012568145,0.000053284213,0.005155842,0.00015255353,0.00085927534,0.00013472683,0.000008712971,0.00024480742],"genre_scores_gemma":[0.99833554,0.00073487003,0.00018633796,0.00024082599,0.000106817635,0.000051162595,0.00017232785,0.000022716189,0.00014939933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792784,0.00022412078,0.00053796143,0.0002484619,0.0007780244,0.0002835627],"domain_scores_gemma":[0.99840415,0.00027352956,0.0002310432,0.00011776239,0.0008931818,0.0000803521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003786498,0.00018868811,0.00041904245,0.0012132574,0.000025460544,0.00009872456,0.00017326305,0.00005084905,0.000026530259],"category_scores_gemma":[0.00006739576,0.000099844336,0.000105752115,0.0010447487,0.00016037084,0.00018622169,0.000018339086,0.0004386232,0.00000423725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1395493,0.003268401,0.7636652,0.00008633301,0.014003195,0.029790882,0.023008024,0.004893777,0.0023223753,0.0002644635,0.0005265722,0.018621476],"study_design_scores_gemma":[0.048809275,0.015937325,0.9274463,0.0002704718,0.001157936,0.00051105174,0.0022960661,0.0006043153,0.00035354315,0.00011248129,0.0023981216,0.0001031138],"about_ca_topic_score_codex":0.00018104058,"about_ca_topic_score_gemma":0.0011619859,"teacher_disagreement_score":0.16378109,"about_ca_system_score_codex":0.0003182354,"about_ca_system_score_gemma":0.0004091513,"threshold_uncertainty_score":0.4071534},"labels":[],"label_agreement":null},{"id":"W4405249152","doi":"10.5489/cuaj.8917","title":"A novel tool to predict lymph node metastasis in patients with prostate cancer based on clinical and 68Ga-PSMA PET/CT parameters","year":2024,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Lymph node metastasis; Lymph node; Cancer; Metastasis; Oncology; Prostate; Radiology; PET-CT; Internal medicine; Positron emission tomography","score_opus":0.027969160673524056,"score_gpt":0.30537606641290355,"score_spread":0.2774069057393795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405249152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728254,0.00016598977,0.000020888981,0.02573778,0.00021887495,0.0005437168,0.0003218092,0.000021109974,0.00014442521],"genre_scores_gemma":[0.99388504,0.000097210184,0.00057576125,0.0049514,0.00009206784,0.000068303,0.000041145933,0.00001933119,0.00026975133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980959,0.00013827594,0.00036413388,0.0003419565,0.0005168846,0.0005428488],"domain_scores_gemma":[0.9985936,0.00023844912,0.000077094046,0.00009622688,0.00016990864,0.00082470366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008513169,0.00016651898,0.00032236506,0.00035714428,0.000113076385,0.00015314085,0.00007037903,0.00003156949,0.00013915013],"category_scores_gemma":[0.0005083631,0.00010564953,0.00008683797,0.00040254835,0.000054289776,0.00008817509,0.0000128279025,0.0005904421,0.000015967906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001077664,0.00013903277,0.98629963,0.000015694899,0.00019055615,0.0010588202,0.000029695424,0.0004073541,0.0000019911733,0.000006094484,0.0015235426,0.009249948],"study_design_scores_gemma":[0.0048690257,0.0013161766,0.9856234,0.00015434761,0.00011332564,0.000063683474,0.000016002461,0.0019196083,0.000004411985,0.000022536078,0.005763436,0.00013400157],"about_ca_topic_score_codex":0.0011587825,"about_ca_topic_score_gemma":0.00064199977,"teacher_disagreement_score":0.021059623,"about_ca_system_score_codex":0.0015235766,"about_ca_system_score_gemma":0.0013359535,"threshold_uncertainty_score":0.4308263},"labels":[],"label_agreement":null},{"id":"W4405308923","doi":"10.1080/14796694.2024.2426425","title":"Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; Pfizer","keywords":"Medicine; Prostate cancer; Enzalutamide; Biochemical recurrence; Radiation therapy; Cancer; Oncology; Testosterone (patch); Quality of life (healthcare); Adverse effect; Internal medicine; Prostatectomy; Urology","score_opus":0.013786439810920353,"score_gpt":0.34443305239049077,"score_spread":0.3306466125795704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405308923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944339,0.002541479,0.0000032054384,0.00119047,0.00018279967,0.0011787227,0.00027534633,0.000043369906,0.0001507121],"genre_scores_gemma":[0.9974228,0.0006117442,0.00060400943,0.0000744445,0.000171937,0.00016230621,0.00015812283,0.00002591111,0.00076872663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854386,0.0001868567,0.0002752636,0.00043280708,0.00025015633,0.0003110344],"domain_scores_gemma":[0.99910104,0.0003412581,0.00010082885,0.00023095122,0.000055687862,0.0001702521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000240134,0.00024489922,0.0007901486,0.00015481161,0.000032740696,0.000013210034,0.000058115274,0.00017834362,0.000038366532],"category_scores_gemma":[0.000068572124,0.0000986652,0.000047834368,0.00021340913,0.00022160988,0.000057466466,0.00003749968,0.00028806584,0.0000023138768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016791295,0.00061829796,0.95544636,0.00039926538,0.00045625624,0.00015511518,0.001739021,1.6569116e-7,0.00063963304,0.000033865923,0.00015224109,0.023568466],"study_design_scores_gemma":[0.034030918,0.026369449,0.92421794,0.00053424726,0.0004592816,0.000012380646,0.0022736979,0.000021800282,0.009659152,0.000041047722,0.0020325962,0.00034750788],"about_ca_topic_score_codex":0.0014939839,"about_ca_topic_score_gemma":0.003339789,"teacher_disagreement_score":0.031228457,"about_ca_system_score_codex":0.0004176689,"about_ca_system_score_gemma":0.0006457127,"threshold_uncertainty_score":0.402345},"labels":[],"label_agreement":null},{"id":"W4405383107","doi":"10.1097/rlu.0000000000005472","title":"18F-DCFPyL in the Detection of Prostate Cancer Spread to the Lumbosacral Plexus","year":2024,"lang":"en","type":"article","venue":"Clinical Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; London Health Sciences Centre; Western University; University Health Network; Centre for Probe Development and Commercialization","funders":"","keywords":"Medicine; Lumbosacral plexus; Prostate cancer; Lumbosacral joint; Plexus; Prostate; Cancer; Anatomy; Internal medicine","score_opus":0.0770375875445151,"score_gpt":0.4439167155611603,"score_spread":0.3668791280166452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405383107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8576479,0.0068233483,0.00000876075,0.1305848,0.0011732084,0.0013197882,0.000014868236,0.00006059132,0.0023667505],"genre_scores_gemma":[0.9907313,0.0029217503,0.000017444656,0.0038597642,0.0010974518,0.000064953805,0.000007321664,0.00002887723,0.0012711353],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998226,0.00017534515,0.00053699367,0.0003065833,0.0004724352,0.00028262648],"domain_scores_gemma":[0.99877787,0.00057088526,0.000046026944,0.00038469772,0.00008177773,0.00013874199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016301807,0.00012789312,0.00035715094,0.00010908092,0.000064894964,0.00001597065,0.00020572582,0.00007083242,0.00034162452],"category_scores_gemma":[0.00053039874,0.00005416789,0.0001127671,0.0006689813,0.0004505262,0.000041487318,0.000059868067,0.00064616575,0.000119131146],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044241818,0.0006768283,0.04496596,0.00085305603,0.00050740445,0.0009017655,0.016022293,0.000016860424,0.008904222,0.000645469,0.11800537,0.8040766],"study_design_scores_gemma":[0.004379284,0.0051957536,0.30312988,0.0020787441,0.00035413055,0.000075675285,0.0033266651,0.0017226213,0.0003089616,0.00041516888,0.67884976,0.00016338006],"about_ca_topic_score_codex":0.00068396406,"about_ca_topic_score_gemma":0.00033403985,"teacher_disagreement_score":0.80391324,"about_ca_system_score_codex":0.00007984357,"about_ca_system_score_gemma":0.00011961037,"threshold_uncertainty_score":0.37405488},"labels":[],"label_agreement":null},{"id":"W4405465567","doi":"10.1016/j.eururo.2024.12.003","title":"Optimal Treatment Strategies for Hormone-sensitive Metastatic Prostate Cancer: Does Local Radiotherapy Play a Role in High-volume Disease?","year":2024,"lang":"en","type":"editorial","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal; Dalhousie University; Université du Québec en Outaouais","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Prostate; Disease; Oncology; Hormone; Prostate disease; Cancer; Internal medicine","score_opus":0.010704047981929475,"score_gpt":0.3039929929434563,"score_spread":0.2932889449615268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405465567","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09245194,0.21723211,0.001106118,0.012781452,0.63742876,0.0139668975,0.022064663,0.0007895909,0.0021784597],"genre_scores_gemma":[0.23842917,0.06920105,0.0011045873,0.00041523782,0.62613434,0.0034896652,0.011929833,0.0011011941,0.048194952],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99642265,0.0004974238,0.0005337085,0.0011519098,0.0004715287,0.0009227617],"domain_scores_gemma":[0.9983765,0.00048900914,0.00015292478,0.00043336098,0.00020153075,0.0003466929],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037021062,0.00069969404,0.0011637876,0.00044603168,0.00009700131,0.000119413475,0.00019210733,0.00021329797,0.000069341615],"category_scores_gemma":[0.0000720109,0.0004460008,0.0003075513,0.0002157279,0.00045255898,0.000095015996,0.00008312494,0.0007667879,0.000091134636],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054027595,0.001262701,0.00023046706,0.0011122084,0.0052691526,0.020616196,0.00705993,0.0040516984,0.0008675968,0.0001892587,0.8840273,0.02128592],"study_design_scores_gemma":[0.012587586,0.008534354,0.0008717731,0.00022518206,0.0014579713,0.000015039968,0.0006570509,0.0022596905,0.00005862476,0.0002928165,0.9724861,0.0005538204],"about_ca_topic_score_codex":0.00063756265,"about_ca_topic_score_gemma":0.00023168461,"teacher_disagreement_score":0.14803106,"about_ca_system_score_codex":0.0010165469,"about_ca_system_score_gemma":0.0023105142,"threshold_uncertainty_score":0.9997992},"labels":[],"label_agreement":null},{"id":"W4405615932","doi":"10.1001/jamaoncol.2024.5661","title":"Government Funding for the Development of Enzalutamide","year":2024,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Enzalutamide; Medicine; Government (linguistics); Drug development; Family medicine; Cancer; Drug; Prostate cancer; Pharmacology; Internal medicine","score_opus":0.07835133754982908,"score_gpt":0.40447987717722983,"score_spread":0.32612853962740074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405615932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87188905,0.017216103,0.0073347995,0.051034544,0.00185179,0.0027085163,0.000051324285,0.00010376088,0.047810115],"genre_scores_gemma":[0.9859331,0.00019662609,0.004239834,0.00028223183,0.00023587752,0.0002734208,0.000010116571,0.00001295073,0.008815837],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993479,0.000014739644,0.00015851829,0.00011646279,0.00018862066,0.00017375224],"domain_scores_gemma":[0.99924845,0.00056455756,0.000022388818,0.00009017523,0.000032257398,0.00004215626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004149746,0.000054894772,0.00013285218,0.000025819863,0.00005916122,0.0000101124115,0.000055911514,0.00005788092,0.00008383571],"category_scores_gemma":[0.000064784836,0.000029401019,0.00005581963,0.000081005404,0.0000546003,0.000022233302,0.000042985463,0.00010043771,0.000017709319],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084882684,0.00013463982,0.0011780491,0.00043129962,0.0004959508,0.00004647991,0.0027352,0.0000020366172,0.026533693,0.0027446179,0.014411956,0.95043725],"study_design_scores_gemma":[0.0013380453,0.0005361795,0.0074666296,0.00010396587,0.00008676106,0.000016179756,0.00084451056,0.0005140071,0.0382956,0.00018106007,0.9505776,0.00003946033],"about_ca_topic_score_codex":0.000003970751,"about_ca_topic_score_gemma":0.000019113844,"teacher_disagreement_score":0.9503978,"about_ca_system_score_codex":0.0007054776,"about_ca_system_score_gemma":0.00056463666,"threshold_uncertainty_score":0.18447994},"labels":[],"label_agreement":null},{"id":"W4405670955","doi":"10.1016/j.celrep.2024.115089","title":"Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer","year":2024,"lang":"en","type":"article","venue":"Cell Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Association of Schools and Colleges of Optometry; Canadian Institutes of Health Research; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; DOD Prostate Cancer Research Program; Türkiye Bilimsel ve Teknolojik Araştırma Kurumu; Movember Foundation; American Society of Clinical Oncology; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Prostate cancer; Androgen receptor; splice; Chromatin; Cancer research; Biology; Transition (genetics); Nuclear receptor; Androgen; Transcription factor; Internal medicine; Cell biology; Endocrinology; Cancer; Medicine; Genetics; DNA; Gene; Hormone","score_opus":0.0192300384475262,"score_gpt":0.3111193689632038,"score_spread":0.2918893305156776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405670955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99372935,0.0019312175,0.000014621834,0.0013808302,0.00028637017,0.001392346,0.00008049922,0.00015443844,0.0010302991],"genre_scores_gemma":[0.99681413,0.0013256781,0.00014626744,0.00021028597,0.00010418896,0.00021397503,0.00017241683,0.000050238727,0.00096279004],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982354,0.000050005532,0.00038781168,0.0005565826,0.0003978617,0.00037235077],"domain_scores_gemma":[0.99922097,0.000055813634,0.00006353605,0.00026653358,0.00008547834,0.00030765584],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021916302,0.00018874701,0.0002813078,0.00024352579,0.00005688691,0.000090358044,0.00007865387,0.00008757203,0.0011557706],"category_scores_gemma":[0.000052631854,0.00014757835,0.00006804927,0.0005927877,0.000042517015,0.00025118524,0.000048591806,0.0002346675,0.00008467604],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012477937,0.0006031711,0.030080562,0.002089134,0.00021739025,0.04062944,0.013392186,0.00006941036,0.8889456,0.00000476666,0.0055646556,0.017155921],"study_design_scores_gemma":[0.0054672123,0.0017874928,0.1457255,0.005924625,0.0003671234,0.0016163666,0.00133156,0.004033111,0.7572701,0.00016164787,0.074889675,0.0014256082],"about_ca_topic_score_codex":0.0015361743,"about_ca_topic_score_gemma":0.00016871616,"teacher_disagreement_score":0.13167548,"about_ca_system_score_codex":0.00035311648,"about_ca_system_score_gemma":0.0005456035,"threshold_uncertainty_score":0.9997573},"labels":[],"label_agreement":null},{"id":"W4405820960","doi":"10.3390/curroncol32010009","title":"Evaluating [68Ga]-Ga PSMA PET/CT for Detecting Prostate Cancer Recurrence Post-High-Intensity Focused Ultrasound and Brachytherapy: A Single-Center Retrospective Study","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Brachytherapy; Prostate cancer; Radiology; Retrospective cohort study; Ultrasound; Nuclear medicine; Cancer; Prostate; Medical physics; Radiation therapy; Oncology; Internal medicine","score_opus":0.16587290043962236,"score_gpt":0.47255851442103614,"score_spread":0.3066856139814138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405820960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98037803,0.010535168,0.000040629853,0.0013974975,0.0027159802,0.004510942,0.0001989688,0.0001580342,0.00006472222],"genre_scores_gemma":[0.9964658,0.00085326814,0.0004274367,0.00008607488,0.00050934375,0.0012276716,0.00007833247,0.00006021958,0.00029183936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973373,0.00021335082,0.00043055732,0.00094893435,0.000397907,0.00067198015],"domain_scores_gemma":[0.9980542,0.000536736,0.00014069754,0.0002634742,0.0007979213,0.00020698327],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009368672,0.00033773604,0.00068566325,0.00023317535,0.00030799254,0.00012013997,0.00010520744,0.000029492214,0.00007642279],"category_scores_gemma":[0.00064871233,0.00025979755,0.00013444373,0.00038409905,0.00021326041,0.00017104878,0.000099261204,0.0006687087,0.000009863835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057990854,0.0027907623,0.51205075,0.000944757,0.0008439479,0.0009015299,0.007132376,0.0000026739765,0.011323428,0.00003159173,0.0010603628,0.45711872],"study_design_scores_gemma":[0.11422679,0.19076222,0.5620259,0.00936341,0.0052641868,0.016266627,0.01889865,0.014059381,0.019988079,0.004389324,0.04105241,0.0037030545],"about_ca_topic_score_codex":0.00016643426,"about_ca_topic_score_gemma":0.00045792325,"teacher_disagreement_score":0.4534157,"about_ca_system_score_codex":0.0015014565,"about_ca_system_score_gemma":0.0006345318,"threshold_uncertainty_score":0.9999854},"labels":[],"label_agreement":null},{"id":"W4405889321","doi":"10.1002/ijc.35323","title":"Life expectancy in rare histological prostate cancer subtypes","year":2024,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Relative survival; Neuroendocrine tumors; Medicine; Population; Internal medicine; Oncology; Prostate cancer; Adenocarcinoma; Cancer; Stage (stratigraphy); Pathology; Cancer registry; Biology","score_opus":0.032857543966418774,"score_gpt":0.39917944636776326,"score_spread":0.3663219024013445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405889321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7633669,0.19285712,0.000024379682,0.03931475,0.0028062868,0.0001661937,0.00003985777,0.00002082137,0.0014036886],"genre_scores_gemma":[0.9772013,0.018392198,0.0000701917,0.0005133423,0.0010460546,0.000044320583,0.0000051226125,0.000015016412,0.002712472],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987459,0.000023527968,0.00034113997,0.00014013417,0.0005819729,0.00016733489],"domain_scores_gemma":[0.99925375,0.000052675972,0.0000858657,0.000053363856,0.00039248975,0.00016183223],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012712694,0.000098565724,0.00021703033,0.000321439,0.0000142047475,0.000047825637,0.00014804158,0.000052666244,0.0015695705],"category_scores_gemma":[0.00009584598,0.00006407516,0.00012114476,0.0001678122,0.000059990245,0.0001725957,0.000028446853,0.00033413756,0.000013241758],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009697359,0.0006610146,0.65171105,0.00033229063,0.0031756929,0.0191911,0.0044362685,0.00034060038,0.013645644,0.001256375,0.074452065,0.22110054],"study_design_scores_gemma":[0.014245513,0.0014109097,0.24783848,0.0084412,0.00044476194,0.0011836071,0.0009251598,0.0012411532,0.017629718,0.0031577835,0.7029075,0.0005742141],"about_ca_topic_score_codex":0.00015067338,"about_ca_topic_score_gemma":0.000096996286,"teacher_disagreement_score":0.6284554,"about_ca_system_score_codex":0.00083097856,"about_ca_system_score_gemma":0.0014356513,"threshold_uncertainty_score":0.99934316},"labels":[],"label_agreement":null},{"id":"W4405890183","doi":"10.56838/icmed.v14i4.228","title":"Supervivencia libre de metástasis en pacientescon cáncer de próstata localizado y localmenteavanzado posterior a prostatectomía vsradioterapia: revisión sistemática y meta-análisis","year":2024,"lang":"es","type":"article","venue":"Interciencia médica","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gynecology; Humanities","score_opus":0.03664752360902896,"score_gpt":0.34696416697076254,"score_spread":0.3103166433617336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405890183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57345104,0.36323357,0.0067964564,0.038890354,0.0019312459,0.0066366913,0.0032034772,0.0011472532,0.0047099344],"genre_scores_gemma":[0.9704511,0.016448656,0.0013344289,0.002551559,0.0007022138,0.00079421874,0.00021822605,0.00030972747,0.0071898717],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.989442,0.0013965529,0.0017020302,0.0023612732,0.0021193086,0.0029788364],"domain_scores_gemma":[0.9949495,0.00092916447,0.00025766977,0.0016538809,0.0005523327,0.0016574143],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0034979084,0.0014006157,0.002303269,0.0012487372,0.00046341083,0.001686207,0.0014623336,0.00067175843,0.004350899],"category_scores_gemma":[0.00090906565,0.0010256798,0.0017517569,0.0024371871,0.0011924545,0.001009245,0.00089471316,0.0017813083,0.0008771387],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0108294105,0.006241253,0.047490157,0.055323455,0.065668166,0.03453756,0.08529958,0.00006307518,0.19205533,0.0024636618,0.107682705,0.39234564],"study_design_scores_gemma":[0.010204037,0.013356574,0.012356608,0.039063483,0.053004686,0.004629808,0.012907862,0.020523855,0.2368856,0.00074890413,0.59164375,0.004674838],"about_ca_topic_score_codex":0.00069351785,"about_ca_topic_score_gemma":0.000051354982,"teacher_disagreement_score":0.48396102,"about_ca_system_score_codex":0.0038700714,"about_ca_system_score_gemma":0.0037834726,"threshold_uncertainty_score":0.99995387},"labels":[],"label_agreement":null},{"id":"W4405944131","doi":"10.3390/curroncol32010015","title":"Focal Therapy for Prostate Cancer: Recent Advances and Insights","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Ablation; Lesion; Radiology; Intensive care medicine; Surgery; Internal medicine","score_opus":0.260636194364567,"score_gpt":0.5517984174686431,"score_spread":0.29116222310407613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405944131","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023905955,0.99094766,0.0000030517467,0.0007825458,0.0029438096,0.004694031,0.0001932157,0.00007219273,0.00033960977],"genre_scores_gemma":[9.979888e-7,0.9924805,0.00003923183,0.0000379697,0.0007100833,0.004761434,0.00050902733,0.000066084685,0.0013946478],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99825174,0.0000972711,0.00042328087,0.0006324403,0.00017476702,0.00042049796],"domain_scores_gemma":[0.99911755,0.00017656684,0.00014503801,0.00019668213,0.0001559587,0.00020822356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014253918,0.00040266057,0.0016542743,0.00024080223,0.000082187486,0.000026861115,0.00010078959,0.00026259106,0.000048782193],"category_scores_gemma":[0.000028111224,0.0002232094,0.00027010211,0.00027059822,0.00020441777,0.00004739624,0.00007956312,0.00057409174,0.000026480411],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029747578,0.00023279876,0.0000127362455,0.040202953,0.00034339848,0.0000376531,0.000253101,1.2720182e-8,2.0066308e-7,0.00006735195,0.010734619,0.9478177],"study_design_scores_gemma":[0.0019914648,0.0018546862,0.0000014698785,0.010211694,0.0012598516,0.000044745164,0.000029199955,0.000005449658,0.000002637886,0.00047900825,0.9839109,0.00020884868],"about_ca_topic_score_codex":0.0000023738178,"about_ca_topic_score_gemma":0.000018072404,"teacher_disagreement_score":0.9731763,"about_ca_system_score_codex":0.0007292101,"about_ca_system_score_gemma":0.0020314602,"threshold_uncertainty_score":0.9102215},"labels":[],"label_agreement":null},{"id":"W4405955605","doi":"10.4103/iju.iju_347_24","title":"Comparison of the duration of androgen deprivation therapy in prostate cancer-RADICALS-HD trial","year":2025,"lang":"en","type":"article","venue":"Indian Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Androgen deprivation therapy; Randomization; Prostate cancer; Prostatectomy; Radiation therapy; Randomized controlled trial; Surgery; Cancer; Internal medicine; Oncology","score_opus":0.039314022705373194,"score_gpt":0.38948702529234586,"score_spread":0.35017300258697265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405955605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98753035,0.0031745539,0.000013360529,0.008489624,0.00025788075,0.00045027432,0.0000041129733,0.0000011570613,0.00007866633],"genre_scores_gemma":[0.9989682,0.0007644255,0.000023562336,0.00011276671,0.000062765466,0.000008993128,0.0000023443665,0.0000036019715,0.000053377582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998954,0.0001474882,0.00055383344,0.000061630446,0.00017525085,0.00010777333],"domain_scores_gemma":[0.99924207,0.00008594615,0.0003991051,0.000094439245,0.00014766229,0.000030788622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036778342,0.00005343609,0.00031374287,0.00023739837,0.000022351607,0.0000028202844,0.000096384785,0.00006507547,0.000026086293],"category_scores_gemma":[0.00010912376,0.00003144091,0.000072452276,0.00027570166,0.00012867378,0.00003779228,0.000012439169,0.00022934533,2.0613899e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039190635,0.00039057422,0.916987,0.000045257042,0.00017897534,0.000031707972,0.0019152581,0.00008121103,0.011600749,0.000043775533,0.00030698167,0.029227853],"study_design_scores_gemma":[0.09465552,0.0067794886,0.7534986,0.00024748038,0.00011649701,0.00006397738,0.00036104058,0.00014722483,0.14019059,0.0016093691,0.0022604244,0.000069783106],"about_ca_topic_score_codex":0.000056703637,"about_ca_topic_score_gemma":0.000048622704,"teacher_disagreement_score":0.16348842,"about_ca_system_score_codex":0.000063770225,"about_ca_system_score_gemma":0.00070391444,"threshold_uncertainty_score":0.1282123},"labels":[],"label_agreement":null},{"id":"W4406063504","doi":"10.1016/j.acra.2024.12.027","title":"Prognostic Value of Response Evaluation Using PSMA PET/CT in Patients with Metastatic Prostate Cancer (RECIP 1.0): A Systematic Review and Meta-analysis","year":2025,"lang":"en","type":"review","venue":"Academic Radiology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Prostate cancer; Meta-analysis; Radiology; Oncology; Nuclear medicine; Cancer; Internal medicine","score_opus":0.13113115915050302,"score_gpt":0.45766114349491627,"score_spread":0.32652998434441327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406063504","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036506031,0.9782358,0.0000031189063,0.00024045416,0.000025517817,0.017574297,0.00025103896,0.000011752429,0.0000074506074],"genre_scores_gemma":[0.00069284794,0.99320155,0.00019244167,0.00013084123,0.000006869983,0.0049735364,0.00036740414,0.000038723745,0.0003957555],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9911016,0.005273827,0.0018108852,0.00075059885,0.00062021555,0.00044283504],"domain_scores_gemma":[0.9957934,0.0018944729,0.0012460039,0.0005565162,0.0003875002,0.00012207522],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004509933,0.0005577016,0.010460328,0.0023707754,0.000043837492,0.0000062048316,0.00021683027,0.00009292116,0.00007288179],"category_scores_gemma":[0.002217199,0.0003017593,0.00077139656,0.0038194486,0.00021178451,0.0000752461,0.000079055615,0.0008338326,0.0000019644833],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037658217,0.00006866029,0.0016194714,0.861268,0.13510391,0.00009096721,0.00006161211,0.000026737463,1.9807636e-7,0.0000064876713,0.000037021724,0.00134039],"study_design_scores_gemma":[0.0013481149,0.00029714926,0.00028818796,0.116705336,0.88047963,0.00020655083,0.000010795933,0.000100437996,3.7157983e-7,0.000011767402,0.00033634575,0.00021530406],"about_ca_topic_score_codex":0.00010148539,"about_ca_topic_score_gemma":0.000008821739,"teacher_disagreement_score":0.74537575,"about_ca_system_score_codex":0.0006002113,"about_ca_system_score_gemma":0.0020189555,"threshold_uncertainty_score":0.99994344},"labels":[],"label_agreement":null},{"id":"W4406102421","doi":"10.1177/11795549241311408","title":"Adaptive Treatment of Metastatic Prostate Cancer Using Generative Artificial Intelligence","year":2025,"lang":"en","type":"review","venue":"Clinical Medicine Insights Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"Toronto Metropolitan University","keywords":"Prostate cancer; Medicine; Metastasis; Cancer; Radiation therapy; Clinical trial; Androgen deprivation therapy; Oncology; Disease; Internal medicine","score_opus":0.5304426451892652,"score_gpt":0.598056034547892,"score_spread":0.06761338935862682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406102421","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000097770644,0.9903509,0.0004168631,0.0009424672,0.0018148323,0.0044926987,0.000106296495,0.000035337318,0.0017428057],"genre_scores_gemma":[0.00006934245,0.9934593,0.0019291791,0.00017943376,0.0015184946,0.00075947354,0.00021601738,0.000054768887,0.0018140057],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99355656,0.0013163486,0.0031107252,0.0010225822,0.00045148385,0.00054230774],"domain_scores_gemma":[0.99267316,0.004464285,0.0011873633,0.0006163805,0.00063003367,0.00042879226],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005407787,0.00074031024,0.0073610214,0.0006937185,0.00011647976,0.000006480514,0.00023457517,0.0006264769,0.0004449479],"category_scores_gemma":[0.00077288493,0.00039013493,0.0008799271,0.0010285601,0.0020368514,0.000048704973,0.00011037451,0.0007535642,0.000023272145],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009672155,0.0017222135,0.000011524715,0.00639686,0.002925314,0.000833711,0.0006900477,0.0000036178765,0.000003817345,0.0006791262,0.00024013378,0.98552644],"study_design_scores_gemma":[0.0026908836,0.028122889,0.0000048648617,0.03420451,0.018851923,0.000094307616,0.00059687695,0.00036761397,0.00012203245,0.0024725876,0.91202897,0.0004425439],"about_ca_topic_score_codex":0.0003185043,"about_ca_topic_score_gemma":0.00013431913,"teacher_disagreement_score":0.9850839,"about_ca_system_score_codex":0.0016702545,"about_ca_system_score_gemma":0.009516708,"threshold_uncertainty_score":0.99985504},"labels":[],"label_agreement":null},{"id":"W4406132320","doi":"10.3389/fonc.2024.1483953","title":"Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial","year":2025,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre hospitalier universitaire de Québec; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Dosimetry; Oncology; Cohort; Clinical trial; Cancer; Internal medicine; Nuclear medicine","score_opus":0.0415762850327111,"score_gpt":0.40894321650862486,"score_spread":0.36736693147591376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406132320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876717,0.0049354364,0.000039348775,0.003220097,0.00085969357,0.0028592204,0.00004690964,0.000005973449,0.000361651],"genre_scores_gemma":[0.9902228,0.008415787,0.00042341882,0.0003016394,0.00009843649,0.0002879492,0.000015473155,0.00001144329,0.00022305356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977983,0.0005949713,0.0006905085,0.00036986358,0.00023926827,0.00030708572],"domain_scores_gemma":[0.9986255,0.0008395485,0.00015273083,0.000283977,0.00004629489,0.00005194867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078280777,0.00016412872,0.0007335863,0.00014887152,0.00006731681,0.000014364459,0.00019636985,0.00012034733,0.000017079688],"category_scores_gemma":[0.00021285916,0.00008605931,0.000060183214,0.0006061081,0.00089881074,0.000052858224,0.00005635445,0.00048599698,2.5354845e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12220013,0.0005539807,0.8269406,0.000016829772,0.00022119803,0.00011035721,0.0026907555,0.00003305846,0.0001821963,0.000018601,0.0009113004,0.04612102],"study_design_scores_gemma":[0.11733802,0.0024719809,0.8723943,0.00030279646,0.00010265038,0.0000050120634,0.0026955782,0.0002993511,0.0015773992,0.00019091493,0.0025093653,0.000112627284],"about_ca_topic_score_codex":0.0022693973,"about_ca_topic_score_gemma":0.0037853601,"teacher_disagreement_score":0.046008393,"about_ca_system_score_codex":0.0004188529,"about_ca_system_score_gemma":0.0014434109,"threshold_uncertainty_score":0.3509397},"labels":[],"label_agreement":null},{"id":"W4406144247","doi":"10.1158/1541-7786.mcr-24-0958","title":"Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; Richmond Hospital; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Mitacs; Terry Fox Research Institute; National Cancer Institute; BC Cancer Foundation; Pacific Northwest Foundation","keywords":"Prostate cancer; Dormancy; LNCaP; Cancer research; Androgen deprivation therapy; Extracellular matrix; Biology; In vivo; Cancer; Medicine; Internal medicine; Cell biology; Genetics","score_opus":0.18518949752817926,"score_gpt":0.4223734758698284,"score_spread":0.23718397834164912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406144247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8318559,0.16038738,0.000025610561,0.0058725486,0.00009393022,0.0012007763,0.00001908581,0.000034668774,0.00051008916],"genre_scores_gemma":[0.9164932,0.07186852,0.000038705326,0.00014312184,0.0000494642,0.004902695,0.000022035289,0.000039811355,0.006442491],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99783695,0.0002135358,0.00028434617,0.0004631895,0.0005706965,0.00063125725],"domain_scores_gemma":[0.99910516,0.0000638159,0.000035148256,0.00034528231,0.00030217582,0.00014844359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005314911,0.00020274046,0.00027064147,0.000933834,0.00017248283,0.00010728153,0.00012447288,0.00006059958,0.00023637209],"category_scores_gemma":[0.000017999262,0.00016967206,0.00006982727,0.0008731282,0.00019924248,0.00024375306,0.00013105612,0.00060415495,0.0000065197705],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051025213,0.00044769543,0.25654382,0.000659159,0.0006823066,0.0011547197,0.0043285796,0.00008007198,0.2942568,0.00096795073,0.0001581465,0.43561822],"study_design_scores_gemma":[0.013945787,0.00083712244,0.18209594,0.0035981566,0.00019049847,0.00004613483,0.007493797,0.0021381725,0.61974937,0.0032119986,0.16578132,0.0009117253],"about_ca_topic_score_codex":0.0022708469,"about_ca_topic_score_gemma":0.00043595379,"teacher_disagreement_score":0.4347065,"about_ca_system_score_codex":0.0005308596,"about_ca_system_score_gemma":0.0006366397,"threshold_uncertainty_score":0.6919026},"labels":[],"label_agreement":null},{"id":"W4406144783","doi":"10.17161/sjm.v1i1.23103","title":"The 2nd SAU Annual Conference on Urological Research","year":2024,"lang":"en","type":"article","venue":"Serican Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Banquet; Opening ceremony; Library science; Cancer; Political science; Internal medicine; History; Art history","score_opus":0.13055902763472632,"score_gpt":0.457281159422445,"score_spread":0.3267221317877187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406144783","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41389394,0.024521798,0.0000553259,0.5272939,0.0011231886,0.00042187117,0.000008806556,0.000037270984,0.032643855],"genre_scores_gemma":[0.985779,0.0057614655,0.000037418333,0.0004616852,0.0015602943,0.000005430756,0.0000023029017,0.000013347315,0.0063790656],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759185,0.00023665189,0.00034364293,0.00015990037,0.0012789892,0.00038895677],"domain_scores_gemma":[0.9978507,0.000809868,0.00005999123,0.00019622475,0.0007503578,0.00033285544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029114252,0.000110332745,0.00030502438,0.00025598455,0.00017144687,0.000035601435,0.00022934438,0.000055127937,0.0005507134],"category_scores_gemma":[0.00070544117,0.0000439407,0.00007648541,0.00056947244,0.001241074,0.000058490157,0.000042376938,0.0012757543,0.00003417287],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011971134,0.0003817314,0.0029872225,0.00020418456,0.0008576239,0.014029337,0.007484077,0.000005600258,0.009880866,0.012176023,0.60150343,0.33851877],"study_design_scores_gemma":[0.0064893514,0.050461,0.022599293,0.0029128143,0.00019331895,0.0035969727,0.017573265,0.00033595698,0.0013250948,0.010083712,0.88424826,0.00018097449],"about_ca_topic_score_codex":0.000012415907,"about_ca_topic_score_gemma":0.0000017157895,"teacher_disagreement_score":0.57188505,"about_ca_system_score_codex":0.00015855345,"about_ca_system_score_gemma":0.00060277025,"threshold_uncertainty_score":0.60299253},"labels":[],"label_agreement":null},{"id":"W4406242232","doi":"10.3390/cancers17020215","title":"Early Versus Delayed Androgen Deprivation Therapy for Biochemical Recurrence After Local Curative Treatment in Non-Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of the Literature","year":2025,"lang":"en","type":"review","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Androgen deprivation therapy; Prostate cancer; Medicine; Oncology; Internal medicine; Hormone therapy; Hormone; Biochemical recurrence; Cancer; Prostatectomy; Breast cancer","score_opus":0.03154324292837274,"score_gpt":0.373053960791964,"score_spread":0.3415107178635913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406242232","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00064085546,0.97786814,0.000020193886,0.00015122331,0.00020871364,0.01957591,0.0015029075,0.000010506331,0.00002154031],"genre_scores_gemma":[0.0009512776,0.97953624,0.000044235294,0.00009995601,0.000038396814,0.018507853,0.0004931106,0.0000369356,0.0002919885],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99760795,0.0002766068,0.0008408479,0.0005573447,0.0003422498,0.00037499735],"domain_scores_gemma":[0.9980112,0.00044398988,0.00050689164,0.0005184458,0.0004198207,0.000099678364],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022999558,0.0005268692,0.0026070168,0.0002003326,0.000051027015,0.00002247294,0.0001819306,0.00017768877,0.0000048461725],"category_scores_gemma":[0.00015092545,0.0002745725,0.00067465403,0.0012610788,0.00019471023,0.00007019756,0.000042328033,0.00032550204,0.0000015262061],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004338577,0.000072667935,0.0000056668528,0.8784091,0.0021163868,0.000045040557,0.0014981077,0.0000013424717,0.0000041663607,0.0000034410207,0.0003829745,0.11312253],"study_design_scores_gemma":[0.004495042,0.0015474895,0.000008285121,0.98449904,0.0040027387,0.0000095844825,0.000116949246,0.000027030836,0.00020258289,0.0000071518466,0.004809564,0.00027452086],"about_ca_topic_score_codex":0.00019134597,"about_ca_topic_score_gemma":0.000035681394,"teacher_disagreement_score":0.11284801,"about_ca_system_score_codex":0.005111978,"about_ca_system_score_gemma":0.0047330824,"threshold_uncertainty_score":0.9999707},"labels":[],"label_agreement":null},{"id":"W4406309903","doi":"10.1101/2025.01.08.631986","title":"AR-V7 condensates drive androgen-independent transcription in castration resistant prostate cancer","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"","keywords":"Prostate cancer; Castration; Androgen; Transcription (linguistics); Internal medicine; Transcription factor; Cancer research; Oncology; Medicine; Cancer; Biology; Hormone; Gene; Genetics","score_opus":0.02179117329751295,"score_gpt":0.2802796386032485,"score_spread":0.25848846530573555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406309903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985859,0.008043197,0.000021145286,0.0013256469,0.0007735775,0.0028578555,0.00087421254,0.00020121354,0.000044178614],"genre_scores_gemma":[0.9939794,0.0037264256,0.00042426106,0.00014118553,0.00021050197,0.0011615385,0.000006498562,0.00007124995,0.00027892005],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966419,0.00015800404,0.0006904672,0.0011354617,0.0006651433,0.00070905837],"domain_scores_gemma":[0.9979881,0.00004024227,0.00025048666,0.0007773387,0.0006513903,0.00029243954],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051654316,0.00057050027,0.00077816506,0.00060719164,0.00013422238,0.00015375832,0.0002271947,0.0005716492,0.00009562817],"category_scores_gemma":[0.000059864873,0.0005379883,0.00018636584,0.0006296181,0.00014789011,0.0001521953,0.00013904567,0.0011112933,0.000022780836],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013272973,0.0003579557,0.040243525,0.0017681506,0.00040230845,0.0005889844,0.00015289661,0.00008936232,0.95475143,0.00014040578,0.00016424102,0.000013411343],"study_design_scores_gemma":[0.0048851627,0.0002453716,0.21812995,0.0033749645,0.00040378762,6.495486e-8,0.000045640765,0.0003209215,0.77012926,0.000008586739,0.0017944122,0.0006618944],"about_ca_topic_score_codex":0.0006378905,"about_ca_topic_score_gemma":0.0002281832,"teacher_disagreement_score":0.18462221,"about_ca_system_score_codex":0.0015767638,"about_ca_system_score_gemma":0.0028205602,"threshold_uncertainty_score":0.99970716},"labels":[],"label_agreement":null},{"id":"W4406321141","doi":"10.1007/978-1-59259-099-5","title":"Prostate Cancer Screening","year":2001,"lang":"en","type":"book","venue":"Humana Press eBooks","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Texas Health Science Center at San Antonio; Erasmus Universiteit Rotterdam; Barbara Ann Karmanos Cancer Institute; Université Laval; University of Washington; School of Medicine, Case Western Reserve University; University of California, Los Angeles; Case Western Reserve University; Wayne State University","keywords":"Prostate cancer; Cancer; Medicine; Oncology; Internal medicine","score_opus":0.12282019431144639,"score_gpt":0.3650875473365562,"score_spread":0.2422673530251098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406321141","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007312144,0.0541662,0.000010546293,0.00010135713,0.00020217574,0.0016977381,0.00012052113,0.0001961107,0.9434322],"genre_scores_gemma":[0.00013049766,0.011945526,0.000095704556,0.00023423394,0.0011591113,0.00049131835,0.0003564101,0.00016175685,0.9854254],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977141,0.00003116585,0.0003408803,0.0006121103,0.00066801585,0.00063371495],"domain_scores_gemma":[0.9987009,0.000033621407,0.00016649938,0.0006049858,0.00020889215,0.0002850855],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011750707,0.00045564826,0.0006558632,0.00020937934,0.00018257534,0.00007368353,0.00020577571,0.00033053165,0.00053496874],"category_scores_gemma":[0.000007014329,0.0003670224,0.00023350916,0.000015494243,0.00024597053,0.00004081973,0.00016974981,0.00081040495,0.00003964866],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011188356,0.00006932166,0.00007228922,0.0014654738,0.0015450204,0.0020234513,0.0010224815,0.0000057747648,0.00004617878,0.0020444477,0.39789608,0.59269065],"study_design_scores_gemma":[0.0023510563,0.00021095655,0.00007682916,0.0017308923,0.00047495504,0.000030190295,0.0000099936005,0.000021228147,0.000443989,0.0004632615,0.9938305,0.0003561359],"about_ca_topic_score_codex":0.00045599777,"about_ca_topic_score_gemma":0.0000861295,"teacher_disagreement_score":0.59593445,"about_ca_system_score_codex":0.0003986271,"about_ca_system_score_gemma":0.00069190067,"threshold_uncertainty_score":0.99987817},"labels":[],"label_agreement":null},{"id":"W4406396521","doi":"10.1016/j.ymed.2014.08.013","title":"10.1016/j.ymed.2014.08.013","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Radium-223; Prostate cancer; Radium; Oncology; Cancer; Overall survival; Prostate; Internal medicine; Radiochemistry","score_opus":0.011095414676153114,"score_gpt":0.2414982462740318,"score_spread":0.2304028315978787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406396521","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040482967,0.0004767547,1.5354465e-7,0.0020282522,0.0000013833819,0.0003920512,0.000014025278,0.000107088745,0.992932],"genre_scores_gemma":[0.0003827676,0.0000065933127,0.00006651221,0.00007890923,0.00019359856,0.000044072614,0.000054872802,0.000026242464,0.9991464],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99906266,0.00002184395,0.00011929285,0.0002134914,0.000254516,0.00032822226],"domain_scores_gemma":[0.99934757,0.000029246577,0.000011547056,0.00028059393,0.000053187152,0.00027784315],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009440344,0.00011746864,0.000186076,0.000082083054,0.00005865358,0.000019492301,0.00008999968,0.000055637935,0.9985641],"category_scores_gemma":[0.000016623453,0.00008826997,0.0000621739,0.00016674811,0.00004661362,0.000048180304,0.00002612631,0.00012120941,0.99738276],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047070658,0.00009057542,0.0000022959987,0.000014653086,0.000043073353,0.00004027246,0.000028383127,0.0000020862565,0.00021444763,2.0271138e-7,0.49392313,0.50517017],"study_design_scores_gemma":[0.0011359073,0.00051061943,0.00021419965,0.000041033716,0.000034774963,0.0000161653,0.0000015297568,0.000041540727,0.00086453324,0.0000040213636,0.9970372,0.00009853159],"about_ca_topic_score_codex":0.000023943217,"about_ca_topic_score_gemma":1.01102465e-7,"teacher_disagreement_score":0.50507164,"about_ca_system_score_codex":0.000084556115,"about_ca_system_score_gemma":0.00008284426,"threshold_uncertainty_score":0.35995448},"labels":[],"label_agreement":null},{"id":"W4406439429","doi":"10.4103/atmr.atmr_185_24","title":"Safety and Efficacy of Niraparib in Metastatic Castration-resistant Prostate Cancer: Systematic Review and Meta-analysis","year":2024,"lang":"en","type":"article","venue":"Journal of Advanced Trends in Medical Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Meta-analysis; Oncology; Medicine; Castration; Cancer; Internal medicine; Prostate","score_opus":0.11117690444059995,"score_gpt":0.4949693219999281,"score_spread":0.38379241755932814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406439429","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04556899,0.9312669,0.000020896608,0.021763872,0.000032700507,0.001058121,0.00005872942,0.000006038972,0.00022373718],"genre_scores_gemma":[0.7413378,0.2564607,0.00050709746,0.000087211396,0.000019848685,0.000110109504,0.000013130814,0.000019688632,0.0014444238],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9949558,0.0007248136,0.0014896356,0.00029238747,0.0021496282,0.00038773371],"domain_scores_gemma":[0.99703836,0.0017646161,0.00019545507,0.00021779866,0.00039264243,0.00039114314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007208885,0.00016773625,0.0024486466,0.0020549982,0.00003955899,0.00003277023,0.00015021747,0.00006347758,0.0005227006],"category_scores_gemma":[0.0021839098,0.00009365517,0.00034214495,0.0035566143,0.00035846373,0.00017462432,0.000067231835,0.0010734256,6.946747e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00925239,0.0020408437,0.0024594625,0.68437433,0.18261492,0.01703821,0.0045110066,0.00039049983,0.0018442797,0.0011511348,0.00058980554,0.0937331],"study_design_scores_gemma":[0.033274867,0.009062517,0.044419847,0.1842439,0.71326274,0.001498236,0.003906709,0.0041321106,0.001496932,0.0018477518,0.0018449802,0.0010094127],"about_ca_topic_score_codex":0.000117456126,"about_ca_topic_score_gemma":0.00042137175,"teacher_disagreement_score":0.6957688,"about_ca_system_score_codex":0.00025520896,"about_ca_system_score_gemma":0.0007096334,"threshold_uncertainty_score":0.5723205},"labels":[],"label_agreement":null},{"id":"W4406455611","doi":"10.1016/s0084-3873(13)00204-6","title":"10.1016/s0084-3873(13)00204-6","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Internal medicine; Chemotherapy; Urology; Cancer","score_opus":0.012247008453356871,"score_gpt":0.2406317136701964,"score_spread":0.2283847052168395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406455611","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003614825,0.00037533816,1.5479755e-7,0.0018398914,0.0000011558972,0.0003997138,0.000016021442,0.00011042241,0.99364245],"genre_scores_gemma":[0.00027961825,0.0000040078953,0.00005765973,0.000046086247,0.00020733994,0.000043865755,0.000055722197,0.000027310587,0.99927837],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99901044,0.000022216118,0.00012896545,0.00022741672,0.00026804788,0.00034293107],"domain_scores_gemma":[0.9993292,0.000027571152,0.000012218306,0.00028779617,0.000056672092,0.0002865034],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0000932489,0.00012665066,0.00019810587,0.00008414013,0.00006780945,0.000020931957,0.000095128664,0.000060547143,0.9983563],"category_scores_gemma":[0.000019628984,0.0000966809,0.00006732348,0.00022895927,0.000047358684,0.000051023264,0.00002817764,0.0001370472,0.9950245],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005501271,0.00010258941,0.0000025672275,0.000015191916,0.00004661507,0.00005413863,0.00002503555,0.0000032474343,0.00019030223,1.9553453e-7,0.2947588,0.7042512],"study_design_scores_gemma":[0.0012378468,0.00057404186,0.00024884692,0.000046572426,0.000038529015,0.000019842279,0.0000017279981,0.000055449847,0.00085735857,0.0000047237254,0.99680746,0.00010762258],"about_ca_topic_score_codex":0.00003449448,"about_ca_topic_score_gemma":1.6324263e-7,"teacher_disagreement_score":0.7041436,"about_ca_system_score_codex":0.00009277324,"about_ca_system_score_gemma":0.0000876914,"threshold_uncertainty_score":0.39425328},"labels":[],"label_agreement":null},{"id":"W4406469505","doi":"10.1016/j.ymed.2015.06.091","title":"10.1016/j.ymed.2015.06.091","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Abiraterone; Medicine; Prostate cancer; Oncology; Internal medicine; Cancer; Androgen receptor","score_opus":0.012671188501217708,"score_gpt":0.2564352585785977,"score_spread":0.24376407007738002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406469505","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024130864,0.0005479562,1.725376e-7,0.0026311711,0.0000011082864,0.00038670382,0.00001583811,0.00010174722,0.9939022],"genre_scores_gemma":[0.00043651933,0.000004806344,0.00006362597,0.00007618439,0.0001980714,0.00004079694,0.00007602412,0.000025196377,0.99907875],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99905425,0.000021554732,0.000119841454,0.00020989857,0.0002642851,0.00033014556],"domain_scores_gemma":[0.9993396,0.000027944372,0.000011508906,0.00027851248,0.000055788314,0.0002866462],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009635406,0.00011770834,0.00018747516,0.000082970466,0.000059687474,0.000018914538,0.00009062952,0.000056298657,0.9972953],"category_scores_gemma":[0.00001958392,0.000088718385,0.00006099255,0.00020244921,0.00004662752,0.000049338203,0.000026659225,0.00012268084,0.9954675],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004108408,0.0000959954,0.0000027832764,0.000013549597,0.00004718364,0.000044677276,0.000023680896,0.000002011598,0.00020153912,2.1293877e-7,0.5441376,0.45501992],"study_design_scores_gemma":[0.0011626926,0.0004637214,0.0002176927,0.00004633166,0.000039025006,0.00001703233,0.0000016172974,0.000042486285,0.0009394587,0.000004063392,0.99696654,0.00009936416],"about_ca_topic_score_codex":0.000023223558,"about_ca_topic_score_gemma":8.852453e-8,"teacher_disagreement_score":0.45492056,"about_ca_system_score_codex":0.000089387606,"about_ca_system_score_gemma":0.000089409376,"threshold_uncertainty_score":0.3617831},"labels":[],"label_agreement":null},{"id":"W4406479414","doi":"10.1016/j.ymed.2015.06.098","title":"10.1016/j.ymed.2015.06.098","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Malignancy; Prostate cancer; Prostate; Cancer; Oncology; Gynecology; Internal medicine","score_opus":0.012630987135969263,"score_gpt":0.2562158488501027,"score_spread":0.2435848617141334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406479414","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027800659,0.0005420448,1.7235527e-7,0.0025908533,0.0000011088024,0.00038677626,0.00001582625,0.000101985235,0.9935812],"genre_scores_gemma":[0.00045551802,0.000004768787,0.00006311681,0.00007581315,0.00019757163,0.000040789222,0.00007403035,0.00002525058,0.99906313],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99905545,0.000021578919,0.00011977756,0.00020977059,0.00026431947,0.00032912008],"domain_scores_gemma":[0.9993412,0.000027988273,0.0000115098865,0.0002782897,0.00005580385,0.0002852228],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000097725075,0.00011764969,0.000187442,0.00008289912,0.00005933041,0.000018828989,0.00008992982,0.000056264318,0.9971185],"category_scores_gemma":[0.000019694433,0.00008869178,0.00006097209,0.00020259399,0.000046499423,0.000049165777,0.000026637068,0.00012267249,0.9954904],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004289379,0.0001003775,0.000002927436,0.000014768374,0.00004790487,0.000046662237,0.000028744367,0.0000021025699,0.00020795024,1.8609026e-7,0.52278435,0.47633508],"study_design_scores_gemma":[0.0011612453,0.00046456986,0.00022317957,0.00004668923,0.000038259892,0.000017192582,0.0000015581015,0.00004250892,0.0009282197,0.000004022584,0.9969733,0.000099280274],"about_ca_topic_score_codex":0.00002398632,"about_ca_topic_score_gemma":8.966133e-8,"teacher_disagreement_score":0.4762358,"about_ca_system_score_codex":0.000089037225,"about_ca_system_score_gemma":0.000078331424,"threshold_uncertainty_score":0.36167455},"labels":[],"label_agreement":null},{"id":"W4406486966","doi":"10.1080/14796694.2024.2440277","title":"Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; University of Alberta; Precision Nanosystems (Canada); University of Ottawa; University of British Columbia; Ottawa Hospital; Queen's University","funders":"National Health and Medical Research Council; Medical Research Council; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Bristol-Myers Squibb","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Internal medicine; Hormone therapy; Cancer; Androgen receptor; Breast cancer","score_opus":0.01844197879047274,"score_gpt":0.35905948134062665,"score_spread":0.3406175025501539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406486966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.944756,0.017772187,0.00020997254,0.026018834,0.0007732327,0.0074988287,0.0012245369,0.00004777697,0.0016986489],"genre_scores_gemma":[0.9411916,0.015689768,0.0045702597,0.0046164924,0.001946875,0.0041924957,0.0005144339,0.0001239539,0.02715409],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99852794,0.00018363543,0.00031046843,0.00032154523,0.00027935323,0.00037704228],"domain_scores_gemma":[0.9986671,0.00047171122,0.00017852706,0.00032767362,0.00027739743,0.00007757041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043016294,0.0002186628,0.0007169568,0.00013502629,0.00015043188,0.000010351727,0.00013600472,0.0001261371,0.00003350707],"category_scores_gemma":[0.00008811667,0.00011166198,0.00016564368,0.0004071782,0.0002639523,0.000041053096,0.000050852654,0.00030356584,8.0063376e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8431498,0.00091502053,0.0013746206,0.00046487266,0.0024718137,0.0002485987,0.009087046,0.000031243166,0.0079176845,0.0005379612,0.036756862,0.09704452],"study_design_scores_gemma":[0.36951017,0.033604946,0.0039802436,0.0006320326,0.0012804286,0.000045655812,0.008639638,0.0001225853,0.07777204,0.00056536274,0.5034718,0.0003750861],"about_ca_topic_score_codex":0.00017613308,"about_ca_topic_score_gemma":0.0009367989,"teacher_disagreement_score":0.47363958,"about_ca_system_score_codex":0.0005606968,"about_ca_system_score_gemma":0.0018397615,"threshold_uncertainty_score":0.45534435},"labels":[],"label_agreement":null},{"id":"W4406496018","doi":"10.1016/j.ymed.2014.08.035","title":"10.1016/j.ymed.2014.08.035","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Abiraterone; Prostate cancer; Oncology; Chemotherapy; Cancer; Internal medicine; Prostate","score_opus":0.011365212872640699,"score_gpt":0.24369884311421197,"score_spread":0.23233363024157128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406496018","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037379342,0.0004847872,1.6133035e-7,0.0019142632,0.0000014051864,0.00038174403,0.00001490348,0.00010418142,0.99336064],"genre_scores_gemma":[0.00041739873,0.0000061222904,0.00006384922,0.00007839316,0.00019844409,0.00004111065,0.000055985714,0.000025744474,0.99911296],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99905795,0.000022018008,0.0001193797,0.00021494905,0.00025667605,0.00032904447],"domain_scores_gemma":[0.99934554,0.000029720522,0.0000116136325,0.0002836156,0.00005216598,0.0002773531],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009848941,0.00011761591,0.00018703898,0.000082586885,0.00006031993,0.000018935867,0.00009064866,0.000055928886,0.99847335],"category_scores_gemma":[0.000017471388,0.000088553745,0.00006283953,0.00016761929,0.00004704987,0.000047019443,0.000026221982,0.0001221053,0.9971581],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052426994,0.00009444342,0.000002560436,0.000015036459,0.000044138353,0.00004463041,0.00002951864,0.000001965285,0.00022056697,2.0446119e-7,0.47160906,0.5274136],"study_design_scores_gemma":[0.001168243,0.0005195073,0.00021508844,0.000041583236,0.000035787387,0.000016578144,0.000001556992,0.000035438457,0.0009097785,0.000004091992,0.9969535,0.00009888864],"about_ca_topic_score_codex":0.000021299524,"about_ca_topic_score_gemma":1.010267e-7,"teacher_disagreement_score":0.5273147,"about_ca_system_score_codex":0.00008581828,"about_ca_system_score_gemma":0.00008545088,"threshold_uncertainty_score":0.3611117},"labels":[],"label_agreement":null},{"id":"W4406500925","doi":"10.1016/j.ymed.2015.06.114","title":"10.1016/j.ymed.2015.06.114","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Chemotherapy; Cancer; Prostate; Internal medicine","score_opus":0.012381240099318302,"score_gpt":0.2551556374692326,"score_spread":0.2427743973699143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406500925","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023255898,0.0005408544,1.8840595e-7,0.0026218006,0.0000011043743,0.00038419227,0.000015584159,0.00010158735,0.9940091],"genre_scores_gemma":[0.00044977496,0.0000046515916,0.00006330003,0.000077152516,0.00019904593,0.000040559888,0.00007438497,0.000025175756,0.99906594],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990552,0.000021883297,0.000119921744,0.000209664,0.0002639549,0.00032937646],"domain_scores_gemma":[0.99934024,0.000028288194,0.000011521905,0.00027832517,0.000055620374,0.0002860028],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000099183875,0.00011755098,0.0001875331,0.0000827665,0.000059505892,0.000018946874,0.00009003569,0.00005619137,0.9972381],"category_scores_gemma":[0.000019771758,0.00008863829,0.000060944232,0.00020195452,0.000046478886,0.000048670754,0.000026525908,0.00012236266,0.9953132],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041580616,0.00009542739,0.0000028151273,0.000014240507,0.00004568107,0.000043859673,0.000023720966,0.0000020861694,0.00019860061,2.1144756e-7,0.53817445,0.46098313],"study_design_scores_gemma":[0.0011569278,0.00047147216,0.00021777679,0.000046487505,0.000038144004,0.000016982103,0.0000015980642,0.00004535582,0.00089471677,0.00000400951,0.99700725,0.00009925185],"about_ca_topic_score_codex":0.000022248181,"about_ca_topic_score_gemma":8.691296e-8,"teacher_disagreement_score":0.46088386,"about_ca_system_score_codex":0.00008859784,"about_ca_system_score_gemma":0.000088272354,"threshold_uncertainty_score":0.36145648},"labels":[],"label_agreement":null},{"id":"W4406501654","doi":"10.1200/jco-24-02314","title":"Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial","year":2025,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Health Sciences North; Queen's University","funders":"","keywords":"Medicine; Prostate cancer; Clinical trial; Oncology; Cancer; Prostate; Internal medicine; Surgery","score_opus":0.27865766790268487,"score_gpt":0.5766301250686224,"score_spread":0.29797245716593757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406501654","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016220508,0.0075366525,0.000011351808,0.96393454,0.008284973,0.0028842313,0.000069140515,0.000008172597,0.001050401],"genre_scores_gemma":[0.011955259,0.026793908,0.00013257461,0.89783245,0.045549393,0.00035432857,0.000033065957,0.00005299019,0.017296003],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9874534,0.004638401,0.006131685,0.00034506072,0.00086607074,0.0005653669],"domain_scores_gemma":[0.9745771,0.020058814,0.004077708,0.00037127367,0.0007154088,0.00019963698],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.018518347,0.00033140706,0.0058799353,0.00041275393,0.000050349056,0.000035171997,0.00044117926,0.0016850102,0.00034189355],"category_scores_gemma":[0.017912896,0.00015206136,0.0017989984,0.00030082164,0.00048719716,0.000072803836,0.0000637898,0.0101519255,0.000014474697],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24377799,0.0005879878,0.0032301494,0.00012346824,0.0017141431,0.0058987197,0.000076901204,0.0000053064086,0.0000047532267,0.0000022670015,0.6509099,0.09366839],"study_design_scores_gemma":[0.23335919,0.009824116,0.002757381,0.0006302667,0.0014561312,0.00005704475,0.00002440761,0.000014790161,0.0000073895344,0.00030568452,0.75145924,0.000104379],"about_ca_topic_score_codex":0.00011761515,"about_ca_topic_score_gemma":0.000088690074,"teacher_disagreement_score":0.100549296,"about_ca_system_score_codex":0.00068244745,"about_ca_system_score_gemma":0.018537683,"threshold_uncertainty_score":0.999611},"labels":[],"label_agreement":null},{"id":"W4406552462","doi":"10.1016/j.prro.2024.09.017","title":"F18-DCFPyL PSMA-PET/CT Versus MRI: Identifying the Prostate Cancer Region Most at Risk of Radiation Therapy Recurrence for Tumor Dose Escalation","year":2025,"lang":"en","type":"article","venue":"Practical Radiation Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Polytechnique Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Université de Montréal","keywords":"Medicine; Prostate cancer; Radiation therapy; Oncology; Magnetic resonance imaging; Cancer; Radiology; Nuclear medicine; Internal medicine","score_opus":0.08006185506429941,"score_gpt":0.45936912862643914,"score_spread":0.3793072735621397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406552462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91334724,0.010007177,0.0026815308,0.06149241,0.002939495,0.006375982,0.000115898474,0.00009769947,0.0029425877],"genre_scores_gemma":[0.96577907,0.030671611,0.00049174594,0.00043129106,0.00022368463,0.0009556667,0.0002014613,0.000020418143,0.001225044],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99820614,0.0003939356,0.00043938117,0.00035599916,0.00028974153,0.0003147961],"domain_scores_gemma":[0.99617934,0.0026684785,0.00048067365,0.0002654378,0.00031103508,0.000095010764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008097814,0.00015554429,0.00031129716,0.00017310762,0.000314897,0.000029529063,0.00008817782,0.00004579203,0.00006633498],"category_scores_gemma":[0.0019922124,0.00010860461,0.00010669958,0.0005332448,0.0001795094,0.00026749214,0.0000401165,0.00032685758,0.000012846315],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04411649,0.00093008595,0.106164865,0.0002734102,0.00086768577,0.000117281146,0.0013961788,0.00033345484,0.0017584693,0.0039007312,0.02235964,0.8177817],"study_design_scores_gemma":[0.05557772,0.005150172,0.23063682,0.0002763793,0.0014849348,0.00019543248,0.00097331294,0.036919184,0.037792332,0.0033061577,0.6271973,0.00049019733],"about_ca_topic_score_codex":0.00020667221,"about_ca_topic_score_gemma":0.00009403047,"teacher_disagreement_score":0.8172915,"about_ca_system_score_codex":0.0012395781,"about_ca_system_score_gemma":0.0011441383,"threshold_uncertainty_score":0.44287673},"labels":[],"label_agreement":null},{"id":"W4406579999","doi":"10.1016/s1541-9800(06)71220-0","title":"10.1016/s1541-9800(06)71220-0","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Index (typography); Medicine; Computer science; World Wide Web","score_opus":0.012606002386336312,"score_gpt":0.24391559924964368,"score_spread":0.23130959686330738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579999","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034677638,0.00037987012,1.7597164e-7,0.0018725256,9.1491455e-7,0.00040401155,0.000017018956,0.00010996346,0.9937478],"genre_scores_gemma":[0.0005041059,0.0000039453907,0.000067024,0.000081255246,0.00019583604,0.00004497579,0.00007841464,0.00002731366,0.99899715],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989987,0.000022736218,0.0001293275,0.00022835961,0.00027032834,0.00035056547],"domain_scores_gemma":[0.99932075,0.000028410272,0.000011957942,0.00029186474,0.000058000798,0.00028904964],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009951274,0.00012722252,0.00019931264,0.000088389366,0.00006811575,0.000021371114,0.00009549131,0.000059530284,0.997891],"category_scores_gemma":[0.000020747597,0.00009705993,0.000069159134,0.00022877968,0.000047646106,0.00005122299,0.000028491024,0.00013391548,0.9961938],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005144609,0.0001220767,0.0000029465552,0.000018389497,0.00005302062,0.00005670537,0.000026433914,0.000003119222,0.0002130946,3.0170747e-7,0.5371651,0.46182433],"study_design_scores_gemma":[0.001297745,0.00049443566,0.00022455286,0.000048545506,0.000040059964,0.00001819678,0.0000016931892,0.000051682062,0.0010320175,0.0000054443394,0.9966776,0.00010805217],"about_ca_topic_score_codex":0.000024196583,"about_ca_topic_score_gemma":9.746928e-8,"teacher_disagreement_score":0.46171626,"about_ca_system_score_codex":0.00009908369,"about_ca_system_score_gemma":0.00009247278,"threshold_uncertainty_score":0.3957989},"labels":[],"label_agreement":null},{"id":"W4406584215","doi":"10.1016/j.yonc.2013.05.017","title":"10.1016/j.yonc.2013.05.017","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Androgen suppression; External beam radiotherapy; External beam radiation; Androgen; Oncology; Radiation therapy; Variation (astronomy); Beam (structure); Urology; Internal medicine; Cancer; Optics; Hormone; Astrophysics","score_opus":0.013742627029859828,"score_gpt":0.24824417015214043,"score_spread":0.2345015431222806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406584215","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028629876,0.00043722798,1.2898249e-7,0.002851253,0.0000015581719,0.00038189953,0.0000149140815,0.00009941585,0.9933506],"genre_scores_gemma":[0.00031402984,0.0000066700964,0.00006612311,0.000078960154,0.00019488514,0.000039651834,0.00005195475,0.000024832567,0.9992229],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990948,0.00001968041,0.00011526014,0.0002072932,0.00024318656,0.00031982505],"domain_scores_gemma":[0.9993567,0.000024902829,0.000012020478,0.00028771468,0.00005349947,0.00026519466],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000088355366,0.00011612269,0.00018456951,0.00007733936,0.000067364825,0.000020683448,0.00009313595,0.000054343498,0.9969358],"category_scores_gemma":[0.000015534048,0.00008756634,0.000061876744,0.0001689447,0.000046929148,0.00005083311,0.000026886386,0.000119693104,0.9935597],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044562007,0.00007832903,0.0000013371948,0.00001265187,0.000038169892,0.000053476648,0.000018692399,0.0000021101237,0.0001499873,1.8363446e-7,0.51161176,0.4875877],"study_design_scores_gemma":[0.0011888032,0.00060412806,0.00017553977,0.000045835797,0.000035621604,0.000022047632,0.0000013164976,0.000049954622,0.0007468424,0.0000039453635,0.99702775,0.00009818683],"about_ca_topic_score_codex":0.00005078218,"about_ca_topic_score_gemma":1.915122e-7,"teacher_disagreement_score":0.48748952,"about_ca_system_score_codex":0.00008437401,"about_ca_system_score_gemma":0.00007981258,"threshold_uncertainty_score":0.35708517},"labels":[],"label_agreement":null},{"id":"W4406584550","doi":"10.1016/j.yonc.2013.05.036","title":"10.1016/j.yonc.2013.05.036","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; PCA3; Prostate; Prostate cancer; Prostate-specific antigen; Oncology; Internal medicine; Gynecology; Cancer","score_opus":0.012975616849038403,"score_gpt":0.2447578067272041,"score_spread":0.2317821898781657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406584550","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027877346,0.0004720436,1.2483515e-7,0.002938214,0.000001543804,0.00038640792,0.0000148108675,0.000100718156,0.9932984],"genre_scores_gemma":[0.000298981,0.0000063136117,0.00006763127,0.00008799117,0.00019504757,0.000040249855,0.00006406309,0.000024985571,0.9992147],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99908304,0.000020407702,0.00011813129,0.00020811245,0.00024682464,0.00032345444],"domain_scores_gemma":[0.9993686,0.00002574467,0.00001137963,0.00027165771,0.000054533695,0.0002680696],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00008860208,0.00011691559,0.00018418409,0.00007945472,0.000062030274,0.000019141427,0.00008813084,0.000055404977,0.9973038],"category_scores_gemma":[0.000014653278,0.00008785618,0.00006184959,0.00019161408,0.00004520594,0.00004979415,0.000026380618,0.000120747245,0.9940101],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045754027,0.00008220423,0.0000011402933,0.000012651143,0.000038744533,0.000048200636,0.00001951307,0.0000023003633,0.00015685831,1.9659349e-7,0.507392,0.49178866],"study_design_scores_gemma":[0.0011862314,0.00060515554,0.0001551651,0.00004348665,0.00003554759,0.000021183621,0.0000014466191,0.000049489066,0.00069213693,0.000003969876,0.9971076,0.00009857204],"about_ca_topic_score_codex":0.00005726586,"about_ca_topic_score_gemma":1.989781e-7,"teacher_disagreement_score":0.49169007,"about_ca_system_score_codex":0.00008686175,"about_ca_system_score_gemma":0.00006989702,"threshold_uncertainty_score":0.3582671},"labels":[],"label_agreement":null},{"id":"W4406674851","doi":"10.1016/j.euf.2025.01.006","title":"Prostate-specific Membrane Antigen–radioguided Surgery in an EMBARK-like Cohort of Patients with Oligorecurrent Hormone-sensitive Prostate Cancer: Delay in Systemic Treatment","year":2025,"lang":"en","type":"article","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Glutamate carboxypeptidase II; Prostate; Oncology; Hormone therapy; Hormone; Cohort; Cancer; Gynecology; Internal medicine; Urology; Breast cancer","score_opus":0.015543688098185345,"score_gpt":0.26914372275600507,"score_spread":0.2536000346578197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406674851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986816,0.008744555,0.000005651987,0.00034537516,0.0002352665,0.0027763962,0.00015268424,0.000052889765,0.000871172],"genre_scores_gemma":[0.9895856,0.009359331,0.000022086486,0.000075942204,0.000035053225,0.00019532364,0.0003812948,0.00006188088,0.00028349346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99671817,0.0007353884,0.00078277604,0.000761323,0.0003145498,0.00068781903],"domain_scores_gemma":[0.99869055,0.00014163056,0.00020964928,0.0004985601,0.00028573105,0.00017390781],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005538948,0.0003908303,0.00096745073,0.0008278103,0.00006901111,0.00001695636,0.00012625351,0.0000888347,0.000013088147],"category_scores_gemma":[0.000024151517,0.00028056072,0.00010182407,0.00080356427,0.00028949947,0.00011214633,0.00006283805,0.00029844037,0.000014054143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010898644,0.0011615003,0.9704406,0.000114796654,0.00032833402,0.0017814022,0.0019177571,0.00018384185,0.0013449005,0.000012105206,0.00031712482,0.01149895],"study_design_scores_gemma":[0.009438847,0.0022844556,0.98285216,0.0003272463,0.00012444465,0.000023778572,0.00014422301,0.00007737255,0.0032426883,0.0000060195866,0.0012353299,0.00024344675],"about_ca_topic_score_codex":0.00041810054,"about_ca_topic_score_gemma":0.00040852453,"teacher_disagreement_score":0.012411503,"about_ca_system_score_codex":0.000593309,"about_ca_system_score_gemma":0.00047678445,"threshold_uncertainty_score":0.99996465},"labels":[],"label_agreement":null},{"id":"W4406704402","doi":"10.1016/j.apsb.2025.01.007","title":"Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors","year":2025,"lang":"en","type":"article","venue":"Acta Pharmaceutica Sinica B","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Prostate Cancer Foundation; National Institutes of Health; DOD Prostate Cancer Research Program; Comprehensive Cancer Center, University of California, Davis; Office of Research and Development; U.S. Department of Veterans Affairs; University of California, Davis; U.S. Department of Defense","keywords":"Prostate cancer; Lineage (genetic); Cancer research; Medicine; Prostate; BRD4; Cancer; Neuroendocrine differentiation; Biology; Bioinformatics; Oncology; Internal medicine; Epigenetics; Bromodomain; Genetics","score_opus":0.021372165384344596,"score_gpt":0.3835841193678404,"score_spread":0.3622119539834958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406704402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98463756,0.0052357763,0.0000073691062,0.0065031406,0.00030148923,0.001941761,0.00009830244,0.00006288674,0.0012117255],"genre_scores_gemma":[0.99513024,0.0023730374,0.000037064663,0.0010848398,0.00007386154,0.00028034838,0.00003166086,0.000032173575,0.0009567868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979641,0.00018377836,0.00053477683,0.0004489274,0.00030658772,0.0005618468],"domain_scores_gemma":[0.9987099,0.0006711175,0.0001313991,0.00018775147,0.00013817579,0.00016162249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002121728,0.00025348,0.00054189155,0.00023024295,0.000071317765,0.000017870312,0.00015125421,0.000040284343,0.00013943302],"category_scores_gemma":[0.0002582881,0.00020047852,0.0001116293,0.00076080457,0.00024251096,0.00010231406,0.00013581268,0.00062334514,0.000005650262],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057408647,0.001372006,0.18965478,0.0010094238,0.0005171311,0.00026033522,0.00031021814,0.000021202804,0.77092093,0.00002599317,0.010012665,0.02015442],"study_design_scores_gemma":[0.00900383,0.00044728955,0.020373233,0.000541778,0.0002843002,0.000008346918,0.00009785131,0.0018565482,0.9282293,0.000024077368,0.038941756,0.0001917099],"about_ca_topic_score_codex":0.00015267097,"about_ca_topic_score_gemma":0.000010608067,"teacher_disagreement_score":0.16928154,"about_ca_system_score_codex":0.0002290705,"about_ca_system_score_gemma":0.00036409742,"threshold_uncertainty_score":0.8175277},"labels":[],"label_agreement":null},{"id":"W4406707301","doi":"10.1002/1878-0261.13805","title":"Clinical significance of stratifying prostate cancer patients through specific circulating genes","year":2025,"lang":"en","type":"article","venue":"Molecular Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Stand Up To Cancer; Movember Foundation; Prostate Cancer Canada; National Human Genome Research Institute; Memorial Sloan-Kettering Cancer Center; Alliance de recherche numérique du Canada; American Association for Cancer Research","keywords":"Prostate cancer; Prostate; Oncology; Medicine; Disease; Pathological; Drug resistance; Clinical trial; Biology; Internal medicine; Cancer; Bioinformatics; Genetics","score_opus":0.06676033333873277,"score_gpt":0.4373600325373966,"score_spread":0.3705996991986638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406707301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817143,0.007005768,0.0005803874,0.0011499121,0.00039885327,0.0010051605,0.00001691634,0.000026976106,0.008101732],"genre_scores_gemma":[0.9946927,0.0019342265,0.0020791623,0.0004547026,0.00005889718,0.00013611866,0.000042831576,0.00001757062,0.00058383046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838877,0.00016413939,0.0005282401,0.0003714673,0.000239782,0.0003075915],"domain_scores_gemma":[0.9991282,0.00011555875,0.00015307647,0.000252021,0.0002827522,0.00006839405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024351623,0.00013659781,0.0004695282,0.00007895351,0.000065168526,0.000009266401,0.000108570806,0.0001516979,0.00007241619],"category_scores_gemma":[0.00006376384,0.000113650065,0.00013656924,0.0003207819,0.00024815832,0.00004131635,0.000073465206,0.0002483109,0.0000060540683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008429832,0.0010017384,0.6834462,0.0003772447,0.00043049705,0.00029863653,0.00043353785,0.00006308346,0.10059581,0.0008479185,0.0010029917,0.21065934],"study_design_scores_gemma":[0.023049667,0.0046589416,0.44077381,0.0010374939,0.000565625,0.000012317713,0.0007547139,0.00038080008,0.39038435,0.0027790887,0.13503426,0.0005689342],"about_ca_topic_score_codex":0.00009386458,"about_ca_topic_score_gemma":0.000011797359,"teacher_disagreement_score":0.2897885,"about_ca_system_score_codex":0.00024922323,"about_ca_system_score_gemma":0.00075827364,"threshold_uncertainty_score":0.46345153},"labels":[],"label_agreement":null},{"id":"W4406759309","doi":"10.1002/ijc.35327","title":"Epigenomics‐guided precision oncology: Chromatin variants in prostate tumor evolution","year":2025,"lang":"en","type":"review","venue":"International Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Government of Ontario; Ontario Institute for Cancer Research","keywords":"Epigenomics; Epigenome; Epigenetics; Chromatin; Biology; Prostate cancer; DNA methylation; Histone; Cancer; Somatic evolution in cancer; Chromatin remodeling; Computational biology; Tumour heterogeneity; Genetics; Cancer research; Bioinformatics; Gene; Gene expression","score_opus":0.05550292702523334,"score_gpt":0.47213972185337194,"score_spread":0.4166367948281386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406759309","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027896388,0.9938293,0.000056781508,0.0009491095,0.0022428695,0.0008502943,0.0001266937,0.0000074797476,0.0016585228],"genre_scores_gemma":[0.00043731395,0.9958336,0.0003614771,0.00008518806,0.0007775366,0.00010390308,0.000052247855,0.000026925589,0.0023218081],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99734527,0.00016851764,0.001277869,0.00024325379,0.00072193757,0.0002431354],"domain_scores_gemma":[0.9975584,0.00023922493,0.0009995686,0.00014869851,0.0009350634,0.00011905242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067323755,0.00025379474,0.001336409,0.0011138075,0.00002644104,0.00004265445,0.00041146966,0.0001526637,0.00026717933],"category_scores_gemma":[0.0003024777,0.00017570789,0.0004221604,0.00033041264,0.00006358548,0.00016220174,0.00011134973,0.0006927105,0.000019388744],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0008165684,0.000271087,0.00030067321,0.003128666,0.0012007402,0.0018831762,0.00008874344,0.000016949716,0.000024189774,0.000057065274,0.0040397826,0.98817235],"study_design_scores_gemma":[0.0036343744,0.00031836602,0.0009404565,0.06876651,0.0006757877,0.0007734747,0.000017849183,0.000026307893,0.000030793573,0.00041858043,0.92424184,0.0001556538],"about_ca_topic_score_codex":0.0001205371,"about_ca_topic_score_gemma":0.000052771997,"teacher_disagreement_score":0.9880167,"about_ca_system_score_codex":0.0066131633,"about_ca_system_score_gemma":0.008468417,"threshold_uncertainty_score":0.99720025},"labels":[],"label_agreement":null},{"id":"W4406789559","doi":"10.1101/2025.01.21.632253","title":"B7-H3 as a Dual Clinically Relevant Checkpoint and Antibody Drug Conjugate Target Expressed Across Adenocarcinoma and Neuroendocrine Prostate Cancers","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Johns Hopkins University; National Cancer Institute; Prostate Cancer Foundation; DOD Prostate Cancer Research Program; Türkiye Bilimsel ve Teknolojik Araştırma Kurumu; U.S. Department of Defense","keywords":"Antibody-drug conjugate; Prostate cancer; Conjugate; Dual (grammatical number); Cancer research; Drug; Antibody; Adenocarcinoma; Oncology; Medicine; Internal medicine; Monoclonal antibody; Cancer; Pharmacology; Immunology; Mathematics","score_opus":0.016500695685995548,"score_gpt":0.3098947213691307,"score_spread":0.29339402568313516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406789559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97900957,0.011823183,0.000030462246,0.003618732,0.00076858624,0.0028795963,0.0014979306,0.00033920875,0.00003273208],"genre_scores_gemma":[0.9779971,0.018256633,0.0016389925,0.0006874944,0.00036689322,0.0004946454,0.000008878741,0.0001481338,0.0004012232],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99467105,0.00023947275,0.0011012251,0.0020542678,0.0006702652,0.0012637409],"domain_scores_gemma":[0.9963867,0.00020823775,0.00048024466,0.001351308,0.00068996486,0.00088352617],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077918626,0.0009201687,0.0014232435,0.0002833439,0.00034258413,0.00034910132,0.00031065027,0.00029937955,0.000039124305],"category_scores_gemma":[0.0005508877,0.0008239752,0.00020808868,0.00043855116,0.0007539548,0.0001801649,0.0014913508,0.001544342,0.000015983633],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055253347,0.0005635029,0.3670601,0.007133465,0.0015616303,0.007273594,0.00037654449,0.000025316875,0.60892594,0.0001570208,0.0013584354,0.000039095423],"study_design_scores_gemma":[0.018342631,0.001688361,0.47596952,0.005741956,0.0010586841,0.000003543731,0.00013655296,0.0014867985,0.4758252,0.000040510633,0.017424867,0.002281403],"about_ca_topic_score_codex":0.00062508427,"about_ca_topic_score_gemma":0.000009811112,"teacher_disagreement_score":0.13310078,"about_ca_system_score_codex":0.00045264047,"about_ca_system_score_gemma":0.0024935356,"threshold_uncertainty_score":0.9994211},"labels":[],"label_agreement":null},{"id":"W4406871448","doi":"10.1590/0001-3765202520231380","title":"Specific immunohistochemical expression of Mmp-26 in prostatic adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Anais da Academia Brasileira de Ciências","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research","funders":"","keywords":"Immunohistochemistry; Prostatic adenocarcinoma; Matrix metalloproteinase; Adenocarcinoma; Expression (computer science); Medicine; Oncology; Pathology; Cancer research; Internal medicine; Cancer; Computer science","score_opus":0.029209539610083476,"score_gpt":0.3359462409068951,"score_spread":0.30673670129681163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406871448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811685,0.013230493,0.00006835148,0.0007366972,0.0000842613,0.0008002537,0.00001403018,0.0000678644,0.0038295533],"genre_scores_gemma":[0.99687487,0.00059543375,0.00052841543,0.000391439,0.00007354583,0.000119662,0.000045237444,0.000035223304,0.0013361708],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796516,0.00009140037,0.0005633662,0.00043833666,0.00040190172,0.0005398537],"domain_scores_gemma":[0.99899274,0.00019703197,0.000110032815,0.0004305149,0.00010616456,0.00016350864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003590821,0.00023170369,0.00052121084,0.000469439,0.000064694024,0.000016349399,0.00026784235,0.0005626666,0.00014399776],"category_scores_gemma":[0.0002244133,0.00019775356,0.00013515461,0.00085094443,0.0002570953,0.00011627673,0.00013470383,0.0012920579,0.000029843868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006028724,0.0001732584,0.6785117,0.00030208274,0.000034014123,0.00009994635,0.00062815327,0.0000016908994,0.3075961,0.00024864837,0.010116924,0.0016846594],"study_design_scores_gemma":[0.0026130897,0.00013384673,0.68478584,0.00094181026,0.000038087957,0.000015031888,0.00026448892,0.000040831826,0.3100058,0.00022014305,0.0008127453,0.0001282759],"about_ca_topic_score_codex":0.00008926691,"about_ca_topic_score_gemma":0.0000030735773,"teacher_disagreement_score":0.015706377,"about_ca_system_score_codex":0.0006476542,"about_ca_system_score_gemma":0.0005392269,"threshold_uncertainty_score":0.80641556},"labels":[],"label_agreement":null},{"id":"W4406971619","doi":"10.1200/go-24-00464","title":"Oral Cyclophosphamide for Patients With Metastatic Castration-Resistant Prostate Cancer in a Scenario of Limited Health Care Resources","year":2025,"lang":"en","type":"article","venue":"JCO Global Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University","funders":"Genentech; Exelixis; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Docetaxel; Prostate cancer; Cyclophosphamide; Regimen; Prostate-specific antigen; Oncology; Internal medicine; Cancer; Prostate; Urology; Chemotherapy","score_opus":0.01873738713748683,"score_gpt":0.3784184127034239,"score_spread":0.35968102556593706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406971619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986748,0.0047324966,0.000010725737,0.0042159874,0.00012266234,0.0025789535,0.00062241405,0.000018174924,0.0009506242],"genre_scores_gemma":[0.99653006,0.0002188529,0.0017060547,0.0005247784,0.000013140734,0.00038604703,0.00020775269,0.000009576341,0.00040374207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867976,0.00008424919,0.00037779097,0.00027122852,0.00020513724,0.0003818593],"domain_scores_gemma":[0.9991403,0.00007912986,0.00015400551,0.00014599966,0.00037715,0.000103382765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013105385,0.00014136526,0.00052732334,0.00011975,0.00006453124,0.000008283086,0.00006920927,0.000061785955,0.0000133753265],"category_scores_gemma":[0.00005539843,0.0000983174,0.00005130377,0.00056816044,0.00013613481,0.000040292474,0.000028906023,0.00010641288,7.105261e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029076952,0.0012206977,0.8998955,0.0013215796,0.00040791123,0.00007460967,0.0027933056,0.0001374133,0.00006929172,0.0003776066,0.0021092668,0.06251587],"study_design_scores_gemma":[0.02582881,0.009674984,0.9319665,0.0006631848,0.00020016865,0.0000023285581,0.0020641065,0.000058290956,0.00020121255,0.00016590625,0.0290354,0.0001391434],"about_ca_topic_score_codex":0.0036211647,"about_ca_topic_score_gemma":0.018706381,"teacher_disagreement_score":0.06237673,"about_ca_system_score_codex":0.002009761,"about_ca_system_score_gemma":0.002838928,"threshold_uncertainty_score":0.9991997},"labels":[],"label_agreement":null},{"id":"W4407011452","doi":"10.1200/po-24-00653","title":"Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Histopathology; Hazard ratio; Proportional hazards model; Medicine; Prostate cancer; Internal medicine; Oncology; Urology; Clinical trial; Confidence interval; Cancer; Pathology","score_opus":0.038948330216087804,"score_gpt":0.4126592573118778,"score_spread":0.37371092709579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407011452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989276,0.0005433585,0.0009397346,0.003125978,0.00013581963,0.005078106,0.00005905794,0.000020674048,0.0008212966],"genre_scores_gemma":[0.996084,0.0002514323,0.0011024566,0.00012038782,0.000022638369,0.0014869481,0.000056786048,0.000012718193,0.0008626288],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978096,0.0003310792,0.0007944753,0.0004622386,0.0002561669,0.00034647543],"domain_scores_gemma":[0.9977246,0.0017391273,0.00014770062,0.00018557192,0.000104398976,0.00009858344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094973895,0.00021382551,0.0011728661,0.00058992766,0.000058437297,0.000049310223,0.00008080808,0.00013305392,0.00006464707],"category_scores_gemma":[0.0006643097,0.0001323738,0.000079908736,0.0004066333,0.00043492785,0.00012854509,0.00005331511,0.0002984515,0.0000031746056],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8089039,0.0016753731,0.0052467478,0.000044791534,0.000092482136,0.0007283658,0.00076027686,0.00012801097,0.0011217464,0.00009535328,0.00002361412,0.18117939],"study_design_scores_gemma":[0.97197837,0.004133047,0.00400128,0.0004327573,0.00015135207,0.000010800699,0.0007070473,0.01401105,0.002402807,0.0018787903,0.0001061732,0.00018654401],"about_ca_topic_score_codex":0.00032625181,"about_ca_topic_score_gemma":0.0018590952,"teacher_disagreement_score":0.18099284,"about_ca_system_score_codex":0.0003681558,"about_ca_system_score_gemma":0.0013200026,"threshold_uncertainty_score":0.53980464},"labels":[],"label_agreement":null},{"id":"W4407116677","doi":"10.21203/rs.3.rs-5869163/v1","title":"PSMA PET-detected Mesorectal Nodal Metastasis: Treatment Outcomes and Clinical Implications","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Metastasis; Medicine; Total mesorectal excision; Oncology; Environmental science; Internal medicine; Colorectal cancer; Cancer","score_opus":0.1696706599052222,"score_gpt":0.5280936298433532,"score_spread":0.35842296993813094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407116677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9268842,0.010553661,0.00007961787,0.039521895,0.00046906708,0.009614284,0.0033967088,0.00042283806,0.009057779],"genre_scores_gemma":[0.95158315,0.01963257,0.0011516808,0.000069129565,0.0003581931,0.0022252768,0.0014116433,0.00007018673,0.023498196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99500704,0.0008682133,0.0007262927,0.0013045215,0.001073032,0.0010209067],"domain_scores_gemma":[0.9952907,0.0014052372,0.000106345724,0.0014211696,0.0010416913,0.0007348767],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001390514,0.00049381965,0.0011720397,0.000903673,0.00042302848,0.00017922337,0.00033743668,0.000390205,0.00019531265],"category_scores_gemma":[0.0008191548,0.0003372628,0.0006239496,0.00060746935,0.00061700994,0.000057431153,0.001301472,0.0020060774,0.000073303585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026038466,0.003441676,0.80327374,0.0023623195,0.006422185,0.0008143634,0.00046207264,0.00000324682,0.00016950157,0.00090891606,0.0046326406,0.1749055],"study_design_scores_gemma":[0.008140278,0.004263871,0.97040546,0.001132908,0.0009748598,0.00009119118,0.00048310045,0.00041940794,0.0006113277,0.0021057061,0.01089049,0.00048141307],"about_ca_topic_score_codex":0.00076362904,"about_ca_topic_score_gemma":0.00022550892,"teacher_disagreement_score":0.17442408,"about_ca_system_score_codex":0.0010803144,"about_ca_system_score_gemma":0.0028904644,"threshold_uncertainty_score":0.9999079},"labels":[],"label_agreement":null},{"id":"W4407119269","doi":"","title":"Identification and characterization of luminal progenitor cells in prostate cancer in men","year":2023,"lang":"en","type":"dissertation","venue":"theses.fr (ABES)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Identification (biology); Progenitor cell; Progenitor; Biology; Cancer; Computational biology; Cancer research; Medicine; Internal medicine; Cell biology; Stem cell; Botany","score_opus":0.020103318484301094,"score_gpt":0.3337052962758499,"score_spread":0.3136019777915488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407119269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960196,0.0005421799,1.8440673e-7,0.00013471127,0.00029624335,0.0018488335,0.00016677653,0.000027893651,0.0009635762],"genre_scores_gemma":[0.980821,0.006665615,0.000004672706,0.0000044149883,0.00011397371,0.0007058338,0.0021096247,0.000057826568,0.009517001],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984894,0.00006344671,0.00046446634,0.00035762976,0.00035953074,0.00026551716],"domain_scores_gemma":[0.9993283,0.000035853544,0.00022603422,0.00019063568,0.00015238892,0.0000667457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029170868,0.00019934613,0.0004142484,0.00050003437,0.000027426153,0.000024918103,0.00008091062,0.00015686381,0.00005148229],"category_scores_gemma":[0.000029395023,0.00017168192,0.000042745036,0.0005030999,0.000052371164,0.00011119773,0.000020349771,0.00024647906,0.000021717859],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013606979,0.00023663935,0.045810714,0.0023787436,0.000091560905,0.000065411885,0.016509585,0.0000015636261,0.9163681,0.00002975031,0.00002094453,0.01712625],"study_design_scores_gemma":[0.0018113668,0.0001229022,0.5260574,0.0017295507,0.00010544317,0.0000018645225,0.0052191224,0.00013341794,0.4643484,0.000054302087,0.00023224505,0.00018398318],"about_ca_topic_score_codex":0.001732491,"about_ca_topic_score_gemma":0.0010531901,"teacher_disagreement_score":0.4802467,"about_ca_system_score_codex":0.00021727968,"about_ca_system_score_gemma":0.0002829623,"threshold_uncertainty_score":0.7000986},"labels":[],"label_agreement":null},{"id":"W4407219723","doi":"10.1073/pnas.2415308122","title":"Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer","year":2025,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"Prostate cancer; Retinoic acid; Androgen receptor; Downregulation and upregulation; Biology; Cancer research; Basal (medicine); Transcriptome; Internal medicine; Endocrinology; Cancer; Medicine; Cell culture; Gene; Gene expression; Genetics","score_opus":0.05805486843673414,"score_gpt":0.38694236751492084,"score_spread":0.3288874990781867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407219723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886517,0.0013428282,2.838243e-7,0.0070478795,0.000021900127,0.0005406671,0.000065102664,0.0000043151313,0.0023253453],"genre_scores_gemma":[0.9980825,0.0005475553,0.00030337888,0.00018117878,0.000020486257,0.00003850789,3.7635064e-7,0.000002100934,0.0008238761],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99866897,0.000009724052,0.0003006949,0.00021485362,0.0006588498,0.00014688322],"domain_scores_gemma":[0.99944866,0.00006690683,0.00015919318,0.0000068301797,0.0002838159,0.000034618522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077953114,0.000085059204,0.00022598887,0.00021988041,0.00013008817,0.000025813526,0.00020037907,0.00005403395,0.0000063411767],"category_scores_gemma":[0.00007731691,0.000054042102,0.000043743403,0.0008977057,0.0006956884,0.00034820024,0.00004892247,0.00016400318,2.2294243e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003660858,0.000107309716,0.042627476,0.0003553475,0.00002886447,4.0125684e-8,0.0010267737,0.000023571149,0.9499342,0.004855462,0.00056359405,0.00011129308],"study_design_scores_gemma":[0.0013386225,0.0000900386,0.40925875,0.00042275462,0.00003286396,0.0000011010792,0.0008259256,0.0004109581,0.5674694,0.020018872,0.00007248712,0.000058197293],"about_ca_topic_score_codex":0.000073211384,"about_ca_topic_score_gemma":0.000006955909,"teacher_disagreement_score":0.38246474,"about_ca_system_score_codex":0.00010370687,"about_ca_system_score_gemma":0.00018581454,"threshold_uncertainty_score":0.2563293},"labels":[],"label_agreement":null},{"id":"W4407251859","doi":"10.3390/curroncol32020092","title":"Radical Prostatectomy in Multimodal Setting: Current Role of Neoadjuvant and Adjuvant Hormonal or Chemotherapy-Based Treatments","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostatectomy; Hormonal therapy; Prostate cancer; Oncology; Adjuvant; Androgen deprivation therapy; Lymph node; Neoadjuvant therapy; Chemotherapy; Internal medicine; Clinical trial; Perioperative; Cancer; Surgery; Breast cancer","score_opus":0.09735222694874743,"score_gpt":0.47838773843694415,"score_spread":0.3810355114881967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407251859","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011943949,0.9932719,0.000008913867,0.00016083993,0.00045151424,0.0043998826,0.0002752202,0.000039942286,0.00019741],"genre_scores_gemma":[0.0003095172,0.9969461,0.00028422556,0.000017242739,0.00015238636,0.0011415476,0.0009078191,0.00005152218,0.00018963653],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99665266,0.0003686251,0.0010546583,0.00082375924,0.00041215486,0.0006881439],"domain_scores_gemma":[0.99823624,0.0005529855,0.00040765828,0.00037483923,0.00012602881,0.00030224508],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034613413,0.00065412215,0.0031318516,0.00077597005,0.000058891117,0.000013447035,0.00020734563,0.00042996803,0.00011120152],"category_scores_gemma":[0.00013180127,0.00040579078,0.00041556093,0.00056993274,0.00040821964,0.000039172486,0.00014164273,0.0010270678,0.000009881358],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00148331,0.0030354979,0.0019964594,0.024098502,0.00028255332,0.00013789957,0.0001396384,2.3075573e-7,0.0000039407814,0.000016424268,0.00033967834,0.96846586],"study_design_scores_gemma":[0.01492135,0.002119759,0.00085208897,0.02995757,0.0011951491,0.000055468663,0.000035717185,0.00021951235,0.000040461888,0.000039937255,0.95023793,0.00032503335],"about_ca_topic_score_codex":0.000018421028,"about_ca_topic_score_gemma":0.000011749063,"teacher_disagreement_score":0.96814084,"about_ca_system_score_codex":0.0012313963,"about_ca_system_score_gemma":0.0058767414,"threshold_uncertainty_score":0.99983937},"labels":[],"label_agreement":null},{"id":"W4407317724","doi":"10.3389/fonc.2025.1491314","title":"Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings","year":2025,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Astellas Pharma; Astellas Pharma US; Pfizer","keywords":"Enzalutamide; Medicine; Abiraterone acetate; Prostate cancer; Oncology; Meta-analysis; Discontinuation; Internal medicine; Adverse effect; Hazard ratio; Androgen deprivation therapy; Prostate-specific antigen; Androgen receptor; Cancer; Confidence interval","score_opus":0.20215864475529127,"score_gpt":0.4953345296009628,"score_spread":0.29317588484567153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407317724","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024899829,0.98417336,0.0001852987,0.00057573174,0.00014169615,0.010965858,0.001371945,0.0000063753573,0.000089740955],"genre_scores_gemma":[0.0023752386,0.983255,0.002436695,0.00001884814,0.000014930227,0.010120645,0.00032432575,0.000025562817,0.001428712],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9960567,0.0014262327,0.0012450549,0.0006211144,0.00025734174,0.00039358088],"domain_scores_gemma":[0.99643254,0.0023214049,0.0005025701,0.0003779381,0.00027616028,0.00008936198],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017252063,0.00047021036,0.0076284143,0.0014520257,0.000057336987,0.000010383327,0.00014851734,0.00012202812,0.000020606058],"category_scores_gemma":[0.000076198274,0.00025588134,0.0008776195,0.0019233802,0.0002715857,0.00003829513,0.00005414539,0.00018497415,3.482259e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016410636,0.0021275722,0.0027542068,0.08362241,0.4747576,0.00018113105,0.007616064,0.0038255183,0.00006793497,0.00011275282,0.0005387608,0.4079854],"study_design_scores_gemma":[0.015398435,0.008619333,0.0026924652,0.006561292,0.8512342,0.000005807835,0.0008051469,0.00058777013,0.0009187006,0.00056431594,0.112018734,0.00059383176],"about_ca_topic_score_codex":0.0015962502,"about_ca_topic_score_gemma":0.013113646,"teacher_disagreement_score":0.40739158,"about_ca_system_score_codex":0.0018020647,"about_ca_system_score_gemma":0.0016332812,"threshold_uncertainty_score":0.99998933},"labels":[],"label_agreement":null},{"id":"W4407384944","doi":"10.1101/2025.02.07.637178","title":"The Landscape of Prostate Tumour Methylation","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Methylation; Prostate; Oncology; Medicine; Internal medicine; Biology; Cancer; Genetics; Gene","score_opus":0.018244783190392563,"score_gpt":0.2763016088933691,"score_spread":0.2580568257029765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407384944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821939,0.011228576,0.00013777002,0.0023727168,0.0009331591,0.0023185783,0.00036527796,0.00021624635,0.00023376782],"genre_scores_gemma":[0.9954025,0.0031064397,0.0006562961,0.00005421646,0.00020391663,0.00027395177,0.0000011901086,0.000042770804,0.0002586737],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980246,0.000117309464,0.0004554035,0.00051421014,0.00047605345,0.0004124665],"domain_scores_gemma":[0.997713,0.00014511817,0.00028629255,0.0009146141,0.0007847818,0.000156158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071554695,0.0003146224,0.0005018826,0.00023993578,0.00017447567,0.000079920486,0.00028288993,0.00026800946,0.000023289287],"category_scores_gemma":[0.00024134733,0.00021555014,0.00017424254,0.00050451444,0.00015361501,0.000051904753,0.00033569883,0.0006504506,0.000015688278],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013601611,0.00045356748,0.09868042,0.0037545504,0.0015168918,0.00012790386,0.000065662374,0.000061979255,0.888791,0.0015319742,0.0035867875,0.000069066475],"study_design_scores_gemma":[0.0019658622,0.0002285304,0.1801905,0.001288847,0.00040787118,1.2170695e-8,0.000010929465,0.0005220796,0.80625385,0.000011002972,0.008776058,0.00034444183],"about_ca_topic_score_codex":0.000039954375,"about_ca_topic_score_gemma":0.0000019276263,"teacher_disagreement_score":0.08253717,"about_ca_system_score_codex":0.00019770567,"about_ca_system_score_gemma":0.0015583277,"threshold_uncertainty_score":0.87898797},"labels":[],"label_agreement":null},{"id":"W4407399358","doi":"10.18632/oncotarget.28692","title":"Correction: Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression","year":2025,"lang":"en","type":"erratum","venue":"Oncotarget","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Androgen receptor; Prostate cancer; Topoisomerase; Cancer research; Medicine; Cancer; Bioinformatics; Oncology; Internal medicine; Biology; DNA; Genetics","score_opus":0.012686079030075834,"score_gpt":0.31467093195397206,"score_spread":0.3019848529238962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407399358","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4917184,0.32913268,0.0000033894012,0.029744139,0.09871682,0.011101489,0.002351318,0.00032599267,0.036905766],"genre_scores_gemma":[0.034118697,0.022865515,0.00007683603,0.00021488695,0.0026225396,0.0007440118,0.00296434,0.00009126824,0.9363019],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997969,0.00008817431,0.00043167625,0.0005163426,0.0005827431,0.00041210724],"domain_scores_gemma":[0.99876136,0.000100837526,0.00025964133,0.00039588325,0.00031043004,0.0001718467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002608972,0.0003615036,0.0006683594,0.00020105719,0.00035370447,0.00003974325,0.00015319357,0.00034175327,0.0002529952],"category_scores_gemma":[0.000093618895,0.0002149455,0.00015073278,0.0004198999,0.00030388235,0.00008545677,0.00023247195,0.00091041013,0.000004180659],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075428834,0.00019372426,0.0077312295,0.0014110289,0.00037429488,0.000038436025,0.0013366236,0.0000024691092,0.0023714982,0.000002024271,0.9774721,0.008312268],"study_design_scores_gemma":[0.0022583536,0.0009145712,0.0006384297,0.0077396035,0.0005221773,0.000020495947,0.0004559788,0.00015028354,0.07284163,0.000023309825,0.9141161,0.00031907097],"about_ca_topic_score_codex":0.00035680312,"about_ca_topic_score_gemma":0.000051952073,"teacher_disagreement_score":0.8993961,"about_ca_system_score_codex":0.00030303246,"about_ca_system_score_gemma":0.0014420123,"threshold_uncertainty_score":0.8765223},"labels":[],"label_agreement":null},{"id":"W4407413403","doi":"10.3390/siuj6010004","title":"The Silent Burden of De Novo Metastatic Prostate Cancer in the Middle East: A Call for Region-Specific Screening Guidelines","year":2025,"lang":"en","type":"article","venue":"Société Internationale d’Urologie Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Middle East; Prostate cancer; Medicine; Cancer; Prostate; Oncology; Internal medicine; Geography","score_opus":0.23350100425400558,"score_gpt":0.4370438617659349,"score_spread":0.20354285751192933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407413403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6482423,0.04884471,0.010628747,0.2869604,0.0010019855,0.0022226807,0.00010983027,0.000028475502,0.0019608494],"genre_scores_gemma":[0.967458,0.017135102,0.002185737,0.0014848743,0.00057459145,0.0005021592,0.000024150391,0.000016632779,0.010618729],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984577,0.00013842333,0.0005133732,0.00015373073,0.00041471905,0.00032207335],"domain_scores_gemma":[0.99801683,0.0007843949,0.0002132646,0.00015757725,0.00078241545,0.000045521552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013569102,0.00012148024,0.00021495225,0.00014981707,0.00022717277,0.000068775975,0.00037240505,0.000045386794,0.0000326342],"category_scores_gemma":[0.0005961144,0.000062493586,0.00019806567,0.0001978859,0.00016353604,0.00006581782,0.00005866011,0.00039105225,6.5544754e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019718764,0.0010009645,0.16584921,0.0005938205,0.0049209534,0.0009377646,0.024275588,0.013721081,0.0046573556,0.0089929495,0.17219888,0.5831327],"study_design_scores_gemma":[0.043105755,0.0028902167,0.08094927,0.0037934815,0.00096276996,0.001585375,0.07613589,0.036549088,0.0032104591,0.051315024,0.6987953,0.00070733397],"about_ca_topic_score_codex":0.000079608115,"about_ca_topic_score_gemma":0.00005395592,"teacher_disagreement_score":0.58242536,"about_ca_system_score_codex":0.00027355633,"about_ca_system_score_gemma":0.0005437039,"threshold_uncertainty_score":0.25484145},"labels":[],"label_agreement":null},{"id":"W4407413759","doi":"10.3390/siuj6010010","title":"The Performance and Role of PSMA PET Scans in Localised Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"Société Internationale d’Urologie Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Prostate; Medicine; Cancer; Nuclear medicine; Internal medicine","score_opus":0.018669605946364385,"score_gpt":0.3538346379859071,"score_spread":0.3351650320395427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407413759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777543,0.006148664,0.0000066497546,0.010540405,0.00022509693,0.00022300292,0.000012396596,0.00000761775,0.0050818524],"genre_scores_gemma":[0.9751173,0.018072682,0.00003979113,0.00025077208,0.000065915745,0.000044434288,0.0000056904505,0.00000465957,0.006398719],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991158,0.000046303645,0.0002611362,0.00011328866,0.00025788404,0.00020553952],"domain_scores_gemma":[0.9993676,0.00016651556,0.00010097528,0.000083467145,0.00023471091,0.000046746893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039706717,0.00008276569,0.00015531841,0.0001338955,0.00013188925,0.000033715558,0.00013651155,0.000035083034,0.000068942696],"category_scores_gemma":[0.00010244602,0.00004997642,0.00005512223,0.00014489036,0.00020823798,0.00008465519,0.000064093845,0.00036732398,9.3215107e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011425455,0.00009054748,0.928974,0.00004649406,0.000212353,0.000034164328,0.00036914556,0.0001433367,0.0013098313,0.0003563788,0.0012898662,0.06603134],"study_design_scores_gemma":[0.006648869,0.00044007017,0.95072526,0.00037093228,0.00006573358,0.00013792058,0.0020309626,0.008618898,0.0059195333,0.0035453665,0.021387395,0.000109056266],"about_ca_topic_score_codex":0.000052238913,"about_ca_topic_score_gemma":0.000055433833,"teacher_disagreement_score":0.065922275,"about_ca_system_score_codex":0.00020622242,"about_ca_system_score_gemma":0.00043739073,"threshold_uncertainty_score":0.20379794},"labels":[],"label_agreement":null},{"id":"W4407493342","doi":"10.1016/j.bpj.2024.11.2936","title":"BPS2025 - Comparing the phase behavior of the androgen receptor (AR) and its splice variant (AR-V7) in prostate cancer","year":2025,"lang":"en","type":"article","venue":"Biophysical Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Androgen receptor; Prostate cancer; splice; Cancer research; Internal medicine; Biology; Oncology; Chemistry; Cancer; Medicine; Genetics; Gene","score_opus":0.03275640441400765,"score_gpt":0.3619190498124346,"score_spread":0.329162645398427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407493342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99323285,0.0016549428,0.0000028761265,0.0040725195,0.00019756379,0.00056405156,0.000027794133,0.000005366003,0.00024206833],"genre_scores_gemma":[0.99731755,0.001261186,0.000017835255,0.000119867145,0.00013773813,0.00005681736,0.0000024268686,0.000007938156,0.0010786394],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99904656,0.00007990966,0.0002387643,0.00014723347,0.00025313423,0.00023440148],"domain_scores_gemma":[0.99952847,0.000054156782,0.0000788816,0.00014295339,0.00010408536,0.000091447095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018314127,0.000110911045,0.0002502342,0.00006347863,0.00015825487,0.000027633692,0.00014415778,0.00003451447,0.000039019396],"category_scores_gemma":[0.000025554129,0.000052777308,0.000082952465,0.00035813445,0.00013599185,0.000060706374,0.00010208404,0.0004276416,0.0000024301883],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021771018,0.0016209127,0.11637339,0.00018615498,0.00031596384,0.00016656706,0.0012618602,0.0000090062495,0.85309213,0.000575081,0.0013925246,0.022829313],"study_design_scores_gemma":[0.02452072,0.00086908776,0.30075836,0.0020865698,0.0008356502,0.00021962111,0.0008588911,0.0026326498,0.65971726,0.00019391875,0.007006153,0.00030110095],"about_ca_topic_score_codex":0.000095777716,"about_ca_topic_score_gemma":0.000016068223,"teacher_disagreement_score":0.19337484,"about_ca_system_score_codex":0.00011912963,"about_ca_system_score_gemma":0.00028320646,"threshold_uncertainty_score":0.21521962},"labels":[],"label_agreement":null},{"id":"W4407517245","doi":"10.1158/2159-8290.cd-23-0882","title":"The Germline and Somatic Origins of Prostate Cancer Heterogeneity","year":2025,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Université Laval; Lunenfeld-Tanenbaum Research Institute; Centre hospitalier de l'Université Laval; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Vector Institute; Ontario Institute for Cancer Research","funders":"National Institute of Environmental Health Sciences; National Cancer Institute; DOD Prostate Cancer Research Program; National Human Genome Research Institute","keywords":"Germline; Somatic cell; Prostate cancer; Germline mutation; Biology; Cancer; Genetics; Cancer research; Computational biology; Mutation; Gene","score_opus":0.020534684418147806,"score_gpt":0.35847919120727056,"score_spread":0.33794450678912274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407517245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9448398,0.04890753,0.000020771144,0.0048067626,0.00027543193,0.00055037194,0.00010390619,0.000015475123,0.0004799906],"genre_scores_gemma":[0.9576698,0.032703564,0.000014431362,0.0002216614,0.000074255004,0.00029802724,0.0000101369415,0.000011091268,0.0089970315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915445,0.000025247973,0.0002000506,0.0002011659,0.00017528093,0.00024378924],"domain_scores_gemma":[0.99946046,0.000079859994,0.00006184697,0.00025026812,0.000086769316,0.000060822156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010677941,0.00011806873,0.00023643539,0.00005465666,0.00013184459,0.000042178166,0.00007561199,0.00003673196,0.000017127546],"category_scores_gemma":[0.00002107227,0.00006572293,0.000064986525,0.00021926373,0.00026949545,0.000113544775,0.00006842457,0.000111660855,0.000001064823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015357871,0.00016440885,0.9116181,0.0015763532,0.00077195716,0.000020430512,0.0004042747,0.00003567297,0.02033248,0.0023215206,0.002898541,0.05832045],"study_design_scores_gemma":[0.008634487,0.00039547097,0.58564866,0.0026541909,0.00077921536,0.000009409272,0.0005391428,0.00061257626,0.31997937,0.0017847456,0.078604236,0.00035846667],"about_ca_topic_score_codex":0.0007059252,"about_ca_topic_score_gemma":0.00041540715,"teacher_disagreement_score":0.32596946,"about_ca_system_score_codex":0.00033887764,"about_ca_system_score_gemma":0.00067157287,"threshold_uncertainty_score":0.26801035},"labels":[],"label_agreement":null},{"id":"W4407584761","doi":"10.3390/siuj6010016","title":"B2B: Prostate Cancer Summary","year":2025,"lang":"en","type":"article","venue":"Société Internationale d’Urologie Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University; University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Prostate; Cancer; Gynecology; Oncology; Internal medicine","score_opus":0.04299821695689084,"score_gpt":0.40766695221899873,"score_spread":0.3646687352621079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407584761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7938654,0.018365858,0.00023115164,0.08339362,0.002968711,0.0006421133,0.000068934794,0.00012669402,0.10033753],"genre_scores_gemma":[0.78668714,0.01453619,0.00034768783,0.004246332,0.00070451316,0.000113703,0.00006866955,0.000016827002,0.19327897],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99869657,0.000055658744,0.0002948538,0.00020457568,0.00041887467,0.00032944826],"domain_scores_gemma":[0.9990636,0.00013309739,0.000107121465,0.00013286133,0.00044491695,0.00011836851],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031365367,0.00013970003,0.00022435731,0.00024970117,0.0001884564,0.00007456042,0.00020215737,0.00009596931,0.0010898229],"category_scores_gemma":[0.00014522782,0.000101893515,0.00018762427,0.00019357077,0.00012770659,0.00014180175,0.00009913319,0.0006312774,0.000022735627],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021459525,0.0004203189,0.6685679,0.00009605893,0.0015527544,0.0005468995,0.00034089468,0.000070429385,0.0029524988,0.0013843036,0.20504303,0.11687896],"study_design_scores_gemma":[0.013805374,0.00078712724,0.4160932,0.0006793156,0.000366635,0.0003949868,0.0010072524,0.0006775008,0.0076651345,0.023454905,0.5346907,0.0003779002],"about_ca_topic_score_codex":0.000025239447,"about_ca_topic_score_gemma":0.000009143612,"teacher_disagreement_score":0.32964763,"about_ca_system_score_codex":0.00054262404,"about_ca_system_score_gemma":0.0008563952,"threshold_uncertainty_score":0.99982333},"labels":[],"label_agreement":null},{"id":"W4407678056","doi":"10.1200/jco.2025.43.5_suppl.tps279","title":"Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Placebo; Oncology; Internal medicine; Hormone receptor; Cohort; Cancer; Androgen; Enzalutamide; Receptor; Prostate; Cancer research; Hormone; Breast cancer; Pathology","score_opus":0.03859430156463788,"score_gpt":0.4102411276178701,"score_spread":0.37164682605323224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407678056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882454,0.00043514222,0.00005360777,0.0007128614,0.00016859299,0.010200386,0.000010937532,0.000013692958,0.00015933244],"genre_scores_gemma":[0.9976771,0.0005641163,0.00083100906,0.000069029265,0.000026430476,0.000588419,0.000052728356,0.000025642852,0.00016554398],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99433404,0.0015568364,0.0026707442,0.00043190407,0.0006888511,0.000317622],"domain_scores_gemma":[0.9941788,0.0014998093,0.0024011761,0.00017244738,0.0015646486,0.0001831168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057608797,0.00029452614,0.00330403,0.00081581034,0.00006191587,0.000019495865,0.00007433304,0.00018409864,0.000007987036],"category_scores_gemma":[0.0006654156,0.0001634109,0.00014627802,0.00071026036,0.00047251297,0.00032716777,0.000034449695,0.0008494048,3.1206488e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6668038,0.012003064,0.30784065,0.000057925,0.0019253201,0.00031165482,0.0013521458,0.00011787932,0.000016468079,0.000010929047,0.000024024399,0.00953616],"study_design_scores_gemma":[0.86002386,0.0653148,0.06987834,0.00053639093,0.0013987477,0.000029275649,0.00189562,0.00036826805,0.00032762263,0.00006552916,0.000013646695,0.00014790214],"about_ca_topic_score_codex":0.00047617353,"about_ca_topic_score_gemma":0.00094342174,"teacher_disagreement_score":0.2379623,"about_ca_system_score_codex":0.00052405125,"about_ca_system_score_gemma":0.002155073,"threshold_uncertainty_score":0.66637033},"labels":[],"label_agreement":null},{"id":"W4407678522","doi":"10.1200/jco.2025.43.5_suppl.tps305","title":"OCOG-RATIONAL: A phase II randomized trial of optimal recurrence-directed therapy (RDT) without or with androgen-deprivation therapy (ADT) in radio-recurrent oligo-metastatic castrate sensitive prostate cancer (romCSPC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Clinical Oncology Group; Memorial University of Newfoundland; McGill University; University of Ottawa; Hôpital Maisonneuve-Rosemont; Ottawa Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Oncology; Recurrent prostate cancer; Internal medicine; Cancer; Randomized controlled trial; Gynecology; Prostatectomy","score_opus":0.13796103542284305,"score_gpt":0.5154813904007078,"score_spread":0.3775203549778648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407678522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884702,0.0026208449,0.0001622632,0.0042186156,0.00072364125,0.003591785,0.0000373816,0.000014914768,0.00016036205],"genre_scores_gemma":[0.9583639,0.03661343,0.0034415012,0.00035356803,0.0003618633,0.00026993355,0.000040357667,0.000023778042,0.0005316956],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99413645,0.0017785055,0.0028263873,0.00032958636,0.00059479463,0.00033426177],"domain_scores_gemma":[0.99344105,0.0028183435,0.002015927,0.00017849752,0.0013240156,0.00022215825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047701993,0.00027072927,0.0029786972,0.00044620395,0.00007331824,0.000016184431,0.00013116859,0.0002018505,0.00011826126],"category_scores_gemma":[0.0016949984,0.0001438401,0.00042610097,0.00067140476,0.00060487876,0.00016680661,0.000027556553,0.0009126235,8.737434e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8032774,0.0065386794,0.0024660253,0.00003923547,0.0018152117,0.00036444666,0.0008025146,0.000055281027,0.00035563155,0.00002455157,0.00027205888,0.18398902],"study_design_scores_gemma":[0.9378153,0.050748903,0.0037307008,0.00073480315,0.00040050974,0.00009522462,0.00018361384,0.0018229492,0.0024536047,0.00015484753,0.0017193834,0.000140126],"about_ca_topic_score_codex":0.00008453375,"about_ca_topic_score_gemma":0.00012017061,"teacher_disagreement_score":0.18384889,"about_ca_system_score_codex":0.0003143847,"about_ca_system_score_gemma":0.008755161,"threshold_uncertainty_score":0.99686426},"labels":[],"label_agreement":null},{"id":"W4407698792","doi":"10.1200/jco.2025.43.5_suppl.147","title":"Deep prostate-specific antigen (PSA) decline among early participants (pts) in LIBERTAS, a phase 3 study of apalutamide (APA) plus continuous versus intermittent androgen deprivation therapy (ADT) in metastatic castration-sensitive prostate cancer (mCSPC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Janssen Biotech","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Prostate-specific antigen; Internal medicine; Prostate; Castration; Oncology; Urology; Hormone; Cancer","score_opus":0.1759869625840245,"score_gpt":0.49849487037549023,"score_spread":0.32250790779146576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407698792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939276,0.0017347651,0.000039669412,0.001274831,0.0006109574,0.0023185075,0.000013326716,0.000007667765,0.00007267891],"genre_scores_gemma":[0.9947139,0.004511451,0.00023234093,0.00016951669,0.00011062075,0.00011716686,0.000014640181,0.000021937689,0.0001084412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99448687,0.0009679648,0.0031560913,0.0003764108,0.0005322912,0.0004803969],"domain_scores_gemma":[0.9956715,0.0016562958,0.0014348108,0.00023303235,0.000757699,0.00024663567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028569077,0.00024134593,0.0019111865,0.0005427054,0.00004417855,0.000025312813,0.00017507645,0.00018192151,0.00002927259],"category_scores_gemma":[0.0010590678,0.00017543,0.00021076204,0.0006705605,0.0003075507,0.0002406654,0.00007795898,0.00089389086,0.0000021968679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09082454,0.008300132,0.681863,0.000040771058,0.0011063841,0.0023900524,0.0053268573,0.00029605132,0.0008099026,0.000008422296,0.000046220484,0.20898764],"study_design_scores_gemma":[0.11299023,0.027845128,0.8512971,0.00040500783,0.00026904905,0.000012808683,0.0036280164,0.0012800146,0.0018135281,0.00010822122,0.00021894758,0.00013197737],"about_ca_topic_score_codex":0.0009423099,"about_ca_topic_score_gemma":0.0067166383,"teacher_disagreement_score":0.20885566,"about_ca_system_score_codex":0.00057726545,"about_ca_system_score_gemma":0.0021200485,"threshold_uncertainty_score":0.7153828},"labels":[],"label_agreement":null},{"id":"W4407698914","doi":"10.1200/jco.2025.43.5_suppl.384","title":"Evaluation of post radiotherapy PSA as a prognostic and predictive biomarker in high risk prostate cancer: A secondary analysis of RTOG 0521.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; London Health Sciences Centre","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Oncology; Internal medicine; Biomarker; Cancer","score_opus":0.07285131951477221,"score_gpt":0.5049981116449364,"score_spread":0.43214679213016416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407698914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829679,0.012021892,0.000025841831,0.0035173942,0.00023327828,0.00069725804,0.00007865875,0.0000021273156,0.0004556535],"genre_scores_gemma":[0.980998,0.018306237,0.00030226124,0.0001928029,0.00005136656,0.000027745122,0.000012672492,0.000006571353,0.000102382015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960263,0.0011954844,0.001840092,0.00018784199,0.0005909979,0.00015927899],"domain_scores_gemma":[0.9940277,0.002396316,0.0014802848,0.00013202176,0.0018312563,0.00013246661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008016424,0.00010417136,0.0014820021,0.00081883604,0.000020409847,0.0000039831652,0.000081458624,0.00021917687,0.00020031862],"category_scores_gemma":[0.00500374,0.000068715155,0.00029848318,0.00089095463,0.0003625851,0.00007748224,0.000030533894,0.0005442979,2.3025277e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015240969,0.001112425,0.67721444,0.00006906648,0.008141039,0.00005319673,0.00039022564,0.00013776882,0.00054561003,0.000009190391,0.00016862425,0.29691744],"study_design_scores_gemma":[0.020488197,0.010153284,0.9516227,0.00028319188,0.009737058,0.000010171597,0.0002147429,0.0062866746,0.0001906411,0.00061586616,0.00035312888,0.000044330587],"about_ca_topic_score_codex":0.0004734856,"about_ca_topic_score_gemma":0.000498716,"teacher_disagreement_score":0.29687312,"about_ca_system_score_codex":0.00036772282,"about_ca_system_score_gemma":0.0064546145,"threshold_uncertainty_score":0.9991779},"labels":[],"label_agreement":null},{"id":"W4407698997","doi":"10.1200/jco.2025.43.5_suppl.263","title":"Approach to treatment of metastatic hormone-sensitive prostate (mHSPC) cancer among cooperative oncology groups (CCTG, SWOG, and Alliance) in North America.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Oncology; Internal medicine; Prostate cancer; Overall survival; Cancer","score_opus":0.1222603444521029,"score_gpt":0.48371376017259965,"score_spread":0.3614534157204967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407698997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867642,0.0046534855,0.00018525333,0.0043887882,0.00030383252,0.0012071306,0.00003468331,0.000005213947,0.0024574096],"genre_scores_gemma":[0.9626271,0.031034222,0.0038724612,0.0008880862,0.00016075827,0.00011236883,0.000014954323,0.000016005368,0.0012740522],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965272,0.0006839599,0.0018074381,0.00034177452,0.0002718371,0.00036780344],"domain_scores_gemma":[0.99655473,0.0013859123,0.0008437336,0.00016025627,0.00065152877,0.00040381137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090779783,0.00022061991,0.0024028174,0.00028448366,0.000045717363,0.000008293951,0.000103478764,0.00017919828,0.0000120812365],"category_scores_gemma":[0.0007281326,0.00013915748,0.00023669632,0.0006346454,0.0006849549,0.0001062843,0.000064213804,0.000579638,0.0000030722501],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05017288,0.013774123,0.34574303,0.00018778678,0.0041263406,0.0032989464,0.013795189,0.0007399124,0.00061459007,0.000102915,0.0023396814,0.5651046],"study_design_scores_gemma":[0.030334044,0.05901354,0.86345774,0.0002301065,0.00103113,0.00009371353,0.004791623,0.0007186643,0.0005167618,0.00008149868,0.03953624,0.00019495992],"about_ca_topic_score_codex":0.00043205806,"about_ca_topic_score_gemma":0.0013217217,"teacher_disagreement_score":0.56490964,"about_ca_system_score_codex":0.00089776685,"about_ca_system_score_gemma":0.0031715964,"threshold_uncertainty_score":0.56746775},"labels":[],"label_agreement":null},{"id":"W4407699006","doi":"10.1200/jco.2025.43.5_suppl.tps282","title":"ACCEL: [Ac-225]-PSMA-62 phase Ia/Ib/II clinical trial to characterize efficacy, safety, tolerability, and dosimetry in oligometastatic hormone-sensitive and metastatic castration-resistant prostate cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre","funders":"Eli Lilly and Company","keywords":"Medicine; Tolerability; Prostate cancer; Oncology; Internal medicine; Dosimetry; Clinical trial; Cancer; Adverse effect; Nuclear medicine","score_opus":0.19159128697433736,"score_gpt":0.5557792121033651,"score_spread":0.36418792512902776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97011346,0.0016362745,0.000045136232,0.024716722,0.0009940608,0.0021585594,0.000083437335,0.000011983672,0.00024037436],"genre_scores_gemma":[0.9875852,0.007641867,0.0017587006,0.0019637651,0.0005010452,0.000048994432,0.00001860309,0.000023507922,0.0004583138],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9923035,0.0014856715,0.0046175416,0.0005791014,0.00050977926,0.000504412],"domain_scores_gemma":[0.9909633,0.006200586,0.0012140558,0.00027844284,0.0005229308,0.00082069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008171661,0.00030817612,0.0029915413,0.0004912352,0.00013633652,0.000052190455,0.00016528726,0.0002978332,0.000045105604],"category_scores_gemma":[0.006820872,0.00021638347,0.00037975376,0.0006021677,0.00062654034,0.00021227158,0.00024363183,0.0015043762,0.000003539431],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5589342,0.010206255,0.013752763,0.00018593366,0.0014924338,0.0020474852,0.00067301415,0.0000061742367,0.003049699,0.000078272176,0.0010048545,0.40856892],"study_design_scores_gemma":[0.3415942,0.0682941,0.5788187,0.00050836266,0.0013589765,0.00013261737,0.00042069197,0.00018650829,0.0004504994,0.00032477416,0.007650305,0.00026025774],"about_ca_topic_score_codex":0.00014401201,"about_ca_topic_score_gemma":0.0002514422,"teacher_disagreement_score":0.5650659,"about_ca_system_score_codex":0.0003582375,"about_ca_system_score_gemma":0.003750364,"threshold_uncertainty_score":0.8823862},"labels":[],"label_agreement":null},{"id":"W4407699397","doi":"10.1200/jco.2025.43.5_suppl.189","title":"Prostate cancer liver metastases: Genomic profiling and clinical outcomes.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Kelowna General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Profiling (computer programming); Metastasis; Cancer","score_opus":0.17432640506470304,"score_gpt":0.5542742172715622,"score_spread":0.3799478122068592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720025,0.009792996,0.0000401979,0.014212626,0.0016480831,0.00051979005,0.000013688505,0.000010619031,0.0017594739],"genre_scores_gemma":[0.9226687,0.05609595,0.0067538614,0.0062420736,0.00096380664,0.000021902972,0.00000597891,0.000024171453,0.0072235614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962513,0.0005195904,0.0024151085,0.00026014293,0.00026513383,0.00028871105],"domain_scores_gemma":[0.995448,0.0026037754,0.00087018416,0.00017674435,0.0004927692,0.00040854176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00485831,0.00014775082,0.0017206012,0.00017794674,0.000058793128,0.000016145888,0.0001359953,0.00030731273,0.00010708091],"category_scores_gemma":[0.002648199,0.0000871567,0.00057163177,0.00015580731,0.00045865728,0.000096471886,0.00012966679,0.0012964595,0.0000113341475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004597138,0.00091091904,0.7653046,0.000072027215,0.0016101131,0.0007342155,0.00003154084,0.000001635094,0.00004313333,0.00011976775,0.0033401607,0.2232347],"study_design_scores_gemma":[0.016747417,0.005357777,0.89129025,0.00017091645,0.0013527569,0.000076392105,0.000118513606,0.000103191574,0.000097748285,0.000382802,0.0842131,0.000089143105],"about_ca_topic_score_codex":0.000049741502,"about_ca_topic_score_gemma":0.000042893553,"teacher_disagreement_score":0.22314556,"about_ca_system_score_codex":0.00021545198,"about_ca_system_score_gemma":0.0043115993,"threshold_uncertainty_score":0.7648592},"labels":[],"label_agreement":null},{"id":"W4407699506","doi":"10.1200/jco.2025.43.5_suppl.22","title":"Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Nova Scotia Cancer Centre; Dalhousie University; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; McMaster University; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Trillium Health Centre; Université de Montréal; Centre Hospitalier de l’Université de Montréal; Université Laval; Credit Valley Hospital; Ottawa Regional Cancer Foundation; CancerCare Manitoba; University Health Network; Hôpital Charles-Le Moyne; McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Prostate cancer; Systemic therapy; Randomized controlled trial; Oncology; Internal medicine; Castration; Cancer; Breast cancer; Hormone","score_opus":0.11886466220176782,"score_gpt":0.5201430815661987,"score_spread":0.40127841936443087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97839934,0.0066049425,0.00006615329,0.00906263,0.0010525133,0.0044478388,0.0001071255,0.000017964396,0.00024151168],"genre_scores_gemma":[0.96679956,0.030066319,0.0009241771,0.0008916799,0.0003521842,0.0004975433,0.000043273914,0.000019445988,0.00040584613],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9919421,0.0030823478,0.0036930104,0.000314575,0.00058605353,0.00038189234],"domain_scores_gemma":[0.99426293,0.0033490013,0.0012075998,0.00019818281,0.00071485055,0.00026744168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010611332,0.00022814119,0.0031567733,0.00090238196,0.00006464767,0.000025802537,0.00014474752,0.00023506388,0.00017996739],"category_scores_gemma":[0.003786452,0.00014214711,0.00049661956,0.0009951903,0.00018353647,0.0001543752,0.000027318742,0.0009008169,0.0000020555772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7755605,0.003446306,0.00035325193,0.00004934569,0.00071106624,0.0007017681,0.00043448183,0.000039822233,0.001875491,0.000033088032,0.0016333616,0.21516155],"study_design_scores_gemma":[0.9245691,0.06278589,0.001384256,0.0009637483,0.00023992459,0.000033598433,0.000272162,0.00012100988,0.00095124793,0.00049989764,0.008062903,0.000116304465],"about_ca_topic_score_codex":0.00024719533,"about_ca_topic_score_gemma":0.00051059463,"teacher_disagreement_score":0.21504524,"about_ca_system_score_codex":0.0009940757,"about_ca_system_score_gemma":0.006286275,"threshold_uncertainty_score":0.99934715},"labels":[],"label_agreement":null},{"id":"W4407699679","doi":"10.1200/jco.2025.43.5_suppl.152","title":"Concomitant G-CSF use in maintaining an efficacious dose and safe delivery of docetaxel in combination with darolutamide in patients with metastatic hormone sensitive prostate cancer (mHSPC): ARASENS, a phase 3 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Université de Montréal; Ottawa Hospital","funders":"","keywords":"Medicine; Docetaxel; Concomitant; Prostate cancer; Oncology; Internal medicine; Cancer","score_opus":0.06289102622858335,"score_gpt":0.44303662251213805,"score_spread":0.3801455962835547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99737966,0.00034797133,0.000011891385,0.00081022974,0.000056382323,0.001347494,0.000021068745,0.0000027726876,0.000022548746],"genre_scores_gemma":[0.99837357,0.0006480445,0.0006759738,0.00022129758,0.000014149933,0.000020912143,0.000011425588,0.000012389626,0.000022266857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966311,0.0009109646,0.0015679332,0.00025573044,0.00036477868,0.00026949903],"domain_scores_gemma":[0.9966316,0.0016706139,0.00080859114,0.00012625194,0.0005886354,0.0001743051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002327608,0.0001629469,0.001469145,0.00056471577,0.000020331514,0.000011765223,0.000060360395,0.00009791411,0.0000025078057],"category_scores_gemma":[0.00074914086,0.00010245134,0.00005096067,0.0004725463,0.00030396052,0.00025702344,0.00003911154,0.0008286059,1.7031083e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13897173,0.013607465,0.8094664,0.000040162613,0.00041765696,0.0037112567,0.0018409946,0.0002126847,0.00006883428,0.000009890919,0.000009494428,0.031643413],"study_design_scores_gemma":[0.14944175,0.048937857,0.7976471,0.00052661356,0.00026089966,0.000017327839,0.0023960867,0.00060264126,0.00003235825,0.000044047407,0.000016183862,0.000077146215],"about_ca_topic_score_codex":0.00049051427,"about_ca_topic_score_gemma":0.0031469534,"teacher_disagreement_score":0.035330392,"about_ca_system_score_codex":0.0004841599,"about_ca_system_score_gemma":0.001785629,"threshold_uncertainty_score":0.41778442},"labels":[],"label_agreement":null},{"id":"W4407699982","doi":"10.1200/jco.2025.43.5_suppl.115","title":"Relationship between androgen deprivation therapy and kidney function in patients with prostate cancer: An analysis of the RADICAL-PC study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Centre Hospitalier de l’Université de Montréal; Impact; University of British Columbia; Population Health Research Institute; London Health Sciences Centre; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Cancer; Oncology; Internal medicine; Prostate; Urology; Kidney cancer; Androgen; Kidney; Gynecology; Hormone","score_opus":0.12963725065966775,"score_gpt":0.4753265225913741,"score_spread":0.34568927193170634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955047,0.00034574635,0.000020931708,0.003451815,0.000103519764,0.0005158943,0.0000065599993,0.0000020415569,0.000048835453],"genre_scores_gemma":[0.99900323,0.00040184136,0.00006264064,0.000378553,0.000055254954,0.000008824677,0.00001134295,0.000004164439,0.00007417258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980487,0.00051952136,0.00092481764,0.00012740085,0.00028431963,0.00009523692],"domain_scores_gemma":[0.99806195,0.00074979867,0.000602464,0.00013777781,0.00031808254,0.00012993217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016201772,0.00006580139,0.00067249703,0.00029921878,0.000045013534,0.000005276815,0.00007189418,0.000118510216,0.0000135560995],"category_scores_gemma":[0.0007904365,0.00003264448,0.00010520878,0.00080270506,0.00015583729,0.00009082066,0.000021854825,0.00043199593,8.05247e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009911771,0.0013281474,0.94463444,0.000010202103,0.0012932409,0.0000038146302,0.0001946502,0.000031478477,0.0000018974007,0.000011148673,0.00006805863,0.042511176],"study_design_scores_gemma":[0.014796215,0.008003147,0.9746405,0.000051738876,0.0015154665,2.582991e-7,0.00008647229,0.00004879552,0.0000102330205,0.00013271482,0.0006868405,0.000027658867],"about_ca_topic_score_codex":0.00008645717,"about_ca_topic_score_gemma":0.0001322666,"teacher_disagreement_score":0.042483516,"about_ca_system_score_codex":0.00013354921,"about_ca_system_score_gemma":0.0011667135,"threshold_uncertainty_score":0.20696998},"labels":[],"label_agreement":null},{"id":"W4407700106","doi":"10.1200/jco.2025.43.5_suppl.tps283","title":"Phase 2 randomized study of high-risk metachronous oligometastatic prostate cancer with high-risk mutations treated with metastasis-directed therapy and niraparib/abiraterone acetate plus prednisone (KNIGHTS) trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Abiraterone acetate; Medicine; Prednisone; Prostate cancer; Oncology; Abiraterone; Internal medicine; Randomized controlled trial; Cancer; Prostate; Gynecology; Androgen deprivation therapy","score_opus":0.07797300144794202,"score_gpt":0.4487236016629508,"score_spread":0.3707506002150088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868163,0.0053198943,0.00025477455,0.0014085688,0.00029392156,0.0056825145,0.00012612199,0.000041181676,0.000056741927],"genre_scores_gemma":[0.9747788,0.020083461,0.0034129499,0.00010297547,0.00013366561,0.00047832364,0.00003492999,0.000045802833,0.00092912035],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99131644,0.0037712876,0.0032177393,0.0005231555,0.000720258,0.0004511304],"domain_scores_gemma":[0.9895309,0.0044797077,0.003751876,0.00038954103,0.0014361258,0.00041182945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048575276,0.00043921993,0.0055785566,0.0006357925,0.00019315763,0.000041920823,0.00019278048,0.00020814841,0.00009244149],"category_scores_gemma":[0.001136937,0.00021416547,0.00035739806,0.00096100173,0.0010584117,0.00022575932,0.00004699246,0.0011367499,0.0000014314235],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8673355,0.017111976,0.007924596,0.00007972018,0.025584815,0.0005635667,0.0012504653,0.00043980769,0.00009458843,0.000015503152,0.00012618746,0.07947329],"study_design_scores_gemma":[0.8483088,0.12016765,0.013223815,0.00019900821,0.015121441,0.000042990854,0.0007430559,0.0003512082,0.0011792119,0.00024711143,0.00023756035,0.00017812937],"about_ca_topic_score_codex":0.0033472327,"about_ca_topic_score_gemma":0.0012122776,"teacher_disagreement_score":0.10305567,"about_ca_system_score_codex":0.00028503945,"about_ca_system_score_gemma":0.003673399,"threshold_uncertainty_score":0.87334144},"labels":[],"label_agreement":null},{"id":"W4407700199","doi":"10.1200/jco.2025.43.5_suppl.267","title":"Population-adjusted network meta-analyses (NMA) to evaluate the efficacy of treatment alternatives for metastatic hormone-sensitive prostate cancer (mHSPC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Oncology; Prostate cancer; Population; Internal medicine; Cancer; Gynecology; Environmental health","score_opus":0.5225097753658603,"score_gpt":0.6219806102795193,"score_spread":0.09947083491365905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94713736,0.014440265,0.00097597647,0.033548724,0.00087687955,0.0025604446,0.00007192333,0.00000833055,0.0003801236],"genre_scores_gemma":[0.9876561,0.003962878,0.004347911,0.0012644192,0.00052996364,0.00016410522,0.000016987879,0.00001746926,0.002040139],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9959774,0.0010130139,0.0020626537,0.00024281822,0.00039579096,0.00030830532],"domain_scores_gemma":[0.9891911,0.0079608755,0.0010989133,0.0002357246,0.0012929607,0.00022042397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033723535,0.00020408301,0.0025938402,0.00018499377,0.000083984065,0.000012281138,0.00015346268,0.00009543782,0.000046133377],"category_scores_gemma":[0.003166927,0.00009088608,0.0013283072,0.00041627875,0.00019663661,0.00006383295,0.00004799319,0.00031269397,0.0000026113237],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15568918,0.0064496994,0.037730202,0.00023277041,0.23675732,0.0004458217,0.0028307545,0.042229995,0.0021722633,0.00077934057,0.01795788,0.49672475],"study_design_scores_gemma":[0.060251158,0.064531915,0.6873582,0.00038745147,0.13151476,0.00005280306,0.00094505027,0.0034409438,0.005238715,0.005015122,0.040939648,0.000324207],"about_ca_topic_score_codex":0.00031174585,"about_ca_topic_score_gemma":0.00019280794,"teacher_disagreement_score":0.64962804,"about_ca_system_score_codex":0.00045532305,"about_ca_system_score_gemma":0.002116383,"threshold_uncertainty_score":0.37913364},"labels":[],"label_agreement":null},{"id":"W4407700221","doi":"10.1200/jco.2025.43.5_suppl.20","title":"Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council","keywords":"Medicine; Androgen receptor; Prostate cancer; Oncology; Internal medicine; Enzalutamide; Meta-analysis; Hormone; Cancer","score_opus":0.3820226163641716,"score_gpt":0.5198747717027395,"score_spread":0.13785215533856793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813815,0.009137588,0.000022436945,0.0063551837,0.00044762387,0.00071766396,0.0018274278,0.0000085401425,0.000102055106],"genre_scores_gemma":[0.99295604,0.0021760284,0.0030551907,0.0007162091,0.00024874645,0.00003646239,0.0004632496,0.00002816408,0.0003199354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944667,0.0007140159,0.0027631859,0.00049246394,0.0011334537,0.00043014952],"domain_scores_gemma":[0.9924284,0.0023154502,0.0022436318,0.0005906043,0.0019815003,0.00044037274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030206323,0.00029826045,0.0032885026,0.00027650353,0.000063367355,0.00002340362,0.00042820224,0.00022661024,0.00016862154],"category_scores_gemma":[0.002388444,0.0001591568,0.0004897699,0.00057680946,0.00043262827,0.00029206078,0.00031532368,0.00096103945,0.0000053777767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.100075126,0.015734132,0.3381312,0.00035631744,0.3265705,0.0013272825,0.0048423386,0.00045168758,0.003185197,0.000049938295,0.025765594,0.18351069],"study_design_scores_gemma":[0.05237122,0.02684071,0.7257124,0.00072257186,0.15085654,0.000023199345,0.0027274857,0.00021429881,0.019958334,0.0005005872,0.019536061,0.000536581],"about_ca_topic_score_codex":0.00038640224,"about_ca_topic_score_gemma":0.00039904276,"teacher_disagreement_score":0.38758123,"about_ca_system_score_codex":0.00014177935,"about_ca_system_score_gemma":0.0039351783,"threshold_uncertainty_score":0.6980837},"labels":[],"label_agreement":null},{"id":"W4407700392","doi":"10.1200/jco.2025.43.5_suppl.101","title":"Treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC): A systematic literature review of 35 real-world observational studies.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Observational study; Oncology; Internal medicine; Overall survival; Systematic review; Cancer; Cabazitaxel; Gynecology; Androgen deprivation therapy; MEDLINE","score_opus":0.24188029539468642,"score_gpt":0.5410807467225567,"score_spread":0.29920045132787026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700392","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6530565,0.31033403,0.000007712415,0.03163684,0.0003770588,0.0028183986,0.00007589988,0.000006382219,0.0016871486],"genre_scores_gemma":[0.34546334,0.64964527,0.0006700883,0.0006027098,0.00010548848,0.00015858434,0.000018687047,0.000010855024,0.0033250023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99639875,0.00065547857,0.0022132096,0.00017833195,0.00038541493,0.00016881732],"domain_scores_gemma":[0.99558955,0.0021102873,0.0011752655,0.00014258901,0.00085301074,0.00012928835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021680207,0.00015601366,0.0022871294,0.00021090494,0.00002707427,0.000009401078,0.0000658361,0.00006420943,0.00001657334],"category_scores_gemma":[0.0008030102,0.00007820096,0.0001681546,0.00044670442,0.00014119953,0.000090586356,0.000024131465,0.0003399016,2.3829118e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014820133,0.0028780315,0.70978206,0.24626036,0.007678828,0.0041107466,0.0013616744,0.000016583343,0.000095310395,0.00081430393,0.0015421073,0.010639851],"study_design_scores_gemma":[0.022204652,0.012325926,0.63504833,0.3246117,0.0031022571,0.00011153658,0.0010000526,0.0000678296,0.000067713576,0.00023085682,0.0010978166,0.00013133865],"about_ca_topic_score_codex":0.00015101145,"about_ca_topic_score_gemma":0.001951484,"teacher_disagreement_score":0.3393112,"about_ca_system_score_codex":0.00054622674,"about_ca_system_score_gemma":0.0027473285,"threshold_uncertainty_score":0.48736426},"labels":[],"label_agreement":null},{"id":"W4407700420","doi":"10.1200/jco.2025.43.5_suppl.tps294","title":"Long-term safety outcomes of <sup>177</sup> Lu-PSMA-617 in patients with prostate cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Prostate cancer; Term (time); Oncology; Prostate; Cancer; Internal medicine; Nuclear medicine; Urology","score_opus":0.06344107666936774,"score_gpt":0.47919631107960914,"score_spread":0.4157552344102414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98829377,0.0007834255,0.00001117469,0.008416566,0.00036831008,0.0005483924,0.000018156394,0.0000052384457,0.001554953],"genre_scores_gemma":[0.994221,0.0021975061,0.0003269199,0.0008096569,0.00013230227,0.00001176066,0.0000102184995,0.000013913418,0.0022767296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99663484,0.00027568417,0.0020890795,0.00020563634,0.0004736068,0.0003211815],"domain_scores_gemma":[0.99681735,0.0010914438,0.000954317,0.00021139186,0.000687168,0.00023835832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014350453,0.00015999957,0.0017397656,0.00027003218,0.00003251996,0.000006132678,0.00018691827,0.00025525177,0.000121423],"category_scores_gemma":[0.0009055634,0.00008987127,0.00028362646,0.0003152705,0.00034226748,0.000110169814,0.00007785258,0.000942461,0.0000033494596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029448817,0.002409487,0.8589601,0.00011890409,0.0007241881,0.0002817452,0.00015022611,0.000056251127,0.000003032381,0.000018141785,0.00056278077,0.10726632],"study_design_scores_gemma":[0.033748034,0.008804408,0.9544007,0.00053306826,0.00028670943,0.000005893103,0.00007587213,0.000020060505,0.000045226865,0.00007317438,0.0019359327,0.00007089708],"about_ca_topic_score_codex":0.000058586233,"about_ca_topic_score_gemma":0.00014095705,"teacher_disagreement_score":0.10719543,"about_ca_system_score_codex":0.0004147039,"about_ca_system_score_gemma":0.0032064808,"threshold_uncertainty_score":0.56881595},"labels":[],"label_agreement":null},{"id":"W4407700443","doi":"10.1200/jco.2025.43.5_suppl.51","title":"Role of liquid biopsy in the detection of homologous recombination repair gene mutations (HRRm) in metastatic prostate cancer (mPC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Homologous recombination; Liquid biopsy; Prostate cancer; Cancer research; Gene; Biopsy; Prostate; Homologous chromosome; Cancer; Oncology; Internal medicine; Genetics; Biology","score_opus":0.07826902302054868,"score_gpt":0.4817508069233256,"score_spread":0.40348178390277695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99088216,0.0032536217,0.000033634333,0.0046345405,0.00029087393,0.0004295868,0.0000056089684,0.000003384048,0.0004665711],"genre_scores_gemma":[0.9960727,0.0027595994,0.00075158186,0.00015581142,0.000046771012,0.00003752871,0.0000035613994,0.0000050058334,0.00016742515],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970826,0.0007130007,0.0017201495,0.000115251474,0.00022738897,0.00014160073],"domain_scores_gemma":[0.99709284,0.0014309728,0.00086188223,0.00012355698,0.00044344677,0.000047310627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035740796,0.0000716433,0.00073154236,0.00042140085,0.000019725789,0.0000021585092,0.00010169905,0.00013197438,0.000020368532],"category_scores_gemma":[0.0017823746,0.000043514712,0.00021897328,0.0006001163,0.00020006526,0.00006721972,0.000021909811,0.0005614664,6.848258e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043108836,0.012405589,0.32973674,0.00055171683,0.0015108825,0.001056753,0.0045600636,0.0005969941,0.08471675,0.00043285705,0.000276337,0.52104646],"study_design_scores_gemma":[0.017415253,0.020280983,0.9177452,0.00046236554,0.0005702456,0.0001785561,0.0023859027,0.00070745713,0.03250883,0.005999203,0.0016633739,0.0000826695],"about_ca_topic_score_codex":0.00031590517,"about_ca_topic_score_gemma":0.0005457464,"teacher_disagreement_score":0.5880084,"about_ca_system_score_codex":0.00023746748,"about_ca_system_score_gemma":0.0017048778,"threshold_uncertainty_score":0.30243802},"labels":[],"label_agreement":null},{"id":"W4407700602","doi":"10.1200/jco.2025.43.5_suppl.155","title":"Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre; CancerCare Manitoba; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Oncology; Androgen deprivation therapy; Cabazitaxel; Overall survival; Internal medicine; Abiraterone; Castration; Androgen receptor; Urology; Cancer; Hormone","score_opus":0.20432873725121756,"score_gpt":0.4870427981683177,"score_spread":0.28271406091710016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729476,0.0065287054,0.00013480581,0.01653768,0.0017696276,0.0014618144,0.00018717586,0.000010887827,0.00042170426],"genre_scores_gemma":[0.96066797,0.017725125,0.0038673438,0.0025561089,0.0022845708,0.00017916481,0.000088291905,0.000038086186,0.012593321],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964426,0.0004515406,0.002042959,0.000324037,0.00038210896,0.0003567227],"domain_scores_gemma":[0.9961185,0.0017534695,0.0008888611,0.00015857759,0.0007663016,0.00031432626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028471667,0.00022394261,0.0014408189,0.00018733046,0.00016109983,0.000051321756,0.000110942376,0.00024271235,0.00032011772],"category_scores_gemma":[0.00089231867,0.00013570799,0.0003452393,0.00018134332,0.00022502427,0.00020683713,0.000032673986,0.0006016876,0.0000016544618],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40660226,0.0055045066,0.031308275,0.00082964444,0.005314569,0.0013710934,0.0007643061,0.000074739895,0.044629335,0.0012828544,0.038683992,0.46363443],"study_design_scores_gemma":[0.17517608,0.05830398,0.10990625,0.00063957955,0.0013825427,0.00028676985,0.00044394145,0.0008765911,0.018695036,0.002207751,0.6315703,0.00051120063],"about_ca_topic_score_codex":0.000044129007,"about_ca_topic_score_gemma":0.00090093986,"teacher_disagreement_score":0.59288627,"about_ca_system_score_codex":0.0002991129,"about_ca_system_score_gemma":0.0068177464,"threshold_uncertainty_score":0.9988127},"labels":[],"label_agreement":null},{"id":"W4407700626","doi":"10.1200/jco.2025.43.5_suppl.310","title":"Impact of testosterone recovery after androgen deprivation therapy on overall survival in patients with high-risk prostate cancer: Long-term data from a phase III trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Cégep de l'Outaouais; Centre Hospitalier de l’Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Université Laval; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; Centre Intégré de Santé et de Services Sociaux du Bas-Saint-Laurent; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Testosterone (patch); Oncology; Internal medicine; Prostate; Androgen; Overall survival; Cancer; Urology; Gynecology; Hormone","score_opus":0.11674083890217178,"score_gpt":0.4892841191672233,"score_spread":0.3725432802650515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996407,0.00087296363,0.000015844025,0.00069892564,0.00058564096,0.0010078707,0.00037352555,0.0000036532456,0.000034581288],"genre_scores_gemma":[0.99140865,0.007620555,0.00013929808,0.00021465468,0.00028166585,0.00001986457,0.00021118131,0.0000141661485,0.00008997805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99694127,0.0004890978,0.0016629805,0.0002822533,0.00040682158,0.0002175842],"domain_scores_gemma":[0.996124,0.0015917054,0.0013604299,0.00041384864,0.00035148414,0.00015852244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015015359,0.00015803639,0.0013162453,0.00021428808,0.00002012702,0.000011161514,0.00021171726,0.00020850167,0.0001494968],"category_scores_gemma":[0.00082851126,0.000087779765,0.00018456524,0.00019114304,0.00012187042,0.00020834107,0.000076515025,0.00068006176,0.0000014499478],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39719424,0.00485842,0.4827259,0.0000073026677,0.00079452456,0.00008509455,0.000027101616,0.000008050143,0.000014888352,2.0788828e-7,0.00017963685,0.11410464],"study_design_scores_gemma":[0.2912686,0.055219103,0.6527797,0.00027105887,0.00018050264,6.1778746e-7,0.000002388994,0.000009420713,0.00005186591,0.000059481725,0.00010804258,0.00004922751],"about_ca_topic_score_codex":0.00080276676,"about_ca_topic_score_gemma":0.00038822924,"teacher_disagreement_score":0.17005382,"about_ca_system_score_codex":0.00040569002,"about_ca_system_score_gemma":0.0025537254,"threshold_uncertainty_score":0.45301992},"labels":[],"label_agreement":null},{"id":"W4407700629","doi":"10.1200/jco.2025.43.5_suppl.159","title":"Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) plus leuprolide (combo): EMBARK post hoc analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Post-hoc analysis; Internal medicine; Post hoc; Cancer; Gynecology; Androgen receptor","score_opus":0.03541493979559037,"score_gpt":0.41242726676455077,"score_spread":0.3770123269689604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907725,0.0024116274,0.0000148697045,0.0045468267,0.00021713717,0.001234215,0.0003191479,0.000019569927,0.00046412766],"genre_scores_gemma":[0.99065804,0.005961902,0.00082025304,0.0011201673,0.0000792443,0.00012786458,0.00020521418,0.000035994846,0.0009913202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951621,0.00065048673,0.0023067668,0.0006065357,0.0006493317,0.0006247472],"domain_scores_gemma":[0.9947142,0.001508304,0.001713091,0.000346407,0.0011936886,0.000524293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089488097,0.00046211516,0.0031421017,0.00067945744,0.00010054438,0.000030121782,0.00022156052,0.00039355241,0.00010555212],"category_scores_gemma":[0.0005939793,0.00024352923,0.00056578795,0.0010149573,0.00065150607,0.00015297632,0.00007046098,0.0013676779,0.0000060348452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08149604,0.0048544807,0.7833293,0.00004407757,0.008374255,0.00050413946,0.00022428102,0.00004098343,0.000039035156,0.000008161306,0.00070926035,0.120376],"study_design_scores_gemma":[0.07842653,0.052420508,0.8598349,0.0003787751,0.005271155,0.0000110613155,0.00021248385,0.000030657968,0.00088235125,0.000042591808,0.0022483899,0.00024058603],"about_ca_topic_score_codex":0.0008930006,"about_ca_topic_score_gemma":0.0018238433,"teacher_disagreement_score":0.12013541,"about_ca_system_score_codex":0.0025267333,"about_ca_system_score_gemma":0.0063784337,"threshold_uncertainty_score":0.99925447},"labels":[],"label_agreement":null},{"id":"W4407700779","doi":"10.1200/jco.2025.43.5_suppl.151","title":"Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada); Université de Montréal","funders":"Bayer","keywords":"Medicine; Prostate cancer; Oncology; Subgroup analysis; Internal medicine; Docetaxel; Disease; Cancer; Confidence interval","score_opus":0.051571423801224495,"score_gpt":0.4635281773739748,"score_spread":0.4119567535727503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908742,0.0015829264,0.00005739451,0.005771553,0.0003436305,0.0010742889,0.00019039735,0.0000031798913,0.00010248375],"genre_scores_gemma":[0.9964902,0.0011937057,0.00010764625,0.00077786803,0.000062528125,0.00003061763,0.000032326287,0.000011515211,0.0012936309],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99626285,0.00075627666,0.0018459808,0.00023995028,0.0006062448,0.00028870476],"domain_scores_gemma":[0.99629956,0.0010617482,0.0013634352,0.0002622657,0.0007134532,0.00029952795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016695076,0.00016228158,0.0019037671,0.0003818867,0.00004029989,0.0000088007855,0.00017321434,0.00010463459,0.00003652855],"category_scores_gemma":[0.0017009282,0.00008356202,0.00057609146,0.0012368764,0.00045612938,0.00010198761,0.000060580915,0.0007485401,9.990332e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5720307,0.0062390184,0.37556013,0.00005540971,0.006886071,0.00030637588,0.0002455181,0.00024125112,0.00004281504,0.000006832766,0.0028950728,0.035490744],"study_design_scores_gemma":[0.23453896,0.010644208,0.74193835,0.00018143404,0.008546369,8.40381e-7,0.0000998911,0.0011305215,0.000048526075,0.000054717064,0.002735146,0.00008106344],"about_ca_topic_score_codex":0.00015790483,"about_ca_topic_score_gemma":0.00018119121,"teacher_disagreement_score":0.3663782,"about_ca_system_score_codex":0.00051616353,"about_ca_system_score_gemma":0.004144049,"threshold_uncertainty_score":0.73513645},"labels":[],"label_agreement":null},{"id":"W4407700904","doi":"10.1200/jco.2025.43.5_suppl.393","title":"Defining subgroups of patients with intermediate risk prostate cancer for whom active surveillance is safe.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Sunnybrook Research Institute","keywords":"Medicine; Prostate cancer; Prostate; Cancer; Watchful waiting; Oncology; Internal medicine; Gynecology; Intensive care medicine","score_opus":0.0459386927962106,"score_gpt":0.46108047085959025,"score_spread":0.41514177806337965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407700904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99335164,0.0011663109,0.000120751516,0.0033401235,0.0007501094,0.00054126536,0.00020235471,0.000003918527,0.00052355666],"genre_scores_gemma":[0.9936875,0.0036507621,0.0010454553,0.0006977841,0.00017314735,0.000028003295,0.000015756328,0.000013676888,0.00068793376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765486,0.00022400891,0.0014027546,0.00018406722,0.00028198358,0.0002523202],"domain_scores_gemma":[0.9937584,0.0028811062,0.0017014722,0.00013377196,0.001356003,0.00016926153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015012558,0.00012243481,0.0012148008,0.00014495979,0.000057155972,0.000007149141,0.00012266384,0.00018303015,0.00005426177],"category_scores_gemma":[0.0022771978,0.00007125327,0.00027918536,0.00018908661,0.00036884443,0.00008271118,0.000046717818,0.0006454968,0.0000017129387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041325334,0.00073948415,0.76413596,0.00009320476,0.0009068289,0.000019632382,0.0002637343,0.0000047103904,0.0000059366907,0.000017695833,0.0029410294,0.18954645],"study_design_scores_gemma":[0.023054084,0.013027825,0.938042,0.00033509053,0.00032192966,0.0000018146818,0.00012366232,0.000037534173,0.0003764029,0.00029789598,0.024318272,0.00006348771],"about_ca_topic_score_codex":0.00004915989,"about_ca_topic_score_gemma":0.000147187,"teacher_disagreement_score":0.18948296,"about_ca_system_score_codex":0.00022639024,"about_ca_system_score_gemma":0.0032049667,"threshold_uncertainty_score":0.5685473},"labels":[],"label_agreement":null},{"id":"W4407701126","doi":"10.1200/jco.2025.43.5_suppl.16","title":"Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of <sup>177</sup> Lu-PSMA-617.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Oncology; Nuclear medicine","score_opus":0.08324424851418714,"score_gpt":0.49096912256259706,"score_spread":0.4077248740484099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933605,0.000057906927,0.000007007607,0.005332533,0.00010403752,0.00082099857,0.000006293417,0.0000019393788,0.00030875547],"genre_scores_gemma":[0.998621,0.00040968257,0.00019107388,0.000415693,0.000089023386,0.0000135271675,0.000006361255,0.000007221213,0.00024641128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99597,0.001109542,0.0019982357,0.00018723652,0.00056400074,0.00017098246],"domain_scores_gemma":[0.99186915,0.006084243,0.0013218748,0.00018451028,0.00045171255,0.00008850203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044826353,0.0001355785,0.0014981405,0.00024536473,0.000024614534,0.00000493659,0.00009578061,0.00023158021,0.000013837594],"category_scores_gemma":[0.0022302044,0.000058885336,0.00014838784,0.00028015784,0.00012971285,0.00007190279,0.000023936054,0.00078567275,6.124757e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021377433,0.021299744,0.9166416,0.000021837248,0.0009242649,0.0000926481,0.00041776375,0.00007454561,2.887031e-7,0.000005869457,0.0002352421,0.038908787],"study_design_scores_gemma":[0.046850096,0.06828989,0.88191444,0.00016435,0.0004579727,0.0000022190945,0.0016557658,0.00007235854,0.000005650879,0.000045329547,0.0005026959,0.00003925365],"about_ca_topic_score_codex":0.00013374447,"about_ca_topic_score_gemma":0.00074477075,"teacher_disagreement_score":0.04699015,"about_ca_system_score_codex":0.0004088328,"about_ca_system_score_gemma":0.0008592137,"threshold_uncertainty_score":0.34134007},"labels":[],"label_agreement":null},{"id":"W4407701171","doi":"10.1200/jco.2025.43.5_suppl.tps432","title":"Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Lévis; McGill University","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Placebo; Internal medicine; Oncology; Biochemical recurrence; breakpoint cluster region; Androgen; Randomized controlled trial; Cancer; Urology; Prostatectomy; Hormone; Pathology; Receptor","score_opus":0.06419575208520342,"score_gpt":0.4573852924826808,"score_spread":0.39318954039747733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901695,0.0019660012,0.00004032721,0.0014425021,0.0004906546,0.0057474156,0.000017164028,0.000007732984,0.0001186931],"genre_scores_gemma":[0.9932337,0.005750204,0.00026973287,0.00014869358,0.0001555828,0.00028132353,0.000015364038,0.000015722158,0.00012968158],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943694,0.0012042449,0.0031081152,0.0003381988,0.00066078245,0.0003192766],"domain_scores_gemma":[0.99329776,0.0027938983,0.0023634445,0.00025503372,0.0010655775,0.0002243032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055565154,0.00023484902,0.0035509986,0.00043835424,0.00004747102,0.000013106866,0.00021622425,0.00027144217,0.000039728042],"category_scores_gemma":[0.0018256296,0.00012986828,0.00037969011,0.0005379968,0.00043363025,0.00012987021,0.000057331206,0.0011448622,0.0000013529841],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62818617,0.00795315,0.32058227,0.000025999623,0.0016338805,0.00006626561,0.00022375652,0.0000357109,0.000021122256,0.000007731818,0.00013715164,0.041126795],"study_design_scores_gemma":[0.93695855,0.021795565,0.038718212,0.000336148,0.00088904484,0.000003584595,0.00014708933,0.00018459716,0.0005651827,0.0001373455,0.00016296493,0.000101709964],"about_ca_topic_score_codex":0.00022930591,"about_ca_topic_score_gemma":0.00007862695,"teacher_disagreement_score":0.3087724,"about_ca_system_score_codex":0.00041921673,"about_ca_system_score_gemma":0.0038892527,"threshold_uncertainty_score":0.68993676},"labels":[],"label_agreement":null},{"id":"W4407701227","doi":"10.1200/jco.2025.43.5_suppl.409","title":"Androgen receptor activity in biopsy specimens at initial diagnosis of prostate cancer and correlation with outcomes and treatment response.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Veracyte","keywords":"Medicine; Prostate cancer; Androgen receptor; Biopsy; Oncology; Prostate; Internal medicine; Correlation; Androgen; Cancer; Pathology; Hormone","score_opus":0.11370550760166957,"score_gpt":0.49731712329695016,"score_spread":0.3836116156952806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98558956,0.0012530396,0.0000019259344,0.012386637,0.00019141576,0.00035866283,0.000018778002,0.0000022114773,0.00019774656],"genre_scores_gemma":[0.9891582,0.009294777,0.000285175,0.00010927936,0.000057871886,0.000025748479,0.0000017546273,0.0000057151783,0.0010614516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986093,0.00030437947,0.0006642836,0.00014218978,0.00014921177,0.0001306337],"domain_scores_gemma":[0.99690616,0.0022925502,0.00044998035,0.0000735932,0.00014500268,0.00013272377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009747968,0.00009624691,0.00087474566,0.0001769991,0.000028524195,0.000004030429,0.000026005504,0.00014948822,0.000043430096],"category_scores_gemma":[0.00050521933,0.00005358417,0.00007903064,0.00013503227,0.00028004675,0.000065443535,0.000034716813,0.00024102205,5.444219e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06877069,0.0008403972,0.8401656,0.000022838161,0.00038192893,0.0002021451,0.00019444866,0.000002801708,0.00029993174,0.0000057747848,0.00014059222,0.088972814],"study_design_scores_gemma":[0.019054206,0.012018139,0.9610562,0.00020104447,0.00022940272,0.000038085345,0.00008026774,0.000018579141,0.0024512624,0.000030283709,0.004779476,0.00004307785],"about_ca_topic_score_codex":0.00009679676,"about_ca_topic_score_gemma":0.00036856293,"teacher_disagreement_score":0.12089054,"about_ca_system_score_codex":0.00043018415,"about_ca_system_score_gemma":0.0011519141,"threshold_uncertainty_score":0.21850988},"labels":[],"label_agreement":null},{"id":"W4407701365","doi":"10.1200/jco.2025.43.5_suppl.65","title":"Relationship between undetectable PSA nadir and outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in IRONMAN, the International Registry for Men with Advanced Prostate Cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of British Columbia","funders":"Movember Foundation; Amgen; Prostate Cancer Foundation","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Cancer; Prostate; Gynecology","score_opus":0.08952338661902576,"score_gpt":0.4735618148242244,"score_spread":0.3840384282051986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96754795,0.000852131,0.00015113637,0.028707959,0.00017824346,0.0021244697,0.00017676264,0.0000053016024,0.00025604968],"genre_scores_gemma":[0.99189997,0.0008612119,0.002928579,0.0005164001,0.00010257708,0.00039067154,0.000032312866,0.000019059162,0.0032492059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981489,0.00012619501,0.000926862,0.00023476522,0.00028875383,0.00027449374],"domain_scores_gemma":[0.9939791,0.004241648,0.00082272524,0.00012666566,0.00069454825,0.00013530326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012001913,0.00015166435,0.00086557755,0.00014027467,0.00009153589,0.000021212167,0.00012527076,0.000097185606,0.0000033919337],"category_scores_gemma":[0.0013771026,0.00007583808,0.000108330205,0.00017428068,0.0002821515,0.00016263609,0.000036127916,0.00052768434,1.9973659e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029783059,0.00029782995,0.93634754,0.00009237864,0.00086662517,0.00002491347,0.0003346495,0.000091622824,0.000007816952,0.00006020825,0.0009741082,0.03111924],"study_design_scores_gemma":[0.03225727,0.007140692,0.9505783,0.0002756795,0.0006108168,0.000004625758,0.0005994851,0.00011066609,0.000052722073,0.0009392351,0.007341934,0.00008861675],"about_ca_topic_score_codex":0.00009360643,"about_ca_topic_score_gemma":0.0005380212,"teacher_disagreement_score":0.031030623,"about_ca_system_score_codex":0.0004764477,"about_ca_system_score_gemma":0.0020477301,"threshold_uncertainty_score":0.36325854},"labels":[],"label_agreement":null},{"id":"W4407701397","doi":"10.1200/jco.2025.43.5_suppl.35","title":"A prospective provincial registry of PSMA PET CT for recurrent prostate cancer (PREP): Results for 4135 men.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Thunder Bay Regional Health Sciences Centre; London Health Sciences Centre; Cancer Care Ontario; McMaster University; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Western University","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Cancer; Prostate; Cancer registry; Gynecology","score_opus":0.11371556228174574,"score_gpt":0.5345541847092006,"score_spread":0.42083862242745484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90145993,0.0047931983,0.00027715886,0.06611981,0.004208624,0.00817047,0.00090803887,0.00002484905,0.0140379],"genre_scores_gemma":[0.9684523,0.003920351,0.007073581,0.0005712841,0.0020743897,0.00064502977,0.000036925576,0.000030495907,0.017195662],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966094,0.00016262189,0.0022881993,0.00030422313,0.000310259,0.00032529444],"domain_scores_gemma":[0.9936779,0.0022220074,0.001835055,0.00022160143,0.0018263442,0.00021708262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031752193,0.00015093533,0.0014221575,0.00015192159,0.00006623981,0.000009159962,0.00018630133,0.000108811786,0.000011526258],"category_scores_gemma":[0.008236322,0.00009725922,0.0006229727,0.00018184171,0.00030125078,0.00007472918,0.000057934296,0.00061995036,6.9246687e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42205322,0.0050965413,0.054583903,0.0013789035,0.0023923763,0.000545645,0.0003429063,0.000011658842,0.0004363901,0.00092500023,0.2394304,0.27280304],"study_design_scores_gemma":[0.17475484,0.12768804,0.13400497,0.0027554813,0.002617172,0.00041895226,0.0008847894,0.0006541787,0.009940898,0.01232801,0.53360003,0.00035261345],"about_ca_topic_score_codex":0.00004728597,"about_ca_topic_score_gemma":0.00014555072,"teacher_disagreement_score":0.29416966,"about_ca_system_score_codex":0.00056399597,"about_ca_system_score_gemma":0.008575943,"threshold_uncertainty_score":0.9970445},"labels":[],"label_agreement":null},{"id":"W4407701510","doi":"10.1200/jco.2025.43.5_suppl.403","title":"Genomic alterations and their pathologic responses in high-risk localized prostate cancer (HRLPC) in subprotocol 1 of the Genomic Umbrella Neoadjuvant study (GUNS).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver Coastal Health; University Health Network; University of British Columbia","funders":"Johnson and Johnson; Terry Fox Research Institute","keywords":"Medicine; Prostate cancer; Genome instability; Cancer; Prostate; Oncology; Cancer research; Pathology; Internal medicine; Genetics; Biology; DNA damage; DNA","score_opus":0.10337828107118216,"score_gpt":0.4887862410277097,"score_spread":0.38540795995652755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868341,0.0021990852,0.000007022951,0.0055033984,0.0003444674,0.0049896287,0.000020546275,0.0000032156745,0.00009853522],"genre_scores_gemma":[0.9939769,0.004384791,0.00014713944,0.00042008067,0.00010129566,0.00041698397,8.284211e-7,0.000010152201,0.0005418405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953955,0.0019133613,0.0020432784,0.0002326985,0.00016975781,0.0002454376],"domain_scores_gemma":[0.99658155,0.0019344061,0.00092292385,0.0002384879,0.00021675325,0.00010589294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004350675,0.00014549952,0.001257791,0.00028996854,0.00006113336,0.000010906348,0.00019908632,0.00019468114,0.000029335908],"category_scores_gemma":[0.0013153484,0.0000732418,0.00018172183,0.00033210038,0.00036983285,0.0000451384,0.0001501911,0.0010916984,0.0000010886691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017314987,0.0020882403,0.9313444,0.000042789325,0.00018817284,0.00037280456,0.0010253824,0.00014028816,0.0019675405,0.00001963965,0.0001202609,0.045375507],"study_design_scores_gemma":[0.024179272,0.0068725,0.9642288,0.0002475939,0.00012499365,0.000034090128,0.00086131186,0.00013672921,0.0003358648,0.00094058487,0.0019785408,0.000059733084],"about_ca_topic_score_codex":0.00064052857,"about_ca_topic_score_gemma":0.002146821,"teacher_disagreement_score":0.045315772,"about_ca_system_score_codex":0.00037367668,"about_ca_system_score_gemma":0.0034863995,"threshold_uncertainty_score":0.6184723},"labels":[],"label_agreement":null},{"id":"W4407701519","doi":"10.1200/jco.2025.43.5_suppl.417","title":"Genomic alterations in intraductal prostate cancer: Insights from the Genomic Umbrella Neoadjuvant study (GUNS) in high-risk localized disease.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of British Columbia; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Disease; Prostate; Cancer; Oncology; Internal medicine","score_opus":0.06518662178121039,"score_gpt":0.4491162345683003,"score_spread":0.3839296127870899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9697002,0.010914349,0.000014763475,0.016804464,0.0012583844,0.0011456838,0.00003295978,0.0000061451374,0.00012306018],"genre_scores_gemma":[0.98267496,0.014997258,0.00014828586,0.0010755967,0.0006841447,0.000059511298,0.000013455555,0.000015079474,0.0003317157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956051,0.0012849555,0.0022114739,0.00031326263,0.00029285633,0.00029234035],"domain_scores_gemma":[0.9963975,0.0021722722,0.00068358803,0.000285119,0.0001879741,0.00027355467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015451649,0.00017363997,0.0012353554,0.0002441461,0.00008898643,0.000026550679,0.00028078633,0.00016292355,0.000068003275],"category_scores_gemma":[0.00093324174,0.00009845324,0.00022864215,0.0003560012,0.0002569756,0.0000832052,0.000117304175,0.0015629957,0.000011903996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016870163,0.0032799398,0.9171788,0.000014380493,0.00054184033,0.0015953695,0.0012247217,0.0004910266,0.00020507908,0.00007093985,0.00088437146,0.057643358],"study_design_scores_gemma":[0.026349094,0.0029465775,0.9591716,0.00020812606,0.00041383674,0.000005491111,0.00075599493,0.0005668064,0.000018887613,0.0026050818,0.0068737795,0.0000847037],"about_ca_topic_score_codex":0.0032615466,"about_ca_topic_score_gemma":0.008680604,"teacher_disagreement_score":0.057558656,"about_ca_system_score_codex":0.00081328175,"about_ca_system_score_gemma":0.005464026,"threshold_uncertainty_score":0.9692947},"labels":[],"label_agreement":null},{"id":"W4407701760","doi":"10.1200/jco.2025.43.5_suppl.143","title":"Age-related efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subgroup analysis of ARASENS.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Bayer","keywords":"Medicine; Docetaxel; Androgen deprivation therapy; Prostate cancer; Oncology; Internal medicine; Subgroup analysis; Cancer; Meta-analysis","score_opus":0.046635863680190286,"score_gpt":0.4207439660642051,"score_spread":0.3741081023840148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407701760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99517554,0.0029680403,0.00003039926,0.0010608898,0.00005381058,0.00060632196,0.000025501364,0.0000025519694,0.00007691509],"genre_scores_gemma":[0.9868885,0.012441812,0.0004204938,0.00014392375,0.000012433865,0.000005163765,0.000021702435,0.000008261344,0.000057707402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728227,0.00038084626,0.0016466298,0.00020382045,0.0003116891,0.00017477704],"domain_scores_gemma":[0.9966695,0.0013389008,0.0011713783,0.00012464865,0.0005594251,0.0001361977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014213072,0.00013339907,0.0017869534,0.0005596064,0.000023034274,0.000004959901,0.000051560448,0.00013257506,0.000008938767],"category_scores_gemma":[0.00054813543,0.00008152399,0.00015728481,0.00085716305,0.000502496,0.00008575036,0.000034501954,0.00044283966,1.1953067e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09292237,0.0017389331,0.81118,0.00007344817,0.009112167,0.00026348382,0.0011250908,0.00031651097,0.00044413575,0.000037212387,0.000028132543,0.08275853],"study_design_scores_gemma":[0.05017279,0.007092824,0.9391834,0.00020688647,0.002245108,0.000005390706,0.00014882917,0.0004527937,0.00023235945,0.0000941355,0.00010445392,0.00006101953],"about_ca_topic_score_codex":0.00012519331,"about_ca_topic_score_gemma":0.00011713109,"teacher_disagreement_score":0.12800342,"about_ca_system_score_codex":0.00016436359,"about_ca_system_score_gemma":0.0009282788,"threshold_uncertainty_score":0.3324452},"labels":[],"label_agreement":null},{"id":"W4407702292","doi":"10.1200/jco.2025.43.5_suppl.15","title":"World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Meta-analysis; Randomized controlled trial; Oncology; Patient data; Internal medicine; Cancer; Medical physics; Database","score_opus":0.45323613473234275,"score_gpt":0.562627143051762,"score_spread":0.10939100831941923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407702292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88040036,0.034403905,0.0031640616,0.07414288,0.0014366822,0.002301533,0.0037903714,0.000024935032,0.00033526664],"genre_scores_gemma":[0.96952623,0.005115089,0.013739168,0.007924434,0.0007174194,0.00015581744,0.0017978766,0.000023331157,0.001000621],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9812421,0.010382584,0.0061248946,0.00066579296,0.0012099814,0.00037460358],"domain_scores_gemma":[0.94211215,0.050047282,0.0047484203,0.0012855561,0.0013520886,0.00045450477],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.026506303,0.00033125616,0.011309561,0.0011086504,0.0001715341,0.00017295271,0.0008640367,0.00020356094,0.0025854784],"category_scores_gemma":[0.020528907,0.00015863548,0.0040562307,0.0039743464,0.00043046146,0.00040146874,0.0003393752,0.001070122,0.0000057257525],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09251478,0.0012119716,0.065759376,0.000009639461,0.799962,0.00022851855,0.0010184663,0.0018931725,0.000016745202,0.000023822238,0.008318413,0.029043127],"study_design_scores_gemma":[0.095361434,0.00090302166,0.039782498,0.000025120398,0.8383937,0.000001038013,0.0012122716,0.003007401,0.00007914891,0.0012233075,0.01985706,0.0001540236],"about_ca_topic_score_codex":0.0025393984,"about_ca_topic_score_gemma":0.0073952735,"teacher_disagreement_score":0.08912588,"about_ca_system_score_codex":0.00028791785,"about_ca_system_score_gemma":0.0042896206,"threshold_uncertainty_score":0.9983263},"labels":[],"label_agreement":null},{"id":"W4407702418","doi":"10.1200/jco.2025.43.5_suppl.165","title":"Efficacy and safety of apalutamide in metastatic castration sensitive prostate cancer patients with a prior history of cardiovascular or metabolic risk factors: A post-hoc analysis of the TITAN study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Johnson and Johnson","keywords":"Medicine; Prostate cancer; Post-hoc analysis; Oncology; Post hoc; Internal medicine; Prostate; Cancer; Gynecology","score_opus":0.05926860180952538,"score_gpt":0.4207456123460205,"score_spread":0.3614770105364951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407702418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952528,0.0033897317,0.000011878068,0.00016464187,0.00013230926,0.0009508246,0.00005743501,0.0000010613467,0.000039347076],"genre_scores_gemma":[0.9973662,0.0022605478,0.00018428889,0.000028353286,0.000014782166,0.0000064978267,0.000003702346,0.00000610673,0.00012954995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99677867,0.00091665325,0.0015493723,0.0001590563,0.00047256425,0.00012370144],"domain_scores_gemma":[0.99590546,0.0013597806,0.00142921,0.00019411897,0.0010310714,0.000080336824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019536389,0.00011163133,0.0020840487,0.00038637567,0.000017962358,0.0000015059787,0.00007575139,0.00007482695,0.000012604935],"category_scores_gemma":[0.0013779339,0.00005203226,0.00045435035,0.00064028037,0.0003463693,0.00005829362,0.00004030338,0.00039994397,3.9656655e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04893163,0.0032710154,0.8804041,0.00009303022,0.02921615,0.000060564973,0.0035683976,0.0006891108,0.00005900686,0.000004229943,0.000010392382,0.033692356],"study_design_scores_gemma":[0.018947791,0.010530916,0.95063853,0.00017028816,0.018075751,0.0000017679691,0.0010864814,0.0000758778,0.00009155492,0.0000042793476,0.00033753397,0.00003921551],"about_ca_topic_score_codex":0.001172983,"about_ca_topic_score_gemma":0.0018258373,"teacher_disagreement_score":0.070234425,"about_ca_system_score_codex":0.00035346672,"about_ca_system_score_gemma":0.003021617,"threshold_uncertainty_score":0.5360219},"labels":[],"label_agreement":null},{"id":"W4407702698","doi":"10.1200/jco.2025.43.5_suppl.349","title":"Population-based assessment of treatment patterns for high-risk localized prostate cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Centre Hospitalier de l’Université de Montréal; Queen Elizabeth II Health Sciences Centre; Dalhousie University; London Health Sciences Centre; University of Toronto; Western University; Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Calgary; University of Alberta; Jewish General Hospital; McGill University; University of Ottawa; University Health Network; Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Population; Risk assessment; Internal medicine; Prostate; Gynecology; Environmental health","score_opus":0.11352595895436436,"score_gpt":0.5506829936409051,"score_spread":0.43715703468654077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407702698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848311,0.0005631852,0.002195708,0.010180718,0.0010084049,0.00089844456,0.00010882227,0.0000069383154,0.00020666582],"genre_scores_gemma":[0.9903389,0.0028804236,0.0048902715,0.00047875653,0.0002945335,0.00008174028,0.0000379459,0.0000113922115,0.0009860242],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732715,0.00030019222,0.0017636225,0.00016784023,0.00023550894,0.00020566508],"domain_scores_gemma":[0.9954644,0.0022242658,0.0013447392,0.00016511892,0.0006204807,0.00018103415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014189283,0.00012462374,0.0014161936,0.00017343709,0.000051111438,0.0000057203424,0.00008889294,0.00019780449,0.00009256971],"category_scores_gemma":[0.00063205406,0.00007435071,0.00048211246,0.00013524554,0.00008694954,0.000037615446,0.000016588745,0.0003161545,4.601179e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072250618,0.0016257156,0.8049132,0.00013406046,0.0009109392,0.000037444337,0.00001957924,0.00031182403,0.00003362879,0.0001394956,0.00045239658,0.18419664],"study_design_scores_gemma":[0.03779634,0.028254142,0.9187665,0.0003233455,0.0011519335,0.0000028327886,0.000052067313,0.0015756225,0.0005356991,0.0007757854,0.010703719,0.00006202253],"about_ca_topic_score_codex":0.0013563009,"about_ca_topic_score_gemma":0.00033336025,"teacher_disagreement_score":0.18413462,"about_ca_system_score_codex":0.0010126773,"about_ca_system_score_gemma":0.0066369055,"threshold_uncertainty_score":0.9989945},"labels":[],"label_agreement":null},{"id":"W4407702707","doi":"10.1200/jco.2025.43.5_suppl.96","title":"Association between sociodemographic marginalization and receipt of intensified treatment for metastatic castrate-sensitive prostate cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Juravinski Cancer Centre; Sunnybrook Health Science Centre; University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Receipt; Internal medicine; Prostate; Gynecology","score_opus":0.17608452862159077,"score_gpt":0.5137218026286796,"score_spread":0.3376372740070889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407702707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756752,0.0014996778,0.0003822869,0.021011995,0.0003734483,0.0007126006,0.000054070417,0.0000046395035,0.00028602837],"genre_scores_gemma":[0.985404,0.010147785,0.0016224146,0.00028843782,0.00020043245,0.000024290466,0.000023798,0.000008828957,0.002280018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979916,0.0003052639,0.0012074066,0.00013766682,0.00018603189,0.00017198478],"domain_scores_gemma":[0.9947881,0.002476707,0.0012250191,0.00006333601,0.0013226429,0.00012416765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019314052,0.00010034156,0.001199214,0.00018696966,0.00004325194,0.000006699563,0.000033658613,0.00017431952,0.000008270445],"category_scores_gemma":[0.0014584762,0.0000658793,0.00026967947,0.00019640202,0.00014458747,0.000059998885,0.000013517901,0.00024503714,3.1288127e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010340773,0.000753391,0.7623349,0.00022323166,0.0059481366,0.00006383681,0.00043228673,0.000009185413,0.00044088933,0.0001421194,0.0024301966,0.21688108],"study_design_scores_gemma":[0.035223506,0.029463068,0.90124834,0.00061815506,0.007136121,0.00002351843,0.0010790388,0.000328062,0.0043931697,0.0033074548,0.017051362,0.00012821823],"about_ca_topic_score_codex":0.00005990499,"about_ca_topic_score_gemma":0.00006699826,"teacher_disagreement_score":0.21675286,"about_ca_system_score_codex":0.00048222038,"about_ca_system_score_gemma":0.0018457242,"threshold_uncertainty_score":0.32742354},"labels":[],"label_agreement":null},{"id":"W4407709054","doi":"10.3390/curroncol32020115","title":"Salvage Ultrasound-Guided Robot-Assisted Video-Endoscopic Inguinal Lymphadenectomy (RAVEIL) as a Metastasis-Directed Therapy (MDT) in Oligoprogressive Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case Report and Review of the Literature","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Prostatectomy; Lymphadenectomy; Metastasis; Androgen deprivation therapy; Salvage therapy; Multimodal therapy; Oncology; Internal medicine; Cancer; Chemotherapy; Androgen receptor","score_opus":0.11844762103751065,"score_gpt":0.48774739002780243,"score_spread":0.36929976899029177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407709054","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025428429,0.9866089,8.2490294e-7,0.00052048505,0.0008098261,0.008748746,0.00052970916,0.00005786629,0.0001807782],"genre_scores_gemma":[0.00052364776,0.99280125,0.00029303934,0.00013938968,0.00012946826,0.0044433456,0.001101861,0.00006508778,0.0005028973],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99354035,0.0018881581,0.0021176538,0.0011108959,0.0006431393,0.00069979957],"domain_scores_gemma":[0.9952791,0.001096251,0.0016434097,0.00090852607,0.00081957993,0.00025315868],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010532641,0.0008818654,0.0040571787,0.0006564112,0.00017908994,0.000073869334,0.0003131175,0.00032193438,0.00010576549],"category_scores_gemma":[0.0016078727,0.0005119735,0.00068797957,0.0026045192,0.0004439353,0.00010591584,0.00017048346,0.0011183133,0.0000019842576],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031723737,0.0008913061,0.0004540536,0.20506352,0.0017224484,0.045030367,0.0005626785,1.3473195e-7,0.000040256175,0.00002505601,0.001568845,0.7443241],"study_design_scores_gemma":[0.0066087185,0.0008154344,0.00066985656,0.44702458,0.005829235,0.071820505,0.00016164285,0.0000016567008,0.00008006585,0.00005076131,0.46643457,0.0005029789],"about_ca_topic_score_codex":0.00040216328,"about_ca_topic_score_gemma":0.0005698773,"teacher_disagreement_score":0.74382114,"about_ca_system_score_codex":0.0015554627,"about_ca_system_score_gemma":0.008477868,"threshold_uncertainty_score":0.9997332},"labels":[],"label_agreement":null},{"id":"W4407765620","doi":"10.2967/jnumed.124.268640","title":"Therapy-Related Myeloid Neoplasms After [<sup>177</sup>Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series","year":2025,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Oncology; Internal medicine; Cancer","score_opus":0.013609726364676965,"score_gpt":0.287880550883258,"score_spread":0.27427082451858104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407765620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795058,0.0065869107,0.0000011575543,0.012407781,0.00014813877,0.0009944128,0.000024584348,0.000019948506,0.00031129437],"genre_scores_gemma":[0.9914773,0.006046729,0.00022797851,0.00096682267,0.00009895047,0.000036308946,0.00001654488,0.00005194836,0.0010774159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976006,0.00014627866,0.0008397107,0.00026177746,0.0007389017,0.00041269424],"domain_scores_gemma":[0.99847704,0.000091807604,0.00032284556,0.0002574323,0.00060878234,0.00024211252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045575848,0.00031248233,0.00077356905,0.00057906547,0.00011641598,0.000036284433,0.00011953133,0.00008366039,0.00062455086],"category_scores_gemma":[0.00006289853,0.00017240037,0.00010297745,0.0007798241,0.00031859023,0.00031096025,0.00002285933,0.00060693297,0.000004495845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25740317,0.0041985,0.40049052,0.0009871032,0.006709158,0.05815832,0.04807883,0.00061230327,0.0072637177,0.00013400379,0.010785389,0.20517899],"study_design_scores_gemma":[0.1985327,0.05215741,0.66693294,0.010563512,0.0013264529,0.0056155855,0.027678283,0.0005581419,0.001141342,0.0004912824,0.03406687,0.00093547814],"about_ca_topic_score_codex":0.0002664749,"about_ca_topic_score_gemma":0.00012072969,"teacher_disagreement_score":0.26644242,"about_ca_system_score_codex":0.00034041528,"about_ca_system_score_gemma":0.00057762855,"threshold_uncertainty_score":0.7030283},"labels":[],"label_agreement":null},{"id":"W4407839683","doi":"10.3390/curroncol32030119","title":"Multicenter Real-World Study: 432 Patients with Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Hormone; Prostate; Cancer; Internal medicine; Cancer research","score_opus":0.07299893019705109,"score_gpt":0.44665693400329587,"score_spread":0.3736580038062448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407839683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916224,0.0012824137,0.0000077708555,0.0010059982,0.00045768745,0.0034322287,0.000052748168,0.000037043315,0.0021017082],"genre_scores_gemma":[0.9956336,0.0010279391,0.00008104441,0.0001424544,0.000038923004,0.00073022424,0.00011326594,0.000021062298,0.0022114655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822277,0.0002114061,0.00034518665,0.0004499943,0.00028661138,0.00048402412],"domain_scores_gemma":[0.9990941,0.00014093572,0.0000980517,0.0002323213,0.00030933318,0.00012525212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020688894,0.00022196765,0.0005658101,0.0004816606,0.00006676429,0.000013551784,0.0000800421,0.000036919126,0.000034822213],"category_scores_gemma":[0.000045820747,0.00014955584,0.000048453672,0.0006872674,0.0001618929,0.000077106946,0.00009407538,0.0004043557,0.000018740999],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006090886,0.0047701388,0.93482107,0.00013120583,0.0003343733,0.00019121419,0.002449993,0.0000094389725,0.00003845457,0.00002406827,0.0011617206,0.049977444],"study_design_scores_gemma":[0.0248782,0.0018402422,0.961976,0.00031359098,0.00034496398,6.4097e-7,0.0011026115,0.0001633686,0.00014930207,0.000027192138,0.009062879,0.00014100112],"about_ca_topic_score_codex":0.000693355,"about_ca_topic_score_gemma":0.004590389,"teacher_disagreement_score":0.049836446,"about_ca_system_score_codex":0.0012276138,"about_ca_system_score_gemma":0.0006566456,"threshold_uncertainty_score":0.60987103},"labels":[],"label_agreement":null},{"id":"W4407877750","doi":"10.3390/curroncol32030127","title":"Evaluation of Adrenal Metastases in Prostate Cancer Patients with [68GA]GA-PSMA PET/CT Imaging","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Hounsfield scale; Standardized uptake value; Radiology; Nuclear medicine; Prostate; Cancer; Positron emission tomography; Internal medicine; Computed tomography","score_opus":0.08959045247687862,"score_gpt":0.47169230195413453,"score_spread":0.3821018494772559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407877750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857598,0.010652232,0.0000051895227,0.00066990074,0.00040188743,0.0012605807,0.000067880945,0.000013063884,0.0011694639],"genre_scores_gemma":[0.9986459,0.0005032792,0.000056564437,0.000033418182,0.000025265092,0.00039841872,0.00019478108,0.000009203698,0.00013314468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984639,0.0002263852,0.00026601175,0.0002564617,0.00051828707,0.00026894515],"domain_scores_gemma":[0.99893564,0.000068406574,0.00010429159,0.00014202832,0.00069024845,0.000059409595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063560164,0.000125373,0.00032673898,0.00031340294,0.000034867448,0.0000058673677,0.00006288263,0.000005444045,0.00018540407],"category_scores_gemma":[0.00011319936,0.00008628291,0.000041322273,0.00035474333,0.00014066412,0.00007266633,0.000048131857,0.0001900262,0.000003751879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084259256,0.0011176344,0.7243146,0.00017213805,0.00011985635,0.00006835584,0.00011144046,0.000031013456,0.000050200106,0.000033337077,0.0008763738,0.27226248],"study_design_scores_gemma":[0.039612032,0.0013031943,0.92845,0.0015551163,0.0016232638,0.00003732821,0.00036559827,0.0030547092,0.004159761,0.0005014183,0.019106317,0.00023127289],"about_ca_topic_score_codex":0.00013308311,"about_ca_topic_score_gemma":0.00018730422,"teacher_disagreement_score":0.2720312,"about_ca_system_score_codex":0.00087706995,"about_ca_system_score_gemma":0.0016451385,"threshold_uncertainty_score":0.3518515},"labels":[],"label_agreement":null},{"id":"W4407895883","doi":"10.1016/j.tranon.2025.102320","title":"Identification of the specific characteristics of neuroendocrine prostate cancer: Immune status, hub genes and treatment","year":2025,"lang":"en","type":"article","venue":"Translational Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Shanghai Jiao Tong University; Shanghai Municipal Health Bureau; National Natural Science Foundation of China; Shanghai Educational Development Foundation; Shanghai Municipal Health Commission","keywords":"Prostate cancer; Immune system; Identification (biology); Gene; Medicine; Prostate; Immune status; Cancer; Oncology; Biology; Bioinformatics; Computational biology; Immunology; Internal medicine; Genetics","score_opus":0.028760854791964725,"score_gpt":0.34960700925077015,"score_spread":0.32084615445880543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407895883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826916,0.008152809,0.000030013704,0.0076884865,0.00018187656,0.000678643,0.00022173466,0.000006669509,0.0003481847],"genre_scores_gemma":[0.98357344,0.014246903,0.00006633085,0.00002495379,0.00002719189,0.00006205152,0.000073732954,0.000005786611,0.0019196286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921453,0.00005022792,0.00035588033,0.0001317927,0.00012471947,0.00012284996],"domain_scores_gemma":[0.999496,0.00008953633,0.000122008074,0.00013357522,0.00013036901,0.000028528344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000055942637,0.00007732746,0.00025107025,0.00008110627,0.000046975074,0.0000031080915,0.000040361116,0.000024141365,0.000042348805],"category_scores_gemma":[0.0000067050546,0.000049626156,0.000056576086,0.00017059661,0.00020545287,0.000025221956,0.000011380649,0.00005753885,6.451554e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021455877,0.00053723296,0.3608561,0.00021172862,0.00027181726,0.000010366429,0.00058120687,0.000021150085,0.28465122,0.0027678178,0.000050977313,0.34789482],"study_design_scores_gemma":[0.0030242829,0.00034706903,0.8829894,0.00004609291,0.00013289537,0.0000058564315,0.00003879892,0.00011807671,0.08841949,0.00029630895,0.02454717,0.000034576507],"about_ca_topic_score_codex":0.000071306196,"about_ca_topic_score_gemma":0.000029517267,"teacher_disagreement_score":0.5221333,"about_ca_system_score_codex":0.0001000987,"about_ca_system_score_gemma":0.00047943235,"threshold_uncertainty_score":0.2023696},"labels":[],"label_agreement":null},{"id":"W4407909431","doi":"10.1097/nm9.0000000000000021","title":"Soft-Tissue Metastases on FDG-PET in Advanced Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"Clinical nuclear medicine open.","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Prostate cancer; Medicine; Soft tissue; Cancer; Prostate; Oncology; Radiology; Internal medicine","score_opus":0.07736367277880182,"score_gpt":0.49668792128351763,"score_spread":0.41932424850471584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407909431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7032747,0.007028124,0.0000055651667,0.184705,0.0020631896,0.0055779903,0.00011535869,0.0001828721,0.09704716],"genre_scores_gemma":[0.91882104,0.011675431,0.0006608087,0.025560822,0.0004656087,0.0003049454,0.00018855897,0.0000973794,0.042225406],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973619,0.00020580622,0.00084790454,0.00069936225,0.00038975224,0.0004952613],"domain_scores_gemma":[0.9982544,0.00059190043,0.0001171977,0.000596914,0.00011530805,0.00032426696],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011278703,0.00026056572,0.001006502,0.00023725188,0.00010986896,0.000032801247,0.00040217605,0.000085134634,0.0025360032],"category_scores_gemma":[0.0011585322,0.00017060977,0.000076912715,0.00063704856,0.0005326723,0.00013356797,0.00029083405,0.0007538814,0.00023062619],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01445387,0.00206331,0.032144804,0.00040099153,0.00044119902,0.0022325136,0.0003206006,0.000021575326,0.0014789705,0.002195278,0.3048515,0.6393954],"study_design_scores_gemma":[0.024259005,0.0043754387,0.052442838,0.003095787,0.00022872571,0.000015333613,0.0008116125,0.00015083668,0.0004014861,0.0005883248,0.91338795,0.00024264435],"about_ca_topic_score_codex":0.00060430914,"about_ca_topic_score_gemma":0.00012502258,"teacher_disagreement_score":0.63915277,"about_ca_system_score_codex":0.00018932481,"about_ca_system_score_gemma":0.00038681927,"threshold_uncertainty_score":0.99837583},"labels":[],"label_agreement":null},{"id":"W4407972777","doi":"10.1038/s41585-025-01002-0","title":"Assessing the effects of prostate cancer therapies on cardiovascular health","year":2025,"lang":"en","type":"review","venue":"Nature Reviews Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Nova Scotia Health Authority; Dalhousie University; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"","keywords":"Medicine; Prostate cancer; Cardiovascular health; Oncology; Cancer; Internal medicine; Intensive care medicine; Disease","score_opus":0.043404490690204627,"score_gpt":0.45850685393305973,"score_spread":0.4151023632428551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407972777","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000025298225,0.98862153,0.0000028368975,0.0021915385,0.00087889045,0.0077522034,0.000023854867,0.000025286587,0.000501312],"genre_scores_gemma":[0.0000116190395,0.9952234,0.000031904685,0.001708013,0.00029881857,0.0016637371,0.0001014717,0.000046082616,0.00091496087],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99569416,0.002090747,0.00073749415,0.0005886757,0.00040430189,0.0004846076],"domain_scores_gemma":[0.99716747,0.0010398166,0.0005203414,0.0010579965,0.00012039409,0.000093983275],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0014447211,0.0005137396,0.0049005053,0.00027877928,0.00013193698,0.000021278775,0.00030404932,0.0007094837,0.000019573135],"category_scores_gemma":[0.00052413566,0.00022479707,0.0018738145,0.00075932185,0.00018320493,0.00003273895,0.000086916574,0.0024398782,0.000012420191],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018738554,0.000054191598,0.00001851067,0.17517924,0.0017270244,0.00003145332,0.00005663438,9.0163574e-8,1.789172e-7,0.000051563435,0.0033030568,0.81955934],"study_design_scores_gemma":[0.00051424874,0.00042757028,0.000034435667,0.057289343,0.0031986935,0.00003470097,0.0000030614283,1.6911213e-7,0.0000021818157,0.000015888661,0.9383563,0.00012343223],"about_ca_topic_score_codex":0.000028891762,"about_ca_topic_score_gemma":0.0000037847515,"teacher_disagreement_score":0.9350532,"about_ca_system_score_codex":0.00028576134,"about_ca_system_score_gemma":0.0019891337,"threshold_uncertainty_score":0.99986154},"labels":[],"label_agreement":null},{"id":"W4408010724","doi":"10.1016/j.eururo.2025.02.006","title":"Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study","year":2025,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma US; Pfizer","keywords":"Medicine; Enzalutamide; Post-hoc analysis; Prostate cancer; Post hoc; Oncology; Gynecology; Internal medicine; Urology; Cancer","score_opus":0.009900175720338578,"score_gpt":0.29311606602587537,"score_spread":0.2832158903055368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408010724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971247,0.00020319261,7.7289417e-7,0.0007252751,0.0000400918,0.0016205737,0.000046508416,0.0000061612805,0.00023274178],"genre_scores_gemma":[0.9996373,0.000029324012,0.0000027631843,0.00019620376,0.0000034883356,0.000053248004,0.000024877398,0.000009917504,0.000042868538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980685,0.0008146076,0.00034885335,0.00025338825,0.00033294898,0.00018167839],"domain_scores_gemma":[0.9984802,0.0005948831,0.0002798605,0.00040440264,0.00021393184,0.000026744749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038269654,0.0001393186,0.00048038512,0.0003065239,0.000028140676,0.0000029583334,0.0001625507,0.000023314467,0.0000075652492],"category_scores_gemma":[0.00029202178,0.00006278046,0.00007516486,0.0008950701,0.00019600116,0.000014382796,0.00008549234,0.00021057314,4.5511678e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009833414,0.0038322702,0.9674728,0.00010233133,0.0026778018,0.000052841584,0.0037424257,0.000024475332,0.0044717467,0.000006618353,0.000035638197,0.007747618],"study_design_scores_gemma":[0.003524183,0.008977045,0.9807843,0.00003442203,0.0012806028,1.8319898e-7,0.000329024,0.000013750829,0.00498687,0.0000017660695,0.00002212039,0.000045718505],"about_ca_topic_score_codex":0.00016199332,"about_ca_topic_score_gemma":0.00009751688,"teacher_disagreement_score":0.013311495,"about_ca_system_score_codex":0.000039147515,"about_ca_system_score_gemma":0.00010522721,"threshold_uncertainty_score":0.2560113},"labels":[],"label_agreement":null},{"id":"W4408020759","doi":"10.1016/j.urolonc.2024.12.219","title":"ADJUVANT VS. SALVAGE RADIOTHERAPY IN MEN WITH PATHOLOGICALLY NODE POSITIVE PROSTATE CANCER AFTER RADICAL PROSTATECTOMY: A SYSTEMATIC REVIEW AND META-ANALYSIS","year":2025,"lang":"en","type":"review","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Adjuvant radiotherapy; Meta-analysis; Radiation therapy; Salvage therapy; Adjuvant; Oncology; Urology; Internal medicine; Cancer; Chemotherapy","score_opus":0.039393911034384055,"score_gpt":0.38228558420460557,"score_spread":0.3428916731702215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408020759","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013763626,0.98210806,0.000012256965,0.008163463,0.000013584049,0.008737277,0.0005186035,0.000046661025,0.00026248142],"genre_scores_gemma":[0.000021512418,0.97406083,0.0053250724,0.0041976017,0.00001892978,0.012930932,0.0003371086,0.000031284042,0.0030767387],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99581444,0.0012251697,0.0010372407,0.0010517391,0.00030303147,0.00056839787],"domain_scores_gemma":[0.99781996,0.00073014054,0.00051418616,0.00043507174,0.00013904841,0.00036161926],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00096805394,0.0007320052,0.008105181,0.00069088273,0.00015171761,0.000051394174,0.00016785384,0.00050352904,0.00016736596],"category_scores_gemma":[0.00016074817,0.00037097605,0.0006080275,0.0015946989,0.001212583,0.000090787806,0.000096718395,0.0009839473,0.000003327524],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086015236,0.00064035016,0.006656435,0.86468035,0.11246378,0.0061810943,0.0007458456,0.0000051882716,7.7347755e-7,0.000251685,0.00093536003,0.00657901],"study_design_scores_gemma":[0.0013118238,0.0023707028,0.00014439927,0.04548415,0.76392925,0.0005736624,0.000033930766,0.000029757855,6.4216493e-7,0.0001132371,0.18551953,0.0004889378],"about_ca_topic_score_codex":0.00007365802,"about_ca_topic_score_gemma":0.000062502215,"teacher_disagreement_score":0.81919616,"about_ca_system_score_codex":0.00050896005,"about_ca_system_score_gemma":0.0016639379,"threshold_uncertainty_score":0.99987423},"labels":[],"label_agreement":null},{"id":"W4408081825","doi":"10.1007/s12325-025-03132-8","title":"Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Astellas Pharma US; Pfizer","keywords":"Medicine; Enzalutamide; Prostate cancer; Abiraterone; Internal medicine; Oncology; Docetaxel; Chemotherapy; Cancer; Abiraterone acetate; Urology; Androgen deprivation therapy; Androgen receptor","score_opus":0.03130694606278112,"score_gpt":0.3684111111346669,"score_spread":0.3371041650718858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408081825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91350317,0.083521925,0.000015547124,0.00045870285,0.00007369088,0.0021271233,0.000013470073,0.000017250728,0.00026914748],"genre_scores_gemma":[0.9497854,0.048860703,0.00014150003,0.00010810956,0.000020070844,0.0007229447,0.0000066871735,0.000026580527,0.0003280219],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982421,0.00021344016,0.00034760617,0.00047142783,0.00034638253,0.0003790604],"domain_scores_gemma":[0.99944043,0.00008749806,0.000053450276,0.00029865353,0.00006538745,0.000054593038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005927443,0.00024288055,0.00062862545,0.00033298242,0.000044607514,0.000029268189,0.000082952356,0.000040033774,0.000029491068],"category_scores_gemma":[0.000009515151,0.00016992017,0.000048877228,0.00069392554,0.00013235863,0.0002371732,0.000017903783,0.0002794691,8.794066e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011487008,0.0010241288,0.8483075,0.00022733618,0.0007680847,0.0007112183,0.0060418136,0.0020258576,0.0028182932,0.00003162199,0.0000027883266,0.12655436],"study_design_scores_gemma":[0.02946915,0.0012585558,0.9599841,0.00048428014,0.00006640364,0.000004860441,0.0027589975,0.00014369939,0.0032806762,0.00034689822,0.0019514967,0.00025088122],"about_ca_topic_score_codex":0.0017153149,"about_ca_topic_score_gemma":0.00821438,"teacher_disagreement_score":0.12630348,"about_ca_system_score_codex":0.0002956213,"about_ca_system_score_gemma":0.00024733148,"threshold_uncertainty_score":0.6929143},"labels":[],"label_agreement":null},{"id":"W4408128329","doi":"10.1093/jncics/pkaf025","title":"Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer","year":2025,"lang":"en","type":"article","venue":"JNCI Cancer Spectrum","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Cancer; Gynecology","score_opus":0.11147967263668813,"score_gpt":0.4476404803388036,"score_spread":0.3361608077021155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408128329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98236614,0.0059466264,0.00013383898,0.002624098,0.00088421325,0.0033134578,0.0045079724,0.000052131763,0.00017149975],"genre_scores_gemma":[0.97288245,0.0128523065,0.0012823163,0.00009408201,0.00015276937,0.0021513298,0.00015214246,0.000041062292,0.010391571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749947,0.00010449631,0.00095789216,0.0005831745,0.00029479098,0.0005602013],"domain_scores_gemma":[0.9987773,0.00021790394,0.0002991555,0.00038686767,0.00015663978,0.00016215695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040271497,0.00030723968,0.001042439,0.00031582115,0.00009567324,0.000020134177,0.000109647204,0.000110608984,0.00010228455],"category_scores_gemma":[0.00012206907,0.00021227909,0.00036016665,0.0004935637,0.00017825681,0.000094369956,0.000034135093,0.00025436236,0.0000028174652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005431431,0.0011076713,0.9753459,0.00036386223,0.0014986078,0.000057839174,0.00032929154,0.00012066843,0.002218965,0.00003988188,0.0003526389,0.013133252],"study_design_scores_gemma":[0.022093043,0.0018588328,0.93834263,0.00041276088,0.00092079665,0.0000018702079,0.00021807692,0.0016851423,0.03286928,0.00023068799,0.0012113008,0.00015556187],"about_ca_topic_score_codex":0.011672292,"about_ca_topic_score_gemma":0.013656766,"teacher_disagreement_score":0.037003245,"about_ca_system_score_codex":0.0010213758,"about_ca_system_score_gemma":0.0019140849,"threshold_uncertainty_score":0.99490905},"labels":[],"label_agreement":null},{"id":"W4408152854","doi":"10.1007/978-3-031-66754-1_42","title":"Correction to: Imaging and Focal Therapy of Early Prostate Cancer","year":2025,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Prostate cancer; Medicine; Medical physics; Cancer; Internal medicine","score_opus":0.021281562983320443,"score_gpt":0.3292740082638134,"score_spread":0.30799244528049297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408152854","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003954289,0.01787765,0.00004663308,0.0028530986,0.0009515111,0.0016578663,0.00005777662,0.00006962244,0.97253156],"genre_scores_gemma":[0.011993649,0.016635012,0.000070499045,0.0002878931,0.000097385186,0.000049737206,0.000023089728,0.000025049576,0.9708177],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992224,0.0000050183835,0.00016206132,0.0002565418,0.00020269716,0.000151312],"domain_scores_gemma":[0.9994912,0.000040690644,0.000045200595,0.00014654217,0.00018062959,0.000095751544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005706008,0.00016630822,0.00030599168,0.00019980448,0.000033831737,0.000013786631,0.00003309861,0.00006358888,0.00039631262],"category_scores_gemma":[0.000006581329,0.00011532022,0.00006406316,0.000038948237,0.00007945235,0.000029241515,0.00003985898,0.00020689187,0.0000067152287],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024166165,0.000038831204,0.015220527,0.00021226137,0.00040686713,0.000052529387,0.000510882,4.3919187e-7,0.0013947315,0.0014106417,0.082428314,0.89590734],"study_design_scores_gemma":[0.010114141,0.0035688325,0.028462542,0.008051563,0.00038604657,0.000048718255,0.00016077486,0.00026091974,0.02584295,0.0027420388,0.9195136,0.0008478985],"about_ca_topic_score_codex":0.0008123915,"about_ca_topic_score_gemma":0.000064958665,"teacher_disagreement_score":0.89505947,"about_ca_system_score_codex":0.0001128013,"about_ca_system_score_gemma":0.00031416686,"threshold_uncertainty_score":0.4702622},"labels":[],"label_agreement":null},{"id":"W4408167066","doi":"10.1200/jco-24-01283","title":"Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Université Laval; Lakeridge Health","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Pembrolizumab; Oncology; Double blind; Internal medicine; Randomized controlled trial; Prostate; Urology; Chemotherapy; Cancer; Placebo; Pathology; Immunotherapy","score_opus":0.2509900570005083,"score_gpt":0.551990400322006,"score_spread":0.30100034332149767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408167066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9377541,0.011222439,0.00042809735,0.030918138,0.004516872,0.012229673,0.00007265011,0.000031377785,0.0028266322],"genre_scores_gemma":[0.9759859,0.010657796,0.00077715213,0.0007717454,0.0017318893,0.0013524544,0.000059854447,0.000039538798,0.008623692],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99311507,0.0011151383,0.004063819,0.00041030656,0.0006765139,0.0006191827],"domain_scores_gemma":[0.98631054,0.009105715,0.0023554803,0.0003860869,0.0014004316,0.0004417668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007632824,0.00035083687,0.0036775116,0.00029466162,0.00026510633,0.00007844035,0.0003679494,0.00031875816,0.00014460742],"category_scores_gemma":[0.0038122577,0.0001803926,0.0016349803,0.0004654413,0.0007820894,0.00019148653,0.00006339366,0.0011857089,0.000006091728],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9503826,0.0026948862,0.00003563565,0.00015642686,0.0054747486,0.0003629493,0.00027725307,0.00007954029,0.00008291646,0.0005728866,0.0048501086,0.035030086],"study_design_scores_gemma":[0.94200057,0.023200314,0.00004630575,0.00022625971,0.006997623,0.00005043595,0.0002467312,0.00066504744,0.00031626926,0.00052717497,0.02557813,0.000145163],"about_ca_topic_score_codex":0.0002718216,"about_ca_topic_score_gemma":0.00033817205,"teacher_disagreement_score":0.038231757,"about_ca_system_score_codex":0.0007908628,"about_ca_system_score_gemma":0.012201781,"threshold_uncertainty_score":0.99339813},"labels":[],"label_agreement":null},{"id":"W4408207552","doi":"10.1080/14796694.2025.2471200","title":"Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Enzalutamide; Medicine; Docetaxel; Abiraterone acetate; Abiraterone; Oncology; Internal medicine; Pharmacology; Prostate cancer; Cancer; Androgen receptor","score_opus":0.09705332580578253,"score_gpt":0.4455255526695369,"score_spread":0.3484722268637544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408207552","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002428291,0.9889656,0.0000025263896,0.00039377142,0.0012428708,0.0018478206,0.000100875375,0.000042509484,0.004975763],"genre_scores_gemma":[0.0007220549,0.99531466,0.00032625624,0.000037930222,0.00035448506,0.00024059374,0.0005515036,0.00004391521,0.002408579],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972846,0.0004377413,0.00089626666,0.0005875154,0.0002696942,0.00052420306],"domain_scores_gemma":[0.9983455,0.0005749097,0.00044163916,0.0003839456,0.00008995507,0.00016405071],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038000994,0.00049417064,0.004344922,0.00071604876,0.000059711143,0.000014254554,0.00021271194,0.00091308367,0.00008090086],"category_scores_gemma":[0.000060276405,0.00035422412,0.00024678354,0.00071096246,0.00022505195,0.000046891248,0.00022597621,0.0012421093,0.000019575817],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024006239,0.00039140138,0.00021188178,0.03981874,0.0008772356,0.000412149,0.0011266102,0.0000015214365,0.000007886076,0.00017705809,0.0016945878,0.9528803],"study_design_scores_gemma":[0.011465769,0.0016902306,0.0003806936,0.011125081,0.0020360143,0.00007577522,0.0005800265,0.0000055879573,0.00002742727,0.000041789426,0.972275,0.00029659676],"about_ca_topic_score_codex":0.00015854016,"about_ca_topic_score_gemma":0.0007976177,"teacher_disagreement_score":0.9705804,"about_ca_system_score_codex":0.0011216612,"about_ca_system_score_gemma":0.0023151452,"threshold_uncertainty_score":0.999891},"labels":[],"label_agreement":null},{"id":"W4408295697","doi":"10.3390/curroncol32030156","title":"Adrenal Insufficiency Induced by Continued Abiraterone Acetate Use in a Prostate Cancer Patient in Remission: The Dangers of Unmonitored Long-Term Therapy Without Corticosteroids","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Adverse effect; CYP17A1; Endocrine system; Oncology; Cancer; Internal medicine; Adrenal insufficiency; Urology; Hormone; Androgen deprivation therapy","score_opus":0.10032215286598374,"score_gpt":0.43236074190259316,"score_spread":0.33203858903660943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408295697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98434615,0.011680343,0.00000310522,0.0012859922,0.000658259,0.0018842263,0.000029788456,0.000016549997,0.000095609816],"genre_scores_gemma":[0.99416304,0.0048655216,0.000009066455,0.00011374107,0.000025409077,0.0004790346,0.000057197558,0.000015116766,0.0002718656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809945,0.000279062,0.00056717533,0.0003598092,0.00025797164,0.00043655283],"domain_scores_gemma":[0.99913514,0.00011690221,0.00019605973,0.0002827305,0.00017373267,0.00009541534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024489965,0.0002050685,0.00052139035,0.000252229,0.0000490638,0.000018438725,0.00015448962,0.000106462474,0.000030496083],"category_scores_gemma":[0.00006177912,0.00012455761,0.000057494144,0.0006077182,0.00027388608,0.000084531486,0.00008734057,0.00049619586,0.0000014305575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035951775,0.0018300773,0.7607927,0.00009354032,0.00005506086,0.00004468938,0.0023922957,0.0000018477268,0.039645687,0.0000023876316,0.00036184554,0.19118473],"study_design_scores_gemma":[0.01838,0.0027443243,0.9315153,0.0013207655,0.000052846775,0.0000063936764,0.00060830807,0.00015175263,0.04172306,0.000012864087,0.00330826,0.000176131],"about_ca_topic_score_codex":0.00025890057,"about_ca_topic_score_gemma":0.00036835406,"teacher_disagreement_score":0.1910086,"about_ca_system_score_codex":0.00079285656,"about_ca_system_score_gemma":0.0007543667,"threshold_uncertainty_score":0.50793123},"labels":[],"label_agreement":null},{"id":"W4408326616","doi":"10.1158/1538-7445.genfunc25-a030","title":"Abstract A030: Lessons learned from the Metformin and Active Surveillance Trial (MAST): An opportunity to address intra-patient heterogeneity for biomarker development and precision medicine in low-risk prostate cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Prostate cancer; Medicine; Biomarker; Precision medicine; Oncology; Cancer; Internal medicine; Metformin; Pathology","score_opus":0.2379643585295032,"score_gpt":0.4860959972787471,"score_spread":0.24813163874924388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408326616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97576255,0.0060500484,0.00001754403,0.011606563,0.0002102478,0.0055489,0.00065843633,0.000019907264,0.00012581235],"genre_scores_gemma":[0.9844203,0.010585461,0.00012276326,0.00022173849,0.00013891455,0.0039605186,0.00015940006,0.000031012736,0.00035990373],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99677235,0.00042818178,0.0005035709,0.00082209206,0.00074748934,0.00072633027],"domain_scores_gemma":[0.9968746,0.0014704302,0.00010520442,0.00043630664,0.0005358844,0.0005776213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002900023,0.00025738214,0.00051749696,0.00036071538,0.00047436744,0.00007703305,0.00022307107,0.00013918006,0.0001372075],"category_scores_gemma":[0.0015980403,0.00015844248,0.00004054477,0.0006931477,0.00044728827,0.00014881472,0.00028149277,0.000619693,0.0000012329754],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09013366,0.00026190092,0.015631942,0.00018855771,0.00028443517,0.000027186914,0.0049592024,0.000011340201,0.007348691,0.000009383022,0.001592159,0.87955153],"study_design_scores_gemma":[0.08601188,0.0030118534,0.70558196,0.0039314637,0.00011244876,0.0000031181441,0.0057655447,0.00038445243,0.14739776,0.00092822226,0.046264894,0.00060642255],"about_ca_topic_score_codex":0.010252735,"about_ca_topic_score_gemma":0.020610075,"teacher_disagreement_score":0.8789451,"about_ca_system_score_codex":0.0007878609,"about_ca_system_score_gemma":0.0021170708,"threshold_uncertainty_score":0.9972612},"labels":[],"label_agreement":null},{"id":"W4408348150","doi":"10.1055/s-0045-1804282","title":"Eine Phase-III-Studie zum Vergleich von Enzalutamid mit der Kombination aus Radium-223 und Enzalutamid bei asymptomatischen oder leicht symptomatischen Patienten mit kastrationsresistentem Prostatakrebs und Knochenmetastasen","year":2025,"lang":"de","type":"article","venue":"Nuklearmedizin - NuclearMedicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Gynecology","score_opus":0.022608541569275494,"score_gpt":0.3479211626876787,"score_spread":0.3253126211184032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408348150","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15551521,0.74566865,0.0019694534,0.049113713,0.011298878,0.016177477,0.0019273404,0.001514147,0.01681513],"genre_scores_gemma":[0.91500634,0.027478242,0.005227829,0.0052072923,0.0048973477,0.0013431687,0.011158919,0.0009351273,0.028745726],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98477906,0.0011533065,0.0036277857,0.0030158993,0.0040697735,0.0033541855],"domain_scores_gemma":[0.9910414,0.00121139,0.0013649412,0.0028621885,0.0018352326,0.0016848317],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","sts","insufficient_payload"],"category_scores_codex":[0.002410351,0.0023166048,0.0032875594,0.0021499002,0.0016284875,0.00051093363,0.0016048396,0.0012045123,0.0018170724],"category_scores_gemma":[0.0013792996,0.00203777,0.0008024222,0.003437083,0.002833506,0.0011034566,0.0011282216,0.0027523339,0.0019173808],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020448783,0.0245913,0.0342058,0.008712946,0.09897072,0.0029410697,0.016245587,0.000052813673,0.01682843,0.0042166994,0.42724037,0.34554547],"study_design_scores_gemma":[0.15157412,0.013342825,0.025401087,0.012787585,0.06882814,0.00006718589,0.0042311735,0.020259444,0.009840191,0.0008728159,0.6892689,0.0035265437],"about_ca_topic_score_codex":0.000779103,"about_ca_topic_score_gemma":0.00022442792,"teacher_disagreement_score":0.75949115,"about_ca_system_score_codex":0.002826024,"about_ca_system_score_gemma":0.0023596643,"threshold_uncertainty_score":0.9998802},"labels":[],"label_agreement":null},{"id":"W4408348184","doi":"10.1055/s-0045-1804292","title":"Tumour dosimetry across 6 cycles of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: results from the VISION sub-study","year":2025,"lang":"en","type":"article","venue":"Nuklearmedizin - NuclearMedicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Prostate cancer; Medicine; Dosimetry; Castration; Prostate; Oncology; Cancer; Urology; Nuclear medicine; Internal medicine; Hormone","score_opus":0.0167347340126513,"score_gpt":0.3425525648121143,"score_spread":0.325817830799463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408348184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877094,0.0018877418,0.0000026439136,0.0058769872,0.0002882895,0.0032498094,0.0005769587,0.000063177824,0.00034497384],"genre_scores_gemma":[0.9977848,0.00058371015,0.00015596769,0.00044071447,0.00012866425,0.00011780576,0.00035458896,0.00006454094,0.00036923675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957015,0.00026255188,0.0010770939,0.0008068413,0.0014069601,0.0007450627],"domain_scores_gemma":[0.9974476,0.00059249956,0.00035714207,0.00094712625,0.00043000132,0.00022564303],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010213802,0.00043609302,0.00093191676,0.0002860185,0.0002671928,0.000057150453,0.00043062377,0.0001053109,0.00008820295],"category_scores_gemma":[0.0004167554,0.0002476863,0.00010169849,0.0014610991,0.0008520077,0.00018427931,0.00022452584,0.0007339532,0.00001587222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046519272,0.004311228,0.87996614,0.00035035805,0.0010556997,0.00032550647,0.013322051,0.000036386336,0.015283909,0.000019468069,0.0051496928,0.033660315],"study_design_scores_gemma":[0.03862154,0.0037705365,0.93973696,0.0018708449,0.000477451,0.0000016623734,0.0104224235,0.0001545092,0.0039307578,0.00004495429,0.0007526395,0.0002157322],"about_ca_topic_score_codex":0.0050472794,"about_ca_topic_score_gemma":0.0020618,"teacher_disagreement_score":0.059770834,"about_ca_system_score_codex":0.0003660307,"about_ca_system_score_gemma":0.0005396969,"threshold_uncertainty_score":0.99999756},"labels":[],"label_agreement":null},{"id":"W4408348202","doi":"10.1055/s-0045-1804283","title":"Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore","year":2025,"lang":"en","type":"article","venue":"Nuklearmedizin - NuclearMedicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Taxane; Prostate cancer; Medicine; Oncology; Internal medicine; Quality of life (healthcare); Castration; Cancer; Breast cancer; Hormone; Nursing","score_opus":0.027743503412874904,"score_gpt":0.37365953645624017,"score_spread":0.34591603304336527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408348202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992431,0.001977443,0.000013068002,0.00122132,0.00006304006,0.0038998884,0.00030643222,0.000021221633,0.000066603534],"genre_scores_gemma":[0.99862367,0.00043292835,0.00016073053,0.00014361652,0.000009781851,0.00015003084,0.0003632611,0.00003399834,0.00008200318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944504,0.0009249249,0.002421174,0.0006137255,0.0010658408,0.0005239575],"domain_scores_gemma":[0.9970103,0.0004954645,0.0011830395,0.00052506715,0.0005091029,0.0002770611],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023470179,0.00039155423,0.0025275433,0.0017072891,0.00007012803,0.000008236841,0.00020604413,0.00010215175,0.000088197805],"category_scores_gemma":[0.0005443713,0.0002865833,0.00013409706,0.0032459393,0.0006696928,0.00013726568,0.00011824316,0.0004910668,4.2643848e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023627933,0.011873424,0.89473027,0.0034415205,0.006889901,0.00008376459,0.036260977,0.000097517,0.0016433325,0.000048960894,0.00013027954,0.02117209],"study_design_scores_gemma":[0.064546786,0.015512377,0.878032,0.0033755933,0.0016627877,0.0000012356577,0.033876512,0.0026000815,0.00013111791,0.000032312197,0.000008378469,0.00022081792],"about_ca_topic_score_codex":0.01498804,"about_ca_topic_score_gemma":0.006999857,"teacher_disagreement_score":0.04091885,"about_ca_system_score_codex":0.00042613962,"about_ca_system_score_gemma":0.0008524906,"threshold_uncertainty_score":0.99995863},"labels":[],"label_agreement":null},{"id":"W4408474335","doi":"10.1186/s40959-025-00322-9","title":"Principles of optimal multidisciplinary management of prostate cancer in clinical practice","year":2025,"lang":"en","type":"letter","venue":"Cardio-Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"Duke Clinical Research Institute","keywords":"Multidisciplinary approach; Prostate cancer; Clinical Practice; Cancer; Prostate; Medicine; Medical physics; Internal medicine; Family medicine; Sociology","score_opus":0.07127853785452255,"score_gpt":0.45992429816813046,"score_spread":0.3886457603136079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408474335","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030544527,0.025094857,0.000032939133,0.7512159,0.0028250022,0.0064599956,0.000739669,0.000061542414,0.18302558],"genre_scores_gemma":[0.043946683,0.39090097,0.063669,0.18324795,0.012994149,0.008716566,0.0043689697,0.00060849113,0.2915472],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963017,0.00061163417,0.0013380466,0.00066498783,0.0005536086,0.0005300319],"domain_scores_gemma":[0.9972942,0.0008698128,0.00061102986,0.00065727386,0.00047920342,0.00008849328],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001420659,0.00031253175,0.0018129273,0.00038638324,0.000031910542,0.000004669922,0.00026296242,0.0010190934,0.000057712103],"category_scores_gemma":[0.00017128128,0.0002514648,0.00046505636,0.0003908268,0.00053158595,0.0000629801,0.0005505394,0.0019833464,0.0000071558984],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015565783,0.0023986723,0.062342286,0.020279724,0.012899955,0.054527692,0.0023994164,0.00065925566,0.00012405976,0.0001878504,0.61125445,0.21736087],"study_design_scores_gemma":[0.0064108055,0.0015608572,0.011741687,0.0017368804,0.0014985965,0.000060219285,0.00086083484,0.00005577208,0.00029450582,0.000010361469,0.9755788,0.00019072245],"about_ca_topic_score_codex":0.00011577574,"about_ca_topic_score_gemma":0.000009096165,"teacher_disagreement_score":0.56796795,"about_ca_system_score_codex":0.00103889,"about_ca_system_score_gemma":0.0023808416,"threshold_uncertainty_score":0.99999374},"labels":[],"label_agreement":null},{"id":"W4408499761","doi":"10.1002/advs.202404938","title":"Deciphering the Transcription Factor Landscape in Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation","year":2025,"lang":"en","type":"article","venue":"Advanced Science","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; BC Cancer Agency","funders":"Terry Fox Research Institute; National Cancer Institute; National Institutes of Health; BC Cancer Foundation; Prostate Cancer Foundation; Prostate Cancer UK; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Society; U.S. Department of Defense","keywords":"Transdifferentiation; Prostate cancer; Lineage (genetic); Transcription factor; Biology; LNCaP; Cancer research; Computational biology; Adenocarcinoma; Tumor progression; Cancer; Gene; Bioinformatics; Cell; Genetics","score_opus":0.039467528209331956,"score_gpt":0.36668711521445096,"score_spread":0.327219587005119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408499761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97485447,0.001198299,0.017243007,0.0031461108,0.00017282684,0.0015341262,0.000010919818,0.000036166115,0.0018040903],"genre_scores_gemma":[0.996895,0.000245742,0.0017632712,0.00015751146,0.000014353275,0.0002227377,0.000005419616,0.0000065279733,0.00068942795],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987291,0.000013495568,0.00015328574,0.00035900157,0.00039721877,0.00034786254],"domain_scores_gemma":[0.99958533,0.000023484221,0.000024883895,0.00018393421,0.000090268964,0.00009208739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019584114,0.00010766676,0.00013902891,0.00018454093,0.00021511553,0.000054682354,0.00015865879,0.000023902843,0.000011654685],"category_scores_gemma":[0.000028324474,0.00006309731,0.000029962683,0.0015536809,0.00017169176,0.00025110436,0.000023062592,0.00014858371,0.0000010170177],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014507481,0.0004690399,0.02948543,0.0002263893,0.000028036531,0.000004959233,0.012663602,0.0027937389,0.7930694,0.000791281,0.000025451971,0.15899193],"study_design_scores_gemma":[0.013239109,0.00058244896,0.7969561,0.0016999171,0.00007216204,0.000010596702,0.009625484,0.022723248,0.15219593,0.00059736765,0.0018540549,0.0004435695],"about_ca_topic_score_codex":0.000019409445,"about_ca_topic_score_gemma":0.00007571606,"teacher_disagreement_score":0.7674707,"about_ca_system_score_codex":0.00028929574,"about_ca_system_score_gemma":0.0003558722,"threshold_uncertainty_score":0.25730336},"labels":[],"label_agreement":null},{"id":"W4408549696","doi":"10.1111/cas.16459","title":"Olaparib Plus Abiraterone in Asian Patients With Metastatic Castration‐Resistant Prostate Cancer: <scp>PROpel</scp> Subset Analysis","year":2025,"lang":"en","type":"article","venue":"Cancer Science","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Placebo; Clinical endpoint; Hazard ratio; Prostate cancer; Internal medicine; Population; Abiraterone; Oncology; Confidence interval; Abiraterone acetate; Urology; Cancer; Clinical trial; Androgen deprivation therapy; Pathology; Biology","score_opus":0.017693361793789317,"score_gpt":0.32202746871712645,"score_spread":0.3043341069233371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408549696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99307615,0.0021053501,0.0000835273,0.0011868242,0.00017108236,0.0012816902,0.00017424767,0.00003845424,0.0018826532],"genre_scores_gemma":[0.9937776,0.00041835554,0.00034313006,0.0002220574,0.000019236704,0.0005415838,0.00006896452,0.000014696772,0.0045943935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971362,0.00005416379,0.00036926722,0.00077010563,0.0009010028,0.0007692667],"domain_scores_gemma":[0.9985437,0.000043406293,0.00013258703,0.0004598533,0.00055572647,0.00026472603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042595118,0.00025068136,0.00052328804,0.0009178198,0.00027735697,0.00016238197,0.00032625234,0.00003880659,0.00005347462],"category_scores_gemma":[0.00007949481,0.00016994873,0.00006622318,0.006920791,0.0007249367,0.0004356041,0.00008532896,0.0002403213,0.0000072662324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064883364,0.00032237274,0.97924036,0.0002756183,0.0006025444,0.00010322566,0.0024484675,0.0016564588,0.0043975683,0.00011822095,0.00050353503,0.009682788],"study_design_scores_gemma":[0.0059368904,0.00041375993,0.9786877,0.0003772523,0.00069174805,9.1947413e-7,0.00064010127,0.0015617895,0.01057356,0.00004401918,0.00095048157,0.000121784615],"about_ca_topic_score_codex":0.0022938477,"about_ca_topic_score_gemma":0.0061835274,"teacher_disagreement_score":0.009561003,"about_ca_system_score_codex":0.0016107264,"about_ca_system_score_gemma":0.0038730437,"threshold_uncertainty_score":0.69303083},"labels":[],"label_agreement":null},{"id":"W4408657525","doi":"10.3390/biology14030315","title":"Unraveling the Prognostic Significance of BRCA1-Associated Protein 1 (BAP1) Expression in Advanced and Castrate-Resistant Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Prostate Cancer Canada; Rockyview General Hospital; University of Alberta; University of Calgary","funders":"Prostate Cancer Canada; Prostate Cancer Foundation","keywords":"PTEN; Prostate cancer; BAP1; Biology; Oncology; Tensin; Androgen receptor; Clinical significance; Cancer; Internal medicine; Cancer research; Medicine; Apoptosis; Melanoma; PI3K/AKT/mTOR pathway; Genetics","score_opus":0.0205230495266871,"score_gpt":0.333524344845254,"score_spread":0.3130012953185669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408657525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896968,0.0066491025,0.0000129904365,0.0014997756,0.000054648237,0.001771054,0.00003539574,0.000016110866,0.00026412637],"genre_scores_gemma":[0.99739337,0.00068805454,0.000108123204,0.000047522077,0.000011993791,0.0005909061,0.0000238036,0.000007674333,0.0011285306],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990328,0.00012511246,0.00024161376,0.00025224715,0.00007580063,0.00027240216],"domain_scores_gemma":[0.9994968,0.00013438697,0.000086664855,0.00013766886,0.00010701008,0.000037462174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002237105,0.0001112125,0.00025685134,0.00009136418,0.00006016928,0.0000060956777,0.00006761767,0.00008908485,0.000013226991],"category_scores_gemma":[0.00024484334,0.000063989704,0.00002538146,0.00029842707,0.0002082904,0.00002321657,0.00004813678,0.00016653785,5.966165e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011568876,0.000101804326,0.16330583,0.000209236,0.000045243673,0.000015531172,0.00032787587,0.000008262532,0.8295765,0.00012269641,0.000024161684,0.005105967],"study_design_scores_gemma":[0.0063206726,0.0010150393,0.56258863,0.002889064,0.000063411564,0.000002007448,0.0008536808,0.00018374025,0.4237998,0.0011746051,0.0009373308,0.0001719955],"about_ca_topic_score_codex":0.00041863753,"about_ca_topic_score_gemma":0.0004184172,"teacher_disagreement_score":0.40577668,"about_ca_system_score_codex":0.00010730969,"about_ca_system_score_gemma":0.000427159,"threshold_uncertainty_score":0.26094243},"labels":[],"label_agreement":null},{"id":"W4408732480","doi":"10.1016/j.radonc.2025.110869","title":"Kinetics of PSMA PET signal after radiotherapy in prostate cancer lesions: A single-center retrospective study","year":2025,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Prostate Cancer Fight Foundation; Prostate Cancer Foundation","keywords":"Prostate cancer; Medicine; Single Center; Radiation therapy; Retrospective cohort study; Nuclear medicine; Oncology; Radiology; Cancer; Internal medicine","score_opus":0.02278123486457347,"score_gpt":0.36127751462457663,"score_spread":0.3384962797600032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408732480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97431785,0.020335,0.000068890455,0.0028295333,0.00015308084,0.0017517668,0.000028957815,0.000019010631,0.00049589935],"genre_scores_gemma":[0.98524445,0.010803969,0.0005935225,0.0007390393,0.00009245862,0.000397577,0.000005858562,0.000022485769,0.0021006481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864435,0.00017831284,0.0003360253,0.00035763634,0.00016843216,0.0003152291],"domain_scores_gemma":[0.9994711,0.000085872285,0.00007726409,0.00018504105,0.00010229247,0.00007839422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001788468,0.00018436549,0.00061167363,0.00032114907,0.00003545232,0.000012217491,0.00006998862,0.00008580418,0.0003183179],"category_scores_gemma":[0.000010868999,0.00013866345,0.00006570487,0.00038493148,0.00024635208,0.000046443125,0.000023139271,0.000244171,4.3725595e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012108046,0.004660148,0.9032363,0.000111256464,0.00051449507,0.00048938254,0.004609482,0.000006960346,0.028001508,0.000038288366,0.00043282818,0.0457913],"study_design_scores_gemma":[0.046193853,0.020219857,0.89916056,0.00050357135,0.00013651428,0.00011108827,0.0012651186,0.00028603498,0.0058534043,0.0002259441,0.025757434,0.00028663388],"about_ca_topic_score_codex":0.00015464505,"about_ca_topic_score_gemma":0.00063663,"teacher_disagreement_score":0.045504663,"about_ca_system_score_codex":0.0013866447,"about_ca_system_score_gemma":0.00021645884,"threshold_uncertainty_score":0.5654531},"labels":[],"label_agreement":null},{"id":"W4408765892","doi":"10.1038/s41391-025-00965-w","title":"Whack-a-met: serial SABR for repeated oligoprogression in metastatic CRPC","year":2025,"lang":"en","type":"editorial","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"SABR volatility model; Medicine; Prostate cancer; Internal medicine; Cancer","score_opus":0.01645618948184608,"score_gpt":0.37102001010847885,"score_spread":0.3545638206266328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408765892","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.040537726,0.26239574,0.00004701669,0.0037381563,0.59835255,0.03274034,0.060664926,0.0006045216,0.0009190248],"genre_scores_gemma":[0.02016706,0.24741846,0.004547193,0.0012329854,0.46260718,0.061681997,0.0768619,0.0010984321,0.12438479],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954827,0.00015677752,0.00095350837,0.0013598987,0.0009738009,0.0010733075],"domain_scores_gemma":[0.9967783,0.0010304543,0.00034215336,0.000544137,0.00076329283,0.00054167013],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042432148,0.000822331,0.0015874341,0.000587325,0.00024532463,0.0002655502,0.00020987204,0.00037901598,0.00012538425],"category_scores_gemma":[0.0011977602,0.00063410413,0.0002769069,0.00065188267,0.00035117805,0.00025405266,0.00018178567,0.00067931245,0.0000052456808],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021715172,0.0007818219,0.008753935,0.019779325,0.00094126316,0.00035229078,0.0011251243,0.000011009612,0.00011482425,0.000030396548,0.85762525,0.08876959],"study_design_scores_gemma":[0.042043906,0.0036393506,0.0026460162,0.016599027,0.004502174,0.000008879521,0.0008792704,0.00037643226,0.0012066637,0.0038986718,0.9225107,0.0016889046],"about_ca_topic_score_codex":0.00042383774,"about_ca_topic_score_gemma":0.000117104806,"teacher_disagreement_score":0.13574538,"about_ca_system_score_codex":0.00056850037,"about_ca_system_score_gemma":0.0043196976,"threshold_uncertainty_score":0.999611},"labels":[],"label_agreement":null},{"id":"W4408776791","doi":"10.1016/j.labinv.2024.103140","title":"907 Intraductal Carcinoma of the Prostate and its Association with Metastasis in High-risk Prostate Cancer: Insights from the PATRON clinical trial","year":2025,"lang":"en","type":"article","venue":"Laboratory Investigation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Prostate; Metastasis; Oncology; Internal medicine; Carcinoma; Prostate carcinoma; Pathology; Cancer","score_opus":0.022851968217465598,"score_gpt":0.3068876668064668,"score_spread":0.2840356985890012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408776791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98805916,0.0029941062,6.663546e-7,0.0063703014,0.00031791083,0.0019143242,0.0003110404,0.000015509197,0.000017003475],"genre_scores_gemma":[0.99789,0.001159087,0.000052606927,0.00032564375,0.00013393698,0.00021218613,0.00007684747,0.000012087291,0.00013759105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809855,0.00058964256,0.00047581387,0.0002882781,0.00037489226,0.00017282004],"domain_scores_gemma":[0.99861777,0.00036888925,0.00037767066,0.00023113942,0.0003350867,0.00006946322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006231567,0.00014051283,0.00030554534,0.00006769571,0.00012910784,0.00003049166,0.000088605935,0.00011091349,0.000004475122],"category_scores_gemma":[0.000603687,0.00007161945,0.000037688376,0.00082257256,0.00020646126,0.00015464469,0.000044437686,0.0004250099,9.5227307e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056821858,0.00007800861,0.9873628,0.000052759937,0.00020871246,0.000003981886,0.0016227642,0.000010544988,0.0024611831,0.00023648284,0.00035632178,0.0019242616],"study_design_scores_gemma":[0.026456207,0.000509795,0.9215703,0.00025127182,0.00035896085,1.4688159e-7,0.00033038572,0.0001330042,0.048844326,0.000977373,0.00048532488,0.00008292277],"about_ca_topic_score_codex":0.0013465506,"about_ca_topic_score_gemma":0.0013728006,"teacher_disagreement_score":0.06579251,"about_ca_system_score_codex":0.00028327107,"about_ca_system_score_gemma":0.0012508462,"threshold_uncertainty_score":0.29205564},"labels":[],"label_agreement":null},{"id":"W4408776838","doi":"10.1016/j.labinv.2024.103097","title":"864 Clinicopathologic Characterisation of Grade Group 2 Prostate Cancer with Metachronous Metastasis Post Radical Prostatectomy","year":2025,"lang":"en","type":"article","venue":"Laboratory Investigation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Prostatectomy; Prostate cancer; Medicine; Urology; Prostate; Metastasis; Cancer; Oncology; Internal medicine","score_opus":0.021308806560594043,"score_gpt":0.31986475313823703,"score_spread":0.298555946577643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408776838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99275476,0.0018204562,0.00005609119,0.0033045744,0.00013151667,0.0014884825,0.0002465406,0.00009632757,0.0001012823],"genre_scores_gemma":[0.9954296,0.0005480655,0.0016785742,0.0008963283,0.00005787847,0.00052411284,0.0005733917,0.00002539221,0.00026665445],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99830705,0.00021618429,0.0004384479,0.0003901124,0.00036883535,0.00027935245],"domain_scores_gemma":[0.9986761,0.00006271612,0.00024920076,0.00029480198,0.0005670991,0.0001500847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044249318,0.00021358674,0.00043229954,0.00027024225,0.00011088172,0.000030038398,0.000083215804,0.00011377071,0.00005009821],"category_scores_gemma":[0.0001097792,0.00014909748,0.000058658978,0.0010687301,0.0005353555,0.00027671352,0.000029566743,0.0002680695,0.000007176417],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023256005,0.0004997447,0.4718196,0.0013813066,0.0005541052,0.00009302904,0.001493949,0.000017731136,0.51054674,0.0013887862,0.00034830495,0.009531069],"study_design_scores_gemma":[0.006003634,0.0016496627,0.58146745,0.0006942241,0.00068722747,0.000008496914,0.00039814648,0.00011964729,0.40548506,0.0005136236,0.0027222103,0.00025063692],"about_ca_topic_score_codex":0.00009451637,"about_ca_topic_score_gemma":0.000030414056,"teacher_disagreement_score":0.10964781,"about_ca_system_score_codex":0.0002326007,"about_ca_system_score_gemma":0.0011589369,"threshold_uncertainty_score":0.6080019},"labels":[],"label_agreement":null},{"id":"W4408777107","doi":"10.1016/j.labinv.2024.103099","title":"866 Comprehensive Comparison Between Systematic and Targeted Biopsies in Prostate Cancer for the Detection of Worst Cancer Features: A Retrospective Review of 1085 Combined Systematic and Targeted Biopsies","year":2025,"lang":"en","type":"review","venue":"Laboratory Investigation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Prostate cancer; Cancer; Medicine; Cancer detection; Oncology; Retrospective cohort study; Prostate; Pathology; Internal medicine","score_opus":0.040045337149632675,"score_gpt":0.36309025433093733,"score_spread":0.3230449171813047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408777107","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044293166,0.97665495,0.000005867141,0.0002670526,0.00017707245,0.017130015,0.0013007347,0.00003262972,0.0000023772811],"genre_scores_gemma":[0.010970014,0.9823081,0.0000550161,0.000064735825,0.00004703135,0.006066635,0.00034562548,0.000042620733,0.00010023968],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99638164,0.00078419986,0.0016258608,0.0004796501,0.00045188016,0.00027675246],"domain_scores_gemma":[0.99512404,0.0013101868,0.0017179097,0.00040853335,0.0013274836,0.00011186488],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007944843,0.0005020054,0.004332346,0.00048374213,0.00014230344,0.000035307123,0.00013920454,0.0002570873,0.0000030849483],"category_scores_gemma":[0.000996746,0.0003036677,0.00017199812,0.0019596582,0.0005226599,0.000119897406,0.000064468026,0.00042238078,3.2716352e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007430591,0.000027503565,0.0034750581,0.99267054,0.0011244264,0.0000017184458,0.00085017405,0.0000010957673,0.00025133102,0.000024621813,0.00010042823,0.0013988069],"study_design_scores_gemma":[0.0013047496,0.00032500073,0.004009051,0.98459476,0.006889564,0.000002697104,0.00073193555,0.00006943497,0.0012790547,0.000040377345,0.0004901892,0.00026317153],"about_ca_topic_score_codex":0.00033759576,"about_ca_topic_score_gemma":0.00020608946,"teacher_disagreement_score":0.011063381,"about_ca_system_score_codex":0.00056013925,"about_ca_system_score_gemma":0.0011129773,"threshold_uncertainty_score":0.9999415},"labels":[],"label_agreement":null},{"id":"W4408808751","doi":"10.1080/14796694.2025.2479374","title":"Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; McGill University; University of Calgary","funders":"Pfizer","keywords":"Medicine; Prostate cancer; Docetaxel; Internal medicine; Bone metastasis; Androgen deprivation therapy; Oncology; Metastasis; Cancer","score_opus":0.02622886707316352,"score_gpt":0.3772367480505685,"score_spread":0.351007880977405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408808751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95395535,0.00034786883,7.576037e-7,0.03340776,0.0004288247,0.0027969864,0.000024936167,0.000011372155,0.009026131],"genre_scores_gemma":[0.9836372,0.00071674224,0.00006332776,0.00035962742,0.00008167123,0.00093247346,0.000116599236,0.000010916621,0.014081441],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986255,0.00020637036,0.00034513947,0.000357151,0.0001476296,0.00031818906],"domain_scores_gemma":[0.99930894,0.00019785571,0.00006998281,0.00019856988,0.00014819355,0.00007647253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012617995,0.00017110578,0.0004977447,0.0003718116,0.000046929483,0.000008261505,0.000045593846,0.00005047221,0.000033294844],"category_scores_gemma":[0.000030802363,0.00012733755,0.00003012213,0.00078551244,0.0000451578,0.00004001043,0.000018704352,0.00021526002,0.0000034264392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004760635,0.0026513347,0.9061845,0.000102340746,0.0005454347,0.0036874674,0.011906751,0.000071690745,0.00043539747,0.0009619082,0.002888424,0.065804094],"study_design_scores_gemma":[0.011983874,0.0017819565,0.944066,0.0001062452,0.00019374372,0.000018395933,0.015539668,0.00023651567,0.00083779544,0.000059727667,0.025039915,0.0001362024],"about_ca_topic_score_codex":0.94600874,"about_ca_topic_score_gemma":0.9991573,"teacher_disagreement_score":0.06566789,"about_ca_system_score_codex":0.0056937267,"about_ca_system_score_gemma":0.006002342,"threshold_uncertainty_score":0.9996327},"labels":[],"label_agreement":null},{"id":"W4408833196","doi":"10.1080/14796694.2025.2476929","title":"Prostate-specific antigen (PSA) response with darolutamide in metastatic hormone-sensitive prostate cancer and its impact on treatment outcomes in the ARASENS trial: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation; Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Prostate-specific antigen; Oncology; Internal medicine; Antigen; Cancer; Immunology","score_opus":0.024508294236586032,"score_gpt":0.3871047592680317,"score_spread":0.36259646503144566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408833196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96633184,0.007736804,3.3374184e-7,0.020244878,0.00011677066,0.004802188,0.00029408172,0.000026949541,0.00044614228],"genre_scores_gemma":[0.98962575,0.0063177072,0.000049637347,0.0006666011,0.00008714352,0.00089419715,0.00011603942,0.000027336506,0.0022156073],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99758214,0.00080545584,0.00032680706,0.00047308588,0.00025774707,0.00055477244],"domain_scores_gemma":[0.9984674,0.00097525085,0.00009864241,0.00029249364,0.00006027016,0.00010596646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076487963,0.00035246648,0.00084392325,0.00051243755,0.00009014103,0.000028705503,0.00008302586,0.00012240387,0.0000118652415],"category_scores_gemma":[0.000068600486,0.00016322243,0.00008804437,0.0006149364,0.00013780958,0.000065656925,0.000030987023,0.00040567585,0.00000523282],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9040466,0.002059973,0.030005824,0.00006743945,0.00077092776,0.011546966,0.029551364,0.0000512024,0.006732816,0.000081248865,0.0017939871,0.013291665],"study_design_scores_gemma":[0.14405899,0.02774781,0.79546,0.0003165339,0.00022429579,0.000087410626,0.018549675,0.00008567204,0.002212667,0.00003757773,0.010922748,0.00029661224],"about_ca_topic_score_codex":0.00050286605,"about_ca_topic_score_gemma":0.002536673,"teacher_disagreement_score":0.7654542,"about_ca_system_score_codex":0.001487186,"about_ca_system_score_gemma":0.001152944,"threshold_uncertainty_score":0.6656018},"labels":[],"label_agreement":null},{"id":"W4408924878","doi":"10.1016/j.urolonc.2025.03.011","title":"Corrigendum to ‘Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide’[Urol Oncol: Semin Original Investigat 41(3) (2023) 253.e1-253.e9]","year":2025,"lang":"en","type":"erratum","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Enzalutamide; Medicine; Prostate cancer; Prostate-specific antigen; Urology; Oncology; Internal medicine; Cancer","score_opus":0.08016892901954187,"score_gpt":0.3852730194740512,"score_spread":0.3051040904545093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408924878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97864515,0.0038485087,0.000016059474,0.004204392,0.0030167701,0.0062386976,0.00259245,0.00007218461,0.0013657697],"genre_scores_gemma":[0.78431964,0.036008712,0.03527255,0.0062784553,0.0009098496,0.0072882576,0.013901964,0.00046310332,0.11555749],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928592,0.0014029832,0.0020712293,0.00143484,0.0011022158,0.0011295634],"domain_scores_gemma":[0.99519044,0.0011028377,0.0013160687,0.0006591059,0.00092113565,0.00081039424],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012714886,0.0009966594,0.002571539,0.0016286728,0.00033835994,0.000058845195,0.00037087148,0.0008844263,0.00014726521],"category_scores_gemma":[0.0009790959,0.0008041635,0.0002067707,0.0022063623,0.0018863527,0.00018371285,0.00022287999,0.002137241,0.000022805041],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08945404,0.0051380065,0.56524307,0.0020421809,0.0015148759,0.0025328333,0.017762195,0.0015539892,0.0031737662,0.0006913826,0.3043792,0.0065144813],"study_design_scores_gemma":[0.012194465,0.06803308,0.09536972,0.005441748,0.0015839174,0.00007546746,0.004048253,0.0016714607,0.008171756,0.0008896934,0.80107266,0.001447763],"about_ca_topic_score_codex":0.0009887817,"about_ca_topic_score_gemma":0.0012097061,"teacher_disagreement_score":0.4966935,"about_ca_system_score_codex":0.0018145309,"about_ca_system_score_gemma":0.008128379,"threshold_uncertainty_score":0.9994409},"labels":[],"label_agreement":null},{"id":"W4409097322","doi":"10.1016/s1470-2045(25)00031-2","title":"First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma US; Pfizer","keywords":"Enzalutamide; Prostate cancer; Placebo; Medicine; Homologous recombination; Oncology; Internal medicine; Cancer research; Gene; Cancer; Biology; Genetics; Pathology; Androgen receptor","score_opus":0.07915377553234595,"score_gpt":0.38702915174321567,"score_spread":0.3078753762108697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409097322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95748395,0.003379308,0.00006497019,0.020436889,0.00059234747,0.016557753,0.00016003438,0.00010685627,0.0012179108],"genre_scores_gemma":[0.9818812,0.0019019305,0.00051048235,0.00060322863,0.00026029872,0.012246243,0.00048973004,0.000038826896,0.00206806],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964705,0.00076747744,0.0010700313,0.0006352634,0.00044953162,0.0006072081],"domain_scores_gemma":[0.9951547,0.0032887647,0.00054317963,0.00063202286,0.00026427174,0.0001170578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017854555,0.00041080054,0.0015452208,0.00021473263,0.00045362907,0.000094814124,0.00021137713,0.00015297187,0.00007162358],"category_scores_gemma":[0.00061698165,0.00021399977,0.00016157891,0.00047609603,0.00039244333,0.00016430425,0.000099861245,0.00058912864,0.0000039300753],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.987086,0.00063145783,0.00073373434,0.00006812724,0.0024033273,0.00044405914,0.0026091952,0.0021159742,0.00052332995,0.00018629679,0.00087337394,0.0023251285],"study_design_scores_gemma":[0.98399764,0.0036681746,0.0006377163,0.0001478014,0.0016280066,0.00003363402,0.0010168132,0.006055754,0.0011136829,0.00044557545,0.0010338427,0.00022136769],"about_ca_topic_score_codex":0.0032251433,"about_ca_topic_score_gemma":0.010659794,"teacher_disagreement_score":0.024397269,"about_ca_system_score_codex":0.0013772626,"about_ca_system_score_gemma":0.0021589904,"threshold_uncertainty_score":0.8726657},"labels":[],"label_agreement":null},{"id":"W4409103399","doi":"10.1016/s1470-2045(25)00030-0","title":"First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma US; Pfizer","keywords":"Enzalutamide; Medicine; Placebo; Prostate cancer; Internal medicine; Clinical trial; Double blind; Oncology; First line; Urology; Cancer; Androgen receptor; Pathology","score_opus":0.12787455261069358,"score_gpt":0.4242313951586915,"score_spread":0.29635684254799793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409103399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9067606,0.005026379,0.0003224778,0.04502774,0.0031401499,0.036512587,0.0009732755,0.0001769192,0.0020598986],"genre_scores_gemma":[0.9588548,0.0015670517,0.000514718,0.0017727456,0.0012546919,0.029318558,0.0009318841,0.00008398952,0.0057015903],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953161,0.0006687294,0.001473601,0.0007851839,0.000658853,0.0010975302],"domain_scores_gemma":[0.98949945,0.008039139,0.0008107926,0.0010177926,0.0004186146,0.00021418728],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021753183,0.00060625107,0.002520963,0.00017726251,0.0007767933,0.00013299358,0.0005211698,0.00022817597,0.00021514365],"category_scores_gemma":[0.001372937,0.00031491756,0.00057173695,0.00046496678,0.0005147652,0.00013680402,0.00016366705,0.0007312452,0.000017525113],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.978634,0.0007128082,0.0001360469,0.00014528721,0.005324168,0.00021133256,0.0017769185,0.0015543057,0.000803622,0.0003597656,0.005742623,0.004599136],"study_design_scores_gemma":[0.9600076,0.0039841705,0.00006852073,0.00014594497,0.0039125816,0.000012460661,0.0010236423,0.0032342868,0.0018305246,0.00062135485,0.024866046,0.00029287313],"about_ca_topic_score_codex":0.0022389167,"about_ca_topic_score_gemma":0.0052678213,"teacher_disagreement_score":0.052094195,"about_ca_system_score_codex":0.0016693353,"about_ca_system_score_gemma":0.0040327865,"threshold_uncertainty_score":0.99993026},"labels":[],"label_agreement":null},{"id":"W4409256811","doi":"10.1016/j.eururo.2025.03.008","title":"Corrigendum to “Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial” [Eur. Urol. 86 (2024) 552–562]","year":2025,"lang":"en","type":"erratum","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Clinical trial; Prostate; Internal medicine; Prostate-specific antigen; Castration; Urology; Cancer; Gynecology; Hormone","score_opus":0.0696067119949764,"score_gpt":0.3896189644759298,"score_spread":0.32001225248095344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409256811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97007304,0.0014085408,0.00003492628,0.0042867465,0.009088431,0.009526988,0.0009942496,0.000061116814,0.0045259544],"genre_scores_gemma":[0.8782144,0.0024856587,0.0005957119,0.0018019928,0.0007474993,0.00064830465,0.0024289151,0.00030217442,0.11277531],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9920711,0.0027180037,0.0019333616,0.0011722435,0.001180947,0.0009243421],"domain_scores_gemma":[0.9964423,0.00080685766,0.0011868506,0.00077726564,0.00058934506,0.0001973869],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0037551739,0.0006394119,0.0016833345,0.0008049222,0.00016106921,0.000095952244,0.00045419458,0.00025411858,0.00010352063],"category_scores_gemma":[0.0010145498,0.00038802225,0.00018216319,0.0011709745,0.00021028376,0.00014868047,0.00015196882,0.0020016292,0.000021924447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.169444,0.003906156,0.6656014,0.00043835505,0.0011661978,0.0014353975,0.005076955,0.00010343129,0.000079246245,0.000010668357,0.1390655,0.013672732],"study_design_scores_gemma":[0.09046867,0.01830266,0.81585044,0.0009388086,0.00046476806,0.0000030640317,0.00043106376,0.000030272011,0.000013915926,0.000010038684,0.07303544,0.00045088655],"about_ca_topic_score_codex":0.00024552178,"about_ca_topic_score_gemma":0.0016687711,"teacher_disagreement_score":0.15024906,"about_ca_system_score_codex":0.0004936004,"about_ca_system_score_gemma":0.0016128545,"threshold_uncertainty_score":0.9998572},"labels":[],"label_agreement":null},{"id":"W4409341244","doi":"10.1038/s41388-025-03407-y","title":"Editorial Expression of Concern: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E","year":2025,"lang":"en","type":"article","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Biology; Prostate cancer; Heat shock protein; Androgen; Cancer research; Cancer; Prostate; Chemotherapy; EIF4E; Internal medicine; Endocrinology; Oncology; Hormone; Genetics; Gene; Messenger RNA; Medicine; Translation (biology)","score_opus":0.018492549433412764,"score_gpt":0.33429402551384446,"score_spread":0.3158014760804317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409341244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98586804,0.004023075,0.000047585345,0.0029552781,0.0026441582,0.0023399363,0.00006481361,0.000021559048,0.0020355764],"genre_scores_gemma":[0.97979695,0.003398661,0.001094521,0.00031548465,0.0029782106,0.0004258111,0.00004014997,0.00003085504,0.011919332],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99891365,0.00004096012,0.0002398916,0.00030088908,0.00027900215,0.00022560034],"domain_scores_gemma":[0.99952185,0.000027673454,0.000042887645,0.00018137455,0.00014981514,0.00007641353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001431951,0.00013426715,0.00030193487,0.00008623455,0.000042427568,0.0000135909195,0.000056066834,0.00008970348,0.000044582644],"category_scores_gemma":[0.000017029573,0.000106747015,0.000032201453,0.0002893601,0.00007991718,0.00007690442,0.00003484202,0.00010817453,0.0000019906481],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050480855,0.00010497928,0.008161277,0.0002821697,0.00004048149,0.000009159664,0.0011221519,0.00001700148,0.9535199,0.000030538497,0.029865645,0.0017986482],"study_design_scores_gemma":[0.0053487825,0.0002172063,0.0005451988,0.00092982437,0.000017386366,2.793336e-7,0.00012343883,0.000009765114,0.9006427,0.00015366536,0.09192287,0.0000888898],"about_ca_topic_score_codex":0.0003126306,"about_ca_topic_score_gemma":0.00014183979,"teacher_disagreement_score":0.062057227,"about_ca_system_score_codex":0.00023926172,"about_ca_system_score_gemma":0.00039971518,"threshold_uncertainty_score":0.4353017},"labels":[],"label_agreement":null},{"id":"W4409344308","doi":"10.1038/s41388-025-03392-2","title":"Correction: Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer","year":2025,"lang":"en","type":"erratum","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Environmental Health Sciences","keywords":"Enzalutamide; Androgen receptor; Biology; Prostate cancer; Cancer research; Androgen; Internal medicine; Cancer; Receptor; Oncology; Endocrinology; Genetics; Hormone; Medicine","score_opus":0.014969959571388015,"score_gpt":0.3107475195043352,"score_spread":0.2957775599329472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409344308","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49462318,0.41204217,0.000034254874,0.004895332,0.02859424,0.008968867,0.009169716,0.00023076359,0.04144146],"genre_scores_gemma":[0.008587147,0.17382126,0.00027655443,0.000113593574,0.00051566865,0.0013602745,0.0049117217,0.000081970786,0.8103318],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99791956,0.000056685785,0.00051235734,0.0006890378,0.00039446916,0.0004278756],"domain_scores_gemma":[0.99899626,0.00007739048,0.00023274764,0.00030141597,0.00022255653,0.00016961453],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012776568,0.00044934457,0.0009548408,0.00037185597,0.000079694844,0.000019643361,0.000061521656,0.00041947133,0.00018313402],"category_scores_gemma":[0.000054568227,0.00035883437,0.00013940565,0.00051837193,0.00016438348,0.00008583031,0.00006654928,0.00041098366,0.0000045426755],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031841192,0.0011745883,0.0033959732,0.0012691934,0.00073522393,0.00008223258,0.0007343172,0.000016702426,0.15136373,0.0000038906273,0.6502965,0.18774353],"study_design_scores_gemma":[0.011191881,0.002153314,0.00046204077,0.0046619037,0.00042051816,0.000022302655,0.0003073076,0.00012400294,0.27664384,0.00001255747,0.70356226,0.00043807423],"about_ca_topic_score_codex":0.0018030007,"about_ca_topic_score_gemma":0.00090855925,"teacher_disagreement_score":0.7688904,"about_ca_system_score_codex":0.0014932426,"about_ca_system_score_gemma":0.0015508085,"threshold_uncertainty_score":0.99988633},"labels":[],"label_agreement":null},{"id":"W4409585810","doi":"10.5489/cuaj.9100","title":"Optimizing therapy for high-risk biochemically recurrent non-metastatic prostate cancer","year":2025,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McMaster University; Queen Elizabeth II Health Sciences Centre; Centre Hospitalier de l’Université de Montréal; Université Laval; University of British Columbia; Centre hospitalier de l'Université Laval; McGill University; Jewish General Hospital; Sunnybrook Health Science Centre; University of Toronto; University Health Network; BC Cancer Agency","funders":"","keywords":"Prostate cancer; Medicine; Prostatectomy; Androgen deprivation therapy; Malignancy; Oncology; breakpoint cluster region; Cancer; Internal medicine; Salvage therapy; Biochemical recurrence; Prostate-specific antigen; Urology; Chemotherapy; Receptor","score_opus":0.03740367739626017,"score_gpt":0.3507992727789043,"score_spread":0.31339559538264417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409585810","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002603275,0.990374,0.000041800857,0.004523756,0.0007393436,0.0025628323,0.0013478717,0.000023106015,0.00012694683],"genre_scores_gemma":[0.00013277397,0.99363995,0.00078609877,0.0006589402,0.0006622385,0.00082297914,0.000578841,0.000041146373,0.0026770504],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971171,0.0002873851,0.000769967,0.00045803693,0.0004260873,0.0009414229],"domain_scores_gemma":[0.996886,0.0006448826,0.0008080562,0.0001786655,0.000609618,0.0008727434],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009637817,0.00042889742,0.0015812159,0.000514731,0.00041809623,0.0001655694,0.00024582402,0.00048084286,0.0002812155],"category_scores_gemma":[0.0009144667,0.00027751434,0.00071189034,0.00051465427,0.000046448542,0.000056978515,0.000025965437,0.0014962624,0.00001788238],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00016768838,0.000084594285,0.0013545331,0.0016167577,0.0014123364,0.00006332757,0.000055856573,0.0000033010676,8.7369324e-7,0.000009656484,0.022083705,0.9731474],"study_design_scores_gemma":[0.0027342497,0.00080490153,0.00033745836,0.003788319,0.0015908508,0.000032767875,0.000011065384,0.000014924125,0.0000041097214,0.00025955497,0.9901211,0.0003006691],"about_ca_topic_score_codex":0.0007805342,"about_ca_topic_score_gemma":0.00021667163,"teacher_disagreement_score":0.9728467,"about_ca_system_score_codex":0.004270567,"about_ca_system_score_gemma":0.0074385204,"threshold_uncertainty_score":0.9999677},"labels":[],"label_agreement":null},{"id":"W4409607351","doi":"10.3390/curroncol32040240","title":"Cost-Effectiveness Analysis of Contemporary Advanced Prostate Cancer Treatment Sequences","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University; Université de Montréal","funders":"Fonds de Recherche du Québec - Santé","keywords":"Medicine; Prostate cancer; Abiraterone; Cost effectiveness; Oncology; Androgen receptor; Internal medicine; Cancer; Risk analysis (engineering)","score_opus":0.20425074740232962,"score_gpt":0.5227096407598004,"score_spread":0.3184588933574708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409607351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9476912,0.0433463,0.00007589931,0.0011017257,0.00070641574,0.0023351337,0.00018096984,0.000041448275,0.004520914],"genre_scores_gemma":[0.98934656,0.007598237,0.00003843724,0.000034943612,0.000027428967,0.0014835481,0.00024279644,0.000007582948,0.0012204607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877244,0.00018653717,0.00029317057,0.00034028207,0.00015133347,0.0002562082],"domain_scores_gemma":[0.9990275,0.00026114116,0.00012055587,0.0002270966,0.00026565272,0.000098087774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018706048,0.00016692668,0.0008177397,0.00052215246,0.0000575016,0.0000054843263,0.00007371348,0.00007637762,0.0000907315],"category_scores_gemma":[0.000036028952,0.000113704526,0.00021778428,0.0011915746,0.0002443226,0.000054637534,0.00003873829,0.00012039598,0.0000033603474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030185343,0.0011898391,0.5860304,0.00031651102,0.0035521383,0.00004127014,0.00048511676,0.0001351859,0.002551183,0.00017932006,0.00027777324,0.4022227],"study_design_scores_gemma":[0.022615014,0.004685868,0.61104864,0.000936105,0.0063042063,0.0000037558948,0.00094719126,0.0013305659,0.05578872,0.00035478454,0.29566917,0.0003160131],"about_ca_topic_score_codex":0.0002589647,"about_ca_topic_score_gemma":0.000121420315,"teacher_disagreement_score":0.40190667,"about_ca_system_score_codex":0.001212019,"about_ca_system_score_gemma":0.0017036618,"threshold_uncertainty_score":0.46367362},"labels":[],"label_agreement":null},{"id":"W4409619744","doi":"10.21037/tcr-2024-2683","title":"Exploiting pre-dormancy tumor immune microenvironment induced by androgen deprivation in prostate cancer","year":2025,"lang":"en","type":"letter","venue":"Translational Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Prostate cancer; Dormancy; Immune system; Prostate; Androgen; Cancer research; Tumor microenvironment; Cancer; Biology; Medicine; Internal medicine; Oncology; Hormone; Immunology; Botany","score_opus":0.07061482232128427,"score_gpt":0.38811809431499955,"score_spread":0.3175032719937153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409619744","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32285264,0.03434181,0.000010634182,0.6354447,0.00020919212,0.0048607374,0.0012569032,0.00006277343,0.0009606284],"genre_scores_gemma":[0.6800942,0.060851913,0.00042494186,0.12664013,0.005766543,0.03190946,0.021399189,0.00067408703,0.07223957],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99430037,0.00034483572,0.00078107044,0.0010043596,0.002293853,0.0012754919],"domain_scores_gemma":[0.99861836,0.00028146856,0.00013768706,0.0004693084,0.00034901075,0.00014413726],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008625301,0.00045687196,0.0006761992,0.0010253808,0.00028059102,0.000086649234,0.00035133553,0.00040032872,0.001101553],"category_scores_gemma":[0.00003525253,0.0004161875,0.00017563849,0.001112676,0.00023127718,0.0002252366,0.00010587143,0.0038696874,0.000031205083],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006190461,0.000784682,0.09427906,0.0074491543,0.0013742252,0.0013322793,0.0032245996,0.00018847661,0.12003299,0.000024187168,0.7110617,0.054058153],"study_design_scores_gemma":[0.0146129085,0.0006364445,0.06589102,0.007522422,0.00025217334,0.000026756255,0.00017137756,0.00043177188,0.08967521,0.0005981427,0.8189843,0.001197471],"about_ca_topic_score_codex":0.004687494,"about_ca_topic_score_gemma":0.00027150777,"teacher_disagreement_score":0.50880456,"about_ca_system_score_codex":0.0018882457,"about_ca_system_score_gemma":0.00255076,"threshold_uncertainty_score":0.999829},"labels":[],"label_agreement":null},{"id":"W4409624400","doi":"10.1158/1538-7445.am2025-1969","title":"Abstract 1969: Advancing metastatic prostate cancer diagnostics: STEAP1-based imaging flow cytometry for circulating tumor cell detection and characterization","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Prostate cancer; Flow cytometry; Medicine; Circulating tumor cell; Cancer; Pathology; Prostate; Cancer research; Oncology; Internal medicine; Metastasis; Immunology","score_opus":0.0345317738888329,"score_gpt":0.3972625829221088,"score_spread":0.3627308090332759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409624400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98028857,0.009599227,0.0036004935,0.0022187838,0.00032648625,0.0033545557,0.00030493655,0.000083296436,0.00022365223],"genre_scores_gemma":[0.992322,0.0027774672,0.00055469584,0.00025200314,0.00019772122,0.0028614919,0.00015026581,0.000060069673,0.00082423905],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974964,0.00010339833,0.00035886906,0.0006007976,0.00058158673,0.0008589057],"domain_scores_gemma":[0.9978678,0.00071872055,0.00010116832,0.00026726018,0.0008147015,0.00023031009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010485225,0.00022391937,0.00036092917,0.0008110349,0.000511398,0.00015447615,0.00010487599,0.000048410435,0.00009697609],"category_scores_gemma":[0.00045461784,0.00019676494,0.000080585305,0.001041031,0.00018016016,0.00023833931,0.000071123985,0.00050372496,0.0000043426853],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012337669,0.00014863018,0.04789867,0.004320953,0.00011605754,0.00008664854,0.00029588645,0.0002658129,0.7788884,0.0000057559546,0.00018421975,0.16655523],"study_design_scores_gemma":[0.011685406,0.0004150293,0.12312728,0.003687581,0.00031555854,0.000009748277,0.0009855367,0.0670644,0.78537107,0.00017931941,0.006666538,0.00049256487],"about_ca_topic_score_codex":0.00045028617,"about_ca_topic_score_gemma":0.000094791496,"teacher_disagreement_score":0.16606265,"about_ca_system_score_codex":0.0010640648,"about_ca_system_score_gemma":0.0013525251,"threshold_uncertainty_score":0.8023842},"labels":[],"label_agreement":null},{"id":"W4409625727","doi":"10.1158/1538-7445.am2025-777","title":"Abstract 777: Revealing the transcriptional and proteomic spatial neighborhoods of early prostate cancer and the tumor microenvironment","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Ontario Institute for Cancer Research","funders":"","keywords":"Prostate cancer; Tumor microenvironment; Cancer; Cancer research; Biology; Medicine; Computational biology; Internal medicine","score_opus":0.03598655560116233,"score_gpt":0.3683330395350453,"score_spread":0.332346483933883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409625727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94640815,0.027138686,0.000006869956,0.023274457,0.00007254236,0.0025607606,0.00008847011,0.000007927434,0.00044210727],"genre_scores_gemma":[0.980982,0.014229856,0.000022532662,0.00020201107,0.00012654896,0.0014012661,0.0000061291403,0.00001713381,0.0030125224],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982584,0.00014832016,0.00025972165,0.0003290037,0.00057638844,0.00042816892],"domain_scores_gemma":[0.99921054,0.00020181068,0.000052250914,0.00026345695,0.00015292862,0.000119012635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011647101,0.00013855447,0.000266711,0.00012515836,0.00035020307,0.00005923935,0.00015550057,0.000047789155,0.00016364545],"category_scores_gemma":[0.000056542216,0.00007021883,0.00005960697,0.00026445132,0.0015882431,0.00005937397,0.000112465066,0.00061060884,0.0000019110719],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021655703,0.000264802,0.18595967,0.0025076475,0.00092963706,0.00005274798,0.00629095,0.00002873177,0.6991916,0.002122329,0.0016567785,0.07933943],"study_design_scores_gemma":[0.010138673,0.00029114657,0.91206247,0.0011251825,0.00012283296,0.000008711435,0.00052822137,0.00012284225,0.070054546,0.0010768328,0.0043436824,0.00012484878],"about_ca_topic_score_codex":0.006469219,"about_ca_topic_score_gemma":0.00019161233,"teacher_disagreement_score":0.7261028,"about_ca_system_score_codex":0.00025938766,"about_ca_system_score_gemma":0.00086513953,"threshold_uncertainty_score":0.9779567},"labels":[],"label_agreement":null},{"id":"W4409626711","doi":"10.1158/1538-7445.am2025-3883","title":"Abstract 3883: Evolution of genomic and epigenomic heterogeneity in prostate cancer from tissue and liquid biopsies","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Epigenomics; Prostate cancer; Prostate; Cancer research; Cancer; Liquid biopsy; Tumor heterogeneity; Medicine; Pathology; Biology; Internal medicine; DNA methylation; Genetics; Gene","score_opus":0.04962733224483373,"score_gpt":0.4188187183103404,"score_spread":0.36919138606550667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409626711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8962088,0.100507066,0.0000017646548,0.0018146799,0.00007440884,0.00093131984,0.00019696576,0.0000124702865,0.00025248982],"genre_scores_gemma":[0.9654193,0.033230994,0.000031494932,0.000022822553,0.0000686705,0.00033072731,0.000020183497,0.00001792753,0.0008578746],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983989,0.00009120106,0.00027816338,0.000456144,0.00029812581,0.00047744808],"domain_scores_gemma":[0.9992185,0.00013604184,0.000043392898,0.00025072062,0.00020839022,0.00014292198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050590496,0.00014290227,0.00034692185,0.0004836108,0.00011292536,0.0000295083,0.00010332699,0.00009519832,0.00012969336],"category_scores_gemma":[0.000043449192,0.00011981389,0.000027692116,0.00039929795,0.0005339143,0.00008538653,0.00018915391,0.0003860117,0.0000055829423],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027199725,0.000076820055,0.24786386,0.0005380489,0.00012211378,0.000035334873,0.0005860287,0.0000128097045,0.73376554,0.0000407257,0.00018372394,0.014055039],"study_design_scores_gemma":[0.0022372843,0.00025331238,0.7394962,0.00056760217,0.000025928459,0.0000014905155,0.00031912097,0.000035515837,0.2551552,0.000293267,0.0015218274,0.00009327075],"about_ca_topic_score_codex":0.027275039,"about_ca_topic_score_gemma":0.0038974765,"teacher_disagreement_score":0.4916323,"about_ca_system_score_codex":0.001017793,"about_ca_system_score_gemma":0.0010745119,"threshold_uncertainty_score":0.97920245},"labels":[],"label_agreement":null},{"id":"W4409631335","doi":"10.1158/1538-7445.am2025-4771","title":"Abstract 4771: A novel immunotherapy for metastatic prostate cancer: A monoclonal antibody that can bind both STEAP1 and STEAP2","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Monoclonal antibody; Prostate cancer; Immunotherapy; Medicine; Cancer; Prostate; Cancer research; Antibody; Monoclonal; Immunology; Oncology; Internal medicine","score_opus":0.1181053066470001,"score_gpt":0.4765475969791997,"score_spread":0.3584422903321996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409631335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9381425,0.04089523,0.00010315223,0.013777528,0.00024673346,0.0047680824,0.0011471211,0.00006051835,0.00085916126],"genre_scores_gemma":[0.93774927,0.03268364,0.0005112016,0.00044251804,0.00018281583,0.0042116004,0.0001828528,0.00009237643,0.023943722],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9966722,0.00008650702,0.0003565414,0.00077528146,0.00090299774,0.0012064517],"domain_scores_gemma":[0.99809134,0.00043735164,0.00008261454,0.00048006157,0.000583597,0.00032504607],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011598935,0.0003246467,0.0006069902,0.0006701993,0.00050500303,0.00019172663,0.0002669377,0.00011339764,0.0002480885],"category_scores_gemma":[0.0000719738,0.0002463023,0.00014270301,0.00083147344,0.0005682988,0.0001591703,0.00013452498,0.0007116511,0.0000045911056],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016120207,0.0011140675,0.11170555,0.0046113757,0.0031733685,0.00016302892,0.003507972,0.000034203422,0.69384474,0.00088119507,0.009989833,0.15485443],"study_design_scores_gemma":[0.0776227,0.0034939672,0.39307266,0.006628825,0.00062236196,0.00005853703,0.006567017,0.0013416752,0.25288847,0.0024786217,0.2537009,0.001524235],"about_ca_topic_score_codex":0.005333124,"about_ca_topic_score_gemma":0.0007781585,"teacher_disagreement_score":0.4409563,"about_ca_system_score_codex":0.0008860363,"about_ca_system_score_gemma":0.0034533276,"threshold_uncertainty_score":0.9999989},"labels":[],"label_agreement":null},{"id":"W4409633492","doi":"10.1158/1538-7445.am2025-4748","title":"Abstract 4748: Understanding the RSAD2/CMPK2 signaling axis in PVT1 exon 9 overexpressed neuroendocrine prostate cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PVT1; Prostate cancer; Exon; Cancer; Medicine; Prostate; Cancer research; Biology; Internal medicine; Genetics; Gene; Long non-coding RNA; RNA","score_opus":0.14421120429211431,"score_gpt":0.44431699319982326,"score_spread":0.30010578890770895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409633492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9439423,0.018767579,0.000042713164,0.025428686,0.0003958927,0.0028204569,0.000092172384,0.00007863141,0.008431571],"genre_scores_gemma":[0.9792176,0.008690671,0.000012964222,0.0003902936,0.00022223308,0.0013081962,0.000026392023,0.00005041588,0.010081217],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99613875,0.00024043638,0.00043086958,0.00069352833,0.0011737392,0.0013226903],"domain_scores_gemma":[0.99818283,0.00061717065,0.00006348798,0.0006010908,0.00031844995,0.00021695816],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010215802,0.00027065893,0.00041926917,0.00066428876,0.0004929395,0.00016982366,0.00040814624,0.00007349595,0.0011569902],"category_scores_gemma":[0.00021130902,0.00018100507,0.00011875946,0.0019369235,0.00049095455,0.00018309482,0.0002661413,0.0015514279,0.00002466574],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0154478485,0.0009249041,0.17680992,0.004245937,0.0010937114,0.0027940243,0.0039721504,0.0018918025,0.6938656,0.00356248,0.059870522,0.03552112],"study_design_scores_gemma":[0.032907914,0.0014838695,0.13567834,0.014677195,0.00032995472,0.000046889178,0.0137746865,0.0022216153,0.68880033,0.016969342,0.09169141,0.0014184312],"about_ca_topic_score_codex":0.0040834183,"about_ca_topic_score_gemma":0.0011380521,"teacher_disagreement_score":0.041131582,"about_ca_system_score_codex":0.0025873042,"about_ca_system_score_gemma":0.0018739532,"threshold_uncertainty_score":0.9997561},"labels":[],"label_agreement":null},{"id":"W4409691031","doi":"10.1158/1538-7445.am2025-350","title":"Abstract 350: AUTX-703, a novel and potent KAT2A and KAT2B protein degrader, induces differentiation and provides a potential therapeutic opportunity in subtypes of prostate cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Supratek Pharma (Canada)","funders":"","keywords":"Prostate cancer; Cancer research; Medicine; Cancer; Oncology; Internal medicine","score_opus":0.09845964466096474,"score_gpt":0.400477444474042,"score_spread":0.30201779981307725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409691031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96449625,0.027311409,0.000008232401,0.0056110015,0.00004411151,0.0023270142,0.00006166478,0.000017261504,0.0001230685],"genre_scores_gemma":[0.9863367,0.011042915,0.000035594545,0.00004759308,0.000040233528,0.0008691815,0.0000184988,0.000020668156,0.0015886019],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99806404,0.000113685615,0.00031061185,0.0004799042,0.0005310332,0.0005007261],"domain_scores_gemma":[0.9990989,0.00009014692,0.00007716833,0.00019292807,0.00032077602,0.00022008341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006784514,0.00019149166,0.00037013504,0.000545888,0.00017038238,0.0000852714,0.00008988118,0.00013418036,0.000054370936],"category_scores_gemma":[0.00009257977,0.00014214257,0.00003242089,0.00049501425,0.0005550956,0.00016794233,0.00015699945,0.00057219015,3.1527082e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030798714,0.00057277235,0.19024219,0.003334491,0.0003320709,0.00004903533,0.0017105932,0.0000036651797,0.64992136,0.00028533692,0.00010803161,0.15036058],"study_design_scores_gemma":[0.005307856,0.0004277815,0.9180957,0.001676827,0.00007500155,0.000006561221,0.0009882365,0.00030542162,0.071579754,0.001135295,0.00023177642,0.00016978953],"about_ca_topic_score_codex":0.005762714,"about_ca_topic_score_gemma":0.0011066734,"teacher_disagreement_score":0.72785354,"about_ca_system_score_codex":0.00024709973,"about_ca_system_score_gemma":0.0013069967,"threshold_uncertainty_score":0.87115383},"labels":[],"label_agreement":null},{"id":"W4409821071","doi":"10.1111/bju.16751","title":"Percentage of free to total <scp>PSA</scp> as a biomarker of survival in metastatic castration‐resistant prostate cancer","year":2025,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"University of Melbourne","keywords":"Medicine; Prostate cancer; Hazard ratio; Enzalutamide; Abiraterone acetate; Proportional hazards model; Urology; Cohort; Oncology; Internal medicine; Prostate-specific antigen; Biomarker; Cancer; Confidence interval; Gynecology; Androgen deprivation therapy; Androgen receptor","score_opus":0.021427784459118075,"score_gpt":0.3267280166951577,"score_spread":0.30530023223603964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409821071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98751676,0.008498624,0.00003216281,0.001750561,0.0002350886,0.00039869596,0.00014725221,0.0000032388652,0.0014176134],"genre_scores_gemma":[0.9962266,0.0016220817,0.00028789096,0.00014614163,0.000030074878,0.000016414559,0.000008409479,0.000011918189,0.0016504738],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983723,0.00017365879,0.000674634,0.00015486231,0.00033721287,0.00028732602],"domain_scores_gemma":[0.9989662,0.00019841988,0.00021879675,0.00013439014,0.00035292382,0.00012925206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005422289,0.000105832485,0.0005708902,0.00039815612,0.000027404732,0.000013091638,0.00014143635,0.000059632497,0.00011553831],"category_scores_gemma":[0.00048658883,0.000099990415,0.00012032476,0.00034996594,0.00015261774,0.00007423494,0.000066690554,0.00024932943,0.0000014247732],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014471654,0.003884405,0.28746453,0.0020797942,0.0038504242,0.023293465,0.004548398,0.000497669,0.5348312,0.00047712817,0.028283486,0.096317835],"study_design_scores_gemma":[0.012236702,0.0029316428,0.9681041,0.00080536073,0.00038255716,0.0020862166,0.001397916,0.00007117749,0.009163349,0.00066085125,0.0020921596,0.00006794173],"about_ca_topic_score_codex":0.0017445103,"about_ca_topic_score_gemma":0.0013683253,"teacher_disagreement_score":0.6806396,"about_ca_system_score_codex":0.000111443565,"about_ca_system_score_gemma":0.0008246157,"threshold_uncertainty_score":0.4077491},"labels":[],"label_agreement":null},{"id":"W4409824143","doi":"10.4103/aja20253","title":"Sexual activity in men undergoing ADT for localized prostate cancer: a narrative literature review","year":2025,"lang":"en","type":"article","venue":"Asian Journal of Andrology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Sexual function; Medicine; Androgen deprivation therapy; Prostate cancer; Sexually active; Confidence interval; Sexual dysfunction; Gynecology; Quality of life (healthcare); Randomized controlled trial; Internal medicine; Cancer; Population","score_opus":0.01672591790270173,"score_gpt":0.3665473244749273,"score_spread":0.3498214065722256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409824143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42354688,0.34379914,0.0005100753,0.22506891,0.00045887104,0.0026236628,0.000042283154,0.000016333275,0.0039338395],"genre_scores_gemma":[0.9278422,0.06625412,0.00032116976,0.0015015356,0.00011171642,0.000092629474,0.000013966894,0.0000137531015,0.0038489145],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907416,0.0001372583,0.00028815473,0.00014393263,0.00011048437,0.0002459926],"domain_scores_gemma":[0.9993429,0.0000905094,0.00015758404,0.000091018286,0.00023320816,0.00008474074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004038124,0.00011162948,0.00052992924,0.00021562027,0.000051456173,0.000011748391,0.00007076686,0.00008751968,0.000028759907],"category_scores_gemma":[0.00012629628,0.00007509433,0.00008680894,0.00034524905,0.00007140784,0.00010580697,0.000019001582,0.00036966449,4.2690698e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055933733,0.0015280149,0.11482153,0.024684006,0.003801499,0.004919117,0.030049087,0.000032257973,0.013051253,0.00062619144,0.089228794,0.6613245],"study_design_scores_gemma":[0.26493135,0.06717572,0.0901834,0.20325533,0.0042657177,0.005356423,0.02073162,0.001128042,0.027702417,0.017312266,0.29609963,0.0018580675],"about_ca_topic_score_codex":0.000006976612,"about_ca_topic_score_gemma":0.00007884852,"teacher_disagreement_score":0.65946645,"about_ca_system_score_codex":0.00017072429,"about_ca_system_score_gemma":0.0009123149,"threshold_uncertainty_score":0.30622578},"labels":[],"label_agreement":null},{"id":"W4409834661","doi":"10.1016/j.jgo.2025.102240","title":"Decision regret in older men with metastatic castration-resistant prostate cancer and associations with treatment received and baseline variables","year":2025,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Princess Margaret Cancer Centre; University of Toronto; Toronto Rehabilitation Institute; Rockyview General Hospital","funders":"Prostate Cancer Canada","keywords":"Medicine; Regret; Prostate cancer; Oncology; Baseline (sea); Internal medicine; Cancer; Gynecology; Gerontology; Demography; Statistics","score_opus":0.019453260203326266,"score_gpt":0.3554230083819791,"score_spread":0.3359697481786528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409834661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845038,0.006227405,0.00016896927,0.007644914,0.000057505284,0.00072112243,0.00003167715,0.0000047529043,0.0006398305],"genre_scores_gemma":[0.96658015,0.01628294,0.014203539,0.00011441692,0.000081779996,0.000083929495,0.000019259203,0.000015727563,0.002618255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897087,0.00012310059,0.00038021087,0.00015873551,0.00018738571,0.00017968909],"domain_scores_gemma":[0.9987853,0.0004800283,0.00026178014,0.00007527109,0.00029450154,0.00010307447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005235494,0.00012421278,0.0004935828,0.00036512595,0.00007298322,0.00002395221,0.000028129914,0.00005506036,0.00002994634],"category_scores_gemma":[0.00008560764,0.00006665892,0.000023176483,0.0004305518,0.000066084736,0.000097139244,0.000011984556,0.00014928334,1.8924555e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059130818,0.0034343486,0.6618933,0.00042239027,0.0038768414,0.0042593763,0.0053050583,0.0006337529,0.007004418,0.00022147958,0.006333127,0.24748507],"study_design_scores_gemma":[0.06279879,0.015687885,0.90604657,0.00087110075,0.0023733734,0.0005615712,0.0021490804,0.0006606224,0.0008618845,0.0006593762,0.0071103317,0.0002193989],"about_ca_topic_score_codex":0.00030582625,"about_ca_topic_score_gemma":0.0011690942,"teacher_disagreement_score":0.24726567,"about_ca_system_score_codex":0.0008255113,"about_ca_system_score_gemma":0.0018601513,"threshold_uncertainty_score":0.32998285},"labels":[],"label_agreement":null},{"id":"W4409913601","doi":"10.1101/2025.04.28.25326584","title":"Identifying Rare Germline Variants Associated with Metastatic Prostate Cancer Through an Extreme Phenotype Study","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; BC Cancer Agency; St. Paul's Hospital; University of British Columbia","funders":"Congressionally Directed Medical Research Programs; National Cancer Institute; Medical Research Council; National Institutes of Health; National Science and Technology Council; National Health and Medical Research Council; Novo Nordisk Fonden; Danmarks Frie Forskningsfond; University of Sydney; University of East Anglia; DOD Prostate Cancer Research Program; Royal Marsden NHS Foundation Trust; Mitacs; BC Children's Hospital; National Institute for Health and Care Research; Novo Nordisk; Petre Foundation; Prostate Cancer Foundation; Movember Foundation; Prostate Cancer UK","keywords":"Nonsynonymous substitution; Prostate cancer; Germline; Germline mutation; Minor allele frequency; Cancer; Allele; Biology; Oncology; Population; Exome; Allele frequency; Genetics; Cancer research; Exome sequencing; Internal medicine; Medicine; Phenotype; Mutation; Gene; Genome","score_opus":0.14224966545621517,"score_gpt":0.40281241304416415,"score_spread":0.26056274758794895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409913601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98697937,0.0046191993,0.00020169995,0.0008513471,0.0006630901,0.004804976,0.000575051,0.00026210878,0.0010431522],"genre_scores_gemma":[0.9802508,0.0014884347,0.00082583877,0.00017700698,0.00018402349,0.0013075004,0.0010201245,0.00010174999,0.014644563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99582964,0.0004644046,0.0006226004,0.0012386686,0.0010990474,0.00074561196],"domain_scores_gemma":[0.99753416,0.00012183988,0.00036117734,0.0010259802,0.00070786633,0.00024898112],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007641611,0.00063234806,0.0012026455,0.00028230727,0.00024050915,0.0001542191,0.00039817503,0.00018375111,0.00045537375],"category_scores_gemma":[0.00019017505,0.0004410587,0.00015099302,0.0007118408,0.0001374518,0.00026458732,0.00049217016,0.0011856424,0.000016007496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004427017,0.007230352,0.93066835,0.0031136428,0.0117129395,0.0050326963,0.029807314,0.00047487777,0.0011990712,0.000065441025,0.00066435605,0.005603956],"study_design_scores_gemma":[0.02603246,0.0031674097,0.94064456,0.0096465545,0.008308801,0.000020603944,0.0042232014,0.0020821488,0.0015979421,0.0019648501,0.0006913416,0.0016201067],"about_ca_topic_score_codex":0.001228662,"about_ca_topic_score_gemma":0.001489945,"teacher_disagreement_score":0.025584113,"about_ca_system_score_codex":0.0005892915,"about_ca_system_score_gemma":0.0017025888,"threshold_uncertainty_score":0.99980414},"labels":[],"label_agreement":null},{"id":"W4409955874","doi":"10.1101/2025.04.25.650369","title":"Longitudinal single-cell RNA sequencing of a neuroendocrine transdifferentiation model reveals transcriptional reprogramming in treatment-induced neuroendocrine prostate cancer","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"BC Cancer Foundation; Türkiye Bilimsel ve Teknolojik Araştırma Kurumu; Terry Fox Research Institute; Canadian Institutes of Health Research; National Science and Technology Council; U.S. Department of Defense","keywords":"Transdifferentiation; Reprogramming; Prostate cancer; Biology; Prostate; Cell; RNA; Cancer research; Cancer; Computational biology; Genetics; Gene","score_opus":0.054488273185840326,"score_gpt":0.2930528945026578,"score_spread":0.2385646213168175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409955874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99127686,0.0031491318,0.00035084804,0.00085441413,0.00044367398,0.0029942933,0.0007027679,0.0002077189,0.000020289857],"genre_scores_gemma":[0.99360853,0.003138777,0.0015550752,0.00006107218,0.00015392253,0.0011797285,0.0000097523225,0.00012003792,0.00017307281],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99545974,0.00018755469,0.0011549084,0.0015228683,0.0006940416,0.0009808796],"domain_scores_gemma":[0.9975565,0.00007054832,0.0004677384,0.0010208667,0.0005643702,0.00031994557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020900439,0.0008207119,0.0013058248,0.0009190582,0.00011767071,0.00009046693,0.0002879804,0.00016001116,0.00003345239],"category_scores_gemma":[0.00006923601,0.0007766339,0.00040673764,0.00089981646,0.000119133714,0.00019410929,0.00013235143,0.00092006114,0.0000022624572],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010742419,0.0012138856,0.040914886,0.002919529,0.00032636942,0.0007557041,0.00008005857,0.0013611483,0.9512038,0.000055030698,0.000009707333,0.00008558899],"study_design_scores_gemma":[0.007552799,0.0007539219,0.04687121,0.0025425495,0.0008417975,4.1897638e-7,0.000011989958,0.011743874,0.92896,0.000007702299,0.00007909337,0.0006346332],"about_ca_topic_score_codex":0.0006196262,"about_ca_topic_score_gemma":0.000050953488,"teacher_disagreement_score":0.022243839,"about_ca_system_score_codex":0.0019665896,"about_ca_system_score_gemma":0.0023246817,"threshold_uncertainty_score":0.99946845},"labels":[],"label_agreement":null},{"id":"W4409979195","doi":"10.1002/minf.202500018","title":"Deep Modeling of Gain‐of‐Function Mutations on Androgen Receptor","year":2025,"lang":"en","type":"article","venue":"Molecular Informatics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Androgen receptor; Prostate cancer; Mutant; Computational biology; Mutation; Antiandrogens; Function (biology); Computer science; Biology; Bioinformatics; Genetics; Gene; Cancer","score_opus":0.01792586232352345,"score_gpt":0.3033978119549671,"score_spread":0.2854719496314437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409979195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7745622,0.00043834533,0.1974779,0.00024704917,0.00009192393,0.00049085845,0.000010060217,0.000023931345,0.026657764],"genre_scores_gemma":[0.9962957,0.00006607378,0.0031580378,0.00016888323,0.000004807958,0.000014824804,0.0001006373,0.00000501627,0.00018604529],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99939805,0.000009519084,0.000275802,0.000037281145,0.0001867941,0.00009255965],"domain_scores_gemma":[0.9995746,0.0000178688,0.000055123026,0.00015384622,0.00016707263,0.000031489068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000079906466,0.000058296682,0.00013276676,0.00017415422,0.000027522272,0.000004443957,0.00003737575,0.000044638953,0.000019304258],"category_scores_gemma":[0.00005255835,0.000046783684,0.00005922648,0.00023305137,0.000031646287,0.000041514028,0.000017708664,0.00007232737,0.000008966092],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047108596,0.0018490265,0.007437673,0.009288666,0.0036384622,0.000038041,0.018956088,0.6455329,0.107508406,0.041680146,0.0026735028,0.15668625],"study_design_scores_gemma":[0.0028097806,0.0006735027,0.000101584425,0.00047441968,0.00022477652,0.0000024608653,0.0017643697,0.7551043,0.23664051,0.0012458492,0.00086274993,0.000095667005],"about_ca_topic_score_codex":0.0000056260487,"about_ca_topic_score_gemma":4.575649e-7,"teacher_disagreement_score":0.22173353,"about_ca_system_score_codex":0.000045379773,"about_ca_system_score_gemma":0.0001105956,"threshold_uncertainty_score":0.19077833},"labels":[],"label_agreement":null},{"id":"W4410014449","doi":"10.1016/j.euo.2025.03.001","title":"Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"Pharmaceuticals Bayer","keywords":"Medicine; Prostate cancer; Oncology; Prostate-specific antigen; Internal medicine; Prostate; Cancer; Clinical trial; Hormone","score_opus":0.030688283063919717,"score_gpt":0.33577459456679093,"score_spread":0.3050863115028712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410014449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97969276,0.010121661,0.0000253613,0.0074123973,0.00010910445,0.0012605455,0.000110605775,0.000026936576,0.0012406021],"genre_scores_gemma":[0.98610824,0.011345281,0.00038656502,0.00049451634,0.000028594253,0.00005048287,0.00006024525,0.00002433567,0.0015017398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960671,0.0023871455,0.00058726687,0.0004629685,0.00015698203,0.00033850313],"domain_scores_gemma":[0.99710596,0.0020996549,0.00034544335,0.00018244066,0.00017797215,0.000088505636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011718181,0.0002153015,0.0011550285,0.0004032817,0.00008545313,0.000015150926,0.000054155957,0.00009516148,0.000011934179],"category_scores_gemma":[0.00056404533,0.00014674131,0.000045920773,0.00027599753,0.0003676187,0.00007152618,0.00007344938,0.00031488386,0.0000052024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07221141,0.000708087,0.81395197,0.00010120268,0.0026583609,0.0033909027,0.009872043,0.000048206624,0.07827566,0.0001624405,0.00076470425,0.017854989],"study_design_scores_gemma":[0.017318305,0.003173708,0.96735847,0.000053759977,0.00042531537,0.000018702976,0.00067459303,0.000081460785,0.0035818648,0.0002943282,0.006876363,0.00014310057],"about_ca_topic_score_codex":0.00022420831,"about_ca_topic_score_gemma":0.000647662,"teacher_disagreement_score":0.1534065,"about_ca_system_score_codex":0.00021057243,"about_ca_system_score_gemma":0.0002951263,"threshold_uncertainty_score":0.59839374},"labels":[],"label_agreement":null},{"id":"W4410018656","doi":"10.5489/cuaj.9240","title":"2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castrationsensitive prostate cancer (Update)","year":2025,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Ottawa; Princess Margaret Cancer Centre; McMaster University; Université de Montréal; University of Alberta; Université Laval; Dalhousie University; University of Toronto; McGill University; University of British Columbia","funders":"Ipsen; Astellas Pharma; Seagen; Canadian Urological Oncology Group; Bavarian Nordic; Sanofi; AstraZeneca; Pfizer; Amgen","keywords":"Guideline; Prostate cancer; Medicine; Oncology; Internal medicine; Cancer; Gynecology; Family medicine; Pathology","score_opus":0.020584141302090787,"score_gpt":0.31662031533452684,"score_spread":0.29603617403243604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410018656","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34022444,0.0033665965,0.000094866424,0.6321793,0.0014985588,0.0022120902,0.001684465,0.00006961632,0.018670049],"genre_scores_gemma":[0.9635632,0.0013533494,0.0006366468,0.02772951,0.00042619664,0.00013354255,0.0005056557,0.000025089044,0.005626805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995762,0.00065406144,0.00087154633,0.0005623312,0.00054880534,0.00160127],"domain_scores_gemma":[0.99438435,0.00050640496,0.0003999645,0.00017466623,0.0015484235,0.0029862076],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001844334,0.00036672657,0.0006659317,0.0011084815,0.0012901921,0.00033851893,0.00017656942,0.00064424076,0.0016033266],"category_scores_gemma":[0.0020011591,0.00031327532,0.00017903626,0.00085984037,0.00013424353,0.00024415657,0.000026613698,0.0013329788,0.000087215274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00023995603,0.00008011548,0.8148998,0.000015965274,0.0010904687,0.0013687141,0.00041285114,0.00012127036,0.00012684471,0.0012314201,0.17145085,0.008961738],"study_design_scores_gemma":[0.0030918578,0.0006426466,0.55252236,0.000039267008,0.0005635529,0.0002906094,0.00063014333,0.00082703185,0.0000251836,0.001941854,0.43907246,0.00035302716],"about_ca_topic_score_codex":0.61376756,"about_ca_topic_score_gemma":0.9232801,"teacher_disagreement_score":0.62333876,"about_ca_system_score_codex":0.015832534,"about_ca_system_score_gemma":0.01814821,"threshold_uncertainty_score":0.99993193},"labels":[],"label_agreement":null},{"id":"W4410018686","doi":"10.5489/cuaj.9228","title":"Summary of changes in the 2025 Canadian Urological Association–Canadian Urologic Oncology Group Guideline on metastatic castration-naive and castration-sensitive prostate cancer","year":2025,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université de Montréal; University of British Columbia","funders":"","keywords":"Prostate cancer; Guideline; Medicine; Oncology; Castration; Internal medicine; Urology; Gynecology; Cancer; Pathology; Hormone","score_opus":0.034367355972301984,"score_gpt":0.32640925651212743,"score_spread":0.2920419005398254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410018686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49539503,0.0015039259,0.0000073734104,0.4896231,0.00047367997,0.0015282838,0.00075257075,0.000015990568,0.010700044],"genre_scores_gemma":[0.9688991,0.0012729293,0.00013216012,0.027859572,0.00021029763,0.00011624437,0.00023727144,0.000011598352,0.0012608732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963622,0.0009676555,0.000684883,0.00039635366,0.0005192489,0.0010696411],"domain_scores_gemma":[0.99681723,0.0009489065,0.00039833452,0.00015327868,0.00073526124,0.00094699964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026761505,0.00027366463,0.0005933341,0.0010267675,0.0005433781,0.0001164983,0.00019496678,0.00048371445,0.00035276575],"category_scores_gemma":[0.001692109,0.00019067344,0.00011339545,0.00088627863,0.00012866693,0.00010522634,0.00001692826,0.0012826017,0.000012278961],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0003456573,0.00013446434,0.94708747,0.000018211955,0.00048618723,0.001021747,0.0009374759,0.0002157983,0.00009936961,0.0014564951,0.039705545,0.008491604],"study_design_scores_gemma":[0.0027173585,0.0018855291,0.8687384,0.000057776684,0.00029419016,0.00011038814,0.001217919,0.0004526846,0.000035172114,0.0015229529,0.122745655,0.00022199174],"about_ca_topic_score_codex":0.505257,"about_ca_topic_score_gemma":0.94914293,"teacher_disagreement_score":0.47350404,"about_ca_system_score_codex":0.0069534834,"about_ca_system_score_gemma":0.0069446363,"threshold_uncertainty_score":0.99868506},"labels":[],"label_agreement":null},{"id":"W4410019190","doi":"10.2967/jnumed.124.269064","title":"A Phase I/II Study of [ <sup>177</sup> Lu]Lu-HTK03170 with Personalized Dosimetry in Patients with Metastatic Castration-Resistant Prostate Cancer: Clinical Trial Protocol","year":2025,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Phase (matter); Chemistry","score_opus":0.05576272752724746,"score_gpt":0.43867043185912297,"score_spread":0.3829077043318755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410019190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95923257,0.00014229355,0.0000034463455,0.0018084483,0.000073083254,0.038551185,0.000015409256,0.000010106007,0.00016344593],"genre_scores_gemma":[0.99693775,0.00005362736,0.00035859065,0.00023394136,0.00019786152,0.0017393198,0.0000100055495,0.00004076159,0.00042813015],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99607354,0.00033041535,0.0015818101,0.00031000844,0.0013729134,0.00033130945],"domain_scores_gemma":[0.9976332,0.00018731513,0.00084384624,0.0002841242,0.0007824252,0.0002690766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013230591,0.0002772551,0.001343338,0.0006037349,0.0001083218,0.000016701124,0.0001774323,0.000067080015,0.00024208461],"category_scores_gemma":[0.0002882401,0.00014372764,0.000112898284,0.0009052477,0.0004102317,0.00016803434,0.00004292257,0.0007116335,7.4419904e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86845297,0.029311383,0.07211881,0.00064269314,0.002212505,0.00081782165,0.007864061,0.000046464516,0.0003106635,0.0000121585945,0.0027486633,0.015461805],"study_design_scores_gemma":[0.7183818,0.2246368,0.037290897,0.0030800586,0.0012969397,0.000017898768,0.012925596,0.00017485059,0.000040972824,0.0000099398885,0.0020031757,0.00014106168],"about_ca_topic_score_codex":0.00018237275,"about_ca_topic_score_gemma":0.000050458155,"teacher_disagreement_score":0.19532542,"about_ca_system_score_codex":0.00027543333,"about_ca_system_score_gemma":0.0011317137,"threshold_uncertainty_score":0.5861043},"labels":[],"label_agreement":null},{"id":"W4410025632","doi":"10.1200/jco-25-00007","title":"Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; McMaster University","funders":"","keywords":"Medicine; Cabazitaxel; Enzalutamide; Guideline; Prostate cancer; Docetaxel; Androgen deprivation therapy; Oncology; Abiraterone; Internal medicine; Family medicine; Intensive care medicine; Gynecology; Cancer; Androgen receptor; Pathology","score_opus":0.16469826149718228,"score_gpt":0.542130665441387,"score_spread":0.37743240394420474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410025632","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032757442,0.99212265,0.0000054204156,0.0012260714,0.00075831177,0.0022558472,0.00011675904,0.000007126437,0.00023205155],"genre_scores_gemma":[0.00040685115,0.99702114,0.000805649,0.0003434494,0.00037182306,0.00010615359,0.00013563091,0.00003812443,0.00077119825],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99195486,0.0010862246,0.00553164,0.00035691168,0.0006914176,0.00037894718],"domain_scores_gemma":[0.9929482,0.0014277956,0.003719236,0.0003042648,0.0012823341,0.0003181682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032919103,0.00038429696,0.005975981,0.00041311843,0.000042733904,0.000020300526,0.00026834547,0.00039607548,0.00008960555],"category_scores_gemma":[0.0008099358,0.0001933247,0.00076220883,0.00053440983,0.00018408048,0.000100084835,0.000045026452,0.0016918184,0.000008884646],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008268208,0.0015135623,0.004278563,0.005952633,0.002067494,0.0010106007,0.000020388674,0.0000055794562,1.179557e-7,0.000009118349,0.0028489344,0.9740248],"study_design_scores_gemma":[0.02159569,0.014857403,0.0026584978,0.033385903,0.0025629667,0.00009042011,0.00002442642,0.000002246851,3.7550635e-7,0.00002381054,0.92460805,0.00019020142],"about_ca_topic_score_codex":0.00006578488,"about_ca_topic_score_gemma":0.000088748246,"teacher_disagreement_score":0.9738346,"about_ca_system_score_codex":0.0009341533,"about_ca_system_score_gemma":0.02003934,"threshold_uncertainty_score":0.98551613},"labels":[],"label_agreement":null},{"id":"W4410051475","doi":"10.1038/s41391-025-00975-8","title":"Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial","year":2025,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Astellas Pharma Global Development; Astellas Pharma Europe","keywords":"Medicine; Enzalutamide; Prostate cancer; Androgen deprivation therapy; Zoledronic acid; Oncology; Internal medicine; Randomized controlled trial; Hormone therapy; Androgen; Urology; Cancer; Hormone; Androgen receptor; Breast cancer","score_opus":0.021572863110218818,"score_gpt":0.3525904308068917,"score_spread":0.33101756769667284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410051475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91368556,0.068411045,0.000036513233,0.0052407198,0.00011720117,0.010852608,0.0015492836,0.000038725255,0.00006831962],"genre_scores_gemma":[0.9308578,0.060852583,0.000101122976,0.0007939648,0.000046585013,0.006473194,0.00029136526,0.00003322959,0.00055017666],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99746823,0.00030976313,0.00073264306,0.00057152484,0.00041886128,0.00049897697],"domain_scores_gemma":[0.99848956,0.00045585714,0.0002379413,0.00027671672,0.00029835448,0.00024159857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061704294,0.00036822294,0.0010313817,0.00036429713,0.00026798595,0.00007682352,0.00008912737,0.00005286078,0.000040147283],"category_scores_gemma":[0.0003011161,0.00023324169,0.00013336497,0.000734899,0.000542053,0.00023827002,0.00010876405,0.000205681,9.114973e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77799475,0.00090453343,0.003462651,0.0006586159,0.0008685253,0.000040375584,0.008075886,0.00003560929,0.0048379493,0.00022973675,0.0006329808,0.2022584],"study_design_scores_gemma":[0.9440744,0.00473182,0.008900203,0.00145392,0.0014193789,0.0000088977185,0.0020495423,0.0012681592,0.029354295,0.0047503756,0.0015069204,0.00048209535],"about_ca_topic_score_codex":0.0006603683,"about_ca_topic_score_gemma":0.00010771869,"teacher_disagreement_score":0.2017763,"about_ca_system_score_codex":0.00019945175,"about_ca_system_score_gemma":0.0009646517,"threshold_uncertainty_score":0.95113206},"labels":[],"label_agreement":null},{"id":"W4410078019","doi":"10.23736/s2241-9136.25.00071-4","title":"The impact of prostate-specific membrane antigen-positron emission tomography imaging on oncologic outcomes in prostate cancer patients with biochemical recurrence after radical local therapy: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Hellenic Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Positron emission tomography; Meta-analysis; Glutamate carboxypeptidase II; Biochemical recurrence; Cancer; Prostate; Radiology; Prostate-specific antigen; Oncology; Internal medicine; Prostatectomy","score_opus":0.03180856935118389,"score_gpt":0.36751829002991593,"score_spread":0.33570972067873206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410078019","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00244192,0.9884926,0.0000022404122,0.000648493,0.000027382053,0.008143855,0.00021048957,0.000016685346,0.000016321466],"genre_scores_gemma":[0.017103577,0.9792334,0.0000080473665,0.0001466323,0.000006335281,0.0030972548,0.00017045836,0.00003251304,0.00020178407],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99576646,0.0010951946,0.0012179456,0.0008410494,0.0004781666,0.00060117384],"domain_scores_gemma":[0.9974689,0.00085271976,0.0005989251,0.00070730556,0.00019747858,0.00017465491],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00072864967,0.0006894984,0.0067487503,0.00066529016,0.0000845263,0.000023262908,0.0002641706,0.0002124991,0.00009620623],"category_scores_gemma":[0.00008266674,0.00026431322,0.0017913523,0.0015362484,0.0005858169,0.00003753219,0.00010876174,0.00075333903,0.0000021912442],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005848974,0.0023703251,0.03423892,0.7119206,0.20336908,0.00029401033,0.0002779971,0.0000035093472,0.0000032373368,0.000003487436,0.00049552496,0.04117429],"study_design_scores_gemma":[0.0075979517,0.0071065268,0.0044081258,0.10796922,0.8620483,0.00006927055,0.000030742915,0.00003890139,0.000038733644,0.000022058704,0.009379367,0.0012907769],"about_ca_topic_score_codex":0.000059107802,"about_ca_topic_score_gemma":0.000009068614,"teacher_disagreement_score":0.65867925,"about_ca_system_score_codex":0.00031197275,"about_ca_system_score_gemma":0.0006143934,"threshold_uncertainty_score":0.9999809},"labels":[],"label_agreement":null},{"id":"W4410085374","doi":"10.1016/j.euo.2025.04.012","title":"Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Janssen Research and Development; Johnson and Johnson","keywords":"Abiraterone acetate; Medicine; Prednisone; Prostate cancer; Abiraterone; Oncology; Castration; Internal medicine; Urology; Cancer; Androgen deprivation therapy; Hormone; Androgen receptor","score_opus":0.08226572202178561,"score_gpt":0.40670531651909064,"score_spread":0.32443959449730503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410085374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746462,0.005152519,0.0006504553,0.01414953,0.0004238574,0.0029806732,0.0001604639,0.000036909267,0.0017993812],"genre_scores_gemma":[0.9912588,0.0015413905,0.00032602245,0.0008872151,0.00011990403,0.00054190535,0.00016675472,0.000025137477,0.0051328437],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974335,0.00084364455,0.0005532144,0.00051010336,0.00014740242,0.0005121486],"domain_scores_gemma":[0.9986454,0.0006806363,0.00015789809,0.0002809167,0.00013375338,0.00010136839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012913689,0.00022755502,0.0007504828,0.00038543477,0.00019051011,0.00003564339,0.00015499262,0.0000683866,0.00008113769],"category_scores_gemma":[0.0001532589,0.00015394429,0.00013233084,0.00048725124,0.00042827113,0.000057495618,0.000098142424,0.0003408307,0.0000062181803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8822148,0.003183578,0.024188815,0.00038113323,0.010705153,0.0024025592,0.0034255174,0.003240578,0.010444147,0.0013094918,0.0030199534,0.055484317],"study_design_scores_gemma":[0.6706325,0.021946944,0.21196932,0.000041033054,0.008480398,0.000047539223,0.00054330047,0.010225518,0.00039187554,0.00047854072,0.07481298,0.00043007007],"about_ca_topic_score_codex":0.00031698664,"about_ca_topic_score_gemma":0.0022357195,"teacher_disagreement_score":0.21158227,"about_ca_system_score_codex":0.00024122791,"about_ca_system_score_gemma":0.00091408537,"threshold_uncertainty_score":0.62776655},"labels":[],"label_agreement":null},{"id":"W4410097456","doi":"10.21203/rs.3.rs-6523400/v1","title":"Clonal Evolution and Transcriptional Plasticity Shape Metastatic Dissemination Routes in Prostate Cancer","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novo Nordisk Fonden; Novo Nordisk","keywords":"Prostate cancer; Cancer; Prostate; Biology; Cancer research; Computational biology; Oncology; Medicine; Genetics","score_opus":0.06266714603926643,"score_gpt":0.4384210334190722,"score_spread":0.37575388737980575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410097456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96099776,0.0244422,0.00014596763,0.0065221423,0.0001818221,0.004090611,0.0024741797,0.00006265207,0.0010826385],"genre_scores_gemma":[0.984119,0.0068486794,0.00021111792,0.000015295722,0.00012311181,0.001576013,0.001034074,0.000022941695,0.0060497653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964557,0.0003584548,0.00037433556,0.0007313396,0.001411365,0.0006688046],"domain_scores_gemma":[0.99823904,0.00049162447,0.0000557218,0.00020749887,0.0007766129,0.00022950616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010102475,0.0002682416,0.00046951495,0.0010821618,0.0001813165,0.000102055536,0.00013939114,0.00017812077,0.00029450646],"category_scores_gemma":[0.00039378816,0.00022192075,0.00010748832,0.00066684943,0.0003248056,0.00012302387,0.00031054174,0.001678849,0.000007569063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014937423,0.003915913,0.7835824,0.045810964,0.0016396461,0.0009924275,0.011539214,0.0013168125,0.01872492,0.014404367,0.005995825,0.09714011],"study_design_scores_gemma":[0.0035649918,0.0005325138,0.95081276,0.010434911,0.00015359769,0.000014139718,0.0010821032,0.025775373,0.0011701739,0.00535796,0.00076929596,0.00033219482],"about_ca_topic_score_codex":0.0014589675,"about_ca_topic_score_gemma":0.0006438648,"teacher_disagreement_score":0.16723037,"about_ca_system_score_codex":0.0016137992,"about_ca_system_score_gemma":0.0020632846,"threshold_uncertainty_score":0.9049666},"labels":[],"label_agreement":null},{"id":"W4410141161","doi":"10.1200/jco-25-00131","title":"Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"SABR volatility model; Medicine; Prostate cancer; Androgen deprivation therapy; Radiation therapy; Internal medicine; Ablative case; Randomized controlled trial; Oncology; Bone metastasis; Urology; Surgery; Cancer","score_opus":0.12960100049302373,"score_gpt":0.5239413866762818,"score_spread":0.39434038618325806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410141161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9586881,0.009179397,0.001304592,0.021440236,0.002949576,0.0058607035,0.000048572478,0.000011015717,0.00051782286],"genre_scores_gemma":[0.96565294,0.022462819,0.0048991246,0.0019083989,0.0007341166,0.00027990452,0.000009944915,0.000051405746,0.0040013636],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943078,0.0017285438,0.0027951887,0.00030871006,0.00045295633,0.00040680234],"domain_scores_gemma":[0.96951073,0.026743863,0.0025113407,0.00028361866,0.00068201346,0.00026843278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064258785,0.00030105407,0.0039387858,0.00033105232,0.00017326853,0.000027310407,0.00021870673,0.00023794668,0.000097521865],"category_scores_gemma":[0.0053610583,0.00015437635,0.001019638,0.0003241528,0.001196737,0.00019344885,0.000041060983,0.0008490687,4.3536747e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92856216,0.0024451283,0.0010113295,0.00009059315,0.017994797,0.000073789524,0.002248281,0.000010272657,0.00010702314,0.00021117003,0.00073569623,0.046509784],"study_design_scores_gemma":[0.92367554,0.057673786,0.0014842062,0.00014786747,0.0024944087,0.000028248744,0.0005522992,0.0007647554,0.00017188929,0.0007942726,0.012088358,0.00012440002],"about_ca_topic_score_codex":0.00006379818,"about_ca_topic_score_gemma":0.000024733952,"teacher_disagreement_score":0.055228658,"about_ca_system_score_codex":0.00067505566,"about_ca_system_score_gemma":0.0037405218,"threshold_uncertainty_score":0.6635525},"labels":[],"label_agreement":null},{"id":"W4410194063","doi":"10.1016/j.eururo.2025.04.022","title":"Corrigendum to “RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression” [Eur. Urol. 76(2) (2019) 157–166]","year":2025,"lang":"en","type":"erratum","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; China Scholarship Council","keywords":"Medicine; Prostate cancer; RNA splicing; Gene; Alternative splicing; Cancer research; Prostate; RNA; Oncology; Internal medicine; Bioinformatics; Cancer; Exon; Genetics; Biology","score_opus":0.01975669613237406,"score_gpt":0.32029214564070396,"score_spread":0.3005354495083299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410194063","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06256081,0.090298176,0.00025884394,0.36610562,0.22661242,0.02919429,0.0033445773,0.00093378883,0.22069147],"genre_scores_gemma":[0.029244294,0.0048760357,0.00009937731,0.014880101,0.0019112654,0.00039284,0.00055478595,0.0002712738,0.94777],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99517095,0.00077101187,0.0008830603,0.0012201901,0.00066609506,0.0012886705],"domain_scores_gemma":[0.9969568,0.00010609936,0.00038833264,0.001439975,0.00064628845,0.00046247625],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042872617,0.0006972712,0.001237573,0.0006181687,0.00026690768,0.000047744263,0.0009660953,0.00015486557,0.00020461497],"category_scores_gemma":[0.00059429504,0.0004527483,0.00031320937,0.0010667092,0.0002977608,0.00003884253,0.0014414109,0.0017335203,0.00020161083],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021738573,0.00020600001,0.005428388,0.000344073,0.00046467752,0.0012211367,0.00024414164,0.000040521732,0.0065187425,0.000040829058,0.9694612,0.0138564175],"study_design_scores_gemma":[0.0025371662,0.001646363,0.025415653,0.0007215203,0.00053837936,0.00008256396,0.00001704261,0.000038867274,0.0054148203,0.000021185204,0.9632406,0.00032583493],"about_ca_topic_score_codex":0.0002160015,"about_ca_topic_score_gemma":0.00008871002,"teacher_disagreement_score":0.72707856,"about_ca_system_score_codex":0.00024670086,"about_ca_system_score_gemma":0.0012721241,"threshold_uncertainty_score":0.9997924},"labels":[],"label_agreement":null},{"id":"W4410236762","doi":"10.1039/d5md00275c","title":"Development and clinical potential of <sup>18</sup>F-PSiMA for prostate cancer PET imaging","year":2025,"lang":"en","type":"article","venue":"RSC Medicinal Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Alberta Cancer Foundation","keywords":"Prostate cancer; Cancer; Prostate; Medicine; Medical physics; Nuclear medicine; Internal medicine","score_opus":0.026472555807054935,"score_gpt":0.3806151280648055,"score_spread":0.3541425722577506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410236762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873737,0.0051053776,0.0002326152,0.0035955773,0.00010738396,0.0006325743,0.000038312715,0.00003170445,0.0028827633],"genre_scores_gemma":[0.9845435,0.0012933383,0.0020997953,0.00029200694,0.00032044575,0.00016591647,0.00012235114,0.000020378377,0.011142265],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985348,0.000013293122,0.00046722413,0.0003521192,0.00030675152,0.00032582844],"domain_scores_gemma":[0.99922484,0.000096698124,0.00008800509,0.00017902484,0.00021418967,0.00019722355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040307746,0.00016494289,0.0004090247,0.000049526065,0.0000856498,0.000010132297,0.00008625911,0.00006279413,0.00017303455],"category_scores_gemma":[0.00014680657,0.00012552823,0.00008746421,0.00012427945,0.00035897826,0.000031646352,0.00007630169,0.00024176284,0.0000010625387],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009504815,0.0010684384,0.36048794,0.014768615,0.0019612648,0.0008387077,0.0013975034,0.000017077884,0.12874061,0.000044646065,0.030786112,0.4503843],"study_design_scores_gemma":[0.04846483,0.00060806714,0.060360152,0.007691369,0.0022400545,0.00040613156,0.0067386525,0.012228355,0.7190375,0.00039603942,0.14095646,0.00087244366],"about_ca_topic_score_codex":0.000026701427,"about_ca_topic_score_gemma":0.0000013417078,"teacher_disagreement_score":0.5902968,"about_ca_system_score_codex":0.00013537782,"about_ca_system_score_gemma":0.001055617,"threshold_uncertainty_score":0.5118893},"labels":[],"label_agreement":null},{"id":"W4410237684","doi":"10.57264/cer-2025-0023","title":"Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USA","year":2025,"lang":"en","type":"article","venue":"Journal of Comparative Effectiveness Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Abiraterone acetate; Medicine; Hazard ratio; Prostate cancer; Confidence interval; Proportional hazards model; Cohort; Internal medicine; Oncology; Urology; Gynecology; Cancer; Androgen deprivation therapy","score_opus":0.09190869354461881,"score_gpt":0.45211489764668883,"score_spread":0.36020620410207005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410237684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963112,0.000072955525,0.00004405456,0.00019241092,0.000046228288,0.0028079657,0.00007275393,0.0000029117848,0.00044954312],"genre_scores_gemma":[0.99941593,0.00007472432,0.00007217493,0.000013164581,0.000012374929,0.00021035859,0.000059489365,0.000015157854,0.00012661722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99380493,0.00295649,0.00064147695,0.00036359552,0.0016951535,0.00053836644],"domain_scores_gemma":[0.9941044,0.0021258853,0.00027375965,0.00026899276,0.0030812442,0.00014570652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021672514,0.00027782208,0.0013702348,0.0029377432,0.00011380487,0.000057035842,0.00020563867,0.000041786687,0.000016561347],"category_scores_gemma":[0.0001013178,0.00014866459,0.0001177491,0.006838413,0.00034628087,0.00025346535,0.000049625713,0.00077522337,0.0000018572705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12042104,0.001736934,0.86030406,0.00016670472,0.0032094256,0.00013365582,0.0026067242,0.010511022,0.00033786832,0.000054866516,0.000011823779,0.0005058966],"study_design_scores_gemma":[0.027510053,0.007649101,0.9587023,0.0011564919,0.0006100675,6.1664366e-7,0.0006432751,0.00040209474,0.0031822661,0.000015139434,0.00000770616,0.0001208921],"about_ca_topic_score_codex":0.0069377436,"about_ca_topic_score_gemma":0.050069254,"teacher_disagreement_score":0.09839825,"about_ca_system_score_codex":0.0013008107,"about_ca_system_score_gemma":0.000985778,"threshold_uncertainty_score":0.99967515},"labels":[],"label_agreement":null},{"id":"W4410264723","doi":"10.21203/rs.3.rs-6536216/v1","title":"Molecular subtyping of endometrial carcinoma cell lines uncovers subtype-specific targetable vulnerabilities","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; University of British Columbia; Terry Fox Research Institute","keywords":"Subtyping; Cancer research; Biology; Computer science; Programming language","score_opus":0.06795126714508072,"score_gpt":0.37867833175208043,"score_spread":0.3107270646069997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410264723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90315866,0.06699581,0.00012277286,0.0010796676,0.00081884576,0.003958419,0.00092091993,0.000091240516,0.022853678],"genre_scores_gemma":[0.9784729,0.0071790596,0.0005660101,0.000016151116,0.0005196326,0.00039189175,0.00091419887,0.000062395804,0.011877757],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9940074,0.0007789878,0.0007050571,0.0010424496,0.002283078,0.0011830012],"domain_scores_gemma":[0.9945107,0.0012174696,0.00015947378,0.0014212277,0.0023295404,0.00036159877],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0022532856,0.0004493482,0.0011533854,0.0021613059,0.00023287385,0.00011248809,0.00056267914,0.0005599034,0.00052776025],"category_scores_gemma":[0.0010689058,0.00037932396,0.0005814623,0.0017013412,0.0005765668,0.0000815066,0.0013498433,0.002479723,0.00003440737],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039996736,0.007059675,0.5213881,0.15270527,0.0035791988,0.004240033,0.0076656914,0.007143562,0.16199706,0.006272517,0.07156612,0.016386],"study_design_scores_gemma":[0.01159931,0.002240708,0.006349356,0.004337808,0.0002232044,0.000008245588,0.0030785918,0.0005801918,0.92951214,0.002853875,0.03845669,0.00075986405],"about_ca_topic_score_codex":0.0019683081,"about_ca_topic_score_gemma":0.000025307618,"teacher_disagreement_score":0.76751506,"about_ca_system_score_codex":0.0010764196,"about_ca_system_score_gemma":0.0040506045,"threshold_uncertainty_score":0.9998659},"labels":[],"label_agreement":null},{"id":"W4410338114","doi":"10.1016/j.euo.2025.02.015","title":"Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health","funders":"Bayer; Astellas Pharma US","keywords":"Medicine; Docetaxel; Pembrolizumab; Prostate cancer; Prednisone; Oncology; Internal medicine; Abiraterone; Enzalutamide; Cancer; Immunotherapy","score_opus":0.017536134480207105,"score_gpt":0.3190061985177405,"score_spread":0.3014700640375334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410338114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99025184,0.00064925686,0.00005672992,0.0035293289,0.00010494785,0.0025923946,0.00007589979,0.00004340498,0.0026961872],"genre_scores_gemma":[0.9957172,0.00010933024,0.00095973205,0.00082932436,0.000014672794,0.00043865532,0.00013410447,0.000040216353,0.0017567523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809027,0.00027620993,0.000443701,0.0005305027,0.00017223893,0.00048707693],"domain_scores_gemma":[0.9989315,0.0002316225,0.00019885346,0.00025015807,0.0002667271,0.00012111219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021610301,0.00025507575,0.0005929867,0.00028626065,0.00011774788,0.000017335937,0.00006999901,0.000060382456,0.00002502194],"category_scores_gemma":[0.00010615444,0.00016101162,0.000038207927,0.00025604462,0.0003643494,0.00007674751,0.000058687037,0.00024981122,0.000003017726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04372539,0.0015873468,0.93566346,0.00020479367,0.0010259039,0.0010707779,0.0011629815,0.00007145365,0.00034102314,0.0001312745,0.00040284937,0.014612747],"study_design_scores_gemma":[0.045846827,0.0134724,0.9319726,0.00006731837,0.0005544066,0.0000420587,0.00015667167,0.000070173985,0.000098621866,0.00007194131,0.00746732,0.00017963188],"about_ca_topic_score_codex":0.000100637764,"about_ca_topic_score_gemma":0.0005806677,"teacher_disagreement_score":0.014433116,"about_ca_system_score_codex":0.00020788415,"about_ca_system_score_gemma":0.0006661122,"threshold_uncertainty_score":0.6565863},"labels":[],"label_agreement":null},{"id":"W4410386494","doi":"10.1016/j.euf.2025.03.019","title":"Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis","year":2025,"lang":"en","type":"review","venue":"European Urology Focus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Agencja Badań Medycznych; Narodowa Agencja Wymiany Akademickiej; European Association of Urology","keywords":"Medicine; Prostate cancer; Androgen receptor; Oncology; Prostate-specific antigen; Internal medicine; Meta-analysis; Prostate; Overall survival; Cancer","score_opus":0.044516159017228954,"score_gpt":0.31639695442617677,"score_spread":0.27188079540894783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410386494","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004249321,0.9658645,0.0000022936847,0.00036378243,0.000030578823,0.026612312,0.0027174917,0.00008019132,0.0000795383],"genre_scores_gemma":[0.0013810426,0.98835963,0.000057606358,0.00013770489,0.00002803002,0.0051452946,0.0011038345,0.00019569331,0.0035911724],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99234545,0.0034998043,0.0013796856,0.001441093,0.00052833755,0.0008056367],"domain_scores_gemma":[0.9965847,0.00086374796,0.00085425517,0.00088024006,0.0005229493,0.00029410917],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013257072,0.0010658281,0.007919691,0.0009767686,0.00012937178,0.00008063008,0.00026417105,0.00019500495,0.00012224246],"category_scores_gemma":[0.00038230023,0.00054657215,0.00091988075,0.0016627465,0.00022742625,0.00010323222,0.0001325416,0.00056363636,0.00002948362],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01982617,0.00084877375,0.0073323366,0.7723713,0.18930322,0.0010900352,0.0004734112,0.0000012455764,0.0000012625263,0.000004562588,0.00024838853,0.008499316],"study_design_scores_gemma":[0.009104498,0.010555197,0.0023866722,0.07685478,0.7907206,0.00004013482,0.000017795264,8.018701e-7,0.00000698066,0.0000021561846,0.10907642,0.0012339574],"about_ca_topic_score_codex":0.0000382112,"about_ca_topic_score_gemma":0.000038873528,"teacher_disagreement_score":0.69551647,"about_ca_system_score_codex":0.00029064398,"about_ca_system_score_gemma":0.0009077335,"threshold_uncertainty_score":0.9996986},"labels":[],"label_agreement":null},{"id":"W4410438430","doi":"10.1148/rycan.240390","title":"Comparison of Prostate-specific Membrane Antigen Reporting and Data System Version 1.0 versus 2.0 for Prostate Cancer Assessment","year":2025,"lang":"en","type":"article","venue":"Radiology Imaging Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Prostate cancer; Glutamate carboxypeptidase II; Prostate; Prostate-specific antigen; Medicine; Antigen; Cancer; Urology; Oncology; Internal medicine; Immunology","score_opus":0.09565663594394183,"score_gpt":0.47343412674540697,"score_spread":0.37777749080146517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410438430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9176873,0.06908839,0.00044206125,0.0055665937,0.0020207067,0.0032496022,0.0006148548,0.00011890253,0.0012116098],"genre_scores_gemma":[0.98949295,0.0072152507,0.0014007187,0.000056248737,0.00014135253,0.00052159524,0.00049039454,0.000027367392,0.00065409474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784666,0.000068886715,0.0007780773,0.00066796097,0.0002004134,0.00043797639],"domain_scores_gemma":[0.9982693,0.00020246042,0.0005786314,0.00058222556,0.0002751978,0.000092175294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007220014,0.00020150637,0.00075618934,0.00019035458,0.0001967183,0.000024642228,0.00017822596,0.000073885734,0.000023208479],"category_scores_gemma":[0.00009054388,0.0001615331,0.00005974329,0.00024603072,0.00027658534,0.00013064266,0.00018304642,0.00022316872,6.642467e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035394705,0.00008337759,0.91586643,0.0019506203,0.0005617446,0.000038244965,0.0003762923,0.00007278071,0.027619852,0.00012354426,0.015325988,0.034441657],"study_design_scores_gemma":[0.05657624,0.0014682063,0.42198253,0.007883094,0.002263467,0.00015002783,0.009480271,0.10807592,0.13038665,0.00006258091,0.26053575,0.0011352529],"about_ca_topic_score_codex":0.00044176308,"about_ca_topic_score_gemma":0.000033313267,"teacher_disagreement_score":0.4938839,"about_ca_system_score_codex":0.0006136782,"about_ca_system_score_gemma":0.0008167379,"threshold_uncertainty_score":0.65871286},"labels":[],"label_agreement":null},{"id":"W4410568479","doi":"10.1080/13696998.2025.2503660","title":"Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"Sanofi; AstraZeneca; Pfizer; Astellas Pharma; Bristol-Myers Squibb","keywords":"Enzalutamide; Medicine; Androgen deprivation therapy; Prostate cancer; Oncology; Internal medicine; Castration; Androgen; Cancer; Androgen receptor; Hormone","score_opus":0.03357280887964614,"score_gpt":0.33903134205413193,"score_spread":0.3054585331744858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410568479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936186,0.002369288,0.00034669775,0.0018161429,0.00027847296,0.0014111045,0.00015189317,0.0000010045652,0.0000067714354],"genre_scores_gemma":[0.9699394,0.029614566,0.00020589889,0.000034232155,0.00005007513,0.00011534216,0.000023267916,0.0000094058005,0.000007810354],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988298,0.00007696635,0.0005322349,0.0001332811,0.0002631428,0.00016457062],"domain_scores_gemma":[0.99780196,0.001254434,0.0004070412,0.000119359465,0.00030717373,0.00011001359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058452785,0.00012552379,0.00055141514,0.00010636668,0.000031369374,0.0000061499723,0.00008780873,0.000046886125,0.00001375727],"category_scores_gemma":[0.00012038645,0.000070335314,0.00008188406,0.00014420871,0.00012378675,0.00004459035,0.000009009992,0.00015935664,6.588789e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14457998,0.0022079884,0.11041428,0.0007534954,0.006957375,0.00016059614,0.0016685936,0.007930812,0.0032678307,0.0001815149,0.00019109466,0.7216864],"study_design_scores_gemma":[0.14742336,0.015783116,0.19230813,0.0032435746,0.0013117741,0.00006187429,0.002849898,0.0131899,0.6219479,0.00035291788,0.0012176579,0.00030991365],"about_ca_topic_score_codex":0.086947374,"about_ca_topic_score_gemma":0.15561828,"teacher_disagreement_score":0.72137654,"about_ca_system_score_codex":0.001550342,"about_ca_system_score_gemma":0.0068069617,"threshold_uncertainty_score":0.9988235},"labels":[],"label_agreement":null},{"id":"W4410614974","doi":"10.47248/chp2502020009","title":"Luminal Transcription Factor Hierarchy Shapes the AR Cistrome in Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Heterogeneity and Plasticity","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Transcription factor; Hierarchy; Prostate; Transcription (linguistics); Biology; Cancer; Oncology; Cancer research; Medicine; Internal medicine; Genetics; Political science; Gene","score_opus":0.03353884538747622,"score_gpt":0.333081068735769,"score_spread":0.2995422233482928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410614974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881477,0.00729082,0.000068171874,0.0030811988,0.00023116973,0.000657714,0.00031517338,0.000027644504,0.0001804342],"genre_scores_gemma":[0.9933661,0.005099655,0.000018649222,0.00044034707,0.000113158254,0.00032631273,0.000015728041,0.0000100768875,0.0006099504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987723,0.00008633931,0.000216333,0.0003457711,0.00020479767,0.00037446353],"domain_scores_gemma":[0.99954844,0.00012281183,0.000037226277,0.00010229041,0.00007062917,0.000118596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012530842,0.00018468172,0.00028381773,0.000120735014,0.00018733308,0.00004590796,0.00008848081,0.00007654914,0.00011161689],"category_scores_gemma":[0.000031227086,0.00012014973,0.00007107496,0.0002867259,0.000257171,0.000093668605,0.00003649958,0.0003344697,0.0000026163164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004677088,0.00024133956,0.8997606,0.00093447417,0.00034986777,0.000075655305,0.001202109,0.00014261718,0.058435477,0.000118167045,0.00039639956,0.033666212],"study_design_scores_gemma":[0.0026540754,0.00017794286,0.9535267,0.0004427577,0.000119274744,0.000008417983,0.00007281862,0.0009439306,0.036410607,0.00013799933,0.005359549,0.00014595478],"about_ca_topic_score_codex":0.00076363486,"about_ca_topic_score_gemma":0.00301924,"teacher_disagreement_score":0.05376608,"about_ca_system_score_codex":0.00025811107,"about_ca_system_score_gemma":0.00033053829,"threshold_uncertainty_score":0.48995638},"labels":[],"label_agreement":null},{"id":"W4410785948","doi":"10.1038/s41591-025-03704-9","title":"Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"National Health and Medical Research Council; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Michael Smith Health Research BC; Prostate Cancer Foundation","keywords":"Cabazitaxel; Lutetium; Medicine; Prostate cancer; Prostate; Oncology; Cancer research; Cancer; Internal medicine; Pharmacology; Chemistry","score_opus":0.02543317374760138,"score_gpt":0.41588751258358053,"score_spread":0.39045433883597913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410785948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95233464,0.024042886,0.000033267017,0.016380273,0.000835117,0.004920629,0.000077589924,0.000033600005,0.0013420162],"genre_scores_gemma":[0.9921746,0.001244405,0.00008102517,0.0013186091,0.00019303325,0.0005036645,0.00009987847,0.000022358054,0.004362421],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99687713,0.0004779738,0.0009265144,0.00044212767,0.0008554234,0.00042085073],"domain_scores_gemma":[0.99760634,0.0010686057,0.00035017153,0.00054904644,0.0003119929,0.00011381945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018759646,0.00030120232,0.0020541113,0.0010115827,0.00010291929,0.000011573344,0.00024453615,0.00013836099,0.00046585072],"category_scores_gemma":[0.002203687,0.00013297457,0.0004343134,0.0044648913,0.00052902824,0.000055481127,0.00006160129,0.0009522975,6.636975e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9467667,0.0009520715,0.003612964,0.0006872988,0.009932756,0.00034810565,0.0050277985,0.00008026099,0.015101622,0.00026203532,0.0014934363,0.015734995],"study_design_scores_gemma":[0.9731546,0.00062584435,0.0025726422,0.0014705169,0.009690162,0.000008172645,0.000900118,0.0036740853,0.0062800143,0.00022734374,0.0012402496,0.00015625206],"about_ca_topic_score_codex":0.0008952246,"about_ca_topic_score_gemma":0.00058147596,"teacher_disagreement_score":0.039839983,"about_ca_system_score_codex":0.00029288017,"about_ca_system_score_gemma":0.0009875044,"threshold_uncertainty_score":0.54225457},"labels":[],"label_agreement":null},{"id":"W4410808236","doi":"10.1200/jco.2025.43.16_suppl.e17127","title":"Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) plus leuprolide (combo): EMBARK post hoc analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Post-hoc analysis; Oncology; Internal medicine; Cancer; Prostate; Gynecology; Urology; Androgen receptor","score_opus":0.03541493979559037,"score_gpt":0.41242726676455077,"score_spread":0.3770123269689604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907725,0.0024116274,0.0000148697045,0.0045468267,0.00021713717,0.001234215,0.0003191479,0.000019569927,0.00046412766],"genre_scores_gemma":[0.99065804,0.005961902,0.00082025304,0.0011201673,0.0000792443,0.00012786458,0.00020521418,0.000035994846,0.0009913202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951621,0.00065048673,0.0023067668,0.0006065357,0.0006493317,0.0006247472],"domain_scores_gemma":[0.9947142,0.001508304,0.001713091,0.000346407,0.0011936886,0.000524293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089488097,0.00046211516,0.0031421017,0.00067945744,0.00010054438,0.000030121782,0.00022156052,0.00039355241,0.00010555212],"category_scores_gemma":[0.0005939793,0.00024352923,0.00056578795,0.0010149573,0.00065150607,0.00015297632,0.00007046098,0.0013676779,0.0000060348452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08149604,0.0048544807,0.7833293,0.00004407757,0.008374255,0.00050413946,0.00022428102,0.00004098343,0.000039035156,0.000008161306,0.00070926035,0.120376],"study_design_scores_gemma":[0.07842653,0.052420508,0.8598349,0.0003787751,0.005271155,0.0000110613155,0.00021248385,0.000030657968,0.00088235125,0.000042591808,0.0022483899,0.00024058603],"about_ca_topic_score_codex":0.0008930006,"about_ca_topic_score_gemma":0.0018238433,"teacher_disagreement_score":0.12013541,"about_ca_system_score_codex":0.0025267333,"about_ca_system_score_gemma":0.0063784337,"threshold_uncertainty_score":0.99925447},"labels":[],"label_agreement":null},{"id":"W4410809237","doi":"10.1200/jco.2025.43.16_suppl.e17074","title":"Impact of BRCA alterations on androgen receptor pathway inhibition treatment outcome in advanced prostate cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Oncology; Internal medicine; Cancer; Androgen; Prostate; Urothelial cancer; Hormone; Bladder cancer","score_opus":0.1388894687987531,"score_gpt":0.5490300485300793,"score_spread":0.4101405797313262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894576,0.0009309593,0.000005870475,0.0072459956,0.00046142587,0.00050900935,0.000044234555,0.0000045216575,0.0013403504],"genre_scores_gemma":[0.9936036,0.003996308,0.0003352383,0.00026786362,0.00017472485,0.000035180314,0.000016076572,0.000008215089,0.001562818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975028,0.00025144228,0.0016921499,0.00015458663,0.0002001028,0.00019890069],"domain_scores_gemma":[0.9979443,0.00071896095,0.0006961763,0.00013318137,0.0003346122,0.00017274938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083807553,0.00012167345,0.0010877026,0.00027779728,0.000028569726,0.000005024184,0.000050121394,0.00017259072,0.000121855985],"category_scores_gemma":[0.0006612207,0.00007054629,0.00044932985,0.0002611426,0.000108478256,0.00008437212,0.00001689557,0.00042171622,0.000004887775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016459981,0.0039005287,0.71379614,0.000038646376,0.00047008612,0.00022643957,0.0001783401,0.00026200069,0.0030726255,0.00006949164,0.0008520364,0.26067367],"study_design_scores_gemma":[0.04969182,0.08044767,0.8410634,0.00085102284,0.00024680403,0.000029322324,0.00013546484,0.00008172448,0.011628861,0.00047902914,0.0152202565,0.00012467605],"about_ca_topic_score_codex":0.0000860467,"about_ca_topic_score_gemma":0.00011508188,"teacher_disagreement_score":0.26054898,"about_ca_system_score_codex":0.0012985576,"about_ca_system_score_gemma":0.0037371463,"threshold_uncertainty_score":0.6629537},"labels":[],"label_agreement":null},{"id":"W4410809328","doi":"10.1200/jco.2025.43.16_suppl.tps5131","title":"Darolutamide plus androgen deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Lévis; McGill University","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Placebo; Oncology; Internal medicine; Biochemical recurrence; Cancer; Urology; Prostatectomy; Pathology","score_opus":0.06389345534634007,"score_gpt":0.4574562585545091,"score_spread":0.39356280320816905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905271,0.0019033352,0.00004261045,0.0013067506,0.00042613858,0.0056604757,0.000016332595,0.000007119994,0.00011017331],"genre_scores_gemma":[0.9939547,0.0050528045,0.00028894102,0.00014083172,0.00014447776,0.00027816437,0.000015770756,0.000014733914,0.00010955741],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99460506,0.0011683172,0.0029677998,0.0003231538,0.00062817615,0.00030749006],"domain_scores_gemma":[0.9935529,0.0027335035,0.0022460707,0.00024239229,0.0010081884,0.00021690215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053074164,0.0002237007,0.003399308,0.0004153849,0.00004544457,0.0000124609505,0.00021176635,0.00026059145,0.000035192403],"category_scores_gemma":[0.0017826268,0.00012344455,0.00035966234,0.0005094537,0.000398335,0.00012507047,0.000056367684,0.001061889,0.000001212523],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5999651,0.0068579274,0.34909678,0.000023461267,0.0015801957,0.000060336795,0.00020699277,0.000036450194,0.000017613625,0.0000057374605,0.0001147885,0.042034622],"study_design_scores_gemma":[0.93365186,0.02010154,0.043744612,0.0003139776,0.00091692404,0.0000034625825,0.00013528927,0.00018831568,0.00057489745,0.00013249506,0.00013988416,0.00009675916],"about_ca_topic_score_codex":0.00024256161,"about_ca_topic_score_gemma":0.00009259941,"teacher_disagreement_score":0.33368674,"about_ca_system_score_codex":0.00040794403,"about_ca_system_score_gemma":0.0037599704,"threshold_uncertainty_score":0.6670026},"labels":[],"label_agreement":null},{"id":"W4410809397","doi":"10.1200/jco.2025.43.16_suppl.tps5129","title":"TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Queen's University; University of British Columbia; Ottawa Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Docetaxel; Prostate cancer; Oncology; Androgen receptor; Internal medicine; Clinical trial; Cancer","score_opus":0.0929500768874752,"score_gpt":0.48969468820828876,"score_spread":0.39674461132081357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98379,0.0004456666,0.00028011904,0.008094979,0.0011935531,0.005985557,0.00017798945,0.0000048799866,0.000027248998],"genre_scores_gemma":[0.9954951,0.0009293315,0.001954704,0.0004537904,0.00046557,0.00031851386,0.000041751915,0.000018163233,0.00032311937],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99319965,0.0023337898,0.0033829205,0.0003223408,0.00046083436,0.00030048622],"domain_scores_gemma":[0.9831065,0.0134884585,0.0017311104,0.00016821787,0.0012231692,0.00028257407],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013475521,0.00020455087,0.0025438985,0.00029987603,0.00007812606,0.00001855222,0.00009404124,0.00023088705,0.000033770062],"category_scores_gemma":[0.010422922,0.000107356645,0.0004799103,0.0003791064,0.00051678054,0.00014437415,0.000043325774,0.00073023763,7.9509374e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.897622,0.0032533768,0.0032941436,0.00004920969,0.0012688914,0.00007495132,0.0003541782,0.00001880134,0.00009701282,0.000015479,0.0013785204,0.092573434],"study_design_scores_gemma":[0.9310322,0.049469866,0.012592485,0.0004231642,0.0012922442,0.000009521591,0.00045756757,0.0002973341,0.00065594574,0.000072882365,0.0035920665,0.000104744955],"about_ca_topic_score_codex":0.0000465133,"about_ca_topic_score_gemma":0.00010328513,"teacher_disagreement_score":0.09246869,"about_ca_system_score_codex":0.0002321616,"about_ca_system_score_gemma":0.004150706,"threshold_uncertainty_score":0.9979127},"labels":[],"label_agreement":null},{"id":"W4410809399","doi":"10.1200/jco.2025.43.16_suppl.tps5118","title":"Trial in progress (XALute): Phase 3 study of xaluritamig vs investigator’s choice of cabazitaxel or second androgen receptor directed therapy (ARDT) in post-taxane metastatic castration-resistant prostate cancer (mCRPC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Amgen","keywords":"Cabazitaxel; Medicine; Taxane; Prostate cancer; Androgen receptor; Oncology; Androgen deprivation therapy; Internal medicine; Androgen; Cancer; Prostate; Gynecology; Breast cancer; Hormone","score_opus":0.17402627177558466,"score_gpt":0.5335429345411211,"score_spread":0.35951666276553645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98775613,0.004271193,3.3897703e-7,0.004086204,0.0006562213,0.003057434,0.00009256841,0.000007605318,0.00007227701],"genre_scores_gemma":[0.99616975,0.0018951127,0.00061972893,0.00029428597,0.00019742508,0.00019109076,0.000016571214,0.000020790261,0.00059526594],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99345696,0.0014854429,0.0038072143,0.00031977965,0.0005834748,0.00034715777],"domain_scores_gemma":[0.99408054,0.0023754255,0.0019327835,0.00024325728,0.0010375824,0.00033038185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034899716,0.00022994101,0.0023773743,0.00060118205,0.0000320184,0.000011510842,0.00022943683,0.00022730324,0.00032889567],"category_scores_gemma":[0.0042912406,0.00014443793,0.00025141623,0.000877385,0.00043164726,0.00016398527,0.00004855432,0.00094110525,7.368619e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66563636,0.035462033,0.17983057,0.00040439566,0.002344777,0.0011789082,0.0023772856,0.000012889543,0.0062948894,0.00000850518,0.0014647841,0.104984626],"study_design_scores_gemma":[0.618127,0.15324491,0.21112789,0.00097525615,0.0006292175,0.000021238804,0.0026752013,0.00007487669,0.005475757,0.00009297674,0.0073392363,0.00021641405],"about_ca_topic_score_codex":0.0007137568,"about_ca_topic_score_gemma":0.008087004,"teacher_disagreement_score":0.11778288,"about_ca_system_score_codex":0.00037460343,"about_ca_system_score_gemma":0.011500556,"threshold_uncertainty_score":0.9941033},"labels":[],"label_agreement":null},{"id":"W4410809403","doi":"10.1200/jco.2025.43.16_suppl.tps5111","title":"Phase 1, open-label, first-in-human study of ABBV-969, a dual variable antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AbbVie","keywords":"Medicine; Conjugate; Antibody-drug conjugate; Prostate cancer; Castration; Antibody; Orchiectomy; Prostate; Oncology; Cancer; Internal medicine; Monoclonal antibody; Immunology; Hormone","score_opus":0.11713708280343747,"score_gpt":0.5319695346725988,"score_spread":0.4148324518691613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949873,0.0003605081,0.0000046702667,0.0016191325,0.00027606147,0.0019626424,0.000032824377,0.0000031769707,0.0007536758],"genre_scores_gemma":[0.99797744,0.000285227,0.00068766973,0.00019599783,0.000048506172,0.000054350523,0.000019845198,0.000014003179,0.0007169669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958172,0.0005387489,0.0025718347,0.00028102117,0.0004699888,0.00032120082],"domain_scores_gemma":[0.996738,0.00092009146,0.0011910467,0.00021279728,0.00074042886,0.00019763212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027614622,0.00017466467,0.0017698039,0.00034331268,0.000067666646,0.000024836729,0.00022780368,0.00009626853,0.00008504121],"category_scores_gemma":[0.0005611253,0.000111317124,0.00006108652,0.00062615186,0.00017385081,0.00023389173,0.00010256067,0.00078710075,8.6106763e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07610871,0.09590287,0.81603277,0.00028610017,0.0013310434,0.0019754802,0.00090471556,0.00018721541,0.00043946333,0.0001224794,0.0010918174,0.00561733],"study_design_scores_gemma":[0.33353212,0.10464587,0.55631006,0.0012725448,0.0007180972,0.000009245229,0.001194299,0.00011157564,0.00013305039,0.0002804228,0.0016450429,0.0001476762],"about_ca_topic_score_codex":0.0014130562,"about_ca_topic_score_gemma":0.004050314,"teacher_disagreement_score":0.25972274,"about_ca_system_score_codex":0.00037113836,"about_ca_system_score_gemma":0.0039620893,"threshold_uncertainty_score":0.7028576},"labels":[],"label_agreement":null},{"id":"W4410809617","doi":"10.1200/jco.2025.43.16_suppl.tps5119","title":"A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator’s choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - rechARge).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Oncology; Internal medicine; Androgen; Cabazitaxel; Androgen deprivation therapy; Castration; Cancer; Hormone","score_opus":0.14199423844536826,"score_gpt":0.4844084449019102,"score_spread":0.34241420645654197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877843,0.000898885,0.0000012895598,0.008069195,0.0015554309,0.0013781812,0.000045645313,0.000008126998,0.00025892004],"genre_scores_gemma":[0.9966515,0.0009223003,0.00074354344,0.00051178475,0.00027553077,0.000075261596,0.000019366113,0.000020277012,0.0007804661],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99623245,0.0007325563,0.0019514121,0.0002283811,0.0005722258,0.00028297387],"domain_scores_gemma":[0.9955743,0.0017728145,0.0013532237,0.00022572633,0.00075890165,0.00031505837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016576577,0.00017371729,0.0012330035,0.00020367728,0.000060039376,0.000012043863,0.00019267536,0.00018767331,0.00005863638],"category_scores_gemma":[0.0040387437,0.00009170813,0.00025789137,0.0006827411,0.00038580626,0.00011610083,0.000040368297,0.0008961729,0.0000013952834],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7813131,0.01097963,0.15541837,0.00016800052,0.0019651037,0.00009668404,0.00030578426,0.00001197959,0.0010906606,0.00003836795,0.0070399567,0.041572347],"study_design_scores_gemma":[0.810478,0.058266368,0.09657516,0.0010864442,0.0014240163,0.000003884883,0.00015424944,0.00004526689,0.0071601216,0.00011301332,0.024521548,0.00017197596],"about_ca_topic_score_codex":0.00020292852,"about_ca_topic_score_gemma":0.000634759,"teacher_disagreement_score":0.05884321,"about_ca_system_score_codex":0.00043860485,"about_ca_system_score_gemma":0.009132175,"threshold_uncertainty_score":0.9964851},"labels":[],"label_agreement":null},{"id":"W4410809622","doi":"10.1200/jco.2025.43.16_suppl.tps5122","title":"A randomized phase III trial investigating platinum and taxane chemotherapy in metastatic castration resistant prostate cancer (mCRPC) patients with alterations in DNA damage response (DDR) genes (OPTION-DDR) CCTG-PR-25 NCT06439225.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; University of Ottawa; McMaster University; Queen's University; Juravinski Cancer Centre; Ottawa Hospital; BC Cancer Agency; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Taxane; Medicine; Prostate cancer; Oncology; Chemotherapy; Internal medicine; Cancer; Prostate; Cancer research; Breast cancer","score_opus":0.10356424987557518,"score_gpt":0.48814089601623,"score_spread":0.38457664614065484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410809622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98598003,0.0006524321,0.00006749958,0.01048526,0.0002798097,0.002413123,0.00002012744,0.0000064428036,0.00009525095],"genre_scores_gemma":[0.9948116,0.0010694885,0.0026235394,0.00059566536,0.0001587699,0.00018475999,0.000028093513,0.000016501483,0.00051155884],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942792,0.0020858971,0.0026717593,0.00028045088,0.00039634499,0.0002863701],"domain_scores_gemma":[0.99377877,0.004074064,0.0013353835,0.00014833448,0.00043786434,0.00022558794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066448743,0.00019717605,0.0017804331,0.0004886347,0.00008235739,0.00003796558,0.0000833083,0.00016592312,0.000037014728],"category_scores_gemma":[0.0041780807,0.00012519167,0.00016040377,0.00045825774,0.0004390739,0.00023117347,0.00002664512,0.000760582,6.025711e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95967025,0.0023185129,0.015246461,0.00006372915,0.00042263832,0.00028067388,0.00096930726,0.000078795885,0.0020704975,0.000044541674,0.00010197882,0.018732624],"study_design_scores_gemma":[0.9308872,0.009978034,0.055306427,0.0006393605,0.00030659605,0.000009068416,0.00036332343,0.0010863862,0.00041571414,0.00042987612,0.000467466,0.000110538116],"about_ca_topic_score_codex":0.0001745252,"about_ca_topic_score_gemma":0.0010118316,"teacher_disagreement_score":0.040059965,"about_ca_system_score_codex":0.00036791604,"about_ca_system_score_gemma":0.0040109735,"threshold_uncertainty_score":0.7115295},"labels":[],"label_agreement":null},{"id":"W4410811254","doi":"10.1200/jco.2025.43.16_suppl.5084","title":"Transcriptional profiling to identify a program of enzalutamide extreme non-response in lethal prostate cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Profiling (computer programming); Oncology; Cancer; Internal medicine; Androgen receptor","score_opus":0.20976517362380884,"score_gpt":0.5743259524163564,"score_spread":0.36456077879254756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97691417,0.001464851,0.00008143475,0.019055296,0.0008026924,0.0010421464,0.000012086002,0.000007730418,0.00061962055],"genre_scores_gemma":[0.9918872,0.0007040682,0.0049905996,0.0006355215,0.00025111652,0.000097550444,0.000002882799,0.00001168232,0.001419376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963523,0.00050327455,0.0021600425,0.00021604709,0.00044905144,0.0003192853],"domain_scores_gemma":[0.99715364,0.0012496153,0.0005390218,0.00013706146,0.0006399327,0.0002807323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050855903,0.00012827077,0.0011919955,0.00047174105,0.000026515927,0.000009173255,0.00017379217,0.00025045496,0.00006663473],"category_scores_gemma":[0.002136129,0.000090623944,0.00037777892,0.000524315,0.0002214745,0.00009429187,0.000045190875,0.0009290051,0.0000041984736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19157627,0.0058947834,0.41768953,0.00034478842,0.0006621779,0.001699325,0.00065297855,0.00014523961,0.072153896,0.000102784004,0.0012505692,0.30782765],"study_design_scores_gemma":[0.016554195,0.01703529,0.9435449,0.0009836212,0.00020812548,0.000058329806,0.00029486822,0.00016416216,0.006028765,0.00035820468,0.014681148,0.0000883829],"about_ca_topic_score_codex":0.000053714764,"about_ca_topic_score_gemma":0.00006447299,"teacher_disagreement_score":0.52585536,"about_ca_system_score_codex":0.00040143033,"about_ca_system_score_gemma":0.0062820218,"threshold_uncertainty_score":0.99935144},"labels":[],"label_agreement":null},{"id":"W4410811460","doi":"10.1200/jco.2025.43.16_suppl.5066","title":"Canadian Cancer Trials Group (CCTG) IND.234/223: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)–A molecularly selected cooperative group platform study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Cancer Care Ontario; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Toronto; Western University; Centre Hospitalier de l’Université de Montréal; McGill University; Juravinski Cancer Centre; Jewish General Hospital; London Health Sciences Centre; McMaster University; University Health Network; Ottawa Hospital; BC Cancer Agency","funders":"F. Hoffmann-La Roche; Pfizer","keywords":"Prostate cancer; Medicine; Cancer; Biomarker; Oncology; Internal medicine; Genetics; Biology","score_opus":0.1594768418501787,"score_gpt":0.5089278038883972,"score_spread":0.34945096203821846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97535336,0.008634231,0.000056489866,0.011508524,0.0013954581,0.002263797,0.00006141428,0.00001817722,0.0007085524],"genre_scores_gemma":[0.9795541,0.015333431,0.00033474306,0.0012969756,0.0005032541,0.0003138158,0.000023198118,0.000028143324,0.0026123063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99472517,0.0011436447,0.0025147682,0.00047795515,0.0004689108,0.0006695406],"domain_scores_gemma":[0.99512553,0.0015295398,0.0010250293,0.00017676562,0.0012109561,0.0009321618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004096881,0.00035292533,0.0024812275,0.0006177846,0.0002713917,0.00006321478,0.00014518353,0.0004396536,0.00030643225],"category_scores_gemma":[0.0012824406,0.00021868237,0.00035184636,0.00094712793,0.0002059176,0.00019087337,0.000058258523,0.00089226663,0.0000043243135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.020579256,0.005196779,0.5397879,0.000044281165,0.009981097,0.0013706121,0.0008708513,0.000013146839,0.0015579936,0.00009694006,0.005834256,0.4146669],"study_design_scores_gemma":[0.063896954,0.041045938,0.81788284,0.00032221802,0.0030502053,0.00011176273,0.0008813254,0.00022889992,0.0007127659,0.00016610698,0.07138471,0.0003163043],"about_ca_topic_score_codex":0.05020307,"about_ca_topic_score_gemma":0.24917018,"teacher_disagreement_score":0.4143506,"about_ca_system_score_codex":0.0040082484,"about_ca_system_score_gemma":0.012603574,"threshold_uncertainty_score":0.99981517},"labels":[],"label_agreement":null},{"id":"W4410811464","doi":"10.1200/jco.2025.43.16_suppl.5090","title":"8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta; University of British Columbia; Ottawa Hospital","funders":"Cancer Council Australia","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Internal medicine; Androgen; Hormone; Cancer; Gynecology; Androgen receptor","score_opus":0.13830183537800853,"score_gpt":0.5165302946858149,"score_spread":0.37822845930780635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98268,0.0023606608,0.00029242362,0.010635459,0.0016925078,0.0010857353,0.00013774565,0.000010022458,0.0011054105],"genre_scores_gemma":[0.98654306,0.0043818047,0.0053420383,0.0011419228,0.00037609873,0.000053535645,0.000013398366,0.000031400974,0.0021167388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99618757,0.00030932162,0.0022462832,0.0003039537,0.0004980807,0.00045481342],"domain_scores_gemma":[0.99271965,0.003970765,0.0013832314,0.00025064105,0.0013387522,0.00033695812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026130753,0.00023699604,0.0026162346,0.00032212248,0.00006670504,0.000013961543,0.00020154397,0.00026981527,0.00003722062],"category_scores_gemma":[0.0026378802,0.00015469581,0.0009178046,0.0002960277,0.00043885477,0.0001387001,0.00009634477,0.00074047723,0.000006211163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23644237,0.0075789406,0.48432553,0.0008285065,0.026306523,0.002037572,0.0016885764,0.0001331593,0.010190921,0.0005968777,0.03217484,0.19769618],"study_design_scores_gemma":[0.17575367,0.05390823,0.6697322,0.0006401849,0.0073026684,0.000081720405,0.0026142914,0.00046167473,0.022935636,0.0010581918,0.0650374,0.0004741402],"about_ca_topic_score_codex":0.00006585731,"about_ca_topic_score_gemma":0.000060563667,"teacher_disagreement_score":0.19722204,"about_ca_system_score_codex":0.00031932176,"about_ca_system_score_gemma":0.0040236395,"threshold_uncertainty_score":0.71377635},"labels":[],"label_agreement":null},{"id":"W4410811469","doi":"10.1200/jco.2025.43.16_suppl.5096","title":"Real-world patient (pt) characteristics, treatment patterns, and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC): Insights by <i>PTEN</i> status.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"PTEN; Medicine; Prostate cancer; Oncology; Overall survival; Internal medicine; Hormone; Metastatic breast cancer; Cancer; Cancer research; Breast cancer; PI3K/AKT/mTOR pathway; Apoptosis; Biology","score_opus":0.06884012411802144,"score_gpt":0.4462633216473706,"score_spread":0.37742319752934916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98834425,0.0032905692,0.000010004667,0.0055251713,0.00083437917,0.00070939946,0.00017188145,0.0000086335385,0.0011057262],"genre_scores_gemma":[0.8960952,0.10015366,0.00017195992,0.0011489597,0.00017801052,0.000038019345,0.00005768791,0.000020053696,0.0021364023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962633,0.0005477535,0.0020059235,0.00033904306,0.00038129304,0.0004626359],"domain_scores_gemma":[0.99652725,0.001469374,0.0009469509,0.00017341848,0.0004228807,0.00046010126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077692425,0.00026103118,0.0019224344,0.0003103865,0.00004769954,0.000024085757,0.000071971495,0.00015285864,0.00003077315],"category_scores_gemma":[0.00035760264,0.00016489819,0.00023230727,0.00020941423,0.00023586974,0.00012940816,0.00007236252,0.0006033196,0.0000035326716],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030680439,0.004514047,0.61059177,0.00014587914,0.0019860233,0.004256779,0.0017479263,0.0000042526563,0.0007386504,0.00013538761,0.0052220593,0.33997682],"study_design_scores_gemma":[0.026076507,0.012970019,0.8749614,0.00042866167,0.00066910184,0.000023676806,0.0005120119,0.00011773172,0.00065696094,0.00033182895,0.08306414,0.00018797307],"about_ca_topic_score_codex":0.0022828626,"about_ca_topic_score_gemma":0.002094437,"teacher_disagreement_score":0.33978882,"about_ca_system_score_codex":0.0011037468,"about_ca_system_score_gemma":0.002277028,"threshold_uncertainty_score":0.6724353},"labels":[],"label_agreement":null},{"id":"W4410811541","doi":"10.1200/jco.2025.43.16_suppl.5056","title":"Substudy C of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A phase II study of darolutamide (DARO) selected by androgen-receptor (AR) circulating tumor DNA (ctDNA) in patients (PTS) with metastatic castration-resistant prostate cancer (mCRPC) after prior AR pathway inhibitors (ARPIs).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; BC Cancer Agency; Princess Margaret Cancer Centre; Dalhousie University; McGill University; Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; Université de Montréal; London Health Sciences Centre; McMaster University; University of Toronto; Western University; Juravinski Cancer Centre; University of British Columbia; University Health Network; Ottawa Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Cancer; Internal medicine; Oncology; Biomarker; Biology","score_opus":0.06804452329736803,"score_gpt":0.4216911073498777,"score_spread":0.35364658405250965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896427,0.0033925166,9.851068e-7,0.0013506989,0.00056896935,0.0045265267,0.0004947958,0.0000072132075,0.000015639376],"genre_scores_gemma":[0.99775237,0.00091069465,0.00010463554,0.00015372176,0.00009337626,0.0007351982,0.000025000803,0.00003713943,0.0001878847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927637,0.0016166822,0.0035729022,0.00054330175,0.00086205796,0.0006413779],"domain_scores_gemma":[0.99443257,0.0007853106,0.0027737604,0.00024266062,0.0012934069,0.00047228867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029076058,0.0004272765,0.0024614253,0.0005265914,0.00027802394,0.00003139723,0.00016151681,0.00018557932,0.00010448706],"category_scores_gemma":[0.00069175375,0.0002441647,0.000260966,0.0012949667,0.00033561853,0.00018598788,0.00006931111,0.00065423525,2.4468594e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03317835,0.011399686,0.8713715,0.00014934287,0.003822808,0.00016242154,0.0027281016,0.00006855181,0.0072648865,0.0000014276877,0.00025954383,0.069593355],"study_design_scores_gemma":[0.08671715,0.038807184,0.86183953,0.0009011587,0.0021067858,0.0000120824425,0.0011399675,0.00010444629,0.0069186813,0.000011038918,0.0011833176,0.00025867834],"about_ca_topic_score_codex":0.053233847,"about_ca_topic_score_gemma":0.41816294,"teacher_disagreement_score":0.3649291,"about_ca_system_score_codex":0.002898965,"about_ca_system_score_gemma":0.011744479,"threshold_uncertainty_score":0.9956747},"labels":[],"label_agreement":null},{"id":"W4410811576","doi":"10.1200/jco.2025.43.16_suppl.5059","title":"Phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) plus carboplatin and etoposide chemotherapy (chemo) or chemo alone for metastatic neuroendocrine prostate cancer (NEPC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Medicine; Carboplatin; Pembrolizumab; Chemotherapy; Etoposide; Docetaxel; Prostate cancer; Oncology; Cohort; Internal medicine; Cancer; Cisplatin; Immunotherapy","score_opus":0.11476497347675564,"score_gpt":0.5275964723278566,"score_spread":0.41283149885110093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9534115,0.004953904,0.0003148971,0.037288044,0.0009860401,0.0019776514,0.0000518806,0.000025299456,0.0009907718],"genre_scores_gemma":[0.9479169,0.022843655,0.005166899,0.0074159373,0.00089036854,0.00022952445,0.000029577042,0.00006974391,0.01543736],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960069,0.00027802054,0.0022426003,0.00044971297,0.0004441755,0.0005785823],"domain_scores_gemma":[0.99490535,0.0025280328,0.0010582015,0.0002818208,0.0007063195,0.0005202695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015398273,0.00031931017,0.002514875,0.0002643448,0.000110948786,0.000031786534,0.00020075272,0.00016584244,0.0001460295],"category_scores_gemma":[0.0020401988,0.00020156542,0.00045865244,0.0003314144,0.00042573974,0.0001407498,0.000082275714,0.0010423505,0.000002573849],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28972644,0.0094874,0.02437888,0.0010931237,0.0050548175,0.00405215,0.0003382986,0.000027550048,0.0050845887,0.00010476469,0.021670194,0.6389818],"study_design_scores_gemma":[0.63226765,0.061387148,0.04453237,0.00094424194,0.0051806294,0.0022622058,0.00034588602,0.00532343,0.026826065,0.0019706292,0.21835688,0.00060289673],"about_ca_topic_score_codex":0.000118167794,"about_ca_topic_score_gemma":0.000102159625,"teacher_disagreement_score":0.6383789,"about_ca_system_score_codex":0.0005309149,"about_ca_system_score_gemma":0.005741767,"threshold_uncertainty_score":0.99989474},"labels":[],"label_agreement":null},{"id":"W4410811580","doi":"10.1200/jco.2025.43.16_suppl.5057","title":"Substudy F of the Canadian Cancer Trials Group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A biomarker-selected phase II study of durvalumab and tremelilumab (DT) in patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC) resistant to AR pathway inhibitors (ARPI).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Western University; McGill University; Jewish General Hospital; Ottawa Hospital; BC Cancer Agency; Queen's University; London Health Sciences Centre; McMaster University; Cancer Care Ontario; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Biomarker; Durvalumab; Cancer; Prostate cancer; Oncology; Internal medicine; Urothelial cancer; Prostate; Bladder cancer; Immunotherapy","score_opus":0.11277655324953961,"score_gpt":0.4520381964419235,"score_spread":0.3392616431923839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98696774,0.003954892,6.487174e-7,0.002266624,0.00036094507,0.0061191404,0.0002887854,0.000007968802,0.00003326967],"genre_scores_gemma":[0.995546,0.0031542226,0.000093535324,0.00010943378,0.00005388879,0.00063012994,0.000018893961,0.00003457791,0.0003593631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9920974,0.0020721508,0.003756839,0.0006084292,0.00081881403,0.00064641534],"domain_scores_gemma":[0.99432874,0.00089916296,0.002301317,0.0002923721,0.0015696723,0.000608713],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003592482,0.0004549464,0.002762312,0.0008625787,0.0003041814,0.000035277037,0.00016662499,0.00021684977,0.000048110647],"category_scores_gemma":[0.00094578916,0.0002514203,0.00022107229,0.0018674801,0.00034486238,0.00014477115,0.00007812369,0.00049498875,1.5850877e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08665376,0.012911813,0.7357418,0.00017554479,0.0047211503,0.0001932896,0.003155163,0.00003685602,0.004349109,0.000003925049,0.00031861418,0.15173897],"study_design_scores_gemma":[0.086791806,0.064031,0.8416128,0.00095134636,0.0023305833,0.000008208371,0.00096782943,0.000049263563,0.0020442668,0.000013277409,0.00099385,0.00020575718],"about_ca_topic_score_codex":0.1349056,"about_ca_topic_score_gemma":0.7508906,"teacher_disagreement_score":0.615985,"about_ca_system_score_codex":0.0029160094,"about_ca_system_score_gemma":0.010394525,"threshold_uncertainty_score":0.9999938},"labels":[],"label_agreement":null},{"id":"W4410811842","doi":"10.1200/jco.2025.43.16_suppl.5002","title":"Prognostic significance of PSA&gt;0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real-world analysis of the IRONMAN registry.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre; University of British Columbia; Ottawa Hospital","funders":"Movember Foundation","keywords":"Medicine; Prostate cancer; Androgen receptor; Oncology; Androgen deprivation therapy; Internal medicine; Cancer","score_opus":0.07017764310688307,"score_gpt":0.432330976317524,"score_spread":0.3621533332106409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878794,0.0020177998,0.00009583431,0.006695256,0.00043916385,0.0018489211,0.000769834,0.000006019987,0.0002477728],"genre_scores_gemma":[0.99159425,0.0018588719,0.0014403382,0.00025509764,0.0001374535,0.00028519286,0.000073454496,0.000018560848,0.004336751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961382,0.000457127,0.002262536,0.0003251076,0.00050620415,0.00031080926],"domain_scores_gemma":[0.99308324,0.0028103164,0.002184955,0.0002773959,0.0014354007,0.00020866735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014375609,0.00023115425,0.001999248,0.00038781116,0.000053978234,0.000008345184,0.00015930746,0.00015847654,0.000032990156],"category_scores_gemma":[0.0018479497,0.0001306871,0.0010793247,0.00078509864,0.0006328745,0.000072164934,0.00005658044,0.00038307076,6.21285e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.112809174,0.013706996,0.63956946,0.0005551731,0.04313697,0.00037394604,0.0028240918,0.000492689,0.02713017,0.00019103842,0.014902224,0.14430806],"study_design_scores_gemma":[0.034787763,0.019414263,0.8328959,0.0009089489,0.019811695,0.000015587173,0.0013037898,0.002063423,0.04931607,0.00025548058,0.0388937,0.00033339427],"about_ca_topic_score_codex":0.00034574885,"about_ca_topic_score_gemma":0.0009697632,"teacher_disagreement_score":0.19332641,"about_ca_system_score_codex":0.00064483704,"about_ca_system_score_gemma":0.003082992,"threshold_uncertainty_score":0.5469095},"labels":[],"label_agreement":null},{"id":"W4410816426","doi":"10.1200/jco.2025.43.16_suppl.5608","title":"Post-hoc analysis evaluating selinexor maintenance therapy in patients with <i>TP53</i> wt endometrial cancer: Progression-free survival by clinical factors in the ENGOT-EN5/GOG-3055/SIENDO study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Karyopharm Therapeutics","keywords":"Medicine; Endometrial cancer; Oncology; Post-hoc analysis; Internal medicine; Overall survival; Post hoc; Progression-free survival; Cancer; Gynecology","score_opus":0.1492335963628104,"score_gpt":0.5535122013311622,"score_spread":0.4042786049683518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410816426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98713523,0.0016221728,0.000015293206,0.007788005,0.001269621,0.0018686763,0.00004527664,0.0000092053215,0.00024653826],"genre_scores_gemma":[0.9944974,0.0029780683,0.00035475678,0.0013033202,0.0005390351,0.00007499227,0.000025995716,0.000020512312,0.00020589943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98889947,0.004395522,0.0039693634,0.00052825,0.0016214825,0.000585928],"domain_scores_gemma":[0.9825632,0.013373778,0.0018130431,0.0005734731,0.001382472,0.00029403792],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.018975146,0.00030323796,0.0027491238,0.0007391613,0.000098204844,0.0000371506,0.00077606254,0.0003870375,0.00008576872],"category_scores_gemma":[0.013508029,0.00014036313,0.00073454436,0.0024231945,0.00037193878,0.0001512925,0.00014810568,0.0025022377,0.0000015035812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05556649,0.009549199,0.7673274,0.000010671596,0.0018948222,0.00017117472,0.00036333618,0.000018102304,0.000007911936,0.0000033404938,0.0011103322,0.16397722],"study_design_scores_gemma":[0.09068045,0.059035722,0.8444037,0.00016046302,0.00092233456,0.0000019336446,0.001310292,0.00006972047,0.000012395498,0.000035543453,0.003244008,0.00012346232],"about_ca_topic_score_codex":0.00031150595,"about_ca_topic_score_gemma":0.0012514696,"teacher_disagreement_score":0.16385375,"about_ca_system_score_codex":0.0004685091,"about_ca_system_score_gemma":0.0034208086,"threshold_uncertainty_score":0.999799},"labels":[],"label_agreement":null},{"id":"W4410884998","doi":"10.1016/j.annonc.2025.05.011","title":"Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma Europe; Astellas Pharma; Bayer HealthCare; Bayer; Astellas Pharma US","keywords":"Medicine; Enzalutamide; Prostate cancer; Radium-223; Oncology; Internal medicine; Cancer; Radium; Urology; Radiochemistry; Bone metastasis","score_opus":0.11903641848419842,"score_gpt":0.4541410662425793,"score_spread":0.3351046477583809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410884998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.959024,0.004674592,0.000002173006,0.02504957,0.0003867949,0.0019853492,0.00018995807,0.000010282157,0.008677294],"genre_scores_gemma":[0.9905156,0.0030260799,0.0000847287,0.00040733424,0.00005081213,0.00018636925,0.000029657223,0.000009690458,0.0056897225],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981109,0.0002814253,0.00074503134,0.00024965857,0.00028599266,0.00032702243],"domain_scores_gemma":[0.99866676,0.00037061385,0.00029020425,0.00032472133,0.00028256312,0.00006511518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085413834,0.00013498735,0.00061562087,0.0002211606,0.000049323167,0.0000055130686,0.00016274827,0.00009057681,0.000030603434],"category_scores_gemma":[0.00043321965,0.000085981264,0.00014260634,0.0005964008,0.00031171716,0.00005000383,0.0000660158,0.0002372474,0.0000017941194],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7381074,0.0043489174,0.0069327727,0.0014926695,0.0018747383,0.00050298916,0.00710113,0.00072160916,0.059200883,0.00345097,0.047797777,0.12846819],"study_design_scores_gemma":[0.4727734,0.017044755,0.07321792,0.0017304352,0.0007021416,0.000020856078,0.0025621834,0.0003641329,0.29961196,0.0043226825,0.12726858,0.00038094516],"about_ca_topic_score_codex":0.002603347,"about_ca_topic_score_gemma":0.0029185074,"teacher_disagreement_score":0.26533395,"about_ca_system_score_codex":0.00023541908,"about_ca_system_score_gemma":0.003344409,"threshold_uncertainty_score":0.5932838},"labels":[],"label_agreement":null},{"id":"W4410930213","doi":"10.1172/jci187490","title":"PROX1 is an early driver of lineage plasticity in prostate cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Dental and Craniofacial Research; Canadian Institutes of Health Research; National Institute of General Medical Sciences; Institute for Prostate Cancer Research; Terry Fox Research Institute; National Cancer Institute; National Institutes of Health; BC Cancer Foundation; Prostate Cancer Foundation","keywords":"Prostate cancer; Lineage (genetic); Prostate; Plasticity; Biology; Cancer research; Cancer; Internal medicine; Medicine; Oncology; Genetics; Gene; Physics","score_opus":0.11794641767646559,"score_gpt":0.4652361321358967,"score_spread":0.34728971445943113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410930213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952337,0.00023866571,0.00003249088,0.0038044269,0.00021651432,0.0002859053,0.00000802079,0.000004401129,0.00017583402],"genre_scores_gemma":[0.9964765,0.00063875964,0.0008950434,0.0005658603,0.0001807094,0.000006951439,0.0000037232294,0.0000065819354,0.0012258741],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815583,0.00013338123,0.0011323012,0.00012915318,0.00031989743,0.00012941365],"domain_scores_gemma":[0.99851054,0.00023255854,0.00046614383,0.00009451094,0.00051517494,0.00018106766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007570952,0.00007947865,0.00044044456,0.00020379489,0.000019931176,0.000011801978,0.00008004782,0.00009998277,0.000040862236],"category_scores_gemma":[0.0007516191,0.000054709988,0.00011345541,0.00032910722,0.00024652973,0.00021779259,0.000021047768,0.0004858666,0.0000018095302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014543498,0.00031380865,0.9860902,0.00014187228,0.00010223355,0.00003796998,0.00056467904,0.00003116654,0.004395842,0.000068526126,0.0008356065,0.005963766],"study_design_scores_gemma":[0.0045897504,0.0013567929,0.9440051,0.0010451095,0.00010969301,0.0000024263245,0.00006073669,0.00095619296,0.04634506,0.0011071479,0.00037350957,0.000048496946],"about_ca_topic_score_codex":0.00010970362,"about_ca_topic_score_gemma":0.000032856184,"teacher_disagreement_score":0.042085093,"about_ca_system_score_codex":0.00007451182,"about_ca_system_score_gemma":0.0010594783,"threshold_uncertainty_score":0.22310086},"labels":[],"label_agreement":null},{"id":"W4410947358","doi":"10.2139/ssrn.5263733","title":"Impact of Hormone Sensitivity Status on Aberrant Expression of Ck7, Ck20, Cdx2, Gata3 and Ttf1 in Prostate Cancer","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"CDX2; Prostate cancer; GATA3; Internal medicine; Oncology; Cancer research; Cancer; Medicine; Biology; Transcription factor; Genetics; Gene","score_opus":0.015979798490148793,"score_gpt":0.34911891976865717,"score_spread":0.33313912127850837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410947358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9591107,0.03893125,0.0000361923,0.00040301133,0.00009687944,0.0008333809,0.00030808663,0.000010402023,0.00027012292],"genre_scores_gemma":[0.817526,0.18134387,0.000031284933,0.00000886235,0.000072565315,0.000025678019,0.000053079842,0.000022156833,0.0009165514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964117,0.00023466462,0.0005649428,0.0004171874,0.000549721,0.0018217779],"domain_scores_gemma":[0.99866515,0.000111861176,0.00042318742,0.00033945794,0.00027054557,0.00018978366],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013506706,0.00035193315,0.0009111567,0.00055156124,0.000059270336,0.000017775328,0.000098995726,0.00018887663,0.00001327679],"category_scores_gemma":[0.00008502107,0.0002402398,0.0002584622,0.00024103923,0.00014861107,0.00007043143,0.00020998124,0.003882297,5.124584e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050922856,0.0032815535,0.52395624,0.0023608075,0.0044930857,0.00056643866,0.005001156,0.0023887202,0.2740851,0.0005003985,0.0012201795,0.13122347],"study_design_scores_gemma":[0.027331345,0.011098301,0.8585815,0.011099967,0.000808428,0.00054762716,0.0015395848,0.0010175381,0.066798374,0.020146077,0.00010802162,0.0009232327],"about_ca_topic_score_codex":0.0048904126,"about_ca_topic_score_gemma":0.0011351152,"teacher_disagreement_score":0.33462524,"about_ca_system_score_codex":0.0031594678,"about_ca_system_score_gemma":0.012651767,"threshold_uncertainty_score":0.99841577},"labels":[],"label_agreement":null},{"id":"W4410950112","doi":"10.1080/14796694.2025.2502318","title":"rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator’s choice in patients with mCRPC","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Enzalutamide; Medicine; Cabazitaxel; Prostate cancer; Androgen receptor; Abiraterone acetate; Oncology; Internal medicine; Docetaxel; Randomized controlled trial; Clinical endpoint; Clinical trial; Androgen deprivation therapy; Pharmacology; Cancer","score_opus":0.01713607726596698,"score_gpt":0.3317622043259618,"score_spread":0.3146261270599948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410950112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790488,0.0012038806,0.0000026655991,0.011667565,0.0012574313,0.004864821,0.00003471898,0.0000509133,0.0018692381],"genre_scores_gemma":[0.9849986,0.00088835036,0.0009088865,0.0026343062,0.001079547,0.0015127497,0.00042429243,0.000059788636,0.0074935104],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99792606,0.0006061128,0.0004969042,0.0003301346,0.00030611604,0.0003346483],"domain_scores_gemma":[0.99859655,0.00045149738,0.00021883716,0.000348387,0.00022529946,0.00015945434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056407345,0.00020964484,0.0010952806,0.00022480452,0.000082823004,0.000007661271,0.00017655473,0.00030696273,0.00009666892],"category_scores_gemma":[0.0008655952,0.00010950192,0.00015699622,0.00087847124,0.00036339433,0.00004631119,0.00006458842,0.00048248342,0.0000038861835],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9512183,0.00208727,0.017676307,0.000098787066,0.00047137542,0.00001060903,0.0005517105,2.3903445e-7,0.0006178711,0.000112892936,0.021192934,0.0059617204],"study_design_scores_gemma":[0.9238865,0.0025187018,0.0024490762,0.00024078669,0.0002973759,0.0000013443074,0.00007390027,0.000014481614,0.0070032068,0.0000704066,0.063342035,0.000102230086],"about_ca_topic_score_codex":0.00013189594,"about_ca_topic_score_gemma":0.00017069664,"teacher_disagreement_score":0.042149104,"about_ca_system_score_codex":0.00035206723,"about_ca_system_score_gemma":0.0017569932,"threshold_uncertainty_score":0.4465359},"labels":[],"label_agreement":null},{"id":"W4410968310","doi":"10.1080/14796694.2025.2510890","title":"Patient, caregiver experiences in metastatic castration-resistant prostate cancer: insights from a multi-national survey","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Johnson and Johnson","keywords":"Medicine; Prostate cancer; Family medicine; Pill; Caregiver burden; Urination; Disease; Internal medicine; Cancer; Nursing","score_opus":0.05312816492137521,"score_gpt":0.3882538557149905,"score_spread":0.33512569079361526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410968310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867372,0.007430668,0.0000086473165,0.0022492805,0.000717146,0.00078306894,0.00021084811,0.000021403848,0.0018417506],"genre_scores_gemma":[0.99599075,0.0005022437,0.0005486559,0.00045383436,0.00010404489,0.00072909094,0.00044386988,0.000008914835,0.0012185733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986077,0.0002482739,0.00028526818,0.00034340055,0.00027891112,0.00023643345],"domain_scores_gemma":[0.9992138,0.0001997632,0.00007820376,0.00012367715,0.00030201825,0.0000825498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114804214,0.00014622026,0.00033680015,0.00022169718,0.000086063556,0.000017437993,0.00007409642,0.00009981479,0.00018908296],"category_scores_gemma":[0.00007588431,0.00010547153,0.000043477317,0.0004649347,0.00013051662,0.00008489594,0.000037045287,0.00021359953,0.000008844233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022997947,0.0056842077,0.5024289,0.00047338157,0.002017046,0.0032785847,0.3023585,0.00018397877,0.02437952,0.0022127999,0.045351844,0.08863331],"study_design_scores_gemma":[0.0149067715,0.0012432429,0.85049343,0.00025244098,0.00010513194,0.0000072154094,0.04172655,0.0004960276,0.0040682084,0.00048794266,0.085912555,0.00030048328],"about_ca_topic_score_codex":0.0048633986,"about_ca_topic_score_gemma":0.03942484,"teacher_disagreement_score":0.34806457,"about_ca_system_score_codex":0.00078307797,"about_ca_system_score_gemma":0.002176414,"threshold_uncertainty_score":0.97810316},"labels":[],"label_agreement":null},{"id":"W4410974204","doi":"10.1007/s00345-025-05733-y","title":"PSMA PET-detected mesorectal nodal metastasis: treatment outcomes and clinical implications","year":2025,"lang":"en","type":"article","venue":"World Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Nephrology; Oncology; Metastasis; Total mesorectal excision; Colorectal cancer; Cancer","score_opus":0.04152050221204991,"score_gpt":0.40657147421078393,"score_spread":0.36505097199873404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410974204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8908724,0.0073436107,0.00018029797,0.098391466,0.00044029774,0.00038046954,0.000018285045,0.000024056159,0.0023490728],"genre_scores_gemma":[0.99237454,0.002528486,0.00063218706,0.0006222149,0.000097287484,0.000011032384,0.0000052763953,0.000008779209,0.003720226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988615,0.00014119252,0.0005113171,0.00015875591,0.00010783335,0.00021941596],"domain_scores_gemma":[0.9989442,0.00039929006,0.00015287372,0.00016875882,0.00016631607,0.00016852572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028343996,0.00012382878,0.00051410636,0.0004211762,0.00007517227,0.000012587589,0.000077435085,0.00004365159,0.000076126395],"category_scores_gemma":[0.00012258711,0.00007543101,0.00021923434,0.00025014326,0.00018122535,0.000039761762,0.00003821766,0.00028542287,0.00000592974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025132687,0.0007801259,0.8536525,0.000015590977,0.0026787426,0.00043846696,0.00005128336,0.0000012064382,0.0005799636,0.0009530139,0.0018349874,0.13650087],"study_design_scores_gemma":[0.007916786,0.0032287284,0.9504629,0.000016369044,0.001226764,0.00084963633,0.000029538507,0.00003063975,0.00015081318,0.0009944114,0.035027884,0.00006554809],"about_ca_topic_score_codex":0.000012147042,"about_ca_topic_score_gemma":0.00008481634,"teacher_disagreement_score":0.13643532,"about_ca_system_score_codex":0.000100971134,"about_ca_system_score_gemma":0.0003223023,"threshold_uncertainty_score":0.30759874},"labels":[],"label_agreement":null},{"id":"W4411028353","doi":"10.3390/ijms26115386","title":"Transforming Prostate Cancer Care: Innovations in Diagnosis, Treatment, and Future Directions","year":2025,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba","funders":"Fundação para a Ciência e a Tecnologia","keywords":"Prostate cancer; Medicine; Management of prostate cancer; Precision medicine; Cancer; Radiation therapy; Malignancy; Medical physics; Intensive care medicine; Internal medicine; Pathology","score_opus":0.03776184234744047,"score_gpt":0.42381365575070146,"score_spread":0.386051813403261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411028353","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001488164,0.99411345,0.000006386268,0.0025381942,0.00069951324,0.0004759301,0.00006885105,0.0000046695595,0.00060483714],"genre_scores_gemma":[0.00048454717,0.99867064,0.00018453493,0.000049595277,0.00024280146,0.00016141743,0.000022480239,0.000007810594,0.00017614773],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987393,0.000052865256,0.0004554654,0.00019541706,0.0004051376,0.00015182361],"domain_scores_gemma":[0.999194,0.000083922154,0.000218248,0.000059945247,0.00038106262,0.00006282107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001723347,0.00017137977,0.0005426517,0.00114683,0.00007498764,0.000080175916,0.00019767424,0.000081073806,0.000019917936],"category_scores_gemma":[0.000032759122,0.000107149965,0.00020759601,0.0008356218,0.00014227796,0.00014634804,0.000025967744,0.00022521924,4.5709592e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019168243,0.00008268197,0.0009890096,0.0006695043,0.0003048416,0.00023436606,0.00045846213,0.0000018789424,0.000005547867,0.0001546324,0.000023276229,0.9970566],"study_design_scores_gemma":[0.00084406516,0.0002665091,0.000087127635,0.009986732,0.00034178392,0.00018933079,0.0002826013,8.6385296e-7,0.00011173027,0.00004310631,0.9877539,0.00009222702],"about_ca_topic_score_codex":0.00009055443,"about_ca_topic_score_gemma":0.000068940535,"teacher_disagreement_score":0.9969644,"about_ca_system_score_codex":0.00055610156,"about_ca_system_score_gemma":0.002301452,"threshold_uncertainty_score":0.43694487},"labels":[],"label_agreement":null},{"id":"W4411028356","doi":"10.1200/jco.2025.43.17_suppl.lba5006","title":"Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Prednisone; Oncology; Internal medicine; Homologous recombination; CYP17A1; Cancer research; Gene; Cancer; Endocrinology; Androgen deprivation therapy; Genetics; Biology","score_opus":0.11947778305563772,"score_gpt":0.49364550539346247,"score_spread":0.37416772233782475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411028356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895825,0.0009675229,0.00067437865,0.0051733996,0.00066098274,0.0027109284,0.000059241956,0.0000145367,0.00015653393],"genre_scores_gemma":[0.9900787,0.0022315278,0.0051190755,0.0005657919,0.00015732567,0.00031941858,0.00008035651,0.000020148098,0.0014276708],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99681574,0.00048960536,0.001806135,0.00032012077,0.00027026015,0.00029812235],"domain_scores_gemma":[0.9963341,0.0012337258,0.0009749145,0.00014538104,0.0011141239,0.00019780122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020356965,0.00018004437,0.001277109,0.00030474443,0.000101595186,0.000030601677,0.000066021006,0.00016482366,0.000012832115],"category_scores_gemma":[0.0009682876,0.00012232257,0.00018382895,0.00026874195,0.0002592683,0.00022069893,0.00002978246,0.00048915547,9.66991e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5551714,0.017772136,0.040217035,0.0004856495,0.0031074937,0.00081410044,0.0018155811,0.00035847555,0.0004784641,0.000289683,0.0026029793,0.37688702],"study_design_scores_gemma":[0.7836539,0.10649664,0.09533909,0.00069541397,0.0018756699,0.0000803479,0.00053872034,0.0027327319,0.0012042342,0.0012460651,0.0058700345,0.0002671323],"about_ca_topic_score_codex":0.00010421554,"about_ca_topic_score_gemma":0.0006447913,"teacher_disagreement_score":0.37661988,"about_ca_system_score_codex":0.0005647477,"about_ca_system_score_gemma":0.0030228542,"threshold_uncertainty_score":0.53624135},"labels":[],"label_agreement":null},{"id":"W4411098527","doi":"10.5489/cuaj.9252","title":"Poster Session 1: Oncology-Prostate (Part 1)","year":2025,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Agency; Canadian Institutes of Health Research; University of Toronto; Dalhousie University; Université de Montréal; University of Alberta; Government of Ontario; McMaster University; Ottawa Hospital Research Institute; University of Ottawa; McGill University; Jewish General Hospital; Impact Fund","keywords":"Session (web analytics); Prostate; Medicine; Oncology; Medical physics; Internal medicine; Computer science; World Wide Web; Cancer","score_opus":0.02292961063886482,"score_gpt":0.31274815805446354,"score_spread":0.2898185474155987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411098527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5794103,0.0012430529,0.000016359998,0.31992117,0.0012064788,0.0004129176,0.000040780287,0.00004523687,0.097703695],"genre_scores_gemma":[0.94979465,0.00046530916,0.000073236115,0.015161851,0.0003468928,0.000014559985,0.000042527776,0.0000075971393,0.0340934],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986773,0.00015426209,0.0002553926,0.00016239923,0.00024826196,0.00050238357],"domain_scores_gemma":[0.9987838,0.00011197739,0.000107666674,0.000087973756,0.00031656434,0.0005919856],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00062871823,0.00010129637,0.00022677246,0.00025362836,0.00032791423,0.00007128967,0.00008405547,0.00026121305,0.0009807122],"category_scores_gemma":[0.00042174757,0.00006960661,0.00010684576,0.0002745594,0.000037861995,0.00007428885,0.000021179567,0.0006764095,0.00012221112],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026664478,0.000075328135,0.781111,0.0000074329346,0.00017590722,0.0003740268,0.00008897666,0.000002416682,0.00027231962,0.00013353367,0.19632,0.021172432],"study_design_scores_gemma":[0.0017935783,0.00038100115,0.35225672,0.000033560325,0.00006054627,0.00008268219,0.000055759876,0.00001775251,0.00012516779,0.00085058814,0.6442798,0.000062870204],"about_ca_topic_score_codex":0.00028915776,"about_ca_topic_score_gemma":0.00028228632,"teacher_disagreement_score":0.44795978,"about_ca_system_score_codex":0.0029485316,"about_ca_system_score_gemma":0.0019542936,"threshold_uncertainty_score":0.9999325},"labels":[],"label_agreement":null},{"id":"W4411099705","doi":"10.5489/cuaj.9264","title":"Poster Session 7: Oncology - Prostate (Part 2)","year":2025,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Research Nova Scotia; Dalhousie University; Dalhousie Medical Research Foundation","keywords":"Session (web analytics); Medicine; Medical physics; Oncology; Internal medicine; Computer science; World Wide Web","score_opus":0.021741308263705385,"score_gpt":0.3153545732476988,"score_spread":0.29361326498399337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411099705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5591871,0.001088936,0.000016540158,0.3368171,0.001166573,0.00050101685,0.000038511305,0.000043326414,0.10114091],"genre_scores_gemma":[0.95142436,0.0003700603,0.00006502304,0.013631586,0.00033886562,0.000017689259,0.00004244022,0.0000073008096,0.034102652],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987144,0.00016382372,0.00024737857,0.00015508014,0.00023064936,0.000488671],"domain_scores_gemma":[0.9988537,0.00010614456,0.00010460877,0.00007909195,0.00030622797,0.0005502496],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005857836,0.000095351235,0.00022122922,0.0002454341,0.00029930394,0.000063620064,0.00007541411,0.000249146,0.0009222446],"category_scores_gemma":[0.00038783482,0.0000650624,0.00009353666,0.00025604578,0.000036108555,0.0000695277,0.00001968039,0.0006301004,0.00010125946],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029766877,0.000085813175,0.80855083,0.0000086049995,0.0001717072,0.00040784484,0.00009607731,0.0000022885495,0.00023506659,0.00016110347,0.16971041,0.020272588],"study_design_scores_gemma":[0.0017284887,0.0004313334,0.31601477,0.000029613138,0.000054557277,0.000091960785,0.000044046243,0.000016468119,0.00011398741,0.0007730889,0.6806438,0.000057916506],"about_ca_topic_score_codex":0.0003051767,"about_ca_topic_score_gemma":0.0003314455,"teacher_disagreement_score":0.5109334,"about_ca_system_score_codex":0.0029019706,"about_ca_system_score_gemma":0.0021672987,"threshold_uncertainty_score":0.99999106},"labels":[],"label_agreement":null},{"id":"W4411099709","doi":"10.5489/cuaj.9250","title":"Podium Session 3: Oncology-Prostate","year":2025,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Session (web analytics); Medicine; Prostate; Oncology; Internal medicine; Medical physics; Computer science; World Wide Web; Cancer","score_opus":0.01839667025459002,"score_gpt":0.3160719860183884,"score_spread":0.29767531576379835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411099709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5849928,0.0014153871,0.000048072292,0.32775095,0.0010362866,0.0004002064,0.000032411626,0.00005232137,0.084271535],"genre_scores_gemma":[0.96307003,0.0004681207,0.00015542815,0.010018712,0.00025436835,0.000012533531,0.000030757925,0.000006373692,0.02598366],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987412,0.00014031738,0.00022890764,0.00015281311,0.000242985,0.00049375935],"domain_scores_gemma":[0.9987968,0.00011244851,0.0001011334,0.00008165979,0.00030826085,0.00059966603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006134768,0.000095505144,0.00021998485,0.0002711453,0.0003481185,0.000064447115,0.00008590101,0.00025813113,0.0006593706],"category_scores_gemma":[0.0004995695,0.00006631742,0.00010252212,0.0003103937,0.00003706879,0.00006338742,0.000019024134,0.0007010692,0.000095843054],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026199658,0.000090429065,0.8160856,0.000008695848,0.00018458425,0.00044363507,0.00009780807,0.000006183329,0.0004955079,0.00034204946,0.14396732,0.038016215],"study_design_scores_gemma":[0.0018769557,0.00035258813,0.4563045,0.000025017289,0.0000580315,0.00007410545,0.00008785523,0.00005151629,0.00012746784,0.0016234718,0.5393564,0.00006211052],"about_ca_topic_score_codex":0.0004493535,"about_ca_topic_score_gemma":0.00028505086,"teacher_disagreement_score":0.39538908,"about_ca_system_score_codex":0.0034264056,"about_ca_system_score_gemma":0.0024007817,"threshold_uncertainty_score":0.8959931},"labels":[],"label_agreement":null},{"id":"W4411100018","doi":"10.5489/cuaj.9267","title":"Poster Session 9: Oncology - Kidney, Testes, Penile","year":2025,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Session (web analytics); Medicine; Urology; Internal medicine; Oncology; Computer science; World Wide Web","score_opus":0.0180438987118386,"score_gpt":0.3131830317095302,"score_spread":0.2951391329976916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411100018","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2963089,0.0013116342,0.000031266667,0.5365297,0.0012513925,0.0005037896,0.00006217808,0.00005580741,0.16394529],"genre_scores_gemma":[0.95186454,0.0001330362,0.00009074531,0.024249986,0.0002928687,0.000011976144,0.000050869796,0.0000066365433,0.023299351],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99874514,0.00015731301,0.00023201262,0.0001560329,0.00023448901,0.00047502702],"domain_scores_gemma":[0.9984418,0.00015445605,0.00009960378,0.000084848776,0.0002948166,0.00092445704],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005026341,0.00009788939,0.00022861805,0.0002556495,0.00030100776,0.000066052955,0.00009385654,0.00028935287,0.0016140209],"category_scores_gemma":[0.0010276812,0.000067814624,0.000099674224,0.00027045462,0.000034415152,0.00006880037,0.000022633643,0.0006600713,0.000111999456],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012902859,0.000073891024,0.73528975,0.000007733668,0.00008957527,0.00029412445,0.0000515087,8.2173034e-7,0.00038386765,0.00013192507,0.25549313,0.008054629],"study_design_scores_gemma":[0.0018310911,0.0004312645,0.37415102,0.00002515012,0.0000661344,0.00012497608,0.00003797339,0.00002281432,0.0001194036,0.0008296723,0.6222983,0.00006217348],"about_ca_topic_score_codex":0.0005284677,"about_ca_topic_score_gemma":0.00024769246,"teacher_disagreement_score":0.6555556,"about_ca_system_score_codex":0.003108528,"about_ca_system_score_gemma":0.0034989775,"threshold_uncertainty_score":0.99929863},"labels":[],"label_agreement":null},{"id":"W4411106890","doi":"10.1038/s41598-025-04717-7","title":"Silencing FGL1 promotes prostate cancer cell apoptosis and inhibits EMT progression","year":2025,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Natural Science Foundation of Qingdao; Natural Science Foundation of Shandong Province","keywords":"Gene silencing; Prostate cancer; Apoptosis; Cancer research; Cancer; Biology; Genetics; Gene","score_opus":0.014747186624515577,"score_gpt":0.3298008829312134,"score_spread":0.31505369630669783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411106890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98188573,0.00861832,0.0000042804995,0.0012337792,0.0017439714,0.0013833357,0.0000035492965,0.00008256582,0.005044439],"genre_scores_gemma":[0.9555414,0.0003682177,0.00028915377,0.000040360515,0.000041142175,0.000229736,0.0000430014,0.000013990471,0.043433003],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979861,0.00002831138,0.00034004025,0.0007584694,0.0004864387,0.00040067252],"domain_scores_gemma":[0.99896365,0.000019891868,0.0001350753,0.00043689634,0.00026972743,0.00017476197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069263903,0.00015560702,0.00023052006,0.0001793811,0.00040224358,0.0001980567,0.000044730874,0.00007015899,0.000089291854],"category_scores_gemma":[0.00006769565,0.0001066946,0.000054498407,0.0005784978,0.00027624474,0.00017884474,0.00012859114,0.00014226223,0.0000043272235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015356114,0.00033980559,0.12941064,0.0012907182,0.00006528568,0.00030407248,0.0020175383,0.000002152055,0.7816023,0.000011333477,0.017956724,0.06684584],"study_design_scores_gemma":[0.00061906053,0.00010268164,0.002728309,0.0010682703,0.000071242604,0.000034675384,0.0003051265,0.00007265527,0.9875265,0.0005578648,0.0067970557,0.00011660119],"about_ca_topic_score_codex":0.00012846706,"about_ca_topic_score_gemma":0.000024012303,"teacher_disagreement_score":0.20592414,"about_ca_system_score_codex":0.0001860714,"about_ca_system_score_gemma":0.00070738595,"threshold_uncertainty_score":0.43508795},"labels":[],"label_agreement":null},{"id":"W4411196916","doi":"10.1016/j.euros.2025.05.014","title":"Corrigendum to “Decreased ATM Protein Expression Is Substantiated with PTEN Loss in Defining Aggressive Phenotype of Prostate Cancer Associated with Lethal Disease” [Eur. Urol. Open Sci. 29 (2021) 93-101]","year":2025,"lang":"en","type":"erratum","venue":"European Urology Open Science","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta; University of Calgary","funders":"","keywords":"PTEN; Phenotype; Prostate cancer; Cancer research; Cancer; Disease; Medicine; Protein expression; Oncology; Biology; Internal medicine; Gene; Apoptosis; Genetics; PI3K/AKT/mTOR pathway","score_opus":0.031634146482729476,"score_gpt":0.3292528767992207,"score_spread":0.2976187303164912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411196916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7356022,0.010759248,0.000079809615,0.011685062,0.005810463,0.032463253,0.003968211,0.00019796815,0.19943382],"genre_scores_gemma":[0.78596663,0.0004321244,0.00044261836,0.0018576231,0.00014331387,0.0009734772,0.0011272152,0.00022053937,0.20883645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99273294,0.0010208355,0.0007806544,0.00240757,0.0015774361,0.001480557],"domain_scores_gemma":[0.9951078,0.00010037067,0.0011329346,0.0013972102,0.0013769218,0.0008847414],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002485736,0.00076577126,0.0014005372,0.0008561478,0.0005816344,0.0004059966,0.0041443277,0.00021108541,0.00048293444],"category_scores_gemma":[0.0011989689,0.0005208942,0.00008062542,0.004050633,0.0020016013,0.00060956867,0.002912478,0.0015425008,0.000058807713],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11187242,0.0034218165,0.4707869,0.0011022054,0.0014681738,0.037469883,0.008037929,0.0004683365,0.009932661,0.00013507158,0.34600112,0.00930347],"study_design_scores_gemma":[0.048435025,0.013346901,0.8147577,0.044717424,0.0016792365,0.000094411254,0.00066255993,0.001289373,0.008906873,0.00010686145,0.062495552,0.0035080975],"about_ca_topic_score_codex":0.0014049719,"about_ca_topic_score_gemma":0.00064269657,"teacher_disagreement_score":0.34397078,"about_ca_system_score_codex":0.00054916734,"about_ca_system_score_gemma":0.012140411,"threshold_uncertainty_score":0.99972427},"labels":[],"label_agreement":null},{"id":"W4411223590","doi":"10.1101/2025.06.06.25328738","title":"Evaluating the role of liquid biopsy to detect pathogenic DNA Damage Repair (DDR) gene alterations in metastatic prostate cancer","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill Genome Centre; McGill University Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Prostate cancer; Liquid biopsy; DNA Damage Repair; Cancer; DNA damage; DNA repair; Cancer research; Gene; Prostate; Medicine; Biopsy; Pathology; DNA; Biology; Oncology; Internal medicine; Genetics","score_opus":0.06226583021807223,"score_gpt":0.40289445036952665,"score_spread":0.3406286201514544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411223590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98474306,0.009104165,0.000038374594,0.0016145394,0.00024619055,0.0033855303,0.00044624374,0.00006725665,0.0003546594],"genre_scores_gemma":[0.9853322,0.0012694934,0.0062298244,0.00018148935,0.00014397461,0.0034617798,0.00018141422,0.000048186143,0.0031516463],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99716246,0.00043455177,0.0006916354,0.0006570926,0.0006034671,0.0004508126],"domain_scores_gemma":[0.99811184,0.00020598967,0.00019576277,0.0009906058,0.00035265455,0.00014314447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014876407,0.00031718507,0.0006246102,0.00042421438,0.00011300364,0.0000297847,0.00030410895,0.00010578927,0.00011111923],"category_scores_gemma":[0.00045550906,0.00020917057,0.00026115446,0.00071140425,0.00010175573,0.000037826263,0.00054027163,0.0006258533,0.000010107809],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032105416,0.00033727713,0.036338612,0.0016217872,0.0011046003,0.00020100297,0.0073651434,0.004820689,0.92799383,0.00003964467,0.00008248315,0.016884387],"study_design_scores_gemma":[0.0054118214,0.0037095656,0.084368765,0.005643038,0.0021714934,0.00003481265,0.0012002622,0.027291846,0.865913,0.001905723,0.0014404831,0.00090919575],"about_ca_topic_score_codex":0.00084980397,"about_ca_topic_score_gemma":0.00043347184,"teacher_disagreement_score":0.06208084,"about_ca_system_score_codex":0.000340376,"about_ca_system_score_gemma":0.0017216024,"threshold_uncertainty_score":0.85297287},"labels":[],"label_agreement":null},{"id":"W4411225349","doi":"10.1016/j.semradonc.2025.04.014","title":"The Evolving Management of Radiorecurrent Prostate Cancer","year":2025,"lang":"en","type":"review","venue":"Seminars in Radiation Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus; Kelowna General Hospital","funders":"Clinical Science Research and Development; U.S. Department of Veterans Affairs","keywords":"Medicine; Prostate cancer; Prostate; Cancer; Management of prostate cancer; Oncology; General surgery; Gynecology; Internal medicine","score_opus":0.03525403164520489,"score_gpt":0.44452281504778657,"score_spread":0.40926878340258166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411225349","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012664593,0.98956835,0.000001461926,0.0004625409,0.000809952,0.0026381318,0.000045355846,0.000013368704,0.0064481637],"genre_scores_gemma":[0.000012362029,0.98668575,0.000113933595,0.00001661956,0.00007546594,0.0016583521,0.00015595173,0.000019199348,0.011262338],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982349,0.00022636744,0.00064463733,0.00031219827,0.00024268593,0.00033920936],"domain_scores_gemma":[0.9986761,0.00053242745,0.00033718266,0.0003109902,0.00008242913,0.00006082265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056487875,0.00022251674,0.0010821249,0.00034264708,0.00007743662,0.000010429681,0.00019110407,0.00022040447,0.000056021036],"category_scores_gemma":[0.000057885314,0.00013788058,0.00020924902,0.00071372185,0.00013942645,0.000027311611,0.000098877004,0.00039943954,0.000006984864],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000849285,0.00011376919,0.0002129774,0.022503363,0.00034838927,0.00008202184,0.00016453385,0.0000020503376,8.560996e-8,0.00017913897,0.007296016,0.96901274],"study_design_scores_gemma":[0.001066252,0.00020595948,0.00012222807,0.0350358,0.00069372536,0.0000095947735,0.00010641706,0.000021563019,0.0000029669998,0.00004658521,0.9625933,0.00009560765],"about_ca_topic_score_codex":0.000024013712,"about_ca_topic_score_gemma":0.00001796682,"teacher_disagreement_score":0.96891713,"about_ca_system_score_codex":0.0023142307,"about_ca_system_score_gemma":0.0016740095,"threshold_uncertainty_score":0.6051633},"labels":[],"label_agreement":null},{"id":"W4411236241","doi":"10.3390/siuj6030044","title":"SIU-ICUD: Epidemiology of Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"Société Internationale d’Urologie Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","keywords":"Epidemiology; Prostate cancer; Prostate; Medicine; Oncology; Cancer; Internal medicine","score_opus":0.08807153285815943,"score_gpt":0.4569229566173316,"score_spread":0.3688514237591722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411236241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91025335,0.015545301,0.00036233253,0.04996654,0.0015213927,0.00041741057,0.000052670217,0.00004064446,0.021840375],"genre_scores_gemma":[0.9560117,0.008129835,0.0005815098,0.0022206772,0.00029531456,0.000059881935,0.000033492546,0.000009059493,0.032658536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998611,0.00014005929,0.0005006976,0.0001885197,0.000247003,0.00031274365],"domain_scores_gemma":[0.99843115,0.00056169217,0.00024829616,0.0001348307,0.000529573,0.00009443753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007566875,0.00012461426,0.00038996746,0.000254524,0.00009521555,0.00000775603,0.00019596604,0.00011649904,0.0007942476],"category_scores_gemma":[0.0009043952,0.00008768687,0.00021682575,0.00017042644,0.00022325588,0.00008048445,0.00008795734,0.0005285059,0.000008005856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010129453,0.00018478921,0.95077944,0.000071704635,0.0007819849,0.00006187928,0.00014478111,0.00009761026,0.00094517536,0.0019096138,0.015355206,0.028654898],"study_design_scores_gemma":[0.008038775,0.0008794369,0.8914305,0.0004146449,0.00025933117,0.0002014005,0.0005488332,0.0006551423,0.0062774783,0.03265179,0.058451913,0.0001907565],"about_ca_topic_score_codex":0.000044307595,"about_ca_topic_score_gemma":0.000007320351,"teacher_disagreement_score":0.059348915,"about_ca_system_score_codex":0.00032580888,"about_ca_system_score_gemma":0.0006976618,"threshold_uncertainty_score":0.8696454},"labels":[],"label_agreement":null},{"id":"W4411260753","doi":"10.1016/s1470-2045(25)00209-8","title":"Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Exelixis","keywords":"Atezolizumab; Cabozantinib; Medicine; Oncology; Prostate cancer; Prostate; Internal medicine; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.3279042008534256,"score_gpt":0.5471206174015985,"score_spread":0.21921641654817287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411260753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96120507,0.0062031997,0.00004097176,0.018446265,0.000536032,0.0054151267,0.00027173388,0.00004410277,0.007837519],"genre_scores_gemma":[0.9779148,0.0048620855,0.0006644693,0.0025612533,0.00042826906,0.0030826118,0.0002943411,0.0000290364,0.010163148],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974264,0.00071709335,0.0005533071,0.00044334686,0.00022901112,0.0006308745],"domain_scores_gemma":[0.998264,0.0008514334,0.00018343278,0.00048782837,0.00010879863,0.000104512845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096314,0.00024521878,0.0015435094,0.00019561996,0.00014100433,0.00006706235,0.00047973156,0.00010182802,0.0005411818],"category_scores_gemma":[0.00024305074,0.0001424246,0.00008667423,0.0005952769,0.00018944562,0.00010558576,0.00021635427,0.00051333907,0.000027962904],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9502315,0.0018708805,0.0006753194,0.000092233066,0.0012038874,0.0007381397,0.0011969476,0.000025895144,0.006405275,0.00022427474,0.012075089,0.025260573],"study_design_scores_gemma":[0.9494996,0.002646715,0.0011200857,0.00022464035,0.00076652225,0.000008757085,0.00029208002,0.0011977267,0.0028358183,0.00082877517,0.04042696,0.00015230346],"about_ca_topic_score_codex":0.0069145756,"about_ca_topic_score_gemma":0.0029591296,"teacher_disagreement_score":0.02835187,"about_ca_system_score_codex":0.00065036624,"about_ca_system_score_gemma":0.0028478322,"threshold_uncertainty_score":0.99969846},"labels":[],"label_agreement":null},{"id":"W4411270263","doi":"10.1016/j.celrep.2025.115828","title":"An integrated proteomic portrait of prostate cancer progression","year":2025,"lang":"en","type":"article","venue":"Cell Reports","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prevention of Organ Failure","funders":"Swiss Cancer Foundation; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Fondazione Gustav e Ruth Jacob; National Cancer Institute; Krebsliga Schweiz; Fondation Nelia et Amadeo Barletta; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"Prostate cancer; Portrait; Cancer; Cancer research; Biology; Medicine; Computational biology; Internal medicine; Art; Art history","score_opus":0.013795220017896577,"score_gpt":0.34856909453441487,"score_spread":0.3347738745165183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411270263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98643816,0.001956628,0.000020258938,0.00037376035,0.00018285129,0.0016654795,0.000007232847,0.000063359184,0.009292262],"genre_scores_gemma":[0.9783639,0.0002859268,0.0005165996,0.00003938754,0.00002676755,0.000295324,0.000109045766,0.00001563156,0.020347418],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99883825,0.000025711433,0.0003617173,0.00030704757,0.00024075819,0.00022649033],"domain_scores_gemma":[0.99908394,0.0000066653306,0.00017003897,0.00036573445,0.00026008478,0.00011354704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021337457,0.000123293,0.00025690417,0.00014424865,0.000046276255,0.000012338369,0.000043583947,0.000077647266,0.00015962897],"category_scores_gemma":[0.000024635694,0.00008102043,0.00006138261,0.00032625115,0.000101091464,0.00006406429,0.000024647234,0.00016078135,0.0000016099303],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000900275,0.0008389839,0.5391346,0.0009451,0.00009739789,0.0017827589,0.00037087995,0.000010703013,0.37534368,0.000011834707,0.0031322057,0.07743154],"study_design_scores_gemma":[0.0011282578,0.0004751744,0.04972429,0.0008472066,0.0000947222,0.000049861355,0.0001159951,0.00007501494,0.93632555,0.00014056948,0.010924648,0.000098738485],"about_ca_topic_score_codex":0.00018388644,"about_ca_topic_score_gemma":0.000008355269,"teacher_disagreement_score":0.5609818,"about_ca_system_score_codex":0.000121954654,"about_ca_system_score_gemma":0.0012238962,"threshold_uncertainty_score":0.3303917},"labels":[],"label_agreement":null},{"id":"W4411277137","doi":"10.3390/siuj6030045","title":"SIU-ICUD: Germline Genetic Susceptibility to Prostate Cancer: Utility and Clinical Implementation","year":2025,"lang":"en","type":"article","venue":"Société Internationale d’Urologie Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Germline; Prostate cancer; Oncology; Medicine; Cancer; Cancer research; Internal medicine; Genetics; Biology; Gene","score_opus":0.0713285831401083,"score_gpt":0.4972833714040743,"score_spread":0.425954788263966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411277137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97036415,0.0020296802,0.00040518938,0.02463581,0.0007743355,0.00071656593,0.000074440635,0.000036442234,0.0009633594],"genre_scores_gemma":[0.9879086,0.0045218216,0.0009592001,0.0020032132,0.00038305332,0.000066555156,0.000051794214,0.000009071412,0.004096683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980895,0.00017015671,0.0006488795,0.0003729898,0.00038790872,0.00033055127],"domain_scores_gemma":[0.9986504,0.0002456161,0.0001508436,0.00017897571,0.00054199604,0.00023218755],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009758676,0.00015588966,0.00030644366,0.00017495773,0.00018595155,0.00007643454,0.00015401076,0.000099655015,0.0009344251],"category_scores_gemma":[0.00033372917,0.000120217555,0.00016356022,0.0001777751,0.00017079765,0.000101662255,0.0001600359,0.0005266656,0.000008308976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008989294,0.00017818487,0.7982581,0.000032783653,0.00031425405,0.00003868593,0.00013735611,0.000004741818,0.0002732783,0.000032187094,0.005679366,0.1941521],"study_design_scores_gemma":[0.0040263114,0.0006222156,0.9794783,0.000048358725,0.00012574816,0.000039703238,0.00046342835,0.00030932005,0.00041976888,0.0017088355,0.012663245,0.00009475954],"about_ca_topic_score_codex":0.00011532068,"about_ca_topic_score_gemma":0.00021317552,"teacher_disagreement_score":0.19405735,"about_ca_system_score_codex":0.0003878877,"about_ca_system_score_gemma":0.00068032194,"threshold_uncertainty_score":0.99997884},"labels":[],"label_agreement":null},{"id":"W4411278169","doi":"10.3390/siuj6030046","title":"SIU-ICUD: Management of Lymph Node–Positive Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"Société Internationale d’Urologie Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lymph node; Medicine; Prostate cancer; Prostate; Oncology; Cancer; Internal medicine","score_opus":0.03203812522956646,"score_gpt":0.3899461817217951,"score_spread":0.3579080564922287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411278169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8630852,0.007626003,0.00055420405,0.026503062,0.0014288226,0.00070808205,0.00011974626,0.00005111085,0.099923745],"genre_scores_gemma":[0.93629986,0.009925749,0.0007321403,0.0010520152,0.00016538396,0.00008907251,0.000048310183,0.000011849432,0.051675618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986327,0.000052912917,0.00035536644,0.00020177454,0.00047940676,0.00027779024],"domain_scores_gemma":[0.9990051,0.00010037172,0.00017471884,0.00013284462,0.0005043046,0.000082668696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002879258,0.00014078364,0.00025580428,0.00022881765,0.00011828704,0.000033746364,0.00020344969,0.00007423393,0.00051937165],"category_scores_gemma":[0.000039041446,0.00010520139,0.00018619794,0.00020584854,0.00014419638,0.000102295766,0.00012936935,0.0003048285,0.0000093401495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005688703,0.0012997194,0.7372538,0.0006934983,0.008690797,0.0013011545,0.0009749596,0.00046268196,0.004177172,0.0070814416,0.020746857,0.21162926],"study_design_scores_gemma":[0.015488022,0.00048211133,0.93602353,0.0015953156,0.00068480714,0.00016011187,0.0021478294,0.00062273623,0.016177671,0.008926876,0.017404577,0.0002863925],"about_ca_topic_score_codex":0.00002970097,"about_ca_topic_score_gemma":0.000001611137,"teacher_disagreement_score":0.21134287,"about_ca_system_score_codex":0.0005629863,"about_ca_system_score_gemma":0.00036748158,"threshold_uncertainty_score":0.5686755},"labels":[],"label_agreement":null},{"id":"W4411382473","doi":"10.3390/siuj6030047","title":"SIU-ICUD: Localized Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"Société Internationale d’Urologie Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Prostate; Cancer; Prostate cancer; Medicine; Internal medicine","score_opus":0.04353362141379054,"score_gpt":0.411677523613997,"score_spread":0.3681439022002065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411382473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8137003,0.014390467,0.0008619501,0.09173625,0.0032063469,0.00090198294,0.00006839572,0.00016484981,0.07496946],"genre_scores_gemma":[0.86687595,0.008360673,0.0004563081,0.004236747,0.0005647359,0.00013280731,0.000057384073,0.000017502978,0.11929791],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850315,0.00007255664,0.0003468954,0.00023037507,0.0004802207,0.00036682942],"domain_scores_gemma":[0.9989202,0.00015336108,0.00012952047,0.00014560804,0.00051380944,0.0001374914],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035871723,0.0001608801,0.0002763692,0.00025905928,0.00019906205,0.000085642736,0.0002174546,0.000111599555,0.0016418559],"category_scores_gemma":[0.00024108964,0.000115156916,0.00021116722,0.00022459804,0.00015501116,0.00013245533,0.00009815557,0.0006485229,0.000031971063],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005218024,0.00078721193,0.64353395,0.00017585547,0.0028920027,0.00091623876,0.000649711,0.00025192767,0.005271691,0.0025641462,0.1574422,0.18029703],"study_design_scores_gemma":[0.02477598,0.0010527764,0.1913678,0.0006682084,0.0004918243,0.0004797131,0.0011718695,0.0018414968,0.01176303,0.021617966,0.74429804,0.00047130356],"about_ca_topic_score_codex":0.00003580866,"about_ca_topic_score_gemma":0.000010004371,"teacher_disagreement_score":0.5868558,"about_ca_system_score_codex":0.0006040678,"about_ca_system_score_gemma":0.0008903046,"threshold_uncertainty_score":0.9992708},"labels":[],"label_agreement":null},{"id":"W4411469637","doi":"10.1016/j.eururo.2025.05.037","title":"Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial","year":2025,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Bayer","keywords":"Medicine; Docetaxel; Taxane; Hazard ratio; Internal medicine; Discontinuation; Prostate cancer; Placebo; Androgen deprivation therapy; Oncology; Post-hoc analysis; Surgery; Chemotherapy; Cancer; Confidence interval; Breast cancer; Pathology","score_opus":0.018835768077948817,"score_gpt":0.31260710923490265,"score_spread":0.2937713411569538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411469637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99664783,0.00044358117,0.000021950598,0.00082091225,0.00003120368,0.0017647118,0.0001275256,0.00000848769,0.00013382144],"genre_scores_gemma":[0.99901295,0.00048203924,0.000041523595,0.00010305956,0.000005990131,0.00002698575,0.00019944881,0.000015787284,0.0001122246],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99836797,0.0006634993,0.0002929233,0.00026264266,0.00024212367,0.00017086421],"domain_scores_gemma":[0.9989836,0.00017405939,0.00024932917,0.00020215225,0.00035151138,0.00003931784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003631672,0.0001399422,0.00045011123,0.00036465426,0.000054285705,0.0000076027895,0.000062172396,0.000026524973,0.000007713463],"category_scores_gemma":[0.00009156022,0.000069578666,0.000042587162,0.00095063366,0.00025950314,0.000055370932,0.000043385993,0.00013549761,1.9049172e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6818401,0.0011994374,0.2976538,0.00004402435,0.0020648327,0.000058070797,0.0017981414,0.00011075014,0.002653031,0.000014103517,0.000013849423,0.012549831],"study_design_scores_gemma":[0.16237615,0.010448104,0.8233428,0.00007894911,0.001072451,0.0000013695559,0.0001900766,0.0005669785,0.0017852806,0.000005573777,0.000053384036,0.00007888205],"about_ca_topic_score_codex":0.00006809653,"about_ca_topic_score_gemma":0.00021496792,"teacher_disagreement_score":0.525689,"about_ca_system_score_codex":0.000047138135,"about_ca_system_score_gemma":0.0001800303,"threshold_uncertainty_score":0.28373355},"labels":[],"label_agreement":null},{"id":"W4411638096","doi":"10.1016/j.euo.2025.04.025","title":"PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Manchester Biomedical Research Centre; Merck Sharp and Dohme; Institute of Cancer Research; Prostate Cancer UK; Cancer Research UK; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Movember Foundation","keywords":"Medicine; Pembrolizumab; Prostate cancer; Open label; Oncology; Internal medicine; Castration; Clinical trial; Immune system; Immunotherapy; Cancer; Immunology; Hormone","score_opus":0.07294500427301906,"score_gpt":0.3603880609852758,"score_spread":0.2874430567122568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411638096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910343,0.00064093224,0.0000074207205,0.00087902584,0.00005149162,0.0023377487,0.0000368515,0.00003534964,0.00497683],"genre_scores_gemma":[0.9979701,0.000012704013,0.00079037185,0.00097295217,0.0000151868135,0.000076405566,0.000040059665,0.00003557618,0.00008663213],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973046,0.0012388078,0.00043248225,0.00047867125,0.00017730567,0.00036809334],"domain_scores_gemma":[0.9986331,0.00039900778,0.00023872998,0.00031417116,0.00029599434,0.00011898808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006333555,0.00022348139,0.0004904855,0.00017802195,0.00015491806,0.000025565701,0.00016731715,0.00005085764,0.000012794095],"category_scores_gemma":[0.00039961826,0.00013402705,0.000020377867,0.00048663717,0.00088492926,0.00008491261,0.000106555766,0.0003097175,0.0000017596019],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7988142,0.029047653,0.07905803,0.00032385188,0.0015449489,0.004155347,0.009656498,0.00034882038,0.06513342,0.000943939,0.00016717581,0.010806118],"study_design_scores_gemma":[0.6455635,0.1710769,0.17340292,0.00038780013,0.0015275672,0.00013245488,0.0017439175,0.0005215253,0.003842903,0.00008884869,0.0012328514,0.00047884777],"about_ca_topic_score_codex":0.0003531208,"about_ca_topic_score_gemma":0.00018699231,"teacher_disagreement_score":0.15325072,"about_ca_system_score_codex":0.00013094449,"about_ca_system_score_gemma":0.001152479,"threshold_uncertainty_score":0.54654646},"labels":[],"label_agreement":null},{"id":"W4411842050","doi":"10.1080/14796694.2025.2475730","title":"Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Disease; Oncology; Cancer; Internal medicine; Androgen receptor","score_opus":0.017160304996255038,"score_gpt":0.4120309966057451,"score_spread":0.39487069160949007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411842050","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028103552,0.9861189,2.6654013e-7,0.002655418,0.00037911488,0.007741385,0.002217883,0.000033652464,0.00057233375],"genre_scores_gemma":[0.000014607532,0.9870722,0.00003683588,0.00034122978,0.00041306557,0.003046443,0.0019257001,0.00005298826,0.0070969253],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976973,0.00029832017,0.0005479779,0.0005508454,0.00035189794,0.0005536771],"domain_scores_gemma":[0.99819815,0.00024670534,0.00045216893,0.00074539497,0.0001405585,0.00021702802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014357087,0.00053823285,0.0025280046,0.00009346966,0.00012072092,0.000008687993,0.0002216113,0.00020339928,0.00020751925],"category_scores_gemma":[0.00004276192,0.00023051337,0.00045843067,0.00056114316,0.00022363917,0.000034021414,0.00007921119,0.00035612905,0.000014459688],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012119794,0.0006467473,0.00050999864,0.072633065,0.0007715513,0.00030548297,0.00039173503,2.1948216e-7,7.370507e-8,0.000014758299,0.0017498034,0.9217646],"study_design_scores_gemma":[0.003515603,0.0018461351,0.00071804965,0.047877286,0.0034960932,0.000007539069,0.000088461195,8.708409e-8,0.000002338887,0.0000032514838,0.94225675,0.00018839371],"about_ca_topic_score_codex":0.000049964197,"about_ca_topic_score_gemma":0.00020651662,"teacher_disagreement_score":0.94050694,"about_ca_system_score_codex":0.0014475844,"about_ca_system_score_gemma":0.0032237903,"threshold_uncertainty_score":0.9400062},"labels":[],"label_agreement":null},{"id":"W4411915953","doi":"10.1101/2025.06.26.25330371","title":"Identification and Quantification of Autoantibodies against Prostate-Specific Antigens by Immunoaffinity-Mass Spectrometry","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Prostate-specific antigen; Identification (biology); Autoantibody; Mass spectrometry; Antigen; Computational biology; Chromatography; Chemistry; Medicine; Prostate; Antibody; Immunology; Biology; Internal medicine; Cancer","score_opus":0.0319232355120944,"score_gpt":0.325004897467849,"score_spread":0.2930816619557546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411915953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662924,0.025342101,0.0022842418,0.0016329668,0.00056665106,0.0015843083,0.0006587169,0.00011475845,0.00152386],"genre_scores_gemma":[0.92912227,0.05949542,0.00092243485,0.000021946542,0.00006641557,0.00011028959,0.0017880148,0.000032733817,0.008440452],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99751014,0.00015380562,0.00073221134,0.0007629241,0.0004995024,0.0003414147],"domain_scores_gemma":[0.9980231,0.0001376881,0.00040033166,0.00091206614,0.00041956827,0.00010724598],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00085980876,0.0003350974,0.0006928593,0.0005734407,0.00013985463,0.000089626796,0.00023407169,0.00028271973,0.000035757985],"category_scores_gemma":[0.00015060834,0.00029123182,0.00015622705,0.0004577829,0.0003429843,0.000076702105,0.00023585914,0.00063791324,0.000013751393],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033587535,0.00034439532,0.10197995,0.0024143134,0.00042629283,0.000017484357,0.00057129347,0.000011938382,0.88645405,0.00027947713,0.002012062,0.0051528607],"study_design_scores_gemma":[0.0017366034,0.00018916512,0.19019184,0.001468358,0.00027025252,0.0000045089337,0.00037931872,0.0008112805,0.79845405,0.0005955651,0.0054476215,0.00045145306],"about_ca_topic_score_codex":0.000032359756,"about_ca_topic_score_gemma":0.0000023677678,"teacher_disagreement_score":0.08821189,"about_ca_system_score_codex":0.00016930715,"about_ca_system_score_gemma":0.0003162132,"threshold_uncertainty_score":0.999954},"labels":[],"label_agreement":null},{"id":"W4411993724","doi":"10.2967/jnumed.125.269653","title":"A Prospective Provincial Registry of <sup>18</sup>F-PSMA PET/CT for Recurrent Prostate Cancer: Results for 4,135 Men","year":2025,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; Thunder Bay Regional Health Sciences Centre; McMaster University; Cancer Care Ontario; Western University; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Cohort; Biochemical recurrence; Radiation therapy; Oncology; Internal medicine; Cancer registry; Prostate-specific antigen; Cancer; Multivariate analysis; Prostate; Prospective cohort study","score_opus":0.02780597531518134,"score_gpt":0.36417173761014,"score_spread":0.3363657622949586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411993724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7823391,0.015385581,0.00019796548,0.1608454,0.0018329199,0.014741939,0.0012938142,0.000097086224,0.023266224],"genre_scores_gemma":[0.9787339,0.0037725125,0.0023896028,0.0005497294,0.0020325591,0.00023380495,0.00006245284,0.00008145905,0.012143979],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976234,0.00004872325,0.0010177393,0.00030506862,0.0006038655,0.0004012087],"domain_scores_gemma":[0.9970329,0.0002618382,0.0007270982,0.0002901223,0.0014614608,0.00022660237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010261162,0.00023347342,0.0009123572,0.00036581737,0.00013153187,0.000011119384,0.00022619782,0.00003612261,0.000054763153],"category_scores_gemma":[0.0014743947,0.00014918885,0.00026289417,0.00035540145,0.00031153637,0.00011077013,0.00005046436,0.00040768122,0.0000010478512],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16799392,0.0013853438,0.0051478776,0.0048271045,0.0022696734,0.00076402223,0.004908157,0.000057120364,0.0077858604,0.0011105414,0.75534934,0.048401035],"study_design_scores_gemma":[0.1718432,0.057366937,0.016378738,0.021147441,0.003916052,0.001483336,0.013367568,0.005912369,0.010659812,0.0050326013,0.69222707,0.0006648965],"about_ca_topic_score_codex":0.00008243977,"about_ca_topic_score_gemma":0.000013438257,"teacher_disagreement_score":0.19639483,"about_ca_system_score_codex":0.000600921,"about_ca_system_score_gemma":0.0011825261,"threshold_uncertainty_score":0.6083745},"labels":[],"label_agreement":null},{"id":"W4412094626","doi":"10.1038/s41698-025-01002-8","title":"Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer","year":2025,"lang":"en","type":"article","venue":"npj Precision Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Dental and Craniofacial Research; National Cancer Institute; National Institutes of Health; National Institute of General Medical Sciences; U.S. Department of Defense","keywords":"Enzalutamide; Prostate cancer; Docetaxel; Oncology; Medicine; Cancer research; Internal medicine; Prostate; Clinical trial; Androgen receptor; Cancer","score_opus":0.06082974284687353,"score_gpt":0.4262125010414085,"score_spread":0.365382758194535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412094626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98675555,0.0030835965,0.000117763564,0.0043606395,0.00033168335,0.0023672823,0.000036777186,0.00004527163,0.002901434],"genre_scores_gemma":[0.98732084,0.0007658546,0.0043294085,0.00016742268,0.000050121434,0.0012355845,0.000036461865,0.000016743232,0.006077546],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980906,0.0002734985,0.0005149858,0.00039252703,0.00033899167,0.0003893444],"domain_scores_gemma":[0.9988759,0.00045620743,0.00008762811,0.00022758367,0.00026149352,0.0000911556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009933058,0.00016703096,0.0005091403,0.0005182782,0.000055967736,0.000011074224,0.0001285252,0.00027439962,0.00019231284],"category_scores_gemma":[0.00023885843,0.00012822646,0.000116916046,0.0005842103,0.00023725498,0.00008322316,0.000060575174,0.00046085345,0.0000075034386],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08001964,0.0025261045,0.109711796,0.0004026128,0.00019242015,0.00031726615,0.0020314779,0.00012414138,0.39255825,0.00033685236,0.00087341573,0.41090602],"study_design_scores_gemma":[0.026830612,0.008830591,0.68151945,0.0018971682,0.00020883667,0.000058780428,0.0012737109,0.0029021343,0.20301719,0.0021946253,0.07090908,0.00035784318],"about_ca_topic_score_codex":0.0001398032,"about_ca_topic_score_gemma":0.00011710576,"teacher_disagreement_score":0.5718076,"about_ca_system_score_codex":0.0005791679,"about_ca_system_score_gemma":0.0021436939,"threshold_uncertainty_score":0.5228923},"labels":[],"label_agreement":null},{"id":"W4412196506","doi":"10.1016/j.urolonc.2025.06.004","title":"Survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium 223: Princess Margaret Cancer Centre (PMCC) experience","year":2025,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Radium-223; Internal medicine; Urology; Cancer; Oncology; Prospective cohort study; Bone metastasis","score_opus":0.0363104111602161,"score_gpt":0.35423736587398685,"score_spread":0.31792695471377075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412196506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98160285,0.0017094328,0.0001672664,0.013509225,0.000050639028,0.0019312116,0.00011117515,0.00006454722,0.0008536459],"genre_scores_gemma":[0.9593817,0.0018269356,0.025793046,0.0005914256,0.000023788887,0.0024905803,0.00017758626,0.00003129302,0.009683638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983335,0.00011314967,0.00027180475,0.00058313523,0.00023993273,0.00045846248],"domain_scores_gemma":[0.99886477,0.0002510328,0.00018881226,0.00017635865,0.00031342334,0.00020557565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022120736,0.00031538543,0.000562858,0.00019198097,0.0004985689,0.0000664529,0.00008975592,0.000103139595,0.000024908126],"category_scores_gemma":[0.000049289993,0.00017909447,0.000026112046,0.0004727929,0.001412641,0.00018729031,0.000029383486,0.00021707242,3.4991618e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028688607,0.00026560712,0.9899944,0.00017948478,0.00035486484,0.00008637028,0.001646639,0.00012525411,0.0004442411,0.0018723378,0.0002797287,0.0018821866],"study_design_scores_gemma":[0.046869442,0.028578324,0.7380738,0.001754338,0.0057803555,0.0006302481,0.019567551,0.0046793125,0.011447844,0.0030298687,0.13786711,0.0017217676],"about_ca_topic_score_codex":0.0011329927,"about_ca_topic_score_gemma":0.003106268,"teacher_disagreement_score":0.25192058,"about_ca_system_score_codex":0.00031312226,"about_ca_system_score_gemma":0.0013160065,"threshold_uncertainty_score":0.73032606},"labels":[],"label_agreement":null},{"id":"W4412363585","doi":"10.1016/j.radonc.2025.111041","title":"The role of stereotactic body radiotherapy in oligoprogressive prostate cancer: A site-specific analysis of the prospective, phase II RADIANT trial","year":2025,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University; Princess Margaret Cancer Centre; BC Cancer Agency; University of British Columbia; University Health Network","funders":"Princess Margaret Cancer Foundation; Conquer Cancer Foundation","keywords":"Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Radiation therapy; Oncology; Systemic therapy; Cumulative incidence; Cohort; Prospective cohort study; Quality of life (healthcare); Cancer; Toxicity; Clinical trial","score_opus":0.012555599021597778,"score_gpt":0.3624922062098307,"score_spread":0.34993660718823294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412363585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8879329,0.10632744,0.000005422033,0.0028913524,0.00018245706,0.0022277879,0.000043357533,0.000008922956,0.0003803579],"genre_scores_gemma":[0.93312687,0.06487902,0.00006500111,0.00013816929,0.000088899185,0.00041601367,0.000007418798,0.000014846998,0.0012637655],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984359,0.0002666659,0.0004626323,0.0003101694,0.00020391858,0.0003207062],"domain_scores_gemma":[0.9988569,0.00034296344,0.00025466958,0.00036874224,0.00011266166,0.00006406883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040624174,0.00017303074,0.0007897594,0.0003607701,0.00020894562,0.000015539126,0.00016131741,0.00012615295,0.000070450245],"category_scores_gemma":[0.00002406925,0.000091349175,0.00021495494,0.0013539937,0.00061148504,0.00003932042,0.000032245494,0.00026278902,9.0661494e-8],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22911516,0.0035467267,0.35362804,0.0000895426,0.008021314,0.00004949172,0.011834742,0.00003877334,0.057017956,0.0017141425,0.0003645762,0.33457956],"study_design_scores_gemma":[0.40793514,0.023911644,0.21229506,0.0004154592,0.0023223506,0.000028034401,0.0017041058,0.0062629576,0.04267562,0.00095412583,0.30106676,0.00042875414],"about_ca_topic_score_codex":0.00030082875,"about_ca_topic_score_gemma":0.00057710515,"teacher_disagreement_score":0.3341508,"about_ca_system_score_codex":0.00078844785,"about_ca_system_score_gemma":0.00067027524,"threshold_uncertainty_score":0.37251112},"labels":[],"label_agreement":null},{"id":"W4412416961","doi":"10.1186/s40644-025-00910-z","title":"The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study","year":2025,"lang":"en","type":"article","venue":"Cancer Imaging","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke; Université Laval","funders":"","keywords":"Medicine; Prostate cancer; Nuclear medicine; Spleen; Urology; Prostate; Body surface area; Population; Kidney; PET-CT; Internal medicine; Cancer; Positron emission tomography","score_opus":0.030329208788776863,"score_gpt":0.3948171014197409,"score_spread":0.36448789263096404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412416961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97318155,0.011284296,0.0000077397335,0.011444715,0.00011430828,0.003560579,0.00024683663,0.000014988503,0.00014500499],"genre_scores_gemma":[0.9953262,0.0005952038,0.000010128917,0.000208916,0.000020708409,0.0030367214,0.000018634613,0.000018061763,0.0007654294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985311,0.00013808951,0.0003753102,0.00038127846,0.0002308559,0.00034335197],"domain_scores_gemma":[0.9986282,0.00056646613,0.00014273093,0.00036495045,0.00023514351,0.000062502244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005839552,0.00019208423,0.00043869053,0.00028210194,0.00035228915,0.000068449415,0.00016060838,0.0000046352275,0.0000070789697],"category_scores_gemma":[0.00015178727,0.000104186074,0.00014771748,0.001413831,0.00012095459,0.00007098447,0.000055861416,0.00018466706,4.1110312e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020832117,0.00045020858,0.887974,0.00067880546,0.0044000912,0.00007704675,0.0012532357,0.0007477232,0.071144566,0.0005370439,0.00081397983,0.029840043],"study_design_scores_gemma":[0.006329828,0.00033512435,0.94254667,0.0005506065,0.0056397356,0.000009504102,0.0011234534,0.0046411543,0.0377048,0.00024007169,0.00068189064,0.00019717032],"about_ca_topic_score_codex":0.00095310214,"about_ca_topic_score_gemma":0.004029615,"teacher_disagreement_score":0.05457262,"about_ca_system_score_codex":0.00041683466,"about_ca_system_score_gemma":0.0006108629,"threshold_uncertainty_score":0.42485848},"labels":[],"label_agreement":null},{"id":"W4412492827","doi":"10.1016/j.euo.2025.04.009","title":"Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health; Movember Foundation; Sanofi; Veracyte; U.S. Department of Defense","keywords":"Docetaxel; Medicine; Prostate cancer; Oncology; Internal medicine; Hazard ratio; Radiation therapy; Metastasis; Chemotherapy; Cancer; Confidence interval","score_opus":0.01989595292806918,"score_gpt":0.3533734733597566,"score_spread":0.33347752043168744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412492827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879873,0.0035870997,0.00031096386,0.0047066384,0.0001806779,0.0022606356,0.00029085716,0.00002618319,0.000649666],"genre_scores_gemma":[0.9942123,0.00328069,0.00054374384,0.0010495534,0.00007596407,0.00038347475,0.000278583,0.000023033625,0.00015264908],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99715203,0.0012249151,0.0005456438,0.0005615413,0.000165139,0.00035070258],"domain_scores_gemma":[0.9981926,0.0010327514,0.00024598849,0.00029173007,0.00014571566,0.000091228314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008288337,0.00021798744,0.00083041616,0.0006260069,0.00012323912,0.000020078847,0.00018819717,0.00013718124,0.00006786676],"category_scores_gemma":[0.00018158428,0.00013516404,0.000093319686,0.00085589866,0.00047768254,0.00006275029,0.00005152733,0.00037312444,0.000002451594],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55098474,0.00353091,0.0972785,0.00008813357,0.008714937,0.000697026,0.02369741,0.00028256158,0.0686592,0.0003394671,0.0008220145,0.24490511],"study_design_scores_gemma":[0.46087533,0.04364829,0.42446002,0.00024221162,0.01755507,0.000036690813,0.003268473,0.0022267557,0.013975003,0.0006197757,0.032528847,0.0005635318],"about_ca_topic_score_codex":0.00084580964,"about_ca_topic_score_gemma":0.0014638369,"teacher_disagreement_score":0.32718152,"about_ca_system_score_codex":0.00019544347,"about_ca_system_score_gemma":0.00035815945,"threshold_uncertainty_score":0.551183},"labels":[],"label_agreement":null},{"id":"W4412521280","doi":"10.1016/j.annonc.2025.07.003","title":"Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Cancer Institute; EMD Serono; Genentech; Sierra Oncology; Amgen; Siemens Healthineers; Astellas Pharma; Eisai; AstraZeneca; Invitae; MacroGenics; Y-mAbs Therapeutics; UroGen Pharma; Ipsen; BeiGene; National Institutes of Health; Menarini Silicon Biosystems; Vertex Pharmaceuticals; Boston Scientific Corporation; Sanofi; Endocyte; Novartis; Cardinal Health; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Hazard ratio; Progression-free survival; Abiraterone acetate; Taxane; Adverse effect; Oncology; Randomized controlled trial; Urology; Androgen receptor; Confidence interval; Androgen deprivation therapy; Chemotherapy; Cancer; Breast cancer","score_opus":0.19551776687375252,"score_gpt":0.4526475834852379,"score_spread":0.2571298166114854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412521280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99486274,0.0010842982,9.4554474e-7,0.00090391864,0.00019641059,0.0017245443,0.0009073962,0.0000025093243,0.00031723187],"genre_scores_gemma":[0.9985258,0.0009749587,0.00006422811,0.000031649055,0.000031824275,0.0001129419,0.000106068524,0.000008359086,0.00014419829],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984023,0.00021798305,0.00062055595,0.00020817813,0.00033067414,0.00022029007],"domain_scores_gemma":[0.99843967,0.00024665997,0.0005215278,0.00019208447,0.00054197176,0.00005810939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036567866,0.00014776136,0.00076972356,0.00019865778,0.000035447298,0.0000025315019,0.00008681922,0.00007404816,0.00003811351],"category_scores_gemma":[0.00013249154,0.00008958139,0.000098023775,0.00039946806,0.0003911546,0.00007537442,0.000056777495,0.00012573965,8.889373e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87145483,0.004616208,0.053104237,0.0010476714,0.0018177317,0.00002898192,0.0033543417,0.000028062046,0.018819982,0.00021815156,0.0004321688,0.045077614],"study_design_scores_gemma":[0.58597696,0.04954887,0.08648209,0.0013297542,0.0008419832,0.0000010998012,0.002178023,0.000046135425,0.27127853,0.00012103937,0.001955133,0.0002404001],"about_ca_topic_score_codex":0.0020990279,"about_ca_topic_score_gemma":0.0014657445,"teacher_disagreement_score":0.2854779,"about_ca_system_score_codex":0.00008056797,"about_ca_system_score_gemma":0.0013021976,"threshold_uncertainty_score":0.3653023},"labels":[],"label_agreement":null},{"id":"W4412522153","doi":"10.1016/s0140-6736(25)00684-1","title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Arena Pharmaceuticals","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Clinical endpoint; Internal medicine; Oncology; Cohort; Androgen deprivation therapy; Cancer; Clinical trial; Androgen receptor; Pathology","score_opus":0.05745369416498963,"score_gpt":0.3570725287255095,"score_spread":0.29961883456051985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412522153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94611543,0.0027571754,0.00002333213,0.03167452,0.00023282028,0.009225825,0.0010515774,0.000052337437,0.008866973],"genre_scores_gemma":[0.9850864,0.00096216355,0.000103361424,0.00047551104,0.0006173246,0.0021583533,0.00034448868,0.000024649788,0.010227774],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99734986,0.0005361847,0.0005990262,0.00041528215,0.00055277447,0.0005468896],"domain_scores_gemma":[0.99738216,0.001574639,0.00020468415,0.00064849225,0.0001077326,0.00008226137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017031658,0.00028344712,0.0011187302,0.00007560394,0.00022497338,0.0001245317,0.0003101724,0.000049517377,0.0000648259],"category_scores_gemma":[0.00039224167,0.0001250174,0.0001264904,0.00033474286,0.00022440127,0.00009475753,0.00005691593,0.00048251537,0.000007573344],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98528033,0.0002547735,0.000345628,0.00004601902,0.0008336311,0.00018127306,0.0014714869,0.00045484267,0.0016945618,0.00020550667,0.008287641,0.0009443111],"study_design_scores_gemma":[0.98949414,0.0007464285,0.0014972955,0.00035835535,0.0005707728,0.0000036058404,0.00061037217,0.0023197047,0.0011065489,0.0005299465,0.002613037,0.0001497978],"about_ca_topic_score_codex":0.0049329363,"about_ca_topic_score_gemma":0.0034215471,"teacher_disagreement_score":0.038970932,"about_ca_system_score_codex":0.0003461335,"about_ca_system_score_gemma":0.0013553246,"threshold_uncertainty_score":0.74571574},"labels":[],"label_agreement":null},{"id":"W4412565706","doi":"10.1097/rlu.0000000000006062","title":"Potential Pitfall","year":2025,"lang":"en","type":"article","venue":"Clinical Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Lymphoma; Follicular lymphoma; Metastasis; Prostate; Cancer; Biopsy; PET-CT; Lymph; Oncology; Positron emission tomography; Radiology; Pathology; Internal medicine","score_opus":0.051717635192855244,"score_gpt":0.44951012005379054,"score_spread":0.3977924848609353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412565706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5490026,0.0033008028,0.00017258216,0.22022288,0.0026585597,0.00087238103,0.0000043819537,0.00031386144,0.22345196],"genre_scores_gemma":[0.95578045,0.0019445943,0.00031320335,0.014357538,0.0010419542,0.0000061463156,0.00002612154,0.000024658031,0.026505318],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99859774,0.000067128436,0.00047323634,0.00031874364,0.00027554657,0.00026763216],"domain_scores_gemma":[0.9990318,0.00016098746,0.00004380614,0.0003763279,0.00012692664,0.00026018333],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054351176,0.00011975935,0.00045269015,0.00012276431,0.000084483036,0.000007309255,0.0001246526,0.00014854797,0.0018752053],"category_scores_gemma":[0.0006238034,0.00007616109,0.0001457835,0.00027138848,0.000608251,0.000029422243,0.00008858796,0.00044566684,0.00037069066],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034354264,0.0009810468,0.04217383,0.0002524329,0.00059637974,0.000785132,0.0001426142,6.215927e-7,0.0028543782,0.005164865,0.798974,0.1446393],"study_design_scores_gemma":[0.013225153,0.0021344565,0.24093008,0.0006438402,0.00040908263,0.000029721206,0.00026729086,0.00041315792,0.00005200834,0.0014253219,0.74034846,0.000121411955],"about_ca_topic_score_codex":0.00002477343,"about_ca_topic_score_gemma":0.0000011641843,"teacher_disagreement_score":0.40677786,"about_ca_system_score_codex":0.000052384792,"about_ca_system_score_gemma":0.00012671188,"threshold_uncertainty_score":0.9990372},"labels":[],"label_agreement":null},{"id":"W4412571666","doi":"10.3390/curroncol32080412","title":"Systematic Literature Review on Economic Evaluations and Health Economic Models in Metastatic Castration-Sensitive Prostate Cancer","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Research, Development and Innovation Office; European Commission","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Systematic review; Psychological intervention; Oncology; MEDLINE; Economic evaluation; Cancer; Internal medicine; Pathology","score_opus":0.2696857006024208,"score_gpt":0.5597454857606459,"score_spread":0.29005978515822506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412571666","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000075009625,0.98490924,0.000003673012,0.0018586039,0.0006939701,0.011418357,0.00074238493,0.000017968221,0.00034828263],"genre_scores_gemma":[0.000009712419,0.992924,0.00003370879,0.0002103202,0.00010211174,0.0047696526,0.0013070569,0.000029306786,0.0006141565],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9965911,0.00096985704,0.0012598104,0.0006539777,0.0001360579,0.00038922974],"domain_scores_gemma":[0.99827045,0.00049346476,0.00060899125,0.00034841875,0.0000970286,0.00018167218],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011590389,0.0004466345,0.0037929805,0.00058887794,0.000078229044,0.000035838213,0.00009466373,0.000140526,0.00003335872],"category_scores_gemma":[0.00005766844,0.00031324622,0.00025921912,0.00023741643,0.00007742678,0.00009594685,0.00005511108,0.00069310615,0.000047485562],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00002037496,0.00010041686,0.00000323391,0.6235082,0.0002728093,0.00003037137,0.00021827176,0.000018621475,4.410756e-9,0.00037749187,0.0018112898,0.3736389],"study_design_scores_gemma":[0.0013255392,0.0004550991,0.000007330636,0.9204363,0.0020853446,0.00011847147,0.00003530113,0.0005275485,9.4215004e-8,0.00012437928,0.07467745,0.00020713343],"about_ca_topic_score_codex":0.000042813852,"about_ca_topic_score_gemma":0.00036810216,"teacher_disagreement_score":0.37343177,"about_ca_system_score_codex":0.005521981,"about_ca_system_score_gemma":0.009781477,"threshold_uncertainty_score":0.999932},"labels":[],"label_agreement":null},{"id":"W4412603160","doi":"10.1016/j.ijrobp.2025.07.1425","title":"Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)","year":2025,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Interior Health","funders":"Astellas Pharma; NRG Oncology; National Cancer Institute; Boston Scientific Corporation; Genentech; American College of Radiation Oncology; Celgene; AstraZeneca; Takeda Pharmaceuticals U.S.A.; Pfizer","keywords":"Androgen deprivation therapy; Prostate cancer; Medicine; Radiation therapy; Oncology; Internal medicine; Clinical trial; Cancer","score_opus":0.02857638083174456,"score_gpt":0.3626273983218109,"score_spread":0.3340510174900663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412603160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98378503,0.005820643,0.004108548,0.002211262,0.0005848591,0.0031567628,0.00024533912,0.000047253972,0.00004029928],"genre_scores_gemma":[0.9014643,0.095893964,0.0008539905,0.00022084692,0.0005681416,0.0002755606,0.0006400571,0.00005008692,0.00003305305],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973565,0.00034723987,0.00096697797,0.0004854359,0.0005064898,0.00033740088],"domain_scores_gemma":[0.99594015,0.0005845249,0.0016494067,0.00021681277,0.0014649372,0.00014416409],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008001322,0.0003949163,0.0008038163,0.00041512775,0.00021541359,0.000075303295,0.00020698704,0.00032162346,0.00002449169],"category_scores_gemma":[0.000114487535,0.00027483393,0.00013516693,0.0004744655,0.00031568253,0.00053421647,0.000022663167,0.00038416704,4.9153994e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2869318,0.0008929743,0.065745674,0.000013009747,0.003014151,0.000004670011,0.0010422551,0.00020726219,0.01991418,0.0002544392,0.0000950043,0.6218846],"study_design_scores_gemma":[0.6703922,0.040567953,0.10259075,0.00017335745,0.0003630236,0.000020862124,0.00016985138,0.003264873,0.17410092,0.0024683983,0.005444637,0.000443176],"about_ca_topic_score_codex":0.00012194022,"about_ca_topic_score_gemma":0.00001791198,"teacher_disagreement_score":0.6214414,"about_ca_system_score_codex":0.0006902403,"about_ca_system_score_gemma":0.001238045,"threshold_uncertainty_score":0.9999704},"labels":[],"label_agreement":null},{"id":"W4412630105","doi":"10.1016/j.humpath.2025.105877","title":"Impact of hormone sensitivity status on aberrant expression of CK7, CK20, CDX2, GATA3 and TTF1 in prostate cancer","year":2025,"lang":"en","type":"article","venue":"Human Pathology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé","keywords":"CDX2; Prostate cancer; GATA3; Prostate; Medicine; Cancer; Internal medicine; Hormone; Oncology; Gynecology; Biology; Gene expression; Transcription factor; Gene; Genetics","score_opus":0.027227637739018817,"score_gpt":0.3851658501440123,"score_spread":0.35793821240499346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412630105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556375,0.0027224838,0.0000035449111,0.00016666573,0.00003367502,0.0004839348,0.000119911725,0.00001089784,0.0008951645],"genre_scores_gemma":[0.99738544,0.0018141711,0.00003703707,0.000034217257,0.000013725257,0.00003484303,0.0000446113,0.00001027046,0.0006257032],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998931,0.00013700857,0.00024367093,0.00025836582,0.00012844072,0.00030150916],"domain_scores_gemma":[0.99945694,0.00007481634,0.000084268424,0.00023021935,0.00008370662,0.00007003033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023401227,0.00012962373,0.0004324943,0.00028215753,0.000036903264,0.0000029428584,0.000027801547,0.00007190022,0.000026077094],"category_scores_gemma":[0.000040215047,0.00008995425,0.000057666457,0.00016539129,0.00025992846,0.000034315854,0.00006251584,0.00020139218,9.353052e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002025159,0.00035610824,0.32005006,0.00014670579,0.000038979022,0.0004203936,0.0011935004,0.000009842186,0.6719416,0.000049902388,0.0006988945,0.0030688776],"study_design_scores_gemma":[0.0043613897,0.0014007799,0.91900235,0.00030089277,0.000030257284,0.000017473636,0.00008877495,0.000024969946,0.07449177,0.00018462348,0.00003360138,0.00006311384],"about_ca_topic_score_codex":0.0010057568,"about_ca_topic_score_gemma":0.00015407371,"teacher_disagreement_score":0.5989523,"about_ca_system_score_codex":0.00013926385,"about_ca_system_score_gemma":0.00019200199,"threshold_uncertainty_score":0.3668228},"labels":[],"label_agreement":null},{"id":"W4412638930","doi":"10.1038/s41698-025-01053-x","title":"Molecular subtyping of endometrial carcinoma cell lines uncovers subtype-specific targetable vulnerabilities","year":2025,"lang":"en","type":"article","venue":"npj Precision Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; BC Children's Hospital; Spinal Cord Injury BC; University of British Columbia; Vancouver Coastal Health","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; University of British Columbia; Terry Fox Research Institute; Canadian Cancer Society; VGH and UBC Hospital Foundation","keywords":"Subtyping; Cancer research; Carcinoma; Biology; Internal medicine; Computer science; Medicine; Programming language","score_opus":0.030067452658908894,"score_gpt":0.33752478253628293,"score_spread":0.30745732987737406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412638930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9492031,0.012769303,0.0007193427,0.00088410184,0.0011010853,0.0007886262,0.000024446277,0.000036785237,0.034473237],"genre_scores_gemma":[0.99049383,0.0011977763,0.0016960091,0.00012285089,0.00013185659,0.000055191213,0.000055784833,0.000018059887,0.0062286435],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99819964,0.00021754841,0.00047860082,0.00039219655,0.0003421308,0.00036989304],"domain_scores_gemma":[0.99794674,0.0010310445,0.00011870175,0.00041313228,0.00037974672,0.00011062338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005995708,0.00017550211,0.0006356366,0.00059885904,0.00008763472,0.000013733095,0.00016941153,0.0002404681,0.00050514075],"category_scores_gemma":[0.00048214823,0.00013746257,0.00018850654,0.0007724214,0.00020261917,0.00006874034,0.00013761647,0.00029973313,0.000026644271],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028683063,0.0027763923,0.16296645,0.0010942854,0.0005073334,0.0006147854,0.0013141515,0.00068572204,0.62536865,0.0040764012,0.045556698,0.12635604],"study_design_scores_gemma":[0.012020692,0.0021014009,0.0053475793,0.00011737079,0.000116482915,0.000010830753,0.0005091762,0.00015708321,0.78110844,0.0016635186,0.19669148,0.00015591437],"about_ca_topic_score_codex":0.00014966216,"about_ca_topic_score_gemma":0.000012099362,"teacher_disagreement_score":0.15761887,"about_ca_system_score_codex":0.0004682727,"about_ca_system_score_gemma":0.0009560204,"threshold_uncertainty_score":0.56055605},"labels":[],"label_agreement":null},{"id":"W4412644626","doi":"10.1007/s00259-025-07438-1","title":"Efficacy and safety of rechallenge therapy with [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"European Journal of Nuclear Medicine and Molecular Imaging","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"University of Bern","keywords":"Medicine; Prostate cancer; Meta-analysis; Internal medicine; Oncology; Systematic review; Urology; Cancer; MEDLINE","score_opus":0.08453496405050136,"score_gpt":0.3819989778234848,"score_spread":0.2974640137729834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412644626","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000069715396,0.99371713,0.000014022268,0.004045955,0.000009717233,0.0018729265,0.000020475825,0.000004913965,0.0002451203],"genre_scores_gemma":[0.0006610371,0.9980975,0.0003190216,0.0007760512,0.000013087649,0.000015677258,0.000012587932,0.000050162438,0.000054897493],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9964495,0.0012117751,0.0013913462,0.00031995695,0.0004261342,0.00020133832],"domain_scores_gemma":[0.9980557,0.00021027503,0.0010071121,0.00028832094,0.00025188056,0.00018671149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002113648,0.00038271936,0.005342305,0.00073679734,0.00005016946,0.00002552369,0.00011691917,0.000020296276,0.000028718403],"category_scores_gemma":[0.00018516538,0.00019172516,0.00039063618,0.00067906146,0.00021824916,0.00006826739,0.00005191535,0.0004418055,2.277741e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005818637,0.00012209987,0.000007024392,0.83647245,0.09670052,0.004931543,0.0013171609,7.933353e-7,0.000060497096,0.000016891265,0.00018256978,0.05960661],"study_design_scores_gemma":[0.004525493,0.0010795455,0.000029308043,0.28114897,0.68697053,0.0006500743,0.00060216314,0.0000037428629,0.0000021442775,0.0000028859827,0.024764212,0.00022092329],"about_ca_topic_score_codex":0.000019727851,"about_ca_topic_score_gemma":0.0000032464945,"teacher_disagreement_score":0.59027,"about_ca_system_score_codex":0.00005333597,"about_ca_system_score_gemma":0.00023518103,"threshold_uncertainty_score":0.7818325},"labels":[],"label_agreement":null},{"id":"W4412781023","doi":"10.5489/cuaj.9341","title":"2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update)","year":2025,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; McMaster University; Ontario Clinical Oncology Group; Université Laval; University of Alberta; Jewish General Hospital; Dalhousie University; University of Toronto; McGill University Health Centre; University of British Columbia; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Guideline; Prostate cancer; Medicine; Oncology; Internal medicine; Cancer; Gynecology; Pathology","score_opus":0.021621370675284073,"score_gpt":0.3183610238595144,"score_spread":0.29673965318423035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412781023","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16999951,0.005126353,0.00005935866,0.7834494,0.0026998662,0.0024210426,0.0018740617,0.00011176991,0.034258645],"genre_scores_gemma":[0.9406605,0.001457551,0.0005813868,0.042673994,0.00067055505,0.00022467609,0.00069025916,0.000040061528,0.013001023],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99428684,0.0007185387,0.0011871491,0.000644926,0.00083858526,0.0023239856],"domain_scores_gemma":[0.99323267,0.0004427511,0.0005193996,0.0002752825,0.0015709178,0.003958968],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026564782,0.00044394474,0.0008399573,0.0013890599,0.0013601477,0.00038239034,0.00039023365,0.00081850385,0.0051434035],"category_scores_gemma":[0.0024723297,0.00036687037,0.0003244804,0.0012466013,0.00010802447,0.00024087889,0.000034183267,0.0016750034,0.00024301352],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00036840915,0.00011331212,0.60448265,0.000020303567,0.0011587527,0.001341082,0.0001672972,0.00014601699,0.00024932192,0.0010091581,0.3833118,0.0076318914],"study_design_scores_gemma":[0.0026274587,0.0004863812,0.27904555,0.000031232976,0.00041061797,0.000066781584,0.00018094898,0.00031261684,0.000020023454,0.0014690693,0.71505886,0.0002904298],"about_ca_topic_score_codex":0.70353574,"about_ca_topic_score_gemma":0.94847846,"teacher_disagreement_score":0.770661,"about_ca_system_score_codex":0.030533714,"about_ca_system_score_gemma":0.026228007,"threshold_uncertainty_score":0.9999399},"labels":[],"label_agreement":null},{"id":"W4412781049","doi":"10.5489/cuaj.9359","title":"Summary of changes in the 2025 Canadian Urological Association/Canadian Urologic Oncology Group guideline on metastatic castration-resistant prostate cancer","year":2025,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia; Université de Montréal","funders":"","keywords":"Guideline; Prostate cancer; Medicine; Oncology; Internal medicine; Cancer; Urology; Gynecology; Pathology","score_opus":0.04022745094060808,"score_gpt":0.33426691922551593,"score_spread":0.29403946828490785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412781049","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28975636,0.0026983472,0.0000043482464,0.68517834,0.0007425869,0.0016283133,0.00086047023,0.000023588358,0.019107666],"genre_scores_gemma":[0.9537449,0.0012725319,0.000121927245,0.04144853,0.00025934042,0.00018137199,0.0002584353,0.000015420981,0.0026975519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99549174,0.0010868199,0.0008649068,0.00041682558,0.00070778216,0.0014319432],"domain_scores_gemma":[0.9965896,0.00088898494,0.00046370685,0.00022836041,0.0006861453,0.0011431967],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003755076,0.00030285993,0.0006739767,0.0013002328,0.0005661351,0.00011847518,0.00039127236,0.00056126434,0.0010636533],"category_scores_gemma":[0.0022185962,0.00020271052,0.00018643429,0.0012717553,0.00010445071,0.00008855075,0.000019927265,0.0015415408,0.000028130036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00053418207,0.00021834811,0.86130136,0.000023643766,0.0005256347,0.0011022785,0.0004321187,0.00027486708,0.00017229414,0.0013256184,0.12659736,0.0074922983],"study_design_scores_gemma":[0.0024090193,0.001593731,0.54782325,0.00004927595,0.00023057661,0.000033017575,0.00042869645,0.00019338379,0.000020825782,0.0015359275,0.4454956,0.00018666519],"about_ca_topic_score_codex":0.6000115,"about_ca_topic_score_gemma":0.96736217,"teacher_disagreement_score":0.66398853,"about_ca_system_score_codex":0.012170792,"about_ca_system_score_gemma":0.009944603,"threshold_uncertainty_score":0.9998495},"labels":[],"label_agreement":null},{"id":"W4412817868","doi":"10.1158/1538-7445.fcs2024-lt10","title":"Abstract LT10: Molecular mechanisms of SOCS1-mediated tumor suppression in prostate cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Oncology; Cancer research; Suppressor of cytokine signaling 1; Internal medicine; Prostate; Suppressor","score_opus":0.04343921628824534,"score_gpt":0.42939145519286454,"score_spread":0.3859522389046192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412817868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800153,0.008898222,0.000021502501,0.005267879,0.00020473792,0.0020045484,0.00014594861,0.000038485126,0.0034034243],"genre_scores_gemma":[0.9917051,0.0036154706,0.000061329105,0.00018114287,0.000038982056,0.0013054926,0.000059265985,0.000037034362,0.0029961658],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99701035,0.00015008498,0.0004124951,0.0005184835,0.0010401561,0.00086844654],"domain_scores_gemma":[0.99838525,0.0002526083,0.00006828286,0.0004443233,0.00063614664,0.00021337545],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009313839,0.00019400349,0.00045124054,0.00084429095,0.00010255262,0.000029073522,0.0002687751,0.00011163323,0.0011141364],"category_scores_gemma":[0.00029056222,0.00015111979,0.00009660468,0.0016184094,0.00031610258,0.00009819428,0.00020138294,0.00085611676,0.00002473237],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021539181,0.00041750591,0.011351565,0.0012585397,0.00014043972,0.00056385994,0.000298444,0.000044470722,0.9712929,0.00042880853,0.004813741,0.007235802],"study_design_scores_gemma":[0.0044687004,0.00021119011,0.033536963,0.0022934338,0.000024695417,0.0000020660252,0.00037091953,0.000108176595,0.954046,0.0023046378,0.002498232,0.00013499381],"about_ca_topic_score_codex":0.003983872,"about_ca_topic_score_gemma":0.00037358233,"teacher_disagreement_score":0.022185398,"about_ca_system_score_codex":0.0008264977,"about_ca_system_score_gemma":0.0025634044,"threshold_uncertainty_score":0.99979895},"labels":[],"label_agreement":null},{"id":"W4412855801","doi":"10.36469/001c.141170","title":"Prostate-Specific Antigen Reduction After Androgen Receptor Pathway Inhibitor Initiation: Real-World Comparison of Disease Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Hazard ratio; Abiraterone acetate; Oncology; Urology; Prostate-specific antigen; Internal medicine; Confidence interval; Cancer; Prostate; Androgen deprivation therapy; Androgen receptor","score_opus":0.0523072026035814,"score_gpt":0.41339692291669683,"score_spread":0.3610897203131154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412855801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901935,0.0032292854,0.0000034828029,0.004315,0.00020037545,0.0018288733,0.00013844951,0.000004847689,0.00008619644],"genre_scores_gemma":[0.9870144,0.011894053,0.00039235706,0.000037285372,0.00006738928,0.00009228863,0.0000825435,0.000020133986,0.00039955394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976477,0.00027567588,0.0009832403,0.0002640145,0.0004398546,0.0003895341],"domain_scores_gemma":[0.9976113,0.00012854762,0.0005884234,0.00016884514,0.0011628038,0.00034007902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011641812,0.00016435859,0.0006839403,0.00071241905,0.00023549095,0.00007114146,0.000060362054,0.000038966566,0.00002842727],"category_scores_gemma":[0.00003610172,0.00010919554,0.000078786805,0.000385045,0.00027466874,0.0003172717,0.000049661176,0.00040971194,0.0000010915089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009540052,0.0004961617,0.9582131,0.0005850254,0.00022590996,0.0000138131045,0.0016610159,0.00003547096,0.00005003673,0.000052993008,0.00039400018,0.02873245],"study_design_scores_gemma":[0.0048741507,0.0017825826,0.98715574,0.0011424418,0.000035244633,0.0000015033662,0.0010119282,0.00008840525,0.002118869,0.00005630712,0.001634129,0.00009872989],"about_ca_topic_score_codex":0.00015485367,"about_ca_topic_score_gemma":0.00015920516,"teacher_disagreement_score":0.028942639,"about_ca_system_score_codex":0.00063014036,"about_ca_system_score_gemma":0.002215106,"threshold_uncertainty_score":0.4452865},"labels":[],"label_agreement":null},{"id":"W4412882053","doi":"10.3389/fonc.2025.1600821","title":"A proof-of-concept study of personalized dosimetry for targeted radioligand therapy using pre-treatment diagnostic dynamic PET/CT and Monte Carlo simulation","year":2025,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Carleton University; Robarts Clinical Trials; Western University","funders":"","keywords":"Voxel; Monte Carlo method; Radioligand; Prostate cancer; Dosimetry; Nuclear medicine; Medicine; Radiology; Cancer; Mathematics; Internal medicine; Statistics","score_opus":0.02472708924408365,"score_gpt":0.38392305466400933,"score_spread":0.3591959654199257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412882053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97306526,0.021332555,0.0011930006,0.000089779365,0.0002704219,0.003996626,0.000027065584,0.000009027099,0.000016290192],"genre_scores_gemma":[0.9969992,0.0005642898,0.0017252136,0.000015927882,0.000015619204,0.00024988226,0.00001713533,0.00001309633,0.00039961486],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9990008,0.00012805047,0.00030036562,0.00025805846,0.00010804222,0.00020470457],"domain_scores_gemma":[0.99911636,0.0005059254,0.00011210827,0.00014165897,0.000080018894,0.000043940643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014677149,0.00014129005,0.0006424908,0.00031002695,0.000047783255,0.000003831121,0.000049670245,0.000029204493,0.0000044788767],"category_scores_gemma":[0.00014573765,0.00010654136,0.00006495176,0.00025594232,0.0001731538,0.000036703907,0.000019326408,0.000076428616,1.5882572e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013215153,0.00504852,0.7953533,0.0003421895,0.0020269845,0.0003159376,0.009822484,0.014731055,0.0015173204,0.000004420329,0.00020719516,0.15741546],"study_design_scores_gemma":[0.14322351,0.038834676,0.16804853,0.0006356704,0.001531932,0.00005980828,0.016736396,0.5942385,0.034304537,0.00032279242,0.0016275251,0.00043610932],"about_ca_topic_score_codex":0.00025147095,"about_ca_topic_score_gemma":0.000040627336,"teacher_disagreement_score":0.62730473,"about_ca_system_score_codex":0.0007064987,"about_ca_system_score_gemma":0.00037822194,"threshold_uncertainty_score":0.43446308},"labels":[],"label_agreement":null},{"id":"W4412931265","doi":"10.1038/s44321-025-00282-8","title":"New frontiers in prostate cancer treatment from systemic therapy to targeted therapy","year":2025,"lang":"en","type":"review","venue":"EMBO Molecular Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Prostate cancer; Targeted therapy; Medicine; Disease; Context (archaeology); Precision medicine; Androgen receptor; Epigenetics; Bioinformatics; Computational biology; Cancer; Biology; Internal medicine; Pathology","score_opus":0.0365041564450985,"score_gpt":0.38051536430291316,"score_spread":0.34401120785781464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412931265","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039290133,0.9862443,0.00023117864,0.0025066829,0.0012101595,0.008628342,0.00016082457,0.00009484887,0.00053075654],"genre_scores_gemma":[0.000043047872,0.98316616,0.00054726587,0.00084736815,0.00054779125,0.0022773687,0.0013170958,0.0001392181,0.011114663],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960936,0.0003331835,0.00094873534,0.0011286517,0.0007288202,0.0007670395],"domain_scores_gemma":[0.9979338,0.00011818828,0.00022439167,0.00097018806,0.00013144138,0.0006219614],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022198715,0.0009793021,0.004007423,0.0011287094,0.0000580773,0.000024285438,0.0003401708,0.000338131,0.00045257297],"category_scores_gemma":[0.00006244261,0.00057011616,0.00048712268,0.0015987932,0.00008562421,0.0000364319,0.000054884298,0.000506194,0.000033889217],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007200869,0.00015041784,0.00030539176,0.0027604238,0.0018844554,0.0012490761,0.00086164597,0.0000022119173,0.00025064746,0.0000036895087,0.013861443,0.9779505],"study_design_scores_gemma":[0.011412686,0.0015878824,0.00008825884,0.06345466,0.0008627744,0.000021933023,0.000121869496,0.0000029830912,0.00034272065,0.000046889116,0.9216178,0.00043953248],"about_ca_topic_score_codex":0.0049361456,"about_ca_topic_score_gemma":0.00004370846,"teacher_disagreement_score":0.977511,"about_ca_system_score_codex":0.0019025163,"about_ca_system_score_gemma":0.0037616617,"threshold_uncertainty_score":0.99967504},"labels":[],"label_agreement":null},{"id":"W4412943418","doi":"10.7150/thno.114534","title":"PTEN restoration and CXCR2 depletion synergistically enhance the effect of enzalutamide and inhibit bone metastatic CRPC","year":2025,"lang":"en","type":"article","venue":"Theranostics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Enzalutamide; PTEN; Cancer research; Chemistry; Androgen receptor; Prostate cancer; Medicine; Cancer; Internal medicine; Apoptosis; PI3K/AKT/mTOR pathway; Biochemistry","score_opus":0.01043598907467403,"score_gpt":0.31980320974752824,"score_spread":0.3093672206728542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412943418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873589,0.0069946838,0.0026043027,0.0019769,0.00005455086,0.000582801,0.000007933202,0.00003901651,0.00038090636],"genre_scores_gemma":[0.9977268,0.0012949588,0.0002499702,0.000115416195,0.000023249038,0.000024551055,0.000011456221,0.000014509182,0.0005391038],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993133,0.00011836351,0.00016264418,0.00013060542,0.00015712183,0.00011797102],"domain_scores_gemma":[0.99891067,0.0007857249,0.000041433446,0.00015280642,0.00006971799,0.000039627947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003468553,0.00009321337,0.00021170422,0.000058558056,0.00005329165,0.00001640363,0.000028680997,0.000035750956,0.000004448821],"category_scores_gemma":[0.0005156939,0.000052338604,0.000021127245,0.00013317156,0.00022587941,0.00002775533,0.000029419993,0.00010838623,0.0000010773057],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008903543,0.0002372633,0.036851164,0.0029936184,0.0008883957,0.00012823076,0.0018385296,0.00007567825,0.8198417,0.009879373,0.0015714089,0.11679113],"study_design_scores_gemma":[0.012343495,0.005572192,0.102097824,0.002052162,0.002500146,0.00006775008,0.0002784663,0.008930913,0.85551184,0.005684825,0.004599279,0.00036109844],"about_ca_topic_score_codex":0.000036462607,"about_ca_topic_score_gemma":0.00001263706,"teacher_disagreement_score":0.11643003,"about_ca_system_score_codex":0.0000306899,"about_ca_system_score_gemma":0.000052288244,"threshold_uncertainty_score":0.21343064},"labels":[],"label_agreement":null},{"id":"W4412954152","doi":"10.7759/cureus.89396","title":"Comparative Effectiveness of Management Strategies for Stage IV Prostate Cancer: A Narrative Review","year":2025,"lang":"en","type":"review","venue":"Cureus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Prostate cancer; Stage (stratigraphy); Gynecology; Management of prostate cancer; Narrative; General surgery; Cancer; Internal medicine; Literature","score_opus":0.09734599773372672,"score_gpt":0.48566891596184786,"score_spread":0.38832291822812115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412954152","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000048556876,0.974074,0.000044146276,0.00004903559,0.00019970493,0.01770474,0.0009797019,0.00003423222,0.006909598],"genre_scores_gemma":[0.000012139915,0.9773375,0.00014398072,0.000023849101,0.0000438904,0.01119858,0.00086696574,0.000031139425,0.010341967],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99785715,0.00034625953,0.0005829345,0.0005523511,0.00029968112,0.0003616107],"domain_scores_gemma":[0.998224,0.00046272637,0.0003647653,0.00046012647,0.0003914817,0.000096877724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050019944,0.00049278786,0.0035530755,0.00015861391,0.000088228335,0.0000220052,0.00021916615,0.0001354122,0.00008091486],"category_scores_gemma":[0.000026878024,0.00032025686,0.0005835732,0.0005419475,0.00016186155,0.00008963314,0.000108566244,0.0002614365,0.000004809313],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036109632,0.00018774233,0.000003793867,0.81372714,0.0030473808,0.000031463846,0.00042979396,8.3401875e-7,8.923032e-7,0.0011828962,0.0037588708,0.17726812],"study_design_scores_gemma":[0.0012087214,0.0004432665,0.000007295655,0.37027097,0.0031985736,0.0000020842201,0.00055770966,0.000001042566,0.000018408193,0.00009724969,0.62400395,0.00019071583],"about_ca_topic_score_codex":0.000047853737,"about_ca_topic_score_gemma":0.000019676181,"teacher_disagreement_score":0.6202451,"about_ca_system_score_codex":0.0005979688,"about_ca_system_score_gemma":0.0020835856,"threshold_uncertainty_score":0.99992496},"labels":[],"label_agreement":null},{"id":"W4412994611","doi":"10.3390/curroncol32080437","title":"Evolving Treatment Paradigms in Metastatic Hormone-Sensitive Prostate Cancer: Expert Narrative Review","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Guideline; Personalized medicine; Disease; Androgen deprivation therapy; Narrative review; Androgen receptor; Clinical trial; Clinical Practice; Oncology; Bioinformatics; Intensive care medicine; Cancer; Internal medicine; Family medicine; Pathology","score_opus":0.21319693119295696,"score_gpt":0.5352435761449091,"score_spread":0.3220466449519522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412994611","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011282777,0.9868063,0.000002412584,0.0011717464,0.0008920551,0.008999323,0.0002487488,0.000054628068,0.0018135281],"genre_scores_gemma":[0.00000574413,0.9861061,0.0000768501,0.00014686085,0.0002106726,0.009369845,0.0011741992,0.000054823573,0.0028549063],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99574673,0.0009461794,0.0011363064,0.000998749,0.00034597842,0.0008260473],"domain_scores_gemma":[0.99780893,0.0006634007,0.00047117326,0.00051283336,0.00026195514,0.00028168398],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039260412,0.00084862736,0.0053208247,0.0006042797,0.00011382603,0.000020076857,0.00018364446,0.00023407956,0.00013549592],"category_scores_gemma":[0.00021987347,0.0005435137,0.00073279656,0.0010562439,0.00022659196,0.00008791691,0.00012518802,0.00083295867,0.000058140555],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00016159158,0.0009154251,0.0000191071,0.056051463,0.00085212785,0.00067591487,0.0020194415,1.1483488e-7,3.607043e-7,0.000017063292,0.015229639,0.9240577],"study_design_scores_gemma":[0.0024815537,0.001249243,0.000010960279,0.1626059,0.0024814385,0.00007796894,0.00026550115,0.000006979713,0.000002378451,0.000013103209,0.8304783,0.00032667333],"about_ca_topic_score_codex":0.0001576011,"about_ca_topic_score_gemma":0.00012108759,"teacher_disagreement_score":0.9237311,"about_ca_system_score_codex":0.0071295546,"about_ca_system_score_gemma":0.007453947,"threshold_uncertainty_score":0.9997016},"labels":[],"label_agreement":null},{"id":"W4413050678","doi":"10.1038/s41388-025-03531-9","title":"Correction: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E","year":2025,"lang":"en","type":"erratum","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Biology; Prostate cancer; Heat shock protein; Androgen; Cancer research; EIF4E; Internal medicine; Endocrinology; Oncology; Cancer; Hormone; Gene; Genetics; Medicine; Translation (biology); Messenger RNA","score_opus":0.01796250951159706,"score_gpt":0.3196957667276832,"score_spread":0.3017332572160861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413050678","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13832174,0.24501191,0.00033102074,0.08438992,0.06616706,0.04355135,0.002128277,0.000643753,0.41945496],"genre_scores_gemma":[0.0027434975,0.028581187,0.0003486965,0.0009831802,0.000769733,0.0009356117,0.00052063214,0.00007551947,0.96504194],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99785584,0.000070016584,0.00037918566,0.00076139794,0.0004444077,0.00048915955],"domain_scores_gemma":[0.9991024,0.00003099407,0.00008391375,0.00037867657,0.00023082095,0.00017316247],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017678147,0.00039664487,0.0007001284,0.00024906968,0.000107275984,0.0000578161,0.00010492118,0.00034704438,0.00021686306],"category_scores_gemma":[0.000025362318,0.00034292426,0.00008434831,0.00063785666,0.00009604428,0.00008862728,0.000056664583,0.0006133877,0.000015629023],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030262975,0.00014964417,0.0013179763,0.0010203312,0.00023296692,0.00014831494,0.0010897937,0.0000130938615,0.013813855,0.000007943531,0.97117996,0.0079998],"study_design_scores_gemma":[0.0037185305,0.00039206998,0.0005191582,0.0038425408,0.00009006713,0.00000680035,0.00013019305,0.00006660652,0.081930146,0.000057800225,0.908896,0.00035003576],"about_ca_topic_score_codex":0.0008896003,"about_ca_topic_score_gemma":0.0021273515,"teacher_disagreement_score":0.545587,"about_ca_system_score_codex":0.0010616916,"about_ca_system_score_gemma":0.0016937747,"threshold_uncertainty_score":0.99990225},"labels":[],"label_agreement":null},{"id":"W4413090999","doi":"10.37349/emed.2025.1001345","title":"Updates on controversies surrounding the staging and management of newly diagnosed localized prostate cancer using prostate-specific membrane antigen (PSMA) positron emission tomography","year":2025,"lang":"en","type":"article","venue":"Exploration of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Western University; Regina General Hospital; University of British Columbia; University of Alberta; University of Saskatchewan","funders":"","keywords":"Medicine; Prostate cancer; Radiation therapy; Androgen deprivation therapy; Prostatectomy; Management of prostate cancer; Positron emission tomography; Brachytherapy; Glutamate carboxypeptidase II; External beam radiotherapy; Oncology; Radiology; Internal medicine; Cancer","score_opus":0.04376162299630791,"score_gpt":0.34355275886283304,"score_spread":0.2997911358665251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413090999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95682824,0.015466948,0.00087341334,0.023434626,0.0003041776,0.0023645416,0.000023860355,0.000037923717,0.0006662553],"genre_scores_gemma":[0.9572237,0.04132832,0.00028538983,0.0002412134,0.000063538166,0.00008170776,0.00009348454,0.000017208271,0.0006654141],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99846464,0.00009651339,0.00042382017,0.00027680257,0.00050681224,0.00023141025],"domain_scores_gemma":[0.9990337,0.00022682865,0.00020317087,0.00024135025,0.0002188523,0.00007610145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005080478,0.00018291251,0.00043442866,0.00035045156,0.00016575903,0.000017219363,0.000081071885,0.00004374875,0.000035138375],"category_scores_gemma":[0.000043921806,0.000108893124,0.000051075735,0.00061474275,0.0003974875,0.00020910075,0.000050474093,0.00013034936,3.3221608e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027200418,0.0009495335,0.24573311,0.0076261493,0.0029295848,0.00024286496,0.024662245,0.0012604728,0.58288777,0.007828371,0.01409663,0.08458283],"study_design_scores_gemma":[0.07748084,0.0040554428,0.050859105,0.032125704,0.0014896714,0.0000076332035,0.055895284,0.005220951,0.7364616,0.0017568998,0.034005493,0.00064136874],"about_ca_topic_score_codex":0.00019499008,"about_ca_topic_score_gemma":0.00000647982,"teacher_disagreement_score":0.194874,"about_ca_system_score_codex":0.000108612345,"about_ca_system_score_gemma":0.00007965267,"threshold_uncertainty_score":0.44405326},"labels":[],"label_agreement":null},{"id":"W4413098862","doi":"10.3332/ecancer.2025.1953","title":"Unlocking artificial intelligence, machine learning and deep learning to combat therapeutic resistance in metastatic castration-resistant prostate cancer: a comprehensive review","year":2025,"lang":"en","type":"review","venue":"ecancermedicalscience","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Prostate cancer; Artificial intelligence; Deep learning; Cancer; Internal medicine; Computer science","score_opus":0.08354280092565135,"score_gpt":0.4314013610721022,"score_spread":0.34785856014645083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413098862","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004277721,0.9935148,0.00013549134,0.0018263006,0.00023397374,0.0038003179,0.000048699443,0.00007086353,0.00032681142],"genre_scores_gemma":[0.0005059631,0.99536467,0.00052197697,0.0005434431,0.00008526777,0.0009856483,0.00010545166,0.000048959515,0.0018386265],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99450177,0.0006825391,0.0013923916,0.0012942777,0.0011466614,0.0009823862],"domain_scores_gemma":[0.9973969,0.000977591,0.0004701658,0.00036490717,0.00028596152,0.00050449657],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012315257,0.0006720755,0.0026231909,0.0007088422,0.0004533955,0.00012189181,0.00040971796,0.0001554579,0.00021479583],"category_scores_gemma":[0.00085457414,0.00049810676,0.0002373125,0.0034769038,0.0006878225,0.00012967848,0.00025272218,0.001697916,0.000021056572],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016835323,0.00007447079,0.000064339525,0.07103189,0.00011632607,0.00023231345,0.0005110592,0.00002093506,0.000020825415,0.00014430471,0.000045906014,0.92756927],"study_design_scores_gemma":[0.00036399817,0.00043133445,0.00008121368,0.21894659,0.0008218743,0.000029351404,0.00028676994,0.00037366693,0.000009655811,0.00023390916,0.7779042,0.0005174516],"about_ca_topic_score_codex":0.00030178198,"about_ca_topic_score_gemma":0.0011572042,"teacher_disagreement_score":0.92705184,"about_ca_system_score_codex":0.000962099,"about_ca_system_score_gemma":0.0029716552,"threshold_uncertainty_score":0.99974704},"labels":[],"label_agreement":null},{"id":"W4413109082","doi":"10.4274/mirt.galenos.2025.15870","title":"Triple Tumors Uncovered: Insights from 68Ga PSMA PET-CT","year":2025,"lang":"en","type":"article","venue":"Molecular Imaging and Radionuclide Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Glutamate carboxypeptidase II; Positron emission tomography; Pathology; Prostate; Prostate carcinoma; Prostate cancer; Positron Emission Tomography-Computed Tomography; Cancer research; Nuclear medicine; Cancer; Internal medicine","score_opus":0.008908454569989002,"score_gpt":0.28681575383183033,"score_spread":0.2779072992618413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413109082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94341,0.044959724,0.00042158697,0.0050786557,0.00022037984,0.00041616726,0.000011691479,0.000098739394,0.005383049],"genre_scores_gemma":[0.99076205,0.0035543635,0.00059116737,0.0027452838,0.00006304111,0.000028847597,0.00008051415,0.00003022623,0.0021444813],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988407,0.00008073509,0.00019719689,0.00038719262,0.00022651016,0.00026764726],"domain_scores_gemma":[0.99938583,0.000049190156,0.00003859273,0.00033287797,0.000058225367,0.00013528875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008229138,0.00020390458,0.000323991,0.00020488098,0.00016225761,0.00007266333,0.000095886,0.000011555038,0.00006513571],"category_scores_gemma":[0.000021514134,0.00014853798,0.00011393772,0.0002802347,0.00013595325,0.00008899212,0.000035562567,0.0002082327,0.000011720086],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040346566,0.00091638014,0.07337257,0.00018941771,0.0020282418,0.024835328,0.0012206191,0.000024499033,0.6371643,0.0027679238,0.022700382,0.23074566],"study_design_scores_gemma":[0.051794033,0.0007651903,0.046666745,0.0015100095,0.00042538645,0.0014258615,0.0013413044,0.0040837685,0.5505491,0.030468943,0.3097344,0.0012352936],"about_ca_topic_score_codex":0.00032007627,"about_ca_topic_score_gemma":0.0000027203432,"teacher_disagreement_score":0.28703403,"about_ca_system_score_codex":0.00010081688,"about_ca_system_score_gemma":0.00017598193,"threshold_uncertainty_score":0.6057203},"labels":[],"label_agreement":null},{"id":"W4413111570","doi":"10.1158/1078-0432.ccr-22-3683","title":"Increased ErbB2 Signaling Is an Early Adaptation to Androgen Signaling Inhibition and Persists in Castration-Resistant Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Foundation Medicine; Puma Biotechnology; Bristol-Myers Squibb; Prostate Cancer Foundation","keywords":"Prostate cancer; Castration; Androgen; Cancer; Medicine; Prostate; Internal medicine; Oncology; Endocrinology; Biology; Hormone","score_opus":0.20686718664398343,"score_gpt":0.5004136707466903,"score_spread":0.2935464841027069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413111570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98757285,0.003138082,0.000014662669,0.007024566,0.000086978216,0.0017968476,0.00009640504,0.0000330946,0.00023652027],"genre_scores_gemma":[0.99527824,0.0014356839,0.00026067373,0.0006285721,0.00020337821,0.00076744513,0.000057916575,0.0000283853,0.0013396906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99656117,0.0005191895,0.0006672225,0.00079403183,0.00080408616,0.0006542707],"domain_scores_gemma":[0.9978777,0.00046971458,0.00006499089,0.00028885066,0.0007952842,0.00050341536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025842325,0.00018949588,0.00042705607,0.000588519,0.00028189726,0.00015038949,0.00011161019,0.00018776061,0.00021203276],"category_scores_gemma":[0.00036052478,0.0001651253,0.00008438547,0.0012644322,0.00029199934,0.00023802891,0.00010260705,0.0007884813,0.000011898113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023180455,0.0009638253,0.6835279,0.00091598165,0.00035062656,0.0003993392,0.009273487,0.0003310755,0.20154865,0.00017144415,0.0014427619,0.07789447],"study_design_scores_gemma":[0.027078858,0.0072774794,0.7550913,0.0075077503,0.0003279105,0.000007057903,0.0105317095,0.0053918744,0.18050411,0.0019840128,0.0033328936,0.0009650067],"about_ca_topic_score_codex":0.012527831,"about_ca_topic_score_gemma":0.0036052938,"teacher_disagreement_score":0.076929465,"about_ca_system_score_codex":0.0006493621,"about_ca_system_score_gemma":0.0019130326,"threshold_uncertainty_score":0.9940478},"labels":[],"label_agreement":null},{"id":"W4413198597","doi":"10.3390/siuj6040051","title":"PSMA PET in Favourable Intermediate-Risk Prostate Cancer? Gold Mine or Money Pit","year":2025,"lang":"en","type":"article","venue":"Société Internationale d’Urologie Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Medicine; Nomogram; Positron emission tomography; Lymph node; Prospective cohort study; Biochemical recurrence; PET-CT; Retrospective cohort study; Prostate; Population; Oncology; Cancer; Radiology; Nuclear medicine; Internal medicine; Prostatectomy","score_opus":0.03735698477208162,"score_gpt":0.3789977976368077,"score_spread":0.3416408128647261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413198597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97000927,0.0033799396,0.00005096339,0.016945021,0.0013559596,0.00054657925,0.00010459829,0.00005583288,0.007551865],"genre_scores_gemma":[0.9020547,0.017459946,0.00029635112,0.0011459792,0.00037545664,0.00017193014,0.00006751732,0.00002108913,0.07840698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779445,0.00013461543,0.00064530666,0.00034539655,0.0005251175,0.00055510213],"domain_scores_gemma":[0.99854946,0.00038712547,0.0002804408,0.00019806082,0.00041211367,0.00017281322],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006864963,0.00024321223,0.00044222915,0.00054685766,0.0001287395,0.00010622935,0.00035913865,0.00011105672,0.0011405589],"category_scores_gemma":[0.0009325895,0.00016710041,0.00019448056,0.0004073607,0.00016804271,0.00023092178,0.00015886998,0.001197244,0.000022068398],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060297553,0.00060604454,0.89639896,0.00011548379,0.00086818886,0.0020092884,0.00065217767,0.0003513949,0.0010590286,0.00012536919,0.036378514,0.055405803],"study_design_scores_gemma":[0.03471484,0.0025181286,0.8403808,0.0013440219,0.00044057023,0.00092748256,0.003520607,0.0073367334,0.0040532514,0.0091887275,0.09490069,0.0006741759],"about_ca_topic_score_codex":0.00025371887,"about_ca_topic_score_gemma":0.0003018875,"teacher_disagreement_score":0.07085512,"about_ca_system_score_codex":0.0010038859,"about_ca_system_score_gemma":0.0010241066,"threshold_uncertainty_score":0.99977255},"labels":[],"label_agreement":null},{"id":"W4413291804","doi":"10.1007/s40273-025-01532-w","title":"Developing a Comprehensive Framework for Cost-Effectiveness Evaluation in Metastatic Castration-Sensitive Prostate Cancer: Insights from a Systematic Review","year":2025,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pharmaceuticals Bayer","keywords":"Health economics; Economic evaluation; Systematic review; Health administration; Cost effectiveness; Prostate cancer; Health care; Health technology; Flexibility (engineering); Agency (philosophy); Cost–benefit analysis; Medicine; Management science; Risk analysis (engineering); MEDLINE; Public health; Cancer; Economics; Sociology","score_opus":0.21509109056000753,"score_gpt":0.5196098635613617,"score_spread":0.3045187730013542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413291804","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000088623856,0.94405925,0.00070154504,0.00020681118,0.0004559124,0.053496096,0.00093486527,0.000029304145,0.000027562828],"genre_scores_gemma":[0.000051728395,0.95278984,0.0013354133,0.00056052767,0.00010179191,0.04245886,0.0025953872,0.00006407138,0.000042360793],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99615645,0.0011159682,0.0013348899,0.00076777954,0.00024414234,0.0003807507],"domain_scores_gemma":[0.994148,0.0040057227,0.00073115004,0.00035105378,0.0006343362,0.000129729],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007177073,0.00060086715,0.0044991076,0.00041275483,0.000101606805,0.000059930717,0.00016747457,0.0001611713,0.000026517519],"category_scores_gemma":[0.00042799904,0.0004761359,0.00047558174,0.00048267623,0.000054472635,0.00014777368,0.00006753129,0.0005193103,0.000025381967],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016887662,0.000062585335,0.0000029651494,0.8763438,0.0021412226,0.000025409852,0.0001667838,0.000021121828,0.0000015437594,0.00025403575,0.000049568538,0.12076212],"study_design_scores_gemma":[0.0029948493,0.000059825416,0.0000062779873,0.95716316,0.018864207,0.000014708681,0.00008333821,0.0008910304,0.00007307377,0.0009295008,0.018469099,0.00045095637],"about_ca_topic_score_codex":0.00012398748,"about_ca_topic_score_gemma":0.00005474653,"teacher_disagreement_score":0.120311156,"about_ca_system_score_codex":0.004001376,"about_ca_system_score_gemma":0.0055379327,"threshold_uncertainty_score":0.9998221},"labels":[],"label_agreement":null},{"id":"W4413408517","doi":"10.1016/j.euo.2025.06.010","title":"A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pharmaceuticals Bayer","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Prostate-specific antigen; Oncology; Internal medicine; Clinical trial; Hormone therapy; Prostate; Androgen; Hormone; Cancer; Breast cancer","score_opus":0.044188780447867254,"score_gpt":0.37906314171303823,"score_spread":0.334874361265171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413408517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796168,0.0003323959,0.00006185704,0.014293913,0.00012319854,0.005259271,0.000062078805,0.00003330542,0.00021714703],"genre_scores_gemma":[0.9876611,0.00033684605,0.00014903084,0.011064383,0.00003712498,0.00032944416,0.00014370144,0.000045438614,0.00023290757],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99354416,0.004132901,0.0007102448,0.00067090924,0.00032884983,0.00061291247],"domain_scores_gemma":[0.99787223,0.0011585095,0.00023050235,0.00039703428,0.00023569698,0.000106040585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025528292,0.0003055827,0.0008730791,0.0004725496,0.0001104673,0.000025315332,0.00020595077,0.00011312418,0.00001741835],"category_scores_gemma":[0.00035649267,0.00017250924,0.000081558275,0.0008173313,0.00039182443,0.00008010474,0.00007343573,0.0006697855,0.00002080967],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57114494,0.0020311575,0.40613753,0.0000035537348,0.0005462961,0.0014797738,0.0057536275,0.000047231246,0.00012878882,0.0000018905645,0.00035395878,0.012371256],"study_design_scores_gemma":[0.22836265,0.022586174,0.7437983,0.000027533222,0.00009413503,0.0000048153374,0.00015880067,0.00005793008,0.000042094216,0.000014060143,0.0047126743,0.00014082566],"about_ca_topic_score_codex":0.000051097417,"about_ca_topic_score_gemma":0.00026740675,"teacher_disagreement_score":0.3427823,"about_ca_system_score_codex":0.00045612198,"about_ca_system_score_gemma":0.00067503867,"threshold_uncertainty_score":0.7034723},"labels":[],"label_agreement":null},{"id":"W4413416608","doi":"10.1016/j.eclinm.2025.103429","title":"Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysis","year":2025,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma; Pfizer","keywords":"Medicine; Post-hoc analysis; Post hoc; Health related quality of life; Suspension (topology); Quality of life (healthcare); Pathology; Internal medicine; Disease; Nursing","score_opus":0.15112010776984644,"score_gpt":0.5243912017409403,"score_spread":0.3732710939710939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413416608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727957,0.0026898554,0.0000035596436,0.021686843,0.00009634713,0.0015136353,0.000031796335,0.000013124941,0.0011690932],"genre_scores_gemma":[0.9966033,0.0017547534,0.000020593818,0.000754001,0.000053131407,0.00003262268,0.00017913415,0.00000765989,0.00059482123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965582,0.00070993596,0.0017058288,0.0003119487,0.0004448568,0.000269242],"domain_scores_gemma":[0.9962201,0.0022910363,0.0004263148,0.0007175671,0.00017999667,0.00016495497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002838405,0.00017713133,0.001647868,0.00055793766,0.000039814873,0.0000030591111,0.00013168687,0.00012121258,0.00025688985],"category_scores_gemma":[0.0019468226,0.00008173781,0.00064871693,0.0019175701,0.0002405946,0.000017197093,0.000026319627,0.0002762158,0.0000051664447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3666464,0.008784043,0.58876276,0.0002917513,0.007292203,0.000057346708,0.0021585736,0.00009891733,0.000564515,0.00035078372,0.004345661,0.020647004],"study_design_scores_gemma":[0.10466004,0.03976691,0.8536203,0.0003631475,0.0006805646,8.180713e-7,0.0004700591,0.00012265179,0.000038636437,0.00013725777,0.000080918966,0.000058694925],"about_ca_topic_score_codex":0.007423942,"about_ca_topic_score_gemma":0.00062255946,"teacher_disagreement_score":0.2648575,"about_ca_system_score_codex":0.00039447867,"about_ca_system_score_gemma":0.0013742521,"threshold_uncertainty_score":0.9991857},"labels":[],"label_agreement":null},{"id":"W4413444520","doi":"10.1016/j.brachy.2025.06.096","title":"PRSOP02  Presentation Time: 11:35 AM","year":2025,"lang":"en","type":"article","venue":"Brachytherapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Clair College","funders":"","keywords":"Medicine; Presentation (obstetrics); Medical physics; Surgery","score_opus":0.017208709480160185,"score_gpt":0.36024047041680674,"score_spread":0.34303176093664656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413444520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91530037,0.005918666,0.00033700818,0.015354365,0.00030846984,0.0018970482,0.000009021671,0.00020748019,0.060667556],"genre_scores_gemma":[0.63039905,0.0016995512,0.0006896687,0.0021565137,0.00031232994,0.00027590684,0.00015580253,0.000030991945,0.36428016],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992463,0.00003783332,0.00013811966,0.00018835136,0.00019260168,0.00019680368],"domain_scores_gemma":[0.99957347,0.00005817521,0.000027461845,0.00021041319,0.0000680066,0.000062460174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010192803,0.00009612788,0.00019473593,0.0001234155,0.000072520066,0.000025746587,0.000055272678,0.000058453643,0.0006388451],"category_scores_gemma":[0.000020905412,0.00006917005,0.00008051136,0.00027327068,0.000053056086,0.000071649076,0.000014636197,0.00009466197,0.00015174114],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008250876,0.0016198236,0.23217137,0.00040228872,0.0011592285,0.00021458937,0.0011129876,0.000014249123,0.10387043,0.0039896425,0.21877907,0.42841545],"study_design_scores_gemma":[0.04852037,0.0014210927,0.3469102,0.0005476718,0.00025842144,0.00004415292,0.00022299316,0.0020252757,0.13231914,0.004031127,0.4632479,0.0004516525],"about_ca_topic_score_codex":0.000030452087,"about_ca_topic_score_gemma":0.000004938069,"teacher_disagreement_score":0.4279638,"about_ca_system_score_codex":0.00007610438,"about_ca_system_score_gemma":0.0001511757,"threshold_uncertainty_score":0.69949055},"labels":[],"label_agreement":null},{"id":"W4413766723","doi":"10.21203/rs.3.rs-7348924/v1","title":"Metastatic Castration-Resistant Prostate Cancer: 14-Year Real-World Sipuleucel-T Outcomes in Urology","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Associated Medical Services","funders":"Dendreon Pharmaceuticals","keywords":"Prostate cancer; Medicine; Urology; Castration; Oncology; Internal medicine; Cancer; Hormone","score_opus":0.09482295586577066,"score_gpt":0.46483509560216213,"score_spread":0.37001213973639147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413766723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8587576,0.014233931,0.000010829956,0.047131423,0.0011306629,0.017958159,0.004359787,0.00036079786,0.05605682],"genre_scores_gemma":[0.8855483,0.015238572,0.00042588887,0.00012886625,0.00019030858,0.004367615,0.0011385296,0.0000884865,0.09287344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931138,0.0010449558,0.00088923814,0.0013197447,0.0019971195,0.001635144],"domain_scores_gemma":[0.996004,0.00090049015,0.00015848983,0.0012488544,0.0012261039,0.00046207078],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0021372307,0.00055110315,0.0013595461,0.0026463992,0.00025242925,0.00016385094,0.00050792,0.00033296182,0.0007086626],"category_scores_gemma":[0.00056664855,0.00043515858,0.0003200711,0.0016524439,0.00047353486,0.000100014724,0.0010196374,0.0034943735,0.00008921004],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011395799,0.0027078032,0.9224898,0.018374808,0.002332409,0.0059626517,0.00354002,0.0011673676,0.001898751,0.0036440997,0.014461537,0.012024933],"study_design_scores_gemma":[0.021379285,0.003501072,0.9143319,0.008215349,0.00074627396,0.000016230173,0.0032044116,0.0016484681,0.0039460002,0.011654517,0.029735766,0.0016207334],"about_ca_topic_score_codex":0.017617386,"about_ca_topic_score_gemma":0.024255486,"teacher_disagreement_score":0.047002558,"about_ca_system_score_codex":0.0021747097,"about_ca_system_score_gemma":0.006589526,"threshold_uncertainty_score":0.99981004},"labels":[],"label_agreement":null},{"id":"W4413817119","doi":"10.3389/fonc.2025.1638405","title":"Comparing the safety and efficacy of systemic therapies for high-risk biochemically recurrent hormone-sensitive prostate cancer: a network meta-analysis","year":2025,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; Pfizer","keywords":"Prostate cancer; Medicine; Meta-analysis; Oncology; Cancer; Internal medicine; Prostate; Hormone therapy; Hormone; Bioinformatics; Biology; Breast cancer","score_opus":0.06996432049823002,"score_gpt":0.38936885673125476,"score_spread":0.3194045362330247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413817119","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023655921,0.9929684,0.0005936534,0.00036188163,0.00040070323,0.0048837196,0.0004803215,0.000015401483,0.000059379432],"genre_scores_gemma":[0.0013811762,0.9945979,0.001637219,0.00002813806,0.00011853081,0.0013807904,0.00038140704,0.00002655661,0.00044828327],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9970583,0.0007633223,0.00096750725,0.00057229743,0.00019427287,0.0004443226],"domain_scores_gemma":[0.99703836,0.0015596456,0.00072907534,0.00040408995,0.00018968448,0.00007915844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010982439,0.00039939978,0.0066710613,0.00042403513,0.000113303155,0.000012286645,0.00020583952,0.0003342754,0.000004318437],"category_scores_gemma":[0.00014446364,0.0002138635,0.0012369705,0.0010748046,0.0003624527,0.000020286549,0.00013618237,0.00058076566,2.8748073e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041330936,0.00017920484,0.0012113665,0.010269853,0.29319447,0.000021307693,0.0011285408,0.00008259952,7.811901e-7,0.00006934921,0.005752032,0.6839574],"study_design_scores_gemma":[0.004960662,0.0010728555,0.00036334287,0.0043275664,0.6796351,0.0000144867045,0.00057432527,0.00019563574,0.0000040942664,0.00012071353,0.3083714,0.00035981057],"about_ca_topic_score_codex":0.00022603892,"about_ca_topic_score_gemma":0.000100190126,"teacher_disagreement_score":0.68359756,"about_ca_system_score_codex":0.0008352134,"about_ca_system_score_gemma":0.0010258261,"threshold_uncertainty_score":0.87211},"labels":[],"label_agreement":null},{"id":"W4414004091","doi":"10.1002/cncr.70070","title":"Association of patient and physician characteristics with androgen‐deprivation‐therapy intensification in patients with de novo hormone‐sensitive metastatic prostate cancer: A population‐based study","year":2025,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; St. Joseph’s Healthcare Hamilton; University of Calgary; Princess Margaret Cancer Centre; Ottawa Hospital; Juravinski Cancer Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"University of Toronto; Canadian Urological Association Scholarship Fund; Bayer","keywords":"Medicine; Docetaxel; Androgen deprivation therapy; Internal medicine; Prostate cancer; Oncology; Cohort; Population; Cancer; Androgen receptor; Gynecology","score_opus":0.012443049904753912,"score_gpt":0.2942349653488312,"score_spread":0.2817919154440773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414004091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970197,0.00028180893,0.000034362336,0.000664913,0.00002514595,0.0018531432,0.00009564566,0.000012869231,0.000012401337],"genre_scores_gemma":[0.9987115,0.00020615882,0.00012644207,0.0002847975,0.000010199233,0.00039467728,0.00016534112,0.000015076719,0.000085768566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990374,0.000066074375,0.00022204146,0.00022068154,0.00027789638,0.00017594562],"domain_scores_gemma":[0.9989611,0.00004483674,0.00021245042,0.00012994345,0.00060888403,0.00004277651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009871569,0.00012781656,0.00028856145,0.00017319982,0.00005029949,0.000014235117,0.000024338528,0.00002787566,0.0000034699808],"category_scores_gemma":[0.000028290213,0.00009046593,0.000016220365,0.00047921098,0.00002968976,0.00007701474,0.000009749642,0.00010190593,1.855076e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038813073,0.0006436731,0.97701186,0.00006198728,0.0003292385,0.000005222332,0.0017847255,0.000062157436,0.00041550476,0.000004122821,0.000018744127,0.015781483],"study_design_scores_gemma":[0.008973768,0.0009984444,0.9862352,0.00028084085,0.00016250998,1.2725705e-7,0.0005020587,0.00024198374,0.0024785134,0.000009614317,0.000028452781,0.000088461005],"about_ca_topic_score_codex":0.00056687795,"about_ca_topic_score_gemma":0.00029457995,"teacher_disagreement_score":0.015693022,"about_ca_system_score_codex":0.0007942515,"about_ca_system_score_gemma":0.00033328962,"threshold_uncertainty_score":0.36890936},"labels":[],"label_agreement":null},{"id":"W4414035710","doi":"10.1016/s1470-2045(25)00351-1","title":"Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Nova Scotia Cancer Centre; Dalhousie University; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; McMaster University; Juravinski Cancer Centre; Trillium Health Centre; London Health Sciences Centre; CancerCare Manitoba; University Health Network; Princess Margaret Cancer Centre; Credit Valley Hospital; Centre hospitalier universitaire de Québec; Université du Québec en Outaouais; Université de Montréal; McGill University Health Centre; McGill University; Hôpital Charles-Le Moyne; Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"Jewish General Hospital; Astellas Pharma Canada","keywords":"Medicine; Prostate cancer; Systemic therapy; Open label; Oncology; Randomized controlled trial; Internal medicine; Castration; Clinical trial; Cancer; Hormone","score_opus":0.0798744365701188,"score_gpt":0.42850142216545367,"score_spread":0.3486269855953349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414035710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739133,0.004967959,0.0000055803816,0.007466954,0.00039229702,0.011912014,0.0008949031,0.000025797095,0.00042117768],"genre_scores_gemma":[0.98333174,0.008852317,0.00018878536,0.0014941163,0.00010690526,0.005437494,0.00020463763,0.000024567033,0.00035942055],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963955,0.0013322763,0.00078736903,0.0004407974,0.00035320924,0.00069082965],"domain_scores_gemma":[0.99835664,0.0008139465,0.0001743396,0.0003745314,0.00016233297,0.00011819269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001656426,0.00026743158,0.001297,0.0003741866,0.000080981685,0.000050300612,0.00032637414,0.00007698501,0.00024042574],"category_scores_gemma":[0.00022755524,0.00017163012,0.000038108457,0.0013423437,0.000072301045,0.00010494046,0.00005783869,0.0004252404,0.0000029253529],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8931202,0.0013587604,0.0019888747,0.00013010898,0.0003160437,0.00077258213,0.0016886119,0.00024448277,0.009133848,0.00004515679,0.0040726867,0.08712863],"study_design_scores_gemma":[0.9766292,0.004225576,0.004017558,0.0007480131,0.00006798487,0.000011864575,0.001421002,0.0006292636,0.002701261,0.00010486652,0.009224046,0.00021936135],"about_ca_topic_score_codex":0.4394241,"about_ca_topic_score_gemma":0.89252037,"teacher_disagreement_score":0.45309627,"about_ca_system_score_codex":0.0044384697,"about_ca_system_score_gemma":0.008700025,"threshold_uncertainty_score":0.99938333},"labels":[],"label_agreement":null},{"id":"W4414065664","doi":"10.1302/1358-992x.2025.6.020","title":"COLD PLASMA TARGETED REDOX THERAPY FOR BREAST CANCER BONE METASTASIS","year":2025,"lang":"en","type":"article","venue":"Orthopaedic Proceedings","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Polytechnique Montréal","funders":"","keywords":"Breast cancer; Metastasis; Bone metastasis; Cancer cell; Prostate cancer; Cancer; Bone marrow","score_opus":0.01890001944506287,"score_gpt":0.31521881737812824,"score_spread":0.29631879793306537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414065664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9329013,0.015076798,0.00008727317,0.036824282,0.0006138436,0.004059652,0.00061095436,0.00040855288,0.009417303],"genre_scores_gemma":[0.9606937,0.0059059,0.001005176,0.001569604,0.00041493485,0.0018697255,0.00006298254,0.00006137275,0.028416583],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981793,0.000006624363,0.00031722683,0.00050938415,0.00039570496,0.0005917707],"domain_scores_gemma":[0.99886125,0.000051342777,0.000097403594,0.00014457892,0.00062413764,0.00022130393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035239145,0.00026734915,0.00047375268,0.00033163483,0.00022804746,0.000059047383,0.00012958651,0.00014124055,0.0002976638],"category_scores_gemma":[0.000073612944,0.00019828296,0.00025129775,0.0008136293,0.00014810415,0.00016755468,0.000054186123,0.00024210598,0.000010381281],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015315338,0.0011001,0.17968395,0.0019111485,0.0025616006,0.00007081494,0.00070026715,0.0000010152755,0.16475904,0.0052642096,0.26333976,0.36529276],"study_design_scores_gemma":[0.039578542,0.0015997755,0.07635149,0.001516161,0.0010746625,0.00016104446,0.0008322337,0.0007637249,0.21524927,0.00075935724,0.6613017,0.00081204256],"about_ca_topic_score_codex":0.000058029207,"about_ca_topic_score_gemma":0.000006886148,"teacher_disagreement_score":0.3979619,"about_ca_system_score_codex":0.00025705434,"about_ca_system_score_gemma":0.00057920144,"threshold_uncertainty_score":0.80857444},"labels":[],"label_agreement":null},{"id":"W4414078879","doi":"10.1016/j.cont.2025.102082","title":"158 - Prostate organoid model as a new model to study the crosstalk between epithelial and stromal cells in benign prostate hyperplasia","year":2025,"lang":"en","type":"article","venue":"Continence","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Stromal cell; Organoid; Prostate; Hyperplasia; Prostate cancer; Fibrosis; Calponin; LNCaP","score_opus":0.026549474560501485,"score_gpt":0.3344934770728875,"score_spread":0.307944002512386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414078879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889548,0.00034510516,0.00049015635,0.005947923,0.00004777656,0.0033492818,0.0000936998,0.0000481774,0.00072308845],"genre_scores_gemma":[0.973529,0.00010640585,0.0008344901,0.000391246,0.000050792594,0.00013685328,0.000013095193,0.000026815951,0.024911346],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998109,0.00005691061,0.0003579193,0.0005713019,0.00035834053,0.0005465264],"domain_scores_gemma":[0.9989936,0.00008720195,0.000053513486,0.00042551674,0.0001359273,0.00030428267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035721678,0.00026141971,0.00041036392,0.00016904496,0.00016494101,0.00011812805,0.00023302123,0.00006863757,0.000012669255],"category_scores_gemma":[0.00013587139,0.00017297911,0.000046412242,0.0005022808,0.00014301368,0.00013410926,0.0002668246,0.00033359326,0.000025836374],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006263654,0.0011629545,0.7146759,0.00022683774,0.0004494979,0.0003940599,0.0358593,0.003751191,0.19231774,0.0003027145,0.004384395,0.04021177],"study_design_scores_gemma":[0.062210582,0.0074728574,0.3662736,0.0013753059,0.0011654464,0.00003986075,0.00817425,0.17214108,0.366434,0.010204059,0.0026868903,0.0018220254],"about_ca_topic_score_codex":0.00037143825,"about_ca_topic_score_gemma":0.00008565183,"teacher_disagreement_score":0.34840226,"about_ca_system_score_codex":0.00009682089,"about_ca_system_score_gemma":0.0010529155,"threshold_uncertainty_score":0.70538837},"labels":[],"label_agreement":null},{"id":"W4414079112","doi":"10.1016/j.euros.2025.08.008","title":"Impact of PARP Inhibitors on Health-related Quality of Life in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis","year":2025,"lang":"en","type":"review","venue":"European Urology Open Science","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Boston Scientific Corporation; Astellas Pharma US","keywords":"Quality of life (healthcare); Prostate; Prostate cancer; PARP inhibitor; Poly ADP ribose polymerase; Prostate disease","score_opus":0.14431771605326177,"score_gpt":0.46177534801771064,"score_spread":0.31745763196444887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414079112","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019421455,0.98792803,5.086965e-7,0.00033637232,0.000013290692,0.009044092,0.0004549132,0.0000056190306,0.00027502736],"genre_scores_gemma":[0.022127118,0.97690177,0.000047362242,0.0001820446,0.0000014313475,0.00029977335,0.00011359664,0.000021131524,0.00030578423],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99237984,0.0033322163,0.002429898,0.00078987906,0.00068787055,0.00038026835],"domain_scores_gemma":[0.99577814,0.0004326796,0.0022845126,0.0008388234,0.00042085562,0.000245013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006793883,0.00038886626,0.008698307,0.0008877378,0.00009374158,0.00003792846,0.0006870945,0.000035729474,0.000056732857],"category_scores_gemma":[0.0010319975,0.00019212012,0.0006084343,0.0040642093,0.00069866213,0.00013391656,0.0002917056,0.0003243393,0.0000032289172],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056493765,0.0006272958,0.0035696565,0.92676824,0.06563594,0.000034397617,0.00029347104,0.000030144263,4.3624968e-7,0.00003382151,0.00006750339,0.0023741187],"study_design_scores_gemma":[0.004903822,0.00802776,0.042701416,0.12316364,0.8203232,0.000007799914,0.00004271253,0.0000061678156,7.3715614e-7,0.000007907431,0.00018587447,0.00062892615],"about_ca_topic_score_codex":0.0014547785,"about_ca_topic_score_gemma":0.0001749092,"teacher_disagreement_score":0.80360466,"about_ca_system_score_codex":0.0002556764,"about_ca_system_score_gemma":0.0039933906,"threshold_uncertainty_score":0.7834431},"labels":[],"label_agreement":null},{"id":"W4414095915","doi":"10.1097/ju9.0000000000000344","title":"Metastatic Squamous Cell Carcinoma of Prostatic Origin: Identification Through Next Generation Sequencing and Treatment With Pembrolizumab: A Case Report","year":2025,"lang":"en","type":"article","venue":"JU Open Plus","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Prostatic adenocarcinoma; Adenocarcinoma; Prostate cancer; DNA sequencing; Radiation therapy; Prostate; Carcinoma; Pembrolizumab; Cancer","score_opus":0.13952067724109343,"score_gpt":0.3775446138727638,"score_spread":0.23802393663167035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414095915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913831,0.0015294661,0.00044940747,0.0004763419,0.00006120284,0.0027855719,0.000021349992,0.0000151406975,0.003278443],"genre_scores_gemma":[0.9837481,0.000094458315,0.0020817344,0.00004868448,0.000024426063,0.00040379592,0.00019655985,0.000017321676,0.013384953],"study_design_codex":"case_report","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987578,0.00006258151,0.00038236048,0.0003885212,0.00020904519,0.00019970651],"domain_scores_gemma":[0.9990981,0.00005396157,0.00017490883,0.0004026238,0.0001967575,0.00007363922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018949942,0.00016801183,0.00037143475,0.00010599948,0.00016923,0.00012217497,0.00006377865,0.00003448483,0.000025168958],"category_scores_gemma":[0.000025055362,0.000112066955,0.00003608908,0.00029872617,0.000097115095,0.00030785636,0.00005250832,0.000072494215,0.0000034373222],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015195683,0.003783342,0.079382434,0.008974371,0.0022052687,0.39484128,0.05680206,0.0007021118,0.36820614,0.0030168958,0.004498937,0.06239145],"study_design_scores_gemma":[0.0687153,0.011140499,0.008578003,0.00065978814,0.004841299,0.056511924,0.016431415,0.03612899,0.7925726,0.0005390533,0.0029302845,0.00095081376],"about_ca_topic_score_codex":0.0061245677,"about_ca_topic_score_gemma":0.00062750134,"teacher_disagreement_score":0.42436647,"about_ca_system_score_codex":0.0007908489,"about_ca_system_score_gemma":0.0015030131,"threshold_uncertainty_score":0.9258555},"labels":[],"label_agreement":null},{"id":"W4414203191","doi":"10.3390/curroncol32090513","title":"Radiotherapy for Genitourinary Cancer","year":2025,"lang":"en","type":"editorial","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Radiation therapy; Prostate cancer; Genitourinary system; Cancer; Prostate","score_opus":0.1133060706425128,"score_gpt":0.5188935511989831,"score_spread":0.40558748055647026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414203191","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001246416,0.12784491,0.000115715746,0.0028379466,0.8652741,0.0017382836,0.0008259485,0.00006114906,0.0011773525],"genre_scores_gemma":[0.000006955074,0.08381326,0.00027542995,0.00005728283,0.8775414,0.0024008367,0.0021872115,0.000047491627,0.0336701],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826986,0.00006977729,0.00029090288,0.0005200594,0.00035393817,0.0004954755],"domain_scores_gemma":[0.99806076,0.0008232939,0.000124208,0.00030859903,0.00052449433,0.00015862753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019411488,0.00029632016,0.0008401807,0.00025696377,0.00010074914,0.000014365244,0.00019358056,0.0008429711,0.00027945155],"category_scores_gemma":[0.00021693784,0.00023126123,0.00028321217,0.00015070819,0.00013144601,0.000023143144,0.00006425895,0.00094207755,0.000009489286],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022977826,0.0004977127,0.00022728834,0.0013893405,0.0004558535,0.00003653968,0.000063734835,2.8755477e-7,0.000029410696,0.00001227362,0.8141176,0.18087216],"study_design_scores_gemma":[0.008060251,0.0017077634,0.000039630064,0.00050952536,0.00044902103,0.0000024813546,0.000011987984,0.000032362463,0.00007308753,0.000120775556,0.98881394,0.00017919275],"about_ca_topic_score_codex":0.000033580807,"about_ca_topic_score_gemma":0.000021344998,"teacher_disagreement_score":0.18069297,"about_ca_system_score_codex":0.0021710526,"about_ca_system_score_gemma":0.0062420233,"threshold_uncertainty_score":0.9993917},"labels":[],"label_agreement":null},{"id":"W4414325726","doi":"10.1158/1538-7755.disp25-c119","title":"Abstract C119: Efficacy and safety of darolutamide in Black/African American patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) across clinical and real-world studies: An analysis of ARAMIS, DAROL, DEAR-EXT","year":2025,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Prostate cancer; Cohort; Prostate-specific antigen; Adverse effect; Observational study; Retrospective cohort study; Cancer; Disease","score_opus":0.07147718522810206,"score_gpt":0.4743066302784982,"score_spread":0.4028294450503961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414325726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921015,0.0050156787,0.000043786724,0.0009982638,0.0000684845,0.0013934649,0.00031371156,0.000014765168,0.000050358092],"genre_scores_gemma":[0.98085886,0.017694386,0.0007460465,0.00008440265,0.000016210637,0.00016623245,0.00026778836,0.00001735236,0.00014869797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962726,0.00075044454,0.0015232199,0.00076006236,0.00020895078,0.00048471932],"domain_scores_gemma":[0.9969247,0.0012645927,0.0009088197,0.00038818148,0.0003208551,0.000192869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024093606,0.00028665367,0.001704887,0.00052663306,0.000098021104,0.0000076131046,0.00010160766,0.00010107812,0.000021435826],"category_scores_gemma":[0.00042578208,0.0002133001,0.00015184871,0.0014733083,0.0025144403,0.00014130944,0.000074356816,0.00024000568,1.8646374e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013591382,0.00050106354,0.92636853,0.0004039675,0.0067122434,0.000007056147,0.0007676628,0.0002731393,0.00030090442,0.00002768886,0.000047965,0.050998412],"study_design_scores_gemma":[0.006469125,0.0010749911,0.98706573,0.0008684529,0.002150035,2.3012392e-7,0.0013916817,0.0005521515,0.00007189566,0.00015063836,0.00004590551,0.0001591443],"about_ca_topic_score_codex":0.009902113,"about_ca_topic_score_gemma":0.04293714,"teacher_disagreement_score":0.06069723,"about_ca_system_score_codex":0.00034119384,"about_ca_system_score_gemma":0.00046452874,"threshold_uncertainty_score":0.99669105},"labels":[],"label_agreement":null},{"id":"W4414357021","doi":"10.1097/mou.0000000000001341","title":"Toxicities of novel androgen receptor pathway inhibitor targeted therapies in advanced prostate cancer","year":2025,"lang":"en","type":"article","venue":"Current Opinion in Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Prostate cancer; Androgen receptor; Androgen Receptor Antagonists; Clinical trial; Adverse effect","score_opus":0.04187859571909012,"score_gpt":0.3701389364889445,"score_spread":0.3282603407698544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414357021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9060662,0.08618017,0.000020879419,0.0034735797,0.0030043633,0.0009494364,0.00012282399,0.000025255975,0.00015731125],"genre_scores_gemma":[0.9785458,0.020182854,0.00009880669,0.0000746634,0.00011423351,0.00051831815,0.00015277145,0.000014846148,0.00029771813],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988435,0.000065419175,0.00036170517,0.00028032492,0.00013554996,0.00031352928],"domain_scores_gemma":[0.999552,0.00007486822,0.0000741067,0.00015809196,0.00009729891,0.00004359544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015252297,0.00014236788,0.0003537055,0.00041179225,0.000023514564,0.000004299218,0.00008062206,0.000094754694,0.00008290144],"category_scores_gemma":[0.000055228924,0.0001140583,0.000049328333,0.00046542694,0.00017142868,0.000060255166,0.000058357426,0.0002590872,0.000002297034],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071660746,0.0021996493,0.7413813,0.0017829268,0.00017317195,0.000004556839,0.0055257007,0.00021339113,0.087573506,0.0018072983,0.0027947356,0.14937767],"study_design_scores_gemma":[0.0605433,0.003485616,0.26239434,0.004331743,0.000042418633,0.000008061891,0.0025782469,0.0012845593,0.15443867,0.0015859094,0.50851756,0.0007895751],"about_ca_topic_score_codex":0.000047660487,"about_ca_topic_score_gemma":0.0000275994,"teacher_disagreement_score":0.5057228,"about_ca_system_score_codex":0.00014082095,"about_ca_system_score_gemma":0.0003917649,"threshold_uncertainty_score":0.46511623},"labels":[],"label_agreement":null},{"id":"W4414410467","doi":"10.3390/curroncol32090526","title":"Cytotoxicity of Esculetin Compared with Vinblastine and Paclitaxel in PC-3 Prostate Cancer Cells","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Universidad de Alcalá","keywords":"Cytotoxicity; Prostate cancer; Paclitaxel; Vinblastine; Prostate; Cell culture; Mechanism of action","score_opus":0.06447265572368338,"score_gpt":0.4184645478877643,"score_spread":0.35399189216408095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414410467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903804,0.00567735,0.000021488677,0.0014562296,0.00016784765,0.00083089864,0.000040240455,0.0000151572785,0.0014104043],"genre_scores_gemma":[0.9966842,0.0022036412,0.00012681434,0.00004969584,0.000028688357,0.0001654858,0.000022244116,0.000007634201,0.0007115873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906284,0.00007261792,0.00023491945,0.0002450994,0.00012494961,0.00025956106],"domain_scores_gemma":[0.99948955,0.00010060322,0.00006983976,0.00012881262,0.00012834469,0.00008287058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001547736,0.00012138104,0.0004326935,0.00017828183,0.000028059074,0.0000043588366,0.000051151106,0.000058412727,0.000059785805],"category_scores_gemma":[0.000025058958,0.000082473416,0.000026792908,0.00030749792,0.00028308475,0.000024525296,0.00006299393,0.00023637559,0.0000022495506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063457945,0.0019987759,0.89897513,0.0016567347,0.00017177215,0.00008749214,0.0013614686,0.000026669864,0.039366197,0.00015939932,0.0030214975,0.04682909],"study_design_scores_gemma":[0.035784777,0.0036329462,0.767751,0.0028917931,0.00028856023,0.000017578637,0.0009843359,0.0012136097,0.13226487,0.0002467315,0.054593094,0.00033075895],"about_ca_topic_score_codex":0.00012790864,"about_ca_topic_score_gemma":0.00031497612,"teacher_disagreement_score":0.13122416,"about_ca_system_score_codex":0.00026411714,"about_ca_system_score_gemma":0.000513707,"threshold_uncertainty_score":0.33631682},"labels":[],"label_agreement":null},{"id":"W4414465977","doi":"10.1158/2326-6074.cimm25-pr-02","title":"Abstract PR-02: Loss of tumor-intrinsic type I IFN facilitates and predicts bone-metastatic progression in advanced prostate cancer and drives radiotherapeutic resistance","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Bone metastasis; Metastasis; Immunotherapy; Tumor microenvironment; Lymph node; Cancer","score_opus":0.03552965024291679,"score_gpt":0.40923102450864074,"score_spread":0.373701374265724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414465977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73486227,0.2605345,6.7920746e-7,0.0026966832,0.00010299896,0.0014820428,0.00005360207,0.0000243295,0.0002428736],"genre_scores_gemma":[0.91376066,0.0803509,0.00018598037,0.000046934514,0.000019589897,0.00075596274,0.000018149722,0.000026313177,0.0048354967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974582,0.00022306383,0.00046683158,0.0006345245,0.0004211814,0.0007961871],"domain_scores_gemma":[0.9984781,0.00037313186,0.00010473635,0.00038373357,0.00053898845,0.00012130097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075076876,0.00024465102,0.0006445133,0.00071203086,0.00017458336,0.000031565003,0.0001611818,0.00011725291,0.00006699143],"category_scores_gemma":[0.00023265582,0.00019037402,0.00003993363,0.0011064798,0.0019228536,0.00017133642,0.0001770149,0.00079764583,0.0000026881396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02299875,0.0004925047,0.6415744,0.0050080917,0.00072719366,0.0004663535,0.0036110845,0.00001266461,0.12628107,0.00037132035,0.0005272815,0.1979293],"study_design_scores_gemma":[0.010226326,0.0010280579,0.9363623,0.0046449425,0.000066682755,0.000021451639,0.0013272262,0.000046129135,0.040189553,0.0010354567,0.004828346,0.00022351612],"about_ca_topic_score_codex":0.0003279088,"about_ca_topic_score_gemma":0.00037666847,"teacher_disagreement_score":0.2947879,"about_ca_system_score_codex":0.00042694755,"about_ca_system_score_gemma":0.0013138425,"threshold_uncertainty_score":0.7763227},"labels":[],"label_agreement":null},{"id":"W4414509940","doi":"10.1016/j.canlet.2026.218535","title":"Canagliflozin Is a Novel Androgen Receptor Pathway Inhibitor in Castrate-Sensitive and Castrate-Resistant Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Letters","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; McMaster University","funders":"Canadian Institutes of Health Research; Hamilton Health Sciences Foundation; Canadian Association of Radiation Oncology","keywords":"Canagliflozin; Prostate cancer; Androgen receptor; Gene knockdown; Androgen Receptor Antagonists; LNCaP; Gene silencing; Olaparib; Small hairpin RNA","score_opus":0.01994474560648594,"score_gpt":0.3011399968525935,"score_spread":0.28119525124610756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414509940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.960003,0.004426935,0.000011305557,0.032744594,0.000370854,0.0011831146,0.000762842,0.000037560683,0.00045979922],"genre_scores_gemma":[0.9859464,0.0018127118,0.00015531383,0.0072165937,0.0002007845,0.0006114378,0.000053695883,0.00004272623,0.0039603016],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980885,0.000042863656,0.00033161568,0.000621401,0.00027919406,0.00063642947],"domain_scores_gemma":[0.99929297,0.000042596734,0.000076002456,0.00023166768,0.00013581268,0.00022096065],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014573782,0.00030562156,0.00045177728,0.0002879863,0.000109161345,0.000060272938,0.000074746604,0.0001076842,0.00010376251],"category_scores_gemma":[0.00001584294,0.00025542077,0.0000706904,0.0006054668,0.00025787004,0.00012278884,0.000058913967,0.00036281312,0.0000076117667],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030104518,0.00014622023,0.054526124,0.00063675136,0.00044093773,0.0005800833,0.0029660533,0.000038918377,0.90453047,0.00004414693,0.02272517,0.010354686],"study_design_scores_gemma":[0.020024417,0.000513244,0.09239061,0.0044903792,0.00032164305,0.000034558798,0.0022997274,0.00041129335,0.8132235,0.00002531536,0.065287374,0.0009779736],"about_ca_topic_score_codex":0.011635876,"about_ca_topic_score_gemma":0.005870149,"teacher_disagreement_score":0.091307,"about_ca_system_score_codex":0.0010590683,"about_ca_system_score_gemma":0.0013866453,"threshold_uncertainty_score":0.9999898},"labels":[],"label_agreement":null},{"id":"W4414542745","doi":"10.3389/fonc.2025.1650378","title":"Time and cost burden associated with docetaxel in patients with metastatic castration-sensitive prostate cancer initiating an androgen receptor pathway inhibitor-based regimen","year":2025,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Johnson and Johnson","keywords":"Docetaxel; Prostate cancer; Androgen receptor; Regimen; Androgen; Androgen deprivation therapy; Chemotherapy; Overall survival","score_opus":0.013718117371147453,"score_gpt":0.2970792387133172,"score_spread":0.28336112134216973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414542745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99572265,0.00028844297,0.000031659252,0.0009944062,0.00010235814,0.002037403,0.00015096072,0.00002550504,0.0006465982],"genre_scores_gemma":[0.99457765,0.000056444125,0.0029884968,0.00029394793,0.000027978345,0.00039071232,0.00079733756,0.000028751003,0.0008387099],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998429,0.00029224253,0.000278812,0.0003885482,0.000221351,0.00039006092],"domain_scores_gemma":[0.9992476,0.00012195227,0.00014233972,0.00013150365,0.0002442951,0.00011228941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003201183,0.00019461532,0.0005429619,0.00036315675,0.00007721516,0.000020544981,0.000047962636,0.000110955254,0.000016917495],"category_scores_gemma":[0.00009484485,0.00014381789,0.000017059281,0.00055478717,0.00027231005,0.00015318929,0.000022415868,0.0002985086,0.0000011825618],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009349144,0.0008210468,0.9583107,0.00008253307,0.00046569144,0.00026884812,0.003107814,0.00034896724,0.00025232194,0.0000056309073,0.0012033693,0.02578391],"study_design_scores_gemma":[0.15149881,0.019877024,0.78789824,0.0041178335,0.000718688,0.000009541386,0.009353972,0.012781513,0.009566016,0.00013526449,0.0029570076,0.00108608],"about_ca_topic_score_codex":0.00028193987,"about_ca_topic_score_gemma":0.0008826778,"teacher_disagreement_score":0.17041248,"about_ca_system_score_codex":0.0012830968,"about_ca_system_score_gemma":0.0014446048,"threshold_uncertainty_score":0.58647233},"labels":[],"label_agreement":null},{"id":"W4414547297","doi":"10.1186/s12880-025-01914-8","title":"Efficacy of PSMA PET/CT radiomics analysis for risk stratification in newly diagnosed prostate cancer: a multicenter study","year":2025,"lang":"en","type":"article","venue":"BMC Medical Imaging","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Radiomics; Prostate cancer; Prostate; Logistic regression; Multicenter study; Random forest; Receiver operating characteristic; Prostate-specific antigen","score_opus":0.02435989158641213,"score_gpt":0.3832247515913676,"score_spread":0.3588648600049555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414547297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99117255,0.0015298732,0.003521316,0.0010702126,0.00010829726,0.002458069,0.000036620324,0.00002729282,0.00007576697],"genre_scores_gemma":[0.9970857,0.0008263945,0.0010365972,0.00009801828,0.00004497036,0.00052921835,0.000094216906,0.000013126398,0.0002717706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817556,0.00015724575,0.00052461127,0.00038466297,0.00045229733,0.00030564258],"domain_scores_gemma":[0.9983545,0.0009039312,0.00013066643,0.0003038065,0.0001476773,0.00015942131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081886555,0.00014185403,0.00047508167,0.0004934443,0.00006281591,0.000023692126,0.00014050899,0.000012215701,0.00006443384],"category_scores_gemma":[0.0013406163,0.00010838979,0.00016573617,0.0009843671,0.00012752063,0.00006496623,0.000042701115,0.00022170431,0.0000013324691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012704597,0.0013581644,0.961175,0.0002563756,0.00059749855,0.00016353374,0.00068242115,0.00014399253,0.00015619949,0.000008137356,0.00019240596,0.03399581],"study_design_scores_gemma":[0.02479172,0.00009911819,0.8812909,0.00036520712,0.0013663997,0.0000022767624,0.0019680085,0.0890056,0.0008758406,0.000025464244,0.00010919352,0.00010023383],"about_ca_topic_score_codex":0.001681399,"about_ca_topic_score_gemma":0.0019812547,"teacher_disagreement_score":0.08886161,"about_ca_system_score_codex":0.00021180662,"about_ca_system_score_gemma":0.00086752645,"threshold_uncertainty_score":0.44200072},"labels":[],"label_agreement":null},{"id":"W4414564476","doi":"10.1016/j.euo.2025.07.014","title":"Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional Cohorts","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke; University Health Network; Prostate Cancer Canada; McGill University Health Centre; Hôtel-Dieu de Québec; Centre Hospitalier de l’Université de Montréal; Université Laval; Centre hospitalier de l'Université Laval","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Prostate cancer; Biomarker; Disease; Androgen; Prostate; Tumor progression; PCA3; Androgen receptor","score_opus":0.018948851700828263,"score_gpt":0.29512109710868834,"score_spread":0.27617224540786006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414564476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97115564,0.015496332,0.00002726853,0.008419131,0.00048378066,0.0031629365,0.00022879893,0.000019361809,0.0010067408],"genre_scores_gemma":[0.99555856,0.0022902656,0.00011294341,0.0010938678,0.0000653374,0.00040780308,0.00006583715,0.000024989884,0.0003804054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972275,0.0010570358,0.00053212175,0.0005032023,0.00019026738,0.00048990635],"domain_scores_gemma":[0.9987277,0.00041150412,0.00018221508,0.00033435863,0.00019558339,0.00014868531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004029683,0.00025659183,0.0005583866,0.0001474698,0.0002933561,0.000010469554,0.0002636718,0.00015885803,0.000042386815],"category_scores_gemma":[0.00015748644,0.0001407392,0.00007322804,0.0005357091,0.0015459076,0.00005184837,0.00012501476,0.00053449074,0.000002308018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035073508,0.00028700975,0.9665972,0.00016506147,0.00024455163,0.00030724885,0.0020245255,0.0011074244,0.016883943,0.00013967138,0.0014653584,0.0072706277],"study_design_scores_gemma":[0.0076414878,0.00043282867,0.95297104,0.0005858736,0.00025557255,0.000014876289,0.00008454573,0.000646382,0.004512059,0.00016051035,0.032546338,0.00014850996],"about_ca_topic_score_codex":0.027159598,"about_ca_topic_score_gemma":0.20598888,"teacher_disagreement_score":0.1788293,"about_ca_system_score_codex":0.00035370307,"about_ca_system_score_gemma":0.003698184,"threshold_uncertainty_score":0.9793186},"labels":[],"label_agreement":null},{"id":"W4414574049","doi":"10.1016/j.ijrobp.2025.06.1270","title":"Hallmark Interferon-Alpha Response Analysis in Localized Prostate Cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, 9902, 0126, and 0521 Clinical Trials","year":2025,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Juravinski Cancer Centre; Western University; Institute for Research in Immunology and Cancer; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Prostate; Clinical trial; Survival analysis; Multivariate analysis; Proportional hazards model; Prostatectomy; Disease; Biological response modifiers","score_opus":0.06840269820230187,"score_gpt":0.4868278750349292,"score_spread":0.4184251768326273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414574049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97025526,0.0036468958,0.0021543335,0.020993974,0.0018309,0.00062927825,0.0002142311,0.000014024711,0.0002611173],"genre_scores_gemma":[0.9893879,0.008124443,0.00045122075,0.0010507703,0.00044085103,0.000043983317,0.00008879786,0.00001450067,0.00039752986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926281,0.003857666,0.002427229,0.00039404794,0.00039966402,0.00029328145],"domain_scores_gemma":[0.99193275,0.004450406,0.0020669005,0.0002948827,0.0011033048,0.00015172893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008491177,0.00024396797,0.0020862625,0.0013676654,0.00007409182,0.000028618993,0.0004914093,0.0003975718,0.000114843875],"category_scores_gemma":[0.003228555,0.0001612037,0.0010942781,0.0022013497,0.00065559713,0.00015291733,0.00018485662,0.00084465113,0.0000020973923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021345524,0.0008385474,0.82471794,0.000015475543,0.022141596,0.000048159116,0.0005534614,0.0009247089,0.0015002685,0.00062464306,0.0008203503,0.12646931],"study_design_scores_gemma":[0.030949343,0.0032508941,0.8821766,0.0002857503,0.015883196,0.000024010531,0.00047140758,0.01668473,0.0023739007,0.0029311893,0.044703092,0.0002658978],"about_ca_topic_score_codex":0.00017780659,"about_ca_topic_score_gemma":0.00024169422,"teacher_disagreement_score":0.12620342,"about_ca_system_score_codex":0.0015903686,"about_ca_system_score_gemma":0.002586801,"threshold_uncertainty_score":0.6573696},"labels":[],"label_agreement":null},{"id":"W4414574474","doi":"10.1016/j.ijrobp.2025.06.1148","title":"The Role of Stereotactic Body Radiotherapy in Oligoprogressive Prostate Cancer: A Site-Specific Analysis of the Prospective, Phase II RADIANT Trial","year":2025,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre; Cancer Care Ontario; University of British Columbia; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Occupational Cancer Research Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institutes of Health; Swim Across America; Prostate Cancer Foundation","keywords":"Prostate cancer; Systemic therapy; Clinical endpoint; Prostate; Radiation therapy; Cumulative incidence; Univariate analysis; Cohort; Clinical trial; Incidence (geometry)","score_opus":0.014389021621599593,"score_gpt":0.3788582610203791,"score_spread":0.3644692393987795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414574474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823027,0.011240605,0.00006898091,0.004044355,0.0010236296,0.00093489885,0.00012593521,0.00000604387,0.00025281025],"genre_scores_gemma":[0.9896692,0.009420427,0.000088237284,0.00010352811,0.00042335442,0.00007582915,0.000028156826,0.000011398033,0.00017989002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810493,0.00029890175,0.00085350464,0.00019207202,0.00033897633,0.00021161335],"domain_scores_gemma":[0.9971678,0.00048453163,0.0012338917,0.0002102783,0.0008477363,0.000055718712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058449275,0.00015239636,0.00062547834,0.00039832035,0.00011289046,0.000018862298,0.00038667375,0.00012022651,0.000032193784],"category_scores_gemma":[0.00015670729,0.00008786091,0.0003866306,0.0009200631,0.00040913039,0.0001048707,0.00006189035,0.0004198046,4.5392812e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044572968,0.002172657,0.7352585,0.000011114438,0.0073897718,0.000020896528,0.0022228055,0.00040921842,0.018995928,0.004390064,0.00023482378,0.18432124],"study_design_scores_gemma":[0.35909167,0.016070053,0.40526783,0.00064379297,0.0035695618,0.000052408526,0.0011343724,0.015661223,0.0899759,0.01534193,0.09272943,0.00046180974],"about_ca_topic_score_codex":0.00007839952,"about_ca_topic_score_gemma":0.000045366214,"teacher_disagreement_score":0.32999068,"about_ca_system_score_codex":0.001168754,"about_ca_system_score_gemma":0.0012640714,"threshold_uncertainty_score":0.3582864},"labels":[],"label_agreement":null},{"id":"W4414623987","doi":"10.5489/cuaj.9426","title":"Poster Session 6: Oncology-Prostate (Part 2)","year":2025,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"","score_opus":0.022321974472823854,"score_gpt":0.3132827617805156,"score_spread":0.29096078730769176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414623987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58062786,0.0012361626,0.000016589482,0.31318322,0.0012248439,0.0004181123,0.00004138802,0.00004577861,0.10320608],"genre_scores_gemma":[0.94964635,0.0004530671,0.00007275885,0.015139717,0.00035013072,0.000014567451,0.000042396627,0.000007600062,0.034273423],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99867874,0.00015444675,0.0002540742,0.00016201542,0.00024824074,0.00050249347],"domain_scores_gemma":[0.9987848,0.00011204947,0.00010721008,0.000087990535,0.00031598672,0.00059195433],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006243935,0.000101310274,0.00022686216,0.00025367294,0.00032803993,0.0000711538,0.000084081854,0.00026121014,0.0009959638],"category_scores_gemma":[0.00042144136,0.00006961334,0.00010690384,0.00027471274,0.000037854843,0.000074317744,0.000021184516,0.00067636365,0.00012230026],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026232607,0.000074741416,0.78168684,0.000007392493,0.00017474945,0.00037109284,0.00008710067,0.0000023730006,0.0002545913,0.00013116871,0.1959876,0.020960024],"study_design_scores_gemma":[0.001789792,0.00038136131,0.35003257,0.000033164873,0.000060362967,0.00008020675,0.00005451538,0.000017498594,0.00012542777,0.00083547516,0.646527,0.000062645704],"about_ca_topic_score_codex":0.00028934827,"about_ca_topic_score_gemma":0.0002889687,"teacher_disagreement_score":0.4505394,"about_ca_system_score_codex":0.0029310095,"about_ca_system_score_gemma":0.0019404999,"threshold_uncertainty_score":0.99991727},"labels":[],"label_agreement":null},{"id":"W4414624007","doi":"10.5489/cuaj.9425","title":"Poster Session 1: Oncology-Prostate","year":2025,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Cliniques Universitaires Saint-Luc; Institut Gustave-Roussy; Sociedade Beneficente Israelita Brasileira Albert Einstein; Rigshospitalet; Institute for Oil Sands Innovation, University of Alberta; Université Catholique de Louvain","keywords":"Session (web analytics); Training (meteorology); Attendance; Intervention (counseling)","score_opus":0.01970365403858692,"score_gpt":0.31627415816028714,"score_spread":0.2965705041217002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414624007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6233061,0.0010537485,0.000020308686,0.2877077,0.0007761146,0.00034406388,0.000025604124,0.00003752577,0.08672888],"genre_scores_gemma":[0.9646652,0.0003053725,0.00007657276,0.012577512,0.000199938,0.000010307698,0.00002644592,0.000005848202,0.022132844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988091,0.00013709566,0.00022043657,0.00014559182,0.00022605716,0.0004617376],"domain_scores_gemma":[0.99887717,0.00010630337,0.00009264652,0.000078503625,0.00029953703,0.0005458566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054758764,0.000091743634,0.00020681416,0.00025715632,0.00030159886,0.00006616006,0.0000782937,0.00024667237,0.0007154239],"category_scores_gemma":[0.00039448,0.00006238577,0.00009915112,0.00026590624,0.000033221393,0.00006770566,0.000019359215,0.00064466376,0.00010269149],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024778998,0.000065854554,0.8777203,0.0000067974247,0.00015509767,0.00036991795,0.00009707373,0.0000021802414,0.0003935663,0.00014233646,0.09522896,0.025570145],"study_design_scores_gemma":[0.0019135118,0.00038519455,0.5552174,0.00002747821,0.000057478654,0.000088791625,0.00006166644,0.000023386536,0.00014028713,0.0012004559,0.44082314,0.000061220046],"about_ca_topic_score_codex":0.0003356525,"about_ca_topic_score_gemma":0.0002548387,"teacher_disagreement_score":0.34559417,"about_ca_system_score_codex":0.0030172588,"about_ca_system_score_gemma":0.0018862814,"threshold_uncertainty_score":0.78900266},"labels":[],"label_agreement":null},{"id":"W4414649724","doi":"10.1016/j.ygyno.2025.03.097","title":"(ENCORE) Long-term safety and efficacy of selinexor maintenance treatment in patients with TP53 wild-type advanced or recurrent endometrial cancer: Follow-up subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study","year":2025,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Subgroup analysis; Endometrial cancer; Overall survival; MEDLINE; Stage (stratigraphy); Maintenance therapy","score_opus":0.02594590860317818,"score_gpt":0.35823256426794303,"score_spread":0.33228665566476484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414649724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99295396,0.0012154698,0.0000119805445,0.00036890674,0.00070243934,0.0043643056,0.00008321636,0.00001860866,0.00028114184],"genre_scores_gemma":[0.99546766,0.0028706368,0.000091953225,0.000059726663,0.000024330328,0.00029774036,0.00007836921,0.000012882286,0.0010967061],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973697,0.00042763219,0.0007737684,0.0006052504,0.00034089325,0.0004827735],"domain_scores_gemma":[0.9969808,0.0015920075,0.0004116537,0.00051691866,0.00039319418,0.000105448285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004566802,0.00030347178,0.0015306491,0.0006938773,0.00010089781,0.0000064884953,0.00023772438,0.00016396835,0.00013433336],"category_scores_gemma":[0.00081014336,0.00014910912,0.0001882199,0.0031733487,0.00033598224,0.000059558704,0.00016970304,0.0002522204,6.887337e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04578617,0.005270264,0.8309411,0.00006309153,0.0025518746,0.00005488233,0.00090378616,0.00016638776,0.00004275033,0.0000180767,0.000022539307,0.11417908],"study_design_scores_gemma":[0.06302915,0.022761384,0.9100683,0.00011546395,0.0027821872,0.000001021709,0.00045667076,0.000059052556,0.00016616915,0.000009052799,0.00042975362,0.00012180626],"about_ca_topic_score_codex":0.00037648625,"about_ca_topic_score_gemma":0.012928956,"teacher_disagreement_score":0.11405728,"about_ca_system_score_codex":0.0016161252,"about_ca_system_score_gemma":0.0010562221,"threshold_uncertainty_score":0.7214661},"labels":[],"label_agreement":null},{"id":"W4414695231","doi":"10.1016/j.euo.2025.07.006","title":"Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Terry Fox Research Institute","keywords":"Cabazitaxel; Enzalutamide; Abiraterone; Prostate cancer; Phases of clinical research; PTEN; Clinical endpoint; Circulating tumor cell","score_opus":0.06026926909396508,"score_gpt":0.4007988400723302,"score_spread":0.3405295709783651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414695231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98793346,0.0013581213,0.00047279074,0.0044421377,0.00040743774,0.0034540691,0.000274615,0.0001046697,0.0015526935],"genre_scores_gemma":[0.9915134,0.00008409921,0.0019179272,0.0013441703,0.0002118262,0.0022920636,0.00021525437,0.000065686116,0.0023556305],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99670184,0.0007121343,0.00071631995,0.00083182304,0.0002479336,0.0007899269],"domain_scores_gemma":[0.99812686,0.0006554853,0.00029971072,0.00034639504,0.0003531306,0.00021842025],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00076786266,0.00038084044,0.0010140208,0.0005322351,0.000237389,0.000050102823,0.00016746912,0.000080298894,0.0003192125],"category_scores_gemma":[0.0003021064,0.0002572924,0.0002559139,0.0010787273,0.0004225583,0.00010002963,0.00008020059,0.00034734883,0.000020145404],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95269144,0.0019262969,0.003933679,0.0002921547,0.011111738,0.007070523,0.0010767562,0.00020165322,0.010443483,0.000086159576,0.0007410841,0.010425015],"study_design_scores_gemma":[0.8167205,0.08280835,0.025898773,0.00016569588,0.036070883,0.00020180747,0.0011504943,0.0027050201,0.0030969116,0.00009094978,0.030164512,0.0009260977],"about_ca_topic_score_codex":0.00012587821,"about_ca_topic_score_gemma":0.0015521433,"teacher_disagreement_score":0.13597095,"about_ca_system_score_codex":0.00042931188,"about_ca_system_score_gemma":0.0015077967,"threshold_uncertainty_score":0.9999879},"labels":[],"label_agreement":null},{"id":"W4414747400","doi":"10.1038/s41467-025-63865-6","title":"Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Congressionally Directed Medical Research Programs; National Institute of Environmental Health Sciences; National Cancer Institute; Medical Research Council; University of New South Wales; National Institute for Health and Care Research; DOD Prostate Cancer Research Program; Royal Marsden NHS Foundation Trust; U.S. Department of Health and Human Services; National Institutes of Health; Prostate Cancer UK; National Health and Medical Research Council; Cancer Research UK; Movember Foundation; Prostate Cancer Foundation; Petre Foundation; U.S. Department of Defense","keywords":"MSH6; Germline; Candidate gene; Gene; Prostate cancer; DNA sequencing; DNA mismatch repair; Genome; Cancer","score_opus":0.06459854155016023,"score_gpt":0.4134262524255371,"score_spread":0.3488277108753769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414747400","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24324445,0.53499424,0.0014648198,0.152018,0.0010314881,0.022516744,0.012708342,0.00041014768,0.031611748],"genre_scores_gemma":[0.96203893,0.0034376779,0.027808433,0.00020380253,0.000069375565,0.0017928119,0.0005481617,0.000020589043,0.0040802383],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991385,0.000041062314,0.00027085913,0.00019693896,0.00011100903,0.00024162729],"domain_scores_gemma":[0.99774224,0.00049088517,0.00012782936,0.0008739219,0.00070284726,0.00006230351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026740835,0.000115160816,0.0002640396,0.00012214345,0.0002608873,0.000012620185,0.00037168674,0.00014351182,0.0000040922046],"category_scores_gemma":[0.00029477678,0.00009189213,0.00008548771,0.00050625013,0.00015863734,0.000047012487,0.00013565259,0.00031321505,3.0363498e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033344813,0.0013865515,0.25443664,0.0028188522,0.0017976548,0.000005661772,0.0015750693,0.000042655716,0.3571973,0.006543453,0.035909217,0.33495244],"study_design_scores_gemma":[0.028940786,0.0021510443,0.414969,0.0040246523,0.003101819,0.000027276476,0.001522118,0.022013107,0.08372603,0.0077325883,0.43070996,0.0010816392],"about_ca_topic_score_codex":0.00014994695,"about_ca_topic_score_gemma":0.0002682001,"teacher_disagreement_score":0.71879447,"about_ca_system_score_codex":0.00013579767,"about_ca_system_score_gemma":0.00078771147,"threshold_uncertainty_score":0.37472522},"labels":[],"label_agreement":null},{"id":"W4414773335","doi":"10.3389/fresc.2025.1655422","title":"The impact of second-generation androgen receptor pathway inhibitors on skeletal muscle morphology and strategies to mitigate their effects in prostate cancer patients","year":2025,"lang":"en","type":"review","venue":"Frontiers in Rehabilitation Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Waterloo","funders":"","keywords":"Prostate cancer; Androgen deprivation therapy; Adverse effect; Androgen receptor; Skeletal muscle; Disease; Androgen; Clinical trial","score_opus":0.021080835300605977,"score_gpt":0.35587524833100576,"score_spread":0.3347944130303998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414773335","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45471716,0.5418253,0.0000015464291,0.00016410393,0.0004822407,0.0026163482,0.000121666606,0.000006017897,0.000065628374],"genre_scores_gemma":[0.065991074,0.9315202,0.0005062245,0.000017931738,0.000053823907,0.001525873,0.00011257845,0.000018881423,0.0002533896],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99791396,0.00046561976,0.00052397425,0.00049517053,0.0002867177,0.00031457326],"domain_scores_gemma":[0.9988086,0.0006310146,0.00018735953,0.00017003778,0.00012241349,0.00008055284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008963669,0.00024849115,0.0007784289,0.0007052087,0.0001253192,0.000060072,0.00014366525,0.000115174524,0.0000065241043],"category_scores_gemma":[0.000432354,0.0001305236,0.00016140155,0.0011742116,0.0005935825,0.0001616853,0.000046637382,0.00020726523,9.328466e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008373223,0.00015674139,0.024174655,0.0041799014,0.0000640009,0.0000024927306,0.001953678,0.00007022655,0.000077854085,0.000025640162,0.0022525142,0.9669586],"study_design_scores_gemma":[0.016848631,0.057655416,0.48316857,0.12192193,0.000492045,0.000008305172,0.017147234,0.00080188323,0.0015413234,0.00491628,0.2925907,0.0029076983],"about_ca_topic_score_codex":0.0001315146,"about_ca_topic_score_gemma":0.0001649213,"teacher_disagreement_score":0.9640509,"about_ca_system_score_codex":0.00050791376,"about_ca_system_score_gemma":0.001382557,"threshold_uncertainty_score":0.53225976},"labels":[],"label_agreement":null},{"id":"W4414803796","doi":"10.2967/jnumed.125.271144","title":"Resisting RECIST: PSMA PET and Regulatory Change in Prostate Cancer","year":2025,"lang":"en","type":"letter","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Cancer; Clinical trial; Response Evaluation Criteria in Solid Tumors; Solid tumor","score_opus":0.05447067980970507,"score_gpt":0.3593218268366391,"score_spread":0.30485114702693406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414803796","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029323375,0.022197079,8.6545015e-8,0.94485277,0.00071581476,0.0005344224,0.000018727984,0.000014100007,0.0023436493],"genre_scores_gemma":[0.019359693,0.067736246,0.00040731768,0.8557636,0.02151317,0.000046182868,0.00008185698,0.00019246983,0.034899466],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975871,0.00011931607,0.00075615884,0.00028713126,0.0008422822,0.0004080295],"domain_scores_gemma":[0.9985308,0.00016802203,0.00051089935,0.00026356638,0.00036028863,0.00016644788],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00080610736,0.000284216,0.0010676442,0.0009244031,0.00008320058,0.000017052284,0.00015409301,0.00023226786,0.00032293214],"category_scores_gemma":[0.0002883254,0.00018593574,0.00010426684,0.00035718014,0.00029028684,0.000101715435,0.000076210206,0.0026113256,0.0000037725113],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010011531,0.000035721743,0.003494403,0.0016244214,0.00021898551,0.017272303,0.0011450789,9.9566e-8,0.00022442834,0.0000038264766,0.95514554,0.01983407],"study_design_scores_gemma":[0.005271539,0.0010006136,0.023524992,0.016671108,0.000393384,0.0011062106,0.00021232304,0.000020610132,0.000010818165,0.00007342053,0.9515618,0.00015317176],"about_ca_topic_score_codex":0.00035015668,"about_ca_topic_score_gemma":0.00002581915,"teacher_disagreement_score":0.08908915,"about_ca_system_score_codex":0.00052926154,"about_ca_system_score_gemma":0.00038399754,"threshold_uncertainty_score":0.9996897},"labels":[],"label_agreement":null},{"id":"W4414886615","doi":"10.1038/s41591-025-03961-8","title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Calgary","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Abiraterone acetate; Hazard ratio; Prednisone; Prostate cancer; Clinical endpoint; Placebo; Confidence interval; Randomized controlled trial","score_opus":0.027248392266540192,"score_gpt":0.4052032772086769,"score_spread":0.3779548849421367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414886615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87855583,0.051967572,0.002028795,0.04403423,0.0017149686,0.019948568,0.00033578856,0.00013007162,0.0012841581],"genre_scores_gemma":[0.97864294,0.003931236,0.0008120538,0.0015056841,0.00044582176,0.002328709,0.0005509438,0.000037456644,0.01174518],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975553,0.00019236974,0.000647692,0.0005832483,0.0005254593,0.0004958862],"domain_scores_gemma":[0.99804634,0.0006983165,0.00019851704,0.000273062,0.0005581129,0.0002256298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012975322,0.00035303365,0.0015670502,0.0003961945,0.00020676716,0.00003444693,0.00007648078,0.00018874783,0.000050226157],"category_scores_gemma":[0.0008229135,0.00021411519,0.00015348957,0.0005183047,0.00064584444,0.00008939709,0.000039614635,0.00059427833,0.0000018312131],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9644028,0.0004114469,0.000024783747,0.0007812102,0.0013440693,0.00011979333,0.002476935,0.000011515371,0.010048126,0.00092240714,0.0050710184,0.014385892],"study_design_scores_gemma":[0.97282493,0.0029135318,0.00006619014,0.00084965775,0.0022064075,0.000029512612,0.0006860542,0.0028451295,0.012501958,0.00051659206,0.0043818615,0.00017816089],"about_ca_topic_score_codex":0.00017877662,"about_ca_topic_score_gemma":0.00006829213,"teacher_disagreement_score":0.10008707,"about_ca_system_score_codex":0.0002840002,"about_ca_system_score_gemma":0.00075283326,"threshold_uncertainty_score":0.8731364},"labels":[],"label_agreement":null},{"id":"W4414914296","doi":"10.1007/978-3-032-00759-9_375","title":"Metastasis Inhibition in Cancer","year":2025,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Research Institute; Lakehead University","funders":"","keywords":"Metastasis; Cancer; Cancer metastasis; Cancer cell; Clinical trial; Molecular oncology; Acquired resistance","score_opus":0.056353856813028354,"score_gpt":0.36286248283971206,"score_spread":0.3065086260266837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414914296","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013963736,0.0066605853,0.0000084082185,0.0031568683,0.00009252103,0.00054305134,0.00007893144,0.000033779284,0.98928624],"genre_scores_gemma":[0.0015423478,0.008813947,0.000095929216,0.00044284976,0.00008638453,0.00007002967,0.00020765215,0.000019231096,0.9887216],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99920315,0.0000050829135,0.00017233386,0.00024478635,0.00021551902,0.00015912621],"domain_scores_gemma":[0.99964434,0.00002280471,0.000029483994,0.00016649495,0.00007519818,0.00006167066],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006437302,0.00016112816,0.00033116393,0.00035848186,0.000017899121,0.000008010552,0.000019912617,0.00017000706,0.006071943],"category_scores_gemma":[0.000005823884,0.00011611022,0.00010140285,0.000048762937,0.000043804477,0.00002490103,0.000039825372,0.00029260968,0.00008157399],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001620252,0.00032065704,0.0013341624,0.0024768263,0.0018676224,0.003669854,0.00020589378,0.0000032759967,0.00078415906,0.18471809,0.3549092,0.44809],"study_design_scores_gemma":[0.004275297,0.0002757,0.00036314793,0.0038381387,0.00050689554,0.00001639869,0.00002285748,0.000018446854,0.008296231,0.008237502,0.97380686,0.0003425233],"about_ca_topic_score_codex":0.00030144549,"about_ca_topic_score_gemma":0.00044469134,"teacher_disagreement_score":0.6188977,"about_ca_system_score_codex":0.00042284504,"about_ca_system_score_gemma":0.0004246618,"threshold_uncertainty_score":0.9948366},"labels":[],"label_agreement":null},{"id":"W4414930819","doi":"10.1038/s41467-025-64042-5","title":"Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Medical Research Council; Royal Society of Medicine; Prostate Cancer UK; National Institute for Health and Care Research; Government of the United Kingdom; National Center for Advancing Translational Sciences; Wellcome Trust; Institute for Prostate Cancer Research; American Association for Cancer Research; Prostate Cancer Foundation; Movember Foundation; Wellcome; University of Washington; Cancer Research UK; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"MCL1; Prostate cancer; Protein kinase B; Downregulation and upregulation; PI3K/AKT/mTOR pathway; Cancer","score_opus":0.04136305652306739,"score_gpt":0.39154931318494257,"score_spread":0.3501862566618752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414930819","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34281033,0.42900324,0.010477025,0.16440168,0.00074770884,0.009860335,0.00035935643,0.00054245995,0.04179788],"genre_scores_gemma":[0.99157095,0.0015389086,0.004304963,0.0004594565,0.000021323336,0.00045476313,0.00038105555,0.000016269834,0.0012523347],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99917763,0.00007969541,0.00020410694,0.00019927733,0.00013244616,0.00020685387],"domain_scores_gemma":[0.9986886,0.00024859127,0.00007119153,0.0005203288,0.00042127885,0.000050025053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021877226,0.00012294528,0.00016638957,0.000115318304,0.0004634754,0.0001296951,0.00022034507,0.00014335095,0.000007344027],"category_scores_gemma":[0.000112734044,0.000103393046,0.00004928234,0.00029782768,0.00016341521,0.00014476938,0.000103473925,0.0005066997,6.207784e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069576077,0.0016683466,0.03262036,0.00108499,0.0014624323,0.000009726416,0.0057021226,0.000030233432,0.62372303,0.2488832,0.006167099,0.07795269],"study_design_scores_gemma":[0.03614711,0.0027300678,0.1766894,0.0032934675,0.0026704764,0.00003883853,0.027194645,0.022226186,0.34966233,0.06787722,0.3093667,0.0021035578],"about_ca_topic_score_codex":0.000050270133,"about_ca_topic_score_gemma":0.000110918285,"teacher_disagreement_score":0.6487606,"about_ca_system_score_codex":0.00011598025,"about_ca_system_score_gemma":0.00037220598,"threshold_uncertainty_score":0.4216246},"labels":[],"label_agreement":null},{"id":"W4414981368","doi":"10.1016/j.fjurol.2025.102998","title":"Chemotherapy use in triplet approach for metastatic hormone-sensitive prostate cancer: French practice survey and expert opinion","year":2025,"lang":"en","type":"article","venue":"The French Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Misericordia Community Hospital","funders":"Association Française d'Urologie; Bayer","keywords":"Expert opinion; Second opinion; Warrant; Disease; Chemotherapy; Prostate","score_opus":0.05897044091488333,"score_gpt":0.3738353770203941,"score_spread":0.31486493610551075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414981368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80757207,0.12539387,0.008226977,0.05430876,0.0006757928,0.0032107132,0.00014798708,0.000016722452,0.00044709642],"genre_scores_gemma":[0.94618404,0.04523491,0.0048308945,0.0025309604,0.0001426297,0.00011492825,0.00004851098,0.000021061931,0.00089208403],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984826,0.0004944363,0.00037864092,0.0001798671,0.00018157557,0.00028288743],"domain_scores_gemma":[0.99775076,0.0013385502,0.00023716726,0.00015137468,0.00044774992,0.00007438873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016847381,0.00014077069,0.00045858588,0.0002411457,0.000070916314,0.000027105601,0.00010248444,0.000066273016,0.0000052529426],"category_scores_gemma":[0.00071145414,0.00008197965,0.000064275475,0.00030100846,0.00019330977,0.00016371536,0.000029992447,0.00037234853,2.4212412e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12803322,0.006990907,0.24576977,0.00072943687,0.012169517,0.00086710876,0.043358922,0.0009783013,0.02506027,0.0007057067,0.2239606,0.31137624],"study_design_scores_gemma":[0.04721649,0.008407257,0.865309,0.00016765436,0.00047399683,0.0011911478,0.0013715996,0.0061733997,0.0023050776,0.0011728912,0.065841496,0.0003699778],"about_ca_topic_score_codex":0.0016521567,"about_ca_topic_score_gemma":0.00012900081,"teacher_disagreement_score":0.61953926,"about_ca_system_score_codex":0.00010702073,"about_ca_system_score_gemma":0.00043857095,"threshold_uncertainty_score":0.33430332},"labels":[],"label_agreement":null},{"id":"W4415040602","doi":"10.3390/cancers17203279","title":"Artemis (DCLRE1C) Acts as a Target to Enhance Radiotherapy Response in Triple-Negative Breast Cancer","year":2025,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; St Joseph's Health Care; Western University; St. Michael's Hospital; London Health Sciences Centre","funders":"","keywords":"Radiation therapy; Biomarker; Breast cancer; Complete response; Radiation sensitivity; Cell","score_opus":0.014198681485378098,"score_gpt":0.3801622659597083,"score_spread":0.3659635844743302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415040602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95534295,0.0055020847,0.00013597122,0.030460553,0.000550142,0.0018356098,0.00014981192,0.000072717405,0.005950169],"genre_scores_gemma":[0.947777,0.0028118375,0.00041648687,0.004599273,0.00015546732,0.0009028551,0.000010183342,0.000033468717,0.043293472],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99831194,0.00012782005,0.00024611023,0.0004884599,0.00029006982,0.0005356272],"domain_scores_gemma":[0.99903,0.00017393216,0.000048785627,0.00033686718,0.0001399142,0.00027047962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003222981,0.00022023814,0.00041635497,0.00039064622,0.000079180885,0.00002538765,0.00015125645,0.000103127306,0.00085075654],"category_scores_gemma":[0.00016742888,0.00018422361,0.0000845093,0.0012138024,0.00012325677,0.00009370361,0.00003264489,0.0002836021,0.000037092424],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33545664,0.00044383307,0.046857554,0.00072055956,0.0017926196,0.0012500202,0.019134924,0.0029939963,0.32729805,0.00026962452,0.14059009,0.1231921],"study_design_scores_gemma":[0.024728032,0.002332922,0.27344313,0.004345555,0.00014344865,0.000055298387,0.0027625652,0.0011216123,0.49046487,0.0006455983,0.19892587,0.0010311244],"about_ca_topic_score_codex":0.0024237947,"about_ca_topic_score_gemma":0.00034772596,"teacher_disagreement_score":0.3107286,"about_ca_system_score_codex":0.0073889657,"about_ca_system_score_gemma":0.004871639,"threshold_uncertainty_score":0.9964215},"labels":[],"label_agreement":null},{"id":"W4415098395","doi":"10.1097/md.0000000000042318","title":"Systemic treatment of metastatic castration-sensitive prostate cancer: A meta-analysis of efficacy and safety","year":2025,"lang":"en","type":"review","venue":"Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Docetaxel; Systemic therapy; Leverage (statistics); Prostate; Clinical trial; Prostate cancer","score_opus":0.15834637285179684,"score_gpt":0.4515305883133317,"score_spread":0.29318421546153484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415098395","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010842264,0.99398094,0.000015787436,0.00049731816,0.000060022016,0.003859286,0.0011458296,0.000014184959,0.00031818153],"genre_scores_gemma":[0.0013977654,0.9923788,0.000064837404,0.000014144955,0.0000444904,0.00049757736,0.0010831483,0.000024631565,0.004494662],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99700975,0.00032710817,0.0013472923,0.0005309171,0.0005248899,0.00026005608],"domain_scores_gemma":[0.99713045,0.001065945,0.000725686,0.000532904,0.0003812155,0.00016377785],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004088011,0.0005082285,0.010058778,0.0012703155,0.000045188674,0.0000040379823,0.00007284591,0.00010893271,0.0002102995],"category_scores_gemma":[0.00011463054,0.00025319488,0.0012805526,0.0019344058,0.00036131206,0.000024085788,0.000029493536,0.0001407514,0.0000012176064],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004273132,0.00029544657,0.00003590642,0.05434788,0.506888,0.0001678391,0.001217954,0.0000073746096,0.0000138900805,0.00004473925,0.00007821072,0.4364755],"study_design_scores_gemma":[0.0033693176,0.0016178386,0.000062906205,0.011449378,0.94101965,0.00005341773,0.00021435136,0.000016647296,0.00003655062,0.000002009562,0.04201485,0.000143061],"about_ca_topic_score_codex":0.0010517174,"about_ca_topic_score_gemma":0.00009452232,"teacher_disagreement_score":0.43633243,"about_ca_system_score_codex":0.00036014998,"about_ca_system_score_gemma":0.0011365553,"threshold_uncertainty_score":0.999992},"labels":[],"label_agreement":null},{"id":"W4415141897","doi":"10.1016/j.ejmech.2025.118259","title":"Development of dual AR/ARV7 degraders with 3,5-dimethylisoxazole to overcome antiandrogen resistance in castration-resistant prostate cancer","year":2025,"lang":"en","type":"article","venue":"European Journal of Medicinal Chemistry","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Science Foundation of Beijing Municipality; National Natural Science Foundation of China; McGill University","keywords":"Androgen receptor; Prostate cancer; Antiandrogen; Drug resistance; Blockade; Androgen Receptor Antagonists; Downregulation and upregulation; Dual (grammatical number); Prostate","score_opus":0.02053667857527498,"score_gpt":0.30500522927693646,"score_spread":0.2844685507016615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415141897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98548865,0.005442912,0.0000567667,0.002536389,0.000059042653,0.00021459759,0.00000970208,0.000006717369,0.006185196],"genre_scores_gemma":[0.9920545,0.00025390027,0.0046939533,0.000120013654,0.000090732065,0.000005928004,0.000008063569,0.000020960799,0.0027519464],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811774,0.0000653751,0.0007120816,0.00019777432,0.00062863,0.0002784214],"domain_scores_gemma":[0.99898815,0.00004112961,0.00025898643,0.00016605417,0.0003101565,0.00023554091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008156355,0.00017483543,0.00041012643,0.00018875532,0.000053404503,0.000013179591,0.00014567925,0.000028642977,0.00006179528],"category_scores_gemma":[0.000080252525,0.00012047898,0.00005646504,0.0005244387,0.00013089937,0.000058850354,0.00003559781,0.00037005192,0.0000017049393],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012118454,0.00037034697,0.026373273,0.0016574995,0.00056898926,0.0046222135,0.005651977,0.00005304415,0.9386346,0.000007877614,0.0022690052,0.0076727234],"study_design_scores_gemma":[0.011397268,0.0005793973,0.15580375,0.009428432,0.00021676326,0.00016420543,0.0036886816,0.0000034090103,0.79996693,0.0000117550035,0.018490227,0.00024916345],"about_ca_topic_score_codex":0.000012274373,"about_ca_topic_score_gemma":0.000054069253,"teacher_disagreement_score":0.13866764,"about_ca_system_score_codex":0.00027942864,"about_ca_system_score_gemma":0.001490103,"threshold_uncertainty_score":0.491299},"labels":[],"label_agreement":null},{"id":"W4415151966","doi":"10.1186/s12943-025-02451-2","title":"Thyroid hormone receptor beta signaling is a targetable driver of prostate cancer growth","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"College of Family Physicians of Canada; University of Toronto","funders":"Siemens Healthineers; Christian Doppler Forschungsgesellschaft; Bundesministerium für Wissenschaft, Forschung und Wirtschaft; Universität Wien; Nemzeti Kutatási, Fejlesztési és Innovaciós Alap; Hungarian Scientific Research Fund; Österreichische Forschungsförderungsgesellschaft; Magyar Tudományos Akadémia; Vienna Science and Technology Fund; Austrian Science Fund; National Research, Development and Innovation Office; Ministerstvo Školství, Mládeže a Tělovýchovy; Bundesministerium für Digitalisierung und Wirtschaftsstandort; Medizinische Universität Wien; European Commission; Österreichische Nationalstiftung für Forschung, Technologie und Entwicklung","keywords":"Prostate cancer; Androgen receptor; Carcinogenesis; Thyroid hormone receptor; Thyroid; Thyroid cancer; Cell growth; Context (archaeology); Signal transduction; Receptor","score_opus":0.01132817604034568,"score_gpt":0.29590165932619067,"score_spread":0.284573483285845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415151966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8730108,0.111691855,0.0002958298,0.009687327,0.00024408207,0.0011446755,0.00021851729,0.000057965797,0.0036489163],"genre_scores_gemma":[0.9660065,0.012416878,0.00070092495,0.0016796873,0.000081697304,0.0005353216,0.000059595965,0.000047549045,0.018471839],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983733,0.000041626135,0.00028737422,0.00041376278,0.00042890015,0.00045500215],"domain_scores_gemma":[0.99903375,0.000018913799,0.00009144112,0.00030169153,0.0004211707,0.00013303828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012471546,0.00021882477,0.000431578,0.0001959673,0.00008405267,0.000020623747,0.00013741075,0.000102720485,0.00076275837],"category_scores_gemma":[0.000017458195,0.00017592251,0.00017249996,0.00066875305,0.00014315908,0.0000876373,0.00008810027,0.00022812097,0.000015360185],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008678663,0.00014987004,0.029383674,0.00040958673,0.00084940274,0.00006023758,0.0006634274,0.000041439238,0.93200785,0.00022442701,0.03216079,0.0031814137],"study_design_scores_gemma":[0.0033571145,0.00021926984,0.0030539536,0.00044584117,0.00029467116,0.0000010355029,0.00007697688,0.000082922386,0.9719098,0.00020196263,0.020178542,0.00017789968],"about_ca_topic_score_codex":0.0014521303,"about_ca_topic_score_gemma":0.000017126486,"teacher_disagreement_score":0.09927498,"about_ca_system_score_codex":0.00036127254,"about_ca_system_score_gemma":0.0008423001,"threshold_uncertainty_score":0.83516693},"labels":[],"label_agreement":null},{"id":"W4415294570","doi":"10.1096/fj.202403170rr","title":"Cell‐ <scp>ELISA</scp> ‐Based High‐Throughput Screening Leads to the Discovery of Androgen Receptor Degraders to Conquer Castration‐Resistant Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chinese Academy of Medical Sciences; Jinhua Science and Technology Bureau; Zhejiang Normal University; National Natural Science Foundation of China; McGill University","keywords":"Androgen receptor; Prostate cancer; Antiandrogen; Dihydrotestosterone; Androgen; Receptor; Testosterone (patch); Androgen Receptor Antagonists; Transcription factor","score_opus":0.029519582884387042,"score_gpt":0.3110914861465858,"score_spread":0.2815719032621988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415294570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9701413,0.0028815002,0.0016845104,0.023130579,0.00034934873,0.0010495551,0.0001903785,0.00001719455,0.0005556214],"genre_scores_gemma":[0.9815533,0.00039378626,0.00084466644,0.001726643,0.00024660083,0.000090263115,0.000027870225,0.00002488388,0.0150919985],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99823207,0.00016470799,0.0003759485,0.00022392473,0.00054280966,0.00046053712],"domain_scores_gemma":[0.9987995,0.00025684945,0.0001387063,0.00033119996,0.000274166,0.00019960455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006026079,0.00019750142,0.00029985435,0.000170952,0.00043205736,0.00014462472,0.00027485014,0.000054095544,0.000059922495],"category_scores_gemma":[0.00011613236,0.00009999782,0.0001361428,0.0005744047,0.00016616147,0.00013529552,0.000068945694,0.0004237462,0.000016053562],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027864957,0.00027071266,0.033077016,0.0002285309,0.00065399037,0.00011756975,0.005609288,0.0051506814,0.8021623,0.00016383373,0.14389268,0.0058869063],"study_design_scores_gemma":[0.0037778514,0.00068263593,0.009878686,0.0007591234,0.00030393354,0.00002231794,0.0034650364,0.000115521034,0.9662846,0.000051689374,0.0145668555,0.00009175181],"about_ca_topic_score_codex":0.00045889773,"about_ca_topic_score_gemma":0.00013264026,"teacher_disagreement_score":0.1641223,"about_ca_system_score_codex":0.0002492697,"about_ca_system_score_gemma":0.0010907674,"threshold_uncertainty_score":0.40777928},"labels":[],"label_agreement":null},{"id":"W4415320990","doi":"10.1002/cncr.70131","title":"Prostate‐specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long‐term survival","year":2025,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Prostate cancer; Prostatectomy; Biochemical recurrence; Positron emission tomography; Glutamate carboxypeptidase II; Complement (music); Prostate-specific antigen; Management of prostate cancer; Cancer recurrence","score_opus":0.015212036855586884,"score_gpt":0.32044576496406313,"score_spread":0.30523372810847627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415320990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87082803,0.120664686,0.0003686134,0.0020073317,0.0013023159,0.0039237905,0.0002363409,0.00027529596,0.00039358213],"genre_scores_gemma":[0.95462555,0.03898087,0.00023448642,0.0003171054,0.0003066809,0.0024425345,0.00032409292,0.000110249144,0.0026584158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99496627,0.00021139388,0.00080802914,0.0015521729,0.0010764396,0.0013857095],"domain_scores_gemma":[0.997503,0.00026562987,0.00018648512,0.0007735875,0.00063972716,0.00063157117],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000437543,0.00073592924,0.00088859745,0.0008844737,0.0004914428,0.00020800946,0.00035558414,0.00022421965,0.00049094966],"category_scores_gemma":[0.00009218744,0.0005796772,0.00040177026,0.0020271544,0.0004240649,0.00039198945,0.00038461678,0.0007707481,0.000026459327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010969127,0.0004991967,0.8869777,0.0012597969,0.00047638937,0.0007920549,0.0013890461,0.00033746645,0.022155922,0.000010734494,0.001695637,0.073436975],"study_design_scores_gemma":[0.02271907,0.00102355,0.7470694,0.025668237,0.0009486495,0.00013487428,0.00025443113,0.012654783,0.17757724,0.0005916032,0.009083045,0.0022750846],"about_ca_topic_score_codex":0.00040619617,"about_ca_topic_score_gemma":0.000081749604,"teacher_disagreement_score":0.15542132,"about_ca_system_score_codex":0.0010909835,"about_ca_system_score_gemma":0.0010427444,"threshold_uncertainty_score":0.99966544},"labels":[],"label_agreement":null},{"id":"W4415331985","doi":"10.1056/nejmoa2510310","title":"Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; SAIT Polytechnic; University of British Columbia","funders":"Astellas Pharma; Pfizer","keywords":"Enzalutamide; Prostate cancer; Overall survival; Prostate; Cancer; Chemotherapy","score_opus":0.01792927997136344,"score_gpt":0.3355385328322519,"score_spread":0.3176092528608884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415331985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9389341,0.016603975,0.000097963944,0.04172755,0.00060672447,0.00039246163,0.0000037829325,0.000010148154,0.0016233035],"genre_scores_gemma":[0.98822415,0.0066755735,0.0003096635,0.00035747947,0.0012356513,0.000010019943,0.000009252088,0.0000147773235,0.0031634117],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986615,0.000056075594,0.00044987202,0.0001544083,0.00040934235,0.00026876206],"domain_scores_gemma":[0.99903727,0.0001294958,0.00015391171,0.00013140854,0.00030016835,0.00024777694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006404276,0.00015097173,0.0005167125,0.0003448764,0.00002389068,0.0000074843147,0.00010005637,0.000052877287,0.00009722519],"category_scores_gemma":[0.00020589982,0.00007786249,0.00004362117,0.00045823352,0.00013207433,0.00005328298,0.000021073132,0.00050813117,5.787402e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03804354,0.0003683362,0.22686245,0.00041524306,0.0006133242,0.0010777891,0.0019589106,0.000016734499,0.11790198,0.00008245244,0.0074650566,0.6051942],"study_design_scores_gemma":[0.643521,0.014340075,0.14078966,0.02016283,0.0012404041,0.00083560083,0.0015630851,0.00033304133,0.0706429,0.001305885,0.104737915,0.0005275717],"about_ca_topic_score_codex":0.00034604123,"about_ca_topic_score_gemma":0.00028241958,"teacher_disagreement_score":0.60547745,"about_ca_system_score_codex":0.00022818588,"about_ca_system_score_gemma":0.0011241972,"threshold_uncertainty_score":0.31751403},"labels":[],"label_agreement":null},{"id":"W4415452624","doi":"10.3390/cancers17213404","title":"Fifty Shades of PSMA-Avid Rib Lesions: A Comprehensive Review","year":2025,"lang":"en","type":"review","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Rib cage; Decision tree; Clinical Practice; MEDLINE; Interpretation (philosophy); Personalized medicine","score_opus":0.14759228084269604,"score_gpt":0.4637396298239683,"score_spread":0.3161473489812723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415452624","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000012588696,0.9926379,0.0000020526045,0.00025090753,0.00026877556,0.0029899376,0.00034213564,0.000038265338,0.003468795],"genre_scores_gemma":[7.4999735e-7,0.9906105,0.000096224816,0.0004765325,0.00010967438,0.0006297355,0.0005276247,0.000037222286,0.007511747],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798626,0.00014743027,0.0006639814,0.0004753653,0.00037293456,0.0003540599],"domain_scores_gemma":[0.99823487,0.00032392604,0.0003094342,0.0006588084,0.0002939391,0.00017899541],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013819695,0.0004055002,0.002995784,0.00024443804,0.000061096674,0.000007793566,0.00025175977,0.0002222254,0.00044747442],"category_scores_gemma":[0.00015833625,0.0002695499,0.00083799235,0.00081366306,0.00022281654,0.000033145934,0.000118428936,0.0004870189,0.000048508613],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021905167,0.00001342578,0.0000033209467,0.36279568,0.0004194231,0.000041116884,0.000013694718,1.6941587e-7,4.1796497e-7,0.00001708092,0.041013557,0.5956602],"study_design_scores_gemma":[0.00039662747,0.000100583624,0.0000039933434,0.33738688,0.002082518,0.000014783084,0.000014255653,4.3156226e-7,0.000004187282,0.0000069177017,0.6598622,0.00012663897],"about_ca_topic_score_codex":0.00012591683,"about_ca_topic_score_gemma":0.000004766623,"teacher_disagreement_score":0.6188486,"about_ca_system_score_codex":0.0019700644,"about_ca_system_score_gemma":0.007827442,"threshold_uncertainty_score":0.9999757},"labels":[],"label_agreement":null},{"id":"W4415468626","doi":"10.1038/s41391-025-01038-8","title":"STEAP1-targeted strategies in advanced prostate cancer: a review on therapeutic and diagnostic implications","year":2025,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Prostate cancer; Prostate; Prostate disease; Disease; Therapeutic approach; Benign prostatic hyperplasia (BPH); Prostate-specific antigen; Prostatic disease","score_opus":0.01948177346396031,"score_gpt":0.3711199151684267,"score_spread":0.3516381417044664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415468626","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2631779,0.7084163,0.000006403776,0.020542603,0.00012215477,0.005852401,0.0010882627,0.00014135992,0.00065263105],"genre_scores_gemma":[0.5364033,0.45313814,0.000050363924,0.0026116294,0.00002077556,0.0058949534,0.00017780591,0.000032930344,0.0016701209],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977882,0.0001008702,0.00049241656,0.0007371698,0.00027369717,0.0006076743],"domain_scores_gemma":[0.9985405,0.0004533858,0.00012962395,0.00035656508,0.00021563875,0.00030427382],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015336619,0.00040428652,0.0006615876,0.00026543168,0.00021007615,0.00012399498,0.00009955948,0.000058636564,0.00007335727],"category_scores_gemma":[0.00019221121,0.0003031143,0.00007016903,0.0007564101,0.00033086742,0.00028364485,0.000074593365,0.0002701949,0.0000035408975],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022150367,0.0005117914,0.3726545,0.015328803,0.00027878446,0.00007129464,0.0010955901,0.000041941737,0.00046669267,0.0013324297,0.0016504747,0.60435265],"study_design_scores_gemma":[0.011614712,0.001223925,0.93404114,0.022953797,0.0012241605,0.0000133971635,0.0015804551,0.0002700047,0.00064412534,0.011975028,0.013687845,0.00077143393],"about_ca_topic_score_codex":0.00029325843,"about_ca_topic_score_gemma":0.00010807742,"teacher_disagreement_score":0.60358125,"about_ca_system_score_codex":0.00023359356,"about_ca_system_score_gemma":0.0012319633,"threshold_uncertainty_score":0.9999421},"labels":[],"label_agreement":null},{"id":"W4415493295","doi":"10.1007/s44178-025-00197-x","title":"Transcription Factor Dynamics in Neuroendocrine Prostate Cancer Development","year":2025,"lang":"en","type":"editorial","venue":"Holistic Integrative Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Prevention of Organ Failure; BC Cancer Agency","funders":"Canadian Institutes of Health Research; BC Cancer Foundation; Terry Fox Research Institute","keywords":"Prostate cancer; Androgen receptor; Transdifferentiation; Transcription factor; Adenocarcinoma; Prostate; Mechanism (biology); FOXA1","score_opus":0.03794200209996328,"score_gpt":0.39936059538374863,"score_spread":0.36141859328378534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415493295","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008120422,0.0034010978,0.00039939905,0.0031214089,0.95923877,0.003921944,0.0031327072,0.00013414002,0.018530136],"genre_scores_gemma":[0.045437478,0.025740711,0.0016917355,0.000680172,0.43384567,0.007667193,0.023903303,0.00029780608,0.46073592],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99714804,0.000226192,0.0006537053,0.00073550956,0.0005598208,0.0006767269],"domain_scores_gemma":[0.99807364,0.00061326683,0.00018216066,0.00024517268,0.0007240476,0.00016173668],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014313002,0.0005391863,0.0012051464,0.0006463493,0.00009088567,0.000029376695,0.00019600724,0.00049335277,0.000310008],"category_scores_gemma":[0.0007751591,0.000388103,0.00013341937,0.0004389471,0.00024484197,0.000059051134,0.0000717925,0.002265774,0.00002691969],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006044272,0.0010170261,0.0013722815,0.0013688804,0.000528845,0.0026823103,0.0026312282,0.0000038481735,0.00018909221,0.0006582307,0.87892073,0.10458325],"study_design_scores_gemma":[0.0054578464,0.0011930761,0.0011024149,0.0013774368,0.00018741206,0.000010336005,0.0006344403,0.0002860727,0.00054847205,0.00018260487,0.9886941,0.00032579052],"about_ca_topic_score_codex":0.0011769144,"about_ca_topic_score_gemma":0.014683273,"teacher_disagreement_score":0.52539307,"about_ca_system_score_codex":0.011866512,"about_ca_system_score_gemma":0.010001262,"threshold_uncertainty_score":0.99985707},"labels":[],"label_agreement":null},{"id":"W4415595419","doi":"10.1016/j.annonc.2025.10.1236","title":"Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McMaster University; Queen's University; Hamilton Health Sciences; Occupational Cancer Research Centre; Ottawa Hospital; Health Sciences Centre; University Health Network; Abbotsford Veterinary Clinic; Jewish General Hospital; Sunnybrook Health Science Centre; Surrey Place Centre; Juravinski Cancer Centre; Canadian Centre for Applied Research in Cancer Control; Princess Margaret Cancer Centre; London Health Sciences Centre; Interior Health; BC Cancer Agency; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Genentech; BC Cancer Foundation; Ipsen; Syöpäsäätiö; Radboud Universitair Medisch Centrum; Astellas Pharma; Institute of Cancer Research; Terry Fox Research Institute; Michael Smith Health Research BC; Suomen Kulttuurirahasto; Academy of Finland; Eisai; EMD Serono; Jane ja Aatos Erkon Säätiö; Radboud Universiteit; Canadian Cancer Society; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Prostate Cancer Foundation","keywords":"Repertoire; Prostate cancer; Locus (genetics); Somatic cell; Hierarchy; Clinical significance","score_opus":0.11491517348765343,"score_gpt":0.5037442646344384,"score_spread":0.388829091146785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415595419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9659778,0.0040586,0.0000028343297,0.024577973,0.00007797041,0.00041149816,0.000033676857,0.000004822889,0.004854819],"genre_scores_gemma":[0.9896031,0.0074496013,0.00015637497,0.00037746326,0.000027595268,0.000048328257,0.000016588918,0.0000040854243,0.002316873],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990488,0.000095745745,0.0004491989,0.00016556047,0.00009033969,0.0001503183],"domain_scores_gemma":[0.9992966,0.00019109708,0.00008818154,0.00013168914,0.00023576031,0.000056653495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034748335,0.000062850486,0.00034103103,0.00016222087,0.00002805789,0.0000030650551,0.000036854537,0.000087982065,0.000033146258],"category_scores_gemma":[0.00014015174,0.000048184454,0.00004909269,0.00020962066,0.00029232728,0.00003877968,0.000028925535,0.00014172446,5.7000244e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011055876,0.0025306758,0.45972213,0.0007480545,0.0006888065,0.00034409235,0.0021389406,0.000031236734,0.03347655,0.004203884,0.011856799,0.47320294],"study_design_scores_gemma":[0.01748364,0.013558596,0.8219799,0.0014088074,0.00023652188,0.000021184014,0.0012035652,0.0004252725,0.06836742,0.005060195,0.07001396,0.00024096937],"about_ca_topic_score_codex":0.00062059244,"about_ca_topic_score_gemma":0.0013431165,"teacher_disagreement_score":0.472962,"about_ca_system_score_codex":0.000039811664,"about_ca_system_score_gemma":0.0010169946,"threshold_uncertainty_score":0.19649051},"labels":[],"label_agreement":null},{"id":"W4415609448","doi":"10.1038/s41388-025-03614-7","title":"Correction: Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity","year":2025,"lang":"en","type":"erratum","venue":"Oncogene","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Carcinogenesis; Cell culture; Cancer; Cell growth; Prostate","score_opus":0.01851466715021476,"score_gpt":0.3234644974337391,"score_spread":0.30494983028352435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415609448","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31942672,0.20606987,0.00004924198,0.02161026,0.08307924,0.0077503626,0.0042269942,0.0006455498,0.35714176],"genre_scores_gemma":[0.036426056,0.041434675,0.00010248288,0.00018461829,0.0018114673,0.00037955368,0.0027774477,0.0000435438,0.91684014],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982602,0.000057368165,0.00028965896,0.0005929865,0.00044422114,0.00035557488],"domain_scores_gemma":[0.9990137,0.00007565077,0.00014820977,0.0002507475,0.00035609872,0.00015555423],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015065193,0.000342525,0.0005658273,0.00018006674,0.0002187949,0.00008163414,0.000039360708,0.0003406936,0.00020326942],"category_scores_gemma":[0.00006628619,0.00028173346,0.00009369522,0.00030209118,0.0001798134,0.00010479786,0.000068766276,0.0005951509,0.0000087057115],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090237893,0.00013596623,0.0001375709,0.0010117951,0.0002844456,0.0002924422,0.00021939295,9.997849e-7,0.11019677,0.0000038917437,0.8606128,0.026201515],"study_design_scores_gemma":[0.0023360567,0.00057756715,0.00159616,0.0040797605,0.00059111393,0.00007721859,0.00020836617,0.000111371526,0.5264677,0.000038707134,0.46350446,0.00041156448],"about_ca_topic_score_codex":0.0007384495,"about_ca_topic_score_gemma":0.0013537721,"teacher_disagreement_score":0.5596984,"about_ca_system_score_codex":0.00042522023,"about_ca_system_score_gemma":0.0018741015,"threshold_uncertainty_score":0.99996346},"labels":[],"label_agreement":null},{"id":"W4415619227","doi":"10.3390/cancers17213427","title":"Evaluating the Role of Liquid Biopsy to Detect Pathogenic Homologous Recombination Repair (HRR) Gene Alterations in Metastatic Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"Cancers","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill Genome Centre; McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Pfizer","keywords":"Liquid biopsy; Homologous recombination; Prostate cancer; Biopsy; Homologous chromosome; Gene; Prospective cohort study","score_opus":0.03973520832211078,"score_gpt":0.3890670919459375,"score_spread":0.3493318836238267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415619227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98770887,0.0084832935,0.000045483823,0.0014101772,0.00019948855,0.0015817228,0.00005088509,0.00003790401,0.0004821807],"genre_scores_gemma":[0.9939241,0.0008039326,0.0017760111,0.00024165491,0.000032154934,0.0014728985,0.000030967636,0.00001595498,0.0017023274],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872416,0.00014377014,0.00032653546,0.00028803592,0.00023647408,0.00028100694],"domain_scores_gemma":[0.9992223,0.00010428901,0.00007949433,0.00029888967,0.00022910745,0.00006594058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005395923,0.00012434558,0.0002451043,0.0002589095,0.00010862524,0.000012146759,0.00009896694,0.00003642693,0.00006236265],"category_scores_gemma":[0.00019230686,0.00008722598,0.0000898638,0.00091363845,0.0000798954,0.000052981704,0.000045137964,0.00015601912,0.000004189689],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049329265,0.00011355843,0.0112871155,0.00035933242,0.00061800214,0.000056975678,0.00558462,0.011911437,0.8000856,0.000215391,0.00047076953,0.16436426],"study_design_scores_gemma":[0.009848872,0.0073127206,0.036212083,0.0017621776,0.0009454098,0.000044460237,0.004031363,0.02925511,0.90484965,0.0032565906,0.0019449246,0.00053665467],"about_ca_topic_score_codex":0.0015408243,"about_ca_topic_score_gemma":0.000504387,"teacher_disagreement_score":0.16382761,"about_ca_system_score_codex":0.0017308072,"about_ca_system_score_gemma":0.0020354467,"threshold_uncertainty_score":0.4526001},"labels":[],"label_agreement":null},{"id":"W4415619535","doi":"10.1056/evidoa2500109","title":"Age and Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer","year":2025,"lang":"en","type":"review","venue":"NEJM Evidence","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Prostate cancer; Radiation therapy; Cancer; Clinical trial; Patient data; Chemotherapy","score_opus":0.18101751678961597,"score_gpt":0.46106767701267415,"score_spread":0.2800501602230582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415619535","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003865268,0.9950169,0.0000035767914,0.00066945853,0.00007962713,0.0035605293,0.00005899471,0.00003025904,0.00019417108],"genre_scores_gemma":[0.0005770493,0.9898044,0.000112639806,0.00006553517,0.000049819053,0.0015693139,0.0001279586,0.00002822329,0.007665063],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99812686,0.00020135145,0.00045248325,0.0006276314,0.00024947608,0.00034220505],"domain_scores_gemma":[0.99864113,0.00056044455,0.00015463718,0.0003626841,0.00014866654,0.00013240964],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023027642,0.00039192257,0.0015711008,0.00040879977,0.0000522438,0.000031874468,0.000076400014,0.00011515932,0.000010486114],"category_scores_gemma":[0.00026183305,0.00025140247,0.0001742853,0.0006206359,0.0001490524,0.000120864985,0.00006724841,0.00030162476,0.00002281186],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020451944,0.00007839328,0.0000866524,0.011289478,0.00027507378,0.0008912037,0.0005486367,1.8971183e-7,0.000015157356,0.000015720065,0.00022697177,0.986368],"study_design_scores_gemma":[0.0031707415,0.0016026103,0.00344595,0.2890275,0.006388927,0.00017349776,0.00043285618,0.00004612666,0.00008674839,0.00006931679,0.6948035,0.00075223204],"about_ca_topic_score_codex":0.00081652805,"about_ca_topic_score_gemma":0.00023755283,"teacher_disagreement_score":0.9856158,"about_ca_system_score_codex":0.001163629,"about_ca_system_score_gemma":0.0013888457,"threshold_uncertainty_score":0.9999938},"labels":[],"label_agreement":null},{"id":"W4415674791","doi":"10.1101/gad.353024.125","title":"ERRγ impedes neuroendocrine prostate cancer development","year":2025,"lang":"en","type":"article","venue":"Genes & Development","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Terry Fox Research Institute; Science and Technology Development Fund; National Natural Science Foundation of China; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Prostate cancer; Prostate; Neuroendocrine differentiation; Downregulation and upregulation; EZH2; Cell growth; Cancer; Neuroendocrine tumors","score_opus":0.023592365175867346,"score_gpt":0.33493288660383264,"score_spread":0.3113405214279653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415674791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675671,0.020153522,0.00013315736,0.005152689,0.0006208053,0.0013463742,0.000006758816,0.0001838273,0.004835767],"genre_scores_gemma":[0.8058574,0.014250923,0.015699683,0.0023100881,0.00017625045,0.0023628375,0.00026190683,0.00008128633,0.15899962],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99796736,0.000027200576,0.00043212707,0.00048773218,0.00042095804,0.00066459394],"domain_scores_gemma":[0.9992643,0.000025939678,0.00005619783,0.0002621332,0.00019060809,0.00020084876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013281201,0.00028516015,0.00033719483,0.00027480905,0.00029131916,0.000045013465,0.00014790382,0.000036727488,0.0002737601],"category_scores_gemma":[0.000016864387,0.00021801058,0.000058008944,0.00044752637,0.00006721935,0.000060135884,0.0002188949,0.00016293209,0.00011760686],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005092398,0.00021491956,0.1214122,0.0003891802,0.00049935834,0.000273826,0.0010072885,0.000009523101,0.007637835,0.0000725263,0.0049097394,0.86306435],"study_design_scores_gemma":[0.0018395986,0.00004476015,0.11870981,0.00023180252,0.000041572974,0.00001933088,0.00012751365,0.000009900914,0.27209094,0.00003662933,0.606659,0.00018912514],"about_ca_topic_score_codex":0.000046385005,"about_ca_topic_score_gemma":0.000071715,"teacher_disagreement_score":0.8628752,"about_ca_system_score_codex":0.0005952025,"about_ca_system_score_gemma":0.0030240696,"threshold_uncertainty_score":0.8890214},"labels":[],"label_agreement":null},{"id":"W4415742993","doi":"10.1016/j.pan.2025.07.103","title":"Estrogen Receptor α-Mediated Sex-Specific Immune Modulation and Tumor Regulation in Pancreatic Cancer","year":2025,"lang":"en","type":"article","venue":"Pancreatology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Pancreatic cancer; Estrogen receptor; Immune system; Estrogen; Immune modulation; CA19-9","score_opus":0.01666549998786778,"score_gpt":0.30188090178241483,"score_spread":0.2852154017945471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415742993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794723,0.01640086,0.000075399585,0.002024384,0.00012245151,0.0006459771,0.000017968492,0.000052362087,0.0011883327],"genre_scores_gemma":[0.9931485,0.0036355196,0.00033223024,0.00009778992,0.000046904406,0.00024549683,0.00024116231,0.0000152035345,0.0022371737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885404,0.00009900771,0.00029329967,0.00033426224,0.00011520943,0.00030416218],"domain_scores_gemma":[0.9994436,0.00014178864,0.000056507255,0.00021719385,0.00007059005,0.000070331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001533992,0.00014613416,0.00043614503,0.00029762497,0.00006326181,0.000011914091,0.00004166238,0.000111065885,0.00021930957],"category_scores_gemma":[0.000058842466,0.00012367211,0.00003745088,0.0004274908,0.00012665911,0.00006132578,0.0000356966,0.00016193127,0.000028369683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009009004,0.000086516695,0.91174626,0.00012048415,0.00010462072,0.000033826876,0.00023429333,0.000009821504,0.071765184,0.0011321391,0.000371313,0.013494605],"study_design_scores_gemma":[0.005003153,0.00013990288,0.96499956,0.0002729071,0.00007826269,0.000033497632,0.00013969811,0.003259769,0.016219396,0.00055105233,0.009159641,0.00014317932],"about_ca_topic_score_codex":0.000628858,"about_ca_topic_score_gemma":0.000047106387,"teacher_disagreement_score":0.05554579,"about_ca_system_score_codex":0.00023447798,"about_ca_system_score_gemma":0.00016065715,"threshold_uncertainty_score":0.50432026},"labels":[],"label_agreement":null},{"id":"W4415751640","doi":"10.1016/j.fpurol.2025.07.085","title":"Darolutamide associé à une suppression androgénique (ADT) chez des patients atteints d’un cancer de la prostate métastatique hormono-sensible (CPHSm) selon le volume tumoral : analyse en sous-groupes de l’essai de phase 3 ARANOTE","year":2025,"lang":"fr","type":"article","venue":"Progrès en Urologie - FMC","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada); Université de Montréal","funders":"","keywords":"Prostate cancer; Prostate disease; Prostate; Medical screening; Respiratory disease","score_opus":0.013346763751564534,"score_gpt":0.3553232267388368,"score_spread":0.3419764629872723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415751640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9630348,0.02162191,0.0028477686,0.007881805,0.00035184133,0.0025410242,0.0005598401,0.00032940222,0.00083158084],"genre_scores_gemma":[0.9695862,0.014864011,0.0057462845,0.0005877274,0.00028556463,0.0011514677,0.00049727794,0.00013460995,0.007146878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9912963,0.0034011307,0.0008638631,0.0011515069,0.00059155375,0.0026956694],"domain_scores_gemma":[0.9969917,0.000816421,0.00035837403,0.0006318792,0.0005133219,0.00068829727],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033338312,0.00082678074,0.001097837,0.00043107753,0.00065414706,0.00026943386,0.000558032,0.0008725969,0.00018084745],"category_scores_gemma":[0.0011432787,0.0007399348,0.0003359412,0.0011604431,0.0012449021,0.0005092607,0.0004793301,0.0017074075,0.000034518598],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00460975,0.0038449336,0.70367926,0.0011177122,0.0013014959,0.0013048609,0.00856492,0.0007087237,0.033148926,0.000049920036,0.0028645864,0.23880489],"study_design_scores_gemma":[0.034751914,0.005095625,0.59185123,0.0018797742,0.0023416043,0.00012411003,0.0015600432,0.027490634,0.3095316,0.009108925,0.0149023915,0.0013621207],"about_ca_topic_score_codex":0.008939021,"about_ca_topic_score_gemma":0.00061310513,"teacher_disagreement_score":0.27638265,"about_ca_system_score_codex":0.0033685537,"about_ca_system_score_gemma":0.0036035366,"threshold_uncertainty_score":0.99950516},"labels":[],"label_agreement":null},{"id":"W4415763898","doi":"10.1038/s41391-025-01047-7","title":"DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis","year":2025,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Calgary","funders":"Bayer HealthCare; Bayer","keywords":"Interim analysis; Prostate cancer; Observational study; Prostate; Benign prostatic hyperplasia (BPH); Interim; Clinical trial; Exploratory analysis","score_opus":0.031569331184562975,"score_gpt":0.3435905932434047,"score_spread":0.31202126205884173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415763898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846583,0.0052329404,0.000017551174,0.0015423762,0.0001122024,0.0059497,0.0021756985,0.00007405757,0.00023718036],"genre_scores_gemma":[0.99087155,0.001102767,0.00019725123,0.00037177416,0.000029213443,0.0033905415,0.00090819015,0.000043320244,0.0030853923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99653524,0.00016841099,0.0008049192,0.0009607965,0.00084085687,0.00068979023],"domain_scores_gemma":[0.99821687,0.00019645048,0.00023675057,0.00044895092,0.0005541573,0.00034680532],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025367935,0.0005038157,0.0009373544,0.00075018517,0.0002620241,0.00023277779,0.00015782722,0.000057920504,0.00015532854],"category_scores_gemma":[0.00008685944,0.00036699613,0.00012484739,0.002111292,0.00030212046,0.00042773344,0.00011319508,0.0002962065,0.0000027522067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016499663,0.0019959437,0.96452695,0.0008564174,0.002433526,0.000089120964,0.0028691082,0.00044543407,0.00007475018,0.000051990424,0.0003469092,0.009810167],"study_design_scores_gemma":[0.013692794,0.0015250153,0.97820425,0.00057627505,0.0028522608,4.579037e-7,0.0015650985,0.00048185332,0.00010343899,0.00030388878,0.00032597908,0.0003686831],"about_ca_topic_score_codex":0.0013429534,"about_ca_topic_score_gemma":0.0020053973,"teacher_disagreement_score":0.013677286,"about_ca_system_score_codex":0.0004987486,"about_ca_system_score_gemma":0.0014475721,"threshold_uncertainty_score":0.9998782},"labels":[],"label_agreement":null},{"id":"W4415765070","doi":"10.1177/10732748251390022","title":"Strategies for Improving Access to Effective Prostate Cancer Medications (Abiraterone and Enzalutamide) in Low- and Middle-Income Countries (LMICs): A Survey Among Nigerian Health Professionals","year":2025,"lang":"en","type":"article","venue":"Cancer Control","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Toronto","funders":"","keywords":"Enzalutamide; Prostate cancer; Abiraterone; Health professionals; Quality of life (healthcare); MEDLINE; Health care","score_opus":0.021080669687238485,"score_gpt":0.39141379838905965,"score_spread":0.37033312870182117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415765070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94400716,0.019675199,0.0005908648,0.025825584,0.00026946742,0.008718332,0.0008481498,0.000037627186,0.000027623351],"genre_scores_gemma":[0.98429203,0.001395718,0.000030586703,0.0029935145,0.000075581054,0.01043908,0.00004535868,0.000024413333,0.0007037235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982313,0.00018792457,0.00037877497,0.00049051316,0.0001952973,0.0005161941],"domain_scores_gemma":[0.9985061,0.0005999482,0.00013351647,0.0001801538,0.00033141425,0.0002488541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008421316,0.00022368474,0.00059778884,0.000280217,0.00023784951,0.00015664278,0.000108161985,0.000092731054,0.000015367308],"category_scores_gemma":[0.00013999532,0.0001710764,0.000029761888,0.0003486697,0.00021911348,0.00031653853,0.000076769975,0.00020154986,4.2507943e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036969492,0.00008499518,0.9773031,0.005123291,0.00029126677,0.0000073590386,0.002707722,0.000039100534,0.00048812156,0.00015122251,0.0003765723,0.009730314],"study_design_scores_gemma":[0.009979864,0.0003391541,0.9818541,0.0049485597,0.000073649935,8.0851083e-7,0.0006727028,0.00086839835,0.00067101954,0.0002153747,0.00020284348,0.00017354103],"about_ca_topic_score_codex":0.008067472,"about_ca_topic_score_gemma":0.026262557,"teacher_disagreement_score":0.040284872,"about_ca_system_score_codex":0.00061062275,"about_ca_system_score_gemma":0.0025353748,"threshold_uncertainty_score":0.9985379},"labels":[],"label_agreement":null},{"id":"W4415870862","doi":"10.1016/j.eururo.2025.09.007","title":"Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis","year":2025,"lang":"en","type":"review","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Docetaxel; Prostate cancer; Disease; Androgen receptor; Systemic therapy; Androgen deprivation therapy; Androgen; Localized disease","score_opus":0.1481872449476207,"score_gpt":0.40238860329595355,"score_spread":0.25420135834833285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415870862","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026492993,0.9961944,0.00006402854,0.00013939149,0.00003899391,0.0013625581,0.0011656572,0.000012579451,0.0007574539],"genre_scores_gemma":[0.0131530315,0.9840325,0.00015355197,0.000051851493,0.000028268512,0.00013985268,0.00036179216,0.00004275945,0.0020363592],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99412316,0.0034712183,0.0010216191,0.0006563453,0.00028614615,0.00044151547],"domain_scores_gemma":[0.9973875,0.0011676396,0.0006606223,0.0004030302,0.0001955502,0.00018563995],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013209347,0.0004688158,0.0064420956,0.00065686053,0.00004460907,0.000011365859,0.00015364321,0.000054277567,0.00010565941],"category_scores_gemma":[0.0001745485,0.00032314676,0.0011433387,0.0014309799,0.00035129333,0.000045310713,0.00026208707,0.00043325598,0.000004855943],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002151849,0.00085802085,0.001594802,0.029964985,0.8847403,0.0012306853,0.0028215642,0.0006547822,0.000010676596,0.000053354353,0.0044168727,0.0715021],"study_design_scores_gemma":[0.00094070134,0.0006494176,0.0019360103,0.0014258681,0.93515396,0.0000063383004,0.00014227412,0.00029354368,0.0000022644658,0.000008354246,0.05906465,0.00037664428],"about_ca_topic_score_codex":0.00016022871,"about_ca_topic_score_gemma":0.00006644074,"teacher_disagreement_score":0.071125455,"about_ca_system_score_codex":0.00006655435,"about_ca_system_score_gemma":0.0004493881,"threshold_uncertainty_score":0.99992204},"labels":[],"label_agreement":null},{"id":"W4415899361","doi":"10.1016/j.euo.2025.10.010","title":"Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Abiraterone; Prostate cancer; Placebo; Olaparib; Prostate-specific antigen; Biomarker; Population","score_opus":0.09922039059211404,"score_gpt":0.41549668792859473,"score_spread":0.31627629733648066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415899361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699649,0.013074377,0.00007862672,0.009167605,0.00047709217,0.005368272,0.00014146804,0.00009557176,0.0016320739],"genre_scores_gemma":[0.98589694,0.006759535,0.00046327608,0.000787962,0.0001101557,0.0011158842,0.00018129525,0.00008966176,0.0045952895],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99553657,0.0015746431,0.0007724518,0.001017654,0.00022537966,0.0008733179],"domain_scores_gemma":[0.9977816,0.0009840033,0.00025336104,0.00042500035,0.0003545229,0.00020155252],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014150895,0.00047247848,0.0010099101,0.0006478121,0.0003163723,0.00006330387,0.00020564697,0.00015575794,0.00009602248],"category_scores_gemma":[0.0002802233,0.00036360818,0.00010346895,0.0006138616,0.0007408286,0.00014567272,0.0001367269,0.00052173977,0.00004070887],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8570793,0.00097595126,0.0030966573,0.0002539322,0.001537118,0.0029090939,0.008130124,0.0012580865,0.10663017,0.000138153,0.0017732398,0.016218172],"study_design_scores_gemma":[0.33528942,0.088599436,0.3416659,0.0003895684,0.0010898686,0.00021233897,0.0040480522,0.002708804,0.026999466,0.00056321174,0.19700423,0.0014296909],"about_ca_topic_score_codex":0.0003392497,"about_ca_topic_score_gemma":0.001221555,"teacher_disagreement_score":0.52178985,"about_ca_system_score_codex":0.0010249057,"about_ca_system_score_gemma":0.0020232003,"threshold_uncertainty_score":0.99988157},"labels":[],"label_agreement":null},{"id":"W4415899403","doi":"10.1016/j.euo.2025.10.001","title":"Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Bayer HealthCare; Bayer Corporation; Bayer","keywords":"Docetaxel; Subgroup analysis; Placebo; Prostate cancer; Clinical trial; Prostate","score_opus":0.019614739825982806,"score_gpt":0.3182689564540624,"score_spread":0.29865421662807956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415899403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952733,0.001472522,0.000014546333,0.0009175776,0.000049425184,0.001765045,0.00007384447,0.000009929269,0.00042383806],"genre_scores_gemma":[0.9980318,0.0014944596,0.000041542957,0.00019950648,0.0000069638545,0.000020782663,0.00009506645,0.000013578299,0.00009629363],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99798584,0.00087129616,0.00046690373,0.00032157893,0.00013657569,0.00021778178],"domain_scores_gemma":[0.9990217,0.0003082566,0.00026874623,0.00021974373,0.00012812938,0.000053427026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050511165,0.00015308788,0.0007271638,0.00042370896,0.000060813916,0.000003857555,0.00006695894,0.000059130685,0.0000072832563],"category_scores_gemma":[0.000100252124,0.0000931115,0.00006130077,0.0008597785,0.00074903993,0.000032532997,0.0000752317,0.00023870652,2.9941728e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6592672,0.0029790762,0.27181777,0.0000644331,0.008996727,0.00037044074,0.006077908,0.0005421223,0.0043911804,0.00019722503,0.000054195705,0.04524172],"study_design_scores_gemma":[0.21331513,0.0060943514,0.77793175,0.000022406874,0.0015826583,0.0000038099677,0.000074247444,0.0004128539,0.00024918222,0.000019809344,0.00022846626,0.000065352884],"about_ca_topic_score_codex":0.00008897989,"about_ca_topic_score_gemma":0.0001077232,"teacher_disagreement_score":0.50611395,"about_ca_system_score_codex":0.000105225976,"about_ca_system_score_gemma":0.00024212565,"threshold_uncertainty_score":0.37969765},"labels":[],"label_agreement":null},{"id":"W4415939711","doi":"10.1016/j.annonc.2025.08.3070","title":"2455P Prevalence and severity of hot flashes and their association with prostate-specific antigen (PSA) response: results from the initial treatment phase of LIBERTAS, a phase 3 study in metastatic hormone-sensitive prostate cancer (mHSPC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Johnson and Johnson","keywords":"Androgen deprivation therapy; Prostate cancer; Prostate-specific antigen; Phases of clinical research; Androgen suppression; Antiandrogen; Hot flash","score_opus":0.11067709328636673,"score_gpt":0.44231026580445554,"score_spread":0.3316331725180888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984513,0.0066930605,0.0000015932618,0.0035748922,0.000027427193,0.0024663866,0.0026385242,0.000006814355,0.00007830343],"genre_scores_gemma":[0.98208016,0.01724836,0.00006537207,0.00007006308,0.000013557175,0.00015961062,0.0000810076,0.000010369751,0.0002714709],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979119,0.00073589786,0.0005271381,0.00034914515,0.00022294422,0.00025300033],"domain_scores_gemma":[0.9971411,0.0017502633,0.0004075361,0.00022559759,0.00041149443,0.00006396542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010279241,0.0001915675,0.00073643844,0.00014050503,0.000052217532,0.000009338363,0.00006276423,0.00006783063,0.0000039519564],"category_scores_gemma":[0.00027033951,0.00010950591,0.000043786473,0.00035477406,0.00035872715,0.000094614916,0.000052230913,0.00014599989,1.8104417e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6137997,0.010767279,0.1119161,0.00022724744,0.0027639754,0.00030400068,0.09275925,0.000008947533,0.0430494,0.000006065271,0.0007207185,0.123677336],"study_design_scores_gemma":[0.06833265,0.052793328,0.6997458,0.00052793935,0.0003909665,0.000005866771,0.008865843,0.000098386845,0.16719119,0.00011873269,0.0017779287,0.00015140699],"about_ca_topic_score_codex":0.0018376001,"about_ca_topic_score_gemma":0.000886185,"teacher_disagreement_score":0.58782965,"about_ca_system_score_codex":0.00016312323,"about_ca_system_score_gemma":0.00081957626,"threshold_uncertainty_score":0.44655216},"labels":[],"label_agreement":null},{"id":"W4415939886","doi":"10.1016/j.annonc.2025.08.3074","title":"2459P Darolutamide efficacy, quality of life, and safety outcomes by age subgroup: ARANOTE post hoc analyses","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Bayer HealthCare","keywords":"Prostate cancer; Placebo; Post-hoc analysis; Post hoc; Radiological weapon; Clinical trial","score_opus":0.16459982559444677,"score_gpt":0.5096159244262625,"score_spread":0.3450160988318157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657059,0.00744504,0.000025919937,0.020086415,0.000069356334,0.00035264454,0.00015173301,0.000017666265,0.0061453595],"genre_scores_gemma":[0.99109274,0.0040265624,0.0001257543,0.0022550162,0.000016607839,0.000009082186,0.00011449648,0.000008409177,0.0023513164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984646,0.0002148303,0.00058128964,0.00024902978,0.00021381288,0.00027644387],"domain_scores_gemma":[0.99834096,0.0007946135,0.0001896509,0.0002915899,0.00024589038,0.00013726538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006021583,0.00014325071,0.0009707841,0.00019894131,0.000050722472,0.000004698531,0.00011267924,0.00015550577,0.0000585986],"category_scores_gemma":[0.00058292603,0.00010349328,0.00017277048,0.00026301364,0.00045474674,0.00004459222,0.00009869801,0.00016176913,0.0000027155322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028646294,0.003688705,0.6634983,0.0012467499,0.004163124,0.00014363481,0.0009998243,0.000007798263,0.11969796,0.001505011,0.032872237,0.14353035],"study_design_scores_gemma":[0.008417928,0.0029476138,0.94828767,0.00007717139,0.00014696369,0.0000023976295,0.0002470757,0.0000075034186,0.01626265,0.00030390365,0.02318741,0.000111728456],"about_ca_topic_score_codex":0.00077362027,"about_ca_topic_score_gemma":0.00017491958,"teacher_disagreement_score":0.28478935,"about_ca_system_score_codex":0.00004160002,"about_ca_system_score_gemma":0.0004076121,"threshold_uncertainty_score":0.42203334},"labels":[],"label_agreement":null},{"id":"W4415940076","doi":"10.1016/j.annonc.2025.08.3151","title":"2537eTiP PSMACare trial-in-progress: a phase II trial of [177Lu]Lu-PSMA-617 with or without ARPI in patients with PSMA-positive non-metastatic castration-resistant prostate cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal General Hospital","funders":"Novartis","keywords":"Prostate cancer; Glutamate carboxypeptidase II; Androgen receptor; Androgen deprivation therapy; Radioligand; Androgen; Phases of clinical research; Prostate-specific antigen","score_opus":0.0617472521708245,"score_gpt":0.45189649003081417,"score_spread":0.3901492378599897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98908323,0.0005687444,0.0000054338702,0.0026087891,0.00013769181,0.0065062866,0.00028158806,0.000011990503,0.0007962442],"genre_scores_gemma":[0.99681735,0.00034256288,0.0004293339,0.00018952898,0.000046425204,0.001165395,0.00016885824,0.000028111615,0.000812416],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973752,0.00023941035,0.00085190934,0.00048049993,0.00050814234,0.00054487045],"domain_scores_gemma":[0.99803627,0.00021506846,0.00047167786,0.0003189951,0.0008200236,0.00013797487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004772219,0.00030153187,0.0012722217,0.0005717586,0.00007352709,0.000012112183,0.00014398589,0.00013063951,0.0000611903],"category_scores_gemma":[0.00010807091,0.00018538593,0.00008961755,0.0009694503,0.0004997936,0.00013701069,0.000057601592,0.00031540665,9.211392e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9056148,0.009724769,0.044366598,0.00042451706,0.0006212449,0.00032369193,0.0026578067,0.000019155088,0.00021621406,0.000021683945,0.00029984728,0.035709653],"study_design_scores_gemma":[0.7938722,0.16696699,0.028342664,0.0018988058,0.0003449654,0.0000035768776,0.0015562988,0.00006427789,0.006249581,0.000057918583,0.00041735437,0.00022541493],"about_ca_topic_score_codex":0.0010090274,"about_ca_topic_score_gemma":0.003946032,"teacher_disagreement_score":0.15724222,"about_ca_system_score_codex":0.00024262573,"about_ca_system_score_gemma":0.0036064486,"threshold_uncertainty_score":0.75598186},"labels":[],"label_agreement":null},{"id":"W4415940213","doi":"10.1016/j.annonc.2025.08.3066","title":"2451P Real-world (RW) genomic landscape, PARP inhibitor (PARPi) treatment (tx) patterns and adverse events (AE) in advanced prostate cancer (PCa): the national CanaDNA Study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University of British Columbia Hospital; University of Alberta; University of Calgary","funders":"","keywords":"PARP inhibitor; Adverse effect; Prostate cancer; Discovery and development of mTOR inhibitors; MEDLINE; Cancer","score_opus":0.0677070143827827,"score_gpt":0.43207682311160883,"score_spread":0.36436980872882613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98127514,0.0009769902,1.959572e-7,0.011821396,0.0001629018,0.0017942409,0.00018095615,0.000012072344,0.0037761347],"genre_scores_gemma":[0.9863206,0.0063953428,0.000013002744,0.0007565718,0.00007986982,0.0006343379,0.00006386981,0.000013410916,0.0057229893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998527,0.00015374989,0.0003787742,0.0003330049,0.00024373495,0.00036373184],"domain_scores_gemma":[0.9991872,0.00020551993,0.00012480344,0.00016963937,0.00021192667,0.000100930905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030248318,0.00017999383,0.00044304912,0.00029011522,0.00008731822,0.0000036427018,0.000093367424,0.00006387011,0.000089047295],"category_scores_gemma":[0.000040078943,0.000116001305,0.000060739992,0.00030377356,0.00008890971,0.000056255074,0.000076704266,0.00015765273,0.0000032158032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027212037,0.001332922,0.95031226,0.000061632476,0.00045052898,0.00009360609,0.0017555803,0.00006671629,0.0003038742,0.000033443233,0.0028289228,0.040039334],"study_design_scores_gemma":[0.010250845,0.002634216,0.96853536,0.000155631,0.00008618391,0.0000031295237,0.0015094995,0.000049905993,0.001264047,0.00012827381,0.015283759,0.00009914267],"about_ca_topic_score_codex":0.012058041,"about_ca_topic_score_gemma":0.10572687,"teacher_disagreement_score":0.093668826,"about_ca_system_score_codex":0.0005370983,"about_ca_system_score_gemma":0.0013213343,"threshold_uncertainty_score":0.9945207},"labels":[],"label_agreement":null},{"id":"W4415940303","doi":"10.1016/j.annonc.2025.08.3087","title":"2472P Initial management of newly diagnosed non-metastatic prostate cancer according to age-group: A RADICAL-PC substudy","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Population Health Research Institute; Université Laval; Centre Hospitalier de l’Université de Montréal; University of British Columbia; McMaster University Medical Centre; McMaster Children's Hospital; McMaster University","funders":"Canadian Cancer Society; Movember Foundation; Hamilton Health Sciences","keywords":"Prostate cancer; Management of prostate cancer; MEDLINE; Prostatectomy; Radiation therapy","score_opus":0.10241004265832686,"score_gpt":0.4712479070483219,"score_spread":0.36883786438999505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97472805,0.001551172,0.00009958004,0.008818632,0.00028901544,0.0020717066,0.000044817752,0.000021964697,0.012375048],"genre_scores_gemma":[0.9912349,0.003074179,0.0010507234,0.0016402097,0.00004763486,0.0005756364,0.000042571002,0.000018240049,0.0023158942],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983094,0.00010078825,0.0005084394,0.00032468198,0.0003004423,0.00045629594],"domain_scores_gemma":[0.9989743,0.0002287339,0.00013985006,0.0002807109,0.0002049997,0.00017139333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044582994,0.00017269964,0.00071878993,0.00037889116,0.00005619364,0.000008432597,0.0001797315,0.0000708213,0.00012105027],"category_scores_gemma":[0.00006387653,0.00013867629,0.00013111238,0.0006942649,0.00021173622,0.000056415356,0.00014448217,0.0001741677,0.000015535494],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0140116615,0.005852299,0.07348248,0.0037695258,0.004970927,0.0061472696,0.0044394066,0.000102769685,0.010939367,0.0012293019,0.044764925,0.8302901],"study_design_scores_gemma":[0.08621038,0.041113194,0.5377338,0.007438177,0.0029529692,0.000038178663,0.02256945,0.00030208283,0.11411773,0.0033686997,0.18302953,0.0011258407],"about_ca_topic_score_codex":0.00071351713,"about_ca_topic_score_gemma":0.000119437536,"teacher_disagreement_score":0.8291642,"about_ca_system_score_codex":0.00012638974,"about_ca_system_score_gemma":0.00035641633,"threshold_uncertainty_score":0.5655055},"labels":[],"label_agreement":null},{"id":"W4415940713","doi":"10.1016/j.annonc.2025.08.3140","title":"2526eP Population-based analysis of lifetime use of prostate cancer therapies","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Prostate cancer; Standard of care; Prostate; Cancer; Overall survival; MEDLINE","score_opus":0.10223193071508699,"score_gpt":0.4567891000637131,"score_spread":0.35455716934862613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882852,0.0028596472,0.0000131423285,0.007779464,0.000043023643,0.00030171068,0.00011814234,0.000007677788,0.0005920204],"genre_scores_gemma":[0.99563956,0.0016649102,0.00022986432,0.00051479205,0.000010099911,0.000034534954,0.00010375684,0.0000054785814,0.0017969726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912137,0.00008004598,0.0003566109,0.0001336464,0.0001599091,0.00014841264],"domain_scores_gemma":[0.9987568,0.00028332483,0.00019975014,0.00020407794,0.00051635795,0.00003968602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018402723,0.000077383826,0.0006029939,0.0005836048,0.00001859823,0.000001975901,0.000057056262,0.00008116731,0.00022483875],"category_scores_gemma":[0.00009154488,0.000056928402,0.00018438124,0.00092207256,0.00014567505,0.00003645138,0.000019650017,0.000064008724,5.357388e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019244063,0.00053122686,0.9513186,0.00020884095,0.0037824633,0.000005596546,0.00036545604,0.00083526626,0.0035844129,0.00019281356,0.0015229239,0.035727955],"study_design_scores_gemma":[0.0017444565,0.001252674,0.952115,0.00013514013,0.0010555066,1.3061384e-7,0.000071395676,0.0010035733,0.03462544,0.00014510183,0.0077992883,0.000052316544],"about_ca_topic_score_codex":0.0028394891,"about_ca_topic_score_gemma":0.00033256641,"teacher_disagreement_score":0.03567564,"about_ca_system_score_codex":0.000041570936,"about_ca_system_score_gemma":0.00054292474,"threshold_uncertainty_score":0.4292477},"labels":[],"label_agreement":null},{"id":"W4415940781","doi":"10.1016/j.annonc.2025.08.3043","title":"2428P Time to response with talazoparib (TALA) + enzalutamide (ENZA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TALAPRO-2","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Enzalutamide; Prostate cancer; Placebo; Post-hoc analysis; Overall survival; Prostate-specific antigen","score_opus":0.040792322447850804,"score_gpt":0.38909276318279906,"score_spread":0.34830044073494826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841904,0.0003949454,0.0000027143356,0.011275909,0.000029288563,0.0019155319,0.000091076734,0.000015843707,0.0020842834],"genre_scores_gemma":[0.9913765,0.000089525245,0.0003941303,0.0009611838,0.000009233739,0.00053603854,0.000060036356,0.000023301396,0.006550008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796784,0.0002682974,0.00047009502,0.00040998863,0.00035842785,0.0005253539],"domain_scores_gemma":[0.99879396,0.0002387917,0.00013788111,0.00027173862,0.00040564057,0.00015199653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006424929,0.00021839327,0.0006493203,0.00065711624,0.00004158751,0.000013109845,0.000112898735,0.000081294456,0.00012950142],"category_scores_gemma":[0.0001605253,0.00015212811,0.000041377425,0.0010707343,0.0001965655,0.000116785806,0.000053815773,0.00024236547,0.00002307109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41761655,0.005625902,0.4860873,0.0006661139,0.0008402633,0.0018799846,0.0039355024,0.0011565365,0.0242692,0.00013152878,0.0063621867,0.05142896],"study_design_scores_gemma":[0.021532774,0.02337142,0.91964954,0.0012470027,0.00011894114,0.000009879894,0.00045541808,0.000088505905,0.020945925,0.000108313565,0.012193469,0.00027880268],"about_ca_topic_score_codex":0.00068322226,"about_ca_topic_score_gemma":0.002802709,"teacher_disagreement_score":0.43356228,"about_ca_system_score_codex":0.0004155546,"about_ca_system_score_gemma":0.0020620888,"threshold_uncertainty_score":0.62036043},"labels":[],"label_agreement":null},{"id":"W4415941040","doi":"10.1016/j.annonc.2025.08.3149","title":"2535eP Incidence of incidental primary lung malignancies vs. solitary prostate cancer lung metastasis detected on PSMA-PET CT scans for prostate cancer staging and surveillance","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Prostate cancer; Incidence (geometry); Lung; Prostate; Lung cancer; Metastasis; Stage (stratigraphy)","score_opus":0.03588269843316088,"score_gpt":0.3979777260730109,"score_spread":0.36209502763985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97027344,0.019276634,0.000023001643,0.006171071,0.0002453491,0.002208918,0.0013108617,0.000039710936,0.00045101298],"genre_scores_gemma":[0.97619635,0.019886194,0.00033556423,0.0011462106,0.00005027271,0.000866604,0.00012272914,0.000035112153,0.0013609459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755055,0.0001768503,0.00066652166,0.0005465801,0.00037503467,0.0006844667],"domain_scores_gemma":[0.9978594,0.00048418334,0.00035841897,0.0003076757,0.00083439716,0.00015593515],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00078268547,0.0003062088,0.0010026322,0.0004132857,0.00014837799,0.000014971154,0.00017901209,0.000059597944,0.000039282135],"category_scores_gemma":[0.00019795095,0.00025150247,0.00014187314,0.0005345578,0.0005133417,0.0001695418,0.00017897334,0.0002526303,4.7015797e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012264299,0.00049853086,0.8841317,0.005156847,0.0015027502,0.000395264,0.0013086781,0.00019165422,0.019202018,0.000117154326,0.010364828,0.06486623],"study_design_scores_gemma":[0.011569167,0.0052421875,0.7980129,0.0027112241,0.000526538,0.000101672995,0.0008773793,0.001947637,0.1732265,0.00045033192,0.004770822,0.00056365196],"about_ca_topic_score_codex":0.002879202,"about_ca_topic_score_gemma":0.0014132616,"teacher_disagreement_score":0.15402448,"about_ca_system_score_codex":0.00045655813,"about_ca_system_score_gemma":0.0021072158,"threshold_uncertainty_score":0.99999374},"labels":[],"label_agreement":null},{"id":"W4415941465","doi":"10.1016/j.annonc.2025.08.3036","title":"2421P Sacituzumab Tirumotecan (sac-TMT) + Pembrolizumab (Pembro) in metastatic castration-resistant prostate cancer (mCRPC): Results from phase II MK-2870-002/SKB264-II-06 Study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Prostate cancer; Cohort; Cancer; Phases of clinical research","score_opus":0.10738357577069794,"score_gpt":0.46260576440841994,"score_spread":0.355222188637722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720447,0.0033153263,0.0000074278328,0.014746319,0.00028608408,0.0027800319,0.0014439848,0.000059760943,0.0053163376],"genre_scores_gemma":[0.98647654,0.0013888748,0.0002065543,0.00063165603,0.00010073464,0.0004615165,0.0005427178,0.000039381746,0.0101520065],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995845,0.00044901256,0.0013629502,0.0008796321,0.0006025321,0.00086087134],"domain_scores_gemma":[0.99758357,0.00042836327,0.00042399214,0.0007127934,0.0005876991,0.00026360253],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00090636814,0.00042924384,0.0013116735,0.00070078956,0.00029910298,0.000028217715,0.0003103376,0.00019667369,0.00027842508],"category_scores_gemma":[0.00036804823,0.00035446518,0.00019153894,0.001008666,0.00033299602,0.00019175166,0.00023901246,0.00057867164,0.00001740663],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24565066,0.065873325,0.015308318,0.0011502987,0.008056651,0.008123469,0.044600513,0.00053029973,0.09944769,0.0009677467,0.09854324,0.41174778],"study_design_scores_gemma":[0.40129334,0.13592762,0.11537435,0.0026311926,0.002617266,0.00006476887,0.016255373,0.0017720113,0.097312815,0.0057073804,0.21924685,0.0017970263],"about_ca_topic_score_codex":0.0110499635,"about_ca_topic_score_gemma":0.012460813,"teacher_disagreement_score":0.40995076,"about_ca_system_score_codex":0.0006417985,"about_ca_system_score_gemma":0.0034031551,"threshold_uncertainty_score":0.99989074},"labels":[],"label_agreement":null},{"id":"W4415942560","doi":"10.1016/j.annonc.2025.08.3104","title":"2489P Association of race and survival in apalutamide treated patients from the TITAN and SPARTAN phase III trials","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Centre Hospitalier de l’Université de Montréal; Ottawa Hospital","funders":"","keywords":"Race (biology); Spartan; Clinical trial; Titan (rocket family); Phases of clinical research","score_opus":0.11229912228663791,"score_gpt":0.46215984439495983,"score_spread":0.3498607221083219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98822755,0.0014372573,0.0000013759487,0.007530429,0.00006997118,0.00044593945,0.000086007974,0.0000035798873,0.0021979124],"genre_scores_gemma":[0.9961248,0.0026193315,0.0000131257175,0.00019027227,0.000023461354,0.000014129328,0.000066739354,0.0000032955622,0.0009448362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989947,0.00029611395,0.00034454052,0.00011941681,0.00011902214,0.00012620405],"domain_scores_gemma":[0.99815106,0.0013779138,0.00019000136,0.0000881973,0.00015877478,0.000034074903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010763375,0.000063392086,0.0005532579,0.00007974509,0.000023293887,0.0000035011715,0.00003417727,0.00009890015,0.000025672078],"category_scores_gemma":[0.0008395717,0.000039698454,0.00003587882,0.00014845893,0.00008151696,0.00002851545,0.00002961681,0.000083295185,4.842853e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049572494,0.0007761602,0.92563945,0.000030774132,0.00039226972,0.000007843327,0.00071432843,2.998937e-7,0.0030307686,0.00012230013,0.0040589334,0.060269635],"study_design_scores_gemma":[0.039863076,0.0028425388,0.9302678,0.00014183445,0.00021336699,2.589207e-7,0.00041899367,0.0000497297,0.017217163,0.001204806,0.0077233906,0.00005704317],"about_ca_topic_score_codex":0.00078105094,"about_ca_topic_score_gemma":0.00049298874,"teacher_disagreement_score":0.06021259,"about_ca_system_score_codex":0.00006185198,"about_ca_system_score_gemma":0.00011593645,"threshold_uncertainty_score":0.16188559},"labels":[],"label_agreement":null},{"id":"W4415942596","doi":"10.1016/j.annonc.2025.08.3005","title":"2389P Final analysis of patients treated with [177Lu]Lu-PSMA-617 in early access program in metastatic castration-resistant prostate cancer (mCRPC) in France","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Prostate cancer; Expanded access; Overall survival; MEDLINE; Prostate","score_opus":0.09703122849621203,"score_gpt":0.4644545704678482,"score_spread":0.3674233419716362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99575865,0.00095343374,0.0000014286685,0.0010530999,0.000021713666,0.0014679135,0.00011226867,0.000008555852,0.0006229395],"genre_scores_gemma":[0.9978535,0.000679952,0.00013400285,0.0001081545,0.000004392884,0.00060240366,0.00013783007,0.0000095842315,0.0004701823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819124,0.00016553246,0.00065206457,0.00032800445,0.00027008227,0.0003930808],"domain_scores_gemma":[0.99897057,0.0001301061,0.00023236327,0.00020370573,0.00040037674,0.000062898616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029812235,0.00016619504,0.0008976747,0.0013658986,0.000018713623,0.000011439771,0.0001415758,0.00008961441,0.000041068964],"category_scores_gemma":[0.00006264372,0.00012362306,0.00008230944,0.0035460184,0.00019941045,0.00014514882,0.00003871975,0.00022207847,4.832312e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005402334,0.0026158495,0.9461459,0.00025594427,0.0007612449,0.00020836346,0.0009141041,0.00046007853,0.00023135527,0.00001970913,0.000050797433,0.042934347],"study_design_scores_gemma":[0.007774823,0.0034775198,0.9844272,0.000333694,0.00030510005,2.806509e-7,0.00014169353,0.00035943487,0.0027900173,0.000048805745,0.00025177572,0.00008963871],"about_ca_topic_score_codex":0.009163844,"about_ca_topic_score_gemma":0.023057448,"teacher_disagreement_score":0.04284471,"about_ca_system_score_codex":0.0001736371,"about_ca_system_score_gemma":0.0008979267,"threshold_uncertainty_score":0.9974342},"labels":[],"label_agreement":null},{"id":"W4415942672","doi":"10.1016/j.annonc.2025.08.3008","title":"2392P PCPro as a prognostic plasma lipidomic biomarker in TheraP (ANZUP 1603): A randomised trial of [177Lu]Lu-PSMA-617 (LuPSMA) vs cabazitaxel in metastatic castration resistant prostate cancer (mCRPC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Cancer Australia; Prostate Cancer Foundation of Australia; Australian Nuclear Science and Technology Organisation; Prostate Cancer Foundation","keywords":"Cabazitaxel; Prostate cancer; Androgen receptor; Biomarker; Progression-free survival; Overall survival; Abiraterone; Androgen","score_opus":0.09464686932957608,"score_gpt":0.4401653355578007,"score_spread":0.3455184662282246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781652,0.0027846554,0.0000038324933,0.009402054,0.00033959106,0.0060036806,0.00007971844,0.000017563289,0.0032036905],"genre_scores_gemma":[0.9926389,0.0032396524,0.00018731962,0.00026216632,0.000045062196,0.0017379577,0.000066310364,0.0000269336,0.0017957147],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966599,0.00064370834,0.0012275472,0.00047877396,0.000389633,0.00060048985],"domain_scores_gemma":[0.99781007,0.0009283971,0.00043372952,0.0003269986,0.0003793501,0.00012145009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001640469,0.00028691159,0.0013285683,0.0008888681,0.000047535603,0.000014779178,0.00017107849,0.00020707096,0.000115419636],"category_scores_gemma":[0.00086859264,0.00022236943,0.00021489509,0.0009389168,0.00035683898,0.00012029212,0.00005841267,0.00033411203,0.000005501917],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87325513,0.0031334953,0.007301683,0.00095571595,0.00091574003,0.0004510826,0.0025617837,0.00004265615,0.048028603,0.0001983236,0.0017320843,0.06142371],"study_design_scores_gemma":[0.86504817,0.018657396,0.05114653,0.0020911787,0.0005324394,0.000028774553,0.0018211501,0.00093516364,0.051902305,0.0020263249,0.005410203,0.0004003593],"about_ca_topic_score_codex":0.002368943,"about_ca_topic_score_gemma":0.0036566583,"teacher_disagreement_score":0.061023355,"about_ca_system_score_codex":0.00029733407,"about_ca_system_score_gemma":0.0036520108,"threshold_uncertainty_score":0.9067963},"labels":[],"label_agreement":null},{"id":"W4415942707","doi":"10.1016/j.annonc.2025.08.3007","title":"2391P LuPARP: Phase I trial of [177Lu]Lu-PSMA-617 (LuPSMA) and olaparib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Olaparib; Radiosensitizer; Prostate cancer; Radiation therapy; PARP inhibitor; Clinical trial","score_opus":0.08780623247322457,"score_gpt":0.45483488395187227,"score_spread":0.3670286514786477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919136,0.0010809738,0.0000044890767,0.0031599253,0.00011787317,0.001661573,0.00011457039,0.000007831262,0.0019391231],"genre_scores_gemma":[0.99708486,0.001337481,0.00018432736,0.00017428113,0.000022627879,0.00019177247,0.00008372503,0.000011310677,0.00090959755],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99847746,0.00015654847,0.00051920215,0.00027349746,0.00026948063,0.0003038017],"domain_scores_gemma":[0.9989361,0.00013924761,0.00024098925,0.00019017373,0.00040076466,0.0000926975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042999632,0.00015020795,0.0006467917,0.0003039745,0.000038933966,0.00000721467,0.00006399464,0.000083049155,0.0000342807],"category_scores_gemma":[0.00010960228,0.000107800006,0.000050285595,0.00038867546,0.00027098542,0.000092601964,0.00003590998,0.00016889298,7.142777e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67701,0.009791161,0.06538465,0.0013502492,0.0011108636,0.00022484502,0.0026843802,0.000026268834,0.006825646,0.0005704763,0.003951038,0.23107043],"study_design_scores_gemma":[0.70850945,0.09768028,0.113817096,0.0013954679,0.00079208816,0.000008751346,0.0016011392,0.00017659998,0.06154045,0.0012500362,0.012853221,0.00037540315],"about_ca_topic_score_codex":0.00068632804,"about_ca_topic_score_gemma":0.00096839503,"teacher_disagreement_score":0.23069502,"about_ca_system_score_codex":0.0001104661,"about_ca_system_score_gemma":0.0011037119,"threshold_uncertainty_score":0.43959567},"labels":[],"label_agreement":null},{"id":"W4415942731","doi":"10.1016/j.annonc.2025.08.3006","title":"2390P Associations between quantitative baseline 68Ga-PSMA-11 PET parameters and 177Lu-PSMA-617 efficacy in the PSMAfore study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Novartis","keywords":"Baseline (sea); Androgen receptor; Androgen; Phases of clinical research; Clinical trial; Disease","score_opus":0.2127818758607951,"score_gpt":0.5083710103296752,"score_spread":0.29558913446888013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9646811,0.00063418923,0.000013591572,0.031093543,0.00006360626,0.0011855313,0.0000959685,0.000013623577,0.0022188695],"genre_scores_gemma":[0.99751943,0.00037177326,0.00029236192,0.0009789246,0.000035407116,0.00007820882,0.000118839554,0.000008549667,0.00059648097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982158,0.0005792941,0.00040209809,0.00025990387,0.00023230587,0.0003106285],"domain_scores_gemma":[0.9968029,0.0025344414,0.00013106238,0.00023712903,0.0002290289,0.000065429624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016894595,0.00013546059,0.00055535045,0.00027388035,0.00010414896,0.0000132953655,0.0001479918,0.00006731554,0.000018435747],"category_scores_gemma":[0.0009321178,0.000089180416,0.000080181235,0.0005294857,0.00021510989,0.000054324428,0.00007082203,0.00028235585,0.000006332729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077776733,0.0039882003,0.9442677,0.0000701704,0.0008496248,0.00032435646,0.007594603,0.000012891899,0.0000619762,0.0010994095,0.013515812,0.027437486],"study_design_scores_gemma":[0.0062051928,0.0054135136,0.97315496,0.00007198779,0.00023418579,0.000005562879,0.0069496543,0.0000527658,0.00038579022,0.0007507024,0.006683736,0.00009194036],"about_ca_topic_score_codex":0.00062280294,"about_ca_topic_score_gemma":0.00082180573,"teacher_disagreement_score":0.032838378,"about_ca_system_score_codex":0.00007224855,"about_ca_system_score_gemma":0.00034919335,"threshold_uncertainty_score":0.3636672},"labels":[],"label_agreement":null},{"id":"W4415963750","doi":"10.51731/cjht.2025.1283","title":"Darolutamide (Nubeqa)","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Prostate cancer; Androgen deprivation therapy; Abiraterone acetate; Abiraterone; Placebo","score_opus":0.032991687298584586,"score_gpt":0.357982561488245,"score_spread":0.3249908741896604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415963750","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033526633,0.7035656,0.00020673749,0.2560055,0.0024283226,0.0006492794,0.000050777166,0.00006866153,0.003498498],"genre_scores_gemma":[0.9629435,0.03131777,0.00022717757,0.001267617,0.00003609764,0.000010055458,0.0000042469533,0.000023070374,0.0041704914],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99635035,0.00015178965,0.00135436,0.00029365145,0.00035625868,0.0014935982],"domain_scores_gemma":[0.99769235,0.0001499646,0.0006129743,0.00058319984,0.0006229027,0.00033861172],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015855586,0.00031260564,0.001076719,0.0031206813,0.0007153296,0.0000994899,0.0007589969,0.00044658882,0.00014401472],"category_scores_gemma":[0.0014353588,0.00025250972,0.00023957767,0.0015771686,0.0011222516,0.00016640121,0.00006963653,0.0016960307,0.00003463945],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001465753,0.000059833976,0.017938891,0.0009364994,0.0004768112,0.0012120534,0.00035192366,0.0000062884333,0.000051597053,0.0021628407,0.04576395,0.9308927],"study_design_scores_gemma":[0.0049729166,0.0028425262,0.03499157,0.008088119,0.00023654968,0.00039964556,0.017599087,0.000040215677,0.0037266563,0.013283455,0.91348755,0.00033170867],"about_ca_topic_score_codex":0.008234777,"about_ca_topic_score_gemma":0.0047931084,"teacher_disagreement_score":0.930561,"about_ca_system_score_codex":0.0036522727,"about_ca_system_score_gemma":0.049087558,"threshold_uncertainty_score":0.9999927},"labels":[],"label_agreement":null},{"id":"W4415966366","doi":"10.2967/jnumed.125.270889","title":"Rechallenge and Extended [ <sup>177</sup> Lu]Lu-PSMA Therapy in Metastatic Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; University of Toronto; Health Sciences North; University Health Network","funders":"","keywords":"Prostate cancer; Adverse effect; Clinical trial; Disease; Prostate-specific antigen; Anemia; Overall survival; Cancer","score_opus":0.04888432368160622,"score_gpt":0.3743388772120323,"score_spread":0.32545455353042607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415966366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87481576,0.04944185,0.0000041090652,0.072469056,0.00018203835,0.0005614501,0.000004515404,0.000016881388,0.00250432],"genre_scores_gemma":[0.879177,0.115720145,0.000385557,0.0022693742,0.0002744854,0.000014130162,0.0000032923547,0.000037182795,0.002118839],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982376,0.00012208622,0.0005993463,0.00021054092,0.00050261634,0.00032778239],"domain_scores_gemma":[0.99898237,0.00013691223,0.00019270323,0.00019125153,0.00027171968,0.00022502292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008571359,0.00019763639,0.0007124373,0.00058522524,0.00006429972,0.000015429878,0.00012172547,0.000071282455,0.00041384788],"category_scores_gemma":[0.00017479486,0.00011790774,0.00007969997,0.00044633038,0.00023878402,0.00013557986,0.000039195165,0.00061230396,0.0000035114729],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015766421,0.0014276025,0.019606834,0.0010344071,0.0019344637,0.004344099,0.021246213,0.0000439767,0.015451901,0.00052103325,0.045345765,0.8732773],"study_design_scores_gemma":[0.1722351,0.028639885,0.305897,0.021507967,0.0018469288,0.0022722427,0.070886984,0.00386855,0.0021789223,0.009091489,0.38061014,0.0009648048],"about_ca_topic_score_codex":0.00009816123,"about_ca_topic_score_gemma":0.000016604978,"teacher_disagreement_score":0.8723125,"about_ca_system_score_codex":0.00023069324,"about_ca_system_score_gemma":0.00032259178,"threshold_uncertainty_score":0.4808138},"labels":[],"label_agreement":null},{"id":"W4415983575","doi":"10.1007/s12149-025-02127-3","title":"Efficacy and safety of Lutetium-177 (177Lu)-PSMA-617 in metastatic Castration-Resistant prostate cancer patients with superscan pattern: A retrospective cohort study","year":2025,"lang":"en","type":"article","venue":"Annals of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Retrospective cohort study; Prostate cancer; Cohort study; MEDLINE; Cohort; Cancer","score_opus":0.028798628389943067,"score_gpt":0.3499445893633985,"score_spread":0.32114596097345544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415983575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898877,0.0008986441,9.2172036e-7,0.005747343,0.000048357062,0.0025856427,0.000080028236,0.00001319951,0.0007381662],"genre_scores_gemma":[0.998231,0.001082846,0.0000212878,0.00029001507,0.000020019626,0.00004962456,0.00004428398,0.000023948654,0.00023698168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980814,0.00009829456,0.0005353269,0.00037078455,0.00062978367,0.00028442792],"domain_scores_gemma":[0.99878675,0.00009133084,0.00016048423,0.00028180736,0.0005576273,0.00012201594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046630547,0.00020402446,0.0007961497,0.00032548475,0.000058852766,0.0000064345995,0.000084593084,0.00003751522,0.00015631657],"category_scores_gemma":[0.0001353345,0.00013120964,0.00003515102,0.0005714068,0.00039256306,0.000081189944,0.000048498994,0.00020543936,7.885878e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008359313,0.0014262147,0.9786546,0.0003652195,0.00083131704,0.000060975923,0.005717525,0.0000038901294,0.0010661843,0.000027190563,0.0008992979,0.00258827],"study_design_scores_gemma":[0.015613876,0.005521817,0.9741681,0.0014195241,0.0003053467,0.000001095292,0.0022749465,0.000022159678,0.00032252955,0.000019607329,0.00023504395,0.00009590721],"about_ca_topic_score_codex":0.0030891327,"about_ca_topic_score_gemma":0.00059146516,"teacher_disagreement_score":0.008343295,"about_ca_system_score_codex":0.000098071374,"about_ca_system_score_gemma":0.00018018774,"threshold_uncertainty_score":0.5350574},"labels":[],"label_agreement":null},{"id":"W4416018691","doi":"10.14740/wjnu1010","title":"Discordance Between Prostate-Specific Antigen and Positron Emission Tomography Imaging in Recurrent Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"World Journal of Nephrology and Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Prostatectomy; Positron emission tomography; Occult; Biochemical recurrence; Recurrent prostate cancer; breakpoint cluster region; Glutamate carboxypeptidase II; Prostate-specific antigen","score_opus":0.01201250962592798,"score_gpt":0.31316598973734217,"score_spread":0.3011534801114142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416018691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.882935,0.08835197,0.00001726931,0.028051678,0.00017003132,0.0002934299,0.0000072778275,0.0000066678613,0.0001667108],"genre_scores_gemma":[0.97669894,0.021745812,0.00010619428,0.0009517646,0.0001122394,0.000015082313,0.000007048432,0.000009327958,0.00035360226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872977,0.00014459308,0.0004056041,0.00025106466,0.00010398521,0.00036497664],"domain_scores_gemma":[0.99939805,0.00011943105,0.00015899177,0.000100439574,0.00009427555,0.00012878528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003504903,0.00015545396,0.00044993832,0.0007844487,0.000099028126,0.000015590327,0.00007161848,0.00006778874,0.000019191266],"category_scores_gemma":[0.000012145448,0.00011208447,0.00005407368,0.00039600724,0.000367558,0.0001045274,0.00007194281,0.00056410424,3.649258e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053638625,0.000084584775,0.9109822,0.00005287805,0.000105075735,0.00027699006,0.00033122353,0.0000018809386,0.010516855,0.00007599215,0.0016583129,0.070550136],"study_design_scores_gemma":[0.0039282013,0.0008347855,0.9387032,0.00017402948,0.000092148664,0.00011396932,0.000049885442,0.000023116758,0.00059218594,0.0014983693,0.053907234,0.00008292038],"about_ca_topic_score_codex":0.000027815198,"about_ca_topic_score_gemma":0.00006520069,"teacher_disagreement_score":0.09376397,"about_ca_system_score_codex":0.00004981326,"about_ca_system_score_gemma":0.0001419598,"threshold_uncertainty_score":0.4570672},"labels":[],"label_agreement":null},{"id":"W4416018986","doi":"10.1016/j.ijgc.2025.102459","title":"RACIAL SUBGROUP ANALYSES OF TUMOR RESPONSE AND SAFETY IN PATIENTS WITH MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH ADVANCED/RECURRENT ENDOMETRIAL CANCER RECEIVING DOSTARLIMAB MONOTHERAPY IN THE GARNET TRIAL","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; University of British Columbia; McMaster University Medical Centre; Spinal Cord Injury BC; McMaster University; Kelowna General Hospital; BC Cancer Agency","funders":"","keywords":"Endometrial cancer; Subgroup analysis; Complete response; Clinical trial; MEDLINE","score_opus":0.030970265410018478,"score_gpt":0.3835874890435213,"score_spread":0.35261722363350284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416018986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99243385,0.0039647515,0.00001566785,0.0018187356,0.00071391766,0.0009121158,0.00009378567,0.0000054002576,0.00004177634],"genre_scores_gemma":[0.996544,0.0027288434,0.0002082782,0.00028390007,0.000108543405,0.00007365431,0.000015641184,0.000007703891,0.000029427054],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99736917,0.00046650067,0.0008859687,0.00026596533,0.0007684764,0.00024389163],"domain_scores_gemma":[0.9973712,0.0014009504,0.00041391904,0.0001269802,0.0006257074,0.0000612401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014820237,0.00017311252,0.0005632802,0.00057142664,0.00004671106,0.000033016582,0.00025181702,0.00007717594,0.0001905466],"category_scores_gemma":[0.0010247154,0.000094849995,0.00015333637,0.00066489534,0.00021073417,0.000145247,0.00005746836,0.00045594748,1.9262794e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5357162,0.0012677003,0.43672404,0.000027003289,0.00026669924,0.00008984201,0.0005587729,0.0002363866,0.0007700951,0.000022722888,0.000026601638,0.024293942],"study_design_scores_gemma":[0.100672916,0.003749247,0.8923036,0.0005196584,0.00007213185,0.000004053663,0.0002080123,0.000029661034,0.0010897345,0.00009886715,0.0011586836,0.00009342984],"about_ca_topic_score_codex":0.0003640156,"about_ca_topic_score_gemma":0.00061645394,"teacher_disagreement_score":0.45557958,"about_ca_system_score_codex":0.0010347104,"about_ca_system_score_gemma":0.0006459474,"threshold_uncertainty_score":0.38678706},"labels":[],"label_agreement":null},{"id":"W4416070035","doi":"10.1016/j.nucmedbio.2025.109223","title":"Synthesis and Evaluation of Dual-Mode Fluorescent-18F-PET Tracers Targeting PSMA","year":2025,"lang":"en","type":"article","venue":"Nuclear Medicine and Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Glutamate carboxypeptidase II; In vivo","score_opus":0.06071997908485195,"score_gpt":0.3954784553582882,"score_spread":0.33475847627343625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416070035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816929,0.0060885265,0.000001943025,0.008023272,0.00008959983,0.00027387554,0.000007276063,0.000015659143,0.0038069177],"genre_scores_gemma":[0.996265,0.0030753436,0.00012032735,0.00031295622,0.000082950675,0.0000091674165,0.000018401404,0.000007038076,0.00010879318],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999155,0.00020289498,0.00017764702,0.00019351997,0.000120278535,0.0001507042],"domain_scores_gemma":[0.9994204,0.00025182267,0.000043898046,0.00009558647,0.00012375719,0.000064532614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093639875,0.00008709834,0.0002792976,0.00015364775,0.000083976636,0.0000026735902,0.00002533412,0.00006017969,0.00027531214],"category_scores_gemma":[0.0006845393,0.000054339274,0.000022149425,0.00012182659,0.00047139538,0.000018862453,0.00003146047,0.00015027066,0.0000017947144],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015605468,0.00020193083,0.05934385,0.0006659219,0.0005541012,0.000034174,0.0029508397,0.0000013906329,0.5692136,0.001552954,0.017389266,0.3465314],"study_design_scores_gemma":[0.07701225,0.013438808,0.51713705,0.008012613,0.010374273,0.0006508142,0.057859905,0.065295994,0.12229361,0.0128431255,0.11368111,0.001400428],"about_ca_topic_score_codex":0.00014546356,"about_ca_topic_score_gemma":0.0000029223638,"teacher_disagreement_score":0.45779324,"about_ca_system_score_codex":0.000039638362,"about_ca_system_score_gemma":0.000070346956,"threshold_uncertainty_score":0.30144748},"labels":[],"label_agreement":null},{"id":"W4416098023","doi":"10.1186/s12929-025-01189-9","title":"Correction: Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models","year":2025,"lang":"en","type":"erratum","venue":"Journal of Biomedical Science","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Reciprocal; Deregulation; Chromoplexy; Cancer","score_opus":0.02412224266371403,"score_gpt":0.34379357881524425,"score_spread":0.3196713361515302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416098023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7399343,0.11431803,0.0012633397,0.06213138,0.05519373,0.0040316335,0.00030372152,0.000048946968,0.022774905],"genre_scores_gemma":[0.8572134,0.044149406,0.001581081,0.0002319142,0.0015197946,0.000040653184,0.000059071677,0.00002790487,0.09517679],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976232,0.00003471646,0.000613186,0.00027764947,0.0011831942,0.0002680651],"domain_scores_gemma":[0.99862427,0.000082019265,0.0003515328,0.000107375956,0.00051567913,0.00031910712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009840025,0.00014547411,0.00047154352,0.00073827885,0.000101610065,0.000045203476,0.00012558851,0.00020347653,0.000029559444],"category_scores_gemma":[0.00025296814,0.000096197306,0.00004906774,0.001102771,0.0013346697,0.00027348223,0.000071618044,0.0006481471,1.2016646e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053251865,0.0009127381,0.0069330237,0.002846272,0.0002706382,0.0006490409,0.0039324574,0.00007672633,0.03335464,0.00013412618,0.4219146,0.5236506],"study_design_scores_gemma":[0.032642532,0.019405505,0.5271693,0.068055846,0.0015713626,0.0024278914,0.0034328727,0.13717204,0.013903821,0.011398882,0.18097915,0.0018408212],"about_ca_topic_score_codex":0.0003246365,"about_ca_topic_score_gemma":0.00012044254,"teacher_disagreement_score":0.52180976,"about_ca_system_score_codex":0.00040689987,"about_ca_system_score_gemma":0.004586485,"threshold_uncertainty_score":0.8136228},"labels":[],"label_agreement":null},{"id":"W4416122029","doi":"10.21203/rs.3.rs-7904335/v1","title":"From Hurdles to Breakthroughs: Building and Validating a PSMA-positive Triple-Negative Breast Cancer Mouse Model for Preclinical Targeted Radionuclide Therapy","year":2025,"lang":"","type":"preprint","venue":"Research Square","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics; Université Clermont-Auvergne; Centre National de la Recherche Scientifique; Ligue Contre le Cancer; Institut National de la Santé et de la Recherche Médicale","keywords":"Immunohistochemistry; Breast cancer; Targeted therapy; Neovascularization; Radionuclide therapy; Positron emission tomography; Angiogenesis","score_opus":0.1396589123819331,"score_gpt":0.495706763243487,"score_spread":0.3560478508615539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416122029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7955989,0.026131438,0.018068297,0.027628794,0.0009683004,0.038736198,0.09215695,0.0002721465,0.00043895398],"genre_scores_gemma":[0.8118108,0.09737742,0.032753855,0.00060950744,0.0045339316,0.020140328,0.0029079479,0.00046309753,0.02940315],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.985867,0.0023829206,0.0018360505,0.003973476,0.002856328,0.0030842288],"domain_scores_gemma":[0.9815656,0.0098261405,0.00044318123,0.0016348374,0.004751089,0.0017791596],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.004840558,0.0013923568,0.0026363626,0.0014166872,0.0018014924,0.0007538181,0.0011778948,0.0013320874,0.00046655253],"category_scores_gemma":[0.0033628205,0.0011801986,0.00082777155,0.0015949246,0.0012217109,0.00044553063,0.0025779027,0.0043528695,0.000021210792],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16395094,0.0065082605,0.0245294,0.012228175,0.019979762,0.0002915616,0.118355654,0.015732909,0.087293275,0.00080571516,0.01673802,0.5335863],"study_design_scores_gemma":[0.06831538,0.008775088,0.016985873,0.05471632,0.0014860086,0.00002720952,0.023384782,0.60293317,0.2007425,0.016485054,0.002057431,0.0040912167],"about_ca_topic_score_codex":0.014997313,"about_ca_topic_score_gemma":0.00036517912,"teacher_disagreement_score":0.5872002,"about_ca_system_score_codex":0.0032796268,"about_ca_system_score_gemma":0.006730458,"threshold_uncertainty_score":0.9999644},"labels":[],"label_agreement":null},{"id":"W4416122151","doi":"10.1186/s40658-025-00808-6","title":"Predicting PSA50 response to $$^{177}$$Lu-PSMA therapy using machine learning and automated total tumor volume","year":2025,"lang":"en","type":"article","venue":"EJNMMI Physics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"Grand Équipement National De Calcul Intensif; LabEx PRIMES; Siemens Healthineers; Direction Générale de l’offre de Soins; Institut National Du Cancer; Centre National de la Recherche Scientifique; Association Nationale de la Recherche et de la Technologie; Centre Léon Bérard; Université de Lyon; Institut National de la Santé et de la Recherche Médicale; Agence Nationale de la Recherche","keywords":"Support vector machine; Workflow; Prostate cancer; Volume (thermodynamics); Segmentation; Regression; Medical imaging; Regression analysis","score_opus":0.021754446873148824,"score_gpt":0.34629124384990084,"score_spread":0.32453679697675203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416122151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99609685,0.0011057759,0.00020105467,0.0010274742,0.00013021177,0.00056675746,0.000020124937,0.0003659836,0.00048574884],"genre_scores_gemma":[0.99110734,0.000062644714,0.0008991609,0.00027811708,0.00017938792,0.000026109443,0.000027734606,0.00003654269,0.007382953],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.998704,0.00013971912,0.00019187378,0.00033292494,0.00025849428,0.0003729581],"domain_scores_gemma":[0.9993666,0.00012521158,0.000051180705,0.00018852684,0.00011230018,0.00015619239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031574105,0.00019359804,0.000299249,0.0001263289,0.0002722703,0.000057960526,0.00006095301,0.000052077914,0.000035452704],"category_scores_gemma":[0.00013548706,0.00016059147,0.000064451975,0.0005103511,0.000075129225,0.00009543273,0.000107670254,0.00032792886,0.000015021014],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010133943,0.00035645685,0.49301428,0.00018844854,0.0004466106,0.00021156187,0.0025817482,0.00051328394,0.46109018,0.000043103173,0.00094179576,0.030478608],"study_design_scores_gemma":[0.015604333,0.0029392282,0.21409734,0.0012587573,0.0002616377,0.00012089703,0.0015567143,0.6387816,0.109319404,0.00024837605,0.015065571,0.0007461441],"about_ca_topic_score_codex":0.00015363714,"about_ca_topic_score_gemma":0.0000034542518,"teacher_disagreement_score":0.63826835,"about_ca_system_score_codex":0.00017336024,"about_ca_system_score_gemma":0.00024737668,"threshold_uncertainty_score":0.654873},"labels":[],"label_agreement":null},{"id":"W4416178980","doi":"10.1073/pnas.2513468122","title":"Circadian regulator REV-ERBα is a master regulator of tumor lineage plasticity and an effective therapeutic target","year":2025,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institutes of Health; National Cancer Institute; Prostate Cancer Foundation; U.S. Department of Veterans Affairs; National Institute of Diabetes and Digestive and Kidney Diseases; U.S. Department of Defense","keywords":"Regulator; Chromatin; Epigenetics; FOXA1; Master regulator; Prostate cancer; Transcriptional regulation; Bivalent chromatin; Chromatin remodeling; Regulation of gene expression","score_opus":0.03733186225387254,"score_gpt":0.3471491453806915,"score_spread":0.309817283126819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416178980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929324,0.000618704,0.0000013737516,0.0037917905,0.000013296934,0.0005206405,0.000025646754,0.000006870633,0.002089326],"genre_scores_gemma":[0.9981881,0.00002950799,0.0006272435,0.00044282267,0.000049378345,0.000019539037,2.1679577e-7,0.0000037886211,0.0006394472],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986312,0.000010088077,0.00024780835,0.00024983316,0.00071386754,0.0001472456],"domain_scores_gemma":[0.9992507,0.00013200965,0.00020490523,0.000011852734,0.00034279414,0.00005771771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072437833,0.00009403076,0.00023727164,0.00023170891,0.00011933032,0.000013481755,0.0002471633,0.00006617384,0.000019538611],"category_scores_gemma":[0.00024341649,0.000055779452,0.000059652233,0.0006509405,0.0011226453,0.00022959833,0.00008253373,0.00014608304,3.0377421e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005772919,0.000220117,0.16447316,0.0009974978,0.00017816988,5.9869784e-8,0.0010313317,0.000005830153,0.808937,0.021262098,0.00076498033,0.001552423],"study_design_scores_gemma":[0.0005770009,0.00020903141,0.38587698,0.0003247768,0.000038700397,0.000003785808,0.0001406164,0.0009117414,0.601438,0.010321148,0.00011769937,0.000040533076],"about_ca_topic_score_codex":0.0000066301063,"about_ca_topic_score_gemma":5.163479e-8,"teacher_disagreement_score":0.2214038,"about_ca_system_score_codex":0.000052291445,"about_ca_system_score_gemma":0.00009306384,"threshold_uncertainty_score":0.41364336},"labels":[],"label_agreement":null},{"id":"W4416187331","doi":"10.1080/14796694.2025.2577633","title":"Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP)","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Bayer","keywords":"Biochemical recurrence; Prostate cancer; Clinical endpoint; Prostatectomy; Prostate-specific antigen; Placebo; Radiation therapy; Glutamate carboxypeptidase II; Adjuvant","score_opus":0.01653389836474592,"score_gpt":0.3473627806221141,"score_spread":0.3308288822573682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416187331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977561,0.013741963,0.000012850416,0.006481208,0.00047342322,0.0007867525,0.000047042413,0.000021263588,0.0008744804],"genre_scores_gemma":[0.97170365,0.026466705,0.00032798777,0.0002818094,0.00021412405,0.00022349332,0.00008463108,0.000010672633,0.0006868998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989424,0.0000962511,0.0002715142,0.0002810391,0.00014982198,0.00025900314],"domain_scores_gemma":[0.9994205,0.000079644546,0.00010462499,0.00020316667,0.0001344411,0.000057594094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001967851,0.00012412944,0.00038831623,0.00020232679,0.00003452147,0.000003962461,0.00009584533,0.00020849511,0.000079754514],"category_scores_gemma":[0.000048277794,0.00009107084,0.000047307592,0.00053893763,0.00014255254,0.00003740819,0.000043786156,0.00033936033,0.0000039510874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00796134,0.00054418034,0.58041596,0.00020669623,0.00023132405,0.00007356173,0.0011282734,0.00001825607,0.0253837,0.0005739774,0.007964829,0.3754979],"study_design_scores_gemma":[0.03457401,0.0033272794,0.6021405,0.000647845,0.00014880582,0.000019771293,0.0007213714,0.00025923023,0.23352715,0.002130896,0.12219528,0.00030784038],"about_ca_topic_score_codex":0.00048112875,"about_ca_topic_score_gemma":0.0001892703,"teacher_disagreement_score":0.37519005,"about_ca_system_score_codex":0.000543925,"about_ca_system_score_gemma":0.0010341963,"threshold_uncertainty_score":0.37137613},"labels":[],"label_agreement":null},{"id":"W4416221617","doi":"10.1101/2025.11.12.687734","title":"NUAK2 is a therapeutically tractable regulator of RNA splicing and tumor progression in neuroendocrine prostate cancer","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill; European Federation of Pharmaceutical Industries and Associations; National Cancer Institute; Ontario Genomics Institute; Merck KGaA; Ontario Genomics; Genome Canada; DOD Prostate Cancer Research Program; McGill University; Genentech; Bayer; Pfizer; Duke Cancer Institute; Bristol-Myers Squibb","keywords":"Prostate cancer; RNA splicing; Spliceosome; Regulator; Tumor progression; Cancer; Mechanism (biology); Prostate; Alternative splicing; Androgen receptor","score_opus":0.01729165076130216,"score_gpt":0.30204405466503104,"score_spread":0.28475240390372886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416221617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834799,0.011250173,0.000009365845,0.0023176107,0.00025087173,0.0022973272,0.00026101683,0.00010534427,0.000028390492],"genre_scores_gemma":[0.9927829,0.004936392,0.001029074,0.00036064832,0.00011249999,0.0005941019,5.099388e-7,0.00007527053,0.000108598855],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972022,0.0000948308,0.00062410225,0.00093692006,0.0004928074,0.00064914627],"domain_scores_gemma":[0.9981723,0.00006240645,0.00029321387,0.0007814209,0.00042523263,0.00026541724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003029434,0.0004763379,0.0008854474,0.00046469137,0.00007764927,0.00006865676,0.00021007299,0.00015864869,0.00004966489],"category_scores_gemma":[0.00007344654,0.0003963522,0.00011492034,0.0006421411,0.00020079306,0.000105184816,0.0003836032,0.0008713988,0.0000020814816],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015128951,0.0006386591,0.18641597,0.0054389047,0.00035998065,0.0005529784,0.000084890475,0.000011528922,0.8044821,0.00013118508,0.00014345076,0.00022745358],"study_design_scores_gemma":[0.0033185144,0.00026767908,0.24547462,0.0062470944,0.0002526561,1.3525911e-7,0.0000071131085,0.00080021017,0.74157,0.0000061614196,0.0016664673,0.00038932578],"about_ca_topic_score_codex":0.00025348723,"about_ca_topic_score_gemma":0.0000068811432,"teacher_disagreement_score":0.06291208,"about_ca_system_score_codex":0.00033524702,"about_ca_system_score_gemma":0.0015988026,"threshold_uncertainty_score":0.99984884},"labels":[],"label_agreement":null},{"id":"W4416265857","doi":"10.1016/j.ejca.2025.116106","title":"Corrigendum to “Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study” [Eur J Cancer 213 (December) (2024) 115078]","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Incidence (geometry); Prostate cancer; Cancer; Population; Regret","score_opus":0.056180627005350245,"score_gpt":0.40335257158238547,"score_spread":0.3471719445770352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416265857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8944521,0.078852564,0.00040122136,0.011247805,0.0031958115,0.0075777834,0.00051644404,0.000033585304,0.0037227042],"genre_scores_gemma":[0.95763946,0.009798274,0.00015964711,0.0010352378,0.00059220864,0.0006862401,0.00002218474,0.000075349126,0.029991386],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99354583,0.00201353,0.0020886336,0.0005570561,0.0011180897,0.00067687914],"domain_scores_gemma":[0.99680346,0.00061284384,0.0008795514,0.0004854149,0.0008288975,0.00038985116],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033490069,0.00052631315,0.0021741292,0.0005187562,0.000292671,0.00018746738,0.00048624398,0.0000364466,0.0010964237],"category_scores_gemma":[0.0004939206,0.000298698,0.0005125458,0.0011387694,0.00023611722,0.00023297005,0.00013491198,0.00087127666,0.000015613912],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90295345,0.0009109413,0.005308216,0.000103275575,0.0074078334,0.0030990886,0.0078068343,0.009881759,0.00851188,0.000015242458,0.022032233,0.031969234],"study_design_scores_gemma":[0.94786245,0.0012497011,0.011087339,0.0022342307,0.0055191754,0.000024977198,0.005479485,0.0014079545,0.0028185886,0.00004419352,0.021802139,0.00046975125],"about_ca_topic_score_codex":0.0074968874,"about_ca_topic_score_gemma":0.012354109,"teacher_disagreement_score":0.06905429,"about_ca_system_score_codex":0.0013655804,"about_ca_system_score_gemma":0.0029296952,"threshold_uncertainty_score":0.99994653},"labels":[],"label_agreement":null},{"id":"W4416333309","doi":"10.51731/cjht.2025.1289","title":"Talazoparib (Talzenna)","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Drug; Prostate; Cancer","score_opus":0.0350540873413844,"score_gpt":0.3577037633705603,"score_spread":0.32264967602917594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416333309","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02114425,0.7237735,0.00019518651,0.2476508,0.0026453568,0.00067089475,0.0000491719,0.00006792737,0.0038029288],"genre_scores_gemma":[0.9661069,0.028115928,0.0001875111,0.00096211716,0.000033669745,0.000010766452,0.00000555991,0.00002270431,0.004554863],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964851,0.00013520378,0.0012748833,0.00029173237,0.0003401069,0.0014729645],"domain_scores_gemma":[0.9977227,0.00012398261,0.00061973475,0.0005559745,0.0006344492,0.0003431513],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014560759,0.00031558034,0.0010502909,0.002899749,0.0007134188,0.00010717752,0.00072217296,0.00045428186,0.00016409012],"category_scores_gemma":[0.001223892,0.00025506222,0.00024270911,0.0015887413,0.0011406562,0.00016749508,0.00007298431,0.0016549125,0.000038258528],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013459501,0.00007746575,0.021210039,0.0009812802,0.00049508945,0.0012720801,0.00032233936,0.0000043475347,0.000045201818,0.0038904063,0.057324085,0.91424304],"study_design_scores_gemma":[0.0041596415,0.0025685064,0.019032743,0.006263385,0.00019376968,0.00040499886,0.013425426,0.000031894655,0.0026678883,0.010696045,0.9402637,0.0002920116],"about_ca_topic_score_codex":0.0064490004,"about_ca_topic_score_gemma":0.0034692248,"teacher_disagreement_score":0.9449626,"about_ca_system_score_codex":0.0031673678,"about_ca_system_score_gemma":0.0421326,"threshold_uncertainty_score":0.99999017},"labels":[],"label_agreement":null},{"id":"W4416380369","doi":"10.1016/j.ejca.2025.116110","title":"Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"Astellas Pharma; Astellas Pharma US; Pfizer","keywords":"Enzalutamide; Post-hoc analysis; Post hoc; Subgroup analysis; Recurrent prostate cancer","score_opus":0.007018902896745158,"score_gpt":0.2850381728637095,"score_spread":0.27801926996696436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416380369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897385,0.0076180794,0.000040171548,0.0012540042,0.00011334552,0.0005514372,0.00017316364,0.000015526151,0.0004957664],"genre_scores_gemma":[0.9904386,0.004738806,0.00051128917,0.00033873008,0.000097395685,0.000025874302,0.00005520548,0.00005032458,0.0037438078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976632,0.00025454472,0.00059308036,0.00034761813,0.0007142019,0.0004273792],"domain_scores_gemma":[0.9982255,0.000039830615,0.0004883044,0.00027116798,0.0007170402,0.00025816276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045187204,0.00028744282,0.00071635784,0.0005450068,0.0000769135,0.00005951293,0.00022229846,0.000031793923,0.00012236011],"category_scores_gemma":[0.000047448986,0.00015315409,0.000120321536,0.0013613146,0.00017008254,0.00013671117,0.000052352363,0.0005993592,0.0000027150277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047223765,0.00039207004,0.89777803,0.00011201463,0.002801212,0.00061087095,0.00057093403,0.00017713397,0.0009556368,8.605447e-7,0.002677853,0.046699587],"study_design_scores_gemma":[0.03330456,0.008805663,0.9310141,0.0029729418,0.0037913276,0.000009977219,0.00023839713,0.000031585576,0.007971393,0.0000043951213,0.011441186,0.0004144384],"about_ca_topic_score_codex":0.00035561394,"about_ca_topic_score_gemma":0.0008269303,"teacher_disagreement_score":0.04628515,"about_ca_system_score_codex":0.0005706306,"about_ca_system_score_gemma":0.0008173637,"threshold_uncertainty_score":0.62454426},"labels":[],"label_agreement":null},{"id":"W4416391612","doi":"10.1016/j.annonc.2025.09.103","title":"LBA87 EMBARK: Overall survival with enzalutamide in biochemically recurrent prostate cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; SAIT Polytechnic; University of British Columbia","funders":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Astellas Pharma; Bristol-Myers Squibb; AstraZeneca; Movember Foundation; University of California, San Francisco; Comprehensive Cancer Center, City of Hope; Exelixis; Memorial Sloan-Kettering Cancer Center; Vanderbilt University; NorthShore University HealthSystem; Genentech; University of Pittsburgh; University of Texas MD Anderson Cancer Center; Pfizer; Cancer Institute, University of Pittsburgh; Roswell Park Cancer Institute","keywords":"Enzalutamide; Overall survival; Prostate cancer; Recurrent prostate cancer; Survival analysis; Progression-free survival","score_opus":0.06934023701720003,"score_gpt":0.4391255060900267,"score_spread":0.36978526907282666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.958035,0.0049700155,0.000003150249,0.01973005,0.00015026232,0.0005427272,0.000026718519,0.00001654604,0.01652553],"genre_scores_gemma":[0.98824936,0.006960573,0.00014710179,0.0009443875,0.000047433045,0.00014705442,0.000036860674,0.000012173169,0.0034550366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882555,0.00007339369,0.00027758846,0.00026231303,0.0001888798,0.00037227897],"domain_scores_gemma":[0.999278,0.00010660917,0.00007715118,0.00018272732,0.0002644373,0.00009106537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027966496,0.00012818177,0.00044173546,0.00020555375,0.000021504375,0.0000046214755,0.00009188022,0.00011035828,0.000089857],"category_scores_gemma":[0.00006670062,0.00008968177,0.00005721534,0.00032723657,0.00018345888,0.00003840205,0.00006056368,0.00023823744,0.000004370084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033474356,0.0033044794,0.5168182,0.0010793627,0.0010116408,0.00066384533,0.0014713025,0.000041260293,0.055693455,0.001932767,0.028412748,0.35609657],"study_design_scores_gemma":[0.029663196,0.011960188,0.42193118,0.002574033,0.0002252262,0.000026886368,0.000533408,0.00013155592,0.3301867,0.0031193001,0.1991285,0.0005198304],"about_ca_topic_score_codex":0.00040560425,"about_ca_topic_score_gemma":0.00043954173,"teacher_disagreement_score":0.35557672,"about_ca_system_score_codex":0.0001592146,"about_ca_system_score_gemma":0.0012872573,"threshold_uncertainty_score":0.36571166},"labels":[],"label_agreement":null},{"id":"W4416391722","doi":"10.1016/j.annonc.2025.09.101","title":"LBA6 Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Phases of clinical research; Clinical trial; Chemotherapy; Phase (matter)","score_opus":0.04062675798568513,"score_gpt":0.39697898191817627,"score_spread":0.3563522239324911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892123,0.00035182203,0.000022399137,0.0034291418,0.00009940054,0.0033060396,0.00058857125,0.000016231184,0.00297413],"genre_scores_gemma":[0.99678695,0.0005573913,0.00020816454,0.0005173114,0.00003025713,0.00041306514,0.00056841155,0.000022795948,0.00089565094],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979604,0.00023202448,0.0005702552,0.00037793478,0.0004094758,0.0004499084],"domain_scores_gemma":[0.99780667,0.00030272483,0.00037933004,0.0002503922,0.0011279617,0.00013289755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003151115,0.00025284383,0.0010985708,0.000438897,0.00006067629,0.000006733075,0.000092738446,0.00010229486,0.000055642802],"category_scores_gemma":[0.00007680182,0.00016994111,0.000092625196,0.0006940479,0.00053563376,0.00013785416,0.000050436647,0.00028329625,0.000002855342],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93657947,0.010620491,0.0075347456,0.00022641911,0.0022528518,0.0003765953,0.002242398,0.00002899748,0.0006439403,0.00028818753,0.0036787253,0.0355272],"study_design_scores_gemma":[0.7133725,0.14790457,0.09342173,0.0011370135,0.00087111874,0.0000070093597,0.0015842204,0.00007442216,0.03985185,0.0003674218,0.0010690945,0.00033900334],"about_ca_topic_score_codex":0.00053702475,"about_ca_topic_score_gemma":0.0003709325,"teacher_disagreement_score":0.22320691,"about_ca_system_score_codex":0.00019114988,"about_ca_system_score_gemma":0.0014805198,"threshold_uncertainty_score":0.6929997},"labels":[],"label_agreement":null},{"id":"W4416391725","doi":"10.1016/j.annonc.2025.09.105","title":"LBA89 A randomized phase II study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Occupational Cancer Research Centre; Princess Margaret Cancer Centre; University of Alberta; Sunnybrook Health Science Centre; Jewish General Hospital; Centre Hospitalier Universitaire de Sherbrooke; University of British Columbia; Centre Hospitalier de l’Université de Montréal; Université Laval; University of British Columbia Hospital; Juravinski Cancer Centre; Western University; London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Docetaxel; Prostate cancer; Randomized controlled trial; Clinical trial; Phases of clinical research","score_opus":0.0752403058241683,"score_gpt":0.4500744677641108,"score_spread":0.3748341619399425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97953165,0.00385542,0.0000018764836,0.0028553968,0.00011829091,0.012529987,0.0009372565,0.000009237306,0.00016086026],"genre_scores_gemma":[0.99545336,0.0009396429,0.00003331697,0.00023835365,0.000025593412,0.0026370017,0.00012211838,0.000022732274,0.00052790524],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959271,0.0013802447,0.0011611676,0.00052846293,0.0004769098,0.00052613736],"domain_scores_gemma":[0.9973291,0.00064126187,0.0005482112,0.0002969456,0.0008035629,0.00038090366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019159862,0.00031774113,0.0023025488,0.0006924579,0.00016138125,0.000019517654,0.00012377805,0.00006896638,0.000088296816],"category_scores_gemma":[0.00047439072,0.00021155382,0.00011971645,0.00065471506,0.0003485175,0.00013730499,0.00006550437,0.00022946576,3.6727002e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6977854,0.023918275,0.23460384,0.000449042,0.0056105214,0.0005081333,0.012270953,0.00004767653,0.00017666852,0.00007146263,0.0006235555,0.023934474],"study_design_scores_gemma":[0.58509487,0.036091667,0.3709267,0.0005755558,0.00254583,7.9551774e-7,0.0038235679,0.000051308238,0.00031922347,0.00011827076,0.00023049008,0.00022171621],"about_ca_topic_score_codex":0.15033408,"about_ca_topic_score_gemma":0.33327767,"teacher_disagreement_score":0.18294361,"about_ca_system_score_codex":0.00034224844,"about_ca_system_score_gemma":0.0036615024,"threshold_uncertainty_score":0.86269146},"labels":[],"label_agreement":null},{"id":"W4416391870","doi":"10.1016/j.annonc.2025.09.107","title":"LBA91 Patient (pt) reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled phase III trial of niraparib (NIRA) and abiraterone acetate (AA) plus prednisone (P) in metastatic hormone-sensitive prostate cancer (mHSPC) with homologous recombination repair mutations (HRRm)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Calgary","funders":"Johnson and Johnson","keywords":"Abiraterone acetate; Prednisone; Prostate cancer; Homologous chromosome; Abiraterone; Phases of clinical research","score_opus":0.049314117480779254,"score_gpt":0.4007666378702927,"score_spread":0.35145252038951347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98231286,0.0026372806,0.00013216642,0.0039165393,0.00016252059,0.010129488,0.00018887411,0.000050655155,0.00046959677],"genre_scores_gemma":[0.9921275,0.002425769,0.0009332483,0.00023970095,0.000012998406,0.0029765267,0.00030124554,0.00002508787,0.0009579582],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961337,0.0008753486,0.0016271047,0.00056087156,0.00038015895,0.00042282778],"domain_scores_gemma":[0.99606603,0.0015226711,0.0011168605,0.00033829812,0.00083171873,0.00012440796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001488018,0.00032385104,0.0030597113,0.00059906335,0.00007374561,0.000015345728,0.000071827024,0.000154341,0.000020411793],"category_scores_gemma":[0.00089078315,0.00022016144,0.00027097823,0.000489754,0.0006471594,0.00014083982,0.000066394416,0.00028001418,7.4831166e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9690649,0.0029570223,0.00069465034,0.00012944748,0.004947633,0.00045398241,0.005905195,0.00009787888,0.0022586924,0.00007328487,0.00023735619,0.013179987],"study_design_scores_gemma":[0.97266847,0.011506937,0.0032308728,0.0002557683,0.0015806906,0.000015248686,0.0010930417,0.0015298214,0.0066644247,0.0011918964,0.000081507635,0.00018130984],"about_ca_topic_score_codex":0.0028162415,"about_ca_topic_score_gemma":0.0007670559,"teacher_disagreement_score":0.012998677,"about_ca_system_score_codex":0.00024637877,"about_ca_system_score_gemma":0.0014446967,"threshold_uncertainty_score":0.89779234},"labels":[],"label_agreement":null},{"id":"W4416392420","doi":"10.1186/s12885-025-15193-7","title":"Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer","year":2025,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"Fonds de Recherche du Québec - Santé; Canada Foundation for Innovation; Centre Hospitalier Universitaire de Québec; Canada Research Chairs; Natural Sciences and Engineering Research Council of Canada; Université de Sherbrooke; Canadian Institutes of Health Research; JW and HM Goodman Family Foundation; Université Laval","keywords":"Prostate cancer; Androgen receptor; Transcriptome; Surgical oncology; Metabolite; Androgen; Receptor","score_opus":0.018240298540470705,"score_gpt":0.3485723313531706,"score_spread":0.3303320328126999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416392420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.970862,0.025702635,0.000008484801,0.0007954132,0.00032267734,0.0011861679,0.00005799204,0.000020253512,0.001044414],"genre_scores_gemma":[0.9824312,0.0024675373,0.00008746755,0.00013565602,0.000054116023,0.00076802744,0.0000141873625,0.00001546933,0.014026372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988723,0.000039685372,0.0002697998,0.00027217553,0.00023243914,0.00031363807],"domain_scores_gemma":[0.99943817,0.000083252125,0.000062030886,0.00021524804,0.000121862206,0.00007945325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009535991,0.00014403704,0.00033272442,0.00022157443,0.000041985862,0.00001097555,0.00006593648,0.00007178922,0.00018284387],"category_scores_gemma":[0.00003634923,0.00011319531,0.000086164924,0.0006059182,0.00009272413,0.000052259147,0.0000312243,0.000120226476,0.0000031955212],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017394393,0.00023634676,0.89090127,0.0024162394,0.0001431247,0.00009146434,0.0004422239,0.00008744719,0.09643039,0.00019842647,0.0026123987,0.0047012283],"study_design_scores_gemma":[0.0111502595,0.00028676025,0.5867658,0.002436942,0.0002884355,0.000004624,0.00017422625,0.00015823865,0.39275068,0.00020731537,0.005566387,0.00021027654],"about_ca_topic_score_codex":0.0029507384,"about_ca_topic_score_gemma":0.010519561,"teacher_disagreement_score":0.30413544,"about_ca_system_score_codex":0.00041302526,"about_ca_system_score_gemma":0.0014732939,"threshold_uncertainty_score":0.5870162},"labels":[],"label_agreement":null},{"id":"W4416404709","doi":"10.3389/fonc.2025.1672802","title":"Prognostic factors for overall survival in patients with metastatic castration-resistant prostate cancer treated with radium-223: a meta-analysis of real-world evidence","year":2025,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Overall survival; Prostate cancer; Baseline (sea); Selection (genetic algorithm); Survival analysis; Survival rate; Proportional hazards model; Clinical trial","score_opus":0.07348137557972151,"score_gpt":0.38059702850719945,"score_spread":0.30711565292747794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416404709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99311495,0.0017364114,0.00027685307,0.0006722647,0.00009023346,0.0035641405,0.00024727,0.000015097699,0.00028277485],"genre_scores_gemma":[0.99227434,0.00025036474,0.003576168,0.00004597065,0.0000049047867,0.0011875312,0.00027925265,0.000019522038,0.0023619654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980413,0.00023100433,0.0005256659,0.00045640965,0.00033330492,0.00041231952],"domain_scores_gemma":[0.998523,0.0005744021,0.00023127746,0.0002511418,0.000333774,0.000086410786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033962104,0.00024593313,0.0017360456,0.001249416,0.000042829884,0.000012549195,0.00010917007,0.00006449422,0.00003898432],"category_scores_gemma":[0.00013567194,0.00014536205,0.00020325328,0.002106925,0.00020431822,0.00011995964,0.000019848136,0.00017244648,1.255905e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01476729,0.0008088465,0.9416367,0.00022986688,0.040403638,0.000038351205,0.00054741354,0.0007111476,0.000031616855,0.000039509367,0.00037031854,0.0004153495],"study_design_scores_gemma":[0.009816191,0.0027503155,0.91958827,0.00013625331,0.06614335,1.2588264e-7,0.00037326416,0.0005351206,0.00027761166,0.00005009335,0.00018259339,0.00014684016],"about_ca_topic_score_codex":0.005494539,"about_ca_topic_score_gemma":0.032149885,"teacher_disagreement_score":0.026655346,"about_ca_system_score_codex":0.0011476207,"about_ca_system_score_gemma":0.0012154365,"threshold_uncertainty_score":0.9855109},"labels":[],"label_agreement":null},{"id":"W4416405197","doi":"10.1016/j.euo.2025.09.010","title":"Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Abiraterone; Olaparib; Placebo; Prostate cancer; Clinical trial","score_opus":0.061145733419048894,"score_gpt":0.38868008007266386,"score_spread":0.32753434665361497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416405197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729337,0.0005607548,0.00005735044,0.008722485,0.0003430406,0.009707599,0.00006692357,0.000071456045,0.00753666],"genre_scores_gemma":[0.9910542,0.0000864748,0.00020173052,0.0010773146,0.000052268086,0.002395998,0.00015877432,0.000060745126,0.0049125417],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957726,0.0015779356,0.0008268081,0.00076119386,0.00031627086,0.0007451756],"domain_scores_gemma":[0.9981194,0.00056194904,0.00033315504,0.0005571054,0.00030285513,0.0001255213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012498532,0.0004030144,0.00093000673,0.00031323946,0.00026623058,0.0000485563,0.00025908288,0.000081379985,0.000055582834],"category_scores_gemma":[0.00020802785,0.0002322174,0.00007690226,0.00045858274,0.00041489565,0.0001048661,0.000101196856,0.00051604206,0.000017574954],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77249074,0.01344068,0.057645634,0.00056975696,0.009204771,0.019137535,0.0591634,0.0017644925,0.009494511,0.00019566574,0.015134322,0.041758474],"study_design_scores_gemma":[0.5932741,0.11551268,0.2234197,0.00017107287,0.004381264,0.00017462642,0.020404909,0.0022445966,0.0008897143,0.00007364006,0.038568385,0.00088530564],"about_ca_topic_score_codex":0.00036081744,"about_ca_topic_score_gemma":0.002207151,"teacher_disagreement_score":0.17921664,"about_ca_system_score_codex":0.0007317801,"about_ca_system_score_gemma":0.0016000374,"threshold_uncertainty_score":0.9469551},"labels":[],"label_agreement":null},{"id":"W4416407902","doi":"10.1101/2025.11.16.688689","title":"ProMPt: A modular preclinical platform for functional modelling of prostate cancer heterogeneity and therapeutic vulnerabilities","year":2025,"lang":"","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Prostate Cancer UK; Cancer Research UK; American Association for Cancer Research","keywords":"Prostate cancer; Prostate; Immune system; Organoid; Transcriptome; CRISPR; Disease; Immunotherapy","score_opus":0.08290485378842888,"score_gpt":0.32042814807391456,"score_spread":0.2375232942854857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416407902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93819356,0.04268017,0.00731127,0.00059968675,0.0012981347,0.006982052,0.0028014337,0.00012863055,0.0000050321087],"genre_scores_gemma":[0.97851384,0.0137196,0.0024936842,0.00012380355,0.0006124064,0.0042775096,0.0000036059048,0.00013198731,0.00012353824],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99423283,0.00019742415,0.0015620323,0.0019803506,0.0008558491,0.0011714954],"domain_scores_gemma":[0.9948625,0.00059816823,0.000677791,0.0012857964,0.0020546508,0.00052106933],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016885598,0.0010089226,0.0017584619,0.00045098588,0.00046381075,0.00014591418,0.00037613502,0.00089013873,0.000058556343],"category_scores_gemma":[0.0002070912,0.0009044387,0.0005066922,0.00050500873,0.00085535843,0.00020741556,0.00050124957,0.0012174003,0.0000030236038],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031156192,0.00558244,0.3716044,0.0742658,0.01920241,0.00006861249,0.0007424884,0.059076287,0.4338996,0.0037134115,0.0001695496,0.00051879697],"study_design_scores_gemma":[0.015324685,0.0021450638,0.08189117,0.009001957,0.0035394744,8.1803336e-8,0.000057674064,0.23847222,0.6436951,0.00013400339,0.0036769188,0.0020616495],"about_ca_topic_score_codex":0.0002094208,"about_ca_topic_score_gemma":0.00001055788,"teacher_disagreement_score":0.28971323,"about_ca_system_score_codex":0.00079944613,"about_ca_system_score_gemma":0.0043588863,"threshold_uncertainty_score":0.99934065},"labels":[],"label_agreement":null},{"id":"W4416413208","doi":"10.3390/cells14221828","title":"FGF12 Enhances Prostate Cancer Cell Survival via the YB1-lncRNA Axis","year":2025,"lang":"en","type":"article","venue":"Cells","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"","keywords":"Prostate cancer; Gene silencing; Long non-coding RNA; Transcriptome; Downregulation and upregulation; Regulator; Prostate; Cell growth; Cancer; Etoposide","score_opus":0.015291066747850598,"score_gpt":0.31873716434264077,"score_spread":0.3034460975947902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416413208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77935493,0.03428109,0.00012996235,0.0093954485,0.0023593467,0.0019520939,0.00006265869,0.00012281224,0.17234163],"genre_scores_gemma":[0.80168694,0.0089951595,0.000045774916,0.0004696115,0.00018513459,0.00016367508,0.000018675199,0.00001789015,0.18841715],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99881715,0.000059394788,0.00017732446,0.00028144047,0.00027457371,0.00039011202],"domain_scores_gemma":[0.9992916,0.00010723232,0.000044831748,0.0003441237,0.000117012,0.00009522393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021178777,0.00015721822,0.00022926014,0.00004592648,0.00016719537,0.000036696416,0.00016398792,0.000062497216,0.000822689],"category_scores_gemma":[0.000008370518,0.00008871453,0.000093320275,0.0002828792,0.0001641786,0.00006191835,0.000076158845,0.00021094929,0.00015076943],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013285374,0.0006063041,0.019274665,0.0010082909,0.00051965046,0.00014693566,0.0030164097,0.000025062793,0.82467383,0.0001642063,0.07503229,0.074203834],"study_design_scores_gemma":[0.0016602894,0.0001504699,0.004053954,0.00012471032,0.00011107885,0.000001189852,0.000422033,0.000085796986,0.8514584,0.00019002263,0.14162108,0.000121017074],"about_ca_topic_score_codex":0.0007278207,"about_ca_topic_score_gemma":0.0001913388,"teacher_disagreement_score":0.07408282,"about_ca_system_score_codex":0.00017999049,"about_ca_system_score_gemma":0.00033350562,"threshold_uncertainty_score":0.90078676},"labels":[],"label_agreement":null},{"id":"W4416535078","doi":"10.1016/j.ebiom.2025.105983","title":"Corrigendum to “A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network” EBioMedicine 2018 Sep: 35: 167-177","year":2025,"lang":"en","type":"erratum","venue":"EBioMedicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; China Scholarship Council; National Natural Science Foundation of China","keywords":"Mechanism (biology); Prostate cancer; Gene; Cancer; Chromoplexy","score_opus":0.027745466870431612,"score_gpt":0.31122023376141583,"score_spread":0.2834747668909842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416535078","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.047594745,0.23881756,0.018207768,0.1672433,0.40206066,0.07956207,0.004862787,0.0023514116,0.039299693],"genre_scores_gemma":[0.024035392,0.01298916,0.006941623,0.0044925436,0.010312813,0.0029188674,0.011156752,0.00056392315,0.92658895],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.991322,0.00012203101,0.0023736514,0.0018366197,0.002151031,0.0021946714],"domain_scores_gemma":[0.99626213,0.00008548009,0.0007909275,0.0011666527,0.00070430926,0.0009904997],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00096475333,0.0013390064,0.0030902075,0.002545253,0.00022716056,0.000027061584,0.00068876473,0.00046690748,0.00058297144],"category_scores_gemma":[0.00024653383,0.0010341045,0.0002545762,0.0039561284,0.00039966413,0.00010797038,0.0007272999,0.0020701473,0.00004808437],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028283456,0.0022009509,0.0016895513,0.0091593405,0.0016652717,0.004140983,0.0035374663,0.000014377391,0.037250593,0.00005343413,0.8802788,0.057180855],"study_design_scores_gemma":[0.02835858,0.0057663894,0.006357759,0.03620705,0.0013486091,0.00052452047,0.00036942388,0.0018729261,0.02217835,0.00026352418,0.89501673,0.0017361601],"about_ca_topic_score_codex":0.0019084312,"about_ca_topic_score_gemma":0.00059004,"teacher_disagreement_score":0.8872892,"about_ca_system_score_codex":0.0017240847,"about_ca_system_score_gemma":0.005185463,"threshold_uncertainty_score":0.9999361},"labels":[],"label_agreement":null},{"id":"W4416630327","doi":"10.1158/1078-0432.30708732","title":"Supplementary Material 1 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial","year":2025,"lang":"","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Amgen Canada; Sanofi; Amgen","keywords":"Cabazitaxel; Prostate; Prostate cancer; Phases of clinical research; Clinical trial; Tirapazamine","score_opus":0.011528298888380807,"score_gpt":0.3039740035212628,"score_spread":0.292445704632882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416630327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9162569,0.001212205,0.000015698526,0.0034249395,0.005058741,0.013135734,0.060630154,0.00008475973,0.00018087601],"genre_scores_gemma":[0.9613863,0.0059776125,0.00040834802,0.00052814843,0.00096616044,0.0017149055,0.017952202,0.00015761795,0.010908663],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99129254,0.000571297,0.0022424029,0.0020583167,0.001438995,0.0023964236],"domain_scores_gemma":[0.99687123,0.00018514069,0.0006653716,0.0011827938,0.0004270386,0.00066839793],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006558652,0.0013509587,0.0021912267,0.0008272645,0.0006723366,0.00029538298,0.0006115794,0.00040045095,0.014649047],"category_scores_gemma":[0.000062687155,0.0009631497,0.00023475419,0.0009896427,0.0005722854,0.00056715106,0.000798665,0.0011302313,0.000044079774],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7985071,0.008479038,0.12453317,0.00041773394,0.0031399222,0.00046839062,0.0034928613,0.00013051096,0.001272537,0.000018256873,0.01066426,0.04887625],"study_design_scores_gemma":[0.8857268,0.0313089,0.021289956,0.0019046881,0.0023614862,8.897563e-7,0.0011609467,0.0004945189,0.046883132,0.00024890888,0.0074197124,0.001200054],"about_ca_topic_score_codex":0.11846981,"about_ca_topic_score_gemma":0.012329971,"teacher_disagreement_score":0.10613984,"about_ca_system_score_codex":0.0031592636,"about_ca_system_score_gemma":0.0034643717,"threshold_uncertainty_score":0.9999241},"labels":[],"label_agreement":null},{"id":"W4416723076","doi":"10.5489/cuaj.9363","title":"Case - Long-term management of oligo-progressive metastatic castrate sensitive prostate cancer with recurrence-directed radiotherapy","year":2025,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Radiation therapy; Prostate cancer; Cancer; Chemotherapy; Management of prostate cancer; Prostate","score_opus":0.021916300026258516,"score_gpt":0.3181871558230278,"score_spread":0.2962708557967693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416723076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98763895,0.0030966452,0.000073592615,0.007167158,0.0001667934,0.0008120073,0.00013405146,0.000025481439,0.0008853191],"genre_scores_gemma":[0.99441236,0.0016347468,0.000739454,0.0005783055,0.00006175013,0.00006539497,0.00003384793,0.000011913885,0.0024622483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984265,0.00020001248,0.00030651878,0.0002310892,0.0003251485,0.00051075884],"domain_scores_gemma":[0.99852294,0.000071777315,0.00027361372,0.000104498686,0.000602753,0.00042441388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034477943,0.0001711757,0.00037679874,0.00027031061,0.00022268233,0.00006049563,0.000067136345,0.00008665942,0.00027842625],"category_scores_gemma":[0.00003667021,0.000113946095,0.00008681502,0.0005653532,0.00010264746,0.00007636002,0.000010818442,0.00042654198,0.000002602524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018890084,0.00022618989,0.8594677,0.00020541223,0.0052647297,0.0799444,0.00079914986,0.000086008455,0.00011434488,0.00016753297,0.0022749044,0.049560606],"study_design_scores_gemma":[0.010123613,0.0016933138,0.97538775,0.0008918093,0.0012860295,0.0068549425,0.0007120025,0.00043464097,0.0010210116,0.00017467902,0.0010798093,0.00034042093],"about_ca_topic_score_codex":0.0009140758,"about_ca_topic_score_gemma":0.001111021,"teacher_disagreement_score":0.115920015,"about_ca_system_score_codex":0.0016073663,"about_ca_system_score_gemma":0.0010758474,"threshold_uncertainty_score":0.4646587},"labels":[],"label_agreement":null},{"id":"W4416723153","doi":"10.5489/cuaj.9278","title":"Case - Non-metastatic castration-resistant prostate cancer in a transgender woman","year":2025,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Prostate cancer; Disease; Cancer; MEDLINE","score_opus":0.026779747204327395,"score_gpt":0.31366189264180966,"score_spread":0.28688214543748225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416723153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95421195,0.0008447417,0.00002149143,0.041626755,0.00020119833,0.000515282,0.00010566511,0.000012291482,0.0024606392],"genre_scores_gemma":[0.9936245,0.00024159357,0.00007736442,0.0021513365,0.000075919204,0.000069908114,0.000016443722,0.00000834798,0.0037345518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984885,0.00012891505,0.0003562108,0.00019904786,0.0002556459,0.0005717141],"domain_scores_gemma":[0.9990351,0.000089389934,0.00009408429,0.00008154921,0.00022071415,0.0004791551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005286298,0.00013311054,0.0002635081,0.00042080923,0.00024902998,0.00009048937,0.00006271562,0.000118554395,0.0006100058],"category_scores_gemma":[0.00015553318,0.000101456055,0.000093020455,0.00053868955,0.000036356894,0.000092399794,0.0000060440516,0.0006000538,0.0000117162535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007166165,0.00022527736,0.9412781,0.00007340062,0.0005213624,0.031299938,0.0014241897,0.00031042987,0.001423351,0.00016408315,0.010662272,0.011900999],"study_design_scores_gemma":[0.008053775,0.00053902133,0.96987814,0.00013014981,0.00022621154,0.0017886454,0.0010305565,0.0008479507,0.00017753772,0.0012298884,0.015845342,0.00025280064],"about_ca_topic_score_codex":0.0064982013,"about_ca_topic_score_gemma":0.0298358,"teacher_disagreement_score":0.03947542,"about_ca_system_score_codex":0.0025586379,"about_ca_system_score_gemma":0.002412256,"threshold_uncertainty_score":0.9878672},"labels":[],"label_agreement":null},{"id":"W4416790102","doi":"10.1080/14796694.2025.2592722","title":"A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma Europe; Astellas Pharma; Bayer HealthCare","keywords":"Enzalutamide; Prostate cancer; Plain language; Cancer; Prostate","score_opus":0.011137181841712232,"score_gpt":0.31419172156580727,"score_spread":0.303054539724095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416790102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98545575,0.009806792,0.0000025045788,0.0011394329,0.00014482338,0.0028357324,0.00029471287,0.00001329901,0.00030698016],"genre_scores_gemma":[0.9975369,0.00053576677,0.00025142636,0.000164995,0.000038827544,0.0002769558,0.00008451286,0.000020921365,0.0010896715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979212,0.00043457357,0.0005373239,0.0003589246,0.00040991072,0.00033803168],"domain_scores_gemma":[0.99889046,0.00022533601,0.00026638497,0.00035459167,0.00017873413,0.00008447014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042851348,0.00023591638,0.00085618324,0.00028679165,0.00008009219,0.000009108541,0.00012193638,0.000080721926,0.000033573786],"category_scores_gemma":[0.00007525669,0.00013620885,0.00005823583,0.00066644565,0.00026751458,0.00007449236,0.00010696833,0.00032076842,3.8127692e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051256977,0.008919293,0.87685287,0.0019722977,0.0027249963,0.00097808,0.027638039,0.00020037006,0.0058061047,0.0002788041,0.003244985,0.020127205],"study_design_scores_gemma":[0.0537621,0.0068823094,0.90589887,0.00068451435,0.001346634,0.000018109338,0.02141012,0.000038090348,0.0061827074,0.000039002258,0.003499837,0.00023768416],"about_ca_topic_score_codex":0.00213689,"about_ca_topic_score_gemma":0.01705232,"teacher_disagreement_score":0.02904604,"about_ca_system_score_codex":0.00044847035,"about_ca_system_score_gemma":0.0010848707,"threshold_uncertainty_score":0.95155954},"labels":[],"label_agreement":null},{"id":"W4416866070","doi":"10.1158/1078-0432.ccr-25-3327","title":"A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"National Institute of Biomedical Imaging and Bioengineering; National Institutes of Health; National Cancer Institute; U.S. Department of Defense; National Heart, Lung, and Blood Institute; U.S. Department of Veterans Affairs","keywords":"Docetaxel; Prostate cancer; Androgen receptor; Prostate; Clinical trial; Cancer; Androgen","score_opus":0.15096268327338347,"score_gpt":0.5233388552715308,"score_spread":0.3723761719981473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416866070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9700078,0.008763438,0.00067648967,0.017280776,0.00016896128,0.002346341,0.00039397264,0.000040097082,0.00032212734],"genre_scores_gemma":[0.96862113,0.018343389,0.002403725,0.0011956337,0.00011116858,0.0021636384,0.00006043841,0.000035176537,0.007065671],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961857,0.00049822754,0.0007745677,0.0008883779,0.00081107003,0.00084204157],"domain_scores_gemma":[0.99721026,0.001187393,0.00006691829,0.00036512353,0.0006936102,0.0004766774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029927082,0.00021197497,0.00074564986,0.0006531039,0.00018836316,0.00005131945,0.0002112931,0.00015524212,0.00016546028],"category_scores_gemma":[0.00082047493,0.00016298235,0.00010035285,0.0012744518,0.0007038922,0.00008307411,0.00036475062,0.0012923881,0.000022888895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012782926,0.0009660212,0.77801603,0.00076937885,0.00045998915,0.00039403848,0.0006607816,0.028772343,0.000108898574,0.001395274,0.0078399265,0.16783439],"study_design_scores_gemma":[0.042068664,0.0029357306,0.66444486,0.0019102577,0.00037547597,0.000014413728,0.00039138796,0.21724743,0.00038402842,0.06299043,0.0067175785,0.00051974616],"about_ca_topic_score_codex":0.0037931046,"about_ca_topic_score_gemma":0.0015099102,"teacher_disagreement_score":0.18847509,"about_ca_system_score_codex":0.00049590116,"about_ca_system_score_gemma":0.0021857705,"threshold_uncertainty_score":0.6646228},"labels":[],"label_agreement":null},{"id":"W4416901850","doi":"10.3390/ijms262311651","title":"Development and In Vitro Evaluation of [64Cu]Cu-NOTA-TP-PSMA, a Novel Radiotheranostic Agent Against Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"LNCaP; Prostate cancer; Cytotoxicity; In vivo; Glutamate carboxypeptidase II; In vitro; Cancer cell; Cancer","score_opus":0.04478195826226714,"score_gpt":0.39327912444163404,"score_spread":0.3484971661793669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416901850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885701,0.0075135077,0.00042366263,0.0024429064,0.00028934915,0.00022018849,0.0000043240248,0.0000016337661,0.000534327],"genre_scores_gemma":[0.99588716,0.0006446364,0.0030910932,0.00024991424,0.000021996319,0.000013789129,0.0000024986773,0.000003128776,0.00008579057],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99823874,0.00004040658,0.0003397201,0.00012579946,0.0011413506,0.000113995855],"domain_scores_gemma":[0.99907565,0.00003713002,0.00016271473,0.00004307118,0.00063502305,0.00004638652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010533356,0.00007124647,0.00015733347,0.00046409093,0.000030899533,0.00003206434,0.0001603306,0.00002341088,0.000013418851],"category_scores_gemma":[0.0001295284,0.000050844475,0.00004227617,0.00025350152,0.00014636973,0.000093342234,0.00003721695,0.000089931316,2.9138167e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074380403,0.00023335632,0.011657811,0.00003470554,0.00030636688,0.00008885091,0.0012534562,0.0014358826,0.82147044,0.000074632706,0.000021475935,0.16267923],"study_design_scores_gemma":[0.00973103,0.00017779371,0.06964096,0.0014368946,0.00012796967,0.000055901528,0.0006445336,0.008807525,0.9075973,0.0003203678,0.0013258083,0.00013392864],"about_ca_topic_score_codex":0.00003315644,"about_ca_topic_score_gemma":0.00001552633,"teacher_disagreement_score":0.1625453,"about_ca_system_score_codex":0.00034852838,"about_ca_system_score_gemma":0.0015362964,"threshold_uncertainty_score":0.2725324},"labels":[],"label_agreement":null},{"id":"W4416907770","doi":"10.5489/cuaj.9401","title":"Expert opinion on the management of anemia in prostate cancer patients receiving PARP inhibitors","year":2025,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Fluidigm (Canada); Université de Montréal; Impact; Centre Hospitalier de l’Université de Montréal; Occupational Cancer Research Centre; University of Toronto; London Health Sciences Centre","funders":"Pfizer Canada; Pfizer","keywords":"Expert opinion; Prostate cancer; Anemia; PARP inhibitor; Disease; Cancer; Quality of life (healthcare)","score_opus":0.03644829252128018,"score_gpt":0.3388889732555034,"score_spread":0.3024406807342232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416907770","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00076629437,0.9884907,1.2238252e-7,0.0061599095,0.00067885837,0.0013662188,0.000087188084,0.0000070974957,0.0024436181],"genre_scores_gemma":[0.0017197256,0.99622667,0.000009422178,0.0004909657,0.00019031046,0.00020156665,0.00009520632,0.000014436891,0.0010516898],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997826,0.00034406493,0.00061077875,0.00024390731,0.00049161667,0.0004836455],"domain_scores_gemma":[0.9986893,0.00026491217,0.00046298726,0.00013248394,0.0001835453,0.00026675026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007075279,0.0002283458,0.00073028676,0.00039585904,0.00014661235,0.000042031374,0.00017694413,0.00027020238,0.00018490746],"category_scores_gemma":[0.00021018357,0.00012672046,0.00024884197,0.0005696918,0.000031472006,0.000035520985,0.000035428006,0.00097204,0.000009324848],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059979302,0.0001239267,0.04311437,0.0017662107,0.00040818733,0.000085340325,0.00012741124,0.0000028218362,5.1922804e-8,0.000047965103,0.02117041,0.9330933],"study_design_scores_gemma":[0.0009008428,0.00023590452,0.019637238,0.014915932,0.00010899021,0.0000038049816,0.000044231074,0.000001271584,7.4631316e-7,0.00004790432,0.96397144,0.00013171739],"about_ca_topic_score_codex":0.0006070543,"about_ca_topic_score_gemma":0.00020381287,"teacher_disagreement_score":0.942801,"about_ca_system_score_codex":0.0043080375,"about_ca_system_score_gemma":0.0012753379,"threshold_uncertainty_score":0.9995142},"labels":[],"label_agreement":null},{"id":"W4417000373","doi":"10.1172/jci196495","title":"Noncanonical functions of UGT2B17 promote castration-resistant prostate cancer progression","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Université Laval; Centre hospitalier universitaire de Québec; Centre hospitalier de l'Université Laval; Vancouver General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Prostate cancer; Tumor progression; Prostate; Cell growth; Androgen; Downregulation and upregulation; Transcription (linguistics); Androgen deprivation therapy","score_opus":0.10355666009587816,"score_gpt":0.4807232916004244,"score_spread":0.3771666315045462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417000373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98508555,0.0013412235,0.00009481226,0.011545314,0.0005905774,0.00052247953,0.0000133686635,0.000010852034,0.0007958314],"genre_scores_gemma":[0.99352884,0.0006815807,0.0023452784,0.00021242774,0.00033535162,0.000023720675,0.000018756215,0.000009862644,0.0028441965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757475,0.00015835348,0.0014677861,0.00015731447,0.00048611828,0.00015566418],"domain_scores_gemma":[0.997603,0.00022864371,0.0007757176,0.00015856592,0.001004838,0.00022924517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012683925,0.00010437731,0.00047888723,0.0001735524,0.00007254337,0.000020464047,0.00008080578,0.00014198828,0.000053192907],"category_scores_gemma":[0.0009529883,0.000068245055,0.00022316627,0.00040092983,0.00035235967,0.00016961803,0.000025328218,0.00049573666,0.0000030035412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008974097,0.0013858005,0.6997412,0.0008349136,0.0009241992,0.000116490795,0.00041314441,0.00010292301,0.12983339,0.00063162495,0.014243847,0.1427984],"study_design_scores_gemma":[0.012589236,0.0060338154,0.87520885,0.0057111853,0.001015879,0.000041261643,0.00023185408,0.00092793535,0.07657038,0.0035946532,0.01788138,0.00019356165],"about_ca_topic_score_codex":0.000024635967,"about_ca_topic_score_gemma":0.000020237709,"teacher_disagreement_score":0.17546767,"about_ca_system_score_codex":0.00010855365,"about_ca_system_score_gemma":0.0030526249,"threshold_uncertainty_score":0.54152256},"labels":[],"label_agreement":null},{"id":"W4417002263","doi":"10.1073/pnas.2500327122","title":"Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancer","year":2025,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research - Antimicrobial Resistance Research Initiative; North Spore; Canadian Institutes of Health Research; National Cancer Institute; Prostate Cancer Foundation; National Institutes of Health; Ulusal Metroloji Enstitüsü, Türkiye Bilimsel ve Teknolojik Araştirma Kurumu; Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi; Türkiye Bilimsel ve Teknolojik Araştırma Kurumu; Prostate Cancer Fight Foundation","keywords":"Prostate cancer; Transcription factor; Chromatin; Androgen receptor; Transcription (linguistics); Chromatin remodeling; Nuclear receptor","score_opus":0.06144974922191876,"score_gpt":0.39117955379978664,"score_spread":0.3297298045778679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417002263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989227,0.0001726102,5.8764203e-7,0.008723859,0.000026434442,0.000381429,0.00007231804,0.000004887654,0.0013908835],"genre_scores_gemma":[0.99861425,0.00021212545,0.00003736583,0.000028875185,0.000018361961,0.00004338002,3.1210695e-7,0.0000019915824,0.0010433486],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989065,0.0000067796773,0.00021210573,0.00016220876,0.00059788674,0.00011450209],"domain_scores_gemma":[0.99947983,0.00008179935,0.00017863922,0.0000067144124,0.00023052261,0.000022506487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023000284,0.00007475496,0.00018477572,0.0002646188,0.00006927373,0.000007936292,0.00017535704,0.000036403784,0.000022832985],"category_scores_gemma":[0.00013265849,0.000041441763,0.000067682966,0.0006384503,0.00050878077,0.00024278146,0.00004439237,0.00017651639,1.06519245e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018412687,0.00016957062,0.3883874,0.00026982045,0.00003385607,6.9974844e-9,0.00044412544,0.000005265478,0.6073465,0.0010702091,0.000099540914,0.0019895977],"study_design_scores_gemma":[0.00033900447,0.000041603165,0.5758083,0.00032531016,0.00001281478,2.3492954e-7,0.00012352696,0.00012673206,0.42149505,0.0016705618,0.000036124442,0.000020775797],"about_ca_topic_score_codex":0.00006296014,"about_ca_topic_score_gemma":0.0000030769927,"teacher_disagreement_score":0.18742086,"about_ca_system_score_codex":0.00014504732,"about_ca_system_score_gemma":0.00009292512,"threshold_uncertainty_score":0.1874624},"labels":[],"label_agreement":null},{"id":"W4417123420","doi":"10.3390/curroncol32120692","title":"Identification of Actionable Mutations in Metastatic Castration-Resistant Prostate Cancer Through Circulating Tumor DNA: Are We There Yet?","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Liquid biopsy; Circulating tumor cell; Microsatellite instability; Androgen receptor; Immune checkpoint; Blockade; Genotyping; Metastatic breast cancer; Homologous recombination","score_opus":0.14768287148129422,"score_gpt":0.47282771341374663,"score_spread":0.3251448419324524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417123420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811774,0.010612362,0.00016412452,0.0051141647,0.0006420553,0.0012302224,0.000101820195,0.000026568356,0.00093127193],"genre_scores_gemma":[0.9968074,0.0013068579,0.00012028991,0.000026871488,0.00003002988,0.0005781478,0.0000981545,0.000010142154,0.0010221214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987481,0.000105950094,0.00048486944,0.00025281482,0.00018507076,0.00022318198],"domain_scores_gemma":[0.9991244,0.00014988403,0.000251329,0.00016322524,0.00027334227,0.000037793503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002002109,0.000112611524,0.00031138936,0.0001923054,0.000091780166,0.000013796962,0.00006205964,0.00003798196,0.00010058035],"category_scores_gemma":[0.00011228374,0.00009444015,0.000058468675,0.00057233917,0.00012347985,0.00013025143,0.000023983788,0.00019940642,0.000006223813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039415215,0.007465105,0.44917306,0.010708536,0.0013778294,0.0005089863,0.017426584,0.0027908338,0.34967735,0.0129440995,0.0069050738,0.137081],"study_design_scores_gemma":[0.024350828,0.0013207652,0.7147058,0.0064484766,0.0015752239,0.00006484747,0.035117257,0.00820241,0.122722484,0.030608129,0.054150507,0.00073324185],"about_ca_topic_score_codex":0.00016163089,"about_ca_topic_score_gemma":0.00050433056,"teacher_disagreement_score":0.26553276,"about_ca_system_score_codex":0.00066565524,"about_ca_system_score_gemma":0.0011348544,"threshold_uncertainty_score":0.38511574},"labels":[],"label_agreement":null},{"id":"W4417164098","doi":"10.1038/s41391-025-01054-8","title":"Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data","year":2025,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital","funders":"National Cancer Institute; Bayer HealthCare","keywords":"Prostate cancer; Prostate; Safety profile; Benign prostatic hyperplasia (BPH); Prostatectomy; MEDLINE","score_opus":0.1944706597870142,"score_gpt":0.4340507174531086,"score_spread":0.2395800576660944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417164098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5965976,0.32646117,0.0011389613,0.008338397,0.0002568186,0.018139834,0.048751865,0.00013054609,0.00018479164],"genre_scores_gemma":[0.94672805,0.038716663,0.003005529,0.00066045736,0.00007374741,0.0031013945,0.004356622,0.000060962026,0.003296596],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9970567,0.0001607067,0.00075989816,0.000994581,0.00040275307,0.0006253469],"domain_scores_gemma":[0.9971998,0.0009816086,0.00034030617,0.0005729355,0.00059109076,0.00031428642],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002592513,0.0004934152,0.0018829462,0.00031745865,0.00042991963,0.00010663066,0.00014240858,0.000053600324,0.000053667398],"category_scores_gemma":[0.000115959934,0.00035725316,0.00032805136,0.0010159417,0.00048088934,0.00030368764,0.00023964808,0.00014923162,5.2536353e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.064225346,0.0017585395,0.14868456,0.010170035,0.6244213,0.00023188433,0.0064379317,0.0044611134,0.0010757031,0.0008137665,0.0033653416,0.13435447],"study_design_scores_gemma":[0.03300401,0.00174052,0.1803549,0.0009600669,0.7618947,0.000016676455,0.0016613344,0.011428204,0.0018734334,0.0025740287,0.0035563675,0.0009357467],"about_ca_topic_score_codex":0.00065941794,"about_ca_topic_score_gemma":0.0002109373,"teacher_disagreement_score":0.3501304,"about_ca_system_score_codex":0.00015836197,"about_ca_system_score_gemma":0.001012409,"threshold_uncertainty_score":0.99988794},"labels":[],"label_agreement":null},{"id":"W4417172069","doi":"10.1097/ju.0000000000004890","title":"Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial","year":2025,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of British Columbia","funders":"","keywords":"Enzalutamide; Recurrent prostate cancer; Prostate cancer; Clinical endpoint; Clinical trial","score_opus":0.0132571991054753,"score_gpt":0.29900999408194834,"score_spread":0.28575279497647305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417172069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975,0.0067131575,0.000021368169,0.017138194,0.00015714706,0.0008311416,0.00004272593,0.000003436473,0.00009278743],"genre_scores_gemma":[0.9937621,0.0057285675,0.00007463189,0.00015642063,0.00009103515,0.000038635866,0.000014228561,0.000009768176,0.00012465997],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99874175,0.00032710057,0.00037346198,0.00011876654,0.00024752412,0.00019138672],"domain_scores_gemma":[0.9987332,0.0004678083,0.0003575169,0.00019920964,0.00019585244,0.0000464111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000395289,0.00013252636,0.00040059342,0.0001169846,0.00005350989,0.000006739798,0.00013217071,0.000059049682,0.000055950044],"category_scores_gemma":[0.00004918136,0.00005102878,0.000052579653,0.00022173626,0.00027071874,0.00004020397,0.000022347358,0.00036059282,7.451127e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77665097,0.0019852093,0.10748164,0.000047865364,0.0022040976,0.00018557893,0.0045941244,0.00013206466,0.006302909,0.00010091835,0.0006082973,0.09970635],"study_design_scores_gemma":[0.44899046,0.06238882,0.40145254,0.0005567496,0.0031949978,0.00025007973,0.0010709754,0.0001526363,0.07341737,0.005657085,0.0026364683,0.0002318057],"about_ca_topic_score_codex":0.0010754353,"about_ca_topic_score_gemma":0.00055727863,"teacher_disagreement_score":0.32766047,"about_ca_system_score_codex":0.0002173865,"about_ca_system_score_gemma":0.0008522639,"threshold_uncertainty_score":0.20808932},"labels":[],"label_agreement":null},{"id":"W4417292872","doi":"10.1016/j.eururo.2025.09.4181","title":"Re: Rebecca Voelker. What Is Prostate Cancer? JAMA. In press. https://doi.org/10.1001/jama.2025.10177","year":2025,"lang":"en","type":"letter","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Prostate; Prostate disease; Prostate cancer; MEDLINE; Prostate-specific antigen","score_opus":0.03738176383428184,"score_gpt":0.3183108469406619,"score_spread":0.2809290831063801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417292872","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014618207,0.039564896,0.0000018509447,0.7656332,0.001372984,0.0018357157,0.00016226113,0.0001966584,0.18977061],"genre_scores_gemma":[0.0013339424,0.038742173,0.00003116397,0.46268314,0.0043473113,0.00025159918,0.0015814861,0.0002075124,0.49082166],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929491,0.0014630257,0.0010440213,0.0019117204,0.0008377174,0.0017943869],"domain_scores_gemma":[0.9968905,0.00040282024,0.00040000048,0.0016206579,0.0004144051,0.00027162797],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00090321084,0.00095936854,0.0014122674,0.000741398,0.0001745979,0.00035889557,0.00093123433,0.0011297172,0.0075010997],"category_scores_gemma":[0.0003121813,0.00080810324,0.0003529729,0.00066374347,0.00055739156,0.00048499394,0.0008119049,0.0076603945,0.0036770497],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019950347,0.00014187161,0.0019799678,0.0009188024,0.0005571202,0.019016942,0.0010597561,0.0000066018983,0.000075776385,0.000005870949,0.95227623,0.021966007],"study_design_scores_gemma":[0.0059852554,0.00096938846,0.0026338745,0.0009838843,0.00041150846,0.000025131008,0.00007431854,0.000041542673,0.0003756091,0.00005582713,0.9878622,0.0005814445],"about_ca_topic_score_codex":0.00071766035,"about_ca_topic_score_gemma":0.0000493458,"teacher_disagreement_score":0.30295005,"about_ca_system_score_codex":0.0006154059,"about_ca_system_score_gemma":0.0009960014,"threshold_uncertainty_score":0.999437},"labels":[],"label_agreement":null},{"id":"W4417410971","doi":"10.1038/s41467-025-67298-z","title":"Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Mount Sinai Hospital; Centre Hospitalier de l’Université de Montréal; Ottawa Hospital","funders":"Prostate Cancer Foundation","keywords":"Enzalutamide; Prostate cancer; Nomogram; Logistic regression; Confidence interval; Brier score; Cohort; Prostate-specific antigen; Androgen receptor","score_opus":0.030418995896594418,"score_gpt":0.35969648968111523,"score_spread":0.3292774937845208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417410971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90152013,0.06631653,0.00002056628,0.025046969,0.00014747254,0.002396838,0.00038435453,0.00012634811,0.0040407977],"genre_scores_gemma":[0.9660445,0.023176322,0.0013354523,0.00030034975,0.000018556904,0.00056730345,0.0003615575,0.00002476089,0.008171201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982415,0.00042737453,0.00034876144,0.00033127447,0.00028720914,0.00036388813],"domain_scores_gemma":[0.9977382,0.00036249685,0.000080794096,0.001263279,0.00045475,0.0001005091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006725236,0.00018835368,0.00032464217,0.000530133,0.0003000155,0.000054748827,0.00029524643,0.0001790956,0.000017486933],"category_scores_gemma":[0.00016576567,0.00015891016,0.0000751151,0.0014988413,0.00025587526,0.0001906999,0.00020134676,0.0013405612,0.000027855647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06205215,0.0042796107,0.40104157,0.0003852026,0.002065418,0.00039287415,0.026862225,0.0001745987,0.3856895,0.0056179785,0.076809555,0.034629308],"study_design_scores_gemma":[0.0045786193,0.00038129606,0.892859,0.0004640446,0.00010488425,0.00000824684,0.0010092185,0.0005537243,0.0066316915,0.00025232104,0.09298169,0.00017531039],"about_ca_topic_score_codex":0.00030385284,"about_ca_topic_score_gemma":0.00030134918,"teacher_disagreement_score":0.49181738,"about_ca_system_score_codex":0.00058279774,"about_ca_system_score_gemma":0.0007215816,"threshold_uncertainty_score":0.6480168},"labels":[],"label_agreement":null},{"id":"W4417464386","doi":"10.51731/cjht.2025.1309","title":"Darolutamide (Nubeqa)","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Enzalutamide; Agency (philosophy); Drug; Drug approval","score_opus":0.032991687298584586,"score_gpt":0.357982561488245,"score_spread":0.3249908741896604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417464386","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033526633,0.7035656,0.00020673749,0.2560055,0.0024283226,0.0006492794,0.000050777166,0.00006866153,0.003498498],"genre_scores_gemma":[0.9629435,0.03131777,0.00022717757,0.001267617,0.00003609764,0.000010055458,0.0000042469533,0.000023070374,0.0041704914],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99635035,0.00015178965,0.00135436,0.00029365145,0.00035625868,0.0014935982],"domain_scores_gemma":[0.99769235,0.0001499646,0.0006129743,0.00058319984,0.0006229027,0.00033861172],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015855586,0.00031260564,0.001076719,0.0031206813,0.0007153296,0.0000994899,0.0007589969,0.00044658882,0.00014401472],"category_scores_gemma":[0.0014353588,0.00025250972,0.00023957767,0.0015771686,0.0011222516,0.00016640121,0.00006963653,0.0016960307,0.00003463945],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001465753,0.000059833976,0.017938891,0.0009364994,0.0004768112,0.0012120534,0.00035192366,0.0000062884333,0.000051597053,0.0021628407,0.04576395,0.9308927],"study_design_scores_gemma":[0.0049729166,0.0028425262,0.03499157,0.008088119,0.00023654968,0.00039964556,0.017599087,0.000040215677,0.0037266563,0.013283455,0.91348755,0.00033170867],"about_ca_topic_score_codex":0.008234777,"about_ca_topic_score_gemma":0.0047931084,"teacher_disagreement_score":0.930561,"about_ca_system_score_codex":0.0036522727,"about_ca_system_score_gemma":0.049087558,"threshold_uncertainty_score":0.9999927},"labels":[],"label_agreement":null},{"id":"W4417479712","doi":"10.1016/j.jval.2025.09.363","title":"PT3 Radiographic Progression-Free Survival (rPFS) as a Surrogate Endpoint for Overall Survival (OS) in First-Line (1L) Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Meta-Analysis and Surrogate Threshold Effect","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Surrogate endpoint; Overall survival; Prostate cancer; Clinical endpoint; Survival analysis; Radiography","score_opus":0.08465402437305819,"score_gpt":0.4039227690628208,"score_spread":0.31926874468976263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417479712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9202788,0.046735696,0.00008095215,0.022381095,0.00033467193,0.0088776145,0.0010669224,0.000089026085,0.00015521917],"genre_scores_gemma":[0.9861735,0.008439464,0.00070267287,0.0002715749,0.00005109346,0.0030515075,0.00038790875,0.00006011378,0.0008621632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99451166,0.0009875189,0.0013220428,0.001089443,0.0009359663,0.0011533683],"domain_scores_gemma":[0.99652094,0.0017046822,0.0003473504,0.0007822334,0.00022975728,0.0004150579],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0054281927,0.00057101616,0.002552363,0.0017661275,0.00027237498,0.00010595733,0.0002489317,0.00013285254,0.00009311426],"category_scores_gemma":[0.0004436051,0.00040441606,0.0007937645,0.0029017136,0.00018458499,0.00018072434,0.0001334342,0.00054447027,0.0000023190223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041758724,0.0035193977,0.78477687,0.023062347,0.10612352,0.0015537771,0.004504414,0.020405004,0.0010536625,0.005700644,0.0006714125,0.006870229],"study_design_scores_gemma":[0.15450548,0.019226566,0.5448653,0.0053046173,0.13588008,0.000058805308,0.0013517871,0.10093145,0.006366217,0.022731781,0.005381486,0.0033964212],"about_ca_topic_score_codex":0.03057456,"about_ca_topic_score_gemma":0.03985755,"teacher_disagreement_score":0.23991156,"about_ca_system_score_codex":0.00062886963,"about_ca_system_score_gemma":0.0014516418,"threshold_uncertainty_score":0.9998408},"labels":[],"label_agreement":null},{"id":"W4417479855","doi":"10.1016/j.jval.2025.09.1538","title":"HPR131 Launches of Oncology Products in LATAM vs. the United States","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Network for Business Sustainability","funders":"","keywords":"Radiation oncology; Clinical Oncology; MEDLINE","score_opus":0.09250560443434454,"score_gpt":0.41100032086951166,"score_spread":0.31849471643516714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417479855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8811574,0.0038464542,0.0000022684405,0.11310661,0.000110406094,0.00088768586,0.000009380826,0.000012717148,0.0008670584],"genre_scores_gemma":[0.9895078,0.0068508023,0.00022801168,0.0017008112,0.000035643756,0.00005836817,0.00009006902,0.000008305272,0.0015201932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988629,0.00027398366,0.00029989632,0.0001619012,0.00013275996,0.0002685429],"domain_scores_gemma":[0.9992922,0.00031250162,0.000055397693,0.0002227012,0.00007410919,0.00004312086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009987109,0.00006740944,0.0002598091,0.0003495702,0.000031672967,0.0000029794783,0.00008052335,0.000046811885,0.000010613001],"category_scores_gemma":[0.00021706798,0.000040660183,0.00001656531,0.0011567958,0.00011295378,0.000017859984,0.00003953202,0.00025379288,0.0000034229945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003999797,0.0024977922,0.8820858,0.0069006328,0.00016128377,0.00016838199,0.018589538,0.0046082335,0.0006521058,0.008090416,0.02427284,0.047973182],"study_design_scores_gemma":[0.015854951,0.005270606,0.54900134,0.003768356,0.000044667555,0.000017533115,0.005848761,0.011576231,0.01207178,0.0067952126,0.38951954,0.00023103009],"about_ca_topic_score_codex":0.017126469,"about_ca_topic_score_gemma":0.00033702003,"teacher_disagreement_score":0.3652467,"about_ca_system_score_codex":0.00043797094,"about_ca_system_score_gemma":0.0016239159,"threshold_uncertainty_score":0.98941857},"labels":[],"label_agreement":null},{"id":"W4417481186","doi":"10.1016/j.jval.2025.09.159","title":"CO57 Comparative Efficacy of First-Line (1L) Therapies for Patients With Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC): An Updated Systematic Literature Review (SLR) and Bayesian Network Meta-Analyses (NMAs)","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Prostate cancer; Systematic review; Clinical trial; Bayesian network; Clinical Practice; Meta-analysis","score_opus":0.11106918028399532,"score_gpt":0.4253436144722152,"score_spread":0.3142744341882199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417481186","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35776755,0.6129913,0.0004445022,0.0049328515,0.00010509543,0.023052497,0.00059887493,0.000072118426,0.00003522851],"genre_scores_gemma":[0.96414495,0.02658579,0.0053653726,0.00063167425,0.000026749422,0.0020452063,0.00092708704,0.000042622643,0.00023057299],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9962091,0.0008766672,0.0014554814,0.00047096083,0.00050818344,0.0004796036],"domain_scores_gemma":[0.99722886,0.000803056,0.0007046621,0.0004828145,0.0005794,0.00020121381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011725447,0.00040273895,0.00249904,0.00029448126,0.00020048575,0.00006175168,0.00012970972,0.00005592106,0.000026947617],"category_scores_gemma":[0.00012108167,0.00022711576,0.0001713531,0.0013049549,0.00013015118,0.00018303923,0.000023965953,0.00019839205,5.0196246e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047269235,0.0031000962,0.032494184,0.9085848,0.026505971,0.00004056978,0.012284986,0.008608156,0.000046789395,0.0010252636,0.0017731118,0.00080919015],"study_design_scores_gemma":[0.040642425,0.015332163,0.073152244,0.73846155,0.041494515,0.000029088253,0.0019047827,0.08515309,0.00036672963,0.0017502266,0.00036293428,0.0013502174],"about_ca_topic_score_codex":0.00040709515,"about_ca_topic_score_gemma":0.00041147665,"teacher_disagreement_score":0.60637736,"about_ca_system_score_codex":0.00025146862,"about_ca_system_score_gemma":0.00062673975,"threshold_uncertainty_score":0.9261512},"labels":[],"label_agreement":null},{"id":"W53088226","doi":"","title":"Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians.","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto East General Hospital","funders":"","keywords":"Medicine; Overdiagnosis; Prostate cancer; Prostate-specific antigen; Oncology; Prostate cancer screening; Randomized controlled trial; Internal medicine; Cancer; Prostate; Cancer screening; Gynecology","score_opus":0.030761374717068492,"score_gpt":0.29650077656970064,"score_spread":0.2657394018526322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W53088226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862221,0.0050441273,0.000011890505,0.0020532364,0.000271481,0.0051547517,0.000351329,0.0001162146,0.0007748792],"genre_scores_gemma":[0.9856273,0.0022748243,0.0011836024,0.00036744445,0.00051337125,0.007224793,0.0008165843,0.00007440361,0.0019176734],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982671,0.00002019618,0.00019263028,0.00051739404,0.0002819581,0.0007206865],"domain_scores_gemma":[0.99893713,0.000031179705,0.00007468095,0.0003436026,0.00028345737,0.00032997545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018094269,0.00022079499,0.00031249644,0.000115127325,0.00019506802,0.000092119706,0.00010711973,0.00009275206,0.00001310889],"category_scores_gemma":[0.00001720866,0.00017226623,0.000066047825,0.00019127372,0.00020886725,0.00026634656,0.000057235637,0.00027951165,0.0000029441803],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015545317,0.00014750568,0.115440436,0.0003410157,0.00008738447,0.000027152579,0.0009900036,9.174442e-7,0.00892243,0.000029009056,0.0012402448,0.8712194],"study_design_scores_gemma":[0.0041678892,0.0002589233,0.87422013,0.0000536687,0.000059361428,0.0000073489755,0.00027377767,0.00002067985,0.011843187,0.000070980896,0.108789556,0.00023446434],"about_ca_topic_score_codex":0.000060043614,"about_ca_topic_score_gemma":0.00010113828,"teacher_disagreement_score":0.8709849,"about_ca_system_score_codex":0.000090916874,"about_ca_system_score_gemma":0.00011384195,"threshold_uncertainty_score":0.7024813},"labels":[],"label_agreement":null},{"id":"W54720350","doi":"10.1007/978-1-60327-829-4_1","title":"Cell Biology of Prostate Cancer and Molecular Targets","year":2010,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"","keywords":"Prostate cancer; Cancer research; Stromal cell; Androgen receptor; Androgen deprivation therapy; Docetaxel; Angiogenesis; Signal transduction; Medicine; Biology; Cancer; Bioinformatics; Internal medicine; Cell biology","score_opus":0.016311571437937333,"score_gpt":0.30235142000070386,"score_spread":0.28603984856276654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W54720350","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020247947,0.05229303,0.0000053126128,0.0012881916,0.00016619315,0.0010387608,0.00019475874,0.000030708274,0.92473507],"genre_scores_gemma":[0.031167584,0.018791154,0.00051961845,0.00017784553,0.00007220192,0.00003501422,0.00016364921,0.000051794465,0.94902116],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99923813,0.000004055841,0.00017031185,0.0002728106,0.00012474449,0.0001899261],"domain_scores_gemma":[0.9994296,0.000016777436,0.00007987351,0.0002074642,0.00014106811,0.00012522998],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000051962405,0.0001917826,0.00039767666,0.000118998236,0.000020923128,0.0000036906365,0.000045440927,0.0003124343,0.001415142],"category_scores_gemma":[0.00000383524,0.00012677134,0.0000724327,0.000013238054,0.00027923283,0.0000118795215,0.000064402535,0.00035693965,0.000016733817],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001473902,0.00020076394,0.0062546358,0.0030319,0.0013229392,0.0006701238,0.0005190945,2.20819e-7,0.87597066,0.045021493,0.005705734,0.059828553],"study_design_scores_gemma":[0.0026839932,0.000751125,0.000083296865,0.00022558264,0.000266084,0.000010775564,0.000008417,0.000003682531,0.4373662,0.008528419,0.549813,0.00025944898],"about_ca_topic_score_codex":0.000116490046,"about_ca_topic_score_gemma":0.000017352115,"teacher_disagreement_score":0.54410726,"about_ca_system_score_codex":0.000030613453,"about_ca_system_score_gemma":0.0002263104,"threshold_uncertainty_score":0.9994977},"labels":[],"label_agreement":null},{"id":"W55002575","doi":"","title":"Prospective phase I study on testicular castration induced by radiation treatment.","year":2015,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Castration; Urology; Testosterone (patch); Radiation therapy; Prospective cohort study; Luteinizing hormone; Orchiectomy; Androgen deprivation therapy; Hormone; Internal medicine; Surgery; Cancer","score_opus":0.10581376844447275,"score_gpt":0.36832386384129673,"score_spread":0.26251009539682396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W55002575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913016,0.0001945132,0.000006849249,0.00061360357,0.00009288414,0.0047043967,0.00001566733,0.00005883601,0.003011653],"genre_scores_gemma":[0.99375683,0.000010396081,0.0000069208504,0.000033630942,0.00012933668,0.004272615,0.00011289387,0.000014071857,0.0016632937],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990606,0.00005067726,0.00011501714,0.0002334762,0.00030655228,0.00023368908],"domain_scores_gemma":[0.99942136,0.000024874622,0.000038212176,0.00016382395,0.000096741205,0.0002550182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015998121,0.00011653826,0.0001548792,0.0000813782,0.000047687197,0.000027842003,0.000026257156,0.000040130588,0.0000057888656],"category_scores_gemma":[0.00012347838,0.0000802777,0.000028472337,0.00018492916,0.00001797802,0.00008487326,0.0000059793956,0.00007354704,0.000025588646],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042466293,0.016904717,0.24646345,0.000012623505,0.0006196117,0.00027080014,0.0036657155,0.000003834314,0.0033126755,0.000030779993,0.0033997993,0.72106934],"study_design_scores_gemma":[0.052671023,0.013958926,0.872578,0.000007878757,0.00026413464,0.000012564604,0.001280204,0.000056015753,0.057691704,0.000073677504,0.0012343813,0.00017148745],"about_ca_topic_score_codex":0.00009330808,"about_ca_topic_score_gemma":0.0000048377337,"teacher_disagreement_score":0.72089785,"about_ca_system_score_codex":0.00083830743,"about_ca_system_score_gemma":0.00011548032,"threshold_uncertainty_score":0.32736295},"labels":[],"label_agreement":null},{"id":"W577600429","doi":"","title":"Risks, benefits, and approaches to hormonal blockade in prostate cancer. Highlights from the European Association of Urology Meeting, March 20-24, 2015, Madrid, Spain.","year":2015,"lang":"en","type":"other","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital","funders":"","keywords":"Medicine; Prostate cancer; Hormone antagonist; Agonist; Gonadotropin-releasing hormone; Prednisone; Urology; Androgen deprivation therapy; Hormone; Internal medicine; Incidence (geometry); Adverse effect; Blockade; Abiraterone acetate; Testosterone (patch); Luteinizing hormone; Oncology; Endocrinology; Cancer; Receptor; Endocrine system","score_opus":0.08587948536225044,"score_gpt":0.27506074105765765,"score_spread":0.18918125569540722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W577600429","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09724766,0.30395135,0.0000020408797,0.12715998,0.001204361,0.017138144,0.0070689195,0.0002678577,0.44595966],"genre_scores_gemma":[0.1149723,0.03681658,0.00021830406,0.0004460935,0.002911539,0.004607985,0.0020870098,0.0007132998,0.83722687],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99755687,0.00046297463,0.0003137868,0.00049758115,0.0005704434,0.00059834775],"domain_scores_gemma":[0.9989226,0.00014733347,0.00028445857,0.00031347008,0.00007921199,0.00025291406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014809258,0.00027711852,0.00053245417,0.00024939326,0.00003851177,0.000025108096,0.00020478203,0.00019605862,0.000055325894],"category_scores_gemma":[0.00015778518,0.00017994415,0.00005096871,0.00026469203,0.00010181606,0.000023574154,0.00018372876,0.00040233895,0.000015796864],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008452871,0.00019065727,0.14447962,0.00013286724,0.00071122363,0.000059222886,0.00080447795,0.000018092856,0.000018106835,0.000019348432,0.7494243,0.10329681],"study_design_scores_gemma":[0.002556407,0.00009251602,0.3917476,0.00013876367,0.00020468804,0.0000022659171,0.000050579478,0.000008981736,0.000055740347,0.000036773585,0.60492635,0.00017936905],"about_ca_topic_score_codex":0.004946118,"about_ca_topic_score_gemma":0.0061414535,"teacher_disagreement_score":0.39126724,"about_ca_system_score_codex":0.00035611834,"about_ca_system_score_gemma":0.00017306421,"threshold_uncertainty_score":0.74770844},"labels":[],"label_agreement":null},{"id":"W58528846","doi":"10.1007/978-3-662-43604-2_8","title":"Clinical Trials of Low-Dose Metronomic Chemotherapy in Castration-Resistant Prostate Cancer","year":2014,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Docetaxel; Cyclophosphamide; Chemotherapy; Oncology; Prostate cancer; Clinical trial; Internal medicine; Randomized controlled trial; Cancer","score_opus":0.13885588029988724,"score_gpt":0.4577179092666787,"score_spread":0.3188620289667915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W58528846","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14501755,0.022656536,0.00006131874,0.009818252,0.0015628717,0.014768436,0.0010697121,0.00015399694,0.80489135],"genre_scores_gemma":[0.08485661,0.01760845,0.00037251212,0.00029023708,0.00060485874,0.00013157667,0.00023612112,0.00010108743,0.89579856],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99686277,0.00013657511,0.0018808007,0.00047916936,0.00035865902,0.00028204412],"domain_scores_gemma":[0.9980884,0.0005149734,0.00061815226,0.00042388137,0.0001749834,0.0001796099],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029050594,0.00032451793,0.0019222681,0.00031231178,0.00002044936,0.000014408107,0.00010936714,0.00037253983,0.0036387881],"category_scores_gemma":[0.00013555134,0.0002176199,0.00050225336,0.00004515834,0.000221825,0.0000292973,0.000028194665,0.00046180858,0.00004556812],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.071836665,0.0015422653,0.027935682,0.004744263,0.007490829,0.00045033003,0.0008117531,0.000028761287,0.022150902,0.031482607,0.035874035,0.7956519],"study_design_scores_gemma":[0.15974787,0.011114971,0.05821363,0.014239118,0.002599672,0.000023911132,0.00023227019,0.00047575892,0.033476476,0.008890604,0.708099,0.002886718],"about_ca_topic_score_codex":0.00033701147,"about_ca_topic_score_gemma":0.0004760478,"teacher_disagreement_score":0.7927652,"about_ca_system_score_codex":0.00033401806,"about_ca_system_score_gemma":0.0012091952,"threshold_uncertainty_score":0.997272},"labels":[],"label_agreement":null},{"id":"W61309911","doi":"10.1016/b978-0-12-396967-5.00014-1","title":"Prostate Cancer Genomics as a Driver of Personalized Medicine","year":2013,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Centre Hospitalier de l’Université de Montréal; Université de Montréal; University of Toronto","funders":"","keywords":"Personalized medicine; Genomics; Prostate cancer; Cancer; Medicine; Computational biology; Biology; Bioinformatics; Internal medicine; Genetics; Genome; Gene","score_opus":0.0281725920179959,"score_gpt":0.30970978133597893,"score_spread":0.28153718931798305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W61309911","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026049532,0.026094293,2.2128437e-7,0.0012773138,0.00024707374,0.0023770272,0.000103905426,0.000045690238,0.9672495],"genre_scores_gemma":[0.0008858609,0.014397462,0.00011942593,0.0005405749,0.0005349548,0.00023876848,0.0001347978,0.00014851365,0.9829996],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977018,0.00002283498,0.0005737603,0.00054261193,0.00073072565,0.00042824761],"domain_scores_gemma":[0.99820596,0.000055346874,0.0003494657,0.00055411406,0.0004986982,0.00033639718],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017559508,0.0005119732,0.0012145792,0.00027772435,0.00007238736,0.000011674991,0.0001851772,0.00033961557,0.009413875],"category_scores_gemma":[0.000020095553,0.00035192494,0.0003007022,0.000023860483,0.00094992976,0.000032222808,0.00011547899,0.00057182036,0.0003886876],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075575366,0.000028596598,0.000110789995,0.00097381114,0.0012552252,0.0002057691,0.0027553826,1.4032754e-7,0.0023290508,0.0025775414,0.0032837458,0.9857242],"study_design_scores_gemma":[0.004102909,0.00066607917,0.00008155687,0.002626154,0.0007871216,0.000045142304,0.000058259542,0.0000045942793,0.0006592862,0.0035386244,0.9871144,0.0003158577],"about_ca_topic_score_codex":0.000037270493,"about_ca_topic_score_gemma":0.000015429257,"teacher_disagreement_score":0.98540837,"about_ca_system_score_codex":0.00046068936,"about_ca_system_score_gemma":0.0009873918,"threshold_uncertainty_score":0.99989325},"labels":[],"label_agreement":null},{"id":"W6901909554","doi":"10.6084/m9.figshare.14576606.v1","title":"Additional file 4 of Functional mapping of androgen receptor enhancer activity","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"","keywords":"Androgen receptor; Enhancer; Ubiquitin-Protein Ligases; Receptor","score_opus":0.07380505446163446,"score_gpt":0.298383695458021,"score_spread":0.22457864099638655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901909554","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006510152,0.00019090668,3.4197095e-7,0.00007657976,0.000013882291,0.00008613984,0.99135935,0.000008805412,0.0076130005],"genre_scores_gemma":[0.0048104916,0.0000055716464,0.00020557323,0.000021722755,0.00011467832,0.00032860786,0.9819638,0.000006809849,0.0125427535],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994686,0.000014553913,0.00008450685,0.00011882102,0.00021813919,0.00009535263],"domain_scores_gemma":[0.9991395,0.00034532827,0.000056127916,0.000100300414,0.0003096035,0.00004915475],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00000885253,0.000052219308,0.00013040856,0.00003750168,0.00002368236,0.000002622917,0.000023489003,0.00004408519,0.9989108],"category_scores_gemma":[0.00077330944,0.00004493329,0.00007872341,0.00016798801,0.000010712643,0.000044018427,0.00003889976,0.0000755116,0.00066409074],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063475345,0.00009685817,0.000011008244,0.00022264136,0.000074575466,0.0000104992,0.000018949826,3.8805086e-7,0.0066299364,3.790061e-7,0.9885986,0.0042727245],"study_design_scores_gemma":[0.00037715613,0.00005435371,0.008225596,0.0022605548,0.0000050234303,0.000008849455,0.000027022521,0.000013907805,0.11899602,0.0000053573126,0.869986,0.00004016711],"about_ca_topic_score_codex":9.82147e-7,"about_ca_topic_score_gemma":0.0000010282325,"teacher_disagreement_score":0.99824667,"about_ca_system_score_codex":0.00004435018,"about_ca_system_score_gemma":0.00058410456,"threshold_uncertainty_score":0.8535764},"labels":[],"label_agreement":null},{"id":"W6902011044","doi":"10.6084/m9.figshare.14576597","title":"Additional file 1 of Functional mapping of androgen receptor enhancer activity","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"","keywords":"Androgen receptor; Enhancer; Receptor; Ubiquitin-Protein Ligases","score_opus":0.07477629335825108,"score_gpt":0.2984287190510678,"score_spread":0.22365242569281674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902011044","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006488555,0.00018892287,3.371909e-7,0.000077139426,0.000013870215,0.00008603332,0.9913937,0.000008802321,0.0075823674],"genre_scores_gemma":[0.0046104533,0.0000054752004,0.00020790844,0.000021691807,0.00011437628,0.0003354251,0.98194015,0.000006805094,0.012757708],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994687,0.000014572285,0.00008442858,0.00011886702,0.00021810381,0.00009534858],"domain_scores_gemma":[0.99913305,0.0003481082,0.000056106514,0.00010041234,0.00031319255,0.00004915639],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000008848947,0.000052223582,0.00013035766,0.000037495964,0.0000236711,0.0000026151117,0.000023486085,0.00004408521,0.998962],"category_scores_gemma":[0.00078622205,0.00004493663,0.00007872216,0.00016808468,0.000010709543,0.000043971988,0.000038915055,0.000075532094,0.0006716262],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006226959,0.00009682365,0.000010959172,0.00022026333,0.00007462111,0.000010310317,0.000018920491,3.941259e-7,0.0067269956,3.6618033e-7,0.988574,0.0042040413],"study_design_scores_gemma":[0.00037143892,0.00005317558,0.008204611,0.00225083,0.0000050121157,0.000008804232,0.000026967804,0.000013771597,0.118433975,0.0000052562887,0.87058616,0.000039991493],"about_ca_topic_score_codex":9.7949e-7,"about_ca_topic_score_gemma":0.0000010154233,"teacher_disagreement_score":0.99829036,"about_ca_system_score_codex":0.000044345263,"about_ca_system_score_gemma":0.0005862686,"threshold_uncertainty_score":0.863262},"labels":[],"label_agreement":null},{"id":"W6902042005","doi":"10.6084/m9.figshare.14576597.v1","title":"Additional file 1 of Functional mapping of androgen receptor enhancer activity","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"","keywords":"Androgen receptor; Enhancer; Receptor; Ubiquitin-Protein Ligases","score_opus":0.07477629335825108,"score_gpt":0.2984287190510678,"score_spread":0.22365242569281674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902042005","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006488555,0.00018892287,3.371909e-7,0.000077139426,0.000013870215,0.00008603332,0.9913937,0.000008802321,0.0075823674],"genre_scores_gemma":[0.0046104533,0.0000054752004,0.00020790844,0.000021691807,0.00011437628,0.0003354251,0.98194015,0.000006805094,0.012757708],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994687,0.000014572285,0.00008442858,0.00011886702,0.00021810381,0.00009534858],"domain_scores_gemma":[0.99913305,0.0003481082,0.000056106514,0.00010041234,0.00031319255,0.00004915639],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000008848947,0.000052223582,0.00013035766,0.000037495964,0.0000236711,0.0000026151117,0.000023486085,0.00004408521,0.998962],"category_scores_gemma":[0.00078622205,0.00004493663,0.00007872216,0.00016808468,0.000010709543,0.000043971988,0.000038915055,0.000075532094,0.0006716262],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006226959,0.00009682365,0.000010959172,0.00022026333,0.00007462111,0.000010310317,0.000018920491,3.941259e-7,0.0067269956,3.6618033e-7,0.988574,0.0042040413],"study_design_scores_gemma":[0.00037143892,0.00005317558,0.008204611,0.00225083,0.0000050121157,0.000008804232,0.000026967804,0.000013771597,0.118433975,0.0000052562887,0.87058616,0.000039991493],"about_ca_topic_score_codex":9.7949e-7,"about_ca_topic_score_gemma":0.0000010154233,"teacher_disagreement_score":0.99829036,"about_ca_system_score_codex":0.000044345263,"about_ca_system_score_gemma":0.0005862686,"threshold_uncertainty_score":0.863262},"labels":[],"label_agreement":null},{"id":"W6902055662","doi":"10.6084/m9.figshare.19522628.v1","title":"Additional file 2 of PPFIA4 promotes castration-resistant prostate cancer by enhancing mitochondrial metabolism through MTHFD2","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Prostate cancer; Table (database); Small interfering RNA; Antibody; Cancer","score_opus":0.030028876883318685,"score_gpt":0.2997547402439574,"score_spread":0.2697258633606387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902055662","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025296822,0.0015773583,7.684883e-8,0.0003856328,0.00006352144,0.00080564216,0.9953161,0.000037650265,0.0015610899],"genre_scores_gemma":[0.0020315917,0.000010873113,0.00037731446,0.00010765342,0.00027506676,0.010570602,0.9731623,0.000028758444,0.013435821],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985118,0.000050239978,0.00025058826,0.00029069462,0.0006053048,0.00029140685],"domain_scores_gemma":[0.99905056,0.0003221419,0.00014937462,0.00017864964,0.00021131159,0.00008796158],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000019056657,0.00014875771,0.00024974236,0.0000547519,0.00023247414,0.000020856522,0.000106321146,0.00004211288,0.99458534],"category_scores_gemma":[0.0005217831,0.0001272346,0.00010641533,0.0002852033,0.000020070644,0.00013184406,0.000103858,0.00024710738,0.00018144393],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029541898,0.00013620616,0.000001165289,0.0001894182,0.00009585591,0.000037267324,0.00034629536,0.0000043044756,0.012285228,0.0000017965417,0.9860993,0.0005077261],"study_design_scores_gemma":[0.001038841,0.00024522096,0.0002606093,0.0008910549,0.000028517987,0.000011543259,0.00018748594,0.00002401517,0.025068399,0.000027567512,0.9720911,0.00012566517],"about_ca_topic_score_codex":0.00007629483,"about_ca_topic_score_gemma":0.00004040421,"teacher_disagreement_score":0.9944039,"about_ca_system_score_codex":0.00016918374,"about_ca_system_score_gemma":0.0009031002,"threshold_uncertainty_score":0.51884764},"labels":[],"label_agreement":null},{"id":"W6902083148","doi":"10.6084/m9.figshare.14576600","title":"Additional file 2 of Functional mapping of androgen receptor enhancer activity","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"","keywords":"Androgen receptor; Enhancer; Ubiquitin-Protein Ligases; Receptor","score_opus":0.07170940262259497,"score_gpt":0.29767418406918184,"score_spread":0.22596478144658688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902083148","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000643761,0.0001923447,3.2887846e-7,0.00007667202,0.000013960428,0.00008584487,0.99120104,0.000008798501,0.007777218],"genre_scores_gemma":[0.004523667,0.000005638364,0.0002026194,0.000021684655,0.000116267955,0.00032796094,0.98199517,0.0000067915557,0.01280023],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99946886,0.000014566635,0.000084471794,0.00011876519,0.0002180414,0.0000953084],"domain_scores_gemma":[0.99913955,0.00034249562,0.000056196404,0.00010019244,0.00031239825,0.000049148326],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000008793774,0.00005220461,0.00013039412,0.00003746792,0.000023673081,0.0000026215973,0.00002347115,0.0000440855,0.9989392],"category_scores_gemma":[0.00077539793,0.00004491985,0.00007870477,0.00016793542,0.000010709374,0.000044006414,0.0000389088,0.000075512224,0.0006634514],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061857434,0.00009674849,0.000010558773,0.0002224552,0.00007459177,0.000010629019,0.000018931083,3.961307e-7,0.006460688,3.7340055e-7,0.9887065,0.0043362263],"study_design_scores_gemma":[0.0003725831,0.00005293538,0.008016944,0.0022087386,0.0000049678847,0.000008784996,0.00002652807,0.000013602135,0.11710628,0.0000052791543,0.8721436,0.00003970778],"about_ca_topic_score_codex":9.907751e-7,"about_ca_topic_score_gemma":0.0000010222922,"teacher_disagreement_score":0.99827576,"about_ca_system_score_codex":0.00004435978,"about_ca_system_score_gemma":0.0005832905,"threshold_uncertainty_score":0.85275465},"labels":[],"label_agreement":null},{"id":"W6902331085","doi":"10.6084/m9.figshare.29137323","title":"Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Prostate cancer; Combination therapy; Androgen deprivation therapy; Clinical trial","score_opus":0.05567308837734985,"score_gpt":0.34458053752454787,"score_spread":0.288907449147198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902331085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9125366,0.0029472888,0.000010729346,0.00015791965,0.000058011097,0.0051234053,0.07914245,0.0000054024654,0.000018180528],"genre_scores_gemma":[0.9817453,0.001065275,0.000055414017,0.000011559416,0.000015281536,0.0034531988,0.013609898,0.0000133244175,0.0000307624],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990956,0.00006349822,0.00021373219,0.00022340495,0.0002098292,0.0001939265],"domain_scores_gemma":[0.9983137,0.000907422,0.00013958038,0.00018771559,0.00040818175,0.00004334988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006471259,0.00015358209,0.00034388385,0.00007573899,0.000047756293,0.0000064989144,0.00005382803,0.000029090656,0.00027336157],"category_scores_gemma":[0.000102234066,0.00008984734,0.00005006925,0.0003378703,0.000024868865,0.00003461737,0.00001011853,0.00007190595,7.1097475e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18730645,0.0032702384,0.08315493,0.0061670826,0.008079442,0.00020826414,0.0044136746,0.0061236406,0.03504507,0.00003103958,0.005434775,0.6607654],"study_design_scores_gemma":[0.025108911,0.0028196794,0.14008673,0.0036534588,0.00020384266,0.0000016957351,0.00045204852,0.0008837036,0.8259435,0.000013682264,0.00070157356,0.00013116968],"about_ca_topic_score_codex":0.1622861,"about_ca_topic_score_gemma":0.24727164,"teacher_disagreement_score":0.79089844,"about_ca_system_score_codex":0.001016126,"about_ca_system_score_gemma":0.0026151494,"threshold_uncertainty_score":0.8432923},"labels":[],"label_agreement":null},{"id":"W6902355398","doi":"10.6084/m9.figshare.28059067.v1","title":"Additional file 1 of First preclinical SPECT/CT imaging and biodistribution of [165Er]ErCl3 and [165Er]Er-PSMA-617","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"","keywords":"Biodistribution; Medical imaging; Radiation therapy; Cancer imaging","score_opus":0.05460946636225286,"score_gpt":0.34426030178670713,"score_spread":0.28965083542445424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902355398","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016048072,0.0033190376,1.4322498e-7,0.00047873065,0.000021195014,0.0002249868,0.9919778,0.000032363172,0.0023409312],"genre_scores_gemma":[0.12985441,0.00009316532,0.00007664051,0.000017850623,0.00012951263,0.00020351702,0.86843765,0.000012335952,0.0011748915],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991942,0.000015995105,0.00019719038,0.00023691505,0.00020058203,0.0001550918],"domain_scores_gemma":[0.998708,0.0009258105,0.00004825853,0.00012114256,0.00009552037,0.000101258054],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003705034,0.00010072119,0.00019874673,0.000079592624,0.000048356385,0.000023835843,0.00004179357,0.00002367652,0.89158225],"category_scores_gemma":[0.0012108424,0.000079893696,0.00006635684,0.00015566818,0.00006809936,0.00008848712,0.0000853554,0.00015038067,0.00016300299],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054349246,0.00005056414,0.00034532818,0.0010330972,0.00005196504,0.00014218134,0.000027207176,6.872654e-8,0.000026771144,0.0000034132997,0.9878442,0.01042084],"study_design_scores_gemma":[0.0006664609,0.00021238456,0.02720462,0.009602957,0.000040587114,0.00020052827,0.00005891991,0.00071120536,0.0019580743,0.00007137794,0.95917135,0.00010155188],"about_ca_topic_score_codex":0.000006618453,"about_ca_topic_score_gemma":0.0000059535214,"teacher_disagreement_score":0.89141923,"about_ca_system_score_codex":0.000047388934,"about_ca_system_score_gemma":0.00015364707,"threshold_uncertainty_score":0.32579702},"labels":[],"label_agreement":null},{"id":"W6902375006","doi":"10.6084/m9.figshare.29578798","title":"Additional file 1 of The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study","year":2025,"lang":"en","type":"article","venue":"Open MIND","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke; Centre hospitalier universitaire de Québec","funders":"","keywords":"Prostate cancer; Sink (geography); Metastasis; Radiation therapy; Prostate","score_opus":0.04730664113897012,"score_gpt":0.38960074442906534,"score_spread":0.34229410329009524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902375006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8429259,0.00011640177,2.0736444e-7,0.0015255114,0.000015918558,0.0039477907,0.15085302,5.945157e-7,0.0006146584],"genre_scores_gemma":[0.98914367,0.000009141432,0.00007417647,0.000028462178,0.000005790573,0.0031602536,0.0027584322,0.00000704809,0.004813009],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9990004,0.00012463298,0.00028947767,0.00024746262,0.0001949231,0.00014311764],"domain_scores_gemma":[0.9982221,0.0011630831,0.00014740383,0.0002712004,0.00016227113,0.000033912027],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025966935,0.00011038618,0.00035089895,0.00015585763,0.00012699298,0.000028335737,0.00018759372,0.00000598091,0.0133468285],"category_scores_gemma":[0.00034690954,0.00005784362,0.00011205142,0.0009983187,0.00007416978,0.000048518872,0.000088198394,0.000096830525,0.000002357843],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01653378,0.012700176,0.18941197,0.0020318653,0.034196597,0.00023833071,0.0061576255,0.0015347179,0.12489516,0.0005710769,0.52045614,0.091272555],"study_design_scores_gemma":[0.004787198,0.0009894635,0.949858,0.00080918014,0.0034068513,0.000007933038,0.00070908247,0.00058364717,0.03215274,0.000087963315,0.006479506,0.0001284428],"about_ca_topic_score_codex":0.00018981977,"about_ca_topic_score_gemma":0.003394937,"teacher_disagreement_score":0.760446,"about_ca_system_score_codex":0.00010361348,"about_ca_system_score_gemma":0.0006413187,"threshold_uncertainty_score":0.9875551},"labels":[],"label_agreement":null},{"id":"W6906072604","doi":"10.15562/tcp.72","title":"68Ga-PSMA-11 PET-CT is superior to bone scintigraphy for detection bone metastasis in low and high grade of prostate cancer","year":2019,"lang":"en","type":"article","venue":"The Cancer Press","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Bone scintigraphy; Bone metastasis; Metastasis; Scintigraphy","score_opus":0.023880916994513893,"score_gpt":0.3169460806114902,"score_spread":0.2930651636169763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6906072604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97688293,0.014652781,0.000010635888,0.0048121787,0.0002591686,0.0029184702,0.0004171011,0.000022350321,0.000024405972],"genre_scores_gemma":[0.99225473,0.0042247497,0.000102406884,0.00027302362,0.00008163421,0.001450987,0.00000992146,0.000036974816,0.0015655739],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985413,0.000051195537,0.00028210724,0.00040944747,0.0003035195,0.00041244467],"domain_scores_gemma":[0.99919593,0.00006903917,0.00008663351,0.00037213863,0.00014666938,0.00012960198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031775868,0.00019526822,0.00047340503,0.00019411379,0.000072406554,0.0000267803,0.00011662125,0.000018930865,0.000113354356],"category_scores_gemma":[0.00001610231,0.0001265072,0.00009794224,0.00037996608,0.00013116721,0.000110540364,0.00007571285,0.00014950531,0.0000021242774],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020090332,0.0010656427,0.36265296,0.011269415,0.002395261,0.00024762275,0.013994254,0.0009209367,0.41904,0.00018637617,0.0059134304,0.16222379],"study_design_scores_gemma":[0.008678774,0.0007629105,0.048062805,0.0009876572,0.00040920934,0.000046955396,0.00039905772,0.00066659885,0.9296258,0.00014916557,0.009914291,0.00029678282],"about_ca_topic_score_codex":0.011022536,"about_ca_topic_score_gemma":0.0020073345,"teacher_disagreement_score":0.5105858,"about_ca_system_score_codex":0.0001497231,"about_ca_system_score_gemma":0.00014135768,"threshold_uncertainty_score":0.99556315},"labels":[],"label_agreement":null},{"id":"W6908652993","doi":"10.26226/morressier.5b9a8cffdbd47e000fbf5999","title":"Evolution of a Model : Creating Stroke Rehabilitation Quality in Community Settings","year":2017,"lang":"en","type":"other","venue":"BiblioBoard Library Catalog (Open Research Library)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rehabilitation; Stroke (engine); Quality of life (healthcare); Health care; Quality (philosophy); Occupational therapy; Depression (economics); Community-based rehabilitation; Activities of daily living; Patient satisfaction","score_opus":0.10779591538133784,"score_gpt":0.42214275352009145,"score_spread":0.31434683813875364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6908652993","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020890415,0.0056936233,0.000016931936,0.005036089,0.00007821494,0.0050295903,0.0023004964,0.0003053995,0.96064925],"genre_scores_gemma":[0.057175476,0.0036168762,0.009409206,0.0001189503,0.00024816126,0.0006567126,0.0053300224,0.00075643655,0.9226882],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99290603,0.0026516363,0.00088911026,0.00089063623,0.0015887544,0.0010738359],"domain_scores_gemma":[0.9945239,0.0013672137,0.0006232125,0.0028376789,0.00014791942,0.00050007465],"candidate_categories":["metaepi_narrow","bibliometrics","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031866168,0.00050303526,0.0013844954,0.0113435965,0.0004948546,0.0006647479,0.0026631046,0.0007306074,0.0015974237],"category_scores_gemma":[0.0012527201,0.0004366768,0.00027384056,0.0045287386,0.0013215779,0.0046929982,0.0038082642,0.0028767292,0.00008060214],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020581186,0.0010248839,0.09782295,0.0036379397,0.00016908317,0.000063610074,0.0005173204,0.000005408806,0.0005103492,0.002925809,0.88908994,0.002174556],"study_design_scores_gemma":[0.023251144,0.006446203,0.21251872,0.028736036,0.00018576109,0.000022354652,0.0036128666,0.002139619,0.007215546,0.019438189,0.6941919,0.00224166],"about_ca_topic_score_codex":0.013046567,"about_ca_topic_score_gemma":0.00035980414,"teacher_disagreement_score":0.19489807,"about_ca_system_score_codex":0.00024650415,"about_ca_system_score_gemma":0.004124684,"threshold_uncertainty_score":0.99986196},"labels":[],"label_agreement":null},{"id":"W6908737729","doi":"10.3205/25swdgu20","title":"Effizienz und Sicherheit von Darolutamid in Kombination mit Androgenentzugstherapie und Docetaxel bei europäischen Patienten aus der Phase 3-Studie ARASENS","year":2025,"lang":"de","type":"article","venue":"German Medical Science (German Research Foundation)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Docetaxel; Antibody therapy; Chemotherapy; Phases of clinical research; Clinical trial","score_opus":0.06204885058934951,"score_gpt":0.4854555482595475,"score_spread":0.423406697670198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6908737729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90420765,0.056497723,0.00032370852,0.02868938,0.0018209583,0.0036223282,0.000050205726,0.00011951638,0.004668553],"genre_scores_gemma":[0.9825684,0.010624882,0.0001243895,0.0009597942,0.0007084329,0.0003508204,0.00061398663,0.00006943952,0.0039798976],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9838188,0.0013646096,0.0014002507,0.0019869301,0.008320414,0.0031089745],"domain_scores_gemma":[0.9936153,0.0010874406,0.00026251547,0.001210703,0.0020214547,0.0018025496],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["sts","insufficient_payload"],"category_scores_codex":[0.011605332,0.00063801993,0.0008812929,0.0027558557,0.0020514152,0.0008535651,0.0016698973,0.00044276728,0.0017057864],"category_scores_gemma":[0.0037264128,0.0005397566,0.00020635224,0.00816597,0.0068511837,0.0012904829,0.0011059986,0.002493432,0.002356954],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037645162,0.014976991,0.05606535,0.0017138883,0.0041470183,0.0042848317,0.009249732,0.0000308688,0.008163306,0.016878737,0.011559833,0.86916494],"study_design_scores_gemma":[0.088378154,0.007294289,0.18811457,0.007182177,0.002565922,0.00003320323,0.0013403355,0.055012085,0.01731508,0.014231564,0.61571616,0.0028164606],"about_ca_topic_score_codex":0.00053697167,"about_ca_topic_score_gemma":0.00027456126,"teacher_disagreement_score":0.86634845,"about_ca_system_score_codex":0.0030997503,"about_ca_system_score_gemma":0.008048597,"threshold_uncertainty_score":0.99980783},"labels":[],"label_agreement":null},{"id":"W6920522321","doi":"10.6084/m9.figshare.16778312","title":"Additional file 1 of Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models","year":2021,"lang":"en","type":"article","venue":"Open MIND","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Reciprocal; Table (database); Chromoplexy; Primer (cosmetics)","score_opus":0.061055429584654396,"score_gpt":0.3458393183437036,"score_spread":0.2847838887590492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920522321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87521553,0.0008139344,0.0000025124498,0.00069206377,0.000011399107,0.00068452937,0.1164775,6.446667e-7,0.006101881],"genre_scores_gemma":[0.9438746,0.00034838752,0.010688687,0.000022215567,0.000035726454,0.0003937274,0.02840724,0.000014562081,0.016214876],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994232,0.000018945017,0.00016828353,0.00016474116,0.00013665184,0.000088198314],"domain_scores_gemma":[0.99955887,0.00012605837,0.000053876433,0.00007398739,0.00013814135,0.000049071157],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005475263,0.0000555737,0.00015820269,0.000043763193,0.000023776576,0.000015806261,0.00002325642,0.00003591223,0.14653158],"category_scores_gemma":[0.000049960086,0.00004637588,0.000012634879,0.00012491971,0.00007966115,0.00013695513,0.000045120272,0.00005023541,0.0000015628327],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005786281,0.0009719416,0.006518422,0.0006863081,0.00034242935,0.00029220592,0.007445475,0.00029335683,0.0694129,0.00008677842,0.2465924,0.6615715],"study_design_scores_gemma":[0.023283394,0.0024424011,0.5176318,0.0092131095,0.00028717358,0.00016522573,0.0059474246,0.02266101,0.26655954,0.004498037,0.14650106,0.0008097871],"about_ca_topic_score_codex":0.00017414062,"about_ca_topic_score_gemma":0.00071827247,"teacher_disagreement_score":0.6607617,"about_ca_system_score_codex":0.000036984282,"about_ca_system_score_gemma":0.00050095463,"threshold_uncertainty_score":0.8542486},"labels":[],"label_agreement":null},{"id":"W6920525091","doi":"10.60692/6fwsa-ebj56","title":"Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients","year":2021,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Propensity score matching; Chemotherapy; Overall survival; Proportional hazards model; Prostate; Clinical trial; Survival analysis","score_opus":0.041809988589031746,"score_gpt":0.2983948244397891,"score_spread":0.25658483585075736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920525091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952242,0.000037346454,0.0000118340295,0.00010397409,0.0001937402,0.001021752,0.00016653605,0.000031065156,0.0032095772],"genre_scores_gemma":[0.99911445,0.000003680495,0.000011492884,0.00010835795,0.000017517707,0.00015396663,0.00013919214,0.000011373452,0.00043996508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865407,0.00015014094,0.00046612349,0.00012581475,0.00041815822,0.00018571992],"domain_scores_gemma":[0.9993116,0.000022626517,0.00017238413,0.00019848338,0.00022176607,0.00007310347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032477643,0.00015038208,0.0004154316,0.00019441053,0.000026114822,0.000026334916,0.00004361194,0.000044947785,0.00003480997],"category_scores_gemma":[0.000022304079,0.00009946381,0.00006671977,0.00022515788,0.000023910987,0.0002195467,0.000019047218,0.00009754987,0.000051464154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031129152,0.000022447128,0.9774205,0.0022870363,0.00014499284,0.000026502245,0.015415115,0.000020892672,0.000018559234,0.000011372821,0.00009144163,0.001428221],"study_design_scores_gemma":[0.05274263,0.0031634795,0.84471333,0.002886357,0.000089688474,0.000011086052,0.002917027,0.00065517856,0.09206576,9.787437e-7,0.0004396409,0.0003148697],"about_ca_topic_score_codex":0.00003521274,"about_ca_topic_score_gemma":3.6674527e-7,"teacher_disagreement_score":0.1327072,"about_ca_system_score_codex":0.00022090883,"about_ca_system_score_gemma":0.00017648294,"threshold_uncertainty_score":0.40560162},"labels":[],"label_agreement":null},{"id":"W6920747668","doi":"10.6084/m9.figshare.28768936","title":"Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Prostate; Androgen deprivation therapy; Metastasis; Bone metastasis; Chemotherapy; Cancer; Androgen; Hormonal therapy","score_opus":0.058749272257968645,"score_gpt":0.3650663436254866,"score_spread":0.30631707136751796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920747668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94101816,0.00057251914,8.39826e-8,0.0081082685,0.000109487526,0.0077418974,0.032635693,0.00003443752,0.00977945],"genre_scores_gemma":[0.9662902,0.000060714538,0.000007946836,0.00011486799,0.0000143892,0.0022526113,0.018680798,0.000011466555,0.012567021],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888986,0.00007527229,0.00026930304,0.00031355236,0.00018627355,0.00026572903],"domain_scores_gemma":[0.99932855,0.00017343533,0.000051891526,0.00020011715,0.00017623167,0.00006979886],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000036497917,0.00015625526,0.0003051694,0.0002884855,0.000040881245,0.000019592513,0.00004433782,0.000020701113,0.001954347],"category_scores_gemma":[0.00015424617,0.00012269267,0.000027841088,0.000769669,0.0000069322696,0.00005950945,0.000022178921,0.00012997558,0.00002530509],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002917622,0.0031225758,0.8556562,0.0009144539,0.00092710403,0.005426262,0.014168234,0.00038469804,0.0002902136,0.00006556871,0.06994291,0.046184137],"study_design_scores_gemma":[0.0062082536,0.00041883474,0.9785189,0.0019937663,0.00007612118,0.000004912356,0.0034036802,0.0008823496,0.0023200351,0.000012271075,0.006001229,0.00015964641],"about_ca_topic_score_codex":0.91785824,"about_ca_topic_score_gemma":0.9965711,"teacher_disagreement_score":0.122862674,"about_ca_system_score_codex":0.0024238885,"about_ca_system_score_gemma":0.0031003752,"threshold_uncertainty_score":0.998958},"labels":[],"label_agreement":null},{"id":"W6920863226","doi":"10.6084/m9.figshare.14576606","title":"Additional file 4 of Functional mapping of androgen receptor enhancer activity","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"","keywords":"Androgen receptor; Enhancer; Ubiquitin-Protein Ligases; Receptor","score_opus":0.07380505446163446,"score_gpt":0.298383695458021,"score_spread":0.22457864099638655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920863226","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006510152,0.00019090668,3.4197095e-7,0.00007657976,0.000013882291,0.00008613984,0.99135935,0.000008805412,0.0076130005],"genre_scores_gemma":[0.0048104916,0.0000055716464,0.00020557323,0.000021722755,0.00011467832,0.00032860786,0.9819638,0.000006809849,0.0125427535],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994686,0.000014553913,0.00008450685,0.00011882102,0.00021813919,0.00009535263],"domain_scores_gemma":[0.9991395,0.00034532827,0.000056127916,0.000100300414,0.0003096035,0.00004915475],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00000885253,0.000052219308,0.00013040856,0.00003750168,0.00002368236,0.000002622917,0.000023489003,0.00004408519,0.9989108],"category_scores_gemma":[0.00077330944,0.00004493329,0.00007872341,0.00016798801,0.000010712643,0.000044018427,0.00003889976,0.0000755116,0.00066409074],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063475345,0.00009685817,0.000011008244,0.00022264136,0.000074575466,0.0000104992,0.000018949826,3.8805086e-7,0.0066299364,3.790061e-7,0.9885986,0.0042727245],"study_design_scores_gemma":[0.00037715613,0.00005435371,0.008225596,0.0022605548,0.0000050234303,0.000008849455,0.000027022521,0.000013907805,0.11899602,0.0000053573126,0.869986,0.00004016711],"about_ca_topic_score_codex":9.82147e-7,"about_ca_topic_score_gemma":0.0000010282325,"teacher_disagreement_score":0.99824667,"about_ca_system_score_codex":0.00004435018,"about_ca_system_score_gemma":0.00058410456,"threshold_uncertainty_score":0.8535764},"labels":[],"label_agreement":null},{"id":"W6921036359","doi":"10.6084/m9.figshare.22622225","title":"Additional file 2 of Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Prostate cancer; Radiation therapy; Proportional hazards model; Hazard ratio; Biochemical recurrence; Confidence interval; Outcome (game theory); Systemic therapy","score_opus":0.04899826894949746,"score_gpt":0.3206239783177493,"score_spread":0.27162570936825187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921036359","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26070517,0.0004887719,7.4650295e-9,0.000020337051,0.000015711681,0.0005569335,0.7381569,0.00003640503,0.000019716927],"genre_scores_gemma":[0.25970936,0.0001667852,0.000065147404,0.000021332226,0.000036755508,0.0027558878,0.73574007,0.00003340368,0.0014712462],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9986887,0.00003834998,0.00035220908,0.0002251259,0.00046887668,0.00022672814],"domain_scores_gemma":[0.9982354,0.0006725853,0.00025339017,0.0002115712,0.00054556713,0.00008149215],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003203574,0.00015487574,0.00048137284,0.00016941632,0.000018892108,0.0000041092308,0.00008064787,0.000022606851,0.8332852],"category_scores_gemma":[0.000429613,0.00009320476,0.00010173671,0.00060789904,0.000050585622,0.000052979118,0.000023594372,0.0001034442,0.000043804546],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032459877,0.00016423887,0.087534264,0.0014029923,0.00017742999,0.00006388229,0.00008652337,6.793401e-7,0.00009244563,1.5132105e-8,0.9059647,0.0012668443],"study_design_scores_gemma":[0.0068100966,0.0012073854,0.8345357,0.054567136,0.000050106264,0.000057558922,0.00009718774,0.00014354644,0.017334819,0.0000015562496,0.08472596,0.0004689486],"about_ca_topic_score_codex":0.00001618708,"about_ca_topic_score_gemma":0.000004634166,"teacher_disagreement_score":0.8332414,"about_ca_system_score_codex":0.000074944466,"about_ca_system_score_gemma":0.00042987813,"threshold_uncertainty_score":0.38007802},"labels":[],"label_agreement":null},{"id":"W6921128933","doi":"10.6084/m9.figshare.28059067","title":"Additional file 1 of First preclinical SPECT/CT imaging and biodistribution of [165Er]ErCl3 and [165Er]Er-PSMA-617","year":2024,"lang":"en","type":"article","venue":"Open MIND","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"","keywords":"Biodistribution; Medical imaging; Radiation therapy; Cancer imaging","score_opus":0.0575786932380305,"score_gpt":0.3848642952190016,"score_spread":0.3272856019809711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921128933","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30616143,0.0045584356,0.000006978275,0.0034554321,0.00013503393,0.0012240203,0.65079135,0.000008210448,0.03365913],"genre_scores_gemma":[0.92241645,0.00061735004,0.0028200187,0.000022219723,0.00020747281,0.00016004514,0.06146164,0.000024300767,0.012270484],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991512,0.000022282258,0.00022966787,0.0002739896,0.00017745151,0.00014542772],"domain_scores_gemma":[0.99901134,0.0006459097,0.000049430342,0.00013303598,0.00006079262,0.00009948495],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015398611,0.000093262104,0.00023269444,0.000069021,0.00005451317,0.00005471818,0.00007032453,0.000019448174,0.3465891],"category_scores_gemma":[0.00025976976,0.00007197601,0.00004608507,0.00014352001,0.0002910342,0.00013476041,0.00014976201,0.0001269022,0.00006876195],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034655616,0.0002017296,0.0041421643,0.00027590597,0.00015892625,0.00030065235,0.00015863722,1.3553755e-7,0.00037906467,0.000013309464,0.77716714,0.21685575],"study_design_scores_gemma":[0.0014277918,0.0003828706,0.022468125,0.0017695519,0.00011281671,0.00027607032,0.0002587319,0.0006235199,0.00880144,0.00013172098,0.9636262,0.000121132805],"about_ca_topic_score_codex":0.000034012828,"about_ca_topic_score_gemma":0.000023785104,"teacher_disagreement_score":0.61625504,"about_ca_system_score_codex":0.000045182256,"about_ca_system_score_gemma":0.00019914513,"threshold_uncertainty_score":0.6540082},"labels":[],"label_agreement":null},{"id":"W6928700241","doi":"10.3897/zookeys.573.7445.figures6-9","title":"Figures 6-9 from: Lopes-Andrade C, Webster RP, Webster VL, Alderson CA, Hughes CC, Sweeney JD (2016) The Ciidae (Coleoptera) of New Brunswick, Canada: New records and new synonyms. In: Webster RP, Bouchard P, Klimaszewski J (Eds) The Coleoptera of New Brunswick and Canada: providing baseline biodiversity and natural history data. ZooKeys 573: 339–366. https://doi.org/10.3897/zookeys.573.7445","year":2016,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Scale (ratio); Face (sociological concept); Power (physics); George (robot); Portrait; Identity (music)","score_opus":0.04463345332204001,"score_gpt":0.24187341417777017,"score_spread":0.19723996085573015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6928700241","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26372704,0.17476045,0.0003636431,0.10628215,0.0036311685,0.016781323,0.0034496796,0.00082900946,0.43017554],"genre_scores_gemma":[0.023482542,0.008954356,0.00017068018,0.0010116751,0.0010540619,3.0928416e-7,0.002339725,0.0010690156,0.96191764],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99581337,0.00049752824,0.00068980904,0.0011436015,0.00105967,0.0007960336],"domain_scores_gemma":[0.99693054,0.00021344592,0.0005418714,0.0012104971,0.00030846588,0.0007951853],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005931427,0.00064494123,0.0009151906,0.00041483724,0.0005501374,0.00024219284,0.0012229425,0.0002732436,0.03596042],"category_scores_gemma":[0.00042753486,0.000438701,0.00008782286,0.00028628396,0.00059586833,0.00036371106,0.0016070296,0.0009186128,0.0004844334],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088495936,0.00008108426,0.005940043,0.00044281885,0.00047454884,0.00011531629,0.00101332,6.113977e-7,0.00011993587,0.000013657835,0.9720024,0.018911345],"study_design_scores_gemma":[0.006195758,0.00030020098,0.022768084,0.0011535031,0.00029501118,0.000019121038,0.00028110508,0.000063021944,0.00022103297,0.000005545157,0.9682445,0.00045312932],"about_ca_topic_score_codex":0.9646266,"about_ca_topic_score_gemma":0.829473,"teacher_disagreement_score":0.5317421,"about_ca_system_score_codex":0.0011146638,"about_ca_system_score_gemma":0.0044067516,"threshold_uncertainty_score":0.99980646},"labels":[],"label_agreement":null},{"id":"W6929919489","doi":"10.5061/dryad.bp6714t","title":"Data from: Hybridization rate and hybrid fitness for Camelina microcarpa Andrz. ex DC (♀) and Camelina sativa (L.) Crantz(Brassicaceae) (♂)","year":2018,"lang":"en","type":"dataset","venue":"Data Archiving and Networked Services (DANS)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Agriculture and Agri-Food Canada","funders":"","keywords":"Camelina; Hybrid; Camelina sativa; Pollen; Introgression; Ploidy; Germination; Cultivar; Plant breeding","score_opus":0.04283799706064175,"score_gpt":0.3252610723042167,"score_spread":0.28242307524357496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929919489","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09161614,0.009003411,0.00039027768,0.0004214758,0.0003274374,0.0013369985,0.8968227,0.000059702772,0.00002187244],"genre_scores_gemma":[0.004830746,0.0358107,0.0008395798,0.00032432267,0.0016611891,0.000052965708,0.9561555,0.00008988188,0.00023511519],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99576426,0.000292833,0.00062555633,0.0021376635,0.0003813039,0.0007983641],"domain_scores_gemma":[0.9950672,0.0009492282,0.00036896337,0.0030022387,0.00012244326,0.0004899371],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009379772,0.0007484096,0.0010957317,0.00022486858,0.00062302174,0.0003793253,0.0013677648,0.00021975614,0.00003976575],"category_scores_gemma":[0.00008936335,0.00059359253,0.000048296362,0.00019723299,0.00053763296,0.0005756516,0.003131062,0.0005752727,0.000011572543],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001651631,0.00013551988,0.0024582671,0.0032324053,0.0006693965,0.00013713213,0.00033067027,0.0000022492486,0.000659775,6.95263e-7,0.98163456,0.009087693],"study_design_scores_gemma":[0.005433604,0.00051369495,0.008732421,0.0038876734,0.0019391334,0.00015774235,0.00033909938,0.04955533,0.00026925353,0.00019950689,0.9280053,0.0009672447],"about_ca_topic_score_codex":0.0027834987,"about_ca_topic_score_gemma":0.0038886622,"teacher_disagreement_score":0.0867854,"about_ca_system_score_codex":0.00004873049,"about_ca_system_score_gemma":0.00021941286,"threshold_uncertainty_score":0.99965155},"labels":[],"label_agreement":null},{"id":"W6930085537","doi":"10.5281/zenodo.11905612","title":"william guy carr des pions sur léchiquier pdf","year":2024,"lang":"fr","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Carr; Pion; Download; Dominion","score_opus":0.037490627027096844,"score_gpt":0.2789474877737767,"score_spread":0.24145686074667985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930085537","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013340074,0.018032743,0.00031787867,0.0020844413,0.0010583902,0.0015866994,0.0010551014,0.0009307819,0.9736],"genre_scores_gemma":[0.012137891,0.007605094,0.00018639624,0.00015731451,0.0019516762,3.8797378e-7,0.004231262,0.009827865,0.9639021],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99561584,0.00057467126,0.0004990935,0.0011071429,0.00089977455,0.001303462],"domain_scores_gemma":[0.9970905,0.000058226684,0.00013911999,0.0009622713,0.0009439676,0.00080591295],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00081219466,0.00055730995,0.00056508987,0.0007917811,0.0018872682,0.0011391888,0.0010853386,0.00038986956,0.5304837],"category_scores_gemma":[0.0008980925,0.0005085668,0.0002656664,0.0012286218,0.0011979807,0.00021605015,0.001691299,0.0012239079,0.48812124],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019170437,0.00041427082,0.000019954068,0.0017378015,0.00080974173,0.0005075731,0.0021455372,0.000008489339,0.0016909307,0.0022856132,0.82285005,0.16733833],"study_design_scores_gemma":[0.0014783951,0.00070765225,0.0006783729,0.001883373,0.0003374373,0.0003326587,0.0004441203,0.00010788007,0.00036034876,0.00044788403,0.9927576,0.00046424175],"about_ca_topic_score_codex":0.00010482164,"about_ca_topic_score_gemma":0.0000059550866,"teacher_disagreement_score":0.16990757,"about_ca_system_score_codex":0.0011566548,"about_ca_system_score_gemma":0.000056578945,"threshold_uncertainty_score":0.9998977},"labels":[],"label_agreement":null},{"id":"W6930368080","doi":"10.5281/zenodo.12253363","title":"Iso 19600 pdf","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Standardization; Accreditation; Conformity assessment; International standard; Principal (computer security); Work (physics); Information security management system; Compliance (psychology); Management system","score_opus":0.03375337473231358,"score_gpt":0.2852550170735541,"score_spread":0.2515016423412405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930368080","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028065166,0.0031606036,0.0000832436,0.001438022,0.00022585545,0.0008365184,0.00038590565,0.0015095717,0.9923322],"genre_scores_gemma":[0.00093554193,0.0014461256,0.00011007484,0.00014128145,0.00071940594,1.02769604e-7,0.004134781,0.011547118,0.98096555],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99807984,0.00012201956,0.00019756914,0.00059477345,0.0005461266,0.00045965548],"domain_scores_gemma":[0.9988154,0.000007704015,0.00006986967,0.0005955091,0.00021686254,0.00029462925],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00027873286,0.00024793344,0.00029791344,0.0006312901,0.0004353126,0.0004598345,0.00048710316,0.00020052865,0.3220031],"category_scores_gemma":[0.00014020805,0.00021430821,0.00011867429,0.0005497074,0.0002185175,0.000046727928,0.0007798823,0.0005734729,0.35433093],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008848295,0.00011490626,7.3966123e-7,0.00061316235,0.0002578566,0.00021374054,0.0001874311,1.409269e-7,0.00034783396,0.00047475737,0.9681029,0.029598102],"study_design_scores_gemma":[0.0008240007,0.00035435153,0.000017966158,0.0004927275,0.0001007311,0.00019809797,0.0000889402,0.00001560538,0.00012222471,0.00009530104,0.997494,0.00019609433],"about_ca_topic_score_codex":0.000036119764,"about_ca_topic_score_gemma":4.7531591e-7,"teacher_disagreement_score":0.032327827,"about_ca_system_score_codex":0.0002696401,"about_ca_system_score_gemma":0.000014109924,"threshold_uncertainty_score":0.8739235},"labels":[],"label_agreement":null},{"id":"W6931477725","doi":"10.5281/zenodo.808148","title":"GBM 381 Intrenational Trade","year":2017,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Guideline; Trade theory; Comparative advantage; Trade barrier; Absolute (philosophy); Economic integration","score_opus":0.0575572031476898,"score_gpt":0.30628590711147424,"score_spread":0.24872870396378444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931477725","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10748067,0.00039953348,0.0006750377,0.043976523,0.00028118,0.0012906906,0.0003929319,0.0010500066,0.84445345],"genre_scores_gemma":[0.9912163,0.00020437947,0.00019662132,0.00020684068,0.00031058313,6.812098e-8,0.0015433938,0.00066832337,0.005653468],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987066,0.000080373095,0.0001502311,0.0003030918,0.0004433516,0.00031636615],"domain_scores_gemma":[0.99883884,0.00001346077,0.000079004945,0.00057233276,0.00026615875,0.00023020251],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00034765017,0.00010770618,0.00013671051,0.00015513695,0.0033949423,0.0007042995,0.00060485,0.000056129556,0.011552298],"category_scores_gemma":[0.0005419248,0.00009479379,0.0000597451,0.00012422723,0.0002827725,0.00023762917,0.0005639484,0.00024683154,0.003702159],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007048194,0.00058290776,0.00024644728,0.00017081852,0.000248596,0.00020374957,0.001163278,0.000005644488,0.013497943,0.010881878,0.4782544,0.4940395],"study_design_scores_gemma":[0.0018441669,0.00030822668,0.024179641,0.00004609326,0.000023662831,0.0001624937,0.00009668764,0.0001599296,0.0022154942,0.00023904169,0.9706148,0.000109770015],"about_ca_topic_score_codex":0.000011971933,"about_ca_topic_score_gemma":2.537651e-7,"teacher_disagreement_score":0.88373566,"about_ca_system_score_codex":0.00018136096,"about_ca_system_score_gemma":0.0000104362325,"threshold_uncertainty_score":0.9979025},"labels":[],"label_agreement":null},{"id":"W6939109914","doi":"10.60692/6bh9s-g1428","title":"Supplementary Materials and Methods from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Androgen receptor; Androgen Receptor Antagonists; Class (philosophy); Cancer; Androgen","score_opus":0.026731230665021533,"score_gpt":0.3091814334911829,"score_spread":0.28245020282616135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939109914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946654,0.000015220979,0.0018381216,0.00020943182,0.00006971281,0.0012798009,0.0018851282,0.000029245322,0.00000797725],"genre_scores_gemma":[0.99665433,0.000027537393,0.0006964339,0.000022349346,0.000027155203,0.00022578602,0.002268019,0.0000106985,0.00006768872],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990172,0.00006063956,0.00046056142,0.00012367673,0.0001958359,0.0001421006],"domain_scores_gemma":[0.9994034,0.0000050992426,0.00028471195,0.00014898012,0.000104867024,0.00005294516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002152375,0.00010817205,0.0002903975,0.00022443877,0.000025803694,0.00002007533,0.000040753395,0.000051157484,0.00003909398],"category_scores_gemma":[0.0000018074439,0.00007636297,0.000018456922,0.0003079461,0.000031885436,0.00022371068,0.000025252752,0.000036259582,0.0000052728465],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051778406,0.000010664294,0.62850624,0.0017714053,0.00025243175,0.0000030080155,0.04975128,0.000031004845,0.28567934,0.000012894504,0.00001484905,0.028789008],"study_design_scores_gemma":[0.0061299764,0.00023601144,0.37858602,0.00049987185,0.000089206136,0.000005692005,0.0045230207,0.00080672075,0.6086839,0.0000023344744,0.00031998314,0.000117268384],"about_ca_topic_score_codex":0.00026488147,"about_ca_topic_score_gemma":0.0000018249285,"teacher_disagreement_score":0.32300454,"about_ca_system_score_codex":0.00008234921,"about_ca_system_score_gemma":0.00011558154,"threshold_uncertainty_score":0.31139916},"labels":[],"label_agreement":null},{"id":"W6939361102","doi":"10.6084/m9.figshare.20317735.v1","title":"Additional file 1 of An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Cabazitaxel; Docetaxel; Prostate cancer; Economic evaluation; Androgen; Chemotherapy; Overall survival; Abiraterone","score_opus":0.055490426647158926,"score_gpt":0.3265631514816914,"score_spread":0.2710727248345325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939361102","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39185125,0.00014503382,1.6400266e-8,0.000027726792,0.0000065010668,0.0018199161,0.6061136,0.000007537944,0.00002843909],"genre_scores_gemma":[0.20350546,0.000005695995,0.00011002263,0.000014246426,0.000016268987,0.008341387,0.78773475,0.000024676847,0.00024750794],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99867487,0.00016374135,0.00020919123,0.00030452653,0.00044517254,0.00020249565],"domain_scores_gemma":[0.9980382,0.00036561096,0.00027066912,0.0001848417,0.0010351477,0.00010553613],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000990075,0.00016494792,0.00023822766,0.000120201046,0.00019803326,0.000021864062,0.00006761666,0.000020131254,0.66344494],"category_scores_gemma":[0.00015092971,0.0001034331,0.000037761973,0.0002095992,0.000049128514,0.00017530688,0.000023317285,0.00009784275,0.0000035772935],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02962903,0.001395058,0.0008732769,0.0006055337,0.0027124078,0.000013040251,0.0076593454,0.0038841409,0.00015827022,0.0000065390695,0.9514419,0.001621446],"study_design_scores_gemma":[0.17236936,0.12127143,0.24776949,0.0064430786,0.005916753,0.000049556093,0.075167745,0.08436453,0.009968625,0.0002453418,0.27389795,0.0025361234],"about_ca_topic_score_codex":0.00024392077,"about_ca_topic_score_gemma":0.0011473745,"teacher_disagreement_score":0.67754394,"about_ca_system_score_codex":0.00048370822,"about_ca_system_score_gemma":0.0009491184,"threshold_uncertainty_score":0.42178792},"labels":[],"label_agreement":null},{"id":"W6939453602","doi":"10.60692/rpe1c-shk89","title":"BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1","year":2018,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"BMI1; Prostate cancer; Enzalutamide; Androgen receptor; Cancer stem cell; Histone; Histone H3; Epigenetics; EZH2","score_opus":0.04621820897189639,"score_gpt":0.28357116862496773,"score_spread":0.23735295965307135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939453602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513614,0.000032430602,0.000010817868,0.00039348955,0.00023911115,0.0011039821,0.0002251239,0.000041111787,0.0028177788],"genre_scores_gemma":[0.99849635,0.000002163728,0.000037514797,0.00008688994,0.000078649085,0.00012174089,0.000028492272,0.000009488874,0.0011387026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865514,0.000064451764,0.0005043321,0.00013456075,0.0003998488,0.00024164045],"domain_scores_gemma":[0.9988784,0.000005508152,0.0002887413,0.00039039794,0.00036570555,0.00007122125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022775382,0.00013035773,0.0002608009,0.00018824407,0.00009165924,0.000034971345,0.00013590719,0.00007100314,0.000117223855],"category_scores_gemma":[0.000019033276,0.00007478672,0.000068543784,0.00036222162,0.00014516809,0.00024804033,0.00008950683,0.0001059829,0.00010647319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007331405,0.000005677663,0.94761145,0.00040785363,0.00008606846,0.0000026475022,0.04977988,0.000007644476,0.00019345744,0.000025398633,0.0005393949,0.00060738705],"study_design_scores_gemma":[0.0058762636,0.00022397876,0.87610155,0.0013977338,0.00005579866,0.00004984931,0.011255363,0.0007005128,0.10307382,0.0000036375452,0.0010879989,0.00017348531],"about_ca_topic_score_codex":0.00012348383,"about_ca_topic_score_gemma":0.0000035944768,"teacher_disagreement_score":0.10288036,"about_ca_system_score_codex":0.0002482858,"about_ca_system_score_gemma":0.00016221037,"threshold_uncertainty_score":0.3049714},"labels":[],"label_agreement":null},{"id":"W6939688588","doi":"10.6084/m9.figshare.22622222.v1","title":"Additional file 1 of Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Radiation therapy; Prostate cancer; Systemic therapy; Biochemical recurrence; Outcome (game theory); Overall survival; Prostatectomy","score_opus":0.0507138659376662,"score_gpt":0.32125482098055996,"score_spread":0.27054095504289377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939688588","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2614384,0.00048085605,7.609743e-9,0.000020409643,0.0000156046,0.0005571255,0.73743194,0.000036364614,0.000019275469],"genre_scores_gemma":[0.26222968,0.00016238714,0.00006639251,0.000021286693,0.00003617228,0.0028008537,0.73318624,0.000033378277,0.0014636188],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9986885,0.000038362294,0.0003520599,0.00022528571,0.00046898774,0.00022680726],"domain_scores_gemma":[0.9982251,0.0006816948,0.00025305385,0.00021195503,0.0005467138,0.00008150301],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000032202086,0.00015492234,0.0004812614,0.0001695213,0.000018890798,0.0000041008107,0.00008069036,0.000022606728,0.83577037],"category_scores_gemma":[0.00043457505,0.0000932336,0.00010175532,0.0006083462,0.000050586284,0.000052944793,0.000023597513,0.000103466744,0.00004425132],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032501407,0.00016365518,0.089657724,0.0013857109,0.0001767433,0.00006203076,0.00008612052,6.736542e-7,0.00009521034,1.4826945e-8,0.90389246,0.001229503],"study_design_scores_gemma":[0.0067089074,0.0011969472,0.8381356,0.05473651,0.000049851762,0.000056950812,0.00009730266,0.00014323393,0.017289154,0.0000015315065,0.0811181,0.00046589324],"about_ca_topic_score_codex":0.000016034252,"about_ca_topic_score_gemma":0.000004608366,"teacher_disagreement_score":0.83572614,"about_ca_system_score_codex":0.000074924166,"about_ca_system_score_gemma":0.00043169517,"threshold_uncertainty_score":0.3801956},"labels":[],"label_agreement":null},{"id":"W6939998369","doi":"10.6084/m9.figshare.28768936.v1","title":"Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Prostate; Androgen deprivation therapy; Metastasis; Bone metastasis; Chemotherapy; Cancer; Androgen; Hormonal therapy","score_opus":0.058749272257968645,"score_gpt":0.3650663436254866,"score_spread":0.30631707136751796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939998369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94101816,0.00057251914,8.39826e-8,0.0081082685,0.000109487526,0.0077418974,0.032635693,0.00003443752,0.00977945],"genre_scores_gemma":[0.9662902,0.000060714538,0.000007946836,0.00011486799,0.0000143892,0.0022526113,0.018680798,0.000011466555,0.012567021],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888986,0.00007527229,0.00026930304,0.00031355236,0.00018627355,0.00026572903],"domain_scores_gemma":[0.99932855,0.00017343533,0.000051891526,0.00020011715,0.00017623167,0.00006979886],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000036497917,0.00015625526,0.0003051694,0.0002884855,0.000040881245,0.000019592513,0.00004433782,0.000020701113,0.001954347],"category_scores_gemma":[0.00015424617,0.00012269267,0.000027841088,0.000769669,0.0000069322696,0.00005950945,0.000022178921,0.00012997558,0.00002530509],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002917622,0.0031225758,0.8556562,0.0009144539,0.00092710403,0.005426262,0.014168234,0.00038469804,0.0002902136,0.00006556871,0.06994291,0.046184137],"study_design_scores_gemma":[0.0062082536,0.00041883474,0.9785189,0.0019937663,0.00007612118,0.000004912356,0.0034036802,0.0008823496,0.0023200351,0.000012271075,0.006001229,0.00015964641],"about_ca_topic_score_codex":0.91785824,"about_ca_topic_score_gemma":0.9965711,"teacher_disagreement_score":0.122862674,"about_ca_system_score_codex":0.0024238885,"about_ca_system_score_gemma":0.0031003752,"threshold_uncertainty_score":0.998958},"labels":[],"label_agreement":null},{"id":"W6940014106","doi":"10.6084/m9.figshare.29578798.v1","title":"Additional file 1 of The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke; Centre hospitalier universitaire de Québec","funders":"","keywords":"Prostate cancer; Sink (geography); Metastasis; Radiation therapy; Prostate","score_opus":0.043468258245326415,"score_gpt":0.3578145653047289,"score_spread":0.3143463070594025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6940014106","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11643359,0.00023069441,1.8658815e-8,0.000749592,0.000008803244,0.0024735334,0.87992543,0.0000051025377,0.00017323867],"genre_scores_gemma":[0.8210416,0.0000038972503,0.000007191302,0.000052787138,0.000008639315,0.008181633,0.16935389,0.000008607221,0.0013417487],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99905884,0.0000945194,0.00025579458,0.00022046015,0.00021747923,0.00015290559],"domain_scores_gemma":[0.99773234,0.0015906706,0.00014659243,0.00025296988,0.00024289044,0.00003450611],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007642026,0.000118947,0.00030863035,0.00017701153,0.00011604903,0.000013944154,0.00012303487,0.00000722949,0.12947778],"category_scores_gemma":[0.0013268635,0.000063803775,0.00015628045,0.0010929136,0.000021278167,0.000033813656,0.000055934535,0.000113878945,0.0000049568694],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060528534,0.0006821229,0.0037656187,0.0011072139,0.0023124286,0.000021916883,0.00023778132,0.00015552902,0.0022376494,0.00003063354,0.9875193,0.0013245175],"study_design_scores_gemma":[0.002298586,0.00054642325,0.9770534,0.0031639342,0.0012853622,0.000005309414,0.00017671993,0.00060525356,0.007988804,0.000047202368,0.0067280033,0.00010099312],"about_ca_topic_score_codex":0.000041734307,"about_ca_topic_score_gemma":0.001001387,"teacher_disagreement_score":0.9807913,"about_ca_system_score_codex":0.00011017219,"about_ca_system_score_gemma":0.00055011245,"threshold_uncertainty_score":0.871318},"labels":[],"label_agreement":null},{"id":"W6940019563","doi":"10.6084/m9.figshare.c.3601754_d1","title":"Additional file 1: of Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review","year":2016,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Stroke (engine); Prostate; Table (database); Androgen deprivation therapy; Prostate cancer; Funnel plot; Scale (ratio); Quality (philosophy)","score_opus":0.09020330166631668,"score_gpt":0.35469428568587325,"score_spread":0.26449098401955656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6940019563","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027065964,0.027189994,5.6975654e-7,0.0008329886,0.0000015115378,0.0026363248,0.9692486,0.000013351059,0.000049576094],"genre_scores_gemma":[0.00090867665,0.0011443034,0.00016406273,0.00030575588,0.000010081768,0.028089797,0.9599174,0.000014738942,0.009445128],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.9992186,0.00003423512,0.0002491902,0.00018039468,0.00019962077,0.0001179884],"domain_scores_gemma":[0.99867034,0.00060430897,0.00014113098,0.00017756905,0.00032691204,0.00007974848],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000054181346,0.00009205397,0.0006597933,0.000108350614,0.000030617462,0.0000063418893,0.00004561222,0.000032289976,0.9303173],"category_scores_gemma":[0.0012151168,0.000045291825,0.00031511116,0.00030800316,0.0000059805625,0.000048281425,0.00001806326,0.00002530998,0.00008699355],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054233795,0.00002137509,0.000009716393,0.025387432,0.020859316,0.0000018583911,0.00002267726,1.2293091e-7,0.000043853866,4.814372e-7,0.9529123,0.0006866883],"study_design_scores_gemma":[0.0045825997,0.0014969608,0.002334448,0.48094833,0.12095159,0.000021784219,0.000038434493,0.00008394513,0.00638249,0.00008561809,0.38252065,0.00055316114],"about_ca_topic_score_codex":0.000003123111,"about_ca_topic_score_gemma":0.0000062093586,"teacher_disagreement_score":0.93023026,"about_ca_system_score_codex":0.000042684922,"about_ca_system_score_gemma":0.00010213436,"threshold_uncertainty_score":0.18469469},"labels":[],"label_agreement":null},{"id":"W6943732611","doi":"10.15562/tcp.77","title":"Ga-68 PSMA-11 PET in progressive prostate cancer","year":2019,"lang":"en","type":"article","venue":"The Cancer Press","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"","score_opus":0.027357800835072395,"score_gpt":0.3592357206358645,"score_spread":0.3318779198007921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6943732611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94536585,0.0397597,5.476168e-7,0.007553059,0.00045392604,0.00270029,0.00009458708,0.00006031582,0.004011735],"genre_scores_gemma":[0.96093184,0.005857036,0.000023957882,0.00047713533,0.00027990274,0.002040046,0.000025321198,0.000047538026,0.03031722],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982967,0.00008023112,0.00021932072,0.00041167287,0.0004157047,0.00057640753],"domain_scores_gemma":[0.99905807,0.00005543469,0.00009220467,0.00052546343,0.00014254128,0.00012626265],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022413826,0.00020695604,0.00033115238,0.00007031042,0.00006769166,0.000041206713,0.00027126257,0.00005121706,0.0013000275],"category_scores_gemma":[0.000013680121,0.00011808883,0.00007284717,0.00025212415,0.00015945065,0.00012203086,0.00013222803,0.0003389552,0.00006990636],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056139915,0.00056541985,0.89926493,0.0015611816,0.00068948383,0.000876756,0.009473187,0.00061938324,0.0067117997,0.00030404975,0.022253774,0.052066054],"study_design_scores_gemma":[0.033862103,0.0012854479,0.38679525,0.0052526374,0.00070424395,0.00020155023,0.001757819,0.0040434184,0.11919439,0.00067283213,0.44478798,0.0014423282],"about_ca_topic_score_codex":0.0035174158,"about_ca_topic_score_gemma":0.00051820395,"teacher_disagreement_score":0.5124697,"about_ca_system_score_codex":0.00028884306,"about_ca_system_score_gemma":0.00044670032,"threshold_uncertainty_score":0.9996129},"labels":[],"label_agreement":null},{"id":"W6943831266","doi":"10.15562/tcp.52","title":"A novel Paclitaxel loaded Noisome: Preparation, Characterization and Cytotoxicity Assessment against human prostate cancer","year":2017,"lang":"en","type":"article","venue":"The Cancer Press","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Cytotoxicity; Prostate cancer; Paclitaxel; Cancer; Prostate; Cell culture","score_opus":0.05705124551413753,"score_gpt":0.4013848915153889,"score_spread":0.3443336460012514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6943831266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881178,0.0015892041,0.00017028284,0.006457713,0.00018887772,0.0018554974,0.00032888766,0.000053004438,0.0012387382],"genre_scores_gemma":[0.9860445,0.004654865,0.000043487944,0.0003401476,0.00034867876,0.0013514479,0.00013061015,0.000029855795,0.0070564034],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99867725,0.000045389712,0.00022623858,0.00038532953,0.00033954106,0.0003262491],"domain_scores_gemma":[0.99868554,0.000020561158,0.00024832002,0.0006969094,0.00021036135,0.00013830853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025769827,0.00019325993,0.00026719208,0.000036554135,0.0009100009,0.00024844575,0.00024330303,0.000071483206,0.00005416289],"category_scores_gemma":[0.00002366657,0.00012298598,0.000047150264,0.00004868873,0.00031185042,0.00032170548,0.00017596016,0.0002258014,0.0000017181694],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005275154,0.00017788344,0.052887555,0.00020878606,0.00027753608,0.000007890773,0.0016997239,0.000016098715,0.93429685,0.0001495911,0.00043933498,0.009311232],"study_design_scores_gemma":[0.0046034777,0.00021649055,0.8291191,0.0003817531,0.00015809797,0.0000054393263,0.00005777264,0.0008993948,0.15789889,0.00005031081,0.006371831,0.0002374557],"about_ca_topic_score_codex":0.0012583948,"about_ca_topic_score_gemma":0.00020053453,"teacher_disagreement_score":0.77639794,"about_ca_system_score_codex":0.00026777716,"about_ca_system_score_gemma":0.00027172282,"threshold_uncertainty_score":0.6999083},"labels":[],"label_agreement":null},{"id":"W6946274435","doi":"10.3205/24urobay32","title":"PSA-Ansprechen unter Darolutamid (DARO) oder Placebo (PBO) + Androgen-Deprivationstherapie (ADT)/Docetaxel (DOC) bei Patienten mit high- und low-volume metastasiertem hormonsensitivem Prostatakrebs (mHSPC) in ARASENS","year":2024,"lang":"de","type":"article","venue":"German Medical Science (German Research Foundation)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"Placebo; Double blind study; Clinical trial; MEDLINE","score_opus":0.05548287831107555,"score_gpt":0.41635353460527796,"score_spread":0.3608706562942024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6946274435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9150014,0.034100935,0.0007072113,0.039574772,0.0024243977,0.005752985,0.0005258795,0.00032374356,0.0015886617],"genre_scores_gemma":[0.98169446,0.007951199,0.00040181552,0.00079577684,0.0013917388,0.0006371445,0.0016698504,0.00017612464,0.0052818917],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97814757,0.0019437318,0.0017405663,0.0029733412,0.010986267,0.0042085224],"domain_scores_gemma":[0.99149835,0.0018619993,0.00025404035,0.0016810418,0.0018628349,0.0028417371],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","research_integrity","insufficient_payload"],"consensus_categories":["sts","insufficient_payload"],"category_scores_codex":[0.013721237,0.00096437417,0.0012594793,0.003493266,0.0018997588,0.001854508,0.0018721607,0.00061137,0.0045967274],"category_scores_gemma":[0.0025917608,0.0007943464,0.00036244665,0.00828941,0.009306304,0.002419312,0.0009890184,0.004209132,0.008619931],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009516191,0.008631839,0.04997728,0.0057031075,0.009500706,0.03276663,0.040163577,0.00011321957,0.017292272,0.01667181,0.057143345,0.75252],"study_design_scores_gemma":[0.041054305,0.0070645497,0.2334009,0.01694839,0.0031177017,0.0005082657,0.004597001,0.16689016,0.021735076,0.013163665,0.48567078,0.005849199],"about_ca_topic_score_codex":0.00091008464,"about_ca_topic_score_gemma":0.00039291728,"teacher_disagreement_score":0.74667084,"about_ca_system_score_codex":0.0040884484,"about_ca_system_score_gemma":0.012144983,"threshold_uncertainty_score":0.9997347},"labels":[],"label_agreement":null},{"id":"W6957870500","doi":"10.6084/m9.figshare.14456832","title":"Additional file 1 of Safety and Effects of Football in Skeletal Metastatic Prostate Cancer: a Subgroup Analysis of the FC Prostate Community Randomised Controlled Trial","year":2021,"lang":"en","type":"article","venue":"Open MIND","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Subgroup analysis; Randomized controlled trial; Prostate; Prostate cancer; Table (database); Meta-analysis; Safety profile","score_opus":0.023380574640839893,"score_gpt":0.325838200210779,"score_spread":0.30245762556993916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957870500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8804317,0.00053651416,7.277498e-7,0.00018350463,0.000028987142,0.0063758176,0.11126981,6.1351443e-7,0.0011723201],"genre_scores_gemma":[0.96274287,0.0004488831,0.0007927923,0.000031313168,0.000016768105,0.0028319259,0.02699894,0.000019372104,0.0061171297],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979112,0.00082757126,0.0005841957,0.00017471323,0.00032898577,0.00017331511],"domain_scores_gemma":[0.9951177,0.0039014127,0.0003657981,0.00030512342,0.0002446863,0.00006526197],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005845497,0.0001299161,0.0012226675,0.00014773203,0.00006680847,0.000014508849,0.00015240026,0.000037740818,0.07605917],"category_scores_gemma":[0.0011640809,0.00007921403,0.00026872155,0.00079007365,0.00025842985,0.00006744951,0.00017714854,0.0002122582,0.0000011731811],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.943627,0.00261045,0.0015399491,0.0007397123,0.010003998,0.00007616842,0.0038338935,0.000053362946,0.0045428015,0.000003791997,0.008570538,0.024398325],"study_design_scores_gemma":[0.95395416,0.0013827631,0.021398848,0.0010890815,0.0035113501,0.000003808526,0.0006873925,0.0006497023,0.012428666,0.000026129843,0.004740108,0.0001280117],"about_ca_topic_score_codex":0.0004399387,"about_ca_topic_score_gemma":0.0016421933,"teacher_disagreement_score":0.084270865,"about_ca_system_score_codex":0.00006510504,"about_ca_system_score_gemma":0.0008089535,"threshold_uncertainty_score":0.92478544},"labels":[],"label_agreement":null},{"id":"W6957953592","doi":"10.60692/1qk3v-d7p20","title":"Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer","year":2020,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Androgen receptor; Androgen; Prostate; Psychological repression; Cancer; Androgen deprivation therapy; SOX2","score_opus":0.03326981697056962,"score_gpt":0.24180639804234674,"score_spread":0.20853658107177714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957953592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99779356,0.00008010562,0.00056950207,0.00040068163,0.000047333986,0.00077010476,0.00005719143,0.000091831935,0.00018970031],"genre_scores_gemma":[0.9994984,0.000007329891,0.00010741674,0.00010975671,0.00005165536,0.00010148906,0.000057095906,0.000009610053,0.000057203528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998983,0.000029177014,0.00036083852,0.00016331139,0.00025297896,0.00021066562],"domain_scores_gemma":[0.99952626,0.0000046825853,0.00011864254,0.00009323637,0.000101869955,0.00015527983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000079688405,0.00013980569,0.00022223621,0.00014107392,0.000073961244,0.000074768854,0.000045386096,0.00007177268,0.000029373192],"category_scores_gemma":[0.00001605226,0.00010059092,0.00003133445,0.00020982325,0.000031358235,0.00044412614,0.00005747852,0.0001043355,0.00006271783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006652204,0.0000037732962,0.9600168,0.0012574884,0.000036997524,0.000026964157,0.035694286,0.00011644294,0.0015431936,0.00000799728,0.000056266817,0.00057459663],"study_design_scores_gemma":[0.0122285215,0.00037436569,0.59960973,0.001984903,0.00011594877,0.00005076018,0.009341198,0.03415416,0.34137097,0.0000032517025,0.00032866898,0.00043753607],"about_ca_topic_score_codex":0.000018734761,"about_ca_topic_score_gemma":1.9354817e-7,"teacher_disagreement_score":0.36040705,"about_ca_system_score_codex":0.00010145036,"about_ca_system_score_gemma":0.00005167994,"threshold_uncertainty_score":0.41019788},"labels":[],"label_agreement":null},{"id":"W6957976044","doi":"10.60692/7akey-f8h94","title":"Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients","year":2021,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Propensity score matching; Chemotherapy; Overall survival; Proportional hazards model; Prostate; Clinical trial; Survival analysis","score_opus":0.041809988589031746,"score_gpt":0.2983948244397891,"score_spread":0.25658483585075736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957976044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952242,0.000037346454,0.0000118340295,0.00010397409,0.0001937402,0.001021752,0.00016653605,0.000031065156,0.0032095772],"genre_scores_gemma":[0.99911445,0.000003680495,0.000011492884,0.00010835795,0.000017517707,0.00015396663,0.00013919214,0.000011373452,0.00043996508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865407,0.00015014094,0.00046612349,0.00012581475,0.00041815822,0.00018571992],"domain_scores_gemma":[0.9993116,0.000022626517,0.00017238413,0.00019848338,0.00022176607,0.00007310347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032477643,0.00015038208,0.0004154316,0.00019441053,0.000026114822,0.000026334916,0.00004361194,0.000044947785,0.00003480997],"category_scores_gemma":[0.000022304079,0.00009946381,0.00006671977,0.00022515788,0.000023910987,0.0002195467,0.000019047218,0.00009754987,0.000051464154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031129152,0.000022447128,0.9774205,0.0022870363,0.00014499284,0.000026502245,0.015415115,0.000020892672,0.000018559234,0.000011372821,0.00009144163,0.001428221],"study_design_scores_gemma":[0.05274263,0.0031634795,0.84471333,0.002886357,0.000089688474,0.000011086052,0.002917027,0.00065517856,0.09206576,9.787437e-7,0.0004396409,0.0003148697],"about_ca_topic_score_codex":0.00003521274,"about_ca_topic_score_gemma":3.6674527e-7,"teacher_disagreement_score":0.1327072,"about_ca_system_score_codex":0.00022090883,"about_ca_system_score_gemma":0.00017648294,"threshold_uncertainty_score":0.40560162},"labels":[],"label_agreement":null},{"id":"W6958280336","doi":"10.6084/m9.figshare.20317735","title":"Additional file 1 of An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Cabazitaxel; Docetaxel; Prostate cancer; Economic evaluation; Androgen; Chemotherapy; Overall survival; Abiraterone","score_opus":0.055490426647158926,"score_gpt":0.3265631514816914,"score_spread":0.2710727248345325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958280336","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39185125,0.00014503382,1.6400266e-8,0.000027726792,0.0000065010668,0.0018199161,0.6061136,0.000007537944,0.00002843909],"genre_scores_gemma":[0.20350546,0.000005695995,0.00011002263,0.000014246426,0.000016268987,0.008341387,0.78773475,0.000024676847,0.00024750794],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99867487,0.00016374135,0.00020919123,0.00030452653,0.00044517254,0.00020249565],"domain_scores_gemma":[0.9980382,0.00036561096,0.00027066912,0.0001848417,0.0010351477,0.00010553613],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000990075,0.00016494792,0.00023822766,0.000120201046,0.00019803326,0.000021864062,0.00006761666,0.000020131254,0.66344494],"category_scores_gemma":[0.00015092971,0.0001034331,0.000037761973,0.0002095992,0.000049128514,0.00017530688,0.000023317285,0.00009784275,0.0000035772935],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02962903,0.001395058,0.0008732769,0.0006055337,0.0027124078,0.000013040251,0.0076593454,0.0038841409,0.00015827022,0.0000065390695,0.9514419,0.001621446],"study_design_scores_gemma":[0.17236936,0.12127143,0.24776949,0.0064430786,0.005916753,0.000049556093,0.075167745,0.08436453,0.009968625,0.0002453418,0.27389795,0.0025361234],"about_ca_topic_score_codex":0.00024392077,"about_ca_topic_score_gemma":0.0011473745,"teacher_disagreement_score":0.67754394,"about_ca_system_score_codex":0.00048370822,"about_ca_system_score_gemma":0.0009491184,"threshold_uncertainty_score":0.42178792},"labels":[],"label_agreement":null},{"id":"W6958313643","doi":"10.6084/m9.figshare.13047075.v1","title":"Additional file 7 of A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Prostate cancer; Key (lock); Gene; Biochemical recurrence; Cancer","score_opus":0.08007190610501959,"score_gpt":0.319462312705212,"score_spread":0.23939040660019245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958313643","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.052299466,0.00031955726,4.727655e-7,0.0003066114,0.0000033133072,0.0010201203,0.9459619,0.000010043279,0.00007853596],"genre_scores_gemma":[0.4810094,0.000032697844,0.00019875003,0.000036756755,0.000018072877,0.0015465232,0.51712817,0.000005986623,0.000023630373],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988949,0.000071416616,0.00029555464,0.00022228912,0.0003560746,0.00015977083],"domain_scores_gemma":[0.99777675,0.0012097021,0.00021443398,0.00014005194,0.00057349686,0.0000855733],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00004196291,0.000107220825,0.00027024292,0.000048176607,0.000025429124,0.0000037276288,0.00012829328,0.00006129177,0.4026792],"category_scores_gemma":[0.0069002197,0.000075980526,0.00006139924,0.00037130562,0.000044561868,0.00003688315,0.000062063045,0.00014240596,0.000017631994],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058335427,0.00034272883,0.00051805034,0.00031242482,0.000064012806,0.000011729428,0.0011625597,0.000041314262,0.0016450019,3.3012665e-7,0.99143016,0.0038883341],"study_design_scores_gemma":[0.006650123,0.0034787988,0.19372001,0.022322297,0.0002699834,0.000008525595,0.0014994236,0.056673843,0.67250884,0.00012538685,0.042059507,0.00068328343],"about_ca_topic_score_codex":0.00009844831,"about_ca_topic_score_gemma":0.000046018034,"teacher_disagreement_score":0.9493706,"about_ca_system_score_codex":0.000058470618,"about_ca_system_score_gemma":0.0005044334,"threshold_uncertainty_score":0.8260706},"labels":[],"label_agreement":null},{"id":"W6958394376","doi":"10.6084/m9.figshare.13047060.v1","title":"Additional file 2 of A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Gene; Prostate cancer; Key (lock); Expression (computer science); Gene expression; Cohort","score_opus":0.07881890093569986,"score_gpt":0.31916693585484646,"score_spread":0.24034803491914658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958394376","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.051688775,0.00032187454,4.5921055e-7,0.0003055156,0.0000033301835,0.0010184065,0.94657147,0.000010043729,0.000080098805],"genre_scores_gemma":[0.4773502,0.000033104636,0.00019737193,0.0000368467,0.000018352168,0.0015523677,0.5207818,0.00000599875,0.000023962393],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889535,0.000071426635,0.0002954599,0.00022215658,0.00035592177,0.00015968768],"domain_scores_gemma":[0.9977827,0.0012038886,0.000214665,0.0001399503,0.0005732625,0.000085549815],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00004171925,0.00010717943,0.00027017263,0.000048140333,0.00002541944,0.0000037258517,0.00012824645,0.00006129079,0.4110866],"category_scores_gemma":[0.006956655,0.00007595395,0.00006138294,0.00037109767,0.00004454451,0.00003687082,0.00006206728,0.00014237982,0.000017694809],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000573896,0.00033888602,0.00049782294,0.0003064426,0.00006336201,0.000011724722,0.0011488986,0.00004104182,0.0015796595,3.2347202e-7,0.99156874,0.0038692143],"study_design_scores_gemma":[0.0067128423,0.003507956,0.19408314,0.02210667,0.0002725249,0.000008636286,0.0015053698,0.05674227,0.6692428,0.00012630361,0.045001954,0.00068955513],"about_ca_topic_score_codex":0.00009825676,"about_ca_topic_score_gemma":0.00004563144,"teacher_disagreement_score":0.94656676,"about_ca_system_score_codex":0.000058459485,"about_ca_system_score_gemma":0.0005031884,"threshold_uncertainty_score":0.83282685},"labels":[],"label_agreement":null},{"id":"W6958647067","doi":"10.6084/m9.figshare.22622222","title":"Additional file 1 of Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Radiation therapy; Prostate cancer; Systemic therapy; Biochemical recurrence; Outcome (game theory); Overall survival; Prostatectomy","score_opus":0.0507138659376662,"score_gpt":0.32125482098055996,"score_spread":0.27054095504289377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958647067","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2614384,0.00048085605,7.609743e-9,0.000020409643,0.0000156046,0.0005571255,0.73743194,0.000036364614,0.000019275469],"genre_scores_gemma":[0.26222968,0.00016238714,0.00006639251,0.000021286693,0.00003617228,0.0028008537,0.73318624,0.000033378277,0.0014636188],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9986885,0.000038362294,0.0003520599,0.00022528571,0.00046898774,0.00022680726],"domain_scores_gemma":[0.9982251,0.0006816948,0.00025305385,0.00021195503,0.0005467138,0.00008150301],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000032202086,0.00015492234,0.0004812614,0.0001695213,0.000018890798,0.0000041008107,0.00008069036,0.000022606728,0.83577037],"category_scores_gemma":[0.00043457505,0.0000932336,0.00010175532,0.0006083462,0.000050586284,0.000052944793,0.000023597513,0.000103466744,0.00004425132],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032501407,0.00016365518,0.089657724,0.0013857109,0.0001767433,0.00006203076,0.00008612052,6.736542e-7,0.00009521034,1.4826945e-8,0.90389246,0.001229503],"study_design_scores_gemma":[0.0067089074,0.0011969472,0.8381356,0.05473651,0.000049851762,0.000056950812,0.00009730266,0.00014323393,0.017289154,0.0000015315065,0.0811181,0.00046589324],"about_ca_topic_score_codex":0.000016034252,"about_ca_topic_score_gemma":0.000004608366,"teacher_disagreement_score":0.83572614,"about_ca_system_score_codex":0.000074924166,"about_ca_system_score_gemma":0.00043169517,"threshold_uncertainty_score":0.3801956},"labels":[],"label_agreement":null},{"id":"W6958869787","doi":"10.6084/m9.figshare.14576600.v1","title":"Additional file 2 of Functional mapping of androgen receptor enhancer activity","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"","keywords":"Androgen receptor; Enhancer; Ubiquitin-Protein Ligases; Receptor","score_opus":0.07170940262259497,"score_gpt":0.29767418406918184,"score_spread":0.22596478144658688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958869787","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000643761,0.0001923447,3.2887846e-7,0.00007667202,0.000013960428,0.00008584487,0.99120104,0.000008798501,0.007777218],"genre_scores_gemma":[0.004523667,0.000005638364,0.0002026194,0.000021684655,0.000116267955,0.00032796094,0.98199517,0.0000067915557,0.01280023],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99946886,0.000014566635,0.000084471794,0.00011876519,0.0002180414,0.0000953084],"domain_scores_gemma":[0.99913955,0.00034249562,0.000056196404,0.00010019244,0.00031239825,0.000049148326],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000008793774,0.00005220461,0.00013039412,0.00003746792,0.000023673081,0.0000026215973,0.00002347115,0.0000440855,0.9989392],"category_scores_gemma":[0.00077539793,0.00004491985,0.00007870477,0.00016793542,0.000010709374,0.000044006414,0.0000389088,0.000075512224,0.0006634514],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061857434,0.00009674849,0.000010558773,0.0002224552,0.00007459177,0.000010629019,0.000018931083,3.961307e-7,0.006460688,3.7340055e-7,0.9887065,0.0043362263],"study_design_scores_gemma":[0.0003725831,0.00005293538,0.008016944,0.0022087386,0.0000049678847,0.000008784996,0.00002652807,0.000013602135,0.11710628,0.0000052791543,0.8721436,0.00003970778],"about_ca_topic_score_codex":9.907751e-7,"about_ca_topic_score_gemma":0.0000010222922,"teacher_disagreement_score":0.99827576,"about_ca_system_score_codex":0.00004435978,"about_ca_system_score_gemma":0.0005832905,"threshold_uncertainty_score":0.85275465},"labels":[],"label_agreement":null},{"id":"W6959562589","doi":"10.1101/2024.07.09.24309949v1","title":"The Interplay Between Molecular Architecture, Pharmacology, and Suspected Adverse Drug Reactions Associated with Non-Steroidal Androgen Antagonists in The United Kingdom","year":2024,"lang":"en","type":"preprint","venue":"University of Birmingham Research Portal (University of Birmingham)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Enzalutamide; Flutamide; Bicalutamide; Androgen receptor; Drug reaction; Drug; Adverse effect","score_opus":0.03195882882469793,"score_gpt":0.33404652884359737,"score_spread":0.30208770001889945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6959562589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99068624,0.00040582515,0.000055455534,0.004239029,0.0000868834,0.0018224284,0.0003570386,0.00006225947,0.0022848574],"genre_scores_gemma":[0.9961025,0.0007357971,0.0001673781,0.000014674344,0.00004319403,0.0000011236943,0.00040372126,0.000038317565,0.0024932963],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.99611527,0.0007323745,0.0003081788,0.0007933488,0.0012618109,0.0007890451],"domain_scores_gemma":[0.9970274,0.00097244733,0.0003571848,0.00062272,0.0007171056,0.0003031685],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002057598,0.00038406625,0.00073234347,0.0017884204,0.00081092905,0.000050686853,0.0009901987,0.00037398507,0.00009189586],"category_scores_gemma":[0.00010183766,0.00030972232,0.00028499527,0.0018257649,0.0031437415,0.00010411171,0.0018850723,0.003145562,0.0000064799633],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040248938,0.0078116865,0.35564032,0.012857149,0.039443865,0.15282477,0.2364252,0.0015479332,0.06774253,0.0030228435,0.05591382,0.026520949],"study_design_scores_gemma":[0.05160746,0.008907589,0.3018722,0.021853164,0.009997797,0.0009331136,0.5029123,0.008062693,0.017244464,0.0041342583,0.06848807,0.003986921],"about_ca_topic_score_codex":0.012571198,"about_ca_topic_score_gemma":0.004298237,"teacher_disagreement_score":0.26648706,"about_ca_system_score_codex":0.00033802632,"about_ca_system_score_gemma":0.0012757804,"threshold_uncertainty_score":0.9999355},"labels":[],"label_agreement":null},{"id":"W6976681746","doi":"10.6084/m9.figshare.16778312.v1","title":"Additional file 1 of Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Reciprocal; Table (database); Chromoplexy; Primer (cosmetics)","score_opus":0.05531447675293577,"score_gpt":0.3069287916960487,"score_spread":0.2516143149431129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976681746","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011957569,0.0010149025,8.643921e-8,0.00016996285,0.0000030944575,0.0002165928,0.9858228,0.0000042415177,0.00081077043],"genre_scores_gemma":[0.14532968,0.00006645574,0.0004052605,0.000022212187,0.000027344517,0.0006106556,0.8515525,0.000009029298,0.0019769042],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9994561,0.000013572894,0.00014338158,0.00014097718,0.00015277456,0.0000931938],"domain_scores_gemma":[0.99943733,0.00018018675,0.000052122716,0.00006681751,0.00021418724,0.0000493683],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000013279181,0.00005916063,0.00013455976,0.00004961163,0.000020730895,0.0000067487836,0.000013659473,0.00004368558,0.723376],"category_scores_gemma":[0.00023063818,0.000050746425,0.00001794638,0.00013406368,0.000018781713,0.00008858687,0.00002560445,0.00005903857,0.00000365341],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002831264,0.00007651368,0.00017444334,0.00076525245,0.000034333676,0.000042508575,0.00036658582,0.000044424356,0.0016087402,0.00000814456,0.98732674,0.009269173],"study_design_scores_gemma":[0.011025556,0.0013478803,0.63809824,0.04863737,0.00010297312,0.000118025666,0.0011611013,0.02422002,0.06206093,0.0026915448,0.20986581,0.0006705571],"about_ca_topic_score_codex":0.000034596724,"about_ca_topic_score_gemma":0.00017844723,"teacher_disagreement_score":0.77746093,"about_ca_system_score_codex":0.000038069335,"about_ca_system_score_gemma":0.00038496876,"threshold_uncertainty_score":0.27687693},"labels":[],"label_agreement":null},{"id":"W6977077076","doi":"10.6084/m9.figshare.19522628","title":"Additional file 2 of PPFIA4 promotes castration-resistant prostate cancer by enhancing mitochondrial metabolism through MTHFD2","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Prostate cancer; Table (database); Small interfering RNA; Antibody; Cancer","score_opus":0.030028876883318685,"score_gpt":0.2997547402439574,"score_spread":0.2697258633606387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977077076","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025296822,0.0015773583,7.684883e-8,0.0003856328,0.00006352144,0.00080564216,0.9953161,0.000037650265,0.0015610899],"genre_scores_gemma":[0.0020315917,0.000010873113,0.00037731446,0.00010765342,0.00027506676,0.010570602,0.9731623,0.000028758444,0.013435821],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985118,0.000050239978,0.00025058826,0.00029069462,0.0006053048,0.00029140685],"domain_scores_gemma":[0.99905056,0.0003221419,0.00014937462,0.00017864964,0.00021131159,0.00008796158],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000019056657,0.00014875771,0.00024974236,0.0000547519,0.00023247414,0.000020856522,0.000106321146,0.00004211288,0.99458534],"category_scores_gemma":[0.0005217831,0.0001272346,0.00010641533,0.0002852033,0.000020070644,0.00013184406,0.000103858,0.00024710738,0.00018144393],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029541898,0.00013620616,0.000001165289,0.0001894182,0.00009585591,0.000037267324,0.00034629536,0.0000043044756,0.012285228,0.0000017965417,0.9860993,0.0005077261],"study_design_scores_gemma":[0.001038841,0.00024522096,0.0002606093,0.0008910549,0.000028517987,0.000011543259,0.00018748594,0.00002401517,0.025068399,0.000027567512,0.9720911,0.00012566517],"about_ca_topic_score_codex":0.00007629483,"about_ca_topic_score_gemma":0.00004040421,"teacher_disagreement_score":0.9944039,"about_ca_system_score_codex":0.00016918374,"about_ca_system_score_gemma":0.0009031002,"threshold_uncertainty_score":0.51884764},"labels":[],"label_agreement":null},{"id":"W6977113486","doi":"10.6084/m9.figshare.19522631","title":"Additional file 3 of PPFIA4 promotes castration-resistant prostate cancer by enhancing mitochondrial metabolism through MTHFD2","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Prostate cancer; Cell growth; Cell; Gene; In vitro; Cell culture; LNCaP; Gene expression; Downregulation and upregulation","score_opus":0.03055029794519995,"score_gpt":0.29989955556394676,"score_spread":0.26934925761874684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977113486","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002567006,0.0015607785,7.904402e-8,0.00038589237,0.000063782434,0.0008072851,0.99535245,0.000037619302,0.0015353932],"genre_scores_gemma":[0.0020900078,0.00001074962,0.00038147747,0.00010761375,0.00027432022,0.010579731,0.97286326,0.000028811352,0.013664013],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985113,0.0000502076,0.00025058843,0.0002907862,0.00060558534,0.0002914931],"domain_scores_gemma":[0.99904656,0.00032387272,0.00014918622,0.00017872373,0.00021371007,0.00008796698],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000019154259,0.00014878437,0.00024970633,0.000054769636,0.00023243626,0.000020854453,0.00010631269,0.00004210895,0.9945517],"category_scores_gemma":[0.00052812585,0.00012724365,0.00010642932,0.00028532042,0.000020072392,0.00013185629,0.000103795755,0.00024711344,0.00018549681],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002987098,0.00013609901,0.0000012050815,0.00019085656,0.0000957131,0.00003668297,0.00034579897,0.000004282216,0.012752582,0.000001752472,0.98563546,0.0005008295],"study_design_scores_gemma":[0.0010449218,0.00024449834,0.0002629565,0.00089920923,0.000028321154,0.0000113914975,0.00018827822,0.00002418686,0.02573966,0.000027391156,0.9714034,0.00012577954],"about_ca_topic_score_codex":0.00007640063,"about_ca_topic_score_gemma":0.000040442566,"teacher_disagreement_score":0.9943662,"about_ca_system_score_codex":0.00016982373,"about_ca_system_score_gemma":0.0009077222,"threshold_uncertainty_score":0.51888454},"labels":[],"label_agreement":null},{"id":"W6979188494","doi":"","title":"Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer.","year":2015,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Prostate; Cancer; Management of prostate cancer; Prostate disease; Radiation therapy","score_opus":0.1562372962732131,"score_gpt":0.3897460266468295,"score_spread":0.2335087303736164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6979188494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57739645,0.2634258,0.00031911756,0.108004496,0.004345881,0.034756258,0.00095168094,0.00028167607,0.010518615],"genre_scores_gemma":[0.9025024,0.015877977,0.002808732,0.00072157243,0.0010774591,0.03780976,0.00008605753,0.00008332822,0.039032687],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99830526,0.000019901221,0.00036209644,0.00027275877,0.0004143232,0.0006256427],"domain_scores_gemma":[0.9984998,0.000047007405,0.00014474489,0.00030568006,0.0007734024,0.00022934523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005657022,0.00017135433,0.00029369345,0.000038438033,0.00010485284,0.0000218001,0.00014817472,0.00004180093,0.00001523578],"category_scores_gemma":[0.00003775414,0.000097921686,0.00009524398,0.00031499137,0.00012354592,0.00006487441,0.00006138619,0.00009249069,9.501354e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077764387,0.00012520183,0.006607014,0.0008423899,0.0013531699,0.00006083705,0.00035450823,0.006336029,0.00012073383,0.00025389617,0.070646055,0.9055237],"study_design_scores_gemma":[0.027986124,0.0008365294,0.26998776,0.001448555,0.002263089,0.000015349555,0.005110722,0.0018226722,0.010088666,0.0015608869,0.6781388,0.0007408792],"about_ca_topic_score_codex":0.00051374047,"about_ca_topic_score_gemma":0.00032802872,"teacher_disagreement_score":0.90478283,"about_ca_system_score_codex":0.00032473556,"about_ca_system_score_gemma":0.00028465735,"threshold_uncertainty_score":0.39931306},"labels":[],"label_agreement":null},{"id":"W6982602978","doi":"","title":"Intégration d'outils APS dans une simulation multi-agent : une application à l'industrie du bois d'œuvre","year":2022,"lang":"fr","type":"other","venue":"Corpus Université Laval (Université Laval)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Sugar industry; Decantation; Production system (computer science); Pilotage","score_opus":0.016166267645551242,"score_gpt":0.24045289334722686,"score_spread":0.22428662570167562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6982602978","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32943752,0.021400841,0.051307015,0.033012696,0.006587186,0.018752199,0.0035263263,0.0022618554,0.53371435],"genre_scores_gemma":[0.3068669,0.012967526,0.00037419115,0.00015232696,0.0008296154,0.00003762904,0.0054452554,0.00040246412,0.6729241],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99497753,0.00045357939,0.0005393613,0.0015899161,0.0012743798,0.0011652444],"domain_scores_gemma":[0.99646616,0.00028514466,0.0007183052,0.0012086262,0.00050410867,0.0008176373],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003481062,0.001041702,0.0010531094,0.0012504542,0.0015352503,0.000079814534,0.00095178006,0.0009959008,0.0049382057],"category_scores_gemma":[0.00006794436,0.0011783292,0.00056033593,0.0031163106,0.00046680818,0.00044197467,0.00074763707,0.0011678145,0.00050624413],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060098544,0.004572356,0.18717428,0.001378169,0.004923771,0.0064946143,0.0687175,0.03063189,0.07476257,0.013785654,0.028242039,0.5733073],"study_design_scores_gemma":[0.012961548,0.0012715608,0.04353509,0.0005017395,0.002832931,0.00007012105,0.021276064,0.038354624,0.004149355,0.00007019654,0.8735431,0.0014336675],"about_ca_topic_score_codex":0.03197823,"about_ca_topic_score_gemma":0.01791541,"teacher_disagreement_score":0.8453011,"about_ca_system_score_codex":0.01204095,"about_ca_system_score_gemma":0.0015302676,"threshold_uncertainty_score":0.9997646},"labels":[],"label_agreement":null},{"id":"W6989290425","doi":"","title":"Androgen manipulation alters oxidative DNA adduct levels in adrogen-sensitive prostate cancer cells grown in vitro and in vivo.","year":2008,"lang":"en","type":"article","venue":"Leicester Research Archive (University of Leicester)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; University of Leicester; Queen's University; Cancer Research UK; Vanderbilt University","keywords":"Prostate cancer; In vitro; Androgen; DNA; Adduct; Oxidative phosphorylation; Prostate; Cancer","score_opus":0.07505775721921926,"score_gpt":0.3172771631895096,"score_spread":0.24221940597029035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6989290425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99565387,0.00044316807,0.00002928205,0.001074536,0.000026565112,0.0017887789,0.00021417793,0.000015583137,0.00075406965],"genre_scores_gemma":[0.9966709,0.0018349877,0.0006525,0.00004016439,0.00002475366,0.000017186534,0.00007065345,0.000026802923,0.0006620509],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9967537,0.0006986872,0.00030859452,0.0006895586,0.00072005746,0.00082939345],"domain_scores_gemma":[0.9987508,0.00035187058,0.00012802232,0.00031630418,0.00019520403,0.00025779443],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007461689,0.00024824482,0.0005763631,0.0016572998,0.00017952318,0.000022840426,0.00024931884,0.0001108093,0.00005908665],"category_scores_gemma":[0.00002886384,0.00025832216,0.00007717508,0.0010512561,0.0009147513,0.00074468984,0.0003680795,0.00078022975,0.000012585322],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009294313,0.00055452937,0.32397193,0.0005121571,0.00013072537,0.004008585,0.051671125,0.0000712087,0.6063197,0.000011431617,0.00008478907,0.0033694934],"study_design_scores_gemma":[0.010004426,0.0006697206,0.8269435,0.0010058316,0.000026374257,0.000074338874,0.009441791,0.0016727202,0.14931437,0.00021284044,0.00029657653,0.0003374925],"about_ca_topic_score_codex":0.0073396517,"about_ca_topic_score_gemma":0.010783043,"teacher_disagreement_score":0.5029716,"about_ca_system_score_codex":0.0004847247,"about_ca_system_score_gemma":0.00045230272,"threshold_uncertainty_score":0.9999869},"labels":[],"label_agreement":null},{"id":"W6990989994","doi":"","title":"Études multiparamétriques de biomarqueurs par immunofluorescence pour mieux suivre la progression du cancer de la prostate","year":2020,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Prostate disease; Prostate cancer; Thermoplastic polymer","score_opus":0.008781991842740961,"score_gpt":0.2540870315092751,"score_spread":0.24530503966653414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6990989994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8343778,0.14989375,0.000081897786,0.0024010367,0.0006965638,0.001425632,0.00020120232,0.00021959686,0.010702505],"genre_scores_gemma":[0.925421,0.046660427,0.0019139622,0.00011878619,0.0005041513,0.00033351438,0.0008514651,0.00009376002,0.024102934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99587655,0.0007596198,0.0004982489,0.00089634303,0.00091009814,0.0010591433],"domain_scores_gemma":[0.997359,0.00043005258,0.0004352905,0.00036231338,0.000524479,0.00088890194],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0005147279,0.00071147404,0.0006708913,0.0003373085,0.00425256,0.00015488917,0.0005111927,0.0008292958,0.00007064589],"category_scores_gemma":[0.00025215762,0.00068833993,0.00041724165,0.0005265907,0.00096698897,0.00036928133,0.00021911252,0.0010477795,0.00004898422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01260271,0.0013527971,0.46088427,0.002110886,0.0018245021,0.030090863,0.0799493,0.00059183687,0.37137273,0.004483322,0.0022620657,0.0324747],"study_design_scores_gemma":[0.009131013,0.0008856378,0.43122438,0.009013628,0.0015971399,0.0023252033,0.038676508,0.009867674,0.38513863,0.00020781784,0.110496186,0.0014362013],"about_ca_topic_score_codex":0.040966816,"about_ca_topic_score_gemma":0.0020934995,"teacher_disagreement_score":0.108234115,"about_ca_system_score_codex":0.012842182,"about_ca_system_score_gemma":0.012258817,"threshold_uncertainty_score":0.9995568},"labels":[],"label_agreement":null},{"id":"W6993064354","doi":"","title":"The novel clinical and functional implications of the 16p 13.3 genomic gain on clinical management of prostate cancer","year":2019,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; McGill University; U.S. Department of Defense","keywords":"Prostate cancer; Cancer; Disease; Prostate; Management of prostate cancer; Clinical Practice","score_opus":0.0711949908731819,"score_gpt":0.3775094163489475,"score_spread":0.3063144254757656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6993064354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9748649,0.001298396,1.0778167e-7,0.0004921951,0.0013827565,0.0025790283,0.0014813385,0.000025075824,0.01787619],"genre_scores_gemma":[0.949899,0.014389543,0.00008570209,0.00023716931,0.000077405675,0.00039545042,0.00042713032,0.00009362109,0.034394983],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963823,0.00027917093,0.0014008855,0.00077839853,0.0007356151,0.0004236461],"domain_scores_gemma":[0.9967621,0.0006829503,0.0008090086,0.0010321308,0.0005115541,0.00020227976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016922806,0.00038259276,0.00073220494,0.0001221302,0.0005958203,0.000023472829,0.00038088692,0.0004161173,0.000065395536],"category_scores_gemma":[0.0002170497,0.00022643978,0.0005203765,0.0003318828,0.00040885026,0.000081360915,0.0001957996,0.0013664755,0.000032036096],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014563302,0.0031799267,0.10582817,0.0031145965,0.007175119,0.000018954384,0.000033195683,0.000086827524,0.019467253,0.10919494,0.00029053018,0.7370472],"study_design_scores_gemma":[0.0060380306,0.00084272685,0.9554451,0.0013287499,0.0010357875,0.000008295976,0.00035483157,0.000021470933,0.0045732344,0.0021681052,0.02785075,0.00033287966],"about_ca_topic_score_codex":0.000102812206,"about_ca_topic_score_gemma":0.0002466957,"teacher_disagreement_score":0.84961694,"about_ca_system_score_codex":0.00029873598,"about_ca_system_score_gemma":0.0002915868,"threshold_uncertainty_score":0.9233946},"labels":[],"label_agreement":null},{"id":"W6995835574","doi":"","title":"Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome","year":2019,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Prostate cancer; Cancer; Cohort; Docetaxel; Overall survival; Abiraterone; Clinical trial; Retrospective cohort study","score_opus":0.4157132859464389,"score_gpt":0.5417045175028039,"score_spread":0.125991231556365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6995835574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996244,0.0013309792,0.000008644023,0.000099111785,0.000030914456,0.0016611882,0.0006131914,0.000002299323,0.000009660648],"genre_scores_gemma":[0.9989319,0.0005378338,0.00007330096,0.000012802841,0.00000222974,0.00004818581,0.0001630299,0.000014283311,0.00021643382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838936,0.00012527783,0.00069440465,0.00020710836,0.00042355512,0.00016029368],"domain_scores_gemma":[0.9980238,0.00045514802,0.00089709676,0.00020035276,0.0003463619,0.000077235614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034568954,0.00016811371,0.0010104114,0.0006311563,0.000055371343,0.00006722879,0.00012836959,0.000037905636,0.0004566772],"category_scores_gemma":[0.000096702475,0.00009733032,0.00012424015,0.0008196619,0.00010275318,0.00033082353,0.00004030706,0.00009418331,1.998567e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016330689,0.00037693474,0.97013485,0.00016622967,0.001548363,0.000002280846,0.00043673493,0.0021673457,0.023020877,0.000004315446,0.000015551268,0.00049345347],"study_design_scores_gemma":[0.004169477,0.00013910094,0.9858179,0.00042549096,0.001353237,2.8585e-7,0.000081939215,0.0008266032,0.0070413514,0.00002955226,0.000025549216,0.00008952613],"about_ca_topic_score_codex":0.11940233,"about_ca_topic_score_gemma":0.13259387,"teacher_disagreement_score":0.015979527,"about_ca_system_score_codex":0.00040301206,"about_ca_system_score_gemma":0.0003665349,"threshold_uncertainty_score":0.8864617},"labels":[],"label_agreement":null},{"id":"W6996153684","doi":"","title":"Regulation of the prostate progenitor cell fate","year":2018,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Fonds de Recherche du Québec - Santé; Prostate Cancer Canada; Canadian Institutes of Health Research; Cancer Research Society; McGill University","keywords":"Progenitor cell; Stem cell; Progenitor; Prostate; Prostate cancer; Cancer stem cell; Adult stem cell; Cellular differentiation","score_opus":0.01865050172262605,"score_gpt":0.27796870872366825,"score_spread":0.2593182070010422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6996153684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92570776,0.0005904831,1.4697285e-8,0.000047474332,0.0011419336,0.0027071906,0.0007482055,0.00010191971,0.06895503],"genre_scores_gemma":[0.88504606,0.00031350838,0.00027627152,0.000054080054,0.00012016069,0.0002641744,0.0013491982,0.00016975887,0.112406805],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99630487,0.0002252666,0.00078210933,0.0007988599,0.0012474182,0.0006414554],"domain_scores_gemma":[0.99689114,0.00006632819,0.00068327796,0.0009996447,0.0010926388,0.00026698285],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053557934,0.00056881196,0.00069492206,0.00029063868,0.0007026896,0.000036098365,0.00042433024,0.0006074345,0.00032751058],"category_scores_gemma":[0.0002331096,0.00039314668,0.00047135403,0.0007212505,0.0001736018,0.00026600139,0.00011879226,0.0010050639,0.00020647925],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042046756,0.00086530636,0.0010556934,0.0037485452,0.0006640688,0.00005242301,0.00008255019,0.0000028004167,0.8870732,0.002083791,0.00012502221,0.100041926],"study_design_scores_gemma":[0.0025514245,0.00057725195,0.014302432,0.0010559817,0.0005213012,0.00001658032,0.00019060414,0.000009991809,0.9375987,0.002862353,0.039904315,0.00040906665],"about_ca_topic_score_codex":0.00011150667,"about_ca_topic_score_gemma":0.00016724173,"teacher_disagreement_score":0.09963286,"about_ca_system_score_codex":0.0006688768,"about_ca_system_score_gemma":0.00027904878,"threshold_uncertainty_score":0.99985206},"labels":[],"label_agreement":null},{"id":"W7000300646","doi":"","title":"The fer tyrosine kinase contributes to aberrant androgen receptor signaling in prostate cancer","year":2018,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Prostate Cancer Canada; Astellas Pharma; Cancer Research Society","keywords":"Prostate cancer; Androgen receptor; Prostate disease; Tyrosine kinase; Signal transduction; Kinase; Phosphorylation; Prostate","score_opus":0.021902312151161993,"score_gpt":0.3035029209771009,"score_spread":0.2816006088259389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7000300646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773662,0.00992266,2.1271186e-8,0.0007591388,0.0014090553,0.003503336,0.0016935893,0.00012391165,0.005222054],"genre_scores_gemma":[0.9278249,0.0055646165,0.00019883939,0.00064732856,0.00021169624,0.0023753638,0.0021850648,0.00031324357,0.060678955],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9953755,0.00026100726,0.00095385086,0.0011369158,0.0009675391,0.0013051805],"domain_scores_gemma":[0.99707204,0.00026275488,0.00031095208,0.0007340927,0.0010836761,0.0005365084],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012619221,0.00076706114,0.0009894485,0.0005123323,0.0012447654,0.00015740428,0.00046252107,0.0004972857,0.00038387167],"category_scores_gemma":[0.00071136816,0.00054061494,0.0002892806,0.0011666454,0.00014046613,0.00025144222,0.00012596465,0.001388803,0.0003569176],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024797933,0.0009794595,0.004086046,0.0015791333,0.0020024916,0.0007296006,0.00017710296,0.000028959741,0.581308,0.0036731975,0.0009957171,0.37964237],"study_design_scores_gemma":[0.005623525,0.00072310894,0.0031345808,0.0034867595,0.00036426785,0.000011156164,0.0005578631,0.000011513896,0.64008325,0.0016434832,0.34357685,0.0007836348],"about_ca_topic_score_codex":0.0010044579,"about_ca_topic_score_gemma":0.0051746336,"teacher_disagreement_score":0.37885872,"about_ca_system_score_codex":0.0020854517,"about_ca_system_score_gemma":0.00037161354,"threshold_uncertainty_score":0.99970454},"labels":[],"label_agreement":null},{"id":"W7009793246","doi":"","title":"Evaluation of novel hormonal agents in metastatic castration-resistant prostate cancer using real-world data in Quebec","year":2024,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Fonds de Recherche du Québec - Santé; Réseau de cancérologie Rossy; McGill University Health Centre; McGill University","keywords":"Prostate cancer; Cancer; Hormone; Disease; Prostate; Hormonal therapy","score_opus":0.20061886573556595,"score_gpt":0.4315737704479766,"score_spread":0.23095490471241067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7009793246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828077,0.0025071162,3.051627e-8,0.000048750262,0.0004890399,0.002872911,0.0054567927,0.00003907385,0.005778588],"genre_scores_gemma":[0.9798564,0.0012752161,0.00048827005,0.000025006668,0.00003854212,0.000456761,0.009890813,0.00016179623,0.0078072483],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9935091,0.00044158226,0.0013762824,0.0012672485,0.0027266163,0.00067915063],"domain_scores_gemma":[0.99718297,0.00014435762,0.0005604332,0.00092785974,0.00096507074,0.00021934143],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036496776,0.00060245075,0.0010302899,0.0016248326,0.0001710382,0.00007699228,0.00041965445,0.00022284406,0.00018108508],"category_scores_gemma":[0.000503498,0.00055489683,0.00015736413,0.0019623311,0.00009805258,0.00075634586,0.00015439524,0.0012460281,0.00001624888],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010588693,0.0043238136,0.0056189643,0.010618898,0.003938875,0.0015552008,0.00053156837,0.0028406968,0.53595316,0.005313186,0.000034275898,0.41868263],"study_design_scores_gemma":[0.055485226,0.0017273587,0.6178664,0.045963496,0.020611001,0.00007194424,0.007828097,0.08067356,0.14862266,0.009621239,0.006491241,0.0050377697],"about_ca_topic_score_codex":0.1945577,"about_ca_topic_score_gemma":0.7770995,"teacher_disagreement_score":0.6122474,"about_ca_system_score_codex":0.005421742,"about_ca_system_score_gemma":0.00233743,"threshold_uncertainty_score":0.99969023},"labels":[],"label_agreement":null},{"id":"W7067685948","doi":"","title":"Molecular imaging targets in prostate cancers with neuroendocrine gene signature","year":2019,"lang":"en","type":"dissertation","venue":"Scholarship at UWindsor (University of Windsor)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Korea Health Industry Development Institute; National Research Foundation of Korea; Ministry of Education, Science and Technology; National Research Foundation; Government of Ontario","keywords":"Prostate cancer; Prostate; Molecular imaging; Phenotype; Transmembrane protein; Lineage (genetic); Cancer; Neuroendocrine differentiation; Neuroendocrine tumors; Gene signature","score_opus":0.008813353077735226,"score_gpt":0.25063977171447677,"score_spread":0.24182641863674154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7067685948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884509,0.0047075385,0.0000032843989,0.00093630585,0.00022557713,0.0015847031,0.00014313644,0.00005696687,0.003891629],"genre_scores_gemma":[0.96841604,0.00071575405,0.00028174068,0.00013061057,0.000033797107,0.0000050164726,0.0026875543,0.000110298264,0.027619202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970143,0.00012731111,0.00025294494,0.0009073626,0.00095061015,0.000747489],"domain_scores_gemma":[0.9983336,0.000040664363,0.00032419106,0.00061172614,0.0003966311,0.00029321187],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001917061,0.00051181053,0.00085309165,0.0008579056,0.00018255229,0.00002935048,0.00040178307,0.00019327305,0.00031531788],"category_scores_gemma":[0.000034818542,0.00051445694,0.00024640147,0.0007869818,0.0001587826,0.00041164635,0.00011148031,0.0015428539,0.000056190835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03622587,0.0005903896,0.66258353,0.0038479264,0.0012725882,0.030328168,0.00591016,0.0005583405,0.25270528,0.000041490664,0.00080476317,0.0051314863],"study_design_scores_gemma":[0.026251052,0.001648969,0.75998086,0.0038059372,0.001224518,0.0003209174,0.008270286,0.00022987269,0.19162957,0.00009303431,0.0049364218,0.0016085765],"about_ca_topic_score_codex":0.00051527115,"about_ca_topic_score_gemma":0.00097069377,"teacher_disagreement_score":0.09739728,"about_ca_system_score_codex":0.0009539126,"about_ca_system_score_gemma":0.0012165866,"threshold_uncertainty_score":0.9997307},"labels":[],"label_agreement":null},{"id":"W7068330218","doi":"","title":"ESSU Apr 2 2016","year":2016,"lang":"en","type":"other","venue":"Bulletin of Miscellaneous Information (Royal Gardens Kew)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bit (key); Football; Ticket; Prime minister","score_opus":0.008174159545824884,"score_gpt":0.23158619780417944,"score_spread":0.22341203825835457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7068330218","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009297923,0.001463068,3.002192e-7,0.00075095415,0.00022718783,0.0006431719,0.00019705493,0.00016108714,0.9965479],"genre_scores_gemma":[0.00013446683,0.0024763322,0.0002701683,0.00021356803,0.00029869992,0.000026756317,0.00021405244,0.00013383118,0.99623215],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99859947,0.000033270877,0.00038872304,0.00018268416,0.00046563536,0.00033021794],"domain_scores_gemma":[0.9989528,0.00005842253,0.0002782379,0.000379203,0.00014914689,0.00018217473],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00012249041,0.000277402,0.00044605226,0.00010862494,0.000038849706,0.000019469971,0.00016099525,0.0003504976,0.6973527],"category_scores_gemma":[0.000049938004,0.0001887594,0.00016900983,0.0000049101386,0.00017295637,9.1143946e-8,0.00006661111,0.00019883894,0.06253899],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028405688,0.000053431453,0.000008104638,0.00070737896,0.00016508397,0.000059427668,0.00003193317,5.9161465e-7,0.0000013453953,0.000012558561,0.99019974,0.008476331],"study_design_scores_gemma":[0.0018348999,0.00022816239,0.000009860207,0.00094912964,0.00009202021,0.000072338,0.000019155555,0.0000011079462,0.000046751295,0.00000571159,0.99653774,0.00020312422],"about_ca_topic_score_codex":0.0013493509,"about_ca_topic_score_gemma":0.000077995326,"teacher_disagreement_score":0.6348137,"about_ca_system_score_codex":0.00008922852,"about_ca_system_score_gemma":0.00010852388,"threshold_uncertainty_score":0.93819094},"labels":[],"label_agreement":null},{"id":"W7068504494","doi":"","title":"Discorder","year":2014,"lang":"en","type":"other","venue":"cIRcle (University of British Columbia)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Indie film; Work (physics); Fashion industry; Point (geometry)","score_opus":0.0099819371124254,"score_gpt":0.2155977860572275,"score_spread":0.2056158489448021,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7068504494","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.047231454,0.0026097447,0.0001647819,0.000227551,0.000234429,0.0007668009,0.00044599196,0.00020914352,0.9481101],"genre_scores_gemma":[0.08119052,0.0014234855,0.00023473505,0.000034290395,0.00011696609,5.5747284e-7,0.00016497707,0.00013350607,0.91670096],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99913013,0.000023522041,0.000059593178,0.00031627773,0.00025792117,0.00021254382],"domain_scores_gemma":[0.9993907,0.000011036943,0.00008747853,0.0003052028,0.000061830644,0.00014371613],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000051482828,0.0000474177,0.00038909342,0.00007540839,0.00005557941,0.0000246605,0.00014417624,0.00019841014,0.004619714],"category_scores_gemma":[0.0000083204295,0.00015981596,0.00014176723,0.00013756422,0.00029140967,0.000029092533,0.00008158724,0.00015993376,0.00022312264],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001808397,0.00010913766,0.0069475397,0.0003942196,0.0001795248,0.00039729214,0.000019190393,2.8934984e-8,0.000016731841,3.293119e-7,0.6954018,0.29651615],"study_design_scores_gemma":[0.0024745676,0.00017449856,0.64959013,0.0011496232,0.00016567863,0.0000561841,0.00016115503,0.0000067121973,1.9294463e-7,0.000024864605,0.34602582,0.00017059037],"about_ca_topic_score_codex":0.1094257,"about_ca_topic_score_gemma":0.21374527,"teacher_disagreement_score":0.64264256,"about_ca_system_score_codex":0.00006343238,"about_ca_system_score_gemma":0.00013983036,"threshold_uncertainty_score":0.9962902},"labels":[],"label_agreement":null},{"id":"W7068628885","doi":"","title":"Bryan McGill 16x9","year":2017,"lang":"en","type":"other","venue":"Bulletin of Miscellaneous Information (Royal Gardens Kew)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Center (category theory); The Internet","score_opus":0.01264486018159541,"score_gpt":0.24032802658052105,"score_spread":0.22768316639892563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7068628885","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019797797,0.00095532724,3.3194173e-8,0.0003995677,0.00023200709,0.0006433053,0.00031977054,0.00014186038,0.99728835],"genre_scores_gemma":[0.00032903816,0.0017951023,0.00026398498,0.00020552131,0.00021748977,0.00002233283,0.0003698422,0.0001291781,0.9966675],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986709,0.000027790764,0.00032182143,0.00019061078,0.00047239615,0.00031650654],"domain_scores_gemma":[0.9986305,0.00003747982,0.00040376876,0.000587107,0.0001530134,0.00018808852],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013091741,0.0002851114,0.00048863573,0.000095139985,0.00010869956,0.0000285292,0.00023541578,0.00037736158,0.39198846],"category_scores_gemma":[0.00010204276,0.00023454736,0.00018621737,0.0000034517932,0.00019092631,1.03115426e-7,0.000087311964,0.00028917487,0.013224075],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021877821,0.0000578935,0.000007447366,0.00084644044,0.0001688704,0.00010283625,0.00003011381,0.0000017717537,4.778624e-7,0.0000074085524,0.99132854,0.0072294297],"study_design_scores_gemma":[0.001540864,0.00028541495,0.000027626937,0.0007760259,0.00011383175,0.0001102036,0.000020147692,0.0000025016502,0.000038225604,0.000003788758,0.9968692,0.00021213837],"about_ca_topic_score_codex":0.0055106566,"about_ca_topic_score_gemma":0.00080502656,"teacher_disagreement_score":0.3787644,"about_ca_system_score_codex":0.00008767794,"about_ca_system_score_gemma":0.00006452205,"threshold_uncertainty_score":0.98754424},"labels":[],"label_agreement":null},{"id":"W7071098263","doi":"","title":"RADIUM-223 TREATMENT IN PATIENTS WITH PROSTATE CANCER IN ONTARIO","year":2025,"lang":"en","type":"dissertation","venue":"MacSphere (McMaster University)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Stage (stratigraphy); Radiation therapy; Cancer; Disease; Prostate-specific antigen; Prostate; Adenocarcinoma; Prostatic acid phosphatase; Immunotherapy","score_opus":0.01242074709729085,"score_gpt":0.23743517386060844,"score_spread":0.2250144267633176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7071098263","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7055561,0.0002921574,2.5009606e-7,0.000087252745,0.00015132224,0.0017758373,0.000059258353,0.000023061206,0.29205477],"genre_scores_gemma":[0.07220688,0.00027667804,0.00003442621,0.000020005713,0.000013312701,0.000028366429,0.0012209736,0.000029459936,0.92616993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984922,0.000048235324,0.00019257802,0.0005445427,0.00028916346,0.0004333055],"domain_scores_gemma":[0.99943554,0.000018779105,0.00009238326,0.00021934144,0.00011292979,0.000121041274],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000027754277,0.00036800213,0.000541071,0.0005676391,0.000052734576,0.000023362854,0.00012218648,0.00022037783,0.019028917],"category_scores_gemma":[0.000002096944,0.0002964425,0.000085587635,0.0006955522,0.000031660053,0.0001236819,0.000028595005,0.0004282134,0.000012466934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014414798,0.0008203811,0.79287297,0.0002370185,0.00026825754,0.00058116106,0.002586189,0.000029984622,0.0000052939663,0.000009964622,0.0000771929,0.18809679],"study_design_scores_gemma":[0.024306959,0.0009827475,0.86717516,0.0016598081,0.00026725797,3.4600893e-7,0.0014262396,0.0000074118702,0.00018328417,0.0000058801597,0.10367779,0.00030711995],"about_ca_topic_score_codex":0.116946176,"about_ca_topic_score_gemma":0.8696105,"teacher_disagreement_score":0.7526643,"about_ca_system_score_codex":0.0055030985,"about_ca_system_score_gemma":0.0021127772,"threshold_uncertainty_score":0.9999488},"labels":[],"label_agreement":null},{"id":"W7071663723","doi":"","title":"Studying the Cell Cycle's Role in the Transdifferentiation of Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"Scholarship at UWindsor (University of Windsor)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Transdifferentiation; Prostate cancer; Disease; Cancer; In vivo; Mechanism (biology); Cell; Tumor progression","score_opus":0.019159525620688775,"score_gpt":0.27207696090391814,"score_spread":0.25291743528322935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7071663723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98938483,0.0016774583,0.000008714422,0.004746034,0.000056451758,0.00083232287,0.000031357602,0.00001137117,0.0032514369],"genre_scores_gemma":[0.9959601,0.00044719336,0.000030060619,0.000095479656,0.00001478307,0.000004287388,0.000020592155,0.000007687024,0.0034198116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987246,0.00021615217,0.00016237603,0.0002248667,0.00042267103,0.00024934413],"domain_scores_gemma":[0.9992544,0.00012547524,0.00010608559,0.00033859417,0.00013286989,0.0000425578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005965569,0.00012373009,0.00025327326,0.000229231,0.000270436,0.00001404653,0.00036865694,0.000090916794,0.00013174908],"category_scores_gemma":[0.00002007852,0.000084254534,0.0001377109,0.0007000741,0.00019935523,0.00017825134,0.00008805244,0.000403384,0.0000056586227],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014784916,0.00043906234,0.9465446,0.00030586962,0.00016952209,0.00002203354,0.02148637,0.00004819984,0.024221074,0.00011123736,0.000116660456,0.0050568944],"study_design_scores_gemma":[0.0039818888,0.0001452867,0.96328074,0.00023490282,0.00022204587,0.0000013398103,0.014059537,0.000072404946,0.016962362,0.00033374986,0.0006270975,0.00007863187],"about_ca_topic_score_codex":0.00046704197,"about_ca_topic_score_gemma":0.00069851754,"teacher_disagreement_score":0.016736167,"about_ca_system_score_codex":0.00015027705,"about_ca_system_score_gemma":0.00020339346,"threshold_uncertainty_score":0.34358004},"labels":[],"label_agreement":null},{"id":"W7073668910","doi":"","title":"New multidisciplinary prostate bone metastases clinic: first of its kind in Canada","year":2007,"lang":"en","type":"article","venue":"PubMed Central","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multidisciplinary approach; Prostate cancer; Malignancy; Prostate; Bone metastasis; Cancer; Metastasis","score_opus":0.033258518673083895,"score_gpt":0.3035716804291447,"score_spread":0.2703131617560608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7073668910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99161315,0.0039769327,0.000013269879,0.0016970276,0.0003599845,0.0012100961,0.00008925964,0.000012744403,0.0010275242],"genre_scores_gemma":[0.99520606,0.00062117615,0.00033371555,0.000046382385,0.00015258825,0.000039502782,0.0000828735,0.00001828556,0.0034994269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974899,0.000023636157,0.00042601384,0.00024231312,0.00041222756,0.00140586],"domain_scores_gemma":[0.9988195,0.000113747345,0.00008691566,0.00017951659,0.000046420202,0.00075394963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051757233,0.0001427777,0.0003378255,0.00012333386,0.000036861653,0.0000060862244,0.00007951212,0.00004319488,0.00020797434],"category_scores_gemma":[0.00012036822,0.000110418834,0.00006607066,0.00032192306,0.000041930074,0.000078212,0.000057542984,0.0002027811,0.0000054416923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024546764,0.00026874943,0.94959414,0.0002623081,0.00011535193,0.0013831876,0.00062073406,0.000016914426,0.00023877331,0.000012491437,0.004085558,0.04094709],"study_design_scores_gemma":[0.004623086,0.000111334215,0.9711823,0.0000942064,0.00004867233,0.000019489959,0.00035532934,0.000026289217,0.018610274,0.000011958221,0.0048082843,0.00010879228],"about_ca_topic_score_codex":0.30964375,"about_ca_topic_score_gemma":0.81877124,"teacher_disagreement_score":0.5091275,"about_ca_system_score_codex":0.0011374297,"about_ca_system_score_gemma":0.0028738268,"threshold_uncertainty_score":0.6949534},"labels":[],"label_agreement":null},{"id":"W7097037475","doi":"","title":"LE TRAITEMENT DU CANCER DE LA PROSTATE: ÉTUDE EX VIVO ET MISE EN PLACE DE MODÈLES IN VIVO","year":2014,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Ex vivo; In vivo; Radiation therapy; Chemotherapy","score_opus":0.015525809251444549,"score_gpt":0.32219842377629887,"score_spread":0.30667261452485434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7097037475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95434254,0.00050483,0.00025427903,0.0076993424,0.000028416282,0.0006206241,0.000018630533,0.00006268272,0.03646867],"genre_scores_gemma":[0.9794199,0.0014770095,0.001079321,0.00087942195,0.00008914911,0.00026495708,0.000008432422,0.000028483808,0.016753329],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987628,0.0001983145,0.00016273728,0.00023245718,0.00022853672,0.00041516844],"domain_scores_gemma":[0.9994153,0.00017463972,0.000026690755,0.00015766999,0.000039497678,0.00018620366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072402885,0.0001395237,0.00020820498,0.00009812623,0.00004315857,0.000030516456,0.000088544395,0.000086403,0.00046991167],"category_scores_gemma":[0.000055050677,0.00010299363,0.000047329224,0.0001224967,0.00007705291,0.00007196023,0.00004260133,0.0001875774,0.000008539207],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043933103,0.003015382,0.47048894,0.0010775275,0.0004775101,0.0005194226,0.032022398,0.004213354,0.39971298,0.0110401455,0.052894752,0.020144291],"study_design_scores_gemma":[0.031892907,0.0012631845,0.1834732,0.0009174312,0.00014831292,0.000088297216,0.0043404424,0.0261242,0.46455258,0.0012355329,0.2852275,0.0007363979],"about_ca_topic_score_codex":0.0043776496,"about_ca_topic_score_gemma":0.002456814,"teacher_disagreement_score":0.28701574,"about_ca_system_score_codex":0.00036956643,"about_ca_system_score_gemma":0.0007147274,"threshold_uncertainty_score":0.6617726},"labels":[],"label_agreement":null},{"id":"W7097378712","doi":"","title":"BMC Medical Genetics BioMed Central Research article Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer","year":2003,"lang":"en","type":"article","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Epidemiology; Mutation; Population; Germline mutation; Germline; Founder effect; Prostate","score_opus":0.07235655701981035,"score_gpt":0.3845540474127864,"score_spread":0.31219749039297606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7097378712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798086,0.0012833949,0.00001587605,0.010183741,0.00007159588,0.0015102581,0.000033064356,0.000024126093,0.0070693004],"genre_scores_gemma":[0.99335206,0.00071038015,0.0005445867,0.0003580598,0.00004766197,0.00040487552,0.00004769383,0.00003491121,0.004499753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962386,0.0002739697,0.00033594485,0.00044115735,0.001137847,0.0015725172],"domain_scores_gemma":[0.9980484,0.00016731149,0.000030844225,0.0002824037,0.00024510935,0.0012259176],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00093003013,0.00017269737,0.00027645205,0.00065380597,0.000127797,0.000057873294,0.00012890507,0.00014502238,0.0013483391],"category_scores_gemma":[0.00025540616,0.00012391481,0.000033075357,0.0014262148,0.0003548977,0.00009460132,0.000027239286,0.00054152147,0.00003544143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031220136,0.00032740508,0.9934239,0.00008777532,0.00005763219,0.0009958084,0.0011450186,0.00011133473,0.00048546417,0.00025257876,0.0014819467,0.0013189364],"study_design_scores_gemma":[0.009173913,0.00030884607,0.9745095,0.00035925454,0.00002300438,0.000040542294,0.0023690558,0.0025047758,0.0073962267,0.00046311595,0.0026206193,0.00023117775],"about_ca_topic_score_codex":0.27174994,"about_ca_topic_score_gemma":0.9517726,"teacher_disagreement_score":0.6800226,"about_ca_system_score_codex":0.0024770573,"about_ca_system_score_gemma":0.0082836095,"threshold_uncertainty_score":0.9995646},"labels":[],"label_agreement":null},{"id":"W7105042705","doi":"10.71781/26829","title":"Études multiparamétriques de biomarqueurs par immunofluorescence pour mieux suivre la progression du cancer de la prostate","year":2020,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Prostate disease; Prostate cancer; Thermoplastic polymer","score_opus":0.008781991842740961,"score_gpt":0.2540870315092751,"score_spread":0.24530503966653414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7105042705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8343778,0.14989375,0.000081897786,0.0024010367,0.0006965638,0.001425632,0.00020120232,0.00021959686,0.010702505],"genre_scores_gemma":[0.925421,0.046660427,0.0019139622,0.00011878619,0.0005041513,0.00033351438,0.0008514651,0.00009376002,0.024102934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99587655,0.0007596198,0.0004982489,0.00089634303,0.00091009814,0.0010591433],"domain_scores_gemma":[0.997359,0.00043005258,0.0004352905,0.00036231338,0.000524479,0.00088890194],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0005147279,0.00071147404,0.0006708913,0.0003373085,0.00425256,0.00015488917,0.0005111927,0.0008292958,0.00007064589],"category_scores_gemma":[0.00025215762,0.00068833993,0.00041724165,0.0005265907,0.00096698897,0.00036928133,0.00021911252,0.0010477795,0.00004898422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01260271,0.0013527971,0.46088427,0.002110886,0.0018245021,0.030090863,0.0799493,0.00059183687,0.37137273,0.004483322,0.0022620657,0.0324747],"study_design_scores_gemma":[0.009131013,0.0008856378,0.43122438,0.009013628,0.0015971399,0.0023252033,0.038676508,0.009867674,0.38513863,0.00020781784,0.110496186,0.0014362013],"about_ca_topic_score_codex":0.040966816,"about_ca_topic_score_gemma":0.0020934995,"teacher_disagreement_score":0.108234115,"about_ca_system_score_codex":0.012842182,"about_ca_system_score_gemma":0.012258817,"threshold_uncertainty_score":0.9995568},"labels":[],"label_agreement":null},{"id":"W7105244903","doi":"10.71781/29670","title":"Rôle de IKKe dans la résistance à castration et dans la progression du cancer de la prostate","year":2021,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate disease; Prostate cancer; Cancer; Colonic disease; Tumor progression","score_opus":0.005747070865997883,"score_gpt":0.24655933574236852,"score_spread":0.24081226487637064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7105244903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8736774,0.040715814,0.00044998145,0.00087178015,0.00069109973,0.00084211986,0.0002551624,0.000107251384,0.0823894],"genre_scores_gemma":[0.9074913,0.01455898,0.0009654622,0.000058963447,0.0003440364,0.0002761613,0.0017049237,0.00007099787,0.074529156],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.996131,0.0010037142,0.00041686321,0.00077161164,0.0008987633,0.00077804533],"domain_scores_gemma":[0.9979102,0.0003452296,0.00035859513,0.00035938446,0.00045910396,0.0005674565],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0006915542,0.00054634875,0.00050177646,0.00023064186,0.0037407745,0.00017243257,0.00027972594,0.0007345088,0.00006384367],"category_scores_gemma":[0.00012333684,0.00056135526,0.00030599604,0.00047104975,0.0008219309,0.00041537936,0.000118836346,0.0009546034,0.00001361992],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0045973524,0.0013193024,0.2973896,0.0015777611,0.0011588699,0.04636311,0.22086728,0.0046296534,0.37533748,0.037756912,0.0007498471,0.008252845],"study_design_scores_gemma":[0.007372379,0.00050004583,0.5195897,0.008059184,0.0017579041,0.0065943133,0.22504151,0.0056468803,0.17365672,0.00040249058,0.050193407,0.0011854325],"about_ca_topic_score_codex":0.03561807,"about_ca_topic_score_gemma":0.021380074,"teacher_disagreement_score":0.22220014,"about_ca_system_score_codex":0.014985356,"about_ca_system_score_gemma":0.0146673,"threshold_uncertainty_score":0.9996838},"labels":[],"label_agreement":null},{"id":"W7116858522","doi":"10.1016/s1470-2045(25)00566-2","title":"Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Bristol-Myers Squibb","keywords":"Docetaxel; Prostate cancer; Placebo; Nivolumab; Androgen receptor; Enzalutamide; Clinical trial; Phases of clinical research","score_opus":0.10426939970091895,"score_gpt":0.42134323272015745,"score_spread":0.3170738330192385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116858522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9586022,0.0061582844,0.0000830699,0.014738918,0.0012037841,0.016185291,0.0007353067,0.00014033513,0.0021528178],"genre_scores_gemma":[0.9562754,0.008068232,0.0012983395,0.001199231,0.0018080845,0.014493546,0.0008959882,0.00013398333,0.015827186],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99704933,0.00035882552,0.00069774175,0.00067448715,0.00035415535,0.0008654581],"domain_scores_gemma":[0.9977196,0.0008561181,0.00034161264,0.0005059825,0.00035454237,0.00022216894],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012571906,0.00045531793,0.0015206691,0.0002138995,0.00041216263,0.00010501069,0.0002485759,0.00022608033,0.00018167967],"category_scores_gemma":[0.00017070868,0.00029461127,0.00022424718,0.00048247795,0.0004797854,0.00013898413,0.00008511395,0.00045532326,0.000012727672],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9683922,0.0004646204,0.000035116118,0.00044884096,0.0020471606,0.00007258833,0.0020178517,0.000031817133,0.0096221045,0.00023100816,0.006983397,0.009653301],"study_design_scores_gemma":[0.932622,0.005193081,0.000016128848,0.0001941538,0.0009849804,0.00001960412,0.0007358502,0.0008944758,0.023786131,0.0002043387,0.03507334,0.0002759012],"about_ca_topic_score_codex":0.00043198504,"about_ca_topic_score_gemma":0.00051101216,"teacher_disagreement_score":0.035770178,"about_ca_system_score_codex":0.0012869914,"about_ca_system_score_gemma":0.0030267162,"threshold_uncertainty_score":0.9999506},"labels":[],"label_agreement":null},{"id":"W7117242635","doi":"10.71781/34060","title":"Tendances d’utilisation des nouvelles thérapies hormonales en données réelles à travers le monde pour le cancer de la prostate sensible à la castration (CPSC) entre 2012 et 2024 : une revue systématique","year":2025,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate disease; Colonic disease; Prostate cancer","score_opus":0.03388060120097267,"score_gpt":0.34538958868177505,"score_spread":0.31150898748080236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117242635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8751934,0.054102544,0.00019585168,0.010107617,0.0005672995,0.0034338236,0.0009332911,0.000016605618,0.055449557],"genre_scores_gemma":[0.5795393,0.09313495,0.0053004795,0.000024405721,0.00027592923,0.0005811953,0.0027989587,0.00007398197,0.3182708],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99652475,0.0010113722,0.000642714,0.0007690121,0.000389134,0.0006629968],"domain_scores_gemma":[0.9978168,0.0009445477,0.00035793407,0.0002918561,0.00037577457,0.00021307333],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011856637,0.00059256324,0.0007389256,0.00033971417,0.00055918004,0.0005693544,0.00036066692,0.0005813678,0.0005262899],"category_scores_gemma":[0.00015544581,0.0005300398,0.00018476941,0.0005207006,0.0004149523,0.0008452594,0.00009753064,0.00069503137,0.00005392836],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005405981,0.0020345384,0.014758394,0.013304959,0.004064838,0.0010297567,0.37128723,0.008268566,0.19940366,0.0055644577,0.01653012,0.3583475],"study_design_scores_gemma":[0.008163241,0.00067481224,0.053599223,0.030707223,0.0019042884,0.00017793805,0.496378,0.0063767526,0.33210465,0.0032878374,0.06519754,0.0014284906],"about_ca_topic_score_codex":0.032095294,"about_ca_topic_score_gemma":0.06135779,"teacher_disagreement_score":0.35691902,"about_ca_system_score_codex":0.0006588934,"about_ca_system_score_gemma":0.0113955205,"threshold_uncertainty_score":0.9997151},"labels":[],"label_agreement":null},{"id":"W7117310578","doi":"10.1002/cam4.71343","title":"Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS","year":2025,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen's University; University Health Network; Mount Sinai Hospital","funders":"European Association of Urology; University of Adelaide; Bayer HealthCare; Bayer","keywords":"Quality of life (healthcare); Prostatectomy; Radiation therapy; Prostate cancer; MEDLINE","score_opus":0.022215426646944137,"score_gpt":0.34815386039520085,"score_spread":0.3259384337482567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117310578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804483,0.014947993,0.000059615282,0.0022142164,0.000033901313,0.0021611827,0.000026725635,0.000010077654,0.000097972166],"genre_scores_gemma":[0.9908075,0.008211128,0.0000134580105,0.000496953,0.00002306276,0.00014580607,0.000019654228,0.000016044354,0.0002664393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844384,0.0001817754,0.0004664227,0.00025037208,0.00044660797,0.00021097658],"domain_scores_gemma":[0.99841464,0.00090223487,0.00018331893,0.00024519092,0.00014918073,0.00010546172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031497568,0.0001832484,0.0008007466,0.00016131987,0.00002620865,0.0000016676805,0.00009711179,0.00007673474,0.00006361089],"category_scores_gemma":[0.00025541036,0.00007891876,0.000033276887,0.0005983266,0.0011795778,0.000020986754,0.000013201459,0.00019918784,7.511061e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12050258,0.0022441996,0.67231387,0.0030620014,0.0010906594,0.000015899946,0.0022048303,0.000008467108,0.04913835,0.00009567069,0.0017178898,0.14760555],"study_design_scores_gemma":[0.06851301,0.0072933254,0.78447515,0.0029316985,0.00009035537,3.5849456e-7,0.0001329877,0.000061560015,0.13572626,0.000008668024,0.000674805,0.00009185357],"about_ca_topic_score_codex":0.00094433315,"about_ca_topic_score_gemma":0.000027866956,"teacher_disagreement_score":0.1475137,"about_ca_system_score_codex":0.00015900863,"about_ca_system_score_gemma":0.00041418688,"threshold_uncertainty_score":0.43462035},"labels":[],"label_agreement":null},{"id":"W7117448944","doi":"10.36469/001c.151273","title":"Comparison of Prostate-Specific Antigen Response in Black Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide vs Abiraterone Acetate","year":2025,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Abiraterone acetate; Prostate cancer; Abiraterone; Prostate-specific antigen; Antiandrogen; Clinical trial","score_opus":0.11931529318118678,"score_gpt":0.46019572109938683,"score_spread":0.34088042791820006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117448944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877388,0.0012986861,0.000003017664,0.009276702,0.000077346755,0.001451619,0.000085422456,0.0000030512183,0.0000653935],"genre_scores_gemma":[0.98966974,0.009593163,0.00019360511,0.00021215079,0.000011115048,0.000021859294,0.000022464308,0.0000204884,0.00025541047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970532,0.00062242494,0.0011579831,0.00025837423,0.00038401128,0.00052402355],"domain_scores_gemma":[0.99771005,0.0006145081,0.0004827835,0.00018376624,0.00080069446,0.00020822654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028463653,0.0001805068,0.0010340151,0.0011040937,0.00013780684,0.000054495238,0.00009357335,0.000050185954,0.0000113964725],"category_scores_gemma":[0.000107716885,0.00012172076,0.000059936425,0.00043373814,0.00031538022,0.00015826517,0.00004738476,0.0006374098,0.000002710945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059594616,0.0007188175,0.92404705,0.00044926634,0.00032814706,0.000058987494,0.0046978346,0.0010127573,0.00014275905,0.000057801743,0.00017981698,0.0087121595],"study_design_scores_gemma":[0.011428797,0.006282305,0.9766635,0.00076281367,0.000016871147,0.0000032306743,0.0022664315,0.00043027799,0.0015200361,0.00006521186,0.00047128292,0.00008925399],"about_ca_topic_score_codex":0.00024018799,"about_ca_topic_score_gemma":0.00022116018,"teacher_disagreement_score":0.052616455,"about_ca_system_score_codex":0.000767318,"about_ca_system_score_gemma":0.0021608989,"threshold_uncertainty_score":0.49636286},"labels":[],"label_agreement":null},{"id":"W7120585673","doi":"","title":"Expression of epithelial-mesenchymal transition markers SNAI1 and ZEB1 results in transcriptional alterations that promote tumor progression and immune evasion in prostate cancer","year":2023,"lang":"pt","type":"dissertation","venue":"Digital Library of Theses and Dissertations  (Universidade de São Paulo)","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"SNAI1; Immune system; Prostate cancer; Tumor progression; LNCaP; Immunotherapy","score_opus":0.016124171628599013,"score_gpt":0.2781922582707112,"score_spread":0.2620680866421122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7120585673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98907834,0.0041861427,0.000005547808,0.0010751472,0.00007744691,0.001689072,0.0033864814,0.00003317536,0.00046861573],"genre_scores_gemma":[0.98511463,0.0049625332,0.00015992379,0.000010081051,0.000016631211,0.00011257739,0.007535336,0.000058834168,0.0020294546],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99776703,0.00013605741,0.00067562016,0.000601817,0.00041954062,0.00039992487],"domain_scores_gemma":[0.99888104,0.0002647209,0.00035773066,0.00018518676,0.00009349499,0.00021779536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019050662,0.00039635698,0.00062940334,0.0011052624,0.00019688682,0.00013844426,0.00012101533,0.00020528334,0.00004584654],"category_scores_gemma":[0.000064850836,0.00035286366,0.00012666934,0.00076124526,0.00023073787,0.0019758535,0.000047644775,0.00034827887,0.000001006866],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07889593,0.0034120816,0.1556469,0.014054947,0.00064324663,0.00092362013,0.26478976,0.0004237707,0.37741196,0.0010079117,0.00009097829,0.10269889],"study_design_scores_gemma":[0.0075700507,0.0011371442,0.8043105,0.013653351,0.00018901151,0.000019695024,0.119410135,0.002993848,0.04951585,0.0007227193,0.00002000346,0.00045768335],"about_ca_topic_score_codex":0.0002657551,"about_ca_topic_score_gemma":0.000326877,"teacher_disagreement_score":0.6486636,"about_ca_system_score_codex":0.00005923536,"about_ca_system_score_gemma":0.00040421623,"threshold_uncertainty_score":0.99989235},"labels":[],"label_agreement":null},{"id":"W7125284583","doi":"10.37287/jppp.v7i6.1064","title":"Androgen Receptor, Resistensi Terapi, dan Pendekatan Terapeutik Baru pada Kanker Prostat","year":2025,"lang":"","type":"article","venue":"Jurnal Penelitian Perawat Profesional","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Androgen deprivation therapy; Enzalutamide; Androgen receptor; Disease","score_opus":0.026350153533422172,"score_gpt":0.3301867631892701,"score_spread":0.3038366096558479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7125284583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7588266,0.09161061,0.0000310239,0.08543448,0.009099474,0.00763454,0.0013511698,0.00031426828,0.045697827],"genre_scores_gemma":[0.78368837,0.0065949014,0.0003951934,0.004925411,0.0015186477,0.0004046831,0.0015213847,0.00017172209,0.2007797],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.98915255,0.0010245246,0.002241486,0.0022474232,0.0026390238,0.0026949882],"domain_scores_gemma":[0.99462295,0.00050110917,0.00043956123,0.0015532377,0.0014689283,0.001414211],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0015821764,0.001425797,0.001679148,0.0020502594,0.0020635794,0.0005708862,0.0009857476,0.0008733518,0.007135127],"category_scores_gemma":[0.00023042176,0.0011545526,0.0009983125,0.0026191673,0.0011399569,0.00086669513,0.00085546274,0.0026496237,0.00074869976],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02618708,0.0068594175,0.345579,0.009228334,0.008855588,0.0052625993,0.007651126,0.000012879828,0.111940175,0.01107217,0.28884238,0.17850924],"study_design_scores_gemma":[0.029005066,0.0029656857,0.3406434,0.012490167,0.0013836202,0.0008384587,0.0065382896,0.000408211,0.037255466,0.0027099133,0.56319946,0.002562273],"about_ca_topic_score_codex":0.00014432835,"about_ca_topic_score_gemma":0.000067486195,"teacher_disagreement_score":0.27435705,"about_ca_system_score_codex":0.00175447,"about_ca_system_score_gemma":0.0067954436,"threshold_uncertainty_score":0.9998492},"labels":[],"label_agreement":null},{"id":"W7131864050","doi":"10.5376/cge.2025.13.0008","title":"Role of Histone Modifications in Prostate Cancer","year":2025,"lang":"","type":"article","venue":"Cancer Genetics and Epigenetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"","score_opus":0.02552307695890751,"score_gpt":0.38126743993105283,"score_spread":0.35574436297214534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7131864050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51576173,0.47873834,0.000027930399,0.0018926195,0.00037999306,0.0009569581,0.00032394394,0.0000073232686,0.0019111839],"genre_scores_gemma":[0.5614136,0.43213284,0.0001610717,0.0000860301,0.00007900344,0.00029602475,0.00001717589,0.000026566515,0.0057877153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973274,0.00007882311,0.0008544182,0.0006665365,0.00035003788,0.0007227794],"domain_scores_gemma":[0.9984062,0.00007315682,0.00020586395,0.00058574683,0.00046295486,0.00026608908],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020745324,0.00037707287,0.00069800054,0.00048321416,0.00014853766,0.000037966667,0.0002303656,0.00021999214,0.00019138292],"category_scores_gemma":[0.00002889083,0.0003680661,0.00010095593,0.0009916808,0.0006786034,0.000031124757,0.00019393807,0.00036523657,0.0000034634647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072643714,0.0007454231,0.53610647,0.0019311102,0.00062728085,0.00001456338,0.0043648877,0.0041059847,0.062686145,0.00092442275,0.00087544264,0.3868918],"study_design_scores_gemma":[0.008179528,0.0007183433,0.6775414,0.0032530855,0.0012886197,0.000002234703,0.0023637465,0.0205482,0.2097819,0.0051660747,0.07037854,0.00077835674],"about_ca_topic_score_codex":0.0020153944,"about_ca_topic_score_gemma":0.0012493588,"teacher_disagreement_score":0.38611346,"about_ca_system_score_codex":0.0005468852,"about_ca_system_score_gemma":0.0021985958,"threshold_uncertainty_score":0.99987715},"labels":[],"label_agreement":null},{"id":"W7131868699","doi":"10.5376/cge.2025.13.0003","title":"Emerging Molecular Pathways in Prostate Cancer Development and Their Therapeutic Implications","year":2025,"lang":"","type":"article","venue":"Cancer Genetics and Epigenetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Cancer; Disease; Prostate disease; Prostate","score_opus":0.033720258564383855,"score_gpt":0.33361211171941296,"score_spread":0.2998918531550291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7131868699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55846035,0.4357832,0.00038551772,0.0036690908,0.0002656139,0.0010066187,0.000098502016,0.000012644628,0.00031843176],"genre_scores_gemma":[0.6219155,0.37587938,0.00025987066,0.00052550586,0.000055475277,0.00057396316,0.000020562467,0.000040625353,0.00072908547],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99721134,0.000086277854,0.0006925266,0.0008631024,0.00021482508,0.0009319036],"domain_scores_gemma":[0.9987371,0.00007114503,0.0001296914,0.000466217,0.0002620285,0.0003338098],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002556803,0.00053014606,0.0005906245,0.00037146173,0.00035395048,0.00012534202,0.00019167496,0.00019817177,0.00005075497],"category_scores_gemma":[0.000011776972,0.00045387197,0.00006528154,0.000735674,0.00038337772,0.000032975724,0.0002977019,0.00039077402,0.000001888571],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013632012,0.00015792467,0.25298288,0.0007400749,0.000528991,0.000018260596,0.006120843,0.0004400074,0.020799091,0.00048031402,0.0000561192,0.7175392],"study_design_scores_gemma":[0.0062378068,0.00038917497,0.6325912,0.0024316981,0.00055644073,0.000006911566,0.0030883343,0.0051439153,0.2316466,0.0054753767,0.11134115,0.0010913968],"about_ca_topic_score_codex":0.00019698859,"about_ca_topic_score_gemma":0.00049046474,"teacher_disagreement_score":0.7164478,"about_ca_system_score_codex":0.00045706285,"about_ca_system_score_gemma":0.0021064521,"threshold_uncertainty_score":0.9997913},"labels":[],"label_agreement":null},{"id":"W7132975980","doi":"","title":"An Economic Evaluation of Docetaxel versus Abiraterone or Enzalutamide in Addition to Androgen Deprivation Therapy for the First-Line Treatment of Metastatic Hormone-sensitive Prostate Cancer in Ontario","year":2022,"lang":"","type":"dissertation","venue":"TSpace","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Enzalutamide; Docetaxel; Prostate cancer; Abiraterone; Androgen deprivation therapy; Overall survival","score_opus":0.12036202861937245,"score_gpt":0.44269437974365244,"score_spread":0.32233235112428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132975980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97649074,0.007323135,0.000018582095,0.0006561031,0.0004350347,0.014145418,0.000881783,0.000008325561,0.0000408552],"genre_scores_gemma":[0.96756065,0.016144931,0.00011805405,0.000022030483,0.00006895024,0.009628296,0.005310771,0.00007270506,0.0010735951],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966647,0.0003622752,0.0009930683,0.00073885574,0.00075042713,0.0004906815],"domain_scores_gemma":[0.9974726,0.0006155941,0.00074124144,0.000511324,0.00054645276,0.00011279687],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001298661,0.0005086161,0.0010375167,0.00056648144,0.00016088696,0.000027057198,0.00016750413,0.00013587675,0.0015050323],"category_scores_gemma":[0.0000834343,0.00035971464,0.00017125583,0.0005019547,0.000083372404,0.0002060856,0.000020688036,0.0002377338,0.000003505862],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3517775,0.0039057925,0.009062952,0.00042363867,0.0029456648,0.00003184729,0.2734421,0.13321896,0.016718384,0.000027855805,0.00005824428,0.20838706],"study_design_scores_gemma":[0.16070643,0.06338329,0.41790846,0.0011924275,0.004378831,0.0000051140396,0.093600504,0.056831967,0.19914553,0.00019080607,0.001553814,0.0011028335],"about_ca_topic_score_codex":0.18374196,"about_ca_topic_score_gemma":0.7737668,"teacher_disagreement_score":0.5900248,"about_ca_system_score_codex":0.008792849,"about_ca_system_score_gemma":0.0044927015,"threshold_uncertainty_score":0.9998855},"labels":[],"label_agreement":null},{"id":"W7135074528","doi":"10.5376/cge.2024.12.0010","title":"Advances and Prospects in Whole-Genome Sequencing Studies of Prostate Cancer","year":2024,"lang":"","type":"article","venue":"Cancer Genetics and Epigenetics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Disease; Cancer; Prostate disease; Prostate-specific antigen; MEDLINE","score_opus":0.0557259192245929,"score_gpt":0.3792822653110463,"score_spread":0.3235563460864534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7135074528","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45866466,0.5381214,0.0000061275564,0.0012440986,0.0006040135,0.0008667147,0.0003801037,0.000013176294,0.000099707766],"genre_scores_gemma":[0.483281,0.51475096,0.0001422611,0.000040387105,0.00026426718,0.00018989123,0.000011694723,0.000050014914,0.0012695456],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99668086,0.000076989956,0.00084699946,0.0009909777,0.00049508264,0.00090911426],"domain_scores_gemma":[0.9986501,0.0001419869,0.00015728266,0.00033294462,0.00036791683,0.00034980744],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000385597,0.00054800295,0.0009691831,0.00039834378,0.00015496957,0.00012066437,0.0001387117,0.0002015226,0.000048274236],"category_scores_gemma":[0.000040619274,0.0004568349,0.00008423321,0.0007940173,0.0011692573,0.00011660773,0.00028423988,0.00045750773,0.0000029231132],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006320457,0.00016427475,0.35136488,0.036996335,0.0016251941,0.0005306467,0.039794285,0.0035308904,0.06523635,0.00019515592,0.00016037043,0.49976957],"study_design_scores_gemma":[0.019640347,0.011393915,0.21669647,0.061582386,0.00601511,0.00013248155,0.03917371,0.03672219,0.20607762,0.01670171,0.380675,0.005189076],"about_ca_topic_score_codex":0.00025975736,"about_ca_topic_score_gemma":0.00079607114,"teacher_disagreement_score":0.4945805,"about_ca_system_score_codex":0.00069451815,"about_ca_system_score_gemma":0.0015059815,"threshold_uncertainty_score":0.99978834},"labels":[],"label_agreement":null},{"id":"W7137905766","doi":"10.6084/m9.figshare.4334603.v1","title":"Additional file 1: of Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review","year":2016,"lang":"","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Stroke (engine); Prostate; Table (database); Androgen deprivation therapy; Prostate cancer; Funnel plot; Scale (ratio); Quality (philosophy)","score_opus":0.09338956397958137,"score_gpt":0.35506399122403876,"score_spread":0.2616744272444574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7137905766","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009408728,0.17493786,8.0861844e-7,0.001225205,0.0000064852075,0.00660061,0.81715655,0.000014240568,0.000048855356],"genre_scores_gemma":[0.0007793728,0.009832413,0.00009503405,0.0003440373,0.000028879624,0.053111464,0.9190184,0.000035551697,0.01675488],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.997624,0.00016072858,0.00082035287,0.0005128043,0.0005255977,0.00035655423],"domain_scores_gemma":[0.9954344,0.002317383,0.0005718446,0.00045376323,0.0009784449,0.0002441418],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017109427,0.0002959345,0.0019324989,0.0002908489,0.00010118717,0.00002515111,0.00014926806,0.00011087665,0.9875217],"category_scores_gemma":[0.004071376,0.00015804806,0.0009636051,0.00088454405,0.000022607961,0.0001356402,0.00006575114,0.000079977865,0.00034770375],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014682305,0.000062254,0.0000068149234,0.09822131,0.081834674,0.0000045750917,0.00007370135,3.9470163e-7,0.000032044536,6.1894326e-7,0.81814164,0.0014751235],"study_design_scores_gemma":[0.0030488423,0.0012936641,0.00040679506,0.6439315,0.17781709,0.000008949884,0.00004450504,0.00009201543,0.0018367232,0.000035083565,0.17099896,0.00048583286],"about_ca_topic_score_codex":0.000008587682,"about_ca_topic_score_gemma":0.000015399868,"teacher_disagreement_score":0.98717403,"about_ca_system_score_codex":0.00014867417,"about_ca_system_score_gemma":0.0004243565,"threshold_uncertainty_score":0.6445013},"labels":[],"label_agreement":null},{"id":"W7138354603","doi":"10.6084/m9.figshare.4334603","title":"Additional file 1: of Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review","year":2016,"lang":"","type":"article","venue":"Figshare","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Stroke (engine); Prostate; Table (database); Androgen deprivation therapy; Prostate cancer; Funnel plot; Scale (ratio); Quality (philosophy)","score_opus":0.09338956397958137,"score_gpt":0.35506399122403876,"score_spread":0.2616744272444574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7138354603","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009408728,0.17493786,8.0861844e-7,0.001225205,0.0000064852075,0.00660061,0.81715655,0.000014240568,0.000048855356],"genre_scores_gemma":[0.0007793728,0.009832413,0.00009503405,0.0003440373,0.000028879624,0.053111464,0.9190184,0.000035551697,0.01675488],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.997624,0.00016072858,0.00082035287,0.0005128043,0.0005255977,0.00035655423],"domain_scores_gemma":[0.9954344,0.002317383,0.0005718446,0.00045376323,0.0009784449,0.0002441418],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017109427,0.0002959345,0.0019324989,0.0002908489,0.00010118717,0.00002515111,0.00014926806,0.00011087665,0.9875217],"category_scores_gemma":[0.004071376,0.00015804806,0.0009636051,0.00088454405,0.000022607961,0.0001356402,0.00006575114,0.000079977865,0.00034770375],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014682305,0.000062254,0.0000068149234,0.09822131,0.081834674,0.0000045750917,0.00007370135,3.9470163e-7,0.000032044536,6.1894326e-7,0.81814164,0.0014751235],"study_design_scores_gemma":[0.0030488423,0.0012936641,0.00040679506,0.6439315,0.17781709,0.000008949884,0.00004450504,0.00009201543,0.0018367232,0.000035083565,0.17099896,0.00048583286],"about_ca_topic_score_codex":0.000008587682,"about_ca_topic_score_gemma":0.000015399868,"teacher_disagreement_score":0.98717403,"about_ca_system_score_codex":0.00014867417,"about_ca_system_score_gemma":0.0004243565,"threshold_uncertainty_score":0.6445013},"labels":[],"label_agreement":null},{"id":"W7151355046","doi":"10.70675/c2bce871z11ffz4c9bz83d8za8a65d0da4a6","title":"Identification et caractérisation des cellules luminales progénitrices dans le cancer de la prostate chez l'homme","year":2023,"lang":"","type":"dissertation","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate disease; Prostate cancer; Tumor cells; Medical screening","score_opus":0.033295608470496556,"score_gpt":0.37438142227101673,"score_spread":0.34108581380052017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7151355046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97810835,0.00985099,0.0002209608,0.0010134703,0.0006104464,0.0032894919,0.00020699887,0.0003074199,0.00639186],"genre_scores_gemma":[0.7897177,0.043276817,0.00013710734,0.00003348261,0.0003001662,0.0026851683,0.0058608693,0.00019022568,0.15779847],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99479496,0.00090606656,0.0010533846,0.0011201132,0.0010755222,0.0010499404],"domain_scores_gemma":[0.9968414,0.0006141491,0.0007352694,0.0005216717,0.00090049347,0.00038705274],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024355946,0.0007477246,0.0007504372,0.00075909914,0.00088968914,0.0005643032,0.00037763335,0.0006772833,0.0002751435],"category_scores_gemma":[0.00034086854,0.0006495854,0.0003002982,0.0013031606,0.00073218683,0.0006345757,0.00007171726,0.0009060034,0.00024780488],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023991885,0.0016573847,0.21249036,0.010085876,0.0016169194,0.00032071894,0.15764181,0.00014331845,0.5507868,0.0011257714,0.0015259527,0.060205925],"study_design_scores_gemma":[0.0025295713,0.0002757838,0.5190388,0.0018302954,0.0009556671,0.000016366143,0.076799095,0.0013352945,0.39481395,0.0012681882,0.0005052161,0.0006317564],"about_ca_topic_score_codex":0.027161073,"about_ca_topic_score_gemma":0.008576042,"teacher_disagreement_score":0.30654845,"about_ca_system_score_codex":0.0015529254,"about_ca_system_score_gemma":0.0047942526,"threshold_uncertainty_score":0.9995955},"labels":[],"label_agreement":null},{"id":"W7161753956","doi":"10.82308/28979","title":"Evaluation of novel hormonal agents in metastatic castration-resistant prostate cancer using real-world data in Quebec","year":2024,"lang":"en","type":"dissertation","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Prostate cancer; Abiraterone; Abiraterone acetate; Medical prescription; Specialty; Disease; Hormonal therapy","score_opus":0.3125339982358543,"score_gpt":0.5068299881811996,"score_spread":0.1942959899453453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7161753956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98942393,0.003526954,0.0000018657756,0.00019884047,0.00024457535,0.002371346,0.0006303166,0.0000146247385,0.0035875356],"genre_scores_gemma":[0.94693106,0.0013494618,0.0007155991,0.000014761594,0.00006762502,0.0003438929,0.016984614,0.00007002135,0.033522967],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9965527,0.000116473544,0.0007471801,0.0006033709,0.0016687408,0.00031152333],"domain_scores_gemma":[0.99866045,0.000054780925,0.00022559207,0.00046158212,0.0005203152,0.00007729024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016049157,0.0002701939,0.00056312396,0.0010320854,0.000025815174,0.000047077316,0.00016016155,0.0000762563,0.00026393964],"category_scores_gemma":[0.00009466696,0.00021369236,0.00005802009,0.0010903334,0.000051817347,0.00022725802,0.000047076745,0.00035558312,0.0000042509578],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030876622,0.010411602,0.12086366,0.034547366,0.009488785,0.0020521597,0.042166505,0.010439798,0.3921392,0.0015521393,0.006708002,0.33875418],"study_design_scores_gemma":[0.013458966,0.0003117636,0.6929974,0.009283178,0.004705946,0.000004776688,0.0076781507,0.2631023,0.007264943,0.0002867593,0.0002377235,0.00066808594],"about_ca_topic_score_codex":0.44282165,"about_ca_topic_score_gemma":0.9321703,"teacher_disagreement_score":0.5721338,"about_ca_system_score_codex":0.001902431,"about_ca_system_score_gemma":0.0066162907,"threshold_uncertainty_score":0.9990153},"labels":[],"label_agreement":null},{"id":"W7161830472","doi":"10.82308/52996","title":"The fer tyrosine kinase contributes to aberrant androgen receptor signaling in prostate cancer","year":2018,"lang":"en","type":"dissertation","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Prostate disease; Androgen receptor; LNCaP; Phosphorylation; Tyrosine kinase","score_opus":0.0215658290158476,"score_gpt":0.3421740115347024,"score_spread":0.3206081825188548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7161830472","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9645182,0.021644574,0.0000015506932,0.00671326,0.00083471276,0.0030114602,0.00011737096,0.00005227394,0.003106587],"genre_scores_gemma":[0.4024346,0.010659159,0.00031745812,0.0009321266,0.0007341256,0.0031786452,0.0033884677,0.00017744907,0.578178],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981933,0.00004545977,0.00038471978,0.00042707508,0.00038509662,0.00056433957],"domain_scores_gemma":[0.9988617,0.00009119317,0.00008396366,0.00027946394,0.00050418946,0.00017952416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035394914,0.00028945852,0.0004479932,0.00020670779,0.00020368781,0.000088293666,0.00014005552,0.0001609345,0.0006322515],"category_scores_gemma":[0.000104608254,0.00015972428,0.000095326985,0.00046916335,0.00006447729,0.000043582684,0.000027086911,0.00031290727,0.00013539275],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058245473,0.0010366208,0.07220038,0.0021297557,0.002510022,0.0005184277,0.010079854,0.000021891636,0.3269708,0.00046422036,0.35569277,0.1701298],"study_design_scores_gemma":[0.0068247137,0.0008417677,0.011056808,0.003223196,0.00025556932,0.0000033570955,0.0027651815,0.00005190645,0.71167046,0.00020159387,0.2626107,0.0004947681],"about_ca_topic_score_codex":0.0010098174,"about_ca_topic_score_gemma":0.0048565357,"teacher_disagreement_score":0.5750714,"about_ca_system_score_codex":0.00045793894,"about_ca_system_score_gemma":0.00066213735,"threshold_uncertainty_score":0.69227105},"labels":[],"label_agreement":null},{"id":"W7162002379","doi":"10.82308/13181","title":"I. Hybrid androgen receptor antagonist – Histone deacetylase inhibitors and II. development of an oxy-Cope / Michael cascade reaction","year":2022,"lang":"en","type":"dissertation","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Histone deacetylase; Androgen receptor; Prostate cancer; Vorinostat; Histone deacetylase inhibitor; Drug discovery; Epigenetics; Histone; Prostate","score_opus":0.0167817726286778,"score_gpt":0.32156342559926354,"score_spread":0.30478165297058574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7162002379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99110764,0.0038493993,7.565963e-7,0.00015044457,0.00055080565,0.0009368474,0.000087138935,0.00006226238,0.0032547282],"genre_scores_gemma":[0.7133085,0.0043747486,0.0034706057,0.00011274436,0.00037443478,0.00058881595,0.048501436,0.00021857036,0.22905016],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99802506,0.000050166145,0.000503079,0.00053582963,0.0005867133,0.00029912786],"domain_scores_gemma":[0.9990675,0.000019983023,0.00023343509,0.00026092018,0.00016143142,0.00025674835],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026281786,0.00031461014,0.0005234748,0.00034231532,0.00041363775,0.000015887324,0.000085983,0.00015830336,0.0007200392],"category_scores_gemma":[0.000024212397,0.00026769456,0.00008417073,0.00016804268,0.00007020408,0.000119640485,0.00006192141,0.0004020132,0.000009138323],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006763889,0.0014629595,0.00034169498,0.0018074687,0.0007978445,0.00021594093,0.009635348,3.72954e-7,0.79763585,0.000032931097,0.011379208,0.1699265],"study_design_scores_gemma":[0.0020555514,0.0008458191,0.0011493973,0.00019174743,0.0001827977,0.00007657082,0.0036866497,0.000009921633,0.9180822,0.0000077942295,0.07341447,0.00029711408],"about_ca_topic_score_codex":0.00058268895,"about_ca_topic_score_gemma":0.00042260662,"teacher_disagreement_score":0.27779913,"about_ca_system_score_codex":0.00076942856,"about_ca_system_score_gemma":0.0010767704,"threshold_uncertainty_score":0.9999775},"labels":[],"label_agreement":null},{"id":"W7162117714","doi":"10.82308/19827","title":"The heath economics of advanced prostate cancer in Canada","year":2025,"lang":"en","type":"dissertation","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Prostate disease; Cancer; Breast cancer","score_opus":0.009953223195951115,"score_gpt":0.3120547242909647,"score_spread":0.3021015010950136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7162117714","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94035226,0.012427543,4.0920007e-8,0.001594095,0.0006079716,0.0010868803,0.00013549141,0.000005745139,0.043789957],"genre_scores_gemma":[0.45130953,0.06271901,0.000020462303,0.000092599796,0.000031500247,0.00041305405,0.0006883459,0.000021412237,0.48470408],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992084,0.00001077158,0.00026726915,0.00017540652,0.000119735654,0.0002184098],"domain_scores_gemma":[0.99950284,0.000070500224,0.000077742174,0.00018625686,0.00011491305,0.000047747428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058155645,0.00012662489,0.00029669047,0.000070915456,0.00004020304,0.000006181516,0.00008253373,0.00005386901,0.000094147894],"category_scores_gemma":[0.00001653382,0.000075579934,0.00004155342,0.00013222203,0.000014225044,0.000019218876,0.000010630761,0.00019486001,3.9595278e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009841453,0.0001308849,0.07309786,0.0024729415,0.00080378633,0.00007350432,0.0012459534,0.00067994,0.0007608457,0.00070737716,0.011245112,0.8989403],"study_design_scores_gemma":[0.022840006,0.0008467451,0.51254636,0.008472879,0.0006453109,0.000004737737,0.045546986,0.0015490206,0.18821795,0.001268888,0.21673922,0.0013218744],"about_ca_topic_score_codex":0.8879185,"about_ca_topic_score_gemma":0.99792117,"teacher_disagreement_score":0.8976185,"about_ca_system_score_codex":0.0013283123,"about_ca_system_score_gemma":0.0146607,"threshold_uncertainty_score":0.99092525},"labels":[],"label_agreement":null},{"id":"W7163871724","doi":"10.31579/2692-9406/191","title":"Treatment Related Neuroendocrine Prostatic Carcinoma: Review and Update","year":2024,"lang":"","type":"article","venue":"Biomedical Research and Clinical Reviews","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Office of the Chief Medical Examiner","funders":"","keywords":"Prostate; Androgen receptor; Disease; Prostate cancer; Carcinoma; Neuroendocrine differentiation; Immunotherapy; Adenocarcinoma; Androgen","score_opus":0.2029353555665539,"score_gpt":0.5279514340065545,"score_spread":0.32501607844000063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7163871724","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0125659825,0.8761983,0.00000468292,0.10209225,0.0006889799,0.007275243,0.00015201328,0.00007107296,0.00095146516],"genre_scores_gemma":[0.04142584,0.9324732,0.00008530267,0.00086518936,0.00069304893,0.0006421411,0.000284113,0.00008735239,0.023443857],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9873877,0.0031569435,0.003290592,0.0022857713,0.0017460892,0.0021328952],"domain_scores_gemma":[0.99030393,0.0038983666,0.00017456635,0.0010728716,0.0003383603,0.0042119133],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0088742,0.00077407324,0.0029253927,0.00052392524,0.0004431163,0.00033845918,0.0003556984,0.00031395053,0.0024194291],"category_scores_gemma":[0.008240181,0.00044180165,0.00060563674,0.0024043361,0.0052637337,0.00021805697,0.0007008239,0.0029008796,0.002239262],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043294768,0.001608905,0.0021090135,0.032530364,0.0006104438,0.0063737514,0.000069383044,5.5470756e-10,0.000028608167,0.0005654472,0.08739072,0.8682804],"study_design_scores_gemma":[0.00423584,0.01658685,0.0025439647,0.019030632,0.0018412366,0.0006490159,0.00005267862,0.00035315717,0.000009454475,0.0007240939,0.953622,0.000351092],"about_ca_topic_score_codex":0.00013646497,"about_ca_topic_score_gemma":0.000012415934,"teacher_disagreement_score":0.86792934,"about_ca_system_score_codex":0.00045501723,"about_ca_system_score_gemma":0.002225617,"threshold_uncertainty_score":0.99980336},"labels":[],"label_agreement":null},{"id":"W776188649","doi":"10.1016/j.eururo.2015.06.022","title":"Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism","year":2015,"lang":"en","type":"article","venue":"European Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Androgen deprivation therapy; Hazard ratio; Prostate cancer; Proportional hazards model; Internal medicine; Cohort; Cohort study; Population; Incidence (geometry); Confidence interval; Confounding; Observational study; Cancer; Oncology","score_opus":0.037103359965196814,"score_gpt":0.31359687545576165,"score_spread":0.27649351549056483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W776188649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981796,0.011631949,0.000049745722,0.0035924313,0.000086362306,0.0008749276,0.000026260495,0.00001658952,0.00192569],"genre_scores_gemma":[0.9928311,0.0061205397,0.000074038355,0.000447093,0.00012394917,0.000048063048,0.000017437824,0.000019695244,0.00031806462],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99933803,0.00018774932,0.00011661918,0.00013340688,0.000082112776,0.0001420825],"domain_scores_gemma":[0.99953085,0.00007733139,0.00007290158,0.00014455854,0.00011794231,0.000056418383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057517673,0.00006747545,0.00019340277,0.000033205935,0.00005069486,0.0000053849762,0.000053313684,0.000020539263,0.0000068185286],"category_scores_gemma":[0.000097723205,0.000035677396,0.00003366176,0.000056497473,0.00025008377,0.000019925776,0.000030680247,0.00008174034,0.0000045858314],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044778127,0.0007605608,0.40470594,0.00014544456,0.0020419967,0.000085288804,0.030047584,0.00013215403,0.0055211624,0.0023956064,0.0095445635,0.49984157],"study_design_scores_gemma":[0.08736892,0.008783066,0.69731593,0.000032301006,0.00067921676,0.00010409215,0.0004457874,0.0011984766,0.0077832956,0.0071552927,0.18886282,0.00027081647],"about_ca_topic_score_codex":0.00007497146,"about_ca_topic_score_gemma":0.0000058358155,"teacher_disagreement_score":0.49957076,"about_ca_system_score_codex":0.000013171253,"about_ca_system_score_gemma":0.00007492894,"threshold_uncertainty_score":0.1454882},"labels":[],"label_agreement":null},{"id":"W802966559","doi":"10.71781/30801","title":"Immuno-oncology of human prostate cancer : phenotypical characterization and study of the tumor-derived, androgen-regulated immunosuppressive microenvironment","year":2010,"lang":"en","type":"dissertation","venue":"Open MIND","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prostate cancer; Tumor microenvironment; Oncology; Cancer research; Cancer; Medicine; Phenotype; Androgen; Internal medicine; Biology; Hormone; Genetics","score_opus":0.022443672500135275,"score_gpt":0.3486485710700877,"score_spread":0.3262048985699524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W802966559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944523,0.00083443325,6.290962e-8,0.00008897759,0.00018675346,0.003998031,0.00016737811,8.8634556e-7,0.00027115518],"genre_scores_gemma":[0.9903891,0.0003612092,0.000025648142,0.0000064453598,0.000029148387,0.00025453576,0.0014795709,0.000033252396,0.007421094],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985677,0.00011490412,0.000480077,0.00036612217,0.00027598525,0.00019521835],"domain_scores_gemma":[0.998772,0.000019805513,0.000593507,0.0004037913,0.00015189403,0.00005899449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013137165,0.00022710656,0.0006215802,0.0000795175,0.00014334833,0.000027364606,0.0002756194,0.00019008819,0.0009032294],"category_scores_gemma":[0.000011899479,0.00014871718,0.000060089125,0.00011569689,0.00019417424,0.00007072065,0.00019564926,0.00035732085,0.0000025748898],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027906587,0.0010648846,0.012430611,0.00011580774,0.00044618628,0.000016782433,0.012582035,4.123158e-7,0.9267512,3.17632e-7,0.000006831588,0.043794278],"study_design_scores_gemma":[0.0052126474,0.0012961845,0.32886675,0.000392665,0.00046959857,0.0000082177785,0.003844712,0.0000030967728,0.65873575,0.0000028540962,0.0010480029,0.00011954032],"about_ca_topic_score_codex":0.000361176,"about_ca_topic_score_gemma":0.00057829707,"teacher_disagreement_score":0.31643614,"about_ca_system_score_codex":0.000109905974,"about_ca_system_score_gemma":0.00036633236,"threshold_uncertainty_score":0.98897284},"labels":[],"label_agreement":null},{"id":"W838649477","doi":"10.1007/978-3-319-16301-7_4","title":"Treatment of the Prostate Cancer","year":2015,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"","keywords":"Prostate cancer; Cancer; Prostate; Medicine; Internal medicine","score_opus":0.0905923449757491,"score_gpt":0.36383587039357695,"score_spread":0.27324352541782787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W838649477","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00053207367,0.019480059,1.926369e-7,0.0031144104,0.00020562389,0.0014002576,0.00016319701,0.000024161172,0.97508],"genre_scores_gemma":[0.0042176745,0.009652661,0.000021864906,0.00003957577,0.0001566096,0.00007123945,0.000043339955,0.00003892352,0.9857581],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999054,0.000005931292,0.00017773644,0.00020104233,0.00039732148,0.00016395767],"domain_scores_gemma":[0.99914426,0.000013764337,0.00009066389,0.00040663528,0.0002310719,0.00011361083],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000029667444,0.00020936616,0.00039170455,0.000056056175,0.000028838673,0.0000045344805,0.00006632713,0.00012914221,0.0017167246],"category_scores_gemma":[0.0000030917317,0.00008937503,0.00019552933,0.000024385601,0.0001652449,0.000012917859,0.000037556245,0.0000983971,0.000055625787],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006753522,0.0013741837,0.020550387,0.0016457441,0.008684319,0.0007832567,0.004091352,0.000011352105,0.0016591063,0.08125122,0.27186617,0.6013294],"study_design_scores_gemma":[0.0029974177,0.001034756,0.0002716426,0.00028241135,0.00041368158,0.000018234225,0.000017297132,0.0000042433403,0.0029479673,0.001750994,0.99014497,0.0001163862],"about_ca_topic_score_codex":0.00023388327,"about_ca_topic_score_gemma":0.00007125907,"teacher_disagreement_score":0.7182788,"about_ca_system_score_codex":0.00057140016,"about_ca_system_score_gemma":0.000939515,"threshold_uncertainty_score":0.9991958},"labels":[],"label_agreement":null},{"id":"W84991782","doi":"10.1007/978-1-4899-8050-2_17","title":"Molecular Testing in Prostate Cancer","year":2014,"lang":"en","type":"book-chapter","venue":"","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canada Research Chairs; University of New Brunswick; University Hospital","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Oncology; Internal medicine","score_opus":0.044945916979351554,"score_gpt":0.32820397804518886,"score_spread":0.2832580610658373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W84991782","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002239228,0.0041538007,0.000010361919,0.0012291479,0.00007264279,0.00087248214,0.000014528786,0.00006435619,0.99134344],"genre_scores_gemma":[0.017064678,0.0009403311,0.0003340197,0.0004497688,0.00012477147,0.000085863685,0.000060693128,0.0000783278,0.98086154],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988341,0.000007048733,0.00021883828,0.000341784,0.00030360304,0.00029464765],"domain_scores_gemma":[0.9993883,0.000043297325,0.000059070906,0.00024673608,0.00013508754,0.00012755544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001061713,0.00023441215,0.00039133,0.00020320971,0.000022059603,0.000013751771,0.000060721515,0.00014169479,0.00081383216],"category_scores_gemma":[0.000028459464,0.00016931149,0.00007260924,0.000047128513,0.00007187192,0.000014854685,0.000053988977,0.0004008851,0.00013090788],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019416776,0.00024202336,0.05505952,0.0047593825,0.0015099378,0.017268544,0.00061342015,0.00012738821,0.014982854,0.092142105,0.022678657,0.7886745],"study_design_scores_gemma":[0.013840822,0.0019579523,0.0036340903,0.01153755,0.000627591,0.00019491823,0.00003501722,0.0009781963,0.013881023,0.015449104,0.93603325,0.0018305044],"about_ca_topic_score_codex":0.00025282454,"about_ca_topic_score_gemma":0.00006894119,"teacher_disagreement_score":0.9133546,"about_ca_system_score_codex":0.0002623158,"about_ca_system_score_gemma":0.00035599901,"threshold_uncertainty_score":0.89108914},"labels":[],"label_agreement":null},{"id":"W888798500","doi":"10.1016/j.jsbmb.2015.07.006","title":"Recent progress in the development of protein–protein interaction inhibitors targeting androgen receptor–coactivator binding in prostate cancer","year":2015,"lang":"en","type":"review","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Prostate cancer; Coactivator; Androgen receptor; Cancer research; Cancer; Nuclear receptor coactivator 3; Androgen; Androgen deprivation therapy; Medicine; Biology; Internal medicine; Transcription factor; Hormone; Genetics; Gene","score_opus":0.03782200396786541,"score_gpt":0.374083640477205,"score_spread":0.3362616365093396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W888798500","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41281918,0.5861181,9.631891e-7,0.00021497563,0.000039556704,0.0007878929,0.000008434202,0.0000013211496,0.000009567316],"genre_scores_gemma":[0.041010246,0.95829725,0.00025358202,0.000011634137,0.00010346496,0.0001809579,0.0000814822,0.000023019278,0.00003835237],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99806166,0.0004093209,0.0008590874,0.00018578669,0.00022639554,0.00025775968],"domain_scores_gemma":[0.9987635,0.00003593575,0.0008097889,0.00014412218,0.0001718534,0.00007482094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017047415,0.0002490337,0.0007829171,0.00016126792,0.000045583867,0.000012950881,0.000199861,0.00019409136,0.000006418751],"category_scores_gemma":[0.00006496466,0.000119284865,0.000093756586,0.00030270798,0.00018619663,0.00003346709,0.000096984404,0.00071879174,5.0521413e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010298282,0.00021884826,0.0004020351,0.0058277785,0.00037843603,0.00007058097,0.0016874416,1.7456702e-7,0.15632878,6.6940373e-7,0.00004347701,0.834012],"study_design_scores_gemma":[0.0023873209,0.000748772,0.0000073093015,0.031394728,0.00030213542,0.00034010314,0.002083595,7.650346e-7,0.6342573,0.000016580743,0.32816187,0.00029952868],"about_ca_topic_score_codex":0.000004534751,"about_ca_topic_score_gemma":0.0000018823512,"teacher_disagreement_score":0.8337124,"about_ca_system_score_codex":0.00035181362,"about_ca_system_score_gemma":0.0009675365,"threshold_uncertainty_score":0.48642954},"labels":[],"label_agreement":null}]}